PMID-sentid Pub_year Sent_text comp_official_name comp_offset protein_name organism prot_offset 3285301-6 1988 In SU-DHL-6 the t(14;18) translocation juxtaposes a truncated bcl-2 gene with J6 in a tail-to-head configuration, resulting in the deregulated expression of chimeric bcl-2/Ig transcripts. su-dhl-6 3-11 BCL2 apoptosis regulator Homo sapiens 62-67 2554236-3 1989 This revealed that high levels of bcl-2 alpha protein made EBV-B cells more resistant to a variety of stresses including the application of heat shock, ethanol, methotrexate and the absence of serum. Ethanol 152-159 BCL2 apoptosis regulator Homo sapiens 34-39 2554236-3 1989 This revealed that high levels of bcl-2 alpha protein made EBV-B cells more resistant to a variety of stresses including the application of heat shock, ethanol, methotrexate and the absence of serum. Methotrexate 161-173 BCL2 apoptosis regulator Homo sapiens 34-39 2543982-5 1989 Although deregulated BCL2 expression as a single agent was not sufficient to confer tumorigenicity to LCLs, it consistently produced a 3- to 4-fold increment in LCL clonogenicity in soft agar. Agar 187-191 BCL2 apoptosis regulator Homo sapiens 21-25 2478890-5 1989 We report here that Bcl-2 alpha has GTP-binding activity and a protein sequence that suggests it belongs to the small molecular weight GTP-binding protein (G protein) family. Guanosine Triphosphate 36-39 BCL2 apoptosis regulator Homo sapiens 20-25 2478890-5 1989 We report here that Bcl-2 alpha has GTP-binding activity and a protein sequence that suggests it belongs to the small molecular weight GTP-binding protein (G protein) family. Guanosine Triphosphate 135-138 BCL2 apoptosis regulator Homo sapiens 20-25 2771409-5 1989 However, in the presence of cycloheximide (inhibitor of protein synthesis), the half-life of some of the bcl-2/Ig mRNAs produced by these cells was prolonged, indicating that in some circumstances mRNA stability may contribute to deregulated bcl-2 expression. Cycloheximide 28-41 BCL2 apoptosis regulator Homo sapiens 105-110 2771409-5 1989 However, in the presence of cycloheximide (inhibitor of protein synthesis), the half-life of some of the bcl-2/Ig mRNAs produced by these cells was prolonged, indicating that in some circumstances mRNA stability may contribute to deregulated bcl-2 expression. Cycloheximide 28-41 BCL2 apoptosis regulator Homo sapiens 242-247 2771409-6 1989 Despite stabilizing some bcl-2 mRNAs, the overall effect of treating cell lines with cycloheximide was a reduction in the levels of accumulated bcl-2 mRNAs through inhibition of bcl-2 gene transcription. Cycloheximide 85-98 BCL2 apoptosis regulator Homo sapiens 25-30 2771409-6 1989 Despite stabilizing some bcl-2 mRNAs, the overall effect of treating cell lines with cycloheximide was a reduction in the levels of accumulated bcl-2 mRNAs through inhibition of bcl-2 gene transcription. Cycloheximide 85-98 BCL2 apoptosis regulator Homo sapiens 144-149 2771409-6 1989 Despite stabilizing some bcl-2 mRNAs, the overall effect of treating cell lines with cycloheximide was a reduction in the levels of accumulated bcl-2 mRNAs through inhibition of bcl-2 gene transcription. Cycloheximide 85-98 BCL2 apoptosis regulator Homo sapiens 144-149 3285301-6 1988 In SU-DHL-6 the t(14;18) translocation juxtaposes a truncated bcl-2 gene with J6 in a tail-to-head configuration, resulting in the deregulated expression of chimeric bcl-2/Ig transcripts. su-dhl-6 3-11 BCL2 apoptosis regulator Homo sapiens 166-171 33932650-13 2021 Supplementation of Niacin to IVM media positively affected the relative expression of genes related to energy and oxidative status (SIRT1), pro-apoptosis (BAX), anti-apoptosis (BCL2), and lipid metabolism (ACACA and PNPLA2) in cumulus cells and oocytes. Niacin 19-25 BCL2 apoptosis regulator Homo sapiens 177-181 33957086-8 2021 In A549 cells, oleic acid and OEA decreased IFN-gamma-induced expression of PD-L1, Bax, Bcl-2, and caspase 3. Oleic Acid 15-25 BCL2 apoptosis regulator Homo sapiens 88-93 33957086-8 2021 In A549 cells, oleic acid and OEA decreased IFN-gamma-induced expression of PD-L1, Bax, Bcl-2, and caspase 3. oleoylethanolamide 30-33 BCL2 apoptosis regulator Homo sapiens 88-93 33982778-11 2021 Moreover, under HG stress, IQC treatment markedly inhibited the increased expression levels of the pro-apoptotic proteins p53, Bax and C-caspase3, and increased the expression levels of the anti-apoptotic protein Bcl-2 in HUVECs. isoquercitrin 27-30 BCL2 apoptosis regulator Homo sapiens 213-218 34013361-10 2021 Furthermore, Tat-SabKIM1 could inhibit Bcl-2-regulated autophagy and mitochondria-mediated apoptosis. tat-sabkim1 13-24 BCL2 apoptosis regulator Homo sapiens 39-44 33640439-11 2021 QZC-induced apoptosis in HCT116 cells was accompanied by the deregulation of the expression of the Bcl-2, Bax, PARP, caspase-3, and caspase-9 proteins. qzc 0-3 BCL2 apoptosis regulator Homo sapiens 99-104 33848578-8 2021 Also, green tea and PTX combination induced apoptosis in ovarian cancer cells by blocking the phosphorylation of Akt and the expression of Bcl-2 while inducing Bax, Cyt-C, cleaved-caspase 3, and cleaved-caspase 9. Paclitaxel 20-23 BCL2 apoptosis regulator Homo sapiens 139-144 33915328-8 2021 A438079 promoted apoptosis via the Bcl-2/caspase9/caspase3 pathway and inhibited pyroptosis through the NLRP3/caspase1 pathway by inhibiting P2X7R in vitro and in vivo. 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine 0-7 BCL2 apoptosis regulator Homo sapiens 35-40 33981363-7 2021 The results showed that 17BIPHE2 significantly increased the apoptosis rate of A549 cells and elevated BAX expression, ERK phosphorylation, and ROS and Ca2+ levels, but decreased the expression of BCL-2, ERK and Ki67. 17biphe2 24-32 BCL2 apoptosis regulator Homo sapiens 197-202 33744756-6 2021 Pt/MgO nanoparticles downregulated Bcl-2 and upregulated Bax and p53 tumor suppressor proteins in the cancer cells. Platinum 0-2 BCL2 apoptosis regulator Homo sapiens 35-40 33900450-3 2021 This study aimed to investigate the efficacy and safety of ibrutinib plus BCL2 inhibitor venetoclax in R/R DLBCL patients with non-GCB subtype and BCL2 overexpression. ibrutinib 59-68 BCL2 apoptosis regulator Homo sapiens 147-151 33900450-14 2021 Combined therapy of ibrutinib and venetoclax showed promising efficacy and synergistic effects in R/R DLBCL patients with non-GCB subtype and BCL2 overexpression, and the toxicities were well-tolerated. ibrutinib 20-29 BCL2 apoptosis regulator Homo sapiens 142-146 33900450-14 2021 Combined therapy of ibrutinib and venetoclax showed promising efficacy and synergistic effects in R/R DLBCL patients with non-GCB subtype and BCL2 overexpression, and the toxicities were well-tolerated. venetoclax 34-44 BCL2 apoptosis regulator Homo sapiens 142-146 33744756-6 2021 Pt/MgO nanoparticles downregulated Bcl-2 and upregulated Bax and p53 tumor suppressor proteins in the cancer cells. mgo 3-6 BCL2 apoptosis regulator Homo sapiens 35-40 33482239-10 2021 qPCR analysis showed that overexpression of PcFas could significantly up-regulate the expression of genes related to Fas/FasL signaling pathway, including bcl-2, bax, and RIP3, while overexpression of PcFasL significantly up-regulate the expression of caspase-3, caspase-9, and MLKL. pcfas 44-49 BCL2 apoptosis regulator Homo sapiens 155-160 33895605-5 2021 Furthermore, the mitochondrial-dependent apoptosis induced by compound b-9 is related with the JAK2/STAT3/Bcl-2 signaling pathway. daminozide 71-74 BCL2 apoptosis regulator Homo sapiens 106-111 33404763-12 2021 Ten-minute NAC treatment downregulated the IL-6 and TNF-alpha expression, whereas the expression of Bcl-2/Bax and Mfn-2/Drp-1 ratios was upregulated at 6 h. CONCLUSIONS: Under the LPS-induced inflammatory condition, NAC stimulated APC survival and decreased inflammation. Acetylcysteine 216-219 BCL2 apoptosis regulator Homo sapiens 100-105 33878320-9 2021 Interestingly, 20-HE revealed proapoptotic activity in MDA-MB-231 and T-47D cells that was manifested by alterations in PARP, Bax, and Bcl-2 levels as well as caspase-3 activation. Ecdysterone 15-20 BCL2 apoptosis regulator Homo sapiens 135-140 33850531-9 2021 The results suggested that ADAMTS9-AS2 downregulated the phosphorylation of AKT and mTOR, the protein expression level of PIK3CB, as well as the expression levels of autophagy protein SQSTM1 and antiapoptotic protein Bcl-2. Aligeron 34-38 BCL2 apoptosis regulator Homo sapiens 217-222 33153817-18 2021 CONCLUSIONS: The hitherto unappreciated attenuation of the CXCR2/BCL-2 axis in taxane-treated mCRPC patients is an acquired vulnerability with potential predictive activity for platinum-based treatments. taxane 79-85 BCL2 apoptosis regulator Homo sapiens 65-70 33153817-18 2021 CONCLUSIONS: The hitherto unappreciated attenuation of the CXCR2/BCL-2 axis in taxane-treated mCRPC patients is an acquired vulnerability with potential predictive activity for platinum-based treatments. Platinum 177-185 BCL2 apoptosis regulator Homo sapiens 65-70 33968184-0 2021 Apatinib inhibits gastric carcinoma development by regulating the expression levels of IL-17 via the Bax/Bcl-2 signaling pathway. apatinib 0-8 BCL2 apoptosis regulator Homo sapiens 105-110 33153817-0 2021 Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. taxane 0-6 BCL2 apoptosis regulator Homo sapiens 40-45 33153817-0 2021 Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. Platinum 81-89 BCL2 apoptosis regulator Homo sapiens 40-45 33153817-14 2021 RESULTS AND LIMITATIONS: Transcriptomic data from taxane-exposed human mCRPC tumors correlate with a marked negative enrichment of apoptosis and inflammatory response pathways accompanied by a marked downregulation of CXCR2 and BCL-2. taxane 50-56 BCL2 apoptosis regulator Homo sapiens 228-233 33153817-16 2021 Further, we demonstrated in experimental models that the sensitivity to cisplatin is dependent on CXCR2 and BCL-2, and that targeting them sensitizes prostate cancer (PC) cells to cisplatin. Cisplatin 72-81 BCL2 apoptosis regulator Homo sapiens 108-113 33968184-13 2021 The findings indicated that apatinib may inhibit gastric carcinoma development by regulating IL-17 expression via the Bax/Bcl-2 signaling pathway. apatinib 28-36 BCL2 apoptosis regulator Homo sapiens 122-127 33230623-5 2021 In addition, treatment of NSCLC cells with 4Ei-10 results in suppression of translation and diminished expression of a cohort of cellular proteins important to maintaining the malignant phenotype and resisting apoptosis such as Bcl-2, survivin, and ornithine decarboxylase (ODC). 4ei-10 43-49 BCL2 apoptosis regulator Homo sapiens 228-233 33417255-5 2021 Using Annexin V/propidium iodide staining, a significant increase in apoptosis was found after chrysophanol treatment on HeLa cells, and this process was mediated by caspases 3/7 with a clear inactivation of the antiapoptotic Bcl-2 family protein. chrysophanic acid 95-107 BCL2 apoptosis regulator Homo sapiens 226-231 33965112-8 2021 Celastrol and Fe3O4/alpha-Fe2O3/CA-PEG-celastrol increased the production of reactive oxygen species in SMMC-7721 cells and promoted apoptosis and apoptosis-related proteins (p53, Bax, Bcl-2) were also changed. alpha-fe2o3 20-31 BCL2 apoptosis regulator Homo sapiens 185-190 33965112-8 2021 Celastrol and Fe3O4/alpha-Fe2O3/CA-PEG-celastrol increased the production of reactive oxygen species in SMMC-7721 cells and promoted apoptosis and apoptosis-related proteins (p53, Bax, Bcl-2) were also changed. ca-peg-celastrol 32-48 BCL2 apoptosis regulator Homo sapiens 185-190 33786632-0 2021 ABT-737, a Bcl-2 family inhibitor, has a synergistic effect with apoptosis by inducing urothelial carcinoma cell necroptosis. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 11-16 33786632-1 2021 ABT-737 is a recently reported inhibitor of members of the Bcl-2 family of apoptosis regulators. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 59-64 33846811-1 2021 The aim of the present study was to investigate the synergistic effect of LY294002 (a PI3K inhibitor) and ABT199 (a BCL2 inhibitor) on the cell cycle in acute myeloid leukemia (AML). venetoclax 106-112 BCL2 apoptosis regulator Homo sapiens 116-120 33639357-5 2021 We found that ghrelin inhibited rotenone-induced cytotoxicity, mitochondrial dysfunction, and apoptosis by improving cell viability, increasing the ratio of red/green of JC-1, inhibiting the production of reactive oxidative species (ROS), and regulating Bcl-2, Bax, Cytochrome c, caspase-9, and caspase-3 expression. Ghrelin 14-21 BCL2 apoptosis regulator Homo sapiens 254-259 33639357-5 2021 We found that ghrelin inhibited rotenone-induced cytotoxicity, mitochondrial dysfunction, and apoptosis by improving cell viability, increasing the ratio of red/green of JC-1, inhibiting the production of reactive oxidative species (ROS), and regulating Bcl-2, Bax, Cytochrome c, caspase-9, and caspase-3 expression. Rotenone 32-40 BCL2 apoptosis regulator Homo sapiens 254-259 33846811-4 2021 At the molecular level, LY294002 and ABT199 combination treatment significantly downregulated Skp2, Bcl2, procaspase-3 and procaspase-9 expression levels, but markedly upregulated p27, Bax, cleaved caspase-3 and caspase-9 expression levels in K562, HL-60 and KG1a cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 24-32 BCL2 apoptosis regulator Homo sapiens 100-104 33846811-4 2021 At the molecular level, LY294002 and ABT199 combination treatment significantly downregulated Skp2, Bcl2, procaspase-3 and procaspase-9 expression levels, but markedly upregulated p27, Bax, cleaved caspase-3 and caspase-9 expression levels in K562, HL-60 and KG1a cells. venetoclax 37-43 BCL2 apoptosis regulator Homo sapiens 100-104 33684465-4 2021 The apoptotic and DNA-damaging effects of colchicine have also been verified by fluorescence imaging and ELISA experiments, and they revealed that while colchicine treatment significantly modulated expression as increases in Bax, cleaved caspase 3, cleaved PARP, and 8-hydroxy-desoxyguanosine protein expressions and as a decrease of BCL-2 protein expression. Colchicine 42-52 BCL2 apoptosis regulator Homo sapiens 334-339 33968208-8 2021 Silymarin increased the levels of Bax, cleaved poly-ADP ribose polymerase, cleaved caspase-9 and phosphorylated (p-)JNK, and decreased the levels of Bcl-2, p-P38 and p-ERK1/2. Silymarin 0-9 BCL2 apoptosis regulator Homo sapiens 149-154 33684465-4 2021 The apoptotic and DNA-damaging effects of colchicine have also been verified by fluorescence imaging and ELISA experiments, and they revealed that while colchicine treatment significantly modulated expression as increases in Bax, cleaved caspase 3, cleaved PARP, and 8-hydroxy-desoxyguanosine protein expressions and as a decrease of BCL-2 protein expression. Colchicine 153-163 BCL2 apoptosis regulator Homo sapiens 334-339 33941323-7 2021 DHA also down-regulated the levels of Bcl-2, N-cadherin, and Vimentin, and up-regulated the levels of Bax, C-caspase-3 and E-cadherin in ovarian cancer cells. artenimol 0-3 BCL2 apoptosis regulator Homo sapiens 38-43 33259592-1 2021 BH3 mimetics like Venetoclax target pro-survival Bcl-2 family proteins and are important therapeutics in the treatment of hematological malignancies. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 49-54 34050131-0 2021 A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. azd0466 21-28 BCL2 apoptosis regulator Homo sapiens 51-56 34050131-4 2021 In this study we show another inhibitor, AZD4320 that targets BCL-XL (and BCL-2), can also potently kill MPM tumor cells in vitro (EC50 values in the 200 nM range) and this effect is enhanced by co-inhibition of MCL-1 using AZD5991. AZD4320 41-48 BCL2 apoptosis regulator Homo sapiens 74-79 34024909-0 2021 FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation. bim 115-118 BCL2 apoptosis regulator Homo sapiens 47-52 34048785-7 2021 Additionally, Gem+Zeb treated cells showed marked decreased in the expressions of anti-apoptotic protein including Bcl-2 and survivin while significantly increased the cleaved caspase-3, and loss of mitochondrial membrane potential was observed. gemcitabine 14-17 BCL2 apoptosis regulator Homo sapiens 115-120 34048785-7 2021 Additionally, Gem+Zeb treated cells showed marked decreased in the expressions of anti-apoptotic protein including Bcl-2 and survivin while significantly increased the cleaved caspase-3, and loss of mitochondrial membrane potential was observed. pyrimidin-2-one beta-ribofuranoside 18-21 BCL2 apoptosis regulator Homo sapiens 115-120 34024909-5 2021 Gilteritinib treatment alone dissociated BIM from MCL-1 but increased the binding of BIM to BCL-2. gilteritinib 0-12 BCL2 apoptosis regulator Homo sapiens 92-97 34027802-8 2021 Also, B[a] P induced DNA damages and activated the apoptotic pathway, presented by upregulated Bax, caspase-3, and downregulated Bcl-2 gens. Benzo(a)pyrene 6-12 BCL2 apoptosis regulator Homo sapiens 129-134 34019713-6 2021 Subsequent Bcl-2 inhibition therapy applied in 28/32 patients harbouring BTKC481S and progressing on ibrutinib conferred clinical and molecular remission across the patients. ibrutinib 101-110 BCL2 apoptosis regulator Homo sapiens 11-16 34036969-2 2021 A Bcl-2 inhibitor, venetoclax, can improve the clinical outcome of acute lung injury based on its pro-apoptotic effect. venetoclax 19-29 BCL2 apoptosis regulator Homo sapiens 2-7 34002651-8 2021 Our results showed that MG132 downregulated the expression of antiapoptotic proteins, including CDK2, CDK4, Bcl-xL, and Bcl-2, whereas it upregulated the expression of proapoptotic proteins, including p21, p27, p53, p-p53 (ser15, ser20, and ser46), cleaved forms of caspase-3, caspase-7, caspase-9, and PARP, and FOXO3 in U2OS cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 24-29 BCL2 apoptosis regulator Homo sapiens 120-125 33783376-8 2021 Moreover, the combined treatment induced more early apoptosis than sorafenib alone through downregulating the Bcl-2 expression. Sorafenib 67-76 BCL2 apoptosis regulator Homo sapiens 110-115 34020281-5 2021 The levels of expressions of Bax and Bak were significantly increased, whereas the expression levels of Mcl-1 and Bcl-2 were considerably decreased after being treated with high levels of Cd. Cadmium 188-190 BCL2 apoptosis regulator Homo sapiens 114-119 33990217-16 2021 Mechanistically, intracellular creatine bolstered cell antioxidant defense by reducing mitochondrial activity and oxygen consumption rates to reduce accumulation of intracellular reactive oxygen species, ultimately activating AKT-ERK signaling, the activation of which protected the viability of hypoxic TNBC cells via mediating the upregulation of Ki-67 and Bcl-2, and the downregulation of Bax and cleaved Caspase-3. Creatine 31-39 BCL2 apoptosis regulator Homo sapiens 359-364 34000859-5 2021 Compared with the cell control group and the non-PD-L1 targeted group, the mediated effect of PD-L1 can significantly enhance the uptake of drugs by cells, and L-PD-SP/Ls can significantly reduce the expression of Bcl-2 and increase the level of LDH in cells. l-pd-sp 160-167 BCL2 apoptosis regulator Homo sapiens 214-219 33999357-3 2021 PME also blocked several 6-OHDA-induced mitochondrial apoptotic cascades, including loss of mitochondrial membrane potential, caspase 3 and PARP activation, and a decrease in the Bcl-2/Bax ratio. Oxidopamine 25-31 BCL2 apoptosis regulator Homo sapiens 179-184 34000513-9 2021 RESULTS: Findings indicated that tripterine suppressed BC cells" viability, proliferation, migration, invasion capacity and Bcl-2 protein expression, but it induced BC cells" Bax protein expression. celastrol 33-43 BCL2 apoptosis regulator Homo sapiens 124-129 33999319-9 2021 Debio-0932 stimulated the down-regulation of anti-apoptotic protein Bcl-2 and the up-regulation of apoptotic protein Bax and cleavage of Casp-9 in cancer cells. CUDC 305 0-10 BCL2 apoptosis regulator Homo sapiens 68-73 33523649-0 2021 Optimization of Benzothiazole and Thiazole Hydrazones as Inhibitors of Schistosome BCL-2. benzothiazole 16-29 BCL2 apoptosis regulator Homo sapiens 83-88 33523649-0 2021 Optimization of Benzothiazole and Thiazole Hydrazones as Inhibitors of Schistosome BCL-2. thiazole hydrazones 34-53 BCL2 apoptosis regulator Homo sapiens 83-88 33990765-3 2022 Preincubation with BELNs decreased the level of reactive oxygen species (ROS), increased the mitochondrial membrane potential, and prevented cell apoptosis by inducing the expression of Bcl-2 and heme oxygenase-1 (HO-1) and decreasing the content of Bax in rotenone-treated HepG2 cells. belns 19-24 BCL2 apoptosis regulator Homo sapiens 186-191 33982799-9 2021 Furthermore, ABT-199 (a BCL2 inhibitor) synergistically enhanced the cytotoxicity of DNR in AML cell lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 13-16 BCL2 apoptosis regulator Homo sapiens 24-28 34054546-13 2021 In vitro studies revealed that naringin exposure was found to promote apoptosis of RA-FLS, increased the activation of caspase-3, and increased the ratio of Bax/Bcl-2 in a dose-dependent manner. naringin 31-39 BCL2 apoptosis regulator Homo sapiens 161-166 33904752-0 2021 Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-XL and BCL-2. Benzoylurea 39-50 BCL2 apoptosis regulator Homo sapiens 76-81 33904752-4 2021 Here, we outline the crystallography-guided development of a structurally distinct series of BCL-XL/BCL-2 inhibitors based on a benzoylurea scaffold, originally proposed as alpha-helix mimetics. Benzoylurea 128-139 BCL2 apoptosis regulator Homo sapiens 100-105 33990623-8 2021 ADPE upregulated the p53, Bax and cleaved caspase-3, thereby leading to the downregulation of Bcl-2 and AKT/mTOR pathway. adpe 0-4 BCL2 apoptosis regulator Homo sapiens 94-99 33982799-9 2021 Furthermore, ABT-199 (a BCL2 inhibitor) synergistically enhanced the cytotoxicity of DNR in AML cell lines. Daunorubicin 85-88 BCL2 apoptosis regulator Homo sapiens 24-28 34055852-8 2021 It was found that pre-incubation with stigmasterol also facilitated the upregulation of forkhead box O (FoxO) 3a, catalase, and anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) in the neurons. Stigmasterol 38-50 BCL2 apoptosis regulator Homo sapiens 151-168 33904752-7 2021 Extension into the hydrophobic p2 pocket yielded the most potent inhibitor in the series, binding strongly to BCL-XL and BCL-2 (nanomolar-range half-maximal inhibitory concentration (IC50)) and displaying mechanism-based killing in cells engineered to depend on BCL-XL for survival. P-2 31-33 BCL2 apoptosis regulator Homo sapiens 121-126 34055852-8 2021 It was found that pre-incubation with stigmasterol also facilitated the upregulation of forkhead box O (FoxO) 3a, catalase, and anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) in the neurons. Stigmasterol 38-50 BCL2 apoptosis regulator Homo sapiens 170-175 33524509-12 2021 RESULTS: CESTG inhibited cell viability, clonal growth and induced cell apoptosis in a dose-dependent manner by silencing the PI3K/AKT/mTOR signaling pathway, which is associated with upregulation of cleaved PARP, caspase 3/7/8/9, cleaved caspase 3/7/8/9, Bax and downregulation of PARP, P-PI3K, PI3K, P-AKT, AKT, P-mTOR, mTOR and Bcl-2. cestg 9-14 BCL2 apoptosis regulator Homo sapiens 331-336 34025440-3 2021 Our data have demonstrated that DMF treatment attenuated HG-induced apoptosis, as confirmed by reduction of BAX/Bcl-2 ratio. Dimethyl Fumarate 32-35 BCL2 apoptosis regulator Homo sapiens 112-117 34026822-10 2021 Results showed that DSCXQ intervention significantly reduced cerebral infarct size, ameliorated behavioral abnormality, inhibited the expression of Sphk1, S1PR1, CD62P, Bax, Cleaved Caspase-3, while increased the level of Bcl-2, and prevented neuronal apoptosis. dscxq 20-25 BCL2 apoptosis regulator Homo sapiens 222-227 34012921-7 2021 The BCL2 inhibitor venetoclax, combined with hypomethylating agents or low dose cytarabine, represents an important new therapy especially for older AML patients. venetoclax 19-29 BCL2 apoptosis regulator Homo sapiens 4-8 33662352-5 2021 The use of 5-FU and L-OHP, either alone or in combination, strongly suppressed Akt activation, Survivin, Bcl-2, and Bcl-xL expression, and enhanced Puma, phospho-p53, and p53 expression in Caco-2 cells than in DLD-1 cells. Fluorouracil 11-15 BCL2 apoptosis regulator Homo sapiens 105-110 33662352-5 2021 The use of 5-FU and L-OHP, either alone or in combination, strongly suppressed Akt activation, Survivin, Bcl-2, and Bcl-xL expression, and enhanced Puma, phospho-p53, and p53 expression in Caco-2 cells than in DLD-1 cells. Oxaliplatin 20-25 BCL2 apoptosis regulator Homo sapiens 105-110 33662352-6 2021 In addition, perifosine enhanced the cytotoxicity of the 5-FU and L-OHP combination, inhibited Akt activation and the expression of Survivin, Bcl-2, and Bcl-xL, and increased the expression of Puma, phospho-p53, and p53 in DLD-1 cells. perifosine 13-23 BCL2 apoptosis regulator Homo sapiens 142-147 33951110-1 2021 Our previous pre-clinical work defined BCL-2 induction as a critical component of the adaptive response to lapatinib-mediated inhibition of HER2. Lapatinib 107-116 BCL2 apoptosis regulator Homo sapiens 39-44 33951110-3 2021 We detected BCL2 mRNA upregulation in both HER2+/ER- as well as HER2+/ER+ patient tumors treated with lapatinib or trastuzumab. Lapatinib 102-111 BCL2 apoptosis regulator Homo sapiens 12-16 33951110-6 2021 BCL-2 upregulation was evident within the majority of lapatinib-treated HER2+/ER+ tumors and was often coupled with increased ER expression and decreased proliferation. Lapatinib 54-63 BCL2 apoptosis regulator Homo sapiens 0-5 33951110-8 2021 Together, these results provide clinical validation of the BCL-2 induction associated with the adaptive response to lapatinib and support evaluation of BCL-2 inhibitors within the context of lapatinib and other HER2-targeted receptor tyrosine kinase inhibitors. Lapatinib 116-125 BCL2 apoptosis regulator Homo sapiens 59-64 33939252-11 2021 Foretinib led to a decrease in Bcl-2, and an increase in p27, Bax, Bim, cleaved PARP-1 and cleaved caspase-3. GSK 1363089 0-9 BCL2 apoptosis regulator Homo sapiens 31-36 33328572-4 2021 We found that BCL2 and BCL(X)L increase the metabolic robustness of MCF7 cells, and that this was associated with increased mitochondrial NAD(P)H and ATP levels. Adenosine Triphosphate 150-153 BCL2 apoptosis regulator Homo sapiens 14-18 33382193-12 2021 CONCLUSION: HBs exposure can activate the Bax/Bcl2 signaling cascade that triggers AIF/Endo G-mediated apoptosis, resulting in sperm DNA fragmentation, sperm injury and death, and a decrease in the sperm fertilizing capacity. hbs 12-15 BCL2 apoptosis regulator Homo sapiens 46-50 33968578-7 2021 Sugiol also triggered increase in Bax and decrease in Bcl-2 expression. sugiol 0-6 BCL2 apoptosis regulator Homo sapiens 54-59 33355179-6 2021 To maintain ATP generation, hyperactive mitochondrial membrane blocks intrinsic apoptosis by increasing BCL2 dependency. Adenosine Triphosphate 12-15 BCL2 apoptosis regulator Homo sapiens 104-108 33328572-5 2021 Experiments with the F1F0 synthase inhibitor oligomycin demonstrated that BCL2 and in particular BCL(X)L, while not affecting ATP synthase activity, more efficiently coupled the mitochondrial proton motive force with ATP production. Oligomycins 45-55 BCL2 apoptosis regulator Homo sapiens 74-78 33595876-10 2021 Results suggest VS-9 as a potential garlic-derived novel anticancer peptide possessing apoptosis-inducing properties against leukemic cell lines via anti-apoptotic Bcl-2 protein family. vs-9 16-20 BCL2 apoptosis regulator Homo sapiens 164-169 33328572-5 2021 Experiments with the F1F0 synthase inhibitor oligomycin demonstrated that BCL2 and in particular BCL(X)L, while not affecting ATP synthase activity, more efficiently coupled the mitochondrial proton motive force with ATP production. Adenosine Triphosphate 217-220 BCL2 apoptosis regulator Homo sapiens 74-78 33347704-10 2021 The results from western blotting demonstrated that the treatment of GEN combined with Asp showed a higher increase in the levels of Bax and Bak (pro-apoptotic proteins) and an active form of caspase-3 and a higher decrease in Bcl-2 (anti-apoptotic protein) than that of GEN or Asp treatment alone. Genistein 69-72 BCL2 apoptosis regulator Homo sapiens 227-232 33838016-0 2021 miR-140-3p inhibits colorectal cancer progression and its liver metastasis by targeting BCL9 and BCL2. mir-140-3p 0-10 BCL2 apoptosis regulator Homo sapiens 97-101 33838016-6 2021 Notably, BCL9 and BCL2 were recognized as direct targets of miR-140-3p. mir-140-3p 60-70 BCL2 apoptosis regulator Homo sapiens 18-22 33666815-0 2021 Urolithin A induces cell cycle arrest and apoptosis by inhibiting Bcl-2, increasing p53-p21 proteins and reactive oxygen species production in colorectal cancer cells. 3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one 0-11 BCL2 apoptosis regulator Homo sapiens 66-71 33666815-10 2021 Similarly, UA treatment inhibited the anti-apoptotic protein expression of Bcl-2. 3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one 11-13 BCL2 apoptosis regulator Homo sapiens 75-80 33159713-11 2021 Furthermore, Bcl-2/Bax ratio was distinctly reduced and Caspase-3 expression was increased in HEMECs after exposure to MEHP. mono-(2-ethylhexyl)phthalate 119-123 BCL2 apoptosis regulator Homo sapiens 13-18 33747186-8 2021 FK18 also increased the Bcl-2/Bax ratio and decreased the level of cleaved-caspase-3 in SY5Y cells, which was reversed by the Akt pathway inhibitor LY294002, but not by the Erk pathway inhibitor U0126. fk18 0-4 BCL2 apoptosis regulator Homo sapiens 24-29 33848887-13 2021 Compared to the control, AgNP-treated HepG2 cells showed elevated -actin levels; however, Bcl-2 was significantly down regulated in AgNP-treated cells, indicating the involvement of Bcl-2 in apoptosis. agnp 25-29 BCL2 apoptosis regulator Homo sapiens 91-96 33283880-0 2021 Signal transducer and activator of transcription 3 mediates apoptosis inhibition through reducing mitochondrial ROS and activating Bcl-2 in gemcitabine-resistant lung cancer A549 cells. gemcitabine 140-151 BCL2 apoptosis regulator Homo sapiens 131-136 33848887-13 2021 Compared to the control, AgNP-treated HepG2 cells showed elevated -actin levels; however, Bcl-2 was significantly down regulated in AgNP-treated cells, indicating the involvement of Bcl-2 in apoptosis. agnp 25-29 BCL2 apoptosis regulator Homo sapiens 183-188 33848887-13 2021 Compared to the control, AgNP-treated HepG2 cells showed elevated -actin levels; however, Bcl-2 was significantly down regulated in AgNP-treated cells, indicating the involvement of Bcl-2 in apoptosis. agnp 133-137 BCL2 apoptosis regulator Homo sapiens 91-96 33848887-13 2021 Compared to the control, AgNP-treated HepG2 cells showed elevated -actin levels; however, Bcl-2 was significantly down regulated in AgNP-treated cells, indicating the involvement of Bcl-2 in apoptosis. agnp 133-137 BCL2 apoptosis regulator Homo sapiens 183-188 33649847-0 2021 Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl-2 pathway. N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 0-9 BCL2 apoptosis regulator Homo sapiens 74-79 33649847-5 2021 Moreover, chidamide promoted cellular apoptosis, which was identified via flow cytometry and western blot analysis, with an increase in cleaved caspase-3 expression and a decrease in Bcl-2 expression. N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 10-19 BCL2 apoptosis regulator Homo sapiens 183-188 33760110-7 2021 The present study used Hoechst 33258 staining to demonstrate that corilagin induced glioma cell apoptosis and observed that the expression of the apoptosis-related gene Bcl-2 was reduced. corilagin 66-75 BCL2 apoptosis regulator Homo sapiens 169-174 33649847-7 2021 Collectively, these data suggested that chidamide can be a potent therapeutic agent to treat DLBCL by inducing the apoptotic death of DLBCL cells by inhibiting the HDACs/STAT3/Bcl-2 pathway. N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 40-49 BCL2 apoptosis regulator Homo sapiens 176-181 33617922-6 2021 Western blotting and RT-PCR revealed that DHAc significantly increased anti-apoptotic Bcl-2 expression and mRNA levels of Nrf2 and HO-1. dihydroactinidiolide 42-46 BCL2 apoptosis regulator Homo sapiens 86-91 33946527-5 2021 Our results showed that the CR significantly inhibited cell growth and induced apoptosis in Hep3B cells through increased expression of Bcl-2 associated x-protein (Bax) and cleavage of poly-ADP ribose polymerase (PARP), reduced expression of Bcl-2, and activated caspases. Chromium 28-30 BCL2 apoptosis regulator Homo sapiens 136-141 33850567-4 2021 Combined HSYB and DOX treatment significantly decreased the expression levels of BCL-2 in MCF-7 cells, while the expression levels of apoptosis-associated proteins, including cleaved caspase-9, BAX and cleaved caspase-3, were markedly increased. Doxorubicin 18-21 BCL2 apoptosis regulator Homo sapiens 81-86 33744595-11 2021 Further mechanism study demonstrated that valtrate could increase the expression level of Bax, suppress Bcl-2 as well as c-Myc and Cyclin B1, inhibit the transcriptional activity of Stat3, while valtrate decreased the expression level of Stat3 and phosphated-Stat3 (Tyr705) and induced the high molecular aggregation of Stat3. valtrate 42-50 BCL2 apoptosis regulator Homo sapiens 104-109 33906980-12 2021 In addition, miR-34c-5p negatively correlated with Bcl-2. mir-34c-5p 13-23 BCL2 apoptosis regulator Homo sapiens 51-56 33906980-13 2021 Upregulation of Bcl-2 reversed the effects of miR-34c-5p on ALP content, calcium deposition, and the expressions of RUNX2 and OCN. Calcium 73-80 BCL2 apoptosis regulator Homo sapiens 16-21 33906980-14 2021 Conclusions: miR-34c-5p could promote osteogenic differentiation and suppress proliferation of BMSCs by inhibiting Bcl-2. mir-34c-5p 13-23 BCL2 apoptosis regulator Homo sapiens 115-120 33995088-4 2021 Surprisingly, TB significantly reduced the viabilities of HOG and U251 cells in a dose-dependent manner, which was accompanied by the upregulation of active-Casp-3, Bax, and PTEN; meanwhile, the antiapoptotic gene Bcl-2 was downregulated. theabrownin 14-16 BCL2 apoptosis regulator Homo sapiens 214-219 33929971-6 2021 Warangalone induced mitochondrial apoptosis by increasing the BAX/BCL-2 ratio. warangalone 0-11 BCL2 apoptosis regulator Homo sapiens 66-71 33962088-5 2021 Therefore, BH3-mimetic drugs are currently investigated for their suitability as BCL-2 inhibitors. BH 3 11-14 BCL2 apoptosis regulator Homo sapiens 81-86 33962088-12 2021 The study identified ZINC68728276 and ZINC14166367 as in silico potential Bcl-2 inhibitors, which can be further considered for in vitro studies. zinc68728276 21-33 BCL2 apoptosis regulator Homo sapiens 74-79 33962088-12 2021 The study identified ZINC68728276 and ZINC14166367 as in silico potential Bcl-2 inhibitors, which can be further considered for in vitro studies. ZINC14166367 38-50 BCL2 apoptosis regulator Homo sapiens 74-79 33926561-15 2021 Furthermore, Cur-EVs increased gene expression of BCL2, ACAN, SOX9, and COL2A1 and decreased gene expression of IL1B, IL6, MMP13, and COL10A1 in IL-1beta-stimulated OA-CH. cur-evs 13-20 BCL2 apoptosis regulator Homo sapiens 50-54 33996900-4 2021 Increased caspase-3 activity and decreased bcl-2 concentration upon treatment indicate that MS13 induces apoptosis in these cells in a dose- and time-dependent manner. ms13 92-96 BCL2 apoptosis regulator Homo sapiens 43-48 33926484-14 2021 Moreover, we found downregulation of CPT1a sentitized BCL-2 inhibitor ABT199 and CPT1a-selective inhibitor ST1326 combined with ABT199 had a strong synergistic effect to induce apoptosis in AML cells and primary patient blasts for the first time. venetoclax 70-76 BCL2 apoptosis regulator Homo sapiens 54-59 33926484-17 2021 CPT1a-selective inhibitor ST1326 combined with Bcl-2 inhibitor ABT199 showed strong synergistic inhibitory effects on AML. venetoclax 63-69 BCL2 apoptosis regulator Homo sapiens 47-52 33953572-0 2021 MiR-140-3p Impedes Gastric Cancer Progression and Metastasis by Regulating BCL2/BECN1-Mediated Autophagy. mir-140-3p 0-10 BCL2 apoptosis regulator Homo sapiens 75-79 33953572-9 2021 MiR-140-3p directly inhibited BCL2 expression and indirectly promoted BECN1 expression, and BCL2 inhibited BECN1 expression. mir-140-3p 0-10 BCL2 apoptosis regulator Homo sapiens 30-34 33953572-12 2021 BCL2 introduction or BECN1 silencing in GC cells partially blocked the effects of miR-140-3p. mir-140-3p 82-92 BCL2 apoptosis regulator Homo sapiens 0-4 33953572-13 2021 In conclusion, miR-140-3p directly downregulated the expression of BCL2, BCL2 downregulation further activated BECN1-dependent autophagy, and autophagy activation further inhibited EMT. mir-140-3p 15-25 BCL2 apoptosis regulator Homo sapiens 67-71 33953572-13 2021 In conclusion, miR-140-3p directly downregulated the expression of BCL2, BCL2 downregulation further activated BECN1-dependent autophagy, and autophagy activation further inhibited EMT. mir-140-3p 15-25 BCL2 apoptosis regulator Homo sapiens 73-77 33953572-14 2021 Conclusion: miR-140-3p may act as a tumor suppressor by targeting BCL2 and regulating downstream BECN1-induced autophagy and metastasis in GC progression. mir-140-3p 12-22 BCL2 apoptosis regulator Homo sapiens 66-70 33953586-16 2021 Moreover, ASIV restored apoptotic protein (Bax and Bcl-2) expression in PA-treated LO2 cells. Protactinium 72-74 BCL2 apoptosis regulator Homo sapiens 51-56 33925065-8 2021 6-Gingerol also induced G0/G1 cell cycle arrest and mitochondrial apoptosis by mediating the BAX/BCL-2 ratio and release of cytochrome c. gingerol 0-10 BCL2 apoptosis regulator Homo sapiens 97-102 33894272-8 2021 KEY FINDINGS: Upon treatment with oleuropein, the expression of P21, P53, and TNFRSF10B increased while that of Bcl-2 and Mcl1 decreased. oleuropein 34-44 BCL2 apoptosis regulator Homo sapiens 112-117 33925117-6 2021 Herein, we review the relationships shared by the cathepsin proteases and the Bcl-2 homology domain proteins, in the context of how the topical approach of adopting "BH3-mimetics" can be explored further in modulating the relationship between the anti- and pro- apoptotic signaling intermediates from the intrinsic apoptosis pathway and their upstream cathepsin protease regulators. BH 3 166-169 BCL2 apoptosis regulator Homo sapiens 78-83 33902540-0 2021 Correction to: Chemopreventive effect of Betulinic acid via mTOR -Caspases/Bcl2/Bax apoptotic signaling in pancreatic cancer. betulinic acid 41-55 BCL2 apoptosis regulator Homo sapiens 75-79 33905764-10 2021 While no changes were observed in the protein levels of apoptotic markers Bax and Bcl-2, pretreatment with 75 muM ACDT led to a 2.09-fold downregulation of ZIP14 import transporter, indicating a potential reduction in the cellular uptake of Mn as an additional neuroprotective mechanism. acdt 114-118 BCL2 apoptosis regulator Homo sapiens 82-87 33981228-10 2021 Consistent with the in vitro experiments, in nude mice exnografted with MGC 803 cells, galangin inhibited tumor growth and reversed the abnormally expressed proteins, such as p-JAK2, p-STAT3, Bcl-2, cleaved caspase-3, cleaved PARP, and Ki67. galangin 87-95 BCL2 apoptosis regulator Homo sapiens 192-197 33891785-10 2021 In addition, ICA significantly increased the expression of P47phox and iNOS, decreased p-JNK/JNK, p-P38/P38, Bax/Bcl-2, active caspase-3, and active caspase-9. icariin 13-16 BCL2 apoptosis regulator Homo sapiens 113-118 33879127-11 2021 Expression of apoptotic proteins, including Bcl-2, Bax, caspase 3 and FADD, indicated that daunorubicin potentially induced both extrinsic and intrinsic apoptosis in both CCRF-CEM and MOLT-4 cells, but only extrinsic apoptosis in SUP-B15 cells. Daunorubicin 91-103 BCL2 apoptosis regulator Homo sapiens 44-49 33880669-7 2021 Consequently, compared to TMPyP4 alone, TMPyP4 and H2O2 combined treatment upregulates the expression of BAX, cleaved caspase 3, and p-JNK and downregulates the expression of Bcl-2 in A549 and PANC cells. tetra(4-N-methylpyridyl)porphine 40-46 BCL2 apoptosis regulator Homo sapiens 175-180 33880669-7 2021 Consequently, compared to TMPyP4 alone, TMPyP4 and H2O2 combined treatment upregulates the expression of BAX, cleaved caspase 3, and p-JNK and downregulates the expression of Bcl-2 in A549 and PANC cells. Hydrogen Peroxide 51-55 BCL2 apoptosis regulator Homo sapiens 175-180 33923922-7 2021 DOX markedly increased the generation of reactive oxygen species, PARP, caspase-3, and TUNEL-positive cell numbers, but reduced the expression of Bcl-2 and antioxidants" intracellular concentrations. Doxorubicin 0-3 BCL2 apoptosis regulator Homo sapiens 146-151 34059487-1 2021 INTRODUCTION: Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in combination with either low-dose cytarabine (ARA-C) or hypomethylating agents. Cytarabine 251-261 BCL2 apoptosis regulator Homo sapiens 59-63 34059487-1 2021 INTRODUCTION: Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in combination with either low-dose cytarabine (ARA-C) or hypomethylating agents. Cytarabine 263-268 BCL2 apoptosis regulator Homo sapiens 59-63 33924053-6 2021 Furthermore, BMI-1026 downregulated Bcl-2 and X-linked inhibitor of apoptosis protein (XIAP) at the transcriptional level and Mcl-1 (L) and cellular FADD-like IL-1beta-converting enzyme inhibitory protein (c-FLIP (L)) at the post-transcriptional level. BMI 1026 13-21 BCL2 apoptosis regulator Homo sapiens 36-41 33953676-6 2021 The results showed that astragalin significantly inhibited the proliferation and diffusion of HCT116 cells by induced apoptosis (by modulation of Bax, Bcl-2, P53, caspase-3, caspase 6, caspase 7, caspase 8, caspase 9 protein express) and cell cycle arrest (by modulation of Cyclin D1, Cyclin E, P21, P27, CDK2, CDK4 protein express). astragalin 24-34 BCL2 apoptosis regulator Homo sapiens 151-156 33876201-6 2021 Interestingly, the BCL-2 specific BH3 mimetic ABT-199 and an inhibitor of ferroptosis suppressor protein 1 synergize with DMF in inducing cell death in DLBCL. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 46-49 BCL2 apoptosis regulator Homo sapiens 19-24 33876201-6 2021 Interestingly, the BCL-2 specific BH3 mimetic ABT-199 and an inhibitor of ferroptosis suppressor protein 1 synergize with DMF in inducing cell death in DLBCL. Dimethyl Fumarate 122-125 BCL2 apoptosis regulator Homo sapiens 19-24 33959188-7 2021 The results demonstrated that quercetin, ephedrine, trigonelline, crocetin, and beta-sitosterol were major effective compounds of LPD responsible for the CG treatment by inhibiting the activation of the JAK 2-STAT 3 signaling pathway to reduce the expressions of cyclin D1 and Bcl-2 proteins. Quercetin 30-39 BCL2 apoptosis regulator Homo sapiens 277-282 33959188-7 2021 The results demonstrated that quercetin, ephedrine, trigonelline, crocetin, and beta-sitosterol were major effective compounds of LPD responsible for the CG treatment by inhibiting the activation of the JAK 2-STAT 3 signaling pathway to reduce the expressions of cyclin D1 and Bcl-2 proteins. crocetin 66-74 BCL2 apoptosis regulator Homo sapiens 277-282 33872672-5 2021 Increased ROS levels can regulate autophagy through several different pathways, such as activation of the AMPK signalling cascade and ULK1 complex, Atg4 oxidation, disruption of the Bcl-2/Beclin-1 interaction, and alteration of mitochondrial homeostasis leading to mitophagy. Reactive Oxygen Species 10-13 BCL2 apoptosis regulator Homo sapiens 182-187 33959188-7 2021 The results demonstrated that quercetin, ephedrine, trigonelline, crocetin, and beta-sitosterol were major effective compounds of LPD responsible for the CG treatment by inhibiting the activation of the JAK 2-STAT 3 signaling pathway to reduce the expressions of cyclin D1 and Bcl-2 proteins. Ephedrine 41-50 BCL2 apoptosis regulator Homo sapiens 277-282 33959188-7 2021 The results demonstrated that quercetin, ephedrine, trigonelline, crocetin, and beta-sitosterol were major effective compounds of LPD responsible for the CG treatment by inhibiting the activation of the JAK 2-STAT 3 signaling pathway to reduce the expressions of cyclin D1 and Bcl-2 proteins. gamma-sitosterol 80-95 BCL2 apoptosis regulator Homo sapiens 277-282 33959188-7 2021 The results demonstrated that quercetin, ephedrine, trigonelline, crocetin, and beta-sitosterol were major effective compounds of LPD responsible for the CG treatment by inhibiting the activation of the JAK 2-STAT 3 signaling pathway to reduce the expressions of cyclin D1 and Bcl-2 proteins. trigonelline 52-64 BCL2 apoptosis regulator Homo sapiens 277-282 33923467-6 2021 Furthermore, BRAs and cyanidin-3-O-rutinoside exhibited cytotoxic effects on t-HSC/Cl-6, HepG2, and Hep3B and induced the apoptosis of HepG2 cells; downregulated the protein expression level of Bcl-2; upregulated the level of Bax; and promoted the release of cytochrome C, cleaved caspase-9, cleaved caspase-3, and cleaved PARP in HepG2 cells. bras 13-17 BCL2 apoptosis regulator Homo sapiens 194-199 33860917-6 2021 Daphnetin restores cellular redox balance by upregulating the antioxidants level (GSH and SOD), anti-apoptotic protein (Bcl-2), as well as by reducing the levels of proinflammatory cytokines, executioner caspase-3, pro-apoptotic-Bax, and oxidative stress markers. daphnetin 0-9 BCL2 apoptosis regulator Homo sapiens 120-125 33923467-6 2021 Furthermore, BRAs and cyanidin-3-O-rutinoside exhibited cytotoxic effects on t-HSC/Cl-6, HepG2, and Hep3B and induced the apoptosis of HepG2 cells; downregulated the protein expression level of Bcl-2; upregulated the level of Bax; and promoted the release of cytochrome C, cleaved caspase-9, cleaved caspase-3, and cleaved PARP in HepG2 cells. cyanidin 3-rutinoside 22-45 BCL2 apoptosis regulator Homo sapiens 194-199 33853293-6 2022 Pevonedistat (PEV), a novel agent that inhibits NEDD8-activating enzyme, and AZA both upregulate NOXA (PMAIP1), a BCL2 family protein that competes with effector molecules at the BH3 binding site of MCL1. BH 3 179-182 BCL2 apoptosis regulator Homo sapiens 114-118 33601175-6 2021 MiR-497-5p was further observed to attenuate silica-induced pulmonary fibrosis by targeting Smad3 and Bcl2. Silicon Dioxide 45-51 BCL2 apoptosis regulator Homo sapiens 102-106 33542074-0 2021 Emergence of Enzalutamide resistance in prostate cancer is associated with BCL-2 and IKKB dependencies. enzalutamide 13-25 BCL2 apoptosis regulator Homo sapiens 75-80 33542074-6 2021 RESULTS: ABT199 (BCL-2 inhibitor) and IMD0354 (IKKB inhibitor), were identified as potent and selective inhibitors of cell viability in ENZ-resistant cell lines in vitro and in vivo which were further validated using loss-of-function assays of BCL-2 and IKKB. venetoclax 9-15 BCL2 apoptosis regulator Homo sapiens 17-22 33542074-6 2021 RESULTS: ABT199 (BCL-2 inhibitor) and IMD0354 (IKKB inhibitor), were identified as potent and selective inhibitors of cell viability in ENZ-resistant cell lines in vitro and in vivo which were further validated using loss-of-function assays of BCL-2 and IKKB. venetoclax 9-15 BCL2 apoptosis regulator Homo sapiens 244-249 33542074-6 2021 RESULTS: ABT199 (BCL-2 inhibitor) and IMD0354 (IKKB inhibitor), were identified as potent and selective inhibitors of cell viability in ENZ-resistant cell lines in vitro and in vivo which were further validated using loss-of-function assays of BCL-2 and IKKB. N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide 38-45 BCL2 apoptosis regulator Homo sapiens 244-249 33542074-7 2021 Notably, we observed that overexpression of BCL-2 and IKKB in ENZ-sensitive cell lines was sufficient for the emergence of ENZ resistance. enzalutamide 62-65 BCL2 apoptosis regulator Homo sapiens 44-49 33853293-3 2022 The selective BCL2 inhibitor, venetoclax (VEN) is used in combination with azacitidine (AZA), a DNA-methyltransferase inhibitor (DNMTi), to treat patients with AML. venetoclax 30-40 BCL2 apoptosis regulator Homo sapiens 14-18 33853293-6 2022 Pevonedistat (PEV), a novel agent that inhibits NEDD8-activating enzyme, and AZA both upregulate NOXA (PMAIP1), a BCL2 family protein that competes with effector molecules at the BH3 binding site of MCL1. pevonedistat 0-12 BCL2 apoptosis regulator Homo sapiens 114-118 33921050-6 2021 Subsequently, there was an increase in the expression of pro-apoptotic protein Bax in a dose-dependent manner, with the corresponding downregulation of Bcl-2 expression and cytochrome C expression following 24 h DA treatment in A375.SM and B16F10 cells. decursin 212-214 BCL2 apoptosis regulator Homo sapiens 152-157 33853293-6 2022 Pevonedistat (PEV), a novel agent that inhibits NEDD8-activating enzyme, and AZA both upregulate NOXA (PMAIP1), a BCL2 family protein that competes with effector molecules at the BH3 binding site of MCL1. pevonedistat 14-17 BCL2 apoptosis regulator Homo sapiens 114-118 33849427-6 2021 Evr also promoted apoptosis by upregulating the pro-apoptotic proteins Bax and cytochrome-c and downregulating the anti-apoptotic protein Bcl-2. Everolimus 0-3 BCL2 apoptosis regulator Homo sapiens 138-143 33853293-6 2022 Pevonedistat (PEV), a novel agent that inhibits NEDD8-activating enzyme, and AZA both upregulate NOXA (PMAIP1), a BCL2 family protein that competes with effector molecules at the BH3 binding site of MCL1. Azacitidine 77-80 BCL2 apoptosis regulator Homo sapiens 114-118 33919958-4 2021 The Bcl-2 inhibitor venetoclax, in combination with hypomethylating agents or low dose cytarabine, has produced impressive results for newly diagnosed AML, while its role in R/R disease is not well defined yet. venetoclax 20-30 BCL2 apoptosis regulator Homo sapiens 4-9 33919958-4 2021 The Bcl-2 inhibitor venetoclax, in combination with hypomethylating agents or low dose cytarabine, has produced impressive results for newly diagnosed AML, while its role in R/R disease is not well defined yet. hypomethylating agents 52-74 BCL2 apoptosis regulator Homo sapiens 4-9 33919958-4 2021 The Bcl-2 inhibitor venetoclax, in combination with hypomethylating agents or low dose cytarabine, has produced impressive results for newly diagnosed AML, while its role in R/R disease is not well defined yet. Cytarabine 87-97 BCL2 apoptosis regulator Homo sapiens 4-9 33937399-16 2021 Gastrin promotes the production of ROS from mitochondria, activates NF-kappaB, and inhibits apoptosis via modulating the expression level of Bcl-2 and Bax. ros 35-38 BCL2 apoptosis regulator Homo sapiens 141-146 33919990-7 2021 Quercetin downregulated the protein expressions of Bax, cleaved caspase-3, and cleaved PARP and upregulated the expression of Bcl-2 through reduced PI3K and pAKT expressions. Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 126-131 33830207-2 2021 The major clinical challenge with targeted therapeutics, such as the BCL-2 inhibitor ABT-199, is the development of acquired resistance. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 85-88 BCL2 apoptosis regulator Homo sapiens 69-74 33830207-8 2021 Notably, this phenotype of reduced BCL-2 dependence could be recapitulated by using human splenic fibroblast coculture experiments and was confirmed in an in vitro chronic ABT-199 resistance model of LOUCY. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 172-175 BCL2 apoptosis regulator Homo sapiens 35-40 33850004-11 2021 This study demonstrates that idasanutlin can overcome resistance to the BCL-2 inhibitor venetoclax in preclinical neuroblastoma model systems, which supports clinical development of a treatment strategy combining the two therapies. RG7388 29-40 BCL2 apoptosis regulator Homo sapiens 72-77 33912037-8 2021 Moreover, 3"-SL significantly inhibited the apoptotic process, as indicated by the downregulation of the pro-apoptotic protein Bax, upregulation of the anti-apoptotic protein Bcl-2 expression, and significant reduction in the number of TUNEL-positive cells in the IL-1beta-treated chondrocytic cells. 3'-sialyllactose 10-15 BCL2 apoptosis regulator Homo sapiens 175-180 33912040-12 2021 In vitro experiments suggested that the mechanism may involve hesperidin and naringenin acting on CASP3, BAX, and BCL2 to affect the apoptosis pathway, attenuating liver fibrosis. Hesperidin 62-72 BCL2 apoptosis regulator Homo sapiens 114-118 33912040-12 2021 In vitro experiments suggested that the mechanism may involve hesperidin and naringenin acting on CASP3, BAX, and BCL2 to affect the apoptosis pathway, attenuating liver fibrosis. naringenin 77-87 BCL2 apoptosis regulator Homo sapiens 114-118 33828027-0 2021 microRNA-221 upregulates the expression of P-gp and Bcl-2 by activating the Stat3 pathway to promote doxorubicin resistance in osteosarcoma cells. Doxorubicin 101-112 BCL2 apoptosis regulator Homo sapiens 52-57 33838689-13 2021 Moreover, downregulation of SOD, NO, BCL2, and GAPDH, and upregulation of VEGFA, ET1, and PARP1 were discovered after cells were exposed to 0.5 mM H2O2 in this study, which could be improved by PARP1 inhibitor and SDMM capsule in a dose-dependent way, whereas worsened by PARP1 activation and GAPDH inhibitor. Hydrogen Peroxide 147-151 BCL2 apoptosis regulator Homo sapiens 37-41 33836050-5 2022 Lupeol could also inhibit proliferation and induce apoptosis of RB cells, with increased Bax level and decreased Ki67, survivin and Bcl-2 levels. lupeol 0-6 BCL2 apoptosis regulator Homo sapiens 132-137 33828027-12 2021 Pretreatment with the Stat3 chemical inhibitor, STAT3-IN-3, significantly inhibited the upregulation of P-gp and Bcl-2 protein expression induced by the miRNA-221 mimic in Saos-2 cells; it also caused the Saos-2 cells to overcome DOX resistance induced by the miRNA-221 mimic. Doxorubicin 230-233 BCL2 apoptosis regulator Homo sapiens 113-118 33828027-13 2021 Thus, miRNA-221 increased the expression of P-gp and Bcl-2 by activating the Stat3 pathway to promote DOX resistance in osteosarcoma cells, indicating a potential use of miRNA-221 in osteosarcoma treatment. Doxorubicin 102-105 BCL2 apoptosis regulator Homo sapiens 53-58 33917026-2 2021 BH3 mimetics, which target anti-apoptotic BCL-2 family members, have shown potential in the treatment of hematological malignancies and offer promise for the treatment of solid tumors as well. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 42-47 33831998-12 2021 Bcl-2 staining limited to the outermost layer of the proliferation is more likely to be found in TB. Terbium 97-99 BCL2 apoptosis regulator Homo sapiens 0-5 33880372-6 2021 Compared with 200 mumol/L PFOS treatment, NAC pretreatment reversed the increase in ROS, Bax, and cleaved-caspase-3 protein caused by PFOS, lowered the apoptosis rate increased by PFOS, and increased the levels of MMP and Bcl-2/Bax ratio decreased by PFOS. Acetylcysteine 42-45 BCL2 apoptosis regulator Homo sapiens 222-227 33823789-13 2021 In addition, dexmedetomidine reduced the expression of Bcl2 and BAX in cocultured cardiomyocytes by suppressing H/R-induced NLRP3 inflammasome activation in cardiac fibroblasts. Dexmedetomidine 13-28 BCL2 apoptosis regulator Homo sapiens 55-59 33880372-4 2021 Compared with the control, 200 mumol/L PFOS increased ROS levels; enhanced the expression of Bax, cleaved-caspase-3, and LC3-II; induced autophagy; decreased MMP; and lowered Bcl-2, p62, and Bcl-2/Bax ratio. perfluorooctane sulfonic acid 39-43 BCL2 apoptosis regulator Homo sapiens 175-180 33880372-7 2021 The autophagy inhibitor 3-methyladenine and chloroquine decreased apoptosis and cleaved-caspase-3 protein level and increased the Bcl-2/Bax ratio. 3-methyladenine 24-39 BCL2 apoptosis regulator Homo sapiens 130-135 33880372-4 2021 Compared with the control, 200 mumol/L PFOS increased ROS levels; enhanced the expression of Bax, cleaved-caspase-3, and LC3-II; induced autophagy; decreased MMP; and lowered Bcl-2, p62, and Bcl-2/Bax ratio. perfluorooctane sulfonic acid 39-43 BCL2 apoptosis regulator Homo sapiens 191-196 33880372-7 2021 The autophagy inhibitor 3-methyladenine and chloroquine decreased apoptosis and cleaved-caspase-3 protein level and increased the Bcl-2/Bax ratio. Chloroquine 44-55 BCL2 apoptosis regulator Homo sapiens 130-135 33368455-0 2021 Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. venetoclax 21-31 BCL2 apoptosis regulator Homo sapiens 10-15 33927966-8 2021 Folate receptor targeted MTX-GNPs showed significant cellular uptake in breast cancer cells along with significant down-regulation in expression of anti-apoptotic gene (Bcl-2) and up-regulation in expression of pro-apoptotic genes (Bax, Caspase-3, Caspase-9, APAF-1, p53). Methotrexate 25-28 BCL2 apoptosis regulator Homo sapiens 169-174 33918511-0 2021 Bcl-2 Family of Proteins in the Control of Mitochondrial Calcium Signalling: An Old Chap with New Roles. Calcium 57-64 BCL2 apoptosis regulator Homo sapiens 0-5 33918511-3 2021 However, in recent years Bcl-2 family members began to emerge as a new class of intracellular calcium (Ca2+) regulators. Calcium 94-101 BCL2 apoptosis regulator Homo sapiens 25-30 33504737-6 2021 Furthermore, candidone was shown to promote cell death by activating caspase-3 and -9, and decreasing the expression of antiapoptotic proteins, including p65, induced myeloid leukemia cell differentiation protein Mcl-1, B-cell lymphoma 2 (Bcl2), Bcl2-associated agonist of cell death and survivin. candidone 13-22 BCL2 apoptosis regulator Homo sapiens 220-237 33549704-0 2021 Cancer cell death strategies by targeting Bcl-2"s BH4 domain. sapropterin 50-53 BCL2 apoptosis regulator Homo sapiens 42-47 33549704-4 2021 This resulted in the development of venetoclax, a Bcl-2 antagonist that acts as a BH3 mimetic. BH 3 82-85 BCL2 apoptosis regulator Homo sapiens 50-55 33504737-6 2021 Furthermore, candidone was shown to promote cell death by activating caspase-3 and -9, and decreasing the expression of antiapoptotic proteins, including p65, induced myeloid leukemia cell differentiation protein Mcl-1, B-cell lymphoma 2 (Bcl2), Bcl2-associated agonist of cell death and survivin. candidone 13-22 BCL2 apoptosis regulator Homo sapiens 239-243 33549704-6 2021 Here, we discuss the role of Bcl-2 as a decision-maker in cell death with focus on the recent advances in anti-cancer therapeutics that target the BH4 domain of Bcl-2, thereby interfering with non-canonical functions of Bcl-2 in Ca2+-signaling modulation. sapropterin 147-150 BCL2 apoptosis regulator Homo sapiens 161-166 33549704-6 2021 Here, we discuss the role of Bcl-2 as a decision-maker in cell death with focus on the recent advances in anti-cancer therapeutics that target the BH4 domain of Bcl-2, thereby interfering with non-canonical functions of Bcl-2 in Ca2+-signaling modulation. sapropterin 147-150 BCL2 apoptosis regulator Homo sapiens 161-166 33504737-6 2021 Furthermore, candidone was shown to promote cell death by activating caspase-3 and -9, and decreasing the expression of antiapoptotic proteins, including p65, induced myeloid leukemia cell differentiation protein Mcl-1, B-cell lymphoma 2 (Bcl2), Bcl2-associated agonist of cell death and survivin. candidone 13-22 BCL2 apoptosis regulator Homo sapiens 246-250 33549704-8 2021 In addition, we present a preliminary analysis of two recently identified molecules that emerged from a molecular modelling approach to target Bcl-2"s BH4 domain, which however failed to induce cell death in two Bcl-2-dependent diffuse large B-cell lymphoma cell models. sapropterin 151-154 BCL2 apoptosis regulator Homo sapiens 143-148 33549704-9 2021 Overall, antagonizing the non-canonical functions of Bcl-2 by interfering with its BH4-domain biology holds promise to elicit cell death in cancer, though improved tools and on-target antagonizing small molecules remain necessary and to be designed. sapropterin 83-86 BCL2 apoptosis regulator Homo sapiens 53-58 33112006-7 2021 Apoptosis was induced by bergenin in bladder cancer cells, as evidenced by increased Bax and cleaved caspase 3 protein levels and decreased Bcl-2 level in bergenin-treated cells. bergenin 155-163 BCL2 apoptosis regulator Homo sapiens 140-145 33927479-9 2021 Western blot analysis showed that compared with propofol group, the expression of Bcl-2 was significantly increased whereas Bax and the ratio of Cleaved caspase3/caspase3 were significantly decreased in pcDNA-HOST2 group. Propofol 48-56 BCL2 apoptosis regulator Homo sapiens 82-87 33692842-7 2021 Furthermore, the expression level of caspase-3 and -9 significantly increased following wogonoside treatment compared with that in non-treated cells, and the protein expression levels of proapoptotic Bax and antiapoptotic Bcl-2 increased and decreased, respectively compared with that in the control group. wogonoside 88-98 BCL2 apoptosis regulator Homo sapiens 222-227 33687436-4 2021 In this study, we induced a mitochondrial damage model in oocytes with the Bcl-2-specific antagonist ABT-199. venetoclax 101-108 BCL2 apoptosis regulator Homo sapiens 75-80 33652105-9 2021 Further, another experiment was used to show that miR-16-5p and miR-92a-2-5p regulated the Bcl2-induced apoptotic effect of Cd on GCs by the Human ovarian GC tumor line (COV434 cell line) miRNA-knockdown model Overall, the results indicate that prenatal Cd exposure has epigenetic transgenerational effect on GCs, Moreover, the underlying mechanism may involve interference with miR-16-5p and miR-92a-2-5p-mediated regulation of Bcl2 genes in offspring. mir-16-5p 50-59 BCL2 apoptosis regulator Homo sapiens 91-95 33652105-9 2021 Further, another experiment was used to show that miR-16-5p and miR-92a-2-5p regulated the Bcl2-induced apoptotic effect of Cd on GCs by the Human ovarian GC tumor line (COV434 cell line) miRNA-knockdown model Overall, the results indicate that prenatal Cd exposure has epigenetic transgenerational effect on GCs, Moreover, the underlying mechanism may involve interference with miR-16-5p and miR-92a-2-5p-mediated regulation of Bcl2 genes in offspring. Cadmium 124-126 BCL2 apoptosis regulator Homo sapiens 91-95 33652105-9 2021 Further, another experiment was used to show that miR-16-5p and miR-92a-2-5p regulated the Bcl2-induced apoptotic effect of Cd on GCs by the Human ovarian GC tumor line (COV434 cell line) miRNA-knockdown model Overall, the results indicate that prenatal Cd exposure has epigenetic transgenerational effect on GCs, Moreover, the underlying mechanism may involve interference with miR-16-5p and miR-92a-2-5p-mediated regulation of Bcl2 genes in offspring. Cadmium 124-126 BCL2 apoptosis regulator Homo sapiens 429-433 33652105-9 2021 Further, another experiment was used to show that miR-16-5p and miR-92a-2-5p regulated the Bcl2-induced apoptotic effect of Cd on GCs by the Human ovarian GC tumor line (COV434 cell line) miRNA-knockdown model Overall, the results indicate that prenatal Cd exposure has epigenetic transgenerational effect on GCs, Moreover, the underlying mechanism may involve interference with miR-16-5p and miR-92a-2-5p-mediated regulation of Bcl2 genes in offspring. Cadmium 254-256 BCL2 apoptosis regulator Homo sapiens 91-95 33652105-9 2021 Further, another experiment was used to show that miR-16-5p and miR-92a-2-5p regulated the Bcl2-induced apoptotic effect of Cd on GCs by the Human ovarian GC tumor line (COV434 cell line) miRNA-knockdown model Overall, the results indicate that prenatal Cd exposure has epigenetic transgenerational effect on GCs, Moreover, the underlying mechanism may involve interference with miR-16-5p and miR-92a-2-5p-mediated regulation of Bcl2 genes in offspring. mir-16-5p 379-388 BCL2 apoptosis regulator Homo sapiens 91-95 33851623-0 2021 Xanthoceraside induces cell apoptosis through downregulation of the PI3K/Akt/Bcl-2/Bax signaling pathway in cell lines of human bladder cancer. xanthoceraside 0-14 BCL2 apoptosis regulator Homo sapiens 77-82 33851623-11 2021 According to further analysis, xanthoceraside induced apoptosis by upregulating Bax and downregulating the expression of Bcl-xL and Bcl-2. xanthoceraside 31-45 BCL2 apoptosis regulator Homo sapiens 132-137 33851623-14 2021 Conclusions: Xanthoceraside induces cell apoptosis through downregulation of the PI3K/Akt/Bcl-2/Bax signaling pathway in cell lines of human bladder cancer. xanthoceraside 13-27 BCL2 apoptosis regulator Homo sapiens 90-95 33732309-8 2021 The results also demonstrated that silencing of CAV3 blocked the beneficial effects of miR-22 inhibitor against DEX-induced cell damage and apoptosis in osteoblasts, as evidenced by the increased expression levels of cleaved caspase-3, Bax and alkaline phosphatase activity as well as decreased cell viability and Bcl-2 levels. Dexamethasone 112-115 BCL2 apoptosis regulator Homo sapiens 314-319 33869050-14 2021 The expression profiles of pAkt, Bcl-2, and Bax were reversed by perifosine treatment. perifosine 65-75 BCL2 apoptosis regulator Homo sapiens 33-38 33393728-4 2021 Increased levels of proapoptotic Bax, Caspase-3, Caspase-9, and cleaved-caspase 3, as well as a decreased level of antiapoptotic Bcl-2 induced by fluoride in human neuroblastoma SH-SY5Y cells, these effects were prevented by pretreatment of mangiferin. Fluorides 146-154 BCL2 apoptosis regulator Homo sapiens 129-134 33421271-8 2021 Furthermore, its cleaved caspase-3, 8, and 9 and Bax gene expression was augmented and Bcl-2 gene expression was diminished after Eu-Pi/PHB-PEG-NC treatment. Polyethylene Glycols 140-143 BCL2 apoptosis regulator Homo sapiens 87-92 33576443-0 2021 Procyanidin B2 inhibits lipopolysaccharide-induced apoptosis by suppressing the Bcl-2/Bax and NF-kappaB signalling pathways in human umbilical vein endothelial cells. procyanidin B2 0-14 BCL2 apoptosis regulator Homo sapiens 80-85 33732382-10 2021 Western blotting results also revealed the upregulation of p53 acetylation and p21, as well as the downregulation of Bcl-2 and cyclin D1 in cells treated with cambinol. cambinol 159-167 BCL2 apoptosis regulator Homo sapiens 117-122 33609644-10 2021 Findings of MTT assay showed that concentrations 85 mug/mL to 100 mug/mL of fertile HCF have the highest mortality (50%-52%) on A375 cells during 24 h. The fold change of Bax/Bcl-2 ratio, Caspase-9, miR-365 and Caspase-3 activity was higher in the fertile HCF-treated melanoma cells compared to infertile fluid treated A375 cells and human normal epithelial cell (as control cell). monooxyethylene trimethylolpropane tristearate 12-15 BCL2 apoptosis regulator Homo sapiens 175-180 31359788-5 2021 The results showed that sacroflavonoside could significantly induce MKN-45 cells apoptosis and autophagy by increasing the expression of Bax, Caspase-3, Beclin1 and LC3-II proteins and decreasing the expression of Bcl-2 protein at low micromole level. sacroflavonoside 24-40 BCL2 apoptosis regulator Homo sapiens 214-219 33295061-4 2021 RESULTS: In vivo, nicotiflorin administration exerted protective effects on renal injury, as demonstrated by reductions in the levels of caspase3 and Bad (p<0.05), the upregulation of Bcl-2 expression (p<0.05) and improved renal histologic changes, which suggested that nicotiflorin can alleviate I/R injury and cell apoptosis. nicotiflorin 18-30 BCL2 apoptosis regulator Homo sapiens 184-189 33649826-7 2021 It was also demonstrated that curcumin regulated the cell cycle- and apoptosis-related proteins (cyclin D1, p21, Bcl2, cleaved-caspase-3 and cleaved-PARP), leading to cell cycle arrest and apoptosis in both ML-2 and OCI-AML5 cells. Curcumin 30-38 BCL2 apoptosis regulator Homo sapiens 113-117 33174291-0 2021 Apoptotic effect of berberine via Bcl-2, ROR1, and mir-21 in patients with B-chronic lymphocytic leukemia. Berberine 20-29 BCL2 apoptosis regulator Homo sapiens 34-39 33677703-9 2021 We also found that cleavages of caspase-7 and PARP by releasing mitochondrial cytochrome c into the cytoplasm were induced by ATG treatment for 72 h through the reduction of Bcl-2 and Bcl-xL levels in mitochondria. arctigenin 126-129 BCL2 apoptosis regulator Homo sapiens 174-179 33174291-9 2021 Examination of treated cells demonstrated that berberine decreased Bcl-2 and ROR1 levels. Berberine 47-56 BCL2 apoptosis regulator Homo sapiens 67-72 33174291-10 2021 Although western blot results did not show any change in Bax as a pro-apoptotic protein, an increased Bax/Bcl-2 ratio indicated that mitochondrial pathway is involved in berberine-induced apoptosis of CLL cells. Berberine 170-179 BCL2 apoptosis regulator Homo sapiens 106-111 33174291-12 2021 Our findings describe some of the molecular mechanisms of berberine by decreasing Bcl-2, ROR1, and mir-21 which may be considered as a novel apoptosis inducer in CLL cells. Berberine 58-67 BCL2 apoptosis regulator Homo sapiens 82-87 33785871-1 2021 High levels of the anti-apoptotic BCL-2 family member MCL-1 are frequently found in breast cancer and, appropriately, BH3-mimetic drugs that specifically target MCL-1"s function in apoptosis are in development as anti-cancer therapy. BH 3 118-121 BCL2 apoptosis regulator Homo sapiens 34-39 33786580-4 2021 KDM5-inhibition reactivated both KMT2D-dependent and -independent genes, resulting in diminished B-cell signalling and altered expression of BCL2 family members, including BCL2 itself. kdm5 0-4 BCL2 apoptosis regulator Homo sapiens 141-145 33868396-5 2021 GE11-CUR/ICG-LPs synergized photochemotherapy could induce reactive oxygen species (ROS) generation and cytoskeleton disruption to activate stronger apoptotic signaling events than the photothermal therapy or chemotherapy alone by regulating Bax/Bcl-2 and PI3K/AKT pathways. lps 13-16 BCL2 apoptosis regulator Homo sapiens 246-251 33786580-4 2021 KDM5-inhibition reactivated both KMT2D-dependent and -independent genes, resulting in diminished B-cell signalling and altered expression of BCL2 family members, including BCL2 itself. kdm5 0-4 BCL2 apoptosis regulator Homo sapiens 172-176 33785651-2 2021 Reflecting the large and hydrophobic BH3-binding groove within BCL-2, venetoclax has significantly higher molecular weight and lipophilicity than most orally administered drugs, along with negligible water solubility. BH 3 37-40 BCL2 apoptosis regulator Homo sapiens 63-68 33884179-10 2021 Although nicotine at concentrations up to 10 muM did not cause cell death, treatment of HCAEC with 10 nM nicotine in the presence of 13.8 mM dextrose aggravated ER stress, increased cell death, increased cleaved caspase 3 and BID, and decreased BCL2. Nicotine 105-113 BCL2 apoptosis regulator Homo sapiens 245-249 33833662-13 2021 Moreover, AS-IV decreased apoptosis rate and Bax/Bcl-2 ratio induced by 6-OHDA (all p < 0.05). Oxidopamine 72-78 BCL2 apoptosis regulator Homo sapiens 49-54 33752282-8 2021 The cell growth and Bcl-2 expression level suppressed under hypoxia were reversed with a decrease of the induced Hif-1alpha and Cav-1 levels after AMPK activation with metformin (1 mM) or phenformin (0.1 microM). Metformin 168-177 BCL2 apoptosis regulator Homo sapiens 20-25 33752282-8 2021 The cell growth and Bcl-2 expression level suppressed under hypoxia were reversed with a decrease of the induced Hif-1alpha and Cav-1 levels after AMPK activation with metformin (1 mM) or phenformin (0.1 microM). Phenformin 188-198 BCL2 apoptosis regulator Homo sapiens 20-25 33884179-10 2021 Although nicotine at concentrations up to 10 muM did not cause cell death, treatment of HCAEC with 10 nM nicotine in the presence of 13.8 mM dextrose aggravated ER stress, increased cell death, increased cleaved caspase 3 and BID, and decreased BCL2. Glucose 141-149 BCL2 apoptosis regulator Homo sapiens 245-249 33743079-4 2021 In general, we currently utilize a backbone regimen of a hypomethylating agent (HMA) or low-intensity chemotherapy with the BCL-2 inhibitor venetoclax for the majority of elderly patients with newly diagnosed AML. venetoclax 140-150 BCL2 apoptosis regulator Homo sapiens 124-129 33741716-0 2021 Dasatinib stimulates its own mechanism of resistance by activating a CRTC3/MITF/Bcl-2 pathway in melanoma with mutant or amplified c-Kit. Dasatinib 0-9 BCL2 apoptosis regulator Homo sapiens 80-85 33741716-9 2021 In conclusion, we showed for the first time that, dasatinib in melanoma stimulate its proper mechanism of resistance, independently of MAPK and PI3K/AKT pathway reactivation commonly associated to secondary c-Kit mutations, but through CRTC3/MITF/Bcl-2 pathway activation at clinically relevant doses which may explain the weak clinical benefit of dasatinib in melanoma patients. Dasatinib 50-59 BCL2 apoptosis regulator Homo sapiens 247-252 33741716-6 2021 More importantly, dasatinib up-regulates MITF and Bcl-2 through SIK2 inhibition revealed by CRTC3 reduced phosphorylation, CREB transcription activation of MITF, MITF transcription activation of Bcl-2 as well as pigmentation. Dasatinib 18-27 BCL2 apoptosis regulator Homo sapiens 50-55 33741716-10 2021 Implications: Dasatinib stimulates its proper mechanism of resistance through CRTC3/MITF/Bcl-2 pathway which may explain its modest clinical efficiency in melanoma patients. Dasatinib 14-23 BCL2 apoptosis regulator Homo sapiens 89-94 33741716-6 2021 More importantly, dasatinib up-regulates MITF and Bcl-2 through SIK2 inhibition revealed by CRTC3 reduced phosphorylation, CREB transcription activation of MITF, MITF transcription activation of Bcl-2 as well as pigmentation. Dasatinib 18-27 BCL2 apoptosis regulator Homo sapiens 195-200 33741716-8 2021 Selective Bcl-2 inhibition by ABT-199 or Bcl-2 knock out restores the sensitivity of melanoma cells to dasatinib, validating the involvement of MITF and Bcl-2 axis in the resistance of melanoma to dasatinib. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 30-33 BCL2 apoptosis regulator Homo sapiens 10-15 33741716-8 2021 Selective Bcl-2 inhibition by ABT-199 or Bcl-2 knock out restores the sensitivity of melanoma cells to dasatinib, validating the involvement of MITF and Bcl-2 axis in the resistance of melanoma to dasatinib. Dasatinib 103-112 BCL2 apoptosis regulator Homo sapiens 10-15 33741716-8 2021 Selective Bcl-2 inhibition by ABT-199 or Bcl-2 knock out restores the sensitivity of melanoma cells to dasatinib, validating the involvement of MITF and Bcl-2 axis in the resistance of melanoma to dasatinib. Dasatinib 103-112 BCL2 apoptosis regulator Homo sapiens 41-46 33741716-8 2021 Selective Bcl-2 inhibition by ABT-199 or Bcl-2 knock out restores the sensitivity of melanoma cells to dasatinib, validating the involvement of MITF and Bcl-2 axis in the resistance of melanoma to dasatinib. Dasatinib 103-112 BCL2 apoptosis regulator Homo sapiens 41-46 33741716-8 2021 Selective Bcl-2 inhibition by ABT-199 or Bcl-2 knock out restores the sensitivity of melanoma cells to dasatinib, validating the involvement of MITF and Bcl-2 axis in the resistance of melanoma to dasatinib. Dasatinib 197-206 BCL2 apoptosis regulator Homo sapiens 10-15 33376097-15 2021 Further study of BCL-2/BCL-xL inhibition to enhance osimertinib activity is warranted. osimertinib 52-63 BCL2 apoptosis regulator Homo sapiens 17-22 33551436-0 2021 DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction. da-epoch-r 0-10 BCL2 apoptosis regulator Homo sapiens 63-67 33465425-7 2021 Western blotting assay indicated that brusatol pronouncedly suppressed the expression levels of mitochondrial apoptotic pathway-associated proteins Bcl-2 and Bcl-xl, accentuated the expression of Bax and Bak, and upregulated the protein expression of XIAP, cleaved caspase-3/pro caspase-3, cleaved caspase-8/pro caspase-8, and cleaved PARP/total PARP. brusatol 38-46 BCL2 apoptosis regulator Homo sapiens 148-153 33719846-12 2021 Baicalin enhanced the effect of cisplatin on promoting apoptosis, arresting cell on S stage and triggering DNA damage accompanied with the upregulation of Bcl-2-associated X protein (Bax) and downregulation of B-cell lymphoma 2 (Bcl-2) and Cyclin D1 in A549/DPP cells. baicalin 0-8 BCL2 apoptosis regulator Homo sapiens 210-227 33719846-12 2021 Baicalin enhanced the effect of cisplatin on promoting apoptosis, arresting cell on S stage and triggering DNA damage accompanied with the upregulation of Bcl-2-associated X protein (Bax) and downregulation of B-cell lymphoma 2 (Bcl-2) and Cyclin D1 in A549/DPP cells. baicalin 0-8 BCL2 apoptosis regulator Homo sapiens 155-160 33719846-12 2021 Baicalin enhanced the effect of cisplatin on promoting apoptosis, arresting cell on S stage and triggering DNA damage accompanied with the upregulation of Bcl-2-associated X protein (Bax) and downregulation of B-cell lymphoma 2 (Bcl-2) and Cyclin D1 in A549/DPP cells. Cisplatin 32-41 BCL2 apoptosis regulator Homo sapiens 210-227 33706615-0 2021 Synthetic pyrethroids common metabolite 3-phenoxybenzoic acid induces caspase-3 and Bcl-2 mediated apoptosis in human hepatocyte cells. Pyrethrins 10-21 BCL2 apoptosis regulator Homo sapiens 84-89 33709108-6 2021 Signal transduction analysis indicated that melatonin targeted the mitochondrial apoptotic Bax/Bcl2 pathway and thus suppressed Leydig cell apoptosis. Melatonin 44-53 BCL2 apoptosis regulator Homo sapiens 95-99 33706615-0 2021 Synthetic pyrethroids common metabolite 3-phenoxybenzoic acid induces caspase-3 and Bcl-2 mediated apoptosis in human hepatocyte cells. 3-phenoxybenzoic acid 40-61 BCL2 apoptosis regulator Homo sapiens 84-89 33707419-7 2021 Sub-toxic doses of Bcl2 inhibitor or Shh inhibitor (<= 5 mumol/l, the expression of Bcl-2 and Bax was down-regulated and the expression of p38 and Caspase-3 was up-regulated. Arsenic 31-38 BCL2 apoptosis regulator Homo sapiens 84-89 32621277-10 2021 When arsenic exposure was < 5 mumol/l, the expression of Bcl-2, Bax, p38 and Caspase-3 was up-regulated. Arsenic 5-12 BCL2 apoptosis regulator Homo sapiens 57-62 33484789-5 2021 In addition, E2 and Fen treatment resulted in elevated levels of the survival-related proteins (Survivin and PCNA), and inhibited apoptosis by increasing the mitochondrial membrane potential and regulating the apoptosis-related proteins (BAX, BCL-2, and Caspase-9). Estradiol 13-15 BCL2 apoptosis regulator Homo sapiens 243-248 32096436-7 2021 In vitro biological activities well correlated with the molecular interaction data suggesting that atranorin had higher interaction with Akt than Bax and Bcl-2 but weak interaction with Bcl-w and Bcl-xL. atranorin 99-108 BCL2 apoptosis regulator Homo sapiens 154-159 33484789-5 2021 In addition, E2 and Fen treatment resulted in elevated levels of the survival-related proteins (Survivin and PCNA), and inhibited apoptosis by increasing the mitochondrial membrane potential and regulating the apoptosis-related proteins (BAX, BCL-2, and Caspase-9). N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide 20-23 BCL2 apoptosis regulator Homo sapiens 243-248 33495823-5 2021 Compared with the control group, KBrO3 treatment significantly decreased the Bcl2/Bax ratio, as determined via western blotting, and caspase-3 mRNA expression levels. kbro3 33-38 BCL2 apoptosis regulator Homo sapiens 77-81 33607534-11 2021 Based on qRT-PCR data, single AZT and combined AZT/IMA treatment also induced BAX/BCL-2 ratio significantly in both K562S and K562R cells. Azithromycin 30-33 BCL2 apoptosis regulator Homo sapiens 82-87 33607534-11 2021 Based on qRT-PCR data, single AZT and combined AZT/IMA treatment also induced BAX/BCL-2 ratio significantly in both K562S and K562R cells. Azithromycin 47-50 BCL2 apoptosis regulator Homo sapiens 82-87 33607534-11 2021 Based on qRT-PCR data, single AZT and combined AZT/IMA treatment also induced BAX/BCL-2 ratio significantly in both K562S and K562R cells. Imatinib Mesylate 51-54 BCL2 apoptosis regulator Homo sapiens 82-87 33721171-11 2021 BB with DOX and CDDP suppressed the proapoptotic Bid gene while overexpressing the anti-apoptotic Bcl-2 gene, separately. Propolis 0-2 BCL2 apoptosis regulator Homo sapiens 98-103 33721171-11 2021 BB with DOX and CDDP suppressed the proapoptotic Bid gene while overexpressing the anti-apoptotic Bcl-2 gene, separately. Doxorubicin 8-11 BCL2 apoptosis regulator Homo sapiens 98-103 33721171-11 2021 BB with DOX and CDDP suppressed the proapoptotic Bid gene while overexpressing the anti-apoptotic Bcl-2 gene, separately. Cisplatin 16-20 BCL2 apoptosis regulator Homo sapiens 98-103 33398363-6 2021 The protein expression levels of Bax, cytochrome c, cleaved caspase-9 and cleaved caspase-3 were upregulated, whereas Bcl-2 expression levels were downregulated in RSV-treated CRC cells compared with control cells. Resveratrol 164-167 BCL2 apoptosis regulator Homo sapiens 118-123 33231085-7 2021 And cell apoptosis was promoted after LIUS-curcumin combination treatment, characterized by the occurrence of more apoptotic cells and a significant increase in Bax level and attenuated Bcl-2 expression. lius 38-42 BCL2 apoptosis regulator Homo sapiens 186-191 30990333-3 2021 The combination of PGG and 5-FU had synergistic effects on reversal the aggressive phenotypes of HepG2 cells, increasing the proportion of Bax/Bcl-2, promoting the activation of caspase-9 and caspase-3, and inducing apoptosis. pentagalloylglucose 19-22 BCL2 apoptosis regulator Homo sapiens 143-148 33231085-7 2021 And cell apoptosis was promoted after LIUS-curcumin combination treatment, characterized by the occurrence of more apoptotic cells and a significant increase in Bax level and attenuated Bcl-2 expression. Curcumin 43-51 BCL2 apoptosis regulator Homo sapiens 186-191 30990333-3 2021 The combination of PGG and 5-FU had synergistic effects on reversal the aggressive phenotypes of HepG2 cells, increasing the proportion of Bax/Bcl-2, promoting the activation of caspase-9 and caspase-3, and inducing apoptosis. Fluorouracil 27-31 BCL2 apoptosis regulator Homo sapiens 143-148 33421743-5 2021 The results suggested that by using the combination of Lopinavir, Ritonavir along with Hydroxychloroquine and Vitamin C may turned out to be the effective line of treatment for SARS-CoV-2 as it shows the involvement of PARP-1, MAPK-8, EGFR, PRKCB, PTGS-2, and BCL-2. Lopinavir 55-64 BCL2 apoptosis regulator Homo sapiens 260-265 33841010-9 2021 GRh2-induced apoptosis in NB4 cells was accompanied by massive production of reactive oxygen species, mitochondrial damage and upregulated Bax/Bcl-2 expression. grh2 0-4 BCL2 apoptosis regulator Homo sapiens 143-148 33421743-5 2021 The results suggested that by using the combination of Lopinavir, Ritonavir along with Hydroxychloroquine and Vitamin C may turned out to be the effective line of treatment for SARS-CoV-2 as it shows the involvement of PARP-1, MAPK-8, EGFR, PRKCB, PTGS-2, and BCL-2. Ritonavir 66-75 BCL2 apoptosis regulator Homo sapiens 260-265 33638996-1 2021 Misregulation of BCL2 expression has been observed with many diseases and is associated with cellular exposure to reactive oxygen species. Reactive Oxygen Species 114-137 BCL2 apoptosis regulator Homo sapiens 17-21 33421743-5 2021 The results suggested that by using the combination of Lopinavir, Ritonavir along with Hydroxychloroquine and Vitamin C may turned out to be the effective line of treatment for SARS-CoV-2 as it shows the involvement of PARP-1, MAPK-8, EGFR, PRKCB, PTGS-2, and BCL-2. Ascorbic Acid 110-119 BCL2 apoptosis regulator Homo sapiens 260-265 33301850-6 2021 Furthermore, cellular assays disclosed that calycosin mitigated the cell mortality, LDH release, ROS level, and expression of Bax, Bcl-2, and Caspase-3 in both mRNA and protein levels induced by tau amyloid fibrils. 7,3'-dihydroxy-4'-methoxyisoflavone 44-53 BCL2 apoptosis regulator Homo sapiens 131-136 33652577-2 2021 This study aims to address gene therapy limitations by encapsidating a plasmid synthesizing a short hairpin RNA (shRNA) that targets the anti-apoptotic Bcl-2 gene using truncated hepatitis B core antigen (tHBcAg) virus-like particle (VLP). thbcag 205-211 BCL2 apoptosis regulator Homo sapiens 152-157 33652577-6 2021 Delivery of FA-tHBcAg-PshRNA VLP into HeLa cells overexpressing the folate receptor significantly downregulated the expression of anti-apoptotic Bcl-2 at 48 and 72 h post-transfection. thbcag 15-21 BCL2 apoptosis regulator Homo sapiens 145-150 33652909-8 2021 The cell-based analysis further indicated that metformin treatment regulated p38/JNK pathway to reduce Cyclin D1 and Bcl-2 expressions. Metformin 47-56 BCL2 apoptosis regulator Homo sapiens 117-122 33259900-7 2021 While co-inhibition of MCL-1 and BCL-XL/BCL-2 was indispensable for apoptosis in drug-naive cells, encorafenib altered cell dependence to MCL-1, and reliance on BCL-XL/BCL-2 was additionally found in cell lines that were highly primed to apoptosis by encorafenib. encorafenib 99-110 BCL2 apoptosis regulator Homo sapiens 168-173 33652595-10 2021 NI-hADSC-CM treatment enhanced the TH expression, stabilized alpha-syn monomers, reduced the levels of toxic insoluble p-S129 alpha-syn, improved the expression of neuronal functional proteins, regulated the Bax/Bcl-2 ratio, and upregulated the expression of pro-caspases, along with PARP-1 inactivation. ni-hadsc-cm 0-11 BCL2 apoptosis regulator Homo sapiens 212-217 33573447-14 2021 NR2F2 overexpression reversed the effect of miR-15-5p mimic on inhibiting cell migration, invasion and the expressions of NR2F2, Bcl-2, MMP-2 and MMP-9, and promoting apoptosis and cleaved caspase-3 level. mir-15-5p 44-53 BCL2 apoptosis regulator Homo sapiens 129-134 32718121-11 2021 Lycopene treatment significantly increased Bax expression (P < 0.0001) and decreased Bcl-2 expression (P < 0.0001) in HeLa cells. Lycopene 0-8 BCL2 apoptosis regulator Homo sapiens 85-90 32718121-13 2021 CONCLUSION: Lycopene increases the sensitization of cervical cancer cells to cisplatin via inhibition of cell viability, up-regulation of Bax expression, and down-regulation of Bcl-2 expression. Lycopene 12-20 BCL2 apoptosis regulator Homo sapiens 177-182 33747905-7 2021 When treated with RSV, the expression levels of full length PARP1, PCNA, and BCL-2 were found to be significantly reduced, and the expression level of Cleaved-PARP1 as well as Cleaved-Caspase3 increased significantly. Resveratrol 18-21 BCL2 apoptosis regulator Homo sapiens 77-82 33747905-10 2021 Furthermore, after RSV treatment, the anti-apoptotic index (PCNA, BCL-2) of MDA-MB-231 cells was found to decrease while the apoptosis index (caspase3) increased. Resveratrol 19-22 BCL2 apoptosis regulator Homo sapiens 66-71 33658794-10 2021 Moreover, ouabain induced significant apoptosis in A375 rather than SK-Mel-28 cells via upregulation of bax expression and downregulation of bcl-2 expression. Ouabain 10-17 BCL2 apoptosis regulator Homo sapiens 141-146 33624885-4 2021 Moreover, IBC induced mitochondrial apoptosis evidenced by reduced mitochondrial membrane potential, increased Bax level, decreased Bcl-2, Bcl-xL, and Mcl-1 levels, elevated cytochrome c level in the cytosol and increased cleavage of caspase-9, caspase-3, and PARP. isobavachalcone 10-13 BCL2 apoptosis regulator Homo sapiens 132-137 33261869-8 2021 Arsenite promotes activation of the NRF2/BCL-2 signaling pathway inhibited CHOP increasing cellular resistance to apoptosis and further promoting malignant transformation. arsenite 0-8 BCL2 apoptosis regulator Homo sapiens 41-46 33669832-7 2021 In addition, costunolide elevated the level of the pro-apoptotic protein Bax while lowering the levels of anti-apoptotic proteins, including Bcl-2 and Bcl-xL. costunolide 13-24 BCL2 apoptosis regulator Homo sapiens 141-146 33598678-8 2021 Targeting JAK/STAT pathway with the JAK1/2 inhibitor ruxolitinib or HDAC with belinostat both independently increased dependence on BCL-2 but not MCL-1, thereby sensitizing T-PLL cells to venetoclax. ruxolitinib 53-64 BCL2 apoptosis regulator Homo sapiens 132-137 33598678-8 2021 Targeting JAK/STAT pathway with the JAK1/2 inhibitor ruxolitinib or HDAC with belinostat both independently increased dependence on BCL-2 but not MCL-1, thereby sensitizing T-PLL cells to venetoclax. belinostat 78-88 BCL2 apoptosis regulator Homo sapiens 132-137 33385409-7 2021 Subsequent observation of the increment in pro-apoptotic Bax as well as the decrement in antiapoptotic Bcl2 revealed that the HLCA-induced cytotoxicity may be triggered by the intrinsic pathway of apoptosis. hlca 126-130 BCL2 apoptosis regulator Homo sapiens 103-107 33639139-6 2021 Further, after treated with CD19-PEG-MTN/DOX nanoparticle, pro-apoptotic proteins Bax and Caspase-3 in KOPN 8 and NALM-6 cells were significantly upregulated, but anti-apoptotic proteins Bcl2, MCL-1, HSP 70, and BAG 3 were downregulated, which indicated the activation of the apoptosis pathway by the nanodrug. Doxorubicin 41-44 BCL2 apoptosis regulator Homo sapiens 187-191 33884168-9 2021 The molecular docking studies showed the binding of PIP with PCNA and Bcl-2 and supported the in vitro findings. piperine 52-55 BCL2 apoptosis regulator Homo sapiens 70-75 33427831-5 2021 The Bax/Bcl2 expression ratio was increased up to 11-fold in cells pre-treated with 60 muM limonoids for 48 h. Apart from this, the limonoids also induced the expression of p21, and exhibited anti-inflammatory activity through decreasing the expression of cox-2, NF-kappaB and IL-6. Limonins 91-100 BCL2 apoptosis regulator Homo sapiens 8-12 33427831-5 2021 The Bax/Bcl2 expression ratio was increased up to 11-fold in cells pre-treated with 60 muM limonoids for 48 h. Apart from this, the limonoids also induced the expression of p21, and exhibited anti-inflammatory activity through decreasing the expression of cox-2, NF-kappaB and IL-6. Limonins 132-141 BCL2 apoptosis regulator Homo sapiens 8-12 33152391-5 2021 As expected, free DOX and PNPs induced overexpression of Bcl-2 in MDA-MB-231 cells, due to acquired drug resistance in a cell culture system. Doxorubicin 18-21 BCL2 apoptosis regulator Homo sapiens 57-62 33569751-11 2021 Our results showed that miRNA-143 overexpression could increase cisplatin-induced apoptosis and increase the sensitivity of CaSki cells to low doses of this chemotherapeutic agent via modulating the expression of apoptosis-related genes including Bcl-2, Bax, and caspase-9. Cisplatin 64-73 BCL2 apoptosis regulator Homo sapiens 247-252 33470993-11 2021 This oxidative mechanism corroborates the induction of reactive oxygen species (ROS), that triggers HCT116 cell death via apoptosis, as proved by the increased expression of BAX protein relative to BCL-2 protein and the depolarization of mitochondrial membrane potential, and via autophagy. Reactive Oxygen Species 55-78 BCL2 apoptosis regulator Homo sapiens 198-203 33560385-3 2021 Screening of a targeted antineoplastic drug library revealed that B-cell lymphoma 2 (BCL2) inhibitors synergize with artemisinins, and validation assays confirmed that the selective BCL2 inhibitor, venetoclax (VEN), synergized with artemisinin analogs to inhibit growth and induce apoptotic cell death of multiple acute leukemia cell lines in vitro. Artemisinins 117-129 BCL2 apoptosis regulator Homo sapiens 66-83 33560385-3 2021 Screening of a targeted antineoplastic drug library revealed that B-cell lymphoma 2 (BCL2) inhibitors synergize with artemisinins, and validation assays confirmed that the selective BCL2 inhibitor, venetoclax (VEN), synergized with artemisinin analogs to inhibit growth and induce apoptotic cell death of multiple acute leukemia cell lines in vitro. artemisinin 117-128 BCL2 apoptosis regulator Homo sapiens 66-83 33560385-3 2021 Screening of a targeted antineoplastic drug library revealed that B-cell lymphoma 2 (BCL2) inhibitors synergize with artemisinins, and validation assays confirmed that the selective BCL2 inhibitor, venetoclax (VEN), synergized with artemisinin analogs to inhibit growth and induce apoptotic cell death of multiple acute leukemia cell lines in vitro. artemisinin 117-128 BCL2 apoptosis regulator Homo sapiens 85-89 33560378-9 2021 Finally, T-ALL exposure to a BCL-2 inhibitor (ABT-199 [venetoclax]) significantly enhances the cytotoxic effects of AK2 depletion. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 46-49 BCL2 apoptosis regulator Homo sapiens 29-34 33470993-11 2021 This oxidative mechanism corroborates the induction of reactive oxygen species (ROS), that triggers HCT116 cell death via apoptosis, as proved by the increased expression of BAX protein relative to BCL-2 protein and the depolarization of mitochondrial membrane potential, and via autophagy. Reactive Oxygen Species 80-83 BCL2 apoptosis regulator Homo sapiens 198-203 33549076-13 2021 UA inhibited Bcl-2 expression and increased Bax expression. ursolic acid 0-2 BCL2 apoptosis regulator Homo sapiens 13-18 33560385-6 2021 Thus, synergy of the SAV combination may involve combined targeting of MCL1 and BCL2 via discrete, tolerable mechanisms, and cellular levels of MCL1 and DDIT3/CHOP may serve as biomarkers for action of artemisinins and SAV. GW612286X 21-24 BCL2 apoptosis regulator Homo sapiens 80-84 33443508-0 2021 Combination of mitochondria targeting doxorubicin with Bcl-2 function-converting peptide NuBCP-9 for synergistic breast cancer metastasis inhibition. nubcp-9 89-96 BCL2 apoptosis regulator Homo sapiens 55-60 33443508-5 2021 After mitochondria were damaged by mitochondria-targeting peptide-modified doxorubicin, apoptosis was effectively enhanced by mitochondrial specifically distributed NuBCP-9 peptides, which converted Bcl-2 function from anti-apoptotic to pro-apoptotic and paved the way for the development of mitochondrial impairment. Doxorubicin 75-86 BCL2 apoptosis regulator Homo sapiens 199-204 33562817-6 2021 At the protein level, myricetin-induced upregulation of PARP-1 and decreased expression of Bcl-2, whereas copper-induced changes in the expression of p53, p73, Bax and NME1 were not further affected by myricetin. myricetin 22-31 BCL2 apoptosis regulator Homo sapiens 91-96 33543488-7 2021 Dex inhibited the cell viability, migration and invasion by promoting Bax and Cleaved Caspase-3 expressions (p <.001) and by inhibiting the expressions of Bcl-2 and miR-222-3p (p <.001). Dexamethasone 0-3 BCL2 apoptosis regulator Homo sapiens 155-160 33543488-9 2021 Tectorigenin up-regulated the expressions of miR-222-3p, Bcl-2, p-Raf1, p-MEK1/2, and p-ERK1/2 (p <.01), but down-regulated the expressions of Bax and Cleaved Caspase-3 (p <.05) in Dex-induced cells. tectorigenin 0-12 BCL2 apoptosis regulator Homo sapiens 57-62 33530998-12 2021 MiR-140-3p mimic inhibited the MH7A cell viability and the expressions of SIRT3, Ki67, and Bcl-2 and promoted the cell apoptosis and the expressions of Bax and cleaved Caspase-3; miR-140-3p inhibitor showed an opposite effect to miR-140-3p mimic on MH7A cells. mir-140-3p 0-10 BCL2 apoptosis regulator Homo sapiens 91-96 33633571-7 2020 The synergistic antineoplastic activity of FLV and MEL combined in the optimized formula was also showed by the marked pronecrotic and pro-apoptotic activities, the latter mediated by the modulation of BAX/BCL-2 ratio in favor of BAX. Fluvastatin 43-46 BCL2 apoptosis regulator Homo sapiens 206-211 33603823-4 2021 Treatment with GFE dose-dependently inhibited intracellular ROS production and apoptosis by regulating the protein expressions of Bax, Bcl-2, and cytochrome C in DEP-stimulated (100 mug/ml) HaCaT cells. 1-(3,4-dichlorophenyl)-6,6-dimethyl-1,3,5-triazine-2,4-diamine 15-18 BCL2 apoptosis regulator Homo sapiens 135-140 33545202-7 2022 Western blot results showed that ERK, P53, P21, Caspase 9, Caspase 8 and Caspase 3 were all activated; cytochrome C and Bax increased; and Bcl-2 decreased when OS was treated with ligustilide. ligustilide 180-191 BCL2 apoptosis regulator Homo sapiens 139-144 33754004-0 2021 R-split-EPOCH plus high dose methotrexate in untreated diffuse large B cell lymphoma with MYC rearrangement or double expression of MYC and BCL-2. Methotrexate 29-41 BCL2 apoptosis regulator Homo sapiens 140-145 33708959-9 2021 HupA exerted a neuroprotective effect against I/R and OGD to attenuate the retinal pathological lesion, improve retinal neuronal cell viability, reverse oxidative stress injury by increasing GSH levels and SOD activity, and decreasing MDA content and reduce the retinal neuronal apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 expression with no effect on the calcium flow tests. huperzine A 0-4 BCL2 apoptosis regulator Homo sapiens 307-312 33387145-9 2021 TCS upregulated Bad expression and downregulated that of Bcl2. Triclosan 0-3 BCL2 apoptosis regulator Homo sapiens 57-61 33576216-11 2021 Bcl-2 gene expression significantly increased in the group exposed to 10 mg/ml of P.ruseliana leaf extract.Despite P.russeliana leaf extract, lower Z.christi leaf extract concentrations inhibited MCF-7 cells proliferation. p.ruseliana leaf extract 82-106 BCL2 apoptosis regulator Homo sapiens 0-5 33211168-12 2021 Mechanistically, we showed that dapagliflozin decreased the cardiac expression of Bax and cleaved caspase 3 but increased Bcl-2. dapagliflozin 32-45 BCL2 apoptosis regulator Homo sapiens 122-127 33576217-10 2021 RESULTS: VPA downregulated class I histone deacetylase (HDAC) 1, 2, and 3, Bcl-2, Bcl-xL, and Mcl-1 and upregulated p21, p53, Bax, Bak, and Bim resulting in apoptosis induction. Valproic Acid 9-12 BCL2 apoptosis regulator Homo sapiens 75-80 33122847-11 2021 Consequently, acetyl-bufalin impaired the complex formation of CDK9 and STAT3, decreased the expressions of P-STAT3, and transcribed target genes such as cyclin B1, CDC2, MCL-1, Survivin, VEGF, BCL2, and it upregulated the expression levels of BAX and caspase-3 activity. acetyl-bufalin 14-28 BCL2 apoptosis regulator Homo sapiens 194-198 33639680-11 2021 Daidzein caused over expression of Bax and down-regulated expression of Bcl2. daidzein 0-8 BCL2 apoptosis regulator Homo sapiens 72-76 33604171-9 2021 QPCR analyses indicated that hirsutine could diminish BCL2 expression and, at the same time, improve Bax, caspase-3 and caspase-9 mRNA levels, thus reiterating a putative correlation of hirsutine treatment in vitro with apoptosis induction and inhibition of cell proliferation (p-value < 0.05). hirsutine 29-38 BCL2 apoptosis regulator Homo sapiens 54-58 33314614-5 2021 Furthermore, ( E )- N -hydroxy-6-(2-(3-nitrobenzylidene)hydrazine-1-carbothioamido)hexanamide possessed potent inhibitory effect on HDAC1 and HDAC6, and could promote K562/A02 cells apoptosis via dose-dependently increasing Bax expression, reducing Bcl-2 protein level, and inducing the cleavage of PARP and caspase3. ( e )- n -hydroxy-6-(2-(3-nitrobenzylidene)hydrazine-1-carbothioamido)hexanamide 13-93 BCL2 apoptosis regulator Homo sapiens 249-254 33347715-0 2021 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models. Actinium-225 0-5 BCL2 apoptosis regulator Homo sapiens 61-66 33302149-4 2021 Increased cell uptake of CTL-PEG-FA/Bcl-2 siRNA was achieved by the synergism of folate mediated endocytosis and charge interaction, and further causing severe HepG2 cells injury through apoptosis mechanism after down-regulation of Bcl-2 protein. ctl-peg-fa 25-35 BCL2 apoptosis regulator Homo sapiens 232-237 33168448-12 2021 miR-766 decreased 5-flurouracil-induced apoptosis by regulation of BAX and Bcl-2 expression. 5-flurouracil 18-31 BCL2 apoptosis regulator Homo sapiens 75-80 33302149-4 2021 Increased cell uptake of CTL-PEG-FA/Bcl-2 siRNA was achieved by the synergism of folate mediated endocytosis and charge interaction, and further causing severe HepG2 cells injury through apoptosis mechanism after down-regulation of Bcl-2 protein. Folic Acid 81-87 BCL2 apoptosis regulator Homo sapiens 36-41 33336554-14 2021 Notably, we found that the combinational inhibition of extracellular signal-regulated kinase or c-Jun N-terminal kinase MAPK pathways significantly decreased the expression of the three antiapoptotic Bcl-2 family proteins, and in particular this reversed induction of Mcl-1 by carfilzomib. carfilzomib 277-288 BCL2 apoptosis regulator Homo sapiens 200-205 33302149-5 2021 In vivo experiments, CTL-PEG-FA/Bcl-2 siRNA complex distinctly accumulated in tumor site and significantly inhibited the growth of tumor, while no obvious toxicity was observed. ctl-peg-fa 21-31 BCL2 apoptosis regulator Homo sapiens 32-37 33581643-9 2021 Further, we identified BCL-2 dependence as a mechanism of treatment resistance in MLL-ALL through BH3 profiling. BH 3 98-101 BCL2 apoptosis regulator Homo sapiens 23-28 33581643-11 2021 Combined inhibition of SFKs/FLT3 by RK-20449 and of BCL-2 by ABT-199 led to substantial elimination of MLL-ALL cells in vitro and in vivo. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 61-64 BCL2 apoptosis regulator Homo sapiens 52-57 33189448-5 2021 Meanwhile, BPAF exposure significantly promoted the expression of pro-apoptotic proteins, including Bax, Bid and Bak, while the expression of anti-apoptotic proteins, such as Bcl-2, Bcl-xL and Mcl-1, decreased significantly. 4,4'-hexafluorisopropylidene diphenol 11-15 BCL2 apoptosis regulator Homo sapiens 175-180 33275947-7 2021 As indicated by western blot, Dex stimulates both pro-apoptosis (activating death-associated protein kinase 1 [DAPK-1] and p53) and anti-apoptotic (up-regulating bcl-2 and bcl-xL) signals in Abeta-treated neuronal cells. Dexmedetomidine 30-33 BCL2 apoptosis regulator Homo sapiens 162-167 33597889-7 2021 In vivo studies further confirmed that crizotinib and sunitinib decreased mitochondrial membrane potential and activated apoptosis-associated proteins (cleaved-PARP, cleaved caspase3, cytochrome c, Bcl2 and Bax). Sunitinib 54-63 BCL2 apoptosis regulator Homo sapiens 198-202 33629301-3 2021 RESULTS: Kaempferol promoted the release of cytochrome C from the mitochondria to cytoplasm, the activation of c-caspase-3 and c-caspase-9 and increased the expression levels of pro-apoptotic factor Bax, meanwhile decreased the expression levels of anti-apoptotic factor Bcl-2. Kaempferols 9-19 BCL2 apoptosis regulator Homo sapiens 271-276 33597889-7 2021 In vivo studies further confirmed that crizotinib and sunitinib decreased mitochondrial membrane potential and activated apoptosis-associated proteins (cleaved-PARP, cleaved caspase3, cytochrome c, Bcl2 and Bax). Crizotinib 39-49 BCL2 apoptosis regulator Homo sapiens 198-202 33459064-2 2021 Venetoclax, an oral BCL-2 inhibitor, is approved by the Food and Drug Administration in combination with hypomethylating agents or low-dose cytarabine in newly-diagnosed AML patients who are ineligible to receive intensive chemotherapy. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 20-25 32648994-2 2021 In this study, we describe how fluorizoline induces BH3-only protein NOXA, without modulating the protein levels of anti-apoptotic BCL-2 family members prior to caspase activation, as well as how it synergizes with the BCL-2 and BCL-XL inhibitor ABT-737 to induce apoptosis. Fluorizoline 31-43 BCL2 apoptosis regulator Homo sapiens 219-224 33352154-6 2021 We also realized that SiO2 NPs increase the cytotoxicity of alpha-syn amyloid fibrils through a significant decrease in cell viability, increase in membrane leakage, activation of caspase-9 and -3, elevation of ROS, and increase in the ratio of Bax/Bcl2 mRNA. Silicon Dioxide 22-26 BCL2 apoptosis regulator Homo sapiens 249-253 33372372-7 2021 Moreover, GA-GNPs plus radiation arrested the cell cycle of U251 at the S and G2/M phases and triggered apoptotic cell death, which is supported by increased BAX protein levels and decreased expression of BCL-2. Gallium 10-12 BCL2 apoptosis regulator Homo sapiens 205-210 33448034-0 2021 Garlic flavonoids alleviate H2 O2 induced oxidative damage in L02 cells and induced apoptosis in HepG2 cells by Bcl-2/Caspase pathway. Flavonoids 7-17 BCL2 apoptosis regulator Homo sapiens 112-117 33448034-9 2021 Moreover, the flavonoids could induce apoptosis in HepG2 cells via Bcl-2/Caspase pathways, where it could up-regulate the expression of Bax and down-regulate the expression of Bcl-2, Bcl-xL, pro-Caspase-3, and pro-Caspase-9 proteins in a dose dependent manner. Flavonoids 14-24 BCL2 apoptosis regulator Homo sapiens 67-72 33448034-9 2021 Moreover, the flavonoids could induce apoptosis in HepG2 cells via Bcl-2/Caspase pathways, where it could up-regulate the expression of Bax and down-regulate the expression of Bcl-2, Bcl-xL, pro-Caspase-3, and pro-Caspase-9 proteins in a dose dependent manner. Flavonoids 14-24 BCL2 apoptosis regulator Homo sapiens 176-181 33448034-11 2021 PRACTICAL APPLICATION: Flavonoids from Laba garlic showed selective toxicity towards HepG2 cells in comparison to L02 cells via regulating Bcl-2/caspase pathway. Flavonoids 23-33 BCL2 apoptosis regulator Homo sapiens 139-144 33154093-6 2021 A BET inhibitor INCB057643 effectively inhibited cell viability and induced apoptosis in DLBCL/HGBCL cells regardless of MYC/BCL2/TP53 status. INCB-057643 16-26 BCL2 apoptosis regulator Homo sapiens 125-129 33210403-12 2021 Furthermore, MTT assay, soft agar colony formation assay and the flow cytometry proved that miR-326 acts as tumor suppressor via inhibiting the expression of Bcl-2. monooxyethylene trimethylolpropane tristearate 13-16 BCL2 apoptosis regulator Homo sapiens 158-163 33321685-7 2021 Antiproliferative examinations displayed that SnO2 nanoparticles can selectively cause the mortality of K562 cells through induction of cell membrane leakage, activation of caspase-9, -8, -3, down regulation of Bcl-2 mRNA, the elevation of ROS level, S phase arrest, and apoptosis. Tin(IV) oxide 46-50 BCL2 apoptosis regulator Homo sapiens 211-216 33247804-12 2021 APAP decreased cell viability, apoptosis resistance, and Bcl-w and Bcl-2 levels whereas increased Bax level in THLE-2 cells. Acetaminophen 0-4 BCL2 apoptosis regulator Homo sapiens 67-72 33376542-5 2021 Bortezomib treatment induced cell apoptosis in NB4 cells, as assessed by Annexin V/propidium iodide analysis, and the detection of cleaved caspase-3, cleaved poly(ADP-ribose) polymerase, Bax and Bcl-2 expression. Bortezomib 0-10 BCL2 apoptosis regulator Homo sapiens 195-200 33111211-2 2021 The protein level of Bcl-2 was significantly reduced and Bax and C-caspase3 were significantly increased in L-lactate-treated cells. L-lactate 108-117 BCL2 apoptosis regulator Homo sapiens 21-26 33300068-7 2021 Compared with those after Abeta exposure alone, emodin ameliorated the dissipation of the mitochondrial membrane potential, inhibited the over-accumulation of reactive oxygen species, enhanced the expression levels of nuclear factor-erythroid-2-related factor 2 (Nrf2), haemeoxygenase-1, superoxide dismutase 1, Bcl-2 and catalase in addition to decreasing the expression levels of Bax. Emodin 48-54 BCL2 apoptosis regulator Homo sapiens 312-317 33201401-7 2021 The protein levels of pro-caspase 3, pro-caspase 9, and PARP1 were up-regulated and the Bax/Bcl-2 ratio was down-regulated in the presence of curcumin. Curcumin 142-150 BCL2 apoptosis regulator Homo sapiens 92-97 33535550-0 2021 Design, Synthesis, Anticancer Activity, and Solid Lipid Nanoparticle Formulation of Indole- and Benzimidazole-Based Compounds as Pro-Apoptotic Agents Targeting Bcl-2 Protein. indole 84-90 BCL2 apoptosis regulator Homo sapiens 160-165 33535550-0 2021 Design, Synthesis, Anticancer Activity, and Solid Lipid Nanoparticle Formulation of Indole- and Benzimidazole-Based Compounds as Pro-Apoptotic Agents Targeting Bcl-2 Protein. benzimidazole 96-109 BCL2 apoptosis regulator Homo sapiens 160-165 33535550-3 2021 Within the current work, we aimed to design and synthesize a new series of benzimidazole- and indole-based derivatives as inhibitors of Bcl-2 protein. benzimidazole 75-88 BCL2 apoptosis regulator Homo sapiens 136-141 32893422-5 2021 In HUVECs, BPA enhanced the levels of LC3A/B, bax/bcl2 ratio, cleaved caspase-3, and vascular cell adhesion molecule-1. bisphenol A 11-14 BCL2 apoptosis regulator Homo sapiens 50-54 33535550-3 2021 Within the current work, we aimed to design and synthesize a new series of benzimidazole- and indole-based derivatives as inhibitors of Bcl-2 protein. indole 94-100 BCL2 apoptosis regulator Homo sapiens 136-141 33524514-14 2021 Furthermore, in an assay of gene and protein expression, we found that DP could downregulate the gene and protein expression levels of Bcl-2, upregulate the gene and protein expression levels of Bax and Bim, and downregulate the protein expression levels of PI3k, p-Akt, and p-FoxO3a. 12-deoxyphorbol 13-palmitate 71-73 BCL2 apoptosis regulator Homo sapiens 135-140 33421904-10 2021 Furthermore, Z-LIG-induced apoptosis was shown to be correlated with the mitochondria localization of Nur77/NOR-1 and subsequent Bcl-2 conformational change, converting Bcl-2 from a cyto-protective phenotype into a cyto-destructive phenotype. ligustilide 13-18 BCL2 apoptosis regulator Homo sapiens 129-134 33421904-10 2021 Furthermore, Z-LIG-induced apoptosis was shown to be correlated with the mitochondria localization of Nur77/NOR-1 and subsequent Bcl-2 conformational change, converting Bcl-2 from a cyto-protective phenotype into a cyto-destructive phenotype. ligustilide 13-18 BCL2 apoptosis regulator Homo sapiens 169-174 33385639-12 2021 Tectorigenin increased Bcl-2 expression and the enzyme activities of SOD and GSH-Px, but decreased LDH leakage, MDA level, and the expressions of Bax and Cleaved Caspase-3 in H2O2-induced HUVECs. tectorigenin 0-12 BCL2 apoptosis regulator Homo sapiens 23-28 32944878-10 2021 Further studies showed that the anti-cancer effects of CZ415 were due to an induction of apoptosis, which was accompanied by an upregulation of Bax and downregulation of Bcl-2 through Lipin-1. CZ415 55-60 BCL2 apoptosis regulator Homo sapiens 170-175 31891780-8 2021 An in silico analysis revealed that ANG1005 and Abraxane nanoformulations have superior and significantly enhanced interactions with the proteins alpha-tubulin and Bcl-2. abraxane 48-56 BCL2 apoptosis regulator Homo sapiens 164-169 33188878-6 2021 The western blot assay showed calycosin decreased the expression of Bcl-2 and increased the expression of Bax, caspase-3, and PARP. 7,3'-dihydroxy-4'-methoxyisoflavone 30-39 BCL2 apoptosis regulator Homo sapiens 68-73 33554791-4 2021 RESULTS: PI3K inhibitor ZSTK474 could inhibit the proliferation and tumorigenicity of U937 cell, induce G1 cell cycle arrest and promote cell apoptosis, and enhance intracellular ROS production and decrease MMP, downregulate Cyclin D1, p-Rb, BCL-2 and upregulate p27, caspase-9, caspase-3, PARP and BAX. ZSTK474 24-31 BCL2 apoptosis regulator Homo sapiens 242-247 33554799-6 2021 Western blot showed that costunolide could down-regulated the expression of p-AKT, p-PI3K, BCL-2, and up-regulated the expression of cleaved-caspase-3, cleaved-PARP significantly. costunolide 25-36 BCL2 apoptosis regulator Homo sapiens 91-96 33502605-6 2021 Moreover, the enhanced apoptosis in cells under SI/R conditions were reduced after aloin treatment, concomitant with the decrease in pro-apoptotic Bax protein levels and increase in anti-apoptotic Bcl-2 protein expression. alloin 83-88 BCL2 apoptosis regulator Homo sapiens 197-202 33501840-5 2021 The results showed that arsenic induced liver damage, increased hepatocyte apoptosis and elevated the expression level of Chk1 and the ratios of p-p53/p53 and Bax/Bcl-2 in liver tissues, which were significantly attenuated by GBE. Arsenic 24-31 BCL2 apoptosis regulator Homo sapiens 163-168 33509300-13 2021 Combination of DOX with EUG induced apoptosis through the higher BAX/ BCl2 ratio, while with AST was through the increase in caspase 8 expressions. Doxorubicin 15-18 BCL2 apoptosis regulator Homo sapiens 70-74 33509300-13 2021 Combination of DOX with EUG induced apoptosis through the higher BAX/ BCl2 ratio, while with AST was through the increase in caspase 8 expressions. Eugenol 24-27 BCL2 apoptosis regulator Homo sapiens 70-74 33469639-3 2021 In the present study, the recently developed interaction entropy approach was employed for the calculation of entropic contribution, and the computational alanine scanning method was used to identify the hot spot in the protein-protein interactions between Bcl-xL/Bcl-2 and Bad/Bax. Alanine 155-162 BCL2 apoptosis regulator Homo sapiens 264-269 33246336-16 2021 The Bax/Bcl2 ratio was also significantly reduced in the NAC150-treated group (P < 0.005). nac150 57-63 BCL2 apoptosis regulator Homo sapiens 8-12 33496895-10 2021 Moreover, PRO promoted the downregulated expressions of cytosolic Bnip3, total Bni3p, Cleaved Caspase-3, and Bax and upregulated the Bcl-2 level. Propofol 10-13 BCL2 apoptosis regulator Homo sapiens 133-138 33495184-4 2021 A combination therapy including venetoclax was used based on efficacy data for Bcl-2 inhibitor venetoclax from available early-phase clinical trials in patients with relapsed multiple myeloma with t(11;14) and other published case studies. venetoclax 32-42 BCL2 apoptosis regulator Homo sapiens 79-84 33487592-3 2021 We sought to elucidate the antitumour action of a BCL-2 inhibitor, AT101 in GEC in vitro, in vivo and in a clinical trial. gossypol acetic acid 67-72 BCL2 apoptosis regulator Homo sapiens 50-55 33495510-0 2021 Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy. azd0466 68-75 BCL2 apoptosis regulator Homo sapiens 48-53 33495510-2 2021 AZD4320, a potent dual Bcl-2/Bcl-xL inhibitor, has shown good efficacy however had dose limiting cardiovascular toxicity in preclinical species, coupled with challenging physicochemical properties, which prevented its clinical development. AZD4320 0-7 BCL2 apoptosis regulator Homo sapiens 23-28 33495510-6 2021 The AZD4320-dendrimer conjugate (AZD0466) identified, through mathematical modelling, has resulted in an improved therapeutic index and thus enabled progression of this promising dual Bcl-2/Bcl-xL inhibitor into clinical development. AZD4320 4-11 BCL2 apoptosis regulator Homo sapiens 184-189 33495510-6 2021 The AZD4320-dendrimer conjugate (AZD0466) identified, through mathematical modelling, has resulted in an improved therapeutic index and thus enabled progression of this promising dual Bcl-2/Bcl-xL inhibitor into clinical development. azd0466 33-40 BCL2 apoptosis regulator Homo sapiens 184-189 33494833-10 2021 Moreover, the neuro-reparative role of SKP-SC-EVs was implicated in the activation of PI3K/Akt, mTOR, and p70S6k, as well as the reduction of Bax/Bcl-2 ratio, that was compromised by LY294002 to some extent. skp-sc-evs 39-49 BCL2 apoptosis regulator Homo sapiens 146-151 33487592-7 2021 AT-101 induced apoptosis, reduced proliferation and tumour sphere formation in MCL-1/BCL-2 high GC cells. gossypol acetic acid 0-6 BCL2 apoptosis regulator Homo sapiens 85-90 33471569-12 2021 Combining API and TMZ significantly inhibited the protein expression of p-AKT, cyclin D1, Bcl-2, Matrix Metallopeptidase 2, and Matrix Metallopeptidase 9. Apigenin 10-13 BCL2 apoptosis regulator Homo sapiens 90-95 33483906-8 2021 A significant decrease in the Bcl-2 level and the Bcl-2/Bax ratio and a significant increase in the protein expression levels of Bax and cleaved caspase 3 and in the percentage of apoptosis were observed under IH exposure. Ile-His 210-212 BCL2 apoptosis regulator Homo sapiens 30-35 33483906-8 2021 A significant decrease in the Bcl-2 level and the Bcl-2/Bax ratio and a significant increase in the protein expression levels of Bax and cleaved caspase 3 and in the percentage of apoptosis were observed under IH exposure. Ile-His 210-212 BCL2 apoptosis regulator Homo sapiens 50-55 33585438-5 2020 Cedrol decreased the cell viability by inducing apoptosis in both cell lines by activation of pro-apoptosis protein BID and inhibition of anti-apoptosis proteins Bcl-X L , Bcl-2, and XIAP. cedrol 0-6 BCL2 apoptosis regulator Homo sapiens 172-177 33494688-4 2021 The review provides an overview of the Bcl-2 inhibiting, IAPs antagonizing, caspase inhibiting and BH3 mimicking actions, mediated by anti-cancer drugs, rendering beneficial outcomes in different forms of cancer. BH 3 99-102 BCL2 apoptosis regulator Homo sapiens 39-44 33552161-14 2021 NI-hBMSC-CM ameliorated the neurotrophic protein expressions, controlled the Bax/Bcl-2 ratio, upregulated procaspases, and inactivated PARP-1. ni-hbmsc 0-8 BCL2 apoptosis regulator Homo sapiens 81-86 33287594-0 2021 Anti-apoptotic effect of silymarin-loaded chitosan nanoparticles on hippocampal Caspase-3 and Bcl-2 expression following cerebral ischemia/reperfusion injury. Silymarin 25-34 BCL2 apoptosis regulator Homo sapiens 94-99 33287594-2 2021 The aim of present study aimed to investigate the anti-apoptotic effects of silymarin-loaded chitosan nanoparticles (SM-CS-NPs) on the expression of Bcl-2 and Caspase-3 genes in hippocampal neurons after I/R injury. Silymarin 76-85 BCL2 apoptosis regulator Homo sapiens 149-154 33471569-12 2021 Combining API and TMZ significantly inhibited the protein expression of p-AKT, cyclin D1, Bcl-2, Matrix Metallopeptidase 2, and Matrix Metallopeptidase 9. Temozolomide 18-21 BCL2 apoptosis regulator Homo sapiens 90-95 33585534-12 2020 LPP treatment improved cell survival rate, reduced intracellular LDH and MDA levels, increased intracellular SOD, CAT, GSH levels, down-regulated Bax, caspases-3, Nrf2, HO-1 expression, and up-regulated Bcl-2 expression. Linalyl diphosphate 0-3 BCL2 apoptosis regulator Homo sapiens 203-208 33480649-2 2021 The BCL-2 inhibitor venetoclax combined with hypomethylating agents like decitabine, has shown favorable responses in elderly patients with acute myeloid leukemia. venetoclax 20-30 BCL2 apoptosis regulator Homo sapiens 4-9 33480649-2 2021 The BCL-2 inhibitor venetoclax combined with hypomethylating agents like decitabine, has shown favorable responses in elderly patients with acute myeloid leukemia. Decitabine 73-83 BCL2 apoptosis regulator Homo sapiens 4-9 33536932-15 2020 The Bcl-2 apoptosis pathway and PI3K/AKT pathway may participate in the damage of CVECs caused by SMG. N-SUCCINYL METHIONINE 98-101 BCL2 apoptosis regulator Homo sapiens 4-9 33183867-6 2021 Further mechanism studies significantly indicated that compound 5h could block MDA-MB-231 cell cycle arrest in G0/G1 phase by down regulating cyclin D1 and CDK4, and induce apoptosis by up-regulation of Bax, down-regulation of Caspase-3, PARP and Bcl-2 proteins, resulting in the reduction of DNA synthesis and cell division arrest. 5h 64-66 BCL2 apoptosis regulator Homo sapiens 247-252 33454870-6 2021 Moreover, the CM increased BDNF and tyrosine hydroxylase (TH) mRNA expression and significantly reduced the apoptosis-related Bax/Bcl-2 ratio in H2O2-treated SH-SY5Y cells. Hydrogen Peroxide 145-149 BCL2 apoptosis regulator Homo sapiens 130-135 33570137-6 2021 Nickel exposure triggered apoptosis in concomitant with the decreased expression of anti-apoptotic B-cell lymphoma protein (Bcl-2) and increased caspase-3/7 activity. Nickel 0-6 BCL2 apoptosis regulator Homo sapiens 124-129 32790056-2 2021 Targeting the BH3-binding pockets of these anti-apoptotic proteins could reactivate apoptosis in BCL-2-depedent cancers. BH 3 14-17 BCL2 apoptosis regulator Homo sapiens 97-102 33130480-7 2021 The decreased in mitochondrial membrane potential, along with upregulation of cytochrome c, caspases 9 and 3, and BAX/BCL2, further suggested that mitochondrial injury were involved in AgNP-induced apoptosis. agnp 185-189 BCL2 apoptosis regulator Homo sapiens 118-122 33519480-2 2020 ABT-263, as an orally bioavailable BCL-2 family inhibitor, has showed great antitumor characteristics by targeting tumor cell apoptosis. navitoclax 0-7 BCL2 apoptosis regulator Homo sapiens 35-40 33253717-7 2021 Moreover, reverse transcript quantitative polymerase chain reaction (RT-qPCR) demonstrated that acyclovir suppressed the expression of caspase 3, caspase 8 and caspase 9, while there was no significant impact on the expression of the apoptosis-inhibiting gene bcl-2 in CCV-infected cells. Acyclovir 96-105 BCL2 apoptosis regulator Homo sapiens 260-265 33451016-11 2021 AZA-LIPO were more effective than the free AZA in reducing Bcl2 expression, while increasing pro-apoptotic Bax and caspase-3 activity. aza-lipo 0-8 BCL2 apoptosis regulator Homo sapiens 59-63 33466812-5 2021 The cytotoxicity of HI 5 was found to be intrinsically mediated apoptosis, which in turn, is associated with low Bcl-2 expression and high activation of caspase 3 and p53. hi 5 20-24 BCL2 apoptosis regulator Homo sapiens 113-118 33520087-8 2021 Following ROS accumulation, the intrinsic apoptotic pathway was triggered by an increase in the ratio of Bax/Bcl-2. Reactive Oxygen Species 10-13 BCL2 apoptosis regulator Homo sapiens 109-114 33445186-7 2022 Moreover, 1"-acetoxychavicol acetate-treated cells exhibited lower expression levels of the anti-apoptotic Bcl-2 and Mcl-1 proteins in addition to enhanced stress-activated kinases/c-Jun N-terminal kinase 1/2 and poly-ADP ribose polymerase cleavage, indicating apoptotic cell induction by 1"-acetoxychavicol acetate. 1'-acetoxychavicol acetate 10-36 BCL2 apoptosis regulator Homo sapiens 107-112 33438556-10 2021 Furthermore expression level of Bax and Bcl2 mRNAs altered significantly in all samples treated with 50 (mug/ml) of naringenin, resveratrol, or simultaneously with both. naringenin 116-126 BCL2 apoptosis regulator Homo sapiens 40-44 33438556-10 2021 Furthermore expression level of Bax and Bcl2 mRNAs altered significantly in all samples treated with 50 (mug/ml) of naringenin, resveratrol, or simultaneously with both. Resveratrol 128-139 BCL2 apoptosis regulator Homo sapiens 40-44 33451016-11 2021 AZA-LIPO were more effective than the free AZA in reducing Bcl2 expression, while increasing pro-apoptotic Bax and caspase-3 activity. Azacitidine 0-3 BCL2 apoptosis regulator Homo sapiens 59-63 33469265-10 2021 Results: Capsaicin significantly inhibited proliferation and induced apoptosis in breast cancer in vitro and in vivo, along with decreased FBI-1, Ki-67, Bcl-2 and Survivin protein expression, increased Bax protein expression and activated Caspase 3. Capsaicin 9-18 BCL2 apoptosis regulator Homo sapiens 153-158 33438566-13 2021 Moreover, anlotinib downregulated the expression of survivin, cyclin D1, CDK4, caspase-3, Bcl-2, MMP-2, MMP-9, vimentin and N-cadherin, but up-regulated cleaved-caspase-3, Bax and E-cadherin and blocked the activity of the PI3K/AKT in HCT-8/5-FU cells. anlotinib 10-19 BCL2 apoptosis regulator Homo sapiens 90-95 33427041-9 2021 COX-independent mechanisms of anticancer effects of aspirin include down-regulation of nuclear factor kappa B activity and Akt activation, modulation of Bcl-2 and Bax family proteins, suppression of vascular endothelial growth factor, induction of apoptosis, disruption of DNA repair mechanisms, and induction of spermidine/spermine N1-acetyltransferase that modulates polyamine catabolism. Aspirin 52-59 BCL2 apoptosis regulator Homo sapiens 153-158 33410342-4 2021 In this study, we demonstrate that chemical inhibition of KLF4 by Kenpaullone, results in suppression of proliferation, cell survival, downregulation of Bcl-2 and increases apoptosis in B-NHL cell lines through YY1 independent pathway. kenpaullone 66-77 BCL2 apoptosis regulator Homo sapiens 153-158 33022330-5 2021 The IC50 values of doxorubicin (DOX) in TAM-embedded TNBC spheroids were significantly higher than those in TNBC spheroids, demonstrating drug resistance, which could be explained by activation of IL-10/IL-10 receptor/STAT3/bcl-2 signaling. Doxorubicin 19-30 BCL2 apoptosis regulator Homo sapiens 224-229 33022330-5 2021 The IC50 values of doxorubicin (DOX) in TAM-embedded TNBC spheroids were significantly higher than those in TNBC spheroids, demonstrating drug resistance, which could be explained by activation of IL-10/IL-10 receptor/STAT3/bcl-2 signaling. tam 40-43 BCL2 apoptosis regulator Homo sapiens 224-229 33436823-3 2021 Contrary to up-regulation of Bax gene after 3 h in control group, there was significant increase in expression of Bcl-2 in mercury-treated groups. Mercury 123-130 BCL2 apoptosis regulator Homo sapiens 114-119 33410342-6 2021 The co-expressions of KLF4/YY1 or KLF4/Bcl-2 in NHL was analyzed using Oncomine Database, exhibiting a positive correlation of expression. oncomine 71-79 BCL2 apoptosis regulator Homo sapiens 39-44 33411349-7 2021 CONCLUSIONS: CD44 might be involved in adriamycin resistance via regulation of P-gp, MMP-2, MMP-9, and Bcl-2/Bax. Doxorubicin 39-49 BCL2 apoptosis regulator Homo sapiens 103-108 33402109-11 2021 Overexpression of miR-383 downregulated Bcl-2, resulting in reduced survival of Fluorouracil-treated GC cells. Fluorouracil 80-92 BCL2 apoptosis regulator Homo sapiens 40-45 33402109-13 2021 CONCLUSION: MiR-383 reduces survival of Fluorouracil-treated GC cells through downregulating of Bcl-2. Fluorouracil 40-52 BCL2 apoptosis regulator Homo sapiens 96-101 33392781-13 2021 5-ALA-PDT can significantly inhibit the growth of human ovarian cancer cells, and the mechanism of this effect is related to the tumor cell apoptosis mediated by the downregulation of Bcl-2 and caspase-3 and upregulation of Bax protein expression. Aminolevulinic Acid 0-5 BCL2 apoptosis regulator Homo sapiens 184-189 33613969-10 2021 CSC-induced apoptosis was further increased, Bax expressions and cleaved-caspase 3/pro-caspase 3 ratio were improved, but Bcl-2 expressions were decreased after 3-MA or 4-PBA treatment. 3-methyladenine 161-165 BCL2 apoptosis regulator Homo sapiens 122-127 33288320-5 2021 The mechanisms study revealed that compound 12h caused the cell cycle arrest in G1 phase, induced apoptosis in a concentration-dependent manner, significantly reduced mitochondrial membrane potential, increased intracellular ROS and Ca2+ levels, up-regulated the expression of Bax, cleaved caspase-9, cleaved caspase-3, and down-regulated the expression of Bcl-2 protein. 12-hydroxydodecanoic acid 44-47 BCL2 apoptosis regulator Homo sapiens 357-362 33488300-8 2021 Bcl-2 protein expression was significantly decreased, and active caspase-3 and Bax protein expression was increased in SGC-7901 cells incubated with z-guggulsterone. pregna-4,17-diene-3,16-dione 149-164 BCL2 apoptosis regulator Homo sapiens 0-5 33520367-0 2021 THZ1, a covalent CDK7 inhibitor, enhances gemcitabine-induced cytotoxicity via suppression of Bcl-2 in urothelial carcinoma. gemcitabine 42-53 BCL2 apoptosis regulator Homo sapiens 94-99 32679024-13 2021 Flow cytometric evaluation showed andrographolide enhanced early and late apoptotic cells and induced upregulation of proapoptotic (Bax and Bad) and downregulation of antiapoptotic Bcl2 in treated SW-480 cells. andrographolide 34-49 BCL2 apoptosis regulator Homo sapiens 181-185 33336620-9 2021 Combined treatment with DAC and a Bcl2 inhibitor, venetoclax, exhibited strong synergistic potency against lung cancer without normal tissue toxicity. Decitabine 24-27 BCL2 apoptosis regulator Homo sapiens 34-38 32079453-2 2021 Platelet apoptosis can be triggered by BH3 mimetics that inhibit the pro-survival Bcl-2 family protein, Bcl-xL. BH 3 39-42 BCL2 apoptosis regulator Homo sapiens 82-87 32974790-7 2021 When miR-512-3p was overexpressed, BAX/BCL2 expression ratio and proportion of sub-G1 cell population were increased in transfected SKBR3 cells, detected by RT-qPCR and flow cytometry, respectively. mir-512-3p 5-15 BCL2 apoptosis regulator Homo sapiens 39-43 32887697-3 2021 We evaluated whether venetoclax, a selective small-molecule inhibitor of BCL-2, would influence the anti-tumor activity of immune checkpoint inhibitors (ICIs). venetoclax 21-31 BCL2 apoptosis regulator Homo sapiens 73-78 33655891-8 2021 Furthermore, tunicamycinreduced BCL-2/BAX ratio was also reversed by 2-APB. tunicamycinreduced 13-31 BCL2 apoptosis regulator Homo sapiens 32-37 32927158-5 2021 Intensive study revealed that after exposure to BPA mitochondrial membrane potential (MMP) dropped down and the protein expression levels of Bak-1, Bax, cytochrome c and Caspase-3 were up-regulated but Bcl-2 were down-regulated significantly. bisphenol A 48-51 BCL2 apoptosis regulator Homo sapiens 202-207 33220236-4 2021 Our experimental results demonstrated that pretreatment with esculetin markedly increased the cell viability while decreased the apoptosis in H2O2-treated human corneal epithelial (HCE) cells, by regulating Bcl-2, Bax and caspase-3 protein expressions and by altering the imbalance of activities of intracellular reactive oxygen species (ROS) and superoxide dismutase (SOD). esculetin 61-70 BCL2 apoptosis regulator Homo sapiens 207-212 33248145-5 2021 In addition, western blotting assay revealed the increased expressions of the p53, Bax, caspase 3, and a reduction of Bcl-2 and CDK2, resulting in Se-TE-induced apoptosis. se-te 147-152 BCL2 apoptosis regulator Homo sapiens 118-123 32347047-10 2021 Results: Arbutin pre-treatment increased the total antioxidative power and cell viability in the MTT assay and reduced BAX/BCL-2 ratio, P53 mRNA expression and necrosis in fibroblasts exposed to the oxidative agent (P<0.001). Arbutin 9-16 BCL2 apoptosis regulator Homo sapiens 123-128 32347047-11 2021 In addition, our results showed that arbutin can decrease cell viability, induce apoptosis and increase BAX/BCL-2 ratio in LNCaP cells at some specific concentrations (P<0.001). Arbutin 37-44 BCL2 apoptosis regulator Homo sapiens 108-113 32998965-1 2021 PURPOSE: Alvocidib is a cyclin-dependent kinase-9 inhibitor leading to down-regulation of the anti-apoptotic BCL-2 family member, MCL-1. alvocidib 9-18 BCL2 apoptosis regulator Homo sapiens 109-114 33268288-9 2021 Moreover, western blotting assay revealed that metformin could decrease Hcy-induced expression of Bax and cleaved caspase3, and increase the expression of Bcl-2. Metformin 47-56 BCL2 apoptosis regulator Homo sapiens 155-160 33397259-8 2021 Molecular investigations have revealed that the NF-kappaB suppression, Notch 1 inhibition, cell cycle stop at S+G2/M-phase, enhanced Bax protein concentrations, mitochondrial membrane potential attenuation, activation of p53 and caspase, Bcl-2 regulation, and ROS formation are crucial mechanisms that could be targeted via various Artemisia species. ros 260-263 BCL2 apoptosis regulator Homo sapiens 238-243 33273978-11 2021 Similarly, western blot analysis revealed no significant difference in ERK1/2 and MMP levels between fluoxetine-treated and control groups, but p-ERK1/2 and Bax were upregulated and Bcl-2 was decreased in the fluoxetine-treated group. Fluoxetine 209-219 BCL2 apoptosis regulator Homo sapiens 182-187 33655891-8 2021 Furthermore, tunicamycinreduced BCL-2/BAX ratio was also reversed by 2-APB. 2-aminoethoxydiphenyl borate 69-74 BCL2 apoptosis regulator Homo sapiens 32-37 33390801-13 2021 Western blotting assay illustrated that the combination of USP37 knockdown with adriamycin treatment significantly upregulated the expression levels of cleaved caspase 3 and Bax, whereas the expression level of Bcl-2 was inhibited. Doxorubicin 80-90 BCL2 apoptosis regulator Homo sapiens 211-216 33723162-9 2021 Furthermore, after 24 h of exposure to hypericin with IC50 concentration, the expression of P53 and Bax genes increased and the expression of the Bcl2, Myc, and Mdm2 gene decreased. hypericin 39-48 BCL2 apoptosis regulator Homo sapiens 146-150 32881195-5 2021 Moreover, the elevation of apoptosis including Bax, Bad, cleaved caspase-3,-9, and decreased protein levels of Bcl-2, Bcl-XL induced by cisplatin were reversed after PD treatment. Cisplatin 136-145 BCL2 apoptosis regulator Homo sapiens 111-116 33531986-9 2021 COL11A1/Akt disturbed the BCL-2/BAX balance, inhibiting cytochrome c (Cyt-C) release and binding of Apaf-1/procaspase-9/Cyt-C, which suppressed the apoptotic program and induced GEM resistance in pancreatic cancer cells. gemcitabine 178-181 BCL2 apoptosis regulator Homo sapiens 26-31 32572959-10 2021 Moreover, AR-A014418 sensitized U937 cells to ABT-263 (BCL2/BCL2L1 inhibitor) cytotoxicity owing to MCL1 suppression. navitoclax 46-53 BCL2 apoptosis regulator Homo sapiens 55-59 33200796-0 2021 Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer. osimertinib 111-122 BCL2 apoptosis regulator Homo sapiens 14-19 34028739-7 2021 In addition, we describe how BH3 profiling can be used to predict myofibroblast responses to therapeutic agents targeting pro-survival BCL-2 proteins, also known as BH3 mimetic drugs. BH 3 29-32 BCL2 apoptosis regulator Homo sapiens 135-140 32865667-5 2021 Further DAPI staining has revealed wikstromol at 10 muM induced apoptosis of cancer cells, which was associated with the activation of caspase-3 following down-regulation of Bcl-2 as well as up-regulation of Bax, cleaved PARP and phosphorylated p53. nortrachelogenin 35-45 BCL2 apoptosis regulator Homo sapiens 174-179 33179084-11 2021 In conclusion, miR-218 could simultaneously suppress cell proliferation and tumor invasiveness and induce cell apoptosis by increasing PTEN and YY1 expression, while decreasing BCL-2 and BMI-1 in Xuanwei lung cancer. mir-218 15-22 BCL2 apoptosis regulator Homo sapiens 199-204 33200796-5 2021 Furthermore, the suppression of Bcl-2 and Bcl-xL through small interfering RNA-mediated gene knockdown or using a small molecule specific inhibitor ABT-263 re-sensitized HCC827/OR cells to osimertinib treatment. osimertinib 189-200 BCL2 apoptosis regulator Homo sapiens 32-37 32933334-7 2021 Furthermore, Western blot analysis showed that capsanthin application increased p53 and Bax protein expressions and caused a decrease in Bcl-2 protein level. capsanthin 47-57 BCL2 apoptosis regulator Homo sapiens 137-142 32657143-7 2021 Meanwhile, the combination showed a synergistic effect within 48 h. In the curcumin treated group, the expression of Bcl-2 and hTERT genes diminished. Curcumin 75-83 BCL2 apoptosis regulator Homo sapiens 117-122 32657143-8 2021 In the metformin treated group, the expression of Bax and PUMA genes was enhanced while the expression of Bcl-2, hTERT, mTOR, and p53 genes declined. Metformin 7-16 BCL2 apoptosis regulator Homo sapiens 106-111 33200228-0 2021 Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFR-mutated NSCLC cells in vitro and in vivo via STAT3/Bcl-2 signaling. Erlotinib Hydrochloride 45-54 BCL2 apoptosis regulator Homo sapiens 153-158 33200228-14 2021 The combined use of HJD with erlotinib significantly reduced tumor growth in erlotinib-resistant HCC827ER and H1975 xenografts, induced caspase 3, and inhibited Ki67, STAT3, and Bcl-2 expression. Erlotinib Hydrochloride 29-38 BCL2 apoptosis regulator Homo sapiens 178-183 33200228-15 2021 HJD significantly alleviated erlotinib resistance by regulating the STAT3/Bcl-2 signaling pathway, which is a promising method to overcome the EGFR-TKI resistance of NSCLC. Erlotinib Hydrochloride 29-38 BCL2 apoptosis regulator Homo sapiens 74-79 33171207-11 2021 By using calcium channel blocker Nimodipine, the increase of intracellular Ca2+ was attenuated, and the death rate of neurons, the ROS and opening of mPTP, decreased ATP production, the expressions of cytochrome c, cleaved caspase-9, cleaved caspase-3 and the ratio of Bax/Bcl-2 were alleviated. Nimodipine 33-43 BCL2 apoptosis regulator Homo sapiens 273-278 33281960-9 2021 Notably, decreased expression of Bcl-2 and increased expression of Bax, cleaved caspase-3, cleaved caspase-9 and cleaved PARP were detected in the cancer cells treated with demethylzeylasteral. demethylzeylasteral 173-192 BCL2 apoptosis regulator Homo sapiens 33-38 33281970-8 2021 Furthermore, the expression levels of BAX, cleaved caspase-3/9 and cleaved poly (ADP-ribose) polymerase were upregulated, and the expression levels of BCL-2 were downregulated by dioscin. dioscin 179-186 BCL2 apoptosis regulator Homo sapiens 151-156 33262826-5 2021 Further investigation into the underlying mechanism revealed that FYGL could inhibit the expression level of the Bcl-2 protein in PANC-1 cells, but not in Mia PaCa-2 cells, leading to an increase in reactive oxygen species (ROS) and a reduction in the mitochondrial membrane potential and cell apoptosis. Reactive Oxygen Species 199-222 BCL2 apoptosis regulator Homo sapiens 113-118 33262826-5 2021 Further investigation into the underlying mechanism revealed that FYGL could inhibit the expression level of the Bcl-2 protein in PANC-1 cells, but not in Mia PaCa-2 cells, leading to an increase in reactive oxygen species (ROS) and a reduction in the mitochondrial membrane potential and cell apoptosis. Reactive Oxygen Species 224-227 BCL2 apoptosis regulator Homo sapiens 113-118 33030593-0 2021 Protective effect of 2-dodecyl-6-methoxycyclohexa-2, 5-diene-1, 4-dione, isolated from Averrhoa carambola L., against Abeta1-42-induced apoptosis in SH-SY5Y cells by reversing Bcl-2/Bax ratio. 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione 21-71 BCL2 apoptosis regulator Homo sapiens 176-181 33030593-8 2021 Moreover, the Bcl-2/Bax ratio was obviously decreased in cells only exposed to Abeta1-42, but, which was suppressed by treated with DMDD. dmdd 132-136 BCL2 apoptosis regulator Homo sapiens 14-19 33285147-5 2021 Furthermore, AS-IV prevented cell death by decreasing the ratio of Bax/Bcl-2, caspase-3, and cleaved caspase-3 expression in vitro. astragaloside A 13-18 BCL2 apoptosis regulator Homo sapiens 71-76 33171207-11 2021 By using calcium channel blocker Nimodipine, the increase of intracellular Ca2+ was attenuated, and the death rate of neurons, the ROS and opening of mPTP, decreased ATP production, the expressions of cytochrome c, cleaved caspase-9, cleaved caspase-3 and the ratio of Bax/Bcl-2 were alleviated. Calcium 9-16 BCL2 apoptosis regulator Homo sapiens 273-278 33390126-14 2021 The findings from various studies demonstrated that polyphenol-nanoformulations accelerated the apoptosis in CRC cells by upregulating the levels of caspases and Bax, whereas inhibiting the CRC cell proliferation by dowregulating the expression of Bcl-2 and ERK1/2. Polyphenols 52-62 BCL2 apoptosis regulator Homo sapiens 248-253 33645129-0 2021 [Effect of swertiamarin, gentiopicrin and sweroside on cell apoptosis and expression of Bcl-2 in rheumatoid arthritis fibroblast-like synoviocytes]. sweroside 42-51 BCL2 apoptosis regulator Homo sapiens 88-93 33645129-7 2021 Swertiamarin, gentiopicrin and sweroside were docked well with Bcl-2(1 GJH). swertiamarin 0-12 BCL2 apoptosis regulator Homo sapiens 63-68 33382670-8 2020 Piperine upregulated the protein expression of Bax, Bad, Cyto C, cleaved PARP, and cleaved caspase-3, but downregulated the protein expression of Bcl-2, Bcl-xl, pPI3k, and pAkt. piperine 0-8 BCL2 apoptosis regulator Homo sapiens 146-151 33645129-7 2021 Swertiamarin, gentiopicrin and sweroside were docked well with Bcl-2(1 GJH). gentiopicroside 14-26 BCL2 apoptosis regulator Homo sapiens 63-68 33645129-7 2021 Swertiamarin, gentiopicrin and sweroside were docked well with Bcl-2(1 GJH). sweroside 31-40 BCL2 apoptosis regulator Homo sapiens 63-68 33645129-11 2021 Gentiopicrin can reduce the Bcl-2 protein expression and the Bcl-2 mRNA expression, so as to promote the RA-FLSs apoptosis. gentiopicroside 0-12 BCL2 apoptosis regulator Homo sapiens 28-33 33645129-11 2021 Gentiopicrin can reduce the Bcl-2 protein expression and the Bcl-2 mRNA expression, so as to promote the RA-FLSs apoptosis. gentiopicroside 0-12 BCL2 apoptosis regulator Homo sapiens 61-66 33396645-6 2020 BCL2L10 is a pro-survival factor in melanoma since its expression reduced the cytotoxic effects of cisplatin, dacarbazine, and ABT-737 (a BCL2, Bcl-xL, and Bcl-w inhibitor). Cisplatin 99-108 BCL2 apoptosis regulator Homo sapiens 0-4 33414642-0 2020 BCL-2 Inhibitor Venetoclax Induces Autophagy-Associated Cell Death, Cell Cycle Arrest, and Apoptosis in Human Breast Cancer Cells. venetoclax 16-26 BCL2 apoptosis regulator Homo sapiens 0-5 33817287-8 2020 Meanwhile, the expression levels of cyclinD1, CDK4, and Bcl-2 were suppressed in cells with decitabine exposure, but Bax and caspase-3 expression levels were upregulated. Decitabine 92-102 BCL2 apoptosis regulator Homo sapiens 56-61 33488926-10 2020 Furthermore, melatonin inhibited significantly the expression of proapoptotic protein (Bax) and increased the expression of antiapoptotic proteins (Bcl-2 and Bcl-XL) (P < 0.05). Melatonin 13-22 BCL2 apoptosis regulator Homo sapiens 148-153 33396645-6 2020 BCL2L10 is a pro-survival factor in melanoma since its expression reduced the cytotoxic effects of cisplatin, dacarbazine, and ABT-737 (a BCL2, Bcl-xL, and Bcl-w inhibitor). Dacarbazine 110-121 BCL2 apoptosis regulator Homo sapiens 0-4 33396645-6 2020 BCL2L10 is a pro-survival factor in melanoma since its expression reduced the cytotoxic effects of cisplatin, dacarbazine, and ABT-737 (a BCL2, Bcl-xL, and Bcl-w inhibitor). ABT-737 127-134 BCL2 apoptosis regulator Homo sapiens 0-4 33505603-14 2020 6-GIN could increase Bcl-2 expression and decrease Bax and caspase-3 expression. gingerol 0-5 BCL2 apoptosis regulator Homo sapiens 21-26 33375871-8 2021 JZL184 treatment prevented OGD/R-caused increases in bax and cleaved caspase-3 expression and a decrease in bcl-2 expression. JZL 184 0-6 BCL2 apoptosis regulator Homo sapiens 108-113 33402832-9 2020 Western blot assay revealed that expression of pro-apoptosis protein Bax and C-Caspase 3 increased, but apoptosis-inhibitory protein Bcl-2 expression decreased with 40 mug/mL cis-platinum, 12.5 mug/mL allicin, 25 mug/mL allicin, and 50 mug/mL allicin, while compared to 40 mug/mL cis-platinum, Bax and C-Caspase 3 expression was increased by 50 mug/mL allicin. Cisplatin 175-187 BCL2 apoptosis regulator Homo sapiens 133-138 33402832-9 2020 Western blot assay revealed that expression of pro-apoptosis protein Bax and C-Caspase 3 increased, but apoptosis-inhibitory protein Bcl-2 expression decreased with 40 mug/mL cis-platinum, 12.5 mug/mL allicin, 25 mug/mL allicin, and 50 mug/mL allicin, while compared to 40 mug/mL cis-platinum, Bax and C-Caspase 3 expression was increased by 50 mug/mL allicin. allicin 201-208 BCL2 apoptosis regulator Homo sapiens 133-138 33372422-11 2020 Furthermore, the treatment of RPMI 2650 cells with dexamethasone increased apoptotic cell death, as shown by increased levels of BAX and cleaved caspase-3, decreased levels of Bcl-2, and an increased percentage of positive annexin V-PE stained cells. Dexamethasone 51-64 BCL2 apoptosis regulator Homo sapiens 176-181 33352965-7 2020 In cholangiocytes exposed to mitochondrial oxidative stress melatonin decreased the expression of proapoptotic stimuli (PTEN, Bax, miR-34), which was accompanied by the inhibition of a pivotal mediator of inflammatory response Nf-kappaB-p65 and the activation of antiapoptotic signaling (miR-132, Bcl2). Melatonin 60-69 BCL2 apoptosis regulator Homo sapiens 297-301 33289541-12 2020 TFNA treatment in IL-1beta-induced chondrocytes reduced apoptosis by activating the BCL2/BAX/caspase-3 pathway, inhibited oxidative stress by regulating the Nrf2/HO-1-signaling pathway, and enhanced autophagy through upregulated LC3-II, Beclin1, and Atg7. 4-(Trifluoromethyl)nicotinic acid 0-4 BCL2 apoptosis regulator Homo sapiens 84-88 33389946-4 2020 Moreover, the combined 5-FU/PCA exposure led to upregulation of p53 and downregulation of Bcl-2 protein when compared to the untreated control cells. Fluorouracil 23-27 BCL2 apoptosis regulator Homo sapiens 90-95 33389946-6 2020 The mechanisms by which the combined 5-FU/PCA exposure exerts its effects are associated with upregulation of p53 gene expression and downregulation of Bcl-2 level. Fluorouracil 37-41 BCL2 apoptosis regulator Homo sapiens 152-157 33389946-7 2020 Therefore, the combination of 5-FU with PCA not only could be a promising approach to potentially reduce the dose requirements of 5-FU but also could promote apoptosis via p53 and Bcl-2 signaling pathways. Fluorouracil 30-34 BCL2 apoptosis regulator Homo sapiens 180-185 33408606-6 2020 In a cellular model of PD, HS significantly attenuated 1-methyl-4-phenylpyridinium (MPP+)-induced apoptosis of DAergic-like neurons differentiated from SH-SY5Y cells by enhancing the expression of Bcl-2, suppressing the expression of cleaved Caspase 3 and preventing depolarization of mitochondrial membrane. 1-Methyl-4-phenylpyridinium 55-82 BCL2 apoptosis regulator Homo sapiens 197-202 33408606-6 2020 In a cellular model of PD, HS significantly attenuated 1-methyl-4-phenylpyridinium (MPP+)-induced apoptosis of DAergic-like neurons differentiated from SH-SY5Y cells by enhancing the expression of Bcl-2, suppressing the expression of cleaved Caspase 3 and preventing depolarization of mitochondrial membrane. mangion-purified polysaccharide (Candida albicans) 84-88 BCL2 apoptosis regulator Homo sapiens 197-202 33519472-7 2020 In STZ-diabetic mice, acacetin significantly upregulated the decreased signaling molecules (i.e. SOD, Bcl-2, PGC-1alpha, pAMPK, Sirt3 and Sirt1) in aorta tissue and attenuated atherosclerosis. acacetin 22-30 BCL2 apoptosis regulator Homo sapiens 102-107 33353129-9 2020 Results showed that crude hexane extract, citronellol, and citronellal significantly reduced cell proliferation, colony formation, and cell migration by inducing cell cycle arrest, while also inducing apoptosis in MDA-MB-231 cells through inhibition of anti-apoptotic Bcl-2 expression, leading to activation of the caspase-3-dependent pathway. Hexanes 26-32 BCL2 apoptosis regulator Homo sapiens 268-273 33353129-9 2020 Results showed that crude hexane extract, citronellol, and citronellal significantly reduced cell proliferation, colony formation, and cell migration by inducing cell cycle arrest, while also inducing apoptosis in MDA-MB-231 cells through inhibition of anti-apoptotic Bcl-2 expression, leading to activation of the caspase-3-dependent pathway. citronellol 42-53 BCL2 apoptosis regulator Homo sapiens 268-273 33353129-9 2020 Results showed that crude hexane extract, citronellol, and citronellal significantly reduced cell proliferation, colony formation, and cell migration by inducing cell cycle arrest, while also inducing apoptosis in MDA-MB-231 cells through inhibition of anti-apoptotic Bcl-2 expression, leading to activation of the caspase-3-dependent pathway. citronellal 59-70 BCL2 apoptosis regulator Homo sapiens 268-273 32603412-0 2020 Changes in Bcl-2 members in response to ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. ibrutinib 40-49 BCL2 apoptosis regulator Homo sapiens 11-16 32603412-4 2020 We investigated expression of Bcl-2 family members in patients under ibrutinib or venetoclax treatment combined with dissecting functional interactions of Bcl-2 family members in an in vitro model for venetoclax resistance. ibrutinib 69-78 BCL2 apoptosis regulator Homo sapiens 30-35 32993961-10 2020 The enhanced-apoptosis, and up-regulated Bax and C caspase-3 were reduced by miR-27a-3p mimic while inhibited by FOXO3; the down-regulated Bcl-2 of the LPS-induced cells was increased by miR-27a-3p mimic while inhibited by FOXO3. mir-27a-3p 77-87 BCL2 apoptosis regulator Homo sapiens 139-144 33381593-5 2020 Further research found ellagic acid and corilagin induced G2 phase cell cycle arrest by upregulating levels of P53, Bcl-2, caspase 3, and caspase 9, while the Bax was reduced. Ellagic Acid 23-35 BCL2 apoptosis regulator Homo sapiens 116-121 33381593-5 2020 Further research found ellagic acid and corilagin induced G2 phase cell cycle arrest by upregulating levels of P53, Bcl-2, caspase 3, and caspase 9, while the Bax was reduced. corilagin 40-49 BCL2 apoptosis regulator Homo sapiens 116-121 32993961-10 2020 The enhanced-apoptosis, and up-regulated Bax and C caspase-3 were reduced by miR-27a-3p mimic while inhibited by FOXO3; the down-regulated Bcl-2 of the LPS-induced cells was increased by miR-27a-3p mimic while inhibited by FOXO3. mir-27a-3p 187-197 BCL2 apoptosis regulator Homo sapiens 139-144 33019979-11 2020 In addition, podocyte apoptosis induced by HDAC4 overexpression was effectively rescued by FK506, a pharmacological inhibitor of CaN, which was accompanied by decreased Bax and increased Bcl-2 expression. Tacrolimus 91-96 BCL2 apoptosis regulator Homo sapiens 187-192 33437371-10 2020 Data from TCGA and Oncomine databases demonstrated that BCL2 was decreased in colon cancer compared with normal mucosa. oncomine 19-27 BCL2 apoptosis regulator Homo sapiens 56-60 33245769-0 2020 Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism. Serine 0-6 BCL2 apoptosis regulator Homo sapiens 25-30 33245769-1 2020 Bcl-2 phosphorylation at serine-70 (S70pBcl2) confers resistance against drug-induced apoptosis. Serine 25-31 BCL2 apoptosis regulator Homo sapiens 0-5 33245769-1 2020 Bcl-2 phosphorylation at serine-70 (S70pBcl2) confers resistance against drug-induced apoptosis. Serine 25-31 BCL2 apoptosis regulator Homo sapiens 36-44 33245769-4 2020 Increased S70pBcl2 levels are inversely correlated with DNA damage in chronic lymphocytic leukemia (CLL) and lymphoma patient-derived primary cells as well as in reactive oxygen species (ROS)- or chemotherapeutic drug-treated cell lines. Reactive Oxygen Species 162-185 BCL2 apoptosis regulator Homo sapiens 10-18 33245769-4 2020 Increased S70pBcl2 levels are inversely correlated with DNA damage in chronic lymphocytic leukemia (CLL) and lymphoma patient-derived primary cells as well as in reactive oxygen species (ROS)- or chemotherapeutic drug-treated cell lines. Reactive Oxygen Species 187-190 BCL2 apoptosis regulator Homo sapiens 10-18 33245769-6 2020 Empirically, sustained expression of the redox-sensitive S70pBcl2 prevents oxidative stress-induced DNA damage and cell death by suppressing mitochondrial ROS production. Reactive Oxygen Species 155-158 BCL2 apoptosis regulator Homo sapiens 57-65 33245769-7 2020 Using cell lines and lymphoma primary cells, we further demonstrate that S70pBcl2 reduces the interaction of Bcl-2 with the mitochondrial complex-IV subunit-5A, thereby reducing mitochondrial complex-IV activity, respiration and ROS production. Reactive Oxygen Species 229-232 BCL2 apoptosis regulator Homo sapiens 73-81 33245769-7 2020 Using cell lines and lymphoma primary cells, we further demonstrate that S70pBcl2 reduces the interaction of Bcl-2 with the mitochondrial complex-IV subunit-5A, thereby reducing mitochondrial complex-IV activity, respiration and ROS production. Reactive Oxygen Species 229-232 BCL2 apoptosis regulator Homo sapiens 109-114 33245769-9 2020 Collectively, we provide a novel facet of the anti-apoptotic Bcl-2 by demonstrating that its phosphorylation at serine-70 functions as a redox sensor to prevent drug-induced oxidative stress-mediated DNA damage and execution with potential therapeutic implications. Serine 112-118 BCL2 apoptosis regulator Homo sapiens 61-66 33334302-10 2021 Apoptotic cell death is inhibited by quercetin via down-regulation of Bax, and caspases, and upregulation of Bcl-2. Quercetin 37-46 BCL2 apoptosis regulator Homo sapiens 109-114 33333817-16 2020 There were 10 candidate compounds tentatively identified by LC-ESI-QTOF-MS. Three of identified compounds (7-octenoic acid, oleamide, and 1-phenyl-2-pentanol) showed anticancer activities by inducing cell cycle arrest and triggering apoptosis through suppressed Bcl-2 expression which subsequently promotes activation of caspase 3, indicators for the apoptosis pathway. 7-octenoic acid 107-122 BCL2 apoptosis regulator Homo sapiens 262-267 32988967-0 2020 AZD4320, a dual inhibitor of Bcl-2 and Bcl-xL, induces tumor regression in hematological cancer models without dose-limiting thrombocytopenia. AZD4320 0-7 BCL2 apoptosis regulator Homo sapiens 29-34 32988967-6 2020 RESULTS: We discovered AZD4320, which has nanomolar affinity for Bcl-2 and Bcl-xL, and mechanistically drives cell death through the mitochondrial apoptotic pathway. AZD4320 23-30 BCL2 apoptosis regulator Homo sapiens 65-70 32988967-7 2020 AZD4320 demonstrates activity in both Bcl-2 and Bcl-xL dependent hematological cancer cell lines and enhanced activity in AML patient samples compared to the Bcl-2 selective agent venetoclax. AZD4320 0-7 BCL2 apoptosis regulator Homo sapiens 38-43 32988967-8 2020 A single intravenous bolus dose of AZD4320 induces tumor regression with transient thrombocytopenia which recovers in less than a week, suggesting a clinical weekly schedule would enable targeting of Bcl-2/Bcl-xL dependent tumors without incurring dose-limiting thrombocytopenia. AZD4320 35-42 BCL2 apoptosis regulator Homo sapiens 200-205 32988967-10 2020 CONCLUSIONS: AZD4320 is a potent molecule with manageable thrombocytopenia risk to explore the utility of a dual Bcl-2/Bcl-xL inhibitor across a broad range of tumor types with dysregulation of Bcl-2 pro-survival proteins. AZD4320 13-20 BCL2 apoptosis regulator Homo sapiens 113-118 32988967-10 2020 CONCLUSIONS: AZD4320 is a potent molecule with manageable thrombocytopenia risk to explore the utility of a dual Bcl-2/Bcl-xL inhibitor across a broad range of tumor types with dysregulation of Bcl-2 pro-survival proteins. AZD4320 13-20 BCL2 apoptosis regulator Homo sapiens 194-199 32404571-3 2020 In this review article, we discuss current treatment strategies for CLL patients in Japan, where the novel targeted agents, the BTK inhibitor ibrutinib and BCL2 antagonist venetoclax, now are available and increasingly used in clinical practice. venetoclax 172-182 BCL2 apoptosis regulator Homo sapiens 156-160 33171188-0 2020 Down-regulation of Survivin and Bcl-2 concomitant with the activation of caspase-3 as a mechanism of apoptotic death in KG1a and K562 cells upon exposure to a derivative from ciprofloxacin family. Ciprofloxacin 175-188 BCL2 apoptosis regulator Homo sapiens 32-37 33171188-7 2020 The qRT PCR analysis showed that 4-DMOCP induces apoptosis in both cell lines via the down-regulation of Survivin and Bcl2, up-regulation of caspase-8 and -9, as well as a time-dependent increase in the Bax/Bcl2 transcripts. 4-dmocp 33-40 BCL2 apoptosis regulator Homo sapiens 118-122 33171188-7 2020 The qRT PCR analysis showed that 4-DMOCP induces apoptosis in both cell lines via the down-regulation of Survivin and Bcl2, up-regulation of caspase-8 and -9, as well as a time-dependent increase in the Bax/Bcl2 transcripts. 4-dmocp 33-40 BCL2 apoptosis regulator Homo sapiens 207-211 33217342-3 2020 BH3 mimetic resistance is characterized by decreased mitochondrial apoptotic priming as measured by BH3 profiling, both in PDX models and human clinical samples, due to alterations in BCL-2 family proteins that vary among cases, but not to acquired mutations in leukemia genes. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 184-189 33217342-1 2020 Acquired resistance to BH3 mimetic antagonists of BCL-2 and MCL-1 is an important clinical problem. BH 3 23-26 BCL2 apoptosis regulator Homo sapiens 50-55 33333817-16 2020 There were 10 candidate compounds tentatively identified by LC-ESI-QTOF-MS. Three of identified compounds (7-octenoic acid, oleamide, and 1-phenyl-2-pentanol) showed anticancer activities by inducing cell cycle arrest and triggering apoptosis through suppressed Bcl-2 expression which subsequently promotes activation of caspase 3, indicators for the apoptosis pathway. oleylamide 124-132 BCL2 apoptosis regulator Homo sapiens 262-267 33333817-16 2020 There were 10 candidate compounds tentatively identified by LC-ESI-QTOF-MS. Three of identified compounds (7-octenoic acid, oleamide, and 1-phenyl-2-pentanol) showed anticancer activities by inducing cell cycle arrest and triggering apoptosis through suppressed Bcl-2 expression which subsequently promotes activation of caspase 3, indicators for the apoptosis pathway. 1-Phenyl-2-pentanol 138-157 BCL2 apoptosis regulator Homo sapiens 262-267 32430093-4 2020 This study describes the mechanistic analyses of the novel anthracycline, pivarubicin, and its in vivo efficacy against human primary TNBC.

Pivarubicin directly activates PKC-delta, triggers rapid mitochondrial-dependent apoptosis and circumvents resistance conferred by overexpression of P-glycoprotein, Bcl-2, Bcl-XL and Bcr-Abl. Anthracyclines 59-72 BCL2 apoptosis regulator Homo sapiens 311-316 33327489-3 2020 The results show that ABN-B inhibited the proliferation of four human lung cancer cell lines (A549, BZR, H1975, and H226) and induced apoptosis, based on the cleavage of caspase-7 and PARP (poly (ADP-ribose) polymerase), as well as the downregulation of Bcl-2. albanol B 22-27 BCL2 apoptosis regulator Homo sapiens 254-259 33403016-10 2020 Navitoclax monotreatment was shown to be highly effective when treating BCL-2-positive cell lines (IC50-values ranging from 96.0 to 323.0 nM). navitoclax 0-10 BCL2 apoptosis regulator Homo sapiens 72-77 33305590-6 2021 Anti-apoptotic protein Bcl-2 was observed to be decreased by 62% at 20 microg/ml concentration and a significant increase in ROS production up to 6.9-fold was observed in time dependent manner. ros 125-128 BCL2 apoptosis regulator Homo sapiens 23-28 33362534-5 2020 Second, we found that quercetin-induced apoptosis depends on the decrease of mitochondria membrane potential (MMP) and Bcl-2 proteins. Quercetin 22-31 BCL2 apoptosis regulator Homo sapiens 119-124 33362534-7 2020 Consistently, cell studies also identified that VEGFR2 and PI3K/Akt signaling pathways are involved in the action of quercetin on mitochondria and Bcl-2 proteins. Quercetin 117-126 BCL2 apoptosis regulator Homo sapiens 147-152 32430093-4 2020 This study describes the mechanistic analyses of the novel anthracycline, pivarubicin, and its in vivo efficacy against human primary TNBC.

Pivarubicin directly activates PKC-delta, triggers rapid mitochondrial-dependent apoptosis and circumvents resistance conferred by overexpression of P-glycoprotein, Bcl-2, Bcl-XL and Bcr-Abl. pivarubicin 74-85 BCL2 apoptosis regulator Homo sapiens 311-316 32430093-4 2020 This study describes the mechanistic analyses of the novel anthracycline, pivarubicin, and its in vivo efficacy against human primary TNBC.

Pivarubicin directly activates PKC-delta, triggers rapid mitochondrial-dependent apoptosis and circumvents resistance conferred by overexpression of P-glycoprotein, Bcl-2, Bcl-XL and Bcr-Abl. pivarubicin 146-157 BCL2 apoptosis regulator Homo sapiens 311-316 33297583-11 2020 Consistently, 2-DG increased mitochondrial dysfunction and upregulated Bax/Bcl-2, promoting cytochrome c release to initiate procaspase 3 cleavage induced by buforin IIb. Deoxyglucose 14-18 BCL2 apoptosis regulator Homo sapiens 75-80 33280362-6 2020 Results: Increasing glucose concentration decreased the proliferation of THP-1-derived macrophages (day 7, A values in low, medium and high glucose groups were 0.369+-0.014, 0.214+-0.009 and 0.200+-0.010, respectively, P<0.01) as well as the survival rate (P<0.05), promoted the expression of miR-126, B-cell lymphoma-2 (Bcl-2)-associated X protein (BAX) and caspase-3 (P<0.05), and suppressed Bcl-2, phosphoinositol-3 kinase regulatory subunit 2 (PIK3R2) expression (P<0.05). Glucose 20-27 BCL2 apoptosis regulator Homo sapiens 302-319 33280362-6 2020 Results: Increasing glucose concentration decreased the proliferation of THP-1-derived macrophages (day 7, A values in low, medium and high glucose groups were 0.369+-0.014, 0.214+-0.009 and 0.200+-0.010, respectively, P<0.01) as well as the survival rate (P<0.05), promoted the expression of miR-126, B-cell lymphoma-2 (Bcl-2)-associated X protein (BAX) and caspase-3 (P<0.05), and suppressed Bcl-2, phosphoinositol-3 kinase regulatory subunit 2 (PIK3R2) expression (P<0.05). Glucose 20-27 BCL2 apoptosis regulator Homo sapiens 321-326 33280362-7 2020 After the miR-126 mimic was transfected in cells in low glucose medium for 72 h, compared with negative control (1.005+-0.118), the expression of miR-126 significantly increased (2 980.227+-170.431, P<0.05), and the proliferation of THP-1 derived macrophages decreased (negative control: 1.816+-0.013, mimic group: 1.310+-0.048, P<0.01), the level of BAX and caspase-3 significantly increased (P<0.01, P<0.05), PIK3R2 and Bcl-2 significantly decreased (P<0.05, P<0.01). Glucose 56-63 BCL2 apoptosis regulator Homo sapiens 422-427 33335403-6 2020 The expression of some apoptotic and autophagy-related genes such as Bax, Bcl2, Beclin1 and ATG7 was significantly induced by carbon-ion beam irradiation alone and was further enhanced when the beam was combined with 5-FU. Carbon 126-132 BCL2 apoptosis regulator Homo sapiens 74-78 33335403-6 2020 The expression of some apoptotic and autophagy-related genes such as Bax, Bcl2, Beclin1 and ATG7 was significantly induced by carbon-ion beam irradiation alone and was further enhanced when the beam was combined with 5-FU. Fluorouracil 217-221 BCL2 apoptosis regulator Homo sapiens 74-78 32810491-9 2020 Moreover, miR-181a was shown to increase the sub G1 cell cycle arrest and apoptosis induction by carmustine via regulating the expression of related genes including caspase-9, Bcl-2, and SIRT1. mir-181a 10-18 BCL2 apoptosis regulator Homo sapiens 176-181 32738393-15 2020 Therefore, we speculated that TMF-induced apoptosis might be achieved by regulating the p53-Bcl-2/Bax-caspase-3 pathways. triflumuron 30-33 BCL2 apoptosis regulator Homo sapiens 92-97 32810491-9 2020 Moreover, miR-181a was shown to increase the sub G1 cell cycle arrest and apoptosis induction by carmustine via regulating the expression of related genes including caspase-9, Bcl-2, and SIRT1. Carmustine 97-107 BCL2 apoptosis regulator Homo sapiens 176-181 33747527-11 2021 EGCG treatment also resulted in a significant decrease in Bcl-2, MCL-1, and Vimentin, and an increase in E-cadherin. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 58-63 33017186-6 2020 Moreover, LPS exposure resulted in increased expression of BAX and cleaved caspase3, and decreased expression of BCL-2 and BMP-7 in vivo and in vitro; TMP195 treatment reversed these responses. TMP195 151-157 BCL2 apoptosis regulator Homo sapiens 113-118 31852250-4 2020 The apoptotic effects were evaluated using flow cytometry, and the results showed that cytisine induced mitochondrial-dependent apoptosis through loss of the mitochondrial membrane potential; increased expression of BAD, cleaved caspase-3, and cleaved-PARP; and decreased expression levels of Bcl-2, pro-caspase-3, and pro-PARP. cytisine 87-95 BCL2 apoptosis regulator Homo sapiens 293-298 33288558-6 2020 In cells, (+)-betulin down-regulated NF-kappaB p50 and 65, IKKalpha and beta, ICAM-1 and bcl-2 expressions. betulin 14-21 BCL2 apoptosis regulator Homo sapiens 89-94 31851841-12 2020 Taraxasterol resulted in a significant decrease in caspase-3 activity and bcl-2 expression, as well as increase in bax expression. taraxasterol 0-12 BCL2 apoptosis regulator Homo sapiens 74-79 32992248-1 2020 Anthracycline anticancer drugs show multiple strategies of action on gene functioning by regulation of telomerase enzyme by apoptotic factors, e.g. ceramide level, p53 activity, bcl-2 protein levels, besides inhibiting DNA/RNA synthesis and topoisomerase-II action. Anthracyclines 0-13 BCL2 apoptosis regulator Homo sapiens 178-183 33068964-4 2020 In this study, hydrogen peroxide (H2O2) administration induced apoptosis in HTR-8/SVneo trophoblast cells, evidenced by decreased level of Bcl-2 and increased levels of Bax and cleaved caspase-3. Hydrogen Peroxide 15-32 BCL2 apoptosis regulator Homo sapiens 139-144 33068964-4 2020 In this study, hydrogen peroxide (H2O2) administration induced apoptosis in HTR-8/SVneo trophoblast cells, evidenced by decreased level of Bcl-2 and increased levels of Bax and cleaved caspase-3. Hydrogen Peroxide 34-38 BCL2 apoptosis regulator Homo sapiens 139-144 33130346-5 2020 Additionally, 6a and 6e counteracted H2O2-induced mitochondrial dysfunction, which was supported by maintaining mitochondrial membrane potential, attenuating BAX protein, and increasing BCL-2 protein within the mitochondria as well as upregulating SOD2 mitochondrial antioxidant enzyme. Hydrogen Peroxide 37-41 BCL2 apoptosis regulator Homo sapiens 186-191 33113434-9 2020 Furthermore, paclitaxel could upregulate the Bax / Bcl-2 ratio by inhibiting HSP27 expression, and in turn, promoting apoptosis due to hyperthermia. Paclitaxel 13-23 BCL2 apoptosis regulator Homo sapiens 51-56 32827965-4 2020 Results showed that apoptosis of treatment groups was significantly inhibited, and decreased reactive oxygen species (ROS) production played a key role in the inhibitory effects by upregulating Bcl-2 and downregulating Caspase-3/9. Reactive Oxygen Species 93-116 BCL2 apoptosis regulator Homo sapiens 194-199 32836151-6 2020 Moreover, co-treatment with Cd and 3-MA could notably elevate Caspase-3, Cyt C, Bax, and Bak-1 mRNA levels, Caspase-3 and cleaved Caspase-3 protein levels, and cell apoptotic rate as well as cell damage, decreased mitochondrial membrane potential (MMP), Bcl-2 mRNA level and the ratio of Bcl-2 to Bax compared to treatment with Cd alone. Cadmium 28-30 BCL2 apoptosis regulator Homo sapiens 254-259 32836151-6 2020 Moreover, co-treatment with Cd and 3-MA could notably elevate Caspase-3, Cyt C, Bax, and Bak-1 mRNA levels, Caspase-3 and cleaved Caspase-3 protein levels, and cell apoptotic rate as well as cell damage, decreased mitochondrial membrane potential (MMP), Bcl-2 mRNA level and the ratio of Bcl-2 to Bax compared to treatment with Cd alone. Cadmium 28-30 BCL2 apoptosis regulator Homo sapiens 288-293 32827965-4 2020 Results showed that apoptosis of treatment groups was significantly inhibited, and decreased reactive oxygen species (ROS) production played a key role in the inhibitory effects by upregulating Bcl-2 and downregulating Caspase-3/9. Reactive Oxygen Species 118-121 BCL2 apoptosis regulator Homo sapiens 194-199 32836151-6 2020 Moreover, co-treatment with Cd and 3-MA could notably elevate Caspase-3, Cyt C, Bax, and Bak-1 mRNA levels, Caspase-3 and cleaved Caspase-3 protein levels, and cell apoptotic rate as well as cell damage, decreased mitochondrial membrane potential (MMP), Bcl-2 mRNA level and the ratio of Bcl-2 to Bax compared to treatment with Cd alone. 3-methyladenine 35-39 BCL2 apoptosis regulator Homo sapiens 254-259 32866757-7 2020 Compounds 4n and 4q acted on mitochondria to cause an increase in intracellular reactive oxygen species and a change in the level of apoptosis-related protein (Bcl-2, Bcl-xL and Bax), which resulted in a decrease in membrane potential and activation of caspase family to induce cancer cells apoptosis. 4q 17-19 BCL2 apoptosis regulator Homo sapiens 160-165 32836151-6 2020 Moreover, co-treatment with Cd and 3-MA could notably elevate Caspase-3, Cyt C, Bax, and Bak-1 mRNA levels, Caspase-3 and cleaved Caspase-3 protein levels, and cell apoptotic rate as well as cell damage, decreased mitochondrial membrane potential (MMP), Bcl-2 mRNA level and the ratio of Bcl-2 to Bax compared to treatment with Cd alone. 3-methyladenine 35-39 BCL2 apoptosis regulator Homo sapiens 288-293 33074527-6 2020 BH3 profiling and other preclinical methods have identified several high-risk subtypes, such as hypodiplod, early T-cell precursor, immature T-cell, KMT2A-rearranged, Ph-positive and TCF-HLF-positive ALL, that may respond to BCL-2 inhibitor venetoclax. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 225-230 33011276-8 2020 The anti-apoptotic effect of MitoQ was associated with upregulation of Bcl-2, downregulation of Bax, and increased Nrf2 expression. mitoquinone 29-34 BCL2 apoptosis regulator Homo sapiens 71-76 32861782-1 2020 The present study aims to evaluate the inhibitory effects of artesunate (a semi-synthetic derivative of artemisinin) on HSP70 and Bcl-2 expression in two breast cancer cell lines, 4T1 and MCF-7. Artesunate 61-71 BCL2 apoptosis regulator Homo sapiens 130-135 32861782-1 2020 The present study aims to evaluate the inhibitory effects of artesunate (a semi-synthetic derivative of artemisinin) on HSP70 and Bcl-2 expression in two breast cancer cell lines, 4T1 and MCF-7. artemisinin 104-115 BCL2 apoptosis regulator Homo sapiens 130-135 32861782-7 2020 Furthermore, artesunate significantly down-regulated the expression of Bcl-2 and HSP70 while enhancing the expression of cleaved caspase-9 in MCF-7 and 4T1 cells. Artesunate 13-23 BCL2 apoptosis regulator Homo sapiens 71-76 32281434-5 2020 Taken together, these results indicated that flaxseed orbitides induced apoptosis via the mitochondrial pathway, releasing Cyt C, increasing Bax/Bcl-2 ratio and elevating the expression of cleaved caspase 9 and 3 in SGC-7901 cells. flaxseed orbitides 45-63 BCL2 apoptosis regulator Homo sapiens 145-150 32367199-0 2020 The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cells. obatoclax 24-33 BCL2 apoptosis regulator Homo sapiens 8-13 32200503-6 2020 CUDC-907 enhanced expressions of death receptor 5 (DR5), reduced the levels of anti-apoptotic molecules XIAP, Bcl-2 and Bcl-xL. CUDC-907 0-8 BCL2 apoptosis regulator Homo sapiens 110-115 33209128-4 2020 Additionally, p53+/+ HeLa cells treated with CDS-3078 presented with dysfunctional mitochondria, as indicated by the decrease in Bcl-2 levels, the increase in Bcl-2 homologous antagonist killer and the increase in cytochrome c release from the mitochondria to the cytoplasm. cds-3078 45-53 BCL2 apoptosis regulator Homo sapiens 129-134 33209128-4 2020 Additionally, p53+/+ HeLa cells treated with CDS-3078 presented with dysfunctional mitochondria, as indicated by the decrease in Bcl-2 levels, the increase in Bcl-2 homologous antagonist killer and the increase in cytochrome c release from the mitochondria to the cytoplasm. cds-3078 45-53 BCL2 apoptosis regulator Homo sapiens 159-164 33209130-9 2020 Taken together, atovaquone reduced the tumorsphere formation and invasion ability of EpCAM+CD44+ HCT-116 cells, at least in part by increasing the expression of TIMP-1 and downregulating the expression of MMP-2 and -9, as well as the cells" viability by inducing cell-cycle arrest in S-phase and induction of apoptosis via the Bcl-2/Bax pathway under hypoxic conditions. Atovaquone 16-26 BCL2 apoptosis regulator Homo sapiens 327-332 33191863-10 2020 VU0359595 also strengthened bortezomib-induced apoptosis via activating caspase-8, caspase-9, caspase-3; and down-regulating the expressions of anti-apoptosis proteins BCL-2. VU0359595 0-9 BCL2 apoptosis regulator Homo sapiens 168-173 33191863-10 2020 VU0359595 also strengthened bortezomib-induced apoptosis via activating caspase-8, caspase-9, caspase-3; and down-regulating the expressions of anti-apoptosis proteins BCL-2. Bortezomib 28-38 BCL2 apoptosis regulator Homo sapiens 168-173 33125094-12 2020 Treatment with the NF-kappaB inhibitor, BAY 11-7082, decreased Cyclin D1 and Bcl-2 expression levels. 3-(4-methylphenylsulfonyl)-2-propenenitrile 40-51 BCL2 apoptosis regulator Homo sapiens 77-82 32781854-5 2020 KM6 retained the sensitivity of LCC2 through upregulation of key enzymes of apoptosis and proteins of cell death including caspases 3, 8, 9, P53, BAX/BCL-2 ratio and LDH in media. km6 0-3 BCL2 apoptosis regulator Homo sapiens 150-155 32208781-5 2020 Afterwards, spirooxindole 6a was assessed for its apoptosis induction potential in HepG2 cells, where its pro-apoptotic impact was approved via the significant elevation in the Bax/Bcl-2 ratio and the expression levels of caspase-3. spirooxindole 6a 12-28 BCL2 apoptosis regulator Homo sapiens 181-186 32522063-0 2020 Novel [(N-alkyl-3-indolylmethylene)hydrazono]oxindoles arrest cell cycle and induce cell apoptosis by inhibiting CDK2 and Bcl-2: synthesis, biological evaluation and in silico studies. [(n-alkyl-3-indolylmethylene)hydrazono]oxindoles 6-54 BCL2 apoptosis regulator Homo sapiens 122-127 32515250-11 2020 Additionally, IKKgamma silencing inhibited expression of Bcl-XL, Bcl-2, and cyclin D1.Conclusions: Curcumin enhances LSCC radiosensitivity via NF-KappaB inhibition by suppressing IKKgamma expression. Curcumin 99-107 BCL2 apoptosis regulator Homo sapiens 65-70 33258341-5 2020 Mechanistically, PTL treatment resulted in downregulation of NF-kappaB activity and Bcl-2 expression, and upregulation of Caspase-8 activity. parthenolide 17-20 BCL2 apoptosis regulator Homo sapiens 84-89 32651543-6 2020 Furthermore, the combination of a pan-RAF and a BCL2 inhibitor overcame resistance to either compound alone in AML cell lines, as well as synergized and induced long-term responses ex vivo in AML patient samples relapsed or refractory to azacitidine + venetoclax treatment. Azacitidine 238-249 BCL2 apoptosis regulator Homo sapiens 48-52 32783381-0 2020 Chidamide acts on the histone deacetylase-mediated miR-34a/Bcl-2 axis to regulate NB4 cell line proliferation and apoptosis. N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 0-9 BCL2 apoptosis regulator Homo sapiens 59-64 32783381-7 2020 Functionally, Chidamide inhibits cell proliferation and promotes apoptosis through miR-34a/Bcl-2. N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14-23 BCL2 apoptosis regulator Homo sapiens 91-96 32783381-8 2020 Chidamide exerts its anticancer effect via the HDAC-mediated miR-34a/Bcl-2 axis, providing potential targets for APL therapy. N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 0-9 BCL2 apoptosis regulator Homo sapiens 69-74 32919690-7 2020 Furthermore, results of real-time quantitative PCR (RT-qPCR) and western blot analysis further validated the anticancer effect of FA-Ce6/DOX/BNPs, as evidenced by elevated gene/protein expression levels of apoptotic biomarkers p53, BID, caspase-3, cleaved poly(ADP-ribose) polymerase 1 (PARP-1), and BAX, contrary to levels of the anti-apoptotic marker Bcl-2. Doxorubicin 137-140 BCL2 apoptosis regulator Homo sapiens 353-358 32919690-5 2020 Moreover, FA-Ce6/DOX/BNPs potentiated mitochondrial reactive oxygen species (ROS) production in HeLa cells under 671-nm laser exposure, leading to activation of key regulator proteins of apoptosis such as BH3 interacting-domain death agonist (BID), B-cell lymphoma 2 (Bcl-2), and Bcl-2-associated X (BAX), as well as induction of the caspase cascade and mitochondrial ROS-mediated cell death. Doxorubicin 17-20 BCL2 apoptosis regulator Homo sapiens 249-266 33174055-2 2020 In the present study, syringic acid (SyrA) was found to exhibit no cytotoxicity on NP cells, and was able to reverse the cytotoxicity, as well as the abnormal expression of Bcl-2 and caspase-3, that were induced by lipopolysaccharide (LPS). syringic acid 22-35 BCL2 apoptosis regulator Homo sapiens 173-178 32919690-5 2020 Moreover, FA-Ce6/DOX/BNPs potentiated mitochondrial reactive oxygen species (ROS) production in HeLa cells under 671-nm laser exposure, leading to activation of key regulator proteins of apoptosis such as BH3 interacting-domain death agonist (BID), B-cell lymphoma 2 (Bcl-2), and Bcl-2-associated X (BAX), as well as induction of the caspase cascade and mitochondrial ROS-mediated cell death. Doxorubicin 17-20 BCL2 apoptosis regulator Homo sapiens 268-273 32767230-7 2020 In contrast, overexpression of Bcl-2, another mitochondrial protein, in Molt-4 cells abolished the endogenous ceramide accumulation and apoptosis. Ceramides 110-118 BCL2 apoptosis regulator Homo sapiens 31-36 32767230-9 2020 In contrast, Bcl-2 functions as a broader inhibitor of both ceramide accumulation and apoptosis. Ceramides 60-68 BCL2 apoptosis regulator Homo sapiens 13-18 32767230-10 2020 Altogether, these results indicate that members of the Bcl-2 family differentially regulate ceramide accumulation and reveal the existence of crosstalk between Bcl-2 family members and ceramide in mediating p53-dependent apoptosis in Molt-4 human T-cell leukemia. Ceramides 92-100 BCL2 apoptosis regulator Homo sapiens 55-60 32767230-10 2020 Altogether, these results indicate that members of the Bcl-2 family differentially regulate ceramide accumulation and reveal the existence of crosstalk between Bcl-2 family members and ceramide in mediating p53-dependent apoptosis in Molt-4 human T-cell leukemia. Ceramides 185-193 BCL2 apoptosis regulator Homo sapiens 55-60 32711615-0 2020 Nano-Cerium Oxide Promotes Proliferation of Hepatoma Cells and Regulates mRNA Expression of Apoptosis-Related Genes Bcl-2 and Bax, as Detected Through Real-Time Fluorescent Quantitative Polymerase Chain Reaction. ceric oxide 5-17 BCL2 apoptosis regulator Homo sapiens 116-121 32711615-1 2020 In this study, we aim to investigate the effects of nano-cerium oxide (CNPs) on the proliferation of hepatoma cells and expression of the Bcl-2 and Bax mRNAs. ceric oxide 57-69 BCL2 apoptosis regulator Homo sapiens 138-143 33174048-8 2020 The results demonstrated that the protein expression levels of Bcl-2 were decreased, whereas those of Bax, cleaved poly ADP-ribose polymerase, cleaved caspase-9 and p53 were upregulated in a dose-dependent manner in apigenin-treated cells compared with those noted in untreated cells. Apigenin 216-224 BCL2 apoptosis regulator Homo sapiens 63-68 33174055-2 2020 In the present study, syringic acid (SyrA) was found to exhibit no cytotoxicity on NP cells, and was able to reverse the cytotoxicity, as well as the abnormal expression of Bcl-2 and caspase-3, that were induced by lipopolysaccharide (LPS). syringic acid 37-41 BCL2 apoptosis regulator Homo sapiens 173-178 33293826-8 2020 Moreover, the combination of apatinib and raltitrexed down-regulated mRNA level of the anti-apoptotic protein Bcl-2, while up-regulated pro-apoptotic protein PARP, Bax, and caspase-3 transcription. apatinib 29-37 BCL2 apoptosis regulator Homo sapiens 110-115 33125135-11 2020 PF treatment significantly decreased the proliferation of Hep3B and Huh7 cells in a dose-dependent manner, reduced the mitochondrial membrane potential, increased ROS levels, decreased the protein levels of Bcl-2, and increased the protein levels of Bax and cleaved caspase-3 and 9, suggesting that PF mediated HCC apoptosis via a mitochondrial pathway. pf 0-2 BCL2 apoptosis regulator Homo sapiens 207-212 33125118-12 2020 In view of these corrections, in the "Matrine induces cell apoptosis by increasing Bim and Bax and decreasing Bcl-2 protein levels in prostate cancer cell lines" subsection of the Results section towards the bottom of p. 2822, in the penultimate sentence, the text "...LY294002 resulted in 25.88% cell apoptosis in the PC-3 cells and 18.88% in the RWPE1 cells, compared to 3.11 and 6.89%, respectively, with LY294002 treatment only (Fig. matrine 38-45 BCL2 apoptosis regulator Homo sapiens 110-115 31875458-5 2020 Moreover, ML downregulated the expression of Bcl-2 and Bcl-xL and induced cell cycle arrest in the G2/M phase. lucidone 10-12 BCL2 apoptosis regulator Homo sapiens 45-50 33303057-12 2020 Moreover, CG can induce apoptosis with bcl-2 protein decrease. cg 10-12 BCL2 apoptosis regulator Homo sapiens 39-44 33243748-13 2020 Blocking autophagy with 3-MA significantly increased DDP- induced apoptosis of SKOV3 cells with IL-17RA silencing, lowered the expression of Bcl-2 and enhanced Bax expression in the cells (P < 0.05). 3-methyladenine 24-28 BCL2 apoptosis regulator Homo sapiens 141-146 33260158-5 2020 Autophagy inhibition using 3-methyladenine (3-MA) or Atg5-targeted siRNA decreased the Bax/Bcl-2 ratio, caspase-3 activation, and PARP cleavage and protected cells against ISO-induced apoptosis. 3-methyladenine 44-48 BCL2 apoptosis regulator Homo sapiens 91-96 33256538-14 2022 H2O2-caused a decrease in bcl-2 expression and increases in bax expression and caspase-3 activity were mitigated by aloperine. Hydrogen Peroxide 0-4 BCL2 apoptosis regulator Homo sapiens 26-31 33256538-14 2022 H2O2-caused a decrease in bcl-2 expression and increases in bax expression and caspase-3 activity were mitigated by aloperine. aloperine 116-125 BCL2 apoptosis regulator Homo sapiens 26-31 33241675-1 2021 BH3-mimetics inhibiting anti-apoptotic BCL-2 proteins represent a novel and promising class of antitumor drugs. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 39-44 33312221-5 2020 Both BBR and miR-214-3p mimic reduced the cell viability, repressed migration and invasion capacities, increased rates of total apoptotic cells and ratio of Bax/Bcl-2, and increased the percentage of G2/M cells of MCF-7 and MDA-MB-231 cells by colony formation and CKK8 assay, scratch wound healing and gelatin-based 3D conformation assay, transwell invasion assay, and cell cycle analysis, respectively. Berberine 5-8 BCL2 apoptosis regulator Homo sapiens 161-166 33312221-5 2020 Both BBR and miR-214-3p mimic reduced the cell viability, repressed migration and invasion capacities, increased rates of total apoptotic cells and ratio of Bax/Bcl-2, and increased the percentage of G2/M cells of MCF-7 and MDA-MB-231 cells by colony formation and CKK8 assay, scratch wound healing and gelatin-based 3D conformation assay, transwell invasion assay, and cell cycle analysis, respectively. mir-214-3p 13-23 BCL2 apoptosis regulator Homo sapiens 161-166 33239070-13 2020 Combination treatment with necroptosis-inducing small molecules, including a SMAC mimetic (LCL161) and a pan-BCL2 inhibitor (ABT-263), showed therapeutic efficacy in YARS-overexpressing breast cancer cells. navitoclax 125-132 BCL2 apoptosis regulator Homo sapiens 109-113 33256166-0 2020 Design, Synthesis and Evaluation of New Bioactive Oxadiazole Derivatives as Anticancer Agents Targeting Bcl-2. Oxadiazoles 50-60 BCL2 apoptosis regulator Homo sapiens 104-109 33256166-1 2020 A series of 2-(1H-indol-3-yl)-5-substituted-1,3,4-oxadiazoles, 4a-m, were designed, synthesized and tested in vitro as potential pro-apoptotic Bcl-2 inhibitory anticancer agents based on our previously reported hit compounds. 2-(1h-indol-3-yl)-5-substituted-1,3,4-oxadiazoles 12-61 BCL2 apoptosis regulator Homo sapiens 143-148 33256166-5 2020 Moreover, 4j showed binding that was two-fold more potent than the positive control gossypol in the Bcl-2 ELISA binding affinity assay. Gossypol 84-92 BCL2 apoptosis regulator Homo sapiens 100-105 33244272-0 2020 Biomolecular Factors Represented by Bcl-2, p53, and Tumor-Infiltrating Lymphocytes Predict Response for Adjuvant Anthracycline Chemotherapy in Patients with Early Triple-Negative Breast Cancer. Anthracyclines 113-126 BCL2 apoptosis regulator Homo sapiens 36-41 33223507-8 2020 SRT2183 inhibited the growth of ovarian cancer cells, increased the accumulation of BAX, cleaved-caspase 3 and cleaved-PARP, and decreased the level of anti-apoptotic Bcl-2 and Mcl-1. SRT2183 0-7 BCL2 apoptosis regulator Homo sapiens 167-172 33262626-15 2020 Conclusion: MIR503HG indirectly regulates Bcl-2 by promoting the co-transcription of miRNA-503 to participate high-glucose-induced proximal tubular cell apoptosis, providing a new target for diabetic nephropathy treatment. Glucose 115-122 BCL2 apoptosis regulator Homo sapiens 42-47 33197310-3 2020 A Bcl-2-dephosphorylation probe, S1-6e, was designed by installing a carboxylic acid group to a Bcl-2 inhibitor. Carboxylic Acids 69-84 BCL2 apoptosis regulator Homo sapiens 2-7 33197310-3 2020 A Bcl-2-dephosphorylation probe, S1-6e, was designed by installing a carboxylic acid group to a Bcl-2 inhibitor. Carboxylic Acids 69-84 BCL2 apoptosis regulator Homo sapiens 96-101 33266494-8 2020 This notion was evidenced by DHME-elicited upregulation of poly (ADP-ribose) polymerase (PARP) cleavage and a cell population positively stained by annexin V, alongside the downregulation of antiapoptotic B-cell lymphoma 2 (BCL-2), whereas the blockade of apoptosis by the pan-caspase inhibitor z-VAD-fmk attenuated DHME-induced cytotoxicity. dhme 29-33 BCL2 apoptosis regulator Homo sapiens 205-222 33266494-8 2020 This notion was evidenced by DHME-elicited upregulation of poly (ADP-ribose) polymerase (PARP) cleavage and a cell population positively stained by annexin V, alongside the downregulation of antiapoptotic B-cell lymphoma 2 (BCL-2), whereas the blockade of apoptosis by the pan-caspase inhibitor z-VAD-fmk attenuated DHME-induced cytotoxicity. dhme 29-33 BCL2 apoptosis regulator Homo sapiens 224-229 33262626-0 2020 LncRNA MIR503HG Promotes High-Glucose-Induced Proximal Tubular Cell Apoptosis by Targeting miR-503-5p/Bcl-2 Pathway. Glucose 30-37 BCL2 apoptosis regulator Homo sapiens 102-107 33262626-12 2020 Bcl-2 expression was inhibited and levels of apoptosis-related proteins Cytc and Bax were increased in HK-2 cells cultured in high glucose, all of which promoted the caspase cascade reaction, leading to increased caspase-9 and caspase-3 shear fragments inducing apoptosis of the mitochondrial pathway. Glucose 131-138 BCL2 apoptosis regulator Homo sapiens 0-5 33312341-7 2020 Western blot analysis showed that 6,8-diprenylorobol treatment increased the expression of cleaved PARP1, cleaved caspase-3, FOXO3, Bax, Bim, p21, and p27 but decreased the expression of Bcl2 and BclXL. 6,8-Diprenylorobol 34-52 BCL2 apoptosis regulator Homo sapiens 187-191 33239867-12 2020 Importantly, loxoprofen showed a beneficial role in protecting endothelial apoptosis by mitigating apoptotic machinery including the balanced expression of Bax, Bcl-2, and caspase-3 cleavage. loxoprofen 13-23 BCL2 apoptosis regulator Homo sapiens 161-166 33312355-5 2020 Our results demonstrated that Selaginellin B induced apoptosis, as evidenced by the increased cleaved caspase-3 level and Bax/Bcl-2 ratio. (R,S)-4-((4'-methoxy-4-(methyl)-3-((4-methoxyphenyl)ethynyl)biphenyl-2-yl)(4-methoxyphenyl)methylene)-2,5-cyclohexadien-1-one, 30-44 BCL2 apoptosis regulator Homo sapiens 126-131 32739595-9 2020 Moreover, GC4419 increased IR-induced Bax levels with decreased Bcl-2 and elevated Bax/Bcl-2 ratio following treatment. imisopasem manganese 10-16 BCL2 apoptosis regulator Homo sapiens 64-69 32739595-9 2020 Moreover, GC4419 increased IR-induced Bax levels with decreased Bcl-2 and elevated Bax/Bcl-2 ratio following treatment. imisopasem manganese 10-16 BCL2 apoptosis regulator Homo sapiens 87-92 33146015-3 2020 Through their design and development, BH3 mimetics that target the hydrophobic groove of specific anti-apoptotic Bcl-2 proteins have the potential to become anticancer drugs. BH 3 38-41 BCL2 apoptosis regulator Homo sapiens 113-118 33199836-6 2021 We hypothesized that PegC-mediated plasma glutamine depletion inhibits 4EBP1 phosphorylation, decreases the expression of proteins such as MCL-1, whose translation is cap dependent, synergizing with the BCL-2 inhibitor Ven. pegc 21-25 BCL2 apoptosis regulator Homo sapiens 203-208 33199836-6 2021 We hypothesized that PegC-mediated plasma glutamine depletion inhibits 4EBP1 phosphorylation, decreases the expression of proteins such as MCL-1, whose translation is cap dependent, synergizing with the BCL-2 inhibitor Ven. Glutamine 42-51 BCL2 apoptosis regulator Homo sapiens 203-208 33184407-6 2020 The bound pro-apoptotic ligands can be displaced by the BCL-2-selective inhibitor ABT-199 efficiently, and thus released to trigger apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 82-85 BCL2 apoptosis regulator Homo sapiens 56-61 33202583-7 2020 MiR-23a-3p mimic transfection reversed ESAT6-induced reduction of reactive oxygen species generation, and augmented ESAT6-induced late apoptosis and phagocytosis, in association with down-regulations of the predicted target genes, including tumor necrosis factor (TNF)-alpha, TLR4, TLR2, IL6, IL10, Notch1, IL6R, BCL2, TGF-beta1, SP1, and IRF1. mir-23a-3p 0-10 BCL2 apoptosis regulator Homo sapiens 313-317 33344906-6 2020 Briefly, the aforementioned in vitro studies in addition to PCR of pro- and antiapoptotic genes (mTOR, p21, JNK, Bcl2, and MDR1) suggest the chemosensitization effect of EMP combination with DOX which can reduce the required therapeutic dose of DOX in TNBC and eventually will decrease its toxic side effects (especially cardiotoxicity), along with decreasing the chemoresistance of TNBC cells to DOX treatment. empagliflozin 170-173 BCL2 apoptosis regulator Homo sapiens 113-117 33173023-11 2020 The B-cell lymphoma (Bcl-2) level in PP-4-one treated U251 and C6 cells was markedly lower relative to the control cells. pp-4-one 37-45 BCL2 apoptosis regulator Homo sapiens 21-26 33173023-13 2020 CONCLUSIONS This study demonstrated that PP-4-one has anti-proliferative potential for glioma cells via targeting cAMP and Bcl-2 levels. pp-4-one 41-49 BCL2 apoptosis regulator Homo sapiens 123-128 33187360-6 2020 Our results further showed that, like FL118, 12e inhibited cell proliferation resulting from cell cycle arrest and apoptosis by blocking the anti-apoptotic gene transcription of survivin, Mcl-1, Bcl-2, and XIAP in both A549 cells and NCI-H446 cells. 7-ethyl-7-hydroxy-10H-1,3-Dioxolo(4,5-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-8,11(7H,12H)-dione 38-43 BCL2 apoptosis regulator Homo sapiens 195-200 32991521-11 2020 Meanwhile, PR-619 promoted the protein levels of Bcl-2, parkin, optineurin, LAMP1 and the LC3-II/I ratio. Praseodymium 11-13 BCL2 apoptosis regulator Homo sapiens 49-54 33177810-9 2020 Furthermore, HHT treatment contributed to notable mitochondrial dysfunction and Parkin-dependent mitophagy, as evidenced by the destruction of mitochondria, the decrease in the mtDNA copy number, decrease in the Bcl-2/Bax ratio, and decrease in the levels of mitochondrial proteins and the optimal expression of Parkin and NDP52. Homoharringtonine 13-16 BCL2 apoptosis regulator Homo sapiens 212-217 33160404-6 2020 We carried out a multivariate Cox regression analysis and developed six ARG-related prognostic signature for the survival prediction of patients with squamous cell cervical cancer (Risk score = - 0.63*ATG3-0.42*BCL2 + 0.85*CD46-0.38*IFNG+ 0.23*NAMPT+ 0.82*TM9SF1). Arginine 72-75 BCL2 apoptosis regulator Homo sapiens 211-215 33155931-9 2021 RESULTS: The array-data demonstrated that dasatinib-treated K562 cells significantly caused the decrease of several genes (AURKA, AURKB, PLK, CHEK1, MYC, XPC, BCL2, and XRCC2). Dasatinib 42-51 BCL2 apoptosis regulator Homo sapiens 159-163 33204292-10 2020 These suggest that HSYA exerts repair effects on H2O2-induced oxidative damage in HUVECs, and the mechanisms may be related to the influence of BAX/Bcl-2 expression and AKT/PTEN signal pathway expression. Hydrogen Peroxide 49-53 BCL2 apoptosis regulator Homo sapiens 148-153 33269821-8 2020 In the PTX group, the apoptosis rate, the number of cells arrested in the G2/M phase and the expression levels of Cleaved caspase-3 and Bax were increased, but the number of invasive cells and the expression levels of Bcl-2, MMP-9, vascular endothelial growth factor (VEGF), p-AKT (Thr308), and p-AKT (Ser473) were decreased. Paclitaxel 7-10 BCL2 apoptosis regulator Homo sapiens 218-223 33204288-10 2020 The compounds-targets network analysis indicated that the 6 compounds, including quercetin, kaempferol, baicalein, wogonin, beta-sitosterol, and eugenol, were linked to >=10 target genes, and the 10 target genes (PTGS1, ESR1, AR, PGR, CHRM3, PPARG, CHRM2, BCL2, CASP3, and RELA) were core target genes in the network. Eugenol 145-152 BCL2 apoptosis regulator Homo sapiens 256-260 33165811-7 2021 Consistent with the previous results, sodium cantharidinate treatment decreased Bcl-2 and mitochondrial cytochrome-c protein expression, as well as phosphorylation of MDM2; meanwhile, it increased the levels of cleaved-caspase-3, cleaved-caspase-9, cleaved-PARP, Bax, and phosphorylated p53, thus inducing the apoptosis of pancreatic cancer cells. Sodium 38-44 BCL2 apoptosis regulator Homo sapiens 80-85 33140502-10 2021 Moreover, we found that N-GFs co-cultured with exosomes showed a great increase in PCNA and Bcl-2 levels, and a moderate increase in Ki67 levels. n-gfs 24-29 BCL2 apoptosis regulator Homo sapiens 92-97 33204288-10 2020 The compounds-targets network analysis indicated that the 6 compounds, including quercetin, kaempferol, baicalein, wogonin, beta-sitosterol, and eugenol, were linked to >=10 target genes, and the 10 target genes (PTGS1, ESR1, AR, PGR, CHRM3, PPARG, CHRM2, BCL2, CASP3, and RELA) were core target genes in the network. Quercetin 81-90 BCL2 apoptosis regulator Homo sapiens 256-260 33204288-10 2020 The compounds-targets network analysis indicated that the 6 compounds, including quercetin, kaempferol, baicalein, wogonin, beta-sitosterol, and eugenol, were linked to >=10 target genes, and the 10 target genes (PTGS1, ESR1, AR, PGR, CHRM3, PPARG, CHRM2, BCL2, CASP3, and RELA) were core target genes in the network. kaempferol 92-102 BCL2 apoptosis regulator Homo sapiens 256-260 33204288-10 2020 The compounds-targets network analysis indicated that the 6 compounds, including quercetin, kaempferol, baicalein, wogonin, beta-sitosterol, and eugenol, were linked to >=10 target genes, and the 10 target genes (PTGS1, ESR1, AR, PGR, CHRM3, PPARG, CHRM2, BCL2, CASP3, and RELA) were core target genes in the network. baicalein 104-113 BCL2 apoptosis regulator Homo sapiens 256-260 33204288-10 2020 The compounds-targets network analysis indicated that the 6 compounds, including quercetin, kaempferol, baicalein, wogonin, beta-sitosterol, and eugenol, were linked to >=10 target genes, and the 10 target genes (PTGS1, ESR1, AR, PGR, CHRM3, PPARG, CHRM2, BCL2, CASP3, and RELA) were core target genes in the network. wogonin 115-122 BCL2 apoptosis regulator Homo sapiens 256-260 33204288-10 2020 The compounds-targets network analysis indicated that the 6 compounds, including quercetin, kaempferol, baicalein, wogonin, beta-sitosterol, and eugenol, were linked to >=10 target genes, and the 10 target genes (PTGS1, ESR1, AR, PGR, CHRM3, PPARG, CHRM2, BCL2, CASP3, and RELA) were core target genes in the network. gamma-sitosterol 124-139 BCL2 apoptosis regulator Homo sapiens 256-260 32893252-0 2020 Galangin Reverses Hepatic Fibrosis by Inducing HSCs Apoptosis via the PI3K/Akt, Bax/Bcl-2, and Wnt/beta-catenin Pathway in LX-2 Cells. galangin 0-8 BCL2 apoptosis regulator Homo sapiens 84-89 32947166-8 2020 Moreover, the acetazolamide/cisplatin combination could decrease the level of PCNA but increase the level of p53; decrease the ratio of Bcl-2/Bax and increase the expression of caspase-3 compared with the single drug treated group. Acetazolamide 14-27 BCL2 apoptosis regulator Homo sapiens 136-141 32947166-8 2020 Moreover, the acetazolamide/cisplatin combination could decrease the level of PCNA but increase the level of p53; decrease the ratio of Bcl-2/Bax and increase the expression of caspase-3 compared with the single drug treated group. Cisplatin 28-37 BCL2 apoptosis regulator Homo sapiens 136-141 32745723-4 2020 Through their different functions and interactions with key proteins such as VDAC and Bcl-2, NEET proteins coordinate different mitochondrial, MAM, ER and cytosolic processes and functions and regulate major signaling molecules such as calcium and reactive oxygen species. Calcium 236-243 BCL2 apoptosis regulator Homo sapiens 86-91 32745723-4 2020 Through their different functions and interactions with key proteins such as VDAC and Bcl-2, NEET proteins coordinate different mitochondrial, MAM, ER and cytosolic processes and functions and regulate major signaling molecules such as calcium and reactive oxygen species. Reactive Oxygen Species 248-271 BCL2 apoptosis regulator Homo sapiens 86-91 32893252-8 2020 Galangin also inhibited the PI3K/Akt and Wnt/beta-catenin signaling pathways and increased the Bax/Bcl-2 ratio. galangin 0-8 BCL2 apoptosis regulator Homo sapiens 99-104 32827690-12 2020 This study further opens new avenues for the use of RG-7388 in treating osteosarcomas that often becomes resistant to chemotherapy due to Bcl-2 overexpression. RG7388 52-59 BCL2 apoptosis regulator Homo sapiens 138-143 32920366-0 2020 Drug-like biimidazole derivatives dually target c-MYC/BCL-2 G-quadruplexes and inhibit acute myeloid leukemia. biimidazole 10-21 BCL2 apoptosis regulator Homo sapiens 54-59 32920366-5 2020 Consequently, two drug-like biimidazole derivatives were identified as selective c-MYC/BCL-2 G4 binders, of which, BIM-2 was selected as the candidate for inhibiting AML cell growth. biimidazole 28-39 BCL2 apoptosis regulator Homo sapiens 87-92 32920366-5 2020 Consequently, two drug-like biimidazole derivatives were identified as selective c-MYC/BCL-2 G4 binders, of which, BIM-2 was selected as the candidate for inhibiting AML cell growth. bisindolylmaleimide II 115-120 BCL2 apoptosis regulator Homo sapiens 87-92 33121344-3 2020 In terms of mechanism, APS up-regulates the proteins Bcl-2, Bcl-xl, and down-regulates the proteins Bax and Bak, which induces a decrease in mitochondrial membrane potential, which induces the release of Cyt-c and AIF, which leads to caspase-dependent and caspase-independent pathway to cause apoptosis. aps 23-26 BCL2 apoptosis regulator Homo sapiens 53-58 32911196-0 2020 Design and synthesis of quinoxaline-1,3,4-oxadiazole hybrid derivatives as potent inhibitors of the anti-apoptotic Bcl-2 protein. quinoxaline-1,3,4-oxadiazole 24-52 BCL2 apoptosis regulator Homo sapiens 115-120 32911196-5 2020 Utilizing information from molecular modelling of the hybrids to the anti-apoptotic Bcl-2 protein, we added substructures including phenyl, piperazine, piperidine, and morpholine rings to their frameworks. acetophenone 132-138 BCL2 apoptosis regulator Homo sapiens 84-89 32911196-5 2020 Utilizing information from molecular modelling of the hybrids to the anti-apoptotic Bcl-2 protein, we added substructures including phenyl, piperazine, piperidine, and morpholine rings to their frameworks. Piperazine 140-150 BCL2 apoptosis regulator Homo sapiens 84-89 32911196-5 2020 Utilizing information from molecular modelling of the hybrids to the anti-apoptotic Bcl-2 protein, we added substructures including phenyl, piperazine, piperidine, and morpholine rings to their frameworks. piperidine 152-162 BCL2 apoptosis regulator Homo sapiens 84-89 32911196-5 2020 Utilizing information from molecular modelling of the hybrids to the anti-apoptotic Bcl-2 protein, we added substructures including phenyl, piperazine, piperidine, and morpholine rings to their frameworks. morpholine 168-178 BCL2 apoptosis regulator Homo sapiens 84-89 32780285-9 2020 Eventually, the relative proteins expression levels of p53, cleaved caspase-9/3, cytochrome c, Fas-L, Fas, FADD and caspase-8 were substantially up-regulated in H2O2-triggered HepG2 cells, and Bax/Bcl-2 ratio and the relative protein expression levels of PARP were dramatically down-regulated. Hydrogen Peroxide 161-165 BCL2 apoptosis regulator Homo sapiens 197-202 32162200-11 2020 Fenamates inhibited glutamate-induced apoptosis through the modulation of the Bcl-2/Bax-dependent cell death pathways. Fenamates 0-9 BCL2 apoptosis regulator Homo sapiens 78-83 32162200-11 2020 Fenamates inhibited glutamate-induced apoptosis through the modulation of the Bcl-2/Bax-dependent cell death pathways. Glutamic Acid 20-29 BCL2 apoptosis regulator Homo sapiens 78-83 32162200-14 2020 The fenamates inhibited glutamate-induced apoptosis through modulation of the Bcl-2/Bax-dependent cell death pathways. Fenamates 4-13 BCL2 apoptosis regulator Homo sapiens 78-83 32162200-14 2020 The fenamates inhibited glutamate-induced apoptosis through modulation of the Bcl-2/Bax-dependent cell death pathways. Glutamic Acid 24-33 BCL2 apoptosis regulator Homo sapiens 78-83 32633026-11 2020 We found that CP-31398 increased the GSK-3ss, p-Slug, Puma, Wtp53, and Bax expressions whereas Wnt, Mtp-53, Slug, Bcl-2, and Ki-67 expressions were decreased. CP 31398 14-22 BCL2 apoptosis regulator Homo sapiens 114-119 32980991-13 2020 Interfering lncPCAT19/overexpression of miR-142-5p decreased glioma cell proliferation, colony formation and invasion, and promoted cell apoptosis by down-regulating expression of Cyclin B1, CDK2, N-cadherin, Bcl-2, and by up-regulating expression of Bax and E-cadherin. mir-142-5p 40-50 BCL2 apoptosis regulator Homo sapiens 209-214 33238796-8 2020 Western blotting revealed that Bcl-2 and p53 expression were significantly lower in the salidroside group than in the other groups, whereas Bax and caspase 3 (17 kDa) expression were increased. rhodioloside 88-99 BCL2 apoptosis regulator Homo sapiens 31-36 33828360-0 2020 Molecular Docking Study of Naturally Derived Flavonoids with Antiapoptotic BCL-2 and BCL-XL Proteins toward Ovarian Cancer Treatment. Flavonoids 45-55 BCL2 apoptosis regulator Homo sapiens 75-80 33828360-4 2020 This study aimed to determine the binding interaction of five naturally derived flavonoids (biochanin A, myricetin, apigenin, galangin, and fisetin) with potential antiapoptotic target proteins (Bcl-2 and Bcl-xl). Flavonoids 80-90 BCL2 apoptosis regulator Homo sapiens 195-200 33828360-7 2020 Our findings showed that all the flavonoids showed better binding affinity with Bcl-xl than that of Bcl-2 proteins. Flavonoids 33-43 BCL2 apoptosis regulator Homo sapiens 100-105 32949585-8 2020 Along with that, arsenic activates caspases and Bax, decreases Bcl2 through mitochondrial dysfunction, and induces apoptosis regulatory mechanism. Arsenic 17-24 BCL2 apoptosis regulator Homo sapiens 63-67 32585423-7 2020 Quercetin treatment also decreases Bcl-2 and increases Bax protein expression, and increases miR-197 mRNA while reducing IGFBP5 mRNA expression. Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 35-40 32585423-9 2020 Quercetin may reduce meningioma cell proliferation and increase apoptosis by activating the miR-197/IGFBP5 cascade and regulating Bcl-2/Bax. Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 130-135 32968431-7 2020 Isoflurane pretreatment also inhibited HR-induced cell apoptosis and Bax expression, and reversed HR-induced downregulation of Bcl-2 expression. Isoflurane 0-10 BCL2 apoptosis regulator Homo sapiens 127-132 32784000-5 2020 CB08035-SCA caused up-regulation of Nrf2, AKT1 and Bcl-2 gene expressions. SMSF0006723 0-7 BCL2 apoptosis regulator Homo sapiens 51-56 32247860-0 2020 Anti-apoptotic molecule BCL2 is a therapeutic target in steroid-refractory graft-versus-host disease. Steroids 56-63 BCL2 apoptosis regulator Homo sapiens 24-28 32247860-5 2020 BCL2 RNA was elevated in multiple organs affected by GVHD and expression correlated with transplant-related mortality and steroid-refractory GVHD. Steroids 122-129 BCL2 apoptosis regulator Homo sapiens 0-4 32247860-7 2020 Inhibition of BCL2 increased the CD4/CD8 ratio in allogeneic T cells in vitro and induced apoptosis of T cells from steroid-pretreated chronic GVHD patients ex vivo. Steroids 116-123 BCL2 apoptosis regulator Homo sapiens 14-18 32247860-9 2020 Collectively, our results highlight BCL2 as important factor for GVHD development and introduce BCL2 inhibition as previously unreported and urgently needed targeted therapy in treatment of steroid-refractory GVHD. Steroids 190-197 BCL2 apoptosis regulator Homo sapiens 36-40 32247860-9 2020 Collectively, our results highlight BCL2 as important factor for GVHD development and introduce BCL2 inhibition as previously unreported and urgently needed targeted therapy in treatment of steroid-refractory GVHD. Steroids 190-197 BCL2 apoptosis regulator Homo sapiens 96-100 33091356-8 2020 Novel BTK inhibitors (acalabrutinib, zanubrutinib, tirabrutinib) and the BCL2 antagonist venetoclax appear safe and active, and represent emerging options for the treatment of Waldenstrom macroglobulinaemia. venetoclax 89-99 BCL2 apoptosis regulator Homo sapiens 73-77 30618284-4 2020 Anticancer property of procyanidin C1 was explored by studying the expression of checkpoint kinases, Bcl-2 and BAX, cell cycle, DNA damage and caspase 3 and 9 levels. Procyanidin C1 23-37 BCL2 apoptosis regulator Homo sapiens 101-106 33141288-11 2020 The mRNA and protein levels of BAX increased, but those of BCL-2 decreased in MEAA-treated cells. meaa 78-82 BCL2 apoptosis regulator Homo sapiens 59-64 32901836-8 2020 In addition, calycosin increased the expression of the proapoptotic antiapoptotic proteins cleaved caspase-3, cleaved caspase-9, cleaved poly(ADP-ribose) polymerase and Bcl-2-associated X protein (Bax), and decreased the expression of the antiapoptotic proapoptotic protein B-cell lymphoma-2 (Bcl-2), thus altering the Bax/Bcl-2 ratio. 7,3'-dihydroxy-4'-methoxyisoflavone 13-22 BCL2 apoptosis regulator Homo sapiens 169-174 32901836-8 2020 In addition, calycosin increased the expression of the proapoptotic antiapoptotic proteins cleaved caspase-3, cleaved caspase-9, cleaved poly(ADP-ribose) polymerase and Bcl-2-associated X protein (Bax), and decreased the expression of the antiapoptotic proapoptotic protein B-cell lymphoma-2 (Bcl-2), thus altering the Bax/Bcl-2 ratio. 7,3'-dihydroxy-4'-methoxyisoflavone 13-22 BCL2 apoptosis regulator Homo sapiens 293-298 30618284-8 2020 Procyanidin C1 decreased the level of Bcl-2 but increased the BAX, caspase 3 and 9 expression in cancer cells. Procyanidin C1 0-14 BCL2 apoptosis regulator Homo sapiens 38-43 31730796-6 2020 Furthermore, palmitate induced mRNA levels of endoplasmic reticulum (ER) stress markers, including Chop, Grp78 and Bax/Bcl2, as well as C/ebp-beta, whereas SNP induced Bax/Bcl2 and C/ebp-beta. Palmitates 13-22 BCL2 apoptosis regulator Homo sapiens 119-123 31730796-6 2020 Furthermore, palmitate induced mRNA levels of endoplasmic reticulum (ER) stress markers, including Chop, Grp78 and Bax/Bcl2, as well as C/ebp-beta, whereas SNP induced Bax/Bcl2 and C/ebp-beta. Palmitates 13-22 BCL2 apoptosis regulator Homo sapiens 172-176 32963615-9 2020 In addition, following treatment of A549/DDP cells with a combination of DMC and DDP, the expression of ERCC1 was reduced, the protein levels of Bcl-2 and Bax were decreased and increased, respectively, whereas caspase-3 was activated, according to results from western blotting. demethoxycurcumin 73-76 BCL2 apoptosis regulator Homo sapiens 145-150 33867334-9 2020 Ciprofloxacin -G2 dendrimer conjugate was able to increase Bcl-2/Bax ratio in a large scale as compared with the control group and CBL alone. Ciprofloxacin 0-13 BCL2 apoptosis regulator Homo sapiens 59-64 33010382-9 2020 Furthermore, 3MA reversed both the nicotine-induced decrease in Bcl-2 and the increase in Bax in both groups. 3-methyladenine 13-16 BCL2 apoptosis regulator Homo sapiens 64-69 33010382-9 2020 Furthermore, 3MA reversed both the nicotine-induced decrease in Bcl-2 and the increase in Bax in both groups. Nicotine 35-43 BCL2 apoptosis regulator Homo sapiens 64-69 32956828-7 2020 However, BEA down-regulated the expression of BCL2. beauvericin 9-12 BCL2 apoptosis regulator Homo sapiens 46-50 33350211-8 2020 The curcumin TPP-PEG-PCL micelles can significantly reduce the mitochondrial membrane potential of breast cancer cells, increase the release of cytochrome C, significantly increase the expression of pro-apoptotic protein Bcl-2 and reduce the expression of anti-apoptotic Bax protein. Curcumin 4-12 BCL2 apoptosis regulator Homo sapiens 221-226 33287924-5 2020 Results showed that after treatment with different concentrations of Dendrobium polysaccharides, MDA levels were decreased in ox-LDL-induced human brain microvascular endothelial cells, SOD and CAT activities were increased, apoptosis rate was decreased, Bcl-2 expression was increased, Bax expression was decreased, miR-378 expression was increased, in a dose-dependent manner (P<0.05). dendrobium polysaccharides 69-95 BCL2 apoptosis regulator Homo sapiens 255-260 33350211-8 2020 The curcumin TPP-PEG-PCL micelles can significantly reduce the mitochondrial membrane potential of breast cancer cells, increase the release of cytochrome C, significantly increase the expression of pro-apoptotic protein Bcl-2 and reduce the expression of anti-apoptotic Bax protein. tpp-peg-pcl 13-24 BCL2 apoptosis regulator Homo sapiens 221-226 33287924-5 2020 Results showed that after treatment with different concentrations of Dendrobium polysaccharides, MDA levels were decreased in ox-LDL-induced human brain microvascular endothelial cells, SOD and CAT activities were increased, apoptosis rate was decreased, Bcl-2 expression was increased, Bax expression was decreased, miR-378 expression was increased, in a dose-dependent manner (P<0.05). Malondialdehyde 97-100 BCL2 apoptosis regulator Homo sapiens 255-260 32985648-11 2020 MiR-25-3p mimic increased the viability, migration, invasion and the expressions of Bcl-2 and Cleaved caspase-3, and inhibited the apoptosis and the expression of Bax in EC cells. mir-25-3p 0-9 BCL2 apoptosis regulator Homo sapiens 84-89 33298868-3 2020 Here, we tested a suite of BH3-mimetic drugs targeting BCL-2 pro-survival proteins of the intrinsic apoptotic pathway. BH 3 27-30 BCL2 apoptosis regulator Homo sapiens 55-60 33118512-7 2020 Treatment with BCTC significantly lowered intracellular Ca2+ fluorescence intensity and the expressions of Bcl-2 and MUC5AC mRNA and protein in the cells stimulated with menthol or with both IL-13 and menthol (P < 0.05), but caused no significant changes in IL-13-stimulated cells (P > 0.05). Menthol 201-208 BCL2 apoptosis regulator Homo sapiens 107-112 33118512-9 2020 CONCLUSIONS: Menthol combined with IL-13 produces a synergistic effect to promote the synthesis and secretion of MUC5AC in 16HBE cells possibly by activating TRPM8 receptor to upregulate the expression of Bcl-2. Menthol 13-20 BCL2 apoptosis regulator Homo sapiens 205-210 33118512-7 2020 Treatment with BCTC significantly lowered intracellular Ca2+ fluorescence intensity and the expressions of Bcl-2 and MUC5AC mRNA and protein in the cells stimulated with menthol or with both IL-13 and menthol (P < 0.05), but caused no significant changes in IL-13-stimulated cells (P > 0.05). BCTC 15-19 BCL2 apoptosis regulator Homo sapiens 107-112 33119667-11 2020 In conclusion, crocin at 1 mM and naringenin at 100 muM seem to improve the post-thawing rooster semen quality, fertility and could protect the sperm by reducing the pro-apoptotic (CASPASE 3) and increasing anti-apoptotic (Bcl-2) genes. crocin 15-21 BCL2 apoptosis regulator Homo sapiens 223-228 33118512-7 2020 Treatment with BCTC significantly lowered intracellular Ca2+ fluorescence intensity and the expressions of Bcl-2 and MUC5AC mRNA and protein in the cells stimulated with menthol or with both IL-13 and menthol (P < 0.05), but caused no significant changes in IL-13-stimulated cells (P > 0.05). Menthol 170-177 BCL2 apoptosis regulator Homo sapiens 107-112 33121235-1 2021 Venetoclax (Ven), an orally administered, potent BCL-2 inhibitor, has demonstrated efficacy in chronic lymphocytic leukaemia (CLL) in combination with rituximab (R) or obinutuzumab (G). venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 49-54 33121235-1 2021 Venetoclax (Ven), an orally administered, potent BCL-2 inhibitor, has demonstrated efficacy in chronic lymphocytic leukaemia (CLL) in combination with rituximab (R) or obinutuzumab (G). venetoclax 0-3 BCL2 apoptosis regulator Homo sapiens 49-54 33119667-11 2020 In conclusion, crocin at 1 mM and naringenin at 100 muM seem to improve the post-thawing rooster semen quality, fertility and could protect the sperm by reducing the pro-apoptotic (CASPASE 3) and increasing anti-apoptotic (Bcl-2) genes. naringenin 34-44 BCL2 apoptosis regulator Homo sapiens 223-228 33126443-9 2020 Linalool mitigated cisplatin-induced apoptotic markers such as caspase 3, caspase 9, and Bax expression, and boosted the anti-apoptotic Bcl2 expression. linalool 0-8 BCL2 apoptosis regulator Homo sapiens 136-140 33149614-7 2020 In addition, flow cytometry and Western blotting results showed that zeaxanthin induces apoptosis by reducing mitochondrial membrane potential; increasing Cytochrome C, Bax, cleaved-caspase-3 (cle-cas-3), and cleaved-PARP (cle-PARP) expression levels; and decreasing Bcl-2, pro-caspase-3 (pro-cas-3), and pro-PARP expression levels. Zeaxanthins 69-79 BCL2 apoptosis regulator Homo sapiens 267-272 33121131-4 2020 However, the combination of DOX with OSMI-1 in HepG2 cells synergistically increased apoptotic cell death through the activation of both the p53 and mitochondrial Bcl2 pathways compared to DOX alone. Doxorubicin 28-31 BCL2 apoptosis regulator Homo sapiens 163-167 32505840-12 2020 The synergetic effect was played by Xiaoaiping injection inhibiting paclitaxel-induced PXR and CAR expression, which subsequently inhibited CYP450 enzymes CYP2C8 and CYP3A4, transporter P-gp and anti-apoptotic proteins Bcl-2 and Bcl-xl in SK-OV-3 cells. Paclitaxel 68-78 BCL2 apoptosis regulator Homo sapiens 219-224 33104794-5 2020 We found that tazemetostat and venetoclax are synergistic in DLBCL cells and 3-dimensional lymphoma organoids that harbor an EZH2 mutation and an IGH/BCL2 translocation but not in wild-type cells. tazemetostat 14-26 BCL2 apoptosis regulator Homo sapiens 150-154 33104794-6 2020 Tazemetostat treatment results in upregulation of proapoptotic Bcl-2 family members and priming of mitochondria to BH3-mediated apoptosis, which may sensitize cells to venetoclax. tazemetostat 0-12 BCL2 apoptosis regulator Homo sapiens 63-68 33097020-8 2020 CONCLUSIONS: The model, consistent with the observed reduction in the Bcl2/BAX ratio, suggests that BRP-induced apoptosis of mitotically-arrested cells is a major contributor to the synergy between BRP and PTX. birinapant 100-103 BCL2 apoptosis regulator Homo sapiens 70-74 33097020-8 2020 CONCLUSIONS: The model, consistent with the observed reduction in the Bcl2/BAX ratio, suggests that BRP-induced apoptosis of mitotically-arrested cells is a major contributor to the synergy between BRP and PTX. Paclitaxel 206-209 BCL2 apoptosis regulator Homo sapiens 70-74 33145357-6 2020 Apoptotic genes that indicating a marked increase in expression are Caspase 3, p53, and Bax, while Bcl2 and AFP showed a downregulation of expression after treatment of HepG2 cells with lectin-loaded chitosan-TPP nanoparticles. Chitosan 200-208 BCL2 apoptosis regulator Homo sapiens 99-103 33497945-6 2020 Combined treatment with Cd and Z-YVAD-FMK remarkably elevated Bcl-2 mRNA and protein levels, inhibited p53, Bax, Bak-1, Cyt C, Caspase-9 and Caspase-3 mRNA levels and p53, Bax, Bak-1, Caspase-9/cleaved Caspase-9 and Caspase-3/cleaved Caspase-3 protein levels, increased mitochondrial membrane potential (MMP), decreased apoptosis ratio and cell damage compared to treatment with Cd alone. Cadmium 24-26 BCL2 apoptosis regulator Homo sapiens 62-67 33497945-6 2020 Combined treatment with Cd and Z-YVAD-FMK remarkably elevated Bcl-2 mRNA and protein levels, inhibited p53, Bax, Bak-1, Cyt C, Caspase-9 and Caspase-3 mRNA levels and p53, Bax, Bak-1, Caspase-9/cleaved Caspase-9 and Caspase-3/cleaved Caspase-3 protein levels, increased mitochondrial membrane potential (MMP), decreased apoptosis ratio and cell damage compared to treatment with Cd alone. benzyloxycarbonyltyrosyl-valyl-alanyl-aspartic acid fluoromethyl ketone 31-41 BCL2 apoptosis regulator Homo sapiens 62-67 33150167-11 2020 Altogether, the results of the present study indicated the potential mechanisms of chemosensitivity of TF in gefitinib-induced apoptosis of NSCLC by downregulating ERK and STAT3 signaling pathways and Bcl2 and Mcl-1 expression and a promising application of TF in therapy of NSCLC with gefitinib resistant. Gefitinib 109-118 BCL2 apoptosis regulator Homo sapiens 201-205 33193889-6 2020 Surfactin-induced apoptosis was associated with caspase activation and poly(ADP-ribose) polymerase (PARP) cleavage and was regulated by the mitochondrial pathway, exemplified by mitochondrial depolarization, mitochondrial-derived reactive oxidative species (ROS) production, cytochrome c release, up-regulation of Bad and Bax, and down-regulation of Bcl-2. surfactin peptide 0-9 BCL2 apoptosis regulator Homo sapiens 350-355 33096926-2 2020 A lot of research has recently been devoted to understanding the interplay between Bcl-2 proteins, the regulation of these interactions within the cell, and how these interactions lead to the changes in calcium homeostasis. Calcium 203-210 BCL2 apoptosis regulator Homo sapiens 83-88 33096926-3 2020 However, the role of Bcl-2 proteins in the mediation of mitochondrial calcium homeostasis, and therefore the induction of cell death pathways, remain underestimated and are still not well understood. Calcium 70-77 BCL2 apoptosis regulator Homo sapiens 21-26 32687450-1 2020 PURPOSE: The B-cell lymphoma 2 (BCL-2) inhibitor venetoclax has an emerging role in acute myeloid leukemia (AML), with promising response rates in combination with hypomethylating agents or low-dose cytarabine in older patients. Cytarabine 199-209 BCL2 apoptosis regulator Homo sapiens 13-30 32687450-1 2020 PURPOSE: The B-cell lymphoma 2 (BCL-2) inhibitor venetoclax has an emerging role in acute myeloid leukemia (AML), with promising response rates in combination with hypomethylating agents or low-dose cytarabine in older patients. Cytarabine 199-209 BCL2 apoptosis regulator Homo sapiens 32-37 32686235-3 2020 In this system, Bcl-2 antisense oligonucleotides (OSAs) were conjugated onto the surface of aggregation-induced emission (AIE) photosensitizer (PS) nanoparticles to form core-shell SNAs. Oligonucleotides 32-48 BCL2 apoptosis regulator Homo sapiens 16-21 33075109-5 2020 Protein kinase C (PKC) agonists bryostatin-1 and prostratin induced phosphorylation and enhanced neutralizing capability of the anti-apoptotic protein BCL2 in a PKC-dependent manner, leading to resistance to apoptosis induced by both intrinsic and extrinsic death stimuli. bryostatin 1 32-44 BCL2 apoptosis regulator Homo sapiens 151-155 33075109-5 2020 Protein kinase C (PKC) agonists bryostatin-1 and prostratin induced phosphorylation and enhanced neutralizing capability of the anti-apoptotic protein BCL2 in a PKC-dependent manner, leading to resistance to apoptosis induced by both intrinsic and extrinsic death stimuli. prostratin 49-59 BCL2 apoptosis regulator Homo sapiens 151-155 33178028-8 2020 Further study disclosed that UDCA significantly inhibited As(III)-induced apoptosis through increasing the expression of Bcl-2 and decreasing the expression of Bax, p53, Cyt C, Cleaved caspase-3 and 9. Ursodeoxycholic Acid 29-33 BCL2 apoptosis regulator Homo sapiens 121-126 33178028-8 2020 Further study disclosed that UDCA significantly inhibited As(III)-induced apoptosis through increasing the expression of Bcl-2 and decreasing the expression of Bax, p53, Cyt C, Cleaved caspase-3 and 9. as(iii) 58-65 BCL2 apoptosis regulator Homo sapiens 121-126 33178586-8 2020 Furthermore, p-CA significantly upregulated the levels of Apaf1 and Bax and downregulated the levels of Bcl-2, and subsequently increased the levels of cytoplasmic cytochrome c (Cyto-c), cleaved caspase-3, and cleaved caspase-9, leading to apoptosis in A375 and B16 cells. p-coumaric acid 13-17 BCL2 apoptosis regulator Homo sapiens 104-109 33194073-10 2020 Additionally, we confirmed that Bcl-2 is associated with the induction of ATRA-induced autophagy instead of the PI3K/Akt/mTOR pathway. Tretinoin 74-78 BCL2 apoptosis regulator Homo sapiens 32-37 33086902-7 2021 The IC50 dose of Geraniol decreased Bcl-2 staining significantly, but it significantly increased Bax staining and TUNEL positive cells. geraniol 17-25 BCL2 apoptosis regulator Homo sapiens 36-41 32470802-5 2020 DWYG-medicated serum protected L-02 cells from carbon tetrachloride-induced damage, reduced the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the culture medium, decreased the expression of Bax and increased the expression of Bcl-2. dwyg 0-4 BCL2 apoptosis regulator Homo sapiens 261-266 33194073-11 2020 These findings suggest that ATRA induces autophagy and autophagic cell death through the Bcl-2/Beclin1 pathway. Tretinoin 28-32 BCL2 apoptosis regulator Homo sapiens 89-94 33069066-4 2020 Human B-cell lymphoma-2 (Bcl-2)-protein inhibitors, including the (R)-enantiomer of the natural product gossypol, were observed to efficiently inhibit AspH, as does the antitumor antibiotic bleomycin A2. Gossypol 104-112 BCL2 apoptosis regulator Homo sapiens 6-23 33069066-4 2020 Human B-cell lymphoma-2 (Bcl-2)-protein inhibitors, including the (R)-enantiomer of the natural product gossypol, were observed to efficiently inhibit AspH, as does the antitumor antibiotic bleomycin A2. Gossypol 104-112 BCL2 apoptosis regulator Homo sapiens 24-30 33069066-4 2020 Human B-cell lymphoma-2 (Bcl-2)-protein inhibitors, including the (R)-enantiomer of the natural product gossypol, were observed to efficiently inhibit AspH, as does the antitumor antibiotic bleomycin A2. Bleomycin 190-202 BCL2 apoptosis regulator Homo sapiens 6-23 33069066-4 2020 Human B-cell lymphoma-2 (Bcl-2)-protein inhibitors, including the (R)-enantiomer of the natural product gossypol, were observed to efficiently inhibit AspH, as does the antitumor antibiotic bleomycin A2. Bleomycin 190-202 BCL2 apoptosis regulator Homo sapiens 24-30 33178666-3 2020 Curcumin inhibits Bcl-2, Bcl-XL, VEGF, c-Myc, ICAM-1, EGFR, STAT3 phosphorylation, and cyclin D1 genes involved in the various stages of breast, prostate, and gastric cancer proliferation, angiogenesis, invasion, and metastasis. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 18-23 32531360-0 2020 GSF3, a polysaccharide from guava (Psidium guajava L.) seeds, inhibits MCF-7 breast cancer cell growth via increasing Bax/Bcl-2 ratio or Fas mRNA expression levels. gsf3 0-4 BCL2 apoptosis regulator Homo sapiens 122-127 32531360-7 2020 GSF3 direct action significantly (P < 0.05) decreased Bcl-2 mRNA expression amount but increased pro-(Bax)/anti-apoptotic (Bcl-2) mRNA expression ratios in the treated cells. gsf3 0-4 BCL2 apoptosis regulator Homo sapiens 54-59 32531360-7 2020 GSF3 direct action significantly (P < 0.05) decreased Bcl-2 mRNA expression amount but increased pro-(Bax)/anti-apoptotic (Bcl-2) mRNA expression ratios in the treated cells. gsf3 0-4 BCL2 apoptosis regulator Homo sapiens 123-128 32249419-9 2020 ABT-199 or ABT-263 inhibitors against BCL2 or BCL2 and BCLXL respectively, induced further cell death when combined with S63845 and I-BET151. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 38-42 33123590-6 2020 Beginning with 0.5 muM BPDE exposure, Bax/Caspase-3 were increased and Bcl-2 decreased. 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide 23-27 BCL2 apoptosis regulator Homo sapiens 71-76 32249419-9 2020 ABT-199 or ABT-263 inhibitors against BCL2 or BCL2 and BCLXL respectively, induced further cell death when combined with S63845 and I-BET151. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 46-50 32249419-9 2020 ABT-199 or ABT-263 inhibitors against BCL2 or BCL2 and BCLXL respectively, induced further cell death when combined with S63845 and I-BET151. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 11-14 BCL2 apoptosis regulator Homo sapiens 38-42 32249419-9 2020 ABT-199 or ABT-263 inhibitors against BCL2 or BCL2 and BCLXL respectively, induced further cell death when combined with S63845 and I-BET151. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 11-14 BCL2 apoptosis regulator Homo sapiens 46-50 33050842-3 2022 Hesperidin and luteolin reduced cell viability in a dose and time-dependent manner, caused a significant accumulation of apoptotic cells into the G0/G1 and sub-G1 cell cycle phases, induced apoptosis through the intrinsic and extrinsic pathways, down-regulated anti-apoptotic, Bcl-2, and upregulated pro-apoptotic, Bax. Hesperidin 0-10 BCL2 apoptosis regulator Homo sapiens 277-282 33050842-3 2022 Hesperidin and luteolin reduced cell viability in a dose and time-dependent manner, caused a significant accumulation of apoptotic cells into the G0/G1 and sub-G1 cell cycle phases, induced apoptosis through the intrinsic and extrinsic pathways, down-regulated anti-apoptotic, Bcl-2, and upregulated pro-apoptotic, Bax. Luteolin 15-23 BCL2 apoptosis regulator Homo sapiens 277-282 33066414-9 2020 Schiff base complex treatment resulted in up-regulation of p53 and Bax genes expression and down-regulation of Bcl2 gene expression in SCCs paralleled with increased protein expression of caspase-3 and Bax and down-regulation of Bcl-2 protein. Schiff Bases 0-11 BCL2 apoptosis regulator Homo sapiens 111-115 32969665-4 2020 The AIE PS engineered mitochondria could not only change the energetic metabolism of cancer cells from aerobic glycolysis to normal oxide phosphorylation for cancer cell growth inhibition, but also activate the apoptotic pathway and reduce the expression of antiapoptotic protein Bcl-2. Oxides 132-137 BCL2 apoptosis regulator Homo sapiens 280-285 33066414-9 2020 Schiff base complex treatment resulted in up-regulation of p53 and Bax genes expression and down-regulation of Bcl2 gene expression in SCCs paralleled with increased protein expression of caspase-3 and Bax and down-regulation of Bcl-2 protein. Schiff Bases 0-11 BCL2 apoptosis regulator Homo sapiens 229-234 33053856-8 2020 Further, chemical inhibition by NE52-QQ57, a selective antagonist of GPR4, and knockout of GPR4 by clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 decreased the Bax/Bcl-2 ratio and ROS generation, and stabilised the DeltaPsim, thus protecting the SH-SY5Y cells from MPP+- or H2O2-induced apoptotic cell death. Reactive Oxygen Species 205-208 BCL2 apoptosis regulator Homo sapiens 189-194 33046037-13 2020 CONCLUSIONS: Three new nucleoside analogue-resistant HL-60 cell variants exhibited reduced production of intracellular analogue triphosphates and enhanced Bcl-2 and Mcl-1 expressions. Nucleosides 23-33 BCL2 apoptosis regulator Homo sapiens 155-160 33045871-9 2021 BBR promoted cell apoptosis by increasing Bax and C caspase-3 expressions and decreasing Bcl-2 expression. Berberine 0-3 BCL2 apoptosis regulator Homo sapiens 89-94 33123316-9 2020 In addition, we found that AG8 increased the Bax/Bcl-2 ratio and the levels of cytoplasmic cytochrome c and significantly decreased phosphorylation of ERK and AKT in BT549 and MDA-MB-157 cells. S-[(2e,6e,10e)-14-(Dimethylamino)-3,7,11-Trimethyltetradeca-2,6,10-Trien-1-Yl] Trihydrogen Thiodiphosphate 27-30 BCL2 apoptosis regulator Homo sapiens 49-54 33053856-5 2020 In GPR4-OE cells, MPP+ and H2O2 were found to significantly increase the expression levels of both mRNA and proteins of the pro-apoptotic Bcl-2-associated X protein (Bax) genes, while they decreased the anti-apoptotic B-cell lymphoma 2 (Bcl-2) genes. mangion-purified polysaccharide (Candida albicans) 18-22 BCL2 apoptosis regulator Homo sapiens 218-235 33053856-5 2020 In GPR4-OE cells, MPP+ and H2O2 were found to significantly increase the expression levels of both mRNA and proteins of the pro-apoptotic Bcl-2-associated X protein (Bax) genes, while they decreased the anti-apoptotic B-cell lymphoma 2 (Bcl-2) genes. mangion-purified polysaccharide (Candida albicans) 18-22 BCL2 apoptosis regulator Homo sapiens 138-143 33053856-5 2020 In GPR4-OE cells, MPP+ and H2O2 were found to significantly increase the expression levels of both mRNA and proteins of the pro-apoptotic Bcl-2-associated X protein (Bax) genes, while they decreased the anti-apoptotic B-cell lymphoma 2 (Bcl-2) genes. Hydrogen Peroxide 27-31 BCL2 apoptosis regulator Homo sapiens 218-235 33053856-5 2020 In GPR4-OE cells, MPP+ and H2O2 were found to significantly increase the expression levels of both mRNA and proteins of the pro-apoptotic Bcl-2-associated X protein (Bax) genes, while they decreased the anti-apoptotic B-cell lymphoma 2 (Bcl-2) genes. Hydrogen Peroxide 27-31 BCL2 apoptosis regulator Homo sapiens 138-143 33053856-8 2020 Further, chemical inhibition by NE52-QQ57, a selective antagonist of GPR4, and knockout of GPR4 by clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 decreased the Bax/Bcl-2 ratio and ROS generation, and stabilised the DeltaPsim, thus protecting the SH-SY5Y cells from MPP+- or H2O2-induced apoptotic cell death. mangion-purified polysaccharide (Candida albicans) 290-294 BCL2 apoptosis regulator Homo sapiens 189-194 33053856-8 2020 Further, chemical inhibition by NE52-QQ57, a selective antagonist of GPR4, and knockout of GPR4 by clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 decreased the Bax/Bcl-2 ratio and ROS generation, and stabilised the DeltaPsim, thus protecting the SH-SY5Y cells from MPP+- or H2O2-induced apoptotic cell death. Hydrogen Peroxide 299-303 BCL2 apoptosis regulator Homo sapiens 189-194 32735880-6 2020 Additionally, reduced expression of the anti-apoptotic protein Bcl2 caused by miR-34a could enhance the anti-tumor efficacy of DPC/miR-34a nanoplex administration. di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone 127-130 BCL2 apoptosis regulator Homo sapiens 63-67 33046085-13 2020 CsA also attenuated the activation of p53, decreased the expression of Bax and cleavage of PARP, and increased the expression of Bcl-2 and pro-caspase-3 in the JEG-3 treated with H2O2. Cyclosporine 0-3 BCL2 apoptosis regulator Homo sapiens 129-134 33046085-13 2020 CsA also attenuated the activation of p53, decreased the expression of Bax and cleavage of PARP, and increased the expression of Bcl-2 and pro-caspase-3 in the JEG-3 treated with H2O2. Hydrogen Peroxide 179-183 BCL2 apoptosis regulator Homo sapiens 129-134 33101585-6 2020 Compared with the H2O2-treated group, the expressions of cleaved caspase-3, cleaved caspase-9, cleaved polymerase (PARP), death receptor Fas, and cleaved caspase-8, as well as Bax/Bcl-2 ratio were decreased in RPE cells after the phillyrin intervention. Hydrogen Peroxide 18-22 BCL2 apoptosis regulator Homo sapiens 180-185 32735880-6 2020 Additionally, reduced expression of the anti-apoptotic protein Bcl2 caused by miR-34a could enhance the anti-tumor efficacy of DPC/miR-34a nanoplex administration. mir-34a 131-138 BCL2 apoptosis regulator Homo sapiens 63-67 33163279-6 2020 Enhanced and rapid cervical cancer cell killing was observed when Alisertib was combined with inhibitors of either Bcl-2 (Venetoclax), Bcl-XL (A1331852) or Mcl-1 (A1210477) proteins, likely by accelerating apoptosis during mitotic delay due to the loss of functional Bcl-2, Mcl-1, or Bcl-XL. MLN 8237 66-75 BCL2 apoptosis regulator Homo sapiens 267-272 33367149-8 2020 Conclusion: Clinoptilolite, which was previously demonstrated to have anticancer properties, decreased cell viability effectively and rapidly and increased the apoptotic cell ratio in a novel use in nanoparticle form, exhibiting this effect by increasing the BAX/BCL2 ratio. clinoptilolite 12-26 BCL2 apoptosis regulator Homo sapiens 263-267 32512042-9 2020 And the HepG2 cells induced at the ethyl acetate fraction could up-regulate Bax gene and protein, while down-regulating Bcl-2 gene and protein (P < 0.05) during S phase in a dose-dependent manner. ethyl acetate 35-48 BCL2 apoptosis regulator Homo sapiens 120-125 33102590-9 2020 Moreover, CoCl2 upregulated the expression levels of Bax and cleaved caspase-3 and then downregulated Bcl-2 levels in a time-dependent manner. cobaltous chloride 10-15 BCL2 apoptosis regulator Homo sapiens 102-107 33074834-7 2020 Results: Compared to the control group, we observed a significant increase in the expression levels of the Bax and P53 genes and the activity levels of caspase-3 and 9, and a significant decrease in the expression level of the Bcl-2 gene in MCF-7 and MG-63 treated with effective concentration of progesterone. Progesterone 297-309 BCL2 apoptosis regulator Homo sapiens 227-232 33111012-10 2020 BAX and BCL-2 expression in cells treated with 5 muM FA-GFLG-MMC was studied by Western blotting. fa-gflg-mmc 53-64 BCL2 apoptosis regulator Homo sapiens 8-13 33111012-11 2020 FA-GFLG-MMC increased the BAX/BCL-2 ratio in HeLa, SiHa, and PC9 cells. fa-gflg-mmc 0-11 BCL2 apoptosis regulator Homo sapiens 30-35 32894380-8 2020 The limonoid suppressed the level of proteins associated with anti-apoptosis (survivin, Bcl-2, Bcl-xL), proliferation (cyclin D1), and invasion (MMP-9). Limonins 4-12 BCL2 apoptosis regulator Homo sapiens 88-93 32988857-7 2020 RESULTS: Poly(I:C) increased expression of HIF1alpha and its targets BCL2 apoptosis regulator and c-MYC. Poly I-C 9-18 BCL2 apoptosis regulator Homo sapiens 69-93 31838736-12 2020 Western blotting showed an up-regulated expression of Caspase-3 and Bax and down-regulated expression of anti-apoptotic protein Bcl-2 after treatment with 5 x 10-4 M fluoride in SW1353 cells. Fluorides 166-174 BCL2 apoptosis regulator Homo sapiens 128-133 31696776-7 2020 We also demonstrated that STYK1 elevated the serine phosphorylation of BECN1, thereby decreasing the interaction between BECN1 and BCL2. cholecystokinin C-terminal flanking peptide 45-51 BCL2 apoptosis regulator Homo sapiens 131-135 32798467-0 2020 The BCL-2 family members NOXA and BIM mediate fluorizoline-induced apoptosis in multiple myeloma cells. Fluorizoline 46-58 BCL2 apoptosis regulator Homo sapiens 4-9 32590026-4 2020 We previously found suppression of LGALS1 in AML cell lines OCI-AML3 and THP-1 sensitized both cell lines to BCL2 inhibitor ABT-737. ABT-737 124-131 BCL2 apoptosis regulator Homo sapiens 109-113 32579960-7 2020 Since rescue experiments proved that RUNX1 could repress cisplatin-induced apoptosis by up-regulating BCL2 via miR-17~92 cluster, combining RUNX1 inhibitor Ro5-3335 and cisplatin showed synergic effect in triggering OC cell apoptosis. Cisplatin 57-66 BCL2 apoptosis regulator Homo sapiens 102-106 32579960-7 2020 Since rescue experiments proved that RUNX1 could repress cisplatin-induced apoptosis by up-regulating BCL2 via miR-17~92 cluster, combining RUNX1 inhibitor Ro5-3335 and cisplatin showed synergic effect in triggering OC cell apoptosis. Ro 5-3335 156-164 BCL2 apoptosis regulator Homo sapiens 102-106 32579960-7 2020 Since rescue experiments proved that RUNX1 could repress cisplatin-induced apoptosis by up-regulating BCL2 via miR-17~92 cluster, combining RUNX1 inhibitor Ro5-3335 and cisplatin showed synergic effect in triggering OC cell apoptosis. Cisplatin 169-178 BCL2 apoptosis regulator Homo sapiens 102-106 32798467-5 2020 Moreover, fluorizoline increased the mRNA and protein levels of the pro-apoptotic BCL-2 family member NOXA both in cell lines and primary samples analyzed. Fluorizoline 10-22 BCL2 apoptosis regulator Homo sapiens 82-87 32464255-8 2020 Western blot analysis showed that the expression of Bcl-2 was noticeably decreased in response to kopetdaghinane A treatment, while the expression of Bax protein was increased. kopetdaghinane 98-112 BCL2 apoptosis regulator Homo sapiens 52-57 32640883-5 2020 Mechanistic studies showed that the combined effects of DTC and TPA were associated with a decrease in Bcl-2. Ditiocarb 56-59 BCL2 apoptosis regulator Homo sapiens 103-108 32640883-5 2020 Mechanistic studies showed that the combined effects of DTC and TPA were associated with a decrease in Bcl-2. Tetradecanoylphorbol Acetate 64-67 BCL2 apoptosis regulator Homo sapiens 103-108 31863662-7 2020 There was a higher expression of the anti-apoptotic gene, BCL2, but a lower expression of the pro-apoptotic gene, BAX, and a significant lower BAX/ BCL2 ratio in the LPA-treated group in comparison with non-treated control group (P<0.05). lysophosphatidic acid 166-169 BCL2 apoptosis regulator Homo sapiens 58-62 31863662-7 2020 There was a higher expression of the anti-apoptotic gene, BCL2, but a lower expression of the pro-apoptotic gene, BAX, and a significant lower BAX/ BCL2 ratio in the LPA-treated group in comparison with non-treated control group (P<0.05). lysophosphatidic acid 166-169 BCL2 apoptosis regulator Homo sapiens 148-152 31863662-9 2020 Conclusion: Supplementation of human ovarian tissue culture medium with LPA improves follicular survival and development by promoting an anti-apoptotic balance in transcription of BCL2 and BAX genes. lysophosphatidic acid 72-75 BCL2 apoptosis regulator Homo sapiens 180-184 32652098-1 2020 The aim of this study was to examine the effects of alpha lipoic acid (ALA) supplementation during semen cryopreservation on the sperm quality, chromatin integrity, oxidative stress, and expression level of BAX, BCL2, HSP70 and iNOS genes in semen samples obtained from infertile men with asthenoteratozoospermia. Thioctic Acid 71-74 BCL2 apoptosis regulator Homo sapiens 212-216 32652098-7 2020 During cryopreservation, treatment of semen with 0.02 mM of ALA, as the optimal concentration, significantly decreased DNA fragmentation and oxidative stress level (P < 0.05), protected the acrosome integrity, and led to insignificant reduction in BAX gene expression level and significant increase in expression level of BCL2, HSP70, and iNOS genes compared with control group. Thioctic Acid 60-63 BCL2 apoptosis regulator Homo sapiens 322-326 32927276-7 2020 Secondly, rucaparib synergised with the BCL2 family inhibitor navitoclax, with preferential activity in ovarian carcinomas that harbour alterations in BRCA1/2, BARD1, or MSH2/6. rucaparib 10-19 BCL2 apoptosis regulator Homo sapiens 40-44 32621200-10 2020 ZNP concentration-dependently elevated mRNA expression and protein level of p53 and Bax while reduced the expression of Bcl-2 and ER-alpha. znp 0-3 BCL2 apoptosis regulator Homo sapiens 120-125 32621200-12 2020 E2 treatment reduced mRNA expression and protein level of maspin and p53, and elevated Bcl-2 expression. Estradiol 0-2 BCL2 apoptosis regulator Homo sapiens 87-92 32750222-7 2020 Additionally, vortioxetine could induce apoptosis and autophagy by increasing the levels of Bax, active caspase-3/-9, Beclin-1 and Light Chain 3 (LC3), as well as downregulating Bcl-2 and P62. Vortioxetine 14-26 BCL2 apoptosis regulator Homo sapiens 178-183 32687646-1 2020 ABT-263 (Navitoclax) is one of the BH3-mimetic drugs targeting anti-apoptotic B-cell lymphoma-2 (BCL-2) family proteins, including BCL-2, BCL-xL, and BCL-w, thereby inducing apoptosis. navitoclax 0-7 BCL2 apoptosis regulator Homo sapiens 97-102 32687646-1 2020 ABT-263 (Navitoclax) is one of the BH3-mimetic drugs targeting anti-apoptotic B-cell lymphoma-2 (BCL-2) family proteins, including BCL-2, BCL-xL, and BCL-w, thereby inducing apoptosis. navitoclax 0-7 BCL2 apoptosis regulator Homo sapiens 131-136 32687646-1 2020 ABT-263 (Navitoclax) is one of the BH3-mimetic drugs targeting anti-apoptotic B-cell lymphoma-2 (BCL-2) family proteins, including BCL-2, BCL-xL, and BCL-w, thereby inducing apoptosis. BH 3 35-38 BCL2 apoptosis regulator Homo sapiens 97-102 32372344-0 2020 Correction to: a facile approach for fabricating CD44-targeted delivery of hyaluronic acid-functionalized PCL nanoparticles in urethane-induced lung cancer: Bcl-2, MMP-9, caspase-9, and BAX as potential markers. Hyaluronic Acid 75-90 BCL2 apoptosis regulator Homo sapiens 157-162 33085231-7 2020 CONCLUSIONS: GSK126 can inhibit the proliferation of CAL-27 cells in tongue squamous cell carcinoma and promote its apoptosis, and the related mechanism may be associated with the inhibition of the MEK/ERK signaling pathway and activation of the Bax/Bcl-2 pathway. GSK-2816126 13-19 BCL2 apoptosis regulator Homo sapiens 250-255 32715755-1 2020 The B-cell lymphoma 2 (BCL-2) anti-apoptotic proteins have become attractive therapeutic targets especially with the development of BH3-mimetics which selectively target these proteins. BH 3 132-135 BCL2 apoptosis regulator Homo sapiens 4-21 32715755-1 2020 The B-cell lymphoma 2 (BCL-2) anti-apoptotic proteins have become attractive therapeutic targets especially with the development of BH3-mimetics which selectively target these proteins. BH 3 132-135 BCL2 apoptosis regulator Homo sapiens 23-28 33085231-6 2020 GSK126 down-regulated the expression of p-ERK and Bcl-2 and increased the expression of Bax and Cleaved caspase-9 (P<0.05). GSK-2816126 0-6 BCL2 apoptosis regulator Homo sapiens 50-55 32945383-8 2020 In validation experiments, RSV significantly reduced cell viability and initiated apoptosis, with an increase in the number of apoptotic cells; it also upregulated cleaved caspase-3 expression and Bax expression, and downregulated the Bcl-2 expression levels. Resveratrol 27-30 BCL2 apoptosis regulator Homo sapiens 235-240 32945376-12 2020 In addition, AC significantly reduced the expression of CDK4 and Cyclin D1 in a dose-dependent manner, significantly upregulated the activation of caspase-9 and caspase-3, and decreased the Bcl-2/Bax mRNA ratio. asiaticoside 13-15 BCL2 apoptosis regulator Homo sapiens 190-195 32881246-8 2020 Pioglitazone also reduced the activation of caspase-3 and caspase-9, lowered the ratio of Bax/Bcl-2, attenuated kidney pathological damage and dysfunction, down-regulated the expression of Acetyl-p53, PUMA-alpha and Bax and abated cell apoptosis after cisplatin treatment. Pioglitazone 0-12 BCL2 apoptosis regulator Homo sapiens 94-99 32881246-6 2020 Pioglitazone treatment significantly increased cell viability, promoted SIRT1-p53 interaction, upregulated Bcl-2 expression, activated SIRT1 and elevated mitochondrial ATP synthesis after cisplatin treatment. Pioglitazone 0-12 BCL2 apoptosis regulator Homo sapiens 107-112 32885410-5 2020 Lycopene also ameliorated H2 O2 -induced damage and reduced the expression of apoptotic markers, such as Bcl-2, Bax, and cleaved caspase 3. Lycopene 0-8 BCL2 apoptosis regulator Homo sapiens 105-110 32990902-0 2020 VD3 and LXR agonist (T0901317) combination demonstrated greater potency in inhibiting cholesterol accumulation and inducing apoptosis via ABCA1-CHOP-BCL-2 cascade in MCF-7 breast cancer cells. T0901317 21-29 BCL2 apoptosis regulator Homo sapiens 149-154 32623836-0 2020 The BCL-2 family protein inhibitor ABT-737 as an additional tool for the treatment of EBV-associated post-transplant lymphoproliferative disorders. ABT-737 35-42 BCL2 apoptosis regulator Homo sapiens 4-9 32623836-4 2020 Here, we show that ABT-737, a small inhibitor of BCL-2, BCL-X(L), and BCL-w, strongly induced apoptosis in vitro in EBV-positive lymphoblastoid cell lines (which is a model for PTLD), whereas BL was less sensitive. ABT-737 19-26 BCL2 apoptosis regulator Homo sapiens 49-54 33571963-7 2020 also, expression levels of Bcl-2 and Bcl-xl proteins were significantly increased compared to those in control cells without melatonin or glucose treatments, whereas the Bax protein level decreased. Melatonin 125-134 BCL2 apoptosis regulator Homo sapiens 27-32 33571963-7 2020 also, expression levels of Bcl-2 and Bcl-xl proteins were significantly increased compared to those in control cells without melatonin or glucose treatments, whereas the Bax protein level decreased. Glucose 138-145 BCL2 apoptosis regulator Homo sapiens 27-32 32447047-9 2020 Concomitantly, hyperoside also attenuated paclitaxel-mediated anti-apoptotic Bcl-2 expression, but enhanced the effects of paclitaxel on pro-apoptotic Bax expression, and pro-inflammatory cytokine IL-6 and IL-6 levels in MDA-MB-231 cells. hyperoside 15-25 BCL2 apoptosis regulator Homo sapiens 77-82 32447047-9 2020 Concomitantly, hyperoside also attenuated paclitaxel-mediated anti-apoptotic Bcl-2 expression, but enhanced the effects of paclitaxel on pro-apoptotic Bax expression, and pro-inflammatory cytokine IL-6 and IL-6 levels in MDA-MB-231 cells. Paclitaxel 42-52 BCL2 apoptosis regulator Homo sapiens 77-82 32945414-7 2020 miR-15a-5p overexpression decreased the proliferation of hBMECs and promoted apoptosis by decreasing Bcl-2 expression levels. mir-15a-5p 0-10 BCL2 apoptosis regulator Homo sapiens 101-106 32831914-10 2020 miR-490-3p mimics significantly induced liver cancer cell apoptosis via upregulating Bax and cleaved caspase-3 and downregulating anti-apoptotic protein Bcl-2. mir-490-3p 0-10 BCL2 apoptosis regulator Homo sapiens 153-158 32863925-9 2020 Overall, the present study revealed that H2 can promote lung cancer cell apoptosis and autophagy via inhibiting the activation of STAT3/Bcl2 signaling and suppression of autophagy can enhance H2 roles in promoting lung cancer cell apoptosis. Deuterium 41-43 BCL2 apoptosis regulator Homo sapiens 136-140 32863906-12 2020 Collectively, the present results suggested that triclosan increased mito-ROS production in melanoma cells, following induced cell death via the STAT3/Bcl-2 pathway and autophagy via the AMPK/p62/LC3 pathway. Triclosan 49-58 BCL2 apoptosis regulator Homo sapiens 151-156 32863897-8 2020 As the concentration of 2-ME increased, the RNA and protein expression levels of VEGF and Bcl-2 decreased gradually, whereas the expression of caspase-3 increased gradually. 2-Methoxyestradiol 24-28 BCL2 apoptosis regulator Homo sapiens 90-95 32863897-13 2020 The mechanism of the anticancer effect of 2-ME may be associated with the actions of Bcl-2, VEGF and caspase-3. 2-Methoxyestradiol 42-46 BCL2 apoptosis regulator Homo sapiens 85-90 32863904-7 2020 Digitoxin also induced mitochondrial apoptosis, which was characterized by changes in the interaction between Bcl-2 and Bax, the release of cytochrome c, as well as the activation of the caspase-3 and -9. Digitoxin 0-9 BCL2 apoptosis regulator Homo sapiens 110-115 32945521-11 2020 Propofol could inhibit Bcl-2 and MMP9 expression, and increase P21 expression in GC cells. Propofol 0-8 BCL2 apoptosis regulator Homo sapiens 23-28 32863925-8 2020 In addition, it was found that H2 treatment induced marked decreases in the protein expression levels of phosphorylated STAT3 and Bcl2, and overexpression of STAT3 abolished H2 roles in promoting cell apoptosis and autophagy. Deuterium 31-33 BCL2 apoptosis regulator Homo sapiens 130-134 32634469-7 2020 Cytotoxic effect of 7-Epi on breast cancer cell lines was associated to its ability to increase BAX/BCL-2 ratio. 7-epiclusianone 20-25 BCL2 apoptosis regulator Homo sapiens 100-105 32307773-4 2020 Numerous studies have shown that curcumin delays the initiation and progression of NSCLC by affecting a wide range of molecular targets and cell signalling pathways including NF-kB, Akt, MAPKS, BCL-2, ROS and microRNAs (miRNAs). Curcumin 33-41 BCL2 apoptosis regulator Homo sapiens 194-199 33067936-11 2020 DNR down-regulated protein expression of BCL-2 (P<0.05) and up-regulated cleaved Caspase-3 (P<0.05). Daunorubicin 0-3 BCL2 apoptosis regulator Homo sapiens 41-46 32998881-4 2020 The crystal structure of a trBcl-2L2:trBak BH3 complex reveals that trBcl-2L2 uses the canonical Bcl-2 ligand binding groove to sequester trBak BH3, indicating that the structural basis for apoptosis control is conserved from T. adhaerens to mammals. BH 3 43-46 BCL2 apoptosis regulator Homo sapiens 29-34 33067961-9 2020 The mRNA levels of mTOR, BCL-2, and NF-kappaB in H929 were all down-regulated in H929 cells during DOX treatment. Doxycycline 99-102 BCL2 apoptosis regulator Homo sapiens 25-30 33040785-9 2020 Results showed that ethyl acetate extract of peony seed coat could reduce cell proliferation rate and the protein levels of PCNA, Bcl-2, p-STAT3, Survivin and the expression level of miR-424-3p (P<0.05), increase apoptosis rate and the protein level of Bax (P<0.05). ethyl acetate 20-33 BCL2 apoptosis regulator Homo sapiens 130-135 33040785-10 2020 After transfection with anti-miR-424-3p, the cell proliferation rate, the protein levels of PCNA and Bcl-2 were significantly reduced (P<0.05), the apoptosis rate and the protein level of Bax were significantly increased (P<0.05), while the effect of miR-424-3p mimics was the opposite. -3p 36-39 BCL2 apoptosis regulator Homo sapiens 101-106 33040785-10 2020 After transfection with anti-miR-424-3p, the cell proliferation rate, the protein levels of PCNA and Bcl-2 were significantly reduced (P<0.05), the apoptosis rate and the protein level of Bax were significantly increased (P<0.05), while the effect of miR-424-3p mimics was the opposite. mir-424-3p 29-39 BCL2 apoptosis regulator Homo sapiens 101-106 32840278-6 2020 With the combined effects, considerable in vitro and in vivo tumor inhibition was achieved by M@AAO@Fe-TA due to the activated Bcl-2/Bax/Cyt C/caspase 3 mitochondrial apoptotic pathway. fe-ta 100-105 BCL2 apoptosis regulator Homo sapiens 127-132 32990233-6 2020 Combined treatment of the cells with Lv/shAURKB and the autophagy inhibitor chloroquine obviously restored the expressions of caspase-3 and Bcl-2 (P < 0.05). Chloroquine 76-87 BCL2 apoptosis regulator Homo sapiens 140-145 32977469-8 2020 TMBIM5-knockout cells were more sensitive to apoptosis elicited by staurosporine and BH3 mimetic inhibitors of Bcl-2 and Bcl-XL. Staurosporine 67-80 BCL2 apoptosis regulator Homo sapiens 111-116 32961826-9 2020 Notably, TAT-FADD mitigates constitutive NF-kappaB activation and associated downstream anti-apoptotic genes Bcl2, cFLIPL, RIP1, and cIAP2, independent of pro-cancerous TNF-alpha priming. tat-fadd 9-17 BCL2 apoptosis regulator Homo sapiens 109-113 32973404-0 2020 LINC02418 promotes colon cancer progression by suppressing apoptosis via interaction with miR-34b-5p/BCL2 axis. linc02418 0-9 BCL2 apoptosis regulator Homo sapiens 101-105 32973404-8 2020 Western blot experiments were conducted to further explore the effect of miR-34b-5p on BCL2 signaling pathway. mir-34b-5p 73-83 BCL2 apoptosis regulator Homo sapiens 87-91 32973404-12 2020 Additionally, LINC02418 could physically bind to miR-34b-5p and subsequently affect BCL2 signaling pathway. linc02418 14-23 BCL2 apoptosis regulator Homo sapiens 84-88 32973404-15 2020 LINC02418 acted as a tumor driver by negatively regulating cell apoptosis through LINC02418/miR-34b-5p/BCL2 axis in CRC. linc02418 0-9 BCL2 apoptosis regulator Homo sapiens 103-107 32971907-6 2020 Our Western blotting analysis indicated that pimozide suppressed the phosphorylation of STAT3 at Tyr705 and Src at Tyr416, and it inhibited the expression of anti-apoptotic markers c-Myc, Mcl-1, and Bcl-2. Pimozide 45-53 BCL2 apoptosis regulator Homo sapiens 199-204 32619887-6 2020 Compound 5q up-regulated the expression of both pro-apoptotic Bax and P53, while down-regulated anti-apoptotic Bcl-2 expression. CHEMBL3739943 9-11 BCL2 apoptosis regulator Homo sapiens 111-116 32948748-2 2020 The selective Bcl-2 inhibitor venetoclax (ABT-199) in combination therapy has been approved for the treatment of newly diagnosed AML patients who are ineligible for intensive chemotherapy, but resistance can be acquired through the upregulation of alternative antiapoptotic proteins. venetoclax 30-40 BCL2 apoptosis regulator Homo sapiens 14-19 32948748-2 2020 The selective Bcl-2 inhibitor venetoclax (ABT-199) in combination therapy has been approved for the treatment of newly diagnosed AML patients who are ineligible for intensive chemotherapy, but resistance can be acquired through the upregulation of alternative antiapoptotic proteins. venetoclax 42-49 BCL2 apoptosis regulator Homo sapiens 14-19 32502906-9 2020 Then, our data showed that PPARgamma agonist (GW 1929) attenuated HgCl2 (15 mug/ml)-induced apoptosis and NLRP3 inflammasome activation via decreasing translocation of NF-kappaB and increasing Bcl2 levels in vitro. Mercuric Chloride 66-71 BCL2 apoptosis regulator Homo sapiens 193-197 32948186-8 2020 The results of Annexin V-FITC/PI, JC-1, Western blot and ROS analysis showed that the expression of cleaved caspase-3 and Bax were up-regulated Bcl-2 was down-regulated in Cepharanthine or Curcumin treated groups, while ROS and MMP value were decreased at different degrees and the apoptosis rate was reduced. ros 57-60 BCL2 apoptosis regulator Homo sapiens 144-149 32948186-8 2020 The results of Annexin V-FITC/PI, JC-1, Western blot and ROS analysis showed that the expression of cleaved caspase-3 and Bax were up-regulated Bcl-2 was down-regulated in Cepharanthine or Curcumin treated groups, while ROS and MMP value were decreased at different degrees and the apoptosis rate was reduced. cepharanthine 172-185 BCL2 apoptosis regulator Homo sapiens 144-149 32948186-8 2020 The results of Annexin V-FITC/PI, JC-1, Western blot and ROS analysis showed that the expression of cleaved caspase-3 and Bax were up-regulated Bcl-2 was down-regulated in Cepharanthine or Curcumin treated groups, while ROS and MMP value were decreased at different degrees and the apoptosis rate was reduced. Curcumin 189-197 BCL2 apoptosis regulator Homo sapiens 144-149 32948186-8 2020 The results of Annexin V-FITC/PI, JC-1, Western blot and ROS analysis showed that the expression of cleaved caspase-3 and Bax were up-regulated Bcl-2 was down-regulated in Cepharanthine or Curcumin treated groups, while ROS and MMP value were decreased at different degrees and the apoptosis rate was reduced. ros 220-223 BCL2 apoptosis regulator Homo sapiens 144-149 32943617-0 2020 BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models. BDA-366 0-7 BCL2 apoptosis regulator Homo sapiens 20-25 32943617-0 2020 BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models. sapropterin 26-29 BCL2 apoptosis regulator Homo sapiens 20-25 32943617-2 2020 BH3 mimetics targeting Bcl-2"s hydrophobic cleft have been developed, including venetoclax as a promising anticancer precision medicine for treating CLL patients. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 23-28 32943617-4 2020 BDA-366 was proposed to switch Bcl-2 from an antiapoptotic into a proapoptotic protein, thereby activating Bax and inducing apoptosis. biotinylated dextran amine 0-3 BCL2 apoptosis regulator Homo sapiens 31-36 32943617-8 2020 Instead, in primary CLL cells and DLBCL cell lines, BDA-366 inhibited the activity of the PI3K/AKT pathway, resulted in Bcl-2 dephosphorylation and reduced Mcl-1-protein levels without affecting the levels of Bcl-2 or Bcl-xL. BDA-366 52-59 BCL2 apoptosis regulator Homo sapiens 120-125 32943617-8 2020 Instead, in primary CLL cells and DLBCL cell lines, BDA-366 inhibited the activity of the PI3K/AKT pathway, resulted in Bcl-2 dephosphorylation and reduced Mcl-1-protein levels without affecting the levels of Bcl-2 or Bcl-xL. BDA-366 52-59 BCL2 apoptosis regulator Homo sapiens 209-214 32943617-9 2020 Hence, our work challenges the current view that BDA-366 is a BH4-domain antagonist of Bcl-2 that turns Bcl-2 into a pro-apoptotic protein. biotinylated dextran amine 49-52 BCL2 apoptosis regulator Homo sapiens 87-92 32943617-9 2020 Hence, our work challenges the current view that BDA-366 is a BH4-domain antagonist of Bcl-2 that turns Bcl-2 into a pro-apoptotic protein. biotinylated dextran amine 49-52 BCL2 apoptosis regulator Homo sapiens 104-109 32943617-9 2020 Hence, our work challenges the current view that BDA-366 is a BH4-domain antagonist of Bcl-2 that turns Bcl-2 into a pro-apoptotic protein. sapropterin 62-65 BCL2 apoptosis regulator Homo sapiens 87-92 32943617-9 2020 Hence, our work challenges the current view that BDA-366 is a BH4-domain antagonist of Bcl-2 that turns Bcl-2 into a pro-apoptotic protein. sapropterin 62-65 BCL2 apoptosis regulator Homo sapiens 104-109 32943617-10 2020 Rather, our results indicate that other mechanisms beyond switching Bcl-2 conformation underlie BDA-366"s cell-death properties that may implicate Mcl-1 downregulation and/or Bcl-2 dephosphorylation. biotinylated dextran amine 96-99 BCL2 apoptosis regulator Homo sapiens 68-73 32943617-10 2020 Rather, our results indicate that other mechanisms beyond switching Bcl-2 conformation underlie BDA-366"s cell-death properties that may implicate Mcl-1 downregulation and/or Bcl-2 dephosphorylation. biotinylated dextran amine 96-99 BCL2 apoptosis regulator Homo sapiens 175-180 32653697-6 2020 The up-regulated Bax and down-regulated Bcl-2 expression levels, caspase-3/7 activation and reduced Fas expression indicated that Mn and Cu induced ROS-dependent mitochondria-mediated intrinsic apoptosis in A549 cells. Copper 137-139 BCL2 apoptosis regulator Homo sapiens 40-45 32634439-10 2020 In addition, 150 muM 6-OHDA-induced down-regulation of Bcl-2 and Akt levels and up-regulation of Bax and cleaved caspase-9/caspase-9 levels were partially restored by 1.25 muM CAPE treatment. Oxidopamine 21-27 BCL2 apoptosis regulator Homo sapiens 55-60 32634439-10 2020 In addition, 150 muM 6-OHDA-induced down-regulation of Bcl-2 and Akt levels and up-regulation of Bax and cleaved caspase-9/caspase-9 levels were partially restored by 1.25 muM CAPE treatment. caffeic acid phenethyl ester 176-180 BCL2 apoptosis regulator Homo sapiens 55-60 32931486-11 2020 IL-37 also inhibited high glucose-induced apoptosis of podocytes by inhibiting the expression of the apoptosis-related proteins Bax and cleaved caspase-3/6/9, and by promoting the expression of Bcl-2. Glucose 26-33 BCL2 apoptosis regulator Homo sapiens 194-199 32645343-5 2020 Besides, BIBR1532 augmented ATO-induced cytotoxic effects via triggering G1 cell cycle arrest and induction of apoptosis coupled with the down-regulation of NF-kappaB target genes that were involved in cell cycle progression (e.g. CCND1 and CDK6) and prevention of apoptosis such as Bcl-2, Bcl-xl, c-IAP2, and Survivin Respectively. BIBR 1532 9-17 BCL2 apoptosis regulator Homo sapiens 283-288 32645343-5 2020 Besides, BIBR1532 augmented ATO-induced cytotoxic effects via triggering G1 cell cycle arrest and induction of apoptosis coupled with the down-regulation of NF-kappaB target genes that were involved in cell cycle progression (e.g. CCND1 and CDK6) and prevention of apoptosis such as Bcl-2, Bcl-xl, c-IAP2, and Survivin Respectively. Arsenic Trioxide 28-31 BCL2 apoptosis regulator Homo sapiens 283-288 32924840-8 2022 Added to this, CDK-6 and Bcl-2 had better glide scores for puerarin than the control (doxorubicin) and molecular simulation showed the stability of the complexes. Doxorubicin 86-97 BCL2 apoptosis regulator Homo sapiens 25-30 32562827-6 2020 The current results showed that the apoptosis in porcine GCs exposed to severe hypoxia (1% O2) was correlated with enhanced activation of c-Jun N-terminal kinase (JNK), nuclear accumulation of FOXO1, as well as elevated level of cleaved caspase-3 and decreased ratio of BCL-2/BAX. Oxygen 91-93 BCL2 apoptosis regulator Homo sapiens 270-275 32924840-9 2022 These findings suggest that inhibiting CDK-6 and Bcl-2 with Puerarin could prove more effective in the management of cancer than doxorubicin. Doxorubicin 129-140 BCL2 apoptosis regulator Homo sapiens 49-54 32982428-12 2020 In addition, STAT3/Bcl-2/survivin signaling pathway was also remarkably inhibited in Res/TMZ-treated GBM cells. Temozolomide 89-92 BCL2 apoptosis regulator Homo sapiens 19-24 32574796-5 2020 miR-455-5p inhibition increased cell viability, PCNA, cyclin D1, and Bcl-2 levels and decreased apoptosis and Bax levels in SH-SY5Y neuroblastoma cells. mir-455-5p 0-10 BCL2 apoptosis regulator Homo sapiens 69-74 32914380-0 2021 MiR-325 Promotes Oxaliplatin-Induced Cytotoxicity Against Colorectal Cancer Through the HSPA12B/PI3K/AKT/Bcl-2 Pathway. Oxaliplatin 17-28 BCL2 apoptosis regulator Homo sapiens 105-110 32915786-8 2020 ZnO-NP treatment reduced the basal levels of reactive oxygen species and Bax/Bcl-2 mRNA ratios; in addition, ZnO-NP decreased the 6-OHDA-induced ROS production, p53 expression, and cell death. zno-np 0-6 BCL2 apoptosis regulator Homo sapiens 77-82 32914380-11 2021 Therefore, overexpression of miR-325 inhibited the phosphorylation of PI3K and AKT and decreased the expression of Bcl-2 to promote the oxaliplatin-induced mitochondrial apoptosis in colorectal cancer. Oxaliplatin 136-147 BCL2 apoptosis regulator Homo sapiens 115-120 32914380-12 2021 CONCLUSIONS: MiR-325 sensitizes the colorectal cancer cells to oxaliplatin-induced cytotoxicity through the HSPA12B/PI3K/AKT/Bcl-2 pathway. Oxaliplatin 63-74 BCL2 apoptosis regulator Homo sapiens 125-130 32982289-8 2020 The molecular data showed that TB up-regulated the gene expressions of NOXA, PUMA, P21, Bax, and Bim and up-regulated the protein expressions of ASK-1, Bax, phosphorylated JNK, and phosphorylated c-Jun with down-regulation of Bcl-2. theabrownin 31-33 BCL2 apoptosis regulator Homo sapiens 226-231 32450402-7 2020 Downstream mTOR and Bcl2 were upregulated by Nrf2 signaling, inhibiting autophagy initiation in arsenite-exposed HaCaT cells. arsenite 96-104 BCL2 apoptosis regulator Homo sapiens 20-24 32450402-8 2020 In conclusion, our data suggest that long-term exposure to arsenite promotes Nrf2 upregulation via the PI3K/Akt pathway and, along with upregulation of downstream mTOR and Bcl2, contributes to autophagy dysfunction in transformed HaCaT cells. arsenite 59-67 BCL2 apoptosis regulator Homo sapiens 172-176 32710621-0 2020 Upregulation of BCL-2 by acridone derivative through gene promoter i-motif for alleviating liver damage of NAFLD/NASH. acridone 25-33 BCL2 apoptosis regulator Homo sapiens 16-21 32898249-6 2020 Idelalisib restored FL dependence on BCL-2 and venetoclax activity. idelalisib 0-10 BCL2 apoptosis regulator Homo sapiens 37-42 32898249-8 2020 In all FL cases, idelalisib exerts a general reshaping of the FL immune microenvironment and restores dependence on BCL-2, predisposing FL to cell death, providing a mechanistic rationale for investigating the combination of PI3Kdelta inhibitors and venetoclax in clinical trials. idelalisib 17-27 BCL2 apoptosis regulator Homo sapiens 116-121 32887384-3 2020 The expression of Bcl2, an essential marker for anagen hair follicle and cell survival, was increased by quercitrin treatment. quercitrin 105-115 BCL2 apoptosis regulator Homo sapiens 18-22 33193866-0 2020 Enhanced anticancer effect of doxorubicin by TPGS-coated liposomes with Bcl-2 siRNA-corona for dual suppression of drug resistance. Doxorubicin 30-41 BCL2 apoptosis regulator Homo sapiens 72-77 32577785-0 2020 Synergistic effects of Bcl-2 inhibitors with AZD9291 on overcoming the acquired resistance of AZD9291 in H1975 cells. osimertinib 94-101 BCL2 apoptosis regulator Homo sapiens 23-28 32577785-3 2020 In the present study, significant upregulation of Bcl-2 was found in AZD9291-resistant H1975 cells (H1975AR) compared with H1975, which may constitute an important resistant mechanism of acquired resistance to AZD9291. osimertinib 69-76 BCL2 apoptosis regulator Homo sapiens 50-55 32311849-7 2020 A complex karyotype with aberrations related to regions in MYC and BCL2/BCL6 was significantly associated with D/THL. Deuterium 111-112 BCL2 apoptosis regulator Homo sapiens 67-71 32311849-7 2020 A complex karyotype with aberrations related to regions in MYC and BCL2/BCL6 was significantly associated with D/THL. Orlistat 113-116 BCL2 apoptosis regulator Homo sapiens 67-71 32878787-14 2020 As for the anticancer activity, ephemeranthol A induced apoptosis by decreasing Bcl-2 followed by the activation of caspase 3 and caspase 9. ephemeranthol A 32-47 BCL2 apoptosis regulator Homo sapiens 80-85 32878788-8 2020 Butyl-Pt, pentyl-Pt and cisplatin arrested the cell cycle in the S-phase and induced apoptotic cell death via regulation of expression of B-cell lymphoma 2 (BCL2) and BCL2-associated X (BAX) proteins. butyl-pt 0-8 BCL2 apoptosis regulator Homo sapiens 138-155 32878788-8 2020 Butyl-Pt, pentyl-Pt and cisplatin arrested the cell cycle in the S-phase and induced apoptotic cell death via regulation of expression of B-cell lymphoma 2 (BCL2) and BCL2-associated X (BAX) proteins. butyl-pt 0-8 BCL2 apoptosis regulator Homo sapiens 157-161 32878788-8 2020 Butyl-Pt, pentyl-Pt and cisplatin arrested the cell cycle in the S-phase and induced apoptotic cell death via regulation of expression of B-cell lymphoma 2 (BCL2) and BCL2-associated X (BAX) proteins. pentyl-pt 10-19 BCL2 apoptosis regulator Homo sapiens 138-155 32878788-8 2020 Butyl-Pt, pentyl-Pt and cisplatin arrested the cell cycle in the S-phase and induced apoptotic cell death via regulation of expression of B-cell lymphoma 2 (BCL2) and BCL2-associated X (BAX) proteins. pentyl-pt 10-19 BCL2 apoptosis regulator Homo sapiens 157-161 32878788-8 2020 Butyl-Pt, pentyl-Pt and cisplatin arrested the cell cycle in the S-phase and induced apoptotic cell death via regulation of expression of B-cell lymphoma 2 (BCL2) and BCL2-associated X (BAX) proteins. Cisplatin 24-33 BCL2 apoptosis regulator Homo sapiens 138-155 32878788-8 2020 Butyl-Pt, pentyl-Pt and cisplatin arrested the cell cycle in the S-phase and induced apoptotic cell death via regulation of expression of B-cell lymphoma 2 (BCL2) and BCL2-associated X (BAX) proteins. Cisplatin 24-33 BCL2 apoptosis regulator Homo sapiens 157-161 32577785-3 2020 In the present study, significant upregulation of Bcl-2 was found in AZD9291-resistant H1975 cells (H1975AR) compared with H1975, which may constitute an important resistant mechanism of acquired resistance to AZD9291. osimertinib 210-217 BCL2 apoptosis regulator Homo sapiens 50-55 32577785-4 2020 More importantly, our study showed that synergism between AZD9291 and Bcl-2 inhibitor ABT263 (0.25 muM) or ABT199 (1 muM) could effectively overcome the acquired resistance of AZD9291 in H1975AR in vitro. navitoclax 86-92 BCL2 apoptosis regulator Homo sapiens 70-75 32577785-4 2020 More importantly, our study showed that synergism between AZD9291 and Bcl-2 inhibitor ABT263 (0.25 muM) or ABT199 (1 muM) could effectively overcome the acquired resistance of AZD9291 in H1975AR in vitro. osimertinib 176-183 BCL2 apoptosis regulator Homo sapiens 70-75 33193866-2 2020 Here, we developed TPGS-coated cationic liposomes with Bcl-2 siRNA corona to load doxorubicin (Dox) i.e., Bcl-2 siRNA/Dox-TPGS-LPs, to enhance anticancer effect of Dox in HCC-MDR. Doxorubicin 82-93 BCL2 apoptosis regulator Homo sapiens 106-111 33193866-2 2020 Here, we developed TPGS-coated cationic liposomes with Bcl-2 siRNA corona to load doxorubicin (Dox) i.e., Bcl-2 siRNA/Dox-TPGS-LPs, to enhance anticancer effect of Dox in HCC-MDR. Doxorubicin 95-98 BCL2 apoptosis regulator Homo sapiens 106-111 33193866-5 2020 The stability and hemolysis evaluation demonstrated Bcl-2 siRNA/Dox-TPGS-LPs had good biocompatibility and siRNA-corona could protect the liposomal core to avoid the attachment of fetal bovine serum. Doxorubicin 64-67 BCL2 apoptosis regulator Homo sapiens 52-57 33193866-9 2020 Bcl-2 siRNA corona successfully entered the cytosol of Bel7402/5-FU MDR cells to downregulate Bcl-2 protein levels in vitro and in vivo. Fluorouracil 63-67 BCL2 apoptosis regulator Homo sapiens 0-5 33193866-9 2020 Bcl-2 siRNA corona successfully entered the cytosol of Bel7402/5-FU MDR cells to downregulate Bcl-2 protein levels in vitro and in vivo. Fluorouracil 63-67 BCL2 apoptosis regulator Homo sapiens 94-99 33193866-10 2020 Bcl-2 siRNA/Dox-TPGS-LPs showed superior to TPGS- (or siRNA-) linked Dox liposomes in cell apoptosis and cytotoxicity assay in Bel7402/5-FU MDR cells, and 7-fold greater effect than free Dox in tumor growth inhibition of Bel7402/5-FU xenograft nude mice. Doxorubicin 12-15 BCL2 apoptosis regulator Homo sapiens 0-5 32563984-2 2020 Obatoclax mesylate (OM), a B cell chronic lymphocytic leukemia/lymphoma 2 (Bcl-2) family antagonist, is a potential antitumor drug. Obatoclax mesylate 0-18 BCL2 apoptosis regulator Homo sapiens 27-73 32563984-2 2020 Obatoclax mesylate (OM), a B cell chronic lymphocytic leukemia/lymphoma 2 (Bcl-2) family antagonist, is a potential antitumor drug. Obatoclax mesylate 0-18 BCL2 apoptosis regulator Homo sapiens 75-80 33193866-10 2020 Bcl-2 siRNA/Dox-TPGS-LPs showed superior to TPGS- (or siRNA-) linked Dox liposomes in cell apoptosis and cytotoxicity assay in Bel7402/5-FU MDR cells, and 7-fold greater effect than free Dox in tumor growth inhibition of Bel7402/5-FU xenograft nude mice. Fluorouracil 135-139 BCL2 apoptosis regulator Homo sapiens 0-5 33193866-10 2020 Bcl-2 siRNA/Dox-TPGS-LPs showed superior to TPGS- (or siRNA-) linked Dox liposomes in cell apoptosis and cytotoxicity assay in Bel7402/5-FU MDR cells, and 7-fold greater effect than free Dox in tumor growth inhibition of Bel7402/5-FU xenograft nude mice. Fluorouracil 229-233 BCL2 apoptosis regulator Homo sapiens 0-5 32309901-0 2020 Platinum nanoparticles induced genotoxicity and apoptotic activity in human normal and cancer hepatic cells via oxidative stress-mediated Bax/Bcl-2 and caspase-3 expression. Platinum 0-8 BCL2 apoptosis regulator Homo sapiens 142-147 32314406-12 2020 Furthermore, apoptosis was promoted, coupled with a decrease of Bcl-2 expression and increases of Bax, cleaved caspase-3 and cleaved caspase-9 expression, in Ropivacaine-treated TPC-1 cells, which was restored following ITGA2 overexpression. Ropivacaine 158-169 BCL2 apoptosis regulator Homo sapiens 64-69 32962811-4 2020 The expression of four key genes involved in inflammation and apoptosis including IL-8, IL-1beta, IL-10 and Bcl2 depicted that the MTX-SA had controversial behavior in different doses on the inflammatory transcription. mtx-sa 131-137 BCL2 apoptosis regulator Homo sapiens 108-112 32765688-12 2020 Furthermore, knockdown of miR-96 combined with oxaliplatin reduced the viability and induced apoptosis of CRC cells, which was further verified by decreased expression of Bcl-2 and the increased expression of TPM1 and BAX. Oxaliplatin 47-58 BCL2 apoptosis regulator Homo sapiens 171-176 33015809-8 2020 WB results showed that compared with the NOR, the expression of apoptosis proteins (Caspase-3, Caspase-9, Bax, and COX-2) in the MOD increased significantly, and the expression of Bcl-2 reduced significantly (all p<0.05), and the addition of propofol improved the expression of corresponding proteins. Propofol 242-250 BCL2 apoptosis regulator Homo sapiens 180-185 32504442-7 2020 The treatment of n-hexane fraction showed downregulation in the gene expression of Bcl-2 and upregulation in the expression level of p53, Bad, and caspase-3 genes analyzed using semi-quantitative RT-PCR in HeLa cells. n-hexane 17-25 BCL2 apoptosis regulator Homo sapiens 83-88 32765780-9 2020 Matrine treatment also promoted the expression of Bax and reduced the expression of Bcl-2 and cyclin D1 compared with the control. matrine 0-7 BCL2 apoptosis regulator Homo sapiens 84-89 32515014-14 2020 HBD-2 and BCL-2 exhibited increased expression in ProRoot MTA with RSV (p<0.05). Resveratrol 67-70 BCL2 apoptosis regulator Homo sapiens 10-15 32429645-6 2020 Results: P. chenur methanolic extract increased significantly the expression of BAX while decreased the expression of BCL-2, AKT1, FAK, RhoA, and MMP genes compared to the control group. chenur methanolic extract 12-37 BCL2 apoptosis regulator Homo sapiens 118-123 32705266-7 2020 Flow cytometry revealed that LPB significantly induced apoptosis of NSCLC cells, along with changes in the expression of apoptosis-associated proteins, including an increase in Bax, caspase-3, and caspase-8 expression, and a decrease in Bcl-2 and Bcl-xl expression. liriopesides B 29-32 BCL2 apoptosis regulator Homo sapiens 237-242 32691972-5 2020 Immunohistochemical analysis and qPCR revealed that topically applied curcumin either before, after or in combination with acidic bile exposure significantly suppressed its induced NF-kappaB activation in regenerating epithelial cells, and overexpression of Rela, Bcl2, Egfr, Stat3, Wnt5a, Tnf, Il6, Ptgs2. Curcumin 70-78 BCL2 apoptosis regulator Homo sapiens 264-268 32582964-5 2020 The results showed that rosuvastatin treatment decreased apoptosis of HCAECs induced by CoCl2 by increasing anti-apoptosis Bcl-xl and Bcl-2 expression, and decreasing pro-apoptosis Bax, Bad, caspase-3 and caspase-9 expression. Rosuvastatin Calcium 24-36 BCL2 apoptosis regulator Homo sapiens 134-139 32374939-7 2020 More importantly, the cisplatin-induced elevated protein levels of Bax, cleaved caspase-3, cleaved caspase-9, and decreased protein level of Bcl-2 were reversed after treatment with Rk1. Cisplatin 22-31 BCL2 apoptosis regulator Homo sapiens 141-146 32584515-6 2020 Bcl-2 protein, one of the apoptotic regulators, was downregulated, while other regulators of apoptosis, including BAX, cleaved caspase-3, and cleaved caspase-9, were upregulated in RA-FLSs under periplocin treatment. periplocin 195-205 BCL2 apoptosis regulator Homo sapiens 0-5 31784978-10 2020 In support, data from q-RT PCR showed that SCFA treatments influenced the expression of the neurogenesis, proliferation, and apoptosis-related genes ATR, BCL2, BID, CASP8, CDK2, E2F1, FAS, NDN, and VEGFA. Fatty Acids, Volatile 43-47 BCL2 apoptosis regulator Homo sapiens 154-158 32585246-13 2020 SIGNIFICANCE: Gedunin induces apoptosis in lung cancer cells by disrupting Hsp90:Beclin-1:Bcl-2 interaction and autophagy downregulation, thus making gedunin a good drug lead for targeting lung cancer. gedunin 14-21 BCL2 apoptosis regulator Homo sapiens 90-95 32585246-13 2020 SIGNIFICANCE: Gedunin induces apoptosis in lung cancer cells by disrupting Hsp90:Beclin-1:Bcl-2 interaction and autophagy downregulation, thus making gedunin a good drug lead for targeting lung cancer. gedunin 150-157 BCL2 apoptosis regulator Homo sapiens 90-95 32567031-0 2020 Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2. prexasertib 83-94 BCL2 apoptosis regulator Homo sapiens 0-5 32567031-2 2020 The combination of prexasertib and GS has a strong antitumor effect and induces apoptosis in pancreatic cancer cells by downregulating anti-apoptotic protein Bcl-2. prexasertib 19-30 BCL2 apoptosis regulator Homo sapiens 158-163 32582989-13 2020 The results of the present study demonstrated that miR-23a-3p inhibited proliferation and induced apoptosis of GC cells, which may be attributable to its direct targeting of BCL2. mir-23a-3p 51-61 BCL2 apoptosis regulator Homo sapiens 174-178 32582964-5 2020 The results showed that rosuvastatin treatment decreased apoptosis of HCAECs induced by CoCl2 by increasing anti-apoptosis Bcl-xl and Bcl-2 expression, and decreasing pro-apoptosis Bax, Bad, caspase-3 and caspase-9 expression. cobaltous chloride 88-93 BCL2 apoptosis regulator Homo sapiens 134-139 32582969-11 2020 Moreover, absence of GPR81 combined with cisplatin exposure increased caspase-3 expression and decreased Bcl-2 levels. Cisplatin 41-50 BCL2 apoptosis regulator Homo sapiens 105-110 32973533-11 2020 DDP and hesperetin also induced significant increases in apoptosis inducing factor (AIF), BCL2 associated X, apoptosis regulator (BAX), cleaved caspase-9, and cleaved caspase-3, and decreased B-cell lymphoma 2 (BCL2), caspase-9, and caspase-3 levels. Cisplatin 0-3 BCL2 apoptosis regulator Homo sapiens 192-209 32705204-5 2020 Apoptosis was involved in the process of cucurbitacin I-induced cell death, with an increase observed in cleaved-caspase 3 and BAX, and a decrease in Bcl-2. cucurbitacin I 41-55 BCL2 apoptosis regulator Homo sapiens 150-155 32377769-7 2020 Pregabalin in high doses (150 mg/kg/day and 300 mg/kg/day) disrupted the ERK/JNK/p38-MAPK signaling, reversed the bax/bcl2 ratio, and induced oxidative stress. Pregabalin 0-10 BCL2 apoptosis regulator Homo sapiens 118-122 32782617-7 2020 Western blotting results indicated that enzalutamide treatment downregulated the expression levels of JNK and activated transcription factor 2, as well as enhanced the Bax/Bcl-2 ratio and induced cleavage of poly-ADP ribose polymerase. enzalutamide 40-52 BCL2 apoptosis regulator Homo sapiens 172-177 32878253-7 2020 These ROS-mediated responses induce caspase-dependent apoptosis via the activation of B-cell lymphoma 2 (Bcl2), Bcl2-associated X protein (Bax), CCAAT/enhancer-binding protein homologous protein (chop), and phosphoprotein p53 gene expressions. Reactive Oxygen Species 6-9 BCL2 apoptosis regulator Homo sapiens 86-103 32878253-7 2020 These ROS-mediated responses induce caspase-dependent apoptosis via the activation of B-cell lymphoma 2 (Bcl2), Bcl2-associated X protein (Bax), CCAAT/enhancer-binding protein homologous protein (chop), and phosphoprotein p53 gene expressions. Reactive Oxygen Species 6-9 BCL2 apoptosis regulator Homo sapiens 105-109 32973533-11 2020 DDP and hesperetin also induced significant increases in apoptosis inducing factor (AIF), BCL2 associated X, apoptosis regulator (BAX), cleaved caspase-9, and cleaved caspase-3, and decreased B-cell lymphoma 2 (BCL2), caspase-9, and caspase-3 levels. hesperetin 8-18 BCL2 apoptosis regulator Homo sapiens 192-209 32785305-3 2020 In this work, we report effects of alkaline earth metal halides BCl2 (B = Mg, Ca, Sr, Ba) as additives on the opto-electronic properties and photovoltaic performance of FAPbI3 based perovskite solar cells (PSCs). Magnesium 74-76 BCL2 apoptosis regulator Homo sapiens 64-68 32785305-3 2020 In this work, we report effects of alkaline earth metal halides BCl2 (B = Mg, Ca, Sr, Ba) as additives on the opto-electronic properties and photovoltaic performance of FAPbI3 based perovskite solar cells (PSCs). Strontium 82-84 BCL2 apoptosis regulator Homo sapiens 64-68 32785305-3 2020 In this work, we report effects of alkaline earth metal halides BCl2 (B = Mg, Ca, Sr, Ba) as additives on the opto-electronic properties and photovoltaic performance of FAPbI3 based perovskite solar cells (PSCs). Barium 86-88 BCL2 apoptosis regulator Homo sapiens 64-68 32872665-4 2020 CD-induced overproduction of reactive oxygen species and reduced mitochondrial membrane potential, associated with reduced expression of Bcl-2 and increased levels of cytosolic cytochrome c, cleaved PARP-1 and caspase-3. Cadmium 0-2 BCL2 apoptosis regulator Homo sapiens 137-142 32943925-3 2020 In this study, the effect of hydroxytyrosol on the expression of genes effective in apoptosis - BAX, BCL2, CASP3, P53, PPAR G, and NFE2L2 - and antioxidant-enzyme activity in LS180 cells of human colorectal cancer was investigated. 3,4-dihydroxyphenylethanol 29-43 BCL2 apoptosis regulator Homo sapiens 101-105 32943925-7 2020 Results: Analysis of gene expression showed that hydroxytyrosol significantly increased the expression of CASP3 and the BAX:BCL2 ratio in treatment groups compared to the control (P<0.05). 3,4-dihydroxyphenylethanol 49-63 BCL2 apoptosis regulator Homo sapiens 124-128 32943925-10 2020 Conclusion: Hydroxytyrosol may induce apoptosis in colorectal cancer cells by increasing the expression of CASP3 gene and increasing the BAX:BCL2 ratio. 3,4-dihydroxyphenylethanol 12-26 BCL2 apoptosis regulator Homo sapiens 141-145 32973533-11 2020 DDP and hesperetin also induced significant increases in apoptosis inducing factor (AIF), BCL2 associated X, apoptosis regulator (BAX), cleaved caspase-9, and cleaved caspase-3, and decreased B-cell lymphoma 2 (BCL2), caspase-9, and caspase-3 levels. hesperetin 8-18 BCL2 apoptosis regulator Homo sapiens 90-94 32973533-11 2020 DDP and hesperetin also induced significant increases in apoptosis inducing factor (AIF), BCL2 associated X, apoptosis regulator (BAX), cleaved caspase-9, and cleaved caspase-3, and decreased B-cell lymphoma 2 (BCL2), caspase-9, and caspase-3 levels. Cisplatin 0-3 BCL2 apoptosis regulator Homo sapiens 90-94 32922006-10 2020 However, at higher concentrations (greater than 16.0 microg/mL), CeO2NPs inhibited osteoclast differentiation and promoted apoptosis of BMMs by reducing Bcl2 expression and increasing the expression of cleaved caspase-3, which may be due to the overproduction of ROS. ceo2nps 65-72 BCL2 apoptosis regulator Homo sapiens 153-157 32858795-0 2020 In-Vitro and In-Silico Evaluations of Heterocyclic-Containing Diarylpentanoids as Bcl-2 Inhibitors Against LoVo Colorectal Cancer Cells. diarylpentanoids 62-78 BCL2 apoptosis regulator Homo sapiens 82-87 32858795-6 2020 Further molecular docking studies revealed that the bromophenyl moieties of 2e could interact with the Bcl-2 surface pocket through hydrophobic interaction, while the tetrahydro-4H-thiopyran-4-one fragment could form additional Pi-sulfur and Pi-alkyl interactions in the same binding site. Sulfur 231-237 BCL2 apoptosis regulator Homo sapiens 103-108 32590070-9 2020 Bax and cytosolic Cyt C expression was enhanced while Bcl-2 and mitochondrial Cyt C expression was reduced in scoulerine-treated CRC cells. discretamine 110-120 BCL2 apoptosis regulator Homo sapiens 54-59 32590072-7 2020 These data suggest that sappanchalcone induces apoptosis through caspase-dependent and caspases-independent mechanisms that were characterized by decreased Bcl-2 expression, mitochondrial targeting, and altered ROS production and AIF translocation to the nuclei. sappanchalcone 24-38 BCL2 apoptosis regulator Homo sapiens 156-161 32507875-8 2020 RESULTS: miR-155 over-expression in COCs suppressed cumulus expansion, oocyte maturation and inhibition of endogenous miR-155 by miR-off 155 improved cumulus expansion and oocyte maturation by downregulation and expression increase of the Smad2 and Bcl2 genes. -off 155 132-140 BCL2 apoptosis regulator Homo sapiens 249-253 32839432-0 2020 The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 30-33 BCL2 apoptosis regulator Homo sapiens 4-9 32839432-5 2020 Mechanistically, ABT-199 mainly affected the multidomain effector BAX by liberating it from BCL-2 inhibition. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 17-20 BCL2 apoptosis regulator Homo sapiens 92-97 32922037-12 2020 However, LY294002 reversed CPA4 overexpression-stimulated cell proliferation and drug resistance in vitro in Bcl2/Bax and caspase3-dependent apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 BCL2 apoptosis regulator Homo sapiens 109-113 32807213-8 2020 Quantitative Polymerase Chain Reaction and Western blot analysis showed increased p21 and decreased cyclin D. Quantitative Polymerase Chain Reaction and western blot analysis showed that levobupivacaine significantly increased Bax expression, accompanied by a significant decreased Bcl-2 expression and inhibition of PI3K/Akt/mTOR signalling pathway. Levobupivacaine 187-202 BCL2 apoptosis regulator Homo sapiens 282-287 32929356-5 2020 Results: Neocuproine-based far-red turn on fluorescence probe TGP18 shows GQ-to-duplex selectivity and specifically recognizes BCL-2 GQ with high affinity through a unique hybrid binding mode involving loop-stacking and groove interactions. neocuproine 9-20 BCL2 apoptosis regulator Homo sapiens 127-132 32929356-7 2020 TGP18 binding to anti-apoptotic BCL-2 GQ ablates the pro-survival function and elicit anti-cancer activity by inducing apoptosis in cancer cells. tgp18 0-5 BCL2 apoptosis regulator Homo sapiens 32-37 32973496-8 2020 Real-Time PCR results verified that GA significantly promoted Caspase-3, Bax, P53, and Cyt-c genes expression, and inhibited Bcl-2, PI3K, Akt, and NF-kappaB p65 genes expression (p < 0.001). Gallic Acid 36-38 BCL2 apoptosis regulator Homo sapiens 125-130 32801295-4 2020 We employ this information to guide the use of BH3 mimetics to specifically inhibit BCL-2 pro-survival proteins, defeat resistance and avoid relapse. BH 3 47-50 BCL2 apoptosis regulator Homo sapiens 84-89 32473523-6 2020 Vinorelbine inhibited the cancer cell proliferation by MTT and colony formation assays and inducing G2/M arrest and cell apoptosis via regulation of Bax, Bcl-2, and Bcl-xL. Vinorelbine 0-11 BCL2 apoptosis regulator Homo sapiens 154-159 32446712-11 2020 In summary, our results indicated that osthole effectively eliminated glioma cells via apoptosis, what was correlated with Bcl-2/Beclin 1 complex formation. osthol 39-46 BCL2 apoptosis regulator Homo sapiens 123-128 32855762-10 2020 Also, we determined the effect of gZnNPs at the molecular level by evaluating the apoptotic and inflammatory markers, in which gZnNPs downregulated Bcl2 and upregulated Bax, caspase-3, and TNF-alpha in HaCaT and A549 cells. gznnps 127-133 BCL2 apoptosis regulator Homo sapiens 148-152 32525019-7 2020 Elevated po-pulation of apoptotic cells, activation of Bax and reduced Bcl2 expression indicated apoptosis by Ch-319. CH-319 110-116 BCL2 apoptosis regulator Homo sapiens 71-75 32470451-0 2020 Bcl2 inhibitor ABT737 reverses the Warburg effect via the Sirt3-HIF1alpha axis to promote oxidative stress-induced apoptosis in ovarian cancer cells. ABT-737 15-21 BCL2 apoptosis regulator Homo sapiens 0-4 32470451-3 2020 ABT737, which inhibits the apoptosis regulator B cell lymphoma 2 (Bcl2), increases the sensitivity of ovarian cancer cells to chemotherapeutic drugs by regulating the glucose metabolism, but the underlying mechanisms remain unclear. Glucose 167-174 BCL2 apoptosis regulator Homo sapiens 66-70 32470451-11 2020 SIGNIFICANCE: The Bcl2 inhibitor ABT737 enhanced the anti-tumor effect of oxidative stress by reversing the Warburg effect in ovarian cancer cells, providing powerful theoretical support for further clinical applications of Bcl2 inhibitors. ABT-737 33-39 BCL2 apoptosis regulator Homo sapiens 18-22 32470451-11 2020 SIGNIFICANCE: The Bcl2 inhibitor ABT737 enhanced the anti-tumor effect of oxidative stress by reversing the Warburg effect in ovarian cancer cells, providing powerful theoretical support for further clinical applications of Bcl2 inhibitors. ABT-737 33-39 BCL2 apoptosis regulator Homo sapiens 224-228 32848792-10 2020 FG-4592 could protect cardiomyocytes against DOX-induced apoptosis and ROS production in line with the upregulation of HIF-1alpha and its target genes of Bcl-2 and SOD2. Doxorubicin 45-48 BCL2 apoptosis regulator Homo sapiens 154-159 32850387-6 2020 Furthermore, sildenafil potentiated vincristine-induced mitochondrial damage, including Mcl-1 downregulation, Bcl-2 phosphorylation and downregulation, Bak upregulation and loss of mitochondrial membrane potential, and sensitized caspase-dependent apoptotic cell death. Sildenafil Citrate 13-23 BCL2 apoptosis regulator Homo sapiens 110-115 32850387-6 2020 Furthermore, sildenafil potentiated vincristine-induced mitochondrial damage, including Mcl-1 downregulation, Bcl-2 phosphorylation and downregulation, Bak upregulation and loss of mitochondrial membrane potential, and sensitized caspase-dependent apoptotic cell death. Vincristine 36-47 BCL2 apoptosis regulator Homo sapiens 110-115 32764382-9 2020 Several mitotic arrest signals were enhanced under combinatory treatment of vinorelbine and YL-9, including an increase of mitotic spindle abnormalities, increased cyclin B1 expression, B-cell lymphoma 2 (Bcl-2) phosphorylation and increased phosphoproteins. Vinorelbine 76-87 BCL2 apoptosis regulator Homo sapiens 186-203 32764382-9 2020 Several mitotic arrest signals were enhanced under combinatory treatment of vinorelbine and YL-9, including an increase of mitotic spindle abnormalities, increased cyclin B1 expression, B-cell lymphoma 2 (Bcl-2) phosphorylation and increased phosphoproteins. Vinorelbine 76-87 BCL2 apoptosis regulator Homo sapiens 205-210 32764382-9 2020 Several mitotic arrest signals were enhanced under combinatory treatment of vinorelbine and YL-9, including an increase of mitotic spindle abnormalities, increased cyclin B1 expression, B-cell lymphoma 2 (Bcl-2) phosphorylation and increased phosphoproteins. yl-9 92-96 BCL2 apoptosis regulator Homo sapiens 186-203 32764382-9 2020 Several mitotic arrest signals were enhanced under combinatory treatment of vinorelbine and YL-9, including an increase of mitotic spindle abnormalities, increased cyclin B1 expression, B-cell lymphoma 2 (Bcl-2) phosphorylation and increased phosphoproteins. yl-9 92-96 BCL2 apoptosis regulator Homo sapiens 205-210 32905449-7 2020 The novel mechanism of CDIM8-mediated inhibition of basal and TGFbeta-induced ERMS cell invasion was due to activation of the Bcl-2-NR4A1 complex, mitochondrial disruption, induction of the tumor suppressor-like cytokine interleukin-24 (IL-24) which in turn downregulates beta-catenin expression. DIM-C-pPhOH 23-28 BCL2 apoptosis regulator Homo sapiens 126-131 32380907-0 2020 MiR-153-5p promotes sensibility of colorectal cancer cells to oxaliplatin via targeting Bcl-2-mediated autophagy pathway. mir-153-5p 0-10 BCL2 apoptosis regulator Homo sapiens 88-93 32380907-0 2020 MiR-153-5p promotes sensibility of colorectal cancer cells to oxaliplatin via targeting Bcl-2-mediated autophagy pathway. Oxaliplatin 62-73 BCL2 apoptosis regulator Homo sapiens 88-93 32380907-7 2020 Dual-luciferase reporter assays validated that Bcl-2 was a direct target of miR-153-5p. mir-153-5p 76-86 BCL2 apoptosis regulator Homo sapiens 47-52 32380907-8 2020 In conclusion, our data suggested that miR-153-5p was a mediator of cisplatin resistance in colorectal cancer by affecting Bcl-2-mediated autophagy, indicating a new therapeutic target for CRC treatment. mir-153-5p 39-49 BCL2 apoptosis regulator Homo sapiens 123-128 32380907-8 2020 In conclusion, our data suggested that miR-153-5p was a mediator of cisplatin resistance in colorectal cancer by affecting Bcl-2-mediated autophagy, indicating a new therapeutic target for CRC treatment. Cisplatin 68-77 BCL2 apoptosis regulator Homo sapiens 123-128 32360763-0 2020 Skin-derived precursor Schwann cells protect SH-SY5Y cells against 6-OHDA-induced neurotoxicity by PI3K/AKT/Bcl-2 pathway. Oxidopamine 67-73 BCL2 apoptosis regulator Homo sapiens 108-113 32360763-6 2020 Our results showed that the treatment with SKP-SCs prevented SH-SY5Y cells from 6-OHDA-induced apoptosis, accompanied by modulation of apoptosis-related proteins (Bcl-2 and Bax) and the decreased expression of active caspase-3. skp-scs 43-50 BCL2 apoptosis regulator Homo sapiens 163-168 32757174-11 2021 While KCNQ1OT1 overexpression removed the effect of curcumin on HCT8/DDP cells via miR-497/ Bcl-2 axis. Curcumin 52-60 BCL2 apoptosis regulator Homo sapiens 92-97 32757174-13 2021 In conclusion, KCNQ1OT1 aggravated cisplatin resistance in CRC cells via the miR-497/Bcl-2 axis. Cisplatin 35-44 BCL2 apoptosis regulator Homo sapiens 85-90 32748663-4 2021 RESULTS: Silibinin significantly suppressed HCT-116 cells proliferation and migration and induced the apoptosis via increasing the Bax/Bcl-2 ratio. Silybin 9-18 BCL2 apoptosis regulator Homo sapiens 135-140 32748821-7 2020 Finally, in vitro cell viability experiments have indicated effective interactions between Cu (II) dendrimers and pro-apoptotic siRNAs: Mcl-1 and Bcl-2 in breast cancer cells. cu (ii) 91-98 BCL2 apoptosis regulator Homo sapiens 146-151 32460188-13 2020 Accordingly, the increased expression of cleaved caspase-3 and the decreased ratio of B-cell lymphoma-2 (Bcl-2) to Bcl-2 associated X Protein (Bax) were significantly attenuated by TMP. tetramethylpyrazine 181-184 BCL2 apoptosis regulator Homo sapiens 105-110 32505823-6 2020 (c) Matrine increased caspase3 expression levels and reduced Bcl-2 expression levels in both TCP-1 and BCPAP cells. matrine 4-11 BCL2 apoptosis regulator Homo sapiens 61-66 32505823-8 2020 (e) After miR-182-5p overexpression, matrine-induced apoptosis and caspase3 activation were inhibited, and the matrine-induced decrease in Bcl-2 expression was abolished. matrine 111-118 BCL2 apoptosis regulator Homo sapiens 139-144 32505823-10 2020 In conclusion, these results demonstrate that matrine exerts antitumor effects possibly by inducing the apoptosis of TCP-1 and BCPAP cells, decreasing the level of Bcl-2, activating caspase3 and suppressing PTC tumor growth by downregulating the expression of miR-182-5p. matrine 46-53 BCL2 apoptosis regulator Homo sapiens 164-169 32599367-9 2020 FN2 in combination with GEM also decreased the level of Bcl-2 and increased the level of Bax. gemcitabine 24-27 BCL2 apoptosis regulator Homo sapiens 56-61 32360763-7 2020 Furthermore, we confirmed that SKP-SCs might exert protective effects and increase the mitochondrial membrane potential (MMP) through PI3K/AKT/Bcl-2 pathway. skp-scs 31-38 BCL2 apoptosis regulator Homo sapiens 143-148 32360763-8 2020 Taken together, our results demonstrated that SKP-SCs protect against 6-OHDA-induced cytotoxicity through PI3K/AKT/Bcl-2 pathway in PD model in vitro, which provides a new theoretical basis for the treatment of PD. skp-scs 46-53 BCL2 apoptosis regulator Homo sapiens 115-120 32360763-8 2020 Taken together, our results demonstrated that SKP-SCs protect against 6-OHDA-induced cytotoxicity through PI3K/AKT/Bcl-2 pathway in PD model in vitro, which provides a new theoretical basis for the treatment of PD. Oxidopamine 70-76 BCL2 apoptosis regulator Homo sapiens 115-120 32484926-7 2020 Signaling pathways required for crizotinib-induced apoptosis of autophagic cells were explored with flow cytometric analysis, Western blot analysis, short-hairpin RNA knockdown of autophagic proteins, and small-molecule inhibitors of STAT3 and BCL-2. Crizotinib 32-42 BCL2 apoptosis regulator Homo sapiens 244-249 32484926-10 2020 Crizotinib treatment of autophagic cancer cells further enhanced autophagy and induced autophagy-mediated apoptosis by decreasing phosphorylated STAT3 and BCL-2 signaling. Crizotinib 0-10 BCL2 apoptosis regulator Homo sapiens 155-160 32592909-2 2020 Targeted drugs already changed the clinical practice in treatment of leukemias, such as imatinib (BCR/ABL inhibitor) in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), ibrutinib (Bruton"s tyrosine kinase inhibitor) in chronic lymphocytic leukemia (CLL), venetoclax (BCL2 inhibitor) in CLL and acute myeloid leukemia (AML) or midostaurin (FLT3 inhibitor) in AML. Imatinib Mesylate 88-96 BCL2 apoptosis regulator Homo sapiens 289-293 32015503-3 2020 Degradation of the antiapoptotic BCL2 family member MCL-1 is considered to set the time until onset of apoptosis upon MTA treatment. mta 118-121 BCL2 apoptosis regulator Homo sapiens 33-37 32592909-2 2020 Targeted drugs already changed the clinical practice in treatment of leukemias, such as imatinib (BCR/ABL inhibitor) in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), ibrutinib (Bruton"s tyrosine kinase inhibitor) in chronic lymphocytic leukemia (CLL), venetoclax (BCL2 inhibitor) in CLL and acute myeloid leukemia (AML) or midostaurin (FLT3 inhibitor) in AML. ibrutinib 191-200 BCL2 apoptosis regulator Homo sapiens 289-293 32422522-1 2020 Several steroids (abiraterone, prednisone, testosterone, cholesterol) and the BCL-2 inhibitor bexarotene were used as starting materials to synthesize iperazinyl-spacered rhodamine B conjugates. Bexarotene 94-104 BCL2 apoptosis regulator Homo sapiens 78-83 32673127-8 2020 EXPERT OPINION: The current approach is to offer a clinical trial or the BCL2 inhibitor venetoclax to patients with ibrutinib resistant CLL. ibrutinib 116-125 BCL2 apoptosis regulator Homo sapiens 73-77 32742352-9 2020 Finally, miR-181-5p was demonstrated to inhibit the expression of KLF6, Bcl-2, Wnt1 and beta-catenin, while increasing the expression levels of Bax and caspase-3. mir-181-5p 9-19 BCL2 apoptosis regulator Homo sapiens 72-77 32765662-9 2020 Bcl-2 levels were also decreased after prazosin treatment (P<0.05). Prazosin 39-47 BCL2 apoptosis regulator Homo sapiens 0-5 32788653-12 2020 We found that the control of BIM (the pro-apoptotic BCL-2 family protein) by the AKT/FOXO3a axis only operated in BMP4-differentiated EGFRhigh cells upon TMZ treatment. Temozolomide 154-157 BCL2 apoptosis regulator Homo sapiens 52-57 32511893-7 2020 We also show that TXNIP overexpression combined with ABT263, a potent inhibitor of Bcl-2 and Bcl-xL, is highly effective at inducing cell death in MLL-rearranged (MLL-r) AML cells. navitoclax 53-59 BCL2 apoptosis regulator Homo sapiens 83-88 32237184-8 2020 Also, induction of autophagy by tunicamycin resulted in apoptosis in diabetic PBMCs as observed by caspase 3 cleavage and reduced expression of Bcl2. Tunicamycin 32-43 BCL2 apoptosis regulator Homo sapiens 144-148 32245900-3 2020 We therefore evaluated combination therapy with ABT-199 (venetoclax), a potent and selective BCL2 inhibitor. venetoclax 48-55 BCL2 apoptosis regulator Homo sapiens 93-97 32245900-4 2020 EXPERIMENTAL DESIGN: BCL2 family member expression was assessed following treatment with endocrine therapy and the CDK4/6 inhibitor palbociclib. palbociclib 132-143 BCL2 apoptosis regulator Homo sapiens 21-25 32167238-8 2020 The results also revealed VPA decreased the 6-OHDA-induced Bax/Bcl2 ratio, as measured at protein level. Valproic Acid 26-29 BCL2 apoptosis regulator Homo sapiens 63-67 32167238-8 2020 The results also revealed VPA decreased the 6-OHDA-induced Bax/Bcl2 ratio, as measured at protein level. Oxidopamine 44-50 BCL2 apoptosis regulator Homo sapiens 63-67 32167238-9 2020 These novel findings indicate that VPA may be capable of protecting the SH-SY5Y dopaminergic neuronal cells from 6-OHDA-induced toxicity via the deceasing of apoptotic caspases (cleaved caspase-3, caspase-7, and caspase-9) and reducing of the Bax/Bcl2 ratio. Valproic Acid 35-38 BCL2 apoptosis regulator Homo sapiens 247-251 32428794-6 2020 Furthermore, we demonstrated that Ixabepilone could bind with Bcl-2 and decrease its protein expression in breast cancer cells. ixabepilone 34-45 BCL2 apoptosis regulator Homo sapiens 62-67 32428794-7 2020 The down-regulation of Bcl-2 by Ixabepilone is resulted from promoting its degradation by affecting p-Bcl-2. ixabepilone 32-43 BCL2 apoptosis regulator Homo sapiens 23-28 32428794-7 2020 The down-regulation of Bcl-2 by Ixabepilone is resulted from promoting its degradation by affecting p-Bcl-2. ixabepilone 32-43 BCL2 apoptosis regulator Homo sapiens 102-107 32422522-1 2020 Several steroids (abiraterone, prednisone, testosterone, cholesterol) and the BCL-2 inhibitor bexarotene were used as starting materials to synthesize iperazinyl-spacered rhodamine B conjugates. rhodamine B 171-182 BCL2 apoptosis regulator Homo sapiens 78-83 32428794-8 2020 We further found that Ixabepilone could induce autophagy by releasing Beclin1 from Beclin1/Bcl-2 complex. ixabepilone 22-33 BCL2 apoptosis regulator Homo sapiens 91-96 32428794-10 2020 In addition, Ixabepilone also decreases Bcl-2 protein expression and induces cytoprotective autophagy in human hepatic carcinoma and glioma cells. ixabepilone 13-24 BCL2 apoptosis regulator Homo sapiens 40-45 32428794-5 2020 Prediction results revealed that Ixabepilone, an epothilone B analog for treating breast cancer patients, may target Bcl-2, an oncogene that contributes to tumor progression and therapy resistance by inhibiting apoptosis. ixabepilone 33-44 BCL2 apoptosis regulator Homo sapiens 117-122 32428794-5 2020 Prediction results revealed that Ixabepilone, an epothilone B analog for treating breast cancer patients, may target Bcl-2, an oncogene that contributes to tumor progression and therapy resistance by inhibiting apoptosis. epothilone B 49-61 BCL2 apoptosis regulator Homo sapiens 117-122 33083332-0 2020 The Effects of Resveratrol Treatment on Bcl-2 and Bax Gene Expression in Endometriotic Compared with Non-Endometriotic Stromal Cells. Resveratrol 15-26 BCL2 apoptosis regulator Homo sapiens 40-45 31601689-1 2020 The BCL-2 specific inhibitor, venetoclax/ABT-199 has exhibited remarkable clinical activity in nearly all cases of chronic lymphocytic leukemia. 2-(4'-diethylaminophenyl)benzothiazole 41-44 BCL2 apoptosis regulator Homo sapiens 4-9 31601689-6 2020 Treatment with ABT-199 displaced BAX and BIM from BCL-2, leading subsequently to BAK activation and apoptosis. 2-(4'-diethylaminophenyl)benzothiazole 15-18 BCL2 apoptosis regulator Homo sapiens 50-55 31727766-0 2020 CD34+ acute myeloid leukemia cells with low levels of reactive oxygen species show increased expression of stemness-genes and can be targeted by the BCL2 inhibitor Venetoclax. Oxygen 63-69 BCL2 apoptosis regulator Homo sapiens 149-153 32626938-6 2020 ISO also increased the expression levels of Bax, cleaved-caspase-3 (cle-cas-3) and poly(ADP-ribose) polymerase (PARP; cle-PARP), and decreased the expression levels of Bcl-2 in A549 cells. homoorientin 0-3 BCL2 apoptosis regulator Homo sapiens 168-173 32626948-12 2020 The results demonstrated the potential of brusatol delivered by plCSA-modified NPs as a chemotherapeutic agent for the targeted therapy of tumors by regulating the BCL2, BAX, cleaved caspase-3, MMP-2 and MMP-9 pathways, and indicated that it may be an effective and safe strategy for the treatment of various tumors. brusatol 42-50 BCL2 apoptosis regulator Homo sapiens 164-168 32623575-9 2020 Immunoblotting analysis demonstrated that GLA suppressed protein expressions of PCNA, Ki-67, MCM2 and bcl-2, while GLA induced bax and cleaved caspase 3 expressions. gamma-Linolenic Acid 42-45 BCL2 apoptosis regulator Homo sapiens 102-107 32626954-9 2020 Furthermore, paeonol dose-dependently induced cell apoptosis, accompanied by an increase in the Bax/Bcl-2 ratio, release of cytochrome c and further activation of caspases. paeonol 13-20 BCL2 apoptosis regulator Homo sapiens 100-105 31476976-4 2020 Also, the morphological changes and expression of Bax/Bcl-2 mRNA in human lymphocyte cell exposed to NiO NPs were assayed by DAPI staining and quantitative real-time PCR (qPCR), respectively. nio 101-104 BCL2 apoptosis regulator Homo sapiens 54-59 33083332-1 2020 Background: We aimed to examine resveratrol effects on gene expression of Bcl-2, Bax and Bcl-2/Bax ratio in endometrial stromal cells derived from women with and without endometriosis. Resveratrol 32-43 BCL2 apoptosis regulator Homo sapiens 74-79 31476976-10 2020 Moreover, morphological and genotoxicity assays revealed that the DNA fragmentation and expression ratio of Bax/Bcl-2 mRNA increased in lymphocyte cells treated with NiO NPs for 24 hr. nio 166-169 BCL2 apoptosis regulator Homo sapiens 112-117 32227673-3 2020 Treatment with tomentosin (IC50 = 20 microM) significantly inhibited cell proliferation and oxidative stress-induced anti-cell proliferative (proliferating cell nuclear antigen and cyclin-D1) also regulated expression, drastically diminished tumor necrosis factor-alpha, nuclear factor-kappaB, interleukin-6, and interleukin-1beta expression levels, significantly upregulated Bcl-2 and Bax expression. tomentosin 15-25 BCL2 apoptosis regulator Homo sapiens 377-382 33083332-1 2020 Background: We aimed to examine resveratrol effects on gene expression of Bcl-2, Bax and Bcl-2/Bax ratio in endometrial stromal cells derived from women with and without endometriosis. Resveratrol 32-43 BCL2 apoptosis regulator Homo sapiens 89-94 33083332-4 2020 Results: Resveratrol treatment increased Bcl-2 expression in CESCs at 24 and 48 h and in EuESCs at 48 h (P<0.05), but had no significant effects on the expression of this gene in EESCs. Resveratrol 9-20 BCL2 apoptosis regulator Homo sapiens 41-46 33083332-6 2020 Regarding the Bcl-2/Bax gene expression ratio, resveratrol treatment increased Bcl-2/Bax gene expression ratio in CESCs and EuESCs at 48 h (P<0.01). Resveratrol 47-58 BCL2 apoptosis regulator Homo sapiens 14-19 33083332-6 2020 Regarding the Bcl-2/Bax gene expression ratio, resveratrol treatment increased Bcl-2/Bax gene expression ratio in CESCs and EuESCs at 48 h (P<0.01). Resveratrol 47-58 BCL2 apoptosis regulator Homo sapiens 79-84 32422307-11 2020 Also, TQ/DOX combination improved apoptosis by increasing caspase-3 expression and decreasing of BCL-2 expression. thymoquinone 6-8 BCL2 apoptosis regulator Homo sapiens 97-102 32802790-7 2020 Conclusion: Our results suggest that vitamin C may modulate Bax and Bcl-2 proteins expression, in maintaining peripheral blood lymphocytes in patients undergoing cardiology in radiation-induced apoptosis. Ascorbic Acid 37-46 BCL2 apoptosis regulator Homo sapiens 68-73 32567157-6 2020 Furthermore, ATX suppressed OGD-caused mitochondrial membrane potential and decomposition of caspase-3 to cleaved caspase-3, and heightened the B-cell lymphoma 2 (Bcl-2)/Bax ratio. astaxanthine 13-16 BCL2 apoptosis regulator Homo sapiens 163-168 32422307-11 2020 Also, TQ/DOX combination improved apoptosis by increasing caspase-3 expression and decreasing of BCL-2 expression. Doxorubicin 9-12 BCL2 apoptosis regulator Homo sapiens 97-102 32325105-5 2020 In addition, inhibition of miR-142-3p dramatically restricted cell proliferation and enhanced apoptosis in HaCaT cells exposed to M5, as exemplified by a decrease in the antiapoptotic Bcl-2 protein, concomitant with an increase in the proapoptotic proteins Bax. mir-142-3p 27-37 BCL2 apoptosis regulator Homo sapiens 184-189 32404407-4 2020 Resistance to apoptosis inducted by the BCL-2 inhibitor ABT-199 (venetoclax) in AML is mediated by pre-existing and ABT-199-induced overexpression of MCL-1 and BCL-XL. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 56-59 BCL2 apoptosis regulator Homo sapiens 40-45 32700127-9 2020 The induction of apoptosis by CB EtOAc in MCF-7 cells was also associated with an increase in the Bax/Bcl-2 ratio and higher expression of caspases. cb etoac 30-38 BCL2 apoptosis regulator Homo sapiens 102-107 32404407-4 2020 Resistance to apoptosis inducted by the BCL-2 inhibitor ABT-199 (venetoclax) in AML is mediated by pre-existing and ABT-199-induced overexpression of MCL-1 and BCL-XL. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 116-119 BCL2 apoptosis regulator Homo sapiens 40-45 32627020-12 2020 In addition, TBMS1 triggered apoptosis via the PI3K/Akt-mediated Bcl-2 signaling pathway. tubeimoside I 13-18 BCL2 apoptosis regulator Homo sapiens 65-70 32686017-8 2020 Our data indicated that the treatment of cells with Parthenolide led to up-regulation of Bax and downregulation of Bcl2 at mRNA level. parthenolide 52-64 BCL2 apoptosis regulator Homo sapiens 115-119 32975155-3 2020 Results: Combination treatment with 5-FU and radiation had a stronger effect on decreasing Bcl-2 expression and increasing expression of Bax, cleaved caspase-9, cleaved caspase-3, cleaved PARP compared with each treatment alone. Fluorouracil 36-40 BCL2 apoptosis regulator Homo sapiens 91-96 32401088-3 2020 We revealed that CuS-NiS2 induced reactive oxygen species (ROS) generation, leading to apoptosis through Bcl-2/Bax pathway of human gastric cancer cells under 808 nm near-infrared (NIR) irradiation. cus-nis2 17-25 BCL2 apoptosis regulator Homo sapiens 105-110 32401088-3 2020 We revealed that CuS-NiS2 induced reactive oxygen species (ROS) generation, leading to apoptosis through Bcl-2/Bax pathway of human gastric cancer cells under 808 nm near-infrared (NIR) irradiation. Reactive Oxygen Species 59-62 BCL2 apoptosis regulator Homo sapiens 105-110 32714040-11 2020 Moreover, western blot and ELISA based analysis revealed that D-pinitol elevated the Bax, Caspase-3, Caspase-9 and attenuated the Bcl-2 expression in leukemic cancer cell. pinitol 62-71 BCL2 apoptosis regulator Homo sapiens 130-135 32752091-0 2020 Caffeic Acid Phenethyl Ester (CAPE) Induced Apoptosis in Serous Ovarian Cancer OV7 Cells by Deregulation of BCL2/BAX Genes. caffeic acid phenethyl ester 0-28 BCL2 apoptosis regulator Homo sapiens 108-112 32312433-0 2020 Characterization of interaction between Bcl-2 oncogene promoter I-Motif DNA and flavonoids using electrospray ionization mass spectrometry and pressure-assisted capillary electrophoresis frontal analysis. Flavonoids 80-90 BCL2 apoptosis regulator Homo sapiens 40-45 32312433-2 2020 The Bcl-2 C-rich promoter element has been shown to form the i-motif (IM) via cytosine-cytosine (C-C+) base pair building blocks, which can be targeted through the binding of ligands associated with Bcl-2 expression modulation. cytosine-cytosine 78-95 BCL2 apoptosis regulator Homo sapiens 4-9 32312433-2 2020 The Bcl-2 C-rich promoter element has been shown to form the i-motif (IM) via cytosine-cytosine (C-C+) base pair building blocks, which can be targeted through the binding of ligands associated with Bcl-2 expression modulation. cytosine-cytosine 78-95 BCL2 apoptosis regulator Homo sapiens 199-204 32312433-11 2020 Taken all these observations into consideration, the specific binding of selected flavonoids to the Bcl-2 IM may prove to be a potential ligand for modulating Bcl-2 gene expression. Flavonoids 82-92 BCL2 apoptosis regulator Homo sapiens 100-105 32729384-6 2020 Western blot analysis demonstrated that the levels of CFTR and Bcl-2 decreased, whereas Bax level increased, and ELISA detection showed a decreased ATP level in BPA-exposed cells. bisphenol A 161-164 BCL2 apoptosis regulator Homo sapiens 63-68 32798398-7 2020 Compared with single-drug treatment group, DAC combined with BTZ significantly increased the inhibitory rate and apoptotic rate of Jeko-1 and Grante519 cells; PCDH8, Caspase 3 and BAX expression levels significantly increased, and the expression levels of NF-kappaB, BCL-2 and CCND1 significantly decreased in Jeko-1 and Grante519 cells. btz 61-64 BCL2 apoptosis regulator Homo sapiens 267-272 32801901-0 2020 miR-31-5p Regulates 14-3-3 e to Inhibit Prostate Cancer 22RV1 Cell Survival and Proliferation via PI3K/AKT/Bcl-2 Signaling Pathway. mir-31-5p 0-9 BCL2 apoptosis regulator Homo sapiens 107-112 32798398-6 2020 High dose BTZ could significantly inhibit the proliferation and induce apoptosis of Jeko-1 and Grante519 cells which shows a dose-and time-dependent manner; single drug BTZ could increase the expression level of Caspase 3 and BAX, and decrease the expression level of NF-kappaB, BCL-2 and CCDN1 in Jeko-1 and Grante519 cells, but there was significant difference in PCDH8 expression level. btz 10-13 BCL2 apoptosis regulator Homo sapiens 279-284 32798398-6 2020 High dose BTZ could significantly inhibit the proliferation and induce apoptosis of Jeko-1 and Grante519 cells which shows a dose-and time-dependent manner; single drug BTZ could increase the expression level of Caspase 3 and BAX, and decrease the expression level of NF-kappaB, BCL-2 and CCDN1 in Jeko-1 and Grante519 cells, but there was significant difference in PCDH8 expression level. btz 169-172 BCL2 apoptosis regulator Homo sapiens 279-284 32798398-7 2020 Compared with single-drug treatment group, DAC combined with BTZ significantly increased the inhibitory rate and apoptotic rate of Jeko-1 and Grante519 cells; PCDH8, Caspase 3 and BAX expression levels significantly increased, and the expression levels of NF-kappaB, BCL-2 and CCND1 significantly decreased in Jeko-1 and Grante519 cells. Decitabine 43-46 BCL2 apoptosis regulator Homo sapiens 267-272 32994681-3 2020 We report the molecular binding features of capsaicin with apoptotic proteins such as Bcl-xl, Bcl-2 and Mcl-1 for further consideration. Capsaicin 44-53 BCL2 apoptosis regulator Homo sapiens 94-99 32752091-0 2020 Caffeic Acid Phenethyl Ester (CAPE) Induced Apoptosis in Serous Ovarian Cancer OV7 Cells by Deregulation of BCL2/BAX Genes. caffeic acid phenethyl ester 30-34 BCL2 apoptosis regulator Homo sapiens 108-112 32752091-6 2020 The cytotoxic and proapoptotic activity of CAPE was investigated by using the XTT-NR-SRB assay, qRT-PCR analysis of BAX/BCL2 expression, and by cytometric evaluation. caffeic acid phenethyl ester 43-47 BCL2 apoptosis regulator Homo sapiens 120-124 32752091-11 2020 In OV7 cells CAPE induced apoptosis via dysregulation of BAX/BCL2 balance, while activated proapoptotic BAX gene expression level was 10 times higher than BCL2. caffeic acid phenethyl ester 13-17 BCL2 apoptosis regulator Homo sapiens 61-65 32752099-6 2020 Coptisine also significantly upregulated expression of proapoptotic Bax protein, downregulated expression of anti-apoptotic Bcl-2 protein, and activated caspase-3, -8, and -9. coptisine 0-9 BCL2 apoptosis regulator Homo sapiens 124-129 32774685-4 2020 Our data show that 200 mug/mL of ethanol extract of Tribulus terrestris (EE-TT) significantly increased the cell viability and prevented the apoptosis of H2O2-treated ARPE-19 cells through the regulation of Bcl2, Bax, cleaved caspase-3, and caspase-9. Ethanol 33-40 BCL2 apoptosis regulator Homo sapiens 207-211 32732360-10 2021 In conclusion, NOTCH1 M are strongly associated with lower bax/bcl-2 ratio, consistent with a defective apoptosis, lower redistribution lymphocytosis and lower nodal shrinkage under ibrutinib treatment, this last responsible for partial responses, subsequent relapses, shorter PFS and OS. ibrutinib 182-191 BCL2 apoptosis regulator Homo sapiens 63-68 32774685-4 2020 Our data show that 200 mug/mL of ethanol extract of Tribulus terrestris (EE-TT) significantly increased the cell viability and prevented the apoptosis of H2O2-treated ARPE-19 cells through the regulation of Bcl2, Bax, cleaved caspase-3, and caspase-9. Hydrogen Peroxide 154-158 BCL2 apoptosis regulator Homo sapiens 207-211 32719967-5 2021 Mechanically, VPA boosted cellular apoptosis and cell-cycle arrest by increased level of cleaved caspase-3/caspase-3, cleaved PARP/PARP and Bax/Bcl-2. Valproic Acid 14-17 BCL2 apoptosis regulator Homo sapiens 144-149 32699295-0 2020 Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway. triptolide 10-20 BCL2 apoptosis regulator Homo sapiens 111-116 32722075-8 2020 In addition, LY and TAM combination induced the apoptotic genes Caspase-3, Caspase-7, and p53, as well as p21 as cell cycle promotor, and significantly downregulated the anti-apoptotic genes Bcl-2 and survivin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-15 BCL2 apoptosis regulator Homo sapiens 191-196 32722075-8 2020 In addition, LY and TAM combination induced the apoptotic genes Caspase-3, Caspase-7, and p53, as well as p21 as cell cycle promotor, and significantly downregulated the anti-apoptotic genes Bcl-2 and survivin. Tamoxifen 20-23 BCL2 apoptosis regulator Homo sapiens 191-196 32722075-11 2020 The results suggested that the synergistic cytotoxic effect of LY and TAM is achieved by the induction of apoptosis and cell cycle arrest through cyclin D1, pAKT, caspases, and Bcl-2 signaling pathways. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 63-65 BCL2 apoptosis regulator Homo sapiens 177-182 32722075-11 2020 The results suggested that the synergistic cytotoxic effect of LY and TAM is achieved by the induction of apoptosis and cell cycle arrest through cyclin D1, pAKT, caspases, and Bcl-2 signaling pathways. Tamoxifen 70-73 BCL2 apoptosis regulator Homo sapiens 177-182 32727149-7 2020 Moreover, naftopidil was demonstrated to modulate the expression of Bcl-2 family pro-apoptotic members which could be used to sensitise cancer cells to targeting therapies and to overcome resistance of cancer cells to apoptosis. naftopidil 10-20 BCL2 apoptosis regulator Homo sapiens 68-73 32703189-14 2020 Exposure to PT resulted in the downregulation of anti-apoptotic proteins (Bcl2, BclxL, XIAP) and alteration in Cyclins expression. Platinum 12-14 BCL2 apoptosis regulator Homo sapiens 74-78 32699295-0 2020 Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 26-29 BCL2 apoptosis regulator Homo sapiens 111-116 32699295-6 2020 The potentiated effect of ABT-199 and TPL against AML was associated with activation of the mitochondrum-related intrinsic apoptotic pathway through a mechanism reciprocally modulating Bcl-2 family proteins. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 26-29 BCL2 apoptosis regulator Homo sapiens 185-190 32699295-8 2020 Conversely, ABT-199 abrogated Bcl-2-mediated cytoprotection against TPL. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 12-15 BCL2 apoptosis regulator Homo sapiens 30-35 32774424-3 2020 To achieve our goal, the cytotoxicity of AVME against tumoral and non-tumoral cell lines was evaluated by resazurin reduction test; flow cytometry allowed us to evaluate the cell cycle and mechanisms of cell death; the mitochondrial transmembrane potential, reactive oxygen species (ROS) levels, and caspase activities as well as apoptosis-regulatory proteins (Bcl-2 and Bcl-XL) were measured in MDA-MB-231 cells. avme 41-45 BCL2 apoptosis regulator Homo sapiens 361-366 32708030-10 2020 Calebin A also suppressed the expression of NF-kappaB-promoted anti-apoptotic (Bcl-2, Bcl-xL, survivin), proliferation (Cyclin D1), invasion (MMP-9), metastasis (CXCR4), and down-regulated apoptosis (Caspase-3) gene biomarkers, leading to apoptosis in HCT116 cells. calebin-A 0-9 BCL2 apoptosis regulator Homo sapiens 79-84 32699295-9 2020 Together, these findings suggest that the regimen combining TPL and ABT-199 might be active against AML by inducing robust apoptosis through reciprocal regulation of anti- and proapoptotic Bcl-2 family proteins, therefore providing a strong rationale for the clinical investigation of this combination regimen for the treatment of AML. triptolide 60-63 BCL2 apoptosis regulator Homo sapiens 189-194 32774424-6 2020 AVME also induced apoptosis in MDA-MB-231 cells, which was accompanied by the activation of caspase-3 and caspase-9 and downregulation of Bcl-2 and Bcl-XL proteins. avme 0-4 BCL2 apoptosis regulator Homo sapiens 138-143 32699295-9 2020 Together, these findings suggest that the regimen combining TPL and ABT-199 might be active against AML by inducing robust apoptosis through reciprocal regulation of anti- and proapoptotic Bcl-2 family proteins, therefore providing a strong rationale for the clinical investigation of this combination regimen for the treatment of AML. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 68-71 BCL2 apoptosis regulator Homo sapiens 189-194 32792943-8 2020 The presence of metformin also sensitized NSCLC cells to celecoxib-induced apoptosis by activating caspase-9, -8, -3, and -7, upregulating the pro-apoptotic proteins Bad and Bax, and downregulating the antiapoptotic proteins Bcl-xl and Bcl-2. Metformin 16-25 BCL2 apoptosis regulator Homo sapiens 236-241 32792943-8 2020 The presence of metformin also sensitized NSCLC cells to celecoxib-induced apoptosis by activating caspase-9, -8, -3, and -7, upregulating the pro-apoptotic proteins Bad and Bax, and downregulating the antiapoptotic proteins Bcl-xl and Bcl-2. Celecoxib 57-66 BCL2 apoptosis regulator Homo sapiens 236-241 32913452-4 2020 Meanwhile, GA induced dose-dependent apoptosis of ESCC cells, repressed the expression of Bcl2 and up-regulated the levels of Bax protein, cleaved-PARP1 and cleaved-caspase 3/9. gambogic acid 11-13 BCL2 apoptosis regulator Homo sapiens 90-94 32708132-2 2020 Yet, such cancer cells often are highly dependent on Bcl-2 for their survival, a feature that is exploited by so-called BH3-mimetic drugs. BH 3 120-123 BCL2 apoptosis regulator Homo sapiens 53-58 32708132-8 2020 We report that Riva VR cells did not become more sensitive to BIRD-2, a peptide targeting the Bcl-2 BH4 domain, and established cross-resistance towards BDA-366, a putative BH4-domain antagonist of Bcl-2. sapropterin 173-176 BCL2 apoptosis regulator Homo sapiens 198-203 32673286-6 2020 As a result, osthole inhibited the phosphorylation of AKT and Bad to decrease the amount of free Bcl-2 in CD133+ HepG2 and Huh7 cells. osthol 13-20 BCL2 apoptosis regulator Homo sapiens 97-102 32579629-2 2020 We found that both of the Pt(ii) complexes exhibited much better selectivity for human telomeric G-quadruplex sequence than promoter G-quadruplexes (c-kit, c-myc, and bcl2) or duplex DNA. pt(ii) 26-32 BCL2 apoptosis regulator Homo sapiens 167-171 32344260-7 2020 In addition, endosulfan obviously inhibited Bcl-2 expression, activated the expressions of cytochrome c/Caspase-9/Caspase-3 signaling pathway, and induced the apoptosis of AC16 cells (p < 0.05). Endosulfan 13-23 BCL2 apoptosis regulator Homo sapiens 44-49 32765594-5 2020 We show here that topotecan treatment significantly down-regulated estrogen receptor alpha (ERalpha/ESR1) and antiapoptotic BCL2 genes in addition to many other p53-regulated genes. Topotecan 18-27 BCL2 apoptosis regulator Homo sapiens 124-128 32677950-12 2020 Overexpression of miR-136-3p significantly inhibited cell growth of LN-229 and U251 by decreasing expression of Cyclin A1 and PCNA (proliferating cell nuclear antigen), and it suppressed glioma cell migration by downregulating N-cadherin and elevating E-cadherin levels, and it also promotes glioma cell apoptosis by promoting Bcl2-associated X (Bax) expression but suppressing Bcl-2 expression. mir-136-3p 18-28 BCL2 apoptosis regulator Homo sapiens 378-383 32320719-7 2020 In silico analysis and reporter gene assays indicated that miR-16-5p directly targets the mRNA encoding the anti-apoptotic factor, B cell lymphoma-2 (BCL-2), in the neuronal cell line. mir-16-5p 59-68 BCL2 apoptosis regulator Homo sapiens 150-155 32774710-6 2020 Da0324 treatment or knockdown of LINC01021 by antisense oligos significantly inhibited gastric cancer cell growth, and also up-regulated P53 expression and down-regulated Bcl-2 expression in vitro and in vivo. Da0324 0-6 BCL2 apoptosis regulator Homo sapiens 171-176 32320719-8 2020 Overexpression of miR-16-5p in SH-SY5Y cells downregulated BCL-2 expression and induced apoptosis. mir-16-5p 18-27 BCL2 apoptosis regulator Homo sapiens 59-64 32760701-0 2020 Involvement of Bcl-2 Activation and G1 Cell Cycle Arrest in Colon Cancer Cells Induced by Titanium Dioxide Nanoparticles Synthesized by Microwave-Assisted Hybrid Approach. titanium dioxide 90-106 BCL2 apoptosis regulator Homo sapiens 15-20 32353602-7 2020 Moreover, Zn could decrease the expression of pro-apoptotic genes (cleaved-caspase-3, caspase-9, and Bax) and increase the expression of anti-apoptotic genes (Bcl-2 and Bcl-xl) to alleviate the cell apoptosis induced by AFB1. Zinc 10-12 BCL2 apoptosis regulator Homo sapiens 159-164 32304943-6 2020 In addition, TDCPP induced cell apoptosis and arrested cell cycle in the G0/G1 phase at 16 and 160 mug/mL by enhancing Bax and Caspase-3 expression besides inhibiting cyclin D1, CDK2, CDK6 and Bcl-2 expression. tris(1,3-dichloro-2-propyl)phosphate 13-18 BCL2 apoptosis regulator Homo sapiens 193-198 32376267-10 2020 Through hemin administration, hepatocyte apoptosis was suppressed companied down-regulation of CHOP, caspase12 and up-regulation of BCL2. Hemin 8-13 BCL2 apoptosis regulator Homo sapiens 132-136 32674299-5 2020 The most important intermediates by which polyphenols exert their protective effect include Bcl-2, UCP2, SIRT-1, AMPK and JNK1. Polyphenols 42-53 BCL2 apoptosis regulator Homo sapiens 92-97 32643899-0 2020 Effect of carboplatin injection on Bcl-2 protein expression and apoptosis induction in Raji cells. Carboplatin 10-21 BCL2 apoptosis regulator Homo sapiens 35-40 32695909-5 2020 The in silico molecular docking studies performed with 3,4-disubstituted pyrazoles as ligand with targets including DNA, BCL-2 and F1-ATP Synthase revealed strong binding affinity with DNA (-7.5 kcal/mol), BCL-2 (-8.1 kcal/mol) and F1-ATP Synthase (-7.2 kcal/mol). 3,4-disubstituted pyrazoles 55-82 BCL2 apoptosis regulator Homo sapiens 121-126 32695909-5 2020 The in silico molecular docking studies performed with 3,4-disubstituted pyrazoles as ligand with targets including DNA, BCL-2 and F1-ATP Synthase revealed strong binding affinity with DNA (-7.5 kcal/mol), BCL-2 (-8.1 kcal/mol) and F1-ATP Synthase (-7.2 kcal/mol). 3,4-disubstituted pyrazoles 55-82 BCL2 apoptosis regulator Homo sapiens 206-211 32733649-5 2020 We demonstrate that triptolide treatment of A549 and H460 NSCLC cells decreases Caveolin-1 (CAV-1) mRNA/protein expression, resulting in activation of the Akt/Bcl-2-mediated mitochondrial apoptosis pathway. triptolide 20-30 BCL2 apoptosis regulator Homo sapiens 159-164 32648127-10 2021 Noni juice treatment inhibited the expression of Ki67, PCNA, and Bcl-2 protein in the tumor; while promoted the expression of caspase-3 protein. noni juice 0-10 BCL2 apoptosis regulator Homo sapiens 65-70 32643899-6 2020 Moreover, the expression of the Bcl-2 protein decreased as the duration of CBP treatment increased, showing a time-dependent manner. Carboplatin 75-78 BCL2 apoptosis regulator Homo sapiens 32-37 32643899-15 2020 CBP injection significantly reduced the expression of the Bcl-2 protein and induced apoptosis of Raji cells in a time-dependent manner. Carboplatin 0-3 BCL2 apoptosis regulator Homo sapiens 58-63 32753846-6 2020 Results: Baicalin treatment decreased the apoptosis rate and the expressions of pro-apoptotic proteins induced by IL-1beta, up-regulated anti-apoptotic Bcl-2 expression, and inhibited the degradation of ECM. baicalin 9-17 BCL2 apoptosis regulator Homo sapiens 152-157 32645016-11 2020 We show that the combination of fadraciclib with BCL2 inhibitors, including venetoclax, is synergistic in leukemic cell models, as predicted from simultaneous inhibition of MCL1 and BCL2 pro-survival pathways. CYC065 32-43 BCL2 apoptosis regulator Homo sapiens 182-186 32645016-12 2020 Fadraciclib preclinical pharmacology data support its therapeutic potential in CDK9- or CDK2-dependent cancers and as a rational combination with BCL2 inhibitors in hematological malignancies. CYC065 0-11 BCL2 apoptosis regulator Homo sapiens 146-150 33088538-1 2020 A case of an early-relapsed high-risk T-ALL with high BCL-2 expression on leukemic blasts was successfully treated with decitabine and venetoclax, achieving a CR. Decitabine 120-130 BCL2 apoptosis regulator Homo sapiens 54-59 33088538-1 2020 A case of an early-relapsed high-risk T-ALL with high BCL-2 expression on leukemic blasts was successfully treated with decitabine and venetoclax, achieving a CR. venetoclax 135-145 BCL2 apoptosis regulator Homo sapiens 54-59 33088538-2 2020 We suggest decitabine and venetoclax should be synergistic in BCL2-positive ALL. Decitabine 11-21 BCL2 apoptosis regulator Homo sapiens 62-66 33088538-2 2020 We suggest decitabine and venetoclax should be synergistic in BCL2-positive ALL. venetoclax 26-36 BCL2 apoptosis regulator Homo sapiens 62-66 32641029-7 2020 Matrine induced apoptosis with decreased Bcl-2 expression and the proteasome-dependent degradation of c-Myc protein in NK92 cells. matrine 0-7 BCL2 apoptosis regulator Homo sapiens 41-46 32724460-2 2020 We previously showed that resistance to regorafenib, a multi-kinase inhibitor for treating colorectal cancer (CRC) patients, can be caused by mutations in the tumor suppressor FBW7, which block degradation of the pro-survival Bcl-2 family protein Mcl-1. regorafenib 40-51 BCL2 apoptosis regulator Homo sapiens 226-231 32439176-7 2020 Salidroside could activate intrinsic and extrinsic apoptotic pathways, by increasing activities of caspase-3, caspase-8 and caspase-9, up-regulating levels of Bax, Cytochrome c and decreasing level of Bcl-2 in HepG2 cells. rhodioloside 0-11 BCL2 apoptosis regulator Homo sapiens 201-206 32410120-9 2020 DECA may promote glioma cell apoptosis by affecting the expression of NFKB2, HRAS, NF1, CBL, RAF1, and BCL-2 genes. decabromobiphenyl ether 0-4 BCL2 apoptosis regulator Homo sapiens 103-108 32427739-4 2020 Additionally, geraniin remarkably induced apoptosis of SW480 and HT-29 cells in a dose-dependent way by Hoechst 33342 staining, flow cytometric analysis, and TdT-mediated dUTP nick-end labeling assays and increased the expressions of Bax, caspase-3, and caspase-9, while decreased the level of Bcl-2. Geraniin 14-22 BCL2 apoptosis regulator Homo sapiens 294-299 32044796-8 2020 C61-LNP, as well as C61-LNP + CDDP treatments, caused pro-apoptotic proteomic changes including an increase in cleaved fragments of caspases-3 and -9 consistent with caspase activation as well as an improvement in the anti-apoptotic Bcl2 and Bax levels. AT 61 0-3 BCL2 apoptosis regulator Homo sapiens 233-237 32044796-8 2020 C61-LNP, as well as C61-LNP + CDDP treatments, caused pro-apoptotic proteomic changes including an increase in cleaved fragments of caspases-3 and -9 consistent with caspase activation as well as an improvement in the anti-apoptotic Bcl2 and Bax levels. Cisplatin 30-34 BCL2 apoptosis regulator Homo sapiens 233-237 31448672-6 2020 Knockdown of PAQR3 abrogates erlotinib-mediated reduction of BECN1 interaction with autophagy inhibitory proteins RUBCN/Rubicon and BCL2. Erlotinib Hydrochloride 29-38 BCL2 apoptosis regulator Homo sapiens 132-136 32092316-2 2020 As a member of the Bcl-2 family of cell death-regulating factors, Bnip3 mediates mPTP opening, mitochondrial potential, oxidative stress, calcium overload, mitochondrial respiratory collapse, and ATP shortage of mitochondria from multiple cells. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 81-85 BCL2 apoptosis regulator Homo sapiens 19-24 32420699-5 2020 Comparative gene expression profiling of the MCL-derived cell lines showed that inhibition of RSK2Ser227 by BI-D1870 caused downregulation of oncogenes, such as c-MYC and MYB; anti-apoptosis genes, such as BCL2 and BCL2L1; genes for B cell development, including IKZF1, IKZF3, and PAX5; and genes constituting the B cell receptor signaling pathway, such as CD19, CD79B, and BLNK. BI D1870 108-116 BCL2 apoptosis regulator Homo sapiens 206-210 32124583-11 2020 Our data revealed that silencing of CCAT1 promoted cisplatin-induced apoptosis via modulating the expression of pro- or anti-apoptotic proteins Bax, Bcl-2 and survivin. Cisplatin 51-60 BCL2 apoptosis regulator Homo sapiens 149-154 32290769-6 2020 On the other hand, miR-181a-5p inhibited apoptosis and elevated Bcl-2 expression while decreasing the expressions of Bax and Caspase 3 in treated cells, but the effects of miR-181a-5p could be rescued by SIRT1. mir-181a-5p 19-30 BCL2 apoptosis regulator Homo sapiens 64-69 32420699-7 2020 In addition, we found favorable combinatory growth inhibitory effects of BI-D1870 with inhibitors of BTK (ibrutinib), AKT (ipatasertib), and BCL2 (venetoclax) in cell characteristic-dependent manners. BI D1870 73-81 BCL2 apoptosis regulator Homo sapiens 141-145 32037595-4 2020 RhNRG-1 pretreatment effectively restored the expression of PGC-1alpha and these membrane proteins, upregulated the expression of the anti-apoptosis proteins Bcl-2 and Bcl-xL, preserved the mitochondrial membrane potential, and attenuated H/R-induced cell apoptosis. Neuregulins 0-5 BCL2 apoptosis regulator Homo sapiens 158-163 32092316-2 2020 As a member of the Bcl-2 family of cell death-regulating factors, Bnip3 mediates mPTP opening, mitochondrial potential, oxidative stress, calcium overload, mitochondrial respiratory collapse, and ATP shortage of mitochondria from multiple cells. Calcium 138-145 BCL2 apoptosis regulator Homo sapiens 19-24 32092316-2 2020 As a member of the Bcl-2 family of cell death-regulating factors, Bnip3 mediates mPTP opening, mitochondrial potential, oxidative stress, calcium overload, mitochondrial respiratory collapse, and ATP shortage of mitochondria from multiple cells. Adenosine Triphosphate 196-199 BCL2 apoptosis regulator Homo sapiens 19-24 32096428-0 2020 2-NDC from dithiocarbamates improves ATRA efficiency and ROS-induced apoptosis via downregulation of Bcl2 and Survivin in human acute promyelocytic NB4 cells. 2-ndc 0-5 BCL2 apoptosis regulator Homo sapiens 101-105 32096428-0 2020 2-NDC from dithiocarbamates improves ATRA efficiency and ROS-induced apoptosis via downregulation of Bcl2 and Survivin in human acute promyelocytic NB4 cells. dithiocarbamates 11-27 BCL2 apoptosis regulator Homo sapiens 101-105 32096428-11 2020 Bax/Bcl2 ratio was modulated and Survivin was downregulated in NB4 cells upon 2-NDC treatment. 2-ndc 78-83 BCL2 apoptosis regulator Homo sapiens 4-8 32342278-7 2020 Dual-luciferase reporter assays confirmed that Bcl-2 is a direct target of miR-153-3p. mir-153-3p 75-85 BCL2 apoptosis regulator Homo sapiens 47-52 32342278-8 2020 Bcl-2 restoration reversed the increased sensitivity to IM induced by miR-153-3p-mimic transfection in IM-resistant CML cells. mir-153-3p 70-80 BCL2 apoptosis regulator Homo sapiens 0-5 33083299-9 2020 Results: Tamoxifen alone and in combination with LG decreased BCL-2 expression 2.64+-0.75 and 6.38+-1.9 fold, respectively, after 48 h (P<0.05). Tamoxifen 9-18 BCL2 apoptosis regulator Homo sapiens 62-67 32377719-0 2020 Inhibiting the NF-kappaB pathway enhances the antitumor effect of cabazitaxel by downregulating Bcl-2 in pancreatic cancer. cabazitaxel 66-77 BCL2 apoptosis regulator Homo sapiens 96-101 32377726-0 2020 Doxorubicin selectively induces apoptosis through the inhibition of a novel isoform of Bcl-2 in acute myeloid leukaemia MOLM-13 cells with reduced Beclin 1 expression. Doxorubicin 0-11 BCL2 apoptosis regulator Homo sapiens 87-92 32377726-2 2020 In the present study, doxorubicin (Dox) was evaluated for its potential to induce selective apoptotic cell death in AML MOLM-13 cells and to modulate autophagy through Bcl-2 and Beclin 1 protein expression. Doxorubicin 22-33 BCL2 apoptosis regulator Homo sapiens 168-173 32377726-2 2020 In the present study, doxorubicin (Dox) was evaluated for its potential to induce selective apoptotic cell death in AML MOLM-13 cells and to modulate autophagy through Bcl-2 and Beclin 1 protein expression. Doxorubicin 35-38 BCL2 apoptosis regulator Homo sapiens 168-173 32377726-9 2020 Dox induced a highly significant inhibition of p15-20-Bcl-2 at concentrations of 0.5, 0.75 and 1 microM (P<0.01). Doxorubicin 0-3 BCL2 apoptosis regulator Homo sapiens 54-59 32377726-11 2020 It was thus postulated that Dox exhibited some selectivity by targeting the p15-20-Bcl-2 isoform in MOLM-13 cells and activating Beclin 1 to induce cell death. Doxorubicin 28-31 BCL2 apoptosis regulator Homo sapiens 83-88 33680016-10 2020 Moreover, Naringenin up-regulated the expression of BAX while decreased the expression of Bcl-2. naringenin 10-20 BCL2 apoptosis regulator Homo sapiens 90-95 31960449-7 2020 Further investigation showed that alpha-mangostin induced mitochondrial depolarization and mitochondrial apoptosis signaling, including upregulation of Bax, downregulation of Mcl-1 and Bcl-2, and activation of caspase-9/3. mangostin 34-49 BCL2 apoptosis regulator Homo sapiens 185-190 33680035-9 2020 Real-time PCR showed that expression level of Bax, p53 and Bax genes increases and Bcl2 gene decreases in AGS cell lines after treatment by hypericin. hypericin 140-149 BCL2 apoptosis regulator Homo sapiens 83-87 33099948-10 2020 The reduction of the proliferative rates was attributed to the induction of ROS triggered apoptosis which was associated with activation of Caspase-3, upregulation of Bax and suppression of Bcl-2. Reactive Oxygen Species 76-79 BCL2 apoptosis regulator Homo sapiens 190-195 32463592-7 2020 Cystic fibrosis transmembrane conductance regulator activates Akt/Bcl2 pathway, and suppression of PI3K/Akt pathway abolishes CFTR overexpression-induced up-regulation of Bcl2 (MK-2206 and LY294002) and cell viability (MK-2206). MK 2206 177-184 BCL2 apoptosis regulator Homo sapiens 171-175 32463592-7 2020 Cystic fibrosis transmembrane conductance regulator activates Akt/Bcl2 pathway, and suppression of PI3K/Akt pathway abolishes CFTR overexpression-induced up-regulation of Bcl2 (MK-2206 and LY294002) and cell viability (MK-2206). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 189-197 BCL2 apoptosis regulator Homo sapiens 171-175 32463592-7 2020 Cystic fibrosis transmembrane conductance regulator activates Akt/Bcl2 pathway, and suppression of PI3K/Akt pathway abolishes CFTR overexpression-induced up-regulation of Bcl2 (MK-2206 and LY294002) and cell viability (MK-2206). MK 2206 219-226 BCL2 apoptosis regulator Homo sapiens 171-175 33099919-13 2020 The expression of Bax was increased and that of Bcl-2 was decreased upon Shionone treatment. shionone 73-81 BCL2 apoptosis regulator Homo sapiens 48-53 32394497-5 2020 Neferine was shown to downregulate the expression of Bcl-2 and CDK4, and upregulate caspase 3, clePARP, p21, p27, and p53. neferine 0-8 BCL2 apoptosis regulator Homo sapiens 53-58 32434944-8 2020 Complementing these data, we found that p53 deficiency or Bcl-2 overexpression reduced fluvastatin-induced apoptosis. Fluvastatin 87-98 BCL2 apoptosis regulator Homo sapiens 58-63 32272506-9 2020 Furthermore, the knockdown of Bcl-2/adenovirus E18-19-kDa interacting protein 3 (BNIP3) expression attenuated the effects of BBR on mitophagy induction to some extent, suggesting that the BBR-induced mitophagy may be, at least in part, mediated in a BNIP3-dependent manner. Berberine 125-128 BCL2 apoptosis regulator Homo sapiens 30-79 32272506-9 2020 Furthermore, the knockdown of Bcl-2/adenovirus E18-19-kDa interacting protein 3 (BNIP3) expression attenuated the effects of BBR on mitophagy induction to some extent, suggesting that the BBR-induced mitophagy may be, at least in part, mediated in a BNIP3-dependent manner. Berberine 188-191 BCL2 apoptosis regulator Homo sapiens 30-79 32377708-13 2020 DHC inhibited the production of proliferation- and anti-apoptosis-associated proteins CDK1, CCND1, BCL2 as well as that of the metastasis-associated proteins MMP2 and MMP9. dehydrocorydalin 0-3 BCL2 apoptosis regulator Homo sapiens 99-103 32558229-5 2020 Moreover, the anticancer mechanism studies reveal that FUdR@affi-RA enhances the expression and activity of apoptosis-associated proteins in the Bcl-2/Bax-caspase 8,9-caspase 3 apoptotic pathway induced by FUdR. Floxuridine 55-59 BCL2 apoptosis regulator Homo sapiens 145-150 32377702-6 2020 Juglone potentiated PLX4032-induced cytotoxicity and mitochondrial apoptosis in both A375R and SK-MEL-5R cells, which was accompanied by a decline in mitochondrial membrane potential and a decrease in Bcl-2/Bax ratio. juglone 0-7 BCL2 apoptosis regulator Homo sapiens 201-206 32377708-16 2020 DHC exerted anticancer effects by downregulating cell proliferation, antiapoptosis, metastasis-associated proteins CDK1, CCND1, BCL2 and metastasis-associated proteins MMP2 and MMP9, and by upregulating the expression of proapoptotic proteins caspase 3/8/9. dehydrocorydalin 0-3 BCL2 apoptosis regulator Homo sapiens 128-132 32527420-8 2020 Also, QNLC meaningfully restored MMP reduction, lysosomal membrane destabilization, and lipid peroxidation and were capable of preventing PQ-treated change in Bax and Bcl2 gene expression. Paraquat 138-140 BCL2 apoptosis regulator Homo sapiens 167-171 32566008-13 2020 The level of Bcl-2 protein was upregulated by propofol at a concentration of 5 microM and downregulated at concentrations of 10 and 20 microM. Propofol 46-54 BCL2 apoptosis regulator Homo sapiens 13-18 32635973-8 2020 Further, proapoptotic Bax and caspase-3 were significantly elevated, but antiapoptotic Bcl2 was reduced in DOX/HSA-CD19 treated KOPN-8 cells, indicating the activation of the apoptosis pathway by the nanodrug. Doxorubicin 107-110 BCL2 apoptosis regulator Homo sapiens 87-91 32653124-7 2020 Furthermore, the mRNA expression of Caspase 3 was down-regulated significantly and the ratio of Bcl-2/Bax was up-regulated significantly in EVs + CDDP group. Cisplatin 146-150 BCL2 apoptosis regulator Homo sapiens 96-101 32578742-14 2020 We found that Bcl-2 was generally expressed at high levels in the enoxaparin group, while there was no difference in terms of Ki-67 between the groups. Enoxaparin 66-76 BCL2 apoptosis regulator Homo sapiens 14-19 32208876-5 2020 Polyphyllin I dose-dependent increased the release of mitochondrial cytochrome c, and levels of Fas, p53, p21, and Bax/ Bcl-2 ratios, as well as the activation of cleaved caspase-3, -8, -9, and subsequent cleavage of the poly (ADP-ribose) polymerase (PARP). polyphyllin I 0-13 BCL2 apoptosis regulator Homo sapiens 120-125 32691555-4 2020 With LY294002 pretreatment, the mitochondrial transmembrane potential level and the expressions of p-PI3K, p-AKt and Bcl-2 were decreased, the expression of Bax and the apoptosis rate were increased. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 5-13 BCL2 apoptosis regulator Homo sapiens 117-122 32666749-0 2020 The Effect of Indocyanine Green Antimicrobial Photothermal/Photodynamic Therapy on the Expression of BCL-2 and BAX Messenger RNA Levels in Human Gingival Fibroblast Cells. Indocyanine Green 14-31 BCL2 apoptosis regulator Homo sapiens 101-106 32884211-3 2020 It is of further interest to design new Bcl2 inhibitors from phyto compounds such as artesunate, bruceantin, maytansin, Salvicine, indicine N-oxide, kamebanin and oxyacanthine. Artesunate 85-95 BCL2 apoptosis regulator Homo sapiens 40-44 32884211-3 2020 It is of further interest to design new Bcl2 inhibitors from phyto compounds such as artesunate, bruceantin, maytansin, Salvicine, indicine N-oxide, kamebanin and oxyacanthine. bruceantin 97-107 BCL2 apoptosis regulator Homo sapiens 40-44 32884211-3 2020 It is of further interest to design new Bcl2 inhibitors from phyto compounds such as artesunate, bruceantin, maytansin, Salvicine, indicine N-oxide, kamebanin and oxyacanthine. Maytansine 109-118 BCL2 apoptosis regulator Homo sapiens 40-44 32884211-3 2020 It is of further interest to design new Bcl2 inhibitors from phyto compounds such as artesunate, bruceantin, maytansin, Salvicine, indicine N-oxide, kamebanin and oxyacanthine. salvicine 120-129 BCL2 apoptosis regulator Homo sapiens 40-44 32884211-3 2020 It is of further interest to design new Bcl2 inhibitors from phyto compounds such as artesunate, bruceantin, maytansin, Salvicine, indicine N-oxide, kamebanin and oxyacanthine. indicine-N-oxide 131-147 BCL2 apoptosis regulator Homo sapiens 40-44 32606309-4 2020 BCL2 expression of 332 patients (221 patients for the training set and 111 patients for the validation set) with newly diagnosed DLBCL who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) were analyzed using the tumor-specific automated quantitative analysis (AQUA) scoring method based on multiplex immunofluorescence. Cyclophosphamide 167-183 BCL2 apoptosis regulator Homo sapiens 0-4 32884211-3 2020 It is of further interest to design new Bcl2 inhibitors from phyto compounds such as artesunate, bruceantin, maytansin, Salvicine, indicine N-oxide, kamebanin and oxyacanthine. Kamebanin 149-158 BCL2 apoptosis regulator Homo sapiens 40-44 32884211-3 2020 It is of further interest to design new Bcl2 inhibitors from phyto compounds such as artesunate, bruceantin, maytansin, Salvicine, indicine N-oxide, kamebanin and oxyacanthine. oxyacanthine 163-175 BCL2 apoptosis regulator Homo sapiens 40-44 32647649-0 2020 The Histone Lysine-specific Demethylase 1 Inhibitor, SP2509 Exerts Cytotoxic Effects against Renal Cancer Cells through Downregulation of Bcl-2 and Mcl-1. Lysine 12-18 BCL2 apoptosis regulator Homo sapiens 138-143 32647649-0 2020 The Histone Lysine-specific Demethylase 1 Inhibitor, SP2509 Exerts Cytotoxic Effects against Renal Cancer Cells through Downregulation of Bcl-2 and Mcl-1. SP2509 53-59 BCL2 apoptosis regulator Homo sapiens 138-143 32714412-9 2020 The mechanism underlying this effect might be mediated by TET-upregulated Caspase-3, Bax, and Bid and downregulated by Bcl-2, Survivin, and PARP. tetrandrine 58-61 BCL2 apoptosis regulator Homo sapiens 119-124 32636646-13 2020 XAV939, an inhibitor of Wnt/beta-catenin signaling pathway, decreased GOLPH3 overexpression-induced proliferation and enhanced cisplatin-induced angiogenesis inhibition and apoptosis, which was supported by the changes of VEGF, Bax and Bcl-2. XAV939 0-6 BCL2 apoptosis regulator Homo sapiens 236-241 32606309-4 2020 BCL2 expression of 332 patients (221 patients for the training set and 111 patients for the validation set) with newly diagnosed DLBCL who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) were analyzed using the tumor-specific automated quantitative analysis (AQUA) scoring method based on multiplex immunofluorescence. Doxorubicin 185-196 BCL2 apoptosis regulator Homo sapiens 0-4 32606309-4 2020 BCL2 expression of 332 patients (221 patients for the training set and 111 patients for the validation set) with newly diagnosed DLBCL who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) were analyzed using the tumor-specific automated quantitative analysis (AQUA) scoring method based on multiplex immunofluorescence. Vincristine 198-209 BCL2 apoptosis regulator Homo sapiens 0-4 32895203-12 2020 The protein expression of Bax increased and that of Bcl-2 decreased following gefitinib treatment in the cells (P < 0.05). Gefitinib 78-87 BCL2 apoptosis regulator Homo sapiens 52-57 32606309-4 2020 BCL2 expression of 332 patients (221 patients for the training set and 111 patients for the validation set) with newly diagnosed DLBCL who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) were analyzed using the tumor-specific automated quantitative analysis (AQUA) scoring method based on multiplex immunofluorescence. Prednisone 215-225 BCL2 apoptosis regulator Homo sapiens 0-4 32597418-9 2020 Treatment with 1 muM WNT974 for 48 h increased the rate of cell apoptosis, inhibited the expression of anti-apoptotic protein Bcl-2, and enhanced pro-apoptotic proteins Bax, cleaved-caspase3, and cleaved-caspase9 expression in both cell lines. LGK974 21-27 BCL2 apoptosis regulator Homo sapiens 126-131 32598308-9 2020 Activation of Akt further activated BcL-2 pathway through upregulation of Mcl-1 expression and downregulation Bax expression in order to inhibit glucose-induced HUVEC apoptosis. Glucose 145-152 BCL2 apoptosis regulator Homo sapiens 36-41 32598308-11 2020 Conclusions In conclusion, our results suggested that melatonin exerted vasculoprotective effects against glucose-induced apoptosis in HUVEC through PI3K/Akt, Bcl-2 and oxLDL/LOX-1 signaling pathways. Melatonin 54-63 BCL2 apoptosis regulator Homo sapiens 159-164 32458964-8 2020 In contrast, in vitro MTX and/or Nar treatment of HepG2 cells for 48 h exhibited a cytotoxic effect and induced apoptosis in a dose-dependent manner mediated by a significant increase in the Bax/Bcl-2 protein expression ratio. Methotrexate 22-25 BCL2 apoptosis regulator Homo sapiens 195-200 32458964-8 2020 In contrast, in vitro MTX and/or Nar treatment of HepG2 cells for 48 h exhibited a cytotoxic effect and induced apoptosis in a dose-dependent manner mediated by a significant increase in the Bax/Bcl-2 protein expression ratio. naringin 33-36 BCL2 apoptosis regulator Homo sapiens 195-200 32458964-9 2020 Noticeably, Nar potentiated the MTX effect on the Bax/Bcl-2 ratio. naringin 12-15 BCL2 apoptosis regulator Homo sapiens 54-59 32515472-6 2020 Compared with the control cells, high glucose significantly increased cell apoptosis ratio and caspase-3/9 activity, upregulated mRNA/protein expression of Bax and caspase-3/cleaved caspase-3, but downregulated mRNA/protein expression of Bcl-2. Glucose 38-45 BCL2 apoptosis regulator Homo sapiens 238-243 32458964-9 2020 Noticeably, Nar potentiated the MTX effect on the Bax/Bcl-2 ratio. Methotrexate 32-35 BCL2 apoptosis regulator Homo sapiens 54-59 32515472-8 2020 However, once ER stress was inhibited by the inhibitor 4-PBA in the high glucose group, cell apoptosis ratio and caspase-3/9 activity were decreased, mRNA/protein expression of Bax and caspase-3/cleaved caspase-3 was downregulated, but mRNA/protein expression of Bcl-2 was upregulated. Glucose 73-80 BCL2 apoptosis regulator Homo sapiens 263-268 32458964-11 2020 Also, our data introduce MTX and Nar as promising antiproliferative agents with a distinctive mode of action, inducing apoptosis in HepG2 tumor cells through activation of Bax and downregulation of Bcl-2 protein expression. Methotrexate 25-28 BCL2 apoptosis regulator Homo sapiens 198-203 32458964-11 2020 Also, our data introduce MTX and Nar as promising antiproliferative agents with a distinctive mode of action, inducing apoptosis in HepG2 tumor cells through activation of Bax and downregulation of Bcl-2 protein expression. naringin 33-36 BCL2 apoptosis regulator Homo sapiens 198-203 32630532-9 2020 The (+)-Brevipolide H also induced the downregulation of anti-apoptotic Bcl-2 family proteins (Bcl-2 and Bcl-xL) and loss of mitochondrial membrane potential, indicating the contribution of mitochondrial dysfunction to apoptosis. brevipolide 8-19 BCL2 apoptosis regulator Homo sapiens 72-77 32699806-3 2020 In in vitro cell culture experiments Alternol inhibits prostate cancer cell proliferation by causing cell cycle arrest, reduces the expression of Bcl-2 and other pro-survival proteins, increases the level of radical oxygen species by activating xanthine dehydrogenase, blunts mitochondrial aerobic respiration and ATP production, and triggers autophagy flux. Alternol 37-45 BCL2 apoptosis regulator Homo sapiens 146-151 32636621-8 2020 Anticancer assays demonstrated that Co3O4 NPs can selectively lead to the reduction of K562 cell viability through the cell membrane damage, activation of caspase-9, -8 and -3, elevation of Bax/Bcl-2 mRNA ratio, ROS production, cell cycle arrest, and apoptosis. co3o4 36-41 BCL2 apoptosis regulator Homo sapiens 194-199 32587235-6 2020 Like ARTS, A4 stimulated poly-ubiquitylation and UPS-mediated degradation of XIAP and Bcl-2, but not cIAP1, resulting in caspase-9 and -3 activation and apoptosis. a4 11-13 BCL2 apoptosis regulator Homo sapiens 86-91 32630532-9 2020 The (+)-Brevipolide H also induced the downregulation of anti-apoptotic Bcl-2 family proteins (Bcl-2 and Bcl-xL) and loss of mitochondrial membrane potential, indicating the contribution of mitochondrial dysfunction to apoptosis. brevipolide 8-19 BCL2 apoptosis regulator Homo sapiens 95-100 32578930-9 2020 The highest fold change in caspase-3 activity and Bax/Bcl-2 ratio was also detected in response to cabazitaxel. cabazitaxel 99-110 BCL2 apoptosis regulator Homo sapiens 54-59 32569380-3 2020 Targeting aberrant cell survival pathways with selective small molecule BH3-mimetic inhibitors of BCL-2 (venetoclax, S55746), BCL-XL (A1331852), or MCL1 (S63845) is an emerging therapeutic option. BH 3 72-75 BCL2 apoptosis regulator Homo sapiens 98-103 32599797-9 2020 AN07 attenuated MG-induced apoptosis by up-regulating the B-cell lymphoma 2 (Bcl-2) protein and down-regulating the cytosolic expression of cytochrome c. Pyruvaldehyde 16-18 BCL2 apoptosis regulator Homo sapiens 58-75 32599797-9 2020 AN07 attenuated MG-induced apoptosis by up-regulating the B-cell lymphoma 2 (Bcl-2) protein and down-regulating the cytosolic expression of cytochrome c. Pyruvaldehyde 16-18 BCL2 apoptosis regulator Homo sapiens 77-82 32572774-8 2021 In addition, carvacrol treatment significantly inhibited PI3K/p-AKT protein expressions leading to induction of apoptosis mediated by decreased Bcl2 and increased Bax protein expressions. carvacrol 13-22 BCL2 apoptosis regulator Homo sapiens 144-148 32560521-0 2020 Isosamidin from Peucedanum japonicum Roots Prevents Methylglyoxal-Induced Glucotoxicity in Human Umbilical Vein Endothelial Cells via Suppression of ROS-Mediated Bax/Bcl-2. Isosamidin 0-10 BCL2 apoptosis regulator Homo sapiens 166-171 32555254-8 2020 SiO2NPs exposure increased reactive oxygen species (ROS) production, decreased mitochondrial transmembrane potential, and decreased protein and mRNA expression of Bcl-2 in L2 cells. sio2nps 0-7 BCL2 apoptosis regulator Homo sapiens 163-168 32636744-11 2020 We also found that C-PC/CMC-CD55sp nanospheres had a significant inhibitory effect on the expression of antiapoptotic protein Bcl-2 and a promotion on the transformation of caspase 3 to cleaved caspase 3. carboxymethyl-chitosan 24-27 BCL2 apoptosis regulator Homo sapiens 126-131 32685011-0 2020 TGF-beta causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization. Docetaxel 16-25 BCL2 apoptosis regulator Homo sapiens 77-82 32685011-11 2020 Furthermore, DTX-induced Bcl-2 degradation depends on a proteasome pathway, and TGF-beta inhibits DTX-induced Bcl-2 ubiquitination. Docetaxel 13-16 BCL2 apoptosis regulator Homo sapiens 25-30 32685011-11 2020 Furthermore, DTX-induced Bcl-2 degradation depends on a proteasome pathway, and TGF-beta inhibits DTX-induced Bcl-2 ubiquitination. Docetaxel 98-101 BCL2 apoptosis regulator Homo sapiens 110-115 32560521-0 2020 Isosamidin from Peucedanum japonicum Roots Prevents Methylglyoxal-Induced Glucotoxicity in Human Umbilical Vein Endothelial Cells via Suppression of ROS-Mediated Bax/Bcl-2. Reactive Oxygen Species 149-152 BCL2 apoptosis regulator Homo sapiens 166-171 32685011-12 2020 Conclusion: Our study demonstrated that the TGF-beta-acetylated KLF5-Bcl-2 signaling axis mediates DTX resistance in prostate cancer and blockade of this pathway could provide clinical insights into chemoresistance of prostate cancer. Docetaxel 99-102 BCL2 apoptosis regulator Homo sapiens 69-74 32560521-7 2020 Isosamidin prevented MGO-induced apoptosis in HUVECs by downregulating the expression of Bax and upregulating the expression of Bcl-2. Isosamidin 0-10 BCL2 apoptosis regulator Homo sapiens 128-133 32560521-7 2020 Isosamidin prevented MGO-induced apoptosis in HUVECs by downregulating the expression of Bax and upregulating the expression of Bcl-2. Pyruvaldehyde 21-24 BCL2 apoptosis regulator Homo sapiens 128-133 32550826-14 2020 The specific mechanism of circHIPK3 was related to the effect of miR-485-3p on partially reversing the up-regulated expressions of Clever caspase-3, Bax, E-Cadherin and down-regulated expressions of Bcl-2, N-Cadherin and Vimentin. mir-485-3p 65-75 BCL2 apoptosis regulator Homo sapiens 199-204 32669949-3 2020 RSF-induced cell death was associated with the down-regulation of B-cell lymphoma 2 (Bcl-2) and the up-regulation of Bcl-2 X-associated protein (Bax). (3r,3as,6ar)-Hexahydrofuro[2,3-B]furan-3-Ol 0-3 BCL2 apoptosis regulator Homo sapiens 66-83 32655799-6 2020 GLE treatment induced apoptosis of HCT116 cells by downregulating of the ratio of Bcl-2 to Bax and increasing cleaved caspase-3 and poly ADP-ribose polymerase (PARP) protein expression. GLE 0-3 BCL2 apoptosis regulator Homo sapiens 82-87 32669949-3 2020 RSF-induced cell death was associated with the down-regulation of B-cell lymphoma 2 (Bcl-2) and the up-regulation of Bcl-2 X-associated protein (Bax). (3r,3as,6ar)-Hexahydrofuro[2,3-B]furan-3-Ol 0-3 BCL2 apoptosis regulator Homo sapiens 85-90 32617130-5 2020 UA pretreatment of HDFs also attenuated the UVB-induced expression of inflammatory (TNF-alpha and NF-kappaB) and apoptotic (p53, Bax, and caspase-3) and MMPs (MMP-2 and MMP-9) and enhanced the Bcl-2 protein levels in 20 muM UA treatment, when compared to concentrations. ursolic acid 0-2 BCL2 apoptosis regulator Homo sapiens 193-198 32595528-6 2020 Compared with OGD-treated cells, xanomeline inhibited apoptosis, reduced ROS production, attenuated the OGD-induced HIF-1alpha increase and partially reversed the reduction of HO-1, Sirtuin-1, Bcl-2, PARP, and p-Akt induced by OGD. xanomeline 33-43 BCL2 apoptosis regulator Homo sapiens 193-198 32402583-9 2020 Additionally, an intracellular calcium rise and subsequent mitochondrial membrane potential collapse, P53 phosphorylation, reduced BcL-2/Bax ratio in the mitochondrial membrane, release cytochrome c from mitochondria, leading to the subsequent activation of caspase 3 activation by H2O2 were all markedly suppressed in the presence of luteolin. Calcium 31-38 BCL2 apoptosis regulator Homo sapiens 131-136 32232486-0 2020 Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations. ibrutinib 46-55 BCL2 apoptosis regulator Homo sapiens 6-10 32402583-9 2020 Additionally, an intracellular calcium rise and subsequent mitochondrial membrane potential collapse, P53 phosphorylation, reduced BcL-2/Bax ratio in the mitochondrial membrane, release cytochrome c from mitochondria, leading to the subsequent activation of caspase 3 activation by H2O2 were all markedly suppressed in the presence of luteolin. Hydrogen Peroxide 282-286 BCL2 apoptosis regulator Homo sapiens 131-136 32513155-0 2020 Chemopreventive effect of Betulinic acid via mTOR -Caspases/Bcl2/Bax apoptotic signaling in pancreatic cancer. betulinic acid 26-40 BCL2 apoptosis regulator Homo sapiens 60-64 32606746-10 2020 Moreover, both Amidine and DNase I groups showed much higher mRNA and protein levels of NF-kappaB p65 and Bax and lower mRNA and protein levels of Bcl-2 than the Control group (P < 0.05). Amidines 15-22 BCL2 apoptosis regulator Homo sapiens 147-152 32551032-11 2020 The western blot analysis revealed that nitroxoline or bortezomib treatment markedly diminished the levels of Bcl-2 and cyclin D1, and increased the levels of p21, Bax, cleaved PARP and cleaved caspase-3. nitroxoline 40-51 BCL2 apoptosis regulator Homo sapiens 110-115 32513939-6 2020 We used genetic knockdown and pharmacologic approaches of BH3 mimetics to target anti-apoptotic BCL2 family members and identified MCL1 and BCLXL as crucial pro-survival members in melanoma. BH 3 58-61 BCL2 apoptosis regulator Homo sapiens 96-100 32551032-11 2020 The western blot analysis revealed that nitroxoline or bortezomib treatment markedly diminished the levels of Bcl-2 and cyclin D1, and increased the levels of p21, Bax, cleaved PARP and cleaved caspase-3. Bortezomib 55-65 BCL2 apoptosis regulator Homo sapiens 110-115 32559583-11 2020 Moreover, periplocin increased the mRNA expression of NOXA, Bak, Bcl-2, and death receptors such as TRAIL-R1 and TRAIL-R2 and the protein expression of ERK/phospho ERK, p38/phospho p38, and JNK/phospho JNK. periplocin 10-20 BCL2 apoptosis regulator Homo sapiens 65-70 32247610-0 2020 EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2/BCL-XL inhibitor is overcome by BIM upregulation in ovarian clear cell carcinoma cells. bim 106-109 BCL2 apoptosis regulator Homo sapiens 68-73 32247610-3 2020 ABT-263 (navitoclax), an inhibitor of the anti-apoptotic BCL-2/BCL-XL, has a potent ability of inducing death in cancer cells; however, the therapeutic effect of ABT-263 in OCCC remains unclear. navitoclax 0-7 BCL2 apoptosis regulator Homo sapiens 57-62 32247610-3 2020 ABT-263 (navitoclax), an inhibitor of the anti-apoptotic BCL-2/BCL-XL, has a potent ability of inducing death in cancer cells; however, the therapeutic effect of ABT-263 in OCCC remains unclear. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 57-62 32522594-11 2021 When Bax was activated by BAM7 or Bcl-2 was inhibited by venetoclax, CCK-8 assays demonstrated that GEM sensitivity was restored in GEM-resistant cells. gemcitabine 100-103 BCL2 apoptosis regulator Homo sapiens 34-39 32522594-11 2021 When Bax was activated by BAM7 or Bcl-2 was inhibited by venetoclax, CCK-8 assays demonstrated that GEM sensitivity was restored in GEM-resistant cells. gemcitabine 132-135 BCL2 apoptosis regulator Homo sapiens 34-39 32253030-0 2020 CircRNACCDC66 regulates cisplatin resistance in gastric cancer via the miR-618/BCL2 axis. Cisplatin 24-33 BCL2 apoptosis regulator Homo sapiens 79-83 32503323-10 2020 Both the extract and major compounds also inhibited the expression of p-p53 and Bax and increased the levels of Bcl-2 that had been previously reduced by MG treatment. Pyruvaldehyde 154-156 BCL2 apoptosis regulator Homo sapiens 112-117 32547354-12 2020 AZA treatment also increased Bcl-2 expression along with decreased Bcl-2 promoter methylation. Decitabine 0-3 BCL2 apoptosis regulator Homo sapiens 29-34 32547354-12 2020 AZA treatment also increased Bcl-2 expression along with decreased Bcl-2 promoter methylation. Decitabine 0-3 BCL2 apoptosis regulator Homo sapiens 67-72 32488024-14 2020 Treatment with both ATF and GTF reduced the release of cytochrome c and the ratio of BAX/Bcl-2. glucose tolerance factor 28-31 BCL2 apoptosis regulator Homo sapiens 89-94 32482196-9 2020 Furthermore, addition of resveratrol led to a decrease of ROS and MDA, and an increase in the content of T-AOC and BCL2. Resveratrol 25-36 BCL2 apoptosis regulator Homo sapiens 115-119 32394008-8 2020 Citarinostat + momelotinib showed strong cytotoxicity; it significantly reduced mitochondrial membrane potential, down-regulated Bcl-2 and Bcl-xL, and activated caspases 9 and 3. Citarinostat 0-12 BCL2 apoptosis regulator Homo sapiens 129-134 32335811-0 2020 BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy. BH 3 62-65 BCL2 apoptosis regulator Homo sapiens 0-5 32647677-13 2020 Tan-I combination with Paclitaxel promotes apoptosis of cancer cells by promoting Bax expression and Bcl-2 expression. Paclitaxel 23-33 BCL2 apoptosis regulator Homo sapiens 101-106 32642412-3 2020 In this study, we showed that high concentrations of As2O3 induced apoptosis of pDCs via mitochondrial pathway with increased BAX/BCL-2 ratio, while independent of reactive oxygen species generation. Arsenic Trioxide 53-58 BCL2 apoptosis regulator Homo sapiens 130-135 32492881-7 2020 The stilbene tended to arrest cell cycle at G2/M, and it also increased intracellular reactive oxygen species (ROS), caspase 3 activity, and the ratio of Bax/Bcl-2 proteins, indicative of apoptosis. Stilbenes 4-12 BCL2 apoptosis regulator Homo sapiens 158-163 32394008-8 2020 Citarinostat + momelotinib showed strong cytotoxicity; it significantly reduced mitochondrial membrane potential, down-regulated Bcl-2 and Bcl-xL, and activated caspases 9 and 3. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 15-26 BCL2 apoptosis regulator Homo sapiens 129-134 32145585-7 2020 Our results showed that Dox-induced damage in HUVECs were reduced through Kae to promote the expression of total protein 14-3-3gamma and mitochondrial Bcl-2, phosphorylate Bad, increase cell viability, NO content, DDAHIIactivity, p-eNOS/eNOS ratio, and MMP levels, maintained NAD+/NADH and GSH/GSSG balance, and decrease LDH and caspase-3 activities, ADMA content, ROS generation, mPTP openness, and apoptosis. Doxorubicin 24-27 BCL2 apoptosis regulator Homo sapiens 151-156 31463762-6 2020 Apoptotic effects of ZnSO4 were determined by measuring biochemical and immunohistochemical parameters including caspase 3 (CASP3), cytochrome C (CYC), Bcl-2-associated X protein (Bax), and B cell CLL/lymphoma 2 (Bcl-2) levels. Zinc Sulfate 21-26 BCL2 apoptosis regulator Homo sapiens 190-211 32248666-13 2020 The AMPK/Erk signaling pathway experiments revealed that the upregulation of Bcl-2 induced by insulin through Erk phosphorylation was inhibited by metformin and that such inhibition could be mitigated by the inhibition of AMPK. Metformin 147-156 BCL2 apoptosis regulator Homo sapiens 77-82 32145585-8 2020 Kae"s effects were abolished with pAD/14-3-3gamma-shRNA downregulating 14-3-3gamma expression, or ABT-737 inhibiting Bcl-2 activity. ABT-737 98-105 BCL2 apoptosis regulator Homo sapiens 117-122 32130660-11 2020 After treatment with si-LINC01234 or miR-193a-5p mimic, EC cells (Eca-109 and EC9706) exhibited cyclinD1 and Bcl-2 downregulation, and caspase-3, p21, Bax and cleaved caspase-3 upregulation. Silicon 21-23 BCL2 apoptosis regulator Homo sapiens 109-114 32241443-4 2020 IDAC/DOX was capable of reversing tumor multidrug resistance (MDR) through reducing multidrug resistance-associated protein 1 (MRP1) level (0.23-fold vs control group) and regulating bcl-2/bax pathway, eventually induced more apoptosis in MCF-7/ADR cells. Doxorubicin 5-8 BCL2 apoptosis regulator Homo sapiens 183-188 32241443-4 2020 IDAC/DOX was capable of reversing tumor multidrug resistance (MDR) through reducing multidrug resistance-associated protein 1 (MRP1) level (0.23-fold vs control group) and regulating bcl-2/bax pathway, eventually induced more apoptosis in MCF-7/ADR cells. idac 0-4 BCL2 apoptosis regulator Homo sapiens 183-188 32633363-12 2020 Western blot results indicated that simvastatin promoted the protein level of Bax and caspase-3, whereas suppressed the protein expression of Bcl-2. Simvastatin 36-47 BCL2 apoptosis regulator Homo sapiens 142-147 32072678-9 2020 Specifically, the combination of ART and CBP at a lower concentration suppressed cell clone numbers, promoted cell cycle arrest at the G2 /M phase, and induced the expression of the cell cycle and apoptosis related proteins BAX, p21, p53, and Caspae-3, while decreasing Bcl-2 and CyclinB1 expression. artesunate 33-36 BCL2 apoptosis regulator Homo sapiens 270-275 32072678-9 2020 Specifically, the combination of ART and CBP at a lower concentration suppressed cell clone numbers, promoted cell cycle arrest at the G2 /M phase, and induced the expression of the cell cycle and apoptosis related proteins BAX, p21, p53, and Caspae-3, while decreasing Bcl-2 and CyclinB1 expression. Carboplatin 41-44 BCL2 apoptosis regulator Homo sapiens 270-275 32072679-6 2020 EX-527 partially ameliorated the effect of Exendin-4 on cell death, migration, and invasion, as well as on the expression of Bcl-2, MMP-9, Bax, cleaved caspase-3 and ICAM-1. 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide 0-6 BCL2 apoptosis regulator Homo sapiens 125-130 31904108-9 2020 The results revealed that OMA significantly increased the cell viability (p < .05), reduced the apoptotic rate (p < .001), and altered the expression levels of Bcl-2, Bax, cleaved caspase3, and cleaved-caspase9 (p < .05 or p < .01) in STZ-induced INS-1 cells. oxalomalic acid 26-29 BCL2 apoptosis regulator Homo sapiens 166-171 32633376-14 2020 The knockdown of VIM-AS1/overexpression of miR-105-5p inhibited glioma cell growth, colony formation, and migration, and enhanced the cell apoptosis by inhibiting expression of Cyclin A1, PCNA, Vimentin, N-cadherin, and Bcl-2, and by increasing the expression of Bax and E-cadherin. mir-105-5p 43-53 BCL2 apoptosis regulator Homo sapiens 220-225 32346444-6 2020 The degree of apoptosis and the expression of apoptosis-related proteins (Bcl-2 and Bax) in CRC cells stimulated by naringin was detected using flow cytometry and western blot assays, respectively. naringin 116-124 BCL2 apoptosis regulator Homo sapiens 74-79 32186749-5 2020 Furthermore, pretreatment with rShh-N or transfection with phShh increased anti-apoptosis protein Bcl-2 expression and decreased cell apoptosis. rshh-n 31-37 BCL2 apoptosis regulator Homo sapiens 98-103 32472755-5 2020 Overexpression of miR-139-5p in OSCC inhibited in vitro and in vivo cell proliferation and in vitro mobility of OSCC and inhibited the expression of WNT responsive c-myc, cyclinD1, and Bcl-2, and such effects were all reversible by an inhibitor of miR-139-5p or over-expression of CXCR4. mir-139-5p 18-28 BCL2 apoptosis regulator Homo sapiens 185-190 31388792-1 2020 Background AT-101 is a BH3 mimetic that inhibits the heterodimerization of Bcl-2, Bcl-xL, Bcl-W, and Mcl-1 with pro-apoptotic proteins, thereby lowering the threshold for apoptosis. BH 3 23-26 BCL2 apoptosis regulator Homo sapiens 75-80 31264066-0 2020 In vivo and in vitro inhibition of osteosarcoma growth by the pan Bcl-2 inhibitor AT-101. gossypol acetic acid 82-88 BCL2 apoptosis regulator Homo sapiens 66-71 32304004-7 2020 Moreover, taurine inhibited cardiomyocyte apoptosis by decreasing the protein expression of calpain-1, Bax, t-Bid, cytosolic cytochrome c, Apaf-1, cleaved caspase-9 and cleaved caspase-3 and by enhancing calpastatin and Bcl-2 protein expression. Taurine 10-17 BCL2 apoptosis regulator Homo sapiens 220-225 31286322-5 2020 Ruxolitinib treatment reduced the expressions of important autophagy regulators, including mTOR/p70S6K/4EBP1 and the STAT/BCL2 axis, in a dose- and time-dependent manner. ruxolitinib 0-11 BCL2 apoptosis regulator Homo sapiens 122-126 31286322-8 2020 In conclusion, ruxolitinib induces autophagy in JAK2V617F cells, potentially by modulation of mTOR-, STAT- and BCL2-mediated signaling. ruxolitinib 15-26 BCL2 apoptosis regulator Homo sapiens 111-115 32128952-6 2020 Moreover, expression levels of BAX, BCL-2, and CASP9 genes were assessed among AGS cells treated with curcumin, doxorubicin, and Dox-Cur. Curcumin 102-110 BCL2 apoptosis regulator Homo sapiens 36-41 32128952-6 2020 Moreover, expression levels of BAX, BCL-2, and CASP9 genes were assessed among AGS cells treated with curcumin, doxorubicin, and Dox-Cur. Doxorubicin 112-123 BCL2 apoptosis regulator Homo sapiens 36-41 32128952-6 2020 Moreover, expression levels of BAX, BCL-2, and CASP9 genes were assessed among AGS cells treated with curcumin, doxorubicin, and Dox-Cur. Doxorubicin 129-132 BCL2 apoptosis regulator Homo sapiens 36-41 32347651-6 2020 Pristimerin inhibited Akt and FoxO3a phosphorylation and induced nuclear accumulation of FoxO3a in UM-1 cells, increased the expression of pro-apoptotic proteins Bim p27Kip1 , cleaved caspase-3, PARP and Bax, and decreased the expression of Cyclin D1 and Bcl-2. pristimerin 0-11 BCL2 apoptosis regulator Homo sapiens 255-260 32031033-1 2020 B-cell leukemia/lymphoma-2 (BCL-2) inhibition with the targeted oral agent venetoclax (ABT-199) has reshaped the treatment landscape for multiple hematological malignancies. 2-(4'-diethylaminophenyl)benzothiazole 87-90 BCL2 apoptosis regulator Homo sapiens 0-26 32031033-1 2020 B-cell leukemia/lymphoma-2 (BCL-2) inhibition with the targeted oral agent venetoclax (ABT-199) has reshaped the treatment landscape for multiple hematological malignancies. 2-(4'-diethylaminophenyl)benzothiazole 87-90 BCL2 apoptosis regulator Homo sapiens 28-33 32356241-6 2020 The molecular docking study revealed that NTZ has better binding affinity and docking score against JAK2 and BCL2 proteins compared to 5-Fluorouracil, which is the standard drug for treatment of CRC. nitazoxanide 42-45 BCL2 apoptosis regulator Homo sapiens 109-113 32356241-9 2020 Moreover, NTZ regulated the Bcl-2 gene family and promoted the loss of mitochondrial function which was depicted by release of cytochrome c (Cyt c), and caspase activation in apoptotic HCT116 cells. nitazoxanide 10-13 BCL2 apoptosis regulator Homo sapiens 28-33 32390192-5 2020 Unexpectedly, Arg84 from SPPV14 forms an ionic interaction with the conserved Asp in the BH3 motif in a manner that replaces the canonical ionic interaction seen in almost all host Bcl-2:BH3 motif complexes. Aspartic Acid 78-81 BCL2 apoptosis regulator Homo sapiens 181-186 32390192-5 2020 Unexpectedly, Arg84 from SPPV14 forms an ionic interaction with the conserved Asp in the BH3 motif in a manner that replaces the canonical ionic interaction seen in almost all host Bcl-2:BH3 motif complexes. BH 3 89-92 BCL2 apoptosis regulator Homo sapiens 181-186 32390192-5 2020 Unexpectedly, Arg84 from SPPV14 forms an ionic interaction with the conserved Asp in the BH3 motif in a manner that replaces the canonical ionic interaction seen in almost all host Bcl-2:BH3 motif complexes. BH 3 187-190 BCL2 apoptosis regulator Homo sapiens 181-186 32390192-6 2020 These results reveal the flexibility of virus encoded Bcl-2 proteins to mimic key interactions from endogenous host signalling pathways to retain BH3-binding and pro-survival functionality. BH 3 146-149 BCL2 apoptosis regulator Homo sapiens 54-59 32240535-8 2020 Most importantly, both compounds reduced p53 mRNA expression, but only imipramine enhanced the Bcl-2/Bax ratio. Imipramine 71-81 BCL2 apoptosis regulator Homo sapiens 95-100 31945545-0 2020 MOP-dependent enhancement of methadone on the effectiveness of ALA-PDT for A172 cells by upregulating phosphorylated JNK and BCL2. Methadone 29-38 BCL2 apoptosis regulator Homo sapiens 125-129 31945545-0 2020 MOP-dependent enhancement of methadone on the effectiveness of ALA-PDT for A172 cells by upregulating phosphorylated JNK and BCL2. 1-phenyl-3,3-dimethyltriazene 63-70 BCL2 apoptosis regulator Homo sapiens 125-129 31945545-7 2020 Phosphorylated JNK and BCL2 induced by ALA-PDT were promoted in the presence of methadone (p < 0.05). 1-phenyl-3,3-dimethyltriazene 39-46 BCL2 apoptosis regulator Homo sapiens 23-27 31945545-7 2020 Phosphorylated JNK and BCL2 induced by ALA-PDT were promoted in the presence of methadone (p < 0.05). Methadone 80-89 BCL2 apoptosis regulator Homo sapiens 23-27 31945545-9 2020 CONCLUSIONS: The results suggest that apoptosis induced by ALA-PDT is enhanced by methadone, mostly MOP-mediated, through the upregulation of accumulation of phosphorylated JNK and BCL2, leading to a promotion of cytotoxicity of ALA-PDT for A172 cells. 1-phenyl-3,3-dimethyltriazene 59-66 BCL2 apoptosis regulator Homo sapiens 181-185 32240535-10 2020 Although both antidepressants reduced Bax and p53 mRNA expression, only the protection mediated by imipramine might be due to its ability to enhance Bcl-2/Bax ratio. Imipramine 99-109 BCL2 apoptosis regulator Homo sapiens 149-154 31945545-9 2020 CONCLUSIONS: The results suggest that apoptosis induced by ALA-PDT is enhanced by methadone, mostly MOP-mediated, through the upregulation of accumulation of phosphorylated JNK and BCL2, leading to a promotion of cytotoxicity of ALA-PDT for A172 cells. Methadone 82-91 BCL2 apoptosis regulator Homo sapiens 181-185 31971313-4 2020 alpha-Conidendrin significantly induced apoptosis in breast cancer cells via reactive oxygen species generation, upregulation of p53 and Bax, downregulation of Bcl-2, depolarization of mitochondrial membrane potential (MMP), release of cytochrome c from mitochondria, and activation of caspases-3 and -9. conidendrin 0-17 BCL2 apoptosis regulator Homo sapiens 160-165 32566099-8 2020 In addition, the ruthenium-phloretin complex was able to control cell proliferation and boosted apoptotic outbursts in cancer cells associated with the increase in cellular response towards Bax while diminishing responses towards Bcl-2, NF-kappaB, and MMP-9. ruthenium-phloretin 17-36 BCL2 apoptosis regulator Homo sapiens 230-235 31884114-6 2020 Finally, the effect of F/HA/AL/OXA nanogels on genes expression of Bax and Bcl2 was evaluated using quantitative real-time polymerase chain reaction (qRT-PCR) technique. oxaliplatin 31-34 BCL2 apoptosis regulator Homo sapiens 75-79 31884114-9 2020 Compared to free OXA and the empty nanogels, the expression of Bax in HT29 cells treated with F/HA/AL/OXA nanogels was significantly increased along with suppression of Bcl-2 (p < .01). oxaliplatin 102-105 BCL2 apoptosis regulator Homo sapiens 169-174 32897218-7 2020 miR-485-3p was identified as the target of MALAT1, and inhibiting miR-485-3p significantly reverse the effect of MALAT1 silencing on IC50 of paclitaxel and the expressions of P-gp, Bcl-2 and Bax in SK-BR-3/PR cells (P < 0.05). mir-485-3p 0-10 BCL2 apoptosis regulator Homo sapiens 181-186 32486166-6 2020 ABZ and A-1210477 (an MCL1 inhibitor) enhanced the cytotoxicity of ABT-263 (a BCL2/BCL2L1 inhibitor) to their effect on MCL1 suppression. Albendazole 0-3 BCL2 apoptosis regulator Homo sapiens 78-82 32486166-6 2020 ABZ and A-1210477 (an MCL1 inhibitor) enhanced the cytotoxicity of ABT-263 (a BCL2/BCL2L1 inhibitor) to their effect on MCL1 suppression. A-1210477 8-17 BCL2 apoptosis regulator Homo sapiens 78-82 32486166-6 2020 ABZ and A-1210477 (an MCL1 inhibitor) enhanced the cytotoxicity of ABT-263 (a BCL2/BCL2L1 inhibitor) to their effect on MCL1 suppression. navitoclax 67-74 BCL2 apoptosis regulator Homo sapiens 78-82 32897218-7 2020 miR-485-3p was identified as the target of MALAT1, and inhibiting miR-485-3p significantly reverse the effect of MALAT1 silencing on IC50 of paclitaxel and the expressions of P-gp, Bcl-2 and Bax in SK-BR-3/PR cells (P < 0.05). Paclitaxel 141-151 BCL2 apoptosis regulator Homo sapiens 181-186 32897218-8 2020 CONCLUSIONS: MALAT1 can modulate paclitaxel resistance in breast cancer cells possibly by targeting miR-485-3p to down-regulate P-gp and Bcl-2 and up-regulate Bax. Paclitaxel 33-43 BCL2 apoptosis regulator Homo sapiens 137-142 32467587-10 2020 MGO also triggered apoptosis by elevating the cleaved caspase-3 to Bax/Bcl-2 ratio and through activation of the ROS-mediated MAPKs (p-JNK, p-p38, and p-ERK) signaling pathway. Pyruvaldehyde 0-3 BCL2 apoptosis regulator Homo sapiens 71-76 32456284-6 2020 miR-23a-3p, a negative regulator of specific pro-apoptotic Bcl-2 family molecules, is rapidly decreased after neuronal irradiation. -23a-3p 3-10 BCL2 apoptosis regulator Homo sapiens 59-64 32536866-18 2020 Further study showed that shikonin decreased the levels of STAT3-targeted genes Mcl-1, Bcl-2, MMP-2, vimentin, and Twist, which are involved in melanoma survival, migration, and invasion. shikonin 26-34 BCL2 apoptosis regulator Homo sapiens 87-92 32624694-5 2020 Cladribine also upregulated the expression of Bax, and downregulated the expression of Mcl-1 and Bcl-2 in a dose-dependent manner. Cladribine 0-10 BCL2 apoptosis regulator Homo sapiens 97-102 32456284-9 2020 The neuroprotective effects of miR-23a-3p administration may not only involve the direct inhibition of pro-apoptotic Bcl-2 molecules downstream of p53 but also include the attenuation of secondary DNA damage upstream of p53. mir-23a-3p 31-41 BCL2 apoptosis regulator Homo sapiens 117-122 32239160-4 2020 Simultaneously, compared with X-ray radiation, carbon ion radiation induced a marked increase in Bax and prominent decreases in cyclin B1 and Bcl-2 in a dose-dependent manner. Carbon 47-53 BCL2 apoptosis regulator Homo sapiens 142-147 32452831-0 2020 Pyrrolo [3,4-b]-quinolin-9-amine compound FZU-0038-056 suppresses triple-negative breast cancer partially through inhibiting the expression of Bcl-2. pyrrolo [3,4-b]-quinolin-9-amine 0-32 BCL2 apoptosis regulator Homo sapiens 143-148 32452831-5 2020 Furthermore, we found FZU-0038-056 induces apoptosis partially through inhibiting the expression of Bcl-2. fzu-0038-056 22-34 BCL2 apoptosis regulator Homo sapiens 100-105 32509787-9 2020 Xanthohumol also induced apoptosis and cell cycle arrest at G1 phase which was associated with the modulation of expression of related makers including cyclin D1, cyclin D3, and cleaved-PARP, Bcl-2, cytochrome c and Bax. xanthohumol 0-11 BCL2 apoptosis regulator Homo sapiens 192-197 32509181-12 2020 In addition, the combination treatment (emodin plus 5-Fu) induced cell apoptosis via inhibiting Bcl-2 and activating cleaved caspase3 and Bax. Emodin 40-46 BCL2 apoptosis regulator Homo sapiens 96-101 32424110-13 2020 After inhibiting autophagy with 3-MA or CQ, compared with OA alone, cell mitochondrial membrane potential and ATP concentration were significantly reduced, cell p62 expression was reduced, and LC3-II expression was increased, apoptosis-related protein Bax protein was increased, and Bcl-2 protein was decreased, which suggested that 3-MA or CQ treatment increased OA-induced apoptosis of SMMC-7721 cells. 3-methyladenine 32-36 BCL2 apoptosis regulator Homo sapiens 283-288 32424110-13 2020 After inhibiting autophagy with 3-MA or CQ, compared with OA alone, cell mitochondrial membrane potential and ATP concentration were significantly reduced, cell p62 expression was reduced, and LC3-II expression was increased, apoptosis-related protein Bax protein was increased, and Bcl-2 protein was decreased, which suggested that 3-MA or CQ treatment increased OA-induced apoptosis of SMMC-7721 cells. Chloroquine 40-42 BCL2 apoptosis regulator Homo sapiens 283-288 32547191-11 2020 Western blot results showed that DIOS significantly suppressed the expression levels of Bcl-2, cdc2, cyclinB1, and promoted the expression levels of Bax, cleaved-caspase3, cleaved-caspase8, cleaved-PARP, Bak, P53, and P21. diosmetin 33-37 BCL2 apoptosis regulator Homo sapiens 88-93 32499869-0 2020 Exosome-mediated delivery of miR-30a sensitize cisplatin-resistant variant of oral squamous carcinoma cells via modulating Beclin1 and Bcl2. Cisplatin 47-56 BCL2 apoptosis regulator Homo sapiens 135-139 32499869-9 2020 Exosomes from the cisplatin-resistant cells that have been transfected with miR-30a mimics, when delivered to the naive cisplatin-resistant cells, caused not only the significant enhancements in miR-30a expression but also a concomitant decrease in Beclin1 and Bcl2 expression (autophagic and anti-apoptotic marker). Cisplatin 18-27 BCL2 apoptosis regulator Homo sapiens 261-265 32499869-9 2020 Exosomes from the cisplatin-resistant cells that have been transfected with miR-30a mimics, when delivered to the naive cisplatin-resistant cells, caused not only the significant enhancements in miR-30a expression but also a concomitant decrease in Beclin1 and Bcl2 expression (autophagic and anti-apoptotic marker). Cisplatin 120-129 BCL2 apoptosis regulator Homo sapiens 261-265 32499869-11 2020 Thus, our study highlighted the role of exosomal-mediated miR-30a transfer in regaining sensitivity of the cisplatin-resistant OSCC cells via Beclin1 and Bcl2 regulation and hence suggests at its potential therapeutic role. Cisplatin 107-116 BCL2 apoptosis regulator Homo sapiens 154-158 32509181-12 2020 In addition, the combination treatment (emodin plus 5-Fu) induced cell apoptosis via inhibiting Bcl-2 and activating cleaved caspase3 and Bax. Fluorouracil 52-56 BCL2 apoptosis regulator Homo sapiens 96-101 32184020-10 2020 AZD5991 exhibited the synergistic action with PNT, anti-cancer drugs and venetoclax (BCL2 inhibitor), suggesting the utility of MCL1 inhibitor alone or in combination as a future clinical option for Ph + leukemia patients. AZD5991 0-7 BCL2 apoptosis regulator Homo sapiens 85-89 32184020-10 2020 AZD5991 exhibited the synergistic action with PNT, anti-cancer drugs and venetoclax (BCL2 inhibitor), suggesting the utility of MCL1 inhibitor alone or in combination as a future clinical option for Ph + leukemia patients. venetoclax 73-83 BCL2 apoptosis regulator Homo sapiens 85-89 32184020-5 2020 Among BCL2 family inhibitors, MCL1 inhibitors (maritoclax and AZD5991) robustly induced cell death, showing the MCL1-dependent survival of TccY/Sr cells. AZD5991 62-69 BCL2 apoptosis regulator Homo sapiens 6-10 32393677-5 2020 Application of sucrose and the resulting shrinkage caused volume-dependent intrinsic apoptosis with all its classical features: inversion of phosphatidylserine, caspase activation and Bcl-2-dependent release of cytochrome c from mitochondria. Sucrose 15-22 BCL2 apoptosis regulator Homo sapiens 184-189 32477148-8 2020 In addition, our experimental results demonstrated that resveratrol markedly enhanced the decreased levels of Bcl-2 and significantly reduced the increased expression of Bax and Caspase-3 in hippocampal neurons induced by glutamate exposure. Resveratrol 56-67 BCL2 apoptosis regulator Homo sapiens 110-115 32398000-10 2020 The expression of Bcl2, an anti-apoptotic protein expressed dominantly in anagen was significantly increased and that of BAD, a pro-apoptotic protein expressed in early catagen was decreased by PM extract in cultured DPCs and/or 3D DPC spheroid culture. dpcs 217-221 BCL2 apoptosis regulator Homo sapiens 18-22 32113682-0 2020 Low DEDD expression in breast cancer cells indicates higher sensitivity to the Bcl-2-specific inhibitor ABT-199. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 104-107 BCL2 apoptosis regulator Homo sapiens 79-84 32457911-13 2020 HOTTIP expression confers cisplatin resistance by regulating the miR-216a-5p/BCL-2/Beclin1/autophagy pathway, which provides a novel strategy to overcome resistance to chemotherapy in GC. Cisplatin 26-35 BCL2 apoptosis regulator Homo sapiens 77-82 32113682-5 2020 DEDD interacts with and stabilizes Bcl-2, and breast cancer cells with low DEDD expression were more sensitive to treatment with a BH3 mimetic, ABT-199, than were those with high DEDD expression. BH 3 131-134 BCL2 apoptosis regulator Homo sapiens 35-40 32113682-5 2020 DEDD interacts with and stabilizes Bcl-2, and breast cancer cells with low DEDD expression were more sensitive to treatment with a BH3 mimetic, ABT-199, than were those with high DEDD expression. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 144-147 BCL2 apoptosis regulator Homo sapiens 35-40 32113682-6 2020 In total, our findings highlight a new strategy for treating breast cancer with no/low DEDD expression by targeting Bcl-2 with the BH3 mimetic ABT-199. BH 3 131-134 BCL2 apoptosis regulator Homo sapiens 116-121 32113682-6 2020 In total, our findings highlight a new strategy for treating breast cancer with no/low DEDD expression by targeting Bcl-2 with the BH3 mimetic ABT-199. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 143-146 BCL2 apoptosis regulator Homo sapiens 116-121 32371868-7 2020 I-BET726 not only downregulated BRD4-regulated proteins (c-Myc, Bcl-2, and cyclin D1), but also inhibited sphingosine kinase 1 (SphK1) and Akt signalings in SCC cells. 4-(1-acetyl-4-((4-chlorophenyl)amino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoic acid 0-8 BCL2 apoptosis regulator Homo sapiens 64-69 32454937-7 2020 In detail, the apoptotic process triggered by Zerumbone involved the upregulation of proapoptotic Bax and the suppression of antiapoptotic Bcl-2 genes expression as determined by qRT-PCR. zerumbone 46-55 BCL2 apoptosis regulator Homo sapiens 139-144 32175625-1 2020 Based on our previously reported Bcl-2/Mcl-1 dual inhibitor 4-thiomorpholinyl-2-cyano-3-amidinophenalenone (A1) that simultaneously occupies the p2 and p4 hydrophobic pockets of Bcl-2 and Mcl-1, we optimized molecules with different bond angles of the groups extending to the p4 pocket and bulky hydrophobic groups to explore p2. 4-thiomorpholinyl-2-cyano-3-amidinophenalenone 60-106 BCL2 apoptosis regulator Homo sapiens 33-38 32366289-0 2020 miR-185-5p response to usnic acid suppresses proliferation and regulating apoptosis in breast cancer cell by targeting Bcl2. usnic acid 23-33 BCL2 apoptosis regulator Homo sapiens 119-123 32366893-11 2020 In vitro lithium also enhanced BCL2 and GSK3B expression in these cells. Lithium 9-16 BCL2 apoptosis regulator Homo sapiens 31-35 32302063-9 2020 FK866 upregulated the expression of Bcl-2, diminished the expression of Bax and caspase 3, and the number of apoptotic cells. N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide 0-5 BCL2 apoptosis regulator Homo sapiens 36-41 32366419-8 2020 p53 and Bax proteins were overexpressed, while p21 and bcl2 gene expression was decreased after treatment with the ciprofloxacin derivative. Ciprofloxacin 115-128 BCL2 apoptosis regulator Homo sapiens 55-59 32175625-1 2020 Based on our previously reported Bcl-2/Mcl-1 dual inhibitor 4-thiomorpholinyl-2-cyano-3-amidinophenalenone (A1) that simultaneously occupies the p2 and p4 hydrophobic pockets of Bcl-2 and Mcl-1, we optimized molecules with different bond angles of the groups extending to the p4 pocket and bulky hydrophobic groups to explore p2. 4-thiomorpholinyl-2-cyano-3-amidinophenalenone 60-106 BCL2 apoptosis regulator Homo sapiens 178-183 32175625-1 2020 Based on our previously reported Bcl-2/Mcl-1 dual inhibitor 4-thiomorpholinyl-2-cyano-3-amidinophenalenone (A1) that simultaneously occupies the p2 and p4 hydrophobic pockets of Bcl-2 and Mcl-1, we optimized molecules with different bond angles of the groups extending to the p4 pocket and bulky hydrophobic groups to explore p2. a1 108-110 BCL2 apoptosis regulator Homo sapiens 33-38 32175625-1 2020 Based on our previously reported Bcl-2/Mcl-1 dual inhibitor 4-thiomorpholinyl-2-cyano-3-amidinophenalenone (A1) that simultaneously occupies the p2 and p4 hydrophobic pockets of Bcl-2 and Mcl-1, we optimized molecules with different bond angles of the groups extending to the p4 pocket and bulky hydrophobic groups to explore p2. a1 108-110 BCL2 apoptosis regulator Homo sapiens 178-183 32132313-6 2020 In addition, DEX-018 inhibited cell apoptosis and reversed the expression of apoptosis-related proteins (Bcl-2, Bax, and caspase-3) in HUVECs stimulated by t-BHP. dex-018 13-20 BCL2 apoptosis regulator Homo sapiens 105-110 32132313-6 2020 In addition, DEX-018 inhibited cell apoptosis and reversed the expression of apoptosis-related proteins (Bcl-2, Bax, and caspase-3) in HUVECs stimulated by t-BHP. t-bhp 156-161 BCL2 apoptosis regulator Homo sapiens 105-110 31566215-2 2020 We previously reported that the Bcl-2 mitochondrial death protein Bcl-2/19kDa interaction protein 3 (Bnip3), is critical for provoking mitochondrial perturbations and necrotic cell death in response to Dox; however, the underlying mechanisms had not been elucidated. Doxorubicin 202-205 BCL2 apoptosis regulator Homo sapiens 32-37 32106377-7 2020 In addition, GA dose-dependently induced apoptosis in gastric cancer cells through activating Caspase-9/-3 and poly(ADP-Ribose) polymerase (PARP), which was along with the reduced Bcl-2 and Bcl-xl expression levels, and the elevated Bax and Bad levels. ginkgolic acid 13-15 BCL2 apoptosis regulator Homo sapiens 180-185 32203216-0 2020 A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma. BH 3 33-36 BCL2 apoptosis regulator Homo sapiens 62-67 32203216-2 2020 Neuroblastoma cells display elevated expression of the antiapoptotic BCL-2 proteins, suggesting that BH3-mimetics may be a promising treatment option. BH 3 101-104 BCL2 apoptosis regulator Homo sapiens 69-74 32203216-4 2020 METHODS: A panel of neuroblastoma cell lines and primary patient-derived cells were exposed to BH3-mimetics targeting BCL-2 (ABT-199), BCL-XL (A1331852) or MCL-1 (S63845). BH 3 95-98 BCL2 apoptosis regulator Homo sapiens 118-123 32203216-6 2020 RESULTS: All tested BH3-mimetics were able to induce apoptosis in neuroblastoma cell lines, indicating that not only BCL-2 but also BCL-XL and MCL-1 may be promising therapeutic targets. BH 3 20-23 BCL2 apoptosis regulator Homo sapiens 117-122 32203216-9 2020 CONCLUSIONS: By using selective BH3-mimetics, this study demonstrates that BCL-2, BCL-XL, and MCL-1 are all relevant therapeutic targets in neuroblastoma. BH 3 32-35 BCL2 apoptosis regulator Homo sapiens 75-80 31566215-2 2020 We previously reported that the Bcl-2 mitochondrial death protein Bcl-2/19kDa interaction protein 3 (Bnip3), is critical for provoking mitochondrial perturbations and necrotic cell death in response to Dox; however, the underlying mechanisms had not been elucidated. Doxorubicin 202-205 BCL2 apoptosis regulator Homo sapiens 66-71 32266019-9 2020 Western blot analysis demonstrated that the expression of Bax and caspase-3 was upregulated and the expression of Bcl-2 was downregulated in TM-treated human melanocytes. Tunicamycin 141-143 BCL2 apoptosis regulator Homo sapiens 114-119 32495867-10 2020 Moreover, Metformin treatment groups (0, 20, and 40 mM) had more apoptotic PANC-1 cells, higher expression levels of pro-apoptosis proteins Caspase-3 and Bax and lower expression levels of anti-apoptosis protein Bcl-2 and the mTOR pathway-related proteins PI3K, p-Akt, and p-mTOR in cells than Control group (p<0.05). Metformin 10-19 BCL2 apoptosis regulator Homo sapiens 212-217 31692265-4 2020 VPA-induced apoptosis occurred through inhibition of the HDAC1/PTEN/Akt signalling pathway and involved alterations in Bcl-2 and Beclin-1. Valproic Acid 0-3 BCL2 apoptosis regulator Homo sapiens 119-124 32062191-3 2020 Here we found that rapamycin inhibited human soluble BAFF (hsBAFF)-stimulated cell proliferation by inducing G1-cell cycle arrest, which was through downregulating the protein levels of CDK2, CDK4, CDK6, cyclin A, cyclin D1, and cyclin E. Rapamycin reduced hsBAFF-stimulated cell survival by downregulating the levels of anti-apoptotic proteins (Mcl-1, Bcl-2, Bcl-xL and survivin) and meanwhile upregulating the levels of pro-apoptotic proteins (BAK and BAX). Sirolimus 19-28 BCL2 apoptosis regulator Homo sapiens 353-358 31904905-8 2020 Coexposure of Si NPs and Cd also augmented mitochondria-mediated apoptosis in HepG2 cells indicated by altered regulation of apoptotic genes (p53, bax, bcl-2, caspase-3, and caspase-9) along with reduced mitochondrial membrane potential. Cadmium 25-27 BCL2 apoptosis regulator Homo sapiens 152-157 32495906-6 2020 The effects of PTX-NK-Exos on messenger ribonucleic acid (mRNA) and protein expressions of B-cell lymphoma-2 (Bcl-2), Bcl-2 associated X protein (Bax) and Caspase-3 in MCF-7 cells were detected using quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blotting, respectively. ptx 15-18 BCL2 apoptosis regulator Homo sapiens 91-108 32319486-3 2020 Cr(vi) could increase the phosphorylation of p38 and JNK, regulate the expression of Bax and Bcl-2 in both cell lines. chromium hexavalent ion 0-6 BCL2 apoptosis regulator Homo sapiens 93-98 31960917-7 2020 Quercetin down-regulated p53, Bax and cleaved-caspase-3 expression, while up-regulated CyclinD1, CDK4 and Bcl-2. Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 106-111 32862580-8 2020 The AO/EB staining assay showed that rosmarinic acid suppressed the viability of cancer cells via induction of apoptotic cell death which was associated with rise in Bax and decrease in Bcl-2 levels. rosmarinic acid 37-52 BCL2 apoptosis regulator Homo sapiens 186-191 32274578-7 2020 Additionally, the real-time quantitative PCR analysis revealed that Cu-TSC triggers apoptosis in both cell lines via the upregulation of caspases-8, -9, and the changing of Bax/Bcl2 ratio. Copper 68-70 BCL2 apoptosis regulator Homo sapiens 177-181 32862572-12 2020 The antiproliferative effects of lanostane were modulated through Bax/Bcl-2 pathway inducing apoptosis of cancer cells. 4,4,14-trimethylcholestane 33-42 BCL2 apoptosis regulator Homo sapiens 70-75 32862589-6 2020 Furthermore, western blot assay was used to study the effects of norwogonin on apoptosis-related protein expressions including Bax, Bcl-2 and autophagy-related proteins. norwogonin 65-75 BCL2 apoptosis regulator Homo sapiens 132-137 32862589-9 2020 The AO/EB staining assay showed that norwogonin suppresses the viability of cancer cells via induction of apoptotic cell death which was associated with increase in Bax and decrease in Bcl-2 levels. norwogonin 37-47 BCL2 apoptosis regulator Homo sapiens 185-190 31928108-1 2020 Venetoclax, a small molecule inhibitor of BCL-2, has promising pre-clinical and early clinical activity in relapsed refractory multiple myeloma (RRMM). venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 42-47 32239627-10 2020 Collectively, miR-153-3p overexpression blocks the interaction between Bcl-2 and Beclin1 via down-regulation of Bcl-2 to promote autophagy of chondrocytes, thus protecting knee joint against IRI after TKA under sevoflurane preconditioning. Sevoflurane 211-222 BCL2 apoptosis regulator Homo sapiens 71-76 32066201-1 2020 OBJECTIVES: Venetoclax, an orally available BCL2-selective inhibitor, has demonstrated promising single-agent anti-tumour activity in myeloma especially patients with t(11;14). venetoclax 12-22 BCL2 apoptosis regulator Homo sapiens 44-48 32862598-9 2020 Matrine-induced apoptosis was linked with upregulation of Bax and suppression of Bcl-2. matrine 0-7 BCL2 apoptosis regulator Homo sapiens 81-86 32862612-0 2020 Solanine inhibits proliferation and promotes apoptosis of the human leukemia cells by targeting the miR-16/Bcl-2 axis. Solanine 0-8 BCL2 apoptosis regulator Homo sapiens 107-112 32862612-11 2020 CONCLUSION: Taken together, these results showed that Solanine inhibits the proliferation of leukemia cells via induction of apoptosis and modulation of miR-16/Bcl-2 axis. Solanine 54-62 BCL2 apoptosis regulator Homo sapiens 160-165 32248385-4 2020 Initially, apoptosis inducing activity of DP was identified using propidium iodide (PI) and acridine orange/ethidium bromide (AO/EB) dual staining, then it was confirmed by DNA fragmentation assay and western blotting analysis of apoptosis related markers Bax, Bcl-2, cytochrome c, caspase-3 and cleaved poly (ADP-ribose) polymerase (PARP). dp 42-44 BCL2 apoptosis regulator Homo sapiens 261-266 31856423-7 2020 Western blotting was performed to investigate changes in the expression levels of YAP, TAZ, Bcl-2, and EGFR in U87 and U251 cells treated with BPD, cisplatin, and paclitaxel, both as monotherapies and in combination. Paclitaxel 163-173 BCL2 apoptosis regulator Homo sapiens 92-97 32161312-7 2020 This promotes the activation of BAK and BAX and caspase-dependent apoptosis, as (1) individual silencing of BMF, BIM, NOXA, BAK, or BAX, (2) overexpression of BCL-2 or MCL-1 or (3) the caspase inhibitor N-Benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethylketone (zVAD.fmk) all rescue JQ1/BYL719-induced cell death. n-benzyloxycarbonyl-val-ala-asp(o-me) fluoromethylketone 203-259 BCL2 apoptosis regulator Homo sapiens 159-164 32161312-7 2020 This promotes the activation of BAK and BAX and caspase-dependent apoptosis, as (1) individual silencing of BMF, BIM, NOXA, BAK, or BAX, (2) overexpression of BCL-2 or MCL-1 or (3) the caspase inhibitor N-Benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethylketone (zVAD.fmk) all rescue JQ1/BYL719-induced cell death. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 261-265 BCL2 apoptosis regulator Homo sapiens 159-164 32064884-10 2020 MiR-769-5p restrained Bcl-2, MMP9, N-cadherin, and Vimentin protein level and accelerated Bax, cleaved-caspase 3 and, E-cadherin protein level, while JAK1 partly overturned these effects. ABT-769 0-10 BCL2 apoptosis regulator Homo sapiens 22-27 32285266-6 2020 Exposed to CsTP upregulated the antiapoptotic gene Bcl-2 expression, diminished the apoptosis induced by H2O2, but promoted the proliferation and migration of LX-2 cells in proper concentration range. cstp 11-15 BCL2 apoptosis regulator Homo sapiens 51-56 32895138-8 2020 CONCLUSIONS: Honokiol can inhibit the proliferation and migration and induce apoptosis of CAL-27 cells in vitro possibly by regulating the expressions of p-Pi3k, p-Fak, MMP-2, MMP-9, p-Akt, Bax, Bcl-2 and cleaved-caspase-3. honokiol 13-21 BCL2 apoptosis regulator Homo sapiens 195-200 32219291-4 2020 Our results demonstrate that oleacein is able to reduce the proliferation of the SH-SY5Y cells by blocking the cell cycle in the S phase and inducing apoptotic cell death through the increase in both Bax and p53 as well as a reduction in the Bcl-2 expression and STAT3 phosphorylation. oleacein 29-37 BCL2 apoptosis regulator Homo sapiens 242-247 32339204-8 2020 RESULTS: High glucose caused HLE cells oxidative stress and apoptosis exhibiting the increase of apoptotic cells and ROS production and decrease of bcl-2/bax ratio, GSH/GSSG ration and SOD activity. Glucose 14-21 BCL2 apoptosis regulator Homo sapiens 148-153 32431514-8 2020 In addition, PTX-induced apoptosis in SKOV3/PTX cells was significantly enhanced by the treatment of TET via upregulating the levels of Bax and cleaved caspase 3, and downregulating the expression of Bcl-2. Paclitaxel 13-16 BCL2 apoptosis regulator Homo sapiens 200-205 32431514-8 2020 In addition, PTX-induced apoptosis in SKOV3/PTX cells was significantly enhanced by the treatment of TET via upregulating the levels of Bax and cleaved caspase 3, and downregulating the expression of Bcl-2. tetrandrine 101-104 BCL2 apoptosis regulator Homo sapiens 200-205 32425601-14 2020 Subsequently, EVO induced cell cycle arrest at the G2/M phase that correlated with reduced levels of cyclin D1 protein, while the apoptotic effects of EVO were associated with the upregulation of Bax and Bad and a decrease in Bcl-2 protein levels. evodiamine 151-154 BCL2 apoptosis regulator Homo sapiens 226-231 32336747-9 2020 Treatment of the DLD-1 and RKO cells with the endomorphin-2 analog increased the expression of Bax and reduced the expression of Bcl-2. endomorphin 2 46-59 BCL2 apoptosis regulator Homo sapiens 129-134 32368152-7 2020 Furthermore, psoralen reversed miR-196a-5p-induced DDP resistance and reduced the expression levels of HOXB7, HER2, Bcl-2 and CCND1. Ficusin 13-21 BCL2 apoptosis regulator Homo sapiens 116-121 32340377-4 2020 Cell death caused by ATG/DOX co-treatment was mediated by the nuclear translocation of apoptosis inducing factor (AIF), reductions in cellular and mitochondrial Bcl-2 and Bcl-xL, and increases in mitochondrial BAX levels. arctigenin 21-24 BCL2 apoptosis regulator Homo sapiens 161-166 32340351-4 2020 BEA and BEA G1 significantly suppressed the growth, clonogenicity, migration, and invasion of A375SM human melanoma cells and promoted caspase-dependent apoptosis through upregulation of death receptors, as well as modulation of pro- and anti-apoptotic Bcl-2 family members. beauvericin 0-3 BCL2 apoptosis regulator Homo sapiens 253-258 32340351-4 2020 BEA and BEA G1 significantly suppressed the growth, clonogenicity, migration, and invasion of A375SM human melanoma cells and promoted caspase-dependent apoptosis through upregulation of death receptors, as well as modulation of pro- and anti-apoptotic Bcl-2 family members. bea g1 8-14 BCL2 apoptosis regulator Homo sapiens 253-258 32340377-4 2020 Cell death caused by ATG/DOX co-treatment was mediated by the nuclear translocation of apoptosis inducing factor (AIF), reductions in cellular and mitochondrial Bcl-2 and Bcl-xL, and increases in mitochondrial BAX levels. Doxorubicin 25-28 BCL2 apoptosis regulator Homo sapiens 161-166 32377295-5 2020 LM-031 and licochalcone A exerted neuroprotective effects by upregulating pCREB and its downstream genes, BCL2 and GADD45B, and enhancing NRF2. licochalcone A 11-25 BCL2 apoptosis regulator Homo sapiens 106-110 32346617-2 2020 Previously we reported that a combination of the selective BCL-2 family inhibitors ABT-263 and A-1210477 decreased cell proliferation in C33A, SiHa and CaSki human cervical cancer cell lines. navitoclax 83-90 BCL2 apoptosis regulator Homo sapiens 59-64 32346617-2 2020 Previously we reported that a combination of the selective BCL-2 family inhibitors ABT-263 and A-1210477 decreased cell proliferation in C33A, SiHa and CaSki human cervical cancer cell lines. A-1210477 95-104 BCL2 apoptosis regulator Homo sapiens 59-64 32346617-9 2020 Co-inhibition of BCL-2 and MCL-1 with ABT-199 and S63845, inhibited cell proliferation of all cancer cell lines, except SiHa. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 38-41 BCL2 apoptosis regulator Homo sapiens 17-22 32325714-0 2020 Iron Oxide Nanoparticle-Induced Autophagic Flux Is Regulated by Interplay between p53-mTOR Axis and Bcl-2 Signaling in Hepatic Cells. ferric oxide 0-10 BCL2 apoptosis regulator Homo sapiens 100-105 32340415-19 2020 It can alleviate the LPS-induced inflammatory responses by regulating the ratio of apoptotic regulators Bax to Bcl-2 and inhibiting apoptosis of human pulmonary epithelial cells. lps 21-24 BCL2 apoptosis regulator Homo sapiens 111-116 32163813-7 2020 By using SIRT5 sensitive substrates, we found that TW-37, a Bcl-2 inhibitor, displayed low micromolar inhibition to SIRT5, which was further validated by isothermal titration calorimetry analyses, offering a new point to develop dual-action SIRT5/Bcl-2 inhibitors against cancers. TW-37 51-56 BCL2 apoptosis regulator Homo sapiens 60-65 32134256-3 2020 When AP228 is codelivered with siRNA targeting Bcl-2, a key regulator of apoptosis, the overall cytotoxic therapeutic effects of the drug are maximized. ap228 5-10 BCL2 apoptosis regulator Homo sapiens 47-52 32045602-11 2020 Vitexin supplement restored the decrease of Sirt1/Bcl-2 expression, restrained the elevation of caspase3, cleaved caspse-3, p53 and ac-p53 expression in vivo and in vitro. vitexin 0-7 BCL2 apoptosis regulator Homo sapiens 50-55 32337074-2 2020 Our results uncovered that ABT-263 (Navitoclax), a potent and orally bioavailable BCL-2 family inhibitor, induced antiproliferative effects in metastatic human uveal melanoma cells through cell cycle arrest at the G0/G1 phase, loss of mitochondrial membrane potential, and subsequently apoptotic cell death monitored by caspase activation and poly-ADP ribose polymerase cleavage. navitoclax 27-34 BCL2 apoptosis regulator Homo sapiens 82-87 32316340-3 2020 These sesquiterpene lactones were cytotoxic against human acute myeloid leukemia (U-937 and HL-60) cells, even in cells over-expressing the pro-survival protein Bcl-2, but melanoma (SK-MEL-1) and human mononuclear cells isolated from blood of healthy donors were more resistant. sesquiterpene lactones 6-28 BCL2 apoptosis regulator Homo sapiens 161-166 32163813-7 2020 By using SIRT5 sensitive substrates, we found that TW-37, a Bcl-2 inhibitor, displayed low micromolar inhibition to SIRT5, which was further validated by isothermal titration calorimetry analyses, offering a new point to develop dual-action SIRT5/Bcl-2 inhibitors against cancers. TW-37 51-56 BCL2 apoptosis regulator Homo sapiens 247-252 32277808-11 2020 Western blotting of HKULC2 cells showed that betulinic acid nanoparticles promoted the expression of p21 and p53 and downregulated CD133, ALDH, BCL2, MCL1, and c-Myc expression. betulinic acid 45-59 BCL2 apoptosis regulator Homo sapiens 144-148 32074494-7 2020 When compared to high insulin level, the presence of thyroxine in low insulin culture conditions yielded higher stromal cell density (P < 0.05), increased estradiol production on Day 1, and higher Bcl2/Bax ratio on Day 7. Thyroxine 53-62 BCL2 apoptosis regulator Homo sapiens 197-201 32322198-14 2020 Pretreatment with brusatol (BT, an Nrf2 inhibitor) attenuated alpha-cyperone-mediated suppression of ROS, cleaved-caspase-3, and Bax, as well as alpha-cyperone-induced Bcl-2 upregulation in H2O2-treated SH-SY5Y cells. alpha-cyperone 145-159 BCL2 apoptosis regulator Homo sapiens 168-173 32029272-3 2020 To widen its therapeutic margin, we investigated whether the antitumor effect of digoxin is potentiated by the depletion of BCL-2-interacting cell death suppressor (BIS) in A549 lung cancer cells. Digoxin 81-88 BCL2 apoptosis regulator Homo sapiens 124-129 32322210-9 2020 We further showed the profound effects of terphenyllin on the expression of apoptosis-associated proteins, including Bax, Bad, Puma, BimL, Bcl-2, phos-Bcl-2 (Ser70), Bcl-xL, caspase 7, and PARP, which contributed to its anti-PC activity. terphenyllin 42-54 BCL2 apoptosis regulator Homo sapiens 139-144 32322198-12 2020 Moreover, alpha-cyperone remarkably reduced the expression of cleaved-caspase-3 and Bax, and upregulated Bcl-2. alpha-cyperone 10-24 BCL2 apoptosis regulator Homo sapiens 105-110 32322198-14 2020 Pretreatment with brusatol (BT, an Nrf2 inhibitor) attenuated alpha-cyperone-mediated suppression of ROS, cleaved-caspase-3, and Bax, as well as alpha-cyperone-induced Bcl-2 upregulation in H2O2-treated SH-SY5Y cells. brusatol 18-26 BCL2 apoptosis regulator Homo sapiens 168-173 32322198-14 2020 Pretreatment with brusatol (BT, an Nrf2 inhibitor) attenuated alpha-cyperone-mediated suppression of ROS, cleaved-caspase-3, and Bax, as well as alpha-cyperone-induced Bcl-2 upregulation in H2O2-treated SH-SY5Y cells. brusatol 28-30 BCL2 apoptosis regulator Homo sapiens 168-173 32308369-1 2020 Background: Thiazole and thiosemicarbazone derivatives are known to have potential anticancer activity with a mechanism of action related to inhibition of matrix metallo-proteinases, kinases and anti-apoptotic BCL2 family proteins. Thiazoles 12-20 BCL2 apoptosis regulator Homo sapiens 210-214 31996318-8 2020 ART-induced apoptosis corresponded to activation of caspase-8/9/3; decreased expression of Bcl-xL, Bcl-2, myeloid cell leukemia-1, survivin, X-linked inhibitor of apoptosis protein and cellular inhibitor of apoptosis 1/2; and increased expression of Bak. artesunate 0-3 BCL2 apoptosis regulator Homo sapiens 99-104 32308369-1 2020 Background: Thiazole and thiosemicarbazone derivatives are known to have potential anticancer activity with a mechanism of action related to inhibition of matrix metallo-proteinases, kinases and anti-apoptotic BCL2 family proteins. Thiosemicarbazones 25-42 BCL2 apoptosis regulator Homo sapiens 210-214 31317470-9 2020 Besides, Zn-treated groups showed a significant reduction in the number of apoptotic cells and caspase-3 from that of EMR group, whereas there was an increase in bcl-2 immunopositivity. Zinc 9-11 BCL2 apoptosis regulator Homo sapiens 162-167 32309275-0 2020 Competition Between Phenothiazines and BH3 Peptide for the Binding Site of the Antiapoptotic BCL-2 Protein. Phenothiazines 20-34 BCL2 apoptosis regulator Homo sapiens 93-98 32309275-0 2020 Competition Between Phenothiazines and BH3 Peptide for the Binding Site of the Antiapoptotic BCL-2 Protein. BH 3 39-42 BCL2 apoptosis regulator Homo sapiens 93-98 32309275-9 2020 Hereafter, the molecular dynamics technique was used to verify the temporal evolution of the BCL-2 complexes with phenothiazinic compounds and the BH3 peptide, the stability and the mobility of these molecules in the BCL-2 binding site. phenothiazinic 114-128 BCL2 apoptosis regulator Homo sapiens 93-98 32309275-11 2020 Thus, it was possible to verify that thioridazine and trifluoperazine tend to increase the stability of the BCL-2 protein and can compete for the binding site with the BH3 peptide. Thioridazine 37-49 BCL2 apoptosis regulator Homo sapiens 108-113 32309275-11 2020 Thus, it was possible to verify that thioridazine and trifluoperazine tend to increase the stability of the BCL-2 protein and can compete for the binding site with the BH3 peptide. Trifluoperazine 54-69 BCL2 apoptosis regulator Homo sapiens 108-113 32233024-4 2020 Here, we show that galacto-conjugation of the BCL-2 family inhibitor Navitoclax results in a potent senolytic prodrug (Nav-Gal), that can be preferentially activated by SA-beta-gal activity in a wide range of cell types. galacto 19-26 BCL2 apoptosis regulator Homo sapiens 46-51 32233024-4 2020 Here, we show that galacto-conjugation of the BCL-2 family inhibitor Navitoclax results in a potent senolytic prodrug (Nav-Gal), that can be preferentially activated by SA-beta-gal activity in a wide range of cell types. nav-gal 119-126 BCL2 apoptosis regulator Homo sapiens 46-51 32233024-4 2020 Here, we show that galacto-conjugation of the BCL-2 family inhibitor Navitoclax results in a potent senolytic prodrug (Nav-Gal), that can be preferentially activated by SA-beta-gal activity in a wide range of cell types. 2-(2-quinolinyl)-1H-indene--1,3(2H)-dione-6'-sulfonic acid 169-180 BCL2 apoptosis regulator Homo sapiens 46-51 32139108-0 2020 CpG Oligodeoxynucleotides Induces Apoptosis of Human Bladder Cancer Cells via Caspase-3-Bax/Bcl-2-p53 Axis. Oligodeoxyribonucleotides 4-25 BCL2 apoptosis regulator Homo sapiens 92-97 32147288-7 2020 Based on the decrease in the mitochondrial membrane potential, upregulation of Bax, downregulation of Bcl-2 and cleavage of caspase-3 and 9, apoptosis was induced by helveticoside via mitochondria-mediated intrinsic apoptotic signaling pathways in colorectal cancer cells. helveticoside 166-179 BCL2 apoptosis regulator Homo sapiens 102-107 31958764-11 2020 Interestingly, down-regulated expressions of endogenous miR-95, SGK1, Bcl-2, Erk1 were observed after genistein treatments in a dose-dependent way. Genistein 102-111 BCL2 apoptosis regulator Homo sapiens 70-75 31317470-11 2020 Zn seems to have protective effects on the EMR by increasing SOD activity and bcl-2 immunopositivity, decreasing lipid peroxidation and caspas-3 immunopositivity. Zinc 0-2 BCL2 apoptosis regulator Homo sapiens 78-83 31972357-12 2020 Furthermore, oleandrin treatment increased expression of Bax and Bim but decreased that of Bcl-2. oleandrin 13-22 BCL2 apoptosis regulator Homo sapiens 91-96 32035700-0 2020 Pro-apoptotic carboxamide analogues of natural fislatifolic acid targeting Mcl-1 and Bcl-2. octyl-6-carboxyquinol-4(1H)-one-3-carboxamide 14-25 BCL2 apoptosis regulator Homo sapiens 85-90 32035700-4 2020 In this series of cyclohexenyl chalcone analogues, six compounds behaved as dual Bcl-xL/Mcl-1 inhibitors in micromolar range and one exhibited sub-micromolar affinities toward Mcl-1 and Bcl-2. cyclohexenyl chalcone 18-39 BCL2 apoptosis regulator Homo sapiens 186-191 31621996-1 2020 Herein, we describe a prolinamide derived peptidomimetic that preferentially binds to c-MYC and BCL2 G-quadruplexes present in the promoter regions of apoptosis related genes ( c-MYC and BCL2 ) over other DNA quadruplexes. enkephalin, Ala(2)-ProNH2(5)- 22-33 BCL2 apoptosis regulator Homo sapiens 96-100 32077746-11 2020 A loss of mitochondrial membrane potential and reduced Bcl-2/Bax expression were also observed in TH287-treated cells. TH287 98-103 BCL2 apoptosis regulator Homo sapiens 55-60 31621996-1 2020 Herein, we describe a prolinamide derived peptidomimetic that preferentially binds to c-MYC and BCL2 G-quadruplexes present in the promoter regions of apoptosis related genes ( c-MYC and BCL2 ) over other DNA quadruplexes. enkephalin, Ala(2)-ProNH2(5)- 22-33 BCL2 apoptosis regulator Homo sapiens 187-191 32107809-4 2020 Hinokiflavone exhibited a time- and dose-dependent manner apoptosis induction by upregulating expression of Bax and downregulating Bcl-2 in breast cancer cells. hinokiflavone 0-13 BCL2 apoptosis regulator Homo sapiens 131-136 31868268-11 2020 However, Bcl2 inhibition (by ABT737) reversed all the effects of SP600125. ABT-737 29-35 BCL2 apoptosis regulator Homo sapiens 9-13 31868268-11 2020 However, Bcl2 inhibition (by ABT737) reversed all the effects of SP600125. pyrazolanthrone 65-73 BCL2 apoptosis regulator Homo sapiens 9-13 31880362-10 2020 The cell apoptosis caused by I/R was inhibited by ozone, and ozone could decrease apoptosis by increasing the ratio of Bcl-2/Bax and inhibiting caspase signaling pathway in SH-SY5Y cells. Ozone 61-66 BCL2 apoptosis regulator Homo sapiens 119-124 32005716-0 2020 Inhibition of BCL2 family members increases the efficacy of copper chelation in BRAFV600E-driven melanoma. Copper 60-66 BCL2 apoptosis regulator Homo sapiens 14-18 32005716-6 2020 Genetic perturbation or pharmacological inhibition of specific members of the BCL2 family of anti-apoptotic proteins (BCL-W, BCL-XL, and MCL-1) selectively reduced cell viability when combined with a Cu chelator and induced CASPASE-dependent cell death. Copper 200-202 BCL2 apoptosis regulator Homo sapiens 78-82 32005716-7 2020 Further, in BRAFV600E-positive melanoma cells evolved to be resistant to BRAF and/or MEK1/2 inhibitors, combined treatment with TTM and the clinically evaluated BCL2 inhibitor, ABT-263, restored tumor growth suppression and induced apoptosis. navitoclax 177-184 BCL2 apoptosis regulator Homo sapiens 161-165 31812766-5 2020 Moreover, formaldehyde significantly potentiated the induction of death receptor-5, caspase 8/10, cleaved caspase 3/7/9, pro-apoptotic proteins (Bim, Bad and Bax), depolarization of MMP (mitochondrial membrane potential) and AIF (apoptosis-inducing factor) induced by acrolein, and synergistically decreased expressions of pro-survival proteins (Bcl-2 and Bcl-XL) and poly ADP-ribose polymerase. Formaldehyde 10-22 BCL2 apoptosis regulator Homo sapiens 346-351 31806643-11 2020 Treatment with the combination of Navitoclax and the Wee1 inhibitor AZD-1775 repressed the growth of SCNPC PDX resistant to single agent BCL2 inhibitors. adavosertib 68-76 BCL2 apoptosis regulator Homo sapiens 137-141 32244824-9 2020 Additionally, MAC-EVs phosphorylated AKT and increased the levels of the survival protein Bcl-2. mac-evs 14-21 BCL2 apoptosis regulator Homo sapiens 90-95 31911391-2 2020 In this work, the solubility and bioavailability of curcumin (Cur) were enhanced by entrapment in a polyamidoamine (PAMAM) dendrimer, and a polyplex was formed by grafting Bcl-2 siRNA onto the surface amine groups to produce PAMAM-Cur/Bcl-2 siRNA nanoparticles (NPs). Curcumin 52-60 BCL2 apoptosis regulator Homo sapiens 172-177 32035785-3 2020 The clinical activity of venetoclax, a selective BCL2 inhibitor, in T-ALL is unknown. venetoclax 25-35 BCL2 apoptosis regulator Homo sapiens 49-53 31911391-2 2020 In this work, the solubility and bioavailability of curcumin (Cur) were enhanced by entrapment in a polyamidoamine (PAMAM) dendrimer, and a polyplex was formed by grafting Bcl-2 siRNA onto the surface amine groups to produce PAMAM-Cur/Bcl-2 siRNA nanoparticles (NPs). Curcumin 52-60 BCL2 apoptosis regulator Homo sapiens 235-240 31911391-4 2020 Moreover, the PAMAM-Cur/Bcl-2 siRNA NPs showed more effective cellular uptake, and higher inhibition of tumor cell proliferation compared to PAMAM-Cur nanoformulation and free Cur, due to the combined effect of co-delivery of Cur and Bcl-2 siRNA. Poly(amidoamine) 14-19 BCL2 apoptosis regulator Homo sapiens 24-29 31911391-4 2020 Moreover, the PAMAM-Cur/Bcl-2 siRNA NPs showed more effective cellular uptake, and higher inhibition of tumor cell proliferation compared to PAMAM-Cur nanoformulation and free Cur, due to the combined effect of co-delivery of Cur and Bcl-2 siRNA. Poly(amidoamine) 14-19 BCL2 apoptosis regulator Homo sapiens 234-239 31911391-4 2020 Moreover, the PAMAM-Cur/Bcl-2 siRNA NPs showed more effective cellular uptake, and higher inhibition of tumor cell proliferation compared to PAMAM-Cur nanoformulation and free Cur, due to the combined effect of co-delivery of Cur and Bcl-2 siRNA. Poly(amidoamine) 141-146 BCL2 apoptosis regulator Homo sapiens 24-29 31911391-5 2020 The newly described PAMAM-Cur/Bcl-2 siRNA polyplex NPs could be a promising co-delivery nanovehicle. Poly(amidoamine) 20-25 BCL2 apoptosis regulator Homo sapiens 30-35 31942711-7 2020 Moreover, nTiO2 potentiated the Cd-induced apoptosis in both cells suggested by altered expression of p53, bax, and bcl-2 genes along with low mitochondrial membrane potential. Titanium 10-15 BCL2 apoptosis regulator Homo sapiens 116-121 31942711-7 2020 Moreover, nTiO2 potentiated the Cd-induced apoptosis in both cells suggested by altered expression of p53, bax, and bcl-2 genes along with low mitochondrial membrane potential. Cadmium 32-34 BCL2 apoptosis regulator Homo sapiens 116-121 32256768-6 2020 At a concentration of 12.5 microM, icaritin induced apoptosis, which was characterized by the increased expression of the cleaved forms of caspases 3, 7, 8 and 9 and poly (ADP-ribose) polymerase, downregulation of BCL2 apoptosis regulator and upregulation of BCL2-associated X, apoptosis regulator expression. icaritin 35-43 BCL2 apoptosis regulator Homo sapiens 214-238 32256723-10 2020 Additionally, downregulation of miR-24-3p increased the levels of Bcl-2L11, caspase-3 and Bax, and decreased Bcl-2 expression in VSMCs; these changes were abolished by Bcl-2L11-siRNA. mir-24-3p 32-41 BCL2 apoptosis regulator Homo sapiens 66-71 32171069-2 2020 The BCL-2 inhibitor, venetoclax, has shown promising activity in combination with hypomethylating agents and low-dose cytarabine in older adults for whom chemotherapy is not suitable with newly diagnosed acute myeloid leukaemia. venetoclax 21-31 BCL2 apoptosis regulator Homo sapiens 4-9 32329824-12 2020 The expressions of pro-apoptotic proteins Bak and caspase-9 in myeloma cells were significantly increased after transfection with the miR-32 inhibitor (p<0.05), and significantly decreased after addition of the PTEN inhibitor SF1670, while the expressions of anti-apoptotic proteins Bcl-2 and survivin were opposite to those of Bak and caspase-9. SF1670 226-232 BCL2 apoptosis regulator Homo sapiens 283-288 32089221-2 2020 Venetoclax is an orally selective BCL-2 inhibitor and BH3 mimetic approved in chronic lymphocytic leukemia and in combination with low dose cytarabine or hypomethylating agent in acute myeloid leukemia for the treatment of patients unfit for intensive chemotherapy. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 34-39 31922618-8 2020 These three polyphenols suppressed Bax/Bcl-2 mRNA ratio, CHOP up-regulation and MMP disruption in NSAIDs-treated cells. Polyphenols 12-23 BCL2 apoptosis regulator Homo sapiens 39-44 31922618-10 2020 The cytoprotective effect of NAR, but not CAF, involved alteration of Bax/Bcl-2 mRNA ratio or MMP disruption, but not CHOP transcription. naringenin 29-32 BCL2 apoptosis regulator Homo sapiens 74-79 31889242-7 2020 Pretreatment with selenomethionine and selenite significantly reduced caspase-3 activity and BAX mRNA levels and increased BCL-2 mRNA levels in a dose-dependent manner. Selenomethionine 18-34 BCL2 apoptosis regulator Homo sapiens 123-128 31889242-7 2020 Pretreatment with selenomethionine and selenite significantly reduced caspase-3 activity and BAX mRNA levels and increased BCL-2 mRNA levels in a dose-dependent manner. Selenious Acid 39-47 BCL2 apoptosis regulator Homo sapiens 123-128 31692055-5 2020 Intriguingly, we found that ABT-737, a BCL-2 inhibitor, significantly enhanced TRAIL-induced BAX degradation in HCT116 cells and increased TRAIL-induced apoptosis in the HCT116 only with the BAX K21R/K123R mutant, not other BAX mutants. ABT-737 28-35 BCL2 apoptosis regulator Homo sapiens 39-44 32171069-2 2020 The BCL-2 inhibitor, venetoclax, has shown promising activity in combination with hypomethylating agents and low-dose cytarabine in older adults for whom chemotherapy is not suitable with newly diagnosed acute myeloid leukaemia. hypomethylating agents 82-104 BCL2 apoptosis regulator Homo sapiens 4-9 32171069-2 2020 The BCL-2 inhibitor, venetoclax, has shown promising activity in combination with hypomethylating agents and low-dose cytarabine in older adults for whom chemotherapy is not suitable with newly diagnosed acute myeloid leukaemia. Cytarabine 118-128 BCL2 apoptosis regulator Homo sapiens 4-9 32218815-7 2020 Combination treatment was associated with increased DEVD-amc cleaving caspase activity that was blocked by the anti-apoptotic protein, BCL2. acetyl-aspartyl-glutamyl-valyl-aspartyl-amino-4-methylcoumarin 52-60 BCL2 apoptosis regulator Homo sapiens 135-139 31638087-7 2020 H2S exerts its antioxidant effect by limiting free radical reactions through the activation of antioxidant enzymes, including superoxide dismutase, catalase, and glutathione peroxidase, which protect against the effects of aging by regulating apoptosis-related genes, including p53, Bax, and Bcl-2. hydrogen sulfite 0-3 BCL2 apoptosis regulator Homo sapiens 292-297 31638087-7 2020 H2S exerts its antioxidant effect by limiting free radical reactions through the activation of antioxidant enzymes, including superoxide dismutase, catalase, and glutathione peroxidase, which protect against the effects of aging by regulating apoptosis-related genes, including p53, Bax, and Bcl-2. Superoxides 126-136 BCL2 apoptosis regulator Homo sapiens 292-297 32319379-8 2020 The study results also revealed that costunolide treatment significantly inhibited the expression of p-JAK2, p-STAT3 and BCL-2, and increased the expression of BAX, cytochrome C, cleaved-caspase-3 and cleaved-PARP. costunolide 37-48 BCL2 apoptosis regulator Homo sapiens 121-126 32355470-15 2020 VC post-conditioning scavenged ROS, downregulated cytochrome C, Bax, and caspase-9 proteins, and upregulated Bcl-2 protein. Ascorbic Acid 0-2 BCL2 apoptosis regulator Homo sapiens 109-114 32244545-7 2020 The anticancer effects were mediated by increased caspase-3, BAX, and decreased BCL2 and PARP-1 expression in DDP and progesterone-calcitriol combination-treated cells. Progesterone 118-130 BCL2 apoptosis regulator Homo sapiens 80-84 32235588-10 2020 CONCLUSION: This study demonstrated that targeting Enz-induced BCL2 with inhibitor ABT263 could increase Enz sensitivity in both Enz-sensitive and Enz-resistant PCa cells through induction of cellular ROS levels and suppression of USP26 activity with a consequent increase of ubiquitin/proteasome-dependent degradation of AR and ARv7 protein expression. navitoclax 83-89 BCL2 apoptosis regulator Homo sapiens 63-67 32296334-7 2020 TMC induces apoptosis through the upregulation of Bax and downregulation of Bcl-2. 3',4',5',4''-tetramethoxychalcone 0-3 BCL2 apoptosis regulator Homo sapiens 76-81 32235588-10 2020 CONCLUSION: This study demonstrated that targeting Enz-induced BCL2 with inhibitor ABT263 could increase Enz sensitivity in both Enz-sensitive and Enz-resistant PCa cells through induction of cellular ROS levels and suppression of USP26 activity with a consequent increase of ubiquitin/proteasome-dependent degradation of AR and ARv7 protein expression. Reactive Oxygen Species 201-204 BCL2 apoptosis regulator Homo sapiens 63-67 32235588-0 2020 Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation. navitoclax 24-30 BCL2 apoptosis regulator Homo sapiens 122-126 32235588-5 2020 METHODS: The study was designed to target Enz-induced BCL2 with inhibitor ABT263 and test Enz sensitivity in Enz-resistant PCa cells by MTT assay. navitoclax 74-80 BCL2 apoptosis regulator Homo sapiens 54-58 32251495-6 2020 When compared with PQ group, the cells in both SP600125+PQ group and SB203580+PQ group had significantly increased viability and level of anti-apoptotic protein Bcl-2; and had decreased apoptotic rates, decreased levels of caspase-3 and -9, and decreased level of pro-apoptotic protein Bax. pyrazolanthrone 47-55 BCL2 apoptosis regulator Homo sapiens 161-166 32235535-6 2020 Norhierridin B (10) interfered with several p53 transcriptional targets, increasing p21, Bax, and MDM2, while decreasing Bcl-2 protein levels, which suggested the potential activation of a p53 pathway. norhierridin b 0-14 BCL2 apoptosis regulator Homo sapiens 121-126 32251495-6 2020 When compared with PQ group, the cells in both SP600125+PQ group and SB203580+PQ group had significantly increased viability and level of anti-apoptotic protein Bcl-2; and had decreased apoptotic rates, decreased levels of caspase-3 and -9, and decreased level of pro-apoptotic protein Bax. Paraquat 56-58 BCL2 apoptosis regulator Homo sapiens 161-166 32251495-6 2020 When compared with PQ group, the cells in both SP600125+PQ group and SB203580+PQ group had significantly increased viability and level of anti-apoptotic protein Bcl-2; and had decreased apoptotic rates, decreased levels of caspase-3 and -9, and decreased level of pro-apoptotic protein Bax. SB 203580 69-77 BCL2 apoptosis regulator Homo sapiens 161-166 32251495-6 2020 When compared with PQ group, the cells in both SP600125+PQ group and SB203580+PQ group had significantly increased viability and level of anti-apoptotic protein Bcl-2; and had decreased apoptotic rates, decreased levels of caspase-3 and -9, and decreased level of pro-apoptotic protein Bax. Paraquat 56-58 BCL2 apoptosis regulator Homo sapiens 161-166 32163135-4 2020 In addition, Bax, cytosolic cytochrome c and cleaved caspase-3 protein were increased while Bcl-2 protein was decreased significantly by 48 h of Colchicine treatment. Colchicine 145-155 BCL2 apoptosis regulator Homo sapiens 92-97 32199933-5 2021 Venetoclax (ABT-199) is a novel, orally bioavailable small-molecule inhibitor of B-cell lymphoma 2 (BCL-2), a key regulator of the intrinsic apoptotic pathway. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 81-98 32163051-3 2020 Cordycepin-induced apoptosis led to increased PUMA, CYTO-C, FAS, DR4/5, and cleaved caspase-3; and decreased BCL-2, XIAP and PDGFR-alpha. cordycepin 0-10 BCL2 apoptosis regulator Homo sapiens 109-114 32083466-3 2020 Prior studies have shown that the small molecule drug ABT-737, which inhibits Bcl-2 to reinstate apoptotic signaling, is a promising candidate for TNBC therapy. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 54-57 BCL2 apoptosis regulator Homo sapiens 78-83 32199933-5 2021 Venetoclax (ABT-199) is a novel, orally bioavailable small-molecule inhibitor of B-cell lymphoma 2 (BCL-2), a key regulator of the intrinsic apoptotic pathway. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 100-105 32256113-9 2020 Oxymatrine upregulated the expression of cleaved-caspase 3 and BAX and downregulated the expression of BCL2, which led to an increase in apoptosis. oxymatrine 0-10 BCL2 apoptosis regulator Homo sapiens 103-107 32199933-5 2021 Venetoclax (ABT-199) is a novel, orally bioavailable small-molecule inhibitor of B-cell lymphoma 2 (BCL-2), a key regulator of the intrinsic apoptotic pathway. venetoclax 12-19 BCL2 apoptosis regulator Homo sapiens 81-98 32199933-5 2021 Venetoclax (ABT-199) is a novel, orally bioavailable small-molecule inhibitor of B-cell lymphoma 2 (BCL-2), a key regulator of the intrinsic apoptotic pathway. venetoclax 12-19 BCL2 apoptosis regulator Homo sapiens 100-105 32197467-9 2020 Moreover, BX795-mediated pharmacological inhibition of PDK1 synergistically enhances the radiosensitivity of erstwhile resistant cells, increased Bax/Bcl-2 apoptotic ratio, while suppressing oncogenicity and clonogenicity. BX795 10-15 BCL2 apoptosis regulator Homo sapiens 150-155 32204409-16 2020 In vitro study confirmed results of animal studies, in that the essential oil of C. zeylanicum displayed significant anticancer efficacy in MCF-7 and MDA-MB-231 cells (using MTS, BrdU, cell cycle, annexin V/PI, caspase-3/7, Bcl-2, PARP, and mitochondrial membrane potential analyses). Oils, Volatile 64-77 BCL2 apoptosis regulator Homo sapiens 224-229 32258129-9 2020 Furthermore, citral suppressed lipogenesis of prostate cancer cells through the activation of AMPK phosphorylation and downregulation of fatty acid synthase (FASN), acetyl coA carboxylase (ACC), 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), and sterol regulatory element-binding protein (SREBP1) and apoptosis of PC3 cells by upregulating BAX and downregulating Bcl-2 expression. citral 13-19 BCL2 apoptosis regulator Homo sapiens 372-377 32265874-7 2020 Furthermore, we found that NaB treatment reduced the production of inflammatory cytokines (IL-1beta, TNF-alpha, and IL-10) and a key anti-apoptotic marker protein Bcl-2 in THP-1 cell infected with M. bovis. nab 27-30 BCL2 apoptosis regulator Homo sapiens 163-168 32258099-12 2020 Further study revealed that metformin may attenuate the phosphorylation of the Stat3 and the Bcl-2 expression, which was restored by IL-6 partly in EC109 cells but not HEECs. Metformin 28-37 BCL2 apoptosis regulator Homo sapiens 93-98 32258099-15 2020 Therefore, the Stat3/Bcl-2 pathway-mediated apoptosis underlies the cell-type-specific drug sensitivity, suggesting metformin possesses a therapeutic activity and selectivity on esophageal cancer. Metformin 116-125 BCL2 apoptosis regulator Homo sapiens 21-26 32183146-5 2020 Then, we noted that EVO arrested the cell cycle, caused apoptosis, and downregulated the expression of various carcinogenic markers such as B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), cyclin D1, cyclooxygenase 2 (COX-2), survivin, vascular endothelial growth factor (VEGF), and matrix metallopeptidases 9 (MMP-9). evodiamine 20-23 BCL2 apoptosis regulator Homo sapiens 140-157 32134102-0 2020 Synthesis, properties and reactivity of BCl2 aza-BODIPY complexes and salts of the aza-dipyrrinato scaffold. azaBDPBA compound 45-55 BCL2 apoptosis regulator Homo sapiens 40-44 32134102-0 2020 Synthesis, properties and reactivity of BCl2 aza-BODIPY complexes and salts of the aza-dipyrrinato scaffold. aza-dipyrrinato 83-98 BCL2 apoptosis regulator Homo sapiens 40-44 32134102-1 2020 The synthesis and characterisation of the BCl2-chelated complexes of both archetypal aza-dipyrrin sub-types are presented. aza-dipyrrin 85-97 BCL2 apoptosis regulator Homo sapiens 42-46 32134102-4 2020 Additionally, the lability of the B-Cl bond enables facile removal of the BCl2 group, i.e. deprotection of F-aza-BODIPYs, under aqueous conditions. f-aza-bodipys 107-120 BCL2 apoptosis regulator Homo sapiens 74-78 32183335-5 2020 Among them, venetoclax is a potent and selective BCL-2 inhibitor, which has demonstrated the strongest clinical activity in mature B-cell malignancies, including chronic lymphoid leukemia, mantle-cell lymphoma, and multiple myeloma. venetoclax 12-22 BCL2 apoptosis regulator Homo sapiens 49-54 32183335-6 2020 Nevertheless, mechanisms of primary and acquired resistance have been recently described and several features such as cytogenetic abnormalities, BCL-2 family expression, and ex vivo drug testing have to be considered for predicting sensitivity to BH3 mimetics and helping in the identification of patients able to respond. BH 3 247-250 BCL2 apoptosis regulator Homo sapiens 145-150 32183146-5 2020 Then, we noted that EVO arrested the cell cycle, caused apoptosis, and downregulated the expression of various carcinogenic markers such as B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), cyclin D1, cyclooxygenase 2 (COX-2), survivin, vascular endothelial growth factor (VEGF), and matrix metallopeptidases 9 (MMP-9). evodiamine 20-23 BCL2 apoptosis regulator Homo sapiens 159-164 32231817-6 2020 Venetoclax, an inhibitor of the antiapoptotic protein BCL-2 used to treat chronic lymphocytic leukemia, is currently being evaluated in clinical trials as a monotherapy in high-risk myelodysplastic syndromes/acute myeloid leukemia. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 54-59 32210629-8 2020 Yes-associated protein (YAP), a key regulator of Hippo signaling pathway, was further examined to characterize the function of melatonin on adjusting GLUT3 and Bcl-2 expression. Melatonin 127-136 BCL2 apoptosis regulator Homo sapiens 160-165 32210629-10 2020 Annexin V/PI staining and MTT assay results demonstrated that melatonin assisted cisplatin-induced apoptosis accompanied with upregulated caspase-3 and poly ADP-ribose polymerase (PARP) cleavage, as well as Bcl-2 expression. Melatonin 62-71 BCL2 apoptosis regulator Homo sapiens 207-212 31241946-0 2020 Bio-Inspired Dual-Selective BCL-2/c-MYC G-Quadruplex Binders: Design, Synthesis, and Anticancer Activity of Drug-like Imidazo[2,1-i]purine Derivatives. 1,N(6)-ethenoadenine 118-138 BCL2 apoptosis regulator Homo sapiens 28-33 32210629-10 2020 Annexin V/PI staining and MTT assay results demonstrated that melatonin assisted cisplatin-induced apoptosis accompanied with upregulated caspase-3 and poly ADP-ribose polymerase (PARP) cleavage, as well as Bcl-2 expression. Cisplatin 81-90 BCL2 apoptosis regulator Homo sapiens 207-212 32210629-13 2020 The YAP depletion in HepG2 and Hep3B cells suppressed mRNA and protein expression of Bcl-2 and GLUT3, whereas overexpression of YAP in melatonin treated cells partly reversed the melatonin-induced inhibition on proliferation, cisplatin-induced apoptosis, and GLUT3 and Bcl-2 expression. Melatonin 135-144 BCL2 apoptosis regulator Homo sapiens 269-274 32210629-13 2020 The YAP depletion in HepG2 and Hep3B cells suppressed mRNA and protein expression of Bcl-2 and GLUT3, whereas overexpression of YAP in melatonin treated cells partly reversed the melatonin-induced inhibition on proliferation, cisplatin-induced apoptosis, and GLUT3 and Bcl-2 expression. Melatonin 179-188 BCL2 apoptosis regulator Homo sapiens 269-274 31241946-2 2020 Hence, a new class of multifunctionalized imidazo[2,1-i]purine derivatives, easily synthesized with a convergent approach, allowed for the identification of the first dual BCL2/c-MYC gene promoter G-quadruplex ligand. 1,N(6)-ethenoadenine 42-62 BCL2 apoptosis regulator Homo sapiens 172-176 32126142-8 2020 The strongest combination was with the B-cell lymphoma 2 (BCL2) inhibitor venetoclax. venetoclax 74-84 BCL2 apoptosis regulator Homo sapiens 39-56 32218719-7 2020 Moreover, NaHS reduced the apoptosis in the SD-exposed hippocampus, and this included decreases in the number of apoptotic cells and the activation of caspase-3, downregulation of Bax expression, and upregulation of Bcl-2 expression. sodium bisulfide 10-14 BCL2 apoptosis regulator Homo sapiens 216-221 32126142-8 2020 The strongest combination was with the B-cell lymphoma 2 (BCL2) inhibitor venetoclax. venetoclax 74-84 BCL2 apoptosis regulator Homo sapiens 58-62 32144272-1 2020 The BCL-2 antagonist venetoclax is highly effective in multiple myeloma (MM) patients exhibiting the 11;14 translocation, the mechanistic basis of which is unknown. venetoclax 21-31 BCL2 apoptosis regulator Homo sapiens 4-9 32210618-0 2020 Long Non-coding RNA BLACAT1 Induces Tamoxifen Resistance in Human Breast Cancer by Regulating miR-503/Bcl-2 Axis. Tamoxifen 36-45 BCL2 apoptosis regulator Homo sapiens 102-107 32152266-7 2020 Immunohistochemistry of a TMA from patients with surgically resected SCLC demonstrated high MCL1 expression with low BCL-XL and BCL-2 to be the most common expression profile. tma 26-29 BCL2 apoptosis regulator Homo sapiens 128-133 31932844-1 2020 The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose cytarabine represents an important new therapy for older or unfit patients with acute myeloid leukemia (AML). venetoclax 20-30 BCL2 apoptosis regulator Homo sapiens 4-9 32210806-9 2020 Meanwhile, 0.25% carteolol treatment resulted in activated caspase-2, -3, -8, and -9, downregulation of Bcl-2 and Bcl-xL, upregulation of Bax and Bad, DeltaPsim disruption, and release of cytoplasmic cytochrome c (Cyt.c) and AIF into the cytoplasm. Carteolol 17-26 BCL2 apoptosis regulator Homo sapiens 104-109 32131385-4 2020 Accordingly, the approval of venetoclax (ABT-199), a small molecule BCL-2 inhibitor, in patients with chronic lymphocytic leukemia and acute myeloid leukemia has become the proverbial torchbearer for novel candidate drug approaches selectively targeting the BCL-2 superfamily. venetoclax 29-39 BCL2 apoptosis regulator Homo sapiens 68-73 32045197-3 2020 Here a fluorescent and gene loading capacity vector DPL, derived from diketopyrrolopyrrole (DPP) was developed for Bcl-2 siRNA targeted delivery and tumor imaging in vitro and in vivo. Diketopyrrolopyrrole 70-90 BCL2 apoptosis regulator Homo sapiens 115-120 32045197-3 2020 Here a fluorescent and gene loading capacity vector DPL, derived from diketopyrrolopyrrole (DPP) was developed for Bcl-2 siRNA targeted delivery and tumor imaging in vitro and in vivo. dpp 92-95 BCL2 apoptosis regulator Homo sapiens 115-120 32194417-12 2020 Gene regulatory network and Western blot analysis suggested that linagliptin inhibited tumor cell proliferation and promoted cell apoptosis through suppressing the expression and phosphorylation of Rb, plus down-regulating the expression of Pro-caspase3 and Bcl-2, respectively. Linagliptin 65-76 BCL2 apoptosis regulator Homo sapiens 258-263 32194422-11 2020 Furthermore, tilianin treatment decreased the level of anti-apoptotic markers Bcl-2 and Bcl-xL, increased the level of apoptotic factors Bad and Bax, and stimulated cytochrome c release, caspase-3 and poly ADP ribose polymerase (PARP) activation in FaDu cells. tilianin 13-21 BCL2 apoptosis regulator Homo sapiens 78-83 32190086-15 2020 Conclusion: Our research provides an important basis that AE induces BT cell apoptosis through upregulation of miR-15a/miR-16-1 that suppresses BCL2. aloe emodin 58-60 BCL2 apoptosis regulator Homo sapiens 144-148 32131385-4 2020 Accordingly, the approval of venetoclax (ABT-199), a small molecule BCL-2 inhibitor, in patients with chronic lymphocytic leukemia and acute myeloid leukemia has become the proverbial torchbearer for novel candidate drug approaches selectively targeting the BCL-2 superfamily. venetoclax 29-39 BCL2 apoptosis regulator Homo sapiens 258-263 32131385-4 2020 Accordingly, the approval of venetoclax (ABT-199), a small molecule BCL-2 inhibitor, in patients with chronic lymphocytic leukemia and acute myeloid leukemia has become the proverbial torchbearer for novel candidate drug approaches selectively targeting the BCL-2 superfamily. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 41-44 BCL2 apoptosis regulator Homo sapiens 68-73 32131385-6 2020 Functional assays, such as through BH3 profiling, may facilitate prediction of treatment response, development of drug resistance and shed light on rational combinations of BCL-2 inhibitors with other branches of cancer therapy. BH 3 35-38 BCL2 apoptosis regulator Homo sapiens 173-178 32131547-3 2020 Treatment with cordycepin or cisplatin (2 mug/mL) alone failed to induce cell death in T24R2 cells, but combination treatment with these drugs significantly induced apoptosis through mitochondrial pathways, including depolarization of mitochondrial membranes, decrease in anti-apoptotic proteins Bcl-2, Bcl-xL, and Mcl-1, and increase in pro-apoptotic proteins Bak and Bax. cordycepin 15-25 BCL2 apoptosis regulator Homo sapiens 296-301 31935534-8 2020 Co-treatment of cisplatin and nicotine attenuated the effect of cisplatin on Bcl-2 expression. Cisplatin 16-25 BCL2 apoptosis regulator Homo sapiens 77-82 32355808-7 2020 ABT-737, a Bcl-2 inhibitor was used to induce platelet apoptosis in PCI patients in vitro, and the influence of enhanced platelet apoptosis on platelet reactivity was explored. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 11-16 32108265-9 2020 Western blot results revealed that taurine also downregulated the expression of calpain-1 and cytosolic cytochrome c while upregulating the expression of Bcl-2/Bax and mitochondrial cytochrome c in broiler cardiomyocytes during RVH. Taurine 35-42 BCL2 apoptosis regulator Homo sapiens 154-159 31935534-8 2020 Co-treatment of cisplatin and nicotine attenuated the effect of cisplatin on Bcl-2 expression. Nicotine 30-38 BCL2 apoptosis regulator Homo sapiens 77-82 31935534-8 2020 Co-treatment of cisplatin and nicotine attenuated the effect of cisplatin on Bcl-2 expression. Cisplatin 64-73 BCL2 apoptosis regulator Homo sapiens 77-82 31935534-9 2020 In addition, the effect of nicotine on cell survival under cisplatin treatment was attenuated with the addition of the Bcl-2 inhibitor ABT-737. Nicotine 27-35 BCL2 apoptosis regulator Homo sapiens 119-124 31935534-9 2020 In addition, the effect of nicotine on cell survival under cisplatin treatment was attenuated with the addition of the Bcl-2 inhibitor ABT-737. Cisplatin 59-68 BCL2 apoptosis regulator Homo sapiens 119-124 31935534-9 2020 In addition, the effect of nicotine on cell survival under cisplatin treatment was attenuated with the addition of the Bcl-2 inhibitor ABT-737. ABT-737 135-142 BCL2 apoptosis regulator Homo sapiens 119-124 31945619-7 2020 With the high concentration of glutathione (GSH) in the cytoplasm to break the disulfide bonds in the polyHCPT, intact HCPT molecules and encapsulated B-cell lymphoma 2 (Bcl-2) siRNA (siBcl-2) could be rapidly released, leading to the synergistic inhibition of tumor growth via the induction of apoptosis by HCPT and the concurrent silencing of the anti-apoptotic gene by siBcl-2. Glutathione 31-42 BCL2 apoptosis regulator Homo sapiens 151-168 31945619-7 2020 With the high concentration of glutathione (GSH) in the cytoplasm to break the disulfide bonds in the polyHCPT, intact HCPT molecules and encapsulated B-cell lymphoma 2 (Bcl-2) siRNA (siBcl-2) could be rapidly released, leading to the synergistic inhibition of tumor growth via the induction of apoptosis by HCPT and the concurrent silencing of the anti-apoptotic gene by siBcl-2. Glutathione 31-42 BCL2 apoptosis regulator Homo sapiens 170-175 31945619-7 2020 With the high concentration of glutathione (GSH) in the cytoplasm to break the disulfide bonds in the polyHCPT, intact HCPT molecules and encapsulated B-cell lymphoma 2 (Bcl-2) siRNA (siBcl-2) could be rapidly released, leading to the synergistic inhibition of tumor growth via the induction of apoptosis by HCPT and the concurrent silencing of the anti-apoptotic gene by siBcl-2. Glutathione 44-47 BCL2 apoptosis regulator Homo sapiens 151-168 31945619-7 2020 With the high concentration of glutathione (GSH) in the cytoplasm to break the disulfide bonds in the polyHCPT, intact HCPT molecules and encapsulated B-cell lymphoma 2 (Bcl-2) siRNA (siBcl-2) could be rapidly released, leading to the synergistic inhibition of tumor growth via the induction of apoptosis by HCPT and the concurrent silencing of the anti-apoptotic gene by siBcl-2. Glutathione 44-47 BCL2 apoptosis regulator Homo sapiens 170-175 31864078-6 2020 Acrolein exposure reduced survival rate of VSMCs, and raised apoptosis percentage through upregulating the expression of Bax, Cytochrome c and Cleaved caspase-3 and downregulating Bcl-2. Acrolein 0-8 BCL2 apoptosis regulator Homo sapiens 180-185 31478937-7 2020 The 5alpha-DHT induced decline in the rise of Bcl-2/Bax proportion and the increase in caspase-3 degrees were mostly reversed by using VEGF and the VEGF"s anti-apoptotic actions were impeded through preventing the activation of phosphoinositide 3-kinase (PI3K)/Akt. Dihydrotestosterone 4-14 BCL2 apoptosis regulator Homo sapiens 46-51 32062064-7 2020 Cell cycle analysis of RPMI-8226 cells treated with the 6-chloro-derivative showed cell cycle arrest at G2/M phase (supported by Caspases-3,8, BAX and Bcl-2 studies) with a significant pro-apoptotic activity as indicated by annexin V-FITC staining. trichlorophene 56-64 BCL2 apoptosis regulator Homo sapiens 151-156 32124956-8 2020 Interestingly, the MEK inhibitor trametinib significantly inhibited the proliferation of PDXPC1 cells, and not that of Panc-1 cells, by inactivating MEK/ERK/MYC signaling and activating the apoptotic pathway via Bcl-2 degradation. trametinib 33-43 BCL2 apoptosis regulator Homo sapiens 212-217 31123034-2 2020 The BCL2 selective inhibitor venetoclax has potent anti-leukemia efficacy; however, resistance can occur due to its inability to inhibit MCL1, which is stabilized by the MAPK pathway. venetoclax 29-39 BCL2 apoptosis regulator Homo sapiens 4-8 31123034-3 2020 In this study, we aimed to determine the anti-leukemia efficacy of concomitant targeting of BCL2 and MAPK pathways by venetoclax and MEK1/2 inhibitor cobimetinib respectively. cobimetinib 150-161 BCL2 apoptosis regulator Homo sapiens 92-96 32111748-6 2020 RESULTS: We demonstrated the cytotoxic effect of BCL-2 inhibition and that dual targeting of BCL-2 and BCR-ABL1 with venetoclax and nilotinib further increases this cytotoxicity. venetoclax 117-127 BCL2 apoptosis regulator Homo sapiens 93-98 32111748-6 2020 RESULTS: We demonstrated the cytotoxic effect of BCL-2 inhibition and that dual targeting of BCL-2 and BCR-ABL1 with venetoclax and nilotinib further increases this cytotoxicity. nilotinib 132-141 BCL2 apoptosis regulator Homo sapiens 93-98 32104214-3 2020 It was identified that ghrelin inhibited apoptosis in MDA-MB-231 cells in vitro and reversed the expression of B-cell lymphoma 2 (Bcl2) and Bcl2-associated X, and cleaved caspase-3 induced by cisplatin. Ghrelin 23-30 BCL2 apoptosis regulator Homo sapiens 111-128 32104214-3 2020 It was identified that ghrelin inhibited apoptosis in MDA-MB-231 cells in vitro and reversed the expression of B-cell lymphoma 2 (Bcl2) and Bcl2-associated X, and cleaved caspase-3 induced by cisplatin. Ghrelin 23-30 BCL2 apoptosis regulator Homo sapiens 130-134 31808304-6 2020 Our data suggested that the PEI inhibited viability and E-cadherin expression of the pathological cells, and blocked the NF-kappaB signal pathway (reducing levels of p-NF-kappaB proteins); The loaded 5-Fu inhibited the inflammatory factors (TNF-alpha and IL-1beta) release and promoted the anti-inflammation/anti-tumor factors (IL-10 and IL-4) release from macrophages, and also suppressed pathological cells migration; Both the PEI and 5-Fu contributed to the upregulation of Bax and Caspase-3 (pro-tumor-apoptosis factor), as well as the downregulation of Bcl-2 (anti-tumor-apoptosis factor) in esophageal tumor cells. poly(ethylene imine) 28-31 BCL2 apoptosis regulator Homo sapiens 558-563 32124101-7 2020 Quantitative real-time PCR data showed that the mRNA levels of apoptotic marker genes such as p53, bax, and caspase-3 were upregulated, whereas bcl-2, an anti-apoptotic gene, was downregulated; therefore, apoptosis was mediated through the p53, bax, caspase-3, and bcl-2 pathways, suggesting a possible mechanism by which QDs and NPs of ZnO mediate their toxicity.Graphic abstract. Zinc Oxide 337-340 BCL2 apoptosis regulator Homo sapiens 144-149 32521901-11 2020 The growth inhibitory effects of Fisetin were mainly due to induction of apoptosis which was accompanied by enhancement of the capsase-3 and Bax and depletion of Bcl-2 expression. fisetin 33-40 BCL2 apoptosis regulator Homo sapiens 162-167 32521892-10 2020 DAPI staining revealed that Sulforaphane triggered the apoptotic cell death of HepG2 cells which was accompanied with activation of caspases 3 and 9, upregulation of Bax and downregulation of Bcl-2. sulforaphane 28-40 BCL2 apoptosis regulator Homo sapiens 192-197 32521858-12 2020 This was also evident from the western blot analysis of Bax and BCl-2 proteins whose concentration remained unchanged under Taraxastane treatment. taraxastane 124-135 BCL2 apoptosis regulator Homo sapiens 64-69 32521905-7 2020 Further, scutellarin was shown to induce apoptosis which was initially exhibited by DAPI and annexin-V/propidium iodide (PI) staining and then confirmed by western blot in which it was shown to trigger regulation of Bax and downregulation of Bcl-2 in K562 human leukemia cells. scutellarin 9-20 BCL2 apoptosis regulator Homo sapiens 242-247 32521863-10 2020 Ursolic acid inhibited the viability of cancer cells via induction of apoptotic cell death which was associated with increase in Bax and decrease in Bcl-2 levels. ursolic acid 0-12 BCL2 apoptosis regulator Homo sapiens 149-154 31399854-11 2020 In addition, BBR induced apoptosis in EMT-like HCoEpiC cells in a concentration-dependent manner with upregulation of Bax and downregulation of Bcl-2. Berberine 13-16 BCL2 apoptosis regulator Homo sapiens 144-149 32521922-4 2020 Further, western blot assay was used to study the effects of Mahanimbine on apoptosis-related protein expressions including Bax and Bcl-2. mahanimbine 61-72 BCL2 apoptosis regulator Homo sapiens 132-137 32521922-9 2020 The AO/EB staining assay showed that Mahanimbine inhibits the viability of cancer cells via induction of apoptotic cell death which was associated with increase in Bax and decrease in Bcl-2 levels. mahanimbine 37-48 BCL2 apoptosis regulator Homo sapiens 184-189 30741049-8 2020 Immunoblotting assay demonstrated b-Dox-NLCs downregulated anti-apoptotic proteins, i.e. bcl-2, MMP-9 while upregulated pro-apoptotic proteins, i.e. caspase-9, p16 and BAX. Doxorubicin 36-39 BCL2 apoptosis regulator Homo sapiens 89-94 31923940-0 2020 Cancer-targeted and intracellular delivery of Bcl-2-converting peptide with functional macroporous silica nanoparticles for biosafe treatment. Silicon Dioxide 99-105 BCL2 apoptosis regulator Homo sapiens 46-51 31923940-1 2020 Therapeutic peptide, NuBCP-9 (N9) as a Bcl-2 functional converter, has been demonstrated to have the remarkable anticancer efficiency in Bcl-2-abundant cancer. phenylalanyl-seryl-arginyl-seryl-leucyl-histidyl-seryl-leucyl-leucine 21-26 BCL2 apoptosis regulator Homo sapiens 39-44 31924023-6 2020 The apoptotic signaling pathway of A549 cells induced by FAC and the protection mechanism of NITPh(OMe)2 were all discussed through the expression of three relating proteins, Bcl-2, Bax and DDIT3. nitph(ome)2 93-104 BCL2 apoptosis regulator Homo sapiens 175-180 32114591-8 2020 Treatment with 3% sevoflurane also promoted the Bax (B cell leukemia/lymphoma 2 (Bcl2)-associated X protein) and cleaved caspase3 protein expressions, and suppressed Bcl-2 and pro-caspase3 expressions in hippocampal neurons. Sevoflurane 18-29 BCL2 apoptosis regulator Homo sapiens 53-79 32114591-8 2020 Treatment with 3% sevoflurane also promoted the Bax (B cell leukemia/lymphoma 2 (Bcl2)-associated X protein) and cleaved caspase3 protein expressions, and suppressed Bcl-2 and pro-caspase3 expressions in hippocampal neurons. Sevoflurane 18-29 BCL2 apoptosis regulator Homo sapiens 81-85 31923940-1 2020 Therapeutic peptide, NuBCP-9 (N9) as a Bcl-2 functional converter, has been demonstrated to have the remarkable anticancer efficiency in Bcl-2-abundant cancer. phenylalanyl-seryl-arginyl-seryl-leucyl-histidyl-seryl-leucyl-leucine 21-26 BCL2 apoptosis regulator Homo sapiens 137-142 32114591-8 2020 Treatment with 3% sevoflurane also promoted the Bax (B cell leukemia/lymphoma 2 (Bcl2)-associated X protein) and cleaved caspase3 protein expressions, and suppressed Bcl-2 and pro-caspase3 expressions in hippocampal neurons. Sevoflurane 18-29 BCL2 apoptosis regulator Homo sapiens 166-171 32392192-10 2020 Furthermore, melatonin not only increased Bcl-2-associated X protein (Bax) but decreased B-cell lymphoma 2 (Bcl-2) expression as dose increases from 0 to 1000 muM. Melatonin 13-22 BCL2 apoptosis regulator Homo sapiens 89-106 31993929-7 2020 Therefore, in our study, we analysed the influence of the c9,t11 linoleic acid isomer on the expression of PPARG and other genes involved in the apoptotic response (BCL-2, BAX, and CDKN1A) in two NSCLC cell lines of different histological origin (A549 and Calu-1) and in normal human bronchial epithelial Beas-2B cells. Linoleic Acids 65-78 BCL2 apoptosis regulator Homo sapiens 165-170 32392192-10 2020 Furthermore, melatonin not only increased Bcl-2-associated X protein (Bax) but decreased B-cell lymphoma 2 (Bcl-2) expression as dose increases from 0 to 1000 muM. Melatonin 13-22 BCL2 apoptosis regulator Homo sapiens 42-47 31843707-9 2020 Curcumin activated AMPK-JNK signaling, which mediated both mTOR inhibition and Bcl-2 upregulation and in turn enhanced autophagy and suppressed apoptosis, respectively. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 79-84 32063101-6 2020 The anticancer effects of Pd/MgO nanoparticles were accentuated by the upregulation of Bax and p53 and downregulation of Bcl-2 protein expressions. Palladium 26-28 BCL2 apoptosis regulator Homo sapiens 121-126 32063101-6 2020 The anticancer effects of Pd/MgO nanoparticles were accentuated by the upregulation of Bax and p53 and downregulation of Bcl-2 protein expressions. Magnesium 29-32 BCL2 apoptosis regulator Homo sapiens 121-126 31809793-8 2020 ERK inhibitor PD98059 significantly alleviated BDMC induced decrease in psim, alteration in BCl-2, caspase-8 activation and PS externalization. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 14-21 BCL2 apoptosis regulator Homo sapiens 93-98 32194739-7 2020 Compound 131, a novel 4,5-dihydrofuran-3-carboxylate, induced apoptosis in HL-60 cells via the increase of intracellular Ca2+ and ROS to alter the mitochondrial membrane potential and the protein level of Bax and Bcl-2, as well as activating caspase-3. 4,5-dihydrofuran-3-carboxylate 22-52 BCL2 apoptosis regulator Homo sapiens 213-218 31498707-10 2020 MiR-483-3p inhibited the doxorubicin-induced apoptosis in Wilms" tumor cells by the regulation of BAX and Bcl-2 expression. Doxorubicin 25-36 BCL2 apoptosis regulator Homo sapiens 106-111 31905252-10 2020 Ascleposide decreased the expression of antiapoptotic Bcl-2 members (eg, Bcl-2 and Mcl-1) but upregulated proapoptotic member (eg, Bak), leading to a significant loss of mitochondrial membrane potential and activation of both caspase-9 and caspase-3. Ascleposide 0-11 BCL2 apoptosis regulator Homo sapiens 54-59 31905252-10 2020 Ascleposide decreased the expression of antiapoptotic Bcl-2 members (eg, Bcl-2 and Mcl-1) but upregulated proapoptotic member (eg, Bak), leading to a significant loss of mitochondrial membrane potential and activation of both caspase-9 and caspase-3. Ascleposide 0-11 BCL2 apoptosis regulator Homo sapiens 73-78 31751608-7 2020 Glyphosate decreased expression of P16 and TP53 as well as an increase in the expression of BCl2, CCND1 and P21. glyphosate 0-10 BCL2 apoptosis regulator Homo sapiens 92-96 31809793-8 2020 ERK inhibitor PD98059 significantly alleviated BDMC induced decrease in psim, alteration in BCl-2, caspase-8 activation and PS externalization. bisdemethoxycurcumin 47-51 BCL2 apoptosis regulator Homo sapiens 93-98 32296028-0 2020 Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia. voruciclib 22-32 BCL2 apoptosis regulator Homo sapiens 84-89 32343239-8 2020 Both lanthanum citrate and KAAD-cyclopamine downregulated the protein expressions of CyclinD1, Bcl-2, Gli1, and Shh and upregulated the protein expressions of p21 and Caspase-3. lanthanum citrate 5-22 BCL2 apoptosis regulator Homo sapiens 95-100 32343239-8 2020 Both lanthanum citrate and KAAD-cyclopamine downregulated the protein expressions of CyclinD1, Bcl-2, Gli1, and Shh and upregulated the protein expressions of p21 and Caspase-3. kaad 27-31 BCL2 apoptosis regulator Homo sapiens 95-100 32343239-8 2020 Both lanthanum citrate and KAAD-cyclopamine downregulated the protein expressions of CyclinD1, Bcl-2, Gli1, and Shh and upregulated the protein expressions of p21 and Caspase-3. cyclopamine 32-43 BCL2 apoptosis regulator Homo sapiens 95-100 32120831-7 2020 Moreover, diminished expression of anti-apoptotic proteins, including Bcl-2, Caspase3, Caspase7, and Caspase8 in METH-exposed SH-SY5y cells, was significantly recovered by treatment with lupenone. Methamphetamine 113-117 BCL2 apoptosis regulator Homo sapiens 70-75 32120831-7 2020 Moreover, diminished expression of anti-apoptotic proteins, including Bcl-2, Caspase3, Caspase7, and Caspase8 in METH-exposed SH-SY5y cells, was significantly recovered by treatment with lupenone. lupenone 187-195 BCL2 apoptosis regulator Homo sapiens 70-75 32063193-11 2020 Compared with the control, caspase-3 activity was significantly increased and the ratio of Bcl-2 to Bad expression significantly decreased following treatment with formaldehyde. Formaldehyde 164-176 BCL2 apoptosis regulator Homo sapiens 91-96 32180717-5 2020 Several gene expression involved in apoptosis was regulated by ZnO QDs, including bcl-2 gene and caspase. Zinc Oxide 63-66 BCL2 apoptosis regulator Homo sapiens 82-87 32190178-11 2020 Further, miR-103 repressed transcription of Bcl-2/adenovirus E1B 19 kDa interacting protein (BNIP3). mir-103 9-16 BCL2 apoptosis regulator Homo sapiens 44-49 32148007-8 2020 We used the the cell line screened out dendrobiine and tetrandrine which could significantly inhibit IL-6/STAT3 signal pathway and down-regulated the expression of Bcl-2 and Bcl-x in a dose-dependent manner. dendrobiine 39-50 BCL2 apoptosis regulator Homo sapiens 164-169 32148007-8 2020 We used the the cell line screened out dendrobiine and tetrandrine which could significantly inhibit IL-6/STAT3 signal pathway and down-regulated the expression of Bcl-2 and Bcl-x in a dose-dependent manner. tetrandrine 55-66 BCL2 apoptosis regulator Homo sapiens 164-169 32106572-7 2020 In addition, a western blot showed that, after DIF treatment, the expression levels of glutathione (GSH), superoxide dismutase (SOD), and B-cell lymphoma-2 (bcl-2) increased, while the expression levels of gamma-glutamyl transferase (GGT), BCL2-associated X (bax), cleaved caspase-3, and mitogen-activated protein kinase (p38 and c-Jun N-terminal kinase ) signal transduction proteins reduced. Diclofenac 47-50 BCL2 apoptosis regulator Homo sapiens 138-155 32106572-7 2020 In addition, a western blot showed that, after DIF treatment, the expression levels of glutathione (GSH), superoxide dismutase (SOD), and B-cell lymphoma-2 (bcl-2) increased, while the expression levels of gamma-glutamyl transferase (GGT), BCL2-associated X (bax), cleaved caspase-3, and mitogen-activated protein kinase (p38 and c-Jun N-terminal kinase ) signal transduction proteins reduced. Diclofenac 47-50 BCL2 apoptosis regulator Homo sapiens 157-162 32190178-14 2020 However, high expression of miR-103 could reduce the accumulation of LC3II and P62 (P < 0.05) by inhibiting the downstream target gene Bcl-2/adenovirus E1B 19 kDa interacting protein (BNIP3), thus reducing the occurrence of cell pyroptosis (P < 0.05). mir-103 28-35 BCL2 apoptosis regulator Homo sapiens 135-140 32180928-7 2020 The combinatorial in situ cycloaddition generated cell-membrane permeable triazole leads for respective DNA targets (c-MYC and BCL2 i-motifs and G-quadruplexes) that selectively promote their formation. Triazoles 74-82 BCL2 apoptosis regulator Homo sapiens 127-131 32093022-7 2020 However, high basal expression of the antiapoptotic factor BCL-2 allowed a subpopulation of cells to survive glaucarubin treatment. Glaucarubin 109-120 BCL2 apoptosis regulator Homo sapiens 59-64 32093022-9 2020 We discovered that treatment with an FDA-approved BCL-2 inhibitor in the context of glaucarubin-induced DNA damage led to near complete killing in multiple MCPyV-positive MCC cell lines that express high levels of BCL-2. Glaucarubin 84-95 BCL2 apoptosis regulator Homo sapiens 50-55 32093022-9 2020 We discovered that treatment with an FDA-approved BCL-2 inhibitor in the context of glaucarubin-induced DNA damage led to near complete killing in multiple MCPyV-positive MCC cell lines that express high levels of BCL-2. Glaucarubin 84-95 BCL2 apoptosis regulator Homo sapiens 214-219 32085398-0 2020 Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 14-19 32085398-2 2020 Venetoclax is a potent and selective BCL-2 inhibitor, approved by the FDA in 2016 for the treatment of patients with chronic lymphocytic leukemia (CLL). venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 37-42 32153394-5 2020 Moreover, Se-PM decreased the expression of cytochrome c and the ratio of Bax to Bcl-2, and enhanced the mitochondrial membrane potential in N2a-sw cells. se-pm 10-15 BCL2 apoptosis regulator Homo sapiens 81-86 32043094-0 2020 Improving the performance of the MM/PBSA and MM/GBSA methods in recognizing the native structure of the Bcl-2 family using the interaction entropy method. poly(tetramethylene succinate-co-tetramethylene adipate) 36-40 BCL2 apoptosis regulator Homo sapiens 104-109 31286496-7 2020 Furthermore, we investigated the role of the antiapoptotic BCL-2 family member MCL-1 in determining the fate of ovarian cancer cells lines with CCNE1 amplification that are challenged with clinically relevant dose of paclitaxel. Paclitaxel 217-227 BCL2 apoptosis regulator Homo sapiens 59-64 32065117-11 2020 Combined treatment with HQH and DEX or PD98059 increased apoptosis in Jurkat and Nalm-6 cells, and concurrently increased BAX, cleaved-caspase-3, GILZ, NFKBIA, and GRalpha and decreased Bcl-2 and pERK. Dexamethasone 32-35 BCL2 apoptosis regulator Homo sapiens 186-191 32065117-11 2020 Combined treatment with HQH and DEX or PD98059 increased apoptosis in Jurkat and Nalm-6 cells, and concurrently increased BAX, cleaved-caspase-3, GILZ, NFKBIA, and GRalpha and decreased Bcl-2 and pERK. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 39-46 BCL2 apoptosis regulator Homo sapiens 186-191 31887302-7 2020 Meanwhile, dauricine could suppress the activation of caspase-3 and to upregulate the expression of Bcl-2. dauricine 11-20 BCL2 apoptosis regulator Homo sapiens 100-105 31735743-7 2020 Mechanism study showed that melatonin significantly reduced the levels of proapoptotic genes p53, Caspase3, and Caspase9 while it upregulated antiapoptotic factors Bcl-2 and Bcl2l1, and antioxidant genes superoxide dismutase 1 and catalase compared with the epirubicin group. Melatonin 28-37 BCL2 apoptosis regulator Homo sapiens 164-169 32103904-11 2020 HG treatment also induced HUVEC cell apoptosis by increasing the protein levels of cleaved caspase 3, Bax and Bcl-2, which were significantly attenuated by H2S or 740 Y-P. ROS production and gp91phox protein level were increased by HG treatment in HUVECs and this effect can be blocked by the treatment with H2S or Y-P 740. Hydrogen Sulfide 156-159 BCL2 apoptosis regulator Homo sapiens 110-115 32103904-11 2020 HG treatment also induced HUVEC cell apoptosis by increasing the protein levels of cleaved caspase 3, Bax and Bcl-2, which were significantly attenuated by H2S or 740 Y-P. ROS production and gp91phox protein level were increased by HG treatment in HUVECs and this effect can be blocked by the treatment with H2S or Y-P 740. Reactive Oxygen Species 172-175 BCL2 apoptosis regulator Homo sapiens 110-115 32075109-11 2020 In the xenograft models, lenvatinib treatment induced significant tumor shrinkage and blocked the proto-oncogene Bcl-2 (B cell lymphoma/leukemia gene-2) and FGFR signaling pathway, along with reduced levels of EMT markers, compared with control and Sorafenib-treated group. lenvatinib 25-35 BCL2 apoptosis regulator Homo sapiens 113-118 32075109-11 2020 In the xenograft models, lenvatinib treatment induced significant tumor shrinkage and blocked the proto-oncogene Bcl-2 (B cell lymphoma/leukemia gene-2) and FGFR signaling pathway, along with reduced levels of EMT markers, compared with control and Sorafenib-treated group. lenvatinib 25-35 BCL2 apoptosis regulator Homo sapiens 120-151 32045477-3 2020 Early trials with venetoclax (ABT-199), a potent, selective inhibitor of BCL2, have revealed responses across a variety of hematologic malignancies. venetoclax 30-37 BCL2 apoptosis regulator Homo sapiens 73-77 31787232-6 2020 Mechanistically, dorsomorphin significantly upregulates the expression of BAD, a pro-apoptotic member of the Bcl-2 gene family involved in initiating apoptosis. dorsomorphin 17-29 BCL2 apoptosis regulator Homo sapiens 109-114 32104190-8 2020 Among them, alpha-viniferin was predicted to target Bcl-2, caspase-3, 8, and 9, MAPK14, CDK2, HSP90AA1, and others, reflecting CML therapeutic strategies. alpha-viniferin 12-27 BCL2 apoptosis regulator Homo sapiens 52-57 32104190-9 2020 In vitro, experimental data showed a nonnecrotic growth limitation of K562 cells caused by alpha-viniferin was predicted to target Bcl-2, caspase-3, 8, and 9, MAPK14, CDK2, HSP90AA1, and others, reflecting CML therapeutic strategies. alpha-viniferin 91-106 BCL2 apoptosis regulator Homo sapiens 131-136 32104190-10 2020 mug mL-1 at 24 h. Finally, we validated the chemotherapeutic effect of alpha-viniferin was predicted to target Bcl-2, caspase-3, 8, and 9, MAPK14, CDK2, HSP90AA1, and others, reflecting CML therapeutic strategies. alpha-viniferin 71-86 BCL2 apoptosis regulator Homo sapiens 111-116 32104190-12 2020 This work also predicts and validates targets in the mitochondrial signaling pathway, providing a novel strategy for CML treatment.alpha-viniferin was predicted to target Bcl-2, caspase-3, 8, and 9, MAPK14, CDK2, HSP90AA1, and others, reflecting CML therapeutic strategies. alpha-viniferin 131-146 BCL2 apoptosis regulator Homo sapiens 171-176 31665708-8 2020 Our results suggested ZH-BCDp-CPT inclusion complex induced cell apoptosis by up-regulation of Bax and P53 and down-regulation of Bcl-2, primarily involved in the mitochondrial pathways. zh-bcdp 22-29 BCL2 apoptosis regulator Homo sapiens 130-135 32046125-9 2020 Cell-migration and expressions of NHE1, V-ATPase, PARP (poly-ADP-ribose-polymerase), pro-Caspase-3, and Bcl-2 were significantly reduced by pretreating with Andrographolide (>=100 muM) for 24-48 h in HeLa. andrographolide 157-172 BCL2 apoptosis regulator Homo sapiens 104-109 32032391-12 2020 Importantly, direct inhibition of BCL-2 by the inhibitor ABT-737, as well as silencing of BCL-2 by siRNA, resulted in apoptosis in staurosporine-exposed hantavirus-infected cells. ABT-737 57-64 BCL2 apoptosis regulator Homo sapiens 34-39 32032391-12 2020 Importantly, direct inhibition of BCL-2 by the inhibitor ABT-737, as well as silencing of BCL-2 by siRNA, resulted in apoptosis in staurosporine-exposed hantavirus-infected cells. Staurosporine 131-144 BCL2 apoptosis regulator Homo sapiens 34-39 31743135-9 2020 Moreover, BBR inhibited the expression of Bax, Bcl-2, c-Myc, and Vimentin and up-regulated the cytokeratin expression in SW480 cells. Berberine 10-13 BCL2 apoptosis regulator Homo sapiens 47-52 32032391-12 2020 Importantly, direct inhibition of BCL-2 by the inhibitor ABT-737, as well as silencing of BCL-2 by siRNA, resulted in apoptosis in staurosporine-exposed hantavirus-infected cells. Staurosporine 131-144 BCL2 apoptosis regulator Homo sapiens 90-95 32018227-8 2020 In vitro studies using DHT-stimulated prostate cells demonstrated an up-regulation of BPH-related and proliferation markers, whereas baicalin clearly reduced the overexpression of AR, PSA, PCNA, and Bcl-2. baicalin 133-141 BCL2 apoptosis regulator Homo sapiens 199-204 31800305-6 2020 The conventional 10% (v/v) Me2SO method yields ~80% post-thaw cell survival and good cell proliferation, but it drastically alters the pattern of the BCL-2 family gene expression. me2so 27-32 BCL2 apoptosis regulator Homo sapiens 150-155 31867678-7 2020 Observations of this investigation suggest that LPA supports survival of T lymphoma cells via altering apoptosis and glucose metabolism through changing the level of reactive species, namely nitric oxide and reactive oxygen species along with expression of various survival and glucose metabolism regulatory molecules, including hypoxia-inducible factor 1-alpha, p53, Bcl2, and glucose transporter 3, hexokinase II, pyruvate kinase muscle isozyme 2, monocarboxylate transporter 1, pyruvate dehydrogenase kinase 1. lysophosphatidic acid 48-51 BCL2 apoptosis regulator Homo sapiens 368-372 32102534-4 2020 The purpose of the present scrutiny was defined to probe the effect of subtoxic prednisolone dose on the level of promoter methylation and gene expression of BAX and BCL2 in the CCRF-CEM cells. Prednisolone 80-92 BCL2 apoptosis regulator Homo sapiens 166-170 32102534-7 2020 RESULTS: Prednisolone can induce apoptosis via alteration in BAX and BCL2 genes, based on our previous scrutiny. Prednisolone 9-21 BCL2 apoptosis regulator Homo sapiens 69-73 32102534-9 2020 CONCLUSION: Lack of alteration through prednisolone treatment in DNA methylation template of BAX and BCL2 genes make this possible that Prednisolone affects apoptotic gene expression via different pathways, which need more research to be done about it.
. Prednisolone 39-51 BCL2 apoptosis regulator Homo sapiens 101-105 32102534-9 2020 CONCLUSION: Lack of alteration through prednisolone treatment in DNA methylation template of BAX and BCL2 genes make this possible that Prednisolone affects apoptotic gene expression via different pathways, which need more research to be done about it.
. Prednisolone 136-148 BCL2 apoptosis regulator Homo sapiens 101-105 32024207-4 2020 Curcumin pre-treatment effectively protected HTR8/SVneo cells against oxidative stress-induced apoptosis via increasing Bcl-2/Bax ratio and decreasing the protein expression level of cleaved-caspase 3. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 120-125 31810012-9 2020 The levels of the pro-apoptotic proteins Bax, cleaved caspase-9, cleaved PARP and cleaved caspase-3 increased with increased concentrations of acetylshikonin, while the level of the anti-apoptotic protein Bcl-2 was downregulated. acetylshikonin 143-157 BCL2 apoptosis regulator Homo sapiens 205-210 31800305-0 2020 Effects of Me2SO and Trehalose on the Cell Viability, Proliferation, and Bcl-2 Family Gene (BCL-2, BAX, and BAD) Expression in Cryopreserved Human Breast Cancer Cells. me2so 11-16 BCL2 apoptosis regulator Homo sapiens 73-78 31800305-0 2020 Effects of Me2SO and Trehalose on the Cell Viability, Proliferation, and Bcl-2 Family Gene (BCL-2, BAX, and BAD) Expression in Cryopreserved Human Breast Cancer Cells. Trehalose 21-30 BCL2 apoptosis regulator Homo sapiens 73-78 31800305-5 2020 The use of Me2SO and trehalose has affected cell survival, proliferation, apoptotic state, as well as BCL-2 family gene expression. me2so 11-16 BCL2 apoptosis regulator Homo sapiens 102-107 31800305-5 2020 The use of Me2SO and trehalose has affected cell survival, proliferation, apoptotic state, as well as BCL-2 family gene expression. Trehalose 21-30 BCL2 apoptosis regulator Homo sapiens 102-107 31800305-9 2020 The presence of trehalose upregulates the expression of both the antiapoptotic gene BCL-2 and proapoptotic genes BAX and BAD. Trehalose 16-25 BCL2 apoptosis regulator Homo sapiens 84-89 32096002-4 2020 METHODS AND RESULTS: Vardenafil decreased the number of TUNEL-positive cells, increased the Bcl2/Bax ratio, and ameliorated the numbers of BrdU-positive cells in H2O2-treated HUVECs. Vardenafil Dihydrochloride 21-31 BCL2 apoptosis regulator Homo sapiens 92-96 32024199-3 2020 METHODS: In in vitro and in vivo HCC models, we tested regorafenib"s effect on the BCL-2 network and the efficacy of BH3-mimetics on HCC treatment. regorafenib 55-66 BCL2 apoptosis regulator Homo sapiens 83-88 32024199-4 2020 RESULTS: In hepatoma cell lines and Hep3B liver spheroids, regorafenib cytotoxicity was potentiated by BCL-xL siRNA transfection or pharmacological inhibition (A-1331852), while BCL-2 antagonism had no effect. regorafenib 59-70 BCL2 apoptosis regulator Homo sapiens 178-183 31959066-6 2020 In contrast, knockdown of the anti-apoptotic Bcl-2 protein, which becomes heavily phosphorylated at Ser70 during MTA treatment, resulted surprisingly in a reduction of MTA-mediated cell death. seryl-seryl-seryl-arginine 100-103 BCL2 apoptosis regulator Homo sapiens 45-50 32096002-10 2020 Vardenafil decreases apoptosis through an improved Bcl-2/Bax ratio and increases cell proliferation. Vardenafil Dihydrochloride 0-10 BCL2 apoptosis regulator Homo sapiens 51-56 31935362-6 2020 Trigonelline also suppressed caspase-3 activity and bax expression, and induced bcl-2 expression in OGD/R-induced hippocampal neurons. trigonelline 0-12 BCL2 apoptosis regulator Homo sapiens 80-85 31797547-7 2020 In addition, treatment of HeLa cells with PGG significantly reduced the protein levels of cyclin D1, Bcl-2 and STAT3 phosphorylation. Glucose 42-45 BCL2 apoptosis regulator Homo sapiens 101-106 31935363-8 2020 Benzoquinone derivatives act as ROS-scavenging molecules, which modulated the TLR4-CD14 signaling pathway to inhibit the expression of procaspase-1 and IL-1beta in cells, induced apoptosis via a mitochondrial pathway by upregulating the ratio of Bax/Bcl-2 and by activating caspase-3, as well as inhibited the expression of the anti-apoptotic proteins FLIP and XIAP in activated LX-2 cells. quinone 0-12 BCL2 apoptosis regulator Homo sapiens 250-255 31784274-4 2020 The results indicated that Emamectin Benzoatecan cause the inhibition of the proliferation, cytochrome c release, activation of caspase-3/9 and increase Bax/Bcl-2 ratio, which means it induced the cytotoxicity on 16HBE cells associated with the mitochondrial apoptosis. emamectin 27-48 BCL2 apoptosis regulator Homo sapiens 157-162 31874349-10 2020 In relation to gene expression profiling of cell death pathways, of the 84 genes examined in cells a greater than 2-fold change was observed for APAF1, BAX, BCL2, CASP3, CASP7, CASP9, SYCP2, TNF, TP53, CTSB, NFkappaB1, PIK3C3, SNCA, SQSTMT, HSPBAP1 and KCNIPI mRNA expression for glyphosate and AMPA exposures. glyphosate 280-290 BCL2 apoptosis regulator Homo sapiens 157-161 31874349-10 2020 In relation to gene expression profiling of cell death pathways, of the 84 genes examined in cells a greater than 2-fold change was observed for APAF1, BAX, BCL2, CASP3, CASP7, CASP9, SYCP2, TNF, TP53, CTSB, NFkappaB1, PIK3C3, SNCA, SQSTMT, HSPBAP1 and KCNIPI mRNA expression for glyphosate and AMPA exposures. ampa 295-299 BCL2 apoptosis regulator Homo sapiens 157-161 31993732-6 2020 Selegiline and rasagiline, inhibitors of type B monoamine oxidase, have been proved to exhibit potent neuroprotective function: regulation of mitochondrial apoptosis system, maintenance of mitochondrial function, increased expression of genes coding antioxidant enzymes, anti-apoptotic Bcl-2 and pro-survival NTFs, and suppression of oligomerization and aggregation of alpha-synuclein and the toxicity in cellular and animal experiments. Selegiline 0-10 BCL2 apoptosis regulator Homo sapiens 286-291 31927215-6 2020 RESULTS: We demonstrated that the Bcl-2/XL/W inhibitor (ABT263) sensitised the UM cell lines to other inhibitors, mainly to mammalian target of rapamycin (mTOR), mitogen-activated protein kinase kinase (MEK) and murine double minute 2 (MDM2) inhibitors. navitoclax 56-62 BCL2 apoptosis regulator Homo sapiens 34-39 31630253-11 2020 The expression of Bax increased 1.62-fold, while the expression of Bcl-2 decreased 0.76-fold at 135.6 microM/mL concentration of Fe3O4@Glu/PTSC compared to untreated A549 cells. ferryl iron 129-134 BCL2 apoptosis regulator Homo sapiens 67-72 31630253-11 2020 The expression of Bax increased 1.62-fold, while the expression of Bcl-2 decreased 0.76-fold at 135.6 microM/mL concentration of Fe3O4@Glu/PTSC compared to untreated A549 cells. glutamyl-glutamic acid 135-138 BCL2 apoptosis regulator Homo sapiens 67-72 31630253-11 2020 The expression of Bax increased 1.62-fold, while the expression of Bcl-2 decreased 0.76-fold at 135.6 microM/mL concentration of Fe3O4@Glu/PTSC compared to untreated A549 cells. picolinaldehyde 139-143 BCL2 apoptosis regulator Homo sapiens 67-72 31960187-6 2020 RESULT: This review tries to highlight the effect of itraconazole on smoothened receptor (SMO) in the Hedgehog pathway, thereby reducing the glioma-associated oncogene homolog (GLI) release and finally exhibiting a range of anticancer effects, promoting apoptosis of cancer cells, and inhibiting proliferation by indirect inhibition of NF-kappaB pathway and inflammation, moreover, promoting the expression of cyclin-dependent kinase inhibitors, inhibiting the expression of target genes transcribed by GLI such as BCL-2 and Cyclin-D1. Itraconazole 53-65 BCL2 apoptosis regulator Homo sapiens 515-520 31960187-7 2020 Besides, itraconazole increases the number of Bnip3, subsequently, inducing the dissociation of the Beclin-1/BCL-2 binding complex, as a result of ultimately promoting autophagy of cancer cells. Itraconazole 9-21 BCL2 apoptosis regulator Homo sapiens 109-114 32010270-7 2020 Bax expression level was increased, while Bcl-2 expression level was decreased in SCC13 cells following AL treatment. avicularin 104-106 BCL2 apoptosis regulator Homo sapiens 42-47 31701353-6 2020 Salidroside also prevented the decreases in CD46 and CD59, and the increases in VCAM-1, ICAM-1, P-selectin and E-selectin caused by OGD/R in HUVEC, which were associated with decreasing LDH release and increasing Bcl-2/Bax ratio. rhodioloside 0-11 BCL2 apoptosis regulator Homo sapiens 213-218 31672622-7 2020 Not only that, the DTX could enhance the anti-tumor effect of AIPH by downregulating the expression of anti-apoptotic Bcl-2 protein. dendrotoxin A 19-22 BCL2 apoptosis regulator Homo sapiens 118-123 31672622-7 2020 Not only that, the DTX could enhance the anti-tumor effect of AIPH by downregulating the expression of anti-apoptotic Bcl-2 protein. VA 061 62-66 BCL2 apoptosis regulator Homo sapiens 118-123 31993732-6 2020 Selegiline and rasagiline, inhibitors of type B monoamine oxidase, have been proved to exhibit potent neuroprotective function: regulation of mitochondrial apoptosis system, maintenance of mitochondrial function, increased expression of genes coding antioxidant enzymes, anti-apoptotic Bcl-2 and pro-survival NTFs, and suppression of oligomerization and aggregation of alpha-synuclein and the toxicity in cellular and animal experiments. rasagiline 15-25 BCL2 apoptosis regulator Homo sapiens 286-291 32005795-9 2020 Bauerane treatment induced apoptosis of A549 cells, which was associated with the upregulation of Bax and down-regulation of Bcl-2. Bauerane 0-8 BCL2 apoptosis regulator Homo sapiens 125-130 31533509-1 2020 Venetoclax is an oral selective BCL2 inhibitor which is highly efficacious in a variety of B-cell lymphoproliferative diseases (B-LPDs) due to their collective dependency on BCL2 over-expression as a central feature of their pathogenesis. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 32-36 31533509-1 2020 Venetoclax is an oral selective BCL2 inhibitor which is highly efficacious in a variety of B-cell lymphoproliferative diseases (B-LPDs) due to their collective dependency on BCL2 over-expression as a central feature of their pathogenesis. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 174-178 32027268-6 2020 Western blot analysis showed that sorafenib combined with decitabine significantly up-regulated the levels of Bax/Bcl-2, P53, C-Caspase3 and C-PARP and activated apoptosis by inhibiting PI3K-AKT pathway. sorafenib 34-43 BCL2 apoptosis regulator Homo sapiens 114-119 31734898-8 2020 Acacetin increased mitochondrial membrane potential depolarization and Bax:Bcl-2 ratio. acacetin 0-8 BCL2 apoptosis regulator Homo sapiens 75-80 31954371-3 2020 Interestingly, Bcl-2 overexpression is associated with a concomitant increase in cFLIP, and reducing superoxide sensitizes Bcl-2 overexpressing cancer cells to receptor-mediated apoptosis via downregulation of cFLIP. Superoxides 101-111 BCL2 apoptosis regulator Homo sapiens 123-128 31894851-11 2020 Pre-treatment with APS concentration-dependently reversed miR-204 expression, leading to disinhibition of SIRT1 and alleviation of ER stress-induced apoptosis indicated by decreased levels of p-PERK, p-IRE-1, cleaved-ATF6, Bax, cleaved caspase-12, -9, -3, and increased levels of Bcl-2 and unleaved PARP. aps 19-22 BCL2 apoptosis regulator Homo sapiens 280-285 32027268-6 2020 Western blot analysis showed that sorafenib combined with decitabine significantly up-regulated the levels of Bax/Bcl-2, P53, C-Caspase3 and C-PARP and activated apoptosis by inhibiting PI3K-AKT pathway. decitabine 58-68 BCL2 apoptosis regulator Homo sapiens 114-119 32005894-7 2020 Real time PCR results indicated that Bax /Bcl2 expression ratio as an apoptosis predicting criterion, in free AUR, AUR loaded TB and AUR loaded PB have increased 6, 9 and 13 times, respectively (p value < 0.05). aurapten 110-113 BCL2 apoptosis regulator Homo sapiens 42-46 32005894-7 2020 Real time PCR results indicated that Bax /Bcl2 expression ratio as an apoptosis predicting criterion, in free AUR, AUR loaded TB and AUR loaded PB have increased 6, 9 and 13 times, respectively (p value < 0.05). aurapten 115-118 BCL2 apoptosis regulator Homo sapiens 42-46 32005894-7 2020 Real time PCR results indicated that Bax /Bcl2 expression ratio as an apoptosis predicting criterion, in free AUR, AUR loaded TB and AUR loaded PB have increased 6, 9 and 13 times, respectively (p value < 0.05). aurapten 115-118 BCL2 apoptosis regulator Homo sapiens 42-46 32000660-8 2020 The expression of Bax/Bcl2 increased after treatment indicates that aspirin can induce apoptosis of PIK3CA-mutant CRC cells. Aspirin 68-75 BCL2 apoptosis regulator Homo sapiens 22-26 32071920-6 2020 In the study on the mechanism of action of germacrone in antiesophageal cancer, we found that germacrone increased the ratio of Bax/Bcl-2 in the cytoplasm of ESCC, resulting in the activation of Caspase-9 and Caspase-3 and decreased the expression of Grp78, thereby reducing the inhibition of Caspase-12 and Caspase-7. germacrone 43-53 BCL2 apoptosis regulator Homo sapiens 132-137 32071920-6 2020 In the study on the mechanism of action of germacrone in antiesophageal cancer, we found that germacrone increased the ratio of Bax/Bcl-2 in the cytoplasm of ESCC, resulting in the activation of Caspase-9 and Caspase-3 and decreased the expression of Grp78, thereby reducing the inhibition of Caspase-12 and Caspase-7. germacrone 94-104 BCL2 apoptosis regulator Homo sapiens 132-137 31639434-8 2020 Parallel effects were observed with bilirubin, which up-regulated apoptotic genes and CSF2 (colony-stimulating factor 2) and down-regulated antiapoptotic genes (BCL2 and BCL2L1), BMP3, BMP4 and RUNX2. Bilirubin 36-45 BCL2 apoptosis regulator Homo sapiens 161-165 31629930-0 2020 Macroporous organosilicon nanocomposites co-deliver Bcl2-converting peptide and chemotherapeutic agent for synergistic treatment against multidrug resistant cancer. Organosilicon Compounds 12-25 BCL2 apoptosis regulator Homo sapiens 52-56 31750487-3 2020 Moreover, Cu-1 dramatically inhibited the expression of the anti-apoptotic protein Bcl-2 and up-regulated the expressions of the proapoptotic proteins caspase-9 and Bax to induce the apoptosis of tumor cells, simultaneously decreasing the density of endothelial cells to inhibit tumor angiogenesis in cisplatin-resistant tumors. Copper 10-14 BCL2 apoptosis regulator Homo sapiens 83-88 31755504-7 2020 Mechanism experiments manifested that Au(i)(3c)2OTf induced the down-regulation of Bcl-2 and up-regulation of Bax, which further indicated that Au(i)(3c)2OTf triggered mitochondria-mediated apoptosis. Gold 38-51 BCL2 apoptosis regulator Homo sapiens 83-88 31755504-7 2020 Mechanism experiments manifested that Au(i)(3c)2OTf induced the down-regulation of Bcl-2 and up-regulation of Bax, which further indicated that Au(i)(3c)2OTf triggered mitochondria-mediated apoptosis. Gold 38-40 BCL2 apoptosis regulator Homo sapiens 83-88 31919522-10 2020 The observed NSC protective activity of clozapine was associated with increased expression of the anti-apoptotic marker Bcl-2 decreased expression of the pro-apoptotic cleaved form of caspase-3 and associated with decreased expression of the autophagosome marker LC3-II. Clozapine 40-49 BCL2 apoptosis regulator Homo sapiens 120-125 31866271-0 2020 A novel phytosterol isolated from Datura inoxia, RinoxiaB is a potential cure colon cancer agent by targeting BAX/Bcl2 pathway. Phytosterols 8-19 BCL2 apoptosis regulator Homo sapiens 114-118 31995555-8 2020 Notably, the triple treatment-induced cytotoxic effects and the elevated expression of p53 and p21 proteins as well as the increased Bax/Bcl-2 ratio, all could be alleviated by the ROS scavenger, N-acetyl-cysteine (NAC). Acetylcysteine 196-213 BCL2 apoptosis regulator Homo sapiens 137-142 31995555-8 2020 Notably, the triple treatment-induced cytotoxic effects and the elevated expression of p53 and p21 proteins as well as the increased Bax/Bcl-2 ratio, all could be alleviated by the ROS scavenger, N-acetyl-cysteine (NAC). Acetylcysteine 215-218 BCL2 apoptosis regulator Homo sapiens 137-142 32047442-11 2019 Moreover, TMEA upregulated the expression of proapoptotic factors Bax and caspase-3 and downregulated the expression of antiapoptotic factors CD31 and Bcl-2 in cancer cells and/or tumor tissues. 3,7,8-tri-O-methylellagic acid 10-14 BCL2 apoptosis regulator Homo sapiens 151-156 31995555-8 2020 Notably, the triple treatment-induced cytotoxic effects and the elevated expression of p53 and p21 proteins as well as the increased Bax/Bcl-2 ratio, all could be alleviated by the ROS scavenger, N-acetyl-cysteine (NAC). Reactive Oxygen Species 181-184 BCL2 apoptosis regulator Homo sapiens 137-142 31983729-11 2020 Ferulic acid reduced the levels of Bcl-2 and Mcl-1, and increased the levels of Bax and reactive oxygen species (ROS). ferulic acid 0-12 BCL2 apoptosis regulator Homo sapiens 35-40 31874162-5 2020 GA-DM treatment decreased the protein expression levels of Bcl-2 and increased the expression levels of Bax, cleaved caspase-3 and cleaved PRAP. 3,7-dioxolanosta-8,24-dien-26-oic acid 0-5 BCL2 apoptosis regulator Homo sapiens 59-64 31840727-8 2020 Meanwhile, 3KLA-TDNs/DOX elevated the pro-apoptotic Bax, reduced the anti-apoptotic Bcl-2 protein expression and increased the Bax/Bcl-2 ratio, which finally activated the mitochondria-mediated, programmed apoptosis pathway to enhance the anticancer efficacy in vitro. Doxorubicin 21-24 BCL2 apoptosis regulator Homo sapiens 84-89 31840727-8 2020 Meanwhile, 3KLA-TDNs/DOX elevated the pro-apoptotic Bax, reduced the anti-apoptotic Bcl-2 protein expression and increased the Bax/Bcl-2 ratio, which finally activated the mitochondria-mediated, programmed apoptosis pathway to enhance the anticancer efficacy in vitro. Doxorubicin 21-24 BCL2 apoptosis regulator Homo sapiens 131-136 31963815-7 2020 Furthermore, FHL2-depleted HepG2 cells showed higher expression of markers for oxidative stress, lower B-cell lymphoma 2 (Bcl2) expression, and higher Bcl2-associated X protein (BAX) expression after stimulation with deoxycholic acid (DCA). Deoxycholic Acid 217-233 BCL2 apoptosis regulator Homo sapiens 122-126 31866271-0 2020 A novel phytosterol isolated from Datura inoxia, RinoxiaB is a potential cure colon cancer agent by targeting BAX/Bcl2 pathway. rinoxiab 49-57 BCL2 apoptosis regulator Homo sapiens 114-118 31866271-9 2020 Thus, the present finding concludes that RB can offer possible apoptotic effects by targeting BAX/Bcl2 pathway in HCT 15 cells, thus alleviating colon cancer. Rubidium 41-43 BCL2 apoptosis regulator Homo sapiens 98-102 31669390-3 2020 To evaluate target engagement of BH3 mimetics in cells, we measured binding potency of ABT-199, A-1210477 and ABT-737 to Bcl-2 and Mcl-1 proteins by using a dose-response cellular thermal shift assay (CETSA), similar affinity rank-order and selectivity were obtained in comparison with in vitro binding assays. BH 3 33-36 BCL2 apoptosis regulator Homo sapiens 121-126 31669390-3 2020 To evaluate target engagement of BH3 mimetics in cells, we measured binding potency of ABT-199, A-1210477 and ABT-737 to Bcl-2 and Mcl-1 proteins by using a dose-response cellular thermal shift assay (CETSA), similar affinity rank-order and selectivity were obtained in comparison with in vitro binding assays. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 87-90 BCL2 apoptosis regulator Homo sapiens 121-126 31669390-3 2020 To evaluate target engagement of BH3 mimetics in cells, we measured binding potency of ABT-199, A-1210477 and ABT-737 to Bcl-2 and Mcl-1 proteins by using a dose-response cellular thermal shift assay (CETSA), similar affinity rank-order and selectivity were obtained in comparison with in vitro binding assays. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 110-113 BCL2 apoptosis regulator Homo sapiens 121-126 32021275-8 2020 These results were further confirmed by that TZN treatment increased the Bax/Bcl-2 ratio in A549 cells. tizanidine 45-48 BCL2 apoptosis regulator Homo sapiens 77-82 31790685-8 2020 KEY FINDINGS: Results showed that Diosgenin inhibited HaCaT cell growth through cell cycle arrest and NFkappaB inhibition while induced apoptosis by regulating Caspase3, Bax and Bcl-2 protein expression. Diosgenin 34-43 BCL2 apoptosis regulator Homo sapiens 178-183 32010177-8 2019 Suppression of SOCS1-STAT3-Bcl-2 pathway and activation of p53-Pten signaling both contribute to anti-miR-221/222-induced sensitivity to cisplatin in MDA-MB-231 cells. Cisplatin 137-146 BCL2 apoptosis regulator Homo sapiens 27-32 31837377-7 2020 Conversely, YM155 sensitized K562 cells to ABT-199 (a BCL2/BCL2L1 inhibitor), and circumvented K562 cell resistance to ABT-199 because of its inhibitory effect on survivin and MCL1 expression. venetoclax 43-50 BCL2 apoptosis regulator Homo sapiens 54-58 31688419-5 2020 Further studies demonstrated that berberine suppressed the production of intracellular reactive oxygen species, restored the mitochondrial transmembrane potential, increased Bcl-2/Bax ratio, and decreased caspase-3 activation that induced by rotenone. Berberine 34-43 BCL2 apoptosis regulator Homo sapiens 174-179 31688419-5 2020 Further studies demonstrated that berberine suppressed the production of intracellular reactive oxygen species, restored the mitochondrial transmembrane potential, increased Bcl-2/Bax ratio, and decreased caspase-3 activation that induced by rotenone. Rotenone 242-250 BCL2 apoptosis regulator Homo sapiens 174-179 31905343-6 2020 The combined treatment of aspirin and cisplatin suppressed the expression of the anti-apoptotic protein Bcl-2 and the EMT-related proteins, up-regulated the levels of the cleaved PARP and Bax, and blocked the PI3K/AKT and RAF-MEK-ERK signaling pathway. Aspirin 26-33 BCL2 apoptosis regulator Homo sapiens 104-109 31905343-6 2020 The combined treatment of aspirin and cisplatin suppressed the expression of the anti-apoptotic protein Bcl-2 and the EMT-related proteins, up-regulated the levels of the cleaved PARP and Bax, and blocked the PI3K/AKT and RAF-MEK-ERK signaling pathway. Cisplatin 38-47 BCL2 apoptosis regulator Homo sapiens 104-109 31733186-9 2020 Moreover, Linagliptin inhibited the AGEs-induced increased ratio of Bax to Bcl-2, translocation of cytochrome C from mitochondria to the cytoplasm, and release of cleaved caspase-3. linagliptin 10-21 BCL2 apoptosis regulator Homo sapiens 75-80 31907357-4 2020 Earlier clinical studies have shown that the combined BCL-2/BCL-XL/BCL-W inhibitor, Navitoclax (ABT-263) induces severe thrombocytopenia caused by direct platelet demise and counteracted by increased megakaryopoiesis. navitoclax 96-103 BCL2 apoptosis regulator Homo sapiens 54-59 32106804-5 2020 Several mechanisms account for anticancer activity of puerarin which include downregulation of NF-kB signalling pathway, mTOR signalling pathway, PI3K and BCl-2 proteins and upregulation of miR-16, caspase proteins, c-Jun N terminal kinase and extracellular signal regulated kinase 1/2. puerarin 54-62 BCL2 apoptosis regulator Homo sapiens 155-160 31906574-6 2020 Results: Diosmetin inhibited U251 cell proliferation, migration, and invasion in vitro, the TGF-beta signaling pathway, and Bcl-2 expression. diosmetin 9-18 BCL2 apoptosis regulator Homo sapiens 124-129 32013837-7 2020 RESULTS: Here, we reported that pisosterol markedly induced G2/M arrest and apoptosis and decreased the cell viability and proliferation potential of glioma cells in a dose-dependent manner by increasing the expression of ATM, CASP3, CDK1, CDKN1A, CDKN2A, CDKN2B, CHEK1, p14ARF and TP53 and decreasing the expression of MYC, BCL2, BMI1 and MDM2. pisosterol 32-42 BCL2 apoptosis regulator Homo sapiens 325-329 31936679-11 2020 To further substantiate the mechanism of cell death mediated by endoplasmic reticulum stress (ERS), we determined the expression of the inositol-requiring enzyme (IRE1), (PKR-like ER kinase) PERK, activating transcription factor 6 (ATF6), and activating transcription factor 4 ATF4, the apoptotic markers p53, Bax, and caspase 3, and the anti-apoptotic marker Bcl-2. Inositol 136-144 BCL2 apoptosis regulator Homo sapiens 360-365 31958042-9 2020 Amygdalin treatment induced cell cycle arrest at G2/M and increased the levels of P53, Bax, cytochrome c, and caspase-3 significantly, while it decreased the level of anti-apoptotic Bcl2. Amygdalin 0-9 BCL2 apoptosis regulator Homo sapiens 182-186 32357825-10 2020 The expression of caspase-3, p53 and Bax were increased and the expression of Bcl2 was decreased with epirubicin treatment on human bladder cells, which were analyzed by western blot. Epirubicin 102-112 BCL2 apoptosis regulator Homo sapiens 78-82 31634424-11 2020 Fisetin reduced the expression of Bcl2, and elevated levels of Bax, caspase-3, and PARP and thus induced apoptosis in HepG2 cells. fisetin 0-7 BCL2 apoptosis regulator Homo sapiens 34-38 32013837-8 2020 Pisosterol also triggered both caspase-independent and caspase-dependent apoptotic pathways by regulating the expression of Bcl-2 and activating caspase-3 and p53. pisosterol 0-10 BCL2 apoptosis regulator Homo sapiens 124-129 32357825-12 2020 CONCLUSION: Epirubicin induced apoptosis in human bladder cancer cells by up-regulating the expression of pro-apoptotic factors (caspase-3, p53 and Bax) and down-regulating the expression of anti-apoptotic factor (Bcl-2). Epirubicin 12-22 BCL2 apoptosis regulator Homo sapiens 214-219 31654873-0 2020 Corrigendum to "Nanoformulated ABT-199 to effectively target Bcl-2 at mitochondrial membrane alleviates airway inflammation by inducing apoptosis" [Biomaterials 192 (2019) 429-439]. 2-(4'-diethylaminophenyl)benzothiazole 31-34 BCL2 apoptosis regulator Homo sapiens 61-66 31785856-9 2020 Apoptosis induction triggered by this flavonoid was blocked by overexpression of the anti-apoptotic protein Bcl-2. Flavonoids 38-47 BCL2 apoptosis regulator Homo sapiens 108-113 31707351-7 2020 In conclusion, 6Br-6a effectively inhibited activation of STAT3 and induced cell cycle arrest and apoptosis via regulating cyclin D1 and Bcl-2 expression. 6br-6a 15-21 BCL2 apoptosis regulator Homo sapiens 137-142 32009115-5 2020 Flow cytometry assay revealed that PTE potently induced the apoptosis of RCC cells in a concentration-dependent manner, which was also testified by up-regulation of the pro-apoptosis-related protein (Cyto C, Bad, Bak, Bax, Cleaved-caspase 3, Cleaved-caspase 9, Cleaved-poly(ADP-ribose)polymerase (PARP)) and down-regulation of the anti-apoptosis-related protein Bcl-2. pterostilbene 35-38 BCL2 apoptosis regulator Homo sapiens 362-367 33164541-10 2020 It was found that propranolol treatment enhanced the activity of caspase-3 while the expression of bax, wee1, gadd153, grp78 and AIF decreased bcl-2 which is antiapoptotic protein in cSCC cell lines. Propranolol 18-29 BCL2 apoptosis regulator Homo sapiens 143-148 31586626-9 2020 In addition, treatment with OGD decreases mRNA levels of AMPK and the neuroprotective genes (Bcl-2 and CREB); however, co-treatment with resveratrol significantly normalizes these effects. resveratrol 137-148 BCL2 apoptosis regulator Homo sapiens 93-98 32348428-7 2020 Further in vitro assays showed that PDT with 5-ALA-GNPs significantly decreased expression of STAT3 and Bcl-2 and increased expression of Bax in A431 cells compared with PDT with 5-ALA. 5-amino levulinic acid 45-50 BCL2 apoptosis regulator Homo sapiens 104-109 31950839-8 2020 Noscapine showed anti-proliferative effects by decreasing Ki-67, cyclin-D1 and apoptotic effects by increasing BAX/Bcl-2 ratio in both breast cancer cells. Noscapine 0-9 BCL2 apoptosis regulator Homo sapiens 115-120 31691320-11 2020 Incubation with myricetin decreased the protein expression levels of Bax, whereas it increased the expression levels of the Bcl-2, compared with HG treatment alone. myricetin 16-25 BCL2 apoptosis regulator Homo sapiens 124-129 32401925-4 2020 Results demonstrated that beta-elemene+paclitaxel induced apoptosis of SKOV3 cells, down-regulated anti-apoptotic Bcl-2 and Bcl-xl gene expression and up-regulated pro-apoptotic P53 and Apaf1 gene expression in SKOV3 cells. beta-elemene 26-38 BCL2 apoptosis regulator Homo sapiens 114-119 32401925-4 2020 Results demonstrated that beta-elemene+paclitaxel induced apoptosis of SKOV3 cells, down-regulated anti-apoptotic Bcl-2 and Bcl-xl gene expression and up-regulated pro-apoptotic P53 and Apaf1 gene expression in SKOV3 cells. Paclitaxel 39-49 BCL2 apoptosis regulator Homo sapiens 114-119 31673827-8 2020 The expression levels of BCL-2 and BUFFY genes which are anti-apoptotic in human and fruit flies have been reduced, and at the same time, increased expression of DECAY, FADD, RAS64B apoptotic genes in D. melanogaster. CD55 Antigens 162-167 BCL2 apoptosis regulator Homo sapiens 25-30 31678753-5 2020 Moreover, pretreatment with gamma-oryzanol inhibited H2O2-induced apoptosis by restoring MMP, upregulating the expression ratio of Bcl-2/Bax, and inhibiting the activation of caspase-9 and caspase-3. gamma-oryzanol 28-42 BCL2 apoptosis regulator Homo sapiens 131-136 31678753-5 2020 Moreover, pretreatment with gamma-oryzanol inhibited H2O2-induced apoptosis by restoring MMP, upregulating the expression ratio of Bcl-2/Bax, and inhibiting the activation of caspase-9 and caspase-3. Hydrogen Peroxide 53-57 BCL2 apoptosis regulator Homo sapiens 131-136 31691320-13 2020 It is concluded that myricetin may protect HUVECs from oxidative stress induced by HG via increasing cell TAC and reducing Bax/Bcl-2 protein ratio, and caspase-3 expression. myricetin 21-30 BCL2 apoptosis regulator Homo sapiens 127-132 30417790-1 2020 This investigation evaluates the pro-apoptotic and anti-inflammatory effects of beta-D-mannuronic acid [M2000] compared to diclofenac, based on gene expression involved in apoptosis and inflammation process [including Bcl2, NFkappaB, IL-8 and Cd49d] in peripheral blood mononuclear cells [PBMCs] of healthy donors under exvivo conditions. mannuronic acid 80-102 BCL2 apoptosis regulator Homo sapiens 218-222 32999148-5 2020 In MCF-7 cells, DABO-Me upregulated the pro-apoptotic protein Bax, downregulated the anti-apoptotic protein Bcl-2, promoted the release of cytochrome c, and activated caspase-3/9. dabo-me 16-23 BCL2 apoptosis regulator Homo sapiens 108-113 33477155-10 2020 The use of venetoclax as a single drug to treat DLBCL BCL2 patients deserves further investigation. venetoclax 11-21 BCL2 apoptosis regulator Homo sapiens 54-58 31698073-2 2020 We enrolled a cohort of 15 GA-treated patients and measured the expression of JNK1, JNK2, phospho-JNK and phospho-Bcl-2 through Western blotting of lysates from peripheral blood mononuclear cells collected at 0, 3, 6, and 12 months after initiating GA therapy. phosphorylleucylphenylalanine 106-113 BCL2 apoptosis regulator Homo sapiens 114-119 31698073-3 2020 We found significantly higher levels of JNK1 p54 and JNK2 p54 and significantly lower levels of p-Bcl-2 in relapse patients and in GA non-responders. glatiramer acetate 131-133 BCL2 apoptosis regulator Homo sapiens 98-103 31698073-4 2020 By using receiver operating characteristic analysis, we found that the probability of accurately detecting relapse and response to GA was: 92% and 75.5%, respectively, for JNK1 p54 and 86% and 94.6%, respectively, for p-Bcl-2. glatiramer acetate 131-133 BCL2 apoptosis regulator Homo sapiens 220-225 31698073-5 2020 Our data suggest that JNK1 and p-Bcl-2 could serve as potential biomarkers for MS relapse and the therapeutic response to GA. glatiramer acetate 122-124 BCL2 apoptosis regulator Homo sapiens 33-38 31957857-6 2020 Propofol could repress the expression of Bcl-2 and up-regulate the expression levels of Caspase-3, Bax, and phosphorylated ERK1/2. Propofol 0-8 BCL2 apoptosis regulator Homo sapiens 41-46 31880257-4 2020 The BCL-2 family includes both pro- and anti-apoptotic proteins, which are structurally and functionally related, containing up to four BCL-2 homology (BH) motifs (BH1-4). BH 3 164-169 BCL2 apoptosis regulator Homo sapiens 4-9 31880257-4 2020 The BCL-2 family includes both pro- and anti-apoptotic proteins, which are structurally and functionally related, containing up to four BCL-2 homology (BH) motifs (BH1-4). BH 3 164-169 BCL2 apoptosis regulator Homo sapiens 136-141 31969092-11 2020 Lupeol, through altering the expression levels of BCL-2, BAX, Survivin, FAS, Caspases, and PI3K-AKT-mTOR signaling pathway, significantly induce cell deaths among therapy-resistant cells. lupeol 0-6 BCL2 apoptosis regulator Homo sapiens 50-55 31789392-13 2020 Importantly, treatment with a pan-caspase inhibitor (z-VAD-fmk) significantly attenuated compound 7a-induced apoptosis, caspase-9 and -3 activation, PARP cleavage, generation of cleaved Bcl-2 and downregulation of Mcl-1 and XIAP in MV4-11 cells. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 53-62 BCL2 apoptosis regulator Homo sapiens 186-191 32016998-5 2020 RESULTS: Compared with the Control group, Rapamycin group, and Rapamycin + Beclin-1 plasmid transfection group had markedly weakened the viability of MG-63 cells, inhibited cell proliferation, remarkably increased cell apoptosis rate, elevated Bax level, notably declined Bcl-2 level, and significantly raised the levels of Beclin-1 and Vps34 proteins in MG-63 cells. Sirolimus 63-72 BCL2 apoptosis regulator Homo sapiens 272-277 31736281-5 2020 Of these genes, ABCG2, AHNAK2, BCL2, FZD1, and TP73 are associated with published evidence for resistance to 5-fluorouracil and cisplatin. Fluorouracil 109-123 BCL2 apoptosis regulator Homo sapiens 31-35 31736281-5 2020 Of these genes, ABCG2, AHNAK2, BCL2, FZD1, and TP73 are associated with published evidence for resistance to 5-fluorouracil and cisplatin. Cisplatin 128-137 BCL2 apoptosis regulator Homo sapiens 31-35 33745261-0 2020 Genistein Induces Bcl-2 Expression in Human Dermal Microvascular Endothelial Cells: a Short Report. Genistein 0-9 BCL2 apoptosis regulator Homo sapiens 18-23 33745261-1 2020 It has been shown previously that oestradiol protects the vascular network, leading to increased skin flap viability associated with Bcl-2, VEGF and FGF-2 up-regulation. Estradiol 34-44 BCL2 apoptosis regulator Homo sapiens 133-138 33745261-3 2020 In the present study we aimed to answer the question whether genistein increases expression of Bcl-2, a potent anti-apoptotic protein, in human dermal microvascular endothelial cells (HMVEC-d) as well. Genistein 61-70 BCL2 apoptosis regulator Homo sapiens 95-100 33745261-4 2020 Our results showed that administration of genistein induces Bcl-2 expression in a concentration-dependent manner. Genistein 42-51 BCL2 apoptosis regulator Homo sapiens 60-65 33745261-5 2020 Cell co-treatment with genistein and anti-ER compounds (MPP, PHTPP, ICI, G-15) diminished the observed positive effect of genistein on Bcl-2 expression. Genistein 23-32 BCL2 apoptosis regulator Homo sapiens 135-140 33745261-5 2020 Cell co-treatment with genistein and anti-ER compounds (MPP, PHTPP, ICI, G-15) diminished the observed positive effect of genistein on Bcl-2 expression. Genistein 122-131 BCL2 apoptosis regulator Homo sapiens 135-140 33745261-6 2020 The decrease in Bcl-2 expression in HMVEC-d was most prominent after co-treatment with ICI (nuclear ER antagonist/ GPR30 agonist) and PHTPP (selective ER-beta antagonist). PHTPP 134-139 BCL2 apoptosis regulator Homo sapiens 16-21 33745261-7 2020 In conclusion, genistein increases Bcl-2 expression in HMVEC-d, contributing to its protective effect on the skin flap viability. Genistein 15-24 BCL2 apoptosis regulator Homo sapiens 35-40 32247577-7 2020 BOK, a BCL-2 family protein thought comparable to multidomain pro-apoptotic proteins BAX and BAK, has recently been identified as a key player in metabolism of and resistance to the commonly used chemotherapeutic 5-FU. Fluorouracil 213-217 BCL2 apoptosis regulator Homo sapiens 7-12 32247581-4 2020 We also provide an overview of the direct blocking of protein-protein interactions with pro-apoptotic Bcl-2 family proteins, including examples of the most promising regulators of Mcl-1 and selective BH3-mimetics, which at present are under clinical evaluation. BH 3 200-203 BCL2 apoptosis regulator Homo sapiens 102-107 31669405-9 2020 After steroid treatment of damaged retinas, BCL-XL, BCL2 and BAX showed characteristic patterns depending on the use of dexamethasone or progesterone on mifepristone or light exposed retinas. Steroids 6-13 BCL2 apoptosis regulator Homo sapiens 52-56 31669405-9 2020 After steroid treatment of damaged retinas, BCL-XL, BCL2 and BAX showed characteristic patterns depending on the use of dexamethasone or progesterone on mifepristone or light exposed retinas. Dexamethasone 120-133 BCL2 apoptosis regulator Homo sapiens 52-56 31669405-9 2020 After steroid treatment of damaged retinas, BCL-XL, BCL2 and BAX showed characteristic patterns depending on the use of dexamethasone or progesterone on mifepristone or light exposed retinas. Progesterone 137-149 BCL2 apoptosis regulator Homo sapiens 52-56 31669405-9 2020 After steroid treatment of damaged retinas, BCL-XL, BCL2 and BAX showed characteristic patterns depending on the use of dexamethasone or progesterone on mifepristone or light exposed retinas. Mifepristone 153-165 BCL2 apoptosis regulator Homo sapiens 52-56 31765699-6 2020 After ligustilide treatment, the proportion of CAFs in the G2-M phase of the cell cycle increased, and the expression of apoptosis-related proteins (p-P53, Bcl-2, Caspase9 and Cytochrome C) changed. ligustilide 6-17 BCL2 apoptosis regulator Homo sapiens 156-161 32608501-8 2020 Western blotting analysis showed that GLA treatment decreased the expression of proliferating cell nuclear antigen (PCNA), microchromosome maintenance complex component 2 (MCM-2) and anti-apoptotic protein Bcl-2, while increased the expression of pro-apoptotic proteins (Bax and Cleaved Caspase-3) (p < 0.05 and p < 0.01). gamma-Linolenic Acid 38-41 BCL2 apoptosis regulator Homo sapiens 206-211 32405344-8 2020 Crocin can induce apoptosis through activation of caspase 8, up-regulation of p53 expression, Bax/Bcl-2 ratio, and down-regulation expression of Bcl-2, survivin, and cyclin D1. crocin 0-6 BCL2 apoptosis regulator Homo sapiens 98-103 32405344-8 2020 Crocin can induce apoptosis through activation of caspase 8, up-regulation of p53 expression, Bax/Bcl-2 ratio, and down-regulation expression of Bcl-2, survivin, and cyclin D1. crocin 0-6 BCL2 apoptosis regulator Homo sapiens 145-150 32277668-8 2020 The AO/EB staining assay showed that Auraptenol inhibited the viability of cancer cells via induction of apoptotic cell death, which was associated with increase in Bax and decrease in Bcl-2 levels. auraptenol 37-47 BCL2 apoptosis regulator Homo sapiens 185-190 32277640-9 2020 Western blot showed that flavokawain-B resulted in downregulation of Bcl-2 and upregulation of Bax in a dose dependent manner. flavokawain B 25-38 BCL2 apoptosis regulator Homo sapiens 69-74 32277642-12 2020 Additionally, Heptaphylline caused increase in Bax and decrease in Bcl-2 expression. heptaphylline 14-27 BCL2 apoptosis regulator Homo sapiens 67-72 32277643-9 2020 Further, the apoptotic effects of limonene were also confirmed by Western blot analysis and the results showed increase in the expression of Bax and caspase-3 and decrease of Bcl-2 expression. Limonene 34-42 BCL2 apoptosis regulator Homo sapiens 175-180 32277651-9 2020 The anticancer effects of Withaferin-A were mainly due to the induction of apoptosis which was linked with upsurge of Bax and depletion of BCl-2. withaferin A 26-38 BCL2 apoptosis regulator Homo sapiens 139-144 31197979-10 2020 Consistently, KL protein reversed the expression levels of the increased pro-apoptotic protein Bax and the decreased anti-apoptotic protein Bcl-2 induced by PA. Palmitic Acid 157-159 BCL2 apoptosis regulator Homo sapiens 140-145 32865918-11 2020 AOAA treatment also led to a significant decrease in Bcl-2 expression and dramatic increase in Caspase-3 expression, though NaHS reversed these effects. Aminooxyacetic Acid 0-4 BCL2 apoptosis regulator Homo sapiens 53-58 32897819-7 2020 Further analyses of the expression of apoptosis-related genes and proteins indicated that miR-96-5p may function to reduce malathion-induced HK-2 cell apoptosis via regulation of the DDIT3/B-cell lymphoma (BCL)-2/caspase-3 signaling pathway. Malathion 123-132 BCL2 apoptosis regulator Homo sapiens 183-212 31573118-7 2020 In addition, beta-carotene decreased the activation of GRP78, CHOP, and JNK/p38 MAPK and the ratio of Bax/Bcl-2. beta Carotene 13-26 BCL2 apoptosis regulator Homo sapiens 106-111 31573118-9 2020 In the present study, beta-carotene pre-treatment attenuated the ratio of Bax/Bcl-2 and prevented TG-induced increases in the level of PERK-CHOP and IRE1-JNK/p38 MAPK pathway activation in a dose-dependent manner. beta Carotene 22-35 BCL2 apoptosis regulator Homo sapiens 78-83 32277638-11 2020 The anticancer effects of levopimaric acid were due to induction of apoptosis which was also associated with modulation of apoptosis-related proteins (Bax and Bcl-2). Levopimaric acid 26-42 BCL2 apoptosis regulator Homo sapiens 159-164 32277673-12 2020 DAPI and annexin V/PI staining assays showed that Daidzein prompted apoptosis in A-375 melanoma cells which was concomitant with depletion of Bcl-2, increase of Bax and activation of cleavage of caspase-3 and caspase-9. daidzein 50-58 BCL2 apoptosis regulator Homo sapiens 142-147 32508446-4 2020 Materials and Methods: Cytotoxic effect of SA was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte trazolium bromide assay, using concentrations of 25 and 50 muM/mL for 24 h. At the end of the treatment period, apoptotic markers such as caspase 3 and 9, bcl-2, bax and cytochrome c were evaluated by semiquantitative reverse transcription-polymerase chain reaction. syringic acid 43-45 BCL2 apoptosis regulator Homo sapiens 263-268 32095097-7 2020 Furthermore, oleanolic acid 3-acetate induced apoptotic cell death as revealed by loss of DeltaPsim, release of cytochrome c, and nuclear translocation of apoptosis-inducing factor with a concomitant activation of many proapoptotic cellular components including poly(ADP-ribose) polymerase, Bcl-2, and caspases-8, caspase-3, and caspase-7. oleanolic acid 3-acetate 13-37 BCL2 apoptosis regulator Homo sapiens 291-296 31603717-7 2020 PCB2 inhibited LPS-induced Bax and active caspase-3 expression, and promoted Bcl-2 expression. procyanidin B 0-4 BCL2 apoptosis regulator Homo sapiens 77-82 31958096-13 2020 Importantly, we found DA-CH5 was superior to Liraglutide in reducing microglia and astrocyte activation, improving mitochondrial activity by reducing the Bax/Bcl-2 ratio and normalising autophagy as found in abnormal expression of LC3 and p62. JMV 641 25-28 BCL2 apoptosis regulator Homo sapiens 158-163 32508446-8 2020 SA treatments modulated bcl-2/bax homeostasis and increased the expressions of cytochrome c and caspases 3 and 9. syringic acid 0-2 BCL2 apoptosis regulator Homo sapiens 24-29 31171817-6 2020 Finally, (-)-SDS-1-021, the most promising synthetic rocaglate, was confirmed to be highly potent as a single agent, and displayed significant synergy with the BCL2 inhibitor ABT199 in inhibiting tumor growth and survival in primary lymphoma cells in vitro and in patient-derived xenograft mouse models. (-)-sds-1-021 9-22 BCL2 apoptosis regulator Homo sapiens 160-164 31171817-6 2020 Finally, (-)-SDS-1-021, the most promising synthetic rocaglate, was confirmed to be highly potent as a single agent, and displayed significant synergy with the BCL2 inhibitor ABT199 in inhibiting tumor growth and survival in primary lymphoma cells in vitro and in patient-derived xenograft mouse models. venetoclax 175-181 BCL2 apoptosis regulator Homo sapiens 160-164 31300747-2 2020 We screened a library of clinical drugs on a cohort of primary human AML specimens and identified the BCL2 inhibitor ABT-199 as a selective agent against NPM1c+ AML. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 117-120 BCL2 apoptosis regulator Homo sapiens 102-106 31753388-5 2020 In vitro release result indicated that DOX was released from HA-SeNPs faster in acidic environment in comparison with normal physiological environment and 76.9% DOX was released in pH 5.4 during initial 30 h. HA-Se@DOX showed high activity to inhibit HeLa cell proliferation and triggered HeLa cell apoptosis via activating Bcl-2 signaling pathway. Doxorubicin 39-42 BCL2 apoptosis regulator Homo sapiens 324-329 31753388-5 2020 In vitro release result indicated that DOX was released from HA-SeNPs faster in acidic environment in comparison with normal physiological environment and 76.9% DOX was released in pH 5.4 during initial 30 h. HA-Se@DOX showed high activity to inhibit HeLa cell proliferation and triggered HeLa cell apoptosis via activating Bcl-2 signaling pathway. Selenium 64-66 BCL2 apoptosis regulator Homo sapiens 324-329 31753388-5 2020 In vitro release result indicated that DOX was released from HA-SeNPs faster in acidic environment in comparison with normal physiological environment and 76.9% DOX was released in pH 5.4 during initial 30 h. HA-Se@DOX showed high activity to inhibit HeLa cell proliferation and triggered HeLa cell apoptosis via activating Bcl-2 signaling pathway. Doxorubicin 161-164 BCL2 apoptosis regulator Homo sapiens 324-329 31753388-5 2020 In vitro release result indicated that DOX was released from HA-SeNPs faster in acidic environment in comparison with normal physiological environment and 76.9% DOX was released in pH 5.4 during initial 30 h. HA-Se@DOX showed high activity to inhibit HeLa cell proliferation and triggered HeLa cell apoptosis via activating Bcl-2 signaling pathway. Selenium 212-214 BCL2 apoptosis regulator Homo sapiens 324-329 31753388-5 2020 In vitro release result indicated that DOX was released from HA-SeNPs faster in acidic environment in comparison with normal physiological environment and 76.9% DOX was released in pH 5.4 during initial 30 h. HA-Se@DOX showed high activity to inhibit HeLa cell proliferation and triggered HeLa cell apoptosis via activating Bcl-2 signaling pathway. Doxorubicin 161-164 BCL2 apoptosis regulator Homo sapiens 324-329 31420720-7 2020 Moreover, norfloxacin induced extrinsic death receptor-mediated apoptosis pathway by activating caspase-2/-8/-3 and intrinsic mitochondrion-dependent apoptosis pathway by downregulating anti-apoptotic Bcl-2 and upregulating of pro-apoptotic Bad, which disrupted mitochondrial transmembrane potential, subsequently upregulated cytoplasmic cytochrome c and apoptosis-inducing factor and finally activated caspase-9/-3. Norfloxacin 10-21 BCL2 apoptosis regulator Homo sapiens 201-206 31918235-9 2020 The autophagy (Beclin-1, LC3-I, LC3-II and ATG4B) and apoptotic (Bax, Bcl-2 and Caspase-3) proteins were regulated by the treatment with ZnONPs in SH-SY5Y neuroblastoma cells. znonps 137-143 BCL2 apoptosis regulator Homo sapiens 70-75 31295040-7 2020 For signaling mechanism, the western blotting results showed elevated p38 MAPK activation, and the reduced Bcl-2 and enhanced Bax upon hesperetin treatment were partly reversed by p38 MAPK inhibitor SB203580. SB 203580 199-207 BCL2 apoptosis regulator Homo sapiens 107-112 31897130-9 2020 PPI network analysis screened out key genes, including acetyl-CoA carboxylase beta, cyclin D1, BCL2, and serpin peptidase inhibitor clade A member 1, which may serve important roles in PTC pathogenesis. Acetyl Coenzyme A 55-65 BCL2 apoptosis regulator Homo sapiens 95-99 31163997-9 2020 Mechanistically, CSO effectively induced expression of pro-apoptotic cleaved caspase-3 and cleaved caspase-9 and down-regulated anti-apoptotic Bcl-2. CSO 17-20 BCL2 apoptosis regulator Homo sapiens 143-148 31786318-10 2020 RESULTS: The results showed that Dulcitol inhibited HepG2 cells proliferation by down-regulating the protein expression of SIRT1, Bcl-2, along with up-regulating p53, acetylated-p53 (K382), cleaved-caspase9, cleaved-caspase3, Bax, and cytochrome c in a dose-dependent manner. Galactitol 33-41 BCL2 apoptosis regulator Homo sapiens 130-135 32079013-12 2020 Importantly, BBM dose-dependently increased the BAX/BCL-2 ratio and induced apoptosis in HFTF cells. berbamine 13-16 BCL2 apoptosis regulator Homo sapiens 52-57 33927788-3 2020 Epidemiological studies have shown that nicotine consumption decreases PD prevalence through neuroprotective mechanisms activation associated with the overstimulation of signaling pathways (SP) such as PI3K/AKT through nicotinic acetylcholine receptors (e.g alpha7 nAChRs) and over-expression of anti-apoptotic genes such as Bcl-2. Nicotine 40-48 BCL2 apoptosis regulator Homo sapiens 325-330 33927788-3 2020 Epidemiological studies have shown that nicotine consumption decreases PD prevalence through neuroprotective mechanisms activation associated with the overstimulation of signaling pathways (SP) such as PI3K/AKT through nicotinic acetylcholine receptors (e.g alpha7 nAChRs) and over-expression of anti-apoptotic genes such as Bcl-2. Acetylcholine 229-242 BCL2 apoptosis regulator Homo sapiens 325-330 33927788-9 2020 Results: Our model was able to predict the potential neuroprotective activity of seven new nicotine analogs based on the binomial Bcl-2 response regulated by the activation of PI3K/AKT. Nicotine 91-99 BCL2 apoptosis regulator Homo sapiens 130-135 29796873-10 2020 We found that atorvastatin and caffeine in combination downregulated phospho-Akt, phospho-Erk1/2, anti-apoptotic Bcl-2 and Survivin protein levels. Atorvastatin 14-26 BCL2 apoptosis regulator Homo sapiens 113-118 29796873-10 2020 We found that atorvastatin and caffeine in combination downregulated phospho-Akt, phospho-Erk1/2, anti-apoptotic Bcl-2 and Survivin protein levels. Caffeine 31-39 BCL2 apoptosis regulator Homo sapiens 113-118 32406319-6 2020 Desloratadine promoted cell apoptosis via modulating the expression of Bcl-2, Bax, cleaved caspase 3, and cleaved caspase 9 in EJ and SW780 cells. desloratadine 0-13 BCL2 apoptosis regulator Homo sapiens 71-76 32065108-7 2020 In Sodium sulphite and boric acid treated cells, expression levels of p53 was up-regulated, while that of the Bcl2 was significantly down-regulated. sodium sulfite 3-18 BCL2 apoptosis regulator Homo sapiens 110-114 32065108-7 2020 In Sodium sulphite and boric acid treated cells, expression levels of p53 was up-regulated, while that of the Bcl2 was significantly down-regulated. boric acid 23-33 BCL2 apoptosis regulator Homo sapiens 110-114 32065108-8 2020 On the other hand, Benzoic acid has shown an anti-apoptotic feature based on the increased expression levels of Bcl-2 in treated cells. Benzoic Acid 19-31 BCL2 apoptosis regulator Homo sapiens 112-117 32215462-2 2020 OBJECTIVES: To evaluate the expression of hormone receptors and markers for proliferation/apoptosis (Ki-67 and Bcl-2) in endometrial polyps in postmenopausal users and nonusers of tamoxifen. Tamoxifen 180-189 BCL2 apoptosis regulator Homo sapiens 111-116 33441515-6 2020 In the patients with BPDCN, BCL-2 was highly expressed in all regions with evidence of tumor cell infiltration, such as skin, bone marrow, and lymph node. bpdcn 21-26 BCL2 apoptosis regulator Homo sapiens 28-33 31672611-9 2020 The rate of DRG cell apoptosis and the expression of gammaH2ax, the ratio of Bax to Bcl-2 also increased under the high-glucose conditions. Glucose 120-127 BCL2 apoptosis regulator Homo sapiens 84-89 31521883-10 2020 Gene expression analysis revealed that the expression of several autophagy related genes (LAMP2, pATG5, and LC3) increased, while the Bax/Bcl2 ratio and pro-apoptotic Bak transcript levels were decreased in the trehalose-treated group. Trehalose 211-220 BCL2 apoptosis regulator Homo sapiens 138-142 31881855-13 2019 Combination drug screening identified the Bcl-2/Bcl-XL inhibitor Navitoclax as a compound that potentiated GQC-05 activity. navitoclax 65-75 BCL2 apoptosis regulator Homo sapiens 42-47 31906234-1 2019 ABT-737, a B cell lymphoma-2 (Bcl-2) family inhibitor, activates apoptosis in cancer cells. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 11-28 31906234-1 2019 ABT-737, a B cell lymphoma-2 (Bcl-2) family inhibitor, activates apoptosis in cancer cells. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 30-35 31906029-8 2019 Disruption of the mitochondrial membrane potential and an increase in B-cell lymphoma-2 (Bcl-2) protein phosphorylation (pBcl-2; Ser70) by TAX and NOC were prevented by adding the PERK inhibitor GSK and JNK inhibitor SP and JNKI. Nocodazole 147-150 BCL2 apoptosis regulator Homo sapiens 70-87 31906029-8 2019 Disruption of the mitochondrial membrane potential and an increase in B-cell lymphoma-2 (Bcl-2) protein phosphorylation (pBcl-2; Ser70) by TAX and NOC were prevented by adding the PERK inhibitor GSK and JNK inhibitor SP and JNKI. Nocodazole 147-150 BCL2 apoptosis regulator Homo sapiens 89-94 31906029-8 2019 Disruption of the mitochondrial membrane potential and an increase in B-cell lymphoma-2 (Bcl-2) protein phosphorylation (pBcl-2; Ser70) by TAX and NOC were prevented by adding the PERK inhibitor GSK and JNK inhibitor SP and JNKI. 7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine 195-198 BCL2 apoptosis regulator Homo sapiens 70-87 31906029-8 2019 Disruption of the mitochondrial membrane potential and an increase in B-cell lymphoma-2 (Bcl-2) protein phosphorylation (pBcl-2; Ser70) by TAX and NOC were prevented by adding the PERK inhibitor GSK and JNK inhibitor SP and JNKI. 7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine 195-198 BCL2 apoptosis regulator Homo sapiens 89-94 31906029-8 2019 Disruption of the mitochondrial membrane potential and an increase in B-cell lymphoma-2 (Bcl-2) protein phosphorylation (pBcl-2; Ser70) by TAX and NOC were prevented by adding the PERK inhibitor GSK and JNK inhibitor SP and JNKI. pyrazolanthrone 217-219 BCL2 apoptosis regulator Homo sapiens 70-87 31906029-8 2019 Disruption of the mitochondrial membrane potential and an increase in B-cell lymphoma-2 (Bcl-2) protein phosphorylation (pBcl-2; Ser70) by TAX and NOC were prevented by adding the PERK inhibitor GSK and JNK inhibitor SP and JNKI. pyrazolanthrone 217-219 BCL2 apoptosis regulator Homo sapiens 89-94 31912704-4 2019 Both diazoxide and diphenyleneiodonium increased cell viability by inhibiting the increase in reactive oxygen species and caspase-3 activity as well as the decrease in Bcl-2 induced by amyloid beta. Diazoxide 5-14 BCL2 apoptosis regulator Homo sapiens 168-173 31912704-4 2019 Both diazoxide and diphenyleneiodonium increased cell viability by inhibiting the increase in reactive oxygen species and caspase-3 activity as well as the decrease in Bcl-2 induced by amyloid beta. diphenyleneiodonium 19-38 BCL2 apoptosis regulator Homo sapiens 168-173 31920345-9 2019 Resveratrol increases levels of cleaved-caspase 3 protein as well as decreases levels of pro-caspase 3 protein and Bcl-2 mRNA. resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 115-120 31920345-12 2019 Conclusion: Resveratrol suppresses proliferation and induces apoptosis in meningioma cells by upregulating miR-34a-3p, which in turn downregulates Bcl-2. resveratrol 12-23 BCL2 apoptosis regulator Homo sapiens 147-152 31889909-13 2019 Conclusion: Our data suggested that miR-149 suppressed cell proliferation and improved Dox chemosensitivity by regulating CDC42 and BCL2 in NB, providing a novel avenue for treatment of NB. Doxorubicin 87-90 BCL2 apoptosis regulator Homo sapiens 132-136 31906029-8 2019 Disruption of the mitochondrial membrane potential and an increase in B-cell lymphoma-2 (Bcl-2) protein phosphorylation (pBcl-2; Ser70) by TAX and NOC were prevented by adding the PERK inhibitor GSK and JNK inhibitor SP and JNKI. seryl-seryl-seryl-arginine 129-132 BCL2 apoptosis regulator Homo sapiens 70-87 31906029-8 2019 Disruption of the mitochondrial membrane potential and an increase in B-cell lymphoma-2 (Bcl-2) protein phosphorylation (pBcl-2; Ser70) by TAX and NOC were prevented by adding the PERK inhibitor GSK and JNK inhibitor SP and JNKI. seryl-seryl-seryl-arginine 129-132 BCL2 apoptosis regulator Homo sapiens 89-94 31906029-8 2019 Disruption of the mitochondrial membrane potential and an increase in B-cell lymphoma-2 (Bcl-2) protein phosphorylation (pBcl-2; Ser70) by TAX and NOC were prevented by adding the PERK inhibitor GSK and JNK inhibitor SP and JNKI. Paclitaxel 139-142 BCL2 apoptosis regulator Homo sapiens 70-87 31906029-8 2019 Disruption of the mitochondrial membrane potential and an increase in B-cell lymphoma-2 (Bcl-2) protein phosphorylation (pBcl-2; Ser70) by TAX and NOC were prevented by adding the PERK inhibitor GSK and JNK inhibitor SP and JNKI. Paclitaxel 139-142 BCL2 apoptosis regulator Homo sapiens 89-94 31892217-4 2019 beta-cryptoxanthin-treated HeLa cells exhibited enhanced levels of oxidative stress correlated with significant downregulation of anti-apoptotic Bcl-2, and upregulation of pro-apoptotic Bax mRNA expression. Cryptoxanthins 0-18 BCL2 apoptosis regulator Homo sapiens 145-150 31881855-17 2019 Treatment with both GQC-05 with a Bcl-2/Bcl-XL inhibitor Navitoclax results in increased cytotoxic activity, which is more pronounced than Navitoclax or GQC-05 alone, and more significant than Navitoclax in combination with cytarabine and doxorubicin that are currently being used clinically. Doxorubicin 239-250 BCL2 apoptosis regulator Homo sapiens 34-39 31881855-17 2019 Treatment with both GQC-05 with a Bcl-2/Bcl-XL inhibitor Navitoclax results in increased cytotoxic activity, which is more pronounced than Navitoclax or GQC-05 alone, and more significant than Navitoclax in combination with cytarabine and doxorubicin that are currently being used clinically. Cytarabine 224-234 BCL2 apoptosis regulator Homo sapiens 34-39 31881805-5 2019 Moreover, diosgenin induced a significant loss of the mitochondrial membrane potential in breast cancer cells, and prominently affected cell death through down-regulation of the anti-apoptotic protein, Bcl-2. Diosgenin 10-19 BCL2 apoptosis regulator Homo sapiens 202-207 31870319-6 2019 Western blot studies confirmed that melatonin alone prominently upregulated the levels of Beclin 1 and LC3 II, which was accompanied by an increase in the expression of Bcl-2, whereas it had no effect on the expression of Bax in the glioblastoma cells. Melatonin 36-45 BCL2 apoptosis regulator Homo sapiens 169-174 31870319-7 2019 Remarkably, co-treatment with 3-MA and melatonin significantly enhanced the apoptotic cell population in the glioblastoma cells, along with a prominent decrease in the expression of bcl-2 and increase in the Bax expression levels, which collectively indicated that the disruption of autophagy triggers the melatonin-induced apoptosis in glioblastoma cells. Methamphetamine 30-34 BCL2 apoptosis regulator Homo sapiens 182-187 31870319-7 2019 Remarkably, co-treatment with 3-MA and melatonin significantly enhanced the apoptotic cell population in the glioblastoma cells, along with a prominent decrease in the expression of bcl-2 and increase in the Bax expression levels, which collectively indicated that the disruption of autophagy triggers the melatonin-induced apoptosis in glioblastoma cells. Melatonin 39-48 BCL2 apoptosis regulator Homo sapiens 182-187 31863577-9 2019 In addition, compared with ox-LDL group, ticagrelor treatment significantly increased the expression levels of Akt, p-Akt, Bcl-2, eNOS, and NO concentration, and significantly decreased the expression levels of Bax and caspase-3. ticagrelor 41-51 BCL2 apoptosis regulator Homo sapiens 123-128 31541949-8 2019 In addition, we found that the knockdown of lncRNAVNN3 reduced phosphorylation of beclin1 and Bcl-2, which mediated 1, 4-benzoquinone-induced autophagy and apoptosis. quinone 119-133 BCL2 apoptosis regulator Homo sapiens 94-99 31763811-5 2019 The cell apoptosis-related protein expression (Bcl-2, Bax, and cleaved caspase-3/9) can be obviously interrupted with the delivery of DNS. 3,5-dinitrosalicylic acid 134-137 BCL2 apoptosis regulator Homo sapiens 47-52 31888155-7 2019 At the molecular level, ITR NPs were more effective than ITR solution in inducing pro-apoptotic Bax and p53 while reducing anti-apoptotic Bcl2 protein expression. Itraconazole 24-27 BCL2 apoptosis regulator Homo sapiens 138-142 31888155-7 2019 At the molecular level, ITR NPs were more effective than ITR solution in inducing pro-apoptotic Bax and p53 while reducing anti-apoptotic Bcl2 protein expression. Itraconazole 57-60 BCL2 apoptosis regulator Homo sapiens 138-142 31737898-10 2019 We found that BCL2 and E2F3 were greatly reduced by 200 mumol/l H2O2 in human lens epithelial cells. Hydrogen Peroxide 64-68 BCL2 apoptosis regulator Homo sapiens 14-18 31908533-0 2019 Baohuoside I Inhibits the Proliferation of Pancreatic Cancer Cells via mTOR/S6K1-Caspases/Bcl2/Bax Apoptotic Signaling. baohuoside I 0-12 BCL2 apoptosis regulator Homo sapiens 90-94 31908478-10 2019 Furthermore, miR-7-induced sensitization of breast cancer to paclitaxel/carboplatin is markedly reversed by restoration of MRP1 and BCL2. Paclitaxel 61-71 BCL2 apoptosis regulator Homo sapiens 132-136 31908478-10 2019 Furthermore, miR-7-induced sensitization of breast cancer to paclitaxel/carboplatin is markedly reversed by restoration of MRP1 and BCL2. Carboplatin 72-83 BCL2 apoptosis regulator Homo sapiens 132-136 31541949-9 2019 Overall, lncRNAVNN3 mediated 1, 4-benzoquinone-induced autophagy and apoptosis though regulating phosphorylation of beclin1 and Bcl-2, suggesting that lncRNAVNN3 might be a novel early sensitive biomarker of benzene-induced hematotoxicity. quinone 32-46 BCL2 apoptosis regulator Homo sapiens 128-133 31541949-9 2019 Overall, lncRNAVNN3 mediated 1, 4-benzoquinone-induced autophagy and apoptosis though regulating phosphorylation of beclin1 and Bcl-2, suggesting that lncRNAVNN3 might be a novel early sensitive biomarker of benzene-induced hematotoxicity. Benzene 208-215 BCL2 apoptosis regulator Homo sapiens 128-133 31817791-6 2019 Western blotting indicated that BITC regulated the expressions of the mitochondria-mediated apoptosis signaling molecules, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), and cytochrome c (Cyt c). benzyl isothiocyanate 32-36 BCL2 apoptosis regulator Homo sapiens 123-140 31934307-7 2019 Furthermore, chidamide enhanced the apoptotic effect of DAC by downregulating expression of Bcl-2 and pro-caspase-3 and upregulating that of Bax, cleaved PARP-1, and caspase-9. N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 13-22 BCL2 apoptosis regulator Homo sapiens 92-97 31915512-7 2019 Our results demonstrate that CoQ10 treatment significantly decreases the expression of the proapoptotic proteins Bax and Caspase-3, as shown through TUNEL-positive staining and the products of oxidative stress (ROS), while increasing the expression of the antiapoptotic protein Bcl-2 and the products of antioxidation, such as glutathione (GSH), against apoptosis and oxidative stress, in a H2O2-induced model. coenzyme Q10 29-34 BCL2 apoptosis regulator Homo sapiens 278-283 31849483-7 2019 Moreover, DCHF-DA staining, flow cytometry and Western blotting analyses proved that baicalein triggered the mitochondrial-dependent apoptotic pathway, as indicated by enhancement the level of intracellular ROS, disruption of mitochondrial membrane potential (DeltaPsim), downregulation of anti-apoptotic protein Bcl-2, upregulation of pro-apoptotic protein Bax, release of cytochrome C and activation of caspase-9 and caspase-3 in MCF-7 cells. baicalein 85-94 BCL2 apoptosis regulator Homo sapiens 313-318 31817791-6 2019 Western blotting indicated that BITC regulated the expressions of the mitochondria-mediated apoptosis signaling molecules, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), and cytochrome c (Cyt c). benzyl isothiocyanate 32-36 BCL2 apoptosis regulator Homo sapiens 142-147 31824157-8 2019 Results: In vitro, compared with chemotherapy alone, apoptosis rate of Fe3O4@MTX mediated thermochemotherapy group was significantly increased, and expression of apoptosis-inducing gene Caspase-3 and Bax were significantly upregulated in OCI-LY18 cells, while expression of apoptosis-inhibiting Bcl-2 gene was significantly downregulated. ferryl iron 71-76 BCL2 apoptosis regulator Homo sapiens 295-300 31808888-3 2019 The BCL2 inhibitor venetoclax in combination with low-dose cytarabine (LDAC) or hypomethylating agents (HMAs) is safe and effective in older patients with newly diagnosed AML ineligible for intensive chemotherapy. venetoclax 19-29 BCL2 apoptosis regulator Homo sapiens 4-8 31920653-7 2019 Mechanistically, sotetsuflavone was able to induce apoptosis by increasing the levels of expression of cytochrome C, cleaved-caspase 3, cleaved-caspase 9, and Bax, and contrastingly decreased levels of expression of Bcl-2. sotetsuflavone 17-31 BCL2 apoptosis regulator Homo sapiens 216-221 31885804-0 2019 Tetramethylpyrazine Attenuates the Endotheliotoxicity and the Mitochondrial Dysfunction by Doxorubicin via 14-3-3gamma/Bcl-2. tetramethylpyrazine 0-19 BCL2 apoptosis regulator Homo sapiens 119-124 31885804-12 2019 However, the protective effects to vascular endothelium of TMP were significantly canceled by pAD/14-3-3gamma-shRNA, an adenovirus that caused knockdown 14-3-3gamma expression, or ABT-737, a specific Bcl-2 inhibitor. tetramethylpyrazine 59-62 BCL2 apoptosis regulator Homo sapiens 200-205 31801941-3 2019 Particularly, the selective BCL-2 inhibitor ABT-199/Venetoclax is demonstrating clinical responses and has recently been approved in combination for the treatment of AML. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 44-47 BCL2 apoptosis regulator Homo sapiens 28-33 31801941-5 2019 We performed a side-by-side comparison of different highly selective and potent BH3-mimetics targeting BCL-2 (ABT-199), MCL-1 (S63845) or BCL-xL (A1331852) in a panel of AML cell lines and primary patient cells. BH 3 80-83 BCL2 apoptosis regulator Homo sapiens 103-108 31801941-7 2019 Western blotting and immunoprecipitations were used to explore the influence of BH3-mimetics on interactions between pro- and antiapoptotic BCL-2 proteins. BH 3 80-83 BCL2 apoptosis regulator Homo sapiens 140-145 31891063-6 2019 On the contrary, cis and trans iodido induced cell death independent of p53 activity, and they induced cell death through Bid activation, so their toxicity could be enhanced in a combined treatment with novel Bcl-2 protein family inhibitors. Linoleic Acid 25-37 BCL2 apoptosis regulator Homo sapiens 209-214 31885804-12 2019 However, the protective effects to vascular endothelium of TMP were significantly canceled by pAD/14-3-3gamma-shRNA, an adenovirus that caused knockdown 14-3-3gamma expression, or ABT-737, a specific Bcl-2 inhibitor. ABT-737 180-187 BCL2 apoptosis regulator Homo sapiens 200-205 31885804-13 2019 In conclusion, this study is the first to demonstrate that TMP protects the vascular endothelium against Dox-induced injury via upregulating 14-3-3gamma expression, promoting translocation of Bcl-2 to the mitochondria, closing mPTP, maintaining MMP, inhibiting RIRR mechanism, suppressing oxidative stress, improving mitochondrial function, and alleviating Dox-induced endotheliotoxicity. tetramethylpyrazine 59-62 BCL2 apoptosis regulator Homo sapiens 192-197 31885804-0 2019 Tetramethylpyrazine Attenuates the Endotheliotoxicity and the Mitochondrial Dysfunction by Doxorubicin via 14-3-3gamma/Bcl-2. Doxorubicin 91-102 BCL2 apoptosis regulator Homo sapiens 119-124 31885804-10 2019 Our results showed that Dox-induced injury to vascular endothelium was decreased by TMP via upregulating 14-3-3gamma expression in total protein and Bcl-2 expression in mitochondria, activating Bad (S112) phosphorylation, maintaining EDD, reducing LDH, CK, and caspase-3 activities, thereby causing a reduction in apoptotic rate, and histopathological changes of vascular endothelium (in vivo). Doxorubicin 24-27 BCL2 apoptosis regulator Homo sapiens 149-154 31885804-10 2019 Our results showed that Dox-induced injury to vascular endothelium was decreased by TMP via upregulating 14-3-3gamma expression in total protein and Bcl-2 expression in mitochondria, activating Bad (S112) phosphorylation, maintaining EDD, reducing LDH, CK, and caspase-3 activities, thereby causing a reduction in apoptotic rate, and histopathological changes of vascular endothelium (in vivo). tetramethylpyrazine 84-87 BCL2 apoptosis regulator Homo sapiens 149-154 31432697-7 2019 Salidroside inhibited GC cells proliferation, migration, invasion and promoted apoptosis, which coupled with the down-regulation of p21, Bcl-2, MMP2, RhoA, p-ROCK1, Vimentin and the up-regulations of CyclinD1, Bax, cleaved caspases. rhodioloside 0-11 BCL2 apoptosis regulator Homo sapiens 137-142 30873887-6 2019 The results showed that astaxanthin increases the expression of Bax and Caspase3 genes and decreases that of Bcl2, thereby, inducing apoptosis and inhibiting growth and proliferation of the cells. astaxanthine 24-35 BCL2 apoptosis regulator Homo sapiens 109-113 30880468-5 2019 The combination of DOX and KIR may promote therapeutic efficacy, at which the anti-apoptotic effect of the tumour cells was inhibited (by downregulating Bcl-2 and upregulating Bax) and the tumour progression-related inflammatory factors, such as tumour necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) were downregulated. Doxorubicin 19-22 BCL2 apoptosis regulator Homo sapiens 153-158 31322007-6 2019 Down-regulation of TRIM14 or NF-kappaB inhibitor PDTC treatment significantly inhibited cell apoptosis, Bax/Bcl-2 ratio and NF-kappaBp65 activation induced by TNF-alpha in HNPC. prolinedithiocarbamate 49-53 BCL2 apoptosis regulator Homo sapiens 108-113 31849650-12 2019 A significant downregulation of apoptotic Bax/Bcl2 mRNA was noted in ONA+C5-I retinae (p = 0.02). peptide C-I-6 73-77 BCL2 apoptosis regulator Homo sapiens 46-50 31705299-7 2019 Moreover, 6,7,4"-THIF attenuated alterations in Bax and Bcl-2 expression and caspase-3 activity in 6-OHDA-induced SH-SY5Y cells. 6,7,4"-thif 10-21 BCL2 apoptosis regulator Homo sapiens 56-61 30963795-7 2019 Moreover, it is indicated that inhibition of SF3b1 by pladienolide B induced Tap73/DeltaNp73 expression and consequently down-regulated Bax/Bcl-2 ratio, cytochrome c release and caspase-3 expression. pladienolide B 54-68 BCL2 apoptosis regulator Homo sapiens 140-145 31571495-9 2019 Additionally, Belinostat induced cell apoptosis, meanwhile dampened Bcl-2 and raised Bax and Cleaved caspase 3 in a dose and time-dependent manner. belinostat 14-24 BCL2 apoptosis regulator Homo sapiens 68-73 31590040-8 2019 RT-PCR analysis demonstrated down-regulation of Bcl-2 expression, while the expression of Bax, caspase-3, -8 and -9 genes was up-regulated in HT-29 cells incubated with 4c compared with control cells. 2-amino-4H-chromene-3-carbonitrile 169-171 BCL2 apoptosis regulator Homo sapiens 48-53 31539270-8 2019 Compared with control group, curcumin significantly inhibited cell cycle progression in G0/G1-S phase, increased the cell number of G0/G1 phase, and downregulated the Bcl-2, CDK4, and cyclin D1 protein expression in cells and tissues (p < 0.05). Curcumin 29-37 BCL2 apoptosis regulator Homo sapiens 167-172 31491344-6 2019 At a cellular mechanistic level, the present study showed that 3-BP sensitized human colon cancer cells to TRAIL-induced apoptosis via reactive oxygen species generation, upregulation of Bax, downregulation of Bcl-2 and survivin, release of cytochrome c into the cytosol, and activation of caspase-3. bromopyruvate 63-67 BCL2 apoptosis regulator Homo sapiens 210-215 31209657-1 2019 BACKGROUND: Venetoclax is a selective B-cell lymphoma-2 (BCL-2) inhibitor approved for use as monotherapy or with rituximab in patients with chronic lymphocytic leukemia (CLL). venetoclax 12-22 BCL2 apoptosis regulator Homo sapiens 38-55 31563593-2 2019 HCT15 cell treatment with DOX resulted in up-regulation of Beclin1, down-regulation of Bcl2, activation of AMPK and JNK, and Akt inactivation, all of which were restored by pretreating with an antioxidant N-acetyl-l-cysteine. Doxorubicin 26-29 BCL2 apoptosis regulator Homo sapiens 87-91 31713440-10 2019 Thus, AS-IV inhibits HG-induced oxidative stress and autophagy and protects cardiomyocytes from injury via the miR-34a/Bcl2/(LC3II/LC3I) and pAKT/Bcl2/(LC3II/LC3I) pathways. astragaloside A 6-11 BCL2 apoptosis regulator Homo sapiens 119-123 31713440-10 2019 Thus, AS-IV inhibits HG-induced oxidative stress and autophagy and protects cardiomyocytes from injury via the miR-34a/Bcl2/(LC3II/LC3I) and pAKT/Bcl2/(LC3II/LC3I) pathways. astragaloside A 6-11 BCL2 apoptosis regulator Homo sapiens 146-150 31209657-1 2019 BACKGROUND: Venetoclax is a selective B-cell lymphoma-2 (BCL-2) inhibitor approved for use as monotherapy or with rituximab in patients with chronic lymphocytic leukemia (CLL). venetoclax 12-22 BCL2 apoptosis regulator Homo sapiens 57-62 31284779-9 2019 The western blot analysing showed that the levels of apoptosis-associated Bcl-2 and Nrf2 were dramatically decreased following the sodium selenite treatment. Sodium 131-137 BCL2 apoptosis regulator Homo sapiens 74-79 31432559-8 2019 Moreover, quinalizarin triggered G2/M phase cell arrest by modulating the protein expression levels of CDK 1/2, cyclin A, cyclin B, p21 and p27, and induced apoptosis by down-regulating the antiapoptotic protein Bcl-2 and upregulating the proapoptotic protein BAD, leading to the activation of caspase-3 and PARP in the caspase cascade in A375 cells. 1,2,5,8-tetrahydroxy anthraquinone 10-22 BCL2 apoptosis regulator Homo sapiens 212-217 31436008-11 2019 BBE attenuated apoptosis by reducing the level of caspase-3 and increasing the Bcl-2/Bax ratio. CHEMBL145735 0-3 BCL2 apoptosis regulator Homo sapiens 79-84 30861214-3 2019 These include venetoclax (BCL-2 inhibitor) in combination with hypomethylating agents (azacitidine or decitabine) or low-dose cytarabine (LDAC), and glasdegib (sonic hedgehog pathway inhibitor) in combination with LDAC. venetoclax 14-24 BCL2 apoptosis regulator Homo sapiens 26-31 31819768-5 2019 Defensin and cathelicidin LL37 activated tumor cell apoptosis, especially for the HT29, but also for A549 line, by increasing gene expression of CHOP and by lowering BCL2 gene expression. Defensins 0-8 BCL2 apoptosis regulator Homo sapiens 166-170 31586637-11 2019 In addition, OMT reversed the Hcy-induced apoptosis related biochemical changes such as decreased mitochondrial membrane potential and Bcl-2/Bax protein ratio, and increased protein expression of caspase-9 and caspase-3. oxymatrine 13-16 BCL2 apoptosis regulator Homo sapiens 135-140 31586637-11 2019 In addition, OMT reversed the Hcy-induced apoptosis related biochemical changes such as decreased mitochondrial membrane potential and Bcl-2/Bax protein ratio, and increased protein expression of caspase-9 and caspase-3. Homocysteine 30-33 BCL2 apoptosis regulator Homo sapiens 135-140 31119602-9 2019 These data suggest that via inhibition of BCL-2 expression, overexpressed NES1 might enhance the effect of radiation therapy of 131I uptake in hNIS overexpressed PC3 cells. Iodine-131 128-132 BCL2 apoptosis regulator Homo sapiens 42-47 31218676-0 2019 Immunohistochemical evaluation of the effect of acitretin and systemic steroid treatments on Ki-67, Bcl-2, and COX-2 levels in cutaneous lichen planus patients. Steroids 71-78 BCL2 apoptosis regulator Homo sapiens 100-105 31541355-8 2019 Cisplatin + compound 4 significantly enhanced p53 phosphorylation, induced Bax amount, reduced Bcl2 protein levels, enhanced PARP cleavage and modulated miRNAs expression profile in TNBCs, with a particular overexpression of miR-125a-5p and miR-181a-5p. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 95-99 31638181-7 2019 Western blotting demonstrated that treatment with bruceine D significantly suppressed the expression of the anti-apoptotic proteins Bcl-2, Bcl-xL and X-linked inhibitor of apoptosis, enhanced the expression levels of apoptotic proteins Bax and Bak, and inhibited the expression of pro-caspase-3 and pro-caspase-8. bruceine D 50-60 BCL2 apoptosis regulator Homo sapiens 132-137 31127617-0 2019 Effect of nucleolin on adriamycin resistance via the regulation of B-cell lymphoma 2 expression in Burkitt"s lymphoma cells. Doxorubicin 23-33 BCL2 apoptosis regulator Homo sapiens 67-84 30734613-5 2019 Molecular docking modes showed that 5c could reasonably bind to the active site of Bcl-2 protein through strong intermolecular hydrogen bonds and significant hydrophobic effect. Hydrogen 127-135 BCL2 apoptosis regulator Homo sapiens 83-88 31218676-6 2019 OBJECTIVE: The purpose of this study was to investigate the effects of prednisolone and acitretin treatments on Ki-67, Bcl-2, and COX-2 expression and apoptosis in patients with LP and the role of Ki-67, Bcl-2, and COX-2 proteins in LP. Prednisolone 71-83 BCL2 apoptosis regulator Homo sapiens 119-124 31218676-6 2019 OBJECTIVE: The purpose of this study was to investigate the effects of prednisolone and acitretin treatments on Ki-67, Bcl-2, and COX-2 expression and apoptosis in patients with LP and the role of Ki-67, Bcl-2, and COX-2 proteins in LP. Acitretin 88-97 BCL2 apoptosis regulator Homo sapiens 119-124 31218676-6 2019 OBJECTIVE: The purpose of this study was to investigate the effects of prednisolone and acitretin treatments on Ki-67, Bcl-2, and COX-2 expression and apoptosis in patients with LP and the role of Ki-67, Bcl-2, and COX-2 proteins in LP. Acitretin 88-97 BCL2 apoptosis regulator Homo sapiens 204-209 31218676-10 2019 RESULTS: Although the percentage of staining with Ki-67 and Bcl-2 after treatment with prednisolone and acitretin decreased significantly (P < 0.05) in both groups, there was no significant difference between groups (P > 0.05). Prednisolone 87-99 BCL2 apoptosis regulator Homo sapiens 60-65 31218676-12 2019 CONCLUSIONS: With this study in cutaneous lichen planus, prednisolone and acitretin treatments reduced Bcl-2 and Ki-67 levels and did not effect COX-2 levels. Prednisolone 57-69 BCL2 apoptosis regulator Homo sapiens 103-108 31218676-12 2019 CONCLUSIONS: With this study in cutaneous lichen planus, prednisolone and acitretin treatments reduced Bcl-2 and Ki-67 levels and did not effect COX-2 levels. Acitretin 74-83 BCL2 apoptosis regulator Homo sapiens 103-108 31127149-7 2019 ONC212 induced apoptogenic effects through the induction of an integrated stress response, and reduced MCL-1 expression, a known resistance factor for BCL-2 inhibition by ABT-199. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 171-174 BCL2 apoptosis regulator Homo sapiens 151-156 31484706-0 2019 Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2-Expressing Neuroblastoma Preclinical Models. Fenretinide 0-11 BCL2 apoptosis regulator Homo sapiens 57-62 31484706-2 2019 Fenretinide (4-HPR) is a cytotoxic retinoid with clinical activity in recurrent neuroblastoma and venetoclax (ABT-199) is a selective inhibitor of the antiapoptotic protein B-cell lymphoma-2 (BCL-2). Fenretinide 0-11 BCL2 apoptosis regulator Homo sapiens 173-190 31484706-10 2019 Thus, fenretinide + venetoclax is a synergistic combination that warrants clinical testing in high BCL-2-expressing neuroblastoma. Fenretinide 6-17 BCL2 apoptosis regulator Homo sapiens 99-104 31484706-10 2019 Thus, fenretinide + venetoclax is a synergistic combination that warrants clinical testing in high BCL-2-expressing neuroblastoma. venetoclax 20-30 BCL2 apoptosis regulator Homo sapiens 99-104 31484706-2 2019 Fenretinide (4-HPR) is a cytotoxic retinoid with clinical activity in recurrent neuroblastoma and venetoclax (ABT-199) is a selective inhibitor of the antiapoptotic protein B-cell lymphoma-2 (BCL-2). Fenretinide 0-11 BCL2 apoptosis regulator Homo sapiens 192-197 31814847-7 2019 The expression levels of the autophagy factor microtubule-associated protein light chain 3-II/I and the anti-apoptotic factor Bcl-2 increased following TUDCA treatment, while the expression of the pro-apoptotic factor Bax decreased. ursodoxicoltaurine 152-157 BCL2 apoptosis regulator Homo sapiens 126-131 31485636-9 2019 Following treatment with curcumin, PQ-induced increases in ROS levels and apoptosis were significantly attenuated, and Bcl-2 expression levels were upregulated, whereas those of Bax were downregulated. Curcumin 25-33 BCL2 apoptosis regulator Homo sapiens 119-124 31485636-9 2019 Following treatment with curcumin, PQ-induced increases in ROS levels and apoptosis were significantly attenuated, and Bcl-2 expression levels were upregulated, whereas those of Bax were downregulated. Paraquat 35-37 BCL2 apoptosis regulator Homo sapiens 119-124 31583572-6 2019 The molecular docking studies of amygdalin within the Bcl-2 (PDB ID: 4LVT) and HER2 (PDB ID: 3RCD) active site, were performed using AutoDock 4.2.5. Amygdalin 33-42 BCL2 apoptosis regulator Homo sapiens 54-59 31583572-8 2019 Also, amygdalin causes an increase in pro-apoptotic Bax protein and a decrease in anti-apoptotic Bcl-2 protein expression in the SK-BR-3 cells. Amygdalin 6-15 BCL2 apoptosis regulator Homo sapiens 97-102 31583572-9 2019 Molecular docking studies showed that amygdalin interacts with the active site amino acids of Bcl-2 and HER2 through hydrogen bonding and some hydrophobic interactions. Amygdalin 38-47 BCL2 apoptosis regulator Homo sapiens 94-99 31583572-9 2019 Molecular docking studies showed that amygdalin interacts with the active site amino acids of Bcl-2 and HER2 through hydrogen bonding and some hydrophobic interactions. Hydrogen 117-125 BCL2 apoptosis regulator Homo sapiens 94-99 31583572-10 2019 Amygdalin can induce apoptotic death in SK-BR-3 cells by increasing pro-apoptotic Bax protein and decreasing anti-apoptotic Bcl-2 protein expression. Amygdalin 0-9 BCL2 apoptosis regulator Homo sapiens 124-129 31807162-12 2019 In addition, combination of radiation and cisplatin had a higher inhibitory effect on Bax protein level and a higher inductive effect on Bcl-2 protein level compared with treatments with radiation and cisplatin alone. Cisplatin 42-51 BCL2 apoptosis regulator Homo sapiens 137-142 31727500-8 2019 In addition, we found that naringin dose-dependently enhanced the expression of Caspase3, cleaved Caspase3 and Bax, and reduced the expression of cyclin D1, c-Myc, survivin, and Bcl-2 in TPC-1 and SW1736 cells. naringin 27-35 BCL2 apoptosis regulator Homo sapiens 178-183 31564190-8 2019 The inhibitory effect of DMEC on MM cells was related to mitochondria-mediated apoptosis via upregulation of the cleaved-caspase-3 (C-3), cleaved-caspase-9 (C-9), Bad, and cytochrome C (Cyto C), but downregulation of the Bcl-2 and poly ADP-ribose polymerase (PARP). 2-(2-diethylamino)-ethoxychalcone 25-29 BCL2 apoptosis regulator Homo sapiens 221-226 31638254-9 2019 In TetC-treated cells, the expression levels of apoptosis-related proteins, including cleaved (CL) caspase-3, Fas, phosphorylated (p)-p38 and p-JNK, were increased, whereas those of caspase-3 and Bcl-2 were decreased. tetc 3-7 BCL2 apoptosis regulator Homo sapiens 196-201 31638254-11 2019 These findings indicated that the potent antitumor activity of TetC may be mediated through an increase in ROS levels, the downregulation of Bcl-2, and the upregulation of CL caspase-3, Fas, p-p38 and p-JNK expression levels. tetc 63-67 BCL2 apoptosis regulator Homo sapiens 141-146 31801186-1 2019 Expression of the anti-apoptotic B-cell lymphoma 2 (BCL-2) protein in patients with diffuse large B-cell lymphoma (DLBCL) strongly correlates with resistance to standard therapy with cyclophosphamide, vincristine, doxorubicin, prednisolone, and rituximab (R-CHOP). Cyclophosphamide 183-199 BCL2 apoptosis regulator Homo sapiens 33-50 31349100-0 2019 Effect of 5-aminolevulinic acid photodynamic therapy on the expression of apoptosis inhibitors Bcl-2 and Survivin in keratinocytes of condyloma acuminatum. 5-amino levulinic acid 10-31 BCL2 apoptosis regulator Homo sapiens 95-100 31349100-4 2019 Here, we investigated possible molecular mechanisms of 5-aminolevulinic acid photodynamic therapy in the treatment of condyloma acuminatum and its effect on the expression of apoptosis inhibitors Bcl-2 and Survivin. 5-amino levulinic acid 55-76 BCL2 apoptosis regulator Homo sapiens 196-201 31349100-8 2019 The positive expression intensity of Bcl-2 and Survivin in condyloma acuminatum keratinocytes before 5-aminolevulinic acid photodynamic therapy was mostly ++ to +++, and that after treatment was mostly - to +. 5-amino levulinic acid 101-122 BCL2 apoptosis regulator Homo sapiens 37-42 31349100-9 2019 There were statistically significant differences in the positive expression rate and the expression intensity of Bcl-2 and Survivin in the two groups before and after 5-aminolevulinic acid photodynamic therapy (P < 0.001). 5-amino levulinic acid 167-188 BCL2 apoptosis regulator Homo sapiens 113-118 31349100-10 2019 There was a positive correlation between the expression of Bcl-2 and Survivin in condyloma acuminatum tissues after 5-aminolevulinic acid photodynamic therapy (r = 0.480, P < 0.05). 5-amino levulinic acid 116-137 BCL2 apoptosis regulator Homo sapiens 59-64 31349100-11 2019 CONCLUSION: 5-aminolevulinic acid photodynamic therapy may promote apoptosis of condyloma acuminatum cells by reducing the expression of Bcl-2 and Survivin, suggesting that this is potentially one of the molecular mechanisms of 5-aminolevulinic acid photodynamic therapy in the treatment of condyloma acuminatum. 5-amino levulinic acid 12-33 BCL2 apoptosis regulator Homo sapiens 137-142 31349100-11 2019 CONCLUSION: 5-aminolevulinic acid photodynamic therapy may promote apoptosis of condyloma acuminatum cells by reducing the expression of Bcl-2 and Survivin, suggesting that this is potentially one of the molecular mechanisms of 5-aminolevulinic acid photodynamic therapy in the treatment of condyloma acuminatum. 5-amino levulinic acid 228-249 BCL2 apoptosis regulator Homo sapiens 137-142 31491480-7 2019 Copper also down-regulated Bcl2 and up-regulated Bax, Casp8 and Casp3 linking the effects of copper to increased apoptosis. Copper 0-6 BCL2 apoptosis regulator Homo sapiens 27-31 31706839-2 2019 Recent work performed on the role of the Bcl2 family (highly specialized proteins which control cellular survival and death) in midbrain dopamine neurons has led to the identification of the Bcl2 factor Mcl1 as a weak link in the survival of these neurons. Dopamine 137-145 BCL2 apoptosis regulator Homo sapiens 41-45 31706839-2 2019 Recent work performed on the role of the Bcl2 family (highly specialized proteins which control cellular survival and death) in midbrain dopamine neurons has led to the identification of the Bcl2 factor Mcl1 as a weak link in the survival of these neurons. Dopamine 137-145 BCL2 apoptosis regulator Homo sapiens 191-195 31430575-0 2019 Importance of Hypericin-Bcl2 interactions for biological effects at subcellular levels. hypericin 14-23 BCL2 apoptosis regulator Homo sapiens 24-28 31430575-8 2019 We designed small peptides corresponding to Bcl2 BH3 and BH1 domains and tested the binding of Hyp and Bcl2 known inhibitor, ABT263, to the peptides in computer modeling and in vitro binding studies. navitoclax 125-131 BCL2 apoptosis regulator Homo sapiens 44-48 31430575-8 2019 We designed small peptides corresponding to Bcl2 BH3 and BH1 domains and tested the binding of Hyp and Bcl2 known inhibitor, ABT263, to the peptides in computer modeling and in vitro binding studies. navitoclax 125-131 BCL2 apoptosis regulator Homo sapiens 103-107 31430575-11 2019 In addition, our computer modeling results suggest that Hyp also interacts with other anti-apoptotic members of Bcl2 family similar to the known BH3 mimetics. BH 3 145-148 BCL2 apoptosis regulator Homo sapiens 112-116 32029037-8 2019 Compared with the LPS group, the oxidative activities and inflammatory factors above were inhibited in EP group [MDA (mumol/L): 12.35+-2.21 vs. 45.95+-1.76, SOD (kU/L): 54.68+-1.42 vs. 40.73+-1.60, IL-6 (ng/L): 67.87+-2.61 vs. 338.92+-20.91, TNF-alpha (ng/L): 19.23+-1.80 vs. 180.69+-6.51], mitochondrial membrane potential and ATP level were significantly increased [mitochondrial membrane potential: (99.43+-0.25)% vs. (69.40+-0.75)%, ATP (x106 RLU): 0.19+-0.01 vs. 0.12+-0.05], the expression of mitochondrial fission protein was significantly decreased (DAPK-2/beta-actin: 0.03+-0.01 vs. 0.61+-0.02), mitochondrial fusion proteins were significantly increased (Mfn-1/beta-actin: 0.43+-0.04 vs. 0.17+-0.01, Mfn-2/beta-actin: 0.201+-0.004 vs. 0.001+-0.001), percentage of cell apoptosis was significantly decreased [(5.25+-0.17)% vs. (34.42+-0.64)%], the expressions of apoptotic proteins were significantly decreased (caspase-3/beta-actin: 0.25+-0.15 vs. 1.76+-0.01, caspase-9/beta-actin: 0.09+-0.02 vs. 1.52+-0.12, Cyt C/beta-actin: 0.001+-0.001 vs. 0.350+-0.030), and the expressions of anti-apoptotic proteins and PARP were significantly increased (Bcl-2/beta-actin: 0.500+-0.010 vs. 0.009+-0.004, Bcl-xL/beta-actin: 0.550+-0.010 vs. 0.009+-0.001, PARP/beta-actin: 0.94+-0.01 vs. 0.16+-0.13), with statistically significant differences (all P < 0.05). ethyl pyruvate 103-105 BCL2 apoptosis regulator Homo sapiens 1155-1160 31654068-7 2019 Moreover, scutellarin significantly upregulated bcl-2 expression and downregulated bax expression in hepatocytes exposed to H/R. scutellarin 10-21 BCL2 apoptosis regulator Homo sapiens 48-53 31801186-1 2019 Expression of the anti-apoptotic B-cell lymphoma 2 (BCL-2) protein in patients with diffuse large B-cell lymphoma (DLBCL) strongly correlates with resistance to standard therapy with cyclophosphamide, vincristine, doxorubicin, prednisolone, and rituximab (R-CHOP). Cyclophosphamide 183-199 BCL2 apoptosis regulator Homo sapiens 52-57 31801186-1 2019 Expression of the anti-apoptotic B-cell lymphoma 2 (BCL-2) protein in patients with diffuse large B-cell lymphoma (DLBCL) strongly correlates with resistance to standard therapy with cyclophosphamide, vincristine, doxorubicin, prednisolone, and rituximab (R-CHOP). Vincristine 201-212 BCL2 apoptosis regulator Homo sapiens 33-50 31801186-1 2019 Expression of the anti-apoptotic B-cell lymphoma 2 (BCL-2) protein in patients with diffuse large B-cell lymphoma (DLBCL) strongly correlates with resistance to standard therapy with cyclophosphamide, vincristine, doxorubicin, prednisolone, and rituximab (R-CHOP). Vincristine 201-212 BCL2 apoptosis regulator Homo sapiens 52-57 31801186-1 2019 Expression of the anti-apoptotic B-cell lymphoma 2 (BCL-2) protein in patients with diffuse large B-cell lymphoma (DLBCL) strongly correlates with resistance to standard therapy with cyclophosphamide, vincristine, doxorubicin, prednisolone, and rituximab (R-CHOP). Doxorubicin 214-225 BCL2 apoptosis regulator Homo sapiens 33-50 31801186-1 2019 Expression of the anti-apoptotic B-cell lymphoma 2 (BCL-2) protein in patients with diffuse large B-cell lymphoma (DLBCL) strongly correlates with resistance to standard therapy with cyclophosphamide, vincristine, doxorubicin, prednisolone, and rituximab (R-CHOP). Doxorubicin 214-225 BCL2 apoptosis regulator Homo sapiens 52-57 31801186-1 2019 Expression of the anti-apoptotic B-cell lymphoma 2 (BCL-2) protein in patients with diffuse large B-cell lymphoma (DLBCL) strongly correlates with resistance to standard therapy with cyclophosphamide, vincristine, doxorubicin, prednisolone, and rituximab (R-CHOP). Prednisolone 227-239 BCL2 apoptosis regulator Homo sapiens 33-50 31801186-1 2019 Expression of the anti-apoptotic B-cell lymphoma 2 (BCL-2) protein in patients with diffuse large B-cell lymphoma (DLBCL) strongly correlates with resistance to standard therapy with cyclophosphamide, vincristine, doxorubicin, prednisolone, and rituximab (R-CHOP). Prednisolone 227-239 BCL2 apoptosis regulator Homo sapiens 52-57 31465840-3 2019 Mechanistic studies revealed that A-1210477 triggers the release of BIM from MCL-1 and its shuttling to BCL-xL and BCL-2. A-1210477 34-43 BCL2 apoptosis regulator Homo sapiens 115-120 31819507-9 2019 Meanwhile, propofol treatment increased the expression of cleaved caspase-3 but decreased Bcl-2, MMP-2 and MMP-9 in SGC-7901 and MKN45 cells. Propofol 11-19 BCL2 apoptosis regulator Homo sapiens 90-95 31751472-6 2019 LAM-003 displayed synergistic activity with chemotherapeutic drugs and FLT3 inhibitors, with the most robust synergy being obtained with venetoclax, a BCL-2 inhibitor. lipoarabinomannan 0-3 BCL2 apoptosis regulator Homo sapiens 151-156 31885796-10 2019 Furthermore, the molecular results showed that pioglitazone significantly decreased the expression of apoptosis-associated proteins, including cyto.cytochrome c, Bax, cleaved caspase-9, and cleaved caspase-3, and promoted Bcl-2 expression. pioglitazone 47-59 BCL2 apoptosis regulator Homo sapiens 222-227 31755322-6 2022 The oleuropein inhibited cell apoptosis via regulation of MAPK signalling pathways and its downstream targets Bax, caspase-3, and Bcl-2 expression.Conclusion: Oleuropein may server as a favourable additional agent for the treatment of patients with DN. oleuropein 4-14 BCL2 apoptosis regulator Homo sapiens 130-135 31755322-6 2022 The oleuropein inhibited cell apoptosis via regulation of MAPK signalling pathways and its downstream targets Bax, caspase-3, and Bcl-2 expression.Conclusion: Oleuropein may server as a favourable additional agent for the treatment of patients with DN. oleuropein 159-169 BCL2 apoptosis regulator Homo sapiens 130-135 31766723-7 2019 Our data demonstrate that elevated Cx43 and reduced Bcl-2 levels may indicate HNSCC sensitivity to taxane-based treatments. taxane 99-105 BCL2 apoptosis regulator Homo sapiens 52-57 31771152-4 2019 MTT assay showed significant inhibition of MCF-7 cells viability with the IC50 value of 13.04 +- 1.03 microg/mL after 48 h. The compound induced down-regulation of anti-apoptotic Bcl-2 protein and increase in the pro-apoptotic Bax/Bcl-2 ratio in MCF-7 cells. thiazolyl blue 0-3 BCL2 apoptosis regulator Homo sapiens 179-184 31771152-4 2019 MTT assay showed significant inhibition of MCF-7 cells viability with the IC50 value of 13.04 +- 1.03 microg/mL after 48 h. The compound induced down-regulation of anti-apoptotic Bcl-2 protein and increase in the pro-apoptotic Bax/Bcl-2 ratio in MCF-7 cells. thiazolyl blue 0-3 BCL2 apoptosis regulator Homo sapiens 231-236 31752970-11 2019 Notably, in a mouse model of DHL bearing primary tumor cells derived from lymphoma patients, combined treatment with XPO1 and BCL2 inhibitors blocks tumor progression, prevents brain metastasis, and extends host survival. Cysteamine 29-32 BCL2 apoptosis regulator Homo sapiens 126-130 31320594-0 2019 Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. midostaurin 74-85 BCL2 apoptosis regulator Homo sapiens 14-19 31638783-8 2019 Interestingly, NQ protected SH-SY5Y cells against H2O2-induced neurotoxicity through scavenging ROS, upregulating the levels of SIRT1 and FOXO3a, increasing the levels of antioxidant enzymes (catalase and superoxide dismutase), promoting antiapoptotic BCL-2 protein expression, and reducing apoptosis. nitroxoline 15-17 BCL2 apoptosis regulator Homo sapiens 252-257 31827715-8 2019 Hydrostatin-SN10 significantly inhibited the IL-6-stimulated JAK2/STAT3 pathway and reduced the number of apoptotic cells via the downregulation of caspase 3 and BAX (proapoptotic) and upregulation of Bcl2 (antiapoptotic) (p < 0.05). hydrostatin 0-11 BCL2 apoptosis regulator Homo sapiens 201-205 31752240-9 2019 Furthermore, the pre-treatment with the association of two non-psychoactive cannabinoids downregulated Bax protein expression and upregulated Bcl-2 expression. Cannabinoids 76-88 BCL2 apoptosis regulator Homo sapiens 142-147 31819366-8 2019 In addition, the expression of migration-related protein Ezrin and MMP2 was increased accordingly, apoptotic-related protein BCL-2 expression was also increased while BAX protein expression was decreased after sevoflurane treatment. sevoflurane 210-221 BCL2 apoptosis regulator Homo sapiens 125-130 31320594-9 2019 In vivo results show that gilteritinib in combination with venetoclax has therapeutic potential.Conclusions: Inhibition of Bcl-2 via venetoclax synergistically enhances the efficacy of midostaurin and gilteritinib in FLT3-mutated AML. venetoclax 133-143 BCL2 apoptosis regulator Homo sapiens 123-128 31320594-9 2019 In vivo results show that gilteritinib in combination with venetoclax has therapeutic potential.Conclusions: Inhibition of Bcl-2 via venetoclax synergistically enhances the efficacy of midostaurin and gilteritinib in FLT3-mutated AML. midostaurin 185-196 BCL2 apoptosis regulator Homo sapiens 123-128 31320594-9 2019 In vivo results show that gilteritinib in combination with venetoclax has therapeutic potential.Conclusions: Inhibition of Bcl-2 via venetoclax synergistically enhances the efficacy of midostaurin and gilteritinib in FLT3-mutated AML. gilteritinib 201-213 BCL2 apoptosis regulator Homo sapiens 123-128 31320594-0 2019 Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. gilteritinib 90-102 BCL2 apoptosis regulator Homo sapiens 14-19 31320594-1 2019 Purpose: To investigate the efficacy of the combination of the FLT3 inhibitors midostaurin or gilteritinib with the Bcl-2 inhibitor venetoclax in FLT3-internal tandem duplication (ITD) acute myeloid leukemia (AML) and the underlying molecular mechanism.Experimental Design: Using both FLT3-ITD cell lines and primary patient samples, Annexin V-FITC/propidium iodide staining and flow cytometry analysis were used to quantify cell death induced by midostaurin or gilteritinib, alone or in combination with venetoclax. venetoclax 132-142 BCL2 apoptosis regulator Homo sapiens 116-121 31320594-9 2019 In vivo results show that gilteritinib in combination with venetoclax has therapeutic potential.Conclusions: Inhibition of Bcl-2 via venetoclax synergistically enhances the efficacy of midostaurin and gilteritinib in FLT3-mutated AML. gilteritinib 26-38 BCL2 apoptosis regulator Homo sapiens 123-128 31320594-9 2019 In vivo results show that gilteritinib in combination with venetoclax has therapeutic potential.Conclusions: Inhibition of Bcl-2 via venetoclax synergistically enhances the efficacy of midostaurin and gilteritinib in FLT3-mutated AML. venetoclax 59-69 BCL2 apoptosis regulator Homo sapiens 123-128 31515455-2 2019 The BCL2 inhibitor venetoclax enhances responses to low intensity AML chemotherapy but its activity is limited by MCL1 upregulation. venetoclax 19-29 BCL2 apoptosis regulator Homo sapiens 4-8 31425677-8 2019 Additionally, CS activates the Akt/Bcl2 pathway. cholesteryl sulfate 14-16 BCL2 apoptosis regulator Homo sapiens 35-39 31442807-8 2019 Furthermore, the levels of pro-apoptotic gene (including CytC, Cas3, Cas8, Cas9, TNF-alpha and Bax) increased after H2S exposure, as well as the expression level of anti-apoptotic gene bcl-2 decreased. Hydrogen Sulfide 116-119 BCL2 apoptosis regulator Homo sapiens 185-190 31563649-6 2019 Nitidine chloride also significantly downregulated bcl-2 and upregulated bax, cleaved caspase-9 and cleaved caspase-3. nitidine 0-17 BCL2 apoptosis regulator Homo sapiens 51-56 32021975-9 2020 The cisplatin-induced apoptosis in endometrial cancer cells was inhibited by miR-135a by regulation of BAX and Bcl-2 expression. Cisplatin 4-13 BCL2 apoptosis regulator Homo sapiens 111-116 31744202-3 2019 Here, polyethyleneimine (PEI)-modified magnetic Fe3O4 nanoparticles were prepared for the delivery of therapeutic siRNAs targeting B-cell lymphoma-2 (BCL2) and Baculoviral IAP repeat-containing 5 (BIRC5) into Ca9-22 oral cancer cells. Polyethyleneimine 6-23 BCL2 apoptosis regulator Homo sapiens 131-148 32009805-9 2019 In addition, Tan IIA obviously enhanced the anti-apoptosis effects of OXA on SW480/OXA cells via decreasing the levels of Bcl-2, p-Akt and p-ERK, and increasing the levels of Bax and active caspase 3. tanshinone 13-20 BCL2 apoptosis regulator Homo sapiens 122-127 31744202-3 2019 Here, polyethyleneimine (PEI)-modified magnetic Fe3O4 nanoparticles were prepared for the delivery of therapeutic siRNAs targeting B-cell lymphoma-2 (BCL2) and Baculoviral IAP repeat-containing 5 (BIRC5) into Ca9-22 oral cancer cells. Polyethyleneimine 6-23 BCL2 apoptosis regulator Homo sapiens 150-154 31744202-3 2019 Here, polyethyleneimine (PEI)-modified magnetic Fe3O4 nanoparticles were prepared for the delivery of therapeutic siRNAs targeting B-cell lymphoma-2 (BCL2) and Baculoviral IAP repeat-containing 5 (BIRC5) into Ca9-22 oral cancer cells. Polyethyleneimine 25-28 BCL2 apoptosis regulator Homo sapiens 131-148 31744202-3 2019 Here, polyethyleneimine (PEI)-modified magnetic Fe3O4 nanoparticles were prepared for the delivery of therapeutic siRNAs targeting B-cell lymphoma-2 (BCL2) and Baculoviral IAP repeat-containing 5 (BIRC5) into Ca9-22 oral cancer cells. Polyethyleneimine 25-28 BCL2 apoptosis regulator Homo sapiens 150-154 31744202-3 2019 Here, polyethyleneimine (PEI)-modified magnetic Fe3O4 nanoparticles were prepared for the delivery of therapeutic siRNAs targeting B-cell lymphoma-2 (BCL2) and Baculoviral IAP repeat-containing 5 (BIRC5) into Ca9-22 oral cancer cells. ferryl iron 48-53 BCL2 apoptosis regulator Homo sapiens 131-148 31744202-3 2019 Here, polyethyleneimine (PEI)-modified magnetic Fe3O4 nanoparticles were prepared for the delivery of therapeutic siRNAs targeting B-cell lymphoma-2 (BCL2) and Baculoviral IAP repeat-containing 5 (BIRC5) into Ca9-22 oral cancer cells. ferryl iron 48-53 BCL2 apoptosis regulator Homo sapiens 150-154 31780901-8 2019 Meanwhile, PNU-282987 upregulated the expression of the antiapoptotic protein Bcl-2 and downregulated the expression of the apoptotic protein Bax and cleaved-caspase-3. PNU-282987 11-21 BCL2 apoptosis regulator Homo sapiens 78-83 31815138-0 2019 Sirt5 Attenuates Cisplatin-Induced Acute Kidney Injury through Regulation of Nrf2/HO-1 and Bcl-2. Cisplatin 17-26 BCL2 apoptosis regulator Homo sapiens 91-96 31815138-12 2019 The levels of Nrf2, HO-1, and Bcl-2 proteins in HK-2 cells were also decreased after CDDP treatment. Cisplatin 85-89 BCL2 apoptosis regulator Homo sapiens 30-35 31815138-13 2019 Moreover, Nrf2 and Bcl-2 siRNA partly abolished the protecting effect of Sirt5 on CDDP-induced apoptosis and cytochrome c release. Cisplatin 82-86 BCL2 apoptosis regulator Homo sapiens 19-24 31815138-15 2019 Together, the results demonstrated that Sirt5 attenuated cisplatin-induced apoptosis and mitochondrial injury in human kidney HK-2 cells, possibly through the regulation of Nrf2/HO-1 and Bcl-2. Cisplatin 57-66 BCL2 apoptosis regulator Homo sapiens 187-192 32009805-9 2019 In addition, Tan IIA obviously enhanced the anti-apoptosis effects of OXA on SW480/OXA cells via decreasing the levels of Bcl-2, p-Akt and p-ERK, and increasing the levels of Bax and active caspase 3. oxaliplatin 70-73 BCL2 apoptosis regulator Homo sapiens 122-127 31684176-9 2019 Eugenol increased caspase-3 activity and the expression of Bax, cytochrome c (Cyt-c), caspase-3, and caspase-9 and decreased the expression of B-cell lymphoma (Bcl)-2, cyclooxygenase-2 (Cox-2), and interleukin-1 beta (IL-1beta) indicating that eugenol mainly induced cell death by apoptosis. Eugenol 0-7 BCL2 apoptosis regulator Homo sapiens 143-166 31703356-4 2019 We show that inhibition of WEE1 by AZD1775 induces DNA damage and pre-mitotic entry in DLBCL, thereby enhancing dependency on BCL-2 and/or MCL-1. adavosertib 35-42 BCL2 apoptosis regulator Homo sapiens 126-131 31494078-5 2019 Research investigations underlying Bcl-2 target have resulted in the generation of small molecule inhibitors, named as "BH3-mimetics" (Bcl-2 homology 3 mimetics). BH 3 120-123 BCL2 apoptosis regulator Homo sapiens 35-40 31494078-8 2019 Thrombocytopenia a major dose-limiting toxicity, associated with ABT-263 had provoked the invention of a highly selective Bcl-2 inhibitor venetoclax. navitoclax 65-72 BCL2 apoptosis regulator Homo sapiens 122-127 31806994-13 2019 Furthermore, DSG induced apoptosis with the increased expressions of cytosol cytochrome C, cleaved-caspase-3, cleaved-PARP1 and the Bax/Bcl-2 ratio. Diosgenin 13-16 BCL2 apoptosis regulator Homo sapiens 136-141 30822359-9 2019 In addition, oxymatrine treatment reduced cellular apoptosis as shown by increased Bcl-2 expression and a decrease in TUNEL-positive cells. oxymatrine 13-23 BCL2 apoptosis regulator Homo sapiens 83-88 31220411-3 2019 We found that metformin decreased the cell apoptosis rate and death, ratio of Bcl-2/Bax, and expression of NR2A and NR2B, and increased the expression of LC3 in Abeta25-35 -treated SH-SY5Y cells. Metformin 14-23 BCL2 apoptosis regulator Homo sapiens 78-83 31609766-5 2019 SIN and cisplatin further decreased the Bcl-2, procaspase-3, and beta-catenin, but increased Bax, cleaved dcaspase 3, MMP9, and MMP2 in combined group than in either alone group. sinomenine 0-3 BCL2 apoptosis regulator Homo sapiens 40-45 31609766-5 2019 SIN and cisplatin further decreased the Bcl-2, procaspase-3, and beta-catenin, but increased Bax, cleaved dcaspase 3, MMP9, and MMP2 in combined group than in either alone group. Cisplatin 8-17 BCL2 apoptosis regulator Homo sapiens 40-45 31625993-3 2019 We also found that PACs induced apoptosis of osteoclast precursors by upregulating the ratio of bax/bcl-2 and activating caspase-3 activity. Proanthocyanidins 19-23 BCL2 apoptosis regulator Homo sapiens 100-105 31386885-9 2019 The marked apoptosis induction in the XN-treated RPMI8226 cells was related to initiation of mitochondrial and extrinsic pathways, as indicated by the altered p53, Bax, and Bcl-2 protein expression, cleavage of procaspase 8 and 9, and elevated caspase-3 activity. xanthohumol 38-40 BCL2 apoptosis regulator Homo sapiens 173-178 31541852-5 2019 Presence of GMG-ITC prior to development of oxidative stress condition, downregulated the expression of cyt-c, p53, Apaf-1, Bax, CASP3, CASP8 and CASP9 genes with concurrent upregulation of Bcl-2 gene in mitochondrial apoptotic signalling pathway. Isothiocyanates 12-19 BCL2 apoptosis regulator Homo sapiens 190-195 30839137-11 2019 We also revealed that BMSC-CM could decrease the expression of Notch1, Hes1, cleave caspase-3, Bax, and increases the expression of Bcl-2 in NSCs, which was induced by H2 O2 . Hydrogen Peroxide 168-173 BCL2 apoptosis regulator Homo sapiens 132-137 31544588-7 2019 In addition, Ganoderiol F up-regulated pro-apoptotic Foxo3, down-regulated anti-apoptotic c-Myc, Bcl-2 and Bcl-w leading to apoptosis in human breast cancer cells MDA-MB-231. ganoderiol F 13-25 BCL2 apoptosis regulator Homo sapiens 97-102 31423807-7 2019 Western blot analysis showed that the protein expression level of Bcl-2 was significantly increased in the BMSCs-Exos group compared with the PBS group, while the protein expression levels of Bax, cleaved caspase-3, and cleaved caspase-9 were significantly decreased. Lead 142-145 BCL2 apoptosis regulator Homo sapiens 66-71 31588915-6 2019 In addition, Isorhamnetin-induced apoptosis was associated with increased expression of Fas/Fas ligand, reduced ratio of Bcl-2/Bax expression, truncation of Bid, cytosolic release of cytochrome c, and activation of caspase-8, -9 and -3. 3-methylquercetin 13-25 BCL2 apoptosis regulator Homo sapiens 121-126 31561314-8 2019 Three new proteins; Receptor-interacting protein 1 (RIP1), Apoptosis signal-regulating kinase 1 (ASK1) and B-cell lymphoma 2 (Bcl-2) from Apoptosis Signaling Pathway revealed best CDOCKER energy with triclosan which was -26.88, -23.34 and -22.96 kcal/mol respectively. Triclosan 200-209 BCL2 apoptosis regulator Homo sapiens 107-124 31561314-8 2019 Three new proteins; Receptor-interacting protein 1 (RIP1), Apoptosis signal-regulating kinase 1 (ASK1) and B-cell lymphoma 2 (Bcl-2) from Apoptosis Signaling Pathway revealed best CDOCKER energy with triclosan which was -26.88, -23.34 and -22.96 kcal/mol respectively. Triclosan 200-209 BCL2 apoptosis regulator Homo sapiens 126-131 31561314-9 2019 The interaction of TCS with RIP1 and ASK1 were mostly hydrophobic; however, hydrogen bond type interaction was found in TCS/Bcl2 complex. Triclosan 19-22 BCL2 apoptosis regulator Homo sapiens 124-128 31561314-9 2019 The interaction of TCS with RIP1 and ASK1 were mostly hydrophobic; however, hydrogen bond type interaction was found in TCS/Bcl2 complex. Hydrogen 76-84 BCL2 apoptosis regulator Homo sapiens 124-128 31561314-9 2019 The interaction of TCS with RIP1 and ASK1 were mostly hydrophobic; however, hydrogen bond type interaction was found in TCS/Bcl2 complex. Triclosan 120-123 BCL2 apoptosis regulator Homo sapiens 124-128 31764121-3 2019 The approval of the BCL-2 inhibitor venetoclax for relapsed/refractory del(17p) CLL in 2016 represented the culmination of decades of molecular and clinical research and has paved the way for new combination therapy regimens in CLL, including the venetoclax + rituximab regimen approved for relapsed/refractory CLL in 2018 and the venetoclax + obinutuzumab regimen approved for frontline CLL treatment in 2019. venetoclax 36-46 BCL2 apoptosis regulator Homo sapiens 20-25 30521787-1 2019 Cabazitaxel as microtubule inhibitor and thymoquinone as HDAC inhibitor affects the important genes like p53, STAT3, Bax, BCL-2, p21 and down regulation of NF-kappaB are reported for potential activity against breast tumors. cabazitaxel 0-11 BCL2 apoptosis regulator Homo sapiens 122-127 30521787-1 2019 Cabazitaxel as microtubule inhibitor and thymoquinone as HDAC inhibitor affects the important genes like p53, STAT3, Bax, BCL-2, p21 and down regulation of NF-kappaB are reported for potential activity against breast tumors. thymoquinone 41-53 BCL2 apoptosis regulator Homo sapiens 122-127 31518035-4 2019 The results indicated that EGCG mitigated both Pb- and beta-AP-induced oxidative stress in scavenging reactive oxygen species and apoptosis by improving the expression levels of Bax and bcl2 and inhibiting annexin V and caspase-3. epigallocatechin gallate 27-31 BCL2 apoptosis regulator Homo sapiens 186-190 31518663-3 2019 Herein, we first identified the expressions of the anti-apoptotic BCL2 and the prostaglandin-endoperoxide synthase-2 (PTGS2) genes, which were abundant in the gastric carcinoma and associated with poor patient survival, were closely related with the resistance against cisplatin. Cisplatin 269-278 BCL2 apoptosis regulator Homo sapiens 66-70 31576639-8 2019 The gene expression analysis revealed that GA could induce apoptosis-mediated proliferation inhibition in MDA-MB-231 cells through upregulation of bax and caspase-3 and downregulation of bcl2 genes. galbanic acid 43-45 BCL2 apoptosis regulator Homo sapiens 187-191 31518663-4 2019 Further investigations revealed that PTGS2 served as an essential mediator involved in the developing process of the resistance against cisplatin via mediating the inhibition effects of cisplatin on BCL2 expression. Cisplatin 136-145 BCL2 apoptosis regulator Homo sapiens 199-203 31518663-4 2019 Further investigations revealed that PTGS2 served as an essential mediator involved in the developing process of the resistance against cisplatin via mediating the inhibition effects of cisplatin on BCL2 expression. Cisplatin 186-195 BCL2 apoptosis regulator Homo sapiens 199-203 31518663-6 2019 In addition, PTGS2 mediated cisplatin-induced BCL2 expression and subsequent resistance to apoptosis via PGE2/EP4/MAPKs (ERK1/2, P38) axis. Cisplatin 28-37 BCL2 apoptosis regulator Homo sapiens 46-50 31518663-8 2019 Moreover, in the xenograft models, inhibition of PTGS2 by celecoxib significantly augmented the cytotoxic efficacy of cisplatin in the resistant gastric cancer via suppression of PTGS2 and BCL2 expressions regulated by ERK1/2 and P38 signal axis, suggesting PTGS2 might be employed as an adjunctive therapeutic target for reversal of the chemoresistance in a subset of cisplatin resistant gastric cancer. Celecoxib 58-67 BCL2 apoptosis regulator Homo sapiens 189-193 31518663-8 2019 Moreover, in the xenograft models, inhibition of PTGS2 by celecoxib significantly augmented the cytotoxic efficacy of cisplatin in the resistant gastric cancer via suppression of PTGS2 and BCL2 expressions regulated by ERK1/2 and P38 signal axis, suggesting PTGS2 might be employed as an adjunctive therapeutic target for reversal of the chemoresistance in a subset of cisplatin resistant gastric cancer. Cisplatin 118-127 BCL2 apoptosis regulator Homo sapiens 189-193 31696694-9 2019 Moreover, progesterone could induce progesterone receptor M to up-regulate apoptotic protein Caspase-3 and down-regulate anti-apoptotic protein Bcl-2, thus it could inhibit the apoptosis of primary cultured uterine leiomyoma cells and promote the proliferation of leiomyoma cells. Progesterone 10-22 BCL2 apoptosis regulator Homo sapiens 144-149 31839811-0 2019 Fenretinide-induced Apoptosis of Acute Myeloid Leukemia Cells via NR4A1 Translocation into Mitochondria and Bcl-2 Transformation. Fenretinide 0-11 BCL2 apoptosis regulator Homo sapiens 108-113 31839811-14 2019 At the same time, fenretinide promoted NR4A1 translocation from nuclei into mitochondria, and enhanced the interaction between NR4A1 and Bcl-2, thereby exposing the BH3 domain of Bcl-2 to exert the anti-apoptotic effect. Fenretinide 18-29 BCL2 apoptosis regulator Homo sapiens 137-142 31839811-14 2019 At the same time, fenretinide promoted NR4A1 translocation from nuclei into mitochondria, and enhanced the interaction between NR4A1 and Bcl-2, thereby exposing the BH3 domain of Bcl-2 to exert the anti-apoptotic effect. Fenretinide 18-29 BCL2 apoptosis regulator Homo sapiens 179-184 31983095-8 2019 Besides, si-ATB remarkably increased the expression of Bcl-2 (p<0.01), and reduced the expressions of cleaved-caspase3 and Cytochrome C (p<0.01) and the apoptosis. si-atb 9-15 BCL2 apoptosis regulator Homo sapiens 55-60 31518035-4 2019 The results indicated that EGCG mitigated both Pb- and beta-AP-induced oxidative stress in scavenging reactive oxygen species and apoptosis by improving the expression levels of Bax and bcl2 and inhibiting annexin V and caspase-3. Lead 47-49 BCL2 apoptosis regulator Homo sapiens 186-190 31983115-12 2019 Moreover, Murrayanine caused increase in the Bax/Bcl-2 ratio and also increased the expression of Caspase-3. murrayanine 10-21 BCL2 apoptosis regulator Homo sapiens 49-54 31518035-4 2019 The results indicated that EGCG mitigated both Pb- and beta-AP-induced oxidative stress in scavenging reactive oxygen species and apoptosis by improving the expression levels of Bax and bcl2 and inhibiting annexin V and caspase-3. beta-ap 55-62 BCL2 apoptosis regulator Homo sapiens 186-190 31983118-10 2019 Xanthohumol also caused activation of caspase-3 and 9 and increased the Bax/Bcl-2 ratio. xanthohumol 0-11 BCL2 apoptosis regulator Homo sapiens 76-81 31218746-11 2019 In conclusion, overexpression of miR-34a-5p activated beclin 1 through Bcl-2 inhibition in CIH and participated in CIH-induced autophagy. cih 91-94 BCL2 apoptosis regulator Homo sapiens 71-76 31462500-8 2019 Conversely, specific inhibitors of BCL-XL, MCL1, or BCL-XL/BCL-2, but not BCL-2 alone, enhanced cell death when combined with cisplatin or paclitaxel. Cisplatin 126-135 BCL2 apoptosis regulator Homo sapiens 59-64 31218746-9 2019 Moreover, exogenous upregulation of Bcl-2 could block miR-34a-5p influence on CIH-induced autophagy through suppressing beclin 1 expression. cih 78-81 BCL2 apoptosis regulator Homo sapiens 36-41 31411791-11 2019 Moreover, SKOV3/DDP cells had a lower miR-1271 level, and enhancing miR-1271 contributed strongly to cisplatin-induced apoptosis through altering the expressions of B-cell lymphoma-2 associated X protein (BAX), cleaved caspase-3 and B-cell lymphoma 2 (Bcl-2). Cisplatin 101-110 BCL2 apoptosis regulator Homo sapiens 233-250 31411791-11 2019 Moreover, SKOV3/DDP cells had a lower miR-1271 level, and enhancing miR-1271 contributed strongly to cisplatin-induced apoptosis through altering the expressions of B-cell lymphoma-2 associated X protein (BAX), cleaved caspase-3 and B-cell lymphoma 2 (Bcl-2). Cisplatin 101-110 BCL2 apoptosis regulator Homo sapiens 252-257 31339188-5 2019 Furthermore, we found that palbociclib suppressed chemerin-induced apoptotic protein expression, reversing the Bcl-2/Bax ratio and inhibiting the p53/p21 waf pathway. palbociclib 27-38 BCL2 apoptosis regulator Homo sapiens 111-116 31462500-8 2019 Conversely, specific inhibitors of BCL-XL, MCL1, or BCL-XL/BCL-2, but not BCL-2 alone, enhanced cell death when combined with cisplatin or paclitaxel. Paclitaxel 139-149 BCL2 apoptosis regulator Homo sapiens 59-64 31674840-4 2021 Further mechanism of action study indicated that melognine demonstrated the ability to induce apoptosis by activation of caspase-3 and p53, and downregulation of Bcl-2 in BT549 cells. melognine 49-58 BCL2 apoptosis regulator Homo sapiens 162-167 31436296-5 2019 Western blot analysis and reverse transcription-quantitative polymerase chain reaction revealed that Fe3O4-TMZ-ICG MNPs with NIR laser irradiation lead to significantly enhanced anticancer effects on U-87 MG glioblastoma cells through the modulation of intrinsic and extrinsic apoptosis genes, including Bcl-2-associated X protein, Bcl-2, cytochrome c, caspase-3, Fas associated via death domain and caspase-8. fe3o4-tmz 101-110 BCL2 apoptosis regulator Homo sapiens 304-309 31076999-5 2019 In addition, NGN inhibited H2O2-induced mitochondrial dysfunctions, including lowered membrane potential, decreased Bcl-2/Bax ratio, cytochrome c release, and the cleavage of caspase-3. Hydrogen Peroxide 27-31 BCL2 apoptosis regulator Homo sapiens 116-121 31612056-6 2019 Furthermore, following treatment with MCL-1-selective antagonist A-1210477 and/or BCL-2/BCL-XL antagonist ABT-737, cell viability was detected. ABT-737 106-113 BCL2 apoptosis regulator Homo sapiens 82-87 31611969-10 2019 MicroRNA-152 downregulation may induce cisplatin resistance in non-small cell lung cancer cells, whereas microRNA-152 upregulation may improve cisplatin sensitivity among A549/cis cells via downregulation of Bcl-2 and NF-kappaB. Cisplatin 143-152 BCL2 apoptosis regulator Homo sapiens 208-213 31485597-9 2019 Silymarin increased the expression of Bax, phosphorylated (p)-JNK and p-p38, and cleaved poly-ADP ribose polymerase, and decreased the levels of Bcl-2 and p-ERK1/2 in a concentration-dependent manner. Silymarin 0-9 BCL2 apoptosis regulator Homo sapiens 145-150 31612056-10 2019 The results of the present study indicated that the MCL-1-selective antagonist could overcome the resistance to the BCL-2/BCL-XL antagonist (ABT-737) in vitro and in vivo. ABT-737 141-148 BCL2 apoptosis regulator Homo sapiens 116-121 31768331-0 2019 Triacontanoic ester of 5""-hydroxyjustisolin: Tumour suppressive role in cervical cancer via Bcl-2, BAX and caspase-3 mediated signalling. Esters 0-19 BCL2 apoptosis regulator Homo sapiens 93-98 31106631-6 2019 Resveratrol (RES), a sirtuin 1 agonist, inhibited PTH-induced apoptosis and restored Bcl-2 expression (p<.05). Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 85-90 31106631-6 2019 Resveratrol (RES), a sirtuin 1 agonist, inhibited PTH-induced apoptosis and restored Bcl-2 expression (p<.05). Resveratrol 13-16 BCL2 apoptosis regulator Homo sapiens 85-90 31670317-6 2019 Specifically, baicalin decreased the expression of p-EGFR, p-AKT, p-MAPK, p-S6, Bcl-2, and VEGF and increased the expression of Bax in mesothelioma cells. baicalin 14-22 BCL2 apoptosis regulator Homo sapiens 80-85 32024623-4 2019 EriB induced apoptosis in MDA-MB231 cells via inhibiting NF-kappaBp65, STAT3 phosphorylation, increasing Bax/Bcl-2 ratio, MMP dissipation, and activation of caspase-3. eriocalyxin B 0-4 BCL2 apoptosis regulator Homo sapiens 109-114 31593741-9 2019 Kidney TWEAK, IL-18, IL-1beta, TNF-alpha, NF-kappaB, Caspase 3 and Bax contents significantly decreased upon nilotinib administration while, kidney contents of Bcl2 and HSP-70 significantly increased. nilotinib 109-118 BCL2 apoptosis regulator Homo sapiens 160-164 31768331-0 2019 Triacontanoic ester of 5""-hydroxyjustisolin: Tumour suppressive role in cervical cancer via Bcl-2, BAX and caspase-3 mediated signalling. gastrofenzin 23-44 BCL2 apoptosis regulator Homo sapiens 93-98 31671654-13 2019 The results of Western Blot analysis (exposure to LEP 10 min, 1, 2, 4 and 24 h) suggest (after 24 h) decrease of p38 MAPK, p44-42 mitogen-activated protein kinase and Bcl-2 phosphorylated at threonine 56. glycyl-threonine 191-200 BCL2 apoptosis regulator Homo sapiens 167-172 31527063-6 2019 Furthermore, YLT-LL-11 facilitated OCI-LY10 cell apoptosis by upregulation of pro-apoptotic protein BAX and downregulation of anti-apoptotic protein Bcl-2. ylt-ll-11 13-22 BCL2 apoptosis regulator Homo sapiens 149-154 31801705-9 2019 Combined treatment of the cells with 3-bromopyruvate and miR-205-5p-inhibitor transfection obviously increased nuclear fragmentation and nuclear pyknosis and significantly increased cell apoptotic rate as compared with the two treatments alone (P < 0.01), causing also decreased expressions of Bcl-2 and Mcl-1 proteins and increased expressions of Bax and Bak proteins. bromopyruvate 37-52 BCL2 apoptosis regulator Homo sapiens 294-299 31801705-10 2019 CONCLUSIONS: Inhibition of miR-205-5p enhances the proapototic effect of 3-bromopyruvate in CNE2Z cells possibly in relation to the down-regulation of Mcl-1 and Bcl-2 and the up-regulation of Bak and Bax proteins. bromopyruvate 73-88 BCL2 apoptosis regulator Homo sapiens 161-166 31694111-8 2019 Compared with LPS group, the survival rate of H9C2 cardiomyocytes in baicalin intervention group increased (P<0.05), the expression level of apoptosis decreased (P<0.05), the internal flow of calcium decreased (P<0.05), the expression levels of cleaved-caspase3, Bax protein decreased (P<0.05), and the level of Bcl-2 protein increased (P<0.05), the expression of STIM1 mRNA and protein level decreased (P<0.05). baicalin 69-77 BCL2 apoptosis regulator Homo sapiens 324-329 31671764-6 2019 We further found that stybenpropol A decreased VCAM-1, ICAM-1, Bax, and caspase-9 protein levels, and increased the protein levels of Bcl-2, IKK-beta, and IkappaB-alpha. stybenpropol a 22-36 BCL2 apoptosis regulator Homo sapiens 134-139 31654522-9 2019 Apoptosis and autophagy induced by xanthoxyletin were also associated with changes in expression of the apoptosis-associated proteins, Bax and Bcl-2, and the autophagy-associated proteins, LC3I, LC3II, Beclin 1, p62, and VSp34. xanthoxyletin 35-48 BCL2 apoptosis regulator Homo sapiens 143-148 31695437-13 2019 Additionally, GDNB also promoted apoptosis of H510A and A549 cells by regulating the expression of Bcl-2, Bax, cleaved caspase 3 and cleaved PARP. ganoderan B 14-18 BCL2 apoptosis regulator Homo sapiens 99-104 31781263-7 2019 In molecular docking, ligustrazine showed binding activity with Bcl-2, Bax, caspase-9, caspase-3, and PARP. tetramethylpyrazine 22-34 BCL2 apoptosis regulator Homo sapiens 64-69 31556592-0 2019 Synthetic alpha-l-Threose Nucleic Acids Targeting BcL-2 Show Gene Silencing and in Vivo Antitumor Activity for Cancer Therapy. erythrose 10-25 BCL2 apoptosis regulator Homo sapiens 50-55 31556592-1 2019 We design and synthesize a sequence-defined alpha-l-threose nucleic acid (TNA) polymer, which is complementary to certain nucleotide sites of target anti-apoptotic proteins, BcL-2 involving in development and progression of tumors. erythrose 44-59 BCL2 apoptosis regulator Homo sapiens 174-179 31777595-9 2019 Furthermore, SSD decreased and increased the expression of P-STAT3 and Bcl-2, respectively. saikosaponin D 13-16 BCL2 apoptosis regulator Homo sapiens 71-76 31692812-4 2019 To address this we tested the potency of a hydrocarbon stapled BIM BH3 peptide (BIM SAHB A ) to overcome both BCL-2 and MCL-1 apoptotic resistance given BIM"s naturally wide ranging affinity for all BCL-2 family multidomain members. Hydrocarbons 43-54 BCL2 apoptosis regulator Homo sapiens 110-115 31692812-4 2019 To address this we tested the potency of a hydrocarbon stapled BIM BH3 peptide (BIM SAHB A ) to overcome both BCL-2 and MCL-1 apoptotic resistance given BIM"s naturally wide ranging affinity for all BCL-2 family multidomain members. N-bromoacetyl-2-iodo-5-methoxytryptamine 80-90 BCL2 apoptosis regulator Homo sapiens 110-115 31692812-4 2019 To address this we tested the potency of a hydrocarbon stapled BIM BH3 peptide (BIM SAHB A ) to overcome both BCL-2 and MCL-1 apoptotic resistance given BIM"s naturally wide ranging affinity for all BCL-2 family multidomain members. N-bromoacetyl-2-iodo-5-methoxytryptamine 80-90 BCL2 apoptosis regulator Homo sapiens 199-204 31692812-6 2019 Despite BIM BH3"s ability to bind all BCL-2 anti-apoptotic proteins, BIM SAHB A "s dominant intracellular target was MCL-1 and this specificity was exploited in sequenced combination BH3-mimetic treatments targeting BCL-2, BCL-XL, and BCL-W. N-bromoacetyl-2-iodo-5-methoxytryptamine 69-79 BCL2 apoptosis regulator Homo sapiens 216-221 31695431-15 2019 The alpha-hederin induced the depletion of GSH (P<0.05) and the accumulation of intracellular ROS (P<0.05), changed the mitochondrial membrane potential (P<0.05), increased the Bax, Apaf-1, AIF, Cyt C, cleaved caspase-3 and cleaved caspase-9 expression and decreased the protein level of Bcl-2, survivin, MMP-9 and MMP-2 (P<0.05). beta-hederin 4-17 BCL2 apoptosis regulator Homo sapiens 297-302 31777595-12 2019 These results indicated that the combination of SSD with gefitinib had an increased antitumor effect in NSCLC cells and that the molecular mechanisms were associated with the inhibition of STAT3/Bcl-2 signaling pathway. saikosaponin D 48-51 BCL2 apoptosis regulator Homo sapiens 195-200 31777595-12 2019 These results indicated that the combination of SSD with gefitinib had an increased antitumor effect in NSCLC cells and that the molecular mechanisms were associated with the inhibition of STAT3/Bcl-2 signaling pathway. gefitinib 57-66 BCL2 apoptosis regulator Homo sapiens 195-200 31443963-0 2019 MiR-143-3p suppresses the progression of nasal squamous cell carcinoma by targeting Bcl-2 and IGF1R. mir-143-3p 0-10 BCL2 apoptosis regulator Homo sapiens 84-89 31627336-0 2019 The Deubiquitinating Enzyme Inhibitor PR-619 Enhances the Cytotoxicity of Cisplatin via the Suppression of Anti-Apoptotic Bcl-2 Protein: In Vitro and In Vivo Study. 2,6-diaminopyridine-3,5-bis(thiocyanate) 38-44 BCL2 apoptosis regulator Homo sapiens 122-127 31695421-12 2019 Moreover, apiosporamide induced apoptosis, activated caspase-3, caspase-8 and caspase-9, and regulated expression of Bax and Bcl-2 in MG63 cells. apiosporamide 10-23 BCL2 apoptosis regulator Homo sapiens 125-130 31637186-11 2019 Additionally, GFX could activate the caspase-8, caspase-9, and caspase-3, induce MTP disruption, downregulate B-cell leukemia-2 (Bcl-2) and B-cell leukemia-XL (Bcl-XL), and upregulate Bcl-2 assaciated X protein (Bax), Bcl-2-associated death promoter (Bad), Bcl-2 interacting domain (Bid) and cytoplasmic cytochrome C in SFs, suggesting that caspase-dependent extrinsic and intrinsic pathways were related to GFX-contributed apoptosis of SFs. gfx 14-17 BCL2 apoptosis regulator Homo sapiens 110-127 31637186-11 2019 Additionally, GFX could activate the caspase-8, caspase-9, and caspase-3, induce MTP disruption, downregulate B-cell leukemia-2 (Bcl-2) and B-cell leukemia-XL (Bcl-XL), and upregulate Bcl-2 assaciated X protein (Bax), Bcl-2-associated death promoter (Bad), Bcl-2 interacting domain (Bid) and cytoplasmic cytochrome C in SFs, suggesting that caspase-dependent extrinsic and intrinsic pathways were related to GFX-contributed apoptosis of SFs. gfx 14-17 BCL2 apoptosis regulator Homo sapiens 129-134 31637186-11 2019 Additionally, GFX could activate the caspase-8, caspase-9, and caspase-3, induce MTP disruption, downregulate B-cell leukemia-2 (Bcl-2) and B-cell leukemia-XL (Bcl-XL), and upregulate Bcl-2 assaciated X protein (Bax), Bcl-2-associated death promoter (Bad), Bcl-2 interacting domain (Bid) and cytoplasmic cytochrome C in SFs, suggesting that caspase-dependent extrinsic and intrinsic pathways were related to GFX-contributed apoptosis of SFs. gfx 14-17 BCL2 apoptosis regulator Homo sapiens 184-189 31637186-11 2019 Additionally, GFX could activate the caspase-8, caspase-9, and caspase-3, induce MTP disruption, downregulate B-cell leukemia-2 (Bcl-2) and B-cell leukemia-XL (Bcl-XL), and upregulate Bcl-2 assaciated X protein (Bax), Bcl-2-associated death promoter (Bad), Bcl-2 interacting domain (Bid) and cytoplasmic cytochrome C in SFs, suggesting that caspase-dependent extrinsic and intrinsic pathways were related to GFX-contributed apoptosis of SFs. gfx 14-17 BCL2 apoptosis regulator Homo sapiens 184-189 31637187-7 2019 In addition, PTL induced the apoptosis of C918 cells, and decreased the expressions of Cyclin D1, B-cell lymphoma-2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-XL). parthenolide 13-16 BCL2 apoptosis regulator Homo sapiens 98-115 31637187-7 2019 In addition, PTL induced the apoptosis of C918 cells, and decreased the expressions of Cyclin D1, B-cell lymphoma-2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-XL). parthenolide 13-16 BCL2 apoptosis regulator Homo sapiens 117-122 31839747-7 2019 LPS+PA treatment group significantly decreases the relative expression level of IRS-1, PI3K, AKT, phosphorylation of AKT, TLR-4, MyD88, phosphorylation of IKKalpha, NF-kappaB, Bcl-2 and increases the relative expression level of Bax, cleaved caspase 3 and cleaved caspase 8, compared with the cells treated with NAFLD model. Palmitic Acid 4-6 BCL2 apoptosis regulator Homo sapiens 176-181 31627336-0 2019 The Deubiquitinating Enzyme Inhibitor PR-619 Enhances the Cytotoxicity of Cisplatin via the Suppression of Anti-Apoptotic Bcl-2 Protein: In Vitro and In Vivo Study. Cisplatin 74-83 BCL2 apoptosis regulator Homo sapiens 122-127 31627336-5 2019 Additionally, co-treatment of PR-619 with cisplatin potentiated cisplatin-induced cytotoxicity in UC cells and was accompanied by the concurrent suppression of Bcl-2. 2,6-diaminopyridine-3,5-bis(thiocyanate) 30-36 BCL2 apoptosis regulator Homo sapiens 160-165 31627336-5 2019 Additionally, co-treatment of PR-619 with cisplatin potentiated cisplatin-induced cytotoxicity in UC cells and was accompanied by the concurrent suppression of Bcl-2. Cisplatin 42-51 BCL2 apoptosis regulator Homo sapiens 160-165 31681603-6 2019 Silencing the identified alternative proteins via siRNA resulted in significant drop in the LC50 of the selected molecularly-targeted drugs cells resistant to ruxolitinib (via targeting Akt), everolimus (via targeting EGFR, MAPK7, RPS6KA5, and HER2), and erlotinib (via silencing Bcl2 and BIRC8). ruxolitinib 159-170 BCL2 apoptosis regulator Homo sapiens 280-284 31686915-0 2019 Isovitexin Suppresses Cancer Stemness Property And Induces Apoptosis Of Osteosarcoma Cells By Disruption Of The DNMT1/miR-34a/Bcl-2 Axis. isovitexin 0-10 BCL2 apoptosis regulator Homo sapiens 126-131 31601785-6 2019 Taken together, this study for the first time found that the effect of 1, 4-BQ on the crosstalk between autophagy and apoptosis were modulated by the ROS generation via enhancing phosphorylation of Bcl-2(Ser70) and phosphorylation of beclin1(Thr119), which offered a novel insight into underlying molecular mechanisms of benzene-induced hematotoxicity, and specifically how the crosstalk between autophagy and apoptosis was involved in benzene toxicity. 1, 4-bq 71-78 BCL2 apoptosis regulator Homo sapiens 198-203 31680958-3 2019 This study found that treatment with erinacine A not only triggers the activation of extrinsic apoptosis pathways (TNFR, Fas, FasL, and caspases) but also suppresses the expression of antiapoptotic molecules Bcl-2 and Bcl-XL via a time-dependent manner in DLD-1 cells. erinacine A 37-48 BCL2 apoptosis regulator Homo sapiens 208-213 31601785-0 2019 The crosstalk between autophagy and apoptosis was mediated by phosphorylation of Bcl-2 and beclin1 in benzene-induced hematotoxicity. Benzene 102-109 BCL2 apoptosis regulator Homo sapiens 81-86 31601785-6 2019 Taken together, this study for the first time found that the effect of 1, 4-BQ on the crosstalk between autophagy and apoptosis were modulated by the ROS generation via enhancing phosphorylation of Bcl-2(Ser70) and phosphorylation of beclin1(Thr119), which offered a novel insight into underlying molecular mechanisms of benzene-induced hematotoxicity, and specifically how the crosstalk between autophagy and apoptosis was involved in benzene toxicity. ros 150-153 BCL2 apoptosis regulator Homo sapiens 198-203 31601785-4 2019 Results showed that benzene metabolite (1, 4-benzoquinone, 1, 4-BQ) dose-dependently induced autophagy and apoptosis via enhancing phosphorylation of Bcl-2 and beclin1. Benzene 20-27 BCL2 apoptosis regulator Homo sapiens 150-155 31601785-4 2019 Results showed that benzene metabolite (1, 4-benzoquinone, 1, 4-BQ) dose-dependently induced autophagy and apoptosis via enhancing phosphorylation of Bcl-2 and beclin1. quinone 40-57 BCL2 apoptosis regulator Homo sapiens 150-155 31618367-11 2019 SchA increased cell apoptosis along with the up-regulation of pro-apoptotic proteins (cleaved-caspase-3, cleaved-caspase-9, and Bax) and the down-regulation of anti-apoptotic protein (Bcl-2). schizandrin A 0-4 BCL2 apoptosis regulator Homo sapiens 184-189 31348906-9 2019 Quercetin increased the expression of Bax, phospho-JNK, phospho-p38 and phospho-ERK1/2, cleaved poly-ADP ribose polymerase and decreased Bcl-2 in a concentration-dependent manner. Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 137-142 31658771-5 2019 Molecular docking and binding energy calculations show that gossypol has a similar affinity to the Bcl2 (B-cell lymphoma 2) family of proteins and several dehydrogenases. Gossypol 60-68 BCL2 apoptosis regulator Homo sapiens 99-103 31658771-5 2019 Molecular docking and binding energy calculations show that gossypol has a similar affinity to the Bcl2 (B-cell lymphoma 2) family of proteins and several dehydrogenases. Gossypol 60-68 BCL2 apoptosis regulator Homo sapiens 105-122 31649888-4 2019 Atorvastatin also induced apoptosis in both cell lines, in which the reactive oxygen species (ROS)-related mitochondrial apoptotic signaling might be involved, with increase of ROS and Bax/Bcl-2 ratio, loss of mitochondrial membrane potential (MMP), release of cytochrome C into cytosol, and activation of Bax/Caspase-9/Caspase-3/PARP pathway. atorvastatin 0-12 BCL2 apoptosis regulator Homo sapiens 189-194 31601054-5 2019 For this situation, actinomycin V decreased the M-phase related proteins (Cdc2, Cdc25A and Cyclin B1) expression, arrested cells in G2/M phase and subsequently triggered apoptosis by mediating the Bcl-2 family proteins" expression (Bax and Bcl-2). Dactinomycin 20-31 BCL2 apoptosis regulator Homo sapiens 197-202 31601054-5 2019 For this situation, actinomycin V decreased the M-phase related proteins (Cdc2, Cdc25A and Cyclin B1) expression, arrested cells in G2/M phase and subsequently triggered apoptosis by mediating the Bcl-2 family proteins" expression (Bax and Bcl-2). Dactinomycin 20-31 BCL2 apoptosis regulator Homo sapiens 240-245 31539237-8 2019 Mechanistic studies demonstrate that PtNP induced apoptosis via mitochondrial pathways by upregulating Bax and Puma and downregulating Bcl-2 proteins, leading to the release of cytochrome c and activation of caspase-3 and caspase-9. ptnp 37-41 BCL2 apoptosis regulator Homo sapiens 135-140 31601785-4 2019 Results showed that benzene metabolite (1, 4-benzoquinone, 1, 4-BQ) dose-dependently induced autophagy and apoptosis via enhancing phosphorylation of Bcl-2 and beclin1. 1, 4-bq 59-66 BCL2 apoptosis regulator Homo sapiens 150-155 31601785-5 2019 Finally, we also found that the elevated ROS was in line with enhancing the phosphorylation of Bcl-2 and beclin1 which contributed to 1, 4-BQ-induced autophagy and apoptosis. ros 41-44 BCL2 apoptosis regulator Homo sapiens 95-100 31601785-5 2019 Finally, we also found that the elevated ROS was in line with enhancing the phosphorylation of Bcl-2 and beclin1 which contributed to 1, 4-BQ-induced autophagy and apoptosis. 1, 4-bq 134-141 BCL2 apoptosis regulator Homo sapiens 95-100 31597910-11 2019 Treatment of DLD-1 cells with imidazole suppressed Bcl-2 and promoted Bax, p53, and cytc expression. imidazole 30-39 BCL2 apoptosis regulator Homo sapiens 51-56 31632027-11 2019 Rh2HAZnO induced apoptotic process through p53-mediated pathway by upregulating p53 and BAX and downregulating BCL2. Rhodium 0-8 BCL2 apoptosis regulator Homo sapiens 111-115 31558028-2 2019 Based on the fluorescence attenuation by graphene oxide, we developed a single-molecule imaging method termed surface-induced fluorescence attenuation (smSIFA), which enabled us to track both vertical and lateral kinetics of singly labeled BCL-2 family protein tBid during membrane permeabilization. graphene oxide 41-55 BCL2 apoptosis regulator Homo sapiens 240-245 31608167-11 2019 In addition, gene expression analysis revealed that MnIII complex exerts its antiproliferative effect via up-and down-regulation of p21 and cyclin D1, respectively, along with increased expression of Bax/Bcl-2 ratio, TNF-alpha, initiator caspase-8 and -10 and effector caspase-3 in MCF-7 and MDA-MB-231 cells. Manganese 52-57 BCL2 apoptosis regulator Homo sapiens 204-209 31590241-5 2019 In addition, isorhamnetin-induced apoptosis was associated with the increased expression of the Fas/Fas ligand, reduced ratio of B-cell lymphoma 2 (Bcl-2)/Bcl-2 associated X protein (Bax) expression, cytosolic release of cytochrome c, and activation of caspases. 3-methylquercetin 13-25 BCL2 apoptosis regulator Homo sapiens 129-146 31590241-5 2019 In addition, isorhamnetin-induced apoptosis was associated with the increased expression of the Fas/Fas ligand, reduced ratio of B-cell lymphoma 2 (Bcl-2)/Bcl-2 associated X protein (Bax) expression, cytosolic release of cytochrome c, and activation of caspases. 3-methylquercetin 13-25 BCL2 apoptosis regulator Homo sapiens 148-153 31590241-5 2019 In addition, isorhamnetin-induced apoptosis was associated with the increased expression of the Fas/Fas ligand, reduced ratio of B-cell lymphoma 2 (Bcl-2)/Bcl-2 associated X protein (Bax) expression, cytosolic release of cytochrome c, and activation of caspases. 3-methylquercetin 13-25 BCL2 apoptosis regulator Homo sapiens 155-160 31047885-8 2019 The highest-dose group of allopurinol (90 mg/kg) attenuated pain-like behaviors compared with the normal saline treated group, and this was accompanied by normalization of iNOS, bax/bcl2, caspase 3, iba-1 and TNF-alpha gene expression changes. Allopurinol 26-37 BCL2 apoptosis regulator Homo sapiens 182-186 31093908-4 2019 Tamarixetin enhanced the expression levels of pro-apoptotic proteins including Bax and cleaved caspase-3 and inhibited the expression levels of anti-apoptotic proteins including Bcl-2 and Bcl-xL in liver cancer cells and their xenografted tumor tissues. tamarixetin 0-11 BCL2 apoptosis regulator Homo sapiens 178-183 31304555-8 2019 Further, IPA-3 treatment caused increased EGR1 protein levels and decreased apoptosis-related BCL-2 and pho-BAD protein levels. 1-isopropyldiazen-1-ium-1,2-diolate 9-14 BCL2 apoptosis regulator Homo sapiens 94-99 31517730-5 2019 At the molecular level, tetrandrine induced downregulation of Bcl-2 and simultaneous upregulation of Bax and caspase-3 as well as enhanced cell apoptosis.Our results demonstrated that tetrandrine inhibited the cell viability and proliferation of CD133 Hep-2 cells by reducing the number of cells in the S-phase of the cell cycle and enhancing cell apoptosis. tetrandrine 24-35 BCL2 apoptosis regulator Homo sapiens 62-67 31517730-5 2019 At the molecular level, tetrandrine induced downregulation of Bcl-2 and simultaneous upregulation of Bax and caspase-3 as well as enhanced cell apoptosis.Our results demonstrated that tetrandrine inhibited the cell viability and proliferation of CD133 Hep-2 cells by reducing the number of cells in the S-phase of the cell cycle and enhancing cell apoptosis. tetrandrine 184-195 BCL2 apoptosis regulator Homo sapiens 62-67 31283994-6 2019 (3) DAla2GIP prevents chondrocyte apoptosis by inhibiting calcium influx of chondrocyte and regulating expression of Bcl-2 and Caspase-3induced by H2O2. Hydrogen Peroxide 147-151 BCL2 apoptosis regulator Homo sapiens 117-122 27025925-5 2019 Psoralidin also increases the expression of pro-apoptosis genes Bax, Bid and p53 while decreases the expression of pro-survival genes Bcl-2 and Bcl-xL, both in a concentration dependent manner between 4 and 64 mumol/L (P<0.05 at 16 and 64 mumol/L). psoralidin 0-10 BCL2 apoptosis regulator Homo sapiens 134-139 30989245-2 2019 Here, we demonstrate that such inhibition occurs under conditions of basal, but not high IP3R activity, since overexpressed and purified Bcl-2 (or its BH4 domain) can inhibit IP3R function provoked by low concentration of agonist or IP3, while fails to attenuate against high concentration of agonist or IP3. Inositol 1,4,5-Trisphosphate 175-178 BCL2 apoptosis regulator Homo sapiens 137-142 30989245-2 2019 Here, we demonstrate that such inhibition occurs under conditions of basal, but not high IP3R activity, since overexpressed and purified Bcl-2 (or its BH4 domain) can inhibit IP3R function provoked by low concentration of agonist or IP3, while fails to attenuate against high concentration of agonist or IP3. sapropterin 151-154 BCL2 apoptosis regulator Homo sapiens 137-142 30989245-4 2019 Using a plethora of computational, biochemical and biophysical methods, we demonstrate that Bcl-2 and more particularly its BH4 domain bind to the ligand-binding domain (LBD) of IP3R1. sapropterin 124-127 BCL2 apoptosis regulator Homo sapiens 92-97 30989245-5 2019 In line with this finding, the interaction between the LBD and Bcl-2 (or its BH4 domain) was sensitive to IP3 and adenophostin A, ligands of the IP3R. sapropterin 77-80 BCL2 apoptosis regulator Homo sapiens 63-68 31581454-6 2019 Our study evidenced that GS treatment altered expression of Bcl-2 mediated the mitochondrial release of cytochrome c which triggered the formation of apoptosome as well as activation of caspase-3/7 leading to death of HCT 116 cells via intrinsic apoptosis pathway. pregna-4,17-diene-3,16-dione 25-27 BCL2 apoptosis regulator Homo sapiens 60-65 31581454-8 2019 In addition, GS was found to inhibit NF-kB signaling in colon cancer cells by quelling the expression of its regulated gene products Bcl-2, cIAP-1, and survivin. pregna-4,17-diene-3,16-dione 13-15 BCL2 apoptosis regulator Homo sapiens 133-138 30989245-5 2019 In line with this finding, the interaction between the LBD and Bcl-2 (or its BH4 domain) was sensitive to IP3 and adenophostin A, ligands of the IP3R. Inositol 1,4,5-Trisphosphate 106-109 BCL2 apoptosis regulator Homo sapiens 63-68 31433961-8 2019 Treatment of A431 cells with TQ-induced apoptosis, which was associated with the induction of p53 and Bax, inhibition of Mdm2, Bcl-2, and Bcl-xl expression, and activation of caspase-9, -7, and -3. thymoquinone 29-31 BCL2 apoptosis regulator Homo sapiens 127-132 30989245-5 2019 In line with this finding, the interaction between the LBD and Bcl-2 (or its BH4 domain) was sensitive to IP3 and adenophostin A, ligands of the IP3R. adenophostin A 114-128 BCL2 apoptosis regulator Homo sapiens 63-68 30989245-6 2019 Vice versa, the BH4 domain of Bcl-2 counteracted the binding of IP3 to the LBD. sapropterin 16-19 BCL2 apoptosis regulator Homo sapiens 30-35 30989245-6 2019 Vice versa, the BH4 domain of Bcl-2 counteracted the binding of IP3 to the LBD. Inositol 1,4,5-Trisphosphate 64-67 BCL2 apoptosis regulator Homo sapiens 30-35 30989245-8 2019 This allows for exquisite modulation of Bcl-2"s inhibitory properties on IP3Rs that is tunable to the level of IP3 signaling in cells. Inositol 1,4,5-Trisphosphate 73-76 BCL2 apoptosis regulator Homo sapiens 40-45 31423616-7 2019 Further, ATO induced mitochondria-dependent apoptosis as indicated by increased Bax/Bcl-2 ratio, cleaved caspase-3, mitochondrial cytochrome c release and Annexin V-fluorescein isothiocyanate/propidium iodide staining. Atorvastatin 9-12 BCL2 apoptosis regulator Homo sapiens 84-89 31631038-11 2019 INTERPRETATION: circHIPK3 functions as a chemoresistant gene in CRC cells by targeting the miR-637/STAT3/Bcl-2/beclin1 axis and might be a prognostic predictor for CRC patients who receive oxaliplatin-based chemotherapy. oxaliplatin 189-200 BCL2 apoptosis regulator Homo sapiens 105-110 31353975-9 2019 Combinations of hypomethylating agents (HMA) with other compounds, and inhibitors of bcl2, such as venetoclax are being developed for higher-risk patients. venetoclax 99-109 BCL2 apoptosis regulator Homo sapiens 85-89 30846494-9 2019 The AZD6244/LBH589 combination was specifically active in cell lines with more BIM:MCL-1 complexes at baseline; resistant cell lines had more BIM:BCL-2 complexes. AZD 6244 4-11 BCL2 apoptosis regulator Homo sapiens 146-151 31276896-4 2019 Furthermore, the amine 4c, naphthoquinone 5, and azo-based 13 and 15 organic selenides were able to down-regulate the expression of Bcl-2 and up-regulate the expression levels of IL-2, IL-6 and CD40 in HepG2 cells compared to untreated cells. Amines 17-22 BCL2 apoptosis regulator Homo sapiens 132-137 31276896-4 2019 Furthermore, the amine 4c, naphthoquinone 5, and azo-based 13 and 15 organic selenides were able to down-regulate the expression of Bcl-2 and up-regulate the expression levels of IL-2, IL-6 and CD40 in HepG2 cells compared to untreated cells. Naphthoquinones 27-41 BCL2 apoptosis regulator Homo sapiens 132-137 31276896-4 2019 Furthermore, the amine 4c, naphthoquinone 5, and azo-based 13 and 15 organic selenides were able to down-regulate the expression of Bcl-2 and up-regulate the expression levels of IL-2, IL-6 and CD40 in HepG2 cells compared to untreated cells. azo-based 49-58 BCL2 apoptosis regulator Homo sapiens 132-137 31276896-4 2019 Furthermore, the amine 4c, naphthoquinone 5, and azo-based 13 and 15 organic selenides were able to down-regulate the expression of Bcl-2 and up-regulate the expression levels of IL-2, IL-6 and CD40 in HepG2 cells compared to untreated cells. selenides 77-86 BCL2 apoptosis regulator Homo sapiens 132-137 31696502-18 2019 After treatment with curcumin, the expression of Bcl-2 was decreased and that of Bax and active caspase-3 was increased. Curcumin 21-29 BCL2 apoptosis regulator Homo sapiens 49-54 31203647-4 2019 RESULTS: Alantolactone induced apoptosis of gastric cancer cells by regulating the expression of Bax, Bcl-2, and p53, which related to intrinsic apoptotic pathway, and suppressed colony formation, migration, and invasion by mediating the expression of matrix metalloproteinase (MMP)-2, MMP-7, and MMP-9. alantolactone 9-22 BCL2 apoptosis regulator Homo sapiens 102-107 31432126-0 2019 [Corrigendum] MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2. Bortezomib 92-102 BCL2 apoptosis regulator Homo sapiens 116-121 31175323-0 2019 Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML. venetoclax 91-101 BCL2 apoptosis regulator Homo sapiens 75-80 31161672-0 2019 Centaurea cyanus extracted 13-O-acetylsolstitialin A decrease Bax/Bcl-2 ratio and expression of cyclin D1/Cdk-4 to induce apoptosis and cell cycle arrest in MCF-7 and MDA-MB-231 breast cancer cell lines. 13-o-acetylsolstitialin 27-50 BCL2 apoptosis regulator Homo sapiens 66-71 31898651-6 2019 Results: Compared with parental HeLa cells, HeLa/Taxol with Taxol resistance had the following biological characteristics: first, they had a lower growth velocity; second, the expression of P-glycoprotein and glutathione S-transferases was significantly increased; Third, the expression of antiapoptotic protein Bcl-2 and apoptosis inhibitor protein survivin was prominently increased. Paclitaxel 49-54 BCL2 apoptosis regulator Homo sapiens 312-317 31898651-6 2019 Results: Compared with parental HeLa cells, HeLa/Taxol with Taxol resistance had the following biological characteristics: first, they had a lower growth velocity; second, the expression of P-glycoprotein and glutathione S-transferases was significantly increased; Third, the expression of antiapoptotic protein Bcl-2 and apoptosis inhibitor protein survivin was prominently increased. Paclitaxel 60-65 BCL2 apoptosis regulator Homo sapiens 312-317 31898651-6 2019 Results: Compared with parental HeLa cells, HeLa/Taxol with Taxol resistance had the following biological characteristics: first, they had a lower growth velocity; second, the expression of P-glycoprotein and glutathione S-transferases was significantly increased; Third, the expression of antiapoptotic protein Bcl-2 and apoptosis inhibitor protein survivin was prominently increased. Glutathione 209-220 BCL2 apoptosis regulator Homo sapiens 312-317 31898651-7 2019 Conclusions: The drug-resistance in HeLa/Taxol is mainly associated with the high expression of multidrug resistance genes, antiapoptotic protein Bcl-2, and apoptosis inhibitor protein survivin as an important reason for the failure of chemotherapy of tumor tissue. Paclitaxel 41-46 BCL2 apoptosis regulator Homo sapiens 146-151 30872780-0 2019 Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma. venetoclax 34-44 BCL2 apoptosis regulator Homo sapiens 74-79 30872780-1 2019 The BCL-2 inhibitor venetoclax has only limited activity in DLBCL despite frequent BCL-2 overexpression. venetoclax 20-30 BCL2 apoptosis regulator Homo sapiens 4-9 30872780-1 2019 The BCL-2 inhibitor venetoclax has only limited activity in DLBCL despite frequent BCL-2 overexpression. venetoclax 20-30 BCL2 apoptosis regulator Homo sapiens 83-88 30872780-3 2019 We report that pharmacological inhibition of SYK or BTK synergistically enhances venetoclax sensitivity in BCL-2-positive DLBCL cell lines with an activated BCR pathway in vitro and in a xenograft model in vivo, despite the only modest direct cytotoxic effect. venetoclax 81-91 BCL2 apoptosis regulator Homo sapiens 107-112 31297844-7 2019 In the presence of enzalutamide, apoptosis occurred which was shown by increased BAX expression, decreased Bcl-2 expression, nuclear pyknosis, and genomic DNA fragmentation. enzalutamide 19-31 BCL2 apoptosis regulator Homo sapiens 107-112 31408847-6 2019 Treatment of porcine embryo with melatonin significantly increased formation rates of blastocysts and their total cell numbers, and also upregulated the expression of Nrf2/ARE signaling and apoptosis-related genes (MT2, Nrf2, UCHL, HO-1, SOD1, and Bcl-2). Melatonin 33-42 BCL2 apoptosis regulator Homo sapiens 248-253 31485626-4 2019 Result from the present study demonstrated that treatment with pemetrexed suppressed lung cancer cell proliferation, inhibited mRNA and protein expression levels of anti-apoptotic Bcl2, and increased the mRNA and the protein expression levels of pro-apoptotic p53 and apoptosis regulator BAX. Pemetrexed 63-73 BCL2 apoptosis regulator Homo sapiens 180-184 31485606-6 2019 Furthermore, MO-B could alleviate H2O2-induced apoptosis in HUVECs, which is consistent with the expression of apoptosis-associated genes and proteins in cells, including Bax/Bcl-2 and caspase-3. methylophiopogonanone B 13-17 BCL2 apoptosis regulator Homo sapiens 175-180 31432162-6 2019 Cisplatin also induced Bcl-2-associated X protein expression, and decreased that of Bcl-2 and c-Myc in lung adenocarcinoma cells. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 23-28 31524277-10 2019 Exposure to PFOA also induced the expression of vimentin, SGK1, cyclin E2, CDK2, AKT, PI3K and Bcl-2, but suppressed the expression of Bax in the RD cells. perfluorooctanoic acid 12-16 BCL2 apoptosis regulator Homo sapiens 95-100 31516599-0 2019 Vitamin C induces human melanoma A375 cell apoptosis via Bax- and Bcl-2-mediated mitochondrial pathways. Ascorbic Acid 0-9 BCL2 apoptosis regulator Homo sapiens 66-71 31516599-8 2019 Furthermore, vitamin C induced apoptosis in A375 cells by activating the Bax- and Bcl-2-mediated mitochondrial pathway. Ascorbic Acid 13-22 BCL2 apoptosis regulator Homo sapiens 82-87 31485606-6 2019 Furthermore, MO-B could alleviate H2O2-induced apoptosis in HUVECs, which is consistent with the expression of apoptosis-associated genes and proteins in cells, including Bax/Bcl-2 and caspase-3. Hydrogen Peroxide 34-38 BCL2 apoptosis regulator Homo sapiens 175-180 31485616-6 2019 In addition, more typical morphological changes associated with apoptosis emerged, and the ratio of Bax/Bcl-2 and activity of caspase-3 were markedly increased in K562/ADM cells treated with HCQ. Hydroxychloroquine 191-194 BCL2 apoptosis regulator Homo sapiens 104-109 31077746-9 2019 Salinomycin abrogated nuclear translocation of NF-kappaB proteins and also caused a concurrent reduction in NF-kappaB regulated expression of pro-survival proteins e.g., survivin, XIAP and BCL-2 in CDDP-resistant cells. salinomycin 0-11 BCL2 apoptosis regulator Homo sapiens 189-194 31579427-1 2019 The aim of the present study was to examine the role of ABT-737, an inhibitor of B-cell lymphoma 2 (Bcl-2), in enhancing the effect of irradiation on uterine cervical cancer. ABT-737 56-63 BCL2 apoptosis regulator Homo sapiens 81-98 31579427-1 2019 The aim of the present study was to examine the role of ABT-737, an inhibitor of B-cell lymphoma 2 (Bcl-2), in enhancing the effect of irradiation on uterine cervical cancer. ABT-737 56-63 BCL2 apoptosis regulator Homo sapiens 100-105 30797877-3 2019 In the present study, we demonstrate that upregulation of cyclin B1/CDK1 is responsible for the increased phosphorylation of the anti-apoptotic proteins Bcl-2 and Bcl-XL in 2-methoxyestradiol-induced, mitotically-arrested cancer cells. 2-Methoxyestradiol 173-191 BCL2 apoptosis regulator Homo sapiens 153-158 31077746-9 2019 Salinomycin abrogated nuclear translocation of NF-kappaB proteins and also caused a concurrent reduction in NF-kappaB regulated expression of pro-survival proteins e.g., survivin, XIAP and BCL-2 in CDDP-resistant cells. cddp 198-202 BCL2 apoptosis regulator Homo sapiens 189-194 31207345-9 2019 NA-2 also delayed the wound healing process, arrested cell cycle at G0/G1 phase and induced apoptosis by enhancing Bax/Bcl-2 ratio. sodium sulfide 0-4 BCL2 apoptosis regulator Homo sapiens 119-124 31607295-8 2019 The study results also revealed that dehydrocostus lactone significantly inhibited the expression of BCR/ABL STAT3, STAT5, CyclinB1, CDK1 and BCL-2, and up-regulated the expression level of BAX and p21. dehydrocostus lactone 37-58 BCL2 apoptosis regulator Homo sapiens 142-147 31607321-7 2019 Western blot showed that the treatment with quercetin (2, 4 and 8 mumol/L) promoted the expression of anti-apoptotic protein BCL-2, inhibited the expression of pro-apoptotic protein BAX, resulting in a significant increase in the ratio of BCL-2/BAX (P<0.01), thereby inhibiting the apoptosis of platelets. Quercetin 44-53 BCL2 apoptosis regulator Homo sapiens 125-130 31607321-7 2019 Western blot showed that the treatment with quercetin (2, 4 and 8 mumol/L) promoted the expression of anti-apoptotic protein BCL-2, inhibited the expression of pro-apoptotic protein BAX, resulting in a significant increase in the ratio of BCL-2/BAX (P<0.01), thereby inhibiting the apoptosis of platelets. Quercetin 44-53 BCL2 apoptosis regulator Homo sapiens 239-244 31607321-9 2019 CONCLUSION: Quercetin can inhibit platelet apoptosis by increasing the ratio of apoptosis-related protein BCL-2/BAX in a concentration-dependent manner. Quercetin 12-21 BCL2 apoptosis regulator Homo sapiens 106-111 31607304-14 2019 CONCLUSION: Baicalin derivative 02-036 can effectively inhibit the proliferation and induce apoptosis of CA46 cells, and its related mechanisms may be correlated with the down-regulation of apoptosis-related molecule expression levels, such as BCL-2, Pro-caspase-9, Pro-caspase-3, PARP and C-MYC. baicalin 12-20 BCL2 apoptosis regulator Homo sapiens 244-249 31880521-4 2019 Western blot assay was used to determine the effect of rubimaillin on the expressions of Bcl-2, Bax, PARP, cleaved PARP, caspase3, cleaved caspase3, and other apoptosis-related proteins in SKOV-3 cells. rubimaillin 55-66 BCL2 apoptosis regulator Homo sapiens 89-94 31575007-7 2019 BT treatment increased annexin-V-positive cells, promoted procaspase-3 and PARP cleavage, and downregulated the mRNA and protein expression of diverse proteins (Bcl-2, Bcl-xl, survivin) in HNSCC cells. brusatol 0-2 BCL2 apoptosis regulator Homo sapiens 161-166 31619992-9 2019 Additional results revealed that NAT-F could up-regulate pro-apoptotic protein Bax and down-regulate anti-apoptotic protein Bcl-2, Mcl-1, and Bcl-xL, resulting in cytochrome c release from mitochondria and sequential activation of caspase-9 and -3, as well as the cleavage of poly (ADP-ribose) polymerase. neoantimycin 33-38 BCL2 apoptosis regulator Homo sapiens 124-129 31421117-4 2019 PPI induced apoptosis via activating JNK pathway, as evidenced by the decreased Bcl-2 levels and increased Bax, cleaved-caspase-3 and phosphorylated-JNK expressions. polyphyllin I 0-3 BCL2 apoptosis regulator Homo sapiens 80-85 31540454-6 2019 Apoptosis and cell cycle arrest were induced by fludioxonil (10-7-10-5 M) in the Jurkat T cells at 24 and 48 h and Ramos B cells at 48 h. Moreover, the protein levels of pro-apoptotic proteins, such as p53, BAX, and cleaved caspase 3, were increased and anti-apoptotic protein Bcl-2 was decreased by fludioxonil. fludioxonil 48-59 BCL2 apoptosis regulator Homo sapiens 277-282 31110129-5 2019 This review summarizes discoveries over the past 30 years that have elucidated Bcl-2"s role in the normal immune system, including its actions in regulating calcium (Ca2+) signals necessary for the immune response, and for Ca2+-mediated apoptosis at the end of an immune response. Calcium 157-164 BCL2 apoptosis regulator Homo sapiens 79-84 31637258-5 2019 Our data showed that overexpression of Bcl-2 dramatically prevented TNFalpha/CHX-induced apoptosis, and then pro-apoptotic protein Bak was downregulated and became more resistant to TNFalpha/CHX-induced apoptosis, because both TNFalpha/CHX-induced PARP cleavage and caspase activation were blocked in BAK-/- cells or using specific siRNA, whereas Bax was dispensable in TNFalpha/CHX-induced apoptosis, as evidenced using specific siRNA. N-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-N,N',N',N'',N''-pentaacetic acid 191-194 BCL2 apoptosis regulator Homo sapiens 39-44 31637258-5 2019 Our data showed that overexpression of Bcl-2 dramatically prevented TNFalpha/CHX-induced apoptosis, and then pro-apoptotic protein Bak was downregulated and became more resistant to TNFalpha/CHX-induced apoptosis, because both TNFalpha/CHX-induced PARP cleavage and caspase activation were blocked in BAK-/- cells or using specific siRNA, whereas Bax was dispensable in TNFalpha/CHX-induced apoptosis, as evidenced using specific siRNA. N-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-N,N',N',N'',N''-pentaacetic acid 191-194 BCL2 apoptosis regulator Homo sapiens 39-44 31637258-5 2019 Our data showed that overexpression of Bcl-2 dramatically prevented TNFalpha/CHX-induced apoptosis, and then pro-apoptotic protein Bak was downregulated and became more resistant to TNFalpha/CHX-induced apoptosis, because both TNFalpha/CHX-induced PARP cleavage and caspase activation were blocked in BAK-/- cells or using specific siRNA, whereas Bax was dispensable in TNFalpha/CHX-induced apoptosis, as evidenced using specific siRNA. N-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-N,N',N',N'',N''-pentaacetic acid 191-194 BCL2 apoptosis regulator Homo sapiens 39-44 31512681-8 2019 Withaferin-A prompted mitochondrial apoptosis, which was also associated with increased level of Bax and decreased Bcl-2 in MDA-MB-231 cells. withaferin A 0-12 BCL2 apoptosis regulator Homo sapiens 115-120 31303271-3 2019 BH3 mimetics have been developed targeting anti-apoptotic proteins of Bcl-2 family as small molecular drugs. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 70-75 31637258-1 2019 TNFalpha/CHX-induced apoptosis is dependent on caspase-8 activation and regulated by Bcl-2. N-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-N,N',N',N'',N''-pentaacetic acid 9-12 BCL2 apoptosis regulator Homo sapiens 85-90 31637258-5 2019 Our data showed that overexpression of Bcl-2 dramatically prevented TNFalpha/CHX-induced apoptosis, and then pro-apoptotic protein Bak was downregulated and became more resistant to TNFalpha/CHX-induced apoptosis, because both TNFalpha/CHX-induced PARP cleavage and caspase activation were blocked in BAK-/- cells or using specific siRNA, whereas Bax was dispensable in TNFalpha/CHX-induced apoptosis, as evidenced using specific siRNA. N-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-N,N',N',N'',N''-pentaacetic acid 77-80 BCL2 apoptosis regulator Homo sapiens 39-44 31319070-7 2019 DOX markedly increased reactive oxygen species production, p53 expression, caspase-3 activity, cleaved caspase-3 levels, and TUNEL-positive cell numbers but reduced Bcl-2 expression and intracellular antioxidant enzyme levels; these effects were effectively antagonized through nicorandil (3 muM, 12 h) pretreatment, which resulted in HUVECs being protected from DOX-induced apoptosis. Doxorubicin 0-3 BCL2 apoptosis regulator Homo sapiens 165-170 31521140-14 2019 Bax was upregulated while bcl-2, cIAP-2, and XIAP levels were downregulated in SW1990 and BxPC3 cells treated with gemcitabine and SN extracts. gemcitabine 115-126 BCL2 apoptosis regulator Homo sapiens 26-31 31648477-0 2019 [Ibrutinib combined with CAR-T cells in the treatment of del (17p) chronic lymphocytic leukemia with BCL-2 inhibitor resistance: a case report and literature review]. ibrutinib 1-10 BCL2 apoptosis regulator Homo sapiens 101-106 31648477-2 2019 Methods: One case of del (17p) CLL patients with BCL-2 inhibitor resistance was treated with ibrutinib combined with CAR-T cells, successfully bridged to allogeneic hematopoietic stem cell transplantation (allo-HSCT) , and the relative literatures were reviewed. ibrutinib 93-102 BCL2 apoptosis regulator Homo sapiens 49-54 31389699-2 2019 We reported success in the development of two PROTACs (C3 and C5) that potently and selectively induce the degradation of Mcl-1 and Bcl-2 (DC50 = 0.7 and 3.0 muM), respectively, by introducing the E3 ligase cereblon-binding ligand pomalidomide to Mcl-1/Bcl-2 dual inhibitors S1-6 and Nap-1 with micromolar-range affinity. pomalidomide 231-243 BCL2 apoptosis regulator Homo sapiens 132-137 31362241-8 2019 VSMCs treated with siRNA-ANXA3 or SP600125 showed decreased expression of JNK, caspase-3, osteopontin (OPN), Bax, and matrix metalloproteinase-9 (MMP-9), as well as phosphate (p)-JNK, but increased the expression of alpha smooth muscle actin (alpha-SMA), beta-tubulin, and Bcl-2. pyrazolanthrone 34-42 BCL2 apoptosis regulator Homo sapiens 273-278 31491956-6 2019 Lycopene decreased cell viability and increased apoptotic indices (DNA fragmentation, apoptosis inducing factor, cleavage of caspase-3 and caspase-9, Bax/Bcl-2 ratio). Lycopene 0-8 BCL2 apoptosis regulator Homo sapiens 154-159 31552178-5 2019 Moreover, cinobufagin clearly inhibited the levels of phosphoinositide 3-kinase (PI3K), phosphorylated PI3K (p-PI3K), AKT, p-AKT, and B-cell lymphoma 2 (Bcl-2). cinobufagin 10-21 BCL2 apoptosis regulator Homo sapiens 134-151 31552178-5 2019 Moreover, cinobufagin clearly inhibited the levels of phosphoinositide 3-kinase (PI3K), phosphorylated PI3K (p-PI3K), AKT, p-AKT, and B-cell lymphoma 2 (Bcl-2). cinobufagin 10-21 BCL2 apoptosis regulator Homo sapiens 153-158 31551765-8 2019 Moreover, we also found that alpha-H downregulated the anti-apoptotic Bcl-2 and Bcl-xL proteins and activated the pro-apoptotic Bid and Bax proteins. MK 316 29-36 BCL2 apoptosis regulator Homo sapiens 70-75 31534865-0 2019 Identification of Aloperine as an anti-apoptotic Bcl2 protein inhibitor in glioma cells. aloperine 18-27 BCL2 apoptosis regulator Homo sapiens 49-53 31534865-8 2019 Moreover, western blot and qPCR analysis showed that ALO downregulated Bcl2 expression in human glioma cell lines, SK-N-AS and U118. sk-n-as 115-122 BCL2 apoptosis regulator Homo sapiens 71-75 31534865-9 2019 Using flow cytometry methods, we further confirmed that ALO significantly promotes apoptosis in SK-N-AS and U118 cell lines, similar to the effect induced by ABT-737, a well-known Bcl2 inhibitor. aloperine 56-59 BCL2 apoptosis regulator Homo sapiens 180-184 31534865-9 2019 Using flow cytometry methods, we further confirmed that ALO significantly promotes apoptosis in SK-N-AS and U118 cell lines, similar to the effect induced by ABT-737, a well-known Bcl2 inhibitor. ABT-737 158-165 BCL2 apoptosis regulator Homo sapiens 180-184 31475956-9 2019 The inhibition of the CSE/H2S pathway, induced by transfection with specific siRNA against human CSE (si-CSE), eliminated the trimetazidine-induced upregulation of cell viability, downregulation of LDH release, increase of caspase-3 activity and apoptosis regulator BAX expression, and the decrease of apoptosis regulator Bcl-2 expression, which suggests involvement of the CSE/H2S pathway in trimetazidine-induced cardioprotection. Trimetazidine 126-139 BCL2 apoptosis regulator Homo sapiens 302-327 31475956-9 2019 The inhibition of the CSE/H2S pathway, induced by transfection with specific siRNA against human CSE (si-CSE), eliminated the trimetazidine-induced upregulation of cell viability, downregulation of LDH release, increase of caspase-3 activity and apoptosis regulator BAX expression, and the decrease of apoptosis regulator Bcl-2 expression, which suggests involvement of the CSE/H2S pathway in trimetazidine-induced cardioprotection. Deuterium 26-29 BCL2 apoptosis regulator Homo sapiens 302-327 31059787-1 2019 BCL-XL, an anti-apoptotic BCL-2 family protein, potently inhibits BAK oligomerization and the formation of toxic mitochondrial pores in response to cellular stress. bakuchiol 66-69 BCL2 apoptosis regulator Homo sapiens 26-31 30880686-10 2019 In addition, modulation of ZEB1 and subsequent change in MRP4 expression correlated with a lower apoptotic response to docetaxel, characterized by lower B-cell lymphoma 2 (Bcl2), high BCL2-associated X protein (Bax), and high active caspase 3 expression. Docetaxel 119-128 BCL2 apoptosis regulator Homo sapiens 153-170 30880686-10 2019 In addition, modulation of ZEB1 and subsequent change in MRP4 expression correlated with a lower apoptotic response to docetaxel, characterized by lower B-cell lymphoma 2 (Bcl2), high BCL2-associated X protein (Bax), and high active caspase 3 expression. Docetaxel 119-128 BCL2 apoptosis regulator Homo sapiens 172-176 31222722-12 2019 The Bcl-2/Bcl-xL inhibitor ABT263 is in clinical trials and might represent a valuable adjunct to the original CUSP. navitoclax 27-33 BCL2 apoptosis regulator Homo sapiens 4-9 31302150-6 2019 Our findings indicate that enzymes of the rate-limiting steps of pyrimidine and purine biosynthesis, the pro-viral MCL1 apoptosis regulator, BCL2 family member protein and the mitochondrial electron transport complex III, play critical roles in the completion of the mammarenavirus life cycle, suggesting they represent potential druggable targets to counter human pathogenic mammarenavirus infections. pyrimidine 65-75 BCL2 apoptosis regulator Homo sapiens 141-145 31302150-6 2019 Our findings indicate that enzymes of the rate-limiting steps of pyrimidine and purine biosynthesis, the pro-viral MCL1 apoptosis regulator, BCL2 family member protein and the mitochondrial electron transport complex III, play critical roles in the completion of the mammarenavirus life cycle, suggesting they represent potential druggable targets to counter human pathogenic mammarenavirus infections. purine 80-86 BCL2 apoptosis regulator Homo sapiens 141-145 30538285-1 2019 Drugs targeting various pro-survival BCL-2 family members (""BH3 mimetics"") have efficacy in hemopoietic malignancies, but the non-targeted pro-survival family members can promote resistance. BH 3 61-64 BCL2 apoptosis regulator Homo sapiens 37-42 30538285-2 2019 Pertinently, the sensitivity of some tumor cell lines to BH3 mimetic ABT737, which targets BCL-2, BCL-XL, and BCL-W but not MCL-1, is enhanced by 2-deoxyglucose (2DG). BH 3 57-60 BCL2 apoptosis regulator Homo sapiens 91-96 30538285-2 2019 Pertinently, the sensitivity of some tumor cell lines to BH3 mimetic ABT737, which targets BCL-2, BCL-XL, and BCL-W but not MCL-1, is enhanced by 2-deoxyglucose (2DG). Deoxyglucose 146-160 BCL2 apoptosis regulator Homo sapiens 91-96 31786843-12 2019 Evodiamine-induced apoptosis was also accompanied by upregulation of caspase-3 and Bax and suppression of Bcl-2. evodiamine 0-10 BCL2 apoptosis regulator Homo sapiens 106-111 31060395-12 2019 The inhibitory effect of DPHC on H2O2-induced apoptosis was associated with a reduced Bax/Bcl-2 ratio, the protection of the activation of caspase-9 and -3 and the inhibition of poly (ADP-ribose) polymerase cleavage, which was associated with the blockage of cytochrome c release to the cytoplasm. diphlorethohydroxycarmalol 25-29 BCL2 apoptosis regulator Homo sapiens 90-95 31060395-12 2019 The inhibitory effect of DPHC on H2O2-induced apoptosis was associated with a reduced Bax/Bcl-2 ratio, the protection of the activation of caspase-9 and -3 and the inhibition of poly (ADP-ribose) polymerase cleavage, which was associated with the blockage of cytochrome c release to the cytoplasm. Hydrogen Peroxide 33-37 BCL2 apoptosis regulator Homo sapiens 90-95 31957703-9 2019 Moreover, Nrf2, HO-1, and Bcl-2 expression was upregulated, whereas, in contrast, transcripts for Bax, caspase3, and caspase9 were downregulated following Dex treatment under OGD/R. Dexmedetomidine 155-158 BCL2 apoptosis regulator Homo sapiens 26-31 31599421-8 2019 According to further studies, the polyoxometalate (50 muM) inhibited the expression of anti-apoptotic gene Bcl-2 and promoted the expression of pro-apoptotic gene Bax. polyoxometalate I 34-49 BCL2 apoptosis regulator Homo sapiens 107-112 31278993-12 2019 Besides, TSA promoted the apoptosis rate (36.84 +- 6.52%) comparing with the CCD-18Co-treated HCoEpiCs (3.52 +- 0.85%, P < 0.05), with promotion of Bax (0.5893+-0.0498 in 2D and 0.8867+-0.0916 in 3D) and reduction of Bcl-2 (0.0476+-0.0053 in 2D and 0.0294+-0.0075 in 3D). trichostatin A 9-12 BCL2 apoptosis regulator Homo sapiens 217-222 31257524-7 2019 miR-92a-3p mimic transfection accelerated ESCC cell migration and invasion and decreased ESCC cell apoptosis via the Bax/Bcl-2 pathway and cleaved caspase-3. -92a 3-7 BCL2 apoptosis regulator Homo sapiens 121-126 31387680-5 2019 Herein, we report a one-step method to conjugate lanthanide-doped nanoparticles with p53-activating peptide (PMI: TSFAEYWALLSP), Bcl2-blocking peptide (BIM: IWIAQELRRIGDEFNAYYARR) and CD13-binding peptide (iNGR: CRNGRGPDC) by mercaptogenic self-assembly. Lanthanoid Series Elements 49-59 BCL2 apoptosis regulator Homo sapiens 129-133 31786865-6 2019 (3) The results of qRT-PCR and Western blotting demonstrated that apatinib was capable of inducing the expression of the pro-apoptotic genes, Bax and Caspase 9, and inhibit the expression of the anti-apoptotic gene Bcl-2. apatinib 66-74 BCL2 apoptosis regulator Homo sapiens 215-220 31786867-10 2019 Plumbagin-induced apoptosis and autophagy were also associated with alteration in apoptosis (Bax and Bcl-2) and autophagy (LC3I, II, and Beclin 1) - related protein expressions. plumbagin 0-9 BCL2 apoptosis regulator Homo sapiens 101-106 31410143-8 2019 Furthermore, treatment with gefitinib decreased the protein expression level of Bcl-2 and increased the protein expression level of Bax. Gefitinib 28-37 BCL2 apoptosis regulator Homo sapiens 80-85 31195042-6 2019 Western blotting exhibited that COG2a increased the expressions of the pro-apoptotic protein caspase-3 and Bax and decreased the expression of the anti-apoptotic proteins Bcl-2. cog2a 32-37 BCL2 apoptosis regulator Homo sapiens 171-176 31786849-11 2019 Berbamine also caused activation of caspase-3 and 9 and increased the Bax/Bcl-2 ratio. berbamine 0-9 BCL2 apoptosis regulator Homo sapiens 74-79 31786860-13 2019 DAPI staining revealed that Psoralidin triggered apoptotic cell death of HepG2 cells which was accompanied with activation of caspases 3 and 9, upregulation of Bax and downregulation of Bcl-2. psoralidin 28-38 BCL2 apoptosis regulator Homo sapiens 186-191 31786865-3 2019 The experimental methods are as follows: (1) The proliferation of HGC-27 cells inhibited by Apatinib and LY294002 was observed by 3-(4,5)-dimethylthiahiazo-(z-y1)-3,5-diphenytetrazoli- umromide (MTT) assay; (2) flow cytometry was adopted to detect the apoptosis of cells after they were treated with drugs and the positive control; (3) different effects of varying concentrations of Apatinib on apoptosis-related genes and proteins, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax) and cysteine-aspartic acid protease (Caspase) 9, were detected via fluorescence quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blotting (WB), and the effects of different concentrations of Apatinib on the protein expressions of PI3K, phosphorylated (p)-PI3K, Akt and p-Akt were detected by Western blotting. apatinib 92-100 BCL2 apoptosis regulator Homo sapiens 433-450 31786865-3 2019 The experimental methods are as follows: (1) The proliferation of HGC-27 cells inhibited by Apatinib and LY294002 was observed by 3-(4,5)-dimethylthiahiazo-(z-y1)-3,5-diphenytetrazoli- umromide (MTT) assay; (2) flow cytometry was adopted to detect the apoptosis of cells after they were treated with drugs and the positive control; (3) different effects of varying concentrations of Apatinib on apoptosis-related genes and proteins, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax) and cysteine-aspartic acid protease (Caspase) 9, were detected via fluorescence quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blotting (WB), and the effects of different concentrations of Apatinib on the protein expressions of PI3K, phosphorylated (p)-PI3K, Akt and p-Akt were detected by Western blotting. apatinib 92-100 BCL2 apoptosis regulator Homo sapiens 452-457 31786865-3 2019 The experimental methods are as follows: (1) The proliferation of HGC-27 cells inhibited by Apatinib and LY294002 was observed by 3-(4,5)-dimethylthiahiazo-(z-y1)-3,5-diphenytetrazoli- umromide (MTT) assay; (2) flow cytometry was adopted to detect the apoptosis of cells after they were treated with drugs and the positive control; (3) different effects of varying concentrations of Apatinib on apoptosis-related genes and proteins, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax) and cysteine-aspartic acid protease (Caspase) 9, were detected via fluorescence quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blotting (WB), and the effects of different concentrations of Apatinib on the protein expressions of PI3K, phosphorylated (p)-PI3K, Akt and p-Akt were detected by Western blotting. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 105-113 BCL2 apoptosis regulator Homo sapiens 433-450 31786865-3 2019 The experimental methods are as follows: (1) The proliferation of HGC-27 cells inhibited by Apatinib and LY294002 was observed by 3-(4,5)-dimethylthiahiazo-(z-y1)-3,5-diphenytetrazoli- umromide (MTT) assay; (2) flow cytometry was adopted to detect the apoptosis of cells after they were treated with drugs and the positive control; (3) different effects of varying concentrations of Apatinib on apoptosis-related genes and proteins, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax) and cysteine-aspartic acid protease (Caspase) 9, were detected via fluorescence quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blotting (WB), and the effects of different concentrations of Apatinib on the protein expressions of PI3K, phosphorylated (p)-PI3K, Akt and p-Akt were detected by Western blotting. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 105-113 BCL2 apoptosis regulator Homo sapiens 452-457 31786875-8 2019 The AO/EB staining showed that Ginsenoside (Rg1) inhibits the viability of cancer cells via induction of apoptotic cell death which was correlated with increase in Bax and decrease in Bcl-2 levels. Ginsenosides 31-42 BCL2 apoptosis regulator Homo sapiens 184-189 31786877-8 2019 In addition, it was observed that the anticancer effects of helenalin are due to induction of mitochondrial-mediated apoptosis which was also associated with enhancement of the expression of Bax and decrease in the expression of Bcl-2. helenalin 60-69 BCL2 apoptosis regulator Homo sapiens 229-234 31155753-7 2019 In conclusion, our results indicate that resveratrol acts as a potential inducer to enhance the chemosensitivity of breast cancer and also suggest that miR-122-5p is involved in the pathway of cell-cycle arrest by targeting Bcl-2 and CDKs. Resveratrol 41-52 BCL2 apoptosis regulator Homo sapiens 224-229 31293090-7 2019 The results also showed that Tan I-induced increased expression of the proapoptotic gene Bax and decreased expression of the anti-apoptotic gene Bcl-2 is the possible mechanism of its anti-cancer effects. tanshinone 29-34 BCL2 apoptosis regulator Homo sapiens 145-150 31489665-4 2019 After the cells were treated with alantolactone, the expression of Bcl-2 decreased, while the expression of Bax increased, the expression of MMP-9, MMP-7, and MMP-2 gradually decreased after alantolactone treatment. alantolactone 34-47 BCL2 apoptosis regulator Homo sapiens 67-72 31155753-6 2019 Further miRNA modulation with miR-122-5p mimics or miR-122-5p inhibitors indicated a major effect of miR-122-5p on the regulation of key antiapoptotic proteins (B-cell lymphoma 2 [Bcl-2]) and cyclin-dependent kinases (CDK2, CDK4, and CDK6) in drug-resistant breast cancer cells in response to resveratrol. Resveratrol 293-304 BCL2 apoptosis regulator Homo sapiens 161-178 30626241-0 2019 MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 62-65 BCL2 apoptosis regulator Homo sapiens 44-49 31175966-9 2019 IGF-1 exerted anti-apoptotic effects by restoring MPP+-induced changes of Bcl-2 and Bax protein expressions as well as mitochondria membrane potential. mangion-purified polysaccharide (Candida albicans) 50-54 BCL2 apoptosis regulator Homo sapiens 74-79 31322235-9 2019 The present results also demonstrated that BNN dose-dependently changed the expression of Bcl-2, Bax, caspases-3/9 and PPARgamma. bavachinin 43-46 BCL2 apoptosis regulator Homo sapiens 90-95 31322237-6 2019 Western blotting demonstrated that DP induced apoptosis through extrinsic and intrinsic pathways by upregulating death receptor 4 (DR4), DR5, cleaved caspase-3/-7/-9 and cleaved poly (ADP-ribose) polymerase (PARP), and by decreasing total PARP, total caspase-3/7, Bcl-2 and caspase-9/-10. dracorhodin 35-37 BCL2 apoptosis regulator Homo sapiens 264-269 31524245-12 2019 RT-qPCR and western blotting showed that LPS promoted caspase-3 and Bax expression, but inhibited that of Bcl-2 in HUVECs; however, these effects were attenuated by pretreatment with NAC or SB203580. Acetylcysteine 183-186 BCL2 apoptosis regulator Homo sapiens 106-111 31524245-12 2019 RT-qPCR and western blotting showed that LPS promoted caspase-3 and Bax expression, but inhibited that of Bcl-2 in HUVECs; however, these effects were attenuated by pretreatment with NAC or SB203580. SB 203580 190-198 BCL2 apoptosis regulator Homo sapiens 106-111 31247208-2 2019 Studies show that the Bcl-2 inhibitor ABT737 can significantly improve the effect of cisplatin and induce mitochondrial pathway apoptosis. ABT-737 38-44 BCL2 apoptosis regulator Homo sapiens 22-27 31247208-2 2019 Studies show that the Bcl-2 inhibitor ABT737 can significantly improve the effect of cisplatin and induce mitochondrial pathway apoptosis. Cisplatin 85-94 BCL2 apoptosis regulator Homo sapiens 22-27 29902665-6 2019 The results also showed that mancozeb-induced apoptosis was accompanied by up-regulation of Bax and down-regulation of Bcl-2 and Bcl-xL. mancozeb 29-37 BCL2 apoptosis regulator Homo sapiens 119-124 31452770-0 2019 MicroRNA-16 sensitizes drug-resistant breast cancer cells to Adriamycin by targeting Wip1 and Bcl-2. Doxorubicin 61-71 BCL2 apoptosis regulator Homo sapiens 94-99 30626241-0 2019 MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 150-153 BCL2 apoptosis regulator Homo sapiens 44-49 31452795-8 2019 Western blot analysis demonstrated significantly decreased ratios of phosphorylated-AKT/AKT and Bcl-2/Bax, and decreased protein levels of cyclin D1 and CDK4 in cells treated with baicalin. baicalin 180-188 BCL2 apoptosis regulator Homo sapiens 96-101 30626241-2 2019 Antagonists of BCL-2 family proteins include BCL-2-selective inhibitor ABT-199, MCL-1-selective inhibitor A-1210477, BCL-xL-selective inhibitor A-1155463. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 71-74 BCL2 apoptosis regulator Homo sapiens 15-20 30626241-2 2019 Antagonists of BCL-2 family proteins include BCL-2-selective inhibitor ABT-199, MCL-1-selective inhibitor A-1210477, BCL-xL-selective inhibitor A-1155463. A-1210477 106-115 BCL2 apoptosis regulator Homo sapiens 15-20 31452796-9 2019 In summary, shikonin can sensitize esophageal cancer cells to paclitaxel-treatment by promoting cell mitotic arrest and reinforcing the susceptibility of esophageal cancer cells to apoptosis induced by paclitaxel, which is potentially associated with altered levels of Bcl-2 and p53. shikonin 12-20 BCL2 apoptosis regulator Homo sapiens 269-274 31452796-9 2019 In summary, shikonin can sensitize esophageal cancer cells to paclitaxel-treatment by promoting cell mitotic arrest and reinforcing the susceptibility of esophageal cancer cells to apoptosis induced by paclitaxel, which is potentially associated with altered levels of Bcl-2 and p53. Paclitaxel 62-72 BCL2 apoptosis regulator Homo sapiens 269-274 30626241-2 2019 Antagonists of BCL-2 family proteins include BCL-2-selective inhibitor ABT-199, MCL-1-selective inhibitor A-1210477, BCL-xL-selective inhibitor A-1155463. A-1155463 144-153 BCL2 apoptosis regulator Homo sapiens 15-20 30626241-4 2019 Our data showed that OCI-AML3 cells and U937 cells were resistant to BCL-2-selective inhibitor ABT-199 in vitro and in vivo, however, while OCI-AML3 cells were sensitive to MCL-1-selective inhibitor A-1210477 in vitro and in vivo, indicating that A-1210477 could counteract the resistance of AML cells to ABT-199 as a single agent in MCL-1-dependent AML cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 95-98 BCL2 apoptosis regulator Homo sapiens 69-74 31433581-9 2019 RESULTS: Epirubicin inhibited proliferation in a dose-dependent manner, induced apoptosis, decreased the expression of Bcl-2, and increased the expressions of Bax, cleaved-caspase-3, and cleaved-PARP1 in osteosarcoma cells. Epirubicin 9-19 BCL2 apoptosis regulator Homo sapiens 119-124 31404628-7 2019 In addition, PPVI induced apoptosis by promoting the protein expression of Bax/Bcl2, caspase-3 and caspase-9, and activated autophagy by improving LC3 II conversion and GFP-LC3 puncta formation in A549 and H1299 cells. ppvi 13-17 BCL2 apoptosis regulator Homo sapiens 79-83 31177019-8 2019 HeLa cells treated with delicaflavone showed the loss of mitochondrial membrane potential, release of Cytochrome c, activation of caspases, alteration of Bax/Bcl-2 balance, and the inhibition of MAPK signaling cascades. delicaflavone 24-37 BCL2 apoptosis regulator Homo sapiens 158-163 31228864-6 2019 In addition, resveratrol also prevented onset and progression of programmed cell death in porcine oocytes, which was confirmed by significant upregulation of the anti-apoptotic B-cell lymphoma 2 (BCL-2) gene and significant downregulation of the pro-apoptotic BCL2-associated X (BAX) gene. Resveratrol 13-24 BCL2 apoptosis regulator Homo sapiens 177-194 31228864-6 2019 In addition, resveratrol also prevented onset and progression of programmed cell death in porcine oocytes, which was confirmed by significant upregulation of the anti-apoptotic B-cell lymphoma 2 (BCL-2) gene and significant downregulation of the pro-apoptotic BCL2-associated X (BAX) gene. Resveratrol 13-24 BCL2 apoptosis regulator Homo sapiens 196-201 31029785-6 2019 Apoptosis caused by p53 phosphorylation following ziyuglycoside II treatment in HCT116 cells involved activation of caspases, increased expression of BAX, mitochondrial cytochrome c and apoptosis inducing factor (AIF) release, while BCL-2 became down-regulated. ziyuglycoside II 50-66 BCL2 apoptosis regulator Homo sapiens 233-238 31029785-8 2019 Overall, these results suggest that ziyuglycoside II induces apoptosis through caspase-dependent and caspases-independent apoptosis, which was characterized by decreased expression of BCL-2, mitochondrial targeting, and altered production of ROS and translocation of AIF to the nuclei. ziyuglycoside II 36-52 BCL2 apoptosis regulator Homo sapiens 184-189 31538075-8 2019 Bcl2 expression was reduced by 69% in the cisplatin+genistein group compared to that in the cisplatin group. Cisplatin 42-51 BCL2 apoptosis regulator Homo sapiens 0-4 31538075-8 2019 Bcl2 expression was reduced by 69% in the cisplatin+genistein group compared to that in the cisplatin group. Genistein 52-61 BCL2 apoptosis regulator Homo sapiens 0-4 31538075-8 2019 Bcl2 expression was reduced by 69% in the cisplatin+genistein group compared to that in the cisplatin group. Cisplatin 92-101 BCL2 apoptosis regulator Homo sapiens 0-4 31632492-7 2019 Rsv enhanced the sensitivity of K562/RA cells to ATO and reduced the required dose of ATO as well as associated adverse reactions by promoting the proliferation inhibitory and apoptosis-inducing effects of ATO, which may be associated with reduced expression of the drug resistance genes mdr1/P-gp, mrp1/MRP1 and bcrp/BCRP, as well as the apoptotic inhibitory genes bcl-2, NF-kappaB and P53, and conversely, activation of caspase-3. resveratrol 0-3 BCL2 apoptosis regulator Homo sapiens 366-371 31544060-5 2019 The cytotoxic effects, the number of colonies, apoptosis, p53 gene expression, and Bcl-2 signaling protein of the combined 5-FU and beta-escin on MCF7 cells were determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, clonogenic assay, flow cytometry, real-time quantitative polymerase chain reaction, and western blotting methods, respectively. Fluorouracil 123-127 BCL2 apoptosis regulator Homo sapiens 83-88 31695369-8 2019 Moreover, cellular assays depicted that CeO2 NPs mitigate the cell mortality, apoptosis, and the ratio of Bax/Bcl-2 gene expression associated with alpha-syn amyloids. Cerium 40-44 BCL2 apoptosis regulator Homo sapiens 110-115 31544060-5 2019 The cytotoxic effects, the number of colonies, apoptosis, p53 gene expression, and Bcl-2 signaling protein of the combined 5-FU and beta-escin on MCF7 cells were determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, clonogenic assay, flow cytometry, real-time quantitative polymerase chain reaction, and western blotting methods, respectively. Escin 132-142 BCL2 apoptosis regulator Homo sapiens 83-88 31695327-10 2019 Polyphyllin VI induced mitochondria-mediated apoptosis with the upregulation of proapoptotic proteins Bax and poly ADP-ribose polymerase, and downregulation of antiapoptotic protein Bcl-2 in U2OS cells. Polyphyllin VI 0-14 BCL2 apoptosis regulator Homo sapiens 182-187 31544060-9 2019 In addition, the number of colonies and Bcl-2 signaling protein in combination of 5-FU and beta-escin decreased with respect to untreated control cells or single treatment of 5-FU and beta-escin. Fluorouracil 82-86 BCL2 apoptosis regulator Homo sapiens 40-45 31544060-9 2019 In addition, the number of colonies and Bcl-2 signaling protein in combination of 5-FU and beta-escin decreased with respect to untreated control cells or single treatment of 5-FU and beta-escin. Escin 91-101 BCL2 apoptosis regulator Homo sapiens 40-45 31544060-9 2019 In addition, the number of colonies and Bcl-2 signaling protein in combination of 5-FU and beta-escin decreased with respect to untreated control cells or single treatment of 5-FU and beta-escin. Fluorouracil 175-179 BCL2 apoptosis regulator Homo sapiens 40-45 31544060-9 2019 In addition, the number of colonies and Bcl-2 signaling protein in combination of 5-FU and beta-escin decreased with respect to untreated control cells or single treatment of 5-FU and beta-escin. Escin 184-194 BCL2 apoptosis regulator Homo sapiens 40-45 31544060-10 2019 The combination of 5-FU and beta-escin not only has synergistic effects by increasing cell apoptosis and p53 gene expression but also decreases Bcl-2 signaling protein in MCF7 cell lines. Fluorouracil 19-23 BCL2 apoptosis regulator Homo sapiens 144-149 31544060-10 2019 The combination of 5-FU and beta-escin not only has synergistic effects by increasing cell apoptosis and p53 gene expression but also decreases Bcl-2 signaling protein in MCF7 cell lines. Escin 28-38 BCL2 apoptosis regulator Homo sapiens 144-149 31144367-5 2019 The title oxoborane compound was synthesized from an air- and moisture-stable BCl2 formazanate complex and subsequently converted to a redox-active boroxine. borage oil 10-19 BCL2 apoptosis regulator Homo sapiens 78-82 31534470-8 2019 DHA treatment downregulated the angiogenic gene ANGPTL2 and the cell proliferation genes CCND1, E2F1, PCNA, and BCL2. artenimol 0-3 BCL2 apoptosis regulator Homo sapiens 112-116 31462891-14 2019 Early intervention strategies by rational combination of Bcl-2 blockage may constitute a promising new treatment option to GC-resistant ALL and significantly improving the chances of treating poor prednisone responders. Prednisone 197-207 BCL2 apoptosis regulator Homo sapiens 57-62 31144367-5 2019 The title oxoborane compound was synthesized from an air- and moisture-stable BCl2 formazanate complex and subsequently converted to a redox-active boroxine. formazanate 83-94 BCL2 apoptosis regulator Homo sapiens 78-82 31144367-5 2019 The title oxoborane compound was synthesized from an air- and moisture-stable BCl2 formazanate complex and subsequently converted to a redox-active boroxine. cyclotriboroxane 148-156 BCL2 apoptosis regulator Homo sapiens 78-82 31497196-6 2019 Moreover, target prediction and luciferase reporter assay demonstrated that miR-16-5p could negatively regulate Bcl-2 and Cyclin-D1 expression. mir-16-5p 76-85 BCL2 apoptosis regulator Homo sapiens 112-117 31438633-6 2019 In addition, genistein increased the cytosolic release of cytochrome c by increasing the Bax/Bcl-2 ratio and destroying mitochondria integrity. Genistein 13-22 BCL2 apoptosis regulator Homo sapiens 93-98 31456915-9 2019 High doses of N2L and ALA also protected hRPE cells from BL-induced apoptosis, which was confirmed by Western blot analysis: BCL-2 expression significantly increased, while BAX and caspase-3 expression slightly decreased compared to the CG. n2l 14-17 BCL2 apoptosis regulator Homo sapiens 125-130 31456915-9 2019 High doses of N2L and ALA also protected hRPE cells from BL-induced apoptosis, which was confirmed by Western blot analysis: BCL-2 expression significantly increased, while BAX and caspase-3 expression slightly decreased compared to the CG. Thioctic Acid 22-25 BCL2 apoptosis regulator Homo sapiens 125-130 31419226-0 2019 DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations. 3-deazaneplanocin 0-5 BCL2 apoptosis regulator Homo sapiens 111-115 31419226-6 2019 We show that DZNep inhibits proliferation and induces apoptosis of these cell lines independent of the type of lymphoma, the EZH2 mutation status and the MYC, BCL2 and BCL6 rearrangement status. 3-deazaneplanocin 13-18 BCL2 apoptosis regulator Homo sapiens 159-163 31443288-4 2019 Cell death induced by H2O2 treatment could be significantly attenuated by the pre-treatment of H2S, resulting in a decrease in the Bax/Bcl-2 ratio and the inhibition of caspase-3 activity in human lung epithelial cell line A549 cells. Hydrogen Peroxide 22-26 BCL2 apoptosis regulator Homo sapiens 135-140 31182435-6 2019 We observed synergistic activity when YK-4-279 and TK-216 were combined with the BCL2 inhibitor venetoclax and with the immunomodulatory drug lenalidomide. venetoclax 96-106 BCL2 apoptosis regulator Homo sapiens 81-85 31443288-4 2019 Cell death induced by H2O2 treatment could be significantly attenuated by the pre-treatment of H2S, resulting in a decrease in the Bax/Bcl-2 ratio and the inhibition of caspase-3 activity in human lung epithelial cell line A549 cells. Hydrogen Sulfide 95-98 BCL2 apoptosis regulator Homo sapiens 135-140 31408950-1 2019 Therapeutic manipulation of the BCL-2 family using BH3 mimetics is an emerging paradigm in cancer treatment and immune modulation. BH 3 51-54 BCL2 apoptosis regulator Homo sapiens 32-37 31616177-11 2019 SNG increased the expression of the proapoptotic protein Bax and reduced the expression of the antiapoptotic protein Bcl-2. sanguinarine 0-3 BCL2 apoptosis regulator Homo sapiens 117-122 31416135-6 2019 The paclitaxel-combined XAV939 treatment induced apoptosis by suppressing Bcl-2 and by increasing the cleavage of caspases-3 and PARP. Paclitaxel 4-14 BCL2 apoptosis regulator Homo sapiens 74-79 31416135-6 2019 The paclitaxel-combined XAV939 treatment induced apoptosis by suppressing Bcl-2 and by increasing the cleavage of caspases-3 and PARP. XAV939 24-30 BCL2 apoptosis regulator Homo sapiens 74-79 31405216-8 2019 Pre-incubation with BAY-11-7082 counteracted visfatin-induced expression of miRNA, BCL2, SOD-2, CAT and NRF2. 3-(4-methylphenylsulfonyl)-2-propenenitrile 20-31 BCL2 apoptosis regulator Homo sapiens 83-87 31408950-4 2019 This study shows that these PA nanostructures are quickly incorporated into cells, are able to specifically bind BCL-2 proteins, are stable at physiologic temperatures and pH, and induce dose-dependent apoptosis in cells. Protactinium 28-30 BCL2 apoptosis regulator Homo sapiens 113-118 31399555-9 2019 MCL1, one of the antiapoptotic BCL2 family members, was significantly inhibited upon THZ1 treatment. THZ1 85-89 BCL2 apoptosis regulator Homo sapiens 31-35 31078737-6 2019 In contrast, the Mcl-1 inhibitor S63845 potently targeted basal-like, but not stem-like cells, highlighting dependency on distinct sentinel Bcl-2 family members. S63845 33-39 BCL2 apoptosis regulator Homo sapiens 140-145 31103719-2 2019 Here we provide evidence that active Rac1 and Bcl-2 work in a positive feedforward loop to promote sustained phosphorylation of Bcl-2 at serine-70 (S70pBcl-2), which stabilizes its anti-apoptotic activity. Serine 137-143 BCL2 apoptosis regulator Homo sapiens 46-51 31103719-2 2019 Here we provide evidence that active Rac1 and Bcl-2 work in a positive feedforward loop to promote sustained phosphorylation of Bcl-2 at serine-70 (S70pBcl-2), which stabilizes its anti-apoptotic activity. Serine 137-143 BCL2 apoptosis regulator Homo sapiens 128-133 31103719-4 2019 Similarly, BH3-mimetic inhibitors of Bcl-2 could disrupt Rac1-Bcl-2 interaction and reduce S70pBcl-2. BH 3 11-14 BCL2 apoptosis regulator Homo sapiens 37-42 31399555-10 2019 Accordingly, combining THZ1 with a BCL2/BCL-XL inhibitor ABT-263 synergized in impairing cell growth and driving apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 57-60 BCL2 apoptosis regulator Homo sapiens 35-39 31103719-4 2019 Similarly, BH3-mimetic inhibitors of Bcl-2 could disrupt Rac1-Bcl-2 interaction and reduce S70pBcl-2. BH 3 11-14 BCL2 apoptosis regulator Homo sapiens 62-67 31440159-5 2019 The prostaglandin E2 (PGE2) derived from PTGS2 catalyzation further strengthened PTGS2 expression via the PGE2-EPs-ERK1/2 positive feedback loop, which induced multidrug resistance of NSCLC cells through up-regulation of BCL2 expression and the subsequent attenuation of cell apoptosis. Dinoprostone 4-20 BCL2 apoptosis regulator Homo sapiens 221-225 31440159-5 2019 The prostaglandin E2 (PGE2) derived from PTGS2 catalyzation further strengthened PTGS2 expression via the PGE2-EPs-ERK1/2 positive feedback loop, which induced multidrug resistance of NSCLC cells through up-regulation of BCL2 expression and the subsequent attenuation of cell apoptosis. Dinoprostone 22-26 BCL2 apoptosis regulator Homo sapiens 221-225 31129157-7 2019 In addition, KHG21834 effectively attenuated glutamate-induced levels of Bax, Bcl-2, cleaved caspase-3, p-p38, p-JNK proteins, and TUNEL positive cells. KHG21834 13-21 BCL2 apoptosis regulator Homo sapiens 78-83 31440159-5 2019 The prostaglandin E2 (PGE2) derived from PTGS2 catalyzation further strengthened PTGS2 expression via the PGE2-EPs-ERK1/2 positive feedback loop, which induced multidrug resistance of NSCLC cells through up-regulation of BCL2 expression and the subsequent attenuation of cell apoptosis. Dinoprostone 106-110 BCL2 apoptosis regulator Homo sapiens 221-225 30982495-3 2019 Among the assayed miRNAs that were involved in regulating the expression of antiapoptotic protein Bcl-2, miR-206 was increased significantly and specifically by GW501516 in C666-1 cells at both the in vitro level and at the in vivo xenograft samples. GW 501516 161-169 BCL2 apoptosis regulator Homo sapiens 98-103 31004603-5 2019 In addition, isoliquiritigenin promoted nasopharyngeal carcinoma cell apoptosis, with the up-regulations of Bax, Caspase-3 and Caspase-9 and the down-regulation of Bcl-2. isoliquiritigenin 13-30 BCL2 apoptosis regulator Homo sapiens 164-169 31129157-7 2019 In addition, KHG21834 effectively attenuated glutamate-induced levels of Bax, Bcl-2, cleaved caspase-3, p-p38, p-JNK proteins, and TUNEL positive cells. Glutamic Acid 45-54 BCL2 apoptosis regulator Homo sapiens 78-83 31381554-8 2019 Salidroside upregulates the level of Bcl-2 and downregulates the level of Bax. rhodioloside 0-11 BCL2 apoptosis regulator Homo sapiens 37-42 31387245-6 2019 Additionally, LCA increased the Bax/Bcl-2 ratio, and reduced the integrity of mitochondria, which contributed to the discharge of cytochrome c from the mitochondria to the cytoplasm. licochalcone A 14-17 BCL2 apoptosis regulator Homo sapiens 36-41 31592119-5 2019 The results of MMP and caspase-3 activity assays, in association with the results corresponding to the BAX and Bcl-2 gene expressions, altogether revealed that Glab can exert apoptogenic effect on these cells. glabridin 160-164 BCL2 apoptosis regulator Homo sapiens 111-116 31592435-10 2019 PC3 cell colony counts and Bcl-2 signaling protein were decreased by 5-FU/rutin combination. Fluorouracil 69-73 BCL2 apoptosis regulator Homo sapiens 27-32 31592099-2 2019 Also, we predicted the interaction of TQ with BCL-XL, BCL-2, and MCL-1anti-apoptotic factors by computer-simulated environment. thymoquinone 38-40 BCL2 apoptosis regulator Homo sapiens 54-59 31592099-5 2019 Changes in energy and the molecular interactions of TQ with BCL-XL, BCL-2 and MCL-1 anti-apoptotic factors were investigated using simulation. thymoquinone 52-54 BCL2 apoptosis regulator Homo sapiens 68-73 31592099-9 2019 TQ makes a more stable and stronger connection with BCL-XL compared to BCL-2 and MCL-1 and inhibits BCL-XL non-competitively. thymoquinone 0-2 BCL2 apoptosis regulator Homo sapiens 71-76 31592435-10 2019 PC3 cell colony counts and Bcl-2 signaling protein were decreased by 5-FU/rutin combination. Rutin 74-79 BCL2 apoptosis regulator Homo sapiens 27-32 31592099-10 2019 Conclusion: Our results demonstrated that TQ not only led to apoptosis, at least partly, due to reduction in the Coil, Turn, and Bend structure of BCL-XL but also caused a decrease in the Rg and RMSD value of BCL-XL, MCL-1, and BCL-2. thymoquinone 42-44 BCL2 apoptosis regulator Homo sapiens 228-233 31592435-11 2019 Conclusion: Synergistic effects of 5-FU/rutin combination on PC3 cells line enhanced apoptosis, p53 gene expression, and down-regulation of Bcl-2 protein, compared to control separate application. Fluorouracil 35-39 BCL2 apoptosis regulator Homo sapiens 140-145 31592435-11 2019 Conclusion: Synergistic effects of 5-FU/rutin combination on PC3 cells line enhanced apoptosis, p53 gene expression, and down-regulation of Bcl-2 protein, compared to control separate application. Rutin 40-45 BCL2 apoptosis regulator Homo sapiens 140-145 31187237-2 2019 We hypothesized that the addition of venetoclax, a BCL-2 inhibitor, to AML patients who previously failed HMA might overcome resistance. venetoclax 37-47 BCL2 apoptosis regulator Homo sapiens 51-56 31197422-4 2019 The results showed that tetrandrine had a high possibility of binding to the N-myc and Bcl-2 G-quadruplexes through hydrogen bonding, whereas the possibility of binding of isotetrandrine was low and it seemed to have no possibility of forming hydrogen bonds. tetrandrine 24-35 BCL2 apoptosis regulator Homo sapiens 87-92 31197422-4 2019 The results showed that tetrandrine had a high possibility of binding to the N-myc and Bcl-2 G-quadruplexes through hydrogen bonding, whereas the possibility of binding of isotetrandrine was low and it seemed to have no possibility of forming hydrogen bonds. Hydrogen 116-124 BCL2 apoptosis regulator Homo sapiens 87-92 31306153-10 2019 Taken together, these results indicate that andrographolide, along with carboplatin, synergistically inhibited cell proliferation and induced mitochondrial apoptosis of Hep-2 cells by increasing the intracellular ROS, regulating the mitogen-activated protein kinase and phosphatidylinositol 3-kinase (PI3K/AKT) pathways, altering the BCL2/BAX ratio, and ultimately activating the cleavage of Caspase-3 and PARP. andrographolide 44-59 BCL2 apoptosis regulator Homo sapiens 334-338 31071337-8 2019 Further analysis these cells treated with DPHP revealed a decrease in mitochondrial membrane potential, an increase in Bax/Bcl2 ratio, the release of cytochrome c, activation of caspases -9, -3/7, and cleavage of the poly-ADP-ribose polymerase. dphp 42-46 BCL2 apoptosis regulator Homo sapiens 123-127 31142701-8 2019 Moreover, QLQX inhibited the apoptosis rate and the pro-apoptosis protein expressions, but improved the Bcl-2 expression as well as the ratios of phospho-AKT/AKT and phospho-GSK3beta/GSK3beta. qlqx 10-14 BCL2 apoptosis regulator Homo sapiens 104-109 31167801-6 2019 We show that, in vitro, the Bcl-2 inhibitors ABT-199 and ABT-263 induced specific cell death in primary CD4+ cells from CTCL patients as well as in the CTCL cell line SeAx, but not in T cells of healthy donors nor in the CTCL cell line HH, which lacks Bcl-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 45-48 BCL2 apoptosis regulator Homo sapiens 28-33 31167801-6 2019 We show that, in vitro, the Bcl-2 inhibitors ABT-199 and ABT-263 induced specific cell death in primary CD4+ cells from CTCL patients as well as in the CTCL cell line SeAx, but not in T cells of healthy donors nor in the CTCL cell line HH, which lacks Bcl-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 45-48 BCL2 apoptosis regulator Homo sapiens 252-257 31167801-6 2019 We show that, in vitro, the Bcl-2 inhibitors ABT-199 and ABT-263 induced specific cell death in primary CD4+ cells from CTCL patients as well as in the CTCL cell line SeAx, but not in T cells of healthy donors nor in the CTCL cell line HH, which lacks Bcl-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 57-60 BCL2 apoptosis regulator Homo sapiens 28-33 31167801-6 2019 We show that, in vitro, the Bcl-2 inhibitors ABT-199 and ABT-263 induced specific cell death in primary CD4+ cells from CTCL patients as well as in the CTCL cell line SeAx, but not in T cells of healthy donors nor in the CTCL cell line HH, which lacks Bcl-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 57-60 BCL2 apoptosis regulator Homo sapiens 252-257 31115604-5 2019 Furthermore, CAGM regimen induced more obvious cell apoptosis than CAG regimen probably by reducing Bcl-2/Bax ratio (P < 0.05). cagm 13-17 BCL2 apoptosis regulator Homo sapiens 100-105 31173474-3 2019 In this study, repetitive applications of conjugated primary bile acids with unconjugated secondary bile acid, deoxycholic acid (DCA), on human hypopharyngeal primary cells reveal that strongly acidic pH (4.0) optimally enhances the tumorigenic effect of bile, by inducing activation of NF-kappaB, STAT3 nuclear translocation, bcl-2 overexpression and significant overexpression of the oncogenic mRNA phenotype, compared to weakly acidic pH (5.5) or neutral pH (7.0). Deoxycholic Acid 111-127 BCL2 apoptosis regulator Homo sapiens 327-332 31102917-12 2019 Ultimately, BPA triggered the cell apoptosis by regulating Bcl-2 family and caspase-dependent signaling pathway. bisphenol A 12-15 BCL2 apoptosis regulator Homo sapiens 59-64 31145521-0 2019 Cysteine-rich protein 61 regulates the chemosensitivity of chronic myeloid leukemia to imatinib mesylate through the nuclear factor kappa B/Bcl-2 pathway. Imatinib Mesylate 87-95 BCL2 apoptosis regulator Homo sapiens 140-145 30949874-0 2019 Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment. venetoclax 40-50 BCL2 apoptosis regulator Homo sapiens 24-29 31449511-0 2019 Venetoclax, the first BCL-2 inhibitor for use in patients with chronic lymphocytic leukemia. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 22-27 30935269-2 2019 Such an observation was associated with the development of molecules inhibiting Bcl-2 activity, and among them, BH3-mimetics represent a novel class of therapeutic compounds. BH 3 112-115 BCL2 apoptosis regulator Homo sapiens 80-85 30995142-6 2019 Moreover, the expression levels of anti-apoptotic protein Bcl-2 decreased while the expression of pro-apoptotic protein active caspase 3 and Bax increased concurrently after UNBS5162 stimulation. UNBS 5162 174-182 BCL2 apoptosis regulator Homo sapiens 58-63 31378899-11 2019 Besides, sevoflurane evidently increased the Bax protein level and inhibited the protein level of Bcl-2, MMP9, and MPP2 in PTC cells. Sevoflurane 9-20 BCL2 apoptosis regulator Homo sapiens 98-103 31339741-0 2019 Recombinant Pierisin-5 Induces Apoptosis and Differential Expression of Bcl-2, Bax, and p53 in Human Cancer Cells. pierisin-5 12-22 BCL2 apoptosis regulator Homo sapiens 72-77 31313099-4 2019 Initial efforts with small molecule BH3 mimetics such as ABT-737 and ABT-263 (navitoclax) pioneered the development of the first-in-class Food and Drug Administration (FDA)-approved oral BCL2 inhibitor, venetoclax. BH 3 36-39 BCL2 apoptosis regulator Homo sapiens 187-191 31313099-4 2019 Initial efforts with small molecule BH3 mimetics such as ABT-737 and ABT-263 (navitoclax) pioneered the development of the first-in-class Food and Drug Administration (FDA)-approved oral BCL2 inhibitor, venetoclax. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 57-60 BCL2 apoptosis regulator Homo sapiens 187-191 31313099-4 2019 Initial efforts with small molecule BH3 mimetics such as ABT-737 and ABT-263 (navitoclax) pioneered the development of the first-in-class Food and Drug Administration (FDA)-approved oral BCL2 inhibitor, venetoclax. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 69-72 BCL2 apoptosis regulator Homo sapiens 187-191 31157476-5 2019 In addition, Western blot analysis indicated that cynaroside protected ARPE-19 cells from apoptosis through downregulation of caspase-3 protein activation which was controlled by the upstream proteins Bcl-2 and Bax. luteolin-7-glucoside 50-60 BCL2 apoptosis regulator Homo sapiens 201-206 31173173-11 2019 In addition, AG490 and S1491 were also identified to alleviate the H/R-induced apoptosis by inhibiting caspase 3 activity and modulating the expression levels of cleaved caspase-3, tumor necrosis factor receptor superfamily member 6 (Fas), Fas ligand, B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X protein. r 69-70 BCL2 apoptosis regulator Homo sapiens 252-269 31173173-11 2019 In addition, AG490 and S1491 were also identified to alleviate the H/R-induced apoptosis by inhibiting caspase 3 activity and modulating the expression levels of cleaved caspase-3, tumor necrosis factor receptor superfamily member 6 (Fas), Fas ligand, B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X protein. r 69-70 BCL2 apoptosis regulator Homo sapiens 271-276 31173173-11 2019 In addition, AG490 and S1491 were also identified to alleviate the H/R-induced apoptosis by inhibiting caspase 3 activity and modulating the expression levels of cleaved caspase-3, tumor necrosis factor receptor superfamily member 6 (Fas), Fas ligand, B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X protein. r 69-70 BCL2 apoptosis regulator Homo sapiens 282-287 31016752-7 2019 Additionally, we confirmed 0.1 mum BBP-induced cell proliferation caused the arrest of cells in S phase and inhibited apoptosis, which might be partially explained by the decreased expression of p53, the increased expression of proliferating cell nuclear antigen, Bcl-2 and cell cycle regulator cyclin-D1, and the activation of aromatase. butylbenzyl phthalate 35-38 BCL2 apoptosis regulator Homo sapiens 264-269 31389609-9 2019 In high glucose group, the expression level of Caspase-3 protein was overtly increased (p<0.01), while that of B-cell lymphoma-2 (Bcl-2)/Bcl-2 associated X protein (Bax) was significantly decreased (p<0.01). Glucose 8-15 BCL2 apoptosis regulator Homo sapiens 111-128 30575033-5 2019 We demonstrated that AdoMet induced apoptosis in Cal-33 and JHU-SCC-011 cells, involving a caspase-dependent mechanism paralleled by an increased Bax/Bcl-2 ratio. S-Adenosylmethionine 21-27 BCL2 apoptosis regulator Homo sapiens 150-155 30526410-7 2019 In order to understand the same, we have carried out docking and molecular dynamic simulations on ABT-263 (Navitoclax), an orally active inhibitor of Bcl-2, Bcl-xL, and Bcl-w proteins; Obatoclax, a pan-Bcl-2 inhibitor as well as Maritoclax, an Mcl-1 specific inhibitor. navitoclax 98-105 BCL2 apoptosis regulator Homo sapiens 150-155 30526410-7 2019 In order to understand the same, we have carried out docking and molecular dynamic simulations on ABT-263 (Navitoclax), an orally active inhibitor of Bcl-2, Bcl-xL, and Bcl-w proteins; Obatoclax, a pan-Bcl-2 inhibitor as well as Maritoclax, an Mcl-1 specific inhibitor. navitoclax 98-105 BCL2 apoptosis regulator Homo sapiens 202-207 30526410-7 2019 In order to understand the same, we have carried out docking and molecular dynamic simulations on ABT-263 (Navitoclax), an orally active inhibitor of Bcl-2, Bcl-xL, and Bcl-w proteins; Obatoclax, a pan-Bcl-2 inhibitor as well as Maritoclax, an Mcl-1 specific inhibitor. navitoclax 107-117 BCL2 apoptosis regulator Homo sapiens 150-155 30526410-7 2019 In order to understand the same, we have carried out docking and molecular dynamic simulations on ABT-263 (Navitoclax), an orally active inhibitor of Bcl-2, Bcl-xL, and Bcl-w proteins; Obatoclax, a pan-Bcl-2 inhibitor as well as Maritoclax, an Mcl-1 specific inhibitor. navitoclax 107-117 BCL2 apoptosis regulator Homo sapiens 202-207 31356549-8 2019 Furthermore, curdione inhibited DOX-induced cell apoptosis and modulated the expression of Bcl-2 and Bax proteins, as well as abrogated DOX-induced reactive oxygen species accumulation and prevented mitochondria dysfunction. curdione 13-21 BCL2 apoptosis regulator Homo sapiens 91-96 30793365-4 2019 The [Cu(L)(2imi)] complex seems to inhibit the expression of bcl-2 in complex-treated HepG2 cancerous cells following the 24- and 48-hour treatment. cu(l)(2imi) 5-16 BCL2 apoptosis regulator Homo sapiens 61-66 30993753-6 2019 Our data from gene expression determined a substantial diminish in the mRNA levels of the Nrf2 and antiapoptotic gene Bcl-2 along with a noticeable increase in the level of the proapoptotic Bax in HT-29 colon cells that underwent cotreatment with 5-FU and stattic (P < 0.05). Fluorouracil 247-251 BCL2 apoptosis regulator Homo sapiens 118-123 30623427-0 2019 The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML. venetoclax 20-30 BCL2 apoptosis regulator Homo sapiens 4-9 31741457-4 2019 In the present study, we showed that lycopene reduces the viability of AGS cells by inducing DNA fragmentation and increasing the Bax/Bcl-2 ratio. Lycopene 37-45 BCL2 apoptosis regulator Homo sapiens 134-139 30623427-0 2019 The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML. hypomethylating agents 87-109 BCL2 apoptosis regulator Homo sapiens 4-9 30623450-10 2019 Furthermore, curcumin has a potent inhibitory effect on the activity of NF-kappaB and COX-2, which are involved in the overexpression of antiapoptosis genes such as Bcl-2. Curcumin 13-21 BCL2 apoptosis regulator Homo sapiens 165-170 31202076-7 2019 Moreover, 6-shogaol infringed Bax and Bcl-2 in which 20 mug 6-shogaol influenced apoptosis in HaCaT cells by investigating augmented appearance of Bax and condensed appearance of Bcl-2 in contrast to control HaCaT cells. shogaol 10-19 BCL2 apoptosis regulator Homo sapiens 38-43 31202076-7 2019 Moreover, 6-shogaol infringed Bax and Bcl-2 in which 20 mug 6-shogaol influenced apoptosis in HaCaT cells by investigating augmented appearance of Bax and condensed appearance of Bcl-2 in contrast to control HaCaT cells. shogaol 10-19 BCL2 apoptosis regulator Homo sapiens 179-184 31202076-7 2019 Moreover, 6-shogaol infringed Bax and Bcl-2 in which 20 mug 6-shogaol influenced apoptosis in HaCaT cells by investigating augmented appearance of Bax and condensed appearance of Bcl-2 in contrast to control HaCaT cells. shogaol 60-69 BCL2 apoptosis regulator Homo sapiens 38-43 31202076-7 2019 Moreover, 6-shogaol infringed Bax and Bcl-2 in which 20 mug 6-shogaol influenced apoptosis in HaCaT cells by investigating augmented appearance of Bax and condensed appearance of Bcl-2 in contrast to control HaCaT cells. shogaol 60-69 BCL2 apoptosis regulator Homo sapiens 179-184 31173255-8 2019 In addition, compared with the control group, metformin significantly enhanced the activity of caspase-3, increased the expression of AMPK/pAMPK/Bax proteins and reduced the expression of mTOR/Bcl-2 proteins (P<0.05). Metformin 46-55 BCL2 apoptosis regulator Homo sapiens 193-198 31279748-6 2019 After lycopene treatment, the protein expression of Bax (an apoptotic protein) in SKOV3 cells increased significantly, and the protein expression of Bcl-2 (an anti-apoptotic protein) decreased significantly. Lycopene 6-14 BCL2 apoptosis regulator Homo sapiens 149-154 31257526-8 2019 Furthermore, miR-342-3p mimics reduced the expression of PDGFRA; miR-342-3p overexpression also reduced the mRNA and protein levels of BCL-2 and Caspase-3. mir-342-3p 13-23 BCL2 apoptosis regulator Homo sapiens 135-140 31173223-0 2019 Long non-coding RNA CASC2 enhances berberine-induced cytotoxicity in colorectal cancer cells by silencing BCL2. Berberine 35-44 BCL2 apoptosis regulator Homo sapiens 106-110 31173223-6 2019 In addition, RNA immunoprecipitation, chromatin immunoprecipitation and western blot analysis were used to identify the functional regulation of CASC2/EZH2/BCL2 axis in berberine-induced CRC cell apoptosis. Berberine 169-178 BCL2 apoptosis regulator Homo sapiens 156-160 31173223-9 2019 Subsequently, the downstream antiapoptotic gene BCL2 was identified as a functional target of the berberine/CASC2 mechanism, as BCL2 reversed the berberine/CASC2-induced cell cytotoxicity. Berberine 98-107 BCL2 apoptosis regulator Homo sapiens 48-52 31173223-9 2019 Subsequently, the downstream antiapoptotic gene BCL2 was identified as a functional target of the berberine/CASC2 mechanism, as BCL2 reversed the berberine/CASC2-induced cell cytotoxicity. Berberine 98-107 BCL2 apoptosis regulator Homo sapiens 128-132 31173223-9 2019 Subsequently, the downstream antiapoptotic gene BCL2 was identified as a functional target of the berberine/CASC2 mechanism, as BCL2 reversed the berberine/CASC2-induced cell cytotoxicity. Berberine 146-155 BCL2 apoptosis regulator Homo sapiens 48-52 31173223-9 2019 Subsequently, the downstream antiapoptotic gene BCL2 was identified as a functional target of the berberine/CASC2 mechanism, as BCL2 reversed the berberine/CASC2-induced cell cytotoxicity. Berberine 146-155 BCL2 apoptosis regulator Homo sapiens 128-132 31233186-7 2019 We also demonstrated that RRM2 is involved in the Bcl-2/caspase cell apoptotic pathway and in the Akt cell signaling pathway, and therefore affects the cell survival following imatinib therapy. Imatinib Mesylate 176-184 BCL2 apoptosis regulator Homo sapiens 50-55 30548945-9 2019 MiR-16-5p overexpression reduced expression of important cell cycle and apoptosis regulators in glioma cells, including CDK6, CDC25A, CCND3, CCNE1, WEE1, CHEK1, BCL2 and MCL1. mir-16-5p 0-9 BCL2 apoptosis regulator Homo sapiens 161-165 31228231-0 2019 Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide. enzalutamide 115-127 BCL2 apoptosis regulator Homo sapiens 22-26 31423257-6 2019 Furthermore, CDS-1548 treatment downregulated the expression of B-cell lymphoma 2, upregulated Bcl-2 homologous antagonist killer, promoted the release of cytochrome c from mitochondria to cytoplasm, and activated the production of caspase 3 and 9. cds-1548 13-21 BCL2 apoptosis regulator Homo sapiens 95-100 31035045-6 2019 Ova-induced apoptosis correlated with increased Bax/Bcl-2 ratio, while inhibition of tumor cell migration and colony formation was associated with reduced Slug, Vimentin, NCadherin and beta-catenin protein expression and increased E-Cadherin. ovatodiolide 0-3 BCL2 apoptosis regulator Homo sapiens 52-57 31035050-15 2019 Fucosterol significantly enhanced the expression of Bax and cleaved caspase-3 which was concomitant with decline in the expression of Bcl-2. fucosterol 0-10 BCL2 apoptosis regulator Homo sapiens 134-139 31202781-4 2019 Dox plus Ori synergistically induced apoptosis in MDA-MB-231 cells, in a manner involving regulation of the Bcl-2/Bax, PARP, Caspase 3 and Survivin signaling pathways. Doxorubicin 0-3 BCL2 apoptosis regulator Homo sapiens 108-113 31228231-8 2019 RESULTS: In the present study, we identify antiapoptotic BCL2 protein signaling as a mechanism of resistance to AR antagonist enzalutamide. enzalutamide 126-138 BCL2 apoptosis regulator Homo sapiens 57-61 31358732-4 2019 Here, we investigated the activity of the BCL-2 inhibitor venetoclax (VEN, ABT-199) in B-cell precursor acute lymphoblastic leukemia and found heterogeneous sensitivities in BCP-ALL cell lines and in a series of patient-derived primografts. venetoclax 58-68 BCL2 apoptosis regulator Homo sapiens 42-47 31203382-5 2019 Moreover, the expression of HIF-1alpha in non-transfected cells induced by chloride cobalt (CoCl2), a commonly used mimetic hypoxia reagent, was concomitant with the enhancement of BCL-2 expression. cobaltous chloride 75-90 BCL2 apoptosis regulator Homo sapiens 181-186 31203382-5 2019 Moreover, the expression of HIF-1alpha in non-transfected cells induced by chloride cobalt (CoCl2), a commonly used mimetic hypoxia reagent, was concomitant with the enhancement of BCL-2 expression. cobaltous chloride 92-97 BCL2 apoptosis regulator Homo sapiens 181-186 31358006-9 2019 Furthermore, we found that melatonin inhibited Cd-induced activation of cleaved caspase-3, restored the ratio of Bax/Bcl-2, and ultimately decreased the apoptosis of granular cells as detected by TUNEL staining. Melatonin 27-36 BCL2 apoptosis regulator Homo sapiens 117-122 31423204-5 2019 Upregulation of PDCD4 significantly enhanced the sensitivity of CRC cells to Taxol, by partially contributing to pro-apoptosis and anti-invasion pathways, both through upregulation of the apoptosis-associated protein Bax, and downregulation of the anti-apoptosis protein Bcl-2 and invasion-associated proteins MMP-9. Paclitaxel 77-82 BCL2 apoptosis regulator Homo sapiens 271-276 31423205-6 2019 In addition, the carboxamide derivatives increased the activity of caspase-3, -8 and -9, and suppressed the expression of Bcl-2 and survivin. carboxamide 17-28 BCL2 apoptosis regulator Homo sapiens 122-127 31358732-6 2019 Importantly, ex vivo VEN sensitivity was most accurately associated with functional BCL-2 dependence detected by BH3 profiling. BH 3 113-116 BCL2 apoptosis regulator Homo sapiens 84-89 31358006-9 2019 Furthermore, we found that melatonin inhibited Cd-induced activation of cleaved caspase-3, restored the ratio of Bax/Bcl-2, and ultimately decreased the apoptosis of granular cells as detected by TUNEL staining. Cadmium 47-49 BCL2 apoptosis regulator Homo sapiens 117-122 31260310-5 2019 Treatment with jorunnamycin A (0.05-0.5 muM) altered the expression of p53 and Bcl-2 family proteins, particularly causing the down-regulation of antiapoptosis Bcl-2 and Mcl-1 proteins. jorunnamycin A 15-29 BCL2 apoptosis regulator Homo sapiens 79-84 31028842-8 2019 Ropivacaine-induced upregulation of Fas activated mitochondria-dependent intrinsic apoptosis, including the decrease of the mitochondria membrane potential, opening the mitochondrial permeability transition pore, releasing cytochrome c, and translocating Bcl-2 family members. Ropivacaine 0-11 BCL2 apoptosis regulator Homo sapiens 255-260 31028842-8 2019 Ropivacaine-induced upregulation of Fas activated mitochondria-dependent intrinsic apoptosis, including the decrease of the mitochondria membrane potential, opening the mitochondrial permeability transition pore, releasing cytochrome c, and translocating Bcl-2 family members. ammonium ferrous sulfate 36-39 BCL2 apoptosis regulator Homo sapiens 255-260 31701713-12 2019 Cell experiments showed: in DMDD group, the proliferation activity of OCI-LY19 cells was decreased significantly and the level of apoptosis was increased significantly (P<0.01), nuclear fragmentation, agglutination, apoptotic bodies occurred and mitochondrial membrane potential was decreased, the LDH release rate was increased significantly (P<0.01), the expressions of caspase-3 and bax genes and the phosphorylation level of Ikappa B alpha in cells were up-regulated significantly, the protein expression levels of bcl-2, bcl-xL, jak2 and stat3 were inhibited significantly (P<0.01). 4-demethyl-6-deoxydoxorubicin 28-32 BCL2 apoptosis regulator Homo sapiens 525-530 31701713-13 2019 CONCLUSION: DMDD can inhibit the expressions of JAK2, STAT3 and p-Ikappa B alpha in JAK2/STAT3 and NF-kappa B signal pathways, down-regulate BCL-2/BAX and activate Caspase-3, finally, activate the endogenous pathway of mitochondrial apoptosis in OCI-LY19 cells and promote the apoptosis of DLBCL cells, inhibit proliferation of OCI-LY19 cells. 4-demethyl-6-deoxydoxorubicin 12-16 BCL2 apoptosis regulator Homo sapiens 141-146 31260310-5 2019 Treatment with jorunnamycin A (0.05-0.5 muM) altered the expression of p53 and Bcl-2 family proteins, particularly causing the down-regulation of antiapoptosis Bcl-2 and Mcl-1 proteins. jorunnamycin A 15-29 BCL2 apoptosis regulator Homo sapiens 160-165 31428632-11 2019 Iron dextran significantly upregulated the expression of Bax and downregulated Bcl2, while astragaloside IV reversed this trend. Iron-Dextran Complex 0-12 BCL2 apoptosis regulator Homo sapiens 79-83 31262976-8 2019 Mifepristone was identified to promote cell autophagy and apoptosis, decrease Bcl-2 level and increase Beclin1 level, accompanied by weakened interaction between Bcl-2 and Beclin1. Mifepristone 0-12 BCL2 apoptosis regulator Homo sapiens 78-83 31262976-8 2019 Mifepristone was identified to promote cell autophagy and apoptosis, decrease Bcl-2 level and increase Beclin1 level, accompanied by weakened interaction between Bcl-2 and Beclin1. Mifepristone 0-12 BCL2 apoptosis regulator Homo sapiens 162-167 31336611-5 2019 IPAH-PASMCs were more resistant to apoptosis than C-PASMCs, consistent with the increase in the Bcl2/Bax ratio. ipah-pasmcs 0-11 BCL2 apoptosis regulator Homo sapiens 96-100 31327069-2 2019 B cell receptor inhibitors that target either bruton tyrosine kinase (ibrutinib) or phosphatidylinositol 3-kinases (idelalisib and duvelisib) and BCL-2 inhibitor venetoclax have become the mainstay of treatment. venetoclax 162-172 BCL2 apoptosis regulator Homo sapiens 146-151 31341643-4 2019 Inhibitors of the anti-apoptotic BCL-2 family proteins, also known as BH3 mimetics, antagonise the pro-survival functions of these proteins and result in rapid apoptosis. BH 3 70-73 BCL2 apoptosis regulator Homo sapiens 33-38 31059712-5 2019 Further DS elicits increased reactive oxygen species level and promote intrinsic apoptotic cell death on A549 cells as evidenced by increased expression of caspase-3, caspase-9, Bax, PARP inactivation, cytochrome-c release, and diminished expression of bcl-2 protein. lyoniside 8-10 BCL2 apoptosis regulator Homo sapiens 253-258 31308179-7 2019 Due to progression on initial treatment, she was treated with decitabine and venetoclax (BCL-2 inhibitor). venetoclax 77-87 BCL2 apoptosis regulator Homo sapiens 89-94 31406460-4 2019 Results: The results showed that noncytotoxic CS NPs-HA of small size (100-200 nm) effectively delivered the Cy3-labeled siRNA to A549 cells via receptor CD44 and inhibited cell proliferation by downregulating the target gene BCL2. Cesium 46-48 BCL2 apoptosis regulator Homo sapiens 226-230 31300048-7 2019 The results also indicated that ropivacaine was able to interact with caspase-3, promote cytoplasmic caspase-3 migration into the nucleus, stimulate cleavage of caspase-3 and PARP-1, caspase-9 proteins, inhibit the expression of Bcl-2, promote expression of Apaf-1 and mitochondria release cytochrome C, and activate the activity of caspase-3. Ropivacaine 32-43 BCL2 apoptosis regulator Homo sapiens 229-234 31187116-0 2019 Neferine-induced apoptosis is dependent on the suppression of Bcl-2 expression via downregulation of p65 in renal cancer cells. neferine 0-8 BCL2 apoptosis regulator Homo sapiens 62-67 31187116-4 2019 Treatments with neferine dose-dependently downregulated B cell lymphoma-2 (Bcl-2) expression at the transcriptional level determined by reverse transcriptase-polymerase chain reaction. neferine 16-24 BCL2 apoptosis regulator Homo sapiens 56-73 31187116-4 2019 Treatments with neferine dose-dependently downregulated B cell lymphoma-2 (Bcl-2) expression at the transcriptional level determined by reverse transcriptase-polymerase chain reaction. neferine 16-24 BCL2 apoptosis regulator Homo sapiens 74-80 31187116-5 2019 The forced expression of Bcl-2 and p65 attenuated the neferine-mediated apoptosis in Caki-1 cells. neferine 54-62 BCL2 apoptosis regulator Homo sapiens 25-30 31187116-6 2019 In addition, neferine induced apoptosis by downregulating Bcl-2 and p65 expression in the other two kidney cancer cell lines determined by flow cytometry and western blot analysis. neferine 13-21 BCL2 apoptosis regulator Homo sapiens 58-63 31187116-8 2019 Collectively, this study demonstrated that neferine-induced apoptosis is mediated by the downregulation of Bcl-2 expression via repression of the NF-kappaB pathway in renal cancer cells. neferine 43-51 BCL2 apoptosis regulator Homo sapiens 107-112 31336786-6 2019 Western blotting indicated that DMC induced proteolytic activation of caspase-3 and -9, degradation of caspase-3 substrate proteins (including poly[ADP-ribose] polymerase [PARP]), augmented bak protein level, while attenuating the expression of bcl-2 in PANC-1 cells. 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone 32-35 BCL2 apoptosis regulator Homo sapiens 245-250 31288832-1 2019 Double/triple-hit lymphomas (DHL/THL) account for 5-10% of diffuse large B cell lymphoma (DLBCL) with rearrangement of MYC and BCL2 and/or BCL6 resulting in MYC overexpression. Orlistat 33-36 BCL2 apoptosis regulator Homo sapiens 127-131 31288832-9 2019 BETi in combination with Pan-HDAC inhibitor had a limited effect on survival of DHL/THL, while combination of BETi and BCL2 inhibitor (ABT-199) had a significant (p < 0.005) inhibitory effect on survival followed by BCL-XL inhibition. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 135-138 BCL2 apoptosis regulator Homo sapiens 119-123 31372077-6 2019 We also identify del13q14.3 as an adverse predictor of response to ibrutinib with respect to both overall survival (p=0.014) and PFS (p=0.008), suggesting that these patients may be better suited to receiving the BCL2 inhibitor venetoclax. ibrutinib 67-76 BCL2 apoptosis regulator Homo sapiens 213-217 31287013-9 2019 In addition, flubendazole also reduced the expression of P-mTOR, P62, BCL2, and upregulated Beclin1 and LC3-I/II, which are major autophagy-related genes. flubendazole 13-25 BCL2 apoptosis regulator Homo sapiens 70-74 30919764-3 2019 METHODS: We constructed a phosphomietic mutant BCL-2(62-206) (t69e, s70e and s87e) (EEEBCL- 2-EK (62-206)), in which the BH4 domain and the part of loop region was truncated (residues 2-61) to enable a backbone resonance assignment. sapropterin 121-124 BCL2 apoptosis regulator Homo sapiens 47-52 30919764-4 2019 The phosphorylation-induced structural change was visualized by overlapping a well dispersed 15N-1H heteronuclear single quantum coherence (HSQC) NMR spectroscopy between EEE-BCL-2-EK (62-206) and BCL-2. 15n 93-96 BCL2 apoptosis regulator Homo sapiens 175-180 30919764-4 2019 The phosphorylation-induced structural change was visualized by overlapping a well dispersed 15N-1H heteronuclear single quantum coherence (HSQC) NMR spectroscopy between EEE-BCL-2-EK (62-206) and BCL-2. Hydrogen 97-99 BCL2 apoptosis regulator Homo sapiens 175-180 30919764-7 2019 CONCLUSION: The phosphorylation of BCL-2 induced structural change in BH3 binding groove. BH 3 70-73 BCL2 apoptosis regulator Homo sapiens 35-40 31277238-8 2019 The results indicated that the expression levels of cleaved caspase-8, -3, -9, and Bax were increased in A2780 cells treated with betulinic acid, whereas those of Bcl-2 were decreased. betulinic acid 130-144 BCL2 apoptosis regulator Homo sapiens 163-168 31108190-4 2019 Administrating EMPA in Pre-DM decreased level of caspase-3, increased that of Bcl-2 to control level and reduced the significantly increased inflammatory cytokines to levels approximated to those of the control group. empagliflozin 15-19 BCL2 apoptosis regulator Homo sapiens 78-83 31360194-15 2019 Genistein also triggered apoptosis which was associated with upregulation of cytosolic cytochrome c, Bax, cleaved caspase 3 and 9 expression and downregulation of Bcl-2 expression in HepG2 cells. Genistein 0-9 BCL2 apoptosis regulator Homo sapiens 163-168 30355438-4 2019 KHG26702 also reduced OGD-R-induced expression of the apoptotic protein caspase-3, the apoptosis regulator Bcl-2, and the autophagy protein becn-1. khg26702 0-8 BCL2 apoptosis regulator Homo sapiens 107-112 30355438-4 2019 KHG26702 also reduced OGD-R-induced expression of the apoptotic protein caspase-3, the apoptosis regulator Bcl-2, and the autophagy protein becn-1. ogd-r 22-27 BCL2 apoptosis regulator Homo sapiens 107-112 31028992-0 2019 Discovery and development of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as Bcl-2/Mcl-1 inhibitors. 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 29-77 BCL2 apoptosis regulator Homo sapiens 93-98 31028992-2 2019 In current study, a series of substituted 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives were developed based on the lead compound 1 (Ki = 5.2 microM against Bcl-2 protein). 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 42-90 BCL2 apoptosis regulator Homo sapiens 172-177 31079964-0 2019 Design, synthesis and preliminary bioactivity studies of indomethacin derivatives as Bcl-2/Mcl-1 dual inhibitors. Indomethacin 57-69 BCL2 apoptosis regulator Homo sapiens 85-90 31079964-3 2019 In this work, we designed and synthesized a series of indomethacin derivatives as new inhibitors for Bcl-2 family proteins. Indomethacin 54-66 BCL2 apoptosis regulator Homo sapiens 101-106 31079964-4 2019 Our results of binding assay to Bcl-2 proteins, MTT assay and apoptotic assay indicated that some compounds had potent binding affinity to Bcl-2/Mcl-1 but not Bcl-XL. monooxyethylene trimethylolpropane tristearate 48-51 BCL2 apoptosis regulator Homo sapiens 139-144 31079964-5 2019 Furthermore, compound 8j showed improved anti-proliferative activity than known Bcl-2 inhibitor WL-276. WL 276 96-102 BCL2 apoptosis regulator Homo sapiens 80-85 30470795-5 2019 The BH3 mimetics tested, alone and in combination with the other drugs, were: ABT-737 which, like its clinical counterpart navitoclax, targets BCL-2, BCL-XL and BCL-W; BCL-2-specific ABT-199 (venetoclax); BCL-XL-specific A-1331852; and S63845, a new MCL-1-specific BH3 mimetic. BH 3 4-7 BCL2 apoptosis regulator Homo sapiens 143-148 30470795-5 2019 The BH3 mimetics tested, alone and in combination with the other drugs, were: ABT-737 which, like its clinical counterpart navitoclax, targets BCL-2, BCL-XL and BCL-W; BCL-2-specific ABT-199 (venetoclax); BCL-XL-specific A-1331852; and S63845, a new MCL-1-specific BH3 mimetic. BH 3 4-7 BCL2 apoptosis regulator Homo sapiens 168-173 30689273-4 2019 Further, mechanism studies indicated that compound 4h induced apoptosis in MDA-MB-231 cells through enhancing reactive oxygen species levels, inducing mitochondrial membrane potential decrease, and influencing the expression of Bax, Bcl-2, caspase-3, and caspase-9. 4h 51-53 BCL2 apoptosis regulator Homo sapiens 233-238 31189128-3 2019 In this study, we provided evidence that 17beta-estradiol (E2) could significantly promote endometrial cancer cells viability, migration and invasion through activation of IL-6 pathway, which involved in its downstream pathway and target genes (p-Stat3, Bcl-2, Mcl-1, CyclinD1 and MMP2). Estradiol 41-57 BCL2 apoptosis regulator Homo sapiens 254-259 31154862-0 2019 A literature review of the patent publications on venetoclax - a selective Bcl-2 inhibitor: discovering the therapeutic potential of a novel chemotherapeutic agent. venetoclax - a 50-64 BCL2 apoptosis regulator Homo sapiens 75-80 31154862-3 2019 Venetoclax selectively inhibits the B-cell lymphoma-2 (Bcl-2) protein, an anti-apoptotic protein that can be overexpressed in most B-cell lymphoid malignancies. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 36-53 31154862-3 2019 Venetoclax selectively inhibits the B-cell lymphoma-2 (Bcl-2) protein, an anti-apoptotic protein that can be overexpressed in most B-cell lymphoid malignancies. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 55-60 30523053-2 2019 In this study, we showed the potential benefit of the BCL2 inhibitor venetoclax in the treatment of this disease. venetoclax 69-79 BCL2 apoptosis regulator Homo sapiens 54-58 31219431-3 2019 Coptisine also restored H2O2-induced mitochondrial dysfunction and decrease of ATP production, and prevented apoptosis by inhibiting Bax/Bcl-2 ratio, caspase-3 activity, and poly(ADP-ribose) polymerase degradation. coptisine 0-9 BCL2 apoptosis regulator Homo sapiens 137-142 31280208-0 2019 Peroxiredoxin V Inhibits Emodin-induced Gastric Cancer Cell Apoptosis via the ROS/Bcl2 Pathway. Emodin 25-31 BCL2 apoptosis regulator Homo sapiens 82-86 31055607-7 2019 AST2017-01 and chrysophanol enhanced expressions of p53 and Bax, whereas inhibited expression of Bcl-2. chrysophanic acid 15-27 BCL2 apoptosis regulator Homo sapiens 97-102 31115521-8 2019 Additionally, IL-6-induced activation of STAT3 target genes (e.g. MCL-1 and BCL-2) was attenuated by TP and homoharringtonine. triptolide 101-103 BCL2 apoptosis regulator Homo sapiens 76-81 31115521-8 2019 Additionally, IL-6-induced activation of STAT3 target genes (e.g. MCL-1 and BCL-2) was attenuated by TP and homoharringtonine. Homoharringtonine 108-125 BCL2 apoptosis regulator Homo sapiens 76-81 30958899-4 2019 Moreover, ABA induced mitochondrial-mediated apoptosis by inducing the loss of mitochondrial membrane potential, upregulation of Bax/Bcl-2, and activation of caspase-3. abamectin 10-13 BCL2 apoptosis regulator Homo sapiens 133-138 30387147-11 2019 TQ treatment significantly elevated the Bax/ Bcl-2 ratio in the lung cancer cells. thymoquinone 0-2 BCL2 apoptosis regulator Homo sapiens 45-50 30443961-5 2019 SCARNA2 promotes chemotherapy resistance via competitively binding miR-342-3p to facilitate epidermal growth factor receptor (EGFR) and B-cell lymphoma 2 (BCL2) expression in CRC cells. mir-342-3p 67-77 BCL2 apoptosis regulator Homo sapiens 136-153 30443961-5 2019 SCARNA2 promotes chemotherapy resistance via competitively binding miR-342-3p to facilitate epidermal growth factor receptor (EGFR) and B-cell lymphoma 2 (BCL2) expression in CRC cells. mir-342-3p 67-77 BCL2 apoptosis regulator Homo sapiens 155-159 30623407-3 2019 It was disclosed that FTY-720 significantly stimulates Bcl2 overexpression. Fingolimod Hydrochloride 22-29 BCL2 apoptosis regulator Homo sapiens 55-59 30623407-5 2019 The increase in Bcl2/Bax ratio increased the cell metabolic activity and decreased propidium iodide-positive cells. Propidium 83-99 BCL2 apoptosis regulator Homo sapiens 16-20 31646812-9 2019 Mangiferin induces apoptosis in the Mia-PaCa2 cells which was associated with enhancement of Bax/Bcl-2 ratio. mangiferin 0-10 BCL2 apoptosis regulator Homo sapiens 97-102 31463132-6 2019 We found that cleaved caspase-3, cleaved capsese-9 and Bax protein expression was increased and Bcl-2 protein expression was decreased after magnolol treatment. magnolol 141-149 BCL2 apoptosis regulator Homo sapiens 96-101 30700841-5 2019 This action was synergistic with the Bcl-2 antagonist ABT-199. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 54-57 BCL2 apoptosis regulator Homo sapiens 37-42 31077716-9 2019 Melatonin through modulation of several apoptosis mediators such as mitochondria, Bax, Bcl-2, endogenous ROS, and apoptosis receptors facilitate apoptosis. Melatonin 0-9 BCL2 apoptosis regulator Homo sapiens 87-92 31180556-9 2019 DEX administration significantly suppressed cell proliferation, promoted apoptosis and decreased the Bcl-2/Bax ratio in TC28 cells; overexpression of miR-214 induced opposing effects, which were reversed by Bax overexpression. Dexamethasone 0-3 BCL2 apoptosis regulator Homo sapiens 101-106 31072625-12 2019 Additionally, transfection of miR-145 mimic further altered expression of key genes involved in cell apoptosis (Bcl-2, Bax, Caspase3) in ESCC cells treated with 5-FU. Fluorouracil 161-165 BCL2 apoptosis regulator Homo sapiens 112-117 31079851-11 2019 Moreover, apatinib increased cisplatin-induced apoptosis on MDA-MB-231 cells via increasing the level of Bax and active caspase 3 and decreasing the expression of Bcl-2. apatinib 10-18 BCL2 apoptosis regulator Homo sapiens 163-168 31079851-11 2019 Moreover, apatinib increased cisplatin-induced apoptosis on MDA-MB-231 cells via increasing the level of Bax and active caspase 3 and decreasing the expression of Bcl-2. Cisplatin 29-38 BCL2 apoptosis regulator Homo sapiens 163-168 31297133-10 2019 At the molecular level, we further found that TCTN1 overexpression reversed the effects of miR-216a-5p transfection on the expression of PCNA, Bcl-2 and Bad. mir-216a 91-99 BCL2 apoptosis regulator Homo sapiens 143-148 31242894-10 2019 Costunolide increased the expression of Bax, cleaved caspase 9, cleaved caspase 7, cleaved caspase 3 and cleaved poly ADP ribose polymerase (PARP) proteins and decreased the expression of Bcl-2, pro-caspase 9, pro-caspase 7, pro-caspase 3 and PARP proteins. costunolide 0-11 BCL2 apoptosis regulator Homo sapiens 188-193 31242894-11 2019 Costunolide upregulated the expression of puma, Bak1 and Bax mRNA and downregulated the expression of Bcl-2 mRNA. costunolide 0-11 BCL2 apoptosis regulator Homo sapiens 102-107 31247931-0 2019 Melatonin Prevents Oxidative Stress-Induced Mitochondrial Dysfunction and Apoptosis in High Glucose-Treated Schwann Cells via Upregulation of Bcl2, NF-kappaB, mTOR, Wnt Signalling Pathways. Melatonin 0-9 BCL2 apoptosis regulator Homo sapiens 142-146 31247931-5 2019 Our results revealed that high glucose promoted apoptosis via mitochondrial-related oxidative stress and downregulated Bcl-2 family proteins in Schwann cells. Glucose 31-38 BCL2 apoptosis regulator Homo sapiens 119-124 31247931-6 2019 In this signalling pathway, Bcl-2, Bcl-XL and Mcl-1 proteins were down-regulated while p-BAD and Puma proteins were up-regulated by high glucose treatment. Glucose 137-144 BCL2 apoptosis regulator Homo sapiens 28-33 31247931-12 2019 Our results concluded that melatonin alleviates high glucose-induced apoptosis in Schwann cells through mitigating mitochondrial-related oxidative stress and the alterations of Bcl-2, NF-kappaB, mTOR and Wnt signalling pathways. Melatonin 27-36 BCL2 apoptosis regulator Homo sapiens 177-182 31228347-9 2019 Moreover, diosmetin treatment significantly downregulated the expression levels of Bcl-2 and Cyclin D1, and upregulated that of p53, Bax, caspase 3, cleaved caspase 9, and cleaved caspase 3. diosmetin 10-19 BCL2 apoptosis regulator Homo sapiens 83-88 31227712-4 2019 Leveraging the robust recombinant expression of alpha7 nAChRs with NACHO, we utilized genome-wide cDNA library screening and discovered that several anti-apoptotic Bcl-2 family proteins further upregulate receptor assembly and cell surface expression. nacho 67-72 BCL2 apoptosis regulator Homo sapiens 164-169 31227712-5 2019 These effects are mediated by an intracellular motif on alpha7 that resembles the BH3 binding domain of pro-apoptotic Bcl-2 proteins, and can be blocked by BH3 mimetic Bcl-2 inhibitors. BH 3 82-85 BCL2 apoptosis regulator Homo sapiens 118-123 31227712-5 2019 These effects are mediated by an intracellular motif on alpha7 that resembles the BH3 binding domain of pro-apoptotic Bcl-2 proteins, and can be blocked by BH3 mimetic Bcl-2 inhibitors. BH 3 82-85 BCL2 apoptosis regulator Homo sapiens 168-173 31227712-5 2019 These effects are mediated by an intracellular motif on alpha7 that resembles the BH3 binding domain of pro-apoptotic Bcl-2 proteins, and can be blocked by BH3 mimetic Bcl-2 inhibitors. BH 3 156-159 BCL2 apoptosis regulator Homo sapiens 118-123 31227712-5 2019 These effects are mediated by an intracellular motif on alpha7 that resembles the BH3 binding domain of pro-apoptotic Bcl-2 proteins, and can be blocked by BH3 mimetic Bcl-2 inhibitors. BH 3 156-159 BCL2 apoptosis regulator Homo sapiens 168-173 31226773-6 2019 The reduced ratio of Bcl-2/Bax further confirmed the apoptosis-inducing effect of mytoxin B and myrothecine A on SMMC-7721 cells. Myrothecine A 96-109 BCL2 apoptosis regulator Homo sapiens 21-26 31357761-9 2019 SP600125 and SB203580 had inhibited oxidative stress and apoptosis induced by palmitic acid (including CYP2E1, MDA, Bax, Bcl-2, caspase3, CHOP) (P< 0.05). pyrazolanthrone 0-8 BCL2 apoptosis regulator Homo sapiens 121-126 31357761-9 2019 SP600125 and SB203580 had inhibited oxidative stress and apoptosis induced by palmitic acid (including CYP2E1, MDA, Bax, Bcl-2, caspase3, CHOP) (P< 0.05). SB 203580 13-21 BCL2 apoptosis regulator Homo sapiens 121-126 31275848-8 2019 Curcumin treatment increased the ratio of Bax/Bcl-2 and resulted in a leaky mitochondrial membrane that led to the discharge of cytochrome c from the mitochondria to the cytoplasm, the activation of caspase 3 and the cleavage of PARP. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 46-51 31340914-6 2019 In HEK293T cells with Cyr61 knockdown, AngII treatment resulted in significantly increased expression of Bcl-2 in HEK293T cells as compared with that of the control group (P &lt; 0.05). Adenosine Monophosphate 175-178 BCL2 apoptosis regulator Homo sapiens 105-110 31319483-12 2019 Western blot analysis shows that simvastatin leads to changes in the expression of regulator proteins involved in apoptosis, such as Bax, Bcl-2, and Bcl-xl. Simvastatin 33-44 BCL2 apoptosis regulator Homo sapiens 138-143 31406477-7 2019 Moreover, the expression levels of Bcl-2, survivin, CDK2 and MMP-2 significantly decreased in SCLC cells treated with paclitaxel targeting nanobubbles, whereas the expression of caspase-3 and Rb were increased. Paclitaxel 118-128 BCL2 apoptosis regulator Homo sapiens 35-40 31085238-5 2019 Of note, BBI608 combined with Bcl-2 inhibitor (i.e., ABT-199) exerts a significantly enhanced anti-leukemia effect in BBI608-resistant cell line Kasumi-1. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 53-56 BCL2 apoptosis regulator Homo sapiens 30-35 31085238-5 2019 Of note, BBI608 combined with Bcl-2 inhibitor (i.e., ABT-199) exerts a significantly enhanced anti-leukemia effect in BBI608-resistant cell line Kasumi-1. napabucasin 118-124 BCL2 apoptosis regulator Homo sapiens 30-35 31409969-7 2019 In addition, the in vivo results indicated that PL can affect the expression of bax/bcl-2 apoptotic marker proteins. plumbagin 48-50 BCL2 apoptosis regulator Homo sapiens 84-89 31301225-10 2019 RESULTS CAHB inhibited the proliferation and promoted the apoptosis of Jurkat cells in a time- and dose-dependent manner by decreasing activation of Akt, reducing the mitochondrial membrane potential, and downregulating the Bcl-2/Bax ratio. cahb 8-12 BCL2 apoptosis regulator Homo sapiens 224-229 31336757-9 2019 Further studies showed that ailanthone remarkably downregulated Bcl-2 and upregulated Apaf-1 and Bax, and subsequently increased mitochondrial membrane permeabilization and released cytochrome c from the mitochondria in B16 cells and A375 cells. ailanthone 28-38 BCL2 apoptosis regulator Homo sapiens 64-69 31295870-7 2019 Gallic acid (1), decursin (17), and decursinol angelate (18) induced apoptotic cell death and significantly increased poly (ADP-ribose) polymerase (PARP) cleavage and the Bcl-2-associated X protein/ B-cell lymphoma 2 (Bax/Bcl-2) ratio. Gallic Acid 0-11 BCL2 apoptosis regulator Homo sapiens 171-176 31295870-7 2019 Gallic acid (1), decursin (17), and decursinol angelate (18) induced apoptotic cell death and significantly increased poly (ADP-ribose) polymerase (PARP) cleavage and the Bcl-2-associated X protein/ B-cell lymphoma 2 (Bax/Bcl-2) ratio. Gallic Acid 0-11 BCL2 apoptosis regulator Homo sapiens 222-227 31295870-7 2019 Gallic acid (1), decursin (17), and decursinol angelate (18) induced apoptotic cell death and significantly increased poly (ADP-ribose) polymerase (PARP) cleavage and the Bcl-2-associated X protein/ B-cell lymphoma 2 (Bax/Bcl-2) ratio. decursin 17-25 BCL2 apoptosis regulator Homo sapiens 171-176 31295870-7 2019 Gallic acid (1), decursin (17), and decursinol angelate (18) induced apoptotic cell death and significantly increased poly (ADP-ribose) polymerase (PARP) cleavage and the Bcl-2-associated X protein/ B-cell lymphoma 2 (Bax/Bcl-2) ratio. decursin 36-55 BCL2 apoptosis regulator Homo sapiens 171-176 31295870-7 2019 Gallic acid (1), decursin (17), and decursinol angelate (18) induced apoptotic cell death and significantly increased poly (ADP-ribose) polymerase (PARP) cleavage and the Bcl-2-associated X protein/ B-cell lymphoma 2 (Bax/Bcl-2) ratio. decursin 36-55 BCL2 apoptosis regulator Homo sapiens 222-227 31288815-12 2019 Our studies demonstrated that five PRGs including Bcl2, FOXO1A, SCGB2A2, CYP26a1 and MMP11 exhibited significant progesterone-hyper-responsiveness in human PrMyoF cells as compared to PrMyoN cells (P < 0.05). Progesterone 113-125 BCL2 apoptosis regulator Homo sapiens 50-54 31323961-8 2019 Moreover, the overexpression of either BCL-2 or BCL-xL abrogated 5-AcTMF-mediated viability reduction and apoptosis induction in GBM cells. [6,7,8-trimethoxy-2-(4-methoxyphenyl)-4-oxochromen-5-yl] acetate 65-72 BCL2 apoptosis regulator Homo sapiens 39-44 31239367-10 2019 miR-142-3p inhibitor significantly decreased the cell viability, the number of cell clones, the migration rate, the number of invasive cells, the contents and expression of IL-6 and MMP-3, and increased the apoptosis rate and the expressions of Bax and Bad, and decreased Bcl-2 expression of TNF-alpha-treated RA-HFLSs. mir-142-3p 0-10 BCL2 apoptosis regulator Homo sapiens 272-277 31276572-2 2019 Cisplatin, most frequently used for HNSCC treatment, activates mitochondria-dependent apoptosis through the BCL-2 family proteins. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 108-113 31276572-4 2019 NOXA binds and inactivates anti-apoptotic MCL-1, while the BCL-2 inhibitor ABT-263 is capable of inactivating anti-apoptotic BCL-2 and BCL-XL. navitoclax 75-82 BCL2 apoptosis regulator Homo sapiens 59-64 31276572-4 2019 NOXA binds and inactivates anti-apoptotic MCL-1, while the BCL-2 inhibitor ABT-263 is capable of inactivating anti-apoptotic BCL-2 and BCL-XL. navitoclax 75-82 BCL2 apoptosis regulator Homo sapiens 125-130 31276572-5 2019 We hypothesized that combination of NOXA and ABT-263 treatment increases cell death by simultaneously inhibiting anti-apoptotic BCL-2 family proteins in HNSCC cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 45-48 BCL2 apoptosis regulator Homo sapiens 128-133 31277394-3 2019 Results of flow cytometry showed that H2O2-induced ARPE-19 cells apoptosis was ameliorated by piceatannol supplementation, along with decreased relative protein expressions of Bax/Bcl-2, Cleave-Caspase-3, and Cleave-PARP. Hydrogen Peroxide 38-42 BCL2 apoptosis regulator Homo sapiens 180-185 31184118-5 2019 The expression of Bcl-2 and Bcl-xL was significantly down-regulated, whereas the expression of Bax, Bad and cyto c was up-regulated, and we later confirmed the involvement of the mitochondrial pathway in juglone-induced apoptosis. juglone 204-211 BCL2 apoptosis regulator Homo sapiens 18-23 30315250-7 2019 In three human breast cancer cell lines, we demonstrated that Akt-mTOR-eEF-2K pathway was involved in TBMS1-induced activation of autophagy, while Akt-mediated downregulations of Mcl-1, Bcl-xl, and Bcl-2 led to the activation of apoptosis of the breast cancer cells. tubeimoside I 102-107 BCL2 apoptosis regulator Homo sapiens 198-203 31309072-9 2019 Conclusion: This study showed that auraptene triggered apoptosis probably through Bax/Bcl-2 regulation, blocked cell cycle progression and inhibited proliferation in U87 GBM cells. aurapten 35-44 BCL2 apoptosis regulator Homo sapiens 86-91 30866601-5 2019 In addition, 7,8,4"-THIF significantly recovered 6-OHDA-induced cleaved caspase-3, cleaved caspase-9, cleaved poly-ADP-ribose polymerase (PARP), increased Bax, and decreased Bcl-2 levels. 7,8,4"-thif 13-24 BCL2 apoptosis regulator Homo sapiens 174-179 30866601-5 2019 In addition, 7,8,4"-THIF significantly recovered 6-OHDA-induced cleaved caspase-3, cleaved caspase-9, cleaved poly-ADP-ribose polymerase (PARP), increased Bax, and decreased Bcl-2 levels. oxidopamine 49-55 BCL2 apoptosis regulator Homo sapiens 174-179 31048321-2 2019 Venetoclax, a selective BCL2 inhibitor, has received FDA approval for the treatment of AML. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 24-28 30470795-5 2019 The BH3 mimetics tested, alone and in combination with the other drugs, were: ABT-737 which, like its clinical counterpart navitoclax, targets BCL-2, BCL-XL and BCL-W; BCL-2-specific ABT-199 (venetoclax); BCL-XL-specific A-1331852; and S63845, a new MCL-1-specific BH3 mimetic. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 78-81 BCL2 apoptosis regulator Homo sapiens 143-148 30470795-7 2019 Elevated MCL-1 or BCL-2 reduced sensitivity to daunorubicin but, surprisingly, not to bortezomib. Daunorubicin 47-59 BCL2 apoptosis regulator Homo sapiens 18-23 30470795-9 2019 Notable synergies were achieved by combining BH3 mimetics with daunorubicin: S63845 increased the sensitivity of both MCL-1 and BCL-2 overexpressing MLL-AF9 AMLs, and ABT-737 aided in killing those overexpressing BCL-2. BH 3 45-48 BCL2 apoptosis regulator Homo sapiens 128-133 30470795-9 2019 Notable synergies were achieved by combining BH3 mimetics with daunorubicin: S63845 increased the sensitivity of both MCL-1 and BCL-2 overexpressing MLL-AF9 AMLs, and ABT-737 aided in killing those overexpressing BCL-2. BH 3 45-48 BCL2 apoptosis regulator Homo sapiens 213-218 30470795-9 2019 Notable synergies were achieved by combining BH3 mimetics with daunorubicin: S63845 increased the sensitivity of both MCL-1 and BCL-2 overexpressing MLL-AF9 AMLs, and ABT-737 aided in killing those overexpressing BCL-2. Daunorubicin 63-75 BCL2 apoptosis regulator Homo sapiens 128-133 30470795-9 2019 Notable synergies were achieved by combining BH3 mimetics with daunorubicin: S63845 increased the sensitivity of both MCL-1 and BCL-2 overexpressing MLL-AF9 AMLs, and ABT-737 aided in killing those overexpressing BCL-2. Daunorubicin 63-75 BCL2 apoptosis regulator Homo sapiens 213-218 30470795-12 2019 Our data suggest that AML patients may benefit from combining conventional cytotoxic drugs with BH3 mimetics targeting BCL-2 or MCL-1 or, if tolerated, both these agents. BH 3 96-99 BCL2 apoptosis regulator Homo sapiens 119-124 31102069-3 2019 RESULTS: After treatment with evodiamine and PXD101, cell viability, the percentage of viable cells and Bcl2 protein levels decreased, whereas cytotoxic activity, the percentage of apoptotic cells, the protein levels of gammaH2AX, acetyl. evodiamine 30-40 BCL2 apoptosis regulator Homo sapiens 104-108 31102069-5 2019 In cells treated with both evodiamine and PXD101, compared with PXD101 alone, decrement of cell viability, the percentage of viable cells, and Bcl2 protein levels as well as increment of cytotoxic activity, the percentage of apoptotic cells, the protein levels of gammaH2AX and cleaved PARP, and ROS production were significant, causing decrement of Bcl2/Bax ratio. evodiamine 27-37 BCL2 apoptosis regulator Homo sapiens 143-147 31102069-5 2019 In cells treated with both evodiamine and PXD101, compared with PXD101 alone, decrement of cell viability, the percentage of viable cells, and Bcl2 protein levels as well as increment of cytotoxic activity, the percentage of apoptotic cells, the protein levels of gammaH2AX and cleaved PARP, and ROS production were significant, causing decrement of Bcl2/Bax ratio. evodiamine 27-37 BCL2 apoptosis regulator Homo sapiens 350-354 31117849-10 2019 Targeted approaches, especially chimeric antigen receptor T-cell therapies and small-molecule inhibitors targeting myc or bcl-2, exhibit the potential of improving outcomes for patients with DHL. Cysteamine 191-194 BCL2 apoptosis regulator Homo sapiens 122-127 31258698-4 2019 The current study demonstrated that HK2 may be involved in high glucose-induced cell apoptosis, as HK2 overexpression partially reversed high glucose-induced downregulation of mitochondrial/cellular HK2 and Bcl-2 as well as upregulation of mitochondrial Bax. Glucose 142-149 BCL2 apoptosis regulator Homo sapiens 207-212 31258699-13 2019 Treatment with G-Rh2 + L-OHP significantly reduced the expression of P-gp and Bcl-2, and enhanced the expression levels of Smad4, Bax and caspase-3. Oxaliplatin 23-28 BCL2 apoptosis regulator Homo sapiens 78-83 30679328-0 2019 Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death. Crizotinib 12-22 BCL2 apoptosis regulator Homo sapiens 31-35 30679328-4 2019 Here, we observed that crizotinib-mediated inactivation of ALK caused an increase in BCL2 levels that restrained the cytotoxic effects of the drug. Crizotinib 23-33 BCL2 apoptosis regulator Homo sapiens 85-89 31020605-7 2019 In H1650 and HCC827/GR cells, combination of D-lys-3-GHRP-6 and gefitinib significantly inhibited cell proliferation and Bcl2 protein level, induced the cell apoptosis and cleaved-caspase3 protein level compared with control group, while there was no significant difference between control and gefitinib group. Gefitinib 64-73 BCL2 apoptosis regulator Homo sapiens 121-125 31059018-6 2019 Notably, KYS05090S attenuated the expression of anti-apoptotic proteins, including cyclin D1 and B-cell lymphoma-2 (Bcl-2), and reduced the phosphorylation of Janus kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3) in ovarian cancer cells. KYS 05090 9-18 BCL2 apoptosis regulator Homo sapiens 97-114 31059018-6 2019 Notably, KYS05090S attenuated the expression of anti-apoptotic proteins, including cyclin D1 and B-cell lymphoma-2 (Bcl-2), and reduced the phosphorylation of Janus kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3) in ovarian cancer cells. KYS 05090 9-18 BCL2 apoptosis regulator Homo sapiens 116-121 31649803-9 2019 Moreover, real-time PCR analysis showed that VCR-induced cytotoxicity was augmented by AAE through alteration of Bax, and Bcl-2 mRNA expression. Vincristine 45-48 BCL2 apoptosis regulator Homo sapiens 122-127 30047840-0 2019 Molecular dynamics investigations of structural and functional changes in Bcl-2 induced by the novel antagonist BDA-366. BDA-366 112-119 BCL2 apoptosis regulator Homo sapiens 74-79 30047840-4 2019 Recent experimental evidences have shown that the antiapoptotic function of Bcl-2 is not immutable, and that BDA-366, a novel antagonist of the BH4 domain, converts Bcl-2 from a survival molecule to an inducer of cell death. BDA-366 109-116 BCL2 apoptosis regulator Homo sapiens 165-170 30047840-4 2019 Recent experimental evidences have shown that the antiapoptotic function of Bcl-2 is not immutable, and that BDA-366, a novel antagonist of the BH4 domain, converts Bcl-2 from a survival molecule to an inducer of cell death. sapropterin 144-147 BCL2 apoptosis regulator Homo sapiens 165-170 30047840-9 2019 The newly identified blocked conformation of the HBS along with the open to closed transition pathway revealed by this study advances the understanding of the Bcl-2 transition from antiapoptotic to proapoptotic function, and yielded new structural insights for novel drug design against the BH4 domain. sapropterin 291-294 BCL2 apoptosis regulator Homo sapiens 159-164 30548625-9 2019 GCDA upregulated the expression of antiapoptosis proteins Mcl-1/Survivin/Bcl-2. Glycochenodeoxycholic Acid 0-4 BCL2 apoptosis regulator Homo sapiens 73-78 30548625-12 2019 CONCLUSIONS: GCDA-reduced HCC cell chemosensitivity may occur by upregulating antiapoptosis proteins Mcl-1/Survivin/Bcl-2. Glycochenodeoxycholic Acid 13-17 BCL2 apoptosis regulator Homo sapiens 116-121 31646804-9 2019 Tangeretin also caused an increase in the Bax/Bcl-2 ratio and activation of the Caspase 3, 8 and 9. tangeretin 0-10 BCL2 apoptosis regulator Homo sapiens 46-51 30516071-6 2019 MiR-221 restoration and STAT5 knockdown in K562/G cells increased the sensitivity of CML cells to imatinib by reducing the Bcl2: Bax ratio. Imatinib Mesylate 98-106 BCL2 apoptosis regulator Homo sapiens 123-127 31209350-2 2019 Venetoclax is the first FDA-approved drug to reactivate apoptosis in cancer by selectively targeting an anti-apoptotic BCL-2 family member. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 119-124 31011879-7 2019 Western blotting results showed that combination of QCT and NaB increased apoptosis by decreasing anti-apoptotic Bcl-2 and increasing pro-apoptotic Bax, decreasing survivin, activating caspase-3, and degrading poly (ADP-ribose) polymerase (PARP). nab 60-63 BCL2 apoptosis regulator Homo sapiens 113-118 31289542-8 2019 Apoptosis of PC3 cells treated with TSA was also investigated, and it was revealed that TSA induced apoptosis by upregulating BAX and downregulating BCL-2. trichostatin A 88-91 BCL2 apoptosis regulator Homo sapiens 149-154 31680075-12 2019 Methadone hydrochloride induced apoptosis in HL-60 cells involved upregulation of Bid and caspase-8 expression and downregulation of Bcl-2, p21 and survivin expression. Methadone 0-23 BCL2 apoptosis regulator Homo sapiens 133-138 31128995-9 2019 Moreover, Inotodiol notably induced tumor cell apoptosis by Annexin-V-FITC apoptosis assay, which is associated with activation pro-apoptotic proteins of PARP, cleaved caspase-3 and Bax expression, inhibition anti-apoptotic protein Bcl-2 expression. inotodiol 10-19 BCL2 apoptosis regulator Homo sapiens 232-237 31602860-7 2019 Moreover,curcumin could inhibit the migration and invasion of MKN45 cells,downregulate the expression of N-cadherin,snail1,Wnt3 a,p-beta-catenin,p-LRP6 and Bcl-2,and upregulate the expression of E-cadherin and Bax,it could increase the activity of caspase-3,caspase-8,caspase-9 and induce apoptosis as well. Curcumin 9-17 BCL2 apoptosis regulator Homo sapiens 156-161 31297133-10 2019 At the molecular level, we further found that TCTN1 overexpression reversed the effects of miR-216a-5p transfection on the expression of PCNA, Bcl-2 and Bad. CHEMBL3740941 100-102 BCL2 apoptosis regulator Homo sapiens 143-148 31242894-13 2019 Costunolide increased the expression of cleaved caspase 9, cleaved caspase 3 and Bax proteins and decreased the expression of Bcl-2 protein in xenografted tumor. costunolide 0-11 BCL2 apoptosis regulator Homo sapiens 126-131 31242894-14 2019 Costunolide upregulated the expression of puma and Bax mRNA and decreased the expression of Bcl-2 mRNA in xenografted tumor. costunolide 0-11 BCL2 apoptosis regulator Homo sapiens 92-97 31248045-6 2019 Overexpression of the anti-apoptotic factor B-cell lymphoma 2 (BCL-2) in HCT116 cells reduced TRAIL/sunitinib-mediated apoptosis, further supporting that sunitinib enhances the anticancer activity of TRAIL via augmented apoptosis. Sunitinib 100-109 BCL2 apoptosis regulator Homo sapiens 44-61 31248045-6 2019 Overexpression of the anti-apoptotic factor B-cell lymphoma 2 (BCL-2) in HCT116 cells reduced TRAIL/sunitinib-mediated apoptosis, further supporting that sunitinib enhances the anticancer activity of TRAIL via augmented apoptosis. Sunitinib 100-109 BCL2 apoptosis regulator Homo sapiens 63-68 31248045-6 2019 Overexpression of the anti-apoptotic factor B-cell lymphoma 2 (BCL-2) in HCT116 cells reduced TRAIL/sunitinib-mediated apoptosis, further supporting that sunitinib enhances the anticancer activity of TRAIL via augmented apoptosis. Sunitinib 154-163 BCL2 apoptosis regulator Homo sapiens 44-61 31248045-6 2019 Overexpression of the anti-apoptotic factor B-cell lymphoma 2 (BCL-2) in HCT116 cells reduced TRAIL/sunitinib-mediated apoptosis, further supporting that sunitinib enhances the anticancer activity of TRAIL via augmented apoptosis. Sunitinib 154-163 BCL2 apoptosis regulator Homo sapiens 63-68 31141661-6 2019 The released CXB not only acted on cyclooxygenase-2 (COX-2) to suppress the production of pro-inflammatory PGE2 in multiple cell types but also suppressed the expression of the anti-apoptotic Bcl-2 gene to sensitize cancer cells to chemotherapy, thus resulting in a synergistic anticancer effect of PTX and CXB. Celecoxib 13-16 BCL2 apoptosis regulator Homo sapiens 192-197 31141661-6 2019 The released CXB not only acted on cyclooxygenase-2 (COX-2) to suppress the production of pro-inflammatory PGE2 in multiple cell types but also suppressed the expression of the anti-apoptotic Bcl-2 gene to sensitize cancer cells to chemotherapy, thus resulting in a synergistic anticancer effect of PTX and CXB. Paclitaxel 299-302 BCL2 apoptosis regulator Homo sapiens 192-197 31141661-6 2019 The released CXB not only acted on cyclooxygenase-2 (COX-2) to suppress the production of pro-inflammatory PGE2 in multiple cell types but also suppressed the expression of the anti-apoptotic Bcl-2 gene to sensitize cancer cells to chemotherapy, thus resulting in a synergistic anticancer effect of PTX and CXB. Celecoxib 307-310 BCL2 apoptosis regulator Homo sapiens 192-197 31293422-0 2019 Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials. venetoclax 39-49 BCL2 apoptosis regulator Homo sapiens 23-28 31293422-2 2019 Venetoclax (ABT-199/GDC-0199) is a highly selective bioavailable inhibitor of BCL-2 protein, which is more effective and less valid against BCL-xL in BCL2-dependent leukemia and lymphoma cell. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 78-83 31293422-2 2019 Venetoclax (ABT-199/GDC-0199) is a highly selective bioavailable inhibitor of BCL-2 protein, which is more effective and less valid against BCL-xL in BCL2-dependent leukemia and lymphoma cell. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 150-154 31293422-2 2019 Venetoclax (ABT-199/GDC-0199) is a highly selective bioavailable inhibitor of BCL-2 protein, which is more effective and less valid against BCL-xL in BCL2-dependent leukemia and lymphoma cell. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 12-15 BCL2 apoptosis regulator Homo sapiens 78-83 31293422-2 2019 Venetoclax (ABT-199/GDC-0199) is a highly selective bioavailable inhibitor of BCL-2 protein, which is more effective and less valid against BCL-xL in BCL2-dependent leukemia and lymphoma cell. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 12-15 BCL2 apoptosis regulator Homo sapiens 150-154 31293422-2 2019 Venetoclax (ABT-199/GDC-0199) is a highly selective bioavailable inhibitor of BCL-2 protein, which is more effective and less valid against BCL-xL in BCL2-dependent leukemia and lymphoma cell. venetoclax 20-28 BCL2 apoptosis regulator Homo sapiens 78-83 31293422-2 2019 Venetoclax (ABT-199/GDC-0199) is a highly selective bioavailable inhibitor of BCL-2 protein, which is more effective and less valid against BCL-xL in BCL2-dependent leukemia and lymphoma cell. venetoclax 20-28 BCL2 apoptosis regulator Homo sapiens 150-154 31032514-10 2019 H2O2 induced the apparent apoptotic characteristics, including fragmentation of DNA, upregulation of Bax/Bcl2, activation of caspase-3, and secretion of inflammation cytokines, which were all ameliorated by SCM-198. Hydrogen Peroxide 0-4 BCL2 apoptosis regulator Homo sapiens 105-109 31220110-9 2019 Mitochondrial damage and intracellular ROS production were observed upon treatment with AgNPs (10mug/mL) and PDT (0.5 mJ/cm2) showed significant reducing cell migration, expression of Bax and suppression of Bcl-2. ros 39-42 BCL2 apoptosis regulator Homo sapiens 207-212 31217472-4 2019 We demonstrated that LZ-101 induced mitochondrial-mediated apoptosis by increasing Bax/Bcl-2 ratio, loss of mitochondrial membrane potential (DeltaPsim), release of cytochrome c (Cyt c) and apoptosis-inducing factor (AIF) in A549 cells. lz-101 21-27 BCL2 apoptosis regulator Homo sapiens 87-92 31357761-9 2019 SP600125 and SB203580 had inhibited oxidative stress and apoptosis induced by palmitic acid (including CYP2E1, MDA, Bax, Bcl-2, caspase3, CHOP) (P< 0.05). Palmitic Acid 78-91 BCL2 apoptosis regulator Homo sapiens 121-126 31095910-3 2019 The assay enables the identification of c-MYC and BCL2 G-quadruplex selective bis-triazole ligands that specifically target promoter G-quadruplexes in cancer cells. BIS-TRIAZOLE 78-90 BCL2 apoptosis regulator Homo sapiens 50-54 31244554-12 2019 Results: Reversine inhibits cell proliferation and induces cell apoptosis by modulating caspase-3 and bax/bcl-2 among the three cell lines. 2-(4-morpholinoanilino)-6-cyclohexylaminopurine 9-18 BCL2 apoptosis regulator Homo sapiens 106-111 31215421-13 2019 Meanwhile, treatment with elemene significantly up-regulates the protein expression of P53, while down-regulate the protein expression of Bcl-2 in the tumor tissues, respectively. elemene 26-33 BCL2 apoptosis regulator Homo sapiens 138-143 31215421-14 2019 Furthermore, the western blot result showed that treatment with elemene increased the expression of P53 and decreased the expression of Bcl-2, compared with the control group, which is similar to the results of immunohistochemical staining. elemene 64-71 BCL2 apoptosis regulator Homo sapiens 136-141 31215421-15 2019 CONCLUSIONS: This study suggests that elemene has a potential anti pancreatic cancer effect, down-regulation the protein expression of Bcl-2 and up-regulation the protein expression of P53 in a dose dependent manner may be is the anti-tumor mechanism. elemene 38-45 BCL2 apoptosis regulator Homo sapiens 135-140 30910472-6 2019 Moreover, BA could induce cell apoptosis by upregulating expression of Bax and cleaved caspase-3 and downregulating protein of Bcl-2. betulinic acid 10-12 BCL2 apoptosis regulator Homo sapiens 127-132 31312348-8 2019 Baicalein decreased the ratio of Bcl-2/Bax but increased the expression of Caspase-3 and Caspase-8. baicalein 0-9 BCL2 apoptosis regulator Homo sapiens 33-38 31186039-11 2019 Notably, our studies revealed the mechanism that Ilamycin C can induce Bax/Bcl-2-related caspase-dependent apoptosis and inhibit migration and invasion through MMP2/MMP9/vimentin/fascin in TNBC by suppressing IL-6-induced STAT3 phosphorylation. ilamycin c 49-59 BCL2 apoptosis regulator Homo sapiens 75-80 31235998-18 2019 Western blotting showed that upregulation of miR-34a combined with treatment with doxorubicin caused significant changes in the expression levels of p-p53, SIRT1, cyclin D1, CDK4, CDK6, BCL-2, MDR1/P-gp and AXL proteins (P < 0.01). Doxorubicin 82-93 BCL2 apoptosis regulator Homo sapiens 186-191 31003773-4 2019 Moreover, we revealed that the anti-cancer ability of TET is associated with a decreased expression of anti-apoptotic Bcl-2. tetrandrine 54-57 BCL2 apoptosis regulator Homo sapiens 118-123 30965082-13 2019 The standard doxorubicin exhibited IC50 in Bcl-2 Jurkat and A-431cell lines at 45.87 muM and 42.37 muM, respectively. Doxorubicin 13-24 BCL2 apoptosis regulator Homo sapiens 43-48 30965082-17 2019 DISCUSSION AND CONCLUSION: The chemical intuition was checked by computation coupled with biological results confirmed that thiazole-based hits have the potential to be developed downstream into potent and safer leads against antiapoptotic Bcl-2 cells. Thiazoles 124-132 BCL2 apoptosis regulator Homo sapiens 240-245 31166681-1 2019 BACKGROUND: The BCL2 inhibitor venetoclax has shown activity in patients with chronic lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with CLL and coexisting conditions is not known. venetoclax 31-41 BCL2 apoptosis regulator Homo sapiens 16-20 31333784-0 2019 A medicinal and edible formula YH0618 ameliorates the toxicity induced by Doxorubicin via regulating the expression of Bax/Bcl-2 and FOXO4. yh0618 31-37 BCL2 apoptosis regulator Homo sapiens 123-128 31333784-0 2019 A medicinal and edible formula YH0618 ameliorates the toxicity induced by Doxorubicin via regulating the expression of Bax/Bcl-2 and FOXO4. Doxorubicin 74-85 BCL2 apoptosis regulator Homo sapiens 123-128 31333785-4 2019 Despite not increasing the intercellular ROS levels in gastric cancer cells, chaetocin did cause a reduction in mitochondrial membrane potential probably through its regulation on the expression of Bcl-2 and BAX. chaetocin 77-86 BCL2 apoptosis regulator Homo sapiens 198-203 30925454-6 2019 Moreover, Western blot analysis also showed that the apoptosis-inducing effects of lobaplatin was associated with the reduction of Bcl-2 expression while upregulation of cleaved-caspase-3, cleaved-caspase-8, cleaved-caspase-9 and Bax. lobaplatin 83-93 BCL2 apoptosis regulator Homo sapiens 131-136 31239643-10 2019 In addtion, notopterol induced the percentage of apoptotic HL-60 cells, reduced the mitochondrial membrane potential, decreased the protein expresstion of Bcl-2 and Mcl-1, and increased the expression of Bax, cleavage of caspase 9, caspase 3, and PARP. notopterol 12-22 BCL2 apoptosis regulator Homo sapiens 155-160 31217754-0 2019 Lobaplatin Inhibits Prostate Cancer Proliferation and Migration Through Regulation of BCL2 and BAX. lobaplatin 0-10 BCL2 apoptosis regulator Homo sapiens 86-90 31217754-10 2019 Meanwhile, lobaplatin treatment regulates apoptosis by downregulation of BCL2 expression and upregulation of BAX expression levels. lobaplatin 11-21 BCL2 apoptosis regulator Homo sapiens 73-77 31217754-11 2019 Our study suggests lobaplatin inhibits prostate cancer proliferation and migration through regulation of BCL2 and BAX expression. lobaplatin 19-29 BCL2 apoptosis regulator Homo sapiens 105-109 31167506-5 2019 PQR620 was largely cytostatic, but the combination with the BCL2 inhibitor venetoclax led to cytotoxicity. venetoclax 75-85 BCL2 apoptosis regulator Homo sapiens 60-64 31092035-6 2019 In addition, pyridoxine induced reactive oxygen species (ROS) generation and alteration of mitochondrial membrane potential transition (MPT), including Bcl-2 family protein expression and consequently Ca2+ accumulation and changes of endoplasmic reticulum (ER) stress-related protein expression such as phospho-PERK, caspase-12, Grp78, and CHOP. Pyridoxine 13-23 BCL2 apoptosis regulator Homo sapiens 152-157 31172986-6 2019 Moreover, phosphorylation of antiapoptotic Bcl-2 protein in NAV-treated HCT116 was observed. NAV 60-63 BCL2 apoptosis regulator Homo sapiens 43-48 31160589-4 2019 The pose of venetoclax in its binding site on BCL-2 reveals small but unexpected differences as compared to published structures of complexes with venetoclax analogues. venetoclax 12-22 BCL2 apoptosis regulator Homo sapiens 46-51 30848542-5 2019 Simultaneously, Ost altered apoptotic related proteins levels, including Bcl-2, Bax, Cleaved-Caspase-9/-8/-3, and Pro-Caspase-3/-8. osthol 16-19 BCL2 apoptosis regulator Homo sapiens 73-78 31074699-3 2019 Results reported herein would demonstrate that Cinchona alkaloids could induce apoptosis in HeLa cells, inhibit the ubiquitination and phosphorylation of both AKT and TAK1, and up-regulate the ratio of Bax/Bcl-2. Cinchona Alkaloids 47-65 BCL2 apoptosis regulator Homo sapiens 206-211 30707764-0 2019 Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Lenalidomide 17-29 BCL2 apoptosis regulator Homo sapiens 127-131 30185825-1 2019 The impressive selectivity and efficacy of BH3 mimetics for treating cancer has largely been limited to BCL-2 dependent hematological malignancies. BH 3 43-46 BCL2 apoptosis regulator Homo sapiens 104-109 30535663-10 2019 Moreover, we also confirmed that overexpression of miR-15b-5p may exacerbate the DOX-induced apoptosis of H9c2 cardiomyocytes by affecting the protein expression ratio of Bcl-2/Bax and Akt activation, while this pro-apoptotic effect was able to be suppressed by Bmpr1a agonist. Doxorubicin 81-84 BCL2 apoptosis regulator Homo sapiens 171-176 30875026-11 2019 A curcumin nanoformulation sized 77 nm and containing of 3% ethanol was more effective in increasing beta1-integrin gene over-expression, anti-apoptosis of fibroblast cells (Bcl2/Bax ratio), and in decreasing Bax and NFkappaB gene expression than that with a particle size of 50 nm. Curcumin 2-10 BCL2 apoptosis regulator Homo sapiens 174-178 30875026-11 2019 A curcumin nanoformulation sized 77 nm and containing of 3% ethanol was more effective in increasing beta1-integrin gene over-expression, anti-apoptosis of fibroblast cells (Bcl2/Bax ratio), and in decreasing Bax and NFkappaB gene expression than that with a particle size of 50 nm. Ethanol 60-67 BCL2 apoptosis regulator Homo sapiens 174-178 31466709-5 2019 RESULTS: Neoadjuvant propranolol decreased expression of the pro-proliferative Ki-67 and pro-survival Bcl-2 markers, and increased pro-apoptotic p53 expression in a patient with stage III breast cancer. Propranolol 21-32 BCL2 apoptosis regulator Homo sapiens 102-107 30867139-6 2019 Apoptotic endpoints were significantly increased by the 5-ASA/HT combined treatment, as evidenced by presence of Annexin V-FITC/PI positive cells, loss of MMP, Bcl-2/Bax ratio alteration, and increased Fas, cleaved Bid, and caspase expression. Mesalamine 56-61 BCL2 apoptosis regulator Homo sapiens 160-165 31116090-11 2019 Western blot analyses revealed that circ-0001785 regulated the PI3K/Akt signaling and Bcl-2 family pathway in osteosarcoma. circ 36-40 BCL2 apoptosis regulator Homo sapiens 86-91 31059100-0 2019 Trichostatin A-induced miR-30a-5p regulates apoptosis and proliferation of keloid fibroblasts via targeting BCL2. trichostatin A 0-14 BCL2 apoptosis regulator Homo sapiens 108-112 31298363-15 2019 The pro-apoptotic activity of PG was confirmed by flow cytometry, activation of caspase-3 and PARP, upregulation of Bax and downregulation of Bcl-2. physcion 8-O-glucopyranoside 30-32 BCL2 apoptosis regulator Homo sapiens 142-147 30953339-9 2019 Expressions of anti-apoptotic factors such as Bcl-2 and Bcl-xL, components of the mitochondria dependent intrinsic apoptosis pathway, significantly decreased following reversine treatment. 2-(4-morpholinoanilino)-6-cyclohexylaminopurine 168-177 BCL2 apoptosis regulator Homo sapiens 46-51 30942428-10 2019 In addition, it was demonstrated that salidroside suppressed ox-LDL-induced mitochondrial dysfunction as demonstrated by the increase in mitochondrial membrane potential and decreases in cytochrome c expression, and Bax/Bcl-2 reductions. rhodioloside 38-49 BCL2 apoptosis regulator Homo sapiens 220-225 30796627-6 2019 Pretreatment with ATO remarkably increased the gene expression levels of antioxidant enzymes and reduced HG-induced elevation of ROS, lipid peroxidation, Bax/Bcl-2 ratio, caspase-3 activation, and JNK and P38 phosphorylation. Atorvastatin 18-21 BCL2 apoptosis regulator Homo sapiens 158-163 30889680-0 2019 Graphene oxide functionalized with chitosan based nanoparticles as a carrier of siRNA in regulating Bcl-2 expression on Saos-2 & MG-63 cancer cells and its inflammatory response on bone marrow derived cells from mice. graphene oxide 0-14 BCL2 apoptosis regulator Homo sapiens 100-105 30889680-0 2019 Graphene oxide functionalized with chitosan based nanoparticles as a carrier of siRNA in regulating Bcl-2 expression on Saos-2 & MG-63 cancer cells and its inflammatory response on bone marrow derived cells from mice. saos-2 120-126 BCL2 apoptosis regulator Homo sapiens 100-105 30889680-0 2019 Graphene oxide functionalized with chitosan based nanoparticles as a carrier of siRNA in regulating Bcl-2 expression on Saos-2 & MG-63 cancer cells and its inflammatory response on bone marrow derived cells from mice. Adenosine Monophosphate 128-131 BCL2 apoptosis regulator Homo sapiens 100-105 30962322-0 2019 Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo. t-dm1 56-61 BCL2 apoptosis regulator Homo sapiens 18-23 30962322-5 2019 Inhibition of BCL-2/XL via navitoclax/ABT-263 significantly enhanced the cytotoxicity of T-DM1 in two of three models derived from advanced and treatment-exposed metastatic breast tumors. navitoclax 38-45 BCL2 apoptosis regulator Homo sapiens 14-19 30962322-5 2019 Inhibition of BCL-2/XL via navitoclax/ABT-263 significantly enhanced the cytotoxicity of T-DM1 in two of three models derived from advanced and treatment-exposed metastatic breast tumors. t-dm1 89-94 BCL2 apoptosis regulator Homo sapiens 14-19 30659877-4 2019 Mechanistically at the molecular level, LRWXG regulates the MAPK pathway induced by oxidative stress: The levels of phosphorylation of JNK and p38 proteins in the groups treated by LRWXG are lower than model group, while compared with corresponding groups of inhibitors, there are no significant difference; For other related proteins, LRWXG reduces the levels of the apoptosis-related proteins BAX and cleaved caspase-3, and increases the level of anti-apoptotic protein BCL2. lrwxg 40-45 BCL2 apoptosis regulator Homo sapiens 472-476 30659877-4 2019 Mechanistically at the molecular level, LRWXG regulates the MAPK pathway induced by oxidative stress: The levels of phosphorylation of JNK and p38 proteins in the groups treated by LRWXG are lower than model group, while compared with corresponding groups of inhibitors, there are no significant difference; For other related proteins, LRWXG reduces the levels of the apoptosis-related proteins BAX and cleaved caspase-3, and increases the level of anti-apoptotic protein BCL2. lrwxg 181-186 BCL2 apoptosis regulator Homo sapiens 472-476 30659877-4 2019 Mechanistically at the molecular level, LRWXG regulates the MAPK pathway induced by oxidative stress: The levels of phosphorylation of JNK and p38 proteins in the groups treated by LRWXG are lower than model group, while compared with corresponding groups of inhibitors, there are no significant difference; For other related proteins, LRWXG reduces the levels of the apoptosis-related proteins BAX and cleaved caspase-3, and increases the level of anti-apoptotic protein BCL2. lrwxg 181-186 BCL2 apoptosis regulator Homo sapiens 472-476 30836210-8 2019 Moreover, apoptosis induced by AC extract with 625 nm irradiation (IR) down-regulated the expression of Bcl-2 protein and up-regulated the expression of Bax protein, as well as that of cleaved PARP-1 protein in both KB and Hep-2 cells. Charcoal 31-33 BCL2 apoptosis regulator Homo sapiens 104-109 30546081-2 2019 We here characterize the curative potential of BH3-mimetics differentially targeting mitochondrial BCL2-family members using a combination therapy approach with dexamethasone and tyrosine kinase inhibitors targeting BCR-ABL. BH 3 47-50 BCL2 apoptosis regulator Homo sapiens 99-103 30546081-3 2019 In BCR-ABL + ALL BH3-mimetics act by redistribution of mitochondrial activator BIM, which is strongly required for cytotoxicity of the BCL2-specific BH3-mimetic ABT-199, tyrosine kinase inhibitors (TKIs) and dexamethasone. BH 3 17-20 BCL2 apoptosis regulator Homo sapiens 135-139 30546081-3 2019 In BCR-ABL + ALL BH3-mimetics act by redistribution of mitochondrial activator BIM, which is strongly required for cytotoxicity of the BCL2-specific BH3-mimetic ABT-199, tyrosine kinase inhibitors (TKIs) and dexamethasone. BH 3 149-152 BCL2 apoptosis regulator Homo sapiens 135-139 30546081-3 2019 In BCR-ABL + ALL BH3-mimetics act by redistribution of mitochondrial activator BIM, which is strongly required for cytotoxicity of the BCL2-specific BH3-mimetic ABT-199, tyrosine kinase inhibitors (TKIs) and dexamethasone. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 161-164 BCL2 apoptosis regulator Homo sapiens 135-139 31004883-11 2019 Finally, proliferation markers including cyclin D1 and c-Myc, and anti-apoptosis proteins such as Bcl-2 and survivin were also down-regulated by PAB treatment in HepG2 cells. pseudolaric acid B 145-148 BCL2 apoptosis regulator Homo sapiens 98-103 30546081-3 2019 In BCR-ABL + ALL BH3-mimetics act by redistribution of mitochondrial activator BIM, which is strongly required for cytotoxicity of the BCL2-specific BH3-mimetic ABT-199, tyrosine kinase inhibitors (TKIs) and dexamethasone. Dexamethasone 208-221 BCL2 apoptosis regulator Homo sapiens 135-139 31115744-4 2019 Venetoclax (ABT-199), a selective Bcl-2 inhibitor, was recently approved for the treatment of acute myeloid leukemia. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 34-39 31115744-4 2019 Venetoclax (ABT-199), a selective Bcl-2 inhibitor, was recently approved for the treatment of acute myeloid leukemia. venetoclax 12-19 BCL2 apoptosis regulator Homo sapiens 34-39 31120636-9 2019 In addition, salidroside increased expressions of pro-apoptotic factors (Bax and cleaved caspase 3) and decreased expression of anti-apoptotic factor (Bcl-2) significantly in WRO cells. rhodioloside 13-24 BCL2 apoptosis regulator Homo sapiens 151-156 31108962-5 2019 Polyphenols can scavenge reactive oxygen and nitrogen species and activate redox-responsible transcription factors to regulate expression of genes, coding antioxidants, anti-apoptotic Bcl-2 protein family, and pro-survival neurotrophic factors. Polyphenols 0-11 BCL2 apoptosis regulator Homo sapiens 184-189 31178739-11 2019 Regulation of cyclin B1, cdk6, and Bcl-2 expression by brevilin A showed dynamic changes according to dose and time. brevilin A 55-65 BCL2 apoptosis regulator Homo sapiens 35-40 31109093-5 2019 Notably, the role of AE-COS in induction of cell apoptosis was observed via decreasing Bcl-2 expression and increasing caspase-3 and -9 activation. ae-cos 21-27 BCL2 apoptosis regulator Homo sapiens 87-92 30716501-10 2019 CONCLUSIONS: Histopathology and immunohistochemical staining (characterized by positive expression of mainly STAT6 but also CD34, Bcl-2 protein, and vimentin) are key in diagnosis and management of ISFTs. isfts 198-203 BCL2 apoptosis regulator Homo sapiens 130-135 31239661-11 2019 OA helped CDDP to overcome the resistance by downregulating the expression of proteins like XIAP, Bcl-2 via NF-kappaB pathway. Cisplatin 10-14 BCL2 apoptosis regulator Homo sapiens 98-103 31127908-5 2019 After 48 hours from theculture, the expressional profiles of apoptosis pathway genes (84 genes) were studied using the PCR array method.Results: The findings demonstrated that the expression of some apoptosis-related genes pertaining to TNF, BCL2,IAP, and caspase families was regulated by (2R, 4S)-N-(2, 5-difluorophenyl)-4-Hydroxy-1-(2, 2, 2-Trifluoroacetyl)Pyrrolidine-2-Carboxamide. (2r, 4s)-n-(2, 5-difluorophenyl)-4-hydroxy-1-(2, 2, 2-trifluoroacetyl)pyrrolidine-2-carboxamide 290-385 BCL2 apoptosis regulator Homo sapiens 242-246 31263600-9 2019 4,5-diCQA-induced accumulation of cells in the S-phase also seems to negatively impact Bcl-2 expression. 4,5-dicaffeoyl quinic acid 0-9 BCL2 apoptosis regulator Homo sapiens 87-92 31117931-10 2019 RESULTS: APS treatment significantly decreased the expression of miR-195, while increased the expression of Bcl-2 with optimized dosages which were induced by HG treatment, even after replacing the HG with NG. aps 9-12 BCL2 apoptosis regulator Homo sapiens 108-113 30946863-6 2019 Bim up-regulation and Bcl-2 down-regulation as the symbol of apoptosis which were found to play the dominant role in the effects of Erianin. Erianin 132-139 BCL2 apoptosis regulator Homo sapiens 22-27 31249651-2 2019 GB activates the proapoptotic B cell CLL/lymphoma 2 (Bcl-2) family member BH3-interacting domain death agonist (BID) to switch on the intrinsic mitochondrial death pathway, leading to Bcl-2-associated X protein (Bax)/Bcl-2 homologous antagonist/killer- (Bak-) dependent mitochondrial outer membrane permeabilization (MOMP), the dissipation of mitochondrial transmembrane potential (DeltaPsim), and the production of reactive oxygen species (ROS). Reactive Oxygen Species 416-439 BCL2 apoptosis regulator Homo sapiens 30-51 31249651-2 2019 GB activates the proapoptotic B cell CLL/lymphoma 2 (Bcl-2) family member BH3-interacting domain death agonist (BID) to switch on the intrinsic mitochondrial death pathway, leading to Bcl-2-associated X protein (Bax)/Bcl-2 homologous antagonist/killer- (Bak-) dependent mitochondrial outer membrane permeabilization (MOMP), the dissipation of mitochondrial transmembrane potential (DeltaPsim), and the production of reactive oxygen species (ROS). Reactive Oxygen Species 416-439 BCL2 apoptosis regulator Homo sapiens 53-58 31249651-2 2019 GB activates the proapoptotic B cell CLL/lymphoma 2 (Bcl-2) family member BH3-interacting domain death agonist (BID) to switch on the intrinsic mitochondrial death pathway, leading to Bcl-2-associated X protein (Bax)/Bcl-2 homologous antagonist/killer- (Bak-) dependent mitochondrial outer membrane permeabilization (MOMP), the dissipation of mitochondrial transmembrane potential (DeltaPsim), and the production of reactive oxygen species (ROS). Reactive Oxygen Species 416-439 BCL2 apoptosis regulator Homo sapiens 184-189 31249651-2 2019 GB activates the proapoptotic B cell CLL/lymphoma 2 (Bcl-2) family member BH3-interacting domain death agonist (BID) to switch on the intrinsic mitochondrial death pathway, leading to Bcl-2-associated X protein (Bax)/Bcl-2 homologous antagonist/killer- (Bak-) dependent mitochondrial outer membrane permeabilization (MOMP), the dissipation of mitochondrial transmembrane potential (DeltaPsim), and the production of reactive oxygen species (ROS). Reactive Oxygen Species 441-444 BCL2 apoptosis regulator Homo sapiens 30-51 31249651-2 2019 GB activates the proapoptotic B cell CLL/lymphoma 2 (Bcl-2) family member BH3-interacting domain death agonist (BID) to switch on the intrinsic mitochondrial death pathway, leading to Bcl-2-associated X protein (Bax)/Bcl-2 homologous antagonist/killer- (Bak-) dependent mitochondrial outer membrane permeabilization (MOMP), the dissipation of mitochondrial transmembrane potential (DeltaPsim), and the production of reactive oxygen species (ROS). Reactive Oxygen Species 441-444 BCL2 apoptosis regulator Homo sapiens 53-58 31249651-2 2019 GB activates the proapoptotic B cell CLL/lymphoma 2 (Bcl-2) family member BH3-interacting domain death agonist (BID) to switch on the intrinsic mitochondrial death pathway, leading to Bcl-2-associated X protein (Bax)/Bcl-2 homologous antagonist/killer- (Bak-) dependent mitochondrial outer membrane permeabilization (MOMP), the dissipation of mitochondrial transmembrane potential (DeltaPsim), and the production of reactive oxygen species (ROS). Reactive Oxygen Species 441-444 BCL2 apoptosis regulator Homo sapiens 184-189 31218209-8 2019 In addition, we found that pristimerin decreased the protein expression of CDK2, CDK4, cyclin E, and BCL-2 and increased the expression of CDKN1B. pristimerin 27-38 BCL2 apoptosis regulator Homo sapiens 101-106 31040202-0 2019 Tetrandrine inhibits colon carcinoma HT-29 cells growth via the Bcl-2/Caspase 3/PARP pathway and G1/S phase. tetrandrine 0-11 BCL2 apoptosis regulator Homo sapiens 64-69 31085176-0 2019 BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 57-60 BCL2 apoptosis regulator Homo sapiens 0-4 31139308-12 2019 QFGs also increased the expression levels of Bax, Fas and FasL, decreased the level of Bcl-2, and stimulated the activation of caspase-3/-8/-9, which were revealed by western blot and caspase activity assays. qfgs 0-4 BCL2 apoptosis regulator Homo sapiens 87-92 31085176-2 2019 Here we report that resistance to the BCL-2 targeting drug ABT-199 in models of mantle cell lymphoma and double-hit lymphoma evolves from outgrowth of persister clones displaying loss of 18q21 amplicons that harbor BCL2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 59-62 BCL2 apoptosis regulator Homo sapiens 38-43 31085176-2 2019 Here we report that resistance to the BCL-2 targeting drug ABT-199 in models of mantle cell lymphoma and double-hit lymphoma evolves from outgrowth of persister clones displaying loss of 18q21 amplicons that harbor BCL2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 59-62 BCL2 apoptosis regulator Homo sapiens 215-219 31086026-5 2019 Additionally, we found that flaccidoxide-13-acetate treatment upregulated the expressions of cleaved caspase 3, cleaved caspase 9, Bax, and Bad, and down-regulated the expressions of Bcl-2, p-Bad, Bcl-x1, and Mcl-1. flaccidoxide 28-40 BCL2 apoptosis regulator Homo sapiens 183-188 31086026-5 2019 Additionally, we found that flaccidoxide-13-acetate treatment upregulated the expressions of cleaved caspase 3, cleaved caspase 9, Bax, and Bad, and down-regulated the expressions of Bcl-2, p-Bad, Bcl-x1, and Mcl-1. 13-acetate 41-51 BCL2 apoptosis regulator Homo sapiens 183-188 30924664-3 2019 Herein, we developed a simple, theranostic nanoassembly containing a hyaluronic acid-stabilized redox-sensitive (HART) polyethylenimine polyplex composed of a doxorubicin (DOX) intercalated Bcl-2 shRNA encoded plasmid along with a green-synthesized hausmannite (Mn3O4) and hematite (Fe3O4) nanoparticle (GMF). Hyaluronic Acid 69-84 BCL2 apoptosis regulator Homo sapiens 190-195 31076571-0 2019 Cancer-associated fibroblasts promote cisplatin resistance in bladder cancer cells by increasing IGF-1/ERbeta/Bcl-2 signalling. Cisplatin 38-47 BCL2 apoptosis regulator Homo sapiens 110-115 31076571-8 2019 The in vivo data also confirmed that CAFs could increase BCa cell resistance to cisplatin by increasing ERbeta/Bcl-2 signalling. Cisplatin 80-89 BCL2 apoptosis regulator Homo sapiens 111-116 31139082-7 2019 Furthermore, arsenic-induced decrease of anti-apoptotic factor Bcl-2 and Bcl-xl, and increase of pro-apoptotic factor Bax and Bad, as well as survival signal related factor caspase 3 activation were reversed by Pts treatment. Arsenic 13-20 BCL2 apoptosis regulator Homo sapiens 63-68 30975734-5 2019 Furthermore, results of western blotting showed that the involvement of mitochondrial apoptotic pathway in the L-securinine-induced apoptosis of DU145 cell, as evidenced by an increase in the protein expression of Bax, cleaved caspase-9, cleaved caspase-3, cytosolic cytochrome c, and cleaved PARP, together with a unchanged cleaved caspase-8 and decreased Bcl-2 protein expression. securinine 111-123 BCL2 apoptosis regulator Homo sapiens 357-362 31807365-5 2019 TiO2 particles induced ER stress-mediated apoptosis in a particle size-dependent manner as seen by a decrease in the expression of Bcl-2, and increases in the expression of Bax, caspase-12, and cleaved caspase-3. Titanium 0-4 BCL2 apoptosis regulator Homo sapiens 131-136 30773463-2 2019 We used loss-of-function CRISPR/Cas9 knockout screening to identify metabolic genes capable of influencing cellular commitment to apoptosis, using sensitization to the BCL-2 inhibitor ABT-199 in BCL-2-dependent acute myeloid leukemia (AML) cell lines as a proxy for apoptotic disposition. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 184-187 BCL2 apoptosis regulator Homo sapiens 168-173 30773463-2 2019 We used loss-of-function CRISPR/Cas9 knockout screening to identify metabolic genes capable of influencing cellular commitment to apoptosis, using sensitization to the BCL-2 inhibitor ABT-199 in BCL-2-dependent acute myeloid leukemia (AML) cell lines as a proxy for apoptotic disposition. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 184-187 BCL2 apoptosis regulator Homo sapiens 195-200 30924664-3 2019 Herein, we developed a simple, theranostic nanoassembly containing a hyaluronic acid-stabilized redox-sensitive (HART) polyethylenimine polyplex composed of a doxorubicin (DOX) intercalated Bcl-2 shRNA encoded plasmid along with a green-synthesized hausmannite (Mn3O4) and hematite (Fe3O4) nanoparticle (GMF). Polyethyleneimine 119-135 BCL2 apoptosis regulator Homo sapiens 190-195 30924664-3 2019 Herein, we developed a simple, theranostic nanoassembly containing a hyaluronic acid-stabilized redox-sensitive (HART) polyethylenimine polyplex composed of a doxorubicin (DOX) intercalated Bcl-2 shRNA encoded plasmid along with a green-synthesized hausmannite (Mn3O4) and hematite (Fe3O4) nanoparticle (GMF). Doxorubicin 159-170 BCL2 apoptosis regulator Homo sapiens 190-195 30924664-5 2019 With Bcl-2 gene silencing induced by the successful delivery of HART in multidrug-resistant MCF7 breast cancer cells, the synergistic cytotoxic effect of Bcl-2 silencing and DOX was achieved. Doxorubicin 174-177 BCL2 apoptosis regulator Homo sapiens 5-10 30499025-6 2019 RESULTS: To know whether p110alpha and p110beta are involved in protecting MCF-7 breast cancer cells against oxidative stress, we subjected MCF-7 cells to H2O2 treatment and observed a dose dependent decrease in cell viability and a marked increase in the levels of pro-apoptotic markers which include PARP, Bcl-2, Bax and procaspase-9. Hydrogen Peroxide 155-159 BCL2 apoptosis regulator Homo sapiens 308-313 31043579-8 2019 RESULTS Costunolide treatment inhibited the growth of OAW42-A cells with an IC50 of 25 microM, resulted in apoptotic cell death, increased the expression of Bax, and decreased the expression of Bcl-2. costunolide 8-19 BCL2 apoptosis regulator Homo sapiens 194-199 30850381-2 2019 Here, we report a phase 1b study investigating dose escalation of the BCL2 inhibitor, venetoclax, in combination with rituximab or obinutuzumab and cyclophosphamide, doxorubicin, vincristine, and prednisone (R-/G-CHOP) chemotherapy in B-cell NHL. venetoclax 86-96 BCL2 apoptosis regulator Homo sapiens 70-74 30850381-2 2019 Here, we report a phase 1b study investigating dose escalation of the BCL2 inhibitor, venetoclax, in combination with rituximab or obinutuzumab and cyclophosphamide, doxorubicin, vincristine, and prednisone (R-/G-CHOP) chemotherapy in B-cell NHL. Vincristine 179-190 BCL2 apoptosis regulator Homo sapiens 70-74 30850381-2 2019 Here, we report a phase 1b study investigating dose escalation of the BCL2 inhibitor, venetoclax, in combination with rituximab or obinutuzumab and cyclophosphamide, doxorubicin, vincristine, and prednisone (R-/G-CHOP) chemotherapy in B-cell NHL. Prednisone 196-206 BCL2 apoptosis regulator Homo sapiens 70-74 31308025-6 2019 beta-DHA-emodin also upregulated the expression of caspase-3/8/9 and Bax and downregulated the expression of Bcl-2. beta-dha-emodin 0-15 BCL2 apoptosis regulator Homo sapiens 109-114 31308026-9 2019 The expression levels of anti-apoptotic protein BCL-2 decreased, and the expression of pro-apoptotic proteins Active Caspase3, Bax increased concurrently after LY404039 stimulation using western blot. 4-aminho-2-thiabicyclo(3.1.0)hexane-4,6-dicarboxylic acid 160-168 BCL2 apoptosis regulator Homo sapiens 48-53 30626284-2 2019 Recent studies have shown that phosphorylation of BECN1 by STK4/MST1 at threonine 108 (T108) within its BH3 domain blocks macroautophagy/autophagy by increasing BECN1 affinity for its negative regulators, the anti-apoptotic proteins BCL2/Bcl-2 and BCL2L1/Bcl-xL. Threonine 72-81 BCL2 apoptosis regulator Homo sapiens 233-237 30626284-2 2019 Recent studies have shown that phosphorylation of BECN1 by STK4/MST1 at threonine 108 (T108) within its BH3 domain blocks macroautophagy/autophagy by increasing BECN1 affinity for its negative regulators, the anti-apoptotic proteins BCL2/Bcl-2 and BCL2L1/Bcl-xL. Threonine 72-81 BCL2 apoptosis regulator Homo sapiens 238-243 30626284-5 2019 We also determined X-ray crystal structures of BCL2 and BCL2L1 with T108-modified BECN1 BH3 peptides, but only showed evidence of an interaction between the BH3 peptide and the conserved histidine residue when the histidine flexibility was restrained due to crystal contacts. Histidine 187-196 BCL2 apoptosis regulator Homo sapiens 47-51 30725494-2 2019 The BCL-2 inhibitor venetoclax demonstrated activity as monotherapy and in combination with chemotherapy or HMA in AML. venetoclax 20-30 BCL2 apoptosis regulator Homo sapiens 4-9 30862722-4 2019 ABT-199, a selective Bcl-2 inhibitor, was effective in reducing leukemic burden in vitro and in vivo in patient-derived xenograft models of hypodiploid B-ALL. venetoclax 0-7 BCL2 apoptosis regulator Homo sapiens 21-26 30856406-5 2019 The decreased GSH would enhance apoptotic cell death by Bcl-2/caspase 3 pathway and reduce expression of P-gp to reverse lenvatinib resistance. Glutathione 14-17 BCL2 apoptosis regulator Homo sapiens 56-61 30420719-6 2019 Suppression of cap-dependent translation by 4EGI-1 resulted in diminished expression of oncogenic proteins c-Myc, Bcl-2, cyclin D1, and survivin, whereas beta-actin expression was left unchanged. cap 15-18 BCL2 apoptosis regulator Homo sapiens 114-119 31014173-6 2019 Here we show that while metformin can significantly inhibit cell growth and induce apoptosis of OSCC cultured alone in a dose-dependent manner through activating p-AMPKT172 and modulating Bcl-2, Bax, and cleaved PARP. Metformin 24-33 BCL2 apoptosis regulator Homo sapiens 188-193 30877973-16 2019 While among these iridoids, catalpol, 10-O-trans-p-coumaroylcatalpol, geniposide and harpagoside, in PD improved the expressions of GDNF and Bcl-2 proteins and TH-positive neurons by increasing the levels of antioxidant enzymes, SOD and GSH-PX and down-regulating insulin/IGF signalling via activation of MEK protein. catalpol 28-36 BCL2 apoptosis regulator Homo sapiens 141-146 30877973-16 2019 While among these iridoids, catalpol, 10-O-trans-p-coumaroylcatalpol, geniposide and harpagoside, in PD improved the expressions of GDNF and Bcl-2 proteins and TH-positive neurons by increasing the levels of antioxidant enzymes, SOD and GSH-PX and down-regulating insulin/IGF signalling via activation of MEK protein. 10-o-trans-p-coumaroylcatalpol 38-68 BCL2 apoptosis regulator Homo sapiens 141-146 30877973-16 2019 While among these iridoids, catalpol, 10-O-trans-p-coumaroylcatalpol, geniposide and harpagoside, in PD improved the expressions of GDNF and Bcl-2 proteins and TH-positive neurons by increasing the levels of antioxidant enzymes, SOD and GSH-PX and down-regulating insulin/IGF signalling via activation of MEK protein. geniposide 70-80 BCL2 apoptosis regulator Homo sapiens 141-146 30725494-2 2019 The BCL-2 inhibitor venetoclax demonstrated activity as monotherapy and in combination with chemotherapy or HMA in AML. 5-(N,N-hexamethylene)amiloride 108-111 BCL2 apoptosis regulator Homo sapiens 4-9 30877973-16 2019 While among these iridoids, catalpol, 10-O-trans-p-coumaroylcatalpol, geniposide and harpagoside, in PD improved the expressions of GDNF and Bcl-2 proteins and TH-positive neurons by increasing the levels of antioxidant enzymes, SOD and GSH-PX and down-regulating insulin/IGF signalling via activation of MEK protein. harpagoside 85-96 BCL2 apoptosis regulator Homo sapiens 141-146 31173289-2 2019 PATIENTS AND METHODS: We detected the expressions of SNHG5, apoptosis-specific genes (Bax and Bcl-2) and drug resistance-specific genes (MDR1 and MRP1) in cisplatin-sensitive and cisplatin-resistant GC patients. Cisplatin 155-164 BCL2 apoptosis regulator Homo sapiens 94-99 31053689-10 2019 Ru-AgNPs could induce apoptosis in MDA-MB-231 cells through upregulation of Bax and downregulation of Bcl-2 gene expression. ru-agnps 0-8 BCL2 apoptosis regulator Homo sapiens 102-107 30467206-4 2019 To mimic such rapid development of chemoresistance, we developed simple resistance models to three different BH3 mimetics, targeting BCL-2 (ABT-199), BCL-XL (A-1331852) or MCL-1 (A-1210477), in relevant hematologic cancer cell lines. BH 3 109-112 BCL2 apoptosis regulator Homo sapiens 133-138 31424641-8 2019 The anticancer effects of curzerenone were due to the induction of apoptosis which was also associated with alteration of apoptosis-related proteins (Bax,Bcl-2). Curzerenone 26-37 BCL2 apoptosis regulator Homo sapiens 154-159 31424652-13 2019 The anticancer effects of Icariin were due to induction of apoptosis which was accompanied with cleavage of caspase 3 and 9, upregulation of Bax and downregulation of Bcl-2. icariin 26-33 BCL2 apoptosis regulator Homo sapiens 167-172 31424653-12 2019 Scopoletin treatment also resulted in enhancement of the Bax, Caspase 3, 8 and 9 expression and decline of the Bcl-2 expression. Scopoletin 0-10 BCL2 apoptosis regulator Homo sapiens 111-116 30988770-5 2019 Furthermore, BOS-93 could induce apoptosis, activate caspase-3 and poly ADP ribose polymerase, and increase the B cell lymphoma (Bcl)-2 associated X protein/Bcl-2 ratio. bos-93 13-19 BCL2 apoptosis regulator Homo sapiens 157-162 30362578-9 2019 Moreover, polyphyllin II treatment increased levels of Fas, Bax, cytochrome c, activated caspase-3, -8, -9, cleaved poly(ADP-ribose) polymerase and decreased Bcl-2 expression levels. polyphyllin II 10-24 BCL2 apoptosis regulator Homo sapiens 158-163 30813073-7 2019 Although APS did not significantly inhibit the growth of MCF-7 cells growth, encouragingly, APS-activated RAW264.7 macrophages present anti-cancer activity as evidenced by (a) cell proliferation inhibition (with an inhibitory rate of 41%), (b) G1-phase cell cycle arrest, as well as (c) the regulation of apoptosis-related genes (Bax/Bcl-2, 13.26-fold increase than untreated cells). aps 92-95 BCL2 apoptosis regulator Homo sapiens 334-339 30424705-5 2019 In addition, the combination of Vorinostat and Palbociclib significantly inhibited the activation of the key molecules of the CDK4/6-Rb pathway and HDAC activity and subsequently decreased the expression of Cyclin-D1 and Bcl-2. Vorinostat 32-42 BCL2 apoptosis regulator Homo sapiens 221-226 30424705-5 2019 In addition, the combination of Vorinostat and Palbociclib significantly inhibited the activation of the key molecules of the CDK4/6-Rb pathway and HDAC activity and subsequently decreased the expression of Cyclin-D1 and Bcl-2. palbociclib 47-58 BCL2 apoptosis regulator Homo sapiens 221-226 30896849-0 2019 Astaxanthin inhibits proliferation and induces apoptosis of LX-2 cells by regulating the miR-29b/Bcl-2 pathway. astaxanthine 0-11 BCL2 apoptosis regulator Homo sapiens 97-102 30926635-4 2019 Here, we report our identification and characterization of DIM-C-pPhCF3 +MeSO3 - (BI1071), an oxidized product derived from indole-3-carbinol metabolite, as a modulator of the Nur77-Bcl-2 apoptotic pathway. 1,1-bis(3'-indolyl)-1-(4-trifluoromethylphenyl)methane 59-71 BCL2 apoptosis regulator Homo sapiens 182-187 30926635-4 2019 Here, we report our identification and characterization of DIM-C-pPhCF3 +MeSO3 - (BI1071), an oxidized product derived from indole-3-carbinol metabolite, as a modulator of the Nur77-Bcl-2 apoptotic pathway. meso3 - 73-80 BCL2 apoptosis regulator Homo sapiens 182-187 30926635-4 2019 Here, we report our identification and characterization of DIM-C-pPhCF3 +MeSO3 - (BI1071), an oxidized product derived from indole-3-carbinol metabolite, as a modulator of the Nur77-Bcl-2 apoptotic pathway. bi1071 82-88 BCL2 apoptosis regulator Homo sapiens 182-187 30926635-4 2019 Here, we report our identification and characterization of DIM-C-pPhCF3 +MeSO3 - (BI1071), an oxidized product derived from indole-3-carbinol metabolite, as a modulator of the Nur77-Bcl-2 apoptotic pathway. indole-3-carbinol 124-141 BCL2 apoptosis regulator Homo sapiens 182-187 30864709-5 2019 The results demonstrated that butyrate treatment significantly inhibited proliferation and induced apoptosis in HCT116 cells with an increased B-cell lymphoma-2 (Bcl-2)-associated X protein/Bcl-2 ratio. Butyrates 30-38 BCL2 apoptosis regulator Homo sapiens 143-160 30864709-5 2019 The results demonstrated that butyrate treatment significantly inhibited proliferation and induced apoptosis in HCT116 cells with an increased B-cell lymphoma-2 (Bcl-2)-associated X protein/Bcl-2 ratio. Butyrates 30-38 BCL2 apoptosis regulator Homo sapiens 162-167 30864709-5 2019 The results demonstrated that butyrate treatment significantly inhibited proliferation and induced apoptosis in HCT116 cells with an increased B-cell lymphoma-2 (Bcl-2)-associated X protein/Bcl-2 ratio. Butyrates 30-38 BCL2 apoptosis regulator Homo sapiens 190-195 30944660-0 2019 Aspirin inhibits growth of ovarian cancer by upregulating caspase-3 and downregulating bcl-2. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 87-92 30896826-0 2019 Songorine suppresses cell growth and metastasis in epithelial ovarian cancer via the Bcl-2/Bax and GSK3beta/beta-catenin signaling pathways. songorine 0-9 BCL2 apoptosis regulator Homo sapiens 85-90 30896826-10 2019 Furthermore, in the in vitro and in vivo experiments, songorine consistently downregulated the expression of N-cadherin, vimentin, matrix metalloproteinase (MMP)-2, MMP-9, phosphorylated-GSK3beta, beta-catenin and Bcl-2, and upregulated the expression of E-cadherin, cleaved caspase-3, cleaved caspase-9 and Bax. songorine 54-63 BCL2 apoptosis regulator Homo sapiens 214-219 30896826-11 2019 In conclusion, songorine exerted its anticancer effect through the GSK3beta/beta-catenin and Bcl-2/Bax signaling pathways. songorine 15-24 BCL2 apoptosis regulator Homo sapiens 93-98 30867124-9 2019 Inhibition of BCL-2 with BAD or ABT-737, a BCL-2 inhibitor, reversed its effect on MST2 and SAV1 proteins. ABT-737 32-39 BCL2 apoptosis regulator Homo sapiens 14-19 31109399-8 2019 The initial mechanism of MCZ-mediated cell death in human breast cancer MDA-MB-231 cells involves an increase in the Bax/Bcl-2 ratio, downregulation of apoptosis induced by Akt and p-Akt-473, a simultaneous upregulation of the receptor-interacting protein 3 (RIP3) and mixed lineage kinase domain-like (MLKL) protein expression, and ROS production to induce necroptosis. Miconazole 25-28 BCL2 apoptosis regulator Homo sapiens 121-126 30885438-6 2019 Furthermore, decrease of mitochondrial membrane potential, increase of reactive oxygen species and the expression of apoptosis-associated protein (Bax/Bcl-2 ratio and activated Caspase-3) were observed in NCI-H1299 and A549 cells after Hymenochirin-1B treatment, suggesting that Hymenochirin-1B induced apoptosis via mitochondrial pathway. hymenochirin-1b 236-251 BCL2 apoptosis regulator Homo sapiens 151-156 31118772-1 2019 Venetoclax (ABT-199), a BH3-mimetic and selective BCL-2 inhibitor, was recently approved by the US Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) in adult patients aged 75 years or older, or otherwise unable to tolerate intensive induction chemotherapy, in combination with either hypomethylating agents or low-dose cytarabine. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 50-55 30867124-9 2019 Inhibition of BCL-2 with BAD or ABT-737, a BCL-2 inhibitor, reversed its effect on MST2 and SAV1 proteins. ABT-737 32-39 BCL2 apoptosis regulator Homo sapiens 43-48 31118772-1 2019 Venetoclax (ABT-199), a BH3-mimetic and selective BCL-2 inhibitor, was recently approved by the US Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) in adult patients aged 75 years or older, or otherwise unable to tolerate intensive induction chemotherapy, in combination with either hypomethylating agents or low-dose cytarabine. venetoclax 12-19 BCL2 apoptosis regulator Homo sapiens 50-55 30997898-10 2019 Investigation of the underlying mechanism revealed that anthecotulide prompts apoptotic cell death of the SK-MEL-24 cells, which was linked with increased expression of Bax and decreased expression of Bcl-2. anthecotulide 56-69 BCL2 apoptosis regulator Homo sapiens 201-206 31044156-0 2019 Resistance to paclitaxel is associated with a variant of the gene BCL2 in multiple tumor types. Paclitaxel 14-24 BCL2 apoptosis regulator Homo sapiens 66-70 31044156-4 2019 Since paclitaxel is known to target BCL2 and TUBB1, we used pan-cancer genomic data from hundreds of patients to show that a single-nucleotide variant in the BCL2 sequence can predict a patient"s response to paclitaxel. Paclitaxel 6-16 BCL2 apoptosis regulator Homo sapiens 36-40 31044156-4 2019 Since paclitaxel is known to target BCL2 and TUBB1, we used pan-cancer genomic data from hundreds of patients to show that a single-nucleotide variant in the BCL2 sequence can predict a patient"s response to paclitaxel. Paclitaxel 6-16 BCL2 apoptosis regulator Homo sapiens 158-162 31044156-4 2019 Since paclitaxel is known to target BCL2 and TUBB1, we used pan-cancer genomic data from hundreds of patients to show that a single-nucleotide variant in the BCL2 sequence can predict a patient"s response to paclitaxel. Paclitaxel 208-218 BCL2 apoptosis regulator Homo sapiens 36-40 31044156-4 2019 Since paclitaxel is known to target BCL2 and TUBB1, we used pan-cancer genomic data from hundreds of patients to show that a single-nucleotide variant in the BCL2 sequence can predict a patient"s response to paclitaxel. Paclitaxel 208-218 BCL2 apoptosis regulator Homo sapiens 158-162 30840434-3 2019 The unbiased interrogation of several human cDNA libraries, displayed on bacteriophage T7, revealed a single human target of artesunate; the intrinsically disordered Bcl-2 antagonist of cell death promoter (BAD). Artesunate 125-135 BCL2 apoptosis regulator Homo sapiens 166-171 31010222-9 2019 Cisplatin increased the expression of Bax and reduced the expression of Bcl-2, which activate and inhibit, respectively, the mitochondrial apoptotic pathway in response to oxidative stress. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 72-77 31005958-11 2019 The anticancer effects of ferruginol were likely due to the induction of apoptosis which was also associated with upregulation of Bax and downregulation of Bcl-2. ferruginol 26-36 BCL2 apoptosis regulator Homo sapiens 156-161 31114159-8 2019 Meanwhile, TET alleviated BUP-induced apoptosis in SH-SY5Y cell via decreasing the expressions of active caspase-3 and Bax and increasing the expression of Bcl-2. tetramethylpyrazine 11-14 BCL2 apoptosis regulator Homo sapiens 156-161 30991627-7 2019 Apoptotic cell count and cell-cycle distribution at G2/M phase significantly increased with increasing concentrations of peperomin E. The down-regulated expression level of Bcl-2 and up-regulated expression level of Bax and cleaved-caspase-3 compared with the controls were also observed after peperomin E treatment. peperomin E 121-132 BCL2 apoptosis regulator Homo sapiens 173-178 31105826-14 2019 TMPP+BO combination exhibited synergistic effects in decreasing apoptosis, and modulating expression of BCL-2, BAX, and VEGFR1. tmpp+bo 0-7 BCL2 apoptosis regulator Homo sapiens 104-109 30654034-3 2019 Also, cytotoxic activity of NiO NPs against SH-SY5Y was determined by MTT, LDH, caspase-9/3 activity, and expression of apoptotic Bax and Bcl-2 genes assays. nio 28-31 BCL2 apoptosis regulator Homo sapiens 138-143 30890405-10 2019 In addition, euxanthone also significantly reversed ox-LDL-triggered loss of mitochondrial membrane potential (MMP), cytochrome C release from mitochondria to cytosol, cleavage of caspase-3 and PARP, and increase in Bax/Bcl-2 ratio. euxanthone 13-23 BCL2 apoptosis regulator Homo sapiens 220-225 31013932-7 2019 Furthermore, the increases of cytosolic release of cytochrome c and ratio of Bax to Bcl-2, and the activation of caspase-9 and caspase-3 by the H2O2 were markedly abolished under the condition of PG pretreatment. Phloroglucinol 196-198 BCL2 apoptosis regulator Homo sapiens 84-89 31114158-9 2019 In addition, we found that emodin significantly enhanced PTX-induced apoptosis in A549 cells via increasing the expressions of Bax and active caspase 3 and decreasing the levels of Bcl-2, p-Akt and p-ERK. Emodin 27-33 BCL2 apoptosis regulator Homo sapiens 181-186 31114158-9 2019 In addition, we found that emodin significantly enhanced PTX-induced apoptosis in A549 cells via increasing the expressions of Bax and active caspase 3 and decreasing the levels of Bcl-2, p-Akt and p-ERK. Paclitaxel 57-60 BCL2 apoptosis regulator Homo sapiens 181-186 30953548-8 2019 We also found that icotinib markedly enhanced the pro-apoptotic activity of pemetrexed via cytochrome-C/Caspase/Bcl-2 signaling pathway. icotinib 19-27 BCL2 apoptosis regulator Homo sapiens 112-117 31183061-1 2019 The one-electron reduction of (CAACMe)BCl3 (CAACMe = 1-(2,6-diisopropylphenyl)-3,3,5,5-tetramethylpyrrolidin-2-ylidene) yields the dichloroboryl radical [(CAACMe)BCl2] . caacme 31-37 BCL2 apoptosis regulator Homo sapiens 162-166 31183061-1 2019 The one-electron reduction of (CAACMe)BCl3 (CAACMe = 1-(2,6-diisopropylphenyl)-3,3,5,5-tetramethylpyrrolidin-2-ylidene) yields the dichloroboryl radical [(CAACMe)BCl2] . 1-(2,6-diisopropylphenyl)-3,3,5,5-tetramethylpyrrolidin-2-ylidene 53-118 BCL2 apoptosis regulator Homo sapiens 162-166 31183061-1 2019 The one-electron reduction of (CAACMe)BCl3 (CAACMe = 1-(2,6-diisopropylphenyl)-3,3,5,5-tetramethylpyrrolidin-2-ylidene) yields the dichloroboryl radical [(CAACMe)BCl2] . dichloroboryl radical 131-152 BCL2 apoptosis regulator Homo sapiens 162-166 31183061-4 2019 A [(CAACMe)BCl2]- boryl anion coordination polymer was isolated as a potential intermediate in these reductions. boryl anion 18-29 BCL2 apoptosis regulator Homo sapiens 11-15 30580026-9 2019 The growth inhibition by MFCP correlated with a 3-fold decreased expression of Bcl-2 and a 4-fold increase in Bax levels at 10 microg/mL in LNCaP cells. mfcp 25-29 BCL2 apoptosis regulator Homo sapiens 79-84 30953548-8 2019 We also found that icotinib markedly enhanced the pro-apoptotic activity of pemetrexed via cytochrome-C/Caspase/Bcl-2 signaling pathway. Pemetrexed 76-86 BCL2 apoptosis regulator Homo sapiens 112-117 30872412-7 2019 Compared with the baseline culture, high glucose culture significantly increased NP cell apoptosis ratio, caspase-3/9 activity, up-regulated expression of Bax, caspase-3, MMP-3, MMP-13 and ADAMTS-4, down-regulated expression of Bcl-2, aggrecan and collagen II, and decreased staining intensity of aggrecan and collagen II. Glucose 41-48 BCL2 apoptosis regulator Homo sapiens 228-233 31089403-8 2019 We showed that H2O2 dramatically reduced the viability and increased the death of HDPCs in a time- and dose-dependent manner by performing MTT, flow cytometry, and TUNEL assays and quantifying the expression changes of Bax and Bcl-2 proteins. Hydrogen Peroxide 15-19 BCL2 apoptosis regulator Homo sapiens 227-232 33911565-9 2019 Results: Treatment with ceramides increased the expression of proteins affecting cell proliferation such as Bcl-2, BAX, phosphorylated-ERK and Cyclin D1. Ceramides 24-33 BCL2 apoptosis regulator Homo sapiens 108-113 30863710-6 2019 Our results showed that EPO alleviates OGD-induced cell apoptosis in a dose-dependent manner; the neuroprotective effect of EPO was further confirmed by the fact that EPO treatment reversed the protein expression of cleaved caspase-3, as well as the Bcl-2/Bax ratio as compared with the OGD treatment. ogd 39-42 BCL2 apoptosis regulator Homo sapiens 250-255 31001122-10 2019 Consistently, THTMP induced the apoptosis by regulating the expression of Bcl-2 family genes and reactive oxygen species while it also changed the expression of several anti-apoptotic genes. thtmp 14-19 BCL2 apoptosis regulator Homo sapiens 74-79 30793438-5 2019 Melatonin supplementation suppressed apoptosis (100 nM, p < 0.05) and enhanced G2/M phase (1 nM, 100 nM, p < 0.05) of cell cycle progression which was further corroborated by decrease in protein expression of caspase-3, p21, and p27 and increase in bcl2. Melatonin 0-9 BCL2 apoptosis regulator Homo sapiens 255-259 30952729-6 2019 Piperine increased the expression of BCL2-associated X, apoptosis regulator (BAX), cleaved poly(ADP-ribose)polymerase, cleaved caspase-9, phospho-c-Jun N-terminal kinase and phospho-p38, and reduced that of B-cell lymphoma 2 (BCL2), X-chromosome-linked inhibitor of apoptosis, and phospho-extracellular signal-regulated protein kinase (ERK1/2) in a concentration-dependent manner. piperine 0-8 BCL2 apoptosis regulator Homo sapiens 207-224 30557204-3 2019 In this study, anticancer activities of the Bcl-2 inhibitor ABT-737 and the Akt-inhibitor erufosine (ErPC3) alone and in combination were compared between CRPC (PC-3 and DU-145) and healthy (PNT-1A) cell lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 60-63 BCL2 apoptosis regulator Homo sapiens 44-49 30952729-6 2019 Piperine increased the expression of BCL2-associated X, apoptosis regulator (BAX), cleaved poly(ADP-ribose)polymerase, cleaved caspase-9, phospho-c-Jun N-terminal kinase and phospho-p38, and reduced that of B-cell lymphoma 2 (BCL2), X-chromosome-linked inhibitor of apoptosis, and phospho-extracellular signal-regulated protein kinase (ERK1/2) in a concentration-dependent manner. piperine 0-8 BCL2 apoptosis regulator Homo sapiens 37-41 30352233-5 2019 In this study, we demonstrated that vincristine induces mitophagy via the disruption of Hsp70 binding with Sirt2, leading to Hsp70 acetylation at K126 and elevated sequestration of Bcl2 by Hsp70 for autophagosome creation. Vincristine 36-47 BCL2 apoptosis regulator Homo sapiens 181-185 30784942-8 2019 However, in the presence of olesoxime, BAX/BCL2 ratio and the activation of caspase-3 were decreased. olesoxime 28-37 BCL2 apoptosis regulator Homo sapiens 43-47 30456590-8 2019 In addition, EGCG treatment also suppressed the accumulation of anti-apoptotic protein Bcl-2 in senescent cells thereby promoting apoptosis mediated cell death. epigallocatechin gallate 13-17 BCL2 apoptosis regulator Homo sapiens 87-92 30456590-0 2019 Epigallocatechin gallate suppresses premature senescence of preadipocytes by inhibition of PI3K/Akt/mTOR pathway and induces senescent cell death by regulation of Bax/Bcl-2 pathway. epigallocatechin gallate 0-24 BCL2 apoptosis regulator Homo sapiens 167-172 30784907-7 2019 Results Sinomenine significantly suppressed cell proliferation, promoted apoptosis and inhibited migration and invasion, as well as down-regulated Cyclin D1, CDK4, Bcl-2, MMP-2, MMP-9, Vimentin protein levels and up-regulated p16 and Bax protein levels in PC3 cells. sinomenine 8-18 BCL2 apoptosis regulator Homo sapiens 164-169 30798133-4 2019 p-Cresyl sulfate induced cell death, and increased Bax/Bcl-2, cleaved caspase-3, Beclin-1, and LC3BII/LC3BI in human renal proximal tubular epithelial (HK-2) cells, which was counteracted by alpha-LA treatment. cresyl sulfate 2-16 BCL2 apoptosis regulator Homo sapiens 55-60 30703684-5 2019 PFOA treatment increased Bax expression and increased Bcl-2 expression at both gene and protein levels. perfluorooctanoic acid 0-4 BCL2 apoptosis regulator Homo sapiens 54-59 30710454-10 2019 Dioscin induced cell apoptosis, autophagy, and DNA damage via increasing expression levels of p53, cleaved PARP, Bax, cleaved caspase-3/9, Beclin-1, and LC3 and suppressing those of Bcl-2, p-Akt, p-mammalian target of rapamycin (mTOR), CDK5, p-ataxia telangiectasia-mutated gene (ATM). dioscin 0-7 BCL2 apoptosis regulator Homo sapiens 182-187 30738023-7 2019 Notably, Daph pretreatment reversed the arsenic-induced decrease in anti-apoptotic factor B-cell lymphoma-2 (Bcl-2) and the increase in pro-apoptotic factor Bcl-2-associated X protein (Bax). daphnetin 9-13 BCL2 apoptosis regulator Homo sapiens 90-107 30738023-7 2019 Notably, Daph pretreatment reversed the arsenic-induced decrease in anti-apoptotic factor B-cell lymphoma-2 (Bcl-2) and the increase in pro-apoptotic factor Bcl-2-associated X protein (Bax). daphnetin 9-13 BCL2 apoptosis regulator Homo sapiens 109-114 30738023-7 2019 Notably, Daph pretreatment reversed the arsenic-induced decrease in anti-apoptotic factor B-cell lymphoma-2 (Bcl-2) and the increase in pro-apoptotic factor Bcl-2-associated X protein (Bax). Arsenic 40-47 BCL2 apoptosis regulator Homo sapiens 90-107 30738023-7 2019 Notably, Daph pretreatment reversed the arsenic-induced decrease in anti-apoptotic factor B-cell lymphoma-2 (Bcl-2) and the increase in pro-apoptotic factor Bcl-2-associated X protein (Bax). Arsenic 40-47 BCL2 apoptosis regulator Homo sapiens 109-114 30738023-9 2019 Accordingly, Daph might ameliorate arsenic-induced cytotoxicity and apoptosis, which may be linked to the induction of Nrf2-dependent antioxidant responses as well as stabilization of the anti-apoptotic factor Bcl-2 in human lung epithelial cells. daphnetin 13-17 BCL2 apoptosis regulator Homo sapiens 210-215 30738023-9 2019 Accordingly, Daph might ameliorate arsenic-induced cytotoxicity and apoptosis, which may be linked to the induction of Nrf2-dependent antioxidant responses as well as stabilization of the anti-apoptotic factor Bcl-2 in human lung epithelial cells. Arsenic 35-42 BCL2 apoptosis regulator Homo sapiens 210-215 30703684-7 2019 Furthermore, we showed that PFOA-mediated induction of apoptosis involved inducing Bax and decreasing Bcl-2 expression as a molecular mechanism of its toxicological effects. perfluorooctanoic acid 28-32 BCL2 apoptosis regulator Homo sapiens 102-107 30684560-9 2019 The mtsERbeta afforded a resistance to oxidative insult-induced apoptosis through the induction of the ROS scavenger enzyme Mn-superoxide dismutase and anti-apoptotic protein Bcl-2. mtserbeta 4-13 BCL2 apoptosis regulator Homo sapiens 175-180 30618158-8 2019 Western blotting assay demonstrated that genistein increased ER stress-associated protein expression such as IRE-1alpha, Calpain 1, GRP78, GADD153, caspase-7, caspase-4, and ATF-6alpha at 20-50 muM treatment and increased apoptosis associated protein expression such as pro-apoptotic protein Bax, PARP-cleavage, caspase-9, and -3, but decreased anti-apoptotic protein such as Bcl-2 and Bid in HL-60 cells. Genistein 41-50 BCL2 apoptosis regulator Homo sapiens 376-381 30690126-4 2019 Further study indicated that vernicilignan A reduced cell apoptosis caused by H2O2 treatment via regulation of some apoptotic related proteins including Bax, Bcl-2, caspase 3 and caspase 9. vernicilignan a 29-44 BCL2 apoptosis regulator Homo sapiens 158-163 30690126-4 2019 Further study indicated that vernicilignan A reduced cell apoptosis caused by H2O2 treatment via regulation of some apoptotic related proteins including Bax, Bcl-2, caspase 3 and caspase 9. Hydrogen Peroxide 78-82 BCL2 apoptosis regulator Homo sapiens 158-163 30720062-9 2019 Metformin altered apoptosis-associated signaling to downregulate the BAD phosphorylation and Bcl-2, pro-caspase-9, pro-caspase-3 and pro-caspase-7 expression, and to upregulate BAD, cytochrome c, and Apaf-1 proteins levels in AGS cells. Metformin 0-9 BCL2 apoptosis regulator Homo sapiens 93-98 30605746-6 2019 Additionally, APS4 treatment could induce the mitochondria-dependent apoptosis, which was closely related to the accumulation of intracellular ROS, the collapse of mitochondrial membrane potential, the increase of the pro-apoptotic/anti-apoptotic (Bax/Bcl-2) ratios, the release of cytochrome c, further activating the expression of caspase-9/-3 and the cleavage of poly-ADP-ribose polymerase (PARP) in MGC-803 cells. aps4 14-18 BCL2 apoptosis regulator Homo sapiens 252-257 30720134-10 2019 The inhibitory effects of TCRV on EMT and the induction of apoptosis were exerted through the suppression of the sonic hedgehog (Shh) pathway, and through the modulation of cyclin D1 and Bcl-2 expression. tcrv 26-30 BCL2 apoptosis regulator Homo sapiens 187-192 29355039-2 2019 In this way, FJ1 was shown to reverse the PQ-induced activation of caspase-9 and caspase-3, the increase in Bax/Bcl-2 ratio, and the release of cytochrome c. Paraquat 42-44 BCL2 apoptosis regulator Homo sapiens 112-117 29931583-0 2019 Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. AZD5153 46-53 BCL2 apoptosis regulator Homo sapiens 138-142 29931583-0 2019 Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. AZD4320 66-73 BCL2 apoptosis regulator Homo sapiens 58-62 29931583-0 2019 Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. AZD4320 66-73 BCL2 apoptosis regulator Homo sapiens 138-142 29931583-8 2019 To augment cell death induction, we added a novel BH3-mimicking BCL2 inhibitor AZD4320 to AZD5153, and found that these two agents had a mostly synergistic antitumor effect by increasing cells undergoing apoptosis in all three cell lines. BH 3 50-53 BCL2 apoptosis regulator Homo sapiens 64-68 29931583-8 2019 To augment cell death induction, we added a novel BH3-mimicking BCL2 inhibitor AZD4320 to AZD5153, and found that these two agents had a mostly synergistic antitumor effect by increasing cells undergoing apoptosis in all three cell lines. AZD4320 79-86 BCL2 apoptosis regulator Homo sapiens 64-68 29931583-9 2019 These results provide a rationale for dual targeting of BRD4 and BCL2 using AZD5153 and AZD4320 as a therapeutic strategy against DHL and DEL. AZD5153 76-83 BCL2 apoptosis regulator Homo sapiens 65-69 29931583-9 2019 These results provide a rationale for dual targeting of BRD4 and BCL2 using AZD5153 and AZD4320 as a therapeutic strategy against DHL and DEL. Cysteamine 130-133 BCL2 apoptosis regulator Homo sapiens 65-69 29931583-9 2019 These results provide a rationale for dual targeting of BRD4 and BCL2 using AZD5153 and AZD4320 as a therapeutic strategy against DHL and DEL. del 138-141 BCL2 apoptosis regulator Homo sapiens 65-69 30259568-8 2019 Treatment with 20(S)-PPD decreased the level of Bcl-2 expression but did not change the level of Bax expression. 20(s)-ppd 15-24 BCL2 apoptosis regulator Homo sapiens 48-53 30506710-6 2019 We also detected a lower expression level of Bcl-2 and upregulation of BAX and caspase in the presence of geraniol and lupeol. geraniol 106-114 BCL2 apoptosis regulator Homo sapiens 45-50 30320906-8 2019 RESULTS: The results demonstrated that oridonin in combination with VPA synergistically inhibited the proliferation of HL-60 cells, and induced obvious caspase-dependent apoptosis through activation of the intrinsic apoptosis pathway, which is involved in the downregulation of Bcl-2/Bax ratio. oridonin 39-47 BCL2 apoptosis regulator Homo sapiens 278-283 30320916-7 2019 Combining the STAT3 inhibitor STATTIC with vemurafenib further inhibited cell proliferation and promoted apoptosis by downregulating STAT3 and BCL-2 expression in RKO cells. Vemurafenib 43-54 BCL2 apoptosis regulator Homo sapiens 143-148 30506710-6 2019 We also detected a lower expression level of Bcl-2 and upregulation of BAX and caspase in the presence of geraniol and lupeol. lupeol 119-125 BCL2 apoptosis regulator Homo sapiens 45-50 30317581-6 2019 Caspase-3 activation, Bcl-2 reduction, and phosphatidylserine inversion were involved in CCE-stimulated apoptosis. Carbamylcholine 89-92 BCL2 apoptosis regulator Homo sapiens 22-27 30701693-0 2019 Trans-3,5,4 -trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498. trans-3,5,4 -trimethoxystilbene 0-31 BCL2 apoptosis regulator Homo sapiens 96-101 30701693-0 2019 Trans-3,5,4 -trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498. Gefitinib 40-49 BCL2 apoptosis regulator Homo sapiens 96-101 30246261-0 2019 Potentiating apoptosis and modulation of p53, Bcl2, and Bax by a novel chrysin ruthenium complex for effective chemotherapeutic efficacy against breast cancer. chrysin ruthenium complex 71-96 BCL2 apoptosis regulator Homo sapiens 46-50 30246261-9 2019 Immunohistochemical analysis revealed upregulation of Bax and p53 and downregulation of Bcl2 proteins and TUNEL assay showed an increase in apoptotic index in ruthenium-chrysin-treated groups as compared to the carcinogen control. ruthenium-chrysin 159-176 BCL2 apoptosis regulator Homo sapiens 88-92 30701693-10 2019 The combination of TMS and gefitinib promoted apoptosis also by miR-345 and miR-498 targeting the MAPK/c-Fos and AKT/Bcl-2 signalling pathways. Gefitinib 27-36 BCL2 apoptosis regulator Homo sapiens 117-122 30816477-10 2019 Additionally, DPT significantly enhanced apoptosis by attenuating the PI3K/Akt-mediated suppression of Bcl-2-associated agonist of cell death expression, which was accompanied by an increased apoptosis regulator BAX/apoptosis regulator Bcl-2 ratio. deoxypodophyllotoxin 14-17 BCL2 apoptosis regulator Homo sapiens 103-108 30214012-0 2019 Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. BH 3 10-13 BCL2 apoptosis regulator Homo sapiens 38-43 30214012-4 2019 We now report the pre-clinical anti-leukemic efficacy of a novel BCL-2 inhibitor S55746, which demonstrates synergistic pro-apoptotic activity in combination with the MCL1 inhibitor S63845. s55746 81-87 BCL2 apoptosis regulator Homo sapiens 65-70 30214012-4 2019 We now report the pre-clinical anti-leukemic efficacy of a novel BCL-2 inhibitor S55746, which demonstrates synergistic pro-apoptotic activity in combination with the MCL1 inhibitor S63845. S63845 182-188 BCL2 apoptosis regulator Homo sapiens 65-70 30277098-8 2019 In vitro treatment of these cell lines with a BCL2-inhibitory drug (ABT-199) selectively stopped their proliferation. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 68-71 BCL2 apoptosis regulator Homo sapiens 46-50 30896891-2 2019 In this study, the anti-infective drug nitroxoline (NXQ) was screened out to effectively inhibit cell survival of small-cell lung cancer (SCLC) cells, and induce SCLC cell apoptosis by suppressing antiapoptotic proteins (such as Bcl-2 and MCL1) and upregulating proapoptotic protein Bim. nitroxoline 39-50 BCL2 apoptosis regulator Homo sapiens 229-234 30896891-2 2019 In this study, the anti-infective drug nitroxoline (NXQ) was screened out to effectively inhibit cell survival of small-cell lung cancer (SCLC) cells, and induce SCLC cell apoptosis by suppressing antiapoptotic proteins (such as Bcl-2 and MCL1) and upregulating proapoptotic protein Bim. 2-[5-fluoranyl-2-[[3-[methyl(oxidanyl)-$l^{3}-sulfanyl]phenyl]methylcarbamoyl]phenoxy]ethanoic acid 52-55 BCL2 apoptosis regulator Homo sapiens 229-234 30824553-0 2019 Re: Dasmahapatra G, Almenara JA, and Grant S, "Flavopiridol and Histone Deacetylase Inhibitors Promote Mitochondrial Injury and Cell Death in Human Leukemia Cells that Overexpress Bcl-2." alvocidib 47-59 BCL2 apoptosis regulator Homo sapiens 180-185 30426393-3 2019 Rotenone exposure enhanced the expression of preapoptotic (cytochrome C (cyto c), caspase-3, -8, -9, and Bax) and down-regulated the expression of anti-apoptotic (Bcl-2) markers. Rotenone 0-8 BCL2 apoptosis regulator Homo sapiens 163-168 30881498-5 2019 Additionally, resveratrol enhanced the expression of tumour protein p53 (p53) and p53 target genes, including Bcl2 associated X, apoptosis regulator and Bcl2 binding component 3 that have a pivotal role in p53-dependent apoptosis. Resveratrol 14-25 BCL2 apoptosis regulator Homo sapiens 110-114 30881498-5 2019 Additionally, resveratrol enhanced the expression of tumour protein p53 (p53) and p53 target genes, including Bcl2 associated X, apoptosis regulator and Bcl2 binding component 3 that have a pivotal role in p53-dependent apoptosis. Resveratrol 14-25 BCL2 apoptosis regulator Homo sapiens 153-157 30939781-6 2019 Lycopene reduced cell viability with increases in active caspase-3 and the Bax to Bcl-2 ratio in PANC-1 cells. Lycopene 0-8 BCL2 apoptosis regulator Homo sapiens 82-87 30816477-10 2019 Additionally, DPT significantly enhanced apoptosis by attenuating the PI3K/Akt-mediated suppression of Bcl-2-associated agonist of cell death expression, which was accompanied by an increased apoptosis regulator BAX/apoptosis regulator Bcl-2 ratio. deoxypodophyllotoxin 14-17 BCL2 apoptosis regulator Homo sapiens 236-241 30816542-6 2019 Furthermore, bufotalin significantly increased BAX expression levels, decreased BCL-2 expression, and then upregulated apoptosis-related proteins, caspase-3/-9, followed by A375 cell apoptosis. bufotalin 13-22 BCL2 apoptosis regulator Homo sapiens 80-85 30686547-8 2019 Compared with control group, Apatinib significantly induced BAX/Bcl-2 ratio elevation, reduced p-STAT3 and p-VEGFR2 expression, which were significantly augmented by the treatment of siSTAT3. apatinib 29-37 BCL2 apoptosis regulator Homo sapiens 64-69 30826569-10 2019 Furthermore, nor-wogonin induced mitochondrial apoptosis, (as evidenced by the increase in % of cells that are apoptotic), decreases in the mitochondrial membrane potential (DeltaPsim), increases in Bax/Bcl-2 ratio, and caspase-3 cleavage. norwogonin 13-24 BCL2 apoptosis regulator Homo sapiens 203-208 30091676-8 2019 In addition, intracellular ROS, cleaved caspase-3, Bax:Bcl-2 ratio, and cytochrome c release were significantly increased in 6-OHDA-incubated cells. Oxidopamine 125-131 BCL2 apoptosis regulator Homo sapiens 55-60 30869573-8 2019 Western blot analysis following exposure to 10 muM vemurafenib revealed that p-ERK1/2 gradually decreased over 24 hours, but the expression of B-cell lymphoma-extralarge (BCL-XL) and BCL-2 increased after 12 hours of treatment. Vemurafenib 51-62 BCL2 apoptosis regulator Homo sapiens 183-188 30869573-5 2019 In addition, the study analyzed the protein expression profiles of phosphorylated ERK1/2 (p-ERK 1/2) and anti-apoptotic BCL-2 family after vemurafenib treatment and selected the target anti-apoptotic protein. Vemurafenib 139-150 BCL2 apoptosis regulator Homo sapiens 120-125 30869573-9 2019 Based on this result, the K1 cells were treated with navitoclax (BCL-2/BCL-XL inhibitor) for 24 hours up to a concentration of 4 muM, which resulted in negligible effects on cell survival. navitoclax 53-63 BCL2 apoptosis regulator Homo sapiens 65-70 30869573-11 2019 CONCLUSIONS: The results of the present study show that vemurafenib increased the expression of anti-apoptotic proteins of the BCL-2 family. Vemurafenib 56-67 BCL2 apoptosis regulator Homo sapiens 127-132 31068299-7 2019 Compared with the cells cultured alone, the co-cultured SMMC-7721 cells showed significantly reduced apoptosis rate in response to sorafenib (P &lt; 0.01) and significantly increased expression of Bcl-2 and Bcl-2/Bax ratio (P &lt; 0.05) with also increased LC3-II/LC3-I ratio (P &lt; 0.001) and lowered expression of p62 (P &lt; 0.05), suggesting a significantly enhanced level of autophagy. smmc 56-60 BCL2 apoptosis regulator Homo sapiens 201-206 30934922-4 2019 Greensporone A treatment of leukemic cells causes inactivation of constitutively activated AKT and its downstream targets, including members GSK3 and FOXO1, and causes downregulation of antiapoptotic genes such as Inhibitor of Apoptosis (IAPs) and Bcl-2. Greensporone A 0-14 BCL2 apoptosis regulator Homo sapiens 248-253 30934922-5 2019 Furthermore, Bax, a proapoptotic member of the Bcl-2 family, was found to be upregulated in leukemic cell lines treated with greensporone A. Greensporone A 125-139 BCL2 apoptosis regulator Homo sapiens 47-52 30934922-7 2019 Greensporone A-mediated increase in Bax/Bcl-2 ratio causes permeabilization of the mitochondrial membrane leading to the accumulation of cytochrome c in the cytoplasm. Greensporone A 0-14 BCL2 apoptosis regulator Homo sapiens 40-45 31068300-10 2019 RRM1 silencing significantly inhibited the proliferation (P &lt; 0.01) and enhanced the apoptosis-inducing effect of paclitaxel in MCF-7/R cells (P &lt; 0.001); RRM1 silencing also resulted in obviously reduced Akt phosphorylation, suppressed Bcl-2 expression and promoted the expression of p53 protein in MCF-7/R cells. Paclitaxel 121-131 BCL2 apoptosis regulator Homo sapiens 251-256 31068299-7 2019 Compared with the cells cultured alone, the co-cultured SMMC-7721 cells showed significantly reduced apoptosis rate in response to sorafenib (P &lt; 0.01) and significantly increased expression of Bcl-2 and Bcl-2/Bax ratio (P &lt; 0.05) with also increased LC3-II/LC3-I ratio (P &lt; 0.001) and lowered expression of p62 (P &lt; 0.05), suggesting a significantly enhanced level of autophagy. smmc 56-60 BCL2 apoptosis regulator Homo sapiens 211-216 31068299-8 2019 CQ treatment significantly inhibited the proliferation of the co-cultured SMMC-7721 cells (P &lt; 0.05), increased the cell apoptosis (P &lt; 0.05) and reduced the Bcl-2/Bax ratio (P &lt; 0.01). Chloroquine 0-2 BCL2 apoptosis regulator Homo sapiens 172-177 30620563-2 2019 Several oligonucleotides (ONs) and ON analogues are under study as potential tools to counteract the Bcl-2 expression. Oligonucleotides 8-24 BCL2 apoptosis regulator Homo sapiens 101-106 30972300-2 2019 Recently, venetoclax, an inhibitor of the anti-apoptotic protein BCL-2, has been approved for the treatment of upfront AML in an unfit, elderly population. venetoclax 10-20 BCL2 apoptosis regulator Homo sapiens 65-70 30912763-6 2019 Additionally, NaHS increased expression of Bcl-2, c-myc, c-fos and c-jun, and the phosphorylation of ERK1/2, PI3K, Akt and GSK-3beta. sodium bisulfide 14-18 BCL2 apoptosis regulator Homo sapiens 43-48 30844579-2 2019 BH3-mimetics such as ABT-263 inhibit anti-apoptotic BCL-2 proteins and have been developed as potential cancer therapeutics. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 52-57 30844579-2 2019 BH3-mimetics such as ABT-263 inhibit anti-apoptotic BCL-2 proteins and have been developed as potential cancer therapeutics. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 21-24 BCL2 apoptosis regulator Homo sapiens 52-57 30874538-6 2019 Moreover, beta-Thujaplicin triggered HepG2 apoptosis and increased cleaved PARP1, cleaved caspase-3, and Bax/Bcl-2 ratio, which indicated that beta-Thujaplicin induced apoptosis mediated by the mitochondrial-dependent pathway. beta-thujaplicin 10-26 BCL2 apoptosis regulator Homo sapiens 109-114 30885150-0 2019 The small molecule Bcl-2/Mcl-1 inhibitor TW-37 shows single-agent cytotoxicity in neuroblastoma cell lines. TW-37 41-46 BCL2 apoptosis regulator Homo sapiens 19-24 30879017-8 2019 Murrayanine treatment increased apoptosis of the A549 cells and increased cleaved of caspase-3 and caspase-9, and the Bax/Bcl-2 ratio. murrayanine 0-11 BCL2 apoptosis regulator Homo sapiens 122-127 30487125-7 2019 As a consequence of enhanced canonical NF-kappaB target gene activation, both anti- and proapoptotic Bcl-2 family members were upregulated in BIRC3low primary CLL cells, which was associated with higher sensitivity to venetoclax treatment in vitro. venetoclax 218-228 BCL2 apoptosis regulator Homo sapiens 101-106 30874538-6 2019 Moreover, beta-Thujaplicin triggered HepG2 apoptosis and increased cleaved PARP1, cleaved caspase-3, and Bax/Bcl-2 ratio, which indicated that beta-Thujaplicin induced apoptosis mediated by the mitochondrial-dependent pathway. beta-thujaplicin 143-159 BCL2 apoptosis regulator Homo sapiens 109-114 30860026-0 2019 Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2. BH 3 28-31 BCL2 apoptosis regulator Homo sapiens 97-102 30468808-8 2019 Indeed, caspase-3 and caspase-9 activation, Bax/Bcl-2 ratio elevation and apoptosis induction were observed after exposure of SH-SY5Y to Mn2O3 NPs. sh-sy5y 126-133 BCL2 apoptosis regulator Homo sapiens 48-53 30468808-8 2019 Indeed, caspase-3 and caspase-9 activation, Bax/Bcl-2 ratio elevation and apoptosis induction were observed after exposure of SH-SY5Y to Mn2O3 NPs. Manganese(III) oxide 137-142 BCL2 apoptosis regulator Homo sapiens 48-53 30708101-8 2019 Furthermore, honokiol treatment decreased cell migration and enhanced cell apoptosis, which is accompanied by the upregulation of the expressions of ER stress-induced apoptotic signaling molecules such as GRP78, phosphorylated PERK, phosphorylated eIF2alpha, CHOP, Bcl-2, Bax, and cleaved Caspase 9. honokiol 13-21 BCL2 apoptosis regulator Homo sapiens 265-270 30875757-2 2019 The goal of this study was to determine whether combining Obatoclax, a BH3 mimetic which inhibits pro-survival Bcl-2 family members, can improve responses to cisplatin chemotherapy, the standard of care treatment for MI-BC. BH 3 71-74 BCL2 apoptosis regulator Homo sapiens 111-116 30875757-2 2019 The goal of this study was to determine whether combining Obatoclax, a BH3 mimetic which inhibits pro-survival Bcl-2 family members, can improve responses to cisplatin chemotherapy, the standard of care treatment for MI-BC. Cisplatin 158-167 BCL2 apoptosis regulator Homo sapiens 111-116 30929387-10 2019 When combination of the two drugs on MV4-11 after 24 hours, the levels of pro-apoptotic protein Bim and the cleaved activation of Caspase-3 and autophagy-related protein LC3B were up-regulated and the anti-apoptotic protein Bcl-2 expressions was down-regulated. mv4-11 37-43 BCL2 apoptosis regulator Homo sapiens 224-229 30929387-11 2019 Conclusion: Combination of artesunate with bortezomib shows a significant synergistic effects on proliferation, apoptosis and autophagy of MV4-11 cell lines, which may be associated with Bcl-2 family proteins expression. Artesunate 27-37 BCL2 apoptosis regulator Homo sapiens 187-192 30929387-11 2019 Conclusion: Combination of artesunate with bortezomib shows a significant synergistic effects on proliferation, apoptosis and autophagy of MV4-11 cell lines, which may be associated with Bcl-2 family proteins expression. Bortezomib 43-53 BCL2 apoptosis regulator Homo sapiens 187-192 32009829-2 2019 Recently, a selective BCL-2 inhibitor ABT-199, venetoclax, has demonstrated remarkable activity in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), both as a single agent and in combination with anti-CD20 immunotherapies, such as rituximab. venetoclax 38-45 BCL2 apoptosis regulator Homo sapiens 22-27 30860026-4 2019 Using automated Fluorescence Lifetime Imaging Microscopy - Fluorescence Resonance Energy Transfer (FLIM-FRET) we show that the two binding interfaces enable Bim to double-bolt lock Bcl-XL and Bcl-2 in complexes resistant to displacement by BH3-mimetic drugs currently in use or being evaluated for cancer therapy. BH 3 240-243 BCL2 apoptosis regulator Homo sapiens 192-197 30155742-0 2019 Probing Gallate-Mediated Selectivity and High-Affinity Binding of Epigallocatechin Gallate: a Way-Forward in the Design of Selective Inhibitors for Anti-apoptotic Bcl-2 Proteins. Gallic acid 8-15 BCL2 apoptosis regulator Homo sapiens 163-168 30545600-3 2019 Herein, we investigated a therapeutic approach involving delivery of a short interfering double-stranded RNA (dsRNA), specific to Bcl2, with 5" triphosphate ends, by lipid calcium phosphate nanoparticles, in an orthotopic allograft KPC model of pancreatic cancer. 5" triphosphate 141-156 BCL2 apoptosis regulator Homo sapiens 130-134 30545600-3 2019 Herein, we investigated a therapeutic approach involving delivery of a short interfering double-stranded RNA (dsRNA), specific to Bcl2, with 5" triphosphate ends, by lipid calcium phosphate nanoparticles, in an orthotopic allograft KPC model of pancreatic cancer. lipid calcium phosphate 166-189 BCL2 apoptosis regulator Homo sapiens 130-134 30545600-4 2019 Retinoic acid-inducible gene I (RIG-I)-like receptors can bind to 5" triphosphate dsRNA (ppp dsRNA), a pathogen-associated molecular pattern, producing type I interferon, while Bcl2 silencing can drive apoptosis of cancer cells. 5" triphosphate 66-81 BCL2 apoptosis regulator Homo sapiens 177-181 30949409-12 2019 In addition, ABC294640 had a synergistic effect with BCL2/BCL-XL inhibitors ABT-263 and Obatoclax in inhibiting cell growth. 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 13-22 BCL2 apoptosis regulator Homo sapiens 53-57 30949409-12 2019 In addition, ABC294640 had a synergistic effect with BCL2/BCL-XL inhibitors ABT-263 and Obatoclax in inhibiting cell growth. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 76-79 BCL2 apoptosis regulator Homo sapiens 53-57 30949409-17 2019 Our study reveals that ABC294640 inhibits cholangiocarcinoma cell growth and sensitizes the antitumor effect of BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation. 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 23-32 BCL2 apoptosis regulator Homo sapiens 112-116 30640793-5 2019 In A549 and H460 cells, cardamonin induced apoptosis by activating caspase-3, upregulating Bax, and downregulating Bcl-2. cardamonin 24-34 BCL2 apoptosis regulator Homo sapiens 115-120 30741544-9 2019 The accumulation of 5-FU resulted in caspase-3 and PARP activation, Bcl-2 reduction, and Bad increase, which ultimately lead to cancer cell apoptosis. Fluorouracil 20-24 BCL2 apoptosis regulator Homo sapiens 68-73 30499168-1 2019 One of the most promising developments in therapy for acute myeloid leukemia (AML) in recent years has been the combination of hypomethylating agents (HMA, either decitabine or 5-azacytidine) with the Bcl-2 inhibitor venetoclax (VEN). Azacitidine 177-190 BCL2 apoptosis regulator Homo sapiens 201-206 30483907-9 2019 Among the proteins related to apoptosis, abundances of CHOP and p53 were reduced, whereas those of Bcl-2 and Bcl-xL were enhanced in the jejunum of 100-200% glycine-supplemented piglets. Glycine 157-164 BCL2 apoptosis regulator Homo sapiens 99-104 30155742-0 2019 Probing Gallate-Mediated Selectivity and High-Affinity Binding of Epigallocatechin Gallate: a Way-Forward in the Design of Selective Inhibitors for Anti-apoptotic Bcl-2 Proteins. epigallocatechin gallate 66-90 BCL2 apoptosis regulator Homo sapiens 163-168 30155742-3 2019 Epigallocatechingallate (EGCG) has been widely reported to selectively inhibit Bcl-2 and Bcl-xL compared to other green tea phenols due to its gallate group. epigallocatechin gallate 0-23 BCL2 apoptosis regulator Homo sapiens 79-84 30155742-3 2019 Epigallocatechingallate (EGCG) has been widely reported to selectively inhibit Bcl-2 and Bcl-xL compared to other green tea phenols due to its gallate group. epigallocatechin gallate 25-29 BCL2 apoptosis regulator Homo sapiens 79-84 30155742-4 2019 Herein, we investigate the interaction dynamics of EGCG at the hydrophobic grooves of Bcl-2 and Bcl-xL and the consequential effects on their BH4 domains. epigallocatechin gallate 51-55 BCL2 apoptosis regulator Homo sapiens 86-91 30155742-5 2019 Arg143 and Asp108 (Bcl-2), and Glu96 and Tyr195 (Bcl-xL) formed high-affinity hydrogen interactions with the gallate group while non-gallate groups of EGCG formed weak interactions. Gallic acid 109-116 BCL2 apoptosis regulator Homo sapiens 19-24 30155742-6 2019 EGCG-bound proteins showed systemic perturbations of BH4 domains coupled with the burial of crucial surface-exposed residues such as Lys17 (Bcl-2) and Asp11 (Bcl-xL); hence, a distortion of non-canonical domain interactions. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 140-145 30639456-11 2019 We demonstrated that miR-142-5p also targeted four other anti-apoptotic genes, baculoviral IAP repeat-containing 3 (BIRC3), B-cell lymphoma-2 (BCL2), BCL2 like 2 (BCL2L2), and myeloid cell leukemia sequence 1 (MCL1) specifically. mir-142-5p 21-31 BCL2 apoptosis regulator Homo sapiens 124-141 30616080-9 2019 PGG affected cell cycle- or apoptosis-related proteins such as cyclin D1, Bcl-2 and Bax. beta-penta-O-galloyl-glucose 0-3 BCL2 apoptosis regulator Homo sapiens 74-79 30639456-11 2019 We demonstrated that miR-142-5p also targeted four other anti-apoptotic genes, baculoviral IAP repeat-containing 3 (BIRC3), B-cell lymphoma-2 (BCL2), BCL2 like 2 (BCL2L2), and myeloid cell leukemia sequence 1 (MCL1) specifically. mir-142-5p 21-31 BCL2 apoptosis regulator Homo sapiens 143-147 30660994-2 2019 G3139 is an ASO that targets Bcl-2 mRNA and induces cell apoptosis. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 29-34 29899382-0 2019 Constitutive IP3 signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP3 receptor disruptor BIRD-2. Inositol 1,4,5-Trisphosphate 13-16 BCL2 apoptosis regulator Homo sapiens 78-83 30468519-5 2019 Moreover, the ectopic endometrial stromal cells isolated from EM patients demonstrated decreased ERK1/2 activation and expression of USP10 and Bcl-2 and increased expression of Bax and Caspase-7 after cultured in DMEM containing CNYP-medicated rat serum, which were reversed by USP10 overexpression and were enhanced by USP10 siRNA. dmem 213-217 BCL2 apoptosis regulator Homo sapiens 143-148 30514704-1 2019 The BCL2 inhibitor venetoclax induces high rates of durable remission in patients with previously treated chronic lymphocytic leukemia (CLL). venetoclax 19-29 BCL2 apoptosis regulator Homo sapiens 4-8 30514704-8 2019 SIGNIFICANCE: Why CLL recurs in patients who achieve remission with the BCL2 inhibitor venetoclax has been unknown. venetoclax 87-97 BCL2 apoptosis regulator Homo sapiens 72-76 30542770-10 2019 As2S2 could increase Bax/Bcl-2 ratio, decrease mitochondrial membrane potential, promote the release of cytochrome c, increase the levels of cleaved caspase-3 and PARP, indicating that As2S2 induced apoptosis in SMMC-7721 cells via mitochondrial-mediated apoptosis pathway. Arsenic(II) sulfide 0-5 BCL2 apoptosis regulator Homo sapiens 25-30 29899382-1 2019 Anti-apoptotic Bcl-2 proteins are upregulated in different cancers, including diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), enabling survival by inhibiting pro-apoptotic Bcl-2-family members and inositol 1,4,5-trisphosphate (IP3) receptor (IP3R)-mediated Ca2+-signaling. Inositol 1,4,5-Trisphosphate 227-255 BCL2 apoptosis regulator Homo sapiens 15-20 29899382-2 2019 A peptide tool (Bcl-2/IP3R Disruptor-2; BIRD-2) was developed to abrogate the interaction of Bcl-2 with IP3Rs by targeting Bcl-2"s BH4 domain. sapropterin 131-134 BCL2 apoptosis regulator Homo sapiens 16-21 30518523-0 2019 A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. venetoclax 69-79 BCL2 apoptosis regulator Homo sapiens 54-58 29899382-2 2019 A peptide tool (Bcl-2/IP3R Disruptor-2; BIRD-2) was developed to abrogate the interaction of Bcl-2 with IP3Rs by targeting Bcl-2"s BH4 domain. sapropterin 131-134 BCL2 apoptosis regulator Homo sapiens 93-98 30518523-0 2019 A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. venetoclax 69-79 BCL2 apoptosis regulator Homo sapiens 114-118 30518523-1 2019 Venetoclax, a potent and selective BCL2 inhibitor, synergizes with endocrine therapy in preclinical models of ER-positive breast cancer. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 35-39 29899382-2 2019 A peptide tool (Bcl-2/IP3R Disruptor-2; BIRD-2) was developed to abrogate the interaction of Bcl-2 with IP3Rs by targeting Bcl-2"s BH4 domain. sapropterin 131-134 BCL2 apoptosis regulator Homo sapiens 93-98 29899382-11 2019 Thus, constitutive IP3 signaling in lymphoma and leukemia cells is not only important for cancer cell survival, but also represents a vulnerability, rendering cancer cells dependent on Bcl-2 to limit IP3R activity. Inositol 1,4,5-Trisphosphate 19-22 BCL2 apoptosis regulator Homo sapiens 185-190 30824486-2 2019 In this issue, Lok and colleagues diverge from this paradigm by combining the BCL2 inhibitor venetoclax with tamoxifen in a phase Ib clinical trial, building on preclinical work to demonstrate that targeting apoptosis could represent a promising new strategy in the treatment of breast cancer.See related article by Lok et al., p. 354. venetoclax 93-103 BCL2 apoptosis regulator Homo sapiens 78-82 30539420-8 2019 The enhanced BCL2 and VEGF parallel with the reduced NFkappaB1, TNF-alpha, IL-1beta, and iNOS mRNA levels in miR-9 mimic or glucosamine-treated cells further substantiated their post-ischemic neuroprotective and regenerative efficacy. Glucosamine 124-135 BCL2 apoptosis regulator Homo sapiens 13-17 30783433-6 2019 Immunohistological analysis revealed that ADV-TK and GCV treatment significantly increased the number of caspase-3-positive cells, reduced the Bax/Bcl-2 ratio and NF-kappaB expression levels and promoted the release of cytochrome c compared with the control group (P<0.01). Ganciclovir 53-56 BCL2 apoptosis regulator Homo sapiens 147-152 30348635-6 2019 The matched cell line pair revealed increased expression of the antiapoptotic protein BCL-2 in the chemotherapy-resistant cells, conferring apoptotic resistance to olaparib. olaparib 164-172 BCL2 apoptosis regulator Homo sapiens 86-91 30348635-10 2019 CONCLUSIONS: These data reveal BCL-2 and BCL-XL act together to drive olaparib resistance in Ewing sarcoma and reveal a novel, rational combination therapy that may be put forward for clinical trial testing. olaparib 70-78 BCL2 apoptosis regulator Homo sapiens 31-36 30638402-7 2019 Efficacy and good tolerability of acalabrutinib gives even greater opportunity for potential upfront use and new therapeutic combinations, including monoclonal antibodies, antibody-drug conjugates, immune checkpoint inhibitors, bcl-2 (B-cell lymphoma-2) or IP3K (phosphoinositide 3-kinase) inhibitors. acalabrutinib 34-47 BCL2 apoptosis regulator Homo sapiens 228-233 30145832-7 2019 CCK-8 assay and TUNEL staining indicated that ketamine effectively decreased the viability of SV-HUC-1 cells and accelerated apoptosis of SV-HUC-1 cells through regulating the expression level of IKBalpha (phospho), nuclear factor kB (P65), Bcl-2, and Bax proteins. Ketamine 46-54 BCL2 apoptosis regulator Homo sapiens 241-246 30628640-10 2019 The EC cells treated with CP-31398 or siRNA against MDM2 exhibited an increased apoptosis and a suppressed migration and invasion, corresponding to an increased expression of p53, p21, Bad, Bax, Cyt-c and caspase-3, as well as to a decreased expression of Bcl-2, Cox-2, MMP-2 and MMP-9. CP 31398 26-34 BCL2 apoptosis regulator Homo sapiens 256-261 30936596-8 2019 Real-time PCR revealed that metformin induced apoptosis in TE8 and TE11 cells by activating p53, down-regulating Bcl-2 expression. Metformin 28-37 BCL2 apoptosis regulator Homo sapiens 113-118 30936596-9 2019 The induced apoptosis by 2DG raised by metformin and the combination modulated the expression of Bcl-2 protein in all cell lines and it was more effective in TE11 cell line. Deoxyglucose 25-28 BCL2 apoptosis regulator Homo sapiens 97-102 30936596-9 2019 The induced apoptosis by 2DG raised by metformin and the combination modulated the expression of Bcl-2 protein in all cell lines and it was more effective in TE11 cell line. Metformin 39-48 BCL2 apoptosis regulator Homo sapiens 97-102 30936596-10 2019 Conclusion: Metformin induced apoptosis in ESCC by down-regulating Bcl-2 expression, and up-regulating p53 and induced apoptosis increased by 2-deoxy-d-glucose. Metformin 12-21 BCL2 apoptosis regulator Homo sapiens 67-72 30229997-6 2019 Oridonin also increased proapoptotic protein Bax and reduced antiapoptotic protein Bcl-2, as well as the increased expression of cleaved caspase-3, -8, and -9. oridonin 0-8 BCL2 apoptosis regulator Homo sapiens 83-88 30664150-6 2019 The TMZ + acteoside combination treatment increased the cleavage of caspase-3 and levels of B-cell lymphoma 2 (Bcl-2)-associated X protein and phosphorylated p53, and decreased the level of Bcl-2. Temozolomide 4-7 BCL2 apoptosis regulator Homo sapiens 92-109 30664150-6 2019 The TMZ + acteoside combination treatment increased the cleavage of caspase-3 and levels of B-cell lymphoma 2 (Bcl-2)-associated X protein and phosphorylated p53, and decreased the level of Bcl-2. Temozolomide 4-7 BCL2 apoptosis regulator Homo sapiens 111-116 30664150-6 2019 The TMZ + acteoside combination treatment increased the cleavage of caspase-3 and levels of B-cell lymphoma 2 (Bcl-2)-associated X protein and phosphorylated p53, and decreased the level of Bcl-2. Temozolomide 4-7 BCL2 apoptosis regulator Homo sapiens 190-195 30664150-6 2019 The TMZ + acteoside combination treatment increased the cleavage of caspase-3 and levels of B-cell lymphoma 2 (Bcl-2)-associated X protein and phosphorylated p53, and decreased the level of Bcl-2. acteoside 10-19 BCL2 apoptosis regulator Homo sapiens 92-109 30664150-6 2019 The TMZ + acteoside combination treatment increased the cleavage of caspase-3 and levels of B-cell lymphoma 2 (Bcl-2)-associated X protein and phosphorylated p53, and decreased the level of Bcl-2. acteoside 10-19 BCL2 apoptosis regulator Homo sapiens 111-116 30664150-6 2019 The TMZ + acteoside combination treatment increased the cleavage of caspase-3 and levels of B-cell lymphoma 2 (Bcl-2)-associated X protein and phosphorylated p53, and decreased the level of Bcl-2. acteoside 10-19 BCL2 apoptosis regulator Homo sapiens 190-195 30825242-8 2019 In addition, pristimerin significantly lowered the expression of apoptosis-related proteins (Bcl-2, Bcl-xL, and procaspase-3), but increased the Bax expression. pristimerin 13-24 BCL2 apoptosis regulator Homo sapiens 93-98 30270549-7 2019 In addition, higenamine inhibited the increases in caspase-3 activity and Bax expression, and inhibited the decrease in Bcl-2 expression. higenamine 13-23 BCL2 apoptosis regulator Homo sapiens 120-125 30548082-8 2019 Moreover, hinokitiol reduced caspase-3 activation, upregulated Bax and downregulated Bcl-2. beta-thujaplicin 10-20 BCL2 apoptosis regulator Homo sapiens 85-90 30548082-11 2019 Hinokitiol prevented H/R-induced caspase-3 activation, PPAR cleavage, Bax overexpression and Bcl-2 downregulation. beta-thujaplicin 0-10 BCL2 apoptosis regulator Homo sapiens 93-98 31128006-7 2019 RESULTS: The expression of Bcl-2 declined, and Bax and Caspase 3 increased in A549 cells treated with Aclidinium Bromide. aclidinium bromide 102-120 BCL2 apoptosis regulator Homo sapiens 27-32 30368882-7 2019 Pretreatment with JNK-specific inhibitors SP600125 markedly upregulated the reduced B-cell lymphoma 2 (Bcl-2) content and downregulated the increased Bcl-2-associated X protein (Bax) level and thereby eventually reduced the proportions of early and late apoptotic cells induced by ACR, while p38 suppression by SB202190 only reversed the decrease in Bcl-2 expression. pyrazolanthrone 42-50 BCL2 apoptosis regulator Homo sapiens 103-108 30368882-7 2019 Pretreatment with JNK-specific inhibitors SP600125 markedly upregulated the reduced B-cell lymphoma 2 (Bcl-2) content and downregulated the increased Bcl-2-associated X protein (Bax) level and thereby eventually reduced the proportions of early and late apoptotic cells induced by ACR, while p38 suppression by SB202190 only reversed the decrease in Bcl-2 expression. pyrazolanthrone 42-50 BCL2 apoptosis regulator Homo sapiens 150-155 30368882-8 2019 Inhibition of NF-kappaB by BAY 11-7082 markedly upregulated Bax level and decreased Bcl-2 expression, and eventually increasing the proportions of neuronal apoptosis compared with that in ACR alone. 3-(4-methylphenylsulfonyl)-2-propenenitrile 27-38 BCL2 apoptosis regulator Homo sapiens 84-89 31128007-7 2019 Further investigations indicated the antiproliferative effects of linderalactone are due to apoptosis induction which was further confirmed by Bax and Bcl-2 expression. linderalactone 66-80 BCL2 apoptosis regulator Homo sapiens 151-156 30679390-5 2019 Proteomic analyses of adaptive responses to GDC-0973 revealed that GDC-0973 upregulated the proapoptotic protein BIM, thus priming the cells for apoptosis regulated by BCL2-family proteins. cobimetinib 67-75 BCL2 apoptosis regulator Homo sapiens 168-172 30569168-5 2019 RSF-induced cell death was associated with the downregulation of BCl-2 and upregulation of Bax. (3r,3as,6ar)-Hexahydrofuro[2,3-B]furan-3-Ol 0-3 BCL2 apoptosis regulator Homo sapiens 65-70 30679390-6 2019 Indeed, combination of both MEK inhibitor and dual BCL-2/XL inhibitor (ABT-263) significantly reduced cell number, increased cell death, and displayed synergy in vitro in most models. navitoclax 71-78 BCL2 apoptosis regulator Homo sapiens 51-56 30478448-5 2019 In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5. Ribavirin 3-12 BCL2 apoptosis regulator Homo sapiens 179-183 30470919-4 2019 Increased apoptotic cell death following cucurbitacin B treatment was correlated with caspase-9 and caspase-3 activations, Bax upregulation, increased cytochrome c, apoptosis-inducing factor release, and decreased Bcl-2 and Bcl-XL levels, suggesting activation of the mitochondrial-mediated apoptosis pathway. cucurbitacin B 41-55 BCL2 apoptosis regulator Homo sapiens 214-219 30592293-0 2019 Bromodomain-containing protein 7 sensitizes breast cancer cells to paclitaxel by activating Bcl2-antagonist/killer protein. Paclitaxel 67-77 BCL2 apoptosis regulator Homo sapiens 92-96 30478448-5 2019 In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5. Ribavirin 135-144 BCL2 apoptosis regulator Homo sapiens 179-183 30503550-7 2019 Isolinderalactone suppressed the expression of B-cell lymphoma 2 (BCL-2), as well as of survivin and X-linked inhibitor of apoptosis protein (XIAP), known as apoptosis inhibitors, and increased the level of cleaved caspase-3. linderalactone 0-17 BCL2 apoptosis regulator Homo sapiens 47-64 30867764-9 2019 In addition, it was observed that celastrol/cisplatin upregulated the expression of Bcl-associated X protein, cytochrome c, caspase-3 and C/EBP homologous protein, and downregulated the expression of Bcl-2, poly(ADP-ribose) polymerase, 78 kDa glucose-regulated protein and caspase-9, whereas the expression of caspase-8 remained unchanged. celastrol 34-43 BCL2 apoptosis regulator Homo sapiens 200-205 30867764-9 2019 In addition, it was observed that celastrol/cisplatin upregulated the expression of Bcl-associated X protein, cytochrome c, caspase-3 and C/EBP homologous protein, and downregulated the expression of Bcl-2, poly(ADP-ribose) polymerase, 78 kDa glucose-regulated protein and caspase-9, whereas the expression of caspase-8 remained unchanged. Cisplatin 44-53 BCL2 apoptosis regulator Homo sapiens 200-205 30448556-10 2019 Overall, our results indicated that HIF-1a overexpression could alleviate ROS and apoptosis caused by 1,4-BQ through targeting Nox4, Bcl-2 and key enzymes in glycolysis. 1,4-bq 102-108 BCL2 apoptosis regulator Homo sapiens 133-138 30747218-4 2019 The results revealed that GA inhibited the proliferation and induced the apoptosis of NSCLC A549 cells in dose- and time-dependent manners, which was associated with upregulated B-cell lymphoma 2 (Bcl-2)-associated X protein (Bax) and downregulated Bcl-2. Gallium 26-28 BCL2 apoptosis regulator Homo sapiens 178-195 30747218-4 2019 The results revealed that GA inhibited the proliferation and induced the apoptosis of NSCLC A549 cells in dose- and time-dependent manners, which was associated with upregulated B-cell lymphoma 2 (Bcl-2)-associated X protein (Bax) and downregulated Bcl-2. Gallium 26-28 BCL2 apoptosis regulator Homo sapiens 197-202 30747218-4 2019 The results revealed that GA inhibited the proliferation and induced the apoptosis of NSCLC A549 cells in dose- and time-dependent manners, which was associated with upregulated B-cell lymphoma 2 (Bcl-2)-associated X protein (Bax) and downregulated Bcl-2. Gallium 26-28 BCL2 apoptosis regulator Homo sapiens 249-254 30747218-5 2019 Notably, the results also indicated that GA enhanced the anticancer effects of cisplatin in the inhibition of cancer cell proliferation and the induction of cell apoptosis following elevated Bax expression and suppressed Bcl-2 expression. Gallium 41-43 BCL2 apoptosis regulator Homo sapiens 221-226 30747218-5 2019 Notably, the results also indicated that GA enhanced the anticancer effects of cisplatin in the inhibition of cancer cell proliferation and the induction of cell apoptosis following elevated Bax expression and suppressed Bcl-2 expression. Cisplatin 79-88 BCL2 apoptosis regulator Homo sapiens 221-226 30824767-7 2019 The anti-tumor roles of fenofibrate on Hep3B cells by inducing apoptosis and necroptosis were dependent on the expression of Bcl-2/caspase family members and RIP1/RIP3 proteins, respectively. Fenofibrate 24-35 BCL2 apoptosis regulator Homo sapiens 125-130 30503550-0 2019 Isolinderalactone regulates the BCL-2/caspase-3/PARP pathway and suppresses tumor growth in a human glioblastoma multiforme xenograft mouse model. linderalactone 0-17 BCL2 apoptosis regulator Homo sapiens 32-37 30503550-7 2019 Isolinderalactone suppressed the expression of B-cell lymphoma 2 (BCL-2), as well as of survivin and X-linked inhibitor of apoptosis protein (XIAP), known as apoptosis inhibitors, and increased the level of cleaved caspase-3. linderalactone 0-17 BCL2 apoptosis regulator Homo sapiens 66-71 30891181-11 2019 Western blot showed that Dex increased Bax, Cyt-c, Apaf-1, cleaved-caspase9, cleaved-caspase3 expression and decreased Bcl-2 expression. Dexamethasone 25-28 BCL2 apoptosis regulator Homo sapiens 119-124 30873034-4 2019 In this study, we found that iron overload induced by 100 muM ferric ammonium citrate (FAC) caused apoptosis of BMSCs, promoted cleaved caspase-3 and BAX protein expressions while inhibited Bcl-2 protein expression, which effects were significantly attenuated by icariin treatment. Iron 29-33 BCL2 apoptosis regulator Homo sapiens 190-195 30873034-4 2019 In this study, we found that iron overload induced by 100 muM ferric ammonium citrate (FAC) caused apoptosis of BMSCs, promoted cleaved caspase-3 and BAX protein expressions while inhibited Bcl-2 protein expression, which effects were significantly attenuated by icariin treatment. ferric ammonium citrate 62-85 BCL2 apoptosis regulator Homo sapiens 190-195 30923410-9 2019 Apoptotic cells, but not necrotic cells, were significantly increased following the combined treatment, and an increase in the Bax/Bcl-2 ratio indicated that the combination of cisplatin and SAHA induced apoptosis through the mitochondrial pathway. Cisplatin 177-186 BCL2 apoptosis regulator Homo sapiens 131-136 30923410-9 2019 Apoptotic cells, but not necrotic cells, were significantly increased following the combined treatment, and an increase in the Bax/Bcl-2 ratio indicated that the combination of cisplatin and SAHA induced apoptosis through the mitochondrial pathway. Vorinostat 191-195 BCL2 apoptosis regulator Homo sapiens 131-136 30813354-4 2019 Clinical results deriving from studies using B-cell lymphoma 2 (BCL-2) inhibitors in combination with standard AML agents, such as azacytidine, decitabine, low-dose cytarabine, provided promising results and strongly support the use of these agents in the treatment of AML patients, particularly of elderly patients. Azacitidine 131-142 BCL2 apoptosis regulator Homo sapiens 45-62 30796196-1 2019 Targeting anti-apoptotic BCL2 family proteins has become an attractive therapeutic strategy for many cancers, and the BCL2-selective inhibitor ABT-199 (venetoclax) has obtained clinical success. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 143-146 BCL2 apoptosis regulator Homo sapiens 118-122 30813354-4 2019 Clinical results deriving from studies using B-cell lymphoma 2 (BCL-2) inhibitors in combination with standard AML agents, such as azacytidine, decitabine, low-dose cytarabine, provided promising results and strongly support the use of these agents in the treatment of AML patients, particularly of elderly patients. Azacitidine 131-142 BCL2 apoptosis regulator Homo sapiens 64-69 30813354-4 2019 Clinical results deriving from studies using B-cell lymphoma 2 (BCL-2) inhibitors in combination with standard AML agents, such as azacytidine, decitabine, low-dose cytarabine, provided promising results and strongly support the use of these agents in the treatment of AML patients, particularly of elderly patients. Decitabine 144-154 BCL2 apoptosis regulator Homo sapiens 45-62 30813354-4 2019 Clinical results deriving from studies using B-cell lymphoma 2 (BCL-2) inhibitors in combination with standard AML agents, such as azacytidine, decitabine, low-dose cytarabine, provided promising results and strongly support the use of these agents in the treatment of AML patients, particularly of elderly patients. Decitabine 144-154 BCL2 apoptosis regulator Homo sapiens 64-69 30813354-4 2019 Clinical results deriving from studies using B-cell lymphoma 2 (BCL-2) inhibitors in combination with standard AML agents, such as azacytidine, decitabine, low-dose cytarabine, provided promising results and strongly support the use of these agents in the treatment of AML patients, particularly of elderly patients. Cytarabine 165-175 BCL2 apoptosis regulator Homo sapiens 45-62 30813354-4 2019 Clinical results deriving from studies using B-cell lymphoma 2 (BCL-2) inhibitors in combination with standard AML agents, such as azacytidine, decitabine, low-dose cytarabine, provided promising results and strongly support the use of these agents in the treatment of AML patients, particularly of elderly patients. Cytarabine 165-175 BCL2 apoptosis regulator Homo sapiens 64-69 31031856-5 2019 In this study, the Bcl-2 inhibitor ABT-737 was used in combination with everolimus to enhance its anti-tumor effectiveness in everolimus-resistant RCC cell lines. ABT-737 35-42 BCL2 apoptosis regulator Homo sapiens 19-24 31031856-0 2019 Dual-Inhibition of mTOR and Bcl-2 Enhances the Anti-tumor Effect of Everolimus against Renal Cell Carcinoma In Vitro and In Vivo. Everolimus 68-78 BCL2 apoptosis regulator Homo sapiens 28-33 31031856-5 2019 In this study, the Bcl-2 inhibitor ABT-737 was used in combination with everolimus to enhance its anti-tumor effectiveness in everolimus-resistant RCC cell lines. Everolimus 126-136 BCL2 apoptosis regulator Homo sapiens 19-24 31031856-7 2019 In both RCC cell lines, everolimus-ABT-737 combination not only induced apoptosis, caspase and PARP-1 cleavage but also a decrease in Bcl-2 protein levels in parallel with a concomitant increase in Bim and Noxa levels. Everolimus 24-34 BCL2 apoptosis regulator Homo sapiens 134-139 31031856-7 2019 In both RCC cell lines, everolimus-ABT-737 combination not only induced apoptosis, caspase and PARP-1 cleavage but also a decrease in Bcl-2 protein levels in parallel with a concomitant increase in Bim and Noxa levels. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 35-38 BCL2 apoptosis regulator Homo sapiens 134-139 30791947-2 2019 Dual targeting BTK and BCL2 with ibrutinib and venetoclax has improved outcomes in MCL patients who were predicted not to respond to conventional therapy, but it is unlikely to be curative. ibrutinib 33-42 BCL2 apoptosis regulator Homo sapiens 23-27 30915355-6 2019 Moreover, Ubenimex reverses the MDR of SGC7901/X and MKN45/X cells and enhances their sensitivity to FOLFOX, in part by decreasing CD13 expression, which is accompanied by downregulation of Bcl-xl, Bcl-2, and survivin expression; increased expression of Bax; and activation of the caspase-3-mediated apoptotic cascade. ubenimex 10-18 BCL2 apoptosis regulator Homo sapiens 198-203 30791594-6 2019 Moreover, COS could significantly increase Bax expression of A549 cells while decreasing Bcl-2 expression. carbonyl sulfide 10-13 BCL2 apoptosis regulator Homo sapiens 89-94 31031868-14 2019 We further display that MSI-1 effectively protects OC cells from paclitaxel-induced apoptosis by increasing the expression of p-Bcl-2 through ERK signaling pathway activation. Paclitaxel 65-75 BCL2 apoptosis regulator Homo sapiens 128-133 30782173-8 2019 Western blot analyses revealed that hypericin-PDT treatment resulted in downregulation of Bcl-2 and enhanced the expression of Bad, cytochrome C, and AIF. hypericin 36-45 BCL2 apoptosis regulator Homo sapiens 90-95 30781512-8 2019 Apart from the BH3 binding groove of Bcl-2, the flexible loop domain (FLD) also plays an important role in regulating the apoptotic process. BH 3 15-18 BCL2 apoptosis regulator Homo sapiens 37-42 30210134-0 2019 Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements. gemcitabine 0-11 BCL2 apoptosis regulator Homo sapiens 126-130 30210134-0 2019 Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements. Cisplatin 32-41 BCL2 apoptosis regulator Homo sapiens 126-130 30668359-12 2019 Celastrol mediated cell apoptosis through the downregulation of the expression of Bcl-2, not Bcl-xL. celastrol 0-9 BCL2 apoptosis regulator Homo sapiens 82-87 30668372-10 2019 TQ pretreatment also inhibited As2O3-induced exacerbation in protein levels of BAX and PARP-1 and restored the loss of Bcl2 levels. thymoquinone 0-2 BCL2 apoptosis regulator Homo sapiens 119-123 30863062-12 2019 Meanwhile, Bax mRNA and protein expression was upregulated, while Bcl-2 mRNA and protein expression was downregulated after PTX-NPs treatment in vivo. Paclitaxel 124-127 BCL2 apoptosis regulator Homo sapiens 66-71 30772887-11 2019 Our investigation of the underlying mechanism revealed that ursolic acid prompts apoptotic cell death of the SK-MEL-24 cells, which was linked with increased expression of Bax and Caspase 3 and 9, and decreased expression of Bcl-2. ursolic acid 60-72 BCL2 apoptosis regulator Homo sapiens 225-230 30658101-10 2019 Treatment with SMI-4a induced apoptosis by downregulating Bcl-2, upregulating Bax and other antiapoptotic proteins, and decreasing protein levels of p-JAK2 and p-STAT3. SMI-4a 15-21 BCL2 apoptosis regulator Homo sapiens 58-63 30503360-5 2019 Here, we found that the combination treatment of scutellarin and cisplatin enhanced apoptosis in ovarian cancer cells via increasing the extent of platinum-DNA adducts and the ratio of Bax/Bcl-2. scutellarin 49-60 BCL2 apoptosis regulator Homo sapiens 189-194 31016071-7 2019 This time, the patient was started on venetoclax (BCL-2 inhibitor) and rituximab which he is tolerating well without any complications. venetoclax 38-48 BCL2 apoptosis regulator Homo sapiens 50-55 30498064-3 2019 The abundance of antiapoptotic BCL2 family members based on immunoblotting or RNA transcript levels correlated poorly with the activity of BH3 mimetics. BH 3 139-142 BCL2 apoptosis regulator Homo sapiens 31-35 30863086-9 2019 Western blot analysis demonstrated that dicerandrol B increased the levels of GRP78, ubiquitin, cleaved PARP, and Bax protein, decreased the levels of PARP and Bcl-2 protein, and caused an increase in the Bax/Bcl-2 ratio in HeLa cells. dicerandrol B 40-53 BCL2 apoptosis regulator Homo sapiens 160-165 30863086-9 2019 Western blot analysis demonstrated that dicerandrol B increased the levels of GRP78, ubiquitin, cleaved PARP, and Bax protein, decreased the levels of PARP and Bcl-2 protein, and caused an increase in the Bax/Bcl-2 ratio in HeLa cells. dicerandrol B 40-53 BCL2 apoptosis regulator Homo sapiens 209-214 30741367-10 2019 Combination therapy that includes venetoclax (BCL2 inhibitor) with hypomethylating agents may also be appropriate for such patients. venetoclax 34-44 BCL2 apoptosis regulator Homo sapiens 46-50 30754643-7 2019 Fluoxetine also significantly induced apoptosis, unregulated extrinsic (activation of first apoptosis signal protein and ligand (Fas/FasL), and caspase-8) and intrinsic (loss of mitochondrial membrane potential (DeltaPsim) pathways and increased Bcl-2 homologous antagonist killer (BAK) apoptosis signaling. Fluoxetine 0-10 BCL2 apoptosis regulator Homo sapiens 246-251 30503360-5 2019 Here, we found that the combination treatment of scutellarin and cisplatin enhanced apoptosis in ovarian cancer cells via increasing the extent of platinum-DNA adducts and the ratio of Bax/Bcl-2. Cisplatin 65-74 BCL2 apoptosis regulator Homo sapiens 189-194 30717701-7 2019 betaOHB (4 mmol/L) and TSA (0.2 mol/L) demonstrated protective effects on BCL-2 expression. betaohb 0-7 BCL2 apoptosis regulator Homo sapiens 74-79 30715623-6 2019 The addition of the BCL2 inhibitor venetoclax appears to markedly improve the results of hypomethylating agents. venetoclax 35-45 BCL2 apoptosis regulator Homo sapiens 20-24 30717701-7 2019 betaOHB (4 mmol/L) and TSA (0.2 mol/L) demonstrated protective effects on BCL-2 expression. trichostatin A 23-26 BCL2 apoptosis regulator Homo sapiens 74-79 31011561-9 2019 Moreover after exposure to 100 muM H2O2, western blotting analysis showed that cell pretreatment with 20 muM H2O2, decremented Bax/Bcl2 ratio and up-regulated HIF-1alpha and pAkt-1 compared to the control group. Hydrogen Peroxide 35-39 BCL2 apoptosis regulator Homo sapiens 131-135 30712054-11 2019 Glychionide-A prompted apoptosis and autophagy and was also associated with alteration in apoptosis- (Bax, Caspase 9 and Bcl-2) and autophagy- (LC3I, II, Beclin 1 and p62) related protein expression. 5,8-dihydroxy-flavone-7-O-beta-D-glucuronide 0-13 BCL2 apoptosis regulator Homo sapiens 121-126 30718665-6 2019 Oxo-aglaiastatin inhibited translation in vitro and in vivo and synergized with doxorubicin, ABT-199 (a Bcl-2 antagonist), and dexamethasone when tested on hematological cancer cells. oxo-aglaiastatin 0-16 BCL2 apoptosis regulator Homo sapiens 104-109 31011561-9 2019 Moreover after exposure to 100 muM H2O2, western blotting analysis showed that cell pretreatment with 20 muM H2O2, decremented Bax/Bcl2 ratio and up-regulated HIF-1alpha and pAkt-1 compared to the control group. Hydrogen Peroxide 109-113 BCL2 apoptosis regulator Homo sapiens 131-135 30600538-5 2019 Molecular docking was performed to investigate the binding between the most active porphyrin derivatives 2c, 2d, 2g, 2h and the two molecular targets Bcl-2 and caspase-3. Deuterium 117-119 BCL2 apoptosis regulator Homo sapiens 150-155 30320607-2 2019 Here, we evaluated the therapeutic potential of the combination of the Bcl-2 antagonist ABT-199 and cytotoxic agent gemcitabine in T-ALL cell lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 88-91 BCL2 apoptosis regulator Homo sapiens 71-76 30320607-7 2019 Moreover, ABT-199 exerted an antagonistic action towards Bcl-2 and Bcl-xL, but to a certain extent moderately increased Mcl-1 level that could be compromised by gemcitabine. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 10-13 BCL2 apoptosis regulator Homo sapiens 57-62 30320607-8 2019 In conclusion, our study showed that the combination of ABT-199 and gemcitabine exhibited synergistic cytotoxicity in T-ALL cells by cooperatively targeting DNA damage repair pathway and Bcl-2 family proteins. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 56-59 BCL2 apoptosis regulator Homo sapiens 187-192 30320607-8 2019 In conclusion, our study showed that the combination of ABT-199 and gemcitabine exhibited synergistic cytotoxicity in T-ALL cells by cooperatively targeting DNA damage repair pathway and Bcl-2 family proteins. gemcitabine 68-79 BCL2 apoptosis regulator Homo sapiens 187-192 30647052-1 2019 The BCL2 inhibitor venetoclax plus the MDM2 inhibitor idasanutlin may be effective in treating relapsed/refractory acute myeloid leukemia. venetoclax 19-29 BCL2 apoptosis regulator Homo sapiens 4-8 30389373-3 2019 The synthetic BH3-mimetic ABT-737 effectively targets BCL2, BCL2 like 1 and BCL2 like 2 but still barely affects cell survival which is presumably due to its inability to inhibit myeloid cell leukemia 1 (MCL1). BH 3 14-17 BCL2 apoptosis regulator Homo sapiens 54-58 30389373-3 2019 The synthetic BH3-mimetic ABT-737 effectively targets BCL2, BCL2 like 1 and BCL2 like 2 but still barely affects cell survival which is presumably due to its inability to inhibit myeloid cell leukemia 1 (MCL1). BH 3 14-17 BCL2 apoptosis regulator Homo sapiens 60-64 30389373-3 2019 The synthetic BH3-mimetic ABT-737 effectively targets BCL2, BCL2 like 1 and BCL2 like 2 but still barely affects cell survival which is presumably due to its inability to inhibit myeloid cell leukemia 1 (MCL1). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 26-29 BCL2 apoptosis regulator Homo sapiens 54-58 30389373-3 2019 The synthetic BH3-mimetic ABT-737 effectively targets BCL2, BCL2 like 1 and BCL2 like 2 but still barely affects cell survival which is presumably due to its inability to inhibit myeloid cell leukemia 1 (MCL1). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 26-29 BCL2 apoptosis regulator Homo sapiens 60-64 30500985-7 2019 In response to Bcl-2 homology 3 (BH3)-only protein Bmf stress, Bcl-2 phosphorylation switched from diminishing to enhancing the Bcl-2 anti-apoptotic ability with increased phosphorylation of Bcl-2, and the turning point was 50% Bcl-2 phosphorylation induced by 0.2 muM paclitaxel treatment. Paclitaxel 269-279 BCL2 apoptosis regulator Homo sapiens 15-20 30500985-7 2019 In response to Bcl-2 homology 3 (BH3)-only protein Bmf stress, Bcl-2 phosphorylation switched from diminishing to enhancing the Bcl-2 anti-apoptotic ability with increased phosphorylation of Bcl-2, and the turning point was 50% Bcl-2 phosphorylation induced by 0.2 muM paclitaxel treatment. Paclitaxel 269-279 BCL2 apoptosis regulator Homo sapiens 63-68 30711951-7 2019 RESULTS: Oxicam derivatives induced apoptosis through a caspase-3-dependent pathway, up-regulated BAX expression, and down-regulated BCL2 expression. oxicam 9-15 BCL2 apoptosis regulator Homo sapiens 133-137 30500985-7 2019 In response to Bcl-2 homology 3 (BH3)-only protein Bmf stress, Bcl-2 phosphorylation switched from diminishing to enhancing the Bcl-2 anti-apoptotic ability with increased phosphorylation of Bcl-2, and the turning point was 50% Bcl-2 phosphorylation induced by 0.2 muM paclitaxel treatment. Paclitaxel 269-279 BCL2 apoptosis regulator Homo sapiens 63-68 30500985-7 2019 In response to Bcl-2 homology 3 (BH3)-only protein Bmf stress, Bcl-2 phosphorylation switched from diminishing to enhancing the Bcl-2 anti-apoptotic ability with increased phosphorylation of Bcl-2, and the turning point was 50% Bcl-2 phosphorylation induced by 0.2 muM paclitaxel treatment. Paclitaxel 269-279 BCL2 apoptosis regulator Homo sapiens 63-68 30500985-9 2019 CONCLUSIONS AND IMPLICATIONS: The model could accurately predict the effects of anti-tumour drugs that involve the Bcl-2 family pathway, as shown with ABT-199 or etoposide. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 151-154 BCL2 apoptosis regulator Homo sapiens 115-120 30500985-9 2019 CONCLUSIONS AND IMPLICATIONS: The model could accurately predict the effects of anti-tumour drugs that involve the Bcl-2 family pathway, as shown with ABT-199 or etoposide. Etoposide 162-171 BCL2 apoptosis regulator Homo sapiens 115-120 30399561-10 2019 We also found that exposure of Bi2O3 NPs induced apoptotic response in MCF-7 cells suggested by impaired regulation of Bcl-2, Bax and caspase-3 genes. bi2o3 31-36 BCL2 apoptosis regulator Homo sapiens 119-124 30399561-11 2019 Altogether, we found that Bi2O3 NPs induced cytotoxicity in MCF-7 cells through modulating the redox homeostasis via Bax/Bcl-2 pathway. bi2o3 26-31 BCL2 apoptosis regulator Homo sapiens 121-126 30599074-5 2019 This cytotoxicity resulted from TTO induced apoptosis in both A-375 and HEp-2 cell lines as evidenced by morphological features of apoptosis and Annexin V/PI staining results in addition to the activation of caspase-3/7 and -9, upregulation of pro-apoptotic genes (P53 and BAX) and downregulation of the anti-apoptotic gene BCL-2. Tea Tree Oil 32-35 BCL2 apoptosis regulator Homo sapiens 324-329 30535471-0 2019 MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2. Bortezomib 78-88 BCL2 apoptosis regulator Homo sapiens 102-107 30342140-7 2019 As expected, GTP (25, 50 and 100 mug/ml) inhibited growth of PC-3 cells via inducing apoptosis, which was achieved by elevation of bax/bcl-2 ratio and caspae-3 protein expression, as well as a decrease of miR-93. Guanosine Triphosphate 13-16 BCL2 apoptosis regulator Homo sapiens 135-140 30535477-8 2019 Following ROS scavenging, the CT-induced apoptosis and altered expression levels of Bcl-2, Bad, cleaved caspase-3 and cleaved PARP were restored. Reactive Oxygen Species 10-13 BCL2 apoptosis regulator Homo sapiens 84-89 30535477-8 2019 Following ROS scavenging, the CT-induced apoptosis and altered expression levels of Bcl-2, Bad, cleaved caspase-3 and cleaved PARP were restored. cryptotanshinone 30-32 BCL2 apoptosis regulator Homo sapiens 84-89 30569096-10 2019 Compared with H2O2, Nrf2 silencing further decreased the expression levels of B-cell lymphoma-2 (Bcl-2), but increased that of Bcl-2-associated X protein and cleaved-caspase-3. Hydrogen Peroxide 14-18 BCL2 apoptosis regulator Homo sapiens 78-95 30535449-8 2019 Furthermore, Cyr61 increased the level of Bcl-2 in Ara-C-treated ALL cells. Cytarabine 51-56 BCL2 apoptosis regulator Homo sapiens 42-47 30431688-4 2019 SA upregulated the expression levels of Bcl-2 and decreased the levels of Bax, cleaved caspase-3, and cleaved caspase-9. salvianolic acid 0-2 BCL2 apoptosis regulator Homo sapiens 40-45 30483745-1 2019 AT-101, an orally available and well-tolerated natural pan-Bcl-2 family protein inhibitor, has been reported to be effective against a variety of cancers. gossypol acetic acid 0-6 BCL2 apoptosis regulator Homo sapiens 59-64 30582951-8 2019 This programmed cell death marketed with cleaved Caspase 3 plus PAPR proteins, up-regulation of BAD and down-regulation of BCL2 is linked the Col suppression to unique calcium-related pathways. Calcium 168-175 BCL2 apoptosis regulator Homo sapiens 123-127 30569137-8 2019 In terms of the underlying mechanism, cos was revealed to inhibit the anti-apoptotic capacity of the cells, possibly via upregulating the expression levels of Bax protein and caspases-3, -8 and -9, and downregulating the expression of Bcl-2 protein. costunolide 38-41 BCL2 apoptosis regulator Homo sapiens 235-240 30668408-13 2019 DMC significantly decreased Bcl-2 protein expressions. demethoxycurcumin 0-3 BCL2 apoptosis regulator Homo sapiens 28-33 30668408-14 2019 Finally, MTT assay indicated that DMC significantly increased CDDP-induced cytotoxicity and was confirmed with an increased Bax/Bcl-2 ratio, indicating upregulation of caspase-3. demethoxycurcumin 34-37 BCL2 apoptosis regulator Homo sapiens 128-133 29930300-4 2019 RPL10 R98S selective sensitivity to the clinically available Bcl-2 inhibitor Venetoclax (ABT-199) was supported by suppression of splenomegaly and the absence of human leukemia cells in the blood of T-ALL xenografted mice. venetoclax 77-87 BCL2 apoptosis regulator Homo sapiens 61-66 29930300-4 2019 RPL10 R98S selective sensitivity to the clinically available Bcl-2 inhibitor Venetoclax (ABT-199) was supported by suppression of splenomegaly and the absence of human leukemia cells in the blood of T-ALL xenografted mice. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 89-92 BCL2 apoptosis regulator Homo sapiens 61-66 30467667-12 2019 In consequence, curcumin treatment for 48 h, prevented autocrine GH-triggered invasion-metastasis, EMT activation through inhibiting NF-kappaB signaling and miR-182-96-183 cluster expression and induced apoptotic cell death by modulating Bcl-2 family members in T47D breast cancer cells. Curcumin 16-24 BCL2 apoptosis regulator Homo sapiens 238-243 30450837-5 2019 Abeta25-35 -induced changes in Ca2+ and B-cell lymphoma-2 (Bcl-2) and Bcl-2-associated X (Bax) protein and gene levels in cells were also reversed by genistein. abeta25 0-7 BCL2 apoptosis regulator Homo sapiens 40-57 30450837-5 2019 Abeta25-35 -induced changes in Ca2+ and B-cell lymphoma-2 (Bcl-2) and Bcl-2-associated X (Bax) protein and gene levels in cells were also reversed by genistein. abeta25 0-7 BCL2 apoptosis regulator Homo sapiens 59-64 30450837-5 2019 Abeta25-35 -induced changes in Ca2+ and B-cell lymphoma-2 (Bcl-2) and Bcl-2-associated X (Bax) protein and gene levels in cells were also reversed by genistein. Genistein 150-159 BCL2 apoptosis regulator Homo sapiens 40-57 30450837-5 2019 Abeta25-35 -induced changes in Ca2+ and B-cell lymphoma-2 (Bcl-2) and Bcl-2-associated X (Bax) protein and gene levels in cells were also reversed by genistein. Genistein 150-159 BCL2 apoptosis regulator Homo sapiens 59-64 30806186-1 2019 Background: Response to neoadjuvant cisplatin treatment in bladder cancer has been linked to expression of Bcl-2 protein by cancer cells. Cisplatin 36-45 BCL2 apoptosis regulator Homo sapiens 107-112 30806186-2 2019 The objective of this study was to test Bcl-2 as a predictive marker of neoadjuvant cisplatin chemotherapy response in a patient cohort from randomized cystectomy trials. Cisplatin 84-93 BCL2 apoptosis regulator Homo sapiens 40-45 30266435-7 2019 Quantitative real-time PCR was performed to investigate the mRNA expression levels of apoptotic (caspase 3) and anti-apoptotic (BCL2) genes Confluent BT-474 monolayers exposed to PVP-SPIONs showed biphasic effects on cell proliferation. pvp-spions 179-189 BCL2 apoptosis regulator Homo sapiens 128-132 30774376-0 2019 Reversing platinum resistance in ovarian cancer multicellular spheroids by targeting Bcl-2. Platinum 10-18 BCL2 apoptosis regulator Homo sapiens 85-90 29924730-0 2019 Selective BH3-mimetics targeting BCL-2, BCL-XL or MCL-1 induce severe mitochondrial perturbations. BH 3 10-13 BCL2 apoptosis regulator Homo sapiens 33-38 29924730-4 2019 Specifically, the selective BH3-mimetics ABT-199, A-1331852 and S63845, which target BCL-2, BCL-XL and MCL-1, respectively, induce comparable ultrastructural changes including mitochondrial swelling, a decrease of mitochondrial matrix density and severe loss of cristae structure. BH 3 28-31 BCL2 apoptosis regulator Homo sapiens 85-90 29924730-4 2019 Specifically, the selective BH3-mimetics ABT-199, A-1331852 and S63845, which target BCL-2, BCL-XL and MCL-1, respectively, induce comparable ultrastructural changes including mitochondrial swelling, a decrease of mitochondrial matrix density and severe loss of cristae structure. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 41-44 BCL2 apoptosis regulator Homo sapiens 85-90 30761271-8 2019 Thirdly, B-cell lymphoma-2 (Bcl2) and Multidrug Resistance-Associated Protein 4 (MRP4) genes were target genes of miR-125a-5p, which modulated paclitaxel resistance of Ishikawa/PA and HEC1A/PA cells through targeted silencing Bcl2 and MRP4. Paclitaxel 143-153 BCL2 apoptosis regulator Homo sapiens 9-26 30761271-8 2019 Thirdly, B-cell lymphoma-2 (Bcl2) and Multidrug Resistance-Associated Protein 4 (MRP4) genes were target genes of miR-125a-5p, which modulated paclitaxel resistance of Ishikawa/PA and HEC1A/PA cells through targeted silencing Bcl2 and MRP4. Paclitaxel 143-153 BCL2 apoptosis regulator Homo sapiens 28-32 30761271-8 2019 Thirdly, B-cell lymphoma-2 (Bcl2) and Multidrug Resistance-Associated Protein 4 (MRP4) genes were target genes of miR-125a-5p, which modulated paclitaxel resistance of Ishikawa/PA and HEC1A/PA cells through targeted silencing Bcl2 and MRP4. Paclitaxel 143-153 BCL2 apoptosis regulator Homo sapiens 226-230 30761271-9 2019 In conclusion, high-expression of CDKN2B-AS is associated with a poor response to paclitaxel of EC patients, and knockdown of CDKN2B-AS inhibits paclitaxel resistance through miR-125a-5p-Bcl2/MRP4 pathway in EC patients. Paclitaxel 145-155 BCL2 apoptosis regulator Homo sapiens 187-191 30686270-8 2019 Staurosporine stimulation and its effects on the expression of Bcl2, BAX, Bad, caspase-8, and caspase-9 were investigated with immunoblot. Staurosporine 0-13 BCL2 apoptosis regulator Homo sapiens 63-67 30774376-7 2019 siRNA was used to verify the anti-cisplatin-induced apoptosis effect of Bcl-2. Cisplatin 34-43 BCL2 apoptosis regulator Homo sapiens 72-77 30774376-8 2019 The Bcl-2 inhibitor, ABT-737, was used for improving the sensitivity of MCS to cisplatin. ABT-737 21-28 BCL2 apoptosis regulator Homo sapiens 4-9 30774376-8 2019 The Bcl-2 inhibitor, ABT-737, was used for improving the sensitivity of MCS to cisplatin. Cisplatin 79-88 BCL2 apoptosis regulator Homo sapiens 4-9 30774376-14 2019 Bcl-2 knockdown by siRNA or blockage by ABT-737 enhanced the cisplatin-induced apoptosis and reduced the 50% inhibitory concentrations of cisplatin for MCS by 58.5% and 88.2%, respectively. Cisplatin 61-70 BCL2 apoptosis regulator Homo sapiens 0-5 30774376-14 2019 Bcl-2 knockdown by siRNA or blockage by ABT-737 enhanced the cisplatin-induced apoptosis and reduced the 50% inhibitory concentrations of cisplatin for MCS by 58.5% and 88.2%, respectively. Cisplatin 138-147 BCL2 apoptosis regulator Homo sapiens 0-5 30774376-15 2019 Conclusion: The upregulated Bcl-2 contributes to cisplatin resistance in our MCS model and targeting it sensitizes the MCS to cisplatin treatment. Cisplatin 49-58 BCL2 apoptosis regulator Homo sapiens 28-33 30774376-15 2019 Conclusion: The upregulated Bcl-2 contributes to cisplatin resistance in our MCS model and targeting it sensitizes the MCS to cisplatin treatment. Cisplatin 126-135 BCL2 apoptosis regulator Homo sapiens 28-33 30679640-7 2019 Subsequent drug combination studies identified the BCL-2 inhibitor ABT-199 to synergize with tivantinib while cytarabine combination with tivantinib was antagonistic. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 67-70 BCL2 apoptosis regulator Homo sapiens 51-56 30681073-0 2019 Berberine Promotes Apoptosis of Colorectal Cancer via Regulation of the Long Non-Coding RNA (lncRNA) Cancer Susceptibility Candidate 2 (CASC2)/AU-Binding Factor 1 (AUF1)/B-Cell CLL/Lymphoma 2 (Bcl-2) Axis. Berberine 0-9 BCL2 apoptosis regulator Homo sapiens 170-191 30681073-0 2019 Berberine Promotes Apoptosis of Colorectal Cancer via Regulation of the Long Non-Coding RNA (lncRNA) Cancer Susceptibility Candidate 2 (CASC2)/AU-Binding Factor 1 (AUF1)/B-Cell CLL/Lymphoma 2 (Bcl-2) Axis. Berberine 0-9 BCL2 apoptosis regulator Homo sapiens 193-198 30681073-10 2019 In addition, anti-apoptotic gene Bcl-2 was suppressed by berberine treatment and lncRNA CASC2, inducing the pro-apoptotic effects. Berberine 57-66 BCL2 apoptosis regulator Homo sapiens 33-38 30681073-12 2019 CONCLUSIONS Our study reveals that lncRNA CASC2 mediates the berberine-induced pro-apoptotic effect via inhibition of Bcl-2 expression at the post-transcriptional level. Berberine 61-70 BCL2 apoptosis regulator Homo sapiens 118-123 30679640-7 2019 Subsequent drug combination studies identified the BCL-2 inhibitor ABT-199 to synergize with tivantinib while cytarabine combination with tivantinib was antagonistic. ARQ 197 93-103 BCL2 apoptosis regulator Homo sapiens 51-56 30680088-12 2019 H2O2 treatment resulted in significant increase in bax expression and decrease in bcl-2 expression, while the changes in the expressions of bax and bcl-2 were reversed by scutellarin treatment. Hydrogen Peroxide 0-4 BCL2 apoptosis regulator Homo sapiens 82-87 30573364-9 2019 Further analyses suggested that magnolol-induced apoptosis was related to the abnormal expression of p53, Bax, Bcl-2, cytochrome c and caspase activation. magnolol 32-40 BCL2 apoptosis regulator Homo sapiens 111-116 30723405-0 2019 Liver-Targeted Combination Therapy Basing on Glycyrrhizic Acid-Modified DSPE-PEG-PEI Nanoparticles for Co-delivery of Doxorubicin and Bcl-2 siRNA. Glycyrrhizic Acid 45-62 BCL2 apoptosis regulator Homo sapiens 134-139 30723405-2 2019 Here, we prepared liver-targeted nanoparticles (GH-DPP) composed of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol-polyetherimide (DSPE-PEG-PEI) with Glycyrrhetinic acid-modified hyaluronic acid (GA-HA) for co-delivery of doxorubicin (DOX) and Bcl-2 siRNA. gh-dpp 48-54 BCL2 apoptosis regulator Homo sapiens 265-270 30680088-12 2019 H2O2 treatment resulted in significant increase in bax expression and decrease in bcl-2 expression, while the changes in the expressions of bax and bcl-2 were reversed by scutellarin treatment. scutellarin 171-182 BCL2 apoptosis regulator Homo sapiens 148-153 32254735-0 2019 A strategy using mesoporous polymer nanospheres as nanocarriers of Bcl-2 siRNA towards breast cancer therapy. mesoporous polymer 17-35 BCL2 apoptosis regulator Homo sapiens 67-72 32254735-6 2019 In this report, a nanomedicine system is constructed using Bcl-2 siRNA as the therapeutic agent and mesoporous polymer nanosphere (MPN) carriers to both improve cellular internalization and achieve Bcl-2 silencing and cell apoptosis. mesoporous polymer 100-118 BCL2 apoptosis regulator Homo sapiens 198-203 30705876-7 2018 The data demonstrated that sildenafil or vardenafil (two structure-related PDE5 inhibitors) but not tadalafil (structure-unrelated to sildenafil) sensitized doxorubicin-induced apoptosis in CRPC cells with deteriorating the down-regulation of anti-apoptotic Bcl-2 family members, including Bcl-xL and Mcl-1, and amplifying caspase activation. Sildenafil Citrate 27-37 BCL2 apoptosis regulator Homo sapiens 258-263 30653551-8 2019 PG exposure increased the levels of the pro-apoptotic proteins cleaved caspase-3, cleaved PARP, Bax, and Bad and a decreased level of the anti-apoptotic protein Bcl-2. Propyl Gallate 0-2 BCL2 apoptosis regulator Homo sapiens 161-166 30429232-5 2019 In addition, the release of cytochrome c, the activation of bax, and the inhibition of bcl-2 were observed in NCI-N87 cells treated with Colchicine. Colchicine 137-147 BCL2 apoptosis regulator Homo sapiens 87-92 30647404-4 2019 Venetoclax and A-1210477 bind and inhibit the antiapoptotic activity of BCL2 and MCL1, respectively, lowering the threshold for apoptosis. A-1210477 15-24 BCL2 apoptosis regulator Homo sapiens 72-76 30647404-5 2019 BETi treatment is shown here to perturb accessible chromatin and activity of enhancers/promoters, attenuating MYC, CDK6, MCL1 and BCL2, while inducing BIM, HEXIM1, CDKN1A expressions and apoptosis of AML cells. beti 0-4 BCL2 apoptosis regulator Homo sapiens 130-134 30651744-9 2019 Moreover, GA-13315 induced apoptosis through the mitochondrial apoptosis pathway by elevating the Bax/Bcl-2 ratio, releasing cytochrome c and activating caspase-9 in A549 cells. 13-chlorine-3,15-dioxy-gibberellic acid methyl ester 10-18 BCL2 apoptosis regulator Homo sapiens 102-107 30643111-10 2019 RTHF increased the expression of Bax and inhibited Bcl-2, pro-caspase3, and pro-caspase9 activity. rthf 0-4 BCL2 apoptosis regulator Homo sapiens 51-56 30634506-6 2019 The exposure of MCF-7 cells to paroxetine resulted in mitochondrion-mediated apoptosis, which is assessed by increase in the number of cells with sub-G1 DNA content, caspase-8/9 activation, poly (ADP-ribose) polymerase cleavage, and Bax/Bcl-2 ratio and a reduction in the mitochondrial membrane potential. Paroxetine 31-41 BCL2 apoptosis regulator Homo sapiens 237-242 30615617-9 2019 The results of Western blotting indicated the expressions of Bcl-2, procaspase-3, procaspase-8, procaspase-9, and PARP decreased in HepG2 cells treated with peiminine, while the expressions of Bax, caspase-3, caspase-8, caspase-9, and cleaved PARP1 increased. peiminine 157-166 BCL2 apoptosis regulator Homo sapiens 61-66 30625181-9 2019 Similarly, cholesterol treatment inverted metformin-reduced several gene expressions (e.g., Bcl-xL, BCL2, Zeb1, vimentin, and BMI-1). Metformin 42-51 BCL2 apoptosis regulator Homo sapiens 100-104 30625181-6 2019 Similarly, metformin treatment suppressed expressions of anti-apoptotic genes BCL2 and Bcl-xL, and mesenchymal genes vimentin, N-cadherin, Zeb1 and Zeb2 with simultaneous enhancement of apoptotic caspase 3 and Bax, and epithelial genes E-cadherin and keratin 19 expressions, confirming an inhibitory effect of metformin in tumorigenesis. Metformin 11-20 BCL2 apoptosis regulator Homo sapiens 78-82 30625181-9 2019 Similarly, cholesterol treatment inverted metformin-reduced several gene expressions (e.g., Bcl-xL, BCL2, Zeb1, vimentin, and BMI-1). Cholesterol 11-22 BCL2 apoptosis regulator Homo sapiens 100-104 30626126-3 2019 Furthermore, with the approval of the FMS-like tyrosine kinase 3 (FLT3) inhibitor Midostaurin a first targeted therapy has been introduced into the first-line therapy of younger patients with FLT3-mutated AML and several other small molecules targeting molecular alterations such as isocitrate dehydrogenase (IDH) mutations or the anti-apoptotic b-cell lymphoma 2 (BCL-2) protein are currently under investigation. midostaurin a 82-95 BCL2 apoptosis regulator Homo sapiens 346-363 30626126-3 2019 Furthermore, with the approval of the FMS-like tyrosine kinase 3 (FLT3) inhibitor Midostaurin a first targeted therapy has been introduced into the first-line therapy of younger patients with FLT3-mutated AML and several other small molecules targeting molecular alterations such as isocitrate dehydrogenase (IDH) mutations or the anti-apoptotic b-cell lymphoma 2 (BCL-2) protein are currently under investigation. midostaurin a 82-95 BCL2 apoptosis regulator Homo sapiens 365-370 30612454-11 2019 Bufalin increased the pro-apoptotic proteins Bax, and apoptotic associated proteins (cytochrome c, caspase-3, -8 and -9, AIF and Endo G) but reduced anti-apoptotic protein Bcl-2 in NPC-TW 076 cells. bufalin 0-7 BCL2 apoptosis regulator Homo sapiens 172-177 30322870-6 2019 The proapoptotic effect of copanlisib was associated with DLBCL subtype-specific dysregulated expression of BCL-2 family members including harakiri (HRK) and its antiapoptotic partner BCL extra large (BCL-xL), BCL2 related protein A1, myeloid cell leukemia 1 (MCL-1), and BCL2 interacting mediator of cell death. copanlisib 27-37 BCL2 apoptosis regulator Homo sapiens 108-113 30322870-6 2019 The proapoptotic effect of copanlisib was associated with DLBCL subtype-specific dysregulated expression of BCL-2 family members including harakiri (HRK) and its antiapoptotic partner BCL extra large (BCL-xL), BCL2 related protein A1, myeloid cell leukemia 1 (MCL-1), and BCL2 interacting mediator of cell death. copanlisib 27-37 BCL2 apoptosis regulator Homo sapiens 210-214 30322870-7 2019 Using functional BH3 profiling, we found that the cytotoxic activity of copanlisib was primarily mediated through BCL-xL and MCL-1-dependent mechanisms that might complement BCL-2 blockade. copanlisib 72-82 BCL2 apoptosis regulator Homo sapiens 174-179 30389635-6 2019 Celastrol induced apoptosis primarily via up-regulation of caspase-3, caspase-8, and Bax, and down-regulation of Bcl-2. celastrol 0-9 BCL2 apoptosis regulator Homo sapiens 113-118 30611710-2 2019 We also discovered that miR-15/16 are negative regulators of the BCL2 oncogene. mir-15 24-30 BCL2 apoptosis regulator Homo sapiens 65-69 30611710-4 2019 A corollary of this is that CLL is very sensitive to the anti BCL2 drug venetoclax that can induce complete remission in CLL patients. venetoclax 72-82 BCL2 apoptosis regulator Homo sapiens 62-66 30169424-8 2019 Bacillomycin D-C16-induced the mitochondrial pathway, as indicated by a reduced Bcl-2/Bax expression ratio, enhanced cytochrome C release, and higher levels of cleaved caspase-3. bacillomycin d-c16 0-18 BCL2 apoptosis regulator Homo sapiens 80-85 30398122-7 2019 Furthermore, western blot analysis showed that DMQ arrested cells at G2/M checkpoint by down-regulation of cyclin B1, cdc2 and cdc25c and up-regulation of p21, and induced cell apoptosis via affecting the ratio of Bax/Bcl-2, causing loss of the mitochondrial membrane potential and enhancing the expression of cleaved caspase-9 (C-caspase-9) and cleaved caspase-3 (C-caspase-3). 3,3'-di-O-methylquercetin 47-50 BCL2 apoptosis regulator Homo sapiens 218-223 30974967-10 2019 Moreover, TQ prevented APAP-induced hepatocytes apoptosis regulated by Bcl-2 and Bax. thymoquinone 10-12 BCL2 apoptosis regulator Homo sapiens 71-76 30987575-6 2019 RESULTS: Incubation of PANC-1 cells with L-kynurenine or L-tryptophan resulted in the increase in antiapoptotic cIAP-1, cIAP-2, XIAP and Bcl-2 expression and a decrease in pro-apoptotic Bax. Tryptophan 57-69 BCL2 apoptosis regulator Homo sapiens 137-142 31364516-13 2019 The antiproliferative action of carvacrol was correlated with apoptosis which was confirmed by nuclear condensation, FITC-Annexin V assay, modulation in expression of Bax, Bcl-2 and caspase activation. carvacrol 32-41 BCL2 apoptosis regulator Homo sapiens 172-177 30987575-9 2019 Incubation of the cells with AhR blocker either alone or together with L-kynurenine or L-tryptophan resulted in the opposite effect, leading to the downregulation of IAPs and Bcl-2, upregulation of Bax and caspases expression. Kynurenine 71-83 BCL2 apoptosis regulator Homo sapiens 175-180 30868965-0 2019 4t-CHQ a Spiro-Quinazolinone Benzenesulfonamide Derivative Induces G0/G1 Cell Cycle arrest and Triggers Apoptosis Through Down-Regulation of Survivin and Bcl2 in the Leukemia Stem-Like KG1-a Cells. 4t-chq a 0-8 BCL2 apoptosis regulator Homo sapiens 154-158 30868965-0 2019 4t-CHQ a Spiro-Quinazolinone Benzenesulfonamide Derivative Induces G0/G1 Cell Cycle arrest and Triggers Apoptosis Through Down-Regulation of Survivin and Bcl2 in the Leukemia Stem-Like KG1-a Cells. spiro-quinazolinone benzenesulfonamide 9-47 BCL2 apoptosis regulator Homo sapiens 154-158 30987575-9 2019 Incubation of the cells with AhR blocker either alone or together with L-kynurenine or L-tryptophan resulted in the opposite effect, leading to the downregulation of IAPs and Bcl-2, upregulation of Bax and caspases expression. Tryptophan 87-99 BCL2 apoptosis regulator Homo sapiens 175-180 30987575-3 2019 OBJECTIVE: The aim of this study was to investigate the changes within the apoptotic pathway in PANC-1 cells subjected to L-kynurenine or L-tryptophan considering the production of anti-apoptotic proteins from the IAPs and Bcl-2 family, as well as the regulation of NF-kappaB signaling. Kynurenine 122-134 BCL2 apoptosis regulator Homo sapiens 223-228 30987575-10 2019 CONCLUSION: 1) L-kynurenine and its precursor promote anti-apoptotic effects through the modulation of IDOdependent pathway and regulation of IAPs, Bcl-2 and NF-kappaB family members in pancreatic carcinoma cells 2) inhibition of AhR by CH223191 exerts an apoptosis-promoting effect, and this observation might suggest the potential use of this compound in pancreatic cancer therapy. Kynurenine 15-27 BCL2 apoptosis regulator Homo sapiens 148-153 30987575-3 2019 OBJECTIVE: The aim of this study was to investigate the changes within the apoptotic pathway in PANC-1 cells subjected to L-kynurenine or L-tryptophan considering the production of anti-apoptotic proteins from the IAPs and Bcl-2 family, as well as the regulation of NF-kappaB signaling. Tryptophan 138-150 BCL2 apoptosis regulator Homo sapiens 223-228 30987575-6 2019 RESULTS: Incubation of PANC-1 cells with L-kynurenine or L-tryptophan resulted in the increase in antiapoptotic cIAP-1, cIAP-2, XIAP and Bcl-2 expression and a decrease in pro-apoptotic Bax. Kynurenine 41-53 BCL2 apoptosis regulator Homo sapiens 137-142 30333377-6 2019 In the present study, the results revealed that polydatin induced the apoptosis of fibroblasts isolated from patients with AS by upregulating the expression of active caspase-3 and Bax, and downregulating the expression of Bcl-2. polydatin 48-57 BCL2 apoptosis regulator Homo sapiens 223-228 30414560-0 2019 TiF4 and NaF varnishes induce low levels of apoptosis in murine and human fibroblasts through mitochondrial Bcl-2 family and death receptor signalling. titanium tetrafluoride 0-4 BCL2 apoptosis regulator Homo sapiens 108-113 30414560-0 2019 TiF4 and NaF varnishes induce low levels of apoptosis in murine and human fibroblasts through mitochondrial Bcl-2 family and death receptor signalling. Sodium Fluoride 9-12 BCL2 apoptosis regulator Homo sapiens 108-113 29925224-5 2019 Shikonin increased mitochondrial membrane depolarization and altered the levels of apoptosis-related proteins, with a decrease in B cell lymphoma (Bcl)-2 and an increase in Bcl-2-associated X protein, and subsequently, increased expression of cleaved forms of caspase-9 and -3. shikonin 0-8 BCL2 apoptosis regulator Homo sapiens 130-153 29925224-5 2019 Shikonin increased mitochondrial membrane depolarization and altered the levels of apoptosis-related proteins, with a decrease in B cell lymphoma (Bcl)-2 and an increase in Bcl-2-associated X protein, and subsequently, increased expression of cleaved forms of caspase-9 and -3. shikonin 0-8 BCL2 apoptosis regulator Homo sapiens 173-178 30396091-0 2019 The impact of Keap1/Nrf2, P38MAPK/NF-kappaB and Bax/Bcl2/caspase-3 signaling pathways in the protective effects of berberine against methotrexate-induced nephrotoxicity. Berberine 115-124 BCL2 apoptosis regulator Homo sapiens 52-56 30551476-0 2019 MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2. mir-181b-5p 0-11 BCL2 apoptosis regulator Homo sapiens 84-89 30481956-7 2019 Furthermore, 7,8-DHF effectively modulated the expression of pro-apoptotic protein (Bax) and anti-apoptotic protein (Bcl-2) under high glucose, thus inhibiting the activation of caspase signaling pathways. 6,7-dihydroxyflavone 13-20 BCL2 apoptosis regulator Homo sapiens 117-122 30481956-7 2019 Furthermore, 7,8-DHF effectively modulated the expression of pro-apoptotic protein (Bax) and anti-apoptotic protein (Bcl-2) under high glucose, thus inhibiting the activation of caspase signaling pathways. Glucose 135-142 BCL2 apoptosis regulator Homo sapiens 117-122 30482548-5 2019 Furthermore, it was found that these three chalcones induced the mitochondrial apoptotic pathway by regulating Bax and Bcl-2 transcripts and by increasing caspase 3/7 activation. Chalcones 43-52 BCL2 apoptosis regulator Homo sapiens 119-124 30551489-7 2019 Moreover, icariin pretreatment significantly reduced cellular apoptosis via reduced levels of Bax, cleaved caspase-3/9, and increased anti-apoptotic protein Bcl-2 in the cells. icariin 10-17 BCL2 apoptosis regulator Homo sapiens 157-162 30551506-8 2019 ICA significantly suppressed cell viability in a dose-dependent manner and induced apoptosis by regulating Bcl-2, Bax and cleaced-Caspase-3/-9 expression in SW579 and TPC1 cells (p < 0.001). icariin 0-3 BCL2 apoptosis regulator Homo sapiens 107-112 30551476-0 2019 MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2. Temozolomide 58-70 BCL2 apoptosis regulator Homo sapiens 84-89 30551476-5 2019 Dual luciferase reporter assay, quantitative real-time PCR (qRT-PCR) and Western blotting were performed to demonstrate that miR-181b-5p directly targets Bcl-2 to reduce the expression. CHEMBL3740941 134-136 BCL2 apoptosis regulator Homo sapiens 154-159 31527329-5 2019 Additionally, cordycepin increased the Bax/Bcl-2 ratio and truncation of Bid, and destroyed the integrity of mitochondria, which contributed to the cytosolic release of cytochrome c. cordycepin 14-24 BCL2 apoptosis regulator Homo sapiens 43-48 30909183-12 2019 CONCLUSION: The results of this study demonstrate that ginsenoside inhibits proliferation and promotes apoptosis of human OS MG-63 and Saos-2 cells by reducing the expressions of beta-catenin, Bcl-2 and Cyclin D1 and increasing the expression of Bax and cleaved caspase-3. Ginsenosides 55-66 BCL2 apoptosis regulator Homo sapiens 193-198 31663349-5 2019 RESULTS: SIM caused Nrf2 over-activation (more localizations in the cellular nucleus), reduction in reactive oxygen species (ROS), induction of autophagy (decrease in p62 expression and increase in LC3II/LC3I ratio) and inhibition of apoptosis (decrease in Bax protein and increase in Bcl-2) in NSCs exposed to H2O2-induced oxidative stress, thereby prolonging the cell viability within 48 hours at low concentration (2 muM). Simvastatin 9-12 BCL2 apoptosis regulator Homo sapiens 285-290 31023040-4 2019 In addition, our data shown that the expression of Bcl-2 was decreased and the level of Bax was increased by lidocaine treatment. Lidocaine 109-118 BCL2 apoptosis regulator Homo sapiens 51-56 30614795-0 2019 The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer. Cisplatin 41-50 BCL2 apoptosis regulator Homo sapiens 13-18 30614795-0 2019 The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 95-98 BCL2 apoptosis regulator Homo sapiens 13-18 30614795-0 2019 The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer. Cisplatin 108-117 BCL2 apoptosis regulator Homo sapiens 13-18 30614795-3 2019 OBJECTIVE: The aim of the study is to investigate the role of Bcl-2 family proteins in predicting SCLC sensitivity to cisplatin treatment, and to identify the potential sensitizer of cisplatin or ratiation treatment in SCLC. Cisplatin 118-127 BCL2 apoptosis regulator Homo sapiens 62-67 30614795-4 2019 METHODS: We collected cisplatin sensitivity data from public available database, and evaluated its possible association with mRNA or protein expression of Bcl-2 family members in SCLC cell lines. Cisplatin 22-31 BCL2 apoptosis regulator Homo sapiens 155-160 30614795-5 2019 RESULTS: The IC50 value of cisplatin was significantly correlated with the ratio of Bcl-2/Bim mRNA expression in 33 SCLC cell lines (P= 0.041) as well as the ratio of Bcl-2/Bim protein expression in 7 SCLC cell lines (P= 0.0252). Cisplatin 27-36 BCL2 apoptosis regulator Homo sapiens 84-89 30614795-7 2019 The synergistic and additive antitumor activity of ABT-263 combined with cisplatin or radiation was associated with the enhanced apoptosis, which may be caused by the disruption of Bcl-2 binding to Bim by ABT-263. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 51-54 BCL2 apoptosis regulator Homo sapiens 181-186 30585547-8 2019 Further western blotting assay showed that the inhibitory effects of EH-42 on cell growth and survival were caused by activating caspase 3/9, suppressing the phospho-STAT3 (Tyr 705) and downregulating anti-apoptotic proteins like Bcl-2/Bcl-xL. eh-42 69-74 BCL2 apoptosis regulator Homo sapiens 230-235 30614795-7 2019 The synergistic and additive antitumor activity of ABT-263 combined with cisplatin or radiation was associated with the enhanced apoptosis, which may be caused by the disruption of Bcl-2 binding to Bim by ABT-263. Cisplatin 73-82 BCL2 apoptosis regulator Homo sapiens 181-186 30614795-7 2019 The synergistic and additive antitumor activity of ABT-263 combined with cisplatin or radiation was associated with the enhanced apoptosis, which may be caused by the disruption of Bcl-2 binding to Bim by ABT-263. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 205-208 BCL2 apoptosis regulator Homo sapiens 181-186 30614795-8 2019 CONCLUSIONS: Our study indicates that the ratio of Bcl-2/Bim could be a SCLC response predictor to cisplatin, and ABT-263 addition could be an effective strategy to improve the activity of chemo- or radio-therapy in SCLC. Cisplatin 99-108 BCL2 apoptosis regulator Homo sapiens 51-56 29666474-2 2019 The human iron-sulfur binding protein NAF-1/CISD2 binds to Bcl-2 and its disruption in cells leads to an increase in apoptosis. Iron 10-14 BCL2 apoptosis regulator Homo sapiens 59-64 29666474-2 2019 The human iron-sulfur binding protein NAF-1/CISD2 binds to Bcl-2 and its disruption in cells leads to an increase in apoptosis. Sulfur 15-21 BCL2 apoptosis regulator Homo sapiens 59-64 30224339-7 2019 RESULTS: We found that T-ALL are hypersensitive to navitoclax, an inhibitor of BCL2 family of antiapoptotic proteins. navitoclax 51-61 BCL2 apoptosis regulator Homo sapiens 79-83 30257981-6 2019 RESULTS: In cisplatin-resistant models, DISARM identified novel candidates including multiple inhibitors of PI3K, MEK, and BCL-2, among other classes, across unrelated malignancies. Cisplatin 12-21 BCL2 apoptosis regulator Homo sapiens 123-128 30244170-6 2019 Production of H2O2-induced reactive oxygen species (ROS), the Bax/Bcl-2 ratio, and the loss of mitochondrial membrane potential were all reversed by PDX, leading to improved cell viability and reduced release of lactate dehydrogenase (LDH). Hydrogen Peroxide 14-18 BCL2 apoptosis regulator Homo sapiens 66-71 30227824-8 2019 Administration of Trolox, carnosic acid and HCG increased the number of healthy cells and decreased the expression of Caspase-3 and Bax, but significantly increased the expression of Bcl-2 compared to the ischemic group. 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid 18-24 BCL2 apoptosis regulator Homo sapiens 183-188 30227824-8 2019 Administration of Trolox, carnosic acid and HCG increased the number of healthy cells and decreased the expression of Caspase-3 and Bax, but significantly increased the expression of Bcl-2 compared to the ischemic group. salvin 26-39 BCL2 apoptosis regulator Homo sapiens 183-188 30651835-6 2019 Finally, the apoptosis of H9c2 cardiomyocyte induced by hypoxia/reoxygenation was prevented by eriodictyol through upregulation of the expression of B-cell lymphoma-2 (Bcl-2) and downregulation of the expression levels of Bcl-2-associated X protein and caspase-3. eriodictyol 95-106 BCL2 apoptosis regulator Homo sapiens 149-166 30537571-5 2019 Concentrations >=20 muM cadmium induced apoptosis and led to intracellular changes including DNA fragmentation, reduced mRNA expression of antioxidant enzymes (i.e., catalase and glutathione S transferase-A4), downregulation of B-cell lymphoma 2 (Bcl-2), and upregulation of Bcl-2-associated X protein (Bax). Cadmium 27-34 BCL2 apoptosis regulator Homo sapiens 231-248 30537571-5 2019 Concentrations >=20 muM cadmium induced apoptosis and led to intracellular changes including DNA fragmentation, reduced mRNA expression of antioxidant enzymes (i.e., catalase and glutathione S transferase-A4), downregulation of B-cell lymphoma 2 (Bcl-2), and upregulation of Bcl-2-associated X protein (Bax). Cadmium 27-34 BCL2 apoptosis regulator Homo sapiens 250-255 30651824-7 2019 Propofol treatment increased the expression level of Bax and decreased that of Bcl-2. Propofol 0-8 BCL2 apoptosis regulator Homo sapiens 79-84 30651835-6 2019 Finally, the apoptosis of H9c2 cardiomyocyte induced by hypoxia/reoxygenation was prevented by eriodictyol through upregulation of the expression of B-cell lymphoma-2 (Bcl-2) and downregulation of the expression levels of Bcl-2-associated X protein and caspase-3. eriodictyol 95-106 BCL2 apoptosis regulator Homo sapiens 168-173 30651886-8 2019 Furthermore, western blot analysis revealed that in NSCLC cell lines, the combined treatment with gefitinib and ginsenoside Rg3 increased protein expression levels of pro-apoptotic proteins Bax and cleaved-caspase-3, whilst the expression level of anti-apoptotic protein Bcl-2 decreased. Gefitinib 98-107 BCL2 apoptosis regulator Homo sapiens 271-276 30651886-8 2019 Furthermore, western blot analysis revealed that in NSCLC cell lines, the combined treatment with gefitinib and ginsenoside Rg3 increased protein expression levels of pro-apoptotic proteins Bax and cleaved-caspase-3, whilst the expression level of anti-apoptotic protein Bcl-2 decreased. Ginsenosides 112-123 BCL2 apoptosis regulator Homo sapiens 271-276 30651835-6 2019 Finally, the apoptosis of H9c2 cardiomyocyte induced by hypoxia/reoxygenation was prevented by eriodictyol through upregulation of the expression of B-cell lymphoma-2 (Bcl-2) and downregulation of the expression levels of Bcl-2-associated X protein and caspase-3. eriodictyol 95-106 BCL2 apoptosis regulator Homo sapiens 222-227 30391273-7 2019 Whereas, AAS treated MCF-7 cells showed upregulation of Bax and downregulation of Bcl-2 gene expression. aas 9-12 BCL2 apoptosis regulator Homo sapiens 82-87 30657580-0 2019 Resveratrol protects against oxidative damage of retinal pigment epithelium cells by modulating SOD/MDA activity and activating Bcl-2 expression. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 128-133 30657580-13 2019 Resveratrol significantly enhanced Bcl-2 levels and decreased cleaved caspase 3 levels compared to that of H2O2 group (p<0.05). Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 35-40 30657580-14 2019 CONCLUSIONS: Resveratrol protected against the oxidative damage of RPE cells by modulating SOD/MDA activity and activating Bcl-2 expression. Resveratrol 13-24 BCL2 apoptosis regulator Homo sapiens 123-128 30458278-8 2019 Moreover, Bcl-2 was involved in Cd-induced autophagy. Cadmium 32-34 BCL2 apoptosis regulator Homo sapiens 10-15 30458278-0 2019 The interaction of Atg4B and Bcl-2 plays an important role in Cd-induced crosstalk between apoptosis and autophagy through disassociation of Bcl-2-Beclin1 in A549 cells. Cadmium 62-64 BCL2 apoptosis regulator Homo sapiens 29-34 30458278-0 2019 The interaction of Atg4B and Bcl-2 plays an important role in Cd-induced crosstalk between apoptosis and autophagy through disassociation of Bcl-2-Beclin1 in A549 cells. Cadmium 62-64 BCL2 apoptosis regulator Homo sapiens 141-146 30458278-10 2019 Taken together, our results demonstrated that the interaction of Atg4B and Bcl-2 might play an important role in Cd-induced crosstalk between apoptosis and autophagy through disassociation of Bcl-2-Beclin1. Cadmium 113-115 BCL2 apoptosis regulator Homo sapiens 75-80 30458278-10 2019 Taken together, our results demonstrated that the interaction of Atg4B and Bcl-2 might play an important role in Cd-induced crosstalk between apoptosis and autophagy through disassociation of Bcl-2-Beclin1. Cadmium 113-115 BCL2 apoptosis regulator Homo sapiens 192-197 30468635-5 2019 Moreover, fisetin attenuated rotenone induced toxicity by down-regulating Bax, caspases-3 protein expression and up-regulating protein expression of Bcl-2, p38/JNK-MAPK and PI3K, Akt, GSK-3beta pathways. fisetin 10-17 BCL2 apoptosis regulator Homo sapiens 149-154 30468657-6 2019 Meanwhile, nobiletin promoted oxaliplatin-induced apoptosis of CRC cells, as demonstrated by the increased expression of pro-apoptotic proteins (Bax and cleaved-caspse3) and the down-regulation of anti-apoptotic protein Bcl-2. nobiletin 11-20 BCL2 apoptosis regulator Homo sapiens 220-225 30468657-6 2019 Meanwhile, nobiletin promoted oxaliplatin-induced apoptosis of CRC cells, as demonstrated by the increased expression of pro-apoptotic proteins (Bax and cleaved-caspse3) and the down-regulation of anti-apoptotic protein Bcl-2. Oxaliplatin 30-41 BCL2 apoptosis regulator Homo sapiens 220-225 31084767-3 2019 Venetoclax, a BCL-2 inhibitor is a promising agent, as BCL-2 overexpression is present in 84% of acute myeloid leukemia patients at diagnosis and 95% of patients at relapse and has been associated with leukemia cell survival, chemotherapy resistance and poor prognosis. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 14-19 31746453-11 2019 The up-regulation of pro-apoptotic genes (CASP3, P53, BAX) and decreased expression of BCL2, respectively, was observed for all analyzed conditions with the highest differences for EP AuNPs and ELFEMF 50 mT/30 min in comparison to control cells. Gold 184-186 BCL2 apoptosis regulator Homo sapiens 87-91 31084767-3 2019 Venetoclax, a BCL-2 inhibitor is a promising agent, as BCL-2 overexpression is present in 84% of acute myeloid leukemia patients at diagnosis and 95% of patients at relapse and has been associated with leukemia cell survival, chemotherapy resistance and poor prognosis. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 55-60 30387805-7 2019 Additionally, resveratrol treatment decreased the protein expression levels of cyclin D1, cyclin E2 and BCL2 apoptosis regulator, while it increased BCL2 associated X and tumor protein p53, all of which are involved in the regulation of cell cycle and apoptosis. Resveratrol 14-25 BCL2 apoptosis regulator Homo sapiens 104-128 30426452-8 2019 Furthermore, LRRC8A downregulation inhibited TMZ-induced mitochondria-dependent apoptosis, including elevated Bcl-2 expression, reduced Bax expression, cytochrome c release, and caspase nine and caspase three activation. Temozolomide 45-48 BCL2 apoptosis regulator Homo sapiens 110-115 30657552-14 2019 Treatment with aclidinium bromide significantly increased cell apoptosis rate, accompanied by the expression of anti-apoptotic protein Bcl-2 decreased, the expression of pro-apoptotic protein Active caspase-3 and Bax significantly increased in U2 OS cells treated with aclidinium bromide. aclidinium bromide 15-33 BCL2 apoptosis regulator Homo sapiens 135-140 30365050-7 2019 Furthermore, decreased COX2 expression potentiated sesamin-induced apoptosis and G1-phase arrest, which was correlated with the suppression of gene products associated with cell apoptosis (Bcl-2 and Bax) and the cell cycle (cyclin E1). sesamin 51-58 BCL2 apoptosis regulator Homo sapiens 189-194 30387805-7 2019 Additionally, resveratrol treatment decreased the protein expression levels of cyclin D1, cyclin E2 and BCL2 apoptosis regulator, while it increased BCL2 associated X and tumor protein p53, all of which are involved in the regulation of cell cycle and apoptosis. Resveratrol 14-25 BCL2 apoptosis regulator Homo sapiens 104-108 30216505-9 2019 Taken together, our findings demonstrate, for the first time, that miR-503-5p can induce apoptosis of HPMECs under simulated microgravity through, at least in part, inhibiting the expression of Bcl-2. mir-503-5p 67-77 BCL2 apoptosis regulator Homo sapiens 194-199 29986023-9 2019 AWB led to increased Bcl-2, reduced cytochrome c and cleaved 85 kDa poly ADP-ribose polymerase apoptotic fragments. Antimycin A 0-3 BCL2 apoptosis regulator Homo sapiens 21-26 30373413-0 2019 Rhazyaminine from Rhazya stricta Inhibits Metastasis and Induces Apoptosis by Downregulating Bcl-2 Gene in MCF7 Cell Line. rhazyaminine 0-12 BCL2 apoptosis regulator Homo sapiens 93-98 30941981-10 2019 The Bax/Bcl-2 expression ratio was also altered upon gentiopicroside treatment. gentiopicroside 53-68 BCL2 apoptosis regulator Homo sapiens 8-13 30353642-4 2019 CUDC-907 inhibited PI3K/AKT and HDAC activity, as expected, but also suppressed RAF/MEK/ERK and STAT3 signalling and reduced the expression of anti-apoptotic BCL-2 family proteins BCL-2, BCL-xL, and MCL-1. CUDC-907 0-8 BCL2 apoptosis regulator Homo sapiens 158-163 30353642-4 2019 CUDC-907 inhibited PI3K/AKT and HDAC activity, as expected, but also suppressed RAF/MEK/ERK and STAT3 signalling and reduced the expression of anti-apoptotic BCL-2 family proteins BCL-2, BCL-xL, and MCL-1. CUDC-907 0-8 BCL2 apoptosis regulator Homo sapiens 180-185 30353642-8 2019 Indeed, combinations of low concentrations of CUDC-907 with inhibitors of BCL2, BTK, or the NF-kappaB pathway showed a potent synergistic effect. CUDC-907 46-54 BCL2 apoptosis regulator Homo sapiens 74-78 30431082-11 2019 Notably, ERp57-siRNA and 100 nM paclitaxel co-treatment downregulated Bcl-2, Bcl-xl, MMP2, MMP9, TUBB3 and P-gp expression levels and upregulated the expression of Bax protein. Paclitaxel 32-42 BCL2 apoptosis regulator Homo sapiens 70-75 30258223-3 2019 Herein, we performed an in vitro biology test and found that 4,4"-SAD stimulated the apoptosis of tumor cells in the human hepatocellular carcinoma cell lines PLC/PRF/5 and HuH-7 by activating caspase-3, caspase-8, caspase-9, PARP, p53, and cyclin B1, as well as by regulating the Bax/Bcl-2 ratio. 4,4"-sad 61-69 BCL2 apoptosis regulator Homo sapiens 285-290 30242876-5 2019 The apoptosis-related proteins p53, p21, Bax, and Bcl-2 in BGC-823 cells and mouse xenotransplant models treated with curcumin L6H4 were determined by Western blot analysis. curcumin l6h4 118-131 BCL2 apoptosis regulator Homo sapiens 50-55 30242876-6 2019 Curcumin L6H4 can significantly inhibit the proliferation and induce the apoptosis of BGC-823 cells, thus enhancing the expression levels of p53, p21, Bax, and Bcl-2 noticeably in vivo and in vitro. curcumin l6h4 0-13 BCL2 apoptosis regulator Homo sapiens 160-165 30806286-8 2019 ATRA inhibits Bcl-2, up-regulates Beclin-1 expression, and reduces induction of mTOR activation/phosphorylation in NB4 cells. Tretinoin 0-4 BCL2 apoptosis regulator Homo sapiens 14-19 30417527-6 2019 Moreover, western blot analysis showed that BA-induced apoptosis associated with increasing of pro-apoptotic protein Bax and cleaved caspase-3 and decreasing of anti-apoptotic protein Bcl-2. betulinic acid 44-46 BCL2 apoptosis regulator Homo sapiens 184-189 31378763-6 2019 Activated caspase-3, caspase-8 and caspase-9, along with a decreased Bcl-2/Bcl-x ratio and loss of mitochondrial membrane potential (Deltapsim), were observed in response to STA treatment. stephanthraniline A 174-177 BCL2 apoptosis regulator Homo sapiens 69-74 30726813-2 2019 MTBITC dose-dependently reduced cell viability and Bcl2 protein expression, while it induced cleavages of caspase-3, caspase-9, and PARP-1, suggesting that reduced cell viability occurred through the mitochondrial apoptotic pathway in KYSE510 cells. 4-(methylthio)-3-butenyl isothiocyanate 0-6 BCL2 apoptosis regulator Homo sapiens 51-55 30198798-7 2019 Moreover, the anti-apoptotic Bcl-2 protein was phosphorylated in G2/M phase, thereby increasing the cell susceptibility to DFMT. dfmt 123-127 BCL2 apoptosis regulator Homo sapiens 29-34 30535995-3 2019 BH3 motifs are present in antiapoptotic and proapoptotic BCL-2 homologs, and in a separate group of unrelated BH3-only proteins often appended to the BCL-2 family. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 57-62 28992684-9 2019 In contrast, paricalcitol treatment decreased Bax expression, increased Bcl-2 expression, and inhibited phosphorylation of MAPK, NF-kappaB p65, and Akt in HK-2 cells. paricalcitol 13-25 BCL2 apoptosis regulator Homo sapiens 72-77 29846950-5 2019 In the first section, the design and development of BCL-2/BCL-XL dual inhibitor navitoclax, as well as the recent advances and clinical experience with selective BCL-2 inhibitor venetoclax, were synopsized. venetoclax 178-188 BCL2 apoptosis regulator Homo sapiens 162-167 30725416-12 2019 AdMETase/SeMET therapy was effective against Bcl-2-overproducing A549 lung cancer cells, which were resistant to staurosporine-induced apoptosis, with a strong bystander effect. Staurosporine 113-126 BCL2 apoptosis regulator Homo sapiens 45-50 30535995-3 2019 BH3 motifs are present in antiapoptotic and proapoptotic BCL-2 homologs, and in a separate group of unrelated BH3-only proteins often appended to the BCL-2 family. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 150-155 30536001-7 2019 The liposomal permeabilization assay has been used to delineate interactions among BCL-2 family members as well as to characterize peptides, small molecules, and lipids that modulate the function of BCL-2 family of proteins. Peptides 131-139 BCL2 apoptosis regulator Homo sapiens 199-204 30536006-0 2019 Methods to Probe Calcium Regulation by BCL-2 Family Members. Calcium 17-24 BCL2 apoptosis regulator Homo sapiens 39-44 30536007-2 2019 The effector B-cell lymphoma 2 (BCL-2) antagonist killer (BAK) forms mitochondrial apoptotic pores to mediate MOMP. bakuchiol 58-61 BCL2 apoptosis regulator Homo sapiens 13-30 30536007-2 2019 The effector B-cell lymphoma 2 (BCL-2) antagonist killer (BAK) forms mitochondrial apoptotic pores to mediate MOMP. bakuchiol 58-61 BCL2 apoptosis regulator Homo sapiens 32-37 30536007-4 2019 Upon direct interactions with the BCL-2 homology 3 (BH3)-only proapoptotic proteins during apoptosis, BAK undergoes conformational changes to form the active species associated with apoptotic pores. bakuchiol 102-105 BCL2 apoptosis regulator Homo sapiens 34-39 30536012-0 2019 CW EPR and DEER Methods to Determine BCL-2 Family Protein Structure and Interactions: Application of Site-Directed Spin Labeling to BAK Apoptotic Pores. bakuchiol 132-135 BCL2 apoptosis regulator Homo sapiens 37-42 30347260-10 2019 Treatment with phenyl benzoxime markedly increased the expression of Bax, caspase-3 and p53 and decreased Bcl-2 mRNA. phenyl benzoxime 15-31 BCL2 apoptosis regulator Homo sapiens 106-111 30542709-7 2019 In addition, it was demonstrated that UDCA induced apoptosis of human melanoma M14 cells through the ROS-triggered mitochondrial-associated pathway, which was indicated by the increased expression of cleaved-caspase-3, cleaved-caspase-9, apoptotic protease activating factor-1, cleaved-poly (ADP-ribose) polymerase 1 and the elevation of B cell lymphoma-2 (Bcl-2) associated X protein/Bcl-2 ratio associated with apoptosis. Reactive Oxygen Species 101-104 BCL2 apoptosis regulator Homo sapiens 338-355 30320388-4 2019 In addition to cell cycle arrest, As2S2 also triggered the induction of apoptosis in cells by activating the expression of pro-apoptotic proteins, including caspase-7 and -8, as well as increasing the B-cell lymphoma 2 (Bcl-2)-associated X protein/Bcl-2 ratio, while decreasing the protein expression of anti-apoptotic B-cell lymphoma extra-large. Arsenic(II) sulfide 34-39 BCL2 apoptosis regulator Homo sapiens 201-218 30320388-4 2019 In addition to cell cycle arrest, As2S2 also triggered the induction of apoptosis in cells by activating the expression of pro-apoptotic proteins, including caspase-7 and -8, as well as increasing the B-cell lymphoma 2 (Bcl-2)-associated X protein/Bcl-2 ratio, while decreasing the protein expression of anti-apoptotic B-cell lymphoma extra-large. Arsenic(II) sulfide 34-39 BCL2 apoptosis regulator Homo sapiens 220-225 30663403-4 2019 In the present study we identified that the expression levels of Bcl-2, Bax, caspase 8, 9 and cyclinD1 using Q-PCR method in SKOV3 cell lines treated with Isochamanetin. Isochamanetin 155-168 BCL2 apoptosis regulator Homo sapiens 65-70 30663403-6 2019 Further the expression levels of Bcl-2, caspase8,9, Cytochrome C and CyclinD1 were significantly down regulated in SKOV3 cancer cells treated with isochamanetin, a specific binding molecule to CyclinD1. Isochamanetin 147-160 BCL2 apoptosis regulator Homo sapiens 33-38 30672332-9 2019 HC treatment decreased Bcl-2 expression, facilitated Bax expression. Hydrocortisone 0-2 BCL2 apoptosis regulator Homo sapiens 23-28 30542720-6 2019 Moreover, as shown using western blot analysis, the levels of p-AKT, p-GSK-3beta, Bcl-2, and cyclin D1 were decreased after AZD6482 treatment. 2-(1-(7-methyl-2-morpholin-4-yl-4-oxo-4H-pyrido(1,2-a)pyrimidin-9-yl)ethylamino)benzoic acid 124-131 BCL2 apoptosis regulator Homo sapiens 82-87 30320388-4 2019 In addition to cell cycle arrest, As2S2 also triggered the induction of apoptosis in cells by activating the expression of pro-apoptotic proteins, including caspase-7 and -8, as well as increasing the B-cell lymphoma 2 (Bcl-2)-associated X protein/Bcl-2 ratio, while decreasing the protein expression of anti-apoptotic B-cell lymphoma extra-large. Arsenic(II) sulfide 34-39 BCL2 apoptosis regulator Homo sapiens 248-253 30542709-7 2019 In addition, it was demonstrated that UDCA induced apoptosis of human melanoma M14 cells through the ROS-triggered mitochondrial-associated pathway, which was indicated by the increased expression of cleaved-caspase-3, cleaved-caspase-9, apoptotic protease activating factor-1, cleaved-poly (ADP-ribose) polymerase 1 and the elevation of B cell lymphoma-2 (Bcl-2) associated X protein/Bcl-2 ratio associated with apoptosis. Reactive Oxygen Species 101-104 BCL2 apoptosis regulator Homo sapiens 357-362 30542709-7 2019 In addition, it was demonstrated that UDCA induced apoptosis of human melanoma M14 cells through the ROS-triggered mitochondrial-associated pathway, which was indicated by the increased expression of cleaved-caspase-3, cleaved-caspase-9, apoptotic protease activating factor-1, cleaved-poly (ADP-ribose) polymerase 1 and the elevation of B cell lymphoma-2 (Bcl-2) associated X protein/Bcl-2 ratio associated with apoptosis. Reactive Oxygen Species 101-104 BCL2 apoptosis regulator Homo sapiens 385-390 30655755-9 2019 Compared with those in the puerarin group, the apoptosis rate in the combination group was decreased, and the expression level of apoptosis-related protein Bax was also significantly decreased, but the expression level of Bcl-2 was increased, and SIRT1 and p53 protein expression levels were also remarkably increased. puerarin 27-35 BCL2 apoptosis regulator Homo sapiens 222-227 30655858-9 2019 Additionally, it was observed that, when compared with Taxol treatment, the combination of Taxol and antagomiR-1207-5p induced a sharp decrease in B-cell lymphoma 2 (Bcl-2) and phosphorylated-protein kinase B expression accompanied by an increase in the Bcl-2-associated X protein expression. Paclitaxel 91-96 BCL2 apoptosis regulator Homo sapiens 147-164 30655768-7 2019 Following CTPG-W treatment, the Deltapsim of Eca-109 was notably decreased, which is associated with the upregulated levels of B-cell lymphoma-2 (Bcl-2)-associated X and downregulated levels of Bcl-2. ctpg-w 10-16 BCL2 apoptosis regulator Homo sapiens 127-144 30655768-7 2019 Following CTPG-W treatment, the Deltapsim of Eca-109 was notably decreased, which is associated with the upregulated levels of B-cell lymphoma-2 (Bcl-2)-associated X and downregulated levels of Bcl-2. ctpg-w 10-16 BCL2 apoptosis regulator Homo sapiens 146-151 30655768-7 2019 Following CTPG-W treatment, the Deltapsim of Eca-109 was notably decreased, which is associated with the upregulated levels of B-cell lymphoma-2 (Bcl-2)-associated X and downregulated levels of Bcl-2. ctpg-w 10-16 BCL2 apoptosis regulator Homo sapiens 194-199 30655812-3 2019 miR-153 upregulation observably decreased cell viability, induced apoptosis, increased caspase-3 and -9 activity, and increased the B-cell lymphoma 2 (Bcl-2)-associated X protein/Bcl-2 protein expression ratio in 13-9B cells. mir-153 0-7 BCL2 apoptosis regulator Homo sapiens 132-149 30655812-3 2019 miR-153 upregulation observably decreased cell viability, induced apoptosis, increased caspase-3 and -9 activity, and increased the B-cell lymphoma 2 (Bcl-2)-associated X protein/Bcl-2 protein expression ratio in 13-9B cells. mir-153 0-7 BCL2 apoptosis regulator Homo sapiens 151-156 30655812-3 2019 miR-153 upregulation observably decreased cell viability, induced apoptosis, increased caspase-3 and -9 activity, and increased the B-cell lymphoma 2 (Bcl-2)-associated X protein/Bcl-2 protein expression ratio in 13-9B cells. mir-153 0-7 BCL2 apoptosis regulator Homo sapiens 179-184 30655812-5 2019 TGF-beta2 inhibitor enhanced the effect of miR-153 upregulation on the inhibition of cell viability, induction of apoptosis, increase in caspase-3 and -9 activity, and increase in Bax/Bcl-2 protein expression ratio in 13-9B cells. mir-153 43-50 BCL2 apoptosis regulator Homo sapiens 184-189 30655858-9 2019 Additionally, it was observed that, when compared with Taxol treatment, the combination of Taxol and antagomiR-1207-5p induced a sharp decrease in B-cell lymphoma 2 (Bcl-2) and phosphorylated-protein kinase B expression accompanied by an increase in the Bcl-2-associated X protein expression. Paclitaxel 91-96 BCL2 apoptosis regulator Homo sapiens 166-171 30655858-9 2019 Additionally, it was observed that, when compared with Taxol treatment, the combination of Taxol and antagomiR-1207-5p induced a sharp decrease in B-cell lymphoma 2 (Bcl-2) and phosphorylated-protein kinase B expression accompanied by an increase in the Bcl-2-associated X protein expression. Paclitaxel 91-96 BCL2 apoptosis regulator Homo sapiens 254-259 30594131-7 2018 Combined treatment with shikonin and TRAIL activated the caspase and JNK pathways, inhibited the STAT3 and AKT pathways, downregulated the expression of Mcl-1, Bcl-2, Bcl-xL, c-FLIP and XIAP and upregulated the expression of Bid. shikonin 24-32 BCL2 apoptosis regulator Homo sapiens 160-165 31039578-12 2019 The Bcl-2/Bax expression ratio was decreased and the caspases-3 and 9 were activated upon chrysophanol treatment of the CH157-MN cells. chrysophanic acid 90-102 BCL2 apoptosis regulator Homo sapiens 4-9 30599890-11 2019 In addition, both curcumin and quercetin induced apoptosis by down-regulating BCL2 and inducing caspase 3/7 through PARP cleavage. Curcumin 18-26 BCL2 apoptosis regulator Homo sapiens 78-82 30599890-11 2019 In addition, both curcumin and quercetin induced apoptosis by down-regulating BCL2 and inducing caspase 3/7 through PARP cleavage. Quercetin 31-40 BCL2 apoptosis regulator Homo sapiens 78-82 30599894-0 2019 Antimalarial Dihydroartemisinin triggers autophagy within HeLa cells of human cervical cancer through Bcl-2 phosphorylation at Ser70. artenimol 13-31 BCL2 apoptosis regulator Homo sapiens 102-107 30599894-8 2019 Interestingly, we firstly demonstrated that DHA induced autophagy through promotion of the phosphorylation of Bcl-2 (Ser70), independent of the phosphorylated JNK1/2 (Thr183/Tyr185). artenimol 44-47 BCL2 apoptosis regulator Homo sapiens 110-115 30599894-11 2019 CONCLUSION: Therefore, DHA upregulates the phosphorylation of Bcl-2 (Ser70) and mTOR (Ser2448) and induces autophagic cell death in Hela cells. artenimol 23-26 BCL2 apoptosis regulator Homo sapiens 62-67 30528428-4 2019 Regarding apoptosis, expression of the anti-apoptotic gene Bcl-2 mRNA was greater at 1 x 10-8 and 1 x 10-9 M BPA and was down-regulated at 1 x 10-4 to 1 x 10-7 M BPA; however, expression of pro-apoptotic genes (Bax, cathepsin B, caspase-3 and c-myc) was reduced at the higher concentrations of BPA. bisphenol A 109-112 BCL2 apoptosis regulator Homo sapiens 59-64 30528428-4 2019 Regarding apoptosis, expression of the anti-apoptotic gene Bcl-2 mRNA was greater at 1 x 10-8 and 1 x 10-9 M BPA and was down-regulated at 1 x 10-4 to 1 x 10-7 M BPA; however, expression of pro-apoptotic genes (Bax, cathepsin B, caspase-3 and c-myc) was reduced at the higher concentrations of BPA. bisphenol A 162-165 BCL2 apoptosis regulator Homo sapiens 59-64 31434088-4 2019 We found that EGCG significantly inhibited PGE2 and EP1-selective agonist induced migration of HCC cells and increased the ratio of Bax/Bcl-2 even in the presence of ONO-DI-004 or PGE2. epigallocatechin gallate 14-18 BCL2 apoptosis regulator Homo sapiens 136-141 30528428-4 2019 Regarding apoptosis, expression of the anti-apoptotic gene Bcl-2 mRNA was greater at 1 x 10-8 and 1 x 10-9 M BPA and was down-regulated at 1 x 10-4 to 1 x 10-7 M BPA; however, expression of pro-apoptotic genes (Bax, cathepsin B, caspase-3 and c-myc) was reduced at the higher concentrations of BPA. bisphenol A 162-165 BCL2 apoptosis regulator Homo sapiens 59-64 30809279-4 2019 Paclitaxel exerts anti-cancer effects but, paradoxically, exacerbates cancer metastasis and drug resistance by increasing the expression of apoptotic B-cell lymphoma-2 protein (BCL-2). Paclitaxel 0-10 BCL2 apoptosis regulator Homo sapiens 150-175 30809279-4 2019 Paclitaxel exerts anti-cancer effects but, paradoxically, exacerbates cancer metastasis and drug resistance by increasing the expression of apoptotic B-cell lymphoma-2 protein (BCL-2). Paclitaxel 0-10 BCL2 apoptosis regulator Homo sapiens 177-182 30809279-5 2019 Thus, low-molecular-weight heparin-coated lipid-siRNA complex (LH-Lip/siBCL-2) was constructed to inhibit cancer metastasis and silence BCL-2 by BCL-2 siRNA (siBCL-2). Heparin 27-34 BCL2 apoptosis regulator Homo sapiens 72-77 30809279-5 2019 Thus, low-molecular-weight heparin-coated lipid-siRNA complex (LH-Lip/siBCL-2) was constructed to inhibit cancer metastasis and silence BCL-2 by BCL-2 siRNA (siBCL-2). Heparin 27-34 BCL2 apoptosis regulator Homo sapiens 136-141 30218747-0 2018 Targeting apoptosis by 1,2-diazole through regulation of EGFR, Bcl-2 and CDK-2 mediated signaling pathway in human non-small cell lung carcinoma A549 cells. pyrazole 23-34 BCL2 apoptosis regulator Homo sapiens 63-68 30218747-4 2018 In the present study the anti-cancer mechanism of pyrazole, was examined by the expression level of proteins Epidermal growth factor receptor (EGFR), Bcl-2-associated X protein (Bax), B-cell lymphoma-2 (Bcl-2) and Cyclin-dependent kinase-2 (CDK-2) which are commonly associated with the cell signaling pathways that control cell survival and apoptosis, that could facilitate to develop a novel target and effective treatment approach for patients with NSCLC. pyrazole 50-58 BCL2 apoptosis regulator Homo sapiens 184-201 30218747-4 2018 In the present study the anti-cancer mechanism of pyrazole, was examined by the expression level of proteins Epidermal growth factor receptor (EGFR), Bcl-2-associated X protein (Bax), B-cell lymphoma-2 (Bcl-2) and Cyclin-dependent kinase-2 (CDK-2) which are commonly associated with the cell signaling pathways that control cell survival and apoptosis, that could facilitate to develop a novel target and effective treatment approach for patients with NSCLC. pyrazole 50-58 BCL2 apoptosis regulator Homo sapiens 150-155 30218747-6 2018 Pyrazole disrupts the mitochondrial membrane potential and modulated the protein levels of Bax and Bcl-2 which could probably lead to caspase-3 activation. pyrazole 0-8 BCL2 apoptosis regulator Homo sapiens 99-104 30587839-10 2018 In addition, honokiol promoted apoptosis and reduced Bcl-2 expression, accompanied by increase in Bax expression. honokiol 13-21 BCL2 apoptosis regulator Homo sapiens 53-58 30580326-5 2018 The effects of naringin, which included downregulation of Cyclin D1, MMP2, and bcl-2, where reproduced by siRNA-mediated Zeb1 silencing, whereas Zeb1 overexpression increased proliferation, migration, and Cyclin D1, MMP2, and bcl-2 levels. naringin 15-23 BCL2 apoptosis regulator Homo sapiens 79-84 30580326-5 2018 The effects of naringin, which included downregulation of Cyclin D1, MMP2, and bcl-2, where reproduced by siRNA-mediated Zeb1 silencing, whereas Zeb1 overexpression increased proliferation, migration, and Cyclin D1, MMP2, and bcl-2 levels. naringin 15-23 BCL2 apoptosis regulator Homo sapiens 226-231 30267303-0 2019 Rab14 overexpression regulates gemcitabine sensitivity through regulation of Bcl-2 and mitochondrial function in pancreatic cancer. gemcitabine 31-42 BCL2 apoptosis regulator Homo sapiens 77-82 30309889-0 2018 BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 49-53 30309889-1 2018 BH3 mimetics are promising drugs for hematologic malignancies that trigger cell death by promoting the release of proapoptotic BCL2 family members from antiapoptotic proteins. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 127-131 30572618-0 2018 Synergistic AML Cell Death Induction by Marine Cytotoxin (+)-1(R), 6(S), 1"(R), 6"(S), 11(R), 17(S)-Fistularin-3 and Bcl-2 Inhibitor Venetoclax. venetoclax 133-143 BCL2 apoptosis regulator Homo sapiens 117-122 30589838-8 2018 Interestingly, the combination of ascorbic acid (vitamin C) and alpha-tocopherol (vitamin E) supplementation attenuated the decrease in B-cell lymphoma 2 (Bcl-2) at 24 hours following acute downhill running. Ascorbic Acid 34-47 BCL2 apoptosis regulator Homo sapiens 136-153 30534799-5 2018 Furthermore, crotonol A promoted the apoptosis of K562 cells through the cleavage of PARP and the accumulation of bax as well as the degradation of bcl-2. crotonol a 13-23 BCL2 apoptosis regulator Homo sapiens 148-153 30589838-8 2018 Interestingly, the combination of ascorbic acid (vitamin C) and alpha-tocopherol (vitamin E) supplementation attenuated the decrease in B-cell lymphoma 2 (Bcl-2) at 24 hours following acute downhill running. Ascorbic Acid 34-47 BCL2 apoptosis regulator Homo sapiens 155-160 30589838-8 2018 Interestingly, the combination of ascorbic acid (vitamin C) and alpha-tocopherol (vitamin E) supplementation attenuated the decrease in B-cell lymphoma 2 (Bcl-2) at 24 hours following acute downhill running. Ascorbic Acid 49-58 BCL2 apoptosis regulator Homo sapiens 136-153 30589838-8 2018 Interestingly, the combination of ascorbic acid (vitamin C) and alpha-tocopherol (vitamin E) supplementation attenuated the decrease in B-cell lymphoma 2 (Bcl-2) at 24 hours following acute downhill running. Ascorbic Acid 49-58 BCL2 apoptosis regulator Homo sapiens 155-160 30589838-8 2018 Interestingly, the combination of ascorbic acid (vitamin C) and alpha-tocopherol (vitamin E) supplementation attenuated the decrease in B-cell lymphoma 2 (Bcl-2) at 24 hours following acute downhill running. alpha-Tocopherol 64-80 BCL2 apoptosis regulator Homo sapiens 136-153 30589838-8 2018 Interestingly, the combination of ascorbic acid (vitamin C) and alpha-tocopherol (vitamin E) supplementation attenuated the decrease in B-cell lymphoma 2 (Bcl-2) at 24 hours following acute downhill running. alpha-Tocopherol 64-80 BCL2 apoptosis regulator Homo sapiens 155-160 30589838-8 2018 Interestingly, the combination of ascorbic acid (vitamin C) and alpha-tocopherol (vitamin E) supplementation attenuated the decrease in B-cell lymphoma 2 (Bcl-2) at 24 hours following acute downhill running. Vitamin E 82-91 BCL2 apoptosis regulator Homo sapiens 136-153 30589838-8 2018 Interestingly, the combination of ascorbic acid (vitamin C) and alpha-tocopherol (vitamin E) supplementation attenuated the decrease in B-cell lymphoma 2 (Bcl-2) at 24 hours following acute downhill running. Vitamin E 82-91 BCL2 apoptosis regulator Homo sapiens 155-160 30584254-7 2018 Notably, midostaurin promoted apoptosis by reducing the phosphorylation of PKC and consequently of downstream Bad, Bcl-2 and NF-kappaB. midostaurin 9-20 BCL2 apoptosis regulator Homo sapiens 115-120 30588027-0 2019 Methotrexate-induced apoptosis in human ovarian adenocarcinoma SKOV-3 cells via ROS-mediated bax/bcl-2-cyt-c release cascading. Methotrexate 0-12 BCL2 apoptosis regulator Homo sapiens 97-102 30588027-0 2019 Methotrexate-induced apoptosis in human ovarian adenocarcinoma SKOV-3 cells via ROS-mediated bax/bcl-2-cyt-c release cascading. Reactive Oxygen Species 80-83 BCL2 apoptosis regulator Homo sapiens 97-102 30562977-6 2018 Furthermore, tectorigenin inhibited apoptosis by reducing caspase-3- and Bcl-2-associated protein-X levels, and increasing Bcl-2 protein levels. tectorigenin 13-25 BCL2 apoptosis regulator Homo sapiens 73-78 30537511-5 2018 The BCL-2 inhibitor venetoclax has been approved for treatment of refractory chronic lymphocytic leukemia and this drug and inhibitors of pro-survival MCL-1 and BCL-XL are being tested in diverse malignancies. venetoclax 20-30 BCL2 apoptosis regulator Homo sapiens 4-9 30588012-0 2018 Resveratrol induces apoptosis in human melanoma cell through negatively regulating Erk/PKM2/Bcl-2 axis. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 92-97 30588012-10 2018 Additionally, we found that resveratrol downregulated antiapoptotic protein Bcl-2 and activated Bax in the protein levels by promoting Bcl-2 degradation and cytochrome c release. Resveratrol 28-39 BCL2 apoptosis regulator Homo sapiens 76-81 30588012-10 2018 Additionally, we found that resveratrol downregulated antiapoptotic protein Bcl-2 and activated Bax in the protein levels by promoting Bcl-2 degradation and cytochrome c release. Resveratrol 28-39 BCL2 apoptosis regulator Homo sapiens 135-140 30588012-11 2018 Moreover, we discovered that PKM2, had a key role in cell apoptosis triggered by resveratrol through interacting with Bcl-2. Resveratrol 81-92 BCL2 apoptosis regulator Homo sapiens 118-123 30588012-12 2018 Based on these results, we overexpressed PKM2 in melanoma cells and found that this prevented resveratrol-induced apoptosis by stabilizing the protein level of Bcl-2. Resveratrol 94-105 BCL2 apoptosis regulator Homo sapiens 160-165 30588012-13 2018 Conclusion: Taken together, our results provided a novel mechanism accounting for the apoptosis induction of resveratrol in melanoma cells and suggested that downregulating Erk/PKM2/Bcl-2 axis appears to be a new approach for the prevention or treatment of melanoma. Resveratrol 109-120 BCL2 apoptosis regulator Homo sapiens 182-187 30132682-7 2018 The relative expression of BAX, as a proapoptotic marker, was similar between all the groups, whereas the relative expression of BCL2 as an antiapoptotic marker was significantly higher in the Y-26732- group. y-26732 193-200 BCL2 apoptosis regulator Homo sapiens 129-133 30458987-7 2018 Inhibition of exosomal miR-214 with antagomir reversed gefitinib resistance conferred by PC-9GR-derived exosomes in vitro, which was confirmed by flow cytometry analysis and westernblot of apoptotic protein (caspase-3, caspase-3 cleaved, bax) and anti-apoptotic protein (bcl-2). Gefitinib 55-64 BCL2 apoptosis regulator Homo sapiens 271-276 30563080-3 2018 Obatoclax, a BH3 mimetic of the Bcl-2 family of proteins, antagonizes Mcl-1 and hence may reverse paclitaxel resistance in Mcl-1-overexpressing tumors. BH 3 13-16 BCL2 apoptosis regulator Homo sapiens 32-37 30563080-3 2018 Obatoclax, a BH3 mimetic of the Bcl-2 family of proteins, antagonizes Mcl-1 and hence may reverse paclitaxel resistance in Mcl-1-overexpressing tumors. Paclitaxel 98-108 BCL2 apoptosis regulator Homo sapiens 32-37 30387987-5 2018 The ARPI-derived bioactive peptides exhibit synergistic anticancer effect with DOX by regulating pro- and antiapoptotic-relevant proteins ( p53, Bax, Bcl-2, pro-caspase-3) at mitochondria. Doxorubicin 79-82 BCL2 apoptosis regulator Homo sapiens 150-155 29186971-5 2018 Studies have thus identified (onco)proteins (Bcl-2, STAT3/5, RAS, Rac1, and Myc) in manipulating ROS level as well as exploiting an altered redox environment to create a milieu conducive for cancer formation and progression. Reactive Oxygen Species 97-100 BCL2 apoptosis regulator Homo sapiens 45-50 30466743-2 2018 This year, 2018, already has seen the regulatory approval of the BCL2 inhibitor venetoclax in the form of breakthrough designation and the IDH1 inhibitor ivosidenib received full FDA approval. venetoclax 80-90 BCL2 apoptosis regulator Homo sapiens 65-69 30372822-6 2018 Moreover, OP-B induced apoptosis by inhibiting the expression of Bax and cleaved caspase 3 and promoting the expression of Bcl-2. ophiopogonin B 10-14 BCL2 apoptosis regulator Homo sapiens 123-128 30212708-7 2018 The study showed that the high (100 muM) and low (100 nM and 10muM) rutin concentrations significantly avert ROS generation by two different mechanisms, by enhancing apoptosis through the modulation of levels of Bcl2, Caspase-3, survivin and its antioxidant activity via stress-related proteins, JNK and p38 MAPK. Rutin 68-73 BCL2 apoptosis regulator Homo sapiens 212-216 30088260-14 2018 Finally, we found that metformin may modulate the pro-apoptotic Bax, anti-apoptotic Bcl-2, MMP-2, MMP-9, miR-21 and miR-155 expression levels. Metformin 23-32 BCL2 apoptosis regulator Homo sapiens 84-89 30254092-4 2018 Susceptibility to BH3 mimetics that target either MCL1 or BCL-xL was determined by the differential binding of proapoptotic BCL2 proteins to MCL1 or BCL-xL, respectively. BH 3 18-21 BCL2 apoptosis regulator Homo sapiens 124-128 30254092-6 2018 This suggests a novel strategy for integrating BH3 mimetics that target different BCL2 family proteins for KRAS-mutant NSCLC. BH 3 47-50 BCL2 apoptosis regulator Homo sapiens 82-86 30185627-2 2018 Induced myeloid leukemia cell differentiation protein (MCL1), an antiapoptotic BCL2 family member, is commonly upregulated in AML cells and is often a primary mode of resistance to treatment with the BCL2 inhibitor venetoclax. venetoclax 215-225 BCL2 apoptosis regulator Homo sapiens 79-83 30185627-2 2018 Induced myeloid leukemia cell differentiation protein (MCL1), an antiapoptotic BCL2 family member, is commonly upregulated in AML cells and is often a primary mode of resistance to treatment with the BCL2 inhibitor venetoclax. venetoclax 215-225 BCL2 apoptosis regulator Homo sapiens 200-204 30185627-5 2018 Importantly, BH3 profiling of patient samples and drug-sensitivity testing ex vivo accurately predicted cellular responses to selective inhibitors of MCL1 or BCL2 and showed benefit of the combination. BH 3 13-16 BCL2 apoptosis regulator Homo sapiens 158-162 30510014-1 2018 Unleashing blocked apoptosis has emerged as an important tool in treating cancer as shown by the recent success of the BCL2 inhibitor venetoclax. venetoclax 134-144 BCL2 apoptosis regulator Homo sapiens 119-123 30603674-11 2018 Compared to cells treated without NAC under hypoxia, the Bcl-2/Bax ratio increased significantly in cells treated with NAC. Acetylcysteine 34-37 BCL2 apoptosis regulator Homo sapiens 57-62 30603674-11 2018 Compared to cells treated without NAC under hypoxia, the Bcl-2/Bax ratio increased significantly in cells treated with NAC. Acetylcysteine 119-122 BCL2 apoptosis regulator Homo sapiens 57-62 30125771-12 2018 Results of Immunohistochemistry indicated that GNA-PEG-LPs significantly suppressed the expression of Bcl-2 and increased the expression of Bax and caspase-3 compared with free GNA. gna-peg-lps 47-58 BCL2 apoptosis regulator Homo sapiens 102-107 30097856-5 2018 Furthermore, Se-beta-Lg suppressed the expression of Bcl-2 and improved the level of Bax, leading to the release of cytochrome c and a higher expression of caspase-3 in A549 cells. se-beta-lg 13-23 BCL2 apoptosis regulator Homo sapiens 53-58 29742927-5 2018 Furthermore, the pro-apoptotic signalling pathway induced by tetracaine was explored through detecting the activation of various caspases, the changes of mitochondrial transmembrane potential (MTP), the expression level of Bcl-2 family proteins and the amount of mitochondria-released apoptosis regulating proteins in cytoplasm. Tetracaine 61-71 BCL2 apoptosis regulator Homo sapiens 223-228 29742927-8 2018 Tetracaine not only resulted in caspase-3, caspase-8 and caspase-9 activation and disruption of MTP but also downregulated Bcl-2 and Bcl-xL and upregulated Bad and Bax, along with the upregulation of cytoplasmic cytochrome c (Cyt. Tetracaine 0-10 BCL2 apoptosis regulator Homo sapiens 123-128 29742927-10 2018 CONCLUSIONS: These results suggested that tetracaine-induced apoptosis might be triggered through Fas death receptors and mediated by Bcl-2 family proteins in the mitochondria-dependent pathway. Tetracaine 42-52 BCL2 apoptosis regulator Homo sapiens 134-139 30469054-4 2018 The present study reports the identification of novel Aplysin analogs as BCL-2 inhibitors from a sequential virtual screening approach using drug-like, ADMET, docking, pharmacophore filters and molecular dynamics simulation. admet 152-157 BCL2 apoptosis regulator Homo sapiens 73-78 30527922-7 2018 The kinase inhibitor idelalisib (plus rituximab) and the bcl2 inhibitor venetoclax are other novel compounds, which showed great efficacy in relapsed CLL even in unfit patients. venetoclax 72-82 BCL2 apoptosis regulator Homo sapiens 57-61 30329161-3 2018 We designed a novel thiazole-based molecule, 4-(dimethylamino)-2-(p-tolylamino) thiazole-5-carbonitrile, which showed potent in vitro anticancer effect against targeted Bcl-2 Jurkat cell-line quantified using 3-(4, 5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Thiazoles 20-28 BCL2 apoptosis regulator Homo sapiens 169-174 30329161-3 2018 We designed a novel thiazole-based molecule, 4-(dimethylamino)-2-(p-tolylamino) thiazole-5-carbonitrile, which showed potent in vitro anticancer effect against targeted Bcl-2 Jurkat cell-line quantified using 3-(4, 5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. 4-(dimethylamino)-2-(p-tolylamino) thiazole-5-carbonitrile 45-103 BCL2 apoptosis regulator Homo sapiens 169-174 30329161-3 2018 We designed a novel thiazole-based molecule, 4-(dimethylamino)-2-(p-tolylamino) thiazole-5-carbonitrile, which showed potent in vitro anticancer effect against targeted Bcl-2 Jurkat cell-line quantified using 3-(4, 5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. 3-(4, 5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide 209-270 BCL2 apoptosis regulator Homo sapiens 169-174 30329161-3 2018 We designed a novel thiazole-based molecule, 4-(dimethylamino)-2-(p-tolylamino) thiazole-5-carbonitrile, which showed potent in vitro anticancer effect against targeted Bcl-2 Jurkat cell-line quantified using 3-(4, 5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. monooxyethylene trimethylolpropane tristearate 272-275 BCL2 apoptosis regulator Homo sapiens 169-174 30575919-10 2018 Meanwhile, overexpression of miR-128 promoted the apoptosis of U87 cells, upregulated protein levels of cleaved Caspase-3 and BCL2-associated X (Bax), and downregulated B-cell lymphoma-2 (Bcl-2). mir-128 29-36 BCL2 apoptosis regulator Homo sapiens 169-186 30575919-10 2018 Meanwhile, overexpression of miR-128 promoted the apoptosis of U87 cells, upregulated protein levels of cleaved Caspase-3 and BCL2-associated X (Bax), and downregulated B-cell lymphoma-2 (Bcl-2). mir-128 29-36 BCL2 apoptosis regulator Homo sapiens 188-193 30542399-11 2018 The mechanism may be through the impact of ROS levels, thereby affecting the p-AMPK and Bcl2/Bax expression. Reactive Oxygen Species 43-46 BCL2 apoptosis regulator Homo sapiens 88-92 30428277-2 2018 Venetoclax (ABT-199) is a BCL-2 inhibitor recently approved by the US food and drug administration for treatment of chronic lymphocytic leukemia but the drug has shown activity in a number of hematological malignancies. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 26-31 30428277-2 2018 Venetoclax (ABT-199) is a BCL-2 inhibitor recently approved by the US food and drug administration for treatment of chronic lymphocytic leukemia but the drug has shown activity in a number of hematological malignancies. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 12-15 BCL2 apoptosis regulator Homo sapiens 26-31 31949673-0 2018 Knockdown of PHGDH potentiates 5-FU cytotoxicity in gastric cancer cells via the Bcl-2/Bax/caspase-3 signaling pathway. Fluorouracil 31-35 BCL2 apoptosis regulator Homo sapiens 81-86 30546402-0 2018 Oridonin enhances the radiosensitivity of lung cancer cells by upregulating Bax and downregulating Bcl-2. oridonin 0-8 BCL2 apoptosis regulator Homo sapiens 99-104 30546402-6 2018 The results demonstrated that the level of Bax was increased and the level of Bcl-2 was decreased in SPC-A-1 cells treated with oridonin and irradiation compared with the group that received irradiation alone. oridonin 128-136 BCL2 apoptosis regulator Homo sapiens 78-83 29658330-6 2018 In HepG2 cells, apoptosis was documented by finding that ROS triggered a decrease in mitochondrial membrane potential, an increase in cytochrome c release, activation of caspase 3 and caspase 9, and a decrease in the ratio of Bcl-2/Bax. Reactive Oxygen Species 57-60 BCL2 apoptosis regulator Homo sapiens 226-231 31949673-12 2018 Additionally, 5-FU treatment downregulated Bcl-2 expression and upregulated the expression of Bax and caspase-3, and this effect was remarkably enhanced by PHGDH knockdown. Fluorouracil 14-18 BCL2 apoptosis regulator Homo sapiens 43-48 31949673-13 2018 In conclusion, knockdown of PHGDH potentiates 5-FU cytotoxicity in GC cells via the Bcl-2/Bax/caspase-3 signaling pathway. Fluorouracil 46-50 BCL2 apoptosis regulator Homo sapiens 84-89 30627375-5 2018 Moreover, Eca109 cells treated with H2O2 alone had enhanced cell proliferation and metastasis but decreased cell apoptosis, as compared with those without any treatment; meanwhile, the declined Cyt C, Bax, and cleaved caspase-3, as well as the elevated Bcl-2 were also observed in Eca109 cells in the H2O2 group, which were reversed by Propofol or Dkk1. Hydrogen Peroxide 36-40 BCL2 apoptosis regulator Homo sapiens 253-258 28374118-1 2018 In the proposed work, we have explicated the mechanism of dibenzo[a,l]pyrene (DBP) and benzo[a]pyrene (BP) modulated cell proliferation by assessing the plausible binding with CASPASES, BAX, Bcl-2, MDM2, p53, p21, p16, CylinD1-CDK4 complex, CylinE1-CDK2 complex, H-Ras, K-Ras, BRCA1, and BRCA2 through exploiting the inherent potential of AutoDock Tools 4.0. Benzo(a)pyrene 87-101 BCL2 apoptosis regulator Homo sapiens 191-196 28374118-1 2018 In the proposed work, we have explicated the mechanism of dibenzo[a,l]pyrene (DBP) and benzo[a]pyrene (BP) modulated cell proliferation by assessing the plausible binding with CASPASES, BAX, Bcl-2, MDM2, p53, p21, p16, CylinD1-CDK4 complex, CylinE1-CDK2 complex, H-Ras, K-Ras, BRCA1, and BRCA2 through exploiting the inherent potential of AutoDock Tools 4.0. Benzo(a)pyrene 79-81 BCL2 apoptosis regulator Homo sapiens 191-196 30218352-7 2018 The data showed that ALA treatment promoted a dose-dependent increase of p53 expression, downregulation of Bcl-2, HMG-CoA reductase and OGG1 and an increase in lipoperoxidation. 5-amino levulinic acid 21-24 BCL2 apoptosis regulator Homo sapiens 107-112 28374118-3 2018 Feeble interactions of BAX and Bcl-2 with diol-epoxides of both PAHs were observed. diol-epoxides 42-55 BCL2 apoptosis regulator Homo sapiens 31-36 28374118-3 2018 Feeble interactions of BAX and Bcl-2 with diol-epoxides of both PAHs were observed. Polycyclic Aromatic Hydrocarbons 64-68 BCL2 apoptosis regulator Homo sapiens 31-36 30539830-8 2018 Materials and Methods: In HepG2 cancer cells treated with various concentrations of ganodermanontriol, the cell proliferation of was detected by MTT assay, cell apoptosis was analyzed by flow cytometry; the mRNA of SATB1, Bcl-2, Bax were detected by reverse transcription-polymerase chain reaction (RT-PCR) and the protein level of SATB1, Bcl-2, Bax, and caspase 3 were analyzed by Western blot. ganodermanontriol 84-101 BCL2 apoptosis regulator Homo sapiens 222-227 30539830-8 2018 Materials and Methods: In HepG2 cancer cells treated with various concentrations of ganodermanontriol, the cell proliferation of was detected by MTT assay, cell apoptosis was analyzed by flow cytometry; the mRNA of SATB1, Bcl-2, Bax were detected by reverse transcription-polymerase chain reaction (RT-PCR) and the protein level of SATB1, Bcl-2, Bax, and caspase 3 were analyzed by Western blot. ganodermanontriol 84-101 BCL2 apoptosis regulator Homo sapiens 339-344 30396468-0 2018 The CD44 variant induces K562 cell acquired with resistance to adriamycin via NF-kappaB/Snail/Bcl-2 pathway. Doxorubicin 63-73 BCL2 apoptosis regulator Homo sapiens 94-99 30396468-6 2018 Therefore, we suggest the CD44v16 could induce the K562 cell acquired with resistance to adriamycin via NF-kappaB/Snail/Bcl-2 pathway, which paved the way for further study the function of CD44v16 in drug resistance. Doxorubicin 89-99 BCL2 apoptosis regulator Homo sapiens 120-125 30136444-9 2018 Furthermore, 2HF decreased expression of Ki67, CD31, vimentin, inhibited phosphorylation of Akt and expression of survivin and Bcl2, and increased levels of Bax, E-cadherin, and cleaved-PARP. 2'-hydroxyflavanone 13-16 BCL2 apoptosis regulator Homo sapiens 127-131 30132966-3 2018 The current study was aimed to assess whether the apoptotic effect of resveratrol on T-cell acute lymphoblastic leukemia cell line, CCRF-CEM, is exerted through DNA methylation of BAX and BCL2 gene promoters. Resveratrol 70-81 BCL2 apoptosis regulator Homo sapiens 188-192 30132966-6 2018 Based on our previous study, the resveratrol treatment can trigger apoptosis in CCRF-CEM cell line via upregulation of apoptotic BAX gene and downregulation of antiapoptotic BCL2 gene. Resveratrol 33-44 BCL2 apoptosis regulator Homo sapiens 174-178 30132966-8 2018 Unchanged status of DNA methylation of BAX and BCL2 genes may suggest that resveratrol causes the gene expression changes through a distinct mechanism which requires further studies to be understood. Resveratrol 75-86 BCL2 apoptosis regulator Homo sapiens 47-51 30596398-2 2018 The Bcl-2-selective inhibitor ABT-199 (Venetoclax) shows promising antileukaemic activity against AML, though Mcl-1 limits its antileukaemic activity. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 30-33 BCL2 apoptosis regulator Homo sapiens 4-9 30596398-8 2018 KPT-330 treatment increased binding of Bcl-2 to Bim but was overcome by ABT-199 treatment, demonstrating that KPT-330 and ABT-199 reciprocally overcome apoptosis resistance. coptisine 0-3 BCL2 apoptosis regulator Homo sapiens 39-44 30596398-8 2018 KPT-330 treatment increased binding of Bcl-2 to Bim but was overcome by ABT-199 treatment, demonstrating that KPT-330 and ABT-199 reciprocally overcome apoptosis resistance. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 122-125 BCL2 apoptosis regulator Homo sapiens 39-44 29795241-10 2018 We further showed that a BCL2 inhibitor was effective in both CAL-1 and PMDC05, indicating that this inhibitor can be used to treat MYC-BPDCN, to which BETis and AKis are probably less effective. pmdc05 72-78 BCL2 apoptosis regulator Homo sapiens 25-29 29795241-10 2018 We further showed that a BCL2 inhibitor was effective in both CAL-1 and PMDC05, indicating that this inhibitor can be used to treat MYC-BPDCN, to which BETis and AKis are probably less effective. bpdcn 136-141 BCL2 apoptosis regulator Homo sapiens 25-29 29679278-6 2018 In the presence of 3,5,3-L-triiodothyronine (T3), the expression of TRbeta in SK-hep1 cells inhibited cancer cell proliferation and impeded tumor cell migration through the up-regulation of 4-1BB, Caspase-3, and Bak gene expression; down-regulation of Bcl-2 gene expression; and activation of the Caspase-3 protein. 3,5,3-l-triiodothyronine 19-43 BCL2 apoptosis regulator Homo sapiens 252-257 29679278-6 2018 In the presence of 3,5,3-L-triiodothyronine (T3), the expression of TRbeta in SK-hep1 cells inhibited cancer cell proliferation and impeded tumor cell migration through the up-regulation of 4-1BB, Caspase-3, and Bak gene expression; down-regulation of Bcl-2 gene expression; and activation of the Caspase-3 protein. Triiodothyronine 45-47 BCL2 apoptosis regulator Homo sapiens 252-257 30272344-5 2018 Berberine treatment inhibited apoptosis of hippocampal pyramidal neurons and increased apoptosis regulator Bcl-2 and Bcl-w expression. Berberine 0-9 BCL2 apoptosis regulator Homo sapiens 107-112 30414102-5 2018 Further, an increased expression of the Caspase 3 and Bax whereas decreased Bcl-2 was confirmed by immunofluorescence and western blotting analysis in MCF-7 cell line, which revealed that PPCEBS has potent apoptosis-inducing property. ppcebs 188-194 BCL2 apoptosis regulator Homo sapiens 76-81 30420752-3 2018 In this report, we show that treatment of older patients with AML with the B cell lymphoma 2 (BCL-2) inhibitor venetoclax in combination with azacitidine results in deep and durable remissions and is superior to conventional treatments. venetoclax 111-121 BCL2 apoptosis regulator Homo sapiens 75-92 30420752-3 2018 In this report, we show that treatment of older patients with AML with the B cell lymphoma 2 (BCL-2) inhibitor venetoclax in combination with azacitidine results in deep and durable remissions and is superior to conventional treatments. venetoclax 111-121 BCL2 apoptosis regulator Homo sapiens 94-99 30308458-6 2018 RESULTS: Incubation of PANC-1 cells with gemcitabine resulted in upregulation of pro-apoptotic bax and caspases proteins expression, downregulation of anti-apoptotic Bcl-2, heat shock proteins (HSPs) and modulation of cellular inhibitors of apoptosis (IAPs). gemcitabine 41-52 BCL2 apoptosis regulator Homo sapiens 166-171 30272369-0 2018 JIB-04 induces cell apoptosis via activation of the p53/Bcl-2/caspase pathway in MHCC97H and HepG2 cells. JIB-04 0-6 BCL2 apoptosis regulator Homo sapiens 56-61 30272369-5 2018 Subsequently, the expression trends of Bcl-2 and p53 were reversed after co-treatment with pifithrin-alpha (PFT-alpha, a p53 inhibitor). pifithrin 91-106 BCL2 apoptosis regulator Homo sapiens 39-44 30144594-9 2018 mRNA expression analysis displayed a marked effect of ASA in reducing VEGF, VEGFR-1, HIF-1alpha, RAS, mitogen-activated protein kinase kinase, AKT, and BCL-2, as well a combined anticancer effect of ASA together with TMZ, BEV, and SUN. Aspirin 54-57 BCL2 apoptosis regulator Homo sapiens 152-157 30290166-8 2018 Pre-incubation with inhibitors of JNK (SP600125) and p38 (SB202190) significantly decreases the BAX/BCL2 ratio. pyrazolanthrone 39-47 BCL2 apoptosis regulator Homo sapiens 100-104 30290166-8 2018 Pre-incubation with inhibitors of JNK (SP600125) and p38 (SB202190) significantly decreases the BAX/BCL2 ratio. 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole 58-66 BCL2 apoptosis regulator Homo sapiens 100-104 30290166-9 2018 However, pre-incubation with the inhibitor of ERK (U0126), significantly increased the BAX/BCL2 ratio. U 0126 51-56 BCL2 apoptosis regulator Homo sapiens 91-95 30485531-0 2018 Selenoprotein S protects against high glucose-induced vascular endothelial apoptosis through the PKCbetaII/JNK/Bcl-2 pathway. Glucose 38-45 BCL2 apoptosis regulator Homo sapiens 111-116 30626478-5 2018 The effects of celastrol on the expression of BAX, B-cell lymphoma 2 (Bcl2), caspase-3, caspase-8, caspase-9 mRNA in A549 cells were detected by real-time quantitative PCR. celastrol 15-24 BCL2 apoptosis regulator Homo sapiens 51-68 30626478-5 2018 The effects of celastrol on the expression of BAX, B-cell lymphoma 2 (Bcl2), caspase-3, caspase-8, caspase-9 mRNA in A549 cells were detected by real-time quantitative PCR. celastrol 15-24 BCL2 apoptosis regulator Homo sapiens 70-74 30626478-8 2018 Compared with the group without celastrol treatment, the mRNA and protein level of Bcl2 in A549 cells treated with (1, 3) mumol/L celastrol decreased significantly, while the expression levels of BAX, caspase-3, caspase-8, caspase-9, c-caspase-3, c-caspase-8, c-caspase-9 increased significantly. celastrol 32-41 BCL2 apoptosis regulator Homo sapiens 83-87 30626478-8 2018 Compared with the group without celastrol treatment, the mRNA and protein level of Bcl2 in A549 cells treated with (1, 3) mumol/L celastrol decreased significantly, while the expression levels of BAX, caspase-3, caspase-8, caspase-9, c-caspase-3, c-caspase-8, c-caspase-9 increased significantly. celastrol 130-139 BCL2 apoptosis regulator Homo sapiens 83-87 30717537-6 2018 In vitro, DT inhibited the proliferation of PC9 cell line in a concentration-dependent manner, and destroyed the structure of mitochondria in PC9 cell, promoted Bax, IRE1alpha, Bip, TRAF2 and caspase 12 protein expressions, lower Bcl-2 protein expression in a time-dependent manner. Thymidine 10-12 BCL2 apoptosis regulator Homo sapiens 230-235 30574046-4 2018 Nobiletin induced apoptosis of breast cancer MCF-7 cells via regulating the protein expression of Bax, Bcl-2, cleaved caspase-3, and p53. nobiletin 0-9 BCL2 apoptosis regulator Homo sapiens 103-108 30485805-5 2018 Mechanistically, vioprolides inhibit MCL-1 and BCL2, which in turn triggers BAX/BAK-dependent mitochondrial outer membrane permeabilization (MOMP). vioprolides 17-28 BCL2 apoptosis regulator Homo sapiens 47-51 30574046-5 2018 The expression of Bcl-2 decreased, while the expression of Bax and p53 increased in MCF-7 cells treated with nobiletin. nobiletin 109-118 BCL2 apoptosis regulator Homo sapiens 18-23 30453545-10 2018 In addition, RA modulated the protein expression of intrinsic mitochondrial apoptotic pathway-related genes, such as Bax, Bcl-2, caspase-3 and poly (ADP-ribose) polymerase 1 (PARP-1) (cleaved) via the upregulation of p53 derived from HDAC2 downregulation, leading to the increased apoptosis of PC-3 and DU145 cells. rosmarinic acid 13-15 BCL2 apoptosis regulator Homo sapiens 122-127 30403243-9 2018 Mechanistic studies by western blot analysis demonstrate that benzylic selenocyanates exhibit anti-proliferative activities by modulating key cellular proteins such as Survivin, Bcl-2 and COX-2; this was further supported by molecular docking studies. selenocyanic acid 71-85 BCL2 apoptosis regulator Homo sapiens 178-183 30584457-5 2018 Our data indicates that kaempferol protects human RPE cells (ARPE-19) from hydrogen peroxide- (H2O2-) induced oxidative cell damage and apoptosis through the signaling pathways involving Bax/Bcl-2 and caspase-3 molecules proofed by real-time PCR and Western blot results. kaempferol 24-34 BCL2 apoptosis regulator Homo sapiens 191-196 30584457-5 2018 Our data indicates that kaempferol protects human RPE cells (ARPE-19) from hydrogen peroxide- (H2O2-) induced oxidative cell damage and apoptosis through the signaling pathways involving Bax/Bcl-2 and caspase-3 molecules proofed by real-time PCR and Western blot results. Hydrogen Peroxide 75-92 BCL2 apoptosis regulator Homo sapiens 191-196 30454003-6 2018 Western blotting and qRT-PCR assay revealed that luteolin increased cisplatin-induced downregulation of Bcl-2 expression. Cisplatin 68-77 BCL2 apoptosis regulator Homo sapiens 104-109 30532558-9 2018 Moreover, polydatin treatment also led to the downregulation of Bcl-2 and Mcl-1 and to activation of Bax. polydatin 10-19 BCL2 apoptosis regulator Homo sapiens 64-69 30532558-10 2018 Ectopic expression of Bcl-2 and Mcl-1 or silencing of Bax could repress the apoptosis that was induced by polydatin. polydatin 106-115 BCL2 apoptosis regulator Homo sapiens 22-27 30429451-6 2018 Cortisol translocated the Hsp70-bound GR into mitochondria which thereafter promoted GR-Bcl-2 interaction. Hydrocortisone 0-8 BCL2 apoptosis regulator Homo sapiens 88-93 30144997-5 2018 Treatment with the myosin II inhibitor blebbistatin attenuated the myosin IIA-actin complex induced actomyosin contractility and prevented cardiomyocytes apoptosis as reflected by inhibition of cleaved caspase-3 expression, normalization of Bcl-2/Bax levels and decreased apoptotic cells. blebbistatin 39-51 BCL2 apoptosis regulator Homo sapiens 241-246 30417424-5 2018 In addition, gene expression analysis showed that transcription of BCL2 was rapidly affected by BETi but this did not cause dramatic increases in cell death. beti 96-100 BCL2 apoptosis regulator Homo sapiens 67-71 30303384-5 2018 Meanwhile, the inhibition of antiapoptotic protein B-cell lymphoma 2 (Bcl-2) expression by AS1411 allows for greatly improved PDT-induced cell apoptosis. AGRO 100 91-97 BCL2 apoptosis regulator Homo sapiens 51-68 30303384-5 2018 Meanwhile, the inhibition of antiapoptotic protein B-cell lymphoma 2 (Bcl-2) expression by AS1411 allows for greatly improved PDT-induced cell apoptosis. AGRO 100 91-97 BCL2 apoptosis regulator Homo sapiens 70-75 30775235-6 2019 The MF-Lip@PEG also exhibits a strong cytoprotective effect against hypoxia-induced apoptosis through regulation of the Bax/Bcl-2/caspase-3 pathway. Polyethylene Glycols 11-14 BCL2 apoptosis regulator Homo sapiens 124-129 30524947-5 2018 Moreover, gAcrp-induced suppression of Bcl-2 expression was abrogated by knockdown of TTP or AUF1. gacrp 10-15 BCL2 apoptosis regulator Homo sapiens 39-44 30417424-7 2018 Indeed, low doses of the BCL2 inhibitor, venetoclax, in combination with the BETi was a potent combination in t(8;21) containing cells. venetoclax 41-51 BCL2 apoptosis regulator Homo sapiens 25-29 30417424-7 2018 Indeed, low doses of the BCL2 inhibitor, venetoclax, in combination with the BETi was a potent combination in t(8;21) containing cells. beti 77-81 BCL2 apoptosis regulator Homo sapiens 25-29 30278333-0 2018 Development of high potent and selective Bcl-2 inhibitors bearing the structural elements of natural product artemisinin. artemisinin 109-120 BCL2 apoptosis regulator Homo sapiens 41-46 30400936-11 2018 The molecular docking showed that licochalcone a and beta-sitosterol can closely bind two targets (BCL2 and PRKCA) that involved in EGFR-TKI resistance pathway. licochalcone A 34-48 BCL2 apoptosis regulator Homo sapiens 99-103 30400936-11 2018 The molecular docking showed that licochalcone a and beta-sitosterol can closely bind two targets (BCL2 and PRKCA) that involved in EGFR-TKI resistance pathway. gamma-sitosterol 53-68 BCL2 apoptosis regulator Homo sapiens 99-103 30278333-1 2018 By taking advantage of the apoptosis-inducing capacity of artemisinin derivatives, we developed several series of compounds by merging the basic structural elements of the natural product artemisinin into the P2 interaction pocket of the clinically prescribed Bcl-2 inhibitor venetoclax. artemisinin 58-69 BCL2 apoptosis regulator Homo sapiens 260-265 30308410-7 2018 This new derivative selectively binds to the Mcl-1 hydrophobic groove and releases Bak and Bim from Mcl-1 to induce cell death and sensitize cancer cells to Bcl-2/Bcl-xL targeting strategies. bakuchiol 83-86 BCL2 apoptosis regulator Homo sapiens 157-162 30278333-1 2018 By taking advantage of the apoptosis-inducing capacity of artemisinin derivatives, we developed several series of compounds by merging the basic structural elements of the natural product artemisinin into the P2 interaction pocket of the clinically prescribed Bcl-2 inhibitor venetoclax. artemisinin 188-199 BCL2 apoptosis regulator Homo sapiens 260-265 30278333-1 2018 By taking advantage of the apoptosis-inducing capacity of artemisinin derivatives, we developed several series of compounds by merging the basic structural elements of the natural product artemisinin into the P2 interaction pocket of the clinically prescribed Bcl-2 inhibitor venetoclax. venetoclax 276-286 BCL2 apoptosis regulator Homo sapiens 260-265 30278333-5 2018 Though further structural optimization is needed to improve the cellular absorptive permeability, the current approach represents an alternative strategy to develop novel Bcl-2 inhibitors with greater selectivity over Bcl-xL, which is related to the off-target adverse effects of venetoclax. venetoclax 280-290 BCL2 apoptosis regulator Homo sapiens 171-176 30292410-5 2018 Cell apoptosis was dramatically promoted in MM cells following silencing of ANXA1 and BTZ administration versus that in ANXA1-silenced alone or BTZ-treated alone cells, as evidenced by decreased expression of phosphorylated signal transducers and activators of transcription 3 and BCL2, and increased expression of BAX. Bortezomib 86-89 BCL2 apoptosis regulator Homo sapiens 281-285 30464531-15 2018 Conclusion: Taken together, our results indicated that TRIM32 is overexpressed in NSCLC and regulates cisplatin resistance, possibly through NF-kappaB and Bcl-2. Cisplatin 102-111 BCL2 apoptosis regulator Homo sapiens 155-160 29304561-4 2018 Of note, the identification of specific domains within the Bcl-2 family of proteins (Bcl-2 homology domains; BH domains) has not only provided a mechanistic insight into the various interactions between the member proteins but has also been the impetus behind the design and development of small molecule inhibitors and BH3 mimetics for clinical use. BH 3 320-323 BCL2 apoptosis regulator Homo sapiens 59-64 30400136-2 2018 In this study, DHA was shown to reduce viability of pancreatic cancer cells (PANC-1) by inducing DNA fragmentation, activating caspase-3, and increasing the ratio of Bax/Bcl-2. Docosahexaenoic Acids 15-18 BCL2 apoptosis regulator Homo sapiens 170-175 29863586-10 2018 Bcl-2 was unchanged in the placebo group but substantially increased (P < 0.05) in the creatine group. Creatine 90-98 BCL2 apoptosis regulator Homo sapiens 0-5 30389907-6 2018 Mechanism studies showed that TBM increased autophagosome by two pathways: First, TBM could initiate autophagy by activating AMPK that would lead to stabilization of the Beclin1-Vps34 complex via dissociating Bcl-2 from Beclin1; Second, TBM could impair lysosomal cathepsin activity and block autophagic flux, leading to accumulation of impaired autophagolysosomes. tubeimoside I 30-33 BCL2 apoptosis regulator Homo sapiens 209-214 30096128-9 2018 I-BET151 synergistically enhanced cisplatin chemosensitivity by down-regulation of survivin and Bcl-2. Cisplatin 34-43 BCL2 apoptosis regulator Homo sapiens 96-101 29304561-4 2018 Of note, the identification of specific domains within the Bcl-2 family of proteins (Bcl-2 homology domains; BH domains) has not only provided a mechanistic insight into the various interactions between the member proteins but has also been the impetus behind the design and development of small molecule inhibitors and BH3 mimetics for clinical use. BH 3 320-323 BCL2 apoptosis regulator Homo sapiens 85-90 30106753-5 2018 HH78 at low micromolar concentrations induced significant cancer cell apoptosis showed by increased caspase-3 activation, annexin V-staining and downregulated prosurvival proteins, including c-Myc, Bcl-2, Mcl-1, and Bcl-xL. hh78 0-4 BCL2 apoptosis regulator Homo sapiens 198-203 29304561-7 2018 However, under states of oxidative stress, overexpression of Bcl-2 functions as a redox sink to prevent excessive buildup of reactive oxygen species, thereby inhibiting execution signals. Reactive Oxygen Species 125-148 BCL2 apoptosis regulator Homo sapiens 61-66 29524194-12 2018 Moreover, a low-Se diet downregulated (P < 0.05) the level of Bcl-2 and upregulated (P < 0.05) the levels of Bax, Bak, Cyt-C, Caspase-9, Caspase-3, and p53. Selenium 16-18 BCL2 apoptosis regulator Homo sapiens 65-70 30396956-5 2018 RESULTS: Evodiamine treatment of cells decreased cell viability, and Bcl2 and phospho-AKT protein levels. evodiamine 9-19 BCL2 apoptosis regulator Homo sapiens 69-73 30396956-7 2018 After co-treatment of wortmannin, cell viability, and phospho-AKT and Bcl2 protein levels decreased, and cytotoxic activity increased. Wortmannin 22-32 BCL2 apoptosis regulator Homo sapiens 70-74 30402442-1 2018 Purpose: This study aimed to validate the synergistic effect of ABT-737 on docetaxel using MDA-MB-231, a triple negative breast cancer (TNBC) cell line overexpressing B-cell lymphoma-2 (Bcl-2). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 64-67 BCL2 apoptosis regulator Homo sapiens 186-191 30053503-3 2018 On the other hand, the BH4 domain of Bcl-2 binds to the inositol 1,4,5-trisphosphate receptor (IP3R), preventing Ca2+ signals that mediate cell death. sapropterin 23-26 BCL2 apoptosis regulator Homo sapiens 37-42 30053503-8 2018 Moreover, the successful development of ABT-199 (Venetoclax), a small molecule targeting the BH3 domain of Bcl-2 but without effects on Ca2+, serves as proof of principle that targeting Bcl-2 can be an effective therapeutic approach. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 40-43 BCL2 apoptosis regulator Homo sapiens 107-112 30402442-12 2018 Conclusion: Combination of ABT-737 with docetaxel elicits synergistic therapeutic effect on MDA-MB-231, a TNBC cell line overexpressing Bcl-2, mainly by activating the intrinsic pathway of apoptosis. ABT-737 27-34 BCL2 apoptosis regulator Homo sapiens 136-141 30402442-12 2018 Conclusion: Combination of ABT-737 with docetaxel elicits synergistic therapeutic effect on MDA-MB-231, a TNBC cell line overexpressing Bcl-2, mainly by activating the intrinsic pathway of apoptosis. Docetaxel 40-49 BCL2 apoptosis regulator Homo sapiens 136-141 30402442-13 2018 Therefore, adjunct of ABT-737 to docetaxel might be a new therapeutic option to overcome docetaxel resistance of TNBCs overexpressing Bcl-2. ABT-737 22-29 BCL2 apoptosis regulator Homo sapiens 134-139 30402442-13 2018 Therefore, adjunct of ABT-737 to docetaxel might be a new therapeutic option to overcome docetaxel resistance of TNBCs overexpressing Bcl-2. Docetaxel 33-42 BCL2 apoptosis regulator Homo sapiens 134-139 29552710-0 2018 Gold and Silver Nanoparticles Biomimetically Synthesized Using Date Palm Pollen Extract-Induce Apoptosis and Regulate p53 and Bcl-2 Expression in Human Breast Adenocarcinoma Cells. Silver 9-15 BCL2 apoptosis regulator Homo sapiens 126-131 30053503-8 2018 Moreover, the successful development of ABT-199 (Venetoclax), a small molecule targeting the BH3 domain of Bcl-2 but without effects on Ca2+, serves as proof of principle that targeting Bcl-2 can be an effective therapeutic approach. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 40-43 BCL2 apoptosis regulator Homo sapiens 186-191 30385739-7 2018 Indeed, antagonising Bcl-2 by ABT-199 allowed TRAIL/TL32711 response synergies to manifest in otherwise TRAIL resistant cell lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 30-33 BCL2 apoptosis regulator Homo sapiens 21-26 30257366-10 2018 The real time PCR assay demonstrated that parthenolide down-regulated the expression of Bcl-2 and up-regulated the expression of E2F1, P53, GADD45, BAX, BIM, and CASP 3,7,8,9, which indicates an activation of P53- dependent apoptosis pathway in response to parthenolide. parthenolide 42-54 BCL2 apoptosis regulator Homo sapiens 88-93 29966582-5 2018 Treatment of KHG26792 significantly attenuated MPP+-induced changes in the protein levels of Bcl-2 and Bax together with efficient suppression of MPP+-induced activation of caspase-3 activity. 3-(naphthalen-2-yl(propoxy)methyl)azetidine hydrochloride 13-21 BCL2 apoptosis regulator Homo sapiens 93-98 29966582-5 2018 Treatment of KHG26792 significantly attenuated MPP+-induced changes in the protein levels of Bcl-2 and Bax together with efficient suppression of MPP+-induced activation of caspase-3 activity. mangion-purified polysaccharide (Candida albicans) 47-50 BCL2 apoptosis regulator Homo sapiens 93-98 30515391-4 2018 Further, SAC treatment dose dependently inhibited H2O2 induced apoptosis via decreasing the Bax/Bcl-2 ratio, restoring mitochondrial membrane potential ( Psim), inhibiting mitochondrial cytochrome c release, and inhibiting proteolytic cleavage of caspase-3. Hydrogen Peroxide 50-54 BCL2 apoptosis regulator Homo sapiens 96-101 30420612-5 2018 Notably, the synergistic effect of IDF-11774 and the ATP6V0C inhibitor, bafilomycin A1, depended on the PIK3CA genetic status and Bcl-2 expression, which regulates autolysosome formation and apoptosis. IDF-11774 35-44 BCL2 apoptosis regulator Homo sapiens 130-135 30420612-5 2018 Notably, the synergistic effect of IDF-11774 and the ATP6V0C inhibitor, bafilomycin A1, depended on the PIK3CA genetic status and Bcl-2 expression, which regulates autolysosome formation and apoptosis. bafilomycin 72-83 BCL2 apoptosis regulator Homo sapiens 130-135 30021909-1 2018 Purpose: Clinically available BH3 mimetic drugs targeting BCLXL and/or BCL2 (navitoclax and venetoclax, respectively) are effective in some hematologic malignancies, but have limited efficacy in solid tumors. BH 3 30-33 BCL2 apoptosis regulator Homo sapiens 71-75 30260685-5 2018 Silencing of miR-125b decreased the rate of yak GC apoptosis and increased the ratio of Bcl2/Bax. mir-125b 13-21 BCL2 apoptosis regulator Homo sapiens 88-92 30021909-1 2018 Purpose: Clinically available BH3 mimetic drugs targeting BCLXL and/or BCL2 (navitoclax and venetoclax, respectively) are effective in some hematologic malignancies, but have limited efficacy in solid tumors. navitoclax 77-87 BCL2 apoptosis regulator Homo sapiens 71-75 30021909-1 2018 Purpose: Clinically available BH3 mimetic drugs targeting BCLXL and/or BCL2 (navitoclax and venetoclax, respectively) are effective in some hematologic malignancies, but have limited efficacy in solid tumors. venetoclax 92-102 BCL2 apoptosis regulator Homo sapiens 71-75 30260685-4 2018 miR-125b overexpression induced apoptosis in yak GC, and affected the mRNA and protein expression of BMPR1B and the ratio of Bcl2/Bax. mir-125b 0-8 BCL2 apoptosis regulator Homo sapiens 125-129 30005287-5 2018 In addition, DOX loaded aptamer-functionalized nanoparticles can induce more significant down-regulation of Bcl-2 and PCNA as well as up-regulation of pRB, PARP and Bax in MCF-7 cells compared with unmodified nanoparticles, indicating the aptamer modification can induce cell apoptosis more effectively. Doxorubicin 13-16 BCL2 apoptosis regulator Homo sapiens 108-113 30152185-5 2018 Results from western blotting showed that quercetin decreased anti-apoptotic protein of Mcl-1, Bcl-2, and Bcl-x but increased pro-apoptotic protein of Bad, Bax, and Bid. Quercetin 42-51 BCL2 apoptosis regulator Homo sapiens 95-100 30344659-2 2018 The aim of the present study was to access the class I-selective histone deacetylase (HDAC) inhibitor (HDACI) MGCD0103 on the expression levels of Bcl-2, nuclear factor (NF)-kappaB and programmed death-ligand 1 (PD-L1) in CHL, to explore the possible therapeutic value of MGCD0103 in combined relative target drugs for patients with CHL. mocetinostat 110-118 BCL2 apoptosis regulator Homo sapiens 147-152 30344659-4 2018 The results demonstrated that MGCD0103 could induce cell apoptosis and cell cycle arrest, down-regulate Bcl-2 and increase NF-kappaB and PD-L1 expression levels in L1236 and L428 cell lines. mocetinostat 30-38 BCL2 apoptosis regulator Homo sapiens 104-109 30344691-7 2018 RT-qPCR results showed that compared with those in the negative control group, the mRNA expression levels of Bcl-2 in the cells of silver amalgam group, glass-ionomer cement group and nichrome group were decreased, while those of Bax were upregulated (P<0.05). Silver 131-137 BCL2 apoptosis regulator Homo sapiens 109-114 30344659-5 2018 MGCD0103 decreases Bcl-2 levels and upregulates PD-L1, which indicates that the combined use of HDACIs and a PD-L1 inhibitor in theory may improve treatment outcomes in patients with CHL. mocetinostat 0-8 BCL2 apoptosis regulator Homo sapiens 19-24 30344696-9 2018 miR-423 inhibited cisplatin-induced apoptosis in endometrial cancer cells by regulation of caspase 3/7 and Bcl-2 expression. Cisplatin 18-27 BCL2 apoptosis regulator Homo sapiens 107-112 30226534-10 2018 Sulforaphane inhibited multiple cancer-associated signaling pathways, including B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein, cytochrome c, Caspase-3, phosphorylated AKT, phosphorylated nuclear factor-kappaB, P53, P27, Cyclin-D1 and cMyc, and reduced the expression levels of human epidermal growth factor receptor 2 in human ovarian cancer cells. sulforaphane 0-12 BCL2 apoptosis regulator Homo sapiens 80-97 30468468-13 2018 Therefore, the expression of AEG-1 and BCL2 was determined in untreated control, cisplatin treated control and miR-136 transfected AGS gastric cancer cells. Cisplatin 81-90 BCL2 apoptosis regulator Homo sapiens 39-43 30468473-5 2018 Western blot was performed to detect protein levels of Prx V, Bcl-2 (B-cell lymphoma 2), BAD ,and caspase-3 in Cisplatin-induced A549 cells. Cisplatin 111-120 BCL2 apoptosis regulator Homo sapiens 62-67 30468473-5 2018 Western blot was performed to detect protein levels of Prx V, Bcl-2 (B-cell lymphoma 2), BAD ,and caspase-3 in Cisplatin-induced A549 cells. Cisplatin 111-120 BCL2 apoptosis regulator Homo sapiens 69-86 30468473-11 2018 With the treatment prolongation of 4 mumol/L Cisplatin in A549 cells, Bcl-2 and caspase-3 were downregulated, while BAD upregulated. Cisplatin 45-54 BCL2 apoptosis regulator Homo sapiens 70-75 30226569-9 2018 Furthermore, the levels of the anti-apoptotic proteins, phosphorylated-protein kinase B and B-cell lymphoma-2 (Bcl-2), were significantly decreased, while the levels of the pro-apoptotic protein Bcl-2-associated X protein were remarkably increased in response to cisplatin treatment. Cisplatin 263-272 BCL2 apoptosis regulator Homo sapiens 195-200 30226534-10 2018 Sulforaphane inhibited multiple cancer-associated signaling pathways, including B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein, cytochrome c, Caspase-3, phosphorylated AKT, phosphorylated nuclear factor-kappaB, P53, P27, Cyclin-D1 and cMyc, and reduced the expression levels of human epidermal growth factor receptor 2 in human ovarian cancer cells. sulforaphane 0-12 BCL2 apoptosis regulator Homo sapiens 99-104 30132509-3 2018 In addition, cells treated with resveratrol displayed higher apoptotic rates, in association with mitochondrial depolarization, cytochrome c release from the mitochondrial compartment to the cytoplasm, apoptosis-inducing factor translocation from the mitochondrial compartment to the nucleus, and altered protein levels of Bcl-2, Bcl-xL and Bax. Resveratrol 32-43 BCL2 apoptosis regulator Homo sapiens 323-328 30226600-8 2018 On examining the potential underlying mechanism, it was revealed that radiation and RA combined induce Bcl-2-associated X protein expression and cell apoptosis in MCF-7 cells. rotundic acid 84-86 BCL2 apoptosis regulator Homo sapiens 103-108 30226534-10 2018 Sulforaphane inhibited multiple cancer-associated signaling pathways, including B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein, cytochrome c, Caspase-3, phosphorylated AKT, phosphorylated nuclear factor-kappaB, P53, P27, Cyclin-D1 and cMyc, and reduced the expression levels of human epidermal growth factor receptor 2 in human ovarian cancer cells. sulforaphane 0-12 BCL2 apoptosis regulator Homo sapiens 107-112 30610811-10 2018 Cycloartenol also caused significant alteration in the expression of Bax and Bcl-2. cycloartenol 0-12 BCL2 apoptosis regulator Homo sapiens 77-82 29760303-15 2018 CONCLUSIONS: The result suggests that miR-140-3p regulates ASMC function via targeting C-Myb and BCL-2 in the process of ISR in PAD. asmc 59-63 BCL2 apoptosis regulator Homo sapiens 97-102 30422391-2 2018 Bisindole-oxadiazole hybrids, T3P mediated synthesis and appraisal of their apoptotic, antimetastatic and computational Bcl-2 binding potential. propylphosphonic anhydride 30-33 BCL2 apoptosis regulator Homo sapiens 120-125 29279995-7 2018 MAO-B inhibitors selegiline and rasagiline protect neurons via increase expression of anti-apoptotic Bcl-2 and pro-survival neurotrophic factors in human neuroblastoma SH-SY5Y and glioblastoma U118MG cell lines. Selegiline 17-27 BCL2 apoptosis regulator Homo sapiens 101-106 29279995-7 2018 MAO-B inhibitors selegiline and rasagiline protect neurons via increase expression of anti-apoptotic Bcl-2 and pro-survival neurotrophic factors in human neuroblastoma SH-SY5Y and glioblastoma U118MG cell lines. rasagiline 32-42 BCL2 apoptosis regulator Homo sapiens 101-106 30221494-10 2018 It was also revealed that the expression of BCL-2 was significantly decreased in MPP+ -treated cells, thereby confirming previous studies regarding a new concept. mangion-purified polysaccharide (Candida albicans) 81-85 BCL2 apoptosis regulator Homo sapiens 44-49 30221494-0 2018 miR-34a/BCL-2 signaling axis contributes to apoptosis in MPP+ -induced SH-SY5Y cells. mangion-purified polysaccharide (Candida albicans) 57-60 BCL2 apoptosis regulator Homo sapiens 8-13 30464341-6 2018 As a result, the administration of mannose in combination with conventional chemotherapy affects levels of anti-apoptotic proteins of the Bcl-2 family, leading to sensitization to cell death. Mannose 35-42 BCL2 apoptosis regulator Homo sapiens 138-143 30384473-8 2018 We found that Evo significantly induced cell cycle arrest at the G2/M phase, upregulated P53 and Bcl-2 associated X proteins (Bax) proteins, and downregulated B-cell lymphoma-2 (Bcl-2), cyclinB1, and cdc2 proteins in HCC cells. evodiamine 14-17 BCL2 apoptosis regulator Homo sapiens 97-102 30132536-7 2018 The expression of Bax (in MCF-7 cells) and caspase-3 (in MDA-MB-231 cells) increased following co-treatment with 3-BP and TRAIL, whereas the expression of the anti-apoptotic protein Bcl-2 decreased. bromopyruvate 113-117 BCL2 apoptosis regulator Homo sapiens 182-187 30405828-7 2018 In addition, DHA treatment induced cell apoptosis, which was accompanied by an increased ratio of Bax/Bcl-2. artenimol 13-16 BCL2 apoptosis regulator Homo sapiens 102-107 30333884-11 2018 Further evaluation revealed that kaempferol causes apoptotic cell death largely by suppressing ERalpha, survivin and Bcl-2 protein. kaempferol 33-43 BCL2 apoptosis regulator Homo sapiens 117-122 30333888-6 2018 Western blot analysis revealed that ATO treatment affected the expression of apoptosis-associated proteins by downregulating the anti-apoptotic protein B-cell lymphoma-2 (Bcl-2) and upregulating the pro-apoptotic protein Bcl-2-associatedX and the degree of caspase-3 cleavage. Arsenic Trioxide 36-39 BCL2 apoptosis regulator Homo sapiens 152-169 30333888-6 2018 Western blot analysis revealed that ATO treatment affected the expression of apoptosis-associated proteins by downregulating the anti-apoptotic protein B-cell lymphoma-2 (Bcl-2) and upregulating the pro-apoptotic protein Bcl-2-associatedX and the degree of caspase-3 cleavage. Arsenic Trioxide 36-39 BCL2 apoptosis regulator Homo sapiens 171-176 30333888-6 2018 Western blot analysis revealed that ATO treatment affected the expression of apoptosis-associated proteins by downregulating the anti-apoptotic protein B-cell lymphoma-2 (Bcl-2) and upregulating the pro-apoptotic protein Bcl-2-associatedX and the degree of caspase-3 cleavage. Arsenic Trioxide 36-39 BCL2 apoptosis regulator Homo sapiens 221-226 30384473-8 2018 We found that Evo significantly induced cell cycle arrest at the G2/M phase, upregulated P53 and Bcl-2 associated X proteins (Bax) proteins, and downregulated B-cell lymphoma-2 (Bcl-2), cyclinB1, and cdc2 proteins in HCC cells. evodiamine 14-17 BCL2 apoptosis regulator Homo sapiens 159-176 30384473-8 2018 We found that Evo significantly induced cell cycle arrest at the G2/M phase, upregulated P53 and Bcl-2 associated X proteins (Bax) proteins, and downregulated B-cell lymphoma-2 (Bcl-2), cyclinB1, and cdc2 proteins in HCC cells. evodiamine 14-17 BCL2 apoptosis regulator Homo sapiens 178-183 30713663-4 2019 The decline of cell viability is due to apoptotic death since arsenite treatment reduces Akt activity and the Bcl2 level but increases caspase 3 activity and the cytochrome c level. arsenite 62-70 BCL2 apoptosis regulator Homo sapiens 110-114 30464390-9 2018 The expression of MTDH and Bcl-2 was inhibited by lobaplatin and that of Bax was increased by lobaplatin. lobaplatin 50-60 BCL2 apoptosis regulator Homo sapiens 27-32 30464390-9 2018 The expression of MTDH and Bcl-2 was inhibited by lobaplatin and that of Bax was increased by lobaplatin. lobaplatin 94-104 BCL2 apoptosis regulator Homo sapiens 27-32 30373097-7 2018 Further examinations using ABT-263 showed that Bcl-2/Bcl-xL inhibition indeed promoted apoptotic programmed cell death. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 27-30 BCL2 apoptosis regulator Homo sapiens 47-52 30498348-9 2018 Cellular and molecular assays revealed that NGOs lead to ROS formation, cell cycle arrest, and apoptosis through the BAX and BCL2 pathway. ros 57-60 BCL2 apoptosis regulator Homo sapiens 125-129 30361551-6 2018 Results: Exposure to increasing concentrations of TiO2 NPs enhanced overall cell survivalof HCT116 cells and reduced the Bcl-2 and Caspase 3 expression while the ratio of Bax/Bcl-2 was down-regulated.TiO2 NPs at 400 and 50 mug/ml concentrations suppressed cell proliferation and induced apoptosis of HT29 cells andalso up-regulated P53 and Bax at the mRNA level, enhanced the Bax/Bcl-2 ratio and eventually up-regulated Caspase3 mRNA. titanium dioxide 50-54 BCL2 apoptosis regulator Homo sapiens 121-126 30361551-6 2018 Results: Exposure to increasing concentrations of TiO2 NPs enhanced overall cell survivalof HCT116 cells and reduced the Bcl-2 and Caspase 3 expression while the ratio of Bax/Bcl-2 was down-regulated.TiO2 NPs at 400 and 50 mug/ml concentrations suppressed cell proliferation and induced apoptosis of HT29 cells andalso up-regulated P53 and Bax at the mRNA level, enhanced the Bax/Bcl-2 ratio and eventually up-regulated Caspase3 mRNA. titanium dioxide 50-54 BCL2 apoptosis regulator Homo sapiens 175-180 30361551-6 2018 Results: Exposure to increasing concentrations of TiO2 NPs enhanced overall cell survivalof HCT116 cells and reduced the Bcl-2 and Caspase 3 expression while the ratio of Bax/Bcl-2 was down-regulated.TiO2 NPs at 400 and 50 mug/ml concentrations suppressed cell proliferation and induced apoptosis of HT29 cells andalso up-regulated P53 and Bax at the mRNA level, enhanced the Bax/Bcl-2 ratio and eventually up-regulated Caspase3 mRNA. titanium dioxide 50-54 BCL2 apoptosis regulator Homo sapiens 175-180 30425998-7 2018 Sensitivity to paclitaxel was also measured and was found to inversely correlate to bcl-2 status. Paclitaxel 15-25 BCL2 apoptosis regulator Homo sapiens 84-89 30114609-17 2018 In conclusion, these findings demonstrate that 8q can induce mitochondrial lesions and promote mitochondrial-mediated pathway apoptosis by regulating the expression of Bcl-2 family proteins and inhibiting the activity of the PI3K/AKT/FOXO1 signaling pathway. 8q 47-49 BCL2 apoptosis regulator Homo sapiens 168-173 30361682-6 2018 Furthermore, combined inhibition of Bcl-2/Bcl-XL and Mcl-1 could revert BMSC-mediated resistance against cytarabine + daunorubicin. BMSC 72-76 BCL2 apoptosis regulator Homo sapiens 36-41 30361682-6 2018 Furthermore, combined inhibition of Bcl-2/Bcl-XL and Mcl-1 could revert BMSC-mediated resistance against cytarabine + daunorubicin. Cytarabine 105-115 BCL2 apoptosis regulator Homo sapiens 36-41 30361682-6 2018 Furthermore, combined inhibition of Bcl-2/Bcl-XL and Mcl-1 could revert BMSC-mediated resistance against cytarabine + daunorubicin. Daunorubicin 118-130 BCL2 apoptosis regulator Homo sapiens 36-41 30406027-4 2018 The BCL-2-selective inhibitor venetoclax has been approved for use in chronic lymphocytic leukemia and is now being studied in a number of other hematologic malignancies. venetoclax 30-40 BCL2 apoptosis regulator Homo sapiens 4-9 30386247-7 2018 Altogether, these results suggest that NER and Bcl-2 protein family proteins are potential targets to improve the response to cisplatin treatment. Cisplatin 126-135 BCL2 apoptosis regulator Homo sapiens 47-52 30450157-0 2018 BH4-mimetics and -antagonists: an emerging class of Bcl-2 protein modulators for cancer therapy. sapropterin 0-3 BCL2 apoptosis regulator Homo sapiens 52-57 30410558-4 2018 We found that the combined use of A549/DDP cells with SFI and cisplatin enhanced cell cycle arrested in the G2/M phase, which was accompanied by upregulation of p53 and p21 protein expression and induced mitochondrial apoptosis in conjunction with the upregulation of Bax and the downregulation of Bcl-2 protein expression. Cisplatin 62-71 BCL2 apoptosis regulator Homo sapiens 298-303 30154155-7 2018 Treatment of Ph+ ALL cells, including samples from relapsed/refractory patients, with the PIM kinase inhibitor AZD1208 and/or the BCL2 family antagonist Sabutoclax markedly suppressed cell growth and leukemogenesis ex vivo and in mice. 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-N5-(2-phenylpropyl)-N5'-(2-phenylpropyl)-2,2'-binaphthyl-5,5'-dicarboxamide 153-163 BCL2 apoptosis regulator Homo sapiens 130-134 30303965-4 2018 Biological methods demonstrated the oxidative damage of P19 neurons and showed that quercetin improved neuronal survival by preventing H2O2-induced p53 and Bcl-2 down-regulation and modulated Akt and ERK1/2 signalling pathways. Quercetin 84-93 BCL2 apoptosis regulator Homo sapiens 156-161 30305055-6 2018 We identified alterations in members of the BCL-2 family of proteins, in particular MCL-1 and BAX, which may play a role in resistance to lapatinib. Lapatinib 138-147 BCL2 apoptosis regulator Homo sapiens 44-49 30304783-5 2018 We found that the combined use of dihydroartemisinin with epirubicin could efficiently inhibit the activity of Bcl-2, facilitate release of Beclin 1, and further activate Bax. artenimol 34-52 BCL2 apoptosis regulator Homo sapiens 111-116 30304783-5 2018 We found that the combined use of dihydroartemisinin with epirubicin could efficiently inhibit the activity of Bcl-2, facilitate release of Beclin 1, and further activate Bax. Epirubicin 58-68 BCL2 apoptosis regulator Homo sapiens 111-116 30203954-0 2018 In Situ Synthesis of Ultrathin ZIF-8 Film-Coated MSNs for Codelivering Bcl 2 siRNA and Doxorubicin to Enhance Chemotherapeutic Efficacy in Drug-Resistant Cancer Cells. ultrathin zif-8 21-36 BCL2 apoptosis regulator Homo sapiens 71-76 30326662-5 2018 Moreover, the levels of cytochrome C in mitochondria, and the expressions of bcl-2 protein, decreased after treatment with beta-carbolines, which indicated that 6i and 6u could induce mitochondria-mediated apoptosis. Carbolines 123-138 BCL2 apoptosis regulator Homo sapiens 77-82 30304567-6 2018 Moreover, GA-induced apoptosis and mitochondrial damage of RAFLS, as evidenced by increased Bax/Bcl-2 ratio and mitochondrial cytochrome c release, and enhanced cleavages of caspase-3, caspase-9, and poly-(ADP-ribose) polymerase. geldanamycin 10-12 BCL2 apoptosis regulator Homo sapiens 96-101 30293083-11 2018 GA treatment significantly decreased the expression levels of DLL1, DLL3, DLL4, Jagged1, Jagged2, Bcl2, and PK3K, inhibited NICD nuclear translocation and Akt phosphorylation, and increased expression level of active caspase3. gambogic acid 0-2 BCL2 apoptosis regulator Homo sapiens 98-102 30284467-6 2018 Furthermore, VBFW (30[Formula: see text][Formula: see text]g/mL) exhibited protective effects against H2O2-induced cell death via inhibition of the H2O2-induced increase in Bax and decrease in Bcl-2 levels within the mitochondria of SH-SY5Y cells. Hydrogen Peroxide 148-152 BCL2 apoptosis regulator Homo sapiens 193-198 30282833-4 2018 E7107 treatment decreased myeloid cell leukemia-1 (MCL1) dependence and increased BCL2 dependence, sensitizing primary human CLL cells and venetoclax-resistant CLL-like cells from an Emu-TCL1-based adoptive transfer murine model to treatment with the BCL2 inhibitor venetoclax. E 7107 0-5 BCL2 apoptosis regulator Homo sapiens 82-86 30303965-4 2018 Biological methods demonstrated the oxidative damage of P19 neurons and showed that quercetin improved neuronal survival by preventing H2O2-induced p53 and Bcl-2 down-regulation and modulated Akt and ERK1/2 signalling pathways. Hydrogen Peroxide 135-139 BCL2 apoptosis regulator Homo sapiens 156-161 30287880-7 2018 In IHC analysis BCL-2 overexpression was associated with inferior DFS (p = 0.002) and DSS (p = 0.002). dss 86-89 BCL2 apoptosis regulator Homo sapiens 16-21 29990855-9 2018 beta-asarone can also induced cell apoptosis, decreased the expression of BCL-2 mRNA and blocked the DNA cycle at the G0/G1 phase for all the two cells. asarone 0-12 BCL2 apoptosis regulator Homo sapiens 74-79 30287880-8 2018 DLBCL with BCL-2 and MYC overexpression conferred inferior survival in all patients (DSS, p = 0.038 and DFS, p = 0.011) and in patients with non-GC phenotype (DSS (p = 0.013) and DFS (p = 0.010). dss 85-88 BCL2 apoptosis regulator Homo sapiens 11-16 30287880-8 2018 DLBCL with BCL-2 and MYC overexpression conferred inferior survival in all patients (DSS, p = 0.038 and DFS, p = 0.011) and in patients with non-GC phenotype (DSS (p = 0.013) and DFS (p = 0.010). dss 159-162 BCL2 apoptosis regulator Homo sapiens 11-16 30370304-5 2018 Treatment with SM or SB was found to significantly reduce the genotoxicity of MMS, upregulate the expression of PTEN and BCL2, and downregulate the expression of BAX and ABL1. Silybin 21-23 BCL2 apoptosis regulator Homo sapiens 121-125 30216289-7 2018 RESULTS: In patients of the RCT, the Bax/Bcl2 mRNA ratio in liver tissue was markedly decreased in the sevoflurane arm (25% +- 21% reduction; P = .001). Sevoflurane 103-114 BCL2 apoptosis regulator Homo sapiens 41-45 30216289-11 2018 When exposed to supernatants from HSC undergoing sevoflurane postconditioning, caspase activation in hepatocytes was reduced by 20% +- 9% (P < .001), similarly to the sevoflurane effect on the BAX/Bcl2 mRNA ratio in the liver samples. Sevoflurane 49-60 BCL2 apoptosis regulator Homo sapiens 200-204 30370304-5 2018 Treatment with SM or SB was found to significantly reduce the genotoxicity of MMS, upregulate the expression of PTEN and BCL2, and downregulate the expression of BAX and ABL1. Silymarin 15-17 BCL2 apoptosis regulator Homo sapiens 121-125 30119256-0 2018 Synergy of theophylline reduces necrotic effect of berberine, induces cell cycle arrest and PARP, HMGB1, Bcl-2 family mediated apoptosis in MDA-MB-231 breast cancer cells. Theophylline 11-23 BCL2 apoptosis regulator Homo sapiens 105-110 30119200-0 2018 Xanthohumol induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI3K/Akt/mTOR-kinase in human gastric cancer cells. xanthohumol 0-11 BCL2 apoptosis regulator Homo sapiens 68-73 30207377-0 2018 Probing the interaction of a quercetin bioconjugate with Bcl-2 in living human cancer cells with in-cell NMR spectroscopy. Quercetin 29-38 BCL2 apoptosis regulator Homo sapiens 57-62 30243887-9 2018 In addition, H2 could increase expression of Bcl-2/Bax ratio and inhibited neurons apoptosis in hippocampus. Hydrogen 13-15 BCL2 apoptosis regulator Homo sapiens 45-50 29987671-6 2018 The anti-CSCs effect of PD173074 was associated with decreased expression of Oct4, Sox-2, Nanog, and c-Myc, as well as suppression of XIAP, Bcl2, and survivin expression, dose-dependently. PD 173074 24-32 BCL2 apoptosis regulator Homo sapiens 140-144 29913420-5 2018 ZPT-induced apoptosis involved an increased Bax/Bcl-2 ratio, loss of mitochondrial membrane potential, cytochrome c release, and enhanced caspase-9/-3 activity. pyrithione zinc 0-3 BCL2 apoptosis regulator Homo sapiens 48-53 30207377-3 2018 Herein, we describe for the first time the monitoring of the quercetin-alanine bioconjugate interaction with the nonlabeled antiapoptotic protein Bcl-2 inside living human cancer cells. quercetin-alanine 61-78 BCL2 apoptosis regulator Homo sapiens 146-151 30015828-4 2018 Alantolactone induced apoptosis of MCF-7 cells by regulating the protein expression levels of B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein, p53, caspase-3 and caspase-12, which are associated with the apoptotic pathway, and suppressed colony formation and migration by regulating the protein expression of matrix metalloproteinase (MMP)-2, MMP-7 and MMP-9. alantolactone 0-13 BCL2 apoptosis regulator Homo sapiens 94-111 30056083-3 2018 Compared to 5-FU alone, MH synergistically enhanced the chemotherapeutic effects of 5-FU, by reducing cell proliferation through the suppression of EGFR, HER2, p-Akt and p-mTOR expression, and promoting apoptosis by the modulation pro-apoptotic (p53, Bax, Cyto c, FasL caspase-3, -8, -9 and cleave-PARP) and anti-apoptotic (Bcl-2) markers. mh 24-26 BCL2 apoptosis regulator Homo sapiens 324-329 30056083-3 2018 Compared to 5-FU alone, MH synergistically enhanced the chemotherapeutic effects of 5-FU, by reducing cell proliferation through the suppression of EGFR, HER2, p-Akt and p-mTOR expression, and promoting apoptosis by the modulation pro-apoptotic (p53, Bax, Cyto c, FasL caspase-3, -8, -9 and cleave-PARP) and anti-apoptotic (Bcl-2) markers. Fluorouracil 84-88 BCL2 apoptosis regulator Homo sapiens 324-329 30236029-2 2018 The results showed that matrine (>=10 muM) caused a significant inhibition on cell viability and 10 and 100 muM matrine induced cell apoptosis via influencing p53, bax, casp3, and bcl-2 expressions in A549 cells. matrine 24-31 BCL2 apoptosis regulator Homo sapiens 183-188 29785506-4 2018 Venetoclax, a BCL-2 inhibitor, has been approved for the treatment of relapsed and/or refractory chronic lymphoid leukemia. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 14-19 29624724-5 2018 At molecular levels, we demonstrated that GM-DCs had distinct pattern of mRNA expression for anti-apoptotic BCL-2 family members, of which, Bcl-x increased significantly following LPS stimulation. gm-dcs 42-48 BCL2 apoptosis regulator Homo sapiens 108-113 30015828-4 2018 Alantolactone induced apoptosis of MCF-7 cells by regulating the protein expression levels of B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein, p53, caspase-3 and caspase-12, which are associated with the apoptotic pathway, and suppressed colony formation and migration by regulating the protein expression of matrix metalloproteinase (MMP)-2, MMP-7 and MMP-9. alantolactone 0-13 BCL2 apoptosis regulator Homo sapiens 113-118 30015828-4 2018 Alantolactone induced apoptosis of MCF-7 cells by regulating the protein expression levels of B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein, p53, caspase-3 and caspase-12, which are associated with the apoptotic pathway, and suppressed colony formation and migration by regulating the protein expression of matrix metalloproteinase (MMP)-2, MMP-7 and MMP-9. alantolactone 0-13 BCL2 apoptosis regulator Homo sapiens 121-126 29431553-2 2018 We modeled dormancy in vitro and investigated the ability of Bcl-2 inhibitors ABT-199 and ABT-737 to overcome chemoprotection of dormant cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 78-81 BCL2 apoptosis regulator Homo sapiens 61-66 29787950-0 2018 Macroporous silica nanoparticles for delivering Bcl2-function converting peptide to treat multidrug resistant-cancer cells. Silicon Dioxide 12-18 BCL2 apoptosis regulator Homo sapiens 48-52 29787950-5 2018 In this paper, an effective delivery platform for Bcl-2-converting peptide was fabricated by us to treat multidrug resistant-cancer cells via tuning the surface functionality of macroporous silica nanoparticles. Silicon Dioxide 190-196 BCL2 apoptosis regulator Homo sapiens 50-55 29787950-6 2018 The resulting large-sized pore silica nanoparticles, especially those modified with thiol group, exhibited the high Bcl-2-converting peptide-loading efficiency of over 40%. Silicon Dioxide 31-37 BCL2 apoptosis regulator Homo sapiens 116-121 29787950-6 2018 The resulting large-sized pore silica nanoparticles, especially those modified with thiol group, exhibited the high Bcl-2-converting peptide-loading efficiency of over 40%. Sulfhydryl Compounds 84-89 BCL2 apoptosis regulator Homo sapiens 116-121 29787950-7 2018 Moreover, the peptide induced MCF7/DOX cells into apoptotic status by penetrating cytomembrane into mitochondria and being bound with Bcl-2 to expose the BH3 domain with the aid of various surface functionalities-decorated MSNs. Doxorubicin 35-38 BCL2 apoptosis regulator Homo sapiens 134-139 29787950-9 2018 Taken together, our study, for the first time, demonstrates a special approach towards pore size and surface functionality-collectively modulated silica-based nanostructural material for effective delivery of bio-macromolecules (e.g., Bcl-2-converting peptide) to treat the multidrug resistant-cancer cells with elevated Bcl-2 levels. Silicon Dioxide 146-152 BCL2 apoptosis regulator Homo sapiens 235-240 29787950-9 2018 Taken together, our study, for the first time, demonstrates a special approach towards pore size and surface functionality-collectively modulated silica-based nanostructural material for effective delivery of bio-macromolecules (e.g., Bcl-2-converting peptide) to treat the multidrug resistant-cancer cells with elevated Bcl-2 levels. Silicon Dioxide 146-152 BCL2 apoptosis regulator Homo sapiens 321-326 29898413-0 2018 Novel pregnenolone derivatives modulate apoptosis via Bcl-2 family genes in hepatocellular carcinoma in vitro. Pregnenolone 6-18 BCL2 apoptosis regulator Homo sapiens 54-59 29898413-11 2018 The present work introduced novel pro-apoptotic pregnenolone derivatives that acted against HepG2 cells through DNA fragmentation, apoptotic morphological changes and were able to increase the pro-apoptotic/anti-apoptotic ratios of Bcl-2 family genes. Pregnenolone 48-60 BCL2 apoptosis regulator Homo sapiens 232-237 29985281-10 2018 MiR-15a-5p mimic was transfected into cardiomyocytes, and the Bcl-2 was detected by immunoblotting. mir-15a-5p 0-10 BCL2 apoptosis regulator Homo sapiens 62-67 29985281-12 2018 Protein expression of Bcl-2 was increased in the simvastatin treatment group before surgery, and Bak expression was increased in the control treatment group after surgery. Simvastatin 49-60 BCL2 apoptosis regulator Homo sapiens 22-27 29985281-18 2018 Coincident with the change in miR-15a-5p, the mRNA expression of Bcl-2 was increased in the simvastatin treatment group. Simvastatin 92-103 BCL2 apoptosis regulator Homo sapiens 65-70 29985281-19 2018 MiR-15a-5p mimic significantly inhibited Bcl-2 expression in cardiomyocytes. mir-15a-5p 0-10 BCL2 apoptosis regulator Homo sapiens 41-46 29985281-20 2018 Our findings strongly suggest that simvastatin treatment preoperatively protected the myocardium in patients undergoing noncoronary artery cardiac surgery, at least in part, by inhibiting apoptosis via suppressing miR-15a-5p expression, leading to increasing expression of Bcl-2 and decreasing expression of Bak. Simvastatin 35-46 BCL2 apoptosis regulator Homo sapiens 273-278 30033314-7 2018 Down-regulation of Bcl-2 (6.6 folds) was higher in NGs + GL group compared to NGs (-GL) (1.94 fold) and mixed micelles (1.19 fold) groups. Glycolipids 57-59 BCL2 apoptosis regulator Homo sapiens 19-24 30033314-7 2018 Down-regulation of Bcl-2 (6.6 folds) was higher in NGs + GL group compared to NGs (-GL) (1.94 fold) and mixed micelles (1.19 fold) groups. Glycolipids 84-86 BCL2 apoptosis regulator Homo sapiens 19-24 30033314-8 2018 Higher Bax up-regulation in NGs + GL compared to other groups supports the Bcl-2 down regulation. Glycolipids 34-36 BCL2 apoptosis regulator Homo sapiens 75-80 30176247-12 2018 SIGNIFICANCE: These findings suggest that treatment with the selective proteasome suppressor MG-132 and TRAIL induces cell death in sebocytes through upregulation of BIK, a member of the Bcl-2 family. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 93-99 BCL2 apoptosis regulator Homo sapiens 187-192 30106096-9 2018 The results of the present study demonstrated that treatment with ethanol inhibited GES-1 cell proliferation, and enhanced ROS levels and apoptosis rates, potentially via downregulation of B-cell lymphoma-2 (Bcl-2) expression and upregulation of Bcl-2-associated X and caspase-3 expression levels, as well as enhancing the phosphorylation levels of ERK, JNK and p38. Ethanol 66-73 BCL2 apoptosis regulator Homo sapiens 189-206 30403172-9 2018 Biochemical analyses showed that the expression level of the anti-apoptosis Bcl-2 protein decreased, while the expression of the pro-apoptosis protein Bax and active caspase-3 increased after lycorine treatment. lycorine 192-200 BCL2 apoptosis regulator Homo sapiens 76-81 30047039-5 2018 By the increase of Bax/Bcl-2 ratio, zeolite X leads to the caspase-3 and caspase-9 activation and allow the cells to enter apoptosis. Zeolites 36-43 BCL2 apoptosis regulator Homo sapiens 23-28 30273298-11 2018 Mahanimbine prompted apoptosis was also associated with decline in Bcl-2 and enhancement of the Bax expression. mahanimbine 0-11 BCL2 apoptosis regulator Homo sapiens 67-72 30106096-9 2018 The results of the present study demonstrated that treatment with ethanol inhibited GES-1 cell proliferation, and enhanced ROS levels and apoptosis rates, potentially via downregulation of B-cell lymphoma-2 (Bcl-2) expression and upregulation of Bcl-2-associated X and caspase-3 expression levels, as well as enhancing the phosphorylation levels of ERK, JNK and p38. Ethanol 66-73 BCL2 apoptosis regulator Homo sapiens 208-213 30106096-9 2018 The results of the present study demonstrated that treatment with ethanol inhibited GES-1 cell proliferation, and enhanced ROS levels and apoptosis rates, potentially via downregulation of B-cell lymphoma-2 (Bcl-2) expression and upregulation of Bcl-2-associated X and caspase-3 expression levels, as well as enhancing the phosphorylation levels of ERK, JNK and p38. Ethanol 66-73 BCL2 apoptosis regulator Homo sapiens 246-251 30138565-2 2018 G3139 and RX-0201, targeting Bcl-2 and Akt-1, respectively, are antisense oligonucleotides (ASOs) that have shown limited efficacy in clinical trials. Oligonucleotides 74-90 BCL2 apoptosis regulator Homo sapiens 29-34 30066940-4 2018 Data obtained from western blotting suggested that astilbin suppressed the expression levels of B-cell lymphoma 2 (Bcl-2), while it increased the expression levels of cleaved caspase-3, -8 and -9, and Bcl-2-associated X protein in breast carcinoma cells. astilbin 51-59 BCL2 apoptosis regulator Homo sapiens 96-113 30138565-2 2018 G3139 and RX-0201, targeting Bcl-2 and Akt-1, respectively, are antisense oligonucleotides (ASOs) that have shown limited efficacy in clinical trials. Oligonucleotides, Antisense 92-96 BCL2 apoptosis regulator Homo sapiens 29-34 30197671-9 2018 Western blotting showed that the protein expression level of Bcl-2 in administration group in different concentrations was significantly increased with the increase of zerumbone concentration, but that of Bcl-2 was significantly decreased in a concentration-dependent manner. zerumbone 168-177 BCL2 apoptosis regulator Homo sapiens 61-66 30066940-4 2018 Data obtained from western blotting suggested that astilbin suppressed the expression levels of B-cell lymphoma 2 (Bcl-2), while it increased the expression levels of cleaved caspase-3, -8 and -9, and Bcl-2-associated X protein in breast carcinoma cells. astilbin 51-59 BCL2 apoptosis regulator Homo sapiens 115-120 30197671-10 2018 Zerumbone can inhibit the proliferation and induce apoptosis of esophageal cancer EC-109 cells, and its induction of apoptosis may be realized through upregulating the mRNA expression of P53 and downregulating the mRNA expression of Bcl-2, and upregulating the protein expression of P53 and downregulating the protein expression of Bcl-2. zerumbone 0-9 BCL2 apoptosis regulator Homo sapiens 233-238 30197671-10 2018 Zerumbone can inhibit the proliferation and induce apoptosis of esophageal cancer EC-109 cells, and its induction of apoptosis may be realized through upregulating the mRNA expression of P53 and downregulating the mRNA expression of Bcl-2, and upregulating the protein expression of P53 and downregulating the protein expression of Bcl-2. zerumbone 0-9 BCL2 apoptosis regulator Homo sapiens 332-337 30066940-4 2018 Data obtained from western blotting suggested that astilbin suppressed the expression levels of B-cell lymphoma 2 (Bcl-2), while it increased the expression levels of cleaved caspase-3, -8 and -9, and Bcl-2-associated X protein in breast carcinoma cells. astilbin 51-59 BCL2 apoptosis regulator Homo sapiens 201-206 30128635-4 2018 We recently reported the development of a novel class of synthetic protein based on scyllatoxin (ScTx) designed to mimic the helical BH3 interaction domain of the pro-apoptotic BCL2 protein Bax. BH 3 133-136 BCL2 apoptosis regulator Homo sapiens 177-181 30197674-9 2018 Furthermore, the western blot assay also indicated that with an increase in the concentration of beta-bourbonene, the protein expression of Bax in the drug-treatment group was significantly elevated, while a decrease was identified in the protein expression of Bcl-2. beta-bourbonene 97-112 BCL2 apoptosis regulator Homo sapiens 261-266 30197674-10 2018 Taken together, beta-bourbonene can inhibit the proliferation and simultaneously, induce apoptosis and G0/G1 arrest of prostate cancer PC-3M cells, which may be realized by upregulation of mRNA expression of Fas and FasL, increase of Bax protein expression and decrease of Bcl-2 protein expression. beta-bourbonene 16-31 BCL2 apoptosis regulator Homo sapiens 273-278 30197679-10 2018 Expression levels of pro-apoptotic protein were upregulated, whereas anti-apoptotic Bcl-2 was downregulated significantly in 143B cells following SAHA/cisplatin treatment. Vorinostat 146-150 BCL2 apoptosis regulator Homo sapiens 84-89 30197679-10 2018 Expression levels of pro-apoptotic protein were upregulated, whereas anti-apoptotic Bcl-2 was downregulated significantly in 143B cells following SAHA/cisplatin treatment. Cisplatin 151-160 BCL2 apoptosis regulator Homo sapiens 84-89 30128635-5 2018 These studies showed that the number and position of native disulfide linkages contained within the ScTx-Bax structure significantly influences the ability for these constructs to target anti-apoptotic BCL2 proteins in vitro. Disulfides 60-69 BCL2 apoptosis regulator Homo sapiens 202-206 30128635-9 2018 Furthermore, we show that select (bis)disulfide ScTx-Bax variants can target Bcl-2 (proper) in vitro and that the position of the disulfide bonds significantly influences binding affinity. (bis)disulfide 33-47 BCL2 apoptosis regulator Homo sapiens 77-82 30128635-9 2018 Furthermore, we show that select (bis)disulfide ScTx-Bax variants can target Bcl-2 (proper) in vitro and that the position of the disulfide bonds significantly influences binding affinity. Disulfides 38-47 BCL2 apoptosis regulator Homo sapiens 77-82 30003979-11 2018 Combination of TMZ and VP increased the ratio of Bax to Bcl-2 expression and thus shifted the equilibrium of cells towards apoptosis. Temozolomide 15-18 BCL2 apoptosis regulator Homo sapiens 56-61 30003979-11 2018 Combination of TMZ and VP increased the ratio of Bax to Bcl-2 expression and thus shifted the equilibrium of cells towards apoptosis. Verapamil 23-25 BCL2 apoptosis regulator Homo sapiens 56-61 30055346-1 2018 Several newly developed drugs including JQ1 (BET inhibitor), ABT199 (BCL2 inhibitor), and bortezomib (proteasome inhibitor) may offer novel therapeutic strategies for aggressive diffuse large B-cell lymphoma (DLBCL). venetoclax 61-67 BCL2 apoptosis regulator Homo sapiens 69-73 30031050-1 2018 BH3 mimetics, such as BH3I-1, act as Bcl-2 antagonists, promote apoptosis and are used in basic research studies on apoptotic signaling and are currently tested as experimental anti-tumor agents. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 37-42 30217947-6 2018 HDAC2 knockdown repressed the proliferation rate and promoted high glucose-induced apoptosis of ECs, which was associated with the activation of apoptotic pathways (Bcl-2, Caspase 3, and Bax). Glucose 67-74 BCL2 apoptosis regulator Homo sapiens 165-170 29902531-9 2018 Furthermore, HE inhibited H2O2-induced changes of apoptosis-related proteins, such as Bcl-2, Bcl-xL, caspases -3, -9 and PARP. Hydrogen Peroxide 26-30 BCL2 apoptosis regulator Homo sapiens 86-91 30250566-10 2018 Erianin treatment also increased the expression of Bax and caspase-3, but decreased levels of Bcl-2 and phosphorylated-ERK1/2. Erianin 0-7 BCL2 apoptosis regulator Homo sapiens 94-99 30255683-6 2018 With the increase of the concentration of celastrol, the ratio of Bax/Bcl-2 protein was up-regulated. celastrol 42-51 BCL2 apoptosis regulator Homo sapiens 70-75 30255241-9 2018 The western blotting analysis also showed that DOP-40, DOP-60, and DOP-70 induced apoptosis in HepG2 human liver cancer cells through the Bcl-2 and Bax-dependent pathway. Diethylhexyl Phthalate 47-50 BCL2 apoptosis regulator Homo sapiens 138-143 30255241-9 2018 The western blotting analysis also showed that DOP-40, DOP-60, and DOP-70 induced apoptosis in HepG2 human liver cancer cells through the Bcl-2 and Bax-dependent pathway. Diethylhexyl Phthalate 55-58 BCL2 apoptosis regulator Homo sapiens 138-143 30255241-9 2018 The western blotting analysis also showed that DOP-40, DOP-60, and DOP-70 induced apoptosis in HepG2 human liver cancer cells through the Bcl-2 and Bax-dependent pathway. Diethylhexyl Phthalate 55-58 BCL2 apoptosis regulator Homo sapiens 138-143 30256055-9 2018 Atorvastatin down-regulatedthe expression of VEGF, CD31 and Bcl-2, and induced the expression of caspase-3 especially at 10muM concentration.These effects are dose dependent. Atorvastatin 0-12 BCL2 apoptosis regulator Homo sapiens 60-65 30257423-4 2018 Nano-TQ effectively augments the anticancer roles of doxorubicin by upregulation of P53 and downregulation of Bcl2 and potentiates paclitaxel"s apoptosis in MCF-7 breast cancer cells. Doxorubicin 53-64 BCL2 apoptosis regulator Homo sapiens 110-114 30255683-9 2018 Taken together, these results indicated that celastrol effectively inhibited the proliferation of adult T-cell leukemia cells by regulating the expression of Bcl-2 family protein, and induced cell apoptosis by activating Caspase dependent pathway. celastrol 45-54 BCL2 apoptosis regulator Homo sapiens 158-163 30248940-6 2018 Combined treatment with melatonin and retinoic acid decreased the expression of the Bcl-2. Melatonin 24-33 BCL2 apoptosis regulator Homo sapiens 84-89 30246777-6 2018 We also found that the protein and mRNA levels of Bax, p53, and Fas dose-dependently increased in DFO-treated K562 cells, while the level of Bcl-2 markedly decreased in a dose-dependent manner. Deferoxamine 98-101 BCL2 apoptosis regulator Homo sapiens 141-146 30248086-0 2018 Cantharidin Inhibits Anti-Apoptotic Bcl-2 Family Proteins and Induces Apoptosis in Human Osteosarcoma Cell Lines MG-63 and MNNG/HOS via Mitochondria-Dependent Pathway. Cantharidin 0-11 BCL2 apoptosis regulator Homo sapiens 36-41 30248086-8 2018 In addition, cantharidin-induced apoptosis was accompanied by increased expression of Bax and PARP and decreased expression of Bcl-2, p-Akt, and p-Cdc2. Cantharidin 13-24 BCL2 apoptosis regulator Homo sapiens 127-132 30160475-3 2018 5"- O-Methyl-3-hydroxyflemingin A (3) inhibited Hh signaling (IC50 7.3 muM), leading to decreasing production of the Hh target proteins BCL2, PTCH1, and BMI1. 5"- o-methyl-3-hydroxyflemingin a 0-33 BCL2 apoptosis regulator Homo sapiens 136-140 30248940-6 2018 Combined treatment with melatonin and retinoic acid decreased the expression of the Bcl-2. Tretinoin 38-51 BCL2 apoptosis regulator Homo sapiens 84-89 30248940-12 2018 The changes in the activation of proliferation in HL-60 cells, the mitotic index, and Bcl-2 expression under combined effect of retinoic acid (10 nM) with melatonin (1 mM) are similar to changes that are induced by 1 muM retinoic acid. Tretinoin 128-141 BCL2 apoptosis regulator Homo sapiens 86-91 30248940-12 2018 The changes in the activation of proliferation in HL-60 cells, the mitotic index, and Bcl-2 expression under combined effect of retinoic acid (10 nM) with melatonin (1 mM) are similar to changes that are induced by 1 muM retinoic acid. Melatonin 155-164 BCL2 apoptosis regulator Homo sapiens 86-91 30242253-2 2018 Previous studies showed that chondrosarcoma cells could be sensitized to chemotherapy by inhibiting the Bcl-2 family members Bcl-2, Bcl-xl and Bcl-w using ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 155-158 BCL2 apoptosis regulator Homo sapiens 104-109 30242253-2 2018 Previous studies showed that chondrosarcoma cells could be sensitized to chemotherapy by inhibiting the Bcl-2 family members Bcl-2, Bcl-xl and Bcl-w using ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 155-158 BCL2 apoptosis regulator Homo sapiens 125-130 30288106-10 2018 Conclusion: Downregulation of S100A9 could significantly increase apoptosis rate, resulting in enhancing sensitivity of SiHa cells to cisplatin, which may be related to Bcl-2, GST-pi, and LRP protein and by altering the AKT/ERK-FOXO1-Nanog signaling pathway. Cisplatin 134-143 BCL2 apoptosis regulator Homo sapiens 169-174 30012635-4 2018 The US Food and Drug Administration (FDA)-approved BCL-2 inhibitor venetoclax was first proven to be highly effective in chronic lymphocytic leukemia and some B-cell non-Hodgkin lymphoma subtypes. venetoclax 67-77 BCL2 apoptosis regulator Homo sapiens 51-56 30275715-8 2018 Mechanistically, NVP-BEZ235 inhibited PI3K/Akt/mTOR signaling; decreased the levels of Bcl-2, MMP9, and VEGF; but increased the levels of Bax and cleaved caspase-3 in MKN-45 xenografts. dactolisib 21-27 BCL2 apoptosis regulator Homo sapiens 87-92 30146257-5 2018 Mechanically, we demonstrated that anlotinib treatment downregulated the anti-apoptotic protein Bcl-2 and Survivin, but upregulated pro-apoptotic molecule Bax, which accounts for its therapeutic effect on HCC. anlotinib 35-44 BCL2 apoptosis regulator Homo sapiens 96-101 30146257-7 2018 Together, this study suggests that anlotinib may have a direct antitumor progression effect on HCC by inhibiting Bcl-2 and Survivin expression, promoting Bax expression via inactivating Erk and Akt pathways and could be a promising agent treating HCC. anlotinib 35-44 BCL2 apoptosis regulator Homo sapiens 113-118 29895707-1 2018 Purpose: The oral BCL-2 inhibitor venetoclax is an effective therapy for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), including disease with high-risk genomic features such as chromosome 17p deletion [del(17p)] or progressive disease following B-cell receptor pathway inhibitors.Patients and Methods: We conducted a comprehensive analysis of the safety of 400 mg daily venetoclax monotherapy in 350 patients with CLL using an integrated dataset from three phase I/II studies.Results: Median age was 66 years and 60% had del(17p). venetoclax 34-44 BCL2 apoptosis regulator Homo sapiens 18-23 30219819-0 2018 MicroRNA-7-5p Promotes Cisplatin Resistance of Cervical Cancer Cells and Modulation of Cellular Energy Homeostasis by Regulating the Expression of the PARP-1 and BCL2 Genes. Cisplatin 23-32 BCL2 apoptosis regulator Homo sapiens 162-166 30001917-5 2018 Mechanism study revealed that H20 caused severe depletion of cellular ATP, dose-dependently activated AMPK, decreased Bcl-2/Bax ratio and induced necrotic cell death. h20 30-33 BCL2 apoptosis regulator Homo sapiens 118-123 29895707-1 2018 Purpose: The oral BCL-2 inhibitor venetoclax is an effective therapy for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), including disease with high-risk genomic features such as chromosome 17p deletion [del(17p)] or progressive disease following B-cell receptor pathway inhibitors.Patients and Methods: We conducted a comprehensive analysis of the safety of 400 mg daily venetoclax monotherapy in 350 patients with CLL using an integrated dataset from three phase I/II studies.Results: Median age was 66 years and 60% had del(17p). venetoclax 400-410 BCL2 apoptosis regulator Homo sapiens 18-23 30210141-10 2018 However, following melatonin treatment in the SAH group, the level of Bcl-2 was increased while the levels of Bax and cleaved caspase-3 were decreased. Melatonin 19-28 BCL2 apoptosis regulator Homo sapiens 70-75 30170927-0 2018 Discovery and development of substituted tyrosine derivatives as Bcl-2/Mcl-1 inhibitors. Tyrosine 41-49 BCL2 apoptosis regulator Homo sapiens 65-70 30170927-3 2018 Based on this, a series of substituted tyrosine derivatives were developed and tested for their binding affinities to Bcl-2 protein. Tyrosine 39-47 BCL2 apoptosis regulator Homo sapiens 118-123 30056019-10 2018 Curcumin treatment also resulted in a decrease in anti-apoptotic proteins, p-Akt, Akt, Bcl-2 and p-Bad, and increase in pro-apoptotic proteins Bad and c-PARP levels in the control cells but not in the HSP27-KD cells. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 87-92 30218002-3 2018 Therefore, we investigated whether Bcl-2 plays a role in CS-induced mucous expression. Cesium 57-59 BCL2 apoptosis regulator Homo sapiens 35-40 30218002-4 2018 Primary airway epithelial cells (AECs) of murine and human origin were treated with CS extract (CSE), and there was a concentration- and time-dependent increase in secretory mucin (MUC5AC), mucous regulator (SPDEF) and Bcl-2 expression. Cesium 84-86 BCL2 apoptosis regulator Homo sapiens 219-224 30218002-6 2018 Bcl-2 activity was blocked using a small molecule BH3 mimetic ABT-263 that disrupts the Bcl-2 interaction with pro-apoptotic proteins. BH 3 50-53 BCL2 apoptosis regulator Homo sapiens 0-5 30218002-6 2018 Bcl-2 activity was blocked using a small molecule BH3 mimetic ABT-263 that disrupts the Bcl-2 interaction with pro-apoptotic proteins. BH 3 50-53 BCL2 apoptosis regulator Homo sapiens 88-93 30218002-6 2018 Bcl-2 activity was blocked using a small molecule BH3 mimetic ABT-263 that disrupts the Bcl-2 interaction with pro-apoptotic proteins. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 62-65 BCL2 apoptosis regulator Homo sapiens 0-5 30218002-6 2018 Bcl-2 activity was blocked using a small molecule BH3 mimetic ABT-263 that disrupts the Bcl-2 interaction with pro-apoptotic proteins. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 62-65 BCL2 apoptosis regulator Homo sapiens 88-93 30218002-9 2018 Therefore, the present study suggests that CS induces Bcl-2 expression to help promote mucous cell survival; and small molecule BH3 mimetics targeting Bcl-2 could be useful in suppressing the CS-induced mucous response. Cesium 43-45 BCL2 apoptosis regulator Homo sapiens 54-59 30218002-9 2018 Therefore, the present study suggests that CS induces Bcl-2 expression to help promote mucous cell survival; and small molecule BH3 mimetics targeting Bcl-2 could be useful in suppressing the CS-induced mucous response. BH 3 128-131 BCL2 apoptosis regulator Homo sapiens 151-156 30218002-9 2018 Therefore, the present study suggests that CS induces Bcl-2 expression to help promote mucous cell survival; and small molecule BH3 mimetics targeting Bcl-2 could be useful in suppressing the CS-induced mucous response. Cesium 192-194 BCL2 apoptosis regulator Homo sapiens 151-156 29373840-6 2018 Meanwhile, icariin inhibited the caspase cascade in podocyte apoptosis by promoting Bcl-2 expression and mitochondrial translocation. icariin 11-18 BCL2 apoptosis regulator Homo sapiens 84-89 29373840-7 2018 The above findings at least partly elucidated the mechanism by which icariin stabilized podocytes by inducing the mitochondrial Bcl-2 translocation and therefore preventing downstream apoptosis. icariin 69-76 BCL2 apoptosis regulator Homo sapiens 128-133 29751043-6 2018 TUDCA alleviated gentamicin-induced cell apoptosis, supported by the decreased Bax/Bcl2 ratio compared with that of gentamicin treated alone. ursodoxicoltaurine 0-5 BCL2 apoptosis regulator Homo sapiens 83-87 29751043-6 2018 TUDCA alleviated gentamicin-induced cell apoptosis, supported by the decreased Bax/Bcl2 ratio compared with that of gentamicin treated alone. Gentamicins 17-27 BCL2 apoptosis regulator Homo sapiens 83-87 30213983-4 2018 HTLA-ER cells, following etoposide exposure, evaded apoptosis by altering Bax/Bcl2 ratio. Etoposide 25-34 BCL2 apoptosis regulator Homo sapiens 78-82 30258282-8 2018 Plasma from AD patients further increased Bax mRNA levels but decreased Bcl2 and alpha-SMA mRNA levels in Ang II-treated HASMCs. hasmcs 121-127 BCL2 apoptosis regulator Homo sapiens 72-76 30203318-7 2018 Cell-of-origin and MYC/BCL2 expression can further build on CNS-IPI to narrow higher risk patients. diprotin A 64-67 BCL2 apoptosis regulator Homo sapiens 23-27 30217003-5 2018 CTT induced an increase of caspase-3, caspase-9, poly-ADP-ribose polymerase (PARP), and Bax, as well as inhibition of Bcl-2, survivin, and cellular-inhibitor of apoptosis protein 1 and 2 (cIAP-1 and -2). cryptotanshinone 0-3 BCL2 apoptosis regulator Homo sapiens 118-123 30201862-4 2018 Furthermore, Moracin D increased sub G1 population; cleaved poly (Adenosine diphosphate (ADP-ribose)) polymerase (PARP); activated cysteine aspartyl-specific protease 3 (caspase 3); and attenuated the expression of c-Myc, cyclin D1, B-cell lymphoma 2 (Bcl-2), and X-linked inhibitor of apoptosis protein (XIAP) in MDA-MB231 cells. Moracin D 13-22 BCL2 apoptosis regulator Homo sapiens 252-257 30185768-8 2018 Furthermore, we found a significant reduction of JAK2/STAT3 activation and the Bax/Bcl-2 ratio in LPS-induced HUVECs response to rosiglitazone treatment. Rosiglitazone 129-142 BCL2 apoptosis regulator Homo sapiens 83-88 30185782-2 2018 BH3 mimetics against members of the BCL-2 family have gained excitement with the recent success in hematological malignancies. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 36-41 30031796-6 2018 However, the protein expression changes of Nrf2, HO-1, GCLC, Bcl-2, Bcl-xl and Bax could be abrogated by Nrf2 antagonist brusatol. brusatol 121-129 BCL2 apoptosis regulator Homo sapiens 61-66 30185782-4 2018 We tested the efficacy of the BH3 mimetic combination of A-1210477 (an MCL-1 inhibitor) and ABT-263 (a BCL-2/BCL-XL/BCL-W inhibitor) in killing melanoma, especially MICs. BH 3 30-33 BCL2 apoptosis regulator Homo sapiens 103-108 30180807-10 2018 RESULTS: Treatment with glibenclamide aggravated the apoptosis of HK-2 cells in high-glucose, as indicated by a significant decrease in the expression of Bcl-2 and increase in Bax. Glyburide 24-37 BCL2 apoptosis regulator Homo sapiens 154-159 30028622-7 2018 It was demonstrated that when the total loaded siRNA amounts were kept the same in the nanocomplexes, the simultaneous silencing of triple genes with co-loaded siRNAs (i.e., Bcl-2, survivin, and AR-targeting siRNAs) enhanced BZT-induced apoptosis of cancer cells more efficiently than the silencing of each single gene alone, offering a novel way of improving the efficacy of gene therapeutics including anticancer drug. bzt 225-228 BCL2 apoptosis regulator Homo sapiens 174-179 30185782-4 2018 We tested the efficacy of the BH3 mimetic combination of A-1210477 (an MCL-1 inhibitor) and ABT-263 (a BCL-2/BCL-XL/BCL-W inhibitor) in killing melanoma, especially MICs. navitoclax 92-99 BCL2 apoptosis regulator Homo sapiens 103-108 29908495-5 2018 The results of mitochondrial membrane potential analysis, cell cycle analysis, FT-IR and Western blotting analysis clearly demonstrated the molecular mechanism of phytol as induction of apoptosis in A549 cells, as evidenced by formation of shrinked cell morphology with membrane blebbing, depolarization of mitochondrial membrane potential, increased cell population in the sub-G0 phase, band variation in the DNA and lipid region, downregulation of Bcl-2, upregulation of Bax and the activation of caspase-9 and -3. Phytol 163-169 BCL2 apoptosis regulator Homo sapiens 450-455 30001609-9 2018 Moreover, knock-down of AUF1 and ZFP36L1 enhanced interaction of Bcl-2 with Beclin-1, and subsequently prevented gAcrp-induced autophagy activation, suggesting that AUF1 and ZFP36L1 induction mediates gAcrp-induced autophagy activation via Bcl-2 mRNA destabilization. gacrp 201-206 BCL2 apoptosis regulator Homo sapiens 240-245 30001609-8 2018 In addition, gene silencing of AUF1 and ZFP36L1 caused restoration of decrease in Bcl-2 expression and Bcl-2 mRNA half-life by gAcrp, indicating crucial roles of AUF1 and ZFP36L1 induction in Bcl-2 mRNA destabilization by gAcrp. gacrp 127-132 BCL2 apoptosis regulator Homo sapiens 82-87 30001609-8 2018 In addition, gene silencing of AUF1 and ZFP36L1 caused restoration of decrease in Bcl-2 expression and Bcl-2 mRNA half-life by gAcrp, indicating crucial roles of AUF1 and ZFP36L1 induction in Bcl-2 mRNA destabilization by gAcrp. gacrp 127-132 BCL2 apoptosis regulator Homo sapiens 103-108 30001609-8 2018 In addition, gene silencing of AUF1 and ZFP36L1 caused restoration of decrease in Bcl-2 expression and Bcl-2 mRNA half-life by gAcrp, indicating crucial roles of AUF1 and ZFP36L1 induction in Bcl-2 mRNA destabilization by gAcrp. gacrp 127-132 BCL2 apoptosis regulator Homo sapiens 103-108 30001609-8 2018 In addition, gene silencing of AUF1 and ZFP36L1 caused restoration of decrease in Bcl-2 expression and Bcl-2 mRNA half-life by gAcrp, indicating crucial roles of AUF1 and ZFP36L1 induction in Bcl-2 mRNA destabilization by gAcrp. gacrp 222-227 BCL2 apoptosis regulator Homo sapiens 82-87 30001609-8 2018 In addition, gene silencing of AUF1 and ZFP36L1 caused restoration of decrease in Bcl-2 expression and Bcl-2 mRNA half-life by gAcrp, indicating crucial roles of AUF1 and ZFP36L1 induction in Bcl-2 mRNA destabilization by gAcrp. gacrp 222-227 BCL2 apoptosis regulator Homo sapiens 103-108 30001609-8 2018 In addition, gene silencing of AUF1 and ZFP36L1 caused restoration of decrease in Bcl-2 expression and Bcl-2 mRNA half-life by gAcrp, indicating crucial roles of AUF1 and ZFP36L1 induction in Bcl-2 mRNA destabilization by gAcrp. gacrp 222-227 BCL2 apoptosis regulator Homo sapiens 103-108 30001609-9 2018 Moreover, knock-down of AUF1 and ZFP36L1 enhanced interaction of Bcl-2 with Beclin-1, and subsequently prevented gAcrp-induced autophagy activation, suggesting that AUF1 and ZFP36L1 induction mediates gAcrp-induced autophagy activation via Bcl-2 mRNA destabilization. gacrp 113-118 BCL2 apoptosis regulator Homo sapiens 65-70 30001609-9 2018 Moreover, knock-down of AUF1 and ZFP36L1 enhanced interaction of Bcl-2 with Beclin-1, and subsequently prevented gAcrp-induced autophagy activation, suggesting that AUF1 and ZFP36L1 induction mediates gAcrp-induced autophagy activation via Bcl-2 mRNA destabilization. gacrp 113-118 BCL2 apoptosis regulator Homo sapiens 240-245 30001609-9 2018 Moreover, knock-down of AUF1 and ZFP36L1 enhanced interaction of Bcl-2 with Beclin-1, and subsequently prevented gAcrp-induced autophagy activation, suggesting that AUF1 and ZFP36L1 induction mediates gAcrp-induced autophagy activation via Bcl-2 mRNA destabilization. gacrp 201-206 BCL2 apoptosis regulator Homo sapiens 65-70 29333561-0 2018 Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus. venetoclax 60-70 BCL2 apoptosis regulator Homo sapiens 24-41 29745420-10 2018 BCL-2 inhibitor initiated cell death in T cells from patients refractory to AZA and reduced lymphocyte count in Il10-/- mice. Azathioprine 76-79 BCL2 apoptosis regulator Homo sapiens 0-5 29745420-15 2018 BCL-2 inhibition could be a new therapy option for patients refractory to AZA. Azathioprine 74-77 BCL2 apoptosis regulator Homo sapiens 0-5 29333561-0 2018 Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus. venetoclax 60-70 BCL2 apoptosis regulator Homo sapiens 43-48 29333561-1 2018 BACKGROUND AND OBJECTIVE: Venetoclax is an oral selective Bcl-2 inhibitor approved for the treatment of patients with chronic lymphocytic leukemia with 17p deletion. venetoclax 26-36 BCL2 apoptosis regulator Homo sapiens 58-63 30015875-6 2018 Secondly, the stable overexpression of Bcl-2 and ability to shift metabolism towards oxidative phosphorylation (OXPHOS) in SKOV3/DDP cells were associated with increased oxygen consumption. Oxygen 170-176 BCL2 apoptosis regulator Homo sapiens 39-44 29972271-7 2018 Simultaneously, nicotine induces pancreatic islet cell apoptosis by modulating DeltaPsim via increased cytosolic Ca2+ level, altered Bcl-2, Bax, cytochrome c, caspase-9, PARP expressions which were prevented by the supplementation of folic acid and vitamin B12 . Nicotine 16-24 BCL2 apoptosis regulator Homo sapiens 133-138 29595064-1 2018 Venetoclax is a highly selective, potent BCL-2 inhibitor that is approved for some patients previously treated for chronic lymphocytic leukemia, and has shown promising activity in adult studies across several hematologic malignancies. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 41-46 30015875-10 2018 Furthermore, when combined with 2-deoxyglucose (2-DG), the anticancer effect of the Bcl-2 inhibitor ABT737 was greatly potentiated and hypoxia-inducible factor 1alpha (HIF-1alpha) appeared to be closely associated with Bcl-2 family members in the regulation of glucose metabolism. Deoxyglucose 32-46 BCL2 apoptosis regulator Homo sapiens 219-224 30015875-10 2018 Furthermore, when combined with 2-deoxyglucose (2-DG), the anticancer effect of the Bcl-2 inhibitor ABT737 was greatly potentiated and hypoxia-inducible factor 1alpha (HIF-1alpha) appeared to be closely associated with Bcl-2 family members in the regulation of glucose metabolism. Deoxyglucose 48-52 BCL2 apoptosis regulator Homo sapiens 84-89 29962003-4 2018 We also found that nimbolide induced cell death through the induction of G2/M phase arrest and mitochondrial dysfunction, accompanied by the increased expression of cleaved caspase-7, caspase-9, caspase-3, caspase-PARP, and Bax and decreased expression of Mcl-1 and Bcl-2. nimbolide 19-28 BCL2 apoptosis regulator Homo sapiens 266-271 29880613-1 2018 Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 16-20 29916532-9 2018 The enhanced ROS-p38-p53 and ER stress pathways promoted apoptosis by downregulating B-cell lymphoma-2 (Bcl-2) expression and upregulating Bcl-2-associated X protein expression. Reactive Oxygen Species 13-16 BCL2 apoptosis regulator Homo sapiens 85-102 29916532-9 2018 The enhanced ROS-p38-p53 and ER stress pathways promoted apoptosis by downregulating B-cell lymphoma-2 (Bcl-2) expression and upregulating Bcl-2-associated X protein expression. Reactive Oxygen Species 13-16 BCL2 apoptosis regulator Homo sapiens 104-109 29916532-9 2018 The enhanced ROS-p38-p53 and ER stress pathways promoted apoptosis by downregulating B-cell lymphoma-2 (Bcl-2) expression and upregulating Bcl-2-associated X protein expression. Reactive Oxygen Species 13-16 BCL2 apoptosis regulator Homo sapiens 139-144 30015875-10 2018 Furthermore, when combined with 2-deoxyglucose (2-DG), the anticancer effect of the Bcl-2 inhibitor ABT737 was greatly potentiated and hypoxia-inducible factor 1alpha (HIF-1alpha) appeared to be closely associated with Bcl-2 family members in the regulation of glucose metabolism. Deoxyglucose 48-52 BCL2 apoptosis regulator Homo sapiens 219-224 30015875-10 2018 Furthermore, when combined with 2-deoxyglucose (2-DG), the anticancer effect of the Bcl-2 inhibitor ABT737 was greatly potentiated and hypoxia-inducible factor 1alpha (HIF-1alpha) appeared to be closely associated with Bcl-2 family members in the regulation of glucose metabolism. ABT-737 100-106 BCL2 apoptosis regulator Homo sapiens 84-89 30015875-9 2018 Furthermore, the inhibition of Bcl-2 reduced the OXPHOS and sensitivity of SKOV3/DDP cells to cisplatin in a selective manner. Cisplatin 94-103 BCL2 apoptosis regulator Homo sapiens 31-36 30015875-10 2018 Furthermore, when combined with 2-deoxyglucose (2-DG), the anticancer effect of the Bcl-2 inhibitor ABT737 was greatly potentiated and hypoxia-inducible factor 1alpha (HIF-1alpha) appeared to be closely associated with Bcl-2 family members in the regulation of glucose metabolism. ABT-737 100-106 BCL2 apoptosis regulator Homo sapiens 219-224 30015875-10 2018 Furthermore, when combined with 2-deoxyglucose (2-DG), the anticancer effect of the Bcl-2 inhibitor ABT737 was greatly potentiated and hypoxia-inducible factor 1alpha (HIF-1alpha) appeared to be closely associated with Bcl-2 family members in the regulation of glucose metabolism. Glucose 39-46 BCL2 apoptosis regulator Homo sapiens 84-89 30015875-10 2018 Furthermore, when combined with 2-deoxyglucose (2-DG), the anticancer effect of the Bcl-2 inhibitor ABT737 was greatly potentiated and hypoxia-inducible factor 1alpha (HIF-1alpha) appeared to be closely associated with Bcl-2 family members in the regulation of glucose metabolism. Glucose 39-46 BCL2 apoptosis regulator Homo sapiens 219-224 30015875-11 2018 These results suggested that the special glucose metabolism in SKOV3/DDP cells might be selectively targeted by disrupting Bcl-2-dependent OXPHOS. Glucose 41-48 BCL2 apoptosis regulator Homo sapiens 123-128 30015875-10 2018 Furthermore, when combined with 2-deoxyglucose (2-DG), the anticancer effect of the Bcl-2 inhibitor ABT737 was greatly potentiated and hypoxia-inducible factor 1alpha (HIF-1alpha) appeared to be closely associated with Bcl-2 family members in the regulation of glucose metabolism. Deoxyglucose 32-46 BCL2 apoptosis regulator Homo sapiens 84-89 29761894-4 2018 Our results indicate that fucoxanthin significantly inhibits the viability of SGC-7901 cells, effectively inducing both autophagy and apoptosis by up-regulating the expressions of beclin-1, LC3, and cleaved caspase-3 (CC3), and by down regulating Bcl-2. fucoxanthin 26-37 BCL2 apoptosis regulator Homo sapiens 247-252 29752478-6 2018 Furthermore, bafilomycin C1 decreased the expression of Bcl-2; increased the expression of Bax, p53, and P-p53; and increased cleavage of caspase-9 and caspase-3, thereby inducing the intrinsic caspase-dependent apoptotic pathway. bafilomycin C1 13-27 BCL2 apoptosis regulator Homo sapiens 56-61 29911313-6 2018 Curcumin effectively reduced bile-induced bcl-2 overexpression at both acidic and neutral pH. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 42-47 30249893-8 2018 Conclusions: Survivin may be implicated in the bcl-2 and p53 pathways and therefore in the biology of PDAC. pdac 102-106 BCL2 apoptosis regulator Homo sapiens 47-52 30524690-11 2018 Expressions of cleaved caspase 3 and Bax protein, as pro-apoptotic proteins, were increased and Bcl-2 protein as anti-apoptotic protein was decreased in response to increases in the concentration of ALN (0.8-25 microM). Alendronate 199-202 BCL2 apoptosis regulator Homo sapiens 96-101 30098987-7 2018 Moreover, IGF-IIR signaling triggered Rab9-dependent autophagosome formation by the JNK-mediated phosphorylation of Bcl-2 at serine 87 and promoted ULK1/Beclin 1-dependent autophagic membrane formation. Serine 125-131 BCL2 apoptosis regulator Homo sapiens 116-121 30076373-3 2018 The oral drug venetoclax is the first-in-class Bcl-2-specific BH3 mimetic. venetoclax 14-24 BCL2 apoptosis regulator Homo sapiens 47-52 30043217-10 2018 Moreover, cantharidin reduced cell proliferation and induced apoptosis with downregulation of STAT3 target genes, such as Bcl-2, COX-2, and cyclin D1. Cantharidin 10-21 BCL2 apoptosis regulator Homo sapiens 122-127 30076373-3 2018 The oral drug venetoclax is the first-in-class Bcl-2-specific BH3 mimetic. BH 3 62-65 BCL2 apoptosis regulator Homo sapiens 47-52 29856104-5 2018 In this study, we for the first time demonstrated that rosiglitazone could sensitize (-)-G to induce apoptosis in cancer cells with high level of Bcl-2. Rosiglitazone 55-68 BCL2 apoptosis regulator Homo sapiens 146-151 29856104-0 2018 The PPARgamma agonist rosiglitazone sensitizes the BH3 mimetic (-)-gossypol to induce apoptosis in cancer cells with high level of Bcl-2. Rosiglitazone 22-35 BCL2 apoptosis regulator Homo sapiens 131-136 29856104-8 2018 Animal experiments showed that rosiglitazone could sensitize (-)-G to repress the growth of cancer cells with high level of Bcl-2 in vivo. Rosiglitazone 31-44 BCL2 apoptosis regulator Homo sapiens 124-129 29856104-0 2018 The PPARgamma agonist rosiglitazone sensitizes the BH3 mimetic (-)-gossypol to induce apoptosis in cancer cells with high level of Bcl-2. BH 3 51-54 BCL2 apoptosis regulator Homo sapiens 131-136 29856104-9 2018 Taken together, our results suggest that the PPARgamma agonists may enhance the therapeutic effect of BH3 mimetics in cancers with high level of Bcl-2 through regulating the DUSP16/JNK/Mcl-1 singling pathway. BH 3 102-105 BCL2 apoptosis regulator Homo sapiens 145-150 29856104-0 2018 The PPARgamma agonist rosiglitazone sensitizes the BH3 mimetic (-)-gossypol to induce apoptosis in cancer cells with high level of Bcl-2. Gossypol 63-75 BCL2 apoptosis regulator Homo sapiens 131-136 29956787-5 2018 H2O2 dose-dependently augmented the numbers of dead (trypan blue-positive) and Annexin V-FITC-stained cells in these cells, which was accompanied by the reduction of Bcl-2 and pro-caspase-3 levels, as well as the upregulation of caspase-3 and -8 activities. Hydrogen Peroxide 0-4 BCL2 apoptosis regulator Homo sapiens 166-171 29961232-2 2018 Our previous studies have demonstrated that Neohesperidin (NH) exhibited neuroprotective effects against cerebral ischemia via the down-regulation of Bcl-2, Akt/PI3K and Nrf2 pathways. neohesperidin 44-57 BCL2 apoptosis regulator Homo sapiens 150-155 29961232-2 2018 Our previous studies have demonstrated that Neohesperidin (NH) exhibited neuroprotective effects against cerebral ischemia via the down-regulation of Bcl-2, Akt/PI3K and Nrf2 pathways. neohesperidin 59-61 BCL2 apoptosis regulator Homo sapiens 150-155 29855616-0 2018 Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide. Niclosamide 155-166 BCL2 apoptosis regulator Homo sapiens 24-29 29855616-6 2018 Niclosamide, a potent inhibitor of STAT3, overcame the radioresistance in TNBC cells via inhibition of STAT3 and Bcl-2 and induction of ROS. Niclosamide 0-11 BCL2 apoptosis regulator Homo sapiens 113-118 29855616-8 2018 These findings demonstrate that activation of STAT3 and Bcl-2 and reduction of ROS contribute to the development of radioresistance in TNBC, and niclosamide acts as a potent radiosensitizer via inhibiting STAT3 and Bcl-2 and increasing ROS generation in TNBC cells and xenograft tumors. Niclosamide 145-156 BCL2 apoptosis regulator Homo sapiens 215-220 29936187-10 2018 mRNA and protein ratios of apoptotic modulators (Bax/Bcl2) are higher in 158JP oligodendrocytes which are also more vulnerable than 158N cells to tunicamycin-induced ER-stress. Tunicamycin 146-157 BCL2 apoptosis regulator Homo sapiens 53-57 29849119-5 2018 Combined PP242 and curcumin treatment induced Bax activation and decreased expression of Mcl-1 and Bcl-2. Curcumin 19-27 BCL2 apoptosis regulator Homo sapiens 99-104 29956797-8 2018 The apoptosis-associated signaling showed that ursolic acid decreased the phosphorylation of AKT (Ser473) and B-cell lymphoma 2 (Bcl-2)-associated agonist of cell death (BAD; Ser136), and the protein levels of Bcl-2 and Bcl-extra large (Bcl-xL), and increased the expression of BAD and Bcl-2-associated X (Bax) protein in CAR cells. ursolic acid 47-59 BCL2 apoptosis regulator Homo sapiens 110-127 29858601-0 2018 BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 26-29 BCL2 apoptosis regulator Homo sapiens 0-5 29858601-1 2018 BH3 mimetics are emerging novel anticancer therapeutics that potently and specifically inhibit antiapoptotic BCL-2 proteins and thereby induce cell death in many cancer entities. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 109-114 29858601-6 2018 Mechanistically, JNJ increases expression levels of the BH3-only protein BIM, while exposure to ABT-199 displaces BIM from BCL-2 and shuttles BIM to MCL-1, which also constitutively sequesters NOXA. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 96-99 BCL2 apoptosis regulator Homo sapiens 123-128 29956797-8 2018 The apoptosis-associated signaling showed that ursolic acid decreased the phosphorylation of AKT (Ser473) and B-cell lymphoma 2 (Bcl-2)-associated agonist of cell death (BAD; Ser136), and the protein levels of Bcl-2 and Bcl-extra large (Bcl-xL), and increased the expression of BAD and Bcl-2-associated X (Bax) protein in CAR cells. ursolic acid 47-59 BCL2 apoptosis regulator Homo sapiens 129-134 30127880-10 2018 The levels of Caspase-3, B-cell lymphoma (Bcl)-2 associated X protein, Wnt2, Wnt3a and beta-catenin were decreased, whereas Bcl-2 was increased by CG treatment dose-dependently, when compared with HF control. Calcium Gluconate 147-149 BCL2 apoptosis regulator Homo sapiens 124-129 29956797-8 2018 The apoptosis-associated signaling showed that ursolic acid decreased the phosphorylation of AKT (Ser473) and B-cell lymphoma 2 (Bcl-2)-associated agonist of cell death (BAD; Ser136), and the protein levels of Bcl-2 and Bcl-extra large (Bcl-xL), and increased the expression of BAD and Bcl-2-associated X (Bax) protein in CAR cells. ursolic acid 47-59 BCL2 apoptosis regulator Homo sapiens 210-215 30127911-6 2018 miR-376a overexpression inhibited lymphoma cell proliferation and induced apoptosis by regulating the expression levels of cyclin D2, cyclin A, Bax and Bcl-2. mir-376a 0-8 BCL2 apoptosis regulator Homo sapiens 152-157 30127910-4 2018 Salidroside induced autophagy, promoted the protein expression of nucleoporin p62 and the microtubule-associated proteins 1A/1B light chain 3B, suppressed phosphoinositide 3-kinase (PI3K) and phosphorylated protein kinase B (p-Akt) expression, inhibited matrix metalloproteinase-9 (MMP-9) expression and increased that of Bcl-2-associated X protein, which functions as an apoptosis regulator in T24 cells. rhodioloside 0-11 BCL2 apoptosis regulator Homo sapiens 322-327 30127971-6 2018 The effects of betulinic acid on the protein expression of B-cell lymphoma-2 (Bcl-2)/Bcl-2-associated X (Bax) were evaluated by western blot analysis. betulinic acid 15-29 BCL2 apoptosis regulator Homo sapiens 59-76 30127932-8 2018 The annexin V-fluorescein isothiocyanate/propidium iodide assay and western blot analysis demonstrated that oridonin was able to induce apoptosis and alter the expression of apoptosis-associated proteins by downregulating anti-apoptotic protein, B-cell lymphoma-2 (Bcl-2), and upregulating pro-apoptosis proteins, Bcl-2-like protein 4, cleaved caspase-3 and cleaved poly(ADP-ribose) polymerase 1. oridonin 108-116 BCL2 apoptosis regulator Homo sapiens 246-263 30127928-5 2018 Furthermore, treatment with resibufogenin effectively increased Bax/Bcl-2 expression, and suppressed cyclin D1, cyclin E, PI3K, phosphorylated AKT, phosphorylated GSK3beta and beta-catenin protein expression in MGC-803 cells. bufogenin 28-41 BCL2 apoptosis regulator Homo sapiens 68-73 30127932-8 2018 The annexin V-fluorescein isothiocyanate/propidium iodide assay and western blot analysis demonstrated that oridonin was able to induce apoptosis and alter the expression of apoptosis-associated proteins by downregulating anti-apoptotic protein, B-cell lymphoma-2 (Bcl-2), and upregulating pro-apoptosis proteins, Bcl-2-like protein 4, cleaved caspase-3 and cleaved poly(ADP-ribose) polymerase 1. oridonin 108-116 BCL2 apoptosis regulator Homo sapiens 265-270 30127971-6 2018 The effects of betulinic acid on the protein expression of B-cell lymphoma-2 (Bcl-2)/Bcl-2-associated X (Bax) were evaluated by western blot analysis. betulinic acid 15-29 BCL2 apoptosis regulator Homo sapiens 78-83 30127971-6 2018 The effects of betulinic acid on the protein expression of B-cell lymphoma-2 (Bcl-2)/Bcl-2-associated X (Bax) were evaluated by western blot analysis. betulinic acid 15-29 BCL2 apoptosis regulator Homo sapiens 85-90 30127988-12 2018 miR-93 can increase the apoptosis of MCF-7/ADM cells and their resistance to adriamycin by inhibiting the expression of Bcl-2 and P-gp proteins. Doxorubicin 77-87 BCL2 apoptosis regulator Homo sapiens 120-125 30127971-10 2018 The betulinic acid exerted anticancer activity via the induction of apoptosis by regulating the Bcl-2/Bax signaling pathway. betulinic acid 4-18 BCL2 apoptosis regulator Homo sapiens 96-101 30141309-4 2018 The aim of this study was to evaluate the effect of high dose prednisolone on inductionof apoptosis and changes in BAX and BCL-2 gene expression at different times. Prednisolone 62-74 BCL2 apoptosis regulator Homo sapiens 123-128 29778718-7 2018 Nimbolide markedly arrested the cell cycle progression and cell survival with loss of mitochondrial membrane potential by reducing Bcl-2 concomitantly inducing Bax and caspases protein expression with modulation of HDAC-2 and H3K27Ac expression. nimbolide 0-9 BCL2 apoptosis regulator Homo sapiens 131-136 30158527-0 2018 Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity. BH 3 90-93 BCL2 apoptosis regulator Homo sapiens 22-27 30158527-5 2018 Together, these results provide a roadmap for rationally targeting BCL-2 family dependencies in diverse human cancers and motivate the development of selective BFL-1 and BCL-w inhibitors to overcome intrinsic resistance to BH3 mimetics. BH 3 223-226 BCL2 apoptosis regulator Homo sapiens 67-72 29981726-7 2018 Moreover this chalcone derivative up-regulated proapoptotic Bax expression and down-regulated antiapoptotic Bcl-2 and Bcl-xL expression. Chalcone 14-22 BCL2 apoptosis regulator Homo sapiens 108-113 29701267-4 2018 We found that costunolide significantly induced mitochondrial apoptosis in K562 cells by modulating the protein levels of Bcl-2 family members and by inducing caspase activation. costunolide 14-25 BCL2 apoptosis regulator Homo sapiens 122-127 29653456-6 2018 Furthermore, high glucose triggered cell apoptosis via the upregulation of caspase-9/3, enhancement of cytochrome c release into the cytosol, and subsequent interruption of the Bax/Bcl-2 balance. Glucose 18-25 BCL2 apoptosis regulator Homo sapiens 181-186 29908299-8 2018 Furthermore, F3-NA and F3-NP could effectively inhibit PI3K/Akt pathway and decrease the expression of Bcl-2 and the cell cycle-dependent kinase inhibitors p-ERK1/2 and Cyclin D1 in both A549 and A549/PTX cells. ptx 201-204 BCL2 apoptosis regulator Homo sapiens 103-108 29997221-2 2018 With the availability of pathway inhibitors (PIs), such as kinase inhibitors and BCL2 antagonists, the outlook of CIT-resistant patients has dramatically improved. Monothiopyrophosphoric acid 45-48 BCL2 apoptosis regulator Homo sapiens 81-85 29997221-2 2018 With the availability of pathway inhibitors (PIs), such as kinase inhibitors and BCL2 antagonists, the outlook of CIT-resistant patients has dramatically improved. cit 114-117 BCL2 apoptosis regulator Homo sapiens 81-85 29958912-6 2018 The elevated ROS could not only evoke the mitochondria-dependent apoptosis by caspase-9/3 activation, but also inhibit inherent and acquired drug resistance by altering expression of Bcl-2 protein family and by reducing mitochondria membrane potential (DeltaPsim) and ATP level in cancer cells. Reactive Oxygen Species 13-16 BCL2 apoptosis regulator Homo sapiens 183-188 29958912-6 2018 The elevated ROS could not only evoke the mitochondria-dependent apoptosis by caspase-9/3 activation, but also inhibit inherent and acquired drug resistance by altering expression of Bcl-2 protein family and by reducing mitochondria membrane potential (DeltaPsim) and ATP level in cancer cells. Adenosine Triphosphate 268-271 BCL2 apoptosis regulator Homo sapiens 183-188 30141309-12 2018 Conclusions: Apoptosis induced by high-dose prednisolone in the CCRF-CEM cells, which is almost resistant,and possibly mediated by reducing the expression of BCL-2 and BAX up-regulation. Prednisolone 44-56 BCL2 apoptosis regulator Homo sapiens 158-163 30317793-13 2018 Conclusion: miR-221/222 may promote the apoptosis of human trophoblastic cells by down regulating the expression of apoptosis inhibitory protein bcl-2, leading to placental dysfunction and impairing the normal bile acid transport function of placenta. Bile Acids and Salts 210-219 BCL2 apoptosis regulator Homo sapiens 145-150 30186159-5 2018 Mechanistic studies indicated that 2-pyridyl cyclohexanone disrupted mitochondrial membrane potential, disturbed the balance of the Bcl-2 family proteins, and triggered apoptosis via the mitochondria-mediated intrinsic pathway. 2-pyridyl cyclohexanone 35-58 BCL2 apoptosis regulator Homo sapiens 132-137 29666304-2 2018 A recent phase I first-in-human study of the BCL-2 inhibitor venetoclax in non-Hodgkin lymphoma showed an overall response rate of 44%. venetoclax 61-71 BCL2 apoptosis regulator Homo sapiens 45-50 29859147-4 2018 Additionally, Se-beta-Lg could induce the disruption of mitochondrial membrane potential (MMP), improve the levels of intracellular reactive oxygen species and Bax, and down-regulate the Bcl-2 expression, further resulting in the release of cytochrome c from mitochondria into cytoplasm, the activation of caspase-9/-3, and the cleavage of poly-ADP-ribose polymerase (PARP). se-beta-lg 14-24 BCL2 apoptosis regulator Homo sapiens 187-192 29859147-5 2018 Taken together, these data clearly indicated that Se-beta-Lg had significantly cytotoxic effects on MGC-803 cells by inducing the caspase-dependent cell apoptosis and triggering the Bax- and Bcl-2-mediated mitochondria apoptosis pathway. se-beta-lg 50-60 BCL2 apoptosis regulator Homo sapiens 191-196 30111297-12 2018 While cisplatin treatment decreased the ratio of Bcl-2 to Bax in normoxic condition, hypoxia conversely increased the ratio in HMM cells treated with cisplatin. Cisplatin 6-15 BCL2 apoptosis regulator Homo sapiens 49-54 30537795-9 2018 The survival rate and Bcl-2/Bax ratio of GIST-T1 cells treated with both Mir-22-3p analogue and cisplatin were significantly decreased, while the apoptosis rate and protein level of caspase-3 were significantly increased (p<0.05). Cisplatin 96-105 BCL2 apoptosis regulator Homo sapiens 22-27 30210693-9 2018 In both cases (chidamide or chidamide combined with decitabine), apoptosis of tumor cells was induced through up-regulation of Bax and Caspase-3, and down-regulation of Bcl-2, showing a synergistic cytotoxicity. N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 15-24 BCL2 apoptosis regulator Homo sapiens 169-174 30210693-9 2018 In both cases (chidamide or chidamide combined with decitabine), apoptosis of tumor cells was induced through up-regulation of Bax and Caspase-3, and down-regulation of Bcl-2, showing a synergistic cytotoxicity. N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 28-37 BCL2 apoptosis regulator Homo sapiens 169-174 30210693-9 2018 In both cases (chidamide or chidamide combined with decitabine), apoptosis of tumor cells was induced through up-regulation of Bax and Caspase-3, and down-regulation of Bcl-2, showing a synergistic cytotoxicity. Decitabine 52-62 BCL2 apoptosis regulator Homo sapiens 169-174 30104508-6 2018 The results showed that exposure to UA affected extrinsic and intrinsic pathways through, reduced expression of Bcl-2, Mcl-1, and TCTP; increased levels of the apoptotic proteins TNF-alpha, Fas, FADD, and Bax; and activation of cleaved caspase-3 and PARP. ursolic acid 36-38 BCL2 apoptosis regulator Homo sapiens 112-117 30103745-4 2018 After treatment with 5 mug/mL cisplatin and 0.64 mg/mL SPS, the induction of apoptosis and the protein and mRNA expression of Bax, Bcl-2, COX-2, and cleaved caspase-3 in HN-6 cells were quantified. Cisplatin 30-39 BCL2 apoptosis regulator Homo sapiens 131-136 30103745-10 2018 Compared with the control group, the expression of Bcl-2 and COX-2 was markedly reduced by SPS treatment, whereas the expression of Bax and cleaved caspase-3 was increased. Sodium phenolsulfonate 91-94 BCL2 apoptosis regulator Homo sapiens 51-56 30109169-12 2018 The increased IL-6 may contribute to sunitinib resistance either via VEGF-mediated angiogenesis or through shifting of the Bcl2/Bax balance in favour of anti-apoptosis. Sunitinib 37-46 BCL2 apoptosis regulator Homo sapiens 123-127 30103745-11 2018 Moreover, SPS significantly inhibited the growth of the tumor xenograft, with similar changes in the expression of Bcl-2, COX-2, Bax, and cleaved caspase-3 in the tumor xenograft to the in vitro analysis. Sodium phenolsulfonate 10-13 BCL2 apoptosis regulator Homo sapiens 115-120 30103745-12 2018 CONCLUSIONS: Our results indicated that SPS may inhibit TSCC development through regulation of Bcl-2, COX-2, Bax, and cleaved caspase-3 expression. Sodium phenolsulfonate 40-43 BCL2 apoptosis regulator Homo sapiens 95-100 29730133-9 2018 It was also observed that Kf-EtOAc produces significant downregulation of apoptosis-related proteins Bcl-2, XIAP, and PKCepsilon and induces DNA fragmentation and cell cycle arrest. KF EtOAc 26-34 BCL2 apoptosis regulator Homo sapiens 101-106 29961319-4 2018 PSB also blocked MPP+-induced apoptotic cascades, including loss of mitochondrial membrane potential, activation of caspase 3, and reduced ratio of Bcl-2/Bax. pinostrobin 0-3 BCL2 apoptosis regulator Homo sapiens 148-153 29961319-4 2018 PSB also blocked MPP+-induced apoptotic cascades, including loss of mitochondrial membrane potential, activation of caspase 3, and reduced ratio of Bcl-2/Bax. mangion-purified polysaccharide (Candida albicans) 17-21 BCL2 apoptosis regulator Homo sapiens 148-153 30017071-2 2018 Bid and its caspase-8 cleavage product, tBid, promote the permeabilization of the mitochondrial outer membrane and sequester antiapoptotic Bcl-2 proteins to counter their cytoprotective activity. tBID 40-44 BCL2 apoptosis regulator Homo sapiens 139-144 30135654-5 2018 Lycorine induces the activation of the caspase-dependent mitochondrial apoptotic pathway, as indicated by activation of caspase and increase of the ratio of Bax/Bcl-2 and mitochondrial depolarization. lycorine 0-8 BCL2 apoptosis regulator Homo sapiens 161-166 30017071-6 2018 Lipoparticle-bound tBid retains an alpha-helical structure and binds Bcl-xL through its third Bcl-2 homology motif, forming a soluble, lipid-associated heteroprotein complex. tBID 19-23 BCL2 apoptosis regulator Homo sapiens 94-99 29733883-9 2018 Accordingly, suppression of BCL-2/BCL-XL by ABT-737 was required in addition to ERK1/2 inhibition for neratinib- or dacomitinib-induced apoptosis in neratinib-resistant BT474 cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 44-47 BCL2 apoptosis regulator Homo sapiens 28-33 30084434-11 2018 Grinimbine treatment resulted in apoptosis of SKOV3 cells, from 2.2% in untreated cells to 58.8% at a dose of 30 microM, which was associated with an increase in the Bax/Bcl-2 ratio. grinimbine 0-10 BCL2 apoptosis regulator Homo sapiens 170-175 29782860-9 2018 In conclusion, the cardioprotection of TMP against LPS-induced injury was through up-regulating the expression of 14-3-3gamma, promoting the translocation of Bcl-2 to mitochondria, and improving the function of mitochondria. tetramethylpyrazine 39-42 BCL2 apoptosis regulator Homo sapiens 158-163 29381896-4 2018 Irrespective of the treatment period, the reduced Bax and caspase-3 gene expressions and improved Bcl-2 mRNA level were observed in the thymus and spleen of spermine-administrated piglets (p&lt;0.05). Spermine 157-165 BCL2 apoptosis regulator Homo sapiens 98-103 30087276-6 2018 Real-time PCR and western blot assay further confirmed that 5q had strong effects to induce MG63 cell apoptosis, suggesting that the action was associated with down-regulation of the anti-apoptotic protein Bcl-2, upregulation of pro-apoptotic protein Bax, and induced activation of caspase-3, 8, and 9. CHEMBL3739943 60-62 BCL2 apoptosis regulator Homo sapiens 206-211 30088538-13 2018 Icariin repressed colon carcinoma cell line HCT116 by enhancing p53 expression and activating p53 functions possibly through Bcl-2/Bax imbalance and caspase-9 and -3 regulation. icariin 0-7 BCL2 apoptosis regulator Homo sapiens 125-130 30174783-9 2018 Furthermore, melatonin reduced the Bax/Bcl-2 ratio and the expression levels of the apoptosis-associated proteins cytochrome c and caspase 7. Melatonin 13-22 BCL2 apoptosis regulator Homo sapiens 39-44 30276148-12 2018 Flow cytometric analysis of Bi and its combination with Dox showed cellular accumulation in the G2/M phase and induction of apoptosis through suppression of Bcl-2 protein expression. Doxorubicin 56-59 BCL2 apoptosis regulator Homo sapiens 157-162 29733883-9 2018 Accordingly, suppression of BCL-2/BCL-XL by ABT-737 was required in addition to ERK1/2 inhibition for neratinib- or dacomitinib-induced apoptosis in neratinib-resistant BT474 cells. neratinib 149-158 BCL2 apoptosis regulator Homo sapiens 28-33 29709701-10 2018 Individual silencing of BIM or NOXA, overexpression of BCL-2 or MCL-1 as well as addition of the caspase inhibitor zVAD.fmk significantly rescue JQ1/JNJ-26481585-induced apoptosis. FMK 120-123 BCL2 apoptosis regulator Homo sapiens 55-60 30116377-6 2018 In addition, curcumin inhibited the phosphorylation of protein kinase B (Akt)/mammalian target of rapamycin (mTOR), decreased B-cell lymphoma 2 (BCL2) and promoted BCL-2-associated X protein (BAX) and cleavage of caspase 3, subsequently inducing apoptosis of breast cancer cells. Curcumin 13-21 BCL2 apoptosis regulator Homo sapiens 126-143 29512905-9 2018 Furthermore, geniposide increased the levels of p-Akt and regulated the expression of downstream proteins in the PI3K-Akt pathway, such as Bcl-2, Bax, and cleaved caspase 3 and 9, in H2 O2 -treated melanocytes. geniposide 13-23 BCL2 apoptosis regulator Homo sapiens 139-144 29512905-9 2018 Furthermore, geniposide increased the levels of p-Akt and regulated the expression of downstream proteins in the PI3K-Akt pathway, such as Bcl-2, Bax, and cleaved caspase 3 and 9, in H2 O2 -treated melanocytes. Hydrogen Peroxide 183-188 BCL2 apoptosis regulator Homo sapiens 139-144 29982865-4 2018 Herein, we will discuss the mechanism and rationale of BCL-2 inhibition in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with an overview of the selective BCL-2 inhibitor venetoclax. venetoclax 190-200 BCL2 apoptosis regulator Homo sapiens 174-179 29982865-8 2018 BCL-2 inhibition with venetoclax is well tolerated and active in older patients with newly diagnosed AML and in the relapsed setting has activity that may be improved in combination with other therapies. venetoclax 22-32 BCL2 apoptosis regulator Homo sapiens 0-5 30116377-6 2018 In addition, curcumin inhibited the phosphorylation of protein kinase B (Akt)/mammalian target of rapamycin (mTOR), decreased B-cell lymphoma 2 (BCL2) and promoted BCL-2-associated X protein (BAX) and cleavage of caspase 3, subsequently inducing apoptosis of breast cancer cells. Curcumin 13-21 BCL2 apoptosis regulator Homo sapiens 145-149 29786746-11 2018 The increased intracellular level of ROS appeared to induce the activation of p53 and elevate the B-cell lymphoma 2 (Bcl-2)-associated X protein/Bcl-2 ratio, which modulates DeltaPsim and triggers the release of cytochrome c, and may increase the activities of apoptotic protease activating factor 1, caspase-3, -8 and -9 to further trigger the destruction of structural and specific proteins and thereby cell apoptosis. Reactive Oxygen Species 37-40 BCL2 apoptosis regulator Homo sapiens 98-115 29627466-5 2018 Also, the tendency of increased protein expression of Bax and cleaved-caspsae-3, as well as decrease of Bcl-2 protein in ARPE-19 cells challenged with H2O2 was changed to individual opposite way, thus inhibiting the apoptotic cell death. Hydrogen Peroxide 151-155 BCL2 apoptosis regulator Homo sapiens 104-109 29767257-7 2018 In addition, western blotting revealed that BMP-6 reversed the decrease in pro-caspase-3 levels and the dysregulation of the B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein (Bax) balance caused by H2O2. Hydrogen Peroxide 202-206 BCL2 apoptosis regulator Homo sapiens 125-142 29767257-7 2018 In addition, western blotting revealed that BMP-6 reversed the decrease in pro-caspase-3 levels and the dysregulation of the B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein (Bax) balance caused by H2O2. Hydrogen Peroxide 202-206 BCL2 apoptosis regulator Homo sapiens 144-149 28750564-6 2018 The mechanism of the enhanced antitumor effect of pan-Bcl-2 inhibitors with M1 virus is mainly due to the inhibition of Bcl-xL, which synergizes with M1-induced upregulation of Bak to trigger apoptosis. bakuchiol 177-180 BCL2 apoptosis regulator Homo sapiens 54-59 29488214-5 2018 In addition, exogenous activation of the Notch signaling though Dox-induced overexpression of any Notch intracellular domains (NICD1-4) could enhance the resistance of PCa cells to ADT under ex vivo 3D culture conditions and upregulate expression of ADT resistance-associated phospho-p38 and Bcl-2 in LNCaP cells. Doxorubicin 64-67 BCL2 apoptosis regulator Homo sapiens 292-297 29786746-11 2018 The increased intracellular level of ROS appeared to induce the activation of p53 and elevate the B-cell lymphoma 2 (Bcl-2)-associated X protein/Bcl-2 ratio, which modulates DeltaPsim and triggers the release of cytochrome c, and may increase the activities of apoptotic protease activating factor 1, caspase-3, -8 and -9 to further trigger the destruction of structural and specific proteins and thereby cell apoptosis. Reactive Oxygen Species 37-40 BCL2 apoptosis regulator Homo sapiens 117-122 29786746-11 2018 The increased intracellular level of ROS appeared to induce the activation of p53 and elevate the B-cell lymphoma 2 (Bcl-2)-associated X protein/Bcl-2 ratio, which modulates DeltaPsim and triggers the release of cytochrome c, and may increase the activities of apoptotic protease activating factor 1, caspase-3, -8 and -9 to further trigger the destruction of structural and specific proteins and thereby cell apoptosis. Reactive Oxygen Species 37-40 BCL2 apoptosis regulator Homo sapiens 145-150 28679068-2 2018 In present study, berberine hydrochloride (BER) triggered proliferative inhibition and G2/M arrest in AGS cells, down-regulated protein expression of cyclin B1, Bcl-2, up-regulated expression of p21, p53 and cleaved caspase 3, but showed no effect on protein expression of CHOP, Bip, and caspase 4. berberine chloride 18-41 BCL2 apoptosis regulator Homo sapiens 161-166 28679068-2 2018 In present study, berberine hydrochloride (BER) triggered proliferative inhibition and G2/M arrest in AGS cells, down-regulated protein expression of cyclin B1, Bcl-2, up-regulated expression of p21, p53 and cleaved caspase 3, but showed no effect on protein expression of CHOP, Bip, and caspase 4. Berberine 43-46 BCL2 apoptosis regulator Homo sapiens 161-166 30106049-6 2018 Western blot assays showed that BCL-2 and Beclin 1 levels were markedly higher in the genistein group than in the rotenone group. Genistein 86-95 BCL2 apoptosis regulator Homo sapiens 32-37 29665051-5 2018 Mechanistic studies revealed that the sensitizing effect of hyperbaric oxygen is due to decreased ratio of Bcl-2/Bax, increased level of p53, cleaved Caspase3, GRP78, CHOP, and LC3. Oxygen 71-77 BCL2 apoptosis regulator Homo sapiens 107-112 29199519-1 2018 High-grade B cell lymphoma with MYC and BCL2 rearrangements (double hit) has a poor prognosis with standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). Cyclophosphamide 127-143 BCL2 apoptosis regulator Homo sapiens 40-44 29199519-1 2018 High-grade B cell lymphoma with MYC and BCL2 rearrangements (double hit) has a poor prognosis with standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). Doxorubicin 145-156 BCL2 apoptosis regulator Homo sapiens 40-44 29199519-1 2018 High-grade B cell lymphoma with MYC and BCL2 rearrangements (double hit) has a poor prognosis with standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). Vincristine 158-169 BCL2 apoptosis regulator Homo sapiens 40-44 29199519-1 2018 High-grade B cell lymphoma with MYC and BCL2 rearrangements (double hit) has a poor prognosis with standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). Prednisone 171-181 BCL2 apoptosis regulator Homo sapiens 40-44 29901126-8 2018 Furthermore, upregulation of the ratio of apoptosis regulator Bcl-2/apoptosis regulator BAX and tumor necrosis factor receptor superfamily member 6 (Fas)/Fas ligand indicated that the silibinin-paclitaxel combination activated the death receptor-mediated pathway in SGC-7901 cells. silibinin-paclitaxel 184-204 BCL2 apoptosis regulator Homo sapiens 62-67 29323715-9 2018 PA treatment also suppressed the interaction between BCL-2 and IP3R in HepG2 cells, whereas this interaction was massively enhanced in the ALR-Tx cells, effectively reducing the IP3R-mediated ER-Ca2+ release and thus mitochondrial Ca2+ influx. Palmitic Acid 0-2 BCL2 apoptosis regulator Homo sapiens 53-58 29974554-9 2018 The mRNA and protein levels of Caspase-3, Fas, Fasl and Bax were increased; while the expression of Bcl-2 was decreased by Zeylenone. zeylenone 123-132 BCL2 apoptosis regulator Homo sapiens 100-105 28758428-5 2018 Our study results indicated that non-cytotoxic levels of SDAPR significantly increased viability rate (LD50 value of cisplatin is 20 muM), which improved antioxidant defence, attenuated apoptosis by decreasing expression levels of cleaved-caspase-3 and Bax, increasing Bcl-2 expression and inhibiting apoptotic positive cells in HEK 293 cells. sdapr 57-62 BCL2 apoptosis regulator Homo sapiens 269-274 30106049-6 2018 Western blot assays showed that BCL-2 and Beclin 1 levels were markedly higher in the genistein group than in the rotenone group. Rotenone 114-122 BCL2 apoptosis regulator Homo sapiens 32-37 30013646-8 2018 Moreover, the expression of Bax, cytochrome c and caspase-3 were markedly increased and Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) was significantly inactivated and BCL-2 expression was decreased following PA treatment in SGC-7901 cells. pachymic acid 244-246 BCL2 apoptosis regulator Homo sapiens 203-208 29989650-6 2018 Treatment with SAL increased Bax/Bcl-2 and cytochrome c expression and activated caspase-3 and -9, thus leading to poly(ADP-ribose) polymerase (PARP) cleavage and resulting in cell apoptosis. salinomycin 15-18 BCL2 apoptosis regulator Homo sapiens 33-38 30008912-5 2018 Anti-apoptosis B-cell lymphoma (Bcl)-2 and Bcl-w genes were downregulated and pro-apoptotic Bcl-2-associated agonist of cell death and caspase-3 genes were upregulated in U-2OS cells following treatment with beta-elemene-paclitaxel. beta-elemene 208-220 BCL2 apoptosis regulator Homo sapiens 92-97 30008912-5 2018 Anti-apoptosis B-cell lymphoma (Bcl)-2 and Bcl-w genes were downregulated and pro-apoptotic Bcl-2-associated agonist of cell death and caspase-3 genes were upregulated in U-2OS cells following treatment with beta-elemene-paclitaxel. Paclitaxel 221-231 BCL2 apoptosis regulator Homo sapiens 92-97 30111401-3 2018 Effects of different concentration of ganglioside GM3 on the mRNA expression level of BCL-2 and BAX were detected by Real-time PCR. Gangliosides 38-49 BCL2 apoptosis regulator Homo sapiens 86-91 30151071-4 2018 Moreover, Dox treatment also resulted in decreased antioxidant levels, antiapoptotic BCL2, pAKT, p-mTOR, and endogenous levels of sFRP2 in the soleus muscle tissue (p < 0.05). Doxorubicin 10-13 BCL2 apoptosis regulator Homo sapiens 85-89 29732634-4 2018 Well-known pathways such as Pl3K/Akt/Bcl-2 pathway, Nrf2/HO-1 pathway, and MAPK signaling pathway help berberine to protect neurons through antiapoptotic, antioxidative, and anti-inflammatory activities. Berberine 103-112 BCL2 apoptosis regulator Homo sapiens 37-42 30067771-6 2018 Synergy with duvelisib was prominent in lymphoma lines with approved and emerging drugs used to treat HM, including dexamethasone, ibrutinib, and the BCL-2 inhibitor venetoclax. duvelisib 13-22 BCL2 apoptosis regulator Homo sapiens 150-155 30067771-6 2018 Synergy with duvelisib was prominent in lymphoma lines with approved and emerging drugs used to treat HM, including dexamethasone, ibrutinib, and the BCL-2 inhibitor venetoclax. venetoclax 166-176 BCL2 apoptosis regulator Homo sapiens 150-155 30111400-5 2018 RESULTS: The combined treatment (100micromol/L Osthole + 40 ng/ml TRAIL) of HL-60 cells for 48 h induced an apoptotic rate of (33.9+-2.7) %, which was significantly higher than that of cells treated with Osthole or TRAIL alone (P<0.05); at the same time, the combined treatment promoted the decrease of MMP and the expression rate of BCL-2/BAX, and potentiated the expression of DR5 and Caspase-3,-8,-9 activity. osthol 47-54 BCL2 apoptosis regulator Homo sapiens 337-342 30111401-3 2018 Effects of different concentration of ganglioside GM3 on the mRNA expression level of BCL-2 and BAX were detected by Real-time PCR. gm3 50-53 BCL2 apoptosis regulator Homo sapiens 86-91 30111412-5 2018 Meanwhile, LY2409881 induced the expression of pro-apoptotic protein BAX and inhibited the expression of anti-apoptotic protein MCL-1 and BCL-2. LY2409881 11-20 BCL2 apoptosis regulator Homo sapiens 138-143 30200738-0 2018 [Effect of rosmarinic acid from Sarcandra glabra in inhibiting proliferation and migration and inducing apoptosis of MDA-MB-231 cells via regulation of expressions of Bcl-2 and Bax]. rosmarinic acid 11-26 BCL2 apoptosis regulator Homo sapiens 167-172 30200738-7 2018 The down-regulation of the Bcl-2 expression and the up-regulation of the Bax expression were observed in MDA-MB-231 cells after rosmarinic acid treatment. rosmarinic acid 128-143 BCL2 apoptosis regulator Homo sapiens 27-32 30200738-8 2018 The results suggested that rosmarinicacid can inhibit the proliferation and migration, and induce the apoptosis of MDA-MB-231 cells, which may be correlated with the down-regulation of Bcl-2 gene and the up-regulation of Bax gene. rosmarinic acid 27-41 BCL2 apoptosis regulator Homo sapiens 185-190 30084792-11 2018 In addition, the occurrence of asiatic acid-induced apoptosis was confirmed by microscopic observation of apoptotic vesicles, down-regulation of anti-apoptotic genes (BCL2 and Survivin/BIRC5) and increased early and late apoptotic cells. asiatic acid 31-43 BCL2 apoptosis regulator Homo sapiens 167-171 30064425-8 2018 The ratio of Bax/Bcl-2 and cleaved caspase-3, two markers of apoptosis were upregulated by PA or cholesterol treatment. Palmitic Acid 91-93 BCL2 apoptosis regulator Homo sapiens 17-22 30064425-8 2018 The ratio of Bax/Bcl-2 and cleaved caspase-3, two markers of apoptosis were upregulated by PA or cholesterol treatment. Cholesterol 97-108 BCL2 apoptosis regulator Homo sapiens 17-22 30100745-13 2018 Euphornin treatment altered the ratio of Bax/Bcl-2 in HeLa cells, which led to the release of cytochrome complex. euphornin 0-9 BCL2 apoptosis regulator Homo sapiens 45-50 29678549-7 2018 The expressions of NF-kB p65, COX-2, pro (BAX, BAK) and anti-apoptotic (BCL-2, BCL-XL) genes were significantly reduced after treatment with FA-RES + DTX-NP. Docetaxel 150-153 BCL2 apoptosis regulator Homo sapiens 72-77 30049286-11 2018 Knockdown of lncRNA PART1 potently promoted the gefitinib-induced cell death, while elevated PART1 promoted gefitinib resistance by competitively binding to miR-129 to facilitate Bcl-2 expression in ESCC cells. mir-129 157-164 BCL2 apoptosis regulator Homo sapiens 179-184 30049286-14 2018 CONCLUSIONS: LncRNA PART1 promotes gefitinib resistance by regulating miR-129/Bcl-2 pathway, and may serve as a therapeutic target for ESCC patients. Gefitinib 35-44 BCL2 apoptosis regulator Homo sapiens 78-83 29651609-6 2018 H/R like stress induced apoptosis of hMSCs was significantly mitigated by DADLE via modulation of the apoptotic regulators (Bcl-2/Bax) along with significant curtailment of ROS and mitochondrial complex 1 activity. r 2-3 BCL2 apoptosis regulator Homo sapiens 124-129 29952351-0 2018 Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway. Cisplatin 77-86 BCL2 apoptosis regulator Homo sapiens 95-100 30147831-11 2018 Pretreatment with the wortmannin further attenuated these effects induced by EEP and resulted in the expression of proapoptotic phenotypes such as oxidative injury, elevated Beclin1/Bcl-2 ratio, cytochrome c leakage, mitochondrial dynamin-1-like protein (Drp-1) expression, and VDAC1 dephosphorylation. Wortmannin 22-32 BCL2 apoptosis regulator Homo sapiens 182-187 29768700-1 2018 Venetoclax (ABT-199) and idasanutlin (RG7388) are efficient anticancer drugs targeting two essential apoptosis markers, Bcl-2 and MDM2, respectively. RG7388 25-36 BCL2 apoptosis regulator Homo sapiens 120-125 30079022-8 2018 We provide evidence that forskolin markedly potentiates GSKJ4-induced antiproliferative effects by apoptotic cell death induction, accompanied by a dramatic BCL2 protein down-regulation as well as caspase 3 activation and PARP protein cleavage. Colforsin 25-34 BCL2 apoptosis regulator Homo sapiens 157-161 30079022-8 2018 We provide evidence that forskolin markedly potentiates GSKJ4-induced antiproliferative effects by apoptotic cell death induction, accompanied by a dramatic BCL2 protein down-regulation as well as caspase 3 activation and PARP protein cleavage. GSK-J4 56-61 BCL2 apoptosis regulator Homo sapiens 157-161 29952351-14 2018 Linc00312 enhanced the sensitivity of SKOV3/DDP cells to cisplatin by promoting cell apoptosis via the Bcl-2/Caspase-3 signaling pathway. Cisplatin 57-66 BCL2 apoptosis regulator Homo sapiens 103-108 30022842-12 2018 Furthermore, Western blot demonstrated that TBMS1 downregulated apoptosis-associated proteins such as PARP, p-ERK1/2, Bcl-2, caspase-3, caspase-7 and caspase-8 and upregulated cleaved PARP, cleaved caspase-3 and cleaved caspase-9. tubeimoside I 44-49 BCL2 apoptosis regulator Homo sapiens 118-123 29724653-0 2018 A naphthalene diimide G-quadruplex ligand inhibits cell growth and down-regulates BCL-2 expression in an imatinib-resistant gastrointestinal cancer cell line. naphthalenediimide 2-21 BCL2 apoptosis regulator Homo sapiens 82-87 29724653-0 2018 A naphthalene diimide G-quadruplex ligand inhibits cell growth and down-regulates BCL-2 expression in an imatinib-resistant gastrointestinal cancer cell line. Imatinib Mesylate 105-113 BCL2 apoptosis regulator Homo sapiens 82-87 30073206-0 2018 BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells. venetoclax 15-22 BCL2 apoptosis regulator Homo sapiens 0-4 30073206-0 2018 BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells. Imatinib Mesylate 91-99 BCL2 apoptosis regulator Homo sapiens 0-4 30073206-9 2018 Moreover, NphA2 and MR87 and their IMT-resistant sublines were sensitive to ABT-199, a specific BCL2 inhibitor. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 76-79 BCL2 apoptosis regulator Homo sapiens 96-100 29909338-4 2018 Western blot analysis showed that BAP 23 markedly reduced the levels of Bcl-2 but increased the levels of cleaved caspase-3and Bax. benzylaminopurine 34-37 BCL2 apoptosis regulator Homo sapiens 72-77 29909338-7 2018 BAP 23 could reasonably bind to the active site of Bcl-2 protein and p65 which is proved by molecular docking modes. benzylaminopurine 0-3 BCL2 apoptosis regulator Homo sapiens 51-56 29710667-10 2018 Moreover, our results indicated that BCP prevented MPP+-induced apoptosis of SH-SY5Y through inhibiting the up-regulation of cleaved Caspase-3, Bax, and restoring the expression of Bcl-2. caryophyllene 37-40 BCL2 apoptosis regulator Homo sapiens 181-186 29655853-19 2018 Furthermore, TSAC increased the expression of pro-apoptotic protein Bax and decreased the expression of anti-apoptotic protein Bcl-2. tsac 13-17 BCL2 apoptosis regulator Homo sapiens 127-132 29683800-12 2018 Western blot analysis indicated that P-gp, Bcl-2, and PARP protein were more abundant in MGC803/PTX and SW620/PTX cells compared with MGC803 and SW620 cells, whereas Bax protein levels were lower in resistant cells. Paclitaxel 96-99 BCL2 apoptosis regulator Homo sapiens 43-48 29683800-12 2018 Western blot analysis indicated that P-gp, Bcl-2, and PARP protein were more abundant in MGC803/PTX and SW620/PTX cells compared with MGC803 and SW620 cells, whereas Bax protein levels were lower in resistant cells. Paclitaxel 110-113 BCL2 apoptosis regulator Homo sapiens 43-48 29778287-6 2018 PGG affected cell-cycle- or apoptosis-related proteins such as cyclin E, CDK2, and Bcl-2, cleaved caspase-3. beta-penta-O-galloyl-glucose 0-3 BCL2 apoptosis regulator Homo sapiens 83-88 29986744-20 2018 Furthermore, JS-K treatment could induce PP2A activation and the substrates of PP2A inactivation such as beta-catenin, c-Myc and p-Bcl-2(Ser70) in DEN-induced hepatocarcinogenesis. Diethylnitrosamine 147-150 BCL2 apoptosis regulator Homo sapiens 131-136 29752258-2 2018 The availability novel agents, including the B-cell receptor inhibitors ibrutinib, acalabrutinib, and idelalisib, as well as venetoclax, which targets the BCL2 pathway, and the success of these agents in treating high-risk disease patients have made it more difficult to assess who should be considered for allo-SCT and when in the treatment course. venetoclax 125-135 BCL2 apoptosis regulator Homo sapiens 155-159 29680739-14 2018 Furthermore, our results revealed that euxanthone induced apoptosis and autophagy by modulating pSTAT3/Bcl-2 signaling. euxanthone 39-49 BCL2 apoptosis regulator Homo sapiens 103-108 29864906-4 2018 TTO at 300 mug/mL increased the number of MCF-7 cells in the early stages of apoptosis and increased the BAX/BCL-2 genes ratio. Tea Tree Oil 0-3 BCL2 apoptosis regulator Homo sapiens 109-114 29710667-10 2018 Moreover, our results indicated that BCP prevented MPP+-induced apoptosis of SH-SY5Y through inhibiting the up-regulation of cleaved Caspase-3, Bax, and restoring the expression of Bcl-2. mangion-purified polysaccharide (Candida albicans) 51-55 BCL2 apoptosis regulator Homo sapiens 181-186 29896263-10 2018 Western blot analysis demonstrated that nimesulide increased expression of cleaved caspase-3 and apoptosis regulator Bax (Bcl-2 associated protein X), and decreased the expression of pro-caspase-3 and apoptosis regulator Bcl-2 (B-cell lymphoma 2). nimesulide 40-50 BCL2 apoptosis regulator Homo sapiens 122-127 29327364-6 2018 Downregulation of Bax/Bcl-2, CHOP, GRP78, inflammatory factors, and reactive oxygen species generation, and the increase of MMP level detected after 4-PBA treatment indicated an inhibitory effect of 4-PBA on cell apoptosis, inflammatory response, and ER stress in OA. 4-phenylbutyric acid 199-204 BCL2 apoptosis regulator Homo sapiens 22-27 29864951-11 2018 Pre-incubation with Anagliptin inhibited NOX-4 mediated the Bax, caspase-3, cleave caspase-3 and Cyto C overexpression, but up-regulated the protein level of Bcl-2 in HUVECs. anagliptin 20-30 BCL2 apoptosis regulator Homo sapiens 158-163 29896263-10 2018 Western blot analysis demonstrated that nimesulide increased expression of cleaved caspase-3 and apoptosis regulator Bax (Bcl-2 associated protein X), and decreased the expression of pro-caspase-3 and apoptosis regulator Bcl-2 (B-cell lymphoma 2). nimesulide 40-50 BCL2 apoptosis regulator Homo sapiens 221-226 29896263-10 2018 Western blot analysis demonstrated that nimesulide increased expression of cleaved caspase-3 and apoptosis regulator Bax (Bcl-2 associated protein X), and decreased the expression of pro-caspase-3 and apoptosis regulator Bcl-2 (B-cell lymphoma 2). nimesulide 40-50 BCL2 apoptosis regulator Homo sapiens 228-245 31949707-8 2018 Additionally, the ratio of Bax/Bcl-2 was decreased in DeltaIL-17-mutant hepatocyte-induced H2O2. Water 91-95 BCL2 apoptosis regulator Homo sapiens 31-36 29658609-7 2018 However, in monolayer culture, the H358 cells and H441 cells in which survivin was silenced, underwent significant apoptosis following combined treatment with ABT-263, a Bcl-2 inhibitor, and trametinib, a MEK inhibitor. navitoclax 159-166 BCL2 apoptosis regulator Homo sapiens 170-175 31565647-6 2018 Moreover, RQ-PCR analysis revealed that the enhanced cytotoxic effect of As2O3 in the presence of melatonin is mediated, at least partly, through suppressing the expression of NF-kappaB anti-apoptotic target genes such as MCL-1, BCL-2, survivin, XIAP, and c-IAP1 in breast cancer cells. Superoxides 73-78 BCL2 apoptosis regulator Homo sapiens 229-234 31565647-6 2018 Moreover, RQ-PCR analysis revealed that the enhanced cytotoxic effect of As2O3 in the presence of melatonin is mediated, at least partly, through suppressing the expression of NF-kappaB anti-apoptotic target genes such as MCL-1, BCL-2, survivin, XIAP, and c-IAP1 in breast cancer cells. Melatonin 98-107 BCL2 apoptosis regulator Homo sapiens 229-234 29876682-12 2018 RT-qPCR showed that the expression of Bcl-2 was lower in the control group compared with the GSH-OEt group; BAX and MnSoD expression levels were higher in the control group than in the GSH-OEt group (p < 0.05). Glutathione 93-96 BCL2 apoptosis regulator Homo sapiens 38-43 29215703-8 2018 These derivative facilitated the induction of reactive oxygen species (ROS) generation leading to downregulation of Bcl2 , and upregulation of Bax expression, thereby dysregulating mitochondrial membrane potential (DeltaPsim ) to release cytochrome c, and activation of intrinsic pathway. Reactive Oxygen Species 46-69 BCL2 apoptosis regulator Homo sapiens 116-120 29876682-12 2018 RT-qPCR showed that the expression of Bcl-2 was lower in the control group compared with the GSH-OEt group; BAX and MnSoD expression levels were higher in the control group than in the GSH-OEt group (p < 0.05). Ethane 97-100 BCL2 apoptosis regulator Homo sapiens 38-43 29215703-8 2018 These derivative facilitated the induction of reactive oxygen species (ROS) generation leading to downregulation of Bcl2 , and upregulation of Bax expression, thereby dysregulating mitochondrial membrane potential (DeltaPsim ) to release cytochrome c, and activation of intrinsic pathway. Reactive Oxygen Species 71-74 BCL2 apoptosis regulator Homo sapiens 116-120 29876682-12 2018 RT-qPCR showed that the expression of Bcl-2 was lower in the control group compared with the GSH-OEt group; BAX and MnSoD expression levels were higher in the control group than in the GSH-OEt group (p < 0.05). S-ethyl glutathione 93-100 BCL2 apoptosis regulator Homo sapiens 38-43 29250709-6 2018 We showed that folic acid increased cell viability and decreased apoptosis in a dose-dependent manner, and that this effect was mediated by decreased caspase-3/7 activity, upregulated BCL2/BAX ratio, and downregulated TP53, CASP3, and CASP8 expressions. Folic Acid 15-25 BCL2 apoptosis regulator Homo sapiens 184-188 29667777-7 2018 The results showed that iPS-CM significantly reduced H2 O2 -induced ILC apoptosis through down-regulation of autophagic and apoptotic proteins LC3-I/II, Beclin-1, P62, P53 and BAX as well as up-regulation of BCL-2, which could be inhibited by LY294002 (25 mumol/L). Hydrogen Peroxide 53-58 BCL2 apoptosis regulator Homo sapiens 208-213 29870059-5 2018 Among constituents in ASS, compounds 1, 2, 4, protocatechuic acid (8), isoquercitrin (11), and luteolin-6-C-glucoside (12) potently scavenged DPPH radicals and intracellular ROS; strongly protected against peroxyl radical-induced DNA scission; and upregulated Nrf2, phosphorylated p38, phosphorylated JNK, and Bcl-2 in HepG2 cells. protocatechuic acid 46-65 BCL2 apoptosis regulator Homo sapiens 310-315 29870059-5 2018 Among constituents in ASS, compounds 1, 2, 4, protocatechuic acid (8), isoquercitrin (11), and luteolin-6-C-glucoside (12) potently scavenged DPPH radicals and intracellular ROS; strongly protected against peroxyl radical-induced DNA scission; and upregulated Nrf2, phosphorylated p38, phosphorylated JNK, and Bcl-2 in HepG2 cells. isoquercitrin 71-84 BCL2 apoptosis regulator Homo sapiens 310-315 29870059-5 2018 Among constituents in ASS, compounds 1, 2, 4, protocatechuic acid (8), isoquercitrin (11), and luteolin-6-C-glucoside (12) potently scavenged DPPH radicals and intracellular ROS; strongly protected against peroxyl radical-induced DNA scission; and upregulated Nrf2, phosphorylated p38, phosphorylated JNK, and Bcl-2 in HepG2 cells. homoorientin 95-117 BCL2 apoptosis regulator Homo sapiens 310-315 29870059-5 2018 Among constituents in ASS, compounds 1, 2, 4, protocatechuic acid (8), isoquercitrin (11), and luteolin-6-C-glucoside (12) potently scavenged DPPH radicals and intracellular ROS; strongly protected against peroxyl radical-induced DNA scission; and upregulated Nrf2, phosphorylated p38, phosphorylated JNK, and Bcl-2 in HepG2 cells. 1,1-diphenyl-2-picrylhydrazyl 142-146 BCL2 apoptosis regulator Homo sapiens 310-315 29806073-5 2018 Furthermore, Taraxasterol upregulated Hint1 and Bax, but downregulated Bcl2 and cyclin D1 expression, accompanied by promoting the demethylation in the Hint1 promoter region in liver cancer cells. taraxasterol 13-25 BCL2 apoptosis regulator Homo sapiens 71-75 29806073-6 2018 The effects of Taraxasterol were abrogated by Hint1 silencing and partially mitigated by Bax silencing, Bcl2 or cyclin D1 over-expression in HepG2 cells. taraxasterol 15-27 BCL2 apoptosis regulator Homo sapiens 104-108 29806073-12 2018 Taraxasterol increases Hint1 levels to regulate Bax, Bcl2, and cyclinD1 expression. taraxasterol 0-12 BCL2 apoptosis regulator Homo sapiens 53-57 29773200-8 2018 LiCl combined with mitomycin C significantly down-regulated HMGB1, MMP9 and Bcl-2 gene expression but significantly increased the level of Bax protein. Lithium Chloride 0-4 BCL2 apoptosis regulator Homo sapiens 76-81 29773200-8 2018 LiCl combined with mitomycin C significantly down-regulated HMGB1, MMP9 and Bcl-2 gene expression but significantly increased the level of Bax protein. Mitomycin 19-30 BCL2 apoptosis regulator Homo sapiens 76-81 29722068-5 2018 In all three cell lines, formononetin increased Akt phosphorylation and Bcl-2 expression. formononetin 25-37 BCL2 apoptosis regulator Homo sapiens 72-77 30197337-9 2018 Conclusion: Our results indicated that biomarkers such as cyclin D1 and Bcl-2 were correlated with measures such as MTV, TLG, and SUV in 18F-FDG PET/CT. mtv 116-119 BCL2 apoptosis regulator Homo sapiens 72-77 30197337-9 2018 Conclusion: Our results indicated that biomarkers such as cyclin D1 and Bcl-2 were correlated with measures such as MTV, TLG, and SUV in 18F-FDG PET/CT. (5r)-3-Acetyl-4-Hydroxy-5-Methyl-5-[(1z)-2-Methylbuta-1,3-Dien-1-Yl]thiophen-2(5h)-One 121-124 BCL2 apoptosis regulator Homo sapiens 72-77 30197337-9 2018 Conclusion: Our results indicated that biomarkers such as cyclin D1 and Bcl-2 were correlated with measures such as MTV, TLG, and SUV in 18F-FDG PET/CT. Fluorodeoxyglucose F18 141-144 BCL2 apoptosis regulator Homo sapiens 72-77 29767235-8 2018 miR-16 did not affect Bcl-2 mRNA expression but downregulated Bcl-2 protein expression. mir-16 0-6 BCL2 apoptosis regulator Homo sapiens 62-67 29749500-8 2018 Mechanistic analysis revealed that Vacq upregulated the expressions of pro-apoptotic proteins [B-cell lymphoma 2 (bcl-2)-associated X protein (Bax) and Bcl-2-like protein 11] and downregulated the pro-survival protein, Bcl-2, expression in HCC cells. vacquinol-1 35-39 BCL2 apoptosis regulator Homo sapiens 95-112 29749500-8 2018 Mechanistic analysis revealed that Vacq upregulated the expressions of pro-apoptotic proteins [B-cell lymphoma 2 (bcl-2)-associated X protein (Bax) and Bcl-2-like protein 11] and downregulated the pro-survival protein, Bcl-2, expression in HCC cells. vacquinol-1 35-39 BCL2 apoptosis regulator Homo sapiens 114-119 29749500-8 2018 Mechanistic analysis revealed that Vacq upregulated the expressions of pro-apoptotic proteins [B-cell lymphoma 2 (bcl-2)-associated X protein (Bax) and Bcl-2-like protein 11] and downregulated the pro-survival protein, Bcl-2, expression in HCC cells. vacquinol-1 35-39 BCL2 apoptosis regulator Homo sapiens 152-157 29750303-7 2018 Furthermore, western blot analysis demonstrated that isofraxidin treatment led to effects on the expression of apoptosis-associated proteins, including members of the Bcl-2 protein family, and invasion-associated proteins, including matrix metallopeptidase (MMP)-2 and MMP-9, which may occur via inhibition of the expression of phosphorylated (p)-epidermal growth factor receptor, p-AKT and p-extracellular signal-regulated kinase. isofraxidin 53-64 BCL2 apoptosis regulator Homo sapiens 167-172 29767235-9 2018 miR-16 inhibitor transfection significantly increased Bcl-2 protein expression and the percentage of apoptotic BM-MSCs was reduced. mir-16 0-6 BCL2 apoptosis regulator Homo sapiens 54-59 29767235-10 2018 The pro-apoptotic effects of miR-16 were partially elevated by knocking down of Bcl-2. mir-16 29-35 BCL2 apoptosis regulator Homo sapiens 80-85 29767235-12 2018 Taken together, the results indicated that miR-16 downregulated Bcl-2 expression and promoted BM-MSC apoptosis, indicating that therapies targeting miR-16 may improve the effectiveness of BM-MSC transplantation therapy. mir-16 43-49 BCL2 apoptosis regulator Homo sapiens 64-69 29767235-12 2018 Taken together, the results indicated that miR-16 downregulated Bcl-2 expression and promoted BM-MSC apoptosis, indicating that therapies targeting miR-16 may improve the effectiveness of BM-MSC transplantation therapy. mir-16 148-154 BCL2 apoptosis regulator Homo sapiens 64-69 29988358-9 2018 Compound-1H also induced mitochondrial-dependent apoptosis by increasing Bax, cleaved caspase-3, cleaved caspase-9 and poly ADP-ribose polymerase expression, and decreasing Bcl-2 expression. Hydrogen 9-11 BCL2 apoptosis regulator Homo sapiens 173-178 30061946-10 2018 PI3K/AKT inhibitor LY294002 restored DTX-induced caspase-3 activation and Bcl-2 phosphorylation, reversed the effect of CCL2 on the viability of A549 cells and enhanced DTX-induced cytotoxicity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 BCL2 apoptosis regulator Homo sapiens 74-79 30081983-52 2018 Compared to control group, relative mRNA expressions of Lin28, Bax, Bcl-2 and Fas were all higher in worker who were smelting arsenic( P < 0. Arsenic 126-133 BCL2 apoptosis regulator Homo sapiens 68-73 29955058-9 2018 Besides, URB significantly inhibited the beclin-1 from beclin-1/Bcl-2 complex to whole-cell lysates. cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester 9-12 BCL2 apoptosis regulator Homo sapiens 64-69 29942660-7 2018 Furthermore, in vivo results indicated that CsA formulated in NPs sensitized Gef-resistant cells and Gef-resistant tumors to Gef treatment by inactivating the STAT3/Bcl-2 signaling pathway. Cyclosporine 44-47 BCL2 apoptosis regulator Homo sapiens 165-170 29955058-10 2018 The above results indicate that URB could inhibit impaired autophagy degradation and the disruption of beclin-1/Bcl-2 complex and subsequently cut off BNIP3-cyt C- and parkin-required mitophagy, finally preventing the abnormal excessive autophagy and mitophagy. cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester 32-35 BCL2 apoptosis regulator Homo sapiens 112-117 29738772-5 2018 Interestingly, co-treatment with DHA could effectively restore the anticancer effect of 5-FU against HCT116 TP53-/- cells, which manifested as the inhibition of proliferation and induction of reactive oxygen species (ROS)-mediated apoptosis and was accompanied by the upregulation of B-cell lymphoma 2 (BCL-2) and downregulation of the BCL-2-associated X protein (BAX). artenimol 33-36 BCL2 apoptosis regulator Homo sapiens 284-301 29738772-5 2018 Interestingly, co-treatment with DHA could effectively restore the anticancer effect of 5-FU against HCT116 TP53-/- cells, which manifested as the inhibition of proliferation and induction of reactive oxygen species (ROS)-mediated apoptosis and was accompanied by the upregulation of B-cell lymphoma 2 (BCL-2) and downregulation of the BCL-2-associated X protein (BAX). artenimol 33-36 BCL2 apoptosis regulator Homo sapiens 303-308 29738772-5 2018 Interestingly, co-treatment with DHA could effectively restore the anticancer effect of 5-FU against HCT116 TP53-/- cells, which manifested as the inhibition of proliferation and induction of reactive oxygen species (ROS)-mediated apoptosis and was accompanied by the upregulation of B-cell lymphoma 2 (BCL-2) and downregulation of the BCL-2-associated X protein (BAX). Fluorouracil 88-92 BCL2 apoptosis regulator Homo sapiens 284-301 29738772-5 2018 Interestingly, co-treatment with DHA could effectively restore the anticancer effect of 5-FU against HCT116 TP53-/- cells, which manifested as the inhibition of proliferation and induction of reactive oxygen species (ROS)-mediated apoptosis and was accompanied by the upregulation of B-cell lymphoma 2 (BCL-2) and downregulation of the BCL-2-associated X protein (BAX). Fluorouracil 88-92 BCL2 apoptosis regulator Homo sapiens 303-308 29738772-6 2018 These findings suggested that DHA could effectively sensitize cells to 5-FU through ROS-mediated apoptosis and the alteration of the BCL-2/BAX expression ratio, which indicated that this may be one of the mechanisms of the DHA-promoted 5-FU anticancer effect. artenimol 30-33 BCL2 apoptosis regulator Homo sapiens 133-138 29738772-6 2018 These findings suggested that DHA could effectively sensitize cells to 5-FU through ROS-mediated apoptosis and the alteration of the BCL-2/BAX expression ratio, which indicated that this may be one of the mechanisms of the DHA-promoted 5-FU anticancer effect. artenimol 223-226 BCL2 apoptosis regulator Homo sapiens 133-138 29803995-8 2018 The results showed that the complexes could induce apoptosis in HeLa cells through an ROS-mediated mitochondrial dysfunction pathway, which was accompanied by the regulation of Bcl-2 family proteins. Reactive Oxygen Species 86-89 BCL2 apoptosis regulator Homo sapiens 177-182 30203776-6 2018 High concentration atorvastatin can up regulate the expression of Bcl-2 and down regulate the expression of Bax protein (P<0.05). Atorvastatin 19-31 BCL2 apoptosis regulator Homo sapiens 66-71 29704506-9 2018 RSV promoted viability, inhibited apoptotic cell rate, increased Bcl-2 expression, decreased Bax, cleaved-Caspase-3, and cleaved-Caspase-9 expressions. Resveratrol 0-3 BCL2 apoptosis regulator Homo sapiens 65-70 29950865-8 2018 Conclusion: In particular, luciferase assay showed that SPL-A inhibited Bcl-2 promoter activity, and p53 inhibitor PFT-alpha could reverse the effect of SPL-A on Bcl-2 expression. spindlactone A 56-61 BCL2 apoptosis regulator Homo sapiens 72-77 29950865-8 2018 Conclusion: In particular, luciferase assay showed that SPL-A inhibited Bcl-2 promoter activity, and p53 inhibitor PFT-alpha could reverse the effect of SPL-A on Bcl-2 expression. spindlactone A 153-158 BCL2 apoptosis regulator Homo sapiens 162-167 29914576-14 2018 Western blot analysis suggested that beta-eudesmol enhanced chemosensitivity was associated with the suppression of NQO1 protein and activation of Bax/Bcl-2 protein expression ratio in CCA cells. beta-eudesmol 37-50 BCL2 apoptosis regulator Homo sapiens 151-156 29977208-9 2018 In addition, trimebutine promoted cell apoptosis and induced Bcl-2 downregulation, accompanied with Bax upregulation. Trimebutine 13-24 BCL2 apoptosis regulator Homo sapiens 61-66 29977208-14 2018 Reduced Bcl-2 and upregulated Bax, as well as perturbed p-AKT and p-ERK signaling pathways were also observed in trimebutine-treated xenograft tissues. Trimebutine 113-124 BCL2 apoptosis regulator Homo sapiens 8-13 29909423-10 2018 Furthermore, we found the expression of anti-apoptotic protein Bcl-2 decreased, whereas the expression of pro-apoptotic protein Caspase3 and Bax increased in the SKOV3 cell line treated with prucalopride, as well as cleaved PARP. prucalopride 191-203 BCL2 apoptosis regulator Homo sapiens 63-68 29899021-3 2018 We report that inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) using statins enhances the proapoptotic activity of the B cell lymphoma-2 (BCL2) inhibitor venetoclax (ABT-199) in primary leukemia and lymphoma cells but not in normal human peripheral blood mononuclear cells. venetoclax 176-186 BCL2 apoptosis regulator Homo sapiens 141-158 29904934-6 2018 The anti-apoptotic protein BCL-2 (B Cell Lymphoma 2) is also upregulated by IL-2 at the most mature DP stage. dp 100-102 BCL2 apoptosis regulator Homo sapiens 27-32 29904934-6 2018 The anti-apoptotic protein BCL-2 (B Cell Lymphoma 2) is also upregulated by IL-2 at the most mature DP stage. dp 100-102 BCL2 apoptosis regulator Homo sapiens 34-51 29643240-6 2018 Ixazomib, a proteasome inhibitor in clinical use, blocks this pathway, increasing the abundance of Casp8p41 and causing more cells to die in a Casp8p41-dependent manner.IMPORTANCE The Casp8p41 pathway of cell death is unique to HIV-infected cells yet is blocked by Bcl2. ixazomib 0-8 BCL2 apoptosis regulator Homo sapiens 265-269 29679655-8 2018 In fact, NAC allows the anti-apoptotic molecule Bcl-2 to reduce the cell death caused by pro-necrotic concentrations of cisplatin, to a significantly greater extent than in the absence of NAC. Acetylcysteine 9-12 BCL2 apoptosis regulator Homo sapiens 48-53 29679655-8 2018 In fact, NAC allows the anti-apoptotic molecule Bcl-2 to reduce the cell death caused by pro-necrotic concentrations of cisplatin, to a significantly greater extent than in the absence of NAC. Cisplatin 120-129 BCL2 apoptosis regulator Homo sapiens 48-53 29899333-5 2018 Glaucocalyxin A induced apoptosis by mitochondrial apoptotic pathway through several steps including increasing the Bax/Bcl-2 ratio, triggering the intracellular reactive oxygen species (ROS) generation, reducing mitochondrial membrane potential (MMP), and inducing cleavage of caspase-9 and caspase-3. glaucocalyxin A 0-15 BCL2 apoptosis regulator Homo sapiens 120-125 29899021-3 2018 We report that inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) using statins enhances the proapoptotic activity of the B cell lymphoma-2 (BCL2) inhibitor venetoclax (ABT-199) in primary leukemia and lymphoma cells but not in normal human peripheral blood mononuclear cells. venetoclax 176-186 BCL2 apoptosis regulator Homo sapiens 160-164 29899021-3 2018 We report that inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) using statins enhances the proapoptotic activity of the B cell lymphoma-2 (BCL2) inhibitor venetoclax (ABT-199) in primary leukemia and lymphoma cells but not in normal human peripheral blood mononuclear cells. venetoclax 188-195 BCL2 apoptosis regulator Homo sapiens 141-158 29899021-3 2018 We report that inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) using statins enhances the proapoptotic activity of the B cell lymphoma-2 (BCL2) inhibitor venetoclax (ABT-199) in primary leukemia and lymphoma cells but not in normal human peripheral blood mononuclear cells. venetoclax 188-195 BCL2 apoptosis regulator Homo sapiens 160-164 32254451-7 2018 The Qtn-PVPylated-TiO2NPs are uptaken via endocytosis by cancer cells and can generate intracellular reactive oxygen species (ROS) in order to increase mitochondrial membrane potential loss (Deltapsim) and enable release of cytochrome-c, followed by dysregulation of Bcl-2 into the cytosol and activation of caspase-3 to induce cancer cell apoptosis. tio2nps 18-25 BCL2 apoptosis regulator Homo sapiens 267-272 32254451-7 2018 The Qtn-PVPylated-TiO2NPs are uptaken via endocytosis by cancer cells and can generate intracellular reactive oxygen species (ROS) in order to increase mitochondrial membrane potential loss (Deltapsim) and enable release of cytochrome-c, followed by dysregulation of Bcl-2 into the cytosol and activation of caspase-3 to induce cancer cell apoptosis. Reactive Oxygen Species 101-124 BCL2 apoptosis regulator Homo sapiens 267-272 32254451-7 2018 The Qtn-PVPylated-TiO2NPs are uptaken via endocytosis by cancer cells and can generate intracellular reactive oxygen species (ROS) in order to increase mitochondrial membrane potential loss (Deltapsim) and enable release of cytochrome-c, followed by dysregulation of Bcl-2 into the cytosol and activation of caspase-3 to induce cancer cell apoptosis. Reactive Oxygen Species 126-129 BCL2 apoptosis regulator Homo sapiens 267-272 29882807-7 2018 In addition, IDH1 inhibitors are in ongoing clinical studies, and the oral BCL-2 inhibitor venetoclax shows preliminary efficacy in this subset of patients. venetoclax 91-101 BCL2 apoptosis regulator Homo sapiens 75-80 29874784-7 2018 EESS also weakened the mitochondria membrane permeabilization by H2O2, and recovered H2O2-induced decreased expression of anti-apoptotic Bcl-2 and pro-caspase-3, and degradation of poly (ADP-ribose) polymerase. Hydrogen Peroxide 85-89 BCL2 apoptosis regulator Homo sapiens 137-142 29874795-4 2018 The study demonstrated that luteoloside could inhibit proliferation remarkably; promote apoptosis and cytochrome C release; decrease the mitochondrial membrane potential and reactive oxygen species level; upregulate the expression of Fas, Bax, p53, phospho-p38, phospho-JNK, and cleaved PARP; downregulate the expression of Bcl-2 and phospho-mTOR; activate caspase-3 and caspase-8; change the nuclear morphology, and fragmentate DNA in Hela cells. luteolin-7-glucoside 28-39 BCL2 apoptosis regulator Homo sapiens 324-329 29665360-8 2018 Mechanistically, co-administration of PNU-282987 with LY294002 (a PI3K inhibitor), AG490 (a JAK2 inhibitor) or Bcl-2 siRNA, but not compound C (an AMPK inhibitor), reduced Bcl-2 level and prevented the modulation of autophagy afforded by PNU-282987 in H/R cardiomyocytes. N-neopentyl-N-nitrosourea 38-41 BCL2 apoptosis regulator Homo sapiens 172-177 29866060-8 2018 RESULTS: As a result, the proliferation, migration and invasiveness of glioma cells were impaired by Prucalopride treatment, the apoptosis rate of glioma cells was enhanced by Prucalopride stimulation, accompanied by the increased pro-apoptosis proteins Bax and Cleaved caspase-3 and decreased anti-apoptosis protein Bcl-2. prucalopride 101-113 BCL2 apoptosis regulator Homo sapiens 317-322 29394130-8 2018 Knockdown of Mcl-1 and/or treatment with specific or pan Bcl-2-family inhibitors (BH3 mimetics) sensitized RKO, SW48, and LoVo cells to apoptosis by Nutlin-3a. BH 3 82-85 BCL2 apoptosis regulator Homo sapiens 57-62 29860266-9 2018 The apoptosis-related protein expression levels of p-p53, Bad, cleaved caspase-3, cleaved PARP and p-JNK were increased in quinalizarin-treated cells, while protein expression levels Bcl-2, p-Akt, p-ERK, and p-STAT3 were decreased. 1,2,5,8-tetrahydroxy anthraquinone 123-135 BCL2 apoptosis regulator Homo sapiens 183-188 29762687-10 2018 The glycine treatment group had greater levels of expression of an antiapoptotic gene (Bcl2) in mature oocytes and cumulus cells and lesser levels of expression of a proapoptotic gene (Bax) in PA blastocysts (P < 0.05). Glycine 4-11 BCL2 apoptosis regulator Homo sapiens 87-91 29508061-4 2018 In the presence of elevated levels of H2S and thiosulfate, the sulfhydryl groups of p53 protein as well as Bcl-2 protein could be modified via HBITC-induced S-sulfuration or by oxidative stress. Hydrogen Sulfide 38-41 BCL2 apoptosis regulator Homo sapiens 107-112 29701777-8 2018 Western blot analysis showed that berbamine increased the protein levels of cleaved caspase-3, cleaved caspase-9, Bax, and decreased the protein level of Bcl-2 in ovarian cancer cells. berbamine 34-43 BCL2 apoptosis regulator Homo sapiens 154-159 29858490-10 2018 We also found that the phenotypic alterations by miR-365 were partially due to downregulation of CCND1 and BCL2 oncogenes. mir-365 49-56 BCL2 apoptosis regulator Homo sapiens 107-111 29361668-8 2018 Terminal deoxyribonucleotide-transferase-mediated dUTP nick-end labeling-positive cells were detected in renal tubules along with enhanced proapoptotic BAX/cleaved caspase-3 and reduced antiapoptotic BCL2. deoxyuridine triphosphate 50-54 BCL2 apoptosis regulator Homo sapiens 200-204 29508061-4 2018 In the presence of elevated levels of H2S and thiosulfate, the sulfhydryl groups of p53 protein as well as Bcl-2 protein could be modified via HBITC-induced S-sulfuration or by oxidative stress. Thiosulfates 46-57 BCL2 apoptosis regulator Homo sapiens 107-112 29438179-6 2018 In addition, 5Br-6b caused the cleavage of caspase-3 and decreased the expression of Bcl-2. 5br-6b 13-19 BCL2 apoptosis regulator Homo sapiens 85-90 30002690-0 2018 miR-181b inhibits chemoresistance in cisplatin-resistant H446 small cell lung cancer cells by targeting Bcl-2. mir-181b 0-8 BCL2 apoptosis regulator Homo sapiens 104-109 30002690-0 2018 miR-181b inhibits chemoresistance in cisplatin-resistant H446 small cell lung cancer cells by targeting Bcl-2. Cisplatin 37-46 BCL2 apoptosis regulator Homo sapiens 104-109 30002690-9 2018 Overexpression of Bcl-2 reversed miR-181b-mediated chemo sensitization, which is accompanied by a reduced apoptotic response. mir-181b 33-41 BCL2 apoptosis regulator Homo sapiens 18-23 29579711-7 2018 Furthermore, upon exposure to osthole, the expression of Cyclin B1, Cdc2, Bcl-2, PARP1 and Survivin was decreased, while the expression of BAX, cleaved PARP1, cleaved Caspase3 and cleaved Caspase9 was increased. osthol 30-37 BCL2 apoptosis regulator Homo sapiens 74-79 28759731-3 2018 We show that clinically relevant doses of piperacillin induce apoptosis in SH-SY5Y and human primary neuron cells through activating caspase-3 activity and decreasing Mcl-1 and Bcl-2 levels. Piperacillin 42-54 BCL2 apoptosis regulator Homo sapiens 177-182 29526801-8 2018 Collectively, our findings identify BCL2 status in PCa as a putative predictor of (i) radiotherapy response and (ii) response to treatment with PARP inhibitor olaparib as a radiosensitizing agent. olaparib 159-167 BCL2 apoptosis regulator Homo sapiens 36-40 29626606-5 2018 Curcumin possessed anti-apoptotic character evidenced by elevating Bcl-2 content and reducing that of cleaved caspase-3. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 67-72 29589053-6 2018 A chemical inhibition of caspases as well as an overexpression of mitochondrial, anti-apoptotic BCL2 family proteins significantly reduces the processing of WT1 and cell death in hydroxyurea-sensitive acute promyelocytic leukemia cells. Hydroxyurea 179-190 BCL2 apoptosis regulator Homo sapiens 96-100 29368407-5 2018 In TSLP-stimulated cells, rutin or HM0601 treatment significantly impaired levels of interleukin (IL)-13 and Bcl2 expression. Rutin 26-31 BCL2 apoptosis regulator Homo sapiens 109-113 29496539-0 2018 Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer. 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-N5-(2-phenylpropyl)-N5'-(2-phenylpropyl)-2,2'-binaphthyl-5,5'-dicarboxamide 0-10 BCL2 apoptosis regulator Homo sapiens 23-28 29496539-5 2018 In the present study, the effect of sabutoclax, a pan-active BCL-2 protein family antagonist, on two chemoresistant breast cancer cell lines was assessed. 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-N5-(2-phenylpropyl)-N5'-(2-phenylpropyl)-2,2'-binaphthyl-5,5'-dicarboxamide 36-46 BCL2 apoptosis regulator Homo sapiens 61-66 29496539-8 2018 Sabutoclax induced the blockage of BCL-2, MCL-1, BCL-xL and BFL-1, which in turn led to caspase-3/7 and caspase-9 activation and modulation of Bax, Bim, PUMA and survivin expression. 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-N5-(2-phenylpropyl)-N5'-(2-phenylpropyl)-2,2'-binaphthyl-5,5'-dicarboxamide 0-10 BCL2 apoptosis regulator Homo sapiens 35-40 29496539-11 2018 Our findings indicate that sabutoclax partially overcomes the drug resistance phenotype of breast cancer cells by reactivation of apoptosis, mediated by the inhibition of several anti-apoptotic BCL-2 family proteins, and eliminates CSCs by abolition of the IL-6/STAT3 pathway. 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-N5-(2-phenylpropyl)-N5'-(2-phenylpropyl)-2,2'-binaphthyl-5,5'-dicarboxamide 27-37 BCL2 apoptosis regulator Homo sapiens 194-199 29436019-12 2018 Melatonin also downregulated Bax, upregulated Bcl-2, and decreased the expression and activity of caspase-3. Melatonin 0-9 BCL2 apoptosis regulator Homo sapiens 46-51 29559471-2 2018 Here, we assessed the efficacy of coadministration of the PI3K/mTOR inhibitor GDC-0980 or the p110beta-sparing PI3K inhibitor taselisib with the selective BCL-2 antagonist venetoclax in AML cells. venetoclax 172-182 BCL2 apoptosis regulator Homo sapiens 155-160 29559471-3 2018 Tetracycline-inducible downregulation of BCL-2 significantly sensitized MV4-11 and MOLM-13 AML cells to PI3K inhibition. Tetracycline 0-12 BCL2 apoptosis regulator Homo sapiens 41-46 29917187-12 2018 The expression of Bcl-2 protein in paclitaxel group and miR-448 mimic group was significantly lower than that in control group and higher than paclitaxel combined with miR-448 mimic group (p<0.05). Paclitaxel 35-45 BCL2 apoptosis regulator Homo sapiens 18-23 29917187-12 2018 The expression of Bcl-2 protein in paclitaxel group and miR-448 mimic group was significantly lower than that in control group and higher than paclitaxel combined with miR-448 mimic group (p<0.05). Paclitaxel 143-153 BCL2 apoptosis regulator Homo sapiens 18-23 29917187-13 2018 CONCLUSIONS: Paclitaxel combined with miR-448 promoted EJ cell apoptosis and inhibited cell proliferation by suppressing Bcl-2 gene expression. Paclitaxel 13-23 BCL2 apoptosis regulator Homo sapiens 121-126 29368407-5 2018 In TSLP-stimulated cells, rutin or HM0601 treatment significantly impaired levels of interleukin (IL)-13 and Bcl2 expression. hm0601 35-41 BCL2 apoptosis regulator Homo sapiens 109-113 29408314-1 2018 BACKGROUND & AIMS: Myeloid cell leukemia 1 (MCL1), a prosurvival member of the BCL2 protein family, has a pivotal role in human cholangiocarcinoma (CCA) cell survival. Adenosine Monophosphate 12-15 BCL2 apoptosis regulator Homo sapiens 83-87 29147952-10 2018 Moreover, gemigliptin has a synergistic activity with PXD101 in the induction of cell death through involvement of Bcl2 family proteins, xIAP and survivin as well as mediation of Akt and AMPK in thyroid carcinoma cells. LC15-0444 10-21 BCL2 apoptosis regulator Homo sapiens 115-119 29779937-8 2018 RESULTS: BCL-2, BAX and NF-KappaB showed decreased expression in MCF7 bulk cancer cells after DOX treatment whereas only BCL-2 and BAX showed decreased expression in MDA-MB-231 bulk cancer cells. Doxorubicin 94-97 BCL2 apoptosis regulator Homo sapiens 9-14 29587241-5 2018 Results demonstrate that milimolar concentrations of butyrate has an anti-proliferative effect in all three colon cancer cell lines under study, leading to a decrease on cell viability, expression of P21, P53 and beta-catenin, being able to modulate P-glycoprotein activity and to induce apoptosis by modulation of BAX/BCL-2 ratio. Butyrates 53-61 BCL2 apoptosis regulator Homo sapiens 319-324 29960844-8 2018 Salidroside treatment exhibited significant increase in Bcl-2 expressions, and decrease in Bax expressions and caspase-3 activity when compared with the H/R group. rhodioloside 0-11 BCL2 apoptosis regulator Homo sapiens 56-61 28838268-1 2018 Venetoclax (ABT-199) is a Bcl-2-specific BH3-mimetic that has shown significant promise in certain subtypes of CLL as well as in several other hematologic malignancies. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 26-31 28838268-1 2018 Venetoclax (ABT-199) is a Bcl-2-specific BH3-mimetic that has shown significant promise in certain subtypes of CLL as well as in several other hematologic malignancies. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 12-15 BCL2 apoptosis regulator Homo sapiens 26-31 28838268-1 2018 Venetoclax (ABT-199) is a Bcl-2-specific BH3-mimetic that has shown significant promise in certain subtypes of CLL as well as in several other hematologic malignancies. BH 3 41-44 BCL2 apoptosis regulator Homo sapiens 26-31 29352505-3 2018 Cisplatin produces anticancer effects primarily via activation of the DNA damage response, followed by inducing BCL-2 family dependent mitochondrial apoptosis. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 112-117 29352505-4 2018 We have previously demonstrated that cisplatin induces the expression of proapoptotic BCL-2 family protein, Noxa, that can bind to the prosurvival BCL-2 family protein, MCL-1, to inactivate its function and induce cell death. Cisplatin 37-46 BCL2 apoptosis regulator Homo sapiens 86-91 29352505-4 2018 We have previously demonstrated that cisplatin induces the expression of proapoptotic BCL-2 family protein, Noxa, that can bind to the prosurvival BCL-2 family protein, MCL-1, to inactivate its function and induce cell death. Cisplatin 37-46 BCL2 apoptosis regulator Homo sapiens 147-152 29890822-7 2018 Further, the cell survival ratio was dramatically increased in OEC-3Cs against H2O2-induced oxidative stress via the augmented expression of Bcl-2, a prosurvival protein. Hydrogen Peroxide 79-83 BCL2 apoptosis regulator Homo sapiens 141-146 32185966-11 2018 Compared with group 0, various doses of E + CoCl2 could up-regulate the expression of Bax and caspase-3 and down-regulate the expression of Bcl-2 at protein and mRNA levels (P < 0.05). e + cocl2 40-49 BCL2 apoptosis regulator Homo sapiens 140-145 32185966-14 2018 Combination of Astragalus polysaccharide and Curcumin increased the expression of Bax and caspase-3, and decreased the expression of Bcl-2 to initiate apoptosis in A549 cells under chemical-induced hypoxia. Curcumin 45-53 BCL2 apoptosis regulator Homo sapiens 133-138 29693193-7 2018 Moreover, following treatment with corilagin, we noted upregulation of Fas and FasL and activation of caspase-8 which represented activation of the death receptor pathway, and we also observed downregulation of Bcl-2 and survivin which was also attributed to the antitumor effect of corilagin. corilagin 35-44 BCL2 apoptosis regulator Homo sapiens 211-216 29671234-7 2018 Gallic acid also lowered the ratio of the pro-apoptotic Bax protein and the anti-apoptotic Bcl-2 protein in SH-SY5Y cells. Gallic Acid 0-11 BCL2 apoptosis regulator Homo sapiens 91-96 29658606-6 2018 CQ-mediated growth inhibition in A549 cells was characterized by the targeting of the PI3K/AKT pathway, thus, inducing mitochondria-mediated apoptosis at relatively higher concentrations by downregulating Bcl-2 expression, increasing the expression level of Bax, decreasing mitochondrial membrane potential, releasing cytochrome c from the mitochondria into the cytosol, activating caspase-3 and cleaving PARP. Chloroquine 0-2 BCL2 apoptosis regulator Homo sapiens 205-210 29928342-7 2018 Furthermore, quercetin increased the levels of activating transcription factor (ATF)-6alpha, ATF-6beta and gastrin-releasing peptide-78 which indicated an increase in endoplasm reticulum stress, increased levels of the pro-apoptotic protein BH3 interacting-domain death antagonist, and decreased levels of anti-apoptotic proteins B-cell lymphoma (Bcl) 2 and Bcl-extra large which may have led to the decreases of DeltaPsim. Quercetin 13-22 BCL2 apoptosis regulator Homo sapiens 330-353 29805606-12 2018 Additionally, the expression of B-cell lymphoma 2 (Bcl-2) was downregulated in the miR-128-inhibited group, compared with that in the control group, whereas the expression levels of SASH1, Bcl-2-associated X protein and caspase-3 were upregulated in the group with miR-128 inhibition (P<0.05). mir-128 83-90 BCL2 apoptosis regulator Homo sapiens 189-194 29805606-12 2018 Additionally, the expression of B-cell lymphoma 2 (Bcl-2) was downregulated in the miR-128-inhibited group, compared with that in the control group, whereas the expression levels of SASH1, Bcl-2-associated X protein and caspase-3 were upregulated in the group with miR-128 inhibition (P<0.05). mir-128 265-272 BCL2 apoptosis regulator Homo sapiens 32-49 29805606-12 2018 Additionally, the expression of B-cell lymphoma 2 (Bcl-2) was downregulated in the miR-128-inhibited group, compared with that in the control group, whereas the expression levels of SASH1, Bcl-2-associated X protein and caspase-3 were upregulated in the group with miR-128 inhibition (P<0.05). mir-128 265-272 BCL2 apoptosis regulator Homo sapiens 51-56 29844823-0 2018 miR-371-5p suppresses the proliferative and migratory capacity of human nasopharyngeal carcinoma by targeting BCL2. mir-371-5p 0-10 BCL2 apoptosis regulator Homo sapiens 110-114 29805582-6 2018 Aspirin also significantly decreased the expression of B-cell lymphoma 2 (Bcl-2) and caspase-3, and increased the expression of Bcl-2-associated X protein, suggesting that aspirin induced apoptosis through the intrinsic apoptotic pathway. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 55-72 29805582-6 2018 Aspirin also significantly decreased the expression of B-cell lymphoma 2 (Bcl-2) and caspase-3, and increased the expression of Bcl-2-associated X protein, suggesting that aspirin induced apoptosis through the intrinsic apoptotic pathway. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 74-79 29805582-6 2018 Aspirin also significantly decreased the expression of B-cell lymphoma 2 (Bcl-2) and caspase-3, and increased the expression of Bcl-2-associated X protein, suggesting that aspirin induced apoptosis through the intrinsic apoptotic pathway. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 128-133 29805582-6 2018 Aspirin also significantly decreased the expression of B-cell lymphoma 2 (Bcl-2) and caspase-3, and increased the expression of Bcl-2-associated X protein, suggesting that aspirin induced apoptosis through the intrinsic apoptotic pathway. Aspirin 172-179 BCL2 apoptosis regulator Homo sapiens 55-72 29805582-6 2018 Aspirin also significantly decreased the expression of B-cell lymphoma 2 (Bcl-2) and caspase-3, and increased the expression of Bcl-2-associated X protein, suggesting that aspirin induced apoptosis through the intrinsic apoptotic pathway. Aspirin 172-179 BCL2 apoptosis regulator Homo sapiens 74-79 29805582-6 2018 Aspirin also significantly decreased the expression of B-cell lymphoma 2 (Bcl-2) and caspase-3, and increased the expression of Bcl-2-associated X protein, suggesting that aspirin induced apoptosis through the intrinsic apoptotic pathway. Aspirin 172-179 BCL2 apoptosis regulator Homo sapiens 128-133 29805606-12 2018 Additionally, the expression of B-cell lymphoma 2 (Bcl-2) was downregulated in the miR-128-inhibited group, compared with that in the control group, whereas the expression levels of SASH1, Bcl-2-associated X protein and caspase-3 were upregulated in the group with miR-128 inhibition (P<0.05). mir-128 83-90 BCL2 apoptosis regulator Homo sapiens 32-49 29805606-12 2018 Additionally, the expression of B-cell lymphoma 2 (Bcl-2) was downregulated in the miR-128-inhibited group, compared with that in the control group, whereas the expression levels of SASH1, Bcl-2-associated X protein and caspase-3 were upregulated in the group with miR-128 inhibition (P<0.05). mir-128 83-90 BCL2 apoptosis regulator Homo sapiens 51-56 29928358-6 2018 Furthermore, resveratrol upregulated the expression of the pro-apoptotic B-cell lymphoma (Bcl)-2-associated X protein and downregulated the expression of the anti-apoptotic proteins Bcl-2 and Bcl-extra large in HeLa cells. Resveratrol 13-24 BCL2 apoptosis regulator Homo sapiens 182-187 29928364-9 2018 Decreased chemosensitivity to cisplatin may be associated with increased expression of phosphorylated-protein kinase B and cyclin dependent kinase 2 and with decreased expression of p21 and the B cell lymphoma (Bcl)-2 associated X/Bcl-2 ratio. Cisplatin 30-39 BCL2 apoptosis regulator Homo sapiens 194-217 29928364-9 2018 Decreased chemosensitivity to cisplatin may be associated with increased expression of phosphorylated-protein kinase B and cyclin dependent kinase 2 and with decreased expression of p21 and the B cell lymphoma (Bcl)-2 associated X/Bcl-2 ratio. Cisplatin 30-39 BCL2 apoptosis regulator Homo sapiens 231-236 29620221-9 2018 In addition, CT-1042 induced mitochondrial-mediated apoptosis by activating p53 and Bax, as well as inhibiting Bcl-2 and survivin. ct-1042 13-20 BCL2 apoptosis regulator Homo sapiens 111-116 29620228-6 2018 Furthermore, the downregulation of beta-arrestin2 reduced the expression of the pro-apoptotic proteins cleaved-caspase-3 and Bax, and increased the expression of the anti-apoptotic protein Bcl-2 after 5-FU treatment. Fluorouracil 201-205 BCL2 apoptosis regulator Homo sapiens 189-194 29571073-14 2018 Conversely, treatment with DAPT alone only increased expression of BAX and P53 (P < .05), suggesting that the reduction of Bcl-2 expression may play an important role in the synergetic antitumor and proapoptosis effects of the combined treatment. dapt 27-31 BCL2 apoptosis regulator Homo sapiens 126-131 29297235-0 2018 L-ascorbic acid and alpha-tocopherol attenuate arsenic trioxide-induced toxicity in H9c2 cardiomyocytes by the activation of Nrf2 and Bcl2 transcription factors. Ascorbic Acid 0-15 BCL2 apoptosis regulator Homo sapiens 134-138 29297235-0 2018 L-ascorbic acid and alpha-tocopherol attenuate arsenic trioxide-induced toxicity in H9c2 cardiomyocytes by the activation of Nrf2 and Bcl2 transcription factors. alpha-Tocopherol 20-36 BCL2 apoptosis regulator Homo sapiens 134-138 29297235-0 2018 L-ascorbic acid and alpha-tocopherol attenuate arsenic trioxide-induced toxicity in H9c2 cardiomyocytes by the activation of Nrf2 and Bcl2 transcription factors. Arsenic Trioxide 47-63 BCL2 apoptosis regulator Homo sapiens 134-138 29928488-5 2018 However, inhibition of BCL-xL/BCL-2 by the BH3 mimetics ABT-737 and navitoclax or BCL-xL by A-1331852 induced caspase-dependent apoptosis involving activation of Bak and Bax synergistically with ruxolitinib in HEL cells. BH 3 43-46 BCL2 apoptosis regulator Homo sapiens 30-35 29928488-5 2018 However, inhibition of BCL-xL/BCL-2 by the BH3 mimetics ABT-737 and navitoclax or BCL-xL by A-1331852 induced caspase-dependent apoptosis involving activation of Bak and Bax synergistically with ruxolitinib in HEL cells. ABT-737 56-63 BCL2 apoptosis regulator Homo sapiens 30-35 29928488-5 2018 However, inhibition of BCL-xL/BCL-2 by the BH3 mimetics ABT-737 and navitoclax or BCL-xL by A-1331852 induced caspase-dependent apoptosis involving activation of Bak and Bax synergistically with ruxolitinib in HEL cells. A-1331852 92-101 BCL2 apoptosis regulator Homo sapiens 30-35 29928488-5 2018 However, inhibition of BCL-xL/BCL-2 by the BH3 mimetics ABT-737 and navitoclax or BCL-xL by A-1331852 induced caspase-dependent apoptosis involving activation of Bak and Bax synergistically with ruxolitinib in HEL cells. ruxolitinib 195-206 BCL2 apoptosis regulator Homo sapiens 30-35 29928488-7 2018 The present study suggests that autophagy as well as the anti-apoptotic BCL-2 family members, regulated at least partly by the mTORC1 pathway downstream of STAT5/Pim-2, protects JAK2-V617F-positive leukemic cells from ruxolitinib-induced apoptosis depending on cell types and may contribute to development of new strategies against JAK2-V617F-positive neoplasms. ruxolitinib 218-229 BCL2 apoptosis regulator Homo sapiens 72-77 29475134-7 2018 The level of cleaved caspase 3 and the ratio of Bax/Bcl-2 were also decreased after treatment with FCPR16 in MPP+-treated cells. mangion-purified polysaccharide (Candida albicans) 109-113 BCL2 apoptosis regulator Homo sapiens 52-57 29297235-4 2018 The present investigation aims to explore protective role of L-ascorbic acid (L-AA) and alpha-tocopherol (alpha-TOC) from As2O3-induced oxidative stress in H9c2 cardiomyocytes through the evaluation of Nrf2 (nuclear factor erythroid 2-related factor 2) and Bcl-2 (B-cell lymphoma 2) transcription factors. Ascorbic Acid 61-76 BCL2 apoptosis regulator Homo sapiens 257-262 29297235-4 2018 The present investigation aims to explore protective role of L-ascorbic acid (L-AA) and alpha-tocopherol (alpha-TOC) from As2O3-induced oxidative stress in H9c2 cardiomyocytes through the evaluation of Nrf2 (nuclear factor erythroid 2-related factor 2) and Bcl-2 (B-cell lymphoma 2) transcription factors. Ascorbic Acid 61-76 BCL2 apoptosis regulator Homo sapiens 264-281 29297235-9 2018 In addition, the cellular calcium concentration and ROS generation were found to be increased on treatment with As2O3 with the alterations in the activity of transcription factors, Nrf2 and Bcl2. Calcium 26-33 BCL2 apoptosis regulator Homo sapiens 190-194 29950226-11 2018 HCQ inhibited the expression of LC3-II/LC3-I and BCL-2, but increased the expression of caspase-3 and PARP. Hydroxychloroquine 0-3 BCL2 apoptosis regulator Homo sapiens 49-54 29297235-9 2018 In addition, the cellular calcium concentration and ROS generation were found to be increased on treatment with As2O3 with the alterations in the activity of transcription factors, Nrf2 and Bcl2. Arsenic Trioxide 112-117 BCL2 apoptosis regulator Homo sapiens 190-194 29297235-10 2018 Co-treatment of antioxidant vitamins with As2O3 resulted in a significant reversal of oxidative stress and alteration on the antioxidant defense through the activation of Nrf2 and Bcl2. Arsenic Trioxide 42-47 BCL2 apoptosis regulator Homo sapiens 180-184 29297235-11 2018 L-AA and alpha-TOC alleviates As2O3-induced oxidative stress in cardiac cells by activating Nrf2 and Bcl2 transcription factors that results in increased cell survival and prevents apoptosis. Arsenic Trioxide 30-35 BCL2 apoptosis regulator Homo sapiens 101-105 29950084-4 2018 The effect of allicin on the expressions of Bax, Bcl-2, survivin and ERK mRNA in KG-1 cells was detected by RT-qPCR. allicin 14-21 BCL2 apoptosis regulator Homo sapiens 49-54 29950084-8 2018 The results of RT-qPCR showed that the expressions of Bax mRNA, Bcl-2, survivin and ERK mRNA in KG-1 cells increased after treatment with allicin. allicin 138-145 BCL2 apoptosis regulator Homo sapiens 64-69 29950084-10 2018 The above results suggest that allicin inhibited the proliferation of KG-1 cells primarily by inducing late apoptosis; the execution of apoptosis involved cleaved caspase 3; the induction of apoptosis involved the protein expression, the decrease of ERK1/2andexpression of survivin and the dose-dependent decrease of p-ERK1/2; the mRNA expression involved the increase of Bax, and the down-regulation of survivin, Bcl-2 and ERK1/2. allicin 31-38 BCL2 apoptosis regulator Homo sapiens 414-419 29654165-9 2018 Furthermore, overexpressed NEAT1 reduced the sensitivity of cisplatin (DDP) and inhibited DDP-induced apoptosis and cell cycle arrest via miR-34c The results in vivo also confirmed that knockdown of NEAT1 sensitized the OS cells to DPP-induced tumor regression, delayed the tumor growth with reduced levels of Ki-67, BCL-2, and cyclin D1 signals, suggesting that NEAT1 is an oncogene and chemotherapy resistant factor in OS. Cisplatin 60-69 BCL2 apoptosis regulator Homo sapiens 317-322 29899697-4 2018 We found that icariin downregulated the protein expression of STAT3 downstream target gene products such as Bcl-2, Bcl-xl, survivin, IAP-1/2, COX-2, VEGF, and matrix metallopeptidase 9 (MMP-9) in a concentration-dependent manner. icariin 14-21 BCL2 apoptosis regulator Homo sapiens 108-113 29655913-7 2018 Adriamycin treatment inhibited the expression of Bcl-2 and induced the expression of Bax, and germacrone enhanced the effect of adriamycin. Doxorubicin 0-10 BCL2 apoptosis regulator Homo sapiens 49-54 29843746-15 2018 The in vivo results showed that miR-519a can enhance apoptosis and sensitized GBM to TMZ treatment by promoting autophagy and targeting the STAT3/Bcl-2/Beclin-1 pathway. Temozolomide 85-88 BCL2 apoptosis regulator Homo sapiens 146-151 29899841-0 2018 BCL2 and BCL(X)L selective inhibitors decrease mitochondrial ATP production in breast cancer cells and are synthetically lethal when combined with 2-deoxy-D-glucose. Adenosine Triphosphate 61-64 BCL2 apoptosis regulator Homo sapiens 0-4 29899841-0 2018 BCL2 and BCL(X)L selective inhibitors decrease mitochondrial ATP production in breast cancer cells and are synthetically lethal when combined with 2-deoxy-D-glucose. Deoxyglucose 147-164 BCL2 apoptosis regulator Homo sapiens 0-4 29899841-7 2018 We next tested the hypothesis that mitochondrial ATP production inhibition with BCL2 or BCL(X)L antagonists was synthetically lethal when combined with glycolysis inhibition. Adenosine Triphosphate 49-52 BCL2 apoptosis regulator Homo sapiens 80-84 29899843-4 2018 In this study, we found that pro-survival protein Bcl-2 is upregulated in paclitaxel resistant cells, potentially contributing to chemotherapy resistance. Paclitaxel 74-84 BCL2 apoptosis regulator Homo sapiens 50-55 29872325-6 2018 Further investigation showed that miR-134 increased the anti-tumor effects of Ara-C through inhibiting phosphorylation of eukaryotic initiation factor 4E and downregulating Mcl-1 and bcl2, which was independent of p38 and Erk1/2 activation. Cytarabine 78-83 BCL2 apoptosis regulator Homo sapiens 183-187 29899843-6 2018 The Nur77 derived peptide preferentially induced apoptosis in paclitaxel-resistant cancer cells with high expression of Bcl-2. Paclitaxel 62-72 BCL2 apoptosis regulator Homo sapiens 120-125 29732892-9 2018 RAP could downregulate the expression of Bax and caspase-3 and upregulate the expression of Bcl-2 in H2O2-induced HUVECs (human umbilical vein endothelial cells). Hydrogen Peroxide 101-105 BCL2 apoptosis regulator Homo sapiens 92-97 29872316-7 2018 Apatinib combined with the aforementioned drugs, especially the combination of Apatinib and 5-FU, decreased the invasion and migration ability of the cells and increased the apoptosis ratio; expression of the anti-apoptotic protein Bcl-2 significantly decreased, and expression of the pro-apoptotic protein Bax increased. apatinib 0-8 BCL2 apoptosis regulator Homo sapiens 232-237 29872316-7 2018 Apatinib combined with the aforementioned drugs, especially the combination of Apatinib and 5-FU, decreased the invasion and migration ability of the cells and increased the apoptosis ratio; expression of the anti-apoptotic protein Bcl-2 significantly decreased, and expression of the pro-apoptotic protein Bax increased. apatinib 79-87 BCL2 apoptosis regulator Homo sapiens 232-237 29872316-7 2018 Apatinib combined with the aforementioned drugs, especially the combination of Apatinib and 5-FU, decreased the invasion and migration ability of the cells and increased the apoptosis ratio; expression of the anti-apoptotic protein Bcl-2 significantly decreased, and expression of the pro-apoptotic protein Bax increased. Fluorouracil 92-96 BCL2 apoptosis regulator Homo sapiens 232-237 29770817-5 2018 The cellular thermal shift assay (CETSA) and notably competitive binding assay by the microscale thermophoresis (MST) method provided the evidence that this flavonoid directly bound to BCL-2. Flavonoids 157-166 BCL2 apoptosis regulator Homo sapiens 185-190 29876013-6 2018 MC2884 induced massive apoptosis in ex vivo human primary leukemia blasts with poor prognosis in vivo, by targeting BCL2 expression. mc2884 0-6 BCL2 apoptosis regulator Homo sapiens 116-120 29795285-5 2018 OX40 promoted the survival of cDNT by regulating the expression of Bcl-2, Bcl-xL, Survivin, and BCL2L11. 4-CHLORO-3,5-DINITROBENZOTRIFLUORIDE 30-34 BCL2 apoptosis regulator Homo sapiens 67-72 29795285-10 2018 IL-2 promoted OX40 expression by downregulating the PPARalpha binding to the OX40 promoter, leading to the elevated expression of Bcl-2, Bcl-xL, and Survivin in cDNT, which finally resulted in the promoted proliferation and decreased apoptosis of cDNT. 4-CHLORO-3,5-DINITROBENZOTRIFLUORIDE 161-165 BCL2 apoptosis regulator Homo sapiens 130-135 29795285-10 2018 IL-2 promoted OX40 expression by downregulating the PPARalpha binding to the OX40 promoter, leading to the elevated expression of Bcl-2, Bcl-xL, and Survivin in cDNT, which finally resulted in the promoted proliferation and decreased apoptosis of cDNT. 4-CHLORO-3,5-DINITROBENZOTRIFLUORIDE 247-251 BCL2 apoptosis regulator Homo sapiens 130-135 29788929-8 2018 Mitochondrial membrane potential and apoptosis-related markers, such as an increased Bax/Bcl-2 ratio, and cleaved forms of caspase-8 and caspase-3, arise following resveratrol addition. Resveratrol 164-175 BCL2 apoptosis regulator Homo sapiens 89-94 29795190-4 2018 Enforced miR-181a expression enhanced 5-FU-induced p53-dependent mitochondrial apoptosis, including declined Bcl-2/Bax ratio, loss of mitochondrial membrane potential, cytochrome c release, and caspase-9 and caspase-3 activation. Fluorouracil 38-42 BCL2 apoptosis regulator Homo sapiens 109-114 29876007-0 2018 Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin. Doxorubicin 73-84 BCL2 apoptosis regulator Homo sapiens 0-5 29876007-5 2018 In this study, we investigated whether Bcl-2 inhibition could sensitize TNBC cells to the genotoxic drug doxorubicin (DR). Doxorubicin 105-116 BCL2 apoptosis regulator Homo sapiens 39-44 29876007-6 2018 Treatment with a combination of the Bcl-2 inhibitor ABT-199 and DR synergistically decreased the viability of the TNBC cell lines MDA-MB-231 and BT-549. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 52-55 BCL2 apoptosis regulator Homo sapiens 36-41 29876013-7 2018 MC2884-treatment reduced acetylation of the BCL2 promoter at higher level than combined p300 and EZH2 inhibition. mc2884 0-6 BCL2 apoptosis regulator Homo sapiens 44-48 29783729-6 2018 Moreover, CGA potentiated the apoptotic effect of Regorafenib by the activation of the pro-apoptotic Annexin V, Bax and Caspase 3/7 and the inhibition of anti-apoptotic Bcl2 and Bcl-xL. regorafenib 50-61 BCL2 apoptosis regulator Homo sapiens 169-173 29876013-4 2018 MC2884 triggered mitochondrial pathway apoptosis by up-regulation of cleaved-BID, and strong down-regulation of BCL2. mc2884 0-6 BCL2 apoptosis regulator Homo sapiens 112-116 30250907-2 2018 The B-cell lymphoma 2 (Bcl-2) family member, Bcl-2-interacting killer (BIK), triggers cell death specifically in these hyperplastic cells because of adequate presence of Death-associated Protein Kinase 1 (DAPk1), BCL-2 Antagonist Killer (BAK), and Extracellular Signal-regulated Kinase 1/2 (ERK1/2). bakuchiol 238-241 BCL2 apoptosis regulator Homo sapiens 4-21 29596834-8 2018 BRD4-regulated proteins, including c-Myc, Bcl-2 and cyclin D1, were significantly downregulated following AZD5153 treatment in TPC-1 and primary cancer cells. AZD5153 106-113 BCL2 apoptosis regulator Homo sapiens 42-47 29596834-10 2018 BRD4-dependent proteins, Myc, Bcl-2 and cyclin D1, were also downregulated in AZD5153-treated tumor tissues. AZD5153 78-85 BCL2 apoptosis regulator Homo sapiens 30-35 29766980-13 2018 Ripasudil treatment increased the phosphorylation of eNOS, increased the expression level of Bcl2, and decreased the expression level of active caspase3 in LPS-treated PMVECs. K-115 0-9 BCL2 apoptosis regulator Homo sapiens 93-97 29604279-7 2018 Resveratrol inhibited UVB-induced apoptosis by upregulating the expression of HSP27, reducing the production of proapoptotic proteins such as p65, Bax, and cleaved caspase-3, and promoting the expression of anti-apoptotic protein Bcl-2. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 230-235 29604279-8 2018 However, UVB irradiation on HaCaT cells pretreated with resveratrol led to the upregulation of Bax, downregulation of Bcl-2, and promotion of p65 and caspase-3 activation after silencing of HSP27 gene. Resveratrol 56-67 BCL2 apoptosis regulator Homo sapiens 118-123 30250907-2 2018 The B-cell lymphoma 2 (Bcl-2) family member, Bcl-2-interacting killer (BIK), triggers cell death specifically in these hyperplastic cells because of adequate presence of Death-associated Protein Kinase 1 (DAPk1), BCL-2 Antagonist Killer (BAK), and Extracellular Signal-regulated Kinase 1/2 (ERK1/2). bakuchiol 238-241 BCL2 apoptosis regulator Homo sapiens 23-28 29604279-10 2018 In summary, resveratrol plays a role in photoprotection by upregulating HSP27 expression, increasing Bcl-2/Bax ratio, and inhibiting caspase-3 activity and p65 expression. Resveratrol 12-23 BCL2 apoptosis regulator Homo sapiens 101-106 29604275-5 2018 We found that short-term priming with OLP attenuated H2O2-induced apoptosis by regulating the pro-apoptotic marker Bax and the anti-apoptotic markers Bcl-2 and Mcl-1. Hydrogen Peroxide 53-57 BCL2 apoptosis regulator Homo sapiens 150-155 29808798-5 2018 Subsequently, we used SIRT1 siRNA to knockdown the expression of SIRT1, and then measured cell proliferation, cell apoptosis rate, cell cycle distribution, and expression levels of Bcl-2 and Bax in PTX-sensitive Hela cell line, PTX-resistant Hela and Sila-resistant cell lines. Paclitaxel 198-201 BCL2 apoptosis regulator Homo sapiens 181-186 29604275-7 2018 Our data suggest that OLP might reduce H2O2-induced autophagy and cell apoptosis in MSCs by regulating both the AMPK-ULK axis and the Bcl-2-Mcl-1 axis. Hydrogen Peroxide 39-43 BCL2 apoptosis regulator Homo sapiens 134-139 29887946-16 2018 Relative to the CDDP group, the CDDP+GSH group exhibited 47.92%, 47.82% and 63.75% downregulation in caspase3, caspase9 and bax mRNA expression, respectively, and a 2.17-fold increase in bcl-2 mRNA level. cddp 32-36 BCL2 apoptosis regulator Homo sapiens 187-192 29887946-16 2018 Relative to the CDDP group, the CDDP+GSH group exhibited 47.92%, 47.82% and 63.75% downregulation in caspase3, caspase9 and bax mRNA expression, respectively, and a 2.17-fold increase in bcl-2 mRNA level. Glutathione 37-40 BCL2 apoptosis regulator Homo sapiens 187-192 29548748-7 2018 MALAT1 knockdown enhanced CDDP-induced apoptosis in vivo, as indicated by upregulation of Bax protein expression and downregulation of Bcl-2 protein expression. Cisplatin 26-30 BCL2 apoptosis regulator Homo sapiens 135-140 29761903-0 2018 The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 87-90 BCL2 apoptosis regulator Homo sapiens 70-75 29761903-2 2018 ABT-199 is a specific Bcl-2 inhibitor in clinical trials for MM; however, its activity as a single agent was limited to myeloma patients with the t(11;14) translocation who acquire resistance due to co-expression of Mcl-1 and Bcl-xL. venetoclax 0-7 BCL2 apoptosis regulator Homo sapiens 22-27 29747654-5 2018 Among the different strategies that have been developed to inhibit BCL-2, BH3-mimetics have emerged as a novel class of compounds with favorable results in different clinical settings, including chronic lymphocytic leukemia (CLL). BH 3 74-77 BCL2 apoptosis regulator Homo sapiens 67-72 29761897-8 2018 Ethanol-induced SATB2 can bind to the promoters of KLF4, Oct4, cMyc, Sox2, Bcl-2 and XIAP genes. Ethanol 0-7 BCL2 apoptosis regulator Homo sapiens 75-80 29760419-0 2018 PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer. Paclitaxel 82-92 BCL2 apoptosis regulator Homo sapiens 42-46 29760419-0 2018 PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer. Cisplatin 97-106 BCL2 apoptosis regulator Homo sapiens 42-46 29760419-6 2018 Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of paclitaxel and cisplatin on the paclitaxel-resistant SKOV3-TR and cisplatin-resistant A2780-CP20 ovarian cancer respectively. Paclitaxel 159-169 BCL2 apoptosis regulator Homo sapiens 63-67 29760419-6 2018 Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of paclitaxel and cisplatin on the paclitaxel-resistant SKOV3-TR and cisplatin-resistant A2780-CP20 ovarian cancer respectively. Cisplatin 174-183 BCL2 apoptosis regulator Homo sapiens 63-67 29760419-6 2018 Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of paclitaxel and cisplatin on the paclitaxel-resistant SKOV3-TR and cisplatin-resistant A2780-CP20 ovarian cancer respectively. Paclitaxel 191-201 BCL2 apoptosis regulator Homo sapiens 63-67 29760419-6 2018 Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of paclitaxel and cisplatin on the paclitaxel-resistant SKOV3-TR and cisplatin-resistant A2780-CP20 ovarian cancer respectively. Cisplatin 225-234 BCL2 apoptosis regulator Homo sapiens 63-67 29635169-6 2018 Furthermore, western blot assay demonstrated that 12c induced the intrinsic apoptotic mitochondrial pathway by upregulating protein expression of Bax, cytochrome c, caspase-3, -9 and p53, and downregulating the relative levels of Bcl-2. 5-(2-formyl-3-hydroxyphenoxy)pentanoic acid 50-53 BCL2 apoptosis regulator Homo sapiens 230-235 29760958-7 2018 In addition, selection of TNBC cells for resistance to ABT-737, which inhibits BCL-2, BCL-xL and BCL-W but not MCL-1 or BCL2A1, is associated with the upregulation of MUC1-C and BCL2A1 expression. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 55-58 BCL2 apoptosis regulator Homo sapiens 79-84 29717538-5 2018 Western blotting indicated that gefitinib combined with CUR, DMC, or BDMC led to decrease Bcl-2 protein expression which is an antiapoptotic protein and to increase ATG5, Beclin 1, p62/SQSTM1, and LC3 expression that associated with cell autophagy in SAS cells. Gefitinib 32-41 BCL2 apoptosis regulator Homo sapiens 90-95 29743557-4 2018 We found that combined treatment with ABT263 and Crizotinib synergistically reduces the proliferation of glioblastoma cells, which was dependent on dual inhibition of Bcl-2 and Bcl-xL. navitoclax 38-44 BCL2 apoptosis regulator Homo sapiens 167-172 29743557-4 2018 We found that combined treatment with ABT263 and Crizotinib synergistically reduces the proliferation of glioblastoma cells, which was dependent on dual inhibition of Bcl-2 and Bcl-xL. Crizotinib 49-59 BCL2 apoptosis regulator Homo sapiens 167-172 29760956-6 2018 These proteins contain four Bcl-2 homology (BH) domains of which the N-terminal BH4 domain exerts critical roles in regulating intracellular Ca2+ release channels. sapropterin 80-83 BCL2 apoptosis regulator Homo sapiens 28-33 29760956-7 2018 The BH4 domain of Bcl-2, but not of Bcl-XL, binds to and inhibits IP3Rs, whereas both BH4 domains inhibit RyRs. sapropterin 4-7 BCL2 apoptosis regulator Homo sapiens 18-23 29760956-9 2018 Here we demonstrate in PACs that the BH4 domains of Bcl-2 and Bcl-XL inhibit RyR activity in response to the physiological agonist cholecystokinin. sapropterin 37-40 BCL2 apoptosis regulator Homo sapiens 52-57 29765202-10 2018 Koenimbin triggered the activation of caspase-3/7 and caspase-9 and the release of cytochrome c, decreased anti-apoptotic Bcl-2 and HSP70 proteins, increased pro-apoptotic Bax proteins, and inhibited NF-kappaB translocation from the cytoplasm to the nucleus, leading to the activation of the intrinsic apoptotic pathway. koenimbin 0-9 BCL2 apoptosis regulator Homo sapiens 122-127 29717538-5 2018 Western blotting indicated that gefitinib combined with CUR, DMC, or BDMC led to decrease Bcl-2 protein expression which is an antiapoptotic protein and to increase ATG5, Beclin 1, p62/SQSTM1, and LC3 expression that associated with cell autophagy in SAS cells. demethoxycurcumin 61-64 BCL2 apoptosis regulator Homo sapiens 90-95 29717538-5 2018 Western blotting indicated that gefitinib combined with CUR, DMC, or BDMC led to decrease Bcl-2 protein expression which is an antiapoptotic protein and to increase ATG5, Beclin 1, p62/SQSTM1, and LC3 expression that associated with cell autophagy in SAS cells. bisdemethoxycurcumin 69-73 BCL2 apoptosis regulator Homo sapiens 90-95 29561706-4 2018 Among these new drugs, venetoclax, an orally bioavailable BCL2 inhibitor, has shown high efficacy also in relapsed/refractory CLL with TP53 disruption. venetoclax 23-33 BCL2 apoptosis regulator Homo sapiens 58-62 29287955-7 2018 Another regulatory protein of IP3R, IP3R-binding protein released with IP3 (IRBIT), cooperates with or counteracts the Bcl-2 family member depending on cellular states. Inositol 1,4,5-Trisphosphate 30-33 BCL2 apoptosis regulator Homo sapiens 119-124 29301388-7 2018 PA treatment of BC cells resulted in increased activity/expression of mitochondrial cytochrome C, caspases 7, 8 and 9 with a significant increase in the Bax:Bcl-2 ratio, suggesting the involvement of a mitochondrial-dependent apoptotic pathway. panduratin A 0-2 BCL2 apoptosis regulator Homo sapiens 157-162 29058801-0 2018 Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects. venetoclax 40-50 BCL2 apoptosis regulator Homo sapiens 24-29 29218444-5 2018 We observed that actinomycin D-induced apoptosis in U-937 cells, evaluated by Annexin V-CY3, DNA fragmentation and caspase-3, caspase-8, caspase-9 activation assays, was inhibited in the presence of L. infantum promastigotes and that, in these conditions, Bcl-2 protein expression resulted significantly upregulated. Dactinomycin 17-30 BCL2 apoptosis regulator Homo sapiens 256-261 29218444-6 2018 Interestingly, L. infantum infection in combination with the Bcl-2 inhibitor, ABT-737, significantly increased the apoptotic process in actinomycin D-treated cells, suggesting a role for Bcl-2 in the anti-apoptotic regulation of human macrophages induced by L. infantum infection. ABT-737 78-85 BCL2 apoptosis regulator Homo sapiens 61-66 29218444-6 2018 Interestingly, L. infantum infection in combination with the Bcl-2 inhibitor, ABT-737, significantly increased the apoptotic process in actinomycin D-treated cells, suggesting a role for Bcl-2 in the anti-apoptotic regulation of human macrophages induced by L. infantum infection. ABT-737 78-85 BCL2 apoptosis regulator Homo sapiens 187-192 29218444-6 2018 Interestingly, L. infantum infection in combination with the Bcl-2 inhibitor, ABT-737, significantly increased the apoptotic process in actinomycin D-treated cells, suggesting a role for Bcl-2 in the anti-apoptotic regulation of human macrophages induced by L. infantum infection. Dactinomycin 136-149 BCL2 apoptosis regulator Homo sapiens 61-66 29218444-6 2018 Interestingly, L. infantum infection in combination with the Bcl-2 inhibitor, ABT-737, significantly increased the apoptotic process in actinomycin D-treated cells, suggesting a role for Bcl-2 in the anti-apoptotic regulation of human macrophages induced by L. infantum infection. Dactinomycin 136-149 BCL2 apoptosis regulator Homo sapiens 187-192 29477371-2 2018 Whereas nonselective agents have been limited by their affinity to different BCL2 members, thus inducing excessive toxicity, the highly selective BCL2 inhibitor venetoclax (ABT-199, Venclexta ) has an acceptable safety profile. venetoclax 161-171 BCL2 apoptosis regulator Homo sapiens 146-150 29477371-2 2018 Whereas nonselective agents have been limited by their affinity to different BCL2 members, thus inducing excessive toxicity, the highly selective BCL2 inhibitor venetoclax (ABT-199, Venclexta ) has an acceptable safety profile. venetoclax 173-180 BCL2 apoptosis regulator Homo sapiens 146-150 29477371-2 2018 Whereas nonselective agents have been limited by their affinity to different BCL2 members, thus inducing excessive toxicity, the highly selective BCL2 inhibitor venetoclax (ABT-199, Venclexta ) has an acceptable safety profile. venetoclax 182-191 BCL2 apoptosis regulator Homo sapiens 146-150 29477371-7 2018 Surprisingly, positive results are being obtained in elderly acute myeloid leukemia patients, in whom inhibition of BCL2 is able to substantially increase the efficacy of low-dose cytarabine or hypomethylating agents. Cytarabine 180-190 BCL2 apoptosis regulator Homo sapiens 116-120 29494960-13 2018 Moreover, I3C attenuate DOX-induced apoptosis by up-regulation of Bcl2 and down-regulation of Bax and caspase-3 expression in bone marrow cells. Doxorubicin 24-27 BCL2 apoptosis regulator Homo sapiens 66-70 29271539-0 2018 The delta opioid peptide D-Alanine 2, Leucine 5 Enkephaline (DADLE)-induces neuroprotection through cross-talk between the UPR and pro-survival MAPK-NGF-Bcl2 signaling pathways via modulation of several micro-RNAs in SH-SY5Y cells subjected to ER stress. d-alanine 2, leucine 5 enkephaline 25-59 BCL2 apoptosis regulator Homo sapiens 153-157 29383865-8 2018 Fisetin inhibited antiapoptotic Bcl-2 family proteins and damaged the mitochondrial transmembrane potential. fisetin 0-7 BCL2 apoptosis regulator Homo sapiens 32-37 29484365-2 2018 Licochalcone A (LicA) is a new chemotherapy drug inducing apoptosis as Bcl-2 inhibitor, but few studies report on LicA-induced autophagy. licochalcone A 0-14 BCL2 apoptosis regulator Homo sapiens 71-76 29491190-9 2018 Results: Our results demonstrate that pre-treatment and post-treatment with glutamine promoted melanocyte viability, increased levels of superoxide dismutase, glutathione-S-transferase and bcl-2, decreased levels of reactive oxygen species, malondialdehyde, bax and caspase-3, and enhanced nuclear factor-E2-related factor 2, heme oxygenase-1, and heat shock protein 70 expression in a dose dependent manner. Glutamine 76-85 BCL2 apoptosis regulator Homo sapiens 189-194 29532860-0 2018 Ciprofloxacin triggers the apoptosis of human triple-negative breast cancer MDA-MB-231 cells via the p53/Bax/Bcl-2 signaling pathway. Ciprofloxacin 0-13 BCL2 apoptosis regulator Homo sapiens 109-114 31938352-10 2018 Further research indicated that the protein levels of p53, pro-apoptotic cleaved-caspase-3, and bax were significantly upregulated, and the level of bcl-2 was decreased after treating with glucose at 30 mmol/L. Glucose 189-196 BCL2 apoptosis regulator Homo sapiens 149-154 31938352-11 2018 The protein levels of bax and cl-caspase-3 were significantly decreased and the expression of bcl-2 was increased after pretreated with p53 specific inhibitor pifithrin-alpha. pifithrin 159-174 BCL2 apoptosis regulator Homo sapiens 94-99 29532860-7 2018 Furthermore, cipfloxacin treatment stimulated the loss of the mitochondrial transmembrane potential via the Bax/Bcl-2-dependent pathway, thus inducing apoptosis. cipfloxacin 13-24 BCL2 apoptosis regulator Homo sapiens 112-117 29057477-5 2018 Moreover, combination treatment with MIP-1alpha neutralizing antibody and melphalan or bortezomib inhibited extracellular signal regulated kinase 1/2 (ERK1/2), Akt, and mammalian target of rapamycin (mTOR) activation, Bcl-2, Bcl-xL, and Survivin expression, and upregulated the expression of Bim and cleaved Poly (ADP-ribose) polymerase (PARP). Melphalan 74-83 BCL2 apoptosis regulator Homo sapiens 218-223 29297590-5 2018 In the present study, the treatment of primary cultured hippocampal neurons with Meth indicated that Meth induced a time- and dose-dependent augmentation of Kv2.1 protein expression, accompanied by elevated cleaved-caspase 3 and declined bcl-2/bax ratio. Methamphetamine 81-85 BCL2 apoptosis regulator Homo sapiens 238-243 29297590-5 2018 In the present study, the treatment of primary cultured hippocampal neurons with Meth indicated that Meth induced a time- and dose-dependent augmentation of Kv2.1 protein expression, accompanied by elevated cleaved-caspase 3 and declined bcl-2/bax ratio. Methamphetamine 101-105 BCL2 apoptosis regulator Homo sapiens 238-243 28511583-7 2018 Therefore, the present work focused on deciphering the molecular basis of recognition between pro-apoptotic Bak peptide binding to different anti-apoptotic (Bcl-xL, Bfl-1, Bcl-W, Mcl-1, and Bcl-2) proteins using advanced Molecular Dynamics (MD) approach such as Molecular Mechanics-Generalized Born Solvent Accessible. bakuchiol 108-111 BCL2 apoptosis regulator Homo sapiens 190-195 29057477-5 2018 Moreover, combination treatment with MIP-1alpha neutralizing antibody and melphalan or bortezomib inhibited extracellular signal regulated kinase 1/2 (ERK1/2), Akt, and mammalian target of rapamycin (mTOR) activation, Bcl-2, Bcl-xL, and Survivin expression, and upregulated the expression of Bim and cleaved Poly (ADP-ribose) polymerase (PARP). Bortezomib 87-97 BCL2 apoptosis regulator Homo sapiens 218-223 29505783-11 2018 In sesamin group, the expression of Bax, caspase-12, GRP78, GADD153, p-IRE1alpha, p-JNK, LC3I/II and beclin-1 was up-regulated while Bcl-2 was down-regulated compared to control group. sesamin 3-10 BCL2 apoptosis regulator Homo sapiens 133-138 30003731-8 2018 RT-qPCR and Western blot showed that the expression levels of anti-apoptotic factor Bcl-2 in A549 cells were significantly decreased at both mRNA and protein levels at 48 hrs after treatment with GEN, but the levels of pro-apoptotic Bax were significantly increased at both mRNA and protein levels. Genistein 196-199 BCL2 apoptosis regulator Homo sapiens 84-89 29512717-2 2018 The results indicated that sodium selenite reduced cell viability and induced apoptosis by activating caspase-3 and members of the poly (ADP-ribose) polymerase and Bcl-2 protein families in SW982 cells. Sodium Selenite 27-42 BCL2 apoptosis regulator Homo sapiens 164-169 29545333-8 2018 MIRTX induced apoptosis in DLD1 with downregulation of antiapoptotic BCL2, BCL-xL, and MCL1 and upregulation of cleaved caspase-3 and cleaved PARP. mirtx 0-5 BCL2 apoptosis regulator Homo sapiens 69-73 29725433-8 2018 After treatment with rapamycin, the expression levels of Bcl-2, Bax, cleaved caspase-3, autophagy-related genes and proteins, p62, LC3-II/I and Atg7 were similar to those in the control group. Sirolimus 21-30 BCL2 apoptosis regulator Homo sapiens 57-62 29568883-6 2018 It was demonstrated that everolimus induced apoptosis through decreasing B cell lymphoma (Bcl)-2 and Bcl-w and increasing caspase-3 and caspase-8 expression levels in breast cancer cells. Everolimus 25-35 BCL2 apoptosis regulator Homo sapiens 73-96 29697268-0 2018 L-Ascorbic Acid and alpha-Tocopherol Reduces Hepatotoxicity Associated with Arsenic Trioxide Chemotherapy by Modulating Nrf2 and Bcl2 Transcription Factors in Chang liver Cells. Ascorbic Acid 0-15 BCL2 apoptosis regulator Homo sapiens 129-133 29697268-0 2018 L-Ascorbic Acid and alpha-Tocopherol Reduces Hepatotoxicity Associated with Arsenic Trioxide Chemotherapy by Modulating Nrf2 and Bcl2 Transcription Factors in Chang liver Cells. alpha-Tocopherol 20-36 BCL2 apoptosis regulator Homo sapiens 129-133 29532884-0 2018 Protective effects of icariin on human vascular endothelial cells induced by oxidized low-density lipoprotein via modulating caspase-3 and Bcl-2. icariin 22-29 BCL2 apoptosis regulator Homo sapiens 139-144 29532884-6 2018 The findings of the present study indicated that icariin prevented injury and apoptosis in HUVECs following ox-LDL treatment, in particular via the regulation of protein and mRNA expression levels of Bcl-2 and caspase-3. icariin 49-56 BCL2 apoptosis regulator Homo sapiens 200-205 29725398-1 2018 Ginkgolic acids may induce malignant cell death via the B-cell lymphoma 2 (Bcl-2)-associated X protein (Bax)/Bcl-2 apoptosis pathway. ginkgolic acid 0-15 BCL2 apoptosis regulator Homo sapiens 56-73 29725398-1 2018 Ginkgolic acids may induce malignant cell death via the B-cell lymphoma 2 (Bcl-2)-associated X protein (Bax)/Bcl-2 apoptosis pathway. ginkgolic acid 0-15 BCL2 apoptosis regulator Homo sapiens 75-80 29725398-1 2018 Ginkgolic acids may induce malignant cell death via the B-cell lymphoma 2 (Bcl-2)-associated X protein (Bax)/Bcl-2 apoptosis pathway. ginkgolic acid 0-15 BCL2 apoptosis regulator Homo sapiens 109-114 29725447-6 2018 Furthermore, the pro-apoptotic member of the Bcl-2 protein family, NOXA, was induced following treatment with betulin, and the downregulation of NOXA markedly suppressed the release of cytochrome c and apoptosis in colon cancer cells. betulin 110-117 BCL2 apoptosis regulator Homo sapiens 45-50 29731848-6 2018 Quantitative polymerase chain reaction analysis revealed that solamargine decreased the mRNA level of B-cell lymphoma-2 (Bcl-2), Bcl-extra-large and X-linked inhibitor of apoptosis protein but increased the mRNA level of Bcl-2-associated X protein (Bax). beta-solamarine 62-73 BCL2 apoptosis regulator Homo sapiens 102-119 29725453-0 2018 Berberine hydrochloride inhibits cell proliferation and promotes apoptosis of non-small cell lung cancer via the suppression of the MMP2 and Bcl-2/Bax signaling pathways. berberine chloride 0-23 BCL2 apoptosis regulator Homo sapiens 141-146 29725453-3 2018 The present study aimed to determine the possible anticancer effects of berberine hydrochloride treatment on human non-small cell lung cancer (NSCLC) cell proliferation and apoptosis via the matrix metalloproteinase 2 (MMP-2) and the B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein (Bax) signaling pathway. berberine chloride 72-95 BCL2 apoptosis regulator Homo sapiens 234-251 29725453-3 2018 The present study aimed to determine the possible anticancer effects of berberine hydrochloride treatment on human non-small cell lung cancer (NSCLC) cell proliferation and apoptosis via the matrix metalloproteinase 2 (MMP-2) and the B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein (Bax) signaling pathway. berberine chloride 72-95 BCL2 apoptosis regulator Homo sapiens 253-258 29725453-8 2018 Subsequently, treatment with berberine hydrochloride significantly downregulated MMP-2 protein expression, increased the activity of the Bcl-2/Bax signaling pathway and suppressed the Jak2/VEGF/NF-kappaB/AP-1signaling pathways. berberine chloride 29-52 BCL2 apoptosis regulator Homo sapiens 137-142 29725453-9 2018 These results suggest that berberine hydrochloride may be a potential novel anticancer drug, since it inhibits cell proliferation and promotes the rate of apoptosis of NSCLC cells by the suppression of the MMP-2, Bcl-2/Bax and Jak2/VEGF/NF-kappaB/AP-1 signaling pathways. berberine chloride 27-50 BCL2 apoptosis regulator Homo sapiens 213-218 29725459-7 2018 The expression levels of the c-Jun, Bcl-2 and Bcl-xL proteins, and levels of c-Jun protein phosphorylation were significantly decreased in SGC-BARF1 cells subsequent to treatment with SP600125, SB203580, and U0126, which were the specific inhibitors of JNK1/2/3, p38 and ERK1/2 respectively. pyrazolanthrone 184-192 BCL2 apoptosis regulator Homo sapiens 36-41 29731848-6 2018 Quantitative polymerase chain reaction analysis revealed that solamargine decreased the mRNA level of B-cell lymphoma-2 (Bcl-2), Bcl-extra-large and X-linked inhibitor of apoptosis protein but increased the mRNA level of Bcl-2-associated X protein (Bax). beta-solamarine 62-73 BCL2 apoptosis regulator Homo sapiens 121-126 29731848-7 2018 In addition, western blot analysis demonstrated that solamargine inhibited the protein expression of Bcl-2 and poly ADP ribose polymerase (PARP), and promoted the protein expression of Bax, cleaved PARP, caspase 3, cleaved caspase 3 and caspase 7. beta-solamarine 53-64 BCL2 apoptosis regulator Homo sapiens 101-106 29849804-8 2018 Additionally, bufalin combined with 5-FU reduced the expression levels of anti-apoptotic proteins, such as Mcl-1, XIAP and Bcl-2 and upregulated the levels of the pro-apoptotic proteins, Bax and Bad. bufalin 14-21 BCL2 apoptosis regulator Homo sapiens 123-128 29731890-7 2018 Reverse transcription-quantitative polymerase chain reaction demonstrated that Solanine modulated the mRNA levels of B-cell lymphoma-2 (Bcl-2) and Bcl-2-associated X protein (Bax). Solanine 79-87 BCL2 apoptosis regulator Homo sapiens 117-134 29731890-7 2018 Reverse transcription-quantitative polymerase chain reaction demonstrated that Solanine modulated the mRNA levels of B-cell lymphoma-2 (Bcl-2) and Bcl-2-associated X protein (Bax). Solanine 79-87 BCL2 apoptosis regulator Homo sapiens 136-141 29849796-6 2018 Zerumbone treatment led to the increased expression of p27, cytochrome c, caspase-3 and-9, and Bcl-2-associated X expression, but the decreased expression of cyclin-dependent kinase 1, cyclin B1, B-cell lymphoma-2, focal adhesion kinase, Ras homolog gene family, member A, Rho-associated protein kinase-1, and matrix metalloproteinase-2 and-9 in HepG2 cells. zerumbone 0-9 BCL2 apoptosis regulator Homo sapiens 95-100 29849804-8 2018 Additionally, bufalin combined with 5-FU reduced the expression levels of anti-apoptotic proteins, such as Mcl-1, XIAP and Bcl-2 and upregulated the levels of the pro-apoptotic proteins, Bax and Bad. Fluorouracil 36-40 BCL2 apoptosis regulator Homo sapiens 123-128 29724295-5 2018 The apoptosis rate of SKOV3 cells treated with JTC-801 was significantly increased (P<0.05), and the expression results of relevant apoptosis proteins (BCL2, BAX, Active Caspase-3) indicated the JTC-801 could induce the apoptosis of SKOV3. N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide 47-54 BCL2 apoptosis regulator Homo sapiens 155-159 29933683-8 2018 Collectively, our data demonstrated that CCS dose-dependently suppressed cell proliferation and induced cell apoptosis in K562 cells, and the mechanism might be associated with inducing cell cycle arrest, regulating Bcl-2/Bax ratio and activating the mitochondrial apoptosis pathway. ovex 41-44 BCL2 apoptosis regulator Homo sapiens 216-221 29616120-4 2018 Salidroside activated caspase-3 and upregulated the levels of apoptosis-inducing factor, Bcl-2-associated X and Bcl-2-associated death promoter (Bad) proteins. rhodioloside 0-11 BCL2 apoptosis regulator Homo sapiens 89-94 29616120-4 2018 Salidroside activated caspase-3 and upregulated the levels of apoptosis-inducing factor, Bcl-2-associated X and Bcl-2-associated death promoter (Bad) proteins. rhodioloside 0-11 BCL2 apoptosis regulator Homo sapiens 112-117 29616120-5 2018 Furthermore, salidroside downregulated the levels of Bcl-2, p-Bad and X-linked inhibitor of apoptosis proteins. rhodioloside 13-24 BCL2 apoptosis regulator Homo sapiens 53-58 29765528-0 2018 Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells. Metformin 34-43 BCL2 apoptosis regulator Homo sapiens 56-61 29577119-10 2018 Moreover, IPT increased the release of mitochondrial cytochrome C, the ratio of Bax/Bcl-2, and the cleavage of caspase-9, caspase-3 and poly (ADP-ribose) polymerase. imperatorin 10-13 BCL2 apoptosis regulator Homo sapiens 84-89 29686228-0 2018 The observed alteration in BCL2 expression following lithium treatment is influenced by the choice of normalization method. Lithium 53-60 BCL2 apoptosis regulator Homo sapiens 27-31 29686228-1 2018 Upregulation of B-cell CLL/lymphoma (BCL)2 expression following lithium treatment is seemingly well established and has been related to the neuroprotective property of the drug. Lithium 64-71 BCL2 apoptosis regulator Homo sapiens 37-42 29686228-3 2018 This manuscript presents a systematic review of currently available reports of lithium"s effect on BCL2 expression. Lithium 79-86 BCL2 apoptosis regulator Homo sapiens 99-103 29686228-7 2018 Using wet bench experiments and reanalysis of publicly available microarray data, here we show that the reference gene chosen for normalization critically impacts the outcome of qPCR analyses of lithium"s effect on BCL2 expression. Lithium 195-202 BCL2 apoptosis regulator Homo sapiens 215-219 29510157-1 2018 Earlier, we reported that Demethoxycurcumin (DMC) suppressed the growth of human glioma U87 MG cells by downregulation of Bcl-2 expression. demethoxycurcumin 26-43 BCL2 apoptosis regulator Homo sapiens 122-127 29686591-7 2018 An increase in ROS generation with a concomitant increase in expression of the proapoptotic protein Bcl-2 and cytochrome c and decrease in the antiapoptosis protein Bax suggested that a mitochondria-mediated pathway was involved in cypermethrin-induced apoptosis. Reactive Oxygen Species 15-18 BCL2 apoptosis regulator Homo sapiens 100-105 29686591-7 2018 An increase in ROS generation with a concomitant increase in expression of the proapoptotic protein Bcl-2 and cytochrome c and decrease in the antiapoptosis protein Bax suggested that a mitochondria-mediated pathway was involved in cypermethrin-induced apoptosis. cypermethrin 232-244 BCL2 apoptosis regulator Homo sapiens 100-105 29674626-3 2018 We aimed to do a systematic review and meta-analysis on the relationships between overexpression MYC and/or BCL2 and DLBCLs treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Cyclophosphamide 148-164 BCL2 apoptosis regulator Homo sapiens 108-112 29674626-3 2018 We aimed to do a systematic review and meta-analysis on the relationships between overexpression MYC and/or BCL2 and DLBCLs treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Vincristine 179-190 BCL2 apoptosis regulator Homo sapiens 108-112 29673198-9 2018 Conclusion: The present study suggest that BaP can reverse the effects of drugs on cancer cells via the activation of survival signaling pathways and upregulation of anti-apoptotic proteins such as Bcl-2 and Bcl-xL. benzylaminopurine 43-46 BCL2 apoptosis regulator Homo sapiens 198-203 29462593-9 2018 Additional experiments demonstrated that CMCS could decrease protein expression of Bax, cytochrome c and caspase-3, while promote Bcl-2 protein expression induced by H2O2. Hydrogen Peroxide 166-170 BCL2 apoptosis regulator Homo sapiens 130-135 29510157-1 2018 Earlier, we reported that Demethoxycurcumin (DMC) suppressed the growth of human glioma U87 MG cells by downregulation of Bcl-2 expression. demethoxycurcumin 45-48 BCL2 apoptosis regulator Homo sapiens 122-127 29305552-2 2018 Venetoclax is a selective, orally bioavailable BCL-2 inhibitor with activity in patients with CLL, including those who are heavily pretreated or have 17p deletion. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 47-52 29477250-5 2018 The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. venetoclax 95-105 BCL2 apoptosis regulator Homo sapiens 78-83 29732004-0 2018 S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. s55746 0-6 BCL2 apoptosis regulator Homo sapiens 32-37 29732004-4 2018 Thus, BCL-2 has become an attractive target for therapeutic strategy in cancer, as demonstrated by the recent approval of ABT-199 (Venclexta ) in relapsed or refractory Chronic Lymphocytic Leukemia with 17p deletion. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 122-125 BCL2 apoptosis regulator Homo sapiens 6-11 29584430-1 2018 A 26-residue peptide BimBH3 binds indiscriminately to multiple oncogenic Bcl2 proteins that regulate apoptosis of cancer cells. bimbh3 21-27 BCL2 apoptosis regulator Homo sapiens 73-77 29732004-5 2018 Here, we describe a novel orally bioavailable BCL-2 selective and potent inhibitor called S55746 (also known as BCL201). s55746 90-96 BCL2 apoptosis regulator Homo sapiens 46-51 29732004-12 2018 Taken together, these data demonstrate that S55746 is a novel, well-tolerated BH3-mimetic targeting selectively and potently the BCL-2 protein. BH 3 78-81 BCL2 apoptosis regulator Homo sapiens 129-134 29943949-7 2018 These findings demonstrated that 2,2-bis(6-bromo-3-indolyl) ethylamine alkaloid-induced apoptosis is regulated by the Bcl-2 protein family upstream of caspase activation. 2,2-bis(6-bromo-3-indolyl) ethylamine alkaloid 33-79 BCL2 apoptosis regulator Homo sapiens 118-123 29644450-1 2018 PURPOSE REVIEW: B cell signaling agents, including ibrutinib, idelalisib, and the BCL-2 inhibitor venetoclax have become an integral part of therapy for patients with non-Hodgkin"s lymphomas. venetoclax 98-108 BCL2 apoptosis regulator Homo sapiens 82-87 29686616-5 2018 We demonstrated that estradiol treatment of adult PA exposed animals induced an increase in estrogen receptor (ER) alpha and insulin-like growth factor receptor (IGF-1R) protein levels, an activation of the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3 beta/beta-catenin signaling pathway and an increase in Bcl-2/Bax ratio in the hippocampus in comparison to PA exposed animals treated with vehicle. Estradiol 21-30 BCL2 apoptosis regulator Homo sapiens 323-328 29631569-8 2018 The reduction of anti-apoptotic proteins including anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) and myeloid cell leukemia 1 (Mcl-1) associating with the diminution of integrin/focal adhesion kinase (FAK)/Proto-oncogene tyrosine-protein kinase (Src) signals were detected in avicequinone B-treated cells. Naphtho[2,3-b]furan-4,9-dione 278-292 BCL2 apoptosis regulator Homo sapiens 93-98 29686616-5 2018 We demonstrated that estradiol treatment of adult PA exposed animals induced an increase in estrogen receptor (ER) alpha and insulin-like growth factor receptor (IGF-1R) protein levels, an activation of the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3 beta/beta-catenin signaling pathway and an increase in Bcl-2/Bax ratio in the hippocampus in comparison to PA exposed animals treated with vehicle. Protactinium 50-52 BCL2 apoptosis regulator Homo sapiens 323-328 29454280-0 2018 8-Chrysoeriol, as a potential BCL-2 inhibitor triggers apoptosis of SW1990 pancreatic cancer cells. 8-chrysoeriol 0-13 BCL2 apoptosis regulator Homo sapiens 30-35 29432993-5 2018 Western blot revealed that oridonin treatment increased the ratio of Bax/Bcl-2, and activated the cleavage of caspase-3, caspase-9 and PARP-1. oridonin 27-35 BCL2 apoptosis regulator Homo sapiens 73-78 29449346-5 2018 Moreover, shikonin-induced apoptosis was characterized by the up-regulation of the pro-apoptotic proteins cleaved-Caspase-3 and Bax, and the down-regulation of the anti-apoptotic protein Bcl-2. shikonin 10-18 BCL2 apoptosis regulator Homo sapiens 187-192 29707107-6 2018 Moreover, we utilized the protein abundance of BCL-2 family members in primary patient samples using flow cytometry as a biomarker to predict ABT-199 treatment response. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 142-145 BCL2 apoptosis regulator Homo sapiens 47-52 29371030-4 2018 By applying western blot, it was found that hr5F alleviates the high glucose-induced superoxide overproduction insults by regulating SIRT1-PGC-1alpha/Nrf2 pathway, together with regulating NRF-1, mtTFA, Bax/Bcl-2 to ameliorate cell apoptosis. hr5f 44-48 BCL2 apoptosis regulator Homo sapiens 207-212 29371030-4 2018 By applying western blot, it was found that hr5F alleviates the high glucose-induced superoxide overproduction insults by regulating SIRT1-PGC-1alpha/Nrf2 pathway, together with regulating NRF-1, mtTFA, Bax/Bcl-2 to ameliorate cell apoptosis. Glucose 69-76 BCL2 apoptosis regulator Homo sapiens 207-212 29454280-1 2018 8-Chrysoeriol, a bioactive flavanoid, was firstly identified to bind directly to BCL-2 as BH3 mimetics by structure-based virtual ligand screening. 8-chrysoeriol 0-13 BCL2 apoptosis regulator Homo sapiens 81-86 29454280-1 2018 8-Chrysoeriol, a bioactive flavanoid, was firstly identified to bind directly to BCL-2 as BH3 mimetics by structure-based virtual ligand screening. BH 3 90-93 BCL2 apoptosis regulator Homo sapiens 81-86 29454280-2 2018 And 3D docking model revealed the molecular basis of 8-Chrysoeriol targeting to BCL-2. 8-chrysoeriol 53-66 BCL2 apoptosis regulator Homo sapiens 80-85 29454280-3 2018 The interaction between 8-Chrysoeriol and BCL-2 was further confirmed using Microscale Thermophoresis (MST) technique. 8-chrysoeriol 24-37 BCL2 apoptosis regulator Homo sapiens 42-47 29454280-4 2018 Meanwhile, high expression level of antiapoptotic protein BCL-2 was detected in SW1990 pancreatic cancer cells and 8-Chrysoeriol showed obvious proapoptosis effect against SW1990 in vitro. 8-chrysoeriol 115-128 BCL2 apoptosis regulator Homo sapiens 58-63 29333604-11 2018 CONCLUSION AND IMPLICATIONS: Beclin-1 phosphorylation and Bcl-2 mRNA destabilization mediated by DAPK1 and TTP are crucial events leading to autophagy and the suppression of inflammatory cytokine production by gAcrp. gacrp 210-215 BCL2 apoptosis regulator Homo sapiens 58-63 29454280-5 2018 Collectively, the results showed that 8-Chrysoeriol as a natural dietary product potentially targeting to BCL-2 could serve as a lead compound for SW1990 pancreatic cancer therapy. 8-chrysoeriol 38-51 BCL2 apoptosis regulator Homo sapiens 106-111 29417442-13 2018 Moreover, augmented caspase-3 up-regulation and bcl-2 down-regulation were found following combined application of DAPT and ATRA. dapt 115-119 BCL2 apoptosis regulator Homo sapiens 48-53 29386225-11 2018 Finally, we found that VSMCs, from human atherosclerotic arteries of individuals with T2D, express low bak/bax and high bcl-2 and miR-296-5p levels. vsmcs 23-28 BCL2 apoptosis regulator Homo sapiens 120-125 29417442-13 2018 Moreover, augmented caspase-3 up-regulation and bcl-2 down-regulation were found following combined application of DAPT and ATRA. Tretinoin 124-128 BCL2 apoptosis regulator Homo sapiens 48-53 29302721-1 2018 PURPOSE: Venetoclax is a selective BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). venetoclax 9-19 BCL2 apoptosis regulator Homo sapiens 35-40 29319219-8 2018 Osthole treatment significantly reduced the expression of the antiapoptotic protein Bcl-2 and increased the expression of the proapoptotic proteins Bax, Bak, BimL, BimS, and t-Bid. osthol 0-7 BCL2 apoptosis regulator Homo sapiens 84-89 29336467-10 2018 In addition, increased expression of Bcl-2 was induced by 400 mM ethanol. Ethanol 65-72 BCL2 apoptosis regulator Homo sapiens 37-42 29762835-7 2018 MiR-520a-3p overexpression could markedly reduce the ratio of p-AKT/AKT, p-PI3K/PI3K and Bcl-2/Bax, the levels of mTOR, matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) compared with control. mir-520a 0-8 BCL2 apoptosis regulator Homo sapiens 89-94 29545835-5 2018 Western blotting demonstrated that the expression of p-FOXO1 and B-cell lymphoma 2 (Bcl2) were significantly reduced, whereas the expression of Bcl-2-associated X protein was significantly increased following treatment with LY294002 and/or UO126 (all P<0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 224-232 BCL2 apoptosis regulator Homo sapiens 65-82 29545835-5 2018 Western blotting demonstrated that the expression of p-FOXO1 and B-cell lymphoma 2 (Bcl2) were significantly reduced, whereas the expression of Bcl-2-associated X protein was significantly increased following treatment with LY294002 and/or UO126 (all P<0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 224-232 BCL2 apoptosis regulator Homo sapiens 84-88 29545835-5 2018 Western blotting demonstrated that the expression of p-FOXO1 and B-cell lymphoma 2 (Bcl2) were significantly reduced, whereas the expression of Bcl-2-associated X protein was significantly increased following treatment with LY294002 and/or UO126 (all P<0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 224-232 BCL2 apoptosis regulator Homo sapiens 144-149 29208357-8 2018 In addition, our data provide evidence for a pattern of IGFBP response to H2O2 treatment that might be associated with distinct expression of apoptosis markers (BCL2, pro-caspase-9, pro-caspase-3) in LS. Hydrogen Peroxide 74-78 BCL2 apoptosis regulator Homo sapiens 161-165 29336467-11 2018 Furthermore, treatment with NOX inhibitor attenuated the ethanol-induced a decrease in cell viability, and an increase in apoptosis and Bcl-2 expression. Ethanol 57-64 BCL2 apoptosis regulator Homo sapiens 136-141 29532878-8 2018 Simvastatin significantly induced apoptosis, increased the Bax/Bcl-2 ratio, and cleavage of caspase-3 and PARP protein. Simvastatin 0-11 BCL2 apoptosis regulator Homo sapiens 63-68 29436642-10 2018 Western blot analysis revealed that these synergistic effects of ruxolitinib and calcitriol were associated with reduced protein levels of JAK2, phosphorylated JAK2, c-Myc proto oncogene protein, cyclin-D1, apoptosis regulator Bcl-2 and Bcl-2-like protein 1, and with increased levels of caspase-3 and Bcl-2-associated agonist of cell death proteins. ruxolitinib 65-76 BCL2 apoptosis regulator Homo sapiens 227-232 29460131-4 2018 RESULTS: Docetaxel could induce autophagy and apoptosis, together with the expression increase in p-JNK, p-Bcl-2 and Beclin1. Docetaxel 9-18 BCL2 apoptosis regulator Homo sapiens 107-112 29460131-7 2018 CONCLUSION: Docetaxel induces protective autophagy in CRPC cells by JNK pathway activation and then Bcl-2 phosphorylation and Beclin1 dissociation. Docetaxel 12-21 BCL2 apoptosis regulator Homo sapiens 100-105 28875417-5 2018 Polymerase chain reaction (PCR) showed that treatment of cells with chlorogenic acid reduced the expression of BCL2 but increased that of both BAX and CASP3. Chlorogenic Acid 68-84 BCL2 apoptosis regulator Homo sapiens 111-115 29393498-11 2018 In contrast, the mRNA and protein expression of the anti-apoptotic molecule B-cell lymphoma 2 (Bcl-2) was significantly lower in treated NPDFs. npdfs 137-142 BCL2 apoptosis regulator Homo sapiens 76-93 29393498-11 2018 In contrast, the mRNA and protein expression of the anti-apoptotic molecule B-cell lymphoma 2 (Bcl-2) was significantly lower in treated NPDFs. npdfs 137-142 BCL2 apoptosis regulator Homo sapiens 95-100 29393498-12 2018 These results indicated that bleomycin A5 could induce apoptosis in primary NPDFs through activation of the Bcl-2 family and caspase cascades in a time-, and concentration-dependent manner. bleomycetin 29-41 BCL2 apoptosis regulator Homo sapiens 108-113 29091297-7 2018 Compared with the resistance group, the anti-miR-128 group showed decreasedBax expression along with a lowered cell inhibition rate and apoptosis rate, but increased JAG1 and Bcl-2 expression with reduced cells arrested in the S phase; while the miR-128 mimic group showed an opposite trend; the si-JAG1 group showed decreased Bcl-2 expression and reduced cells in the S phase. mir-128 45-52 BCL2 apoptosis regulator Homo sapiens 175-180 29091297-7 2018 Compared with the resistance group, the anti-miR-128 group showed decreasedBax expression along with a lowered cell inhibition rate and apoptosis rate, but increased JAG1 and Bcl-2 expression with reduced cells arrested in the S phase; while the miR-128 mimic group showed an opposite trend; the si-JAG1 group showed decreased Bcl-2 expression and reduced cells in the S phase. mir-128 45-52 BCL2 apoptosis regulator Homo sapiens 327-332 29453988-11 2018 However, the Bcl-2 expression was up-regulated, and the increase of ROS and the loss of MMP were alleviated. Reactive Oxygen Species 68-71 BCL2 apoptosis regulator Homo sapiens 13-18 29436625-5 2018 Reverse transcription-quantitative polymerase chain reaction and western blot analysis were used to detect the effect of Allicin on the expression levels of Fas/Fas ligand (FasL), caspase-3, B-cell lymphoma 2 and Bcl-2-associated X protein. allicin 121-128 BCL2 apoptosis regulator Homo sapiens 213-218 29436666-3 2018 It has been demonstrated that daidzein [7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one] may induce apoptosis in a number of cancer types via the mitochondrial apoptotic pathway by altering the B-cell lymphoma (Bcl)-2/Bcl-2 associated X, apoptosis regulator (Bax) ratio, and activating the caspase cascade. daidzein 30-38 BCL2 apoptosis regulator Homo sapiens 193-216 29436666-3 2018 It has been demonstrated that daidzein [7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one] may induce apoptosis in a number of cancer types via the mitochondrial apoptotic pathway by altering the B-cell lymphoma (Bcl)-2/Bcl-2 associated X, apoptosis regulator (Bax) ratio, and activating the caspase cascade. daidzein 30-38 BCL2 apoptosis regulator Homo sapiens 217-222 29436666-3 2018 It has been demonstrated that daidzein [7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one] may induce apoptosis in a number of cancer types via the mitochondrial apoptotic pathway by altering the B-cell lymphoma (Bcl)-2/Bcl-2 associated X, apoptosis regulator (Bax) ratio, and activating the caspase cascade. daidzein 40-86 BCL2 apoptosis regulator Homo sapiens 193-216 29436642-10 2018 Western blot analysis revealed that these synergistic effects of ruxolitinib and calcitriol were associated with reduced protein levels of JAK2, phosphorylated JAK2, c-Myc proto oncogene protein, cyclin-D1, apoptosis regulator Bcl-2 and Bcl-2-like protein 1, and with increased levels of caspase-3 and Bcl-2-associated agonist of cell death proteins. ruxolitinib 65-76 BCL2 apoptosis regulator Homo sapiens 237-242 29436666-3 2018 It has been demonstrated that daidzein [7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one] may induce apoptosis in a number of cancer types via the mitochondrial apoptotic pathway by altering the B-cell lymphoma (Bcl)-2/Bcl-2 associated X, apoptosis regulator (Bax) ratio, and activating the caspase cascade. daidzein 40-86 BCL2 apoptosis regulator Homo sapiens 217-222 29436666-10 2018 Expression levels of cleaved poly(ADP-ribose) polymerase, cleaved caspase-3 and cleaved caspase-9 increased following treatment with daidzein, whereas the Bcl-2/Bax ratio decreased in a dose-dependent manner. daidzein 133-141 BCL2 apoptosis regulator Homo sapiens 155-160 29436642-10 2018 Western blot analysis revealed that these synergistic effects of ruxolitinib and calcitriol were associated with reduced protein levels of JAK2, phosphorylated JAK2, c-Myc proto oncogene protein, cyclin-D1, apoptosis regulator Bcl-2 and Bcl-2-like protein 1, and with increased levels of caspase-3 and Bcl-2-associated agonist of cell death proteins. Calcitriol 81-91 BCL2 apoptosis regulator Homo sapiens 227-232 29436642-10 2018 Western blot analysis revealed that these synergistic effects of ruxolitinib and calcitriol were associated with reduced protein levels of JAK2, phosphorylated JAK2, c-Myc proto oncogene protein, cyclin-D1, apoptosis regulator Bcl-2 and Bcl-2-like protein 1, and with increased levels of caspase-3 and Bcl-2-associated agonist of cell death proteins. Calcitriol 81-91 BCL2 apoptosis regulator Homo sapiens 237-242 29629025-5 2018 Moreover, we determined whether PO and ALA regulated the apoptosis-related protein expressions, such as cleaved-poly ADP ribose polymerase (PARP), cleaved caspase-9 and -3, BCL-2 and BAX. perilla seed oil 32-34 BCL2 apoptosis regulator Homo sapiens 173-178 29363721-0 2018 Paeoniflorin induces G2/M cell cycle arrest and caspase-dependent apoptosis through the upregulation of Bcl-2 X-associated protein and downregulation of B-cell lymphoma 2 in human osteosarcoma cells. peoniflorin 0-12 BCL2 apoptosis regulator Homo sapiens 104-109 29363721-0 2018 Paeoniflorin induces G2/M cell cycle arrest and caspase-dependent apoptosis through the upregulation of Bcl-2 X-associated protein and downregulation of B-cell lymphoma 2 in human osteosarcoma cells. peoniflorin 0-12 BCL2 apoptosis regulator Homo sapiens 153-170 29353886-4 2018 ABT-199 (venetoclax) is a potent and selective small-molecule antagonist of BCL-2 recently approved for the treatment of a specific subtype of lymphoid neoplasm. venetoclax 0-7 BCL2 apoptosis regulator Homo sapiens 76-81 29353886-4 2018 ABT-199 (venetoclax) is a potent and selective small-molecule antagonist of BCL-2 recently approved for the treatment of a specific subtype of lymphoid neoplasm. venetoclax 9-19 BCL2 apoptosis regulator Homo sapiens 76-81 29353886-9 2018 Together, these findings highlight the relevance of BFL-1 in DH lymphoma-associated drug resistance and support the combined use of a BCL-2 antagonist and a BET inhibitor as a promising therapeutic strategy for patients with aggressive DHL. Cysteamine 236-239 BCL2 apoptosis regulator Homo sapiens 134-139 29543494-8 2018 In addition, piperlongumine was reported to interfere with the expression of p21, p27, cleaved caspases-3, Bax, Bcl-2, and p-Jun N-terminal kinase (JNK), which are typical regulators associated with cell proliferation, intrinsic apoptosis, and JNKs pathway. piperlonguminine 13-27 BCL2 apoptosis regulator Homo sapiens 112-117 29629025-5 2018 Moreover, we determined whether PO and ALA regulated the apoptosis-related protein expressions, such as cleaved-poly ADP ribose polymerase (PARP), cleaved caspase-9 and -3, BCL-2 and BAX. alpha-Linolenic Acid 39-42 BCL2 apoptosis regulator Homo sapiens 173-178 29629025-8 2018 Furthermore, cleaved-PARP, cleaved caspase-9 and -3 activations were significantly decreased in the presence of PO and ALA, and the H2O2-mediated up-regulated BAX/BCL-2 ratio was blocked after treatment with PO and ALA. perilla seed oil 112-114 BCL2 apoptosis regulator Homo sapiens 163-168 29629025-8 2018 Furthermore, cleaved-PARP, cleaved caspase-9 and -3 activations were significantly decreased in the presence of PO and ALA, and the H2O2-mediated up-regulated BAX/BCL-2 ratio was blocked after treatment with PO and ALA. alpha-Linolenic Acid 119-122 BCL2 apoptosis regulator Homo sapiens 163-168 29629025-8 2018 Furthermore, cleaved-PARP, cleaved caspase-9 and -3 activations were significantly decreased in the presence of PO and ALA, and the H2O2-mediated up-regulated BAX/BCL-2 ratio was blocked after treatment with PO and ALA. Hydrogen Peroxide 132-136 BCL2 apoptosis regulator Homo sapiens 163-168 29391601-2 2018 However, nothing is known about the putative tyrosine phosphorylation of this Bcl-2 family member and its potential impact on Bim function and subsequent Bax/Bak-mediated cytochrome c release and apoptosis. Tyrosine 45-53 BCL2 apoptosis regulator Homo sapiens 78-83 29629025-8 2018 Furthermore, cleaved-PARP, cleaved caspase-9 and -3 activations were significantly decreased in the presence of PO and ALA, and the H2O2-mediated up-regulated BAX/BCL-2 ratio was blocked after treatment with PO and ALA. alpha-Linolenic Acid 215-218 BCL2 apoptosis regulator Homo sapiens 163-168 29552164-5 2018 The results indicated that steviol inhibits U2OS cells through inducing G1 phase cell cycle arrest, downregulating the ability of colony formation via a mitochondrial apoptotic pathway, which was indicated by an increase of the Bax/Bcl-2 ratio and activation of cyclin-dependent kinase inhibitor 1, tumor protein 53 and cyclin-dependent kinase; whereas a Survivin and Caspase 3-independent mechanism was involved. steviol 27-34 BCL2 apoptosis regulator Homo sapiens 232-237 29541236-5 2018 Anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein expression was reduced to 50-67% of the control following a single treatment with CPT-11, SN-38, or DAC, and was markedly reduced to 7-8% following the combination of CPT-11/SN-38 with DAC. Irinotecan 139-144 BCL2 apoptosis regulator Homo sapiens 34-39 29541236-5 2018 Anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein expression was reduced to 50-67% of the control following a single treatment with CPT-11, SN-38, or DAC, and was markedly reduced to 7-8% following the combination of CPT-11/SN-38 with DAC. Irinotecan 216-222 BCL2 apoptosis regulator Homo sapiens 34-39 29541236-5 2018 Anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein expression was reduced to 50-67% of the control following a single treatment with CPT-11, SN-38, or DAC, and was markedly reduced to 7-8% following the combination of CPT-11/SN-38 with DAC. Irinotecan 223-228 BCL2 apoptosis regulator Homo sapiens 34-39 29541236-7 2018 Wilms" tumor protein (WT1), which has been shown to be a positive regulator of Bcl-2 in HCT116 cells through WT1-kncokdown experiments, was downregulated in HCT116 and HT29 cells when treated with CPT-11/SN-38 combined with DAC, with decreases greater than any single administration of CPT-11, SN-38, or DAC. Irinotecan 197-203 BCL2 apoptosis regulator Homo sapiens 79-84 29541236-7 2018 Wilms" tumor protein (WT1), which has been shown to be a positive regulator of Bcl-2 in HCT116 cells through WT1-kncokdown experiments, was downregulated in HCT116 and HT29 cells when treated with CPT-11/SN-38 combined with DAC, with decreases greater than any single administration of CPT-11, SN-38, or DAC. Irinotecan 204-209 BCL2 apoptosis regulator Homo sapiens 79-84 29541236-7 2018 Wilms" tumor protein (WT1), which has been shown to be a positive regulator of Bcl-2 in HCT116 cells through WT1-kncokdown experiments, was downregulated in HCT116 and HT29 cells when treated with CPT-11/SN-38 combined with DAC, with decreases greater than any single administration of CPT-11, SN-38, or DAC. Irinotecan 286-292 BCL2 apoptosis regulator Homo sapiens 79-84 29541236-7 2018 Wilms" tumor protein (WT1), which has been shown to be a positive regulator of Bcl-2 in HCT116 cells through WT1-kncokdown experiments, was downregulated in HCT116 and HT29 cells when treated with CPT-11/SN-38 combined with DAC, with decreases greater than any single administration of CPT-11, SN-38, or DAC. Irinotecan 294-299 BCL2 apoptosis regulator Homo sapiens 79-84 29541233-6 2018 The results of xenograft analysis indicated that chrysotoxene (20 mg/kg) significantly (P<0.01) inhibited the growth of HepG2 cell-induced tumors by regulating the aforementioned apoptotic proteins (Smac, Cytochrome c, Survivin, Bcl-2, Bax, Apaf-1, c-caspase-9 and c-caspase-3), compared with the control group. Chrysotoxene 49-61 BCL2 apoptosis regulator Homo sapiens 232-237 29541236-5 2018 Anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein expression was reduced to 50-67% of the control following a single treatment with CPT-11, SN-38, or DAC, and was markedly reduced to 7-8% following the combination of CPT-11/SN-38 with DAC. Irinotecan 131-137 BCL2 apoptosis regulator Homo sapiens 34-39 29552208-4 2018 Expression of the apoptosis-related genes Bcl-2, Bax and caspase-9 after apatinib treatment was detected by reverse transcription-quantitative PCR (RT-qPCR) and western blot analysis. apatinib 73-81 BCL2 apoptosis regulator Homo sapiens 42-47 29552208-8 2018 Results of RT-qPCR and western blot analysis showed that apatinib was able to induce the expression of pro-apoptotic genes Bax and caspase-9 and inhibited the expression of anti-apoptotic gene Bcl-2. apatinib 57-65 BCL2 apoptosis regulator Homo sapiens 193-198 29552208-10 2018 The results of the present show that apatinib is capable of promoting the apoptosis of SMMC-7721 cells by inhibiting the PI3K/Akt signal transduction pathway, upregulating the expression of pro-apoptotic genes Bax and caspase-9, and downregulating the expression level of the anti-apoptotic gene Bcl-2. apatinib 37-45 BCL2 apoptosis regulator Homo sapiens 296-301 29541236-8 2018 The extent of CPT-11/SN-38 potentiation by DAC may depend on Bcl-2 expression levels in human colorectal cancer cells. Irinotecan 14-20 BCL2 apoptosis regulator Homo sapiens 61-66 29541236-8 2018 The extent of CPT-11/SN-38 potentiation by DAC may depend on Bcl-2 expression levels in human colorectal cancer cells. Irinotecan 21-26 BCL2 apoptosis regulator Homo sapiens 61-66 29556305-6 2018 The present data indicate that Taxol may enhance the pro-apoptotic effects of TRAIL overexpression in HeLa cells by increasing cleaved caspase-3 and DR5 expression levels and decreasing Bcl-2 expression levels. Paclitaxel 31-36 BCL2 apoptosis regulator Homo sapiens 186-191 29541237-10 2018 The apoptosis level, expression of Bax and the intracellular concentration of Rhodamine-123 were increased, whereas the expression of p65, Bcl-2, MDR1 and MRP1 were decreased, in celecoxib-treated Jurkat and Hut-78 cells compared with those without celecoxib treatment. Celecoxib 179-188 BCL2 apoptosis regulator Homo sapiens 139-144 29665895-5 2018 CONCLUSION: Down-regulation of miR-125b can inhibit K562 cell proliferation via down-regulating the expressions of BCL-2 and up-regulating the expression of BAK1, p53 and Puma. mir-125b 31-39 BCL2 apoptosis regulator Homo sapiens 115-120 29665904-1 2018 OBJECTIVE: To explore the effects of BTZ plus HHT on proliferation and apoptosis of K562 cells, and to clarify the relationship between the mechanism inderlying the effect of BTZ plus HHT on K562 cells and BCL-2, BAX, MCL-1 proteins. btz 175-178 BCL2 apoptosis regulator Homo sapiens 206-211 29665904-7 2018 The BCL-2 protein level of K562 cells in combined group was significantly lower than that in BTZ and HHT alone group(P<0.05). btz 93-96 BCL2 apoptosis regulator Homo sapiens 4-9 29552219-5 2018 Furthermore, LY-15 effectively inhibited the B16 cell migration, increased the expressions levels of caspase-3, caspase-9 and the pro-apoptotic Bax, and reduced that of the anti-apoptotic Bcl-2. ly-15 13-18 BCL2 apoptosis regulator Homo sapiens 188-193 29368435-7 2018 Verteporfin generated crosslinked p62 oligomers, resulting in inhibition of autophagy and constitutive activation of Nrf2 as well as its target genes, Bcl-2 and TNF-alpha. Verteporfin 0-11 BCL2 apoptosis regulator Homo sapiens 151-156 29414782-9 2018 Although an initial report has suggested that an unstructured loop region between the Bcl-2 BH4 and BH3 domains is required for Bcl-2"s interaction with Nur77/Nor-1, we found that it is dispensable for this interaction. sapropterin 92-95 BCL2 apoptosis regulator Homo sapiens 86-91 29590547-1 2018 BACKGROUND: Both the BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax are active as monotherapy in the treatment of mantle-cell lymphoma. venetoclax 68-78 BCL2 apoptosis regulator Homo sapiens 53-57 29414782-9 2018 Although an initial report has suggested that an unstructured loop region between the Bcl-2 BH4 and BH3 domains is required for Bcl-2"s interaction with Nur77/Nor-1, we found that it is dispensable for this interaction. sapropterin 92-95 BCL2 apoptosis regulator Homo sapiens 128-133 29414782-11 2018 Bcl-2 alanine mutants at this region could no longer interact with Nur77/Nor-1 and could not initiate Nur77/Bcl-2-mediated cell death. Alanine 6-13 BCL2 apoptosis regulator Homo sapiens 0-5 29636622-0 2018 miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells. Fluorouracil 18-22 BCL2 apoptosis regulator Homo sapiens 47-52 29682179-0 2018 Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. Sorafenib 39-48 BCL2 apoptosis regulator Homo sapiens 14-19 29682179-0 2018 Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. regorafenib 49-60 BCL2 apoptosis regulator Homo sapiens 14-19 29682179-0 2018 Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. BH 3 76-79 BCL2 apoptosis regulator Homo sapiens 14-19 29682179-2 2018 BCL-2 proteins participate in the response to tyrosine kinase inhibitors; however, their role in HCC therapy with sorafenib/regorafenib remains uncertain. Sorafenib 114-123 BCL2 apoptosis regulator Homo sapiens 0-5 29682179-2 2018 BCL-2 proteins participate in the response to tyrosine kinase inhibitors; however, their role in HCC therapy with sorafenib/regorafenib remains uncertain. regorafenib 124-135 BCL2 apoptosis regulator Homo sapiens 0-5 29682179-3 2018 BH3-mimetic ABT-263 (navitoclax) enhanced sorafenib activity, inducing cell death via a mitochondrial caspase-dependent mechanism, after BCL-xL/BCL-2 inhibition. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 144-149 29682179-3 2018 BH3-mimetic ABT-263 (navitoclax) enhanced sorafenib activity, inducing cell death via a mitochondrial caspase-dependent mechanism, after BCL-xL/BCL-2 inhibition. navitoclax 12-19 BCL2 apoptosis regulator Homo sapiens 144-149 29682179-4 2018 Sorafenib-resistant hepatoma cells (HepG2R and Hep3BR) exhibited altered mRNA expression of BCL-2 and other anti-apoptotic family members, such as MCL-1, priming drug-resistant cancer cells to death by BH3-mimetics. Sorafenib 0-9 BCL2 apoptosis regulator Homo sapiens 92-97 29682179-4 2018 Sorafenib-resistant hepatoma cells (HepG2R and Hep3BR) exhibited altered mRNA expression of BCL-2 and other anti-apoptotic family members, such as MCL-1, priming drug-resistant cancer cells to death by BH3-mimetics. BH 3 202-205 BCL2 apoptosis regulator Homo sapiens 92-97 29682179-6 2018 Moreover, in mice xenografts from patient-derived BCLC9 cells, better tumor response to sorafenib was associated to higher changes in the BCL-2 mRNA pattern. Sorafenib 88-97 BCL2 apoptosis regulator Homo sapiens 138-143 29682179-8 2018 Moreover, regorafenib administration also modified the BCL-2/MCL-1 ratio and navitoclax sensitized hepatoma cells to regorafenib by a mitochondrial caspase-dependent mechanism. regorafenib 10-21 BCL2 apoptosis regulator Homo sapiens 55-60 29682179-9 2018 In conclusion, sorafenib/regorafenib response is determined by BCL-2 proteins, while increased BCL-2/MCL-1 ratio in HCC sensitizes drug resistant-tumors against ABT-263 co-administration. Sorafenib 15-24 BCL2 apoptosis regulator Homo sapiens 63-68 29682179-9 2018 In conclusion, sorafenib/regorafenib response is determined by BCL-2 proteins, while increased BCL-2/MCL-1 ratio in HCC sensitizes drug resistant-tumors against ABT-263 co-administration. regorafenib 25-36 BCL2 apoptosis regulator Homo sapiens 63-68 29682179-9 2018 In conclusion, sorafenib/regorafenib response is determined by BCL-2 proteins, while increased BCL-2/MCL-1 ratio in HCC sensitizes drug resistant-tumors against ABT-263 co-administration. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 161-164 BCL2 apoptosis regulator Homo sapiens 95-100 29636622-9 2018 We also identified miR-206 targeting Bcl-2 directly in CRC, which is required for miR-206 mediated-5-FU resistance. Fluorouracil 99-103 BCL2 apoptosis regulator Homo sapiens 37-42 29590547-19 2018 CONCLUSIONS: In this study involving historical controls, dual targeting of BTK and BCL2 with ibrutinib and venetoclax was consistent with improved outcomes in patients with mantle-cell lymphoma who had been predicted to have poor outcomes with current therapy. ibrutinib 94-103 BCL2 apoptosis regulator Homo sapiens 84-88 29682179-10 2018 Thus, changes in the BCL-2 profile, altered in HCC patients, could help to follow-up sorafenib efficacy, allowing patient selection for combined therapy with BH3-mimetics or early switch them to second line therapy. Sorafenib 85-94 BCL2 apoptosis regulator Homo sapiens 21-26 29682179-10 2018 Thus, changes in the BCL-2 profile, altered in HCC patients, could help to follow-up sorafenib efficacy, allowing patient selection for combined therapy with BH3-mimetics or early switch them to second line therapy. BH 3 158-161 BCL2 apoptosis regulator Homo sapiens 21-26 29590547-19 2018 CONCLUSIONS: In this study involving historical controls, dual targeting of BTK and BCL2 with ibrutinib and venetoclax was consistent with improved outcomes in patients with mantle-cell lymphoma who had been predicted to have poor outcomes with current therapy. venetoclax 108-118 BCL2 apoptosis regulator Homo sapiens 84-88 29459277-3 2018 Here, we describe the binding of benzimidazole-carbazole ligands to G-quadruplex structures formed in G-rich DNA sequences containing the promoter regions of human c-MYC, c-KIT1, c-KIT2, VEGF and BCL2 proto-oncogenes. benzimidazole 33-46 BCL2 apoptosis regulator Homo sapiens 196-200 29701186-10 2018 Compared with the control group, the cell survival rates were decreased in the 100 mumol/L H2O2 group and the negative control group (both P<0.05), along with enhanced apoptotic rates, inhibited cellular SOD activities and CAT activities, reduced GSH contents, augmented MDA contents, down-regulated Trx-2 and Bcl-2 expression and up-regulated Bax and caspase-3 expression (all P<0.05). Hydrogen Peroxide 91-95 BCL2 apoptosis regulator Homo sapiens 313-318 29580266-3 2018 BH3-mimetics that inhibit specific BCL-2 anti-apoptotic proteins may hold encouraging treatment outcomes for cervical cancer management. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 35-40 29580266-4 2018 Hence, the aim of this pilot study is to investigate the sensitivity of cervical cancer cell lines to combination of two BH3-mimetics namely ABT-263 which selectively inhibits BCL-2, BCL-XL and BCL-w and A-1210477, a selective MCL-1 inhibitor. BH 3 121-124 BCL2 apoptosis regulator Homo sapiens 176-181 29580266-4 2018 Hence, the aim of this pilot study is to investigate the sensitivity of cervical cancer cell lines to combination of two BH3-mimetics namely ABT-263 which selectively inhibits BCL-2, BCL-XL and BCL-w and A-1210477, a selective MCL-1 inhibitor. navitoclax 141-148 BCL2 apoptosis regulator Homo sapiens 176-181 29421656-7 2018 Also, zileuton treatment attenuates pancreatic tissue pathology, upregulates caspase-3, downregulates B-cell lymphoma 2 (Bcl-2), and activates tissue apoptosis evaluated by TUNEL staining. zileuton 6-14 BCL2 apoptosis regulator Homo sapiens 102-119 29421656-7 2018 Also, zileuton treatment attenuates pancreatic tissue pathology, upregulates caspase-3, downregulates B-cell lymphoma 2 (Bcl-2), and activates tissue apoptosis evaluated by TUNEL staining. zileuton 6-14 BCL2 apoptosis regulator Homo sapiens 121-126 29459277-3 2018 Here, we describe the binding of benzimidazole-carbazole ligands to G-quadruplex structures formed in G-rich DNA sequences containing the promoter regions of human c-MYC, c-KIT1, c-KIT2, VEGF and BCL2 proto-oncogenes. carbazole 47-56 BCL2 apoptosis regulator Homo sapiens 196-200 29628889-6 2018 Mechanistically, kurarinone significantly decreased the ratio of Bcl-2/Bax, thereby causing the activation of caspase 9 and caspase 3, and reduced the expression of Grp78, which led to relieve the inhibition of caspase-12 and caspase-7, as well as suppressing the activity of AKT. kurarinone 17-27 BCL2 apoptosis regulator Homo sapiens 65-70 29587440-5 2018 In addition, the 7-AB-induced anti-proliferation towards NCI-N87 cells was associated with the release of cytochrome c from mitochondria, activation of pro-apoptotic proteins (such as caspase-3/-9, Bax and Bad), and inhibition of anti-apoptotic proteins (Bcl-2, Bcl-xL, and Mcl-1). 7-acetylsinumaximol B 17-21 BCL2 apoptosis regulator Homo sapiens 255-260 29501489-6 2018 In addition, compared with the control groups, rApoptin-treated tissues showed significantly higher expression of Bax and Cyt c while Bcl-2 expression was decreased by rApoptin treatment. rapoptin 47-55 BCL2 apoptosis regulator Homo sapiens 134-139 29501489-6 2018 In addition, compared with the control groups, rApoptin-treated tissues showed significantly higher expression of Bax and Cyt c while Bcl-2 expression was decreased by rApoptin treatment. rapoptin 168-176 BCL2 apoptosis regulator Homo sapiens 134-139 29765497-4 2018 The next study indicated that growth inhibition is involved in ROS generation in mechanism; accordingly, the changes in mitochondrial membrane permeability, apoptotic genes, cytochrome c, bax, and bcl-2 were observed, implying that the growth inhibition of DpdtbA is involved in ROS-mediated apoptosis. dpdtba 257-263 BCL2 apoptosis regulator Homo sapiens 197-202 29725496-3 2018 In this study, we found that melatonin impaired the proliferation and apoptosis resistance of oral cancer cells by inactivating ROS-dependent Akt signaling, involving in downregulation of cyclin D1, PCNA, and Bcl-2 and upregulation of Bax. Melatonin 29-38 BCL2 apoptosis regulator Homo sapiens 209-214 29408091-6 2018 Aspirin disrupted the interaction between Bcl-2 and Beclin-1. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 42-47 29588573-3 2018 Results: On SH-SY5Y cells, methyl-4-phenylpyridine (MPP+) treatment suppressed cell viability, induced apoptosis, and increased Bax/Bcl-2 ratio and caspase-3 activity. methyl-4-phenylpyridine 27-50 BCL2 apoptosis regulator Homo sapiens 132-137 29588573-3 2018 Results: On SH-SY5Y cells, methyl-4-phenylpyridine (MPP+) treatment suppressed cell viability, induced apoptosis, and increased Bax/Bcl-2 ratio and caspase-3 activity. mangion-purified polysaccharide (Candida albicans) 52-56 BCL2 apoptosis regulator Homo sapiens 132-137 29725496-3 2018 In this study, we found that melatonin impaired the proliferation and apoptosis resistance of oral cancer cells by inactivating ROS-dependent Akt signaling, involving in downregulation of cyclin D1, PCNA, and Bcl-2 and upregulation of Bax. Reactive Oxygen Species 128-131 BCL2 apoptosis regulator Homo sapiens 209-214 29345419-0 2018 Targeting the BCL2 Gene Promoter G-Quadruplex with a New Class of Furopyridazinone-Based Molecules. furopyridazinone 66-82 BCL2 apoptosis regulator Homo sapiens 14-18 29788725-10 2018 Finally, western blot analysis of TMPZ-treated cells revealed the activation of Caspase-3 and the increase of the ratio of Bax/Bcl-2. tetramethylpyrazine 34-38 BCL2 apoptosis regulator Homo sapiens 127-132 29788725-11 2018 These results demonstrated that TMPZ could suppress carcinogenesis of lung cancer cells through blocking cell cycle and inducing mitochondria-dependent apoptosis by regulating Caspase-3 and Bax/Bcl-2, suggesting that TMPZ may be a promising drug to treat lung cancer. tetramethylpyrazine 32-36 BCL2 apoptosis regulator Homo sapiens 194-199 29788725-11 2018 These results demonstrated that TMPZ could suppress carcinogenesis of lung cancer cells through blocking cell cycle and inducing mitochondria-dependent apoptosis by regulating Caspase-3 and Bax/Bcl-2, suggesting that TMPZ may be a promising drug to treat lung cancer. tetramethylpyrazine 217-221 BCL2 apoptosis regulator Homo sapiens 194-199 29534504-8 2018 Finally, formononetin-inhibited c-Jun N-terminal kinase (JNK) phosphorylation, cleavage of caspase-8 and caspase-3, and the ratio of Bax to Bcl-2 increased with cisplatin. formononetin 9-21 BCL2 apoptosis regulator Homo sapiens 140-145 29534504-8 2018 Finally, formononetin-inhibited c-Jun N-terminal kinase (JNK) phosphorylation, cleavage of caspase-8 and caspase-3, and the ratio of Bax to Bcl-2 increased with cisplatin. Cisplatin 161-170 BCL2 apoptosis regulator Homo sapiens 140-145 29523174-7 2018 Atorvastatin inhibited the proliferation of immortalized and primary uterine fibroids cells in a dose and time-dependent manner and stimulated apoptosis of uterine fibroids cells by inducing caspase-3 activation, up-regulating Bim and down-regulating Bcl-2. Atorvastatin 0-12 BCL2 apoptosis regulator Homo sapiens 251-256 29518944-7 2018 Tannic acid treatment affirmed upregulation of apoptosis-associated markers (Bak, Bim, cleaved caspase 3, and cleaved PARP), while downregulation of pro-survival proteins (Bcl-2 and Bcl-xL). Tannins 0-11 BCL2 apoptosis regulator Homo sapiens 172-177 29333953-0 2018 The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells. neratinib 37-46 BCL2 apoptosis regulator Homo sapiens 66-71 29507357-6 2018 We confirmed that miR-125a-5p and miR-16-5p (both enriched in ADEV-IL-1beta and ADEV-TNFalpha) targeted NTKR3 and its downstream effector Bcl2. mir-125a-5p 18-29 BCL2 apoptosis regulator Homo sapiens 138-142 29507357-6 2018 We confirmed that miR-125a-5p and miR-16-5p (both enriched in ADEV-IL-1beta and ADEV-TNFalpha) targeted NTKR3 and its downstream effector Bcl2. mir-16-5p 34-43 BCL2 apoptosis regulator Homo sapiens 138-142 29333953-0 2018 The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells. venetoclax 82-92 BCL2 apoptosis regulator Homo sapiens 66-71 29333953-2 2018 Venetoclax (ABT199) is a BCL-2 inhibitor. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 25-30 29333953-2 2018 Venetoclax (ABT199) is a BCL-2 inhibitor. venetoclax 12-18 BCL2 apoptosis regulator Homo sapiens 25-30 29535541-8 2018 Finally, Evo induced apoptosis in cancer cells by suppressing PI3K/AKT signaling and inducing MAPK phosphorylation (p38 and JNK, but not ERK) to regulate apoptotic proteins (Bax, Bcl-2, Cytochrome c, Caspase-3, and PARP). evodiamine 9-12 BCL2 apoptosis regulator Homo sapiens 179-184 29280311-8 2018 PEG-PCD-F polyplexes with siRNA against Bcl2 inhibit breast tumor growth following systemic intravenous administration. peg-pcd-f 0-9 BCL2 apoptosis regulator Homo sapiens 40-44 29218851-0 2018 Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. venetoclax 44-54 BCL2 apoptosis regulator Homo sapiens 29-33 29218851-1 2018 INTRODUCTION: Venetoclax (VEN), a selective BCL2 inhibitor, has single-agent activity in relapsed and refractory (R/R) acute myeloid leukemia (AML), and efficacy in lower intensity combinations for treatment-naive elderly AML patients. venetoclax 14-24 BCL2 apoptosis regulator Homo sapiens 44-48 29218851-1 2018 INTRODUCTION: Venetoclax (VEN), a selective BCL2 inhibitor, has single-agent activity in relapsed and refractory (R/R) acute myeloid leukemia (AML), and efficacy in lower intensity combinations for treatment-naive elderly AML patients. venetoclax 26-29 BCL2 apoptosis regulator Homo sapiens 44-48 29158005-9 2018 In the 1,25(OH)2D3 + HDAC2 overexpression group, the expressions of p53, Bax, DR5 and caspase 8 were significantly lower but the expression of Bcl-2 was significantly higher than those of the 1,25(OH)2D3 treatment group (P < 0.05). Calcitriol 7-18 BCL2 apoptosis regulator Homo sapiens 143-148 29214600-4 2018 Additionally, alantolactone triggered the mitochondrial-mediated caspase cascade apoptotic pathway, which was confirmed by increased Bax/Bcl-2 ratio, loss of MMP, release of cytc from mitochondria to cytoplasm, activation of caspase 9/3, and subsequent cleavage of PARP. alantolactone 14-27 BCL2 apoptosis regulator Homo sapiens 137-142 29196192-7 2018 Moreover, macrovipecetin alone or combined with cisplatin induced the expression of TRADD, p53, Bax, Bim and Bad and down-regulated the Bcl-2 expression and ROS levels in SK-MEL-28 cells. Cisplatin 48-57 BCL2 apoptosis regulator Homo sapiens 136-141 29662863-4 2018 Methods: In this study, we investigated the effect of different doses of resveratrol (15, 50 and 100 microM) and prednisolone (700 microM) on BAX (apoptosis promoter) and BCL2 (apoptosis inhibitor) expressions following 24 and 48 hours of treatment on CCRF-CEM cells, using real-time PCR, and on apoptosis induction using flow cytometry. Resveratrol 73-84 BCL2 apoptosis regulator Homo sapiens 171-175 29456111-3 2018 Methyllucidone decreased the expression levels of STAT3 target genes, such as cyclin D1, cyclin A, Bcl-2, Mcl-1, and survivin. methyllucidone 0-14 BCL2 apoptosis regulator Homo sapiens 99-104 29158005-9 2018 In the 1,25(OH)2D3 + HDAC2 overexpression group, the expressions of p53, Bax, DR5 and caspase 8 were significantly lower but the expression of Bcl-2 was significantly higher than those of the 1,25(OH)2D3 treatment group (P < 0.05). 25(oh) 9-15 BCL2 apoptosis regulator Homo sapiens 143-148 29367107-7 2018 Moreover, SAL acted synergistically with the Bcl-2 inhibitor ABT-263, whereas 2,2,2-trifluoroethyl ester, the most active analog of SAL, antagonized ABT-263, suggesting possible differences in molecular mechanism. salinomycin 10-13 BCL2 apoptosis regulator Homo sapiens 45-50 29367107-7 2018 Moreover, SAL acted synergistically with the Bcl-2 inhibitor ABT-263, whereas 2,2,2-trifluoroethyl ester, the most active analog of SAL, antagonized ABT-263, suggesting possible differences in molecular mechanism. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 61-64 BCL2 apoptosis regulator Homo sapiens 45-50 29349624-3 2018 Remarkably, the combined treatment with aspirin and vitamin D3 significantly suppressed the expression of Bcl-2 protein and p-Erk1/2 protein, examined by western blot analysis. Aspirin 40-47 BCL2 apoptosis regulator Homo sapiens 106-111 29349624-3 2018 Remarkably, the combined treatment with aspirin and vitamin D3 significantly suppressed the expression of Bcl-2 protein and p-Erk1/2 protein, examined by western blot analysis. Cholecalciferol 52-62 BCL2 apoptosis regulator Homo sapiens 106-111 29662863-4 2018 Methods: In this study, we investigated the effect of different doses of resveratrol (15, 50 and 100 microM) and prednisolone (700 microM) on BAX (apoptosis promoter) and BCL2 (apoptosis inhibitor) expressions following 24 and 48 hours of treatment on CCRF-CEM cells, using real-time PCR, and on apoptosis induction using flow cytometry. Prednisolone 113-125 BCL2 apoptosis regulator Homo sapiens 171-175 29662863-7 2018 Combined resveratrol and prednisolone treatment showed synergistic effects on the overexpression of BAX and the downregulation of BCL2. Resveratrol 9-20 BCL2 apoptosis regulator Homo sapiens 130-134 29662863-7 2018 Combined resveratrol and prednisolone treatment showed synergistic effects on the overexpression of BAX and the downregulation of BCL2. Prednisolone 25-37 BCL2 apoptosis regulator Homo sapiens 130-134 28705421-0 2018 Bcl-2 inhibitors as anti-cancer therapeutics: The impact of and on calcium signaling. Calcium 67-74 BCL2 apoptosis regulator Homo sapiens 0-5 28705421-5 2018 Different Bcl-2 inhibitors have already been developed including the hydrophobic cleft-targeting BH3 mimetics, which antagonize Bcl-2"s ability to scaffold and neutralize pro-apoptotic Bcl-2-family members. BH 3 97-100 BCL2 apoptosis regulator Homo sapiens 128-133 28705421-5 2018 Different Bcl-2 inhibitors have already been developed including the hydrophobic cleft-targeting BH3 mimetics, which antagonize Bcl-2"s ability to scaffold and neutralize pro-apoptotic Bcl-2-family members. BH 3 97-100 BCL2 apoptosis regulator Homo sapiens 10-15 28705421-5 2018 Different Bcl-2 inhibitors have already been developed including the hydrophobic cleft-targeting BH3 mimetics, which antagonize Bcl-2"s ability to scaffold and neutralize pro-apoptotic Bcl-2-family members. BH 3 97-100 BCL2 apoptosis regulator Homo sapiens 128-133 29381777-10 2018 The targeting of BCL-2 with BH3 mimetics effectively reduced viability and induced apoptosis in a subset of ULM spheroids. BH 3 28-31 BCL2 apoptosis regulator Homo sapiens 17-22 29068538-0 2018 Novel 1,3,5-triazine derivatives exert potent anti-cervical cancer effects by modulating Bax, Bcl2 and Caspases expression. 1,3,5-TRIAZINE 6-20 BCL2 apoptosis regulator Homo sapiens 94-98 29382644-1 2018 The BCL2 inhibitor venetoclax is approved in the United States for only a subset of patients with refractory chronic lymphocytic leukemia. venetoclax 19-29 BCL2 apoptosis regulator Homo sapiens 4-8 29408764-9 2018 Our results showed marked increase in all measured parameters except SOD, TAC, eNOS immunoexpression and Bcl2 mRNA gene expression which decreased in Cd induced hepatotoxicity group. Cadmium 150-152 BCL2 apoptosis regulator Homo sapiens 105-109 29381777-12 2018 In conclusion, BCL-2 mediates AKT survival of ULM, providing compelling evidence for further evaluation of BH3 mimetics for ULM treatment. BH 3 107-110 BCL2 apoptosis regulator Homo sapiens 15-20 28549767-3 2018 Venetoclax, an inhibitor of BCL-2 known to play an important role in regulating cell death, has been approved recently for treatment of patients with chronic lymphocytic leukemia with Del17p who have received at least one prior therapy. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 28-33 29456707-12 2018 The present results demonstrated that Res-induced apoptosis of K562/ADM cells was autophagy-dependent and the released Cath D may trigger caspase-dependent cell death through the Bcl-2 family of proteins. Resveratrol 38-41 BCL2 apoptosis regulator Homo sapiens 179-184 29456710-7 2018 In addition, goniothalamin decreased the level of anti-apoptotic proteins myeloid cell leukemia 1, B cell lymphoma (Bcl)-2 and Bcl-extra large, whereas it increased the level of pro-apoptotic proteins, Bcl-2 Associated X, apoptosis regulator, t-BID and Bim in A375 treated cells. goniothalamin 13-26 BCL2 apoptosis regulator Homo sapiens 99-122 29513792-9 2018 Polydatin also induced cell apoptosis in a concentration-dependent manner possibly via increasing the caspase-3 activity, and up-regulating the protein expression of caspase-3, caspase-9, Bax, and down-regulating the protein expression of Bcl-2. polydatin 0-9 BCL2 apoptosis regulator Homo sapiens 239-244 31938232-6 2018 Midazolam significantly induced A549 cell apoptosis and modulated expression of Bcl-2, Bax, and Caspase-3. Midazolam 0-9 BCL2 apoptosis regulator Homo sapiens 80-85 29358461-7 2018 The STIM2-associated increase in the resting [Ca2+]cyt is also involved in upregulating Bcl-2 that makes PAH-PASMCs resistant to apoptosis, and thus plays an important role in sustained pulmonary vasoconstriction and excessive pulmonary vascular remodeling in patients with PAH. pasmcs 109-115 BCL2 apoptosis regulator Homo sapiens 88-93 29358461-4 2018 Furthermore, the STIM2-associated increase in the resting [Ca2+]cyt also upregulates the antiapoptotic protein Bcl-2 in PAH-PASMCs. pasmcs 124-130 BCL2 apoptosis regulator Homo sapiens 111-116 28776671-0 2018 beta-asarone inhibited cell growth and promoted autophagy via P53/Bcl-2/Bclin-1 and P53/AMPK/mTOR pathways in Human Glioma U251 cells. asarone 0-12 BCL2 apoptosis regulator Homo sapiens 66-71 29745074-9 2018 Besides, boswellic acid altered the Bax/Bcl-2 ratio in the HCT-116 cancer cells and inhibited their migration as indicated by the cell migration assay. boswellic acid 9-23 BCL2 apoptosis regulator Homo sapiens 40-45 28776671-12 2018 We got the results that beta-asarone changed the cellular morphology, inhibited cell proliferation, and enhanced the expression of P53, LC3-II/I, Beclin-1, AMPK, and pAMPK while inhibiting the expression of P62, Bcl-2, mTOR, and pmTOR. asarone 24-36 BCL2 apoptosis regulator Homo sapiens 212-217 29407584-4 2018 In the present study, we examined the effects of MG-132 (a proteasome inhibitor), LiCl (a glycogen synthase kinase-3 inhibitor) and/or TRAIL on pro-apoptotic Bcl-2 family proteins such as Bim and Bid. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 49-55 BCL2 apoptosis regulator Homo sapiens 158-163 29358277-3 2018 Using intracellular BH3 profiling, we defined the Bcl2 dependency of B cell subsets from human peripheral blood and tonsillar lymphoid tissue as well as mitogen-activated B cells. BH 3 20-23 BCL2 apoptosis regulator Homo sapiens 50-54 29260413-8 2018 Our study confirmed the protective effect of berberine against H/R-induced apoptosis in HK-2 cells through promoting cells viability, inhibiting cells apoptosis, and down-regulating p-P38, caspase-3, caspase-9 as well as SPHK1, while up regulating the ratio of Bcl-2/Bax. Berberine 45-54 BCL2 apoptosis regulator Homo sapiens 261-266 29407584-4 2018 In the present study, we examined the effects of MG-132 (a proteasome inhibitor), LiCl (a glycogen synthase kinase-3 inhibitor) and/or TRAIL on pro-apoptotic Bcl-2 family proteins such as Bim and Bid. Lithium Chloride 82-86 BCL2 apoptosis regulator Homo sapiens 158-163 28343296-9 2018 While cypermethrin increased the expression of interleukin-1beta, interleukin-4, interferon-gamma, inducible nitric oxide synthase, caspase-3, caspase-9 and B-cell lymphoma (Bcl)-xl proteins, it attenuated Bcl-2 expression. cypermethrin 6-18 BCL2 apoptosis regulator Homo sapiens 206-211 28283885-8 2018 Atorvastatin induced the expression of caspase-3 and caspase-8 and downregulated the expression of Bcl-2, TRAF3IP2, and IL-17RA especially at 10 muM concentration. Atorvastatin 0-12 BCL2 apoptosis regulator Homo sapiens 99-104 29344652-0 2018 Chrysophanol inhibits proliferation and induces apoptosis through NF-kappaB/cyclin D1 and NF-kappaB/Bcl-2 signaling cascade in breast cancer cell lines. chrysophanic acid 0-12 BCL2 apoptosis regulator Homo sapiens 100-105 29286113-0 2018 Synergistic effect of nutlin-3 combined with aspirin in hepatocellular carcinoma HepG2 cells through activation of Bcl-2/Bax signaling pathway. Aspirin 45-52 BCL2 apoptosis regulator Homo sapiens 115-120 29286113-15 2018 The synergistic effect of nutlin-3 in aspirin antitumor therapy contributed to diminishing the dose of aspirin required and decreased the occurrence of adverse drug events in HCC through targeting the Bcl-2/Bax signaling pathway. nutlin 3 26-34 BCL2 apoptosis regulator Homo sapiens 201-206 29286113-15 2018 The synergistic effect of nutlin-3 in aspirin antitumor therapy contributed to diminishing the dose of aspirin required and decreased the occurrence of adverse drug events in HCC through targeting the Bcl-2/Bax signaling pathway. Aspirin 38-45 BCL2 apoptosis regulator Homo sapiens 201-206 29063678-9 2018 MCL1 protein levels are rapidly decreased by CCT068127 treatment and this associates with synergistic antiproliferative activity after combined treatment with CCT068127 and ABT263, a BCL2 family inhibitor. CCT68127 45-54 BCL2 apoptosis regulator Homo sapiens 183-187 29063678-9 2018 MCL1 protein levels are rapidly decreased by CCT068127 treatment and this associates with synergistic antiproliferative activity after combined treatment with CCT068127 and ABT263, a BCL2 family inhibitor. CCT68127 159-168 BCL2 apoptosis regulator Homo sapiens 183-187 29063678-9 2018 MCL1 protein levels are rapidly decreased by CCT068127 treatment and this associates with synergistic antiproliferative activity after combined treatment with CCT068127 and ABT263, a BCL2 family inhibitor. navitoclax 173-179 BCL2 apoptosis regulator Homo sapiens 183-187 29363719-8 2018 Administration of picropodophyllotoxin suppressed IGF-1 protein expression, promoted apoptosis, increased caspase-3 and caspase-9 activity levels, and induced the protein expression of Bax/Bcl-2. picropodophyllin 18-38 BCL2 apoptosis regulator Homo sapiens 189-194 29344652-9 2018 In addition, chrysophanol downregulated apoptosis regulator Bcl-2 protein, and transcription factor p65 and IkappaB phosphorylation. chrysophanic acid 13-25 BCL2 apoptosis regulator Homo sapiens 60-65 29435010-5 2018 The inhibition of autophagy by CQ enhanced sunitinib-induced apoptosis, which was characterized by the activation of caspase-3, caspase-9, Bcl-2 and p53. Chloroquine 31-33 BCL2 apoptosis regulator Homo sapiens 139-144 29363722-9 2018 Furthermore, the present study revealed that beta-elemene induced apoptosis in SiHa cells by enhancing the expression of p53 and Bax, and suppressing the expression of Bcl-2. beta-elemene 45-57 BCL2 apoptosis regulator Homo sapiens 168-173 29417471-7 2018 Pretreated SH-SY5Y cells with phenolic compounds also helped to upregulate H2O2-induced depletion of the expressions of sirtuin-1 (SIRT1) and forkhead box O (FoxO) 3a as well as induce the levels of antioxidant (superoxide dismutase (SOD) 2 and catalase) and antiapoptotic B-cell lymphoma 2 (Bcl-2) proteins. Hydrogen Peroxide 75-79 BCL2 apoptosis regulator Homo sapiens 273-290 29417471-7 2018 Pretreated SH-SY5Y cells with phenolic compounds also helped to upregulate H2O2-induced depletion of the expressions of sirtuin-1 (SIRT1) and forkhead box O (FoxO) 3a as well as induce the levels of antioxidant (superoxide dismutase (SOD) 2 and catalase) and antiapoptotic B-cell lymphoma 2 (Bcl-2) proteins. Hydrogen Peroxide 75-79 BCL2 apoptosis regulator Homo sapiens 292-297 29435054-5 2018 In addition, DHA downregulated the levels of B-cell lymphoma (Bcl)-2, protein kinase B (Akt)1, Akt2 and Akt3 gene expression, and increased the expression of the Bcl-2-associated X protein apoptosis regulator. artenimol 13-16 BCL2 apoptosis regulator Homo sapiens 45-68 29431743-4 2018 Sorafenib-related IL-15 production caused an increase in CD8+CD107a+IFN-gamma+ T cells with features of longevity (high levels of Bcl-2 and reduced PD-1 levels), which eradicated leukemia in secondary recipients. Sorafenib 0-9 BCL2 apoptosis regulator Homo sapiens 130-135 29286126-0 2018 Bcl-2 overexpression reduces cisplatin cytotoxicity by decreasing ER-mitochondrial Ca2+ signaling in SKOV3 cells. Cisplatin 29-38 BCL2 apoptosis regulator Homo sapiens 0-5 29286126-4 2018 Bcl-2 is reported to block cisplatin-induced apoptosis via regulating Ca2+ signaling in a variety of cancer cell lines. Cisplatin 27-36 BCL2 apoptosis regulator Homo sapiens 0-5 29286126-6 2018 The present study revealed that Bcl-2 overexpression reduced cisplatin-induced growth inhibition and apoptosis in SKOV3 human ovarian cancer cells. Cisplatin 61-70 BCL2 apoptosis regulator Homo sapiens 32-37 29286126-7 2018 Furthermore, Bcl-2 inhibited cisplatin-induced Ca2+ release from the ER to the cytoplasm and mitochondria, which reduced cisplatin-induced ER stress-mediated apoptosis through the mitochondrial apoptotic pathway. Cisplatin 29-38 BCL2 apoptosis regulator Homo sapiens 13-18 29286126-7 2018 Furthermore, Bcl-2 inhibited cisplatin-induced Ca2+ release from the ER to the cytoplasm and mitochondria, which reduced cisplatin-induced ER stress-mediated apoptosis through the mitochondrial apoptotic pathway. Cisplatin 121-130 BCL2 apoptosis regulator Homo sapiens 13-18 29286126-8 2018 The overexpression of Bcl-2 inhibited the cisplatin-induced increase in the number of ER-mitochondrial contact sites in SKOV3 human ovarian cancer cells. Cisplatin 42-51 BCL2 apoptosis regulator Homo sapiens 22-27 29286126-9 2018 In addition, the present study provided evidence that Bcl-2 reduced the anticancer activity of cisplatin towards ovarian cancer cells in vivo. Cisplatin 95-104 BCL2 apoptosis regulator Homo sapiens 54-59 29286126-10 2018 These results revealed that Bcl-2 attenuates cisplatin cytotoxicity via downregulating ER-mitochondrial Ca2+ signaling transduction. Cisplatin 45-54 BCL2 apoptosis regulator Homo sapiens 28-33 29286151-0 2018 Polysaccharide sulphated derivative from Aconitum coreanum induces cell apoptosis in the human brain glioblastoma U87MG cell line via the NF-kappaB/Bcl-2 cell apoptotic signaling pathway. Polysaccharides 0-14 BCL2 apoptosis regulator Homo sapiens 148-153 29435010-5 2018 The inhibition of autophagy by CQ enhanced sunitinib-induced apoptosis, which was characterized by the activation of caspase-3, caspase-9, Bcl-2 and p53. Sunitinib 43-52 BCL2 apoptosis regulator Homo sapiens 139-144 29467861-10 2018 The antiapoptotic-protein Bcl-2 was downregulated, and the proapoptotic protein Bax was upregulated following treatment with the oleanolic acid derivative for 48 h. The oleanolic acid derivative induced the cleavage of caspase-9 and caspase-3 as well as promoted annexin V-FITC/PI uptake in SMMC-7721 cells. Oleanolic Acid 129-143 BCL2 apoptosis regulator Homo sapiens 26-31 29467861-10 2018 The antiapoptotic-protein Bcl-2 was downregulated, and the proapoptotic protein Bax was upregulated following treatment with the oleanolic acid derivative for 48 h. The oleanolic acid derivative induced the cleavage of caspase-9 and caspase-3 as well as promoted annexin V-FITC/PI uptake in SMMC-7721 cells. Oleanolic Acid 169-183 BCL2 apoptosis regulator Homo sapiens 26-31 29363570-4 2018 Here, we first demonstrated that the suppression of autophagy through the JNK/BCL-2/BECN1 signaling is engaged in melatonin-mediated GCs protection against oxidative damage. Melatonin 114-123 BCL2 apoptosis regulator Homo sapiens 78-83 29309850-10 2018 Apoptosis induced by ALA-PDT involved in down-regulation of Bcl-2 protein, up-regulation of Bax protein and cleaved-PARP protein. Alanine 21-24 BCL2 apoptosis regulator Homo sapiens 60-65 29355734-6 2018 RESULTS: PpIX-PDT results in nuclear condensation, increased the expression of Caspase-3, Bax, and PARP, and decreased expression of Bcl-2. protoporphyrin IX 9-13 BCL2 apoptosis regulator Homo sapiens 133-138 29355734-7 2018 PpIX-PDT also induces the double membrane autophagosome, up-regulates LC3B, Atg7, Beclin-1, and Bcl-2 expression and down-regulates P62 expression. protoporphyrin IX 0-4 BCL2 apoptosis regulator Homo sapiens 96-101 29363570-8 2018 Importantly, we found that the enhanced interaction between BCL-2 and BECN1 might be a responsive mechanism for autophagy suppression via the melatonin/JNK pathway. Melatonin 142-151 BCL2 apoptosis regulator Homo sapiens 60-65 29495429-3 2018 The acquired beta-CD-modified Au DENPs (Au DENPs-beta-CD) were complexed with two different types of therapeutic siRNA (B-cell lymphoma/leukemia-2 (Bcl-2) siRNA and vascular endothelial growth factor (VEGF) siRNA). betadex 13-20 BCL2 apoptosis regulator Homo sapiens 120-146 29495429-3 2018 The acquired beta-CD-modified Au DENPs (Au DENPs-beta-CD) were complexed with two different types of therapeutic siRNA (B-cell lymphoma/leukemia-2 (Bcl-2) siRNA and vascular endothelial growth factor (VEGF) siRNA). betadex 13-20 BCL2 apoptosis regulator Homo sapiens 148-153 29495429-7 2018 Our data reveals that the formed Au DENPs-beta-CD carrier enables efficiently delivery of siRNA to glioma cells, has good cytocompatibility once complexed with the siRNA, and enables enhanced gene silencing to inhibit the expression of Bcl-2 and VEGF proteins. Gold 33-35 BCL2 apoptosis regulator Homo sapiens 236-241 29495429-7 2018 Our data reveals that the formed Au DENPs-beta-CD carrier enables efficiently delivery of siRNA to glioma cells, has good cytocompatibility once complexed with the siRNA, and enables enhanced gene silencing to inhibit the expression of Bcl-2 and VEGF proteins. denps-beta-cd 36-49 BCL2 apoptosis regulator Homo sapiens 236-241 29472583-5 2018 Quercetin and green tea reduced tumor growth in HL-60 xenografts accompanied by decreased expression of anti-apoptotic proteins, BCL-2, BCL-XL and MCL-1 and increased expression of BAX, a pro-apoptotic protein. Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 129-134 29682582-8 2018 Additionally, vitamin D3 reduced vascular endothelial growth factor (VEGF) expression and the Bax/Bcl-2 ratio. Cholecalciferol 14-24 BCL2 apoptosis regulator Homo sapiens 98-103 29492513-9 2018 In addition, hirsutine down-regulated the protein level of Bcl-2 and up-regulated the protein level of Bax (P < 0.05). hirsutine 13-22 BCL2 apoptosis regulator Homo sapiens 59-64 29492513-10 2018 These results suggest that hirsutine may induce apoptosis of human breast cancer MDA-MB-231 cells through decreasing the ratio of Bcl-2 to Bax, opening MPTP, releasing Cyt C from mitochondria, and activating caspase 9 and caspase 3. hirsutine 27-36 BCL2 apoptosis regulator Homo sapiens 130-135 29463802-2 2018 To this end, we analyzed whole-exome sequencing data of eight chronic lymphocytic leukemia (CLL) patients that developed resistance upon BCL2-inhibition by venetoclax. venetoclax 156-166 BCL2 apoptosis regulator Homo sapiens 137-141 29277717-9 2018 In addition, treatment with relatively high concentrations of isoliquiritigenin induced apoptosis, mainly associated with enhancing apoptosis regulator (Bax/Bcl-2) ratio. isoliquiritigenin 62-79 BCL2 apoptosis regulator Homo sapiens 157-162 29309768-11 2018 The mRNA levels of apoptosis-related genes BAX and CASP3 were increased, and the anti-apoptotic gene BCL2 was decreased in oocytes exposed to DHA. artenimol 142-145 BCL2 apoptosis regulator Homo sapiens 101-105 29032342-0 2018 A light-up probe targeting for Bcl-2 2345 G-quadruplex DNA with carbazole TO. carbazole 64-73 BCL2 apoptosis regulator Homo sapiens 31-36 29032342-3 2018 In the present study, the fluorescence of the dye (carbazole TO) increased almost 70 fold in the presence of bcl-2 2345 G4 compared to that alone in aqueous buffer condition with almost no fluorescence and 10-30 fold than those in the presence of other DNAs. carbazole 51-60 BCL2 apoptosis regulator Homo sapiens 109-114 29324335-4 2018 In particular, four compounds were found to protect SH-SY5Y cells from H2O2-induced toxicity by increasing Bcl-2/Bax ratio, regulating PI3-K/Akt cascade and inhibiting the ERK pathway. Hydrogen Peroxide 71-75 BCL2 apoptosis regulator Homo sapiens 107-112 29531815-9 2018 In addition, Flubendazole promoted cell apoptosis by regulating the classical apoptosis protein BCL-2 expression. flubendazole 13-25 BCL2 apoptosis regulator Homo sapiens 96-101 29562450-7 2018 Treatment with BGJ398 at 1.4 micromol/L led to significant increases in the expression levels of caspase-3, and decreases in the expression of Bcl-2 (P<0.005). infigratinib 15-21 BCL2 apoptosis regulator Homo sapiens 143-148 29497611-4 2018 At the level of these organelles, Bcl-2 family proteins not only regulate MOMP in a remote fashion but also participate in major cellular processes including calcium homeostasis, cell cycle control and cell migration. Calcium 158-165 BCL2 apoptosis regulator Homo sapiens 34-39 29440688-5 2018 In contrast, LC-SP had a substantially higher percentage of CD4, BCl2 and neutrophils than ATL lesions. lc-sp 13-18 BCL2 apoptosis regulator Homo sapiens 65-69 29568392-0 2018 MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2. Cisplatin 34-43 BCL2 apoptosis regulator Homo sapiens 128-133 29568392-4 2018 The aim was to examine the possible association between miR-630 (and its targeting of Bcl-2 expression) and the response to cisplatin-based chemotherapy. Cisplatin 124-133 BCL2 apoptosis regulator Homo sapiens 86-91 29568392-5 2018 Patients with tumors expressing low miR-630, high Bcl-2, and a combination of both were more likely than their counterparts to show unfavorable responses to cisplatin-based chemotherapy. Cisplatin 157-166 BCL2 apoptosis regulator Homo sapiens 50-55 29568392-9 2018 Mechanistically, low miR-630 expression conferred cisplatin resistance and colony formation by de-targeting Bcl-2 in NSCLC cells. Cisplatin 50-59 BCL2 apoptosis regulator Homo sapiens 108-113 28772088-8 2018 After 72 h of treatment with zoledronate, the percentage of apoptotic DPSCs significantly increased, which was accompanied by an increased level of pro-apoptotic proteins caspase-3 and Bax and decreased the level of the anti-apoptotic protein Bcl-2. Zoledronic Acid 29-40 BCL2 apoptosis regulator Homo sapiens 243-248 29531808-7 2018 Thapsigargin or hydrogen peroxide treatment activated multiple death signals including JNK, Bcl-2 family members, and caspases. Thapsigargin 0-12 BCL2 apoptosis regulator Homo sapiens 92-97 29531808-7 2018 Thapsigargin or hydrogen peroxide treatment activated multiple death signals including JNK, Bcl-2 family members, and caspases. Hydrogen Peroxide 16-33 BCL2 apoptosis regulator Homo sapiens 92-97 28980048-8 2018 Our findings suggested that piceid pretreatment inhibited the dopamine-induced increase in caspase-3/7 activity and dopamine-induced loss of Bcl-2 expression. Dopamine 116-124 BCL2 apoptosis regulator Homo sapiens 141-146 29195909-7 2018 Furthermore, a significant suppression of p-p38, improved Bax/Bcl-2 ratio expression, and reduced caspase-3 activity was exhibited in the cells after gamma-mangostin pretreatment. gamma-mangostin 150-165 BCL2 apoptosis regulator Homo sapiens 62-67 28512695-5 2018 In line with this, protein levels of Bax and cytochrome C were increased and Bcl-2 was decreased by arsenic treatments. Arsenic 100-107 BCL2 apoptosis regulator Homo sapiens 77-82 29290491-0 2018 Induction of apoptosis by pyrazolo[3,4-d]pyridazine derivative in lung cancer cells via disruption of Bcl-2/Bax expression balance. pyrazolo[3,4-d]pyridazine 26-51 BCL2 apoptosis regulator Homo sapiens 102-107 28993998-8 2018 Also, an increase in pro-apoptotic p53 protein expression and a decrease in anti-apoptotic Bcl-2 protein expression were observed after LCA treatment of MCF-7 cells. Lithocholic Acid 136-139 BCL2 apoptosis regulator Homo sapiens 91-96 29203930-7 2018 The expression levels of Bax and Cyt-c proteins were upregulated, but the expression levels of Bcl-2 and Bcl-xL proteins were downregulated by blocking CDH17 gene in gastric cancer BGC823 cells after treatment with cisplatin. Cisplatin 215-224 BCL2 apoptosis regulator Homo sapiens 95-100 29222657-7 2018 Moreover, fucoxanthin and fucoxanthinol markedly increased the expression level of Bcl-2/Bax. fucoxanthin 10-21 BCL2 apoptosis regulator Homo sapiens 83-88 29053140-6 2018 We not only assess the relative contributions of anti- and proapoptotic BCL2 family members to BH3-only tolerance, but also illustrate how the study of this parameter can be used to understand cellular sensitivity to anticancer drugs and new combinations. BH 3 95-98 BCL2 apoptosis regulator Homo sapiens 72-76 29144987-6 2018 In the mechanism, BPDE significantly increased pro-apoptosis protein (P53 and Bak1) and decreased anti-apoptosis protein (Bcl-2). 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide 18-22 BCL2 apoptosis regulator Homo sapiens 122-127 29222657-8 2018 These results demonstrated that both fucoxanthin and fucoxanthinol effectively prevented cytotoxicity in HepG2 cells treated with TBT, and the protective effect was likely associated with decreased intracellular ROS and MDA and increased Bcl-2/Bax levels. fucoxanthinol 53-66 BCL2 apoptosis regulator Homo sapiens 238-243 29218545-10 2018 In addition, we found that the application of BAY606583 led to CSC cell cycle arrest and apoptosis through the cyclin-D1/Cdk-4 and Bax/Bcl-2 pathways, respectively. bay606583 46-55 BCL2 apoptosis regulator Homo sapiens 135-140 29135079-3 2018 Western blot assay revealed that the protein expressions of p53, Bax, and CCAAT-enhancer-binding protein homologous protein (CHOP) increased, while the levels of Bcl-2 were reduced following CS extract treatment. Cesium 191-193 BCL2 apoptosis regulator Homo sapiens 162-167 29222657-7 2018 Moreover, fucoxanthin and fucoxanthinol markedly increased the expression level of Bcl-2/Bax. fucoxanthinol 26-39 BCL2 apoptosis regulator Homo sapiens 83-88 29064593-3 2018 Results from early phase clinical trials utilizing the selective Bcl-2 inhibitor, venetoclax, as a single agent in patients with relapsed MM have had remarkable efficacy among patients with t (11;14) abnormality. venetoclax 82-92 BCL2 apoptosis regulator Homo sapiens 65-70 29222657-8 2018 These results demonstrated that both fucoxanthin and fucoxanthinol effectively prevented cytotoxicity in HepG2 cells treated with TBT, and the protective effect was likely associated with decreased intracellular ROS and MDA and increased Bcl-2/Bax levels. fucoxanthin 37-48 BCL2 apoptosis regulator Homo sapiens 238-243 29434780-12 2018 Berbamine (10, 20, 40 micromol/l) significantly enhanced Bax and p53 levels and decreased Bcl-2 and survivin levels compared with control group, according to RT-sqPCR and western blot assay findings. berbamine 0-9 BCL2 apoptosis regulator Homo sapiens 90-95 29207009-3 2018 Recently, the B-cell lymphoma 2 (Bcl-2) BH4 domain has been reported to mediate the prosurvival activity of Bcl-2 in cancer; however, the involvement of the BH4 domain of Bcl-2 in the cisplatin resistance of ovarian carcinoma cells is not entirely clear. sapropterin 40-43 BCL2 apoptosis regulator Homo sapiens 14-31 29806604-14 2018 C-glycosyl flavone treatment caused marked loss of mitochondrial membrane potential, decrease in Bcl2/BAX ratio and activation of caspase-3 and release of caspase-9 and cytochrome c. c-glycosyl flavone 0-18 BCL2 apoptosis regulator Homo sapiens 97-101 29207009-3 2018 Recently, the B-cell lymphoma 2 (Bcl-2) BH4 domain has been reported to mediate the prosurvival activity of Bcl-2 in cancer; however, the involvement of the BH4 domain of Bcl-2 in the cisplatin resistance of ovarian carcinoma cells is not entirely clear. sapropterin 157-160 BCL2 apoptosis regulator Homo sapiens 108-113 29258953-4 2018 In addition, butein-induced apoptosis is mediated through the activation of caspase-3, which is associated with changes in the expression of Bcl-2 and Bax proteins. butein 13-19 BCL2 apoptosis regulator Homo sapiens 141-146 29207009-3 2018 Recently, the B-cell lymphoma 2 (Bcl-2) BH4 domain has been reported to mediate the prosurvival activity of Bcl-2 in cancer; however, the involvement of the BH4 domain of Bcl-2 in the cisplatin resistance of ovarian carcinoma cells is not entirely clear. sapropterin 40-43 BCL2 apoptosis regulator Homo sapiens 33-38 29207051-8 2018 RT-qPCR analysis revealed a decrease in Bcl-2 and an increase in Bax in hLECs following exposure to H2O2 for 24 h, regardless of CGA presence. Hydrogen Peroxide 100-104 BCL2 apoptosis regulator Homo sapiens 40-45 29207009-3 2018 Recently, the B-cell lymphoma 2 (Bcl-2) BH4 domain has been reported to mediate the prosurvival activity of Bcl-2 in cancer; however, the involvement of the BH4 domain of Bcl-2 in the cisplatin resistance of ovarian carcinoma cells is not entirely clear. sapropterin 40-43 BCL2 apoptosis regulator Homo sapiens 108-113 29207009-3 2018 Recently, the B-cell lymphoma 2 (Bcl-2) BH4 domain has been reported to mediate the prosurvival activity of Bcl-2 in cancer; however, the involvement of the BH4 domain of Bcl-2 in the cisplatin resistance of ovarian carcinoma cells is not entirely clear. sapropterin 40-43 BCL2 apoptosis regulator Homo sapiens 108-113 29207126-8 2018 Melatonin further stimulated the expression of the pro-apoptotic BAD and BAX genes, and enhanced the inhibition of the anti-apoptotic gene BCL-2 induced by docetaxel. Melatonin 0-9 BCL2 apoptosis regulator Homo sapiens 139-144 29207009-3 2018 Recently, the B-cell lymphoma 2 (Bcl-2) BH4 domain has been reported to mediate the prosurvival activity of Bcl-2 in cancer; however, the involvement of the BH4 domain of Bcl-2 in the cisplatin resistance of ovarian carcinoma cells is not entirely clear. sapropterin 157-160 BCL2 apoptosis regulator Homo sapiens 14-31 29207126-8 2018 Melatonin further stimulated the expression of the pro-apoptotic BAD and BAX genes, and enhanced the inhibition of the anti-apoptotic gene BCL-2 induced by docetaxel. Docetaxel 156-165 BCL2 apoptosis regulator Homo sapiens 139-144 29207009-3 2018 Recently, the B-cell lymphoma 2 (Bcl-2) BH4 domain has been reported to mediate the prosurvival activity of Bcl-2 in cancer; however, the involvement of the BH4 domain of Bcl-2 in the cisplatin resistance of ovarian carcinoma cells is not entirely clear. sapropterin 157-160 BCL2 apoptosis regulator Homo sapiens 33-38 29207009-3 2018 Recently, the B-cell lymphoma 2 (Bcl-2) BH4 domain has been reported to mediate the prosurvival activity of Bcl-2 in cancer; however, the involvement of the BH4 domain of Bcl-2 in the cisplatin resistance of ovarian carcinoma cells is not entirely clear. sapropterin 157-160 BCL2 apoptosis regulator Homo sapiens 108-113 29207009-3 2018 Recently, the B-cell lymphoma 2 (Bcl-2) BH4 domain has been reported to mediate the prosurvival activity of Bcl-2 in cancer; however, the involvement of the BH4 domain of Bcl-2 in the cisplatin resistance of ovarian carcinoma cells is not entirely clear. Cisplatin 184-193 BCL2 apoptosis regulator Homo sapiens 14-31 29207009-3 2018 Recently, the B-cell lymphoma 2 (Bcl-2) BH4 domain has been reported to mediate the prosurvival activity of Bcl-2 in cancer; however, the involvement of the BH4 domain of Bcl-2 in the cisplatin resistance of ovarian carcinoma cells is not entirely clear. Cisplatin 184-193 BCL2 apoptosis regulator Homo sapiens 33-38 29207009-3 2018 Recently, the B-cell lymphoma 2 (Bcl-2) BH4 domain has been reported to mediate the prosurvival activity of Bcl-2 in cancer; however, the involvement of the BH4 domain of Bcl-2 in the cisplatin resistance of ovarian carcinoma cells is not entirely clear. Cisplatin 184-193 BCL2 apoptosis regulator Homo sapiens 108-113 29207009-3 2018 Recently, the B-cell lymphoma 2 (Bcl-2) BH4 domain has been reported to mediate the prosurvival activity of Bcl-2 in cancer; however, the involvement of the BH4 domain of Bcl-2 in the cisplatin resistance of ovarian carcinoma cells is not entirely clear. Cisplatin 184-193 BCL2 apoptosis regulator Homo sapiens 108-113 29207009-6 2018 The present study demonstrated that TAT-fused inositol 1,4,5-trisphosphate receptor-derived peptide (TAT-IDPS), which targets the BH4 domain of Bcl-2, increased cisplatin-induced Ca2+ flux from the endoplasmic reticulum (ER) into the cytosol and mitochondria. sapropterin 130-133 BCL2 apoptosis regulator Homo sapiens 144-149 29207009-6 2018 The present study demonstrated that TAT-fused inositol 1,4,5-trisphosphate receptor-derived peptide (TAT-IDPS), which targets the BH4 domain of Bcl-2, increased cisplatin-induced Ca2+ flux from the endoplasmic reticulum (ER) into the cytosol and mitochondria. Cisplatin 161-170 BCL2 apoptosis regulator Homo sapiens 144-149 28949029-9 2018 Decreased expression of pro-apoptotic Bcl-2 family proteins (Noxa and Bid) and increased expression of anti-apoptotic proteins (Bcl-xL, Mcl-1 and XIAP) were observed after combined treatment with Fen and CdCl2 . Cadmium Chloride 204-209 BCL2 apoptosis regulator Homo sapiens 38-43 29257139-10 2018 Venetoclax, an oral BH3 mimetic inhibiting BCL2, showed single agent activity in MM with t(11;14), and is being studied in combination with bortezomib/dexamethasone. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 43-47 28691866-2 2018 The safety, tolerability, and pharmacodynamics of the selective Bcl-2 inhibitor venetoclax (ABT-199) were assessed in women with systemic lupus erythematosus. venetoclax 80-90 BCL2 apoptosis regulator Homo sapiens 64-69 28751770-3 2018 Preclinical and clinical studies indicate modest single-agent activity with selective BCL-2 inhibitors (for example, venetoclax). venetoclax 117-127 BCL2 apoptosis regulator Homo sapiens 86-91 28949029-9 2018 Decreased expression of pro-apoptotic Bcl-2 family proteins (Noxa and Bid) and increased expression of anti-apoptotic proteins (Bcl-xL, Mcl-1 and XIAP) were observed after combined treatment with Fen and CdCl2 . fenvalerate 196-199 BCL2 apoptosis regulator Homo sapiens 38-43 28500758-4 2018 Further co-culture of UCB MSCs have shown to induce anti-inflammatory cytokines like IL-4, IL-10 and TGF-beta and anti-apoptotic Bclxl/Bcl2 expression in the DPN sera stressed cells. NAD 158-161 BCL2 apoptosis regulator Homo sapiens 135-139 29208281-5 2018 Thanks to the cationic nanoparticle complex formation ability and high transfection efficiency to express Bcl-2 conversion proteins, PHB-PDMAEMA/PTX@polyplex could partially impair P-glycoprotein induced PTX efflux and activate the apoptotic function of previous prosurvival Bcl-2 protein. Paclitaxel 145-148 BCL2 apoptosis regulator Homo sapiens 106-111 29208281-5 2018 Thanks to the cationic nanoparticle complex formation ability and high transfection efficiency to express Bcl-2 conversion proteins, PHB-PDMAEMA/PTX@polyplex could partially impair P-glycoprotein induced PTX efflux and activate the apoptotic function of previous prosurvival Bcl-2 protein. Paclitaxel 145-148 BCL2 apoptosis regulator Homo sapiens 275-280 29208281-5 2018 Thanks to the cationic nanoparticle complex formation ability and high transfection efficiency to express Bcl-2 conversion proteins, PHB-PDMAEMA/PTX@polyplex could partially impair P-glycoprotein induced PTX efflux and activate the apoptotic function of previous prosurvival Bcl-2 protein. Paclitaxel 204-207 BCL2 apoptosis regulator Homo sapiens 106-111 29208281-5 2018 Thanks to the cationic nanoparticle complex formation ability and high transfection efficiency to express Bcl-2 conversion proteins, PHB-PDMAEMA/PTX@polyplex could partially impair P-glycoprotein induced PTX efflux and activate the apoptotic function of previous prosurvival Bcl-2 protein. Paclitaxel 204-207 BCL2 apoptosis regulator Homo sapiens 275-280 29251335-7 2018 It was observed that marmesin treatment triggered upregulation of Bax and downregulation of Bcl-2 causing significant increase in the Bax/Bcl-2 ratio, marmesin could also induce ROS mediated alterations in mitochondrial membrane potential. ros 178-181 BCL2 apoptosis regulator Homo sapiens 138-143 29022246-3 2018 In this study, we investigated the role of endogenous antioxidant alpha-lipoic acid (ALA) as ROSs scavenger in the OLGs loss and myelin degeneration during cuprizone (cup)-induced demyelination in the experimental model of MS. Our results have shown that ALA treatment significantly increased population of mature OLGs (MOG+ cells), as well as decreased oxidative stress (ROSs, COX-2 and PGE2) and apoptosis mediators (caspase-3 and Bax/Bcl2 ratio) in corpus callosum (CC). Thioctic Acid 85-88 BCL2 apoptosis regulator Homo sapiens 437-441 29257242-9 2018 However, the miR-138 inhibitor inhibited the effects induced by miR-138 mimic or A293 treatment, as demonstrated by a decrease in proliferation and MMP level in HPASMCs, accompanied by a decrease of Bcl-2 and an increase of caspase-3 expression levels, as well as ERK1/2 activation. mir-138 13-20 BCL2 apoptosis regulator Homo sapiens 199-204 29257242-9 2018 However, the miR-138 inhibitor inhibited the effects induced by miR-138 mimic or A293 treatment, as demonstrated by a decrease in proliferation and MMP level in HPASMCs, accompanied by a decrease of Bcl-2 and an increase of caspase-3 expression levels, as well as ERK1/2 activation. mir-138 64-71 BCL2 apoptosis regulator Homo sapiens 199-204 29434958-6 2018 The anticancer effects of HCPT were demonstrated to significantly activate the protein expression of p53, PARP-1 and cytochrome c, and suppress Bcl-2 protein expression and promote the activity of caspase-9 and caspase-3 in human osteosarcoma cells. 10-hydroxycamptothecin 26-30 BCL2 apoptosis regulator Homo sapiens 144-149 29434967-6 2018 Celastrol may also decrease the phosphorylation levels of signal transducer and activator of transcription 3 (STAT3) and the B cell lymphoma-2 (Bcl-2)/Bcl-2 associated C protein (Bax) ratio. celastrol 0-9 BCL2 apoptosis regulator Homo sapiens 125-142 29434967-6 2018 Celastrol may also decrease the phosphorylation levels of signal transducer and activator of transcription 3 (STAT3) and the B cell lymphoma-2 (Bcl-2)/Bcl-2 associated C protein (Bax) ratio. celastrol 0-9 BCL2 apoptosis regulator Homo sapiens 144-149 29434967-6 2018 Celastrol may also decrease the phosphorylation levels of signal transducer and activator of transcription 3 (STAT3) and the B cell lymphoma-2 (Bcl-2)/Bcl-2 associated C protein (Bax) ratio. celastrol 0-9 BCL2 apoptosis regulator Homo sapiens 151-156 29207064-8 2018 Quinalizarin induced apoptosis by upregulating the expression of B-cell lymphoma 2 (Bcl-2)-associated agonist of cell death, cleaved-caspase-3 and cleaved-poly (adenosine diphosphate-ribose) polymerase, and downregulating the expression of Bcl-2. 1,2,5,8-tetrahydroxy anthraquinone 0-12 BCL2 apoptosis regulator Homo sapiens 65-82 29207064-8 2018 Quinalizarin induced apoptosis by upregulating the expression of B-cell lymphoma 2 (Bcl-2)-associated agonist of cell death, cleaved-caspase-3 and cleaved-poly (adenosine diphosphate-ribose) polymerase, and downregulating the expression of Bcl-2. 1,2,5,8-tetrahydroxy anthraquinone 0-12 BCL2 apoptosis regulator Homo sapiens 84-89 29207064-8 2018 Quinalizarin induced apoptosis by upregulating the expression of B-cell lymphoma 2 (Bcl-2)-associated agonist of cell death, cleaved-caspase-3 and cleaved-poly (adenosine diphosphate-ribose) polymerase, and downregulating the expression of Bcl-2. 1,2,5,8-tetrahydroxy anthraquinone 0-12 BCL2 apoptosis regulator Homo sapiens 240-245 28412840-5 2018 In addition, further molecular mechanistic investigation demonstrated that cinobufagin significantly increased Bax expression, decreased Bcl-2 expression level and up-regulated the ratio of the pro-apoptosis/anti-apoptosis protein Bax/Bcl-2, which were demonstrated by RT-qPCR and western blot assays. cinobufagin 75-86 BCL2 apoptosis regulator Homo sapiens 137-142 28412840-5 2018 In addition, further molecular mechanistic investigation demonstrated that cinobufagin significantly increased Bax expression, decreased Bcl-2 expression level and up-regulated the ratio of the pro-apoptosis/anti-apoptosis protein Bax/Bcl-2, which were demonstrated by RT-qPCR and western blot assays. cinobufagin 75-86 BCL2 apoptosis regulator Homo sapiens 235-240 29434911-6 2018 The results of the present study demonstrated that Bcl-2-associated X protein translocated to the mitochondria from the cytosol following 3,28-di-(2-nitroxy-acetyl)-oxy-BT treatment. 3,28-di-(2-nitroxy-acetyl)-oxy-bt 138-171 BCL2 apoptosis regulator Homo sapiens 51-56 28947240-1 2018 ABT-263 (navitoclax), a Bcl-2 family protein inhibitor, was clinically tested as an anti-cancer agent. navitoclax 0-7 BCL2 apoptosis regulator Homo sapiens 24-29 29387107-7 2018 Western blot assay following treatment with nardosinen showed that the expression levels of the Bax were significantly up-regulated and the expression levels of the Bcl-2 were significantly down-regulated. nardosinen 44-54 BCL2 apoptosis regulator Homo sapiens 165-170 28947240-1 2018 ABT-263 (navitoclax), a Bcl-2 family protein inhibitor, was clinically tested as an anti-cancer agent. navitoclax 9-19 BCL2 apoptosis regulator Homo sapiens 24-29 29054700-0 2018 Rebamipide suppresses 5-fluorouracil-induced cell death via the activation of Akt/mTOR pathway and regulates the expression of Bcl-2 family proteins. rebamipide 0-10 BCL2 apoptosis regulator Homo sapiens 127-132 29054700-7 2018 In addition, rebamipide increased the levels of phosphorylated Akt and mTOR, enhanced the Bcl-2 and Bcl-xL expressions, and suppressed the expression of Bax and Bim. rebamipide 13-23 BCL2 apoptosis regulator Homo sapiens 90-95 28986287-9 2018 To account for coumestrol-mediated up-regulation of Bax and apoptosis induction, direct binding potential between coumestrol and Bax/Bcl-2 was studied using in silico molecular docking studies. Coumestrol 15-25 BCL2 apoptosis regulator Homo sapiens 133-138 29305864-7 2018 Fenofibrate also increased the expression of Bad and decreased the expression of Bcl-2 and Survivin. Fenofibrate 0-11 BCL2 apoptosis regulator Homo sapiens 81-86 28986287-9 2018 To account for coumestrol-mediated up-regulation of Bax and apoptosis induction, direct binding potential between coumestrol and Bax/Bcl-2 was studied using in silico molecular docking studies. Coumestrol 114-124 BCL2 apoptosis regulator Homo sapiens 133-138 28986287-10 2018 We propose that coumestrol directly enters cells and combines with Bax/Bcl-2 to alter their structures, thereby causing Bax binding to the outer mitochondrial membrane and Bcl-2 release from the mitochondria to initiate apoptosis. Coumestrol 16-26 BCL2 apoptosis regulator Homo sapiens 71-76 28986287-10 2018 We propose that coumestrol directly enters cells and combines with Bax/Bcl-2 to alter their structures, thereby causing Bax binding to the outer mitochondrial membrane and Bcl-2 release from the mitochondria to initiate apoptosis. Coumestrol 16-26 BCL2 apoptosis regulator Homo sapiens 172-177 30023766-0 2018 Total Synthesis of Desmethyl Jahanyne and Its Lipo-Tetrapeptide Conjugates Derived from Parent Skeleton as BCL-2-Mediated Apoptosis-Inducing Agents. desmethyl jahanyne 19-37 BCL2 apoptosis regulator Homo sapiens 107-112 29339518-5 2018 Critical to the design of effective inhibitors was our introduction of an all-hydrocarbon cross-link or "staple" that stabilizes alpha-helical structure, increases target binding affinity, and independently confers binding specificity for Mcl-1 over related Bcl-2 family paralogs. Hydrocarbons 78-89 BCL2 apoptosis regulator Homo sapiens 258-263 29054700-8 2018 This is in contrast to 5-FU-induced suppression of Akt and mTOR activation, Bcl-2 and Bcl-xL expressions, and the enhanced expression of Bax and Bim. Fluorouracil 23-27 BCL2 apoptosis regulator Homo sapiens 76-81 29386360-5 2018 In line with these findings, tigecycline and two related antibiotics, tetracycline and doxycycline, synergized with venetoclax in killing human MYC/BCL2 DHL cells. Tigecycline 29-40 BCL2 apoptosis regulator Homo sapiens 148-152 29386360-5 2018 In line with these findings, tigecycline and two related antibiotics, tetracycline and doxycycline, synergized with venetoclax in killing human MYC/BCL2 DHL cells. Tetracycline 70-82 BCL2 apoptosis regulator Homo sapiens 148-152 29386360-5 2018 In line with these findings, tigecycline and two related antibiotics, tetracycline and doxycycline, synergized with venetoclax in killing human MYC/BCL2 DHL cells. Doxycycline 87-98 BCL2 apoptosis regulator Homo sapiens 148-152 29386360-5 2018 In line with these findings, tigecycline and two related antibiotics, tetracycline and doxycycline, synergized with venetoclax in killing human MYC/BCL2 DHL cells. venetoclax 116-126 BCL2 apoptosis regulator Homo sapiens 148-152 29441020-5 2018 EDT also remarkably suppressed the levels of Bax and cleaved Caspase-3, and up-regulated the level of Bcl-2 in cardiac tissues from EDT-treated groups. eriodictyol 0-3 BCL2 apoptosis regulator Homo sapiens 102-107 29441020-5 2018 EDT also remarkably suppressed the levels of Bax and cleaved Caspase-3, and up-regulated the level of Bcl-2 in cardiac tissues from EDT-treated groups. eriodictyol 132-135 BCL2 apoptosis regulator Homo sapiens 102-107 29441065-5 2018 Mitochondrial apoptosis was also detected after PA treatment, indicated by a decrease in cytochrome c release, downregulation of Bcl-2, upregulation of Bax, and increased caspase-3 activity. Palmitates 48-50 BCL2 apoptosis regulator Homo sapiens 129-134 29362360-0 2018 Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad through Bcl-2-dependent attenuation of autophagy. Mitoxantrone 17-29 BCL2 apoptosis regulator Homo sapiens 89-94 29367738-3 2018 When HepG2 cells were treated with 400 muM oleic acid (OA), increased reticulophagy was induced 8 h after treatment, which correlated with an anti-apoptotic response as shown by the activation of the PI3K/AKT pathway, an increase in BCL-2 expression, and the downregulation of OA-induced lipotoxicity. Oleic Acid 43-53 BCL2 apoptosis regulator Homo sapiens 233-238 29225136-6 2018 The apoptotic properties of DMQA on THP-1 cells were characterized by change in nuclear morphology, DNA fragmentation, reduction of pro-caspases-3, 9, Bax/Bcl-2 levels, cleavage of poly (ADP-ribose) polymerase and cytosolic release of cytochrome c. N,N'-Dimethylquinacridone 28-32 BCL2 apoptosis regulator Homo sapiens 155-160 29370087-5 2018 BOS-102 could also induce apoptosis, including activating caspase-3 and poly (ADP-ribose) polymerase (PARP), increasing the Bax/Bcl-2 ratio, enhancing reactive oxygen species (ROS) generation, decreasing mitochondrial membrane potential (MMP, DeltaPsim), and leading cytochrome c release from mitochondria. BOS-102 0-7 BCL2 apoptosis regulator Homo sapiens 128-133 29362360-2 2018 Replication-selective oncolytic adenoviruses deleted in the functional Bcl-2 homologue E1B19K potently synergise with apoptosis-inducing chemotherapeutic drugs, including mitoxantrone for prostate cancer. Mitoxantrone 171-183 BCL2 apoptosis regulator Homo sapiens 71-76 29416349-0 2018 ROS-dependent Bax/Bcl2 and caspase 3 pathway-mediated apoptosis induced by zineb in human keratinocyte cells. ros 0-3 BCL2 apoptosis regulator Homo sapiens 18-22 29416349-0 2018 ROS-dependent Bax/Bcl2 and caspase 3 pathway-mediated apoptosis induced by zineb in human keratinocyte cells. Zineb 75-80 BCL2 apoptosis regulator Homo sapiens 18-22 29416349-7 2018 Zineb increased levels of Bax and caspase 3 and inhibited the level of Bcl2, which subsequently induced apoptosis via the Bax/Bcl2 and caspase pathway. Zineb 0-5 BCL2 apoptosis regulator Homo sapiens 71-75 29416349-7 2018 Zineb increased levels of Bax and caspase 3 and inhibited the level of Bcl2, which subsequently induced apoptosis via the Bax/Bcl2 and caspase pathway. Zineb 0-5 BCL2 apoptosis regulator Homo sapiens 126-130 29263137-8 2018 Using the signaling pathway inhibitor LY294002, we found that Bcl-2 expression and eNOS phosphorylation after Ninj1 blockade were regulated via PI3K/Akt signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 BCL2 apoptosis regulator Homo sapiens 62-67 29495168-12 2018 (4) Compared with the normal control group, Bcl-2 protein expression in PQ group was significantly decreased and BAX protein expression in PQ group was significantly increased (P<0.05) ; compared with PQ group, Bcl-2 protein expression in PQ+XBJ group was significantly increased, BAX protein expression in PQ+XBJ group was significantly decreased (P<0.05). Paraquat 72-74 BCL2 apoptosis regulator Homo sapiens 44-49 29352235-8 2018 In silico predictions by DR_MOMP revealed substantial differences in treatment responses of BCL(X)L, BCL2 or MCL1 inhibitors combinations with cisplatin that were successfully validated in cell lines. Cisplatin 143-152 BCL2 apoptosis regulator Homo sapiens 101-105 29495168-12 2018 (4) Compared with the normal control group, Bcl-2 protein expression in PQ group was significantly decreased and BAX protein expression in PQ group was significantly increased (P<0.05) ; compared with PQ group, Bcl-2 protein expression in PQ+XBJ group was significantly increased, BAX protein expression in PQ+XBJ group was significantly decreased (P<0.05). Paraquat 139-141 BCL2 apoptosis regulator Homo sapiens 214-219 29495168-12 2018 (4) Compared with the normal control group, Bcl-2 protein expression in PQ group was significantly decreased and BAX protein expression in PQ group was significantly increased (P<0.05) ; compared with PQ group, Bcl-2 protein expression in PQ+XBJ group was significantly increased, BAX protein expression in PQ+XBJ group was significantly decreased (P<0.05). Paraquat 139-141 BCL2 apoptosis regulator Homo sapiens 214-219 29495168-12 2018 (4) Compared with the normal control group, Bcl-2 protein expression in PQ group was significantly decreased and BAX protein expression in PQ group was significantly increased (P<0.05) ; compared with PQ group, Bcl-2 protein expression in PQ+XBJ group was significantly increased, BAX protein expression in PQ+XBJ group was significantly decreased (P<0.05). pq+xbj 242-248 BCL2 apoptosis regulator Homo sapiens 214-219 29118061-2 2018 Despite notable advances in SCLC genomics, new therapies remain elusive, largely due to a lack of druggable targets.Experimental Design: We used a high-throughput drug screen to identify a venetoclax-sensitive SCLC subpopulation and validated the findings with multiple patient-derived xenografts of SCLC.Results: Our drug screen consisting of a very large collection of cell lines demonstrated that venetoclax, an FDA-approved BCL-2 inhibitor, was found to be active in a substantial fraction of SCLC cell lines. venetoclax 189-199 BCL2 apoptosis regulator Homo sapiens 428-433 29348439-7 2018 Indeed, combined inhibition of the anti-apoptotic BCL-2 repertoire with BH3-mimetics, OXPHOS, and oncogenic MAPK signaling induces fulminant apoptosis and eliminates clonogenic survival. BH 3 72-75 BCL2 apoptosis regulator Homo sapiens 50-55 29229225-0 2018 Design, synthesis and pharmacological evaluation of new acyl sulfonamides as potent and selective Bcl-2 inhibitors. acyl sulfonamides 56-73 BCL2 apoptosis regulator Homo sapiens 98-103 29229225-2 2018 Herein, we report a different structural modification approach on ABT-263 by merging the piperazinyl-phenyl fragment into a bicyclic framework leading to a series of novel analogues, among which tetrahydroisoquinoline 13 was nearly equally potent against Bcl-2 as ABT-263. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 66-69 BCL2 apoptosis regulator Homo sapiens 255-260 29323103-6 2018 We demonstrated that oridonin induced mitochondrial-mediated apoptosis by increasing Bax/Bcl-2 ratio, loss of mitochondrial membrane potential (MMP), triggering reactive oxygen species (ROS) generation and activating caspase-3 and caspase-9 cleavage in MG-63 and HOS cells. oridonin 21-29 BCL2 apoptosis regulator Homo sapiens 89-94 29229225-3 2018 Further SAR in the P4-interaction pocket affored the difluoroazetidine substituted analogue 55, which retained good Bcl-2 activity with improved Bcl-2/Bcl-xL selectivity. difluoroazetidine 53-70 BCL2 apoptosis regulator Homo sapiens 116-121 29229225-3 2018 Further SAR in the P4-interaction pocket affored the difluoroazetidine substituted analogue 55, which retained good Bcl-2 activity with improved Bcl-2/Bcl-xL selectivity. difluoroazetidine 53-70 BCL2 apoptosis regulator Homo sapiens 145-150 29331104-8 2018 H2O2 challenge induced massive MSC cell death along with reduction of expression of proliferation marker Ki67 and survival-related genes Bcl-2 and Survivin. Hydrogen Peroxide 0-4 BCL2 apoptosis regulator Homo sapiens 137-142 29351194-0 2018 Involvement of Bax and Bcl-2 in Induction of Apoptosis by Essential Oils of Three Lebanese Salvia Species in Human Prostate Cancer Cells. Oils, Volatile 58-72 BCL2 apoptosis regulator Homo sapiens 23-28 29433671-9 2018 Both the ROS-p38-p53 and ER stress-mediated pathway induced the mitochondrial apoptotic pathway by attenuating Bcl-2 expression and upregulating BAX. Reactive Oxygen Species 9-12 BCL2 apoptosis regulator Homo sapiens 111-116 29108775-3 2018 SK-N-SH cell treatment with a lethal concentration of PQ facilitated ROS production within 6 h. The treatment also promoted formation of 8-hydroxy-deoxyguanosine, p53 activation, elevation of Bax/Bcl-2 ratio, lowering of mitochondrial membrane potential, and resultant activation of caspase-9 and caspase-3, inferring that ROS production, DNA damage and mitochondrial dysfunction are crucial processes of the PQ-triggered SK-N-SH cell apoptosis. sk-n 0-4 BCL2 apoptosis regulator Homo sapiens 196-201 29546056-11 2018 The present study showed that elevated ROS levels served as an inhibition on Bcl-2 activity that is at least in part responsible for apoptosis. ros 39-42 BCL2 apoptosis regulator Homo sapiens 77-82 29021634-5 2018 RESULTS: The results have shown that SRM 2786 induces cell damage and apoptosis of 16HBE cells as demonstrated by significant decrease in expression of Bcl-2 and increase in expression of Bax. srm 2786 37-45 BCL2 apoptosis regulator Homo sapiens 152-157 29108775-3 2018 SK-N-SH cell treatment with a lethal concentration of PQ facilitated ROS production within 6 h. The treatment also promoted formation of 8-hydroxy-deoxyguanosine, p53 activation, elevation of Bax/Bcl-2 ratio, lowering of mitochondrial membrane potential, and resultant activation of caspase-9 and caspase-3, inferring that ROS production, DNA damage and mitochondrial dysfunction are crucial processes of the PQ-triggered SK-N-SH cell apoptosis. 9,10-phenanthrenequinone 54-56 BCL2 apoptosis regulator Homo sapiens 196-201 29298347-1 2018 The BH3-only apoptosis agonists BAD and NOXA target BCL-2 and MCL-1 respectively and co-operate to induce apoptosis. BH 3 4-7 BCL2 apoptosis regulator Homo sapiens 52-57 29174417-8 2018 Quantitative PCR results of MDA-MB-231 treated with asaricin (1) and isoasarone (2) showed altered expression of Bcl-2: Bax level. myristicin 52-60 BCL2 apoptosis regulator Homo sapiens 113-118 29174417-8 2018 Quantitative PCR results of MDA-MB-231 treated with asaricin (1) and isoasarone (2) showed altered expression of Bcl-2: Bax level. asarone 69-79 BCL2 apoptosis regulator Homo sapiens 113-118 29155028-9 2018 COS treatment promoted mitosis, late stage apoptosis and S cell cycle arrest in HCT116 cells, and enhanced the mRNA expression of BAK and reduce BCL-2 and BCL-xL. carbonyl sulfide 0-3 BCL2 apoptosis regulator Homo sapiens 145-150 29298347-8 2018 In conclusion, dynamic BH3 profiling is a useful mechanism-based tool for understanding and predicting co-operative lethality between drugs sensitising to BCL-2 antagonism and drugs sensitising to MCL-1 antagonism. BH 3 23-26 BCL2 apoptosis regulator Homo sapiens 155-160 30081791-17 2018 Pyrogallol induced apoptosis by simultaneous down-regulation of Bcl-2 and up-regulation of BAX and cytochrome c. Pyrogallol 0-10 BCL2 apoptosis regulator Homo sapiens 64-69 29298347-9 2018 A plethora of agents sensitised cells to BAD-BH3-mediated mitochondrial outer membrane permeabilisation in the dynamic BH3 profiling assay and this was associated with effective co-operation with the BCL-2 inhibitory compounds ABT-199 or JQ1. BH 3 45-48 BCL2 apoptosis regulator Homo sapiens 200-205 29298347-9 2018 A plethora of agents sensitised cells to BAD-BH3-mediated mitochondrial outer membrane permeabilisation in the dynamic BH3 profiling assay and this was associated with effective co-operation with the BCL-2 inhibitory compounds ABT-199 or JQ1. BH 3 119-122 BCL2 apoptosis regulator Homo sapiens 200-205 29298347-9 2018 A plethora of agents sensitised cells to BAD-BH3-mediated mitochondrial outer membrane permeabilisation in the dynamic BH3 profiling assay and this was associated with effective co-operation with the BCL-2 inhibitory compounds ABT-199 or JQ1. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 227-230 BCL2 apoptosis regulator Homo sapiens 200-205 28745237-8 2018 Pro-apoptotic potential of anethole was accompanied by generation of ROS, permeabilization of the mitochondrial and lysosomal membranes, activation of caspase-3 and -9, DNA damage, PARP cleavage and induction of Bax/Bcl-2 protein ratio. anethole 27-35 BCL2 apoptosis regulator Homo sapiens 216-221 28429287-5 2018 The results revealed that overexpressed SelX reduced the H2O2-induced intracellular ROS generation, inhibited the H2O2-induced upregulation of Bax and downregulation of Bcl-2, and increased the mRNA and protein ratio of Bcl-2/Bax. Hydrogen Peroxide 114-118 BCL2 apoptosis regulator Homo sapiens 169-174 28918503-5 2018 CoQ0 treatment induced apoptosis, which was associated with DNA fragmentation, cytochrome c release, caspase-3 and PARP activation, and Bax/Bcl-2 dysregulation. ubiquinone-O 0-4 BCL2 apoptosis regulator Homo sapiens 140-145 28429287-5 2018 The results revealed that overexpressed SelX reduced the H2O2-induced intracellular ROS generation, inhibited the H2O2-induced upregulation of Bax and downregulation of Bcl-2, and increased the mRNA and protein ratio of Bcl-2/Bax. Hydrogen Peroxide 114-118 BCL2 apoptosis regulator Homo sapiens 220-225 28948407-3 2018 Moreover, 10-chlorocanthin-6-one induced apoptosis through the activation of poly(ADP-ribose) polymerase and caspase-3 cleavage, upregulation of Bcl-2, and downregulation of Bim, x-linked inhibitor of apoptosis protein (XIAP), and survivin in HO8910PM cells. 10-chlorocanthin-6-one 10-32 BCL2 apoptosis regulator Homo sapiens 145-150 29091869-0 2018 Galangin (GG) combined with cisplatin (DDP) to suppress human lung cancer by inhibition of STAT3-regulated NF-kappaB and Bcl-2/Bax signaling pathways. Cisplatin 28-37 BCL2 apoptosis regulator Homo sapiens 121-126 29136958-7 2018 Cellular function of miR-182-5p indicated that miR-182-5p suppression in AML cells could decrease cell proliferation and reverse cisplatin (DDP) resistance via targeting BCL2L12 and BCL2 expression. Cisplatin 129-138 BCL2 apoptosis regulator Homo sapiens 170-174 30175773-5 2018 Piceatannol also resulted in a significant increase in mitochondrial depolarization, along with a decline in Bcl-2 expression, which was not restored by NAC. 3,3',4,5'-tetrahydroxystilbene 0-11 BCL2 apoptosis regulator Homo sapiens 109-114 30175773-6 2018 Conversely, ectopic Bcl-2 overexpression moderately inhibited piceatannol-induced apoptosis. 3,3',4,5'-tetrahydroxystilbene 62-73 BCL2 apoptosis regulator Homo sapiens 20-25 30175779-2 2018 NuBCP-9, a peptide that induces apoptosis in B-cell lymphoma 2 (Bcl-2)-expressing cancer cells, has been reported to promote the uptake and non-specific cytotoxicity of R8, also called octaarginine. octaarginine 185-197 BCL2 apoptosis regulator Homo sapiens 64-69 28948407-6 2018 The underlying molecular mechanisms of 10-chlorocanthin-6-one include activation of the Bim-mediated mitochondrial apoptotic pathway via upregulation of Bim and downregulation of Bcl-2, XIAP, and survivin. 10-chlorocanthin-6-one 39-61 BCL2 apoptosis regulator Homo sapiens 179-184 29914005-13 2018 MiR-29a down-regulation is correlated with drug resistance of nasopharyngeal carcinoma cell line CNE-1 and MiR-29a up-regulation decreases Taxol resistance of nasopharyngeal carcinoma CNE-1 cells possibly via inhibiting STAT3 and Bcl-2 expression. Paclitaxel 139-144 BCL2 apoptosis regulator Homo sapiens 230-235 27523575-0 2018 The selectivity of Marinopyrrole A to induce apoptosis in MCL1high BCL2low expressing myeloma cells is related to its ability to impair protein translation. marinopyrrole A 19-34 BCL2 apoptosis regulator Homo sapiens 67-71 28947136-1 2018 BH3 mimetics are a promising new class of anticancer agents that inhibit antiapoptotic BCL-2 proteins. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 87-92 28947136-2 2018 Here, we report that BH3 mimetics selectively targeting BCL-xL, BCL-2 or MCL-1 (i.e. A-1331852, ABT-199, A-1210477) act in concert with multiple chemotherapeutic agents (i.e. vincristine (VCR), etoposide (ETO), doxorubicin, actinomycin D and cyclophosphamide) to induce apoptosis in rhabdomyosarcoma (RMS) cells. BH 3 21-24 BCL2 apoptosis regulator Homo sapiens 64-69 30355923-13 2018 In addition, Erinacine was found to decrease the mitochondrial membrane potential, expression of PI3K, Akt, GSK-3beta, CyclinD1, Vimentin, beta-catenin, and Bcl-2, cell proliferation, colony formation ability, migration, invasion, and xenograft tumor size, while E-cadherin, Bax, and caspase-9 expression, and cell apoptosis were elevated in a dose-dependent manner. erinacine S 13-22 BCL2 apoptosis regulator Homo sapiens 157-162 30600718-8 2018 The results showed lower cell viability rate, higher apoptosis ratio, higher BAX gene, and lower KI67 and BCL-2 genes" expression in cells exposed to MVs in combination with ATO compared to cells treated with each agent alone and non-treated control. Arsenic Trioxide 174-177 BCL2 apoptosis regulator Homo sapiens 106-111 29742265-4 2018 Results revealed that urolithin A induced cytotoxicity in HepG2.2.15 cells, which was accompanied by the cleavage of caspase-3 protein and down-regulation of Bcl-2/Bax ratio. 3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one 22-33 BCL2 apoptosis regulator Homo sapiens 158-163 29562495-11 2018 Compared to control group, sclareol significantly depressed mitochondrial membrane potential of MG63 cells, increased the expression of cytochrome c and Bax, but decreased Bcl-2 expression. sclareol 27-35 BCL2 apoptosis regulator Homo sapiens 172-177 29995568-7 2018 Furthermore, ALL cells pretreated with PCB retained susceptibility to the Bcl-2/Bcl-xL inhibitor ABT-263, indicating that downstream apoptotic signaling was unaffected. palbociclib 39-42 BCL2 apoptosis regulator Homo sapiens 74-79 28984869-8 2018 Very recently, a specific BCL2 inhibitor ABT-199 (Venetoclax) was developed and approved by FDA for CLL treatment. venetoclax 41-48 BCL2 apoptosis regulator Homo sapiens 26-30 28984869-8 2018 Very recently, a specific BCL2 inhibitor ABT-199 (Venetoclax) was developed and approved by FDA for CLL treatment. venetoclax 50-60 BCL2 apoptosis regulator Homo sapiens 26-30 29099483-4 2018 Successful clinical trials of venetoclax/ABT-199, a specific inhibitor of BCL-2, have led to its approval for a refractory form of chronic lymphocytic leukaemia and to scores of on-going trials for other malignancies. venetoclax/abt-199 30-48 BCL2 apoptosis regulator Homo sapiens 74-79 29099483-5 2018 Furthermore, encouraging preclinical studies of BH3 mimetics that target other BCL-2 pro-survival members, particularly MCL-1, offer promise for cancers resistant to venetoclax. BH 3 48-51 BCL2 apoptosis regulator Homo sapiens 79-84 29099483-6 2018 This review sketches the impact of the BCL-2 family on cancer development and therapy, describes how interactions of family members trigger apoptosis and discusses the potential of BH3 mimetic drugs to advance cancer therapy. BH 3 181-184 BCL2 apoptosis regulator Homo sapiens 39-44 30231236-15 2018 However, this study showed that ghrelin decreased the intracellular NO production (38.9%, P< 0.05), protein S-nitrosylation levels (33.5%, P< 0.05), Bax protein expression (70.2%, P< 0.05), whereas increasing Bcl-2 protein expression (14.1%, P< 0.05) and mitochondrial transmembrane potential ( PsiM) (20.7%, P< 0.05) in the presence of LPS. Ghrelin 32-39 BCL2 apoptosis regulator Homo sapiens 218-223 29316551-12 2018 A combination of radiation and chloroquine enhanced the apoptosis rate of EJ and T24 cells and down-regulated the expression of Bcl-2 while up-regulating the expression of caspase-3. Chloroquine 31-42 BCL2 apoptosis regulator Homo sapiens 128-133 29399562-5 2018 In addition, mRNA expression of pro-apoptotic genes, p21 and Bax, was decreased and of anti-apoptotic genes, Bcl-2 and Bcl-xl, was increased with metformin treatment compared to QUIN-induced cells. Metformin 146-155 BCL2 apoptosis regulator Homo sapiens 109-114 29669353-16 2018 Moreover, cinobufagin treatment increased the expression of the pro-apoptotic protein Bax and decreased the expression of the anti-apoptitic protein Bcl-2, thus altering the ratio of Bax to Bcl-2. cinobufagin 10-21 BCL2 apoptosis regulator Homo sapiens 149-154 29669353-16 2018 Moreover, cinobufagin treatment increased the expression of the pro-apoptotic protein Bax and decreased the expression of the anti-apoptitic protein Bcl-2, thus altering the ratio of Bax to Bcl-2. cinobufagin 10-21 BCL2 apoptosis regulator Homo sapiens 190-195 29913449-11 2018 MiR-98 targets at the signal transducer and activator of the transcription 3 (STAT3), and thus aggravated H2O2-induced the reduction of Bcl-2 protein. Hydrogen Peroxide 106-110 BCL2 apoptosis regulator Homo sapiens 136-141 30731458-8 2018 BCL2 expression was downregulated by ginsenoside-Rg5 treatment via inactivating the AKT signaling pathway. Ginsenosides 37-48 BCL2 apoptosis regulator Homo sapiens 0-4 30731458-9 2018 BCL2 overexpression completely eliminated the inhibitory effect of ginsenoside-Rg5 on cancer cell viability. ginsenoside Rg5 67-82 BCL2 apoptosis regulator Homo sapiens 0-4 30731458-10 2018 CONCLUSION: Ginsenoside-Rg5 inhibits cell proliferation and induces apoptosis in retinoblastoma cells by inactivating the AKT signaling pathway, thereby downregulating BCL2 expression. Ginsenosides 12-23 BCL2 apoptosis regulator Homo sapiens 168-172 30659540-8 2018 The authors have developed and tested successfully, several series of indole pharmacore containing inhibitors for Bcl-2 and Bcl-xL proteins based on the homology modeling, docking and suitable biochemical and apoptosis assays. indole 70-76 BCL2 apoptosis regulator Homo sapiens 114-119 30417780-6 2018 The imbalance in favor of Bcl2 promotes mitochondria functions and blocks in turn caspases activation while at the same time, ODN also activates the endogenous antioxidant system i.e. glutathione biosynthesis, and expression and activities of antioxidant enzymes. Glutathione 184-195 BCL2 apoptosis regulator Homo sapiens 26-30 29216561-6 2018 AQ-S-S-(Ahx)6MBP85-99 could bind to HLA II DRB1*-1501 antigen with reasonable affinity (IC50 of 56 nM) The compound was localized to the nucleus of Jurkat cells (an immortalized line of human T lymphocytes) 10 min after its addition to the medium and resulted in lowered Bcl-2 levels (apoptosis). aq-s-s 0-6 BCL2 apoptosis regulator Homo sapiens 271-276 30417784-9 2018 On the other hand, treatment of SK-BR-3 cells with any of these vinca alkaloids led to an increase in the BAX/BCL2 mRNA ratio, implying the activation of the intrinsic apoptotic pathway. Vinca Alkaloids 64-79 BCL2 apoptosis regulator Homo sapiens 110-114 30417787-3 2018 OBJECTIVE: The purpose of this study was to assess the molecular effects of doxorubicin (a 14-OH derivative of the natural product daunorubicin) and common chemotherapeutic drugs (used in the clinical practice to treat CRC) on the expression of the most prominent members of the BCL2 family, namely BCL2, BAX, BCLX, and MCL1. Doxorubicin 76-87 BCL2 apoptosis regulator Homo sapiens 279-283 30417787-3 2018 OBJECTIVE: The purpose of this study was to assess the molecular effects of doxorubicin (a 14-OH derivative of the natural product daunorubicin) and common chemotherapeutic drugs (used in the clinical practice to treat CRC) on the expression of the most prominent members of the BCL2 family, namely BCL2, BAX, BCLX, and MCL1. Doxorubicin 76-87 BCL2 apoptosis regulator Homo sapiens 299-303 28843007-0 2018 Bcl-2 protects TK6 cells against hydroquinone-induced apoptosis through PARP-1 cytoplasm translocation and stabilizing mitochondrial membrane potential. hydroquinone 33-45 BCL2 apoptosis regulator Homo sapiens 0-5 28843007-2 2018 This study aimed to investigate the role of Bcl-2 in controlling the mitochondrial pathway of apoptosis during hydroquinone (HQ)-induced TK6 cytotoxicity. hydroquinone 111-123 BCL2 apoptosis regulator Homo sapiens 44-49 28843007-5 2018 Inhibition of Bcl-2 using the BH3 mimetic, ABT-737, suppressed the PARP-1 nuclear to cytoplasm translocation and sensitized TK6 cells to HQ-induced apoptosis through depolarization of the MMP. BH 3 30-33 BCL2 apoptosis regulator Homo sapiens 14-19 28843007-5 2018 Inhibition of Bcl-2 using the BH3 mimetic, ABT-737, suppressed the PARP-1 nuclear to cytoplasm translocation and sensitized TK6 cells to HQ-induced apoptosis through depolarization of the MMP. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 43-46 BCL2 apoptosis regulator Homo sapiens 14-19 28767174-8 2018 We found that UA inhibited collagen synthesis and induced cell apoptosis in HSFBs, evidenced by the deregulated expression of Bim, Bcl-2 and Cyto C. Furthermore, we demonstrated that UA induced autophagy and inactivation of autophagy promoted UA-induced apoptosis and collagen synthesis inhibition in HSFBs. ursolic acid 14-16 BCL2 apoptosis regulator Homo sapiens 131-136 28767174-8 2018 We found that UA inhibited collagen synthesis and induced cell apoptosis in HSFBs, evidenced by the deregulated expression of Bim, Bcl-2 and Cyto C. Furthermore, we demonstrated that UA induced autophagy and inactivation of autophagy promoted UA-induced apoptosis and collagen synthesis inhibition in HSFBs. ursolic acid 183-185 BCL2 apoptosis regulator Homo sapiens 131-136 28767174-8 2018 We found that UA inhibited collagen synthesis and induced cell apoptosis in HSFBs, evidenced by the deregulated expression of Bim, Bcl-2 and Cyto C. Furthermore, we demonstrated that UA induced autophagy and inactivation of autophagy promoted UA-induced apoptosis and collagen synthesis inhibition in HSFBs. ursolic acid 183-185 BCL2 apoptosis regulator Homo sapiens 131-136 29131545-0 2018 A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function. Sapropterin 85-88 BCL2 apoptosis regulator Homo sapiens 55-60 28767174-10 2018 Overexpression of Bcl-2 prevents UA-induced autophagy, Beclin-1 upregulation, apoptosis and collagen synthesis inhibition in HSFBs. ursolic acid 33-35 BCL2 apoptosis regulator Homo sapiens 18-23 29131545-3 2018 The involvement of the BH4 domain in Bcl-2"s antiapoptotic functions has been proposed based on Gly-based substitutions of the Ile14/Val15 amino acids, two hydrophobic residues located in the center of Bcl-2"s BH4 domain. Sapropterin 23-26 BCL2 apoptosis regulator Homo sapiens 37-42 29131545-3 2018 The involvement of the BH4 domain in Bcl-2"s antiapoptotic functions has been proposed based on Gly-based substitutions of the Ile14/Val15 amino acids, two hydrophobic residues located in the center of Bcl-2"s BH4 domain. Sapropterin 23-26 BCL2 apoptosis regulator Homo sapiens 202-207 29131545-3 2018 The involvement of the BH4 domain in Bcl-2"s antiapoptotic functions has been proposed based on Gly-based substitutions of the Ile14/Val15 amino acids, two hydrophobic residues located in the center of Bcl-2"s BH4 domain. Glycine 96-99 BCL2 apoptosis regulator Homo sapiens 37-42 29434685-10 2018 The reversal effects of SAL on H/R-induced alternation of B-cell lymphoma (Bcl-2) and Bcl-2 associated X protein expression were also attenuated by sirtinol. rhodioloside 24-27 BCL2 apoptosis regulator Homo sapiens 75-80 29131545-3 2018 The involvement of the BH4 domain in Bcl-2"s antiapoptotic functions has been proposed based on Gly-based substitutions of the Ile14/Val15 amino acids, two hydrophobic residues located in the center of Bcl-2"s BH4 domain. Sapropterin 210-213 BCL2 apoptosis regulator Homo sapiens 37-42 29434685-10 2018 The reversal effects of SAL on H/R-induced alternation of B-cell lymphoma (Bcl-2) and Bcl-2 associated X protein expression were also attenuated by sirtinol. rhodioloside 24-27 BCL2 apoptosis regulator Homo sapiens 86-91 30739528-6 2018 Chemical hypoxia caused by CoCl2 resulted in high LDH activity, increased migration and invasion, decreased E-cadherin/N-cadherin ratio, enhanced EMT phenotype, higher Bcl-2/Bax ratio and elevated GRP78 expression. cobaltous chloride 27-32 BCL2 apoptosis regulator Homo sapiens 168-173 29131545-3 2018 The involvement of the BH4 domain in Bcl-2"s antiapoptotic functions has been proposed based on Gly-based substitutions of the Ile14/Val15 amino acids, two hydrophobic residues located in the center of Bcl-2"s BH4 domain. Sapropterin 210-213 BCL2 apoptosis regulator Homo sapiens 202-207 29434685-10 2018 The reversal effects of SAL on H/R-induced alternation of B-cell lymphoma (Bcl-2) and Bcl-2 associated X protein expression were also attenuated by sirtinol. r 33-34 BCL2 apoptosis regulator Homo sapiens 75-80 29131545-8 2018 Therefore, Bcl-2 structure/function studies require pre-emptive and reliable determination of protein stability upon introduction of point mutations at the level of the BH4 domain. Sapropterin 169-172 BCL2 apoptosis regulator Homo sapiens 11-16 29434685-10 2018 The reversal effects of SAL on H/R-induced alternation of B-cell lymphoma (Bcl-2) and Bcl-2 associated X protein expression were also attenuated by sirtinol. r 33-34 BCL2 apoptosis regulator Homo sapiens 86-91 29434685-10 2018 The reversal effects of SAL on H/R-induced alternation of B-cell lymphoma (Bcl-2) and Bcl-2 associated X protein expression were also attenuated by sirtinol. sirtinol 148-156 BCL2 apoptosis regulator Homo sapiens 86-91 29217266-6 2018 Further, cellular ROS levels increased in LNCaP cells treated with auriculasin and blocking ROS accumulation with ROS scavengers resulted in inhibition of auriculasin-induced PARP cleavage, AIF increase, upregulation of Bax/Bcl-2 ratio, and decrease in AKT/mTOR phosphorylation. Reactive Oxygen Species 92-95 BCL2 apoptosis regulator Homo sapiens 224-229 29227976-1 2018 OBJECTIVE: To investigate whether ulipristal acetate (UPA) treatment modifies the expression of progesterone receptor (PR), its nuclear cofactors steroid receptor coactivator-1 (SRC1) and nuclear corepressor-1 (NCoR1), prosurvival factor B-cell lymphoma 2 (Bcl-2), and Akt in uterine myomas. ulipristal acetate 34-52 BCL2 apoptosis regulator Homo sapiens 238-255 29227976-1 2018 OBJECTIVE: To investigate whether ulipristal acetate (UPA) treatment modifies the expression of progesterone receptor (PR), its nuclear cofactors steroid receptor coactivator-1 (SRC1) and nuclear corepressor-1 (NCoR1), prosurvival factor B-cell lymphoma 2 (Bcl-2), and Akt in uterine myomas. ulipristal acetate 34-52 BCL2 apoptosis regulator Homo sapiens 257-262 29138795-6 2018 Hesperidin was identified to induce A549 cell apoptosis by downregulating the levels of B-cell lymphoma-2 (Bcl-2) and Bcl extra large protein and simultaneously upregulating the levels of Bcl-2-associated X protein, BH3 interacting-domain death agonist (Bid), tBid, cleaved caspase-9, cleaved caspase-3 and cleaved poly(adenosine diphosphate ribose)polymerase. Hesperidin 0-10 BCL2 apoptosis regulator Homo sapiens 88-105 29138795-6 2018 Hesperidin was identified to induce A549 cell apoptosis by downregulating the levels of B-cell lymphoma-2 (Bcl-2) and Bcl extra large protein and simultaneously upregulating the levels of Bcl-2-associated X protein, BH3 interacting-domain death agonist (Bid), tBid, cleaved caspase-9, cleaved caspase-3 and cleaved poly(adenosine diphosphate ribose)polymerase. Hesperidin 0-10 BCL2 apoptosis regulator Homo sapiens 107-112 29138795-6 2018 Hesperidin was identified to induce A549 cell apoptosis by downregulating the levels of B-cell lymphoma-2 (Bcl-2) and Bcl extra large protein and simultaneously upregulating the levels of Bcl-2-associated X protein, BH3 interacting-domain death agonist (Bid), tBid, cleaved caspase-9, cleaved caspase-3 and cleaved poly(adenosine diphosphate ribose)polymerase. Hesperidin 0-10 BCL2 apoptosis regulator Homo sapiens 188-193 28930531-4 2018 Moreover, ILF attenuated rotenone induced toxicity by down-regulating Bax, caspases-3, 6, 8 and 9 expression and up-regulating of Bcl-2 expression. Rotenone 25-33 BCL2 apoptosis regulator Homo sapiens 131-136 28905994-8 2018 Moreover, miR-324-5p potentiated the anti-MM efficacy of bortezomib through regulating the activities of multidrug-resistance proteins and the expression of Bcl-2 family genes. Bortezomib 57-67 BCL2 apoptosis regulator Homo sapiens 157-162 31938109-7 2018 We also found that the expression of Bcl-2 was increased, and the levels of cleaved caspase-9 and cleaved PARP were reduced after gamma-radiation combined with cisplatin treatment of HeLa-siIER5 cells. Cisplatin 160-169 BCL2 apoptosis regulator Homo sapiens 37-42 29217266-6 2018 Further, cellular ROS levels increased in LNCaP cells treated with auriculasin and blocking ROS accumulation with ROS scavengers resulted in inhibition of auriculasin-induced PARP cleavage, AIF increase, upregulation of Bax/Bcl-2 ratio, and decrease in AKT/mTOR phosphorylation. Reactive Oxygen Species 92-95 BCL2 apoptosis regulator Homo sapiens 224-229 29197725-2 2018 ABT-199 is one of the most promising selective Bcl-2 inhibitors, and A-1155463 selectively inhibits Bcl-XL. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 47-52 29552785-9 2018 Additionally, sugiol caused cell cycle arrest in G2/M phase of the cell cycle and upregulated the expression of Bax, with concomitant downregulation of Bcl-2 expression in comparison to the untreated cells. sugiol 14-20 BCL2 apoptosis regulator Homo sapiens 152-157 29552788-12 2018 Lactucopicrin could upregulate the expression of Bax which was associated with concomitant downregulation of Bcl-2 expression. intybin 0-13 BCL2 apoptosis regulator Homo sapiens 109-114 29628632-12 2018 Conclusions: Iodine therapy reduced expression of Bcl-2 and a significant expression of Bax and finally increased the ratio of Bax/Bcl-2. Iodine 13-19 BCL2 apoptosis regulator Homo sapiens 50-55 29628632-12 2018 Conclusions: Iodine therapy reduced expression of Bcl-2 and a significant expression of Bax and finally increased the ratio of Bax/Bcl-2. Iodine 13-19 BCL2 apoptosis regulator Homo sapiens 131-136 29197725-5 2018 We confirmed that ASP103 of Bcl-2 is a key residue and that hydrogen bonding between ASP103 and ABT-199 confers the Bcl-2 selectivity of this inhibitor. Hydrogen 60-68 BCL2 apoptosis regulator Homo sapiens 116-121 30148119-8 2018 Moreover, ACH caused increase in the perinuclear localization of estrogen receptor alpha in MCF-7 breast cancer cells and increase in the mitochondrial Bcl-2 protein, possibly affecting receptors-mediated mitochondrial actions and mitochondrial-dependent apoptosis. aluminum chlorhydrate 10-13 BCL2 apoptosis regulator Homo sapiens 152-157 29197725-5 2018 We confirmed that ASP103 of Bcl-2 is a key residue and that hydrogen bonding between ASP103 and ABT-199 confers the Bcl-2 selectivity of this inhibitor. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 96-99 BCL2 apoptosis regulator Homo sapiens 28-33 29197725-5 2018 We confirmed that ASP103 of Bcl-2 is a key residue and that hydrogen bonding between ASP103 and ABT-199 confers the Bcl-2 selectivity of this inhibitor. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 96-99 BCL2 apoptosis regulator Homo sapiens 116-121 29435156-1 2018 Cis-trimethoxy resveratrol (cis-3M-RES) induced dose-dependent cytotoxicity and apoptotic DNA fragmentation in Jurkat T cell clones (JT/Neo); however, it induced only cytostasis in BCL-2-overexpressing cells (JT/BCL-2). cis-trimethoxy resveratrol 0-26 BCL2 apoptosis regulator Homo sapiens 181-186 28629311-6 2018 Moreover, nitidine chloride downregulated Cyclin B1, CDK1 and Bcl-2, upregulated p27 and Bax, inactivated PARP, activated Caspase-3 in AML cells. nitidine 10-27 BCL2 apoptosis regulator Homo sapiens 62-67 28805013-7 2018 The mitochondrial depolarization also stems from the Bcl-2 inhibition mediated by DFMT, followed by the cytochrome c release that activates caspase signaling. dfmt 82-86 BCL2 apoptosis regulator Homo sapiens 53-58 29111964-3 2018 Antimycin is an inhibitor of mitochondrial cytochrome c reductase and more recently was shown to inhibit Bcl-2/Bcl-XL-related anti-apoptotic proteins commonly overproduced by cancerous cells. antimycin 0-9 BCL2 apoptosis regulator Homo sapiens 105-110 29115419-6 2018 Dex also induced apoptosis and inhibited autophagy of osteoblasts, evidenced by upregulated B-cell lymphoma 2 (Bcl-2)-associated X protein/Bcl-2 ratio and the activation of mammalian target of rapamycin (mTOR), and decreased expression levels of Beclin-1, autophagy protein 5 and microtubule-associated protein 1 light chain 3 II. Dexamethasone 0-3 BCL2 apoptosis regulator Homo sapiens 92-109 29115419-6 2018 Dex also induced apoptosis and inhibited autophagy of osteoblasts, evidenced by upregulated B-cell lymphoma 2 (Bcl-2)-associated X protein/Bcl-2 ratio and the activation of mammalian target of rapamycin (mTOR), and decreased expression levels of Beclin-1, autophagy protein 5 and microtubule-associated protein 1 light chain 3 II. Dexamethasone 0-3 BCL2 apoptosis regulator Homo sapiens 111-116 29115419-6 2018 Dex also induced apoptosis and inhibited autophagy of osteoblasts, evidenced by upregulated B-cell lymphoma 2 (Bcl-2)-associated X protein/Bcl-2 ratio and the activation of mammalian target of rapamycin (mTOR), and decreased expression levels of Beclin-1, autophagy protein 5 and microtubule-associated protein 1 light chain 3 II. Dexamethasone 0-3 BCL2 apoptosis regulator Homo sapiens 139-144 29115429-7 2018 In addition, the expression of the anti-apoptosis gene B-cell lymphoma 2 (Bcl-2) was downregulated by resveratrol, and the expression of pro-apoptosis gene Bcl-2-associated X was upregulated at the mRNA and protein levels. Resveratrol 102-113 BCL2 apoptosis regulator Homo sapiens 55-72 29115429-7 2018 In addition, the expression of the anti-apoptosis gene B-cell lymphoma 2 (Bcl-2) was downregulated by resveratrol, and the expression of pro-apoptosis gene Bcl-2-associated X was upregulated at the mRNA and protein levels. Resveratrol 102-113 BCL2 apoptosis regulator Homo sapiens 74-79 29115429-7 2018 In addition, the expression of the anti-apoptosis gene B-cell lymphoma 2 (Bcl-2) was downregulated by resveratrol, and the expression of pro-apoptosis gene Bcl-2-associated X was upregulated at the mRNA and protein levels. Resveratrol 102-113 BCL2 apoptosis regulator Homo sapiens 156-161 29322787-0 2018 Beclin1 enhances cisplatin-induced apoptosis via Bcl-2-modulated autophagy in laryngeal carcinoma cells Hep-2. Cisplatin 17-26 BCL2 apoptosis regulator Homo sapiens 49-54 29322787-8 2018 The effect of Bcl-2 overexpression on increased cisplatin-sensitivity and autophagy induced by Beclin1 was investigated using Bcl-2 cDNA transfection. Cisplatin 48-57 BCL2 apoptosis regulator Homo sapiens 14-19 29322787-13 2018 Overexpression of Bcl-2 decreased the cisplatin-induced apoptosis and inhibited Beclin1-induced autophagy. Cisplatin 38-47 BCL2 apoptosis regulator Homo sapiens 18-23 29322787-14 2018 In conclusion, Beclin1 enhances cisplatin-induced apoptosis in laryngeal carcinoma cells Hep-2 via Bcl-2 modulated autophagy. Cisplatin 32-41 BCL2 apoptosis regulator Homo sapiens 99-104 29387241-7 2018 Furthermore, 48 h exposure to erlotinib disturbed mitochondrial function by decreasing the ratio of B-cell lymphoma 2 (Bcl-2) to Bcl-associated X proteins and reducing mitochondrial membrane potential. Erlotinib Hydrochloride 30-39 BCL2 apoptosis regulator Homo sapiens 100-117 29387241-7 2018 Furthermore, 48 h exposure to erlotinib disturbed mitochondrial function by decreasing the ratio of B-cell lymphoma 2 (Bcl-2) to Bcl-associated X proteins and reducing mitochondrial membrane potential. Erlotinib Hydrochloride 30-39 BCL2 apoptosis regulator Homo sapiens 119-124 29380956-7 2018 Change in Bcl-2 phosphorylation at 1H was significantly greater in PL compared to CON (P = 0.001). Hydrogen 35-37 BCL2 apoptosis regulator Homo sapiens 10-15 29877243-3 2018 Furthermore, venetoclax, a selective BCL-2 inhibitor, and chimeric antigen receptor (CAR) T-cell therapy that work against B-cell maturation antigen (BCMA) have reportedly shown great efficacy in phase 1 studies. venetoclax 13-23 BCL2 apoptosis regulator Homo sapiens 37-42 29131417-14 2018 The enhanced capability of EGM2 cultured NICC to resist apoptosis was associated with their elevated protein levels of anti-apoptotic Bcl-2 family member Mcl-1. egm2 27-31 BCL2 apoptosis regulator Homo sapiens 134-139 28987383-0 2017 HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2. 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide 21-27 BCL2 apoptosis regulator Homo sapiens 64-69 28987383-0 2017 HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2. 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide 21-27 BCL2 apoptosis regulator Homo sapiens 127-132 28987383-0 2017 HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2. ABT-737 81-88 BCL2 apoptosis regulator Homo sapiens 64-69 28987383-0 2017 HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2. ABT-737 81-88 BCL2 apoptosis regulator Homo sapiens 127-132 28987383-2 2017 Although ABT-737, a B-cell lymphoma-2 (BCL-2) inhibitor, exerts anticancer effects against BCL-2-expressing SCLC, monotherapy with ABT-737 is associated with limited clinical activity because of the development of resistance and toxicity. ABT-737 9-16 BCL2 apoptosis regulator Homo sapiens 20-37 28987383-2 2017 Although ABT-737, a B-cell lymphoma-2 (BCL-2) inhibitor, exerts anticancer effects against BCL-2-expressing SCLC, monotherapy with ABT-737 is associated with limited clinical activity because of the development of resistance and toxicity. ABT-737 9-16 BCL2 apoptosis regulator Homo sapiens 39-44 28987383-2 2017 Although ABT-737, a B-cell lymphoma-2 (BCL-2) inhibitor, exerts anticancer effects against BCL-2-expressing SCLC, monotherapy with ABT-737 is associated with limited clinical activity because of the development of resistance and toxicity. ABT-737 9-16 BCL2 apoptosis regulator Homo sapiens 91-96 28987383-4 2017 We found that the combination of ABT-737 and NVP-AUY922 synergistically induced the apoptosis of BCL-2-expressing SCLC cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 33-36 BCL2 apoptosis regulator Homo sapiens 97-102 29317830-5 2018 The combination of irradiation and quercetin treatment aggravated DNA damages and caused typical apoptotic cell death; as well the expression of Bax and p21 elevated and the expression of Bcl-2 decreased. Quercetin 35-44 BCL2 apoptosis regulator Homo sapiens 188-193 29246803-3 2018 Venetoclax is a selective, orally bioavailable inhibitor of BCL-2 active in previously treated patients with relapsed or refractory chronic lymphocytic leukaemia. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 60-65 29387217-10 2018 Furthermore, lapatinib induced apoptosis by decreasing Bcl-2 and PML-RARalpha levels, and by increasing the levels of Bax, cleaved PARP, cleaved caspase-3 and cleaved caspase-9. Lapatinib 13-22 BCL2 apoptosis regulator Homo sapiens 55-60 29982258-7 2018 Further, MPP+ increased the Bax/Bcl-2 ratio, which was partly reversed by cyanidin. mangion-purified polysaccharide (Candida albicans) 9-13 BCL2 apoptosis regulator Homo sapiens 32-37 29982258-7 2018 Further, MPP+ increased the Bax/Bcl-2 ratio, which was partly reversed by cyanidin. cyanidin 74-82 BCL2 apoptosis regulator Homo sapiens 32-37 30099456-7 2018 Furthermore, ROS production, malondialdehyde content, Bax and Caspase-3 expressions, and cell apoptosis were elevated in H2O2-induced hLEC, whereas the activities of superoxide dismutase and glutathione peroxidase, Bcl-2 expression, MMP, as well as the mitochondrial energy metabolism genes were reduced. Hydrogen Peroxide 121-125 BCL2 apoptosis regulator Homo sapiens 215-220 30069633-4 2018 Venetoclax (ABT-199) is a novel, orally bioavailable small-molecule inhibitor for selective targeting of B-cell lymphoma 2 (BCL2). venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 105-122 30069633-4 2018 Venetoclax (ABT-199) is a novel, orally bioavailable small-molecule inhibitor for selective targeting of B-cell lymphoma 2 (BCL2). venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 124-128 30069633-4 2018 Venetoclax (ABT-199) is a novel, orally bioavailable small-molecule inhibitor for selective targeting of B-cell lymphoma 2 (BCL2). venetoclax 12-19 BCL2 apoptosis regulator Homo sapiens 105-122 30069633-4 2018 Venetoclax (ABT-199) is a novel, orally bioavailable small-molecule inhibitor for selective targeting of B-cell lymphoma 2 (BCL2). venetoclax 12-19 BCL2 apoptosis regulator Homo sapiens 124-128 29269744-5 2017 Econazole decreased the protein levels of p-AKT and Bcl-2, but had no effect on the phosphorylation level of ERK. Econazole 0-9 BCL2 apoptosis regulator Homo sapiens 52-57 29269870-0 2017 Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. voruciclib 0-10 BCL2 apoptosis regulator Homo sapiens 124-128 29269870-3 2017 While clinical inhibition of BCL-2 has been achieved with the BH3 mimetic venetoclax, anti-tumor efficacy is limited by compensatory induction of MCL-1. BH 3 62-65 BCL2 apoptosis regulator Homo sapiens 29-34 29435156-1 2018 Cis-trimethoxy resveratrol (cis-3M-RES) induced dose-dependent cytotoxicity and apoptotic DNA fragmentation in Jurkat T cell clones (JT/Neo); however, it induced only cytostasis in BCL-2-overexpressing cells (JT/BCL-2). cis-trimethoxy resveratrol 0-26 BCL2 apoptosis regulator Homo sapiens 212-217 29269870-3 2017 While clinical inhibition of BCL-2 has been achieved with the BH3 mimetic venetoclax, anti-tumor efficacy is limited by compensatory induction of MCL-1. venetoclax 74-84 BCL2 apoptosis regulator Homo sapiens 29-34 29435156-1 2018 Cis-trimethoxy resveratrol (cis-3M-RES) induced dose-dependent cytotoxicity and apoptotic DNA fragmentation in Jurkat T cell clones (JT/Neo); however, it induced only cytostasis in BCL-2-overexpressing cells (JT/BCL-2). cis-3m 28-34 BCL2 apoptosis regulator Homo sapiens 181-186 29435156-1 2018 Cis-trimethoxy resveratrol (cis-3M-RES) induced dose-dependent cytotoxicity and apoptotic DNA fragmentation in Jurkat T cell clones (JT/Neo); however, it induced only cytostasis in BCL-2-overexpressing cells (JT/BCL-2). cis-3m 28-34 BCL2 apoptosis regulator Homo sapiens 212-217 29435156-1 2018 Cis-trimethoxy resveratrol (cis-3M-RES) induced dose-dependent cytotoxicity and apoptotic DNA fragmentation in Jurkat T cell clones (JT/Neo); however, it induced only cytostasis in BCL-2-overexpressing cells (JT/BCL-2). Rhenium 35-38 BCL2 apoptosis regulator Homo sapiens 181-186 29435156-1 2018 Cis-trimethoxy resveratrol (cis-3M-RES) induced dose-dependent cytotoxicity and apoptotic DNA fragmentation in Jurkat T cell clones (JT/Neo); however, it induced only cytostasis in BCL-2-overexpressing cells (JT/BCL-2). Rhenium 35-38 BCL2 apoptosis regulator Homo sapiens 212-217 29435156-2 2018 Treatment with 0.25 muM cis-3M-RES induced G2/M arrest, BAK activation, Deltapsim loss, caspase-9 and caspase-3 activation, and poly (ADP-ribose) polymerase (PARP) cleavage in JT/Neo cells time-dependently but did not induce these events, except G2/M arrest, in JT/BCL-2 cells. cis-3m 24-30 BCL2 apoptosis regulator Homo sapiens 265-270 29435156-5 2018 Cis-3M-RES-induced phosphorylation of BCL-2 family proteins and mitochondrial apoptotic events were suppressed by a validated CDK1 inhibitor RO3306. cis-3m-res 0-10 BCL2 apoptosis regulator Homo sapiens 38-43 29435156-5 2018 Cis-3M-RES-induced phosphorylation of BCL-2 family proteins and mitochondrial apoptotic events were suppressed by a validated CDK1 inhibitor RO3306. RO 3306 141-147 BCL2 apoptosis regulator Homo sapiens 38-43 29416779-11 2018 Co-administration of the Bcl-2 inhibitor GDC-0199 further potentiated ABC294640"s anti-tumor activity. venetoclax 41-49 BCL2 apoptosis regulator Homo sapiens 25-30 29258429-10 2017 The expression levels of HK2 and ADRB1 regulated by miR143 and Bcl-2 decreased under H2O2 treatment but were restored following MSC-CM treatment. Hydrogen Peroxide 85-89 BCL2 apoptosis regulator Homo sapiens 63-68 29311933-8 2017 Further, apoptosis due to DEAE-Dextran, initially determined by downregulation of Bcl2, was confirmed with flow cytometry. DEAE-Dextran 26-38 BCL2 apoptosis regulator Homo sapiens 82-86 29257079-8 2017 Consistently, sulfuretin decreased p53 expression and the Bax/Bcl-2 ratio. sulfuretin 14-24 BCL2 apoptosis regulator Homo sapiens 62-67 29416779-11 2018 Co-administration of the Bcl-2 inhibitor GDC-0199 further potentiated ABC294640"s anti-tumor activity. 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 70-79 BCL2 apoptosis regulator Homo sapiens 25-30 29258224-6 2017 High glucose also disturbed Bax and Bcl-2 expression, interrupted Bcl-2/Bax balance, and triggered subsequent cytochrome c release into the cytosol and activation of caspase-3. Glucose 5-12 BCL2 apoptosis regulator Homo sapiens 36-41 29258224-6 2017 High glucose also disturbed Bax and Bcl-2 expression, interrupted Bcl-2/Bax balance, and triggered subsequent cytochrome c release into the cytosol and activation of caspase-3. Glucose 5-12 BCL2 apoptosis regulator Homo sapiens 66-71 28972014-0 2017 First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. venetoclax 43-53 BCL2 apoptosis regulator Homo sapiens 27-32 29080630-8 2017 Specifically, the levels of cleaved caspase-3 and Bax and the rate of cell death increased, and the level of Bcl-2 decreased, in cells treated with 50 muM quercetin. Quercetin 155-164 BCL2 apoptosis regulator Homo sapiens 109-114 29423045-8 2018 Additionally, Ova alone or in combination with Imatinib suppressed the hCSC traits of the CD34+/CD38- cells, resulting in loss of their ability to form tumorspheres, enhanced apoptosis, increase in the Bax/Bcl-2 ratio, and dysregulation of the PI3K/AKT/mTOR signaling pathway. ovatodiolide 14-17 BCL2 apoptosis regulator Homo sapiens 206-211 29423045-8 2018 Additionally, Ova alone or in combination with Imatinib suppressed the hCSC traits of the CD34+/CD38- cells, resulting in loss of their ability to form tumorspheres, enhanced apoptosis, increase in the Bax/Bcl-2 ratio, and dysregulation of the PI3K/AKT/mTOR signaling pathway. Imatinib Mesylate 47-55 BCL2 apoptosis regulator Homo sapiens 206-211 29110485-0 2017 Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2). aromatic carbamates 13-32 BCL2 apoptosis regulator Homo sapiens 152-157 29110485-7 2017 Herein, we demonstrate that neuroprotective aromatic carbamates function to increase the Bcl-2/Bax ratio to an antiapoptotic state and activate autophagy through induction of beclin 1. Carbamates 53-63 BCL2 apoptosis regulator Homo sapiens 89-94 29054969-8 2017 Compared with HUVECs cultured in 5 mM glucose, cells cultured in 30 mM glucose exhibited a higher apoptosis rate, up-regulation of cleaved caspase-3 and Bax (proapoptotic proteins), down-regulation of Bcl-2 (anti-apoptotic protein), increased ceramide concentration, and enhanced ASM activity (all P<0.05). Glucose 71-78 BCL2 apoptosis regulator Homo sapiens 201-206 29054969-9 2017 alpha-Mangostin (15 microM) significantly attenuated the high-glucose induced increase in apoptosis rate (8.64 +- 2.16 compared with 19.6 +- 3.54%), up-regulation of cleaved caspase-3 and Bax, down-regulation of Bcl-2, elevation of ceramide level, and enhancement of ASM activity (all P<0.05). mangostin 0-15 BCL2 apoptosis regulator Homo sapiens 212-217 29416647-9 2018 Protein microarray analysis showed that A172 cells treated with TMZ+RT+dactolisib had higher p27 and lower Bcl-2 expression than other groups. dactolisib 71-81 BCL2 apoptosis regulator Homo sapiens 107-112 29216925-10 2017 Notably, docetaxel-induced miR-193a-5p upregulation, which in turn inhibits Bach2 expression and thus relieves Bach2 repression of HO-1 expression, partly counteracted docetaxel-induced apoptosis, as evidenced by the increased Bcl-2 and decreased Bax expression. Docetaxel 9-18 BCL2 apoptosis regulator Homo sapiens 227-232 29220397-5 2017 DEA induces cell cycle arrest in the G0/G1 phase, which may contribute to the inhibition of cell proliferation, and shifts the Bax/Bcl-2 ratio to initiate apoptosis, induce AIF nuclear translocation, and activate PARP-1 cleavage and caspase-3 activation. desethylamiodarone 0-3 BCL2 apoptosis regulator Homo sapiens 131-136 29216925-10 2017 Notably, docetaxel-induced miR-193a-5p upregulation, which in turn inhibits Bach2 expression and thus relieves Bach2 repression of HO-1 expression, partly counteracted docetaxel-induced apoptosis, as evidenced by the increased Bcl-2 and decreased Bax expression. Docetaxel 168-177 BCL2 apoptosis regulator Homo sapiens 227-232 28972014-3 2017 We found that the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax (ABT-199) demonstrated the strongest T-PLL-specific response when comparing individual ex vivo drug response in 86 patients with refractory hematologic malignancies. venetoclax 54-64 BCL2 apoptosis regulator Homo sapiens 18-35 28972014-3 2017 We found that the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax (ABT-199) demonstrated the strongest T-PLL-specific response when comparing individual ex vivo drug response in 86 patients with refractory hematologic malignancies. venetoclax 54-64 BCL2 apoptosis regulator Homo sapiens 37-42 28972014-3 2017 We found that the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax (ABT-199) demonstrated the strongest T-PLL-specific response when comparing individual ex vivo drug response in 86 patients with refractory hematologic malignancies. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 66-69 BCL2 apoptosis regulator Homo sapiens 18-35 28972014-3 2017 We found that the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax (ABT-199) demonstrated the strongest T-PLL-specific response when comparing individual ex vivo drug response in 86 patients with refractory hematologic malignancies. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 66-69 BCL2 apoptosis regulator Homo sapiens 37-42 28713162-2 2017 ABT-263 (Navitoclax), a novel BH3 mimetic and orally bioavailable Bcl-2 family inhibitor with high affinity for Bcl-xL, Bcl-2 and Bcl-w has entered clinical trials for cancer treatment. navitoclax 0-7 BCL2 apoptosis regulator Homo sapiens 66-71 29416644-8 2018 Subsequent Verteporfin treatment in CAL27 cells revealed that the transcription and translation of BCL-2 and C-MYC both decreased. Verteporfin 11-22 BCL2 apoptosis regulator Homo sapiens 99-104 29211704-10 2017 Western blotting, the siRNA assay, and qPCR showed that FOXO3a, the Bcl-2 family of proteins, survivin, and FasL were involved in SAHA-induced apoptosis in prostate cancer cells grown in vitro. Vorinostat 130-134 BCL2 apoptosis regulator Homo sapiens 68-73 29340082-2 2017 BH3 mimetics (e.g. ABT-199 (venetoclax)) kill cancer cells by targeting Bcl-2"s hydrophobic cleft and disrupting Bcl-2/Bim complexes. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 72-77 29340082-2 2017 BH3 mimetics (e.g. ABT-199 (venetoclax)) kill cancer cells by targeting Bcl-2"s hydrophobic cleft and disrupting Bcl-2/Bim complexes. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 113-118 29340082-2 2017 BH3 mimetics (e.g. ABT-199 (venetoclax)) kill cancer cells by targeting Bcl-2"s hydrophobic cleft and disrupting Bcl-2/Bim complexes. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 19-22 BCL2 apoptosis regulator Homo sapiens 72-77 29340082-2 2017 BH3 mimetics (e.g. ABT-199 (venetoclax)) kill cancer cells by targeting Bcl-2"s hydrophobic cleft and disrupting Bcl-2/Bim complexes. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 19-22 BCL2 apoptosis regulator Homo sapiens 113-118 29340082-3 2017 Some cancers with elevated Bcl-2 display poor responses towards BH3 mimetics, suggesting an additional function for anti-apoptotic Bcl-2 in these cancers. BH 3 64-67 BCL2 apoptosis regulator Homo sapiens 27-32 29340082-3 2017 Some cancers with elevated Bcl-2 display poor responses towards BH3 mimetics, suggesting an additional function for anti-apoptotic Bcl-2 in these cancers. BH 3 64-67 BCL2 apoptosis regulator Homo sapiens 131-136 29340082-4 2017 Indeed, Bcl-2 via its BH4 domain prevents cytotoxic Ca2+ release from the endoplasmic reticulum (ER) by directly inhibiting the inositol 1,4,5-trisphosphate receptor (IP3R). sapropterin 22-25 BCL2 apoptosis regulator Homo sapiens 8-13 29340082-5 2017 The cell-permeable Bcl-2/IP3R disruptor-2 (BIRD-2) peptide can kill these Bcl-2-dependent cancers by targeting Bcl-2"s BH4 domain, unleashing pro-apoptotic Ca2+-release events. sapropterin 119-122 BCL2 apoptosis regulator Homo sapiens 19-24 29340082-5 2017 The cell-permeable Bcl-2/IP3R disruptor-2 (BIRD-2) peptide can kill these Bcl-2-dependent cancers by targeting Bcl-2"s BH4 domain, unleashing pro-apoptotic Ca2+-release events. sapropterin 119-122 BCL2 apoptosis regulator Homo sapiens 74-79 29340082-5 2017 The cell-permeable Bcl-2/IP3R disruptor-2 (BIRD-2) peptide can kill these Bcl-2-dependent cancers by targeting Bcl-2"s BH4 domain, unleashing pro-apoptotic Ca2+-release events. sapropterin 119-122 BCL2 apoptosis regulator Homo sapiens 74-79 29212036-0 2017 DeltaNp63 Inhibits Oxidative Stress-Induced Cell Death, Including Ferroptosis, and Cooperates with the BCL-2 Family to Promote Clonogenic Survival. deltanp63 0-9 BCL2 apoptosis regulator Homo sapiens 103-108 29202800-7 2017 Moreover, genistein can inhibit the expression of notch-1, p-NF-kappaB and NF-kappaB, while promote the expression of Bax/Bcl-2 and caspase-3 in HT-29 cells. Genistein 10-19 BCL2 apoptosis regulator Homo sapiens 122-127 29207557-5 2017 In addition, the increased level of Bax, cleaved caspase-3, -9 and -8, and the suppression of Bcl-2 were observed in the Lobocrassin B treated cells. lobocrassin B 121-134 BCL2 apoptosis regulator Homo sapiens 94-99 28713162-2 2017 ABT-263 (Navitoclax), a novel BH3 mimetic and orally bioavailable Bcl-2 family inhibitor with high affinity for Bcl-xL, Bcl-2 and Bcl-w has entered clinical trials for cancer treatment. navitoclax 0-7 BCL2 apoptosis regulator Homo sapiens 120-125 28713162-2 2017 ABT-263 (Navitoclax), a novel BH3 mimetic and orally bioavailable Bcl-2 family inhibitor with high affinity for Bcl-xL, Bcl-2 and Bcl-w has entered clinical trials for cancer treatment. navitoclax 9-19 BCL2 apoptosis regulator Homo sapiens 66-71 28713162-2 2017 ABT-263 (Navitoclax), a novel BH3 mimetic and orally bioavailable Bcl-2 family inhibitor with high affinity for Bcl-xL, Bcl-2 and Bcl-w has entered clinical trials for cancer treatment. navitoclax 9-19 BCL2 apoptosis regulator Homo sapiens 120-125 28963947-2 2017 High expression level of BCL2 family proteins is a characteristic feature of cancer cells, especially in cisplatin-resistant cancer cells. Cisplatin 105-114 BCL2 apoptosis regulator Homo sapiens 25-29 28963947-5 2017 Here, we report that the BCL2/BCLXL inhibitor ABT737 induced apoptosis more potently in cisplatin-resistant SKOV3/DDP ovarian cancer cells than in cisplatin-sensitive SKOV3 ovarian cancer cells. ABT-737 46-52 BCL2 apoptosis regulator Homo sapiens 25-29 28978811-7 2017 Furthermore, the protective effects of TMP were related to increased Bcl-2 expression, attenuated Bax expression, and enhanced levels of phosphorylated Akt (p-Akt) and extracellular regulated protein kinases1/2 (p-ERK1/2). tetramethylpyrazine 39-42 BCL2 apoptosis regulator Homo sapiens 69-74 28963947-5 2017 Here, we report that the BCL2/BCLXL inhibitor ABT737 induced apoptosis more potently in cisplatin-resistant SKOV3/DDP ovarian cancer cells than in cisplatin-sensitive SKOV3 ovarian cancer cells. Cisplatin 88-97 BCL2 apoptosis regulator Homo sapiens 25-29 28963947-5 2017 Here, we report that the BCL2/BCLXL inhibitor ABT737 induced apoptosis more potently in cisplatin-resistant SKOV3/DDP ovarian cancer cells than in cisplatin-sensitive SKOV3 ovarian cancer cells. Cisplatin 147-156 BCL2 apoptosis regulator Homo sapiens 25-29 29239817-6 2017 Mechanistically, the application of TALE and ferruginol (3) resulted in a significant decrease in mitochondria membrane potential, which was coupled with an increase in the Bax/Bcl-2 ratio and caspase-3/-9 activity. ferruginol 45-55 BCL2 apoptosis regulator Homo sapiens 177-182 29169726-0 2017 Piperine (PP) enhanced mitomycin-C (MMC) therapy of human cervical cancer through suppressing Bcl-2 signaling pathway via inactivating STAT3/NF-kappaB. piperine 0-8 BCL2 apoptosis regulator Homo sapiens 94-99 29169726-0 2017 Piperine (PP) enhanced mitomycin-C (MMC) therapy of human cervical cancer through suppressing Bcl-2 signaling pathway via inactivating STAT3/NF-kappaB. Mitomycin 23-34 BCL2 apoptosis regulator Homo sapiens 94-99 29169726-0 2017 Piperine (PP) enhanced mitomycin-C (MMC) therapy of human cervical cancer through suppressing Bcl-2 signaling pathway via inactivating STAT3/NF-kappaB. Mitomycin 36-39 BCL2 apoptosis regulator Homo sapiens 94-99 29169726-7 2017 Additionally, the presence of PP potentiated the effects of MMC on apoptosis induction in cervical cancer cells with drug resistance, which was dependent on Bcl-2 inhibition. Mitomycin 60-63 BCL2 apoptosis regulator Homo sapiens 157-162 29169726-10 2017 Our data indicated a novel therapeutic strategy of PP to potentiate MMC-induced anti-tumor effect on cervical cancer cells with drug resistance through blocking p-STAT3/p65 and Bcl-2 activation. Mitomycin 68-71 BCL2 apoptosis regulator Homo sapiens 177-182 29191192-12 2017 These data imply that ETBO induces apoptosis by caspase activation through the modulation of pro-apoptotic and anti-apoptotic gene, p53 and Bcl-2, respectively. etbo 22-26 BCL2 apoptosis regulator Homo sapiens 140-145 28923482-9 2017 Our study may provide mechanistic insights into the heterogeneity of tumor cells and the efficiency of BH3 mimetic-mediated killing of cancer cells, and suggest that a combination treatment might be required to overcome apoptosis resistance in the Bcl-2 family targeted therapies. BH 3 103-106 BCL2 apoptosis regulator Homo sapiens 248-253 28964970-5 2017 Mechanistically, metformin altered UPR activated by bortezomib, leading to a reduced expression of BiP, up-regulation of CHOP and down-regulation of Bcl-2. Metformin 17-26 BCL2 apoptosis regulator Homo sapiens 149-154 28281027-7 2017 Epoxomicin treatment also resulted in accumulation of Bcl-2 family members-proapoptotic Noxa and antiapoptotic Mcl-1, which were postulated as the targets for bortezomib in melanoma. Bortezomib 159-169 BCL2 apoptosis regulator Homo sapiens 54-59 29146569-0 2017 Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax. venetoclax 115-125 BCL2 apoptosis regulator Homo sapiens 90-94 29146569-3 2017 Innovative medicinal chemistry and structure-based drug design, coupled with a strong fundamental understanding of BCL2 biology, were essential to the development of BH3 mimetics such as the BCL2-selective inhibitor venetoclax. BH 3 166-169 BCL2 apoptosis regulator Homo sapiens 115-119 29146569-3 2017 Innovative medicinal chemistry and structure-based drug design, coupled with a strong fundamental understanding of BCL2 biology, were essential to the development of BH3 mimetics such as the BCL2-selective inhibitor venetoclax. BH 3 166-169 BCL2 apoptosis regulator Homo sapiens 191-195 29146569-4 2017 We review a number of preclinical studies that have deepened our understanding of BCL2 biology and facilitated the clinical development of venetoclax.Significance: Basic research into the pathways governing programmed cell death have paved the way for the discovery of apoptosis-inducing agents such as venetoclax, a BCL2-selective inhibitor that was recently approved by the FDA and the European Medicines Agency. venetoclax 139-149 BCL2 apoptosis regulator Homo sapiens 317-321 28964970-5 2017 Mechanistically, metformin altered UPR activated by bortezomib, leading to a reduced expression of BiP, up-regulation of CHOP and down-regulation of Bcl-2. Bortezomib 52-62 BCL2 apoptosis regulator Homo sapiens 149-154 28804952-8 2017 Most significantly, propofol induced apoptotic effects by decreasing Bcl-2 but increasing Bax, cleaved caspase-9/caspase-3 levels, which were partially reversed by NAC. Propofol 20-28 BCL2 apoptosis regulator Homo sapiens 69-74 28937872-9 2017 In addition, Bcl-2 expression was significantly increased in both the CAPE and CAPE-bevacizumab combination groups compared to the H2O2 group. Hydrogen Peroxide 131-135 BCL2 apoptosis regulator Homo sapiens 13-18 29272019-4 2017 Nitrate reduction method was used to measure the content of nitric oxide (NO) and radioimmunoassay was used to measure endothelin-1; Western blot assay was used to detect the expression of B-cell lymphoma-2 (Bcl-2), and flow cytometry was used to detect the intracellular level of reactive oxygen (ROS) and apoptosis of HUVECs. reactive oxygen 281-296 BCL2 apoptosis regulator Homo sapiens 208-213 29243778-10 2017 In the apatinib combined with DDP group, the levels of cleaved caspase-3, cleaved caspase-9 and B-cell lymphoma-2 (Bcl-2)-associated X (BAX) proteins were significantly upregulated, while the level of Bcl-2 proteins was downregulated. apatinib 7-15 BCL2 apoptosis regulator Homo sapiens 96-113 29243778-10 2017 In the apatinib combined with DDP group, the levels of cleaved caspase-3, cleaved caspase-9 and B-cell lymphoma-2 (Bcl-2)-associated X (BAX) proteins were significantly upregulated, while the level of Bcl-2 proteins was downregulated. apatinib 7-15 BCL2 apoptosis regulator Homo sapiens 115-120 29243778-10 2017 In the apatinib combined with DDP group, the levels of cleaved caspase-3, cleaved caspase-9 and B-cell lymphoma-2 (Bcl-2)-associated X (BAX) proteins were significantly upregulated, while the level of Bcl-2 proteins was downregulated. apatinib 7-15 BCL2 apoptosis regulator Homo sapiens 201-206 29243778-10 2017 In the apatinib combined with DDP group, the levels of cleaved caspase-3, cleaved caspase-9 and B-cell lymphoma-2 (Bcl-2)-associated X (BAX) proteins were significantly upregulated, while the level of Bcl-2 proteins was downregulated. Cisplatin 30-33 BCL2 apoptosis regulator Homo sapiens 96-113 29243778-10 2017 In the apatinib combined with DDP group, the levels of cleaved caspase-3, cleaved caspase-9 and B-cell lymphoma-2 (Bcl-2)-associated X (BAX) proteins were significantly upregulated, while the level of Bcl-2 proteins was downregulated. Cisplatin 30-33 BCL2 apoptosis regulator Homo sapiens 201-206 29272019-4 2017 Nitrate reduction method was used to measure the content of nitric oxide (NO) and radioimmunoassay was used to measure endothelin-1; Western blot assay was used to detect the expression of B-cell lymphoma-2 (Bcl-2), and flow cytometry was used to detect the intracellular level of reactive oxygen (ROS) and apoptosis of HUVECs. ros 298-301 BCL2 apoptosis regulator Homo sapiens 208-213 29272021-8 2017 In addition, findings from Western blotting method indicated that digoxin intervention showed reduced Bcl-2 expression and elevated Bax level in MM231 cells, characterized by increased Bax/Bcl-2 ratio. Digoxin 66-73 BCL2 apoptosis regulator Homo sapiens 102-107 29272021-8 2017 In addition, findings from Western blotting method indicated that digoxin intervention showed reduced Bcl-2 expression and elevated Bax level in MM231 cells, characterized by increased Bax/Bcl-2 ratio. Digoxin 66-73 BCL2 apoptosis regulator Homo sapiens 189-194 29372687-2 2017 The aim of presented study was to determine the effect of ABT-737 inhibitor of anti-apoptotic proteins Bcl-2, Bcl-XL and Bcl-w as well as cyclin-dependent kinase 2 (CDK2) inhibitor SU9516 alone and in combination with ABT-737 on survival of colorectal cell lines HT29 and Caco-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 58-61 BCL2 apoptosis regulator Homo sapiens 103-108 29285102-10 2017 Furthermore, the apoptosis of H9c2 cardiomyocytes resulted from hypoxia/reoxygenation was inhibited by carnosic acid through the upregulation of Bcl-2 and the downregulation of Bax and caspase-3 levels. salvin 103-116 BCL2 apoptosis regulator Homo sapiens 145-150 29051117-7 2017 Resistance to oxidative stress was enhanced and expression of the antiapoptotic gene Bcl-2 was increased by inclusion of 0.1mM melatonin in the cryoprotectant. Melatonin 127-136 BCL2 apoptosis regulator Homo sapiens 85-90 29372687-2 2017 The aim of presented study was to determine the effect of ABT-737 inhibitor of anti-apoptotic proteins Bcl-2, Bcl-XL and Bcl-w as well as cyclin-dependent kinase 2 (CDK2) inhibitor SU9516 alone and in combination with ABT-737 on survival of colorectal cell lines HT29 and Caco-2. ABT-737 58-65 BCL2 apoptosis regulator Homo sapiens 103-108 29074436-5 2017 Treatment of the cells with DHPAC induced cell apoptosis by reducing mitochondrial membrane potential and altered the expression of several apoptosis-related proteins such as Bcl-2, Bax, Caspase-9, Cytochrome c and PARP. dhpac 28-33 BCL2 apoptosis regulator Homo sapiens 175-180 31966505-7 2017 Bcl-2-associated X protein (Bax) expression was promoted and B-cell lymphoma-2 (Bcl-2) expression was suppressed, In addition, Notch1, Notch1 intracellular domain (NICD1) and hairy and enhancer of split 1 (Hes-1) were decreased dramatically in HT29 cells treated with Cur combined with DDP. Curcumin 268-271 BCL2 apoptosis regulator Homo sapiens 0-5 29039470-12 2017 Additionally, baicalein was capable of upregulating the expression of the pro-apoptotic proteins Bax and cytochrome c, reducing the expression of the anti-apoptotic protein Bcl-2, elevating the ratio of Bax/Bcl-2, and triggering the mitochondrial apoptotic pathway, which led to caspase-3 and caspase-9 activation and PARP cleavage. baicalein 14-23 BCL2 apoptosis regulator Homo sapiens 173-178 29039448-7 2017 As shown by western blot analysis, the protective effects of AS-IV against SH-SY5Y cell injury induced by H2O2 were also mediated via the downregulation of the ratio of Bax/Bcl-2. Hydrogen Peroxide 106-110 BCL2 apoptosis regulator Homo sapiens 173-178 31966505-7 2017 Bcl-2-associated X protein (Bax) expression was promoted and B-cell lymphoma-2 (Bcl-2) expression was suppressed, In addition, Notch1, Notch1 intracellular domain (NICD1) and hairy and enhancer of split 1 (Hes-1) were decreased dramatically in HT29 cells treated with Cur combined with DDP. 2-dimethylaminoethyl(dimethylamido)phosphonofluoridate 286-289 BCL2 apoptosis regulator Homo sapiens 0-5 31966519-5 2017 The results showed that H2O2 inhibited cell proliferation, induced cell apoptosis, IL-6 and TNFalpha release, the increase of caspase-3 protein and the decrease of Bcl-2, while transfection with S10012A shRNA significantly repaired the situation above. Water 24-28 BCL2 apoptosis regulator Homo sapiens 164-169 29039470-12 2017 Additionally, baicalein was capable of upregulating the expression of the pro-apoptotic proteins Bax and cytochrome c, reducing the expression of the anti-apoptotic protein Bcl-2, elevating the ratio of Bax/Bcl-2, and triggering the mitochondrial apoptotic pathway, which led to caspase-3 and caspase-9 activation and PARP cleavage. baicalein 14-23 BCL2 apoptosis regulator Homo sapiens 207-212 28550445-10 2017 The protein expression studies showed that beta-carotene at 1 microM concentration effectively decreases the expression of the anti-apoptotic protein, Bcl-2 and PARP, and survival protein, NF-kB. beta Carotene 43-56 BCL2 apoptosis regulator Homo sapiens 151-156 29390581-9 2017 OUTCOMES: The patient was treated with venetoclax, a Bcl-2 inhibitor, and exhibits complete resolution of prior skin findings and continues to remain free of new cutaneous lesions 10 months posttreatment initiation with venetoclax. venetoclax 39-49 BCL2 apoptosis regulator Homo sapiens 53-58 28888009-11 2017 Furthermore, our data suggested that ZnO QDs regulated apoptosis via Bax and Bcl-2 proteins as validated by immunofluorescence and western blot. Zinc Oxide 37-40 BCL2 apoptosis regulator Homo sapiens 77-82 29390581-10 2017 LESSONS: Herein, we present a case that supports the use of venetoclax, a Bcl-2 inhibitor, in the off-label treatment of BPDCN with Bcl-2 overexpression. bpdcn 121-126 BCL2 apoptosis regulator Homo sapiens 74-79 28944882-7 2017 In addition, TMZ suppressed cell proliferation and induced apoptosis, by promoting the expression of miR-34a, in a dose-dependent manner, and also inhibited the expression of Bcl-2. Temozolomide 13-16 BCL2 apoptosis regulator Homo sapiens 175-180 29390581-10 2017 LESSONS: Herein, we present a case that supports the use of venetoclax, a Bcl-2 inhibitor, in the off-label treatment of BPDCN with Bcl-2 overexpression. bpdcn 121-126 BCL2 apoptosis regulator Homo sapiens 132-137 29344176-7 2017 In conclusion, fraxetin can inhibit the proliferation of MCF-7 cells, induce apoptosis, upregulate Fas, FasL and Bax, and downregulate Bcl-2 to induce apoptosis. fraxetin 15-23 BCL2 apoptosis regulator Homo sapiens 135-140 28983625-4 2017 TUNEL assay revealed that resveratrol induced cell apoptosis by increasing HCC apoptosis rate from 3+-0.78% to 16+-1.12% with upregulation of B-cell lymphoma (Bcl)-2 associated X, apoptosis regulator and cleaved-poly (ADP-Ribose) polymerase 1 (PARP), and downregulation of Bcl-2, caspase-3, caspase-7 and PARP. Resveratrol 26-37 BCL2 apoptosis regulator Homo sapiens 273-278 28990084-9 2017 CS also significantly attenuated WT and A53T mutant alpha-SYN-induced dysfunction, including decrease of mitochondrial membrane potential, decrease of Bcl-2 expression, and increase of Bax expression, release of Cyt-c from the mitochondria and activation of caspase-3 and caspase-9, which demonstrated that CS suppressed alpha-SYN-induced apoptosis possibly through mitochondria protection. Chondroitin Sulfates 0-2 BCL2 apoptosis regulator Homo sapiens 151-156 29151915-8 2017 Additionally, phloretin exhibited potent anticancer activity in vitro, as evidenced by the downregulation of the anti-apoptosis-associated molecule B-cell lymphoma 2 (bcl-2) and an increase in the levels of the apoptosis-associated molecules bcl-2-like protein 4 and tumor protein p53. Phloretin 14-23 BCL2 apoptosis regulator Homo sapiens 148-165 29151915-8 2017 Additionally, phloretin exhibited potent anticancer activity in vitro, as evidenced by the downregulation of the anti-apoptosis-associated molecule B-cell lymphoma 2 (bcl-2) and an increase in the levels of the apoptosis-associated molecules bcl-2-like protein 4 and tumor protein p53. Phloretin 14-23 BCL2 apoptosis regulator Homo sapiens 167-172 29344202-8 2017 The present study demonstrated that expression of p-ERK1/2, VEGF, VEGFR2 and Bcl-2 was downregulated by treatment with increasing concentrations of metformin, whereas expression of Bax and caspase-3 was evidently upregulated. Metformin 148-157 BCL2 apoptosis regulator Homo sapiens 77-82 28983595-0 2017 Bufalin induced apoptosis in SCC-4 human tongue cancer cells by decreasing Bcl-2 and increasing Bax expression via the mitochondria-dependent pathway. bufalin 0-7 BCL2 apoptosis regulator Homo sapiens 75-80 29250183-6 2017 Additionally, SP600125 (a JNK inhibitor) and SB203580 (a p38-MAPK inhibitor) effectively inhibited apoptosis and attenuated the expression of X-linked IAP-associated factor 1 (XAF1) and apoptotic Bcl-2 family proteins (BCL2 antagonist/killer 1 and BCL2-associated X protein) in Amp-treated colon cancer cells. pyrazolanthrone 14-22 BCL2 apoptosis regulator Homo sapiens 219-223 29250183-6 2017 Additionally, SP600125 (a JNK inhibitor) and SB203580 (a p38-MAPK inhibitor) effectively inhibited apoptosis and attenuated the expression of X-linked IAP-associated factor 1 (XAF1) and apoptotic Bcl-2 family proteins (BCL2 antagonist/killer 1 and BCL2-associated X protein) in Amp-treated colon cancer cells. pyrazolanthrone 14-22 BCL2 apoptosis regulator Homo sapiens 248-252 29250183-6 2017 Additionally, SP600125 (a JNK inhibitor) and SB203580 (a p38-MAPK inhibitor) effectively inhibited apoptosis and attenuated the expression of X-linked IAP-associated factor 1 (XAF1) and apoptotic Bcl-2 family proteins (BCL2 antagonist/killer 1 and BCL2-associated X protein) in Amp-treated colon cancer cells. SB 203580 45-53 BCL2 apoptosis regulator Homo sapiens 219-223 29250183-6 2017 Additionally, SP600125 (a JNK inhibitor) and SB203580 (a p38-MAPK inhibitor) effectively inhibited apoptosis and attenuated the expression of X-linked IAP-associated factor 1 (XAF1) and apoptotic Bcl-2 family proteins (BCL2 antagonist/killer 1 and BCL2-associated X protein) in Amp-treated colon cancer cells. SB 203580 45-53 BCL2 apoptosis regulator Homo sapiens 248-252 29344231-6 2017 Bcl-2 was upregulated in 38 (32.5%) PDAC, 11 (25.6%) SPN and 24 (75.0%) CP cases. pdac 36-40 BCL2 apoptosis regulator Homo sapiens 0-5 28847998-2 2017 Venetoclax is a selective, orally bioavailable small-molecule BCL-2 inhibitor; bortezomib can indirectly inhibit MCL-1. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 62-67 29344231-6 2017 Bcl-2 was upregulated in 38 (32.5%) PDAC, 11 (25.6%) SPN and 24 (75.0%) CP cases. spn 53-56 BCL2 apoptosis regulator Homo sapiens 0-5 29262889-5 2017 RESULTS: Compared with the healthy control group, the positive rates of BCL-2 and PD-L1 in the bone marrow specimens of AL patients significantly increased (P<0.01). Aluminum 120-122 BCL2 apoptosis regulator Homo sapiens 72-77 28980375-1 2017 A triaminotriborane(3) was isolated as purple crystals through the reduction of (TMP)BCl2 (TMP=2,2,6,6-tetramethylpiperidino) by sodium naphthalenide. triaminotriborane 2-19 BCL2 apoptosis regulator Homo sapiens 85-89 28980375-1 2017 A triaminotriborane(3) was isolated as purple crystals through the reduction of (TMP)BCl2 (TMP=2,2,6,6-tetramethylpiperidino) by sodium naphthalenide. Thymidine Monophosphate 81-84 BCL2 apoptosis regulator Homo sapiens 85-89 28980375-1 2017 A triaminotriborane(3) was isolated as purple crystals through the reduction of (TMP)BCl2 (TMP=2,2,6,6-tetramethylpiperidino) by sodium naphthalenide. Thymidine Monophosphate 91-94 BCL2 apoptosis regulator Homo sapiens 85-89 28980375-1 2017 A triaminotriborane(3) was isolated as purple crystals through the reduction of (TMP)BCl2 (TMP=2,2,6,6-tetramethylpiperidino) by sodium naphthalenide. 2,2,6,6-tetramethylpiperidino 95-124 BCL2 apoptosis regulator Homo sapiens 85-89 28980375-1 2017 A triaminotriborane(3) was isolated as purple crystals through the reduction of (TMP)BCl2 (TMP=2,2,6,6-tetramethylpiperidino) by sodium naphthalenide. SODIUM NAPHTHALENIDE 129-149 BCL2 apoptosis regulator Homo sapiens 85-89 28356020-7 2017 Supporting the observations, Treatment with the cyanidin-3-glucoside showed active apoptosis by caspase-3 cleavage and DNA fragmentation through Bcl-2 and Bax pathway. cyanidin-3-o-glucoside 48-68 BCL2 apoptosis regulator Homo sapiens 145-150 28356024-7 2017 Citalopram caused an increase in mitochondrial Bax levels and a decrease in Bcl2 levels and also caused cytochrome c release. Citalopram 0-10 BCL2 apoptosis regulator Homo sapiens 76-80 28356024-9 2017 Oxidant scavengers and Bay 11-7082 (an irreversible inhibitor of NFkappaB activation) prevented the citalopram-associated cell death, increased BAX and decreased Bcl2. 3-(4-methylphenylsulfonyl)-2-propenenitrile 23-34 BCL2 apoptosis regulator Homo sapiens 162-166 29344242-0 2017 In vivo and in vitro induction of the apoptotic effects of oxysophoridine on colorectal cancer cells via the Bcl-2/Bax/caspase-3 signaling pathway. oxysophoridine 59-73 BCL2 apoptosis regulator Homo sapiens 109-114 29173002-7 2017 CONCLUSION: Our study demonstrates that miR-509-3p could sensitize ovarian cancer cells to cisplatin treatment by targeting multiple anti-apoptosis genes including BCL2. Cisplatin 91-100 BCL2 apoptosis regulator Homo sapiens 164-168 29136581-6 2017 Honokiol promoted apoptosis of 3T3-L1 white adipocytes and inhibited apoptosis of HIB1B brown adipocytes via opposite regulation of the pro-apoptotic protein BAX and anti-apoptotic protein Bcl-2. honokiol 0-8 BCL2 apoptosis regulator Homo sapiens 189-194 28597454-4 2017 In comparison with 2-O-methylantimycin, which acts at the locus of Bcl-2, none of the new derivatives exhibited a difference in cytotoxicity toward cells expressing different levels of Bcl-2. 2-o-methylantimycin 19-38 BCL2 apoptosis regulator Homo sapiens 67-72 29183320-11 2017 Furthermore, fungal EDT induced apoptosis in HepG2 cells in a dose-dependent manner associated with ROS generation and increased Bax/Bcl-2 ratio, p38 MAPKs and PARP cleavage. edt 20-23 BCL2 apoptosis regulator Homo sapiens 133-138 28847998-3 2017 In preclinical studies, venetoclax enhanced bortezomib activity, suggesting that cotargeting of BCL-2 and MCL-1 could be an effective treatment strategy in myeloma. venetoclax 24-34 BCL2 apoptosis regulator Homo sapiens 96-101 29018077-1 2017 Venetoclax is a selective, orally bioavailable BCL-2 inhibitor that induces cell death in multiple myeloma (MM) cells, particularly in those harboring t(11;14), which express high levels of BCL-2 relative to BCL-XL and MCL-1. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 47-52 29200826-6 2017 Results: At 3, 6, 12, and 24 microg/mL exposure, DEN and DEN-HPbetaCD complex significantly affected apoptosis in HT-29 cells through the down-regulation of Bcl-2 and cyclin A in turn, and up-regulation of Bax, p53, p21, cytochrome c at both protein and mRNA levels. den-hpbetacd 57-69 BCL2 apoptosis regulator Homo sapiens 157-162 29200826-6 2017 Results: At 3, 6, 12, and 24 microg/mL exposure, DEN and DEN-HPbetaCD complex significantly affected apoptosis in HT-29 cells through the down-regulation of Bcl-2 and cyclin A in turn, and up-regulation of Bax, p53, p21, cytochrome c at both protein and mRNA levels. dentatin 49-52 BCL2 apoptosis regulator Homo sapiens 157-162 29018077-1 2017 Venetoclax is a selective, orally bioavailable BCL-2 inhibitor that induces cell death in multiple myeloma (MM) cells, particularly in those harboring t(11;14), which express high levels of BCL-2 relative to BCL-XL and MCL-1. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 190-195 29218010-8 2017 Moreover, exposure to H2O2 significantly increased the levels of Bax, cleaved caspase-3, and cleaved PARP, and decreased the level of Bcl-2, resulting in cell apoptosis. Hydrogen Peroxide 22-26 BCL2 apoptosis regulator Homo sapiens 134-139 29200826-8 2017 Conclusion: Results of this study indicate that the apoptotic pathway caused by DEN and DEN-HPbetaCD complex are mediated by the regulation of caspases and Bcl-2 families in human colon HT-29 cancer cells. dentatin 80-83 BCL2 apoptosis regulator Homo sapiens 156-161 29200826-8 2017 Conclusion: Results of this study indicate that the apoptotic pathway caused by DEN and DEN-HPbetaCD complex are mediated by the regulation of caspases and Bcl-2 families in human colon HT-29 cancer cells. den-hpbetacd 88-100 BCL2 apoptosis regulator Homo sapiens 156-161 29018077-14 2017 Venetoclax monotherapy at a daily dose up to 1200 mg has an acceptable safety profile and evidence of single-agent antimyeloma activity in patients with relapsed/refractory MM, predominantly in patients with t(11;14) abnormality and those with a favorable BCL2 family profile. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 256-260 29291023-2 2017 Anti-apoptotic BCL-2 family inhibitors, such as venetoclax, are promising therapies for AML. venetoclax 48-58 BCL2 apoptosis regulator Homo sapiens 15-20 28972015-4 2017 To test this, we developed a screening assay for evaluating the sensitivity of CTCL cells to targeted molecular agents, and compared a novel BCL2 inhibitor, venetoclax, alone and in combination with a histone deacetylase (HDAC) inhibitor, vorinostat or romidepsin. venetoclax 157-167 BCL2 apoptosis regulator Homo sapiens 141-145 28972015-7 2017 Furthermore, this anti-BCL2 effect was markedly potentiated by concurrent HDAC inhibition with 93% of samples treated with venetoclax and vorinostat and 73% of samples treated with venetoclax and romidepsin showing synergistic effects. venetoclax 123-133 BCL2 apoptosis regulator Homo sapiens 23-27 28972015-7 2017 Furthermore, this anti-BCL2 effect was markedly potentiated by concurrent HDAC inhibition with 93% of samples treated with venetoclax and vorinostat and 73% of samples treated with venetoclax and romidepsin showing synergistic effects. Vorinostat 138-148 BCL2 apoptosis regulator Homo sapiens 23-27 28972015-7 2017 Furthermore, this anti-BCL2 effect was markedly potentiated by concurrent HDAC inhibition with 93% of samples treated with venetoclax and vorinostat and 73% of samples treated with venetoclax and romidepsin showing synergistic effects. venetoclax 181-191 BCL2 apoptosis regulator Homo sapiens 23-27 28847482-3 2017 Mechanism study indicated that esculetin induced gastric cancer MGC-803 cells apoptosis by triggering the activation of mitochondrial apoptotic pathway through reducing the mitochondrial membrane potential (MMP), increasing Bax/Bcl-2 ratio, activating caspase-3 and caspase-9 activity, and increasing cytochrome c release from mitochondria. esculetin 31-40 BCL2 apoptosis regulator Homo sapiens 228-233 29145424-11 2017 Moreover, apoptosis after IRI is reduced in treated vs. untreated hepatocytes, and levosimendan prevents down-regulation of the anti-apoptotic protein Bcl-2 as well as up-regulation of the pro-apoptotic protein BAX. Simendan 83-95 BCL2 apoptosis regulator Homo sapiens 151-156 29145424-13 2017 Our findings suggest that treatment with levosimendan during reperfusion attenuates apoptosis of human hepatocytes by influencing BAX and Bcl-2 levels. Simendan 41-53 BCL2 apoptosis regulator Homo sapiens 138-143 28972015-7 2017 Furthermore, this anti-BCL2 effect was markedly potentiated by concurrent HDAC inhibition with 93% of samples treated with venetoclax and vorinostat and 73% of samples treated with venetoclax and romidepsin showing synergistic effects. romidepsin 196-206 BCL2 apoptosis regulator Homo sapiens 23-27 28895735-6 2017 Cell apoptosis study and Western blotting analysis exhibited TPNPs could significantly increase cell apoptosis via modulating the levels of Bcl-2 protein and Caspase-3, which might be triggered by excess cellular reactive oxygen species (ROS) production through an intracellular ROS detection test. Reactive Oxygen Species 279-282 BCL2 apoptosis regulator Homo sapiens 140-145 29291023-8 2017 Combined, venetoclax and alvocidib modulate the balance of BCL-2 family proteins through complementary, yet variable mechanisms favoring apoptosis, highlighting this combination as a promising therapy for AML or high-risk MDS with the capacity to overcome intrinsic apoptosis mechanisms of resistance. venetoclax 10-20 BCL2 apoptosis regulator Homo sapiens 59-64 29291023-8 2017 Combined, venetoclax and alvocidib modulate the balance of BCL-2 family proteins through complementary, yet variable mechanisms favoring apoptosis, highlighting this combination as a promising therapy for AML or high-risk MDS with the capacity to overcome intrinsic apoptosis mechanisms of resistance. alvocidib 25-34 BCL2 apoptosis regulator Homo sapiens 59-64 28774732-3 2017 PB induced apoptosis by decreasing mitochondrial membrane potential and elevating the Bax/Bcl-2 protein expression ratio in MDA-MB-231 and MCF-7 cells. physapubenolide 0-2 BCL2 apoptosis regulator Homo sapiens 90-95 28852876-3 2017 The inhibition of proliferation of the investigated cells by DATS was correlated with an increase in the inactivated form of Bcl-2. diallyl trisulfide 61-65 BCL2 apoptosis regulator Homo sapiens 125-130 28946186-4 2017 Mechanistic study revealed that Cryptotanshinone suppressed the expression of p-STAT3, Bcl-2, CDK2, Snail and MMP2, and induced the expression of E-cadherin, P53, P21 and beta-catenin. cryptotanshinone 32-48 BCL2 apoptosis regulator Homo sapiens 87-92 29061817-0 2017 Synergistic Inhibition of Human Carcinoma Cell Growth via Co-Delivery of p53 Plasmid DNA and bcl-2 Antisense Oligodeoxyribonucleotide by Cholic Acid-modified Polyethylenimine. Oligodeoxyribonucleotides 109-133 BCL2 apoptosis regulator Homo sapiens 93-98 29061817-0 2017 Synergistic Inhibition of Human Carcinoma Cell Growth via Co-Delivery of p53 Plasmid DNA and bcl-2 Antisense Oligodeoxyribonucleotide by Cholic Acid-modified Polyethylenimine. Cholic Acid 137-148 BCL2 apoptosis regulator Homo sapiens 93-98 29061817-0 2017 Synergistic Inhibition of Human Carcinoma Cell Growth via Co-Delivery of p53 Plasmid DNA and bcl-2 Antisense Oligodeoxyribonucleotide by Cholic Acid-modified Polyethylenimine. Polyethyleneimine 158-174 BCL2 apoptosis regulator Homo sapiens 93-98 29061817-6 2017 CONCLUSION: The co-delivery of p53 plasmid DNA and bcl-2 AS ODN in PEI-CA complexes enhanced therapeutic activities of both p53 plasmid DNA and bcl-2 AS ODN. pei-ca 67-73 BCL2 apoptosis regulator Homo sapiens 51-56 29061817-6 2017 CONCLUSION: The co-delivery of p53 plasmid DNA and bcl-2 AS ODN in PEI-CA complexes enhanced therapeutic activities of both p53 plasmid DNA and bcl-2 AS ODN. pei-ca 67-73 BCL2 apoptosis regulator Homo sapiens 144-149 28823845-4 2017 The upconversion nanophotosensitizer contains the photosensitizing molecules - Zinc phthalocyanine (ZnPc) and Bcl-2 inhibitor - ABT737 small molecules, denoted as ABT737@ZnPc-UCNPs. ABT-737 128-134 BCL2 apoptosis regulator Homo sapiens 110-115 28823845-7 2017 Upon reaching to lysosomes, the acidic environment changes the solubility of PEG-b-PHis, resulting in the burst-release of ABT737 molecules which deplete the Bcl-2 level in tumor cells and leave the tumor cells out from the protection of anti-apoptotic survival pathway in advance. Polyethylene Glycols 77-80 BCL2 apoptosis regulator Homo sapiens 158-163 28950657-1 2017 Colorectal cancer (CRC) cells undergo apoptosis in the presence of the small-molecule inhibitor ABT-263 by up-regulating antiapoptotic Bcl-2 family members. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 96-99 BCL2 apoptosis regulator Homo sapiens 135-140 28865364-0 2017 Antitumor activity of Lobaplatin against esophageal squamous cell carcinoma through caspase-dependent apoptosis and increasing the Bax/Bcl-2 ratio. lobaplatin 22-32 BCL2 apoptosis regulator Homo sapiens 135-140 28865364-8 2017 Lobaplatin significantly inhibited the growth of KYSE-410 and EC-109 cells in a dose- and time-dependent manner and induced cell apoptosis by increasing expressions of cleaved-caspase-3, cleaved-caspase-8, cleaved-caspase-9 and Bax, decreasing expression of Bcl-2. lobaplatin 0-10 BCL2 apoptosis regulator Homo sapiens 258-263 28803443-4 2017 Solasodine was also found to fuel caspase-cascade reaction and increase the ratio between Bax and Bcl-2 so as to induce CRC cell apoptosis. solasodine 0-10 BCL2 apoptosis regulator Homo sapiens 98-103 28938426-9 2017 NMDA specifically induces the mitochondrial-dependent pathway of apoptosis in beta-cells through upregulation of the proapoptotic Bim and Bax, and downregulation of antiapoptotic Bcl-2. N-Methylaspartate 0-4 BCL2 apoptosis regulator Homo sapiens 179-184 28370377-10 2017 Upregulation of Erdr1 and a significant decrease in expression of p53 and bcl-2 were observed after treatment with ingenol mebutate. 3-ingenyl angelate 115-131 BCL2 apoptosis regulator Homo sapiens 74-79 28370377-11 2017 Ingenol mebutate treatment for AK resulted in the modulation of apoptosis-associated molecules with an increase in the expression of Erdr1 and a decrease in the expression of p53 and bcl-2. 3-ingenyl angelate 0-16 BCL2 apoptosis regulator Homo sapiens 183-188 28370377-0 2017 Analysis of apoptosis-associated molecules Erythroid differentiation regulator 1, bcl-2 and p53 in actinic keratosis after treatment with ingenol mebutate. 3-ingenyl angelate 138-154 BCL2 apoptosis regulator Homo sapiens 82-87 28370377-7 2017 The purpose of this study was to investigate whether the expression of apoptosis-associated molecules such as Erdr1, p53 and bcl-2 was affected by the treatment of ingenol mebutate in AK. 3-ingenyl angelate 164-180 BCL2 apoptosis regulator Homo sapiens 125-130 28838842-1 2017 The Bcl-2 protein Bnip3 is crucial for provoking oxidative injury to mitochondria following anthracycline treatment or ischemia-reperfusion injury. Anthracyclines 92-105 BCL2 apoptosis regulator Homo sapiens 4-9 29067118-10 2017 Tectorigenin also inhibited the MPP+-induced changes of Bax and Bcl-2 levels. tectorigenin 0-12 BCL2 apoptosis regulator Homo sapiens 64-69 29067118-10 2017 Tectorigenin also inhibited the MPP+-induced changes of Bax and Bcl-2 levels. mangion-purified polysaccharide (Candida albicans) 32-36 BCL2 apoptosis regulator Homo sapiens 64-69 29067124-11 2017 MTT assays demonstrated that the viability of OCI-LY3 cells was decreased when cells were transfected with miR-21 inhibitor or Bcl-2 small interfering RNA and compared with those of control and negative control groups (all P<0.05). monooxyethylene trimethylolpropane tristearate 0-3 BCL2 apoptosis regulator Homo sapiens 127-132 28972395-1 2017 INTRODUCTION: Venetoclax, an orally bioavailable inhibitor of BCL-2, was approved in 2016 by the United States Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia (CLL) patients with 17p deletion [del(17p)], who have received at least one prior therapy. venetoclax 14-24 BCL2 apoptosis regulator Homo sapiens 62-67 28646535-9 2017 Treatment with HO-3867 resulted in a decrease in Bcl-2 and increase of cleavage of caspase 3, caspase 7, and PARP, confirming induction of apoptosis after treatment with HO-3867. Holmium 15-17 BCL2 apoptosis regulator Homo sapiens 49-54 28888620-8 2017 These data suggest that anti-apoptotic Bcl-2 proteins play an important role in mitochondrial ROS generation by preventing cytochrome c release. Reactive Oxygen Species 94-97 BCL2 apoptosis regulator Homo sapiens 39-44 28958615-14 2017 Also, mRNA gene expression and protein expression of pro-apoptotic (BAX) and anti-apoptotic (BCL-2) genes were analyzed by qRT-PCR and western blot analysis upon styrene substituted biscoumarin treatment to MDA-MB-231 cells. Styrene 162-169 BCL2 apoptosis regulator Homo sapiens 93-98 28958615-14 2017 Also, mRNA gene expression and protein expression of pro-apoptotic (BAX) and anti-apoptotic (BCL-2) genes were analyzed by qRT-PCR and western blot analysis upon styrene substituted biscoumarin treatment to MDA-MB-231 cells. biscoumarin 182-193 BCL2 apoptosis regulator Homo sapiens 93-98 28958615-15 2017 Our results showed that styrene substituted biscoumarin downregulated BCL-2 gene expression and upregulated BAX gene expression to trigger apoptotic process. Styrene 24-31 BCL2 apoptosis regulator Homo sapiens 70-75 28958615-15 2017 Our results showed that styrene substituted biscoumarin downregulated BCL-2 gene expression and upregulated BAX gene expression to trigger apoptotic process. biscoumarin 44-55 BCL2 apoptosis regulator Homo sapiens 70-75 28646535-9 2017 Treatment with HO-3867 resulted in a decrease in Bcl-2 and increase of cleavage of caspase 3, caspase 7, and PARP, confirming induction of apoptosis after treatment with HO-3867. Holmium 170-172 BCL2 apoptosis regulator Homo sapiens 49-54 28280274-0 2017 The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression. 4-fluorobenzoyl-TN-14003 20-27 BCL2 apoptosis regulator Homo sapiens 87-92 31966420-6 2017 More importantly, 9-cis-RA treatment could reduce the apoptotic rate of neurons caused by H2O2 or Abeta stimulation via enhancing the expression level of Bcl-2 protein. retinol acetate 18-26 BCL2 apoptosis regulator Homo sapiens 154-159 31966420-6 2017 More importantly, 9-cis-RA treatment could reduce the apoptotic rate of neurons caused by H2O2 or Abeta stimulation via enhancing the expression level of Bcl-2 protein. Water 90-94 BCL2 apoptosis regulator Homo sapiens 154-159 31966431-6 2017 Furthermore studies showed that miR-181a directly targeted Bcl-2, and Bcl-2 downregulation inhibited the remedy effect of miR-181a inhibitor on DDVP induced cell toxicity. Dichlorvos 144-148 BCL2 apoptosis regulator Homo sapiens 59-64 31966431-6 2017 Furthermore studies showed that miR-181a directly targeted Bcl-2, and Bcl-2 downregulation inhibited the remedy effect of miR-181a inhibitor on DDVP induced cell toxicity. Dichlorvos 144-148 BCL2 apoptosis regulator Homo sapiens 70-75 31966431-7 2017 It is, therefore, concluded that miR-181a knockdown could protect hepatic cells from DDVP induced oxidative stress and apoptosis by targeting bcl-2. Dichlorvos 85-89 BCL2 apoptosis regulator Homo sapiens 142-147 28724188-5 2017 Docking simulations with anti-apoptotic protein Bcl-2, which is also involved in cancer metastasis displayed good affinity and high binding energy of 3a into the well characterized BH3 binding site. BH 3 181-184 BCL2 apoptosis regulator Homo sapiens 48-53 29332355-0 2017 Antitumor activity of 4-O-Methylhonokiol in human oral cancer cells is mediated via ROS generation, disruption of mitochondrial potential, cell cycle arrest and modulation of Bcl-2/Bax proteins. 4-O-methylhonokiol 22-40 BCL2 apoptosis regulator Homo sapiens 175-180 28964887-1 2017 The aim of this study is to determine the behavior of relative expression of Bcl-2, caspase-8, caspase-9, and caspase-3 genes of/in SK-MEL-3 cancer cells and explore molecular mechanisms responsible for the apoptosis response during an in vitro photodynamic therapy (PDT) with Zinc Phthalocyanine (ZnPc) using different doses of the light source. Zn(II)-phthalocyanine 277-296 BCL2 apoptosis regulator Homo sapiens 77-82 28964887-1 2017 The aim of this study is to determine the behavior of relative expression of Bcl-2, caspase-8, caspase-9, and caspase-3 genes of/in SK-MEL-3 cancer cells and explore molecular mechanisms responsible for the apoptosis response during an in vitro photodynamic therapy (PDT) with Zinc Phthalocyanine (ZnPc) using different doses of the light source. Zn(II)-phthalocyanine 298-302 BCL2 apoptosis regulator Homo sapiens 77-82 28280274-9 2017 Importantly, treatment with a BCL-2 inhibitor induced apoptosis and act together with BL-8040 to enhance cell death. 4-fluorobenzoyl-TN-14003 86-93 BCL2 apoptosis regulator Homo sapiens 30-35 28835385-6 2017 Combination treatments of PDT and BEZ235 exhibited a cooperative inhibition of antiapoptotic Bcl-2 family protein Mcl-1 and induced more cell apoptosis than each treatment alone. dactolisib 34-40 BCL2 apoptosis regulator Homo sapiens 93-98 28714224-0 2017 Codelivery for Paclitaxel and Bcl-2 Conversion Gene by PHB-PDMAEMA Amphiphilic Cationic Copolymer for Effective Drug Resistant Cancer Therapy. copolymer 88-97 BCL2 apoptosis regulator Homo sapiens 30-35 27785753-10 2017 Melatonin also effectively exerted an antiapoptotic and anti-inflammatory action by regulating Bax, Bcl-2, p-NFkappaB, and iNOS expressions in SH-SY5Y cells. Melatonin 0-9 BCL2 apoptosis regulator Homo sapiens 100-105 28985947-0 2017 Induction of the chromosomal translocation t(14;18) by targeting the BCL-2 locus with specific binding I-125-labeled triplex-forming oligonucleotides. Iodine-125 103-108 BCL2 apoptosis regulator Homo sapiens 69-74 28901518-8 2017 In conclusion, ailanthone may inhibit the proliferation of SGC-7901 cells by inducing G2/M phase cell cycle arrest and apoptosis via altering the protein and mRNA expression levels of Bcl-2 and Bax in SGC-7901 cells. ailanthone 15-25 BCL2 apoptosis regulator Homo sapiens 184-189 28944894-15 2017 In conclusion, the metabolic changes of sphingolipids caused by the lack of GCS may be involved in the proliferation and apoptosis of liver cells through the Bcl-2/Bax signaling pathway. Sphingolipids 40-53 BCL2 apoptosis regulator Homo sapiens 158-163 28985947-0 2017 Induction of the chromosomal translocation t(14;18) by targeting the BCL-2 locus with specific binding I-125-labeled triplex-forming oligonucleotides. triplex-forming oligonucleotides 117-149 BCL2 apoptosis regulator Homo sapiens 69-74 28985947-3 2017 We studied gene expression, translocation frequency and protein expression in SCL-II cells after transfection with the AEE Iodine-125 (I-125) labeled TFO-BCL2 targeting the human BCL2 gene. aspirin eugenol ester 119-122 BCL2 apoptosis regulator Homo sapiens 154-158 28985947-3 2017 We studied gene expression, translocation frequency and protein expression in SCL-II cells after transfection with the AEE Iodine-125 (I-125) labeled TFO-BCL2 targeting the human BCL2 gene. aspirin eugenol ester 119-122 BCL2 apoptosis regulator Homo sapiens 179-183 28985947-3 2017 We studied gene expression, translocation frequency and protein expression in SCL-II cells after transfection with the AEE Iodine-125 (I-125) labeled TFO-BCL2 targeting the human BCL2 gene. tfo 150-153 BCL2 apoptosis regulator Homo sapiens 154-158 28985947-3 2017 We studied gene expression, translocation frequency and protein expression in SCL-II cells after transfection with the AEE Iodine-125 (I-125) labeled TFO-BCL2 targeting the human BCL2 gene. tfo 150-153 BCL2 apoptosis regulator Homo sapiens 179-183 28985947-4 2017 The TFO-BCL2 binds to the BCL2 gene in close proximity to a known major-breakage-region (mbr). tfo 4-7 BCL2 apoptosis regulator Homo sapiens 8-12 28982057-4 2017 RESULTS: BIX-01294 inhibits expression of Bcl-2, upregulates expression of Bax and caspase-3 and induces cell apoptosis. BIX 01294 9-18 BCL2 apoptosis regulator Homo sapiens 42-47 28985947-4 2017 The TFO-BCL2 binds to the BCL2 gene in close proximity to a known major-breakage-region (mbr). tfo 4-7 BCL2 apoptosis regulator Homo sapiens 26-30 28985947-10 2017 The relative gene expression of BCL2 in I-125-TFO-BCL2 transfected cells showed a significant up-regulation when compared to controls. tfo 46-49 BCL2 apoptosis regulator Homo sapiens 32-36 28985947-10 2017 The relative gene expression of BCL2 in I-125-TFO-BCL2 transfected cells showed a significant up-regulation when compared to controls. tfo 46-49 BCL2 apoptosis regulator Homo sapiens 50-54 29113186-11 2017 Puerarin treatment suppressed the expression of p-Akt and Bcl-2 but promoted the expression of Bax and cleaved caspase-3 in SW1353 cells. puerarin 0-8 BCL2 apoptosis regulator Homo sapiens 58-63 28901484-6 2017 These DOX-resistant cells also showed increases in p21, Bcl-2 and MDR-1 expression. Doxorubicin 6-9 BCL2 apoptosis regulator Homo sapiens 56-61 28901484-7 2017 Supplementation with 200 microM I2 exerted similar effects in both cell lines: it decreased the proliferation rate by ~40%, and I2 co-administration with DOX significantly increased the inhibitory effect (to ~60%) and also increased apoptosis (BAX/Bcl-2 index), principally by inhibiting Bcl-2 expression. Doxorubicin 154-157 BCL2 apoptosis regulator Homo sapiens 248-253 28901484-7 2017 Supplementation with 200 microM I2 exerted similar effects in both cell lines: it decreased the proliferation rate by ~40%, and I2 co-administration with DOX significantly increased the inhibitory effect (to ~60%) and also increased apoptosis (BAX/Bcl-2 index), principally by inhibiting Bcl-2 expression. Doxorubicin 154-157 BCL2 apoptosis regulator Homo sapiens 288-293 28901519-4 2017 Sal downregulated the expression of Bax and p53 and increased the ratio of Bcl-2/Bax, which indicated that Sal inhibited the radiation-induced apoptosis through p53-dependent pathways. rhodioloside 0-3 BCL2 apoptosis regulator Homo sapiens 75-80 28901519-4 2017 Sal downregulated the expression of Bax and p53 and increased the ratio of Bcl-2/Bax, which indicated that Sal inhibited the radiation-induced apoptosis through p53-dependent pathways. rhodioloside 107-110 BCL2 apoptosis regulator Homo sapiens 75-80 29098037-7 2017 It was also demonstrated that doxorubicin, an anticancer agent, reduced cell viability, induced a significant increase in the B-cell lymphoma (Bcl)-2 associated X protein (Bax)/Bcl-2 ratio and decreased pro-caspase-3 levels in wild-type HepG2 cells. Doxorubicin 30-41 BCL2 apoptosis regulator Homo sapiens 177-182 29113197-7 2017 Acidic pHe 6.5 induced ratio expression of B-cell lymphoma 2 (Bcl2)/Bcl2 associated X-protein (Bax), which in turn induced apoptosis, and inhibited cellular proliferation and other functional activities, with involvement of activation of VEGF receptor 2, protein kinase B and p38 mitogen activated protein kinase. Phenylalanine 7-10 BCL2 apoptosis regulator Homo sapiens 43-60 29113197-7 2017 Acidic pHe 6.5 induced ratio expression of B-cell lymphoma 2 (Bcl2)/Bcl2 associated X-protein (Bax), which in turn induced apoptosis, and inhibited cellular proliferation and other functional activities, with involvement of activation of VEGF receptor 2, protein kinase B and p38 mitogen activated protein kinase. Phenylalanine 7-10 BCL2 apoptosis regulator Homo sapiens 62-66 29061914-2 2017 Clinical utility for selective inhibition of specific anti-apoptotic Bcl-2 family proteins has recently been realized with the Food and Drug Administration (FDA) approval of venetoclax (formerly ABT-199/GDC-0199) in relapsed chronic lymphocytic leukemia (CLL) with 17p deletion. venetoclax 174-184 BCL2 apoptosis regulator Homo sapiens 69-74 29073244-5 2017 We found that 10 muM resveratrol improved the proliferation of porcine PSCs, increased the expression of A-beta-catenin (active beta-catenin), Pcna, C-Myc, Bcl-2 and sirtuin-1 (Sirt1), and decreased the expression of P53, Caspase3. Resveratrol 21-32 BCL2 apoptosis regulator Homo sapiens 156-161 29110583-8 2017 The beta-mangostin-catalyzed apoptosis action through caspase-3, caspase-7, and caspase-9 activation overproduced reactive oxygen species which downregulated the expression of antiapoptotic genes Bcl-2 and HSP70. beta-Mangostin 4-18 BCL2 apoptosis regulator Homo sapiens 196-201 29110583-8 2017 The beta-mangostin-catalyzed apoptosis action through caspase-3, caspase-7, and caspase-9 activation overproduced reactive oxygen species which downregulated the expression of antiapoptotic genes Bcl-2 and HSP70. Reactive Oxygen Species 114-137 BCL2 apoptosis regulator Homo sapiens 196-201 29228621-9 2017 Compared with the DDP group and UA group, the expressions of Bcl-2 and NF-kappaB p65 in DDP +UA group were decreased, while the expressions of Bax, Caspase-3 and PARP cleavage were observably increased. ursolic acid 32-34 BCL2 apoptosis regulator Homo sapiens 61-66 29228621-9 2017 Compared with the DDP group and UA group, the expressions of Bcl-2 and NF-kappaB p65 in DDP +UA group were decreased, while the expressions of Bax, Caspase-3 and PARP cleavage were observably increased. ursolic acid 93-95 BCL2 apoptosis regulator Homo sapiens 61-66 29065135-1 2017 TW-37 is a novel, potent and non-peptide Bcl-2 small-molecule inhibitor. TW-37 0-5 BCL2 apoptosis regulator Homo sapiens 41-46 29061914-2 2017 Clinical utility for selective inhibition of specific anti-apoptotic Bcl-2 family proteins has recently been realized with the Food and Drug Administration (FDA) approval of venetoclax (formerly ABT-199/GDC-0199) in relapsed chronic lymphocytic leukemia (CLL) with 17p deletion. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 195-198 BCL2 apoptosis regulator Homo sapiens 69-74 29061914-2 2017 Clinical utility for selective inhibition of specific anti-apoptotic Bcl-2 family proteins has recently been realized with the Food and Drug Administration (FDA) approval of venetoclax (formerly ABT-199/GDC-0199) in relapsed chronic lymphocytic leukemia (CLL) with 17p deletion. venetoclax 203-211 BCL2 apoptosis regulator Homo sapiens 69-74 29061914-5 2017 In addition to direct targeting of Bcl-2 family proteins with BH3 mimetics, combination therapies that aim at down-regulating expression of anti-apoptotic BCL-2 family members or restoring expression of pro-apoptotic BH3 family proteins may provide a means to deepen responses to venetoclax and extend the utility to additional indications. BH 3 62-65 BCL2 apoptosis regulator Homo sapiens 35-40 29245959-0 2017 Low concentration of formononetin promotes proliferation of estrogen receptor-positive cells through an ERalpha-miR-375-PTEN-ERK1/2-bcl-2 pathway. formononetin 21-33 BCL2 apoptosis regulator Homo sapiens 132-137 29089887-10 2017 In addition, pretreatment with CSZ suppressed Abeta-induced apoptosis and increased cell viability via suppression of Bax (a proapoptotic protein), upregulation of Bcl-2 (an antiapoptotic protein) and Cu/Zn-SOD (a superoxide scavenging enzyme), and phosphorylation of CREB. Cilostazol 31-34 BCL2 apoptosis regulator Homo sapiens 164-169 29245959-9 2017 In addition, 0.1 and 0.3 muM formononetin significantly increased estrogen receptor-alpha (ERalpha) and bcl-2, but decreased protein-phosphatase and tensin homologue (PTEN) protein expression, all of which was reversed by the miR-375 inhibitor. formononetin 29-41 BCL2 apoptosis regulator Homo sapiens 104-109 29245959-12 2017 Taken together, our study demonstrates that a low concentration of formononetin can promote growth of CNE2 cells and uterine tissues, possibly through regulating the ERalpha-miR-375-PTEN-ERK1/2-bcl-2 signaling pathway. formononetin 67-79 BCL2 apoptosis regulator Homo sapiens 194-199 29254203-3 2017 PROS exerted significant cytotoxicity, induced sub-G1 phase and S phase arrest, increased apoptotic bodies, and attenuated the expression of pro-PARP, Bcl-2, Cyclin E, Cyclin A, CDK2, E2F1, p-Src, p-STAT3, p-ERK, p-AKT, COX-2 and SOCS-1 in A549 and H460 cells along with disrupted binding of STAT3 with CDK2 or VEGF. Proline 0-4 BCL2 apoptosis regulator Homo sapiens 151-156 29045843-6 2017 Senescent melanoma and lung cancer cells acquire sensitivity to the BCL2 family inhibitor ABT263. navitoclax 90-96 BCL2 apoptosis regulator Homo sapiens 68-72 28991436-5 2017 Furthermore, AS1411 can inhibit NF-kappaB signaling and reduce the expression of bcl-2. AGRO 100 13-19 BCL2 apoptosis regulator Homo sapiens 81-86 28976960-9 2017 Drug discontinuation synergized with the melanoma chemotherapeutic agent dacarbazine by further suppressing MITF and its prosurvival target, B-cell lymphoma 2 (BCL-2), and by inducing DNA damage in cancer cells. Dacarbazine 73-84 BCL2 apoptosis regulator Homo sapiens 141-158 29290992-5 2017 Moreover, Oridonin dose-dependently inhibited the expression of several anti-apoptotic proteins, such as Bcl-2, Mcl-1, and x-linked inhibitor of apoptosis (xIAP) in HCC cells. oridonin 10-18 BCL2 apoptosis regulator Homo sapiens 105-110 28866374-0 2017 1-Phenyl-1H-indole derivatives as a new class of Bcl-2/Mcl-1 dual inhibitors: Design, synthesis, and preliminary biological evaluation. 1-Phenyl-1H-indole 0-18 BCL2 apoptosis regulator Homo sapiens 49-54 28866374-3 2017 The preliminary biological studies (binding assay for Bcl-2 proteins and MTT assay) suggested that some active compounds showed potent inhibitory activities on Bcl-2/Mcl-1 without binding on Bcl-XL. monooxyethylene trimethylolpropane tristearate 73-76 BCL2 apoptosis regulator Homo sapiens 160-165 29085821-7 2017 Additionally, metformin increased the expression levels of p53, Bax, Bad while it reduced expression levels of Akt, Bcl-2, and Mdm2. Metformin 14-23 BCL2 apoptosis regulator Homo sapiens 116-121 28976960-9 2017 Drug discontinuation synergized with the melanoma chemotherapeutic agent dacarbazine by further suppressing MITF and its prosurvival target, B-cell lymphoma 2 (BCL-2), and by inducing DNA damage in cancer cells. Dacarbazine 73-84 BCL2 apoptosis regulator Homo sapiens 160-165 29190954-7 2017 Combined delivery of UA and PTX synergistically reduced cell proliferation and induced apoptosis in these cells by lowering COX-2, PCNA, and Bcl-2 expression and by increasing Bax expression. ursolic acid 21-23 BCL2 apoptosis regulator Homo sapiens 141-146 29020630-6 2017 Lysine 17 in Bcl-2 serves as the main acceptor for ubiquitylation, and a Bcl-2 K17A mutant has increased stability and is more potent in protection against apoptosis. Lysine 0-6 BCL2 apoptosis regulator Homo sapiens 13-18 29262554-6 2017 SCH772984 potentiates the cytotoxic effect of CuB on pancreatic cancer cells through complementary inhibition of EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling, followed by an increase in the pro-apoptotic protein Bim and a decrease in the anti-apoptotic proteins Mcl-1, Bcl-2, Bcl-xl and survivin. SCH772984 0-9 BCL2 apoptosis regulator Homo sapiens 269-274 29024661-5 2017 Concomitantly paclitaxel impairs axonal trafficking of RNA-granules and reduces synthesis of Bclw (bcl2l2), a Bcl2 family member that binds IP3R1 and restrains axon degeneration. Paclitaxel 14-24 BCL2 apoptosis regulator Homo sapiens 110-114 29190954-7 2017 Combined delivery of UA and PTX synergistically reduced cell proliferation and induced apoptosis in these cells by lowering COX-2, PCNA, and Bcl-2 expression and by increasing Bax expression. Paclitaxel 28-31 BCL2 apoptosis regulator Homo sapiens 141-146 28968471-5 2017 Our results showed that siHuR decreased transcriptional expressions of galectin-3, beta-catenin, cyclin D1, Bcl-2, P-gp, MRP1, and MRP2 in epirubicin-treated colon cancer cells. Epirubicin 139-149 BCL2 apoptosis regulator Homo sapiens 108-113 28923920-2 2017 Indeed, an inhibitor of Bcl2, venetoclcax, is highly active in the treatment of patients with CLL. venetoclcax 30-41 BCL2 apoptosis regulator Homo sapiens 24-28 28923920-7 2017 We find that this mAb can enhance the in vitro cytotoxic activity of venetoclcax for CLL cells with high-level expression of ROR1, indicating that combining these agents, which target ROR1 and Bcl2, may have additive, if not synergistic, activity in patients with this disease. venetoclcax 69-80 BCL2 apoptosis regulator Homo sapiens 193-197 28974650-10 2017 YK-4-279 also increased the abundance of proapoptotic isoforms of MCL1 and BCL2, presumably through inhibition of alternative splicing by EWS-FLI1, thus promoting cell death in response to vincristine. Vincristine 189-200 BCL2 apoptosis regulator Homo sapiens 75-79 28981599-7 2017 Moreover, DKK4-knockdown promoted the pro-apoptotic effect of docetaxel characterized with caspase 3 activation and inhibition of BCL-2 expression in A549/DTX cells, which was possibly mediated by inducing the activation of c-Jun N-terminal kinase (JNK)-related signaling pathway. Docetaxel 62-71 BCL2 apoptosis regulator Homo sapiens 130-135 28981599-7 2017 Moreover, DKK4-knockdown promoted the pro-apoptotic effect of docetaxel characterized with caspase 3 activation and inhibition of BCL-2 expression in A549/DTX cells, which was possibly mediated by inducing the activation of c-Jun N-terminal kinase (JNK)-related signaling pathway. Digitoxigenin 155-158 BCL2 apoptosis regulator Homo sapiens 130-135 28972959-8 2017 RESULTS Pretreatment with paeonol remarkably rescued MPP+-induced cell viability reduction, up-regulation of cell apoptosis, caspase-1 activity, COX-2, iNOS, and Bax/Bcl-2 ratio in primary astrocytes. paeonol 26-33 BCL2 apoptosis regulator Homo sapiens 166-171 28968471-4 2017 The effects and mechanisms of epirubicin treatment on the expressions of upstream survival signals (e.g., beta-catenin) and downstream MDR transporters (e.g., P-gp) and anti-apoptotic pathways (e.g., Bcl-2) were assessed with or without HuR knockdown (siHuR) or overexpression (overHuR; ectopic HuR or pcDNA3/HA-HuR). Epirubicin 30-40 BCL2 apoptosis regulator Homo sapiens 200-205 28968471-10 2017 The combined treatments of siHuR and epirubicin significantly reduced the expression of Bcl-2, but increased the expression of Bax, as well as activity and expression levels of caspase-3 and -9. sihur 27-32 BCL2 apoptosis regulator Homo sapiens 88-93 28968471-10 2017 The combined treatments of siHuR and epirubicin significantly reduced the expression of Bcl-2, but increased the expression of Bax, as well as activity and expression levels of caspase-3 and -9. Epirubicin 37-47 BCL2 apoptosis regulator Homo sapiens 88-93 28712306-3 2017 They focus on the anti-apoptotic Bcl-2 family members of proteins and the recent drug developments in that field with a special focus on BH3-mimetics. BH 3 137-140 BCL2 apoptosis regulator Homo sapiens 33-38 28821161-4 2017 Additionally, by using western blot and Real-time PCR, we observed that Britannin induced apoptosis by decreasing the expression of BCL-2 and increasing the expression of BAX. britannin 72-81 BCL2 apoptosis regulator Homo sapiens 132-137 28836414-10 2017 Taraxerol could induce the down-regulation of the anti-apoptotic protein Bcl-2 and up-regulation of pro-apoptotic protein Bax. taraxerol 0-9 BCL2 apoptosis regulator Homo sapiens 73-78 28374108-5 2017 We found that geraniin treatment for 48 h significantly (P < 0.05) impaired the phosphorylation of STAT3 and reduced the expression of downstream target genes Bcl-xL, Mcl-1, Bcl-2, and cyclin D1. Geraniin 14-22 BCL2 apoptosis regulator Homo sapiens 177-182 28374108-8 2017 Overexpression of constitutively active STAT3 significantly (P < 0.05) reversed geraniin-mediated growth suppression and apoptosis, which was accompanied by restoration of Bcl-xL, Mcl-1, Bcl-2, and cyclin D1 expression. Geraniin 83-91 BCL2 apoptosis regulator Homo sapiens 190-195 28840508-7 2017 Downregulation of VEGF-A, Bcl-2 and Notch1 proteins in thyroid carcinoma cells were noted in cells that transiently transfected with miR-34b-5p mimic. CHEMBL3740941 141-143 BCL2 apoptosis regulator Homo sapiens 26-31 28799432-8 2017 In addition, most current studies demonstrating the role of BCL-2 inhibitors namely ABT-199/venetoclax in AML will also be discussed. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 84-87 BCL2 apoptosis regulator Homo sapiens 60-65 29544887-9 2017 Artesunate can inhibit the growth of gastric adenocarcinoma cells SGC-7901 and induce the cell apoptosis, the mechanism may be related to the regulation of CDC25A, Bcl-2, Bax, Caspase-3 and mitochondrial membrane potential in SGC-7901 cells. Artesunate 0-10 BCL2 apoptosis regulator Homo sapiens 164-169 28712306-4 2017 With the discovery of BH3-mimetics that interfere with anti-apoptotic Bcl-2 family members in the low nanomolar range significant excitement has been generated towards these class of inhibitors, such as ABT-737, ABT-263 and the most recent successor, ABT-199 which is most advanced with respect to clinical application. BH 3 22-25 BCL2 apoptosis regulator Homo sapiens 70-75 28810525-5 2017 Treatment with osthole resulted in a significant, dose-dependent increase in the expression of pro-apoptotic proteins (cleaved caspase-3 and Bax) and decreased expression of anti-apoptotic proteins (Bcl-2 and survivin), which were consistent with evidence of apoptotic nuclear morphology revealed by DAPI staining. osthol 15-22 BCL2 apoptosis regulator Homo sapiens 199-204 28712306-4 2017 With the discovery of BH3-mimetics that interfere with anti-apoptotic Bcl-2 family members in the low nanomolar range significant excitement has been generated towards these class of inhibitors, such as ABT-737, ABT-263 and the most recent successor, ABT-199 which is most advanced with respect to clinical application. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 203-206 BCL2 apoptosis regulator Homo sapiens 70-75 28712306-4 2017 With the discovery of BH3-mimetics that interfere with anti-apoptotic Bcl-2 family members in the low nanomolar range significant excitement has been generated towards these class of inhibitors, such as ABT-737, ABT-263 and the most recent successor, ABT-199 which is most advanced with respect to clinical application. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 212-215 BCL2 apoptosis regulator Homo sapiens 70-75 28810535-8 2017 In addition, curcumin enhanced radiosensitivity was through markedly inhibiting IR-induced NF-kappaB signaling by modulating the related protein expressions including NF-kappaBP65, I-kappaB, VEGF, COX2, and Bcl-2 in ACHN cells, which was further strengthened by NF-kappaB inhibitor PDTC treatment. Curcumin 13-21 BCL2 apoptosis regulator Homo sapiens 207-212 28712306-4 2017 With the discovery of BH3-mimetics that interfere with anti-apoptotic Bcl-2 family members in the low nanomolar range significant excitement has been generated towards these class of inhibitors, such as ABT-737, ABT-263 and the most recent successor, ABT-199 which is most advanced with respect to clinical application. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 212-215 BCL2 apoptosis regulator Homo sapiens 70-75 28912852-9 2017 Baicalein-treated cells also exhibited significantly reduced expression of Bcl-2, PCNA and cyclin D1 compared with control cells (P<0.05). baicalein 0-9 BCL2 apoptosis regulator Homo sapiens 75-80 28757460-5 2017 Meanwhile, olaquindox activated AKT and Nrf2/HO-1 pathway, up-regulated Bax/Bcl-2 ratio, disrupted mitochondrial membrane potential (MMP) and subsequently caused cytochrome c release and a cascade activation of caspase, eventually induced apoptosis. olaquindox 11-21 BCL2 apoptosis regulator Homo sapiens 76-81 29042970-7 2017 The underlying mechanism may be that 17-DMAG induces oxidative stress, which inhibits the expression of HSPA5 and Bcl-2 and promotes the expression of Bax, leading to the apoptosis of SU-DHL-4 cells. 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin 37-44 BCL2 apoptosis regulator Homo sapiens 114-119 28836501-2 2017 Our data has shown that all-trans retinoic acid significantly reduced expression of RXRalpha mRNA, Bcl2 and enhanced expression of BAX proteins. retinoic 34-42 BCL2 apoptosis regulator Homo sapiens 99-103 28807874-10 2017 DHA induced the Bax/Bcl-2 ratio, mitochondrial accumulation of OSGIN1 and p53, and cytochrome c release; knockdown of OSGIN1 diminished these effects. Docosahexaenoic Acids 0-3 BCL2 apoptosis regulator Homo sapiens 20-25 31966353-6 2017 Furthermore, treatment with rosiglitazone led to decrease the anti-apoptotic protein Bcl-2 level and increase the pro-apoptotic protein caspase 3 level in 5637 and T24 cells. rosiglitazonermsf 28-41 BCL2 apoptosis regulator Homo sapiens 85-90 28692636-0 2017 The Effect of Thymoquinone on Apoptosis of SK-OV-3 Ovarian Cancer Cell by Regulation of Bcl-2 and Bax. thymoquinone 14-26 BCL2 apoptosis regulator Homo sapiens 88-93 28692636-13 2017 Thymoquinone could also activate apoptosis by regulating Bcl-2 and Bax genes. thymoquinone 0-12 BCL2 apoptosis regulator Homo sapiens 57-62 28902342-5 2017 Osthole also significantly induced mitochondrial-dependent apoptosis by upregulating Bax, cleaved caspase-3, cleaved caspase-9, and cleaved poly ADP-ribose polymerase expression, and by downregulating Bcl-2 expression. osthol 0-7 BCL2 apoptosis regulator Homo sapiens 201-206 29552052-11 2017 Furthermore, combinational treatment of paclitaxel and noscapine showed significant decrease in the mRNA expression of B-cell CLL/Lymphoma (Bcl-2) and increase in the mRNA expression of Bcl-2-associated X protein (Bax(, and Bax/Bcl-2 ratio in LNCaP and PC-3 cells (P<0.05. Paclitaxel 40-50 BCL2 apoptosis regulator Homo sapiens 140-145 28871998-11 2017 Greater plasma FLT3 ligand, BCLXL, and BCL2 modulation was observed in patients receiving 131I-MIBG in combination with radiation sensitizers. 3-Iodobenzylguanidine 90-99 BCL2 apoptosis regulator Homo sapiens 39-43 29552052-11 2017 Furthermore, combinational treatment of paclitaxel and noscapine showed significant decrease in the mRNA expression of B-cell CLL/Lymphoma (Bcl-2) and increase in the mRNA expression of Bcl-2-associated X protein (Bax(, and Bax/Bcl-2 ratio in LNCaP and PC-3 cells (P<0.05. Paclitaxel 40-50 BCL2 apoptosis regulator Homo sapiens 186-191 29552052-11 2017 Furthermore, combinational treatment of paclitaxel and noscapine showed significant decrease in the mRNA expression of B-cell CLL/Lymphoma (Bcl-2) and increase in the mRNA expression of Bcl-2-associated X protein (Bax(, and Bax/Bcl-2 ratio in LNCaP and PC-3 cells (P<0.05. Noscapine 55-64 BCL2 apoptosis regulator Homo sapiens 140-145 29552052-11 2017 Furthermore, combinational treatment of paclitaxel and noscapine showed significant decrease in the mRNA expression of B-cell CLL/Lymphoma (Bcl-2) and increase in the mRNA expression of Bcl-2-associated X protein (Bax(, and Bax/Bcl-2 ratio in LNCaP and PC-3 cells (P<0.05. Noscapine 55-64 BCL2 apoptosis regulator Homo sapiens 186-191 28695374-8 2017 In addition, both ruthenium complexes decreased Bcl-2/Bax ratio causing cytochrome c mitochondrial release, the activation of caspase-3 and induction of apoptosis. Ruthenium 18-27 BCL2 apoptosis regulator Homo sapiens 48-53 28300289-4 2017 Dehydrocostus lactone also induces apoptosis by increasing the generation of reactive oxygen species (ROS), disruption of mitochondrial membrane potential (MMP), and modulating the protein levels of Bcl-2 family members. dehydrocostus lactone 0-21 BCL2 apoptosis regulator Homo sapiens 199-204 28300289-5 2017 We also found that dehydrocostus lactone significantly inhibits the phosphorylation expression of Bcr/Abl, STAT5, JAK2, and STAT3 and downstream molecules including p-CrkL, Mcl-1, Bcl-XL, and Bcl-2 proteins in K562 cells. Lactones 33-40 BCL2 apoptosis regulator Homo sapiens 192-197 29254309-9 2017 However, a negative non-significant correlation was observed between BCL-2 and TOS and LDH and TOS (each with; p>0.05). tos 79-82 BCL2 apoptosis regulator Homo sapiens 69-74 28278714-4 2017 Dramatically, Cucurbitacin B (CuB), an effective component of the dichloromethane extraction from Trichosanthes kirilowii Maxim, synergistically eliminated the apoptosis resistance of Burkitt"s lymphoma Ramos cells to ATO by inhibiting the phosphorylation of STAT3, followed in turn by downregulation of Bcl-2 and upregulation of Bax. cucurbitacin B 14-28 BCL2 apoptosis regulator Homo sapiens 304-309 29058293-10 2017 After 24-h exposure to CE-SS, the expression of cleaved-caspase-9, cleaved-caspase-8 and cleaved-caspase-3 protein was activated, the expression of p53 protein increased while the ratio of Bax/Bcl-2 also increased. ce-ss 23-28 BCL2 apoptosis regulator Homo sapiens 193-198 27357816-5 2017 Venetoclax (ABT-199), the recently FDA-approved BCL2 inhibitor, as well as several other agents and therapy combinations in the pipeline offer great promise for patients with chronic lymphocytic leukemia, particularly in the relapsed/refractory setting. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 48-52 27357816-5 2017 Venetoclax (ABT-199), the recently FDA-approved BCL2 inhibitor, as well as several other agents and therapy combinations in the pipeline offer great promise for patients with chronic lymphocytic leukemia, particularly in the relapsed/refractory setting. venetoclax 12-19 BCL2 apoptosis regulator Homo sapiens 48-52 28111464-7 2017 In contrast, treatment with the selective BCL-2 inhibitor venetoclax enhanced overall mitochondrial priming without increasing BCL-2 dependence. venetoclax 58-68 BCL2 apoptosis regulator Homo sapiens 42-47 28482721-4 2017 A potential partner to ibrutinib with a distinct mechanism of action that is likely to lead to deeper responses is the BCL-2 inhibitor venetoclax. ibrutinib 23-32 BCL2 apoptosis regulator Homo sapiens 119-124 28482721-4 2017 A potential partner to ibrutinib with a distinct mechanism of action that is likely to lead to deeper responses is the BCL-2 inhibitor venetoclax. venetoclax 135-145 BCL2 apoptosis regulator Homo sapiens 119-124 29025288-5 2017 New classes of drugs like kinase inhibitors and BCL-2 inhibitors (ibrutinib, idelalisib and venetoclax) are the treatment of choice in CLL patients with relapsed/refractory disease, with the exception of high risk disease, where the optimal treatment is frontline ibrutinib monotherapy. ibrutinib 66-75 BCL2 apoptosis regulator Homo sapiens 48-53 28874608-0 2017 Correction to "6-Mercaptopurine Decreases the Bcl-2/Bax Ratio and Induces Apoptosis in Activated Splenic B Lymphocytes". Mercaptopurine 15-31 BCL2 apoptosis regulator Homo sapiens 46-51 28461171-7 2017 Bcl-2 family proteins also have multifaceted influences on cells and mitochondria, including calcium handling, autophagy and energetics, as well as the subcellular localization of mitochondrial organelles to neuronal synapses. Calcium 93-100 BCL2 apoptosis regulator Homo sapiens 0-5 28869838-5 2017 We also identified activation of PI3K/AKT signaling targeting ER-Ser167 and regulation of Bcl-2 expression as a mediator of FGFR2-promoted resistance to tamoxifen. Tamoxifen 153-162 BCL2 apoptosis regulator Homo sapiens 90-95 29085504-0 2017 Curcumin inhibits cell proliferation and promotes apoptosis of laryngeal cancer cells through Bcl-2 and PI3K/Akt, and by upregulating miR-15a. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 94-99 29085504-2 2017 The aim of the present study was to investigate whether curcumin inhibits cell proliferation and promotes apoptosis of laryngeal cancer through Bcl-2 and phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt), and by upregulating microRNA-15a (miR-15a). Curcumin 56-64 BCL2 apoptosis regulator Homo sapiens 144-149 29085504-4 2017 Furthermore, curcumin decreased Bcl-2 and PI3K protein expression, and decreased the phospho (p)-Akt protein expression of human laryngeal cancer cells. Curcumin 13-21 BCL2 apoptosis regulator Homo sapiens 32-37 28765902-11 2017 In conclusion, miR-26 could facilitate apoptosis and inhibit proliferation/invasion of neuroglioma cells via downregulating Bcl-2 expression and potentiating caspase-3 activity. mir-26 15-21 BCL2 apoptosis regulator Homo sapiens 124-129 28765913-7 2017 Further research indicated that DSS- and cellular tumor antigen p53 (p53)-alone or combination treatment was able to decrease the expression levels of apoptosis regulator BAX and caspase-3, and increase the expression of apoptosis regulator B-cell lymphoma (Bcl)-2 in ALD-stimulated cardiomyocytes. 3,4-dihydroxyphenyllactic acid 32-35 BCL2 apoptosis regulator Homo sapiens 241-264 28945232-5 2017 Anti-apoptotic BCL-2 protein/SUFU feedforward signalling promotes cancer cell survival and growth, and can be disabled with BH3 mimetics-small molecules that target anti-apoptotic BCL-2 proteins. BH 3 124-127 BCL2 apoptosis regulator Homo sapiens 15-20 28945232-5 2017 Anti-apoptotic BCL-2 protein/SUFU feedforward signalling promotes cancer cell survival and growth, and can be disabled with BH3 mimetics-small molecules that target anti-apoptotic BCL-2 proteins. BH 3 124-127 BCL2 apoptosis regulator Homo sapiens 180-185 28849162-1 2017 ABT-737 is a BH-3 mimetic that inhibits Bcl-2 and induces apoptosis of cancer cells, which has potential for anticancer therapies. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 40-45 28849162-7 2017 We found that the combination of ABT-737 and DDP upregulated the expression of the pro-apoptotic protein Bax and downregulated the expression of the pro-survival protein Bcl-2, resulting in a change in the Bax/Bcl-2 ratio, release of cytochrome c, and activation of the mitochondrial apoptotic pathway, which resulted in caspase-9 and caspase-3 activation and PARP cleavage. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 33-36 BCL2 apoptosis regulator Homo sapiens 170-175 28849162-7 2017 We found that the combination of ABT-737 and DDP upregulated the expression of the pro-apoptotic protein Bax and downregulated the expression of the pro-survival protein Bcl-2, resulting in a change in the Bax/Bcl-2 ratio, release of cytochrome c, and activation of the mitochondrial apoptotic pathway, which resulted in caspase-9 and caspase-3 activation and PARP cleavage. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 33-36 BCL2 apoptosis regulator Homo sapiens 210-215 29085504-7 2017 The results of the present study suggest that curcumin inhibits cell proliferation and promotes apoptosis of laryngeal cancer cells through Bcl-2 and PI3K/Akt, and by upregulating miR-15a. Curcumin 46-54 BCL2 apoptosis regulator Homo sapiens 140-145 29025288-5 2017 New classes of drugs like kinase inhibitors and BCL-2 inhibitors (ibrutinib, idelalisib and venetoclax) are the treatment of choice in CLL patients with relapsed/refractory disease, with the exception of high risk disease, where the optimal treatment is frontline ibrutinib monotherapy. idelalisib 77-87 BCL2 apoptosis regulator Homo sapiens 48-53 29025288-5 2017 New classes of drugs like kinase inhibitors and BCL-2 inhibitors (ibrutinib, idelalisib and venetoclax) are the treatment of choice in CLL patients with relapsed/refractory disease, with the exception of high risk disease, where the optimal treatment is frontline ibrutinib monotherapy. venetoclax 92-102 BCL2 apoptosis regulator Homo sapiens 48-53 29025288-5 2017 New classes of drugs like kinase inhibitors and BCL-2 inhibitors (ibrutinib, idelalisib and venetoclax) are the treatment of choice in CLL patients with relapsed/refractory disease, with the exception of high risk disease, where the optimal treatment is frontline ibrutinib monotherapy. ibrutinib 264-273 BCL2 apoptosis regulator Homo sapiens 48-53 28988613-9 2017 CONCLUSION: The expression of Bax and Bcl2 is considered one of the mechanisms underlying APAP-induced nephrotoxicity. Acetaminophen 90-94 BCL2 apoptosis regulator Homo sapiens 38-42 28646740-10 2017 In gene expression, EGCG (80muM) significantly increased Bax/Bcl-2 ratio to 8-fold vise 15-fold in tamoxifen (20muM)-treated T47D cells during 72h. epigallocatechin gallate 20-24 BCL2 apoptosis regulator Homo sapiens 61-66 28646740-10 2017 In gene expression, EGCG (80muM) significantly increased Bax/Bcl-2 ratio to 8-fold vise 15-fold in tamoxifen (20muM)-treated T47D cells during 72h. Tamoxifen 99-108 BCL2 apoptosis regulator Homo sapiens 61-66 28646740-11 2017 In protein expression of Bax/Bcl-2, EGCG significantly increased 6-fold while this ratio augmented 10-fold in tamoxifen group. epigallocatechin gallate 36-40 BCL2 apoptosis regulator Homo sapiens 29-34 28646740-11 2017 In protein expression of Bax/Bcl-2, EGCG significantly increased 6-fold while this ratio augmented 10-fold in tamoxifen group. Tamoxifen 110-119 BCL2 apoptosis regulator Homo sapiens 29-34 28964574-7 2017 EGCG induced apoptosis, decreased the bcl-2 protein expression and increased the expression of bax and caspase-3 protein. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 38-43 28988613-0 2017 Amelioration of panadol-induced nephrotoxicity via down-regulation of Bax/Bcl2 ratio with some antioxidants. Acetaminophen 16-23 BCL2 apoptosis regulator Homo sapiens 74-78 28651465-10 2017 The results also demonstrate that lathyrane diterpene up-regulated Bax and down-regulated Bcl-2 proteins. lathyrane diterpene 34-53 BCL2 apoptosis regulator Homo sapiens 90-95 28624474-7 2017 Permethrin also induced ETV6-RUNX1 and IGH-BCL2 fusions in K562 cells, and malathion induced KMT2A-AFF1 and ETV6-RUNX1 fusions. Permethrin 0-10 BCL2 apoptosis regulator Homo sapiens 43-47 28982309-0 2017 TWIST mediates resistance to paclitaxel by regulating Akt and Bcl-2 expression in gastric cancer cells. Paclitaxel 29-39 BCL2 apoptosis regulator Homo sapiens 62-67 28982309-6 2017 Furthermore, treatment with paclitaxel decreased Akt phosphorylation and Bcl-2 expression, whereas these effects were suppressed by TWIST overexpression. Paclitaxel 28-38 BCL2 apoptosis regulator Homo sapiens 73-78 28982310-15 2017 Furthermore, gemigliptin synergizes with AUY922 in induction of cytotoxicity via regulation of Akt, extracellular signal-regulated kinase 1/2, and adenosine monophosphate-activated protein kinase as well as involvement of Bcl2 family proteins in thyroid carcinoma cells. LC15-0444 13-24 BCL2 apoptosis regulator Homo sapiens 222-226 28982309-7 2017 Treatment of cells with Akt inhibitor or small interfering RNA targeting for Bcl-2 led to increased paclitaxel-induced cell death, indicating that TWIST elicits resistance to paclitaxel via the regulation of the Akt and Bcl-2 pathway. Paclitaxel 100-110 BCL2 apoptosis regulator Homo sapiens 77-82 28982310-15 2017 Furthermore, gemigliptin synergizes with AUY922 in induction of cytotoxicity via regulation of Akt, extracellular signal-regulated kinase 1/2, and adenosine monophosphate-activated protein kinase as well as involvement of Bcl2 family proteins in thyroid carcinoma cells. 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide 41-47 BCL2 apoptosis regulator Homo sapiens 222-226 28982309-7 2017 Treatment of cells with Akt inhibitor or small interfering RNA targeting for Bcl-2 led to increased paclitaxel-induced cell death, indicating that TWIST elicits resistance to paclitaxel via the regulation of the Akt and Bcl-2 pathway. Paclitaxel 100-110 BCL2 apoptosis regulator Homo sapiens 220-225 28982309-7 2017 Treatment of cells with Akt inhibitor or small interfering RNA targeting for Bcl-2 led to increased paclitaxel-induced cell death, indicating that TWIST elicits resistance to paclitaxel via the regulation of the Akt and Bcl-2 pathway. Paclitaxel 175-185 BCL2 apoptosis regulator Homo sapiens 77-82 28982309-7 2017 Treatment of cells with Akt inhibitor or small interfering RNA targeting for Bcl-2 led to increased paclitaxel-induced cell death, indicating that TWIST elicits resistance to paclitaxel via the regulation of the Akt and Bcl-2 pathway. Paclitaxel 175-185 BCL2 apoptosis regulator Homo sapiens 220-225 28973972-3 2017 Mechanistically, ME exhibited protection from H2O2-induced neurotoxicity via caspase-3 inactivation, Bcl-2 downregulation, Bax upregulation, and MAPK activation (ERK 1/2, JNK 1/2, and p38 MAPK) in vitro. methionylglutamic acid 17-19 BCL2 apoptosis regulator Homo sapiens 101-106 28710745-0 2017 The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells. gossypol acetic acid 23-28 BCL2 apoptosis regulator Homo sapiens 8-12 28710745-3 2017 AT101 binds to the BH3 motif of all Bcl-2 family anti-apoptotic proteins and demonstrates anti-tumor activity in multiple types of tumor. BH 3 19-22 BCL2 apoptosis regulator Homo sapiens 36-41 29163807-9 2017 Furthermore, macitentan cooperates with ibrutinib inhibiting the BCR pathway and with ABT-199 disrupting BCL2 pathway. macitentan 13-23 BCL2 apoptosis regulator Homo sapiens 105-109 29071206-8 2017 The expression of p-p65, p-AKT and Bcl-2 was significantly reduced by LY294002, but increased by ERbeta siRNA (p < 0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 70-78 BCL2 apoptosis regulator Homo sapiens 35-40 29033852-5 2017 Over-expression of BCL-2 (but not BCL-XL) inhibited formation of ER oligomeric BAX/BAK by GA. Our results demonstrated that activation of the CK II by GA is required for the BIK-mediated ROS-dependent apoptotic activity of ER-associated BAX/BAK. Gallic Acid 90-92 BCL2 apoptosis regulator Homo sapiens 19-24 29033852-5 2017 Over-expression of BCL-2 (but not BCL-XL) inhibited formation of ER oligomeric BAX/BAK by GA. Our results demonstrated that activation of the CK II by GA is required for the BIK-mediated ROS-dependent apoptotic activity of ER-associated BAX/BAK. Reactive Oxygen Species 187-190 BCL2 apoptosis regulator Homo sapiens 19-24 29212196-6 2017 Anti-apoptotic members Bcl-2 and Bcl-xl were reduced, and pro-apoptotic members Bax and Bad were enhanced in cells and animals receiving juglanin. juglanin 137-145 BCL2 apoptosis regulator Homo sapiens 23-28 29163807-9 2017 Furthermore, macitentan cooperates with ibrutinib inhibiting the BCR pathway and with ABT-199 disrupting BCL2 pathway. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 86-89 BCL2 apoptosis regulator Homo sapiens 105-109 29156797-0 2017 JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 40-43 BCL2 apoptosis regulator Homo sapiens 24-29 28989285-1 2017 INTRODUCTION: Previous research suggested that a novel compound PNT2258 inhibits B-cell lymphoma 2 (BCL-2) transcription by DNA interference (DNAi) and demonstrated its activity in preclinical xenograft models and in a pilot Phase II clinical trial in non-Hodgkin"s lymphoma (NHL). PNT100 64-71 BCL2 apoptosis regulator Homo sapiens 81-98 28989285-1 2017 INTRODUCTION: Previous research suggested that a novel compound PNT2258 inhibits B-cell lymphoma 2 (BCL-2) transcription by DNA interference (DNAi) and demonstrated its activity in preclinical xenograft models and in a pilot Phase II clinical trial in non-Hodgkin"s lymphoma (NHL). PNT100 64-71 BCL2 apoptosis regulator Homo sapiens 100-105 28669729-6 2017 The expressions of caspase-3, caspase-9 and Bax/Bcl-2 were increased with H2O2 treatment, and MAN can reverse these changes. Hydrogen Peroxide 74-78 BCL2 apoptosis regulator Homo sapiens 48-53 28935920-7 2017 Moreover, BAY treatment reversed the Abeta-induced changes in IL-22 and IL-17 and the ratio of Bax/Bcl-2. 2-(3,4-dimethoxybenzyl)-7-(1-(1-hydroxyethyl)-4-phenylbutyl)-5-methylimidazo(5,1-f)(1,2,4)triazin-4 (3H)-one 10-13 BCL2 apoptosis regulator Homo sapiens 99-104 29156797-3 2017 Previous clinical study showed that single agent targeting Bcl-2 with ABT-263 was of limited efficacy in SCLC. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 70-73 BCL2 apoptosis regulator Homo sapiens 59-64 29156797-8 2017 ABT-263 and JQ1 co-treatment in MYCN-amplified SCLC cells markedly disrupted Bim/Bcl-2 interaction, and prevented Bim"s interaction with Mcl-1. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 81-86 29294513-8 2017 PQ dramatically induced HK-2 apoptosis evidenced by increasing expressions of caspase-9, caspase-3 and Bax, while decreasing Bcl-2 level. Paraquat 0-2 BCL2 apoptosis regulator Homo sapiens 125-130 28688761-6 2017 Overexpression of Gm4419 in injury-treated astrocytes increased protein expressions of TNF-alpha, Bax, cleaved caspase-3 and cleaved caspase-9, decreased levels of Bcl-2 and CyclinD1, and significantly led to cellular apoptosis. gm4419 18-24 BCL2 apoptosis regulator Homo sapiens 164-169 28673964-6 2017 Unlike the protonophore carbonyl cyanide m-chlorophenylhydrazone, which activates the mitophagy response, sorafenib treatment triggers PINK1/Parkin-dependent cellular apoptosis, which is attenuated upon Bcl-2 overexpression. Sorafenib 106-115 BCL2 apoptosis regulator Homo sapiens 203-208 28979680-10 2017 After treatment of cisplatin, SKOV3 and hey cells showed increased apoptotic rate in flow cytometry assay, increased protein levels of cleaved caspase 3, cleaved PARP and Bax, and decreased protein levels of Bcl-2 and Bcl-XL. Cisplatin 19-28 BCL2 apoptosis regulator Homo sapiens 208-213 28979133-9 2017 In addition, we confirmed that knockdown of BEZ235 and PI3KCA induced cell apoptosis through the upregulated levels of cleavage caspase 3 and Bax and downregulated expression of Bcl-2 and Bim. dactolisib 44-50 BCL2 apoptosis regulator Homo sapiens 178-183 28711493-7 2017 Sequential therapy with doxorubicin did not affect the replication of ZD55-shMYCN in doxorubicin-resistant neuroblastoma cells, but decreased the expression of Bcl-2, Bcl-XL, MMP-1. Doxorubicin 24-35 BCL2 apoptosis regulator Homo sapiens 160-165 29245930-6 2017 HMNQ-treated cells resulted in apoptotic cell death through PARP-1 cleavage, Bax upregulation and Bcl-2 downregulation. hmnq 0-4 BCL2 apoptosis regulator Homo sapiens 98-103 28974890-9 2017 After treatment with DHM, the protein expression of Notch1 was downregulated, the apoptosis-related protein Bax was upregulated and Bcl2 was downregulated. dihydromyricetin 21-24 BCL2 apoptosis regulator Homo sapiens 132-136 28586716-0 2017 Design, synthesis and characterization of novel quinacrine analogs that preferentially kill cancer over non-cancer cells through the down-regulation of Bcl-2 and up-regulation of Bax and Bad. Quinacrine 48-58 BCL2 apoptosis regulator Homo sapiens 152-157 28793767-5 2017 Meanwhile, 20(S)-Rh2 promoted Nur77 translocation from the nucleus to mitochondria and enhanced the interaction between Nur77 and Bcl-2, resulting in the exposure of the BH3 domain of Bcl-2 and activation of Bax. (s)-rh2 13-20 BCL2 apoptosis regulator Homo sapiens 130-135 29088864-12 2017 NF-kappaB inhibitor BAY 11-7082 abolished the effects of Rab27 on cisplatin resistance and Bcl-2 protein. 3-(4-methylphenylsulfonyl)-2-propenenitrile 20-31 BCL2 apoptosis regulator Homo sapiens 91-96 28793767-5 2017 Meanwhile, 20(S)-Rh2 promoted Nur77 translocation from the nucleus to mitochondria and enhanced the interaction between Nur77 and Bcl-2, resulting in the exposure of the BH3 domain of Bcl-2 and activation of Bax. (s)-rh2 13-20 BCL2 apoptosis regulator Homo sapiens 184-189 28799743-7 2017 Moreover, GNP-DTX/Qu/IMA demonstrated obvious advantages in inducing apoptosis and mediating the expression of apoptosis-related proteins (Caspase 3, Caspase 9, and bcl-2). Docetaxel 14-17 BCL2 apoptosis regulator Homo sapiens 165-170 28780868-7 2017 Using this reference-free method based on CE-FA data, jatrorrhizine and palmatine were found to bind specifically to the Bcl-2 promoter G-quadruplex with stoichiometries of 4:1 and 3:1, respectively. jatrorrhizine 54-67 BCL2 apoptosis regulator Homo sapiens 121-126 28780868-7 2017 Using this reference-free method based on CE-FA data, jatrorrhizine and palmatine were found to bind specifically to the Bcl-2 promoter G-quadruplex with stoichiometries of 4:1 and 3:1, respectively. palmatine 72-81 BCL2 apoptosis regulator Homo sapiens 121-126 28564582-4 2017 Moreover, miR-145 protected GCs against H2O2-induced apoptosis by targeting KLF4, which promoted H2O2-induced GC apoptosis via the BAX/BCL-2 pathway. Hydrogen Peroxide 40-44 BCL2 apoptosis regulator Homo sapiens 135-140 28603046-10 2017 Knockdown of PERK decreased the ratio of Bax/Bcl-2, GRP78 and CHOP expression, suggesting that PERK signal pathway was involved in HCPT-induced fibroblast apoptosis. hydroxycamptothecinum 131-135 BCL2 apoptosis regulator Homo sapiens 45-50 28564582-4 2017 Moreover, miR-145 protected GCs against H2O2-induced apoptosis by targeting KLF4, which promoted H2O2-induced GC apoptosis via the BAX/BCL-2 pathway. Hydrogen Peroxide 97-101 BCL2 apoptosis regulator Homo sapiens 135-140 28596293-8 2017 Autophagic dysfunction due to CS exposure coupled with Zn depletion also induced apoptosis, with the reduction of antiapoptotic and antiautophagic proteins Bcl2 and XIAP and PARP cleavage. Cesium 30-32 BCL2 apoptosis regulator Homo sapiens 156-160 27689466-10 2017 Moreover, Pretreatment with E2 followed by cisplatin decreased the expression of cleaved PARP, and increased the expression of anti-apoptotic protein Bcl-2. Cisplatin 43-52 BCL2 apoptosis regulator Homo sapiens 150-155 28928657-7 2017 Our study in metastatic MDA-MB-231 cells showed that both ethanol and acetone pulp extracts decreased transcript levels of the anti-apoptotic genes BCL2 and BCLXL, and a reverse effect was observed for the pro-apoptotic genes BAX and caspase 3. Ethanol 58-65 BCL2 apoptosis regulator Homo sapiens 148-152 28928657-7 2017 Our study in metastatic MDA-MB-231 cells showed that both ethanol and acetone pulp extracts decreased transcript levels of the anti-apoptotic genes BCL2 and BCLXL, and a reverse effect was observed for the pro-apoptotic genes BAX and caspase 3. Acetone 70-77 BCL2 apoptosis regulator Homo sapiens 148-152 27362495-6 2017 Comparing IMAB-AgNPs to AgNPs and Imatinib revealed the ability of IMAB-AgNPs to up-regulating Bax/Bcl-2 ratio. Imatinib Mesylate 34-42 BCL2 apoptosis regulator Homo sapiens 99-104 28562380-1 2017 Venetoclax is a first-in-class orally available, B-cell lymphoma (BCL)-2 inhibitor indicated for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) harboring the 17p deletion. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 49-72 27519795-18 2017 Restoration of miR-204-5p in PCa could therefore be considered as a novel strategy by targeting antiapoptotic BCL2. mir-204-5p 15-25 BCL2 apoptosis regulator Homo sapiens 110-114 28444938-6 2017 Knockdown of STAT3 reduced expressions of cyclin D1, COX-2, PCNA, and BCL2 induced by arsenite. arsenite 86-94 BCL2 apoptosis regulator Homo sapiens 70-74 28715864-8 2017 Treatment with 2-acetyl-benzylamine decreased the Bcl-2 activity and increased the Bax expression; cytochrome c was released and caspases-3 was activated in MOLM-14 and NB-4 cells. 2-acetyl benzylamine 15-35 BCL2 apoptosis regulator Homo sapiens 50-55 28715864-11 2017 Molecular docking study has been performed to investigate the binding mode and to estimate the binding energy of 2-acetyl-benzylamine with the active site of JAK-2, AKT1, FLT3 and Bcl-2. 2-acetyl benzylamine 113-133 BCL2 apoptosis regulator Homo sapiens 180-185 28710022-3 2017 The cholesterol oxidation products also induced a decrease in the levels of Bid and Bcl-2, increase in the levels of p53 and Bax, loss of the mitochondrial transmembrane potential, release of cytochrome c, activation of caspases (-8, -9 and -3), production of reactive oxygen species, depletion of GSH and cell death in both cell lines. Cholesterol 4-15 BCL2 apoptosis regulator Homo sapiens 84-89 28653252-10 2017 Furthermore, Western blot assay demonstrated that cell death induced by sIL-24 was associated with upregulation of the Bax/Bcl-2 ratio, cytochrome c release, and the expression of cleaved caspase-3, suggesting that sIL-24 induced apoptosis mainly through the mitochondrial pathway. sil-24 72-78 BCL2 apoptosis regulator Homo sapiens 123-128 28653252-10 2017 Furthermore, Western blot assay demonstrated that cell death induced by sIL-24 was associated with upregulation of the Bax/Bcl-2 ratio, cytochrome c release, and the expression of cleaved caspase-3, suggesting that sIL-24 induced apoptosis mainly through the mitochondrial pathway. sil-24 215-221 BCL2 apoptosis regulator Homo sapiens 123-128 28711572-2 2017 DHL encompasses various histologies of lymphomas where the MYC oncogene and either BCL2 or BCL6 oncogenes are present concomitantly. Cysteamine 0-3 BCL2 apoptosis regulator Homo sapiens 83-87 28804913-1 2017 Preclinical Research BH3 mimetics are anticancer agents that reproduce the spatial arrangement of the BH3 domain of Bcl-2 family proteins. BH 3 21-24 BCL2 apoptosis regulator Homo sapiens 116-121 28804913-4 2017 Given that BH3 mimetics shift the balance between the prosurvival and proapoptotic Bcl-2 members, they might indirectly exert effects on intracellular Ca2+ signals. BH 3 11-14 BCL2 apoptosis regulator Homo sapiens 83-88 28444938-7 2017 In conclusion, arsenic induced proliferation in human uroepithelial cells after short and long term exposure to arsenite and JAK2/STAT3 signaling pathway might be pivotal in arsenite-induced proliferation by regulating cyclin D1, COX-2, PCNA, and BCL2. Arsenic 15-22 BCL2 apoptosis regulator Homo sapiens 247-251 28444938-7 2017 In conclusion, arsenic induced proliferation in human uroepithelial cells after short and long term exposure to arsenite and JAK2/STAT3 signaling pathway might be pivotal in arsenite-induced proliferation by regulating cyclin D1, COX-2, PCNA, and BCL2. arsenite 112-120 BCL2 apoptosis regulator Homo sapiens 247-251 28444938-7 2017 In conclusion, arsenic induced proliferation in human uroepithelial cells after short and long term exposure to arsenite and JAK2/STAT3 signaling pathway might be pivotal in arsenite-induced proliferation by regulating cyclin D1, COX-2, PCNA, and BCL2. arsenite 174-182 BCL2 apoptosis regulator Homo sapiens 247-251 28962106-10 2017 During the celecoxib-induced apoptosis of BGC823 cells, celecoxib upregulated Fas expression and downregulated FasL and Bcl-2 expression in a concentration-dependent manner. Celecoxib 11-20 BCL2 apoptosis regulator Homo sapiens 120-125 28738256-7 2017 Mimicking the MITF effect via cyclic adenosine monophosphate activation conferred resistance to MEK inhibition and upregulated Bcl-2 expression. Cyclic AMP 30-60 BCL2 apoptosis regulator Homo sapiens 127-132 28738256-9 2017 More importantly, selective Bcl-2 inhibition by ABT-199 or Bcl-2 knockout using CRISPR/Cas9 system annihilated the acquired resistance and restored the sensitivity of NRAS-mutant melanoma cells to MEK inhibition. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 48-51 BCL2 apoptosis regulator Homo sapiens 28-33 28962106-10 2017 During the celecoxib-induced apoptosis of BGC823 cells, celecoxib upregulated Fas expression and downregulated FasL and Bcl-2 expression in a concentration-dependent manner. Celecoxib 56-65 BCL2 apoptosis regulator Homo sapiens 120-125 28962106-11 2017 These results suggest that celecoxib inhibited the growth and induced apoptosis of BGC823 gastric cancer cells by regulating the protein expression of Fas, FasL and Bcl-2. Celecoxib 27-36 BCL2 apoptosis regulator Homo sapiens 165-170 28677720-8 2017 Pre-incubation of the EPCs with BAY11 for 1 h followed by treatment with visfatin (150 ng/ml) for 48 h also abolished visfatin-induced apoptosis; it also abolished the promoting effects of visfatin on the expression of caspase-3, Bax, ICAM-1 and IL-6, and its suppressive effects on the protein expression of Bcl-2. bay11 32-37 BCL2 apoptosis regulator Homo sapiens 309-314 28655725-8 2017 Apoptotic parameters, including altered Bcl2:Bax ratio and PARP1 cleavage induced by palmitate, were improved by 4-PBA. 4-phenylbutyric acid 113-118 BCL2 apoptosis regulator Homo sapiens 40-44 28677808-6 2017 Additionally, IMBP potentiated the therapeutic efficacy of doxorubicin-based breast cancer chemotherapy via the activation of cell cycle arrest and cell apoptosis pathway genes including p53, p21, CDK2, cyclin A, caspase 9, Bcl-2 and Bax. Doxorubicin 59-70 BCL2 apoptosis regulator Homo sapiens 224-229 27821721-10 2017 Furthermore, CoQ0 induced apoptosis in MCF-7 cells, which was associated with PARP degradation, Bcl-2/Bax dysregulation, and p53 expression as shown by western blot. ubiquinone-O 13-17 BCL2 apoptosis regulator Homo sapiens 96-101 28214344-5 2017 Furthermore our results revealed that neferine combined with cisplatin down regulate the expression of Bcl-2 and up regulate the expression of Bax, Bad, Bak, release of cytochrome c, p53 levels, then activated cleavage forms of caspase-9, caspase-3, and PARP. neferine 38-46 BCL2 apoptosis regulator Homo sapiens 103-108 28214344-5 2017 Furthermore our results revealed that neferine combined with cisplatin down regulate the expression of Bcl-2 and up regulate the expression of Bax, Bad, Bak, release of cytochrome c, p53 levels, then activated cleavage forms of caspase-9, caspase-3, and PARP. Cisplatin 61-70 BCL2 apoptosis regulator Homo sapiens 103-108 28577058-0 2017 Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline. Selegiline 200-210 BCL2 apoptosis regulator Homo sapiens 84-89 28577058-0 2017 Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline. rasagiline 215-225 BCL2 apoptosis regulator Homo sapiens 84-89 28577058-3 2017 However, the role of MAO-B itself in the regulation of cell death processing remains elusive, whereas type A MAO (MAO-A) mediates the induction of anti-apoptotic Bcl-2 genes by rasagiline and selegiline. rasagiline 177-187 BCL2 apoptosis regulator Homo sapiens 162-167 28577058-3 2017 However, the role of MAO-B itself in the regulation of cell death processing remains elusive, whereas type A MAO (MAO-A) mediates the induction of anti-apoptotic Bcl-2 genes by rasagiline and selegiline. Selegiline 192-202 BCL2 apoptosis regulator Homo sapiens 162-167 28927122-6 2017 P53 and Bcl-2 expression levels were determined using western blot analysis in the si-P53, EGCG and EGCG-combined si-P53 groups. Silicon 20-22 BCL2 apoptosis regulator Homo sapiens 8-13 28779236-8 2017 Additionally, TMPP and the combined therapy regulated Bax and Bcl-2. TMPP 14-18 BCL2 apoptosis regulator Homo sapiens 62-67 28927780-9 2017 The combination of specific inhibitors of ERK1/2, JNK or PI3K/Akt pathway and metformin further promoted cell apoptosis and the up-regulation of p21, Bax, Bad, cleaved caspase-3 and -9 as well as the down-regulation of Bcl-2 mediated by metformin alone, but inhibition of p38 pathway exhibited the opposite results. Metformin 78-87 BCL2 apoptosis regulator Homo sapiens 219-224 28713965-10 2017 DHA and gefitinib co-administration also downregulated the expression levels of phosphorylated (p)-Akt, p-mechanistic target of rapamycin, p-signal transducer and activator of transcription 3 and B-cell lymphoma 2 (Bcl-2), and upregulated the expression of Bcl-2-associated X protein. artenimol 0-3 BCL2 apoptosis regulator Homo sapiens 196-213 28713965-10 2017 DHA and gefitinib co-administration also downregulated the expression levels of phosphorylated (p)-Akt, p-mechanistic target of rapamycin, p-signal transducer and activator of transcription 3 and B-cell lymphoma 2 (Bcl-2), and upregulated the expression of Bcl-2-associated X protein. artenimol 0-3 BCL2 apoptosis regulator Homo sapiens 215-220 28713965-10 2017 DHA and gefitinib co-administration also downregulated the expression levels of phosphorylated (p)-Akt, p-mechanistic target of rapamycin, p-signal transducer and activator of transcription 3 and B-cell lymphoma 2 (Bcl-2), and upregulated the expression of Bcl-2-associated X protein. artenimol 0-3 BCL2 apoptosis regulator Homo sapiens 257-262 28927092-7 2017 The rate of apoptosis, caspase-3/caspase-8 activity and the expression of Bax were significantly increased, whereas Bcl-2 expression was significantly reduced following treatment with curcumin and/or FP, compared with the untreated control group. Curcumin 184-192 BCL2 apoptosis regulator Homo sapiens 116-121 28927092-9 2017 Therefore, curcumin may enhance the anticancer effects of FP chemotherapy in MGC-803 cells through the promotion of apoptosis via the caspase-3/caspase-8, Bcl-2 and Bax signaling pathways. Curcumin 11-19 BCL2 apoptosis regulator Homo sapiens 155-160 28927122-6 2017 P53 and Bcl-2 expression levels were determined using western blot analysis in the si-P53, EGCG and EGCG-combined si-P53 groups. epigallocatechin gallate 100-104 BCL2 apoptosis regulator Homo sapiens 8-13 28017967-6 2017 The BCL2 inhibitor venetoclax induced greater apoptosis in ex vivo-cultured CLL cells obtained from patients on duvelisib compared with pre-treatment CLL cells from the same patients. venetoclax 19-29 BCL2 apoptosis regulator Homo sapiens 4-8 28017967-6 2017 The BCL2 inhibitor venetoclax induced greater apoptosis in ex vivo-cultured CLL cells obtained from patients on duvelisib compared with pre-treatment CLL cells from the same patients. duvelisib 112-121 BCL2 apoptosis regulator Homo sapiens 4-8 28140720-1 2017 The approval of venetoclax, a "BH3-mimetic" antagonist of the BCL-2 anti-apoptotic protein, for chronic lymphocytic leukemia represents a major milestone in translational apoptosis research. venetoclax 16-26 BCL2 apoptosis regulator Homo sapiens 62-67 28140720-1 2017 The approval of venetoclax, a "BH3-mimetic" antagonist of the BCL-2 anti-apoptotic protein, for chronic lymphocytic leukemia represents a major milestone in translational apoptosis research. BH 3 31-34 BCL2 apoptosis regulator Homo sapiens 62-67 28713965-10 2017 DHA and gefitinib co-administration also downregulated the expression levels of phosphorylated (p)-Akt, p-mechanistic target of rapamycin, p-signal transducer and activator of transcription 3 and B-cell lymphoma 2 (Bcl-2), and upregulated the expression of Bcl-2-associated X protein. Gefitinib 8-17 BCL2 apoptosis regulator Homo sapiens 196-213 28713965-10 2017 DHA and gefitinib co-administration also downregulated the expression levels of phosphorylated (p)-Akt, p-mechanistic target of rapamycin, p-signal transducer and activator of transcription 3 and B-cell lymphoma 2 (Bcl-2), and upregulated the expression of Bcl-2-associated X protein. Gefitinib 8-17 BCL2 apoptosis regulator Homo sapiens 215-220 28713965-10 2017 DHA and gefitinib co-administration also downregulated the expression levels of phosphorylated (p)-Akt, p-mechanistic target of rapamycin, p-signal transducer and activator of transcription 3 and B-cell lymphoma 2 (Bcl-2), and upregulated the expression of Bcl-2-associated X protein. Gefitinib 8-17 BCL2 apoptosis regulator Homo sapiens 257-262 28731137-0 2017 Phosphorylation of Bcl-2 plays an important role in glycochenodeoxycholate-induced survival and chemoresistance in HCC. Glycochenodeoxycholic Acid 52-74 BCL2 apoptosis regulator Homo sapiens 19-24 28731137-4 2017 In the present study, we found that GCDA can induce the chemoresistance of human liver cancer cells and specific depletion of Bcl-2 by RNA interference blocks GCDA-stimulated chemoresistance, which indicate the pivotal role of Bcl-2 in such process. Glycochenodeoxycholic Acid 159-163 BCL2 apoptosis regulator Homo sapiens 126-131 28731137-5 2017 Mechanistically, GCDA simultaneously stimulates phosphorylation of Bcl-2 at Ser70 site and activates extracellular signal-regulated kinase 1/2 (ERK1/2), and inhibition of ERK1/2 by PD98059 (MAPK/ERK1/2 inhibitor) or siRNA (targeting ERK1/2) suppresses GCDA-stimulated phosphorylation of Bcl-2 and significantly attenuates the survival and chemoresistance induced by GCDA in liver cancer cells. Glycochenodeoxycholic Acid 17-21 BCL2 apoptosis regulator Homo sapiens 67-72 28731137-5 2017 Mechanistically, GCDA simultaneously stimulates phosphorylation of Bcl-2 at Ser70 site and activates extracellular signal-regulated kinase 1/2 (ERK1/2), and inhibition of ERK1/2 by PD98059 (MAPK/ERK1/2 inhibitor) or siRNA (targeting ERK1/2) suppresses GCDA-stimulated phosphorylation of Bcl-2 and significantly attenuates the survival and chemoresistance induced by GCDA in liver cancer cells. Glycochenodeoxycholic Acid 17-21 BCL2 apoptosis regulator Homo sapiens 287-292 28731137-5 2017 Mechanistically, GCDA simultaneously stimulates phosphorylation of Bcl-2 at Ser70 site and activates extracellular signal-regulated kinase 1/2 (ERK1/2), and inhibition of ERK1/2 by PD98059 (MAPK/ERK1/2 inhibitor) or siRNA (targeting ERK1/2) suppresses GCDA-stimulated phosphorylation of Bcl-2 and significantly attenuates the survival and chemoresistance induced by GCDA in liver cancer cells. Glycochenodeoxycholic Acid 252-256 BCL2 apoptosis regulator Homo sapiens 67-72 28731137-5 2017 Mechanistically, GCDA simultaneously stimulates phosphorylation of Bcl-2 at Ser70 site and activates extracellular signal-regulated kinase 1/2 (ERK1/2), and inhibition of ERK1/2 by PD98059 (MAPK/ERK1/2 inhibitor) or siRNA (targeting ERK1/2) suppresses GCDA-stimulated phosphorylation of Bcl-2 and significantly attenuates the survival and chemoresistance induced by GCDA in liver cancer cells. Glycochenodeoxycholic Acid 252-256 BCL2 apoptosis regulator Homo sapiens 67-72 28731137-6 2017 Thus, GCDA-induced survival and chemoresistance of liver cancer cells may occur through activation of Bcl-2 by phosphorylation at Ser70 site through MAPK/ERK1/2 pathway, which may contribute to the development of human liver cancer and chemoresistance. Glycochenodeoxycholic Acid 6-10 BCL2 apoptosis regulator Homo sapiens 102-107 28927122-11 2017 The Bcl-2 expression level in the EGCG-combined si-P53 group was lower than that of the si-P53 group and higher than that of the EGCG group. epigallocatechin gallate 34-38 BCL2 apoptosis regulator Homo sapiens 4-9 28927122-11 2017 The Bcl-2 expression level in the EGCG-combined si-P53 group was lower than that of the si-P53 group and higher than that of the EGCG group. Silicon 16-18 BCL2 apoptosis regulator Homo sapiens 4-9 28927122-11 2017 The Bcl-2 expression level in the EGCG-combined si-P53 group was lower than that of the si-P53 group and higher than that of the EGCG group. Silicon 48-50 BCL2 apoptosis regulator Homo sapiens 4-9 28927122-11 2017 The Bcl-2 expression level in the EGCG-combined si-P53 group was lower than that of the si-P53 group and higher than that of the EGCG group. epigallocatechin gallate 129-133 BCL2 apoptosis regulator Homo sapiens 4-9 28927142-7 2017 In addition, treatment with ATO resulted in the downregulation of X-linked inhibitor of apoptosis, B-cell lymphoma-2 (Bcl-2), E2F transcription factor 1 (E2F1), thymidylate synthase and ribonucleotide reductase M1 in addition to the upregulation of Bcl-2 antagonist/killer protein, cleaved poly ADP-ribose polymerase and cleaved caspase 3 in a cell-line specific manner. Arsenic Trioxide 28-31 BCL2 apoptosis regulator Homo sapiens 99-116 28927142-7 2017 In addition, treatment with ATO resulted in the downregulation of X-linked inhibitor of apoptosis, B-cell lymphoma-2 (Bcl-2), E2F transcription factor 1 (E2F1), thymidylate synthase and ribonucleotide reductase M1 in addition to the upregulation of Bcl-2 antagonist/killer protein, cleaved poly ADP-ribose polymerase and cleaved caspase 3 in a cell-line specific manner. Arsenic Trioxide 28-31 BCL2 apoptosis regulator Homo sapiens 118-123 28927142-7 2017 In addition, treatment with ATO resulted in the downregulation of X-linked inhibitor of apoptosis, B-cell lymphoma-2 (Bcl-2), E2F transcription factor 1 (E2F1), thymidylate synthase and ribonucleotide reductase M1 in addition to the upregulation of Bcl-2 antagonist/killer protein, cleaved poly ADP-ribose polymerase and cleaved caspase 3 in a cell-line specific manner. Arsenic Trioxide 28-31 BCL2 apoptosis regulator Homo sapiens 249-254 29218943-12 2017 Compared with normal group, the contents of PGI2, NO, T-NOS, t-PA, SOD, GSH-Px and Bcl-2 mRNA expressions were lower after damaged with H2O2. Hydrogen Peroxide 136-140 BCL2 apoptosis regulator Homo sapiens 83-88 29084683-8 2017 The treatment of crocin plus cisplatin significantly increased the expression of p53 and Bax (p< 0.05), and significantly decreased the Bcl-2 expression (p<0.05). Cisplatin 29-38 BCL2 apoptosis regulator Homo sapiens 139-144 29084689-5 2017 Inhibition of ROS generation by scavengers suppressed apoptosis and Bcl-2 expression induced by curcumin, indicating the critical roles of ROS in the apoptotic process. Reactive Oxygen Species 14-17 BCL2 apoptosis regulator Homo sapiens 68-73 29084689-5 2017 Inhibition of ROS generation by scavengers suppressed apoptosis and Bcl-2 expression induced by curcumin, indicating the critical roles of ROS in the apoptotic process. Curcumin 96-104 BCL2 apoptosis regulator Homo sapiens 68-73 28703366-5 2017 Furthermore, the combination of TAB significantly enhanced apoptosis in Jurkat cells, and the apoptosis most likely resulted from the modulation of the level of Bcl-2 family members. tab 32-35 BCL2 apoptosis regulator Homo sapiens 161-166 28928812-10 2017 Furthermore, western blot analysis demonstrated that AMP treatment induced apoptosis through activation of caspases 9 and 3, which was validated by the increasing ratio of B-cell lymphoma 2 (Bcl-2)-associated X protein to Bcl-2. ampelopsin 53-56 BCL2 apoptosis regulator Homo sapiens 172-189 28928812-10 2017 Furthermore, western blot analysis demonstrated that AMP treatment induced apoptosis through activation of caspases 9 and 3, which was validated by the increasing ratio of B-cell lymphoma 2 (Bcl-2)-associated X protein to Bcl-2. ampelopsin 53-56 BCL2 apoptosis regulator Homo sapiens 191-196 28928812-10 2017 Furthermore, western blot analysis demonstrated that AMP treatment induced apoptosis through activation of caspases 9 and 3, which was validated by the increasing ratio of B-cell lymphoma 2 (Bcl-2)-associated X protein to Bcl-2. ampelopsin 53-56 BCL2 apoptosis regulator Homo sapiens 222-227 28928824-9 2017 The results of the present study suggest that IBC induces apoptosis in Tca8113 cells and that the induction may be associated with the activation of Bcl-2, Bax and caspase-3, and the inactivation of Akt and ERK. Bucrylate 46-49 BCL2 apoptosis regulator Homo sapiens 149-154 28438509-4 2017 MATERIALS AND METHODS: In this study the effect of PDT based on indocyanine green (ICG) as a photosensitizer with the diode laser were tested on the expression of BAX and BCL-2 genes in monolayers of HGF cells. Indocyanine Green 64-81 BCL2 apoptosis regulator Homo sapiens 171-176 28438509-4 2017 MATERIALS AND METHODS: In this study the effect of PDT based on indocyanine green (ICG) as a photosensitizer with the diode laser were tested on the expression of BAX and BCL-2 genes in monolayers of HGF cells. Indocyanine Green 83-86 BCL2 apoptosis regulator Homo sapiens 171-176 29218943-14 2017 Compared with model group, the contents of PGI2, NO, T-NOS, t-PA, SOD, GSH-Px and Bcl-2 mRNA expressions were increased after treated with germacrone. germacrone 139-149 BCL2 apoptosis regulator Homo sapiens 82-87 29088842-11 2017 2HF reversed the pro-/anti-apoptotic ratio of BAX/BCL-2 by decreasing anti-apoptotic protein BCL-2 and increasing pro-apoptotic proteins BAX and BIM in vivo. 2'-hydroxyflavanone 0-3 BCL2 apoptosis regulator Homo sapiens 50-55 28837148-0 2017 Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. apatinib 0-8 BCL2 apoptosis regulator Homo sapiens 63-68 28837148-13 2017 STAT3 and BCL-2 were downregulated by Apatinib. apatinib 38-46 BCL2 apoptosis regulator Homo sapiens 10-15 28837148-15 2017 BCL-2 inhibits autophagy and was apoptosis restrained by Apatinib too. apatinib 57-65 BCL2 apoptosis regulator Homo sapiens 0-5 28837148-16 2017 Overexpression of BCL-2 decreased Apatinib-induced apoptosis and autophagy. apatinib 34-42 BCL2 apoptosis regulator Homo sapiens 18-23 28837148-17 2017 Apatinib repressed the expression of STAT3 and BCL-2 and suppressed the growth of osteosarcoma in vivo. apatinib 0-8 BCL2 apoptosis regulator Homo sapiens 47-52 28837148-18 2017 To sum up, deactivation of VEGFR2/STAT3/BCL-2 signal pathway leads to Apatinib-induced growth inhibition of osteosarcoma. apatinib 70-78 BCL2 apoptosis regulator Homo sapiens 40-45 28676392-8 2017 The expression of mitochondrial apoptosis related protein bax increased and bcl-2 decreased in high glucose-induced HUVECs. Glucose 100-107 BCL2 apoptosis regulator Homo sapiens 76-81 29088826-8 2017 Finally, alpha-ketoglutarate stabilized the mitochondrial membrane potential, increased the ratio of Bcl-2/Bax, decreased the release of cytochrome c and activation of caspase-3, thereby prevented cell apoptosis. Ketoglutaric Acids 9-28 BCL2 apoptosis regulator Homo sapiens 101-106 29088842-11 2017 2HF reversed the pro-/anti-apoptotic ratio of BAX/BCL-2 by decreasing anti-apoptotic protein BCL-2 and increasing pro-apoptotic proteins BAX and BIM in vivo. 2'-hydroxyflavanone 0-3 BCL2 apoptosis regulator Homo sapiens 93-98 28827731-7 2017 In addition, inhibition of miR-7641 boosted doxorubicin-mediated apoptosis of cancer cells via upregulation of apoptotic molecules Caspase 9 (CAS9) and poly ADP ribose polymerase (PARP) and downregulation of anti-apoptotic molecule BCL2. Doxorubicin 44-55 BCL2 apoptosis regulator Homo sapiens 232-236 28801290-8 2017 Western blotting results showed that quinalizarin also up-regulated the expression levels of the apoptotic proteins including p-p38, p-JNK, Bad, cleaved caspase-3, and cleaved PARP-1 (P<0.05), and down-regulated the expression of the anti-apoptotic proteins p-Akt, p-ERK, and Bcl-2 (P<0.05). 1,2,5,8-tetrahydroxy anthraquinone 37-49 BCL2 apoptosis regulator Homo sapiens 279-284 28347817-4 2017 Meanwhile, activation Wnt3a/beta-catenin signal with exogenous Wnt3alpha protein (100 ng/ml) or Lithium Chloride (LiCl, 4 mM) decreased significantly apoptosis of BMECs induced by OGD with increasing expression of Bcl-2 in the whole cell and beta-catenin in the nucleus. Lithium Chloride 96-112 BCL2 apoptosis regulator Homo sapiens 214-219 28347817-4 2017 Meanwhile, activation Wnt3a/beta-catenin signal with exogenous Wnt3alpha protein (100 ng/ml) or Lithium Chloride (LiCl, 4 mM) decreased significantly apoptosis of BMECs induced by OGD with increasing expression of Bcl-2 in the whole cell and beta-catenin in the nucleus. Lithium Chloride 114-118 BCL2 apoptosis regulator Homo sapiens 214-219 28347817-5 2017 But, inhibition Wnt3a/beta-catenin signal with DKK1 (100 ng/ml) or 2.4-diamino quinazoline (DQ, 0.2 muM) increased apoptosis of BMECs with decreasing expression of Bcl-2. 2,4-diaminoquinazoline 67-90 BCL2 apoptosis regulator Homo sapiens 164-169 28666825-6 2017 Cell biological studies showed that triptonide at the doses of 2.5-10nM notably suppressed B-lymphoma cell colony-forming capability, and that triptonide at the dose of 20nM promoted apoptosis through activation of PARP and caspase 3, but reduction of BCL2 protein levels in the lymphoma cells. triptonide 143-153 BCL2 apoptosis regulator Homo sapiens 252-256 28494251-9 2017 Furthermore, in western blot assay, 13b increased the expression of Bax, Cyt c and caspase 3, and reduced the relative levels of Bcl-2, Bcl-xl and pro-caspase 3 in HepG-2 cells. CHEMBL3741121 36-39 BCL2 apoptosis regulator Homo sapiens 129-134 28525842-0 2017 Indole-coumarin-thiadiazole hybrids: An appraisal of their MCF-7 cell growth inhibition, apoptotic, antimetastatic and computational Bcl-2 binding potential. indole-coumarin-thiadiazole 0-27 BCL2 apoptosis regulator Homo sapiens 133-138 28525842-8 2017 The ability of IPTBC to inhibit the antiapoptotic Bcl-2 protein by acting as a small molecule BH3 mimetic was explored through docking simulation studies. iptbc 15-20 BCL2 apoptosis regulator Homo sapiens 50-55 28525842-8 2017 The ability of IPTBC to inhibit the antiapoptotic Bcl-2 protein by acting as a small molecule BH3 mimetic was explored through docking simulation studies. BH 3 94-97 BCL2 apoptosis regulator Homo sapiens 50-55 28808311-4 2017 CoQ0-induced autophagy as a survival mechanism was evidenced by increased accumulation of LC3-II, GFP-LC3 puncta, AVOs formation and Beclin-1/Bcl-2 dysregulation. ubiquinone-O 0-4 BCL2 apoptosis regulator Homo sapiens 142-147 28797284-9 2017 Western blot results demonstrated that gambogic acid sensitized gemcitabine-induced apoptosis by enhancing the expression of cleaved caspase-3, cleaved caspase-9, cleaved-PARP, and Bax, and reducing the expression of Bcl-2. gambogic acid 39-52 BCL2 apoptosis regulator Homo sapiens 217-222 28856117-8 2017 MH induced apoptosis of MDA-MB-231 cells through activation of caspases 8, 9, 6, and 3/7 and this correlated with a loss of Bcl-2 and increased Bax protein expression in MH-treated cells. mh 0-2 BCL2 apoptosis regulator Homo sapiens 124-129 28856117-8 2017 MH induced apoptosis of MDA-MB-231 cells through activation of caspases 8, 9, 6, and 3/7 and this correlated with a loss of Bcl-2 and increased Bax protein expression in MH-treated cells. mh 170-172 BCL2 apoptosis regulator Homo sapiens 124-129 28619982-8 2017 Moreover, the JAK1/2 inhibitor ruxolitinib restored sensitivity to the BCL2 inhibitor venetoclax in AML patient cells ex vivo in different model systems and in vivo in an AML xenograft mouse model. ruxolitinib 31-42 BCL2 apoptosis regulator Homo sapiens 71-75 28619982-8 2017 Moreover, the JAK1/2 inhibitor ruxolitinib restored sensitivity to the BCL2 inhibitor venetoclax in AML patient cells ex vivo in different model systems and in vivo in an AML xenograft mouse model. venetoclax 86-96 BCL2 apoptosis regulator Homo sapiens 71-75 28671455-4 2017 After paclitaxel encapsulation, PEG-siRNA-PCL micelles containing antiapoptotic Bcl-2-specific siRNA were stabilized with linear polyethylenimine via electrostatic interactions. Polyethyleneimine 129-145 BCL2 apoptosis regulator Homo sapiens 80-85 28671455-6 2017 The strong anticancer activity of paclitaxel-incorporated siRNA micelles can be attributed to the synergistic effect of Bcl-2 siRNA and paclitaxel. Paclitaxel 34-44 BCL2 apoptosis regulator Homo sapiens 120-125 29069816-6 2017 Ubenimex inhibits the expression of the proto-oncogene, Pim-3, which is accompanied by decreased expression of BCL-2 and BCL-XL, decreased phosphorylation of Bad, and increased tumor apoptosis. ubenimex 0-8 BCL2 apoptosis regulator Homo sapiens 111-116 28797284-9 2017 Western blot results demonstrated that gambogic acid sensitized gemcitabine-induced apoptosis by enhancing the expression of cleaved caspase-3, cleaved caspase-9, cleaved-PARP, and Bax, and reducing the expression of Bcl-2. gemcitabine 64-75 BCL2 apoptosis regulator Homo sapiens 217-222 28789701-7 2017 Ad5/F11p-PSCAE-UPII-E1A plus cisplatin could upregulate the proteins expression of p53, Bax, and cleaved caspase-3, and downregulated Bcl-2 protein expression in T24, EJ and 5637 cells. Cisplatin 29-38 BCL2 apoptosis regulator Homo sapiens 134-139 28531805-0 2017 Troxerutin (TXN) potentiated 5-Fluorouracil (5-Fu) treatment of human gastric cancer through suppressing STAT3/NF-kappaB and Bcl-2 signaling pathways. troxerutin 0-10 BCL2 apoptosis regulator Homo sapiens 125-130 28777347-7 2017 gamma-tocotrienol-induced apoptosis in HeLa cells was accompanied by down-regulation of Bcl-2, up-regulation of Bax, release of cytochrome from mitochondria, activation of caspase-9 and caspase-3, and subsequent poly (ADP-ribose) polymerase (PARP) cleavage. plastochromanol 8 0-17 BCL2 apoptosis regulator Homo sapiens 88-93 28769027-9 2017 Concomitant treatment with paclitaxel and GSI or siRNA downregulated Bcl-2 expression and upregulated Bax expression levels. Paclitaxel 27-37 BCL2 apoptosis regulator Homo sapiens 69-74 28769027-9 2017 Concomitant treatment with paclitaxel and GSI or siRNA downregulated Bcl-2 expression and upregulated Bax expression levels. 2-(5-Chlorothiophen-2-Yl)-N-[(3s)-1-(4-{2-[(Dimethylamino)methyl]-1h-Imidazol-1-Yl}-2-Fluorophenyl)-2-Oxopyrrolidin-3-Yl]ethanesulfonamide 42-45 BCL2 apoptosis regulator Homo sapiens 69-74 28609685-8 2017 Moreover, knockdown of TLR4 significantly blocked palmitate-induced ROS generation and VSMC apoptosis accompanied by inhibition of caspase 3, caspase 9, p53 expression and restoration of BCL-2 expression. Palmitates 50-59 BCL2 apoptosis regulator Homo sapiens 187-192 28531805-11 2017 Our data indicated a novel therapeutic strategy to potentiate 5-FU-induced anti-tumor effect in gastric cancer cells with resistance to 5-FU by TXN through suppression of p-STAT3/NF-kappaB (p65 and p50) and Bcl-2. Fluorouracil 62-66 BCL2 apoptosis regulator Homo sapiens 207-212 28531805-11 2017 Our data indicated a novel therapeutic strategy to potentiate 5-FU-induced anti-tumor effect in gastric cancer cells with resistance to 5-FU by TXN through suppression of p-STAT3/NF-kappaB (p65 and p50) and Bcl-2. Fluorouracil 136-140 BCL2 apoptosis regulator Homo sapiens 207-212 28109089-5 2017 In addition, BA significantly promoted mitochondrial apoptosis, as reflected by an increase in TUNEL+ cells and the activities of caspases 3 and 9, an increase in Bax expression, and a decrease in Bcl-2 expression and the mitochondrial oxygen consumption rate. betulinic acid 13-15 BCL2 apoptosis regulator Homo sapiens 197-202 28777796-7 2017 It can down-regulate Bcl-2 and up-regulate Bax, to induce dissipation of mitochondrial membrane potential and generation of reactive oxygen species. Reactive Oxygen Species 124-147 BCL2 apoptosis regulator Homo sapiens 21-26 28768804-1 2017 The development of BH3 mimetics, which antagonize prosurvival proteins of the BCL-2 family, represents a potential breakthrough in cancer therapy. BH 3 19-22 BCL2 apoptosis regulator Homo sapiens 78-83 27927016-0 2017 Inhibition of Cathepsin S Induces Mitochondrial ROS That Sensitizes TRAIL-Mediated Apoptosis Through p53-Mediated Downregulation of Bcl-2 and c-FLIP. Reactive Oxygen Species 48-51 BCL2 apoptosis regulator Homo sapiens 132-137 27927016-5 2017 ZFL downregulated Bcl-2 expression at the transcriptional level in a p53-dependent manner, and overexpression of Bcl-2 also markedly blocked apoptosis induced by combined treatment with ZFL and TRAIL. zfl 0-3 BCL2 apoptosis regulator Homo sapiens 18-23 28528183-4 2017 Quercetin treatment also induced apoptosis via deregulating the expression of apoptotic genes, including Bax and Bcl-2, and arrested cell cycle at G2/M phases. Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 113-118 28531805-0 2017 Troxerutin (TXN) potentiated 5-Fluorouracil (5-Fu) treatment of human gastric cancer through suppressing STAT3/NF-kappaB and Bcl-2 signaling pathways. troxerutin 12-15 BCL2 apoptosis regulator Homo sapiens 125-130 28531805-0 2017 Troxerutin (TXN) potentiated 5-Fluorouracil (5-Fu) treatment of human gastric cancer through suppressing STAT3/NF-kappaB and Bcl-2 signaling pathways. Fluorouracil 29-43 BCL2 apoptosis regulator Homo sapiens 125-130 28575805-7 2017 In addition, the occurrence of TPC-1 apoptosis was correlated with activation of Bax and cleaved caspases-3, and inhibition of Bcl-2 and the mitochondrial membrane potential (DeltaYm), indicating that niclosamide may induce apoptosis through a mitochondria-mediated intrinsic apoptotic pathway. Niclosamide 201-212 BCL2 apoptosis regulator Homo sapiens 127-132 28531805-0 2017 Troxerutin (TXN) potentiated 5-Fluorouracil (5-Fu) treatment of human gastric cancer through suppressing STAT3/NF-kappaB and Bcl-2 signaling pathways. Fluorouracil 45-49 BCL2 apoptosis regulator Homo sapiens 125-130 28531805-8 2017 Additionally, the presence of TXN sensitized gastric cancer cells resistant to 5-FU to 5-FU-induced apoptosis by suppressing Bcl-2. Fluorouracil 87-91 BCL2 apoptosis regulator Homo sapiens 125-130 28591691-4 2017 Moreover, PV serum increased the expression of bax and caspase-3, and decreased the expression of bcl-2; but naringenin significantly suppressed the expression of bax and caspase-3, induced the expression of bcl-2. naringenin 109-119 BCL2 apoptosis regulator Homo sapiens 208-213 28370734-12 2017 Adenosine also induced apoptosis by regulation of Bax/Bcl-2 ratio, mitochondrial membrane potential depletion and activation of caspase-6. Adenosine 0-9 BCL2 apoptosis regulator Homo sapiens 54-59 28449207-4 2017 The first BCL2-specific inhibitor, venetoclax, has shown extraordinary single agent activity in chronic lymphocytic leukaemia (CLL), with surprisingly little toxicity given the expression of BCL2 in normal tissues. venetoclax 35-45 BCL2 apoptosis regulator Homo sapiens 10-14 28449207-4 2017 The first BCL2-specific inhibitor, venetoclax, has shown extraordinary single agent activity in chronic lymphocytic leukaemia (CLL), with surprisingly little toxicity given the expression of BCL2 in normal tissues. venetoclax 35-45 BCL2 apoptosis regulator Homo sapiens 191-195 28597042-2 2017 In our study, we investigated the mechanism by which cisplatin induces LRP, Bcl-2, Bcl-xL, XIAP, and Survivin expression in human lung adenocarcinoma A549 cells and human H446 small cell lung cancer cells at mRNA and protein levels. Cisplatin 53-62 BCL2 apoptosis regulator Homo sapiens 76-81 28597042-6 2017 RESULTS: Cisplatin increased Bcl-2, LRP, and Survivin expression, but decreased Bcl-xL and XIAP expression in a dose-dependent manner. Cisplatin 9-18 BCL2 apoptosis regulator Homo sapiens 29-34 28527359-7 2017 Further, indium oxide nanocubes induced a mitochondrial membrane potential loss and altered the mRNA expression levels of apoptotic genes (p53, bax, bcl-2, CASP3 & CASP9). indium oxide 9-21 BCL2 apoptosis regulator Homo sapiens 149-154 28579554-6 2017 Importantly, STAT3-mutant cells were more sensitive to death induced by the BCL2-inhibitor ABT-737 indicating a dependence on anti-apoptotic BCL2 proteins and potential novel therapeutic options. ABT-737 91-98 BCL2 apoptosis regulator Homo sapiens 76-80 28579554-6 2017 Importantly, STAT3-mutant cells were more sensitive to death induced by the BCL2-inhibitor ABT-737 indicating a dependence on anti-apoptotic BCL2 proteins and potential novel therapeutic options. ABT-737 91-98 BCL2 apoptosis regulator Homo sapiens 141-145 27866306-3 2017 Our present study revealed that nanomolar concentrations of BPA can significantly increase the proliferation, migration and invasion of NB SH-SY5Y and SiMa cells, further evidenced by the upregulation of human proliferating cell nuclear antigen, Bcl-2, vimentin and fibronectin. bisphenol A 60-63 BCL2 apoptosis regulator Homo sapiens 246-251 28810561-0 2017 Cytotoxic T lymphocytes promote cytarabine-induced acute myeloid leukemia cell apoptosis via inhibiting Bcl-2 expression. Cytarabine 32-42 BCL2 apoptosis regulator Homo sapiens 104-109 28670929-1 2017 INTRODUCTION: Direct targeting of Bcl-2 members for therapeutic purposes in cancer has become a clinical reality with the FDA approval of ABT-199/Venetoclax. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 138-141 BCL2 apoptosis regulator Homo sapiens 34-39 28321778-6 2017 Compared to silibinin, miR-21 mimic transfection in combination with silibinin caused a slight modulation in some of the examined silibinin effects including apoptosis, Bcl2 mRNA and PTEN mRNA and protein levels. Silybin 69-78 BCL2 apoptosis regulator Homo sapiens 169-173 28321778-6 2017 Compared to silibinin, miR-21 mimic transfection in combination with silibinin caused a slight modulation in some of the examined silibinin effects including apoptosis, Bcl2 mRNA and PTEN mRNA and protein levels. Silybin 69-78 BCL2 apoptosis regulator Homo sapiens 169-173 28810561-7 2017 Western blotting revealed that Bcl-2 expression was downregulated in AML cells following cytarabine and CTL treatment, indicating that the synergistic effect of this treatment on AML cell apoptosis is due to the downregulation of Bcl-2. Cytarabine 89-99 BCL2 apoptosis regulator Homo sapiens 31-36 28810561-7 2017 Western blotting revealed that Bcl-2 expression was downregulated in AML cells following cytarabine and CTL treatment, indicating that the synergistic effect of this treatment on AML cell apoptosis is due to the downregulation of Bcl-2. Cytarabine 89-99 BCL2 apoptosis regulator Homo sapiens 230-235 28555524-8 2017 Mechanistically, ellipticine reduced the phosphorylation of STAT3 and downregulated the expression of Mcl-1, cyclin D1 and Bcl-2. ellipticine 17-28 BCL2 apoptosis regulator Homo sapiens 123-128 28283461-3 2017 This Se-GBLP-induced apoptosis is associated with an increased protein expression of pro-apoptotic Bax, decreased expression of anti-apoptotic Bcl-2, loss of mitochondrial membrane potential, and cleavage of caspase-9, caspase-3 and PARP, suggesting that Se-GBLP-induced apoptosis occurs through the mitochondria-dependent pathway. se-gblp 5-12 BCL2 apoptosis regulator Homo sapiens 143-148 31966711-6 2017 Consistently, TGF-beta1 inhibitor LY2109761 treatment could weaken the effects of ERbeta-selective antagonist PHTPP on the expression of IGF-1, survivin and bcl-2 in prostate cancer cells. LY2109761 34-43 BCL2 apoptosis regulator Homo sapiens 157-162 31966711-6 2017 Consistently, TGF-beta1 inhibitor LY2109761 treatment could weaken the effects of ERbeta-selective antagonist PHTPP on the expression of IGF-1, survivin and bcl-2 in prostate cancer cells. 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol 110-115 BCL2 apoptosis regulator Homo sapiens 157-162 27504932-6 2017 While pharmacological inhibition of either MDR1, ABCG2, Bcl-2 with Verapamil, Sorafenib, or Obatoclax, respectively decreased the levels of their target proteins under routine culture conditions as expected, such inhibition did not reverse PX resistance in PPSS conditions. Verapamil 67-76 BCL2 apoptosis regulator Homo sapiens 56-61 27504932-6 2017 While pharmacological inhibition of either MDR1, ABCG2, Bcl-2 with Verapamil, Sorafenib, or Obatoclax, respectively decreased the levels of their target proteins under routine culture conditions as expected, such inhibition did not reverse PX resistance in PPSS conditions. Sorafenib 78-87 BCL2 apoptosis regulator Homo sapiens 56-61 27504932-6 2017 While pharmacological inhibition of either MDR1, ABCG2, Bcl-2 with Verapamil, Sorafenib, or Obatoclax, respectively decreased the levels of their target proteins under routine culture conditions as expected, such inhibition did not reverse PX resistance in PPSS conditions. obatoclax 92-101 BCL2 apoptosis regulator Homo sapiens 56-61 28714512-8 2017 UA decreased the expression of downstream target genes of STAT3, such as Bcl-2, Bcl-xl and survivin in general, with difference in these cell lines. ursolic acid 0-2 BCL2 apoptosis regulator Homo sapiens 73-78 28106278-8 2017 Moreover, we have demonstrated that caffeine is able to prevent outer BRB damage by inhibiting apoptotic cell death induced by hyperglycemic/hypoxic insult since it downregulates the proapoptotic Bax and upregulates the anti-apoptotic Bcl-2 genes. Caffeine 36-44 BCL2 apoptosis regulator Homo sapiens 235-240 28555524-10 2017 Overexpression of constitutively active STAT3 reversed the suppressive effects of ellipticine on RA-FLSs, which was accompanied by restoration of Mcl-1, cyclin D1 and Bcl-2. ellipticine 82-93 BCL2 apoptosis regulator Homo sapiens 167-172 28668518-6 2017 The Bax and bcl-2 gene expression ratio are highly responsible for the regulation of MMP balance, and these ratio was significantly altered following TDZ treatment. thidiazuron 150-153 BCL2 apoptosis regulator Homo sapiens 12-17 28779993-6 2017 Furthermore, S14161 dissociated the Beclin 1/Bcl-2 complex and enhanced the formation of Beclin 1/Vps34 complex. 8-ethoxy-2-(4-fluorophenyl)-3-nitro-2H-chromene 13-19 BCL2 apoptosis regulator Homo sapiens 45-50 28487996-0 2017 miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression. Paclitaxel 20-30 BCL2 apoptosis regulator Homo sapiens 91-96 28487996-7 2017 In addition, miR-30a-5p increases paclitaxel sensitivity by promoting chemotherapy-induced apoptosis via downregulating BCL-2, a key apoptosis regulator. Paclitaxel 34-44 BCL2 apoptosis regulator Homo sapiens 120-125 28487996-13 2017 miR-30a-5p sensitizes NSCLC cells to paclitaxel by inducing apoptosis through BCL-2 inhibition. Paclitaxel 37-47 BCL2 apoptosis regulator Homo sapiens 78-83 28264627-3 2017 In the present study, we found that all polyphenols (apigenin, fisetin, galangin and luteolin) bind to the hydrophobic groove of BCL-2 and the interaction is stable throughout MD simulation run. Polyphenols 40-51 BCL2 apoptosis regulator Homo sapiens 129-134 28264627-6 2017 Finally, on the basis of data obtained during the study, it can be concluded that these polyphenols have the potential to be used as lead molecules for BCL-2 inhibition. Polyphenols 88-99 BCL2 apoptosis regulator Homo sapiens 152-157 28646646-4 2017 ARTS lowered cellular BCL-2 level via ROS induction and increased the cytotoxicity of the BCL-2 inhibitor venetoclax (ABT-199). venetoclax 106-116 BCL2 apoptosis regulator Homo sapiens 90-95 28646646-4 2017 ARTS lowered cellular BCL-2 level via ROS induction and increased the cytotoxicity of the BCL-2 inhibitor venetoclax (ABT-199). venetoclax 118-125 BCL2 apoptosis regulator Homo sapiens 90-95 28337703-5 2017 UMI-77 alone or in combination with TRAIL untethered pro-apoptotic Bcl-2 proteins Bim and Bak from the sequestration of Mcl-1 and promoted the conformational activation of Bak. UMI-77 0-6 BCL2 apoptosis regulator Homo sapiens 67-72 28656225-5 2017 Further investigation of the apoptotic mechanism revealed that gossypol increased the ratio of B-cell lymphoma 2 (Bcl-2)-associated X protein/Bcl-2 protein levels and upregulated the expression of caspase-3. Gossypol 63-71 BCL2 apoptosis regulator Homo sapiens 95-112 28468776-7 2017 ABBV-075 enhanced the expression of proapoptotic protein BIM and downregulated antiapoptotic proteins BCL2 and BCLxl to a lesser extent. mivebresib 0-8 BCL2 apoptosis regulator Homo sapiens 102-106 28468776-9 2017 Indeed, strong synergy was observed both in vitro and in vivo when cotreating the cells with BET inhibitor and the BH3-mimetic, BCL2 inhibitor venetoclax (ABT-199). venetoclax 143-153 BCL2 apoptosis regulator Homo sapiens 128-132 28468776-9 2017 Indeed, strong synergy was observed both in vitro and in vivo when cotreating the cells with BET inhibitor and the BH3-mimetic, BCL2 inhibitor venetoclax (ABT-199). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 155-158 BCL2 apoptosis regulator Homo sapiens 128-132 28468776-10 2017 ABBV-075 interaction with venetoclax positively correlated with BCL2 expression. mivebresib 0-8 BCL2 apoptosis regulator Homo sapiens 64-68 28656225-5 2017 Further investigation of the apoptotic mechanism revealed that gossypol increased the ratio of B-cell lymphoma 2 (Bcl-2)-associated X protein/Bcl-2 protein levels and upregulated the expression of caspase-3. Gossypol 63-71 BCL2 apoptosis regulator Homo sapiens 114-119 28656225-5 2017 Further investigation of the apoptotic mechanism revealed that gossypol increased the ratio of B-cell lymphoma 2 (Bcl-2)-associated X protein/Bcl-2 protein levels and upregulated the expression of caspase-3. Gossypol 63-71 BCL2 apoptosis regulator Homo sapiens 142-147 28627691-7 2017 SBGE suppressed mitochondrial membrane potentials and SBGE-induced apoptotic cell death was identified to be associated with downregulation of Bcl-2, but upregulation of Bax. sbge 0-4 BCL2 apoptosis regulator Homo sapiens 143-148 28453190-8 2017 The increased expression of genes involved in the NGFR-MAPK10-TP53-Bax/Bcl2 pathway during incubation with AZA plus everolimus was validated by western blotting in MZ-CRC-1 cells. Decitabine 107-110 BCL2 apoptosis regulator Homo sapiens 71-75 28453190-8 2017 The increased expression of genes involved in the NGFR-MAPK10-TP53-Bax/Bcl2 pathway during incubation with AZA plus everolimus was validated by western blotting in MZ-CRC-1 cells. Everolimus 116-126 BCL2 apoptosis regulator Homo sapiens 71-75 28627691-7 2017 SBGE suppressed mitochondrial membrane potentials and SBGE-induced apoptotic cell death was identified to be associated with downregulation of Bcl-2, but upregulation of Bax. sbge 54-58 BCL2 apoptosis regulator Homo sapiens 143-148 28656255-8 2017 Additionally, upregulation of miR-320b could markedly promote apoptosis by increasing the level of Bax and reducing Bcl-2 expression in glioma. mir-320b 30-38 BCL2 apoptosis regulator Homo sapiens 116-121 28789432-6 2017 In addition, luteolin combined with LY294002 markedly increased the Bax/Bcl-2 ratio, while when combined with U0126, luteolin had less effects on the Bax/Bcl-2 ratio compared with luteolin treatment alone, suggesting that both the MAPK and PI3K signaling pathways are involved in the apoptosis induced by luteolin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 BCL2 apoptosis regulator Homo sapiens 72-77 28718669-8 2017 We also showed fruit polyphenol-mediated release of mitochondrial pro- and antiapoptotic proteins of the Bcl-2 family and modulation activity of the Akt, p38 MAPK, and Erk 1/2 pathways as well as the signaling of ROS-mediated DNA damage. Polyphenols 21-31 BCL2 apoptosis regulator Homo sapiens 105-110 28718669-8 2017 We also showed fruit polyphenol-mediated release of mitochondrial pro- and antiapoptotic proteins of the Bcl-2 family and modulation activity of the Akt, p38 MAPK, and Erk 1/2 pathways as well as the signaling of ROS-mediated DNA damage. ros 213-216 BCL2 apoptosis regulator Homo sapiens 105-110 28781641-8 2017 Therefore, the present results indicated that the anticancer effects of liriodenine suppress cell growth and induce the apoptosis of human breast cancer MCF-7 cells through inhibition of Bcl-2, cyclin D1 and VEGF expression, and upregulation of p53 expression. liriodenine 72-83 BCL2 apoptosis regulator Homo sapiens 187-192 28366708-2 2017 ABT-737 competitively binds to surface hydrophobic grooves of anti-apoptotic proteins of Bcl-2 family, counteracting their protective effect. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 89-94 28591670-10 2017 Furthermore, altered levels of ROS triggers intrinsic apoptotic cascade, as evidenced by dissipated mitochondrial membrane potential (psi), decrease in Bcl-2/Bax ratio, cytochrome c release and cleavage of procaspase-3. ros 31-34 BCL2 apoptosis regulator Homo sapiens 152-157 28366708-7 2017 Moreover, the simultaneous treatment of leukemia cells with ABT-737 and resveratrol resulted in a reduction in mitochondrial membrane potential, an increase of p53 protein level and up-regulation of the Bax/Bcl-2 ratio. ABT-737 60-67 BCL2 apoptosis regulator Homo sapiens 207-212 28366708-7 2017 Moreover, the simultaneous treatment of leukemia cells with ABT-737 and resveratrol resulted in a reduction in mitochondrial membrane potential, an increase of p53 protein level and up-regulation of the Bax/Bcl-2 ratio. Resveratrol 72-83 BCL2 apoptosis regulator Homo sapiens 207-212 28627461-14 2017 8-MOP reduced the phosphorylation of AKT308, decreased the expression of Bcl-2, increased the Bax protein level, and activated caspases -8, -9, and -3 in both cell lines. Methoxsalen 0-5 BCL2 apoptosis regulator Homo sapiens 73-78 29139274-7 2017 Western blot results showed that the expression of Bcl-2 protein was down-regulated; the expression of Bax protein was up-regulated; the ration of Bax/Bcl-2 was increased and the protein expression levels of Cleaved caspase-3, Cleaved caspase-9 and Cyto C were increased after dihydroartemisinin treatment. artenimol 277-295 BCL2 apoptosis regulator Homo sapiens 51-56 28712374-4 2017 In addition, the level of maturation-promoting factor (MPF) was significantly decreased in oocytes activated by an EP and treated with 10 microM AZD5438 for 4 h. Finally, the mRNA expression levels of apoptosis-related genes (Bax and Bcl-2) and pluripotency-related genes (Oct4, Nanog, and Sox2) were checked by RT-PCR; however, there were no differences between the AZD5438-treated and non-treated control groups. AZD5438 145-152 BCL2 apoptosis regulator Homo sapiens 234-239 28823263-5 2017 RESULTS: Phenelzine inhibited proliferation and promoted apoptosis of Jeko-1 cells in a dose-dependent way by increasing the expression of apoptosis related protein BAX, Caspase-3 and p21, while decreasing anti-apoptotic protein BCL-2. Phenelzine 9-19 BCL2 apoptosis regulator Homo sapiens 229-234 28522442-11 2017 A highly selective BCL2 inhibitor, venetoclax, was recently introduced as breakthrough therapy. venetoclax 35-45 BCL2 apoptosis regulator Homo sapiens 19-23 28775672-11 2017 Subsequently, a significantly decreased expression of p-AKT and Bcl-2, increased expression of Caspase-3 were observed in the LY294002 plus radiation group compared with radiation alone group, while these influences caused by LY294002 or X-ray radiation were reversed after COL1A1 activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 126-134 BCL2 apoptosis regulator Homo sapiens 64-69 29254147-7 2017 In conclusion, Bcl-2 negative, HER2-positive and smaller (<=2 cm) tumor sizes are independent predictors of pCR in ER-positive patients treated with dose-dense (biweekly) paclitaxel/carboplatin NCT. Carboplatin 185-196 BCL2 apoptosis regulator Homo sapiens 15-20 29254147-7 2017 In conclusion, Bcl-2 negative, HER2-positive and smaller (<=2 cm) tumor sizes are independent predictors of pCR in ER-positive patients treated with dose-dense (biweekly) paclitaxel/carboplatin NCT. Paclitaxel 174-184 BCL2 apoptosis regulator Homo sapiens 15-20 29348830-5 2017 Meanwhile, leflunomide treatment induced cell apoptosis and deficiency of DHODH sensitized cells to drug-induced apoptosis in BCL-2 deficient melanoma cells, while not in BCL-2 abundant melanoma cells. Leflunomide 11-22 BCL2 apoptosis regulator Homo sapiens 126-131 29029479-6 2017 At the same time Bcl-2 &Bcl-xL expression decreased, Bim expression increased, and Bax was activated. Adenosine Monophosphate 24-27 BCL2 apoptosis regulator Homo sapiens 17-22 28702620-0 2017 Nanoparticle delivery of curcumin induces cellular hypoxia and ROS-mediated apoptosis via modulation of Bcl-2/Bax in human neuroblastoma. Curcumin 25-33 BCL2 apoptosis regulator Homo sapiens 104-109 28728544-11 2017 Moreover treatment of Cladosporol A significantly induced MMP loss, release of cytochrome c, Bcl-2 down regulation, Bax upregulation as well as increased monodansylcadaverine (MDC) staining and leads to LC3-I to LC3-II conversion. cladosporol A 22-35 BCL2 apoptosis regulator Homo sapiens 93-98 29348830-7 2017 Moreover, BCL-2 also showed to promote cell cycle arrest and to inhibit autophagy induced by leflunomide. Leflunomide 93-104 BCL2 apoptosis regulator Homo sapiens 10-15 28537875-0 2017 N-myc downstream-regulated gene 1 promotes oxaliplatin-triggered apoptosis in colorectal cancer cells via enhancing the ubiquitination of Bcl-2. Oxaliplatin 43-54 BCL2 apoptosis regulator Homo sapiens 138-143 28696828-4 2017 In the present study, we explored the influences of TW-37, a small molecule inhibitor of Bcl-2 and Mcl-1, on the efficiency of chemotherapy for NPC. TW-37 52-57 BCL2 apoptosis regulator Homo sapiens 89-94 28696828-6 2017 And our results reveal that chemotherapeutics, Cisplatin (CDDP) and 5-Fluoracil (5-FU), result in the greater decrease of protein level of Bcl-2 and Mcl-1 in NPC cells than those in NPE cells. Cisplatin 47-56 BCL2 apoptosis regulator Homo sapiens 139-144 28696828-6 2017 And our results reveal that chemotherapeutics, Cisplatin (CDDP) and 5-Fluoracil (5-FU), result in the greater decrease of protein level of Bcl-2 and Mcl-1 in NPC cells than those in NPE cells. Cisplatin 58-62 BCL2 apoptosis regulator Homo sapiens 139-144 28696828-6 2017 And our results reveal that chemotherapeutics, Cisplatin (CDDP) and 5-Fluoracil (5-FU), result in the greater decrease of protein level of Bcl-2 and Mcl-1 in NPC cells than those in NPE cells. Fluorouracil 68-79 BCL2 apoptosis regulator Homo sapiens 139-144 28696828-6 2017 And our results reveal that chemotherapeutics, Cisplatin (CDDP) and 5-Fluoracil (5-FU), result in the greater decrease of protein level of Bcl-2 and Mcl-1 in NPC cells than those in NPE cells. Fluorouracil 81-85 BCL2 apoptosis regulator Homo sapiens 139-144 28537893-3 2017 We found that alpha-mangostin effectively inhibited cell viability, resulted in loss of mitochondrial membrane potential (MMP), release of cytochrome C, increase of Bax, decrease of Bcl-2, and activation of caspase-9/caspase-3 cascade in cervical cancer cells. mangostin 14-29 BCL2 apoptosis regulator Homo sapiens 182-187 28714472-6 2017 As doxorubicin and dinaciclib also reduced BCL-XL, the combinations of BCL-2 inhibitor ABT-199 (venetoclax) with doxorubicin or dinaciclib provided effective therapeutic strategies for SCLC. venetoclax 87-94 BCL2 apoptosis regulator Homo sapiens 71-76 28714472-3 2017 ABT-263 (navitoclax), a BCL-2/BCL-XL inhibitor, prevented BCL-XL from sequestering activator BH3-only molecules (BH3s) and BAX but not BAK. navitoclax 0-7 BCL2 apoptosis regulator Homo sapiens 24-29 28714472-6 2017 As doxorubicin and dinaciclib also reduced BCL-XL, the combinations of BCL-2 inhibitor ABT-199 (venetoclax) with doxorubicin or dinaciclib provided effective therapeutic strategies for SCLC. venetoclax 96-106 BCL2 apoptosis regulator Homo sapiens 71-76 28714472-3 2017 ABT-263 (navitoclax), a BCL-2/BCL-XL inhibitor, prevented BCL-XL from sequestering activator BH3-only molecules (BH3s) and BAX but not BAK. navitoclax 9-19 BCL2 apoptosis regulator Homo sapiens 24-29 28706229-3 2017 Using fluorescence cross-correlation spectroscopy to quantify the interactions within a minimal Bcl-2 network, comprised by cBid, Bax, and Bcl-xL, we show that membrane insertion drastically alters the pattern of Bcl-2 complexes, and that the C-terminal helix of Bcl-xL determines its binding preferences. cbid 124-128 BCL2 apoptosis regulator Homo sapiens 96-101 28288819-1 2017 BH3 mimetics are a novel class of anticancer agents designed to specifically target pro-survival proteins of the Bcl-2 family. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 113-118 28288819-2 2017 Like endogenous BH3-only proteins, BH3 mimetics competitively bind to surface hydrophobic grooves of pro-survival Bcl-2 family members, counteracting their protective effects and thus facilitating apoptosis in cancer cells. BH 3 16-19 BCL2 apoptosis regulator Homo sapiens 114-119 28288819-8 2017 For the optimization and clinical implementation of BH3 mimetics, a detailed understanding of their role as inhibitors of the pro-survival Bcl-2 proteins, but also of their possible additional effects is required. BH 3 52-55 BCL2 apoptosis regulator Homo sapiens 139-144 28714901-5 2017 Se-PPC induced depletion of mitochondrial membrane potential (DeltaPsim) in A549 cells through regulating the expression of anti-apoptotic (Bcl-2, Bcl-XL) and pro-apoptotic (Bax, Bid) proteins, resulting in disruption of the activation of caspase-9. se-ppc 0-6 BCL2 apoptosis regulator Homo sapiens 140-145 28455421-7 2017 Accordingly, we found that combining the BCL-2/BCL-XL inhibitors ABT-263/ABT199 with the CDK7 inhibitor THZ1 synergized in producing growth inhibition and apoptosis of human TNBC cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 65-68 BCL2 apoptosis regulator Homo sapiens 41-46 28455421-7 2017 Accordingly, we found that combining the BCL-2/BCL-XL inhibitors ABT-263/ABT199 with the CDK7 inhibitor THZ1 synergized in producing growth inhibition and apoptosis of human TNBC cells. venetoclax 73-79 BCL2 apoptosis regulator Homo sapiens 41-46 28119366-8 2017 BLI and PB were subsequently used to evaluate efficacy of the Bcl-2 inhibitor venetoclax.Results: BLI considerably accelerated and enhanced detection of leukemia burden compared with PB and identified sites of residual disease during treatment in a quantitative manner, highlighting limitations in current PB-based scoring criteria. venetoclax 78-88 BCL2 apoptosis regulator Homo sapiens 62-67 28549559-12 2017 CONCLUSION: According to these findings, the novel indole derivative 2-AITFEI-3-F probably triggered apoptosis of NB4 cells by modulating Bax/Bcl-2 ratio. indole 51-57 BCL2 apoptosis regulator Homo sapiens 142-147 28660943-7 2017 Mechanistically, UA@M-CS-FA induced cancer cell apoptosis and inhibited migration via cell cycle arrest in the G0/G1 stage, regulating the PARP/Bcl-2/MMP-9/CD44/PTEN/P53. ursolic acid 17-19 BCL2 apoptosis regulator Homo sapiens 144-149 28660943-7 2017 Mechanistically, UA@M-CS-FA induced cancer cell apoptosis and inhibited migration via cell cycle arrest in the G0/G1 stage, regulating the PARP/Bcl-2/MMP-9/CD44/PTEN/P53. m-cs-fa 20-27 BCL2 apoptosis regulator Homo sapiens 144-149 29050237-3 2017 In this study, we examined the regulation of the Nur77-Bcl-2 pathway by CCE9, a xanthone compound. cce9 72-76 BCL2 apoptosis regulator Homo sapiens 55-60 28706229-6 2017 Our study disentangles the hierarchy of Bcl-2 complex formation in relation to their environment: Bcl-xL association with cBid occurs in solution and in membranes, where the complex is stabilized, whereas Bcl-xL binding to Bax occurs only in membranes and with lower affinity than to cBid, leading instead to Bax retrotranslocation.The permeabilization of the mitochondrial outer membrane to induce apoptosis is regulated by complex interactions between Bcl-2 family members. cbid 122-126 BCL2 apoptosis regulator Homo sapiens 40-45 28706229-6 2017 Our study disentangles the hierarchy of Bcl-2 complex formation in relation to their environment: Bcl-xL association with cBid occurs in solution and in membranes, where the complex is stabilized, whereas Bcl-xL binding to Bax occurs only in membranes and with lower affinity than to cBid, leading instead to Bax retrotranslocation.The permeabilization of the mitochondrial outer membrane to induce apoptosis is regulated by complex interactions between Bcl-2 family members. cbid 284-288 BCL2 apoptosis regulator Homo sapiens 40-45 29050237-3 2017 In this study, we examined the regulation of the Nur77-Bcl-2 pathway by CCE9, a xanthone compound. xanthone 80-88 BCL2 apoptosis regulator Homo sapiens 55-60 28515304-0 2017 Reactive Oxygen Species-Mediated c-Jun NH2-Terminal Kinase Activation Contributes to Hepatitis B Virus X Protein-Induced Autophagy via Regulation of the Beclin-1/Bcl-2 Interaction. Reactive Oxygen Species 0-23 BCL2 apoptosis regulator Homo sapiens 162-167 28515304-12 2017 Further data showed that ROS-JNK activation by HBx resulted in the release of beclin-1 from its association with Bcl-2 to form a complex with VPS34, thus enhancing autophagosome formation. Reactive Oxygen Species 25-28 BCL2 apoptosis regulator Homo sapiens 113-118 28187446-6 2017 Gene expression profiling of paclitaxel-residual, -resistant and naive MDA-MB-231 cells demonstrated that paclitaxel-residual, as opposed to -resistant cells, were characterized by an apoptotic signature, with downregulation of anti-apoptotic genes (BCL2, BIRC5), induction of apoptosis inducers (IL24, PDCD4), and enrichment of TNFalpha/NF-kappaB pathway, including upregulation of TNFSF15, coupled with cell-cycle arrest. Paclitaxel 106-116 BCL2 apoptosis regulator Homo sapiens 250-254 28696369-4 2017 It was discovered that DHAP downregulated the expression of oncogenic gene products like Bcl-xl, Bcl-2, Mcl-1, Survivin, Cyclin D1, IAP-1, Cyclin E, COX-2, and MMP-9, and upregulated the expression of Bax and p21 proteins, consistent with the induction of G2/M phase cell cycle arrest and apoptosis in U266 cells. Dihydroxyacetone Phosphate 23-27 BCL2 apoptosis regulator Homo sapiens 97-102 28537899-7 2017 Mechanistically, this synergistic apoptosis induction by Sorafenib and Vorinostat is based on the downregulation of the anti-apoptotic protein Mcl-1, but not of other Bcl-2 family members. Sorafenib 57-66 BCL2 apoptosis regulator Homo sapiens 167-172 28537899-7 2017 Mechanistically, this synergistic apoptosis induction by Sorafenib and Vorinostat is based on the downregulation of the anti-apoptotic protein Mcl-1, but not of other Bcl-2 family members. Vorinostat 71-81 BCL2 apoptosis regulator Homo sapiens 167-172 28698660-5 2017 After treatment with 25-50 muM NaHS, the protein levels of p-EGFR, p-ERK, MMP-2, and p-AKT were increased, whereas the levels of PTEN and the ratio of BAX/BCL-2 were down-regulated. sodium bisulfide 31-35 BCL2 apoptosis regulator Homo sapiens 155-160 28463795-8 2017 Western blot analysis indicated remarkable concentration dependent alterations in the expression of proliferation and survival proteins CD1, E2F, CE1, p53, p21, BAX, BCL-2, cytochrome C and cleaved PARP in cisatracurium-treated groups as compared with the untreated group. cisatracurium 206-219 BCL2 apoptosis regulator Homo sapiens 166-171 28400209-3 2017 AST pretreatment attenuated glutamate-induced activation of caspase-3, reduction of anti-apoptotic protein Bcl-2, and increase of pro-apoptotic protein Bak. Glutamic Acid 28-37 BCL2 apoptosis regulator Homo sapiens 107-112 28690874-10 2017 Further, SFN-Cys triggered the activation of ERK1/2, which resulted in the upregulation of maspin, Bax, cleaved caspase-3 and downregulation of pro-caspase-3, Bcl-2, alpha-tubulin. sfn-cys 9-16 BCL2 apoptosis regulator Homo sapiens 159-164 28740380-0 2017 Inhibition of cell proliferation through an ATP-responsive co-delivery system of doxorubicin and Bcl-2 siRNA. Adenosine Triphosphate 44-47 BCL2 apoptosis regulator Homo sapiens 97-102 28740380-1 2017 Herein, DNA duplex was constructed through the hybridization of adenosine triphosphate (ATP)-responsive aptamer and its cDNA in which GC-rich motif could be used to load doxorubicin (DOX), and then, cationic polymer PEI25K was used as a carrier to simultaneously condense DOX-Duplex and Bcl-2 siRNA to prepare the ternary nanocomplex polyethylenimine (PEI)/DOX-Duplex/siRNA. Adenosine Triphosphate 64-86 BCL2 apoptosis regulator Homo sapiens 287-292 28740380-1 2017 Herein, DNA duplex was constructed through the hybridization of adenosine triphosphate (ATP)-responsive aptamer and its cDNA in which GC-rich motif could be used to load doxorubicin (DOX), and then, cationic polymer PEI25K was used as a carrier to simultaneously condense DOX-Duplex and Bcl-2 siRNA to prepare the ternary nanocomplex polyethylenimine (PEI)/DOX-Duplex/siRNA. Adenosine Triphosphate 88-91 BCL2 apoptosis regulator Homo sapiens 287-292 28740380-1 2017 Herein, DNA duplex was constructed through the hybridization of adenosine triphosphate (ATP)-responsive aptamer and its cDNA in which GC-rich motif could be used to load doxorubicin (DOX), and then, cationic polymer PEI25K was used as a carrier to simultaneously condense DOX-Duplex and Bcl-2 siRNA to prepare the ternary nanocomplex polyethylenimine (PEI)/DOX-Duplex/siRNA. Doxorubicin 170-181 BCL2 apoptosis regulator Homo sapiens 287-292 28740380-1 2017 Herein, DNA duplex was constructed through the hybridization of adenosine triphosphate (ATP)-responsive aptamer and its cDNA in which GC-rich motif could be used to load doxorubicin (DOX), and then, cationic polymer PEI25K was used as a carrier to simultaneously condense DOX-Duplex and Bcl-2 siRNA to prepare the ternary nanocomplex polyethylenimine (PEI)/DOX-Duplex/siRNA. Doxorubicin 183-186 BCL2 apoptosis regulator Homo sapiens 287-292 28740380-1 2017 Herein, DNA duplex was constructed through the hybridization of adenosine triphosphate (ATP)-responsive aptamer and its cDNA in which GC-rich motif could be used to load doxorubicin (DOX), and then, cationic polymer PEI25K was used as a carrier to simultaneously condense DOX-Duplex and Bcl-2 siRNA to prepare the ternary nanocomplex polyethylenimine (PEI)/DOX-Duplex/siRNA. Doxorubicin 272-275 BCL2 apoptosis regulator Homo sapiens 287-292 28740380-1 2017 Herein, DNA duplex was constructed through the hybridization of adenosine triphosphate (ATP)-responsive aptamer and its cDNA in which GC-rich motif could be used to load doxorubicin (DOX), and then, cationic polymer PEI25K was used as a carrier to simultaneously condense DOX-Duplex and Bcl-2 siRNA to prepare the ternary nanocomplex polyethylenimine (PEI)/DOX-Duplex/siRNA. Polyethyleneimine 334-350 BCL2 apoptosis regulator Homo sapiens 287-292 28740380-1 2017 Herein, DNA duplex was constructed through the hybridization of adenosine triphosphate (ATP)-responsive aptamer and its cDNA in which GC-rich motif could be used to load doxorubicin (DOX), and then, cationic polymer PEI25K was used as a carrier to simultaneously condense DOX-Duplex and Bcl-2 siRNA to prepare the ternary nanocomplex polyethylenimine (PEI)/DOX-Duplex/siRNA. Polyethyleneimine 216-219 BCL2 apoptosis regulator Homo sapiens 287-292 28740380-1 2017 Herein, DNA duplex was constructed through the hybridization of adenosine triphosphate (ATP)-responsive aptamer and its cDNA in which GC-rich motif could be used to load doxorubicin (DOX), and then, cationic polymer PEI25K was used as a carrier to simultaneously condense DOX-Duplex and Bcl-2 siRNA to prepare the ternary nanocomplex polyethylenimine (PEI)/DOX-Duplex/siRNA. Doxorubicin 272-275 BCL2 apoptosis regulator Homo sapiens 287-292 28740380-5 2017 Overall, the ATP-responsive nanocarrier for co-delivering DOX and Bcl-2 siRNA has been demonstrated to be a smart delivery system with favorable anti-proliferative effect, especially for solving the multidrug resistance of tumors. Adenosine Triphosphate 13-16 BCL2 apoptosis regulator Homo sapiens 66-71 28389687-6 2017 New options include two agents targeting B cell receptor (BCR) signaling pathways (ibrutinib and idelalisib) and a B cell lymphoma-2 (BCL-2) inhibitor (venetoclax). venetoclax 152-162 BCL2 apoptosis regulator Homo sapiens 134-139 28327438-6 2017 LPS (10mug/mL) induced significant inhibition of cell proliferation and cell apoptosis, and a significant decrease in the BCL2/BAX ratio in the cells cultured with 5.5mmol/L glucose. Glucose 174-181 BCL2 apoptosis regulator Homo sapiens 122-126 28918747-0 2017 Omega-3 Polyunsaturated Fatty Acids Eicosapentaenoic Acid and Docosahexaenoic Acid Enhance Dexamethasone Sensitivity in Multiple Myeloma Cells by the p53/miR-34a/Bcl-2 Axis. omega-3 polyunsaturated fatty acids 0-35 BCL2 apoptosis regulator Homo sapiens 162-167 28918747-0 2017 Omega-3 Polyunsaturated Fatty Acids Eicosapentaenoic Acid and Docosahexaenoic Acid Enhance Dexamethasone Sensitivity in Multiple Myeloma Cells by the p53/miR-34a/Bcl-2 Axis. Eicosapentaenoic Acid 36-57 BCL2 apoptosis regulator Homo sapiens 162-167 28918747-0 2017 Omega-3 Polyunsaturated Fatty Acids Eicosapentaenoic Acid and Docosahexaenoic Acid Enhance Dexamethasone Sensitivity in Multiple Myeloma Cells by the p53/miR-34a/Bcl-2 Axis. Docosahexaenoic Acids 62-82 BCL2 apoptosis regulator Homo sapiens 162-167 28918747-0 2017 Omega-3 Polyunsaturated Fatty Acids Eicosapentaenoic Acid and Docosahexaenoic Acid Enhance Dexamethasone Sensitivity in Multiple Myeloma Cells by the p53/miR-34a/Bcl-2 Axis. Dexamethasone 91-104 BCL2 apoptosis regulator Homo sapiens 162-167 28705212-13 2017 Finally, MAC was found to trigger apoptotic death pathway (based on expression levels of cleaved-caspase 3, Bax/Bcl-2 balance, p53 and p21). mac 9-12 BCL2 apoptosis regulator Homo sapiens 112-117 28574829-5 2017 Consistent with these clinical observations, in vitro assays, we found that the subpopulation of EpCAM-positive ovarian cancer cells shows a significantly higher viability compared with EpCAM-negative cells in response to cisplatin treatment by preventing chemotherapy-induced apoptosis, which is regulated by EpCAM-Bcl-2 axis. Cisplatin 222-231 BCL2 apoptosis regulator Homo sapiens 316-321 28673319-12 2017 Further, TGZ induced chromatin condensation, elevated caspase-3 activity, and increased Bax/Bcl-2 relative expression in MIA Paca2 cells. Troglitazone 9-12 BCL2 apoptosis regulator Homo sapiens 92-97 28499239-8 2017 Additionally, HSFs treated with rhEndostatin (100mg/L) in vitro accumulated in early and late apoptosis and displayed significantly decreased expression of c-jun, c-fos, NF-kappaB, fas, caspase-3 and bcl-2. rhendostatin 32-44 BCL2 apoptosis regulator Homo sapiens 200-205 28499239-9 2017 In sum, these results demonstrate that rhEndostatin induces HSF apoptosis, and this phenotypeis partially due to downregulation of NF-kappaB and bcl-2. rhendostatin 39-51 BCL2 apoptosis regulator Homo sapiens 145-150 28463801-9 2017 Moreover, myricetin up-regulated the activation of caspase cascades and the Bax:Bcl-2 expression ratio. myricetin 10-19 BCL2 apoptosis regulator Homo sapiens 80-85 28522750-6 2017 In like manner, suppressing either Bcl-2, Bcl-xL, or Mcl-1 recapitulated the effects of BH3 mimetics and enhanced the effects of gamitrinib-TPP. BH 3 88-91 BCL2 apoptosis regulator Homo sapiens 35-40 28177662-5 2017 Meanwhile, esculetin increased the activities of caspase-3 and caspase-9, promoted bax expression, decreased bcl-2 expression, and triggered collapse of mitochondrial membrane potential, and increased cytochrome c release from mitochondria. esculetin 11-20 BCL2 apoptosis regulator Homo sapiens 109-114 28522750-6 2017 In like manner, suppressing either Bcl-2, Bcl-xL, or Mcl-1 recapitulated the effects of BH3 mimetics and enhanced the effects of gamitrinib-TPP. Gamitrinib-TPP 129-143 BCL2 apoptosis regulator Homo sapiens 35-40 28067996-0 2017 Virtual screening, SAR, and discovery of 5-(indole-3-yl)-2-[(2-nitrophenyl)amino] [1,3,4]-oxadiazole as a novel Bcl-2 inhibitor. 5-(indole-3-yl)-2-[(2-nitrophenyl)amino] [1,3,4]-oxadiazole 41-100 BCL2 apoptosis regulator Homo sapiens 112-117 28604448-11 2017 Furthermore, either MAP2K6-FP alone or in combination with paclitaxel increased the ratio of expressions of Beclin-1/Bcl-2, another autophagy-related markers, compared with paclitaxel alone. Paclitaxel 59-69 BCL2 apoptosis regulator Homo sapiens 117-122 28067996-1 2017 A new series of oxadiazoles were designed to act as inhibitors of the anti-apoptotic Bcl-2 protein. Oxadiazoles 16-27 BCL2 apoptosis regulator Homo sapiens 85-90 28067996-2 2017 Virtual screening led to the discovery of new hits that interact with Bcl-2 at the BH3 binding pocket. BH 3 83-86 BCL2 apoptosis regulator Homo sapiens 70-75 28067996-3 2017 Further study of the structure-activity relationship of the most active compound of the first series, compound 1, led to the discovery of a novel oxadiazole analogue, compound 16j, that was a more potent small-molecule inhibitor of Bcl-2. Oxadiazoles 146-156 BCL2 apoptosis regulator Homo sapiens 232-237 28504421-4 2017 The results suggest that signaling proteins affected by EGCG in ovarian cancer, which include JUN, FADD, NFKB1, Bcl-2, HIF1alpha, and MMP, are involved primarily in cell cycle, cellular assembly and organization, DNA replication, etc. epigallocatechin gallate 56-60 BCL2 apoptosis regulator Homo sapiens 112-117 28536906-11 2017 Combination trials of ibrutinib with venetoclax, a Bcl-2 inhibitor, are underway and are supported by sound preclinical rationale. ibrutinib 22-31 BCL2 apoptosis regulator Homo sapiens 51-56 28536906-11 2017 Combination trials of ibrutinib with venetoclax, a Bcl-2 inhibitor, are underway and are supported by sound preclinical rationale. venetoclax 37-47 BCL2 apoptosis regulator Homo sapiens 51-56 28318508-6 2017 TBMEHP induced a marked G0/G1 cell cycle arrest and robust cell apoptosis at 1mug/mL by inducing expression of p53, GADD45alpha and cyclin dependent kinase (CDK) inhibitors (p21and p27) while suppressing the expression of cyclin D1, CDK2, CDK6, and Bcl-2. tbmehp 0-6 BCL2 apoptosis regulator Homo sapiens 249-254 28770967-13 2017 Transfection of si-beta-catenin and XAV939 suppressed beta-catenin and Bcl-2 expression, and significantly enhanced ADM sensitivity and ADM-induced apoptosis. XAV939 36-42 BCL2 apoptosis regulator Homo sapiens 71-76 27922187-9 2017 Moreover, tomentosin induced a decrease in mitochondrial membrane potential (DeltaPsim) and an increase in reactive oxygen species (ROS), accompanied by a decrease in Bcl-2 expression. tomentosin 10-20 BCL2 apoptosis regulator Homo sapiens 167-172 28534969-6 2017 Co-treatment with purvalanol A and taxol weakened the expression of Bcl-2 and activated the extrinsic cell death pathway through the activation of caspase-3 and caspase-8. 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine 18-30 BCL2 apoptosis regulator Homo sapiens 68-73 28534969-6 2017 Co-treatment with purvalanol A and taxol weakened the expression of Bcl-2 and activated the extrinsic cell death pathway through the activation of caspase-3 and caspase-8. Paclitaxel 35-40 BCL2 apoptosis regulator Homo sapiens 68-73 28428442-4 2017 Ibrutinib-resistant TMD8 cells had higher BCL2 gene expression and increased sensitivity to ABT-199, a BCL-2 inhibitor. ibrutinib 0-9 BCL2 apoptosis regulator Homo sapiens 42-46 28169456-6 2017 DADS in 1, 5, 10, and 25 muM concentrations had no cytotoxic effect after 24 h. Pretreatment with DADS remarkably increased Nrf2 nuclear translocation as well as the genes expression of detoxifying phase II/antioxidant enzymes and reduced IL-1beta-induced elevation of ROS, lipid peroxidation, Bax/Bcl-2 ratio, caspase-3 activation, and JNK and P38 phosphorylation. amsonic acid 98-102 BCL2 apoptosis regulator Homo sapiens 298-303 28181078-10 2017 Further study demonstrated that puerarin suppressed activation of apoptosis-related proteins including PARP and caspase-3, downregulation of bcl-2, and upregulation of intracellular distribution of bax from cytosol to mitochondria, which was induced by glucose fluctuation. puerarin 32-40 BCL2 apoptosis regulator Homo sapiens 141-146 28550736-0 2017 Piperine attenuates UV-R induced cell damage in human keratinocytes via NF-kB, Bax/Bcl-2 pathway: An application for photoprotection. piperine 0-8 BCL2 apoptosis regulator Homo sapiens 83-88 27808579-1 2017 Treatment options for chronic lymphocytic leukemia (CLL) have improved with the introduction of the B-cell receptor inhibitors ibrutinib and idelalisib, and of the BCL2 inhibitor venetoclax. venetoclax 179-189 BCL2 apoptosis regulator Homo sapiens 164-168 28671570-5 2017 Along with the increase in Bax expression and reduction in Bcl-2, the MeCDDA treatment also significantly decreased Akt and mTOR phosphorylation. mecdda 70-76 BCL2 apoptosis regulator Homo sapiens 59-64 27209189-9 2017 Further, amikacin effectively increased the expression of bcl-2 in SH-SY5Y cells subjected to OGD. Amikacin 9-17 BCL2 apoptosis regulator Homo sapiens 58-63 27209189-11 2017 Our study provides strong evidence that amikacin inhibits miR-497 maturation and promotes ischemic neuronal survival by upregulating anti-apoptotic protein, bcl-2. Amikacin 40-48 BCL2 apoptosis regulator Homo sapiens 157-162 28487980-7 2017 In addition, cotreatment with bortezomib and daunorubicin enhanced the collapse of mitochondrial transmembrane potential and upregulated the proapoptotic protein, B-cell lymphoma 2 (Bcl-2)-interacting mediator of cell death (Bim), but not Bcl-2 or Bcl-extra large. Bortezomib 30-40 BCL2 apoptosis regulator Homo sapiens 163-180 28487980-7 2017 In addition, cotreatment with bortezomib and daunorubicin enhanced the collapse of mitochondrial transmembrane potential and upregulated the proapoptotic protein, B-cell lymphoma 2 (Bcl-2)-interacting mediator of cell death (Bim), but not Bcl-2 or Bcl-extra large. Bortezomib 30-40 BCL2 apoptosis regulator Homo sapiens 182-187 28487980-7 2017 In addition, cotreatment with bortezomib and daunorubicin enhanced the collapse of mitochondrial transmembrane potential and upregulated the proapoptotic protein, B-cell lymphoma 2 (Bcl-2)-interacting mediator of cell death (Bim), but not Bcl-2 or Bcl-extra large. Bortezomib 30-40 BCL2 apoptosis regulator Homo sapiens 239-244 28742207-14 2017 SOCS3 overexpression and/or FLLL32 treatment significantly downregulated p-JAK2, p-STAT3, and Bcl-2 expressions, attenuated cell proliferation, and elevated sensitivity to ADM induced cell apoptosis. FLLL 32 28-34 BCL2 apoptosis regulator Homo sapiens 94-99 28084852-8 2017 Besides, digoxin inhibited NF-kappaB and TNF-alpha-stimulated NF-kappaB activity, and suppressed NF-kappaB initiating genes (Bcl-2, Bcl-xL, cyclin D1, and c-myc), however, increased p21cip1. Digoxin 9-16 BCL2 apoptosis regulator Homo sapiens 125-130 28482576-0 2017 Folate-decorated PEGylated triblock copolymer as a pH/reduction dual-responsive nanovehicle for targeted intracellular co-delivery of doxorubicin and Bcl-2 siRNA. Folic Acid 0-6 BCL2 apoptosis regulator Homo sapiens 150-155 28482576-0 2017 Folate-decorated PEGylated triblock copolymer as a pH/reduction dual-responsive nanovehicle for targeted intracellular co-delivery of doxorubicin and Bcl-2 siRNA. triblock copolymer 27-45 BCL2 apoptosis regulator Homo sapiens 150-155 28482576-3 2017 In this study, a novel folate-conjugated PEGylated cationic triblock copolymer, poly(acrylhydrazine)-block-poly(3-dimethylaminopropyl methacrylamide)-block-poly(acrylhydrazine) (PAH-b-PDMAPMA-b-PAH), was synthesized and evaluated as a stimuli-sensitive vehicle for the targeted co-delivery of doxorubicin (DOX) and Bcl-2 siRNA into breast cancer MCF-7 cells. Folic Acid 23-29 BCL2 apoptosis regulator Homo sapiens 315-320 28482576-3 2017 In this study, a novel folate-conjugated PEGylated cationic triblock copolymer, poly(acrylhydrazine)-block-poly(3-dimethylaminopropyl methacrylamide)-block-poly(acrylhydrazine) (PAH-b-PDMAPMA-b-PAH), was synthesized and evaluated as a stimuli-sensitive vehicle for the targeted co-delivery of doxorubicin (DOX) and Bcl-2 siRNA into breast cancer MCF-7 cells. triblock copolymer 60-78 BCL2 apoptosis regulator Homo sapiens 315-320 28482576-3 2017 In this study, a novel folate-conjugated PEGylated cationic triblock copolymer, poly(acrylhydrazine)-block-poly(3-dimethylaminopropyl methacrylamide)-block-poly(acrylhydrazine) (PAH-b-PDMAPMA-b-PAH), was synthesized and evaluated as a stimuli-sensitive vehicle for the targeted co-delivery of doxorubicin (DOX) and Bcl-2 siRNA into breast cancer MCF-7 cells. poly(acrylhydrazine)-block-poly(3-dimethylaminopropyl methacrylamide)-block-poly(acrylhydrazine) 80-176 BCL2 apoptosis regulator Homo sapiens 315-320 28482576-7 2017 The PEGylated triblock copolymer could chemically conjugate DOX onto PAH blocks via pH-responsive hydrazone bonds and simultaneously complex negatively charged Bcl-2 siRNA with cationic PDMAPMA blocks through electrostatic interactions at N/P ratios>=32:1 to form multifunctional nanomicelleplexes. triblock copolymer 14-32 BCL2 apoptosis regulator Homo sapiens 160-165 28482576-7 2017 The PEGylated triblock copolymer could chemically conjugate DOX onto PAH blocks via pH-responsive hydrazone bonds and simultaneously complex negatively charged Bcl-2 siRNA with cationic PDMAPMA blocks through electrostatic interactions at N/P ratios>=32:1 to form multifunctional nanomicelleplexes. Doxorubicin 60-63 BCL2 apoptosis regulator Homo sapiens 160-165 28482576-7 2017 The PEGylated triblock copolymer could chemically conjugate DOX onto PAH blocks via pH-responsive hydrazone bonds and simultaneously complex negatively charged Bcl-2 siRNA with cationic PDMAPMA blocks through electrostatic interactions at N/P ratios>=32:1 to form multifunctional nanomicelleplexes. Nitrogen 169-170 BCL2 apoptosis regulator Homo sapiens 160-165 28482576-7 2017 The PEGylated triblock copolymer could chemically conjugate DOX onto PAH blocks via pH-responsive hydrazone bonds and simultaneously complex negatively charged Bcl-2 siRNA with cationic PDMAPMA blocks through electrostatic interactions at N/P ratios>=32:1 to form multifunctional nanomicelleplexes. Phosphorus 4-5 BCL2 apoptosis regulator Homo sapiens 160-165 28482576-11 2017 Confocal laser scanning microscopy, flow cytometry and MTT analyses confirmed that, compared with folate-undecorated nanomicelleplexes, folate-decorated nanomicelleplexes could more effectively co-deliver DOX and Bcl-2 siRNA into MCF-7 cells and showed a stronger cell-killing effect. Folic Acid 136-142 BCL2 apoptosis regulator Homo sapiens 213-218 28482577-0 2017 Targeted delivery of Bcl-2 conversion gene by MPEG-PCL-PEI-FA cationic copolymer to combat therapeutic resistant cancer. mpeg-pcl-pei-fa 46-61 BCL2 apoptosis regulator Homo sapiens 21-26 28482577-0 2017 Targeted delivery of Bcl-2 conversion gene by MPEG-PCL-PEI-FA cationic copolymer to combat therapeutic resistant cancer. copolymer 71-80 BCL2 apoptosis regulator Homo sapiens 21-26 28482577-7 2017 More importantly, MPEG-PCL-PEI-FA copolymer exhibited excellent growth inhibition ability on therapeutic resistant HeLa/Bcl-2 cancer cells, which was FR overexpressed HeLa cervical cancer cells with high expression of Bcl-2 protein, thanks to its FA induced targeting ability, high gene transfection efficiency, and low cytotoxicity. mpeg-pcl-pei-fa copolymer 18-43 BCL2 apoptosis regulator Homo sapiens 120-125 28482577-7 2017 More importantly, MPEG-PCL-PEI-FA copolymer exhibited excellent growth inhibition ability on therapeutic resistant HeLa/Bcl-2 cancer cells, which was FR overexpressed HeLa cervical cancer cells with high expression of Bcl-2 protein, thanks to its FA induced targeting ability, high gene transfection efficiency, and low cytotoxicity. mpeg-pcl-pei-fa copolymer 18-43 BCL2 apoptosis regulator Homo sapiens 218-223 28482577-8 2017 This work signifies the first time that cationic amphiphilic MPEG-PCL-PEI-FA copolymers could be utilized for the gene delivery to therapeutic resistant cancer cells with high expression of anti-apoptosis Bcl-2 protein and the positive results are encouraging for the further design of polymeric platforms for combating drug resistant tumors. mpeg-pcl-pei-fa copolymers 61-87 BCL2 apoptosis regulator Homo sapiens 205-210 28560420-9 2017 TUNEL, Annexin V-fluorescein isothiocyanate/propidium iodide, and ratio of Bcl-2-associated X protein and B cell lymphoma 2 indicated that baicalein and U0126 induced HeLa cell apoptosis. U 0126 153-158 BCL2 apoptosis regulator Homo sapiens 75-80 28487980-7 2017 In addition, cotreatment with bortezomib and daunorubicin enhanced the collapse of mitochondrial transmembrane potential and upregulated the proapoptotic protein, B-cell lymphoma 2 (Bcl-2)-interacting mediator of cell death (Bim), but not Bcl-2 or Bcl-extra large. Daunorubicin 45-57 BCL2 apoptosis regulator Homo sapiens 163-180 28487980-7 2017 In addition, cotreatment with bortezomib and daunorubicin enhanced the collapse of mitochondrial transmembrane potential and upregulated the proapoptotic protein, B-cell lymphoma 2 (Bcl-2)-interacting mediator of cell death (Bim), but not Bcl-2 or Bcl-extra large. Daunorubicin 45-57 BCL2 apoptosis regulator Homo sapiens 182-187 28487980-7 2017 In addition, cotreatment with bortezomib and daunorubicin enhanced the collapse of mitochondrial transmembrane potential and upregulated the proapoptotic protein, B-cell lymphoma 2 (Bcl-2)-interacting mediator of cell death (Bim), but not Bcl-2 or Bcl-extra large. Daunorubicin 45-57 BCL2 apoptosis regulator Homo sapiens 239-244 28586001-4 2017 DHA decreased the expression of B-cell lymphoma 2 (Bcl-2), whereas the expression of Bcl-2-associated X protein was increased. Docosahexaenoic Acids 0-3 BCL2 apoptosis regulator Homo sapiens 32-49 28586001-4 2017 DHA decreased the expression of B-cell lymphoma 2 (Bcl-2), whereas the expression of Bcl-2-associated X protein was increased. Docosahexaenoic Acids 0-3 BCL2 apoptosis regulator Homo sapiens 51-56 28428442-4 2017 Ibrutinib-resistant TMD8 cells had higher BCL2 gene expression and increased sensitivity to ABT-199, a BCL-2 inhibitor. ibrutinib 0-9 BCL2 apoptosis regulator Homo sapiens 103-108 28586041-6 2017 Western blot analysis indicated that the protein expression levels of Bcl-2 were decreased, whereas the expression levels of BAX, caspase-9, caspase-3 and cytochrome c were increased following DMC treatment compared with in untreated cells. demethoxycurcumin 193-196 BCL2 apoptosis regulator Homo sapiens 70-75 28428442-4 2017 Ibrutinib-resistant TMD8 cells had higher BCL2 gene expression and increased sensitivity to ABT-199, a BCL-2 inhibitor. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 92-95 BCL2 apoptosis regulator Homo sapiens 103-108 28428442-5 2017 Consistently, clinical samples from ABC-DLBCL patients who experienced poorer response to ibrutinib had higher BCL2 gene expression. ibrutinib 90-99 BCL2 apoptosis regulator Homo sapiens 111-115 28693160-12 2017 MK-8776 (an inhibitor of CDK2) antagonized the apoptosis induced by ISL, and, compared with treatment with ISL alone, pretreatment with MK-8776 inhibited the decrease in DeltaPsim, downregulated the mRNA expression of Bax, Bim, Apaf-1, caspase-9 and caspase-3, and upregulated Bcl-2 mRNA expression. MK-8776 0-7 BCL2 apoptosis regulator Homo sapiens 277-282 28586051-6 2017 GW2974, an EGFR inhibitor, suppressed the protein expression of EGFR, inhibited cell proliferation, increased LDH activity, induced apoptosis and promoted caspase-3/-8 activities and Bax/Bcl-2 protein expression, downregulated PI3K, p-Akt and p-mTOR protein expression in the transfected HCC cells overexpressing miRNA-133b. GW2974 0-6 BCL2 apoptosis regulator Homo sapiens 187-192 28693160-12 2017 MK-8776 (an inhibitor of CDK2) antagonized the apoptosis induced by ISL, and, compared with treatment with ISL alone, pretreatment with MK-8776 inhibited the decrease in DeltaPsim, downregulated the mRNA expression of Bax, Bim, Apaf-1, caspase-9 and caspase-3, and upregulated Bcl-2 mRNA expression. MK-8776 136-143 BCL2 apoptosis regulator Homo sapiens 277-282 28120452-9 2017 Silibinin treatment of ASZ001-Sant-1-resistant cells also decreased bcl-2 but increased cleaved caspase 3 and PARP cleavage, suggesting induction of apoptosis. Silybin 0-9 BCL2 apoptosis regulator Homo sapiens 68-73 28693250-0 2017 Bcl-2/Bcl-xL inhibitor ABT-737 sensitizes pancreatic ductal adenocarcinoma to paclitaxel-induced cell death. ABT-737 23-30 BCL2 apoptosis regulator Homo sapiens 0-5 28693250-0 2017 Bcl-2/Bcl-xL inhibitor ABT-737 sensitizes pancreatic ductal adenocarcinoma to paclitaxel-induced cell death. Paclitaxel 78-88 BCL2 apoptosis regulator Homo sapiens 0-5 28693250-3 2017 The present study analyzed the effect of the B-cell lymphoma-2 (Bcl-2)/B-cell lymphoma extra-large (Bcl-xL) inhibitor, ABT-737, on paclitaxel-induced PDA cell death. ABT-737 119-126 BCL2 apoptosis regulator Homo sapiens 45-62 28693250-3 2017 The present study analyzed the effect of the B-cell lymphoma-2 (Bcl-2)/B-cell lymphoma extra-large (Bcl-xL) inhibitor, ABT-737, on paclitaxel-induced PDA cell death. Paclitaxel 131-141 BCL2 apoptosis regulator Homo sapiens 45-62 28693250-3 2017 The present study analyzed the effect of the B-cell lymphoma-2 (Bcl-2)/B-cell lymphoma extra-large (Bcl-xL) inhibitor, ABT-737, on paclitaxel-induced PDA cell death. Paclitaxel 131-141 BCL2 apoptosis regulator Homo sapiens 64-69 28693250-8 2017 ABT-737 lowered the half maximal inhibitory concentration (IC50) by >2-fold in PDA cells with high Bcl-2/Bcl-xL expression, but not in PDA cells with low Bcl-2/Bcl-xL expression and high TUBB3 expression. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 102-107 28693250-8 2017 ABT-737 lowered the half maximal inhibitory concentration (IC50) by >2-fold in PDA cells with high Bcl-2/Bcl-xL expression, but not in PDA cells with low Bcl-2/Bcl-xL expression and high TUBB3 expression. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 157-162 28558327-7 2017 The intracellular ROS production upon H2O2 treatment as determined by CM-H2DCFDA staining was repressed, the anti-apoptotic marker Bcl-2 was upregulated along with a significant suppression in the expression levels of pro-apoptotic proteins Bax and Bad upon DOR activation. Reactive Oxygen Species 18-21 BCL2 apoptosis regulator Homo sapiens 131-136 28808395-8 2017 The Bax/Bcl-2 ratio and active caspase-3 level were higher in H2O2 + vehicle-treated cells. Hydrogen Peroxide 62-66 BCL2 apoptosis regulator Homo sapiens 8-13 28808395-12 2017 SUMMARY: The gallotannin (69.2%), gallic acid (26.6%), and methyl gallate (4.2%) are the main constituents of water extracts of GRGEGR was more potent in DPPH scavenging, and gallotannin contributes to this extract activityGEGR significantly reduced the increase of apoptosis, Bax/Bcl-2 ratio, and active caspase-3 level after H2O2 treatmentGEGR pretreatment showed protection against H2O2-induced ROS production in DCFH-DA staining analysis. Hydrolyzable Tannins 13-24 BCL2 apoptosis regulator Homo sapiens 281-286 28808395-12 2017 SUMMARY: The gallotannin (69.2%), gallic acid (26.6%), and methyl gallate (4.2%) are the main constituents of water extracts of GRGEGR was more potent in DPPH scavenging, and gallotannin contributes to this extract activityGEGR significantly reduced the increase of apoptosis, Bax/Bcl-2 ratio, and active caspase-3 level after H2O2 treatmentGEGR pretreatment showed protection against H2O2-induced ROS production in DCFH-DA staining analysis. Water 110-115 BCL2 apoptosis regulator Homo sapiens 281-286 28558327-7 2017 The intracellular ROS production upon H2O2 treatment as determined by CM-H2DCFDA staining was repressed, the anti-apoptotic marker Bcl-2 was upregulated along with a significant suppression in the expression levels of pro-apoptotic proteins Bax and Bad upon DOR activation. Hydrogen Peroxide 38-42 BCL2 apoptosis regulator Homo sapiens 131-136 28666466-15 2017 RSV had little effect on cell proliferation and only slightly affected the Bax/Bcl2 ratio. Resveratrol 0-3 BCL2 apoptosis regulator Homo sapiens 79-83 28744359-9 2017 Apoptosis-inducing effect on KYSE-70 cells was observed in 10, 300, 600, and 1,200 ppm H2-silica, and only 1,200 ppm H2-silica caused a 2.4-fold increase in apoptosis in HEEpiCs compared with the control group as the index of Bax/Bcl-2. h2-silica 117-126 BCL2 apoptosis regulator Homo sapiens 230-235 28713815-4 2017 The results suggest that signaling proteins affected by EGCG in breast cancer, which include JUN, FADD, NFKB1, Bcl-2, GNAO1, and MMP14, are involved primarily in cell death and survival; DNA replication, recombination and repair; and the cell cycle. epigallocatechin gallate 56-60 BCL2 apoptosis regulator Homo sapiens 111-116 28978065-0 2017 The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells. obatoclax 33-41 BCL2 apoptosis regulator Homo sapiens 8-13 32913964-0 2017 Changes in Bcl-2 Family Protein Profile During Idelalisib Therapy Mimic Those During Duvelisib Therapy in Chronic Lymphocytic Leukemia Lymphocytes. idelalisib 47-57 BCL2 apoptosis regulator Homo sapiens 11-16 32913964-0 2017 Changes in Bcl-2 Family Protein Profile During Idelalisib Therapy Mimic Those During Duvelisib Therapy in Chronic Lymphocytic Leukemia Lymphocytes. duvelisib 85-94 BCL2 apoptosis regulator Homo sapiens 11-16 28690214-0 2017 [MiR-503 sensitizes human hepatocellular carcinoma cells to cisplatin by targeting bcl-2]. Cisplatin 60-69 BCL2 apoptosis regulator Homo sapiens 83-88 29108234-4 2017 In addition, metapristone inhibited anti-apoptotic marker Bcl-2, and activated pro-apoptotic key signaling proteins caspase-3, and poly (ADP-ribose) polymerase. metapristone 13-25 BCL2 apoptosis regulator Homo sapiens 58-63 28653617-4 2017 Further, I-BET151 resulted in a statistically significant decrease in BCL2 expression in MV4;11 cells, but not in K-562 cells; again this is similar to the findings reported in the original study (Figure 3D; Dawson et al., 2011). GSK1210151A 9-17 BCL2 apoptosis regulator Homo sapiens 70-74 28721010-10 2017 The present study confirmed that cytarabine inhibits proliferation and promotes apoptosis of U87 cells, and molecular analysis of this effect showed that cytarabine significantly reduces expression of phosphatidylinositol 3-kinase/serine/threonine kinase also known as the protein kinase B/mechanistic target of rapamycin (PI3K/Akt/mTOR) pathway, Ki-67, BCL2, and 4-1BB, and upregulates Bax and cleaved caspase-3. Cytarabine 154-164 BCL2 apoptosis regulator Homo sapiens 354-358 28684914-0 2017 Regulation of apoptosis through bcl-2/bax proteins expression and DNA damage by nano-sized gadolinium oxide. gadolinium oxide 91-107 BCL2 apoptosis regulator Homo sapiens 32-37 28644386-6 2017 Western blotting and quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) were used to measure capsaicin-induced autophagy via involvement of the class III PI3K/Beclin-1/Bcl-2 signaling pathway. Capsaicin 123-132 BCL2 apoptosis regulator Homo sapiens 198-203 28637496-9 2017 ABT-199 directly targeted Bcl-2 on endothelial cells, induced endothelial cell apoptosis and inhibited tumor angiogenesis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 26-31 28395218-7 2017 These data imply that bergenin/cinnamic acid hybrids could serve as novel Akt/Bcl-2 inhibitors for further preclinical studies. cinnamic acid 31-44 BCL2 apoptosis regulator Homo sapiens 78-83 28473407-1 2017 The BCL2 inhibitor venetoclax achieves responses in ~79% of patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (RR-CLL/SLL), irrespective of risk factors associated with poor response to chemoimmunotherapy. venetoclax 19-29 BCL2 apoptosis regulator Homo sapiens 4-8 28380464-7 2017 N-Acetyl-L-Cysteine was shown to inhibit ROS generation, suppress permeabilization of lysosomal membranes, decrease levels of cathepsin B and cytochrome C in the cytosol, and inhibit Bax/Bcl2 ratio, caspase-9 and caspase-3 activity both in vitro and in vivo. Acetylcysteine 0-19 BCL2 apoptosis regulator Homo sapiens 187-191 28380464-8 2017 Mitochondrial damage was alleviated when the models were pre-treated with CA-074 Me both in vitro and in vivo, decreasing cathepsin B and cytochrome C levels in the cytosol, Bax/Bcl2 ratio, caspase-9 and caspase-3 activity. CA 074 methyl ester 74-83 BCL2 apoptosis regulator Homo sapiens 178-182 28476618-8 2017 Mechanistically, repaglinide significantly reduced Bcl-2, Beclin-1 and PD-L1 expression in glioma tissues, indicating that repaglinide may exert its anti-cancer effects via apoptotic, autophagic and immune checkpoint signaling. repaglinide 17-28 BCL2 apoptosis regulator Homo sapiens 51-56 28476618-8 2017 Mechanistically, repaglinide significantly reduced Bcl-2, Beclin-1 and PD-L1 expression in glioma tissues, indicating that repaglinide may exert its anti-cancer effects via apoptotic, autophagic and immune checkpoint signaling. repaglinide 123-134 BCL2 apoptosis regulator Homo sapiens 51-56 28455228-9 2017 And we inferred that brusatol illustrates anticancer attribution via JNK/p38 MAPK/NF-kappab/Stat3/Bcl-2 signaling pathway. brusatol 21-29 BCL2 apoptosis regulator Homo sapiens 98-103 28670110-13 2017 CONCLUSION: CTS induced CCA cell apoptosis by suppressing both the JAK2/STAT3 and PI3K/Akt/NFkappaB signaling pathways and altering the expression of Bcl-2/Bax family, which was regulated by these two signaling pathways. cryptotanshinone 12-15 BCL2 apoptosis regulator Homo sapiens 150-155 28515021-12 2017 SF induced apoptosis in a concentration-dependent manner which was associated with the oxidative stress, mitochondria dysfunction, increased Bax:Bcl2 ratio and ADRP levels. sulphoraphene 0-2 BCL2 apoptosis regulator Homo sapiens 145-149 29034364-2 2017 To identify such combinations, we previously performed a combinatorial drug screen and identified the Bcl-2 inhibitor venetoclax (VEN) as a promising partner for combination with IBR in Mantle Cell Lymphoma (MCL). venetoclax 118-128 BCL2 apoptosis regulator Homo sapiens 102-107 28455228-0 2017 Brusatol inhibits growth and induces apoptosis in pancreatic cancer cells via JNK/p38 MAPK/NF-kappab/Stat3/Bcl-2 signaling pathway. brusatol 0-8 BCL2 apoptosis regulator Homo sapiens 107-112 28652654-10 2017 Moreover, PLK inhibition decreases protein levels of Bcl-2; an effect that can be reversed by the proteasomal degradation inhibitor MG-132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 132-138 BCL2 apoptosis regulator Homo sapiens 53-58 28635220-14 2017 The expressions of anti-apoptotic protein Bcl-2 in control, BPA, BPA+ ICA(50), BPA+ ICA(200) groups were 7 120+-151, 9 801+-286, 5 902+-171 and 4 203+-216, respectively (P<0.01). bisphenol A 60-63 BCL2 apoptosis regulator Homo sapiens 42-47 28740556-5 2017 YD277 also reduced the protein expression levels of Cyclin D1, Bcl2 and Bclxl and promoted the expression of p21 and p27. yd277 0-5 BCL2 apoptosis regulator Homo sapiens 63-67 28455228-3 2017 Through researches brusatol was proved to inhibit growth and induce apoptosis in both PATU-8988 and PANC-1 cells by decreasing the expression level of Bcl-2 and increasing the expression levels of Bax, Cleaved Caspase-3. brusatol 19-27 BCL2 apoptosis regulator Homo sapiens 151-156 28455228-5 2017 However, SP600125 could not only abrogated the JNK activation caused by brusatol, but also reverse the p38 activation and the decrease of Bcl-2 as SB203580 did. pyrazolanthrone 9-17 BCL2 apoptosis regulator Homo sapiens 138-143 28455228-7 2017 Furthermore, BAY 11-7082 and S3I-201 indeed had the similar effect as brusatol had on the expression of Phospho-Stat3 and Bcl-2. brusatol 70-78 BCL2 apoptosis regulator Homo sapiens 122-127 28415755-9 2017 Mechanistically, BET-inhibitors and Gamitrinib mediated a pronounced integrated stress response with a PERK-dependent up regulation of ATF4 and subsequent modulation of Bcl-2 family of proteins with down-regulation of Mcl-1 and its interacting partner, Usp9X, and an increase in pro-apoptotic Noxa. Gamitrinib 36-46 BCL2 apoptosis regulator Homo sapiens 169-174 28635220-14 2017 The expressions of anti-apoptotic protein Bcl-2 in control, BPA, BPA+ ICA(50), BPA+ ICA(200) groups were 7 120+-151, 9 801+-286, 5 902+-171 and 4 203+-216, respectively (P<0.01). bisphenol A 65-68 BCL2 apoptosis regulator Homo sapiens 42-47 28635220-14 2017 The expressions of anti-apoptotic protein Bcl-2 in control, BPA, BPA+ ICA(50), BPA+ ICA(200) groups were 7 120+-151, 9 801+-286, 5 902+-171 and 4 203+-216, respectively (P<0.01). icariin 70-73 BCL2 apoptosis regulator Homo sapiens 42-47 28635220-14 2017 The expressions of anti-apoptotic protein Bcl-2 in control, BPA, BPA+ ICA(50), BPA+ ICA(200) groups were 7 120+-151, 9 801+-286, 5 902+-171 and 4 203+-216, respectively (P<0.01). bisphenol A 65-68 BCL2 apoptosis regulator Homo sapiens 42-47 28635220-14 2017 The expressions of anti-apoptotic protein Bcl-2 in control, BPA, BPA+ ICA(50), BPA+ ICA(200) groups were 7 120+-151, 9 801+-286, 5 902+-171 and 4 203+-216, respectively (P<0.01). icariin 84-87 BCL2 apoptosis regulator Homo sapiens 42-47 28638890-7 2017 On the molecular level, chitosan oligosaccharide decreased Bcl-2 and increased Caspase-3 expression which may be related to the apoptosis of hepatoma cells. Oligosaccharides 33-48 BCL2 apoptosis regulator Homo sapiens 59-64 28247997-4 2017 The BCL2 variants identified in PRIMA patients affected the BH1, BH2, and BH3 functional motifs at a lower frequency than the N-terminus and flexible loop domain, with mostly conservative aminoacid changes. bh1 60-63 BCL2 apoptosis regulator Homo sapiens 4-8 28578655-1 2017 BACKGROUND: Venetoclax (ABT-199), a first-in-class orally bioavailable BCL-2-selective inhibitor, was recently approved by the FDA for use in patients with 17p-deleted chronic lymphocytic leukemia who have received prior therapy. venetoclax 12-22 BCL2 apoptosis regulator Homo sapiens 71-76 28578655-1 2017 BACKGROUND: Venetoclax (ABT-199), a first-in-class orally bioavailable BCL-2-selective inhibitor, was recently approved by the FDA for use in patients with 17p-deleted chronic lymphocytic leukemia who have received prior therapy. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 24-27 BCL2 apoptosis regulator Homo sapiens 71-76 28247997-4 2017 The BCL2 variants identified in PRIMA patients affected the BH1, BH2, and BH3 functional motifs at a lower frequency than the N-terminus and flexible loop domain, with mostly conservative aminoacid changes. bh2 65-68 BCL2 apoptosis regulator Homo sapiens 4-8 28247997-4 2017 The BCL2 variants identified in PRIMA patients affected the BH1, BH2, and BH3 functional motifs at a lower frequency than the N-terminus and flexible loop domain, with mostly conservative aminoacid changes. BH 3 74-77 BCL2 apoptosis regulator Homo sapiens 4-8 28400072-8 2017 Compared with the control group, the mRNA abundances of HES1, MYC, BAX, BCL2 and CYP19A1 in DAPT-treated groups was lower (P<0.05), respectively; whereas, the expression of CCND2, CDKN1A and TP53 mRNA showed no remarkable difference compared with control group. dapt 92-96 BCL2 apoptosis regulator Homo sapiens 72-76 28462831-8 2017 Mechanistic studies showed that growth inhibition and apoptosis in PC-3 cells treated with brefeldin A and docetaxel were associated with decrease in the level of Bcl-2. Brefeldin A 91-102 BCL2 apoptosis regulator Homo sapiens 163-168 28386751-10 2017 RLX co-treatment led to a decrease in the Bax/Bcl-2 ratio as well as the cleaved form of caspase-3 compared to the AA-I only treated cells. Relaxin 0-3 BCL2 apoptosis regulator Homo sapiens 46-51 27817049-0 2017 Overexpression of Endogenous Anti-Oxidants with Selenium Supplementation Protects Trophoblast Cells from Reactive Oxygen Species-Induced Apoptosis in a Bcl-2-Dependent Manner. Selenium 48-56 BCL2 apoptosis regulator Homo sapiens 152-157 27817049-0 2017 Overexpression of Endogenous Anti-Oxidants with Selenium Supplementation Protects Trophoblast Cells from Reactive Oxygen Species-Induced Apoptosis in a Bcl-2-Dependent Manner. Reactive Oxygen Species 105-128 BCL2 apoptosis regulator Homo sapiens 152-157 27817049-9 2017 Rotenone, 100 muM treatment for 4 h, caused trophoblast cell apoptosis as evidenced by increased Annexin V binding and decreased expression of Bcl-2. Rotenone 0-8 BCL2 apoptosis regulator Homo sapiens 143-148 27817049-10 2017 In both assays of apoptosis, selenium supplementation was able to prevent apoptosis, preserve Bcl-2 expression and protect trophoblast cells from mitochondrial oxidative stress. Selenium 29-37 BCL2 apoptosis regulator Homo sapiens 94-99 28351005-8 2017 As a result, the Bcl-2 level was negatively regulated by PI4K-AKT/JNK signaling under AgNP-induced stress, leading to enhanced cell death. agnp 86-90 BCL2 apoptosis regulator Homo sapiens 17-22 28351005-9 2017 Together, our findings unearthed that Nrf2-mediated lncRNA ODRUL was indispensable for AgNP-induced toxicity in erythroid cells through regulation of AKT/JNK-Bcl-2 signaling dependent on a physical interaction with PI4Kalpha. agnp 87-91 BCL2 apoptosis regulator Homo sapiens 158-163 28441715-4 2017 Our findings show that downregulation of Bcl-2, Bcl-XL and Mcl-1 can significantly promote EC109/PTX cell apoptosis and reduce the EC109/PTX cell resistance index (RI). Paclitaxel 137-140 BCL2 apoptosis regulator Homo sapiens 41-46 28441715-6 2017 These results suggest that targeting of the Bcl-2 family and P-gp is capable of reversing the resistance in EC109/PTX cells and the two-inhibitor combination may be a novel treatment strategy for resistant esophageal cancer. Paclitaxel 114-117 BCL2 apoptosis regulator Homo sapiens 44-49 28462831-9 2017 The present study indicates that combined brefeldin A with docetaxel may represent a novel approach for improving the efficacy of docetaxel, and Bcl-2 may serve as a target for brefeldin A to enhance the effects of docetaxel chemotherapy. Brefeldin A 177-188 BCL2 apoptosis regulator Homo sapiens 145-150 27913204-0 2017 The selective Bcl-2 inhibitor venetoclax, a BH3 mimetic, does not dysregulate intracellular Ca2+ signaling. venetoclax 30-40 BCL2 apoptosis regulator Homo sapiens 14-19 27913204-1 2017 Anti-apoptotic B cell-lymphoma-2 (Bcl-2) proteins are emerging as therapeutic targets in a variety of cancers for precision medicines, like the BH3-mimetic drug venetoclax (ABT-199), which antagonizes the hydrophobic cleft of Bcl-2. BH 3 144-147 BCL2 apoptosis regulator Homo sapiens 15-32 27913204-1 2017 Anti-apoptotic B cell-lymphoma-2 (Bcl-2) proteins are emerging as therapeutic targets in a variety of cancers for precision medicines, like the BH3-mimetic drug venetoclax (ABT-199), which antagonizes the hydrophobic cleft of Bcl-2. BH 3 144-147 BCL2 apoptosis regulator Homo sapiens 34-39 27913204-1 2017 Anti-apoptotic B cell-lymphoma-2 (Bcl-2) proteins are emerging as therapeutic targets in a variety of cancers for precision medicines, like the BH3-mimetic drug venetoclax (ABT-199), which antagonizes the hydrophobic cleft of Bcl-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 173-176 BCL2 apoptosis regulator Homo sapiens 15-32 27913204-1 2017 Anti-apoptotic B cell-lymphoma-2 (Bcl-2) proteins are emerging as therapeutic targets in a variety of cancers for precision medicines, like the BH3-mimetic drug venetoclax (ABT-199), which antagonizes the hydrophobic cleft of Bcl-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 173-176 BCL2 apoptosis regulator Homo sapiens 34-39 27913204-1 2017 Anti-apoptotic B cell-lymphoma-2 (Bcl-2) proteins are emerging as therapeutic targets in a variety of cancers for precision medicines, like the BH3-mimetic drug venetoclax (ABT-199), which antagonizes the hydrophobic cleft of Bcl-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 173-176 BCL2 apoptosis regulator Homo sapiens 226-231 27913204-9 2017 Furthermore, venetoclax-induced cell death in Bcl-2-dependent cancer cells is not mediated by intracellular Ca2+ overload. venetoclax 13-23 BCL2 apoptosis regulator Homo sapiens 46-51 28441715-0 2017 Targeting the Bcl-2 family and P-glycoprotein reverses paclitaxel resistance in human esophageal carcinoma cell line. Paclitaxel 55-65 BCL2 apoptosis regulator Homo sapiens 14-19 28441715-2 2017 In this study, we investigated the changes of Bcl-2 family members in the moderate paclitaxel-resistance of esophageal carcinoma EC109/PTX cells both in vitro and in vivo. Paclitaxel 83-93 BCL2 apoptosis regulator Homo sapiens 46-51 28441715-2 2017 In this study, we investigated the changes of Bcl-2 family members in the moderate paclitaxel-resistance of esophageal carcinoma EC109/PTX cells both in vitro and in vivo. Paclitaxel 135-138 BCL2 apoptosis regulator Homo sapiens 46-51 28441715-4 2017 Our findings show that downregulation of Bcl-2, Bcl-XL and Mcl-1 can significantly promote EC109/PTX cell apoptosis and reduce the EC109/PTX cell resistance index (RI). Paclitaxel 97-100 BCL2 apoptosis regulator Homo sapiens 41-46 28462831-8 2017 Mechanistic studies showed that growth inhibition and apoptosis in PC-3 cells treated with brefeldin A and docetaxel were associated with decrease in the level of Bcl-2. Docetaxel 107-116 BCL2 apoptosis regulator Homo sapiens 163-168 28341962-15 2017 Importantly, two key genes in apoptosis and stemness, BCL2 and ABCG2, were also upregulated in EP300-knockout colon carcinoma cells and their paclitaxel-resistant derivatives. Paclitaxel 142-152 BCL2 apoptosis regulator Homo sapiens 54-58 28203756-3 2017 The N-terminal BH4 domain of Bcl-2 and Bcl-xL is responsible for the interaction with other proteins that do not belong to Bcl-2 protein family. sapropterin 15-18 BCL2 apoptosis regulator Homo sapiens 29-34 27995757-6 2017 Our results showed that pretreatment with BSBHp significantly attenuates Abeta40 -induced toxicity by retaining cell viability, suppressing generation of ROS, Ca2+ levels, and effectively protects neuronal apoptosis by suppressing pro-apoptotic protein Bax and up-regulating antiapoptotic protein Bcl-2. bsbhp 42-47 BCL2 apoptosis regulator Homo sapiens 297-302 28203756-3 2017 The N-terminal BH4 domain of Bcl-2 and Bcl-xL is responsible for the interaction with other proteins that do not belong to Bcl-2 protein family. sapropterin 15-18 BCL2 apoptosis regulator Homo sapiens 123-128 28203756-5 2017 During the last two decades a strong effort has been made to dissect the molecular pathways involved the capability of BH4 domain to regulate the canonical antiapoptotic and the non-canonical activities of Bcl-2 and Bcl-xL, creating the basis for the development of novel anticancer agents targeting this domain. sapropterin 119-122 BCL2 apoptosis regulator Homo sapiens 206-211 28416490-5 2017 Apoptosis induced by ABBV-075 was mediated in part by modulation of the intrinsic apoptotic pathway, exhibiting synergy with the BCL-2 inhibitor venetoclax in preclinical models of AML. mivebresib 21-29 BCL2 apoptosis regulator Homo sapiens 129-134 28378944-9 2017 We found that metformin can exert growth-suppressive effects on these cell lines via inhibition of p-Akt activity and the Bcl-2 family. Metformin 14-23 BCL2 apoptosis regulator Homo sapiens 122-127 28401485-8 2017 CONCLUSIONS: Taken together, we conclude that ERK1/2 signaling pathway inhibition by silymarin and silibinin increases the expression of the pro-apoptotic Bcl-2 family member Bim which, subsequently, induces mitochondria-mediated apoptosis in salivary gland cancer-derived cells. Silymarin 85-94 BCL2 apoptosis regulator Homo sapiens 155-160 28401485-8 2017 CONCLUSIONS: Taken together, we conclude that ERK1/2 signaling pathway inhibition by silymarin and silibinin increases the expression of the pro-apoptotic Bcl-2 family member Bim which, subsequently, induces mitochondria-mediated apoptosis in salivary gland cancer-derived cells. Silybin 99-108 BCL2 apoptosis regulator Homo sapiens 155-160 28381544-1 2017 A rationale exists for pharmacologic manipulation of the serine (S)184 phosphorylation site of the proapoptotic Bcl2 family member Bax as an anticancer strategy. Serine 57-63 BCL2 apoptosis regulator Homo sapiens 112-116 28416490-5 2017 Apoptosis induced by ABBV-075 was mediated in part by modulation of the intrinsic apoptotic pathway, exhibiting synergy with the BCL-2 inhibitor venetoclax in preclinical models of AML. venetoclax 145-155 BCL2 apoptosis regulator Homo sapiens 129-134 28416490-6 2017 In germinal center diffuse large B-cell lymphoma, BCL-2 levels or venetoclax sensitivity predicted the apoptotic response to ABBV-075 treatment. mivebresib 125-133 BCL2 apoptosis regulator Homo sapiens 50-55 28475750-9 2017 It was shown that ATX improved radiosensitivity of ESCC cells and induced apoptosis and G2/M arrest via inhibiting Bcl2, CyclinB1, Cdc2, and promoting Bax expression. astaxanthine 18-21 BCL2 apoptosis regulator Homo sapiens 115-119 28197783-17 2017 Western blotting analysis on the expression of apoptosis regulatory proteins showed enhancement of proteocleavage-activated caspases 3, 8, and 9 and higher ratios of Bax/Bcl2 in the liquid nitrogen- and freezing nitrogen ethanol composite-treated samples. Nitrogen 212-220 BCL2 apoptosis regulator Homo sapiens 170-174 28197783-17 2017 Western blotting analysis on the expression of apoptosis regulatory proteins showed enhancement of proteocleavage-activated caspases 3, 8, and 9 and higher ratios of Bax/Bcl2 in the liquid nitrogen- and freezing nitrogen ethanol composite-treated samples. Ethanol 221-228 BCL2 apoptosis regulator Homo sapiens 170-174 28332162-12 2017 The expression of bcl-2 anti-apoptotic gene, in contrast to bax pro-apoptotic gene, significantly decreased after treatment by standard and fungal taxols. Paclitaxel 147-153 BCL2 apoptosis regulator Homo sapiens 18-23 27530507-11 2017 Teneligliptin improves proliferation rates in human umbilical vein endothelial cells exposed to high glucose, regulating the expression of cell-cycle inhibitors markers (P53, P21 and P27), and reducing proapoptotic genes (BAX and CASP3), while promotes BCL2 expression. 3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine 0-13 BCL2 apoptosis regulator Homo sapiens 253-257 28588670-11 2017 beta-elemene with hyperthermia treatment significantly promoted P21 and Bax mRNA expression (P<0.01) and significantly decreased caspase-9, Bcl-2 and survivin mRNA expression (P<0.01) in A549 cells. beta-elemene 0-12 BCL2 apoptosis regulator Homo sapiens 143-148 28411581-4 2017 The results showed that Pb exposure alone induced mitochondria-dependent apoptosis in A549 cells, as evidenced by increased apoptotic rate and Bax/Bcl-2 ratio, up-regulated caspases 3 and 9 expressions as well as decreased mitochondrial membrane potential. Lead 24-26 BCL2 apoptosis regulator Homo sapiens 147-152 28587395-8 2017 However, the IC50 for etoposide in sensitive K562 cells was markedly lower than that of K562/ADM cells (50.6+-16.5 and 194+-8.46 microM, respectively), suggesting that the higher expression levels of MDR1 and/or BCL-2 mRNA in resistant cells may be partially responsible for this effect. Etoposide 22-31 BCL2 apoptosis regulator Homo sapiens 212-217 27922189-4 2017 In addition, the pro-survival protein P-Bcl2 Ser70 was found to be associated with decreased AraC-induced cell death following XMD8-92 treatment, suggesting a regulatory role of ERK5 on Bcl2 phosphorylation. Cytarabine 93-97 BCL2 apoptosis regulator Homo sapiens 40-44 28440400-7 2017 Caspase-3 signaling pathway was promoted in carnosic acid and fisetin co-treatment, which was accompanied by anti-apoptotic proteins of Bcl-2 and Bcl-xl decreasing and pro-apoptotic signals of Bax and Bad increasing. salvin 44-57 BCL2 apoptosis regulator Homo sapiens 136-141 28440400-7 2017 Caspase-3 signaling pathway was promoted in carnosic acid and fisetin co-treatment, which was accompanied by anti-apoptotic proteins of Bcl-2 and Bcl-xl decreasing and pro-apoptotic signals of Bax and Bad increasing. fisetin 62-69 BCL2 apoptosis regulator Homo sapiens 136-141 28492339-1 2017 Venetoclax is a potent, selective inhibitor of BCL-2, a key regulator of the intrinsic pathway of apoptosis. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 47-52 28492339-2 2017 In preclinical studies, venetoclax bound to BCL-2 with high affinity and rapidly induced apoptosis in chronic lymphocytic leukemia (CLL) cells. venetoclax 24-34 BCL2 apoptosis regulator Homo sapiens 44-49 28197857-13 2017 DADS also increased the cell apoptosis rate through down-regulating the level of Bcl-2. diallyl disulfide 0-4 BCL2 apoptosis regulator Homo sapiens 81-86 28197857-16 2017 Further, it abolishes the apoptotic resistance induced by DCA in an NF-kappaB/Bcl-2 dependent manner. Deoxycholic Acid 58-61 BCL2 apoptosis regulator Homo sapiens 78-83 27957827-6 2017 Further observation demonstrated that sanguinarine up-regulated the expression of DUSP4 and Bcl-2-associated X protein (Bax), but down-regulated phosphorylated extracellular signal-regulated kinase (p-ERK), proliferating cell nuclear antigen (PCNA), matrix metalloproteinase 2 (MMP-2) and B-cell lymphoma 2 (Bcl-2) expression. sanguinarine 38-50 BCL2 apoptosis regulator Homo sapiens 289-306 27922189-4 2017 In addition, the pro-survival protein P-Bcl2 Ser70 was found to be associated with decreased AraC-induced cell death following XMD8-92 treatment, suggesting a regulatory role of ERK5 on Bcl2 phosphorylation. Cytarabine 93-97 BCL2 apoptosis regulator Homo sapiens 186-190 27957827-6 2017 Further observation demonstrated that sanguinarine up-regulated the expression of DUSP4 and Bcl-2-associated X protein (Bax), but down-regulated phosphorylated extracellular signal-regulated kinase (p-ERK), proliferating cell nuclear antigen (PCNA), matrix metalloproteinase 2 (MMP-2) and B-cell lymphoma 2 (Bcl-2) expression. sanguinarine 38-50 BCL2 apoptosis regulator Homo sapiens 92-97 28487945-9 2017 Inhibition of the Notch pathway via DAPT increased Bcl-2 expression, decreased Bax and cleaved caspase-3 levels and prevented HKC cell apoptosis. dapt 36-40 BCL2 apoptosis regulator Homo sapiens 51-56 28393225-7 2017 However, treatment of MKN45 cells with cisplatin induced upregulation of p53beta and downregulation of bcl-2 mRNA expression levels, and these effects were enhanced by combination treatment with rmhTNF. Cisplatin 39-48 BCL2 apoptosis regulator Homo sapiens 103-108 28266029-7 2017 The mRNA expression of Bcl-2 gene in the AFPmAb-PLGA-rhDCN-treated groups appeared significantly to decrease and the caspase-3 gene had the opposite trend as compared with that of control group (P < 0.01). rhdcn 53-58 BCL2 apoptosis regulator Homo sapiens 23-28 28498473-10 2017 Due to the fact that SFN did not enhance the DNA platination levels upon cisplatin treatment, SFN may have exerted its activity via the inhibition of the anti-apoptotic proteins Bcl-2 and XIAP, as we observed. sulforaphane 94-97 BCL2 apoptosis regulator Homo sapiens 178-183 28599444-5 2017 Furthermore, SFN-paclitaxel-induced apoptosis was inhibited by overexpression of Bcl-2. sulforaphane 13-16 BCL2 apoptosis regulator Homo sapiens 81-86 28599419-7 2017 The combination of ZD55-IL-24 + TMZ induced higher protein expression levels of the proapoptotic proteins B-cell lymphoma-2 (Bcl-2)-like protein 4 and phosphorylated protein, gamma-H2A histone family member X (gamma-H2AX), and reduced the levels of the antiapoptotic proteins Bcl-2, myeloid cell leukemia-1and nuclear factor-kappaB compared with either treatment individually. Temozolomide 32-35 BCL2 apoptosis regulator Homo sapiens 125-130 28588714-8 2017 Oxymatrine also induced apoptosis and cell cycle arrest in the cells, in association with the upregulation of caspase-3 and Bax, and the downregulation of survivin, Bcl-2 and p53 expression. oxymatrine 0-10 BCL2 apoptosis regulator Homo sapiens 165-170 28599444-5 2017 Furthermore, SFN-paclitaxel-induced apoptosis was inhibited by overexpression of Bcl-2. Paclitaxel 17-27 BCL2 apoptosis regulator Homo sapiens 81-86 28599489-6 2017 The results demonstrated that maslinic acid treatment significantly reduced cell proliferation, induced apoptosis and was accompanied by a significant decrease in Bcl-2, Bax and Bad expression levels. maslinic acid 30-43 BCL2 apoptosis regulator Homo sapiens 163-168 28599444-4 2017 In addition, treatment with SFN and paclitaxel resulted in downregulation of the nuclear factor kappa B signaling pathway, and reduced protein expression of apoptosis regulator Bcl-2 and phosphorylated AKT serine/threonine kinase. sulforaphane 28-31 BCL2 apoptosis regulator Homo sapiens 177-182 28618944-6 2017 The combination of ultraviolet radiation B irradiation with demethoxycurcumin synergistically induced apoptotic cell death in A431 and HaCaT cells through activation of p53 and caspase pathways, as well as through upregulation of Bax and p-p65 expression and downregulation of Bcl-2, Mcl-1, and nuclear factor-kappaB expression. demethoxycurcumin 60-77 BCL2 apoptosis regulator Homo sapiens 277-282 28599444-4 2017 In addition, treatment with SFN and paclitaxel resulted in downregulation of the nuclear factor kappa B signaling pathway, and reduced protein expression of apoptosis regulator Bcl-2 and phosphorylated AKT serine/threonine kinase. Paclitaxel 36-46 BCL2 apoptosis regulator Homo sapiens 177-182 28383142-4 2017 Consistently, auraptene cleaved poly(ADP-ribose) polymerase, activated caspase-9 and caspase-3, suppressed the expression of anti-apoptotic proteins, including Bcl-2 and myeloid cell leukemia 1 (Mcl-1), and also activated pro-apoptotic protein Bax in both prostate cancer cells. aurapten 14-23 BCL2 apoptosis regulator Homo sapiens 160-165 28399781-6 2017 N-acetyl-l-cysteine (NAC), a ROS scavenger, partially reduced PCB 118-induced apoptosis and Bax/Bcl-2 ratios in HUVECs. Acetylcysteine 0-19 BCL2 apoptosis regulator Homo sapiens 96-101 28631572-10 2017 With the increased tunicamycin concentration, there were increased expressions of Bax and cleaved caspase-3, decreased expression of Bcl-2, and lower phosphorylation of PI3K/Akt/mTOR signaling pathway-related proteins. Tunicamycin 19-30 BCL2 apoptosis regulator Homo sapiens 133-138 28476378-5 2017 Moreover, we found that the mechanism underlying NS-mediated sorafenib resistance involved dysregulated expression of p53, and downstream Bax and Bcl-2 proteins. Sorafenib 61-70 BCL2 apoptosis regulator Homo sapiens 146-151 28373118-10 2017 RESULTS: A pretreatment of glioma cells with rottlerin before hypericin induced PDT led to significant increase in apoptosis accompanied by the decrease of intracellular oxidative stress and increase of phosphorylated Bcl-2 in the cytoplasm of U87 MG cells. rottlerin 45-54 BCL2 apoptosis regulator Homo sapiens 218-223 28641627-13 2017 CONCLUSION: Resveratrol shows the effect of reversing the drug resisitance of HL-60/ADR cells in acute myeloid leukemia, possibly via promoting the apoptosis of HL-60/ADR cells and inhibiting the expression of MRP1, which may be related with the inhibition of BCL-2 expression and the promotion of BAX expression. Resveratrol 12-23 BCL2 apoptosis regulator Homo sapiens 260-265 28536473-8 2017 Also, AMC strongly inhibited the cell growth and induced apoptosis and cell cycle arrest in HepG2 cells by significantly upregulating the protein expressions of Fas, Fas-L, Bax/Bcl-2, cyto-c, cleaved caspase-3, and PARP in a dose-dependent manner, which indicates AMC induces apoptosis in HepG2 cells through both intrinsic and extrinsic pathways. 7-amino-4-methylcoumarin 6-9 BCL2 apoptosis regulator Homo sapiens 177-182 28822194-5 2017 These results indicated that the apoptosis-inducing effect of oridonin on MDA-MB-231 cells might be correlated with increase of intracellular ROS level, down-regulation of Bcl-2 protein and activation of caspase-3. oridonin 62-70 BCL2 apoptosis regulator Homo sapiens 172-177 28548645-0 2017 Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. ibrutinib 105-114 BCL2 apoptosis regulator Homo sapiens 139-144 28548645-6 2017 Cytotoxicity studies using the AKT inhibitor, MK2206+-ibrutinib, and the Bcl-2-specific inhibitor, venetoclax+-ibrutinib, demonstrated synergistic loss of cell viability when either MK22016 or venetoclax were used in combination with ibrutinib. venetoclax+-ibrutinib 99-120 BCL2 apoptosis regulator Homo sapiens 73-78 28548645-6 2017 Cytotoxicity studies using the AKT inhibitor, MK2206+-ibrutinib, and the Bcl-2-specific inhibitor, venetoclax+-ibrutinib, demonstrated synergistic loss of cell viability when either MK22016 or venetoclax were used in combination with ibrutinib. mk22016 182-189 BCL2 apoptosis regulator Homo sapiens 73-78 28548645-6 2017 Cytotoxicity studies using the AKT inhibitor, MK2206+-ibrutinib, and the Bcl-2-specific inhibitor, venetoclax+-ibrutinib, demonstrated synergistic loss of cell viability when either MK22016 or venetoclax were used in combination with ibrutinib. venetoclax 99-109 BCL2 apoptosis regulator Homo sapiens 73-78 28548645-7 2017 Our findings demonstrate that induction of ibrutinib resistance in WM cells can arise independent of BTKC481S and CXCR4WHIM-like mutations and sustained pressure from ibrutinib appears to activate compensatory AKT signaling as well as reshuffling of Bcl-2 family proteins for maintenance of cell survival. ibrutinib 43-52 BCL2 apoptosis regulator Homo sapiens 250-255 28822194-4 2017 The results showed that oridonin exhibited a significant effect in inducing apoptosis of MDA-MB-231 cells, enhancing intracellular ROS level, down-regulating expression of Bcl-2 protein, and promoting cleavage of caspase-3 and its substrate PARP. oridonin 24-32 BCL2 apoptosis regulator Homo sapiens 172-177 28580175-6 2017 Indeed, we found that heightened CWID sensitivity in EM-derived effectors coincided with higher expression of the pro-apoptotic Bcl-2 family protein BIM, both at steady state and with de novo induction following withdrawal of exogenous IL-2. cwid 33-37 BCL2 apoptosis regulator Homo sapiens 128-133 28531122-0 2017 Microwave-Assisted Synthesis of Imidazo[4,5-f][1,10]phenanthroline Derivatives as Apoptosis Inducers in Chemotherapy by Stabilizing Bcl-2 G-quadruplex DNA. IMIDAZO[4,5-F][1,10]PHENANTHROLINE 32-66 BCL2 apoptosis regulator Homo sapiens 132-137 28518145-5 2017 The RAP1-mediated cisplatin resistance was associated with the activation of NF-kappaB signaling and the upregulation of the antiapoptosis factor BCL-2. Cisplatin 18-27 BCL2 apoptosis regulator Homo sapiens 146-151 28330870-7 2017 Basal ROS levels were extremely low in NiT cells and were correlated with elevated expression levels of both antioxidant enzymes (e.g. catalase and superoxide dismutases) and antiapoptotic proteins (e.g. Bcl-2 and Bcl-xL). Reactive Oxygen Species 6-9 BCL2 apoptosis regulator Homo sapiens 204-209 28518145-7 2017 Furthermore, in established cisplatin-resistant A549 cells, RAP1 depletion caused BCL2 depletion, caspase activation and dramatic lethality to the cells. Cisplatin 28-37 BCL2 apoptosis regulator Homo sapiens 82-86 28518145-8 2017 Hence, our results demonstrate that the cytoplasmic RAP1-NF-kappaB-BCL2 axis represents a key pathway to cisplatin resistance in NSCLC cells, identifying RAP1 as a marker and a potential therapeutic target for cisplatin resistance of NSCLC. Cisplatin 105-114 BCL2 apoptosis regulator Homo sapiens 67-71 28518145-8 2017 Hence, our results demonstrate that the cytoplasmic RAP1-NF-kappaB-BCL2 axis represents a key pathway to cisplatin resistance in NSCLC cells, identifying RAP1 as a marker and a potential therapeutic target for cisplatin resistance of NSCLC. Cisplatin 210-219 BCL2 apoptosis regulator Homo sapiens 67-71 28430601-8 2017 Raloxifene inhibited the targets of STAT3, such as Bcl-2, Bcl-xl and survivin and cell viability, cell migration, and colony formation in liver cancer cells. Raloxifene Hydrochloride 0-10 BCL2 apoptosis regulator Homo sapiens 51-56 29069735-8 2017 Interestingly, suppressing HMGB1 expression attenuated gemcitabine-induced ERK and JNK activation and Bcl-2 phosphorylation. gemcitabine 55-66 BCL2 apoptosis regulator Homo sapiens 102-107 28804691-3 2017 Celecoxib hinders tumor growth interacting with various apoptotic genes, such as cyclooxygenase-2 (Cox-2), B-cell lymphoma 2 (Bcl-2) family, phosphor-inositide-3 kinase/serine-threonine-specific protein kinase (PI3K/Akt), and inhibitors of apoptosis proteins (IAP) family. Celecoxib 0-9 BCL2 apoptosis regulator Homo sapiens 107-124 28804691-3 2017 Celecoxib hinders tumor growth interacting with various apoptotic genes, such as cyclooxygenase-2 (Cox-2), B-cell lymphoma 2 (Bcl-2) family, phosphor-inositide-3 kinase/serine-threonine-specific protein kinase (PI3K/Akt), and inhibitors of apoptosis proteins (IAP) family. Celecoxib 0-9 BCL2 apoptosis regulator Homo sapiens 126-131 28331083-6 2017 This effect can be overcome by treating cells with the clinically approved BCL2 antagonist venetoclax, which prevents Casp8p41 from binding BCL2, thereby allowing Casp8p41 to bind Bak and kill the infected cell. venetoclax 91-101 BCL2 apoptosis regulator Homo sapiens 75-79 28331083-6 2017 This effect can be overcome by treating cells with the clinically approved BCL2 antagonist venetoclax, which prevents Casp8p41 from binding BCL2, thereby allowing Casp8p41 to bind Bak and kill the infected cell. venetoclax 91-101 BCL2 apoptosis regulator Homo sapiens 140-144 28559993-4 2017 Propofol exposure for 48 h led to reduction of proliferation and induction of apoptosis in RA-FLSs, which was coupled with increased Bax and decreased Bcl-2 and survivin levels. Propofol 0-8 BCL2 apoptosis regulator Homo sapiens 151-156 29069735-7 2017 Further, gemcitabine activated c-Jun N-terminal kinase (JNK) and extracellular regulated protein kinase (ERK) and Bcl-2 phosphorylation, and blocking ERK and JNK inhibited autophagy and increased apoptosis in gemcitabine-treated cells. gemcitabine 9-20 BCL2 apoptosis regulator Homo sapiens 114-119 28486557-9 2017 Moreover, ABT-737, which binds to and inhibits anti-apoptotic proteins of the Bcl-2 family, rendered HCC cells resistant to apoptosis induced by ANP32B silencing. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 10-13 BCL2 apoptosis regulator Homo sapiens 78-83 28415572-9 2017 Taken together, melatonin protected BMSCs from iron overload induced apoptosis and necrosis by regulating Bcl-2, Bax, Cleaved Caspase-3, RIP1 and RIP3 pathways. Melatonin 16-25 BCL2 apoptosis regulator Homo sapiens 106-111 28415610-3 2017 Autophagy is critical for MG-2477-induced death and is regulated by the BH3-only protein PMAIP1/NOXA which sequesters the anti-apoptotic BCL2-protein BCLXL and thereby displaces and activates the autophagy-regulator BECN1/beclin1. Magnesium 26-28 BCL2 apoptosis regulator Homo sapiens 137-141 28415735-4 2017 Western blot showed that the expression of the apoptosis-related protein Bcl-2, Bcl-xl and survivin was significantly reduced in MDA-MB-231 after treatment with Salicylate Phenanthroline Copper (II) Complex. salicylate phenanthroline 161-187 BCL2 apoptosis regulator Homo sapiens 73-78 28233940-5 2017 The iron(II) complex activated p53-mediated mitochondrial dysfunction as can be seen by the upregulation in the expression of p53 and proapoptotic Bcl-2 family proteins, and downregulation in the expression of Bcl-2 family proteins. ammonium ferrous sulfate 4-12 BCL2 apoptosis regulator Homo sapiens 147-152 28233940-5 2017 The iron(II) complex activated p53-mediated mitochondrial dysfunction as can be seen by the upregulation in the expression of p53 and proapoptotic Bcl-2 family proteins, and downregulation in the expression of Bcl-2 family proteins. ammonium ferrous sulfate 4-12 BCL2 apoptosis regulator Homo sapiens 210-215 28915591-7 2017 Furthermore eugenol for external (1 mg) markedly decreased the protein expressions of HER2 (62.9%), AKT (58.6%), PDK1 (56.4%), p85 (54.3%), Bcl2 (59.3%), NF-kappaB (65.7%), Bad (64.0%), Cyclin D1 (43.0%), while p21, p27 and Bax protein expressions were respectively increased 1.83-, 2.52- and 2.51-fold. Eugenol 12-19 BCL2 apoptosis regulator Homo sapiens 140-144 28463955-8 2017 Oxaliplatin combined with CPS-C decreased the expressions of PI3K, phospho-Akt, phospho-mTOR, Bcl-2, and Bcl-XL, and increased the expression of Bax and caspase-3 significantly compared to oxaliplatin-only treatment. Oxaliplatin 0-11 BCL2 apoptosis regulator Homo sapiens 94-99 28415735-4 2017 Western blot showed that the expression of the apoptosis-related protein Bcl-2, Bcl-xl and survivin was significantly reduced in MDA-MB-231 after treatment with Salicylate Phenanthroline Copper (II) Complex. cupric ion 188-199 BCL2 apoptosis regulator Homo sapiens 73-78 28463955-8 2017 Oxaliplatin combined with CPS-C decreased the expressions of PI3K, phospho-Akt, phospho-mTOR, Bcl-2, and Bcl-XL, and increased the expression of Bax and caspase-3 significantly compared to oxaliplatin-only treatment. capilliposide C 26-31 BCL2 apoptosis regulator Homo sapiens 94-99 28415735-5 2017 In vivo, Salicylate Phenanthroline Copper (II) Complex administration significantly attenuated tumor growth of MDA-MB-231 xenografts, and the expression levels of Bcl-2, Bcl-xL and survivin were reduced as measured by immunohistochemical staining. Salicylates 9-19 BCL2 apoptosis regulator Homo sapiens 164-169 28415735-5 2017 In vivo, Salicylate Phenanthroline Copper (II) Complex administration significantly attenuated tumor growth of MDA-MB-231 xenografts, and the expression levels of Bcl-2, Bcl-xL and survivin were reduced as measured by immunohistochemical staining. Phenanthrolines 21-35 BCL2 apoptosis regulator Homo sapiens 164-169 28415735-5 2017 In vivo, Salicylate Phenanthroline Copper (II) Complex administration significantly attenuated tumor growth of MDA-MB-231 xenografts, and the expression levels of Bcl-2, Bcl-xL and survivin were reduced as measured by immunohistochemical staining. cupric ion 36-47 BCL2 apoptosis regulator Homo sapiens 164-169 28056525-0 2017 Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 34-39 28121635-9 2017 Lidocaine may exert these functions by causing an increase in Bax protein and activated caspase-3 and a corresponding decrease in Bcl-2 protein through the extracellular signal-regulated kinase 1/2 and p38 pathways. Lidocaine 0-9 BCL2 apoptosis regulator Homo sapiens 130-135 28317089-7 2017 Moreover, EGCG dose-dependently prevented Hcy-induced HUVECs cytotoxicity and apoptotic biochemical changes such as reducing mitochondrial membrane potential (MMP), decreasing Bcl-2/Bax protein ratio and activating caspase-9 and 3. epigallocatechin gallate 10-14 BCL2 apoptosis regulator Homo sapiens 176-181 28317089-7 2017 Moreover, EGCG dose-dependently prevented Hcy-induced HUVECs cytotoxicity and apoptotic biochemical changes such as reducing mitochondrial membrane potential (MMP), decreasing Bcl-2/Bax protein ratio and activating caspase-9 and 3. Homocysteine 42-45 BCL2 apoptosis regulator Homo sapiens 176-181 28216375-6 2017 The DOX/VCPA combination treatment caused an imbalance in the ratio of Bcl-2 to Bax and induced a lethal mitochondrial dysfunction. Doxorubicin 4-7 BCL2 apoptosis regulator Homo sapiens 71-76 28476801-9 2017 However, the levels of BCL-2 were down-regulated in Dox and AzaC+Dox among a different group of cells. Doxorubicin 52-55 BCL2 apoptosis regulator Homo sapiens 23-28 28476801-9 2017 However, the levels of BCL-2 were down-regulated in Dox and AzaC+Dox among a different group of cells. Azacitidine 60-64 BCL2 apoptosis regulator Homo sapiens 23-28 28231544-0 2017 Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-kappaB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer. Ginsenosides 0-11 BCL2 apoptosis regulator Homo sapiens 110-115 28231544-0 2017 Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-kappaB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer. Paclitaxel 41-51 BCL2 apoptosis regulator Homo sapiens 110-115 28231544-10 2017 Ginsenoside Rg3 combined Paclitaxel inhibited NF-kappaB activation, decreased NF-kappaB p65 and Bcl-2 protein expressions, increased Bax and Caspase-3 protein expressions. Ginsenosides 0-11 BCL2 apoptosis regulator Homo sapiens 96-101 28231544-10 2017 Ginsenoside Rg3 combined Paclitaxel inhibited NF-kappaB activation, decreased NF-kappaB p65 and Bcl-2 protein expressions, increased Bax and Caspase-3 protein expressions. Paclitaxel 25-35 BCL2 apoptosis regulator Homo sapiens 96-101 28231544-11 2017 The ratio of Bax/Bcl-2 was significantly enhanced by the Ginsenoside Rg3 to Paclitaxel. Ginsenosides 57-68 BCL2 apoptosis regulator Homo sapiens 17-22 28231544-11 2017 The ratio of Bax/Bcl-2 was significantly enhanced by the Ginsenoside Rg3 to Paclitaxel. Paclitaxel 76-86 BCL2 apoptosis regulator Homo sapiens 17-22 28267517-4 2017 CPS-A also played a protective role against TNF-alpha induced L02 cells apoptosis via up-regulation of Bcl-2 and down-regulation of Bid, Bax, cleaved caspase-3, cleaved caspase-9 and ROS production. cps-a 0-5 BCL2 apoptosis regulator Homo sapiens 103-108 28476801-9 2017 However, the levels of BCL-2 were down-regulated in Dox and AzaC+Dox among a different group of cells. Doxorubicin 65-68 BCL2 apoptosis regulator Homo sapiens 23-28 28267674-11 2017 SAHA upregulated Bax and downregulated Bcl-2, Ku70, Ku86, RAD51, RAD54 protein expression of irradiated Panc-1 cells. Vorinostat 0-4 BCL2 apoptosis regulator Homo sapiens 39-44 28216375-6 2017 The DOX/VCPA combination treatment caused an imbalance in the ratio of Bcl-2 to Bax and induced a lethal mitochondrial dysfunction. vcpa 8-12 BCL2 apoptosis regulator Homo sapiens 71-76 28359723-4 2017 Demethoxyfumitremorgin C induced apoptosis was associated with downregulation of anti-apoptotic proteins: Ras, PI3K, Akt, Bcl-xL, and Bcl-2, and upregulation of pro-apoptotic Bax. demethoxyfumitremorgin C 0-24 BCL2 apoptosis regulator Homo sapiens 134-139 27762064-0 2017 CCND1-BCL2 Gene Network: A direct target of Amifostine in human acute megakaryocytic leukemia cells. Amifostine 44-54 BCL2 apoptosis regulator Homo sapiens 6-10 27762064-5 2017 Through whole-genome microarray and bioinformatics analyses, we found that amifostine affected the gene expression of CCND1, BCL2, and CASP3 which revealed the mechanism amifostine acted on Dami cells. Amifostine 75-85 BCL2 apoptosis regulator Homo sapiens 125-129 27762064-5 2017 Through whole-genome microarray and bioinformatics analyses, we found that amifostine affected the gene expression of CCND1, BCL2, and CASP3 which revealed the mechanism amifostine acted on Dami cells. Amifostine 170-180 BCL2 apoptosis regulator Homo sapiens 125-129 27762064-6 2017 Thus, CCND1-BCL2 Gene Network is predicted to be a direct target of amifostine treating human acute megakaryocytic leukemia, which may provide a novel potential target for the therapy of several subtypes of human AML. Amifostine 68-78 BCL2 apoptosis regulator Homo sapiens 12-16 28565839-0 2017 miR-365 induces hepatocellular carcinoma cell apoptosis through targeting Bcl-2. mir-365 0-7 BCL2 apoptosis regulator Homo sapiens 74-79 27697994-6 2017 Cerdulatinib induced apoptosis of CLL cells, in a time- and concentration-dependent manner, and particularly in IGHV-unmutated samples with greater BCR signaling capacity and response to IL4, or samples expressing higher levels of sIgM, CD49d+, or ZAP70+ Cerdulatinib overcame anti-IgM, IL4/CD40L, or NLC-mediated protection by preventing upregulation of MCL-1 and BCL-XL; however, BCL-2 expression was unaffected. 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide 0-12 BCL2 apoptosis regulator Homo sapiens 382-387 28237821-5 2017 Furthermore, CUR-NPs treatment markedly inhibited the reduced Bcl-2/Bax ratio elicited by PA exposure. Palmitates 90-92 BCL2 apoptosis regulator Homo sapiens 62-67 28565875-9 2017 In conclusion, GDC-0449 was shown to inhibit the replication of colon cancer cells and trigger apoptosis through downregulating Bcl-2. HhAntag691 15-23 BCL2 apoptosis regulator Homo sapiens 128-133 28565839-14 2017 In conclusion, the results of the present study demonstrated that miR-365 may serve a role in inducing HCC apoptosis via directly targeting Bcl-2. mir-365 66-73 BCL2 apoptosis regulator Homo sapiens 140-145 28279700-0 2017 Molecular and immunohistochemical expression of apoptotic proteins Bax, Bcl-2 and Caspase 3 in infantile hemangioma tissues as an effect of propranolol treatment. Propranolol 140-151 BCL2 apoptosis regulator Homo sapiens 72-77 28154089-0 2017 Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma. Cyclophosphamide 59-75 BCL2 apoptosis regulator Homo sapiens 24-28 28154089-0 2017 Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma. Doxorubicin 77-88 BCL2 apoptosis regulator Homo sapiens 24-28 28154089-0 2017 Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma. Vincristine 90-101 BCL2 apoptosis regulator Homo sapiens 24-28 28154089-0 2017 Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma. Prednisone 106-116 BCL2 apoptosis regulator Homo sapiens 24-28 28185768-5 2017 Our results demonstrated that PA showed significant anti-tumor activity on lung cancer in vitro; the mechanisms were involved in inducing mitochondria-mediated apoptosis via up-regulation of caspase-3, caspase-8, caspase-9, Bid, Bax, down-regulation of Bcl-2 and stimulating the release of Cyto-C from mitochondria. paederosidic acid 30-32 BCL2 apoptosis regulator Homo sapiens 253-258 28279700-6 2017 RESULTS: Both methods revealed a statistically significant decrease in Bcl-2 expression and an increase in Bax in IHs tissues after propranolol treatment. Propranolol 132-143 BCL2 apoptosis regulator Homo sapiens 71-76 28279700-7 2017 CONCLUSIONS: The results obtained for Bax and Bcl-2 proteins may indicate a link between the effect of propranolol and apoptosis. Propranolol 103-114 BCL2 apoptosis regulator Homo sapiens 46-51 28279700-8 2017 Higher Bax and lower Bcl-2 expression in the propranolol treated group indicates a strong pro- apoptotic action countering any anti-apoptotic activity; apoptosis was indicted in IH tissue as a potential result of propranolol treatment, with potential clinical impact in other tumors. Propranolol 45-56 BCL2 apoptosis regulator Homo sapiens 21-26 28522217-7 2017 In addition, celastrol inhibited the expression of CIP2A, c-MYC, and suppressed apoptotic proteins BAX and caspase-8 in human CS cells, on the other hand, it induced the expression of antiapoptotic protein Bcl-2. celastrol 13-22 BCL2 apoptosis regulator Homo sapiens 206-211 28326661-2 2017 We recently developed a class of synthetic peptide based on scyllatoxin (ScTx) designed to mimic the helical BH3 interaction domain of the pro-apoptotic Bcl-2 protein Bax. BH 3 109-112 BCL2 apoptosis regulator Homo sapiens 153-158 27606834-6 2017 In addition, naringenin-induced loss of mitochondrial membrane potential and increased Bax and decreased Bcl-2 proteins in PC3 cells, but not LNCaP cells. naringenin 13-23 BCL2 apoptosis regulator Homo sapiens 105-110 28421904-11 2017 which is an active metabolite of vitamin D3, induces Ishikawa endometrial cancer cell death in a concentration-dependent manner by activation of caspase-3 and -9, along with elevation of Bcl-2 and Bcl-xL. Cholecalciferol 33-43 BCL2 apoptosis regulator Homo sapiens 187-192 28171799-7 2017 Combination treatment with CS055 and Doxorubicin significantly changed mitochondrial membrane potential and H3 acetylated level, resulting in up-regulating DNA damage protein p-gammaH2AX and apoptosis proteins including cleaved-caspase-3, cleaved-caspase-9 and cleaved-PARP, and down-regulating anti-apoptosis protein Bcl-2. N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 27-32 BCL2 apoptosis regulator Homo sapiens 318-323 28471109-8 2017 In addition, cisplatin increased the ratio of Bax to Bcl-2 in K562, which can influence the mitochondrial membrane permeability. Cisplatin 13-22 BCL2 apoptosis regulator Homo sapiens 53-58 28471109-11 2017 However, Ethaselen can induce a high level of ROS in K562/CDDP by TrxR activity inhibition and increased ratio of Bax to Bcl-2 in K562/CDDP by nuclear factor kappaB (NF-kappaB) suppression, which subsequently induces the release of cytochrome c in K562/CDDP. (1,2-bis(1,2-benzisoselenazolone-3(2H)-ketone))ethane 9-18 BCL2 apoptosis regulator Homo sapiens 121-126 28171799-7 2017 Combination treatment with CS055 and Doxorubicin significantly changed mitochondrial membrane potential and H3 acetylated level, resulting in up-regulating DNA damage protein p-gammaH2AX and apoptosis proteins including cleaved-caspase-3, cleaved-caspase-9 and cleaved-PARP, and down-regulating anti-apoptosis protein Bcl-2. Doxorubicin 37-48 BCL2 apoptosis regulator Homo sapiens 318-323 28120212-1 2017 ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2, and Bcl-w, and it has been reported for anti-cancer effects in various types of cancer cells. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 46-51 27023223-5 2017 Furthermore, miR-106b-5p antagomir markedly reduced malondialdehyde (MDA) content, restored superoxide dismutase (SOD) activity, increased the expression of myeloid cell leukemia-1 (Mcl-1) and B cell lymphoma-2 (Bcl-2), and decreased the expression of Bax in the ischemic cortex. mir-106b-5p 13-24 BCL2 apoptosis regulator Homo sapiens 193-210 27023223-5 2017 Furthermore, miR-106b-5p antagomir markedly reduced malondialdehyde (MDA) content, restored superoxide dismutase (SOD) activity, increased the expression of myeloid cell leukemia-1 (Mcl-1) and B cell lymphoma-2 (Bcl-2), and decreased the expression of Bax in the ischemic cortex. mir-106b-5p 13-24 BCL2 apoptosis regulator Homo sapiens 212-217 28120212-1 2017 ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2, and Bcl-w, and it has been reported for anti-cancer effects in various types of cancer cells. BH 3 13-16 BCL2 apoptosis regulator Homo sapiens 46-51 28350133-9 2017 Pretreatment of HUVECs with CQ markedly increased LSS-induced apoptosis, which was associated with an increased expression of Bax and a decreased expression of Bcl-2. Chloroquine 28-30 BCL2 apoptosis regulator Homo sapiens 160-165 28324237-2 2017 Cyclosporine"s anti-apoptotic activity in human gingival fibroblast is due to desensitization of mitochondrial permeability transition pore (MPTP) and augmentation of anti-apoptotic, Bcl2. Cyclosporine 0-12 BCL2 apoptosis regulator Homo sapiens 183-187 28521469-8 2017 Furthermore, treatment with Lico-E increased the expression of pro-apoptotic factors, including apoptosis regulator BAX, Bcl-2-associated agonist of cell death, apoptotic protease-activating factor 1, caspase-9 and tumor suppressor p53, while decreasing the expression of anti-apoptotic factors, including apoptosis regulator Bcl-2 and Bcl-2-like protein 1 in FaDu cells. licochalcone E 28-34 BCL2 apoptosis regulator Homo sapiens 121-126 28649658-5 2017 We found that the pro-survival protein BCL2 is selectively induced in the niche-protected tumor cells following lapatinib treatment, and combined inhibition of HER2 and BCL-2/XL enhanced targeting of these residual tumor cells. Lapatinib 112-121 BCL2 apoptosis regulator Homo sapiens 39-43 28393231-7 2017 Furthermore, western blot analysis demonstrated that SFN-Cys induced activation of ERK1/2 in a sustained manner and the activation contributed to upregulation of Bax/Bcl-2 ratio and cleaved caspase 3, and these results can be reversed by the ERK1/2 blocker PD98059. sfn-cys 53-60 BCL2 apoptosis regulator Homo sapiens 166-171 28214212-8 2017 Steroid-sensitive tissue of the uterus and breast in both cases didn"t express ER and PR, in all cases the tissue had overexpression of Ki-67, p53, bax and bcl-2 receptors. Steroids 0-7 BCL2 apoptosis regulator Homo sapiens 156-161 28521469-8 2017 Furthermore, treatment with Lico-E increased the expression of pro-apoptotic factors, including apoptosis regulator BAX, Bcl-2-associated agonist of cell death, apoptotic protease-activating factor 1, caspase-9 and tumor suppressor p53, while decreasing the expression of anti-apoptotic factors, including apoptosis regulator Bcl-2 and Bcl-2-like protein 1 in FaDu cells. licochalcone E 28-34 BCL2 apoptosis regulator Homo sapiens 326-331 28459364-10 2017 In conclusion, our results suggest that celastrol induces cytotoxicity through involvement of Bcl2 family proteins and death receptor, and modulation of phospho-NF-kappaB, Akt, and mitogen-activated protein kinase in association with endoplasmic reticulum stress and reactive oxygen species production in anaplastic thyroid carcinoma cells. celastrol 40-49 BCL2 apoptosis regulator Homo sapiens 94-98 28407860-5 2017 Expression of BCL-2, OCT4, NANOG and CDX2 in SCNT blastocysts developed from SCNT embryos and oocytes treated with MG132 was increased significantly (P < 0.01), while the expression of pro-apoptotic BAX gene was suppressed significantly (P < 0.01). benzyloxycarbonylleucyl-leucyl-leucine aldehyde 115-120 BCL2 apoptosis regulator Homo sapiens 14-19 28490955-0 2017 Protection of oxidative stress induced apoptosis in osteosarcoma cells by dihydromyricetin through down-regulation of caspase activation and up-regulation of BcL-2. dihydromyricetin 74-90 BCL2 apoptosis regulator Homo sapiens 158-163 28490955-8 2017 The expression level of Bcl-2 was decreased significantly by 100 muM concentration of hydrogen peroxide in MG63 cells. Hydrogen Peroxide 86-103 BCL2 apoptosis regulator Homo sapiens 24-29 28490955-9 2017 However, pre-treatment of MG63 cells with 30 muM dose of dihydromyricetin for 48 h significantly prevented hydrogen peroxide induced increase in caspase-3 and -9 levels and reduction in Bcl-2 level. dihydromyricetin 57-73 BCL2 apoptosis regulator Homo sapiens 186-191 28490955-9 2017 However, pre-treatment of MG63 cells with 30 muM dose of dihydromyricetin for 48 h significantly prevented hydrogen peroxide induced increase in caspase-3 and -9 levels and reduction in Bcl-2 level. Hydrogen Peroxide 107-124 BCL2 apoptosis regulator Homo sapiens 186-191 28490955-10 2017 Thus dihydromyricetin prevents hydrogen peroxide induced reduction in viability and induction of apoptosis in MG63 cells through down-regulation of caspase activation and up-regulation of Bcl-2 levels. dihydromyricetin 5-21 BCL2 apoptosis regulator Homo sapiens 188-193 28490955-10 2017 Thus dihydromyricetin prevents hydrogen peroxide induced reduction in viability and induction of apoptosis in MG63 cells through down-regulation of caspase activation and up-regulation of Bcl-2 levels. Hydrogen Peroxide 31-48 BCL2 apoptosis regulator Homo sapiens 188-193 28466786-8 2017 Dephosphorylation of Bcl2-associated agonist of cell death protein was increased after methoxyphenyl chalcone treatment that led to activation of caspases. methoxyphenyl chalcone 87-109 BCL2 apoptosis regulator Homo sapiens 21-25 28230534-11 2017 In conclusion, silencing antiapoptotic genes such as BCL-2 and BCL-xL through the use of siRNA carried by hybrid nanoparticles showed to be effective in vitro, and presents a promising strategy for pre-clinical analysis, especially when combined with DOX against breast cancer. Doxorubicin 251-254 BCL2 apoptosis regulator Homo sapiens 53-58 28315329-4 2017 In present study, We found that overexpression of C/EBPbeta significantly abrogated the effect of atorvastatin on increasing Bcl-2/Bax and PGC-1alpha while the early and late apoptosis rate increased and mitochondrial membrane potential (MMP) was reduced. Atorvastatin 98-110 BCL2 apoptosis regulator Homo sapiens 125-130 28502300-12 2017 Moreover, with the down-regulation of SphK1, the expressions of ki67 and Bcl-2 were depressed; the expressions of caspase-9 and caspase-3 were raised, especially after treated with DDP. Cisplatin 181-184 BCL2 apoptosis regulator Homo sapiens 73-78 28431397-2 2017 Herein we found that autophagy was concomitantly induced in tamoxifen-resistant MCF-7 (MCF-7TR5) cells through the dissociation of Bcl-2 from Beclin 1 and subsequent enhancement of interaction among the ATG14-Beclin1-PI3KC3 complex. Tamoxifen 60-69 BCL2 apoptosis regulator Homo sapiens 131-136 28638272-7 2017 Furthermore, ETCH-induced apoptosis was mediated by increase in pro-apoptotic proteins including cleaved caspase-3 and p53, and by decrease in anti-apoptotic protein, Bcl-2 in ETCH-treated cancer cells. etch 13-17 BCL2 apoptosis regulator Homo sapiens 167-172 28638272-7 2017 Furthermore, ETCH-induced apoptosis was mediated by increase in pro-apoptotic proteins including cleaved caspase-3 and p53, and by decrease in anti-apoptotic protein, Bcl-2 in ETCH-treated cancer cells. etch 176-180 BCL2 apoptosis regulator Homo sapiens 167-172 28423649-5 2017 The Stel B-induced apoptosis might be in mitochondrial pathway, with increase of Bad and Bax, decrease of Bcl-2 and activation of caspase-9. stellettin B 4-10 BCL2 apoptosis regulator Homo sapiens 106-111 28441753-4 2017 The subsequent, Cr(VI)-induced mitochondrial damage and apoptosis were characterized by reactive oxygen species (ROS) accumulation, caspase-3 and caspase-9 activation, decreased superoxide dismutase (SOD) and ATP production, increased methane dicarboxylic aldehyde (MDA) content, mitochondrial membrane depolarization and mitochondrial permeability transition pore (MPTP) opening, increased Ca2+ levels, Cyt c release, decreased Bcl-2 expression, and significantly elevated Bax expression. chromium hexavalent ion 16-22 BCL2 apoptosis regulator Homo sapiens 429-434 28228354-4 2017 The decreased endogenous estradiol through cAMP-CREB signaling mechanism may decline germ cells proliferation (PCNA) and survival (Bcl2). Cyclic AMP 43-47 BCL2 apoptosis regulator Homo sapiens 131-135 28881742-7 2017 Importantly, overexpression of BCL-2 or addition of the broad-range caspase inhibitor zVAD.fmk significantly rescue eribulin- as well as eribulin/BI 6727-induced cell death. FMK 91-94 BCL2 apoptosis regulator Homo sapiens 31-36 28938575-6 2017 Morphological changes, increased levels of tumor necrosis factor receptor superfamily member 1B, c-Jun N-terminal kinase, Bak, Bax, Cyt-c, caspase9 and caspase3 and decreased levels of Bcl-2 demonstrated that selenium deficiency induced apoptosis in the spleen tissues. Selenium 209-217 BCL2 apoptosis regulator Homo sapiens 185-190 28419143-7 2017 Additionally, chaetocin treatment significantly up-regulated the protein levels of Bax, cleaved caspase-9/-3, simultaneously down-regulated the protein levels of Bcl-2, procaspase-9/-3, and activated caspase-9/-3 activity in the melanoma cells. chaetocin 14-23 BCL2 apoptosis regulator Homo sapiens 162-167 28427190-6 2017 First, over-expression of Pygo2 inhibited the PTX-induced phosphorylation of B-cell lymphoma 2 (Bcl-2), suppressing the proteolytic cleavage of procaspase-8/9 and further inhibiting the activation of caspase-3, which also inhibits the activation of the JNK/SAPK pathway, ultimately inhibiting cell apoptosis. Paclitaxel 46-49 BCL2 apoptosis regulator Homo sapiens 77-94 28427190-6 2017 First, over-expression of Pygo2 inhibited the PTX-induced phosphorylation of B-cell lymphoma 2 (Bcl-2), suppressing the proteolytic cleavage of procaspase-8/9 and further inhibiting the activation of caspase-3, which also inhibits the activation of the JNK/SAPK pathway, ultimately inhibiting cell apoptosis. Paclitaxel 46-49 BCL2 apoptosis regulator Homo sapiens 96-101 29263915-0 2017 Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. venetoclax 81-88 BCL2 apoptosis regulator Homo sapiens 55-60 28553168-11 2017 The combination of low-dose docetaxel and YK-4-279 caused a stronger decrease in the levels of ETV1, AR, PSA, p-STAT3, survivin, Bcl-2, and p-Akt in LNCaP cells and of p-Akt, Bcl-2, and p-STAT3 in PC-3 cells compared with either drug alone. Docetaxel 28-37 BCL2 apoptosis regulator Homo sapiens 129-134 28553168-11 2017 The combination of low-dose docetaxel and YK-4-279 caused a stronger decrease in the levels of ETV1, AR, PSA, p-STAT3, survivin, Bcl-2, and p-Akt in LNCaP cells and of p-Akt, Bcl-2, and p-STAT3 in PC-3 cells compared with either drug alone. Docetaxel 28-37 BCL2 apoptosis regulator Homo sapiens 175-180 28469788-7 2017 Mechanistically, Stachydrine hydrochloride treatment induced caspase-3 activation and decreased the expression of the anti-apoptotic protein Bcl-2. stachydrine 17-42 BCL2 apoptosis regulator Homo sapiens 141-146 28147236-6 2017 METH significantly decreased expression level of Bcl-2 and increased expression level of cleaved caspase-3 in the PFC. Methamphetamine 0-4 BCL2 apoptosis regulator Homo sapiens 49-54 29263915-6 2017 ABT-199, a BH3 mimetic, was developed to target antiapoptotic protein Bcl-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 70-75 29263915-6 2017 ABT-199, a BH3 mimetic, was developed to target antiapoptotic protein Bcl-2. BH 3 11-14 BCL2 apoptosis regulator Homo sapiens 70-75 29263915-8 2017 Previous studies in AML show that ABT-199 alone decreases the association of proapoptotic protein Bim with Bcl-2, but this is compensated by increased association of Bim with prosurvival protein Mcl-1, stabilizing Mcl-1, resulting in resistance to ABT-199. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 34-37 BCL2 apoptosis regulator Homo sapiens 107-112 26552712-5 2017 In this work, we made an attempt to investigate the cytotoxic effect of a novel Bcl-2 family inhibitor, ABT-737, on CD34+ AML cell lines (KG1a and Kasumi-1) as well as CD34+ primary AML cells. ABT-737 104-111 BCL2 apoptosis regulator Homo sapiens 80-85 28278051-0 2017 Bcl-2 delays cell cycle through mitochondrial ATP and ROS. Adenosine Triphosphate 46-49 BCL2 apoptosis regulator Homo sapiens 0-5 28278051-0 2017 Bcl-2 delays cell cycle through mitochondrial ATP and ROS. Reactive Oxygen Species 54-57 BCL2 apoptosis regulator Homo sapiens 0-5 28278051-6 2017 In addition, ROS levels were significant lower in synchronized Bcl-2 cells than those in PB controls. Reactive Oxygen Species 13-16 BCL2 apoptosis regulator Homo sapiens 63-68 28278051-7 2017 After re-stimulation, ATP levels increased with time, reaching peak value 1-3 hours ahead of S phase entry for both Bcl-2 cells and PB controls. Adenosine Triphosphate 22-25 BCL2 apoptosis regulator Homo sapiens 116-121 28278051-8 2017 Consistent with 2 hours of S phase delay, Bcl-2 cells reached ATP peaks 2 hours later than PB control, which suggests a rise in ATP levels is required for S phase entry. Adenosine Triphosphate 62-65 BCL2 apoptosis regulator Homo sapiens 42-47 28278051-8 2017 Consistent with 2 hours of S phase delay, Bcl-2 cells reached ATP peaks 2 hours later than PB control, which suggests a rise in ATP levels is required for S phase entry. Adenosine Triphosphate 128-131 BCL2 apoptosis regulator Homo sapiens 42-47 28278051-11 2017 Our results support the hypothesis that Bcl-2 protein regulates mitochondrial metabolism to produce less ATP and ROS, which contributes to S phase entry delay in Bcl-2 cells. Adenosine Triphosphate 105-108 BCL2 apoptosis regulator Homo sapiens 40-45 28278051-11 2017 Our results support the hypothesis that Bcl-2 protein regulates mitochondrial metabolism to produce less ATP and ROS, which contributes to S phase entry delay in Bcl-2 cells. Adenosine Triphosphate 105-108 BCL2 apoptosis regulator Homo sapiens 162-167 28278051-11 2017 Our results support the hypothesis that Bcl-2 protein regulates mitochondrial metabolism to produce less ATP and ROS, which contributes to S phase entry delay in Bcl-2 cells. Reactive Oxygen Species 113-116 BCL2 apoptosis regulator Homo sapiens 40-45 28278051-11 2017 Our results support the hypothesis that Bcl-2 protein regulates mitochondrial metabolism to produce less ATP and ROS, which contributes to S phase entry delay in Bcl-2 cells. Reactive Oxygen Species 113-116 BCL2 apoptosis regulator Homo sapiens 162-167 28188387-0 2017 Quercetin induces protective autophagy and apoptosis through ER stress via the p-STAT3/Bcl-2 axis in ovarian cancer. Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 87-92 28188387-6 2017 Further functional studies revealed that Qu-induced ER stress could activate protective autophagy concomitantly by activating the p-STAT3/Bcl-2 axis in this process. qu 41-43 BCL2 apoptosis regulator Homo sapiens 138-143 28263595-1 2017 Several variants of a nucleic acid binding motif (RRM1) of putative transcription factor hnRNP LL containing nucleobase amino acids at specific positions have been prepared and used to study binding affinity for the BCL2 i-motif DNA. nucleobase amino acids 109-131 BCL2 apoptosis regulator Homo sapiens 216-220 26552712-10 2017 RESULTS: Inhibition of Bcl-2 by ABT-737 effectively inhibited growth and induced apoptosis in CD34+ AML cell lines and CD34+ primary AML cells without affecting CD34+ normal hematopoietic cells. ABT-737 32-39 BCL2 apoptosis regulator Homo sapiens 23-28 28229391-7 2017 In addition, kadsuphilactone B altered the expression levels of B cell lymphoma 2 (Bcl-2) family proteins. kadsuphilactone 13-28 BCL2 apoptosis regulator Homo sapiens 64-81 28229391-7 2017 In addition, kadsuphilactone B altered the expression levels of B cell lymphoma 2 (Bcl-2) family proteins. kadsuphilactone 13-28 BCL2 apoptosis regulator Homo sapiens 83-88 28229391-9 2017 Taken together, these results show that kadsuphilactone B induces caspase-dependent apoptosis in human cancer cells via the regulation of Bcl-2 family protein and MAPK signaling. kadsuphilactone B 40-57 BCL2 apoptosis regulator Homo sapiens 138-143 28202415-6 2017 Moreover, TRAIL/Gln deprivation upregulated the apoptotic sub-G1 phase accompanied with a remarkable decrease of pro-caspase-3, pro-caspase-9, and anti-apoptotic xIAP, and Bcl-2. Glutamine 16-19 BCL2 apoptosis regulator Homo sapiens 172-177 27565798-5 2017 Moreover, Western blotting analysis showed that treatment of keloid fibroblasts with Se-ZGTP-I (200 and 400 mug/ml) or NG2 shRNA resulted in an increase of pro-apoptotic protein Bax expression and a decrease in expression levels of anti-apoptotic protein Bcl-2 and NG2. se-zgtp-i 85-94 BCL2 apoptosis regulator Homo sapiens 255-260 27859472-0 2017 Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. Ketoconazole 10-22 BCL2 apoptosis regulator Homo sapiens 91-96 28107698-11 2017 The combination of the IC50 doses of apigenin (15muM) and cisplatin (7.5muM) for 48h significantly enhanced cisplatin"s cytotoxic and apoptotic effects through downregulation of Bcl-2, sharpin and survivin; and upregulation of caspase-8, Apaf-1 and p53 mRNA expression. Apigenin 37-45 BCL2 apoptosis regulator Homo sapiens 178-183 28107698-11 2017 The combination of the IC50 doses of apigenin (15muM) and cisplatin (7.5muM) for 48h significantly enhanced cisplatin"s cytotoxic and apoptotic effects through downregulation of Bcl-2, sharpin and survivin; and upregulation of caspase-8, Apaf-1 and p53 mRNA expression. Cisplatin 58-67 BCL2 apoptosis regulator Homo sapiens 178-183 27859472-0 2017 Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. venetoclax 77-87 BCL2 apoptosis regulator Homo sapiens 91-96 29960293-5 2017 Reversetranscription polymerase chain reaction and enzyme-linked immunosorbent assays were usedto determine the effects of icariin on the expression of Fas, FasL, Bcl-2, and Bax. icariin 123-130 BCL2 apoptosis regulator Homo sapiens 163-168 28095588-7 2017 Further studies showed that dioscin significantly down-regulated Akt1 levels, and thus induced cell apoptosis by increasing the levels of Bax, Apaf-1, cleaved caspase-3/9, cleaved PARP, suppressing Bcl-2 levels, and causing cytochrome c release. dioscin 28-35 BCL2 apoptosis regulator Homo sapiens 198-203 28485781-0 2017 Effects of hTERT antisense oligodeoxynucleotide on cell apoptosis and expression of hTERT and bcl-2 mRNA in keloid fibroblasts. Oligodeoxyribonucleotides 27-47 BCL2 apoptosis regulator Homo sapiens 94-99 28485781-1 2017 OBJECTIVE: This study was purposed to investigate the effects of hTERT antisense oligodeoxynucleotide (ASODN) on cell apoptosis and expression of hTERT and bcl-2 mRNA in keloid fibroblasts and to explore its anti-keloid effect. Oligodeoxyribonucleotides 81-101 BCL2 apoptosis regulator Homo sapiens 156-161 28485781-1 2017 OBJECTIVE: This study was purposed to investigate the effects of hTERT antisense oligodeoxynucleotide (ASODN) on cell apoptosis and expression of hTERT and bcl-2 mRNA in keloid fibroblasts and to explore its anti-keloid effect. asodn 103-108 BCL2 apoptosis regulator Homo sapiens 156-161 28522946-10 2017 PT also inhibited the expression of antiapoptotic proteins (Bcl-2 and Bcl-xL) and activated apoptosis terminal factor (caspase-3) in a dose-dependent manner. parthenolide 0-2 BCL2 apoptosis regulator Homo sapiens 60-65 27558232-0 2017 Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma. venetoclax 20-30 BCL2 apoptosis regulator Homo sapiens 40-45 27558232-1 2017 Venetoclax is a selective BCL-2 inhibitor that is approved in the United States for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion who have received at least 1 prior therapy. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 26-31 28373432-13 2017 The mechanism of myricetin-induced cell death involved an increase in the activation of caspase cascades and the Bax:Bcl-2 ratio at a concentration of 100 muM. myricetin 17-26 BCL2 apoptosis regulator Homo sapiens 117-122 27749098-7 2017 Furthermore, latanoprost can induce activation of caspase-3, -8 and -9; disruption of MTP; downregulation of anti-apoptotic Bcl-2; upregulation of pro-apoptotic Bax; and cytoplasmic cytochrome c release. Latanoprost 13-24 BCL2 apoptosis regulator Homo sapiens 124-129 28233699-8 2017 Furthermore, SA treatment prevented the upregulation of caspase 3 and Bax protein expression and upregulated Bcl-2 protein expression. sinapinic acid 13-15 BCL2 apoptosis regulator Homo sapiens 109-114 27401020-8 2017 DHA treatment upregulated the expression of Bax, cleaved caspase-3 and -9, and degraded form of PARP, and downregulated the Bcl-2 expression and Bcl-2/Bax ratio. artenimol 0-3 BCL2 apoptosis regulator Homo sapiens 124-129 27401020-8 2017 DHA treatment upregulated the expression of Bax, cleaved caspase-3 and -9, and degraded form of PARP, and downregulated the Bcl-2 expression and Bcl-2/Bax ratio. artenimol 0-3 BCL2 apoptosis regulator Homo sapiens 145-150 29960296-4 2017 RESULTS: In BGC-823 and MGC-803 gastric cancer cells treated with 80, 120, and 160 mumol/L baicalinfor 48 h, a 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide assay showed thatbaicalin significantly inhibited cell proliferation in a dose-dependent manner, while flow cytometricanalysis demonstrated that baicalin could induce apoptosis, also in a dose-dependent manner.Moreover, baicalin up-regulated the expression of caspase-3, caspase-9, and B cell lymphoma(Bcl-2)-associated X protein and down-regulated the expression of Bcl-2 at both the mRNA andprotein level. baicalin 91-99 BCL2 apoptosis regulator Homo sapiens 479-484 27863037-1 2017 Multivalent aptamer-siRNA conjugates containing multiple mucin-1 aptamers and BCL2-specific siRNA are synthesized, and doxorubicin, an anthracycline anticancer drug, is loaded into these conjugates through intercalation with nucleic acids. Doxorubicin 119-130 BCL2 apoptosis regulator Homo sapiens 78-82 29960296-4 2017 RESULTS: In BGC-823 and MGC-803 gastric cancer cells treated with 80, 120, and 160 mumol/L baicalinfor 48 h, a 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide assay showed thatbaicalin significantly inhibited cell proliferation in a dose-dependent manner, while flow cytometricanalysis demonstrated that baicalin could induce apoptosis, also in a dose-dependent manner.Moreover, baicalin up-regulated the expression of caspase-3, caspase-9, and B cell lymphoma(Bcl-2)-associated X protein and down-regulated the expression of Bcl-2 at both the mRNA andprotein level. baicalin 91-99 BCL2 apoptosis regulator Homo sapiens 544-549 28209992-4 2017 Clinical experience with navitoclax prompted the generation of the highly selective BCL-2 inhibitor venetoclax, which is now approved in the United States for the treatment of patients with chronic lymphocytic leukaemia with 17p deletion who have received at least one prior therapy. navitoclax 25-35 BCL2 apoptosis regulator Homo sapiens 84-89 28259931-8 2017 In addition, knockdown of CD164 was demonstrated to upregulate the Bax/Bcl2 ratio and phosphatase and tensin homolog (PTEN) expression, reduce protein kinase B (AKT) phosphorylation and promote the expression of p53 in U87 cells. cd164 26-31 BCL2 apoptosis regulator Homo sapiens 71-75 28553347-6 2017 Mitomycin C upregulated the expression levels of Fas, DR4, DR5, cleaved caspase-8/9, Bax, Bim and cleaved caspase-3 proteins, and it downregulated Bcl-2 and Bcl-xL expression. Mitomycin 0-11 BCL2 apoptosis regulator Homo sapiens 147-152 28209992-4 2017 Clinical experience with navitoclax prompted the generation of the highly selective BCL-2 inhibitor venetoclax, which is now approved in the United States for the treatment of patients with chronic lymphocytic leukaemia with 17p deletion who have received at least one prior therapy. venetoclax 100-110 BCL2 apoptosis regulator Homo sapiens 84-89 28454469-10 2017 Baicalein and baicalein-cisplatin combination treatments also inhibited B cell lymphoma-2 (Bcl-2) and increased Bcl-2-associated X protein (Bax) expression. Cisplatin 24-33 BCL2 apoptosis regulator Homo sapiens 72-89 28454469-10 2017 Baicalein and baicalein-cisplatin combination treatments also inhibited B cell lymphoma-2 (Bcl-2) and increased Bcl-2-associated X protein (Bax) expression. Cisplatin 24-33 BCL2 apoptosis regulator Homo sapiens 91-96 28454469-13 2017 The present study concluded that baicalein combined with cisplatin induced cytotoxicity and apoptosis of A549 cells, and such activity may be associated with the regulation of Bcl-2, Bax and caspase-3, indicating a promising alternative method for lung cancer. baicalein 33-42 BCL2 apoptosis regulator Homo sapiens 176-181 28454475-7 2017 Furthermore, the protein expression levels of B-cell lymphoma 2 were decreased and those of Bcl-2-associated X protein were increased following oridonin treatment. oridonin 144-152 BCL2 apoptosis regulator Homo sapiens 92-97 28193524-7 2017 Furthermore, this peptide was able to prevent the decrease of caspase-3 activity and the increase of the ratio of Bcl-2/Bax protein in VSMCs exposed to high glucose. Glucose 157-164 BCL2 apoptosis regulator Homo sapiens 114-119 28443465-7 2017 In addition, bauerenol treatment diminished the mitochondrial membrane potential, by inducing the efflux of cytochrome c, downregulating the levels of anti-apoptotic Bcl-2 as well as upregulating the levels of pro-apoptotic Bax, and inducing caspase activation and poly (ADP-ribose) polymerase cleavage. bauerenol 13-22 BCL2 apoptosis regulator Homo sapiens 166-171 28355175-8 2017 Cisplatin combined with beta-elemene decreased the expressions of p-STAT3, p-JAK2, and Bcl-2, and increased the expressions of Bax and caspase-3 significantly compared to cisplatin only treatment, as well as in the xenograft model. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 87-92 28355175-8 2017 Cisplatin combined with beta-elemene decreased the expressions of p-STAT3, p-JAK2, and Bcl-2, and increased the expressions of Bax and caspase-3 significantly compared to cisplatin only treatment, as well as in the xenograft model. beta-elemene 24-36 BCL2 apoptosis regulator Homo sapiens 87-92 30090515-5 2017 The results showed that low concentration arsenite increased the expressions of proliferative factors BCL2, cyclin D1, COX-2, MMP1 and PCNA in SV-HUC-1 cells, and ATF2 siRNA partly decreased the expressions of BCL2, cyclin D1, and COX-2. arsenite 42-50 BCL2 apoptosis regulator Homo sapiens 102-106 30090515-5 2017 The results showed that low concentration arsenite increased the expressions of proliferative factors BCL2, cyclin D1, COX-2, MMP1 and PCNA in SV-HUC-1 cells, and ATF2 siRNA partly decreased the expressions of BCL2, cyclin D1, and COX-2. arsenite 42-50 BCL2 apoptosis regulator Homo sapiens 210-214 28408883-8 2017 An autophagy inhibitor, 3-methyladenine, could partially reverse cell viability and conversely change the ratio of LC3II/LC3I and the protein expression of Bcl-2 and Kim-1. 3-methyladenine 24-39 BCL2 apoptosis regulator Homo sapiens 156-161 28189683-12 2017 Evodiamine decreased p-Akt levels activated by SC79, which led to the increase of bax/bcl-2 and cleaved-caspase3. evodiamine 0-10 BCL2 apoptosis regulator Homo sapiens 86-91 28122742-6 2017 The BCL2-inhibitor venetoclax was highly active below 10 nM in B-cell precursor ALL (BCP-ALL) subsets, including MLL-AF4 and TCF3-HLF ALL, and in some T-cell ALLs (T-ALLs), predicting in vivo activity as a single agent and in combination with dexamethasone and vincristine. venetoclax 19-29 BCL2 apoptosis regulator Homo sapiens 4-8 28323898-18 2017 The potential mechanism may be associated with the following signaling pathways: 1) the signaling pathways of NF-kappaB and MAPK, which inhibit inflammation and reactive oxygen species (ROS); and 2) the signaling pathways of Bcl-2/Bax and caspase-3, which inhibit apoptosis. Reactive Oxygen Species 186-189 BCL2 apoptosis regulator Homo sapiens 225-230 28377354-7 2017 Apatinib induced the expression of the pro-apoptotic genes Bax and caspase-3 at both the mRNA and protein levels while inhibited the expression of the anti- apoptotic gene Bcl-2. apatinib 0-8 BCL2 apoptosis regulator Homo sapiens 172-177 28323898-0 2017 Perfluorocarbon reduces cell damage from blast injury by inhibiting signal paths of NF-kappaB, MAPK and Bcl-2/Bax signaling pathway in A549 cells. Fluorocarbons 0-15 BCL2 apoptosis regulator Homo sapiens 104-109 28323898-18 2017 The potential mechanism may be associated with the following signaling pathways: 1) the signaling pathways of NF-kappaB and MAPK, which inhibit inflammation and reactive oxygen species (ROS); and 2) the signaling pathways of Bcl-2/Bax and caspase-3, which inhibit apoptosis. Reactive Oxygen Species 161-184 BCL2 apoptosis regulator Homo sapiens 225-230 28122742-6 2017 The BCL2-inhibitor venetoclax was highly active below 10 nM in B-cell precursor ALL (BCP-ALL) subsets, including MLL-AF4 and TCF3-HLF ALL, and in some T-cell ALLs (T-ALLs), predicting in vivo activity as a single agent and in combination with dexamethasone and vincristine. Dexamethasone 243-256 BCL2 apoptosis regulator Homo sapiens 4-8 28122742-6 2017 The BCL2-inhibitor venetoclax was highly active below 10 nM in B-cell precursor ALL (BCP-ALL) subsets, including MLL-AF4 and TCF3-HLF ALL, and in some T-cell ALLs (T-ALLs), predicting in vivo activity as a single agent and in combination with dexamethasone and vincristine. Vincristine 261-272 BCL2 apoptosis regulator Homo sapiens 4-8 28291789-5 2017 We showed recently that La protects cells against cisplatin treatment by stimulating the protein synthesis of the anti-apoptotic factor Bcl2. Cisplatin 50-59 BCL2 apoptosis regulator Homo sapiens 136-140 28386348-5 2017 Firstly, we found cisplatin induced cell apoptosis in mesangial cells shown by increased number of apoptotic cells in parallel with the upregulation of Bax and the downregulation of Bcl-2. Cisplatin 18-27 BCL2 apoptosis regulator Homo sapiens 182-187 28386348-7 2017 Importantly, inhibition of COX-2 via a specific COX-2 inhibitor celecoxib markedly blocked cisplatin-induced mesangial cell apoptosis as evidenced by the decreased number of apoptotic cells, blocked increments of cleaved caspase-3 and Bax, and reversed Bcl-2 downregulation. Celecoxib 64-73 BCL2 apoptosis regulator Homo sapiens 253-258 28386348-7 2017 Importantly, inhibition of COX-2 via a specific COX-2 inhibitor celecoxib markedly blocked cisplatin-induced mesangial cell apoptosis as evidenced by the decreased number of apoptotic cells, blocked increments of cleaved caspase-3 and Bax, and reversed Bcl-2 downregulation. Cisplatin 91-100 BCL2 apoptosis regulator Homo sapiens 253-258 28335434-5 2017 In addition, FKA induces apoptosis in SKBR3 cells by increasing the protein expression of Bim and BAX and decreasing expression of Bcl2, BclX/L, XIAP, and survivin. flavokawain A 13-16 BCL2 apoptosis regulator Homo sapiens 131-135 28233676-0 2017 Design, synthesis and preliminary biological evaluation of indole-3-carboxylic acid-based skeleton of Bcl-2/Mcl-1 dual inhibitors. indole-3-carboxylic acid 59-83 BCL2 apoptosis regulator Homo sapiens 102-107 28233676-3 2017 According to the results, rhodanine derivatives show potent binding affinity for Bcl-2 and Mcl-1 protein and show weaker activity against Bcl-XL protein. Rhodanine 26-35 BCL2 apoptosis regulator Homo sapiens 81-86 28233676-4 2017 Based on the previous results, a new class of indole-3-carboxylic acid-based derivatives were designed and synthesized as Bcl-2/Mcl-1 dual inhibitors. indole-3-carboxylic acid 46-70 BCL2 apoptosis regulator Homo sapiens 122-127 28272477-6 2017 Expression levels of both anti- and pro-apoptotic markers (Bcl-2 and Bax, respectively) decreased with increasing eugenol concentration, with no variation in their relative ratios. Eugenol 114-121 BCL2 apoptosis regulator Homo sapiens 59-64 28095146-2 2017 A phase I trial in patients with NHL was conducted to determine safety, pharmacokinetics, and efficacy of venetoclax, a selective, potent, orally bioavailable BCL-2 inhibitor. venetoclax 106-116 BCL2 apoptosis regulator Homo sapiens 159-164 28095146-12 2017 Conclusion Selective targeting of BCL-2 with venetoclax was well tolerated, and single-agent activity varied among NHL subtypes. venetoclax 45-55 BCL2 apoptosis regulator Homo sapiens 34-39 28273655-5 2017 Here we report that fisetin, a naturally-occurring flavone with low toxicity, and A1331852 and A1155463, selective BCL-XL inhibitors that may have less hematological toxicity than the less specific BCL-2 family inhibitor navitoclax, are senolytic. navitoclax 221-231 BCL2 apoptosis regulator Homo sapiens 198-203 28331288-2 2017 Venetoclax (Venclexta , formerly ABT-199, GDC-0199) is a highly selective BCL-2 inhibitor, which mimics its BCL-2 homology 3-domain to induce apoptosis. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 74-79 28331288-2 2017 Venetoclax (Venclexta , formerly ABT-199, GDC-0199) is a highly selective BCL-2 inhibitor, which mimics its BCL-2 homology 3-domain to induce apoptosis. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 108-113 28331288-2 2017 Venetoclax (Venclexta , formerly ABT-199, GDC-0199) is a highly selective BCL-2 inhibitor, which mimics its BCL-2 homology 3-domain to induce apoptosis. venetoclax 12-21 BCL2 apoptosis regulator Homo sapiens 74-79 28331288-2 2017 Venetoclax (Venclexta , formerly ABT-199, GDC-0199) is a highly selective BCL-2 inhibitor, which mimics its BCL-2 homology 3-domain to induce apoptosis. venetoclax 12-21 BCL2 apoptosis regulator Homo sapiens 108-113 28331288-2 2017 Venetoclax (Venclexta , formerly ABT-199, GDC-0199) is a highly selective BCL-2 inhibitor, which mimics its BCL-2 homology 3-domain to induce apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 33-36 BCL2 apoptosis regulator Homo sapiens 74-79 28331288-2 2017 Venetoclax (Venclexta , formerly ABT-199, GDC-0199) is a highly selective BCL-2 inhibitor, which mimics its BCL-2 homology 3-domain to induce apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 33-36 BCL2 apoptosis regulator Homo sapiens 108-113 28331288-2 2017 Venetoclax (Venclexta , formerly ABT-199, GDC-0199) is a highly selective BCL-2 inhibitor, which mimics its BCL-2 homology 3-domain to induce apoptosis. venetoclax 42-50 BCL2 apoptosis regulator Homo sapiens 74-79 28331288-2 2017 Venetoclax (Venclexta , formerly ABT-199, GDC-0199) is a highly selective BCL-2 inhibitor, which mimics its BCL-2 homology 3-domain to induce apoptosis. venetoclax 42-50 BCL2 apoptosis regulator Homo sapiens 108-113 28272477-7 2017 Eugenol-treated MCF-7 cells overexpressing Bcl-2 exhibited results similar to those of MCF-7. Eugenol 0-7 BCL2 apoptosis regulator Homo sapiens 43-48 28272477-8 2017 Our findings indicate that eugenol toxicity is non-apoptotic Bcl-2 independent, affecting mitochondrial function and plasma membrane integrity with no effect on migration or invasion. Eugenol 27-34 BCL2 apoptosis regulator Homo sapiens 61-66 28178653-9 2017 Blockage of AKT signaling by LY294005 abolished the effects of Derlin-1 on Bcl-2 and cisplatin resistance. 1L-6-hydroxymethyl-chiro-inositol 2(R)-2-O-methyl-3-O-octadecylcarbonate 29-37 BCL2 apoptosis regulator Homo sapiens 75-80 27092880-3 2017 Using dynamic BH3 profiling, we show that the agent TG02, which downregulates MCL-1, sensitises to the BCL-2-inhibitory BAD-BH3 peptide, whereas the BCL-2 antagonist ABT-199 sensitises to MCL-1 inhibitory NOXA-BH3 peptide in acute myeloid leukaemia (AML) cells. BH 3 14-17 BCL2 apoptosis regulator Homo sapiens 103-108 27092880-3 2017 Using dynamic BH3 profiling, we show that the agent TG02, which downregulates MCL-1, sensitises to the BCL-2-inhibitory BAD-BH3 peptide, whereas the BCL-2 antagonist ABT-199 sensitises to MCL-1 inhibitory NOXA-BH3 peptide in acute myeloid leukaemia (AML) cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 166-169 BCL2 apoptosis regulator Homo sapiens 149-154 28252652-1 2017 BH3 mimetics are small-molecule inhibitors of B-cell lymphoma-2 (Bcl-2) and Bcl-xL, which disrupt the heterodimerisation of anti- and pro-apoptotic Bcl-2 family members sensitising cells to apoptotic death. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 46-63 28252652-1 2017 BH3 mimetics are small-molecule inhibitors of B-cell lymphoma-2 (Bcl-2) and Bcl-xL, which disrupt the heterodimerisation of anti- and pro-apoptotic Bcl-2 family members sensitising cells to apoptotic death. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 65-70 28256505-0 2017 miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gallbladder cancer. mir-125b-5p 0-11 BCL2 apoptosis regulator Homo sapiens 78-82 28252652-1 2017 BH3 mimetics are small-molecule inhibitors of B-cell lymphoma-2 (Bcl-2) and Bcl-xL, which disrupt the heterodimerisation of anti- and pro-apoptotic Bcl-2 family members sensitising cells to apoptotic death. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 148-153 28256505-0 2017 miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gallbladder cancer. Cisplatin 49-58 BCL2 apoptosis regulator Homo sapiens 78-82 28252652-3 2017 Application of a chemotherapeutic drug supported with a BH3 mimetic has the potential to overcome drug resistance in cancers overexpressing anti-apoptotic Bcl-2 proteins and thus increase the success rate of the treatment. BH 3 56-59 BCL2 apoptosis regulator Homo sapiens 155-160 27580587-3 2017 The results show that CD exhibits cytotoxicity by inducing apoptosis and cell cycle arrest in TNBC cells via modulation of Bcl-2, Bax, cyt-C, cleaved caspase-3, and PARP. cardamonin 22-24 BCL2 apoptosis regulator Homo sapiens 123-128 27887793-3 2017 Our results showed that quercetin triggered BCL2/BAX-mediated apoptosis, as well as necrosis and mitotic catastrophe, and inhibited the migratory potential of A549 cells. Quercetin 24-33 BCL2 apoptosis regulator Homo sapiens 44-48 27873035-4 2017 In the molecular level, we observed that DMFC treatment decreases Bcl-2 level by a post-transcriptional mechanism and activates Bim transcription to increase Bim mRNA and protein level in hepatoma cells. 3,5-dimethyl-7H-furo(3,2-g)chromen-7-one 41-45 BCL2 apoptosis regulator Homo sapiens 66-71 27873035-5 2017 Furthermore, co-immunoprecipitation studies revealed that DMFC-induced Bim interrupts interactions between Bcl-2 and Bax and between Mcl-1 and Bak, resulting in dissociation of Bax from Bcl-2 and Bak from Mcl-1 and subsequent activation of both Bax and Bak. 3,5-dimethyl-7H-furo(3,2-g)chromen-7-one 58-62 BCL2 apoptosis regulator Homo sapiens 107-112 27873035-5 2017 Furthermore, co-immunoprecipitation studies revealed that DMFC-induced Bim interrupts interactions between Bcl-2 and Bax and between Mcl-1 and Bak, resulting in dissociation of Bax from Bcl-2 and Bak from Mcl-1 and subsequent activation of both Bax and Bak. 3,5-dimethyl-7H-furo(3,2-g)chromen-7-one 58-62 BCL2 apoptosis regulator Homo sapiens 186-191 27873035-8 2017 Therefore, we determine that DMFC suppresses hepatoma growth through decreasing Bcl-2 and increasing Bim to induce tumor cell apoptosis and hold great promise for further development as a therapeutic agent to treat chemoresistant hepatoma. 3,5-dimethyl-7H-furo(3,2-g)chromen-7-one 29-33 BCL2 apoptosis regulator Homo sapiens 80-85 28187375-0 2017 A comparative study of nuclear 8-hydroxyguanosine expression in Autoimmune Thyroid Diseases and Papillary Thyroid Carcinoma and its relationship with p53, Bcl-2 and Ki-67 cancer related proteins. 8-hydroxyguanosine 31-49 BCL2 apoptosis regulator Homo sapiens 155-160 27757735-2 2017 However, 9-aminoacridine derivatives, which have the same structural scaffold as amsacrine, induce cancer cell apoptosis by altering the expression of BCL2 family proteins. Aminacrine 9-24 BCL2 apoptosis regulator Homo sapiens 151-155 27757735-2 2017 However, 9-aminoacridine derivatives, which have the same structural scaffold as amsacrine, induce cancer cell apoptosis by altering the expression of BCL2 family proteins. Amsacrine 81-90 BCL2 apoptosis regulator Homo sapiens 151-155 27757735-3 2017 Therefore, in the present study, we assessed whether BCL2 family proteins mediated the cytotoxic effects of amsacrine on human leukemia U937 cells. Amsacrine 108-117 BCL2 apoptosis regulator Homo sapiens 53-57 28441707-6 2017 In MCF-7 derived cancer stemcells, fentanyl treatment decreased the expression of Bax, Bcl2, Oct4, Sox2, Nanog genes when compared to untreatedcells. Fentanyl 35-43 BCL2 apoptosis regulator Homo sapiens 87-91 28426875-9 2017 BPA also caused a corresponding increase in expression of SOD1 and anti-apoptotic Bcl-2, key markers of antioxidant and anti-apoptotic processes. bisphenol A 0-3 BCL2 apoptosis regulator Homo sapiens 82-87 28035139-5 2017 In the mitochondria, PKM2 interacts with and phosphorylates Bcl2 at threonine (T) 69. Threonine 68-77 BCL2 apoptosis regulator Homo sapiens 60-64 28035139-13 2017 Our findings uncover a novel mechanism through which mitochondrial PKM2 phosphorylates Bcl2 and inhibits apoptosis directly, highlight the essential role of PKM2 in ROS adaptation of cancer cells, and implicate HSP90-PKM2-Bcl2 axis as a potential target for therapeutic intervention in glioblastoma. ros 165-168 BCL2 apoptosis regulator Homo sapiens 87-91 27993930-0 2017 Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites. venetoclax 66-76 BCL2 apoptosis regulator Homo sapiens 38-55 27302958-7 2017 Hypericin prevented MGO-induced apoptosis in HUVECs by increasing Bcl-2 expression and decreasing Bax expression. hypericin 0-9 BCL2 apoptosis regulator Homo sapiens 66-71 27302958-7 2017 Hypericin prevented MGO-induced apoptosis in HUVECs by increasing Bcl-2 expression and decreasing Bax expression. Pyruvaldehyde 20-23 BCL2 apoptosis regulator Homo sapiens 66-71 27993930-1 2017 Venetoclax (ABT-199), a B-cell lymphoma-2 (Bcl-2) protein inhibitor, is currently in clinical development for the treatment of hematologic malignancies. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 24-41 27993930-1 2017 Venetoclax (ABT-199), a B-cell lymphoma-2 (Bcl-2) protein inhibitor, is currently in clinical development for the treatment of hematologic malignancies. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 12-15 BCL2 apoptosis regulator Homo sapiens 24-41 27993930-1 2017 Venetoclax (ABT-199), a B-cell lymphoma-2 (Bcl-2) protein inhibitor, is currently in clinical development for the treatment of hematologic malignancies. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 12-15 BCL2 apoptosis regulator Homo sapiens 43-48 27993930-1 2017 Venetoclax (ABT-199), a B-cell lymphoma-2 (Bcl-2) protein inhibitor, is currently in clinical development for the treatment of hematologic malignancies. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 43-48 27352821-7 2017 However, exposure to MC-LR for 24 h failed to trigger either apoptosis or proliferation, which might be related to PP2A-inhibition-induced hyperphosphorylation of Bcl-2 and Bad and the activation status of Akt. cyanoginosin LR 21-26 BCL2 apoptosis regulator Homo sapiens 163-168 27200496-6 2017 EGCG markedly increased the protein levels of Bax, cleaved caspase-9, cleaved caspase-3, Atg5, Atg7, Atg12, Beclin-1, and LC3B-II, as well as significantly decreased the expression of Bcl-2, phosphorylated AKT (Ser473) and phosphorylation of STAT3 on Tyr705 by western blotting in CAR cells. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 184-189 27160946-12 2017 Using the benign CRCs as controls, we identified the Bcl-2 family inhibitor navitoclax as the most potent cancer-specific drug for the CRCs from a CRPC patient. navitoclax 76-86 BCL2 apoptosis regulator Homo sapiens 53-58 28197632-7 2017 Additionally, AKT signaling and Bcl-2 family were also involved in the hyperoside-induced autophagy and apoptosis. hyperoside 71-81 BCL2 apoptosis regulator Homo sapiens 32-37 28056551-11 2017 Hepatitis B X-interacting protein and cisplatin cooperated to induce apoptosis and increase the expression of c-caspase 3 as well as the Bax/Bcl-2 ratio. Cisplatin 38-47 BCL2 apoptosis regulator Homo sapiens 141-146 28338173-13 2017 Meanwhile, the upregulation of p-ERK, p-eIF-2a and CHOP, downregulation of Bcl-2, and activation of Caspase-3 caused by AT1-AA were reversed after pre-incubated with valsartan. Valsartan 166-175 BCL2 apoptosis regulator Homo sapiens 75-80 28204825-7 2017 H2O2 induced a reduction in mitochondrial membrane potential, increased caspase-3 activity, and caused downregulation of B cell lymphoma-2 (Bcl-2) and upregulation of Bcl-2-associated X protein (Bax) expression. Hydrogen Peroxide 0-4 BCL2 apoptosis regulator Homo sapiens 121-138 28204825-7 2017 H2O2 induced a reduction in mitochondrial membrane potential, increased caspase-3 activity, and caused downregulation of B cell lymphoma-2 (Bcl-2) and upregulation of Bcl-2-associated X protein (Bax) expression. Hydrogen Peroxide 0-4 BCL2 apoptosis regulator Homo sapiens 140-145 28204825-9 2017 Thus, morroniside protects human neuroblastoma cells against oxidative damage by inhibiting ROS production while suppressing Bax and stimulating Bcl-2 expression, thereby blocking mitochondrial-mediated apoptosis. morroniside 6-17 BCL2 apoptosis regulator Homo sapiens 145-150 28108275-6 2017 Moreover, benzofuran derivatives induced apoptosis, increased poly (ADP-ribose) polymerase cleavage and Bax/Bcl-2 ratio along with a marked DNA fragmentation along with a marked DNA fragmentation and a strong increase in TUNEL-positive breast cancer cells. benzofuran 10-20 BCL2 apoptosis regulator Homo sapiens 108-113 28166401-3 2017 Here, we used detailed spectroscopic characterization to demonstrate rapid formation of Pt-guanosine adducts within 30 min after coincubation of oxaliplatin [OxaPt(II)] or cisplatin [CisPt(II)] with either guanosine monophosphate or B-cell lymphoma 2 (BCL-2) siRNA. pt-guanosine 88-100 BCL2 apoptosis regulator Homo sapiens 233-250 28166401-9 2017 Coincorporation of BCL-2 siRNA and platinum(IV) analogues in a single micelle enabled maximal suppression of BCL-2 mRNA levels (to <10% of baseline), augmented the intracellular levels of platinum (by ~4x) and the numbers of resultant Pt-DNA adducts (by >5x), increased the cellular fractions that underwent apoptosis (by ~4x), and enhanced the in vitro antiproliferative activity of the corresponding platinum(II) agent (by 10-100x, depending on the cancer cell line). Platinum 191-199 BCL2 apoptosis regulator Homo sapiens 19-24 28204832-7 2017 Furthermore, western blot analysis revealed that Jesridonin upregulated the expression of p53, p53 upregulated modulator of apoptosis (PUMA), cleaved-caspase-9 and cleaved-caspase-3 in EC109/Taxol cells, and downregulated the expression of procaspase-3, procaspase-9 and Bcl-2 in the EC109/Taxol cells in a concentration-dependent manner. jesridonin 49-59 BCL2 apoptosis regulator Homo sapiens 271-276 28166401-3 2017 Here, we used detailed spectroscopic characterization to demonstrate rapid formation of Pt-guanosine adducts within 30 min after coincubation of oxaliplatin [OxaPt(II)] or cisplatin [CisPt(II)] with either guanosine monophosphate or B-cell lymphoma 2 (BCL-2) siRNA. pt-guanosine 88-100 BCL2 apoptosis regulator Homo sapiens 252-257 28166401-3 2017 Here, we used detailed spectroscopic characterization to demonstrate rapid formation of Pt-guanosine adducts within 30 min after coincubation of oxaliplatin [OxaPt(II)] or cisplatin [CisPt(II)] with either guanosine monophosphate or B-cell lymphoma 2 (BCL-2) siRNA. Oxaliplatin 145-156 BCL2 apoptosis regulator Homo sapiens 233-250 28166401-3 2017 Here, we used detailed spectroscopic characterization to demonstrate rapid formation of Pt-guanosine adducts within 30 min after coincubation of oxaliplatin [OxaPt(II)] or cisplatin [CisPt(II)] with either guanosine monophosphate or B-cell lymphoma 2 (BCL-2) siRNA. Oxaliplatin 145-156 BCL2 apoptosis regulator Homo sapiens 252-257 28166401-3 2017 Here, we used detailed spectroscopic characterization to demonstrate rapid formation of Pt-guanosine adducts within 30 min after coincubation of oxaliplatin [OxaPt(II)] or cisplatin [CisPt(II)] with either guanosine monophosphate or B-cell lymphoma 2 (BCL-2) siRNA. oxapt 158-163 BCL2 apoptosis regulator Homo sapiens 233-250 28166401-3 2017 Here, we used detailed spectroscopic characterization to demonstrate rapid formation of Pt-guanosine adducts within 30 min after coincubation of oxaliplatin [OxaPt(II)] or cisplatin [CisPt(II)] with either guanosine monophosphate or B-cell lymphoma 2 (BCL-2) siRNA. oxapt 158-163 BCL2 apoptosis regulator Homo sapiens 252-257 28166401-3 2017 Here, we used detailed spectroscopic characterization to demonstrate rapid formation of Pt-guanosine adducts within 30 min after coincubation of oxaliplatin [OxaPt(II)] or cisplatin [CisPt(II)] with either guanosine monophosphate or B-cell lymphoma 2 (BCL-2) siRNA. cispt 183-188 BCL2 apoptosis regulator Homo sapiens 233-250 28166401-3 2017 Here, we used detailed spectroscopic characterization to demonstrate rapid formation of Pt-guanosine adducts within 30 min after coincubation of oxaliplatin [OxaPt(II)] or cisplatin [CisPt(II)] with either guanosine monophosphate or B-cell lymphoma 2 (BCL-2) siRNA. cispt 183-188 BCL2 apoptosis regulator Homo sapiens 252-257 28166401-4 2017 After 3 h of exposure to these platinum(II) agents, >50% of BCL-2 siRNA transcripts were platinated and unable to effectively suppress mRNA levels. Platinum 31-39 BCL2 apoptosis regulator Homo sapiens 63-68 28166401-9 2017 Coincorporation of BCL-2 siRNA and platinum(IV) analogues in a single micelle enabled maximal suppression of BCL-2 mRNA levels (to <10% of baseline), augmented the intracellular levels of platinum (by ~4x) and the numbers of resultant Pt-DNA adducts (by >5x), increased the cellular fractions that underwent apoptosis (by ~4x), and enhanced the in vitro antiproliferative activity of the corresponding platinum(II) agent (by 10-100x, depending on the cancer cell line). Platinum 35-43 BCL2 apoptosis regulator Homo sapiens 109-114 28166401-9 2017 Coincorporation of BCL-2 siRNA and platinum(IV) analogues in a single micelle enabled maximal suppression of BCL-2 mRNA levels (to <10% of baseline), augmented the intracellular levels of platinum (by ~4x) and the numbers of resultant Pt-DNA adducts (by >5x), increased the cellular fractions that underwent apoptosis (by ~4x), and enhanced the in vitro antiproliferative activity of the corresponding platinum(II) agent (by 10-100x, depending on the cancer cell line). Platinum 191-199 BCL2 apoptosis regulator Homo sapiens 19-24 28040581-5 2017 Western blot confirmed that EGCG induced apoptosis in SW780 cells by activation of caspases-8, -9 and -3, Bax, Bcl-2 and PARP. epigallocatechin gallate 28-32 BCL2 apoptosis regulator Homo sapiens 111-116 28112379-9 2017 Physiological concentrations of testosterone protected the HUVECs from AGE-induced apoptosis, mediated by caspase-3 and Bax/Bcl-2. Testosterone 32-44 BCL2 apoptosis regulator Homo sapiens 124-129 27872497-0 2017 Bcl-2 protein family expression pattern determines synergistic pro-apoptotic effects of BH3 mimetics with hemisynthetic cardiac glycoside UNBS1450 in acute myeloid leukemia. BH 3 88-91 BCL2 apoptosis regulator Homo sapiens 0-5 27872497-0 2017 Bcl-2 protein family expression pattern determines synergistic pro-apoptotic effects of BH3 mimetics with hemisynthetic cardiac glycoside UNBS1450 in acute myeloid leukemia. Glycosides 128-137 BCL2 apoptosis regulator Homo sapiens 0-5 28138710-10 2017 Furthermore, a decrease in Bcl2 expression, and an increase in the expression levels of Bak and Bax, was detected following treatment with moscatilin, resulting in an increase in the proapoptotic/anti-apoptotic expression ratio (Bax/Bcl2) in Panc-1 cells. dendrophenol 139-149 BCL2 apoptosis regulator Homo sapiens 233-237 28138710-10 2017 Furthermore, a decrease in Bcl2 expression, and an increase in the expression levels of Bak and Bax, was detected following treatment with moscatilin, resulting in an increase in the proapoptotic/anti-apoptotic expression ratio (Bax/Bcl2) in Panc-1 cells. dendrophenol 139-149 BCL2 apoptosis regulator Homo sapiens 27-31 28283087-5 2017 On the other hand, BDMC promoted the X-ray-induced dephosphorylation at Ser 70 in Bcl-2"s flexible loop regulatory domain and Bcl-2 binding to p53. Serine 72-75 BCL2 apoptosis regulator Homo sapiens 82-87 28283087-0 2017 Bisdemethoxycurcumin enhances X-ray-induced apoptosis possibly through p53/Bcl-2 pathway. bisdemethoxycurcumin 0-20 BCL2 apoptosis regulator Homo sapiens 75-80 28283087-5 2017 On the other hand, BDMC promoted the X-ray-induced dephosphorylation at Ser 70 in Bcl-2"s flexible loop regulatory domain and Bcl-2 binding to p53. bisdemethoxycurcumin 19-23 BCL2 apoptosis regulator Homo sapiens 82-87 28283087-5 2017 On the other hand, BDMC promoted the X-ray-induced dephosphorylation at Ser 70 in Bcl-2"s flexible loop regulatory domain and Bcl-2 binding to p53. bisdemethoxycurcumin 19-23 BCL2 apoptosis regulator Homo sapiens 126-131 28283087-7 2017 Our results indicate that BDMC stimulates the dephosphorylation and p53-binding activity of Bcl-2 and suggest that BDMC may induce a neutralization of Bcl-2"s anti-apoptotic function, thereby enhancing X-ray-induced apoptosis. bisdemethoxycurcumin 26-30 BCL2 apoptosis regulator Homo sapiens 92-97 28283087-7 2017 Our results indicate that BDMC stimulates the dephosphorylation and p53-binding activity of Bcl-2 and suggest that BDMC may induce a neutralization of Bcl-2"s anti-apoptotic function, thereby enhancing X-ray-induced apoptosis. bisdemethoxycurcumin 26-30 BCL2 apoptosis regulator Homo sapiens 151-156 28283087-7 2017 Our results indicate that BDMC stimulates the dephosphorylation and p53-binding activity of Bcl-2 and suggest that BDMC may induce a neutralization of Bcl-2"s anti-apoptotic function, thereby enhancing X-ray-induced apoptosis. bisdemethoxycurcumin 115-119 BCL2 apoptosis regulator Homo sapiens 92-97 28283087-7 2017 Our results indicate that BDMC stimulates the dephosphorylation and p53-binding activity of Bcl-2 and suggest that BDMC may induce a neutralization of Bcl-2"s anti-apoptotic function, thereby enhancing X-ray-induced apoptosis. bisdemethoxycurcumin 115-119 BCL2 apoptosis regulator Homo sapiens 151-156 28454332-4 2017 Furthermore, pretreatment with zoledronic acid (ZOL) appeared to resensitize the CDDP-resistant cells by inducing S-phase cell cycle arrest and the mitochondrial apoptotic pathway by upregulating the expression of B-cell lymphoma-2 (BCL-2)-associated X protein and caspase-9 and downregulating the expression of BCL-2. Zoledronic Acid 31-46 BCL2 apoptosis regulator Homo sapiens 214-231 28449478-10 2017 Moreover, the expression of caspase-3 decreased and the expression of Bcl-2 increased significantly after propofol preconditioning. Propofol 106-114 BCL2 apoptosis regulator Homo sapiens 70-75 28454332-4 2017 Furthermore, pretreatment with zoledronic acid (ZOL) appeared to resensitize the CDDP-resistant cells by inducing S-phase cell cycle arrest and the mitochondrial apoptotic pathway by upregulating the expression of B-cell lymphoma-2 (BCL-2)-associated X protein and caspase-9 and downregulating the expression of BCL-2. Zoledronic Acid 31-46 BCL2 apoptosis regulator Homo sapiens 233-238 28454332-4 2017 Furthermore, pretreatment with zoledronic acid (ZOL) appeared to resensitize the CDDP-resistant cells by inducing S-phase cell cycle arrest and the mitochondrial apoptotic pathway by upregulating the expression of B-cell lymphoma-2 (BCL-2)-associated X protein and caspase-9 and downregulating the expression of BCL-2. Zoledronic Acid 31-46 BCL2 apoptosis regulator Homo sapiens 312-317 28454332-4 2017 Furthermore, pretreatment with zoledronic acid (ZOL) appeared to resensitize the CDDP-resistant cells by inducing S-phase cell cycle arrest and the mitochondrial apoptotic pathway by upregulating the expression of B-cell lymphoma-2 (BCL-2)-associated X protein and caspase-9 and downregulating the expression of BCL-2. Zoledronic Acid 48-51 BCL2 apoptosis regulator Homo sapiens 214-231 28454332-4 2017 Furthermore, pretreatment with zoledronic acid (ZOL) appeared to resensitize the CDDP-resistant cells by inducing S-phase cell cycle arrest and the mitochondrial apoptotic pathway by upregulating the expression of B-cell lymphoma-2 (BCL-2)-associated X protein and caspase-9 and downregulating the expression of BCL-2. Zoledronic Acid 48-51 BCL2 apoptosis regulator Homo sapiens 233-238 28454332-4 2017 Furthermore, pretreatment with zoledronic acid (ZOL) appeared to resensitize the CDDP-resistant cells by inducing S-phase cell cycle arrest and the mitochondrial apoptotic pathway by upregulating the expression of B-cell lymphoma-2 (BCL-2)-associated X protein and caspase-9 and downregulating the expression of BCL-2. Zoledronic Acid 48-51 BCL2 apoptosis regulator Homo sapiens 312-317 28454332-4 2017 Furthermore, pretreatment with zoledronic acid (ZOL) appeared to resensitize the CDDP-resistant cells by inducing S-phase cell cycle arrest and the mitochondrial apoptotic pathway by upregulating the expression of B-cell lymphoma-2 (BCL-2)-associated X protein and caspase-9 and downregulating the expression of BCL-2. Cisplatin 81-85 BCL2 apoptosis regulator Homo sapiens 214-231 28454332-4 2017 Furthermore, pretreatment with zoledronic acid (ZOL) appeared to resensitize the CDDP-resistant cells by inducing S-phase cell cycle arrest and the mitochondrial apoptotic pathway by upregulating the expression of B-cell lymphoma-2 (BCL-2)-associated X protein and caspase-9 and downregulating the expression of BCL-2. Cisplatin 81-85 BCL2 apoptosis regulator Homo sapiens 233-238 28454332-4 2017 Furthermore, pretreatment with zoledronic acid (ZOL) appeared to resensitize the CDDP-resistant cells by inducing S-phase cell cycle arrest and the mitochondrial apoptotic pathway by upregulating the expression of B-cell lymphoma-2 (BCL-2)-associated X protein and caspase-9 and downregulating the expression of BCL-2. Cisplatin 81-85 BCL2 apoptosis regulator Homo sapiens 312-317 28115640-6 2017 Furthermore, we found that clonidine treatment resulted in activated caspase-2, -3, -8, and -9, disruption of the mitochondrial transmembrane potential, downregulation of Bcl-2, and upregulation of Bad, cytoplasmic cytochrome c and apoptosis inducing factor, suggesting that clonidine-induced apoptosis is triggered through Fas/TNFR1 death receptors and Bcl-2 family proteins-mediated mitochondria-dependent pathways. Clonidine 27-36 BCL2 apoptosis regulator Homo sapiens 171-176 28115640-6 2017 Furthermore, we found that clonidine treatment resulted in activated caspase-2, -3, -8, and -9, disruption of the mitochondrial transmembrane potential, downregulation of Bcl-2, and upregulation of Bad, cytoplasmic cytochrome c and apoptosis inducing factor, suggesting that clonidine-induced apoptosis is triggered through Fas/TNFR1 death receptors and Bcl-2 family proteins-mediated mitochondria-dependent pathways. Clonidine 27-36 BCL2 apoptosis regulator Homo sapiens 354-359 28347224-3 2017 Furthermore, crocodile choline accelerated apoptosis through the mitochondrial apoptotic pathway with the decrease in mitochondrial membrane potential, the increase in reactive oxygen species production and Bax/Bcl-2 ratio, and the activation of caspase-3 along with the release of cytochrome c. Choline 23-30 BCL2 apoptosis regulator Homo sapiens 211-216 28347251-8 2017 Meanwhile, knockdown of methyl methanesulfonate and ultraviolet-sensitive gene clone 81 activated the p53/Bcl-2 pathway in response to cisplatin. Methyl Methanesulfonate 24-47 BCL2 apoptosis regulator Homo sapiens 106-111 28347251-8 2017 Meanwhile, knockdown of methyl methanesulfonate and ultraviolet-sensitive gene clone 81 activated the p53/Bcl-2 pathway in response to cisplatin. Cisplatin 135-144 BCL2 apoptosis regulator Homo sapiens 106-111 27998772-8 2017 In cervical carcinoma cells, regardless of HPV-infection, CIZAR induces apoptosis by the activation of the p53-independent pathways through the up-regulation of p21waf1, the down-regulation of c-Myc, and by decreasing the Bcl-2/Bax ratio. cizar 58-63 BCL2 apoptosis regulator Homo sapiens 222-227 28349834-7 2017 Herein, we demonstrate that doxorubicin decreases GATA4 expression and alters the expression pattern of BCL2 family members, most profoundly that of BCL2 and BAK, in the HUH6 hepatoblastoma cell line. Doxorubicin 28-39 BCL2 apoptosis regulator Homo sapiens 104-108 28349834-7 2017 Herein, we demonstrate that doxorubicin decreases GATA4 expression and alters the expression pattern of BCL2 family members, most profoundly that of BCL2 and BAK, in the HUH6 hepatoblastoma cell line. Doxorubicin 28-39 BCL2 apoptosis regulator Homo sapiens 149-153 28349834-7 2017 Herein, we demonstrate that doxorubicin decreases GATA4 expression and alters the expression pattern of BCL2 family members, most profoundly that of BCL2 and BAK, in the HUH6 hepatoblastoma cell line. bakuchiol 158-161 BCL2 apoptosis regulator Homo sapiens 104-108 28351307-5 2017 In addition, coptisine was found to increase reactive oxygen species generation, upregulate Bax/Bcl-2 ratio, disrupt mitochondrial membrane potential, and cause cytochrome c release into the cytosol. coptisine 13-22 BCL2 apoptosis regulator Homo sapiens 96-101 28289382-5 2017 Moreover, treatment of melanoma cells with ADA reduced nuclear translocation and activation of NF-kappaB, decreased the expression of the anti-apoptotic proteins c-FLIP, XIAP, and Bcl-2 and inhibited the phosphorylation and activation of both AKT and ERK proteins, two of the most frequently deregulated pathways in melanoma. N-(2-acetamido)iminodiacetic acid 43-46 BCL2 apoptosis regulator Homo sapiens 180-185 28144994-2 2017 Thus, in the present study, the anti-metastatic effect of Dehydrocorydaline was examined in non-small cell lung carcinoma (NSCLC) cells, mainly targeting matrix metalloproteinases (MMPs) and B cell lymphoma-2 (Bcl-2) signaling. dehydrocorydalin 58-75 BCL2 apoptosis regulator Homo sapiens 191-208 28144994-2 2017 Thus, in the present study, the anti-metastatic effect of Dehydrocorydaline was examined in non-small cell lung carcinoma (NSCLC) cells, mainly targeting matrix metalloproteinases (MMPs) and B cell lymphoma-2 (Bcl-2) signaling. dehydrocorydalin 58-75 BCL2 apoptosis regulator Homo sapiens 210-215 28144994-3 2017 Here, Dehydrocorydaline exerted weak cytotoxicity and attenuated the protein expression of Bcl-2 and activated Bax in a concentration-dependent manner in NSCLC cells, such as A549, H460, H1299, and H596 cells. dehydrocorydalin 6-23 BCL2 apoptosis regulator Homo sapiens 91-96 28144994-6 2017 Of note, Bcl-2 overexpression reduced the cytotoxic and anti-metastatic effects of Dehydrocorydaline on pCDNA-Bcl-2 transfected H1299 cells. dehydrocorydalin 83-100 BCL2 apoptosis regulator Homo sapiens 9-14 28144994-6 2017 Of note, Bcl-2 overexpression reduced the cytotoxic and anti-metastatic effects of Dehydrocorydaline on pCDNA-Bcl-2 transfected H1299 cells. dehydrocorydalin 83-100 BCL2 apoptosis regulator Homo sapiens 110-115 28144994-7 2017 Overall, our findings provide scientific evidence that Dehydrocorydaline exerts anti-metastatic potential via suppression of MMPs and Bcl-2 signaling in NSCLC cells. dehydrocorydalin 55-72 BCL2 apoptosis regulator Homo sapiens 134-139 28038454-0 2017 Reactive oxygen species mediate heat stress-induced apoptosis via ERK dephosphorylation and Bcl-2 ubiquitination in human umbilical vein endothelial cells. Reactive Oxygen Species 0-23 BCL2 apoptosis regulator Homo sapiens 92-97 28049729-10 2017 However, under conditions of cell stress induced by rTpo and serum deprivation, ABA stimulates, in a PKA- and cADPR-dependent fashion, the mitogen-activated kinase ERK 1/2, resulting in the modulation of lymphoma 2 (Bcl-2) family members, increased Mk survival, and higher rates of platelet production. Abscisic Acid 80-83 BCL2 apoptosis regulator Homo sapiens 216-221 28165738-7 2017 A decrease in mitochondrial membrane potential and an increase in Bax/Bcl-2 ratio, accompanied by activated caspase-3 cleavage, were observed in MCF-7 cells after treatment with 13p, suggesting that the mitochondrial pathway was involved in the 13p-mediated apoptosis. 13p 178-181 BCL2 apoptosis regulator Homo sapiens 70-75 28382170-6 2017 We also observed that expression of anti-apoptotic Bcl-2 increased substantially following BRAF inhibitor treatment in Vemurafenib-resistant K1 cells, and both Obatoclax and LY3009120 efficiently induced apoptosis of these resistant cells. LY3009120 174-183 BCL2 apoptosis regulator Homo sapiens 51-56 28082672-5 2017 We show here that in both squamous cell carcinoma cells and melanoma tumor cells, CQ induced NF-kappaB activation and the expression of its target genes HIF-1alpha, IL-8, BCL-2, and BCL-XL through the accumulation of autophagosomes, p62, and JNK signaling. Chloroquine 82-84 BCL2 apoptosis regulator Homo sapiens 171-176 28382170-6 2017 We also observed that expression of anti-apoptotic Bcl-2 increased substantially following BRAF inhibitor treatment in Vemurafenib-resistant K1 cells, and both Obatoclax and LY3009120 efficiently induced apoptosis of these resistant cells. Vemurafenib 119-130 BCL2 apoptosis regulator Homo sapiens 51-56 28038454-5 2017 In addition, we explored the mechanism by which superoxide regulates the apoptotic effect of intense heat stress, and found that it involved Bcl-2 down-regulation through ubiquitin - proteasomal degradation. Superoxides 48-58 BCL2 apoptosis regulator Homo sapiens 141-146 28038454-6 2017 Superoxide production also led to Bcl-2 dephosphorylation through inactivation of MAP kinase ERK1/2, which promoted Bcl-2 ubiquitination. Superoxides 0-10 BCL2 apoptosis regulator Homo sapiens 34-39 28038454-6 2017 Superoxide production also led to Bcl-2 dephosphorylation through inactivation of MAP kinase ERK1/2, which promoted Bcl-2 ubiquitination. Superoxides 0-10 BCL2 apoptosis regulator Homo sapiens 116-121 28026162-2 2017 Members of the antiapoptotic Bcl-2 proteins, including Bcl-2, Mcl-1, Bcl-xL, Bcl-w, and Bfl-1, inhibit apoptosis by selectively binding to conserved alpha-helical regions, named BH3 domains, of pro-apoptotic proteins such as Bim, tBid, Bad, or NOXA. tBID 230-234 BCL2 apoptosis regulator Homo sapiens 29-34 28026162-2 2017 Members of the antiapoptotic Bcl-2 proteins, including Bcl-2, Mcl-1, Bcl-xL, Bcl-w, and Bfl-1, inhibit apoptosis by selectively binding to conserved alpha-helical regions, named BH3 domains, of pro-apoptotic proteins such as Bim, tBid, Bad, or NOXA. tBID 230-234 BCL2 apoptosis regulator Homo sapiens 55-60 28119023-4 2017 Further study showed that khasuanine A was able to induce the apoptosis of PC3 cells by activation of caspase 3 and p53, and by inhibition of Bcl-2. khasuanine A 26-38 BCL2 apoptosis regulator Homo sapiens 142-147 28087272-0 2017 Synthesis and evaluation of 5-(1H-indol-3-yl)-N-aryl-1,3,4-oxadiazol-2-amines as Bcl-2 inhibitory anticancer agents. 5-(1h-indol-3-yl)-n-aryl-1,3,4-oxadiazol-2-amines 28-77 BCL2 apoptosis regulator Homo sapiens 81-86 28087272-1 2017 A series of 5-(1H-indol-3-yl)-N-aryl-1,3,4-oxadiazol-2-amines 8a-j has been designed, synthesized and tested in vitro as potential pro-apoptotic Bcl-2-inhibitory anticancer agents based on our previous lead compound 8a. 5-(1h-indol-3-yl)-n-aryl-1,3,4-oxadiazol-2-amines 12-61 BCL2 apoptosis regulator Homo sapiens 145-150 28196062-11 2017 CONCLUSIONS Elemene can inhibit the proliferation and induce the apoptosis of gastric cancer cells associated with the ERK 1/2 signaling pathway and expression levels of Bax mRNA and Bcl-2 mRNA. elemene 12-19 BCL2 apoptosis regulator Homo sapiens 183-188 28131165-9 2017 OGD-insulted NSCs with ginsenoside Rg1 treatment displayed reduced expressions of pro-apoptotic proteins cleaved Caspase3 and Bax, and elevated expression of anti-apoptotic protein Bcl-2 than the NSCs with OGD insult. Ginsenosides 23-34 BCL2 apoptosis regulator Homo sapiens 181-186 28208696-11 2017 Meanwhile, VPA administration also increased the ratio of Bcl-2/Bax. Valproic Acid 11-14 BCL2 apoptosis regulator Homo sapiens 58-63 28246472-7 2017 Dramatically increased CCAAT-enhancer-binding protein homologous protein level, suppressed COX-2 and decreased Bcl-2/Bax ratio by melatonin or ATF-6 siRNA contributed the enhanced HepG2 cell apoptosis under tunicamycin (an ER stress inducer) stimulation. Melatonin 130-139 BCL2 apoptosis regulator Homo sapiens 111-116 28246472-7 2017 Dramatically increased CCAAT-enhancer-binding protein homologous protein level, suppressed COX-2 and decreased Bcl-2/Bax ratio by melatonin or ATF-6 siRNA contributed the enhanced HepG2 cell apoptosis under tunicamycin (an ER stress inducer) stimulation. Tunicamycin 207-218 BCL2 apoptosis regulator Homo sapiens 111-116 28246474-8 2017 CONCLUSION: ST ethanol extracts induced the apoptosis of hepatocellular carcinoma SMMC-7721 cells through up-regulated Fas, caspase-8, caspse-3 and p53, and down-regulated FasL and Bcl-2 in the mitochondrial pathway. Ethanol 15-22 BCL2 apoptosis regulator Homo sapiens 181-186 28187727-11 2017 We also found that ATO combined with CT reversed the upregulated expression of phosphorylated-STAT3Tyr705 stimulated by interleukin-6 and downregulated STAT3 direct target genes and the anti-apoptotic proteins Bcl-2, XIAP, and survivin but obviously upregulated the promoting apoptosis proteins Bak,.In vivo studies showed that ATO combined with CT decreased tumor growth. Arsenic Trioxide 19-22 BCL2 apoptosis regulator Homo sapiens 210-215 28187727-11 2017 We also found that ATO combined with CT reversed the upregulated expression of phosphorylated-STAT3Tyr705 stimulated by interleukin-6 and downregulated STAT3 direct target genes and the anti-apoptotic proteins Bcl-2, XIAP, and survivin but obviously upregulated the promoting apoptosis proteins Bak,.In vivo studies showed that ATO combined with CT decreased tumor growth. cryptotanshinone 37-39 BCL2 apoptosis regulator Homo sapiens 210-215 28208611-6 2017 Inhibition of cell survival by BA at 10 and 20 microM concentrations occurred as a result of alteration in Bax/Bcl-2 ratio in both cell lines that led to an increased cytochrome C release, caspase activation and poly(ADP)ribose polymerase (PARP) cleavage, leading to apoptosis. betulinic acid 31-33 BCL2 apoptosis regulator Homo sapiens 111-116 28181540-2 2017 We have previously shown that TREM-1 prolongs survival of macrophages treated with lipoolysaccharide through Egr2-Bcl2 signaling. lipoolysaccharide 83-100 BCL2 apoptosis regulator Homo sapiens 114-118 27749061-3 2017 Accordingly, strategies to antagonize the antiapoptotic Bcl-2 proteins have largely focused on the development of low-molecular-weight, synthetic BH3 mimetics ("magic bullets") to disrupt the protein-protein interactions between anti- and proapoptotic Bcl-2 proteins. BH 3 146-149 BCL2 apoptosis regulator Homo sapiens 56-61 27749061-6 2017 Indeed, the selective Bcl-2 inhibitor venetoclax (Venclexta) recently received FDA approval for the treatment of a specific subset of patients with chronic lymphocytic leukemia. venetoclax 38-48 BCL2 apoptosis regulator Homo sapiens 22-27 27749061-6 2017 Indeed, the selective Bcl-2 inhibitor venetoclax (Venclexta) recently received FDA approval for the treatment of a specific subset of patients with chronic lymphocytic leukemia. venetoclax 50-59 BCL2 apoptosis regulator Homo sapiens 22-27 27792037-12 2017 PA induced cell apoptosis by regulating the expressions of apoptosis-related proteins (caspase-3, PARP, Bcl-2, and Bax) and suppressing the mitochondrial capacity of GC cell lines in vitro in a dose-dependent manner. pachymic acid 0-2 BCL2 apoptosis regulator Homo sapiens 104-109 28178219-7 2017 Altholactone treatment also results in down-regulation of STAT3 target genes such as survivin, and Bcl-2 followed by up regulation of pro-apoptotic Bax protein. altholactone 0-12 BCL2 apoptosis regulator Homo sapiens 99-104 28178193-8 2017 Cearoin increased the phosporylation of ERK, the conversion of LC3B-I to LC3B-II, decrease in Bcl2 expression, the activation of caspase-3, and the cleavage of PARP, indicating the induction of autophagy and apoptosis. Cearoin 0-7 BCL2 apoptosis regulator Homo sapiens 94-98 28081301-7 2017 RESULTS: EtOH dose dependently induces depolarization of mitochondrial inner transmembrane potential, up-regulation of Bax, down-regulation of Bcl-2, and caspase-3 activation. Ethanol 9-13 BCL2 apoptosis regulator Homo sapiens 143-148 27807662-6 2017 Sorafenib plus C2-ceramide stimulated significantly the production of reactive oxygen species (ROS) and mitochondrial depolarization, which promoted caspases-dependent cell apoptosis as illustrated by related protein expression including caspase 3, caspase 9, Bax, Bcl-2, and cytochrome c. Sorafenib 0-9 BCL2 apoptosis regulator Homo sapiens 265-270 27807662-6 2017 Sorafenib plus C2-ceramide stimulated significantly the production of reactive oxygen species (ROS) and mitochondrial depolarization, which promoted caspases-dependent cell apoptosis as illustrated by related protein expression including caspase 3, caspase 9, Bax, Bcl-2, and cytochrome c. N-acetylsphingosine 15-26 BCL2 apoptosis regulator Homo sapiens 265-270 27894814-10 2017 Finally, the apoptotic molecules such as Bax/Bcl2, cleavage caspase 3 and the cell cycle regulation factors including p21, cyclin D1, and CDK6 were changed by Tanshinone IIA. tanshinone 159-169 BCL2 apoptosis regulator Homo sapiens 45-49 27486855-4 2017 We used EBSS treatment with the BH3 domain of Bcl-2 family proteins (BH3) mimetic ABT737, which targets Bcl-2/Bcl-xL, to examine mitochondrial dynamics and the interactive regulatory mechanisms between nutrition and Bcl-2 proteins. ebss 8-12 BCL2 apoptosis regulator Homo sapiens 46-51 28345832-9 2017 Furthermore, metformin exposure resultedin decreased STAT3 activation and down-regulation of anti-apoptotic protein Bcl-2 and Mcl-1 expression. Metformin 13-22 BCL2 apoptosis regulator Homo sapiens 116-121 28179288-5 2017 As a mechanism of synthetic lethality, active BCL2 associated X, apoptosis regulator (BAX) was induced by TAK-901. TAK-901 106-113 BCL2 apoptosis regulator Homo sapiens 46-50 28237486-4 2017 CONCLUSIONS: Targeted inhibition of Notch1 gene may enhance the killing effects of paclitaxel on triple negative breast cancer cells by up-regulating the expression of Caspase-3 and Caspase-9 and inhibiting the expression of Bcl-2. Paclitaxel 83-93 BCL2 apoptosis regulator Homo sapiens 225-230 28011381-6 2017 Moreover, DANPT induced Bax and inhibited Bcl-2 expression, which results in increasing Bax/Bcl-2 ratio and activation of caspase-3. danpt 10-15 BCL2 apoptosis regulator Homo sapiens 42-47 28011381-6 2017 Moreover, DANPT induced Bax and inhibited Bcl-2 expression, which results in increasing Bax/Bcl-2 ratio and activation of caspase-3. danpt 10-15 BCL2 apoptosis regulator Homo sapiens 92-97 28064447-0 2017 Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2. Temozolomide 47-59 BCL2 apoptosis regulator Homo sapiens 100-105 27986708-2 2017 We found that primary BPDCN cells were dependent on the antiapoptotic protein BCL2 and were uniformly sensitive to the BCL2 inhibitor venetoclax, as measured by direct cytotoxicity, apoptosis assays, and dynamic BH3 profiling. bpdcn 22-27 BCL2 apoptosis regulator Homo sapiens 78-82 27986708-2 2017 We found that primary BPDCN cells were dependent on the antiapoptotic protein BCL2 and were uniformly sensitive to the BCL2 inhibitor venetoclax, as measured by direct cytotoxicity, apoptosis assays, and dynamic BH3 profiling. bpdcn 22-27 BCL2 apoptosis regulator Homo sapiens 119-123 27986708-2 2017 We found that primary BPDCN cells were dependent on the antiapoptotic protein BCL2 and were uniformly sensitive to the BCL2 inhibitor venetoclax, as measured by direct cytotoxicity, apoptosis assays, and dynamic BH3 profiling. venetoclax 134-144 BCL2 apoptosis regulator Homo sapiens 119-123 27986708-4 2017 We propose that venetoclax or other BCL2 inhibitors undergo expedited clinical evaluation in BPDCN, alone or in combination with other therapies. bpdcn 93-98 BCL2 apoptosis regulator Homo sapiens 36-40 28345329-0 2017 Lycopene Extracts from Different Tomato-Based Food Products Induce Apoptosis in Cultured Human Primary Prostate Cancer Cells and Regulate TP53, Bax and Bcl-2 Transcript Expression Carotenoids are the main tomato components, especially lycopene. Lycopene 0-8 BCL2 apoptosis regulator Homo sapiens 152-157 28345329-0 2017 Lycopene Extracts from Different Tomato-Based Food Products Induce Apoptosis in Cultured Human Primary Prostate Cancer Cells and Regulate TP53, Bax and Bcl-2 Transcript Expression Carotenoids are the main tomato components, especially lycopene. Carotenoids 180-191 BCL2 apoptosis regulator Homo sapiens 152-157 28345329-5 2017 Using real time PCR assay, we found that lycopene promotedan upregulation of TP53 and Bax transcript expression and also downregulation of Bcl-2 expression in PCa cells. Lycopene 41-49 BCL2 apoptosis regulator Homo sapiens 139-144 28064447-7 2017 In addition, the knockdown of mTOR and Bcl-2 reduced the tolerance of glioma cells to TMZ. Temozolomide 86-89 BCL2 apoptosis regulator Homo sapiens 39-44 27907860-5 2017 This was further supported using a flow-cytometry (Annexin V/propidium iodide assay), which revealed a significant increase in apoptotic cells in both the cell lines after the co-administration of VP-16 and Bcl-2 Aso using oMWCNTs-PEG hybrid, and fluorescence microscopy, which showed an increase in reactive oxygen species identified after Bcl-2 knock-down. Reactive Oxygen Species 300-323 BCL2 apoptosis regulator Homo sapiens 207-212 27907860-0 2017 Co-delivery of VP-16 and Bcl-2-targeted antisense on PEG-grafted oMWCNTs for synergistic in vitro anti-cancer effects in non-small and small cell lung cancer. Polyethylene Glycols 53-56 BCL2 apoptosis regulator Homo sapiens 25-30 27907860-1 2017 Present study describes the preparation of a polyethylene glycol-grafted oxidized multi-walled carbon nanotubes (oMWCNTs-PEG) hybrid nanosystem as a carrier of etoposide (VP-16) and Bcl-2 phosphorothioate antisense deoxyoligonucleotides (Aso) to achieve a superior cytostastic efficacy in non-small and small cell lung cancer in vitro. Polyethylene Glycols 45-64 BCL2 apoptosis regulator Homo sapiens 182-187 27907860-1 2017 Present study describes the preparation of a polyethylene glycol-grafted oxidized multi-walled carbon nanotubes (oMWCNTs-PEG) hybrid nanosystem as a carrier of etoposide (VP-16) and Bcl-2 phosphorothioate antisense deoxyoligonucleotides (Aso) to achieve a superior cytostastic efficacy in non-small and small cell lung cancer in vitro. Etoposide 160-169 BCL2 apoptosis regulator Homo sapiens 182-187 27907860-5 2017 This was further supported using a flow-cytometry (Annexin V/propidium iodide assay), which revealed a significant increase in apoptotic cells in both the cell lines after the co-administration of VP-16 and Bcl-2 Aso using oMWCNTs-PEG hybrid, and fluorescence microscopy, which showed an increase in reactive oxygen species identified after Bcl-2 knock-down. Propidium 61-77 BCL2 apoptosis regulator Homo sapiens 207-212 27907860-5 2017 This was further supported using a flow-cytometry (Annexin V/propidium iodide assay), which revealed a significant increase in apoptotic cells in both the cell lines after the co-administration of VP-16 and Bcl-2 Aso using oMWCNTs-PEG hybrid, and fluorescence microscopy, which showed an increase in reactive oxygen species identified after Bcl-2 knock-down. Polyethylene Glycols 231-234 BCL2 apoptosis regulator Homo sapiens 207-212 27907860-7 2017 Moreover, Aso specifically binding to the first six codons of the Bcl-2 mRNA gave a satisfactorily decrease in Bcl-2 translation and an increase in NCIH2135 chemosensitivity towards VP-16. 1,5-anhydroglucitol 10-13 BCL2 apoptosis regulator Homo sapiens 66-71 27907860-7 2017 Moreover, Aso specifically binding to the first six codons of the Bcl-2 mRNA gave a satisfactorily decrease in Bcl-2 translation and an increase in NCIH2135 chemosensitivity towards VP-16. 1,5-anhydroglucitol 10-13 BCL2 apoptosis regulator Homo sapiens 111-116 28008585-6 2017 Exenatide (1-100 nmol/L) increased the ratio of Bax/Bcl-2 in a dose-dependent manner, whereas liraglutide increased Bax/Bcl-2 ratio only at concentrations of 10 nmol/L. Exenatide 0-9 BCL2 apoptosis regulator Homo sapiens 52-57 27939626-0 2017 MiR-34a, a promising novel biomarker for benzene toxicity, is involved in cell apoptosis triggered by 1,4-benzoquinone through targeting Bcl-2. Benzene 41-48 BCL2 apoptosis regulator Homo sapiens 137-142 27939626-0 2017 MiR-34a, a promising novel biomarker for benzene toxicity, is involved in cell apoptosis triggered by 1,4-benzoquinone through targeting Bcl-2. quinone 102-118 BCL2 apoptosis regulator Homo sapiens 137-142 27654302-2 2017 Here, we report that fucoidan-induced apoptosis in 5637 human bladder cancer cells was associated with an increase in the Bax/Bcl-2 ratio, the dissipation of the mitochondrial membrane potential (MMP, Deltapsim), and cytosolic release of cytochrome c from the mitochondria. fucoidan 21-29 BCL2 apoptosis regulator Homo sapiens 126-131 27939626-11 2017 Results revealed that 1,4-benzoquinone induced abnormal cell apoptosis and simultaneously upregulated miR-34a accompanied with decreased Bcl-2. quinone 22-38 BCL2 apoptosis regulator Homo sapiens 137-142 27939626-13 2017 In conclusion, miR-34a was observed to be involved in benzene-induced hematotoxicity by targeting Bcl-2 and could be regarded as a potential novel biomarker for benzene toxicity. Benzene 54-61 BCL2 apoptosis regulator Homo sapiens 98-103 27939626-13 2017 In conclusion, miR-34a was observed to be involved in benzene-induced hematotoxicity by targeting Bcl-2 and could be regarded as a potential novel biomarker for benzene toxicity. Benzene 161-168 BCL2 apoptosis regulator Homo sapiens 98-103 28239804-9 2017 RESULTS: Compared with normal control, As2O3 significantly increased BGC-823 cell apoptosis, blocked cell cycle in G0/G1 phase, elevated cAMP and Bax level, as well as downregulated PKC, Bcl-2 and Survivin expression (p < 0.05). Arsenic Trioxide 39-44 BCL2 apoptosis regulator Homo sapiens 187-192 28112004-0 2017 Torulene and torularhodin, protects human prostate stromal cells from hydrogen peroxide-induced oxidative stress damage through the regulation of Bcl-2/Bax mediated apoptosis. torularhodin 13-25 BCL2 apoptosis regulator Homo sapiens 146-151 28112004-0 2017 Torulene and torularhodin, protects human prostate stromal cells from hydrogen peroxide-induced oxidative stress damage through the regulation of Bcl-2/Bax mediated apoptosis. torulene 0-8 BCL2 apoptosis regulator Homo sapiens 146-151 28112004-0 2017 Torulene and torularhodin, protects human prostate stromal cells from hydrogen peroxide-induced oxidative stress damage through the regulation of Bcl-2/Bax mediated apoptosis. Hydrogen Peroxide 70-87 BCL2 apoptosis regulator Homo sapiens 146-151 28112004-4 2017 Finally, pretreatment of cells with carotenoids resulted in the regulation of the mRNA and protein expression of Bcl-2 and Bax in H2O2-exposed prostate stromal cells. Carotenoids 36-47 BCL2 apoptosis regulator Homo sapiens 113-118 28112004-4 2017 Finally, pretreatment of cells with carotenoids resulted in the regulation of the mRNA and protein expression of Bcl-2 and Bax in H2O2-exposed prostate stromal cells. Hydrogen Peroxide 130-134 BCL2 apoptosis regulator Homo sapiens 113-118 28112004-5 2017 The present results indicate that both torulene and torularhodin can protect human prostate stromal cells from oxidative stress damage via Bcl-2/Bax mediated apoptosis. torulene 39-47 BCL2 apoptosis regulator Homo sapiens 139-144 28112004-5 2017 The present results indicate that both torulene and torularhodin can protect human prostate stromal cells from oxidative stress damage via Bcl-2/Bax mediated apoptosis. torularhodin 52-64 BCL2 apoptosis regulator Homo sapiens 139-144 27668844-0 2017 Sorafenib with ASC-J9 synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals. Sorafenib 0-9 BCL2 apoptosis regulator Homo sapiens 99-103 28000897-7 2017 Mechanistically, signal transducer and activator of transcription 3 (Stat3) and its downstream targets Bcl-2, cyclin D1 and c-Myc was inactivated by bortezomib treatment. Bortezomib 149-159 BCL2 apoptosis regulator Homo sapiens 103-108 27493089-12 2017 Also IL-22 increased Bcl-2 expression in SNP-treated RA-FLS, and the effect was reversed by treatment with HO3867 or STA21. (3,5-bis((4-fluorophenyl)methylidene)-1-((1-hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl)piperidin-4-one) 107-113 BCL2 apoptosis regulator Homo sapiens 21-26 27998022-8 2017 Moreover, cells treated with 5-AZA displayed reduced reactive oxygen species (ROS) accumulation, ameliorated superoxide dismutase activity and increased BCL-2/BAX ratio in comparison to control group. Azacitidine 29-34 BCL2 apoptosis regulator Homo sapiens 153-158 27499136-1 2017 Inhibitors of B-cell lymphoma-2 (BCL-2) such as venetoclax (ABT-199) and navitoclax (ABT-263) are clinically explored in several cancer types, including acute myeloid leukemia (AML), to selectively induce apoptosis in cancer cells. venetoclax 48-58 BCL2 apoptosis regulator Homo sapiens 14-31 28376214-11 2017 Conclusions: In this prospective multiple biomarker analysis in men with prostate cancer treated with RT+-ADT, both Ki-67 and bcl2&bax were independently related to early BCDF; however, Ki-67 alone is indicated to be the most clinically meaningful by C-index analysis and is universally available. Adenosine Monophosphate 131-134 BCL2 apoptosis regulator Homo sapiens 126-130 27499136-1 2017 Inhibitors of B-cell lymphoma-2 (BCL-2) such as venetoclax (ABT-199) and navitoclax (ABT-263) are clinically explored in several cancer types, including acute myeloid leukemia (AML), to selectively induce apoptosis in cancer cells. venetoclax 48-58 BCL2 apoptosis regulator Homo sapiens 33-38 27499136-1 2017 Inhibitors of B-cell lymphoma-2 (BCL-2) such as venetoclax (ABT-199) and navitoclax (ABT-263) are clinically explored in several cancer types, including acute myeloid leukemia (AML), to selectively induce apoptosis in cancer cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 60-63 BCL2 apoptosis regulator Homo sapiens 14-31 27916734-2 2017 In the present study, we hypothesized that azithromycin alleviated airway epithelium injury through inhibiting airway epithelium apoptosis via down regulation of caspase-3 and Bax/Bcl2 ratio in vivo and in vitro. Azithromycin 43-55 BCL2 apoptosis regulator Homo sapiens 180-184 27916734-10 2017 In vitro, azithromycin significantly suppressed TGF-beta1-induced BEAS-2B cells apoptosis (P<0.05) and reversed TGF-beta1 elevated Caspase-3 mRNA level and Bax/Bcl-2 ratio (P<0.05). Azithromycin 10-22 BCL2 apoptosis regulator Homo sapiens 163-168 27916734-11 2017 SIGNIFICANCE: Azithromycin is an attractive treatment option for reducing airway epithelial cell apoptosis by improving the imbalance of Bax/Bcl-2 ratio and inhibiting Caspase-3 level in airway epithelium. Azithromycin 14-26 BCL2 apoptosis regulator Homo sapiens 141-146 27499136-1 2017 Inhibitors of B-cell lymphoma-2 (BCL-2) such as venetoclax (ABT-199) and navitoclax (ABT-263) are clinically explored in several cancer types, including acute myeloid leukemia (AML), to selectively induce apoptosis in cancer cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 60-63 BCL2 apoptosis regulator Homo sapiens 33-38 27499136-1 2017 Inhibitors of B-cell lymphoma-2 (BCL-2) such as venetoclax (ABT-199) and navitoclax (ABT-263) are clinically explored in several cancer types, including acute myeloid leukemia (AML), to selectively induce apoptosis in cancer cells. navitoclax 73-83 BCL2 apoptosis regulator Homo sapiens 14-31 27499136-1 2017 Inhibitors of B-cell lymphoma-2 (BCL-2) such as venetoclax (ABT-199) and navitoclax (ABT-263) are clinically explored in several cancer types, including acute myeloid leukemia (AML), to selectively induce apoptosis in cancer cells. navitoclax 73-83 BCL2 apoptosis regulator Homo sapiens 33-38 27499136-1 2017 Inhibitors of B-cell lymphoma-2 (BCL-2) such as venetoclax (ABT-199) and navitoclax (ABT-263) are clinically explored in several cancer types, including acute myeloid leukemia (AML), to selectively induce apoptosis in cancer cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 85-88 BCL2 apoptosis regulator Homo sapiens 14-31 28089635-1 2017 BACKGROUND: Selective BCL2 inhibition with venetoclax has substantial activity in patients with relapsed or refractory chronic lymphocytic leukaemia. venetoclax 43-53 BCL2 apoptosis regulator Homo sapiens 22-26 27499136-1 2017 Inhibitors of B-cell lymphoma-2 (BCL-2) such as venetoclax (ABT-199) and navitoclax (ABT-263) are clinically explored in several cancer types, including acute myeloid leukemia (AML), to selectively induce apoptosis in cancer cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 85-88 BCL2 apoptosis regulator Homo sapiens 33-38 28000873-4 2017 The aim of the present study was to elucidate the role of ROS in mediating the effect of SalB on drug resistance and the correlation with drug resistance-associated protein, P-glycoprotein (P-gp), and apoptosis-associated proteins, B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X (Bax). Reactive Oxygen Species 58-61 BCL2 apoptosis regulator Homo sapiens 232-249 28050764-1 2017 Cutaneous melanoma (CM) cells are resistant to apoptosis, and steroid hormones are involved in this process through regulation of TP53, MDM2, BAX, and BCL2 expression. Steroids 62-78 BCL2 apoptosis regulator Homo sapiens 151-155 28000873-4 2017 The aim of the present study was to elucidate the role of ROS in mediating the effect of SalB on drug resistance and the correlation with drug resistance-associated protein, P-glycoprotein (P-gp), and apoptosis-associated proteins, B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X (Bax). Reactive Oxygen Species 58-61 BCL2 apoptosis regulator Homo sapiens 251-256 27854008-4 2017 Western blots revealed that ethanol preconditioning upregulated expression of the anti-apoptotic protein Bcl-2 and downregulated the pro-apoptotic protein Bax. Ethanol 28-35 BCL2 apoptosis regulator Homo sapiens 105-110 28088561-6 2017 In vitro study showed that mutant human umbilical vein endothelial cells (DD genotype HUVECs) were more susceptible to H2O2-induced apoptosis, which was accompanied with a decreased Bcl-2 expression. Hydrogen Peroxide 119-123 BCL2 apoptosis regulator Homo sapiens 182-187 28000884-8 2017 The expression of some apoptosis genes (Bax and caspase-3) was upregulated after treatment with THIO, while that of the anti-apoptosis gene Bcl-2 was downregulated. Thioridazine 96-100 BCL2 apoptosis regulator Homo sapiens 140-145 27864689-3 2017 In the MTX-BLPD group, EBV+ patients showed lower median CIMP than EBV- patients (2.3 vs. 3.2); they also had significantly lower hypermethylation incidence in four apoptosis-related genes, especially death-associated protein kinase (14 vs. 55 %), higher incidence of massive tumor necrosis (86 vs. 27 %), and lower BCL2 protein expression (19 vs. 86 %) than did the control DLBCL group (P < 0.01 for all). Methotrexate 7-10 BCL2 apoptosis regulator Homo sapiens 316-320 28356941-10 2017 Treatment with ASA+BTZ significantly suppressed the level of Bcl-2, compared with either agent alone. asa+btz 15-22 BCL2 apoptosis regulator Homo sapiens 61-66 28356941-11 2017 ASA may potentiate the antimyeloma activity of BTZ against myeloma cells via suppression of AKT phosphorylation, survivin and Bcl-2, indicating the potential of ASA+BTZ in treating MM, particularly for cases of BTZ-refractory/relapsed MM. Aspirin 0-3 BCL2 apoptosis regulator Homo sapiens 126-131 28356941-11 2017 ASA may potentiate the antimyeloma activity of BTZ against myeloma cells via suppression of AKT phosphorylation, survivin and Bcl-2, indicating the potential of ASA+BTZ in treating MM, particularly for cases of BTZ-refractory/relapsed MM. Bortezomib 47-50 BCL2 apoptosis regulator Homo sapiens 126-131 28356941-0 2017 Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 95-100 28356941-0 2017 Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT. Bortezomib 43-53 BCL2 apoptosis regulator Homo sapiens 95-100 28959845-4 2017 OMT pretreatment could significantly reduce the release of LDH induced by LPS stimulation(P<0.05 or P<0.01), reduce the p38 and JNK phosphorylation, decrease the expression of Caspase-3 and Bax/Bcl-2(P<0.01), and diminish the apoptosis of hippocampal neurons.In conclusion, OMT could reduce the LPS-induced phosphorylation of p38 and JNK, down-regulate the Bax/Bcl-2 ratio and expression of Caspase-3, thus inhibiting apoptosis of hippocampal neurons. omt 0-3 BCL2 apoptosis regulator Homo sapiens 200-205 28245382-5 2017 The expression of BCL-2 protein at 48 h decreased significantly in icaritin-treated group, compared with that in control group (P<0.05), while the expression of BAX and Caspase3 protein at 48 h increased significantly in icaritin-treated group, compared with that in control group (P<0.05). icaritin 67-75 BCL2 apoptosis regulator Homo sapiens 18-23 28245385-8 2017 Meanwhile, isoalantolactone significantly down-regulated the expression of BCL-2 protein and up-regulated the expression of BAX, cytochrome C, cleaved-caspase-9, cleaved-caspase-3, and cleaved-PARP. isoalantolactone 11-27 BCL2 apoptosis regulator Homo sapiens 75-80 28959845-4 2017 OMT pretreatment could significantly reduce the release of LDH induced by LPS stimulation(P<0.05 or P<0.01), reduce the p38 and JNK phosphorylation, decrease the expression of Caspase-3 and Bax/Bcl-2(P<0.01), and diminish the apoptosis of hippocampal neurons.In conclusion, OMT could reduce the LPS-induced phosphorylation of p38 and JNK, down-regulate the Bax/Bcl-2 ratio and expression of Caspase-3, thus inhibiting apoptosis of hippocampal neurons. omt 0-3 BCL2 apoptosis regulator Homo sapiens 370-375 28091656-1 2017 The first examples of p-block coordination complexes of biquinoline, namely [(biq)BCl2]Cl and [(biq)BCl2] , were synthesized and structurally characterized. 2,2'-BIQUINOLINE 56-67 BCL2 apoptosis regulator Homo sapiens 82-86 27921110-4 2017 In this study, we report the use of polyethyleneimine (PEI)-entrapped gold nanoparticles (Au PENPs) modified with an arginine-glycine-aspartic (Arg-Gly-Asp, RGD) peptide via a poly(ethylene glycol) (PEG) spacer as a vector for Bcl-2 (B-cell lymphoma-2) siRNA delivery to glioblastoma cells. aziridine 36-53 BCL2 apoptosis regulator Homo sapiens 227-232 27921110-4 2017 In this study, we report the use of polyethyleneimine (PEI)-entrapped gold nanoparticles (Au PENPs) modified with an arginine-glycine-aspartic (Arg-Gly-Asp, RGD) peptide via a poly(ethylene glycol) (PEG) spacer as a vector for Bcl-2 (B-cell lymphoma-2) siRNA delivery to glioblastoma cells. aziridine 36-53 BCL2 apoptosis regulator Homo sapiens 234-251 27921110-4 2017 In this study, we report the use of polyethyleneimine (PEI)-entrapped gold nanoparticles (Au PENPs) modified with an arginine-glycine-aspartic (Arg-Gly-Asp, RGD) peptide via a poly(ethylene glycol) (PEG) spacer as a vector for Bcl-2 (B-cell lymphoma-2) siRNA delivery to glioblastoma cells. pei 55-58 BCL2 apoptosis regulator Homo sapiens 227-232 27921110-4 2017 In this study, we report the use of polyethyleneimine (PEI)-entrapped gold nanoparticles (Au PENPs) modified with an arginine-glycine-aspartic (Arg-Gly-Asp, RGD) peptide via a poly(ethylene glycol) (PEG) spacer as a vector for Bcl-2 (B-cell lymphoma-2) siRNA delivery to glioblastoma cells. pei 55-58 BCL2 apoptosis regulator Homo sapiens 234-251 27921110-4 2017 In this study, we report the use of polyethyleneimine (PEI)-entrapped gold nanoparticles (Au PENPs) modified with an arginine-glycine-aspartic (Arg-Gly-Asp, RGD) peptide via a poly(ethylene glycol) (PEG) spacer as a vector for Bcl-2 (B-cell lymphoma-2) siRNA delivery to glioblastoma cells. arginine-glycine 117-133 BCL2 apoptosis regulator Homo sapiens 227-232 27921110-4 2017 In this study, we report the use of polyethyleneimine (PEI)-entrapped gold nanoparticles (Au PENPs) modified with an arginine-glycine-aspartic (Arg-Gly-Asp, RGD) peptide via a poly(ethylene glycol) (PEG) spacer as a vector for Bcl-2 (B-cell lymphoma-2) siRNA delivery to glioblastoma cells. arginine-glycine 117-133 BCL2 apoptosis regulator Homo sapiens 234-251 27921110-4 2017 In this study, we report the use of polyethyleneimine (PEI)-entrapped gold nanoparticles (Au PENPs) modified with an arginine-glycine-aspartic (Arg-Gly-Asp, RGD) peptide via a poly(ethylene glycol) (PEG) spacer as a vector for Bcl-2 (B-cell lymphoma-2) siRNA delivery to glioblastoma cells. Arginine 144-147 BCL2 apoptosis regulator Homo sapiens 227-232 27921110-4 2017 In this study, we report the use of polyethyleneimine (PEI)-entrapped gold nanoparticles (Au PENPs) modified with an arginine-glycine-aspartic (Arg-Gly-Asp, RGD) peptide via a poly(ethylene glycol) (PEG) spacer as a vector for Bcl-2 (B-cell lymphoma-2) siRNA delivery to glioblastoma cells. Arginine 144-147 BCL2 apoptosis regulator Homo sapiens 234-251 28091656-1 2017 The first examples of p-block coordination complexes of biquinoline, namely [(biq)BCl2]Cl and [(biq)BCl2] , were synthesized and structurally characterized. 2,2'-BIQUINOLINE 56-67 BCL2 apoptosis regulator Homo sapiens 100-104 27921110-4 2017 In this study, we report the use of polyethyleneimine (PEI)-entrapped gold nanoparticles (Au PENPs) modified with an arginine-glycine-aspartic (Arg-Gly-Asp, RGD) peptide via a poly(ethylene glycol) (PEG) spacer as a vector for Bcl-2 (B-cell lymphoma-2) siRNA delivery to glioblastoma cells. Glycine 148-151 BCL2 apoptosis regulator Homo sapiens 227-232 27921110-4 2017 In this study, we report the use of polyethyleneimine (PEI)-entrapped gold nanoparticles (Au PENPs) modified with an arginine-glycine-aspartic (Arg-Gly-Asp, RGD) peptide via a poly(ethylene glycol) (PEG) spacer as a vector for Bcl-2 (B-cell lymphoma-2) siRNA delivery to glioblastoma cells. Glycine 148-151 BCL2 apoptosis regulator Homo sapiens 234-251 28088783-6 2017 Additionally, alpha-asarone increased ER phosphorylation of bcl-2 facilitating beclin-1 entry to autophagic process. asarone 14-27 BCL2 apoptosis regulator Homo sapiens 60-65 28124680-0 2017 Chemosensitizing Effect of Astragalus Polysaccharides on Nasopharyngeal Carcinoma Cells by Inducing Apoptosis and Modulating Expression of Bax/Bcl-2 Ratio and Caspases. Polysaccharides 38-53 BCL2 apoptosis regulator Homo sapiens 143-148 27810405-2 2017 We report that itraconazole was cytotoxic to MCF-7 and SKBR-3 breast cancer cell lines via apoptosis by altering mitochondria membrane potential, reducing BCL-2 expression and elevating caspase-3 activity. Itraconazole 15-27 BCL2 apoptosis regulator Homo sapiens 155-160 28055968-4 2017 AT101 is a well-established BCL-2 homology domain 3 (BH3) mimetic that we recently demonstrated functions as an iron chelator and thus acts as a hypoxia mimetic. Iron 112-116 BCL2 apoptosis regulator Homo sapiens 28-33 28055968-8 2017 Additionally, this study investigates a potential mechanism of BH3 mimetic-mediated CXCL12 suppression: liberation of a negative CXCL12 transcriptional regulator, poly (ADP-Ribose) polymerase I (PARP1) from its physical interaction with BCL-2. BH 3 63-66 BCL2 apoptosis regulator Homo sapiens 237-242 28124680-9 2017 The level of Bcl-2 decreased, while the levels of Bax, caspase-3, and caspase-9 increased in cisplatin combined with APS treatment compared to cisplatin only treatment. Cisplatin 93-102 BCL2 apoptosis regulator Homo sapiens 13-18 28124680-10 2017 The ratio of Bax to Bcl-2 was significantly enhanced by the APS to cisplatin. Cisplatin 67-76 BCL2 apoptosis regulator Homo sapiens 20-25 28124680-11 2017 CONCLUSIONS APS enhanced the anti-proliferative and apoptotic effect of cisplatin by modulating expression of Bax/Bcl-2 ratio and caspases on nasopharyngeal carcinoma cells and in the xenograft model. Cisplatin 72-81 BCL2 apoptosis regulator Homo sapiens 114-119 27939866-0 2017 Natural pyrethrins induces apoptosis in human hepatocyte cells via Bax- and Bcl-2-mediated mitochondrial pathway. Pyrethrins 8-18 BCL2 apoptosis regulator Homo sapiens 76-81 27939866-5 2017 In addition, the current data indicate that natural pyrethrins cause a reduction in the mitochondrial membrane potential (Deltapsim), increase reactive oxygen species production, and up-regulate the Bax/Bcl-2 expression, leading to the release of cytochrome-c into the cytosol, activation of caspase-9 and caspase-3 and cleavage of poly (ADP-ribose) polymerase (PARP). Pyrethrins 52-62 BCL2 apoptosis regulator Homo sapiens 203-208 27888104-6 2017 Treatment with 10 or 20 muM U0126 followed by CGZ or TGZ induced the down-regulation of ERK1/2 activity and a decrease in Bcl-2 expression accompanied by the collapse of mitochondrial membrane potential, which in turn significantly enhanced CGZ- or TGZ-induced apoptotic cell death. U 0126 28-33 BCL2 apoptosis regulator Homo sapiens 122-127 27939866-6 2017 Taken together, the results indicate that natural pyrethrins has potentially exert adverse effects on human health by inducing caspase-dependent apoptosis in hepatocytes through Bax- and Bcl-2-mediated mitochondrial pathway. Pyrethrins 50-60 BCL2 apoptosis regulator Homo sapiens 187-192 28116660-8 2017 Moreover, 10 and 20 mug/mL Sal B reduced the expression levels of p53, increased the Bcl-2/Bax ratio and inhibited the caspase-3 activity in ox-LDL-treated HUVECs (P<0.05). sal 27-30 BCL2 apoptosis regulator Homo sapiens 85-90 27888104-6 2017 Treatment with 10 or 20 muM U0126 followed by CGZ or TGZ induced the down-regulation of ERK1/2 activity and a decrease in Bcl-2 expression accompanied by the collapse of mitochondrial membrane potential, which in turn significantly enhanced CGZ- or TGZ-induced apoptotic cell death. ciglitazone 46-49 BCL2 apoptosis regulator Homo sapiens 122-127 27888104-6 2017 Treatment with 10 or 20 muM U0126 followed by CGZ or TGZ induced the down-regulation of ERK1/2 activity and a decrease in Bcl-2 expression accompanied by the collapse of mitochondrial membrane potential, which in turn significantly enhanced CGZ- or TGZ-induced apoptotic cell death. Troglitazone 53-56 BCL2 apoptosis regulator Homo sapiens 122-127 28112219-6 2017 Mechanistic studies revealed that c-Myb knockdown increased cellular levels of reactive oxygen species and decreased Bcl-2 expression, both of which are likely to be responsible for the increased sensitivity of c-Myb knockdown cells to neomycin. Neomycin 236-244 BCL2 apoptosis regulator Homo sapiens 117-122 28117722-8 2017 alpha-T at nanomolar and micromolar concentrations prevented a great increase of the proapoptotic to antiapoptotic proteins (Bax/Bcl-2) ratio, elicited by neuron exposure to H2O2. alpha-Tocopherol 0-7 BCL2 apoptosis regulator Homo sapiens 129-134 28117722-8 2017 alpha-T at nanomolar and micromolar concentrations prevented a great increase of the proapoptotic to antiapoptotic proteins (Bax/Bcl-2) ratio, elicited by neuron exposure to H2O2. Hydrogen Peroxide 174-178 BCL2 apoptosis regulator Homo sapiens 129-134 28102286-0 2017 Chelerythrine down regulates expression of VEGFA, BCL2 and KRAS by arresting G-Quadruplex structures at their promoter regions. chelerythrine 0-13 BCL2 apoptosis regulator Homo sapiens 50-54 28241697-13 2017 The protein expressions of bax and caspase3 significantly increased while bcl-2 significantly decreased treated with PQ compared with control group (P<0.05). Primaquine 117-119 BCL2 apoptosis regulator Homo sapiens 74-79 28102286-1 2017 A putative anticancer plant alkaloid, Chelerythrine binds to G-quadruplexes at promoters of VEGFA, BCL2 and KRAS genes and down regulates their expression. chelerythrine 38-51 BCL2 apoptosis regulator Homo sapiens 99-103 28102286-8 2017 Binding of Chelerythrine with BCL2, VEGFA and KRAS genes involved in evasion, angiogenesis and self sufficiency of cancer cells provides a new insight for the development of future therapeutics against cancer. chelerythrine 11-24 BCL2 apoptosis regulator Homo sapiens 30-34 28079887-1 2017 The concept of using BH3 mimetics as anticancer agents has been substantiated by the efficacy of selective drugs, such as Navitoclax and Venetoclax, in treating BCL-2-dependent haematological malignancies. BH 3 21-24 BCL2 apoptosis regulator Homo sapiens 161-166 27956235-7 2017 And we also observed that VPA up-regulated the active caspase-3 and Bcl-2/Bax ratio and inhibited cytochrome c (Cyt c) release from mitochondria to the cytoplasm. Valproic Acid 26-29 BCL2 apoptosis regulator Homo sapiens 68-73 28079887-1 2017 The concept of using BH3 mimetics as anticancer agents has been substantiated by the efficacy of selective drugs, such as Navitoclax and Venetoclax, in treating BCL-2-dependent haematological malignancies. navitoclax 122-132 BCL2 apoptosis regulator Homo sapiens 161-166 28079887-1 2017 The concept of using BH3 mimetics as anticancer agents has been substantiated by the efficacy of selective drugs, such as Navitoclax and Venetoclax, in treating BCL-2-dependent haematological malignancies. venetoclax 137-147 BCL2 apoptosis regulator Homo sapiens 161-166 28075415-6 2017 Some lactic acid bacteria (LAB) strains have ability to inhibit the growth of the colorectal cancer cell line HT-29 Bax/Bcl-2 pathway or NO production. Lactic Acid 5-16 BCL2 apoptosis regulator Homo sapiens 120-125 28056970-3 2017 METHODS AND RESULTS: Q-PCR and Western blot results showed that alcohol exposure increased gene and active forms of caspase-3 and caspase-8, while decreased gene and protein of bcl-2. Alcohols 64-71 BCL2 apoptosis regulator Homo sapiens 177-182 28061782-5 2017 RESULTS: Three cases of DHL were detected: two with translocations of MYC and BCL2 and one with translocations of MYC and BCL6, all leading to death in less than six months. Cysteamine 24-27 BCL2 apoptosis regulator Homo sapiens 78-82 28219227-2 2017 Methods: Drug-resistant myeloma cell-line RPMI8226/DOX was established by culturing RPMI8226 cells with continuous low concentration and intermittent gradually increasing concentration of doxorubicin in vitro; The levels of miR155 mRNA were measured by qRT-PCR, and both proteins FOXO3a and BCL-2 expressions were detected by Western blot in cell-lines RPMI8226/S and RPMI8226/Dox. rpmi8226 42-50 BCL2 apoptosis regulator Homo sapiens 291-296 28219227-2 2017 Methods: Drug-resistant myeloma cell-line RPMI8226/DOX was established by culturing RPMI8226 cells with continuous low concentration and intermittent gradually increasing concentration of doxorubicin in vitro; The levels of miR155 mRNA were measured by qRT-PCR, and both proteins FOXO3a and BCL-2 expressions were detected by Western blot in cell-lines RPMI8226/S and RPMI8226/Dox. Doxorubicin 51-54 BCL2 apoptosis regulator Homo sapiens 291-296 28056970-6 2017 In vitro experiments demonstrated that curcumin treatment could reverse the up-regulation of active forms of caspase-3 and caspase-8, and down-regulation of bcl-2 induced by alcohol treatment. Alcohols 174-181 BCL2 apoptosis regulator Homo sapiens 157-162 28056970-4 2017 ChIP assay results showed that, alcohol exposure increased the acetylation of histone H3K9 near the promoter region of caspase-3 and caspase-8, and decreased the acetylation of histone H3K9 near the promoter region of bcl-2. Alcohols 32-39 BCL2 apoptosis regulator Homo sapiens 218-223 28067784-6 2017 Incubation of SLT (50 microg/mL) increased superoxide dismutase (SOD) activity and suppressed the H2O2-enhanced Bax/Bcl-2 ratio and cleaved caspase-3 expression. Hydrogen Peroxide 98-102 BCL2 apoptosis regulator Homo sapiens 116-121 28056970-6 2017 In vitro experiments demonstrated that curcumin treatment could reverse the up-regulation of active forms of caspase-3 and caspase-8, and down-regulation of bcl-2 induced by alcohol treatment. Curcumin 39-47 BCL2 apoptosis regulator Homo sapiens 157-162 28046018-8 2017 Joint application of 3-MA or Atg7 siRNA enhanced the cell growth inhibition and apoptosis effects of NVP-AEW541 by arresting cells at G1/G0 phase and increasing Bax expression and decreasing that of Bcl-2. 3-methyladenine 21-25 BCL2 apoptosis regulator Homo sapiens 199-204 28070171-8 2017 Casticin also induced G0/G1 arrest and mitochondrial-related apoptosis by upregulating Bax, cleaved caspase-3, cleaved caspase-9 and cleaved poly ADP-ribose polymerase expression, and by downregulating Bcl-2 expression. casticin 0-8 BCL2 apoptosis regulator Homo sapiens 202-207 27935869-9 2017 Use of the Bcl-2 inhibitor ABT-737 showed that ABT-737 binds to Bcl-2 but not Mcl-1 and releases Bax/Bak which leads to cell apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 27-30 BCL2 apoptosis regulator Homo sapiens 11-16 27935869-9 2017 Use of the Bcl-2 inhibitor ABT-737 showed that ABT-737 binds to Bcl-2 but not Mcl-1 and releases Bax/Bak which leads to cell apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 27-30 BCL2 apoptosis regulator Homo sapiens 64-69 27935869-9 2017 Use of the Bcl-2 inhibitor ABT-737 showed that ABT-737 binds to Bcl-2 but not Mcl-1 and releases Bax/Bak which leads to cell apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 47-50 BCL2 apoptosis regulator Homo sapiens 11-16 27935869-9 2017 Use of the Bcl-2 inhibitor ABT-737 showed that ABT-737 binds to Bcl-2 but not Mcl-1 and releases Bax/Bak which leads to cell apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 47-50 BCL2 apoptosis regulator Homo sapiens 64-69 27935869-12 2017 The combination of cisplatin and Bcl-2 family protein inhibitor could be a strategy for the treatment of cisplatin-resistant ovarian cancer. Cisplatin 105-114 BCL2 apoptosis regulator Homo sapiens 33-38 27935869-0 2017 The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer. Cisplatin 75-84 BCL2 apoptosis regulator Homo sapiens 19-24 27935869-2 2017 The aim of this study was to examine the potential involvement of the Bcl-2 family proteins in AKT-regulated cell survival in response to cisplatin treatment. Cisplatin 138-147 BCL2 apoptosis regulator Homo sapiens 70-75 28071969-3 2017 In the present study, we demonstrated that curcumin induced G2/M cell cycle arrest and apoptosis by increasing the expression levels of cleaved caspase-3, cleaved PARP and decreasing the expression of BCL-2 in U937 human leukemic cells but not in K562 cells. Curcumin 43-51 BCL2 apoptosis regulator Homo sapiens 201-206 28123844-6 2017 Further mechanism studies showed that the combined treatment of melatonin and cisplatin enhanced the cleavage of caspase-3, caspase-9 and poly-(ADP-ribose) polymerase (PARP), decreased the expression of Bcl-2 and p-IKKalpha/beta, suppressed the nuclear translocation of NF-kappaB p50/p65 proteins, and abrogated the binding of p65 to COX-2 promoter, thereby inhibiting COX-2 expression. Melatonin 64-73 BCL2 apoptosis regulator Homo sapiens 203-208 28231749-7 2017 Furthermore, total flavonoids and total tannins increased the expression of Bax, decreased the expression of Bcl-2, and promoted cytochrome [Formula: see text] release. Flavonoids 19-29 BCL2 apoptosis regulator Homo sapiens 109-114 28567457-6 2017 Linalool decreased mitochondrial oxygen consumption rate, increased the expression of Bax and Bak, reduced the expression of Bcl-2 and Bcl-xl, and increased the activities of caspase 3 and caspase 9, leading to increase of apoptosis. linalool 0-8 BCL2 apoptosis regulator Homo sapiens 125-130 28385078-9 2017 PPEE promoted apoptosis in 143B cell via caspase activation, increased Bax/Bcl-2 ratio and PARP cleavage. ppee 0-4 BCL2 apoptosis regulator Homo sapiens 75-80 28123844-6 2017 Further mechanism studies showed that the combined treatment of melatonin and cisplatin enhanced the cleavage of caspase-3, caspase-9 and poly-(ADP-ribose) polymerase (PARP), decreased the expression of Bcl-2 and p-IKKalpha/beta, suppressed the nuclear translocation of NF-kappaB p50/p65 proteins, and abrogated the binding of p65 to COX-2 promoter, thereby inhibiting COX-2 expression. Cisplatin 78-87 BCL2 apoptosis regulator Homo sapiens 203-208 26478521-8 2017 In addition, DHTI induced apoptosis of 143B cells through caspase pathways to activate caspase-3, caspase-8, caspase-9, Bax, and PARP cleavage but reduce the expression of Bcl-2. dhts 13-17 BCL2 apoptosis regulator Homo sapiens 172-177 28769005-7 2017 The remarkable reduction in the ratio of Bcl-2/Bax was also observed in oxymatrine treated breast cancer cells. oxymatrine 72-82 BCL2 apoptosis regulator Homo sapiens 41-46 27911011-1 2017 Based on a known selective Mcl-1 inhibitor, 6-chloro-3-(3-(4-chloro-3,5-dimethylphenoxy)propyl)-1H-indole-2-carboxylic acid, we applied a fragment-based approach to obtain new molecules that extended into the p1 pocket of the BH3 groove and then exhibited binding selectivity for the Mcl-1 over the Bcl-2 protein. CHEMBL2314209 44-123 BCL2 apoptosis regulator Homo sapiens 299-304 27585868-7 2017 Furthermore, we detected elevated phosphorylation levels of Bcl-2 at serine-70 and Akt at serine-473 and threonine-308, which are related to cell survival, in the cells expressing SR-WT and SR-Q155D. Serine 69-75 BCL2 apoptosis regulator Homo sapiens 60-65 27585868-7 2017 Furthermore, we detected elevated phosphorylation levels of Bcl-2 at serine-70 and Akt at serine-473 and threonine-308, which are related to cell survival, in the cells expressing SR-WT and SR-Q155D. Serine 90-96 BCL2 apoptosis regulator Homo sapiens 60-65 28044934-5 2017 Results &amp; Conclusion: Studies on cells revealed that 2 (i) demonstrated a high antiproliferative effect, which was higher toward HeLa and C6 cancer cells than toward healthy Vero cells; (ii) impaired the migration of HeLa cells; (iii) altered the P53-Bcl-2 ratio in favor of apoptosis; (iv) strongly bound to DNA/BSA macromolecules; and (v) inhibited human topoisomerase I and KpnI or BamHI restriction endonucleases. Adenosine Monophosphate 13-16 BCL2 apoptosis regulator Homo sapiens 259-264 27639965-8 2017 The incubation with Bcl-2 21 changes the distribution of SERCA3b during sucrose density gradient centrifugation, likely as the result of Bcl-2 21-induced conformational change of SERCA3b. Sucrose 72-79 BCL2 apoptosis regulator Homo sapiens 20-25 27639965-8 2017 The incubation with Bcl-2 21 changes the distribution of SERCA3b during sucrose density gradient centrifugation, likely as the result of Bcl-2 21-induced conformational change of SERCA3b. Sucrose 72-79 BCL2 apoptosis regulator Homo sapiens 137-142 27639965-11 2017 Furthermore, overexpression of Bcl-2 reduced fluorescein isothiocyanate (FITC) labeling of SERCA3b. Fluorescein-5-isothiocyanate 45-71 BCL2 apoptosis regulator Homo sapiens 31-36 27639965-11 2017 Furthermore, overexpression of Bcl-2 reduced fluorescein isothiocyanate (FITC) labeling of SERCA3b. Fluorescein-5-isothiocyanate 73-77 BCL2 apoptosis regulator Homo sapiens 31-36 27889234-15 2017 Moreover, ICA showed strong binding avidity for Bcl-2 protein in silico, which could result in induction of apoptosis. isocyanic acid 10-13 BCL2 apoptosis regulator Homo sapiens 48-53 28540295-14 2017 As a result, the Bax/Bcl-2 ratio increased after treatment with ioversol. ioversol 64-72 BCL2 apoptosis regulator Homo sapiens 21-26 28884131-0 2017 MiR-219-5p Inhibits the Growth and Metastasis of Malignant Melanoma by Targeting BCL-2. mir-219-5p 0-10 BCL2 apoptosis regulator Homo sapiens 81-86 26822402-4 2017 The results showed that NaHS treatment significantly improved brain edema and neurobehavioral function, and attenuated neuronal cell death in the prefrontal cortex, associated with a decrease in Bax/Bcl-2 ratio and suppression of caspase-3 activation at 48 h after SAH. sodium bisulfide 24-28 BCL2 apoptosis regulator Homo sapiens 199-204 28091910-2 2017 Incubation of cells in atmosphere with carbon monoxide in the presence of recombinant IL-2 was accompanied by accumulation of Bcl-2 protein with simultaneous decrease of survivin content. Carbon Monoxide 39-54 BCL2 apoptosis regulator Homo sapiens 126-131 27878359-13 2017 The results indicated that GAS5 regulated the chemotherapy resistance to doxorubicin via Bcl2 partly. Doxorubicin 73-84 BCL2 apoptosis regulator Homo sapiens 89-93 28091910-3 2017 It was concluded that carbon monoxide plays a role in the dysregulation of apoptosis of human blood lymphocytes Bcl-2 (i.e. CO inhibits the proapoptotic effect of recombinant IL-2). Carbon Monoxide 22-37 BCL2 apoptosis regulator Homo sapiens 112-117 28803233-8 2017 Both oils induced a caspase-dependent and -independent apoptosis in MCF-7 and MDA-MB-231 cells, and altered the levels of Bcl-2 and Bax proteins. Oils 5-9 BCL2 apoptosis regulator Homo sapiens 122-127 27689871-0 2017 Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling. BH 3 96-99 BCL2 apoptosis regulator Homo sapiens 29-34 27689871-9 2017 Using novel BH3-mimetics, we found that naive and memory B-cells depend on BCL-2, GC cells predominantly on MCL-1, whereas plasma cells need both BCL-XL and MCL-1 for survival. BH 3 12-15 BCL2 apoptosis regulator Homo sapiens 75-80 28222424-8 2017 Treatment of Ishikawa cells with 1,25(OH)2D3 (100 nM) further triggered apoptosis, an effect paralleled by decreased phosphorylation of AKT and FOXO3A as well as decreased abundance of BCL-2. Calcitriol 33-44 BCL2 apoptosis regulator Homo sapiens 185-190 28222424-10 2017 Despite stimulation of glycolysis, 1,25(OH)2D3 stimulates slightly but significantly suicidal cell death, an effect presumably in part due to decreased activation of AKT with decreased inhibition of pro-apoptotic transcription factor FOXO3A and downregulation of the anti-apoptotic protein BCL-2. Calcitriol 35-46 BCL2 apoptosis regulator Homo sapiens 290-295 28618418-8 2017 In addition, upregulation of miR-7 increases the sensitivity of LA cells to CDDP via induction of apoptosis by targeting Bcl-2. Cisplatin 76-80 BCL2 apoptosis regulator Homo sapiens 121-126 28118642-9 2017 MTX-induced cell apoptosis of PPTC was confirmed by increased expression of Fas, FasL, Bax, cleaved caspases 3, 7, 8, and 9, and decreased expression of Bcl-2. Methotrexate 0-3 BCL2 apoptosis regulator Homo sapiens 153-158 28118642-9 2017 MTX-induced cell apoptosis of PPTC was confirmed by increased expression of Fas, FasL, Bax, cleaved caspases 3, 7, 8, and 9, and decreased expression of Bcl-2. S,N,N'-tripropylthiocarbamate 30-34 BCL2 apoptosis regulator Homo sapiens 153-158 27806433-0 2017 Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies. BH 3 20-23 BCL2 apoptosis regulator Homo sapiens 10-14 27806433-3 2017 Since then, a series of high affinity small organic molecules that inhibits the interaction of BCL2 with the apoptotic machinery, the so-called BH3-mimetics, have been developed. BH 3 144-147 BCL2 apoptosis regulator Homo sapiens 95-99 27774879-9 2017 In silico docking of NJRE marker compounds: oroselol, jatamansinol, nardostachysin, jatamansinone and nardosinone have revealed their synergistic and multi-targeted interactions with Vestigial endothelial growth factor receptor 2 (VEGFR2), Cyclin dependent kinase 2 (CDK2), B-cell lymphoma 2 (BCL2) and Epidermal growth factor receptor (EGFR). nardostachysin 68-82 BCL2 apoptosis regulator Homo sapiens 274-291 28714389-8 2017 Treatment with PDp could effectively ameliorated Abeta1-40 induced neurotoxicity and attenuates ROS generation that mediates apoptotic signaling through Bcl-2, Bax, Caspase-3 activity and cytochrome c in the cells. Reactive Oxygen Species 96-99 BCL2 apoptosis regulator Homo sapiens 153-158 27774879-9 2017 In silico docking of NJRE marker compounds: oroselol, jatamansinol, nardostachysin, jatamansinone and nardosinone have revealed their synergistic and multi-targeted interactions with Vestigial endothelial growth factor receptor 2 (VEGFR2), Cyclin dependent kinase 2 (CDK2), B-cell lymphoma 2 (BCL2) and Epidermal growth factor receptor (EGFR). nardostachysin 68-82 BCL2 apoptosis regulator Homo sapiens 293-297 27774879-9 2017 In silico docking of NJRE marker compounds: oroselol, jatamansinol, nardostachysin, jatamansinone and nardosinone have revealed their synergistic and multi-targeted interactions with Vestigial endothelial growth factor receptor 2 (VEGFR2), Cyclin dependent kinase 2 (CDK2), B-cell lymphoma 2 (BCL2) and Epidermal growth factor receptor (EGFR). nardosinone 102-113 BCL2 apoptosis regulator Homo sapiens 274-291 27774879-9 2017 In silico docking of NJRE marker compounds: oroselol, jatamansinol, nardostachysin, jatamansinone and nardosinone have revealed their synergistic and multi-targeted interactions with Vestigial endothelial growth factor receptor 2 (VEGFR2), Cyclin dependent kinase 2 (CDK2), B-cell lymphoma 2 (BCL2) and Epidermal growth factor receptor (EGFR). nardosinone 102-113 BCL2 apoptosis regulator Homo sapiens 293-297 27903235-11 2017 Moreover, the coadministration of Epo and H2O2 resulted in a decrease of cell numbers, as well as Bcl-2 expression. Hydrogen Peroxide 42-46 BCL2 apoptosis regulator Homo sapiens 98-103 29210647-13 2017 Further study showed that alpha-mangostin increased the ratio of Bax/Bcl-2 and increased the ROS generation in MH7A cells. mangostin 26-41 BCL2 apoptosis regulator Homo sapiens 69-74 29210647-14 2017 CONCLUSION: alpha-Mangostin induces the apoptosis of MH7A cells through increasing ROS accumulation and the ratio of Bax/Bcl-2, suggesting that alpha-mangostin should be benefit to the therapy of RA. mangostin 12-27 BCL2 apoptosis regulator Homo sapiens 121-126 29210647-14 2017 CONCLUSION: alpha-Mangostin induces the apoptosis of MH7A cells through increasing ROS accumulation and the ratio of Bax/Bcl-2, suggesting that alpha-mangostin should be benefit to the therapy of RA. mangostin 144-159 BCL2 apoptosis regulator Homo sapiens 121-126 28653191-4 2017 Thus, loss of miR-15/16 leads to overexpression of BCL2 that can be targeted by the new drug, venetoclax, that was recently approved by the FDA for the treatment of aggressive CLLs. mir-15 14-20 BCL2 apoptosis regulator Homo sapiens 51-55 28653191-4 2017 Thus, loss of miR-15/16 leads to overexpression of BCL2 that can be targeted by the new drug, venetoclax, that was recently approved by the FDA for the treatment of aggressive CLLs. venetoclax 94-104 BCL2 apoptosis regulator Homo sapiens 51-55 28487599-8 2017 Furthermore, rapamycin, a specific inhibitor of the mTOR/p70S6K signaling pathway, decreased the levels of Ki-67 and Bcl-2/Bax ratio, inhibited cell proliferation, and promoted apoptosis in EC cells. Sirolimus 13-22 BCL2 apoptosis regulator Homo sapiens 117-122 27716527-8 2017 The PTX-M remarkably increased the upregulation of Bax, caspase-3, caspase-9, and PARP-1 expression and downregulated the Bcl-2 expression in K562 cancer cells. Paclitaxel 4-7 BCL2 apoptosis regulator Homo sapiens 122-127 27960113-7 2017 Briefly, these results suggest that tebufenozide- induces cell cycle arrest and apoptosis through activating p53 protein in a Bax- and Bcl-2-triggered mitochondrial pathway. tebufenozide 36-48 BCL2 apoptosis regulator Homo sapiens 135-140 26494474-6 2017 Also As2 O3 plus DTT upregulated Bax and Bak, downregulated Bcl-2 and p53, caused a loss of mitochondria membrane potential in oral cancer cells. Dithiothreitol 17-20 BCL2 apoptosis regulator Homo sapiens 60-65 29256858-7 2017 Further, oridonin-induced apoptosis was mediated by the mitochondrial pathway in NPC cells, which was confirmed by the loss of MMP, downregulation of anti-apoptotic Bcl-2 family protein Mcl-1 and Bcl-2, upregulation of pro-apoptotic Bcl-2 family member Bax, and activation of caspase-3 and PARP. oridonin 9-17 BCL2 apoptosis regulator Homo sapiens 165-170 29333179-4 2017 Liensinine treatment led to the increased Bax/Bcl-2 ratio, activation of caspase-3, and subsequent cleavage of PARP. liensinine 0-10 BCL2 apoptosis regulator Homo sapiens 46-51 28785288-3 2017 NnV strongly induced cytotoxicity of HepG2 cells through apoptotic cell death, as demonstrated by alterations of chromatic morphology, activation of procaspase-3, and an increase in the Bax/Bcl-2 ratio. (1r,5as,6r)-1,2,5,5a,6,7-Hexahydrophenazine-1,6-Dicarboxylic Acid 0-3 BCL2 apoptosis regulator Homo sapiens 190-195 29081818-11 2017 Protein expression of Bax and LC3II was upregulated, while Bcl2 was downregulated in the high dosing groups of curcumin. Curcumin 111-119 BCL2 apoptosis regulator Homo sapiens 59-63 29256858-7 2017 Further, oridonin-induced apoptosis was mediated by the mitochondrial pathway in NPC cells, which was confirmed by the loss of MMP, downregulation of anti-apoptotic Bcl-2 family protein Mcl-1 and Bcl-2, upregulation of pro-apoptotic Bcl-2 family member Bax, and activation of caspase-3 and PARP. oridonin 9-17 BCL2 apoptosis regulator Homo sapiens 196-201 29256858-7 2017 Further, oridonin-induced apoptosis was mediated by the mitochondrial pathway in NPC cells, which was confirmed by the loss of MMP, downregulation of anti-apoptotic Bcl-2 family protein Mcl-1 and Bcl-2, upregulation of pro-apoptotic Bcl-2 family member Bax, and activation of caspase-3 and PARP. oridonin 9-17 BCL2 apoptosis regulator Homo sapiens 196-201 26705936-8 2017 However, only tyrosine phosphorylated STAT3 was detected in the nucleus, which induced upregulation of Bcl-2 and downregulation of Bax and Bak. Tyrosine 14-22 BCL2 apoptosis regulator Homo sapiens 103-108 28966729-12 2017 Western blot data showed that ATO upregulated the expression of caspase 3, Bax, and cytochrome C, and down-regulated the expression of Bcl-2. Arsenic Trioxide 30-33 BCL2 apoptosis regulator Homo sapiens 135-140 28365943-10 2017 CONCLUSION: Papaverine showed selective antitumor properties against PC-3 human prostate cancer cells by inducing early and late apoptosis, sub-G1 cell cycle arrest, modulation of apoptosis-related proteins like Bcl-2, Bax, Bid, XIAP and cytochrome C along with downregulation of NFkB, PI3K/Akt signalling pathway. Papaverine 12-22 BCL2 apoptosis regulator Homo sapiens 212-217 27930969-4 2017 Moreover, rhapontin prevented DSS-induced impairment in the colon epithelium barrier by increasing the expression of tight junction proteins, such as zonula occludens-1(ZO-1) and occludin, and reduced apoptosis-associated protein (cyt-c, the ratio of bcl-2/bax and cleaved-capase9) expression in the colon. dss 30-33 BCL2 apoptosis regulator Homo sapiens 251-256 27909720-11 2017 Importantly, Tet treatment significantly repressed the nuclear translocation and expression of beta-catenin and induced apoptosis in GSLCs, as indicated in part by the upregulation of Bax, the cleavage of PARP and the downregulation of Bcl-2. tetrandrine 13-16 BCL2 apoptosis regulator Homo sapiens 236-241 28496480-8 2017 The dose dependent down regulation of Bcl-2 in treated cells demonstrated that saponin fraction can trigger intrinsic apoptotic pathway in cancer cells. Saponins 79-86 BCL2 apoptosis regulator Homo sapiens 38-43 27088439-0 2017 Differentiating responses of lung cancer cell lines to Doxorubicin exposure: in vitro Raman micro spectroscopy, oxidative stress and bcl-2 protein expression. Doxorubicin 55-66 BCL2 apoptosis regulator Homo sapiens 133-138 27664163-5 2017 Furthermore, we demonstrated that Bax/Bcl-2 ratio as well as caspase-3 activation, as the executioner of apoptosis, noticeably decreased by CsA pretreatment. Cyclosporine 140-143 BCL2 apoptosis regulator Homo sapiens 38-43 27510267-0 2017 Neuroserpin Attenuates H2O2-Induced Oxidative Stress in Hippocampal Neurons via AKT and BCL-2 Signaling Pathways. Hydrogen Peroxide 23-27 BCL2 apoptosis regulator Homo sapiens 88-93 28485162-6 2017 Furthermore, by Western blotting with antibodies specific for EGFR, Erk 1/2 (p-Erk 1/2), Mek (p-Mek), Bcl-2, and Bax, it was demonstrated that EGCG could reduce the expression of EGFR, inhibit phosphorylation of Erk 1/2 and Mek, downregulate Bcl-2, and upregulate Bax. epigallocatechin gallate 143-147 BCL2 apoptosis regulator Homo sapiens 102-107 28010928-3 2017 Total triterpenes induced apoptosis in MCF-7 cells by down-regulating the levels of cyclin D1, Bcl-2, Bcl-xL and also by up-regulating the levels of Bax and caspase-9. Triterpenes 6-17 BCL2 apoptosis regulator Homo sapiens 95-100 28485162-6 2017 Furthermore, by Western blotting with antibodies specific for EGFR, Erk 1/2 (p-Erk 1/2), Mek (p-Mek), Bcl-2, and Bax, it was demonstrated that EGCG could reduce the expression of EGFR, inhibit phosphorylation of Erk 1/2 and Mek, downregulate Bcl-2, and upregulate Bax. epigallocatechin gallate 143-147 BCL2 apoptosis regulator Homo sapiens 242-247 28123519-9 2017 Furthermore, the overexpression of Bax, and the downregulation of P-gP, P53 and Bcl-2 observed demonstrated the potential mechanism(s) of NaI131 and GA intervention. nai131 138-144 BCL2 apoptosis regulator Homo sapiens 80-85 27816613-4 2017 By using morphological examination, flow cytometry, and mitochondrial membrane potential (DeltaYm) measurement, we confirmed that exposure to TDCIPP caused apoptosis accompanied by the activation of apoptosis-related genes (e.g. Bax and Bcl-2) and caspase 3 protein in SH-SY5Y cells. tris(1,3-dichloro-2-propyl)phosphate 142-148 BCL2 apoptosis regulator Homo sapiens 237-242 27878299-15 2017 Flow cytometric analysis showed that the Bcl-2 expression levels in the CSQAH-treated groups were downregulated, while Bax expression levels were upregulated, and the effects were dosage-dependent. csqah 72-77 BCL2 apoptosis regulator Homo sapiens 41-46 27819395-3 2017 Here, we describe the mechanisms through which TCA affects human astrocytes, demonstrating: a late apoptotic process, mediated by caspases 9 and 3 activation, involving the Bcl2-Bak-axis; an early and late p38 MAPK activation; an interference with the IL-8 and MCP-1 secretory response. Trichloroacetic Acid 47-50 BCL2 apoptosis regulator Homo sapiens 173-177 28717410-4 2017 FSCP also prevent cell apoptosis by repressing Bax expression, caspase-3 activity, and cytochrome c release and by upregulating Bcl-2 protein levels in CoCl2- or TNF-alpha-stimulated HaCaT cells. cobaltous chloride 152-157 BCL2 apoptosis regulator Homo sapiens 128-133 28123591-8 2017 The results of the xenograft assay indicated that isoimperatorin significantly inhibited the growth of SGC-7901 cell-induced tumor in vivo by increasing the expression levels of pro-apoptotic proteins (Bax, c-caspase-3 and c-caspase-9) and reducing the expression levels of anti-apoptotic proteins (Survivin and Bcl-2) without adverse effects on the increasing body weight of nude mice. isoimperatorin 50-64 BCL2 apoptosis regulator Homo sapiens 312-317 28690763-7 2017 Moreover, tanshinone IIA can inhibit glutamate-induced apoptosis through regulation of apoptosis-related protein expression and MAPK activation, including elevation of Bcl-2 protein level, decrease in Bax and cleaved caspase-3 levels, and suppression of JNK and p38 MAPK activation. tanshinone 10-24 BCL2 apoptosis regulator Homo sapiens 168-173 28690763-7 2017 Moreover, tanshinone IIA can inhibit glutamate-induced apoptosis through regulation of apoptosis-related protein expression and MAPK activation, including elevation of Bcl-2 protein level, decrease in Bax and cleaved caspase-3 levels, and suppression of JNK and p38 MAPK activation. Glutamic Acid 37-46 BCL2 apoptosis regulator Homo sapiens 168-173 28630659-4 2017 Furthermore, prolonged Hcy treatment increased the expression of NOX4 and the production of intracellular ROS but decreased the ratio of Bcl-2/Bax and mitochondrial membrane potential (MMP), resulting in the leakage of cytochrome c and activation of caspase-3. Homocysteine 23-26 BCL2 apoptosis regulator Homo sapiens 137-142 28170185-4 2017 Iron oxide cores were sequentially coated with branched polyethyleneimine, minicircle plasmid encoding green fluorescent protein and Bcl-2, and poly-beta-amino ester. ferric oxide 0-10 BCL2 apoptosis regulator Homo sapiens 133-138 28367185-10 2017 CONCLUSION: Ferulic acid could significantly descend osteosarcoma cell viability through the promoting apoptosis pathway in which FA activates both caspase-3 and Bax and inactivates Bcl-2. ferulic acid 12-24 BCL2 apoptosis regulator Homo sapiens 182-187 28356907-5 2017 We show that protein levels of Bcl-2 and ERK were reduced in the MPP+-treated group compared with the control group. mangion-purified polysaccharide (Candida albicans) 65-69 BCL2 apoptosis regulator Homo sapiens 31-36 28356907-6 2017 This effect was observed to be reversed upon treatment with 2,4-thiazolidinedione, as Bcl-2 and ERK expression levels were increased. 2,4-thiazolidinedione 60-81 BCL2 apoptosis regulator Homo sapiens 86-91 28240161-6 2017 Meanwhile, we confirmed that DHM showed antitumor activity by regulating the activation of the p53-dependent pathways (MDM2, P-MDM2, BAX and Bcl-2). Dihydromorphine 29-32 BCL2 apoptosis regulator Homo sapiens 141-146 28255307-7 2017 Compared with MSC, MSC-HO-1 significantly attenuated H2O2-induced injury of RGC-5, including decrease in cellular ROS level and apoptosis, activation of antiapoptotic proteins p-Akt and Bcl-2, and blockage of proapoptotic proteins cleaved caspase 3 and Bax. Hydrogen Peroxide 53-57 BCL2 apoptosis regulator Homo sapiens 186-191 28766546-3 2017 The majority of DHL is represented by s-MYC/BCL2 cases. Cysteamine 16-19 BCL2 apoptosis regulator Homo sapiens 44-48 27697610-4 2016 The decrease in Mcl-1 was associated with protein translation inhibition and identified as a crucial factor in Thapsigargin sensitivity, since it was the only Bcl-2 family protein differentially modified between sensitive and resistant myeloma cells. Thapsigargin 111-123 BCL2 apoptosis regulator Homo sapiens 159-164 27863383-5 2016 Next, by using co-culture system of myeloma and adipocytes, and pharmacologic enhancement of leptin, we found that increased growth of myeloma cells and reduced toxicity of bortezomib were best observed at 50 ng/ml of leptin, along with increased expression of cyclinD1, Bcl-2 and decreased caspase-3 expression. Bortezomib 173-183 BCL2 apoptosis regulator Homo sapiens 271-276 28082995-4 2016 Total peroxidase activity was lower in Bcl-2 21 treated microspore cultures at 96 h of treatment compared to control and Ac-DEVD-CHO. acetyl-aspartyl-glutamyl-valyl-aspartal 121-132 BCL2 apoptosis regulator Homo sapiens 39-44 28082995-6 2016 Bcl-2 21 scavenged approximately 50% hydroxyl radical (HO ) formed, whereas Ac-DEVD-CHO scavenged approximately 20% of HO . Hydroxyl Radical 37-53 BCL2 apoptosis regulator Homo sapiens 0-5 28082995-6 2016 Bcl-2 21 scavenged approximately 50% hydroxyl radical (HO ) formed, whereas Ac-DEVD-CHO scavenged approximately 20% of HO . Hydroxyl Radical 55-57 BCL2 apoptosis regulator Homo sapiens 0-5 27693384-2 2016 Previously, we have described characterization of a novel BCL2 inhibitor, Disarib, which showed selective cytotoxicity in BCL2 "high" cancer cells and CLL patient cells. disarib 74-81 BCL2 apoptosis regulator Homo sapiens 58-62 27729282-12 2016 In addition, clausenidin caused decreased expression of the anti-apoptotic protein, Bcl 2 and increased expression of the pro-apoptotic protein, Bax. Clausenidin 13-24 BCL2 apoptosis regulator Homo sapiens 84-89 27822577-9 2016 Western blotting and real time PCR results showed that several p53 downstream genes responded strongly and synergistically to BTZ function and p53 restored expression (accumulation of p21 and bax, activation of caspase 3, down-regulation of Bcl-2, etc.). Bortezomib 126-129 BCL2 apoptosis regulator Homo sapiens 241-246 27829238-3 2016 Here we examined whether combining a GSI (gamma-Secretase Inhibitor) with ABT-737 (a small molecule BCL-2/BCL-XL/BCL-W inhibitor) can kill both the non-MICs (bulk of melanoma) and MICs. ABT-737 74-81 BCL2 apoptosis regulator Homo sapiens 100-105 29114584-2 2017 For example, HBx interacts with anti-apoptotic proteins, Bcl-2 and Bcl-xL, through its BH3-like motif, which leads to elevated cytosolic calcium levels, efficient viral DNA replication and the induction of apoptosis. Calcium 137-144 BCL2 apoptosis regulator Homo sapiens 57-62 27705937-7 2016 Up-regulated expressions of Bax, cleaved caspase-3 and down-regulated expression of Bcl-2 were observed in RSV+ MET group in comparison with RSV group either in vitro or in vivo. Resveratrol 107-110 BCL2 apoptosis regulator Homo sapiens 84-89 27999372-7 2016 Western blot analysis in vitro and in vivo showed that triptolide induced apoptotic protein Bax expression and inhibited phosph-NF-kappaB p65, Bcl-2 and VEGF proteins without affecting other NF-kappaB related protein expression. triptolide 55-65 BCL2 apoptosis regulator Homo sapiens 143-148 27693384-2 2016 Previously, we have described characterization of a novel BCL2 inhibitor, Disarib, which showed selective cytotoxicity in BCL2 "high" cancer cells and CLL patient cells. disarib 74-81 BCL2 apoptosis regulator Homo sapiens 122-126 27930712-10 2016 Cantharidin also increased Bax, Bid, and Bak protein expressions and decreased Bcl-2 protein expression. Cantharidin 0-11 BCL2 apoptosis regulator Homo sapiens 79-84 28077996-7 2016 Real-time PCR was used to test mRNA expression of Bcl-2 and Bax in glioma cells under the effect of pterostilbene, while Western blotting was used to detect alternation of Bcl-2 and Bax protein levels. pterostilbene 100-113 BCL2 apoptosis regulator Homo sapiens 50-55 27931239-4 2016 RESULTS: MCL-1 inhibition caused apoptosis of basal-like MDA-MB-468-2A cells grown as monolayers, and sensitized them to the BCL-2/BCL-XL inhibitor ABT-263, demonstrating that MCL-1 regulated cell survival. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 148-151 BCL2 apoptosis regulator Homo sapiens 125-130 27819368-1 2016 A tumor active targeting beta-cyclodextrin based nanocarrier beta-NC-OEI-SS-FA was designed by the modification of star shaped cationic derivatives beta-NC-OEI with folic acid through a disulfide bond, to co-deliver chemotherapeutic paclitaxel and the Nur77 gene for overcoming Bcl-2 mediated non-pump resistance by an "enemy to friend" strategy for potential drug resistant cancer therapy. betadex 25-42 BCL2 apoptosis regulator Homo sapiens 278-283 27924828-4 2016 Furthermore, we demonstrate that rpL3 significantly enhances the apoptosis of 5-FU treated Calu-6 cells promoting the overexpression of the pro-apoptotic proteins Bax and the inhibition of the anti-apoptotic protein Bcl-2. Fluorouracil 78-82 BCL2 apoptosis regulator Homo sapiens 216-221 27665848-10 2016 Consistent with the apoptotic rate, pretreating cells with different concentrations of NTU283 and Abeta significantly increased the activities of caspase-3 and caspase-7 as well as the ratio of Bax/Bcl-2. 1,3-dimethyl-2-((2-oxopropyl)sulfanyl)-1H-imidazol-3-ium 87-93 BCL2 apoptosis regulator Homo sapiens 198-203 27994550-9 2016 The real time PCR assay demonstrated that TB down-regulated the expression of TOPO I, TOPO II, and BCL-2, and up-regulated the expression of E2F1, P53, GADD45, BAX, BIM, and CASP 3,7,8,9, which suggests an activation of P53-mediated apoptotic (caspase-dependent) pathway in response to TB treatment. theabrownin 42-44 BCL2 apoptosis regulator Homo sapiens 99-104 27738771-7 2016 Treatment of the Bcl-2-overexpressing cells with both portimine and the Bcl-2 inhibitor ABT-737 proved a powerful combination, causing >90 % death. Portimine 54-63 BCL2 apoptosis regulator Homo sapiens 17-22 27738771-7 2016 Treatment of the Bcl-2-overexpressing cells with both portimine and the Bcl-2 inhibitor ABT-737 proved a powerful combination, causing >90 % death. ABT-737 88-95 BCL2 apoptosis regulator Homo sapiens 17-22 27738771-5 2016 Jurkat cells overexpressing the anti-apoptotic protein Bcl-2 or Bax/Bak knockout MEFs were completely protected from portimine. Portimine 117-126 BCL2 apoptosis regulator Homo sapiens 55-60 27738771-7 2016 Treatment of the Bcl-2-overexpressing cells with both portimine and the Bcl-2 inhibitor ABT-737 proved a powerful combination, causing >90 % death. ABT-737 88-95 BCL2 apoptosis regulator Homo sapiens 72-77 27738772-10 2016 In addition, the PI3K inhibitor partially blocked the effects of DMY on the upregulation of Bcl-2, Bcl-xl, procaspase-3, -8, and -9 protein expression and the downregulation of HIF-1alpha, Bnip3, Bax, Cyt-c, cleaved caspase-3, -8, and -9 protein expression. dihydromyricetin 65-68 BCL2 apoptosis regulator Homo sapiens 92-97 27847212-5 2016 Gallic acid restrained the activation of EGFR, ERK1/2 and AKT proteins and down regulated expression of Cyclin D and Bcl-2 genes, but upregulated the expression of p21 gene in EGF-induced SPC212 cells. Gallic Acid 0-11 BCL2 apoptosis regulator Homo sapiens 117-122 27693049-6 2016 Based on in vivo studies, the growth of breast tumor and expression of CD31, Bcl-2 and nonfunctional p53 were inhibited more effectively by ES-R than by ES-Zn. Erbium 140-144 BCL2 apoptosis regulator Homo sapiens 77-82 27693049-6 2016 Based on in vivo studies, the growth of breast tumor and expression of CD31, Bcl-2 and nonfunctional p53 were inhibited more effectively by ES-R than by ES-Zn. es-zn 153-158 BCL2 apoptosis regulator Homo sapiens 77-82 27881234-0 2016 DENSpm overcame Bcl-2 mediated resistance against Paclitaxel treatment in MCF-7 breast cancer cells via activating polyamine catabolic machinery. Paclitaxel 50-60 BCL2 apoptosis regulator Homo sapiens 16-21 27881234-10 2016 In addition, we determined that resistance against Paclitaxel-induced apoptotic cell death in Bcl-2 overexpressed MCF-7 cells was overcome due to activation of polyamine catabolic pathway, which caused depletion of polyamines. Paclitaxel 51-61 BCL2 apoptosis regulator Homo sapiens 94-99 27685789-10 2016 The combination of FK228 and TMZ-induced apoptosis was demonstrated by increased expression of cleaved-Caspase 3, Bax, cleaved-PARP, and decreased Bcl-2 expression. romidepsin 19-24 BCL2 apoptosis regulator Homo sapiens 147-152 27881234-10 2016 In addition, we determined that resistance against Paclitaxel-induced apoptotic cell death in Bcl-2 overexpressed MCF-7 cells was overcome due to activation of polyamine catabolic pathway, which caused depletion of polyamines. Polyamines 160-169 BCL2 apoptosis regulator Homo sapiens 94-99 27881234-10 2016 In addition, we determined that resistance against Paclitaxel-induced apoptotic cell death in Bcl-2 overexpressed MCF-7 cells was overcome due to activation of polyamine catabolic pathway, which caused depletion of polyamines. Polyamines 215-225 BCL2 apoptosis regulator Homo sapiens 94-99 27621033-13 2016 Moreover, the expression of activated PI3K/AKT and Bcl-2 were down-regulated upon quercetin nanoparticle treatment in human neuroglioma cells. Quercetin 82-91 BCL2 apoptosis regulator Homo sapiens 51-56 27881234-0 2016 DENSpm overcame Bcl-2 mediated resistance against Paclitaxel treatment in MCF-7 breast cancer cells via activating polyamine catabolic machinery. Polyamines 115-124 BCL2 apoptosis regulator Homo sapiens 16-21 27881234-2 2016 Conventional chemotherapeutics such as Paclitaxel, a commonly used in the treatment of metastatic breast cancer, is not sufficient to overcome Bcl-2 mediated drug resistance mechanism. Paclitaxel 39-49 BCL2 apoptosis regulator Homo sapiens 143-148 27881234-9 2016 Co-treatment of Paclitaxel (30nM) with DENSpm (20muM) further increased the cytoxicity of Paclitaxel (30nM) compared to alone Paclitaxel (30nM) treatment in MCF-7 Bcl-2+ breast cancer cells. Paclitaxel 16-26 BCL2 apoptosis regulator Homo sapiens 163-168 27881234-9 2016 Co-treatment of Paclitaxel (30nM) with DENSpm (20muM) further increased the cytoxicity of Paclitaxel (30nM) compared to alone Paclitaxel (30nM) treatment in MCF-7 Bcl-2+ breast cancer cells. Paclitaxel 90-100 BCL2 apoptosis regulator Homo sapiens 163-168 27881234-9 2016 Co-treatment of Paclitaxel (30nM) with DENSpm (20muM) further increased the cytoxicity of Paclitaxel (30nM) compared to alone Paclitaxel (30nM) treatment in MCF-7 Bcl-2+ breast cancer cells. Paclitaxel 90-100 BCL2 apoptosis regulator Homo sapiens 163-168 27657825-12 2016 The apoptosis related protein p53 expression was increased, and apoptosis suppressor Bcl-2 was inhibited in DU-145 after curcumin treatment. du-145 108-114 BCL2 apoptosis regulator Homo sapiens 85-90 27657825-12 2016 The apoptosis related protein p53 expression was increased, and apoptosis suppressor Bcl-2 was inhibited in DU-145 after curcumin treatment. Curcumin 121-129 BCL2 apoptosis regulator Homo sapiens 85-90 27685789-10 2016 The combination of FK228 and TMZ-induced apoptosis was demonstrated by increased expression of cleaved-Caspase 3, Bax, cleaved-PARP, and decreased Bcl-2 expression. Temozolomide 29-32 BCL2 apoptosis regulator Homo sapiens 147-152 27390258-1 2016 Docetaxel acts through the inhibition of tubulin polymerization and reduction in the expression of BCL-2 gene. Docetaxel 0-9 BCL2 apoptosis regulator Homo sapiens 99-104 27390258-2 2016 In this study, nanoparticles containing Docetaxel were prepared and their effects on the gene expression levels of BCL-2 and BAX genes were investigated. Docetaxel 40-49 BCL2 apoptosis regulator Homo sapiens 115-120 28154777-2 2016 Numerous reports demonstrate the diverse expression of Bcl-2 family members under sex steroid regulation. Steroids 86-93 BCL2 apoptosis regulator Homo sapiens 55-60 26472167-7 2016 Furthermore, ROS generation and subsequent activation of JNK and ERK might be involved in PM2.5 -induced apoptosis and G0/G1 phase arrest by downregulating Bcl-2/Bax protein ratio and upregulating p15INK4B , p16INK4A , and p21WAF1/CIP1 transcription level. ros 13-16 BCL2 apoptosis regulator Homo sapiens 156-161 27390258-9 2016 BAX and BCL-2 gene expressions were decreased in nanoparticle-treated cells in comparison with intact cells, while the BAX/BCL-2 ratio was significantly elevated compared with free drug-treated cells after 72 h. Docetaxel-conjugated NPs may offer a promising treatment with low off-target toxicity for breast cancer. Docetaxel 212-221 BCL2 apoptosis regulator Homo sapiens 8-13 27390258-9 2016 BAX and BCL-2 gene expressions were decreased in nanoparticle-treated cells in comparison with intact cells, while the BAX/BCL-2 ratio was significantly elevated compared with free drug-treated cells after 72 h. Docetaxel-conjugated NPs may offer a promising treatment with low off-target toxicity for breast cancer. Docetaxel 212-221 BCL2 apoptosis regulator Homo sapiens 123-128 27812249-5 2016 Additionally, combination of 2.5 mumol/L DAC and 5 mumol/L ATO led to a significantly higher apoptosis rate and more significantly decreased the Bcl2/Bax ratio than either compound alone (P < 0.001). Arsenic Trioxide 59-62 BCL2 apoptosis regulator Homo sapiens 145-149 27981537-6 2016 The administration of aconitine in Miapaca-2 and PANC-1 cells also induced cell apoptosis by upregulating the expression of pro-apoptotic factors Bax, cl-caspase-3, cl-caspase-9, and cleaved poly (ADP-ribose) polymerase 1 (PARP1), and by decreasing the anti-apoptotic Bcl-2 expression. Aconitine 22-31 BCL2 apoptosis regulator Homo sapiens 268-273 27990281-2 2016 Here we summarize recent advances in understanding of the biology of BCL2 family members that shed light on the action of BH3 mimetics, review preclinical and clinical studies leading to the regulatory approval of venetoclax, and discuss future investigation of this new class of antineoplastic agent. BH 3 122-125 BCL2 apoptosis regulator Homo sapiens 69-73 27990281-2 2016 Here we summarize recent advances in understanding of the biology of BCL2 family members that shed light on the action of BH3 mimetics, review preclinical and clinical studies leading to the regulatory approval of venetoclax, and discuss future investigation of this new class of antineoplastic agent. venetoclax 214-224 BCL2 apoptosis regulator Homo sapiens 69-73 28675694-7 2016 Western blotting indicated that BITC induced Fas, Fas-L, FADD, caspase-8, caspase -3, and pro-apoptotic protein (Bax, Bid, and Bak), but inhibited the ant-apoptotic proteins (Bcl-2 and Bcl-x) in GBM 8401 cells. benzyl isothiocyanate 32-36 BCL2 apoptosis regulator Homo sapiens 175-180 27856932-9 2016 Western blotting indicated that taccaoside upregulated Bax expression and downregulated Bcl-2 expression. taccaoside 32-42 BCL2 apoptosis regulator Homo sapiens 88-93 27779649-12 2016 When paclitaxel and curcumin were combined the expression of Bcl-2 protein was decreased. Paclitaxel 5-15 BCL2 apoptosis regulator Homo sapiens 61-66 27779649-12 2016 When paclitaxel and curcumin were combined the expression of Bcl-2 protein was decreased. Curcumin 20-28 BCL2 apoptosis regulator Homo sapiens 61-66 27569824-13 2016 CONCLUSION: L-carnitine may reduce cardiopulmonary bypass-induced myocardial apoptosis through modulating the expressions of Bcl-2 and Bax, resulting in a protective effect from MIRI. Carnitine 12-23 BCL2 apoptosis regulator Homo sapiens 125-130 27748803-2 2016 However, the function of Bcl-2 in cisplatin resistance in human ovarian cancer cells is not fully understood. Cisplatin 34-43 BCL2 apoptosis regulator Homo sapiens 25-30 27748803-3 2016 In this study, we found that the pharmacological inhibitor ABT737 or genetic knockdown of Bcl-2 increased cisplatin cytotoxicity in cisplatin-resistant ovarian cancer cells. Cisplatin 106-115 BCL2 apoptosis regulator Homo sapiens 90-95 27748803-3 2016 In this study, we found that the pharmacological inhibitor ABT737 or genetic knockdown of Bcl-2 increased cisplatin cytotoxicity in cisplatin-resistant ovarian cancer cells. Cisplatin 132-141 BCL2 apoptosis regulator Homo sapiens 90-95 27748803-4 2016 Additionally, treatment with ABT737 or Bcl-2 siRNA increased cisplatin-induced free Ca2+ levels in the cytosol and mitochondria, which increased endoplasmic reticulum (ER)-associated and mitochondria-mediated apoptosis. Cisplatin 61-70 BCL2 apoptosis regulator Homo sapiens 39-44 27748803-5 2016 In addition, ABT737 or Bcl-2 siRNA increased the ER-mitochondria contact sites induced by cisplatin in cisplatin-resistant SKOV3/DDP ovarian cancer cells. Cisplatin 90-99 BCL2 apoptosis regulator Homo sapiens 23-28 27748803-5 2016 In addition, ABT737 or Bcl-2 siRNA increased the ER-mitochondria contact sites induced by cisplatin in cisplatin-resistant SKOV3/DDP ovarian cancer cells. Cisplatin 103-112 BCL2 apoptosis regulator Homo sapiens 23-28 27748803-7 2016 Collectively, these results indicate that pharmacological inhibitors or genetic knockdown of Bcl-2 may be a potential strategy for improving cisplatin treatment of ovarian cancer. Cisplatin 141-150 BCL2 apoptosis regulator Homo sapiens 93-98 26764221-6 2016 Furthermore, DHNQ decreased expression of cyclins that caused G1 arrest and decreased Bcl-2/Bax ratio after mitochondrial membrane potential loss, reactive oxygen species generation, and an increase in cytosolic Ca2+ loads that is responsible for the decreased CRC cell proliferation and survival. dhnq 13-17 BCL2 apoptosis regulator Homo sapiens 86-91 27565895-8 2016 BCP pre-treatment prior to the initiation of OGD/R significantly (i) decreased BBB permeability and neuronal apoptosis, (ii) mitigated oxidative stress damage and the release of inflammatory cytokines, (iii) down-regulated Bax expression, metalloproteinase-9 activity and expression, and (iv) up-regulated claudin-5, occludin, ZO-1, growth-associated protein-43 and Bcl-2 expression. caryophyllene 0-3 BCL2 apoptosis regulator Homo sapiens 366-371 27534652-10 2016 In addition, inhibition of miR-181a promoted apoptosis of HeLa and CaSKi cells due to increasing Bax expression and decreasing Bcl-2 expression. mir-181a 27-35 BCL2 apoptosis regulator Homo sapiens 127-132 28105222-10 2016 Furthermore, while curcumin induced cell apoptosis and enhanced the expression ratio of Bax/Bcl-2, which are downstream molecules of p53, ectopic expression of H19 inhibited curcumin-induced cell apoptosis. Curcumin 19-27 BCL2 apoptosis regulator Homo sapiens 92-97 27779703-6 2016 In addition, resveratrol was observed to arrest cell cycle progression in G1/S phase by increasing the protein expression levels of p53 and p21, and concurrently reducing the protein expression levels of CDK2, cyclin A and cyclin E. Furthermore, resveratrol treatment significantly induced apoptosis in eosinophils, likely through the upregulation of Bim and Bax protein expression levels and the downregulation of Bcl-2 protein expression. Resveratrol 13-24 BCL2 apoptosis regulator Homo sapiens 415-420 27157620-9 2016 Targeting BCL2 by the specific inhibitor ABT-199 synergized with ibrutinib in inhibiting growth of both ibrutinib-sensitive and -resistant cancer cells in vitro and in vivo. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 41-44 BCL2 apoptosis regulator Homo sapiens 10-14 27157620-9 2016 Targeting BCL2 by the specific inhibitor ABT-199 synergized with ibrutinib in inhibiting growth of both ibrutinib-sensitive and -resistant cancer cells in vitro and in vivo. ibrutinib 65-74 BCL2 apoptosis regulator Homo sapiens 10-14 27157620-9 2016 Targeting BCL2 by the specific inhibitor ABT-199 synergized with ibrutinib in inhibiting growth of both ibrutinib-sensitive and -resistant cancer cells in vitro and in vivo. ibrutinib 104-113 BCL2 apoptosis regulator Homo sapiens 10-14 27157620-10 2016 These results suggest co-targeting of BTK and BCL2 as a new therapeutic strategy in MCL, especially for patients with primary resistance to ibrutinib. ibrutinib 140-149 BCL2 apoptosis regulator Homo sapiens 46-50 28105222-7 2016 The protein expression of p53, B-cell lymphoma (Bcl)-2, Bcl-2-associated X protein (Bax) and c-Myc in curcumin-treated cells was detected by western blotting. Curcumin 102-110 BCL2 apoptosis regulator Homo sapiens 31-54 28105237-7 2016 By contrast, the protein expression of Bcl-2 and Mcl-1 was significantly decreased following treatment with 40 microM xanthohumol. xanthohumol 118-129 BCL2 apoptosis regulator Homo sapiens 39-44 28105237-8 2016 Taken together, the results of the present study indicated that xanthohumol mediates growth suppression and apoptosis induction, which was mediated via the suppression of Bcl-2 and Mcl-1 and activation of PARP, p53 and AIF signaling pathways. xanthohumol 64-75 BCL2 apoptosis regulator Homo sapiens 171-176 27748898-6 2016 In addition, after angelicin treatment, the expression levels of Bax, cleaved caspase-3 and cleaved caspase-9 were increased, and Bcl-2 expression was decreased. angelicin 19-28 BCL2 apoptosis regulator Homo sapiens 130-135 27779684-6 2016 ABT-737 is an inhibitor of anti-apoptotic proteins Bcl-2, Bcl-xL, Bcl-w, while MIM-1 is an Mcl-1 protein inhibitor. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 51-56 27748909-3 2016 Thalidomide was added to osteosarcoma cells and studied by cytotoxicity assay, evaluating apoptosis, cell cycle arrest, mitochondrial membrane potential (DeltaPsim), and reactive oxygen species (ROS) levels and the expression of Bcl-2, Bax, caspase-3 and NF-kappaB. Thalidomide 0-11 BCL2 apoptosis regulator Homo sapiens 229-234 27748909-8 2016 By western blot analysis, thalidomide resulted in the decreasing expression of Bcl-2 and NF-kappaB, and the increasing expression of Bcl-2/Bax and caspase-3. Thalidomide 26-37 BCL2 apoptosis regulator Homo sapiens 79-84 27748909-8 2016 By western blot analysis, thalidomide resulted in the decreasing expression of Bcl-2 and NF-kappaB, and the increasing expression of Bcl-2/Bax and caspase-3. Thalidomide 26-37 BCL2 apoptosis regulator Homo sapiens 133-138 27748929-8 2016 Furthermore, idelalisib induced apoptosis in the K562 cells, with increased expression of pro-apoptotic molecules such as Bad and Bax, cleavage of caspase-9, -8 and -3, and PARP, in contrast to downregulation of anti-apoptotic protein Bcl-2. idelalisib 13-23 BCL2 apoptosis regulator Homo sapiens 235-240 27748934-4 2016 In addition, salidroside induced cell apoptosis, accompanied by an increase of chromatin condensation and nuclear fragmentation, and a decrease of Bcl-2/Bax protein expression ratio. rhodioloside 13-24 BCL2 apoptosis regulator Homo sapiens 147-152 27879593-11 2016 Interestingly, triptolide could increase the mixed chimerism level of recipients, possibly by inhibiting the apoptosis of transplanted bone marrow cells by means of regulation of the apoptotic genes bcl-2 and Bax. triptolide 15-25 BCL2 apoptosis regulator Homo sapiens 199-204 28101238-0 2016 Diosmetin triggers cell apoptosis by activation of the p53/Bcl-2 pathway and inactivation of the Notch3/NF-kappaB pathway in HepG2 cells. diosmetin 0-9 BCL2 apoptosis regulator Homo sapiens 59-64 28101239-0 2016 Naphthazarin suppresses cell proliferation and induces apoptosis in human colorectal cancer cells via the B-cell lymphoma 2/B-cell associated X protein signaling pathway. naphthazarin 0-12 BCL2 apoptosis regulator Homo sapiens 106-123 28101239-8 2016 The results revealed that naphthazarin exhibited cell growth inhibition, an increase in cytotoxicity and apoptosis induction in SW480 cells, which was associated with activation of the Bax/Bcl-2 signaling pathway and cleaved caspase-3 activation. naphthazarin 26-38 BCL2 apoptosis regulator Homo sapiens 189-194 27907160-0 2016 AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin. AGRO 100 0-6 BCL2 apoptosis regulator Homo sapiens 96-101 27907160-3 2016 Here we report that AS1411 induces cell apoptosis and cycle arrest, and inhibits cell viability by up-regulation of p53 and down-regulation of Bcl-2 and Akt1 in human glioma cells. AGRO 100 20-26 BCL2 apoptosis regulator Homo sapiens 143-148 27805250-7 2016 Our study is the first time to show that autophagy may be a way to remove the ER membrane reorganization induced by Bcl-2 inhibitors ABT-737 and S1 and it may help us to analyze autophagy in certain diseases. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 133-136 BCL2 apoptosis regulator Homo sapiens 116-121 27907160-7 2016 Further, AS1411 induced cell apoptosis, which was prevented by silencing of p53 and overexpression of Bcl-2. AGRO 100 9-15 BCL2 apoptosis regulator Homo sapiens 102-107 27907195-13 2016 Moreover, Flavipin inhibited growth and adhesion of both cell lines by suppressing gene expressions of B-cell lymphoma 2 (Bcl2) and integrinalpha4 (ITGA4). flavipin 10-18 BCL2 apoptosis regulator Homo sapiens 103-120 27907195-13 2016 Moreover, Flavipin inhibited growth and adhesion of both cell lines by suppressing gene expressions of B-cell lymphoma 2 (Bcl2) and integrinalpha4 (ITGA4). flavipin 10-18 BCL2 apoptosis regulator Homo sapiens 122-126 27644134-7 2016 In addition, both PA- and SCNT-derived blastocysts from the 40 muM Cx-treated group showed significantly increased mRNA expression of Bcl2 and Oct4 and decreased Caspase3 expression level (p < .05), when compared with the control group. Protactinium 18-20 BCL2 apoptosis regulator Homo sapiens 134-138 27907212-5 2016 Instead, U-2946 cells expressed the antiapoptotic BCL2 family member MCL1 which was highly amplified genomically (14n). 4-(4-methylpiperazin-1-yl)benzoic acid 114-117 BCL2 apoptosis regulator Homo sapiens 50-54 27907212-9 2016 The MCL1 inhibitor A-1210477 triggered apoptosis in U-2946 (MCL1pos/BCL2neg) cells. A-1210477 19-28 BCL2 apoptosis regulator Homo sapiens 68-72 27907212-9 2016 The MCL1 inhibitor A-1210477 triggered apoptosis in U-2946 (MCL1pos/BCL2neg) cells. u-2946 52-58 BCL2 apoptosis regulator Homo sapiens 68-72 27644134-7 2016 In addition, both PA- and SCNT-derived blastocysts from the 40 muM Cx-treated group showed significantly increased mRNA expression of Bcl2 and Oct4 and decreased Caspase3 expression level (p < .05), when compared with the control group. Canthaxanthin 67-69 BCL2 apoptosis regulator Homo sapiens 134-138 26744308-7 2016 Meanwhile, we showed that Bcl-2 was inversely correlated with miR-125b in osteosarcoma tissues. mir-125b 62-70 BCL2 apoptosis regulator Homo sapiens 26-31 27765486-7 2016 TUNEL assay showed that TUDCA treatment significantly reduced apoptosis in porcine SCNT blastocysts confirmed by decreased pro-apoptotic BAX and increased anti-apoptotic BCL2 mRNA levels. ursodoxicoltaurine 24-29 BCL2 apoptosis regulator Homo sapiens 170-174 26744308-8 2016 More importantly, we proved that miR-125b increased the chemosensitivity of osteosarcoma cell lines to cisplatin by targeting Bcl-2. mir-125b 33-41 BCL2 apoptosis regulator Homo sapiens 126-131 26744308-8 2016 More importantly, we proved that miR-125b increased the chemosensitivity of osteosarcoma cell lines to cisplatin by targeting Bcl-2. Cisplatin 103-112 BCL2 apoptosis regulator Homo sapiens 126-131 28078067-6 2016 The results demonstrated that ALA protective effect on C2C12 myoblasts was associated with a decrease in caspase-3 activity and an increase of the Bcl-2/Bax ratio. alpha-Linolenic Acid 30-33 BCL2 apoptosis regulator Homo sapiens 147-152 28024472-5 2016 The levels of C-MYC,CDK6 and BCL-2 mRNA transcripts in SUP-B15 cells were reduced in GSK525762A-treated group. molibresib 85-95 BCL2 apoptosis regulator Homo sapiens 29-34 27885275-0 2016 TDB protects vascular endothelial cells against oxygen-glucose deprivation/reperfusion-induced injury by targeting miR-34a to increase Bcl-2 expression. TDB 0-3 BCL2 apoptosis regulator Homo sapiens 135-140 27885275-7 2016 TDB-induced suppression of miR-34a resulted in a significant upregulation of Bcl-2 protein, MMP maintenance, and the survival of vascular cells following OGD/R. TDB 0-3 BCL2 apoptosis regulator Homo sapiens 77-82 27886059-11 2016 Oleandrin also down-regulated the expression of bcl-2, but up-regulated bax, caspase-9, Fas, FasL, caspase-8 and caspase-3. oleandrin 0-9 BCL2 apoptosis regulator Homo sapiens 48-53 27770735-8 2016 Moreover, they surprisingly boosted the Bax/Bcl2 ratio 5936 & 33,000 folds, respectively compared to the control. Adenosine Monophosphate 61-64 BCL2 apoptosis regulator Homo sapiens 44-48 27811363-6 2016 Moreover, resveratrol exerted an anti-apoptotic effect, as assessed by TUNEL staining, and altered the expression of the apoptosis-related genes Bax, Bcl-2 and caspase3. Resveratrol 10-21 BCL2 apoptosis regulator Homo sapiens 150-155 27769058-9 2016 Bortezomib up-regulated pro-apoptotic proteins of the Bcl-2 protein family, Bax and Noxa in wild-type HCC cells. Bortezomib 0-10 BCL2 apoptosis regulator Homo sapiens 54-59 28078067-7 2016 Indeed, the effect of ALA was directed to rescuing Bcl-2 expression and to revert Bax translocation to mitochondria both affected in an opposite way by TNF, a major pro-inflammatory cytokine expressed in damaged skeletal muscle. alpha-Linolenic Acid 22-25 BCL2 apoptosis regulator Homo sapiens 51-56 27895482-3 2016 Specifically, natural silica-based nanoparticles (diatomite) were modified to actively target the antiapoptotic factor B-cell lymphoma/leukemia 2 (Bcl2) with small interfering RNA (siRNA). Silicon Dioxide 22-28 BCL2 apoptosis regulator Homo sapiens 119-145 27895482-3 2016 Specifically, natural silica-based nanoparticles (diatomite) were modified to actively target the antiapoptotic factor B-cell lymphoma/leukemia 2 (Bcl2) with small interfering RNA (siRNA). Silicon Dioxide 22-28 BCL2 apoptosis regulator Homo sapiens 147-151 27747355-3 2016 In addition, it was found that agrimonolide-induced cell apoptosis was associated with the increase in the (Bcl-2 Associated X Protein, BAX)/(B-cell lymphoma-2, Bcl-2) ratio and the activation of cleaved caspase-3. agrimonolide 31-43 BCL2 apoptosis regulator Homo sapiens 108-113 27756602-0 2016 Synergistic effect of piperine and paclitaxel on cell fate via cyt-c, Bax/Bcl-2-caspase-3 pathway in ovarian adenocarcinomas SKOV-3 cells. piperine 22-30 BCL2 apoptosis regulator Homo sapiens 74-79 27756602-0 2016 Synergistic effect of piperine and paclitaxel on cell fate via cyt-c, Bax/Bcl-2-caspase-3 pathway in ovarian adenocarcinomas SKOV-3 cells. Paclitaxel 35-45 BCL2 apoptosis regulator Homo sapiens 74-79 27640886-8 2016 NBP attenuated Meth-associated cell injury and apoptosis via blockage of Meth-mediated upregulation of intracellular ROS production and inhibition of Meth-induced decrease of cleaved caspase-3/caspase-3 and Bcl-2/Bax ratios. Methamphetamine 73-77 BCL2 apoptosis regulator Homo sapiens 207-212 27640886-8 2016 NBP attenuated Meth-associated cell injury and apoptosis via blockage of Meth-mediated upregulation of intracellular ROS production and inhibition of Meth-induced decrease of cleaved caspase-3/caspase-3 and Bcl-2/Bax ratios. Methamphetamine 73-77 BCL2 apoptosis regulator Homo sapiens 207-212 27678524-6 2016 Subsequently, ABT-751 triggered apoptosis with marked downregulation of B-cell CLL/lymphoma 2, upregulation of mitochondrial BCL2 antagonist/killer 1 and BCL2 like 11 protein levels, and cleavages of caspase 8 (CASP8), CASP9, CASP3 and DNA fragmentation factor subunit alpha proteins. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 14-17 BCL2 apoptosis regulator Homo sapiens 125-129 27834342-0 2016 Allyl Isothiocyanate Inhibits the Proliferation of Renal Carcinoma Cell Line GRC-1 by Inducing an Imbalance Between Bcl2 and Bax. allyl isothiocyanate 0-20 BCL2 apoptosis regulator Homo sapiens 116-120 27904693-5 2016 Berberine also downregulated the expression of SP1, CCND1, and BCL2, determined with western blotting. Berberine 0-9 BCL2 apoptosis regulator Homo sapiens 63-67 27904693-8 2016 Therefore, we conclude that berberine treatment suppresses cancer cell growth by regulating miR-22-3p and SP1 and its downstream targets, CCND1 and BCL2, in HCC. Berberine 28-37 BCL2 apoptosis regulator Homo sapiens 148-152 27452798-7 2016 It was noted that melatonin treatment retained GR into cytoplasm by inhibiting the dissociation of HSP90 from GR-HSP90 complex and enhanced expression of Nrf2/HO-1 and Bcl-2 expression. Melatonin 18-27 BCL2 apoptosis regulator Homo sapiens 168-173 27452798-9 2016 Our observations suggest that the declined GR nuclear translocation upon melatonin treatment might be responsible for the up-regulation of Nrf2 mediated HO-1 activity and increased Bcl-2/Bax ratio in PBMCs to maintain the immune homeostasis under stress condition. Melatonin 73-82 BCL2 apoptosis regulator Homo sapiens 181-186 27765352-0 2016 Dioscin suppresses hepatocellular carcinoma tumor growth by inducing apoptosis and regulation of TP53, BAX, BCL2 and cleaved CASP3. dioscin 0-7 BCL2 apoptosis regulator Homo sapiens 108-112 27765352-14 2016 Moreover, we demonstrated that Dioscin displayed anticancer activity via up-regulating expression of TP53, BAX and CASP3 protein, as well as down-regulating BCL2 in Bel-7402 cells. dioscin 31-38 BCL2 apoptosis regulator Homo sapiens 157-161 27765352-16 2016 CONCLUSIONS: Dioscin inhibited tumor growth via inducing apoptosis, which was accompanied by altered expression of apoptotic pathway proteins, such as TP53, BAX, BCL2 and CASP3. dioscin 13-20 BCL2 apoptosis regulator Homo sapiens 162-166 27832139-8 2016 In summary, curcumin treatment might produce a P73-dependent apoptotic cell death in chronic myelogenous leukemia cells (K562), which was triggered by mitotic catastrophe, due to sustained BAX and survivin expression and impairment of the anti-apoptotic proteins BCL-2 and XIAP. Curcumin 12-20 BCL2 apoptosis regulator Homo sapiens 263-268 27747355-3 2016 In addition, it was found that agrimonolide-induced cell apoptosis was associated with the increase in the (Bcl-2 Associated X Protein, BAX)/(B-cell lymphoma-2, Bcl-2) ratio and the activation of cleaved caspase-3. agrimonolide 31-43 BCL2 apoptosis regulator Homo sapiens 161-166 27715057-7 2016 Moreover, both anti- and pro-apoptotic B-cell lymphoma 2 (Bcl-2) family proteins participated in lagunamide A-induced mitochondrial apoptosis, especially myeloid cell leukemia-1 (Mcl-1). lagunamide A 97-109 BCL2 apoptosis regulator Homo sapiens 58-63 27824091-4 2016 8h also induced cancer cell apoptosis in an Annexin V-FITC/propidium iodide flow cytometry assay, and triggered the mitochondrial/caspase apoptosis by decreasing mitochondrial membrane potential which was associated with up-regulation of Bax, down-regulation of Bcl-2 and activation levels of the caspase cascade in a concentration-dependent manner. 8h 0-2 BCL2 apoptosis regulator Homo sapiens 262-267 27693243-8 2016 Notably, BITC-induced apoptosis was associated with reduced Mcl-1 and Bcl-2 expression, diminished mitochondrial membrane potential (DeltaPsim), and increased PARP cleavage. benzyl isothiocyanate 9-13 BCL2 apoptosis regulator Homo sapiens 70-75 27569395-2 2016 In this study, we further evaluated the antitumor activity of LS-007 alone and in combination with a Bcl-2 inhibitor ABT-199 in acute leukemia (AL) cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 117-120 BCL2 apoptosis regulator Homo sapiens 101-106 27569395-12 2016 CONCLUSION: CDK inhibitor LS-007 potently inhibits the established human AL cell lines and primary AL blasts, and it also shows remarkable synergy with Bcl-2 inhibitor ABT-199. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 168-171 BCL2 apoptosis regulator Homo sapiens 152-157 27882181-5 2016 The addition of neamine had no effect on cell proliferation, but did significantly (P<0.001) increase expression of Bcl-2-associated X protein and protein levels of activated caspase-3 in CD4+ T-cells isolated from the MLRs, indicating that angiogenin reduces apoptosis. neamine 16-23 BCL2 apoptosis regulator Homo sapiens 119-124 29871174-2 2016 DHA also downregulated the expression of antiapoptotic proteins (Bcl-2, Bcl-xl, and Mcl-1) and upregulated the expression of proapoptotic proteins (Bax and C-PARP).Conclusion:DHA remarkably inhibited proliferation and induction of apoptosis in Fadu cells via affecting proteins of Bcl-2 family. artenimol 0-3 BCL2 apoptosis regulator Homo sapiens 65-70 29871174-2 2016 DHA also downregulated the expression of antiapoptotic proteins (Bcl-2, Bcl-xl, and Mcl-1) and upregulated the expression of proapoptotic proteins (Bax and C-PARP).Conclusion:DHA remarkably inhibited proliferation and induction of apoptosis in Fadu cells via affecting proteins of Bcl-2 family. artenimol 0-3 BCL2 apoptosis regulator Homo sapiens 281-286 29441966-11 2016 Moreover, CHIR99021 treatment significantly reversed H2O2-induced decrease in p-GSK-3betaSer9 , Bcl-2, Bcl-xl, survivin and beta-catenin expression, whereas it significantly attenuated H2O2-induced increase in caspase-3, cleaved caspase-3 and p-JNK protein expression. Hydrogen Peroxide 53-57 BCL2 apoptosis regulator Homo sapiens 96-101 28032735-0 2016 Combined Treatment with Stattic and Docetaxel Alters the Bax/Bcl-2 Gene Expression Ratio in Human Prostate Cancer Cells Docetaxel, recognized as a stabilizing microtubule agent, is frequently administrated as a first line treatment forprostate cancers. stattic 24-31 BCL2 apoptosis regulator Homo sapiens 61-66 28032735-0 2016 Combined Treatment with Stattic and Docetaxel Alters the Bax/Bcl-2 Gene Expression Ratio in Human Prostate Cancer Cells Docetaxel, recognized as a stabilizing microtubule agent, is frequently administrated as a first line treatment forprostate cancers. Docetaxel 36-45 BCL2 apoptosis regulator Homo sapiens 61-66 28032735-0 2016 Combined Treatment with Stattic and Docetaxel Alters the Bax/Bcl-2 Gene Expression Ratio in Human Prostate Cancer Cells Docetaxel, recognized as a stabilizing microtubule agent, is frequently administrated as a first line treatment forprostate cancers. Docetaxel 120-129 BCL2 apoptosis regulator Homo sapiens 61-66 28032735-5 2016 The IC50 values for docetaxel and stattic were 3.7 +- 0.9 nM and 4.6+-0.8 muM, respectively.Evaluation of key gene expression levels revealed a noticeable decrease in antiapoptotic Bcl-2 and Mcl-1 along withan increase in pro-apoptotic Bax mRNA levels (p<0.05). Docetaxel 20-29 BCL2 apoptosis regulator Homo sapiens 181-186 27469405-6 2016 Finally, we showed that low concentrations of dinaciclib enhanced cell sensitivity to ibrutinib and the BCL2 inhibitor ABT-199, two drugs with known effects on CLL. dinaciclib 46-56 BCL2 apoptosis regulator Homo sapiens 104-108 27469405-6 2016 Finally, we showed that low concentrations of dinaciclib enhanced cell sensitivity to ibrutinib and the BCL2 inhibitor ABT-199, two drugs with known effects on CLL. venetoclax 119-126 BCL2 apoptosis regulator Homo sapiens 104-108 27591926-4 2016 CDDP/RSV increased ROS production and depolarization of mitochondrial membrane potential with an increase in the Bax/Bcl-2 ratio. Cisplatin 0-4 BCL2 apoptosis regulator Homo sapiens 117-122 27802519-13 2016 Analysis of the antiapoptotic mechanisms triggered by ACh showed that ACh downregulates expression of FasL-induced NF-kappaB RNA expression, upregulates expression of antiapoptotic protein Bcl-2, downregulates expression of proapoptotic protein Bad, reduces cytochrome c release, and prevents proapoptotic Bid protein cleavage. Acetylcholine 70-73 BCL2 apoptosis regulator Homo sapiens 189-194 27664187-10 2016 DNA ladder and the expression of Bax to Bcl-2 ratio were much higher in tamoxifen citrate encapsulated in nanoparticles than that in tamoxifen citrate alone. Tamoxifen 72-89 BCL2 apoptosis regulator Homo sapiens 40-45 27029823-0 2016 Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor. venetoclax 61-71 BCL2 apoptosis regulator Homo sapiens 100-105 27374973-12 2016 Furthermore, the existence of caspase-independent apoptotic pathway induced by treatment of ABT-737 was not yet seen until combined with DMC, which shed light on an alternative mechanism involved in Bcl-2 inhibitor-induced apoptosis. ABT-737 92-99 BCL2 apoptosis regulator Homo sapiens 199-204 27374973-12 2016 Furthermore, the existence of caspase-independent apoptotic pathway induced by treatment of ABT-737 was not yet seen until combined with DMC, which shed light on an alternative mechanism involved in Bcl-2 inhibitor-induced apoptosis. 2,5-dimethylcelecoxib 137-140 BCL2 apoptosis regulator Homo sapiens 199-204 26953185-0 2016 Evaluation of Rifampin"s Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study. venetoclax 103-113 BCL2 apoptosis regulator Homo sapiens 117-122 27633052-7 2016 DAPK inhibition may also reverse the effect of Hcy by the upregulation of B cell leukemia/lymphoma 2 (Bcl2) and poly ADP-ribose polymerase, and the downregulation of Bcl2-associated X protein (Bax) and of caspase 3. Homocysteine 47-50 BCL2 apoptosis regulator Homo sapiens 74-100 27847436-11 2016 Besides, 10~30 mM of ethanol induced increased expression of pERK1, p-p90rsk, NHE1 and Bcl-2. Ethanol 21-28 BCL2 apoptosis regulator Homo sapiens 87-92 27847436-12 2016 Moreover treatment of p90rsk inhibitor attenuated the ethanol-induced increase in cell viability and NHE1 and Bcl-2 expression. Ethanol 54-61 BCL2 apoptosis regulator Homo sapiens 110-115 27847436-13 2016 In summary, these results suggest that p90rsk, a downstream kinase of ERK, plays a stimulatory role on ethanol-induced hepatocellular carcinoma progression by activating anti-apoptotic factor Bcl-2 and NHE1 known to regulate cell survival. Ethanol 103-110 BCL2 apoptosis regulator Homo sapiens 192-197 26373689-0 2016 AMP-activated protein kinase couples 3-bromopyruvate-induced energy depletion to apoptosis via activation of FoxO3a and upregulation of proapoptotic Bcl-2 proteins. bromopyruvate 37-52 BCL2 apoptosis regulator Homo sapiens 149-154 27633052-0 2016 Upregulation of DAPK contributes to homocysteine-induced endothelial apoptosis via the modulation of Bcl2/Bax and activation of caspase 3. Homocysteine 36-48 BCL2 apoptosis regulator Homo sapiens 101-105 27633052-7 2016 DAPK inhibition may also reverse the effect of Hcy by the upregulation of B cell leukemia/lymphoma 2 (Bcl2) and poly ADP-ribose polymerase, and the downregulation of Bcl2-associated X protein (Bax) and of caspase 3. Homocysteine 47-50 BCL2 apoptosis regulator Homo sapiens 102-106 27633052-8 2016 In conclusion, the present study demonstrated that DAPK contributed to the Hcy-induced endothelial apoptosis via modulation of Bcl2/Bax expression levels and activation of caspase 3. Homocysteine 75-78 BCL2 apoptosis regulator Homo sapiens 127-131 27748874-9 2016 BIX-01294 inhibited the proliferation of U251, downregulated expression of Bcl-2, and upregulated expression of Bax, caspase-3 and caspase-9, and induced apoptosis of U251. BIX 01294 0-9 BCL2 apoptosis regulator Homo sapiens 75-80 27748879-8 2016 Western blot analysis revealed that quercetin reduced the protein expression levels of phosphorylated-Akt and increased CSN6 protein degradation; therefore, affecting the expression levels of Myc, p53, B-cell lymphoma 2 (Bcl-2) and Bcl-2 associated X protein. Quercetin 36-45 BCL2 apoptosis regulator Homo sapiens 202-219 27748879-8 2016 Western blot analysis revealed that quercetin reduced the protein expression levels of phosphorylated-Akt and increased CSN6 protein degradation; therefore, affecting the expression levels of Myc, p53, B-cell lymphoma 2 (Bcl-2) and Bcl-2 associated X protein. Quercetin 36-45 BCL2 apoptosis regulator Homo sapiens 221-226 27748879-8 2016 Western blot analysis revealed that quercetin reduced the protein expression levels of phosphorylated-Akt and increased CSN6 protein degradation; therefore, affecting the expression levels of Myc, p53, B-cell lymphoma 2 (Bcl-2) and Bcl-2 associated X protein. Quercetin 36-45 BCL2 apoptosis regulator Homo sapiens 232-237 27487563-7 2016 We also identified that pro-caspase-9 cleavage, Bcl2 family expression changes, mitochondrial dysfunction, and intracellular ROS generation also participated in XN-induced glioma cell death. xanthohumol 161-163 BCL2 apoptosis regulator Homo sapiens 48-52 27487563-14 2016 XN"s inhibition of the IGFBP2/AKT/Bcl2 pathway via miR-204-3p targeting played a critical role in mediating glioma cell death. mir-204-3p 51-61 BCL2 apoptosis regulator Homo sapiens 34-38 27473386-6 2016 Apigenin attenuated the proteasome inhibitors (MG132 and MG115)-induced decrease in the levels of Bid and Bcl-2, increase in the levels of Bax and p53, loss of the mitochondrial transmembrane potential, release of cytochrome c, activation of caspases (-8, -9 and -3), cleavage of PARP-1 and cell death in both cell lines. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 47-52 BCL2 apoptosis regulator Homo sapiens 106-111 27687512-10 2016 Death receptor marker tumor necrosis factor-alpha (TNF-alpha), executor caspase-8 and pro-apoptotic gene (Bax) were induced, while antiapoptotic gene (Bcl-2) was decreased in Cd-treated cells. Cadmium 175-177 BCL2 apoptosis regulator Homo sapiens 151-156 27473386-6 2016 Apigenin attenuated the proteasome inhibitors (MG132 and MG115)-induced decrease in the levels of Bid and Bcl-2, increase in the levels of Bax and p53, loss of the mitochondrial transmembrane potential, release of cytochrome c, activation of caspases (-8, -9 and -3), cleavage of PARP-1 and cell death in both cell lines. carbobenzoxy-leucyl-leucyl-norvalinal 57-62 BCL2 apoptosis regulator Homo sapiens 106-111 27826624-6 2016 Western blotting also confirmed that GMSCs could upregulate expression of pro-apoptotic genes including p-JNK, cleaved PARP, cleaved caspase-3, Bax expression and downregulate proliferation- and anti-apoptosis-related gene expression such as p-ERK1/2, Bcl-2, CDK4, cyclin D1, PCNA and survivin. gmscs 37-42 BCL2 apoptosis regulator Homo sapiens 252-257 27895723-5 2016 The present study also demonstrated that cisplatin substantially inhibited beta-catenin, causing a marked downregulation of survivin and B-cell lymphoma (Bcl)-2. Cisplatin 41-50 BCL2 apoptosis regulator Homo sapiens 137-160 27895723-6 2016 Taken together, the present results uncovered a novel mechanism of cisplatin that could simultaneously trigger the inhibition of three prominent antiapoptotic effector molecules (Bcl-2, survivin and GRP78) and effectively promote GSH depletion by inhibiting gamma-GCSh. Cisplatin 67-76 BCL2 apoptosis regulator Homo sapiens 179-184 27895730-7 2016 Furthermore, it was noted that Osthole or Embelin alone increased the expression of BAX, caspase-3, caspase-9, cleaved caspase-3 and cleaved caspase-9, and decreased Bcl-2 levels following treatment. osthol 31-38 BCL2 apoptosis regulator Homo sapiens 166-171 27666165-8 2016 Moreover, melatonin treatment activated the mitogen-activated protein kinase pathways (c-jun N-terminal kinase and extracellular-regulated kinase 1/2), which increased Bax protein expression and caspase-3 cleavage and decreased Bcl-2 protein expression. Melatonin 10-19 BCL2 apoptosis regulator Homo sapiens 228-233 27544635-0 2016 Role of Cyt-C/caspases-9,3, Bax/Bcl-2 and the FAS death receptor pathway in apoptosis induced by zinc oxide nanoparticles in human aortic endothelial cells and the protective effect by alpha-lipoic acid. Zinc Oxide 97-107 BCL2 apoptosis regulator Homo sapiens 32-37 27774945-12 2016 Treatment by baicalein alone or in combination with U0126 for 24 hours significantly decreased ERK1/2 and Bcl-2 mRNA expressions, and upregulated Bax mRNA expression. U 0126 52-57 BCL2 apoptosis regulator Homo sapiens 106-111 27687545-4 2016 Compared with PC3, PC3-PR exhibited some unique phenotypes that might be associated with PTX resistance, including decreased expression of acetylated alpha-tubulin and the cell cycle regulator p21, and increased expression of betaIII tubulin, histone deacetylase 6 (HDAC6), and the anti-apoptotic protein Bcl2. Paclitaxel 89-92 BCL2 apoptosis regulator Homo sapiens 305-309 27786239-6 2016 Tumor inhibition response attributes to the synergistic effect of PTX potency and MDR reversing ability of Bcl-2 siRNA in the tumor supporting that kojic acid based liposomal pH-sensitive nanocarrier as efficient vehicle for systemic co-delivery of drugs and siRNA. kojic acid 148-158 BCL2 apoptosis regulator Homo sapiens 107-112 28281963-9 2016 Furthermore, miR-1284 overexpression and Akt inhibitor GSK690693 downregulated the levels of p-Akt and Bcl-2 while upregulating the levels of Bax and caspase 3. GSK690693 55-64 BCL2 apoptosis regulator Homo sapiens 103-108 27602962-4 2016 In this study, Polyphyllin G can potently induced apoptosis dependent on the activations of caspase-8, -3, and -9 and the changes of Bcl-2, Bcl-xL and Bax protein expression in different human NPC cell lines (HONE-1 and NPC-039). polyphyllin VII 15-28 BCL2 apoptosis regulator Homo sapiens 133-138 27894402-0 2016 HSP90 inhibitor enhances anti-proliferative and apoptotic effects of celecoxib on HT-29 colorectal cancer cells via increasing BAX/BCL-2 ratio. Celecoxib 69-78 BCL2 apoptosis regulator Homo sapiens 131-136 27894402-10 2016 The BAX/BCL-2 ratio in the combination group was increased compared to 17-AAG or celecoxib alone, mainly via decreasing BCL-2 levels. Celecoxib 81-90 BCL2 apoptosis regulator Homo sapiens 8-13 27894402-10 2016 The BAX/BCL-2 ratio in the combination group was increased compared to 17-AAG or celecoxib alone, mainly via decreasing BCL-2 levels. Celecoxib 81-90 BCL2 apoptosis regulator Homo sapiens 120-125 27544635-6 2016 Exposure to ZnO NPs was found to induce apoptosis at 12 h and necrosis after 24 h. Apoptosis was confirmed using reactive oxygen species that triggered a decrease in mitochondria membrane potential, increase in Cyt-C release, activation of caspases 3 and caspases9 and increase in the ratio of Bax/Bcl-2. Zinc Oxide 12-15 BCL2 apoptosis regulator Homo sapiens 298-303 27544635-6 2016 Exposure to ZnO NPs was found to induce apoptosis at 12 h and necrosis after 24 h. Apoptosis was confirmed using reactive oxygen species that triggered a decrease in mitochondria membrane potential, increase in Cyt-C release, activation of caspases 3 and caspases9 and increase in the ratio of Bax/Bcl-2. Reactive Oxygen Species 113-136 BCL2 apoptosis regulator Homo sapiens 298-303 27661108-2 2016 This study investigates activity of the BH3 mimetic venetoclax (ABT-199), which targets BCL-2, and mechanisms of acquired resistance in FL.The sensitivity of FL cells to venetoclax treatment correlated with BCL-2/BIM ratio. BH 3 40-43 BCL2 apoptosis regulator Homo sapiens 88-93 27661108-2 2016 This study investigates activity of the BH3 mimetic venetoclax (ABT-199), which targets BCL-2, and mechanisms of acquired resistance in FL.The sensitivity of FL cells to venetoclax treatment correlated with BCL-2/BIM ratio. BH 3 40-43 BCL2 apoptosis regulator Homo sapiens 207-212 27776559-11 2016 The drug combination caused AKT dephosphorylation and a downregulation of Bcl2, while nelarabine alone induced an increase in p-AKT and Bcl2 signaling in the resistant T-ALL cells and relapsed patient samples. nelarabine 86-96 BCL2 apoptosis regulator Homo sapiens 136-140 27661108-2 2016 This study investigates activity of the BH3 mimetic venetoclax (ABT-199), which targets BCL-2, and mechanisms of acquired resistance in FL.The sensitivity of FL cells to venetoclax treatment correlated with BCL-2/BIM ratio. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 64-67 BCL2 apoptosis regulator Homo sapiens 88-93 27661108-2 2016 This study investigates activity of the BH3 mimetic venetoclax (ABT-199), which targets BCL-2, and mechanisms of acquired resistance in FL.The sensitivity of FL cells to venetoclax treatment correlated with BCL-2/BIM ratio. venetoclax 52-62 BCL2 apoptosis regulator Homo sapiens 88-93 27661108-2 2016 This study investigates activity of the BH3 mimetic venetoclax (ABT-199), which targets BCL-2, and mechanisms of acquired resistance in FL.The sensitivity of FL cells to venetoclax treatment correlated with BCL-2/BIM ratio. venetoclax 52-62 BCL2 apoptosis regulator Homo sapiens 207-212 27661108-4 2016 Venetoclax induced dissociation of BCL-2/ BIM complex and a decrease in mitochondrial potential. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 35-40 27826299-5 2016 An increased nitric oxide (NO) response and reduced parasitic burden was observed upon Bcl-2 inhibition, where restitution of the NO response accounted for parasite mortality. Nitric Oxide 13-25 BCL2 apoptosis regulator Homo sapiens 87-92 27781257-13 2016 Western blot revealed that after EGCG treatment, the expression levels of drug-resistance-related proteins (ABCG2, P-gp, MDR-1 and GST-pi) in the drug-resistant cell line SGC-7901/5-FU decreased significantly; the expression levels of apoptosis marker protein PARP and pro-apoptotic protein Bax increased significantly; and the expression levels of anti-apoptotic protein Survivin and Bcl-2 decreased significantly (all P<0.05). epigallocatechin gallate 33-37 BCL2 apoptosis regulator Homo sapiens 385-390 27781257-14 2016 CONCLUSION: EGCG can reduce the resistance of gastric cancer resistant cell line SGC-7901/5-FU, whose role may be via the inhibition of the expression of drug-resistance-related proteins, and the elevation of the protein expression ratio of PARP/Survivin and Bax/Bcl-2. epigallocatechin gallate 12-16 BCL2 apoptosis regulator Homo sapiens 263-268 27343853-7 2016 Selenoquinones 18, 21, 22 and 23 were selected to monitor the expression levels of caspase-8, Bcl-2 and Ki-67 molecular biomarkers. selenoquinones 0-14 BCL2 apoptosis regulator Homo sapiens 94-99 27852416-5 2016 Western blot analysis showed that the Bax, cleaved-caspase 3 expression of itraconazole group and itraconazole+ PDMP group was significantly higher than control group, while Bcl-2 expression was significantly lower than the control; the Bax, cleaved-caspase 3 expression ofitraconazole+ CerS1-shRNA group was significantly lower than itraconazole group, while Bcl-2 expression was significantly higher than the itraconazole group.After 5, 10, 20 mumol/L itraconazole treatment, the expression of p-Akt and p-mTORC1 were significantly lower than the control group; the expression of p-Akt and p-mTORC1 in itraconazole+ CerS-1-shRNA group were significantly higher than itraconazole group. Itraconazole 75-87 BCL2 apoptosis regulator Homo sapiens 360-365 27852416-6 2016 Conclusion: Itraconazole induces apoptosis of PC-3 cell through increasing the intracellular ceramide content, which might relate to upregulation of cleavage-caspase 3 and Bax, downregulation of Bcl-2 and inactivation of Akt-mTORC signal pathway. Itraconazole 12-24 BCL2 apoptosis regulator Homo sapiens 195-200 27852416-6 2016 Conclusion: Itraconazole induces apoptosis of PC-3 cell through increasing the intracellular ceramide content, which might relate to upregulation of cleavage-caspase 3 and Bax, downregulation of Bcl-2 and inactivation of Akt-mTORC signal pathway. Ceramides 93-101 BCL2 apoptosis regulator Homo sapiens 195-200 27994761-6 2016 The molecular modeling analysis demonstrated a possible binding mode for these compounds with Bcl-2, which could explain the binding affinity of the novel gossypol Schiff bases with these proteins. gossypol schiff bases 155-176 BCL2 apoptosis regulator Homo sapiens 94-99 27404761-6 2016 The cells treated with 50microM of curcumin, 30.91microM (NEC-1), 20.70microM (NEC-2) and 16.86microM (NEC-3) showed enhanced activation of p53 and elevated bax/Bcl2 expression (NEC-3), increased cytochrome-c in cytosol (NEC-2) confirming the enhanced cytotoxicity. Curcumin 35-43 BCL2 apoptosis regulator Homo sapiens 161-165 27612418-6 2016 Mebendazole as a single agent decreased COX2 expression, blood vessel formation, VEGFR2 phosphorylation, and worked synergistically with sulindac to reduce overexpression of MYC, BCL2, and various pro-inflammatory cytokines. Mebendazole 0-11 BCL2 apoptosis regulator Homo sapiens 179-183 27612418-6 2016 Mebendazole as a single agent decreased COX2 expression, blood vessel formation, VEGFR2 phosphorylation, and worked synergistically with sulindac to reduce overexpression of MYC, BCL2, and various pro-inflammatory cytokines. Sulindac 137-145 BCL2 apoptosis regulator Homo sapiens 179-183 27280688-5 2016 At the molecular and cellular level, curcumin can blunt epithelial-to-mesenchymal transition and affect many targets that are involved in melanoma initiation and progression (e.g., BCl2, MAPKS, p21 and some microRNAs). Curcumin 37-45 BCL2 apoptosis regulator Homo sapiens 181-185 27562715-5 2016 Molecularly, C6 ceramide downregulated Bcl-2 to increase AT406"s sensitivity in pancreatic cancer cells. Ceramides 16-24 BCL2 apoptosis regulator Homo sapiens 39-44 27562715-6 2016 Intriguingly, C6 ceramide-mediated AT406 sensitization was nullified with Bcl-2 shRNA knockdown or pretreatment of the Bcl-2 inhibitor ABT-737. Ceramides 17-25 BCL2 apoptosis regulator Homo sapiens 74-79 27562715-6 2016 Intriguingly, C6 ceramide-mediated AT406 sensitization was nullified with Bcl-2 shRNA knockdown or pretreatment of the Bcl-2 inhibitor ABT-737. Ceramides 17-25 BCL2 apoptosis regulator Homo sapiens 119-124 27562715-6 2016 Intriguingly, C6 ceramide-mediated AT406 sensitization was nullified with Bcl-2 shRNA knockdown or pretreatment of the Bcl-2 inhibitor ABT-737. N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 35-40 BCL2 apoptosis regulator Homo sapiens 74-79 27562715-6 2016 Intriguingly, C6 ceramide-mediated AT406 sensitization was nullified with Bcl-2 shRNA knockdown or pretreatment of the Bcl-2 inhibitor ABT-737. N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 35-40 BCL2 apoptosis regulator Homo sapiens 119-124 27562715-6 2016 Intriguingly, C6 ceramide-mediated AT406 sensitization was nullified with Bcl-2 shRNA knockdown or pretreatment of the Bcl-2 inhibitor ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 135-138 BCL2 apoptosis regulator Homo sapiens 119-124 27562715-10 2016 Together, we demonstrate that C6 ceramide sensitizes AT406-mediated anti-pancreatic cancer cell activity possibly via downregulating Bcl-2. Ceramides 33-41 BCL2 apoptosis regulator Homo sapiens 133-138 27562715-10 2016 Together, we demonstrate that C6 ceramide sensitizes AT406-mediated anti-pancreatic cancer cell activity possibly via downregulating Bcl-2. N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 53-58 BCL2 apoptosis regulator Homo sapiens 133-138 27760664-11 2016 The expression of Bcl-2 was down-regulated by doxorubicin and further decreased in response to combination.There were no differences among groups in MG63 cells. Doxorubicin 46-57 BCL2 apoptosis regulator Homo sapiens 18-23 27588477-9 2016 Furthermore, we found that the PI3K/AKT pathway and Bcl-2/Bax ratio might be responsible for the eIF4E-induced cisplatin resistance in ESCC. Cisplatin 111-120 BCL2 apoptosis regulator Homo sapiens 52-57 27735939-5 2016 We also found pectolinarigenin significantly suppressed osteosarcoma cell proliferation, induced apoptosis and reduced the level of STAT3 downstream proteins cyclin D1, Survivin, B-cell lymphoma 2 (Bcl-2), B-cell lymphoma extra-large (Bcl-xl) and myeloid cell leukemia 1 (Mcl-1). pectolinarigenin 14-30 BCL2 apoptosis regulator Homo sapiens 179-196 27735939-5 2016 We also found pectolinarigenin significantly suppressed osteosarcoma cell proliferation, induced apoptosis and reduced the level of STAT3 downstream proteins cyclin D1, Survivin, B-cell lymphoma 2 (Bcl-2), B-cell lymphoma extra-large (Bcl-xl) and myeloid cell leukemia 1 (Mcl-1). pectolinarigenin 14-30 BCL2 apoptosis regulator Homo sapiens 198-203 27731405-5 2016 Furthermore, DOX/RES-loaded NPS could overcome DOX resistance by inhibiting the expression of drug resistance-related protein such as P-gp, MRP-1 and BCRP, and induce apoptosis through down-regulating the expression of NF-kappaB and BCL-2. Doxorubicin 13-16 BCL2 apoptosis regulator Homo sapiens 233-238 27785026-0 2016 Amorphous silica nanoparticles trigger vascular endothelial cell injury through apoptosis and autophagy via reactive oxygen species-mediated MAPK/Bcl-2 and PI3K/Akt/mTOR signaling. Silicon Dioxide 10-16 BCL2 apoptosis regulator Homo sapiens 146-151 27785026-0 2016 Amorphous silica nanoparticles trigger vascular endothelial cell injury through apoptosis and autophagy via reactive oxygen species-mediated MAPK/Bcl-2 and PI3K/Akt/mTOR signaling. Reactive Oxygen Species 108-131 BCL2 apoptosis regulator Homo sapiens 146-151 27785026-10 2016 The N-acetylcysteine supplement attenuated SiNPs-induced endothelial toxicity through inhibition of apoptosis and autophagy via MAPK/Bcl-2 and PI3K/Akt/mTOR signaling, as well as suppression of intracellular ROS property via activating antioxidant enzyme and Nrf2 signaling. Acetylcysteine 4-20 BCL2 apoptosis regulator Homo sapiens 133-138 27785026-10 2016 The N-acetylcysteine supplement attenuated SiNPs-induced endothelial toxicity through inhibition of apoptosis and autophagy via MAPK/Bcl-2 and PI3K/Akt/mTOR signaling, as well as suppression of intracellular ROS property via activating antioxidant enzyme and Nrf2 signaling. sinps 43-48 BCL2 apoptosis regulator Homo sapiens 133-138 27785026-11 2016 In summary, the results demonstrated that SiNPs triggered autophagy and apoptosis via ROS-mediated MAPK/Bcl-2 and PI3K/Akt/mTOR signaling in endothelial cells, and subsequently disturbed the endothelial homeostasis and impaired endothelium. Reactive Oxygen Species 86-89 BCL2 apoptosis regulator Homo sapiens 104-109 27510278-8 2016 In addition, quantitative analysis of the time course of both ERK1/2 and Bcl-2 in doxorubicin (DOX)-treated MCF-7/WT cells confirmed these findings. Doxorubicin 82-93 BCL2 apoptosis regulator Homo sapiens 73-78 27822420-0 2016 Genetic variants of BCL2 gene predict clinical outcomes of non-small-cell lung cancer patients treated with platinum-based chemotherapy in a Chinese population. Platinum 108-116 BCL2 apoptosis regulator Homo sapiens 20-24 27822420-1 2016 Platinum agents induce cancer cell death through BCL2-dependent intrinsic apoptotic pathway and are commonly used as anti-tumor drug. Platinum 0-8 BCL2 apoptosis regulator Homo sapiens 49-53 27822420-2 2016 In this study, we evaluated whether single nucleotide polymorphism (SNPs) of BCL2 can affect the overall survival (OS) and progression-free survival (PFS) in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Platinum 215-223 BCL2 apoptosis regulator Homo sapiens 77-81 27822420-3 2016 We genotyped 48 SNPs of BCL2 gene by Illumina Custom Designed Chip in 972 advanced NSCLC patients treated with platinum-based chemotherapy. Platinum 111-119 BCL2 apoptosis regulator Homo sapiens 24-28 27822420-10 2016 To conclude, polymorphisms of BCL2 gene may have an impact on the OS of platinum-based chemotherapy in NSCLC patients, which may be prognostic biomarkers of chemotherapy if validated in larger studies. Platinum 72-80 BCL2 apoptosis regulator Homo sapiens 30-34 27542247-6 2016 Fluorizoline increased the mRNA and protein levels of the pro-apoptotic BCL-2 family member NOXA both in cell lines and primary samples analyzed. Fluorizoline 0-12 BCL2 apoptosis regulator Homo sapiens 72-77 27510278-8 2016 In addition, quantitative analysis of the time course of both ERK1/2 and Bcl-2 in doxorubicin (DOX)-treated MCF-7/WT cells confirmed these findings. Doxorubicin 95-98 BCL2 apoptosis regulator Homo sapiens 73-78 27181027-4 2016 1,25-Dihydroxyvitamin D3 increased the expression of the cleaved PARP1, active Caspase3, Bax, and Bim but decreased the expression of Bcl2 in ACHN cells. Calcitriol 0-24 BCL2 apoptosis regulator Homo sapiens 134-138 27520483-0 2016 18alpha-Glycyrrhetinic acid lethality for neuroblastoma cells via de-regulating the Beclin-1/Bcl-2 complex and inducing apoptosis. 18alpha-glycyrrhetinic acid 0-27 BCL2 apoptosis regulator Homo sapiens 93-98 27520485-7 2016 At the molecular level, the expression of several key TPA-induced pro-survival and pro-proliferative genes (Bcl2, Cyclin D1, and c-Myc) decreased rapidly after BET inhibition. Tetradecanoylphorbol Acetate 54-57 BCL2 apoptosis regulator Homo sapiens 108-112 27193257-7 2016 Tungsten oxide nanoplates down regulated the expression of B cell lymphoma 2 (Bcl-2) and metalloproteinase-7 (MMP7) genes. tungsten oxide 0-14 BCL2 apoptosis regulator Homo sapiens 59-76 27193257-7 2016 Tungsten oxide nanoplates down regulated the expression of B cell lymphoma 2 (Bcl-2) and metalloproteinase-7 (MMP7) genes. tungsten oxide 0-14 BCL2 apoptosis regulator Homo sapiens 78-83 27379929-0 2016 KSP inhibitor SB743921 inhibits growth and induces apoptosis of breast cancer cells by regulating p53, Bcl-2, and DTL. SB 743921 14-22 BCL2 apoptosis regulator Homo sapiens 103-108 27431785-8 2016 This study demonstrates that the combination of NCS and PTX can potentiate the effect on survival and apoptosis of glioma cells via suppression of Akt, bcl-2, and activations of p53; Meanwhile, the in vivo studies also confirmed that the combination of NCS and PTX synergistically inhibit the gliom growth. Paclitaxel 56-59 BCL2 apoptosis regulator Homo sapiens 152-157 26987391-11 2016 BAY 11-7082 (NF-kappaB inhibitor) partly attenuated the effect of TRIM29 on expression of cyclin and Bcl-2. 3-(4-methylphenylsulfonyl)-2-propenenitrile 0-11 BCL2 apoptosis regulator Homo sapiens 101-106 27479192-6 2016 The treatment with zerumbone downregulated Cyp A and Bcl-2 levels, upregulated Bax levels, and caused Cytochrome c (Cyt-C) to release, activating Caspase-3. zerumbone 19-28 BCL2 apoptosis regulator Homo sapiens 53-58 27541047-4 2016 Meanwhile,it also induced cell apoptosis by down-regulating Bcl-2 and up-regulating cleaved Caspase-3 and Bax protein expression.The results of the present study demonstrates the potential utility of Chidamide for the treatment of Myelodysplastic syndromes. N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 200-209 BCL2 apoptosis regulator Homo sapiens 60-65 27775793-10 2016 In contrast, ectopic expression of miR-125b accelerated ROS production and apoptotic response in HK-2 cells, which was coupled with induction of Bax and reduction of Bcl-2. mir-125b 35-43 BCL2 apoptosis regulator Homo sapiens 166-171 27371891-1 2016 In this study, the conjugation of phenylboronic acid (PBA) to amine-terminated polyamidoamine (PAMAM) was successfully conducted to prepare a tumor-targeted gene carrier PBA-functionalized PAMAM (PPP) for Bcl-2 siRNA delivery, using a heterobifunctional crosslinker NHS-PEG5k-Mal. Poly(amidoamine) 79-93 BCL2 apoptosis regulator Homo sapiens 205-210 27371891-1 2016 In this study, the conjugation of phenylboronic acid (PBA) to amine-terminated polyamidoamine (PAMAM) was successfully conducted to prepare a tumor-targeted gene carrier PBA-functionalized PAMAM (PPP) for Bcl-2 siRNA delivery, using a heterobifunctional crosslinker NHS-PEG5k-Mal. Poly(amidoamine) 95-100 BCL2 apoptosis regulator Homo sapiens 205-210 27371891-1 2016 In this study, the conjugation of phenylboronic acid (PBA) to amine-terminated polyamidoamine (PAMAM) was successfully conducted to prepare a tumor-targeted gene carrier PBA-functionalized PAMAM (PPP) for Bcl-2 siRNA delivery, using a heterobifunctional crosslinker NHS-PEG5k-Mal. Poly(amidoamine) 189-194 BCL2 apoptosis regulator Homo sapiens 205-210 27371891-5 2016 Furthermore, owing to the knock-down of Bcl-2, PPP/siRNA could significantly inhibit the cell proliferation by inducing the cell apoptosis, and also enhance the antitumor efficiency of doxorubicin by suppressing the resistance of tumor cells to chemotherapeutics. Doxorubicin 185-196 BCL2 apoptosis regulator Homo sapiens 40-45 26739487-2 2016 Bcl-2 siRNA has been widely used to induce cancer cell apoptosis, and doxorubicin (Dox) can destroy cancer cells by binding with cancer cell DNA. Doxorubicin 70-81 BCL2 apoptosis regulator Homo sapiens 0-5 26739487-3 2016 OBJECTIVE: To investigate the therapeutic effect on lung cancer of simultaneously delivering Dox and Bcl-2-siRNA using epidermal growth factor (EGF) modified monomethoxy (polyethylene glycol)-poly (D, L-lactide-co-glycolide)-poly(L-lysine) (mPEG-PLGA-PLL, PEAL) NPs (EGF-PEAL). monomethoxypolyethylene glycol 158-191 BCL2 apoptosis regulator Homo sapiens 101-106 26739487-3 2016 OBJECTIVE: To investigate the therapeutic effect on lung cancer of simultaneously delivering Dox and Bcl-2-siRNA using epidermal growth factor (EGF) modified monomethoxy (polyethylene glycol)-poly (D, L-lactide-co-glycolide)-poly(L-lysine) (mPEG-PLGA-PLL, PEAL) NPs (EGF-PEAL). Polylactic Acid-Polyglycolic Acid Copolymer 192-223 BCL2 apoptosis regulator Homo sapiens 101-106 26739487-3 2016 OBJECTIVE: To investigate the therapeutic effect on lung cancer of simultaneously delivering Dox and Bcl-2-siRNA using epidermal growth factor (EGF) modified monomethoxy (polyethylene glycol)-poly (D, L-lactide-co-glycolide)-poly(L-lysine) (mPEG-PLGA-PLL, PEAL) NPs (EGF-PEAL). poly(l-lysine) 225-239 BCL2 apoptosis regulator Homo sapiens 101-106 26739487-3 2016 OBJECTIVE: To investigate the therapeutic effect on lung cancer of simultaneously delivering Dox and Bcl-2-siRNA using epidermal growth factor (EGF) modified monomethoxy (polyethylene glycol)-poly (D, L-lactide-co-glycolide)-poly(L-lysine) (mPEG-PLGA-PLL, PEAL) NPs (EGF-PEAL). monomethoxypolyethylene glycol 241-245 BCL2 apoptosis regulator Homo sapiens 101-106 26739487-10 2016 Dox and Bcl-2-siRNA-loaded NPs were taken up by cells and induced the apoptosis of H1299 cells more effectively than using Dox or Bcl-2 siRNA alone. Doxorubicin 0-3 BCL2 apoptosis regulator Homo sapiens 130-135 26739487-10 2016 Dox and Bcl-2-siRNA-loaded NPs were taken up by cells and induced the apoptosis of H1299 cells more effectively than using Dox or Bcl-2 siRNA alone. Doxorubicin 123-126 BCL2 apoptosis regulator Homo sapiens 8-13 27520294-1 2016 We present a phase II, single-arm study evaluating 800 mg daily venetoclax, a highly selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor in patients with high-risk relapsed/refractory acute myelogenous leukemia (AML) or unfit for intensive chemotherapy. venetoclax 64-74 BCL2 apoptosis regulator Homo sapiens 116-142 27520294-1 2016 We present a phase II, single-arm study evaluating 800 mg daily venetoclax, a highly selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor in patients with high-risk relapsed/refractory acute myelogenous leukemia (AML) or unfit for intensive chemotherapy. venetoclax 64-74 BCL2 apoptosis regulator Homo sapiens 144-148 27520294-6 2016 BH3 profiling was consistent with on-target BCL2 inhibition and identified potential resistance mechanisms. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 44-48 27371891-0 2016 Phenylboronic acid-functionalized polyamidoamine-mediated Bcl-2 siRNA delivery for inhibiting the cell proliferation. benzeneboronic acid 0-18 BCL2 apoptosis regulator Homo sapiens 58-63 27371891-0 2016 Phenylboronic acid-functionalized polyamidoamine-mediated Bcl-2 siRNA delivery for inhibiting the cell proliferation. Poly(amidoamine) 34-48 BCL2 apoptosis regulator Homo sapiens 58-63 27371891-1 2016 In this study, the conjugation of phenylboronic acid (PBA) to amine-terminated polyamidoamine (PAMAM) was successfully conducted to prepare a tumor-targeted gene carrier PBA-functionalized PAMAM (PPP) for Bcl-2 siRNA delivery, using a heterobifunctional crosslinker NHS-PEG5k-Mal. benzeneboronic acid 34-52 BCL2 apoptosis regulator Homo sapiens 205-210 27371891-1 2016 In this study, the conjugation of phenylboronic acid (PBA) to amine-terminated polyamidoamine (PAMAM) was successfully conducted to prepare a tumor-targeted gene carrier PBA-functionalized PAMAM (PPP) for Bcl-2 siRNA delivery, using a heterobifunctional crosslinker NHS-PEG5k-Mal. benzeneboronic acid 54-57 BCL2 apoptosis regulator Homo sapiens 205-210 27371891-1 2016 In this study, the conjugation of phenylboronic acid (PBA) to amine-terminated polyamidoamine (PAMAM) was successfully conducted to prepare a tumor-targeted gene carrier PBA-functionalized PAMAM (PPP) for Bcl-2 siRNA delivery, using a heterobifunctional crosslinker NHS-PEG5k-Mal. Amines 62-67 BCL2 apoptosis regulator Homo sapiens 205-210 27198552-6 2016 Combination of carmustine and selenite treatment significantly increased reactive oxygen species, apoptosis and growth inhibition in CRPC cells with down regulation of anti-apoptotic (Bcl-2 and Mcl-1) and proliferative proteins (c-Myc and cyclin-D1). Carmustine 15-25 BCL2 apoptosis regulator Homo sapiens 184-189 27178341-4 2016 In IL-1beta-treated chondrocytes, COS downregulated the expression of Bax and caspase-3 but upregulated the expression of Bcl-2 by inhibiting the phosphorylated p38 mitogen-activated protein kinase (MAPK). carbonyl sulfide 34-37 BCL2 apoptosis regulator Homo sapiens 122-127 27198552-6 2016 Combination of carmustine and selenite treatment significantly increased reactive oxygen species, apoptosis and growth inhibition in CRPC cells with down regulation of anti-apoptotic (Bcl-2 and Mcl-1) and proliferative proteins (c-Myc and cyclin-D1). Selenious Acid 30-38 BCL2 apoptosis regulator Homo sapiens 184-189 26740170-11 2016 Interestingly, the Bax/Bcl-2 protein ratios decreased with increased CS exposure, suggesting cell resistance. Cesium 69-71 BCL2 apoptosis regulator Homo sapiens 23-28 27499272-0 2016 Wogonin inhibits the proliferation and invasion, and induces the apoptosis of HepG2 and Bel7402 HCC cells through NF-kappaB/Bcl-2, EGFR and EGFR downstream ERK/AKT signaling. wogonin 0-7 BCL2 apoptosis regulator Homo sapiens 124-129 27354299-3 2016 Our objective was to analyze treatment with all-trans-retinoic acid (ATRA) by suppression of the phosphoinositide 3-kinase (PI3K) pathway on growth, signaling pattern and interactions among PI3K/B-cell lymphoma 2 (Bcl2)/retinol leiomyoma proteins. Tretinoin 44-67 BCL2 apoptosis regulator Homo sapiens 190-212 27354299-3 2016 Our objective was to analyze treatment with all-trans-retinoic acid (ATRA) by suppression of the phosphoinositide 3-kinase (PI3K) pathway on growth, signaling pattern and interactions among PI3K/B-cell lymphoma 2 (Bcl2)/retinol leiomyoma proteins. Tretinoin 44-67 BCL2 apoptosis regulator Homo sapiens 214-218 27354299-3 2016 Our objective was to analyze treatment with all-trans-retinoic acid (ATRA) by suppression of the phosphoinositide 3-kinase (PI3K) pathway on growth, signaling pattern and interactions among PI3K/B-cell lymphoma 2 (Bcl2)/retinol leiomyoma proteins. Tretinoin 69-73 BCL2 apoptosis regulator Homo sapiens 190-212 27354299-3 2016 Our objective was to analyze treatment with all-trans-retinoic acid (ATRA) by suppression of the phosphoinositide 3-kinase (PI3K) pathway on growth, signaling pattern and interactions among PI3K/B-cell lymphoma 2 (Bcl2)/retinol leiomyoma proteins. Tretinoin 69-73 BCL2 apoptosis regulator Homo sapiens 214-218 27354299-11 2016 CONCLUSIONS: ATRA treatment on PI3K pathway suppression significantly affected growth, signaling pattern and interactions among PI3K/Bcl2/retinol proteins involved in the growth, survival and apoptosis of leiomyomas. Tretinoin 13-17 BCL2 apoptosis regulator Homo sapiens 133-137 27538988-12 2016 Nuclear protein analysis by electrophoretic mobility shift assay showed the association of progesterone with progesterone response element (PRE), which may lead to downregulation of Bcl-2. Progesterone 91-103 BCL2 apoptosis regulator Homo sapiens 182-187 27538988-12 2016 Nuclear protein analysis by electrophoretic mobility shift assay showed the association of progesterone with progesterone response element (PRE), which may lead to downregulation of Bcl-2. Progesterone 109-121 BCL2 apoptosis regulator Homo sapiens 182-187 27599894-9 2016 In addition, C. setidens inhibited ROS-induced apoptosis of MSCs by increasing the expression levels of the anti-apoptotic protein B-cell lymphoma 2 (BCL-2), and decreasing the expression levels of the proapoptotic protein BCL-2-associated X protein. Reactive Oxygen Species 35-38 BCL2 apoptosis regulator Homo sapiens 131-148 27512118-10 2016 Accordingly, bcl-2 inhibitors (Obatoclax, ABT-199) markedly synergized with trabectedin paralleled by deregulated expression of the bcl-2 family members bcl-2, bim, bax, Mcl-1, and bcl-xL as a consequence of trabectedin exposure. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 42-45 BCL2 apoptosis regulator Homo sapiens 13-18 27512118-10 2016 Accordingly, bcl-2 inhibitors (Obatoclax, ABT-199) markedly synergized with trabectedin paralleled by deregulated expression of the bcl-2 family members bcl-2, bim, bax, Mcl-1, and bcl-xL as a consequence of trabectedin exposure. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 42-45 BCL2 apoptosis regulator Homo sapiens 132-137 27512118-10 2016 Accordingly, bcl-2 inhibitors (Obatoclax, ABT-199) markedly synergized with trabectedin paralleled by deregulated expression of the bcl-2 family members bcl-2, bim, bax, Mcl-1, and bcl-xL as a consequence of trabectedin exposure. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 42-45 BCL2 apoptosis regulator Homo sapiens 132-137 27512118-10 2016 Accordingly, bcl-2 inhibitors (Obatoclax, ABT-199) markedly synergized with trabectedin paralleled by deregulated expression of the bcl-2 family members bcl-2, bim, bax, Mcl-1, and bcl-xL as a consequence of trabectedin exposure. Trabectedin 76-87 BCL2 apoptosis regulator Homo sapiens 13-18 27465521-10 2016 In contrast, blocking of the mitochondrial pathway of apoptosis either with a caspase-9 inhibitor or overexpressing the anti-apoptotic protein Bcl-2 (U937/Bcl-2) reduced the number of apoptotic cells in response to hyperthermia but it was unable to suppress melatonin enhancement. Melatonin 258-267 BCL2 apoptosis regulator Homo sapiens 143-148 27465521-10 2016 In contrast, blocking of the mitochondrial pathway of apoptosis either with a caspase-9 inhibitor or overexpressing the anti-apoptotic protein Bcl-2 (U937/Bcl-2) reduced the number of apoptotic cells in response to hyperthermia but it was unable to suppress melatonin enhancement. Melatonin 258-267 BCL2 apoptosis regulator Homo sapiens 155-160 27617402-10 2016 Restoration of the apoptotic machinery by inhibition of Bcl-2 family members sensitizes MCS170 mesenchymal chondrosarcoma cells to conventional chemotherapy. mcs170 88-94 BCL2 apoptosis regulator Homo sapiens 56-61 27599675-11 2016 Furthermore, the expression levels of Bcl-2 (P<0.05) and p-AKT (P<0.05) were significantly decreased, whereas, p53 (P=0.001), Bax (P<0.01) and GDF-5 (P<0.01) were increased by co-culture of FLS with UC-MSCs compared with FLS alone. CHEMBL1232769 202-205 BCL2 apoptosis regulator Homo sapiens 38-43 27601129-0 2016 p53, Bcl-2 and cox-2 are involved in berberine hydrochloride-induced apoptosis of HeLa229 cells. berberine chloride 37-60 BCL2 apoptosis regulator Homo sapiens 5-10 27601129-5 2016 Berberine hydrochloride upregulated the mRNA expression levels of p53, and downregulated mRNA expression levels of Bcl-2 and cox-2, in a dose-dependent manner. berberine chloride 0-23 BCL2 apoptosis regulator Homo sapiens 115-120 27599894-9 2016 In addition, C. setidens inhibited ROS-induced apoptosis of MSCs by increasing the expression levels of the anti-apoptotic protein B-cell lymphoma 2 (BCL-2), and decreasing the expression levels of the proapoptotic protein BCL-2-associated X protein. Reactive Oxygen Species 35-38 BCL2 apoptosis regulator Homo sapiens 150-155 27601129-6 2016 In conclusion, berberine hydrochloride inhibited the proliferation and induced apoptosis of HeLa229 cells, potentially via the upregulation of p53 and the downregulation of Bcl-2 and cox-2 mRNA expression levels. berberine chloride 15-38 BCL2 apoptosis regulator Homo sapiens 173-178 27599894-9 2016 In addition, C. setidens inhibited ROS-induced apoptosis of MSCs by increasing the expression levels of the anti-apoptotic protein B-cell lymphoma 2 (BCL-2), and decreasing the expression levels of the proapoptotic protein BCL-2-associated X protein. Reactive Oxygen Species 35-38 BCL2 apoptosis regulator Homo sapiens 223-228 27573448-0 2016 Thymoquinone induces apoptosis through downregulation of c-FLIP and Bcl-2 in renal carcinoma Caki cells. thymoquinone 0-12 BCL2 apoptosis regulator Homo sapiens 68-73 27513630-8 2016 Treating MM cells with 500 micromol/l NaHS for 24 h markedly increased the expression level of Bcl-2 and the activation of p-Akt, however, the expression level of caspase-3 was decreased, cell viability was increased, and cell cycle progression was accelerated in MM cells. sodium bisulfide 38-42 BCL2 apoptosis regulator Homo sapiens 95-100 27499090-7 2016 Mechanistically, western blot analysis indicated that Sch B induced apoptosis by upregulating Bax, cleaved caspase-3, cleaved caspase-9 and cleaved PARP, and by downregulating cyclin D1, Bcl-2 and CDK-4. schizandrin B 54-59 BCL2 apoptosis regulator Homo sapiens 187-192 27573448-4 2016 Moreover, thymoquinone-mediated apoptosis caused downregulation of c-FLIP and Bcl-2, the master regulators of the anti-apoptotic mechanism. thymoquinone 10-22 BCL2 apoptosis regulator Homo sapiens 78-83 27573448-8 2016 Our results postulate that thymoquinone induces apoptosis through downregulating c-FLIP and Bcl-2 which can be utilized as a chemotherapeutic agent to treat renal carcinoma. thymoquinone 27-39 BCL2 apoptosis regulator Homo sapiens 92-97 27495233-9 2016 Furthermore, miRNA-363 inhibition induced the downregulation of AKT, cyclin-D1, matrix metalloproteinase (MMP)-2, MMP-9, and Bcl-2 and upregulation of caspase 3. mirna-363 13-22 BCL2 apoptosis regulator Homo sapiens 125-130 27253232-10 2016 Streptozotocin and alloxan decreased transcription of BCL2 while increasing transcription of BAX. Streptozocin 0-14 BCL2 apoptosis regulator Homo sapiens 54-58 27468725-0 2016 Dimethylfumarate inhibits melanoma cell proliferation via p21 and p53 induction and bcl-2 and cyclin B1 downregulation. Dimethyl Fumarate 0-16 BCL2 apoptosis regulator Homo sapiens 84-89 27468725-15 2016 These data provide evidence that DMF inhibits melanoma proliferation by reinduction of important cell cycle inhibitors leading to a concentration-dependent G0/G1 or G2/M cell cycle arrest and induction of apoptosis via downregulation of bcl-2 and induction of p53 and PARP-1 cleavage. Dimethyl Fumarate 33-36 BCL2 apoptosis regulator Homo sapiens 237-242 27695617-1 2016 Venetoclax (VEN, ABT-199/GDC-0199) is an orally bioavailable BH3-mimetic that specifically inhibits the anti-apoptotic B-cell lymphoma/leukemia 2 (BCL2) protein. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 119-145 27695617-1 2016 Venetoclax (VEN, ABT-199/GDC-0199) is an orally bioavailable BH3-mimetic that specifically inhibits the anti-apoptotic B-cell lymphoma/leukemia 2 (BCL2) protein. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 147-151 27695617-1 2016 Venetoclax (VEN, ABT-199/GDC-0199) is an orally bioavailable BH3-mimetic that specifically inhibits the anti-apoptotic B-cell lymphoma/leukemia 2 (BCL2) protein. venetoclax 12-15 BCL2 apoptosis regulator Homo sapiens 119-145 27695617-1 2016 Venetoclax (VEN, ABT-199/GDC-0199) is an orally bioavailable BH3-mimetic that specifically inhibits the anti-apoptotic B-cell lymphoma/leukemia 2 (BCL2) protein. venetoclax 12-15 BCL2 apoptosis regulator Homo sapiens 147-151 27695617-1 2016 Venetoclax (VEN, ABT-199/GDC-0199) is an orally bioavailable BH3-mimetic that specifically inhibits the anti-apoptotic B-cell lymphoma/leukemia 2 (BCL2) protein. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 17-20 BCL2 apoptosis regulator Homo sapiens 119-145 27695617-1 2016 Venetoclax (VEN, ABT-199/GDC-0199) is an orally bioavailable BH3-mimetic that specifically inhibits the anti-apoptotic B-cell lymphoma/leukemia 2 (BCL2) protein. venetoclax 25-33 BCL2 apoptosis regulator Homo sapiens 119-145 27695617-1 2016 Venetoclax (VEN, ABT-199/GDC-0199) is an orally bioavailable BH3-mimetic that specifically inhibits the anti-apoptotic B-cell lymphoma/leukemia 2 (BCL2) protein. venetoclax 25-33 BCL2 apoptosis regulator Homo sapiens 147-151 27695617-1 2016 Venetoclax (VEN, ABT-199/GDC-0199) is an orally bioavailable BH3-mimetic that specifically inhibits the anti-apoptotic B-cell lymphoma/leukemia 2 (BCL2) protein. BH 3 61-64 BCL2 apoptosis regulator Homo sapiens 119-145 27613092-6 2016 Despite the lack of effect on global calcium responses, PMCA2 silencing augmented Bcl-2 inhibitor (ABT-263)-mediated MDA-MB-231 breast cancer cell death. navitoclax 99-106 BCL2 apoptosis regulator Homo sapiens 82-87 27784359-10 2016 Compared with the control group, the expressions of drug resistance related protein P-gp, MRP1, GSTpi and BCL-2 were significantly decreased in dose-dependent manner in DMY (5, 10 and 20 mg/L) group (r1=-0.41, r2=-0.37, r3=-0.58, r=-0.46). 5,6-dehydrokawain 169-172 BCL2 apoptosis regulator Homo sapiens 106-111 27784359-11 2016 Compared with the ADM group, the protein expressions of drug resistance related genes P-gp, MRP1, GSTpi and BCL-2 in DMY (5, 10 and 20 mg/L)+ADM group were significantly decreased in dose-dependent manner (r1=-0.55, r2=-0.41, r3 =-0.38, r4=-0.44). 5,6-dehydrokawain 117-120 BCL2 apoptosis regulator Homo sapiens 108-113 27784359-12 2016 CONCLUSION: DMY enhances the sensitivity of K562/A02 cells to ADM, its mechanism may be related with decrease of P-gp, MRP1, GSTpi and BCL-2 expressions. 5,6-dehydrokawain 12-15 BCL2 apoptosis regulator Homo sapiens 135-140 27617850-3 2016 Drugging the BH3-binding pockets of anti-apoptotic proteins has become a highest-priority goal, fueled by the clinical success of ABT-199, a selective BCL-2 inhibitor, in reactivating apoptosis in BCL-2-dependent cancers. BH 3 13-16 BCL2 apoptosis regulator Homo sapiens 151-156 27669008-11 2016 Some patients had BCL2 overexpression in CD34+ ROS-high as well as ROS-low fractions which may be indicative of poor early response to standard chemotherapy. ros 47-50 BCL2 apoptosis regulator Homo sapiens 18-22 27924158-7 2016 Mechanistically, proteasomal degradation of HMGB1 by lycorine inhibits the activation of MEK-ERK thereby decreases phosphorylation of Bcl-2 resulting in constitutive association of Bcl-2 with Beclin-1. lycorine 53-61 BCL2 apoptosis regulator Homo sapiens 134-139 27924158-7 2016 Mechanistically, proteasomal degradation of HMGB1 by lycorine inhibits the activation of MEK-ERK thereby decreases phosphorylation of Bcl-2 resulting in constitutive association of Bcl-2 with Beclin-1. lycorine 53-61 BCL2 apoptosis regulator Homo sapiens 181-186 27681638-5 2016 As the gene of Bcl-2 interacting mediator of cell death (BIM) was proved to be a target of miR-24 in MG-63/R cells, we further observed that the miR-24 inhibitors promoted the DOX-induced apoptosis via mitochondrial pathway. Doxorubicin 176-179 BCL2 apoptosis regulator Homo sapiens 15-20 27671231-5 2016 Co-treatment of DY and 5-FU significantly elevated ROS levels, up-regulated Bax/Bcl-2 ratio and triggered mitochondrial dysfunction, followed by a release of cytochrome c and up-regulation of proteins such as cleaved-caspase-9/3 and cleaved-PARP. Fluorouracil 23-27 BCL2 apoptosis regulator Homo sapiens 80-85 27617850-3 2016 Drugging the BH3-binding pockets of anti-apoptotic proteins has become a highest-priority goal, fueled by the clinical success of ABT-199, a selective BCL-2 inhibitor, in reactivating apoptosis in BCL-2-dependent cancers. BH 3 13-16 BCL2 apoptosis regulator Homo sapiens 197-202 27617850-3 2016 Drugging the BH3-binding pockets of anti-apoptotic proteins has become a highest-priority goal, fueled by the clinical success of ABT-199, a selective BCL-2 inhibitor, in reactivating apoptosis in BCL-2-dependent cancers. venetoclax 130-137 BCL2 apoptosis regulator Homo sapiens 151-156 27669220-8 2016 The novel fatty acid also induced apoptosis mediated by downregulation of cyclin B1, upregulation of Bax, and downregulation of Bcl-2, resulting in the G2/M transition arrest. Fatty Acids 10-20 BCL2 apoptosis regulator Homo sapiens 128-133 27617850-3 2016 Drugging the BH3-binding pockets of anti-apoptotic proteins has become a highest-priority goal, fueled by the clinical success of ABT-199, a selective BCL-2 inhibitor, in reactivating apoptosis in BCL-2-dependent cancers. venetoclax 130-137 BCL2 apoptosis regulator Homo sapiens 197-202 27725868-3 2016 While the Bcl-2-selective inhibitor ABT-199 has demonstrated promising preclinical anti-leukemic activities, intrinsic drug resistance remains a problem. venetoclax 36-43 BCL2 apoptosis regulator Homo sapiens 10-15 27899819-6 2016 Further investigation showed that 4-cholesten-3-one promoted ROS generation, which transiently activated AMPKalpha1, increased HIF1alpha expression, reduced Bcl-2 expression and caused autophagy. cholest-4-en-3-one 34-51 BCL2 apoptosis regulator Homo sapiens 157-162 27899819-6 2016 Further investigation showed that 4-cholesten-3-one promoted ROS generation, which transiently activated AMPKalpha1, increased HIF1alpha expression, reduced Bcl-2 expression and caused autophagy. ros 61-64 BCL2 apoptosis regulator Homo sapiens 157-162 27494880-7 2016 We also successfully employed this approach to predict whether individual GBM cell lines could be sensitized to TMZ or TRAIL via the selective targeting of Bcl-2/Bcl-xL proteins with ABT-737. Temozolomide 112-115 BCL2 apoptosis regulator Homo sapiens 156-161 27494880-7 2016 We also successfully employed this approach to predict whether individual GBM cell lines could be sensitized to TMZ or TRAIL via the selective targeting of Bcl-2/Bcl-xL proteins with ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 183-186 BCL2 apoptosis regulator Homo sapiens 156-161 27538638-6 2016 PCB strikingly inhibited Abeta25-35-induced mitochondrial dysfunctions, including lowered membrane potential, decreased Bcl-2/Bax ratio. pinocembrin 0-3 BCL2 apoptosis regulator Homo sapiens 120-125 27187865-0 2016 N"-((2-(6-bromo-2-oxo-2H-chromen-3-yl)-1H-indol-3-yl)methylene)benzohydrazide as a probable Bcl-2/Bcl-xL inhibitor with apoptotic and anti-metastatic potential. n"-((2-(6-bromo-2-oxo-2h-chromen-3-yl)-1h-indol-3-yl)methylene)benzohydrazide 0-77 BCL2 apoptosis regulator Homo sapiens 92-97 27489133-7 2016 Furthermore, RSV pretreatment substantially upregulated the expression of the SIRT1 gene by 6.8 fold, reduced the acetylation level of the forkhead transcription factor FOXO3a, and decreased the expression ratio of Bax/Bcl-2. Resveratrol 13-16 BCL2 apoptosis regulator Homo sapiens 219-224 27444344-10 2016 Trifolin increased Bcl-2-associated X protein (Bax) levels and decreased b-cell lymphoma 2 (Bcl-2) levels, while the levels of Bcl-xL were not altered. kaempferol-3-O-galactoside 0-8 BCL2 apoptosis regulator Homo sapiens 73-90 27444344-10 2016 Trifolin increased Bcl-2-associated X protein (Bax) levels and decreased b-cell lymphoma 2 (Bcl-2) levels, while the levels of Bcl-xL were not altered. kaempferol-3-O-galactoside 0-8 BCL2 apoptosis regulator Homo sapiens 19-24 27187865-2 2016 The aim of the present study was to synthesize a series of halogen incorporated indole-coumarin hybrid schiff bases - N"-((2-(2-oxo-2H-chromen-3-yl)-1H-indol-3-yl)methylene)benzohydrazides and to investigate their apoptotic and anti-migratory potential in human breast adenocarcinoma cells as well as to examine their Bcl-2 and Bcl-xL protein binding ability via in silico docking. Halogens 59-66 BCL2 apoptosis regulator Homo sapiens 318-323 27187865-2 2016 The aim of the present study was to synthesize a series of halogen incorporated indole-coumarin hybrid schiff bases - N"-((2-(2-oxo-2H-chromen-3-yl)-1H-indol-3-yl)methylene)benzohydrazides and to investigate their apoptotic and anti-migratory potential in human breast adenocarcinoma cells as well as to examine their Bcl-2 and Bcl-xL protein binding ability via in silico docking. indole-coumarin 80-95 BCL2 apoptosis regulator Homo sapiens 318-323 27187865-2 2016 The aim of the present study was to synthesize a series of halogen incorporated indole-coumarin hybrid schiff bases - N"-((2-(2-oxo-2H-chromen-3-yl)-1H-indol-3-yl)methylene)benzohydrazides and to investigate their apoptotic and anti-migratory potential in human breast adenocarcinoma cells as well as to examine their Bcl-2 and Bcl-xL protein binding ability via in silico docking. schiff bases - n"-((2-(2-oxo-2h-chromen-3-yl)-1h-indol-3-yl)methylene)benzohydrazides 103-188 BCL2 apoptosis regulator Homo sapiens 318-323 27425252-7 2016 The combination of bufalin and SAHA was particular efficient in attenuating AKT activation and reducing Bcl-2 levels. bufalin 19-26 BCL2 apoptosis regulator Homo sapiens 104-109 27387230-7 2016 Bcl-2 inhibition (by ABT-737) or shRNA knockdown dramatically sensitized Panc-1 cells to AT406. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 21-24 BCL2 apoptosis regulator Homo sapiens 0-5 27387230-7 2016 Bcl-2 inhibition (by ABT-737) or shRNA knockdown dramatically sensitized Panc-1 cells to AT406. N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 89-94 BCL2 apoptosis regulator Homo sapiens 0-5 27425252-7 2016 The combination of bufalin and SAHA was particular efficient in attenuating AKT activation and reducing Bcl-2 levels. Vorinostat 31-35 BCL2 apoptosis regulator Homo sapiens 104-109 27533080-5 2016 The Bcl-2 inhibitor ABT-263 (navitoclax) increased sensitivity to the mTORC1/2 inhibitor AZD8055 in TP53 wild type GSCs, while sensitivity to AZD8055 in TP53 mutated GSCs remained unchanged. navitoclax 20-27 BCL2 apoptosis regulator Homo sapiens 4-9 27343252-1 2016 The clinical success of the BCL-2-selective BH3-mimetic venetoclax in patients with poor prognosis chronic lymphocytic leukemia (CLL) highlights the potential of targeting the BCL-2-regulated apoptotic pathway in previously untreatable lymphoid malignancies. BH 3 44-47 BCL2 apoptosis regulator Homo sapiens 28-33 27343252-1 2016 The clinical success of the BCL-2-selective BH3-mimetic venetoclax in patients with poor prognosis chronic lymphocytic leukemia (CLL) highlights the potential of targeting the BCL-2-regulated apoptotic pathway in previously untreatable lymphoid malignancies. BH 3 44-47 BCL2 apoptosis regulator Homo sapiens 176-181 27656146-6 2016 The expression of anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) was attenuated in UVB-exposed cells but restored in UVB/cyanidin-3-O-glucoside-treated cells. cyanidin-3-o 123-135 BCL2 apoptosis regulator Homo sapiens 60-65 27656146-6 2016 The expression of anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) was attenuated in UVB-exposed cells but restored in UVB/cyanidin-3-O-glucoside-treated cells. Glucosides 136-145 BCL2 apoptosis regulator Homo sapiens 41-58 27656146-6 2016 The expression of anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) was attenuated in UVB-exposed cells but restored in UVB/cyanidin-3-O-glucoside-treated cells. Glucosides 136-145 BCL2 apoptosis regulator Homo sapiens 60-65 27517324-5 2016 In this study, we demonstrated that preconditioning of NaHS, a H2S donor, effectively suppressed hypoxia-ischemic-induced apoptosis whereby the rise in Bax/Bcl-2 ratio. sodium bisulfide 55-59 BCL2 apoptosis regulator Homo sapiens 156-161 27517324-5 2016 In this study, we demonstrated that preconditioning of NaHS, a H2S donor, effectively suppressed hypoxia-ischemic-induced apoptosis whereby the rise in Bax/Bcl-2 ratio. Hydrogen Sulfide 63-66 BCL2 apoptosis regulator Homo sapiens 156-161 27656146-6 2016 The expression of anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) was attenuated in UVB-exposed cells but restored in UVB/cyanidin-3-O-glucoside-treated cells. cyanidin-3-o 123-135 BCL2 apoptosis regulator Homo sapiens 41-58 27533080-5 2016 The Bcl-2 inhibitor ABT-263 (navitoclax) increased sensitivity to the mTORC1/2 inhibitor AZD8055 in TP53 wild type GSCs, while sensitivity to AZD8055 in TP53 mutated GSCs remained unchanged. (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol 89-96 BCL2 apoptosis regulator Homo sapiens 4-9 27533080-5 2016 The Bcl-2 inhibitor ABT-263 (navitoclax) increased sensitivity to the mTORC1/2 inhibitor AZD8055 in TP53 wild type GSCs, while sensitivity to AZD8055 in TP53 mutated GSCs remained unchanged. (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol 142-149 BCL2 apoptosis regulator Homo sapiens 4-9 27343560-6 2016 Inhibition of Bcl-2 by ABT-737 (a known Bcl-2 inhibitor) or Bcl-2 shRNA dramatically potentiated AZD-2014 lethality against HNSCC cells. azd 97-100 BCL2 apoptosis regulator Homo sapiens 14-19 27246734-8 2016 Moreover, Western blot and immunofluorescence results indicated that caspase 3 activation was reduced, whereas bcl-2 level was significantly increased by metformin. Metformin 154-163 BCL2 apoptosis regulator Homo sapiens 111-116 27233802-1 2016 Venetoclax (ABT-199/GDC-0199) is a selective, potent, first-in-class BCL-2 inhibitor that restores apoptosis in cancer cells and has demonstrated clinical efficacy in a variety of hematological malignancies. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 69-74 27402273-7 2016 Further, evodiamine increased (4-fold) mitochondrial membrane depolarization with 6-fold increase in apoptosis and a slight increase in Bax/Bcl-2 ratio. evodiamine 9-19 BCL2 apoptosis regulator Homo sapiens 140-145 27598175-6 2016 RESULTS: 11-Dehydrosinulariolide attenuated SCI-induced cell apoptosis by upregulating the antiapoptotic protein Bcl-2 and cell survival-related pathway proteins p-Akt and p-ERK, 8 h after SCI. 11-dehydrosinulariolide 9-32 BCL2 apoptosis regulator Homo sapiens 113-118 27598175-7 2016 Furthermore, the transcription factor p-CREB, which regulates Bcl-2 expression, was upregulated after 11-dehydrosinulariolide treatment. 11-dehydrosinulariolide 102-125 BCL2 apoptosis regulator Homo sapiens 62-67 27343560-0 2016 Inhibition of Bcl-2 potentiates AZD-2014-induced anti-head and neck squamous cell carcinoma cell activity. azd 32-35 BCL2 apoptosis regulator Homo sapiens 14-19 27343560-5 2016 In an effect to identify possible AZD-2014 resistance factors, we showed that the anti-apoptosis protein Bcl-2 was upregulated in AZD-2014-resistant SQ20B HNSCC cells. azd 34-37 BCL2 apoptosis regulator Homo sapiens 105-110 27343560-5 2016 In an effect to identify possible AZD-2014 resistance factors, we showed that the anti-apoptosis protein Bcl-2 was upregulated in AZD-2014-resistant SQ20B HNSCC cells. azd 130-133 BCL2 apoptosis regulator Homo sapiens 105-110 27343560-6 2016 Inhibition of Bcl-2 by ABT-737 (a known Bcl-2 inhibitor) or Bcl-2 shRNA dramatically potentiated AZD-2014 lethality against HNSCC cells. ABT-737 23-30 BCL2 apoptosis regulator Homo sapiens 14-19 27233802-1 2016 Venetoclax (ABT-199/GDC-0199) is a selective, potent, first-in-class BCL-2 inhibitor that restores apoptosis in cancer cells and has demonstrated clinical efficacy in a variety of hematological malignancies. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 12-15 BCL2 apoptosis regulator Homo sapiens 69-74 27233802-1 2016 Venetoclax (ABT-199/GDC-0199) is a selective, potent, first-in-class BCL-2 inhibitor that restores apoptosis in cancer cells and has demonstrated clinical efficacy in a variety of hematological malignancies. venetoclax 20-28 BCL2 apoptosis regulator Homo sapiens 69-74 27477115-8 2016 Moreover, the expression of BCL-2, CYP17A1, CYP19A1, SOD1, and GPX4 were up-regulated by 0.01ng/mL melatonin or combined with IIK7, but decreased for the mRNA levels of BAX, P53, and CASPASE-3, as compared with control or groups treated with Luzindole or 4P-PDOT in the presence of melatonin. Melatonin 282-291 BCL2 apoptosis regulator Homo sapiens 28-33 27477115-8 2016 Moreover, the expression of BCL-2, CYP17A1, CYP19A1, SOD1, and GPX4 were up-regulated by 0.01ng/mL melatonin or combined with IIK7, but decreased for the mRNA levels of BAX, P53, and CASPASE-3, as compared with control or groups treated with Luzindole or 4P-PDOT in the presence of melatonin. Melatonin 99-108 BCL2 apoptosis regulator Homo sapiens 28-33 27271333-3 2016 Downregulation of the anti-apoptosis proteins Bcl-2 and XIAP was involved during betulin-induced cell apoptosis. betulin 81-88 BCL2 apoptosis regulator Homo sapiens 46-51 27262539-5 2016 Our studies have shown significant differences in apoptotic cells by chromatin condensation, formation of apoptotic bodies and exposure of phosphatidylserine (PS) on the extracellular surface when the cells where treated with a potent Bcl-2 family inhibitor drug (ABT-263). Phosphatidylserines 139-157 BCL2 apoptosis regulator Homo sapiens 235-240 27262539-5 2016 Our studies have shown significant differences in apoptotic cells by chromatin condensation, formation of apoptotic bodies and exposure of phosphatidylserine (PS) on the extracellular surface when the cells where treated with a potent Bcl-2 family inhibitor drug (ABT-263). Phosphatidylserines 159-161 BCL2 apoptosis regulator Homo sapiens 235-240 27262539-5 2016 Our studies have shown significant differences in apoptotic cells by chromatin condensation, formation of apoptotic bodies and exposure of phosphatidylserine (PS) on the extracellular surface when the cells where treated with a potent Bcl-2 family inhibitor drug (ABT-263). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 264-267 BCL2 apoptosis regulator Homo sapiens 235-240 27196819-7 2016 However, a simpler, IPI independent model incorporated LMO2 and BCL2 and assigned 33% of the patients with a 3-year PFS of 35% vs. 82% for low risk group (P < 0 001). diprotin A 20-23 BCL2 apoptosis regulator Homo sapiens 64-68 27477115-8 2016 Moreover, the expression of BCL-2, CYP17A1, CYP19A1, SOD1, and GPX4 were up-regulated by 0.01ng/mL melatonin or combined with IIK7, but decreased for the mRNA levels of BAX, P53, and CASPASE-3, as compared with control or groups treated with Luzindole or 4P-PDOT in the presence of melatonin. luzindole 242-251 BCL2 apoptosis regulator Homo sapiens 28-33 27332950-7 2016 Moreover, CsV inhibited H2O2-induced down-regulation of Bcl-2 and up-regulation of Bax in a dose-dependent manner and, thus, increased the ratio of Bcl-2/Bax. Hydrogen Peroxide 24-28 BCL2 apoptosis regulator Homo sapiens 56-61 27332950-7 2016 Moreover, CsV inhibited H2O2-induced down-regulation of Bcl-2 and up-regulation of Bax in a dose-dependent manner and, thus, increased the ratio of Bcl-2/Bax. Hydrogen Peroxide 24-28 BCL2 apoptosis regulator Homo sapiens 148-153 27314518-6 2016 In the present work, we focused on Hypericin (Hyp) and HypPDT effects on the cell viability, oxidative stress, and the distribution of Bcl2 family members in human coronary artery endothelial (HCAEC) cells. hypericin 35-44 BCL2 apoptosis regulator Homo sapiens 135-139 25865073-7 2016 Furthermore, the levels of pro-apoptotic molecules, Bax and cleaved-PARP, increased significantly, whereas Bcl2 declined after exposed to 100 nM TCDD. Polychlorinated Dibenzodioxins 145-149 BCL2 apoptosis regulator Homo sapiens 107-111 27448221-6 2016 In addition, western blot showed that 5Z-7-oxozeaenol enhanced HT-induced expressions of cleaved caspase-3, cleaved caspase-8, and HSP70 and decreased HT-induced expressions of Bcl-2, p-p38, p-JNK, and LC3. 5-7-oxo-zeaenol 38-53 BCL2 apoptosis regulator Homo sapiens 177-182 27103402-3 2016 Immunoprecipitation of Bim and Mcl-1 were used to determine the effect of ABT-199 treatment on their interactions with Bcl-2 family members. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 74-77 BCL2 apoptosis regulator Homo sapiens 119-124 27649657-0 2016 miRNA-21 sensitizes gastrointestinal stromal tumors (GISTs) cells to Imatinib via targeting B-cell lymphoma 2 (Bcl-2). Imatinib Mesylate 69-77 BCL2 apoptosis regulator Homo sapiens 92-109 27490211-13 2016 Anti-GSK3 beta, pGSK3 beta, Bcl-2, Akt-1, p-Akt1 protein levels were observed with cells exposed to Tideglusib and Lithium chloride. Lithium Chloride 115-131 BCL2 apoptosis regulator Homo sapiens 28-33 27458702-4 2016 Compared to the control group, olaquindox treatment at 400 and 800mug/mL increased the expression level of GADD45a protein and reactive oxygen species (ROS) production, decreased mitochondrial membrane potential (MMP), and subsequently increased the expression of Bax while decreased the expression of Bcl-2, leading to the release of cytochrome c (Cyt c). olaquindox 31-41 BCL2 apoptosis regulator Homo sapiens 302-307 27649657-0 2016 miRNA-21 sensitizes gastrointestinal stromal tumors (GISTs) cells to Imatinib via targeting B-cell lymphoma 2 (Bcl-2). Imatinib Mesylate 69-77 BCL2 apoptosis regulator Homo sapiens 111-116 27288242-11 2016 Besides, sunitinib boosted cortical and hippocampal p53 and executioner caspase-3 and decreased nuclear factor kappa B and Bcl-2 levels promoting apoptotic cell death. Sunitinib 9-18 BCL2 apoptosis regulator Homo sapiens 123-128 27602089-5 2016 The results suggested that numerous genes were regulated by lovastatin, including certain genes associated with cell survival, such as PTK2B, BCL2 and MAP3K3. Lovastatin 60-70 BCL2 apoptosis regulator Homo sapiens 142-146 27444341-3 2016 Disarib showed selective cytotoxicity in BCL2 high cancer cell lines, and CLL patient primary cells, as compared to BCL2 low cell lines. disarib 0-7 BCL2 apoptosis regulator Homo sapiens 41-45 27573873-10 2016 VC-A also induced mitochondrial depolarization and release of cytochrome c and it inhibited Bcl-2 family proteins that regulate apoptosis (Bcl-2, Bcl-xL, Bax and Bad). muconomycin A 0-4 BCL2 apoptosis regulator Homo sapiens 139-144 27500741-5 2016 Quantitative PCR analysis demonstrated that CIMO decreases the relative mRNA expression of genes that are involved in cell cycle progression (CCND1) and cell survival (BCL2, BCL-xL, BAD, CASP 3/7/9, and TP53). cimo 44-48 BCL2 apoptosis regulator Homo sapiens 168-172 27573873-10 2016 VC-A also induced mitochondrial depolarization and release of cytochrome c and it inhibited Bcl-2 family proteins that regulate apoptosis (Bcl-2, Bcl-xL, Bax and Bad). muconomycin A 0-4 BCL2 apoptosis regulator Homo sapiens 92-97 27078502-6 2016 Costunolide triggered apoptosis in esophageal cancer cells via the upregulation of Bax, downregulation of Bcl-2, and significant activation of caspase-3 and poly ADP-ribose polymerase. costunolide 0-11 BCL2 apoptosis regulator Homo sapiens 106-111 27424191-8 2016 Using the proteomic and human apoptosis array screening approaches, differential regulation of several proteins, including members of the bcl-2 family, was found, giving first insights into the mode of action of cabazitaxel in GCT. cabazitaxel 212-223 BCL2 apoptosis regulator Homo sapiens 138-143 27043233-5 2016 Thus, numerous approaches have been developed to block or modulate the production of BCL-2 at the RNA level using antisense oligonucleotides or at the protein level with BCL-2 inhibitors, such as the novel ABT737. Oligonucleotides 124-140 BCL2 apoptosis regulator Homo sapiens 85-90 27721874-10 2016 BCL2-positive expression was also associated with favorable 5-year RFS (p=0.008, 91.4%) and DSS (p=0.036, 95.6%) in all the patients. dss 92-95 BCL2 apoptosis regulator Homo sapiens 0-4 27484725-10 2016 The results of immunohistochemistry analysis demonstrated that Bax expression was increased and Bcl-2 was decreased in the Ad-ING4-P53 + cisplatin group. Cisplatin 137-146 BCL2 apoptosis regulator Homo sapiens 96-101 27721874-11 2016 BCL2-positive expression in luminal A breast cancer resulted in significantly favorable 5-year RFS and DSS (p=0.023 and p=0.041, respectively). dss 103-106 BCL2 apoptosis regulator Homo sapiens 0-4 27430155-6 2016 Quinine, a natural alkaloid that is well-known for its therapeutic treatment of malaria, exhibited a distinct antiproliferative and pro-apoptotic effect in HeLa and A549 tumor cell lines via the inhibition of the antiapoptotic protein, B-cell lymphoma (BCL)-2, and activation of the pro-apoptotic factor, BCL-2-associated X protein. Quinine 0-7 BCL2 apoptosis regulator Homo sapiens 236-259 27485202-4 2016 The results indicated that evodiamine significantly inhibited proliferation, induced apoptosis and the expression of reactive oxygen species, arrested the cell cycle, regulated the expression of Survivin, Bcl-2 and Cyclin B1, regulated the activity of caspase-3/8 and glutathione in tumor cells, and decreased the activity of AKT/nuclear factor-kappaB (NF-kappaB) and Sonic hedgehog/GLI family zinc finger 1 (SHH/GLI1) signaling pathways in A549 cells. evodiamine 27-37 BCL2 apoptosis regulator Homo sapiens 205-210 27160168-9 2016 With elevation of intracellular ROS level, flow cytometry measurement verified mitochondrial transmembrane potential collapse, which was accompanied by the up-regulation of Bax and down-regulation of Bcl-2. Reactive Oxygen Species 32-35 BCL2 apoptosis regulator Homo sapiens 200-205 27430517-9 2016 Furthermore, downregulation of miR-16 using the anti-miR-16 plasmid reversed the effect of apigenin on cell viability, BCL2 protein expression and the NF-kappaB/MMP-9 pathway in U87 cells. mir-16 31-37 BCL2 apoptosis regulator Homo sapiens 119-123 27484725-11 2016 This suggested that the enhanced cisplatin chemosensitivity with Ad-ING4-P53 gene therapy in hypopharyngeal cancer xenografts may be associated with apoptosis induction through upregulation of Bax expression and downregulation of Bcl-2. Cisplatin 33-42 BCL2 apoptosis regulator Homo sapiens 230-235 26243186-10 2016 We found that cocaine-induced autophagy was mediated by sigma 1 receptor, and autophagy signaling proteins p-mTOR, Atg5, Atg7, and p-Bcl-2/Beclin-1 were also involved, and this was confirmed by using selective inhibitors and small interfering RNAs (siRNAs). Cocaine 14-21 BCL2 apoptosis regulator Homo sapiens 133-138 27535975-0 2016 BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics. BH 3 62-65 BCL2 apoptosis regulator Homo sapiens 0-4 27535975-4 2016 However, resistance to ABT-199 is mediated by other BCL2 proteins including BCLXL and MCL1. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 23-26 BCL2 apoptosis regulator Homo sapiens 52-56 27535975-5 2016 Considerable effort has been expended seeking novel "BH3 mimetics" that inhibit all of these BCL2 proteins. BH 3 53-56 BCL2 apoptosis regulator Homo sapiens 93-97 27535975-6 2016 While many BH3 mimetics inhibit BCL2 proteins in vitro, they fail to directly inhibit them in intact cells. BH 3 11-14 BCL2 apoptosis regulator Homo sapiens 32-36 27367429-6 2016 LiCl was less effective in decreasing the MK and B cell lymphoma-2 (Bcl-2) levels compared with the combination treatment. Lithium Chloride 0-4 BCL2 apoptosis regulator Homo sapiens 49-66 27367429-6 2016 LiCl was less effective in decreasing the MK and B cell lymphoma-2 (Bcl-2) levels compared with the combination treatment. Lithium Chloride 0-4 BCL2 apoptosis regulator Homo sapiens 68-73 27432595-6 2016 Moreover, GSH-sensitive MM allows for an efficient downregulation of Bcl2, survivin, and notch1 (65%, 55%, and 46%, respectively) in HT1080 cells. Glutathione 10-13 BCL2 apoptosis regulator Homo sapiens 69-73 27588132-8 2016 Western blotting confirmed that the expression of pro-apoptosis-associated proteins Bax and LC3II, and phosphorylated-ERK were upregulated, and anti-apoptosis protein Bcl-2 was downregulated in a time-dependent manner following treatment with matrine. matrine 243-250 BCL2 apoptosis regulator Homo sapiens 167-172 27588132-10 2016 In addiiton, expression of LC3II/LC3I decreased and the expression of BAX/Bcl-2 increased in the matrine + U0126 group compared with the matrine alone group. matrine 97-104 BCL2 apoptosis regulator Homo sapiens 74-79 27588132-10 2016 In addiiton, expression of LC3II/LC3I decreased and the expression of BAX/Bcl-2 increased in the matrine + U0126 group compared with the matrine alone group. U 0126 107-112 BCL2 apoptosis regulator Homo sapiens 74-79 26730946-7 2016 Treatment with POS significantly upregulated the levels of caspase-3 (p < 0.01), caspase-7 (p < 0.01), caspase-9 (p < 0.01) and Bax (p < 0.01) in A549 cells, and Bcl-2 was downregulated (p < 0.01). puerarin 6'-O-xyloside 15-18 BCL2 apoptosis regulator Homo sapiens 174-179 27432558-6 2016 Propranolol treatment inhibited growth and induced apoptosis of 8505C cells in vitro and in vivo, which are closely associated with decreased expressions of cyclin D1 and anti-apoptotic Bcl-2. Propranolol 0-11 BCL2 apoptosis regulator Homo sapiens 186-191 27729798-8 2016 Furthermore, Western blot assays demonstrated that atracurium upregulated the proapoptotic Bad and Bax proteins, downregulated the antiapoptotic p-Bad and Bcl-2 proteins, and enhanced caspase-3 activity. Atracurium 51-61 BCL2 apoptosis regulator Homo sapiens 155-160 27609577-6 2016 After the cells were treated with 0.5 mg/L(IC50) epirubicin, the apoptosis rate of MGC-803 cells was raised, the protein expressions of caspase-3 , caspase-9 and Bax were significantly upregulated and Bcl-2 was downregulated. Epirubicin 49-59 BCL2 apoptosis regulator Homo sapiens 201-206 27216471-0 2016 Cytotoxicity of carteolol to human corneal epithelial cells by inducing apoptosis via triggering the Bcl-2 family protein-mediated mitochondrial pro-apoptotic pathway. Carteolol 16-25 BCL2 apoptosis regulator Homo sapiens 101-106 27378626-7 2016 Biochemical evidence of apoptosis came from elevating the intracellular ROS level that was accompanied by mitochondrial membrane potential loss, decreasing the expression profile of anti-apoptotic protein Bcl-2, whereas it augments cleavage of caspase-3 and PARP-1, activates caspase-8 and 9 with concomitant increase in expression of proapoptotic protein Bax in a dose dependent manner. ros 72-75 BCL2 apoptosis regulator Homo sapiens 205-210 27494891-6 2016 Mechanistic studies suggested that treatment of cells with PHPO or with PHPO + cisplatin differentially inhibited the PI3K/Akt, MAPK and ATM/Chk2 pathways, which consequently suppressed the anti-apoptotic factors Bcl-xL, Bcl-2 and XIAP, but activated the pro-apoptotic factors Bad, Bax, p53, caspase 9, caspase 8, caspase 7 and PARP. phpo 59-63 BCL2 apoptosis regulator Homo sapiens 221-226 27494891-6 2016 Mechanistic studies suggested that treatment of cells with PHPO or with PHPO + cisplatin differentially inhibited the PI3K/Akt, MAPK and ATM/Chk2 pathways, which consequently suppressed the anti-apoptotic factors Bcl-xL, Bcl-2 and XIAP, but activated the pro-apoptotic factors Bad, Bax, p53, caspase 9, caspase 8, caspase 7 and PARP. phpo 72-76 BCL2 apoptosis regulator Homo sapiens 221-226 27494891-6 2016 Mechanistic studies suggested that treatment of cells with PHPO or with PHPO + cisplatin differentially inhibited the PI3K/Akt, MAPK and ATM/Chk2 pathways, which consequently suppressed the anti-apoptotic factors Bcl-xL, Bcl-2 and XIAP, but activated the pro-apoptotic factors Bad, Bax, p53, caspase 9, caspase 8, caspase 7 and PARP. Cisplatin 79-88 BCL2 apoptosis regulator Homo sapiens 221-226 27451028-8 2016 It has been demonstrated that 6-gingerol suppressed the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR signaling pathway, increased the expression of Beclin1 to promote autophagy, and increased Bcl-2 expression to inhibit apoptosis. gingerol 30-40 BCL2 apoptosis regulator Homo sapiens 193-198 27524613-5 2016 SNP rs539846 C>A, the most highly associated variant (p = 1.42 x 10(-13), odds ratio = 1.35), localizes to a super-enhancer defined by extensive histone H3 lysine 27 acetylation in intron 3 of B cell lymphoma 2 (BCL2)-modifying factor (BMF). Lysine 159-165 BCL2 apoptosis regulator Homo sapiens 196-213 27560714-5 2016 These data were confirmed with novel highly specific BH3-mimetic compounds that target either BCL-2, BCL-XL or MCL-1. BH 3 53-56 BCL2 apoptosis regulator Homo sapiens 94-99 27560714-8 2016 More markedly, loss of MCL-1 greatly sensitizes PC populations to BCL-2 inhibition using ABT-737, even though the total wild-type PC pool in the spleen is not significantly affected by this drug and the bone marrow (BM) PC population only slightly. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 89-92 BCL2 apoptosis regulator Homo sapiens 66-71 27524613-5 2016 SNP rs539846 C>A, the most highly associated variant (p = 1.42 x 10(-13), odds ratio = 1.35), localizes to a super-enhancer defined by extensive histone H3 lysine 27 acetylation in intron 3 of B cell lymphoma 2 (BCL2)-modifying factor (BMF). Lysine 159-165 BCL2 apoptosis regulator Homo sapiens 215-219 27419628-5 2016 The results showed that both glutamine deprivation and BPTES pretreatments increased the toxic effects of cisplatin and etoposide on HCC1937 cells, as demonstrated by their reduced proliferation, increased expression of apoptosis-related proteins (cleaved-PARP, cleaved-caspase 9, and cleaved-caspase 3) and decreased Bcl-2/BAX ratio. Glutamine 29-38 BCL2 apoptosis regulator Homo sapiens 318-323 27494888-6 2016 We therefore propose a novel model, in which the Bcl-2"s C-terminus serves as a functional anchor, which beyond mere ER-membrane targeting, underlies efficient IP3R inhibition by (i) positioning the BH4 domain in the close proximity of its binding site on IP3R, thus facilitating their interaction; (ii) inhibiting IP3R-channel openings through a direct interaction with the C-terminal region of the channel downstream of the channel-pore. sapropterin 199-202 BCL2 apoptosis regulator Homo sapiens 49-54 27419628-5 2016 The results showed that both glutamine deprivation and BPTES pretreatments increased the toxic effects of cisplatin and etoposide on HCC1937 cells, as demonstrated by their reduced proliferation, increased expression of apoptosis-related proteins (cleaved-PARP, cleaved-caspase 9, and cleaved-caspase 3) and decreased Bcl-2/BAX ratio. bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 55-60 BCL2 apoptosis regulator Homo sapiens 318-323 27419628-5 2016 The results showed that both glutamine deprivation and BPTES pretreatments increased the toxic effects of cisplatin and etoposide on HCC1937 cells, as demonstrated by their reduced proliferation, increased expression of apoptosis-related proteins (cleaved-PARP, cleaved-caspase 9, and cleaved-caspase 3) and decreased Bcl-2/BAX ratio. Cisplatin 106-115 BCL2 apoptosis regulator Homo sapiens 318-323 27419628-5 2016 The results showed that both glutamine deprivation and BPTES pretreatments increased the toxic effects of cisplatin and etoposide on HCC1937 cells, as demonstrated by their reduced proliferation, increased expression of apoptosis-related proteins (cleaved-PARP, cleaved-caspase 9, and cleaved-caspase 3) and decreased Bcl-2/BAX ratio. Etoposide 120-129 BCL2 apoptosis regulator Homo sapiens 318-323 27551974-5 2016 CPX also enhanced apoptotic cell death by downregulation of anti-apoptotic proteins such as Bcl-2, Bcl-xL, and Mcl-1. Ciclopirox 0-3 BCL2 apoptosis regulator Homo sapiens 92-97 27582059-5 2016 Recently, a selective inhibitor of B cell lymphoma 2 (BCL-2), ABT-199 (venetoclax), has shown impressive activity against hematologic malignancies. venetoclax 62-69 BCL2 apoptosis regulator Homo sapiens 35-52 27582059-5 2016 Recently, a selective inhibitor of B cell lymphoma 2 (BCL-2), ABT-199 (venetoclax), has shown impressive activity against hematologic malignancies. venetoclax 62-69 BCL2 apoptosis regulator Homo sapiens 54-59 27556439-7 2016 Curcumin pre-treatment consistently and markedly down-regulated the mRNA expression levels of p53, Bax, caspase-9 and -3 and up-regulated the mRNA expression level of Bcl-2. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 167-172 27601896-0 2016 Synergistic and complete reversal of the multidrug resistance of mitoxantrone hydrochloride by three-in-one multifunctional lipid-sodium glycocholate nanocarriers based on simultaneous BCRP and Bcl-2 inhibition. Mitoxantrone 65-91 BCL2 apoptosis regulator Homo sapiens 194-199 27601896-0 2016 Synergistic and complete reversal of the multidrug resistance of mitoxantrone hydrochloride by three-in-one multifunctional lipid-sodium glycocholate nanocarriers based on simultaneous BCRP and Bcl-2 inhibition. Glycocholic Acid 130-149 BCL2 apoptosis regulator Homo sapiens 194-199 27297795-1 2016 Novel agents such as the Bcl-2 inhibitor venetoclax (ABT-199) are changing treatment paradigms for chronic lymphocytic leukemia (CLL) but important problems remain. venetoclax 41-51 BCL2 apoptosis regulator Homo sapiens 25-30 27297795-1 2016 Novel agents such as the Bcl-2 inhibitor venetoclax (ABT-199) are changing treatment paradigms for chronic lymphocytic leukemia (CLL) but important problems remain. venetoclax 53-60 BCL2 apoptosis regulator Homo sapiens 25-30 27537523-8 2016 However, apoptosis was substantially increased in infected Bcl-XL-deficient macrophages or macrophages treated with the Bcl-2/Bcl-XL-inhibitor ABT-737. ABT-737 143-150 BCL2 apoptosis regulator Homo sapiens 120-125 27537525-9 2016 Human CRC tissue was cultured ex vivo and treated with the small molecule compound ABT-737, which inhibits Bcl-xL and Bcl-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 83-86 BCL2 apoptosis regulator Homo sapiens 118-123 27520705-0 2016 IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis. Astatine 31-33 BCL2 apoptosis regulator Homo sapiens 88-93 27520705-6 2016 Finally, Birinapant and AT-406 can synergise with BCL-2 inhibitor ABT-199 to reduce viability of adenocarcinoma cells with high BCL-2 expression. N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 24-30 BCL2 apoptosis regulator Homo sapiens 128-133 27520705-6 2016 Finally, Birinapant and AT-406 can synergise with BCL-2 inhibitor ABT-199 to reduce viability of adenocarcinoma cells with high BCL-2 expression. venetoclax 66-73 BCL2 apoptosis regulator Homo sapiens 50-55 27520705-6 2016 Finally, Birinapant and AT-406 can synergise with BCL-2 inhibitor ABT-199 to reduce viability of adenocarcinoma cells with high BCL-2 expression. venetoclax 66-73 BCL2 apoptosis regulator Homo sapiens 128-133 27425825-2 2016 Antiapoptotic B-cell-2 (Bcl-2) family member Bcl-XL protein, a 5-carboxyfluorescein labeled peptide truncated from the BH3 domain of Bid (F-Bid) as the ligand, and a known Bcl-XL-Bid interaction inhibitor ABT-263 were employed as an experimental model for the proof of concept. 4-carboxyfluorescein 63-83 BCL2 apoptosis regulator Homo sapiens 14-22 27425825-2 2016 Antiapoptotic B-cell-2 (Bcl-2) family member Bcl-XL protein, a 5-carboxyfluorescein labeled peptide truncated from the BH3 domain of Bid (F-Bid) as the ligand, and a known Bcl-XL-Bid interaction inhibitor ABT-263 were employed as an experimental model for the proof of concept. 4-carboxyfluorescein 63-83 BCL2 apoptosis regulator Homo sapiens 24-29 27425825-2 2016 Antiapoptotic B-cell-2 (Bcl-2) family member Bcl-XL protein, a 5-carboxyfluorescein labeled peptide truncated from the BH3 domain of Bid (F-Bid) as the ligand, and a known Bcl-XL-Bid interaction inhibitor ABT-263 were employed as an experimental model for the proof of concept. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 205-208 BCL2 apoptosis regulator Homo sapiens 14-22 27425825-2 2016 Antiapoptotic B-cell-2 (Bcl-2) family member Bcl-XL protein, a 5-carboxyfluorescein labeled peptide truncated from the BH3 domain of Bid (F-Bid) as the ligand, and a known Bcl-XL-Bid interaction inhibitor ABT-263 were employed as an experimental model for the proof of concept. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 205-208 BCL2 apoptosis regulator Homo sapiens 24-29 27312872-6 2016 The protein level assays revealed that TCDD increased cyclin-dependent kinases 4 (cdk4), cyclin D1, cyclin E and p21 (Waf1/Cip1) but not cdk2, bcl-2, cyclin B1 and cyclin A. Polychlorinated Dibenzodioxins 39-43 BCL2 apoptosis regulator Homo sapiens 143-148 27330076-5 2016 Mechanistically, knockdown or inhibition of PDK4 significantly increases the inhibitory effect of 5-FU on expression of the anti-apoptotic factors Bcl-2 and survivin. Fluorouracil 98-102 BCL2 apoptosis regulator Homo sapiens 147-152 27520705-6 2016 Finally, Birinapant and AT-406 can synergise with BCL-2 inhibitor ABT-199 to reduce viability of adenocarcinoma cells with high BCL-2 expression. birinapant 9-19 BCL2 apoptosis regulator Homo sapiens 128-133 27525951-2 2016 Therefore, target fishing of glycopentalone using a combined approach of inverse docking and reverse pharmacophore mapping approach was used to identify potential targets of glycopentalone, and gain insight into its binding modes against the selected molecular targets, viz., CDK-2, CDK-6, Topoisomerase I, Bcl-2, VEGFR-2, Telomere:G-quadruplex and Topoisomerase II. 1-(2-hydroxy-3- methyl 4,5-dimethoxyphenyl)-3-(1H-pyrrol-2-yl)-2-propen-1-one 29-43 BCL2 apoptosis regulator Homo sapiens 307-312 27525951-2 2016 Therefore, target fishing of glycopentalone using a combined approach of inverse docking and reverse pharmacophore mapping approach was used to identify potential targets of glycopentalone, and gain insight into its binding modes against the selected molecular targets, viz., CDK-2, CDK-6, Topoisomerase I, Bcl-2, VEGFR-2, Telomere:G-quadruplex and Topoisomerase II. 1-(2-hydroxy-3- methyl 4,5-dimethoxyphenyl)-3-(1H-pyrrol-2-yl)-2-propen-1-one 174-188 BCL2 apoptosis regulator Homo sapiens 307-312 27517917-10 2016 Metformin treatment reduced breast cancer cell viability, increased miR-26a expression, and led to a reduction in BCL-2, EZH2, and PTEN expression. Metformin 0-9 BCL2 apoptosis regulator Homo sapiens 114-119 27525951-5 2016 Further, the binding affinities of glycopentalone to the targets were in the order: Telomere:G-quadruplex > VEGFR-2 > CDK-6 > CDK-2 > Topoisomerase II > Topoisomerase I > Bcl-2. 1-(2-hydroxy-3- methyl 4,5-dimethoxyphenyl)-3-(1H-pyrrol-2-yl)-2-propen-1-one 35-49 BCL2 apoptosis regulator Homo sapiens 189-194 27138804-4 2016 The aim of the present study is to investigate the value of Pan-Bcl-2 inhibitor as sensitizer for the chemotherapy of cisplatin-resistant non-small cell lung cancer (NSCLC) cells. Cisplatin 118-127 BCL2 apoptosis regulator Homo sapiens 64-69 27367032-5 2016 By using PCR arrays and FACS analysis, we found that the CPS-treated BC cells displayed typical mesenchymal features of the epithelial mesenchymal transition (EMT) as elongated shape and over-expression of vimentin, alpha5 and beta1 integrin subunits, integrin-like kinase and the anti-apoptotic Bcl-2 proteins. Capsaicin 57-60 BCL2 apoptosis regulator Homo sapiens 296-301 27283492-3 2016 We also report that, like other FAO inhibitors, both agents and the related biguanide, Phenformin, increase sensitivity to apoptosis induction by the bcl-2 inhibitor ABT-737 supporting the notion that electron transport antagonizes activation of the intrinsic apoptosis pathway in leukemia cells. Biguanides 76-85 BCL2 apoptosis regulator Homo sapiens 150-155 27283492-3 2016 We also report that, like other FAO inhibitors, both agents and the related biguanide, Phenformin, increase sensitivity to apoptosis induction by the bcl-2 inhibitor ABT-737 supporting the notion that electron transport antagonizes activation of the intrinsic apoptosis pathway in leukemia cells. Phenformin 87-97 BCL2 apoptosis regulator Homo sapiens 150-155 27283492-3 2016 We also report that, like other FAO inhibitors, both agents and the related biguanide, Phenformin, increase sensitivity to apoptosis induction by the bcl-2 inhibitor ABT-737 supporting the notion that electron transport antagonizes activation of the intrinsic apoptosis pathway in leukemia cells. ABT-737 166-173 BCL2 apoptosis regulator Homo sapiens 150-155 27506388-8 2016 RSV-GSE also induced mitochondrial-mediated apoptosis in colon CSCs characterized by elevated p53, Bax/Bcl-2 ratio and cleaved PARP. Resveratrol 0-3 BCL2 apoptosis regulator Homo sapiens 103-108 27176035-7 2016 Simultaneously, EPA downregulated the phosphorylation status of mTOR, which may act as an upstream regulator of EPA-blocked nuclear factor kappaB (NF-kappaB) p65 translocation from the cytoplasm into the nucleus; the apoptotic mechanism of SKOV-3 cells induced by EPA was associated with the release of cytochrome c, Bax-to-Bcl-2 expression ratio, and activation of caspase-3 and caspase-9. Eicosapentaenoic Acid 16-19 BCL2 apoptosis regulator Homo sapiens 324-329 27483435-0 2016 Protein Kinase RNA-Like Endoplasmic Reticulum Kinase-Mediated Bcl-2 Protein Phosphorylation Contributes to Evodiamine-Induced Apoptosis of Human Renal Cell Carcinoma Cells. evodiamine 107-117 BCL2 apoptosis regulator Homo sapiens 62-67 27483435-4 2016 EVO disruption of the mitochondrial membrane potential (MMP) with increased protein levels of the phosphorylated Bcl-2 protein (p-Bcl-2) was prevented by JNK inhibitors in A498 cells. evodiamine 0-3 BCL2 apoptosis regulator Homo sapiens 113-118 27483435-4 2016 EVO disruption of the mitochondrial membrane potential (MMP) with increased protein levels of the phosphorylated Bcl-2 protein (p-Bcl-2) was prevented by JNK inhibitors in A498 cells. evodiamine 0-3 BCL2 apoptosis regulator Homo sapiens 130-135 27483435-5 2016 A structure-activity relationship study showed that a methyl group at position 14 in EVO was important for its apoptotic effects and increased p-Bcl-2 protein in A498 cells. evodiamine 85-88 BCL2 apoptosis regulator Homo sapiens 145-150 27391065-4 2016 Metformin also triggers the apoptotic pathway, shown by the decreased expression of Bcl-2 and HSP27, HSP60 and HSP70, and enhanced membrane exposure of annexin V, resulting in activation of caspase-3 apoptotic effector. Metformin 0-9 BCL2 apoptosis regulator Homo sapiens 84-89 27176035-7 2016 Simultaneously, EPA downregulated the phosphorylation status of mTOR, which may act as an upstream regulator of EPA-blocked nuclear factor kappaB (NF-kappaB) p65 translocation from the cytoplasm into the nucleus; the apoptotic mechanism of SKOV-3 cells induced by EPA was associated with the release of cytochrome c, Bax-to-Bcl-2 expression ratio, and activation of caspase-3 and caspase-9. Eicosapentaenoic Acid 112-115 BCL2 apoptosis regulator Homo sapiens 324-329 27328368-14 2016 (R)(S)(S)-BF65 in turn suppresses Bcl-2 and MAPKs induced by MK-2206. MK 2206 61-68 BCL2 apoptosis regulator Homo sapiens 34-39 27328368-4 2016 (R)(S)(S)-BF65 induced phosphorylation and inactivation of Bcl-2, and downregulated Mcl-1, consequently may lead to apoptosis. Sulfur 3-6 BCL2 apoptosis regulator Homo sapiens 59-64 27505095-2 2016 However, recent research has revealed that in addition to regulation of mitochondrial apoptosis, proteins of the Bcl-2 family play important roles in regulating other cellular pathways with a strong impact on cell survival like autophagy, endoplasmic reticulum (ER) stress response, intracellular calcium dynamics, cell cycle progression, mitochondrial dynamics and energy metabolism. Calcium 297-304 BCL2 apoptosis regulator Homo sapiens 113-118 27328368-4 2016 (R)(S)(S)-BF65 induced phosphorylation and inactivation of Bcl-2, and downregulated Mcl-1, consequently may lead to apoptosis. (s)-bf65 6-14 BCL2 apoptosis regulator Homo sapiens 59-64 27328368-9 2016 Interestingly, MK-2206 upregulated Bcl-2 and induced activation of MAPKs in SKOV3 cells; however, when combined with (R)(S)(S)-BF65, these prosurvival effects were reversed. MK 2206 15-22 BCL2 apoptosis regulator Homo sapiens 35-40 27099069-3 2016 Parthenolide (6 microM) induces mitochondrial-mediated apoptosis and autophagy by activation of caspase-3, upregulation of Bax, Beclin-1, ATG5, ATG3 and down-regulation of Bcl-2 and mTOR. parthenolide 0-12 BCL2 apoptosis regulator Homo sapiens 172-177 27480872-0 2016 Correction: Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 51-54 BCL2 apoptosis regulator Homo sapiens 25-29 26936916-10 2016 High TMTV individualized in molecular-low-risk patients a group with a poor outcome (MYC, PFS=51%, OS=55% BCL2, PFS=49%, OS=49% or DE PFS=50%, OS=50%) and a group with a good outcome (MYC, PFS=93%, OS=93% BCL2, PFS=86%, OS=86%, or DE PFS=81%, OS=81%). tmtv 5-9 BCL2 apoptosis regulator Homo sapiens 106-110 26936916-10 2016 High TMTV individualized in molecular-low-risk patients a group with a poor outcome (MYC, PFS=51%, OS=55% BCL2, PFS=49%, OS=49% or DE PFS=50%, OS=50%) and a group with a good outcome (MYC, PFS=93%, OS=93% BCL2, PFS=86%, OS=86%, or DE PFS=81%, OS=81%). tmtv 5-9 BCL2 apoptosis regulator Homo sapiens 205-209 27480872-0 2016 Correction: Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 51-54 BCL2 apoptosis regulator Homo sapiens 89-93 27480872-0 2016 Correction: Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. Homoharringtonine 63-80 BCL2 apoptosis regulator Homo sapiens 25-29 27480872-0 2016 Correction: Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. Homoharringtonine 63-80 BCL2 apoptosis regulator Homo sapiens 89-93 26392091-4 2016 The analysis of the changes in the expression of genes involved in the response to DNA damage (CDKN1A, GADD45A, MDM2), apoptosis (BAX, BCL2) and oncogenesis (MYC, JUN) showed that 5-FU, CDDP and ET upregulated the genes involved in DNA damage response, while the anti-apoptotic gene BCL2 and oncogene MYC were downregulated. Fluorouracil 180-184 BCL2 apoptosis regulator Homo sapiens 135-139 27030608-0 2016 Exendin-4 protects HUVECs from t-BHP-induced apoptosis via PI3K/Akt-Bcl-2-caspase-3 signaling. tert-Butylhydroperoxide 31-36 BCL2 apoptosis regulator Homo sapiens 68-73 27030608-8 2016 Exendin-4 downregulated caspase-3 activity and increased Bcl-2 protein levels in t-BHP-treated HUVECs. tert-Butylhydroperoxide 81-86 BCL2 apoptosis regulator Homo sapiens 57-62 26392091-4 2016 The analysis of the changes in the expression of genes involved in the response to DNA damage (CDKN1A, GADD45A, MDM2), apoptosis (BAX, BCL2) and oncogenesis (MYC, JUN) showed that 5-FU, CDDP and ET upregulated the genes involved in DNA damage response, while the anti-apoptotic gene BCL2 and oncogene MYC were downregulated. Fluorouracil 180-184 BCL2 apoptosis regulator Homo sapiens 283-287 26392091-4 2016 The analysis of the changes in the expression of genes involved in the response to DNA damage (CDKN1A, GADD45A, MDM2), apoptosis (BAX, BCL2) and oncogenesis (MYC, JUN) showed that 5-FU, CDDP and ET upregulated the genes involved in DNA damage response, while the anti-apoptotic gene BCL2 and oncogene MYC were downregulated. Cisplatin 186-190 BCL2 apoptosis regulator Homo sapiens 135-139 27368132-5 2016 Furthermore, it was shown that a combination of D5D knockdown along with DGLA treatment could also significantly sensitize BxPC-3 cells to various chemotherapy drugs, likely via a p53-independent pathway through downregulating of anti-apoptotic proteins (e.g., Bcl-2) and activating pro-apoptotic proteins (e.g., caspase 3, -9). d5d 48-51 BCL2 apoptosis regulator Homo sapiens 261-266 27177833-6 2016 DTX showed remarkable downregulation in expression of bcl-2, survivin and pAKT in Nos pre-treated MDA-MB-231 cells. Docetaxel 0-3 BCL2 apoptosis regulator Homo sapiens 54-59 27446244-8 2016 Oxycodone induced a dose-dependent increase in the expression levels of p53 and Bax apoptosis-related genes, whereas it decreased the gene expression levels of Bcl-2. Oxycodone 0-9 BCL2 apoptosis regulator Homo sapiens 160-165 27368132-5 2016 Furthermore, it was shown that a combination of D5D knockdown along with DGLA treatment could also significantly sensitize BxPC-3 cells to various chemotherapy drugs, likely via a p53-independent pathway through downregulating of anti-apoptotic proteins (e.g., Bcl-2) and activating pro-apoptotic proteins (e.g., caspase 3, -9). 8,11,14-Eicosatrienoic Acid 73-77 BCL2 apoptosis regulator Homo sapiens 261-266 27278454-7 2016 Western blot analysis revealed that OGD/R promoted cell apoptosis with concomitant increases in Bax and caspase-3 expression, and reduced Bcl-2 expression, which was reversed by pre-treatment with SA in a dose-dependent manner. syringic acid 197-199 BCL2 apoptosis regulator Homo sapiens 138-143 27278810-3 2016 PG inhibited the growth of HPF cells with an IC50 of ~50-100 microM at 24 h. PG induced a G1 phase arrest of the cell cycle and also triggered cell death accompanied by the loss of mitochondrial membrane potential (MMP; psim), Bcl-2 decrease, p53 increase and the activation of caspase-3. Pyrogallol 0-2 BCL2 apoptosis regulator Homo sapiens 228-233 27278553-5 2016 These studies showed that Dox decreased anti-apoptotic Bcl-2 protein expression and affected oxidative stress by increasing hydrogen peroxide production and simultaneously decreasing NF-kappaB gene and protein expression in MCF-7, a tumorigenic triple-positive cell line. Doxorubicin 26-29 BCL2 apoptosis regulator Homo sapiens 55-60 27278810-3 2016 PG inhibited the growth of HPF cells with an IC50 of ~50-100 microM at 24 h. PG induced a G1 phase arrest of the cell cycle and also triggered cell death accompanied by the loss of mitochondrial membrane potential (MMP; psim), Bcl-2 decrease, p53 increase and the activation of caspase-3. Pyrogallol 77-79 BCL2 apoptosis regulator Homo sapiens 228-233 27278820-4 2016 Moreover, quercetin induced cell apoptosis in a mitochondrial-dependent manner, as shown by the reduction in mitochondrial membrane potential, the activation of caspase-3 and -9, and the downregulation of Bcl-2, as well as the upregulation of Bax and cytochrome c (Cyt-c). Quercetin 10-19 BCL2 apoptosis regulator Homo sapiens 205-210 27278553-6 2016 Results also indicated that Dox induced apoptosis by upregulating Bax, caspase-8 and caspase-3 and downregulation of Bcl-2 protein expression. Doxorubicin 28-31 BCL2 apoptosis regulator Homo sapiens 117-122 27278553-8 2016 It can be concluded that Dox activated apoptosis by inducing proteolytic processing of Bcl-2 family, caspases and simultaneously decreased oxidative stress by influencing ROS damage in MCF-7 and MDA-MB-231 cell lines. Doxorubicin 25-28 BCL2 apoptosis regulator Homo sapiens 87-92 27278820-6 2016 Notably, FB1 enhanced the expression of Bcl-2, which was inhibited by quercetin, and prevented the decrease in mitochondrial membrane potential induced by quercetin. Quercetin 70-79 BCL2 apoptosis regulator Homo sapiens 40-45 26134921-7 2016 The results of PCR and Western blotting showed that curcumin increased the FasL mRNA level; inhibited Bcl-2, NF-kappaB, and ERK expression; and activated P38 MAPK, JNK, and caspase-3. Curcumin 52-60 BCL2 apoptosis regulator Homo sapiens 102-107 27038929-5 2016 At the same time, we found that pretreatment with EGCG attenuated the upregulation of Bax and the downregulation of Bcl-2, thus confirming the cellular protective properties of EGCG against ADMA-induced apoptosis. epigallocatechin gallate 50-54 BCL2 apoptosis regulator Homo sapiens 116-121 27038929-5 2016 At the same time, we found that pretreatment with EGCG attenuated the upregulation of Bax and the downregulation of Bcl-2, thus confirming the cellular protective properties of EGCG against ADMA-induced apoptosis. epigallocatechin gallate 177-181 BCL2 apoptosis regulator Homo sapiens 116-121 27038929-5 2016 At the same time, we found that pretreatment with EGCG attenuated the upregulation of Bax and the downregulation of Bcl-2, thus confirming the cellular protective properties of EGCG against ADMA-induced apoptosis. N,N-dimethylarginine 190-194 BCL2 apoptosis regulator Homo sapiens 116-121 27208745-6 2016 Notably, the anti-apoptotic potential of DHM was correlated with an increased expression of anti-apoptotic proteins (Bcl-2 and Bcl-xl) and decreased expression of pro-apoptotic proteins (Bax), as well as the inhibition of caspase proteins activation. Dihydromorphine 41-44 BCL2 apoptosis regulator Homo sapiens 117-122 26252372-4 2016 The results of Western blotting indicated that tanshinone IIA can suppress the expression of anti-apoptotic protein Bcl-2, increase (0.28 vs. 0.62) the expression of pro-apoptotic protein Bax (0.83 vs. 0.24) in SKOV3 cells. tanshinone 47-61 BCL2 apoptosis regulator Homo sapiens 116-121 27446381-6 2016 The combination of HM and PTX exerted synergistic effects on proliferation inhibition and apoptosis induction in SGC-7901 cells, with down-regulation of COX-2, PCNA and Bcl-2 and up-regulation of Bax expression. Paclitaxel 26-29 BCL2 apoptosis regulator Homo sapiens 169-174 27446383-8 2016 In conclusion, cordycepin-induced apoptosis in HepG2 cells involved the extrinsic and intrinsic signaling pathway and was primarily regulated by the Bcl-2 family proteins. cordycepin 15-25 BCL2 apoptosis regulator Homo sapiens 149-154 27446394-10 2016 HP exerted its antitumor effect on HCC cells through the regulation of the expression of the apoptosis-related proteins B-cell lymphoma (Bcl)-2, Bcl-2-associated X protein and survivin. Hematoporphyrins 0-2 BCL2 apoptosis regulator Homo sapiens 120-143 29714913-1 2016 Lung cancer is the leading cause of cancer-related deaths worldwide.Despite the development and use of several targeting drugs for lung cancer therapy,the five-year survival rate has remained as low as 15%for the past three decades.Cisplatin-based chemotherapy is considered the first-line therapeutic strategy for lung cancer.However,developments of chemoresistance is a major obstacle for the successful treatment.Therefore,the development of novel therapy against cisplatin-resistance lung cancer is imperative.Photodynamic therapy(PDT),which is a non-invasive combinatorial therapeutic modality using light,photosensitizer(PS)and oxygen,may provide an unprecedented tool to develop more effective treatments.To provide experimental basis for its application in cisplatin-resistance lung cancer,we will discuss the biological effects of MPPa-photodynamic therapy in human cisplatin-resistance lung cancer cells in this article.Human cisplatin-resistance lung cancer cells A549/DDP were co-cultured with MPPa(0,1,2,4,8,16mumol/L)and exposed to light(0,0.6,1.2,2.4,3.6,4.8J/cm2),and cell viability was determined with CCK-8assay.Flow cytometry was used to detect apoptosis,DCFH-DA staining was employed to observe reactive oxygen species(ROS),and Western blot was used to detect the expressions of B-cell lymphoma-2(Bcl-2)protein and Bcl-2associated X protein(Bax).The proliferation of A549/DDP cells was suppressed by PDT.The apoptotic rate in the PDT group was significantly higher than that in the control,MPPa or light group(P<0.05).The level of ROS was increased.The expression of Bax was increased,and that of Bcl-2was decreased.MPPa-photodynamic therapy can significantly suppress cell viability,and induce apoptosis in human cisplatin-resistance lung cancer cells. Cisplatin 232-241 BCL2 apoptosis regulator Homo sapiens 1317-1322 27180010-5 2016 Segetoside I pretreatment of HepG2 resulted in apoptotic induction, dose-dependent DNA fragmentation, inhibition of cell migration, up-regulation of Bax and down-regulation of Bcl-2, which indicated that an apoptotic signaling event could have been initiated. segetoside I 0-12 BCL2 apoptosis regulator Homo sapiens 176-181 29714913-1 2016 Lung cancer is the leading cause of cancer-related deaths worldwide.Despite the development and use of several targeting drugs for lung cancer therapy,the five-year survival rate has remained as low as 15%for the past three decades.Cisplatin-based chemotherapy is considered the first-line therapeutic strategy for lung cancer.However,developments of chemoresistance is a major obstacle for the successful treatment.Therefore,the development of novel therapy against cisplatin-resistance lung cancer is imperative.Photodynamic therapy(PDT),which is a non-invasive combinatorial therapeutic modality using light,photosensitizer(PS)and oxygen,may provide an unprecedented tool to develop more effective treatments.To provide experimental basis for its application in cisplatin-resistance lung cancer,we will discuss the biological effects of MPPa-photodynamic therapy in human cisplatin-resistance lung cancer cells in this article.Human cisplatin-resistance lung cancer cells A549/DDP were co-cultured with MPPa(0,1,2,4,8,16mumol/L)and exposed to light(0,0.6,1.2,2.4,3.6,4.8J/cm2),and cell viability was determined with CCK-8assay.Flow cytometry was used to detect apoptosis,DCFH-DA staining was employed to observe reactive oxygen species(ROS),and Western blot was used to detect the expressions of B-cell lymphoma-2(Bcl-2)protein and Bcl-2associated X protein(Bax).The proliferation of A549/DDP cells was suppressed by PDT.The apoptotic rate in the PDT group was significantly higher than that in the control,MPPa or light group(P<0.05).The level of ROS was increased.The expression of Bax was increased,and that of Bcl-2was decreased.MPPa-photodynamic therapy can significantly suppress cell viability,and induce apoptosis in human cisplatin-resistance lung cancer cells. Cisplatin 232-241 BCL2 apoptosis regulator Homo sapiens 1335-1340 27531776-6 2016 Chlorambucil of 0, 5, 10, 20 micromol/L increased the apoptotic rate of Jeko-1 cells, upregulated the expression of BAX, procaspase 3, procaspase 8, procaspase 9 and PI3K, increased the phosphorylation of AKT and down-regulated the expression of BCL-2. Chlorambucil 0-12 BCL2 apoptosis regulator Homo sapiens 246-251 28741496-3 2016 Successful initial clinical trials of the BH3 mimetic venetoclax/ABT-199, specific for BCL-2, have led to its recent licensing for refractory chronic lymphocytic leukemia and to multiple ongoing trials for other malignancies. BH 3 42-45 BCL2 apoptosis regulator Homo sapiens 87-92 28741496-4 2016 Moreover, preclinical studies herald the potential of emerging BH3 mimetics targeting other BCL-2 pro-survival members, particularly myeloid cell leukemia (MCL)-1, for multiple cancer types. BH 3 63-66 BCL2 apoptosis regulator Homo sapiens 92-97 28741496-6 2016 This review sketches the discovery of the BCL-2 family and its impact on cancer development and therapy; describes how interactions of family members trigger apoptosis; outlines the development of BH3 mimetic drugs; and discusses their potential to advance cancer therapy. BH 3 197-200 BCL2 apoptosis regulator Homo sapiens 42-47 26846106-12 2016 Furthermore, in both in vitro and in vivo experiments, SDT plus HT group expressed significantly higher protein levels of Bax and cleaved caspase-3, 8, and 9 compared to SDT, HT, and control groups and significantly lower protein level of bcl-2 than the other three groups, while the expression of these proteins was unchanged between HT and control groups. 3,4-Dihydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione 55-58 BCL2 apoptosis regulator Homo sapiens 239-244 27525860-11 2016 The results suggest that the mechanism of juglone-induced apoptosis in MCF-7 cells is characterized by elevated ROS levels, reduced Bcl-2 expression, increased Bax expression, decreased mitochondrial membrane potential, increased intracellular Ca(2+) concentration, outer mitochondrial-membrane rupture, cytochrome C release, and caspase-3 activation. juglone 42-49 BCL2 apoptosis regulator Homo sapiens 132-137 27453171-11 2016 In addition, thioridazine and irradiation treatment induced apoptosis through up-regulation of cleaved capase-3 and 9, as well as an increase in the expression of Bax and Bak and a decrease in the expression of Bcl-2 and Bcl-xl. Thioridazine 13-25 BCL2 apoptosis regulator Homo sapiens 211-216 30204390-10 2016 Conclusion: Sal B is capable of suppressing IHG-induced injury and apoptosis in HUVECs, which might be attributed to the attenuation of oxidative stress, regulation of BCL-2/BAX protein expression, and subsequent suppression of Caspase-3 activity. salvianolic acid B 12-17 BCL2 apoptosis regulator Homo sapiens 168-173 26640142-0 2016 Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Glutamine 10-19 BCL2 apoptosis regulator Homo sapiens 75-80 26640142-5 2016 We and others have demonstrated that glucose maintains levels of key resistance-promoting BCL-2 family member, myeloid cell leukemic factor 1 (MCL-1). Glucose 37-44 BCL2 apoptosis regulator Homo sapiens 90-95 26640142-8 2016 Our investigation revealed that cells surviving glutamine withdrawal in particular, enhance expression and binding of BIM to BCL-2, consequently sensitizing these cells to the BH3 mimetic venetoclax. Glutamine 48-57 BCL2 apoptosis regulator Homo sapiens 125-130 26640142-8 2016 Our investigation revealed that cells surviving glutamine withdrawal in particular, enhance expression and binding of BIM to BCL-2, consequently sensitizing these cells to the BH3 mimetic venetoclax. BH 3 176-179 BCL2 apoptosis regulator Homo sapiens 125-130 27508028-4 2016 Erianin induced apoptosis in T47D cells through reducing Bcl-2 expression and activating caspase signaling. Erianin 0-7 BCL2 apoptosis regulator Homo sapiens 57-62 27150036-1 2016 Our recent finding that paclitaxel behaves as a peptidomimetic of the endogenous protein Nur77 inspired the design of two peptides (PEP1 and PEP2) reproducing the effects of paclitaxel on Bcl-2 and tubulin, proving the peptidomimetic nature of paclitaxel. Paclitaxel 24-34 BCL2 apoptosis regulator Homo sapiens 188-193 27431492-4 2016 In this study, enhanced antitumor effect of AT-101, a-pan-Bcl-2 inhibitor, on gefitinib was explored in NSCLC with T790M mutation. gossypol acetic acid 44-50 BCL2 apoptosis regulator Homo sapiens 58-63 27431492-4 2016 In this study, enhanced antitumor effect of AT-101, a-pan-Bcl-2 inhibitor, on gefitinib was explored in NSCLC with T790M mutation. Gefitinib 78-87 BCL2 apoptosis regulator Homo sapiens 58-63 27431492-10 2016 The apoptotic effects of the use of AT-101 was related to the blocking of antiapoptotic protein: Bcl-2, Bcl-xl, and Mcl-1 and downregrulation of the molecules in EGFR pathway. gossypol acetic acid 36-42 BCL2 apoptosis regulator Homo sapiens 97-102 27302173-8 2016 The ability of BE3 to induce programmed cell death was examined in human colon cancer cell lines LS180 and HT-29 by measuring caspase activation, DNA fragmentation and expression of BAX, BCL2, TP53 and CDKN1A genes. be3 15-18 BCL2 apoptosis regulator Homo sapiens 187-191 27391369-10 2016 Finally and interestingly, the potential underlying signaling pathways were evidently related to an increase in the Bax/Bcl-2 ratio, the abundant generation of reactive oxygen species and the activation of cleaved caspase-3. Reactive Oxygen Species 160-183 BCL2 apoptosis regulator Homo sapiens 120-125 27125788-5 2016 Asplatin promotes the apoptosis via the BCL-2 associated mitochondrial pathway. asplatin 0-8 BCL2 apoptosis regulator Homo sapiens 40-45 27478384-7 2016 The downstream proteins regulated by STAT3, including the antiapoptotic proteins (Bcl-2 and Survivin) and the invasion-related proteins (MMP-2, MMP-9), were also downregulated after theaflavins treatment. theaflavin 182-193 BCL2 apoptosis regulator Homo sapiens 82-87 27259268-5 2016 (-)-Oleocanthal also reduced STAT3 nuclear translocation and DNA binding activity, ultimately downregulating its downstream effectors, including the cell cycle protein Cyclin D1, the anti-apoptotic proteins Bcl-2 and survivin, and the invasion-related protein MMP 2. oleocanthal 0-15 BCL2 apoptosis regulator Homo sapiens 207-212 27233606-7 2016 In the presence of SP600125, expression of cleaved caspase-9/-3 and p53 as well as the ratio of Bax to Bcl-2 was significantly decreased compared to treatment with TNF-alpha alone. pyrazolanthrone 19-27 BCL2 apoptosis regulator Homo sapiens 103-108 27233606-8 2016 Our results therefore indicate that SP600125 improves the migration capacity of TNF-alpha-treated BMSCs and exerts a significant effect on the viability of TNF-alpha-treated BMSCs through reducing the up-regulation of p53, caspase-9/-3 and the Bcl-2 family induced by TNF-alpha. pyrazolanthrone 36-44 BCL2 apoptosis regulator Homo sapiens 244-249 27391608-14 2016 TMP could effectively reverse MDR of Pumc-91/ADM and T24/DDP cells and its mechanisms might be correlated with the alteration of MRP1, GST, BCL-2 and TOPO-II. tetramethylpyrazine 0-3 BCL2 apoptosis regulator Homo sapiens 140-145 27391608-12 2016 Compared to the control group, an obvious decrease of MRP1, GST, BCL-2 and an increase of TOPO-II were shown in TMP groups with a dose-dependency in mRNA and protein levels. tetramethylpyrazine 112-115 BCL2 apoptosis regulator Homo sapiens 65-70 27068261-9 2016 Moreover, KTH-13-Me highly enhanced the activation of caspase-3 and caspase-9, and decreased the protein level of Bcl-2. kth-13-me 10-19 BCL2 apoptosis regulator Homo sapiens 114-119 27196724-4 2016 Moreover, Soya-I effectively inhibited the elevated intracellular accumulation of reactive oxygen species as well as the Bax/Bcl-2 ratio caused by MPP. soyasaponin I 10-16 BCL2 apoptosis regulator Homo sapiens 125-130 27196724-4 2016 Moreover, Soya-I effectively inhibited the elevated intracellular accumulation of reactive oxygen species as well as the Bax/Bcl-2 ratio caused by MPP. 1-Methyl-4-phenylpyridinium 147-150 BCL2 apoptosis regulator Homo sapiens 125-130 27306040-2 2016 The three complexes react very differently with Group 13 trihalogenides, providing access to zwitterionic anti- GaCl3 and the unique bis(metalloid) BCl2, with the boron center part of a highly unusual anionic four-membered ring (charge on C) and Ga bound to P. The coordination chemistry and the various transformations are supported by DFT calculations, X-ray crystallography and multinuclear NMR spectroscopic data. trihalogenides 57-71 BCL2 apoptosis regulator Homo sapiens 149-153 27306040-2 2016 The three complexes react very differently with Group 13 trihalogenides, providing access to zwitterionic anti- GaCl3 and the unique bis(metalloid) BCl2, with the boron center part of a highly unusual anionic four-membered ring (charge on C) and Ga bound to P. The coordination chemistry and the various transformations are supported by DFT calculations, X-ray crystallography and multinuclear NMR spectroscopic data. Boron 164-169 BCL2 apoptosis regulator Homo sapiens 149-153 28852738-7 2016 RESULTS: Our results showed that kaempferol"s inhibition of MCF-7 breast cancer cell growth may through inducing apoptosis and downregulation of Bcl2 expression. kaempferol 33-43 BCL2 apoptosis regulator Homo sapiens 145-149 27153796-6 2016 Parallely, Bcl-2 decreased along with TiO2NP concentration increase. tio2np 38-44 BCL2 apoptosis regulator Homo sapiens 11-16 27283896-2 2016 The DNAi PNT2258, a 24 base single-stranded phosphodiester DNA oligodeoxynucleotide (PNT100) encapsulated in a protective liposome, was precisely designed to treat cancers that over-express BCL-2. Oligodeoxyribonucleotides 63-83 BCL2 apoptosis regulator Homo sapiens 190-195 27283896-7 2016 The data are consistent with the idea that BCL-2 inhibition by PNT2258 activates apoptotic pathways in WSU-FSCCL cells. PNT100 63-70 BCL2 apoptosis regulator Homo sapiens 43-48 27292614-9 2016 In DU145 cells, TBMS1 induced mitochondrial apoptosis, evidenced by ROS generation, mitochondrial dysfunction, endoplasmic reticulum stress, modulated Bcl-2 family protein and cleaved caspase-3, and activated ASK-1 and its downstream targets p38 and JNK. tubeimoside I 16-21 BCL2 apoptosis regulator Homo sapiens 151-156 27554119-8 2016 Our data revealed that MnCl2-induced apoptosis in 16HBE cells was mediated by decreased expression of Bcl-2 and increased levels of cleaved caspase-3. manganese chloride 23-28 BCL2 apoptosis regulator Homo sapiens 102-107 27261572-11 2016 CSPCs also induced the expression of Bad, Bax and Beclin-1 proteins and decreased the expression of Bcl-2, which was inhibited by 3-MA and Z-VAD. 3-methyladenine 130-134 BCL2 apoptosis regulator Homo sapiens 100-105 27261572-11 2016 CSPCs also induced the expression of Bad, Bax and Beclin-1 proteins and decreased the expression of Bcl-2, which was inhibited by 3-MA and Z-VAD. z-vad 139-144 BCL2 apoptosis regulator Homo sapiens 100-105 27554119-11 2016 Additionally, the pan-caspase inhibitor Z-VAD-FMK increased the cellular levels of Bcl-2 and decreased apoptosis, but did not affect the cellular levels of LC3B in MnCl2-treated 16HBE cells. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 40-49 BCL2 apoptosis regulator Homo sapiens 83-88 26990576-12 2016 Immunoblotting showed ACT treatment reversed DEN-induced NF-kappaB, Bax, Cytochrome C, Bcl-2, and Stat-3 levels. Diethylnitrosamine 45-48 BCL2 apoptosis regulator Homo sapiens 87-92 26576853-9 2016 Moreover, rutin also inhibited the up-regulation of caspase-3 and Bax expression and rescued down-regulation of Bcl-2 expression. Rutin 10-15 BCL2 apoptosis regulator Homo sapiens 112-117 26576853-12 2016 The involved mechanisms may be related to the regulation of ROS production, the inhabitation of lipid peroxidation, the protection of intracellular antioxidant system and its modulation of Bcl-2/Bax family and NF-kB/p65 signaling pathway. Reactive Oxygen Species 60-63 BCL2 apoptosis regulator Homo sapiens 189-194 27347020-6 2016 Notably, these SP cells demonstrated high resistance against chemotherapeutic drugs and apoptosis via elevated transcriptional regulation of several ATPase binding cassette (ABC) transporter and anti-apoptotic proteins, including ABCG2, ABCB1/MDR1 ABCB5, B cell lymphoma-2 (Bcl-2) and Bcl-2 associated X protein, respectively. sp 15-17 BCL2 apoptosis regulator Homo sapiens 255-272 27317992-6 2016 Furthermore, dioscin significantly decreased the expression levels of FasL, Fas, p53, Bak, Caspase-3/9, and upregulated Bcl-2 level through decreasing IRF9 level against apoptosis. dioscin 13-20 BCL2 apoptosis regulator Homo sapiens 120-125 27262990-5 2016 In addition, FA, Bz, and IP increased the protein expression of pro-apoptotic genes, C/EBP homologous protein (CHOP) and Bax, and reduced the protein expression of anti-apoptotic gene, Bcl-2. Benzene 17-19 BCL2 apoptosis regulator Homo sapiens 185-190 27262990-5 2016 In addition, FA, Bz, and IP increased the protein expression of pro-apoptotic genes, C/EBP homologous protein (CHOP) and Bax, and reduced the protein expression of anti-apoptotic gene, Bcl-2. isoprene 25-27 BCL2 apoptosis regulator Homo sapiens 185-190 27347020-6 2016 Notably, these SP cells demonstrated high resistance against chemotherapeutic drugs and apoptosis via elevated transcriptional regulation of several ATPase binding cassette (ABC) transporter and anti-apoptotic proteins, including ABCG2, ABCB1/MDR1 ABCB5, B cell lymphoma-2 (Bcl-2) and Bcl-2 associated X protein, respectively. sp 15-17 BCL2 apoptosis regulator Homo sapiens 274-279 27460740-13 2016 Also, we observed H2O2 treatments inhibited Bcl-2 expressions at both protein and mRNA levels. Hydrogen Peroxide 18-22 BCL2 apoptosis regulator Homo sapiens 44-49 27347020-6 2016 Notably, these SP cells demonstrated high resistance against chemotherapeutic drugs and apoptosis via elevated transcriptional regulation of several ATPase binding cassette (ABC) transporter and anti-apoptotic proteins, including ABCG2, ABCB1/MDR1 ABCB5, B cell lymphoma-2 (Bcl-2) and Bcl-2 associated X protein, respectively. sp 15-17 BCL2 apoptosis regulator Homo sapiens 285-290 27460740-14 2016 Inhibition of miR-181a restores Bcl-2 expressions, leading to increased resistance to H2O2. Hydrogen Peroxide 86-90 BCL2 apoptosis regulator Homo sapiens 32-37 27460740-15 2016 Moreover, restoration of Bcl-2 in miR-181a-overexpressing HUVECs renders cells tolerate higher concentrations of H2O2. Hydrogen Peroxide 113-117 BCL2 apoptosis regulator Homo sapiens 25-30 27022135-7 2016 Moreover, 2.5 g/L atropine could also induce caspase-2/-3/-9 activation, mitochondrial transmembrane potential disruption, downregulation of anti-apoptotic Bcl-2 and Bcl-xL, upregulation of pro-apoptotic Bax and Bad, and upregulation of cytoplasmic cytochrome c and apoptosis-inducing factor. Atropine 18-26 BCL2 apoptosis regulator Homo sapiens 156-161 27104314-3 2016 Polyphyllin D induced apoptosis via the mitochondrial apoptotic pathway, as evidenced by the decreased Bcl-2 and Bcr/Abl expression levels, the disruption of MMP and increased Bax, cytochrome c and cleaved-caspase-3 levels. polyphyllin D 0-13 BCL2 apoptosis regulator Homo sapiens 103-108 27129202-2 2016 Pro-apoptotic and anti-apoptotic Bcl-2 family proteins reciprocally modulate their activities in large part through protein interactions involving a motif known as BH3 (Bcl-2 homology 3). BH 3 164-167 BCL2 apoptosis regulator Homo sapiens 33-38 27067393-7 2016 RESULTS: sBCC treated with diclofenac showed a significant decrease in Ki-67 (P < .001) and Bcl-2 (P = .001), and after combination therapy for Ki-67 (P = .012). Diclofenac 27-37 BCL2 apoptosis regulator Homo sapiens 95-100 27129202-2 2016 Pro-apoptotic and anti-apoptotic Bcl-2 family proteins reciprocally modulate their activities in large part through protein interactions involving a motif known as BH3 (Bcl-2 homology 3). BH 3 164-167 BCL2 apoptosis regulator Homo sapiens 169-174 27176644-6 2016 Additionally, reverse transcription-polymerase chain reaction and western blot analysis revealed that hyperoside significantly decreased the mRNA expression levels of B-cell lymphoma (Bcl)-2 associated X protein (Bax), cleaved caspase-3 and phosphorylated-p38, while increasing the mRNA expression of Bcl-2 in H2O2-induced HUVECs. hyperoside 102-112 BCL2 apoptosis regulator Homo sapiens 301-306 28911558-5 2016 ZTP-caused cell apoptosis was associated with an increase in Bax/Bcl-2 ratio, and activation of caspase-3 and -9. ztp 0-3 BCL2 apoptosis regulator Homo sapiens 65-70 26989860-6 2016 Meanwhile, SCAD siRNA treatment triggered the same apoptosis as cardiomyocytes treated with tBHP, such as the increase in cell apoptotic rate, the activation of caspase3 and the decrease in the Bcl-2/Bax ratio, which showed that SCAD may play an important role in primary cardiomyocyte apoptosis. tert-Butylhydroperoxide 92-96 BCL2 apoptosis regulator Homo sapiens 194-199 27128210-5 2016 CoCl2 inhibited the proliferation of H8 cells, promoted apoptosis, and up-regulated CASP3 activation and BAX expression while inhibiting BCL2 expression. cobaltous chloride 0-5 BCL2 apoptosis regulator Homo sapiens 137-141 27128210-7 2016 Edaravone significantly increased H8 cell proliferation; inhibited apoptosis by down-regulating CASP3 activation and BAX production while promoting BCL2 stability; and ameliorated the migration and invasion phenotypes associated with CoCl2 treatment. Edaravone 0-9 BCL2 apoptosis regulator Homo sapiens 148-152 27176933-8 2016 Immunohistochemistry was used to reveal that the expression of Bcl-2, phosphorylated Akt and Her-2 was significantly decreased, while Bax was increased in the xenograft tumors subjected to radiation, which was significantly enhanced by EVO. SCHEMBL9731684 236-239 BCL2 apoptosis regulator Homo sapiens 63-68 27220903-6 2016 Based on an in vitro podocyte injury model, the present study found that the application of melatonin significantly reduced AngII-induced apoptosis and increased the proliferative rate of cells, as evidenced by decreased expression levels of apoptotic proteins, including Caspase-3 and Bax, and a change in the ratio of Bax/Bcl-2. Melatonin 92-101 BCL2 apoptosis regulator Homo sapiens 324-329 27177038-0 2016 5-Aminolevulinic acid photodynamic therapy in human cervical cancer via the activation of microRNA-143 and suppression of the Bcl-2/Bax signaling pathway. 5-amino levulinic acid 0-21 BCL2 apoptosis regulator Homo sapiens 126-131 27177038-2 2016 The present study aimed to investigate the effect of ALA-PDT on human cervical cancer through the regulation of microRNA-143 (miR-143) and the Bcl-2/Bax signaling pathway. Alanine 53-56 BCL2 apoptosis regulator Homo sapiens 143-148 27177038-7 2016 However, downregulation of miR-143 expression inhibited the effect of ALA-PDT on Bcl-2/Bax protein expression. Alanine 70-73 BCL2 apoptosis regulator Homo sapiens 81-86 27177038-8 2016 In conclusion, the current study demonstrated that ALA-PDT affected human cervical cancer via the activation of miR-143 and the suppression of the Bcl-2/Bax signaling pathway. Alanine 51-54 BCL2 apoptosis regulator Homo sapiens 147-152 27221642-9 2016 The cell viability (P<0.05) and proliferation (P<0.05) in the ET-1+IPT group were lower than those in the ET-1 group, and the expression of Bax/Bcl-2 was higher than that in the ET-1 group (P<0.05). N-(1-methylethyl)-1,1,2-trimethylpropylamine 73-76 BCL2 apoptosis regulator Homo sapiens 150-155 27543313-8 2016 Second, we discuss the probable consequences of mutations on the binding ability of BCL2 to non-BCL2 family member proteins crucial for 1) maintaining mitochondrial energetics and calcium hemostasis such as VDAC, IP3R, and RyR and 2) oncogenic pathways implicated in the acquisition of the "hallmarks of cancer" such as SOD, Raf-1, NFAT, p53, HIF-1alpha, and gelsolin. Calcium 180-187 BCL2 apoptosis regulator Homo sapiens 84-88 27221642-10 2016 The cell viability (P<0.05) and proliferation (P<0.05) in the ET-1+IPT+GLI group were higher than those in the ET-1+IPT group, and the expression of Bax/Bcl-2 was lower than that in the ET-1+IPT group (P<0.05). N-(1-methylethyl)-1,1,2-trimethylpropylamine 73-76 BCL2 apoptosis regulator Homo sapiens 159-164 27221642-10 2016 The cell viability (P<0.05) and proliferation (P<0.05) in the ET-1+IPT+GLI group were higher than those in the ET-1+IPT group, and the expression of Bax/Bcl-2 was lower than that in the ET-1+IPT group (P<0.05). Glycerol 1,2-di-(9Z,12Z-octadecadienoate) 3-octadecanoate 77-80 BCL2 apoptosis regulator Homo sapiens 159-164 27543313-8 2016 Second, we discuss the probable consequences of mutations on the binding ability of BCL2 to non-BCL2 family member proteins crucial for 1) maintaining mitochondrial energetics and calcium hemostasis such as VDAC, IP3R, and RyR and 2) oncogenic pathways implicated in the acquisition of the "hallmarks of cancer" such as SOD, Raf-1, NFAT, p53, HIF-1alpha, and gelsolin. Calcium 180-187 BCL2 apoptosis regulator Homo sapiens 96-100 26994872-4 2016 Moreover, TA effectively inhibited the elevated intracellular accumulation of reactive oxygen species as well as Bax/Bcl-2 ratio caused by MPP(+). euscaphic acid 10-12 BCL2 apoptosis regulator Homo sapiens 117-122 27173050-6 2016 In addition, miR-139-5p inhibited the expression of the miR-139-5p target gene NOTCH-1 and its downstream molecules MRP-1 and BCL-2, two key MDR-associated genes. mir-139-5p 13-23 BCL2 apoptosis regulator Homo sapiens 126-131 27177238-7 2016 After treatment of BBR and cisplatin, the cellular pro-apoptotic capase-3 and cleaved capspase-3 and caspase-9 were upregulated and the anti-apoptotic Bcl-2 was downregulated. Berberine 19-22 BCL2 apoptosis regulator Homo sapiens 151-156 27177238-7 2016 After treatment of BBR and cisplatin, the cellular pro-apoptotic capase-3 and cleaved capspase-3 and caspase-9 were upregulated and the anti-apoptotic Bcl-2 was downregulated. Cisplatin 27-36 BCL2 apoptosis regulator Homo sapiens 151-156 26790437-10 2016 The levels of Bcl-2 and the anti-apoptotic Mcl-1 isoform increased dramatically after ixabepilone treatment in scrambled control cells but not in A7-nAChR-KD cells. ixabepilone 86-97 BCL2 apoptosis regulator Homo sapiens 14-19 27357941-5 2016 The activation of Akt/CREB/Bcl-2 signaling mediated by MeHg was, at least in part, linked to cellular defence because either pretreatment with wortmannin to block PI3K/Akt signaling or knockdown of Bcl-2 enhanced MeHg-mediated cytotoxicity. Wortmannin 143-153 BCL2 apoptosis regulator Homo sapiens 27-32 30480417-3 2016 Agmatine has been shown to exert direct corrective effects on leukocyte apoptosis: the content of r53 and Bcl-2 proteins was normalized, apoptotic index was decreased, the process of nuclear DNA degradation was ceased, while the amount of cells with early and late signs of apoptosis was diminished. Agmatine 0-8 BCL2 apoptosis regulator Homo sapiens 106-111 27359113-6 2016 Among the drugs tested, the BCL2/BCLxL inhibitor ABT-263 was identified as the one agent that synergized with Abraxane to enhance acute induction of localized apoptosis in this model of human pancreatic cancer. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 49-52 BCL2 apoptosis regulator Homo sapiens 28-32 27362941-0 2016 DNA Hypermethylation of CREB3L1 and Bcl-2 Associated with the Mitochondrial-Mediated Apoptosis via PI3K/Akt Pathway in Human BEAS-2B Cells Exposure to Silica Nanoparticles. Silicon Dioxide 151-157 BCL2 apoptosis regulator Homo sapiens 36-41 27362941-8 2016 The methyltransferase inhibitor, 5-aza, further verified that the DNA hypermethylation status of CREB3L1 and Bcl-2 were associated with downregulation of their mRNA levels. Azacitidine 33-38 BCL2 apoptosis regulator Homo sapiens 109-114 27366113-8 2016 ETME treatment resulted in increasing Bax/Bcl-2 ratio, BID truncation and activation of caspase cascade. etme 0-4 BCL2 apoptosis regulator Homo sapiens 42-47 27471554-6 2016 Notch1 signaling activation affected the expression of serial genes, especially the genes associated with cAMP signaling, with an increase of genes like THBS1, VCL, p63, c-Myc and SCG2, a decrease of genes like NR4A2, PCK2 and BCL-2. Cyclic AMP 106-110 BCL2 apoptosis regulator Homo sapiens 227-232 27069256-0 2016 The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. venetoclax 29-39 BCL2 apoptosis regulator Homo sapiens 4-8 27106530-10 2016 In conclusion, CuE induced ROS-dependent apoptosis through Bcl-2 family and caspases in 95D lung cancer cells. Reactive Oxygen Species 27-30 BCL2 apoptosis regulator Homo sapiens 59-64 27069256-2 2016 Venetoclax (ABT-199) is a small-molecule selective inhibitor of BCL2 currently in clinical trials for CLL and other malignancies. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 64-68 27069256-2 2016 Venetoclax (ABT-199) is a small-molecule selective inhibitor of BCL2 currently in clinical trials for CLL and other malignancies. venetoclax 12-19 BCL2 apoptosis regulator Homo sapiens 64-68 27514545-10 2016 Exposure to lead acetate elevated the expression of Bax, cytochrome C, and caspase-3 and reduced Bcl-2 expression. lead acetate 12-24 BCL2 apoptosis regulator Homo sapiens 97-102 27095788-1 2016 The Bcl-2 antagonist ABT-199 (venetoclax) has demonstrated promising clinical activity in patients with chronic lymphocytic leukemia (CLL). venetoclax 21-28 BCL2 apoptosis regulator Homo sapiens 4-9 27347927-7 2016 Cyanidin-3-O-glucoside chloride decreased mutant p21 expression, and increased the ratio of Bax/Bcl-2 and the activation of caspase-3 to induce apoptosis. asterin 0-31 BCL2 apoptosis regulator Homo sapiens 96-101 27420953-0 2016 Borax-induced apoptosis in HepG2 cells involves p53, Bcl-2, and Bax. borax 0-5 BCL2 apoptosis regulator Homo sapiens 53-58 27420953-10 2016 The apoptotic process triggered by borax involved the upregulation of p53 and Bax and the downregulation of Bcl-2, which was confirmed by a change in the mitochondrial membrane potential. borax 35-40 BCL2 apoptosis regulator Homo sapiens 108-113 27420953-11 2016 These results elucidate a borax-induced apoptotic pathway in HepG2 cells that involves the upregulation of p53 and Bax and the downregulation of Bcl-2. borax 26-31 BCL2 apoptosis regulator Homo sapiens 145-150 27311010-9 2016 We further demonstrated that propofol pretreatment attenuated or inhibited the effects caused by TG, such as upregulation of Bax, BiP, C/EBP homologous protein (CHOP), active caspase 12, and cleaved caspase 3, and downregulation of Bcl2. Thapsigargin 97-99 BCL2 apoptosis regulator Homo sapiens 232-236 27322225-5 2016 The results showed that the two trichothecene mycotoxins induced the apoptosis of cancer cell HepG-2 via activation of caspase-9 and caspase-3, up-regulation of bax gene expression, down-regulation of bcl-2 gene expression, and disruption of the mitochondrial membrane potential of the HepG-2 cell. trichothecene mycotoxins 32-56 BCL2 apoptosis regulator Homo sapiens 201-206 27761203-7 2016 Furthermore, This SP had that capacity to disrupt the mitochondrial function by altering the bax/bcl-2 ratio of expression which has considered an important element in apoptosis induction. sp 18-20 BCL2 apoptosis regulator Homo sapiens 97-102 27235707-9 2016 Moreover, Farrerol reduced the phosphorylation levels of Erk, Akt, mTOR, Jak2 and Stat3 as well as protein expression of Bcl-2 and Bcl-xl. farrerol 10-18 BCL2 apoptosis regulator Homo sapiens 121-126 27056884-6 2016 Running computational simulations on these virtual cell line models, we identified a synergistic effect of two drug agents on cell proliferation and viability; namely, the Jak2 kinase inhibitor, G6, and the Bcl-2 inhibitor, ABT737. ABT-737 224-230 BCL2 apoptosis regulator Homo sapiens 207-212 27311010-9 2016 We further demonstrated that propofol pretreatment attenuated or inhibited the effects caused by TG, such as upregulation of Bax, BiP, C/EBP homologous protein (CHOP), active caspase 12, and cleaved caspase 3, and downregulation of Bcl2. Propofol 29-37 BCL2 apoptosis regulator Homo sapiens 232-236 27166183-0 2016 Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. venetoclax 80-87 BCL2 apoptosis regulator Homo sapiens 54-59 27286976-15 2016 However, among patients treated with combined high-dose methotrexate, vincristine and procarbazine and radiotherapy, dual MYC and BCL2 overexpression (a cutoff score of 60) was an independent poor prognostic indicator (P = 0.010). Methotrexate 56-68 BCL2 apoptosis regulator Homo sapiens 130-134 27286976-15 2016 However, among patients treated with combined high-dose methotrexate, vincristine and procarbazine and radiotherapy, dual MYC and BCL2 overexpression (a cutoff score of 60) was an independent poor prognostic indicator (P = 0.010). Vincristine 70-81 BCL2 apoptosis regulator Homo sapiens 130-134 27286976-15 2016 However, among patients treated with combined high-dose methotrexate, vincristine and procarbazine and radiotherapy, dual MYC and BCL2 overexpression (a cutoff score of 60) was an independent poor prognostic indicator (P = 0.010). Procarbazine 86-98 BCL2 apoptosis regulator Homo sapiens 130-134 27283158-1 2016 ABT-199, a potent and selective small-molecule antagonist of BCL-2, is being clinically vetted as pharmacotherapy for the treatment of acute myeloid leukemia (AML). venetoclax 0-7 BCL2 apoptosis regulator Homo sapiens 61-66 27270209-3 2016 In p53 expressing ECC-1 and OVCAR-3 but not in p53-deficient SKOV-3 cells, citral induces G1/S cell cycle arrest and apoptosis as determined by Annexin V staining and increased cleaved caspase3 and Bax and decreased Bcl-2. citral 75-81 BCL2 apoptosis regulator Homo sapiens 216-221 27166183-2 2016 The Bcl-2-selective inhibitor ABT-199 has demonstrated encouraging preclinical results, drug resistance remains a concern. venetoclax 30-37 BCL2 apoptosis regulator Homo sapiens 4-9 27260506-11 2016 Bax, caspase-3, and cleaved caspase-3 were down-regulated, and Bcl-2 was up-regulated by budesonide. Budesonide 89-99 BCL2 apoptosis regulator Homo sapiens 63-68 27263652-8 2016 Inhibition of JNK by SP600125 markedly decreased LC3-II and Beclin1, restored phosphorylated Bcl-2, and reduced the cytotoxicity induced by the two compounds in combination. pyrazolanthrone 21-29 BCL2 apoptosis regulator Homo sapiens 93-98 27271587-8 2016 In addition, dioscin significantly up-regulated the protein levels of Bak, Bax, Bid, p53, caspase-3, caspase-9, and down-regulated the protein levels of Bcl-2 and Bcl-xl. dioscin 13-20 BCL2 apoptosis regulator Homo sapiens 153-158 27086081-2 2016 In this study, we investigated the binding activity of perylene and coronene derivatives PPL3C, CORON and EMICORON to G4 structures formed within the promoter regions of two important cancer-related genes, c-MYC and BCL-2, and their biochemical effects on gene and protein expression. Perylene 55-63 BCL2 apoptosis regulator Homo sapiens 216-221 29797935-5 2016 Meanwhile, we confirmed that CXCR4 affected the expression of bcl-2 through regulating the expression of let-7a to modulate the chemoresistance of CNE2/DPP to cisplatin. Cisplatin 159-168 BCL2 apoptosis regulator Homo sapiens 62-67 29797935-5 2016 Meanwhile, we confirmed that CXCR4 affected the expression of bcl-2 through regulating the expression of let-7a to modulate the chemoresistance of CNE2/DPP to cisplatin. dipalmitoylphosphatidylserine 152-155 BCL2 apoptosis regulator Homo sapiens 62-67 27160664-4 2016 Herein, triphenylphosphine (TPP)-coated positively charged 131.6 nm spherical nanoparticles (NPs) comprised of alpha-tocopheryl succinate (TOS, inhibitor of complex II in electron transport chain) and obatoclax (Obt, inhibitor of Bcl-2) were engineered. triphenylphosphine 8-26 BCL2 apoptosis regulator Homo sapiens 230-235 27160664-4 2016 Herein, triphenylphosphine (TPP)-coated positively charged 131.6 nm spherical nanoparticles (NPs) comprised of alpha-tocopheryl succinate (TOS, inhibitor of complex II in electron transport chain) and obatoclax (Obt, inhibitor of Bcl-2) were engineered. triphenylphosphine 28-31 BCL2 apoptosis regulator Homo sapiens 230-235 27160664-5 2016 The TOS-TPP-Obt-NPs entered into acidic lysosomes via macropinocytosis, followed by lysosomal escape and finally homed into mitochondria over a period of 24 h. Subsequently, these TOS-TPP-Obt-NPs triggered mitochondrial outer membrane permeabilization (MOMP) by inhibiting antiapoptotic Bcl-2, leading to Cytochrome C release. tos-tpp 4-11 BCL2 apoptosis regulator Homo sapiens 287-292 27160664-5 2016 The TOS-TPP-Obt-NPs entered into acidic lysosomes via macropinocytosis, followed by lysosomal escape and finally homed into mitochondria over a period of 24 h. Subsequently, these TOS-TPP-Obt-NPs triggered mitochondrial outer membrane permeabilization (MOMP) by inhibiting antiapoptotic Bcl-2, leading to Cytochrome C release. obatoclax 12-15 BCL2 apoptosis regulator Homo sapiens 287-292 27160664-5 2016 The TOS-TPP-Obt-NPs entered into acidic lysosomes via macropinocytosis, followed by lysosomal escape and finally homed into mitochondria over a period of 24 h. Subsequently, these TOS-TPP-Obt-NPs triggered mitochondrial outer membrane permeabilization (MOMP) by inhibiting antiapoptotic Bcl-2, leading to Cytochrome C release. tos-tpp 180-187 BCL2 apoptosis regulator Homo sapiens 287-292 27160664-5 2016 The TOS-TPP-Obt-NPs entered into acidic lysosomes via macropinocytosis, followed by lysosomal escape and finally homed into mitochondria over a period of 24 h. Subsequently, these TOS-TPP-Obt-NPs triggered mitochondrial outer membrane permeabilization (MOMP) by inhibiting antiapoptotic Bcl-2, leading to Cytochrome C release. obatoclax 188-191 BCL2 apoptosis regulator Homo sapiens 287-292 26502273-6 2016 Graphene activates apoptosis in macrophages through the TGFbr/Smad/Bcl-2 pathway and also through JNK kinases that are stimulated by an increase of ROS in the cell or through a signal received by Smad proteins. Graphite 0-8 BCL2 apoptosis regulator Homo sapiens 67-72 27086081-2 2016 In this study, we investigated the binding activity of perylene and coronene derivatives PPL3C, CORON and EMICORON to G4 structures formed within the promoter regions of two important cancer-related genes, c-MYC and BCL-2, and their biochemical effects on gene and protein expression. coronene 68-76 BCL2 apoptosis regulator Homo sapiens 216-221 27084994-0 2016 Di-(2-ethylhexyl) phthalate induces apoptosis of GC-2spd cells via TR4/Bcl-2 pathway. Diethylhexyl Phthalate 0-27 BCL2 apoptosis regulator Homo sapiens 71-76 26706847-3 2016 The experimental results indicated that the KS can significantly increase cell viability and reduce apoptosis on H2 O2 -injured VSMCs, as well as reverse the effects of H2 O2 on Bcl-2, Bad, and caspase-3 expressions. ks 44-46 BCL2 apoptosis regulator Homo sapiens 178-183 26706847-3 2016 The experimental results indicated that the KS can significantly increase cell viability and reduce apoptosis on H2 O2 -injured VSMCs, as well as reverse the effects of H2 O2 on Bcl-2, Bad, and caspase-3 expressions. Hydrogen Peroxide 169-174 BCL2 apoptosis regulator Homo sapiens 178-183 26631752-0 2016 BH4 domain of Bcl-2 as a novel target for cancer therapy. sapropterin 0-3 BCL2 apoptosis regulator Homo sapiens 14-19 26631752-3 2016 In this critical review, we focus on the structural and functional basis of targeting the BH4 domain of Bcl-2, and highlight the recent advances in drug discovery efforts toward small-molecule BH4 domain inhibitors (e.g. BDA-366). sapropterin 90-93 BCL2 apoptosis regulator Homo sapiens 104-109 26711051-5 2016 Here, we tested whether the Bcl-2 family inhibitors, navitoclax (N) and TW-37 (T), are senolytic. navitoclax 53-63 BCL2 apoptosis regulator Homo sapiens 28-33 26711051-5 2016 Here, we tested whether the Bcl-2 family inhibitors, navitoclax (N) and TW-37 (T), are senolytic. TW-37 72-77 BCL2 apoptosis regulator Homo sapiens 28-33 27100736-4 2016 Bcl-2 was overexpressed in gastric cells treated with Tanshinone I or not, and autophagy relative protein was investigated; the interaction between Beclin-1 and Bcl-2 was detected by immunoprecipitation. tanshinone 54-66 BCL2 apoptosis regulator Homo sapiens 0-5 27100736-7 2016 RESULTS: Tanshinone I inhibited the proliferation of BGC823 and SGC7901 cells, and induced cell apoptosis by inhibiting anti-apoptosis protein Bcl-2. tanshinone 9-21 BCL2 apoptosis regulator Homo sapiens 143-148 27100736-9 2016 However, the Beclin-1 VPS34 complexes were increased after Tanshinone I treatment via inhibiting Bcl-2 expression. tanshinone 59-71 BCL2 apoptosis regulator Homo sapiens 97-102 27100736-12 2016 CONCLUSIONS: Tanshinone I induced apoptosis and pro-survival autophagy via inhibiting Bcl-2 expression on gastric cancer, and the combination of chloroquine and Tanshinone I could inhibit tumor growth more efficiently than monotherapy, which might be considered as an effective strategy for the treatment for gastric cancer. tanshinone 13-23 BCL2 apoptosis regulator Homo sapiens 86-91 27100736-12 2016 CONCLUSIONS: Tanshinone I induced apoptosis and pro-survival autophagy via inhibiting Bcl-2 expression on gastric cancer, and the combination of chloroquine and Tanshinone I could inhibit tumor growth more efficiently than monotherapy, which might be considered as an effective strategy for the treatment for gastric cancer. Chloroquine 145-156 BCL2 apoptosis regulator Homo sapiens 86-91 27100736-12 2016 CONCLUSIONS: Tanshinone I induced apoptosis and pro-survival autophagy via inhibiting Bcl-2 expression on gastric cancer, and the combination of chloroquine and Tanshinone I could inhibit tumor growth more efficiently than monotherapy, which might be considered as an effective strategy for the treatment for gastric cancer. tanshinone 13-25 BCL2 apoptosis regulator Homo sapiens 86-91 27179035-7 2016 Moreover, TMP altered expression of p53 and the Bcl-2/Bax protein ratio, which revealed that TMP induced cell cycle arrest and caspase-dependent mitochondrial apoptosis in HepG2 cells in vitro. tetramethylpyrazine 10-13 BCL2 apoptosis regulator Homo sapiens 48-53 26836460-7 2016 GA-treated HaCaT cells also exhibited elevated antiapoptotic Bcl-2 protein, concomitant with reduced caspase-3 cleavage and decreased PARP-1 protein. Glycyrrhizic Acid 0-2 BCL2 apoptosis regulator Homo sapiens 61-66 26670665-0 2016 Effects of low dose of tibolone on steroid receptors and Bcl-2 on the postmenopausal endometrium. tibolone 23-31 BCL2 apoptosis regulator Homo sapiens 57-62 26670665-1 2016 OBJECTIVE: A prospective randomized controlled trial was conducted to evaluate the effect of low dose of tibolone on the histology, expression of estrogen (ER) and progesterone receptors (PR) and Bcl-2 protein, in endometrium of postmenopausal women. tibolone 105-113 BCL2 apoptosis regulator Homo sapiens 196-201 27179035-7 2016 Moreover, TMP altered expression of p53 and the Bcl-2/Bax protein ratio, which revealed that TMP induced cell cycle arrest and caspase-dependent mitochondrial apoptosis in HepG2 cells in vitro. tetramethylpyrazine 93-96 BCL2 apoptosis regulator Homo sapiens 48-53 26669750-7 2016 Aotaphenazine (1) enhanced the levels of apoptosis inducing proteins DR4, DR5, p53 and also decreased the levels of cell survival protein Bcl-2 in TRAIL-resistant human gastric adenocarcinoma (AGS) cells in a dose-dependent manner. Aotaphenazine 0-13 BCL2 apoptosis regulator Homo sapiens 138-143 27082738-0 2016 Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells. Docetaxel 0-9 BCL2 apoptosis regulator Homo sapiens 18-23 27082738-8 2016 Fluorescent microscopy revealed that Bcl-2-overexpression had no effect on the docetaxel-induced death of DU145 cells, but significantly decreased DU145 cell death induced by cisplatin or TNF-alpha. Cisplatin 175-184 BCL2 apoptosis regulator Homo sapiens 37-42 27082738-9 2016 Interestingly, docetaxel hardly induced caspase-3/7 activation in control or Bcl-2-overexpressing DU145 cells, but did at a low level in LNCaP cells, another prostate cancer cell line. Docetaxel 15-24 BCL2 apoptosis regulator Homo sapiens 77-82 27082738-10 2016 Moreover, in contrast to LNCaP cells, the reduced viabilities of docetaxel-treated control and Bcl-2-overexpressing DU145 cells were not restored by the addition of either a Bid inhibitor or a panel of pro-apoptotic caspase inhibitors. Docetaxel 65-74 BCL2 apoptosis regulator Homo sapiens 95-100 27055778-6 2016 Phosphorylated-fingolimod was shown in vitro to reduce S1PR1 RNA and protein, to slightly increase viability and to activate anti-apoptotic Bcl2 in transformed B cells of patients with MS. Fingolimod Hydrochloride 15-25 BCL2 apoptosis regulator Homo sapiens 140-144 27081867-10 2016 Our results showed that noscapine had lower toxicity in normal cells and was an effective anticancer agent that induced apoptosis in breast cancer cells because it increases Bax gene and protein expression in three cell lines, while decreases Bcl-xL gene expression, and Bcl-2 protein expression decreased in breast cancer cell lines. Noscapine 24-33 BCL2 apoptosis regulator Homo sapiens 271-276 27082253-10 2016 Western blot analysis revealed that oridonin downregulated Bcl-2 protein (the anti-apoptotic factor) and upregulated Bax protein (pro-apoptotic factor), eventually leading to a reduction in the ratio of Bcl-2/Bax proteins. oridonin 36-44 BCL2 apoptosis regulator Homo sapiens 59-64 27082253-10 2016 Western blot analysis revealed that oridonin downregulated Bcl-2 protein (the anti-apoptotic factor) and upregulated Bax protein (pro-apoptotic factor), eventually leading to a reduction in the ratio of Bcl-2/Bax proteins. oridonin 36-44 BCL2 apoptosis regulator Homo sapiens 203-208 27171502-6 2016 Furthermore, UA-treated MG-63 cells also exhibited an enhancement in Bax/Bcl-2 ratio, whereas anti-apoptotic XIAP and survivin were down-regulated. ursolic acid 13-15 BCL2 apoptosis regulator Homo sapiens 73-78 27262527-0 2016 BIM (BCL-2 interacting mediator of cell death) SAHB (stabilized alpha helix of BCL2) not always convinces BAX (BCL-2-associated X protein) for apoptosis. sahb 47-51 BCL2 apoptosis regulator Homo sapiens 5-10 27376803-7 2016 Furthermore, C60-GSH inhibited intracellular calcium mobilization, and subsequent cell apoptosis via bcl-2/bax-caspase-3 signaling pathway induced by H2O2 stimulation in HEK 293T cells. Glutathione 17-20 BCL2 apoptosis regulator Homo sapiens 101-106 27376803-7 2016 Furthermore, C60-GSH inhibited intracellular calcium mobilization, and subsequent cell apoptosis via bcl-2/bax-caspase-3 signaling pathway induced by H2O2 stimulation in HEK 293T cells. Hydrogen Peroxide 150-154 BCL2 apoptosis regulator Homo sapiens 101-106 27262527-0 2016 BIM (BCL-2 interacting mediator of cell death) SAHB (stabilized alpha helix of BCL2) not always convinces BAX (BCL-2-associated X protein) for apoptosis. sahb 47-51 BCL2 apoptosis regulator Homo sapiens 79-83 27262527-1 2016 The interaction of BAX (BCL-2-associated X protein) with BIM (BCL-2 interacting mediator of cell death) SAHB (stabilized alpha helix of BCL2) directly initiates BAX-mediated mitochondrial apoptosis. sahb 104-108 BCL2 apoptosis regulator Homo sapiens 24-29 27262527-1 2016 The interaction of BAX (BCL-2-associated X protein) with BIM (BCL-2 interacting mediator of cell death) SAHB (stabilized alpha helix of BCL2) directly initiates BAX-mediated mitochondrial apoptosis. sahb 104-108 BCL2 apoptosis regulator Homo sapiens 62-67 27262527-1 2016 The interaction of BAX (BCL-2-associated X protein) with BIM (BCL-2 interacting mediator of cell death) SAHB (stabilized alpha helix of BCL2) directly initiates BAX-mediated mitochondrial apoptosis. sahb 104-108 BCL2 apoptosis regulator Homo sapiens 136-140 27468551-9 2016 Evodiamine induced G2/M arrest with an increase of cyclin B1 level, and promoted cell apoptosis with a decrease of B cell lymphoma/lewkmia-2 (Bcl-2) and an increase of Bcl-2-associated X protein (Bax) level. evodiamine 0-10 BCL2 apoptosis regulator Homo sapiens 115-140 27109251-7 2016 Pretreatment with KMUP-1, atorvastatin and simvastatin significantly prevented hypoxia-induced EPCs death and apoptosis, with associated increased of the Bcl-2/Bax ratio, and reduced caspase-3 and caspase-9 expression. KMUP 1 18-24 BCL2 apoptosis regulator Homo sapiens 154-159 27109251-7 2016 Pretreatment with KMUP-1, atorvastatin and simvastatin significantly prevented hypoxia-induced EPCs death and apoptosis, with associated increased of the Bcl-2/Bax ratio, and reduced caspase-3 and caspase-9 expression. Atorvastatin 26-38 BCL2 apoptosis regulator Homo sapiens 154-159 27109251-7 2016 Pretreatment with KMUP-1, atorvastatin and simvastatin significantly prevented hypoxia-induced EPCs death and apoptosis, with associated increased of the Bcl-2/Bax ratio, and reduced caspase-3 and caspase-9 expression. Simvastatin 43-54 BCL2 apoptosis regulator Homo sapiens 154-159 27178240-2 2016 Venetoclax is an oral small-molecule BCL2 inhibitor that induces chronic lymphocytic leukaemia cell apoptosis. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 37-41 26999659-10 2016 The observed antiapoptotic effect of DTA0118 was associated with the upregulation of antiapoptotic Bcl-2 and downregulation of proapoptotic Bax and active caspase-3 protein levels. dta0118 37-44 BCL2 apoptosis regulator Homo sapiens 99-104 27468551-9 2016 Evodiamine induced G2/M arrest with an increase of cyclin B1 level, and promoted cell apoptosis with a decrease of B cell lymphoma/lewkmia-2 (Bcl-2) and an increase of Bcl-2-associated X protein (Bax) level. evodiamine 0-10 BCL2 apoptosis regulator Homo sapiens 142-147 27046645-18 2016 BCL2 and GSK3B, the top CFG scoring validated biomarkers, as well as PIK3C3, have anti-apoptotic and neurotrophic effects, are decreased in expression in suicidality and are known targets of the anti-suicidal mood stabilizer drug lithium, which increases their expression and/or activity. Lithium 230-237 BCL2 apoptosis regulator Homo sapiens 0-4 26086416-7 2016 Blockage of ROS production totally reversed WZ26-induced JNK activation, Bcl-2/Bax decrease, ER stress activation, and final cell apoptosis in SGC-7901 cells. ros 12-15 BCL2 apoptosis regulator Homo sapiens 73-78 26086416-7 2016 Blockage of ROS production totally reversed WZ26-induced JNK activation, Bcl-2/Bax decrease, ER stress activation, and final cell apoptosis in SGC-7901 cells. wz26 44-48 BCL2 apoptosis regulator Homo sapiens 73-78 27121658-7 2016 Western blotting indicated that treatment with OP-B increased the protein expression levels of caspase-3 and B-cell lymphoma 2 (Bcl-2)-associated X protein, whereas the expression levels of Bcl-2 and the phosphorylation levels of extracellular signal-regulated kinases 1/2 and c-Jun N-terminal kinases 1/2 were decreased. ophiopogonin B 47-51 BCL2 apoptosis regulator Homo sapiens 109-126 27121018-10 2016 Treatment of the HEp-2 cells with genistein and TSA led to a significant reduction in the phosphorylation of Akt and activation of its downstream target, and resulted in peroxisome proliferator-activated receptor-gamma cleavage, increased expression of B cell lymphoma-2 (Bcl-2)-associated X protein and reduced the expression of Bcl-2. Genistein 34-43 BCL2 apoptosis regulator Homo sapiens 253-270 27121018-10 2016 Treatment of the HEp-2 cells with genistein and TSA led to a significant reduction in the phosphorylation of Akt and activation of its downstream target, and resulted in peroxisome proliferator-activated receptor-gamma cleavage, increased expression of B cell lymphoma-2 (Bcl-2)-associated X protein and reduced the expression of Bcl-2. Genistein 34-43 BCL2 apoptosis regulator Homo sapiens 272-277 27121658-7 2016 Western blotting indicated that treatment with OP-B increased the protein expression levels of caspase-3 and B-cell lymphoma 2 (Bcl-2)-associated X protein, whereas the expression levels of Bcl-2 and the phosphorylation levels of extracellular signal-regulated kinases 1/2 and c-Jun N-terminal kinases 1/2 were decreased. ophiopogonin B 47-51 BCL2 apoptosis regulator Homo sapiens 128-133 27121018-10 2016 Treatment of the HEp-2 cells with genistein and TSA led to a significant reduction in the phosphorylation of Akt and activation of its downstream target, and resulted in peroxisome proliferator-activated receptor-gamma cleavage, increased expression of B cell lymphoma-2 (Bcl-2)-associated X protein and reduced the expression of Bcl-2. Genistein 34-43 BCL2 apoptosis regulator Homo sapiens 330-335 27121018-10 2016 Treatment of the HEp-2 cells with genistein and TSA led to a significant reduction in the phosphorylation of Akt and activation of its downstream target, and resulted in peroxisome proliferator-activated receptor-gamma cleavage, increased expression of B cell lymphoma-2 (Bcl-2)-associated X protein and reduced the expression of Bcl-2. trichostatin A 48-51 BCL2 apoptosis regulator Homo sapiens 253-270 27121658-7 2016 Western blotting indicated that treatment with OP-B increased the protein expression levels of caspase-3 and B-cell lymphoma 2 (Bcl-2)-associated X protein, whereas the expression levels of Bcl-2 and the phosphorylation levels of extracellular signal-regulated kinases 1/2 and c-Jun N-terminal kinases 1/2 were decreased. ophiopogonin B 47-51 BCL2 apoptosis regulator Homo sapiens 190-195 27121018-10 2016 Treatment of the HEp-2 cells with genistein and TSA led to a significant reduction in the phosphorylation of Akt and activation of its downstream target, and resulted in peroxisome proliferator-activated receptor-gamma cleavage, increased expression of B cell lymphoma-2 (Bcl-2)-associated X protein and reduced the expression of Bcl-2. trichostatin A 48-51 BCL2 apoptosis regulator Homo sapiens 272-277 27313767-0 2016 Alantolactone induces apoptosis of human cervical cancer cells via reactive oxygen species generation, glutathione depletion and inhibition of the Bcl-2/Bax signaling pathway. alantolactone 0-13 BCL2 apoptosis regulator Homo sapiens 147-152 27121018-10 2016 Treatment of the HEp-2 cells with genistein and TSA led to a significant reduction in the phosphorylation of Akt and activation of its downstream target, and resulted in peroxisome proliferator-activated receptor-gamma cleavage, increased expression of B cell lymphoma-2 (Bcl-2)-associated X protein and reduced the expression of Bcl-2. trichostatin A 48-51 BCL2 apoptosis regulator Homo sapiens 330-335 27320891-10 2016 The cells exposed to DHA showed significantly down-regulation of Bcl-2, MMP-9 and VEGF proteins and up-regulation of cleaved-caspase 3 and Bax. Docosahexaenoic Acids 21-24 BCL2 apoptosis regulator Homo sapiens 65-70 27320891-11 2016 CONCLUSION: DHA can promote cervical carcinoma cell apoptosis by down-regulating the anti-apoptotic proteins Bax, Bcl-2 and cleaved-caspase3 and suppress cell invasion by decreasing MMP-9 and VEGF expressions. Docosahexaenoic Acids 12-15 BCL2 apoptosis regulator Homo sapiens 114-119 27320892-8 2016 Lycorine up-regulated the mRNA levels of CDK4, Bax, caspase-3 while down-regulated the levels of survivin, Bcl-2 and Cyclin D1; the protein levels of CDK4 and Bax were increased and cyclin D1, Bcl-2 and surviving expressions were decreased, but caspase-3 expression showed no significant changes following the treatment. lycorine 0-8 BCL2 apoptosis regulator Homo sapiens 107-112 27320892-8 2016 Lycorine up-regulated the mRNA levels of CDK4, Bax, caspase-3 while down-regulated the levels of survivin, Bcl-2 and Cyclin D1; the protein levels of CDK4 and Bax were increased and cyclin D1, Bcl-2 and surviving expressions were decreased, but caspase-3 expression showed no significant changes following the treatment. lycorine 0-8 BCL2 apoptosis regulator Homo sapiens 193-198 27108782-9 2016 In addition, NaHS treatment reduced apoptosis, as indicated by the increased bcl-2 expression and decreased cleaved caspase-3 and bax expression. sodium bisulfide 13-17 BCL2 apoptosis regulator Homo sapiens 77-82 27159560-3 2016 Although drugging the BH3-binding groove has been achieved for BCL-2, translating this approach to MCL-1 has been challenging. BH 3 22-25 BCL2 apoptosis regulator Homo sapiens 63-68 27313767-8 2016 Alantolactone additionally markedly inhibited the Bcl-2/Bax signaling pathway in HeLa cells. alantolactone 0-13 BCL2 apoptosis regulator Homo sapiens 50-55 27313767-9 2016 Therefore, administration of alantolactone induced apoptosis of human cervical cancer cells via ROS generation, GSH depletion and inhibition of the Bcl-2/Bax signaling pathway. alantolactone 29-42 BCL2 apoptosis regulator Homo sapiens 148-153 27161405-7 2016 The intrinsic apoptotic pathway induced by cathachunine was evidenced by B-cell lymphoma 2/Bcl-2-associated X protein (Bcl-2/Bax) dysregulation, loss of mitochondrial membrane potential, translocation of cytochrome c, and cleavage of caspase-3 and poly-ADP ribose polymerase (PARP). cathachunine 43-55 BCL2 apoptosis regulator Homo sapiens 91-96 27161405-11 2016 The induction of apoptosis by cathachunine occurred through an ROS-dependent mitochondria-mediated intrinsic pathway rather than an extrinsic pathway, and was regulated by the Bcl-2 protein family. cathachunine 30-42 BCL2 apoptosis regulator Homo sapiens 176-181 27016270-7 2016 In HT-29 cells, treatment with 10muM of GTN induced apoptosis by increasing BAX/BCL2, p-JNK1/JNK1, p-P38/P38 ratios as well as through ROS generation. goniothalamin 40-43 BCL2 apoptosis regulator Homo sapiens 80-84 26009496-3 2016 In addition, SMMC-7721 xenograft tumors were established in male nude BALB/c mice, and oxymatrine was intravenously administered to evaluate the anticancer capacity in vivo Our results showed that oxymatrine inhibited the proliferation and induced apoptosis of Hep-G2 and SMMC-7721 cells in a dose-dependent manner in vitro Furthermore, the RNA and protein expression of Bax and caspase 3 levels were significantly upregulated, whereas the expression of Bcl-2 was downregulated. oxymatrine 197-207 BCL2 apoptosis regulator Homo sapiens 454-459 26009496-6 2016 Immunohistochemistry analysis demonstrated an increase of Bax and caspase 3 and a decrease of Bcl-2 in tumor tissues following oxymatrine treatment which are consistent with the in vitro results. oxymatrine 127-137 BCL2 apoptosis regulator Homo sapiens 94-99 27097871-5 2016 Western-blot analysis showed that Geraniin induced phosphorylation of the anti-apoptotic Bcl-2, and the cleavage of poly (ADP-ribose) polymerase (PARP) and caspase-3 in MCF-7 cells. Geraniin 34-42 BCL2 apoptosis regulator Homo sapiens 89-94 27083050-0 2016 Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2. Cisplatin 52-61 BCL2 apoptosis regulator Homo sapiens 103-108 27491234-10 2016 ICT and DOX could cause either early or late stage apoptosis, down-regulate Bcl-2 gene expression, and up-regulate gene expressions of Caspase-3 and p21 respectively (P < 0.05). Doxorubicin 8-11 BCL2 apoptosis regulator Homo sapiens 76-81 27491234-12 2016 CONCLUSION: CT combined DOX had additive or synergistic inhibition effect for the proliferation of osteosarcoma MG-63 cells, which might be related with regulating gene expressions of bcl-2, caspase-3, and p21. Doxorubicin 24-27 BCL2 apoptosis regulator Homo sapiens 184-189 26666823-9 2016 LB-100 downregulated Bcl-2 expression and enhanced sorafenib-induced apoptosis in HCC cells. lb100 0-6 BCL2 apoptosis regulator Homo sapiens 21-26 26676634-0 2016 Hyperoside induces apoptosis and inhibits growth in pancreatic cancer via Bcl-2 family and NF-kappaB signaling pathway both in vitro and in vivo. hyperoside 0-10 BCL2 apoptosis regulator Homo sapiens 74-79 26676634-4 2016 Our in vitro results showed that hyperoside suppressed the proliferation and promoted apoptosis of two different human pancreatic cancer cell lines, which correlated with up-regulation of the ratios of Bax/Bcl-2 and Bcl-xL and down-regulation of levels of nuclear factor-kappaB (NF-kappaB) and NF-kappaB"s downstream gene products. hyperoside 33-43 BCL2 apoptosis regulator Homo sapiens 206-211 27371847-6 2016 Western blotting showed that astaxanthin up-regulated the expression of Bax and down-regulated the expressions of Bcl-2, STAT3 and JAK1. astaxanthine 29-40 BCL2 apoptosis regulator Homo sapiens 114-119 30156815-15 2016 RT PCR and Western blot demonstrated that gambogenic acid up-regulated the expressions of BAX and E-cadherin and down-regulated the expression of mRNA and protein of BCL-2 and NF-kappaB. neo-gambogic acid 42-57 BCL2 apoptosis regulator Homo sapiens 166-171 28901078-5 2016 Compared with PM2.5 group, puerarin increased the cells survival rate, down-regulated p-ERK1/2 protein level and Bax/Bcl-2 ratio in a dose dependent manner to inhibit the apoptosis; decreased the contents of TNF-alpha, IL-6 and MDA, the activity of LDH, but increased SOD activity in the EA.hy926 cells (P<0.05). puerarin 27-35 BCL2 apoptosis regulator Homo sapiens 117-122 27083050-7 2016 Bcl-2 de-targeted by E6-mediated miR- 184 reduction was responsible for cisplatin resistance. Cisplatin 72-81 BCL2 apoptosis regulator Homo sapiens 0-5 27083050-12 2016 Patients with low-mR-184, E6-positive, high-Bcl-2 tumors, and both combinations were more prevalently occurred unfavorable response to cisplatin-based chemotherapy than their counterparts. Cisplatin 135-144 BCL2 apoptosis regulator Homo sapiens 44-49 27129176-11 2016 We concluded that the addition of thalidomide to the CHOP regimen significantly improved the CRR and showed a trend of improving clinical outcome in patients with DLBCL, especially for patients with Bcl-2 positive and Bcl-6 negative B-cell phenotype, without increased toxicity. Thalidomide 34-45 BCL2 apoptosis regulator Homo sapiens 199-204 27083050-13 2016 In conclusion, a decrease in miR-184 level by E6 oncoprotein may predict unfavorable response to cisplatin-based chemotherapy in HPV-infected NSCLC patients via increasing Bcl-2 expression. Cisplatin 97-106 BCL2 apoptosis regulator Homo sapiens 172-177 27247353-12 2016 Sensitivity to ABT-737 correlated with higher ASCL1 and BCL2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 15-18 BCL2 apoptosis regulator Homo sapiens 56-60 27262804-6 2016 Bcl2 expression in HDCP group was notably lower than the control and was increased by 100 mumol/L hydrogen. Hydrogen 98-106 BCL2 apoptosis regulator Homo sapiens 0-4 27195679-8 2016 Specifically, we find that Myt3 suppression sensitizes islet cells to high glucose-induced cell death via upregulation of the pro-apoptotic Bcl2 family member Bim. Glucose 75-82 BCL2 apoptosis regulator Homo sapiens 140-144 27223122-8 2016 Furthermore, APY606 treatment directly inhibited Ras-GTP and the downstream activation of MAPK, which resulted in the down-regulation of anti-apoptotic protein Bcl-2, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, cytosolic Cytochrome c and Caspase 3) and of cyclin-dependent kinase 2 and Cyclin A, E. These data suggest that impairing Ras-MAPK signaling is a novel mechanism of action for APY606 during therapeutic intervention in pancreatic cancer. apy606 13-19 BCL2 apoptosis regulator Homo sapiens 160-165 27223122-8 2016 Furthermore, APY606 treatment directly inhibited Ras-GTP and the downstream activation of MAPK, which resulted in the down-regulation of anti-apoptotic protein Bcl-2, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, cytosolic Cytochrome c and Caspase 3) and of cyclin-dependent kinase 2 and Cyclin A, E. These data suggest that impairing Ras-MAPK signaling is a novel mechanism of action for APY606 during therapeutic intervention in pancreatic cancer. ras-gtp 49-56 BCL2 apoptosis regulator Homo sapiens 160-165 27217294-5 2016 The small molecules ABT-737 and ABT-263 target BCL-2, BCL-XL and BCL-w, but not MCL-1. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 20-23 BCL2 apoptosis regulator Homo sapiens 47-52 27217294-5 2016 The small molecules ABT-737 and ABT-263 target BCL-2, BCL-XL and BCL-w, but not MCL-1. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 32-35 BCL2 apoptosis regulator Homo sapiens 47-52 28773504-0 2016 Microwave-Assisted Synthesis of Arene Ru(II) Complexes Induce Tumor Cell Apoptosis Through Selectively Binding and Stabilizing bcl-2 G-Quadruplex DNA. arene 32-37 BCL2 apoptosis regulator Homo sapiens 127-132 27105491-0 2016 The La protein counteracts cisplatin-induced cell death by stimulating protein synthesis of anti-apoptotic factor Bcl2. Cisplatin 27-36 BCL2 apoptosis regulator Homo sapiens 114-118 27105491-3 2016 Our data demonstrate that depletion of the RNA-binding protein La in head and neck squamous cell carcinoma cells (HNSCC) increases the sensitivity toward cisplatin-induced cell death paralleled by reduced expression of the anti-apoptotic factor Bcl2. Cisplatin 154-163 BCL2 apoptosis regulator Homo sapiens 245-249 27105491-4 2016 Furthermore, it is shown that transient expression of Bcl2 in La-depleted cells protects against cisplatin-induced cell death. Cisplatin 97-106 BCL2 apoptosis regulator Homo sapiens 54-58 27105491-5 2016 By dissecting the underlying mechanism we report herein, that the La protein is required for Bcl2 protein synthesis in cisplatin-treated cells. Cisplatin 119-128 BCL2 apoptosis regulator Homo sapiens 93-97 28773504-0 2016 Microwave-Assisted Synthesis of Arene Ru(II) Complexes Induce Tumor Cell Apoptosis Through Selectively Binding and Stabilizing bcl-2 G-Quadruplex DNA. ru(ii) 38-44 BCL2 apoptosis regulator Homo sapiens 127-132 27105491-7 2016 Altogether, our data support a novel model, whereby cancer-associated La protein contributes to cisplatin resistance by stimulating the translation of anti-apoptotic factor Bcl2 in HNSCC cells. Cisplatin 96-105 BCL2 apoptosis regulator Homo sapiens 173-177 27038543-4 2016 Accordingly, chaetominine induced apoptosis by upregulating ROS, pro-apoptotic Bax and downregulating anti-apoptotic Bcl-2. chaetominine 13-25 BCL2 apoptosis regulator Homo sapiens 117-122 27064014-0 2016 Isololiolide, a carotenoid metabolite isolated from the brown alga Cystoseira tamariscifolia, is cytotoxic and able to induce apoptosis in hepatocarcinoma cells through caspase-3 activation, decreased Bcl-2 levels, increased p53 expression and PARP cleavage. isololiolide 0-12 BCL2 apoptosis regulator Homo sapiens 201-206 27064014-11 2016 Moreover, western blot analysis showed that isololiolide altered the expression of proteins that are important in the apoptotic cascade, increasing PARP cleavage and p53 expression while decreasing procaspase-3 and Bcl-2 levels. isololiolide 44-56 BCL2 apoptosis regulator Homo sapiens 215-220 27073162-1 2016 Here we explored the potential synergism between the novel Bcl-2 antagonist ABT-737 and the AKT inhibitor perifosine in lung cancer cells. ABT-737 76-83 BCL2 apoptosis regulator Homo sapiens 59-64 27038543-8 2016 In summary, chaetominine strongly reverses drug resistance by interfering with the PI3K/Akt/Nrf2 signaling, resulting in reduction of MRP1-mediated drug efflux and induction of Bax/Bcl-2-dependent apoptosis in an ADR-resistant K562/Adr leukemia cell line. chaetominine 12-24 BCL2 apoptosis regulator Homo sapiens 181-186 27226226-0 2016 Downregulation of B-cell lymphoma/leukemia-2 by overexpressed microRNA 34a enhanced titanium dioxide nanoparticle-induced autophagy in BEAS-2B cells. titanium dioxide 84-100 BCL2 apoptosis regulator Homo sapiens 18-44 27056887-0 2016 High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition. venetoclax 37-43 BCL2 apoptosis regulator Homo sapiens 21-26 27056887-0 2016 High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition. venetoclax 37-43 BCL2 apoptosis regulator Homo sapiens 60-65 27056887-0 2016 High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition. venetoclax 45-55 BCL2 apoptosis regulator Homo sapiens 21-26 27056887-0 2016 High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition. venetoclax 45-55 BCL2 apoptosis regulator Homo sapiens 60-65 27056887-2 2016 In this study, the selective BCL-2 inhibitor ABT199 was tested in a panel of neuroblastoma cell lines with diverse expression levels of BCL-2 and other BCL-2 family proteins. venetoclax 45-51 BCL2 apoptosis regulator Homo sapiens 29-34 27056887-2 2016 In this study, the selective BCL-2 inhibitor ABT199 was tested in a panel of neuroblastoma cell lines with diverse expression levels of BCL-2 and other BCL-2 family proteins. venetoclax 45-51 BCL2 apoptosis regulator Homo sapiens 136-141 27056887-2 2016 In this study, the selective BCL-2 inhibitor ABT199 was tested in a panel of neuroblastoma cell lines with diverse expression levels of BCL-2 and other BCL-2 family proteins. venetoclax 45-51 BCL2 apoptosis regulator Homo sapiens 136-141 27056887-3 2016 ABT199 caused apoptosis more potently in neuroblastoma cell lines expressing high BCL-2 and BIM/BCL-2 complex levels than low expressing cell lines. venetoclax 0-6 BCL2 apoptosis regulator Homo sapiens 82-87 27056887-3 2016 ABT199 caused apoptosis more potently in neuroblastoma cell lines expressing high BCL-2 and BIM/BCL-2 complex levels than low expressing cell lines. venetoclax 0-6 BCL2 apoptosis regulator Homo sapiens 96-101 27056887-6 2016 We showed that neuroblastoma cells might survive ABT199 treatment due to its acute upregulation of the anti-apoptotic BCL-2 family protein myeloid cell leukaemia sequence 1 (MCL-1) and BIM sequestration by MCL-1. venetoclax 49-55 BCL2 apoptosis regulator Homo sapiens 118-123 27056887-8 2016 Our findings suggest that neuroblastoma patients with high BCL-2 and BIM/BCL-2 complex levels might benefit from combination treatment with ABT199 and compounds that inhibit MCL-1 expression. venetoclax 140-146 BCL2 apoptosis regulator Homo sapiens 59-64 27056887-8 2016 Our findings suggest that neuroblastoma patients with high BCL-2 and BIM/BCL-2 complex levels might benefit from combination treatment with ABT199 and compounds that inhibit MCL-1 expression. venetoclax 140-146 BCL2 apoptosis regulator Homo sapiens 73-78 27049723-0 2016 BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. sapropterin 5-8 BCL2 apoptosis regulator Homo sapiens 0-4 27049723-0 2016 BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. BDA-366 20-27 BCL2 apoptosis regulator Homo sapiens 0-4 27049723-3 2016 BH3 mimetics have been developed to disrupt the binding between BCL2 and its pro-apoptotic BCL2 family partners for the treatment of MM, but with limited therapeutic efficacy. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 64-68 27049723-3 2016 BH3 mimetics have been developed to disrupt the binding between BCL2 and its pro-apoptotic BCL2 family partners for the treatment of MM, but with limited therapeutic efficacy. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 91-95 27049723-4 2016 We recently identified a small molecule BDA-366 as a BCL2 BH4 domain antagonist, converting it from an anti-apoptotic into a pro-apoptotic molecule. biotinylated dextran amine 40-43 BCL2 apoptosis regulator Homo sapiens 53-57 27049723-4 2016 We recently identified a small molecule BDA-366 as a BCL2 BH4 domain antagonist, converting it from an anti-apoptotic into a pro-apoptotic molecule. sapropterin 58-61 BCL2 apoptosis regulator Homo sapiens 53-57 27049723-5 2016 In this study, we demonstrated that BDA-366 induces robust apoptosis in MM cell lines and primary MM cells by inducing BCL2 conformational change. BDA-366 36-43 BCL2 apoptosis regulator Homo sapiens 119-123 27049723-7 2016 Thus, BDA-366 functions as a novel BH4-based BCL2 inhibitor and offers an entirely new tool for MM therapy. BDA-366 6-13 BCL2 apoptosis regulator Homo sapiens 45-49 27049723-7 2016 Thus, BDA-366 functions as a novel BH4-based BCL2 inhibitor and offers an entirely new tool for MM therapy. sapropterin 35-38 BCL2 apoptosis regulator Homo sapiens 45-49 32262971-3 2016 The pDNA that can encode luciferase (Luc) or enhanced green fluorescent protein (EGFP) and the Bcl-2 siRNA that can knockdown the expression of the Bcl-2 protein were successfully packaged by the partially PEGylated Au DENPs and effectively delivered into HeLa cells. Gold 216-218 BCL2 apoptosis regulator Homo sapiens 95-100 32262971-3 2016 The pDNA that can encode luciferase (Luc) or enhanced green fluorescent protein (EGFP) and the Bcl-2 siRNA that can knockdown the expression of the Bcl-2 protein were successfully packaged by the partially PEGylated Au DENPs and effectively delivered into HeLa cells. Gold 216-218 BCL2 apoptosis regulator Homo sapiens 148-153 32262971-5 2016 We show that the modified mPEG and entrapped Au NPs can significantly improve the encoding of Luc and EGFP or silence the Bcl-2 protein expression, and the {(Au0)50-G5.NH2-mPEG2K} DENPs display the best DNA or siRNA delivery efficiency among all the designed partially PEGylated Au DENPs. monomethoxypolyethylene glycol 26-30 BCL2 apoptosis regulator Homo sapiens 122-127 32262971-5 2016 We show that the modified mPEG and entrapped Au NPs can significantly improve the encoding of Luc and EGFP or silence the Bcl-2 protein expression, and the {(Au0)50-G5.NH2-mPEG2K} DENPs display the best DNA or siRNA delivery efficiency among all the designed partially PEGylated Au DENPs. Gold 45-47 BCL2 apoptosis regulator Homo sapiens 122-127 27226712-9 2016 In addition, both catechin extract and nanoemulsion could induce apoptosis of PC-3 cells through decrease in B-cell lymphoma 2 (bcl-2) expression and increase in cytochrome c expression for activation of caspase-3, caspase-8, and caspase-9. Catechin 18-26 BCL2 apoptosis regulator Homo sapiens 109-126 27226712-9 2016 In addition, both catechin extract and nanoemulsion could induce apoptosis of PC-3 cells through decrease in B-cell lymphoma 2 (bcl-2) expression and increase in cytochrome c expression for activation of caspase-3, caspase-8, and caspase-9. Catechin 18-26 BCL2 apoptosis regulator Homo sapiens 128-133 27055473-6 2016 Together, our results revealed that abrin P2-induced apoptosis in HCT-8 cells was associated with the activation of caspases-3/-8/-9, the reduction in the Bcl-2/Bax ratio, the loss of mitochondrial membrane potential, and the increase in cytochrome c release. abrin p2 36-44 BCL2 apoptosis regulator Homo sapiens 155-160 27013583-6 2016 Both downregulated PLAG1 and elevated expression of miR-424&27a led to Bcl2 downregulation and augmented cleavage of Caspase8, Caspase3 and PARP in the presence of TRAIL. Adenosine Monophosphate 60-63 BCL2 apoptosis regulator Homo sapiens 75-79 27058891-9 2016 Sal inhibited constitutive STAT3 activation by blocking its DNA binding and reduced various gene products including Bcl-2, Bcl-xL and VEGF both at mRNA and protein levels. salinomycin 0-3 BCL2 apoptosis regulator Homo sapiens 116-121 27136675-9 2016 A unique 25-kDa fragment of B-cell lymphoma 2 (Bcl-2) lacking BH4 was observed 60-180 min post TRAIL treatment in MuD-depleted cells, suggesting that Bcl-2 is converted from its anti-apoptotic form to the truncated pro-apoptotic form. sapropterin 62-65 BCL2 apoptosis regulator Homo sapiens 28-45 27136675-9 2016 A unique 25-kDa fragment of B-cell lymphoma 2 (Bcl-2) lacking BH4 was observed 60-180 min post TRAIL treatment in MuD-depleted cells, suggesting that Bcl-2 is converted from its anti-apoptotic form to the truncated pro-apoptotic form. sapropterin 62-65 BCL2 apoptosis regulator Homo sapiens 47-52 27063218-8 2016 PG-induced apoptosis was mediated via the intrinsic mitochondrial pathway, as evidenced by the decreased Bcl-2, increased Bax and Bax/Bcl-2 ratio, as well as the loss of MMP, caspase-9 activation, and increased cytosolic cytochrome c. physcion 8-O-glucopyranoside 0-2 BCL2 apoptosis regulator Homo sapiens 105-110 27629726-9 2016 Forty-eighthour treatment of thalidomide 350 mug/mL and IFN 1400 U/mL could significantly decrease Bcl-2 expression and increase the expression levels of phosphor-P38, BAX, cytochrome c, and cleaved caspase-3, -8, and -9 as compared to the control group. Thalidomide 29-40 BCL2 apoptosis regulator Homo sapiens 99-104 27063218-8 2016 PG-induced apoptosis was mediated via the intrinsic mitochondrial pathway, as evidenced by the decreased Bcl-2, increased Bax and Bax/Bcl-2 ratio, as well as the loss of MMP, caspase-9 activation, and increased cytosolic cytochrome c. physcion 8-O-glucopyranoside 0-2 BCL2 apoptosis regulator Homo sapiens 134-139 27168791-8 2016 Moreover, metformin downregulated the expression of the anti-apoptotic proteins B-cell lymphoma 2 (BCL-2) and myeloid cell leukemia-1, and upregulated the expression of the pro-apoptotic BCL-2-associated X protein in MDA-MB-231 cells. Metformin 10-19 BCL2 apoptosis regulator Homo sapiens 80-97 26892009-5 2016 This study demonstrates that combination of doxorubicin and sorafenib induces apoptosis in MPNST cells through downregulation of B cell lymphoma protein 2 (Bcl-2), Bcl-2-related protein long form of Bcl-x (Bcl-xl), and myeloid cell leukemia 1 (Mcl-1). Doxorubicin 44-55 BCL2 apoptosis regulator Homo sapiens 129-154 26892009-5 2016 This study demonstrates that combination of doxorubicin and sorafenib induces apoptosis in MPNST cells through downregulation of B cell lymphoma protein 2 (Bcl-2), Bcl-2-related protein long form of Bcl-x (Bcl-xl), and myeloid cell leukemia 1 (Mcl-1). Doxorubicin 44-55 BCL2 apoptosis regulator Homo sapiens 156-161 26892009-5 2016 This study demonstrates that combination of doxorubicin and sorafenib induces apoptosis in MPNST cells through downregulation of B cell lymphoma protein 2 (Bcl-2), Bcl-2-related protein long form of Bcl-x (Bcl-xl), and myeloid cell leukemia 1 (Mcl-1). Doxorubicin 44-55 BCL2 apoptosis regulator Homo sapiens 164-169 26892009-5 2016 This study demonstrates that combination of doxorubicin and sorafenib induces apoptosis in MPNST cells through downregulation of B cell lymphoma protein 2 (Bcl-2), Bcl-2-related protein long form of Bcl-x (Bcl-xl), and myeloid cell leukemia 1 (Mcl-1). Sorafenib 60-69 BCL2 apoptosis regulator Homo sapiens 129-154 26892009-5 2016 This study demonstrates that combination of doxorubicin and sorafenib induces apoptosis in MPNST cells through downregulation of B cell lymphoma protein 2 (Bcl-2), Bcl-2-related protein long form of Bcl-x (Bcl-xl), and myeloid cell leukemia 1 (Mcl-1). Sorafenib 60-69 BCL2 apoptosis regulator Homo sapiens 156-161 26892009-5 2016 This study demonstrates that combination of doxorubicin and sorafenib induces apoptosis in MPNST cells through downregulation of B cell lymphoma protein 2 (Bcl-2), Bcl-2-related protein long form of Bcl-x (Bcl-xl), and myeloid cell leukemia 1 (Mcl-1). Sorafenib 60-69 BCL2 apoptosis regulator Homo sapiens 164-169 26892009-8 2016 Bcl-2 or Mcl-1 mRNA suppression by Sec6 or Sec8 depletion resulted in significant changes in nuclear factor-kappa B, cAMP response element, and p53 transcriptional activity. Cyclic AMP 117-121 BCL2 apoptosis regulator Homo sapiens 0-5 27133040-10 2016 ALA also elevated the bcl-2 and reduced caspase3, 9 expressions in the HCY- induced HAECs. Thioctic Acid 0-3 BCL2 apoptosis regulator Homo sapiens 22-27 27133064-4 2016 Furthermore, we found Costunolide induced the loss of mitochondrial transmembrane potential, down-regulated Bcl-2/Bax ratio, encouraged Cyt-c release and caspase activation. costunolide 22-33 BCL2 apoptosis regulator Homo sapiens 108-113 27183435-8 2016 Furthermore, the expression of MRP-1 and Bcl-2 was also inhibited, suggesting that the LRIG1could negatively control MRP-1 and the apoptosis to improve the sensitivity of VP16-related chemotherapy. Etoposide 171-175 BCL2 apoptosis regulator Homo sapiens 41-46 27168791-8 2016 Moreover, metformin downregulated the expression of the anti-apoptotic proteins B-cell lymphoma 2 (BCL-2) and myeloid cell leukemia-1, and upregulated the expression of the pro-apoptotic BCL-2-associated X protein in MDA-MB-231 cells. Metformin 10-19 BCL2 apoptosis regulator Homo sapiens 99-104 26878773-0 2016 Antioxidant tert-butylhydroquinone ameliorates arsenic-induced intracellular damages and apoptosis through induction of Nrf2-dependent antioxidant responses as well as stabilization of anti-apoptotic factor Bcl-2 in human keratinocytes. 2-tert-butylhydroquinone 12-34 BCL2 apoptosis regulator Homo sapiens 207-212 27168791-8 2016 Moreover, metformin downregulated the expression of the anti-apoptotic proteins B-cell lymphoma 2 (BCL-2) and myeloid cell leukemia-1, and upregulated the expression of the pro-apoptotic BCL-2-associated X protein in MDA-MB-231 cells. Metformin 10-19 BCL2 apoptosis regulator Homo sapiens 187-192 26878773-0 2016 Antioxidant tert-butylhydroquinone ameliorates arsenic-induced intracellular damages and apoptosis through induction of Nrf2-dependent antioxidant responses as well as stabilization of anti-apoptotic factor Bcl-2 in human keratinocytes. Arsenic 47-54 BCL2 apoptosis regulator Homo sapiens 207-212 26971222-11 2016 Also, increased Bax and decreased Bcl-2 levels suggest that BAEO-induced apoptosis is mediated through both death receptor and mitochondrial pathways. baeo 60-64 BCL2 apoptosis regulator Homo sapiens 34-39 26930265-9 2016 Expressions of Bax/Bcl-2, Cox-2, and caspase-9 were upregulated (p < 0.05) in CTBs treated with >=150 mg/dL glucose. bromebric acid 81-85 BCL2 apoptosis regulator Homo sapiens 19-24 26930265-9 2016 Expressions of Bax/Bcl-2, Cox-2, and caspase-9 were upregulated (p < 0.05) in CTBs treated with >=150 mg/dL glucose. Glucose 114-121 BCL2 apoptosis regulator Homo sapiens 19-24 26892433-5 2016 The results showed that alpha-mangostin induced cell proliferation inhibition, DNA fragmentation, nuclear condensation, increased cleaved caspase-3 and cleaved caspase-9, but decreased Bcl-2 and Mcl-1 expression. mangostin 24-39 BCL2 apoptosis regulator Homo sapiens 185-190 27133421-4 2016 In this study, we report that gamma-tocotrienol (gammaT3), an isomer of vitamin E, can inhibit Bcl-2 to induce apoptosis. plastochromanol 8 30-47 BCL2 apoptosis regulator Homo sapiens 95-100 27133421-4 2016 In this study, we report that gamma-tocotrienol (gammaT3), an isomer of vitamin E, can inhibit Bcl-2 to induce apoptosis. Vitamin E 72-81 BCL2 apoptosis regulator Homo sapiens 95-100 27162479-8 2016 In contrast, KTH-13-t-Bu upregulated the levels of pro- and cleaved forms of caspase-3, -8, and -9 and Bcl-2. kth-13-t-bu 13-24 BCL2 apoptosis regulator Homo sapiens 103-108 26878773-8 2016 More interestingly, arsenic-induced decrease of anti-apoptotic factor B-cell lymphoma-2 (Bcl-2) and increase of pro-apoptotic factor Bcl-2-associated X protein (Bax) could all be reversed by tBHQ pretreatment. Arsenic 20-27 BCL2 apoptosis regulator Homo sapiens 70-87 26878773-8 2016 More interestingly, arsenic-induced decrease of anti-apoptotic factor B-cell lymphoma-2 (Bcl-2) and increase of pro-apoptotic factor Bcl-2-associated X protein (Bax) could all be reversed by tBHQ pretreatment. Arsenic 20-27 BCL2 apoptosis regulator Homo sapiens 89-94 26878773-8 2016 More interestingly, arsenic-induced decrease of anti-apoptotic factor B-cell lymphoma-2 (Bcl-2) and increase of pro-apoptotic factor Bcl-2-associated X protein (Bax) could all be reversed by tBHQ pretreatment. 2-tert-butylhydroquinone 191-195 BCL2 apoptosis regulator Homo sapiens 70-87 26878773-9 2016 These results suggested together that tBHQ could ameliorate arsenic-induced cytotoxicity and apoptosis, which might be linked with the induction of Nrf2-dependent antioxidant responses as well as stabilization of anti-apoptotic factor Bcl-2 in human keratinocytes. 2-tert-butylhydroquinone 38-42 BCL2 apoptosis regulator Homo sapiens 235-240 26878773-9 2016 These results suggested together that tBHQ could ameliorate arsenic-induced cytotoxicity and apoptosis, which might be linked with the induction of Nrf2-dependent antioxidant responses as well as stabilization of anti-apoptotic factor Bcl-2 in human keratinocytes. Arsenic 60-67 BCL2 apoptosis regulator Homo sapiens 235-240 27398330-7 2016 Mechanistically, berberine inhibits PI3K/AKT activation that, in turn, results in up-regulating the expression of Bax, and PARP and down-regulating the expression of Bcl-2 and caspase3. Berberine 17-26 BCL2 apoptosis regulator Homo sapiens 166-171 26133723-4 2016 Correlating with these observations, silibinin suppressed the expression of Bcl-2, survivin and JunB, all of which are found to be upregulated by NPM-ALK and pathogenetically important in ALK+ALCL. Silybin 37-46 BCL2 apoptosis regulator Homo sapiens 76-81 26707935-0 2016 Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Dexamethasone 0-13 BCL2 apoptosis regulator Homo sapiens 33-38 26707935-0 2016 Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. venetoclax 98-108 BCL2 apoptosis regulator Homo sapiens 33-38 26892272-5 2016 Co-treatment with lupeol and 5-Fu induced apoptosis through up-regulating the expressions of Bax and p53 and down-regulating the expressions of survivin and Bcl-2. Fluorouracil 29-33 BCL2 apoptosis regulator Homo sapiens 157-162 26707935-1 2016 Venetoclax (ABT-199), a specific inhibitor of the anti-apoptotic protein Bcl-2, is currently in phase I clinical trials for multiple myeloma. venetoclax 0-10 BCL2 apoptosis regulator Homo sapiens 73-78 26707935-1 2016 Venetoclax (ABT-199), a specific inhibitor of the anti-apoptotic protein Bcl-2, is currently in phase I clinical trials for multiple myeloma. venetoclax 12-19 BCL2 apoptosis regulator Homo sapiens 73-78 26707935-6 2016 The mechanism by which this occurs is an increase in the expression of both Bcl-2 and Bim upon addition of Dex. Dexamethasone 107-110 BCL2 apoptosis regulator Homo sapiens 76-81 26707935-8 2016 Dex shifts Bim binding towards Bcl-2 resulting in increased sensitivity to venetoclax. Dexamethasone 0-3 BCL2 apoptosis regulator Homo sapiens 31-36 27035331-5 2016 Additionally, lycopene counteracted H2O2-induced mitochondrial dysfunction, which was evidenced by suppression of mitochondrial permeability transition pore opening, attenuation of the decline of the mitochondrial membrane potential, and inhibition of the increase of Bax and decrease of Bcl-2 levels within the mitochondria. Lycopene 14-22 BCL2 apoptosis regulator Homo sapiens 288-293 27035331-5 2016 Additionally, lycopene counteracted H2O2-induced mitochondrial dysfunction, which was evidenced by suppression of mitochondrial permeability transition pore opening, attenuation of the decline of the mitochondrial membrane potential, and inhibition of the increase of Bax and decrease of Bcl-2 levels within the mitochondria. Hydrogen Peroxide 36-40 BCL2 apoptosis regulator Homo sapiens 288-293 26939706-0 2016 Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. venetoclax 115-125 BCL2 apoptosis regulator Homo sapiens 22-27 26939706-0 2016 Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. venetoclax 115-125 BCL2 apoptosis regulator Homo sapiens 88-93 26939706-2 2016 Indeed, multiple myeloma cells are sensitive to antagonists that selectively target prosurvival proteins such as BCL-2/BCL-XL (ABT-737 and ABT-263/navitoclax) or BCL-2 only (ABT-199/GDC-0199/venetoclax). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 127-130 BCL2 apoptosis regulator Homo sapiens 113-118 26939706-2 2016 Indeed, multiple myeloma cells are sensitive to antagonists that selectively target prosurvival proteins such as BCL-2/BCL-XL (ABT-737 and ABT-263/navitoclax) or BCL-2 only (ABT-199/GDC-0199/venetoclax). venetoclax 182-190 BCL2 apoptosis regulator Homo sapiens 113-118 26939706-2 2016 Indeed, multiple myeloma cells are sensitive to antagonists that selectively target prosurvival proteins such as BCL-2/BCL-XL (ABT-737 and ABT-263/navitoclax) or BCL-2 only (ABT-199/GDC-0199/venetoclax). venetoclax 191-201 BCL2 apoptosis regulator Homo sapiens 113-118 26939706-6 2016 Multiple myeloma cells that coexpress BCL-2 and BCL-XL were resistant to venetoclax but sensitive to a BCL-XL-selective inhibitor (A-1155463). venetoclax 73-83 BCL2 apoptosis regulator Homo sapiens 38-43 26939706-6 2016 Multiple myeloma cells that coexpress BCL-2 and BCL-XL were resistant to venetoclax but sensitive to a BCL-XL-selective inhibitor (A-1155463). A-1155463 131-140 BCL2 apoptosis regulator Homo sapiens 38-43 26939706-8 2016 Resistance to venetoclax was mitigated by cotreatment with bortezomib in xenografts that coexpressed BCL-2 and MCL-1 due to upregulation of NOXA, a proapoptotic factor that neutralizes MCL-1. venetoclax 14-24 BCL2 apoptosis regulator Homo sapiens 101-106 26939706-8 2016 Resistance to venetoclax was mitigated by cotreatment with bortezomib in xenografts that coexpressed BCL-2 and MCL-1 due to upregulation of NOXA, a proapoptotic factor that neutralizes MCL-1. Bortezomib 59-69 BCL2 apoptosis regulator Homo sapiens 101-106 26939706-9 2016 In contrast, xenografts that expressed BCL-XL, MCL-1, and BCL-2 were more sensitive to the combination of bortezomib with a BCL-XL selective inhibitor (A-1331852) but not with venetoclax cotreatment when compared with monotherapies. Bortezomib 106-116 BCL2 apoptosis regulator Homo sapiens 58-63 26939706-9 2016 In contrast, xenografts that expressed BCL-XL, MCL-1, and BCL-2 were more sensitive to the combination of bortezomib with a BCL-XL selective inhibitor (A-1331852) but not with venetoclax cotreatment when compared with monotherapies. A-1331852 152-161 BCL2 apoptosis regulator Homo sapiens 58-63 27052425-6 2016 This was paralleled with an upregulation of Nox4 as well as ROS overproduction, which activated the phosphorylation of P38/ERK and caused an imbalance of Bax/Bcl-2 in HK-2 cells. nox4 44-48 BCL2 apoptosis regulator Homo sapiens 158-163 27052425-6 2016 This was paralleled with an upregulation of Nox4 as well as ROS overproduction, which activated the phosphorylation of P38/ERK and caused an imbalance of Bax/Bcl-2 in HK-2 cells. Reactive Oxygen Species 60-63 BCL2 apoptosis regulator Homo sapiens 158-163 26987063-4 2016 Goniothalamin also increased the Bax/Bcl-2 ratio and expression of cleaved caspase-7, cleaved caspase-9 and cleaved PARP, but decreased Bcl-2 expression. goniothalamin 0-13 BCL2 apoptosis regulator Homo sapiens 136-141 26985864-5 2016 Curcumin also regulated B-cell lymphoma 2 (Bcl-2), Bax and p-Akt protein expression in MDA-MB-231 cells. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 24-41 26985864-5 2016 Curcumin also regulated B-cell lymphoma 2 (Bcl-2), Bax and p-Akt protein expression in MDA-MB-231 cells. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 43-48 26987063-4 2016 Goniothalamin also increased the Bax/Bcl-2 ratio and expression of cleaved caspase-7, cleaved caspase-9 and cleaved PARP, but decreased Bcl-2 expression. goniothalamin 0-13 BCL2 apoptosis regulator Homo sapiens 37-42 26608367-6 2016 SB-3CT, an inhibitor of MMP-9, promoted apoptosis, inhibited cell proliferation, induced cell cycle arrest, and downregulated the expression of antiapoptotic genes Bcl-2 and Bcl-xl in MCF-7 cells. SB 3CT compound 0-6 BCL2 apoptosis regulator Homo sapiens 164-169 27563220-14 2016 SUMMARY: OSEO inhibited proliferation of MCF-7 cells with an IC50 of 170 mug/mLOSEO at 500 mug/mL increased the population of apoptotic cells by 84%OSEO up-regulated the expression of apoptotic genes and as well increased the Bax/Bcl2 ratio. oseo 79-83 BCL2 apoptosis regulator Homo sapiens 230-234 27563220-12 2016 OSEO has the ability to up-regulate the apoptotic genes p53 and Bid and as well as elevates the ratio of Bax/Bcl-2. oseo 0-4 BCL2 apoptosis regulator Homo sapiens 109-114 27563220-14 2016 SUMMARY: OSEO inhibited proliferation of MCF-7 cells with an IC50 of 170 mug/mLOSEO at 500 mug/mL increased the population of apoptotic cells by 84%OSEO up-regulated the expression of apoptotic genes and as well increased the Bax/Bcl2 ratio. oseo 9-13 BCL2 apoptosis regulator Homo sapiens 230-234 26662109-5 2016 Treatment of the cells with PX-12 (5 muM) and trastuzumab (10 mug/ml) reduced cells viabilities, p-Akt, and Bcl2 levels while increasing the levels of reactive oxygen species (ROS) and p-JNK with consequent higher levels of G1 arrest and apoptosis among the resistant cells compared to parental trastuzumab sensitive cells. 1-methylpropyl-2-imidazolyl disulfide 28-33 BCL2 apoptosis regulator Homo sapiens 108-112 27029054-6 2016 Furthermore, Exo-GF co-incubation with cisplatin increased autophagic activity and reduced apoptosis, as demonstrated by an upregulation of LC3-II and Bcl-2 protein levels and downregulation of p62 and Bax protein levels. Cisplatin 39-48 BCL2 apoptosis regulator Homo sapiens 151-156 30133211-6 2016 The result of Western blot confirmed that mulberry anthocyanins can increase the ratio of LC3-II /LC3-I,BAX / BCL-2 ratio and the expression of Caspase-8,Beclin1 of SGC-7901 cells. Anthocyanins 51-63 BCL2 apoptosis regulator Homo sapiens 110-115 26996126-4 2016 In contrast, the expression of proapoptotic multidomain Bcl-2-family members, Bak and Bax, was induced by cisplatin in p53-dependent and -independent manners, respectively. Cisplatin 106-115 BCL2 apoptosis regulator Homo sapiens 56-61 26996126-6 2016 Furthermore, both Bak- and Bax-induced apoptosis was enhanced by the antiapoptotic Bcl-2 family member, Bcl-XL knockdown, but not by Mcl-1 knockdown. bakuchiol 18-21 BCL2 apoptosis regulator Homo sapiens 83-88 26996126-7 2016 From this result, we tested the effect of ABT-263 (Navitoclax), the specific inhibitor of Bcl-2 and Bcl-XL, but not Mcl-1, and found that ABT-263 synergistically enhanced cisplatin-induced apoptosis in NSCLC cells in the presence or absence of p53. navitoclax 51-61 BCL2 apoptosis regulator Homo sapiens 90-95 26996126-7 2016 From this result, we tested the effect of ABT-263 (Navitoclax), the specific inhibitor of Bcl-2 and Bcl-XL, but not Mcl-1, and found that ABT-263 synergistically enhanced cisplatin-induced apoptosis in NSCLC cells in the presence or absence of p53. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 138-141 BCL2 apoptosis regulator Homo sapiens 90-95 27102814-13 2016 The increased ROS production up-regulated the p53 protein level, which led to the up-regulation of Bax and down-regulation of Bcl-2. Reactive Oxygen Species 14-17 BCL2 apoptosis regulator Homo sapiens 126-131 27097161-4 2016 Furthermore, CIP downregulated the phosphorylation of Akt, PDK and mTOR proteins and decreased expression of cyclin D1, Bcl-2, survivin, VEGF, procaspase-3 and increased cleavage of PARP. cip 13-16 BCL2 apoptosis regulator Homo sapiens 120-125 27104510-6 2016 The western blot results revealed that exposure to UA was associated with decreased expression of the anti-apoptotic proteins Mcl-1, Bcl-xL, Bcl-2, and TCTP and increased expression of apoptosis-related proteins TNF-alpha, Fas, FADD, Bax, cleaved caspase-3, caspase-8, caspase-9, and PARP. ursolic acid 51-53 BCL2 apoptosis regulator Homo sapiens 141-146 27110775-7 2016 Smad3 upregulated p21(Waf1/Cip1) and downregulated c-myc and bcl2 with the treatment of cisplatin. Cisplatin 88-97 BCL2 apoptosis regulator Homo sapiens 61-65 27084510-13 2016 Bax and Apaf-1 expression were notably increased with decreased Bcl-2 and Bcl-xL expression in andrographolide-treated cells. andrographolide 95-110 BCL2 apoptosis regulator Homo sapiens 64-69 26844930-2 2016 One such dysregulated PPI is that between the anti-apoptotic Bcl-2 proteins, including myeloid cell leukemia-1 (Mcl-1), and the alpha-helical Bcl-2 homology-3 (BH3) domains of its pro-apoptotic counterparts, such as Bak. bakuchiol 216-219 BCL2 apoptosis regulator Homo sapiens 61-66 26844930-2 2016 One such dysregulated PPI is that between the anti-apoptotic Bcl-2 proteins, including myeloid cell leukemia-1 (Mcl-1), and the alpha-helical Bcl-2 homology-3 (BH3) domains of its pro-apoptotic counterparts, such as Bak. bakuchiol 216-219 BCL2 apoptosis regulator Homo sapiens 142-147 26909600-7 2016 In addition, miR-329 promoted NSCLC cell apoptosis, as indicated by up-regulation of key apoptosis gene cleaved caspase-3, and down-regulation of anti-apoptosis gene Bcl2. mir-329 13-20 BCL2 apoptosis regulator Homo sapiens 166-170 27096074-11 2016 The supplementation of NaHS also decreased the activity of LDH and CK, MDA contents, ROS levels and the phosphorylation of IkappaBalpha, NF-kappaB, JNK2 and STAT3, and increased cell viability, the expression of Bcl-2, the activity of SOD, CAT and GSH-PX. sodium bisulfide 23-27 BCL2 apoptosis regulator Homo sapiens 212-217 26942461-7 2016 Interestingly, caspase-9-deficient Jurkat cells or Bcl-2- and Bcl-xL-overexpressing cells were strongly resistant to hydralazine treatment, thereby demonstrating the dependence of hydralazine-induced apoptosis on the mitochondrial death pathway. Hydralazine 117-128 BCL2 apoptosis regulator Homo sapiens 51-56 26942461-7 2016 Interestingly, caspase-9-deficient Jurkat cells or Bcl-2- and Bcl-xL-overexpressing cells were strongly resistant to hydralazine treatment, thereby demonstrating the dependence of hydralazine-induced apoptosis on the mitochondrial death pathway. Hydralazine 180-191 BCL2 apoptosis regulator Homo sapiens 51-56 27080533-1 2016 BACKGROUND: BH3 mimetics are a class of drugs that antagonize the Bcl-2 family of apoptosis inhibitors. BH 3 12-15 BCL2 apoptosis regulator Homo sapiens 66-71 27186296-5 2016 The most likely mechanism is icotinib inhibited the gene expression levels of JAK2, STAT3 and Bcl-2, so with the P-STAT3 and IL-6 protein levels, and mediated gene Bax overexpression. icotinib 29-37 BCL2 apoptosis regulator Homo sapiens 94-99 27002411-15 2016 In contrast, Bcl-2, Hsp70 and survivin decreased in expression upon cleistopholine treatment. cleistopholine 68-82 BCL2 apoptosis regulator Homo sapiens 13-18 27143925-7 2016 Then, treatment of Tca-8113 cells with carvacrol resulted in downregulation of Bcl-2, Cox2, and upregulation of Bax. Trichloroacetic Acid 19-22 BCL2 apoptosis regulator Homo sapiens 79-84 27143925-7 2016 Then, treatment of Tca-8113 cells with carvacrol resulted in downregulation of Bcl-2, Cox2, and upregulation of Bax. carvacrol 39-48 BCL2 apoptosis regulator Homo sapiens 79-84 27080533-4 2016 This has led to the development of ABT-199 which specifically inhibits Bcl-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 35-38 BCL2 apoptosis regulator Homo sapiens 71-76 29931964-2 2016 METHODS: Human breast cancer MCF-7 cells were treated with arecoline at the concentrations of 0,10,30,50, 100,300,500mumol/L, the cell proliferation were detected by MTT assay, cell apoptosis were analyzed by Hoechst 33342 staining and flow cy-tometry, the protein expression of Bax,Bcl-2 and P53 were detected by Western blot. Arecoline 59-68 BCL2 apoptosis regulator Homo sapiens 283-288 26257067-5 2016 More recently, an increasing number of BH3 mimetics, which bind and neutralize BCL-2 and/or its pro-survival relatives, have been developed. BH 3 39-42 BCL2 apoptosis regulator Homo sapiens 79-84 27110097-6 2016 Docking results revealed that the acetogenins, such as annomuricin A, annohexocin, muricatocin A, annomuricin-D-one, and muricatetrocin A/B, exhibited strong binding interactions with Bcl-Xl when compared to Bcl-2 and Mcl-1. annomuricin A 55-68 BCL2 apoptosis regulator Homo sapiens 208-213 27110097-6 2016 Docking results revealed that the acetogenins, such as annomuricin A, annohexocin, muricatocin A, annomuricin-D-one, and muricatetrocin A/B, exhibited strong binding interactions with Bcl-Xl when compared to Bcl-2 and Mcl-1. muricatocin A 83-96 BCL2 apoptosis regulator Homo sapiens 208-213 27110097-6 2016 Docking results revealed that the acetogenins, such as annomuricin A, annohexocin, muricatocin A, annomuricin-D-one, and muricatetrocin A/B, exhibited strong binding interactions with Bcl-Xl when compared to Bcl-2 and Mcl-1. annomuricin D-one 98-115 BCL2 apoptosis regulator Homo sapiens 208-213 27110097-6 2016 Docking results revealed that the acetogenins, such as annomuricin A, annohexocin, muricatocin A, annomuricin-D-one, and muricatetrocin A/B, exhibited strong binding interactions with Bcl-Xl when compared to Bcl-2 and Mcl-1. Muricatetrocin A 121-137 BCL2 apoptosis regulator Homo sapiens 208-213 27054332-0 2016 BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors. bim 0-3 BCL2 apoptosis regulator Homo sapiens 81-86 29931964-4 2016 However, high concentration(100,300,500mumol/L) arecoline inhibited proliferation and induced apoptosis of MCF-7 cells in a concentration-dependent manner, arecoline also significantly increased P53 and Bax protein expression and decreased Bcl-2 protein expression. Arecoline 48-57 BCL2 apoptosis regulator Homo sapiens 240-245 29931964-4 2016 However, high concentration(100,300,500mumol/L) arecoline inhibited proliferation and induced apoptosis of MCF-7 cells in a concentration-dependent manner, arecoline also significantly increased P53 and Bax protein expression and decreased Bcl-2 protein expression. Arecoline 156-165 BCL2 apoptosis regulator Homo sapiens 240-245 29931964-5 2016 CONCLUSIONS: High concentration arecoline inhibited the proliferation and induced the apoptosis of MCF-7 cells, the mechanism was probably corrected with increasing P53 and Bax protein expression and decreasing Bcl-2 pro-tein expression. Arecoline 32-41 BCL2 apoptosis regulator Homo sapiens 211-216 26915975-6 2016 Treatment with 2,3-dihydroxy-9,10-anthraquinone was found to trigger intrinsic apoptotic pathway as indicated by down regulation of Bcl-2, Bcl-xl; up regulation of Bim, Bax, Bad; release of cytochrome c and pro-caspases cleaving to caspases. 2,3-dihydroxy-9,10-anthraquinone 15-47 BCL2 apoptosis regulator Homo sapiens 132-137 27044825-14 2016 sCD40L in combination with cisplatin decreased the expression levels of GST-pi, LRP, Survivin, p53 and Bcl-2 in both epithelial ovarian cancer cell lines. Cisplatin 27-36 BCL2 apoptosis regulator Homo sapiens 103-108 27043783-10 2016 CONCLUSIONS: The combined treatment using wilfortrine and paclitaxel can inhibit proliferation and invasion of liver cancer cells via down-regulating Bcl-2 and up-regulating Bax, with better efficacy than single use of either drug. wilfortrine 42-53 BCL2 apoptosis regulator Homo sapiens 150-155 27043783-10 2016 CONCLUSIONS: The combined treatment using wilfortrine and paclitaxel can inhibit proliferation and invasion of liver cancer cells via down-regulating Bcl-2 and up-regulating Bax, with better efficacy than single use of either drug. Paclitaxel 58-68 BCL2 apoptosis regulator Homo sapiens 150-155 26769704-5 2016 Further studies showed that FBRA extract induced the cleavage of caspase-8, -9, and -3, and decreased Bcl-2 protein expression. fbra 28-32 BCL2 apoptosis regulator Homo sapiens 102-107 26803409-5 2016 Molecular docking studies suggested that intact curcumin from nanoparticles, bind with BAX in BIM SAHB site and attenuate it to undergo apoptosis while upregulating anti-apoptotic genes like BCL2. Curcumin 48-56 BCL2 apoptosis regulator Homo sapiens 191-195 27042160-3 2016 The BH3 mimetic ABT-737 belongs to a new class of drugs that target anti-apoptotic proteins of the BCL-2 family and facilitate cell death. BH 3 4-7 BCL2 apoptosis regulator Homo sapiens 99-104 27042160-3 2016 The BH3 mimetic ABT-737 belongs to a new class of drugs that target anti-apoptotic proteins of the BCL-2 family and facilitate cell death. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 16-19 BCL2 apoptosis regulator Homo sapiens 99-104 26564153-8 2016 The results of Western blot showed that BPIQ down-regulates the levels of anti-apoptotic proteins Bcl-2, survivin and XIAP while up-regulates the pro-apoptotic proteins Bad, Bax and Bid. bpiq 40-44 BCL2 apoptosis regulator Homo sapiens 98-103 26721623-8 2016 This was also observed with the organelle-specific variants Bcl-xL-ActA and Bcl-2-ActA (mitochondrial) as well as Bcl-xL-cb5 and Bcl-2-cb5 (ER) which all reduced AT-101-induced cell death, but did not affect the death-enhancing effects of 3-MA. 3-methyladenine 239-243 BCL2 apoptosis regulator Homo sapiens 76-81 26721623-8 2016 This was also observed with the organelle-specific variants Bcl-xL-ActA and Bcl-2-ActA (mitochondrial) as well as Bcl-xL-cb5 and Bcl-2-cb5 (ER) which all reduced AT-101-induced cell death, but did not affect the death-enhancing effects of 3-MA. 3-methyladenine 239-243 BCL2 apoptosis regulator Homo sapiens 129-134 26721648-10 2016 Propofol was associated with an increase in myocardial Bcl-2 protein expression (P = 0.005), a lower incidence of a CS cTnI threshold for myocardial infarction (P = 0.014), and fewer heart failure events (P < 0.001). Propofol 0-8 BCL2 apoptosis regulator Homo sapiens 55-60 26923693-0 2016 Stabilization of G-quadruplex DNA and inhibition of Bcl-2 expression by a pyridostatin analog. pyridostatin 74-86 BCL2 apoptosis regulator Homo sapiens 52-57 26882972-6 2016 Moringin showed to be effective in inducing apoptosis through p53 and Bax activation and Bcl-2 inhibition. moringin 0-8 BCL2 apoptosis regulator Homo sapiens 89-94 26511813-7 2016 DTX robustly enhanced Bcl-2 inactivation by CAV-1 in MDA-MB-231 cells, while p53-mediated cell cycle arrest by DTX was more pronounced in CAV-1-low but p53-functional MCF-7 cells. Docetaxel 0-3 BCL2 apoptosis regulator Homo sapiens 22-27 26899021-1 2016 Small-molecule BH3 mimetics are designed to mimic the BH3 domain of BH3-only BCL-2 family members which are antagonists of the prosurvival members (such as BCL-2, BCL-XL and MCL-1). BH 3 15-18 BCL2 apoptosis regulator Homo sapiens 77-82 26899021-1 2016 Small-molecule BH3 mimetics are designed to mimic the BH3 domain of BH3-only BCL-2 family members which are antagonists of the prosurvival members (such as BCL-2, BCL-XL and MCL-1). BH 3 15-18 BCL2 apoptosis regulator Homo sapiens 156-161 26899021-3 2016 Both navitoclax (BCL-2/BCL-XL antagonist) and ABT-199/venetoclax (BCL-2-selective inhibitor) have demonstrated therapeutic efficacy especially in chronic lymphocytic leukemia (CLL). navitoclax 5-15 BCL2 apoptosis regulator Homo sapiens 17-22 26899021-3 2016 Both navitoclax (BCL-2/BCL-XL antagonist) and ABT-199/venetoclax (BCL-2-selective inhibitor) have demonstrated therapeutic efficacy especially in chronic lymphocytic leukemia (CLL). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 46-49 BCL2 apoptosis regulator Homo sapiens 66-71 26899021-3 2016 Both navitoclax (BCL-2/BCL-XL antagonist) and ABT-199/venetoclax (BCL-2-selective inhibitor) have demonstrated therapeutic efficacy especially in chronic lymphocytic leukemia (CLL). venetoclax 54-64 BCL2 apoptosis regulator Homo sapiens 66-71 26846275-7 2016 RT-PCR and western blot assays proved that apoptosis induction effect of doxycycline was achieved via inducing the expression of caspase-3 and bax, as well as attenuating the expression of survivin and bcl-2. Doxycycline 73-84 BCL2 apoptosis regulator Homo sapiens 202-207 27073461-7 2016 CAPE-NO2 also upregulated the myocardial IR-induced expression levels of Bcl-2, phosphoinositide-3-kinase, phosphorylated Akt and mammalian target of rapamycin. cape-no2 0-8 BCL2 apoptosis regulator Homo sapiens 73-78 26828285-10 2016 The results show that the complexes induce BEL-7402 cells apoptosis through a ROS-mediated mitochondrial dysfunction pathway, which was accompanied by regulation of the expression of Bcl-2 family proteins. Reactive Oxygen Species 78-81 BCL2 apoptosis regulator Homo sapiens 183-188 26898562-7 2016 Recombinant overexpression of Bcl2 inhibited the osteogenic/odontogenic potential of DPSCs, as indicated by lower levels of alkaline phosphatase activity and mineralized calcium deposition, together with the down-regulated expression of several key osteogenic/odontogenic gene markers including collagen I, osteocalcin, dentin matrix protein-1, bone sialoprotein, and alkaline phosphatase. Calcium 170-177 BCL2 apoptosis regulator Homo sapiens 30-34 26951885-7 2016 alpha-mangostin also increased the levels of Bax (pro-apoptotic), cleaved caspase-3, cleaved caspase-9 and cleaved-poly(ADP-ribose) polymerase (PARP), whereas the levels of the anti-apoptotic factors, Bcl-2 and c-myc, decreased in a dose-dependent manner. mangostin 0-15 BCL2 apoptosis regulator Homo sapiens 201-206 26616367-7 2016 Meanwhile, Carboxy-PTIO and BAPTA-AM treatment both attenuate JS-K-induced apoptosis through upregulation of Bcl-2, downregulation of Bax, reduction of Cyt c release from mitochondria to cytoplasm and inactivation of caspase-9/3. 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole 11-23 BCL2 apoptosis regulator Homo sapiens 109-114 26616367-7 2016 Meanwhile, Carboxy-PTIO and BAPTA-AM treatment both attenuate JS-K-induced apoptosis through upregulation of Bcl-2, downregulation of Bax, reduction of Cyt c release from mitochondria to cytoplasm and inactivation of caspase-9/3. 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester 28-36 BCL2 apoptosis regulator Homo sapiens 109-114 27400478-8 2016 Transmission electron microscopy confirmed apoptotic morphology upon treatment with 20 mumol/L oridonin and western blot revealed decreased expressions of the apoptosis suppressors survivin, Bcl-2 and pro-caspase-3 proteins, and the increased expression of the apoptosis inducer Bax. oridonin 95-103 BCL2 apoptosis regulator Homo sapiens 191-196 26785286-10 2016 CONCLUSION: These data reveal that 5-FU-induced cellular apoptosis in corneal epithelial cells may be mediated through caspase-8, caspase-9, and mitochondria-regulated pathways, as well as by upregulation of p21 and downregulation of Bcl-2-dependent signal transduction pathways. Fluorouracil 35-39 BCL2 apoptosis regulator Homo sapiens 234-239 27150997-11 2016 RT-PCR results showed that treatment of HL-60 cells with magnolol up-regulated the expression of BAX, whereas down-regulated the expression of BCL-2. magnolol 57-65 BCL2 apoptosis regulator Homo sapiens 143-148 26973118-5 2016 In addition, Abeta decreases hNSC messenger RNA (mRNA) levels of 2 neuroprotective factors (Bcl-2 and CREB), but co-treatment with rosiglitazone significantly rescues these effects. Rosiglitazone 131-144 BCL2 apoptosis regulator Homo sapiens 92-97 26547583-12 2016 Caspase-dependent apoptosis induced by SZC014 was confirmed to be associated with upregulation of Bax and downregulation of Bcl-2 and Bcl-xL, while upregulation of Beclin 1 and ATG 5 was inferred to be involved in SZC014-induced autophagy. 2-(pyrrolidine-1-yl)methyl-3-oxoolean-12-en-28-oic acid 39-45 BCL2 apoptosis regulator Homo sapiens 124-129 27073518-5 2016 Furthermore, western blot analysis indicated that NDP decreased the protein expression of P-glycoprotein, tumor protein p53 and B-cell lymphoma 2, and increased the expression of Bcl-2-associated X protein, all of which could possibly improve the NDP intracellular drug concentration and promote cell apoptosis. nedaplatin 50-53 BCL2 apoptosis regulator Homo sapiens 179-184 27073518-5 2016 Furthermore, western blot analysis indicated that NDP decreased the protein expression of P-glycoprotein, tumor protein p53 and B-cell lymphoma 2, and increased the expression of Bcl-2-associated X protein, all of which could possibly improve the NDP intracellular drug concentration and promote cell apoptosis. nedaplatin 247-250 BCL2 apoptosis regulator Homo sapiens 179-184 27073552-6 2016 Through upregulation in the expression of p53 and Bax, and downregulation in the expression of Bcl-2 and activation of caspase-3, costunolide-induced apoptosis was confirmed by western blot analysis. costunolide 130-141 BCL2 apoptosis regulator Homo sapiens 95-100 26787261-4 2016 Consistently, arjunic acid cleaved poly (ADP-ribose) polymerase (PARP), activated Bax, and phosphorylation of c-Jun N-terminal kinases (JNK), and also attenuated the expression of pro-caspase-3 and Bcl-2 in A549 and H460 cells. arjunic acid 14-26 BCL2 apoptosis regulator Homo sapiens 198-203 27150997-13 2016 CONCLUSION: The magnolol can significantly inhibit the proliferation of HL-60 cells and induce the apoptosis of HL-60 cells, which may occur through up-regulation of BAX, down-regulation of BCL-2 and the activation of caspases. magnolol 16-24 BCL2 apoptosis regulator Homo sapiens 190-195 27028622-10 2016 Nicotine increased the Bax/Bcl-2 ratio, which was attenuated by N-acetyl-L-cysteine, the NF-kappaB inhibitor, Bay 11-7082, and hexamethonium, a non-specific nAChR blocker. Nicotine 0-8 BCL2 apoptosis regulator Homo sapiens 27-32 27030982-8 2016 Conversely, all tested cell types appeared to be highly resistant to the Bcl-2 specific inhibitor, ABT-199. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 99-102 BCL2 apoptosis regulator Homo sapiens 73-78 27028622-10 2016 Nicotine increased the Bax/Bcl-2 ratio, which was attenuated by N-acetyl-L-cysteine, the NF-kappaB inhibitor, Bay 11-7082, and hexamethonium, a non-specific nAChR blocker. Acetylcysteine 64-83 BCL2 apoptosis regulator Homo sapiens 27-32 27028622-10 2016 Nicotine increased the Bax/Bcl-2 ratio, which was attenuated by N-acetyl-L-cysteine, the NF-kappaB inhibitor, Bay 11-7082, and hexamethonium, a non-specific nAChR blocker. 3-(4-methylphenylsulfonyl)-2-propenenitrile 110-121 BCL2 apoptosis regulator Homo sapiens 27-32 27028622-10 2016 Nicotine increased the Bax/Bcl-2 ratio, which was attenuated by N-acetyl-L-cysteine, the NF-kappaB inhibitor, Bay 11-7082, and hexamethonium, a non-specific nAChR blocker. Hexamethonium 127-140 BCL2 apoptosis regulator Homo sapiens 27-32 27019365-8 2016 Further investigation into the depletion of mitochondrial membrane potential and release of cytochrome c revealed that artonin E treatment induced apoptosis via regulation of the expression of pro-survival and pro-apoptotic Bcl-2 family members. artonin E 119-128 BCL2 apoptosis regulator Homo sapiens 224-229 26910119-1 2016 BH3 mimetic compounds induce tumor cell death through targeted inhibition of anti-apoptotic BCL2 proteins. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 92-96 26910119-7 2016 Our data uncover a novel level at which the BCL2 family is regulated; furthermore, they suggest targeting MARCH5-dependent signaling will be an effective strategy for treatment of BH3 mimetic-resistant tumors, even in the presence of high MCL1. BH 3 180-183 BCL2 apoptosis regulator Homo sapiens 44-48 26842479-10 2016 Antagonizing BCL-2 with venetoclax derepresses this antagonism, resulting in death, preferentially in HIV DNA containing cells, since only these cells generate Casp8p41. venetoclax 24-34 BCL2 apoptosis regulator Homo sapiens 13-18 27012679-8 2016 Treatment of these SP-derived spheres with honokiol resulted in apoptosis induction via Bax/Bcl-2 and caspase-3-dependent pathway. sp 19-21 BCL2 apoptosis regulator Homo sapiens 92-97 27012679-8 2016 Treatment of these SP-derived spheres with honokiol resulted in apoptosis induction via Bax/Bcl-2 and caspase-3-dependent pathway. honokiol 43-51 BCL2 apoptosis regulator Homo sapiens 92-97 27050990-3 2016 Resveratrol exposure also induced an increase in Caspase-3 activity and a decrease in Bcl-2, which caused an increase in membrane permeability, and the opening of mitochondrial permeability transition pores and mitochondrial depolarization. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 86-91 26982588-6 2016 The expression rate of the anti-apoptotic genes (bcl-2 and bcl-xL), and the pro-apoptotic genes (bax and bak) were quantified, and it was found that the expression rate of bcl-2 and bcl-xL genes significantly were decreased when MCF-7 cells were incubated by sulforaphane-loaded nanoparticles. sulforaphane 259-271 BCL2 apoptosis regulator Homo sapiens 172-177 26969381-13 2016 SiRNA to Tribbles-2 affected the protein levels of Bcl-2, Bax and MAPKs, suggesting that dioscin decreased Tribbles-2 level leading to cell apoptosis. dioscin 89-96 BCL2 apoptosis regulator Homo sapiens 51-56 26954718-2 2016 The balance between the different BCL-2 family members forms the basis of BH3 profiling, a peptide-based technique used to predict chemosensitivity of cancer cells. BH 3 74-77 BCL2 apoptosis regulator Homo sapiens 34-39 26759243-5 2016 We further reveal that the expression signatures of the apoptotic genes BCL2, BCL2L1, and BAD significantly predict response to BETi. beti 128-132 BCL2 apoptosis regulator Homo sapiens 72-76 26972597-6 2016 In addition, FADD negatively regulates cellular inhibitor of apoptosis protein 2 (cIAP2) and Bcl-2. fadd 13-17 BCL2 apoptosis regulator Homo sapiens 93-98 26974552-0 2016 Correction: Curcumin Significantly Enhances Dual PI3K/Akt and mTOR Inhibitor NVP-BEZ235-Induced Apoptosis in Human Renal Carcinoma Caki Cells through Down-Regulation of p53-Dependent Bcl-2 Expression and Inhibition of Mcl-1 Protein Stability. Curcumin 12-20 BCL2 apoptosis regulator Homo sapiens 183-188 26978376-4 2016 It was found that astaxanthin protected cells from apoptosis by ameliorating the effect of acetaldehyde on the expression of Bcl-2 family proteins, preventing the reduction of anti-apoptotic protein Bcl-2 and the increase of pro-apoptotic protein Bak induced by acetaldehyde. astaxanthine 18-29 BCL2 apoptosis regulator Homo sapiens 125-130 26978376-4 2016 It was found that astaxanthin protected cells from apoptosis by ameliorating the effect of acetaldehyde on the expression of Bcl-2 family proteins, preventing the reduction of anti-apoptotic protein Bcl-2 and the increase of pro-apoptotic protein Bak induced by acetaldehyde. astaxanthine 18-29 BCL2 apoptosis regulator Homo sapiens 199-204 26978376-4 2016 It was found that astaxanthin protected cells from apoptosis by ameliorating the effect of acetaldehyde on the expression of Bcl-2 family proteins, preventing the reduction of anti-apoptotic protein Bcl-2 and the increase of pro-apoptotic protein Bak induced by acetaldehyde. Acetaldehyde 91-103 BCL2 apoptosis regulator Homo sapiens 125-130 26849940-6 2016 Furthermore, U0126, an ERK1/2 inhibitor, markedly down-regulated Bcl-2 level, up-regulated the levels of Bax, cleaved caspase-3/9, and enhanced Cytochrome c release inducted by dioscin. U 0126 13-18 BCL2 apoptosis regulator Homo sapiens 65-70 27022281-10 2016 In addition, we found that prenylamine not only affected several classic apoptosis-related proteins, including Bax, Bcl-2, and cytochrome c, but also increased caspase-3 activity. Prenylamine 27-38 BCL2 apoptosis regulator Homo sapiens 116-121 26967820-0 2016 Loss in MCL-1 function sensitizes non-Hodgkin"s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). venetoclax 101-111 BCL2 apoptosis regulator Homo sapiens 75-80 26967820-0 2016 Loss in MCL-1 function sensitizes non-Hodgkin"s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 113-116 BCL2 apoptosis regulator Homo sapiens 75-80 26950068-1 2016 Obatoclax belongs to a class of compounds known as BH3 mimetics which function as antagonists of Bcl-2 family apoptosis regulators. BH 3 51-54 BCL2 apoptosis regulator Homo sapiens 97-102 26849940-5 2016 In addition, dioscin significantly down-regulated the levels of p-ERK, Bcl-2, up-regulated the levels of p-JNK, p-p38, Bax, cleaved caspase-3/-9, and caused Cytochrome c release. dioscin 13-20 BCL2 apoptosis regulator Homo sapiens 71-76 26800624-11 2016 The TPP-BLM treatment synergistically induced apoptosis through caspase-3, caspase-8 and caspase-9 activation, Bcl-2 upregulation and p53 overexpression. tpp-blm 4-11 BCL2 apoptosis regulator Homo sapiens 111-116 26849940-7 2016 While, SP600125 (one JNK inhibitor) and SB203580 (one p38 inhibitor) markedly up-regulated Bcl-2 level, down-regulated the levels of Bax, cleaved caspase-3/9, and obviously boosted Cytochrome c release induced by dioscin. pyrazolanthrone 7-15 BCL2 apoptosis regulator Homo sapiens 91-96 26849940-7 2016 While, SP600125 (one JNK inhibitor) and SB203580 (one p38 inhibitor) markedly up-regulated Bcl-2 level, down-regulated the levels of Bax, cleaved caspase-3/9, and obviously boosted Cytochrome c release induced by dioscin. SB 203580 40-48 BCL2 apoptosis regulator Homo sapiens 91-96 26872218-6 2016 2alpha-Hydroxyursolic acid induced apoptosis in MDA-MB-231 cells by significantly increasing the Bax/Bcl-2 ratio and inducing the cleaved caspase-3. 2-hydroxyursolic acid 0-26 BCL2 apoptosis regulator Homo sapiens 101-106 26872218-7 2016 Additionally, treatment of SB203580, a p38 MAPK specific inhibitor, reversed the inhibition of PCNA, cyclin D1, and Bcl-2 expression induced by 2alpha-hydroxyursolic acid in MDA-MB-231 cells. SB 203580 27-35 BCL2 apoptosis regulator Homo sapiens 116-121 26872218-7 2016 Additionally, treatment of SB203580, a p38 MAPK specific inhibitor, reversed the inhibition of PCNA, cyclin D1, and Bcl-2 expression induced by 2alpha-hydroxyursolic acid in MDA-MB-231 cells. 2-hydroxyursolic acid 144-170 BCL2 apoptosis regulator Homo sapiens 116-121 25630439-2 2016 AIM: This article aims to investigate the effect of poly(ethylene oxide)-poly(propylene oxide) (PEO-PPO) block copolymers with a wide range of biomedical and pharmaceutical applications on apoptosis and/or cell immortalization, by flow cytometry and multiplex RT-PCR for bax, bcl-2, and human telomerase reverse transcriptase (hTERT). Polyethylene Glycols 52-72 BCL2 apoptosis regulator Homo sapiens 276-281 26883800-5 2016 Kaempferol was found to decrease the expression of Bcl-2 and increase the expressions of Bax, Fas, cleaved-caspase 3, cleaved-caspase 8, cleaved-caspase 9, and cleaved-PARP. kaempferol 0-10 BCL2 apoptosis regulator Homo sapiens 51-56 26946947-3 2016 Reduced graphene oxide (RGO) layers were used as substrate to immobilize Bcl-2 and Bax antibodies for further capturing target antigens. graphene oxide 8-22 BCL2 apoptosis regulator Homo sapiens 73-78 26946947-4 2016 CdSeTe@CdS quantum dots (QDs) and Ag nanoclusters (NCs) with antibody modification and mesoporous silica amplification were used as signal probes, which were proportional to the amount of Bcl-2 and Bax antigens. cdsete 0-6 BCL2 apoptosis regulator Homo sapiens 188-193 26946947-4 2016 CdSeTe@CdS quantum dots (QDs) and Ag nanoclusters (NCs) with antibody modification and mesoporous silica amplification were used as signal probes, which were proportional to the amount of Bcl-2 and Bax antigens. Cadmium 0-3 BCL2 apoptosis regulator Homo sapiens 188-193 26946947-6 2016 The Bcl-2 and Bax proteins were determined indirectly by the detection of oxidation peak currents of Cd and Ag using anodic stripping voltammetry, showing a good linear relationship in the protein concentration range from 1 ng/mL to 250 ng/mL. Cadmium 101-103 BCL2 apoptosis regulator Homo sapiens 4-9 26946947-8 2016 The biosensor was further introduced to investigate Bcl-2 and Bax expressions from nilotinib-treated chronic myeloid leukemia K562 cells. nilotinib 83-92 BCL2 apoptosis regulator Homo sapiens 52-57 25630439-2 2016 AIM: This article aims to investigate the effect of poly(ethylene oxide)-poly(propylene oxide) (PEO-PPO) block copolymers with a wide range of biomedical and pharmaceutical applications on apoptosis and/or cell immortalization, by flow cytometry and multiplex RT-PCR for bax, bcl-2, and human telomerase reverse transcriptase (hTERT). polypropylene glycol 73-94 BCL2 apoptosis regulator Homo sapiens 276-281 25630439-2 2016 AIM: This article aims to investigate the effect of poly(ethylene oxide)-poly(propylene oxide) (PEO-PPO) block copolymers with a wide range of biomedical and pharmaceutical applications on apoptosis and/or cell immortalization, by flow cytometry and multiplex RT-PCR for bax, bcl-2, and human telomerase reverse transcriptase (hTERT). copolymers 111-121 BCL2 apoptosis regulator Homo sapiens 276-281 26467384-3 2016 Pharmacologic targeting of BCL2, MCL1, and BCL-XL with ABT-199, homoharringtonine (HHT), and ABT-737. Homoharringtonine 64-81 BCL2 apoptosis regulator Homo sapiens 27-31 26902083-5 2016 Under chaetominine treatment, the Bax/Bcl-2 ratio was upregulated (from 0.3 to 8), which was followed by a decrease in mitochondrial membrane potential, release of cytochrome c from mitochondria into the cytosol, and stimulation of Apaf-1. chaetominine 6-18 BCL2 apoptosis regulator Homo sapiens 38-43 26427013-4 2016 All the three copper complexes can effectively induce apoptosis of the three human tumor cells, which was accompanied with upregulation of the expression of p53 and Bax, while Bcl-2 decreased. Copper 14-20 BCL2 apoptosis regulator Homo sapiens 176-181 26467384-3 2016 Pharmacologic targeting of BCL2, MCL1, and BCL-XL with ABT-199, homoharringtonine (HHT), and ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 93-96 BCL2 apoptosis regulator Homo sapiens 27-31 26459180-2 2016 We aim to improve ATRA therapy of AML by enhancing apoptosis through repression of the antiapoptotic proteins Bcl-2 and Mcl-1. Tretinoin 18-22 BCL2 apoptosis regulator Homo sapiens 110-115 26467384-9 2016 We demonstrated that concurrent inhibition of BCL2 and MCL1 with ABT-199 and HHT induced significant synthetic lethality in most BCL2-expressing DLBCL cell lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 65-68 BCL2 apoptosis regulator Homo sapiens 46-50 26459180-5 2016 RESULTS: In differentiation-responsive AML cells, ATRA treatment induces long-lasting repression of Bcl-2 while first upmodulating and then reducing the Mcl-1 level. Tretinoin 50-54 BCL2 apoptosis regulator Homo sapiens 100-105 26459180-8 2016 Sorafenib blocks ATRA-induced Mcl-1 increase by reversing p90RSK activation and GSK3beta inactivation, maintains the repressed Bcl-2 level, and enhances ATRA induced apoptosis in non-APL AML cell lines and in primary AML cells. Sorafenib 0-9 BCL2 apoptosis regulator Homo sapiens 127-132 26459180-8 2016 Sorafenib blocks ATRA-induced Mcl-1 increase by reversing p90RSK activation and GSK3beta inactivation, maintains the repressed Bcl-2 level, and enhances ATRA induced apoptosis in non-APL AML cell lines and in primary AML cells. Tretinoin 17-21 BCL2 apoptosis regulator Homo sapiens 127-132 26459180-10 2016 ATRA and sorafenib can be developed as a novel drug combination therapy for AML patients because this drug combination augments apoptosis by inhibiting Bcl-2 and Mcl-1. Tretinoin 0-4 BCL2 apoptosis regulator Homo sapiens 152-157 26459180-10 2016 ATRA and sorafenib can be developed as a novel drug combination therapy for AML patients because this drug combination augments apoptosis by inhibiting Bcl-2 and Mcl-1. Sorafenib 9-18 BCL2 apoptosis regulator Homo sapiens 152-157 26467384-9 2016 We demonstrated that concurrent inhibition of BCL2 and MCL1 with ABT-199 and HHT induced significant synthetic lethality in most BCL2-expressing DLBCL cell lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 65-68 BCL2 apoptosis regulator Homo sapiens 129-133 26467384-0 2016 Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 39-42 BCL2 apoptosis regulator Homo sapiens 13-17 26467384-0 2016 Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 39-42 BCL2 apoptosis regulator Homo sapiens 77-81 26809061-2 2016 Nickel(II) elicited apoptosis, as signified by pyknotic and fragmented nuclei, increased caspase-3/7 activity, and an increase in annexin V binding, hypodiploid DNA, and Bax/Bcl-2 protein ratio. Nickel(2+) 0-10 BCL2 apoptosis regulator Homo sapiens 174-179 26467384-0 2016 Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. Homoharringtonine 51-68 BCL2 apoptosis regulator Homo sapiens 13-17 26467384-3 2016 Pharmacologic targeting of BCL2, MCL1, and BCL-XL with ABT-199, homoharringtonine (HHT), and ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 55-58 BCL2 apoptosis regulator Homo sapiens 27-31 26479129-5 2016 RESULTS: Carvedilol decreased the protein levels of p53, Bax and cytochrome c and increased that of Bcl-2 in HL-1 cells expressing E334K MyBPC. Carvedilol 9-19 BCL2 apoptosis regulator Homo sapiens 100-105 26809061-6 2016 p53 reporter gene assay and analyses of p53, Puma, Bax, and Bcl-2 protein levels indicated that NAC inhibited nickel(II)-induced activation of p53-mediated mitochondrial apoptotic pathway. Acetylcysteine 96-99 BCL2 apoptosis regulator Homo sapiens 60-65 26809061-6 2016 p53 reporter gene assay and analyses of p53, Puma, Bax, and Bcl-2 protein levels indicated that NAC inhibited nickel(II)-induced activation of p53-mediated mitochondrial apoptotic pathway. Nickel 110-116 BCL2 apoptosis regulator Homo sapiens 60-65 26424560-0 2016 MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. diprotin A 57-60 BCL2 apoptosis regulator Homo sapiens 8-13 26973650-3 2016 Targeted pharmacological modulation of this pathway with a small molecule Bcl-2/Bcl-xL inhibitor (ABT-737) caused a selective depletion of effector T cells and a relative enrichment of Tregs in vivo. ABT-737 98-105 BCL2 apoptosis regulator Homo sapiens 74-79 26998041-6 2016 TSA also decreased the expression levels of VEGF, c-Myc, COX-2 and Bcl-2. tanshinone 0-3 BCL2 apoptosis regulator Homo sapiens 67-72 26424560-7 2016 Compared with the IPI, the MYC and BCL-2 adjusted-IPI (A-IPI) better discriminated patients in the high-risk subgroup (4-year overall survival [OS]: 33.3%) than did the IPI (4 year OS: 48.0%). diprotin A 50-53 BCL2 apoptosis regulator Homo sapiens 35-40 26424560-7 2016 Compared with the IPI, the MYC and BCL-2 adjusted-IPI (A-IPI) better discriminated patients in the high-risk subgroup (4-year overall survival [OS]: 33.3%) than did the IPI (4 year OS: 48.0%). diprotin A 50-53 BCL2 apoptosis regulator Homo sapiens 35-40 26424560-7 2016 Compared with the IPI, the MYC and BCL-2 adjusted-IPI (A-IPI) better discriminated patients in the high-risk subgroup (4-year overall survival [OS]: 33.3%) than did the IPI (4 year OS: 48.0%). diprotin A 50-53 BCL2 apoptosis regulator Homo sapiens 35-40 26424560-8 2016 In the era of R-CHOP treatment, MYC and BCL-2 adjusted-IPI is more powerful than the IPI for helping guide treatment planning and interpretation of clinical trials. diprotin A 55-58 BCL2 apoptosis regulator Homo sapiens 40-45 26988436-10 2016 Further, increases in p53 expression, Bax expression, cytochrome c release, along with reduction of Bcl-2 level and caspase-3 activation were observed after Psorinum 6x treatment, which eventually drove A549 cells towards the mitochondria-mediated caspase-3-dependent pathway. psorinum 6x 157-168 BCL2 apoptosis regulator Homo sapiens 100-105 26247921-8 2016 Furthermore, the binding of p65 and cAMP response element binding protein (CREB) binding protein (CBP) or p300 decreased and NF-kappaB related genes which were inhibitors of NF-kappaB alpha (IkappaBalpha), A20, B cell lymphoma protein 2 (Bcl-2), and monocyte chemoattractant protein-1 (MCP-1) were low in cells transfected with Sec6 siRNAs in response to TNF-alpha stimulation. Cyclic AMP 36-40 BCL2 apoptosis regulator Homo sapiens 211-236 26247921-8 2016 Furthermore, the binding of p65 and cAMP response element binding protein (CREB) binding protein (CBP) or p300 decreased and NF-kappaB related genes which were inhibitors of NF-kappaB alpha (IkappaBalpha), A20, B cell lymphoma protein 2 (Bcl-2), and monocyte chemoattractant protein-1 (MCP-1) were low in cells transfected with Sec6 siRNAs in response to TNF-alpha stimulation. Cyclic AMP 36-40 BCL2 apoptosis regulator Homo sapiens 238-243 26988436-12 2016 CONCLUSION: Psorinum 6x triggered apoptosis in A549 cells via both up- and down-regulations of relevant signal proteins, including p53, caspase-3, Bax and Bcl-2. psorinum 6x 12-23 BCL2 apoptosis regulator Homo sapiens 155-160 26174630-0 2016 BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 53-58 26781500-8 2016 Furthermore, flow cytometric analysis demonstrated that REG can induce the apoptosis of HL-60 cells, as well as increase the levels of cytochrome c, c-caspases-3 and -9, and Bax, as well as downregulate the expression of Bcl-2. resveratrol-4-O-(2'-galloyl)glucopyranoside 56-59 BCL2 apoptosis regulator Homo sapiens 221-226 26883975-4 2016 KEY FINDINGS: Our results demonstrate that the nanoparticulate formulation of dimercaptosuccinic acid (DMSA) and chitosan coated As2O3 is capable of inducing morphological changes, DNA damage and caspase-dependent apoptosis along with the expression of cyclin-dependent kinase inhibitor p21 by upregulation of Bax and downregulation of Bcl-2 and Bcl-xL proteins. Succimer 78-101 BCL2 apoptosis regulator Homo sapiens 336-341 26883975-4 2016 KEY FINDINGS: Our results demonstrate that the nanoparticulate formulation of dimercaptosuccinic acid (DMSA) and chitosan coated As2O3 is capable of inducing morphological changes, DNA damage and caspase-dependent apoptosis along with the expression of cyclin-dependent kinase inhibitor p21 by upregulation of Bax and downregulation of Bcl-2 and Bcl-xL proteins. Succimer 103-107 BCL2 apoptosis regulator Homo sapiens 336-341 26883975-4 2016 KEY FINDINGS: Our results demonstrate that the nanoparticulate formulation of dimercaptosuccinic acid (DMSA) and chitosan coated As2O3 is capable of inducing morphological changes, DNA damage and caspase-dependent apoptosis along with the expression of cyclin-dependent kinase inhibitor p21 by upregulation of Bax and downregulation of Bcl-2 and Bcl-xL proteins. Chitosan 113-121 BCL2 apoptosis regulator Homo sapiens 336-341 26883975-4 2016 KEY FINDINGS: Our results demonstrate that the nanoparticulate formulation of dimercaptosuccinic acid (DMSA) and chitosan coated As2O3 is capable of inducing morphological changes, DNA damage and caspase-dependent apoptosis along with the expression of cyclin-dependent kinase inhibitor p21 by upregulation of Bax and downregulation of Bcl-2 and Bcl-xL proteins. Arsenic Trioxide 129-134 BCL2 apoptosis regulator Homo sapiens 336-341 26821367-15 2016 Expression of Bcl-2, survivin and p53 were reduced in LoVo cells co-cultured with TAMs, compared with the control group (P<0.05), whereas Smac expression was increased in the co-culture groups (P<0.01). tams 82-86 BCL2 apoptosis regulator Homo sapiens 14-19 25663261-10 2016 After treatment with formononetin, ERalpha, miR-375, p-Akt, and Bcl-2 expression was significantly upregulated. formononetin 21-33 BCL2 apoptosis regulator Homo sapiens 64-69 26820261-4 2016 The rates of cell proliferation and apoptosis, the cell cycle profiles and the mRNA expression of B-cell lymphoma 2 (Bcl-2) were detected using cell counting kit-8, multicaspase assays, propidium iodide staining and reverse transcription-quantitative polymerase chain reaction, respectively. Propidium 186-202 BCL2 apoptosis regulator Homo sapiens 117-122 26781771-6 2016 Treatment with curcumin (5 or 20 micromol/l) significantly inhibited apoptosis, and reversed the alterations in caspase-3, Bcl-2 and Bax expression. Curcumin 15-23 BCL2 apoptosis regulator Homo sapiens 123-128 26847687-6 2016 These results indicated that JZL184 may induce tumor cell apoptosis by regulating the expression of Bcl-2 and Bax. JZL 184 29-35 BCL2 apoptosis regulator Homo sapiens 100-105 26846193-10 2016 The present results demonstrated that PSs induced radiosensitivity in gefitinib-resistant cells by inducing G2/M phase arrest and by enhancing the apoptotic response via the modulation of caspase-3, Bax, Bcl-2 and p21/Waf1/Cip1 expression. pss 38-41 BCL2 apoptosis regulator Homo sapiens 204-209 26846193-10 2016 The present results demonstrated that PSs induced radiosensitivity in gefitinib-resistant cells by inducing G2/M phase arrest and by enhancing the apoptotic response via the modulation of caspase-3, Bax, Bcl-2 and p21/Waf1/Cip1 expression. Gefitinib 70-79 BCL2 apoptosis regulator Homo sapiens 204-209 26833196-0 2016 Anti-leukemic, anti-lung, and anti-breast cancer potential of the microbial polyketide 2, 4-diacetylphloroglucinol (DAPG) and its interaction with the metastatic proteins than the antiapoptotic Bcl-2 proteins. dapg 116-120 BCL2 apoptosis regulator Homo sapiens 194-199 26833196-6 2016 Similarly, DAPG inhibited the Bcl-2, Bcl-xL and Bcl-w activities with the high IC50 concentration of 29.8 +- 1.9, 85.9 +- 2.7, and 97.4 +- 1.5 muM, respectively. dapg 11-15 BCL2 apoptosis regulator Homo sapiens 30-35 26708213-7 2016 Furthermore, 3-BrPA and SCT upregulated the expression of pro-apoptotic proteins (Bax, cytochrome c, and cleaved caspase-3) and downregulated the expression of anti-apoptotic proteins (Bcl-2 and survivin). bromopyruvate 13-19 BCL2 apoptosis regulator Homo sapiens 185-190 26848042-6 2016 The results showed that poly (I:C) transfection markedly induced HeLa apoptosis, increased the protein levels of pro-apoptotic B cell lymphoma-2 (Bcl-2)-associated X protein (Bax) and BH3 interacting-domain death agonist (Bid), and suppressed the protein expression levels of anti-apoptotic Bcl-2 and Survivin. Poly I-C 24-34 BCL2 apoptosis regulator Homo sapiens 146-151 26848042-6 2016 The results showed that poly (I:C) transfection markedly induced HeLa apoptosis, increased the protein levels of pro-apoptotic B cell lymphoma-2 (Bcl-2)-associated X protein (Bax) and BH3 interacting-domain death agonist (Bid), and suppressed the protein expression levels of anti-apoptotic Bcl-2 and Survivin. Poly I-C 24-34 BCL2 apoptosis regulator Homo sapiens 291-296 25502462-5 2016 Furthermore, UDCA amended alterations in Bax and Bcl-2 and reduced the activities of caspase-8, caspase-9, and caspase-3, indicating that it suppressed rotenone-induced apoptosis via modulating both intrinsic and extrinsic pathways. Ursodeoxycholic Acid 13-17 BCL2 apoptosis regulator Homo sapiens 49-54 26718494-7 2016 The results showed that both BNMPH and its copper complex induced reactive oxygen species (ROS) generation, and caused upregulation of caspase 8 and Bax as well as the downregulation of Bcl-2, indicating that apoptosis was involved in the cytotoxic effects. bnmph 29-34 BCL2 apoptosis regulator Homo sapiens 186-191 26707712-10 2016 Furthermore, the activation of caspase-3 and -9, upregulation of Bax and downregulation of Bcl-2 demonstrated the occurrence of apoptosis by darbufelone. darbufelone 141-152 BCL2 apoptosis regulator Homo sapiens 91-96 26998069-9 2016 Increased Bcl-2 expression may explain why PAB did not affect the mitochondrial membrane potential. pseudolaric acid B 43-46 BCL2 apoptosis regulator Homo sapiens 10-15 26998069-10 2016 A Bcl-2 binding test demonstrated that PAB treatment inhibits the binding of Bcl-2 and Beclin-1, which may free Beclin-1 to participate in autophagy. pseudolaric acid B 39-42 BCL2 apoptosis regulator Homo sapiens 2-7 26718494-7 2016 The results showed that both BNMPH and its copper complex induced reactive oxygen species (ROS) generation, and caused upregulation of caspase 8 and Bax as well as the downregulation of Bcl-2, indicating that apoptosis was involved in the cytotoxic effects. Copper 43-49 BCL2 apoptosis regulator Homo sapiens 186-191 26998069-10 2016 A Bcl-2 binding test demonstrated that PAB treatment inhibits the binding of Bcl-2 and Beclin-1, which may free Beclin-1 to participate in autophagy. pseudolaric acid B 39-42 BCL2 apoptosis regulator Homo sapiens 77-82 26848703-14 2016 In conclusion, thymoquinone increased the effectiveness of the chemotherapeutic reagent topotecan by inhibiting proliferation and lowering toxicity through p53- and Bax/Bcl2-independent mechanisms. thymoquinone 15-27 BCL2 apoptosis regulator Homo sapiens 169-173 26676298-9 2016 Moreover, the inhibition of autophagy by 3-methyladenine or Atg5 siRNA significantly enhanced ramalin-induced apoptosis, which was accompanied by a decrease in Bcl-2 levels and an increase in Bax levels. 3-methyladenine 41-56 BCL2 apoptosis regulator Homo sapiens 160-165 26676298-9 2016 Moreover, the inhibition of autophagy by 3-methyladenine or Atg5 siRNA significantly enhanced ramalin-induced apoptosis, which was accompanied by a decrease in Bcl-2 levels and an increase in Bax levels. Ramalin 94-101 BCL2 apoptosis regulator Homo sapiens 160-165 27183711-0 2016 Oxymatrine mediates Bax and Bcl-2 expression in human breast cancer MCF-7 cells. oxymatrine 0-10 BCL2 apoptosis regulator Homo sapiens 28-33 27183711-4 2016 Real-time PCR was performed for the mRNA abundance of Bax and Bcl-2 after the cells were treated with oxymatrine at concentration of 0, 25, 50, and 100 microg/mL at the time points of 24, 48, and 72 h. Western blotting was performed when the cells were treated with oxymatrine at various concentrations for 72h. oxymatrine 102-112 BCL2 apoptosis regulator Homo sapiens 62-67 27183711-6 2016 Oxymatrine at 100 microg/mL up regulated Bax mRNA abundance by 169 % at 72 h (t = 18.32, p = 0.001), and reduced Bcl-2 mRNA abundance by 24 % at 72 h (t = 6.30, p = 0.001) compared with control. oxymatrine 0-10 BCL2 apoptosis regulator Homo sapiens 113-118 27183711-7 2016 Oxymatrine enhanced the expression of Bax protein while reduced the expression of Bcl-2 protein. oxymatrine 0-10 BCL2 apoptosis regulator Homo sapiens 82-87 27183711-8 2016 Oxymatrine treatment showed pro-apoptotic effects in breast cancer MCF-7 cells, and these effects correlated with the up regulation of Bax transcription and protein expression and the down regulation of Bcl-2 transcription and protein expression in a time- and dose-dependent manner. oxymatrine 0-10 BCL2 apoptosis regulator Homo sapiens 203-208 27183711-9 2016 CONCLUSION: Oxymatrine had effects in promoting apoptosis in human breast cancer MCF-7 cells by mediating the mRNA and protein expression levels of Bax and Bcl-2. oxymatrine 12-22 BCL2 apoptosis regulator Homo sapiens 156-161 26848703-14 2016 In conclusion, thymoquinone increased the effectiveness of the chemotherapeutic reagent topotecan by inhibiting proliferation and lowering toxicity through p53- and Bax/Bcl2-independent mechanisms. Topotecan 88-97 BCL2 apoptosis regulator Homo sapiens 169-173 26482622-9 2016 Patients with high Bcl-2-expressing tumors treated with cisplatin-based chemotherapy showed unfavorable predictive values in a subset of this study population. Cisplatin 56-65 BCL2 apoptosis regulator Homo sapiens 19-24 26357974-9 2016 Western blot analysis demonstrated that GA-induced cell cycle arrest and apoptosis in CNE-2 cells was associated with upregulated expression of caspase-3 and Bax and downregulated expression of Bcl-2 and cyclin B1/p-cdc2 in hypoxia. gambogic acid 40-42 BCL2 apoptosis regulator Homo sapiens 194-199 26427661-0 2016 Synthetic Tet-inducible small hairpin RNAs targeting hTERT or Bcl-2 inhibit malignant phenotypes of bladder cancer T24 and 5637 cells. Tetracycline 10-13 BCL2 apoptosis regulator Homo sapiens 62-67 26482622-10 2016 Therefore, we suggest that cytoplasmic p27 (N-/C+) via ERK-activated Bcl-2 expression may predict an unfavorable response to cisplatin-based chemotherapy and poor outcomes in NSCLC. Cisplatin 125-134 BCL2 apoptosis regulator Homo sapiens 69-74 26597031-9 2016 In conclusion, our study demonstrates for the first time that MEHP induces miR-16, which in turn, alters BCL-2/BAX ratio leading to increased apoptosis. mono-(2-ethylhexyl)phthalate 62-66 BCL2 apoptosis regulator Homo sapiens 105-110 26490978-12 2016 Gemcitabine treatment upregulated the levels of anti-apoptosis proteins (Mcl-2 and Bcl-2) in both scrambled control and maspin-KD cells; however, the fold changes in Mcl-1 and Bcl-2 expression were larger in gemcitabine-treated scrambled control cells than in maspin-KD cells. gemcitabine 0-11 BCL2 apoptosis regulator Homo sapiens 83-88 26490978-12 2016 Gemcitabine treatment upregulated the levels of anti-apoptosis proteins (Mcl-2 and Bcl-2) in both scrambled control and maspin-KD cells; however, the fold changes in Mcl-1 and Bcl-2 expression were larger in gemcitabine-treated scrambled control cells than in maspin-KD cells. gemcitabine 0-11 BCL2 apoptosis regulator Homo sapiens 176-181 26916669-0 2016 Low concentration of formononetin stimulates the proliferation of nasopharyngeal carcinoma cell line CNE2 by upregulating bcl-2 and p-ERK1/2 expression. formononetin 21-33 BCL2 apoptosis regulator Homo sapiens 122-127 26046302-7 2016 Prolonged mitotic arrest leads to phosphorylation-mediated inactivation of BCL-2 and BCL-XL as well as downregulation of MCL-1, since inhibition of mitotic arrest by RO-3306 also prevents phosphorylation of BCL-2 and BCL-XL and MCL-1 downregulation. RO 3306 166-173 BCL2 apoptosis regulator Homo sapiens 207-212 26907262-9 2016 These results suggest that apoptosis in HepG2 was induced through: (i) a caspase-dependent intrinsic pathway; and (ii) by alterations in the cellular levels of Bcl-2 family proteins, and also, that the chalcone moiety could be a potent candidate as novel anticancer agents acting on human hepatomas. Chalcone 202-210 BCL2 apoptosis regulator Homo sapiens 160-165 27076234-9 2016 ABT-199 is another novel drug; it inhibits BCL2 signaling, not the BCR pathway, and can be administered orally. venetoclax 0-7 BCL2 apoptosis regulator Homo sapiens 43-47 26909550-12 2016 This effect correlated with the induction of Bcl-2, Bax, Survivin and Caspase-3 by nicotine in gastric cell lines. Nicotine 83-91 BCL2 apoptosis regulator Homo sapiens 45-50 26758421-2 2016 Here, we show that Bufalin can inhibit cervical cancer cell proliferation, block cell cycle in G2/M phase, induce cellular apoptosis and reduce cell metastasis through stimulation of p21(waf/cip1), p27(cip/kip), Bax and E-cadherin, and suppression of cyclin A, cyclin B1, CDK2, Bcl-2, Bcl-xl, MMP9 and SNAIL1. bufalin 19-26 BCL2 apoptosis regulator Homo sapiens 278-283 26812885-8 2016 Nevertheless, inhibition of BCL2 alone either by MYB knockdown or by ABT-199 treatment was insufficient for significant induction of apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 69-72 BCL2 apoptosis regulator Homo sapiens 28-32 26843613-7 2016 Furthermore, physalin A abrogated the nuclear translocation and transcriptional activity of STAT3, thereby decreasing the expression levels of STAT3, its target genes, such as Bcl-2 and XIAP. physalin A 13-23 BCL2 apoptosis regulator Homo sapiens 176-181 26858413-6 2016 A BH3-like motif in HBx (residues 110-135) binds Bcl-2 with a dissociation constant of ~193 muM, which is drastically lower than that for a canonical BH3 motif from Bim or Bad. BH 3 2-5 BCL2 apoptosis regulator Homo sapiens 49-54 26858413-6 2016 A BH3-like motif in HBx (residues 110-135) binds Bcl-2 with a dissociation constant of ~193 muM, which is drastically lower than that for a canonical BH3 motif from Bim or Bad. BH 3 150-153 BCL2 apoptosis regulator Homo sapiens 49-54 26858413-7 2016 Structural analysis reveals that, similar to other BH3 motifs, the BH3-like motif of HBx adopts an amphipathic alpha-helix and binds the conserved BH3-binding groove on Bcl-2. BH 3 51-54 BCL2 apoptosis regulator Homo sapiens 169-174 26858413-7 2016 Structural analysis reveals that, similar to other BH3 motifs, the BH3-like motif of HBx adopts an amphipathic alpha-helix and binds the conserved BH3-binding groove on Bcl-2. BH 3 67-70 BCL2 apoptosis regulator Homo sapiens 169-174 26858413-7 2016 Structural analysis reveals that, similar to other BH3 motifs, the BH3-like motif of HBx adopts an amphipathic alpha-helix and binds the conserved BH3-binding groove on Bcl-2. BH 3 67-70 BCL2 apoptosis regulator Homo sapiens 169-174 26858413-8 2016 Unlike the helical Bim or Bad BH3 motif, the C-terminal portion of the bound HBx BH3-like motif has an extended conformation and makes considerably fewer interactions with Bcl-2. BH 3 81-84 BCL2 apoptosis regulator Homo sapiens 172-177 26916669-9 2016 The mRNA levels of bax and bcl-2 were down- and upregulated, respectively, by formononetin. formononetin 78-90 BCL2 apoptosis regulator Homo sapiens 27-32 26884599-8 2016 Overexpression of BCL-2 protected against ONC201-induced apoptosis, and the combination of ONC201 and the BCL-2 antagonist ABT-199 synergistically increased apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 123-126 BCL2 apoptosis regulator Homo sapiens 106-111 26826383-6 2016 Furthermore, inhibition of STAT3 signaling with Cryptotanshinone could down-regulate the expression of Bcl-2 and Survivin, thus weaken the post-target resistance to Cispaltin mediating by CAFs-CM in ovarian cancer cells. cryptotanshinone 48-64 BCL2 apoptosis regulator Homo sapiens 103-108 26826383-6 2016 Furthermore, inhibition of STAT3 signaling with Cryptotanshinone could down-regulate the expression of Bcl-2 and Survivin, thus weaken the post-target resistance to Cispaltin mediating by CAFs-CM in ovarian cancer cells. cispaltin 165-174 BCL2 apoptosis regulator Homo sapiens 103-108 26889092-15 2016 Solamargine disrupted the intrinsic apoptosis pathway as revealed by the down regulation of hILP/XIAP, resulting in caspase-3 cleavage, upregulation of Bcl-xL, and Bcl2, and down regulation of Apaf-1 and Bax in WM115 and WM239 cells only. beta-solamarine 0-11 BCL2 apoptosis regulator Homo sapiens 164-168 26890143-4 2016 Resveratrol-mediated miRNA modulation regulates key anti-apoptotic and cell cycle proteins including Bcl-2, X-linked inhibitor of apoptosis protein and CDKs, which are critical for its activity. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 101-106 27019266-6 2016 The retinoic acid differentiated SH-S cell line (10 muM) shows a clear apoptosis when treated with H2O2 150 muM, with a Bax/Bcl-2 ratio of 3.75 (SD 0.80) in contrast to the differentiated control cells subjected to H2O2 and with extract, which have the same ratio of 1.02 (SD 0.01-0.03). Tretinoin 4-17 BCL2 apoptosis regulator Homo sapiens 124-129 27019266-6 2016 The retinoic acid differentiated SH-S cell line (10 muM) shows a clear apoptosis when treated with H2O2 150 muM, with a Bax/Bcl-2 ratio of 3.75 (SD 0.80) in contrast to the differentiated control cells subjected to H2O2 and with extract, which have the same ratio of 1.02 (SD 0.01-0.03). Hydrogen Peroxide 99-103 BCL2 apoptosis regulator Homo sapiens 124-129 26874859-4 2016 Bcl-2 dependent xenografts derived from aggressive human NB tumors are cured with a combination of cyclophosphamide and ABT-737, a Bcl-2/Bcl-XL/Bcl-w small molecule antagonist. Cyclophosphamide 99-115 BCL2 apoptosis regulator Homo sapiens 0-5 27158338-6 2016 After transfection of the miR-125b mimic or miR-125b inhibitor into CML cells, we found that the inhibition of miR-125b decreased the proliferation rates and promoted apoptosis with cell cycle arrest at the G0/G1 phase in both K562 and NB-4 cells, increased the expression of BAK1 and Caspase-3, and decreased the expression of Bcl-2 and c-myc; the miR-125b mimic yielded the opposite results. mir-125b 26-34 BCL2 apoptosis regulator Homo sapiens 328-333 26607805-4 2016 Melatonin enhanced the ATO-induced apoptotic cell death via changes in the protein levels of Survivin, Bcl-2, and Bax, thus affecting cytochrome c release from the mitochondria to the cytosol. Melatonin 0-9 BCL2 apoptosis regulator Homo sapiens 103-108 26607805-4 2016 Melatonin enhanced the ATO-induced apoptotic cell death via changes in the protein levels of Survivin, Bcl-2, and Bax, thus affecting cytochrome c release from the mitochondria to the cytosol. Arsenic Trioxide 23-26 BCL2 apoptosis regulator Homo sapiens 103-108 26740400-6 2016 Results indicated that loss of mitochondrial membrane potential, cytochrome c releasing, upregulation of Bcl-2-associated X protein (Bax), downregulation of B-cell CLL/lymphoma 2 (Bcl-2) and caspases activation were reversed by IP6. Phytic Acid 228-231 BCL2 apoptosis regulator Homo sapiens 157-178 27158379-0 2016 Polydatin promotes apoptosis through upregulation the ratio of Bax/Bcl-2 and inhibits proliferation by attenuating the beta-catenin signaling in human osteosarcoma cells. polydatin 0-9 BCL2 apoptosis regulator Homo sapiens 67-72 27158383-6 2016 Moreover, ferulic acid upregulated Bax, downregulated Bcl-2, and subsequently enhanced caspase-3 activity. ferulic acid 10-22 BCL2 apoptosis regulator Homo sapiens 54-59 26874859-4 2016 Bcl-2 dependent xenografts derived from aggressive human NB tumors are cured with a combination of cyclophosphamide and ABT-737, a Bcl-2/Bcl-XL/Bcl-w small molecule antagonist. ABT-737 120-127 BCL2 apoptosis regulator Homo sapiens 0-5 26874859-6 2016 This led to the creation of a Bcl-2 selective inhibitor, ABT-199 (Venetoclax). venetoclax 57-64 BCL2 apoptosis regulator Homo sapiens 30-35 26874859-6 2016 This led to the creation of a Bcl-2 selective inhibitor, ABT-199 (Venetoclax). venetoclax 66-76 BCL2 apoptosis regulator Homo sapiens 30-35 26874859-12 2016 RESULTS: Bcl-2 dependent NB cell lines are exquisitely sensitive to ABT-199 (IC50 1.5-5 nM) in vitro, where Mcl-1 dependent NBs are completely resistant. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 68-71 BCL2 apoptosis regulator Homo sapiens 9-14 26874859-12 2016 RESULTS: Bcl-2 dependent NB cell lines are exquisitely sensitive to ABT-199 (IC50 1.5-5 nM) in vitro, where Mcl-1 dependent NBs are completely resistant. Niobium 124-127 BCL2 apoptosis regulator Homo sapiens 9-14 26874859-4 2016 Bcl-2 dependent xenografts derived from aggressive human NB tumors are cured with a combination of cyclophosphamide and ABT-737, a Bcl-2/Bcl-XL/Bcl-w small molecule antagonist. Cyclophosphamide 99-115 BCL2 apoptosis regulator Homo sapiens 131-136 26874859-13 2016 Treatment with ABT-199 displaces Bim from Bcl-2 in NB to activate caspase 3, confirming the restoration of mitochondrial apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 15-18 BCL2 apoptosis regulator Homo sapiens 42-47 26874859-16 2016 In contrast, Bcl-2 dependent xenografts responded to ABT-199 alone and had sustained complete remission (CR) to the ABT-199/cyclophosphamide combination, with one recurrent tumor maintaining Bcl-2 dependence and obtaining a second CR after a second course of therapy. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 53-56 BCL2 apoptosis regulator Homo sapiens 13-18 26866271-10 2016 Moreover, we demonstrated that the BH4 domain of bcl-2 has a role in maintaining this binding. sapropterin 35-38 BCL2 apoptosis regulator Homo sapiens 49-54 26874859-16 2016 In contrast, Bcl-2 dependent xenografts responded to ABT-199 alone and had sustained complete remission (CR) to the ABT-199/cyclophosphamide combination, with one recurrent tumor maintaining Bcl-2 dependence and obtaining a second CR after a second course of therapy. venetoclax 53-60 BCL2 apoptosis regulator Homo sapiens 13-18 26874859-16 2016 In contrast, Bcl-2 dependent xenografts responded to ABT-199 alone and had sustained complete remission (CR) to the ABT-199/cyclophosphamide combination, with one recurrent tumor maintaining Bcl-2 dependence and obtaining a second CR after a second course of therapy. Cyclophosphamide 124-140 BCL2 apoptosis regulator Homo sapiens 13-18 26874859-18 2016 Our data confirms that Bcl-2 selective inhibitors like ABT-199 are equally potent in HR NB in vitro and in vivo and given their lack of platelet toxicity, should be translated into the clinic for HR NB. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 55-58 BCL2 apoptosis regulator Homo sapiens 23-28 26863116-12 2016 Bcl-2 was immunolabeled in a low percentage of cells in WDT-UMP. wdt-ump 56-63 BCL2 apoptosis regulator Homo sapiens 0-5 26865041-5 2016 Furthermore, the perichondral spindle cells and marrow osteoblasts/fibroblasts of BPOP showed stronger immunoreaction of PCNA, p53, beta-catenin, BCL2, pAKT, survivin, 14-3-3, CEA, EMA, pan-K, and S-100 than the tumor cells of osteochondroma. bpop 82-86 BCL2 apoptosis regulator Homo sapiens 146-150 26859456-3 2016 Using data from our large drug screen we predicted, and subsequently demonstrated, that MYCN-amplified neuroblastomas are sensitive to the BCL-2 inhibitor ABT-199. venetoclax 155-162 BCL2 apoptosis regulator Homo sapiens 139-144 26773499-6 2016 6-OHDA-induced intracellular generation of ROS and mitochondrial dysfunctions, release of cytochrome c, imbalance of Bax/Bcl-2, cleaved caspase-9/caspase-9 and cleaved caspase-3/caspase-3 ratio, and p-p53 activation were strikingly attenuated by SJP pretreatment. Oxidopamine 0-6 BCL2 apoptosis regulator Homo sapiens 121-126 26848099-2 2016 Treatment of cells with miltirone resulted in apoptosis, mitochondria membrane potential (MMP) collapses, increase of Bax/Bcl-2 ratio, and cytochrome c release. miltirone 24-33 BCL2 apoptosis regulator Homo sapiens 122-127 26865836-11 2015 ICC analysis for bcl2 and p53 also confirmed our results; in treated samples for the dose of LD50 in 24 and 48 h of cisplatin and hypercin, more cells expressed p53 (guardian of cells in front of tumor formation/progression) and less expressed bcl2 (which has anti apoptotic activity) compared to untreated samples. Cisplatin 116-125 BCL2 apoptosis regulator Homo sapiens 17-21 26865836-11 2015 ICC analysis for bcl2 and p53 also confirmed our results; in treated samples for the dose of LD50 in 24 and 48 h of cisplatin and hypercin, more cells expressed p53 (guardian of cells in front of tumor formation/progression) and less expressed bcl2 (which has anti apoptotic activity) compared to untreated samples. Cisplatin 116-125 BCL2 apoptosis regulator Homo sapiens 244-248 26865836-11 2015 ICC analysis for bcl2 and p53 also confirmed our results; in treated samples for the dose of LD50 in 24 and 48 h of cisplatin and hypercin, more cells expressed p53 (guardian of cells in front of tumor formation/progression) and less expressed bcl2 (which has anti apoptotic activity) compared to untreated samples. hypercin 130-138 BCL2 apoptosis regulator Homo sapiens 17-21 26865836-11 2015 ICC analysis for bcl2 and p53 also confirmed our results; in treated samples for the dose of LD50 in 24 and 48 h of cisplatin and hypercin, more cells expressed p53 (guardian of cells in front of tumor formation/progression) and less expressed bcl2 (which has anti apoptotic activity) compared to untreated samples. hypercin 130-138 BCL2 apoptosis regulator Homo sapiens 244-248 26724845-5 2016 Western blot analysis showed that Bax expression was increased, whereas Bcl-2 expression was significantly decreased in carvacrol exposed HL-60 cells and Jurkat cells. carvacrol 120-129 BCL2 apoptosis regulator Homo sapiens 72-77 26792731-4 2016 cAMP signaling inhibited JNK activation, which decreased the phosphorylation of Bcl-2, thereby reducing autophagy, and the phosphorylation of Itch, thereby reducing ubiquitination. Cyclic AMP 0-4 BCL2 apoptosis regulator Homo sapiens 80-85 26758192-9 2016 Additionally, triticumoside regulated expression of apoptosis-associated proteins, such as B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X, and procaspase-3/9. triticumoside 14-27 BCL2 apoptosis regulator Homo sapiens 91-108 26758192-9 2016 Additionally, triticumoside regulated expression of apoptosis-associated proteins, such as B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X, and procaspase-3/9. triticumoside 14-27 BCL2 apoptosis regulator Homo sapiens 110-115 27003174-4 2016 We found that DMAc triggered LO-2 apoptosis in a obviously dose-dependent manner, caused by increased ROS generation and activation of Bcl-2 pathway. dimethylacetamide 14-18 BCL2 apoptosis regulator Homo sapiens 135-140 26612416-8 2016 Moreover, Se@LDH-pooled siRNAs could induce cell apoptosis, change cell morphology and increase cellular ROS levels through change the expression of Bcl-2/Bax, activation of caspase-3, PI3K/AKT/mTOR and MAPK/ERK pathways. ros 105-108 BCL2 apoptosis regulator Homo sapiens 149-154 26796279-9 2016 The combination of LY294002, PI3K inhibitor, and curcumin induced cell cycle arrest by decreasing CDK4, CDK2 and cyclin E2 in Bcl-2+ MCF-7 cells. Curcumin 49-57 BCL2 apoptosis regulator Homo sapiens 126-131 26796279-10 2016 Moreover, LY294002 further inhibited the phosphorylation of Akt in Bcl-2+ MCF-7 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 BCL2 apoptosis regulator Homo sapiens 67-72 26621844-0 2016 Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species. Reactive Oxygen Species 127-150 BCL2 apoptosis regulator Homo sapiens 0-5 26621844-3 2016 While the mechanisms underlying these new functions of Bcl-2 proteins are just beginning to be studied, reactive oxygen species (ROS) have emerged as inducers of cell invasion and the production of ROS from mitochondrial respiration is known to be promoted and suppressed by the pro-survival and multidomain pro-apoptotic Bcl-2 family members, respectively. Reactive Oxygen Species 198-201 BCL2 apoptosis regulator Homo sapiens 55-60 26621844-3 2016 While the mechanisms underlying these new functions of Bcl-2 proteins are just beginning to be studied, reactive oxygen species (ROS) have emerged as inducers of cell invasion and the production of ROS from mitochondrial respiration is known to be promoted and suppressed by the pro-survival and multidomain pro-apoptotic Bcl-2 family members, respectively. Reactive Oxygen Species 198-201 BCL2 apoptosis regulator Homo sapiens 322-327 26796279-0 2016 The inhibition of PI3K and NFkappaB promoted curcumin-induced cell cycle arrest at G2/M via altering polyamine metabolism in Bcl-2 overexpressing MCF-7 breast cancer cells. Curcumin 45-53 BCL2 apoptosis regulator Homo sapiens 125-130 26796279-0 2016 The inhibition of PI3K and NFkappaB promoted curcumin-induced cell cycle arrest at G2/M via altering polyamine metabolism in Bcl-2 overexpressing MCF-7 breast cancer cells. Polyamines 101-110 BCL2 apoptosis regulator Homo sapiens 125-130 26796279-4 2016 In this study, we investigated the role of curcumin in induction of cell cycle arrest via regulating of NFkappaB and polyamine biosynthesis in wt and Bcl-2+ MCF-7 cells. Curcumin 43-51 BCL2 apoptosis regulator Homo sapiens 150-155 26796279-8 2016 However, Bcl-2 overexpression prevented the inhibition of cell cycle associated proteins after curcumin treatment. Curcumin 95-103 BCL2 apoptosis regulator Homo sapiens 9-14 26796279-9 2016 The combination of LY294002, PI3K inhibitor, and curcumin induced cell cycle arrest by decreasing CDK4, CDK2 and cyclin E2 in Bcl-2+ MCF-7 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 BCL2 apoptosis regulator Homo sapiens 126-131 26796279-12 2016 The combination of wedelolactone, NFkappaB inhibitor, and curcumin acted different on SSAT expression in wt MCF-7 and Bcl-2+ MCF-7 cells. wedelolactone 19-32 BCL2 apoptosis regulator Homo sapiens 118-123 26796279-12 2016 The combination of wedelolactone, NFkappaB inhibitor, and curcumin acted different on SSAT expression in wt MCF-7 and Bcl-2+ MCF-7 cells. Curcumin 58-66 BCL2 apoptosis regulator Homo sapiens 118-123 26476589-0 2016 A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer. gossypol acetic acid 20-26 BCL2 apoptosis regulator Homo sapiens 39-44 26796279-13 2016 NFkappaB inhibition increased the SSAT after curcumin treatment in Bcl-2 overexpressed MCF-7 cells. Curcumin 45-53 BCL2 apoptosis regulator Homo sapiens 67-72 26683082-0 2016 Fasudil, a Rho kinase inhibitor, promotes the autophagic degradation of A53T alpha-synuclein by activating the JNK 1/Bcl-2/beclin 1 pathway. fasudil 0-7 BCL2 apoptosis regulator Homo sapiens 117-122 26683082-7 2016 Its underlying mechanism was supported by that fasudil could increase the macroautophagy activation via JNK 1 and Bcl-2 phosphorylation and beclin 1/Vps34 complex formation. fasudil 47-54 BCL2 apoptosis regulator Homo sapiens 114-119 26701089-1 2016 Results from an international phase II study show that the investigational BCL2 inhibitor venetoclax is effective in patients with chronic lymphocytic leukemia and the chromosome 17p deletion, whose prognosis is particularly poor. venetoclax 90-100 BCL2 apoptosis regulator Homo sapiens 75-79 26493374-0 2016 Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding. BH 3 87-90 BCL2 apoptosis regulator Homo sapiens 0-5 26493374-0 2016 Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 100-103 BCL2 apoptosis regulator Homo sapiens 0-5 26493374-0 2016 Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 109-112 BCL2 apoptosis regulator Homo sapiens 0-5 26493374-0 2016 Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 109-112 BCL2 apoptosis regulator Homo sapiens 0-5 26493374-6 2016 KEY RESULTS: The ratio of (Mcl-1 + pBcl-2) to Bcl-2 expression provided the most significant predictive marker for the cytotoxic potential of ABT-737, ABT-263 and ABT-199 in the panel of CLL samples. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 142-145 BCL2 apoptosis regulator Homo sapiens 36-41 26493374-6 2016 KEY RESULTS: The ratio of (Mcl-1 + pBcl-2) to Bcl-2 expression provided the most significant predictive marker for the cytotoxic potential of ABT-737, ABT-263 and ABT-199 in the panel of CLL samples. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 151-154 BCL2 apoptosis regulator Homo sapiens 36-41 26493374-6 2016 KEY RESULTS: The ratio of (Mcl-1 + pBcl-2) to Bcl-2 expression provided the most significant predictive marker for the cytotoxic potential of ABT-737, ABT-263 and ABT-199 in the panel of CLL samples. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 151-154 BCL2 apoptosis regulator Homo sapiens 36-41 26493374-7 2016 Mechanistically, pBcl-2 inhibited the effects of the ABT compounds on the displacement of Bax and Bim from Bcl-2, thereby suppressing mitochondrial apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 53-56 BCL2 apoptosis regulator Homo sapiens 18-23 26493374-8 2016 The ABT compounds exhibited 100-300-fold lower binding affinity to the glutamic acid, phosphomimetic, mutant of Bcl-2 (T69E, S70E and S87E; EEE-Bcl-2). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 4-7 BCL2 apoptosis regulator Homo sapiens 112-117 26493374-8 2016 The ABT compounds exhibited 100-300-fold lower binding affinity to the glutamic acid, phosphomimetic, mutant of Bcl-2 (T69E, S70E and S87E; EEE-Bcl-2). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 4-7 BCL2 apoptosis regulator Homo sapiens 144-149 26493374-8 2016 The ABT compounds exhibited 100-300-fold lower binding affinity to the glutamic acid, phosphomimetic, mutant of Bcl-2 (T69E, S70E and S87E; EEE-Bcl-2). Glutamic Acid 71-84 BCL2 apoptosis regulator Homo sapiens 112-117 26493374-8 2016 The ABT compounds exhibited 100-300-fold lower binding affinity to the glutamic acid, phosphomimetic, mutant of Bcl-2 (T69E, S70E and S87E; EEE-Bcl-2). Glutamic Acid 71-84 BCL2 apoptosis regulator Homo sapiens 144-149 26493374-10 2016 CONCLUSIONS AND IMPLICATIONS: Our study suggested that a structural alteration in the BH3-binding groove was induced by phosphorylation of Bcl-2. BH 3 86-89 BCL2 apoptosis regulator Homo sapiens 139-144 26080839-5 2016 Through inhibition of AKT1, BEZ235 was able to alleviate AKT1-mediated suppression of dexamethasone-induced apoptotic pathways leading to increased expression of the proapoptotic BCL-2 protein BIM. dactolisib 28-34 BCL2 apoptosis regulator Homo sapiens 179-184 26476589-1 2016 UNLABELLED: In a phase II multicenter study, men with castration sensitive metastatic prostate cancer were treated with AT-101, a small molecule Bcl-2 inhibitor, and androgen deprivation therapy. gossypol acetic acid 120-126 BCL2 apoptosis regulator Homo sapiens 145-150 26893664-5 2016 In the present study, naringenin and a Bcl-2 inhibitor, ABT-737, were used to investigate their combinative anticancer effect in the SGC7901 gastric cancer cell line. ABT-737 56-63 BCL2 apoptosis regulator Homo sapiens 39-44 26586460-4 2016 In multivariate analysis, high expression of Bcl-2 was a significant independent prognostic factor of poor PFS (P = 0.026) and OS (P = 0.007) along with high IPI. diprotin A 158-161 BCL2 apoptosis regulator Homo sapiens 45-50 26893624-10 2016 In addition, puerarin significantly decreased LPS-induced phosphorylated nuclear factor (p-NF)-kappaB p65 and Bax expression levels, and increased the expression levels of Bcl-2, as compared with the LPS group (P<0.05). puerarin 13-21 BCL2 apoptosis regulator Homo sapiens 172-177 26673746-10 2016 Treatment with PI3K inhibitor LY294003 increased the impact of TKP on mitochondria-related apoptosis proteins (cytochrome c, Bcl-2, Bax, caspase-9 and caspase-3) and cell apoptosis. ly294003 30-38 BCL2 apoptosis regulator Homo sapiens 125-130 26228975-7 2016 Additionally, the levels of anti-apoptotic Bcl-2 proteins (Bcl-xL and Mcl-1) were significantly reduced by SAHA. Vorinostat 107-111 BCL2 apoptosis regulator Homo sapiens 43-48 25381586-6 2016 CONCLUSION: The miR-21 in osteosarcoma cells is a significant modulator of the anti-tumor effect of CDDP by regulating the expression of bcl-2, and the study reveals a novel mechanism of osteosarcoma drug resistance. Cisplatin 100-104 BCL2 apoptosis regulator Homo sapiens 137-142 26676928-5 2016 The results demonstrated that the lower concentration of oridonin in combination with lower concentration of VPA synergistically inhibited the proliferation of HL-60 cells, and induced obvious caspase-dependent apoptosis through activation of the intrinsic apoptosis pathway, which is involved in the downregulation of Bcl-2/Bax ratio, release of cytochrome c to cytosol and caspase-9 activation, as well as through the extrinsic apoptosis pathway mediated by Fas/FasL and caspase-8 activation. oridonin 57-65 BCL2 apoptosis regulator Homo sapiens 319-324 26677054-11 2016 The Bax/Bcl-2 ratio was dose-dependently decreased by EtOH and by high-dose EtP in A549 cells, indicating a reduction in apoptosis, whereas this effect was not observed in Huh7 cells. Ethanol 54-58 BCL2 apoptosis regulator Homo sapiens 8-13 26677054-11 2016 The Bax/Bcl-2 ratio was dose-dependently decreased by EtOH and by high-dose EtP in A549 cells, indicating a reduction in apoptosis, whereas this effect was not observed in Huh7 cells. ethyl pyruvate 76-79 BCL2 apoptosis regulator Homo sapiens 8-13 26692364-5 2016 We further confirmed that phloretin dose-dependently suppressed the expression of Bcl-2, increased the protein expression of cleaved-caspase-3 and -9, and deregulated the expression of matrix metalloproteinases (MMP)-2 and -9 on gene and protein levels. Phloretin 26-35 BCL2 apoptosis regulator Homo sapiens 82-87 26174106-11 2016 We also report that AdoMet consistently causes an increase of p53 and p21 cell-cycle inhibitor, a decrease of cyclin A and cyclin E protein levels, and a marked increase of pro-apoptotic Bax/Bcl-2 ratio, with caspase-3 activation and PARP cleavage. S-Adenosylmethionine 20-26 BCL2 apoptosis regulator Homo sapiens 191-196 26692364-7 2016 Moreover, phloretin facilitated the effects of cisplatin on deregulation of Bcl-2, MMP-2 and -9, and upregulation of cleaved-caspase-3 and -9. Phloretin 10-19 BCL2 apoptosis regulator Homo sapiens 76-81 26692364-7 2016 Moreover, phloretin facilitated the effects of cisplatin on deregulation of Bcl-2, MMP-2 and -9, and upregulation of cleaved-caspase-3 and -9. Cisplatin 47-56 BCL2 apoptosis regulator Homo sapiens 76-81 26189652-6 2016 A low (but not high) concentration of NO (10 muM) induced expression of RUNX2 and Bcl-2, conferring resistance to docetaxel. Docetaxel 114-123 BCL2 apoptosis regulator Homo sapiens 82-87 26488112-8 2016 However, by combining SSA with the Bcl-2/Bcl-x(L) antagonists ABT-263 or ABT-199, we were able to overcome this pro-survival effect. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 62-65 BCL2 apoptosis regulator Homo sapiens 35-40 26088877-3 2016 In prostate cancer cell lines, the Pim kinase inhibitor SMI-4a and the Bcl-2 antagonist ABT-737 resulted in synergistic cytotoxicity. ABT-737 88-95 BCL2 apoptosis regulator Homo sapiens 71-76 26241894-5 2016 Nitric oxide was found to negatively regulate autophagy initiation and autophagic flux by nitrosylating Bcl-2 and stabilizing its interaction with Beclin-1, resulting in inhibition of Beclin-1 activity. Nitric Oxide 0-12 BCL2 apoptosis regulator Homo sapiens 104-109 26241894-7 2016 Pre-treatments with ABT-737 (Bcl-2 inhibitor) and aminoguanidine (NO inhibitor), and transfection with a non-nitrosylable Bcl-2 cysteine double-mutant plasmid resulted in increased autophagic flux (LC3-II/p62 upregulation) corresponding with decreased S-nitrocysteine expression, thus corroborating the regulatory role of Bcl-2 S-nitrosylation in autophagy. ABT-737 20-27 BCL2 apoptosis regulator Homo sapiens 29-34 26241894-7 2016 Pre-treatments with ABT-737 (Bcl-2 inhibitor) and aminoguanidine (NO inhibitor), and transfection with a non-nitrosylable Bcl-2 cysteine double-mutant plasmid resulted in increased autophagic flux (LC3-II/p62 upregulation) corresponding with decreased S-nitrocysteine expression, thus corroborating the regulatory role of Bcl-2 S-nitrosylation in autophagy. Cysteine 128-136 BCL2 apoptosis regulator Homo sapiens 122-127 26241894-7 2016 Pre-treatments with ABT-737 (Bcl-2 inhibitor) and aminoguanidine (NO inhibitor), and transfection with a non-nitrosylable Bcl-2 cysteine double-mutant plasmid resulted in increased autophagic flux (LC3-II/p62 upregulation) corresponding with decreased S-nitrocysteine expression, thus corroborating the regulatory role of Bcl-2 S-nitrosylation in autophagy. Cysteine 128-136 BCL2 apoptosis regulator Homo sapiens 122-127 26676867-10 2016 In addition, further investigations confirmed B cell lymphoma-2 (Bcl-2) as the downstream molecular mechanism of GDC-0449 efficacy. HhAntag691 113-121 BCL2 apoptosis regulator Homo sapiens 46-63 26621869-8 2016 To induce MOMP, selected sperm were treated at 37 C for 4 h with a mimetic of a Bcl-2 pro-apoptotic protein, ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 109-112 BCL2 apoptosis regulator Homo sapiens 80-85 26676867-10 2016 In addition, further investigations confirmed B cell lymphoma-2 (Bcl-2) as the downstream molecular mechanism of GDC-0449 efficacy. HhAntag691 113-121 BCL2 apoptosis regulator Homo sapiens 65-70 26707422-0 2016 Dodecyl gallate induces apoptosis by upregulating the caspase-dependent apoptotic pathway and inhibiting the expression of anti-apoptotic Bcl-2 family proteins in human osteosarcoma cells. lauryl gallate 0-15 BCL2 apoptosis regulator Homo sapiens 138-143 26676867-12 2016 By repressing the expression of Bcl-2, GDC-0449 inhibited the normal proliferation of SGC-7901 cells, and accelerated the apoptotic rate of the cells. HhAntag691 39-47 BCL2 apoptosis regulator Homo sapiens 32-37 26834954-2 2016 The most commonly seen DHL is diffuse large B-cell lymphoma (DLBCL) with t(14;18) and t(8;14) or t(8;22) resulting in overexpression of BCL2 and MYC, respectively. Cysteamine 23-26 BCL2 apoptosis regulator Homo sapiens 136-140 26893680-0 2016 Role of BCL2-associated athanogene in resistance to platinum-based chemotherapy in non-small-cell lung cancer. Platinum 52-60 BCL2 apoptosis regulator Homo sapiens 8-12 26621341-3 2016 Cultured human SH-SY5Y neuroblastoma cells were treated (bupivacaine) or untreated (control) with bupivacaine for 24 h. Compared to the control group, bupivacaine significantly increased cyto-inhibition, cellular reactive oxygen species, DNA damage, mitochondrial injury, apoptosis (increased TUNEL-positive cells, cleaved caspase 3, and Bcl-2/Bax), and activated autophagy (enhanced LC3II/LC3I ratio). Bupivacaine 98-109 BCL2 apoptosis regulator Homo sapiens 338-343 26621341-3 2016 Cultured human SH-SY5Y neuroblastoma cells were treated (bupivacaine) or untreated (control) with bupivacaine for 24 h. Compared to the control group, bupivacaine significantly increased cyto-inhibition, cellular reactive oxygen species, DNA damage, mitochondrial injury, apoptosis (increased TUNEL-positive cells, cleaved caspase 3, and Bcl-2/Bax), and activated autophagy (enhanced LC3II/LC3I ratio). Bupivacaine 98-109 BCL2 apoptosis regulator Homo sapiens 338-343 26718026-5 2016 In addition, 48-h treatment with xanthohumol suppressed NF-kappaB expression and promoted p53, cleaved PARP, AIF and cytochrome c expression and downregulated XIAP and Bcl-2/Bax expression in human liver cancer HepG2 cells. xanthohumol 33-44 BCL2 apoptosis regulator Homo sapiens 168-173 27014985-8 2016 (4) Phenelzine could upregulate the expression of Bax, caspase-3, p21, and downregulate Bcl-2 expression. Phenelzine 4-14 BCL2 apoptosis regulator Homo sapiens 88-93 26100943-3 2016 ABT-737 is a high affinity Bcl-2 inhibitor that fails to target Mcl-1. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 27-32 26100943-5 2016 METHODS: Urothelial cancer cells were treated with the BH3 mimetics ABT-737 and (-)-gossypol, a pan-Bcl-2 inhibitor which inhibits also Mcl-1. BH 3 55-58 BCL2 apoptosis regulator Homo sapiens 100-105 26100943-5 2016 METHODS: Urothelial cancer cells were treated with the BH3 mimetics ABT-737 and (-)-gossypol, a pan-Bcl-2 inhibitor which inhibits also Mcl-1. ABT-737 68-75 BCL2 apoptosis regulator Homo sapiens 100-105 26100943-5 2016 METHODS: Urothelial cancer cells were treated with the BH3 mimetics ABT-737 and (-)-gossypol, a pan-Bcl-2 inhibitor which inhibits also Mcl-1. Gossypol 80-92 BCL2 apoptosis regulator Homo sapiens 100-105 26913405-7 2016 RESULTS: The BCL-2/BAX ratio decreased, the activity of caspase-3 and p-ERK1/2 increased, the cell cycle was arrested in G2/M phase after treatment with 5-azacitidine. Azacitidine 153-166 BCL2 apoptosis regulator Homo sapiens 13-18 26913405-9 2016 CONCLUSION: 5-azacitidine exerts apoptosis-inducing and grow-inhibiting effects on MM cell lines, its mechanism may be related with the decrease of BCL-2/BAX ratio, caspase-3 activation and the arrest of cell cycle. Azacitidine 12-25 BCL2 apoptosis regulator Homo sapiens 148-153 26918059-9 2016 Analysis of protein expression levels in SGC-7901 cells showed downregulation of Bcl-2 and upregulation of Bax in response to baicalein treatment. baicalein 126-135 BCL2 apoptosis regulator Homo sapiens 81-86 28868869-6 2016 Western blot results showed that Bcl-2 and Bcl-xl protein levels were significantly decreased after treating with total terpenoids (6.25x10-5, 3.125x10-5, 1.562 5x10-5 g mL-1), while the protein expression of caspase-3 was significantly increased. Terpenes 120-130 BCL2 apoptosis regulator Homo sapiens 33-38 28868869-7 2016 q-PCR results were the same with western blot results, that mRNA expressions of Bcl-2 and Bcl-xl were significantly decreased while mRNA expression of caspase-3 was significantly increased after treating with total terpenoids (6.25x10-5, 3.125x10-5, 1.562 5x10-5 g mL-1). Terpenes 215-225 BCL2 apoptosis regulator Homo sapiens 80-85 26572448-5 2016 Western blot analysis revealed that EPS increased the ratio of Bax/Bcl-2 and promoted the release of cytochrome c into the cytoplasm. eps 36-39 BCL2 apoptosis regulator Homo sapiens 67-72 26612655-4 2016 More specifically, we found that SZC015 was able to activate intrinsic apoptosis, which was proved by activations of caspase3, caspase9, release of cytochrome C, cleavage of PARP and increasing ratio of Bax/Bcl-2. 2-morpholinomethyl-3-oxoolean-12-en-28-oic acid 33-39 BCL2 apoptosis regulator Homo sapiens 207-212 26816615-8 2016 The results showed that knockdown of CLIC4 with or without 100 muM adenosine triphosphate (ATP) treatment significantly increased the expression of Bax, active caspase 3, active caspase 4 and CHOP but suppressed Bcl-2 expression in HN4 cells. Adenosine Triphosphate 67-89 BCL2 apoptosis regulator Homo sapiens 212-217 26816615-8 2016 The results showed that knockdown of CLIC4 with or without 100 muM adenosine triphosphate (ATP) treatment significantly increased the expression of Bax, active caspase 3, active caspase 4 and CHOP but suppressed Bcl-2 expression in HN4 cells. Adenosine Triphosphate 91-94 BCL2 apoptosis regulator Homo sapiens 212-217 26639348-16 2016 CONCLUSIONS: Selective targeting of BCL2 with venetoclax had a manageable safety profile and induced substantial responses in patients with relapsed CLL or SLL, including those with poor prognostic features. venetoclax 46-56 BCL2 apoptosis regulator Homo sapiens 36-40 26701852-9 2016 The results reported here demonstrate that miR-101 disrupted cellular mitochondrial function and induced cellular apoptosis via the mitochondrial pathway; for example, MMP and ATP levels decreased, while there was an increase in ADP/ATP ratios and ROS levels, levels of cleaved Caspase-9 and cleaved-PARP, the Bax/Bcl-2 ratios, and Smac release from the mitochondria to the cytoplasm. mir-101 43-50 BCL2 apoptosis regulator Homo sapiens 314-319 26491047-8 2016 The Bcl-2/Bax ratio was increased in lung cancer cells following treatment with ATP; however, the antiapoptotic protein Bcl-2 demonstrated more sensitivity to ATP than proapoptotic protein Bax. Adenosine Triphosphate 159-162 BCL2 apoptosis regulator Homo sapiens 4-9 26672764-5 2016 Further mechanism study showed that melatonin promoted the cleavage of caspse-9 and PARP, enhanced the inhibition of Bcl2, and triggered the releasing of cytochrome C (Cyto C), thereby increasing the berberine-induced apoptosis. Melatonin 36-45 BCL2 apoptosis regulator Homo sapiens 117-121 26657288-6 2016 Moreover, in DLBCL cells initially resistant to BH3 mimetic drugs, BCL6 inhibition induces a newly developed reliance on anti-apoptotic BCL2-family members for survival that translates in acquired susceptibility to BH3 mimetic drugs ABT-737 and obatoclax. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 233-236 BCL2 apoptosis regulator Homo sapiens 136-140 26657288-7 2016 In germinal center B cell-like (GCB)-DLBCL cells, the proteasome inhibitor bortezomib and the NEDD inhibitor MLN4924 post-transcriptionally activated the BH3-only sensitizer NOXA thus counteracting the oncogenic switch to BCL2 induced by BCL6-targeting. Bortezomib 75-85 BCL2 apoptosis regulator Homo sapiens 222-226 26491047-0 2016 ATP promotes cell survival via regulation of cytosolic [Ca2+] and Bcl-2/Bax ratio in lung cancer cells. Adenosine Triphosphate 0-3 BCL2 apoptosis regulator Homo sapiens 66-71 27551490-7 2016 DBME induced G2/M phase arrest and apoptosis in MCF-7 cells by suppressing the expression of cyclin A1, cyclin B1 and Cdk-1 and increasing the expression of p53, Bax/Bcl-2 ratio leading to activation of caspases and PARP degradation. dbme 0-4 BCL2 apoptosis regulator Homo sapiens 166-171 26491047-8 2016 The Bcl-2/Bax ratio was increased in lung cancer cells following treatment with ATP; however, the antiapoptotic protein Bcl-2 demonstrated more sensitivity to ATP than proapoptotic protein Bax. Adenosine Triphosphate 159-162 BCL2 apoptosis regulator Homo sapiens 120-125 26491047-3 2016 We examined ATP-induced Ca(2+) signaling and its effects on antiapoptotic (Bcl-2) and proapoptotic (Bax) proteins in normal human airway epithelial cells and lung cancer cells. Adenosine Triphosphate 12-15 BCL2 apoptosis regulator Homo sapiens 75-80 26491047-9 2016 Decreasing extracellular Ca(2+) or chelating intracellular Ca(2+) with BAPTA-AM significantly inhibited ATP-induced increase in Bcl-2/Bax ratio, indicating that a rise in [Ca(2+)]cyt through Ca(2+) influx is the critical mediator for ATP-mediated increase in Bcl-2/Bax ratio. 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester 71-79 BCL2 apoptosis regulator Homo sapiens 128-133 26491047-8 2016 The Bcl-2/Bax ratio was increased in lung cancer cells following treatment with ATP; however, the antiapoptotic protein Bcl-2 demonstrated more sensitivity to ATP than proapoptotic protein Bax. Adenosine Triphosphate 80-83 BCL2 apoptosis regulator Homo sapiens 4-9 26491047-9 2016 Decreasing extracellular Ca(2+) or chelating intracellular Ca(2+) with BAPTA-AM significantly inhibited ATP-induced increase in Bcl-2/Bax ratio, indicating that a rise in [Ca(2+)]cyt through Ca(2+) influx is the critical mediator for ATP-mediated increase in Bcl-2/Bax ratio. 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester 71-79 BCL2 apoptosis regulator Homo sapiens 259-264 26491047-8 2016 The Bcl-2/Bax ratio was increased in lung cancer cells following treatment with ATP; however, the antiapoptotic protein Bcl-2 demonstrated more sensitivity to ATP than proapoptotic protein Bax. Adenosine Triphosphate 80-83 BCL2 apoptosis regulator Homo sapiens 120-125 26491047-9 2016 Decreasing extracellular Ca(2+) or chelating intracellular Ca(2+) with BAPTA-AM significantly inhibited ATP-induced increase in Bcl-2/Bax ratio, indicating that a rise in [Ca(2+)]cyt through Ca(2+) influx is the critical mediator for ATP-mediated increase in Bcl-2/Bax ratio. Adenosine Triphosphate 104-107 BCL2 apoptosis regulator Homo sapiens 128-133 26491047-9 2016 Decreasing extracellular Ca(2+) or chelating intracellular Ca(2+) with BAPTA-AM significantly inhibited ATP-induced increase in Bcl-2/Bax ratio, indicating that a rise in [Ca(2+)]cyt through Ca(2+) influx is the critical mediator for ATP-mediated increase in Bcl-2/Bax ratio. Adenosine Triphosphate 104-107 BCL2 apoptosis regulator Homo sapiens 259-264 26491047-9 2016 Decreasing extracellular Ca(2+) or chelating intracellular Ca(2+) with BAPTA-AM significantly inhibited ATP-induced increase in Bcl-2/Bax ratio, indicating that a rise in [Ca(2+)]cyt through Ca(2+) influx is the critical mediator for ATP-mediated increase in Bcl-2/Bax ratio. Adenosine Triphosphate 234-237 BCL2 apoptosis regulator Homo sapiens 128-133 26491047-11 2016 Increasing the Bcl-2/Bax ratio by exposure to high extracellular ATP may, therefore, be an important selective pressure promoting transformation and cancer progression. Adenosine Triphosphate 65-68 BCL2 apoptosis regulator Homo sapiens 15-20 26707639-4 2016 Increased level of active caspase-3 and decreased levels of Bcl-2 and Mcl-1 were also observed in Jurkat and lymphoma T-cells but not normal T-cells treated with pyrvinium. pyrvinium 162-171 BCL2 apoptosis regulator Homo sapiens 60-65 26694802-5 2016 RA induced the increment of p53 levels, caspase-3 activation, and poly-ADP-ribose polymerase cleavage and the reduction of the procaspase-3 and Bcl2. rosmarinic acid 0-2 BCL2 apoptosis regulator Homo sapiens 144-148 26631315-3 2016 A series of methylazacalix[n]pyridine (n=4, 6, 7, 8, 9) has been tested to stabilize the intermolecular human telomeric G-quadruplex (T12 and H12), intramolecular TBA, c-kit and bcl-2 G-quadruplex by CD denaturation experiments. methylazacalix[n]pyridine 12-37 BCL2 apoptosis regulator Homo sapiens 178-183 26766586-2 2016 A recent paper by Roberts and colleagues describes an additional therapeutic target by reporting encouraging clinical results with venetoclax, an inhibitor of the antiapoptotic protein BCL2. venetoclax 131-141 BCL2 apoptosis regulator Homo sapiens 185-189 26711147-5 2016 In addition, ASA could led to a loss in the mitochondrial out membrane potential, up-regulate p53, phosphorylated p53 and Bax, down-regulate Bcl-2, release cytochrome c from the mitochondria to the cytoplasm, and activate caspase-9 and caspase-3 in A549 cells, which revealed that ASA could also induce apoptosis through the mitochondria mediated pathway. Aspirin 13-16 BCL2 apoptosis regulator Homo sapiens 141-146 26260669-2 2016 Navitoclax (ABT-263), an orally bio-available small-molecule mimetic of the Bcl-2 homology domain 3, specifically inhibits Bcl-2, Bcl-xL and Bcl-w. navitoclax 0-10 BCL2 apoptosis regulator Homo sapiens 76-81 26260669-2 2016 Navitoclax (ABT-263), an orally bio-available small-molecule mimetic of the Bcl-2 homology domain 3, specifically inhibits Bcl-2, Bcl-xL and Bcl-w. navitoclax 0-10 BCL2 apoptosis regulator Homo sapiens 123-128 26260669-2 2016 Navitoclax (ABT-263), an orally bio-available small-molecule mimetic of the Bcl-2 homology domain 3, specifically inhibits Bcl-2, Bcl-xL and Bcl-w. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 12-15 BCL2 apoptosis regulator Homo sapiens 76-81 26260669-2 2016 Navitoclax (ABT-263), an orally bio-available small-molecule mimetic of the Bcl-2 homology domain 3, specifically inhibits Bcl-2, Bcl-xL and Bcl-w. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 12-15 BCL2 apoptosis regulator Homo sapiens 123-128 26260669-5 2016 In this study, we show that HTLV-1-associated adult T-cell leukemia/lymphoma (ATL) cells, which over-express Bcl-2, Bcl-xL and Bcl-w, show a 10- to 20-fold higher sensitivity (EC50 = ~ 25-50 nM) to Navitoclax compared to non-HTLV-1-associated leukemic cells (EC50 = ~ 1 muM). navitoclax 198-208 BCL2 apoptosis regulator Homo sapiens 109-114 26505786-6 2016 Treatment with 5-FU or DOX in combination with curcumin induced apoptosis by inhibiting Bcl-2 and increasing Bax, caspase-3, and poly-ADP ribose polymerase (PARP) in NT8e cells. Fluorouracil 15-19 BCL2 apoptosis regulator Homo sapiens 88-93 26505786-6 2016 Treatment with 5-FU or DOX in combination with curcumin induced apoptosis by inhibiting Bcl-2 and increasing Bax, caspase-3, and poly-ADP ribose polymerase (PARP) in NT8e cells. Doxorubicin 23-26 BCL2 apoptosis regulator Homo sapiens 88-93 26505786-6 2016 Treatment with 5-FU or DOX in combination with curcumin induced apoptosis by inhibiting Bcl-2 and increasing Bax, caspase-3, and poly-ADP ribose polymerase (PARP) in NT8e cells. Curcumin 47-55 BCL2 apoptosis regulator Homo sapiens 88-93 26563651-0 2016 Targeting anti-apoptotic Bcl2 proteins with scyllatoxin-based BH3 domain mimetics. BH 3 62-65 BCL2 apoptosis regulator Homo sapiens 25-29 26563651-2 2016 Intrinsically disordered ScTx variants were found to bind Bcl2 with nanomolar affinity, indicating that an induced fit binding mechanism is required for favorable BH3 : Bcl2 interaction. BH 3 163-166 BCL2 apoptosis regulator Homo sapiens 58-62 26563651-2 2016 Intrinsically disordered ScTx variants were found to bind Bcl2 with nanomolar affinity, indicating that an induced fit binding mechanism is required for favorable BH3 : Bcl2 interaction. BH 3 163-166 BCL2 apoptosis regulator Homo sapiens 169-173 25405259-1 2016 In this study, the ability of methotrexate (MTX)-loaded stimuli-responsive novel silica nanocomposites (MSNs) (with mean diameter of +- 60 nm) in the induction of apoptosis, and change in the Bax/Bcl-2 mRNA levels, were investigated. Methotrexate 30-42 BCL2 apoptosis regulator Homo sapiens 196-201 26506538-8 2016 Besides, MC-LR also led to hyperphosphorylation of c-Myc, c-Jun, Bcl-2 and Bad and activation of Cdk1. cyanoginosin LR 9-14 BCL2 apoptosis regulator Homo sapiens 65-70 26729257-4 2016 We showed that a pretreatment with morphine (1 mug/ml) inhibited the sensitivity of CNE-2 cells to cisplatin by inhibiting cisplatin-induced CNE-2 cell apoptosis, decreasing caspase-3 activity and increasing the Bcl-2/Bax ratio. Morphine 35-43 BCL2 apoptosis regulator Homo sapiens 212-217 26729257-4 2016 We showed that a pretreatment with morphine (1 mug/ml) inhibited the sensitivity of CNE-2 cells to cisplatin by inhibiting cisplatin-induced CNE-2 cell apoptosis, decreasing caspase-3 activity and increasing the Bcl-2/Bax ratio. Cisplatin 99-108 BCL2 apoptosis regulator Homo sapiens 212-217 26725939-4 2016 Galangin induced down-regulation of Bcl-2 protein at the transcriptional level via inhibition of NF-kappaB activation but not p53 pathway. galangin 0-8 BCL2 apoptosis regulator Homo sapiens 36-41 26702744-7 2016 The results also indicated that Bax/Bcl2 ratio and caspase-3 expression, known as proapoptotic factors, were increased in the presence of sodium selenite and G-Rh2 alone. Sodium Selenite 138-153 BCL2 apoptosis regulator Homo sapiens 36-40 26625317-4 2016 To counteract the anti-apoptotic effect of BCL-2, BH3 mimetics have been developed to target cancer cells. BH 3 50-53 BCL2 apoptosis regulator Homo sapiens 43-48 26456186-3 2016 Our previous BH3 profiling analysis, a functional assay that assesses the contribution of Bcl-2 proteins towards cellular survival, identified two Bcl-2 proteins, cellular Mcl-1 and viral KsBcl-2, as potential regulators of mitochondria polarization within a latently infected B-cell line, Bcbl-1. BH 3 13-16 BCL2 apoptosis regulator Homo sapiens 90-95 26456186-3 2016 Our previous BH3 profiling analysis, a functional assay that assesses the contribution of Bcl-2 proteins towards cellular survival, identified two Bcl-2 proteins, cellular Mcl-1 and viral KsBcl-2, as potential regulators of mitochondria polarization within a latently infected B-cell line, Bcbl-1. BH 3 13-16 BCL2 apoptosis regulator Homo sapiens 147-152 26722046-0 2016 p21CIP1 Induces Apoptosis via Binding to BCL2 in LNCaP Prostate Cancer Cells Treated with MCS-C3, A Novel Carbocyclic Analog of Pyrrolopyrimidine. mcs-c3 90-96 BCL2 apoptosis regulator Homo sapiens 41-45 26722046-10 2016 In the present study, we identified the cellular functions and underlying molecular mechanisms of p53-dependent and AR-associated p21(CIP1) on apoptotic induction via direct binding to BCL2 in LNCaP cells treated with 6 muM MCS-C3. mcs-c3 224-230 BCL2 apoptosis regulator Homo sapiens 185-189 25405259-1 2016 In this study, the ability of methotrexate (MTX)-loaded stimuli-responsive novel silica nanocomposites (MSNs) (with mean diameter of +- 60 nm) in the induction of apoptosis, and change in the Bax/Bcl-2 mRNA levels, were investigated. Methotrexate 44-47 BCL2 apoptosis regulator Homo sapiens 196-201 26851786-6 2016 In the case of apoptotic molecules, the expression of Bax, Caspase 3 and Caspase 9 was increased significantly while the expression of anti-apoptotic molecule Bcl2 was decreased significantly in resveratrol groups with a dose-dependent manner. Resveratrol 195-206 BCL2 apoptosis regulator Homo sapiens 159-163 25405259-1 2016 In this study, the ability of methotrexate (MTX)-loaded stimuli-responsive novel silica nanocomposites (MSNs) (with mean diameter of +- 60 nm) in the induction of apoptosis, and change in the Bax/Bcl-2 mRNA levels, were investigated. Silicon Dioxide 81-87 BCL2 apoptosis regulator Homo sapiens 196-201 25405259-3 2016 MTX-loaded MSNs caused marked decrease in the percentage of viable cells, with a significant down-regulation in the level of expression of the anti-apoptotic gene (Bcl-2), and up-regulation in the apoptotic gene (Bax). Methotrexate 0-3 BCL2 apoptosis regulator Homo sapiens 164-169 27268647-8 2016 Bcl-2 expression decreased in all of the examined cells under silibinin treatment. Silybin 62-71 BCL2 apoptosis regulator Homo sapiens 0-5 27221858-3 2016 Expression of apoptosis-related proteins Bax and Bcl-2 of SP before and after the intervention was determined by Western-blotting. sp 58-60 BCL2 apoptosis regulator Homo sapiens 49-54 27034925-2 2016 The goal of this study was to develop a nanoparticle system for delivery of ASO G3139, which targets mRNA of antiapoptotic protein Bcl-2, to acute myeloid leukemia (AML) cells. Oligonucleotides, Antisense 76-79 BCL2 apoptosis regulator Homo sapiens 131-136 26561936-2 2016 Meanwhile, monoclonal antibodies (mAb198.3) against the FAT1 antigen and Bcl-2 siRNA were conjugated onto PEGylated Au-PEG-COOH nanoparticles. au-peg 116-122 BCL2 apoptosis regulator Homo sapiens 73-78 26561936-2 2016 Meanwhile, monoclonal antibodies (mAb198.3) against the FAT1 antigen and Bcl-2 siRNA were conjugated onto PEGylated Au-PEG-COOH nanoparticles. Carbonic Acid 123-127 BCL2 apoptosis regulator Homo sapiens 73-78 27069917-7 2016 Potassium ions induced apoptosis through regulating Bcl-2 family members and depolarized the mitochondrial membrane, especially for HepG2 cell. Potassium 0-9 BCL2 apoptosis regulator Homo sapiens 52-57 26246283-0 2016 Enhancement of paclitaxel-induced breast cancer cell death via the glycogen synthase kinase-3beta-mediated B-cell lymphoma 2 regulation. Paclitaxel 15-25 BCL2 apoptosis regulator Homo sapiens 107-124 27635399-11 2016 Moreover, Bcl-2 and Nrf2 mRNA expression were significantly higher than Bak and Bax in irradiated SKPs. skps 98-102 BCL2 apoptosis regulator Homo sapiens 10-15 27644631-6 2016 An increased level of caspase-3, apoptosis inducing factor (AIF), cleaved PARP-1 and decreased level of Bcl2 was observed in leukemia cells after 24h of curcumin treatment. Curcumin 153-161 BCL2 apoptosis regulator Homo sapiens 104-108 26246283-2 2016 Here, we show that B-cell lymphoma 2 (Bcl-2), an anti-apoptotic protein, is regulated by GSK-3beta and that GSK-3beta-mediated regulation of Bcl-2 is crucial for mitochondrial-dependent cell death in paclitaxel-stimulated cells. Paclitaxel 200-210 BCL2 apoptosis regulator Homo sapiens 19-36 26246283-2 2016 Here, we show that B-cell lymphoma 2 (Bcl-2), an anti-apoptotic protein, is regulated by GSK-3beta and that GSK-3beta-mediated regulation of Bcl-2 is crucial for mitochondrial-dependent cell death in paclitaxel-stimulated cells. Paclitaxel 200-210 BCL2 apoptosis regulator Homo sapiens 38-43 26246283-2 2016 Here, we show that B-cell lymphoma 2 (Bcl-2), an anti-apoptotic protein, is regulated by GSK-3beta and that GSK-3beta-mediated regulation of Bcl-2 is crucial for mitochondrial-dependent cell death in paclitaxel-stimulated cells. Paclitaxel 200-210 BCL2 apoptosis regulator Homo sapiens 141-146 26773176-11 2016 In paclitaxel-resistant cells, there was a significant increase in Six1 and BCL-2 mRNA levels (p = 0.0007) with a marked decrease in pro-apoptotic Bax mRNA expression level (p = 0.03); however, there was no significant change in P53 expression (p = 0.025). Paclitaxel 3-13 BCL2 apoptosis regulator Homo sapiens 76-81 26246283-3 2016 We demonstrate that MCF7 GSK-3beta siRNA cells are more sensitive to cell death than MCF7 GFP control cells and that in the absence of GSK-3beta, Bcl-2 levels are reduced, a result enhanced by paclitaxel. Paclitaxel 193-203 BCL2 apoptosis regulator Homo sapiens 146-151 26246283-4 2016 Paclitaxel-induced JNK (c-Jun N-terminal kinase) activation is critical for Bcl-2 modulation. Paclitaxel 0-10 BCL2 apoptosis regulator Homo sapiens 76-81 26246283-7 2016 Taken together, our data suggest that GSK-3beta-dependent regulation of Bcl-2 is crucial for mitochondria-dependent cell death in paclitaxel-mediated breast cancer therapy. Paclitaxel 130-140 BCL2 apoptosis regulator Homo sapiens 72-77 26575826-3 2016 BH3 mimetic antagonists, such as ABT-737 and its orally available derivative ABT-263 (navitoclax) have been developed to block the function of pro-survival BCL-2 family members. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 156-161 26511491-5 2016 FLLL12 strongly inhibited the expression of p-EGFR, EGFR, p-AKT, AKT, Bcl-2, and Bid and increased the expression of Bim. flll12 0-6 BCL2 apoptosis regulator Homo sapiens 70-75 26511491-6 2016 Overexpression of constitutively active AKT or Bcl-2 or ablation of Bim or Bid significantly inhibited FLLL12-induced apoptosis. flll12 103-109 BCL2 apoptosis regulator Homo sapiens 47-52 26511491-9 2016 Taken together, our results strongly suggest that FLLL12 is a potent curcumin analogue with more favorable pharmacokinetic properties that induces apoptosis of head and neck cancer cell lines by inhibition of survival proteins including EGFR, AKT, and Bcl-2 and increasing of the proapoptotic protein Bim. flll12 50-56 BCL2 apoptosis regulator Homo sapiens 252-257 26575826-3 2016 BH3 mimetic antagonists, such as ABT-737 and its orally available derivative ABT-263 (navitoclax) have been developed to block the function of pro-survival BCL-2 family members. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 33-36 BCL2 apoptosis regulator Homo sapiens 156-161 26575826-3 2016 BH3 mimetic antagonists, such as ABT-737 and its orally available derivative ABT-263 (navitoclax) have been developed to block the function of pro-survival BCL-2 family members. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 77-80 BCL2 apoptosis regulator Homo sapiens 156-161 26575826-5 2016 We have previously shown that the expression of Noxa, a BH3-only pro-apoptotic BCL-2 family protein, is a critical determinant of sensitivity to ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 145-148 BCL2 apoptosis regulator Homo sapiens 79-84 26841018-6 2016 Adding the Bcl-2 antagonist venetoclax could further intensify the treatment of CLL. venetoclax 28-38 BCL2 apoptosis regulator Homo sapiens 11-16 26909517-13 2016 Selenium inhibited the apoptosis of endothelial cells induced by homocysteine, through downregulating of Caspase-3 activity and expression of Caspase-3 and Bax, and by stimulating Bcl-2 expression. Selenium 0-8 BCL2 apoptosis regulator Homo sapiens 180-185 27889776-9 2016 The western blot analysis results showed that KLF6, Fas-L, Bax, P53 and caspase-3 protein expression was drastically increased in the CNE2 cells after treatment with 2 mmol/L CINN, whereas Bcl-2 and cyclin D1 protein expression was markedly reduced. cinnamic acid 175-179 BCL2 apoptosis regulator Homo sapiens 189-194 27226901-4 2016 We show that the chemotherapeutic drug cisplatin initiates an apoptotic pathway by phosphorylation of a pro-survival Bcl-2 family member, Bcl-xL, by cyclin-dependent kinase 2. Cisplatin 39-48 BCL2 apoptosis regulator Homo sapiens 117-122 27336467-4 2016 It was shown that high glucose significantly increased the protein expression of Bax and decreased Bcl-2 protein in HK-2 cells, which was reversed by CPU0213. Glucose 23-30 BCL2 apoptosis regulator Homo sapiens 99-104 27811212-3 2016 Priming can be measured via BH3 profiling, which uses BH3 peptides derived from the BH3 domain of pro-apoptotic BH3-only BCL-2 family members to provoke a response from viable mitochondria. BH 3 28-31 BCL2 apoptosis regulator Homo sapiens 121-126 27855372-6 2016 Furthermore, TH-39 also induced cell apoptosis, which was associated with activation of caspase-3, down-regulation of Bcl-2 expression and up-regulation of Bax. th-39 13-18 BCL2 apoptosis regulator Homo sapiens 118-123 27811212-4 2016 BH3 profiling can be performed on tumor cells and can identify mechanisms a cell uses to evade apoptosis and anti-apoptotic dependency to the anti-apoptotic BCL-2 family members. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 157-162 26708201-8 2016 Additionally, inhibited autophagy via chloroquine (CQ) markedly enhanced the apoptosis induced by TG, which was linked to the Bcl-2 family. Chloroquine 38-49 BCL2 apoptosis regulator Homo sapiens 126-131 27095936-0 2016 Reduced BCL2 and CCND1 mRNA expression in human cervical cancer HeLa cells treated with a combination of everolimus and paclitaxel. Everolimus 105-115 BCL2 apoptosis regulator Homo sapiens 8-12 27095936-0 2016 Reduced BCL2 and CCND1 mRNA expression in human cervical cancer HeLa cells treated with a combination of everolimus and paclitaxel. Paclitaxel 120-130 BCL2 apoptosis regulator Homo sapiens 8-12 27095936-3 2016 In this study, we aimed to investigate the effects of everolimus, gemcitabine, and paclitaxel in terms of cell viability and mRNA expression levels of GRP78, CCND1, CASP2, and BCL2 genes. Everolimus 54-64 BCL2 apoptosis regulator Homo sapiens 176-180 27095936-3 2016 In this study, we aimed to investigate the effects of everolimus, gemcitabine, and paclitaxel in terms of cell viability and mRNA expression levels of GRP78, CCND1, CASP2, and BCL2 genes. gemcitabine 66-77 BCL2 apoptosis regulator Homo sapiens 176-180 27095936-3 2016 In this study, we aimed to investigate the effects of everolimus, gemcitabine, and paclitaxel in terms of cell viability and mRNA expression levels of GRP78, CCND1, CASP2, and BCL2 genes. Paclitaxel 83-93 BCL2 apoptosis regulator Homo sapiens 176-180 27150132-0 2016 Bcl-2 Family Proteins Regulate Apoptosis and Epithelial to Mesenchymal Transition by Calcium Signals. Calcium 85-92 BCL2 apoptosis regulator Homo sapiens 0-5 27095936-11 2016 However, combined treatment of everolimus and paclitaxel significantly reduced BCL2 and CCND1 mRNA expression (p < 0.05). Everolimus 31-41 BCL2 apoptosis regulator Homo sapiens 79-83 27095936-11 2016 However, combined treatment of everolimus and paclitaxel significantly reduced BCL2 and CCND1 mRNA expression (p < 0.05). Paclitaxel 46-56 BCL2 apoptosis regulator Homo sapiens 79-83 27095936-13 2016 CONCLUSIONS: Down-regulation of CCND1 and BCL2 expression may be an important mechanism by which everolimus increases the therapeutic window of paclitaxel in cervical cancers. Everolimus 97-107 BCL2 apoptosis regulator Homo sapiens 42-46 27095936-13 2016 CONCLUSIONS: Down-regulation of CCND1 and BCL2 expression may be an important mechanism by which everolimus increases the therapeutic window of paclitaxel in cervical cancers. Paclitaxel 144-154 BCL2 apoptosis regulator Homo sapiens 42-46 25059546-10 2016 Andrographolide caused a dose-dependent increase in Cleaved-Caspase3/Bax protein expression and a decrease in Bcl-2/NF-kappab expression. andrographolide 0-15 BCL2 apoptosis regulator Homo sapiens 110-115 26708201-8 2016 Additionally, inhibited autophagy via chloroquine (CQ) markedly enhanced the apoptosis induced by TG, which was linked to the Bcl-2 family. Chloroquine 51-53 BCL2 apoptosis regulator Homo sapiens 126-131 26708201-8 2016 Additionally, inhibited autophagy via chloroquine (CQ) markedly enhanced the apoptosis induced by TG, which was linked to the Bcl-2 family. Thapsigargin 98-100 BCL2 apoptosis regulator Homo sapiens 126-131 26483208-6 2016 The immunoblot analysis indicated that TVN efficiently regulated the cleavage of caspase family, p53, Bax and Bcl-2, all mediated by SIRT1. N-{(2R)-4-(methylamino)-4-oxo-2-[4-(phosphonooxy)benzyl]butanoyl}-L-valyl-L-aspartamide 39-42 BCL2 apoptosis regulator Homo sapiens 110-115 26521020-7 2016 Further, 0.45 and 4.5 muM of violacein increased apoptotic genes, such as Bax, p53, caspase 3, Fas, FADD and markedly reduced Bcl-2 and MDM2 expression levels to two fold when compared to control. violacein 29-38 BCL2 apoptosis regulator Homo sapiens 126-131 27168690-12 2016 Thus, it is possible to conclude that 1-(3,4,5-trihydroxyphenyl)-dodecylbenzoate induces apoptosis by inhibiting the antiapoptotic protein Bcl-2 and by increasing the release of AIF, Bax and p53. 1-(3,4,5-trihydroxyphenyl)-dodecylbenzoate 38-80 BCL2 apoptosis regulator Homo sapiens 139-144 26612919-0 2016 Sulforaphene promotes Bax/Bcl2, MAPK-dependent human gastric cancer AGS cells apoptosis and inhibits migration via EGFR, p-ERK1/2 down-regulation. sulphoraphene 0-12 BCL2 apoptosis regulator Homo sapiens 26-30 26654708-8 2016 Echinomycin inhibited cell proliferation and induced apoptotic cell death of the eESCs, and significantly inhibited expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL. Echinomycin 0-11 BCL2 apoptosis regulator Homo sapiens 158-163 26654708-9 2016 Echinomycin inhibits VEGF production and induces apoptosis of eESCs by suppression of Bcl-2 and Bcl-xL. Echinomycin 0-11 BCL2 apoptosis regulator Homo sapiens 86-91 26575528-12 2016 In KKU-100 cells, growth inhibition was accompanied by upregulation of p53 and p21 and downregulation of CDK4 and Bcl-2 due to exposure to cisplatin, SAHA and TSA alone or in combination. Cisplatin 139-148 BCL2 apoptosis regulator Homo sapiens 114-119 26573558-9 2016 However, treatment with resveratrol (12.5 microM) for 48 h significantly alleviated ioxitalamate (30 mg/ml)-induced cytotoxicity, by reducing cytosolic DNA fragmentation, increasing the expression of the anti-apoptotic protein, Bcl-2 (B-cell lymphoma 2), and survivin, activating caspase-3, preventing autophagic death and suppressing the production of reactive oxygen species (ROS). Resveratrol 24-35 BCL2 apoptosis regulator Homo sapiens 228-233 26573558-9 2016 However, treatment with resveratrol (12.5 microM) for 48 h significantly alleviated ioxitalamate (30 mg/ml)-induced cytotoxicity, by reducing cytosolic DNA fragmentation, increasing the expression of the anti-apoptotic protein, Bcl-2 (B-cell lymphoma 2), and survivin, activating caspase-3, preventing autophagic death and suppressing the production of reactive oxygen species (ROS). Resveratrol 24-35 BCL2 apoptosis regulator Homo sapiens 235-252 26573558-9 2016 However, treatment with resveratrol (12.5 microM) for 48 h significantly alleviated ioxitalamate (30 mg/ml)-induced cytotoxicity, by reducing cytosolic DNA fragmentation, increasing the expression of the anti-apoptotic protein, Bcl-2 (B-cell lymphoma 2), and survivin, activating caspase-3, preventing autophagic death and suppressing the production of reactive oxygen species (ROS). ioxitalamic acid 84-96 BCL2 apoptosis regulator Homo sapiens 228-233 26573558-9 2016 However, treatment with resveratrol (12.5 microM) for 48 h significantly alleviated ioxitalamate (30 mg/ml)-induced cytotoxicity, by reducing cytosolic DNA fragmentation, increasing the expression of the anti-apoptotic protein, Bcl-2 (B-cell lymphoma 2), and survivin, activating caspase-3, preventing autophagic death and suppressing the production of reactive oxygen species (ROS). ioxitalamic acid 84-96 BCL2 apoptosis regulator Homo sapiens 235-252 26592196-5 2016 Higher levels of B-cell lymphoma-2 (Bcl-2) and tissue factor (TF) but lower apoptotic rate were found in hippocampus of CPZ-treated schizophrenic patients compared with non-antipsychotic treated controls. Chlorpromazine 120-123 BCL2 apoptosis regulator Homo sapiens 17-34 26592196-5 2016 Higher levels of B-cell lymphoma-2 (Bcl-2) and tissue factor (TF) but lower apoptotic rate were found in hippocampus of CPZ-treated schizophrenic patients compared with non-antipsychotic treated controls. Chlorpromazine 120-123 BCL2 apoptosis regulator Homo sapiens 36-41 26648023-4 2016 Treatment of Caki cells with GA decreased the levels of antiapoptotic proteins, such as Bcl-2 and XIAP in a dose-dependent manner. gambogic acid 29-31 BCL2 apoptosis regulator Homo sapiens 88-93 26575528-12 2016 In KKU-100 cells, growth inhibition was accompanied by upregulation of p53 and p21 and downregulation of CDK4 and Bcl-2 due to exposure to cisplatin, SAHA and TSA alone or in combination. Vorinostat 150-154 BCL2 apoptosis regulator Homo sapiens 114-119 26575528-12 2016 In KKU-100 cells, growth inhibition was accompanied by upregulation of p53 and p21 and downregulation of CDK4 and Bcl-2 due to exposure to cisplatin, SAHA and TSA alone or in combination. trichostatin A 159-162 BCL2 apoptosis regulator Homo sapiens 114-119 27523007-0 2016 MYC/BCL2 Double-hit Lymphoma in a Patient with Rheumatoid Arthritis Associated with Methotrexate Treatment. Methotrexate 84-96 BCL2 apoptosis regulator Homo sapiens 4-8 26966728-10 2016 CONCLUSIONS: The BCL2, MCM7, and CCNE1 genes might play distinctive roles in cisplatin resistance in BC. Cisplatin 77-86 BCL2 apoptosis regulator Homo sapiens 17-21 27523007-2 2016 We herein describe the case of a 71-year-old woman with rheumatoid arthritis who developed MYC/BCL2 double-hit lymphoma associated with MTX therapy. Methotrexate 136-139 BCL2 apoptosis regulator Homo sapiens 95-99 26966728-0 2016 Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines. Cisplatin 57-66 BCL2 apoptosis regulator Homo sapiens 26-30 26966728-0 2016 Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines. Cisplatin 133-142 BCL2 apoptosis regulator Homo sapiens 26-30 27061547-11 2016 We also observed a dose-dependent increase in Bax and Bad levels and a dose-dependent decrease in Bcl-2 and Bcl-xl expression levels following myricetin treatment. myricetin 143-152 BCL2 apoptosis regulator Homo sapiens 98-103 26966728-0 2016 Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines. Cisplatin 133-142 BCL2 apoptosis regulator Homo sapiens 26-30 26966728-9 2016 Western blot analyses also confirmed the upregulation of BCL2, MCM7, and CCNE1 at the protein level, indicating their crucial association with cisplatin resistance. Cisplatin 143-152 BCL2 apoptosis regulator Homo sapiens 57-61 26836165-5 2016 In the present study, we showed that Aluminum maltolate (Al-malt), a lipophilic Al complex which is a common component of human diet with the ability to facilitate the entry of Al into the brain, induced apoptosis in human neuroblastoma SH-SY5Y cells, along with downregulation of miR-19a/miR-19b, upregulation of miR-19-targeted PTEN, and alterations of its downstream apoptosis related proteins including AKT, p53, Bax, and Bcl-2. aluminum maltolate 37-55 BCL2 apoptosis regulator Homo sapiens 426-431 26836165-5 2016 In the present study, we showed that Aluminum maltolate (Al-malt), a lipophilic Al complex which is a common component of human diet with the ability to facilitate the entry of Al into the brain, induced apoptosis in human neuroblastoma SH-SY5Y cells, along with downregulation of miR-19a/miR-19b, upregulation of miR-19-targeted PTEN, and alterations of its downstream apoptosis related proteins including AKT, p53, Bax, and Bcl-2. Aluminum 37-39 BCL2 apoptosis regulator Homo sapiens 426-431 26836165-5 2016 In the present study, we showed that Aluminum maltolate (Al-malt), a lipophilic Al complex which is a common component of human diet with the ability to facilitate the entry of Al into the brain, induced apoptosis in human neuroblastoma SH-SY5Y cells, along with downregulation of miR-19a/miR-19b, upregulation of miR-19-targeted PTEN, and alterations of its downstream apoptosis related proteins including AKT, p53, Bax, and Bcl-2. Aluminum 57-59 BCL2 apoptosis regulator Homo sapiens 426-431 26619119-7 2016 Accordingly, SLAMF1-silenced cells or SLAMF1(lo) primary CLL cells were resistant to autophagy-activating therapeutic agents, such as fludarabine and the BCL2 homology domain 3 mimetic ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 185-188 BCL2 apoptosis regulator Homo sapiens 154-158 26937364-9 2016 The immunolocalization of Bcl-2 protein was performed using the labeled streptavidin biotin method. Biotin 85-91 BCL2 apoptosis regulator Homo sapiens 26-31 26641257-0 2016 Differential Expression of Bcl-2 Family Proteins Determines the Sensitivity of Human Follicular Lymphoma Cells to Dexamethasone-mediated and Anti-BCR-mediated Apoptosis. Dexamethasone 114-127 BCL2 apoptosis regulator Homo sapiens 27-32 26641257-9 2016 It is interesting to note that, a Bcl-2-specific inhibitor, ABT-199, sensitized HF28 cells to Dex-induced or anti-BCR-induced apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 60-63 BCL2 apoptosis regulator Homo sapiens 34-39 26641257-9 2016 It is interesting to note that, a Bcl-2-specific inhibitor, ABT-199, sensitized HF28 cells to Dex-induced or anti-BCR-induced apoptosis. Dexamethasone 94-97 BCL2 apoptosis regulator Homo sapiens 34-39 26641257-11 2016 In conclusion, these data show that the expression levels of Bcl-2 family proteins may serve to predict tumor response to BH3 mimetics and the sensitivity of FL cells to Dex-induced and anti-BCR-induced apoptosis. BH 3 122-125 BCL2 apoptosis regulator Homo sapiens 61-66 26641257-11 2016 In conclusion, these data show that the expression levels of Bcl-2 family proteins may serve to predict tumor response to BH3 mimetics and the sensitivity of FL cells to Dex-induced and anti-BCR-induced apoptosis. Dexamethasone 170-173 BCL2 apoptosis regulator Homo sapiens 61-66 26682233-8 2016 Administration of CoQ10 ameliorated high glucose-induced EPC apoptosis, including downregulation of caspase 3, upregulation of Bcl-2, and increase in mitochondrial membrane potential. Glucose 41-48 BCL2 apoptosis regulator Homo sapiens 127-132 26733551-6 2016 Leukapheresis followed by partial CTC enrichment allowed for the development of a differential high-throughput drug screen and demonstrated sensitivity to investigational BH3-mimetic inhibitors of BCL-2 that could not be tested in the patient because requests to the pharmaceutical sponsors were denied. BH 3 171-174 BCL2 apoptosis regulator Homo sapiens 197-202 26265185-4 2016 BCL2 expression was downregulated after AUY922 treatment, and although this effect was necessary for AUY922-induced apoptosis, it was not sufficient because many T-ALL cell lines were resistant to ABT-199, a specific inhibitor of BCL2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 197-200 BCL2 apoptosis regulator Homo sapiens 0-4 26153654-3 2016 To overcome the acquired apoptotic resistance in high-risk MDS, we investigated the induction of apoptosis by inhibition of pro-survival BCL-2 proteins using the BCL-2/-XL/-W inhibitor ABT-737 or the BCL-2-selective inhibitor ABT-199. venetoclax 226-233 BCL2 apoptosis regulator Homo sapiens 137-142 26265185-6 2016 Thus, the potent cytotoxicity of AUY922 involves the synergistic combination of BCL2 downregulation coupled with upregulation of the proapoptotic proteins BIM and BAD. 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide 33-39 BCL2 apoptosis regulator Homo sapiens 80-84 26648158-4 2016 Bufalin-induced apoptosis was accompanied with a significant reduction of the mitochondrial membrane potential, release of mitochondrial cytochrome c into the cytosol, activation of caspase-3, caspase-9 and poly(adenosine diphosphate ribose) polymerase, as well as downregulation of B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein. bufalin 0-7 BCL2 apoptosis regulator Homo sapiens 283-300 26707825-6 2016 The treated keratinocytes show a dose-dependent growth reduction to DHT and T. DHT increases the expression of TR3 in keratinocytes, associated with a concomitant increase of BAD and decrease of Bcl-2 expression. Dihydrotestosterone 79-82 BCL2 apoptosis regulator Homo sapiens 195-200 26369531-6 2016 However, knockout of beta-catenin or treatment with DKK1 facilitated the H2O2-induced decreases in viability, mitochondrial membrane potential, and Bcl-2 induction. Hydrogen Peroxide 73-77 BCL2 apoptosis regulator Homo sapiens 148-153 26572916-6 2016 Propofol was also observed to prevent apoptotic signals by reducing the ratio of Bcl-2-associated X protein to B-cell lymphoma 2, reducing the expression level of cleaved caspase-3 and attenuating cytochrome c release. Propofol 0-8 BCL2 apoptosis regulator Homo sapiens 81-86 26718738-12 2016 In addition, in the cells targeted with FEN1-siRNA and exposed to CDDP, the levels of Bcl-2-associated X protein were significantly increased, whereas the expression levels of Bcl-2 and Bcl-extra large were effectively decreased, compared with the cells exposed to negative control-siRNA and CDDP. Cisplatin 66-70 BCL2 apoptosis regulator Homo sapiens 86-91 26718738-12 2016 In addition, in the cells targeted with FEN1-siRNA and exposed to CDDP, the levels of Bcl-2-associated X protein were significantly increased, whereas the expression levels of Bcl-2 and Bcl-extra large were effectively decreased, compared with the cells exposed to negative control-siRNA and CDDP. Cisplatin 66-70 BCL2 apoptosis regulator Homo sapiens 176-181 26648402-8 2016 In addition, MG-132 inhibited the protein expression of the anti-apoptotic protein, B-cell lymphoma (Bcl)-2, whereas the expression levels of Bcl-2-associated X protein and caspase-3 were upregulated. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 13-19 BCL2 apoptosis regulator Homo sapiens 84-107 26648539-5 2016 The results showed that shHSP27 and quercetin synergistically inhibited U937 cell proliferation and induced apoptosis by decreasing the Bcl2-to-Bax ratio. Quercetin 36-45 BCL2 apoptosis regulator Homo sapiens 136-140 26648158-4 2016 Bufalin-induced apoptosis was accompanied with a significant reduction of the mitochondrial membrane potential, release of mitochondrial cytochrome c into the cytosol, activation of caspase-3, caspase-9 and poly(adenosine diphosphate ribose) polymerase, as well as downregulation of B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein. bufalin 0-7 BCL2 apoptosis regulator Homo sapiens 302-307 26648158-4 2016 Bufalin-induced apoptosis was accompanied with a significant reduction of the mitochondrial membrane potential, release of mitochondrial cytochrome c into the cytosol, activation of caspase-3, caspase-9 and poly(adenosine diphosphate ribose) polymerase, as well as downregulation of B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein. bufalin 0-7 BCL2 apoptosis regulator Homo sapiens 309-314 26774143-8 2016 Western blot analysis showed that after being treated with fengycin, Bax, Caspase-3, and Caspase-6 expressions were increased, however, Bcl-2, and CDK4/cyclin D1 expressions were decreased (P<0.05).Our study suggested that fengycin may play certain inhibit roles in the development and progression of colon cancer through involving in the cell apoptosis and cell cycle processes by targeting the Bax/Bcl-2 pathway. fengycin 59-67 BCL2 apoptosis regulator Homo sapiens 136-141 26774143-8 2016 Western blot analysis showed that after being treated with fengycin, Bax, Caspase-3, and Caspase-6 expressions were increased, however, Bcl-2, and CDK4/cyclin D1 expressions were decreased (P<0.05).Our study suggested that fengycin may play certain inhibit roles in the development and progression of colon cancer through involving in the cell apoptosis and cell cycle processes by targeting the Bax/Bcl-2 pathway. fengycin 59-67 BCL2 apoptosis regulator Homo sapiens 403-408 27957345-6 2016 Results of western blot demonstrated that mechanisms underlying the toxicity of glutamate and the protection of edaravone were related to the PI3K pathway and Bcl-2 protein family. Glutamic Acid 80-89 BCL2 apoptosis regulator Homo sapiens 159-164 27468876-8 2016 Further studies indicated that noscapine induced antive-capsase-3, cleavage PARP, and decreased the ratio of Bcl-2/Bax. Noscapine 31-40 BCL2 apoptosis regulator Homo sapiens 109-114 27565326-10 2016 The ratios of Bax/Bcl-2 in cells exposed to both oxaliplatin and rapamycin were significantly increased compared to those in cells subjected to oxaliplatin or rapamycin alone treatment. Oxaliplatin 49-60 BCL2 apoptosis regulator Homo sapiens 18-23 27565326-10 2016 The ratios of Bax/Bcl-2 in cells exposed to both oxaliplatin and rapamycin were significantly increased compared to those in cells subjected to oxaliplatin or rapamycin alone treatment. Sirolimus 65-74 BCL2 apoptosis regulator Homo sapiens 18-23 27957345-6 2016 Results of western blot demonstrated that mechanisms underlying the toxicity of glutamate and the protection of edaravone were related to the PI3K pathway and Bcl-2 protein family. Edaravone 112-121 BCL2 apoptosis regulator Homo sapiens 159-164 26943884-6 2016 It was found that in all the cell lines, quercetin induced inhibition of the metabolic activity and cell death by apoptosis, followed by increase in BAX/BCL-2 ratio. Quercetin 41-50 BCL2 apoptosis regulator Homo sapiens 153-158 27178823-2 2016 Although ABT-737, as a Bcl-2/Bcl-xL inhibitor, has recently emerged as a novel cancer therapeutic reagent, apoptosis induced by ABT-737 is often blocked in several types of cancer cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 9-12 BCL2 apoptosis regulator Homo sapiens 23-28 26870290-0 2016 Mangiferin inhibition of proliferation and induction of apoptosis in human prostate cancer cells is correlated with downregulation of B-cell lymphoma-2 and upregulation of microRNA-182. mangiferin 0-10 BCL2 apoptosis regulator Homo sapiens 134-151 26870201-0 2016 Differential effect of psoralidin in enhancing apoptosis of colon cancer cells via nuclear factor-kappaB and B-cell lymphoma-2/B-cell lymphoma-2-associated X protein signaling pathways. psoralidin 23-33 BCL2 apoptosis regulator Homo sapiens 109-126 26870201-0 2016 Differential effect of psoralidin in enhancing apoptosis of colon cancer cells via nuclear factor-kappaB and B-cell lymphoma-2/B-cell lymphoma-2-associated X protein signaling pathways. psoralidin 23-33 BCL2 apoptosis regulator Homo sapiens 127-144 26870201-8 2016 Bcl-2 inhibitor ABT-737 was added to SW480 cells and the subsequent effects and mechanism of action of psoralidin on SW480 colon cancer cells was studied. ABT-737 16-23 BCL2 apoptosis regulator Homo sapiens 0-5 26870201-12 2016 Furthermore, psoralidin was able to reduce Bcl-2 protein expression and increase Bax protein expression in SW480 cells. psoralidin 13-23 BCL2 apoptosis regulator Homo sapiens 43-48 27178823-2 2016 Although ABT-737, as a Bcl-2/Bcl-xL inhibitor, has recently emerged as a novel cancer therapeutic reagent, apoptosis induced by ABT-737 is often blocked in several types of cancer cells. ABT-737 9-16 BCL2 apoptosis regulator Homo sapiens 23-28 26870201-13 2016 Notably, Bcl-2 inhibitor was observed to enhance the effects of psoralidin on SW480 cells. psoralidin 64-74 BCL2 apoptosis regulator Homo sapiens 9-14 26870201-14 2016 The results of the present study suggest that psoralidin may be a candidate drug for the treatment of colon cancer by inhibition of the NF-kappaB and Bcl-2/Bax signaling pathways. psoralidin 46-56 BCL2 apoptosis regulator Homo sapiens 150-155 26682012-3 2016 In the present study, we used confocal-fluorescence microscopy, flow cytometry analysis, Hoechst staining, H2DCFDA staining, transmission electron microscopy, and immunoblot analysis; the results revealed that slightly higher concentrations of D-limonene (125-1800 muM) reduced the H2O2-induced ROS generation and inhibited the H2O2-induced caspase-3 and caspase-9 activation and decreased the Bcl-2/Bax ratio. Limonene 244-254 BCL2 apoptosis regulator Homo sapiens 394-399 27889784-5 2016 Additionally, the observation of high expression levels of the anti-apoptotic mitochondrial protein Bcl-2 in CLL has led to the development of venetoclax, a BH3 mimetic compound that inhibits Bcl-2 and has shown high efficacy in CLL. venetoclax 143-153 BCL2 apoptosis regulator Homo sapiens 100-105 27889784-5 2016 Additionally, the observation of high expression levels of the anti-apoptotic mitochondrial protein Bcl-2 in CLL has led to the development of venetoclax, a BH3 mimetic compound that inhibits Bcl-2 and has shown high efficacy in CLL. venetoclax 143-153 BCL2 apoptosis regulator Homo sapiens 192-197 27889784-5 2016 Additionally, the observation of high expression levels of the anti-apoptotic mitochondrial protein Bcl-2 in CLL has led to the development of venetoclax, a BH3 mimetic compound that inhibits Bcl-2 and has shown high efficacy in CLL. BH 3 157-160 BCL2 apoptosis regulator Homo sapiens 100-105 26697130-4 2016 MCF-7 cells were treated with different concentrations of TAM and/or CAPE for 48 h. This novel combination exerted synergistic cytotoxic effects against MCF-7 cells via induction of apoptotic machinery with activation of caspases and DNA fragmentation, along with downregulation of Bcl-2 and Beclin 1 expression levels. Tamoxifen 58-61 BCL2 apoptosis regulator Homo sapiens 282-287 26788243-6 2016 Furthermore, our results demonstrated that green tea polyphenols restored the dysfunction of mitochondrial pro- or antiapoptotic proteins Bax, Bcl-2, and caspase-3 caused by glutamate. Polyphenols 53-64 BCL2 apoptosis regulator Homo sapiens 143-148 26788243-6 2016 Furthermore, our results demonstrated that green tea polyphenols restored the dysfunction of mitochondrial pro- or antiapoptotic proteins Bax, Bcl-2, and caspase-3 caused by glutamate. Glutamic Acid 174-183 BCL2 apoptosis regulator Homo sapiens 143-148 26697130-4 2016 MCF-7 cells were treated with different concentrations of TAM and/or CAPE for 48 h. This novel combination exerted synergistic cytotoxic effects against MCF-7 cells via induction of apoptotic machinery with activation of caspases and DNA fragmentation, along with downregulation of Bcl-2 and Beclin 1 expression levels. caffeic acid phenethyl ester 69-73 BCL2 apoptosis regulator Homo sapiens 282-287 26881030-5 2016 TUNEL, fluorometric assays, and Western blotting showed that OSI upregulated the apoptosis ratio, the activity of caspase-3 and the level of proapoptotic protein Bax and decreased the level of antiapoptotic protein Bcl-2. silicon monoxide 61-64 BCL2 apoptosis regulator Homo sapiens 215-220 26839633-8 2016 Apoptosis-resistant Bcl-2-overexpressing cells even can afford higher TRPM2 activity without risking a hazardous Ca(2+)-overload-induced mitochondrial superoxide anion formation. Superoxides 151-167 BCL2 apoptosis regulator Homo sapiens 20-25 27057270-0 2016 Propofol Suppressed Hypoxia/Reoxygenation-Induced Apoptosis in HBVSMC by Regulation of the Expression of Bcl-2, Bax, Caspase3, Kir6.1, and p-JNK. Propofol 0-8 BCL2 apoptosis regulator Homo sapiens 105-110 27057270-13 2016 These findings suggested that the protective effect of propofol against H/R injury in the HBVSMC was through the inhibition of apoptosis by inducing the expression of Bcl-2 and p-mTOR as well as inhibiting the expression levels of Bax, Caspase3, Kir6.1, and p-JNK. Propofol 55-63 BCL2 apoptosis regulator Homo sapiens 167-172 26720343-3 2015 SCLC cells often overexpress Bcl-2, which protects cells from apoptosis both by sequestering pro-apoptotic family members and by modulating inositol 1,4,5-trisphosphate receptor (IP3R)-mediated calcium signaling. Calcium 194-201 BCL2 apoptosis regulator Homo sapiens 29-34 27803763-4 2016 miR-21 mimics efficiently reduced H2O2-induced apoptosis in c-kit+ CSC, as evidenced by the downregulation of the proapoptosis proteins caspase-3 and Bax and upregulation of the antiapoptotic Bcl-2. Hydrogen Peroxide 34-38 BCL2 apoptosis regulator Homo sapiens 192-197 26527395-9 2016 DBE (50 microg/mL) also significantly decreased the ratio of Bax to Bcl-2 expression, inhibited the active caspase-3 expression. Ethylene Dibromide 0-3 BCL2 apoptosis regulator Homo sapiens 68-73 26527395-12 2016 DBE attenuated cell apoptosis and cell cycle arrest through the decrease of Bax/Bcl-2 ratio and the reduction of active caspase-3 expression. Ethylene Dibromide 0-3 BCL2 apoptosis regulator Homo sapiens 80-85 26460503-4 2016 Expression levels of Bcl-2 family proteins were quantified by immunohistochemistry of fixed tonsillar sections and Western blot analyzes of TMCs lysates. trimethylsilyl chloride 140-144 BCL2 apoptosis regulator Homo sapiens 21-26 26460503-6 2016 RESULTS: Compared to TMCs from the control group, TMCs from the IgAN group demonstrated lower rates of apoptosis, higher expression levels of the anti-apoptosis proteins Bcl-2 and Bcl-xL, and lower expression levels of the pro-apoptosis protein Bax. trimethylsilyl chloride 50-54 BCL2 apoptosis regulator Homo sapiens 170-175 26460503-9 2016 CONCLUSION: TMCs from IgAN patients may be in a state of inhibited apoptosis mediated by Bcl-2 family proteins, which may be reversed by TP treatment. trimethylsilyl chloride 12-16 BCL2 apoptosis regulator Homo sapiens 89-94 26446980-5 2016 Mechanistic investigations revealed that ML-7 and quinocetone act in concert to trigger the cleavage of caspase-8 as well as Bax/Bcl-2 ratio up-regulation and subsequent cleavage of Bid, capsases-9 and -3. quinocetone 50-61 BCL2 apoptosis regulator Homo sapiens 129-134 26209294-11 2016 The results showed that salinomycin induced apoptosis and G2/M arrest, increased Bax and cleaved Caspase3, decreased Bcl-2 expression, and increased the formation of gamma-H2AX nuclear foci. salinomycin 24-35 BCL2 apoptosis regulator Homo sapiens 117-122 26649137-5 2016 In this study, we investigated the cytotoxic effects of acetaldehyde in SH-SY5Y cells and found that acetaldehyde induced apoptosis of SH-SY5Y cells by downregulating the expression of antiapoptotic Bcl-2 and Bcl-xL and upregulating the expression of proapoptotic Bax. Acetaldehyde 101-113 BCL2 apoptosis regulator Homo sapiens 199-204 27062783-5 2016 RESULTS: Platinum-resistant patients had significantly higher levels of expression of miR-130a and BCL-2, and lower level of PTEN than platinum-sensitive patients (P < 0.05). Platinum 9-17 BCL2 apoptosis regulator Homo sapiens 99-104 27062783-7 2016 CONCLUSION: MiR-130a may mediate the generation of platinum resistance in epithelial ovarian cancer through inhibiting PTEN to activate PI3K/AKT signaling pathway and increasing BCL-2 to inhibit tumor cell apoptosis. Platinum 51-59 BCL2 apoptosis regulator Homo sapiens 178-183 26805734-7 2016 Down-regulated of endogenous TRIM24 and ShTRIM24 with Gifitinib could also reduce the protein related apoptosis, such as p-BAD and Bcl-2, and the protein PIK3CA related AKT signal path in A549 cell. gifitinib 54-63 BCL2 apoptosis regulator Homo sapiens 131-136 26720343-5 2015 Here we report for the first time that Bcl-2-IP3 receptor disruptor-2 (BIRD-2), a decoy peptide that binds to the BH4 domain of Bcl-2 and prevents Bcl-2 interaction with IP3Rs, induces cell death in a wide range of SCLC lines, including ABT-263-resistant lines. sapropterin 114-117 BCL2 apoptosis regulator Homo sapiens 39-44 26720343-5 2015 Here we report for the first time that Bcl-2-IP3 receptor disruptor-2 (BIRD-2), a decoy peptide that binds to the BH4 domain of Bcl-2 and prevents Bcl-2 interaction with IP3Rs, induces cell death in a wide range of SCLC lines, including ABT-263-resistant lines. sapropterin 114-117 BCL2 apoptosis regulator Homo sapiens 128-133 26720343-5 2015 Here we report for the first time that Bcl-2-IP3 receptor disruptor-2 (BIRD-2), a decoy peptide that binds to the BH4 domain of Bcl-2 and prevents Bcl-2 interaction with IP3Rs, induces cell death in a wide range of SCLC lines, including ABT-263-resistant lines. sapropterin 114-117 BCL2 apoptosis regulator Homo sapiens 128-133 26720343-5 2015 Here we report for the first time that Bcl-2-IP3 receptor disruptor-2 (BIRD-2), a decoy peptide that binds to the BH4 domain of Bcl-2 and prevents Bcl-2 interaction with IP3Rs, induces cell death in a wide range of SCLC lines, including ABT-263-resistant lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 237-240 BCL2 apoptosis regulator Homo sapiens 39-44 26720343-5 2015 Here we report for the first time that Bcl-2-IP3 receptor disruptor-2 (BIRD-2), a decoy peptide that binds to the BH4 domain of Bcl-2 and prevents Bcl-2 interaction with IP3Rs, induces cell death in a wide range of SCLC lines, including ABT-263-resistant lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 237-240 BCL2 apoptosis regulator Homo sapiens 128-133 26720343-5 2015 Here we report for the first time that Bcl-2-IP3 receptor disruptor-2 (BIRD-2), a decoy peptide that binds to the BH4 domain of Bcl-2 and prevents Bcl-2 interaction with IP3Rs, induces cell death in a wide range of SCLC lines, including ABT-263-resistant lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 237-240 BCL2 apoptosis regulator Homo sapiens 128-133 26720343-7 2015 By targeting different regions of the Bcl-2 protein and different mechanisms of action, BIRD-2 and ABT-263 induce cell death synergistically. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 99-102 BCL2 apoptosis regulator Homo sapiens 38-43 26676786-6 2015 Treatment with the Bcl-2 antagonist ABT-199 only reduced the prosurvival effects of HCMV in target monocytes beginning at 48 hpi, suggesting that Mcl-1 controls survival prior to 48 hpi, while Bcl-2 promotes survival after 48 hpi. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 36-39 BCL2 apoptosis regulator Homo sapiens 19-24 26711339-0 2015 MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 137-140 BCL2 apoptosis regulator Homo sapiens 54-59 26711339-0 2015 MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 137-140 BCL2 apoptosis regulator Homo sapiens 111-116 26711339-4 2015 In this study, we show that t(4;11) patient cells express high levels of BCL-2 and are highly sensitive to treatment with the BCL-2-specific BH3 mimetic ABT-199. BH 3 141-144 BCL2 apoptosis regulator Homo sapiens 73-78 26711339-4 2015 In this study, we show that t(4;11) patient cells express high levels of BCL-2 and are highly sensitive to treatment with the BCL-2-specific BH3 mimetic ABT-199. BH 3 141-144 BCL2 apoptosis regulator Homo sapiens 126-131 26363202-2 2015 The present study revealed that nanomolar BPA significantly promoted the proliferation of both estrogen receptor (ER) positive (MCF-7) and negative (SkBr3) breast cancer cells, which was confirmed by up regulation of proliferating cell nuclear antigen (PCNA) and Bcl-2. bisphenol A 42-45 BCL2 apoptosis regulator Homo sapiens 263-268 26673922-7 2015 Sulindac sulfide also decreased expression of several Sp-regulated genes that are critical for cancer cell survival, proliferation and angiogenesis and these include survivin, bcl-2, epidermal growth factor receptor (EGFR), cyclin D1, p65 subunit of NFkappaB and vascular endothelial growth factor (VEGF). sulindac sulfide 0-16 BCL2 apoptosis regulator Homo sapiens 176-181 26556865-4 2015 In this process, PPARalpha/C102 was critical for PPARalpha binding to BH3 domain of Bcl2, subsequently, PPARalpha transferred K48-linked polyubiquitin to lysine-22 site of Bcl2 resulting in its ubiquitination and proteasome-dependent degradation. Lysine 154-160 BCL2 apoptosis regulator Homo sapiens 84-88 26556865-4 2015 In this process, PPARalpha/C102 was critical for PPARalpha binding to BH3 domain of Bcl2, subsequently, PPARalpha transferred K48-linked polyubiquitin to lysine-22 site of Bcl2 resulting in its ubiquitination and proteasome-dependent degradation. Lysine 154-160 BCL2 apoptosis regulator Homo sapiens 172-176 27064894-1 2015 The addition of AlCl3 to four-coordinate boranes of the general formula (C-N-chelate)BCl2 results in halide abstraction and formation of three-coordinate borenium cations of the general formula [(C-N-chelate)BCl]+. Aluminum Chloride 16-21 BCL2 apoptosis regulator Homo sapiens 85-89 27064894-1 2015 The addition of AlCl3 to four-coordinate boranes of the general formula (C-N-chelate)BCl2 results in halide abstraction and formation of three-coordinate borenium cations of the general formula [(C-N-chelate)BCl]+. c-n 73-76 BCL2 apoptosis regulator Homo sapiens 85-89 27064894-1 2015 The addition of AlCl3 to four-coordinate boranes of the general formula (C-N-chelate)BCl2 results in halide abstraction and formation of three-coordinate borenium cations of the general formula [(C-N-chelate)BCl]+. halide 101-107 BCL2 apoptosis regulator Homo sapiens 85-89 27064894-1 2015 The addition of AlCl3 to four-coordinate boranes of the general formula (C-N-chelate)BCl2 results in halide abstraction and formation of three-coordinate borenium cations of the general formula [(C-N-chelate)BCl]+. c-n 196-199 BCL2 apoptosis regulator Homo sapiens 85-89 27064894-3 2015 Catalytic quantities of AlCl3 were sufficient to effect high-yielding arylation of (C-N-chelate)BCl2. Aluminum Chloride 24-29 BCL2 apoptosis regulator Homo sapiens 96-100 26606906-4 2015 Thus an addition of a bcl-2 antagonist dissociates Bak from Bcl-xL, triggering cytochrome c release and inducing apoptosis. bakuchiol 51-54 BCL2 apoptosis regulator Homo sapiens 22-27 26676786-6 2015 Treatment with the Bcl-2 antagonist ABT-199 only reduced the prosurvival effects of HCMV in target monocytes beginning at 48 hpi, suggesting that Mcl-1 controls survival prior to 48 hpi, while Bcl-2 promotes survival after 48 hpi. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 36-39 BCL2 apoptosis regulator Homo sapiens 193-198 26407653-6 2015 Celecoxib-induced apoptosis of SGC-7901/DDP cells led to increased p53 expression, decreased Bcl-2/Bax ratio and up-regulated caspase-3 level. Celecoxib 0-9 BCL2 apoptosis regulator Homo sapiens 93-98 26658189-12 2015 Combination of I-BET762 with BH3-only mimetics ABT-263 or obatoclax, restored sensitivity to I-BET762 lymphoma killing; however, success was determined by expression of Bcl-2 family antiapoptotic proteins. molibresib 15-23 BCL2 apoptosis regulator Homo sapiens 169-174 26636651-10 2015 Critically, we demonstrate that combined vemurafenib therapy with BCL2/MCL1 inhibitor increases metastatic BRAF(V600E)-PTC cell death and ameliorates response to vemurafenib treatment as compared to single agent treatment. Vemurafenib 41-52 BCL2 apoptosis regulator Homo sapiens 66-70 26636651-10 2015 Critically, we demonstrate that combined vemurafenib therapy with BCL2/MCL1 inhibitor increases metastatic BRAF(V600E)-PTC cell death and ameliorates response to vemurafenib treatment as compared to single agent treatment. Vemurafenib 162-173 BCL2 apoptosis regulator Homo sapiens 66-70 26692822-13 2015 In addition, As2O3 in combination with 5-FU treatment caused up-regulation of DR5, caspase 3, caspase 8, and caspase 9, and down-regulation of BCL-2, but had no effect of DR4. Arsenic Trioxide 13-18 BCL2 apoptosis regulator Homo sapiens 143-148 26692822-13 2015 In addition, As2O3 in combination with 5-FU treatment caused up-regulation of DR5, caspase 3, caspase 8, and caspase 9, and down-regulation of BCL-2, but had no effect of DR4. Fluorouracil 39-43 BCL2 apoptosis regulator Homo sapiens 143-148 26690471-6 2015 Furthermore, AZT or d4T treatment significantly increased oxidative stress, adiposity index and expression of Bax protein, but reduced Bcl-2 protein expression compared to controls, respectively. Zidovudine 13-16 BCL2 apoptosis regulator Homo sapiens 135-140 26497680-6 2015 Among the Nrf2 downstream genes, Bcl-2 and Bcl-xL contribute more strongly to Nrf2-mediated cisplatin resistance when compared with heme oxygenase 1 (HO-1). Cisplatin 92-101 BCL2 apoptosis regulator Homo sapiens 33-38 26506422-4 2015 Both ABT-263 and ABT-737 inhibited the function of Bcl-2, Bcl-xL, and Bcl-w. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 5-8 BCL2 apoptosis regulator Homo sapiens 51-56 26506422-4 2015 Both ABT-263 and ABT-737 inhibited the function of Bcl-2, Bcl-xL, and Bcl-w. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 17-20 BCL2 apoptosis regulator Homo sapiens 51-56 26656462-0 2015 Polymorphisms of BCL2 and BAX Genes Associate with Outcomes in Advanced Non-small cell lung cancer Patients treated with platinum-based Chemotherapy. Platinum 121-129 BCL2 apoptosis regulator Homo sapiens 17-21 26656462-5 2015 The data from the current study provide evidence that BCL2-938C>A and BAX-248G>A polymorphisms may be useful in predicting clinical outcomes of patients with advanced inoperable NSCLC to platinum-based chemotherapy. Platinum 193-201 BCL2 apoptosis regulator Homo sapiens 54-58 26497680-7 2015 Cox regression analysis showed that patients with high-Nrf2, high-Bcl-2, high-Bcl-xL mRNA tumors were more commonly occurred unfavorable response to cisplatin-based chemotherapy than their counterparts. Cisplatin 149-158 BCL2 apoptosis regulator Homo sapiens 66-71 26634523-6 2015 Furthermore, DHM also regulated the expression of apoptotic genes such as p53 and B-cell lymphoma-2 (bcl-2) in a dose- and time-dependent manner. dihydromyricetin 13-16 BCL2 apoptosis regulator Homo sapiens 82-99 26415618-12 2015 Bcl-2 protein was down regulated; Bid and Bax were up regulated after the treatment with methyl caffeate. methyl caffeate 89-104 BCL2 apoptosis regulator Homo sapiens 0-5 26634523-6 2015 Furthermore, DHM also regulated the expression of apoptotic genes such as p53 and B-cell lymphoma-2 (bcl-2) in a dose- and time-dependent manner. dihydromyricetin 13-16 BCL2 apoptosis regulator Homo sapiens 101-106 26592509-8 2015 Platycodin D (5-20 mumol/L) dose-dependently increased BEL-7402 cell apoptosis, increased the Bax/Bcl-2 ratio and the levels of cleaved PARP and cleaved caspase-3, and decreased the level of Bcl-2. platycodin D 0-12 BCL2 apoptosis regulator Homo sapiens 98-103 26630272-5 2015 Effects of the alpha-tomatine and curcumin combination were associated with synergistic inhibition of NF-kappaB activity and a potent decrease in the expression of its downstream gene Bcl-2 in the cells. alpha-tomatine 15-29 BCL2 apoptosis regulator Homo sapiens 184-189 26630272-5 2015 Effects of the alpha-tomatine and curcumin combination were associated with synergistic inhibition of NF-kappaB activity and a potent decrease in the expression of its downstream gene Bcl-2 in the cells. Curcumin 34-42 BCL2 apoptosis regulator Homo sapiens 184-189 26592517-8 2015 Treatment with Fe(2+) increased the Bax level and caspase-3 activity, and decreased the Bcl-2 level, resulting in cell apoptosis. ammonium ferrous sulfate 15-21 BCL2 apoptosis regulator Homo sapiens 88-93 26415776-7 2015 The co-delivery system (CDS) successfully delivered siRNAs and DOX to the cytoplasm and nuclei, respectively, and resulted in a down-regulation of ABCG2- and BCL2 mRNAs in CSCs by 60% and 65%, respectively, compared to the control. cds 24-27 BCL2 apoptosis regulator Homo sapiens 158-162 26469742-0 2015 Some new indole-coumarin hybrids; Synthesis, anticancer and Bcl-2 docking studies. indole-coumarin 9-24 BCL2 apoptosis regulator Homo sapiens 60-65 26592509-8 2015 Platycodin D (5-20 mumol/L) dose-dependently increased BEL-7402 cell apoptosis, increased the Bax/Bcl-2 ratio and the levels of cleaved PARP and cleaved caspase-3, and decreased the level of Bcl-2. platycodin D 0-12 BCL2 apoptosis regulator Homo sapiens 191-196 27259314-4 2015 Anisodamine treatment decreases the expression of caspase-3 and caspase-8, and increases Bcl-2/Bax ratio in cardiomyocytes. anisodamine 0-11 BCL2 apoptosis regulator Homo sapiens 89-94 26558516-0 2015 Design, synthesis and preliminary bioactivity studies of imidazolidine-2,4-dione derivatives as Bcl-2 inhibitors. imidazolidine-2,4-dione 57-80 BCL2 apoptosis regulator Homo sapiens 96-101 26558516-2 2015 In the present study, a series of imidazolidine-2,4-dione derivatives were designed and synthesized to test their inhibitory activities against anti-apoptotic Bcl-2 proteins. imidazolidine-2,4-dione 34-57 BCL2 apoptosis regulator Homo sapiens 159-164 26045046-12 2015 ABT-199, which selectively inhibits Bcl-2, did not synergize with Mcl-1 knockdown, indicating the relatively low importance of Bcl-2 in these lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 36-41 26812869-0 2015 The effect of nicotine on the expressions of the alpha7 nicotinic receptor gene and Bax and Bcl-2 proteins in the mammary gland epithelial-7 breast cancer cell line and its relationship to drug resistance. Nicotine 14-22 BCL2 apoptosis regulator Homo sapiens 92-97 26812869-4 2015 This study focuses on the effect of nicotine on the expressions of the alpha7 nicotinic receptor gene and Bax and Bcl-2 proteins in mammary gland epithelial-7 (MCF-7) breast cancer cells and its relationship to drug resistance. Nicotine 36-44 BCL2 apoptosis regulator Homo sapiens 114-119 25736303-8 2015 The combination of 5-FU and Res significantly increased the percentage of apoptotic cells and the level of activated caspase-3, cleaved PARP and p53 proteins as well as increased the Bax/Bcl-2 ratio. Fluorouracil 19-23 BCL2 apoptosis regulator Homo sapiens 187-192 26843455-6 2015 Using Western blot analysis, we found that Gaillardin upregulated the pro-apoptotic protein Bax and p53 and downregulated the anti-apoptotic protein Bcl-2. gaillardin 43-53 BCL2 apoptosis regulator Homo sapiens 149-154 26454548-4 2015 Through CS-PEI-mediated miR-34a transfection, obvious cell apoptosis was observed with early apoptotic cells of 47.49%, and meanwhile the activation of caspase-3, -8 and -9, and decreased expression level of Bcl-2 were detected. Cesium 8-10 BCL2 apoptosis regulator Homo sapiens 208-213 26454548-4 2015 Through CS-PEI-mediated miR-34a transfection, obvious cell apoptosis was observed with early apoptotic cells of 47.49%, and meanwhile the activation of caspase-3, -8 and -9, and decreased expression level of Bcl-2 were detected. pei 11-14 BCL2 apoptosis regulator Homo sapiens 208-213 26452980-0 2015 Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 87-90 BCL2 apoptosis regulator Homo sapiens 63-68 26452980-2 2015 Tetracycline-inducible Bcl-2/Bcl-xL dual knockdown markedly sensitized acute myeloid leukemia cells to the dual TORC1/2 inhibitor INK128 in vitro as well as in vivo. Tetracycline 0-12 BCL2 apoptosis regulator Homo sapiens 23-28 26452980-2 2015 Tetracycline-inducible Bcl-2/Bcl-xL dual knockdown markedly sensitized acute myeloid leukemia cells to the dual TORC1/2 inhibitor INK128 in vitro as well as in vivo. INK128 130-136 BCL2 apoptosis regulator Homo sapiens 23-28 26452980-3 2015 Moreover, INK128 co-administered with the Bcl-2/xL antagonist ABT-737 sharply induced cell death in multiple acute myeloid leukemia cell lines, including TKI-resistant FLT3-ITD mutants and primary acute myeloid leukemia blasts carrying various genetic aberrations e.g., FLT3, IDH2, NPM1, and Kras, while exerting minimal toxicity toward normal hematopoietic CD34(+) cells. INK128 10-16 BCL2 apoptosis regulator Homo sapiens 42-47 26452980-3 2015 Moreover, INK128 co-administered with the Bcl-2/xL antagonist ABT-737 sharply induced cell death in multiple acute myeloid leukemia cell lines, including TKI-resistant FLT3-ITD mutants and primary acute myeloid leukemia blasts carrying various genetic aberrations e.g., FLT3, IDH2, NPM1, and Kras, while exerting minimal toxicity toward normal hematopoietic CD34(+) cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 62-65 BCL2 apoptosis regulator Homo sapiens 42-47 26717387-8 2015 Cooccurrence of TP53 and BCL2 aberrations ameliorated the poor prognostic impact of single TP53+ or BCL2+ in MYC positive patients.This pilot study generates evidence for the complex interplay between the alterations of genetic pathways in DLBCL, which goes beyond the concept of DHL. Cysteamine 280-283 BCL2 apoptosis regulator Homo sapiens 25-29 26254912-5 2015 Results showed that probucol protected against ADMA-induced HBMEC injury in a dose-dependent manner; probucol pretreatment also significantly reduced the level of reactive oxygen species (ROS) and malondialdehyde (MDA), downregulated the expression of pro-apoptotic gene Bax and caspase-3 activity, as well as increased the brain-derived neurotrophic factor (BDNF) release and promoted anti-apoptotic gene Bcl-2 and eNOS expression in the cultured HBMECs. Probucol 20-28 BCL2 apoptosis regulator Homo sapiens 406-411 27093815-5 2015 RESULT: The results showed that PTX could increase the apoptosis and the expression of Caspase3, PARP, CytC, AIF and Bax and reduce the proliferation, membrane potential and the expression of PI3K, p-AKT, p53, p21, Cleavage-PARP, Cleavage-Caspase3 and Bcl-2 in CNE2 cell in a concentration-dependent manner. ptx 32-35 BCL2 apoptosis regulator Homo sapiens 252-257 26529485-0 2015 Dioxinodehydroeckol protects human keratinocyte cells from UVB-induced apoptosis modulated by related genes Bax/Bcl-2 and caspase pathway. dioxinodehydroeckol 0-19 BCL2 apoptosis regulator Homo sapiens 112-117 26717387-8 2015 Cooccurrence of TP53 and BCL2 aberrations ameliorated the poor prognostic impact of single TP53+ or BCL2+ in MYC positive patients.This pilot study generates evidence for the complex interplay between the alterations of genetic pathways in DLBCL, which goes beyond the concept of DHL. Cysteamine 280-283 BCL2 apoptosis regulator Homo sapiens 100-104 26397390-0 2015 ABL-N may induce apoptosis of human prostate cancer cells through suppression of KLF5, ICAM-1 and Stat5b, and upregulation of Bax/Bcl-2 ratio: An in vitro and in vivo study. abl-n 0-5 BCL2 apoptosis regulator Homo sapiens 130-135 26498992-4 2015 CQAH induced caspase-3 and PARP cleavage, reduced the expression of the anti-apoptotic proteins myeloid cell leukemia-1 and B-cell lymphoma (Bcl) extra large protein and elevated the expression of the pro-apoptotic protein Bcl-2 homologous antagonist killer. cqah 0-4 BCL2 apoptosis regulator Homo sapiens 223-228 26503508-5 2015 Moreover, berberine activated the mitochondria-dependent apoptotic signaling pathway by upregulating pro-apoptotic factors, such as Bax, Bad, Apaf-1, and the active form of caspase-9, and downregulating anti-apoptotic factors, such as Bcl-2 and Bcl-xL. Berberine 10-19 BCL2 apoptosis regulator Homo sapiens 235-240 26398820-5 2015 The negative correlation with Bcl2 and survivin, and the chemotherapy drug 5-FU increased the level of autophagy and the autophagy inhibitor 3-MA inhibited this effect in SSCC cells, time- and dose-dependently. 3-methyladenine 141-145 BCL2 apoptosis regulator Homo sapiens 30-34 26502896-7 2015 Quantitative real-time PCR and western blotting found that beta-asarone significantly activated caspase-3, caspase-8, caspase-9, Bax, Bak and suppressed Bcl-2, Bcl-xL and survivin activity. asarone 59-71 BCL2 apoptosis regulator Homo sapiens 153-158 26397390-8 2015 ABL-N administration induced apoptosis of PC3 cells in a dose-dependent manner, along with the enhanced activity of caspases and increased Bax/Bcl-2 ratio. abl-n 0-5 BCL2 apoptosis regulator Homo sapiens 143-148 26397390-11 2015 ABL-N induces apoptosis of prostate cancer cells through activation of caspases, increasing the ratio of Bax/Bcl-2, as well as suppression of KLF5, Stat5b and ICAM-1 expressions. abl-n 0-5 BCL2 apoptosis regulator Homo sapiens 109-114 24988056-7 2015 Furthermore, anti-miR-34a oligonucleotides (AMO) partly reverse luteolin-induced Bcl-2 downregulation in gastric cancer cells. Oligonucleotides 26-42 BCL2 apoptosis regulator Homo sapiens 81-86 26788175-4 2015 The results revealed that low or negative expression of p53, Bcl-2 and COX-2, and high or positive expression of cleaved caspase-3 were significantly correlated with high sensitivity to NDP. nedaplatin 186-189 BCL2 apoptosis regulator Homo sapiens 61-66 26725384-0 2015 [Effects of Rapamycin and Rapamycin-loaded Poly(lactic-co-glycolic)Acid Nanoparticles on Apoptosis and Expression of bcl-2 and p27(kip1) Proteins of Human Umbilical Arterial Vascular Smooth Muscle Cell]. Polylactic Acid-Polyglycolic Acid Copolymer 43-71 BCL2 apoptosis regulator Homo sapiens 117-122 26343756-5 2015 Moreover, Bis-GMA induced a depletion of mitochondrial membrane potential, an increase in the Bax/Bcl-2 ratio, an activation of caspase-3 and altered expressions of cell cycle-related proteins (p21, PCNA, cyclinD1). Bisphenol A-Glycidyl Methacrylate 10-17 BCL2 apoptosis regulator Homo sapiens 98-103 26136123-10 2015 We analyzed expression levels of survival and apoptosis-associated proteins (pAkt, Akt, Mcl-1, Bcl-2, Bad, and Bax) altered by 5-FU treatment. Fluorouracil 127-131 BCL2 apoptosis regulator Homo sapiens 95-100 26136123-11 2015 Survival and antiapoptosis signaling (pAkt, Akt, Mcl-1 and Bcl-2) was downregulated, and the proapoptotic proteins (Bad and Bax) were upregulated in 5-FU-treated control cells but expression levels of Bcl-2, Bad, and Bad were not altered in 5-FU-treated A7-nAChR-KD cells. Fluorouracil 149-153 BCL2 apoptosis regulator Homo sapiens 59-64 26136123-11 2015 Survival and antiapoptosis signaling (pAkt, Akt, Mcl-1 and Bcl-2) was downregulated, and the proapoptotic proteins (Bad and Bax) were upregulated in 5-FU-treated control cells but expression levels of Bcl-2, Bad, and Bad were not altered in 5-FU-treated A7-nAChR-KD cells. Fluorouracil 149-153 BCL2 apoptosis regulator Homo sapiens 201-206 26541461-5 2015 The implied corollaries are that BH3s have a broad phylogenetic distribution and could potentially bind to non-BCL-2-like structural domains with distinct functions. BH 3 33-37 BCL2 apoptosis regulator Homo sapiens 111-116 26706948-9 2015 Western blot analysis showed that, compared with the control group, thioridazine reduced the expressions of CyclinD1, Bcl-2 and Bcl-xl (P<0.01) and increased the expression of Bax (P<0.01). Thioridazine 68-80 BCL2 apoptosis regulator Homo sapiens 118-123 26706948-11 2015 CONCLUSIONS: The mechanism of thioridazine inhibiting the proliferation of PC9 cells may be related to stimulation of Caspase apoptotic pathway, down-regulation of CyclinD1, Bcl-2, Bcl-xl and up-regulation of Bax. Thioridazine 30-42 BCL2 apoptosis regulator Homo sapiens 174-179 26708887-9 2015 The copolymer of ART with MNPs-Fe(3)O(4) could trigger changes in the expression levels of apoptosis-related genes in SKM-1 cells, among which up-regulation of BAX and down-regulation of survivin and BCL-2 are the 2 major alterations. fe(3) 31-36 BCL2 apoptosis regulator Homo sapiens 200-205 26739070-8 2015 Compared with the control group and the DDP group, the Bcl-2 level was reduced significantly in the LMWH plus DDP group (both P<0.05), while the level of Bax was increased obviously (both P<0.05). Heparin, Low-Molecular-Weight 100-104 BCL2 apoptosis regulator Homo sapiens 55-60 26606261-12 2015 CONCLUSION: Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. gemcitabine 106-117 BCL2 apoptosis regulator Homo sapiens 160-165 26634500-9 2015 After wilfortrine treatment, Bcl- 2 expression decreased significantly (P < 0.05); on the contrary, Bax expression increased noticeably compared with the control group (P < 0.05). wilfortrine 6-17 BCL2 apoptosis regulator Homo sapiens 29-35 26634500-10 2015 Wilfortrine can induce liver cancer cell HepG2 apoptosis, but with no effect on the cell cycle, mainly by promoting Bax expression and inhibiting anti-apoptotic protein Bcl-2 expression. wilfortrine 0-11 BCL2 apoptosis regulator Homo sapiens 169-174 26421995-0 2015 Design, synthesis and biological evaluation of 3-aryl-rhodanine benzoic acids as anti-apoptotic protein Bcl-2 inhibitors. 3-aryl-rhodanine benzoic acids 47-77 BCL2 apoptosis regulator Homo sapiens 104-109 26497851-6 2015 In addition, miR-139-5p induced apoptosis, as indicated by up-regulation of key apoptosis gene cleaved caspase-3, and down-regulation of anti-apoptosis gene Bcl2. mir-139-5p 13-23 BCL2 apoptosis regulator Homo sapiens 157-161 26589495-5 2015 In this review, we summarized the latest clinical development of ABT-199/venetoclax and other novel agents targeting the BCL-2 proteins. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 65-68 BCL2 apoptosis regulator Homo sapiens 121-126 26813281-1 2015 OBJECTIVE: To explore the effect of emodin-8-O-beta-D-glucoside (EG) on cell apoptosis and expression levels of Bcl-2 family proteins in human ovarian cancer SKOV3 cells. emodin-8-O-beta-D-glucoside 65-67 BCL2 apoptosis regulator Homo sapiens 112-117 26585387-7 2015 Relief of hypersuccinylation by overexpressing the desuccinylase SIRT5 or supplementing glycine rescued mitochondrial dysfunctions, reversed BCL-2 accumulation, and slowed the oncogenic growth of hypersuccinylated IDH1(R132C)-harboring HT1080 cells. Glycine 88-95 BCL2 apoptosis regulator Homo sapiens 141-146 26421995-1 2015 A new class of 3-aryl-rhodanine benzoic acid derivatives were designed, synthesized, and evaluated for their inhibition activities against anti-apoptotic Bcl-2 proteins. 3-aryl-rhodanine benzoic acid 15-44 BCL2 apoptosis regulator Homo sapiens 154-159 26884975-8 2015 More importantly, treatment with allicin significantly decreased HIF-1alpha protein level, thereby reducing Bcl-2 and VEGF expression. allicin 33-40 BCL2 apoptosis regulator Homo sapiens 108-113 26567361-6 2015 Here, we discuss the biology of the intrinsic pathway of apoptosis, an assay known as BH3 profiling that can interrogate this pathway, early attempts to target BCL-2 clinically, and the recent promising results with the BCL-2 antagonist venetoclax (ABT-199) in clinical trials in hematologic malignancies. venetoclax 237-247 BCL2 apoptosis regulator Homo sapiens 220-225 26567361-6 2015 Here, we discuss the biology of the intrinsic pathway of apoptosis, an assay known as BH3 profiling that can interrogate this pathway, early attempts to target BCL-2 clinically, and the recent promising results with the BCL-2 antagonist venetoclax (ABT-199) in clinical trials in hematologic malignancies. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 249-252 BCL2 apoptosis regulator Homo sapiens 220-225 26884981-9 2015 In addition, compared with the OGD model group, the Bcl-2/Bax ratios were significantly elevated in the propofol-treated groups, indicating the protective effects of propofol against cellular apoptosis. Propofol 104-112 BCL2 apoptosis regulator Homo sapiens 52-57 26884981-9 2015 In addition, compared with the OGD model group, the Bcl-2/Bax ratios were significantly elevated in the propofol-treated groups, indicating the protective effects of propofol against cellular apoptosis. Propofol 166-174 BCL2 apoptosis regulator Homo sapiens 52-57 26884987-0 2015 beta-asarone prevents Abeta25-35-induced inflammatory responses and autophagy in SH-SY5Y cells: down expression Beclin-1, LC3B and up expression Bcl-2. asarone 0-12 BCL2 apoptosis regulator Homo sapiens 145-150 26884987-8 2015 Meanwhile, beta-asarone could significantly reduce Beclin-1, LC3B and increase anti-apoptotic protein Bcl-2 level. asarone 11-23 BCL2 apoptosis regulator Homo sapiens 102-107 26884987-9 2015 These results showed that beta-asarone protected cells from Abeta25-35 induced inflammation and attenuated autophagy via Bcl-2/Beclin-1 pathway. asarone 26-38 BCL2 apoptosis regulator Homo sapiens 121-126 26276080-3 2015 Pre-treatment with PQQ prevented cultured SH-SY5Y cells from rotenone-induced apoptosis, accompanied by modulation of apoptosis-related proteins (Bcl-2, Bax and Smac), restoration of the mitochondrial membrane potential, inhibition of intracellular reactive oxygen species (ROS) production, suppression of tyrosine residues nitration, and dopamine redistribution. PQQ Cofactor 19-22 BCL2 apoptosis regulator Homo sapiens 146-151 26565405-0 2015 Loss in MCL-1 function sensitizes non-Hodgkin"s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). venetoclax 101-111 BCL2 apoptosis regulator Homo sapiens 75-80 26565405-0 2015 Loss in MCL-1 function sensitizes non-Hodgkin"s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 113-116 BCL2 apoptosis regulator Homo sapiens 75-80 26565405-1 2015 As a population, non-Hodgkin"s lymphoma (NHL) cell lines positive for the t(14;18) translocation and/or possessing elevated BCL2 copy number (CN; BCL2(High)) are exquisitely sensitive to navitoclax or the B-cell lymphoma protein-2 (BCL-2)-selective inhibitor venetoclax. navitoclax 187-197 BCL2 apoptosis regulator Homo sapiens 124-128 26565405-1 2015 As a population, non-Hodgkin"s lymphoma (NHL) cell lines positive for the t(14;18) translocation and/or possessing elevated BCL2 copy number (CN; BCL2(High)) are exquisitely sensitive to navitoclax or the B-cell lymphoma protein-2 (BCL-2)-selective inhibitor venetoclax. navitoclax 187-197 BCL2 apoptosis regulator Homo sapiens 146-150 26565405-1 2015 As a population, non-Hodgkin"s lymphoma (NHL) cell lines positive for the t(14;18) translocation and/or possessing elevated BCL2 copy number (CN; BCL2(High)) are exquisitely sensitive to navitoclax or the B-cell lymphoma protein-2 (BCL-2)-selective inhibitor venetoclax. navitoclax 187-197 BCL2 apoptosis regulator Homo sapiens 205-230 26565405-1 2015 As a population, non-Hodgkin"s lymphoma (NHL) cell lines positive for the t(14;18) translocation and/or possessing elevated BCL2 copy number (CN; BCL2(High)) are exquisitely sensitive to navitoclax or the B-cell lymphoma protein-2 (BCL-2)-selective inhibitor venetoclax. navitoclax 187-197 BCL2 apoptosis regulator Homo sapiens 232-237 26565405-4 2015 Chemical segregation of this synergy with the BCL-2-selective inhibitor venetoclax or BCL-XL-selective inhibitor A-1155463 indicated that MCL-1 and BCL-2 are the two key anti-apoptotic targets for sensitization. venetoclax 72-82 BCL2 apoptosis regulator Homo sapiens 46-51 26473375-5 2015 These changes in the ratio of pro- and antiapoptotic Bcl-2 proteins contribute to JNJ-26481585/Doxorubicin-mediated apoptosis, since knockdown of Bim or Noxa significantly inhibits cell death. Doxorubicin 95-106 BCL2 apoptosis regulator Homo sapiens 53-58 26473375-7 2015 Consistently, overexpression of Bcl-2 significantly reduces JNJ-26481585/Doxorubicin-mediated apoptosis. Doxorubicin 73-84 BCL2 apoptosis regulator Homo sapiens 32-37 26565405-4 2015 Chemical segregation of this synergy with the BCL-2-selective inhibitor venetoclax or BCL-XL-selective inhibitor A-1155463 indicated that MCL-1 and BCL-2 are the two key anti-apoptotic targets for sensitization. venetoclax 72-82 BCL2 apoptosis regulator Homo sapiens 148-153 26565405-4 2015 Chemical segregation of this synergy with the BCL-2-selective inhibitor venetoclax or BCL-XL-selective inhibitor A-1155463 indicated that MCL-1 and BCL-2 are the two key anti-apoptotic targets for sensitization. A-1155463 113-122 BCL2 apoptosis regulator Homo sapiens 148-153 26565405-5 2015 Similarly, the CDK inhibitor flavopiridol downregulated MCL-1 expression and synergized with venetoclax in BCL2(High) NHL cell lines to a similar extent as A-1210477. alvocidib 29-41 BCL2 apoptosis regulator Homo sapiens 107-111 26472030-1 2015 Bortezomib inhibits the ubiquitin/proteasome pathway to achieve its anti-cancer effect and its well characterized activity is the NF-kappaB inhibition through which the anti-apoptotic bcl-2 expression is down-regulated and apoptosis is subsequently induced. Bortezomib 0-10 BCL2 apoptosis regulator Homo sapiens 184-189 26544184-5 2015 The decreased flux of glucose associated to caffeic acid affected HG induced apoptosis by down-regulating the expression of initiator (caspase 8 and 9) and effector caspases (caspase 7 and 3) and by increasing the levels of phosphorylated Bcl-2. Glucose 22-29 BCL2 apoptosis regulator Homo sapiens 239-244 26544184-5 2015 The decreased flux of glucose associated to caffeic acid affected HG induced apoptosis by down-regulating the expression of initiator (caspase 8 and 9) and effector caspases (caspase 7 and 3) and by increasing the levels of phosphorylated Bcl-2. caffeic acid 44-56 BCL2 apoptosis regulator Homo sapiens 239-244 26544558-12 2015 HHT and Bortezomib synergistically induced cell apoptosis by regulating members of caspase 9, caspase 3 and Bcl-2 family (P < 0.01). Bortezomib 8-18 BCL2 apoptosis regulator Homo sapiens 108-113 26537004-2 2015 We have reported that acquired resistance to the BCL-2 inhibitor ABT-199 (venetoclax) is associated with increased BCL-xL expression. venetoclax 65-72 BCL2 apoptosis regulator Homo sapiens 49-54 26474387-5 2015 In this study, we show that TIC10/ONC201, a promising compound that is currently in planned clinical development, along with Bcl-2/Bcl-xL inhibition by ABT263 yields a strong synergistic antiproliferative effect on pediatric, adult, proneural glioblastoma and glioma stem-like cells. navitoclax 152-158 BCL2 apoptosis regulator Homo sapiens 125-130 26537004-2 2015 We have reported that acquired resistance to the BCL-2 inhibitor ABT-199 (venetoclax) is associated with increased BCL-xL expression. venetoclax 74-84 BCL2 apoptosis regulator Homo sapiens 49-54 26447615-6 2015 Among the numerous available small molecule BH3 mimetics, ABT-737, a potent small molecule that binds to Bcl-2/Bcl-xL with high affinity, has anti-tumor activity in a wide variety of cancer cells. BH 3 44-47 BCL2 apoptosis regulator Homo sapiens 105-110 26447615-6 2015 Among the numerous available small molecule BH3 mimetics, ABT-737, a potent small molecule that binds to Bcl-2/Bcl-xL with high affinity, has anti-tumor activity in a wide variety of cancer cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 58-61 BCL2 apoptosis regulator Homo sapiens 105-110 26416351-8 2015 Nevertheless, pharmacological inhibition of a range of Bcl-2 family members showed that inhibitors targeting Bcl-xL synergistically enhanced the response to the chemotherapeutic agent, doxorubicin. Doxorubicin 185-196 BCL2 apoptosis regulator Homo sapiens 55-60 26460954-5 2015 In this study, we use BH3 profiling to confirm that BCL-2 and BCL-XL support survival following PI3K pathway inhibition, and that the dual PI3K/mTOR inhibitor BEZ235 strongly synergizes with BCL-2 antagonists in DLBCL. BH 3 22-25 BCL2 apoptosis regulator Homo sapiens 52-57 26460954-5 2015 In this study, we use BH3 profiling to confirm that BCL-2 and BCL-XL support survival following PI3K pathway inhibition, and that the dual PI3K/mTOR inhibitor BEZ235 strongly synergizes with BCL-2 antagonists in DLBCL. dactolisib 159-165 BCL2 apoptosis regulator Homo sapiens 52-57 26460954-5 2015 In this study, we use BH3 profiling to confirm that BCL-2 and BCL-XL support survival following PI3K pathway inhibition, and that the dual PI3K/mTOR inhibitor BEZ235 strongly synergizes with BCL-2 antagonists in DLBCL. dactolisib 159-165 BCL2 apoptosis regulator Homo sapiens 191-196 26246329-7 2015 Gossypol inhibits Bcl-2 and Bcl-XL, antiapoptotic proteins that are overexpressed in various cancer cells. Gossypol 0-8 BCL2 apoptosis regulator Homo sapiens 18-23 26218299-0 2015 Clinical and pathological features of Burkitt lymphoma showing expression of BCL2--an analysis including gene expression in formalin-fixed paraffin-embedded tissue. Formaldehyde 124-132 BCL2 apoptosis regulator Homo sapiens 77-81 26535076-6 2015 Furthermore, lycopene pretreatment decreased the expression of cleaved poly (ADP ribose) polymerase-1 (PARP-1) and caspase-3 and increased the expression of B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X protein (Bax), which were induced by H2O2 treatment. Lycopene 13-21 BCL2 apoptosis regulator Homo sapiens 157-174 26535076-6 2015 Furthermore, lycopene pretreatment decreased the expression of cleaved poly (ADP ribose) polymerase-1 (PARP-1) and caspase-3 and increased the expression of B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X protein (Bax), which were induced by H2O2 treatment. Lycopene 13-21 BCL2 apoptosis regulator Homo sapiens 176-181 26841510-4 2015 The decreased Bax mRNA expression and increased Bcl-2 mRNA expression after incubation .of the cells with genistein also demonstrate the cytoprotective, anti-apoptotic effect of genistein. Genistein 106-115 BCL2 apoptosis regulator Homo sapiens 48-53 26201092-8 2015 Salinomycin, but not paclitaxel, increased apoptosis, decreased the migration capacity of MCF-7 MS cells, accompanied by a decreased expression of c-Myc, Bcl-2 and Snail, the target genes of the Hh pathway. salinomycin 0-11 BCL2 apoptosis regulator Homo sapiens 154-159 26232616-0 2015 Ceramide generation during curcumin-induced apoptosis is controlled by crosstalk among Bcl-2, Bcl-xL, caspases and glutathione. Ceramides 0-8 BCL2 apoptosis regulator Homo sapiens 87-92 26232616-0 2015 Ceramide generation during curcumin-induced apoptosis is controlled by crosstalk among Bcl-2, Bcl-xL, caspases and glutathione. Curcumin 27-35 BCL2 apoptosis regulator Homo sapiens 87-92 26232616-5 2015 These data place nSMase activation downstream of caspase-8 and Bcl-xL and indicate a mutual regulation between nSMase and caspase-3 activity on one hand, and Bcl-2 level on the other hand in curcumin-treated cells. Curcumin 191-199 BCL2 apoptosis regulator Homo sapiens 158-163 26420235-1 2015 PURPOSE: Navitoclax (ABT-263), a novel, oral Bcl-2 inhibitor, enhances the antitumor effects of chemotherapy in vitro by lowering the apoptotic threshold. navitoclax 9-19 BCL2 apoptosis regulator Homo sapiens 45-50 26420235-1 2015 PURPOSE: Navitoclax (ABT-263), a novel, oral Bcl-2 inhibitor, enhances the antitumor effects of chemotherapy in vitro by lowering the apoptotic threshold. navitoclax 21-28 BCL2 apoptosis regulator Homo sapiens 45-50 25847773-4 2015 RESULTS: ZJP exerted evident inhibitory effect on SGC-7901 cells by activating production of reactive oxygen species and elevating Bax/Bcl-2 ratio in SGC-7901 cells, leading to attenuation of mitochondrial membrane potential and DNA fragmentation. zjp 9-12 BCL2 apoptosis regulator Homo sapiens 135-140 26546525-0 2015 Suppression of BCL2 by Antisense Oligonucleotides and Compensation by Non-Targeted Genes May Enhance Tumor Proliferation. Oligonucleotides 33-49 BCL2 apoptosis regulator Homo sapiens 15-19 25716014-8 2015 mRNA and protein expression of caspase-3 and caspase-9 and proapoptotic genes was increased in cells treated with a combination of curcumin and carboplatin, whereas expression of the antiapoptotic Bcl-2 gene was suppressed. Curcumin 131-139 BCL2 apoptosis regulator Homo sapiens 197-202 25716014-8 2015 mRNA and protein expression of caspase-3 and caspase-9 and proapoptotic genes was increased in cells treated with a combination of curcumin and carboplatin, whereas expression of the antiapoptotic Bcl-2 gene was suppressed. Carboplatin 144-155 BCL2 apoptosis regulator Homo sapiens 197-202 26546525-2 2015 Our previous studies showed that oligonucleotide-treated LNCaP prostate cancer cells compensate for diminished expression of B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2), an apoptosis inhibitor, by suppressing the expression of caspase-3 (an apoptosis promoter) while enhancing that of serine/threonine protein kinase (AKT1) (another apoptosis inhibitor). Oligonucleotides 33-48 BCL2 apoptosis regulator Homo sapiens 125-171 26546525-2 2015 Our previous studies showed that oligonucleotide-treated LNCaP prostate cancer cells compensate for diminished expression of B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2), an apoptosis inhibitor, by suppressing the expression of caspase-3 (an apoptosis promoter) while enhancing that of serine/threonine protein kinase (AKT1) (another apoptosis inhibitor). Oligonucleotides 33-48 BCL2 apoptosis regulator Homo sapiens 173-177 26546525-8 2015 As a result, we propose that oligonucleotide-mediated treatment could be more effective when directed towards KI-67 and BCL2. Oligonucleotides 29-44 BCL2 apoptosis regulator Homo sapiens 120-124 26949498-10 2015 Vitamin D up-regulated the expression levels of Bcl-2 by (18.87 fold increase), and down-regulated expression of Bax (23%) and FasL (25%). Vitamin D 0-9 BCL2 apoptosis regulator Homo sapiens 48-53 26823806-4 2015 The expression levels of Bax and Bcl-2 proteins were detected by Annexin V/propidium iodide coupled staining. Propidium 75-91 BCL2 apoptosis regulator Homo sapiens 33-38 26823840-11 2015 Apoptotic proteins including caspase-3, caspase-9 and bcl-2 were all up-regulated by TSA. trichostatin A 85-88 BCL2 apoptosis regulator Homo sapiens 54-59 25982455-0 2015 Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients" poor response to treatment and short-term relapse. bfm 41-44 BCL2 apoptosis regulator Homo sapiens 18-22 25982455-7 2015 Moreover, the upregulation of BCL2 and BAX following BFM treatment induction was shown to represent an independent predictor of patients" short-term relapse, which was further confirmed in ch-ALL patients with favorable prognostic markers. bfm 53-56 BCL2 apoptosis regulator Homo sapiens 30-34 26329131-10 2015 Therefore, the present study demonstrated that, at an optimum concentration of 10-5 mol/l, icariin inhibited the proliferation of the HepG2 cells, promoted apoptosis by decreasing the expression of Bcl-2, and disrupted the actin cytoskeleton. icariin 91-98 BCL2 apoptosis regulator Homo sapiens 198-203 26291582-7 2015 The complex induces apoptosis of A549 cells through an intrinsic ROS-mediated mitochondrial dysfunction pathway, which was accompanied by regulating the expression of caspases and Bcl-2 family proteins. Reactive Oxygen Species 65-68 BCL2 apoptosis regulator Homo sapiens 180-185 26505960-2 2015 HMF increases the expression of BCL2/adenovirus E1B 19 kDa protein-interacting protein (Bnip3) and cell death; the prostaglandin analogue misoprostol will rescue this effect. Prostaglandins 115-128 BCL2 apoptosis regulator Homo sapiens 32-36 26505960-2 2015 HMF increases the expression of BCL2/adenovirus E1B 19 kDa protein-interacting protein (Bnip3) and cell death; the prostaglandin analogue misoprostol will rescue this effect. Misoprostol 138-149 BCL2 apoptosis regulator Homo sapiens 32-36 25174976-4 2015 The silymarin-induced apoptosis of human melanoma cells was associated with a reduction in the levels of anti-apoptotic proteins (Bcl-2 and Bcl-xl), an increase in the levels of pro-apoptotic protein (Bax), and activation of caspases. Silymarin 4-13 BCL2 apoptosis regulator Homo sapiens 130-135 26352605-4 2015 As a novel gossypol derivative targeting antiapoptotic proteins of the Bcl-2 family, apogossypolone (ApoG2) exhibits antitumor properties in various cancer types, although its effects against CRC remain to be fully elucidated. apogossypolone 85-99 BCL2 apoptosis regulator Homo sapiens 71-76 26299281-6 2015 In addition, H2S upregulated the anti-apoptotic protein, Bcl-2 and downregulated the pro-apoptotic protein, Bax. Hydrogen Sulfide 13-16 BCL2 apoptosis regulator Homo sapiens 57-62 26323996-0 2015 Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma. Silybin 0-9 BCL2 apoptosis regulator Homo sapiens 64-68 26397392-7 2015 Licochalcone C treatment reduced the levels of the anti-apoptotic mRNAs (Bcl-2, Bcl-w and Bcl-XL) and increased expression of the pro-apoptotic mRNAs (Bax and Bim). licochalcone C 0-14 BCL2 apoptosis regulator Homo sapiens 73-78 26397392-8 2015 The Bcl-2 family inhibitor (ABT-737) reduced apoptosis induced by licochalcone C in T24 cells. ABT-737 28-35 BCL2 apoptosis regulator Homo sapiens 4-9 26397392-8 2015 The Bcl-2 family inhibitor (ABT-737) reduced apoptosis induced by licochalcone C in T24 cells. licochalcone 66-78 BCL2 apoptosis regulator Homo sapiens 4-9 26398137-10 2015 The opposing changes in the mRNA expression levels of Bcl-2 and Egr-1 in patients with early-stage hypothyroidism indicates their potential as prognostic markers of early-stage hypothyroidism induced by iodine-131 treatment. Iodine 203-209 BCL2 apoptosis regulator Homo sapiens 54-59 26722323-7 2015 Moreover, western blot analysis indicated that DHA-induced apoptosis was accompanied by inactivation of the Raf/MEK/ERK and PI3K/AKT signaling pathways, in addition to the downregulation of anti-apoptotic proteins Mcl-1 and Bcl-2 expression levels. artenimol 47-50 BCL2 apoptosis regulator Homo sapiens 224-229 26323996-3 2015 In the present study, we confirmed that silibinin induced growth inhibition of RCC through caspase-dependent apoptosis and downregulation of GLI1 and BCL2, which could be partially reversed by GLI1 overexpression. Silybin 40-49 BCL2 apoptosis regulator Homo sapiens 150-154 26323996-6 2015 In conclusion, our findings demonstrated for the first time that silibinin induces apoptosis of RCC cells through inhibition of the mTOR-GLI1-BCL2 pathway. Silybin 65-74 BCL2 apoptosis regulator Homo sapiens 142-146 26414101-8 2015 Intravital rhodamine dextran injections demonstrated that surviving glomeruli were perfused through Bcl-2-EC-derived microvessels. rhodamine dextran 11-28 BCL2 apoptosis regulator Homo sapiens 100-105 26360379-9 2015 RESULTS: p38 MAPK phosphorylation, expression of Cox-2 and Bax/Bcl-2 was upregulated (*p < 0.05) in CTBs exposed to >= 0.1 nM CTSs. ctbs 103-107 BCL2 apoptosis regulator Homo sapiens 63-68 26586936-8 2015 When As4S4 was combined with chemotherapy drug cisplatin or COX2 inhibitor celecoxib, its inhibition of COX2, BCL2, and p38 expression was enhanced. as4s4 5-10 BCL2 apoptosis regulator Homo sapiens 110-114 26887774-11 2015 RESULTS: (1) The mRNA expressions of GRP78, beclin1, Bcl-2 and CHOP in the group of BAPTA-AM were 0.583+-0.025, 0.860+-0.055, 0.714+-0.032 and 0.811+-0.004, respectively. 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester 84-92 BCL2 apoptosis regulator Homo sapiens 53-58 26887774-14 2015 While the protein expressions of GRP78, beclin1, Bcl-2 and CHOP in the group of BAPTA-AM were 0.423+-0.035, 0.952+-0.022, 0.385+-0.032, 0.681+-0.095, respectively. 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester 80-88 BCL2 apoptosis regulator Homo sapiens 49-54 26887774-15 2015 The protein expressions of GRP78, beclin1, Bcl-2 and CHOP in the group of A23187 were 0.743+-0.032, 0.638+-0.025, 0.596+-0.029, 0.431+-0.095, respectively. Calcimycin 74-80 BCL2 apoptosis regulator Homo sapiens 43-48 26586936-8 2015 When As4S4 was combined with chemotherapy drug cisplatin or COX2 inhibitor celecoxib, its inhibition of COX2, BCL2, and p38 expression was enhanced. Cisplatin 47-56 BCL2 apoptosis regulator Homo sapiens 110-114 26887260-13 2015 There was a negative correlation between ROS level and the expression level of Bcl-2 mRNA (r=-0.703,P<0.05). Reactive Oxygen Species 41-44 BCL2 apoptosis regulator Homo sapiens 79-84 26586936-8 2015 When As4S4 was combined with chemotherapy drug cisplatin or COX2 inhibitor celecoxib, its inhibition of COX2, BCL2, and p38 expression was enhanced. Celecoxib 75-84 BCL2 apoptosis regulator Homo sapiens 110-114 26503418-6 2015 By inducing microtubule acetylation, flubendazole activates JNK1 leading to Bcl-2 phosphorylation, causing release of Beclin1 from Bcl-2-Beclin1 complexes for autophagy induction, thus uncovering a new approach to inducing autophagic flux that may be applicable in disease treatment. flubendazole 37-49 BCL2 apoptosis regulator Homo sapiens 76-81 26516138-9 2015 CONCLUSIONS: Increased miR-451 expression may negatively regulate Bcl-2 mRNA and protein expression, followed by affecting the protein expression of caspase 3, and accelerate the apoptosis in breast cancer, indicating that miR-451 might influence the drug resistances of the Paclitaxel-resistant breast cancer cell line. Paclitaxel 275-285 BCL2 apoptosis regulator Homo sapiens 66-71 26503418-6 2015 By inducing microtubule acetylation, flubendazole activates JNK1 leading to Bcl-2 phosphorylation, causing release of Beclin1 from Bcl-2-Beclin1 complexes for autophagy induction, thus uncovering a new approach to inducing autophagic flux that may be applicable in disease treatment. flubendazole 37-49 BCL2 apoptosis regulator Homo sapiens 131-136 26511969-12 2015 Overexpression of miR-429 inhibited Bcl-2-mediated cell survival against temozolomide-induced apoptosis, while depletion of miR-429 augmented it. Temozolomide 73-85 BCL2 apoptosis regulator Homo sapiens 36-41 26430964-0 2015 Overexpression of Bcl-2 induces STAT-3 activation via an increase in mitochondrial superoxide. Superoxides 83-93 BCL2 apoptosis regulator Homo sapiens 18-23 26474854-0 2015 Bcl-2 confers survival in cisplatin treated cervical cancer cells: circumventing cisplatin dose-dependent toxicity and resistance. Cisplatin 26-35 BCL2 apoptosis regulator Homo sapiens 0-5 26430964-4 2015 Bcl-2-induced STAT3 activation was a function of GTP-loaded Rac1 and NADPH oxidase (Nox)-dependent increase in intracellular superoxide (O2 -). Guanosine Triphosphate 49-52 BCL2 apoptosis regulator Homo sapiens 0-5 26430964-4 2015 Bcl-2-induced STAT3 activation was a function of GTP-loaded Rac1 and NADPH oxidase (Nox)-dependent increase in intracellular superoxide (O2 -). Superoxides 125-135 BCL2 apoptosis regulator Homo sapiens 0-5 26430964-4 2015 Bcl-2-induced STAT3 activation was a function of GTP-loaded Rac1 and NADPH oxidase (Nox)-dependent increase in intracellular superoxide (O2 -). Superoxides 137-139 BCL2 apoptosis regulator Homo sapiens 0-5 26430964-5 2015 Furthermore, ABT199, a BH-3 specific inhibitor of Bcl-2, as well as silencing of Bcl-2 blocked STAT3 phosphorylation. venetoclax 13-19 BCL2 apoptosis regulator Homo sapiens 50-55 26485709-11 2015 According to the results, trabectedin induced cytotoxicity and apoptosis at the IC50 dose, resulting in a significant increase expression of caspase-3, caspase-8, caspase-9, p53 and decrease expression of bcl-2 in dose-dependent manner. Trabectedin 26-37 BCL2 apoptosis regulator Homo sapiens 205-210 26516844-8 2015 In conclusion, the JNK-Bcl-2/Bcl-xL-Bax/Bak pathway mediates the crosstalk between matrine-induced autophagy and apoptosis via interplay with Beclin 1. matrine 83-90 BCL2 apoptosis regulator Homo sapiens 23-28 26492346-8 2015 PNAP-6h induced apoptosis, most likely by the promotion of Fas expression, increased PARP activity, caspase-7, caspase-8, and caspase-9 expression, the Bax/Bcl-2 ratio, and the phosphorylation of p38, and decreased the phosphorylation of ERK. 6H 5-7 BCL2 apoptosis regulator Homo sapiens 156-161 26384351-2 2015 Cytotoxic effect was increased by decitabine through activation of p53 and inhibition of c-Myc, Survivin and Bcl-2. Decitabine 34-44 BCL2 apoptosis regulator Homo sapiens 109-114 26505392-11 2015 The rate of apoptosis in pediatric A-BLL leukemic cells was observed to increase significantly after transfection with Bcl-2-siRNA compared to the control, liposome empty transfection, and unrelated sequence oligonucleotide groups (P < 0.05). Oligonucleotides 208-223 BCL2 apoptosis regulator Homo sapiens 119-124 26474854-0 2015 Bcl-2 confers survival in cisplatin treated cervical cancer cells: circumventing cisplatin dose-dependent toxicity and resistance. Cisplatin 81-90 BCL2 apoptosis regulator Homo sapiens 0-5 26474854-3 2015 Bcl-2 up-regulation has been implicated in the resistance to cisplatin in a variety of cancer cell lines, however its role in cervical cancer is confounding. Cisplatin 61-70 BCL2 apoptosis regulator Homo sapiens 0-5 26474854-5 2015 Bcl-2 expression was determined through Western blotting and immunocytochemistry before and after treatment with cisplatin. Cisplatin 113-122 BCL2 apoptosis regulator Homo sapiens 0-5 26474854-6 2015 To assess the reliance of the cervical cancer cells on Bcl-2 in the presence of cisplatin, Bcl-2 knock-down was achieved through RNA interference, where after apoptosis was assessed through PARP cleavage (Western blotting), Caspase activity (Caspase-Glo( )) and PI inclusion analysis (Flow cytometry). Cisplatin 80-89 BCL2 apoptosis regulator Homo sapiens 55-60 26474854-8 2015 RESULTS: Cervical cancer cells upregulate Bcl-2 when treated with a non-cytotoxic concentration of cisplatin, which when silenced, effectively enhanced cisplatin sensitivity, and therefore significantly induced apoptosis. Cisplatin 99-108 BCL2 apoptosis regulator Homo sapiens 42-47 26474854-8 2015 RESULTS: Cervical cancer cells upregulate Bcl-2 when treated with a non-cytotoxic concentration of cisplatin, which when silenced, effectively enhanced cisplatin sensitivity, and therefore significantly induced apoptosis. Cisplatin 152-161 BCL2 apoptosis regulator Homo sapiens 42-47 26202948-6 2015 Antitumor activity was associated with PF-03084014-induced inhibition of Notch pathway signaling; decreased survival signals (cyclin E; MEK/ERK, PI3K/AKT, EGFR and NF-kappaB pathway; BCL-2, BCL-XL); increased apoptotic signals (BAK, BAX; cleaved caspase-3); reduced microvessel density; reduced epithelial-mesenchymal transition; and reduced cancer stem-like cells in the tumor. nirogacestat 39-50 BCL2 apoptosis regulator Homo sapiens 183-188 26342429-5 2015 Moreover, silibinin increased caspase-3 activation, upregulated pro-apoptotic Bax, and suppressed anti-apoptotic Bcl-2 expression, effects enhanced by FoxM1 knockdown. Silybin 10-19 BCL2 apoptosis regulator Homo sapiens 113-118 26472348-5 2015 METHODS: Bcl-2 expression was immunohistochemically evaluated and compared with other clinicopathological factors, including clinical outcome, in 1081 breast cancer cases with long follow-up, separately analyzing 634 cases without any adjuvant therapy and 447 cases with tamoxifen monotherapy. Tamoxifen 271-280 BCL2 apoptosis regulator Homo sapiens 9-14 26770403-5 2015 Fe-NTA-induced ROS increased mRNA and protein level of anti-apoptosis Bcl-2 and decreased mRNA protein level of pro-apoptosis gene Bax, As a result, maintaining mitochondrial membrane potential of HSCs. ferric nitrilotriacetate 0-6 BCL2 apoptosis regulator Homo sapiens 70-75 26770403-0 2015 Ferric nitrilotriacetate (Fe-NTA)-induced reactive oxidative species protects human hepatic stellate cells from apoptosis by regulating Bcl-2 family proteins and mitochondrial membrane potential. ferric nitrilotriacetate 0-24 BCL2 apoptosis regulator Homo sapiens 136-141 26770403-0 2015 Ferric nitrilotriacetate (Fe-NTA)-induced reactive oxidative species protects human hepatic stellate cells from apoptosis by regulating Bcl-2 family proteins and mitochondrial membrane potential. ferric nitrilotriacetate 26-32 BCL2 apoptosis regulator Homo sapiens 136-141 26770403-5 2015 Fe-NTA-induced ROS increased mRNA and protein level of anti-apoptosis Bcl-2 and decreased mRNA protein level of pro-apoptosis gene Bax, As a result, maintaining mitochondrial membrane potential of HSCs. Reactive Oxygen Species 15-18 BCL2 apoptosis regulator Homo sapiens 70-75 26770403-6 2015 Fe-NTA-induced ROS play a protective role in human HSCs by regulating Bcl-2 family proteins and mitochondrial membrane potential. ferric nitrilotriacetate 0-6 BCL2 apoptosis regulator Homo sapiens 70-75 26770403-6 2015 Fe-NTA-induced ROS play a protective role in human HSCs by regulating Bcl-2 family proteins and mitochondrial membrane potential. Reactive Oxygen Species 15-18 BCL2 apoptosis regulator Homo sapiens 70-75 26259535-8 2015 In conclusion, although SAHA treatment as used in this study significantly decreased bax1/bcl2 and Dnmt1 transcripts of donor nuclei, as well as increased H3 acetylation, it was not enough to increase in vivo developmental competence of cloned dog embryos. Vorinostat 24-28 BCL2 apoptosis regulator Homo sapiens 90-94 26213322-9 2015 Of importance, RT-PCR and Western blotting demonstrated that high glucose inhibited DNA-damage-inducible transcript 4 (DDIT4) and TSC1/TSC2, up-regulated Rheb/mTOR/p70S6K and enhanced expression of the apoptosis regulating proteins, such as phospho-Bcl-2, cytochrome C and cleaved caspase. Glucose 66-73 BCL2 apoptosis regulator Homo sapiens 249-254 26188279-9 2015 Combination treatment with both TMZ and NVP-BEZ235 resulted in synergistically inhibited glioma cell growth and induced apoptosis (combination index CI<1) in a subset of glioma cell lines, as shown in the increased levels of Bax, and active Caspase-3, and decreased level of Bcl-2. Temozolomide 32-35 BCL2 apoptosis regulator Homo sapiens 278-283 26473951-6 2015 In KOSR-protected CML cells, imatinib still inhibited the BCR-ABL tyrosine kinase, reduced the phosphorylation of STAT, ERK and AKT, down-regulated BCL2, BCLxL, MCL1 and up-regulated BIM. Imatinib Mesylate 29-37 BCL2 apoptosis regulator Homo sapiens 148-152 26392332-0 2015 Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. BH 3 73-76 BCL2 apoptosis regulator Homo sapiens 16-21 26392332-3 2015 We showed that a low Mcl-1/Bcl-2 plus Bcl-xL protein ratio determined ABT-737 responsiveness. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 70-73 BCL2 apoptosis regulator Homo sapiens 27-32 26392332-5 2015 Co-inhibition of Bcl-2 and the mTOR pathway resulted cytotoxic on ABT-737 resistant models, by downregulating mTORC1 activity and Mcl-1 in a proteasome-independent manner. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 66-69 BCL2 apoptosis regulator Homo sapiens 17-22 26392332-9 2015 Co-targeting of the Bcl-2 protein family and mTOR pathway enhanced drug-induced cytotoxicity by suppressing Mcl-1, providing a novel therapeutic approach to overcome BH3 mimetics resistance in ALL. BH 3 166-169 BCL2 apoptosis regulator Homo sapiens 20-25 26397135-4 2015 Exogenous expression of miR-15a/16 mimics re-sensitized resistant cells to tamoxifen by inhibiting Cyclin E1 and B cell lymphoma-2 (Bcl-2) to induce cell growth arrest and apoptosis respectively. Tamoxifen 75-84 BCL2 apoptosis regulator Homo sapiens 113-130 26397135-4 2015 Exogenous expression of miR-15a/16 mimics re-sensitized resistant cells to tamoxifen by inhibiting Cyclin E1 and B cell lymphoma-2 (Bcl-2) to induce cell growth arrest and apoptosis respectively. Tamoxifen 75-84 BCL2 apoptosis regulator Homo sapiens 132-137 26397135-7 2015 Together, our results suggest that overexpression of E2F7 represses miR-15a/16 and then increases Cyclin E1 and Bcl-2 that result in tamoxifen resistance. Tamoxifen 133-142 BCL2 apoptosis regulator Homo sapiens 112-117 26188279-9 2015 Combination treatment with both TMZ and NVP-BEZ235 resulted in synergistically inhibited glioma cell growth and induced apoptosis (combination index CI<1) in a subset of glioma cell lines, as shown in the increased levels of Bax, and active Caspase-3, and decreased level of Bcl-2. dactolisib 44-50 BCL2 apoptosis regulator Homo sapiens 278-283 26296464-5 2015 Western blot demonstrated that SFN-induced apoptosis was mediated via the mitochondrial apoptosis pathway based on increased cleavage of poly-ADP-ribose-polymerase (PARP), release of cytochrome c into the cytoplasm, and activation of caspase-3, as well as decreased Bcl-2/Bax ratio. sulforaphane 31-34 BCL2 apoptosis regulator Homo sapiens 266-271 26209360-6 2015 Furthermore, treatment of cells with tanshinone IIA significantly increased apoptotic cell death rate, as shown by the increase in Annexin V-stained cell populations, Bcl-2 associated X protein (Bax)/B-cell lymphoma 2 (Bcl-2) ratio, and poly (ADP-ribose) polymerase 1 (PARP-1) cleavage in HepG2 cells. tanshinone 37-51 BCL2 apoptosis regulator Homo sapiens 167-172 26209360-6 2015 Furthermore, treatment of cells with tanshinone IIA significantly increased apoptotic cell death rate, as shown by the increase in Annexin V-stained cell populations, Bcl-2 associated X protein (Bax)/B-cell lymphoma 2 (Bcl-2) ratio, and poly (ADP-ribose) polymerase 1 (PARP-1) cleavage in HepG2 cells. tanshinone 37-51 BCL2 apoptosis regulator Homo sapiens 219-224 26505349-6 2015 BCL2-positive clones were screened by neomycin 418 (G418). neomycin 418 38-50 BCL2 apoptosis regulator Homo sapiens 0-4 26505349-6 2015 BCL2-positive clones were screened by neomycin 418 (G418). antibiotic G 418 52-56 BCL2 apoptosis regulator Homo sapiens 0-4 26396258-7 2015 The selective JAK inhibitor ruxolitinib was examined in a high-throughput matrix screen combined with >450 potential therapeutic agents, and Bcl-2/Bcl-xL inhibitor navitoclax was identified as a strong candidate for multicomponent therapy. ruxolitinib 28-39 BCL2 apoptosis regulator Homo sapiens 144-149 26164795-4 2015 The activation of caspase-3, caspase-9, and the increased expression ratio of Bax/Bcl-2 were detected in III-10-induced apoptosis. III-10 105-111 BCL2 apoptosis regulator Homo sapiens 82-87 26297991-7 2015 The mechanisms involved in these effects of XN were associated with cell growth inhibition by induction of cell cycle arrest in the G1 phase, increased p53 and p21/WAF1 expression levels, downregulation of cyclin D1 and Bcl-2, and activation of caspases-9, -8, and -3. xanthohumol 44-46 BCL2 apoptosis regulator Homo sapiens 220-225 26525307-0 2015 Antagonizing Bcl-2"s BH4 domain in cancer. sapropterin 21-24 BCL2 apoptosis regulator Homo sapiens 13-18 26181229-8 2015 Western blot analysis showed that aspidin PB inhibited Bcl-2 expression and induced Bax expression to disintegrate the outer mitochondrial membrane and caused cytochrome C release. aspidin PB 34-44 BCL2 apoptosis regulator Homo sapiens 55-60 26297542-0 2015 miR-125a-5p inhibits cell proliferation and induces apoptosis in colon cancer via targeting BCL2, BCL2L12 and MCL1. mir-125a-5p 0-11 BCL2 apoptosis regulator Homo sapiens 92-96 26408697-4 2015 CHM-1 treatment induced phosphorylation on Thr 69 of B cell lymphoma 2 and inhibited phosphorylation of Ser 136 on Bcl-2-associated death promoter, that were reversed by overexpression of GRP78. Serine 104-107 BCL2 apoptosis regulator Homo sapiens 115-120 26605009-11 2015 Additionally, polysaccharide extracted induced intrinsic apoptosis via up-regulation of caspase-3, caspase-9 and Bax along with down-regulation of Bcl-2 in HeLa cells. Polysaccharides 14-28 BCL2 apoptosis regulator Homo sapiens 147-152 26275811-3 2015 The induction of apoptosis by farnesol was inhibited by the addition of the pan-caspase inhibitor Z-VAD-fmk and by the exogenous expression of the anti-apoptotic protein Bcl2. Farnesol 30-38 BCL2 apoptosis regulator Homo sapiens 170-174 26622477-9 2015 In conclusion, As2O3 nanoparticles, prepared using the sol-gel method, were found to produce a stronger cytotoxic effect on tumor cells than that produced by the As2O3 solution, possibly by inhibiting Bcl-2 expression. Arsenic Trioxide 15-20 BCL2 apoptosis regulator Homo sapiens 201-206 26266765-9 2015 Metformin induced apoptosis by down-regulating Bcl-2 and Bcl-xL expression, and up-regulating Bax and Cytochrome c expression. Metformin 0-9 BCL2 apoptosis regulator Homo sapiens 47-52 26296992-7 2015 Furthermore, atropine could also induce activations of caspase-2, -3 and -9, disruption of mitochondrial transmembrane potential, downregulation of Bcl-2 and Bcl-xL, upregulation of Bax and Bad, and upregulation of cytoplasmic cytochrome c and apoptosis-inducing factor, implying a death receptor-mediated mitochondrion-dependent pathway is most probably involved in the apoptosis of HCEP cells induced by atropine. Atropine 13-21 BCL2 apoptosis regulator Homo sapiens 148-153 26722459-0 2015 MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells. Temozolomide 16-28 BCL2 apoptosis regulator Homo sapiens 54-59 26256949-8 2015 Inhibition of endogenous Akt by LY294002 resulted in decreased expression of Sox2, ALDH1, and CD133, leading to enhancement of cobalt chloride-mediated apoptotic events due to altered ratio of bcl-2 to bax expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 BCL2 apoptosis regulator Homo sapiens 193-198 26722459-9 2015 In addition, the downregulation of miR-16 in temozolomide-sensitive AM38 cells was concurrent with the upregulation of Bcl-2 protein. Temozolomide 45-57 BCL2 apoptosis regulator Homo sapiens 119-124 26722459-10 2015 Conversely, overexpression of miR-16 in temozolomide-resistant cells inhibited Bcl-2 expression and decreased temozolomide resistance. Temozolomide 40-52 BCL2 apoptosis regulator Homo sapiens 79-84 26722459-11 2015 In conclusion, MiR-16 mediated temozolomide-resistance in glioma cells by modulation of apoptosis via targeting Bcl-2, which suggesting that miR-16 and Bcl-2 would be potential therapeutic targets for glioma therapy. Temozolomide 31-43 BCL2 apoptosis regulator Homo sapiens 112-117 26722459-11 2015 In conclusion, MiR-16 mediated temozolomide-resistance in glioma cells by modulation of apoptosis via targeting Bcl-2, which suggesting that miR-16 and Bcl-2 would be potential therapeutic targets for glioma therapy. Temozolomide 31-43 BCL2 apoptosis regulator Homo sapiens 152-157 26323558-0 2015 MiR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2. Cisplatin 54-63 BCL2 apoptosis regulator Homo sapiens 77-82 26310353-14 2015 FoxO3a target genes involved in cell cycle progression and apoptosis were also investigated, and combined treatment with butein and cisplatin resulted in the downregulation of cyclin D1 and Bcl-2 and the upregulation of p27 and Bax. butein 121-127 BCL2 apoptosis regulator Homo sapiens 190-195 26310353-14 2015 FoxO3a target genes involved in cell cycle progression and apoptosis were also investigated, and combined treatment with butein and cisplatin resulted in the downregulation of cyclin D1 and Bcl-2 and the upregulation of p27 and Bax. Cisplatin 132-141 BCL2 apoptosis regulator Homo sapiens 190-195 26314326-4 2015 It has been found that resveratrol inhibited the proliferation of H838 and H520 cells in a dose- and time-dependent manner, and apoptosis was increased in cells treated with resveratrol which was associated with the depolarization of mitochondrial membrane potential, release of cytochrome c from mitochondria to cytosol, and abnormal expression of Bcl-2 and Bax proteins. Resveratrol 23-34 BCL2 apoptosis regulator Homo sapiens 349-354 26314326-4 2015 It has been found that resveratrol inhibited the proliferation of H838 and H520 cells in a dose- and time-dependent manner, and apoptosis was increased in cells treated with resveratrol which was associated with the depolarization of mitochondrial membrane potential, release of cytochrome c from mitochondria to cytosol, and abnormal expression of Bcl-2 and Bax proteins. Resveratrol 174-185 BCL2 apoptosis regulator Homo sapiens 349-354 26323558-8 2015 A luciferase reporter assay further confirmed that Bcl-2 was a direct target of miR-873, and miR-873 decreased the level of the Bcl-2 protein in cisplatin-resistant glioma cells. Cisplatin 145-154 BCL2 apoptosis regulator Homo sapiens 51-56 26314326-5 2015 Above all, resveratrol enhanced the effects of cisplatin on inhibition of cancer cell proliferation, induction of cell apoptosis, depolarization of mitochondrial membrane potential, release of cytochrome c and regulation on expression of Bcl-2 and Bax. Resveratrol 11-22 BCL2 apoptosis regulator Homo sapiens 238-243 26323558-8 2015 A luciferase reporter assay further confirmed that Bcl-2 was a direct target of miR-873, and miR-873 decreased the level of the Bcl-2 protein in cisplatin-resistant glioma cells. Cisplatin 145-154 BCL2 apoptosis regulator Homo sapiens 128-133 26314326-5 2015 Above all, resveratrol enhanced the effects of cisplatin on inhibition of cancer cell proliferation, induction of cell apoptosis, depolarization of mitochondrial membrane potential, release of cytochrome c and regulation on expression of Bcl-2 and Bax. Cisplatin 47-56 BCL2 apoptosis regulator Homo sapiens 238-243 26323558-9 2015 Notably, re-expression of Bcl-2 attenuated the function of miR-873 in cisplatin-resistant glioma cells and the sensitivity of the cells to cisplatin. Cisplatin 70-79 BCL2 apoptosis regulator Homo sapiens 26-31 26323558-9 2015 Notably, re-expression of Bcl-2 attenuated the function of miR-873 in cisplatin-resistant glioma cells and the sensitivity of the cells to cisplatin. Cisplatin 139-148 BCL2 apoptosis regulator Homo sapiens 26-31 26489625-9 2015 Moreover, SBZCC significantly reduced the mitochondrial membrane potential and induced apoptosis, accompanied with increased Bax/Bcl-2 and FlasL/Fas expression as well as caspase-3/8/9 cleavage. sbzcc 10-15 BCL2 apoptosis regulator Homo sapiens 129-134 25857363-4 2015 HS alone and ASA + HS caused a major up-regulation of HSP70 mRNA in the first 2 h, while HSP70 protein increased gradually and was especially abundant from 2 h to 24 h. Regarding Bcl-2, all treatments rendered similar results: gene expression was down-regulated in the first 2 h, after which there was protein elevation (12-48 h after HS). Aspirin 13-16 BCL2 apoptosis regulator Homo sapiens 179-184 25857363-6 2015 In conclusion, 0.4 mM ASA + HS does not act as a co-inducer of HSP70 in HepG2 cells, but promotes Bcl-2 protein expression during prolonged treatment. Aspirin 22-25 BCL2 apoptosis regulator Homo sapiens 98-103 26889365-7 2015 Also western blotting was employed to evaluate the effect of GFJ on Bax:Bcl-2 ratio. 4-[1-(5,8-difluoroquinolin-4-yl)-2-methyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzimidazol-6-yl]-3-fluoropyridin-2-amine 61-64 BCL2 apoptosis regulator Homo sapiens 72-77 26889365-11 2015 Consistently, after treating KB cells with GFJ(1mug/mL), caspase-3 activity and Bax:Bcl-2 ratio were raised by 7.3+-0.6 and (P <0.001) folds, respectively. 4-[1-(5,8-difluoroquinolin-4-yl)-2-methyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzimidazol-6-yl]-3-fluoropyridin-2-amine 43-46 BCL2 apoptosis regulator Homo sapiens 84-89 26323360-7 2015 The mechanisms involved in 17-DR-induced apoptosis included the downregulation of myeloid cell leukemia-1 (Mcl-1), and upregulation of Bcl-2 antagonist killer 1 (Bak). 17-dr 27-32 BCL2 apoptosis regulator Homo sapiens 135-140 26495060-6 2015 RESULTS: H2O2 treatment induced the activation of caspase-3, downregulated Bcl-2 expression, and up-regulated Bax expression, all of which were dose-dependently attenuated by propofol pretreatment. Hydrogen Peroxide 9-13 BCL2 apoptosis regulator Homo sapiens 75-80 26109525-0 2015 Tamoxifen-Induced Cell Death of Malignant Glioma Cells Is Brought About by Oxidative-Stress-Mediated Alterations in the Expression of BCL2 Family Members and Is Enhanced on miR-21 Inhibition. Tamoxifen 0-9 BCL2 apoptosis regulator Homo sapiens 134-138 26109525-4 2015 In the present study, tamoxifen was found to bring about autophagic cell death of human glioma cells that was accompanied by oxidative stress induction, JNK activation, downregulation of anti-autophagic BCL2 family members, viz. Tamoxifen 22-31 BCL2 apoptosis regulator Homo sapiens 203-207 26109525-6 2015 Oxidative stress induction appears to be primarily responsible for the tamoxifen-induced cell death since the cell death, JNK activation, and the alterations in the expression levels of BCL2 family members were abrogated on pretreatment with antioxidant vitamin E. Tamoxifen 71-80 BCL2 apoptosis regulator Homo sapiens 186-190 26109525-6 2015 Oxidative stress induction appears to be primarily responsible for the tamoxifen-induced cell death since the cell death, JNK activation, and the alterations in the expression levels of BCL2 family members were abrogated on pretreatment with antioxidant vitamin E. Vitamin E 254-263 BCL2 apoptosis regulator Homo sapiens 186-190 25863936-7 2015 The association of the pore opening with Ca(2+) efflux and ROS increase was proved by the inhibition of Bcl-2 overexpression and cyclosporine A treatment. ros 59-62 BCL2 apoptosis regulator Homo sapiens 104-109 26495060-6 2015 RESULTS: H2O2 treatment induced the activation of caspase-3, downregulated Bcl-2 expression, and up-regulated Bax expression, all of which were dose-dependently attenuated by propofol pretreatment. Propofol 175-183 BCL2 apoptosis regulator Homo sapiens 75-80 26151347-4 2015 Various molecular techniques were used to assess the expression of FOXO3a and B cell lymphoma 2 (Bcl-2)-interacting mediator of cell death (Bim) in cisplatin-sensitive and -resistant ovarian cancer cells. Cisplatin 148-157 BCL2 apoptosis regulator Homo sapiens 78-95 25971460-7 2015 Mechanistically, we also found that Sevoflurane treatment resulted in a reduced amount of the cytosolic anti-apoptotic protein Bcl-2 but an increased amount of Bax, which was exacerbated by knockdown of Sestrin-2. Sevoflurane 36-47 BCL2 apoptosis regulator Homo sapiens 127-132 24962868-9 2015 As compared to the vehicle control, 6SG also suppressed the expression of STAT3-regulated gene products such as Bcl-2, Bcl-xL, and Survivin in tumor tissues. shogaol 36-39 BCL2 apoptosis regulator Homo sapiens 112-117 26166196-9 2015 In addition, curcumin induced apoptosis by decreasing the Bcl-2/Bax protein ratio and increasing caspase-9/3 activation in the pancreatic cancer cells. Curcumin 13-21 BCL2 apoptosis regulator Homo sapiens 58-63 26151347-4 2015 Various molecular techniques were used to assess the expression of FOXO3a and B cell lymphoma 2 (Bcl-2)-interacting mediator of cell death (Bim) in cisplatin-sensitive and -resistant ovarian cancer cells. Cisplatin 148-157 BCL2 apoptosis regulator Homo sapiens 97-102 26252504-10 2015 Furthermore, treatment with PGE1 significantly reduced SD-induced apoptosis, decreased the protein expression levels of Bax and caspase-3, and increased the expression levels of Bcl-2. Alprostadil 28-32 BCL2 apoptosis regulator Homo sapiens 178-183 26206337-8 2015 Finally, we showed that 2-DG decreases Mcl-1 protein expression in AML cells and induces sensitization to both the BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w, ABT-737, and cytarabine. Deoxyglucose 24-28 BCL2 apoptosis regulator Homo sapiens 148-153 26252504-10 2015 Furthermore, treatment with PGE1 significantly reduced SD-induced apoptosis, decreased the protein expression levels of Bax and caspase-3, and increased the expression levels of Bcl-2. SD 0006 55-57 BCL2 apoptosis regulator Homo sapiens 178-183 26299305-6 2015 Furthermore, colchicine treatment induced a loss of Deltapsim, increased ROS production, activated caspase-3, upregulated BAX expression and downregulated Bcl-2 expression, which evidenced the colchicine activity on apoptosis, potentially by acting via the intrinsic apoptotic signaling pathway. Colchicine 13-23 BCL2 apoptosis regulator Homo sapiens 155-160 26516589-1 2015 The Bcl-2 family inhibitors venetoclax and navitoclax demonstrated potent antitumor activity in chronic lymphocytic leukemia patients, notably in reducing marrow load and adenopathy. venetoclax 28-38 BCL2 apoptosis regulator Homo sapiens 4-9 26299305-6 2015 Furthermore, colchicine treatment induced a loss of Deltapsim, increased ROS production, activated caspase-3, upregulated BAX expression and downregulated Bcl-2 expression, which evidenced the colchicine activity on apoptosis, potentially by acting via the intrinsic apoptotic signaling pathway. Colchicine 193-203 BCL2 apoptosis regulator Homo sapiens 155-160 26547331-8 2015 Compared with cells treated with oxaliplatin alone, the cells treated with both BAF and oxaliplatin showed significantly lowered autophagosome accumulation, suppressed cell proliferation, migration and invasion, increased cell apoptosis, increased Bax expression and lowered Bcl-2 expression. Oxaliplatin 88-99 BCL2 apoptosis regulator Homo sapiens 275-280 26516589-1 2015 The Bcl-2 family inhibitors venetoclax and navitoclax demonstrated potent antitumor activity in chronic lymphocytic leukemia patients, notably in reducing marrow load and adenopathy. navitoclax 43-53 BCL2 apoptosis regulator Homo sapiens 4-9 26314849-7 2015 More importantly, AZD5582 induced a decrease of Mcl-1 protein, a member of the Bcl-2 family, but not that of Bcl-2 and Bcl-xL. N,N'-(2,2'-(hexa-2,4-diyne-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(1-(2-cyclohexyl-2-(2-(methylamino)propanamido)acetyl)pyrrolidine-2-carboxamide) 18-25 BCL2 apoptosis regulator Homo sapiens 79-84 26148472-0 2015 Pachymic Acid Induces Apoptosis of EJ Bladder Cancer Cells by DR5 Up-Regulation, ROS Generation, Modulation of Bcl-2 and IAP Family Members. pachymic acid 0-13 BCL2 apoptosis regulator Homo sapiens 111-116 26148472-6 2015 Furthermore, PA activates Bid and induced the loss of mitochondrial membrane potential (DeltaPsim ) with up-regulated pro-apoptotic proteins (Bax and Bad), down-regulated anti-apoptotic proteins (Bcl-2 and Bcl-xL) and cytochrome c release. pachymic acid 13-15 BCL2 apoptosis regulator Homo sapiens 196-201 26524020-7 2015 CONCLUSION: Emodin combined AZT can synergistically inhibit the proliferation, induce cell apoptosis, and down regulate the expression of NF-kappaB, BCL-2 and TGF-beta mRNA and proteins in the CLSC, the possible mechanism of synergistic effect may be associated with inhibiton of BCL-2 activation and down-regulation of the expression of NF-kappaB, and TGF-beta. Zidovudine 28-31 BCL2 apoptosis regulator Homo sapiens 149-154 26524020-7 2015 CONCLUSION: Emodin combined AZT can synergistically inhibit the proliferation, induce cell apoptosis, and down regulate the expression of NF-kappaB, BCL-2 and TGF-beta mRNA and proteins in the CLSC, the possible mechanism of synergistic effect may be associated with inhibiton of BCL-2 activation and down-regulation of the expression of NF-kappaB, and TGF-beta. Zidovudine 28-31 BCL2 apoptosis regulator Homo sapiens 280-285 26313152-8 2015 Expression of anti-apoptotic proteins Bcl-2 and Mcl-1 and DNA repair associated molecules ATM, CHK1, TP73, p53, and ERCC1 were significantly up regulated in cisplatin-treated A549sc and H157sc cells, but no increase was detected in A549IL-6si and H157IL-6si cells. Cisplatin 157-166 BCL2 apoptosis regulator Homo sapiens 38-43 26216510-7 2015 Exposure of ciPTEC to pCG caused epithelial-to-mesenchymal transition, indicated by increased expression of vimentin and Bcl-2, and diminished E-cadherin. ciptec 12-18 BCL2 apoptosis regulator Homo sapiens 121-126 26216510-7 2015 Exposure of ciPTEC to pCG caused epithelial-to-mesenchymal transition, indicated by increased expression of vimentin and Bcl-2, and diminished E-cadherin. 4-cresylglucuronide 22-25 BCL2 apoptosis regulator Homo sapiens 121-126 26524020-0 2015 [Effect of Emodin Combined with AZT on the Proliferation and the Expression of BCL-2, NF-kappaB, TGF-beta in the Leukemia Stem Cells-KG-1a cells]. Zidovudine 32-35 BCL2 apoptosis regulator Homo sapiens 79-84 25714012-6 2015 Noxa, a pro-apoptotic Bcl-2 family member essential for the cytotoxicity of BZM, was significantly hypomethylated and induced following BZM treatment. Bortezomib 76-79 BCL2 apoptosis regulator Homo sapiens 22-27 25714012-6 2015 Noxa, a pro-apoptotic Bcl-2 family member essential for the cytotoxicity of BZM, was significantly hypomethylated and induced following BZM treatment. Bortezomib 136-139 BCL2 apoptosis regulator Homo sapiens 22-27 26317541-0 2015 A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2. sapropterin 34-37 BCL2 apoptosis regulator Homo sapiens 48-53 26317541-0 2015 A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2. sapropterin 34-37 BCL2 apoptosis regulator Homo sapiens 194-199 26317541-0 2015 A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2. BH 3 172-175 BCL2 apoptosis regulator Homo sapiens 48-53 26317541-0 2015 A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2. BH 3 172-175 BCL2 apoptosis regulator Homo sapiens 194-199 26394044-6 2015 Down-regulation of BCL2 by antisense oligonucleotides or siRNA also significantly down-regulated miRNA-10b, suggesting that BCL2 is a major mediator of the effects of miRNA-10b. Oligonucleotides 37-53 BCL2 apoptosis regulator Homo sapiens 19-23 26317541-3 2015 In the other mechanism, the BH4 domain mediates interaction of Bcl-2 with inositol 1,4, 5-trisphosphate receptors (IP3Rs), inhibiting pro-apoptotic Ca2+ signals. sapropterin 28-31 BCL2 apoptosis regulator Homo sapiens 63-68 26317541-4 2015 The current anti-Bcl-2 agents, ABT-263 (Navitoclax) and ABT-199 (Venetoclax), induce apoptosis by displacing pro-apoptotic proteins from the hydrophobic pocket, but do not inhibit Bcl-2-IP3R interaction. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 31-34 BCL2 apoptosis regulator Homo sapiens 17-22 26317541-4 2015 The current anti-Bcl-2 agents, ABT-263 (Navitoclax) and ABT-199 (Venetoclax), induce apoptosis by displacing pro-apoptotic proteins from the hydrophobic pocket, but do not inhibit Bcl-2-IP3R interaction. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 31-34 BCL2 apoptosis regulator Homo sapiens 180-185 26317541-4 2015 The current anti-Bcl-2 agents, ABT-263 (Navitoclax) and ABT-199 (Venetoclax), induce apoptosis by displacing pro-apoptotic proteins from the hydrophobic pocket, but do not inhibit Bcl-2-IP3R interaction. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 56-59 BCL2 apoptosis regulator Homo sapiens 17-22 26317541-4 2015 The current anti-Bcl-2 agents, ABT-263 (Navitoclax) and ABT-199 (Venetoclax), induce apoptosis by displacing pro-apoptotic proteins from the hydrophobic pocket, but do not inhibit Bcl-2-IP3R interaction. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 56-59 BCL2 apoptosis regulator Homo sapiens 180-185 26317541-5 2015 Therefore, to target this interaction we developed BIRD-2 (Bcl-2 IP3 Receptor Disruptor-2), a decoy peptide that binds to the BH4 domain, blocking Bcl-2-IP3R interaction and thus inducing Ca2+-mediated apoptosis in chronic lymphocytic leukemia, multiple myeloma, and follicular lymphoma cells, including cells resistant to ABT-263, ABT-199, or the Bruton"s tyrosine kinase inhibitor Ibrutinib. sapropterin 126-129 BCL2 apoptosis regulator Homo sapiens 59-64 26317541-5 2015 Therefore, to target this interaction we developed BIRD-2 (Bcl-2 IP3 Receptor Disruptor-2), a decoy peptide that binds to the BH4 domain, blocking Bcl-2-IP3R interaction and thus inducing Ca2+-mediated apoptosis in chronic lymphocytic leukemia, multiple myeloma, and follicular lymphoma cells, including cells resistant to ABT-263, ABT-199, or the Bruton"s tyrosine kinase inhibitor Ibrutinib. sapropterin 126-129 BCL2 apoptosis regulator Homo sapiens 147-152 26317541-5 2015 Therefore, to target this interaction we developed BIRD-2 (Bcl-2 IP3 Receptor Disruptor-2), a decoy peptide that binds to the BH4 domain, blocking Bcl-2-IP3R interaction and thus inducing Ca2+-mediated apoptosis in chronic lymphocytic leukemia, multiple myeloma, and follicular lymphoma cells, including cells resistant to ABT-263, ABT-199, or the Bruton"s tyrosine kinase inhibitor Ibrutinib. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 323-326 BCL2 apoptosis regulator Homo sapiens 59-64 26317541-5 2015 Therefore, to target this interaction we developed BIRD-2 (Bcl-2 IP3 Receptor Disruptor-2), a decoy peptide that binds to the BH4 domain, blocking Bcl-2-IP3R interaction and thus inducing Ca2+-mediated apoptosis in chronic lymphocytic leukemia, multiple myeloma, and follicular lymphoma cells, including cells resistant to ABT-263, ABT-199, or the Bruton"s tyrosine kinase inhibitor Ibrutinib. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 323-326 BCL2 apoptosis regulator Homo sapiens 147-152 26317541-5 2015 Therefore, to target this interaction we developed BIRD-2 (Bcl-2 IP3 Receptor Disruptor-2), a decoy peptide that binds to the BH4 domain, blocking Bcl-2-IP3R interaction and thus inducing Ca2+-mediated apoptosis in chronic lymphocytic leukemia, multiple myeloma, and follicular lymphoma cells, including cells resistant to ABT-263, ABT-199, or the Bruton"s tyrosine kinase inhibitor Ibrutinib. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 332-335 BCL2 apoptosis regulator Homo sapiens 59-64 26317541-5 2015 Therefore, to target this interaction we developed BIRD-2 (Bcl-2 IP3 Receptor Disruptor-2), a decoy peptide that binds to the BH4 domain, blocking Bcl-2-IP3R interaction and thus inducing Ca2+-mediated apoptosis in chronic lymphocytic leukemia, multiple myeloma, and follicular lymphoma cells, including cells resistant to ABT-263, ABT-199, or the Bruton"s tyrosine kinase inhibitor Ibrutinib. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 332-335 BCL2 apoptosis regulator Homo sapiens 147-152 26317541-5 2015 Therefore, to target this interaction we developed BIRD-2 (Bcl-2 IP3 Receptor Disruptor-2), a decoy peptide that binds to the BH4 domain, blocking Bcl-2-IP3R interaction and thus inducing Ca2+-mediated apoptosis in chronic lymphocytic leukemia, multiple myeloma, and follicular lymphoma cells, including cells resistant to ABT-263, ABT-199, or the Bruton"s tyrosine kinase inhibitor Ibrutinib. ibrutinib 383-392 BCL2 apoptosis regulator Homo sapiens 59-64 26317541-5 2015 Therefore, to target this interaction we developed BIRD-2 (Bcl-2 IP3 Receptor Disruptor-2), a decoy peptide that binds to the BH4 domain, blocking Bcl-2-IP3R interaction and thus inducing Ca2+-mediated apoptosis in chronic lymphocytic leukemia, multiple myeloma, and follicular lymphoma cells, including cells resistant to ABT-263, ABT-199, or the Bruton"s tyrosine kinase inhibitor Ibrutinib. ibrutinib 383-392 BCL2 apoptosis regulator Homo sapiens 147-152 26317541-7 2015 Overall, these findings provide strong rationale for developing novel therapeutic agents that mimic the action of BIRD-2 in targeting the BH4 domain of Bcl-2 and disrupting Bcl-2-IP3R interaction. sapropterin 138-141 BCL2 apoptosis regulator Homo sapiens 152-157 26284974-4 2015 The underlying mechanisms of idebenone included inhibition of oxidative damage, suppression of the down-regulation of Bcl-2 and up-regulation of Bax and cleaved caspase-3 in human umbilical vein endothelial cells (HUVECs) exposed to oxLDL. idebenone 29-38 BCL2 apoptosis regulator Homo sapiens 118-123 26378049-7 2015 Cells lacking the two pro-apoptotic multidomain proteins from the BCL-2 family, BAX and BAK, were less susceptible to LTX-315-mediated killing. LTX-315 118-125 BCL2 apoptosis regulator Homo sapiens 66-71 26411306-1 2015 We showed previously that phosphorylation of Noxa, a 54-residue Bcl-2 protein, at serine 13 (Ser13) inhibited its ability to promote apoptosis through interactions with canonical binding partner, Mcl-1. Serine 82-88 BCL2 apoptosis regulator Homo sapiens 64-69 26406239-5 2015 Pro-apoptotic Bcl-2 antagonist killer 1 (Bak) plays an important role in Taxol-induced apoptosis in breast cancer. Paclitaxel 73-78 BCL2 apoptosis regulator Homo sapiens 14-19 26247420-8 2015 Furthermore, BPA increased the levels of the anti-apoptotic proteins (Bcl-2 and Hsp70) and decreased HIF-1alpha levels during stress-induced conditions. bisphenol A 13-16 BCL2 apoptosis regulator Homo sapiens 70-75 26394044-7 2015 ABT-737 and ABT-199, potent inhibitors of BCL2, downregulated the expression of miRNA-10b and increased apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 42-46 26394044-7 2015 ABT-737 and ABT-199, potent inhibitors of BCL2, downregulated the expression of miRNA-10b and increased apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 12-15 BCL2 apoptosis regulator Homo sapiens 42-46 26550453-8 2015 Treatment with PX-12 increased the expression of bax and reduced the expression of bcl-2, indicating that PX-12-mediated apoptosis is mitochondria-dependent. 1-methylpropyl-2-imidazolyl disulfide 15-20 BCL2 apoptosis regulator Homo sapiens 83-88 26378933-4 2015 In vitro analysis revealed a higher resistance to bortezomib possibly due to an altered gene expression profile caused by del(8)(p21) including genes such as TRAIL-R4, CCDC25, RHOBTB2, PTK2B, SCARA3, MYC, BCL2 and TP53. Bortezomib 50-60 BCL2 apoptosis regulator Homo sapiens 205-209 26375587-2 2015 We hypothesized that basal levels of prosurvival BCL-2 family proteins may modulate the predictive power of BH3 profiling and termed it mitochondrial profiling. BH 3 108-111 BCL2 apoptosis regulator Homo sapiens 49-54 26375587-4 2015 We found that the apoptogenic efficacies of ABT-199 and cytarabine correlated well with BH3 profiling reflecting BCL2, but not BCL-XL or MCL-1 dependence. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 44-47 BCL2 apoptosis regulator Homo sapiens 113-117 26375587-4 2015 We found that the apoptogenic efficacies of ABT-199 and cytarabine correlated well with BH3 profiling reflecting BCL2, but not BCL-XL or MCL-1 dependence. BH 3 88-91 BCL2 apoptosis regulator Homo sapiens 113-117 26375587-5 2015 Baseline BCL-2 protein expression analysis increased the ability of BH3 profiling to predict resistance mediated by MCL-1. BH 3 68-71 BCL2 apoptosis regulator Homo sapiens 9-14 26375587-6 2015 By utilizing engineered cells with overexpression or knockdown of BCL-2 family proteins, Ara-C was found to be independent, while ABT-199 was dependent on BCL-XL. Cytarabine 89-94 BCL2 apoptosis regulator Homo sapiens 66-71 26550453-8 2015 Treatment with PX-12 increased the expression of bax and reduced the expression of bcl-2, indicating that PX-12-mediated apoptosis is mitochondria-dependent. 1-methylpropyl-2-imidazolyl disulfide 106-111 BCL2 apoptosis regulator Homo sapiens 83-88 26370970-12 2015 The decrease in mitochondrial membrane potential, increased ROS production, increased Bax and decreased Bcl-2 mRNA expression are mitochondrial events involved in cadmium-induced apoptosis. Cadmium 163-170 BCL2 apoptosis regulator Homo sapiens 104-109 26235879-3 2015 Shikonin-induced apoptosis was associated with activation of caspase-3, poly(ADP-ribose) polymerase (PARP) cleavage, up-regulation of p73, and down-regulation of BCL-2. shikonin 0-8 BCL2 apoptosis regulator Homo sapiens 162-167 26240231-9 2015 The prognostic significance of COO was particularly evident in patients with intermediate IPI scores and the non-MYC-positive/BCL2-positive subgroup (log-rank P < .001 for time to progression). coo 31-34 BCL2 apoptosis regulator Homo sapiens 126-130 26400287-3 2015 Berberine was reported to inhibit the proliferation of A431 cells in a dose- and time-dependent manner and was observed to induce a series of biochemical events, including the loss of mitochondrial membrane potential, release of cytochrome-c to cytosol, induction of proteins of the Bcl-2 family and caspases, and the cleavage of poly(ADP)-ribose polymerase. Berberine 0-9 BCL2 apoptosis regulator Homo sapiens 283-288 26367393-11 2015 SDT groups also show a rather high expression of apoptosis-promoting proteins, including Bax, Fas and Fas-L, and a significant low expression of apoptosis-suspending proteins including Bcl-2 and Survivin. 3,4-Dihydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione 0-3 BCL2 apoptosis regulator Homo sapiens 185-190 26186940-9 2015 Finally, glutaminolysis inhibition activated mitochondrial apoptosis and synergistically sensitized leukemic cells to priming with the BCL-2 inhibitor ABT-199. venetoclax 151-158 BCL2 apoptosis regulator Homo sapiens 135-140 26347142-7 2015 Up-regulation of apoptotic genes (e.g. p53, bax/bcl2 ratio, caspase-3 &caspase-9) along with loss of mitochondrial membrane potential suggested that Al-doped ZnO nanoparticles induced apoptosis in MCF-7 cells through mitochondrial pathway. Aluminum 153-155 BCL2 apoptosis regulator Homo sapiens 48-52 25524010-4 2015 METHODS: This study analyzed the expression of Bcl-2 family proteins in polyploidization induced by AZD1152 and the in vitro synergistic effects of AZD1152 with control of the Bcl-2 family pathway in human HCC cells. 2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate 100-107 BCL2 apoptosis regulator Homo sapiens 47-52 26665397-13 2015 Cell cycle regulatory genes (TP53, CDKN1A) expression and protein products of genes involved in mitochondial apoptosis pathway (BAX, BCL-2) expression are changed by the presence of phenothiazine derivatives during culturing. phenothiazine 182-195 BCL2 apoptosis regulator Homo sapiens 133-138 26665399-12 2015 Stimulation with calcitriol and other vitamin D analogs led to decrease BCL-2/BAX mRNA ratio in each cell lines. Calcitriol 17-27 BCL2 apoptosis regulator Homo sapiens 72-77 26665399-12 2015 Stimulation with calcitriol and other vitamin D analogs led to decrease BCL-2/BAX mRNA ratio in each cell lines. Vitamin D 38-47 BCL2 apoptosis regulator Homo sapiens 72-77 26116623-3 2015 In vitro, C6 and vincristine coadministration induced substantial necrosis and apoptosis in multiple human cancer cell lines, which were accompanied by a profound AMP-activated protein kinase (AMPK) activation, subsequent p53 activation, mTORC1 inactivation and Bcl-2/HIF-1alpha downregulation. Vincristine 17-28 BCL2 apoptosis regulator Homo sapiens 262-267 26214321-8 2015 At the molecular level, carvacrol downregulated the expression of Bcl-2 and induced the phosphorylation of the extracellular-regulated protein kinase and protein kinase B (p-Akt). carvacrol 24-33 BCL2 apoptosis regulator Homo sapiens 66-71 26375862-3 2015 In gynecologic cancers, p53 is a pivotal determinant of cisplatin sensitivity, while BCL-2 family members are associated with taxane sensitivity. taxane 126-132 BCL2 apoptosis regulator Homo sapiens 85-90 26051518-6 2015 Treatment with 5-Fluorouracil (5-FU), a frequently used but often clinically ineffective chemotherapy drug, induced apoptosis, down-regulation of anti-apoptotic genes (BCL-2, TRAF1, and c-FLIP) and decreased cell numbers in 2D, but only "nucleolar stress" in p3D and xenografts. Fluorouracil 15-29 BCL2 apoptosis regulator Homo sapiens 168-173 26051518-6 2015 Treatment with 5-Fluorouracil (5-FU), a frequently used but often clinically ineffective chemotherapy drug, induced apoptosis, down-regulation of anti-apoptotic genes (BCL-2, TRAF1, and c-FLIP) and decreased cell numbers in 2D, but only "nucleolar stress" in p3D and xenografts. Fluorouracil 31-35 BCL2 apoptosis regulator Homo sapiens 168-173 26051518-7 2015 Conversely, BCL-2 inhibitor ABT-199 induced cytotoxic effects in p3D but not in 2D cultures. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 28-31 BCL2 apoptosis regulator Homo sapiens 12-17 25942994-0 2015 Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. navitoclax 93-103 BCL2 apoptosis regulator Homo sapiens 78-82 25942994-1 2015 The oral BCL2 inhibitor navitoclax has moderate single-agent efficacy in chronic lymphocytic leukaemia (CLL) and minor activity in lymphoma in Phase 1 trials. navitoclax 24-34 BCL2 apoptosis regulator Homo sapiens 9-13 25701954-9 2015 In addition, the expression of Bax in cytoplasm was elevated significantly along with the sharply decline of Bcl-2 expression in DHA-treated HCT-116 cells. artenimol 129-132 BCL2 apoptosis regulator Homo sapiens 109-114 26412425-2 2015 Herein, isochamaejasmin was found to show similar bioactivity against Bcl-2 family proteins to the reference Bcl-2 ligand (-)-gossypol through 3D similarity search. Gossypol 122-134 BCL2 apoptosis regulator Homo sapiens 109-114 25966046-7 2015 The mRNA levels for the tumor suppressor gene p53 and the apoptotic genes bax, CASP3 and CASP9 were up-regulated, while the anti-apoptotic gene bcl-2 was down-regulated following nickel ferrite NP exposure. Nickel 179-185 BCL2 apoptosis regulator Homo sapiens 144-149 26061993-7 2015 Furthermore, farrerol decreased the gene expression of Bcl-2, whereas the gene expression level of Bax was found to increase after farrerol treatment. farrerol 13-21 BCL2 apoptosis regulator Homo sapiens 55-60 26015514-6 2015 In the neoadjuvant clinical study, lapatinib treatment for 2 weeks was associated with parallel upregulation of ER and Bcl2 (Spearman coefficient: 0.70; P = 0.0002). Lapatinib 35-44 BCL2 apoptosis regulator Homo sapiens 119-123 25979647-14 2015 Also, immunoblotting assays exhibited increased Bax and decreased Bcl-2, suggesting that autophagy inhibition by CQ could increase cell apoptosis and thus overcome the antagonistic effects. Chloroquine 113-115 BCL2 apoptosis regulator Homo sapiens 66-71 24604693-7 2015 Moreover, PCB29-pQ exposure induced B-cell lymphoma 2 (Bcl-2) downregulation and Bcl-2-associated X (Bax) upregulation, poly(ADP-ribose) polymerase cleavage, accompanied with the increased caspase-3/9 and p53 expressions. 2,3,5-trichloro-6-phenyl-(1,4)benzoquinone 10-18 BCL2 apoptosis regulator Homo sapiens 36-53 24604693-7 2015 Moreover, PCB29-pQ exposure induced B-cell lymphoma 2 (Bcl-2) downregulation and Bcl-2-associated X (Bax) upregulation, poly(ADP-ribose) polymerase cleavage, accompanied with the increased caspase-3/9 and p53 expressions. 2,3,5-trichloro-6-phenyl-(1,4)benzoquinone 10-18 BCL2 apoptosis regulator Homo sapiens 55-60 25975837-0 2015 ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2. Bortezomib 60-70 BCL2 apoptosis regulator Homo sapiens 121-126 26400523-9 2015 Furthermore, caffeine induced cell apoptosis, decreased expression of Bcl-2, and increased expression of Cyt-C and Caspase-3. Caffeine 13-21 BCL2 apoptosis regulator Homo sapiens 70-75 26201988-10 2015 Amantadine treatment also reduced Bcl-2 and increased the Bax protein and mRNA levels. Amantadine 0-10 BCL2 apoptosis regulator Homo sapiens 34-39 26201988-11 2015 Additionally, Bcl-2/Bax ratios were lower in the two HCC cell lines following amantadine treatment. Amantadine 78-88 BCL2 apoptosis regulator Homo sapiens 14-19 26202061-8 2015 Additionally, upon treatment with TA, the expression of mitochondrial pore factors Bax, Bcl-2 and Bcl-XL were changed. Tannins 34-36 BCL2 apoptosis regulator Homo sapiens 88-93 26301373-9 2015 Despite the expression of BCL2, which is considered as a poor prognosis marker, our patient responded very well to the combined radiotherapy and chemotherapy with the R-MPV (rituximab, MTX, procarbazine, and vincristine) regimen. r-mpv 167-172 BCL2 apoptosis regulator Homo sapiens 26-30 26617773-8 2015 Survivin and Bcl-2 were considerably downregulated in U266/PDCD5 cells and combined DXM group than in the single agent group. Dexamethasone 84-87 BCL2 apoptosis regulator Homo sapiens 13-18 26617858-9 2015 As compared with the control (GIST-R cells without any treatment), the expression levels of p-mTOR and Bcl-2 proteins of GIST-R cells in combination of Peg-IFNalpha-2b and imatinib group were decreased (P<0.01). Imatinib Mesylate 172-180 BCL2 apoptosis regulator Homo sapiens 103-108 25633717-0 2015 The tubulysin analogue KEMTUB10 induces apoptosis in breast cancer cells via p53, Bim and Bcl-2. kemtub10 23-31 BCL2 apoptosis regulator Homo sapiens 90-95 25633717-8 2015 KEMTUB10-induced apoptosis involves p53 and Bim, and to some extent Bcl-2 phosphorylation. kemtub10 0-8 BCL2 apoptosis regulator Homo sapiens 68-73 26372842-3 2015 Data showed that H2 O2 enhanced Bax, caspase-3 and caspase-8 expression, and declined Bcl-2 expression. Hydrogen Peroxide 17-22 BCL2 apoptosis regulator Homo sapiens 86-91 26104578-3 2015 The analysis of gene expression revealed that myricetin inhibits PAK1 by abrogating the Ras-mediated signaling by decelerating Wnt signaling, the downstream of Erk/Akt, thereby inducing intrinsic caspase-mediated mitochondrial apoptosis by downregulating the expression of anti-apoptotic Bcl-2 and survivin and upregulating pro-apoptotic Bax. myricetin 46-55 BCL2 apoptosis regulator Homo sapiens 288-293 26452526-6 2015 Moreover, schisandrin pretreatment inhibited cell apoptosis, as evidenced by inhibiting activation of caspase-3 and increasing the Bcl-2/Bax ratio. schizandrin 10-21 BCL2 apoptosis regulator Homo sapiens 131-136 25341848-0 2015 Comment on "Complex disruption effect of natural polyphenols on Bcl-2-Bax: molecular dynamics simulation and essential dynamics study" by S. Verma, A. Singh and A. Mishra. Polyphenols 49-60 BCL2 apoptosis regulator Homo sapiens 64-69 26214592-7 2015 Striking on-target sensitivity was achieved with the BCL2-specific inhibitor venetoclax (ABT-199). venetoclax 77-87 BCL2 apoptosis regulator Homo sapiens 53-57 26101222-4 2015 Moreover, BEZ cotreatment significantly improved the effects of DOX toward both cell viability and cell death in part through reduced Bcl-2 expression and increased expression of the shorter, more cytotoxic forms of BIM. dactolisib 10-13 BCL2 apoptosis regulator Homo sapiens 134-139 26101222-4 2015 Moreover, BEZ cotreatment significantly improved the effects of DOX toward both cell viability and cell death in part through reduced Bcl-2 expression and increased expression of the shorter, more cytotoxic forms of BIM. Doxorubicin 64-67 BCL2 apoptosis regulator Homo sapiens 134-139 26214592-7 2015 Striking on-target sensitivity was achieved with the BCL2-specific inhibitor venetoclax (ABT-199). venetoclax 89-96 BCL2 apoptosis regulator Homo sapiens 53-57 26081917-13 2015 We have developed a (177)Lu-DOTA-anti-bcl-2-PNA-Tyr(3)-octreotate conjugate for targeted antisense radiotherapy, in which down-regulation of bcl-2 and delivery of cytotoxic radiation occur simultaneously. lu-dota 25-32 BCL2 apoptosis regulator Homo sapiens 38-43 26594769-5 2015 The results revealed that siomycin A induced apoptosis by influencing the downstream events of FoxM1, including inhibiting the expression of Bcl-2 and Mcl-1, as well as leading to caspase-3 cleavage. siomycin A 26-36 BCL2 apoptosis regulator Homo sapiens 141-146 26165547-10 2015 Furthermore, we observed that celastrol upregulated the expression of the pro-apoptotic proteins Bax and cytochrome c and altered the ratio of Bax/Bcl-2, and triggered the mitochondrial apoptotic pathway, resulting in caspase-3 and -9 activation and PARP cleavage. celastrol 30-39 BCL2 apoptosis regulator Homo sapiens 147-152 26121939-1 2015 OBJECTIVES: To evaluate the anti-tumor effect of BM-1197, a new potent and highly specific small molecule inhibitor of Bcl-2/Bcl-xL, in preclinical models of human adenoid cystic carcinoma (ACC). BM-1197 49-56 BCL2 apoptosis regulator Homo sapiens 119-124 26622683-0 2015 Guggulsterone inhibits human cholangiocarcinoma Sk-ChA-1 and Mz-ChA-1 cell growth by inducing caspase-dependent apoptosis and downregulation of survivin and Bcl-2 expression. pregna-4,17-diene-3,16-dione 0-13 BCL2 apoptosis regulator Homo sapiens 157-162 26622683-10 2015 In addition, guggulsterone-induced apoptosis of cholangiocarcinoma cells was demonstrated to be partially inhibited by the caspase inhibitors z-VAD-fmk, z-LEHD-fmk and z-IETD-fmk, accompanied by the activation of caspases-3, -8 and -9, accumulation of cleaved PARP and decreased expression of survivin and Bcl-2. pregna-4,17-diene-3,16-dione 13-26 BCL2 apoptosis regulator Homo sapiens 306-311 26622683-11 2015 In conclusion, the present study demonstrated that guggulsterone was able to suppress the proliferation of cholangiocarcinoma by inducing caspase-dependent apoptosis and downregulating survivin and Bcl-2. pregna-4,17-diene-3,16-dione 51-64 BCL2 apoptosis regulator Homo sapiens 198-203 26194899-5 2015 Moreover, the activation of caspase 3 followed decrease in the Bcl-2/Bax ratio after treatment with 3EZ, 20Ac-ingenol, and accumulation of sub-G1 phase cells was observed in flow cytometry analyses. 20ac-ingenol 105-117 BCL2 apoptosis regulator Homo sapiens 63-68 25916210-9 2015 In addition, the expressions of Bcl-2 and Mcl-1 were decreased in 786-O and A-498 cells after nimbolide treatment. nimbolide 94-103 BCL2 apoptosis regulator Homo sapiens 32-37 26180030-14 2015 Phentolamine induced the phosphorylation and degradation of Bcl-2 and Bcl-xL, two anti-apoptotic Bcl-2 family members, and the loss of DeltaPsim indicating the induction of mitochondrial damage. Phentolamine 0-12 BCL2 apoptosis regulator Homo sapiens 60-65 26180030-14 2015 Phentolamine induced the phosphorylation and degradation of Bcl-2 and Bcl-xL, two anti-apoptotic Bcl-2 family members, and the loss of DeltaPsim indicating the induction of mitochondrial damage. Phentolamine 0-12 BCL2 apoptosis regulator Homo sapiens 97-102 26713524-6 2015 Combination of carbo and ABT888 significantly down-regulated the expression of anti-apoptosis factors Bcl-2 and up-regulated the pro-apoptosis proteins Bax and cleaved caspase-3. carbo 15-20 BCL2 apoptosis regulator Homo sapiens 102-107 26713524-6 2015 Combination of carbo and ABT888 significantly down-regulated the expression of anti-apoptosis factors Bcl-2 and up-regulated the pro-apoptosis proteins Bax and cleaved caspase-3. veliparib 25-31 BCL2 apoptosis regulator Homo sapiens 102-107 26056043-0 2015 Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. Metformin 0-9 BCL2 apoptosis regulator Homo sapiens 154-159 26622760-0 2015 Wogonoside induces apoptosis in Bel-7402, a hepatocellular carcinoma cell line, by regulating Bax/Bcl-2. wogonoside 0-10 BCL2 apoptosis regulator Homo sapiens 98-103 26056043-0 2015 Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. Aspirin 24-31 BCL2 apoptosis regulator Homo sapiens 154-159 26110568-7 2015 Targeting Bcl-2 with the selective BH3-mimetic agent ABT-199 sensitized Bcl-2high MCL cells to acadesine. BH 3 35-38 BCL2 apoptosis regulator Homo sapiens 72-77 26056043-10 2015 Taken together, the combination of metformin and aspirin significantly inhibited pancreatic cancer cell growth in vitro and in vivo by regulating the pro- and anti-apoptotic Bcl-2 family members, supporting the continued investigation of this two drug combination as chemopreventive or chemotherapeutic agents for pancreatic cancer. Metformin 35-44 BCL2 apoptosis regulator Homo sapiens 174-179 26110568-7 2015 Targeting Bcl-2 with the selective BH3-mimetic agent ABT-199 sensitized Bcl-2high MCL cells to acadesine. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 53-56 BCL2 apoptosis regulator Homo sapiens 10-15 26056043-7 2015 Remarkably, metformin combined with aspirin significantly downregulated the anti-apoptotic proteins Mcl-1 and Bcl-2, and upregulated the pro-apoptotic proteins Bim and Puma, as well as interrupted their interactions. Metformin 12-21 BCL2 apoptosis regulator Homo sapiens 110-115 26110568-7 2015 Targeting Bcl-2 with the selective BH3-mimetic agent ABT-199 sensitized Bcl-2high MCL cells to acadesine. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 53-56 BCL2 apoptosis regulator Homo sapiens 72-77 26056043-10 2015 Taken together, the combination of metformin and aspirin significantly inhibited pancreatic cancer cell growth in vitro and in vivo by regulating the pro- and anti-apoptotic Bcl-2 family members, supporting the continued investigation of this two drug combination as chemopreventive or chemotherapeutic agents for pancreatic cancer. Aspirin 49-56 BCL2 apoptosis regulator Homo sapiens 174-179 26056043-7 2015 Remarkably, metformin combined with aspirin significantly downregulated the anti-apoptotic proteins Mcl-1 and Bcl-2, and upregulated the pro-apoptotic proteins Bim and Puma, as well as interrupted their interactions. Aspirin 36-43 BCL2 apoptosis regulator Homo sapiens 110-115 26110568-0 2015 Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199. acadesine 55-64 BCL2 apoptosis regulator Homo sapiens 0-5 26110568-0 2015 Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 70-73 BCL2 apoptosis regulator Homo sapiens 0-5 26110568-7 2015 Targeting Bcl-2 with the selective BH3-mimetic agent ABT-199 sensitized Bcl-2high MCL cells to acadesine. acadesine 95-104 BCL2 apoptosis regulator Homo sapiens 10-15 26110568-9 2015 These findings support the notions that antiapoptotic proteins of the Bcl-2 family regulate MCL cell sensitivity to acadesine and that the combination of this agent with Bcl-2 inhibitors might be an interesting therapeutic option to treat MCL patients. acadesine 116-125 BCL2 apoptosis regulator Homo sapiens 70-75 26306624-5 2015 By knocking down the proapoptotic BCL-2 family member BIM, we proved this protein to be involved in the synergistic induction of apoptosis by dexamethasone and forskolin. Dexamethasone 142-155 BCL2 apoptosis regulator Homo sapiens 34-39 26234731-8 2015 Catechin treatment also up-regulated Bcl-2 levels and restored MSU-induced mitochondrial transmembrane potential impairment. Catechin 0-8 BCL2 apoptosis regulator Homo sapiens 37-42 26405692-2 2015 The G-quadruplex (G4) sequences regulating the c-MYC, KRAS, VEGF, BCL-2, HIF-1alpha, and RET oncogenes, as examples, are targets for oxidation at loop and 5"-core guanines (G) as showcased in this study by CO3 - oxidation of the VEGF G4. Guanine 163-171 BCL2 apoptosis regulator Homo sapiens 66-71 26405692-2 2015 The G-quadruplex (G4) sequences regulating the c-MYC, KRAS, VEGF, BCL-2, HIF-1alpha, and RET oncogenes, as examples, are targets for oxidation at loop and 5"-core guanines (G) as showcased in this study by CO3 - oxidation of the VEGF G4. co3 206-209 BCL2 apoptosis regulator Homo sapiens 66-71 26110568-7 2015 Targeting Bcl-2 with the selective BH3-mimetic agent ABT-199 sensitized Bcl-2high MCL cells to acadesine. BH 3 35-38 BCL2 apoptosis regulator Homo sapiens 10-15 26188358-6 2015 Addition of ABT-263, a Bcl-2 family inhibitor, to Ox-1, or the other polyploidy-inducer, ZM447439 (ZM), produces a synergistic loss of cell viability with greater sustained tumor growth inhibition in AML cell lines and primary AML blasts. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 12-15 BCL2 apoptosis regulator Homo sapiens 23-28 26306624-5 2015 By knocking down the proapoptotic BCL-2 family member BIM, we proved this protein to be involved in the synergistic induction of apoptosis by dexamethasone and forskolin. Colforsin 160-169 BCL2 apoptosis regulator Homo sapiens 34-39 26307972-6 2015 Immunohistochemical and Western blot analysis revealed that curcumol could decrease the expression of ki-67, Bcl-2 as well as CREB1, and increase the expression of Bax and the phosphorylation of p38, which were consistent with our in vitro study. curcumol 60-68 BCL2 apoptosis regulator Homo sapiens 109-114 26345420-8 2015 CONCLUSION: Fe3O4-MNP can promote GA-induced apoptosis of SMMC-7721 cells, which may be related to the downregulation of Bcl-2 and upregulation of caspase-3. gambogic acid 34-36 BCL2 apoptosis regulator Homo sapiens 121-126 26285204-9 2015 The significant upregulation of the key antiapoptotic protein Bcl-2 in Mino/FR cells was associated with the markedly increased sensitivity of the fludarabine-resistant MCL cells to Bcl-2-specific inhibitor ABT199 compared to fludarabine-sensitive cells. fludarabine 147-158 BCL2 apoptosis regulator Homo sapiens 62-67 26285204-9 2015 The significant upregulation of the key antiapoptotic protein Bcl-2 in Mino/FR cells was associated with the markedly increased sensitivity of the fludarabine-resistant MCL cells to Bcl-2-specific inhibitor ABT199 compared to fludarabine-sensitive cells. fludarabine 147-158 BCL2 apoptosis regulator Homo sapiens 182-187 26285204-9 2015 The significant upregulation of the key antiapoptotic protein Bcl-2 in Mino/FR cells was associated with the markedly increased sensitivity of the fludarabine-resistant MCL cells to Bcl-2-specific inhibitor ABT199 compared to fludarabine-sensitive cells. venetoclax 207-213 BCL2 apoptosis regulator Homo sapiens 62-67 26285204-9 2015 The significant upregulation of the key antiapoptotic protein Bcl-2 in Mino/FR cells was associated with the markedly increased sensitivity of the fludarabine-resistant MCL cells to Bcl-2-specific inhibitor ABT199 compared to fludarabine-sensitive cells. venetoclax 207-213 BCL2 apoptosis regulator Homo sapiens 182-187 26285204-9 2015 The significant upregulation of the key antiapoptotic protein Bcl-2 in Mino/FR cells was associated with the markedly increased sensitivity of the fludarabine-resistant MCL cells to Bcl-2-specific inhibitor ABT199 compared to fludarabine-sensitive cells. fludarabine 226-237 BCL2 apoptosis regulator Homo sapiens 62-67 26550240-6 2015 The PCR chip detection found 13 up-regulating genes and 15 down-regulating genes, among which the expression of Bim, Caspase 9, Caspase 14, B-cell lymphoma-2 (BCL2) and BAX increased with the doses of sodium fluoride, while the expression of Caspase 3 down-regulated in 5 mg/L sodium fluoride but up-regulated at the concentration of sodium fluoride more than 10 mg/L. Sodium Fluoride 201-216 BCL2 apoptosis regulator Homo sapiens 140-157 25829398-8 2015 RESULTS: The BCL-2 antagonists, especially ABT-199, induced high cell death during ex vivo incubations. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 43-46 BCL2 apoptosis regulator Homo sapiens 13-18 25829398-11 2015 Among the three BCL-2 family antiapoptotic proteins that are overexpressed in CLL, levels of MCL-1 and BCL-XL were decreased after ibrutinib while ABT-199 selectively antagonizes BCL-2. ibrutinib 131-140 BCL2 apoptosis regulator Homo sapiens 16-21 25829398-11 2015 Among the three BCL-2 family antiapoptotic proteins that are overexpressed in CLL, levels of MCL-1 and BCL-XL were decreased after ibrutinib while ABT-199 selectively antagonizes BCL-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 147-150 BCL2 apoptosis regulator Homo sapiens 16-21 25829398-11 2015 Among the three BCL-2 family antiapoptotic proteins that are overexpressed in CLL, levels of MCL-1 and BCL-XL were decreased after ibrutinib while ABT-199 selectively antagonizes BCL-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 147-150 BCL2 apoptosis regulator Homo sapiens 179-184 26287184-3 2015 Culture studies found that methyl sartortuoate inhibited colon cancer cell (LoVo and RKO) growth and caused apoptotic death in a concentration- and time-dependent manner, by activation of caspase-8, caspase-9, caspase-3, p53 and Bax, and inactivation of B-cell lymphoma 2 (Bcl-2) apoptosis regulating proteins. methyl sartortuoate 27-46 BCL2 apoptosis regulator Homo sapiens 254-271 26287184-3 2015 Culture studies found that methyl sartortuoate inhibited colon cancer cell (LoVo and RKO) growth and caused apoptotic death in a concentration- and time-dependent manner, by activation of caspase-8, caspase-9, caspase-3, p53 and Bax, and inactivation of B-cell lymphoma 2 (Bcl-2) apoptosis regulating proteins. methyl sartortuoate 27-46 BCL2 apoptosis regulator Homo sapiens 273-278 26287184-9 2015 Taken together, these findings suggest that methyl sartortuoate is capable of leading to activation of caspase-8, -9, -3, increasing p53 and Bax/Bcl-2 ratio apoptosis through MAPK-dependent apoptosis and results in G2-M phase arrest in LoVo and RKO cells. methyl sartortuoate 44-63 BCL2 apoptosis regulator Homo sapiens 145-150 26550240-6 2015 The PCR chip detection found 13 up-regulating genes and 15 down-regulating genes, among which the expression of Bim, Caspase 9, Caspase 14, B-cell lymphoma-2 (BCL2) and BAX increased with the doses of sodium fluoride, while the expression of Caspase 3 down-regulated in 5 mg/L sodium fluoride but up-regulated at the concentration of sodium fluoride more than 10 mg/L. Sodium Fluoride 201-216 BCL2 apoptosis regulator Homo sapiens 159-163 26550421-8 2015 The results showed that the expression of miR-29a and the Bax/Bcl-2 ratio in myocardial cells were significantly increased after the cells were cultured in high glucose medium for 72 h, which was consistent with increased apoptosis of myocardial cells. glucose medium 161-175 BCL2 apoptosis regulator Homo sapiens 62-67 26550240-6 2015 The PCR chip detection found 13 up-regulating genes and 15 down-regulating genes, among which the expression of Bim, Caspase 9, Caspase 14, B-cell lymphoma-2 (BCL2) and BAX increased with the doses of sodium fluoride, while the expression of Caspase 3 down-regulated in 5 mg/L sodium fluoride but up-regulated at the concentration of sodium fluoride more than 10 mg/L. Sodium Fluoride 277-292 BCL2 apoptosis regulator Homo sapiens 140-157 26550240-6 2015 The PCR chip detection found 13 up-regulating genes and 15 down-regulating genes, among which the expression of Bim, Caspase 9, Caspase 14, B-cell lymphoma-2 (BCL2) and BAX increased with the doses of sodium fluoride, while the expression of Caspase 3 down-regulated in 5 mg/L sodium fluoride but up-regulated at the concentration of sodium fluoride more than 10 mg/L. Sodium Fluoride 277-292 BCL2 apoptosis regulator Homo sapiens 159-163 26550240-6 2015 The PCR chip detection found 13 up-regulating genes and 15 down-regulating genes, among which the expression of Bim, Caspase 9, Caspase 14, B-cell lymphoma-2 (BCL2) and BAX increased with the doses of sodium fluoride, while the expression of Caspase 3 down-regulated in 5 mg/L sodium fluoride but up-regulated at the concentration of sodium fluoride more than 10 mg/L. Sodium Fluoride 277-292 BCL2 apoptosis regulator Homo sapiens 140-157 26550240-6 2015 The PCR chip detection found 13 up-regulating genes and 15 down-regulating genes, among which the expression of Bim, Caspase 9, Caspase 14, B-cell lymphoma-2 (BCL2) and BAX increased with the doses of sodium fluoride, while the expression of Caspase 3 down-regulated in 5 mg/L sodium fluoride but up-regulated at the concentration of sodium fluoride more than 10 mg/L. Sodium Fluoride 277-292 BCL2 apoptosis regulator Homo sapiens 159-163 26268226-7 2015 RESULTS: Bcl2, an anti-apoptotic molecule and oncoprotein, effectively inhibits the endonuclease activity of mitochondrial APE1 (mtAPE1), leading to significant retardation of mtDNA repair and enhanced frequency of mtDNA mutations following exposure of cells to hydrogen peroxide (H2O2) or nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK, a carcinogen in cigarette smoke). Hydrogen Peroxide 262-279 BCL2 apoptosis regulator Homo sapiens 9-13 26550150-0 2015 MicroRNA 192 regulates chemo-resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl-2. gemcitabine 67-78 BCL2 apoptosis regulator Homo sapiens 123-128 26550150-0 2015 MicroRNA 192 regulates chemo-resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl-2. Cisplatin 83-92 BCL2 apoptosis regulator Homo sapiens 123-128 26550150-12 2015 In this study, we demonstrate that miR-192 regulates chemoresistance for gemcitabine and cisplatin combined chemotherapy in human adenocarcinoma lung cancer A549 cells, and Bcl-2 is the target of miR-192. gemcitabine 73-84 BCL2 apoptosis regulator Homo sapiens 173-178 26550158-5 2015 The MIA-PaCa-2 cells were transfected with an antisense oligonucleotide (ASO) against clusterin, which led to a decreased protein level of the antiapoptotic gene BCL-2. Oligonucleotides 56-71 BCL2 apoptosis regulator Homo sapiens 162-167 26550158-5 2015 The MIA-PaCa-2 cells were transfected with an antisense oligonucleotide (ASO) against clusterin, which led to a decreased protein level of the antiapoptotic gene BCL-2. Oligonucleotides, Antisense 73-76 BCL2 apoptosis regulator Homo sapiens 162-167 26268226-7 2015 RESULTS: Bcl2, an anti-apoptotic molecule and oncoprotein, effectively inhibits the endonuclease activity of mitochondrial APE1 (mtAPE1), leading to significant retardation of mtDNA repair and enhanced frequency of mtDNA mutations following exposure of cells to hydrogen peroxide (H2O2) or nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK, a carcinogen in cigarette smoke). Hydrogen Peroxide 281-285 BCL2 apoptosis regulator Homo sapiens 9-13 26268226-7 2015 RESULTS: Bcl2, an anti-apoptotic molecule and oncoprotein, effectively inhibits the endonuclease activity of mitochondrial APE1 (mtAPE1), leading to significant retardation of mtDNA repair and enhanced frequency of mtDNA mutations following exposure of cells to hydrogen peroxide (H2O2) or nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK, a carcinogen in cigarette smoke). SCHEMBL420028 290-348 BCL2 apoptosis regulator Homo sapiens 9-13 26079328-0 2015 Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside. BH 3 82-85 BCL2 apoptosis regulator Homo sapiens 0-5 26067553-0 2015 RLIP76-dependent suppression of PI3K/AKT/Bcl-2 pathway by miR-101 induces apoptosis in prostate cancer. mir-101 58-65 BCL2 apoptosis regulator Homo sapiens 41-46 26067553-6 2015 We found miR-101 transfection significantly suppresses RLIP76 expression, which can transactivate phosphorylation of PI3K-Akt signaling, and resulted in an amplification of Bcl2-induced apoptosis. mir-101 9-16 BCL2 apoptosis regulator Homo sapiens 173-177 26067553-8 2015 Taken together, our results revealed that the effect of miR-101 on prostate cancer cell apoptosis was due to RLIP76 regulation of the PI3K/Akt/Bcl-2 signaling pathway. mir-101 56-63 BCL2 apoptosis regulator Homo sapiens 143-148 26266540-3 2015 In the present study, we used human embryonic stem cell (hESC)-derived cortical neurons as in vitro cellular models to investigate alcohol-induced expression changes of genes involved in alcohol metabolism (ALDH2), anti-apoptosis (BCL2 and CCND2), neurotransmission (NMDA receptor subunit genes: GRIN1, GRIN2A, GRIN2B, and GRIN2D), calcium channel activity (ITPR2), or transcriptional repression (JARID2). Alcohols 131-138 BCL2 apoptosis regulator Homo sapiens 231-235 26079328-3 2015 Advances in the knowledge of the mechanism of action of anti-apoptotic and pro-apoptotic members of the Bcl-2 family have enabled the development of the so-called "BH3 mimetics". BH 3 164-167 BCL2 apoptosis regulator Homo sapiens 104-109 25979368-6 2015 Here, we reported that curcumin induced apoptosis by inhibition of AKT/mTOR and ABL/STAT5 signaling, down-regulation of BCR/ABL expression, and induction of the BCL2/BAX imbalance. Curcumin 23-31 BCL2 apoptosis regulator Homo sapiens 161-165 26622397-10 2015 In addition, examination of cytoplasmic vacuolization using microscopy indicated that there were a small number of paraptosis cells present at 24 h. The expression levels of Bcl-2 was significantly decreased, while Bax was significantly increased at 48 h. Furthermore, cycloheximide treatment was demonstrated to significantly increase Bcl-2 expression, while decreasing Bax expression (P>0.05). Cycloheximide 269-282 BCL2 apoptosis regulator Homo sapiens 174-179 26367732-11 2015 Furthermore, caffeine markedly reduced the expression of Bcl-2 (C6, U87MG: p<0.01, p<0.01), and promoted the expression of Cyt-C (C6, U87MG: p<0.05, p<0.01) and Caspase-3 (C6, U87MG: p<0.01, p<0.01), comparing to the normal control. Caffeine 13-21 BCL2 apoptosis regulator Homo sapiens 57-62 26043797-5 2015 Western blot analyses showed that MHY218 treatment resulted in decreased protein levels of procaspase-8, -9, and -3; cleavage of poly(ADP-ribose) polymerase (PARP); and alterations in the ratio of Bax/Bcl-2 protein expression. N1-hydroxy-N8-(4-phenoxyphenyl)octanediamide 34-40 BCL2 apoptosis regulator Homo sapiens 201-206 26055514-7 2015 Additionally, miR-101a significantly reversed the hypoxia-induced up-regulation of Bax and Caspase-3, the down-regulation of Bcl-2 and the activation of Caspase-3 in CFs. mir-101a 14-22 BCL2 apoptosis regulator Homo sapiens 125-130 26095084-9 2015 Metronomic vinorelbine decreased the Bcl-2/Bax ratio in normoxia whereas the ratio was reduced in severe hypoxia but unaltered by vinorelbine treatment. Vinorelbine 11-22 BCL2 apoptosis regulator Homo sapiens 37-42 25891953-7 2015 Treatment with PAB suppressed the expression of anti-apoptotic factor B cell lymphoma-2, and promoted the expression of pro-apoptotic factor Bcl-2-associated X protein. pseudolaric acid B 15-18 BCL2 apoptosis regulator Homo sapiens 141-146 25204891-12 2015 In addition, hesperetin also induced apoptosis in triple negative breast cancer MDA-MB-231 cells via intrinsic pathway via activation of caspase -9 and -3 and increase in Bax:Bcl-2 ratio. hesperetin 13-23 BCL2 apoptosis regulator Homo sapiens 175-180 25892089-10 2015 Acteoside could protect the cells from X-ray induced damage through enhancing the scavenging activity of ROS, decreasing the Bax/Bcl-2 ratio and downregulating the activity of procaspase-3, as well as modulating the mitogen-activated protein kinase signaling pathways. acteoside 0-9 BCL2 apoptosis regulator Homo sapiens 129-134 25882699-4 2015 Dinaciclib induces apoptosis in DLBCL cells but is completely overcome by increased activity of BCL2. dinaciclib 0-10 BCL2 apoptosis regulator Homo sapiens 96-100 25882699-6 2015 The BH3 mimetic ABT-199 potently and specifically targets BCL2. BH 3 4-7 BCL2 apoptosis regulator Homo sapiens 58-62 25882699-6 2015 The BH3 mimetic ABT-199 potently and specifically targets BCL2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 16-19 BCL2 apoptosis regulator Homo sapiens 58-62 25892089-8 2015 Radiation could induce upregulation of Bax and downregulation of Bcl-2; however, it was reversed completely after administration of acteoside or paeoniflorin. acteoside 132-141 BCL2 apoptosis regulator Homo sapiens 65-70 25910896-0 2015 MiR-34a promotes Fas-mediated cartilage endplate chondrocyte apoptosis by targeting Bcl-2. ammonium ferrous sulfate 17-20 BCL2 apoptosis regulator Homo sapiens 84-89 25955510-6 2015 In addition, the expression of caspase-3 increased, while that of B-cell lymphoma (Bcl)-2 decreased markedly in theS and G2/M cells following SDT. 3,4-Dihydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione 142-145 BCL2 apoptosis regulator Homo sapiens 66-89 25936899-7 2015 Furthermore, it was shown that SPARC negatively regulated bufalin-induced intrinsic apoptosis by protecting mitochondrial integrity, decreasing the release of cytoplasmic cytochrome c and increasing the ratio of Bcl-2/Bax. bufalin 58-65 BCL2 apoptosis regulator Homo sapiens 212-217 25937271-7 2015 The decrease in Bcl-2, increase in Bax and, finally, the activation of caspase-3 in HepG2 cells indicated that the apoptotic process induced by SQS was irreversible. 22-O-angeloylcamelliagenin C-3-O-(glucopyranosyl-1-2)(glucopyranosyl-1-2-O-arabinopyranosyl-1-3-)glucopyranosiduronic acid 144-147 BCL2 apoptosis regulator Homo sapiens 16-21 25955510-9 2015 It was hypothesized that high expression levels of cyclin A in the S and G2/M cells may promote the induction of caspase-3 and reduce the induction of Bcl-2 by SDT and, therefore, enhance apoptosis. 3,4-Dihydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione 160-163 BCL2 apoptosis regulator Homo sapiens 151-156 25943027-8 2015 In summary, Sal A attenuates TNF-alpha- and D-GalN-induced both ER stress and mitochondrial-dependent apoptosis by suppression of Bax/Bcl-2 ratio and prevention of calcium release, which support the notion that Sal A could be developed into a novel hepatic protectant. salvianolic acid 12-17 BCL2 apoptosis regulator Homo sapiens 134-139 25943027-0 2015 Salvianolic acid A attenuates TNF-alpha- and D-GalN-induced ER stress-mediated and mitochondrial-dependent apoptosis by modulating Bax/Bcl-2 ratio and calcium release in hepatocyte LO2 cells. salvianolic acid A 0-18 BCL2 apoptosis regulator Homo sapiens 135-140 26403730-5 2015 beta-elemene decreased clonogenic survival of SGC7901 cells, increased the proportion of G2/M phase cells, decreased the expression of Bcl-2, and increased the expression of Bax and cleaved caspase-3. beta-elemene 0-12 BCL2 apoptosis regulator Homo sapiens 135-140 25943027-7 2015 Furthermore, the decreased levels of Bax/Bcl-2 ratio and calcium release were measured in Sal A-treated cells. salvianolic acid 90-95 BCL2 apoptosis regulator Homo sapiens 41-46 26403730-7 2015 CONCLUSION: beta-elemene inhibits the proliferation and induces apoptosis of gastric cancer cells possibly by inhibiting Pak1/ERK signaling and regulating apoptosis-associated proteins such as Bcl-2 and Bax. beta-elemene 12-24 BCL2 apoptosis regulator Homo sapiens 193-198 26403741-6 2015 The STOML-2-overexpressing cells exhibited an obvious resistance to IC50 Cisplatin-induced apoptosis as shown by both fluorescence microscopy and flow cytometry and presented with decreased expressions of cleaved caspase-3, Bax, and cytosol Cyt C and increased expressions of caspase-3, Bcl-2, and mitochondrial Cyt C. Cisplatin 73-82 BCL2 apoptosis regulator Homo sapiens 287-292 26059173-5 2015 Betulin activated caspase family proteins, including caspase-3, -7, -8 and -9, and increased the expression of apoptosis-related proteins, including PARP and Bcl-2 family members. betulin 0-7 BCL2 apoptosis regulator Homo sapiens 158-163 26035796-6 2015 The expression of B-cell lymphoma-2 (Bcl-2) was increased by administration of ADM; meanwhile, this effect was reversed by exogenously adding U0126, a selective inhibitor of MEK or ADM22-52 (ADM-specific receptor antagonist). U 0126 142-147 BCL2 apoptosis regulator Homo sapiens 18-35 26035796-6 2015 The expression of B-cell lymphoma-2 (Bcl-2) was increased by administration of ADM; meanwhile, this effect was reversed by exogenously adding U0126, a selective inhibitor of MEK or ADM22-52 (ADM-specific receptor antagonist). U 0126 142-147 BCL2 apoptosis regulator Homo sapiens 37-42 26622578-3 2015 In the present study, it was identified that the administration of a combination of ABT263 [navitoclax; a Bcl-2/Bcl-extra large (Bcl-xL) inhibitor] and PF4708671 (an S6K1 inhibitor) markedly increased apoptotic cell death in the BT474 breast cancer cells compared with the administration of either agent alone. navitoclax 84-90 BCL2 apoptosis regulator Homo sapiens 106-111 26622578-3 2015 In the present study, it was identified that the administration of a combination of ABT263 [navitoclax; a Bcl-2/Bcl-extra large (Bcl-xL) inhibitor] and PF4708671 (an S6K1 inhibitor) markedly increased apoptotic cell death in the BT474 breast cancer cells compared with the administration of either agent alone. navitoclax 92-102 BCL2 apoptosis regulator Homo sapiens 106-111 26622596-10 2015 These results showed that Embelin inhibited growth and induced apoptosis of Jurkat cells in vitro, by activating the endogenous caspase-dependent apoptotic pathway through inhibition of XIAP and proapoptotic Bcl-2 family members. embelin 26-33 BCL2 apoptosis regulator Homo sapiens 208-213 25957473-6 2015 Here, the importance of the hydrophobic cleft of Bcl-2 in binding to and inhibiting the RyR was assessed by using a genetic approach based on site-directed mutagenesis of Bcl-2"s hydrophobic cleft and a pharmacological approach based on the selective Bcl-2 hydrophobic cleft inhibitor, ABT-199. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 286-289 BCL2 apoptosis regulator Homo sapiens 49-54 26142734-3 2015 A variety of the signaling pathways have been developed to promote cell death including overexpression of pro-apoptotic members of Bcl-2 family, overloaded calcium, and elevated reactive oxygen species (ROS) play a key role in the promoting mitochondrial cytochrome c release through MOMP and eventually leads to cell death. Calcium 156-163 BCL2 apoptosis regulator Homo sapiens 131-136 26142734-3 2015 A variety of the signaling pathways have been developed to promote cell death including overexpression of pro-apoptotic members of Bcl-2 family, overloaded calcium, and elevated reactive oxygen species (ROS) play a key role in the promoting mitochondrial cytochrome c release through MOMP and eventually leads to cell death. Reactive Oxygen Species 178-201 BCL2 apoptosis regulator Homo sapiens 131-136 26142734-3 2015 A variety of the signaling pathways have been developed to promote cell death including overexpression of pro-apoptotic members of Bcl-2 family, overloaded calcium, and elevated reactive oxygen species (ROS) play a key role in the promoting mitochondrial cytochrome c release through MOMP and eventually leads to cell death. Reactive Oxygen Species 203-206 BCL2 apoptosis regulator Homo sapiens 131-136 26009469-2 2015 We investigated the BH3 binding properties of the herpesvirus Bcl-2 homologs KSBcl-2, BHRF1, and M11, as they relate to those of the human Bcl-2 homologs Mcl-1, Bfl-1, Bcl-w, Bcl-xL, and Bcl-2. BH 3 20-23 BCL2 apoptosis regulator Homo sapiens 62-67 26009469-2 2015 We investigated the BH3 binding properties of the herpesvirus Bcl-2 homologs KSBcl-2, BHRF1, and M11, as they relate to those of the human Bcl-2 homologs Mcl-1, Bfl-1, Bcl-w, Bcl-xL, and Bcl-2. BH 3 20-23 BCL2 apoptosis regulator Homo sapiens 79-84 26009469-2 2015 We investigated the BH3 binding properties of the herpesvirus Bcl-2 homologs KSBcl-2, BHRF1, and M11, as they relate to those of the human Bcl-2 homologs Mcl-1, Bfl-1, Bcl-w, Bcl-xL, and Bcl-2. BH 3 20-23 BCL2 apoptosis regulator Homo sapiens 79-84 26013319-3 2015 For example, navitoclax, a BCL-2/BCL-XL/BCL-W inhibitor, is currently in phase I/II clinical trials in numerous malignancies. navitoclax 13-23 BCL2 apoptosis regulator Homo sapiens 27-32 25930665-6 2015 alpha-H induced activation of caspase-8 and caspase-9 and also increased levels of the proapoptotic protein Bax, decreasing antiapoptotic proteins (Bcl-2, X-IAP and IAP-1) in HepG2 cells. alpha-h 0-7 BCL2 apoptosis regulator Homo sapiens 148-153 26790307-8 2015 The results showed that lycorine significantly inhibited the proliferation of A549 cells (P < 0.05), induced the apoptosis on A549 cells (P < 0.05), increased the activities of Bax and p53, reduced Bcl-2 activity and mitochondrial membrane potential, and notably changed the gene expressions of Bcl-2, Bax, p53 and Survivin (P < 0.05). lycorine 24-32 BCL2 apoptosis regulator Homo sapiens 204-209 26790307-8 2015 The results showed that lycorine significantly inhibited the proliferation of A549 cells (P < 0.05), induced the apoptosis on A549 cells (P < 0.05), increased the activities of Bax and p53, reduced Bcl-2 activity and mitochondrial membrane potential, and notably changed the gene expressions of Bcl-2, Bax, p53 and Survivin (P < 0.05). lycorine 24-32 BCL2 apoptosis regulator Homo sapiens 301-306 26264004-5 2015 Anti-proliferative and cancer preventing influences of fucoxanthin and fucoxanthinol are mediated through different signalling pathways, including the caspases, Bcl-2 proteins, MAPK, PI3K/Akt, JAK/STAT, AP-1, GADD45, and several other molecules that are involved in cell cycle arrest, apoptosis, anti-angiogenesis or inhibition of metastasis. fucoxanthin 55-66 BCL2 apoptosis regulator Homo sapiens 161-166 26264004-5 2015 Anti-proliferative and cancer preventing influences of fucoxanthin and fucoxanthinol are mediated through different signalling pathways, including the caspases, Bcl-2 proteins, MAPK, PI3K/Akt, JAK/STAT, AP-1, GADD45, and several other molecules that are involved in cell cycle arrest, apoptosis, anti-angiogenesis or inhibition of metastasis. fucoxanthinol 71-84 BCL2 apoptosis regulator Homo sapiens 161-166 25979325-3 2015 Here we report a simple and biocompatible co-delivering formulation based on a unique complexation method, i.e., multiple monocomplexation-induced hydrophobic association between Bcl-2 targeting siRNA and a monocationic anticancer agent (benzethonium chloride, BZT). Benzethonium 238-259 BCL2 apoptosis regulator Homo sapiens 179-184 26229588-7 2015 Additionally, NaHS increased Bcl-2 expression, promoted PKC-epsilon translocation to the cell membrane, and activated mitochondrial ATP-sensitive K channels (mitoKATP). sodium bisulfide 14-18 BCL2 apoptosis regulator Homo sapiens 29-34 26223311-0 2015 Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer. gossypol acetic acid 34-40 BCL2 apoptosis regulator Homo sapiens 25-30 26223311-5 2015 The aim of this study was to evaluate combined effects of radiation and the pan-Bcl-2 inhibitor AT-101 in HNSCC in vitro. gossypol acetic acid 96-102 BCL2 apoptosis regulator Homo sapiens 80-85 26223974-11 2015 After paclitaxel treatment, decreased apoptosis and G2 phase ratio, increased cell migration, increased level of Bcl-2, and decreased level of Bax were found in miRNA-149-down-regulated A2780 cells. Paclitaxel 6-16 BCL2 apoptosis regulator Homo sapiens 113-118 25979325-3 2015 Here we report a simple and biocompatible co-delivering formulation based on a unique complexation method, i.e., multiple monocomplexation-induced hydrophobic association between Bcl-2 targeting siRNA and a monocationic anticancer agent (benzethonium chloride, BZT). Benzethonium 261-264 BCL2 apoptosis regulator Homo sapiens 179-184 25980588-9 2015 Decrease of the BCL2 expression levels, loss of the mitochondrial membrane potential, release of cytochrome c and increase of caspase 9 activity highlight a key role for mitochondria in Permethylated Anigopreissin A-induced apoptosis. Anigopreissin A 200-215 BCL2 apoptosis regulator Homo sapiens 16-20 32262573-8 2015 Further studies demonstrated that PAH-UCNPs also decreased Bcl-2 but increased Beclin1 and Atg14 expression, suggesting that PAH-UCNPs-induced autophagy was associated with increased PI3KC3-Beclin1 activity. polyallylamine 34-37 BCL2 apoptosis regulator Homo sapiens 59-64 32262573-8 2015 Further studies demonstrated that PAH-UCNPs also decreased Bcl-2 but increased Beclin1 and Atg14 expression, suggesting that PAH-UCNPs-induced autophagy was associated with increased PI3KC3-Beclin1 activity. polyallylamine 125-128 BCL2 apoptosis regulator Homo sapiens 59-64 26204252-7 2015 On the other hand, a BH-3 mimetic Bcl-xL/Bcl-2 inhibitor ABT-737, as well as siRNA-mediated knockdown of Bcl-xL or Bcl-2, enhanced the activity of VS-5584 in melanoma cells. ABT-737 57-64 BCL2 apoptosis regulator Homo sapiens 41-46 26396928-3 2015 Our study revealed that cisplatin and AITC combination synergistically inhibits cancer cell growth and colony formation, and enhances apoptosis in association with the downregulation of antiapoptotic proteins Bcl-2 and survivin. Cisplatin 24-33 BCL2 apoptosis regulator Homo sapiens 209-214 26198850-3 2015 BH3 mimetics are a new class of drugs that target anti-apoptotic proteins of the BCL-2 family and promote cell death. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 81-86 26045609-0 2015 Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. ABT-737 76-83 BCL2 apoptosis regulator Homo sapiens 33-38 26045609-2 2015 Furthermore, it has been demonstrated that Mcl-1 upregulation renders several types of cancers resistant to the Bcl-2/Bcl-xL inhibitors ABT-737 and ABT-263. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 136-139 BCL2 apoptosis regulator Homo sapiens 112-117 26396928-3 2015 Our study revealed that cisplatin and AITC combination synergistically inhibits cancer cell growth and colony formation, and enhances apoptosis in association with the downregulation of antiapoptotic proteins Bcl-2 and survivin. allyl isothiocyanate 38-42 BCL2 apoptosis regulator Homo sapiens 209-214 26025920-4 2015 The observed antiproliferative action of melatonin was associated with an arrest at S-phase, decreased oxygen consumption, down-regulation of BCL-2 expression and an increase in oxidative stress culminating with caspase-3-independent cell death. Melatonin 41-50 BCL2 apoptosis regulator Homo sapiens 142-147 25968887-5 2015 In parallel with these responses, decitabine also upregulated the proapoptotic BCL-2 family member BNIP3, which is known to be regulated by MEK and ERK, and heightened the activity of proapoptotic small-molecule navitoclax, a BCL-2 family inhibitor. Decitabine 34-44 BCL2 apoptosis regulator Homo sapiens 79-84 25968887-5 2015 In parallel with these responses, decitabine also upregulated the proapoptotic BCL-2 family member BNIP3, which is known to be regulated by MEK and ERK, and heightened the activity of proapoptotic small-molecule navitoclax, a BCL-2 family inhibitor. Decitabine 34-44 BCL2 apoptosis regulator Homo sapiens 226-231 25860284-0 2015 Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2. Erlotinib Hydrochloride 15-24 BCL2 apoptosis regulator Homo sapiens 127-132 25987560-6 2015 In addition, scanning fluorescence cross-correlation spectroscopy and FRET measurements revealed that the BCL2-like structural fold of MCL1, but not that of BAK, forms stable heterodimeric complexes with cBID in a manner adjustable by membrane cardiolipin content and curvature degree. cbid 204-208 BCL2 apoptosis regulator Homo sapiens 106-110 25860284-2 2015 We have previously reported that the combination of the EGFR-TKI erlotinib and epigallocatechin-3-gallate (EGCG) exhibited synergistic chemopreventive effects in head and neck cancers by inducing the expression of Bim, p21, p27, and by inhibiting the phosphorylation of ERK and AKT and expression of Bcl-2. epigallocatechin gallate 79-105 BCL2 apoptosis regulator Homo sapiens 300-305 25860284-2 2015 We have previously reported that the combination of the EGFR-TKI erlotinib and epigallocatechin-3-gallate (EGCG) exhibited synergistic chemopreventive effects in head and neck cancers by inducing the expression of Bim, p21, p27, and by inhibiting the phosphorylation of ERK and AKT and expression of Bcl-2. epigallocatechin gallate 107-111 BCL2 apoptosis regulator Homo sapiens 300-305 26219338-2 2015 Here, we show that cyclin E/Cdk2 phosphorylates and stabilizes the pro-survival Bcl-2 family protein Mcl-1, a key cell death resistance determinant to the small molecule Bcl-2 family inhibitors ABT-199 and ABT-737, mimetics of the Bcl-2 homology domain 3 (BH3). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 194-197 BCL2 apoptosis regulator Homo sapiens 80-85 26219338-2 2015 Here, we show that cyclin E/Cdk2 phosphorylates and stabilizes the pro-survival Bcl-2 family protein Mcl-1, a key cell death resistance determinant to the small molecule Bcl-2 family inhibitors ABT-199 and ABT-737, mimetics of the Bcl-2 homology domain 3 (BH3). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 194-197 BCL2 apoptosis regulator Homo sapiens 170-175 26219338-2 2015 Here, we show that cyclin E/Cdk2 phosphorylates and stabilizes the pro-survival Bcl-2 family protein Mcl-1, a key cell death resistance determinant to the small molecule Bcl-2 family inhibitors ABT-199 and ABT-737, mimetics of the Bcl-2 homology domain 3 (BH3). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 194-197 BCL2 apoptosis regulator Homo sapiens 170-175 26219338-2 2015 Here, we show that cyclin E/Cdk2 phosphorylates and stabilizes the pro-survival Bcl-2 family protein Mcl-1, a key cell death resistance determinant to the small molecule Bcl-2 family inhibitors ABT-199 and ABT-737, mimetics of the Bcl-2 homology domain 3 (BH3). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 206-209 BCL2 apoptosis regulator Homo sapiens 80-85 26219338-2 2015 Here, we show that cyclin E/Cdk2 phosphorylates and stabilizes the pro-survival Bcl-2 family protein Mcl-1, a key cell death resistance determinant to the small molecule Bcl-2 family inhibitors ABT-199 and ABT-737, mimetics of the Bcl-2 homology domain 3 (BH3). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 206-209 BCL2 apoptosis regulator Homo sapiens 170-175 26219338-2 2015 Here, we show that cyclin E/Cdk2 phosphorylates and stabilizes the pro-survival Bcl-2 family protein Mcl-1, a key cell death resistance determinant to the small molecule Bcl-2 family inhibitors ABT-199 and ABT-737, mimetics of the Bcl-2 homology domain 3 (BH3). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 206-209 BCL2 apoptosis regulator Homo sapiens 170-175 25894537-7 2015 In addition, decreased Bcl-2 expression and increased BID cleavage and cytochrome C release were detected in C2 cells after cisplatin challenge. Cisplatin 124-133 BCL2 apoptosis regulator Homo sapiens 23-28 25894537-8 2015 Treating the cells with cisplatin, in combination with a Bcl-2 inhibitor, decreased the viability of NT3 cells to the same level as C2 cells after cisplatin. Cisplatin 24-33 BCL2 apoptosis regulator Homo sapiens 57-62 25894537-8 2015 Treating the cells with cisplatin, in combination with a Bcl-2 inhibitor, decreased the viability of NT3 cells to the same level as C2 cells after cisplatin. Cisplatin 147-156 BCL2 apoptosis regulator Homo sapiens 57-62 25860284-8 2015 Taken together, our results strongly suggest that the combination of erlotinib and EGCG induces apoptosis of SCCHN cells by regulating Bim and Bcl-2 at the posttranscriptional level. Erlotinib Hydrochloride 69-78 BCL2 apoptosis regulator Homo sapiens 143-148 25860284-8 2015 Taken together, our results strongly suggest that the combination of erlotinib and EGCG induces apoptosis of SCCHN cells by regulating Bim and Bcl-2 at the posttranscriptional level. epigallocatechin gallate 83-87 BCL2 apoptosis regulator Homo sapiens 143-148 25860284-0 2015 Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2. epigallocatechin gallate 29-33 BCL2 apoptosis regulator Homo sapiens 127-132 25860284-2 2015 We have previously reported that the combination of the EGFR-TKI erlotinib and epigallocatechin-3-gallate (EGCG) exhibited synergistic chemopreventive effects in head and neck cancers by inducing the expression of Bim, p21, p27, and by inhibiting the phosphorylation of ERK and AKT and expression of Bcl-2. Erlotinib Hydrochloride 65-74 BCL2 apoptosis regulator Homo sapiens 300-305 25891473-8 2015 The results of western blot revealed that PE induced apoptosis in HepG2 cells by enhancing Bax/Bcl-2 ratio, increasing cytochrome c in cytosol and activating caspase-3/9. naphtha 42-44 BCL2 apoptosis regulator Homo sapiens 95-100 25322954-5 2015 PEP-1-Catalase transduced into SH-SY5Y cells significantly protecting them against MPP+-induced death by decreasing ROS and regulating cellular survival signals including Akt, Bax, Bcl-2, and p38. mangion-purified polysaccharide (Candida albicans) 83-87 BCL2 apoptosis regulator Homo sapiens 181-186 25582069-0 2015 The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. venetoclax 20-27 BCL2 apoptosis regulator Homo sapiens 4-8 25936772-3 2015 Bcl-2 family proteins play critical roles in orchestrating mitochondrial dynamics, and are involved in the resistance to cisplatin. Cisplatin 121-130 BCL2 apoptosis regulator Homo sapiens 0-5 25936772-11 2015 ABT737 might enhance cholangiocarcinoma sensitivity to cisplatin through regulation of mitochondrial dynamics and the balance within Bcl-2 family proteins. Cisplatin 55-64 BCL2 apoptosis regulator Homo sapiens 133-138 25429725-4 2015 Immunohistologically, BCL2 expression was detected in 35% of patients with MTX-BLPD, which was lower than 93% of control DLBCL patients (P < 0.01). Methotrexate 75-78 BCL2 apoptosis regulator Homo sapiens 22-26 26351561-0 2015 The correlation between telomerase activity and Bax/Bcl-2 ratio in valproic acid-treated MCF-7 breast cancer cell line. Valproic Acid 67-80 BCL2 apoptosis regulator Homo sapiens 52-57 26351561-10 2015 CONCLUSION: Our study demonstrated that cell viability of MCF-7 cells was decreased after treatment with VPA, probably through a reduction of telomerase activity and an increase in Bax/bcl-2 ratio. Valproic Acid 105-108 BCL2 apoptosis regulator Homo sapiens 185-190 25042557-6 2015 The autophagy inhibitor 3-methyladenine significantly increased the apoptotic rate induced by olaquindox, which was correlated with increased ratio of Bax/Bcl-2. 3-methyladenine 24-39 BCL2 apoptosis regulator Homo sapiens 155-160 25042557-6 2015 The autophagy inhibitor 3-methyladenine significantly increased the apoptotic rate induced by olaquindox, which was correlated with increased ratio of Bax/Bcl-2. olaquindox 94-104 BCL2 apoptosis regulator Homo sapiens 155-160 25582069-0 2015 The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. ibrutinib 61-70 BCL2 apoptosis regulator Homo sapiens 4-8 25582069-0 2015 The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. idelalisib 75-85 BCL2 apoptosis regulator Homo sapiens 4-8 26045015-1 2015 The small molecule BDA-366 selectively inhibits BCL2, converting it to a cell death inducer. BDA-366 19-26 BCL2 apoptosis regulator Homo sapiens 48-52 25576341-9 2015 H2O2 upregulated p53 and miR-143, but downregulated ATG2B, Bcl-2, and LC3-I expression in U2OS cells (wild-type p53) but not in SAOS-2 (p53-null) cells. Hydrogen Peroxide 0-4 BCL2 apoptosis regulator Homo sapiens 59-64 25981694-6 2015 In the present study, we investigated the mechanism of beta-carotene-induced apoptosis of gastric cancer AGS cells by determining cell viability, DNA fragmentation, apoptotic indices (increases in cytochrome c and Bax, decrease in Bcl-2), ROS levels, mitochondrial membrane potential, caspase-3 activity, Ku70/80 levels, and Ku-DNA-binding activity of the cells treated with or without antioxidant N-acetyl cysteine and caspase-3 inhibitor z-DEVED-fmk. beta Carotene 55-68 BCL2 apoptosis regulator Homo sapiens 231-236 25862630-6 2015 Treatment of ACHN/sh-Akt1 with sorafenib, but not that of ACHN/C, induced marked downregulation of antiapoptotic proteins, including Bcl-2, Bcl-xL, and c-Myc. Sorafenib 31-40 BCL2 apoptosis regulator Homo sapiens 133-138 25740014-6 2015 Treatment of SK-N-BE2 and IMR-32 cells with 75 muMu wogonin for 48 h significantly promoted apoptosis, the release of cytochrome c, altered the expression of certain members of Bcl-2 family (Bcl-2, Bax and Bid), and increased the activation of caspase-3, caspase-8, caspase-9, and PARP-1, which demonstrated that the cytotoxic effect of wogonin in SK-N-BE2 and IMR-32 cells is mediated by mitochondrial dysfunction. sk-n-be2 13-21 BCL2 apoptosis regulator Homo sapiens 177-182 25740014-6 2015 Treatment of SK-N-BE2 and IMR-32 cells with 75 muMu wogonin for 48 h significantly promoted apoptosis, the release of cytochrome c, altered the expression of certain members of Bcl-2 family (Bcl-2, Bax and Bid), and increased the activation of caspase-3, caspase-8, caspase-9, and PARP-1, which demonstrated that the cytotoxic effect of wogonin in SK-N-BE2 and IMR-32 cells is mediated by mitochondrial dysfunction. sk-n-be2 13-21 BCL2 apoptosis regulator Homo sapiens 191-196 25724148-4 2015 The dissipation of mitochondrial membrane potential, release of cytochrome c from mitochondria to cytosol, down-regulation of Bcl-2, and up-regulation of Bax levels were also found in 9-EE-KODE-treated cells in a dose-dependent manner. 13-OxoODE 189-193 BCL2 apoptosis regulator Homo sapiens 126-131 25740014-6 2015 Treatment of SK-N-BE2 and IMR-32 cells with 75 muMu wogonin for 48 h significantly promoted apoptosis, the release of cytochrome c, altered the expression of certain members of Bcl-2 family (Bcl-2, Bax and Bid), and increased the activation of caspase-3, caspase-8, caspase-9, and PARP-1, which demonstrated that the cytotoxic effect of wogonin in SK-N-BE2 and IMR-32 cells is mediated by mitochondrial dysfunction. wogonin 52-59 BCL2 apoptosis regulator Homo sapiens 177-182 25740014-6 2015 Treatment of SK-N-BE2 and IMR-32 cells with 75 muMu wogonin for 48 h significantly promoted apoptosis, the release of cytochrome c, altered the expression of certain members of Bcl-2 family (Bcl-2, Bax and Bid), and increased the activation of caspase-3, caspase-8, caspase-9, and PARP-1, which demonstrated that the cytotoxic effect of wogonin in SK-N-BE2 and IMR-32 cells is mediated by mitochondrial dysfunction. wogonin 52-59 BCL2 apoptosis regulator Homo sapiens 191-196 26099171-0 2015 Regulation of BAX/BCL2 gene expression in breast cancer cells by docetaxel-loaded human serum albumin nanoparticles. Docetaxel 65-74 BCL2 apoptosis regulator Homo sapiens 18-22 25373508-0 2015 ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 49-54 25373508-0 2015 ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells. BH 3 11-14 BCL2 apoptosis regulator Homo sapiens 49-54 25373508-0 2015 ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells. Bortezomib 105-115 BCL2 apoptosis regulator Homo sapiens 49-54 25373508-2 2015 Both ABT-737, a Bcl-2/Bcl-XL inhibitor, and ABT-199, which selectively targets Bcl-2, were potently cytotoxic against DHL cell lines Sc-1 and OcI-LY18, the RL cell line and primary human DHL cells, but not Ramos cells, which lack Bcl-2 expression. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 5-8 BCL2 apoptosis regulator Homo sapiens 16-21 25373508-2 2015 Both ABT-737, a Bcl-2/Bcl-XL inhibitor, and ABT-199, which selectively targets Bcl-2, were potently cytotoxic against DHL cell lines Sc-1 and OcI-LY18, the RL cell line and primary human DHL cells, but not Ramos cells, which lack Bcl-2 expression. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 5-8 BCL2 apoptosis regulator Homo sapiens 79-84 25373508-2 2015 Both ABT-737, a Bcl-2/Bcl-XL inhibitor, and ABT-199, which selectively targets Bcl-2, were potently cytotoxic against DHL cell lines Sc-1 and OcI-LY18, the RL cell line and primary human DHL cells, but not Ramos cells, which lack Bcl-2 expression. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 5-8 BCL2 apoptosis regulator Homo sapiens 79-84 25373508-2 2015 Both ABT-737, a Bcl-2/Bcl-XL inhibitor, and ABT-199, which selectively targets Bcl-2, were potently cytotoxic against DHL cell lines Sc-1 and OcI-LY18, the RL cell line and primary human DHL cells, but not Ramos cells, which lack Bcl-2 expression. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 44-47 BCL2 apoptosis regulator Homo sapiens 79-84 25373508-2 2015 Both ABT-737, a Bcl-2/Bcl-XL inhibitor, and ABT-199, which selectively targets Bcl-2, were potently cytotoxic against DHL cell lines Sc-1 and OcI-LY18, the RL cell line and primary human DHL cells, but not Ramos cells, which lack Bcl-2 expression. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 44-47 BCL2 apoptosis regulator Homo sapiens 79-84 26099171-9 2015 In conclusion, a significant overexpression of BAX gene and changes in BAX/BCL2 ratio were observed for DTX-loaded HSA nanoparticles compared with free DTX and may provide a potential therapy to inhibit anticancer drug resistance. Docetaxel 104-107 BCL2 apoptosis regulator Homo sapiens 75-79 25760096-13 2015 Furthermore, paeonol significantly sensitized the MCF-7/PTX to paclitaxel via regulation of ABC transporters, B cell lymphoma-2 (Bcl-2) and Bcl-2-associated X protein. paeonol 13-20 BCL2 apoptosis regulator Homo sapiens 110-127 25738368-4 2015 The present study demonstrated that simvastatin inhibited the proliferation of MDA-MB-231 human breast cancer cells in a dose-dependent manner, decreased the protein expression of B cell lymphoma 2 (Bcl-2) and increased the protein expression of Bcl-2-associated X protein in time- and dose-dependent manners. Simvastatin 36-47 BCL2 apoptosis regulator Homo sapiens 180-197 25738368-4 2015 The present study demonstrated that simvastatin inhibited the proliferation of MDA-MB-231 human breast cancer cells in a dose-dependent manner, decreased the protein expression of B cell lymphoma 2 (Bcl-2) and increased the protein expression of Bcl-2-associated X protein in time- and dose-dependent manners. Simvastatin 36-47 BCL2 apoptosis regulator Homo sapiens 199-204 25738368-4 2015 The present study demonstrated that simvastatin inhibited the proliferation of MDA-MB-231 human breast cancer cells in a dose-dependent manner, decreased the protein expression of B cell lymphoma 2 (Bcl-2) and increased the protein expression of Bcl-2-associated X protein in time- and dose-dependent manners. Simvastatin 36-47 BCL2 apoptosis regulator Homo sapiens 246-251 25695595-1 2015 It was previously reported that the histone deacetylase inhibitor (HDACI) trichostatin A (TSA) induced B cell lymphoma 2 (Bcl-2)-associated X protein (Bax)-dependent apoptosis in colorectal cancer (CRC) cells. trichostatin A 74-88 BCL2 apoptosis regulator Homo sapiens 103-120 25695595-1 2015 It was previously reported that the histone deacetylase inhibitor (HDACI) trichostatin A (TSA) induced B cell lymphoma 2 (Bcl-2)-associated X protein (Bax)-dependent apoptosis in colorectal cancer (CRC) cells. trichostatin A 74-88 BCL2 apoptosis regulator Homo sapiens 122-127 25695595-1 2015 It was previously reported that the histone deacetylase inhibitor (HDACI) trichostatin A (TSA) induced B cell lymphoma 2 (Bcl-2)-associated X protein (Bax)-dependent apoptosis in colorectal cancer (CRC) cells. trichostatin A 90-93 BCL2 apoptosis regulator Homo sapiens 103-120 25695595-1 2015 It was previously reported that the histone deacetylase inhibitor (HDACI) trichostatin A (TSA) induced B cell lymphoma 2 (Bcl-2)-associated X protein (Bax)-dependent apoptosis in colorectal cancer (CRC) cells. trichostatin A 90-93 BCL2 apoptosis regulator Homo sapiens 122-127 25760477-0 2015 Curcumin triggers apoptosis via upregulation of Bax/Bcl-2 ratio and caspase activation in SW872 human adipocytes. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 52-57 25760096-13 2015 Furthermore, paeonol significantly sensitized the MCF-7/PTX to paclitaxel via regulation of ABC transporters, B cell lymphoma-2 (Bcl-2) and Bcl-2-associated X protein. paeonol 13-20 BCL2 apoptosis regulator Homo sapiens 129-134 25760477-5 2015 In addition, curcumin treatment resulted in an increased expression of Bax, and a decrease in that of of Bcl-2, with a concomitant upregulation of the Bax/Bcl-2 ratio. Curcumin 13-21 BCL2 apoptosis regulator Homo sapiens 105-110 25760477-5 2015 In addition, curcumin treatment resulted in an increased expression of Bax, and a decrease in that of of Bcl-2, with a concomitant upregulation of the Bax/Bcl-2 ratio. Curcumin 13-21 BCL2 apoptosis regulator Homo sapiens 155-160 25760096-13 2015 Furthermore, paeonol significantly sensitized the MCF-7/PTX to paclitaxel via regulation of ABC transporters, B cell lymphoma-2 (Bcl-2) and Bcl-2-associated X protein. paeonol 13-20 BCL2 apoptosis regulator Homo sapiens 140-145 25760096-13 2015 Furthermore, paeonol significantly sensitized the MCF-7/PTX to paclitaxel via regulation of ABC transporters, B cell lymphoma-2 (Bcl-2) and Bcl-2-associated X protein. Paclitaxel 63-73 BCL2 apoptosis regulator Homo sapiens 140-145 25815462-0 2015 Apoptosis of HL-60 human leukemia cells induced by Asiatic acid through modulation of B-cell lymphoma 2 family proteins and the mitogen-activated protein kinase signaling pathway. asiatic acid 51-63 BCL2 apoptosis regulator Homo sapiens 86-103 25997700-11 2015 Bax, caspase-3 and caspase-9 expression were upregulated, and Bcl-2 expression was downregulated in the combined treatment group (gefitinib+siRNA) compared with the gefitinib (4 mM, 24 h) only group in the MGC-803 and MKN-45 cells (P<0.05). Gefitinib 130-139 BCL2 apoptosis regulator Homo sapiens 62-67 25815518-9 2015 VPA and ATO had synergistic effects on the proliferation of RPMI8226 cells, which may have been associated with the decreased expression of Bcl-2 and the increased expression levels of Bcl-2-associated X protein, Caspase 8 and Caspase 9. Valproic Acid 0-3 BCL2 apoptosis regulator Homo sapiens 140-145 25815518-9 2015 VPA and ATO had synergistic effects on the proliferation of RPMI8226 cells, which may have been associated with the decreased expression of Bcl-2 and the increased expression levels of Bcl-2-associated X protein, Caspase 8 and Caspase 9. Valproic Acid 0-3 BCL2 apoptosis regulator Homo sapiens 185-190 25815518-9 2015 VPA and ATO had synergistic effects on the proliferation of RPMI8226 cells, which may have been associated with the decreased expression of Bcl-2 and the increased expression levels of Bcl-2-associated X protein, Caspase 8 and Caspase 9. Arsenic Trioxide 8-11 BCL2 apoptosis regulator Homo sapiens 140-145 25815518-9 2015 VPA and ATO had synergistic effects on the proliferation of RPMI8226 cells, which may have been associated with the decreased expression of Bcl-2 and the increased expression levels of Bcl-2-associated X protein, Caspase 8 and Caspase 9. Arsenic Trioxide 8-11 BCL2 apoptosis regulator Homo sapiens 185-190 26033682-5 2015 6-OHDA-induced dysfunctions, including the decrease of mitochondrial membrane potential (DeltaPsim), increase of intracellular free Ca(2+), imbalance of Bcl-2/Bax ratio, release of Cyt-c from the mitochondria and activation of caspase-3 and caspase-9 were attenuated by CS pretreatment, which demonstrated that CS suppressed 6-OHDA-induced apoptosis in SH-SY5Y cells possibly through mitochondria protection. Oxidopamine 0-6 BCL2 apoptosis regulator Homo sapiens 153-158 25998836-4 2015 The results showed that melatonin significantly affected the behavior of RMS cells, leading to inhibition of cell proliferation and impairment of myogenic differentiation followed by increased apoptotic cell death, as observed by immunoblotting analysis of apoptosis-related markers including Bax, Bcl-2 and caspase-3. Melatonin 24-33 BCL2 apoptosis regulator Homo sapiens 298-303 25816073-7 2015 In addition, agmatine treatment inhibited glucose-induced Muller cell apoptosis, which was associated with the regulation of Bax and Bcl-2 expression. Agmatine 13-21 BCL2 apoptosis regulator Homo sapiens 133-138 25816073-7 2015 In addition, agmatine treatment inhibited glucose-induced Muller cell apoptosis, which was associated with the regulation of Bax and Bcl-2 expression. Glucose 42-49 BCL2 apoptosis regulator Homo sapiens 133-138 26297434-2 2015 Here we investigated the STAT3/myeloid cell leukemia 1 (MCL1) signaling pathway as a target to overcome the resistance of glioma cells to the Bcl-2-inhibiting synthetic BH3 mimetic ABT-737. BH 3 169-172 BCL2 apoptosis regulator Homo sapiens 142-147 26297434-2 2015 Here we investigated the STAT3/myeloid cell leukemia 1 (MCL1) signaling pathway as a target to overcome the resistance of glioma cells to the Bcl-2-inhibiting synthetic BH3 mimetic ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 181-184 BCL2 apoptosis regulator Homo sapiens 142-147 26170994-9 2015 Therefore, the activation of the Bcl-2/Bax and caspase signaling pathways may be involved in the SM-induced apoptosis of hepatoma cells. beta-solamarine 97-99 BCL2 apoptosis regulator Homo sapiens 33-38 26171069-6 2015 It was observed that combined administration of cisplatin and bortezomib induced upregulation of caspase-3, -8 and -9, B-cell lymphoma-2 (Bcl-2)-like 11 and Bcl-2-interacting killer, but downregulated Bcl-2 and Bcl-extra large protein expression levels in T24 cells in a dose-dependent manner. Cisplatin 48-57 BCL2 apoptosis regulator Homo sapiens 119-136 26171069-6 2015 It was observed that combined administration of cisplatin and bortezomib induced upregulation of caspase-3, -8 and -9, B-cell lymphoma-2 (Bcl-2)-like 11 and Bcl-2-interacting killer, but downregulated Bcl-2 and Bcl-extra large protein expression levels in T24 cells in a dose-dependent manner. Cisplatin 48-57 BCL2 apoptosis regulator Homo sapiens 138-143 26171069-6 2015 It was observed that combined administration of cisplatin and bortezomib induced upregulation of caspase-3, -8 and -9, B-cell lymphoma-2 (Bcl-2)-like 11 and Bcl-2-interacting killer, but downregulated Bcl-2 and Bcl-extra large protein expression levels in T24 cells in a dose-dependent manner. Cisplatin 48-57 BCL2 apoptosis regulator Homo sapiens 157-162 26171069-6 2015 It was observed that combined administration of cisplatin and bortezomib induced upregulation of caspase-3, -8 and -9, B-cell lymphoma-2 (Bcl-2)-like 11 and Bcl-2-interacting killer, but downregulated Bcl-2 and Bcl-extra large protein expression levels in T24 cells in a dose-dependent manner. Bortezomib 62-72 BCL2 apoptosis regulator Homo sapiens 119-136 25892665-4 2015 Consistently, Phytol cleaved poly (adenosine diphosphate-ribose) polymerase (PARP), activated caspase-9/3, and Bax attenuated the expression of survival genes such as Bcl-2, Mcl-1, and c-Myc in Huh7 and HepG2 cells. Phytol 14-20 BCL2 apoptosis regulator Homo sapiens 167-172 26171069-6 2015 It was observed that combined administration of cisplatin and bortezomib induced upregulation of caspase-3, -8 and -9, B-cell lymphoma-2 (Bcl-2)-like 11 and Bcl-2-interacting killer, but downregulated Bcl-2 and Bcl-extra large protein expression levels in T24 cells in a dose-dependent manner. Bortezomib 62-72 BCL2 apoptosis regulator Homo sapiens 138-143 26171069-6 2015 It was observed that combined administration of cisplatin and bortezomib induced upregulation of caspase-3, -8 and -9, B-cell lymphoma-2 (Bcl-2)-like 11 and Bcl-2-interacting killer, but downregulated Bcl-2 and Bcl-extra large protein expression levels in T24 cells in a dose-dependent manner. Bortezomib 62-72 BCL2 apoptosis regulator Homo sapiens 157-162 25958204-6 2015 SP600125 (SAPK/JNK inhibitor) and SB203580 (p38 MAPK inhibitor) attenuated down-regulation of Bcl-xL/Bcl-2, mitochondrial translocation of Bax, and cytochrome c release from mitochondria. pyrazolanthrone 0-8 BCL2 apoptosis regulator Homo sapiens 101-106 25958204-6 2015 SP600125 (SAPK/JNK inhibitor) and SB203580 (p38 MAPK inhibitor) attenuated down-regulation of Bcl-xL/Bcl-2, mitochondrial translocation of Bax, and cytochrome c release from mitochondria. SB 203580 34-42 BCL2 apoptosis regulator Homo sapiens 101-106 25819224-5 2015 Resveratrol supported significantly higher cleavage and blastocyst formation rates than the control (80.3% and 38.0% vs. 71.1% and 22.4%, respectively) by downregulating Bax/Bcl-2, Caspase-3, and Bak. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 174-179 26132849-0 2015 Mechanism of Ascorbate-Induced Cell Death in Human Pancreatic Cancer Cells: Role of Bcl-2, Beclin 1 and Autophagy. Ascorbic Acid 13-22 BCL2 apoptosis regulator Homo sapiens 84-89 25519716-6 2015 In addition, the ratio of BAX/BCL2 also increased after adding vitamin C under conditions of 2% O2, while the gene expression level of BCL2 increased after adding vitamin C under increasing oxygen concentrations. Ascorbic Acid 63-72 BCL2 apoptosis regulator Homo sapiens 30-34 25519716-6 2015 In addition, the ratio of BAX/BCL2 also increased after adding vitamin C under conditions of 2% O2, while the gene expression level of BCL2 increased after adding vitamin C under increasing oxygen concentrations. Oxygen 96-98 BCL2 apoptosis regulator Homo sapiens 30-34 25519716-6 2015 In addition, the ratio of BAX/BCL2 also increased after adding vitamin C under conditions of 2% O2, while the gene expression level of BCL2 increased after adding vitamin C under increasing oxygen concentrations. Ascorbic Acid 163-172 BCL2 apoptosis regulator Homo sapiens 135-139 25519716-6 2015 In addition, the ratio of BAX/BCL2 also increased after adding vitamin C under conditions of 2% O2, while the gene expression level of BCL2 increased after adding vitamin C under increasing oxygen concentrations. Oxygen 190-196 BCL2 apoptosis regulator Homo sapiens 135-139 25819224-8 2015 On the basis of these results, we applied sequential treatments with resveratrol and trolox to SCNT, and blastocyst formation rates and total cell numbers were significantly increased compared with the control (17.2% and 52.1 vs. 11.8% and 36.6, respectively), with increased GSH, decreased ROS levels, upregulated proliferating cell nuclear antigen, and downregulated Bax/Bcl-2 and Caspase-3. Resveratrol 69-80 BCL2 apoptosis regulator Homo sapiens 373-378 25819224-8 2015 On the basis of these results, we applied sequential treatments with resveratrol and trolox to SCNT, and blastocyst formation rates and total cell numbers were significantly increased compared with the control (17.2% and 52.1 vs. 11.8% and 36.6, respectively), with increased GSH, decreased ROS levels, upregulated proliferating cell nuclear antigen, and downregulated Bax/Bcl-2 and Caspase-3. 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid 85-91 BCL2 apoptosis regulator Homo sapiens 373-378 25722114-4 2015 Our results showed that 3B was primarily accumulated in mitochondria, increased the level of ROS, induced apoptotic cells death via Bcl-2 family, and its activity could be blocked by the caspase inhibitor (Z-VAD-FMK). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 206-215 BCL2 apoptosis regulator Homo sapiens 132-137 25652471-7 2015 In addition, Western blotting analysis showed that treatment of A549 cells with evodiamine or MTDH shRNA resulted in an increase of proapoptotic protein Bax expression but decreased the expression levels of antiapoptotic protein Bcl-2 and MTDH, which altogether account for apoptotic cell death. evodiamine 80-90 BCL2 apoptosis regulator Homo sapiens 229-234 26182866-9 2015 The changes in apoptosis-related proteins BCL2, BAX, and CASP3 were investigated using Western blot for 24 h. RESULTS: Solasonine reduced the survival ratio of H446 cells and inhibited the proliferation with a dose-related effect. alpha-solamargine 119-129 BCL2 apoptosis regulator Homo sapiens 42-46 26304078-10 2015 Moreover, c-MYC, Bcl-2 and CDK6 protein levels decreased in GSK525762A treated group. molibresib 60-70 BCL2 apoptosis regulator Homo sapiens 17-22 26009874-6 2015 In this study, we found that knocking down Mcl-1 sensitized OSCC cells to ABT-737, which binds to Bcl-2/Bcl-xL but not Mcl-1. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 74-77 BCL2 apoptosis regulator Homo sapiens 98-103 26009874-7 2015 We report for the first time that a BH3 mimetic, Sabutoclax, which functions as an inhibitor of all anti-apoptotic Bcl-2 proteins, induced cancer-specific cell death in an Mcl-1-dependent manner through both apoptosis and toxic mitophagy. BH 3 36-39 BCL2 apoptosis regulator Homo sapiens 115-120 26009874-7 2015 We report for the first time that a BH3 mimetic, Sabutoclax, which functions as an inhibitor of all anti-apoptotic Bcl-2 proteins, induced cancer-specific cell death in an Mcl-1-dependent manner through both apoptosis and toxic mitophagy. 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-N5-(2-phenylpropyl)-N5'-(2-phenylpropyl)-2,2'-binaphthyl-5,5'-dicarboxamide 49-59 BCL2 apoptosis regulator Homo sapiens 115-120 26084280-6 2015 RESULTS: Lapatinib treatment of "sensitive" Her2(+) cells induces apoptotic cell death and enhances transcript and protein levels of Bim, a pro-apoptotic Bcl2 family member. Lapatinib 9-18 BCL2 apoptosis regulator Homo sapiens 154-158 25666751-5 2015 Moreover, TRP induced the apoptosis of U-2 OS cells via a mitochondria-dependent pathway, as evidenced by an increase in Bax/Bcl-2 ratio, a loss of mitochondrial membrane potential (Deltapsim), release of cytochrome c from the mitochondria to the cytosol, activation of caspase-9 and caspase-3, and cleavage of poly(ADP-ribose) polymerase (PARP) in U-2 OS cells. Tryptophan 10-13 BCL2 apoptosis regulator Homo sapiens 125-130 26288699-9 2015 Furthermore, the screening results led us to test the combination of the Bcl-2 inhibitor ABT-263, and the mTOR inhibitor AZD-8055, which we found to be synergistic in a subset of patient-derived GBM models. navitoclax 89-96 BCL2 apoptosis regulator Homo sapiens 73-78 26710702-8 2015 CONCLUSIONS: PinX1 gene can enhance the chemotherapy sensitivity of nasopharyngeal carcinoma cells in response to Cisplatin, which may be mediated by the down-regulation of telomerase activity and the inhibition of LRP and Bcl-2 gene in nasopharyngeal carcinoma cells. Cisplatin 114-123 BCL2 apoptosis regulator Homo sapiens 223-228 25669168-9 2015 Finally, in response to shikonin treatment, Mcl-1 and Bcl-2 levels increased in the scrambled control cells treated with shikonin, whereas Bcl-2 decreased and Mcl-1 slightly increased in the GRP78KD PC-3 cells. shikonin 24-32 BCL2 apoptosis regulator Homo sapiens 54-59 25669168-9 2015 Finally, in response to shikonin treatment, Mcl-1 and Bcl-2 levels increased in the scrambled control cells treated with shikonin, whereas Bcl-2 decreased and Mcl-1 slightly increased in the GRP78KD PC-3 cells. shikonin 24-32 BCL2 apoptosis regulator Homo sapiens 139-144 25672608-0 2015 Calycosin induces apoptosis in human ovarian cancer SKOV3 cells by activating caspases and Bcl-2 family proteins. 7,3'-dihydroxy-4'-methoxyisoflavone 0-9 BCL2 apoptosis regulator Homo sapiens 91-96 25672608-10 2015 In summary, calycosin might exert anti-growth and induce-apoptosis activity against ovarian cancer SKOV3 cells through activating caspases and Bcl-2 family proteins, therefore presenting as a promising therapeutic agent for the treatment of ovarian cancer. 7,3'-dihydroxy-4'-methoxyisoflavone 12-21 BCL2 apoptosis regulator Homo sapiens 143-148 26110921-6 2015 Mechanistic studies suggested that As4S4 acted synergistically with As3+ to down-regulate Bcl-2 and nuclear factor-kappaB expression, up-regulate Bax and p53 expression, and induce activation of caspase-12 and caspase-3. as4s4 35-40 BCL2 apoptosis regulator Homo sapiens 90-95 26110921-6 2015 Mechanistic studies suggested that As4S4 acted synergistically with As3+ to down-regulate Bcl-2 and nuclear factor-kappaB expression, up-regulate Bax and p53 expression, and induce activation of caspase-12 and caspase-3. as3+ 68-72 BCL2 apoptosis regulator Homo sapiens 90-95 26091107-5 2015 RESULTS: Without hypoxic pretreatment, 2.0 MAC of isoflurane slightly increased TUNEL intensity compared to control and sevoflurane, but without any significant changes in the Bax and Bcl-2 ratio. Isoflurane 50-60 BCL2 apoptosis regulator Homo sapiens 184-189 26091107-6 2015 After hypoxic pretreatment, exposure to isoflurane led to a multifold increase in the Bax and Bcl-2 ratio in a dose dependent manner, which was also significantly higher than the ratio observed in the 2 MAC sevoflurane group. Isoflurane 40-50 BCL2 apoptosis regulator Homo sapiens 94-99 26091107-6 2015 After hypoxic pretreatment, exposure to isoflurane led to a multifold increase in the Bax and Bcl-2 ratio in a dose dependent manner, which was also significantly higher than the ratio observed in the 2 MAC sevoflurane group. Sevoflurane 207-218 BCL2 apoptosis regulator Homo sapiens 94-99 25849284-4 2015 Apoptosis in the polyamine-depleted cells occurs by the mitochondrial intrinsic pathway, as evidenced by loss of mitochondrial membrane potential, increase in pro-apoptotic Bax, decrease in anti-apoptotic Bcl-xl, Bcl2 and Mcl-1 and release of cytochrome c from mitochondria, upon transduction with AdSAT1. Polyamines 17-26 BCL2 apoptosis regulator Homo sapiens 213-217 25904702-9 2015 Western blot analysis showed higher expression of P-Erk1/2, Bcl-2, SOD-1, and HO-1 in the HK-2 cells exposed to cisplatin in the presence of CM from melatonin-pretreated hASCs. Cisplatin 112-121 BCL2 apoptosis regulator Homo sapiens 60-65 25858412-6 2015 Exposure of HepG2 cells to tolvaptan enhanced cytochrome C release and triggered apoptosis by modulating Bcl-2 family members. Tolvaptan 27-36 BCL2 apoptosis regulator Homo sapiens 105-110 25858412-7 2015 The activation of p38 contributed to tolvaptan-mediated apoptosis via down-regulation of Bcl-2. Tolvaptan 37-46 BCL2 apoptosis regulator Homo sapiens 89-94 25904702-9 2015 Western blot analysis showed higher expression of P-Erk1/2, Bcl-2, SOD-1, and HO-1 in the HK-2 cells exposed to cisplatin in the presence of CM from melatonin-pretreated hASCs. Melatonin 149-158 BCL2 apoptosis regulator Homo sapiens 60-65 25838396-4 2015 The small molecule ABT-199, which antagonizes the activity of BCL-2, is currently the furthest in clinical trials and shows promising activity in many lymphoid malignancies as a single agent and in combination with conventional chemotherapy agents. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 19-22 BCL2 apoptosis regulator Homo sapiens 62-67 26309548-6 2015 Moreover, baicalin induced apoptotic cell death in Hep G2 and SMMC-7721 cells, which was accompanied by upregulation of Bax, downregulation of Bcl-2, and cleavages of Caspase-9, Caspase-3, and PARP. baicalin 10-18 BCL2 apoptosis regulator Homo sapiens 143-148 26008975-2 2015 The antiapoptotic Bcl-2 family protein Mcl-1 is overexpressed in glioblastoma and represents an important resistance factor to the BH-3 mimetic ABT263. navitoclax 144-150 BCL2 apoptosis regulator Homo sapiens 18-23 26309712-10 2015 Moreover, puerarin treatment suppressed the expression of p-Akt and Bcl-2 and promoted the expression of Bax and cleaved caspase-3 in U251 cells. puerarin 10-18 BCL2 apoptosis regulator Homo sapiens 68-73 26004684-0 2015 Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. sapropterin 20-23 BCL2 apoptosis regulator Homo sapiens 15-19 26004684-1 2015 The BH4 domain of Bcl2 is required for its antiapoptotic function, thus constituting a promising anticancer target. sapropterin 4-7 BCL2 apoptosis regulator Homo sapiens 18-22 26004684-2 2015 We identified a small-molecule Bcl2-BH4 domain antagonist, BDA-366, that binds BH4 with high affinity and selectivity. sapropterin 36-39 BCL2 apoptosis regulator Homo sapiens 31-35 26004684-2 2015 We identified a small-molecule Bcl2-BH4 domain antagonist, BDA-366, that binds BH4 with high affinity and selectivity. biotinylated dextran amine 59-62 BCL2 apoptosis regulator Homo sapiens 31-35 26004684-2 2015 We identified a small-molecule Bcl2-BH4 domain antagonist, BDA-366, that binds BH4 with high affinity and selectivity. sapropterin 79-82 BCL2 apoptosis regulator Homo sapiens 31-35 26004684-7 2015 Development of this Bcl2-BH4 antagonist may provide a strategy to improve lung cancer outcome. sapropterin 25-28 BCL2 apoptosis regulator Homo sapiens 20-24 26047480-10 2015 The expression of Bax was upregulated with downregulation of Bcl-2 following treatment with EADs. eads 92-96 BCL2 apoptosis regulator Homo sapiens 61-66 26047480-11 2015 The elevated Bax/Bcl-2 ratio and the depolarization of mitochondrial membrane potential suggest that EADs-induced apoptosis is mitochondria-dependent. eads 101-105 BCL2 apoptosis regulator Homo sapiens 17-22 26019371-2 2015 By tailoring this substance such that it can participate in salt bridging with the protein surface, we have prepared the first prodiginine inspired structure that shows direct, saturable binding to a recombinant Bcl-2 family member in vitro. Salts 60-64 BCL2 apoptosis regulator Homo sapiens 212-217 26019371-2 2015 By tailoring this substance such that it can participate in salt bridging with the protein surface, we have prepared the first prodiginine inspired structure that shows direct, saturable binding to a recombinant Bcl-2 family member in vitro. prodiginine 127-138 BCL2 apoptosis regulator Homo sapiens 212-217 26086415-7 2015 In vitro, 2% IP and a specific inhibitor of TLR4, CLI-095, down-regulated the expression of TLR4, MyD88, IL-1beta, TNF-alpha and Bax, and up-regulated IkappaB-alpha and Bcl-2 expression compared with OGD group. ip 13-15 BCL2 apoptosis regulator Homo sapiens 169-174 26089640-0 2015 Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer. gossypol acetic acid 51-57 BCL2 apoptosis regulator Homo sapiens 35-40 26089640-0 2015 Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer. Cisplatin 93-102 BCL2 apoptosis regulator Homo sapiens 35-40 25714087-6 2015 Moreover, chabamide could regulate the changes in the mitochondrial membrane potential, increase the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decrease the protein expression levels of Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt. chabamide 10-19 BCL2 apoptosis regulator Homo sapiens 219-224 25374342-9 2015 The expression of Bax protein was upregulated and Bcl2 protein was downregulated in HepG2 cells treated with GLH assessed by Western blotting, and they were in a dose-dependent manner. glaucocalyxin H 109-112 BCL2 apoptosis regulator Homo sapiens 50-54 25374342-10 2015 Taken together, GLH can inhibit the growth of hepatoma cells in vivo and in vitro by inducing cell apoptosis due to the decreased Bcl2 and increased Bax proteins suggesting that GLH could be a potential candidate as an anti-hepatoma agent for the therapeutic treatment of hepatoma. glaucocalyxin H 16-19 BCL2 apoptosis regulator Homo sapiens 130-134 25374342-10 2015 Taken together, GLH can inhibit the growth of hepatoma cells in vivo and in vitro by inducing cell apoptosis due to the decreased Bcl2 and increased Bax proteins suggesting that GLH could be a potential candidate as an anti-hepatoma agent for the therapeutic treatment of hepatoma. glaucocalyxin H 178-181 BCL2 apoptosis regulator Homo sapiens 130-134 25712455-7 2015 The primary CD34(+) CML cells from this patient showed increased sensitivity to the combination of ponatinib and ABT-263, a BCL2 inhibitor with a negligible effect against the normal CD34(+) cells. ponatinib 99-108 BCL2 apoptosis regulator Homo sapiens 124-128 25712455-7 2015 The primary CD34(+) CML cells from this patient showed increased sensitivity to the combination of ponatinib and ABT-263, a BCL2 inhibitor with a negligible effect against the normal CD34(+) cells. navitoclax 113-120 BCL2 apoptosis regulator Homo sapiens 124-128 25856291-9 2015 Xenon treatment enhanced p-mTOR, HIF-1alpha, and Bcl-2 expression and, in turn, promoted cell proliferation in the lung. Xenon 0-5 BCL2 apoptosis regulator Homo sapiens 49-54 25193624-3 2015 Additionally, bishonokiol A (1) induced apoptosis, as well as down-regulated the expression of the anti-apoptotic protein Bcl-2 and caspase-3 cleavage in HepG2 cell line. bishonokiol A 14-27 BCL2 apoptosis regulator Homo sapiens 122-127 25820140-5 2015 At molecular level, PCN instigates apoptosis by mitochondrial intrinsic apoptotic pathway via the overexpression of p53, Bax, cytochrome C release and activation of caspase-3 with the inhibition of oncogenic anti-apoptotic proteins such as PARP and Bcl-2 family proteins (Bcl-2, Bcl-w and Bcl-xL). Pregnenolone Carbonitrile 20-23 BCL2 apoptosis regulator Homo sapiens 249-254 25820140-5 2015 At molecular level, PCN instigates apoptosis by mitochondrial intrinsic apoptotic pathway via the overexpression of p53, Bax, cytochrome C release and activation of caspase-3 with the inhibition of oncogenic anti-apoptotic proteins such as PARP and Bcl-2 family proteins (Bcl-2, Bcl-w and Bcl-xL). Pregnenolone Carbonitrile 20-23 BCL2 apoptosis regulator Homo sapiens 272-277 25820140-6 2015 The in silico docking studies of PCN targeted against the anti-apoptotic members of Bcl-2 family proteins revealed the interaction of PCN with the BH3 domain, which might lead to the induction of apoptosis due to the inhibition of antiapoptotic proteins. Pregnenolone Carbonitrile 33-36 BCL2 apoptosis regulator Homo sapiens 84-89 25820140-6 2015 The in silico docking studies of PCN targeted against the anti-apoptotic members of Bcl-2 family proteins revealed the interaction of PCN with the BH3 domain, which might lead to the induction of apoptosis due to the inhibition of antiapoptotic proteins. Pregnenolone Carbonitrile 134-137 BCL2 apoptosis regulator Homo sapiens 84-89 25820140-7 2015 Due to its innate inhibition potential of antiapoptotic Bcl-2 family proteins, PCN may be used as potent anticancer agent against both lung and breast cancer. Pregnenolone Carbonitrile 79-82 BCL2 apoptosis regulator Homo sapiens 56-61 25790909-6 2015 5"-Br was found to trigger intrinsic apoptotic pathway as indicated by depolarization of the mitochondrial inner membrane, decreased level of cellular ATP, modulated expression and phosphorylation of Bcl-2 leading to loss of its association with Bax, and increased release of cytochrome c. 5"-br 0-5 BCL2 apoptosis regulator Homo sapiens 200-205 26009182-7 2015 Like for IP3Rs, binding of Bcl-2 to RyRs also involved its BH4 domain and suppressed RyR-mediated Ca2+ release. sapropterin 59-62 BCL2 apoptosis regulator Homo sapiens 27-32 25819915-9 2015 Further, BPTQ activates the mitochondria-mediated apoptosis pathway, as explicated by a decrease in mitochondrial membrane potential, increase in the Bax:Bcl-2 ratio, and activation of caspases. bptq 9-13 BCL2 apoptosis regulator Homo sapiens 154-159 25914345-7 2015 Vinblastine treatment had an antiproliferative effect via the induction of apoptosis producing Bax/Bcl-2 imbalance. Vinblastine 0-11 BCL2 apoptosis regulator Homo sapiens 99-104 25804936-6 2015 Finally, a series Phase I/II studies of BCL-2 inhibitor (i.e., venetoclax, GDC-0199) used alone or in combination provide promising results in patients with relapsed/refractory CLL. venetoclax 63-73 BCL2 apoptosis regulator Homo sapiens 40-45 26032425-2 2015 Sabutoclax, a small-molecule BH3 mimetic, inhibits the function of antiapoptotic Bcl-2 proteins. 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-N5-(2-phenylpropyl)-N5'-(2-phenylpropyl)-2,2'-binaphthyl-5,5'-dicarboxamide 0-10 BCL2 apoptosis regulator Homo sapiens 81-86 26032425-2 2015 Sabutoclax, a small-molecule BH3 mimetic, inhibits the function of antiapoptotic Bcl-2 proteins. BH 3 29-32 BCL2 apoptosis regulator Homo sapiens 81-86 25754349-1 2015 PURPOSE: Two clinical-stage anticancer drugs, the Bcl-2 inhibitor ABT-263, and the MDM2 inhibitor SAR405838 achieve complete tumor regression in animal models of leukemia but also induce acquired resistance. navitoclax 66-73 BCL2 apoptosis regulator Homo sapiens 50-55 25804936-6 2015 Finally, a series Phase I/II studies of BCL-2 inhibitor (i.e., venetoclax, GDC-0199) used alone or in combination provide promising results in patients with relapsed/refractory CLL. venetoclax 75-83 BCL2 apoptosis regulator Homo sapiens 40-45 25818165-6 2015 Meanwhile, celastrol triggered reactive oxygen species production with collapse of mitochondrial membrane potential, down-regulation of Bcl-2 and up-regulation of Bax expression. celastrol 11-20 BCL2 apoptosis regulator Homo sapiens 136-141 25847449-5 2015 The potent effects of the combination treatment on PANC-1 cells were associated with the inhibition of nuclear factor-kappaB (NF-kappaB) activation and the decreased expression of Bcl-2 induced by DDTC, as shown by NF-kappaB-dependent reporter gene expression assay and western blot analysis. Ditiocarb 197-201 BCL2 apoptosis regulator Homo sapiens 180-185 25720812-3 2015 Western blot data demonstrated that THF inhibited the H2O2-induced up- or down-regulation of cleaved caspase-3, cleaved caspase-9, cleaved poly-ADP-ribose polymerase (PARP), Bax, Bcl-2, and Bcl-xL, and attenuated the H2O2-induced release of cytochrome c from the mitochondria to the cytosol. 3',4',7-trihydroxyflavone 36-39 BCL2 apoptosis regulator Homo sapiens 179-184 25720812-3 2015 Western blot data demonstrated that THF inhibited the H2O2-induced up- or down-regulation of cleaved caspase-3, cleaved caspase-9, cleaved poly-ADP-ribose polymerase (PARP), Bax, Bcl-2, and Bcl-xL, and attenuated the H2O2-induced release of cytochrome c from the mitochondria to the cytosol. Hydrogen Peroxide 54-58 BCL2 apoptosis regulator Homo sapiens 179-184 25847862-10 2015 Treatment with curcumin downregulated the expression of Bcl-2, and elevated the phosphorylation level of IP3R in a concentration-dependent manner. Curcumin 15-23 BCL2 apoptosis regulator Homo sapiens 56-61 25663373-7 2015 Quantitative real-time PCR data demonstrated that the mRNA level of tumor suppressor gene p53 and apoptotic genes (bax, CASP3 and CASP9) were up-regulated whereas the anti-apoptotic gene bcl-2 was down-regulated in HEp2 and HepG2 cells exposed to dolomite NPs. calcium magnesium carbonate 247-255 BCL2 apoptosis regulator Homo sapiens 187-192 25847862-12 2015 In conclusion, the cytotoxic effects of curcumin on lung cancer cells were induced by calcium overload, which involves Bcl-2 mediated IP3R phosphorylation. Curcumin 40-48 BCL2 apoptosis regulator Homo sapiens 119-124 25847862-12 2015 In conclusion, the cytotoxic effects of curcumin on lung cancer cells were induced by calcium overload, which involves Bcl-2 mediated IP3R phosphorylation. Calcium 86-93 BCL2 apoptosis regulator Homo sapiens 119-124 25895100-13 2015 Treatment with the myricetin led to down-regulation of mRNA expression of EGFR, IR, mTOR, and Bcl-2. myricetin 19-28 BCL2 apoptosis regulator Homo sapiens 94-99 25891879-6 2015 We demonstrated that hydrogen peroxide (H2O2) increased Nox4-dependent-ROS aggregation, as well as the expression of TGF-beta1, Smad2, Bax and caspase-3, decreased Bcl-2 expression and increased the apoptosis of human umbilical vein endothelial cells (HUVECs). Hydrogen Peroxide 21-38 BCL2 apoptosis regulator Homo sapiens 164-169 25891879-6 2015 We demonstrated that hydrogen peroxide (H2O2) increased Nox4-dependent-ROS aggregation, as well as the expression of TGF-beta1, Smad2, Bax and caspase-3, decreased Bcl-2 expression and increased the apoptosis of human umbilical vein endothelial cells (HUVECs). Hydrogen Peroxide 40-44 BCL2 apoptosis regulator Homo sapiens 164-169 25895534-7 2015 Moreover, elevated CO2 induced the expression of Bcl-2 and Bcl-xL, antiapoptotic factors that negatively regulate autophagy by blocking Beclin 1, an essential component of the autophagy initiation complex. N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide 19-22 BCL2 apoptosis regulator Homo sapiens 49-54 25604244-0 2015 TTP mediates cisplatin-induced apoptosis of head and neck cancer cells by down-regulating the expression of Bcl-2. Cisplatin 13-22 BCL2 apoptosis regulator Homo sapiens 108-113 25604244-2 2015 B-cell lymphoma 2 (Bcl-2) is an anti-apoptotic protein that is overexpressed in cancer cells and confers resistance to cisplatin. Cisplatin 119-128 BCL2 apoptosis regulator Homo sapiens 0-17 25604244-2 2015 B-cell lymphoma 2 (Bcl-2) is an anti-apoptotic protein that is overexpressed in cancer cells and confers resistance to cisplatin. Cisplatin 119-128 BCL2 apoptosis regulator Homo sapiens 19-24 25604244-3 2015 Thus, inhibition of Bcl-2 expression may enhance the cisplatin sensitivity of cancer cells. Cisplatin 53-62 BCL2 apoptosis regulator Homo sapiens 20-25 25604244-4 2015 In this study, we report that the AU-rich element (ARE) binding protein tristetraprolin (TTP) inhibits the expression of Bcl-2 and enhances cisplatin sensitivity of HNSCC cells. Gold 34-36 BCL2 apoptosis regulator Homo sapiens 121-126 25604244-5 2015 Cisplatin-sensitive HNSCC cells express high levels of TTP and low levels of Bcl-2, while cisplatin-resistant HNSCC cells have low levels of TTP and high levels of Bcl-2. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 77-82 25604244-5 2015 Cisplatin-sensitive HNSCC cells express high levels of TTP and low levels of Bcl-2, while cisplatin-resistant HNSCC cells have low levels of TTP and high levels of Bcl-2. Cisplatin 90-99 BCL2 apoptosis regulator Homo sapiens 164-169 25604244-8 2015 Together, the results of the present study suggest that TTP expression enhances cisplatin sensitivity in HNSCC cells by reducing levels of Bcl-2. Cisplatin 80-89 BCL2 apoptosis regulator Homo sapiens 139-144 25634603-8 2015 TSA also induced cell apoptosis by enhancing the expression of pro-apoptotic protein Bax and decreasing the expression of anti-apoptotic protein Bcl-2. trichostatin A 0-3 BCL2 apoptosis regulator Homo sapiens 145-150 25818183-8 2015 Conversely after exposure to doxorubicin, these cells displayed an up-regulation of the anti-apoptotic proteins Bcl-2 and Bcl-xL with concomitant down-regulation of Bak and decreased caspase 3/7 activity. Doxorubicin 29-40 BCL2 apoptosis regulator Homo sapiens 112-117 25818183-9 2015 Inhibition of drug efflux transporters enhanced the cellular uptake of doxorubicin, being encompassed by an up-regulation the pro-apoptotic protein Bak and suppression of Bcl-2, favoring the commitment of CSCs towards apoptosis. Doxorubicin 71-82 BCL2 apoptosis regulator Homo sapiens 171-176 25818185-11 2015 Finally, pretreatment of cells with DMY prior to H2O2 exposure resulted in the inhibition of p53 activation, followed by the regulation of the expression of Bcl-2 and Bax, the release of cytochrome c, the cleavage (activation) of caspase-9 and caspase-3, and then the suppression of PARP cleavage in H2O2-induced HUVECs. dihydromyricetin 36-39 BCL2 apoptosis regulator Homo sapiens 157-162 25755089-5 2015 Interestingly, DADS significantly inhibited activation of the beta-catenin signaling pathway, which regulated Bcl-2 family members, MMP-9 and EMT in TNBC cells. diallyl disulfide 15-19 BCL2 apoptosis regulator Homo sapiens 110-115 25672487-1 2015 Apogossypol, a gossypol derivative, is a novel small-molecule inhibitor of the Bcl-2 family proteins and has been demonstrated to have anti-tumor activities. apogossypol 0-11 BCL2 apoptosis regulator Homo sapiens 79-84 25672487-1 2015 Apogossypol, a gossypol derivative, is a novel small-molecule inhibitor of the Bcl-2 family proteins and has been demonstrated to have anti-tumor activities. Gossypol 3-11 BCL2 apoptosis regulator Homo sapiens 79-84 25672487-7 2015 Furthermore, immunofluorescence revealed that apogossypol inhibited the growth and proliferation of prostate cancer cells by downregulating Bcl-2 protein expression and activating caspase-3 and -8. apogossypol 46-57 BCL2 apoptosis regulator Homo sapiens 140-145 25891311-6 2015 In addition, silibinin triggered the conversion of light chain 3 (LC3)-I to LC3-II, promoted the upregulation of Atg12-Atg5 formation, increased Beclin-1 expression, and decreased the Bcl-2 level. Silybin 13-22 BCL2 apoptosis regulator Homo sapiens 184-189 25673156-9 2015 These findings suggested that the protective effect of curcumin against H/R injury in the H9c2 myocytes was through the inhibition of apoptosis and autophagy by inducing the expression of Bcl-2 and inhibiting the expression levels of Bax, beclin-1, BNIP3 and SIRT1. Curcumin 55-63 BCL2 apoptosis regulator Homo sapiens 188-193 26111693-6 2015 The expressions of caspase-3 and Bax protein were significantly increased (P<0.05) and Bcl-2 protein expression was decreased (P<0.05) with a lowered Bcl-2/Bax ratio in AGEs-treated fibroblasts (P<0.05), and such changes were significantly reversed by metformin treatment (P<0.05). Metformin 261-270 BCL2 apoptosis regulator Homo sapiens 156-161 26111693-7 2015 CONCLUSION: Metformin can antagonize AGEs-induced apoptosis in human dermal fibroblasts by regulating the expressions of caspase-3, Bax and Bcl-2. Metformin 12-21 BCL2 apoptosis regulator Homo sapiens 140-145 25845399-4 2015 We found that the proliferation of PC3 cells, as determined using the MTT assay, and the expression of cyclin D1, COX-2, Bcl-2 and survivin proteins elevated by LPS were distinctly inhibited by sesamin in a dose-dependent manner. sesamin 194-201 BCL2 apoptosis regulator Homo sapiens 121-126 25891311-8 2015 Silibinin stimulated the expression of Bcl-2 adenovirus E1B 19-kDa-interacting protein 3 (BNIP3), a pro-death Bcl-2 family member, and silencing of BNIP3 greatly inhibited silibinin-induced cell death, decreased ROS production, and sustained DeltaPsim and ATP levels. Silybin 0-9 BCL2 apoptosis regulator Homo sapiens 39-44 25891311-8 2015 Silibinin stimulated the expression of Bcl-2 adenovirus E1B 19-kDa-interacting protein 3 (BNIP3), a pro-death Bcl-2 family member, and silencing of BNIP3 greatly inhibited silibinin-induced cell death, decreased ROS production, and sustained DeltaPsim and ATP levels. Silybin 172-181 BCL2 apoptosis regulator Homo sapiens 39-44 25891311-8 2015 Silibinin stimulated the expression of Bcl-2 adenovirus E1B 19-kDa-interacting protein 3 (BNIP3), a pro-death Bcl-2 family member, and silencing of BNIP3 greatly inhibited silibinin-induced cell death, decreased ROS production, and sustained DeltaPsim and ATP levels. Reactive Oxygen Species 212-215 BCL2 apoptosis regulator Homo sapiens 39-44 25891311-8 2015 Silibinin stimulated the expression of Bcl-2 adenovirus E1B 19-kDa-interacting protein 3 (BNIP3), a pro-death Bcl-2 family member, and silencing of BNIP3 greatly inhibited silibinin-induced cell death, decreased ROS production, and sustained DeltaPsim and ATP levels. Adenosine Triphosphate 256-259 BCL2 apoptosis regulator Homo sapiens 39-44 25962755-0 2015 Cantharidin inhibits cell proliferation and promotes apoptosis in tongue squamous cell carcinoma through suppression of miR-214 and regulation of p53 and Bcl-2/Bax. Cantharidin 0-11 BCL2 apoptosis regulator Homo sapiens 154-159 25962755-10 2015 Cantharidin markedly weakened miR-214 expression level, activated p53 protein expression, and suppressed the Bcl-2/Bax signaling pathway in Tca8113 cells. Cantharidin 0-11 BCL2 apoptosis regulator Homo sapiens 109-114 25962755-12 2015 However, the overexpression of miR-214 reduced the anticancer effect of cantharidin on the proliferation and apoptosis of TSCC Tca8113 cells, inhibited p53 protein expression, and increased the Bcl-2/Bax signaling pathway. Cantharidin 72-83 BCL2 apoptosis regulator Homo sapiens 194-199 26055133-1 2015 Nakai ex Kitam ethanol extract against cisplatin-induced apoptosis of human HaCaT keratinocytes: Involvement of NF-kappa B- and Bcl-2-controlled mitochondrial signaling. Cisplatin 39-48 BCL2 apoptosis regulator Homo sapiens 128-133 26189302-6 2015 In addition, we showed that resveratrol could also activate caspase-3 and alter the Bax/Bcl-2 apoptotic signaling. Resveratrol 28-39 BCL2 apoptosis regulator Homo sapiens 88-93 26055133-14 2015 CONCLUSION: Collectively, our results suggest that Aa-EE protects HaCaT cells by inhibiting cisplatin-induced mitochondrial damage associated with Bcl-2 activity and by inhibiting nuclear translocation of NF-kappaB. Cisplatin 92-101 BCL2 apoptosis regulator Homo sapiens 147-152 25616695-0 2015 BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy. Anthracyclines 111-124 BCL2 apoptosis regulator Homo sapiens 0-4 25616695-12 2015 In conclusion, high BCL2 expression is a significant independent predictor of poor outcome in TNBC patients treated with anthracycline-based adjuvant chemotherapy, and this is the first study showing the BCL2 prediction in BL TNBC. Anthracyclines 121-134 BCL2 apoptosis regulator Homo sapiens 20-24 25616695-6 2015 High BCL2 expression predicted poor relapse-free survival (RFS) in patients treated with anthracycline-based adjuvant chemotherapy (p = 0.035), poor breast cancer-specific survival (BCSS) (p = 0.048), and a trend to poor overall survival (OS) (p = 0.085). Anthracyclines 89-102 BCL2 apoptosis regulator Homo sapiens 5-9 25616695-7 2015 High levels of BCL2 expression predicted poor OS in basal-like (BL) TNBC patients treated with adjuvant anthracycline-based regimens (log-rank p = 0.033, hazard ratio (HR) 3.04, 95 % confidence interval (CI) 1.04-8.91) and a trend to poor RFS (log-rank p = 0.079) and poor BCSS (log-rank p = 0.056). Anthracyclines 104-117 BCL2 apoptosis regulator Homo sapiens 15-19 25743928-9 2015 The 24h exposition of TPT-Cl induced substantial diminution of Bcl-2 protein expression in comparison with both, untreated cells and TBT-Cl treated cells. triphenyltin chloride 22-28 BCL2 apoptosis regulator Homo sapiens 63-68 26117010-8 2015 Also, the expression of BCL-2 and survivin significantly decreased, while the expression of BAX, P21 and P27 was significantly upregulated in HL-60 cells after being treated with 5.0 micromol/L As2O3. Arsenic Trioxide 194-199 BCL2 apoptosis regulator Homo sapiens 24-29 25618598-10 2015 Finally, we observed a decrease in the level of Bcl-2 and an increase in the levels of Bad and Bax in GRP78KD cells treated with 17-DMAG. 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin 129-136 BCL2 apoptosis regulator Homo sapiens 48-53 26062416-8 2015 Western blotting showed that the expressions of JAK2, p-STAT3 and Bcl-2 were gradually reduced, while the expression of Bax was raised with the increasing concentration of AG490. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 172-177 BCL2 apoptosis regulator Homo sapiens 66-71 26221229-7 2015 Furthermore, Sch B triggered A549 cell apoptosis by increasing Bax, cleaved caspase-3, 9, Cyto C, but decreasing Bcl-2 and PCNA expression. schizandrin B 13-18 BCL2 apoptosis regulator Homo sapiens 113-118 26552178-7 2015 According to the results of Real-time PCR and Western blot, TMP could down-regulate the expression of apoptosis-related molecule bcl-2, cycle-related protein cyclin E1 and CDK2 and up-regulate caspase-3 and P27. tetramethylpyrazine 60-63 BCL2 apoptosis regulator Homo sapiens 129-134 26074734-9 2015 CONCLUSION: Our previous finding that 3-NC down regulates Inhibitor of Apoptosis Proteins (IAPs) and the present observation that Bax is upregulated and Bcl2 is down regulated upon 3-NC treatment, this chromene derivative has the potential to overcome chemotherapy resistance caused by up regulation of these proteins. Benzopyrans 202-210 BCL2 apoptosis regulator Homo sapiens 153-157 26074776-10 2015 Lithium treated cells showed increased anti-apoptotic protein BCL2 and decreased pro-apoptotic protein BAX expression. Lithium 0-7 BCL2 apoptosis regulator Homo sapiens 62-66 26028971-7 2015 Abrogation of Bcl2 activity by the Bcl2-specific inhibitor ABT 737 led to cell death in the presence of both cytarabine and daunorubicin, demonstrating that the cell adhesion-mediated drug resistance induced by Bcl2 and p27(Kip1) in the scaffold was similar to that seen in vivo. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 59-62 BCL2 apoptosis regulator Homo sapiens 14-18 26028971-7 2015 Abrogation of Bcl2 activity by the Bcl2-specific inhibitor ABT 737 led to cell death in the presence of both cytarabine and daunorubicin, demonstrating that the cell adhesion-mediated drug resistance induced by Bcl2 and p27(Kip1) in the scaffold was similar to that seen in vivo. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 59-62 BCL2 apoptosis regulator Homo sapiens 35-39 26028971-7 2015 Abrogation of Bcl2 activity by the Bcl2-specific inhibitor ABT 737 led to cell death in the presence of both cytarabine and daunorubicin, demonstrating that the cell adhesion-mediated drug resistance induced by Bcl2 and p27(Kip1) in the scaffold was similar to that seen in vivo. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 59-62 BCL2 apoptosis regulator Homo sapiens 35-39 26028971-7 2015 Abrogation of Bcl2 activity by the Bcl2-specific inhibitor ABT 737 led to cell death in the presence of both cytarabine and daunorubicin, demonstrating that the cell adhesion-mediated drug resistance induced by Bcl2 and p27(Kip1) in the scaffold was similar to that seen in vivo. Cytarabine 109-119 BCL2 apoptosis regulator Homo sapiens 14-18 26028971-7 2015 Abrogation of Bcl2 activity by the Bcl2-specific inhibitor ABT 737 led to cell death in the presence of both cytarabine and daunorubicin, demonstrating that the cell adhesion-mediated drug resistance induced by Bcl2 and p27(Kip1) in the scaffold was similar to that seen in vivo. Cytarabine 109-119 BCL2 apoptosis regulator Homo sapiens 35-39 25996383-11 2015 Polycerasoidin induced mitochondrial-dependent apoptosis in breast cancer cells via caspase activation and changes in the mRNA and protein expression of Bax and Bcl-2. Polycerasoidin 0-14 BCL2 apoptosis regulator Homo sapiens 161-166 25909286-7 2015 By co-culture with CAFs, SDF-1/CXCR4/PI3K/AKT signaling was activated and apoptosis was markedly repressed with an increased Bcl-2/BAX ratio in Huh7 cells. cafs 19-23 BCL2 apoptosis regulator Homo sapiens 125-130 26059440-2 2015 Specific and potent inhibitors of the BCL-2 family, such as ABT-263 (navitoclax) and ABT-199, are only effective against some members of the BCL-2 family but do not target MCL-1, which is commonly amplified in tumors and associated with chemoresistance. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 60-63 BCL2 apoptosis regulator Homo sapiens 38-43 26059440-2 2015 Specific and potent inhibitors of the BCL-2 family, such as ABT-263 (navitoclax) and ABT-199, are only effective against some members of the BCL-2 family but do not target MCL-1, which is commonly amplified in tumors and associated with chemoresistance. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 60-63 BCL2 apoptosis regulator Homo sapiens 141-146 26059440-2 2015 Specific and potent inhibitors of the BCL-2 family, such as ABT-263 (navitoclax) and ABT-199, are only effective against some members of the BCL-2 family but do not target MCL-1, which is commonly amplified in tumors and associated with chemoresistance. navitoclax 69-79 BCL2 apoptosis regulator Homo sapiens 38-43 26059440-2 2015 Specific and potent inhibitors of the BCL-2 family, such as ABT-263 (navitoclax) and ABT-199, are only effective against some members of the BCL-2 family but do not target MCL-1, which is commonly amplified in tumors and associated with chemoresistance. navitoclax 69-79 BCL2 apoptosis regulator Homo sapiens 141-146 26059440-2 2015 Specific and potent inhibitors of the BCL-2 family, such as ABT-263 (navitoclax) and ABT-199, are only effective against some members of the BCL-2 family but do not target MCL-1, which is commonly amplified in tumors and associated with chemoresistance. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 85-88 BCL2 apoptosis regulator Homo sapiens 38-43 26059440-2 2015 Specific and potent inhibitors of the BCL-2 family, such as ABT-263 (navitoclax) and ABT-199, are only effective against some members of the BCL-2 family but do not target MCL-1, which is commonly amplified in tumors and associated with chemoresistance. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 85-88 BCL2 apoptosis regulator Homo sapiens 141-146 26221255-10 2015 Moreover, p53, p21 and Bax/Bcl-2 were significantly upregulated by honokiol treatment. honokiol 67-75 BCL2 apoptosis regulator Homo sapiens 27-32 26028971-7 2015 Abrogation of Bcl2 activity by the Bcl2-specific inhibitor ABT 737 led to cell death in the presence of both cytarabine and daunorubicin, demonstrating that the cell adhesion-mediated drug resistance induced by Bcl2 and p27(Kip1) in the scaffold was similar to that seen in vivo. Cytarabine 109-119 BCL2 apoptosis regulator Homo sapiens 35-39 26028971-7 2015 Abrogation of Bcl2 activity by the Bcl2-specific inhibitor ABT 737 led to cell death in the presence of both cytarabine and daunorubicin, demonstrating that the cell adhesion-mediated drug resistance induced by Bcl2 and p27(Kip1) in the scaffold was similar to that seen in vivo. Daunorubicin 124-136 BCL2 apoptosis regulator Homo sapiens 14-18 26028971-7 2015 Abrogation of Bcl2 activity by the Bcl2-specific inhibitor ABT 737 led to cell death in the presence of both cytarabine and daunorubicin, demonstrating that the cell adhesion-mediated drug resistance induced by Bcl2 and p27(Kip1) in the scaffold was similar to that seen in vivo. Daunorubicin 124-136 BCL2 apoptosis regulator Homo sapiens 35-39 26028971-7 2015 Abrogation of Bcl2 activity by the Bcl2-specific inhibitor ABT 737 led to cell death in the presence of both cytarabine and daunorubicin, demonstrating that the cell adhesion-mediated drug resistance induced by Bcl2 and p27(Kip1) in the scaffold was similar to that seen in vivo. Daunorubicin 124-136 BCL2 apoptosis regulator Homo sapiens 35-39 25844895-4 2015 Here, we describe the discovery of potent tricyclic 2-indole carboxylic acid inhibitors that exhibit single digit nanomolar binding affinity to Mcl-1 and greater than 1700-fold selectivity over Bcl-xL and greater than 100-fold selectivity over Bcl-2. indole-2-carboxylic acid 52-76 BCL2 apoptosis regulator Homo sapiens 244-249 28962410-0 2015 Occupational health hazards of trichloroethylene among workers in relation to altered mRNA expression of cell cycle regulating genes (p53, p21, bax and bcl-2) and PPARA. Trichloroethylene 31-48 BCL2 apoptosis regulator Homo sapiens 152-157 25770930-4 2015 Combination of chrysin and cisplatin increased the phosphorylation and accumulation of p53 through activating ERK1/2 in Hep G2 cells, which led to the overexpression of the pro-apoptotic proteins Bax and DR5 and the inhibition of the anti-apoptotic protein Bcl-2. chrysin 15-22 BCL2 apoptosis regulator Homo sapiens 257-262 25770930-4 2015 Combination of chrysin and cisplatin increased the phosphorylation and accumulation of p53 through activating ERK1/2 in Hep G2 cells, which led to the overexpression of the pro-apoptotic proteins Bax and DR5 and the inhibition of the anti-apoptotic protein Bcl-2. Cisplatin 27-36 BCL2 apoptosis regulator Homo sapiens 257-262 25818766-0 2015 Design, synthesis and preliminary bioactivity studies of 2-thioxo-4-thiazolidinone derivatives as Bcl-2 inhibitors. Rhodanine 57-82 BCL2 apoptosis regulator Homo sapiens 98-103 25595658-9 2015 Furthermore, co-treatment of hNSCs with metformin significantly blocked AGE-mediated reductions in the expression levels of several neuroprotective genes (PPARgamma, Bcl-2 and CREB). Metformin 40-49 BCL2 apoptosis regulator Homo sapiens 166-171 25747710-6 2015 In addition, cepharanthine triggered apoptosis in non-small lung cancer cells via the upregulation of Bax, downregulation of Bcl-2 and significant activation of caspase-3 and PARP. cepharanthine 13-26 BCL2 apoptosis regulator Homo sapiens 125-130 25818766-2 2015 In the present study, a series of 2-thioxo-4-thiazolidinone derivatives were designed and synthesized as Bcl-2 inhibitors. Rhodanine 34-59 BCL2 apoptosis regulator Homo sapiens 105-110 25539708-5 2015 Treatment of 786-O cells with EGCG and TRAIL downregulated c-FLIP, Mcl-1, and Bcl-2 proteins in a caspase-dependent pathway. epigallocatechin gallate 30-34 BCL2 apoptosis regulator Homo sapiens 78-83 26054686-8 2015 Oridonin treatment upregulated the expression levels of Bim, Bax, cytosolic cytochrome c, cleaved caspase-9 and cleaved caspase-3 proteins, downregulated the expression levels of Bcl-2, procaspase-9 and procaspase-3 proteins, and meanwhile obviously activated caspase-9 and caspase-3 in a dose-dependent manner in HCT-116 and LoVo cells. oridonin 0-8 BCL2 apoptosis regulator Homo sapiens 179-184 25323586-0 2015 Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer. Fluorouracil 40-54 BCL2 apoptosis regulator Homo sapiens 0-5 25323586-3 2015 An adaptor protein paxillin (PXN) is phosphorylated at Y31/Y118 (pPXN-Y31/Y118) by Src contributes to cell mobility and Ser (S)272 of PXN in LD4 domain is important to the interaction between PXN and Bcl-2. Serine 120-123 BCL2 apoptosis regulator Homo sapiens 200-205 25323586-4 2015 We thus hypothesized that pPXN-Y31/Y118 may be required for Bcl-2 protein stability via PXN interacting with Bcl-2 to confer 5-FU resistance in colorectal cancer. Fluorouracil 125-129 BCL2 apoptosis regulator Homo sapiens 60-65 25323586-4 2015 We thus hypothesized that pPXN-Y31/Y118 may be required for Bcl-2 protein stability via PXN interacting with Bcl-2 to confer 5-FU resistance in colorectal cancer. Fluorouracil 125-129 BCL2 apoptosis regulator Homo sapiens 109-114 25323586-7 2015 An increase in Bcl-2 expression by PXN is responsible for resistance to 5-FU. Fluorouracil 72-76 BCL2 apoptosis regulator Homo sapiens 15-20 25323586-8 2015 The resistance to 5-FU can be abolished by inhibitor of Src and PAK1 or Bcl-2 antagonist in cell and animal models. Fluorouracil 18-22 BCL2 apoptosis regulator Homo sapiens 72-77 25539708-6 2015 Moreover, we found that pretreatment with NAC markedly inhibited the expression levels of c-FLIP, Mcl-1, and Bcl-2 downregulated by the combinatory treatment, suggesting that the regulating effect of EGCG on these above apoptosis-relevant molecules was partially mediated by generation of ROS. epigallocatechin gallate 200-204 BCL2 apoptosis regulator Homo sapiens 109-114 25323586-10 2015 Patients with high PXN/high Bcl-2 or high pPXN-S272/high Bcl-2 tumors are commonly to have an unfavorable response to 5-FU-based chemotherapy, compared with patients who have high PXN, high pPXN-S272 or high Bcl-2 tumors alone. Fluorouracil 118-122 BCL2 apoptosis regulator Homo sapiens 28-33 25323586-10 2015 Patients with high PXN/high Bcl-2 or high pPXN-S272/high Bcl-2 tumors are commonly to have an unfavorable response to 5-FU-based chemotherapy, compared with patients who have high PXN, high pPXN-S272 or high Bcl-2 tumors alone. Fluorouracil 118-122 BCL2 apoptosis regulator Homo sapiens 57-62 25539708-6 2015 Moreover, we found that pretreatment with NAC markedly inhibited the expression levels of c-FLIP, Mcl-1, and Bcl-2 downregulated by the combinatory treatment, suggesting that the regulating effect of EGCG on these above apoptosis-relevant molecules was partially mediated by generation of ROS. ros 289-292 BCL2 apoptosis regulator Homo sapiens 109-114 25323586-10 2015 Patients with high PXN/high Bcl-2 or high pPXN-S272/high Bcl-2 tumors are commonly to have an unfavorable response to 5-FU-based chemotherapy, compared with patients who have high PXN, high pPXN-S272 or high Bcl-2 tumors alone. Fluorouracil 118-122 BCL2 apoptosis regulator Homo sapiens 57-62 25323586-11 2015 Therefore, we suggest that Src, PAK1 or Bcl-2 inhibitor may potentially overcome the resistance of 5-FU-based chemotherapy and consequently to improve outcomes in patients with PXN/Bcl-2 and pPXN-S272/Bcl-2-positive tumors. Fluorouracil 99-103 BCL2 apoptosis regulator Homo sapiens 40-45 25539708-7 2015 Taken together, the present study demonstrates that EGCG sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis by downregulation of c-FLIP, Mcl-1, and Bcl-2. epigallocatechin gallate 52-56 BCL2 apoptosis regulator Homo sapiens 174-179 24376112-8 2015 However, the acrolein-induced cardiomyocyte contractile and intracellular Ca(2+) anomalies, as well as apoptosis (as evidenced by Bcl-2, Bax, FasL, Caspase-3 and -8), were negated by the reactive oxygen species (ROS) scavenger glutathione or the TRPV1 antagonist capsazepine. Acrolein 13-21 BCL2 apoptosis regulator Homo sapiens 130-135 26136904-9 2015 Western blot analysis showed that with increasing afatinib concentrations, Bcl-2, phosphorylated (p)-ERK1/2, p-Akt, MMP-2 and MMP-9 expression levels were significantly decreased, whereas total (t)-ERK1/2 and t-Akt expression levels remained basically unchanged, and Bax expression levels were greatly increased. Afatinib 50-58 BCL2 apoptosis regulator Homo sapiens 75-80 25820747-6 2015 Western blotting indicated that flavonoids increased cytochrome c release, upregulated the ratio of Bax/Bcl-2, and activated the caspases-9 and -3. Flavonoids 32-42 BCL2 apoptosis regulator Homo sapiens 104-109 25832198-10 2015 delta-Tocopherol prevented MGO-induced apoptosis in HUVECs by increasing Bcl-2 expression and decreasing Bax expression. delta-tocopherol 0-16 BCL2 apoptosis regulator Homo sapiens 73-78 25832198-10 2015 delta-Tocopherol prevented MGO-induced apoptosis in HUVECs by increasing Bcl-2 expression and decreasing Bax expression. Pyruvaldehyde 27-30 BCL2 apoptosis regulator Homo sapiens 73-78 26191229-8 2015 Stable Bcl-2 overexpression led to reduced apoptosis rates as well as Cyt-C and Caspase-3 expressions in Jurkat cells after VP-16 application, which was similar in leucocytes of remission patients. Etoposide 124-129 BCL2 apoptosis regulator Homo sapiens 7-12 25739041-6 2015 In contrast, the anti-apoptotic protein Bcl2 inhibitor ABT199 enhanced cell killing after PDT+4HPR. venetoclax 55-61 BCL2 apoptosis regulator Homo sapiens 40-44 25964548-6 2015 Co-treatment with CAL-101 and celecoxib triggered the ER stress response and the down-regulation of BCL2 and BCL-XL. idelalisib 18-25 BCL2 apoptosis regulator Homo sapiens 100-104 25964548-6 2015 Co-treatment with CAL-101 and celecoxib triggered the ER stress response and the down-regulation of BCL2 and BCL-XL. Celecoxib 30-39 BCL2 apoptosis regulator Homo sapiens 100-104 26191156-6 2015 Western blotting of Akt, Bcl-2, Bax, and caspase 3 showed that the levels of the antiapoptotic proteins, Akt and Bcl-2, in the cells pretreated with ghrelin alone were higher than those in the cells pretreated with D-Lys3-GHRP-6 or antagomiR-21. Ghrelin 149-156 BCL2 apoptosis regulator Homo sapiens 25-30 26191156-6 2015 Western blotting of Akt, Bcl-2, Bax, and caspase 3 showed that the levels of the antiapoptotic proteins, Akt and Bcl-2, in the cells pretreated with ghrelin alone were higher than those in the cells pretreated with D-Lys3-GHRP-6 or antagomiR-21. Ghrelin 149-156 BCL2 apoptosis regulator Homo sapiens 113-118 26191156-8 2015 CONCLUSION: Ghrelin inhibits GES-1 cell apoptosis through GHS-R-dependent signaling in which miR-21 activates the PI3K/Akt pathway, which upregulates Bcl-2 and downregulates Bax and caspase 3 expression. Ghrelin 12-19 BCL2 apoptosis regulator Homo sapiens 150-155 25826779-7 2015 Annexin V/PI staining suggested that cecropinXJ induced both early and late phases of apoptosis through activation of mitochondrial-mediated caspase pathway, upregulation of Bax expression and downregulation of Bcl-2 expression. cecropinxj 37-47 BCL2 apoptosis regulator Homo sapiens 211-216 25251374-7 2015 Intriguingly, the inhibition of UCP2 by oroxylin A was able to block Bcl-2 translocation to the mitochondria, keeping MPTP at open-state. 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one 40-50 BCL2 apoptosis regulator Homo sapiens 69-74 25829494-5 2015 Both roscovitine and heat shock treatment caused increased accumulation of NOXA a pro-apoptotic BH3-only member of the BCL2 family. Roscovitine 5-16 BCL2 apoptosis regulator Homo sapiens 119-123 25766763-11 2015 The down-regulation of AMPK activity via pharmacological inhibition and genetic silencing resulted in reduced IMQ-induced apoptosis but did not influence autophagy, and this rescue effect was associated with the retention of translation factor activity and anti-apoptotic Bcl-2 family member Mcl-1 protein expression levels. Imiquimod 110-113 BCL2 apoptosis regulator Homo sapiens 272-277 25752481-8 2015 Furthermore, melatonin decreased H3 acetylation on bcl-2 promoter, leading to a reduction of bcl-2 expression, whereas constitutively active CaMKIIalpha(T286D) or HDAC4-specific siRNA abrogated the effect of melatonin. Melatonin 13-22 BCL2 apoptosis regulator Homo sapiens 51-56 25752481-8 2015 Furthermore, melatonin decreased H3 acetylation on bcl-2 promoter, leading to a reduction of bcl-2 expression, whereas constitutively active CaMKIIalpha(T286D) or HDAC4-specific siRNA abrogated the effect of melatonin. Melatonin 13-22 BCL2 apoptosis regulator Homo sapiens 93-98 26214636-4 2015 METHODS: The immunohistochemical (IHC) expression of CD10, BCL6, MUM1 and BCL2 on paraffin-embedded formalin-fixed tumor samples from 103 centroblastic DLBCLs was analyzed. Paraffin 82-90 BCL2 apoptosis regulator Homo sapiens 74-78 25740993-0 2015 BH3 Profiling Reveals Selectivity by Herpesviruses for Specific Bcl-2 Proteins To Mediate Survival of Latently Infected Cells. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 64-69 25740993-2 2015 BH3 profiling, which assesses the contribution of Bcl-2 proteins towards cellular survival, was able to globally determine the level of dependence on individual cellular and viral Bcl-2 proteins within latently infected cells. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 50-55 25740993-2 2015 BH3 profiling, which assesses the contribution of Bcl-2 proteins towards cellular survival, was able to globally determine the level of dependence on individual cellular and viral Bcl-2 proteins within latently infected cells. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 180-185 25740993-3 2015 Moreover, BH3 profiling predicted the sensitivity of infected cells to small-molecule inhibitors of Bcl-2 proteins. BH 3 10-13 BCL2 apoptosis regulator Homo sapiens 100-105 25933104-4 2015 Furthermore, the following study showed that ARG treatment led to a loss in the mitochondrial out membrane potential, up-regulation of Bax, down-regulation of Bcl-2, a release of cytochrome c, caspase-9 and caspase-3 activation and a cleavage of poly (ADP-ribose) polymerase in both Hep G2 and SMMC7721 cells, suggesting ARG-induced apoptosis was associated with the mitochondria mediated pathway. arctigenin 45-48 BCL2 apoptosis regulator Homo sapiens 159-164 25811406-7 2015 More importantly, we identified that Lambda-WH0402 treatment reduced the interaction between Bcl-2 and Beclin-1, and increased the expression of autophagic activation marker LC3B-II in HCCLM6 cells. wh0402 44-50 BCL2 apoptosis regulator Homo sapiens 93-98 25812605-9 2015 Cells treated with TMP exhibited significantly attenuated GSK-3beta, NF-kappaB (p65) and c-myc expression, followed by downregulation of bcl-2, cox-2 and survivin and an upregulation of p27. tetramethylpyrazine 19-22 BCL2 apoptosis regulator Homo sapiens 137-142 25607114-5 2015 However, co-treatment with anti-VEGF significantly restored etoposide-induced cell apoptosis and cell cycle arrest, as indicated by the elimination of B-cell lymphoma 2 (Bcl-2), procaspase 3, cyclin B1 and Cdc2. Etoposide 60-69 BCL2 apoptosis regulator Homo sapiens 151-168 25607114-5 2015 However, co-treatment with anti-VEGF significantly restored etoposide-induced cell apoptosis and cell cycle arrest, as indicated by the elimination of B-cell lymphoma 2 (Bcl-2), procaspase 3, cyclin B1 and Cdc2. Etoposide 60-69 BCL2 apoptosis regulator Homo sapiens 170-175 26229223-0 2015 BAX/BCL-2 mRNA and protein expression in human breast MCF-7 cells exposed to drug vehicles-methanol and dimethyl sulfoxide (DMSO) for 24 hrs. Methanol 91-99 BCL2 apoptosis regulator Homo sapiens 4-9 26229223-0 2015 BAX/BCL-2 mRNA and protein expression in human breast MCF-7 cells exposed to drug vehicles-methanol and dimethyl sulfoxide (DMSO) for 24 hrs. Dimethyl Sulfoxide 104-122 BCL2 apoptosis regulator Homo sapiens 4-9 26229223-0 2015 BAX/BCL-2 mRNA and protein expression in human breast MCF-7 cells exposed to drug vehicles-methanol and dimethyl sulfoxide (DMSO) for 24 hrs. Dimethyl Sulfoxide 124-128 BCL2 apoptosis regulator Homo sapiens 4-9 25748801-6 2015 Furthermore PFOS reduced cell viability and induced apoptosis in human placental syncytiotrophoblasts as revealed by increases of pro-apoptosis proteins such as Bax and cleaved-caspase3, and decreases of pro-caspase3 and anti-apoptosis protein Bcl-2. perfluorooctane sulfonic acid 12-16 BCL2 apoptosis regulator Homo sapiens 244-249 25589462-11 2015 Western blot analysis revealed that doxorubicin-induced Bcl-2 protein expression was inhibited by I3C. Doxorubicin 36-47 BCL2 apoptosis regulator Homo sapiens 56-61 25542229-6 2015 Real-time RT-PCR showed that ibuprofen altered the expression of several genes including Akt, P53, PCNA, Bax, and Bcl2 in the AGS cells. Ibuprofen 29-38 BCL2 apoptosis regulator Homo sapiens 114-118 25833690-0 2015 Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes. gemcitabine 0-11 BCL2 apoptosis regulator Homo sapiens 154-158 25542230-0 2015 The small-molecule compound BM-1197 inhibits the antiapoptotic regulators Bcl-2/Bcl-xL and triggers apoptotic cell death in human colorectal cancer cells. BM-1197 28-35 BCL2 apoptosis regulator Homo sapiens 74-79 25995634-9 2015 Furthermore, the combination of BTZ-GA/MNPs activated phosphorylated Akt levels, Caspase-3, and Bax expression, and down-regulated the PI3K and Bcl-2 levels significantly. Bortezomib 32-35 BCL2 apoptosis regulator Homo sapiens 144-149 25637161-9 2015 Also, overexpression of antiapoptotic BCL-2 leads to a significant reduction of BEZ235/CQ-induced apoptosis, emphasizing that an intact mitochondrial pathway of apoptosis is required for BEZ235/CQ-induced cell death. dactolisib 80-86 BCL2 apoptosis regulator Homo sapiens 38-43 25637161-9 2015 Also, overexpression of antiapoptotic BCL-2 leads to a significant reduction of BEZ235/CQ-induced apoptosis, emphasizing that an intact mitochondrial pathway of apoptosis is required for BEZ235/CQ-induced cell death. Chloroquine 87-89 BCL2 apoptosis regulator Homo sapiens 38-43 25637161-9 2015 Also, overexpression of antiapoptotic BCL-2 leads to a significant reduction of BEZ235/CQ-induced apoptosis, emphasizing that an intact mitochondrial pathway of apoptosis is required for BEZ235/CQ-induced cell death. dactolisib 187-193 BCL2 apoptosis regulator Homo sapiens 38-43 25637161-9 2015 Also, overexpression of antiapoptotic BCL-2 leads to a significant reduction of BEZ235/CQ-induced apoptosis, emphasizing that an intact mitochondrial pathway of apoptosis is required for BEZ235/CQ-induced cell death. Chloroquine 194-196 BCL2 apoptosis regulator Homo sapiens 38-43 25661734-1 2015 We recently found that Rottlerin not only inhibits proliferation but also causes Bcl-2- and Beclin 1-independent autophagic death in apoptosis-resistant breast adenocarcinoma MCF-7 cells. rottlerin 23-32 BCL2 apoptosis regulator Homo sapiens 81-86 25720435-4 2015 In addition, shikonin evidently induced apoptosis due to decreasing Bcl-2 expression, increasing Bax expression, activating caspase and inactivating NF-kappaB, while pretreatment with a pan-caspase inhibitor Z-Asp-CH2-DCB abrogated shikonin-induced apoptosis. shikonin 13-21 BCL2 apoptosis regulator Homo sapiens 68-73 25875797-6 2015 In addition, triptolide decreased levels of HSP70, its transcription factor HSF1, as well as the antiapoptotic proteins Bcl-xL, Bcl-2, and Mcl-1, which are known to be up-regulated in pancreatic cancer. triptolide 13-23 BCL2 apoptosis regulator Homo sapiens 128-133 25637161-8 2015 Importantly, our molecular studies reveal that BEZ235/CQ-induced apoptosis is mediated by cooperative downregulation of the antiapoptotic BCL-2 family protein MCL-1, since stabilization of MCL-1 by expression of a non-degradable MCL-1 phospho-defective mutant significantly decreases BEZ235/CQ-induced apoptosis. dactolisib 47-53 BCL2 apoptosis regulator Homo sapiens 138-143 25637161-8 2015 Importantly, our molecular studies reveal that BEZ235/CQ-induced apoptosis is mediated by cooperative downregulation of the antiapoptotic BCL-2 family protein MCL-1, since stabilization of MCL-1 by expression of a non-degradable MCL-1 phospho-defective mutant significantly decreases BEZ235/CQ-induced apoptosis. Chloroquine 54-56 BCL2 apoptosis regulator Homo sapiens 138-143 28352705-9 2015 With increasing puerarin concentration, expression of cleaved-caspase-3 in JEG-3 cells increased, whereas that of Bcl-2 decreased. puerarin 16-24 BCL2 apoptosis regulator Homo sapiens 114-119 25915649-0 2015 Dihydromyricetin Enhances the Chemo-Sensitivity of Nedaplatin via Regulation of the p53/Bcl-2 Pathway in Hepatocellular Carcinoma Cells. dihydromyricetin 0-16 BCL2 apoptosis regulator Homo sapiens 88-93 25915649-9 2015 Furthermore, we demonstrated that the combination of DHM and NDP activated the p53/Bcl-2 signaling pathway, which resulted in mitochondrial dysfunction and induced cell death and growth inhibition in HCC cells. dihydromyricetin 53-56 BCL2 apoptosis regulator Homo sapiens 83-88 25915649-9 2015 Furthermore, we demonstrated that the combination of DHM and NDP activated the p53/Bcl-2 signaling pathway, which resulted in mitochondrial dysfunction and induced cell death and growth inhibition in HCC cells. nedaplatin 61-64 BCL2 apoptosis regulator Homo sapiens 83-88 25833690-3 2015 Herein, we sought to investigate the impact of gemcitabine on the expression levels of the BCL2 family members BCL2, BAX, and BCL2L12 and the apoptosis-related microRNAs miR-182, miR-96, miR-145, and miR-16 in the human bladder and kidney cancer cell lines T24 and Caki-1, respectively. gemcitabine 47-58 BCL2 apoptosis regulator Homo sapiens 91-95 25833690-3 2015 Herein, we sought to investigate the impact of gemcitabine on the expression levels of the BCL2 family members BCL2, BAX, and BCL2L12 and the apoptosis-related microRNAs miR-182, miR-96, miR-145, and miR-16 in the human bladder and kidney cancer cell lines T24 and Caki-1, respectively. gemcitabine 47-58 BCL2 apoptosis regulator Homo sapiens 111-115 25909282-7 2015 NAC/AAP prevents apoptotic cell death via decreasing the activation of BAX, increasing the expression of BCL2, and reducing cytochrome c release from mitochondria that might lead to the activation of caspase cascade. Acetylcysteine 0-3 BCL2 apoptosis regulator Homo sapiens 105-109 25909282-7 2015 NAC/AAP prevents apoptotic cell death via decreasing the activation of BAX, increasing the expression of BCL2, and reducing cytochrome c release from mitochondria that might lead to the activation of caspase cascade. ascorbate-2-phosphate 4-7 BCL2 apoptosis regulator Homo sapiens 105-109 25960653-0 2015 Reversal of multidrug resistance in MCF-7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-beta-cyclodextrin nanocarrier. Folic Acid 104-114 BCL2 apoptosis regulator Homo sapiens 85-89 25910231-3 2015 In the current manuscript, we investigated the mechanism of curcumin-induced apoptosis in upper aerodigestive tract cancer cell lines and showed that curcumin-induced apoptosis is mediated by the modulation of multiple pathways such as induction of p73, and inhibition of p-AKT and Bcl-2. Curcumin 150-158 BCL2 apoptosis regulator Homo sapiens 282-287 25910231-6 2015 Curcumin treatment also strongly inhibited p-AKT and Bcl-2 and overexpression of constitutively active AKT or Bcl-2 significantly inhibited curcumin-induced apoptosis. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 53-58 25910231-6 2015 Curcumin treatment also strongly inhibited p-AKT and Bcl-2 and overexpression of constitutively active AKT or Bcl-2 significantly inhibited curcumin-induced apoptosis. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 110-115 25910231-6 2015 Curcumin treatment also strongly inhibited p-AKT and Bcl-2 and overexpression of constitutively active AKT or Bcl-2 significantly inhibited curcumin-induced apoptosis. Curcumin 140-148 BCL2 apoptosis regulator Homo sapiens 110-115 25910231-3 2015 In the current manuscript, we investigated the mechanism of curcumin-induced apoptosis in upper aerodigestive tract cancer cell lines and showed that curcumin-induced apoptosis is mediated by the modulation of multiple pathways such as induction of p73, and inhibition of p-AKT and Bcl-2. Curcumin 60-68 BCL2 apoptosis regulator Homo sapiens 282-287 25910231-7 2015 Taken together, our findings suggest that curcumin-induced apoptosis is mediated via activating tumor suppressor p73 and inhibiting p-AKT and Bcl-2. Curcumin 42-50 BCL2 apoptosis regulator Homo sapiens 142-147 25960653-0 2015 Reversal of multidrug resistance in MCF-7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-beta-cyclodextrin nanocarrier. polyethylenimine hydroxypropyl-beta-cyclodextrin 126-174 BCL2 apoptosis regulator Homo sapiens 85-89 25960653-2 2015 In this study, we developed a simple multifunctional nanocarrier based on polyethylenimine (PEI) to codeliver doxorubicin (DOX) and BCL2 small interfering RNA (siRNA) for overcoming multidrug resistance (MDR) and enhancing apoptosis in MCF-7/Adr cancer cells by combining chemotherapy and RNA interference (RNAi) therapy. Polyethyleneimine 92-95 BCL2 apoptosis regulator Homo sapiens 132-136 25960653-4 2015 The drug-loaded nanocomplexes (FA-HP-beta-CD-PEI/DOX/siRNA) showed uniform size distribution, high cellular uptake, and significant gene suppression of BCL2, displaying the potential of overcoming MDR for enhancing the effect of anticancer drugs. fa-hp-beta-cd-pei 31-48 BCL2 apoptosis regulator Homo sapiens 152-156 25960653-4 2015 The drug-loaded nanocomplexes (FA-HP-beta-CD-PEI/DOX/siRNA) showed uniform size distribution, high cellular uptake, and significant gene suppression of BCL2, displaying the potential of overcoming MDR for enhancing the effect of anticancer drugs. Doxorubicin 49-52 BCL2 apoptosis regulator Homo sapiens 152-156 25960653-5 2015 Furthermore, the nanocomplexes achieved significant cell apoptosis through a mechanism of downregulating the antiapoptotic protein BCL2, resulted in improving therapeutic efficacy of the coadministered DOX by tumor targeting and RNA interference. Doxorubicin 202-205 BCL2 apoptosis regulator Homo sapiens 131-135 25914461-8 2015 Alternol activated caspase 3, upregulated p53 and p21 expression, and downregulated Bcl-2 expression in a dose-dependent manner. Alternol 0-8 BCL2 apoptosis regulator Homo sapiens 84-89 25797245-2 2015 Herein, we investigate the ability of ABT-199, the Bcl-2-selective BH3 mimetic, to kill MCL cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 38-41 BCL2 apoptosis regulator Homo sapiens 51-56 25797245-0 2015 Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 106-109 BCL2 apoptosis regulator Homo sapiens 75-80 25908963-12 2015 Increased caspase 6-, caspase 7- and caspase 8 activities, upregulation of p53 protein expression and a decrease in phosphorylation status of Bcl-2 at serine 70 in tumorigenic and non-tumorigenic lines were demonstrated. Serine 151-157 BCL2 apoptosis regulator Homo sapiens 142-147 25826088-0 2015 Paxillin promotes colorectal tumor invasion and poor patient outcomes via ERK-mediated stabilization of Bcl-2 protein by phosphorylation at Serine 87. Serine 140-146 BCL2 apoptosis regulator Homo sapiens 104-109 25826088-1 2015 Stabilization of Bcl-2 protein by paxillin (PXN)-mediated ERK activation was recently reported to cause an unfavorable response to 5-Fluorouracil-based chemotherapy. Fluorouracil 131-145 BCL2 apoptosis regulator Homo sapiens 17-22 25826088-2 2015 Here, we present evidence from cell and animal models to demonstrate that stabilization of Bcl-2 protein by phosphorylation at Serine 87 (pBcl-2-S87) via PXN-mediated ERK activation is responsible for cancer cell invasiveness and occurs via upregulation of MMP2 expression. Serine 127-133 BCL2 apoptosis regulator Homo sapiens 91-96 25797245-2 2015 Herein, we investigate the ability of ABT-199, the Bcl-2-selective BH3 mimetic, to kill MCL cells. BH 3 67-70 BCL2 apoptosis regulator Homo sapiens 51-56 26131123-10 2015 Treatment of MGC-803 cells with honokiol significantly increased the pro-apoptotic Bax level and decreased the anti-apoptotic Bcl-2 level. honokiol 32-40 BCL2 apoptosis regulator Homo sapiens 126-131 25641804-1 2015 One-pot solution mineralization can encapsulate epirubicin (EPI) and pooled siRNAs (Pgp and Bcl-2 siRNAs) in calcium phosphate (CaP). calcium phosphate 109-126 BCL2 apoptosis regulator Homo sapiens 92-97 25945059-8 2015 Arsenic trioxide treatment also reduced Gli1 downstream target gene expression, such as Bcl2 and CCND1. Arsenic Trioxide 0-16 BCL2 apoptosis regulator Homo sapiens 88-92 25945055-8 2015 Furthermore, the treatment with artesunate promoted the expression of proapoptotic factor Bax and suppressed the expression of antiapoptotic factor Bcl-2. Artesunate 32-42 BCL2 apoptosis regulator Homo sapiens 148-153 25732194-4 2015 Concomitant treatment of JT/Neo cells with 2-MeO-E2 and the G1/S blocking agent aphidicolin resulted in G1/S arrest and abrogation of all apoptotic events, including Cdk1 activation, phosphorylation of Bcl-2, Mcl-1 and Bim, and ROS accumulation. 2-Methoxyestradiol 43-51 BCL2 apoptosis regulator Homo sapiens 202-207 25732194-4 2015 Concomitant treatment of JT/Neo cells with 2-MeO-E2 and the G1/S blocking agent aphidicolin resulted in G1/S arrest and abrogation of all apoptotic events, including Cdk1 activation, phosphorylation of Bcl-2, Mcl-1 and Bim, and ROS accumulation. Aphidicolin 80-91 BCL2 apoptosis regulator Homo sapiens 202-207 25732194-5 2015 The 2-MeO-E2-induced phosphorylation of Bcl-2 family proteins and mitochondrial apoptotic events were suppressed by a Cdk1 inhibitor, but not by an Aurora A kinase (AURKA), Aurora B kinase (AURKB), JNK, or p38 MAPK inhibitor. 2-Methoxyestradiol 4-12 BCL2 apoptosis regulator Homo sapiens 40-45 25732194-8 2015 These results demonstrate that the apoptogenic effect of 2-MeO-E2 (0.5-1.0 muM) was attributable to mitotic spindle defect-mediated prometaphase arrest, Cdk1 activation, phosphorylation of Bcl-2, Mcl-1, and Bim, and activation of Bak and mitochondria-dependent caspase cascade. 2-Methoxyestradiol 57-65 BCL2 apoptosis regulator Homo sapiens 189-194 25801171-6 2015 A mutant mimicking constitutive MFN1 phosphorylation was less efficient in oligomerizing and mitochondria tethering but bound more avidly to the proapoptotic BCL-2 family member BAK, facilitating its activation and cell death. bakuchiol 178-181 BCL2 apoptosis regulator Homo sapiens 158-163 25732194-2 2015 Exposure of Jurkat T cell clone (JT/Neo) to 2-MeO-E2 (0.5-1.0 muM) caused G2/M arrest, Bak activation, Deltapsim loss, caspase-9 and -3 activation, PARP cleavage, intracellular ROS accumulation, and apoptotic DNA fragmentation, whereas none of these events except for G2/M arrest were induced in Jurkat T cells overexpressing Bcl-2 (JT/Bcl-2). 2-Methoxyestradiol 44-52 BCL2 apoptosis regulator Homo sapiens 326-331 25732194-2 2015 Exposure of Jurkat T cell clone (JT/Neo) to 2-MeO-E2 (0.5-1.0 muM) caused G2/M arrest, Bak activation, Deltapsim loss, caspase-9 and -3 activation, PARP cleavage, intracellular ROS accumulation, and apoptotic DNA fragmentation, whereas none of these events except for G2/M arrest were induced in Jurkat T cells overexpressing Bcl-2 (JT/Bcl-2). 2-Methoxyestradiol 44-52 BCL2 apoptosis regulator Homo sapiens 336-341 25885284-3 2015 The small-molecule pan-Bcl-2 inhibitor (-)-gossypol (AT-101) is known to induce apoptotic cell death, but can also induce autophagy through release of the pro-autophagic BH3 only protein Beclin-1 from Bcl-2. Gossypol 39-51 BCL2 apoptosis regulator Homo sapiens 23-28 25872771-2 2015 Bcl-2, via its N-terminal Bcl-2 homology (BH) 4 domain, inhibits both inositol 1,4,5-trisphosphate receptors (IP3Rs) and ryanodine receptors (RyRs), while Bcl-XL, likely independently of its BH4 domain, sensitizes IP3Rs. sapropterin 191-194 BCL2 apoptosis regulator Homo sapiens 0-5 25762636-7 2015 HOXA9 also mediated resistance to temozolomide treatment in vitro and in vivo via upregulation of BCL2. Temozolomide 34-46 BCL2 apoptosis regulator Homo sapiens 98-102 25762636-8 2015 Importantly, the pharmacological inhibition of BCL2 with the BH3 mimetic ABT-737 reverted temozolomide resistance in HOXA9-positive cells. BH 3 61-64 BCL2 apoptosis regulator Homo sapiens 47-51 25762636-8 2015 Importantly, the pharmacological inhibition of BCL2 with the BH3 mimetic ABT-737 reverted temozolomide resistance in HOXA9-positive cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 73-76 BCL2 apoptosis regulator Homo sapiens 47-51 25762636-8 2015 Importantly, the pharmacological inhibition of BCL2 with the BH3 mimetic ABT-737 reverted temozolomide resistance in HOXA9-positive cells. Temozolomide 90-102 BCL2 apoptosis regulator Homo sapiens 47-51 25744407-8 2015 Overexpression of Bcl-2 significantly suppressed the sensitization of U937 cells to an enhanced apoptotic response to AZT following co-treatment with the NF-kB inhibitor. Zidovudine 118-121 BCL2 apoptosis regulator Homo sapiens 18-23 25855960-7 2015 PCAF was also found to sensitize HCC cells to 5-fluorouracil (5-FU) treatment by regulating GLI1/Bcl-2/BAX axis-dependent apoptosis. Fluorouracil 46-60 BCL2 apoptosis regulator Homo sapiens 97-102 25855960-7 2015 PCAF was also found to sensitize HCC cells to 5-fluorouracil (5-FU) treatment by regulating GLI1/Bcl-2/BAX axis-dependent apoptosis. Fluorouracil 62-66 BCL2 apoptosis regulator Homo sapiens 97-102 25855960-10 2015 Together, these results show that PCAF can induce cell apoptosis by modulating a GLI1/Bcl-2/BAX axis that in turn suppresses HCC progression, and suggest that 5-FU may exert a stronger anti-tumor effect in patients with PCAF expression in HCC tumors. Fluorouracil 159-163 BCL2 apoptosis regulator Homo sapiens 86-91 25885284-3 2015 The small-molecule pan-Bcl-2 inhibitor (-)-gossypol (AT-101) is known to induce apoptotic cell death, but can also induce autophagy through release of the pro-autophagic BH3 only protein Beclin-1 from Bcl-2. Gossypol 39-51 BCL2 apoptosis regulator Homo sapiens 201-206 25885284-3 2015 The small-molecule pan-Bcl-2 inhibitor (-)-gossypol (AT-101) is known to induce apoptotic cell death, but can also induce autophagy through release of the pro-autophagic BH3 only protein Beclin-1 from Bcl-2. gossypol acetic acid 53-59 BCL2 apoptosis regulator Homo sapiens 23-28 25885284-3 2015 The small-molecule pan-Bcl-2 inhibitor (-)-gossypol (AT-101) is known to induce apoptotic cell death, but can also induce autophagy through release of the pro-autophagic BH3 only protein Beclin-1 from Bcl-2. gossypol acetic acid 53-59 BCL2 apoptosis regulator Homo sapiens 201-206 25721973-1 2015 Crispene E, a new clerodane-type diterpene, inhibited STAT3 dimerization in a cell-free fluorescent polarisation assay and was found to have significant toxicity against STAT3-dependent MDA-MB 231 breast cancer cell line and selectively inhibited the expression of STAT3 and STAT3 target genes cyclin D1, Fascin and bcl-2. crispene E 0-10 BCL2 apoptosis regulator Homo sapiens 316-321 25885284-9 2015 Cisplatin- and gemcitabine-resistant bladder cancer cells exhibit enhanced basal and drug-induced autophagosome formation and lysosomal activity which is accompanied by an attenuated apoptotic cell death after treatment with both (-)-gossypol and ABT-737, a Bcl-2 inhibitor which spares Mcl-1, in comparison to parental cells. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 258-263 25885284-9 2015 Cisplatin- and gemcitabine-resistant bladder cancer cells exhibit enhanced basal and drug-induced autophagosome formation and lysosomal activity which is accompanied by an attenuated apoptotic cell death after treatment with both (-)-gossypol and ABT-737, a Bcl-2 inhibitor which spares Mcl-1, in comparison to parental cells. gemcitabine 15-26 BCL2 apoptosis regulator Homo sapiens 258-263 25885284-9 2015 Cisplatin- and gemcitabine-resistant bladder cancer cells exhibit enhanced basal and drug-induced autophagosome formation and lysosomal activity which is accompanied by an attenuated apoptotic cell death after treatment with both (-)-gossypol and ABT-737, a Bcl-2 inhibitor which spares Mcl-1, in comparison to parental cells. Gossypol 230-242 BCL2 apoptosis regulator Homo sapiens 258-263 25596561-2 2015 However, high levels of Bcl-2 family proteins in CML could resist paclitaxel-induced apoptosis. Paclitaxel 66-76 BCL2 apoptosis regulator Homo sapiens 24-29 25837691-8 2015 Western blot analysis of carboplatin resistant (treated) MDA-MB-231 (highly invasive, basal-like) and T47D (low-invasive, luminal) BCCs showed an increase in Bcl-2, Oct-4 and Sox-2, suggesting protection from apoptosis and increase in stem-like markers. Carboplatin 25-36 BCL2 apoptosis regulator Homo sapiens 158-163 25660381-11 2015 The protein expression of caspase3 in 30mul/ml and 40mul/ml SFI groups significantly decreased whereas Bcl2 protein expressions in 20mul/ml, 30mul/ml and 40mul/ml SFI groups were higher than H2O2 group, with Bax protein expression much lower than H2O2 group (p<0.05 and p<0.01). Hydrogen Peroxide 191-195 BCL2 apoptosis regulator Homo sapiens 103-107 25660381-11 2015 The protein expression of caspase3 in 30mul/ml and 40mul/ml SFI groups significantly decreased whereas Bcl2 protein expressions in 20mul/ml, 30mul/ml and 40mul/ml SFI groups were higher than H2O2 group, with Bax protein expression much lower than H2O2 group (p<0.05 and p<0.01). Hydrogen Peroxide 247-251 BCL2 apoptosis regulator Homo sapiens 103-107 25633409-6 2015 In addition, the ratio of Bax/Bcl-2 was increased in siRNA/ALR groups treated with H2O2. Hydrogen Peroxide 83-87 BCL2 apoptosis regulator Homo sapiens 30-35 25960218-9 2015 With respect to the cytotoxic effect of I-7ab, it induced apoptosis via increasing the Bax/Bcl-2 ratio and suppressing the translocation of NF-kappaB. i-7ab 40-45 BCL2 apoptosis regulator Homo sapiens 91-96 25588160-6 2015 Also, the expressions of apoptosis markers, such as cleaved caspase-3, Bcl-2/Bax, were altered by the gefitinib and SF1126 combination. Gefitinib 102-111 BCL2 apoptosis regulator Homo sapiens 71-76 25960232-0 2015 Inhibition of PI3K signaling triggered apoptotic potential of curcumin which is hindered by Bcl-2 through activation of autophagy in MCF-7 cells. Curcumin 62-70 BCL2 apoptosis regulator Homo sapiens 92-97 25960232-2 2015 Curcumin triggers intrinsic apoptotic cell death by activating mitochondrial permeabilization due to the altered expression of pro- and anti-apoptotic Bcl-2 family members. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 151-156 25681439-3 2015 We previously demonstrated that the Bcl-2 homology 4 (BH4) domain of Bcl-2 protects against Ca(2+)-dependent apoptosis by binding and inhibiting IP3Rs, although the BH4 domain of Bcl-XL was protective independently of binding IP3Rs. Sapropterin 54-57 BCL2 apoptosis regulator Homo sapiens 36-41 25681439-3 2015 We previously demonstrated that the Bcl-2 homology 4 (BH4) domain of Bcl-2 protects against Ca(2+)-dependent apoptosis by binding and inhibiting IP3Rs, although the BH4 domain of Bcl-XL was protective independently of binding IP3Rs. Sapropterin 54-57 BCL2 apoptosis regulator Homo sapiens 69-74 25681439-3 2015 We previously demonstrated that the Bcl-2 homology 4 (BH4) domain of Bcl-2 protects against Ca(2+)-dependent apoptosis by binding and inhibiting IP3Rs, although the BH4 domain of Bcl-XL was protective independently of binding IP3Rs. Sapropterin 165-168 BCL2 apoptosis regulator Homo sapiens 69-74 25681439-4 2015 Here, we report that in contrast to the BH4 domain of Bcl-2, the BH4 domain of Bcl-XL binds and inhibits VDAC1. Sapropterin 40-43 BCL2 apoptosis regulator Homo sapiens 54-59 26173295-0 2015 Upregulation of Bcl-2 enhances secretion of growth factors by adipose-derived stem cells deprived of oxygen and glucose. Oxygen 103-109 BCL2 apoptosis regulator Homo sapiens 16-21 26173295-0 2015 Upregulation of Bcl-2 enhances secretion of growth factors by adipose-derived stem cells deprived of oxygen and glucose. Glucose 114-121 BCL2 apoptosis regulator Homo sapiens 16-21 25960232-4 2015 We found that Bcl-2 overexpression is a limiting factor for curcumin-induced apoptosis in highly metastatic MCF-7 breast cancer cells. Curcumin 60-68 BCL2 apoptosis regulator Homo sapiens 14-19 25960232-5 2015 Forced overexpression of Bcl-2 also blocked curcumin-induced autophagy in MCF-7 cells, through its inhibitory interactions with Beclin-1. Curcumin 44-52 BCL2 apoptosis regulator Homo sapiens 25-30 25649768-4 2015 BH3 profiling indicated that the ALL cultures were Bcl-2 dependent. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 51-56 25960232-6 2015 Pre-treatment of PI3K inhibitor LY294002 enhanced curcumin-induced cell death, apoptosis, and autophagy via modulating the expression of Bcl-2 family members and autophagosome formation in MCF-7 breast cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 BCL2 apoptosis regulator Homo sapiens 137-142 25960232-6 2015 Pre-treatment of PI3K inhibitor LY294002 enhanced curcumin-induced cell death, apoptosis, and autophagy via modulating the expression of Bcl-2 family members and autophagosome formation in MCF-7 breast cancer cells. Curcumin 50-58 BCL2 apoptosis regulator Homo sapiens 137-142 25960232-7 2015 Atg7 silencing further increased apoptotic potential of curcumin in the presence or absence of LY294002 in wt and Bcl-2+ MCF-7 cells. Curcumin 56-64 BCL2 apoptosis regulator Homo sapiens 114-119 25960232-8 2015 The findings of this study support the hypothesis that blocking the PI3K/Akt pathway may further increased curcumin-induced apoptosis and overcome forced Bcl-2 expression level mediated autophagic responses against curcumin treatment in MCF-7 cells. Curcumin 215-223 BCL2 apoptosis regulator Homo sapiens 154-159 25611086-7 2015 Ginkgetin induced STAT3 dephosphorylation at Try705 and inhibited its localization to the nucleus, leading to the inhibition of expression of STAT3 target genes such as cell survival-related genes (cyclin D1 and survivin) and anti-apoptotic proteins (Bcl-2 and Bcl-xL). ginkgetin 0-9 BCL2 apoptosis regulator Homo sapiens 251-256 26173295-2 2015 This study modified ADSCs with the Bcl-2 gene in order to increase the secretion of growth factors during oxygen-glucose deprivation (OGD). oxygen-glucose 106-120 BCL2 apoptosis regulator Homo sapiens 35-40 26173295-9 2015 In addition, Bcl-2 overexpression enhanced the secretion of VEGF, bFGF, and HGF by 14.47%, 16.9%, and 91%, respectively, compared to ADSCs alone that were deprived of oxygen and glucose. Oxygen 167-173 BCL2 apoptosis regulator Homo sapiens 13-18 26173295-9 2015 In addition, Bcl-2 overexpression enhanced the secretion of VEGF, bFGF, and HGF by 14.47%, 16.9%, and 91%, respectively, compared to ADSCs alone that were deprived of oxygen and glucose. Glucose 178-185 BCL2 apoptosis regulator Homo sapiens 13-18 26173295-10 2015 These data suggest that Bcl-2 overexpression enhances secretion of angiogenic growth factors by ADSCs deprived of oxygen and glucose. Oxygen 114-120 BCL2 apoptosis regulator Homo sapiens 24-29 26173295-10 2015 These data suggest that Bcl-2 overexpression enhances secretion of angiogenic growth factors by ADSCs deprived of oxygen and glucose. Glucose 125-132 BCL2 apoptosis regulator Homo sapiens 24-29 25649765-2 2015 Intrinsic apoptosis, regulated by the BCL2 family, integrates diverse apoptotic signals to determine cell death commitment and then activates the nodal effector protein BAK to initiate the apoptotic cascade. bakuchiol 169-172 BCL2 apoptosis regulator Homo sapiens 38-42 25649768-6 2015 ABT-263 disrupted Bcl-2:Bim interaction in cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 18-23 25649768-8 2015 Freshly isolated pediatric ALL blasts also expressed high levels of Bcl-2 and exhibited high sensitivity to Bcl-2 inhibition by the BH3 mimetic compounds. BH 3 132-135 BCL2 apoptosis regulator Homo sapiens 108-113 25336154-6 2015 In human neuroblastoma SH-SY5Y cells, rBRI276-266 slightly decreased cell viability and increased up to two-fold the Bax/Bcl-2 ratio and the subsequent activity of caspases 3 and 9, indicating activation of apoptosis. rbri276-266 38-49 BCL2 apoptosis regulator Homo sapiens 121-126 25158671-12 2015 Elevated levels of reactive oxygen species decreased Bcl-2 expression and increased PTEN expression and phosphorylation, which lead to the subsequent inhibition of ILK-Akt signaling, elevation of Bax expression, and activation of caspase-3. Reactive Oxygen Species 19-42 BCL2 apoptosis regulator Homo sapiens 53-58 25158671-10 2015 Silencing Nox4 significantly normalized the levels of reactive oxygen species in glucose-treated cells; 20 mM glucose obviously upregulated Nox4, PTEN, phosphor-PTEN, and Bax levels, but significantly reduced integrin-linked kinase (ILK) activity, Bcl-2 (B cell lymphoma 2) expression, and protein kinase B (Akt) phosphorylation at serine 473. Glucose 81-88 BCL2 apoptosis regulator Homo sapiens 248-253 25158671-10 2015 Silencing Nox4 significantly normalized the levels of reactive oxygen species in glucose-treated cells; 20 mM glucose obviously upregulated Nox4, PTEN, phosphor-PTEN, and Bax levels, but significantly reduced integrin-linked kinase (ILK) activity, Bcl-2 (B cell lymphoma 2) expression, and protein kinase B (Akt) phosphorylation at serine 473. Glucose 81-88 BCL2 apoptosis regulator Homo sapiens 255-272 25349027-0 2015 15d-prostaglandin J2 protects cortical neurons against oxygen-glucose deprivation/reoxygenation injury: involvement of inhibiting autophagy through upregulation of Bcl-2. 15-deoxyprostaglandin J2 0-20 BCL2 apoptosis regulator Homo sapiens 164-169 25158671-10 2015 Silencing Nox4 significantly normalized the levels of reactive oxygen species in glucose-treated cells; 20 mM glucose obviously upregulated Nox4, PTEN, phosphor-PTEN, and Bax levels, but significantly reduced integrin-linked kinase (ILK) activity, Bcl-2 (B cell lymphoma 2) expression, and protein kinase B (Akt) phosphorylation at serine 473. Glucose 110-117 BCL2 apoptosis regulator Homo sapiens 248-253 25158671-10 2015 Silencing Nox4 significantly normalized the levels of reactive oxygen species in glucose-treated cells; 20 mM glucose obviously upregulated Nox4, PTEN, phosphor-PTEN, and Bax levels, but significantly reduced integrin-linked kinase (ILK) activity, Bcl-2 (B cell lymphoma 2) expression, and protein kinase B (Akt) phosphorylation at serine 473. Glucose 110-117 BCL2 apoptosis regulator Homo sapiens 255-272 25349027-3 2015 This study was designed to test the hypothesis that 15d-PGJ2 upregulated Bcl-2 which binds to Beclin 1, and thereby inhibits autophagy. 15-deoxyprostaglandin J2 52-60 BCL2 apoptosis regulator Homo sapiens 73-78 25349027-9 2015 15d-PGJ2 treatment upregulated Bcl-2 expression and decreased Beclin 1 expression, and inhibit the dissociation of Beclin1 from Bcl-2 significantly. 15-deoxyprostaglandin J2 0-8 BCL2 apoptosis regulator Homo sapiens 31-36 25826029-17 2015 Another class of drugs with potential impact for chemo-free treatment strategies in CLL is the BH3-mimetic inhibitor of the Bcl-2 family of pro-survival proteins, ABT-199. BH 3 95-98 BCL2 apoptosis regulator Homo sapiens 124-129 25349027-9 2015 15d-PGJ2 treatment upregulated Bcl-2 expression and decreased Beclin 1 expression, and inhibit the dissociation of Beclin1 from Bcl-2 significantly. 15-deoxyprostaglandin J2 0-8 BCL2 apoptosis regulator Homo sapiens 128-133 25349027-10 2015 Bcl-2 siRNA abrogated the effect of 15d-PGJ2 on Beclin 1, LC3-II and p62, and influence cell viability and LDH level, while scRNA did not. 15-deoxyprostaglandin J2 36-44 BCL2 apoptosis regulator Homo sapiens 0-5 25349027-12 2015 The inhibition of autophagy by 15d-PGJ2 is mediated through upregulation of Bcl-2. 15-deoxyprostaglandin J2 31-39 BCL2 apoptosis regulator Homo sapiens 76-81 25352420-8 2015 Furthermore, EAL inhibited H2O2-induced apoptosis by increases in the Bcl-2/Bax ratio, decreases in cytochrome c release, and attenuation of caspase-3, caspase-9 activities, and expressions. Hydrogen Peroxide 27-31 BCL2 apoptosis regulator Homo sapiens 70-75 25377066-4 2015 Results indicate that pretreatment with PB for 4 h significantly reduced the 6-OHDA-induced cell viability loss, apoptotic rate and decreased Bcl-2/Bax ratio. pinocembrin 40-42 BCL2 apoptosis regulator Homo sapiens 142-147 25377066-4 2015 Results indicate that pretreatment with PB for 4 h significantly reduced the 6-OHDA-induced cell viability loss, apoptotic rate and decreased Bcl-2/Bax ratio. Oxidopamine 77-83 BCL2 apoptosis regulator Homo sapiens 142-147 25344906-7 2015 Thymoquinone pretreatment and gemcitabine also induced down-regulation of anti-apoptotic Bcl-2, Bcl-xL, XIAP and up-regulation and activation of pro-apoptotic molecules including Caspase-3, Caspase-9, Bax and increased release of cytochrome c. thymoquinone 0-12 BCL2 apoptosis regulator Homo sapiens 89-94 25344906-7 2015 Thymoquinone pretreatment and gemcitabine also induced down-regulation of anti-apoptotic Bcl-2, Bcl-xL, XIAP and up-regulation and activation of pro-apoptotic molecules including Caspase-3, Caspase-9, Bax and increased release of cytochrome c. gemcitabine 30-41 BCL2 apoptosis regulator Homo sapiens 89-94 25539992-9 2015 Most importantly, chromatin immunoprecipitation assays revealed differential STAT3 binding to the anti-apoptotic BCL2 and pro-apoptotic WWOX gene promoters in MCF-7 and MCF-7/HER2 cells, leading to concomitant modifications of its mRNA/protein expression levels, thus providing a selective advantage to HER2 over-expressing MCF-7/HER2 cells after treatment with tamoxifen and tamoxifen plus leptin. Tamoxifen 362-371 BCL2 apoptosis regulator Homo sapiens 113-117 25539992-9 2015 Most importantly, chromatin immunoprecipitation assays revealed differential STAT3 binding to the anti-apoptotic BCL2 and pro-apoptotic WWOX gene promoters in MCF-7 and MCF-7/HER2 cells, leading to concomitant modifications of its mRNA/protein expression levels, thus providing a selective advantage to HER2 over-expressing MCF-7/HER2 cells after treatment with tamoxifen and tamoxifen plus leptin. Tamoxifen 376-385 BCL2 apoptosis regulator Homo sapiens 113-117 25826029-17 2015 Another class of drugs with potential impact for chemo-free treatment strategies in CLL is the BH3-mimetic inhibitor of the Bcl-2 family of pro-survival proteins, ABT-199. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 163-166 BCL2 apoptosis regulator Homo sapiens 124-129 25602436-4 2015 Western blot showed that the Bortezomib strongly increased the levels of p-JNK, caspase-3, PARP, and bax proteins while it increased the level of bcl-2. Bortezomib 29-39 BCL2 apoptosis regulator Homo sapiens 146-151 25495168-1 2015 The aim of this proof-of-concept study was to determine the effects of three-month Metformin therapy on the expression of tumor-regulatory genes (p53, cyclin D2 and BCL-2) in the endometrium of women with polycystic ovary syndrome (PCOS). Metformin 83-92 BCL2 apoptosis regulator Homo sapiens 165-170 25647297-0 2015 (-)-Epigallocatechingallate induces apoptosis in B lymphoma cells via caspase-dependent pathway and Bcl-2 family protein modulation. epigallocatechin gallate 0-27 BCL2 apoptosis regulator Homo sapiens 100-105 25625567-9 2015 Furthermore, rottlerin reduced the expression of important anti-apoptotic proteins (e.g., survivin, XIAP, Bcl-xL and c-FLIP) and Bcl-2 phosphorylation, and activated the pro-apoptotic protein Bax. rottlerin 13-22 BCL2 apoptosis regulator Homo sapiens 129-134 25647297-6 2015 In agreement, EGCG upregulated the mRNA expression of Fas and Bax while downregulating Bcl-2. epigallocatechin gallate 14-18 BCL2 apoptosis regulator Homo sapiens 87-92 25647297-7 2015 Protein expression levels of Bax, activated caspase-3, -7, -8, and -9, and PARP were increased, while Bcl-2 protein levels were reduced by EGCG treatment. epigallocatechin gallate 139-143 BCL2 apoptosis regulator Homo sapiens 102-107 26020182-7 2015 Moreover, DS-ZnO increased (P < 0.05) occludin, claudin-1, and zonula occluden-1 expressions; reduced (P < 0.05) caspase-9 and caspase-3 activity and Bax expression; and improved (P < 0.05) Bcl2, XIAP, and PCNA expression. ds-zno 10-16 BCL2 apoptosis regulator Homo sapiens 199-203 25779760-3 2015 Results showed that H2O2 significantly upregulated both Bax and cleaved caspase-3 expression, and also downregulated Bcl-2 expression in test cells. Hydrogen Peroxide 20-24 BCL2 apoptosis regulator Homo sapiens 117-122 25715790-8 2015 Analysis of apoptosis-related genes in oocytes after IVM revealed lesser transcript abundances for Bax gene, and higher transcript abundances for Bcl-2 gene in ALA-treated oocytes as compared with the control oocytes. alpha-Linolenic Acid 160-163 BCL2 apoptosis regulator Homo sapiens 146-151 25501628-8 2015 Western blot analysis confirmed the upregulation of Bax and the downregulation of Bcl-2 by SBHA. suberoyl bis-hydroxamic acid 91-95 BCL2 apoptosis regulator Homo sapiens 82-87 25642592-6 2015 Concurrently, triclosan induced apoptosis of human placental syncytiotrophoblasts as demonstrated by observations of increased nuclear condensation, DNA fragmentation and pro-apoptosis proteins such as Bax and cleaved-caspase3, decreased pro-caspase-3 and anti-apoptosis protein such as Bcl-2. Triclosan 14-23 BCL2 apoptosis regulator Homo sapiens 287-292 25744050-0 2015 The NADPH oxidase inhibitor DPI can abolish hypoxia-induced apoptosis of human kidney proximal tubular epithelial cells through Bcl2 up-regulation via ERK activation without ROS reduction. 3-aminodiphenyleneiodium 28-31 BCL2 apoptosis regulator Homo sapiens 128-132 25744050-10 2015 Treatment of CoCl2 and HK-2 cells treated with DPI, but not NAC, significantly induced ERK activation and Bcl2 expression. cobaltous chloride 13-18 BCL2 apoptosis regulator Homo sapiens 106-110 25744050-10 2015 Treatment of CoCl2 and HK-2 cells treated with DPI, but not NAC, significantly induced ERK activation and Bcl2 expression. 3-aminodiphenyleneiodium 47-50 BCL2 apoptosis regulator Homo sapiens 106-110 25434584-9 2015 In addition, icaritin triggered the mitochondrial/caspase apoptotic pathway, by decreasing the Bcl-2/Bax protein ratio and increasing activation of caspase-3. icaritin 13-21 BCL2 apoptosis regulator Homo sapiens 95-100 25879420-10 2015 Shikonin also induced the mitochondrial apoptotic pathway mediated through the enhanced expression of the pro-apoptotic Bax and inhibition of Bcl-2, disruption of the mitochondrial membrane potential (MMP) followed by the activation of caspase-9, caspase-3, and PARP cleavage. shikonin 0-8 BCL2 apoptosis regulator Homo sapiens 142-147 25737432-8 2015 And the results of Western blot showed that hesperetin caused an increase in the levels of cytosolic AIF, cytosolic Apaf-1, cytosolic Cyt C, caspase-3, caspase-9 and Bax and a decrease in that of Bcl-2, mitochondrial AIF, mitochondrial Apaf-1 and mitochondrial Cyt C (P < 0.05). hesperetin 44-54 BCL2 apoptosis regulator Homo sapiens 196-201 25515142-8 2015 Upregulation of Fas and downregulation of Bcl-2 expression levels were observed following iodine-131 treatment. Iodine-131 90-100 BCL2 apoptosis regulator Homo sapiens 42-47 25501628-9 2015 In conclusion, these results indicate that SBHA exerts cytotoxic effects against human breast cancer cells, which involves the modulation of p21, p27 and Bcl-2 family proteins, consequently leading to cell-cycle arrest and apoptosis. suberoyl bis-hydroxamic acid 43-47 BCL2 apoptosis regulator Homo sapiens 154-159 25515142-11 2015 In conclusion, iodine-131 may induce apoptosis in HTori-3 cells by downregulating the expression of Bcl-2 and upregulating the expression of Fas. Iodine-131 15-25 BCL2 apoptosis regulator Homo sapiens 100-105 25684043-0 2015 Quinacrine induces apoptosis in human leukemia K562 cells via p38 MAPK-elicited BCL2 down-regulation and suppression of ERK/c-Jun-mediated BCL2L1 expression. Quinacrine 0-10 BCL2 apoptosis regulator Homo sapiens 80-84 25907934-9 2015 Thioridazine treatment of the cells resulted in up-regulated PDCD4 mRNA expression and down-regulated mRNA expressions of CCND1, CDK4, c-MYC, BCL2, CASPASE3, PARP1 and EIF4A, increased PDCD4 protein expression and reduced p-AKT protein expression. Thioridazine 0-12 BCL2 apoptosis regulator Homo sapiens 142-146 25301240-0 2015 The role of BIM-EL and BCL2-alpha on the efficacy of erlotinib and gefitinib in lung cancer. Erlotinib Hydrochloride 53-62 BCL2 apoptosis regulator Homo sapiens 23-27 25301240-8 2015 BCL2-alpha revealed a counter-regulation effect on BIM-EL and this effect is probably one of the causes of secondary resistance to erlotinib and gefitinib. Erlotinib Hydrochloride 131-140 BCL2 apoptosis regulator Homo sapiens 0-4 25301240-8 2015 BCL2-alpha revealed a counter-regulation effect on BIM-EL and this effect is probably one of the causes of secondary resistance to erlotinib and gefitinib. Gefitinib 145-154 BCL2 apoptosis regulator Homo sapiens 0-4 25492481-0 2015 Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2. Cisplatin 26-35 BCL2 apoptosis regulator Homo sapiens 95-99 25492481-7 2015 It was also downregulated in cisplatin-resistant gastric cancer cell line SGC7901/cisplatin (DDP), which was concurrent with the upregulation of IGF1R and BCL2, compared with the parental SGC7901 cell line, respectively. Cisplatin 29-38 BCL2 apoptosis regulator Homo sapiens 155-159 25492481-7 2015 It was also downregulated in cisplatin-resistant gastric cancer cell line SGC7901/cisplatin (DDP), which was concurrent with the upregulation of IGF1R and BCL2, compared with the parental SGC7901 cell line, respectively. Cisplatin 82-91 BCL2 apoptosis regulator Homo sapiens 155-159 25492481-11 2015 Our findings suggested that hsa-miR-143 could modulate cisplatin resistance of human gastric cancer cell line at least in part by targeting IGF1R and BCL2. Cisplatin 55-64 BCL2 apoptosis regulator Homo sapiens 150-154 25492486-0 2015 Metformin sensitizes hepatocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bcl2 expression. Metformin 0-9 BCL2 apoptosis regulator Homo sapiens 102-106 25492486-0 2015 Metformin sensitizes hepatocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bcl2 expression. Arsenic Trioxide 49-65 BCL2 apoptosis regulator Homo sapiens 102-106 25492486-4 2015 Metformin is reported to decrease Bcl2 expression, and the purpose of this study was to verify whether metformin could potentiate the anti-HCC efficacy of ATO in vitro. Metformin 0-9 BCL2 apoptosis regulator Homo sapiens 34-38 25492486-4 2015 Metformin is reported to decrease Bcl2 expression, and the purpose of this study was to verify whether metformin could potentiate the anti-HCC efficacy of ATO in vitro. Arsenic Trioxide 155-158 BCL2 apoptosis regulator Homo sapiens 34-38 25492486-7 2015 Furthermore, this activity proceeded via a mechanism involving metformin-induced downregulation of Bcl2. Metformin 63-72 BCL2 apoptosis regulator Homo sapiens 99-103 25356658-0 2015 Ethyl acetate extract from Glycosmis parva leaf induces apoptosis and cell-cycle arrest by decreasing expression of COX-2 and altering BCL-2 family gene expression in human colorectal cancer HT-29 cells. ethyl acetate 0-13 BCL2 apoptosis regulator Homo sapiens 135-140 25416439-7 2015 ATO downregulated the expression of Bcl-2 and Bcl-xL and upregulated the expression of Bax, indicating that ATO could induce the apoptosis of HCC cells through the intrinsic pathways; but sorafenib showed little effects on these proteins of Bcl-2 family. Arsenic Trioxide 0-3 BCL2 apoptosis regulator Homo sapiens 36-41 25416439-7 2015 ATO downregulated the expression of Bcl-2 and Bcl-xL and upregulated the expression of Bax, indicating that ATO could induce the apoptosis of HCC cells through the intrinsic pathways; but sorafenib showed little effects on these proteins of Bcl-2 family. Arsenic Trioxide 0-3 BCL2 apoptosis regulator Homo sapiens 241-246 25596645-2 2015 METHODS: Bcl-2 expression was analyzed in 2 different tissue microarrays (TMAs). tmas 74-78 BCL2 apoptosis regulator Homo sapiens 9-14 25596645-6 2015 RESULTS: In both TMA cohorts, Bcl-2 overexpression was significantly (P<0.05) more frequent in LN metastases than in primary tumors (chemotherapy-naive TMA group: 18/148 [12%] in primary tumors vs. 39/143 [27%] in metastases; postchemotherapy TMA: ypT+7/35 [20%] vs. ypN+11/19 [58%]). tma 17-20 BCL2 apoptosis regulator Homo sapiens 30-35 25596645-6 2015 RESULTS: In both TMA cohorts, Bcl-2 overexpression was significantly (P<0.05) more frequent in LN metastases than in primary tumors (chemotherapy-naive TMA group: 18/148 [12%] in primary tumors vs. 39/143 [27%] in metastases; postchemotherapy TMA: ypT+7/35 [20%] vs. ypN+11/19 [58%]). tma 155-158 BCL2 apoptosis regulator Homo sapiens 30-35 25596645-6 2015 RESULTS: In both TMA cohorts, Bcl-2 overexpression was significantly (P<0.05) more frequent in LN metastases than in primary tumors (chemotherapy-naive TMA group: 18/148 [12%] in primary tumors vs. 39/143 [27%] in metastases; postchemotherapy TMA: ypT+7/35 [20%] vs. ypN+11/19 [58%]). tma 155-158 BCL2 apoptosis regulator Homo sapiens 30-35 25684043-3 2015 Quinacrine induced K562 cell apoptosis accompanied with ROS generation, mitochondrial depolarization, and down-regulation of BCL2L1 and BCL2. Quinacrine 0-10 BCL2 apoptosis regulator Homo sapiens 125-129 25684043-8 2015 Over-expression of BCL2L1 and BCL2 attenuated quinacrine-evoked mitochondrial depolarization and rescued the viability of quinacrine-treated cells. Quinacrine 46-56 BCL2 apoptosis regulator Homo sapiens 19-23 25684043-8 2015 Over-expression of BCL2L1 and BCL2 attenuated quinacrine-evoked mitochondrial depolarization and rescued the viability of quinacrine-treated cells. Quinacrine 122-132 BCL2 apoptosis regulator Homo sapiens 19-23 25684043-9 2015 Taken together, our data indicate that quinacrine-induced K562 cell apoptosis is mediated through mitochondrial alterations triggered by p38 MAPK-mediated BCL2 down-regulation and suppression of ERK/c-Jun-mediated BCL2L1 expression. Quinacrine 39-49 BCL2 apoptosis regulator Homo sapiens 155-159 25748272-5 2015 We predominantly focus on recent findings that link select BCL-2 proteins to carbon substrate utilization at the level of mitochondrial fuel choice, electron transport, and metabolite import independent of their cell death regulatory function. Carbon 77-83 BCL2 apoptosis regulator Homo sapiens 59-64 25786063-5 2015 In SNU-C5/5-FU treated with LS-1 of 7.1 muM (IC50), we could observe the various apoptotic characteristics, such as the increase of apoptotic bodies, the increase of the sub-G1 hypodiploid cell population, the decrease of the Bcl-2 level, the increase of procaspase-9 cleavage, the increase of procaspase-3 cleavage and the increase of poly(ADP-ribose) polymerase cleavage. snu-c5 3-9 BCL2 apoptosis regulator Homo sapiens 226-231 25940182-6 2015 Processed by 17-DMAG 100 nmol/L, oxaliplatin 50 mg/L and half-dose combination of 2 drugs, transcription level of the apoptosis inhibitory gene (Bcl-2) in SW480 and HCT116 cells was decreased, the level of apoptosis promoting gene (Bax) transcription and protein PARP-1 spliceosome expression was increased, and the above trend was more obvious when using half-dose combination of 2 drugs. Oxaliplatin 33-44 BCL2 apoptosis regulator Homo sapiens 145-150 25948188-7 2015 With the increasing of YM155 concentration and prolonging of action time, the expression levels of mRNA and protein of survivin and BCL-2 decreased, while the expression levels of caspase-3, PARP, beclin1 and LC-3 increased. YM 155 23-28 BCL2 apoptosis regulator Homo sapiens 132-137 25714024-7 2015 AML cells expressing Bcl-xL, or with overexpression of Bcl-2, have decreased sensitivity to DHA and X-11-induced apoptosis which could be overcome by addition of Bcl-2/Bcl-xL inhibitor ABT-737. artenimol 92-95 BCL2 apoptosis regulator Homo sapiens 55-60 25714024-7 2015 AML cells expressing Bcl-xL, or with overexpression of Bcl-2, have decreased sensitivity to DHA and X-11-induced apoptosis which could be overcome by addition of Bcl-2/Bcl-xL inhibitor ABT-737. artenimol 92-95 BCL2 apoptosis regulator Homo sapiens 162-167 25714024-7 2015 AML cells expressing Bcl-xL, or with overexpression of Bcl-2, have decreased sensitivity to DHA and X-11-induced apoptosis which could be overcome by addition of Bcl-2/Bcl-xL inhibitor ABT-737. ABT-737 185-192 BCL2 apoptosis regulator Homo sapiens 55-60 25714024-7 2015 AML cells expressing Bcl-xL, or with overexpression of Bcl-2, have decreased sensitivity to DHA and X-11-induced apoptosis which could be overcome by addition of Bcl-2/Bcl-xL inhibitor ABT-737. ABT-737 185-192 BCL2 apoptosis regulator Homo sapiens 162-167 25787766-1 2015 The BCL-2/BCL-XL/BCL-W inhibitor ABT-263 (navitoclax) has shown promising clinical activity in lymphoid malignancies such as chronic lymphocytic leukemia. navitoclax 33-40 BCL2 apoptosis regulator Homo sapiens 4-9 25787766-3 2015 This prompted the generation of the BCL-2-selective inhibitor venetoclax (ABT-199/GDC-0199), which demonstrates robust activity in these cancers but spares platelets. venetoclax 62-72 BCL2 apoptosis regulator Homo sapiens 36-41 25787766-3 2015 This prompted the generation of the BCL-2-selective inhibitor venetoclax (ABT-199/GDC-0199), which demonstrates robust activity in these cancers but spares platelets. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 74-77 BCL2 apoptosis regulator Homo sapiens 36-41 25787766-3 2015 This prompted the generation of the BCL-2-selective inhibitor venetoclax (ABT-199/GDC-0199), which demonstrates robust activity in these cancers but spares platelets. venetoclax 82-90 BCL2 apoptosis regulator Homo sapiens 36-41 25787766-6 2015 Selective BCL-2 inhibition suppressed granulopoiesis in vitro and in vivo, potentially accounting for the exacerbated neutropenia observed when navitoclax was combined with docetaxel clinically. navitoclax 144-154 BCL2 apoptosis regulator Homo sapiens 10-15 25787766-6 2015 Selective BCL-2 inhibition suppressed granulopoiesis in vitro and in vivo, potentially accounting for the exacerbated neutropenia observed when navitoclax was combined with docetaxel clinically. Docetaxel 173-182 BCL2 apoptosis regulator Homo sapiens 10-15 25608107-9 2015 Interestingly, PCP and TCHQ were proved as mild tumor promoters in two-stage tumorigenesis models, in which the possible mechanism could be through ROS generation and changed Bcl-2 gene expression. Pentachlorophenol 15-18 BCL2 apoptosis regulator Homo sapiens 175-180 25608107-9 2015 Interestingly, PCP and TCHQ were proved as mild tumor promoters in two-stage tumorigenesis models, in which the possible mechanism could be through ROS generation and changed Bcl-2 gene expression. 2,3,5,6-tetrachlorohydroquinone 23-27 BCL2 apoptosis regulator Homo sapiens 175-180 25940182-6 2015 Processed by 17-DMAG 100 nmol/L, oxaliplatin 50 mg/L and half-dose combination of 2 drugs, transcription level of the apoptosis inhibitory gene (Bcl-2) in SW480 and HCT116 cells was decreased, the level of apoptosis promoting gene (Bax) transcription and protein PARP-1 spliceosome expression was increased, and the above trend was more obvious when using half-dose combination of 2 drugs. 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin 13-20 BCL2 apoptosis regulator Homo sapiens 145-150 25788262-7 2015 Co-treatment of CAPE with PI3K inhibitor LY294002 or Bcl-2 inhibitor ABT737 showed synergistic suppressive effects. ABT-737 69-75 BCL2 apoptosis regulator Homo sapiens 53-58 25711460-1 2015 Although the role of Bcl-2 phosphorylation is still under debate, it has been identified in a resistance mechanism to BH3 mimetics, for example ABT-737 and S1. BH 3 118-121 BCL2 apoptosis regulator Homo sapiens 21-26 25711460-4 2015 In vitro binding assays showed that S1-16 binds to the BH3 binding groove of EEE-Bcl-2 (Kd =0.38 muM by ITC; IC50 =0.16 muM by ELISA), as well as nonphosphorylated Bcl-2 (npBcl-2; Kd =0.38 muM; IC50 =0.12 muM). BH 3 55-58 BCL2 apoptosis regulator Homo sapiens 81-86 25711460-5 2015 However, ABT-737 and S1 had much weaker affinities to EEE-Bcl-2 (IC50 =1.43 and >10 muM, respectively), compared with npBcl-2 (IC50 =0.011 and 0.74 muM, respectively). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 9-12 BCL2 apoptosis regulator Homo sapiens 58-63 25711460-6 2015 The allosteric effect on BH3 binding groove by Bcl-2 phosphorylation in the loop region was illustrated for the first time. BH 3 25-28 BCL2 apoptosis regulator Homo sapiens 47-52 25486070-2 2015 Small molecules that inhibit the protein-protein interactions between prosurvival and proapoptotic Bcl-2 family members (so-called "BH3 mimetics") have a potential therapeutic value, as indicated by clinical findings obtained with ABT-263 (navitoclax), a Bcl-2/Bcl-xL antagonist, and more recently with GDC-0199/ABT-199, a more selective antagonist of Bcl-2. BH 3 132-135 BCL2 apoptosis regulator Homo sapiens 99-104 25486070-2 2015 Small molecules that inhibit the protein-protein interactions between prosurvival and proapoptotic Bcl-2 family members (so-called "BH3 mimetics") have a potential therapeutic value, as indicated by clinical findings obtained with ABT-263 (navitoclax), a Bcl-2/Bcl-xL antagonist, and more recently with GDC-0199/ABT-199, a more selective antagonist of Bcl-2. BH 3 132-135 BCL2 apoptosis regulator Homo sapiens 255-260 25486070-2 2015 Small molecules that inhibit the protein-protein interactions between prosurvival and proapoptotic Bcl-2 family members (so-called "BH3 mimetics") have a potential therapeutic value, as indicated by clinical findings obtained with ABT-263 (navitoclax), a Bcl-2/Bcl-xL antagonist, and more recently with GDC-0199/ABT-199, a more selective antagonist of Bcl-2. BH 3 132-135 BCL2 apoptosis regulator Homo sapiens 255-260 25486070-2 2015 Small molecules that inhibit the protein-protein interactions between prosurvival and proapoptotic Bcl-2 family members (so-called "BH3 mimetics") have a potential therapeutic value, as indicated by clinical findings obtained with ABT-263 (navitoclax), a Bcl-2/Bcl-xL antagonist, and more recently with GDC-0199/ABT-199, a more selective antagonist of Bcl-2. navitoclax 231-238 BCL2 apoptosis regulator Homo sapiens 99-104 25486070-2 2015 Small molecules that inhibit the protein-protein interactions between prosurvival and proapoptotic Bcl-2 family members (so-called "BH3 mimetics") have a potential therapeutic value, as indicated by clinical findings obtained with ABT-263 (navitoclax), a Bcl-2/Bcl-xL antagonist, and more recently with GDC-0199/ABT-199, a more selective antagonist of Bcl-2. navitoclax 240-250 BCL2 apoptosis regulator Homo sapiens 99-104 25486070-2 2015 Small molecules that inhibit the protein-protein interactions between prosurvival and proapoptotic Bcl-2 family members (so-called "BH3 mimetics") have a potential therapeutic value, as indicated by clinical findings obtained with ABT-263 (navitoclax), a Bcl-2/Bcl-xL antagonist, and more recently with GDC-0199/ABT-199, a more selective antagonist of Bcl-2. venetoclax 303-311 BCL2 apoptosis regulator Homo sapiens 99-104 25486070-2 2015 Small molecules that inhibit the protein-protein interactions between prosurvival and proapoptotic Bcl-2 family members (so-called "BH3 mimetics") have a potential therapeutic value, as indicated by clinical findings obtained with ABT-263 (navitoclax), a Bcl-2/Bcl-xL antagonist, and more recently with GDC-0199/ABT-199, a more selective antagonist of Bcl-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 231-234 BCL2 apoptosis regulator Homo sapiens 99-104 25693888-8 2015 Incubation of BaP-challenged cells with AuNP-HA-IAP-2 siRNAs silenced the expression of IAP-2, decreased cell proliferation and triggered pronounced cell apoptosis by the decrease in Bcl-2 protein and the increase in Bax protein as well as the active form of caspases-3. Benzo(a)pyrene 14-17 BCL2 apoptosis regulator Homo sapiens 183-188 28962387-12 2015 Western blot analysis has shown that GA/MG treatment down regulated Bcl-2 and up regulated cleaved caspase-3 with respect to increasing doses. Gallic Acid 37-39 BCL2 apoptosis regulator Homo sapiens 68-73 26064333-5 2015 RESULTS: Combined treatment with ATRA and Genistein was able to reduce the expressions of Bcl-2, MUC1 and ICAM-1 and exerted synergistic effects to inhibit the invasion of A549 cells. Tretinoin 33-37 BCL2 apoptosis regulator Homo sapiens 90-95 26064333-5 2015 RESULTS: Combined treatment with ATRA and Genistein was able to reduce the expressions of Bcl-2, MUC1 and ICAM-1 and exerted synergistic effects to inhibit the invasion of A549 cells. Genistein 42-51 BCL2 apoptosis regulator Homo sapiens 90-95 26064333-6 2015 CONCLUSION: ATRA and Genistein may synergistically inhibit MUC1 and ICAM-1 expressions and affect the expressions of cell cycle related proteins (CDK4, Rb and p-ERK1/2) and apoptosis related proteins (Bax and Bcl-2), inhibit the metastatic potential of lung cancer A549 cells. Tretinoin 12-16 BCL2 apoptosis regulator Homo sapiens 209-214 26064333-6 2015 CONCLUSION: ATRA and Genistein may synergistically inhibit MUC1 and ICAM-1 expressions and affect the expressions of cell cycle related proteins (CDK4, Rb and p-ERK1/2) and apoptosis related proteins (Bax and Bcl-2), inhibit the metastatic potential of lung cancer A549 cells. Genistein 21-30 BCL2 apoptosis regulator Homo sapiens 209-214 25837276-4 2015 Tanapsin was cytotoxic against leukemia and melanoma cells, including cells that overexpress Bcl-2 and Bcl-xL, with IC50 values of approximately 10 microM, but not against quiescent or proliferating human peripheral blood mononuclear cells. tanapsin 0-8 BCL2 apoptosis regulator Homo sapiens 93-98 25766319-8 2015 Crystal structures of variola F1L bound to Bid and Bak BH3 domains reveal that variola F1L forms a domain-swapped Bcl-2 fold, which accommodates Bid and Bak BH3 in the canonical Bcl-2-binding groove, in a manner similar to VV F1L. bak bh3 51-58 BCL2 apoptosis regulator Homo sapiens 114-119 25521557-11 2015 In addition, both the FasL inhibitor (AF-016) and the Bcl-2 family inhibitor (GX15-070) could prevent the cell apoptosis induced by AG4. obatoclax 78-86 BCL2 apoptosis regulator Homo sapiens 54-59 25684204-5 2015 Hydrogen-deuterium exchange mass spectrometry demonstrated that the N-terminal conformational changes in BAX induced by a triggering BIM BH3 helix were suppressed by the BCL-2 BH4 helix. Hydrogen 0-8 BCL2 apoptosis regulator Homo sapiens 170-175 25684204-5 2015 Hydrogen-deuterium exchange mass spectrometry demonstrated that the N-terminal conformational changes in BAX induced by a triggering BIM BH3 helix were suppressed by the BCL-2 BH4 helix. Deuterium 9-18 BCL2 apoptosis regulator Homo sapiens 170-175 25684204-5 2015 Hydrogen-deuterium exchange mass spectrometry demonstrated that the N-terminal conformational changes in BAX induced by a triggering BIM BH3 helix were suppressed by the BCL-2 BH4 helix. BH 3 137-140 BCL2 apoptosis regulator Homo sapiens 170-175 25684204-5 2015 Hydrogen-deuterium exchange mass spectrometry demonstrated that the N-terminal conformational changes in BAX induced by a triggering BIM BH3 helix were suppressed by the BCL-2 BH4 helix. sapropterin 176-179 BCL2 apoptosis regulator Homo sapiens 170-175 25684204-7 2015 These data reveal a previously unappreciated binding site for targeted inhibition of BAX and suggest that the BCL-2 BH4 domain may participate in apoptosis blockade by a noncanonical interaction mechanism. sapropterin 116-119 BCL2 apoptosis regulator Homo sapiens 110-115 25545322-0 2015 Folate-decorated hydrophilic three-arm star-block terpolymer as a novel nanovehicle for targeted co-delivery of doxorubicin and Bcl-2 siRNA in breast cancer therapy. Folic Acid 0-6 BCL2 apoptosis regulator Homo sapiens 128-133 25545322-9 2015 The folate-decorated nanomicelleplexes could deliver doxorubicin and Bcl-2 siRNA more efficiently into the same MCF-7 cell and exhibited a higher cytotoxicity than non-targeted nanomicelleplexes. Folic Acid 4-10 BCL2 apoptosis regulator Homo sapiens 69-74 25521557-11 2015 In addition, both the FasL inhibitor (AF-016) and the Bcl-2 family inhibitor (GX15-070) could prevent the cell apoptosis induced by AG4. CHEMBL1099124 132-135 BCL2 apoptosis regulator Homo sapiens 54-59 25762616-3 2015 We found that garcinol inhibited the viability of a panel of diverse HNSCC cell lines, enhanced the apoptotic effect of cisplatin, suppressed constitutive as well as cisplatin-induced NF-kappaB activation, and downregulated the expression of various oncogenic gene products (cyclin D1, Bcl-2, survivin and VEGF). garcinol 14-22 BCL2 apoptosis regulator Homo sapiens 286-291 25751724-5 2015 Ceramide enhances oligomerization of pro-apoptotic Bcl-2 family proteins, ceramide channel, and reduces anti-apoptotic Bcl-2 proteins in the MOM. Ceramides 0-8 BCL2 apoptosis regulator Homo sapiens 51-56 25751724-5 2015 Ceramide enhances oligomerization of pro-apoptotic Bcl-2 family proteins, ceramide channel, and reduces anti-apoptotic Bcl-2 proteins in the MOM. Ceramides 0-8 BCL2 apoptosis regulator Homo sapiens 119-124 25751724-9 2015 Crosstalk between Bcl-2 family proteins, ROS, and many signaling pathways regulates ceramide-induced apoptosis. Ceramides 84-92 BCL2 apoptosis regulator Homo sapiens 18-23 25890231-9 2015 Cell apoptosis here is induced by following the ROS-mediated mitochondrial pathway, combined with downregulation of the expression levels of mRNA of XIAP and PARP-1 and upregulation of caspase3, Bcl-2 and Bcl-xL. ros 48-51 BCL2 apoptosis regulator Homo sapiens 195-200 25619389-10 2015 Moreover, PL markedly increased the expression of the apoptotic proteins (Bax, Bcl-2 and caspase-3) and autophagic proteins (Beclin-1 and LC3B), and phosphorylation of p38 and JNK in BMMNCs from the patients with myeloid leukemias, whereas pretreatment with the specific p38 inhibitor SB203580 or the specific JNK inhibitor SP600125 partially reversed PL-induced ROS production, apoptotic/autophagic signaling activation and cytotoxicity. piperlonguminine 10-12 BCL2 apoptosis regulator Homo sapiens 79-84 25776476-0 2015 Cytotoxic activity of sunitinib and everolimus in Caki-1 renal cancer cells is accompanied by modulations in the expression of apoptosis-related microRNA clusters and BCL2 family genes. Sunitinib 22-31 BCL2 apoptosis regulator Homo sapiens 167-171 25767680-6 2015 Specifically, kahweol increased the expression of caspase-3, a pro-apoptotic factor, and decreased the expression of anti-apoptotic factors, such as Bcl-2 and phosphorylated Akt. kahweol 14-21 BCL2 apoptosis regulator Homo sapiens 149-154 25776512-9 2015 Moreover, Western blotting analysis showed that apoptosis induced by RSV-GNPs is associated with the increased Bax, p53, p21, caspase-3 protein levels, and decreased Bcl-2 and NF-kappaB proteins expression, which indicates the involvement of mitochondria-dependent apoptosis in the anticancer efficacy of RSV-GNPs in NCI-H460 cells. Resveratrol 69-72 BCL2 apoptosis regulator Homo sapiens 166-171 25776476-0 2015 Cytotoxic activity of sunitinib and everolimus in Caki-1 renal cancer cells is accompanied by modulations in the expression of apoptosis-related microRNA clusters and BCL2 family genes. Everolimus 36-46 BCL2 apoptosis regulator Homo sapiens 167-171 25776476-3 2015 Herein, we sought to evaluate the cytotoxic activity of sunitinib and everolimus against renal cancer cells Caki-1 and moreover to assess their impact on the expression levels of three BCL2 family members and three apoptosis-related microRNA clusters upon incubation with the drugs or following recovery from treatment. Sunitinib 56-65 BCL2 apoptosis regulator Homo sapiens 185-189 25776512-11 2015 CONCLUSIONS: Taken together, the results of our study clearly suggested that the cell death induced by the combination of RSV-GNPs would involve alteration in expression of p53, p21, caspase-3, Bax, Bcl-2 and NF-kappaB, indicating oxidative mechanism in NCI-H460 cells. Resveratrol 122-125 BCL2 apoptosis regulator Homo sapiens 199-204 25776476-3 2015 Herein, we sought to evaluate the cytotoxic activity of sunitinib and everolimus against renal cancer cells Caki-1 and moreover to assess their impact on the expression levels of three BCL2 family members and three apoptosis-related microRNA clusters upon incubation with the drugs or following recovery from treatment. Everolimus 70-80 BCL2 apoptosis regulator Homo sapiens 185-189 25776476-8 2015 Overall, our data support the notion that sunitinib and everolimus are able to directly induce cell death in renal cancer cells and simultaneously affect the expression levels of their apoptosis-related microRNAs and BCL2 family members upon this process. Sunitinib 42-51 BCL2 apoptosis regulator Homo sapiens 217-221 25776476-8 2015 Overall, our data support the notion that sunitinib and everolimus are able to directly induce cell death in renal cancer cells and simultaneously affect the expression levels of their apoptosis-related microRNAs and BCL2 family members upon this process. Everolimus 56-66 BCL2 apoptosis regulator Homo sapiens 217-221 25234615-6 2015 Additionally, GABA up-regulated the ratio of pro-apoptotic protein Bax to anti-apoptotic protein Bcl-2, and thus facilitated caspase-3 cleavage, leading to tumor cells apoptosis in a mitochondrial-dependent pathway. gamma-Aminobutyric Acid 14-18 BCL2 apoptosis regulator Homo sapiens 97-102 25181965-7 2015 Importantly, we also report that edaravone reduced gamma-irradiation-induced apoptosis through downregulation of Bax, upregulation of Bcl-2, and consequent reduction of the Bax:Bcl-2 ratio. Edaravone 33-42 BCL2 apoptosis regulator Homo sapiens 134-139 25181965-7 2015 Importantly, we also report that edaravone reduced gamma-irradiation-induced apoptosis through downregulation of Bax, upregulation of Bcl-2, and consequent reduction of the Bax:Bcl-2 ratio. Edaravone 33-42 BCL2 apoptosis regulator Homo sapiens 177-182 25260394-6 2015 The antitumor activity of hispidulin and its enhancement of the antitumor activity of sunitinib correlated with the suppression of pStat3 signaling and the consequent downregulation of Bcl-2 and survivin. Sunitinib 86-95 BCL2 apoptosis regulator Homo sapiens 185-190 25542900-9 2015 Ritonavir and metformin effectively suppressed AKT and mTORC1 phosphorylation and prosurvival BCL-2 family member MCL-1 expression in multiple myeloma cell lines in vitro and in vivo. Ritonavir 0-9 BCL2 apoptosis regulator Homo sapiens 94-99 25835364-6 2015 The experiment of reverse transcriptase-polymerase chain reaction further proved that PP inhibited apoptosis via modulating the expression of Bax/Bcl-2 in STZ-damaged islet cells. Streptozocin 155-158 BCL2 apoptosis regulator Homo sapiens 146-151 25542900-9 2015 Ritonavir and metformin effectively suppressed AKT and mTORC1 phosphorylation and prosurvival BCL-2 family member MCL-1 expression in multiple myeloma cell lines in vitro and in vivo. Metformin 14-23 BCL2 apoptosis regulator Homo sapiens 94-99 25748094-5 2015 1S-cis-BF also induced ROS production, up-regulated Bax protein expression and down-regulated Bcl-2 expression levels. 1s-cis-bf 0-9 BCL2 apoptosis regulator Homo sapiens 94-99 25459486-7 2015 Increased phosphorylation of ERK and Bcl2, after reperfusion in groups stored in glyceryl-trinitrate, cariporide or both along with increased phospho-STAT3 levels in the glyceryl-trinitrate/cariporide group correlated with functional recovery. Nitroglycerin 81-100 BCL2 apoptosis regulator Homo sapiens 37-41 25461257-6 2015 A similar phenomenon was triggered after addition of Thioflavin S, which was shown to block BAG-1/BCL-2 interaction and to increase cell death, enforcing a prosurvival role of the BAG-1 protein in AML. thioflavin T 53-65 BCL2 apoptosis regulator Homo sapiens 98-103 25675448-8 2015 Furthermore, genistein induced the inactivation of IGF-1R and p-Akt and downregulated the Bcl-2/Bax protein ratio. Genistein 13-22 BCL2 apoptosis regulator Homo sapiens 90-95 25675448-9 2015 These results suggest that genistein inhibited cell proliferation by inactivating the IGF-1R-PI3 K/Akt pathway and decreasing the Bcl-2/Bax mRNA and protein expressions. Genistein 27-36 BCL2 apoptosis regulator Homo sapiens 130-135 25818986-4 2015 Moreover, esculetin increased mitochondrial membrane depolarization, released cytochrome c into cytosol, and modulated the expression of apoptosis-associated proteins, resulting in reduced expression of B cell lymphoma-2, increased expression of Bcl-2-associated X protein, and activation of caspase-9 and caspase-3. esculetin 10-19 BCL2 apoptosis regulator Homo sapiens 246-251 25667663-5 2015 Compared with that in the control group, the mRNA and protein expression of MMP-2, MMP-14 and Bcl-2 in the YC-1 and ABT-737 groups was significantly reduced. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 116-119 BCL2 apoptosis regulator Homo sapiens 94-99 21809366-3 2015 The use of antisense oligonucleotides to down-regulate Bcl-2 protein can reverse chemotherapy resistance. Oligonucleotides 21-37 BCL2 apoptosis regulator Homo sapiens 55-60 25381036-4 2015 Moreover, fisetin significantly modulated the expression of apoptosis-associated proteins, resulting in reduced expression of B cell lymphoma-2, increased expression of Bcl-2-associated X protein, and activation of caspase-9 and caspase-3. fisetin 10-17 BCL2 apoptosis regulator Homo sapiens 169-174 25459486-7 2015 Increased phosphorylation of ERK and Bcl2, after reperfusion in groups stored in glyceryl-trinitrate, cariporide or both along with increased phospho-STAT3 levels in the glyceryl-trinitrate/cariporide group correlated with functional recovery. cariporide 102-112 BCL2 apoptosis regulator Homo sapiens 37-41 26045757-12 2015 Moreover, PAL administration significantly decreased the mRNA and proteins expression of Bcl-2 as well as increased the mRNA expression of BAX and the protein expression of caspase-3 and caspase-8 as compare to those of control group, but APS treatment could reverse PA-induced HCMs apoptosis. Protactinium 10-12 BCL2 apoptosis regulator Homo sapiens 89-94 24863670-11 2015 CONCLUSION: Nitric oxide induced apoptosis in human gingival fibroblast through the mitochondria-mediated pathway by regulation of Bcl-2 family and JNK activation. Nitric Oxide 12-24 BCL2 apoptosis regulator Homo sapiens 131-136 26045758-3 2015 We found that after treatment with PLGM, drug sensitivity and apoptosis rate of these drug resistance cancer cells were improved, cell cycle was arrested, the expressions of P-gp, MDR1, MRP1, Top-II, GST-pi, Survivin, Bcl-2, CDK1, ABCB1 and ABCG1 was decreased, while the activities of caspase-3/8 and intracellular content of Rh-123 was increased. piperlonguminine 35-39 BCL2 apoptosis regulator Homo sapiens 218-223 25527525-6 2015 The decreased expression of Bcl-2 and the increased expression of cleaved-caspase-3 induced by Sept4_i1 could be reversed by GW501516, a PPAR-beta/delta agonist that has been reported by others to enhance Akt signaling. GW 501516 125-133 BCL2 apoptosis regulator Homo sapiens 28-33 25573072-6 2015 Combinatorial TP/HCPT treatment significantly enhanced the activation of caspase-3 and -9, Bax/Bcl-2 ratio, release of cytochrome c from mitochondrial and subsequent apoptosis. triptolide 14-16 BCL2 apoptosis regulator Homo sapiens 95-100 25573072-6 2015 Combinatorial TP/HCPT treatment significantly enhanced the activation of caspase-3 and -9, Bax/Bcl-2 ratio, release of cytochrome c from mitochondrial and subsequent apoptosis. hydroxycamptothecinum 17-21 BCL2 apoptosis regulator Homo sapiens 95-100 25612549-7 2015 As hsa-miR-32-5p was described to target genes being involved in the regulation of apoptosis, the effect of alpha-eleostearic acid on the expression of the apoptosis-associated genes BCL2L11, BCL-2, and BCL-XL was examined. eleostearic acid 108-130 BCL2 apoptosis regulator Homo sapiens 192-197 25830055-5 2015 RESULTS: Results revealed that quercetin could induce apoptosis in A549 cells through mitochondrial depolarization by causing an imbalance in B-cell lymphoma 2/ Bcl2 Antagonist X (Bcl2/Bax) ratio and by down-regulating the interleukine-6/signal transducer and activator of transcription 3 (IL-6/STAT3) signaling pathway. Quercetin 31-40 BCL2 apoptosis regulator Homo sapiens 161-165 25830055-5 2015 RESULTS: Results revealed that quercetin could induce apoptosis in A549 cells through mitochondrial depolarization by causing an imbalance in B-cell lymphoma 2/ Bcl2 Antagonist X (Bcl2/Bax) ratio and by down-regulating the interleukine-6/signal transducer and activator of transcription 3 (IL-6/STAT3) signaling pathway. Quercetin 31-40 BCL2 apoptosis regulator Homo sapiens 180-184 25350317-2 2015 ABT-737, a small molecule BCL-2/BCL-XL/BCL-W inhibitor, is promising in cancer treatments, but not very effective against melanoma, with the antiapoptotic protein MCL-1 as the main contributor to resistance. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 26-31 25563418-5 2015 Additionally, MH decreased the expression of Bcl-2 and Bcl-XL, inducing the intrinsic pathway in MH-treated SiHa cells. 4-O-methylhonokiol 14-16 BCL2 apoptosis regulator Homo sapiens 45-50 25472572-5 2015 Changes of manganese superoxide dismutase, Bcl-2, and Bim were also reversed by ICA, and apoptosis was reduced. icariin 80-83 BCL2 apoptosis regulator Homo sapiens 43-48 25641428-3 2015 Recent advances in targeted therapies have resulted in novel agents such as B-cell receptor pathway and BCL2 antagonists yielding high response rates in 17p- CLL, but these patients continue to relapse at an increased rate when compared to patients without 17p-. 17 alpha-Hydroxyprogesterone Caproate 153-156 BCL2 apoptosis regulator Homo sapiens 104-108 25694047-7 2015 Furthermore, baicalin-copper treatment significantly increased the Bax/Bcl-2 ratio and p38 levels, as well as decreased the expression of caspase-3, p-PI3K, p-Akt and p-mTOR (P < 0.01). baicalin 13-21 BCL2 apoptosis regulator Homo sapiens 71-76 25694047-7 2015 Furthermore, baicalin-copper treatment significantly increased the Bax/Bcl-2 ratio and p38 levels, as well as decreased the expression of caspase-3, p-PI3K, p-Akt and p-mTOR (P < 0.01). Copper 22-28 BCL2 apoptosis regulator Homo sapiens 71-76 25612549-8 2015 The qPCR results indicate that fatty acid-mediated downregulation of hsa-miR-32-5p is accompanied by a downregulation of BCL-2 and BCL2L11 mRNA whereas BCL-XL was shown to be simultaneously upregulated. Fatty Acids 31-41 BCL2 apoptosis regulator Homo sapiens 121-126 25373554-6 2015 The results demonstrated that baicalein inhibits the proliferation of HeLa cells and induces apoptosis in a caspase-3-dependent pathway, through downregulation of the B-cell lymphoma 2 (Bcl-2) protein and upregulation of the Bcl-2-associated X protein (Bax), Fas, Fas ligand (FasL) and caspase-8. baicalein 30-39 BCL2 apoptosis regulator Homo sapiens 186-191 25702644-2 2015 We previously showed that melatonin inhibits the intrinsic apoptotic pathway in leukocytes via stimulation of high affinity MT1/MT2 receptors, thereby promoting re-localization of the anti-apoptotic Bcl-2 protein to mitochondria. Melatonin 26-35 BCL2 apoptosis regulator Homo sapiens 199-204 25702644-3 2015 Here we show that Bcl-2 sequesters pro-apoptotic Bax into mitochondria in an inactive form after melatonin treatment, thus reducing cell propensity to apoptosis. Melatonin 97-106 BCL2 apoptosis regulator Homo sapiens 18-23 25702644-4 2015 Bax translocation and the anti-apoptotic effect of melatonin are strictly dependent on the presence of Bcl-2, and on the 5-lipoxygenase (5-LOX) metabolite 5-hydroxyeicosatetraenoic acid (5-HETE), which we have previously shown to be produced as a consequence of melatonin binding to its low affinity target calmodulin. Melatonin 51-60 BCL2 apoptosis regulator Homo sapiens 103-108 25373554-6 2015 The results demonstrated that baicalein inhibits the proliferation of HeLa cells and induces apoptosis in a caspase-3-dependent pathway, through downregulation of the B-cell lymphoma 2 (Bcl-2) protein and upregulation of the Bcl-2-associated X protein (Bax), Fas, Fas ligand (FasL) and caspase-8. baicalein 30-39 BCL2 apoptosis regulator Homo sapiens 167-184 25378060-0 2015 Roscovitine-treated HeLa cells finalize autophagy later than apoptosis by downregulating Bcl-2. Roscovitine 0-11 BCL2 apoptosis regulator Homo sapiens 89-94 25405848-0 2015 Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-kappaB/Bcl-2 pathway. Temozolomide 79-91 BCL2 apoptosis regulator Homo sapiens 133-138 25405848-0 2015 Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-kappaB/Bcl-2 pathway. Cisplatin 96-105 BCL2 apoptosis regulator Homo sapiens 133-138 25378060-7 2015 The marked decrease in Bcl-2 following exposure to roscovitine (20 microM) for 48 h prompted us to determine the autophagic regulation. Roscovitine 51-62 BCL2 apoptosis regulator Homo sapiens 23-28 25378060-10 2015 The expression levels of different Bcl-2 family members determined whether apoptosis or autophagy were induced following incubation with roscovitine for different time periods. Roscovitine 137-148 BCL2 apoptosis regulator Homo sapiens 35-40 25530218-0 2015 Nitidine chloride induces apoptosis in human hepatocellular carcinoma cells through a pathway involving p53, p21, Bax and Bcl-2. nitidine 0-17 BCL2 apoptosis regulator Homo sapiens 122-127 25592064-0 2015 Combined treatment with ABT-737 and VX-680 induces apoptosis in Bcl-2- and c-FLIP-overexpressing breast carcinoma cells. ABT-737 24-31 BCL2 apoptosis regulator Homo sapiens 64-69 25522911-9 2015 These results indicate that Ethyl gallate suppresses proliferation and invasion in human breast cancer cells by modulating the PI3K/Akt pathway, which may contribute to inhibiting their downstream targets such as NF-kappaB p-65, Bcl-2/Bax, and mRNA levels of MMP-2 and MMP-9 in breast cancer cells. ethyl gallate 28-41 BCL2 apoptosis regulator Homo sapiens 229-234 25324174-0 2015 A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1. BH 3 8-11 BCL2 apoptosis regulator Homo sapiens 109-114 25761368-6 2015 Chemical inhibition of Mcl-1 and the related proteins Bcl-2 and Bcl-xL by a BH3 mimetic enhances the mitotic DDR, promotes p53 activation and inhibits subsequent cell cycle progression. BH 3 76-79 BCL2 apoptosis regulator Homo sapiens 54-59 25592064-0 2015 Combined treatment with ABT-737 and VX-680 induces apoptosis in Bcl-2- and c-FLIP-overexpressing breast carcinoma cells. VX680 36-42 BCL2 apoptosis regulator Homo sapiens 64-69 25592064-1 2015 ABT-737, a BH3-mimetic small-molecule inhibitor, binds with very high affinity to Bcl-2, Bcl-xL and Bcl-w, and inhibits their activity. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 82-87 25592064-1 2015 ABT-737, a BH3-mimetic small-molecule inhibitor, binds with very high affinity to Bcl-2, Bcl-xL and Bcl-w, and inhibits their activity. BH 3 11-14 BCL2 apoptosis regulator Homo sapiens 82-87 25592064-5 2015 Combined treatment with ABT-737 and VX-680 led to the downregulation of Bcl-2 expression at the transcriptional level and the downregulation of c-FLIP and Mcl-1 expression at the post-transcriptional level. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 24-27 BCL2 apoptosis regulator Homo sapiens 72-77 25592064-9 2015 Taken together, our study demonstrated that combined treatment with ABT-737 and VX-680 induced apoptosis in anti-apoptotic protein (Bcl-2 or c-FLIP)-overexpressing cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 68-71 BCL2 apoptosis regulator Homo sapiens 132-137 25324174-4 2015 pMcl-1 antagonized the known BH3 mimetics by sequestering pro-apoptotic proteins that were released from Bcl-2/Mcl-1. BH 3 29-32 BCL2 apoptosis regulator Homo sapiens 105-110 25324174-5 2015 Furthermore, an anthraquinone BH3 mimetic, compound 6, was identified to be the first small molecule to that induces endogenous apoptosis in melanoma cells by directly binding Bcl-2, Mcl-1, and pMcl-1 and disrupting the heterodimers of these proteins. Anthraquinones 16-29 BCL2 apoptosis regulator Homo sapiens 176-181 25324174-5 2015 Furthermore, an anthraquinone BH3 mimetic, compound 6, was identified to be the first small molecule to that induces endogenous apoptosis in melanoma cells by directly binding Bcl-2, Mcl-1, and pMcl-1 and disrupting the heterodimers of these proteins. BH 3 30-33 BCL2 apoptosis regulator Homo sapiens 176-181 26081859-7 2015 RESULTS: The result showed that after treatment of 150 micromol/L CoCl2 for 24 h, mRNA level of HIF-1alpha, VEGF and Bcl-2 was increased by 6.00 +- 0.20, 5.40 +- 0.40, 5.40 +- 0.30 (SCC-4); 5.60 +- 0.30, 5.20 +- 0.60, 5.80 +- 0.40(HSC-3). cobaltous chloride 66-71 BCL2 apoptosis regulator Homo sapiens 117-122 25663456-8 2015 In xenograft tumors, CP-31398 modulated the expression of Bax, Bcl-2, caspase 3, cyclin D, and Mdm2 and then blocked the growth of xenograft tumors. CP 31398 21-29 BCL2 apoptosis regulator Homo sapiens 63-68 25997235-21 2015 05), and that of Bcl-2 mRNA for 48 h hypoxia + taurine group was two times higher than the hypoxia group (P <0. Taurine 47-54 BCL2 apoptosis regulator Homo sapiens 17-22 25591861-10 2015 Further investigation revealed that Shikonin induces apoptosis in scar fibroblasts by differentially regulating the expression of caspase 3, Bcl-2, phospho-Erk1/2 and phospho-p38. shikonin 36-44 BCL2 apoptosis regulator Homo sapiens 141-146 25916440-1 2015 OBJECTIVE: To investigate the effect of nickel-smelting fumes on the expression of bcl-2 and bax in mammalian cells. Nickel 40-46 BCL2 apoptosis regulator Homo sapiens 83-88 25759564-10 2015 RESULTS: Koenimbin-induced apoptosis in MCF7 cells was mediated by cell death-transducing signals regulating the mitochondrial membrane potential by downregulating Bcl2 and upregulating Bax, due to cytochrome c release from the mitochondria to the cytosol. koenimbin 9-18 BCL2 apoptosis regulator Homo sapiens 164-168 25848915-0 2015 Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Tamoxifen 44-53 BCL2 apoptosis regulator Homo sapiens 130-135 25848915-0 2015 Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Tamoxifen 75-84 BCL2 apoptosis regulator Homo sapiens 130-135 25848915-12 2015 This model conveyed tamoxifen resistance through transcriptional upregulation of Bcl-2 and c-Myc, and downregulation of the cell cycle checkpoint protein p21, manifesting in accelerated growth and reduced cell death. Tamoxifen 20-29 BCL2 apoptosis regulator Homo sapiens 81-86 25848915-14 2015 Treatment with HDAC inhibitors reversed the altered transcriptional events and reestablished the sensitivity of the ER to tamoxifen resulting in substantial Bcl-2 downregulation, growth arrest and apoptosis. Tamoxifen 122-131 BCL2 apoptosis regulator Homo sapiens 157-162 25598309-1 2015 Obatoclax is an indole-pyrrole compound that induces cancer cell apoptosis through targeting the anti-apoptotic Bcl-2 protein family. indole-pyrrole 16-30 BCL2 apoptosis regulator Homo sapiens 112-117 25605018-5 2015 Furthermore, the caspase-9 and caspase-3 cascade was activated by the functional DOX nanoparticles through upregulation of the pro-apoptotic proteins Bax and Bid and suppression of the antiapoptotic protein Bcl-2, thereby enhancing apoptosis by acting on the mitochondrial signaling pathways. Doxorubicin 81-84 BCL2 apoptosis regulator Homo sapiens 207-212 25719742-9 2015 Moreover, boldine induced apoptosis concomitantly with increasing the expression of bax/bcl2 (p < 0.02) and p21 (p < 0.01) genes. boldine 10-17 BCL2 apoptosis regulator Homo sapiens 88-92 25880226-0 2015 pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression. gemcitabine 62-73 BCL2 apoptosis regulator Homo sapiens 115-120 25823945-9 2015 Treatment with TW-37 inhibited bcl-2 expression in bcl-2 overexpressed OVCAR3, OV-90 and SKOV3DDP cells , and inhibited growth and induced apoptosis ,and increased cisplain killing of the bcl-2 overexpressed cells in a does and time-dependant manner in vitro. TW-37 15-20 BCL2 apoptosis regulator Homo sapiens 31-36 25880226-3 2015 It has also shown that Bcl-2 confers resistance and Bax sensitizes to gemcitabine-induced apoptosis in pancreatic cancer cells. gemcitabine 70-81 BCL2 apoptosis regulator Homo sapiens 23-28 25880226-5 2015 We therefore tested the hypothesis that pancreatic cancer cells are resistant to gemcitabine and this resistance is due to activation of ERK1/2 and subsequent upregulation of Bcl-2 and downregulation of Bax. gemcitabine 81-92 BCL2 apoptosis regulator Homo sapiens 175-180 25880226-11 2015 Inhibition of the ERK1/2 by PD98059 could downregulate Bcl-2 and upregulate Bax and was associated with restoration of sensitivity to gemcitabine in BXPC-3 cells. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 28-35 BCL2 apoptosis regulator Homo sapiens 55-60 25880226-11 2015 Inhibition of the ERK1/2 by PD98059 could downregulate Bcl-2 and upregulate Bax and was associated with restoration of sensitivity to gemcitabine in BXPC-3 cells. gemcitabine 134-145 BCL2 apoptosis regulator Homo sapiens 55-60 25880226-12 2015 Depletion of endogenous Bcl-2 expression by specific small interfering RNA transfection significantly increased gemcitabine-induced cell apoptosis. gemcitabine 112-123 BCL2 apoptosis regulator Homo sapiens 24-29 25880226-14 2015 CONCLUSIONS: The upregulation of ERK1/2-dependent Bcl-2 and downregulation of ERK1/2-dependent Bax can protect human pancreatic cancer cells from gemcitabine-induced apoptosis. gemcitabine 146-157 BCL2 apoptosis regulator Homo sapiens 50-55 25880226-15 2015 Targeting the ERK1/2-Bax/Bcl-2 pathway may in part lead to sensitization of pancreatic cancer to gemcitabine. gemcitabine 97-108 BCL2 apoptosis regulator Homo sapiens 25-30 25823945-0 2015 Small-molecule inhibitor of Bcl-2 (TW-37) suppresses growth and enhances cisplatin-induced apoptosis in ovarian cancer cells. TW-37 35-40 BCL2 apoptosis regulator Homo sapiens 28-33 25823945-0 2015 Small-molecule inhibitor of Bcl-2 (TW-37) suppresses growth and enhances cisplatin-induced apoptosis in ovarian cancer cells. Cisplatin 73-82 BCL2 apoptosis regulator Homo sapiens 28-33 25823945-2 2015 It has previously reported that TW-37, a small-molecule inhibitor of Bcl-2 family proteins, inhibited cell growth and induced apoptosis in many cancer cells. TW-37 32-37 BCL2 apoptosis regulator Homo sapiens 69-74 25823945-5 2015 The effects of TW-37 alone or combined with cisplain on growth and apoptosis in bcl-2 overexpressed OVCAR3, OV-90 and SKOV3DDP cells was detected by MTT,clonogenic assay, ELISA and terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) assay. TW-37 15-20 BCL2 apoptosis regulator Homo sapiens 80-85 25823945-9 2015 Treatment with TW-37 inhibited bcl-2 expression in bcl-2 overexpressed OVCAR3, OV-90 and SKOV3DDP cells , and inhibited growth and induced apoptosis ,and increased cisplain killing of the bcl-2 overexpressed cells in a does and time-dependant manner in vitro. TW-37 15-20 BCL2 apoptosis regulator Homo sapiens 51-56 25823945-9 2015 Treatment with TW-37 inhibited bcl-2 expression in bcl-2 overexpressed OVCAR3, OV-90 and SKOV3DDP cells , and inhibited growth and induced apoptosis ,and increased cisplain killing of the bcl-2 overexpressed cells in a does and time-dependant manner in vitro. TW-37 15-20 BCL2 apoptosis regulator Homo sapiens 51-56 25823945-10 2015 CONCLUSION: Bcl-2 level positively correlated with sensitivity to cisplain. cisplain 66-74 BCL2 apoptosis regulator Homo sapiens 12-17 25709900-6 2015 LBP inhibited the H2O2-induced down-regulation of Bcl-2 and up-regulation of Bax. Hydrogen Peroxide 18-22 BCL2 apoptosis regulator Homo sapiens 50-55 25823945-11 2015 Treatment with TW-37 was effective alone and in combination with cisplain in bcl-2 overexpressed OC cell lines in vitro. TW-37 15-20 BCL2 apoptosis regulator Homo sapiens 77-82 25823945-11 2015 Treatment with TW-37 was effective alone and in combination with cisplain in bcl-2 overexpressed OC cell lines in vitro. cisplain 65-73 BCL2 apoptosis regulator Homo sapiens 77-82 25887673-10 2015 Additionally, Icaritin upregulates Bax, downregulates Bcl-2 and pBad, and activates caspase-3 and caspase-9. icaritin 14-22 BCL2 apoptosis regulator Homo sapiens 54-59 25733817-6 2015 CDDO-Me significantly decreased B-cell lymphoma-extra large (Bcl-xl), B-cell lymphoma 2 (Bcl-2), cleaved caspase-9, and cleaved poly ADP ribose polymerase (PARP) levels but increased the expression level of Bcl-2-associated X (Bax). bardoxolone methyl 0-7 BCL2 apoptosis regulator Homo sapiens 70-87 25733817-6 2015 CDDO-Me significantly decreased B-cell lymphoma-extra large (Bcl-xl), B-cell lymphoma 2 (Bcl-2), cleaved caspase-9, and cleaved poly ADP ribose polymerase (PARP) levels but increased the expression level of Bcl-2-associated X (Bax). bardoxolone methyl 0-7 BCL2 apoptosis regulator Homo sapiens 89-94 25582599-2 2015 The proapoptotic Bcl-2 family proteins Bax and Bak are essential for cisplatin-induced apoptosis. Cisplatin 69-78 BCL2 apoptosis regulator Homo sapiens 17-22 25932127-9 2015 On the molecular level, tanshinone IIA administration altered the expression of apoptosis-related proteins such as p53, Bax, Bcl-2 and cyto C. In addition, MGO treatment remarkably increased the phosphorylation of MAPK family including p38, JNK and ERK. Pyruvaldehyde 156-159 BCL2 apoptosis regulator Homo sapiens 125-130 25932150-6 2015 Furthermore, As2O3 initiated apoptosis by triggering of the mitochondria apoptotic pathway as indicated by inhibited Bcl-2 expression, a collapse of the mitochondrial membrane potential (MMP), release of cytochrome c and activation of the caspase cascade. Arsenic Trioxide 13-18 BCL2 apoptosis regulator Homo sapiens 117-122 28962382-6 2015 Flow cytometric analysis, DNA fragmentation and PARP-cleavage analysis clearly indicated that 5 mM NaF together with radiation (1 Gy) induced apoptosis in both U87 and K562 cells due to down regulation of expression of anti-apoptotic proteins, like Bcl2 in U87 and inhibitors of apoptotic proteins like survivin and cIAP in K562 cells. Sodium Fluoride 99-102 BCL2 apoptosis regulator Homo sapiens 249-253 24608435-6 2015 Indeed, the latter hypothesis is supported by our observations as the addition of ABT-737, an inhibitor to anti-apoptotic BCL-2 proteins, revealed massive apoptosis following PLX-4032 exposure. ABT-737 82-89 BCL2 apoptosis regulator Homo sapiens 122-127 24608435-8 2015 Furthermore, PLX-4032-resistant cells demonstrated collateral resistance to conventional chemotherapy, yet could be re-sensitized to PLX-4032 by BCL-2 family inhibition in vivo and conventional chemotherapies in vitro. Vemurafenib 13-21 BCL2 apoptosis regulator Homo sapiens 145-150 24608435-8 2015 Furthermore, PLX-4032-resistant cells demonstrated collateral resistance to conventional chemotherapy, yet could be re-sensitized to PLX-4032 by BCL-2 family inhibition in vivo and conventional chemotherapies in vitro. Vemurafenib 133-141 BCL2 apoptosis regulator Homo sapiens 145-150 25281200-5 2015 We further investigated the possible mechanism and found out that melatonin attenuated (Hy/SD)-induced cell death could be via effectively reducing the generation of intracellular reactive oxygen species, an increase in the ratio of Bax/Bcl-2, loss of mitochondrial membrane potential and then activation of caspase-3 in MSCs in response to Hy/SD exposure. Melatonin 66-75 BCL2 apoptosis regulator Homo sapiens 237-242 25545058-6 2015 We found that oridonin markedly increased the expression of proapoptotic Bcl-2 family protein Bim in uveal melanoma cells, and knockdown Bim by small interfering RNA significantly attenuated oridonin-induced cell death, indicating an essential role of Bim in oridonin-mediated anticancer activity. oridonin 14-22 BCL2 apoptosis regulator Homo sapiens 73-78 25528518-7 2015 Similarly in leukemic cells, Bcl-2 is down-regulated by the proteasome inhibitor, bortezomib, and also by melatonin. Bortezomib 82-92 BCL2 apoptosis regulator Homo sapiens 29-34 25528518-7 2015 Similarly in leukemic cells, Bcl-2 is down-regulated by the proteasome inhibitor, bortezomib, and also by melatonin. Melatonin 106-115 BCL2 apoptosis regulator Homo sapiens 29-34 25665064-0 2015 Silver nanoparticles biosynthesized using Achillea biebersteinii flower extract: apoptosis induction in MCF-7 cells via caspase activation and regulation of Bax and Bcl-2 gene expression. Silver 0-6 BCL2 apoptosis regulator Homo sapiens 165-170 25178491-7 2015 Specific JNK inhibitor SP600125 prevented the PYDDT-induced down-regulation of Bcl-2, mitochondrial translocation of Bax, activation of caspase 3, and apoptosis of SW620 cells. pyrazolanthrone 23-31 BCL2 apoptosis regulator Homo sapiens 79-84 25652218-8 2015 TEM analysis demonstrated that denatonium causes large amplitude swelling of mitochondria, which was confirmed by the loss of mitochondrial membrane potential, the down-regulation of Bcl-2 protein and the subsequent enhancement of the mitochondrial release of cytochrome c and Smac/DIABLO after denatonium treatment. denatonium 31-41 BCL2 apoptosis regulator Homo sapiens 183-188 25685063-3 2015 Navitoclax (ABT-263) is a Bcl-2/Bcl-xL inhibitor that restores the ability of cancer cells to undergo apoptosis. navitoclax 0-10 BCL2 apoptosis regulator Homo sapiens 26-31 25685063-3 2015 Navitoclax (ABT-263) is a Bcl-2/Bcl-xL inhibitor that restores the ability of cancer cells to undergo apoptosis. navitoclax 12-19 BCL2 apoptosis regulator Homo sapiens 26-31 25685066-14 2015 Mechanically, western blot analysis indicated that Sch B induced apoptosis by caspase-3, caspase-9, PARP, and Bcl-2 activation. schizandrin B 51-56 BCL2 apoptosis regulator Homo sapiens 110-115 25178491-7 2015 Specific JNK inhibitor SP600125 prevented the PYDDT-induced down-regulation of Bcl-2, mitochondrial translocation of Bax, activation of caspase 3, and apoptosis of SW620 cells. 2-(pro-1-ynyl)-5-(5,6-dihydroxypenta-1,3-diynyl)thiophene 46-51 BCL2 apoptosis regulator Homo sapiens 79-84 25398535-4 2015 The simple BH3-only proteins bear only a BH3-motif and are intrinsically disordered proteins and antagonize or activate the other group, the multi-motif Bcl-2 proteins that have up to four BH motifs, BH1-BH4. Bh 11-13 BCL2 apoptosis regulator Homo sapiens 153-158 25641608-0 2015 Novel Mcl-1/Bcl-2 dual inhibitors created by the structure-based hybridization of drug-divided building blocks and a fragment deconstructed from a known two-face BH3 mimetic. BH 3 162-165 BCL2 apoptosis regulator Homo sapiens 12-17 25398535-4 2015 The simple BH3-only proteins bear only a BH3-motif and are intrinsically disordered proteins and antagonize or activate the other group, the multi-motif Bcl-2 proteins that have up to four BH motifs, BH1-BH4. bh1 200-203 BCL2 apoptosis regulator Homo sapiens 153-158 25398535-4 2015 The simple BH3-only proteins bear only a BH3-motif and are intrinsically disordered proteins and antagonize or activate the other group, the multi-motif Bcl-2 proteins that have up to four BH motifs, BH1-BH4. sapropterin 204-207 BCL2 apoptosis regulator Homo sapiens 153-158 25398535-5 2015 Multi-motif Bcl-2 proteins are either pro-survival or pro-apoptotic in action and have remarkably similar alpha-helical bundle structures that provide a binding groove formed from the BH1, BH2, and BH3-motifs for their BH3-bearing antagonists. bh1 184-187 BCL2 apoptosis regulator Homo sapiens 12-17 25398535-5 2015 Multi-motif Bcl-2 proteins are either pro-survival or pro-apoptotic in action and have remarkably similar alpha-helical bundle structures that provide a binding groove formed from the BH1, BH2, and BH3-motifs for their BH3-bearing antagonists. bh2 189-192 BCL2 apoptosis regulator Homo sapiens 12-17 25398535-5 2015 Multi-motif Bcl-2 proteins are either pro-survival or pro-apoptotic in action and have remarkably similar alpha-helical bundle structures that provide a binding groove formed from the BH1, BH2, and BH3-motifs for their BH3-bearing antagonists. BH 3 198-201 BCL2 apoptosis regulator Homo sapiens 12-17 25398535-5 2015 Multi-motif Bcl-2 proteins are either pro-survival or pro-apoptotic in action and have remarkably similar alpha-helical bundle structures that provide a binding groove formed from the BH1, BH2, and BH3-motifs for their BH3-bearing antagonists. BH 3 219-222 BCL2 apoptosis regulator Homo sapiens 12-17 25398535-8 2015 Their role in disease has made the Bcl-2 family the focus of drug design attempts and clinical trials are showing promise for "BH3-mimics", drugs that mimic the ability of BH3-only proteins to neutralize selected pro-survival proteins to induce cell death in tumor cells. BH 3 127-130 BCL2 apoptosis regulator Homo sapiens 35-40 25641608-3 2015 2-Phenyl-1H-benzo[d]imidazole as a new scaffold for two-face Bim mimetics was developed; based on this, a series of Mcl-1/Bcl-2 dual inhibitors were obtained. 2-phenylbenzimidazole 0-29 BCL2 apoptosis regulator Homo sapiens 122-127 24965577-4 2015 Treatment with PGE2 activated anti-apoptotic proteins such as Bcl-2 and Bcl-xL while reducing pro-apoptotic proteins, thereby enhancing cell survival. Dinoprostone 15-19 BCL2 apoptosis regulator Homo sapiens 62-67 25435430-0 2015 MiR-16 targets Bcl-2 in paclitaxel-resistant lung cancer cells and overexpression of miR-16 along with miR-17 causes unprecedented sensitivity by simultaneously modulating autophagy and apoptosis. Paclitaxel 24-34 BCL2 apoptosis regulator Homo sapiens 15-20 25069567-7 2015 Consistently, cranberry procyanidins alleviated OxS-dependent mitochondrial dysfunctions as shown by the rise in ATP production and the up-regulation of Bcl-2, as well as the decline of protein expression of cytochrome c and apoptotic-inducing factor. Proanthocyanidins 24-36 BCL2 apoptosis regulator Homo sapiens 153-158 25498972-0 2015 Collateral sensitivity to cold stress and differential BCL-2 family expression in new daunomycin-resistant lymphoblastoid cell lines. Daunorubicin 86-96 BCL2 apoptosis regulator Homo sapiens 55-60 25393500-3 2015 Furthermore, the treatment of reconstructed embryos with TSA enhanced expression of the pluripotency-related gene POU5F1 and stimulated expression of the anti-apoptotic gene BCL-2. trichostatin A 57-60 BCL2 apoptosis regulator Homo sapiens 174-179 25435430-7 2015 We demonstrated that anti-apoptotic protein Bcl-2 was directly targeted miR-16 in paclitaxel resistant lung cancer cells. Paclitaxel 82-92 BCL2 apoptosis regulator Homo sapiens 44-49 25499851-3 2015 Therefore, we hypothesized that MnSOD-mediated NF-kappaB activation might confer cisplatin resistance in lung adenocarcinoma via the NF-kappaB/Bcl-2/Snail pathway. Cisplatin 81-90 BCL2 apoptosis regulator Homo sapiens 143-148 25433364-6 2015 Hydrogen peroxide (H2O2) and/or its derived or cooperating reactive oxygen species reduced the mitochondrial membrane potential, downregulated the expression of the antiapoptotic protein Bcl2, activated poly(ADP-ribose) polymerase-1, and released apoptosis-inducing factor from mitochondria with endoplasmic reticulum stress. Hydrogen Peroxide 0-17 BCL2 apoptosis regulator Homo sapiens 187-191 25433364-6 2015 Hydrogen peroxide (H2O2) and/or its derived or cooperating reactive oxygen species reduced the mitochondrial membrane potential, downregulated the expression of the antiapoptotic protein Bcl2, activated poly(ADP-ribose) polymerase-1, and released apoptosis-inducing factor from mitochondria with endoplasmic reticulum stress. Hydrogen Peroxide 19-23 BCL2 apoptosis regulator Homo sapiens 187-191 25433364-6 2015 Hydrogen peroxide (H2O2) and/or its derived or cooperating reactive oxygen species reduced the mitochondrial membrane potential, downregulated the expression of the antiapoptotic protein Bcl2, activated poly(ADP-ribose) polymerase-1, and released apoptosis-inducing factor from mitochondria with endoplasmic reticulum stress. Reactive Oxygen Species 59-82 BCL2 apoptosis regulator Homo sapiens 187-191 25499851-6 2015 Mechanistically, an increase in Bcl-2 by MnSOD-mediated NF-kappaB activation confers greater cisplatin resistance than cIAP2, Bcl-xL, Mcl-1, and Snail. Cisplatin 93-102 BCL2 apoptosis regulator Homo sapiens 32-37 25499851-7 2015 MnSOD-mediated cisplatin resistance can be overcome by a Bcl-2 antagonist (ABT-199) or IKKbeta inhibitor (curcumin) in cells and xenograft tumors. Cisplatin 15-24 BCL2 apoptosis regulator Homo sapiens 57-62 25499851-7 2015 MnSOD-mediated cisplatin resistance can be overcome by a Bcl-2 antagonist (ABT-199) or IKKbeta inhibitor (curcumin) in cells and xenograft tumors. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 75-78 BCL2 apoptosis regulator Homo sapiens 57-62 25499851-9 2015 A retrospective study indicated that it was more common for MnSOD-positive, nuclear p65-positive, or high Bcl-2 mRNA tumors to have an unfavorable response to cisplatin-based chemotherapy than their counterparts. Cisplatin 159-168 BCL2 apoptosis regulator Homo sapiens 106-111 25499851-10 2015 Therefore, we suggest that ABT-199 or curcumin may be potentially useful to improve tumor regression and chemotherapeutic response in patients with MnSOD/Bcl-2-positive tumors. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 27-30 BCL2 apoptosis regulator Homo sapiens 154-159 25499851-10 2015 Therefore, we suggest that ABT-199 or curcumin may be potentially useful to improve tumor regression and chemotherapeutic response in patients with MnSOD/Bcl-2-positive tumors. Curcumin 38-46 BCL2 apoptosis regulator Homo sapiens 154-159 25434456-8 2015 Subsequent studies confirmed the results of array and demonstrated that fluvastatin activated mitochondrial apoptosis through enhancing bax/bcl-2 ratio, releasing cytochrome c, in turn activating caspase-9 and caspase-3, and eventually cleaving PARP. Fluvastatin 72-83 BCL2 apoptosis regulator Homo sapiens 140-145 24895203-0 2015 Targeting CDK9 by wogonin and related natural flavones potentiates the anti-cancer efficacy of the Bcl-2 family inhibitor ABT-263. Flavones 46-54 BCL2 apoptosis regulator Homo sapiens 99-104 24895203-2 2015 ABT-263 (Navitoclax), an orally bio-available small-molecule mimetic of the Bcl-2 homology domain 3, inhibits Bcl-2, Bcl-x(L), and Bcl-w and has shown anti-cancer effects mainly on lymphomas and lymphocytic leukemia. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 76-81 24895203-2 2015 ABT-263 (Navitoclax), an orally bio-available small-molecule mimetic of the Bcl-2 homology domain 3, inhibits Bcl-2, Bcl-x(L), and Bcl-w and has shown anti-cancer effects mainly on lymphomas and lymphocytic leukemia. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 110-115 24895203-2 2015 ABT-263 (Navitoclax), an orally bio-available small-molecule mimetic of the Bcl-2 homology domain 3, inhibits Bcl-2, Bcl-x(L), and Bcl-w and has shown anti-cancer effects mainly on lymphomas and lymphocytic leukemia. navitoclax 9-19 BCL2 apoptosis regulator Homo sapiens 76-81 24895203-2 2015 ABT-263 (Navitoclax), an orally bio-available small-molecule mimetic of the Bcl-2 homology domain 3, inhibits Bcl-2, Bcl-x(L), and Bcl-w and has shown anti-cancer effects mainly on lymphomas and lymphocytic leukemia. navitoclax 9-19 BCL2 apoptosis regulator Homo sapiens 110-115 24895203-4 2015 ABT-199 specifically inhibits Bcl-2; however, its use is limited to tumors over-expressing only Bcl-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 30-35 24895203-4 2015 ABT-199 specifically inhibits Bcl-2; however, its use is limited to tumors over-expressing only Bcl-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 96-101 25434832-5 2015 HMGB1-triggered cell death is associated with intracellular ROS release, and overexpression of Bcl-2 blocks both the increase of ROS as well as HMGB1-dependent cell death. ros 129-132 BCL2 apoptosis regulator Homo sapiens 95-100 25599133-3 2015 IDH1- and IDH2-mutant primary human AML cells were more sensitive than IDH1/2 wild-type cells to ABT-199, a highly specific BCL-2 inhibitor that is currently in clinical trials for hematologic malignancies, both ex vivo and in xenotransplant models. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 97-100 BCL2 apoptosis regulator Homo sapiens 124-129 25743751-0 2015 Spiroquinazolinone-induced cytotoxicity and apoptosis in K562 human leukemia cells: alteration in expression levels of Bcl-2 and Bax. spiroquinazolinone 0-18 BCL2 apoptosis regulator Homo sapiens 119-124 25743751-7 2015 Furthermore, RT-PCR and Western blot analysis revealed that treatment of the K562 cells with 4t-QTC down-regulates and up-regulates the expression of Bcl-2 (anti-apoptotic) and Bax (pro-apoptotic), respectively. 4t-QTC 93-99 BCL2 apoptosis regulator Homo sapiens 150-155 25572805-7 2015 The possible TAMs-modulated drug resistance mechanism involved may be associated with elevation of bcl-2 gene expression and up-regulation of STAT3 signaling in tumor cells. tams 13-17 BCL2 apoptosis regulator Homo sapiens 99-104 25572805-8 2015 Furthermore, the blockage of TAMs-derived IL-10 by neutralizing antibody resulted in attenuation of STAT3 activation and decrease of bcl-2 mRNA expression, consequently enhanced sensitivity of breast cancer cells. tams 29-33 BCL2 apoptosis regulator Homo sapiens 133-138 25572805-9 2015 Our data suggested that TAMs might induce drug resistance through IL-10/STAT3/bcl-2 signaling pathway, providing possible new targets for breast tumor therapy. tams 24-28 BCL2 apoptosis regulator Homo sapiens 78-83 25752436-0 2015 Atrazine induces apoptosis of SH-SY5Y human neuroblastoma cells via the regulation of Bax/Bcl-2 ratio and caspase-3-dependent pathway. Atrazine 0-8 BCL2 apoptosis regulator Homo sapiens 90-95 25621054-6 2015 The effect of evodiamine on the protein expression levels of B-cell lymphoma-2 (Bcl-2), Bcl-2-associated X protein (Bax), caspase-3 and survivin were detected by performing western blot analysis. evodiamine 14-24 BCL2 apoptosis regulator Homo sapiens 61-78 25621054-6 2015 The effect of evodiamine on the protein expression levels of B-cell lymphoma-2 (Bcl-2), Bcl-2-associated X protein (Bax), caspase-3 and survivin were detected by performing western blot analysis. evodiamine 14-24 BCL2 apoptosis regulator Homo sapiens 80-85 25621054-8 2015 Western blotting demonstrated that evodiamine downregulated the expression of Bcl-2, caspase-3 and survivin, and upregulated the expression of Bax in human osteosarcoma cells. evodiamine 35-45 BCL2 apoptosis regulator Homo sapiens 78-83 25621054-9 2015 Evodiamine effectively inhibited proliferation and induced apoptosis of osteosarcoma cells in a dose-dependent manner via downregulation of Bcl-2, caspase-3 and survivin protein expression levels and upregulation of Bax protein expression levels. evodiamine 0-10 BCL2 apoptosis regulator Homo sapiens 140-145 25621065-5 2015 Ursolic acid efficiently induced apoptosis, possibly via the downregulation of B-cell lymphoma 2 (Bcl-2), the upregulation of Bcl-2-associated X protein and the proteolytic activation of caspase-3. ursolic acid 0-12 BCL2 apoptosis regulator Homo sapiens 79-96 25621065-5 2015 Ursolic acid efficiently induced apoptosis, possibly via the downregulation of B-cell lymphoma 2 (Bcl-2), the upregulation of Bcl-2-associated X protein and the proteolytic activation of caspase-3. ursolic acid 0-12 BCL2 apoptosis regulator Homo sapiens 98-103 25621065-5 2015 Ursolic acid efficiently induced apoptosis, possibly via the downregulation of B-cell lymphoma 2 (Bcl-2), the upregulation of Bcl-2-associated X protein and the proteolytic activation of caspase-3. ursolic acid 0-12 BCL2 apoptosis regulator Homo sapiens 126-131 25484022-0 2015 Lactate promotes resistance to glucose starvation via upregulation of Bcl-2 mediated by mTOR activation. Lactic Acid 0-7 BCL2 apoptosis regulator Homo sapiens 70-75 25484022-0 2015 Lactate promotes resistance to glucose starvation via upregulation of Bcl-2 mediated by mTOR activation. Glucose 31-38 BCL2 apoptosis regulator Homo sapiens 70-75 25484022-10 2015 In conclusion, this study showed that lactate rescues cancer cells from glucose starvation-induced cell death through regulation of the PI3K/Akt/mTOR/Bcl-2 signaling pathway. Lactic Acid 38-45 BCL2 apoptosis regulator Homo sapiens 150-155 25484022-10 2015 In conclusion, this study showed that lactate rescues cancer cells from glucose starvation-induced cell death through regulation of the PI3K/Akt/mTOR/Bcl-2 signaling pathway. Glucose 72-79 BCL2 apoptosis regulator Homo sapiens 150-155 25484022-11 2015 These data suggest that lactate is an important determinant of the sensitivity of tumors to glucose starvation, and reducing lactate or inhibiting the PI3K/Akt/mTOR/Bcl-2 signaling pathway may influence the response of cancers to glucose starvation. Lactic Acid 24-31 BCL2 apoptosis regulator Homo sapiens 165-170 25500692-8 2015 In addition, kaempferol treatment markedly decreased the level of Bcl-2 concomitant with an increase in Bax expression, resulting in the upregulation of cleaved caspase-3 and -9, which promoted PARP cleavage. kaempferol 13-23 BCL2 apoptosis regulator Homo sapiens 66-71 25277658-11 2015 Finally, we evaluated levels of Bcl-2, BAX, and Bad and found that an increase of Bcl-2 level was observed in GRP78KD cells treated with curcumin. Curcumin 137-145 BCL2 apoptosis regulator Homo sapiens 32-37 25301444-0 2015 Waltonitone induces apoptosis through mir-663-induced Bcl-2 downregulation in non-small cell lung cancer. 28-hydroxy-3-oxo-12-ursene 0-11 BCL2 apoptosis regulator Homo sapiens 54-59 25301444-7 2015 In addition, both waltonitone treatment and transfection of miR-663 mimic upregulated Bcl-2 mRNA and protein expression. 28-hydroxy-3-oxo-12-ursene 18-29 BCL2 apoptosis regulator Homo sapiens 86-91 25301444-8 2015 Bcl-2 transfection alleviated waltonitone-induced toxicity. 28-hydroxy-3-oxo-12-ursene 30-41 BCL2 apoptosis regulator Homo sapiens 0-5 25301444-10 2015 In summary, the present study demonstrated that waltonitone induced apoptosis of lung cancer cells through, at least partly, miR-663-induced Bcl-2 downregulation. 28-hydroxy-3-oxo-12-ursene 48-59 BCL2 apoptosis regulator Homo sapiens 141-146 25594541-3 2015 MicroRNAs (miRNAs) encoded by the miR-15 cluster are known to induce G1 arrest and apoptosis by targeting G1 checkpoints and the anti-apoptotic B cell lymphoma 2 (BCL-2) gene. mir-15 34-40 BCL2 apoptosis regulator Homo sapiens 144-161 25594541-3 2015 MicroRNAs (miRNAs) encoded by the miR-15 cluster are known to induce G1 arrest and apoptosis by targeting G1 checkpoints and the anti-apoptotic B cell lymphoma 2 (BCL-2) gene. mir-15 34-40 BCL2 apoptosis regulator Homo sapiens 163-168 25342596-6 2015 The Western blot analysis showed that the expression of Bcl-2 was noticeably decreased in response to britannin treatment, while the expression of Bax protein was increased, which were positively correlated with elevated expression of p53. britannin 102-111 BCL2 apoptosis regulator Homo sapiens 56-61 25277658-11 2015 Finally, we evaluated levels of Bcl-2, BAX, and Bad and found that an increase of Bcl-2 level was observed in GRP78KD cells treated with curcumin. Curcumin 137-145 BCL2 apoptosis regulator Homo sapiens 82-87 25687043-0 2015 [Relationship between BH3 mimetic S1 and expression of BCL-2 family members in acute myeloid leukemia]. BH 3 22-25 BCL2 apoptosis regulator Homo sapiens 55-60 25652864-2 2015 METHODS: The level of Bcl-2 in 68 HCC tissues was detected by reverse transcription PCR, SP immunohistochemistry and Western blotting. TFF2 protein, human 89-91 BCL2 apoptosis regulator Homo sapiens 22-27 25687043-12 2015 PD98059 suppressed BCL-2 phosphorylation. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 0-7 BCL2 apoptosis regulator Homo sapiens 19-24 25687043-13 2015 When PD98059 suppressed BCL-2 phosphorylation, the apoptotic rate of drug-resistant cells induced by S1 increased from 9.8% to 64.5% (combination index, CI = 0.4), accompanied by more dissociation of BCL-2 heterodimers. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 5-12 BCL2 apoptosis regulator Homo sapiens 24-29 25778893-9 2015 AZD8330 induced Raji cell apoptosis and upregulated expression of Bcl-2, Bcl-xl, VEFG and decreased the expression of caspase-3 in a dose and time dependent manner, and statistically significant differences were observed in groups of different time and concentration treatment (P<0.05). AZD8330 0-7 BCL2 apoptosis regulator Homo sapiens 66-71 25687043-13 2015 When PD98059 suppressed BCL-2 phosphorylation, the apoptotic rate of drug-resistant cells induced by S1 increased from 9.8% to 64.5% (combination index, CI = 0.4), accompanied by more dissociation of BCL-2 heterodimers. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 5-12 BCL2 apoptosis regulator Homo sapiens 200-205 25687043-14 2015 CONCLUSION: The combination of S1 with PD98059 decrease pBCL-2 level of AML patients and inhibits of the anti-apoptotic function of BCL-2 through enhancing the dissociation of BCL-2 heterodimers. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 39-46 BCL2 apoptosis regulator Homo sapiens 57-62 25687043-14 2015 CONCLUSION: The combination of S1 with PD98059 decrease pBCL-2 level of AML patients and inhibits of the anti-apoptotic function of BCL-2 through enhancing the dissociation of BCL-2 heterodimers. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 39-46 BCL2 apoptosis regulator Homo sapiens 132-137 25596735-0 2015 Carnosic acid sensitized TRAIL-mediated apoptosis through down-regulation of c-FLIP and Bcl-2 expression at the post translational levels and CHOP-dependent up-regulation of DR5, Bim, and PUMA expression in human carcinoma caki cells. salvin 0-13 BCL2 apoptosis regulator Homo sapiens 88-93 25596735-4 2015 Carnosic acid induced down-regulation of c-FLIP and Bcl-2 expression at the post-translational levels, and the over-expression of c-FLIP and Bcl-2 markedly blocked carnosic acid-induced TRAIL sensitization. salvin 164-177 BCL2 apoptosis regulator Homo sapiens 141-146 25596735-5 2015 Furthermore, carnosic acid induced death receptor (DR)5, Bcl-2 interacting mediator of cell death (Bim), and p53 up-regulated modulator of apoptosis (PUMA) expression at the transcriptional levels via CCAAT/enhancer-binding protein-homologous protein (CHOP). salvin 13-26 BCL2 apoptosis regulator Homo sapiens 57-62 25596735-4 2015 Carnosic acid induced down-regulation of c-FLIP and Bcl-2 expression at the post-translational levels, and the over-expression of c-FLIP and Bcl-2 markedly blocked carnosic acid-induced TRAIL sensitization. salvin 0-13 BCL2 apoptosis regulator Homo sapiens 52-57 25596735-7 2015 Taken together, our study demonstrates that carnosic acid enhances sensitization against TRAIL-mediated apoptosis through the down-regulation of c-FLIP and Bcl-2 expression, and up-regulation of ER stress-mediated DR5, Bim, and PUMA expression at the transcriptional levels. salvin 44-57 BCL2 apoptosis regulator Homo sapiens 156-161 25973303-4 2015 Additionally, we demonstrated that bortezomib promoted the disruption of the Bcl-2/Beclin-1 complex and increased the formation of the Beclin-1/PI3KC3 complex, leading to the initiation of autophagy. Bortezomib 35-45 BCL2 apoptosis regulator Homo sapiens 77-82 25537793-6 2015 Furthermore, pleuroton B (2) could trigger the apoptosis of DU-145 cells through the detection of apoptosis cells using annexin V-FITC staining by flow cytometry, the observation of condensed nuclei in the apoptosis cells, and the western blot analysis for the expression of apoptosis-related proteins Bcl-2, Bak, and Bax. Pleuroton B 13-24 BCL2 apoptosis regulator Homo sapiens 302-307 25608854-5 2015 In addition, DPT caused cyclin B1, Cdc2 and Cdc25C to accumulate, decreased the expression of Bcl-2 and activated caspase-3 and PARP, suggesting that caspase-mediated pathways were involved in DPT-induced apoptosis. deoxypodophyllotoxin 13-16 BCL2 apoptosis regulator Homo sapiens 94-99 25590800-1 2015 The anti-apoptotic protein MCL-1 is a key regulator of cancer cell survival and a known resistance factor for small-molecule BCL-2 family inhibitors such as ABT-263 (navitoclax), making it an attractive therapeutic target. navitoclax 157-164 BCL2 apoptosis regulator Homo sapiens 125-130 25590800-1 2015 The anti-apoptotic protein MCL-1 is a key regulator of cancer cell survival and a known resistance factor for small-molecule BCL-2 family inhibitors such as ABT-263 (navitoclax), making it an attractive therapeutic target. navitoclax 166-176 BCL2 apoptosis regulator Homo sapiens 125-130 25590803-0 2015 MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 61-64 BCL2 apoptosis regulator Homo sapiens 45-50 25729938-5 2015 The microscopy results showed that HeLa cells were severely distorted and showed slow growth; some cells became round in shape when treated with 5 mg/mL BBE for 24 h. The DNA ladder results revealed excessive DNA fragmentation in HeLa cells treated with 7 mg/mL BBE for 36 h. The proapoptotic activity of the BBE was attributed to its ability to modulate the expression of Bcl-2 and Bax genes. CHEMBL145735 153-156 BCL2 apoptosis regulator Homo sapiens 373-378 25785018-4 2015 Sophoridine also triggered significant down-regulated the expression of p27, CDK2, Survivin, Livin, Bcl-2, E2F1 and the transcriptional activity of FoxM1, NF-kappab and AP-1, meanwhile, up-regulated the expression of caspase-3/8, p53, Smac, c-JNK and p38-MAPK. matrine 0-11 BCL2 apoptosis regulator Homo sapiens 100-105 25729938-5 2015 The microscopy results showed that HeLa cells were severely distorted and showed slow growth; some cells became round in shape when treated with 5 mg/mL BBE for 24 h. The DNA ladder results revealed excessive DNA fragmentation in HeLa cells treated with 7 mg/mL BBE for 36 h. The proapoptotic activity of the BBE was attributed to its ability to modulate the expression of Bcl-2 and Bax genes. CHEMBL145735 262-265 BCL2 apoptosis regulator Homo sapiens 373-378 25729938-5 2015 The microscopy results showed that HeLa cells were severely distorted and showed slow growth; some cells became round in shape when treated with 5 mg/mL BBE for 24 h. The DNA ladder results revealed excessive DNA fragmentation in HeLa cells treated with 7 mg/mL BBE for 36 h. The proapoptotic activity of the BBE was attributed to its ability to modulate the expression of Bcl-2 and Bax genes. CHEMBL145735 262-265 BCL2 apoptosis regulator Homo sapiens 373-378 25729938-6 2015 The mRNA and protein expression levels of Bax were remarkably higher whereas those of Bcl-2 were lower than those in the control cells; this led to an increased Bax/Bcl-2 ratio in cells treated with the BBE for 36 h. The results suggest that the BBE might play an important role in tumor growth suppression by inducing apoptosis in human cervical cancer cells via the regulation of the Bcl-2- and Bax-mediated apoptotic pathways. CHEMBL145735 203-206 BCL2 apoptosis regulator Homo sapiens 86-91 25729938-6 2015 The mRNA and protein expression levels of Bax were remarkably higher whereas those of Bcl-2 were lower than those in the control cells; this led to an increased Bax/Bcl-2 ratio in cells treated with the BBE for 36 h. The results suggest that the BBE might play an important role in tumor growth suppression by inducing apoptosis in human cervical cancer cells via the regulation of the Bcl-2- and Bax-mediated apoptotic pathways. CHEMBL145735 203-206 BCL2 apoptosis regulator Homo sapiens 165-170 25729938-6 2015 The mRNA and protein expression levels of Bax were remarkably higher whereas those of Bcl-2 were lower than those in the control cells; this led to an increased Bax/Bcl-2 ratio in cells treated with the BBE for 36 h. The results suggest that the BBE might play an important role in tumor growth suppression by inducing apoptosis in human cervical cancer cells via the regulation of the Bcl-2- and Bax-mediated apoptotic pathways. CHEMBL145735 203-206 BCL2 apoptosis regulator Homo sapiens 165-170 25446857-7 2015 Immunoblots showed that the reduction of the Bcl-2/Bax ratio, the induction of caspase 3 cleavage, and the induction of poly(ADP-ribose) polymerase (PARP) cleavage by 6-OHDA was reversed in the presence of SB203580 (a p38 inhibitor) or SP600125 (a JNK inhibitor) in SH-SY5Y cells. Oxidopamine 167-173 BCL2 apoptosis regulator Homo sapiens 45-50 25588213-5 2015 Western blot analysis was used to detect the active form of caspase-3 as well as Bax and B-cell lymphoma-2 (Bcl-2) expressions after cells were treated with different concentrations of ponicidin. ponicidin 185-194 BCL2 apoptosis regulator Homo sapiens 89-106 25588213-5 2015 Western blot analysis was used to detect the active form of caspase-3 as well as Bax and B-cell lymphoma-2 (Bcl-2) expressions after cells were treated with different concentrations of ponicidin. ponicidin 185-194 BCL2 apoptosis regulator Homo sapiens 108-113 25446852-3 2015 DHTMF significantly suppressed growth and induced apoptosis in lung carcinoma cells in a dose-dependent manner, as indicated by a decrease in Bcl-2 levels and increases in Bax and cleaved caspase-3 levels. dhtmf 0-5 BCL2 apoptosis regulator Homo sapiens 142-147 24993472-12 2015 CONCLUSIONS: As2O3 could restore the expression of TMS1 by inhibiting DNMT to reverse the hypermethylation and induced apoptosis of K562 cells by downregulation of Bcl-2/Bax expression. Arsenic Trioxide 13-18 BCL2 apoptosis regulator Homo sapiens 164-169 26119958-8 2015 6-Shogaol induced apoptosis, mainly through the mitochondrial pathway, and the bcl-2 family might act as a key regulator. shogaol 0-9 BCL2 apoptosis regulator Homo sapiens 79-84 25649747-4 2015 The phosphorylation of Bcl-2, and PI3K-III, LC3-II and Beclin-1 protein levels in J5 cells were increased after alpha-PA treatment (p < 0.05). alpha phellandrene 112-120 BCL2 apoptosis regulator Homo sapiens 23-28 26119952-9 2015 Western blot analysis revealed that butein down-regulated the anti-apoptotic proteins Bcl-2 and Bcl-xL and increased the pro-apoptotic proteins Bax and Bad. butein 36-42 BCL2 apoptosis regulator Homo sapiens 86-91 25280462-7 2015 Gln also increased mRNA levels for Bcl-2, mTOR, p70S6 kinase, 4E-BP1, COX7C, ASCT2, ODC, SGLT-1, CFTR, Na(+)/K(+)-ATPase, HSP70, and ZO-1. Glutamine 0-3 BCL2 apoptosis regulator Homo sapiens 35-40 25318106-1 2015 In silico analysis predicts interaction between Na-K-ATPase (NKA) and Bcl-2 protein canonical BH3- and BH1-like motifs, consistent with NKA inhibition by the benzo-phenanthridine alkaloid chelerythrine, a BH3 mimetic, in fetal human lens epithelial cells (FHLCs) (Lauf PK, Heiny J, Meller J, Lepera MA, Koikov L, Alter GM, Brown TL, Adragna NC. BH 3 94-97 BCL2 apoptosis regulator Homo sapiens 70-75 25318106-1 2015 In silico analysis predicts interaction between Na-K-ATPase (NKA) and Bcl-2 protein canonical BH3- and BH1-like motifs, consistent with NKA inhibition by the benzo-phenanthridine alkaloid chelerythrine, a BH3 mimetic, in fetal human lens epithelial cells (FHLCs) (Lauf PK, Heiny J, Meller J, Lepera MA, Koikov L, Alter GM, Brown TL, Adragna NC. bh1 103-106 BCL2 apoptosis regulator Homo sapiens 70-75 25318106-1 2015 In silico analysis predicts interaction between Na-K-ATPase (NKA) and Bcl-2 protein canonical BH3- and BH1-like motifs, consistent with NKA inhibition by the benzo-phenanthridine alkaloid chelerythrine, a BH3 mimetic, in fetal human lens epithelial cells (FHLCs) (Lauf PK, Heiny J, Meller J, Lepera MA, Koikov L, Alter GM, Brown TL, Adragna NC. Benzophenanthridines 158-178 BCL2 apoptosis regulator Homo sapiens 70-75 25318106-1 2015 In silico analysis predicts interaction between Na-K-ATPase (NKA) and Bcl-2 protein canonical BH3- and BH1-like motifs, consistent with NKA inhibition by the benzo-phenanthridine alkaloid chelerythrine, a BH3 mimetic, in fetal human lens epithelial cells (FHLCs) (Lauf PK, Heiny J, Meller J, Lepera MA, Koikov L, Alter GM, Brown TL, Adragna NC. chelerythrine 188-201 BCL2 apoptosis regulator Homo sapiens 70-75 25318106-1 2015 In silico analysis predicts interaction between Na-K-ATPase (NKA) and Bcl-2 protein canonical BH3- and BH1-like motifs, consistent with NKA inhibition by the benzo-phenanthridine alkaloid chelerythrine, a BH3 mimetic, in fetal human lens epithelial cells (FHLCs) (Lauf PK, Heiny J, Meller J, Lepera MA, Koikov L, Alter GM, Brown TL, Adragna NC. BH 3 205-208 BCL2 apoptosis regulator Homo sapiens 70-75 26503559-5 2015 The induction of apoptosis by UA was associated with a decrease in the levels of Bcl-2, Bcl-xl, survivin, and activated caspase-3. ursolic acid 30-32 BCL2 apoptosis regulator Homo sapiens 81-86 25398539-7 2015 Caspase-dependent renal cell apoptosis was induced through attenuation of Bcl-2 and enhanced caspase-3 and caspase-9 expression by MSU crystals, which was significantly reversed by ascorbic acid and transfection of IL-1beta siRNA to HEK293 cells. Ascorbic Acid 181-194 BCL2 apoptosis regulator Homo sapiens 74-79 25832828-7 2015 Rasagiline changed biomarkers over 12 months, such that the mitochondrial membrane potential increased (JC-1 red/green fluorescent ratio 1.92, p = 0.0001) and apoptosis markers decreased (Bcl-2/Bax ratio 0.24, p < 0.0001). rasagiline 0-10 BCL2 apoptosis regulator Homo sapiens 188-193 25612679-4 2015 The testosterone (TE) aromatization in estradiol (E2) was indirectly evaluated in terms of inhibition of TE-induced cell proliferation, ERalpha phosphorylation/activation and Bcl-2 and IGF-1R ERE-regulated protein accumulation. Estradiol 39-48 BCL2 apoptosis regulator Homo sapiens 175-180 25612679-7 2015 Moreover, CTet inhibited Bcl-2 and IGF-1R accumulation induced by TE but not that which was induced by E2. ctet 10-14 BCL2 apoptosis regulator Homo sapiens 25-30 25344893-10 2015 These data suggest that a reduction in the prosurvival Bcl-2 family member Mcl-1 due to increased proteasomal degradation is correlated with the ability of DCA to reduce proliferation of HCT116 human colorectal cancer cells without causing apoptosis. Dichloroacetic Acid 156-159 BCL2 apoptosis regulator Homo sapiens 55-60 25980816-7 2015 ROS generated by estrogens affect pro-proliferative (e.g. cyclin D1, Cdc2), prosurvival (e.g. AKT), antiapoptotic (e.g. BCl2) and pro-inflammatory (e.g. NF-kappaB) molecules. Reactive Oxygen Species 0-3 BCL2 apoptosis regulator Homo sapiens 120-124 25991546-9 2015 The expression levels of Bax and caspase-3 were increased significantly, whereas Bcl-2 was down-regulated after TSA treatment. trichostatin A 112-115 BCL2 apoptosis regulator Homo sapiens 81-86 26625764-8 2015 Furthermore, expression of LMW-Es sensitized cells to beta-estradiol (E2) mediated growth and changed expression patterns of estrogen receptor and Bcl-2. 2-(4-Amino-N-ethylanilino)ethanol 27-30 BCL2 apoptosis regulator Homo sapiens 147-152 25550551-7 2015 At the same time, S-petasin and iso-S-petasin increased mitochondrial membrane permeability and cytochrome c release from mitochondria to the cytosol via reducing the ratio of BCL2/BAX in DU145 and PC3 cells, and up-regulating the levels of p53 in DU145 cells but down-regulating it in PC3 cells. petasin 18-27 BCL2 apoptosis regulator Homo sapiens 176-180 25550551-7 2015 At the same time, S-petasin and iso-S-petasin increased mitochondrial membrane permeability and cytochrome c release from mitochondria to the cytosol via reducing the ratio of BCL2/BAX in DU145 and PC3 cells, and up-regulating the levels of p53 in DU145 cells but down-regulating it in PC3 cells. iso-s-petasin 32-45 BCL2 apoptosis regulator Homo sapiens 176-180 26107205-5 2015 Then expression of Bcl-2 and vascular endothelial growth factor (VEGF) was analyzed by SABC immunohistochemistry. sabc 87-91 BCL2 apoptosis regulator Homo sapiens 19-24 26107205-7 2015 High-dose triptolide showed a similar tumor-inhibitory effect as cisplatin (-50%); high-dose triptolide significantly inhibited Bcl-2 and VEGF expression in the xenograft model compared to normal saline control (P<0.05). triptolide 93-103 BCL2 apoptosis regulator Homo sapiens 128-133 25803782-0 2015 PAWR-mediated suppression of BCL2 promotes switching of 3-azido withaferin A (3-AWA)-induced autophagy to apoptosis in prostate cancer cells. 3-azidowithaferin A 56-76 BCL2 apoptosis regulator Homo sapiens 29-33 25715028-0 2015 BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 33-36 BCL2 apoptosis regulator Homo sapiens 69-73 25715028-1 2015 Disruption of the complex of BECN1 with BCL2 or BCL2L1/BCL-XL is an essential switch that turns on cellular autophagy in response to environmental stress or treatment with BH3 peptidomimetics. BH 3 172-175 BCL2 apoptosis regulator Homo sapiens 40-44 25715028-4 2015 We conclude that the BH3 mimetic ABT-737 induces autophagy through a BAX and BAK1-independent mechanism that likely involves disruption of BECN1 binding to antiapoptotic BCL2 family members. BH 3 21-24 BCL2 apoptosis regulator Homo sapiens 170-174 26514477-12 2015 CONCLUSIONS: Metformin was able to induce apoptosis in primary ovarian cancer cells by modulating the expression of Bcl-2 family proteins. Metformin 13-22 BCL2 apoptosis regulator Homo sapiens 116-121 25715028-4 2015 We conclude that the BH3 mimetic ABT-737 induces autophagy through a BAX and BAK1-independent mechanism that likely involves disruption of BECN1 binding to antiapoptotic BCL2 family members. ABT-737 33-40 BCL2 apoptosis regulator Homo sapiens 170-174 25803782-0 2015 PAWR-mediated suppression of BCL2 promotes switching of 3-azido withaferin A (3-AWA)-induced autophagy to apoptosis in prostate cancer cells. 3-azidowithaferin A 78-83 BCL2 apoptosis regulator Homo sapiens 29-33 25803782-6 2015 Second, higher toxic concentrations of 3-AWA stimulated ER stress in CaP cells to turn on apoptosis within 12 h by elevating the expression of the proapoptotic protein PAWR, which in turn suppressed the autophagy-related proteins BCL2 and BECN1. 3-azidowithaferin A 39-44 BCL2 apoptosis regulator Homo sapiens 230-234 26424010-0 2015 SPATA4 Counteracts Etoposide-Induced Apoptosis via Modulating Bcl-2 Family Proteins in HeLa Cells. Etoposide 19-28 BCL2 apoptosis regulator Homo sapiens 62-67 25446991-0 2015 Threonine 56 phosphorylation of Bcl-2 is required for LRRK2 G2019S-induced mitochondrial depolarization and autophagy. Threonine 0-9 BCL2 apoptosis regulator Homo sapiens 32-37 25446991-3 2015 Here, we demonstrated that LRRK2 G2019S bound to and phosphorylated Bcl-2, a mitochondrial anti-apoptotic protein, at Threonine 56. Threonine 118-127 BCL2 apoptosis regulator Homo sapiens 68-73 24930392-11 2015 Supranutritional dose of selenite when combined with imatinib induced apoptotic machinery by decreasing Bcl-2 expression, increasing caspase-3 activity and subsequently fragmenting DNA and blunted cytoprotective autophagy by decreasing Beclin-1 expression and autophagosomes formation. Selenious Acid 25-33 BCL2 apoptosis regulator Homo sapiens 104-109 24930392-11 2015 Supranutritional dose of selenite when combined with imatinib induced apoptotic machinery by decreasing Bcl-2 expression, increasing caspase-3 activity and subsequently fragmenting DNA and blunted cytoprotective autophagy by decreasing Beclin-1 expression and autophagosomes formation. Imatinib Mesylate 53-61 BCL2 apoptosis regulator Homo sapiens 104-109 26366416-6 2015 Our study found that cisplatin induced apoptosis of Hela cell through inhibiting expression of Bcl-2, upregulating the expression of Bax, Fas-L, and the enzyme activity of caspase-3 (p < 0.05); LPA significantly provided protection against the apoptosis induced by cisplatin by inhibiting the above alterations in apoptotic factor caused by cisplatin (p < 0.05). Cisplatin 21-30 BCL2 apoptosis regulator Homo sapiens 95-100 26405930-11 2015 Oxymatrine can induce apoptosis of the A549 cells by regulating the expression of Bcl-2 and Bax. oxymatrine 0-10 BCL2 apoptosis regulator Homo sapiens 82-87 25947916-8 2015 Levels of the antiapoptotic protein Bcl-2 in luteolin-treated MCF-7 cells were significantly higher than those in doxorubicin-treated MCF-7 cells. Doxorubicin 114-125 BCL2 apoptosis regulator Homo sapiens 36-41 25947916-9 2015 Our results suggest that a low concentration of luteolin attenuates doxorubicin-induced cytotoxicity to MCF-7 cells through a combination of antioxidant activity and an increase in levels of Bcl-2 protein. Doxorubicin 68-79 BCL2 apoptosis regulator Homo sapiens 191-196 26090392-6 2015 Furthermore, the expression levels of downstream genes (c-FOS, BCL-2, and CYCLIN D1) were increased by 17beta-estradiol and this effect was independently associated with activity of the EGFR-MAPK pathway. Estradiol 103-119 BCL2 apoptosis regulator Homo sapiens 63-68 25517601-9 2015 We also unravel the contribution of anti-apoptotic Bcl-2 family molecules in curcumin response. Curcumin 77-85 BCL2 apoptosis regulator Homo sapiens 51-56 25921655-5 2015 Salidroside induced the intracellular mRNA expression, protein expression, and enzymatic activities of catalase and Mn-SOD and increased the ratio of Bcl2/Bax. rhodioloside 0-11 BCL2 apoptosis regulator Homo sapiens 150-154 25921655-6 2015 Our results demonstrated that salidroside protected retinal endothelial cells against oxidative injury through increasing the Bcl2/Bax signaling pathway and activation of endogenous antioxidant enzymes. rhodioloside 30-41 BCL2 apoptosis regulator Homo sapiens 126-130 25482928-7 2015 We found that cotreatment with cucurbitacin-I significantly increased Bcl(-)2/Bcl(-)xL family member antagonist ABT-737-induced cell death regardless of EGFR/PTEN/p53 status of malignant human glioma cell lines. cucurbitacin I 31-45 BCL2 apoptosis regulator Homo sapiens 70-77 25411358-7 2015 Removal of TPA from the growth medium resulted in the rapid induction of BCL2, increasing the ratio of anti-: pro-apoptotic proteins, together with overexpression of Cyclin A/CDK2 proteins. terephthalic acid 11-14 BCL2 apoptosis regulator Homo sapiens 73-77 25482928-7 2015 We found that cotreatment with cucurbitacin-I significantly increased Bcl(-)2/Bcl(-)xL family member antagonist ABT-737-induced cell death regardless of EGFR/PTEN/p53 status of malignant human glioma cell lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 112-115 BCL2 apoptosis regulator Homo sapiens 70-77 26176330-6 2015 This may be explained by the observation that the depletion of ARF1 suppressed gefitinib-mediated activation of key mediators of survival such as ERK1/2, AKT and Src, while enhancing cascades leading to apoptosis such as the p38MAPK and JNK pathways, modifying the Bax/Bcl2 ratio and cytochrome c release. Gefitinib 79-88 BCL2 apoptosis regulator Homo sapiens 269-273 25756510-4 2015 We found that NB cell lines derived to resist the Bcl(-)2/-xl/-w antagonist, ABT-737, acquire a dependence on Mcl(-)1 and show increased expression and activation of the RTK, EGFR. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 77-80 BCL2 apoptosis regulator Homo sapiens 50-57 25756510-6 2015 Inhibition of EGFR by shRNA or erlotinib in Mcl(-)1 dependent NBs disrupts Bim binding to Mcl(-)1 and enhances its affinity for Bcl(-)2, restoring sensitivity to ABT-737 as well as cytotoxics in vitro. Erlotinib Hydrochloride 31-40 BCL2 apoptosis regulator Homo sapiens 128-135 25756510-7 2015 Mechanistically treatment of NBs with small molecule inhibitors of EGFR (erlotinib, cetuximab) and ERK (U0126) increases Noxa expression and dephosphorylates Bim to promote Bim binding to Bcl(-)2. Erlotinib Hydrochloride 73-82 BCL2 apoptosis regulator Homo sapiens 188-195 25756510-7 2015 Mechanistically treatment of NBs with small molecule inhibitors of EGFR (erlotinib, cetuximab) and ERK (U0126) increases Noxa expression and dephosphorylates Bim to promote Bim binding to Bcl(-)2. U 0126 104-109 BCL2 apoptosis regulator Homo sapiens 188-195 26381132-0 2015 Formononetin induces apoptosis of human osteosarcoma cell line U2OS by regulating the expression of Bcl-2, Bax and MiR-375 in vitro and in vivo. formononetin 0-12 BCL2 apoptosis regulator Homo sapiens 100-105 26381132-3 2015 This study investigates formononetin induction of apoptosis of human osteosarcoma cell line U2OS by regulating Bcl-2 and Bax expression in vitro and in vivo. formononetin 24-36 BCL2 apoptosis regulator Homo sapiens 111-116 26513239-11 2015 Overexpression of miR-429 inhibited Bcl-2-mediated cell survival against apoptosis induced by Fluorouracil, while depletion of miR-429 augmented it. Fluorouracil 94-106 BCL2 apoptosis regulator Homo sapiens 36-41 26381132-9 2015 Moreover, compared to control group the expression of Bcl-2 and miR-375 decreases with formononetin in the U2OS cells, while Bax increases. formononetin 87-99 BCL2 apoptosis regulator Homo sapiens 54-59 26645893-6 2015 Moreover, MAPK pathways (p38, JNK and ERK) were activated by melatonin treatment, which also significantly increased caspase-3 cleavage and Bax protein expression and decreased Bcl-2 protein expression in a time-dependent manner. Melatonin 61-70 BCL2 apoptosis regulator Homo sapiens 177-182 26584290-9 2015 Furthermore, sitagliptin regulated cell autophagy by Bcl-2/ Beclin 1 pathway in H/SD condition. Sitagliptin Phosphate 13-24 BCL2 apoptosis regulator Homo sapiens 53-58 25791820-0 2015 Synergistic anticancer potential of dichloroacetate and estradiol analogue exerting their effect via ROS-JNK-Bcl-2-mediated signalling pathways. Dichloroacetic Acid 36-51 BCL2 apoptosis regulator Homo sapiens 109-114 26645893-8 2015 Finally, melatonin was able to strengthen cisplatin-mediated antitumour effects in human gastric carcinoma cells by up-regulating the expression of Bax, down-regulating the expression of Bcl-2 and activating the caspase-dependent apoptotic pathway. Melatonin 9-18 BCL2 apoptosis regulator Homo sapiens 187-192 26645893-8 2015 Finally, melatonin was able to strengthen cisplatin-mediated antitumour effects in human gastric carcinoma cells by up-regulating the expression of Bax, down-regulating the expression of Bcl-2 and activating the caspase-dependent apoptotic pathway. Cisplatin 42-51 BCL2 apoptosis regulator Homo sapiens 187-192 25791820-0 2015 Synergistic anticancer potential of dichloroacetate and estradiol analogue exerting their effect via ROS-JNK-Bcl-2-mediated signalling pathways. Estradiol 56-65 BCL2 apoptosis regulator Homo sapiens 109-114 25791820-0 2015 Synergistic anticancer potential of dichloroacetate and estradiol analogue exerting their effect via ROS-JNK-Bcl-2-mediated signalling pathways. ros 101-104 BCL2 apoptosis regulator Homo sapiens 109-114 25833196-5 2015 Furthermore, CB-PIC sensitized resistant cancer cells to adriamycin via downregulation of survival proteins such as survivin, Bcl-xL and Bcl-2, along with MDR1 suppression leading to accumulation of drug in the intracellular region. cb-pic 13-19 BCL2 apoptosis regulator Homo sapiens 137-142 25871324-8 2015 In addition, the compound triggered generation of Reactive Oxygen Species (ROS), caused depolarization of the mitochondrial inner membrane, decreased the level of cellular ATP, modulated the expression and phosphorylation of Bcl-2 leading to loss of its association with Bax and increased the release of cytochrome c to the cytosol of treated cells. Reactive Oxygen Species 75-78 BCL2 apoptosis regulator Homo sapiens 225-230 25791820-7 2015 The occurrence of apoptosis was associated with increased hypo- and hyper-phosphorylation of Bcl-2 Ser(70) and caspase 7 activation. Serine 99-102 BCL2 apoptosis regulator Homo sapiens 93-98 25791820-8 2015 Kinase inhibition revealed sustained activation of the JNK pathway caused increased Bcl-2 protein Ser(70) hypo-and hyper-phosphorylation. Serine 98-101 BCL2 apoptosis regulator Homo sapiens 84-89 25791820-12 2015 Antimitotic compound C9 in combination with a glycolytic inhibitor dichloroacetate eradicates breast cancer cells through ROS-JNK-Bcl-2-mediated signalling pathways in vitro and it is argued that autophagy acts as protective mechanism in the treated cells before apoptosis occurs. Dichloroacetic Acid 67-82 BCL2 apoptosis regulator Homo sapiens 130-135 25791820-12 2015 Antimitotic compound C9 in combination with a glycolytic inhibitor dichloroacetate eradicates breast cancer cells through ROS-JNK-Bcl-2-mediated signalling pathways in vitro and it is argued that autophagy acts as protective mechanism in the treated cells before apoptosis occurs. ros 122-125 BCL2 apoptosis regulator Homo sapiens 130-135 26843836-2 2015 There are several docetaxel resistance mechanisms in prostate cancer: unfavorable tumor microenvironment, drug efflux pump, alterations in microtubule structure and/or function, and apoptotic defects (e.g. up regulation of Bcl-2 and clusterin or activation of the PTEN/PI3K/mTOR pathway or activation of the MAPK/ERK pathway). Docetaxel 18-27 BCL2 apoptosis regulator Homo sapiens 223-228 26477352-3 2015 Its association with the EWS-FLI1 fusion product, as well as the finding that its suppression can be synthetic lethal with the BCL-2 family inhibitor ABT-737 indicates a potential role in tumor maintenance. ABT-737 150-157 BCL2 apoptosis regulator Homo sapiens 127-132 26125273-9 2015 The ratio of bax to Bcl-2 mRNA in the combination treatment group was higher than that in the carboplatin-treated group. Carboplatin 94-105 BCL2 apoptosis regulator Homo sapiens 20-25 25714700-12 2015 Mechanisms data showed that overexpression of miR-153 down regulated the activity of luciferase reporters, p15-Luc and p21-Luc; and enhanced the protein level of pro-survival or anti-apoptosis proteins Survivin and BCL-2. mir-153 46-53 BCL2 apoptosis regulator Homo sapiens 215-220 25348020-9 2015 Moreover, our results demonstrated that the mechanism of TXNL1 regulating cisplatin-induced apoptosis was closely associated with Bcl-2 mediated mitochondria apoptosis pathway. Cisplatin 74-83 BCL2 apoptosis regulator Homo sapiens 130-135 25528413-3 2015 In this study we sought to investigate the effect of Pb and Se on the endogenous expression of APP, Abeta40 and Bcl-2 family proteins. Lead 53-55 BCL2 apoptosis regulator Homo sapiens 112-117 25528413-3 2015 In this study we sought to investigate the effect of Pb and Se on the endogenous expression of APP, Abeta40 and Bcl-2 family proteins. Selenium 60-62 BCL2 apoptosis regulator Homo sapiens 112-117 26125273-10 2015 Finally, phosphorylation of Bcl-2 protein was increased stronger in the combination treatment group compared with the carboplatin-treated group. Carboplatin 118-129 BCL2 apoptosis regulator Homo sapiens 28-33 26125273-13 2015 Moreover, 2-ME promoted the mRNA and protein expression of Bax, thereby, increasing the Bax/Bcl-2 expression ratio and activating the mitochondrial apoptosis pathway. 2-Methoxyestradiol 10-14 BCL2 apoptosis regulator Homo sapiens 92-97 25148824-4 2015 Analysis of the mechanism of these events indicated that [10]-gingerol-treated cells exhibited an increased ratio of Bax/Bcl-2, resulting in the activation of caspase-9, caspase-3, and poly-ADP-ribose polymerase in a dose-dependent manner, which are hallmarks of apoptosis. gingerol 62-70 BCL2 apoptosis regulator Homo sapiens 121-126 26089933-10 2015 Consistent with results in vitro, YSC-ZDC increased Bax expression and inhibited Bcl-2 expression in tumor tissue. ysc-zdc 34-41 BCL2 apoptosis regulator Homo sapiens 81-86 25125501-0 2015 Telmisartan induces apoptosis and regulates Bcl-2 in human renal cancer cells. Telmisartan 0-11 BCL2 apoptosis regulator Homo sapiens 44-49 25125501-13 2015 Taken together, these results suggest that telmisartan induces apoptosis via down-regulation of Bcl-2 and involvement of caspase-3 in human RCC cells. Telmisartan 43-54 BCL2 apoptosis regulator Homo sapiens 96-101 25972907-9 2015 Within the PG2 signature, there were five genes associated with doxorubicin: IL-8, MDM4, BCL2, PRODH2, and BIRC5. Doxorubicin 64-75 BCL2 apoptosis regulator Homo sapiens 89-93 26260683-5 2015 A peptide tool (BIRD-2) that targets the BH4 domain of Bcl-2 reverses Bcl-2"s inhibitory action on IP3Rs and can trigger pro-apoptotic Ca(2+)signals in B-cell cancer cells. sapropterin 41-44 BCL2 apoptosis regulator Homo sapiens 55-60 25755693-0 2015 Wogonoside induces cell cycle arrest and mitochondrial mediated apoptosis by modulation of Bcl-2 and Bax in osteosarcoma cancer cells. wogonoside 0-10 BCL2 apoptosis regulator Homo sapiens 91-96 25755693-11 2015 Wogonoside led to reduced Bcl-2 expression and increased Bax expression, while as it led to s decrease in the levels of mitochondrial cytochrome c and an increase in cytosolic fraction and expressions of cytosolic apoptotic protease activating factor-1 (Apaf-1). wogonoside 0-10 BCL2 apoptosis regulator Homo sapiens 26-31 26260683-5 2015 A peptide tool (BIRD-2) that targets the BH4 domain of Bcl-2 reverses Bcl-2"s inhibitory action on IP3Rs and can trigger pro-apoptotic Ca(2+)signals in B-cell cancer cells. sapropterin 41-44 BCL2 apoptosis regulator Homo sapiens 70-75 26064977-4 2015 In the present study we demonstrate that the FFA palmitate blocks the ubiquitin-proteasome system (UPS) and causes apoptosis through induction of ER stress and deregulation of Bcl-2 proteins. Fatty Acids, Nonesterified 45-48 BCL2 apoptosis regulator Homo sapiens 176-181 25310526-7 2015 p53 and Bax were upregulated and Bcl2 was downregulated in the EB1-depleted PTX-treated MCF-7 cells, indicating that the apoptosis occurs via a p53-dependent pathway. Paclitaxel 76-79 BCL2 apoptosis regulator Homo sapiens 33-37 25892545-0 2015 The flavonoid morin from Moraceae induces apoptosis by modulation of Bcl-2 family members and Fas receptor in HCT 116 cells. Flavonoids 4-13 BCL2 apoptosis regulator Homo sapiens 69-74 24903407-0 2015 Complex disruption effect of natural polyphenols on Bcl-2-Bax: molecular dynamics simulation and essential dynamics study. Polyphenols 37-48 BCL2 apoptosis regulator Homo sapiens 52-57 24903407-4 2015 Quercetin and taxifolin (natural polyphenols) efficiently bound to hydrophobic groove of Bcl-2 and altered the structure by inducing conformational changes. Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 89-94 24903407-4 2015 Quercetin and taxifolin (natural polyphenols) efficiently bound to hydrophobic groove of Bcl-2 and altered the structure by inducing conformational changes. taxifolin 14-23 BCL2 apoptosis regulator Homo sapiens 89-94 24903407-4 2015 Quercetin and taxifolin (natural polyphenols) efficiently bound to hydrophobic groove of Bcl-2 and altered the structure by inducing conformational changes. Polyphenols 33-44 BCL2 apoptosis regulator Homo sapiens 89-94 24903407-6 2015 Taxifolin and quercetin were found to dissociate the Bcl-2-Bax complex during 12 ns MD simulation. taxifolin 0-9 BCL2 apoptosis regulator Homo sapiens 53-58 24903407-6 2015 Taxifolin and quercetin were found to dissociate the Bcl-2-Bax complex during 12 ns MD simulation. Quercetin 14-23 BCL2 apoptosis regulator Homo sapiens 53-58 24903407-7 2015 The effect of taxifolin and quercetin was, further validated by the MD simulation of ligand-unbound Bcl-2-Bax which showed stability during the simulation. taxifolin 14-23 BCL2 apoptosis regulator Homo sapiens 100-105 24903407-7 2015 The effect of taxifolin and quercetin was, further validated by the MD simulation of ligand-unbound Bcl-2-Bax which showed stability during the simulation. Quercetin 28-37 BCL2 apoptosis regulator Homo sapiens 100-105 24903407-8 2015 Obatoclax (an inhibitor of Bcl-2) had no significant dissociation effect on Bcl-2-Bax during simulation which favored the previous experimental results and disruption effect of taxifolin and quercetin. obatoclax 0-9 BCL2 apoptosis regulator Homo sapiens 27-32 25370579-5 2015 The EGCG-induced apoptosis of HCCLM6 cells was associated with a significant decrease in Bcl-2 and NF-kappaB expression. epigallocatechin gallate 4-8 BCL2 apoptosis regulator Homo sapiens 89-94 25355727-6 2015 Moreover, the expression of the anti-apoptotic protein Bcl-2 was decreased, while the expression of the pro-apoptotic protein Bax was elevated, after ferruginol treatment in both lung cancer cell lines. ferruginol 150-160 BCL2 apoptosis regulator Homo sapiens 55-60 24578216-6 2015 Compared with the control group, manganese deficiency significantly decreased the proliferative zone width and Bcl-2 mRNA expression level, while significantly increased the apoptotic rates and the expression level of p21 gene in chondrocytes. Manganese 33-42 BCL2 apoptosis regulator Homo sapiens 111-116 26064977-4 2015 In the present study we demonstrate that the FFA palmitate blocks the ubiquitin-proteasome system (UPS) and causes apoptosis through induction of ER stress and deregulation of Bcl-2 proteins. Palmitates 49-58 BCL2 apoptosis regulator Homo sapiens 176-181 26064977-5 2015 We found that palmitate and the proteasome inhibitor MG132 induced ER stress in beta-cells, resulting in decreased expression of the prosurvival proteins Bcl-2, Mcl-1, and Bcl-XL, and upregulation of the prodeath BH3-only protein PUMA. Palmitates 14-23 BCL2 apoptosis regulator Homo sapiens 154-159 26064977-5 2015 We found that palmitate and the proteasome inhibitor MG132 induced ER stress in beta-cells, resulting in decreased expression of the prosurvival proteins Bcl-2, Mcl-1, and Bcl-XL, and upregulation of the prodeath BH3-only protein PUMA. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 53-58 BCL2 apoptosis regulator Homo sapiens 154-159 26064977-6 2015 On the other hand, pharmacological activation of the UPS by sulforaphane ameliorated ER stress, upregulated prosurvival Bcl-2 proteins, and protected beta-cells from FFA-induced cell death. sulforaphane 60-72 BCL2 apoptosis regulator Homo sapiens 120-125 25464291-7 2015 Firstly, reactive oxygen species (ROS) is generated induced by MnO@SiO2 NPs, then p53 is activated followed by an increase in the bax and a decrease in the bcl-2, ultimately leading to G2/M phase arrest, increasing the activity of caspase-3 and inducing apoptosis. Reactive Oxygen Species 9-32 BCL2 apoptosis regulator Homo sapiens 156-161 25464291-7 2015 Firstly, reactive oxygen species (ROS) is generated induced by MnO@SiO2 NPs, then p53 is activated followed by an increase in the bax and a decrease in the bcl-2, ultimately leading to G2/M phase arrest, increasing the activity of caspase-3 and inducing apoptosis. Reactive Oxygen Species 34-37 BCL2 apoptosis regulator Homo sapiens 156-161 25510413-6 2015 In parallel, the interaction between the level of BCL2, BAX and PTEN with the specific PI3K/AKT inhibitor-LY294002 was highly significant for BCL2 and nearly significant for PTEN and BAX. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 106-114 BCL2 apoptosis regulator Homo sapiens 50-54 25173233-10 2015 EGCG also induced apoptosis, downregulation of p-Akt and Bcl-2, and cleaving PARP in a dose-dependent manner. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 57-62 25510413-6 2015 In parallel, the interaction between the level of BCL2, BAX and PTEN with the specific PI3K/AKT inhibitor-LY294002 was highly significant for BCL2 and nearly significant for PTEN and BAX. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 106-114 BCL2 apoptosis regulator Homo sapiens 142-146 26357513-8 2015 Bax/Bcl-2 expression ratio and expression of p53 were significantly lower in cells cocultured with alpha-mangostin and MPP(+). mangostin 99-114 BCL2 apoptosis regulator Homo sapiens 4-9 24679006-6 2015 Our findings indicate a significant difference between these two types of DHL at a molecular level with pathogenetic implications, as arguably, TP53 mutations inhibiting p53 mediated promotion of apoptosis pose a synergistic advantage in clonal evolution of cells with malignantly enforced overexpression of BCL2. Cysteamine 74-77 BCL2 apoptosis regulator Homo sapiens 308-312 26688757-3 2015 In metformin-sensitive cells, autophagy was not induced but rather it blocked proliferation by means of arresting cells in the S and G2/M phases which was associated with the downregulation of cyclin A, cyclin B1, and cdc2, but not that of cyclin E. In 10E1-CEM cells that overexpress Bcl-2 and are drug-resistant, the effect of metformin on proliferation was more pronounced, also inducing the activation of the caspases 3/7 and hence apoptosis. Metformin 3-12 BCL2 apoptosis regulator Homo sapiens 285-290 25797560-0 2015 A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. BH 3 23-26 BCL2 apoptosis regulator Homo sapiens 35-39 25797560-0 2015 A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. navitoclax 50-60 BCL2 apoptosis regulator Homo sapiens 35-39 25797560-0 2015 A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. navitoclax 62-69 BCL2 apoptosis regulator Homo sapiens 35-39 25262359-9 2015 Curcumin stimulated the expression of pro-apoptotic Bax, and inhibited the activation of anti-apoptotic Mcl-1 and Bcl-2. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 114-119 25429836-11 2015 Our data suggest that prodigiosin-induced apoptosis may ascribe to Bcl-2 and survivin inhibition in HT-29 cells and these genes may provide promising molecular targets of prodigiosin. Prodigiosin 22-33 BCL2 apoptosis regulator Homo sapiens 67-72 25452172-12 2015 Treatment with EGCG resulted in decrease in Bcl-2 but increase in Bax and activated caspase-3 and caspase-7. epigallocatechin gallate 15-19 BCL2 apoptosis regulator Homo sapiens 44-49 25339540-6 2015 In addition, treatment of K562/ADR cells with quercetin alone or in combination with ADR resulted in loss of mitochondrial membrane potential, activation of caspase-8, -9 and -3, reduced expression of the anti-apoptotic proteins B-cell lymphoma (Bcl)-2 and Bcl-extra large and enhanced expression of the pro-apoptotic proteins Bcl-2-interacting mediator of cell death, Bcl-2-associated death promoter and Bcl-2-associated X protein in the cells. Quercetin 46-55 BCL2 apoptosis regulator Homo sapiens 229-252 25333250-6 2015 Certain changes in apoptotic protein expression were detected following exposure to AMP, including X-linked inhibitor of apoptosis protein release, reduced B-cell lymphoma 2, myeloid cell leukemia 1 and survivin expression levels, increased Bcl-2-associated X protein expression levels and cleaved-poly ADP ribose polymerase expression. ampelopsin 84-87 BCL2 apoptosis regulator Homo sapiens 241-246 25339540-6 2015 In addition, treatment of K562/ADR cells with quercetin alone or in combination with ADR resulted in loss of mitochondrial membrane potential, activation of caspase-8, -9 and -3, reduced expression of the anti-apoptotic proteins B-cell lymphoma (Bcl)-2 and Bcl-extra large and enhanced expression of the pro-apoptotic proteins Bcl-2-interacting mediator of cell death, Bcl-2-associated death promoter and Bcl-2-associated X protein in the cells. Quercetin 46-55 BCL2 apoptosis regulator Homo sapiens 327-332 25348361-9 2015 In conclusion, DNA-PKcs suppression had complementary effects in combination with CDDP and 5-Fu treatment in HepG2 cells, which was associated with suppression of NF-kappaB signaling pathway cascade, activation of caspase-3 and p53, as well as down-regulation of Bcl-2 and GSH. Cisplatin 82-86 BCL2 apoptosis regulator Homo sapiens 263-268 25339540-6 2015 In addition, treatment of K562/ADR cells with quercetin alone or in combination with ADR resulted in loss of mitochondrial membrane potential, activation of caspase-8, -9 and -3, reduced expression of the anti-apoptotic proteins B-cell lymphoma (Bcl)-2 and Bcl-extra large and enhanced expression of the pro-apoptotic proteins Bcl-2-interacting mediator of cell death, Bcl-2-associated death promoter and Bcl-2-associated X protein in the cells. Quercetin 46-55 BCL2 apoptosis regulator Homo sapiens 369-374 25348361-9 2015 In conclusion, DNA-PKcs suppression had complementary effects in combination with CDDP and 5-Fu treatment in HepG2 cells, which was associated with suppression of NF-kappaB signaling pathway cascade, activation of caspase-3 and p53, as well as down-regulation of Bcl-2 and GSH. Fluorouracil 91-95 BCL2 apoptosis regulator Homo sapiens 263-268 25563364-0 2015 Changes in gene expression of CXCR4, CCR7 and BCL2 after treatment of breast cancer cells with saponin extract from Tribulus terrestris. Saponins 95-102 BCL2 apoptosis regulator Homo sapiens 46-50 25771977-6 2015 Gene expression profiles revealed increased S100P and BAX and decreased BCL2 expression in RT4 cells following AITC treatment. allyl isothiocyanate 111-115 BCL2 apoptosis regulator Homo sapiens 72-76 25355159-11 2015 Further, EA promoted the expression of Bax, caspase-3, and cytochrome c, and suppression of Bcl-2 activity in HCT-15 cells that was determined by western blot analysis. Ellagic Acid 9-11 BCL2 apoptosis regulator Homo sapiens 92-97 25563364-7 2015 While CXCR4 expression was reduced in both cell lines, CCR7 and BCL2 levels decreased only in tumorigenic MCF7 cells, implying cell-specificity of the saponin action. Saponins 151-158 BCL2 apoptosis regulator Homo sapiens 64-68 25394466-7 2015 Flow cytometry assay further confirmed a pro-apoptotic effect of oxamate, and this was likely through increased expression of Bax, activated caspase-3, and decreased expression of Bcl-2. Oxamic Acid 65-72 BCL2 apoptosis regulator Homo sapiens 180-185 25567982-4 2015 Here we found that expression of Bcl2 results in decreased HR activity and retards the repair of DSBs induced by HZE particles (i.e. (56)iron and (28)silicon) by inhibiting Mre11 complex activity. dsbs 97-101 BCL2 apoptosis regulator Homo sapiens 33-37 25567982-4 2015 Here we found that expression of Bcl2 results in decreased HR activity and retards the repair of DSBs induced by HZE particles (i.e. (56)iron and (28)silicon) by inhibiting Mre11 complex activity. Iron 137-141 BCL2 apoptosis regulator Homo sapiens 33-37 25567982-4 2015 Here we found that expression of Bcl2 results in decreased HR activity and retards the repair of DSBs induced by HZE particles (i.e. (56)iron and (28)silicon) by inhibiting Mre11 complex activity. Silicon 150-157 BCL2 apoptosis regulator Homo sapiens 33-37 25567982-5 2015 Exposure of cells to (56)iron or (28)silicon promotes Bcl2 to interact with Mre11 via the BH1 and BH4 domains. Iron 25-29 BCL2 apoptosis regulator Homo sapiens 54-58 25567982-5 2015 Exposure of cells to (56)iron or (28)silicon promotes Bcl2 to interact with Mre11 via the BH1 and BH4 domains. Silicon 37-44 BCL2 apoptosis regulator Homo sapiens 54-58 25567982-5 2015 Exposure of cells to (56)iron or (28)silicon promotes Bcl2 to interact with Mre11 via the BH1 and BH4 domains. sapropterin 98-101 BCL2 apoptosis regulator Homo sapiens 54-58 25481090-7 2015 In addition, the protein levels of p-AKT, p-ERK, Bcl-2, matrix metallopeptidase 9 (MMP-9) and fibronectin (FN) were significantly reduced following quercetin treatment. Quercetin 148-157 BCL2 apoptosis regulator Homo sapiens 49-54 25514492-5 2015 Apoptosis analysis showed that quercetin at 50 or 100 mumol/L induced apoptosis of KB/VCR cells by suppressing expression of Bax and inducing the expression of Caspase-3 and Bcl-2. Quercetin 31-40 BCL2 apoptosis regulator Homo sapiens 174-179 25435973-3 2015 An increased number of apoptotic cells, decreased ratio of B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein and increased caspase-3 expression was also observed following treatment with BDMC, indicating that BDMC may promote apoptosis in tumors via mitochondrial modulation. bisdemethoxycurcumin 190-194 BCL2 apoptosis regulator Homo sapiens 59-76 25435973-3 2015 An increased number of apoptotic cells, decreased ratio of B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein and increased caspase-3 expression was also observed following treatment with BDMC, indicating that BDMC may promote apoptosis in tumors via mitochondrial modulation. bisdemethoxycurcumin 190-194 BCL2 apoptosis regulator Homo sapiens 78-83 26044821-0 2015 Idebenone Prevents Oxidative Stress, Cell Death and Senescence of Retinal Pigment Epithelium Cells by Stabilizing BAX/Bcl-2 Ratio. idebenone 0-9 BCL2 apoptosis regulator Homo sapiens 118-123 25435973-3 2015 An increased number of apoptotic cells, decreased ratio of B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein and increased caspase-3 expression was also observed following treatment with BDMC, indicating that BDMC may promote apoptosis in tumors via mitochondrial modulation. bisdemethoxycurcumin 190-194 BCL2 apoptosis regulator Homo sapiens 85-90 25435973-3 2015 An increased number of apoptotic cells, decreased ratio of B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein and increased caspase-3 expression was also observed following treatment with BDMC, indicating that BDMC may promote apoptosis in tumors via mitochondrial modulation. bisdemethoxycurcumin 212-216 BCL2 apoptosis regulator Homo sapiens 78-83 25435973-3 2015 An increased number of apoptotic cells, decreased ratio of B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein and increased caspase-3 expression was also observed following treatment with BDMC, indicating that BDMC may promote apoptosis in tumors via mitochondrial modulation. bisdemethoxycurcumin 212-216 BCL2 apoptosis regulator Homo sapiens 85-90 25722793-0 2015 Glutathione suppresses cerebral infarct volume and cell death after ischemic injury: involvement of FOXO3 inactivation and Bcl2 expression. Glutathione 0-11 BCL2 apoptosis regulator Homo sapiens 123-127 26044821-9 2015 The reduction of proapoptotic BAX and the elevation of antiapoptotic Bcl-2 under idebenone show that this process is rather mediated by inhibiting H2O2-induced apoptosis, not necrosis. idebenone 81-90 BCL2 apoptosis regulator Homo sapiens 69-74 26044821-9 2015 The reduction of proapoptotic BAX and the elevation of antiapoptotic Bcl-2 under idebenone show that this process is rather mediated by inhibiting H2O2-induced apoptosis, not necrosis. Hydrogen Peroxide 147-151 BCL2 apoptosis regulator Homo sapiens 69-74 26044821-10 2015 CONCLUSION: In this study, idebenone increased survival of ARPE-19 cells and reduced cell death, senescence, and oxidative stress by stabilizing the BAX/Bcl-2 ratio. idebenone 27-36 BCL2 apoptosis regulator Homo sapiens 153-158 26080563-4 2015 The ratio of Bcl-2/Bax was elevated in SH-SY5Y with notoginsenoside R1 treatment. notoginsenoside 52-67 BCL2 apoptosis regulator Homo sapiens 13-18 25838866-6 2015 RESULTS: Upregulation of cleaved-caspases 3 and 9 and BAX and downregulation of Bcl-2, p-mTOR, and E-cadherin were found following H2O2 treatment, and all of these were reversed by Dex. Hydrogen Peroxide 131-135 BCL2 apoptosis regulator Homo sapiens 80-85 26090071-6 2015 Ceramides may initiate a cascade of biochemical alterations, which ultimately leads to neuronal death by diverse mechanisms, including depolarization and permeabilization of mitochondria, increased production of reactive oxygen species (ROS), cytochrome c release, Bcl-2 depletion, and caspase-3 activation, mainly by modulating intracellular signalling, particularly along the pathways related to Akt/PKB kinase and mitogen-activated protein kinases (MAPKs). Ceramides 0-9 BCL2 apoptosis regulator Homo sapiens 265-270 25289524-8 2015 Parthenolide-treated cells showed up-regulation of p53, Bax, caspase-3, -6, and -3 genes and down-regulation of Bcl-2 gene (p <= 0.008). parthenolide 0-12 BCL2 apoptosis regulator Homo sapiens 112-117 24955606-3 2015 In this study, we show that carmustine dose-dependently induced depolarization of mitochondrial inner transmembrane potential (DeltaPsim), up-regulation of Bax, down-regulation of Bcl-2 and caspase-3 activation. Carmustine 28-38 BCL2 apoptosis regulator Homo sapiens 180-185 26824820-7 2015 The DHL group showed a correlation between the rearrangement of the BCL2+/MYC+ genes and the expression of MYC and BCL2 proteins in 5 out of 6 patients. Cysteamine 4-7 BCL2 apoptosis regulator Homo sapiens 68-72 26824820-7 2015 The DHL group showed a correlation between the rearrangement of the BCL2+/MYC+ genes and the expression of MYC and BCL2 proteins in 5 out of 6 patients. Cysteamine 4-7 BCL2 apoptosis regulator Homo sapiens 115-119 25510742-8 2015 RESULTS: Anthocyanin treatment of DU-145 cells resulted in 1) significant increase in apoptosis in a dose-dependent manner, 2) significant decrease in p53 and Bcl-2 expressions (with increased Bax expression), and 3) significant decrease in PSA and AR expressions. du 34-36 BCL2 apoptosis regulator Homo sapiens 159-164 25301449-8 2014 Moreover, SKLB316 could induce cancer cell apoptosis, which was associated with activation of caspase 9, downregulation of Bcl-2 and upregulation of Bax. sklb316 10-17 BCL2 apoptosis regulator Homo sapiens 123-128 25304383-1 2014 ABT-737 is a novel anti-apoptotic Bcl-2 family protein inhibitor with high affinity to Bcl-2, Bcl-xl and Bcl-w but relatively low affinity to Mcl-1/A1. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 34-39 25179905-5 2014 Following 2-MeO-E2 treatment, only HCT116 (p53(+/+)) cells exhibited an enhancement in the levels of p53, p-p53 (Ser-15), p21(WAF1/CIP1), and Bax; however, the Bak level remained relatively constant in both cell types, and the Bcl-2 level decreased only in HCT116 (p53(+/+)) cells. 2-meo 10-15 BCL2 apoptosis regulator Homo sapiens 227-232 25179905-8 2014 These results show that among 2-MeO-E2-induced apoptotic events, including prometaphase arrest, up-regulation of Bax level, down-regulation of Bcl-2 level, activation of both Bak and Bax, and mitochondria-dependent caspase activation, the modulation of Bax and Bcl-2 levels is the target of the pro-apoptotic action of p53. 2-Methoxyestradiol 30-38 BCL2 apoptosis regulator Homo sapiens 143-148 25179905-8 2014 These results show that among 2-MeO-E2-induced apoptotic events, including prometaphase arrest, up-regulation of Bax level, down-regulation of Bcl-2 level, activation of both Bak and Bax, and mitochondria-dependent caspase activation, the modulation of Bax and Bcl-2 levels is the target of the pro-apoptotic action of p53. 2-Methoxyestradiol 30-38 BCL2 apoptosis regulator Homo sapiens 261-266 25304383-1 2014 ABT-737 is a novel anti-apoptotic Bcl-2 family protein inhibitor with high affinity to Bcl-2, Bcl-xl and Bcl-w but relatively low affinity to Mcl-1/A1. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 87-92 25314294-3 2014 Site-directed mutagenesis and fluorescence spectroscopic analyses revealed that the BCL2 homology region of MCL1 (MCL1DeltaNDeltaC) inhibits permeabilization of MOM-like membranes exclusively via canonical BH3-into-groove interactions with both cBID-like activators and BAX-like effectors. BH 3 206-209 BCL2 apoptosis regulator Homo sapiens 84-88 25565814-0 2015 Ferroferric oxide nanoparticles induce prosurvival autophagy in human blood cells by modulating the Beclin 1/Bcl-2/VPS34 complex. Ferrosoferric Oxide 0-17 BCL2 apoptosis regulator Homo sapiens 109-114 25565814-5 2015 Mechanistically, Fe3O4 NP-induced autophagy was accompanied by increased Beclin 1 and VPS34 and decreased Bcl-2, thus promoting the formation of the critical complex in autophagy initiation. ferryl iron 17-22 BCL2 apoptosis regulator Homo sapiens 106-111 25565814-7 2015 Therefore, this study suggested that Fe3O4 NPs can induce prosurvival autophagy in blood cells by modulating the Beclin l/Bcl-2/VPS34 complex. ferryl iron 37-42 BCL2 apoptosis regulator Homo sapiens 122-127 25536335-8 2014 Furthermore, high expression of a pro-apoptotic Bcl-2 member, BimEL, in the follicles was found to be associated with a low serum testosterone level. Testosterone 130-142 BCL2 apoptosis regulator Homo sapiens 48-53 25211642-0 2014 Direct binding of Bcl-2 family proteins by quercetin triggers its pro-apoptotic activity. Quercetin 43-52 BCL2 apoptosis regulator Homo sapiens 18-23 25211642-4 2014 It may be concluded that, quercetin binds directly to the BH3 domain of Bcl-2 and Bcl-xL proteins, thereby inhibiting their activity and promoting cancer cell apoptosis. Quercetin 26-35 BCL2 apoptosis regulator Homo sapiens 72-77 25314294-3 2014 Site-directed mutagenesis and fluorescence spectroscopic analyses revealed that the BCL2 homology region of MCL1 (MCL1DeltaNDeltaC) inhibits permeabilization of MOM-like membranes exclusively via canonical BH3-into-groove interactions with both cBID-like activators and BAX-like effectors. cbid 245-249 BCL2 apoptosis regulator Homo sapiens 84-88 25526081-7 2014 However, supplementation of dietary sodium selenite at the concentration of 0.4 mg/kg Se may ameliorate AFB1-induced apoptosis by increasing Bcl-2 mRNA expression, and decreasing Bax and Caspase-3 mRNA expression. Sodium Selenite 36-51 BCL2 apoptosis regulator Homo sapiens 141-146 25517116-3 2014 Mathematical simulations combined with biochemical experimentation of beta-AR signalling pathways show that the gradual increment of isoproterenol (a non-selective beta1/beta2-AR agonist) induces the switching response of Bcl-2 expression from the initial increase followed by a decrease below its basal level. Isoproterenol 133-146 BCL2 apoptosis regulator Homo sapiens 222-227 25526081-6 2014 In conclusion, 0.3 mg/kg AFB1 in the diet can increase cell apoptosis, decrease Bcl-2 mRNA expression, and increase of Bax and Caspase-3 mRNA expression in broiler"s jejunum. Aflatoxin B1 25-29 BCL2 apoptosis regulator Homo sapiens 80-85 25506932-7 2014 EVO induced cell cycle arrest at G2/M phase, induced apoptosis by up-regulating the expression of caspase-12 and cytochrome C protein, and induced the expression of Bax mRNA and by down-regulating of the expression of Bcl-2 mRNA in both H446 and H1688 cells. evodiamine 0-3 BCL2 apoptosis regulator Homo sapiens 218-223 25301704-0 2014 ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 31-36 25516654-6 2014 RESULTS: Lobaplatin inhibited the proliferation of human gastric cancer cells and induced apoptosis, which may be associated with the up-regulation of Bax expression, poly(ADP-ribose) polymerase (PARP) cleavage, p53 expression and the reduction of Bcl-2 expression. lobaplatin 9-19 BCL2 apoptosis regulator Homo sapiens 248-253 25301704-3 2014 Here, we evaluated B-cell lymphoma (BCL)-2 inhibition by the BH3 mimetic ABT-199 as a new therapeutic strategy in human T-ALL. BH 3 61-64 BCL2 apoptosis regulator Homo sapiens 19-42 25301704-3 2014 Here, we evaluated B-cell lymphoma (BCL)-2 inhibition by the BH3 mimetic ABT-199 as a new therapeutic strategy in human T-ALL. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 73-76 BCL2 apoptosis regulator Homo sapiens 19-42 25301704-8 2014 In conclusion, our study highlights BCL-2 as an attractive molecular target in specific subtypes of human T-ALL that could be exploited by ABT-199. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 139-142 BCL2 apoptosis regulator Homo sapiens 36-41 25431245-0 2014 Propofol inhibits proliferation and induces neuroapoptosis of hippocampal neurons in vitro via downregulation of NF-kappaB p65 and Bcl-2 and upregulation of caspase-3. Propofol 0-8 BCL2 apoptosis regulator Homo sapiens 131-136 26579413-5 2014 The combination also decreased the MMP, down-regulated Bcl-2 and pro-proteins of the caspase family, and up-regulated Bax and BID, all of which were reversed by the p53 inhibitor, pifithrin-alpha. pifithrin 180-189 BCL2 apoptosis regulator Homo sapiens 55-60 25200837-9 2014 Moreover, the compound Thiotanib could inhibit phosphorylation of Akt and mTOR, increase beclin-1 and Vps34, and block the formation of the Bcl-2 and Beclin-1 complex. Thiotanib 23-32 BCL2 apoptosis regulator Homo sapiens 140-145 25240837-10 2014 The early ceramide generation by nSMase was indispensable for the later lipid accumulation, modulation of Bax, Bcl-2 and caspase 3 levels, and for reduction of cell viability in curcumin-treated cells, as all these events were inhibited by GW4869 or nSMase2 depletion. Ceramides 10-18 BCL2 apoptosis regulator Homo sapiens 111-116 25240837-10 2014 The early ceramide generation by nSMase was indispensable for the later lipid accumulation, modulation of Bax, Bcl-2 and caspase 3 levels, and for reduction of cell viability in curcumin-treated cells, as all these events were inhibited by GW4869 or nSMase2 depletion. Curcumin 178-186 BCL2 apoptosis regulator Homo sapiens 111-116 25216733-9 2014 In a dose-dependent manner copper also provoked transcriptional changes of genes involved in intracellular signaling and induction of apoptosis (p53, c-fos, Bcl-2 and Bax). Copper 27-33 BCL2 apoptosis regulator Homo sapiens 157-162 25464339-5 2014 p,p"-DDT treatment elevated the level of reactive oxygen species (ROS) generation, induced mitochondrial membrane potential, and released cytochrome c into the cytosol, with subsequent elevations of Bax and p53, along with suppression of Bcl-2. p,p"-ddt 0-8 BCL2 apoptosis regulator Homo sapiens 238-243 25300800-0 2014 Effect of PKCalpha expression on Bcl-2 phosphorylation and cell death by hypericin. hypericin 73-82 BCL2 apoptosis regulator Homo sapiens 33-38 25293876-3 2014 Quercetin caused pronounced apoptosis in P39 leukemia cells, followed by Bcl-2, Bcl-xL, Mcl-1 downregulation, Bax upregulation, and mitochondrial translocation, triggering cytochrome c release and caspases activation. Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 73-78 25034785-4 2014 Whereas chemotherapeutic agents were scarcely effective against LCSC, the small molecule Bcl-2/Bcl-XL inhibitor ABT-737, but not the selective Bcl-2 inhibitor ABT-199, induced LCSC death at nanomolar concentrations. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 112-115 BCL2 apoptosis regulator Homo sapiens 89-94 25431245-5 2014 Moreover, propofol treatment decreased the nuclear factor kappaB (NF-kappaB) p65 expression, which was accompanied by a reduction in B-cell lymphoma 2 (Bcl-2) mRNA and protein levels, increased caspase-3 mRNA and activation of caspase-3 protein. Propofol 10-18 BCL2 apoptosis regulator Homo sapiens 133-150 25431245-5 2014 Moreover, propofol treatment decreased the nuclear factor kappaB (NF-kappaB) p65 expression, which was accompanied by a reduction in B-cell lymphoma 2 (Bcl-2) mRNA and protein levels, increased caspase-3 mRNA and activation of caspase-3 protein. Propofol 10-18 BCL2 apoptosis regulator Homo sapiens 152-157 25431245-6 2014 These results indicated that downregulation of NF-kappaB p65 and Bcl-2 were involved in the potential mechanisms of propofol-induced neurotoxicity. Propofol 116-124 BCL2 apoptosis regulator Homo sapiens 65-70 25433549-6 2014 RESULTS: We found that BDMC-A can induce apoptosis in Hep-2 cells by regulating the expression of both intrinsic and extrinsic apoptotic proteins, i.e., Bcl-2, Bax, apoptososme complex and death receptors, more efficiently than curcumin. bdmc-a 23-29 BCL2 apoptosis regulator Homo sapiens 153-158 25231749-0 2014 Gossypol induces apoptosis in multiple myeloma cells by inhibition of interleukin-6 signaling and Bcl-2/Mcl-1 pathway. Gossypol 0-8 BCL2 apoptosis regulator Homo sapiens 98-103 25451915-6 2014 RESULTS: Compared with treatment with HG 72h, pretreatment with HNG for 3h significantly increased cell viability (P<0.001), reduced nuclear fluorescence of HUVECs (P<0.05), the levels of cleaved PARP (P<0.05), ROS formation (P<0.05) and the ratio of bax/bcl-2 (P<0.05) compared with treatment with HG for 72h. Tritium 72-74 BCL2 apoptosis regulator Homo sapiens 267-272 25461359-5 2014 Increased gammaH2AX expression was observed in the pBSO and STICs compared with the controls whereas expression patterns of Ki67, p53 and bcl2 were low to moderate in the pBSO group. pbso 171-175 BCL2 apoptosis regulator Homo sapiens 138-142 25674209-6 2014 Meanwhile, the apoptosis-related proteins cleaved caspase-3, bax and bcl-2 were also changed following treatment with formononetin. formononetin 118-130 BCL2 apoptosis regulator Homo sapiens 69-74 25231749-4 2014 Recent studies have shown that Gos is an inhibitor for Bcl-2 or Bcl-XL acting as BH3 mimetics that interfere interaction between pro-apoptotic BH3-only proteins and Bcl-2/Bcl-XL. Gossypol 31-34 BCL2 apoptosis regulator Homo sapiens 55-60 25281403-6 2014 Targeting GCS by siRNA also enhanced ceramide accumulation, which is involved in GCS knockdown-induced inhibition of ERK activation and Bcl-2 expression levels. Ceramides 37-45 BCL2 apoptosis regulator Homo sapiens 136-141 25231749-4 2014 Recent studies have shown that Gos is an inhibitor for Bcl-2 or Bcl-XL acting as BH3 mimetics that interfere interaction between pro-apoptotic BH3-only proteins and Bcl-2/Bcl-XL. Gossypol 31-34 BCL2 apoptosis regulator Homo sapiens 165-170 25231749-4 2014 Recent studies have shown that Gos is an inhibitor for Bcl-2 or Bcl-XL acting as BH3 mimetics that interfere interaction between pro-apoptotic BH3-only proteins and Bcl-2/Bcl-XL. BH 3 81-84 BCL2 apoptosis regulator Homo sapiens 55-60 25231749-4 2014 Recent studies have shown that Gos is an inhibitor for Bcl-2 or Bcl-XL acting as BH3 mimetics that interfere interaction between pro-apoptotic BH3-only proteins and Bcl-2/Bcl-XL. BH 3 81-84 BCL2 apoptosis regulator Homo sapiens 165-170 25231749-8 2014 Further investigation revealed that phosphorylation of Bcl-2 at serine-70 was attenuated by Gos treatment, while protein levels were not affected. Serine 64-70 BCL2 apoptosis regulator Homo sapiens 55-60 25231749-8 2014 Further investigation revealed that phosphorylation of Bcl-2 at serine-70 was attenuated by Gos treatment, while protein levels were not affected. Gossypol 92-95 BCL2 apoptosis regulator Homo sapiens 55-60 25231749-11 2014 Moreover, JAK2 inhibition mimicked the effect of Gos in OPM2 cells including Bcl-2 dephosphorylation and Mcl-1 downregulation. Gossypol 49-52 BCL2 apoptosis regulator Homo sapiens 77-82 25231749-12 2014 These results demonstrated that Gos induces apoptosis in MM cells not only through displacing BH3-only proteins from Bcl-2, but also through inhibiting IL-6 signaling, which leads to Bcl-2 dephosphorylation and Mcl-1 downregulation. Gossypol 32-35 BCL2 apoptosis regulator Homo sapiens 117-122 25231749-12 2014 These results demonstrated that Gos induces apoptosis in MM cells not only through displacing BH3-only proteins from Bcl-2, but also through inhibiting IL-6 signaling, which leads to Bcl-2 dephosphorylation and Mcl-1 downregulation. Gossypol 32-35 BCL2 apoptosis regulator Homo sapiens 183-188 25047139-0 2014 Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer. navitoclax 71-81 BCL2 apoptosis regulator Homo sapiens 113-118 25005788-1 2014 PURPOSE: The aim of this retrospective study was to investigate the effect of B cell lymphoma 2 (BCL-2) expression on disease-free survival (DFS) in 172 early breast cancer (BC) patients treated with anthracycline-based adjuvant chemotherapy. Anthracyclines 200-213 BCL2 apoptosis regulator Homo sapiens 78-95 25005788-1 2014 PURPOSE: The aim of this retrospective study was to investigate the effect of B cell lymphoma 2 (BCL-2) expression on disease-free survival (DFS) in 172 early breast cancer (BC) patients treated with anthracycline-based adjuvant chemotherapy. Anthracyclines 200-213 BCL2 apoptosis regulator Homo sapiens 97-102 25047139-0 2014 Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer. navitoclax 83-90 BCL2 apoptosis regulator Homo sapiens 113-118 25047139-1 2014 WHAT IS KNOWN AND OBJECTIVE: Navitoclax, a first-in-class small molecule Bcl-2 family inhibitor, is metabolized in vitro by the hepatic microsomal cytochrome P450 (CYP) enzymes CYP3A4. navitoclax 29-39 BCL2 apoptosis regulator Homo sapiens 73-78 25081647-8 2014 This study shows that BCAR3, BCL2 and NAT1 in particular exhibit predictive promise regarding the efficacy of tamoxifen treatment in recurrent disease, in addition to the previously shown favorable outcome in the adjuvant setting. Tamoxifen 110-119 BCL2 apoptosis regulator Homo sapiens 29-33 25139025-2 2014 Identification of therapeutic strategies to enhance the efficacy of the Bcl-2 inhibitor ABT-737 in human glioma is of interest. ABT-737 88-95 BCL2 apoptosis regulator Homo sapiens 72-77 24679008-0 2014 A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma. Obatoclax mesylate 46-64 BCL2 apoptosis regulator Homo sapiens 30-35 24679008-1 2014 Obatoclax, a BH3 mimetic inhibitor of anti-apoptotic Bcl-2 proteins, demonstrates synergy with bortezomib in preclinical models of mantle cell lymphoma (MCL). obatoclax 0-9 BCL2 apoptosis regulator Homo sapiens 53-58 25084985-0 2014 ELF-MF attenuates quercetin-induced apoptosis in K562 cells through modulating the expression of Bcl-2 family proteins. Quercetin 18-27 BCL2 apoptosis regulator Homo sapiens 97-102 25242370-6 2014 Western blot and quantitative polymerase chain reaction analyses demonstrated that the expression levels of the anti-apoptotic gene Bcl-2 and the Bcl-2/Bax ratio in the oridonin and the oridonin plus gemcitabine groups were significantly downregulated as compared with the gemcitabine treatment and control groups. oridonin 169-177 BCL2 apoptosis regulator Homo sapiens 132-137 25242370-6 2014 Western blot and quantitative polymerase chain reaction analyses demonstrated that the expression levels of the anti-apoptotic gene Bcl-2 and the Bcl-2/Bax ratio in the oridonin and the oridonin plus gemcitabine groups were significantly downregulated as compared with the gemcitabine treatment and control groups. oridonin 169-177 BCL2 apoptosis regulator Homo sapiens 146-151 25084985-4 2014 In addition, the simultaneous treatments for 24 h with quercetin plus ELF-MF increased Bcl-2 protein expression and prevented quercetin-induced downregulation of Mcl-1 and Bcl-xL. Quercetin 55-64 BCL2 apoptosis regulator Homo sapiens 87-92 25242370-6 2014 Western blot and quantitative polymerase chain reaction analyses demonstrated that the expression levels of the anti-apoptotic gene Bcl-2 and the Bcl-2/Bax ratio in the oridonin and the oridonin plus gemcitabine groups were significantly downregulated as compared with the gemcitabine treatment and control groups. oridonin 186-194 BCL2 apoptosis regulator Homo sapiens 132-137 25242370-6 2014 Western blot and quantitative polymerase chain reaction analyses demonstrated that the expression levels of the anti-apoptotic gene Bcl-2 and the Bcl-2/Bax ratio in the oridonin and the oridonin plus gemcitabine groups were significantly downregulated as compared with the gemcitabine treatment and control groups. oridonin 186-194 BCL2 apoptosis regulator Homo sapiens 146-151 25310083-2 2014 TPA-treated macrophages were more resistant to arsenite-induced apoptosis than monocytes, which may be associated with the induction of Bcl-2 expression. Tetradecanoylphorbol Acetate 0-3 BCL2 apoptosis regulator Homo sapiens 136-141 25242370-6 2014 Western blot and quantitative polymerase chain reaction analyses demonstrated that the expression levels of the anti-apoptotic gene Bcl-2 and the Bcl-2/Bax ratio in the oridonin and the oridonin plus gemcitabine groups were significantly downregulated as compared with the gemcitabine treatment and control groups. gemcitabine 200-211 BCL2 apoptosis regulator Homo sapiens 132-137 25242370-6 2014 Western blot and quantitative polymerase chain reaction analyses demonstrated that the expression levels of the anti-apoptotic gene Bcl-2 and the Bcl-2/Bax ratio in the oridonin and the oridonin plus gemcitabine groups were significantly downregulated as compared with the gemcitabine treatment and control groups. gemcitabine 200-211 BCL2 apoptosis regulator Homo sapiens 146-151 25242370-6 2014 Western blot and quantitative polymerase chain reaction analyses demonstrated that the expression levels of the anti-apoptotic gene Bcl-2 and the Bcl-2/Bax ratio in the oridonin and the oridonin plus gemcitabine groups were significantly downregulated as compared with the gemcitabine treatment and control groups. gemcitabine 273-284 BCL2 apoptosis regulator Homo sapiens 132-137 25242370-8 2014 The results suggested that oridonin improved the anti-tumor effects of gemcitabine through the enhancement of gemcitabine-induced apoptosis.This mechanism may be through the downregulation of Bcl-2 expression and the upregulation of Bax expression, resulting in the reduction of the Bcl-2/Bax ratio. oridonin 27-35 BCL2 apoptosis regulator Homo sapiens 192-197 25242370-8 2014 The results suggested that oridonin improved the anti-tumor effects of gemcitabine through the enhancement of gemcitabine-induced apoptosis.This mechanism may be through the downregulation of Bcl-2 expression and the upregulation of Bax expression, resulting in the reduction of the Bcl-2/Bax ratio. oridonin 27-35 BCL2 apoptosis regulator Homo sapiens 283-288 25242370-8 2014 The results suggested that oridonin improved the anti-tumor effects of gemcitabine through the enhancement of gemcitabine-induced apoptosis.This mechanism may be through the downregulation of Bcl-2 expression and the upregulation of Bax expression, resulting in the reduction of the Bcl-2/Bax ratio. gemcitabine 71-82 BCL2 apoptosis regulator Homo sapiens 192-197 25242370-8 2014 The results suggested that oridonin improved the anti-tumor effects of gemcitabine through the enhancement of gemcitabine-induced apoptosis.This mechanism may be through the downregulation of Bcl-2 expression and the upregulation of Bax expression, resulting in the reduction of the Bcl-2/Bax ratio. gemcitabine 71-82 BCL2 apoptosis regulator Homo sapiens 283-288 25242370-8 2014 The results suggested that oridonin improved the anti-tumor effects of gemcitabine through the enhancement of gemcitabine-induced apoptosis.This mechanism may be through the downregulation of Bcl-2 expression and the upregulation of Bax expression, resulting in the reduction of the Bcl-2/Bax ratio. gemcitabine 110-121 BCL2 apoptosis regulator Homo sapiens 283-288 25270341-11 2014 Doxorubicin in combination with SB203580 significantly reduced cell viability (P<0.01) and increased cell death (P<0.01), which may be associated with the inactivation of the p38 MAPK signaling pathway, followed by the induced expression of the pro-apoptotic protein Bax and a concomitant decrease in Bcl-2 expression. Doxorubicin 0-11 BCL2 apoptosis regulator Homo sapiens 307-312 25270341-11 2014 Doxorubicin in combination with SB203580 significantly reduced cell viability (P<0.01) and increased cell death (P<0.01), which may be associated with the inactivation of the p38 MAPK signaling pathway, followed by the induced expression of the pro-apoptotic protein Bax and a concomitant decrease in Bcl-2 expression. SB 203580 32-40 BCL2 apoptosis regulator Homo sapiens 307-312 25310083-2 2014 TPA-treated macrophages were more resistant to arsenite-induced apoptosis than monocytes, which may be associated with the induction of Bcl-2 expression. arsenite 47-55 BCL2 apoptosis regulator Homo sapiens 136-141 25230779-13 2014 Therefore, CD133 may inhibit 5-FU-induced apoptosis by regulating the expression of P-gp and Bcl-2 family mediated by phosphoinositide 3-kinase/Akt/p70S6K pathway in GC cells. Fluorouracil 29-33 BCL2 apoptosis regulator Homo sapiens 93-98 25322760-8 2014 Treatment with increasing doses of paeonol led to increased expression of pro-apoptotic factor Bax and decreased expression of anti-apoptotic factor Bcl-2. paeonol 35-42 BCL2 apoptosis regulator Homo sapiens 149-154 25269486-3 2014 Resveratrol inhibited proliferation and induced apoptosis in HepG2 cells via activation of caspase-9 and caspase-3, upregulation of the Bax/Bcl-2 ratio and induction of p53 expression. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 140-145 25310109-2 2014 In the present study, we reported that celastrol potentiated tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis, affected activation of caspase-8, caspase-3 and PARP cleavage, and inhibited the expression of anti-apoptotic proteins such as cellular inhibitor of apoptosis protein 1 and 2 (cIAP1 and cIAP2), cellular FLICE-inhibitory protein (FLIP), and B-cell lymphoma 2 (Bcl-2). celastrol 39-48 BCL2 apoptosis regulator Homo sapiens 360-377 25310109-2 2014 In the present study, we reported that celastrol potentiated tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis, affected activation of caspase-8, caspase-3 and PARP cleavage, and inhibited the expression of anti-apoptotic proteins such as cellular inhibitor of apoptosis protein 1 and 2 (cIAP1 and cIAP2), cellular FLICE-inhibitory protein (FLIP), and B-cell lymphoma 2 (Bcl-2). celastrol 39-48 BCL2 apoptosis regulator Homo sapiens 379-384 25333301-3 2014 GX15-070 is a pan-Bcl-2 inhibitor which has shown promising antitumor activity in different malignancies. obatoclax 0-8 BCL2 apoptosis regulator Homo sapiens 18-23 25333301-10 2014 CQ significantly enhanced GX15-070-induced apoptosis in the cell line models, possibly due to downregulation of Bcl-2, Bcl-xL and Mcl-1 in the cells by the two agents. Chloroquine 0-2 BCL2 apoptosis regulator Homo sapiens 112-117 25443739-5 2014 RESULTS: An upregulation of cell cycle regulators: cyclin D1/cdk4 and cyclin E/cdk2 and anti-apoptotic Bcl-2, along with the suppression of DNA repair enzymes: MLH1 and MSH2; tumour suppressors: p53, p21and Rb and pro-apoptotic proteins: Bax and Bad were observed in the DSS, DMH and DSS+DMH groups. Dextran Sulfate 284-287 BCL2 apoptosis regulator Homo sapiens 103-108 25443739-5 2014 RESULTS: An upregulation of cell cycle regulators: cyclin D1/cdk4 and cyclin E/cdk2 and anti-apoptotic Bcl-2, along with the suppression of DNA repair enzymes: MLH1 and MSH2; tumour suppressors: p53, p21and Rb and pro-apoptotic proteins: Bax and Bad were observed in the DSS, DMH and DSS+DMH groups. 1,2-Dimethylhydrazine 288-291 BCL2 apoptosis regulator Homo sapiens 103-108 25443739-5 2014 RESULTS: An upregulation of cell cycle regulators: cyclin D1/cdk4 and cyclin E/cdk2 and anti-apoptotic Bcl-2, along with the suppression of DNA repair enzymes: MLH1 and MSH2; tumour suppressors: p53, p21and Rb and pro-apoptotic proteins: Bax and Bad were observed in the DSS, DMH and DSS+DMH groups. Dextran Sulfate 271-274 BCL2 apoptosis regulator Homo sapiens 103-108 25443739-5 2014 RESULTS: An upregulation of cell cycle regulators: cyclin D1/cdk4 and cyclin E/cdk2 and anti-apoptotic Bcl-2, along with the suppression of DNA repair enzymes: MLH1 and MSH2; tumour suppressors: p53, p21and Rb and pro-apoptotic proteins: Bax and Bad were observed in the DSS, DMH and DSS+DMH groups. 1,2-Dimethylhydrazine 276-279 BCL2 apoptosis regulator Homo sapiens 103-108 25142231-8 2014 ZA-induced cell death displayed features characteristic to both apoptosis and autophagy and was associated with different changes in the levels of Bcl-2 and Bax in the various cervical cancer lines. Zoledronic Acid 0-2 BCL2 apoptosis regulator Homo sapiens 147-152 25409124-0 2014 Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1. ABT-737 70-77 BCL2 apoptosis regulator Homo sapiens 53-58 25409124-7 2014 A small molecule inhibitor of Bcl-2, ABT-737, was used to target anti-apoptotic Bcl-2 family proteins. ABT-737 37-44 BCL2 apoptosis regulator Homo sapiens 30-35 25409124-7 2014 A small molecule inhibitor of Bcl-2, ABT-737, was used to target anti-apoptotic Bcl-2 family proteins. ABT-737 37-44 BCL2 apoptosis regulator Homo sapiens 80-85 25510701-10 2014 Although expressions of both BCL2 and BAX were decreased in women with POR after DHEA supplementation compared to those before treatment, the ratio of BCL2 and BAX was significantly increased in women with POR after DHEA supplementation, suggesting that DHEA supplementation might activate the antiapoptosis process of CCs, which might be beneficial to the improvement of ovarian function in women with POR. Dehydroepiandrosterone 216-220 BCL2 apoptosis regulator Homo sapiens 151-155 25510701-10 2014 Although expressions of both BCL2 and BAX were decreased in women with POR after DHEA supplementation compared to those before treatment, the ratio of BCL2 and BAX was significantly increased in women with POR after DHEA supplementation, suggesting that DHEA supplementation might activate the antiapoptosis process of CCs, which might be beneficial to the improvement of ovarian function in women with POR. Dehydroepiandrosterone 216-220 BCL2 apoptosis regulator Homo sapiens 151-155 25179840-0 2014 Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy. Anthracyclines 109-122 BCL2 apoptosis regulator Homo sapiens 27-32 25179840-6 2014 Among patients treated with an anthracycline, Bcl-2 expression also showed an association with decreased survival (OS, P = 0.004; DFS, P = 0.003) in the non-basal subgroup. Anthracyclines 31-44 BCL2 apoptosis regulator Homo sapiens 46-51 25164609-6 2014 Furthermore, nobiletin effectively induced apoptosis of HL-60 cells through caspase-8, caspase-9, and caspases-3 activation concomitantly with a marked induction of p38 mitogen-activated protein kinase (MAPK) activation, but without affecting expression levels of Bcl-2, Bax, or Bid. nobiletin 13-22 BCL2 apoptosis regulator Homo sapiens 264-269 25008202-1 2014 The ABT-analogous 737, 263 and 199 are BH3 mimetics showing potent anti-myeloma (MM) activity, but only on defined molecular subgroups of MM patients presenting a Bcl-2high/Mcl-1low profile. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 4-7 BCL2 apoptosis regulator Homo sapiens 163-168 25008202-5 2014 Knockdown of Bcl-2 by shRNA protected MM cells to ABT-737, while Mcl-1 shRNA sensitized the cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 50-53 BCL2 apoptosis regulator Homo sapiens 13-18 25543488-3 2014 The effects of mitoxantrone on the expression of BCL-2, BAX, caspase-3 mRNA were detected by RT-PCR, the BCL-2, BAX, caspase-3 protein expression of RPMI-8226 cells was analyzed by Western blot. Mitoxantrone 15-27 BCL2 apoptosis regulator Homo sapiens 49-54 25333266-11 2014 These findings indicate that Bcl-xL inhibition can sensitize DTX-resistant prostate cancer cells to DTX, and they reveal a unique apoptotic pathway in which antagonism of Bcl-2 family members in caspase-9-inhibited prostate cancer cells triggers caspase-8-dependent apoptosis. Docetaxel 61-64 BCL2 apoptosis regulator Homo sapiens 171-176 25333266-11 2014 These findings indicate that Bcl-xL inhibition can sensitize DTX-resistant prostate cancer cells to DTX, and they reveal a unique apoptotic pathway in which antagonism of Bcl-2 family members in caspase-9-inhibited prostate cancer cells triggers caspase-8-dependent apoptosis. Docetaxel 100-103 BCL2 apoptosis regulator Homo sapiens 171-176 25333266-0 2014 Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition. Docetaxel 66-75 BCL2 apoptosis regulator Homo sapiens 0-5 25333266-5 2014 In contrast to ABT-199, which inhibits Bcl-2 and Bcl-w, both ABT-263 and ABT-737, which inhibit Bcl-2, Bcl-xL, and Bcl-w, significantly augmented the antitumor effect of DTX on PC3 cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 15-18 BCL2 apoptosis regulator Homo sapiens 39-44 25008202-2 2014 IGF-1 is a major survival factor in MM regulating the expression of Bcl-2 proteins and might therefore be a resistance factor to these ABT-analogous. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 135-138 BCL2 apoptosis regulator Homo sapiens 68-73 25546354-10 2014 Q-PCR showed the combination of Suberoylanilide hydroxamic acid and paclitaxel reduced intracellular bcl-2 and c-myc gene expression and increased bax gene expression more distinctly than the application of SAHA or paclitaxel alone. Vorinostat 32-63 BCL2 apoptosis regulator Homo sapiens 101-106 25371999-8 2014 The toxic mechanism is that p-GO interacts directly with the protein receptors to inhibit their ligand-binding ability, leading to ROS-dependent passive apoptosis through the B-cell lymphoma-2 (Bcl-2) pathway. Reactive Oxygen Species 131-134 BCL2 apoptosis regulator Homo sapiens 175-192 25371999-8 2014 The toxic mechanism is that p-GO interacts directly with the protein receptors to inhibit their ligand-binding ability, leading to ROS-dependent passive apoptosis through the B-cell lymphoma-2 (Bcl-2) pathway. Reactive Oxygen Species 131-134 BCL2 apoptosis regulator Homo sapiens 194-199 25546354-10 2014 Q-PCR showed the combination of Suberoylanilide hydroxamic acid and paclitaxel reduced intracellular bcl-2 and c-myc gene expression and increased bax gene expression more distinctly than the application of SAHA or paclitaxel alone. Paclitaxel 68-78 BCL2 apoptosis regulator Homo sapiens 101-106 25296980-6 2014 RES+CUR compared to CUR increased the PARP-1 cleavage, the Bax/Bcl-2 ratio, the inhibition of ERK1 and ERK2 phosphorylation, and the expression of LC3 II simultaneously with the formation of autophagic vacuoles. Resveratrol 0-4 BCL2 apoptosis regulator Homo sapiens 63-68 25242120-7 2014 Additionally, silymarin treatment for 24h at 50 and 100microg/ml resulted in a reduction of mitochondrial membrane potential and cytochrome C release, and significantly induced apoptosis in A2780s and PA-1 cells by increasing Bax and decreasing Bcl-2 protein expression, and activation of caspase-9 and caspase-3. Silymarin 14-23 BCL2 apoptosis regulator Homo sapiens 245-250 25411798-9 2014 Se-methylselenocysteine (MSC) at an optimum concentration of 1 muM could reverse the alteration in antioxidative capacity, Bcl2/Bax ratio and caspase-8 activity caused by Clu-knockdown, thus inhibiting apoptosis and maintaining cell viability. Se-methylselenocysteine 0-23 BCL2 apoptosis regulator Homo sapiens 123-127 25111583-8 2014 The interactions of PUMA with MCL-1 and/or BCL-2 were enhanced when cells were exposed to Bu+Clo+Flu or Bu+Clo+Flu+Sor. bu+clo 90-96 BCL2 apoptosis regulator Homo sapiens 43-48 25375379-1 2014 Although ABT-737, a small-molecule Bcl-2/Bcl-xL inhibitor, has recently emerged as a novel cancer therapeutic agent, ABT-737-induced apoptosis is often blocked in several types of cancer cells with elevated expression of Mcl-1. ABT-737 9-16 BCL2 apoptosis regulator Homo sapiens 35-40 25375379-1 2014 Although ABT-737, a small-molecule Bcl-2/Bcl-xL inhibitor, has recently emerged as a novel cancer therapeutic agent, ABT-737-induced apoptosis is often blocked in several types of cancer cells with elevated expression of Mcl-1. ABT-737 117-124 BCL2 apoptosis regulator Homo sapiens 35-40 25107702-3 2014 Here we report another frequent alteration accompanying CDDP resistance, namely upregulation of the antiapoptotic BCL-2 family protein MCL-1. Cisplatin 56-60 BCL2 apoptosis regulator Homo sapiens 114-119 25288797-3 2014 This process requires the BH3-only activator protein (i.e. tBid) and can be inhibited by anti-apoptotic Bcl-2 family proteins such as Bcl-xL. tBID 59-63 BCL2 apoptosis regulator Homo sapiens 104-109 25228695-6 2014 In contrast, the reconstitution of 14-3-3beta expression in miR-152(high) cells increased the expression of the anti-apoptotic BCL2 gene, enhances the proliferative activity in the presence of the cytostatic drug paclitaxel, and causes resistance to apoptosis induced by this drug. Paclitaxel 213-223 BCL2 apoptosis regulator Homo sapiens 127-131 25382610-0 2014 Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenstroms macroglobulinemia. nimbolide 0-9 BCL2 apoptosis regulator Homo sapiens 18-22 25382610-6 2014 In silico analysis revealed the antiapoptotic protein BCL2 was the preferential binding partner of nimbolide. nimbolide 99-108 BCL2 apoptosis regulator Homo sapiens 54-58 25382610-7 2014 The significance of this finding was further tested in vitro in RS4;11 (BCL2-dependent) tumor cells, in which nimbolide induced significantly more apoptosis compared with BCL2 mutated (Jurkat BCL2(Ser70-Ala)) cells. nimbolide 110-119 BCL2 apoptosis regulator Homo sapiens 72-76 25382610-9 2014 Overall, our data demonstrate that nimbolide is highly active in WM cells, as well as other B-cell cancers, and engages BCL2 to exert its cytotoxic activity. nimbolide 35-44 BCL2 apoptosis regulator Homo sapiens 120-124 25387078-8 2014 Sorafenib regularly down regulated the anti-apoptotic myeloid cell leukemia 1 (Mcl-1) protein, but combinatorial treatment with ABT-737 targeting other B-cell lymphoma 2 (Bcl-2) family proteins did not result in synergistic effects. Sorafenib 0-9 BCL2 apoptosis regulator Homo sapiens 171-176 25387078-8 2014 Sorafenib regularly down regulated the anti-apoptotic myeloid cell leukemia 1 (Mcl-1) protein, but combinatorial treatment with ABT-737 targeting other B-cell lymphoma 2 (Bcl-2) family proteins did not result in synergistic effects. ABT-737 128-135 BCL2 apoptosis regulator Homo sapiens 152-169 25387078-8 2014 Sorafenib regularly down regulated the anti-apoptotic myeloid cell leukemia 1 (Mcl-1) protein, but combinatorial treatment with ABT-737 targeting other B-cell lymphoma 2 (Bcl-2) family proteins did not result in synergistic effects. ABT-737 128-135 BCL2 apoptosis regulator Homo sapiens 171-176 25265580-5 2014 Alteration of expression levels of bax/bcl2, and dapk1a by increasing concentration of chelidonine approves switching the death mode from apoptosis induced by very low to autophagy by high concentrations of this compound. chelidonine 87-98 BCL2 apoptosis regulator Homo sapiens 39-43 25363213-0 2014 Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: sequential delivery of doxorubicin and Bcl-2 siRNA. glycol-chitosan 0-15 BCL2 apoptosis regulator Homo sapiens 113-118 25090972-7 2014 NADA enhances angiogenesis in endothelial vascular cells and promotes the expression of genes such as erythropoietin (EPO), vascular endothelial growth factor A (VEGFA), heme oxygenase 1 (HMOX-1), hexokinase 2 (HK2) and Bcl-2/E1B-nineteen kiloDalton interacting protein (BNIP3) in primary astrocytes. arachidonyl dopamine 0-4 BCL2 apoptosis regulator Homo sapiens 220-225 25111583-8 2014 The interactions of PUMA with MCL-1 and/or BCL-2 were enhanced when cells were exposed to Bu+Clo+Flu or Bu+Clo+Flu+Sor. fludarabine 97-100 BCL2 apoptosis regulator Homo sapiens 43-48 25111583-8 2014 The interactions of PUMA with MCL-1 and/or BCL-2 were enhanced when cells were exposed to Bu+Clo+Flu or Bu+Clo+Flu+Sor. Busulfan 90-92 BCL2 apoptosis regulator Homo sapiens 43-48 25111583-8 2014 The interactions of PUMA with MCL-1 and/or BCL-2 were enhanced when cells were exposed to Bu+Clo+Flu or Bu+Clo+Flu+Sor. Clofarabine 93-96 BCL2 apoptosis regulator Homo sapiens 43-48 25111583-8 2014 The interactions of PUMA with MCL-1 and/or BCL-2 were enhanced when cells were exposed to Bu+Clo+Flu or Bu+Clo+Flu+Sor. fludarabine 111-114 BCL2 apoptosis regulator Homo sapiens 43-48 25408532-4 2014 Here, using MTT assay and EB/AO staining as well as TUNEL assay we show that RA in a concentration-dependent manner induces apoptosis through upregulating Caspase expression and increasing Bax/Bcl2 ratio. Tretinoin 77-79 BCL2 apoptosis regulator Homo sapiens 193-197 25111583-8 2014 The interactions of PUMA with MCL-1 and/or BCL-2 were enhanced when cells were exposed to Bu+Clo+Flu or Bu+Clo+Flu+Sor. Sorafenib 115-118 BCL2 apoptosis regulator Homo sapiens 43-48 25584387-0 2014 Design, synthesis and structure-activity relationship studies of morpholino-1H-phenalene derivatives that antagonize Mcl-1/Bcl-2. morpholino-1h-phenalene 65-88 BCL2 apoptosis regulator Homo sapiens 123-128 24938898-6 2014 Further, 5-ATAN induced the loss of mitochondrial membrane potential (Deltapsim) by regulating the Bax/Bcl-2 ratio. 5-acetyl-6,7,8,4'-tetramethylnortangeretin 9-15 BCL2 apoptosis regulator Homo sapiens 103-108 24990093-7 2014 Cisplatin and [Pt(O,O"-acac)(gamma-acac)(DMS)] caused activation of caspases, proteolysis of PARP and modulation of Bcl-2, Bax and Bid. gamma-acac 29-39 BCL2 apoptosis regulator Homo sapiens 116-121 24990093-7 2014 Cisplatin and [Pt(O,O"-acac)(gamma-acac)(DMS)] caused activation of caspases, proteolysis of PARP and modulation of Bcl-2, Bax and Bid. dimethyl sulfide 41-44 BCL2 apoptosis regulator Homo sapiens 116-121 24990093-7 2014 Cisplatin and [Pt(O,O"-acac)(gamma-acac)(DMS)] caused activation of caspases, proteolysis of PARP and modulation of Bcl-2, Bax and Bid. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 116-121 24990093-7 2014 Cisplatin and [Pt(O,O"-acac)(gamma-acac)(DMS)] caused activation of caspases, proteolysis of PARP and modulation of Bcl-2, Bax and Bid. pt(o,o"-acac) 15-28 BCL2 apoptosis regulator Homo sapiens 116-121 24845152-6 2014 These results suggest that psoralen induces apoptosis in cancer cells via mechanisms that involve caspase-3, p53, Bax, and Bcl-2 pathway. Ficusin 27-35 BCL2 apoptosis regulator Homo sapiens 123-128 24997623-6 2014 Furthermore, a disruption of mitochondrial membrane potential and an up-regulation of cleaved caspases-3, and-9 and downregulation of Bax/Bcl-2 was evidenced in the oxymatrine-treated cells. oxymatrine 165-175 BCL2 apoptosis regulator Homo sapiens 138-143 25289059-6 2014 Even low concentrations of GA (0.02 mumol/l) were found to inhibit the Bcl-2 and cyclin D1 protein expression induced by VEGF-C. geldanamycin 27-29 BCL2 apoptosis regulator Homo sapiens 71-76 25128071-3 2014 In this study, we primarily found that selenite exposure inhibited phosphorylation of cyclic adenosine monophosphate (cAMP)-response element binding protein (CREB), leading to suppression of Bcl-2 in HCT116 and SW480 colorectal cancer (CRC) cells. Cyclic AMP 118-122 BCL2 apoptosis regulator Homo sapiens 191-196 25128071-7 2014 Our results demonstrated that a supranutritional dose of selenite induced CRC cell apoptosis through inhibition of the PKD1/CREB/Bcl-2 axis both in vitro and in vivo. Selenious Acid 57-65 BCL2 apoptosis regulator Homo sapiens 129-134 24749765-9 2014 On the other hand, Bcl2 was increased from anthocyanin-treated lens cells. Anthocyanins 43-54 BCL2 apoptosis regulator Homo sapiens 19-23 25128071-0 2014 The p38 MAPK-regulated PKD1/CREB/Bcl-2 pathway contributes to selenite-induced colorectal cancer cell apoptosis in vitro and in vivo. Selenious Acid 62-70 BCL2 apoptosis regulator Homo sapiens 33-38 25128071-3 2014 In this study, we primarily found that selenite exposure inhibited phosphorylation of cyclic adenosine monophosphate (cAMP)-response element binding protein (CREB), leading to suppression of Bcl-2 in HCT116 and SW480 colorectal cancer (CRC) cells. Selenious Acid 39-47 BCL2 apoptosis regulator Homo sapiens 191-196 25138901-8 2014 However, Bcl-2 increased significantly from 5.0 (SD 4.5) to 9.1 % (SD 6.7), p = 0.0004, in the antrum after omeprazole. Omeprazole 108-118 BCL2 apoptosis regulator Homo sapiens 9-14 25196280-0 2014 Hsp90 inhibitor 17-AAG sensitizes Bcl-2 inhibitor (-)-gossypol by suppressing ERK-mediated protective autophagy and Mcl-1 accumulation in hepatocellular carcinoma cells. Gossypol 50-62 BCL2 apoptosis regulator Homo sapiens 34-39 25289068-6 2014 Furthermore, the results from the western blot analysis demonstrated that augmenting ADR treatment with germacrone resulted in a reduction of anti-apoptotic protein expression levels (bcl-2) and enhancement of pro-apoptotic protein expression levels (p53 and bax) in MCF-7/ADR cells compared with the levels achieved by treatment with ADR alone. germacrone 104-114 BCL2 apoptosis regulator Homo sapiens 184-189 25096910-3 2014 Our study revealed that treatment with CAY10598 significantly reduced the cell viability and induced apoptosis in HCT116 cells, as evidenced by the induction of p53 and Bax, release of cytochrome c, cleavage of caspase-9, -7, and -3, and PARP, and the inhibition of Bcl-2, Bcl-xL and survivin expression. CAY10598 39-47 BCL2 apoptosis regulator Homo sapiens 266-271 25214070-9 2014 Additionally, urolithins induced apoptosis in LNCaP cells, and this effect correlated with a decrease in Bcl-2 protein levels. urolithins 14-24 BCL2 apoptosis regulator Homo sapiens 105-110 25151121-0 2014 Nicotine mediates oxidative stress and apoptosis through cross talk between NOX1 and Bcl-2 in lung epithelial cells. Nicotine 0-8 BCL2 apoptosis regulator Homo sapiens 85-90 25151121-8 2014 Overexpression of Bcl-2 completely prevented nicotine"s detrimental effects, suggesting Bcl-2as a downstream key regulator in nicotine/NOX1-induced cell damage. Nicotine 45-53 BCL2 apoptosis regulator Homo sapiens 18-23 25151121-8 2014 Overexpression of Bcl-2 completely prevented nicotine"s detrimental effects, suggesting Bcl-2as a downstream key regulator in nicotine/NOX1-induced cell damage. Nicotine 45-53 BCL2 apoptosis regulator Homo sapiens 88-93 25151121-8 2014 Overexpression of Bcl-2 completely prevented nicotine"s detrimental effects, suggesting Bcl-2as a downstream key regulator in nicotine/NOX1-induced cell damage. Nicotine 126-134 BCL2 apoptosis regulator Homo sapiens 18-23 25151121-8 2014 Overexpression of Bcl-2 completely prevented nicotine"s detrimental effects, suggesting Bcl-2as a downstream key regulator in nicotine/NOX1-induced cell damage. Nicotine 126-134 BCL2 apoptosis regulator Homo sapiens 88-93 25354679-7 2014 Bcl-2/Bcl-xL inhibitor ABT-737 sensitised cells to apoptosis, which indicates that Bcl-2 family proteins play a role in hyperthermia-induced apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 23-26 BCL2 apoptosis regulator Homo sapiens 0-5 25568669-2 2014 We study the efficacy of SAHA/RTx and LBH589/RTx when manipulating Bcl-2 family proteins using the Bcl-2 inhibitor Obatoclax in patient-derived glioblastoma stem-like cell (GSC) cultures. Panobinostat 38-44 BCL2 apoptosis regulator Homo sapiens 67-72 25135879-4 2014 The results showed that NG had strong cytotoxicity to induce apoptosis, which was characterized by a significant externalization of phosphatidylserine, nuclear morphological changes and enhanced Bax-to-Bcl-2 ratio. Nitroglycerin 24-26 BCL2 apoptosis regulator Homo sapiens 202-207 25354679-7 2014 Bcl-2/Bcl-xL inhibitor ABT-737 sensitised cells to apoptosis, which indicates that Bcl-2 family proteins play a role in hyperthermia-induced apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 23-26 BCL2 apoptosis regulator Homo sapiens 83-88 25272292-16 2014 Mean Ki-67 and Bcl-2 decreases following medroxyprogesterone acetate were greater in histologic responders than nonresponders, but not decreases in ER, PR, PRB, and Casp3. Medroxyprogesterone Acetate 41-68 BCL2 apoptosis regulator Homo sapiens 15-20 24963595-3 2014 Elevation of ROS production, associated with changes in Bax/Bcl-2 ratio, led to loss of mitochondrial membrane potential (Deltapsim) and cytochrome c release in VA-treated cells. Reactive Oxygen Species 13-16 BCL2 apoptosis regulator Homo sapiens 60-65 25304678-3 2014 The objective of this multi-institutional phase 2 trial was to evaluate the efficacy and toxicity of paclitaxel and bcl-2 modulators (13-cis retinoic acid and interferon alfa-2b) in patients with advanced-stage or recurrent cervical cancer. Isotretinoin 134-154 BCL2 apoptosis regulator Homo sapiens 116-121 25174355-10 2014 Treatment with ATO resulted in phosphatidylserine externalization in H23 cells and mitochondrial membrane depolarization in all cell lines, associated with truncation of Bid, downregulation of Bcl-2, upregulation of Bax and Bak, caspase-9 and -3 activation and PARP cleavage. Arsenic Trioxide 15-18 BCL2 apoptosis regulator Homo sapiens 193-198 24780492-1 2014 Small-molecule inhibitors that antagonize anti-apoptotic Bcl-2 proteins such as BH3 mimetics are currently considered as promising cancer therapeutics to engage the mitochondrial pathway of apoptosis in cancer cells. BH 3 80-83 BCL2 apoptosis regulator Homo sapiens 57-62 24954615-0 2014 Mitochondrial ROS and involvement of Bcl-2 as a mitochondrial ROS regulator. Reactive Oxygen Species 62-65 BCL2 apoptosis regulator Homo sapiens 37-42 24954615-5 2014 In addition to its canonical anti-apoptotic activity, Bcl-2 has been implicated in mitoROS regulation by its effect on mitochondrial complex IV activity, facilitating the mitochondrial incorporation of GSH and interaction with the small GTPase-Rac1 at the mitochondria. Glutathione 202-205 BCL2 apoptosis regulator Homo sapiens 54-59 25204604-11 2014 The levels of the anti-apoptotic genes Bcl-2 and Bcl-xl in A549 cells decreased, while expression of P53 and production of exosomes increased after beta-elemene treatment. beta-elemene 148-160 BCL2 apoptosis regulator Homo sapiens 39-44 24780492-2 2014 However, BH3 mimetics may be effective as monotherapy only in cancers that critically depend on anti-apoptotic Bcl-2 proteins for their survival. BH 3 9-12 BCL2 apoptosis regulator Homo sapiens 111-116 25190487-6 2014 miR-138 directly targeted Limk1 and inhibited ovarian cancer cell growth by PCNA and Bcl-2. mir-138 0-7 BCL2 apoptosis regulator Homo sapiens 85-90 23661569-4 2014 Zeb also induced A549 cell death, which was accompanied by the loss of mitochondrial membrane potential (MMP; DeltaPsim ), Bcl-2 decrease, Bax increase, p53 increase and activation of caspase-3 and -8. pyrimidin-2-one beta-ribofuranoside 0-3 BCL2 apoptosis regulator Homo sapiens 123-128 25199623-10 2014 In addition, combined exposure to oxaliplatin and SAHA increased gammaH2AX expression and decreased Bcl-2 expression. Oxaliplatin 34-45 BCL2 apoptosis regulator Homo sapiens 100-105 25199623-10 2014 In addition, combined exposure to oxaliplatin and SAHA increased gammaH2AX expression and decreased Bcl-2 expression. Vorinostat 50-54 BCL2 apoptosis regulator Homo sapiens 100-105 25174967-7 2014 Furthermore, Bcl-2 expression was decreased and the ratio of Bcl-2 to Bax was significantly decreased by isatin. Isatin 105-111 BCL2 apoptosis regulator Homo sapiens 13-18 25174967-7 2014 Furthermore, Bcl-2 expression was decreased and the ratio of Bcl-2 to Bax was significantly decreased by isatin. Isatin 105-111 BCL2 apoptosis regulator Homo sapiens 61-66 24865355-5 2014 Isoalantolactone also induced apoptosis via increase generation of reactive oxygen species, modulation of the protein levels of Bcl-2 family members, caspase activation, poly ADP-ribose polymerase (PARP) cleavage, and release of cytochrome c. isoalantolactone 0-16 BCL2 apoptosis regulator Homo sapiens 128-133 25175462-11 2014 Western blotting and densitometric assay showed that the expression of Bcl-2 was decreased after the combined treatment of ginsenoside Rg3 and cisplatin, whereas the expression of cytochrome c and caspase-3 were increased, suggesting the activation of the intrinsic apoptotic pathway. ginsenoside Rg3 123-138 BCL2 apoptosis regulator Homo sapiens 71-76 25175462-11 2014 Western blotting and densitometric assay showed that the expression of Bcl-2 was decreased after the combined treatment of ginsenoside Rg3 and cisplatin, whereas the expression of cytochrome c and caspase-3 were increased, suggesting the activation of the intrinsic apoptotic pathway. Cisplatin 143-152 BCL2 apoptosis regulator Homo sapiens 71-76 25266739-6 2014 In contrast, ABT199, an inhibitor of the anti-apoptotic protein Bcl2, enhanced cell killing after PDT. venetoclax 13-19 BCL2 apoptosis regulator Homo sapiens 64-68 25118092-9 2014 Cardiac Bax/Bcl-2 levels (index of apoptosis) correlated negatively with F2alpha isoprostanes at Week 2 (r = -0.88) and with hsCRP at Week 52 (r = -0.67). f2alpha isoprostanes 73-93 BCL2 apoptosis regulator Homo sapiens 12-17 25571712-18 2014 Oridonin down-regulated the level of anti apoptotic protein Bcl-2 and up-regulated the expression of pro-apoptotic protein Bax. oridonin 0-8 BCL2 apoptosis regulator Homo sapiens 60-65 25128065-6 2014 In the present study, we demonstrated that genistein could induce apoptosis in human colon cancer LoVo and HT-29 cells through inhibiting NF-kappaB pathway, as well as downregulation of Bcl-2 and upregulation of Bax, thus providing basis for clinical application of genistein in colon cancer cases. Genistein 43-52 BCL2 apoptosis regulator Homo sapiens 186-191 25195082-13 2014 Immunofluorescence analysis depicted the up-regulation of Bax and down-regulation of Bcl-2 proteins while treated with EEAM. eeam 119-123 BCL2 apoptosis regulator Homo sapiens 85-90 25220273-6 2014 The mechanism underlying the effect of SDT involves, in part, the induction of a conspicuous loss in mitochondrial membrane potential and, in part, the induction of apoptosis through upregulation of Bax expression, downregulation of Bcl-2 and increased activation of procaspase-3. 3,4-Dihydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione 39-42 BCL2 apoptosis regulator Homo sapiens 233-238 26027111-13 2014 The results of Western blot assay showed that this ratio of drugs could significantly increase the protein expression of Bax,P53 and P21 and decreased the expression of BCL-2, Casepase-3, p-Erk, p-Ras and p-c-Raf in SMMC-7721 cells. smmc 216-220 BCL2 apoptosis regulator Homo sapiens 169-174 25356567-6 2014 Western blotting analysis indicated that the effects of BFA may be mediated by the down-regulation of breast CSC marker CD44 and anti-apoptotic proteins Bcl-2 and Mcl-1, as well as the reversal of epithelial-mesenchymal transition. Brefeldin A 56-59 BCL2 apoptosis regulator Homo sapiens 153-158 25344679-9 2014 Western blot analysis showed that FTY720 induced cleavage of caspases 3, 8 and 9, and of PARP, in a dose-dependent manner, consistent with a substantial decrease in p-STAT3, Bcl-xL, Bcl-2, survivin, cyclin D1, cyclin E, N-cadherin, vimentin, VEGF and TWIST1. Fingolimod Hydrochloride 34-40 BCL2 apoptosis regulator Homo sapiens 182-187 25342459-4 2014 13-AC-induced apoptosis was confirmed through observation of a change in DeltaPsim, up-regulated expression levels of Bax and Bad proteins, down-regulated expression levels of Bcl-2, Bcl-xl and Mcl-1 proteins, and the activation of caspase-3, caspase-9, p38 and JNK. 13-acetoxysarcocrassolide 0-5 BCL2 apoptosis regulator Homo sapiens 176-181 25365293-5 2014 On the contrary, apoptosis and concomitant alteration in balance of BCL-2 and BAX expression as well as activation of caspase-3 were equally affected between both cells by flavonoid treatment. Flavonoids 172-181 BCL2 apoptosis regulator Homo sapiens 68-73 25338001-7 2014 It was also demonstrated that irisin reduced high glucose-induced apoptosis by up-regulating Bcl-2 expression and down-regulating Bax, Caspase-9 and Caspase-3 expression. Glucose 50-57 BCL2 apoptosis regulator Homo sapiens 93-98 25181458-0 2014 c-Jun NH2-terminal kinase-induced proteasomal degradation of c-FLIPL/S and Bcl2 sensitize prostate cancer cells to Fas- and mitochondria-mediated apoptosis by tetrandrine. tetrandrine 159-170 BCL2 apoptosis regulator Homo sapiens 75-79 25330300-11 2014 Caspase-8 and -3 levels were increased in cells exposed to MTX, but the modulation of these genes, as well as that of the Bax and Bcl-2 genes involved in the apoptosis pathway, presented a modulation that was dependent on the SOD2 genotype. Methotrexate 59-62 BCL2 apoptosis regulator Homo sapiens 130-135 25181458-4 2014 JNK1/2-mediated proteasomal degradation of c-FLIPL/S and Bcl2 proteins are key events in the sensitization of prostate cancer cells to Fas- and mitochondria-mediated apoptosis by tetrandrine. tetrandrine 179-190 BCL2 apoptosis regulator Homo sapiens 57-61 25181458-5 2014 Tetrandrine-induced JNK1/2 activation caused the translocation of Bax to mitochondria by disrupting its association with Bcl2 which was accompanied by collapse of mitochondrial membrane potential (MMP), cytosolic release of cytochrome c and Smac, and apoptotic cell death. tetrandrine 0-11 BCL2 apoptosis regulator Homo sapiens 121-125 25181458-6 2014 Additionally, tetrandrine-induced JNK1/2 activation increased the phosphorylation of Bcl2 at Ser70 and facilitated its degradation via the ubiquitin-mediated proteasomal pathway. tetrandrine 14-25 BCL2 apoptosis regulator Homo sapiens 85-89 25333252-0 2014 The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. venetoclax 19-26 BCL2 apoptosis regulator Homo sapiens 4-8 25419360-6 2014 As a result, protein abundance of Bcl-2 and cyclin D1 was decreased and PTEN was increased in cells exposed to metformin. Metformin 111-120 BCL2 apoptosis regulator Homo sapiens 34-39 25333252-2 2014 The BH3 mimetic, ABT-263, targets prosurvival BCL2 family members, and has activity against CML progenitors. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 17-20 BCL2 apoptosis regulator Homo sapiens 46-50 25333252-0 2014 The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. Imatinib Mesylate 50-58 BCL2 apoptosis regulator Homo sapiens 4-8 25333252-4 2014 A second-generation BH3 mimetic, ABT-199, has been developed to specifically bind BCL2 but not BCL-XL. BH 3 20-23 BCL2 apoptosis regulator Homo sapiens 82-86 25333784-9 2014 LBPs also inhibited H2O2-induced downregulated Bcl-2 and upregulated Bax proteins and increased the levels of SOD and GSH enzyme activity. Hydrogen Peroxide 20-24 BCL2 apoptosis regulator Homo sapiens 47-52 25333252-4 2014 A second-generation BH3 mimetic, ABT-199, has been developed to specifically bind BCL2 but not BCL-XL. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 33-36 BCL2 apoptosis regulator Homo sapiens 82-86 25333252-2 2014 The BH3 mimetic, ABT-263, targets prosurvival BCL2 family members, and has activity against CML progenitors. BH 3 4-7 BCL2 apoptosis regulator Homo sapiens 46-50 25333252-6 2014 We find that BCL2 expression levels predict sensitivity to ABT-199 in CML and NCB progenitors, and that high NCB BCL2 levels may explain the reported hematologic toxicities in ABT-199-treated patients. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 59-62 BCL2 apoptosis regulator Homo sapiens 13-17 25219883-2 2014 Proteasome inhibitors and melatonin are both intimately involved in the regulation of major signal transduction proteins including p53, cyclin p27, transcription factor NF-kappaB, apoptotic factors Bax and Bim, caspase 3, caspase 9, anti-apoptotic factor Bcl-2, TRAIL, NRF2 and transcription factor beta-catenin. Melatonin 26-35 BCL2 apoptosis regulator Homo sapiens 255-260 25333252-6 2014 We find that BCL2 expression levels predict sensitivity to ABT-199 in CML and NCB progenitors, and that high NCB BCL2 levels may explain the reported hematologic toxicities in ABT-199-treated patients. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 176-179 BCL2 apoptosis regulator Homo sapiens 113-117 25082878-0 2014 Ser70 phosphorylation of Bcl-2 by selective tyrosine nitration of PP2A-B56delta stabilizes its antiapoptotic activity. Tyrosine 44-52 BCL2 apoptosis regulator Homo sapiens 25-30 25290311-11 2014 Furthermore, ADP sensitized HUVEC to cisplatin-induced cell death by the down-regulation of Bcl-2 expression. Adenosine Diphosphate 13-16 BCL2 apoptosis regulator Homo sapiens 92-97 25290311-11 2014 Furthermore, ADP sensitized HUVEC to cisplatin-induced cell death by the down-regulation of Bcl-2 expression. Cisplatin 37-46 BCL2 apoptosis regulator Homo sapiens 92-97 25230140-0 2014 miR-135a inhibition protects A549 cells from LPS-induced apoptosis by targeting Bcl-2. mir-135a 0-8 BCL2 apoptosis regulator Homo sapiens 80-85 25230140-10 2014 Furthermore, bioinformatic analysis and luciferase activity assays were conducted to confirm that miR-135a binds directly to the 3"-untranslated region of Bcl-2 and suppresses its expression. mir-135a 98-106 BCL2 apoptosis regulator Homo sapiens 155-160 25289887-4 2014 This was further underscored by kinetics of dinaciclib-induced downregulation of the antiapoptotic BCL2 family member MCL1 and correlation of sensitivity with the MCL1-to-BCL-xL mRNA ratio or MCL1 amplification in solid tumor models in vitro and in vivo. dinaciclib 44-54 BCL2 apoptosis regulator Homo sapiens 99-103 25082878-4 2014 This redox-dependent regulation of Bcl-2 phosphorylation is due to nitrosative modification of B56delta, which we identify as the regulatory subunit mediating PP2A-dependent Bcl-2 dephosphorylation. b56delta 95-103 BCL2 apoptosis regulator Homo sapiens 35-40 25082878-4 2014 This redox-dependent regulation of Bcl-2 phosphorylation is due to nitrosative modification of B56delta, which we identify as the regulatory subunit mediating PP2A-dependent Bcl-2 dephosphorylation. b56delta 95-103 BCL2 apoptosis regulator Homo sapiens 174-179 25082878-6 2014 Although nitrated B56delta(Y289) binds efficiently to ser70-phosphorylated Bcl-2, this specific modification inhibits the recruitment of the PP2A catalytic core (A and C subunits). b56delta 18-26 BCL2 apoptosis regulator Homo sapiens 75-80 25082878-6 2014 Although nitrated B56delta(Y289) binds efficiently to ser70-phosphorylated Bcl-2, this specific modification inhibits the recruitment of the PP2A catalytic core (A and C subunits). y289 27-31 BCL2 apoptosis regulator Homo sapiens 75-80 25319084-0 2014 Design, synthesis and structure-activity relationship studies of morpholino-1H-phenalene derivatives that antagonize Mcl-1/Bcl-2. morpholino-1h-phenalene 65-88 BCL2 apoptosis regulator Homo sapiens 123-128 25082878-7 2014 Furthermore, inhibition of B56delta(Y289) nitration restores PP2A holoenzyme assembly, thereby permitting S70 dephosphorylation of Bcl-2 and inhibiting its antiapoptotic activity. b56delta 27-35 BCL2 apoptosis regulator Homo sapiens 131-136 25082878-7 2014 Furthermore, inhibition of B56delta(Y289) nitration restores PP2A holoenzyme assembly, thereby permitting S70 dephosphorylation of Bcl-2 and inhibiting its antiapoptotic activity. y289 36-40 BCL2 apoptosis regulator Homo sapiens 131-136 25082878-8 2014 More important, in primary cells derived from clinical lymphomas, Bcl-2 phosphorylation at S70 directly correlates with B56delta nitration and repression of SOD1, but inversely correlates with B56delta interaction with the PP2A-C catalytic subunit. b56delta 120-128 BCL2 apoptosis regulator Homo sapiens 66-71 24642270-0 2014 Bcl-2 regulation of the inositol 1,4,5-trisphosphate receptor and calcium signaling in normal and malignant lymphocytes: potential new target for cancer treatment. Calcium 66-73 BCL2 apoptosis regulator Homo sapiens 0-5 25275021-2 2014 MATERIALS AND METHODS: The potential of combining the Bcl-2 homology 3 mimetic ABT-737, which blocks Bcl-2, Bcl-XL, and Bcl-w, with either the proteasome inhibitor bortezomib or histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) to inhibit the growth of human T-lymphotropic virus type-I (HTLV-1) infected T-cell lines and its mechanism was further evaluated. ABT-737 79-86 BCL2 apoptosis regulator Homo sapiens 54-59 25275021-2 2014 MATERIALS AND METHODS: The potential of combining the Bcl-2 homology 3 mimetic ABT-737, which blocks Bcl-2, Bcl-XL, and Bcl-w, with either the proteasome inhibitor bortezomib or histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) to inhibit the growth of human T-lymphotropic virus type-I (HTLV-1) infected T-cell lines and its mechanism was further evaluated. ABT-737 79-86 BCL2 apoptosis regulator Homo sapiens 101-106 25126723-5 2014 Mechanistically, we demonstrate that BCL2L1, but not BCL2, interacts with and inhibits PGAM5, a mitochondrially localized phosphatase, to prevent the dephosphorylation of FUNDC1 at serine 13 (Ser13), which activates hypoxia-induced mitophagy. Serine 181-187 BCL2 apoptosis regulator Homo sapiens 37-41 24723333-0 2014 Relative stability of G-quadruplex structures: Interactions between the human Bcl2 promoter region and derivatives of carbazole and diphenylamine. carbazole 118-127 BCL2 apoptosis regulator Homo sapiens 78-82 25108507-11 2014 The results of this study on apoptosis-related factors might help to develop novel protective and therapeutic approaches, such as isoflavonoids and isothiocyanates, which were associated with decreased Bcl-2/Bax ratio, against the malignant epithelial ovarian tumors. isoflavonoids 130-143 BCL2 apoptosis regulator Homo sapiens 202-207 25108507-11 2014 The results of this study on apoptosis-related factors might help to develop novel protective and therapeutic approaches, such as isoflavonoids and isothiocyanates, which were associated with decreased Bcl-2/Bax ratio, against the malignant epithelial ovarian tumors. Isothiocyanates 148-163 BCL2 apoptosis regulator Homo sapiens 202-207 25136804-6 2014 Using differentiated SK-N-BE neuroblastoma cells, we found that monomers hamper the formation of the autophagic BCL2-BECN1/Beclin 1 complex and activate the MAPK8/JNK1-MAPK9/JNK2 pathway phosphorylating BCL2. sk-n 21-25 BCL2 apoptosis regulator Homo sapiens 112-116 24927687-6 2014 Treatment with obacunone increased apoptosis by up-regulating expression of the pro-apoptotic protein Bax and down-regulating the anti-apoptotic protein Bcl2, as well as inducing G1 cell cycle arrest. obacunone 15-24 BCL2 apoptosis regulator Homo sapiens 153-157 24723333-0 2014 Relative stability of G-quadruplex structures: Interactions between the human Bcl2 promoter region and derivatives of carbazole and diphenylamine. Diphenylamine 132-145 BCL2 apoptosis regulator Homo sapiens 78-82 25019692-4 2014 Abyssinones promoted apoptosis by up regulation of p53 and Bax, along with down regulation of Bcl-2. abyssinones 0-11 BCL2 apoptosis regulator Homo sapiens 94-99 24768714-8 2014 Bcl-2 at the ER acts via its N-terminal BH4 domain, which directly binds and inhibits the inositol 1,4,5-trisphosphate receptor (IP3R), the main intracellular Ca(2+)-release channel. sapropterin 40-43 BCL2 apoptosis regulator Homo sapiens 0-5 24768714-9 2014 Tools targeting the BH4 domain of Bcl-2 reverse Bcl-2"s inhibitory action on IP3Rs and trigger pro-apoptotic Ca(2+) signaling in cancer B-cells, including chronic lymphocytic leukemia (CLL) cells and diffuse large B-cell lymphoma (DLBCL) cells. sapropterin 20-23 BCL2 apoptosis regulator Homo sapiens 34-39 24768714-9 2014 Tools targeting the BH4 domain of Bcl-2 reverse Bcl-2"s inhibitory action on IP3Rs and trigger pro-apoptotic Ca(2+) signaling in cancer B-cells, including chronic lymphocytic leukemia (CLL) cells and diffuse large B-cell lymphoma (DLBCL) cells. sapropterin 20-23 BCL2 apoptosis regulator Homo sapiens 48-53 25086254-8 2014 Real time polymerase chain reaction and luciferase assays show that the phenanthroline derivative has down-modulated Bcl-2 transcription activity in a concentration-dependent manner. Phenanthrolines 72-86 BCL2 apoptosis regulator Homo sapiens 117-122 25011606-3 2014 Treatment with KHG26377 attenuated the Abeta25-35-induced apoptosis by decreasing the Bax/Bcl-2 ratio and suppressing the activation of caspase-3. 2-cyclopropylimino-3-methyl-1,3-thiazoline hydrochloride 15-23 BCL2 apoptosis regulator Homo sapiens 90-95 24803299-4 2014 Consistent with inhibition of CDK9, AAP1742 decreases the phosphorylation of RNA polymerase II and inhibits mRNA synthesis of anti-apoptotic proteins Mcl-1, Bcl-2, and XIAP, followed by apoptosis in the RPMI-8226 cell line in a dose- and a time-dependent manner. AAP1742 36-43 BCL2 apoptosis regulator Homo sapiens 157-162 25443365-7 2014 Several anti-apoptotic characteristics of TMP, including the ability to increase cell viability, inhibit caspase-9 activation, and upregulate Bcl-2 and down-regulate Bax in 4Gy-irradiated lymphocytes were determined. tetramethylpyrazine 42-45 BCL2 apoptosis regulator Homo sapiens 142-147 24928376-8 2014 The Bcl-2 and Cyclin D1, targets of Hh signaling, also decreased after treatment with quercetin, respectively. Quercetin 86-95 BCL2 apoptosis regulator Homo sapiens 4-9 24951472-2 2014 Previously, we reported that in response to ABT-737, ABT-737-resistant ALL cell lines showed an apparent increase in Mcl-1 (an anti-apoptotic Bcl-2 family protein that is not effectively inhibited by ABT-737) while ABT-737-sensitive ALL cell lines showed decreased Mcl-1 levels. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 44-47 BCL2 apoptosis regulator Homo sapiens 142-147 24643702-11 2014 E(2) + P4 promoted the expression of let-7a and miR-34b and reduced the expression of Bcl-2 in ovarian cancer cells. e(2) + p4 0-9 BCL2 apoptosis regulator Homo sapiens 86-91 24643702-13 2014 CONCLUSION: E(2) + P4 significantly inhibited the cell survival, promoted the cell apoptosis, induced the expression of let-7a and miR-34b, and reduced the expression of Bcl-2 in ovarian cancer cells. e(2) + p4 12-21 BCL2 apoptosis regulator Homo sapiens 170-175 24766194-0 2014 Aspirin inhibits proliferation and induces apoptosis of multiple myeloma cells through regulation of Bcl-2 and Bax and suppression of VEGF. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 101-106 24766194-8 2014 The myeloma cells exposed to ASA treatment displayed concentration-dependent apoptosis, which was closely associated with activation of caspases, upregulation of Bax, and downregulation of Bcl-2 and VEGF. Aspirin 29-32 BCL2 apoptosis regulator Homo sapiens 189-194 24951472-2 2014 Previously, we reported that in response to ABT-737, ABT-737-resistant ALL cell lines showed an apparent increase in Mcl-1 (an anti-apoptotic Bcl-2 family protein that is not effectively inhibited by ABT-737) while ABT-737-sensitive ALL cell lines showed decreased Mcl-1 levels. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 53-56 BCL2 apoptosis regulator Homo sapiens 142-147 25088254-4 2014 BCL-2 family proteins regulate apoptosis and over-expression of anti-apoptotic B-cell leukemia/lymphoma 2 (BCL-2) family proteins has been associated with chemotherapeutic resistance in APL including impairment of the ability of atRA to induce growth arrest and differentiation. Tretinoin 229-233 BCL2 apoptosis regulator Homo sapiens 0-5 24951472-2 2014 Previously, we reported that in response to ABT-737, ABT-737-resistant ALL cell lines showed an apparent increase in Mcl-1 (an anti-apoptotic Bcl-2 family protein that is not effectively inhibited by ABT-737) while ABT-737-sensitive ALL cell lines showed decreased Mcl-1 levels. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 53-56 BCL2 apoptosis regulator Homo sapiens 142-147 25088254-4 2014 BCL-2 family proteins regulate apoptosis and over-expression of anti-apoptotic B-cell leukemia/lymphoma 2 (BCL-2) family proteins has been associated with chemotherapeutic resistance in APL including impairment of the ability of atRA to induce growth arrest and differentiation. Tretinoin 229-233 BCL2 apoptosis regulator Homo sapiens 79-105 25088254-4 2014 BCL-2 family proteins regulate apoptosis and over-expression of anti-apoptotic B-cell leukemia/lymphoma 2 (BCL-2) family proteins has been associated with chemotherapeutic resistance in APL including impairment of the ability of atRA to induce growth arrest and differentiation. Tretinoin 229-233 BCL2 apoptosis regulator Homo sapiens 107-112 24951472-2 2014 Previously, we reported that in response to ABT-737, ABT-737-resistant ALL cell lines showed an apparent increase in Mcl-1 (an anti-apoptotic Bcl-2 family protein that is not effectively inhibited by ABT-737) while ABT-737-sensitive ALL cell lines showed decreased Mcl-1 levels. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 53-56 BCL2 apoptosis regulator Homo sapiens 142-147 25088254-5 2014 Here we investigated the novel BH3 domain mimetic, JY-1-106, which antagonizes the anti-apoptotic BCL-2 family members B-cell lymphoma-extra large (BCL-xL) and myeloid cell leukemia-1 (MCL-1) alone and in combination with retinoids including atRA, AM580 (RARalpha agonist), and SR11253 (RARgamma antagonist). Retinoids 222-231 BCL2 apoptosis regulator Homo sapiens 98-103 25090918-3 2014 Herein, we compare 2 alternative rabbit monoclonal antibodies (E17 and SP66) to the 124 clone in staining for BCL2 in formalin-fixed, paraffin-embedded DLBCL tissues. Formaldehyde 118-126 BCL2 apoptosis regulator Homo sapiens 110-114 25088254-5 2014 Here we investigated the novel BH3 domain mimetic, JY-1-106, which antagonizes the anti-apoptotic BCL-2 family members B-cell lymphoma-extra large (BCL-xL) and myeloid cell leukemia-1 (MCL-1) alone and in combination with retinoids including atRA, AM580 (RARalpha agonist), and SR11253 (RARgamma antagonist). Tretinoin 242-246 BCL2 apoptosis regulator Homo sapiens 98-103 25088254-5 2014 Here we investigated the novel BH3 domain mimetic, JY-1-106, which antagonizes the anti-apoptotic BCL-2 family members B-cell lymphoma-extra large (BCL-xL) and myeloid cell leukemia-1 (MCL-1) alone and in combination with retinoids including atRA, AM580 (RARalpha agonist), and SR11253 (RARgamma antagonist). Am 580 248-253 BCL2 apoptosis regulator Homo sapiens 98-103 25088254-5 2014 Here we investigated the novel BH3 domain mimetic, JY-1-106, which antagonizes the anti-apoptotic BCL-2 family members B-cell lymphoma-extra large (BCL-xL) and myeloid cell leukemia-1 (MCL-1) alone and in combination with retinoids including atRA, AM580 (RARalpha agonist), and SR11253 (RARgamma antagonist). sr11253 278-285 BCL2 apoptosis regulator Homo sapiens 98-103 24993441-8 2014 Especially, we found that BAI plus LB42708-induced apoptosis was significantly attenuated by overexpression of Bcl-2 and partially blocked by overexpression of c-FLIP (L). LB42708 35-42 BCL2 apoptosis regulator Homo sapiens 111-116 24752615-7 2014 Moreover, bufalin induced apoptosis and mitochondrial damage of RAFLSs, which was associated with Bcl-2 downregulation, Bax upregulation, mitochondrial cytochrome c release, and enhanced cleavages of caspase-3 and poly-(ADP-ribose) polymerase. bufalin 10-17 BCL2 apoptosis regulator Homo sapiens 98-103 24993616-4 2014 Sulforaphane-induced apoptosis was associated with mitochondria dysfunction, cytochrome c release and Bcl-2/Bax dysregulation. sulforaphane 0-12 BCL2 apoptosis regulator Homo sapiens 102-107 25074868-12 2014 Furthermore, western blot assay demonstrated that the tetrandrine induced apoptosis in SGC-996 cells by regulating the ratio of Bcl-2/Bax and activating the expression of cleaved caspase-3. tetrandrine 54-65 BCL2 apoptosis regulator Homo sapiens 128-133 25092426-5 2014 Following treatment with cisplatin, the protein expression of GPR40 in the kidneys was decreased in association with an increase in serum creatinine levels and the Bax/Bcl-2 expression ratio. Cisplatin 25-34 BCL2 apoptosis regulator Homo sapiens 168-173 25092426-10 2014 Treatment with cisplatin increased the Bax/Bcl-2 expression ratio and cleaved caspase-3 expression, and promoted the activation of nuclear factor-kappaB (NF-kappaB). Cisplatin 15-24 BCL2 apoptosis regulator Homo sapiens 43-48 25096914-5 2014 Auranofin treatment activates the pro-apoptotic caspase-3, increases protein levels of apoptosis-inducing proteins Bax and Bim and reduces the expression of the anti-apoptotic mediator Bcl-2 in SKOV3 cells. Auranofin 0-9 BCL2 apoptosis regulator Homo sapiens 185-190 24916770-0 2014 A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. navitoclax 28-38 BCL2 apoptosis regulator Homo sapiens 65-70 24155182-0 2014 Borrelidin has limited anti-cancer effects in bcl-2 overexpressing breast cancer and leukemia cells and reveals toxicity in non-malignant breast epithelial cells. borrelidin 0-10 BCL2 apoptosis regulator Homo sapiens 46-51 24155182-6 2014 Reduced sensitivity to borrelidin was associated with elevated bcl-2 expression in these cell lines. borrelidin 23-33 BCL2 apoptosis regulator Homo sapiens 63-68 24155182-7 2014 In conclusion, the results presented show that borrelidin displays high and selective cytotoxicity against subgroups of cancer cells and endothelial cells, but, owing to its non-specific toxicity to non-malignant cells, its clinical application might be restricted because of likely adverse effects and limited efficacy in bcl2-overexpressing cancer cells. borrelidin 47-57 BCL2 apoptosis regulator Homo sapiens 323-327 25096193-6 2014 The apoptosis-enhancing activity of quercetin in cell lines and B-CLL cells depends upon the modulated expression and activity of Mcl-1, an anti-apoptotic protein belonging to the Bcl-2 family. Quercetin 36-45 BCL2 apoptosis regulator Homo sapiens 180-185 25382724-7 2014 LPC treated cells showed typical apoptotic morphological changes including cytoplasmic vacuolation, swollen mitochondria, and characteristic biochemical hallmarks of apoptosis including loss of mitochondrial membrane potential, activation of caspase-3, decrease of Bcl-2, increase of PARP-1, upregulation of Bax, and release of cytochrome C, all of which were apparently inhibited by TSG pretreatment. Lysophosphatidylcholines 0-3 BCL2 apoptosis regulator Homo sapiens 265-270 24930917-6 2014 GB induced HepG2 apoptosis through a mitochondrial apoptotic pathway, which was demonstrated by GB-induced increase in the ratio of Bax/Bcl-2, cytochrome C release, the ratio of cleaved caspase-3/procaspase-3, and the ratio of cleaved poly ADP-ribose polymerase (cleaved PARP)/poly ADP-ribose polymerase (PARP). glycoborinine 0-2 BCL2 apoptosis regulator Homo sapiens 136-141 24930917-6 2014 GB induced HepG2 apoptosis through a mitochondrial apoptotic pathway, which was demonstrated by GB-induced increase in the ratio of Bax/Bcl-2, cytochrome C release, the ratio of cleaved caspase-3/procaspase-3, and the ratio of cleaved poly ADP-ribose polymerase (cleaved PARP)/poly ADP-ribose polymerase (PARP). glycoborinine 96-98 BCL2 apoptosis regulator Homo sapiens 136-141 25318886-7 2014 In addition, quercetin could down-regulate expression of bcl-2, up-regulate Bax, but exerted no effect on the overall expression of Akt. Quercetin 13-22 BCL2 apoptosis regulator Homo sapiens 57-62 25050836-7 2014 The results revealed that CXB sensitized TRAIL-resistant MG-63 OS cells to TRAIL-induced apoptosis through downregulation of cellular B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein, caspase-8 and caspase-3. Celecoxib 26-29 BCL2 apoptosis regulator Homo sapiens 134-151 25113166-3 2014 By examining the interactions of estradiol (E2) and progesterone (P4) in women, we propose that changes in physiologic reproductive hormone templates of exposure and timing can affect fertility and even cancer through the silencing or amplification of gene products; such as P53 and Bcl-2 in women. Estradiol 33-42 BCL2 apoptosis regulator Homo sapiens 283-288 25113166-3 2014 By examining the interactions of estradiol (E2) and progesterone (P4) in women, we propose that changes in physiologic reproductive hormone templates of exposure and timing can affect fertility and even cancer through the silencing or amplification of gene products; such as P53 and Bcl-2 in women. Progesterone 52-64 BCL2 apoptosis regulator Homo sapiens 283-288 25050836-7 2014 The results revealed that CXB sensitized TRAIL-resistant MG-63 OS cells to TRAIL-induced apoptosis through downregulation of cellular B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein, caspase-8 and caspase-3. Celecoxib 26-29 BCL2 apoptosis regulator Homo sapiens 153-158 25050836-7 2014 The results revealed that CXB sensitized TRAIL-resistant MG-63 OS cells to TRAIL-induced apoptosis through downregulation of cellular B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein, caspase-8 and caspase-3. Celecoxib 26-29 BCL2 apoptosis regulator Homo sapiens 161-166 25070748-4 2014 Phloroglucinol treatment of HT-29 cells resulted in characteristic apoptosis-related changes: altered Bcl-2 family proteins, cytochrome c release, and activation of caspase-3 and caspase-8. Phloroglucinol 0-14 BCL2 apoptosis regulator Homo sapiens 102-107 25175641-7 2014 The molecule markers showed that DADS induced apoptosis through activating caspases, altering the Bax/Bcl-2 balance and suppressing the MEK-ERK pathway. diallyl disulfide 33-37 BCL2 apoptosis regulator Homo sapiens 102-107 25111376-8 2014 Down-modulation of anti-apoptotic Bcl-2 protein by siRNA sensitized LNCaP cells to taxanes and starvation induced cell death. Taxoids 83-90 BCL2 apoptosis regulator Homo sapiens 34-39 25109871-8 2014 We also found that isoalantolactone-induced apoptosis was associated with the downregulation of Bcl-2 and upregulation of Bax, which finally led to the activation of caspase-3 and its downstream substrate, PARP, in osteosarcoma U2OS cells. isoalantolactone 19-35 BCL2 apoptosis regulator Homo sapiens 96-101 25110043-4 2014 Moreover, As2O3 also promoted the formation of autophagic vacuoles, as well as increased the degradation of autophagy substrate P62 protein, which was accompanied by an upregulation of Beclin-1 gene and a downregulation of Bcl-2 gene expression. Arsenic Trioxide 10-15 BCL2 apoptosis regulator Homo sapiens 223-228 25110043-5 2014 3-Methyladenine, an autophagy inhibitor, not only increased cell viability through inhibiting autophagic cell death and apoptosis, but also reversed the upregulation of Beclin-1 gene and the downregulation of Bcl-2 gene in the Raji cells induced by As2O3. 3-methyladenine 0-15 BCL2 apoptosis regulator Homo sapiens 209-214 25111376-9 2014 CONCLUSIONS: Silencing Bcl-2 in PTEN-mutated prostate cancer cells enhances the apoptotic effects of combined starvation and taxol treatments, indicating that inhibition of Bcl-2 may be of significant value in PTEN-mutant tumor therapy. Paclitaxel 125-130 BCL2 apoptosis regulator Homo sapiens 23-28 25111376-0 2014 Down-modulation of Bcl-2 sensitizes PTEN-mutated prostate cancer cells to starvation and taxanes. Taxoids 89-96 BCL2 apoptosis regulator Homo sapiens 19-24 25027398-3 2014 Here, we demonstrated that VA inhibited the growth of MCF-7 breast cancer cells, increased the levels of reactive oxygen species (ROS), and subsequently induced mitochondrial membrane potential (Deltapsim) loss, leading to the increase of Bax/Bcl-2 ratio, cytochrome c release, caspase activation, PARP degradation, and apoptosis. muconomycin A 27-29 BCL2 apoptosis regulator Homo sapiens 243-248 25345952-8 2014 Treatment of MCF-7 cells with high-concentration xy2004 reduced the cellular expression of Bcl-2 protein and increased Bax protein expression. xy2004 49-55 BCL2 apoptosis regulator Homo sapiens 91-96 25338570-9 2014 Arsenic trioxide combined with curcumin can effectively inhibit the KG1a cell proliferation and induce apoptosis, which may be associated with the downregulation of BCL-2 and PARP protein expression and the upregulation of BAX protein expression. Arsenic Trioxide 0-16 BCL2 apoptosis regulator Homo sapiens 165-170 25338565-7 2014 After GSK525762A treatment, the mRNA levels of proliferation-promoting genes ( C-MYC and CDK6) and pro-survival genes ( BCL-2 and BCL-xL) decreased, while the transcription level of pro-apoptosis genes BAK and BAX increased, as compared to that of the control group. molibresib 6-16 BCL2 apoptosis regulator Homo sapiens 120-125 25338565-8 2014 It is concluded that GSK525762A can inhibit the proliferation of KU812 cells and induce cell apoptosis possibly through depressing the transcription of C-MYC, BCL-2, CDK6 and BCL-xL gene, and down-regulating BAK and BAX transcription. molibresib 21-31 BCL2 apoptosis regulator Homo sapiens 159-164 25338583-5 2014 The effects of sorafenib on the expression of caspase-3, BCL-2 and MCL-1 mRNA and protein were assayed by RT-PCR and Western blot respectively. Sorafenib 15-24 BCL2 apoptosis regulator Homo sapiens 57-62 25338570-9 2014 Arsenic trioxide combined with curcumin can effectively inhibit the KG1a cell proliferation and induce apoptosis, which may be associated with the downregulation of BCL-2 and PARP protein expression and the upregulation of BAX protein expression. Curcumin 31-39 BCL2 apoptosis regulator Homo sapiens 165-170 25338583-9 2014 Typical apoptotic morphological and ultrastructural changes of MM cells could be observed under transmission electron microscope, Examination of cellular signaling pathways showed that sorafenib induced upregulation of cleaved-caspase-3 expression, and simultaneous downregulation of BCL-2 and MCL-1 expression. Sorafenib 185-194 BCL2 apoptosis regulator Homo sapiens 284-289 25533359-3 2014 RESULTS: Bcl-2 mRNA expression levels increased significantly in normal liver cells and CYP2E1-overexpressing cells after TCE treatment, Bcl-2 levels were 20%~50%higher in CYP2E1-overexpressing cells than in L02 liver cells at doses of 0.25~2.0 mmol/L TCE. Trichloroethylene 122-125 BCL2 apoptosis regulator Homo sapiens 9-14 25547582-9 2014 As the glucose concentration increased and duration prolonged, the expression of anti-apoptotic protein Bcl-2 was decreased and pro-apoptotic protein Bax was increased.Intracellular ROS and MDA induced by high glucose were increased significantly with dose-and time-dependence. Glucose 7-14 BCL2 apoptosis regulator Homo sapiens 104-109 25547582-9 2014 As the glucose concentration increased and duration prolonged, the expression of anti-apoptotic protein Bcl-2 was decreased and pro-apoptotic protein Bax was increased.Intracellular ROS and MDA induced by high glucose were increased significantly with dose-and time-dependence. ros 182-185 BCL2 apoptosis regulator Homo sapiens 104-109 25533359-3 2014 RESULTS: Bcl-2 mRNA expression levels increased significantly in normal liver cells and CYP2E1-overexpressing cells after TCE treatment, Bcl-2 levels were 20%~50%higher in CYP2E1-overexpressing cells than in L02 liver cells at doses of 0.25~2.0 mmol/L TCE. Trichloroethylene 252-255 BCL2 apoptosis regulator Homo sapiens 9-14 25547582-9 2014 As the glucose concentration increased and duration prolonged, the expression of anti-apoptotic protein Bcl-2 was decreased and pro-apoptotic protein Bax was increased.Intracellular ROS and MDA induced by high glucose were increased significantly with dose-and time-dependence. Glucose 210-217 BCL2 apoptosis regulator Homo sapiens 104-109 25268519-0 2014 Synthesis and characterization of novel 2-amino-chromene-nitriles that target Bcl-2 in acute myeloid leukemia cell lines. 2-amino-chromene-nitriles 40-65 BCL2 apoptosis regulator Homo sapiens 78-83 25547582-14 2014 When resveratrol (5.0, 15.0, 25.0, 35.0 mg/L) was added to 25.0 mmol/L glucose medium, respectively, the apoptotic cells were decreased, the expression of pro-apoptotic protein Bax was decreased and anti-apoptotic protein Bcl-2 was increased.Intracellular ROS (compared with the basic concentration of 5.5 mmol/L, F values were 14.76, 7.018, 13.96, 4.733, 1.921, P values were 0.000, 0.000, 0.003, 0.086, 0.100 respectively) and MDA (compared with the basic concentration of 5.5 mmol/L, F values were 2.454, 1.108, 1.630, 1.563, 2.250, P values were 0.000, 0.001, 0.026, 0.068, 0.183 respectively) were decreased. Resveratrol 5-16 BCL2 apoptosis regulator Homo sapiens 222-227 25567306-7 2014 The expression of Bcl-2 mRNA in patients with complete remission (CR) (0.71 +- 0.58) was significantly lower vs. 2.42 +- 0.91 in patients with no CR (P < 0.05). Chromium 66-68 BCL2 apoptosis regulator Homo sapiens 18-23 25268131-7 2014 KEY RESULTS: U-II reduced the quantity of cleaved caspase-3 and cytosol cytochrome c and increased Bcl-2 expression, which results in protecting HUVECs from DOX-induced apoptosis. Doxorubicin 157-160 BCL2 apoptosis regulator Homo sapiens 99-104 25115399-3 2014 Analysis revealed that this function is mediated by Bcl-2 family proteins: Cytoplasmic p53 binds Bcl-w, liberating Bax, which then binds ND5, a subunit of respiratory complex-I, thereby suppressing complex-I activity and thus ROS production. Reactive Oxygen Species 226-229 BCL2 apoptosis regulator Homo sapiens 52-57 25115399-7 2014 This study demonstrates a link between p53 and Bcl-2 proteins as regulators of ROS production and cellular invasiveness, and reveals complex-I, especially ND5, as their functional target. Reactive Oxygen Species 79-82 BCL2 apoptosis regulator Homo sapiens 47-52 25268882-8 2014 Furthermore, G503 increased the ratio of Bax to Bcl-2 in the mitochondria and decreased the ratio in the cytosol. g503 13-17 BCL2 apoptosis regulator Homo sapiens 48-53 25218158-8 2014 Piceatannol induced apoptosis by promoting expression of miR-129, and then inhibiting expression of Bcl-2, an known target for miR-129. 3,3',4,5'-tetrahydroxystilbene 0-11 BCL2 apoptosis regulator Homo sapiens 100-105 25297825-9 2014 Pre-treatment with DEX could up-regulate the expressions of members of anti-apoptotic Bcl-2 family (Bcl-2 and Bcl-XL) and members of IAP family (survivin). Dexamethasone 19-22 BCL2 apoptosis regulator Homo sapiens 86-91 25297825-9 2014 Pre-treatment with DEX could up-regulate the expressions of members of anti-apoptotic Bcl-2 family (Bcl-2 and Bcl-XL) and members of IAP family (survivin). Dexamethasone 19-22 BCL2 apoptosis regulator Homo sapiens 100-105 25138585-1 2014 The reaction of 8-(trimethylsiloxy)quinoline (QOTMS) with BCl3 and (aryl)BCl2 forms QOBCl2 and QOBCl(aryl). Quinoline, 8-[(trimethylsilyl)oxy]- 16-44 BCL2 apoptosis regulator Homo sapiens 73-77 25255962-6 2014 Annexin-V translocation and caspase-3 activation indicated an apoptotic component in ouabain cytoxicity, which was accompanied with reduced Bcl-2 expression and mitochondrial membrane potential. Ouabain 85-92 BCL2 apoptosis regulator Homo sapiens 140-145 25172783-13 2014 Further studies demonstrated the inhibitory effects of guggulsterone on Bcl-2 and P-glycoprotein expression were the possible reason to increase chemosensitivity of MCF-7/DOX cells to doxorubicin in vivo. pregna-4,17-diene-3,16-dione 55-68 BCL2 apoptosis regulator Homo sapiens 72-77 25108166-4 2014 Our results revealed that H2O2 reduced viability of cells through up-regulation of p53 followed by increase in Bax/Bcl2 ratio. Hydrogen Peroxide 26-30 BCL2 apoptosis regulator Homo sapiens 115-119 25172783-13 2014 Further studies demonstrated the inhibitory effects of guggulsterone on Bcl-2 and P-glycoprotein expression were the possible reason to increase chemosensitivity of MCF-7/DOX cells to doxorubicin in vivo. Doxorubicin 171-174 BCL2 apoptosis regulator Homo sapiens 72-77 25172783-13 2014 Further studies demonstrated the inhibitory effects of guggulsterone on Bcl-2 and P-glycoprotein expression were the possible reason to increase chemosensitivity of MCF-7/DOX cells to doxorubicin in vivo. Doxorubicin 184-195 BCL2 apoptosis regulator Homo sapiens 72-77 25096574-4 2014 However, the success of these "BH3 mimetics" in the clinic has been limited, likely due to an incomplete understanding of how these drugs function in the presence of multiple BCL-2 family members. BH 3 31-34 BCL2 apoptosis regulator Homo sapiens 175-180 25096574-8 2014 Together, these data suggest that although the presence of anti-apoptotic BCL-2 proteins primarily dictates cellular sensitivity to BH3 mimetics, additional specificity is conferred by proapoptotic BCL-2 proteins. BH 3 132-135 BCL2 apoptosis regulator Homo sapiens 74-79 25229655-9 2014 Antiproliferative effect of DHA ester of phloridzin could be related to the down regulation of anti-apoptotic gene (BCL2), growth factor receptors (EBFR family, IGF1R/IGF2, PDGFR) and its downstream signalling partners (PI3k/AKT/mTOR, Ras/Raf/MAPK), cell cycle machinery (CDKs, TERT, TOP2A, TOP2B) as well as epigenetics regulators (HDACs). Phlorhizin 41-51 BCL2 apoptosis regulator Homo sapiens 116-120 25122609-10 2014 ABC294640, per se, did not affect the expression of B-cell lymphoma 2 (Bcl-2), but acted synergistically with ABT-737 (a Bcl-2 inhibitor) in inducing myeloma cell death. ABT-737 110-117 BCL2 apoptosis regulator Homo sapiens 121-126 25229655-9 2014 Antiproliferative effect of DHA ester of phloridzin could be related to the down regulation of anti-apoptotic gene (BCL2), growth factor receptors (EBFR family, IGF1R/IGF2, PDGFR) and its downstream signalling partners (PI3k/AKT/mTOR, Ras/Raf/MAPK), cell cycle machinery (CDKs, TERT, TOP2A, TOP2B) as well as epigenetics regulators (HDACs). dha ester 28-37 BCL2 apoptosis regulator Homo sapiens 116-120 25230315-7 2014 We show that ganglioside triggered four key pathways leading to apoptosis in human platelets: (i) mitochondrial inner transmembrane potential (DeltaPsim) depolarization; (ii) elevated expression of pro-apoptotic Bax and Bak proteins with reduced expression of anti-apoptotic Bcl-2 protein; (iii) phosphatidylserine exposure and (iv), microparticle formation. Gangliosides 13-24 BCL2 apoptosis regulator Homo sapiens 275-280 25229941-6 2014 Bcl-2 protein expression in UM-SCC-17B cancer cells was inhibited by 30% after treatment for 72 h. Results show that pH-sensitive comb-like polymer complex anti-Bcl-2 siRNA forming "smart" nanoparticles that deliver their cargo into the cytoplasm of HeLa and UM-SCC-17B cancer cells causing Bcl-2 knockdown at the mRNA and protein levels. Polymers 140-147 BCL2 apoptosis regulator Homo sapiens 0-5 25229941-6 2014 Bcl-2 protein expression in UM-SCC-17B cancer cells was inhibited by 30% after treatment for 72 h. Results show that pH-sensitive comb-like polymer complex anti-Bcl-2 siRNA forming "smart" nanoparticles that deliver their cargo into the cytoplasm of HeLa and UM-SCC-17B cancer cells causing Bcl-2 knockdown at the mRNA and protein levels. Polymers 140-147 BCL2 apoptosis regulator Homo sapiens 161-166 25229941-6 2014 Bcl-2 protein expression in UM-SCC-17B cancer cells was inhibited by 30% after treatment for 72 h. Results show that pH-sensitive comb-like polymer complex anti-Bcl-2 siRNA forming "smart" nanoparticles that deliver their cargo into the cytoplasm of HeLa and UM-SCC-17B cancer cells causing Bcl-2 knockdown at the mRNA and protein levels. Polymers 140-147 BCL2 apoptosis regulator Homo sapiens 161-166 25221997-5 2014 In the HL-60 cells, A398 induced apoptosis in a time and concentration-dependent manner, promoting mitochondrial depolarization, inhibition of Bcl-2, phosphatidylserine exposure, activation of caspases -8, -9 and -3, and DNA fragmentation. a398 20-24 BCL2 apoptosis regulator Homo sapiens 143-148 25400762-11 2014 However, the apoptosis rate (P < 0.01) of the cholesterol group was significantly higher than that of the normal group or the steatosis group, and the protein expressions of Bax and caspase-3, but not P53, Bcl-2, cyclin A, cyclin B1 and cyclin E, were also increased in the cholesterol group. Cholesterol 49-60 BCL2 apoptosis regulator Homo sapiens 209-214 25210795-2 2014 We thus investigated the role of various anti-apoptotic Bcl-2 proteins for apoptosis protection in SCC using the BH3 agonist ABT737 that can overcome multidomain Bcl-2 protein protection. BH 3 113-116 BCL2 apoptosis regulator Homo sapiens 162-167 25210795-2 2014 We thus investigated the role of various anti-apoptotic Bcl-2 proteins for apoptosis protection in SCC using the BH3 agonist ABT737 that can overcome multidomain Bcl-2 protein protection. ABT-737 125-131 BCL2 apoptosis regulator Homo sapiens 162-167 24995577-8 2014 Treatments with progressively increasing concentrations (from 100 muM to 500 muM) of esculetin produced a reduction of Bcl2/Bax ratio in NB4 cells at 19 h, without affecting p53 levels. esculetin 85-94 BCL2 apoptosis regulator Homo sapiens 119-123 24999019-7 2014 Silencing CFTR with adenovirus-mediated CFTR specific siRNA further enhanced H2O2-induced BASMC injury, mitochondrial cytochrome c release into cytoplasm, cleaved caspase-3 and -9 protein expression and oxidized glutathione levels; while decreased cell viability, the Bcl-2/Bax ratio, mitochondrial membrane potential, total glutathione levels, activities of superoxide dismutase and catalase. Hydrogen Peroxide 77-81 BCL2 apoptosis regulator Homo sapiens 268-273 25246769-7 2014 The expression of Bcl-2, Bax, Beclin-1, and LC3-2, which play important roles in the apoptosis and autophagy pathways, were also clearly affected by NaHS. sodium bisulfide 149-153 BCL2 apoptosis regulator Homo sapiens 18-23 25202081-8 2014 Pre-treatment with N-acetylcysteine blocked loss of MMP, caused increase of Bcl-2-associated X protein (Bax)/B-cell lymphoma 2 (Bcl-2) ratio, caspase-8 activation, and apoptosis induced by equol. Acetylcysteine 19-35 BCL2 apoptosis regulator Homo sapiens 76-81 25013123-7 2014 Among BCL2 family members, in vivo ABT-263 sensitivity correlated best with low MCL1 mRNA expression levels. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 35-38 BCL2 apoptosis regulator Homo sapiens 6-10 24786833-7 2014 SAG knockdown caused the accumulation of proapoptotic Bax and SARM, imbalance of Bcl-2/Bax in the mitochondria, induction of cytosolic cytochrome c and activation of caspase-9 and -3, all of which led to disequilibrium between life and death of macrophages. sagopilone 0-3 BCL2 apoptosis regulator Homo sapiens 81-86 24994123-7 2014 Our findings demonstrate that BCL-2 is a clinically relevant target for therapeutic intervention with ABT-199 in ETP-ALL. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 102-105 BCL2 apoptosis regulator Homo sapiens 30-35 24994123-9 2014 We have discovered, through BH3 profiling, that ETP-ALL is BCL-2 dependent and is very sensitive to in vitro and in vivo treatment with ABT-199, a drug well tolerated in clinical trials. BH 3 28-31 BCL2 apoptosis regulator Homo sapiens 59-64 24994123-9 2014 We have discovered, through BH3 profiling, that ETP-ALL is BCL-2 dependent and is very sensitive to in vitro and in vivo treatment with ABT-199, a drug well tolerated in clinical trials. venetoclax 136-143 BCL2 apoptosis regulator Homo sapiens 59-64 25128771-8 2014 And, high dose of ATO increased Bax/Bcl-2 ratio in a time-dependent fashion and activated caspase-3 apoptotic signaling. Arsenic Trioxide 18-21 BCL2 apoptosis regulator Homo sapiens 36-41 25136776-4 2014 Treatment of sorafenib still significantly increased caspase-3, bax, cyt-c protein expression and decreased bcl-2 protein in a dose-dependent manner. Sorafenib 13-22 BCL2 apoptosis regulator Homo sapiens 108-113 24192507-12 2014 Treatment with relatively high concentration of As2S2 resulted in the downregulation of Bcl-2 and Bid proteins in HL-60 cells. Arsenic(II) sulfide 48-53 BCL2 apoptosis regulator Homo sapiens 88-93 24930757-6 2014 Ilimaquinone also reduced the cell survival proteins Bcl2 and Bcl-xL, while strongly up-regulating death receptor (DR) 4 and DR5 expression. ilimaquinone 0-12 BCL2 apoptosis regulator Homo sapiens 53-57 24917472-10 2014 LCA and solar lentigo showed different keratin 10 and Bcl-2 signal intensities. Lithocholic Acid 0-3 BCL2 apoptosis regulator Homo sapiens 54-59 24919770-0 2014 Apogossypolone, a small-molecule inhibitor of Bcl-2, induces radiosensitization of nasopharyngeal carcinoma cells by stimulating autophagy. apogossypolone 0-14 BCL2 apoptosis regulator Homo sapiens 46-51 24919770-3 2014 Previously, we showed that apogossypolone (ApoG2) induced apoptosis by blocking the binding of Bcl-2 to Bax, arresting the cell cycle in the S phase, in turn inhibiting proliferation of NPC cells both in vitro and in vivo. apogossypolone 27-41 BCL2 apoptosis regulator Homo sapiens 95-100 25189901-0 2014 Additional compensatory mechanisms altering antisense oligonucleotide suppression of BCL2: effects upon AKT1 and STAT3. Oligonucleotides 54-69 BCL2 apoptosis regulator Homo sapiens 85-89 25189901-2 2014 We evaluated mono- and bispecific oligonucleotides which targeted and comparably suppressed B-cell lymphoma-2 BCL-2 (an apoptosis-inhibitory protein) expression in LNCaP cells. Oligonucleotides 34-50 BCL2 apoptosis regulator Homo sapiens 110-115 24597985-4 2014 Compared with the use of DEX or low-dose anisomycin alone, co-treatment with them resulted in a significant increase of growth inhibition, apoptosis and cell cycle arrest in CEM-C1 cells through induction of activated caspase-3 and up-regulation of Bim, p21and p27, and down-regulation of Mcl-1, Bcl-2, c-myc, cyclin A and cyclin D1. Dexamethasone 25-28 BCL2 apoptosis regulator Homo sapiens 296-301 24997137-1 2014 OBJECTIVE: This randomized phase II study assessed the efficacy and safety of obatoclax mesylate, a small-molecule Bcl-2 inhibitor, added to carboplatin/etoposide chemotherapy as initial treatment for extensive-stage small-cell lung cancer (ES-SCLC). obatoclax 78-87 BCL2 apoptosis regulator Homo sapiens 115-120 25070854-5 2014 Prosurvival factors of the Bcl-2 family, such as Bcl-xL, are often upregulated in B cell lymphomas and are intimately linked to sphingolipid metabolism, as well as the endocytic compartments. Sphingolipids 128-140 BCL2 apoptosis regulator Homo sapiens 27-32 24986090-8 2014 The expression of cleaved caspase-3 increased, while Bcl-2 decreased in each cell line following treatment with shHDGF and TMZ, as compared to TMZ alone. Temozolomide 123-126 BCL2 apoptosis regulator Homo sapiens 53-58 24289107-4 2014 This exploratory study was designed to correlate the mRNA expression levels of candidate genes mainly involved in the doxorubicin pathway (ABCB1, GSTP1, TOPO2alpha, BCL2, PKCbetaII) with the outcome of 54 patients with DLBCL undergoing a dose-dense R-CHOP regimen. Doxorubicin 118-129 BCL2 apoptosis regulator Homo sapiens 165-169 24597985-4 2014 Compared with the use of DEX or low-dose anisomycin alone, co-treatment with them resulted in a significant increase of growth inhibition, apoptosis and cell cycle arrest in CEM-C1 cells through induction of activated caspase-3 and up-regulation of Bim, p21and p27, and down-regulation of Mcl-1, Bcl-2, c-myc, cyclin A and cyclin D1. Anisomycin 41-51 BCL2 apoptosis regulator Homo sapiens 296-301 24970681-5 2014 Immunohistochemistry and western blot assays showed that SAMC induced the apoptosis of cancer cells by activating TGF-beta1, TbetaRII, p-smad2/3, smad4 and smad7 signals, and promoting Bim expression while decreasing Bcl-2 expression and finally activating the mitochondrial apoptosis pathway proteins caspase-3 and caspase-9 in the HepG2 cell line. S-allylmercaptocysteine 57-61 BCL2 apoptosis regulator Homo sapiens 217-222 24932697-5 2014 In addition, gastrodin inhibited MPP(+)-induced lowered membrane potential, decreased Bcl-2/Bax ratio. gastrodin 13-22 BCL2 apoptosis regulator Homo sapiens 86-91 25014175-0 2014 The impact of anti-apoptotic gene Bcl-2 expression on CHO central metabolism. CAV protocol 55-58 BCL2 apoptosis regulator Homo sapiens 34-39 25014175-5 2014 Expression of Bcl-2Delta reduced lactate accumulation by redirecting the fate of intracellular pyruvate toward mitochondrial oxidation during the lactate-producing phase, and it significantly increased lactate re-uptake during the lactate-consuming phase. Lactic Acid 33-40 BCL2 apoptosis regulator Homo sapiens 14-19 25014175-5 2014 Expression of Bcl-2Delta reduced lactate accumulation by redirecting the fate of intracellular pyruvate toward mitochondrial oxidation during the lactate-producing phase, and it significantly increased lactate re-uptake during the lactate-consuming phase. Pyruvic Acid 95-103 BCL2 apoptosis regulator Homo sapiens 14-19 25014175-5 2014 Expression of Bcl-2Delta reduced lactate accumulation by redirecting the fate of intracellular pyruvate toward mitochondrial oxidation during the lactate-producing phase, and it significantly increased lactate re-uptake during the lactate-consuming phase. Lactic Acid 146-153 BCL2 apoptosis regulator Homo sapiens 14-19 25014175-5 2014 Expression of Bcl-2Delta reduced lactate accumulation by redirecting the fate of intracellular pyruvate toward mitochondrial oxidation during the lactate-producing phase, and it significantly increased lactate re-uptake during the lactate-consuming phase. Lactic Acid 146-153 BCL2 apoptosis regulator Homo sapiens 14-19 25014175-5 2014 Expression of Bcl-2Delta reduced lactate accumulation by redirecting the fate of intracellular pyruvate toward mitochondrial oxidation during the lactate-producing phase, and it significantly increased lactate re-uptake during the lactate-consuming phase. Lactic Acid 146-153 BCL2 apoptosis regulator Homo sapiens 14-19 24903379-5 2014 The increase in ABP-induced apoptosis was accompanied by loss of mitochondria membrane potential ( Psim), cytochrome c release from the mitochondria, activation of caspase-3, degradation of poly(ADP-ribose) polymerase (PARP), and the elevated ratio of Bcl-2-associated X (Bax)/B-cell lymphoma 2 (Bcl-2). abp 16-19 BCL2 apoptosis regulator Homo sapiens 252-257 24561640-7 2014 RESULTS: L-Arg significantly inhibited growth of SCG-7901 gastric cancer cells and downregulated expression of antiapoptotic gene Bcl-2 and survivin. Arginine 9-14 BCL2 apoptosis regulator Homo sapiens 130-135 24561640-9 2014 CONCLUSION: Regulation of apoptosis by L-Arg via downregulation of antiapoptotic proteins Bcl-2 and surviving, and upregulation of proapoptotic protein p53 may represent the mechanism behind antitumor effects of L-Arg. Arginine 39-44 BCL2 apoptosis regulator Homo sapiens 90-95 24352336-5 2014 Among the BH3-only family, Noxa stands out as exceptional for its specificity to bind Mcl-1 and Bcl-2 and blunt their biological properties. BH 3 10-13 BCL2 apoptosis regulator Homo sapiens 96-101 24814395-6 2014 Also, cotreatment with SAHA and Doxorubicin changes the ratio of pro- and antiapoptotic Bcl-2 proteins with downregulation of Mcl-1 and Bcl-xL, dephosphorylation of Bcl-2 and upregulation of BimEL, thus shifting the balance towards apoptosis. Vorinostat 23-27 BCL2 apoptosis regulator Homo sapiens 88-93 24814395-6 2014 Also, cotreatment with SAHA and Doxorubicin changes the ratio of pro- and antiapoptotic Bcl-2 proteins with downregulation of Mcl-1 and Bcl-xL, dephosphorylation of Bcl-2 and upregulation of BimEL, thus shifting the balance towards apoptosis. Vorinostat 23-27 BCL2 apoptosis regulator Homo sapiens 165-170 24814395-6 2014 Also, cotreatment with SAHA and Doxorubicin changes the ratio of pro- and antiapoptotic Bcl-2 proteins with downregulation of Mcl-1 and Bcl-xL, dephosphorylation of Bcl-2 and upregulation of BimEL, thus shifting the balance towards apoptosis. Doxorubicin 32-43 BCL2 apoptosis regulator Homo sapiens 88-93 24814395-6 2014 Also, cotreatment with SAHA and Doxorubicin changes the ratio of pro- and antiapoptotic Bcl-2 proteins with downregulation of Mcl-1 and Bcl-xL, dephosphorylation of Bcl-2 and upregulation of BimEL, thus shifting the balance towards apoptosis. Doxorubicin 32-43 BCL2 apoptosis regulator Homo sapiens 165-170 24814395-8 2014 Overexpression of Bcl-2 significantly rescues SAHA/Doxorubicin-mediated apoptosis, underscoring the requirement of the mitochondrial apoptotic pathway for the synergistic induction of apoptosis by SAHA and Doxorubicin. Vorinostat 46-50 BCL2 apoptosis regulator Homo sapiens 18-23 24814395-8 2014 Overexpression of Bcl-2 significantly rescues SAHA/Doxorubicin-mediated apoptosis, underscoring the requirement of the mitochondrial apoptotic pathway for the synergistic induction of apoptosis by SAHA and Doxorubicin. Doxorubicin 51-62 BCL2 apoptosis regulator Homo sapiens 18-23 24814395-8 2014 Overexpression of Bcl-2 significantly rescues SAHA/Doxorubicin-mediated apoptosis, underscoring the requirement of the mitochondrial apoptotic pathway for the synergistic induction of apoptosis by SAHA and Doxorubicin. Vorinostat 197-201 BCL2 apoptosis regulator Homo sapiens 18-23 24814395-8 2014 Overexpression of Bcl-2 significantly rescues SAHA/Doxorubicin-mediated apoptosis, underscoring the requirement of the mitochondrial apoptotic pathway for the synergistic induction of apoptosis by SAHA and Doxorubicin. Doxorubicin 206-217 BCL2 apoptosis regulator Homo sapiens 18-23 24096476-2 2014 We hypothesized that phosphorylation of PXN by the EGFR/Src pathway might contribute to cisplatin resistance via increased Bcl-2 expression. Cisplatin 88-97 BCL2 apoptosis regulator Homo sapiens 123-128 24096476-7 2014 A subsequent increase in Bcl-2 levels by a PXN/ERK axis was responsible for the resistance to cisplatin. Cisplatin 94-103 BCL2 apoptosis regulator Homo sapiens 25-30 25165862-5 2014 Western blot analysis of Sch B-treated cells revealed the upregulation of Bax, cleaved caspase-9, cleaved caspase-3, cleaved PARP and downregulation of Bcl-2, NF-kappaB, cyclin D1 and CDK-4. schizandrin B 25-30 BCL2 apoptosis regulator Homo sapiens 152-157 25372635-10 2014 Higher expression of IGFBP-3 and lower expression of Bcl-2 in LNCaP cells treated with IP6 were found at both mRNA and protein levels. Phytic Acid 87-90 BCL2 apoptosis regulator Homo sapiens 53-58 25372635-14 2014 CONCLUSION: IP6 can inhibit the proliferation of LNCaP cells, which may be associated with the changes of IGFBP-3 level through Bcl-2 expression. Phytic Acid 12-15 BCL2 apoptosis regulator Homo sapiens 128-133 25170898-11 2014 DHMEQ increased cell apoptosis by decreasing the anti-apoptotic protein expressions-Bcl-2, XIAP-and activating caspase pathway. dehydroxymethylepoxyquinomicin 0-5 BCL2 apoptosis regulator Homo sapiens 84-89 24096476-10 2014 Patients with tumors positive for PXN, phosphorylated PXN, phosphorylated ERK and Bcl-2 more commonly showed a poorer response to cisplatin-based chemotherapy than did patients with negative tumors. Cisplatin 130-139 BCL2 apoptosis regulator Homo sapiens 82-87 24096476-11 2014 Collectively, PXN phosphorylation might contribute to cisplatin resistance via activating ERK-mediated Bcl-2 transcription. Cisplatin 54-63 BCL2 apoptosis regulator Homo sapiens 103-108 25139387-1 2014 ABT-737 inhibits the anti-apoptotic proteins B-cell lymphoma 2 (BCL-2) and BCL-X(L). ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 45-62 25148076-9 2014 Furthermore, it was found that the antiapoptotic bcl-2 gene was down-regulated while the proapoptotic bax gene was up-regulated after betulinic acid treatment in HeLa cells. betulinic acid 134-148 BCL2 apoptosis regulator Homo sapiens 49-54 25139387-1 2014 ABT-737 inhibits the anti-apoptotic proteins B-cell lymphoma 2 (BCL-2) and BCL-X(L). ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 64-69 25023790-8 2014 RESULTS: beta-OH-S infusion prior to reperfusion reduced coronary and cardiac oxidative DNA-damage, diminished neutrophil infiltration at the site of ischemia, preserved mitochondrial membrane potential and reduced apoptosis in the ischemic myocardium (lower mRNA levels of Fas, casp8, p53, and casp3 and mitochondrial-p-Bcl2; and reduced TUNEL and active caspase-3; p<0.05 vs. vehicle/control). beta-oh-s 9-18 BCL2 apoptosis regulator Homo sapiens 321-325 24907101-0 2014 Inhibition of oxygen-glucose deprivation-induced apoptosis of human adipose-derived stem cells by genetic modification with antiapoptotic protein bcl-2. oxygen-glucose 14-28 BCL2 apoptosis regulator Homo sapiens 146-151 25055196-1 2014 In order to overcome poor cell permeability of antisense peptide nucleic acid (PNA), a fluorescent mesoporous silica nanoparticle (MSNP) carrier was developed to successfully deliver antisense PNA into cancer cells for effective silence of B-cell lymphoma 2 (Bcl-2) protein expression in vitro. Silicon Dioxide 110-116 BCL2 apoptosis regulator Homo sapiens 240-257 25055196-1 2014 In order to overcome poor cell permeability of antisense peptide nucleic acid (PNA), a fluorescent mesoporous silica nanoparticle (MSNP) carrier was developed to successfully deliver antisense PNA into cancer cells for effective silence of B-cell lymphoma 2 (Bcl-2) protein expression in vitro. Silicon Dioxide 110-116 BCL2 apoptosis regulator Homo sapiens 259-264 25011914-3 2014 In addition, The apoptosis induction abilities of the isosclerone was studied by analyzing the expression of caspase-3, -8 and -9, Bcl-2 family, NF-kappa-B P50, P65, and IKK proteins. isosclerone 54-65 BCL2 apoptosis regulator Homo sapiens 131-136 25011914-4 2014 Western blot and RT-PCR analysis have indicated that isosclerone induce cancer cells apoptosis through down-regulated Bcl-2 family and up-regulated caspases, and activating the NF-kappa-B signaling pathway. isosclerone 53-64 BCL2 apoptosis regulator Homo sapiens 118-123 25011914-5 2014 Our data demonstrate that isosclerone specifically binds to crystal structure of apoptosis regulator BCL-2 and pseudo-activated procaspase-3 proteins through down-regulated Bcl-2 family and up-regulated caspases, and activating the NF-kappa-B signaling pathway. isosclerone 26-37 BCL2 apoptosis regulator Homo sapiens 101-106 25011914-5 2014 Our data demonstrate that isosclerone specifically binds to crystal structure of apoptosis regulator BCL-2 and pseudo-activated procaspase-3 proteins through down-regulated Bcl-2 family and up-regulated caspases, and activating the NF-kappa-B signaling pathway. isosclerone 26-37 BCL2 apoptosis regulator Homo sapiens 173-178 25091565-8 2014 Melittin attenuated the H2O2-induced decrease in mRNA and protein production of the anti-apoptotic factor Bcl-2. Hydrogen Peroxide 24-28 BCL2 apoptosis regulator Homo sapiens 106-111 25100434-5 2014 By RT-PCR and western blot assays, Kuding tea polyphenol significantly induced apoptosis in BcaCD885 cancer cells (p < 0.05) by upregulating caspase-3, caspase-8, caspase-9, Fas/FasL, Bax, p53, p21, E2F1, p73 and downregulating Bcl-2, Bcl-xL, HIAP-1, and HIAP-2 mRNA and protein expressions. Polyphenols 46-56 BCL2 apoptosis regulator Homo sapiens 231-236 25025490-10 2014 The levels of apoptosis-related proteins Bax, Bcl-2, and pro-caspase-3 were all decreased in Chang liver cells after 24 h of exposure to REC or OREC at 5, 7.5, 10 mug/mL. orec 144-148 BCL2 apoptosis regulator Homo sapiens 46-51 25337187-8 2014 FoxM1 inhibition by thiostrepton induced apoptosis of NPC cells by down-regulation of bcl-2, up-regulation of bax and p53, and inducing release of cytochrome c accompanied by activation of caspase-9, cleaved caspase-3 and cleaved PARP. Thiostrepton 20-32 BCL2 apoptosis regulator Homo sapiens 86-91 25118932-6 2014 Moreover, COD-B treatment resulted in JNK and p38 phosphorylation, downregulation of Bcl-2, upregulation of Bax, activated caspase-3 and cytochrome C release, which likely responded to freshly produced hydrogen peroxide that accompanied cholesterol oxidation. Hydrogen Peroxide 202-219 BCL2 apoptosis regulator Homo sapiens 85-90 25044115-6 2014 Our study further showed that HKL 2H treatment caused the dissipation of mitochondrial membrane potential, activated caspase-3 and lowered the Bcl-2/Bax ratio in K562 cells, suggesting that the HKL 2H-causing programmed cell death of K562 cells was caused via the mitochondrial apoptotic pathway. Deuterium 34-36 BCL2 apoptosis regulator Homo sapiens 143-148 25044115-6 2014 Our study further showed that HKL 2H treatment caused the dissipation of mitochondrial membrane potential, activated caspase-3 and lowered the Bcl-2/Bax ratio in K562 cells, suggesting that the HKL 2H-causing programmed cell death of K562 cells was caused via the mitochondrial apoptotic pathway. Deuterium 198-200 BCL2 apoptosis regulator Homo sapiens 143-148 24907101-3 2014 In this study we aimed to inhibit oxygen-glucose deprivation (OGD)-induced apoptosis of human ADSCs by genetic modification with antiapoptotic protein Bcl-2. oxygen-glucose 34-48 BCL2 apoptosis regulator Homo sapiens 151-156 24911634-8 2014 Pretreatment with irestatin 9389, salubrinal, or AEBSF also blocked ox-LDL-induced expression of CHOP and Bcl-2 and activation of caspase-12 activity, leading to an attenuation of endothelial cell apoptosis. irestatin 18-27 BCL2 apoptosis regulator Homo sapiens 106-111 24318305-3 2014 Treatment of MCF-7 cell lines with paclitaxel and curcumin induced the apoptosis of regulatory protein Bcl-2 but decreased Bax expression. Paclitaxel 35-45 BCL2 apoptosis regulator Homo sapiens 103-108 24318305-3 2014 Treatment of MCF-7 cell lines with paclitaxel and curcumin induced the apoptosis of regulatory protein Bcl-2 but decreased Bax expression. Curcumin 50-58 BCL2 apoptosis regulator Homo sapiens 103-108 24911634-8 2014 Pretreatment with irestatin 9389, salubrinal, or AEBSF also blocked ox-LDL-induced expression of CHOP and Bcl-2 and activation of caspase-12 activity, leading to an attenuation of endothelial cell apoptosis. salubrinal 34-44 BCL2 apoptosis regulator Homo sapiens 106-111 24911634-8 2014 Pretreatment with irestatin 9389, salubrinal, or AEBSF also blocked ox-LDL-induced expression of CHOP and Bcl-2 and activation of caspase-12 activity, leading to an attenuation of endothelial cell apoptosis. 4-(2-aminoethyl)benzenesulfonylfluoride 49-54 BCL2 apoptosis regulator Homo sapiens 106-111 24451410-4 2014 The BCL-XL, BCL-2 and BCL-w inhibitor ABT-737 sensitized most cell lines more potently compared with the selective BCL-2 inhibitor ABT-199, which synergized with 5-Azacytidine mostly at higher doses. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 131-134 BCL2 apoptosis regulator Homo sapiens 115-120 24286323-4 2014 According to the results, Stigmasterol has up-regulated the expression of pro-apoptotic gene expressions (Bax, p53) while down-regulating the anti-apoptotic genes (Bcl-2). Stigmasterol 26-38 BCL2 apoptosis regulator Homo sapiens 164-169 24395092-6 2014 PB strikingly inhibited MPP(+)-induced mitochondrial dysfunctions, including lowered membrane potential, decreased Bcl-2/Bax ratio, and the release of cytochrome c. pinocembrin 0-2 BCL2 apoptosis regulator Homo sapiens 115-120 24768477-7 2014 Furthermore, an interaction was found between high BCL2 expression in the TU (but not in LN) and benefit to CMF over anthracycline-based chemotherapy (interaction p value EFS: 0.042; OS = 0.01). Anthracyclines 117-130 BCL2 apoptosis regulator Homo sapiens 51-55 24768477-10 2014 BCL2 expression in the TU but not in the LN was predictive of increased benefit to CMF vs anthracycline-based chemotherapy. Anthracyclines 90-103 BCL2 apoptosis regulator Homo sapiens 0-4 24877754-10 2014 Curcumol could cause cell cycle arrest at the S phase, induce cell apoptosis, and inhibit the expression of Bcl-2 in a dose-dependent manner. curcumol 0-8 BCL2 apoptosis regulator Homo sapiens 108-113 24877754-12 2014 In conclusion, the underlying mechanism of curcumol on suppressing CD4(+) T cell proliferation and inducing apoptosis might partly be mediated by inhibition of Jak3-STAT5-related molecular activities and Bcl-2 expression, respectively; further studies are required in vivo to test the use of curcumol as a promising therapeutic option for RA. curcumol 43-51 BCL2 apoptosis regulator Homo sapiens 204-209 24451410-0 2014 BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Azacitidine 25-38 BCL2 apoptosis regulator Homo sapiens 0-5 24451410-8 2014 Functional interrogation of BCL-2 family proteins by BH3 profiling performed on patient samples significantly discriminated clinical response versus resistance to 5-Azacytidine-based therapies. Azacitidine 163-176 BCL2 apoptosis regulator Homo sapiens 28-33 24451410-2 2014 RNA-interference drug modifier screens identified antiapoptotic BCL-2 family members as potent 5-Azacytidine-sensitizing targets. Azacitidine 95-108 BCL2 apoptosis regulator Homo sapiens 64-69 24359549-7 2014 CONCLUSION: We conclude that the apoptosome, together with proapoptotic proteins of the Bcl-2 family of proteins, is central to amine-modified polystyrene nanoparticle-induced cell death. Amines 128-133 BCL2 apoptosis regulator Homo sapiens 88-93 24802382-0 2014 Ciprofloxacin as a potential radio-sensitizer to tumor cells and a radio-protectant for normal cells: differential effects on gamma-H2AX formation, p53 phosphorylation, Bcl-2 production, and cell death. Ciprofloxacin 0-13 BCL2 apoptosis regulator Homo sapiens 169-174 24802382-8 2014 CIP pretreatment reduced Bcl-2 production but promoted p53 phosphorylation, caspase-3 activation and cell death. Ciprofloxacin 0-3 BCL2 apoptosis regulator Homo sapiens 25-30 24802382-10 2014 In normal healthy human PBMCs, CIP failed to block the radiation-induced gamma-H2AX increase but effectively increased Bcl-2 production, but blocked the phospho-p53 increase and subsequent cell death. Ciprofloxacin 31-34 BCL2 apoptosis regulator Homo sapiens 119-124 24420784-5 2014 Ceramide also decreased anti-apoptotic (Bcl-2) and increased pro-apoptotic (Bax, Hrk) mRNA/protein levels. Ceramides 0-8 BCL2 apoptosis regulator Homo sapiens 40-45 24420784-10 2014 It was also revealed that the S1P and PARP-1 inhibitor (PJ-34) decreased oxidative stress, gene expression of the pro-apoptotic Hrk protein and up-regulated the anti-apoptotic Bcl-2 protein. N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride 56-61 BCL2 apoptosis regulator Homo sapiens 176-181 24359549-7 2014 CONCLUSION: We conclude that the apoptosome, together with proapoptotic proteins of the Bcl-2 family of proteins, is central to amine-modified polystyrene nanoparticle-induced cell death. Polystyrenes 143-154 BCL2 apoptosis regulator Homo sapiens 88-93 24891300-4 2014 Therefore, targeting Bcl-2 with small molecule inhibitor ABT-263 could be a novel strategy for treatment of neuroblastoma. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 57-60 BCL2 apoptosis regulator Homo sapiens 21-26 24866280-8 2014 The results demonstrated that beta-elemene inhibited the proliferation of U87 glioblastoma cells through the GMFbeta-dependent inactivation of the ERK1/2-Bcl-2/survivin pathway. beta-elemene 30-42 BCL2 apoptosis regulator Homo sapiens 154-159 24866280-9 2014 Furthermore, inhibition of ERK1/2 by PD98059 enhanced the antitumor effect of beta-elemene and impaired the expression levels of Bcl-2 and survivin. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 37-44 BCL2 apoptosis regulator Homo sapiens 129-134 24866280-11 2014 In conclusion, these results suggested that GMFbeta-dependent inactivation of the ERK1/2-Bcl-2/survivin pathway mediated the antiproliferative effect of beta-elemene on glioblastoma. beta-elemene 153-165 BCL2 apoptosis regulator Homo sapiens 89-94 24867323-5 2014 Cell response to homocysteine-induced DNA damage involved the up-regulation of Bax and, at a greater extent, Bcl-2, but not caspase-3, in association with a p53-independent increase of p21 levels; concomitantly, also p16 levels were increased. Homocysteine 17-29 BCL2 apoptosis regulator Homo sapiens 109-114 24889088-5 2014 Flow cytometric analysis and DNA fragmentation revealed that germacrone promoted apoptosis of glioma cells, associated with an increased expression of p53 and bax and decreased expression of bcl-2. germacrone 61-71 BCL2 apoptosis regulator Homo sapiens 191-196 25064737-6 2014 The human homologue of LET-99, DEPDC1, similarly regulates vincristine-induced cell death by promoting JNK-dependent degradation of the BCL-2 family protein MCL1. Vincristine 59-70 BCL2 apoptosis regulator Homo sapiens 136-141 24747292-5 2014 Moreover, quantitative real-time PCR showed that 1-methoxybrassinin upregulated the expression of pro-apoptotic Bax and downregulated the expression of anti-apoptotic genes Bcl-2 and Bcl-xL. Methoxybrassinin 49-67 BCL2 apoptosis regulator Homo sapiens 173-178 24839007-0 2014 Role of Bax/Bcl-2 family members in green tea polyphenol induced necroptosis of p53-deficient Hep3B cells. Polyphenols 46-56 BCL2 apoptosis regulator Homo sapiens 12-17 24839007-8 2014 Furthermore, overexpression of Bcl-2 could ameliorate GTP-induced cytochrome c release and necroptosis. Guanosine Triphosphate 54-57 BCL2 apoptosis regulator Homo sapiens 31-36 25130819-3 2014 The results demonstrated that CUS could down-regulate the protein expression levels of Notch1, Jagged-2, P-Akt and NF-KB in the myeloma cells and with time-and concentration-dependent way, at the same time CUS could also decrease the expressions of BCL-2 and P-Akt. cupric sulfide 30-33 BCL2 apoptosis regulator Homo sapiens 249-254 25202943-10 2014 CONCLUSION: Silence of endogenous NOR1 facilitates the cell viability and growth of HeLa cells, and attenuates HeLa cells apoptosis induced by H2O2, which might be mediated by up-regulation of Bcl-2 level and down-regulation of the cleaved caspase 9 cascade. Hydrogen Peroxide 143-147 BCL2 apoptosis regulator Homo sapiens 193-198 25130820-9 2014 It is concluded that VPA can enhance the sensitivity of RPMI 8226 cells to ATO-induced apoptosis, which may be associated with decreasing the BCL-2 expression and increasing the BAX, caspase-8 and caspase-9 gene expression. Valproic Acid 21-24 BCL2 apoptosis regulator Homo sapiens 142-147 25130820-9 2014 It is concluded that VPA can enhance the sensitivity of RPMI 8226 cells to ATO-induced apoptosis, which may be associated with decreasing the BCL-2 expression and increasing the BAX, caspase-8 and caspase-9 gene expression. Arsenic Trioxide 75-78 BCL2 apoptosis regulator Homo sapiens 142-147 24974804-3 2014 Reduction of the azabutadienyl chelate boron dichloride [ArN C(R)CH C(R)]BCl2 (2, Ar=2,6-Me2 C6 H3 , R=tBu) with two equivalents of potassium yielded the novel 2-chloro-azaborolyl anion [ArNC(R)CHC(R)BCl]K(thf) (3) as a stable product in good yield. azabutadienyl 17-30 BCL2 apoptosis regulator Homo sapiens 73-77 25161699-0 2014 Pyrroloquinoline Quinone Induces Cancer Cell Apoptosis via Mitochondrial-Dependent Pathway and Down-Regulating Cellular Bcl-2 Protein Expression. PQQ Cofactor 0-24 BCL2 apoptosis regulator Homo sapiens 120-125 25161699-4 2014 The apoptosis of the 3 tumor cell lines induced by PQQ were increased in a concentration-dependent manner, which might be attributed to the accumulation of intracellular reactive oxygen species (ROS), decline in ATP levels and dissipation of mitochondrial membrane potential (MMP), in conjunction with down-regulation of Bcl-2 protein expression, up-regulation of activated caspase-3, and disturbed phosphorylated MAPK protein levels. PQQ Cofactor 51-54 BCL2 apoptosis regulator Homo sapiens 321-326 24974804-3 2014 Reduction of the azabutadienyl chelate boron dichloride [ArN C(R)CH C(R)]BCl2 (2, Ar=2,6-Me2 C6 H3 , R=tBu) with two equivalents of potassium yielded the novel 2-chloro-azaborolyl anion [ArNC(R)CHC(R)BCl]K(thf) (3) as a stable product in good yield. boron dichloride 39-55 BCL2 apoptosis regulator Homo sapiens 73-77 24974804-3 2014 Reduction of the azabutadienyl chelate boron dichloride [ArN C(R)CH C(R)]BCl2 (2, Ar=2,6-Me2 C6 H3 , R=tBu) with two equivalents of potassium yielded the novel 2-chloro-azaborolyl anion [ArNC(R)CHC(R)BCl]K(thf) (3) as a stable product in good yield. 2,6-me2 85-92 BCL2 apoptosis regulator Homo sapiens 73-77 24974804-3 2014 Reduction of the azabutadienyl chelate boron dichloride [ArN C(R)CH C(R)]BCl2 (2, Ar=2,6-Me2 C6 H3 , R=tBu) with two equivalents of potassium yielded the novel 2-chloro-azaborolyl anion [ArNC(R)CHC(R)BCl]K(thf) (3) as a stable product in good yield. tert-Butyl Alcohol 103-106 BCL2 apoptosis regulator Homo sapiens 73-77 24974804-3 2014 Reduction of the azabutadienyl chelate boron dichloride [ArN C(R)CH C(R)]BCl2 (2, Ar=2,6-Me2 C6 H3 , R=tBu) with two equivalents of potassium yielded the novel 2-chloro-azaborolyl anion [ArNC(R)CHC(R)BCl]K(thf) (3) as a stable product in good yield. Potassium 132-141 BCL2 apoptosis regulator Homo sapiens 73-77 24974804-3 2014 Reduction of the azabutadienyl chelate boron dichloride [ArN C(R)CH C(R)]BCl2 (2, Ar=2,6-Me2 C6 H3 , R=tBu) with two equivalents of potassium yielded the novel 2-chloro-azaborolyl anion [ArNC(R)CHC(R)BCl]K(thf) (3) as a stable product in good yield. 2-chloro-azaborolyl anion 160-185 BCL2 apoptosis regulator Homo sapiens 73-77 24974804-3 2014 Reduction of the azabutadienyl chelate boron dichloride [ArN C(R)CH C(R)]BCl2 (2, Ar=2,6-Me2 C6 H3 , R=tBu) with two equivalents of potassium yielded the novel 2-chloro-azaborolyl anion [ArNC(R)CHC(R)BCl]K(thf) (3) as a stable product in good yield. tetrahydrofuran 206-209 BCL2 apoptosis regulator Homo sapiens 73-77 25221599-4 2014 Peroxynitrite triggered apoptosis in these cells, and increased the expression of Fas-associated death domain, Bax, caspa-se-8 and Bcl-2. Peroxynitrous Acid 0-13 BCL2 apoptosis regulator Homo sapiens 131-136 24950407-2 2014 Recently, it has been demonstrated that HBx can directly interact with Bcl-2 and Bcl-xL through a sequence (termed the BH3-like motif) that is related to the BH3 motif of pro-apoptotic BH3-only proteins. BH 3 119-122 BCL2 apoptosis regulator Homo sapiens 71-76 24950407-2 2014 Recently, it has been demonstrated that HBx can directly interact with Bcl-2 and Bcl-xL through a sequence (termed the BH3-like motif) that is related to the BH3 motif of pro-apoptotic BH3-only proteins. BH 3 158-161 BCL2 apoptosis regulator Homo sapiens 71-76 25026173-9 2014 DADS induced apoptosis by activating a mitochondria-dependent pathway with the executor of caspase-3, increasing p53 level and Bax/Bcl-2 ratio, and downregulating the RAF/MEK/ERK pathway in ECA109 xenograft tumosr. diallyl disulfide 0-4 BCL2 apoptosis regulator Homo sapiens 131-136 25015769-6 2014 In contrast, doxorubicin treatment resulted in increased apoptotic cells in Surv-2B#17 but not Surv-DeltaEx3#34 cells, along with decreased expression of bcl-2 relative to bax. Doxorubicin 13-24 BCL2 apoptosis regulator Homo sapiens 154-159 25019346-0 2014 Knockdown of EpCAM enhances the chemosensitivity of breast cancer cells to 5-fluorouracil by downregulating the antiapoptotic factor Bcl-2. Fluorouracil 75-89 BCL2 apoptosis regulator Homo sapiens 133-138 25013907-7 2014 Moreover, the expression of survivin and bcl-2 decreased after treatment with sorafenib and sunitinib was concomitant with variations in STAT3 activity. Sorafenib 78-87 BCL2 apoptosis regulator Homo sapiens 41-46 25013907-7 2014 Moreover, the expression of survivin and bcl-2 decreased after treatment with sorafenib and sunitinib was concomitant with variations in STAT3 activity. Sunitinib 92-101 BCL2 apoptosis regulator Homo sapiens 41-46 25014217-6 2014 RNA electrophoretic mobility shift assay experiments revealed that ZFP36L1 interacted with the BCL2 adenine uridine rich element. adenine uridine 100-115 BCL2 apoptosis regulator Homo sapiens 95-99 25002129-9 2014 In addition, the essential oil caused a disruption of the mitochondrial transmembrane potential (DeltaPsim), increased the release of cytochrome c to the cytosol, and altered the expression of certain members of Bcl-2 family (Bcl-2, Bax and Bid), Apaf-1 and XIAP. Oils, Volatile 17-30 BCL2 apoptosis regulator Homo sapiens 212-217 25014217-8 2014 3" untranslated region luciferase reporter assays in HEK293T cells showed that wild type but not zinc finger mutant ZFP36L1 protein was able to downregulate a BCL2 construct containing the BCL2 adenine uridine rich element and removal of the adenine uridine rich core from the BCL2 3" untranslated region in the reporter construct significantly reduced the ability of ZFP36L1 to mediate this effect. adenine uridine 194-209 BCL2 apoptosis regulator Homo sapiens 189-193 25014217-8 2014 3" untranslated region luciferase reporter assays in HEK293T cells showed that wild type but not zinc finger mutant ZFP36L1 protein was able to downregulate a BCL2 construct containing the BCL2 adenine uridine rich element and removal of the adenine uridine rich core from the BCL2 3" untranslated region in the reporter construct significantly reduced the ability of ZFP36L1 to mediate this effect. adenine uridine 194-209 BCL2 apoptosis regulator Homo sapiens 189-193 24668891-6 2014 Moreover, the dual stimuli-responsive design of micellar carriers allows microenviroment-specific rapid release of both DOX and BCL-2 siRNA inside acidic lysosomes with enriched reducing agent, glutathione (GSH, up to 10 mM). Glutathione 207-210 BCL2 apoptosis regulator Homo sapiens 128-133 24668891-7 2014 Consequently, the expression of anti-apoptotic BCL-2 protein induced by DOX treatment is significantly down-regulated, which results in synergistically enhanced apoptosis of human ovarian cancer SKOV-3 cells and thus dramatically inhibited tumor growth. Doxorubicin 72-75 BCL2 apoptosis regulator Homo sapiens 47-52 24668891-6 2014 Moreover, the dual stimuli-responsive design of micellar carriers allows microenviroment-specific rapid release of both DOX and BCL-2 siRNA inside acidic lysosomes with enriched reducing agent, glutathione (GSH, up to 10 mM). Glutathione 194-205 BCL2 apoptosis regulator Homo sapiens 128-133 25002129-11 2014 CONCLUSIONS: The results demonstrate that the EO-induced apoptosis in HL-60 cells is mediated by caspase-dependent pathways, involving caspases-3, -9, and -8, which are initiated by Bcl-2/Bax/Bid-dependent loss of DeltaPsim leading to release of cytochrome c to the cytoplasm to activate the caspase cascade. Oils, Volatile 46-48 BCL2 apoptosis regulator Homo sapiens 182-187 25002129-9 2014 In addition, the essential oil caused a disruption of the mitochondrial transmembrane potential (DeltaPsim), increased the release of cytochrome c to the cytosol, and altered the expression of certain members of Bcl-2 family (Bcl-2, Bax and Bid), Apaf-1 and XIAP. Oils, Volatile 17-30 BCL2 apoptosis regulator Homo sapiens 226-231 24746965-5 2014 Consequently, the PTX treatment-inducible antiapoptosis in HepG2 cells was effectively suppressed by the codelivered siRNA targeting an antiapoptosis gene (BCL-2 siRNA) during chemotherapy. Paclitaxel 18-21 BCL2 apoptosis regulator Homo sapiens 156-161 24999743-8 2014 The 127 older patients with TNBCs showed lower rates of Ki67 and CK 7/8 positivity and high rates of bcl2 and CK18 positivity when compared with their younger counterparts (p<0.05). tnbcs 28-33 BCL2 apoptosis regulator Homo sapiens 101-105 25000265-7 2014 Melatonin also blocked the hypoxic responses that reduced pro-apoptotic proteins and increased anti-apoptotic proteins including Bcl-2 and Bcl-xL. Melatonin 0-9 BCL2 apoptosis regulator Homo sapiens 129-134 24832164-9 2014 Our series of IC-PBL and PT-PBL cases revealed differential expression of CD10 (0% vs. 42%, respectively), CD56 (22% vs. 42%, respectively), TP53 (67% vs. 8%, respectively), and BCL2 (88% vs. 25%, respectively). ic-pbl 14-20 BCL2 apoptosis regulator Homo sapiens 178-182 24771279-4 2014 Dioscin decreased expressions of Bcl-2 and cIAP-1 proteins, which were down-regulated at the transcriptional level. dioscin 0-7 BCL2 apoptosis regulator Homo sapiens 33-38 24771279-10 2014 Taken together, our results demonstrate that dioscin-induced cell death was mediated via AIF-facilitating caspase-independent pathway as well as down-regulating anti-apoptotic proteins such as Bcl-2, cIAP-1, and Mcl-1 in breast cancer cells. dioscin 45-52 BCL2 apoptosis regulator Homo sapiens 193-198 24594224-10 2014 HMJ-38 stimulated the activation of CDK1 activity that modulated phosphorylation on Ser70 of Bcl-2-mediated mitotic arrest and apoptosis. 2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone 0-6 BCL2 apoptosis regulator Homo sapiens 93-98 24745612-6 2014 The enhanced inhibitory effects of CLDR on lung cancer cell growth may be, at least in part, due to the increased Bax/Bcl2 ratio and cyclin B1-mediated G2/M arrest. cldr 35-39 BCL2 apoptosis regulator Homo sapiens 118-122 24571452-3 2014 ABT-263, a second-generation BH3 mimic, binds to the anti-apoptotic family members Bcl-2, Bcl-xL and Bcl-w, and has been demonstrated to enhance TNFSF10 (TRAIL)-induced apoptosis in human hepatocarcinoma cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 83-88 24832107-0 2014 Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide. Oligonucleotides 75-90 BCL2 apoptosis regulator Homo sapiens 40-45 24832107-1 2014 PNT100 is a 24-base, chemically unmodified DNA oligonucleotide sequence that is complementary to a region upstream of the BCL-2 gene. Oligonucleotides 47-62 BCL2 apoptosis regulator Homo sapiens 122-127 24858462-0 2014 Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501). Isotretinoin 22-42 BCL2 apoptosis regulator Homo sapiens 57-62 24858462-3 2014 We conducted a phase II study to evaluate if modulation of Bcl-2 with 13-cis-retinoic acid (13-CRA) and interferon alpha could improve response rates when combined with paclitaxel in patients with recurrent SCLC. Isotretinoin 70-90 BCL2 apoptosis regulator Homo sapiens 59-64 24908637-3 2014 Apoptotic studies showed that BL EthOH was able to induce apoptosis and western blot studies demonstrated that BL EthOH significantly decreased the Phospho-NF-kappaB (ser536), PCNA, anti-apoptotic protein Bcl-2 expression and increased the expression of pro-apoptotic protein Bax, in MDA-MB-231 and MDA-MB-453 cell lines when compared with untreated cells. ethoh 114-119 BCL2 apoptosis regulator Homo sapiens 205-210 24782462-12 2014 We propose that the compounds with the 3-phenylthiophene-2-sulfonamide core moiety are worth further optimization as effective apoptosis inducers with an interesting selectivity towards Mcl-1 and Bcl-2. SCHEMBL3100642 39-70 BCL2 apoptosis regulator Homo sapiens 196-201 25050134-7 2014 This peroxidase activity of hemin complexed with the G-quadruplex-forming sequence in the Bcl-2 gene promoter may imply a potential mechanism of hemin-mediated cellular injury. Hemin 28-33 BCL2 apoptosis regulator Homo sapiens 90-95 24782462-0 2014 Development of 3-phenyl-N-(2-(3-phenylureido)ethyl)-thiophene-2-sulfonamide compounds as inhibitors of antiapoptotic Bcl-2 family proteins. 3-phenyl-n-(2-(3-phenylureido)ethyl)-thiophene-2-sulfonamide compounds 15-85 BCL2 apoptosis regulator Homo sapiens 117-122 24782462-4 2014 It contains a phenyltetrazole and a hydrazinecarbothioamide moiety, and it represents a structural scaffold not observed among known Bcl-2 inhibitors. 5-Phenyl-1H-tetrazole 14-29 BCL2 apoptosis regulator Homo sapiens 133-138 24782462-4 2014 It contains a phenyltetrazole and a hydrazinecarbothioamide moiety, and it represents a structural scaffold not observed among known Bcl-2 inhibitors. thiosemicarbazide 36-59 BCL2 apoptosis regulator Homo sapiens 133-138 24782462-8 2014 Some of the compounds with a 3-phenylthiophene-2-sulfonamide core moiety showed sub-micromolar binding affinities to Mcl-1 (Ki =0.3-0.4 muM) or Bcl-2 (Ki 1 muM). SCHEMBL3100642 29-60 BCL2 apoptosis regulator Homo sapiens 144-149 24973666-5 2014 Cordycepin treatment caused a dose-dependent increase of pro-apoptotic Bax and decrease of anti-apoptotic Bcl-2, triggering collapse of the mitochondrial membrane potential and activation of caspase-9 and -3. cordycepin 0-10 BCL2 apoptosis regulator Homo sapiens 106-111 24939178-2 2014 Proteomics-based analysis in this study revealed that SOD2, associated with downregulation of reactive oxygen species (ROS), was significantly up-regulated in docetaxel-resistant (PC3/Doc) cells if compared to sensitive cells, and the expression of redox-regulated genes such as IGF-1R, CXCR4, and BCL2 was increased as well. Docetaxel 159-168 BCL2 apoptosis regulator Homo sapiens 298-302 24944602-6 2014 In addition, ATO significantly decreased the expression of antiapoptotic proteins, B-cell lymphoma 2 (Bcl-2) and B cell lymphoma-extra large (Bcl-xL), but markedly increased the expression of proapoptotic proteins, including c-Jun N-terminal kinase (JNK), phosphorylated-JNK, Bax, full length caspase-3 and cleaved caspase-3. Arsenic Trioxide 13-16 BCL2 apoptosis regulator Homo sapiens 83-100 24751974-2 2014 The exposure of ovarian cancer SKOV3 cells to DHA2 resulted in the downregulation of the anti-apoptotic X-linked inhibitor of apoptosis protein (XIAP) and Bcl-2 and led to caspase-independent cell death. dha2 46-50 BCL2 apoptosis regulator Homo sapiens 155-160 24944602-6 2014 In addition, ATO significantly decreased the expression of antiapoptotic proteins, B-cell lymphoma 2 (Bcl-2) and B cell lymphoma-extra large (Bcl-xL), but markedly increased the expression of proapoptotic proteins, including c-Jun N-terminal kinase (JNK), phosphorylated-JNK, Bax, full length caspase-3 and cleaved caspase-3. Arsenic Trioxide 13-16 BCL2 apoptosis regulator Homo sapiens 102-107 24944602-7 2014 These results indicated that ATO inhibited the proliferation and induced apoptosis in THP1 cells partially via blocking the inhibitory effects of EVI-1 on the JNK signaling pathway with the involvement of apoptosis-associated proteins, including Bax, Bcl-2, Bcl-xL and caspase-3. Arsenic Trioxide 29-32 BCL2 apoptosis regulator Homo sapiens 251-256 24554216-7 2014 CPS-C-induced apoptosis was confirmed by the activation of caspases, down-regulation of Bcl-2, JNK, and P38alpha/beta, and up-regulation of Bax, p-JNK, and p-P38. capilliposide C 0-5 BCL2 apoptosis regulator Homo sapiens 88-93 24821075-10 2014 In conclusion, the results suggested that PE-induced apoptosis is involved in upregulating the Bax/Bcl-2 protein ratio and decreasing the DeltaPsim. phosphatidylethanolamine 42-44 BCL2 apoptosis regulator Homo sapiens 99-104 24804820-8 2014 Furthermore, as shown by our results, the inhibition of gemcitabine-induced autophagy by chloroquine shifts the expression of the p53 protein, Bcl-2 family proteins and the relative Bax/Bcl-xL ratio in favor of promoting apoptosis. gemcitabine 56-67 BCL2 apoptosis regulator Homo sapiens 143-148 24804820-8 2014 Furthermore, as shown by our results, the inhibition of gemcitabine-induced autophagy by chloroquine shifts the expression of the p53 protein, Bcl-2 family proteins and the relative Bax/Bcl-xL ratio in favor of promoting apoptosis. Chloroquine 89-100 BCL2 apoptosis regulator Homo sapiens 143-148 25276192-10 2014 Evidence of apoptosis and protein expression of p53 and Bcl-2 indicated that both single applications and combinations of CPE and doxorubicin are able to increase apoptotic bodies of MCF-7 cells by increasing the proteins expression. Doxorubicin 130-141 BCL2 apoptosis regulator Homo sapiens 56-61 25261655-11 2014 By comparison, SAHA could downregulate the mRNA expression of bcl-2. Vorinostat 15-19 BCL2 apoptosis regulator Homo sapiens 62-67 25261655-13 2014 CONCLUSION: SAHA inhibited cell proliferation and promoted human hepatoma Bel-7402 cell apoptosis by affecting caspase-3 protein activity and mRNA expressions of p53, bcl-2 and bax genes. Vorinostat 12-16 BCL2 apoptosis regulator Homo sapiens 167-172 23958447-6 2014 Furthermore, AMS36 reversed 6-OHDA-induced loss of tyrosine hydroxylase and attenuated 6-OHDA-induced activation of caspase-3, triggering apoptosis, intracellular generation of reactive oxygen species and mitochondrial dysfunction, including the release of cytochrome c and an imbalanced Bax/Bcl-2 ratio. Oxidopamine 28-34 BCL2 apoptosis regulator Homo sapiens 292-297 24741074-1 2014 Identification of therapeutic strategies that might enhance the efficacy of B-cell lymphoma-2 (Bcl-2) inhibitor ABT-737 [N-{4-[4-(4-chloro-biphenyl-2-ylmethyl)-piperazin-1-yl]-benzoyl}-4-(3-dimethylamino-1-phenylsulfanylmethyl-propylamino)-3-nitro-benzenesulfonamide] is of great interest in many cancers, including glioma. ABT-737 112-119 BCL2 apoptosis regulator Homo sapiens 76-93 24741074-1 2014 Identification of therapeutic strategies that might enhance the efficacy of B-cell lymphoma-2 (Bcl-2) inhibitor ABT-737 [N-{4-[4-(4-chloro-biphenyl-2-ylmethyl)-piperazin-1-yl]-benzoyl}-4-(3-dimethylamino-1-phenylsulfanylmethyl-propylamino)-3-nitro-benzenesulfonamide] is of great interest in many cancers, including glioma. ABT-737 112-119 BCL2 apoptosis regulator Homo sapiens 95-100 24531733-0 2014 Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199. venetoclax 154-161 BCL2 apoptosis regulator Homo sapiens 128-133 24880464-7 2014 Triptolide-induced apoptosis was accompanied by cytochrome c release and caspase-3 activation and was associated with downregulation of Bcl-2 and upregulation of Bax. triptolide 0-10 BCL2 apoptosis regulator Homo sapiens 136-141 24739393-5 2014 We next incorporated the BH3 mimetic ABT-737 into this combination regimen to block Bcl-2, which further enhanced the apoptogenic effect of MEK/mTOR inhibition. BH 3 25-28 BCL2 apoptosis regulator Homo sapiens 84-89 24739393-5 2014 We next incorporated the BH3 mimetic ABT-737 into this combination regimen to block Bcl-2, which further enhanced the apoptogenic effect of MEK/mTOR inhibition. ABT-737 37-44 BCL2 apoptosis regulator Homo sapiens 84-89 23958447-6 2014 Furthermore, AMS36 reversed 6-OHDA-induced loss of tyrosine hydroxylase and attenuated 6-OHDA-induced activation of caspase-3, triggering apoptosis, intracellular generation of reactive oxygen species and mitochondrial dysfunction, including the release of cytochrome c and an imbalanced Bax/Bcl-2 ratio. Oxidopamine 87-93 BCL2 apoptosis regulator Homo sapiens 292-297 24841429-4 2014 In the present study, we explored some mechanisms associated with resistance to tamoxifen, such as pharmacologic mechanisms, loss or modification in estrogen receptor expression, alterations in co-regulatory proteins and the regulation of the different signaling pathways that participate in different cellular processes such as survival, proliferation, stress, cell cycle, inhibition of apoptosis regulated by the Bcl-2 family, autophagy, altered expression of microRNA, and signaling pathways that regulate the epithelial-mesenchymal transition in the tumor microenvironment. Tamoxifen 80-89 BCL2 apoptosis regulator Homo sapiens 415-420 24392814-11 2014 Hoechst 33258 fluorescence staining results indicated the apoptosis of A549 cells induced by 3.125 muM of ardisiphenol D. About 0.39 and 0.78 muM of ardisiphenol D also potently increased the caspase-3 enzyme activity in 24 h. Furthermore, 0.39-3.125 muM of ardisiphenol D induced the activation of caspase-3 protein and the up-regulation of the ratio of bax/bcl-2 protein expression in A549 cells. ardisiphenol 106-118 BCL2 apoptosis regulator Homo sapiens 359-364 24859825-6 2014 NBNMA-induced apoptosis was observed in parallel with an increased ratio of pro-apoptotic Bax and Bad/anti-apoptotic Bcl-2 and Bcl-xL, and inhibition of inhibitor of apoptosis protein (IAP) family members XIAP and cIAP-1. nbnma 0-5 BCL2 apoptosis regulator Homo sapiens 117-122 24859932-6 2014 Mechanistically, besides its known inhibitory effects on aldo-keto reductase activity and de novo androgen synthesis, 2HF also markedly suppressed AKT phosphorylation, signal transducer and activator of transcription-3 (STAT3) phosphorylation and transactivation subsequently regulating the expression of members of the BCL-2 family (i.e., Mcl-1, Bcl-2 and Bax) and modulating caspase-mediated cell apoptosis. 2'-hydroxyflavanone 118-121 BCL2 apoptosis regulator Homo sapiens 320-325 24859932-6 2014 Mechanistically, besides its known inhibitory effects on aldo-keto reductase activity and de novo androgen synthesis, 2HF also markedly suppressed AKT phosphorylation, signal transducer and activator of transcription-3 (STAT3) phosphorylation and transactivation subsequently regulating the expression of members of the BCL-2 family (i.e., Mcl-1, Bcl-2 and Bax) and modulating caspase-mediated cell apoptosis. 2'-hydroxyflavanone 118-121 BCL2 apoptosis regulator Homo sapiens 347-352 24655414-4 2014 Studies using BH3-mimetics indicate that the antiapoptotic BCL-2 protein MCL-1 and its antagonist NOXA are particularly important regulators of BCL-2 family signaling, while SMAC-mimetic studies show that both XIAP and the cIAPs must be targeted to effectively induce apoptosis of cancer cells. BH 3 14-17 BCL2 apoptosis regulator Homo sapiens 59-64 24392814-11 2014 Hoechst 33258 fluorescence staining results indicated the apoptosis of A549 cells induced by 3.125 muM of ardisiphenol D. About 0.39 and 0.78 muM of ardisiphenol D also potently increased the caspase-3 enzyme activity in 24 h. Furthermore, 0.39-3.125 muM of ardisiphenol D induced the activation of caspase-3 protein and the up-regulation of the ratio of bax/bcl-2 protein expression in A549 cells. ardisiphenol 149-161 BCL2 apoptosis regulator Homo sapiens 359-364 24392814-11 2014 Hoechst 33258 fluorescence staining results indicated the apoptosis of A549 cells induced by 3.125 muM of ardisiphenol D. About 0.39 and 0.78 muM of ardisiphenol D also potently increased the caspase-3 enzyme activity in 24 h. Furthermore, 0.39-3.125 muM of ardisiphenol D induced the activation of caspase-3 protein and the up-regulation of the ratio of bax/bcl-2 protein expression in A549 cells. ardisiphenol 149-161 BCL2 apoptosis regulator Homo sapiens 359-364 24392814-14 2014 DISCUSSION AND CONCLUSION: Ardisiphenol D induced apoptosis of A549 cells via activation of caspase-3 and up-regulation of the ratio of bax/bcl-2 protein expression. ardisiphenol D 27-41 BCL2 apoptosis regulator Homo sapiens 140-145 24824212-5 2014 Much work in recent years has focused on strategies to enhance the therapeutic potential of the bona fide BH3-mimetic, ABT-737, which inhibits B-cell lymphoma 2 (Bcl-2) and Bcl-xL. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 119-122 BCL2 apoptosis regulator Homo sapiens 143-160 24824212-5 2014 Much work in recent years has focused on strategies to enhance the therapeutic potential of the bona fide BH3-mimetic, ABT-737, which inhibits B-cell lymphoma 2 (Bcl-2) and Bcl-xL. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 119-122 BCL2 apoptosis regulator Homo sapiens 162-167 24983357-0 2014 Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. BH 3 135-138 BCL2 apoptosis regulator Homo sapiens 22-27 24983357-3 2014 We analyzed BCL-2 family member expression levels of 34 samples from 17 patients collected before and 10 to 14 days after treatment initiation with either vemurafenib or dabrafenib/trametinib combination. Vemurafenib 155-166 BCL2 apoptosis regulator Homo sapiens 12-17 24983357-3 2014 We analyzed BCL-2 family member expression levels of 34 samples from 17 patients collected before and 10 to 14 days after treatment initiation with either vemurafenib or dabrafenib/trametinib combination. dabrafenib 170-180 BCL2 apoptosis regulator Homo sapiens 12-17 24983357-4 2014 The observed changes in mRNA and protein levels with BRAFi treatment led us to hypothesize that combining BRAFi with a BCL-2 inhibitor (the BH3-mimetic navitoclax) would improve outcome. BH 3 140-143 BCL2 apoptosis regulator Homo sapiens 119-124 24643683-9 2014 Moreover, we demonstrated that the pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) was a direct target of miR-125b. mir-125b 105-113 BCL2 apoptosis regulator Homo sapiens 49-54 25136525-7 2014 There was a significant association between Bcl-2 and Bax in TCs with ECs. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 61-64 BCL2 apoptosis regulator Homo sapiens 44-49 25027422-0 2014 [The effect of reactive oxygen species regulation of expression of Bcl-2 and Bax in apoptosis of human umbilical vein endothelial cell induced by heat stress]. Reactive Oxygen Species 15-38 BCL2 apoptosis regulator Homo sapiens 67-72 25027422-1 2014 OBJECTIVE: To observe the effect of heat stress-induced reactive oxygen species (ROS) burst on the regulation of expression of Bcl-2 and Bax in human umbilical vein endothelial cell (HUVEC) apoptosis induced by heat stress, and explore the pathogenesis of vascular endothelial damage caused by severe heat stroke. Reactive Oxygen Species 56-79 BCL2 apoptosis regulator Homo sapiens 127-132 25080915-6 2014 The expression of Bax increased, Bcl-2 expression decreased, and Bax/Bcl-2 in the ketamine cultured SV-HUC-1 cells was significantly higher. Ketamine 82-90 BCL2 apoptosis regulator Homo sapiens 69-74 25027422-1 2014 OBJECTIVE: To observe the effect of heat stress-induced reactive oxygen species (ROS) burst on the regulation of expression of Bcl-2 and Bax in human umbilical vein endothelial cell (HUVEC) apoptosis induced by heat stress, and explore the pathogenesis of vascular endothelial damage caused by severe heat stroke. Reactive Oxygen Species 81-84 BCL2 apoptosis regulator Homo sapiens 127-132 25027422-15 2014 CONCLUSIONS: A burst in an increase of ROS plays an important role on heat stress-induced HUVEC apoptosis, and the mechanism is probably related to the expressions of Bcl-2 and Bax. Reactive Oxygen Species 39-42 BCL2 apoptosis regulator Homo sapiens 167-172 24786774-0 2014 Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. BH 3 72-75 BCL2 apoptosis regulator Homo sapiens 22-26 24534203-1 2014 In this study, we explored the antitumor activities of the PARP inhibitor AZD2281 (Olaparib) and the pan-Bcl-2 inhibitor GX15-070 (Obatoclax) in six pancreatic cancer cell lines. obatoclax 121-129 BCL2 apoptosis regulator Homo sapiens 105-110 24786774-0 2014 Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 84-87 BCL2 apoptosis regulator Homo sapiens 22-26 24786774-2 2014 Recently, a BCL2-selective BH3 mimetic termed ABT-199 showed promising therapeutic results in BCL2-dependent tumors. BH 3 27-30 BCL2 apoptosis regulator Homo sapiens 12-16 24786774-2 2014 Recently, a BCL2-selective BH3 mimetic termed ABT-199 showed promising therapeutic results in BCL2-dependent tumors. BH 3 27-30 BCL2 apoptosis regulator Homo sapiens 94-98 24786774-2 2014 Recently, a BCL2-selective BH3 mimetic termed ABT-199 showed promising therapeutic results in BCL2-dependent tumors. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 46-49 BCL2 apoptosis regulator Homo sapiens 12-16 24786774-2 2014 Recently, a BCL2-selective BH3 mimetic termed ABT-199 showed promising therapeutic results in BCL2-dependent tumors. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 46-49 BCL2 apoptosis regulator Homo sapiens 94-98 25120804-0 2014 Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression. Bortezomib 0-10 BCL2 apoptosis regulator Homo sapiens 110-115 25083341-0 2014 Potential utility of the pan-Bcl-2 inhibitor GX15-070 (obatoclax) in cancer immunotherapy. obatoclax 45-53 BCL2 apoptosis regulator Homo sapiens 29-34 25120759-6 2014 Subsequent studies reveal that the PI3K/AKT, MAPK/ERK pathway and members of the anti-apoptotic Bcl-2 family may be involved in the pro-survival and anti-apoptotic effect of PNMA1 on PDAC. pdac 183-187 BCL2 apoptosis regulator Homo sapiens 96-101 24967846-2 2014 Pro-apoptotic family members contain a weakly conserved BH3 motif that can adopt an alpha-helical structure and bind to a groove on prosurvival partners Bcl-xL, Bcl-w, Bcl-2, Mcl-1 and Bfl-1. BH 3 56-59 BCL2 apoptosis regulator Homo sapiens 168-173 24961145-11 2014 We further investigated the potential mechanisms involved in the inhibitory effect of extracellular ATP on the growth of NPC cells and found that extracellular ATP could reduce Bcl-2 and p-AKT levels while elevating Bax and cleaved caspase-3 levels in NPC cells. Adenosine Triphosphate 100-103 BCL2 apoptosis regulator Homo sapiens 177-182 24961145-11 2014 We further investigated the potential mechanisms involved in the inhibitory effect of extracellular ATP on the growth of NPC cells and found that extracellular ATP could reduce Bcl-2 and p-AKT levels while elevating Bax and cleaved caspase-3 levels in NPC cells. Adenosine Triphosphate 160-163 BCL2 apoptosis regulator Homo sapiens 177-182 24941119-8 2014 The PI3K inhibitor LY294002 reverses the AEG-1 dependent effects on Akt phosphorylation, Bcl-2 expression and anoikis resistance. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 BCL2 apoptosis regulator Homo sapiens 89-94 24762814-5 2014 Purified RyR domains containing the putative Bcl-2-binding site bound full-length Bcl-2 in pulldown experiments and interacted with the BH4 domain of Bcl-2 in surface plasmon resonance (SPR) experiments, suggesting a direct interaction. sapropterin 136-139 BCL2 apoptosis regulator Homo sapiens 45-50 24762814-6 2014 Exogenous expression of full-length Bcl-2 or electroporation loading of the BH4 domain of Bcl-2 dampened RyR-mediated Ca(2+) release in HEK293 cell models. sapropterin 76-79 BCL2 apoptosis regulator Homo sapiens 90-95 25120804-8 2014 CONCLUSION: We recommend bortezomib-containing regimens for NDMM with single or double-positive Bcl-2 and survivin expression. Bortezomib 25-35 BCL2 apoptosis regulator Homo sapiens 96-101 24755484-6 2014 PQQ neuroprotection was associated with inhibition of intracellular ROS production, modulation of the expression of apoptosis-related Bcl-2 and Bax, and regulation of the level of superoxide dismutase, glutathione, and malondialdehyde. PQQ Cofactor 0-3 BCL2 apoptosis regulator Homo sapiens 134-139 24944509-9 2014 In addition, protein array and Western blotting analysis showed that treatment with boldine resulted in downregulation of Bcl-2 and heat shock protein 70 and upregulation of Bax in the MDA-MB-231 cell line. boldine 84-91 BCL2 apoptosis regulator Homo sapiens 122-127 24778183-1 2014 Gossypol is a putative BH3 mimetic proposed to inhibit BCL2 and BCLXL based on cell-free assays. Gossypol 0-8 BCL2 apoptosis regulator Homo sapiens 55-59 24778183-1 2014 Gossypol is a putative BH3 mimetic proposed to inhibit BCL2 and BCLXL based on cell-free assays. BH 3 23-26 BCL2 apoptosis regulator Homo sapiens 55-59 24793593-5 2014 In fact, the hexamethylbenzene-ruthenium complexes activated caspase activity, with consequent DNA fragmentation, accumulation of pro-apoptotic proteins (p27, p53, p89 PARP fragments), and the concomitant down-regulation of antiapoptotic protein Bcl-2. hexamethylbenzene 13-30 BCL2 apoptosis regulator Homo sapiens 246-251 24793593-5 2014 In fact, the hexamethylbenzene-ruthenium complexes activated caspase activity, with consequent DNA fragmentation, accumulation of pro-apoptotic proteins (p27, p53, p89 PARP fragments), and the concomitant down-regulation of antiapoptotic protein Bcl-2. Ruthenium 31-40 BCL2 apoptosis regulator Homo sapiens 246-251 24962386-8 2014 In addition, the treatment of shikonin in HLEs significantly increased the ratio of Bax/Bcl-2, disrupted mitochondria membrane potential (MMP) and activated caspases. shikonin 30-38 BCL2 apoptosis regulator Homo sapiens 88-93 24778183-8 2014 The BCL2 inhibitor ABT-199 is currently in clinical trials for CLL. venetoclax 19-26 BCL2 apoptosis regulator Homo sapiens 4-8 24778183-9 2014 Resistance to ABT-199 can occur from up-regulation of other BCL2 family proteins, and this resistance can be mimicked by culturing CLL cells on CD154(+) stroma cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 14-17 BCL2 apoptosis regulator Homo sapiens 60-64 24892421-9 2014 In addition, clotrimazole induced apoptosis in OSCC cells, and significantly down-regulated the anti-apoptotic protein Bcl-2 and up-regulated the pro-apoptotic protein Bax. Clotrimazole 13-25 BCL2 apoptosis regulator Homo sapiens 119-124 24824514-9 2014 Moreover, the ability of doxorubicin, SN-38 and CDDP to induce proapoptotic signals was weaker in Rho cells, as evidenced by survivin upregulation and reductions in Bax/Bcl-2 expression ratios. Doxorubicin 25-36 BCL2 apoptosis regulator Homo sapiens 169-174 24824514-9 2014 Moreover, the ability of doxorubicin, SN-38 and CDDP to induce proapoptotic signals was weaker in Rho cells, as evidenced by survivin upregulation and reductions in Bax/Bcl-2 expression ratios. Irinotecan 38-43 BCL2 apoptosis regulator Homo sapiens 169-174 24824514-9 2014 Moreover, the ability of doxorubicin, SN-38 and CDDP to induce proapoptotic signals was weaker in Rho cells, as evidenced by survivin upregulation and reductions in Bax/Bcl-2 expression ratios. Cisplatin 48-52 BCL2 apoptosis regulator Homo sapiens 169-174 23831571-7 2014 In addition, Chal-24 strongly induced autophagy that is dependent on JNK-mediated phosphorylation of Bcl-2 and Bcl-xL and dissociation of Bcl-2 or Bcl-xL from Beclin-1. 3-(3-hydroxy-4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one 13-20 BCL2 apoptosis regulator Homo sapiens 101-106 23831571-7 2014 In addition, Chal-24 strongly induced autophagy that is dependent on JNK-mediated phosphorylation of Bcl-2 and Bcl-xL and dissociation of Bcl-2 or Bcl-xL from Beclin-1. 3-(3-hydroxy-4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one 13-20 BCL2 apoptosis regulator Homo sapiens 138-143 24843155-6 2014 We also demonstrate that TvMIF binds the human CD74 MIF receptor with high affinity, comparable to that of HuMIF, which triggers activation of ERK, Akt, and Bcl-2-associated death promoter phosphorylation at a physiologically relevant concentration (1 ng/mL, 80 pM). tvmif 25-30 BCL2 apoptosis regulator Homo sapiens 157-162 24892421-11 2014 Clotrimazole also markedly reduced Bcl-2 expression and increased the protein level of Bax in tumor tissues of xenograft model. Clotrimazole 0-12 BCL2 apoptosis regulator Homo sapiens 35-40 24751000-4 2014 Concentrations of 10, 50, and 100 ng/mL of 5-FU chemotherapeutic were added separately in Hep-2 cell line for 24 hours at 37 C. Cell sensibility was evaluated with fluorescein isothiocyanate (FITC) label Bcl-2 by flow cytometry. Fluorouracil 43-47 BCL2 apoptosis regulator Homo sapiens 205-210 24893165-9 2014 Together, our data suggest that the interaction between alisertib plus VCR plus rituximab is synergistic and synthetic lethal in Myc and Bcl-2 co-expressing DLBCL. MLN 8237 56-65 BCL2 apoptosis regulator Homo sapiens 137-142 24658017-9 2014 Testosterone also reduced Bax-to-Bcl-2 ratio but not cytochrome-c release from mitochondria. Testosterone 0-12 BCL2 apoptosis regulator Homo sapiens 33-38 24677263-6 2014 CDK1-mediated Bcl-2 serine 70 phosphorylation enhances its pro-apoptotic function, whereas CDK1-mediated Bad serine 128 phosphorylation promotes apoptosis. Serine 20-26 BCL2 apoptosis regulator Homo sapiens 14-19 24234731-4 2014 DHL is group accompanied by IGH-BCL2 and MYC rearrangement, behaving highly aggressively, with a complex and distinct karyotype which can not be extrapolated solely by morphological pathological assessment, since it has not been entirely characteristic. Cysteamine 0-3 BCL2 apoptosis regulator Homo sapiens 32-36 24399255-6 2014 These results suggested that TBME is able to induce anticancer effects on both lung and breast cancer cell lines through the modulation of Bcl-2 family proteins. methyl tert-butyl ether 29-33 BCL2 apoptosis regulator Homo sapiens 139-144 24699624-5 2014 This effect triggered cytoskeletal conformational changes that decreased PI3K/Akt/Bcl2 signaling, an obligatory step in chemosensitization by AS101. ammonium trichloro(dioxoethylene-O,O'-)tellurate 142-147 BCL2 apoptosis regulator Homo sapiens 82-86 24604609-5 2014 Furthermore, Western blotting indicated that DCB-induced apoptosis was accompanied by the down-regulation of Bcl-2/Bax ratio. 3,3'-Dichlorobenzidine 45-48 BCL2 apoptosis regulator Homo sapiens 109-114 24604609-6 2014 These results suggested that DCB led to cytotoxicity involving activation of mitochondrial-dependent apoptosis through Bax/Bcl-2 pathways in HepG2 cells. 3,3'-Dichlorobenzidine 29-32 BCL2 apoptosis regulator Homo sapiens 123-128 24703900-0 2014 Glucocorticoid sensitisation in Mixed Lineage Leukaemia-rearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101. Gossypol 132-140 BCL2 apoptosis regulator Homo sapiens 108-113 24703900-0 2014 Glucocorticoid sensitisation in Mixed Lineage Leukaemia-rearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101. gossypol acetic acid 145-151 BCL2 apoptosis regulator Homo sapiens 108-113 24703900-7 2014 Remarkably, the GC-sensitising effects of gossypol and AT-101 appeared not to be mediated by down-regulation MCL1 or other anti-apoptotic BCL-2 family members, but rather involved up-regulation of multiple pro-apoptotic BCL-2 family members, in particular that of BIM and BID. Gossypol 42-50 BCL2 apoptosis regulator Homo sapiens 138-143 24703900-7 2014 Remarkably, the GC-sensitising effects of gossypol and AT-101 appeared not to be mediated by down-regulation MCL1 or other anti-apoptotic BCL-2 family members, but rather involved up-regulation of multiple pro-apoptotic BCL-2 family members, in particular that of BIM and BID. Gossypol 42-50 BCL2 apoptosis regulator Homo sapiens 220-225 24703900-7 2014 Remarkably, the GC-sensitising effects of gossypol and AT-101 appeared not to be mediated by down-regulation MCL1 or other anti-apoptotic BCL-2 family members, but rather involved up-regulation of multiple pro-apoptotic BCL-2 family members, in particular that of BIM and BID. Astatine 55-57 BCL2 apoptosis regulator Homo sapiens 138-143 24703900-7 2014 Remarkably, the GC-sensitising effects of gossypol and AT-101 appeared not to be mediated by down-regulation MCL1 or other anti-apoptotic BCL-2 family members, but rather involved up-regulation of multiple pro-apoptotic BCL-2 family members, in particular that of BIM and BID. Astatine 55-57 BCL2 apoptosis regulator Homo sapiens 220-225 24703900-8 2014 CONCLUDING REMARKS: In conclusion, gossypol and AT-101 induce GC sensitivity in MLL-rearranged ALL cells, most likely mediated by the activation of BID and BIM without the necessity to down-regulate anti-apoptotic BCL-2 family members like MCL1. Gossypol 35-43 BCL2 apoptosis regulator Homo sapiens 214-219 24703900-8 2014 CONCLUDING REMARKS: In conclusion, gossypol and AT-101 induce GC sensitivity in MLL-rearranged ALL cells, most likely mediated by the activation of BID and BIM without the necessity to down-regulate anti-apoptotic BCL-2 family members like MCL1. gossypol acetic acid 48-54 BCL2 apoptosis regulator Homo sapiens 214-219 24632453-8 2014 Pretreatment of cells with glutathione reversed the apoptosis induced by combined regimen and recovered the Bcl2/Bax ratio. Glutathione 27-38 BCL2 apoptosis regulator Homo sapiens 108-112 24552218-13 2014 When EGCs were pretreated with IkappaB-alpha small interfering RNA, high E2-induced B cell lymphoma 2 (Bcl-2) down-regulation did not occur and EGCs apoptosis was reduced. egcs 5-9 BCL2 apoptosis regulator Homo sapiens 84-101 24552218-13 2014 When EGCs were pretreated with IkappaB-alpha small interfering RNA, high E2-induced B cell lymphoma 2 (Bcl-2) down-regulation did not occur and EGCs apoptosis was reduced. egcs 5-9 BCL2 apoptosis regulator Homo sapiens 103-108 24552218-14 2014 Bcl-2 overexpression also rescued high E2-induced EGCs from apoptosis. Estradiol 39-41 BCL2 apoptosis regulator Homo sapiens 0-5 24552218-14 2014 Bcl-2 overexpression also rescued high E2-induced EGCs from apoptosis. egcs 50-54 BCL2 apoptosis regulator Homo sapiens 0-5 24737008-10 2014 FZQJ-induced apoptosis was accompanied by the loss of psi, downregulation of Bcl-2 and upregulation of Bax expression, and the activation of caspase-3, -9 and P38 MAPK. fzqj 0-4 BCL2 apoptosis regulator Homo sapiens 78-83 24667300-1 2014 In a previous large randomized, open-label study, retrospective subset analysis revealed that the addition of the Bcl-2 antisense oligonucleotide oblimersen to dacarbazine (Dac) significantly improved overall survival, progression-free survival, and the response rate in chemotherapy-naive patients with advanced melanoma and normal baseline serum lactate dehydrogenase (LDH) levels. Oligonucleotides 130-145 BCL2 apoptosis regulator Homo sapiens 114-119 24667300-1 2014 In a previous large randomized, open-label study, retrospective subset analysis revealed that the addition of the Bcl-2 antisense oligonucleotide oblimersen to dacarbazine (Dac) significantly improved overall survival, progression-free survival, and the response rate in chemotherapy-naive patients with advanced melanoma and normal baseline serum lactate dehydrogenase (LDH) levels. Dacarbazine 160-171 BCL2 apoptosis regulator Homo sapiens 114-119 24667300-1 2014 In a previous large randomized, open-label study, retrospective subset analysis revealed that the addition of the Bcl-2 antisense oligonucleotide oblimersen to dacarbazine (Dac) significantly improved overall survival, progression-free survival, and the response rate in chemotherapy-naive patients with advanced melanoma and normal baseline serum lactate dehydrogenase (LDH) levels. Dacarbazine 173-176 BCL2 apoptosis regulator Homo sapiens 114-119 24456325-7 2014 The treatment of insulin had played a protective effect on H2O2-induced oxidative stress related to the Akt/Bcl-2 pathways. Hydrogen Peroxide 59-63 BCL2 apoptosis regulator Homo sapiens 108-113 24402163-0 2014 Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 145-148 BCL2 apoptosis regulator Homo sapiens 134-139 24402163-2 2014 The first effective BH3 mimetic inhibitors of Bcl-2, ABT-737 and navitoclax, also target Bcl-xL, causing dose-limiting thrombocytopenia. BH 3 20-23 BCL2 apoptosis regulator Homo sapiens 46-51 24402163-8 2014 These results pinpoint the probable impact of the pharmacological inhibition of Bcl-2 by ABT-199 on the normal mature haemopoietic cell lineages in patients, and have implications for monitoring during ABT-199 therapy as well as for the clinical utility of this very promising targeted agent. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 89-92 BCL2 apoptosis regulator Homo sapiens 80-85 24402163-8 2014 These results pinpoint the probable impact of the pharmacological inhibition of Bcl-2 by ABT-199 on the normal mature haemopoietic cell lineages in patients, and have implications for monitoring during ABT-199 therapy as well as for the clinical utility of this very promising targeted agent. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 202-205 BCL2 apoptosis regulator Homo sapiens 80-85 24515389-5 2014 It"s found the inhibition rate of 5-FU, L-OHP to well-differentiated GC tissues and cell line was lower than that in the poorly differentiated tissues and cell line; expressions of ZNF139 and MDR1/P-gp, MRP1 and Bcl-2 in well-differentiated GC tissues and cell line MKN28 were higher, while Bax expression was lower. Fluorouracil 34-38 BCL2 apoptosis regulator Homo sapiens 212-217 24515389-5 2014 It"s found the inhibition rate of 5-FU, L-OHP to well-differentiated GC tissues and cell line was lower than that in the poorly differentiated tissues and cell line; expressions of ZNF139 and MDR1/P-gp, MRP1 and Bcl-2 in well-differentiated GC tissues and cell line MKN28 were higher, while Bax expression was lower. Oxaliplatin 40-45 BCL2 apoptosis regulator Homo sapiens 212-217 24341565-10 2014 In addition, intracellular ROS and calcium levels, activated caspase-3, Bax:Bcl-2 ratio, cytochrome c release, as well as DNA fragmentation were significantly increased in 6-OHDA-treated cells. Oxidopamine 172-178 BCL2 apoptosis regulator Homo sapiens 76-81 24700345-8 2014 Altholactone treatment was also found to result in a significant loss of mitochondrial membrane potential, Bcl-2 downregulation and caspase-3 activation. altholactone 0-12 BCL2 apoptosis regulator Homo sapiens 107-112 24700345-9 2014 Pretreatment of T24 cells with the antioxidant N-acetylcysteine (NAC) significantly inhibited activation of caspase-3 and MAPK-p38 and prevented inactivation of Akt and Bcl-2. Acetylcysteine 47-63 BCL2 apoptosis regulator Homo sapiens 169-174 24700345-9 2014 Pretreatment of T24 cells with the antioxidant N-acetylcysteine (NAC) significantly inhibited activation of caspase-3 and MAPK-p38 and prevented inactivation of Akt and Bcl-2. Acetylcysteine 65-68 BCL2 apoptosis regulator Homo sapiens 169-174 24932256-14 2014 As for the apoptosis signaling genes, the combination of cisplatin and fractionated IR therapy resulted in a significant decrease in Bcl-2 expression and a marked upregulation of p21 expression. Cisplatin 57-66 BCL2 apoptosis regulator Homo sapiens 133-138 24932277-7 2014 During sorbitol-induced apoptosis, the mitochondrial pathway was activated by a dose-dependent increase in Bax expression and cytochrome c release, while the expression of anti-apoptotic protein Bcl-2 was significantly decreased in a dose-dependent manner. Sorbitol 7-15 BCL2 apoptosis regulator Homo sapiens 195-200 24218065-0 2014 Antiapoptotic Bcl-2 homolog CED-9 in Caenorhabditis elegans: dynamics of BH3 and CED-4 binding regions and comparison with mammalian antiapoptotic Bcl-2 proteins. BH 3 73-76 BCL2 apoptosis regulator Homo sapiens 14-19 24218065-3 2014 The BH3-motif of proapoptotic proteins bind to the hydrophobic groove of prosurvival proteins formed by the Bcl-2 helical fold. BH 3 4-7 BCL2 apoptosis regulator Homo sapiens 108-113 24218065-8 2014 The BH3-binding region of Bcl-2 is less flexible among the mammalian proteins and this lends support to the studies that Bcl-2 binds to less number of BH3 peptides with high affinity. BH 3 4-7 BCL2 apoptosis regulator Homo sapiens 26-31 24218065-8 2014 The BH3-binding region of Bcl-2 is less flexible among the mammalian proteins and this lends support to the studies that Bcl-2 binds to less number of BH3 peptides with high affinity. BH 3 4-7 BCL2 apoptosis regulator Homo sapiens 121-126 24434019-3 2014 The present study showed that destruxin B (DB) inhibits the proliferation and induces the apoptosis of HCC cells by decreasing the protein expression of anti-apoptotic Bcl-2 and Bcl-xL and increasing the expression of the proapoptotic protein Bax. destruxin B 30-41 BCL2 apoptosis regulator Homo sapiens 168-173 24887326-11 2014 Imidazotetrazine analogues of TMZ and the BH3 mimetic obatoclax are promising clinical candidates in drug resistant MB tumours expressing MGMT and BCL2 anti-apoptotic members respectively. imidazotetrazine 0-16 BCL2 apoptosis regulator Homo sapiens 147-151 24563336-0 2014 Oxymatrine triggers apoptosis by regulating Bcl-2 family proteins and activating caspase-3/caspase-9 pathway in human leukemia HL-60 cells. oxymatrine 0-10 BCL2 apoptosis regulator Homo sapiens 44-49 24563336-4 2014 The increase in apoptosis upon treatment with oxymatrine was correlated with downregulation of anti-apoptotic Bcl-2 expression and upregulation of pro-apoptotic Bax expression. oxymatrine 46-56 BCL2 apoptosis regulator Homo sapiens 110-115 24989276-14 2014 The mechanism of THP-1 cell apoptosis induced by brucine may be related to the inhibition of BCL-2 and activation of BAX. brucine 49-56 BCL2 apoptosis regulator Homo sapiens 93-98 24519064-6 2014 We also found that DHA decreased the mitochondrial membrane potential; activated the caspase-3, caspase-8, and caspase-9; and increased the ratio of Bax/Bcl-2. artenimol 19-22 BCL2 apoptosis regulator Homo sapiens 153-158 24989280-0 2014 [Role of BCL-2, caspase-3 and NF-kappaB in astragaloside inducing apoptosis of human NB4 cells]. astragaloside 43-56 BCL2 apoptosis regulator Homo sapiens 9-14 24989280-5 2014 Simultaneously, the mRNA expression of BCL-2 was down-regulated, Western blot analysis showed that the protein expression levels of BCL-2 and NF-kappaB decreased after astragalosides treatment, while caspase-3 protein expression level increased. astragalosides 168-182 BCL2 apoptosis regulator Homo sapiens 39-44 24989280-5 2014 Simultaneously, the mRNA expression of BCL-2 was down-regulated, Western blot analysis showed that the protein expression levels of BCL-2 and NF-kappaB decreased after astragalosides treatment, while caspase-3 protein expression level increased. astragalosides 168-182 BCL2 apoptosis regulator Homo sapiens 132-137 24989280-6 2014 It is concluded that the molecular mechanism of the astragalosides-induced apoptosis in NB4 cells may be associated with down-regulation of the expression of BCL-2 and NF-kappaB, finally the relative activity of caspase-3 activated. astragalosides 52-66 BCL2 apoptosis regulator Homo sapiens 158-163 24989284-7 2014 After being treated with Tet alone, FQ-PCR and Western blot showed that the expressions of caspase-3 mRNA and caspase-3 protein were up-regulated, the expressions of BCL-2 mRNA and protein were down-regulated, the effect of both drug combination was more significant. tet 25-28 BCL2 apoptosis regulator Homo sapiens 166-171 24989284-9 2014 Combination of IM with Tet shows obvious synergistic effect, mechanism of which may associate with up-regulation of caspase-3 mRNA and protein expressions, and down-regulation of BCL-2 mRNA and protein expressions. tet 23-26 BCL2 apoptosis regulator Homo sapiens 179-184 24874286-8 2014 Concomitantly, cell apoptosis resulting from the co-treatment of gefitinib and decitabine was accompanied by induction of BAX, cleaved caspase 3 and cleaved PARP, along with reduction of Bcl-2 compared to treatment with either drug alone. Gefitinib 65-74 BCL2 apoptosis regulator Homo sapiens 187-192 24874286-8 2014 Concomitantly, cell apoptosis resulting from the co-treatment of gefitinib and decitabine was accompanied by induction of BAX, cleaved caspase 3 and cleaved PARP, along with reduction of Bcl-2 compared to treatment with either drug alone. Decitabine 79-89 BCL2 apoptosis regulator Homo sapiens 187-192 24887326-11 2014 Imidazotetrazine analogues of TMZ and the BH3 mimetic obatoclax are promising clinical candidates in drug resistant MB tumours expressing MGMT and BCL2 anti-apoptotic members respectively. BH 3 42-45 BCL2 apoptosis regulator Homo sapiens 147-151 24959385-9 2014 FL118 was found to not only inhibit multiple antiapoptotic proteins (survivin, XIAP, cIAP2) in the inhibitor of apoptosis (IAP) family, but to also inhibit the antiapoptotic protein Mcl-1 in the Bcl-2 family, while inducing the pro-apoptotic proteins Bax and Bim expression. 7-ethyl-7-hydroxy-10H-1,3-Dioxolo(4,5-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-8,11(7H,12H)-dione 0-5 BCL2 apoptosis regulator Homo sapiens 195-200 24899815-9 2014 We also found that manumycin downregulated Bcl-2 expression and upregulated Bax expression. manumycin 19-28 BCL2 apoptosis regulator Homo sapiens 43-48 24858012-8 2014 In MCF-7 cells metformin decreased the activation of IRbeta, Akt and ERK1/2, increased p-AMPK, FOXO3a, p27, Bax and cleaved caspase-3, and decreased phosphorylation of p70S6K and Bcl-2 protein expression. Metformin 15-24 BCL2 apoptosis regulator Homo sapiens 179-184 24631568-3 2014 Here, we shows that in the cultured human brain microvascular endothelial cells (HBMEC), we found that venlafaxine protects methylglyoxal (MGO)-induced cell injury, and the venlafaxine significant reduction in the level of reactive oxygen species, down-regulated expression of pro-apoptotic activated caspase-3 and Bax, increased BDNF release and expression of anti-apoptotic Bcl-2 in the cultured HBMEC. Venlafaxine Hydrochloride 173-184 BCL2 apoptosis regulator Homo sapiens 376-381 24899815-10 2014 CONCLUSION: Our data suggest that manumycin induces apoptosis in prostate cancer cells through regulation of the Bcl-2 family involving caspase-9 activation. manumycin 34-43 BCL2 apoptosis regulator Homo sapiens 113-118 24630927-0 2014 Cardiac glycoside ouabain induces autophagic cell death in non-small cell lung cancer cells via a JNK-dependent decrease of Bcl-2. Glycosides 8-17 BCL2 apoptosis regulator Homo sapiens 124-129 24904829-10 2014 Further molecular analysis suggests that DHA-mediated cell death involves different sets of pro-apoptotic Bcl-2 family members. artenimol 41-44 BCL2 apoptosis regulator Homo sapiens 106-111 24836450-5 2014 In present study, MEHP induced a dose-dependent cell injury in HUVEC cell via an apoptosis pathway as characterized by increased percentage of sub-G1, activation of caspase-3, -8 and -9, and increased ratio of Bax/bcl-2 mRNA and protein expression as well as cytochrome C releasing. mono-(2-ethylhexyl)phthalate 18-22 BCL2 apoptosis regulator Homo sapiens 214-219 24680927-7 2014 Further knockdown of JNK by siRNA could inhibit ziyuglycoside II-mediated apoptosis with attenuating the up-regulation of Bax and Fas/FasL as well as the down-regulation of Bcl-2. ziyuglycoside 48-61 BCL2 apoptosis regulator Homo sapiens 173-178 24833880-1 2014 AIM: To investigate the changes in apoptosis in gastrointestinal cancer cells from patients with gastrointestinal cancers treated with arsenic trioxide (As2O3); and to study the possible molecular mechanisms of such changes by detecting the expression levels of p53 and Bcl-2. Arsenic Trioxide 135-151 BCL2 apoptosis regulator Homo sapiens 270-275 24811082-3 2014 We investigated the implication of major proteins of the Bcl-2 family in TMZ-induced cell death in GBM cell lines at concentrations closed to that reached in the brain during the treatments. Temozolomide 73-76 BCL2 apoptosis regulator Homo sapiens 57-62 24833880-10 2014 However, Bcl-2 protein expression in gastrointestinal tissues was down-regulated by As2O3 (P < 0.01). Arsenic Trioxide 84-89 BCL2 apoptosis regulator Homo sapiens 9-14 24829158-4 2014 CDDP induced apoptosis within cells through the generation of reactive oxygen species (ROS), regulated the ROS-mediated expression of Bax, Bcl-2, and p53, and induced the degradation of the poly (ADP-ribosyl) polymerase (PARP). Cisplatin 0-4 BCL2 apoptosis regulator Homo sapiens 139-144 24833880-11 2014 CONCLUSION: These results demonstrate that As2O3 treatment in patients with gastrointestinal cancers can induce apoptosis in gastrointestinal cancer cells and down-regulate Bcl-2 protein expression. Arsenic Trioxide 43-48 BCL2 apoptosis regulator Homo sapiens 173-178 24829158-4 2014 CDDP induced apoptosis within cells through the generation of reactive oxygen species (ROS), regulated the ROS-mediated expression of Bax, Bcl-2, and p53, and induced the degradation of the poly (ADP-ribosyl) polymerase (PARP). Reactive Oxygen Species 107-110 BCL2 apoptosis regulator Homo sapiens 139-144 24628241-7 2014 Both raft- and ER-mediated proapoptotic responses require a mitochondrial-related step to eventually promote cell death, and overexpression of Bcl-2 or Bcl-xL prevents edelfosine-induced apoptosis. edelfosine 168-178 BCL2 apoptosis regulator Homo sapiens 143-148 24872679-4 2014 Gossypol is a Bcl-2 homology 3 (BH3)-mimetic agent and is able to bind to the BH3 domain of B-cell lymphoma 2 (Bcl-2) family members. Gossypol 0-8 BCL2 apoptosis regulator Homo sapiens 14-19 24872679-4 2014 Gossypol is a Bcl-2 homology 3 (BH3)-mimetic agent and is able to bind to the BH3 domain of B-cell lymphoma 2 (Bcl-2) family members. Gossypol 0-8 BCL2 apoptosis regulator Homo sapiens 92-109 24872679-4 2014 Gossypol is a Bcl-2 homology 3 (BH3)-mimetic agent and is able to bind to the BH3 domain of B-cell lymphoma 2 (Bcl-2) family members. Gossypol 0-8 BCL2 apoptosis regulator Homo sapiens 111-116 24872679-4 2014 Gossypol is a Bcl-2 homology 3 (BH3)-mimetic agent and is able to bind to the BH3 domain of B-cell lymphoma 2 (Bcl-2) family members. BH 3 32-35 BCL2 apoptosis regulator Homo sapiens 111-116 24872679-4 2014 Gossypol is a Bcl-2 homology 3 (BH3)-mimetic agent and is able to bind to the BH3 domain of B-cell lymphoma 2 (Bcl-2) family members. BH 3 78-81 BCL2 apoptosis regulator Homo sapiens 92-109 24872679-4 2014 Gossypol is a Bcl-2 homology 3 (BH3)-mimetic agent and is able to bind to the BH3 domain of B-cell lymphoma 2 (Bcl-2) family members. BH 3 78-81 BCL2 apoptosis regulator Homo sapiens 111-116 24786233-11 2014 Furthermore, QSN-10c dose-dependently decreased the Deltapsim in K562 cells, increased the release of cytochrome c and the level of Bax, and decreased the level of Bcl-2, suggesting that QSN-10c-induced apoptosis of K562 cells was mediated via the mitochondrial apoptotic pathway. qsn-10c 13-20 BCL2 apoptosis regulator Homo sapiens 164-169 24786233-11 2014 Furthermore, QSN-10c dose-dependently decreased the Deltapsim in K562 cells, increased the release of cytochrome c and the level of Bax, and decreased the level of Bcl-2, suggesting that QSN-10c-induced apoptosis of K562 cells was mediated via the mitochondrial apoptotic pathway. qsn-10c 187-194 BCL2 apoptosis regulator Homo sapiens 164-169 24619961-6 2014 Combined treatment of berbamine and gemcitabine resulted in down-regulation of anti-apoptotic proteins (Bcl-2, Bcl-xL) and up-regulation of pro-apoptotic proteins (Bax, Bid). berbamine 22-31 BCL2 apoptosis regulator Homo sapiens 104-109 24619961-6 2014 Combined treatment of berbamine and gemcitabine resulted in down-regulation of anti-apoptotic proteins (Bcl-2, Bcl-xL) and up-regulation of pro-apoptotic proteins (Bax, Bid). gemcitabine 36-47 BCL2 apoptosis regulator Homo sapiens 104-109 24705122-1 2014 Our previous studies have shown that quercetin inhibits Cox-2 and Bcl-2 expressions, and induces human leukemia HL-60 cell apoptosis. Quercetin 37-46 BCL2 apoptosis regulator Homo sapiens 66-71 24705122-11 2014 Taken together, these findings suggested that quercetin activates AMPK expression in HL-60 cells independent of LKB1 activation, inhibits Cox-2 expression by activating AMPK, and further regulates the Bcl-2-dependent pathways of apoptosis to exert its anti-leukemia effect. Quercetin 46-55 BCL2 apoptosis regulator Homo sapiens 201-206 24622325-10 2014 In drug development, targeting the ubiquitination machinery of prosurvival Bcl-2 proteins will complement and potentially improve on targeting Bcl-2 protein interactions with BH3 mimetics. BH 3 175-178 BCL2 apoptosis regulator Homo sapiens 143-148 24593988-8 2014 Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest. tetrahydrocurcumin 43-46 BCL2 apoptosis regulator Homo sapiens 211-216 24576507-0 2014 HCC cells with high levels of Bcl-2 are resistant to ABT-737 via activation of the ROS-JNK-autophagy pathway. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 53-56 BCL2 apoptosis regulator Homo sapiens 30-35 24576507-0 2014 HCC cells with high levels of Bcl-2 are resistant to ABT-737 via activation of the ROS-JNK-autophagy pathway. Reactive Oxygen Species 83-86 BCL2 apoptosis regulator Homo sapiens 30-35 24576507-1 2014 The Bcl-2 inhibitor ABT-737 has shown promising antitumor efficacy in vivo and in vitro. ABT-737 20-27 BCL2 apoptosis regulator Homo sapiens 4-9 24622325-10 2014 In drug development, targeting the ubiquitination machinery of prosurvival Bcl-2 proteins will complement and potentially improve on targeting Bcl-2 protein interactions with BH3 mimetics. BH 3 175-178 BCL2 apoptosis regulator Homo sapiens 75-80 25009698-4 2014 Treatment with beta-lapachone caused mitochondrial transmembrane potential dissipation, stimulated the mitochondria-mediated intrinsic apoptotic pathway, as indicated by caspase-9 activation, cytochrome c release, Bcl-2 downregulation and Bax upregulation, as well as death receptor-mediated extrinsic apoptotic pathway, as indicated by activation of caspase-8 and truncation of Bid. beta-lapachone 15-29 BCL2 apoptosis regulator Homo sapiens 214-219 24556569-7 2014 Furthermore, NAC prevented the changes of MSG-induced Bcl-2 expression level. Acetylcysteine 13-16 BCL2 apoptosis regulator Homo sapiens 54-59 24561580-10 2014 The cytotoxic effect of 7-DHC was associated with an increase in Bax levels, decrease in Bcl-2/Bax ratio, reduction of mitochondrial membrane potential, increase in apoptosis-inducing factor levels, unchanged caspase-3 activity, and absence of cleavage of PARP-1. 7-dehydrocholesterol 24-29 BCL2 apoptosis regulator Homo sapiens 89-94 24576507-3 2014 In this study, we found that HCC cells with high levels of Bcl-2 were markedly resistant to ABT-737 compared to HCC cells with low levels of Bcl-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 92-95 BCL2 apoptosis regulator Homo sapiens 59-64 24576507-4 2014 In HCC cells with high levels of Bcl-2 (such as HepG2 cells), ABT-737 induced protective autophagy via the sequential triggering of reactive oxygen species (ROS) accumulation, short-term activation of JNK, enhanced phosphorylation of Bcl-2, and dissociation of Beclin 1 from the Bcl-2/Beclin 1 complex. ABT-737 62-69 BCL2 apoptosis regulator Homo sapiens 33-38 24593988-8 2014 Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest. SB 203580 71-79 BCL2 apoptosis regulator Homo sapiens 211-216 24576507-4 2014 In HCC cells with high levels of Bcl-2 (such as HepG2 cells), ABT-737 induced protective autophagy via the sequential triggering of reactive oxygen species (ROS) accumulation, short-term activation of JNK, enhanced phosphorylation of Bcl-2, and dissociation of Beclin 1 from the Bcl-2/Beclin 1 complex. ABT-737 62-69 BCL2 apoptosis regulator Homo sapiens 234-239 24576507-4 2014 In HCC cells with high levels of Bcl-2 (such as HepG2 cells), ABT-737 induced protective autophagy via the sequential triggering of reactive oxygen species (ROS) accumulation, short-term activation of JNK, enhanced phosphorylation of Bcl-2, and dissociation of Beclin 1 from the Bcl-2/Beclin 1 complex. ABT-737 62-69 BCL2 apoptosis regulator Homo sapiens 234-239 24593988-8 2014 Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest. tetrahydrocurcumin 179-182 BCL2 apoptosis regulator Homo sapiens 211-216 24576507-6 2014 In HCC cells with low levels of Bcl-2 (i.e., Huh7 cells), ABT-737 induced apoptosis via the sequential stimulation of ROS, sustained activation of JNK, enhanced translocation of Bax from the cytosol to the mitochondria, and release of cytochrome c. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 58-61 BCL2 apoptosis regulator Homo sapiens 32-37 24593988-8 2014 Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest. tetrahydrocurcumin 179-182 BCL2 apoptosis regulator Homo sapiens 211-216 24576507-7 2014 In sum, this study indicated that the activation of the ROS-JNK-autophagy pathway may be an important mechanism by which HCC cells with high levels of Bcl-2 are resistant to ABT-737. Reactive Oxygen Species 56-59 BCL2 apoptosis regulator Homo sapiens 151-156 24576507-7 2014 In sum, this study indicated that the activation of the ROS-JNK-autophagy pathway may be an important mechanism by which HCC cells with high levels of Bcl-2 are resistant to ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 174-177 BCL2 apoptosis regulator Homo sapiens 151-156 23846545-9 2014 BAY 11-7082 induced rapid apoptosis in HGC-27 cells through activating the mitochondrial pathway, as well as down-regulation of Bcl-2 and up-regulation of Bax. 3-(4-methylphenylsulfonyl)-2-propenenitrile 0-11 BCL2 apoptosis regulator Homo sapiens 128-133 24603988-0 2014 Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-kappaB/mTOR signaling proteins and anti-apoptotic Bcl-2. pristimerin 0-11 BCL2 apoptosis regulator Homo sapiens 185-190 24603988-6 2014 Treatment with PM also inhibited the expression of anti-apoptotic Bcl-2 and survivin but not Bcl-xL. pristimerin 15-17 BCL2 apoptosis regulator Homo sapiens 66-71 24603988-7 2014 The downregulation of Bcl-2 by PM was not due to proteasomal or lysosomal proteolytic degradation of Bcl-2, since treatment with PM in the presence of proteasomal inhibitors MG132 or lactacystin (LAC) or calpain inhibitor MG101 failed to block the downregulation of Bcl-2 by PM. pristimerin 31-33 BCL2 apoptosis regulator Homo sapiens 22-27 24603988-7 2014 The downregulation of Bcl-2 by PM was not due to proteasomal or lysosomal proteolytic degradation of Bcl-2, since treatment with PM in the presence of proteasomal inhibitors MG132 or lactacystin (LAC) or calpain inhibitor MG101 failed to block the downregulation of Bcl-2 by PM. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 174-179 BCL2 apoptosis regulator Homo sapiens 22-27 24603988-7 2014 The downregulation of Bcl-2 by PM was not due to proteasomal or lysosomal proteolytic degradation of Bcl-2, since treatment with PM in the presence of proteasomal inhibitors MG132 or lactacystin (LAC) or calpain inhibitor MG101 failed to block the downregulation of Bcl-2 by PM. lactacystin 183-194 BCL2 apoptosis regulator Homo sapiens 22-27 24603988-7 2014 The downregulation of Bcl-2 by PM was not due to proteasomal or lysosomal proteolytic degradation of Bcl-2, since treatment with PM in the presence of proteasomal inhibitors MG132 or lactacystin (LAC) or calpain inhibitor MG101 failed to block the downregulation of Bcl-2 by PM. lactacystin 196-199 BCL2 apoptosis regulator Homo sapiens 22-27 24603988-7 2014 The downregulation of Bcl-2 by PM was not due to proteasomal or lysosomal proteolytic degradation of Bcl-2, since treatment with PM in the presence of proteasomal inhibitors MG132 or lactacystin (LAC) or calpain inhibitor MG101 failed to block the downregulation of Bcl-2 by PM. acetylleucyl-leucyl-norleucinal 222-227 BCL2 apoptosis regulator Homo sapiens 22-27 24603988-8 2014 On the other hand, RT-PCR analysis showed the inhibition of Bcl-2 mRNA by PM in a dose-related manner, indicating that inhibition of Bcl-2 by PM is mediated through the suppression of Bcl-2 gene expression. pristimerin 74-76 BCL2 apoptosis regulator Homo sapiens 60-65 24603988-8 2014 On the other hand, RT-PCR analysis showed the inhibition of Bcl-2 mRNA by PM in a dose-related manner, indicating that inhibition of Bcl-2 by PM is mediated through the suppression of Bcl-2 gene expression. pristimerin 74-76 BCL2 apoptosis regulator Homo sapiens 133-138 24603988-8 2014 On the other hand, RT-PCR analysis showed the inhibition of Bcl-2 mRNA by PM in a dose-related manner, indicating that inhibition of Bcl-2 by PM is mediated through the suppression of Bcl-2 gene expression. pristimerin 74-76 BCL2 apoptosis regulator Homo sapiens 133-138 24513610-0 2014 A ruthenium(II) complex capable of inducing and stabilizing bcl-2 G-quadruplex formation as a potential cancer inhibitor. Ruthenium(II) 2-15 BCL2 apoptosis regulator Homo sapiens 60-65 24584843-4 2014 Farnesol increased the expression of p53, p-c-Jun N-terminal kinase, cleaved-caspase-3, Bax, and cleaved-caspase-9, but decreased the expression of p-phosphatidylinositol-3-kinase (PI3K), p-Akt, p-p38, Bcl-2, and p-extracellular signal-regulated protein kinase, in a dose-dependent manner. Farnesol 0-8 BCL2 apoptosis regulator Homo sapiens 202-207 24720439-9 2014 HH-CO2 induced apoptosis and significantly inhibited the expression of Bcl-2, MMP-2, ICAM-1 and CD44, and increased Bax and E-cadherin expression in colon cancer cells. N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide 3-6 BCL2 apoptosis regulator Homo sapiens 71-76 22505597-4 2014 FNQ-induced apoptosis was accompanied by Bax and Bad upregulation, and the downregulation of Bcl-2, Bcl-XL, Mcl-1, and X-linked inhibitor of apoptosis (XIAP), resulting in cytochrome C release and sequential activation of caspase-9 and caspase-3. furano-1,2-naphthoquinone 0-3 BCL2 apoptosis regulator Homo sapiens 93-98 24325805-5 2014 Polyphyllin D-induced apoptosis via the mitochondrial apoptotic pathway as evidenced by decreased Bcl-2 expression levels, disruption of MMP and increased Bax, cytochrome C and cleaved-caspase-3 levels. polyphyllin D 0-13 BCL2 apoptosis regulator Homo sapiens 98-103 24390959-8 2014 Furthermore, EPO increased the expression of phosphorylated Akt and phosphorylated FoxO3a, and abrogated the 6-OHDA-induced dysregulation of Bcl-2, Bax and Caspase-3 in PC12 cells and in striatal neurons. Oxidopamine 109-115 BCL2 apoptosis regulator Homo sapiens 141-146 24342948-0 2014 BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 24-27 BCL2 apoptosis regulator Homo sapiens 0-4 24342948-0 2014 BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines. Cytarabine 57-67 BCL2 apoptosis regulator Homo sapiens 0-4 24435446-1 2014 The bromodomain and extra-terminal (BET) protein family members, including BRD4, bind to acetylated lysines on histones and regulate the expression of important oncogenes, for example, c-MYC and BCL2. Lysine 100-107 BCL2 apoptosis regulator Homo sapiens 195-199 24636337-4 2014 This Mcl-1-dependence suggests a pivotal role of Bcl-2 family protein-mediated apoptosis to vorinostat/GO in AML patients. Vorinostat 92-102 BCL2 apoptosis regulator Homo sapiens 49-54 24573886-8 2014 Genistein increased in three times proapoptotic BAX/Bcl-2 ratio and promoted a parallel downregulation of 20 times of antiapoptotic survivin. Genistein 0-9 BCL2 apoptosis regulator Homo sapiens 52-57 24496855-4 2014 In addition, Curcumin dose-dependently decreased gene Bcl-2 mRNA expression. Curcumin 13-21 BCL2 apoptosis regulator Homo sapiens 54-59 24502926-6 2014 BKT140 induced apoptotic cell death, decreasing the levels of HSP70 and HSP90 chaperones and antiapoptotic proteins BCL-2 and BCL-XL, subsequently promoting the release of mitochondrial factors cytochrome c and SMAC/Diablo. BKT140 0-6 BCL2 apoptosis regulator Homo sapiens 116-121 24560445-7 2014 In contrast, all three platinum refractory PDXs overexpressed dominant oncogenes (CCNE1, LIN28B and/or BCL2). Platinum 23-31 BCL2 apoptosis regulator Homo sapiens 103-107 24772309-2 2014 In order to clarify the prognostic significance of Bcl-2 status in patients with AL, a systematic review and meta-analysis of 5 published studies including a total of 665 subjects was performed. Aluminum 81-83 BCL2 apoptosis regulator Homo sapiens 51-56 24772309-6 2014 The summary hazard ratio of Bcl-2 negativity/positivity for CR was 0.62 [95% confidence interval: 0.53-0.81, P<0.001]. Chromium 60-62 BCL2 apoptosis regulator Homo sapiens 28-33 24772309-7 2014 Although this meta-analysis was based on data abstracted from observational studies, our results may justify the use of risk-adapted therapeutic strategies for AL according to the Bcl-2 expression status. Aluminum 160-162 BCL2 apoptosis regulator Homo sapiens 180-185 24604218-11 2014 Curcumin and EF-24 increased the Bax/Bcl-2 ratio significantly. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 37-42 24774218-10 2014 And, in cervical SCC patients after treatment with Taxol chemotherapy, the expression level of miR-143 was higher and the positive expression of bcl-2 protein was lower. Paclitaxel 51-56 BCL2 apoptosis regulator Homo sapiens 145-150 24627081-8 2014 Western blot analysis of oxidative stress pathway-related proteins demonstrated that oridonin treatment increased p-JNK, p-p38 and p-p53, and decreased Bcl-2 protein expression levels, promoted cytochrome c release, decreased mitochondrial membrane potential, and activated caspase-9 and caspase-3. oridonin 85-93 BCL2 apoptosis regulator Homo sapiens 152-157 24627125-12 2014 The combination of beta-ELE and cisplatin enhanced the protein expression of cytochrome c, caspase-3 and Bad, and reduced protein levels of Bcl-2 and procaspase-3 in the A549/DDP lung cancer cells. Cisplatin 32-41 BCL2 apoptosis regulator Homo sapiens 140-145 24855827-9 2014 Celecoxib inhibited the activation of STAT3 phosphorylation in HONE1 cells and the downstream genes of STAT3 (Survivin, Mcl-1, Bcl-2 and Cyclin D1) were downregulated after treatment with celecoxib. Celecoxib 0-9 BCL2 apoptosis regulator Homo sapiens 127-132 24779770-0 2014 The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 23-26 BCL2 apoptosis regulator Homo sapiens 4-9 24779770-2 2014 ABT-263 is a newly synthesized, orally available Bcl-2/xL inhibitor that shows promising efficacy in HCC therapy. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 49-54 24779770-3 2014 ABT-263 inhibits the anti-apoptotic activity of Bcl-2 and Bcl-xL, but not Mcl-1. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 48-53 24603952-7 2014 The responsible mechanism is at least partially due to TQ inhibiting the growth of CCA cell lines induced by downregulation of PI3K/Akt and NF-kappaB and regulated gene products, including p-AKT, p65, XIAP, Bcl-2, COX-2, VEGF. thymoquinone 55-57 BCL2 apoptosis regulator Homo sapiens 207-212 24236568-9 2014 The increase of apoptosis induced by osthole was correlated with down-regulation expression of anti-apoptotic Bcl-2 protein and up-regulation expression of pro-apoptotic Bax and p53 proteins. osthol 37-44 BCL2 apoptosis regulator Homo sapiens 110-115 24563380-6 2014 The addition of Andro to CDDP induced synergistic apoptosis, which could be corroborated to the changes in protein and mRNA levels of Bax and Bcl-2, and the increased Fas/FasL association in these cells, resulting in increased release of cytochrome c, and activation of caspases. andrographolide 16-21 BCL2 apoptosis regulator Homo sapiens 142-147 24563380-6 2014 The addition of Andro to CDDP induced synergistic apoptosis, which could be corroborated to the changes in protein and mRNA levels of Bax and Bcl-2, and the increased Fas/FasL association in these cells, resulting in increased release of cytochrome c, and activation of caspases. Cisplatin 25-29 BCL2 apoptosis regulator Homo sapiens 142-147 24570183-0 2014 Bufalin inhibited the growth of human osteosarcoma MG-63 cells via down-regulation of Bcl-2/Bax and triggering of the mitochondrial pathway. bufalin 0-7 BCL2 apoptosis regulator Homo sapiens 86-91 24570183-6 2014 By western blot analysis, we found that the up-regulation of Apaf-1, cleaved PARP, cleaved caspase-3, cleaved caspase-9, and Bax/Bcl-2, varies with different concentration of Bufalin. bufalin 175-182 BCL2 apoptosis regulator Homo sapiens 129-134 24795530-4 2014 Also, gallotannin attenuated the expression of pro-caspase9, pro-caspase3, Bcl2 and integrin beta1 and cleaved poly(ADP)-ribose polymerase (PARP) in Hep G2 and Chang cancer cells. Hydrolyzable Tannins 6-17 BCL2 apoptosis regulator Homo sapiens 75-79 24570003-7 2014 Furthermore, PI-1840 sensitizes human cancer cells to the mdm2/p53 disruptor, nutlin, and to the pan-Bcl-2 antagonist BH3-M6. PI-1840 13-20 BCL2 apoptosis regulator Homo sapiens 101-106 24570003-7 2014 Furthermore, PI-1840 sensitizes human cancer cells to the mdm2/p53 disruptor, nutlin, and to the pan-Bcl-2 antagonist BH3-M6. bh3-m6 118-124 BCL2 apoptosis regulator Homo sapiens 101-106 24799992-9 2014 Melatonin reduced cisplatin-induced cell death, decreasing phosphorylated p53 apoptotic protein, cleaved caspase 3 and Bax levels but increasing anti-apoptotic Bcl-2 gene and protein expression. Melatonin 0-9 BCL2 apoptosis regulator Homo sapiens 160-165 24743574-13 2014 Ectopic expression of Bcl-2 also inhibited apoptosis in NVP-BE235 plus curcumin-treated cells. Curcumin 71-79 BCL2 apoptosis regulator Homo sapiens 22-27 24758901-0 2014 Hydrogen sulfide attenuates the recruitment of CD11b+Gr-1+ myeloid cells and regulates Bax/Bcl-2 signaling in myocardial ischemia injury. Hydrogen Sulfide 0-16 BCL2 apoptosis regulator Homo sapiens 91-96 24758901-3 2014 The results demonstrated that the administration of NaHS improved survival, preserved left ventricular function, limited infarct size, and improved H2S levels in cardiac tissue to attenuate the recruitment of CD11b(+)Gr-1(+) myeloid cells and to regulate the Bax/Bcl-2 pathway. sodium bisulfide 52-56 BCL2 apoptosis regulator Homo sapiens 263-268 24758901-5 2014 These observations suggest that the novel mechanism underlying the cardioprotective function of H2S is secondary to a combination of attenuation the recruitment of CD11b(+)Gr-1(+) myeloid cells and regulation of the Bax/Bcl-2 apoptotic signaling. Hydrogen Sulfide 96-99 BCL2 apoptosis regulator Homo sapiens 220-225 24755677-7 2014 Celastrol down-modulated antiapoptotic proteins including Bcl-2 and survivin expression. celastrol 0-9 BCL2 apoptosis regulator Homo sapiens 58-63 24743574-0 2014 Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 171-176 24743574-9 2014 Furthermore, the down-regulation of Bcl-2 was involved in curcumin plus NVP-BEZ235-induced apoptosis. Curcumin 58-66 BCL2 apoptosis regulator Homo sapiens 36-41 24743574-15 2014 Taken together, combined treatment with NVP-BEZ235 and curcumin induces apoptosis through p53-dependent Bcl-2 mRNA down-regulation at the transcriptional level and Mcl-1 protein down-regulation at the post-transcriptional level. dactolisib 44-50 BCL2 apoptosis regulator Homo sapiens 104-109 24743574-9 2014 Furthermore, the down-regulation of Bcl-2 was involved in curcumin plus NVP-BEZ235-induced apoptosis. dactolisib 76-82 BCL2 apoptosis regulator Homo sapiens 36-41 24743574-11 2014 Combined treatment with NVP-BEZ235 and curcumin reduced Bcl-2 expression in wild-type p53 HCT116 human colon carcinoma cells but not p53-null HCT116 cells. dactolisib 28-34 BCL2 apoptosis regulator Homo sapiens 56-61 24743574-15 2014 Taken together, combined treatment with NVP-BEZ235 and curcumin induces apoptosis through p53-dependent Bcl-2 mRNA down-regulation at the transcriptional level and Mcl-1 protein down-regulation at the post-transcriptional level. Curcumin 55-63 BCL2 apoptosis regulator Homo sapiens 104-109 24743574-11 2014 Combined treatment with NVP-BEZ235 and curcumin reduced Bcl-2 expression in wild-type p53 HCT116 human colon carcinoma cells but not p53-null HCT116 cells. Curcumin 39-47 BCL2 apoptosis regulator Homo sapiens 56-61 24462458-0 2014 Dicoumarol sensitizes renal cell carcinoma Caki cells to TRAIL-induced apoptosis through down-regulation of Bcl-2, Mcl-1 and c-FLIP in a NQO1-independent manner. Dicumarol 0-10 BCL2 apoptosis regulator Homo sapiens 108-113 24743574-12 2014 Moreover, Bcl-2 expression was completely reversed by treatment with pifithrin-alpha, a p53-specific inhibitor. pifithrin 69-84 BCL2 apoptosis regulator Homo sapiens 10-15 24462458-4 2014 We found that dicoumarol transcriptionally down-regulated Bcl-2 expression via inhibition of NF-kappaB and CREB activity, whereas it down-regulated Mcl-1 and c-FLIP expression at the post-translational level. Dicumarol 14-24 BCL2 apoptosis regulator Homo sapiens 58-63 24462458-5 2014 Overexpression of Bcl-2, Mcl-1, or c-FLIP overcame the dicoumarol plus TRAIL-induced apoptosis, indicating that down-regualtion of these anti-apoptotic proteins may critically contribute to the sensitizing effect of dicoumarol on TRAIL-mediated apoptosis. Dicumarol 55-65 BCL2 apoptosis regulator Homo sapiens 18-23 24462458-5 2014 Overexpression of Bcl-2, Mcl-1, or c-FLIP overcame the dicoumarol plus TRAIL-induced apoptosis, indicating that down-regualtion of these anti-apoptotic proteins may critically contribute to the sensitizing effect of dicoumarol on TRAIL-mediated apoptosis. Dicumarol 216-226 BCL2 apoptosis regulator Homo sapiens 18-23 24733045-5 2014 In further analysis, we show that JNK activation and phosphorylation of Bcl-2 are key determinants in 5-FU-induced autophagy. Fluorouracil 102-106 BCL2 apoptosis regulator Homo sapiens 72-77 24566868-4 2014 In addition, RSF1-overexpressing paclitaxel-resistant ovarian cancer cell lines were found to express elevated levels of genes regulated by NF-kappaB, including some involved with the evasion of apoptosis (CFLAR, XIAP, BCL2, and BCL2L1) and inflammation (PTGS2). Paclitaxel 33-43 BCL2 apoptosis regulator Homo sapiens 219-223 24733045-6 2014 Inhibition of JNK by the compound SP600125 or JNK siRNA suppressed autophagy and phosphorylation of c-Jun and Bcl-2 but increased 5-FU-induced apoptosis in both HCT116 p53(-/-) and HT29 cells. pyrazolanthrone 34-42 BCL2 apoptosis regulator Homo sapiens 110-115 24733045-7 2014 Taken together, our results suggest that JNK activation confers 5-FU resistance in HCT116 p53(-/-) and HT29 cells by promoting autophagy as a pro-survival effect, likely via inducing Bcl-2 phosphorylation. Fluorouracil 64-68 BCL2 apoptosis regulator Homo sapiens 183-188 24599950-4 2014 Exposure of GBM cells to cucurbitacin I resulted in pronounced apoptotic cell death through activating bcl-2 family proteins. cucurbitacin I 25-39 BCL2 apoptosis regulator Homo sapiens 103-108 24599950-7 2014 Stable overexpression of hypoxia-inducible factor 1alpha induced by FG-4497 prevented cucurbitacin I-induced autophagy and down-regulation of bcl-2. cucurbitacin I 86-100 BCL2 apoptosis regulator Homo sapiens 142-147 24599950-9 2014 A coimmunoprecipitation assay showed that the interaction of Bcl-2 and Beclin 1/hVps34 decreased markedly in cells treated with cucurbitacin I. cucurbitacin I 128-142 BCL2 apoptosis regulator Homo sapiens 61-66 24706857-7 2014 NAF-1 binds to both the pro- and antiapoptotic regions (BH3 and BH4) of Bcl-2, as demonstrated by a nested protein fragment analysis in a peptide array and DXMS analysis. BH 3 56-59 BCL2 apoptosis regulator Homo sapiens 72-77 24706857-7 2014 NAF-1 binds to both the pro- and antiapoptotic regions (BH3 and BH4) of Bcl-2, as demonstrated by a nested protein fragment analysis in a peptide array and DXMS analysis. sapropterin 64-67 BCL2 apoptosis regulator Homo sapiens 72-77 24706857-8 2014 A combination of the solution studies together with a new application of DCA to the eukaryotic proteins NAF-1 and Bcl-2 provided sufficient constraints at amino acid resolution to predict the interaction surfaces and orientation of the protein-protein interactions involved in the docked structure. dichloroacetylene 73-76 BCL2 apoptosis regulator Homo sapiens 114-119 24548862-0 2014 Nicotine increases the resistance of lung cancer cells to cisplatin through enhancing Bcl-2 stability. Nicotine 0-8 BCL2 apoptosis regulator Homo sapiens 86-91 25350143-4 2014 Apoptosis induction by inhibition of BCL2 with ABT-199 is reported with likewise promising clinical results. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 47-50 BCL2 apoptosis regulator Homo sapiens 37-41 24548862-0 2014 Nicotine increases the resistance of lung cancer cells to cisplatin through enhancing Bcl-2 stability. Cisplatin 58-67 BCL2 apoptosis regulator Homo sapiens 86-91 24548862-3 2014 METHODS: In this study, we used immunoblotting and immunoprecipitation methods to test the ubiquitination and degradation of Bcl-2 affected by nicotine in lung cancer cells. Nicotine 143-151 BCL2 apoptosis regulator Homo sapiens 125-130 24548862-5 2014 RESULTS: We demonstrated that the addition of nicotine greatly attenuated Bcl-2 ubiquitination and degradation, which further desensitised lung cancer cells to cisplatin-induced cytotoxicity. Nicotine 46-54 BCL2 apoptosis regulator Homo sapiens 74-79 24548862-6 2014 In this process, Bcl-2 was persistently phosphorylated in the cells cotreated with nicotine and cisplatin. Nicotine 83-91 BCL2 apoptosis regulator Homo sapiens 17-22 24548862-6 2014 In this process, Bcl-2 was persistently phosphorylated in the cells cotreated with nicotine and cisplatin. Cisplatin 96-105 BCL2 apoptosis regulator Homo sapiens 17-22 24548862-7 2014 Furthermore, Akt was proven to be responsible for sustained activation of Bcl-2 by nicotine, which further antagonised cisplatin-mediated apoptotic signalling. Nicotine 83-91 BCL2 apoptosis regulator Homo sapiens 74-79 24548862-7 2014 Furthermore, Akt was proven to be responsible for sustained activation of Bcl-2 by nicotine, which further antagonised cisplatin-mediated apoptotic signalling. Cisplatin 119-128 BCL2 apoptosis regulator Homo sapiens 74-79 24548862-8 2014 CONCLUSIONS: Our study suggested that nicotine activates its downstream signalling to interfere with the ubiquitination process and prevent Bcl-2 from being degraded in lung cancer cells, resulting in the increase of chemoresistance. Nicotine 38-46 BCL2 apoptosis regulator Homo sapiens 140-145 24413389-6 2014 The sensitizing effect of ZnPP was associated with caspase activation, bcl-2 downregulation, and PARP activation. zinc protoporphyrin 26-30 BCL2 apoptosis regulator Homo sapiens 71-76 24210071-6 2014 RESULTS: It was shown that in MCF-7 cells, the proliferation was inhibited, the apoptosis was promoted, the Bcl-2 expression was suppressed and the Bax expression was promoted by both 5-FU alone and morphine alone, while the superior effects were achieved in combination with the two drugs. Fluorouracil 184-188 BCL2 apoptosis regulator Homo sapiens 108-113 24692714-4 2014 TMC caused DNA double-strand breaks, and enhanced expression of caspase-3 and -9, poly (ADP-ribose) polymerase, cytochrome c, calpain-1 and -2, phosphorylation of histone H2AX, phosphorylation of checkpoint kinases 2, p53, BCL2-antagonist/killer and BCL2-associated x protein, while reducing the mitochondrial membrane potential, and expression of B-cell lymphoma-2. tmc 0-3 BCL2 apoptosis regulator Homo sapiens 223-227 24692714-4 2014 TMC caused DNA double-strand breaks, and enhanced expression of caspase-3 and -9, poly (ADP-ribose) polymerase, cytochrome c, calpain-1 and -2, phosphorylation of histone H2AX, phosphorylation of checkpoint kinases 2, p53, BCL2-antagonist/killer and BCL2-associated x protein, while reducing the mitochondrial membrane potential, and expression of B-cell lymphoma-2. tmc 0-3 BCL2 apoptosis regulator Homo sapiens 250-254 24206264-2 2014 Conformationally active Bax, Bak and Bax/Bak-activating BH3-only proteins, such as Bim, are restrained by anti-apoptotic Bcl-2 proteins in cells that are "primed for death". bakuchiol 29-32 BCL2 apoptosis regulator Homo sapiens 121-126 24206264-2 2014 Conformationally active Bax, Bak and Bax/Bak-activating BH3-only proteins, such as Bim, are restrained by anti-apoptotic Bcl-2 proteins in cells that are "primed for death". bakuchiol 41-44 BCL2 apoptosis regulator Homo sapiens 121-126 24206264-3 2014 Inhibition of Bcl-2/Bcl-xL/Bcl-w by the antagonist ABT-737 causes rapid apoptosis of primed cells. ABT-737 51-58 BCL2 apoptosis regulator Homo sapiens 14-19 24483236-7 2014 RESULTS: We found that Acr induced ROS generation, which was accompanied by reduced Bcl2/Bax ratio, substantial decline in mitochondrial membrane potential, and further promoted apoptosis of MGCs. Reactive Oxygen Species 35-38 BCL2 apoptosis regulator Homo sapiens 84-88 24483236-8 2014 Furthermore, Rapamycin was capable of alleviating Acr-induced ROS, reducing ROS-induced apoptosis by increasing ratio of Bcl2/Bax mRNA and proteins, and protecting MGC mitochondrial membranes. Reactive Oxygen Species 76-79 BCL2 apoptosis regulator Homo sapiens 121-125 25003352-3 2014 First-generation BH3 mimetics such as navitoclax (ABT-263) had a broad range of inhibitory activity against Bcl-2 family members, including Bcl-2, Bcl-XL, and Bcl-w. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 50-53 BCL2 apoptosis regulator Homo sapiens 140-145 25003352-5 2014 Through an elegant reengineering of navitoclax, ABT-199 was developed as a Bcl-2-selective small molecule inhibitor. venetoclax 48-55 BCL2 apoptosis regulator Homo sapiens 75-80 25003352-6 2014 In preclinical studies, ABT-199 was shown to have greater than 100-fold selectivity for Bcl-2 over Bcl-XL. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 24-27 BCL2 apoptosis regulator Homo sapiens 88-93 24735445-3 2014 First, we used this assay to identify biomarkers for BCL2 inhibitors to obtain a quantitative measure of expression of anti-apoptotic proteins (BCL2, BCLxL, and MCL1) in a panel of cell lines and correlated their response to BCL2/BCLxL inhibitor, ABT-263 (navitoclax). navitoclax 247-254 BCL2 apoptosis regulator Homo sapiens 53-57 24735445-3 2014 First, we used this assay to identify biomarkers for BCL2 inhibitors to obtain a quantitative measure of expression of anti-apoptotic proteins (BCL2, BCLxL, and MCL1) in a panel of cell lines and correlated their response to BCL2/BCLxL inhibitor, ABT-263 (navitoclax). navitoclax 256-266 BCL2 apoptosis regulator Homo sapiens 53-57 24467740-2 2014 This has been driven by the advent of BH3 mimetic drugs that target BCL2 family proteins to induce apoptosis in tumour cells: agents such as ABT-263 (navitoclax, which targets BCL2, BCL-XL [BCL2L1] and BCL2L2) and ABT-199 (a BCL2-specific agent) are showing great promise in early stage clinical trials. BH 3 38-41 BCL2 apoptosis regulator Homo sapiens 68-72 24467740-2 2014 This has been driven by the advent of BH3 mimetic drugs that target BCL2 family proteins to induce apoptosis in tumour cells: agents such as ABT-263 (navitoclax, which targets BCL2, BCL-XL [BCL2L1] and BCL2L2) and ABT-199 (a BCL2-specific agent) are showing great promise in early stage clinical trials. BH 3 38-41 BCL2 apoptosis regulator Homo sapiens 176-180 24467740-2 2014 This has been driven by the advent of BH3 mimetic drugs that target BCL2 family proteins to induce apoptosis in tumour cells: agents such as ABT-263 (navitoclax, which targets BCL2, BCL-XL [BCL2L1] and BCL2L2) and ABT-199 (a BCL2-specific agent) are showing great promise in early stage clinical trials. BH 3 38-41 BCL2 apoptosis regulator Homo sapiens 176-180 24467740-2 2014 This has been driven by the advent of BH3 mimetic drugs that target BCL2 family proteins to induce apoptosis in tumour cells: agents such as ABT-263 (navitoclax, which targets BCL2, BCL-XL [BCL2L1] and BCL2L2) and ABT-199 (a BCL2-specific agent) are showing great promise in early stage clinical trials. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 141-144 BCL2 apoptosis regulator Homo sapiens 68-72 24467740-2 2014 This has been driven by the advent of BH3 mimetic drugs that target BCL2 family proteins to induce apoptosis in tumour cells: agents such as ABT-263 (navitoclax, which targets BCL2, BCL-XL [BCL2L1] and BCL2L2) and ABT-199 (a BCL2-specific agent) are showing great promise in early stage clinical trials. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 141-144 BCL2 apoptosis regulator Homo sapiens 176-180 24467740-2 2014 This has been driven by the advent of BH3 mimetic drugs that target BCL2 family proteins to induce apoptosis in tumour cells: agents such as ABT-263 (navitoclax, which targets BCL2, BCL-XL [BCL2L1] and BCL2L2) and ABT-199 (a BCL2-specific agent) are showing great promise in early stage clinical trials. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 141-144 BCL2 apoptosis regulator Homo sapiens 176-180 25003352-1 2014 ABT-199, a second-generation BH3 mimetic, is an orally bioavailable, small molecule inhibitor that selectively targets B-cell lymphoma/leukemia 2 (Bcl-2). venetoclax 0-7 BCL2 apoptosis regulator Homo sapiens 119-145 25003352-1 2014 ABT-199, a second-generation BH3 mimetic, is an orally bioavailable, small molecule inhibitor that selectively targets B-cell lymphoma/leukemia 2 (Bcl-2). venetoclax 0-7 BCL2 apoptosis regulator Homo sapiens 147-152 25003352-1 2014 ABT-199, a second-generation BH3 mimetic, is an orally bioavailable, small molecule inhibitor that selectively targets B-cell lymphoma/leukemia 2 (Bcl-2). BH 3 29-32 BCL2 apoptosis regulator Homo sapiens 119-145 25003352-1 2014 ABT-199, a second-generation BH3 mimetic, is an orally bioavailable, small molecule inhibitor that selectively targets B-cell lymphoma/leukemia 2 (Bcl-2). BH 3 29-32 BCL2 apoptosis regulator Homo sapiens 147-152 25003352-3 2014 First-generation BH3 mimetics such as navitoclax (ABT-263) had a broad range of inhibitory activity against Bcl-2 family members, including Bcl-2, Bcl-XL, and Bcl-w. BH 3 17-20 BCL2 apoptosis regulator Homo sapiens 108-113 25003352-3 2014 First-generation BH3 mimetics such as navitoclax (ABT-263) had a broad range of inhibitory activity against Bcl-2 family members, including Bcl-2, Bcl-XL, and Bcl-w. BH 3 17-20 BCL2 apoptosis regulator Homo sapiens 140-145 25003352-3 2014 First-generation BH3 mimetics such as navitoclax (ABT-263) had a broad range of inhibitory activity against Bcl-2 family members, including Bcl-2, Bcl-XL, and Bcl-w. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 50-53 BCL2 apoptosis regulator Homo sapiens 108-113 24210071-6 2014 RESULTS: It was shown that in MCF-7 cells, the proliferation was inhibited, the apoptosis was promoted, the Bcl-2 expression was suppressed and the Bax expression was promoted by both 5-FU alone and morphine alone, while the superior effects were achieved in combination with the two drugs. Morphine 199-207 BCL2 apoptosis regulator Homo sapiens 108-113 24480042-4 2014 alpha-Mangostin also activated caspases-8, -9, and -7; increased the protein levels of Bax, p53, and cytosolic cytochrome c; and induced PARP cleavage while reducing Bid and Bcl-2 protein expression. mangostin 0-15 BCL2 apoptosis regulator Homo sapiens 174-179 24504921-8 2014 Mechanistically, depletion of the transcription factor GATA4 resulting in decreased levels of its prosurvival targets Bcl-2 and Bcl-XL was an underlying cause of imatinib toxicity. Imatinib Mesylate 162-170 BCL2 apoptosis regulator Homo sapiens 118-123 24965402-8 2014 Of the non-TBNC patients 86.7% and 50% of TNBC patients showed Bcl-2 expression. tbnc 11-15 BCL2 apoptosis regulator Homo sapiens 63-68 24481553-5 2014 Incubation with carnosol elevated the expression of Bax and inhibited the levels of Bcl-2 and Bcl-xl. carnosol 16-24 BCL2 apoptosis regulator Homo sapiens 84-89 24481835-8 2014 The protein expression of caspase-3, -8 and -9 and Bax increased, and the expression of Bcl-2 decreased following treatment with evodiamine. evodiamine 129-139 BCL2 apoptosis regulator Homo sapiens 88-93 24486291-0 2014 Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK(+) anaplastic large cell lymphoma. Crizotinib 0-10 BCL2 apoptosis regulator Homo sapiens 78-83 24399465-9 2014 TQ treatment stimulated mRNA expression of pro-apoptotic Bcl-xS and TRAIL death receptors, and inhibited expression of the anti-apoptotic gene Bcl-2. thymoquinone 0-2 BCL2 apoptosis regulator Homo sapiens 143-148 24481835-9 2014 These results suggest that evodiamine is able to inhibit the proliferation of SGC-7901 cells by inhibiting the cell cycle at G2/M phase and inducing apoptosis in SGC-7901 cells by activating caspase-3, -8 and -9, and altering the expression of caspase-3, Bax and Bcl-2. evodiamine 27-37 BCL2 apoptosis regulator Homo sapiens 263-268 24272201-6 2014 In addition, piperine treatment decreased Bcl-2 protein expression, but increased Bax protein expression in A549 cells, which were positively correlated with an elevated expression of p53 compared to control. piperine 13-21 BCL2 apoptosis regulator Homo sapiens 42-47 24534136-7 2014 Consistently, 15-oxo-ETE attenuated nuclear fragmentation and DNA strand breaks, decreased caspase-3 activity, reduced mitochondrial depolarization, and increased Bcl-2 expression. 15-oxo-5,8,11,13-eicosatetraenoic acid 14-24 BCL2 apoptosis regulator Homo sapiens 163-168 24535223-0 2014 Resveratrol induces apoptosis of bladder cancer cells via miR-21 regulation of the Akt/Bcl-2 signaling pathway. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 87-92 24535223-7 2014 Resveratrol decreased the expression of miR-21, the level of phospho-Akt and Bcl-2 protein expression. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 77-82 24535223-11 2014 Collectively, data revealed that the effect of resveratrol on bladder cancer cell apoptosis was due to miR-21 regulation of the Akt/Bcl-2 signaling pathway. Resveratrol 47-58 BCL2 apoptosis regulator Homo sapiens 132-137 23818450-8 2014 It was found that nobiletin downregulated the expressions of Bcl-2 and COX-2 and up-regulated the expressions of Bax and caspase-3 in SMMC-7721 cells by western blotting. nobiletin 18-27 BCL2 apoptosis regulator Homo sapiens 61-66 23818450-9 2014 The experiment in vivo demonstrated that nobiletin significantly inhibited the growth of H22 transplantable tumor, downregulated the expressions of COX-2, up-regulated the expressions of Bax and caspase-3 detected by immunohistochemistry and western blotting, and the ratios of Bcl-2/Bax were decreased. nobiletin 41-50 BCL2 apoptosis regulator Homo sapiens 278-283 24115198-8 2014 This BH3D undergoes a dramatic conformational change from coil to alpha-helix upon binding to BCL2s, with the C-terminal half of this BH3D constituting a binding motif, which serves to anchor the interaction of the BH3D to BCL2s. bh3d 5-9 BCL2 apoptosis regulator Homo sapiens 94-98 24115198-8 2014 This BH3D undergoes a dramatic conformational change from coil to alpha-helix upon binding to BCL2s, with the C-terminal half of this BH3D constituting a binding motif, which serves to anchor the interaction of the BH3D to BCL2s. bh3d 5-9 BCL2 apoptosis regulator Homo sapiens 223-227 24115198-8 2014 This BH3D undergoes a dramatic conformational change from coil to alpha-helix upon binding to BCL2s, with the C-terminal half of this BH3D constituting a binding motif, which serves to anchor the interaction of the BH3D to BCL2s. bh3d 134-138 BCL2 apoptosis regulator Homo sapiens 94-98 24115198-8 2014 This BH3D undergoes a dramatic conformational change from coil to alpha-helix upon binding to BCL2s, with the C-terminal half of this BH3D constituting a binding motif, which serves to anchor the interaction of the BH3D to BCL2s. bh3d 134-138 BCL2 apoptosis regulator Homo sapiens 223-227 24115198-8 2014 This BH3D undergoes a dramatic conformational change from coil to alpha-helix upon binding to BCL2s, with the C-terminal half of this BH3D constituting a binding motif, which serves to anchor the interaction of the BH3D to BCL2s. bh3d 134-138 BCL2 apoptosis regulator Homo sapiens 94-98 24115198-8 2014 This BH3D undergoes a dramatic conformational change from coil to alpha-helix upon binding to BCL2s, with the C-terminal half of this BH3D constituting a binding motif, which serves to anchor the interaction of the BH3D to BCL2s. bh3d 134-138 BCL2 apoptosis regulator Homo sapiens 223-227 24272201-7 2014 Taken together, these results suggested that piperine could induce p53-mediated cell cycle arrest and apoptosis via activation of caspase-3 and caspase-9 cascades, as well as increasing the Bax/Bcl-2 ratio. piperine 45-53 BCL2 apoptosis regulator Homo sapiens 194-199 24310501-7 2014 Mechanistic studies revealed that deproteinized asparagus polysaccharide might exert its activity through an apoptosis-associated pathway by modulating the expression of Bax, Bcl-2, and caspase-3. asparagus polysaccharide 48-72 BCL2 apoptosis regulator Homo sapiens 175-180 24323562-0 2014 p21 overexpression sensitizes osteosarcoma U2OS cells to cisplatin via evoking caspase-3 and Bax/Bcl-2 cascade. Cisplatin 57-66 BCL2 apoptosis regulator Homo sapiens 97-102 24323562-7 2014 However, U2O3-p21 cells underwent more obvious apoptotic morphological changes than U2OS and U2OS-vec cells after being treated with cisplatin (5 mug) for 72 h. Besides, increased expression of cleaved caspase-3 and Bax/Bcl-2 ratio was observed in cisplatin-treated U2O3-p21 cells. Cisplatin 133-142 BCL2 apoptosis regulator Homo sapiens 220-225 24323562-8 2014 These data clearly indicated that exogenous p21 gene transfection could enhance the cisplatin-induced cytotoxicity against human osteosarcoma U2OS cells, at least in part, by activating caspase-3 cascade and increasing Bax/Bcl-2 ratio. Cisplatin 84-93 BCL2 apoptosis regulator Homo sapiens 223-228 24763006-8 2014 The apoptotic rate of U266 cells increased in dose and time dependent manners; after treatment of U266 cells with oridonin the mRNA levels of FGFR3, BCL2, CCND1 and MYC as well as the their protein levels decreased. oridonin 114-122 BCL2 apoptosis regulator Homo sapiens 149-153 24664296-9 2014 The ratio of Bax/Bcl-2 was also significantly increased in cells exposed to BaP and this increase was reversed by VE co-treatment. Benzo(a)pyrene 76-79 BCL2 apoptosis regulator Homo sapiens 17-22 24456637-8 2014 Interestingly, GHB, which strongly decreased elevated basal levels of TUNEL-staining, activated caspase 3-labeling and Bax/Bcl-2 in APPwt-transfected cells, also counteracted H2O2-evoked increased apoptotic markers in native and genetically modified SH-SY5Y cells. Sodium Oxybate 15-18 BCL2 apoptosis regulator Homo sapiens 123-128 24456637-8 2014 Interestingly, GHB, which strongly decreased elevated basal levels of TUNEL-staining, activated caspase 3-labeling and Bax/Bcl-2 in APPwt-transfected cells, also counteracted H2O2-evoked increased apoptotic markers in native and genetically modified SH-SY5Y cells. Hydrogen Peroxide 175-179 BCL2 apoptosis regulator Homo sapiens 123-128 24456637-9 2014 Since GHB did not promote cell proliferation, anti-apoptotic action through the down-regulation of Bax/Bcl-2 ratios and/or caspase 3 activity appears as a critical mechanism involved in GHB-induced protection of SH-SY5Y cells against APPwt-overexpression- or H2O2-evoked death. Sodium Oxybate 186-189 BCL2 apoptosis regulator Homo sapiens 103-108 24664296-10 2014 Taken together, BaP-induced cytotoxicity occurs through DNA damage, cell cycle arrest, ROS production, modulation of metabolizing enzymes, and the expression/activation of p53, PARP-1, survivin, and Bax/Bcl-2. Benzo(a)pyrene 16-19 BCL2 apoptosis regulator Homo sapiens 203-208 24641804-9 2014 This iron-induced apoptosis was linked to enhanced caspase 8, reduced Bcl-2, Bcl-xL, phosphorylated Akt and GATA-4. Iron 5-9 BCL2 apoptosis regulator Homo sapiens 70-75 24559410-7 2014 The BCL2 levels reduced by the hairpin-binding compound led to chemosensitization to etoposide in both in vitro and in vivo models. Etoposide 85-94 BCL2 apoptosis regulator Homo sapiens 4-8 24655726-13 2014 In contrast, we observed inhibition of NF-kappaB nuclear translocation and an increase Bax/Bcl-2 ratio accompanied by activated caspase-3, caspase-9 and PARP-1 cleavage after treatment with oridonin, which indicate that the mitochondrial pathway is involved in oridonin-mediated apoptosis. oridonin 190-198 BCL2 apoptosis regulator Homo sapiens 91-96 24641804-11 2014 In iron pretreated cardiomyocytes, the siRNA2 transfection further increased caspase 8 expression and decreased the expression of GATA-4, Bcl-2, Bcl-xL and phosphorylated Akt than iron pretreatment alone, but caspase 9 levels remained unchanged. Iron 3-7 BCL2 apoptosis regulator Homo sapiens 138-143 24637737-2 2014 In the present study, we designed antisense oligonucleotides (ASOs) against MDR1, MDR-associated protein (MRP)1, MRP2, and/or BCL-2/BCL-xL to reverse MDR transporters and induce apoptosis, respectively. Oligonucleotides 44-60 BCL2 apoptosis regulator Homo sapiens 126-131 24643073-4 2014 Furthermore, the up-regulation of Bax and down-regulation of Bcl-2 as well as the activation of caspase-3 were observed, which indicated that DBDFT treatment triggered the mitochondrial apoptotic pathway with an increase of Bax/Bcl-2 ratios, resulting in mitochondrial membrane potential loss and caspase-9 activation in DBDFT treated SGC-7901 cells. di-n-butyl-(2,6-difluorobenzohydroxamato)tin(IV) 142-147 BCL2 apoptosis regulator Homo sapiens 61-66 24643073-4 2014 Furthermore, the up-regulation of Bax and down-regulation of Bcl-2 as well as the activation of caspase-3 were observed, which indicated that DBDFT treatment triggered the mitochondrial apoptotic pathway with an increase of Bax/Bcl-2 ratios, resulting in mitochondrial membrane potential loss and caspase-9 activation in DBDFT treated SGC-7901 cells. di-n-butyl-(2,6-difluorobenzohydroxamato)tin(IV) 142-147 BCL2 apoptosis regulator Homo sapiens 228-233 24637737-2 2014 In the present study, we designed antisense oligonucleotides (ASOs) against MDR1, MDR-associated protein (MRP)1, MRP2, and/or BCL-2/BCL-xL to reverse MDR transporters and induce apoptosis, respectively. Oligonucleotides, Antisense 62-66 BCL2 apoptosis regulator Homo sapiens 126-131 24637737-8 2014 Epirubicin and ASOs in PEGylated liposomes remarkably decreased mRNA expression levels of human MDR1, MRP1, MRP2, and BCL-2. Epirubicin 0-10 BCL2 apoptosis regulator Homo sapiens 118-123 24637737-8 2014 Epirubicin and ASOs in PEGylated liposomes remarkably decreased mRNA expression levels of human MDR1, MRP1, MRP2, and BCL-2. Oligonucleotides, Antisense 15-19 BCL2 apoptosis regulator Homo sapiens 118-123 24637737-10 2014 The formulation of epirubicin and ASOs targeting both pump resistance of MDR1, MRP1, and MRP2 and nonpump resistance of BCL-2/BCL-xL demonstrated more superior effect to all the other formulations used in this study. Epirubicin 19-29 BCL2 apoptosis regulator Homo sapiens 120-125 23872323-5 2014 Live-cell FRET imaging has been applied to identify conformational changes between two native cysteines in Bax, a member of the Bcl-2 family of proteins that regulates apoptosis. Cysteine 94-103 BCL2 apoptosis regulator Homo sapiens 128-133 24516200-0 2014 Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy. obatoclax 21-29 BCL2 apoptosis regulator Homo sapiens 4-9 24757411-10 2014 Treatment with LY294002 further decreased the expression of survivin and Bcl-2 and increased caspase-3 levels. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 BCL2 apoptosis regulator Homo sapiens 73-78 24516200-2 2014 In this study we explored the potential for combining the pan-Bcl-2 inhibitor GX15-070 (GX15; obatoclax) with immunotherapeutic modalities. obatoclax 78-86 BCL2 apoptosis regulator Homo sapiens 62-67 24626299-0 2014 BEX1 promotes imatinib-induced apoptosis by binding to and antagonizing BCL-2. Imatinib Mesylate 14-22 BCL2 apoptosis regulator Homo sapiens 72-77 24624962-6 2014 A decrease in mitochondrial membrane potential (MMP) with a concomitant increase in the expression of Bax/Bcl-2 ratio suggested that the mitochondria also mediated the pathway involved in ZnO NP-induced apoptosis. zno np 188-194 BCL2 apoptosis regulator Homo sapiens 106-111 24626299-9 2014 Furthermore, we demonstrated that the interaction between BCL-2 and BEX1 promotes imatinib-induced apoptosis by suppressing the formation of anti-apoptotic BCL-2/BCL-2-associated X protein (BAX) heterodimers. Imatinib Mesylate 82-90 BCL2 apoptosis regulator Homo sapiens 58-63 24626299-9 2014 Furthermore, we demonstrated that the interaction between BCL-2 and BEX1 promotes imatinib-induced apoptosis by suppressing the formation of anti-apoptotic BCL-2/BCL-2-associated X protein (BAX) heterodimers. Imatinib Mesylate 82-90 BCL2 apoptosis regulator Homo sapiens 156-161 24626299-10 2014 Our results revealed an interaction between BEX1 and BCL-2 and a novel mechanism of imatinib resistance mediated by the BEX1/BCL-2 pathway. Imatinib Mesylate 84-92 BCL2 apoptosis regulator Homo sapiens 125-130 24618722-6 2014 Thiacremonone (0-50 mug/ml) inhibited lung cancer cell growth in a concentration dependent manner through induction of apoptotic cell death accompanied by induction of cleaved caspase-3, -8, -9, Bax, p21 and p53, but decrease of xIAP, cIAP and Bcl2 expression. thiacremonone 0-13 BCL2 apoptosis regulator Homo sapiens 244-248 24612549-9 2014 In addition, these tamoxifen-induced effects that were enhanced by metformin may be involved in the bax/bcl-2 apoptotic pathway and the AMPK/mTOR/p70S6 growth pathway. Tamoxifen 19-28 BCL2 apoptosis regulator Homo sapiens 104-109 24612549-9 2014 In addition, these tamoxifen-induced effects that were enhanced by metformin may be involved in the bax/bcl-2 apoptotic pathway and the AMPK/mTOR/p70S6 growth pathway. Metformin 67-76 BCL2 apoptosis regulator Homo sapiens 104-109 24482231-3 2014 Here, we report that gene silencing of CD166 promoted apoptosis via down-regulation of Bcl-2 in liver cancer cells. cd166 39-44 BCL2 apoptosis regulator Homo sapiens 87-92 24338158-6 2014 Additionally, hASCs modified by empty-vector inhibited caspase-3 expression and up-regulated Bcl-2 expression in cisplatin-treated HK-2 cells, an effect even more pronounced with hASCs modified by HIF-1alpha. Cisplatin 113-122 BCL2 apoptosis regulator Homo sapiens 93-98 24606718-0 2014 Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells. Hyaluronic Acid 0-10 BCL2 apoptosis regulator Homo sapiens 87-92 24365254-7 2014 In our study, BDMC-A exerted more potent effect on the modulation of selective apoptotic markers (intrinsic pathway: p53, Bcl-2, Bax, cyt c, Apaf-1, caspase-9, 3, PARP; extrinsic pathway: FasL, caspase 8) compared to curcumin. BDMC-A 14-20 BCL2 apoptosis regulator Homo sapiens 122-127 24365254-8 2014 mRNA expression studies for Bcl2/Bax also supported the increased efficacy of BDMC-A. BDMC-A 78-84 BCL2 apoptosis regulator Homo sapiens 28-32 24411335-8 2014 Western blotting and caspase activation studies revealed that EGFP-p53/PEI/PAH-Cit/AuNP-CS complexes may induce PC-3 apoptosis via the mitochondria-mediated signaling pathway by up-regulation of Bax, down-regulation of Bcl-2, and activation of caspase-3. p-Aminohippuric Acid 75-78 BCL2 apoptosis regulator Homo sapiens 219-224 24648735-5 2014 Incubation with Y2O3 NPs (12.25-50 mug/mL) increased the ratio of Bax/Bcl-2, caspase-3 expression and promoted apoptotic- and necrotic-mediated cell death in both a concentration and a time-dependent manner. y2o3 16-20 BCL2 apoptosis regulator Homo sapiens 70-75 24308865-6 2014 We concluded that the increase in cytosolic cytochrome c and available intracellular ATP should be responsible for the increase in caspase-9 activity; the activation of caspase-9 could be limited by the subsequent depletion of ATP; the postmortem release level of cytochrome c could be determined by the ratio of bax to bcl-2 in fresh tissues. Adenosine Triphosphate 85-88 BCL2 apoptosis regulator Homo sapiens 320-325 24596202-2 2014 Cellular BH3 profiling can help decide which are likely to respond to BCL-2-targeted BH3 mimetics. BH 3 9-12 BCL2 apoptosis regulator Homo sapiens 70-75 24335512-0 2014 Dihydroartemisinin induces apoptosis of cervical cancer cells via upregulation of RKIP and downregulation of bcl-2. artenimol 0-18 BCL2 apoptosis regulator Homo sapiens 109-114 24335512-4 2014 We evaluated the role of DHA on the expression of bcl-2 and Raf kinase inhibitor protein (RKIP), which is a suppressor of metastasis. artenimol 25-28 BCL2 apoptosis regulator Homo sapiens 50-55 24335512-10 2014 The expression of RKIP was significantly upregulated and the expression of bcl-2 was significantly downregulated in DHA-treated cells compared with control cells. artenimol 116-119 BCL2 apoptosis regulator Homo sapiens 75-80 24335512-12 2014 Our data suggest that DHA inhibits cervical cancer growth via upregulation of RKIP and downregulation of bcl-2. artenimol 22-25 BCL2 apoptosis regulator Homo sapiens 105-110 24346116-0 2014 Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 30-33 BCL2 apoptosis regulator Homo sapiens 10-15 24411335-8 2014 Western blotting and caspase activation studies revealed that EGFP-p53/PEI/PAH-Cit/AuNP-CS complexes may induce PC-3 apoptosis via the mitochondria-mediated signaling pathway by up-regulation of Bax, down-regulation of Bcl-2, and activation of caspase-3. aunp-cs 83-90 BCL2 apoptosis regulator Homo sapiens 219-224 24418124-8 2014 Our results also indicated that upregulation of miR-16 promoted apoptosis by suppressing BCL2 expression. mir-16 48-54 BCL2 apoptosis regulator Homo sapiens 89-93 24418124-10 2014 Taken together, our experiments have validated the important role of miR-16 as a tumor suppressor gene in glioma growth and invasiveness, and revealed a novel mechanism of miR-16-mediated regulation in glioma growth and invasiveness through inhibition of BCL2 and the NF-kappaB1/MMP-9 signaling pathway. mir-16 172-178 BCL2 apoptosis regulator Homo sapiens 255-259 24596202-2 2014 Cellular BH3 profiling can help decide which are likely to respond to BCL-2-targeted BH3 mimetics. BH 3 85-88 BCL2 apoptosis regulator Homo sapiens 70-75 25337571-8 2014 Ethanol-induced cell death was accompanied by increased cytochrome c release and caspase 3 activity observed at 12 h. In contrast, the level of anti-apoptotic Bcl-2 protein did not change. Ethanol 0-7 BCL2 apoptosis regulator Homo sapiens 159-164 24118733-7 2014 From the results, it was found that HA14-1 occupied all three domains; BH1, BH2, and BH3 within the hydrophobic pocket of Bcl-2. bh1 71-74 BCL2 apoptosis regulator Homo sapiens 122-127 24118733-7 2014 From the results, it was found that HA14-1 occupied all three domains; BH1, BH2, and BH3 within the hydrophobic pocket of Bcl-2. bh2 76-79 BCL2 apoptosis regulator Homo sapiens 122-127 24118733-7 2014 From the results, it was found that HA14-1 occupied all three domains; BH1, BH2, and BH3 within the hydrophobic pocket of Bcl-2. BH 3 85-88 BCL2 apoptosis regulator Homo sapiens 122-127 24476894-11 2014 The addition of LY294002 enabled to suppress Bcl-2 expression and cell proliferation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 16-24 BCL2 apoptosis regulator Homo sapiens 45-50 24293112-6 2014 After treating with DMPPQA, apoptosis-related protein expression of Bax, cytochrome c, caspase-9, caspase-3, PARP-1 and P53 increased and Bcl-2 protein expression decreased. 5,7-dimethoxy-2-phenyl-N-propylquinolin-4-amine 20-26 BCL2 apoptosis regulator Homo sapiens 138-143 24637250-10 2014 The expression of Bcl-2 were down-regulated after CIT treatment, whereas the levels of Bax was significantly up-regulated. citreoviridin 50-53 BCL2 apoptosis regulator Homo sapiens 18-23 25337567-9 2014 Evodiamine also significantly increased the ratio of Bax/Bcl-2 and decreased procaspase-3, suggesting evodiamine-induced apoptosis via the intrinsic apoptotic pathway. evodiamine 0-10 BCL2 apoptosis regulator Homo sapiens 57-62 25337567-9 2014 Evodiamine also significantly increased the ratio of Bax/Bcl-2 and decreased procaspase-3, suggesting evodiamine-induced apoptosis via the intrinsic apoptotic pathway. evodiamine 102-112 BCL2 apoptosis regulator Homo sapiens 57-62 25337568-0 2014 Polyphenols Isolated from Allium cepa L. Induces Apoptosis by Induction of p53 and Suppression of Bcl-2 through Inhibiting PI3K/Akt Signaling Pathway in AGS Human Cancer Cells. Polyphenols 0-11 BCL2 apoptosis regulator Homo sapiens 98-103 24233024-6 2014 Simvastatin suppressed the proliferation of gastric cancer cells, enhanced the apoptotic effects of capecitabine, suppressed the constitutive activation of NF-kappaB, and abrogated the expression of cyclooxygenase-2 (COX-2), cyclin D1, Bcl-2, survivin, CXC motif receptor 4, and MMP-9 proteins. Simvastatin 0-11 BCL2 apoptosis regulator Homo sapiens 236-241 24249678-1 2014 UNLABELLED: Elevated expression of the antiapoptotic factor Bcl-2 is believed to be one of the contributing factors to an increased relapse rate associated with multiple cisplatin-resistant cancers. Cisplatin 170-179 BCL2 apoptosis regulator Homo sapiens 60-65 23741975-4 2014 Combined treatment with rapamycin and IDA down-regulated Bcl-2 and Mcl-1, and inhibited the activation of phosphoinositide 3-kinase (PI3K)/mTOR and extracellular signal-related kinase (ERK). Sirolimus 24-33 BCL2 apoptosis regulator Homo sapiens 57-62 24496564-0 2014 Phase II study of low-dose fixed-rate infusion of gemcitabine combined with cisplatin and dexamethasone in resistant non-Hodgkin lymphoma and correlation with Bcl-2 and MDR expression. gemcitabine 50-61 BCL2 apoptosis regulator Homo sapiens 159-164 24496564-1 2014 This study aims to assess the efficacy of low-dose fixed-rate infusion of gemcitabine, cisplatin and dexamethasone in resistant non-Hodgkin lymphoma (NHL) patients in addition to evaluating the prognostic value of B cell lymphoma 2 (Bcl-2) and multidrug resistant (MDR) expression in this cohort of patients. gemcitabine 74-85 BCL2 apoptosis regulator Homo sapiens 233-238 24249678-2 2014 DNA damage-binding protein complex subunit 2 (DDB2) has recently been revealed to play an important role in sensitizing human ovarian cancer cells to cisplatin-induced apoptosis through the downregulation of Bcl-2, but the underlying molecular mechanism remains poorly defined. Cisplatin 150-159 BCL2 apoptosis regulator Homo sapiens 208-213 23430344-8 2014 CAPE and both chemotherapeutic agents reduced Bcl-2, while only CAPE and MG132 significantly increased Bax level. caffeic acid phenethyl ester 0-4 BCL2 apoptosis regulator Homo sapiens 46-51 24425042-9 2014 Furthermore, the level of the anti-apoptotic protein Bcl-2 was found to be reduced following alpha-ESA treatment. eleostearic acid 93-102 BCL2 apoptosis regulator Homo sapiens 53-58 24961104-9 2014 Gene and protein detection showed that under the given concentration and time, BMC can downregulate the expression of Bcl-2 gene in SMMC-7721 cells, and significantly decrease the expression of Bcl-2 protein, at the same time, with the increase of expression of Bax gene, the Bax protein"s expression increased significantly. S-benzyl-N-malonylcysteine 79-82 BCL2 apoptosis regulator Homo sapiens 118-123 24961104-9 2014 Gene and protein detection showed that under the given concentration and time, BMC can downregulate the expression of Bcl-2 gene in SMMC-7721 cells, and significantly decrease the expression of Bcl-2 protein, at the same time, with the increase of expression of Bax gene, the Bax protein"s expression increased significantly. S-benzyl-N-malonylcysteine 79-82 BCL2 apoptosis regulator Homo sapiens 194-199 24961104-10 2014 Which indicates that BMC restrain cell proliferation and cell apoptosis by stopping cell cycle, reducing the expression of Bcl-2 and increasing that of Bax; The anti-tumor activities of three kinds of complexes were: baicalin-copper (BC-Cu) > baicalin-cobalt (BC-Co) > baicalin-nickel (BC-Ni) > baicalin (BC), showing the dose-response relationship. S-benzyl-N-malonylcysteine 21-24 BCL2 apoptosis regulator Homo sapiens 123-128 24634186-5 2014 A combination of mifepristone upregulated the Bax/Bcl-2 protein expression ratio and apoptosis in HeLa/MMC cells. Mifepristone 17-29 BCL2 apoptosis regulator Homo sapiens 50-55 24666483-10 2014 CONCLUSION: As2O3 could up-regulate TMS1 gene expression by reversing its hypermethylation and induced apoptosis by down-regulation of Bcl-2/Bax ratio in K562 cells. Arsenic Trioxide 12-17 BCL2 apoptosis regulator Homo sapiens 135-140 24577086-8 2014 Mechanistically, signal transducer and activator of transcription 3 (Stat3) and its downstream target Bcl-2 was inactivated by metformin treatment. Metformin 127-136 BCL2 apoptosis regulator Homo sapiens 102-107 24577086-10 2014 Similarly, the Bcl-2 proto-oncogene, an inhibitor of both apoptosis and autophagy, was repressed by metformin. Metformin 100-109 BCL2 apoptosis regulator Homo sapiens 15-20 24577086-11 2014 Ectopic expression of Bcl-2 protected cells from metformin-mediated autophagy and apoptosis. Metformin 49-58 BCL2 apoptosis regulator Homo sapiens 22-27 24577086-12 2014 In vivo, metformin downregulated Stat3 activity and Bcl-2 expression, induced apoptosis and autophagy, and inhibited tumor growth. Metformin 9-18 BCL2 apoptosis regulator Homo sapiens 52-57 24577086-13 2014 Together, inactivation of Stat3-Bcl-2 pathway contributes to metformin-induced growth inhibition of ESCC by facilitating crosstalk between apoptosis and autophagy. Metformin 61-70 BCL2 apoptosis regulator Homo sapiens 32-37 24634186-7 2014 Mifepristone reversed the resistance of HeLa/MMC cells to MMC in vitro; the overexpression of the GCS gene and the increased expression of apoptosis-related protein Bcl-2 may play important roles in the formation of multidrug resistance in cervical cancer. Mifepristone 0-12 BCL2 apoptosis regulator Homo sapiens 165-170 24549172-2 2014 Furthermore, the actions of paclitaxel attenuated Bcl-2 resistance to apoptosis through endoplasmic reticulum-mediated calcium release. Paclitaxel 28-38 BCL2 apoptosis regulator Homo sapiens 50-55 24566325-9 2014 Finally, western blot analysis of triptolide-treated cells revealed the activation of caspase-3, caspase-9, PARP, and Bcl-2; this result demonstrated that triptolide induced apoptosis in gallbladder cancer cells by regulating apoptosis-related protein expression, and suggests that triptolide may be a promising drug to treat gallbladder carcinoma. triptolide 34-44 BCL2 apoptosis regulator Homo sapiens 118-123 24566325-9 2014 Finally, western blot analysis of triptolide-treated cells revealed the activation of caspase-3, caspase-9, PARP, and Bcl-2; this result demonstrated that triptolide induced apoptosis in gallbladder cancer cells by regulating apoptosis-related protein expression, and suggests that triptolide may be a promising drug to treat gallbladder carcinoma. triptolide 155-165 BCL2 apoptosis regulator Homo sapiens 118-123 24566325-9 2014 Finally, western blot analysis of triptolide-treated cells revealed the activation of caspase-3, caspase-9, PARP, and Bcl-2; this result demonstrated that triptolide induced apoptosis in gallbladder cancer cells by regulating apoptosis-related protein expression, and suggests that triptolide may be a promising drug to treat gallbladder carcinoma. triptolide 155-165 BCL2 apoptosis regulator Homo sapiens 118-123 24456288-6 2014 These compounds bind in the canonical BH3 binding groove in a binding mode distinct from previously known BCL-2 inhibitors. BH 3 38-41 BCL2 apoptosis regulator Homo sapiens 106-111 24586874-5 2014 Lidocaine and bupivacaine caused disruption of mitochondrial membrane potential and release of cytochrome c, accompanied by activation of caspase 3 and 7, PARP cleavage, and induction of a higher ratio of Bax/Bcl-2. Lidocaine 0-9 BCL2 apoptosis regulator Homo sapiens 209-214 24586874-5 2014 Lidocaine and bupivacaine caused disruption of mitochondrial membrane potential and release of cytochrome c, accompanied by activation of caspase 3 and 7, PARP cleavage, and induction of a higher ratio of Bax/Bcl-2. Bupivacaine 14-25 BCL2 apoptosis regulator Homo sapiens 209-214 24549172-2 2014 Furthermore, the actions of paclitaxel attenuated Bcl-2 resistance to apoptosis through endoplasmic reticulum-mediated calcium release. Calcium 119-126 BCL2 apoptosis regulator Homo sapiens 50-55 24176842-9 2014 In addition, harmine significantly inhibited the expression of COX-2, PCNA, Bcl-2 and MMP-2 as well as increased Bax expression in gastric cancer cells. Harmine 13-20 BCL2 apoptosis regulator Homo sapiens 76-81 24406249-9 2014 Exposure of drug sensitive and resistant cell lines to PBOX-6/carboplatin induced cleavage of Bcl-2, a downregulation of Mcl-1 and a concomitant increase in Bak. PBOX-6 55-61 BCL2 apoptosis regulator Homo sapiens 94-99 24406249-9 2014 Exposure of drug sensitive and resistant cell lines to PBOX-6/carboplatin induced cleavage of Bcl-2, a downregulation of Mcl-1 and a concomitant increase in Bak. Carboplatin 62-73 BCL2 apoptosis regulator Homo sapiens 94-99 24551054-11 2014 Further Western blot analyses showed subditine (1) induced down-regulation of Bcl-2 and Bcl-xl expression, whereas p53 was up-regulated in LNCaP (p53-wild-type), but not in PC-3 (p53-null). subditine 37-46 BCL2 apoptosis regulator Homo sapiens 78-83 24518825-5 2014 Results showed that TVA inhibited the proliferation of MCF-7 cells but not MCF-10A cells by down-regulating the expression of Bcl-2 as well as procaspase-9. 11-octadecenoic acid 20-23 BCL2 apoptosis regulator Homo sapiens 126-131 24523919-9 2014 We found that co-treatment of PF271 with ABT-737, a BCL-2/BCL-XL antagonist, was profoundly effective at inducing apoptosis. N-methyl-N-(3-((2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino)-methyl)-pyridin-2-yl)-methanesulfonamide 30-35 BCL2 apoptosis regulator Homo sapiens 52-57 24523919-9 2014 We found that co-treatment of PF271 with ABT-737, a BCL-2/BCL-XL antagonist, was profoundly effective at inducing apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 41-44 BCL2 apoptosis regulator Homo sapiens 52-57 24525728-2 2014 We have previously shown that the expression of Noxa, a BH3-only pro-apoptotic BCL-2 family protein, is the critical determinant of ABT-737 sensitivity. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 132-135 BCL2 apoptosis regulator Homo sapiens 79-84 24507386-14 2014 The tumor tissues were harvested after treatment, and ACBP-L and Cisplatin treatment suppressed Bcl-2, and induced Bax, Caspase 3, and Caspase 8 molecules as detected by RT-PCR and immunohistochemistry. Cisplatin 65-74 BCL2 apoptosis regulator Homo sapiens 96-101 23435429-2 2014 In this study, we demonstrate that following treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the activation of nuclear factor-kappaB (NF-kappaB), and that BRCA1 and NF-kappaB cooperate to regulate the expression of the NF-kappaB antiapoptotic targets BCL2 and XIAP. Etoposide 85-94 BCL2 apoptosis regulator Homo sapiens 292-296 24513107-10 2014 With the LoopDARPin scaffold, binders for BCL-2 with an affinity of 30 pM were isolated with only a single round of ribosome display,an enrichment that has not been described for any scaffold. loopdarpin 9-19 BCL2 apoptosis regulator Homo sapiens 42-47 23435429-2 2014 In this study, we demonstrate that following treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the activation of nuclear factor-kappaB (NF-kappaB), and that BRCA1 and NF-kappaB cooperate to regulate the expression of the NF-kappaB antiapoptotic targets BCL2 and XIAP. Camptothecin 98-110 BCL2 apoptosis regulator Homo sapiens 292-296 24495785-5 2014 The combination of PEITC and taxol also reduced expressions of cell cycle regulator Cdk1, and anti-apoptotic protein bcl-2, enhanced expression of Bax and cleavage of PARP proteins. phenethyl isothiocyanate 19-24 BCL2 apoptosis regulator Homo sapiens 117-122 24365492-5 2014 Cu(II) compound treatment also induced apoptosis of HeLa and SGC-7901 cells which were accompanied with decrease in mitochondrial membrane potential, increase in reactive oxygen species production, release of cytochrome C, cleavage of caspase-9, caspase-3 and poly ADP-ribose polymerase (PARP) as well as activations of bcl-2 and bax. cu(ii) 0-6 BCL2 apoptosis regulator Homo sapiens 320-325 24495785-5 2014 The combination of PEITC and taxol also reduced expressions of cell cycle regulator Cdk1, and anti-apoptotic protein bcl-2, enhanced expression of Bax and cleavage of PARP proteins. Paclitaxel 29-34 BCL2 apoptosis regulator Homo sapiens 117-122 24472193-3 2014 The small-molecule Bcl-2/Bcl-XL inhibitor ABT-737 efficiently induced apoptosis in alloreactive Tm in vitro and in vivo and prolonged skin graft survival in sensitized recipients. ABT-737 42-49 BCL2 apoptosis regulator Homo sapiens 19-24 24495648-9 2014 Therefore, MG132 decreases senescence, p65 phosphorylation, and the DOX-induced Bcl-2 antiapoptotic protein. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 11-16 BCL2 apoptosis regulator Homo sapiens 80-85 24495648-9 2014 Therefore, MG132 decreases senescence, p65 phosphorylation, and the DOX-induced Bcl-2 antiapoptotic protein. Doxorubicin 68-71 BCL2 apoptosis regulator Homo sapiens 80-85 24363397-5 2014 AZD1208 causes cell cycle arrest and apoptosis in MOLM-16 cells, accompanied by a dose-dependent reduction in phosphorylation of Bcl-2 antagonist of cell death, 4EBP1, p70S6K, and S6, as well as increases in cleaved caspase 3 and p27. AZD1208 0-7 BCL2 apoptosis regulator Homo sapiens 129-134 24450639-3 2014 Pre-clinical studies have identified several potential new therapeutic strategies, and we review the potential for use of BH3 (Bcl-2 homology) mimetics, autotaxin inhibitors and statins to treat ovarian cancer. BH 3 122-125 BCL2 apoptosis regulator Homo sapiens 127-132 24511002-0 2014 Myricetin induces cell death of human colon cancer cells via BAX/BCL2-dependent pathway. myricetin 0-9 BCL2 apoptosis regulator Homo sapiens 65-69 24511002-6 2014 We also determined that myricetin increases the BCL2-associated X protein/B-cell lymphoma 2 ratio, but not cleavage of caspase-3 and -9. myricetin 24-33 BCL2 apoptosis regulator Homo sapiens 48-52 24761411-11 2014 In addition to survivin restoration, resveratrol cotreatment also induced restoration of Bcl-2/caspase-3 expression suppressed by oxaliplatin only treatment. Resveratrol 37-48 BCL2 apoptosis regulator Homo sapiens 89-94 24761411-11 2014 In addition to survivin restoration, resveratrol cotreatment also induced restoration of Bcl-2/caspase-3 expression suppressed by oxaliplatin only treatment. Oxaliplatin 130-141 BCL2 apoptosis regulator Homo sapiens 89-94 23956031-6 2014 this study indicates that FA modified MNPs enhances the DOX-induced apoptosis in both of the human ovarian cancer cell lines with sharp decreases in the levels of bcl-2 and surviving, and increased expression of caspase-3. Doxorubicin 56-59 BCL2 apoptosis regulator Homo sapiens 163-168 24236538-4 2014 Thus, we investigated the anti-tumour effects of a pan-BCL2 inhibitor, AT-101, which has high binding specificity for BCL2 and MCL1 in preclinical models of plasma cell cancers (Multiple myeloma and Waldenstrom macroglobulinaemia). gossypol acetic acid 71-77 BCL2 apoptosis regulator Homo sapiens 55-59 24236538-4 2014 Thus, we investigated the anti-tumour effects of a pan-BCL2 inhibitor, AT-101, which has high binding specificity for BCL2 and MCL1 in preclinical models of plasma cell cancers (Multiple myeloma and Waldenstrom macroglobulinaemia). gossypol acetic acid 71-77 BCL2 apoptosis regulator Homo sapiens 118-122 24236538-7 2014 This cytotoxic effect and BCL2 downregulation were further potentiated when AT-101 was combined with lenalidomide/dexamethasone (LDA). gossypol acetic acid 76-82 BCL2 apoptosis regulator Homo sapiens 26-30 24236538-7 2014 This cytotoxic effect and BCL2 downregulation were further potentiated when AT-101 was combined with lenalidomide/dexamethasone (LDA). Lenalidomide 101-113 BCL2 apoptosis regulator Homo sapiens 26-30 24236538-7 2014 This cytotoxic effect and BCL2 downregulation were further potentiated when AT-101 was combined with lenalidomide/dexamethasone (LDA). Dexamethasone 114-127 BCL2 apoptosis regulator Homo sapiens 26-30 24236538-7 2014 This cytotoxic effect and BCL2 downregulation were further potentiated when AT-101 was combined with lenalidomide/dexamethasone (LDA). lda 129-132 BCL2 apoptosis regulator Homo sapiens 26-30 24248414-0 2014 miR-449a Regulates proliferation and chemosensitivity to cisplatin by targeting cyclin D1 and BCL2 in SGC7901 cells. Cisplatin 57-66 BCL2 apoptosis regulator Homo sapiens 94-98 24327721-13 2014 Naproxen-induced cell death was mainly because of apoptosis in which a prominent downregulation of Bcl-2 and upregulation of Bax were involved. Naproxen 0-8 BCL2 apoptosis regulator Homo sapiens 99-104 23910058-7 2014 Molecularly, LY294002 treatment down-regulated AEG-1 expression, AKT and GSK3beta phosphorylation, and expression of cyclinD1, CDK4, VEGF and Bcl2, but up-regulated Bax and c-Myc expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 BCL2 apoptosis regulator Homo sapiens 142-146 24155029-7 2014 Increased expression of ATG5, p53 and DRAM, along with an increase in BCLN1/Bcl-2 ratio, indicated that acetazolamide inhibited the proliferation of T-47D cells by inducing autophagy. Acetazolamide 104-117 BCL2 apoptosis regulator Homo sapiens 76-81 24286513-6 2014 Genes displaying increase in expression of apoptosis, related to cisplatin treatment, were Casp8, Bcl10, Bcl2, Bcl2l1, Bcl2l2, Bid, Naip1, Bnip3l, Card6, Pak7, Cd40, Trp 53inp1, Cideb and Cd70. Cisplatin 65-74 BCL2 apoptosis regulator Homo sapiens 105-109 23729350-5 2014 Furthermore, high levels of Bcl-2 (>50%) were expressed only in DP/BH endometrium. dp 67-69 BCL2 apoptosis regulator Homo sapiens 28-33 23729350-5 2014 Furthermore, high levels of Bcl-2 (>50%) were expressed only in DP/BH endometrium. Bh 70-72 BCL2 apoptosis regulator Homo sapiens 28-33 24140706-7 2014 Blocking p38 with a specific inhibitor suppresses ATG-mediated Bcl-2 downregulation and apoptosis. arctigenin 50-53 BCL2 apoptosis regulator Homo sapiens 63-68 24317440-9 2014 In addition, ATPR (50 microM), but not ATRA, significantly increased the population of AGS and MKN-74 cells in the subG1 phase and decreased the Bcl-2/Bax ratio (P<0.05). 4-amino-2-trifluoromethyl-phenyl retinate 13-17 BCL2 apoptosis regulator Homo sapiens 145-150 24285354-8 2014 Consistent with its ability to induce apoptosis, the acacetin-mediated inhibition of the pro-survival pathway, Akt, and of the NF-kappaB pathway was accompanied by a marked reduction in the levels of the NF-kappaB-regulated anti-apoptotic proteins, Bcl-2 and X-linked inhibitor of apoptosis protein (XIAP), as well as of the proliferative protein, cyclooxygenase (COX)-2. acacetin 53-61 BCL2 apoptosis regulator Homo sapiens 249-254 24189165-7 2014 In addition, the expression levels of protein such as acetyl-p53, p-p53, Bcl-2 and caspase-9 inducing apoptosis were increased in the presence of spermine. Spermine 146-154 BCL2 apoptosis regulator Homo sapiens 73-78 24219966-4 2014 RESULT: The inhibitory effects of osthole on the expression of BCL-2, BAX, and caspase-3 were detected by Western blotting. osthol 34-41 BCL2 apoptosis regulator Homo sapiens 63-68 24219966-6 2014 Western blotting demonstrated that osthole downregulated the expressions of BCL-2 and caspase-3 and upregulated the expression of BAX in human osteosarcoma cells. osthol 35-42 BCL2 apoptosis regulator Homo sapiens 76-81 24219966-7 2014 CONCLUSION: Osthole can inhibit osteosarcoma cell proliferation and induced apoptosis effectively in a dose-dependent manner through downregulating the expression of BCL-2 and caspase-3 proteins levels and upregulating the expression of BAX proteins levels. osthol 12-19 BCL2 apoptosis regulator Homo sapiens 166-171 24078116-0 2014 Bcl-2 family in inter-organelle modulation of calcium signaling; roles in bioenergetics and cell survival. Calcium 46-53 BCL2 apoptosis regulator Homo sapiens 0-5 24337183-10 2014 Bcl-2 was markedly downregulated in dose-dependent cisplatin-treated Barkor-transfected-Saos-2 cells. Cisplatin 51-60 BCL2 apoptosis regulator Homo sapiens 0-5 24078116-1 2014 Bcl-2 family proteins, known for their apoptosis functioning at the mitochondria, have been shown to localize to other cellular compartments to mediate calcium (Ca2+) signals. Calcium 152-159 BCL2 apoptosis regulator Homo sapiens 0-5 24461407-11 2014 LPA could effectively rescue HDPCs from ischemia-induced apoptosis via regulation of Bax and Bcl-2 and the activation of phosphorylated FAK and phosphorylated ERK. lysophosphatidic acid 0-3 BCL2 apoptosis regulator Homo sapiens 93-98 24738333-12 2014 Moreover, transcription and protein expression of bcl-2, NFKB, survivin, bax, p53 and caspase-3 of Raji cells were regulated at the most remarkable extent in ADM-As2O3, MNPs group as compared with other groups. Arsenic Trioxide 162-167 BCL2 apoptosis regulator Homo sapiens 50-55 23955071-7 2014 Apoptosis induction by L-779,450/TRAIL was prevented by Bcl-2 overexpression and was dependent on Bax. l-779 23-28 BCL2 apoptosis regulator Homo sapiens 56-61 24326530-0 2014 1-Methyl-4-phenylpyridinium-induced cell death via autophagy through a Bcl-2/Beclin 1 complex-dependent pathway. 1-Methyl-4-phenylpyridinium 0-27 BCL2 apoptosis regulator Homo sapiens 71-76 23697845-7 2014 Furthermore, treatment of ABC cell lines with bortezomib for 48 h also down-regulated the expression of NFkappaB-regulated gene products, such as IkappaBalpha, Bcl-2, Bcl-Xl, XIAP and survivin, leading to apoptosis via the mitochondrial apoptotic pathway. Bortezomib 46-56 BCL2 apoptosis regulator Homo sapiens 160-165 24270314-6 2014 The results suggested that the protective effect of Rg1 on lidocaine-induced apoptosis is mediated by altering the level of B-cell lymphoma-2 (BCL-2) family proteins and downregulating caspase-3 expression. Lidocaine 59-68 BCL2 apoptosis regulator Homo sapiens 124-141 24270314-6 2014 The results suggested that the protective effect of Rg1 on lidocaine-induced apoptosis is mediated by altering the level of B-cell lymphoma-2 (BCL-2) family proteins and downregulating caspase-3 expression. Lidocaine 59-68 BCL2 apoptosis regulator Homo sapiens 143-148 24270314-8 2014 In addition, the study demonstrated that Rg1 is a notable antiapoptotic molecule that is capable of blocking the caspase-dependent signaling cascade in Jurkat cells, and that the protective effect of Rg1 on lidocaine-induced apoptosis is mediated by altering levels of BCL-2 family proteins and downregulating caspase-3 expression. Lidocaine 207-216 BCL2 apoptosis regulator Homo sapiens 269-274 24402872-10 2014 In contrast, CDDP-treated group showed a significant down regulation in the expression levels of Bcl-2 mRNA as compared to untreated control group. cddp 13-17 BCL2 apoptosis regulator Homo sapiens 97-102 24496691-0 2014 Dioscin-induced apoptosis of human LNCaP prostate carcinoma cells through activation of caspase-3 and modulation of Bcl-2 protein family. dioscin 0-7 BCL2 apoptosis regulator Homo sapiens 116-121 24496691-9 2014 These results suggested that dioscin possessed potential anti-tumor activity in human LNCaP cells through the apoptosis pathway, which might be associated with caspase-3 and Bcl-2 protein family. dioscin 29-36 BCL2 apoptosis regulator Homo sapiens 174-179 22949227-4 2014 In this study, we present evidence showing that the up-regulated cyclin B1/Cdc2 complex in nocodazole-treated human breast cancer cells is also responsible for the increased phosphorylation of Bcl-2 and Bcl-XL . Nocodazole 91-101 BCL2 apoptosis regulator Homo sapiens 193-198 22949227-6 2014 In addition, evidence is presented to show that mitotic arrest deficient 2 (MAD2) is a key upstream mediator of the up-regulation of cyclin B1/Cdc2 as well as the subsequent increase in phosphorylationof Bcl-2 and Bcl-XL in nocodazole-treated cancer cells. Nocodazole 224-234 BCL2 apoptosis regulator Homo sapiens 204-209 24337453-5 2014 Cleaved caspase-3 was increased and Bcl-2 was reduced by treatment with capsaicin in AGS cells. Capsaicin 72-81 BCL2 apoptosis regulator Homo sapiens 36-41 23862748-8 2014 Functional analyses indicated that the restoration of miR-34a reduced cell viability, promoted cell apoptosis and potentiated sorafenib-induced apoptosis and toxicity in HCC cell lines by inhibiting Bcl-2 expression. Sorafenib 126-135 BCL2 apoptosis regulator Homo sapiens 199-204 24709422-5 2014 Moreover, these cells were relatively resistant to the Bcl-2 homology domain 3 (BH3) mimetic ABT-737, which directly targets the Bcl-2 family of apoptosis regulators. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 93-96 BCL2 apoptosis regulator Homo sapiens 55-60 24709422-5 2014 Moreover, these cells were relatively resistant to the Bcl-2 homology domain 3 (BH3) mimetic ABT-737, which directly targets the Bcl-2 family of apoptosis regulators. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 93-96 BCL2 apoptosis regulator Homo sapiens 129-134 24216166-4 2014 Obatoclax is a small-molecule antagonist of the BH3-binding groove of anti-apoptotic BCL-2 family. BH 3 48-51 BCL2 apoptosis regulator Homo sapiens 85-90 24239278-3 2014 MATERIALS AND METHODS: The expression of EGFR, p53, Cyclin D1, p16, p21, p27, p-AKT, HIF-1alpha, Caspase 3 and BCL2 was analyzed by immunohistochemistry in 41 primary laryngeal/hypopharyngeal squamous cell carcinomas of patients that received induction chemotherapy (cisplatin and 5-fluorouracil) as part of their treatment. Cisplatin 267-276 BCL2 apoptosis regulator Homo sapiens 111-115 24287118-9 2014 In addition, ghrelin protected HUVECs against high glucose induced apoptosis by increasing Bcl-2/Bax ratio. Ghrelin 13-20 BCL2 apoptosis regulator Homo sapiens 91-96 24287118-9 2014 In addition, ghrelin protected HUVECs against high glucose induced apoptosis by increasing Bcl-2/Bax ratio. Glucose 51-58 BCL2 apoptosis regulator Homo sapiens 91-96 24239278-3 2014 MATERIALS AND METHODS: The expression of EGFR, p53, Cyclin D1, p16, p21, p27, p-AKT, HIF-1alpha, Caspase 3 and BCL2 was analyzed by immunohistochemistry in 41 primary laryngeal/hypopharyngeal squamous cell carcinomas of patients that received induction chemotherapy (cisplatin and 5-fluorouracil) as part of their treatment. Fluorouracil 281-295 BCL2 apoptosis regulator Homo sapiens 111-115 24640606-4 2014 Further studies showed that kirenol treatment caused externalization of phosphatidylserine, accumulation of ROS (reactive oxygen species), alteration of mitochondrial membrane potential, release of cytochrome c, reduction in the level of the Bcl-2 protein and upregulation of Bax and tBid, kirenol induced cell apoptosis in a caspase-independent manner. kirenol 28-35 BCL2 apoptosis regulator Homo sapiens 242-247 24014050-0 2014 The role of Bax and Bcl-2 in gemcitabine-mediated cytotoxicity in uveal melanoma cells. gemcitabine 29-40 BCL2 apoptosis regulator Homo sapiens 20-25 24078465-8 2014 Furthermore, we found that oxymatrine considerably inhibited the expression of Bcl-2 whilst increasing that of Bax. oxymatrine 27-37 BCL2 apoptosis regulator Homo sapiens 79-84 24048756-5 2014 Moreover, Western blot analysis demonstrated that PD induced downregulation of protein expression of PI3K, P-Akt, and Bcl-2, whereas cleaved products of caspase-3 and -9 and PARP were upregulated by PD treatment. platycodin D 50-52 BCL2 apoptosis regulator Homo sapiens 118-123 24048756-8 2014 Thus, the increasing ratio of Bax to Bcl-2, activation of caspase-3 and -9 and PARP, and inactivation of the PI3K/Akt signaling pathway significantly enhanced PD-induced apoptosis in HepG2 cells. platycodin D 159-161 BCL2 apoptosis regulator Homo sapiens 37-42 24598658-6 2014 It is concluded that Honokiol combined Gemcitabine can synergistically inhibit the proliferation, induce cell apoptosis, and down-regulate the expression of BCL-2 in Raji cells. honokiol 21-29 BCL2 apoptosis regulator Homo sapiens 157-162 24197975-5 2014 Furthermore, Western blot analysis showed that EI-SP treatment led to decreased protein expression of Bcl-2 and an increase in Bax, cleaved caspase-3, cleaved caspase-9 and cleaved poly(ADP-ribose) polymerase (PARP). ei-sp 47-52 BCL2 apoptosis regulator Homo sapiens 102-107 24194395-5 2014 Sertraline activated the intrinsic checkpoint protein caspase-9 and caused the release of cytochrome c from mitochondria to cytosol; this process was Bcl-2 family dependent because antiapoptotic Bcl-2 family proteins were decreased. Sertraline 0-10 BCL2 apoptosis regulator Homo sapiens 150-155 24194395-5 2014 Sertraline activated the intrinsic checkpoint protein caspase-9 and caused the release of cytochrome c from mitochondria to cytosol; this process was Bcl-2 family dependent because antiapoptotic Bcl-2 family proteins were decreased. Sertraline 0-10 BCL2 apoptosis regulator Homo sapiens 195-200 24598658-6 2014 It is concluded that Honokiol combined Gemcitabine can synergistically inhibit the proliferation, induce cell apoptosis, and down-regulate the expression of BCL-2 in Raji cells. gemcitabine 39-50 BCL2 apoptosis regulator Homo sapiens 157-162 24796455-8 2014 In addition, the expressions of Bcl2 mRNA and protein were 1.05 +- 0.04 and 0.21 +- 0.03 in the miR-224 ASO group, significantly lower than that in the control group (4.87 +- 0.96 and 0.88 +- 0.09, P < 0.01). Oligonucleotides, Antisense 104-107 BCL2 apoptosis regulator Homo sapiens 32-36 24466103-3 2014 Here we show that ATO dose-dependently induces depolarization of mitochondrial inner transmembrane potential (DeltaPsim), up-regulation of Bax and down-regulation of Bcl-2 and Bcl-XL, caspase-3 activation, and phosphotidylserine (PS) exposure in platelets. Arsenic Trioxide 18-21 BCL2 apoptosis regulator Homo sapiens 166-171 24252419-4 2014 Moreover, we found alantolactone could increase the ratio of Bax/Bcl-2, and activate caspase-9 and caspase-3 in the cancer cells with high expression of TSP50, surprisingly, the same effects can also be observed in the same cells just by knockdown of TSP50 gene expression. alantolactone 19-32 BCL2 apoptosis regulator Homo sapiens 65-70 24172751-0 2014 Dexamethasone differentially regulates Bcl-2 family proteins in human proliferative chondrocytes: role of pro-apoptotic Bid. Dexamethasone 0-13 BCL2 apoptosis regulator Homo sapiens 39-44 24321340-9 2014 We also identified that pretreatment of Bcl-2 inhibitor (ABT-737) could significantly enhance anticancer activity of CA-4 due to inhibition of autophagy. ABT-737 57-64 BCL2 apoptosis regulator Homo sapiens 40-45 24427275-9 2014 This dysfunctional autophagy plays a pro-death role in GNA-treated cells by activating p53, Bax and cleaved caspase-3 while decreasing Bcl-2. neo-gambogic acid 55-58 BCL2 apoptosis regulator Homo sapiens 135-140 24427286-7 2014 However, pharmacological inhibition of BCL-2 and BCL-X(L) with ABT-737 also sensitized cells to heat shock, most likely through liberation of BIM. ABT-737 63-70 BCL2 apoptosis regulator Homo sapiens 39-44 24393539-0 2014 Novel 9-(alkylthio)-Acenaphtho[1,2-e]-1,2,4-triazine derivatives: synthesis, cytotoxic activity and molecular docking studies on B-cell lymphoma 2 (Bcl-2). 9-(alkylthio)-acenaphtho[1,2-e]-1,2,4-triazine 6-52 BCL2 apoptosis regulator Homo sapiens 129-146 24393539-0 2014 Novel 9-(alkylthio)-Acenaphtho[1,2-e]-1,2,4-triazine derivatives: synthesis, cytotoxic activity and molecular docking studies on B-cell lymphoma 2 (Bcl-2). 9-(alkylthio)-acenaphtho[1,2-e]-1,2,4-triazine 6-52 BCL2 apoptosis regulator Homo sapiens 148-153 25276123-11 2014 Osthole induced apoptosis by downregulating antiapoptotic Bcl-2 in only PC3 cells and upregulating the proapoptotic genes Bax and Smac/DIABLO in PC3, SKNMC, and H1299 cells. osthol 0-7 BCL2 apoptosis regulator Homo sapiens 58-63 24875127-0 2014 miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. Cisplatin 19-28 BCL2 apoptosis regulator Homo sapiens 111-115 24942548-8 2014 Our findings suggest that the steroidal Na(+)/K(+) ATPase inhibitor 3-R-POD induces apoptosis, paralleled by altered BCL-2 and c-Fos gene transcription, inhibition of the pro-survival FAK signalling, up-regulation of the pro-apoptotic p38 MAPK pathway and stimulation of caspase-3 activity. r- 70-72 BCL2 apoptosis regulator Homo sapiens 117-122 24146141-9 2014 Interestingly, stimulation of GSH loss by MK571 also enhanced the initiator phase of apoptosis by stimulating initiator caspase 8 and 9 activity and pro-apoptotic BCL-2 interacting domain cleavage. Glutathione 30-33 BCL2 apoptosis regulator Homo sapiens 163-168 24146141-9 2014 Interestingly, stimulation of GSH loss by MK571 also enhanced the initiator phase of apoptosis by stimulating initiator caspase 8 and 9 activity and pro-apoptotic BCL-2 interacting domain cleavage. verlukast 42-47 BCL2 apoptosis regulator Homo sapiens 163-168 24166139-0 2014 Prometaphase arrest-dependent phosphorylation of Bcl-2 and Bim reduces the association of Bcl-2 with Bak or Bim, provoking Bak activation and mitochondrial apoptosis in nocodazole-treated Jurkat T cells. Nocodazole 169-179 BCL2 apoptosis regulator Homo sapiens 49-54 24220853-7 2014 Using this approach, we describe thiolutin, CD437 and TPEN as the most potentially valuable drug candidates for addressing drug-resistance caused by aberrant expression of Bcl-2 family proteins in tumor cells. acetopyrrothine 33-42 BCL2 apoptosis regulator Homo sapiens 172-177 24220853-7 2014 Using this approach, we describe thiolutin, CD437 and TPEN as the most potentially valuable drug candidates for addressing drug-resistance caused by aberrant expression of Bcl-2 family proteins in tumor cells. N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine 54-58 BCL2 apoptosis regulator Homo sapiens 172-177 24467547-4 2014 FUR also affected the signaling molecules that regulate apoptosis in 95-D cells revealed by the down-regulation of the protein levels of full PARP, pro-caspase-7, survivin, and Bcl-2, and the up-regulation of cleaved PARP. furanodiene 0-3 BCL2 apoptosis regulator Homo sapiens 177-182 24072590-1 2014 S1 is a putative BH3 mimetic proposed to inhibit BCL2 and MCL1 based on cell-free assays. BH 3 17-20 BCL2 apoptosis regulator Homo sapiens 49-53 24072590-4 2014 The BCL2 inhibitors, ABT-737, ABT-263, and ABT-199, have demonstrated pro-apoptotic efficacy in cell lines, while ABT-263 and ABT-199 have demonstrated efficacy in early clinical trials. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 21-24 BCL2 apoptosis regulator Homo sapiens 4-8 24072590-4 2014 The BCL2 inhibitors, ABT-737, ABT-263, and ABT-199, have demonstrated pro-apoptotic efficacy in cell lines, while ABT-263 and ABT-199 have demonstrated efficacy in early clinical trials. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 30-33 BCL2 apoptosis regulator Homo sapiens 4-8 24072590-4 2014 The BCL2 inhibitors, ABT-737, ABT-263, and ABT-199, have demonstrated pro-apoptotic efficacy in cell lines, while ABT-263 and ABT-199 have demonstrated efficacy in early clinical trials. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 30-33 BCL2 apoptosis regulator Homo sapiens 4-8 24072590-4 2014 The BCL2 inhibitors, ABT-737, ABT-263, and ABT-199, have demonstrated pro-apoptotic efficacy in cell lines, while ABT-263 and ABT-199 have demonstrated efficacy in early clinical trials. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 30-33 BCL2 apoptosis regulator Homo sapiens 4-8 24072590-4 2014 The BCL2 inhibitors, ABT-737, ABT-263, and ABT-199, have demonstrated pro-apoptotic efficacy in cell lines, while ABT-263 and ABT-199 have demonstrated efficacy in early clinical trials. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 30-33 BCL2 apoptosis regulator Homo sapiens 4-8 24166139-0 2014 Prometaphase arrest-dependent phosphorylation of Bcl-2 and Bim reduces the association of Bcl-2 with Bak or Bim, provoking Bak activation and mitochondrial apoptosis in nocodazole-treated Jurkat T cells. Nocodazole 169-179 BCL2 apoptosis regulator Homo sapiens 90-95 24166139-8 2014 NOC-induced phosphorylation of Bcl-2 and Bim, Deltapsim loss, and mitochondria-dependent apoptotic events were significantly suppressed by a Cdk1 inhibitor roscovitine, but not by the JNK inhibitor SP600125 or the p38 MAPK inhibitor SB203580. Roscovitine 156-167 BCL2 apoptosis regulator Homo sapiens 31-36 24166139-8 2014 NOC-induced phosphorylation of Bcl-2 and Bim, Deltapsim loss, and mitochondria-dependent apoptotic events were significantly suppressed by a Cdk1 inhibitor roscovitine, but not by the JNK inhibitor SP600125 or the p38 MAPK inhibitor SB203580. SB 203580 233-241 BCL2 apoptosis regulator Homo sapiens 31-36 25520141-9 2014 Furthermore, the expression of apoptosis-related proteins including cleaved caspase-3, caspase-9 and Bax was increased in curdione treatment groups, while the expression of the anti-apoptotic Bcl-2 was decreased. curdione 122-130 BCL2 apoptosis regulator Homo sapiens 192-197 24870784-0 2014 Rice bran phytic acid induced apoptosis through regulation of Bcl-2/Bax and p53 genes in HepG2 human hepatocellular carcinoma cells. Phytic Acid 10-21 BCL2 apoptosis regulator Homo sapiens 62-67 25556484-7 2014 Real-time quantitative PCR and Western-blotting assay were performed to investigated the influence of beta-elemene on expression levels of Fas/FasL, caspase-3, Bcl-2 and Bax. beta-elemene 102-114 BCL2 apoptosis regulator Homo sapiens 160-165 24935585-7 2014 Furthermore, the down-regulation of Bcl-2 and up-regulation of Bax that led to the cleavage of caspase-3 and increased cleaved PARP was observed in SGC-7901 cells treated with curcumin. Curcumin 176-184 BCL2 apoptosis regulator Homo sapiens 36-41 25556484-0 2014 beta-elemene induces caspase-dependent apoptosis in human glioma cells in vitro through the upregulation of Bax and Fas/ FasL and downregulation of Bcl-2. beta-elemene 0-12 BCL2 apoptosis regulator Homo sapiens 148-153 24870784-9 2014 PA treated HepG2 cells showed up-regulation of p53, Bax, Caspase-3 and -9, and down- regulation of Bcl-2 gene (p <= 0.01). Phytic Acid 0-2 BCL2 apoptosis regulator Homo sapiens 99-104 24998560-6 2014 DAPI and TUNEL staining showed that parthenolide could increase the number of apoptotic nuclei, while reducing the expression of the anti-apoptotic protein Bcl-2 and elevating the expression of related proteins, like p53, Bax, cleaved caspase9 and cleaved caspase3. parthenolide 36-48 BCL2 apoptosis regulator Homo sapiens 156-161 25227792-0 2014 Mangiferin induces apoptosis by regulating Bcl-2 and Bax expression in the CNE2 nasopharyngeal carcinoma cell line. mangiferin 0-10 BCL2 apoptosis regulator Homo sapiens 43-48 24998564-6 2014 RESULTS: Celecoxib can inhibit proliferation and induce apoptosis in a dose- and time-dependent manner, repress telomerase activity, decrease hTERT mRNA and Bcl-2 protein expression and increase Bax protein expression, PGE2 had no effect on telomerase. Celecoxib 9-18 BCL2 apoptosis regulator Homo sapiens 157-162 24998578-6 2014 Expression of ac-H3, ac-H4 and NF-kappaB/ac-p65 proteins in E2-treated MCF-7 cells was increased, this being inhibited by garcinol but not ac- H4.The nuclear translocation of NF-kappaB/p65 in E2-treated MCF-7 cells was also inhibited, along with cyclin D1, Bcl-2 and Bcl-xl in mRNA and protein expression levels. garcinol 122-130 BCL2 apoptosis regulator Homo sapiens 257-262 25374178-0 2014 Roles of the Bcl-2/Bax ratio, caspase-8 and 9 in resistance of breast cancer cells to paclitaxel. Paclitaxel 86-96 BCL2 apoptosis regulator Homo sapiens 13-18 25081695-7 2014 Paclitaxel treatment caused cell cycle arrest and apoptosis via downregulating Bcl-2 expression. Paclitaxel 0-10 BCL2 apoptosis regulator Homo sapiens 79-84 25081695-9 2014 CONCLUSIONS: IGFBP-3 exhibits anti-apoptotic effects on paclitaxel-treated SGC-7901 cells via elevating Bcl-2 expression. Paclitaxel 56-66 BCL2 apoptosis regulator Homo sapiens 104-109 24606472-0 2014 Expression of bcl-2 and p53 in induction of esophageal cancer cell apoptosis by ECRG2 in combination with cisplatin. Cisplatin 106-115 BCL2 apoptosis regulator Homo sapiens 14-19 25338992-3 2014 Moreover, apoptosis of both cells was significantly increased with the treatment of olanzapine as evidenced by increased Bcl-2 expression, Hoechst 33258 staining and annexinV-FITC/PI staining. Olanzapine 84-94 BCL2 apoptosis regulator Homo sapiens 121-126 24568489-5 2014 CONCLUSION: ASMq total phenolics, combined with cisplatin and docetaxel, could promote the apoptosis of Hela cells possibly through reducing the expression of Bcl-2 and survivin. Cisplatin 48-57 BCL2 apoptosis regulator Homo sapiens 159-164 24568489-5 2014 CONCLUSION: ASMq total phenolics, combined with cisplatin and docetaxel, could promote the apoptosis of Hela cells possibly through reducing the expression of Bcl-2 and survivin. Docetaxel 62-71 BCL2 apoptosis regulator Homo sapiens 159-164 24641396-6 2014 A549 cells treated by Withaferin A for 48 h were markedly lower in Bcl-2 level and obviously higher in Bax and cleaved caspase-3 levels than those treated by 0 mumol L-1 Withaferin A (P<0.05), and there were significant differences among 5, 10 and 20 mumol L-1 Withaferin A (P<0.05). withaferin A 22-34 BCL2 apoptosis regulator Homo sapiens 67-72 24761910-7 2014 In addition, formononetin increased the proportion of early apoptotic DU-145 cells, down-regulated the protein levels of Bcl-2 and up-regulated those of RASD1 and Bax. formononetin 13-25 BCL2 apoptosis regulator Homo sapiens 121-126 24641404-0 2014 D-pinitol promotes apoptosis in MCF-7 cells via induction of p53 and Bax and inhibition of Bcl-2 and NF-kappaB. pinitol 0-9 BCL2 apoptosis regulator Homo sapiens 91-96 24641404-9 2014 The results revealed that D-pinitol significantly inhibited the proliferation of MCF-7 cells in a concentration-dependent manner, while upregulating the expression of p53, Bax and down regulating Bcl-2 and NF-kB. pinitol 26-35 BCL2 apoptosis regulator Homo sapiens 196-201 25226915-6 2014 Furthermore, Ad-GDNF significantly decreased the levels of IL-6 and TNF-a and increased Bcl-2/Bax ratio in BMSCs treated by H2O2. Hydrogen Peroxide 124-128 BCL2 apoptosis regulator Homo sapiens 88-93 25484085-10 2014 Ethanol may stimulate autophagy through multiple mechanisms; these include induction of oxidative stress and endoplasmic reticulum stress, modulation of MTOR and AMPK signaling, alterations in BCL2 family proteins, and disruption of intracellular calcium (Ca2+) homeostasis. Ethanol 0-7 BCL2 apoptosis regulator Homo sapiens 193-197 25087947-8 2014 Furthermore, combination treatment of GNA and 5-FU showed up-regulated of caspase-3, caspase-9, bax, RIP1, apoptosis-inducing factor (AIF), voltage-dependent anion channel (VDAC), cytochrome c and cyclophilin D and down-regulated bcl-2. neo-gambogic acid 38-41 BCL2 apoptosis regulator Homo sapiens 230-235 25087947-8 2014 Furthermore, combination treatment of GNA and 5-FU showed up-regulated of caspase-3, caspase-9, bax, RIP1, apoptosis-inducing factor (AIF), voltage-dependent anion channel (VDAC), cytochrome c and cyclophilin D and down-regulated bcl-2. Fluorouracil 46-50 BCL2 apoptosis regulator Homo sapiens 230-235 24815470-0 2014 Inotodiol inhabits proliferation and induces apoptosis through modulating expression of cyclinE, p27, bcl-2, and bax in human cervical cancer HeLa cells. inotodiol 0-9 BCL2 apoptosis regulator Homo sapiens 102-107 25478603-5 2014 Salinomycin was also tested on the expression levels of key genes involved in proliferation and survival signaling and revealed that salinomycin down-regulates the expression of PDGFRbeta, MYC, p21 and Bcl-2 as well as up-regulates the expression of cyclin A. salinomycin 0-11 BCL2 apoptosis regulator Homo sapiens 202-207 25478603-5 2014 Salinomycin was also tested on the expression levels of key genes involved in proliferation and survival signaling and revealed that salinomycin down-regulates the expression of PDGFRbeta, MYC, p21 and Bcl-2 as well as up-regulates the expression of cyclin A. salinomycin 133-144 BCL2 apoptosis regulator Homo sapiens 202-207 25197664-5 2014 Importantly, proteomic and western blot analysis showed that apoptosis regulators BAK and Bax were upregulated in gossypol-treated cells, indicating that Bcl-2 associated death pathway was activated. bakuchiol 82-85 BCL2 apoptosis regulator Homo sapiens 154-159 24197132-4 2014 Here, we demonstrate that either endogenous or exogenous expression of Bcl2 results in decreases in RNR activity and intracellular dNTP, retardation of DNA replication fork progression, and increased rate of fork asymmetry leading to DNA replication stress. Parathion 131-135 BCL2 apoptosis regulator Homo sapiens 71-75 25197664-5 2014 Importantly, proteomic and western blot analysis showed that apoptosis regulators BAK and Bax were upregulated in gossypol-treated cells, indicating that Bcl-2 associated death pathway was activated. Gossypol 114-122 BCL2 apoptosis regulator Homo sapiens 154-159 24995326-9 2014 Baicalein induced apoptosis via endoplasmic reticulum (ER) stress, possibly by downregulating prosurvival Bcl-2 family, increasing intracellular calcium, and activating JNK. baicalein 0-9 BCL2 apoptosis regulator Homo sapiens 106-111 24949471-5 2014 Mechanically, solanine promotes the opening of mitochondrial membrane permeability transition pore (MPTP) by downregulating the Bcl-2/Bax ratio; thereafter, Cytochrome c and Smac are released from mitochondria into cytosol to process the caspase-3 zymogen into an activated form. Solanine 14-22 BCL2 apoptosis regulator Homo sapiens 128-133 24895574-1 2014 Icaritin (ICT), a hydrolytic product of icariin from Epimedium genus, exhibits antitumor activities in several human solid-tumor and myeloid leukemia cells with extensive influence on various cell signal molecules, such as MAPKs being involved in cell proliferation and Bcl-2 participating in cell apoptosis. icaritin 0-8 BCL2 apoptosis regulator Homo sapiens 270-275 24895574-1 2014 Icaritin (ICT), a hydrolytic product of icariin from Epimedium genus, exhibits antitumor activities in several human solid-tumor and myeloid leukemia cells with extensive influence on various cell signal molecules, such as MAPKs being involved in cell proliferation and Bcl-2 participating in cell apoptosis. icaritin 10-13 BCL2 apoptosis regulator Homo sapiens 270-275 24895574-5 2014 We also observed that icaritin was able to decrease Bcl-2 levels, thus shifting the Bcl-2/Bax ratio, and it could obviously reduce c-Myc, a specific molecular target in Burkitt lymphoma. icaritin 22-30 BCL2 apoptosis regulator Homo sapiens 52-57 24895574-5 2014 We also observed that icaritin was able to decrease Bcl-2 levels, thus shifting the Bcl-2/Bax ratio, and it could obviously reduce c-Myc, a specific molecular target in Burkitt lymphoma. icaritin 22-30 BCL2 apoptosis regulator Homo sapiens 84-89 24738081-5 2014 LQ treatment resulted in a reduction of the expressions of B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xL), and an increase of the phosphorylation of c-Jun N-terminal kinases (JNK) and P38. liquiritigenin 0-2 BCL2 apoptosis regulator Homo sapiens 59-76 24738081-5 2014 LQ treatment resulted in a reduction of the expressions of B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xL), and an increase of the phosphorylation of c-Jun N-terminal kinases (JNK) and P38. liquiritigenin 0-2 BCL2 apoptosis regulator Homo sapiens 78-83 25036678-5 2014 Furthermore, z-VAD-fmk (a pan-caspase inhibitor) and z-IETD-fmk (a specific caspase-8 inhibitor) abolished the DHS-induced activation of the caspase-8, -9, and -3, cleavage of PARP, the depolarization of Deltapsim, the release of cytochrome c, the cleavage of Bid, and the downregulation of Bcl-2. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 13-22 BCL2 apoptosis regulator Homo sapiens 291-296 25036678-5 2014 Furthermore, z-VAD-fmk (a pan-caspase inhibitor) and z-IETD-fmk (a specific caspase-8 inhibitor) abolished the DHS-induced activation of the caspase-8, -9, and -3, cleavage of PARP, the depolarization of Deltapsim, the release of cytochrome c, the cleavage of Bid, and the downregulation of Bcl-2. benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone 53-63 BCL2 apoptosis regulator Homo sapiens 291-296 25036678-5 2014 Furthermore, z-VAD-fmk (a pan-caspase inhibitor) and z-IETD-fmk (a specific caspase-8 inhibitor) abolished the DHS-induced activation of the caspase-8, -9, and -3, cleavage of PARP, the depolarization of Deltapsim, the release of cytochrome c, the cleavage of Bid, and the downregulation of Bcl-2. Silybin 111-114 BCL2 apoptosis regulator Homo sapiens 291-296 24197132-6 2014 Removal of the BH4 domain of Bcl2 abrogates its inhibitory effects on RNR activity, dNTP pool level, and DNA replication. sapropterin 15-18 BCL2 apoptosis regulator Homo sapiens 29-33 24197132-6 2014 Removal of the BH4 domain of Bcl2 abrogates its inhibitory effects on RNR activity, dNTP pool level, and DNA replication. Parathion 84-88 BCL2 apoptosis regulator Homo sapiens 29-33 24197132-7 2014 Intriguingly, Bcl2 directly inhibits RNR activity by disrupting the functional hRRM1/hRRM2 complex via its BH4 domain. sapropterin 107-110 BCL2 apoptosis regulator Homo sapiens 14-18 24197132-8 2014 Our findings argue that Bcl2 reduces intracellular dNTPs by inhibiting ribonucleotide reductase activity, thereby providing insight into how Bcl2 triggers DNA replication stress. Parathion 51-56 BCL2 apoptosis regulator Homo sapiens 24-28 24197132-8 2014 Our findings argue that Bcl2 reduces intracellular dNTPs by inhibiting ribonucleotide reductase activity, thereby providing insight into how Bcl2 triggers DNA replication stress. Parathion 51-56 BCL2 apoptosis regulator Homo sapiens 141-145 25199820-6 2014 Melatonin-mediated cell death resulted in decreased phosphorylation of EGFR and Akt, leading to attenuated expression of survival proteins, such as Bcl-2, Bcl-xL and survivin, and activated caspase 3 in H1975 cells, but not in HCC827 cells. Melatonin 0-9 BCL2 apoptosis regulator Homo sapiens 148-153 25170541-9 2014 Furthermore, treatment of formononetin led to significant inactivation of ERK and Akt, followed by downregulation of Bcl-2, upregulation of Bax and finally increased expression of caspase-3. formononetin 26-38 BCL2 apoptosis regulator Homo sapiens 117-122 24854841-7 2014 The mechanism was at least partially due to DHA deactivated PDT-induced NF-kappaB activation, so as to decrease tremendously the expression of its target gene Bcl-2. artenimol 44-47 BCL2 apoptosis regulator Homo sapiens 159-164 25562170-10 2014 RESULTS: TMZ had a significant protective effect against H/SD-induced apoptosis, accompanied by an increase in Bcl-2 and p-Akt. Trimetazidine 9-12 BCL2 apoptosis regulator Homo sapiens 111-116 24931256-8 2014 Additionally, downregulation of miR-503 in the cisplatin (DDP)-resistant gastric cancer cell line SGC7901/DDP was concurrent with the upregulation of insulin-like growth factor-1 receptor (IGF1R) and B-cell lymphoma 2 (BCL2) expression compared with the parental SGC7901 cell line. Cisplatin 47-56 BCL2 apoptosis regulator Homo sapiens 200-217 23943192-7 2014 Meanwhile, Bcl-2, Caspase-3, and Caspase-9 were in the U373-MG and T98G lines expressed after NaBu treatment. sethoxydim 94-98 BCL2 apoptosis regulator Homo sapiens 11-16 24931256-8 2014 Additionally, downregulation of miR-503 in the cisplatin (DDP)-resistant gastric cancer cell line SGC7901/DDP was concurrent with the upregulation of insulin-like growth factor-1 receptor (IGF1R) and B-cell lymphoma 2 (BCL2) expression compared with the parental SGC7901 cell line. Cisplatin 47-56 BCL2 apoptosis regulator Homo sapiens 219-223 23943192-8 2014 The effect of 5-aza induced an increase in the expression of Bax and Bcl-2, while NaBu produced a similar effect on the Bak-1 and Bax genes. Azacitidine 14-19 BCL2 apoptosis regulator Homo sapiens 69-74 24931256-12 2014 CONCLUSION: Our findings suggest that hsa-miR-503 modulates cisplatin resistance of human gastric cancer cells at least in part by targeting IGF1R and BCL2. Cisplatin 60-69 BCL2 apoptosis regulator Homo sapiens 151-155 24931256-0 2014 MiR-503 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R and BCL2. Cisplatin 18-27 BCL2 apoptosis regulator Homo sapiens 97-101 25610487-7 2014 Moreover, EOFAZ was found to upregulate Bcl-2 protein and mRNA levels and to attenuate ox-LDL-induced HAECs injury caused by apoptosis, revealing both its therapeutic potential for endothelial cell injury protection and its clinical application for atherosclerosis. eofaz 10-15 BCL2 apoptosis regulator Homo sapiens 40-45 25374001-10 2014 We and others show, that low BCL2 expression was associated with good outcome of TNBC patients treated with both adjuvant and neoadjuvant anthracycline-based chemotherapy. Anthracyclines 138-151 BCL2 apoptosis regulator Homo sapiens 29-33 25268087-10 2014 On the molecular level, our results showed that saikosaponin-d treatment increased the expression of p53 and bax, and decreased the expression of Bcl-2. saikosaponin D 48-62 BCL2 apoptosis regulator Homo sapiens 146-151 25016705-2 2014 METHODS: The presence of the Bcl-2/IgH fusion gene was detected in BM samples and paraffin-embedded lymph node (LN) samples from 103 patients with DLBCLs using FISH. Paraffin 82-90 BCL2 apoptosis regulator Homo sapiens 29-34 25016705-4 2014 RESULTS: Bcl-2/IgH translocation in paraffin-embedded LN tissue sections was observed in 43 (41.7%) patients by FISH. Paraffin 36-44 BCL2 apoptosis regulator Homo sapiens 9-14 24091880-12 2014 Bax mRNA and protein levels were increased while bcl-2 mRNA levels were decreased after daphnoretin treatment. daphnoretin 88-99 BCL2 apoptosis regulator Homo sapiens 49-54 24812569-8 2014 The data showed that incubation of cells with TCE (200 and 250 mu g/mL) significantly increased cell damage, activated caspase 3 and Bax/Bcl2 ratio. Trichloroethylene 46-49 BCL2 apoptosis regulator Homo sapiens 138-142 24211866-2 2014 Exposure of human HCC HepG2 cells to OLO-2 results in significant loss of mitochondrial transmembrane potential (DeltaPsim), the release of cytochrome c, the recruitment of B-cell lymphoma 2 (Bcl-2) assaciated X protein (Bax) and the downregulation of Bcl-2. olean-28-13beta-olide-2 37-42 BCL2 apoptosis regulator Homo sapiens 173-190 24231340-7 2014 Treatment with gamma-tocotrienol also caused a reduction in PI3K/Akt/mTOR signaling and a corresponding increase in the Bax/Bcl-2 ratio, cleaved caspase-3, and cleaved poly (ADP-ribose) polymerase (PARP) levels in these cancer cell lines, suggesting that gamma-tocotrienol-induced autophagy may be involved in the initiation of apoptosis. plastochromanol 8 15-32 BCL2 apoptosis regulator Homo sapiens 124-129 24173143-8 2014 We found that GA downregulated the expression of the anti-apoptotic protein Bcl-2, and upregulated the expression of the pro-apoptotic protein Bax, and the activation of caspase-3 and caspase-9. Gallic Acid 14-16 BCL2 apoptosis regulator Homo sapiens 76-81 24403829-9 2014 Further experiments including fluorescence activated cell sorting and Western blotting indicated that this Trojan strategy of delivering Tet in PVP-b-PCL nanoparticles via endocytosis leads to enhanced induction of apoptosis in the non-small cell lung cancer cell A549 line; enhanced apoptosis is achieved by inhibiting the expression of anti-apoptotic Bcl-2 and Bcl-xL proteins. tetrandrine 137-140 BCL2 apoptosis regulator Homo sapiens 353-358 24685625-9 2014 Western blot and immunofluorescence analysis showed that exposure to celastrol increased HSP-70 and Bcl-2 expression but decreased NFkappaB activity, phosphorylated glycogen synthase kinase-3beta (GSK-3beta) at tyrosine 216 and cyclooxygenase-2 (COX-2) expression, Abeta accumulation together with a reduction of superoxide and hydrogen peroxide generation. celastrol 69-78 BCL2 apoptosis regulator Homo sapiens 100-105 25176222-7 2014 Furthermore, l-NBP could partially reverse the elevations of Abeta25-35-induced active caspase-3, caspase-9, and cytochrome c expressions, and the downregulation of anti-apoptosis protein Bcl-2. l 13-14 BCL2 apoptosis regulator Homo sapiens 188-193 25176222-7 2014 Furthermore, l-NBP could partially reverse the elevations of Abeta25-35-induced active caspase-3, caspase-9, and cytochrome c expressions, and the downregulation of anti-apoptosis protein Bcl-2. nbp 15-18 BCL2 apoptosis regulator Homo sapiens 188-193 24190517-11 2014 In particular, MHY412 is a new candidate agent for the treatment of Bcl-2 overexpressed doxorubicin-resistant human breast cancer. mhy412 15-21 BCL2 apoptosis regulator Homo sapiens 68-73 24190517-11 2014 In particular, MHY412 is a new candidate agent for the treatment of Bcl-2 overexpressed doxorubicin-resistant human breast cancer. Doxorubicin 88-99 BCL2 apoptosis regulator Homo sapiens 68-73 24279338-11 2014 CONCLUSIONS: The data suggests that FASLG, BCL2, CASP3 and apoptosis play a role in the inflammatory responses following prolonged plutonium exposure. Plutonium 131-140 BCL2 apoptosis regulator Homo sapiens 43-47 24685625-11 2014 CONCLUSION: This study demonstrates that celastrol reduced both LPS-induced cell death and Abeta production in vitro through increasing HSP-70 and Bcl-2 expression and reducing NFkappaB, COX-2, and GSK-3beta expression and oxidative stress. celastrol 41-50 BCL2 apoptosis regulator Homo sapiens 147-152 24028527-8 2014 At 800 K, the Bcl-2 core is destabilized suggesting a possible mechanism for protein unfolding, where the alpha helices 1 and 6 were the most stable, and a reduction in the number of hydrogen bonds initially occurs. Hydrogen 183-191 BCL2 apoptosis regulator Homo sapiens 14-19 24211866-2 2014 Exposure of human HCC HepG2 cells to OLO-2 results in significant loss of mitochondrial transmembrane potential (DeltaPsim), the release of cytochrome c, the recruitment of B-cell lymphoma 2 (Bcl-2) assaciated X protein (Bax) and the downregulation of Bcl-2. olean-28-13beta-olide-2 37-42 BCL2 apoptosis regulator Homo sapiens 192-197 24211866-2 2014 Exposure of human HCC HepG2 cells to OLO-2 results in significant loss of mitochondrial transmembrane potential (DeltaPsim), the release of cytochrome c, the recruitment of B-cell lymphoma 2 (Bcl-2) assaciated X protein (Bax) and the downregulation of Bcl-2. olean-28-13beta-olide-2 37-42 BCL2 apoptosis regulator Homo sapiens 252-257 24292713-7 2014 Treatment with both ATN-224 and ABT-263, an inhibitor of the apoptosis regulators BCL2/BCLXL, augmented cell death. tetrathiomolybdate 20-27 BCL2 apoptosis regulator Homo sapiens 82-86 24659662-7 2014 Increased mRNA expressions of caspase gene family members, activated caspase-3 and decreased mRNA and protein expression of BCL-2 gene indicated apoptotic response to capsaicin. Capsaicin 167-176 BCL2 apoptosis regulator Homo sapiens 124-129 24292713-7 2014 Treatment with both ATN-224 and ABT-263, an inhibitor of the apoptosis regulators BCL2/BCLXL, augmented cell death. navitoclax 32-39 BCL2 apoptosis regulator Homo sapiens 82-86 24558306-5 2014 Ginsenoside 20(S)-Rg3 induced apoptosis through activation of caspase-3, caspase-8, and caspase-9, as well as regulation of Bcl-2 and Bax expression. ginsenoside 20 0-14 BCL2 apoptosis regulator Homo sapiens 124-129 25509983-7 2014 Treatment with PM also inhibited the expression of NF-kappaB-regulated antiapoptotic Bcl-2, Bcl-xL, c-IAP1 and survivin. pristimerin 15-17 BCL2 apoptosis regulator Homo sapiens 85-90 24558306-5 2014 Ginsenoside 20(S)-Rg3 induced apoptosis through activation of caspase-3, caspase-8, and caspase-9, as well as regulation of Bcl-2 and Bax expression. Sulfur 14-17 BCL2 apoptosis regulator Homo sapiens 124-129 23797737-7 2014 Further studies found that pre-incubation with calycosin at 1 x 10(-8) M dramatically increased anti-apoptotic Bcl-2 while decreased pro-apoptotic Bax and Bad expressions as detected by immunocytochemistry, and the effect of calycosin on rebalancing the ratio of Bcl-2/Bax was more significant than that of its glycoside, calycosin-7-O-beta-D-glucopyranoside (CG). 7,3'-dihydroxy-4'-methoxyisoflavone 47-56 BCL2 apoptosis regulator Homo sapiens 111-116 24052572-3 2014 We and others have shown recently that neoplastic MC in ASM and MCL express antiapoptotic Mcl-1, Bcl-2, and Bcl-xL. Methylcholanthrene 50-52 BCL2 apoptosis regulator Homo sapiens 97-102 23797737-7 2014 Further studies found that pre-incubation with calycosin at 1 x 10(-8) M dramatically increased anti-apoptotic Bcl-2 while decreased pro-apoptotic Bax and Bad expressions as detected by immunocytochemistry, and the effect of calycosin on rebalancing the ratio of Bcl-2/Bax was more significant than that of its glycoside, calycosin-7-O-beta-D-glucopyranoside (CG). 7,3'-dihydroxy-4'-methoxyisoflavone 47-56 BCL2 apoptosis regulator Homo sapiens 263-268 24881958-3 2014 Here, we reported that UA induced apoptosis through the mitochondrial intrinsic pathway in HeLa cells, as shown by release of cytosol cytochrome c, activation of caspase-9 and -3, reduction of Bcl-2 and Bcl-xL, and increase of Bax and Bak. ursolic acid 23-25 BCL2 apoptosis regulator Homo sapiens 193-198 24881958-6 2014 U0126 markedly increased UA-induced the Bax/Bcl-2 ratio, the increase of cytosol cytochrome c, and the levels of cleaved caspase-3, but SB203580 had little effects on the above characters, suggesting the ERK1/2 signaling pathway is required for apoptosis. U 0126 0-5 BCL2 apoptosis regulator Homo sapiens 44-49 24881958-6 2014 U0126 markedly increased UA-induced the Bax/Bcl-2 ratio, the increase of cytosol cytochrome c, and the levels of cleaved caspase-3, but SB203580 had little effects on the above characters, suggesting the ERK1/2 signaling pathway is required for apoptosis. ursolic acid 25-27 BCL2 apoptosis regulator Homo sapiens 44-49 24248012-10 2014 Furthermore, western blot analysis showed that PAB treatment upregulated the protein levels of Bax, Bad and downregulated Bcl-2 and Bcl-xl expression. pseudolaric acid B 47-50 BCL2 apoptosis regulator Homo sapiens 122-127 24346101-0 2014 Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer. Obatoclax mesylate 0-18 BCL2 apoptosis regulator Homo sapiens 26-31 24346101-1 2014 INTRODUCTION: The proapoptotic small-molecule pan-Bcl-2 inhibitor obatoclax mesylate (GX15-070) may enhance the cytotoxicity of chemotherapy in relapsed/refractory non-small-cell lung cancer (NSCLC). Obatoclax mesylate 66-84 BCL2 apoptosis regulator Homo sapiens 50-55 24346101-1 2014 INTRODUCTION: The proapoptotic small-molecule pan-Bcl-2 inhibitor obatoclax mesylate (GX15-070) may enhance the cytotoxicity of chemotherapy in relapsed/refractory non-small-cell lung cancer (NSCLC). obatoclax 86-94 BCL2 apoptosis regulator Homo sapiens 50-55 25343295-6 2014 Auranofin activated caspase-3 and -8 in a concentration-dependent manner and decreased the levels of mitochondrial anti-apoptotic factors, such as Bcl-2 and Bcl-xL. Auranofin 0-9 BCL2 apoptosis regulator Homo sapiens 147-152 23860449-0 2014 The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. BH 3 19-22 BCL2 apoptosis regulator Homo sapiens 4-9 23966347-6 2014 The micelleplexes are further exploited for co-delivery of siRNA-Bcl-2 and PTX to Bcl-2 overexpressing A549 lung cancer cells (A549-Bcl-2). Paclitaxel 75-78 BCL2 apoptosis regulator Homo sapiens 82-87 23966347-6 2014 The micelleplexes are further exploited for co-delivery of siRNA-Bcl-2 and PTX to Bcl-2 overexpressing A549 lung cancer cells (A549-Bcl-2). Paclitaxel 75-78 BCL2 apoptosis regulator Homo sapiens 82-87 23966347-7 2014 The experimental results show that the micelleplexes could sensitize A549-Bcl-2 cells to PTX via down-regulation of anti-apoptosis gene of Bcl-2, suggesting that PDMA-b-PDPA micelleplexes are promising nanovectors for siRNA and anti-cancer drug co-delivery to overcome cancer MDR. Paclitaxel 89-92 BCL2 apoptosis regulator Homo sapiens 74-79 23966347-7 2014 The experimental results show that the micelleplexes could sensitize A549-Bcl-2 cells to PTX via down-regulation of anti-apoptosis gene of Bcl-2, suggesting that PDMA-b-PDPA micelleplexes are promising nanovectors for siRNA and anti-cancer drug co-delivery to overcome cancer MDR. Paclitaxel 89-92 BCL2 apoptosis regulator Homo sapiens 139-144 23715406-8 2014 In tissues from postmenopausal women, DHT either induced or repressed BCL2 expression, and the antiandrogenic effect of MPA on BCL2 was variable. Dihydrotestosterone 38-41 BCL2 apoptosis regulator Homo sapiens 70-74 24966472-7 2014 The expression of Bcl-2, Bax, Beclin-1, and LC3, which play important roles in the regulation of the apoptosis and autophagy pathways, was also clearly affected by NaHS. sodium bisulfide 164-168 BCL2 apoptosis regulator Homo sapiens 18-23 24974285-4 2014 For example, we developed stabilized alpha-helices of BCL-2 domains (SAHBs) to dissect and target protein interactions of the BCL-2 family, a critical network that regulates the apoptotic pathway. sahbs 69-74 BCL2 apoptosis regulator Homo sapiens 54-59 24974285-4 2014 For example, we developed stabilized alpha-helices of BCL-2 domains (SAHBs) to dissect and target protein interactions of the BCL-2 family, a critical network that regulates the apoptotic pathway. sahbs 69-74 BCL2 apoptosis regulator Homo sapiens 126-131 24974285-5 2014 SAHBs are alpha-helical surrogates that bind both stable and transient physiologic interactors and have effectively uncovered novel sites of BCL-2 family protein interaction. sahbs 0-5 BCL2 apoptosis regulator Homo sapiens 141-146 24190492-7 2014 In addition Bcl-2 is a critical target for Purvalanol A, since Bcl-2 overexpressed cells are more resistant to Purvalanol A-mediated apoptosis. 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine 43-55 BCL2 apoptosis regulator Homo sapiens 12-17 24190492-7 2014 In addition Bcl-2 is a critical target for Purvalanol A, since Bcl-2 overexpressed cells are more resistant to Purvalanol A-mediated apoptosis. 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine 43-55 BCL2 apoptosis regulator Homo sapiens 63-68 24190492-7 2014 In addition Bcl-2 is a critical target for Purvalanol A, since Bcl-2 overexpressed cells are more resistant to Purvalanol A-mediated apoptosis. 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine 111-123 BCL2 apoptosis regulator Homo sapiens 12-17 24190492-7 2014 In addition Bcl-2 is a critical target for Purvalanol A, since Bcl-2 overexpressed cells are more resistant to Purvalanol A-mediated apoptosis. 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine 111-123 BCL2 apoptosis regulator Homo sapiens 63-68 24173825-5 2014 Pretreatment of CRC cells with caffeine significantly inhibited paclitaxel-induced cytotoxicity by increasing the levels of the antiapoptotic Bcl-2 family member, Mcl-1. Caffeine 31-39 BCL2 apoptosis regulator Homo sapiens 142-147 24173825-5 2014 Pretreatment of CRC cells with caffeine significantly inhibited paclitaxel-induced cytotoxicity by increasing the levels of the antiapoptotic Bcl-2 family member, Mcl-1. Paclitaxel 64-74 BCL2 apoptosis regulator Homo sapiens 142-147 24190282-7 2014 Tetracycline on/off transfected cell lines exhibited a lower relative expression of antiapoptotic Bcl-2 compared with their originating LYD cells. Tetracycline 0-12 BCL2 apoptosis regulator Homo sapiens 98-103 25196016-5 2014 Everolimus induced cell cycle arrest at the G1 phase by downregulating cyclin D1 and upregulating p27, and increased apoptosis by downregulating Bcl-2, upregulating Bad and activating capsase-3 and poly ADP ribose polymerase. Everolimus 0-10 BCL2 apoptosis regulator Homo sapiens 145-150 24299314-0 2014 Autophagy inhibition enhances pan-Bcl-2 inhibitor AT-101-induced apoptosis in non-small cell lung cancer. gossypol acetic acid 50-56 BCL2 apoptosis regulator Homo sapiens 34-39 26629938-4 2014 Our results showed the increase of the percent of apoptotic cells and G1 phase, the inhibition of cell migrations well as the decrease of the expression of Bax, caspase 3 and Bcl-2 in BGC-823 cells after the treatment with UA. ursolic acid 223-225 BCL2 apoptosis regulator Homo sapiens 175-180 24214023-6 2014 Similarly, celastrol treatment inhibited cytochrome c release, Bax/Bcl-2 ratio changes, and caspase-9/3 activation. celastrol 11-20 BCL2 apoptosis regulator Homo sapiens 67-72 25095809-8 2014 CAG treatment not only induced the expression of bcl2, a CREB-regulated gene, but also the expression of telomerase reverse transcriptase in primary cortical neurons. cycloastragenol 0-3 BCL2 apoptosis regulator Homo sapiens 49-53 24660968-5 2014 After LPAE treatment, the proliferation and colony formation of cancer cells decreased; apoptotic cells increased; DNA fragmentations were evident; mRNA and protein expressions of PPARgamma, Bax, and caspase-3 genes increased and expressions of cyclin D1 and Bcl-2 genes decreased; in vivo experiment, LPAE inhibited human beast cancer growth. lpae 6-10 BCL2 apoptosis regulator Homo sapiens 259-264 24660968-6 2014 The findings in this experimental study suggested that LPAE has potential cytotoxic and apoptotic effects on human breast cancer cells in vitro and inhibits the cancer growth in vivo, and its mechanism of activity might be associated with apoptosis induction of cancer cells through upregulation of the mRNA and protein expressions of PPARgamma, Bax, and capase-3 genes and downregulation of the expressions of cyclin D1 and Bcl-2 genes. lpae 55-59 BCL2 apoptosis regulator Homo sapiens 425-430 24666255-0 2014 Formononetin induces apoptosis in PC-3 prostate cancer cells through enhancing the Bax/Bcl-2 ratios and regulating the p38/Akt pathway. formononetin 0-12 BCL2 apoptosis regulator Homo sapiens 87-92 24854102-2 2014 When compared with a blank control group, the proportion of apoptotic cells undergoing Beclin 1 interfering increased significantly after cisplatin treatment, accompanied by reduction in mitochondrial membrane potential, increase in activities of caspase-9/3 and cytoplasmic cytochrome C, elevation of Bax expression, and reduction in Bcl-2 expression. Cisplatin 138-147 BCL2 apoptosis regulator Homo sapiens 335-340 24195616-4 2014 PEITC treatment induced G2/M phase cell cycle arrest, downregulated the antiapoptotic proteins Bcl-2 and Bcl-XL, upregulated the proapoptotic protein Bak, and suppressed Notch 1 and 2 levels. phenethyl isothiocyanate 0-5 BCL2 apoptosis regulator Homo sapiens 95-100 24348832-12 2014 Cisplatin reduced the expression of Bcl-2 protein, while VX680 did not. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 36-41 25140197-1 2014 While p53-dependent apoptosis is triggered by combination of methyltransferase inhibitor decitabine (DAC) and histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in leukemic cell line CML-T1, reactive oxygen species (ROS) generation as well as survivin and Bcl-2 deregulation participated in DAC + SAHA-induced apoptosis in p53-deficient HL-60 cell line. Vorinostat 173-177 BCL2 apoptosis regulator Homo sapiens 274-279 26629939-4 2014 Treatment with brucine reduced the expression of BCL-2 and cyclooxygenase-2 (COX-2), while upregulated BAX expression in U251 human glioma cells resulted in reduced glioma cell survival rate and inhibited the growth of xenograft tumors. brucine 15-22 BCL2 apoptosis regulator Homo sapiens 49-54 25247444-9 2014 Cell apoptosis triggered by high glucose was also inhibited by L-carnitine, characterized by the downregulation of caspase-9, caspase-3 and Bax/Bcl-2. Glucose 33-40 BCL2 apoptosis regulator Homo sapiens 144-149 24662601-4 2014 Treatment of tBHP resulted in apoptotic cell death as assessed by TUNEL assay and the expression of apoptosis regulator proteins, Bcl-2 family, caspases and cytochrome c. tert-Butylhydroperoxide 13-17 BCL2 apoptosis regulator Homo sapiens 130-135 25247444-9 2014 Cell apoptosis triggered by high glucose was also inhibited by L-carnitine, characterized by the downregulation of caspase-9, caspase-3 and Bax/Bcl-2. Carnitine 63-74 BCL2 apoptosis regulator Homo sapiens 144-149 24338554-4 2014 Western blotting analysis elucidated that: A) Tenacissoside C induced K562 cell cycle (G0/G1) arrest via downregulating cycline D1 protein expression; and B) Tenacissoside C induced K562 cell apoptosis via the mitochondrial pathway by downregulating Bcl-2 and Bcl-xL protein expression, upregulating Bax and Bak protein expression, and activating caspase-9 and caspase-3. tenacissoside C 46-61 BCL2 apoptosis regulator Homo sapiens 250-255 24338554-4 2014 Western blotting analysis elucidated that: A) Tenacissoside C induced K562 cell cycle (G0/G1) arrest via downregulating cycline D1 protein expression; and B) Tenacissoside C induced K562 cell apoptosis via the mitochondrial pathway by downregulating Bcl-2 and Bcl-xL protein expression, upregulating Bax and Bak protein expression, and activating caspase-9 and caspase-3. tenacissoside C 158-173 BCL2 apoptosis regulator Homo sapiens 250-255 24414307-2 2014 A further in vitro experiment showed that the pretreatment with arctigenin on cultured human neuroblastoma SH-SY5Y cells could obviously attenuate the decrease of cell survival rates caused by treatment with 1-methyl-4-phenylpyridinium ion by way of acting against cell apoptosis through the decrease of Bax/Bcl-2 and caspase-3, and by antioxidative action through reduction of the surplus reactive oxygen species production and downregulation of mitochondrial membrane potential. arctigenin 64-74 BCL2 apoptosis regulator Homo sapiens 308-313 24414307-2 2014 A further in vitro experiment showed that the pretreatment with arctigenin on cultured human neuroblastoma SH-SY5Y cells could obviously attenuate the decrease of cell survival rates caused by treatment with 1-methyl-4-phenylpyridinium ion by way of acting against cell apoptosis through the decrease of Bax/Bcl-2 and caspase-3, and by antioxidative action through reduction of the surplus reactive oxygen species production and downregulation of mitochondrial membrane potential. 1-Methyl-4-phenylpyridinium 208-239 BCL2 apoptosis regulator Homo sapiens 308-313 24967145-0 2014 Bcl2 Family Functions as Signaling Target in Nicotine-/NNK-Induced Survival of Human Lung Cancer Cells. Nicotine 45-53 BCL2 apoptosis regulator Homo sapiens 0-4 24967145-7 2014 In the past several years, multiple signaling links between nicotine/NNK and Bcl2 family members have been identified that regulate survival and proliferation. Nicotine 60-68 BCL2 apoptosis regulator Homo sapiens 77-81 24240096-4 2013 NMR experiments revealed that the interaction critically depends on a three-residue segment (EWD) of Bcl-2 adjacent to the BH4 region, which is anchored to one of the two hydrophobic pockets on the GABARAP molecule. sapropterin 123-126 BCL2 apoptosis regulator Homo sapiens 101-106 25696988-0 2014 [Dexamethasone affect on the expression of bcl-2 and mTOR genes in T-lymphocytes from healthy donors]. Dexamethasone 1-14 BCL2 apoptosis regulator Homo sapiens 43-48 25696988-4 2014 Therefore, in this paper we have analyzed the influence of dexamethasone on the expression of bcl-2 and mTOR genes in T-lymphocytes from healthy donors. Dexamethasone 59-72 BCL2 apoptosis regulator Homo sapiens 94-99 25696988-5 2014 The results showed that dexamethasone reduced the expression of bcl-2 and mTOR genes. Dexamethasone 24-37 BCL2 apoptosis regulator Homo sapiens 64-69 25696988-6 2014 However, the nature of the effect of dexamethasone on mTOR and bcl-2 expression was different: the expression of bcl-2 gene in the long-term cultivation was maintained at the same reduced level, while the expression of mTOR was first reduced and then increased. Dexamethasone 37-50 BCL2 apoptosis regulator Homo sapiens 63-68 25696988-6 2014 However, the nature of the effect of dexamethasone on mTOR and bcl-2 expression was different: the expression of bcl-2 gene in the long-term cultivation was maintained at the same reduced level, while the expression of mTOR was first reduced and then increased. Dexamethasone 37-50 BCL2 apoptosis regulator Homo sapiens 113-118 24370277-6 2013 Besides, negative Bcl-2 expression was significantly associated with good OR and pathological CR in anthracycline-based chemotherapy subgroup. Anthracyclines 100-113 BCL2 apoptosis regulator Homo sapiens 18-23 24370277-7 2013 Furthermore, there were significant links between negative Bcl-2 expression and taxane-based chemotherapy with pathological CR, but not OR. taxane 80-86 BCL2 apoptosis regulator Homo sapiens 59-64 23929391-6 2014 Moreover, we found that depletion of GRP94 altered the levels of the apoptosis-related proteins Bcl2 and Bad, leading to sensitivity to taxane. taxane 136-142 BCL2 apoptosis regulator Homo sapiens 96-100 23685020-3 2014 PATIENTS AND METHODS: A retrospective analysis was conducted on 221 patients with mCRPC treated with docetaxel plus prednisone combined with AT-101 (bcl-2 antagonist) or placebo on a prospective randomized phase II trial. gossypol acetic acid 141-147 BCL2 apoptosis regulator Homo sapiens 149-154 25552063-3 2014 In experimental studies it was showed that synthetic antineoplastons (A10-3-phenyl-acetyl-amino-2,6-piperidinedione and AS2-1--a mixture of phenylacetic acid and phenylacetylglutamine) were able to prevent the introduction of glutamine into the cell, to block the action of Bcl-2, to activate p53 and p21, to inhibit histone deacetylase, to induce apoptosis. a10-3-phenyl-acetyl-amino-2,6-piperidinedione 70-115 BCL2 apoptosis regulator Homo sapiens 274-279 25552063-3 2014 In experimental studies it was showed that synthetic antineoplastons (A10-3-phenyl-acetyl-amino-2,6-piperidinedione and AS2-1--a mixture of phenylacetic acid and phenylacetylglutamine) were able to prevent the introduction of glutamine into the cell, to block the action of Bcl-2, to activate p53 and p21, to inhibit histone deacetylase, to induce apoptosis. as2-1--a 120-128 BCL2 apoptosis regulator Homo sapiens 274-279 25548604-0 2014 Simvastatin inhibits apoptosis of endothelial cells induced by sepsis through upregulating the expression of Bcl-2 and downregulating Bax. Simvastatin 0-11 BCL2 apoptosis regulator Homo sapiens 109-114 25548604-8 2014 Expression of the Bcl-2 gene in HUVECs decreased obviously, but the expression of the Bax gene increased obviously after 24-hour incubation with sepsis serum; however, the expression of the Bcl-2 and Bax genes was just the opposite in the simvastatin group. Simvastatin 239-250 BCL2 apoptosis regulator Homo sapiens 18-23 25548604-8 2014 Expression of the Bcl-2 gene in HUVECs decreased obviously, but the expression of the Bax gene increased obviously after 24-hour incubation with sepsis serum; however, the expression of the Bcl-2 and Bax genes was just the opposite in the simvastatin group. Simvastatin 239-250 BCL2 apoptosis regulator Homo sapiens 190-195 25548604-9 2014 CONCLUSIONS: Our study suggests that simvastatin can inhibit apoptosis of endothelial cells induced by sepsis through upregulating the expression of Bcl-2 and downregulating Bax. Simvastatin 37-48 BCL2 apoptosis regulator Homo sapiens 149-154 24161785-7 2013 The root cause for increase in BAD and decrease in Bcl-2 which altogether initiated caspase-dependent apoptosis were predominantly due to down-regulation the expression of EGFR after PS-101 treatment. PS-101 183-189 BCL2 apoptosis regulator Homo sapiens 51-56 24368570-9 2013 Gliotoxin-induced activation of caspase-3, caspase-8 and caspase-9, down-regulation of Bcl-2, up-regulation of Bax and cytochromec (cyt c) release showed evidence for the gliotoxin activity on apoptosis. Gliotoxin 0-9 BCL2 apoptosis regulator Homo sapiens 87-92 24351910-4 2013 Towards achieving this goal, several researchers have carried out studies in various cell lines and in vivo and have deciphered that fucoxanthin exerts its anti-proliferative and cancer preventing influence via different molecules and pathways including the Bcl-2 proteins, MAPK, NFkappaB, Caspases, GADD45, and several other molecules that are involved in either cell cycle arrest, apoptosis, or metastasis. fucoxanthin 133-144 BCL2 apoptosis regulator Homo sapiens 258-263 24367627-2 2013 The present study examined whether the BH3 mimetics, Obatoclax and ABT-737, which inhibit multiple anti-apoptotic Bcl-2 family proteins, would overcome resistance to apoptosis. BH 3 39-42 BCL2 apoptosis regulator Homo sapiens 114-119 24367627-2 2013 The present study examined whether the BH3 mimetics, Obatoclax and ABT-737, which inhibit multiple anti-apoptotic Bcl-2 family proteins, would overcome resistance to apoptosis. ABT-737 67-74 BCL2 apoptosis regulator Homo sapiens 114-119 24367627-4 2013 These results demonstrate that inhibition of anti-apoptotic Bcl-2 proteins by Obatoclax and ABT-737 appears to elicit a protective feedback response in melanoma cells, by upregulation of Mcl-1 via induction of the UPR. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 92-95 BCL2 apoptosis regulator Homo sapiens 60-65 24231363-4 2013 DPMA inhibited microtubule formation and induced expression of Bax, cleaved caspase-3, p53 and ROS, and inhibited Bcl-2 expression. CGS 24012 0-4 BCL2 apoptosis regulator Homo sapiens 114-119 24161785-8 2013 PS-101 strongly down-regulated the EGFR expression to trigger proapototic protein BAD increase and antiproapototic protein Bcl-2 decrease, which altogether actived effector caspase-3/9 to initiate cell apoptisis. PS-101 0-6 BCL2 apoptosis regulator Homo sapiens 123-128 24215352-4 2013 The key structure for Bcl-xL inhibition was further confirmed through the substructural analysis of ABT-263, a representative Bcl-xL/Bcl-2/Bcl-w inhibitor developed by Abbott Laboratories. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 100-103 BCL2 apoptosis regulator Homo sapiens 133-138 24363520-10 2013 The up-regulation of Bax and down-regulation of Bcl-2 showed that the essential mechanism of apoptosis induced by SIN and 5-FU occurs via the mitochondrial pathway. sinomenine 114-117 BCL2 apoptosis regulator Homo sapiens 48-53 24133218-4 2013 Here, we identify a new synergistic lethality of AZD8055 together with ABT-737, a BH3 mimetic that antagonizes Bcl-2, Bcl-xL, and Bcl-w but not Mcl-1. (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol 49-56 BCL2 apoptosis regulator Homo sapiens 111-116 24133218-4 2013 Here, we identify a new synergistic lethality of AZD8055 together with ABT-737, a BH3 mimetic that antagonizes Bcl-2, Bcl-xL, and Bcl-w but not Mcl-1. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 71-74 BCL2 apoptosis regulator Homo sapiens 111-116 24133218-4 2013 Here, we identify a new synergistic lethality of AZD8055 together with ABT-737, a BH3 mimetic that antagonizes Bcl-2, Bcl-xL, and Bcl-w but not Mcl-1. BH 3 82-85 BCL2 apoptosis regulator Homo sapiens 111-116 24363520-10 2013 The up-regulation of Bax and down-regulation of Bcl-2 showed that the essential mechanism of apoptosis induced by SIN and 5-FU occurs via the mitochondrial pathway. Fluorouracil 122-126 BCL2 apoptosis regulator Homo sapiens 48-53 24349321-12 2013 Paclitaxel, androgen, and inhibitors for PI3K/Akt, EGFR, Src, or Bcl-2 seem to be potential choices for treatment of advanced prostate cancers. Paclitaxel 0-10 BCL2 apoptosis regulator Homo sapiens 65-70 23455184-3 2013 The major aim of this study was to further define the expression pattern and the prognostic role of Bcl-2 together with BAG-1, BAG-3, and BAG-4 proteins in EOC patients receiving platinum/taxane-based chemotherapy. Platinum 179-187 BCL2 apoptosis regulator Homo sapiens 100-105 24002658-3 2013 We recently had demonstrated that the beta-adrenoceptor/cAMP-PKA pathway triggers apoptosis through the transcriptional induction of the pro-apoptotic BH3-only Bcl-2 family member BIM in tissues, such as the thymus and the heart. Cyclic AMP 56-60 BCL2 apoptosis regulator Homo sapiens 160-165 23438827-3 2013 Moreover, myricetin triggered translocation of the pro-apoptotic protein Bax to the mitochondria, downregulation of anti-apoptotic Bcl-2 expression and upregulated the expression of pro-apoptotic protein Bad in the mitochondria. myricetin 10-19 BCL2 apoptosis regulator Homo sapiens 131-136 24324063-5 2013 Furthermore, the production of lactate and expression of the nuclear factor-kappa B (NF-kappaB)-regulated genes B cell lymphoma-2 (BCL2), cyclooxygenase-2 (COX2), and vascular endothelial growth factor (VEGF) were higher in 3D cultures than in 2D cultures. Lactic Acid 31-38 BCL2 apoptosis regulator Homo sapiens 112-129 24324063-5 2013 Furthermore, the production of lactate and expression of the nuclear factor-kappa B (NF-kappaB)-regulated genes B cell lymphoma-2 (BCL2), cyclooxygenase-2 (COX2), and vascular endothelial growth factor (VEGF) were higher in 3D cultures than in 2D cultures. Lactic Acid 31-38 BCL2 apoptosis regulator Homo sapiens 131-135 23455184-3 2013 The major aim of this study was to further define the expression pattern and the prognostic role of Bcl-2 together with BAG-1, BAG-3, and BAG-4 proteins in EOC patients receiving platinum/taxane-based chemotherapy. taxane 188-194 BCL2 apoptosis regulator Homo sapiens 100-105 24145463-12 2013 2DG decreased LAMP1 and increased BCL2 levels suggesting that its effects on autophagy may be mediated by more than one mechanism. Deoxyglucose 0-3 BCL2 apoptosis regulator Homo sapiens 34-38 24099795-9 2013 In summary, the data suggest that reevesioside F induces apoptosis through the down-regulation of survivin and Mcl-1, and the formation of pro-apoptotic fragments from Bcl-2 family members. reevesioside F 34-48 BCL2 apoptosis regulator Homo sapiens 168-173 23988738-5 2013 Several pathways have been described where we highlight the participation of the BCL-2 family of proteins and ER calcium release. Calcium 113-120 BCL2 apoptosis regulator Homo sapiens 81-86 24219281-3 2013 Flow cytometry and caspases activity assays revealed apoptosis had been induced in these cells; RT-PCR and Western blot analyses revealed the suppression of Bcl-2 and up-regulation of Bax expression in AGS cells treated with crocetin. crocetin 225-233 BCL2 apoptosis regulator Homo sapiens 157-162 24097825-0 2013 Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance. bakuchiol 41-44 BCL2 apoptosis regulator Homo sapiens 16-21 23803693-3 2013 Treatment of Panc1, L3.6pL and Panc28 pancreatic cancer cells with metformin downregulated Sp1, Sp3 and Sp4 proteins and several pro-oncogenic Sp-regulated genes including bcl-2, survivin, cyclin D1, vascular endothelial growth factor and its receptor, and fatty acid synthase. Metformin 67-76 BCL2 apoptosis regulator Homo sapiens 172-177 23841818-8 2013 During ischemia, MG caused an impairment of survival pathways and Bcl-2/Bax ratio, a marker of apoptosis. Pyruvaldehyde 17-19 BCL2 apoptosis regulator Homo sapiens 66-71 24097825-1 2013 Bcl-2 is phosphorylated on Ser(70) after treatment of cells with spindle poisons. Serine 27-30 BCL2 apoptosis regulator Homo sapiens 0-5 24097825-4 2013 Surface plasmon resonance indicated that phosphorylated Bcl-2, Bcl-2 S70E, and Bcl-2 S70A exhibit enhanced binding to Bim and Bak compared with unmodified Bcl-2. bakuchiol 126-129 BCL2 apoptosis regulator Homo sapiens 56-61 24097825-4 2013 Surface plasmon resonance indicated that phosphorylated Bcl-2, Bcl-2 S70E, and Bcl-2 S70A exhibit enhanced binding to Bim and Bak compared with unmodified Bcl-2. bakuchiol 126-129 BCL2 apoptosis regulator Homo sapiens 63-68 24097825-2 2013 On the basis of effects observed in cells overexpressing Bcl-2 S70E or S70A mutants, various studies have concluded that Ser(70) phosphorylation either enhances or diminishes Bcl-2 function. Serine 121-124 BCL2 apoptosis regulator Homo sapiens 57-62 24097825-4 2013 Surface plasmon resonance indicated that phosphorylated Bcl-2, Bcl-2 S70E, and Bcl-2 S70A exhibit enhanced binding to Bim and Bak compared with unmodified Bcl-2. bakuchiol 126-129 BCL2 apoptosis regulator Homo sapiens 63-68 24097825-4 2013 Surface plasmon resonance indicated that phosphorylated Bcl-2, Bcl-2 S70E, and Bcl-2 S70A exhibit enhanced binding to Bim and Bak compared with unmodified Bcl-2. bakuchiol 126-129 BCL2 apoptosis regulator Homo sapiens 63-68 24097825-2 2013 On the basis of effects observed in cells overexpressing Bcl-2 S70E or S70A mutants, various studies have concluded that Ser(70) phosphorylation either enhances or diminishes Bcl-2 function. Serine 121-124 BCL2 apoptosis regulator Homo sapiens 175-180 24097825-6 2013 Furthermore, Bcl-2 S70E and S70A bound more Bak and Bim than wild-type Bcl-2 in pull-downs and afforded greater protection against several chemotherapeutic agents. bakuchiol 44-47 BCL2 apoptosis regulator Homo sapiens 13-18 24289071-5 2013 Western blot analysis showed that geraniin inhibited Bcl-2 expression and induced Bax expression to disintegrate the outer mitochondrial membrane and cause cytochrome c release. Geraniin 34-42 BCL2 apoptosis regulator Homo sapiens 53-58 24097825-7 2013 Importantly, binding of endogenous Bcl-2 to Bim also increased during mitosis, when Bcl-2 is endogenously phosphorylated, and disruption of this mitotic Bcl-2/Bim binding with navitoclax or ABT-199, like Bcl-2 downregulation, enhanced the cytotoxicity of paclitaxel. navitoclax 176-186 BCL2 apoptosis regulator Homo sapiens 35-40 24097825-7 2013 Importantly, binding of endogenous Bcl-2 to Bim also increased during mitosis, when Bcl-2 is endogenously phosphorylated, and disruption of this mitotic Bcl-2/Bim binding with navitoclax or ABT-199, like Bcl-2 downregulation, enhanced the cytotoxicity of paclitaxel. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 190-193 BCL2 apoptosis regulator Homo sapiens 35-40 24097825-7 2013 Importantly, binding of endogenous Bcl-2 to Bim also increased during mitosis, when Bcl-2 is endogenously phosphorylated, and disruption of this mitotic Bcl-2/Bim binding with navitoclax or ABT-199, like Bcl-2 downregulation, enhanced the cytotoxicity of paclitaxel. Paclitaxel 255-265 BCL2 apoptosis regulator Homo sapiens 35-40 24097825-8 2013 Collectively, these results provide not only a mechanistic basis for the enhanced antiapoptotic activity of phosphorylated Bcl-2, but also an explanation for the ability of BH3 mimetics to enhance taxane sensitivity. BH 3 173-176 BCL2 apoptosis regulator Homo sapiens 123-128 24097825-8 2013 Collectively, these results provide not only a mechanistic basis for the enhanced antiapoptotic activity of phosphorylated Bcl-2, but also an explanation for the ability of BH3 mimetics to enhance taxane sensitivity. taxane 197-203 BCL2 apoptosis regulator Homo sapiens 123-128 24124106-3 2013 In this study, we designed four series of benzylpiperazine derivatives as plausible Bcl-2 inhibitors based on the outcomes of a computational algorithm. 1-benzylpiperazine 42-58 BCL2 apoptosis regulator Homo sapiens 84-89 24140468-5 2013 In addition, PBDE-47 activated the p53-dependent mitochondrial apoptotic pathway as evidenced by up-regulation of p53 and Bax, down-regulation of Bcl-2 and Bcl-2/Bax ration, enhancement of Cyt c release from mitochondria into the cytosol, activation of caspase-3 as well as ultrastructural abnormalities of mitochondria. 2,2',4,4'-tetrabromodiphenyl ether 13-20 BCL2 apoptosis regulator Homo sapiens 146-151 24033664-3 2013 In this study, cyproheptadine was found to decrease the expression of anti-apoptotic proteins, including Bcl-2, Mcl-1, and XIAP. Cyproheptadine 15-29 BCL2 apoptosis regulator Homo sapiens 105-110 24140468-5 2013 In addition, PBDE-47 activated the p53-dependent mitochondrial apoptotic pathway as evidenced by up-regulation of p53 and Bax, down-regulation of Bcl-2 and Bcl-2/Bax ration, enhancement of Cyt c release from mitochondria into the cytosol, activation of caspase-3 as well as ultrastructural abnormalities of mitochondria. 2,2',4,4'-tetrabromodiphenyl ether 13-20 BCL2 apoptosis regulator Homo sapiens 156-161 24161692-10 2013 Taken together, quinocetone induced apoptosis in HepG2 cells via activation of caspase, interaction of TNF-alpha and TNFR1 and modulation of the protein levels of Bid, Bax and Bcl-2, involving the participation of p53, p38 and JNK. quinocetone 16-27 BCL2 apoptosis regulator Homo sapiens 176-181 24772972-4 2013 Western blot analysis showed that the levels of procaspase-8, -9, Bcl-2, Bid and mitochondrial cytochrome c were downregulated in triptolide-treated U2OS cells, whereas the levels of Fas, FasL, Bax, cytosolic cytochrome c, cleaved caspase-3 and cleaved PARP were upregulated. triptolide 130-140 BCL2 apoptosis regulator Homo sapiens 66-71 23770200-8 2013 Further, fidarestat inhibited acrolein-induced translocation of the proapoptotic proteins Bax and Bad from the cytosol to the mitochondria and that of Bcl2 and BclXL from the mitochondria to the cytosol. fidarestat 9-19 BCL2 apoptosis regulator Homo sapiens 151-155 23770200-8 2013 Further, fidarestat inhibited acrolein-induced translocation of the proapoptotic proteins Bax and Bad from the cytosol to the mitochondria and that of Bcl2 and BclXL from the mitochondria to the cytosol. Acrolein 30-38 BCL2 apoptosis regulator Homo sapiens 151-155 23940089-7 2013 Incubation of HL-60 cells with NaBu was associated with increased level of pro-apoptotic protein BIMEL and decreased levels of anti-apoptotic proteins of Bcl-2 family as well as GRP78 involved in ER stress signalling. sethoxydim 31-35 BCL2 apoptosis regulator Homo sapiens 154-159 23940089-8 2013 It seems that ABT-737 accelerates NaBu-induced death of HL-60 cells due to mitochondrial apoptosis resulting from ABT-737-mediated inhibition of functions and NaBu-induced decrease of the levels of anti-apoptotic Bcl-2 family proteins as well as due to accelerated decrease of GRP78 observed after the treatment of cells with combination of NaBu and ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 14-17 BCL2 apoptosis regulator Homo sapiens 213-218 23940089-8 2013 It seems that ABT-737 accelerates NaBu-induced death of HL-60 cells due to mitochondrial apoptosis resulting from ABT-737-mediated inhibition of functions and NaBu-induced decrease of the levels of anti-apoptotic Bcl-2 family proteins as well as due to accelerated decrease of GRP78 observed after the treatment of cells with combination of NaBu and ABT-737. sethoxydim 34-38 BCL2 apoptosis regulator Homo sapiens 213-218 23940089-8 2013 It seems that ABT-737 accelerates NaBu-induced death of HL-60 cells due to mitochondrial apoptosis resulting from ABT-737-mediated inhibition of functions and NaBu-induced decrease of the levels of anti-apoptotic Bcl-2 family proteins as well as due to accelerated decrease of GRP78 observed after the treatment of cells with combination of NaBu and ABT-737. sethoxydim 159-163 BCL2 apoptosis regulator Homo sapiens 213-218 23940089-8 2013 It seems that ABT-737 accelerates NaBu-induced death of HL-60 cells due to mitochondrial apoptosis resulting from ABT-737-mediated inhibition of functions and NaBu-induced decrease of the levels of anti-apoptotic Bcl-2 family proteins as well as due to accelerated decrease of GRP78 observed after the treatment of cells with combination of NaBu and ABT-737. sethoxydim 159-163 BCL2 apoptosis regulator Homo sapiens 213-218 23770082-7 2013 Finally, exogenous iron loading recapitulated the effects of H2O2 on the expression of BH3-only Bcl-2 proteins. Iron 19-23 BCL2 apoptosis regulator Homo sapiens 96-101 23770082-7 2013 Finally, exogenous iron loading recapitulated the effects of H2O2 on the expression of BH3-only Bcl-2 proteins. Hydrogen Peroxide 61-65 BCL2 apoptosis regulator Homo sapiens 96-101 24033376-5 2013 Melanotic bulbar melanocytes express high levels of BCL-2 to enable survival from melanogenesis- and ultraviolet A (UVA)-induced reactive oxygen species (ROS) attacks. Reactive Oxygen Species 129-152 BCL2 apoptosis regulator Homo sapiens 52-57 24033376-5 2013 Melanotic bulbar melanocytes express high levels of BCL-2 to enable survival from melanogenesis- and ultraviolet A (UVA)-induced reactive oxygen species (ROS) attacks. Reactive Oxygen Species 154-157 BCL2 apoptosis regulator Homo sapiens 52-57 24005536-5 2013 For the mechanism study, we found that AMPK activation was required for capsaicin-induced mTORC1 (mTOR complex 1) inhibition, B cell lymphoma 2 (Bcl-2) downregulation and Bax upregulation in MG63 cells. Capsaicin 72-81 BCL2 apoptosis regulator Homo sapiens 126-143 24337851-12 2013 As compared with blank control group, cells from the mild hyperthermia plus docetaxel group exhibited significantly decreased B-cell lymphoma 2 (Bcl-2) protein expression but slightly increased Bcl-2-associated X protein (Bax) expression. Docetaxel 76-85 BCL2 apoptosis regulator Homo sapiens 126-143 24337851-12 2013 As compared with blank control group, cells from the mild hyperthermia plus docetaxel group exhibited significantly decreased B-cell lymphoma 2 (Bcl-2) protein expression but slightly increased Bcl-2-associated X protein (Bax) expression. Docetaxel 76-85 BCL2 apoptosis regulator Homo sapiens 145-150 23963993-8 2013 The data obtain in this study indicate that rotenone-induced cytotoxicity in HepG2 cells via ROS-induced oxidative stress and mitochondria-mediated apoptosis involving p53, Bax/Bcl-2, and caspase-3. Rotenone 44-52 BCL2 apoptosis regulator Homo sapiens 177-182 23600973-10 2013 Immunohistochemical positivity for Bcl2, a marker for resistance to apoptosis, was less frequently detected in prostate cancer cells of men who received naftopidil compared with tamsulosin (P < 0.05). naftopidil 153-163 BCL2 apoptosis regulator Homo sapiens 35-39 23600973-10 2013 Immunohistochemical positivity for Bcl2, a marker for resistance to apoptosis, was less frequently detected in prostate cancer cells of men who received naftopidil compared with tamsulosin (P < 0.05). Tamsulosin 178-188 BCL2 apoptosis regulator Homo sapiens 35-39 23955073-2 2013 Here, we demonstrate the antileukemic effects of simultaneous inhibition of PI3K by the selective class I PI3K inhibitor GDC-0941 and of Bcl-2 family members by the BH3 mimetic ABT-737 in the context of the bone marrow microenvironment, where hypoxia and interactions with bone marrow stromal cells promote AML cell survival and chemoresistance. BH 3 165-168 BCL2 apoptosis regulator Homo sapiens 137-142 23955073-2 2013 Here, we demonstrate the antileukemic effects of simultaneous inhibition of PI3K by the selective class I PI3K inhibitor GDC-0941 and of Bcl-2 family members by the BH3 mimetic ABT-737 in the context of the bone marrow microenvironment, where hypoxia and interactions with bone marrow stromal cells promote AML cell survival and chemoresistance. ABT-737 177-184 BCL2 apoptosis regulator Homo sapiens 137-142 24005536-5 2013 For the mechanism study, we found that AMPK activation was required for capsaicin-induced mTORC1 (mTOR complex 1) inhibition, B cell lymphoma 2 (Bcl-2) downregulation and Bax upregulation in MG63 cells. Capsaicin 72-81 BCL2 apoptosis regulator Homo sapiens 145-150 24005536-6 2013 Capsaicin administration induced p53 activation, mitochondrial translocation and Bcl-2 killer association, such effects were dependent on AMPK activation. Capsaicin 0-9 BCL2 apoptosis regulator Homo sapiens 81-86 24055891-6 2013 We found that DMU-212 caused up-regulation of pro-apoptotic Bak1, Bok, Bik, Noxa, Bad, Bax, p53 and Apaf1 transcripts level in DLD-1 cell line, whereas anti-apoptotic Bcl-2, Bcl-xL and Bag1 mRNA expression was decreased. dmu-212 14-21 BCL2 apoptosis regulator Homo sapiens 167-172 24135219-10 2013 In addition, intracellular ROS, activated caspase 3, Bax/Bcl-2 ratio, cytochrome c as well as DNA fragmentation were significantly increased in 6-OHDA-treated cells. Oxidopamine 144-150 BCL2 apoptosis regulator Homo sapiens 57-62 24260077-0 2013 Apoptosis induced by beta,beta-dimethylacrylshikonin is associated with Bcl-2 and NF-kappaB in human breast carcinoma MCF-7 cells. beta, beta-dimethylacrylshikonin 21-52 BCL2 apoptosis regulator Homo sapiens 72-77 24134853-8 2013 Both chalcones increased Bax/Bcl2 ratios and decreased Ki67 and CD71 antigen expressions. Chalcones 5-14 BCL2 apoptosis regulator Homo sapiens 29-33 24370051-8 2013 Salidroside significantly inhibited the apoptosis of MSC and reversed the mRNA expression of BCL-2 and BAX. rhodioloside 0-11 BCL2 apoptosis regulator Homo sapiens 93-98 24370051-7 2013 The apoptosis of hBMMSC treated with salidroside were significantly higher as compared with control group (P < 0.05); RT-PCR results demonstrated that the BCL-2 expression was significantly down regulated but BAX mRNA expressions was up-regulated in Ara- C group as compared with those in the control group. rhodioloside 37-48 BCL2 apoptosis regulator Homo sapiens 158-163 24370051-7 2013 The apoptosis of hBMMSC treated with salidroside were significantly higher as compared with control group (P < 0.05); RT-PCR results demonstrated that the BCL-2 expression was significantly down regulated but BAX mRNA expressions was up-regulated in Ara- C group as compared with those in the control group. Cytarabine 253-259 BCL2 apoptosis regulator Homo sapiens 158-163 23907579-6 2013 Furthermore, DHA significantly induced apoptosis through suppressing Bcl-2 as well as activating caspase-9 and PARP. artenimol 13-16 BCL2 apoptosis regulator Homo sapiens 69-74 23907579-7 2013 Treatment of gastric cancer cells with DHA increased miR-15b and miR-16 expression, caused a downregulation of Bcl-2, resulting in apoptosis of gastric cancer cells. artenimol 39-42 BCL2 apoptosis regulator Homo sapiens 111-116 24370051-9 2013 It is concluded that salidroside can inhibit the apoptosis of hBMMSC induced by Ara-C, its mechanism may be related with the regulation of BCL-2/BAX expression. rhodioloside 21-32 BCL2 apoptosis regulator Homo sapiens 139-144 24267199-8 2013 In prostate cancer PC-3cell line, bufalin-induced apoptosis can be largely attenuated by a miR-181a inhibitor, which blocked bufalin-induced Bcl-2 reduction and caspase-3 activation. bufalin 125-132 BCL2 apoptosis regulator Homo sapiens 141-146 24370029-3 2013 Effect of midazolam on the expression of BCL-2, cytochrome C (Cyto-C), pro-caspase-9, pro-caspase-8 and pro-caspase-3 protein were detected by Western blot. Midazolam 10-19 BCL2 apoptosis regulator Homo sapiens 41-46 24370029-7 2013 It is concluded that midazolam possibly initiates the mitochondrial pathway, not the death receptor pathway, by reducing the expression of BCL-2, leading in turn to the releasing of Cyto-C in mitochondria, then activating caspase-9 and caspase-3 protein, triggers the caspase cascade, and induces the apoptosis of JeKo-1 cells ultimately. Midazolam 21-30 BCL2 apoptosis regulator Homo sapiens 139-144 24319338-13 2013 However, unlike the SB216763-treated cells, the UO126-treated cells showed a marked absence of Bcl-2, as well as phosphorylated Bcl-2 relative to the controls. U 0126 48-53 BCL2 apoptosis regulator Homo sapiens 95-100 24319338-13 2013 However, unlike the SB216763-treated cells, the UO126-treated cells showed a marked absence of Bcl-2, as well as phosphorylated Bcl-2 relative to the controls. U 0126 48-53 BCL2 apoptosis regulator Homo sapiens 128-133 24267199-7 2013 RESULTS: Bufalin was found to induce the expression of miR-181a, a small non-coding RNA believed to induce apoptosis by repressing its target gene, BCL-2. bufalin 9-16 BCL2 apoptosis regulator Homo sapiens 148-153 24267199-8 2013 In prostate cancer PC-3cell line, bufalin-induced apoptosis can be largely attenuated by a miR-181a inhibitor, which blocked bufalin-induced Bcl-2 reduction and caspase-3 activation. bufalin 34-41 BCL2 apoptosis regulator Homo sapiens 141-146 24278406-9 2013 Moreover, saponin 1 caused a decrease in the Bcl-2/Bax ratio and initiated apoptosis by activating caspase-9 and caspase-3 in the GBM cell lines. saponin 1 10-19 BCL2 apoptosis regulator Homo sapiens 45-50 24256941-0 2013 Ardipusilloside I induces apoptosis by regulating Bcl-2 family proteins in human mucoepidermoid carcinoma Mc3 cells. ardipusilloside I 0-17 BCL2 apoptosis regulator Homo sapiens 50-55 24256941-10 2013 Characteristic morphological changes of apoptosis, including nuclear condensation, boundary aggregation and splitting, and DNA fragmentation, were seen after treatment with 10 mug/ml ardipusilloside I for 48 h. Western blots demonstrated that ardipusilloside I caused Mc3 cell death through the induction of apoptosis by downregulation of Bcl-2 protein levels and upregulation of Bax and caspase-3 protein levels. ardipusilloside I 183-200 BCL2 apoptosis regulator Homo sapiens 339-344 24256941-10 2013 Characteristic morphological changes of apoptosis, including nuclear condensation, boundary aggregation and splitting, and DNA fragmentation, were seen after treatment with 10 mug/ml ardipusilloside I for 48 h. Western blots demonstrated that ardipusilloside I caused Mc3 cell death through the induction of apoptosis by downregulation of Bcl-2 protein levels and upregulation of Bax and caspase-3 protein levels. ardipusilloside I 243-260 BCL2 apoptosis regulator Homo sapiens 339-344 23954456-7 2013 Catechin downregulated Bcl-2, initiated the release of cytochrome c into the cytosol and upregulated Bax, caspase-3,-9 and p53 in the HepG2 cells. Catechin 0-8 BCL2 apoptosis regulator Homo sapiens 23-28 24123533-10 2013 By simultaneously delivering both doxorubicin (Dox) and siRNA against the Bcl-2 protein into the HeLa cells, the expression of the anti-apoptotic protein Bcl-2 was successfully suppressed, leading to an enhanced therapeutic efficacy. Doxorubicin 34-45 BCL2 apoptosis regulator Homo sapiens 154-159 24278362-0 2013 Chemoresistance to concanamycin A1 in human oral squamous cell carcinoma is attenuated by an HDAC inhibitor partly via suppression of Bcl-2 expression. Concanamycin 19-31 BCL2 apoptosis regulator Homo sapiens 134-139 24278362-11 2013 SAHA treatment led to a significantly decrease in the Bcl-2 expression in CMA-treated SQUU-B cells, resulting in a dramatically increased Bax/Bcl-2 ratio in comparison with that observed in the SQUU-B cells treated with CMA alone. Vorinostat 0-4 BCL2 apoptosis regulator Homo sapiens 54-59 24278362-11 2013 SAHA treatment led to a significantly decrease in the Bcl-2 expression in CMA-treated SQUU-B cells, resulting in a dramatically increased Bax/Bcl-2 ratio in comparison with that observed in the SQUU-B cells treated with CMA alone. Vorinostat 0-4 BCL2 apoptosis regulator Homo sapiens 142-147 23994555-0 2013 Safflor yellow B suppresses angiotensin II-mediated human umbilical vein cell injury via regulation of Bcl-2/p22(phox) expression. Safflor Yellow B 0-16 BCL2 apoptosis regulator Homo sapiens 103-108 23994555-3 2013 Safflor yellow B (SYB) effectively inhibits ROS generation by upregulating Bcl-2 expression. Safflor Yellow B 0-16 BCL2 apoptosis regulator Homo sapiens 75-80 23994555-3 2013 Safflor yellow B (SYB) effectively inhibits ROS generation by upregulating Bcl-2 expression. Reactive Oxygen Species 44-47 BCL2 apoptosis regulator Homo sapiens 75-80 24123533-10 2013 By simultaneously delivering both doxorubicin (Dox) and siRNA against the Bcl-2 protein into the HeLa cells, the expression of the anti-apoptotic protein Bcl-2 was successfully suppressed, leading to an enhanced therapeutic efficacy. Doxorubicin 47-50 BCL2 apoptosis regulator Homo sapiens 154-159 24877026-7 2013 ROS plays a role in down-regulation of Bcl-2, since treatment with PM in the presence of various ROS modulators, e.g., n-acetylcysteine (NAC), a general purpose antioxidant; diphenylene iodonium (DPI), a NADPH inhibitor; rotenone (ROT), a mitochondrial electron transport chain interrupter rotenone or MnTBAP, a O2 scavenger, attenuated the down-regulation of Bcl-2. Reactive Oxygen Species 0-3 BCL2 apoptosis regulator Homo sapiens 39-44 24223914-4 2013 The over-expression of Bcl2 in MDA-MB-468 cells abolished NOHA-induced apoptosis, suggesting that the mitochondria may be the main site of NOHA"s action. N(omega)-hydroxyarginine 58-62 BCL2 apoptosis regulator Homo sapiens 23-27 24201808-11 2013 Furthermore, viral Bcl-2 proteins modulate innate immune responses regulated by NF-kappaB through an interface separate from the canonical BH3-binding groove. BH 3 139-142 BCL2 apoptosis regulator Homo sapiens 19-24 24877026-0 2013 Pristimerin Induces Apoptosis in Prostate Cancer Cells by Down-regulating Bcl-2 through ROS-dependent Ubiquitin-proteasomal Degradation Pathway. pristimerin 0-11 BCL2 apoptosis regulator Homo sapiens 74-79 24877026-0 2013 Pristimerin Induces Apoptosis in Prostate Cancer Cells by Down-regulating Bcl-2 through ROS-dependent Ubiquitin-proteasomal Degradation Pathway. Reactive Oxygen Species 88-91 BCL2 apoptosis regulator Homo sapiens 74-79 24877026-7 2013 ROS plays a role in down-regulation of Bcl-2, since treatment with PM in the presence of various ROS modulators, e.g., n-acetylcysteine (NAC), a general purpose antioxidant; diphenylene iodonium (DPI), a NADPH inhibitor; rotenone (ROT), a mitochondrial electron transport chain interrupter rotenone or MnTBAP, a O2 scavenger, attenuated the down-regulation of Bcl-2. Reactive Oxygen Species 0-3 BCL2 apoptosis regulator Homo sapiens 360-365 24877026-7 2013 ROS plays a role in down-regulation of Bcl-2, since treatment with PM in the presence of various ROS modulators, e.g., n-acetylcysteine (NAC), a general purpose antioxidant; diphenylene iodonium (DPI), a NADPH inhibitor; rotenone (ROT), a mitochondrial electron transport chain interrupter rotenone or MnTBAP, a O2 scavenger, attenuated the down-regulation of Bcl-2. Reactive Oxygen Species 97-100 BCL2 apoptosis regulator Homo sapiens 39-44 24877026-7 2013 ROS plays a role in down-regulation of Bcl-2, since treatment with PM in the presence of various ROS modulators, e.g., n-acetylcysteine (NAC), a general purpose antioxidant; diphenylene iodonium (DPI), a NADPH inhibitor; rotenone (ROT), a mitochondrial electron transport chain interrupter rotenone or MnTBAP, a O2 scavenger, attenuated the down-regulation of Bcl-2. Acetylcysteine 119-135 BCL2 apoptosis regulator Homo sapiens 39-44 24877026-7 2013 ROS plays a role in down-regulation of Bcl-2, since treatment with PM in the presence of various ROS modulators, e.g., n-acetylcysteine (NAC), a general purpose antioxidant; diphenylene iodonium (DPI), a NADPH inhibitor; rotenone (ROT), a mitochondrial electron transport chain interrupter rotenone or MnTBAP, a O2 scavenger, attenuated the down-regulation of Bcl-2. Acetylcysteine 137-140 BCL2 apoptosis regulator Homo sapiens 39-44 24877026-7 2013 ROS plays a role in down-regulation of Bcl-2, since treatment with PM in the presence of various ROS modulators, e.g., n-acetylcysteine (NAC), a general purpose antioxidant; diphenylene iodonium (DPI), a NADPH inhibitor; rotenone (ROT), a mitochondrial electron transport chain interrupter rotenone or MnTBAP, a O2 scavenger, attenuated the down-regulation of Bcl-2. Acetylcysteine 137-140 BCL2 apoptosis regulator Homo sapiens 360-365 24223706-0 2013 Dihydromyricetin reduced Bcl-2 expression via p53 in human hepatoma HepG2 cells. dihydromyricetin 0-16 BCL2 apoptosis regulator Homo sapiens 25-30 24223706-11 2013 These findings defined and supported a novel function that DHM could induce human hepatocellular carcinoma HepG2 cells apoptosis by up-regulating Bax/Bcl-2 expression via p53 signal pathway. dihydromyricetin 59-62 BCL2 apoptosis regulator Homo sapiens 150-155 24877026-7 2013 ROS plays a role in down-regulation of Bcl-2, since treatment with PM in the presence of various ROS modulators, e.g., n-acetylcysteine (NAC), a general purpose antioxidant; diphenylene iodonium (DPI), a NADPH inhibitor; rotenone (ROT), a mitochondrial electron transport chain interrupter rotenone or MnTBAP, a O2 scavenger, attenuated the down-regulation of Bcl-2. diphenyleneiodonium 174-194 BCL2 apoptosis regulator Homo sapiens 39-44 24877026-7 2013 ROS plays a role in down-regulation of Bcl-2, since treatment with PM in the presence of various ROS modulators, e.g., n-acetylcysteine (NAC), a general purpose antioxidant; diphenylene iodonium (DPI), a NADPH inhibitor; rotenone (ROT), a mitochondrial electron transport chain interrupter rotenone or MnTBAP, a O2 scavenger, attenuated the down-regulation of Bcl-2. diphenyleneiodonium 196-199 BCL2 apoptosis regulator Homo sapiens 39-44 24877026-7 2013 ROS plays a role in down-regulation of Bcl-2, since treatment with PM in the presence of various ROS modulators, e.g., n-acetylcysteine (NAC), a general purpose antioxidant; diphenylene iodonium (DPI), a NADPH inhibitor; rotenone (ROT), a mitochondrial electron transport chain interrupter rotenone or MnTBAP, a O2 scavenger, attenuated the down-regulation of Bcl-2. NADP 204-209 BCL2 apoptosis regulator Homo sapiens 39-44 24877026-7 2013 ROS plays a role in down-regulation of Bcl-2, since treatment with PM in the presence of various ROS modulators, e.g., n-acetylcysteine (NAC), a general purpose antioxidant; diphenylene iodonium (DPI), a NADPH inhibitor; rotenone (ROT), a mitochondrial electron transport chain interrupter rotenone or MnTBAP, a O2 scavenger, attenuated the down-regulation of Bcl-2. Rotenone 221-229 BCL2 apoptosis regulator Homo sapiens 39-44 24877026-7 2013 ROS plays a role in down-regulation of Bcl-2, since treatment with PM in the presence of various ROS modulators, e.g., n-acetylcysteine (NAC), a general purpose antioxidant; diphenylene iodonium (DPI), a NADPH inhibitor; rotenone (ROT), a mitochondrial electron transport chain interrupter rotenone or MnTBAP, a O2 scavenger, attenuated the down-regulation of Bcl-2. Rotenone 290-298 BCL2 apoptosis regulator Homo sapiens 39-44 24877026-8 2013 Furthermore, ROS is also involved in the ubiquitination and proteasomal degradation of Bcl-2 as both of these events were blocked by O 2- scavenger MnTBAP. Reactive Oxygen Species 13-16 BCL2 apoptosis regulator Homo sapiens 87-92 24877026-9 2013 Thus, pristimerin induces apoptosis in prostate cancer cells predominately through the mitochondrial apoptotic pathway by inhibiting antiapoptic Bcl-2 through a ROS-dependent ubiquitin-proteasomal degradation pathway. pristimerin 6-17 BCL2 apoptosis regulator Homo sapiens 145-150 24877026-9 2013 Thus, pristimerin induces apoptosis in prostate cancer cells predominately through the mitochondrial apoptotic pathway by inhibiting antiapoptic Bcl-2 through a ROS-dependent ubiquitin-proteasomal degradation pathway. Reactive Oxygen Species 161-164 BCL2 apoptosis regulator Homo sapiens 145-150 23881281-4 2013 Meanwhile, curcumin induced endoplasmic reticulum (ER) stress and mitochondrial dysfunction as evidenced by up-regulation of CCAAT/enhancer binding protein homologous protein (CHOP), phosphorylation of JNK and down-regulation of SERCA2ATPase, release of cytochrome c, decrease of Bcl-2 and reduction of mitochondrial membrane potential in both AGS and HT-29 cells. Curcumin 11-19 BCL2 apoptosis regulator Homo sapiens 280-285 23908177-0 2013 Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. Anthracyclines 106-119 BCL2 apoptosis regulator Homo sapiens 0-4 23908177-5 2013 Moreover, Bcl2- expression was an independent predictor of pathological complete response of primary locally advanced triple negative breast cancer (PLA-TNBC) treated with neoadjuvant-ATC-CT (P = 0.008). neoadjuvant-atc-ct 172-190 BCL2 apoptosis regulator Homo sapiens 10-14 24222107-5 2013 Release of cytochrome c from mitochondria and activation of Bcl-2 family protein (BAX) were recorded, indicating that DMTreCn induced apoptosis of Hep-G2 and HuH-7 cells through mitochondrial pathway via BAX. dmtrecn 118-125 BCL2 apoptosis regulator Homo sapiens 60-65 23471661-6 2013 In addition, the present study revealed that Sunitinib inhibited Stat3 and down-regulated Bcl-2 in SGC7901/VCR cells, which might also contribute to the reversal of MDR. Sunitinib 45-54 BCL2 apoptosis regulator Homo sapiens 90-95 23993674-2 2013 To date, BH3 mimetics that abrogate anti-apoptotic activity have largely been directed at Bcl-2 and/or Bcl-xL. BH 3 9-12 BCL2 apoptosis regulator Homo sapiens 90-95 24331535-6 2013 Western blotting revealed that resveratrol significantly decreased the expression of antiapoptotic proteins (Mcl-1 and Bcl-2) and increased the expression of proapoptotic proteins (Bax, Bim, and Bad), and induced cleaved-caspase-3 in a time-dependent manner. Resveratrol 31-42 BCL2 apoptosis regulator Homo sapiens 119-124 23471661-7 2013 In conclusion, Sunitinib reverses multidrug resistance in gastric cancer cells by inhibiting P-gp transporter function and modulating Stat3 and Bcl-2. Sunitinib 15-24 BCL2 apoptosis regulator Homo sapiens 144-149 23764753-8 2013 Interestingly, de4 EGFR transfectants displayed significantly lower sensitivity to cisplatin than EGFR transfectants, which could be ascribed to the upregulation of Bcl-2 and downregulation of BAD in the de4 EGFR transfectants. Cisplatin 83-92 BCL2 apoptosis regulator Homo sapiens 165-170 24139157-11 2013 To the best of our knowledge this is the first report demonstrating that NiO NPs caused cytotoxicity via ROS and induced apoptosis in HepG2 cells, which is likely to be mediated through bax/bcl-2 pathway. nio 73-76 BCL2 apoptosis regulator Homo sapiens 190-195 23836782-1 2013 Beyond its classical role as apoptosis inhibitor, bcl-2 protein promotes tumor angiogenesis and the removal of N-terminal bcl-2 homology (BH4) domain abrogates bcl-2-induced hypoxia-inducible factor 1 (HIF-1)-mediated vascular endothelial growth factor (VEGF) expression in hypoxic cancer cells. sapropterin 138-141 BCL2 apoptosis regulator Homo sapiens 50-55 23836782-1 2013 Beyond its classical role as apoptosis inhibitor, bcl-2 protein promotes tumor angiogenesis and the removal of N-terminal bcl-2 homology (BH4) domain abrogates bcl-2-induced hypoxia-inducible factor 1 (HIF-1)-mediated vascular endothelial growth factor (VEGF) expression in hypoxic cancer cells. sapropterin 138-141 BCL2 apoptosis regulator Homo sapiens 122-127 23836782-1 2013 Beyond its classical role as apoptosis inhibitor, bcl-2 protein promotes tumor angiogenesis and the removal of N-terminal bcl-2 homology (BH4) domain abrogates bcl-2-induced hypoxia-inducible factor 1 (HIF-1)-mediated vascular endothelial growth factor (VEGF) expression in hypoxic cancer cells. sapropterin 138-141 BCL2 apoptosis regulator Homo sapiens 122-127 23836782-3 2013 Moreover, xenografts derived from cells expressing bcl-2 lacking BH4 domain showed a reduction of metastatic potential compared with tumors derived from wild-type bcl-2 transfectants injection. sapropterin 65-68 BCL2 apoptosis regulator Homo sapiens 51-56 23836782-5 2013 Indeed, lacking of BH4 domain abolishes the interaction between bcl-2 and HIF-1alpha proteins and the capability of exogenous bcl-2 protein to localize in the nucleus. sapropterin 19-22 BCL2 apoptosis regulator Homo sapiens 64-69 23836782-5 2013 Indeed, lacking of BH4 domain abolishes the interaction between bcl-2 and HIF-1alpha proteins and the capability of exogenous bcl-2 protein to localize in the nucleus. sapropterin 19-22 BCL2 apoptosis regulator Homo sapiens 126-131 23836782-7 2013 These results demonstrate that BH4 domain of bcl-2 is required for the ability of this protein to increase tumor angiogenesis and progression and indicate that bcl-2 nuclear localization may be required for bcl-2-mediated induction of HIF-1/VEGF axis. sapropterin 31-34 BCL2 apoptosis regulator Homo sapiens 45-50 23836782-7 2013 These results demonstrate that BH4 domain of bcl-2 is required for the ability of this protein to increase tumor angiogenesis and progression and indicate that bcl-2 nuclear localization may be required for bcl-2-mediated induction of HIF-1/VEGF axis. sapropterin 31-34 BCL2 apoptosis regulator Homo sapiens 160-165 23836782-7 2013 These results demonstrate that BH4 domain of bcl-2 is required for the ability of this protein to increase tumor angiogenesis and progression and indicate that bcl-2 nuclear localization may be required for bcl-2-mediated induction of HIF-1/VEGF axis. sapropterin 31-34 BCL2 apoptosis regulator Homo sapiens 160-165 23954820-4 2013 Mitochondria-mediated apoptosis pathway contributed importantly to PQ-induced apoptosis, as revealed by the activation of caspase-3/-9, cleavage of PARP, depletion of mitochondrial membrane potential regulated by Bcl-2 family members, and overproduction of reactive oxygen species, which were also effectively blocked by CF. Paraquat 67-69 BCL2 apoptosis regulator Homo sapiens 213-218 23735541-0 2013 Apoptosis induced by paclitaxel via Bcl-2, Bax and caspases 3 and 9 activation in NB4 human leukaemia cells is not modulated by ERK inhibition. Paclitaxel 21-31 BCL2 apoptosis regulator Homo sapiens 36-41 23735541-10 2013 Decrease of p53 and Bcl-2, fragmentation of DNA, increase of Bax and, finally, activation of caspases 3 and 9 in NB4 leukaemia cells make the apoptotic process induced by Ptx irreversible. Paclitaxel 171-174 BCL2 apoptosis regulator Homo sapiens 20-25 23900721-4 2013 Rotenone insult significantly reduced cell viability (MTT assay) and resulted in 78 % apoptosis (dual staining) by altering Bcl-2, Bax, caspase-3, and cytochrome C expression. Rotenone 0-8 BCL2 apoptosis regulator Homo sapiens 124-129 23970333-7 2013 In addition, the ratio of Bax to Bcl-2 was increased by CDDP treatment in SNU-1 cells, but not in SNU-16 cells. Cisplatin 56-60 BCL2 apoptosis regulator Homo sapiens 33-38 24048272-8 2013 Saponin B increased the Bax and caspase-3 ratio and decreased the protein expression of Bcl-2. Saponin B 0-9 BCL2 apoptosis regulator Homo sapiens 88-93 24021754-10 2013 Moreover, kobophenol A treatment up-regulated the Bcl-2 level, but down-regulated the level of Bax expression. kobophenol A 10-22 BCL2 apoptosis regulator Homo sapiens 50-55 24002547-16 2013 Bcl-2, Bax, Procaspase-3 and P-gp are involved in the resistance of cell lines to PTX, which are invaluable tools to study the resistance of anticancer drugs and to identify the methods to overcome resistance. Paclitaxel 82-85 BCL2 apoptosis regulator Homo sapiens 0-5 24002667-7 2013 In addition, immunocytochemistry and western blotting showed that PAE significantly decreased the expression of Bcl-2, while the expression of Bax and cleaved caspase-3 in HepG2 cells and SMMC-7721 cells was significantly increased after treatment with PAE. 2-(Isopropylamino)ethanol 66-69 BCL2 apoptosis regulator Homo sapiens 112-117 24002667-8 2013 These results clearly demonstrated that PAE induced hepatoma cell apoptosis through increasing the Bax-to-Bcl-2 ratio and upregulating the activation of caspase-3. 2-(Isopropylamino)ethanol 40-43 BCL2 apoptosis regulator Homo sapiens 106-111 22976841-5 2013 In this study, PFOS induced a dose-dependent increase in A549 cell toxicity via an apoptosis pathway as characterized by increased percentage of sub-G1, activation of caspase-3 and -9, and increased ratio of Bax/bcl-2 mRNA expression. perfluorooctane sulfonic acid 15-19 BCL2 apoptosis regulator Homo sapiens 212-217 23890703-15 2013 The inhibitory effect of CA-074Me on apoptosis was associated with down-regulation of Bax expression and consequent increase in the ratio of Bcl-2/Bax. CA 074 methyl ester 25-33 BCL2 apoptosis regulator Homo sapiens 141-146 24102557-4 2013 It is Bcl-2 and its interaction with Beclin-1 that has refocussed research attention on doxorubicin, albeit this time for its ability to induce autophagy. Doxorubicin 88-99 BCL2 apoptosis regulator Homo sapiens 6-11 24299604-9 2013 RT-PCR and immunoblot studies revealed that myricanone activated the apoptotic signalling cascades through down-regulation of transcription factors like nuclear factor-kappaB (NF-kappaB) (p65), and signal transducers and activators of transcription 3 (STAT3); cell cycle regulators like cyclin D1, and survivin and other signal proteins like Bcl-2 and up-regulation of Bax, caspase-9 and caspase-3. myricanone 44-54 BCL2 apoptosis regulator Homo sapiens 342-347 24102557-3 2013 KEY FINDINGS: More recently, major biomarkers such as AMPK, p53 and Bcl-2 have been identified as important to apoptosis induction by doxorubicin. Doxorubicin 134-145 BCL2 apoptosis regulator Homo sapiens 68-73 23783021-11 2013 Moreover, the Bcl-2/Bax ratio was found to be increased in cells pretreated with Losartan, which indicates a proapoptotic role of AT1R in cultured HT-29 cell lines. Losartan 81-89 BCL2 apoptosis regulator Homo sapiens 14-19 23955846-5 2013 The results reveal that H2 O2 can induce apoptosis effectively by regulating the activity of apoptosis-related biomolecules, including pro-apoptotic factors p53 and Bax, and anti-apoptotic factor Bcl-2. Hydrogen Peroxide 24-29 BCL2 apoptosis regulator Homo sapiens 196-201 23640104-0 2013 Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo. Gossypol 0-8 BCL2 apoptosis regulator Homo sapiens 53-57 23640104-0 2013 Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo. ABT-737 68-75 BCL2 apoptosis regulator Homo sapiens 53-57 24179549-8 2013 Oridonin increased the activity of caspase-3 and the expression of cleaved caspase-9 and cytochrome c in the cytoplasm and decreased the Bcl-2:Bax ratio in a concentration-dependent manner. oridonin 0-8 BCL2 apoptosis regulator Homo sapiens 137-142 24064771-3 2013 The results showed that citrate inhibits the expression of Bcl-2, while it induces the activation of caspases-3 and -9. Citric Acid 24-31 BCL2 apoptosis regulator Homo sapiens 59-64 24624885-8 2013 Along with the growth inhibition of DPCs by 6-gingerol, the Bax/Bcl-2 ratio increased obviously. dpcs 36-40 BCL2 apoptosis regulator Homo sapiens 64-69 23867991-8 2013 Finally, TSA reduced the expression of Bcl-2, an important survival protein in lung cancer cells, partly through upregulation of miR-15a/16-1. trichostatin A 9-12 BCL2 apoptosis regulator Homo sapiens 39-44 24956827-8 2013 CONCLUSION: The total flavones of Chrysanthemum indicum can inhibit the proliferation of osteosarcoma cell line Saos-2 by inducing cell apoptosis,the mechanism of which might be related with reducing BCL-2/BAX and activating Caspase-3. Flavones 22-30 BCL2 apoptosis regulator Homo sapiens 200-205 24624885-8 2013 Along with the growth inhibition of DPCs by 6-gingerol, the Bax/Bcl-2 ratio increased obviously. gingerol 44-54 BCL2 apoptosis regulator Homo sapiens 64-69 24624885-10 2013 CONCLUSIONS: 6-Gingerol can suppress human hair shaft elongation because it has pro-apoptotic effects on DPCs via increasing Bax/Bcl-2 ratio. gingerol 13-23 BCL2 apoptosis regulator Homo sapiens 129-134 24120870-3 2013 Employing a "BCL-XL-addiction" model, we show that neutralization of BCL-XL by the BH3 mimetic ABT-737 resulted in death only when cells were reconstituted with BCL-XL:BAK, but not BCL-2/ BCL-XL:BIM complexes. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 95-98 BCL2 apoptosis regulator Homo sapiens 181-186 25206585-5 2013 The level of active Caspase-3 and the ratio of Bax/Bcl-2 in hippocampal neurons treated with TLR4 antibody or the GSK-3beta inhibitor, LiCl, creased before intervention with lipopolysaccharide, but increased after treatment with the AKT hibitor, LY294002. Lithium Chloride 135-139 BCL2 apoptosis regulator Homo sapiens 51-56 23971075-0 2013 Raman micro spectroscopy study of the interaction of vincristine with A549 cells supported by expression analysis of bcl-2 protein. Vincristine 53-64 BCL2 apoptosis regulator Homo sapiens 117-122 23971075-7 2013 Results are correlated with a similar dose dependent expression analysis of the bcl-2 protein, an anti-apoptotic protein associated with DNA damage, in the vincristine treated A549 cells using flow cytometry. Vincristine 156-167 BCL2 apoptosis regulator Homo sapiens 80-85 24138843-10 2013 The combination of ZD6474 with UV-B vs. either agent alone also more potently down-regulated the anti-apoptotic bcl-2 protein, up-regulated pro-apoptotic signaling events involving expression of bax, activation of caspase-3 and caspase-7 proteins, and induced poly (ADP-ribose) polymerase resulting in apoptosis. vandetanib 19-25 BCL2 apoptosis regulator Homo sapiens 112-117 24161202-6 2013 CpG-ODN or 5-FU could down-regulate the mRNA expression of Bcl-2 within HepG2 cells. Fluorouracil 11-15 BCL2 apoptosis regulator Homo sapiens 59-64 25206585-4 2013 Both the expression of P-AKT(Ser473) and P-GSK-3beta(Ser9) in hippocampal neurons stimulated by lipopo-polysaccharide decreased compared with the control, while the level of active Caspase-3 and the ratio of Bax/Bcl-2 were significantly increased. lipopo-polysaccharide 96-117 BCL2 apoptosis regulator Homo sapiens 212-217 25206585-5 2013 The level of active Caspase-3 and the ratio of Bax/Bcl-2 in hippocampal neurons treated with TLR4 antibody or the GSK-3beta inhibitor, LiCl, creased before intervention with lipopolysaccharide, but increased after treatment with the AKT hibitor, LY294002. hibitor 126-133 BCL2 apoptosis regulator Homo sapiens 51-56 32261085-3 2013 The obtained PEGylated PEI-grafted graphene/Au composites (PPGA) allow efficient loading of siRNA, forming PPGA/siRNA complexes to transport into HL-60 cells and downregulated anti-apoptosis Bcl-2 protein, indicating PPGA is a suitable platform for gene delivery. Graphite 35-43 BCL2 apoptosis regulator Homo sapiens 191-196 24036132-8 2013 The anti-apoptotic BCL2 gene was significantly overexpressed in six SCLC cell lines and the BCL2 inhibitor ABT-737 increased apoptosis in all three cell lines tested. ABT-737 107-114 BCL2 apoptosis regulator Homo sapiens 19-23 24036132-8 2013 The anti-apoptotic BCL2 gene was significantly overexpressed in six SCLC cell lines and the BCL2 inhibitor ABT-737 increased apoptosis in all three cell lines tested. ABT-737 107-114 BCL2 apoptosis regulator Homo sapiens 92-96 32261085-3 2013 The obtained PEGylated PEI-grafted graphene/Au composites (PPGA) allow efficient loading of siRNA, forming PPGA/siRNA complexes to transport into HL-60 cells and downregulated anti-apoptosis Bcl-2 protein, indicating PPGA is a suitable platform for gene delivery. Gold 44-46 BCL2 apoptosis regulator Homo sapiens 191-196 24124567-7 2013 In neuroblast SH-SY5Y cells, ASI dose-dependently reduced cellular ROS level and phosphorylation of tau in response to hydrogen peroxide challenge by modulation of Bcl-2/Bax ratio. astragaloside A 29-32 BCL2 apoptosis regulator Homo sapiens 164-169 24113271-0 2013 Aspirin-induced Bcl-2 translocation and its phosphorylation in the nucleus trigger apoptosis in breast cancer cells. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 16-21 24113271-1 2013 Here, we report that B-cell lymphoma 2 (Bcl-2) is a novel target molecule of aspirin in breast cancer cells. Aspirin 77-84 BCL2 apoptosis regulator Homo sapiens 21-38 24113271-1 2013 Here, we report that B-cell lymphoma 2 (Bcl-2) is a novel target molecule of aspirin in breast cancer cells. Aspirin 77-84 BCL2 apoptosis regulator Homo sapiens 40-45 24113271-2 2013 Aspirin influenced the formation of a complex by Bcl-2 and FKBP38 and induced the nuclear translocation of Bcl-2 and its phosphorylation. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 49-54 24113271-2 2013 Aspirin influenced the formation of a complex by Bcl-2 and FKBP38 and induced the nuclear translocation of Bcl-2 and its phosphorylation. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 107-112 24113271-4 2013 Bcl-2 knockdown using small interfering RNA (siRNA) delayed apoptotic cell death, which correlated with increased proliferation following aspirin exposure. Aspirin 138-145 BCL2 apoptosis regulator Homo sapiens 0-5 24113271-5 2013 In contrast, Bcl-2 overexpression enhanced the onset of aspirin-induced apoptosis, which was also associated with a significant increase in Bcl-2 phosphorylation in the nucleus. Aspirin 56-63 BCL2 apoptosis regulator Homo sapiens 13-18 24113271-6 2013 Therefore, this study may provide novel insight into the molecular mechanism of aspirin, particularly its anticancer effects in Bcl-2- and estrogen receptor-positive breast cancer cells. Aspirin 80-87 BCL2 apoptosis regulator Homo sapiens 128-133 24228120-7 2013 The positive rate of Bcl-2 expression was 80%, and Bcl-2 expression was significantly associated with chemoresistance to 5-FU (r(s) = 0.265, P = 0.041), ADM (r(s) = 0.425, P = 0.001) and MMC (r(s) = 0.40, P = 0.002). Fluorouracil 121-125 BCL2 apoptosis regulator Homo sapiens 51-56 24228120-9 2013 CONCLUSION: Overexpression of Bcl-2 may predict a loss of the efficacy of the chemotherapy drugs 5-FU, ADM and MMC in patients with gastric cancer. Fluorouracil 97-101 BCL2 apoptosis regulator Homo sapiens 30-35 23983126-9 2013 As expected, treating HCT-116 cancer cells with cantharidin significantly decreased the amounts of BCL-2, BCL-xL, and MCL-1 protein and induced apoptotic cell death. Cantharidin 48-59 BCL2 apoptosis regulator Homo sapiens 99-104 24124611-6 2013 Specifically, treatment of NCI-H441 and SK-MES-1 cells with delphindin (5-60 microM) resulted in (i) cleavage of PARP protein, (ii) activation of caspase-3 and -9, (iii) downregulation of anti-apoptotic proteins (Bcl2, Bcl-xL and Mcl-1), (iv) upregulation of pro-apoptotic proteins (Bax and Bak), and (v) decreased expression of PCNA and cyclin D1. delphindin 60-70 BCL2 apoptosis regulator Homo sapiens 213-217 24124567-7 2013 In neuroblast SH-SY5Y cells, ASI dose-dependently reduced cellular ROS level and phosphorylation of tau in response to hydrogen peroxide challenge by modulation of Bcl-2/Bax ratio. Hydrogen Peroxide 119-136 BCL2 apoptosis regulator Homo sapiens 164-169 24123010-7 2013 Citric acid increased the level of Bcl-2-associated X protein (BAX) and reduced the levels of B-cell lymphoma-2 (BCL-2), B-cell lymphoma-extra large (BCL-XL) and activated caspase-9 and caspase-3, which subsequently induced apoptosis via caspase-dependent and caspase-independent pathways. Citric Acid 0-11 BCL2 apoptosis regulator Homo sapiens 94-111 23887890-6 2013 We determined that the underlying mechanism of action involved an increase in protein levels of the anti-apoptotic Bcl-2 family members Mcl-1 and/or Bcl-xL which resulted in reduced Bax and Bak activation. bakuchiol 190-193 BCL2 apoptosis regulator Homo sapiens 115-120 24088574-7 2013 Within the high-risk group, 50% of BCL2-938CC patients were classified as high-risk due to poor prednisone response whereas only 33% of patients with AC and AA genotypes were classified as high-risk for the same reason. Prednisone 96-106 BCL2 apoptosis regulator Homo sapiens 35-39 23943012-6 2013 DCA treatment could also increase the ratio of Bax to Bcl-2 in SGC-7901 cells. Deoxycholic Acid 0-3 BCL2 apoptosis regulator Homo sapiens 54-59 23943012-8 2013 These results suggest that DCA induces apoptosis of gastric carcinoma cells through an intrinsic mitochondrial-dependent pathway, and the increase in the Bax/Bcl-2 ratio and collapse of the mitochondrial membrane potential may play important roles in DCA-induced apoptosis of gastric carcinoma cells. Deoxycholic Acid 251-254 BCL2 apoptosis regulator Homo sapiens 158-163 24123010-7 2013 Citric acid increased the level of Bcl-2-associated X protein (BAX) and reduced the levels of B-cell lymphoma-2 (BCL-2), B-cell lymphoma-extra large (BCL-XL) and activated caspase-9 and caspase-3, which subsequently induced apoptosis via caspase-dependent and caspase-independent pathways. Citric Acid 0-11 BCL2 apoptosis regulator Homo sapiens 113-118 23982889-11 2013 Other cellular proteins and processes targeted by ROS/Ca(2+) (metallothioneins, Bcl-2 proteins, ubiquitin-proteasome system, ER stress-associated unfolded protein response, autophagy, cell cycle) can evoke death or survival. Reactive Oxygen Species 50-53 BCL2 apoptosis regulator Homo sapiens 80-85 23881702-6 2013 Isoalantolactone-induced apoptosis of SGC-7901 cells was associated with the dissipation of mitochondrial membrane potential (DeltaPsi m) that was due to the down-regulation of Bcl-2 and up-regulation of Bax that led to the cleavage of caspase-3. isoalantolactone 0-16 BCL2 apoptosis regulator Homo sapiens 177-182 23707954-0 2013 Prometaphase arrest-dependent phosphorylation of Bcl-2 family proteins and activation of mitochondrial apoptotic pathway are associated with 17alpha-estradiol-induced apoptosis in human Jurkat T cells. alfatradiol 141-158 BCL2 apoptosis regulator Homo sapiens 49-54 23524027-5 2013 In this review we present the two key examples of ceramide and cardiolipin in apoptosis, focusing particularly on BCL-2 family-regulated pathways at the mitochondrial level. Ceramides 50-58 BCL2 apoptosis regulator Homo sapiens 114-119 23707954-1 2013 In Jurkat T cell clone (JT/Neo), G2/M arrest, apoptotic sub-G1 peak, mitochondrial membrane potential (Deltapsim) loss, and TUNEL-positive DNA fragmentation were induced following exposure to 17alpha-estradiol (17alpha-E2), whereas none of these events (except for G2/M arrest) were induced in Jurkat cells overexpressing Bcl-2 (JT/Bcl-2). alfatradiol 192-209 BCL2 apoptosis regulator Homo sapiens 322-327 23917726-7 2013 Meanwhile, Gal-3 was found to inhibit ATO-induced apoptosis through enhancing Bcl-2 expression and stabilizing mitochondria. Arsenic Trioxide 38-41 BCL2 apoptosis regulator Homo sapiens 78-83 23707954-1 2013 In Jurkat T cell clone (JT/Neo), G2/M arrest, apoptotic sub-G1 peak, mitochondrial membrane potential (Deltapsim) loss, and TUNEL-positive DNA fragmentation were induced following exposure to 17alpha-estradiol (17alpha-E2), whereas none of these events (except for G2/M arrest) were induced in Jurkat cells overexpressing Bcl-2 (JT/Bcl-2). alfatradiol 192-209 BCL2 apoptosis regulator Homo sapiens 332-337 23707954-3 2013 However, the 17alpha-E2-induced upregulation of Bak levels, activation of Bak, activation of caspase-3, and PARP degradation were abrogated by Bcl-2 overexpression. 17alpha-e2 13-23 BCL2 apoptosis regulator Homo sapiens 143-148 23707954-5 2013 The 17alpha-E2-induced phosphorylation of Bcl-2 family proteins and mitochondrial apoptotic events were suppressed by a Cdk1 inhibitor but not by aurora A and aurora B kinase inhibitors. 17alpha-e2 4-14 BCL2 apoptosis regulator Homo sapiens 42-47 24015987-3 2013 OkA-induced apoptosis was also due to the suppression of expression of Bcl-2, Bcl-x(L) and XIAP, and the activation of caspases-3, -8 and -9, and caspase-3 downstream mammalian STE20-like kinase 1 and H2AX. Okadaic Acid 0-3 BCL2 apoptosis regulator Homo sapiens 71-76 24085367-8 2013 Another class of drugs with potential impact for chemo-free treatment strategies in CLL are the BH3-mimetic inhibitors of the Bcl-2 family of pro-survival proteins. BH 3 96-99 BCL2 apoptosis regulator Homo sapiens 126-131 24156707-7 2013 RESULTS: Estrogenic effect of BPA was confirmed in the following checkpoints: mRNA expression of estrogen receptor alpha, expression of cyclin D1 and A2 proteins and CCNA2 gene, Bax and Bcl2 protein levels. bisphenol A 30-33 BCL2 apoptosis regulator Homo sapiens 186-190 23747297-5 2013 METHODS: Clerocidin was used to footprint G-quadruplex structures formed by telomeric and oncogene promoter sequences (c-myc, bcl-2, c-kit2), and by the thrombin binding aptamer. clerocidin 9-19 BCL2 apoptosis regulator Homo sapiens 126-131 23826785-0 2013 ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 29-33 23740383-5 2013 While the beta blocker carvedilol (1 muM) normalized the level of p53 and Bcl-2 and the calcium channel blocker (CCB) bepridil (0.5 muM) normalized that of Bcl-2, both the CCB azelnidipine (1 muM) and the angiotensin receptor blocker (ARB) olmesartan (10 muM) normalized those of p53, Bax, cytochrome c, and Bcl-XL. Carvedilol 23-33 BCL2 apoptosis regulator Homo sapiens 74-79 23740383-5 2013 While the beta blocker carvedilol (1 muM) normalized the level of p53 and Bcl-2 and the calcium channel blocker (CCB) bepridil (0.5 muM) normalized that of Bcl-2, both the CCB azelnidipine (1 muM) and the angiotensin receptor blocker (ARB) olmesartan (10 muM) normalized those of p53, Bax, cytochrome c, and Bcl-XL. Bepridil 118-126 BCL2 apoptosis regulator Homo sapiens 156-161 23959101-0 2013 Daidzein causes cytochrome c-mediated apoptosis via the Bcl-2 family in human hepatic cancer cells. daidzein 0-8 BCL2 apoptosis regulator Homo sapiens 56-61 23959101-8 2013 Daidzein-induced apoptosis in SK-HEP-1 cells was also associated with the up-regulation of Bak and down-regulation of Bcl-2 and Bcl-xL proteins. daidzein 0-8 BCL2 apoptosis regulator Homo sapiens 118-123 23736301-6 2013 Mitochondrial damage, including increased mitochondrial volume, excess superoxide production and increased exposure of the toxic BH3 domain of Bcl-2, tracks positively with the presence of misfolded SOD1. BH 3 129-132 BCL2 apoptosis regulator Homo sapiens 143-148 23810409-6 2013 Following incubation with ALR, an increase in pro-caspase8, pro-caspase3, pro-PARP and Bcl-2 levels was observed in vincristine-treated Jurkat cells. Vincristine 116-127 BCL2 apoptosis regulator Homo sapiens 87-92 23907405-3 2013 While several approaches were considered to selectively inhibit Bcl-2 family anti-apoptotic proteins, the discovery that gossypol binds and antagonizes anti-apoptotic effect of Bcl-2 family proteins was a major breakthrough in identifying specific Bcl-2 antagonists. Gossypol 121-129 BCL2 apoptosis regulator Homo sapiens 177-182 23824714-7 2013 Consistently, melatonin effectively suppressed the generation of intracellular ROS, expression ratio of Bax/Bcl-2, activation of caspase-3 and expression of phospho-P38MAPK in H2O2-induced MSCs. Melatonin 14-23 BCL2 apoptosis regulator Homo sapiens 108-113 23824714-7 2013 Consistently, melatonin effectively suppressed the generation of intracellular ROS, expression ratio of Bax/Bcl-2, activation of caspase-3 and expression of phospho-P38MAPK in H2O2-induced MSCs. Hydrogen Peroxide 176-180 BCL2 apoptosis regulator Homo sapiens 108-113 23996493-0 2013 Biophysical basis of the promiscuous binding of B-cell lymphoma protein 2 apoptotic repressor to BH3 ligands. BH 3 97-100 BCL2 apoptosis regulator Homo sapiens 48-73 23996493-2 2013 Herein, we investigate the biophysical basis of such promiscuity of Bcl2 toward its cognate BH3 ligands. BH 3 92-95 BCL2 apoptosis regulator Homo sapiens 68-72 23996493-5 2013 Consistent with this notion, the A + 4 residue within the BH3 ligands harboring the LXXXAD motif engages in key intermolecular van der Waals contacts with A149 lining the ligand binding groove within Bcl2, whereas A + 4G/S substitution results in the disruption of such favorable binding interactions. BH 3 58-61 BCL2 apoptosis regulator Homo sapiens 200-204 23996493-7 2013 This salient observation is indicative of the fact that hydrophobic forces not only play a dominant but also a universal role in driving the Bcl2-BH3 interactions. BH 3 146-149 BCL2 apoptosis regulator Homo sapiens 141-145 23900299-6 2013 Triptolide treatment resulted in a significant decrease in mRNA expression levels in genes encoding Bcl-2, cyclin D1, p27 and survivin and an increase in those encoding Bax and p21 in THP-1 cells. triptolide 0-10 BCL2 apoptosis regulator Homo sapiens 100-105 23907405-3 2013 While several approaches were considered to selectively inhibit Bcl-2 family anti-apoptotic proteins, the discovery that gossypol binds and antagonizes anti-apoptotic effect of Bcl-2 family proteins was a major breakthrough in identifying specific Bcl-2 antagonists. Gossypol 121-129 BCL2 apoptosis regulator Homo sapiens 177-182 23907405-7 2013 Its oral compound ABT-263 has demonstrated the substantial susceptibility of chronic lymphocytic leukemia cells through Bcl-2 inhibition. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 18-21 BCL2 apoptosis regulator Homo sapiens 120-125 23688794-10 2013 Decrease in mitochondrial Bcl-2 was suppressed by SOWP alone and SOWP + PGE1 treatment, and Bax in the mitochondria was significantly suppressed by SOWP + PGE1. Alprostadil 72-76 BCL2 apoptosis regulator Homo sapiens 26-31 23962569-11 2013 Consistently, Ibrutinib treatment decreased the levels of anti-apoptotic Bcl-2, Bcl-xL, and Mcl-1 protein. ibrutinib 14-23 BCL2 apoptosis regulator Homo sapiens 73-78 23894143-3 2013 Here, we found that inhibition of EGFR by erlotinib induces STAT3 phosphorylation at Tyr705 in association with increased Bcl2/Bcl-XL at both mRNA and protein levels in various human lung cancer cells. Erlotinib Hydrochloride 42-51 BCL2 apoptosis regulator Homo sapiens 122-126 23883584-6 2013 The alteration of the AMPK/mTOR signaling pathway by the inhibition of glucose metabolism induced specific downregulation of Mcl-1, a member of the antiapoptotic Bcl-2 family, through translational control. Glucose 71-78 BCL2 apoptosis regulator Homo sapiens 162-167 23398207-0 2013 Natural Bcl-2 inhibitor (-)- gossypol induces protective autophagy via reactive oxygen species-high mobility group box 1 pathway in Burkitt lymphoma. Gossypol 24-37 BCL2 apoptosis regulator Homo sapiens 8-13 23398207-0 2013 Natural Bcl-2 inhibitor (-)- gossypol induces protective autophagy via reactive oxygen species-high mobility group box 1 pathway in Burkitt lymphoma. Reactive Oxygen Species 71-94 BCL2 apoptosis regulator Homo sapiens 8-13 23398207-1 2013 (-)- Gossypol, a natural inhibitor of anti-apoptotic Bcl-2 proteins, has presented an effective anti-tumor activity in numerous preclinical trials. Gossypol 0-13 BCL2 apoptosis regulator Homo sapiens 53-58 23807740-9 2013 Expression profiles of certain relevant genes and proteins like p53, Akt, Bcl-2, Bax, cytochrome c and caspase 3 also provided evidence of ROS mediated p53 up-regulation and further boost in Bax expression and followed by cytochrome c release and activation of caspase 3. Reactive Oxygen Species 139-142 BCL2 apoptosis regulator Homo sapiens 74-79 23894143-9 2013 These findings uncover a novel mechanism of erlotinib resistance and provide a novel approach to overcome resistance by blocking the STAT3/Bcl2/Bcl-XL survival signaling pathway in human lung cancer. Erlotinib Hydrochloride 44-53 BCL2 apoptosis regulator Homo sapiens 139-143 23894143-6 2013 Because elevated levels of phosphorylated STAT3 (pSTAT3), Bcl2, and Bcl-XL were observed in erlotinib-resistant lung cancer (HCC827/ER) cells as compared with erlotinib-sensitive parental HCC827 cells, we postulate that the erlotinib-activated STAT3/Bcl2/Bcl-XL survival pathway may contribute to acquired resistance to erlotinib. Erlotinib Hydrochloride 92-101 BCL2 apoptosis regulator Homo sapiens 58-62 23970102-6 2013 Western blotting indicated that exposure of RKO cells to alantolactone is associated with the downregulation of Bcl-2, induction of Bax and activation of caspase-3 and -9. alantolactone 57-70 BCL2 apoptosis regulator Homo sapiens 112-117 23894143-6 2013 Because elevated levels of phosphorylated STAT3 (pSTAT3), Bcl2, and Bcl-XL were observed in erlotinib-resistant lung cancer (HCC827/ER) cells as compared with erlotinib-sensitive parental HCC827 cells, we postulate that the erlotinib-activated STAT3/Bcl2/Bcl-XL survival pathway may contribute to acquired resistance to erlotinib. Erlotinib Hydrochloride 92-101 BCL2 apoptosis regulator Homo sapiens 250-254 24035100-5 2013 SB203580, a selective p38MAPK inhibitor, blocked the apoptosis induced by alpha-calendic acid and beta-calendic acid by upregulating Bcl-2/Bax ratio and inhibition of the activation of Caspase-3 and Caspase-9. SB 203580 0-8 BCL2 apoptosis regulator Homo sapiens 133-138 24144737-6 2013 TSA treatment obviously increased Bax expression but decreased Bcl2 expression in the cells. trichostatin A 0-3 BCL2 apoptosis regulator Homo sapiens 63-67 23661153-9 2013 Naringenin triggered the mitochondrial-mediated apoptosis pathway as shown by an increased ratio of Bax/Bcl-2, subsequent release of cytochrome C, and sequential activation of caspase-3. naringenin 0-10 BCL2 apoptosis regulator Homo sapiens 104-109 24035100-5 2013 SB203580, a selective p38MAPK inhibitor, blocked the apoptosis induced by alpha-calendic acid and beta-calendic acid by upregulating Bcl-2/Bax ratio and inhibition of the activation of Caspase-3 and Caspase-9. calendic acid 74-93 BCL2 apoptosis regulator Homo sapiens 133-138 24035100-5 2013 SB203580, a selective p38MAPK inhibitor, blocked the apoptosis induced by alpha-calendic acid and beta-calendic acid by upregulating Bcl-2/Bax ratio and inhibition of the activation of Caspase-3 and Caspase-9. beta-calendic acid 98-116 BCL2 apoptosis regulator Homo sapiens 133-138 23760980-11 2013 Finally, we evaluated the levels of Bcl-2, Bax, and Bad, and found a decrease of Bcl-2 levels and increase of Bad levels in the J5-control cells treated with curcumin. Curcumin 158-166 BCL2 apoptosis regulator Homo sapiens 36-41 23760980-11 2013 Finally, we evaluated the levels of Bcl-2, Bax, and Bad, and found a decrease of Bcl-2 levels and increase of Bad levels in the J5-control cells treated with curcumin. Curcumin 158-166 BCL2 apoptosis regulator Homo sapiens 81-86 24378094-10 2013 Western blotting results revealed that the expression of CD133, phosphorylated Akt and the Bcl-2/Bax ratio were downregulated, and PTEN was upregulated in the Huh-7 cells after treated with 25 mmol/L metformin for 48 hrs. Metformin 200-209 BCL2 apoptosis regulator Homo sapiens 91-96 23830811-5 2013 Apoptosis related proteins measurement results revealed that DES-induced apoptosis was concurrent with the increasing of Bax and cleavage fragment caspase-3 and the decreasing of Bcl-2 and full length procaspase-3. diethyl sulfate 61-64 BCL2 apoptosis regulator Homo sapiens 179-184 24058878-0 2013 ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 26-31 24086672-4 2013 We found that bortezomib induced up-regulation of the pro-survival and pro-death ER stress molecules BIP and CHOP and activated c-Jun NH2-terminal kinase (JNK), resulting in Bcl-2 phosphorylation and induction of autophagy. Bortezomib 14-24 BCL2 apoptosis regulator Homo sapiens 174-179 24086397-11 2013 Expression of the anti-apoptosis gene Bcl-xl and Bcl-2 in DU145 cells are decreased and expression of the pro-apoptosis gene Bax and Bak increased after NaB treatment. nab 153-156 BCL2 apoptosis regulator Homo sapiens 49-54 24058878-4 2013 ABT-737 is a small molecule that binds to Bcl-2/Bcl-xL (but not Mcl-1) with high affinity and disrupts their interaction with pro-apoptotic Bax/Bak, thus enhancing apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 42-47 24058878-8 2013 Furthermore, we find that the ability of docetaxel to increase cyclin B1/Cdk1-mediated phosphorylation of Bcl-2/Bcl-xL and decrease Mcl-1 is required for ABT-737 to enhance apoptosis in PC3 cells, as determined by addition of Cdk1 inhibitor purvalanol A and expression of shRNA specific for cyclin B1. Docetaxel 41-50 BCL2 apoptosis regulator Homo sapiens 106-111 24058878-8 2013 Furthermore, we find that the ability of docetaxel to increase cyclin B1/Cdk1-mediated phosphorylation of Bcl-2/Bcl-xL and decrease Mcl-1 is required for ABT-737 to enhance apoptosis in PC3 cells, as determined by addition of Cdk1 inhibitor purvalanol A and expression of shRNA specific for cyclin B1. ABT-737 154-161 BCL2 apoptosis regulator Homo sapiens 106-111 24058878-8 2013 Furthermore, we find that the ability of docetaxel to increase cyclin B1/Cdk1-mediated phosphorylation of Bcl-2/Bcl-xL and decrease Mcl-1 is required for ABT-737 to enhance apoptosis in PC3 cells, as determined by addition of Cdk1 inhibitor purvalanol A and expression of shRNA specific for cyclin B1. 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine 241-253 BCL2 apoptosis regulator Homo sapiens 106-111 24058878-9 2013 Overall, our data suggests that the high levels of anti-apoptotic proteins in Bax-expressing CRPC cells can be overcome by targeting Bcl-2/Bcl-xL with ABT-737 and Mcl-1 with antimitotics. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 151-154 BCL2 apoptosis regulator Homo sapiens 133-138 23900644-5 2013 The increase in BAX/BCL-2 ratio and in the activated caspase 3 expression levels, the decrease in mitochondria membrane potential, as well as the increase in superoxide production, supports the mitochondria contribution on selenium-induced apoptosis. Selenium 223-231 BCL2 apoptosis regulator Homo sapiens 20-25 24022053-5 2013 NL-Bcl-2-siRNA treatment significantly increased the efficacy of chemotherapy when combined with doxorubicin in both MDA-MB-231 and MCF-7 animal models (P < 0.05). Doxorubicin 97-108 BCL2 apoptosis regulator Homo sapiens 3-8 24005866-5 2013 Subsequent apoptosis induced by ziyuglycoside II was accompanied with the activation of mitochondrial pathway, in particular a decreased mitochondrial membrane potential (MMP) as well as increased Bax/Bcl-2 ratio, cytochrome c release and the activity of caspase-3 and caspase-9. ziyuglycoside II 32-48 BCL2 apoptosis regulator Homo sapiens 201-206 23708819-4 2013 Molecular pathological analysis showed that amitriptyline induced p53, activated caspase-3, and decreased antiapoptotic Bcl-2 and Mcl-1 in tumor tissues. Amitriptyline 44-57 BCL2 apoptosis regulator Homo sapiens 120-125 23557083-1 2013 Small molecule S1 is a pan-BH3 mimetic that can bind antiapoptotic Bcl-2, Bcl-xL and Mcl-1 proteins. BH 3 27-30 BCL2 apoptosis regulator Homo sapiens 67-72 23557083-3 2013 We identified that S1 exhibited broader antitumour spectrum than ABT-737 through disruption of more Bcl-2 interactions including Mcl-1/Bak interaction. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 65-68 BCL2 apoptosis regulator Homo sapiens 100-105 23684481-6 2013 Results showed that the siRNA could downregulate Bcl-2 expression, which increased apoptosis and sensitivity of SGC-7901 cell to 5-Fluorouracil (P<0.05). Fluorouracil 129-143 BCL2 apoptosis regulator Homo sapiens 49-54 23684481-7 2013 This study indicated that inhibition of Bcl-2 expression by siRNA would be useful a new useful protocol to increase the effect of 5-Fluorouracil on treatment of gastric adenocarcinoma, which may play an important role in developing novel therapeutic strategies in the future. Fluorouracil 130-144 BCL2 apoptosis regulator Homo sapiens 40-45 23893415-9 2013 Mutagenesis of the alpha6 helix disrupted apoptotic function because a chimera of Bak with the alpha6 derived from Bcl-2 could be activated by truncated Bid (tBid) and could form BH3:groove homodimers but could not form high molecular weight oligomers or mediate cell death. tBID 158-162 BCL2 apoptosis regulator Homo sapiens 115-120 23893415-9 2013 Mutagenesis of the alpha6 helix disrupted apoptotic function because a chimera of Bak with the alpha6 derived from Bcl-2 could be activated by truncated Bid (tBid) and could form BH3:groove homodimers but could not form high molecular weight oligomers or mediate cell death. BH 3 179-182 BCL2 apoptosis regulator Homo sapiens 115-120 23726950-7 2013 H2O2 treatment induced an increased ratio of Bax/Bcl-2, cleaved caspase-3, and the number of condensed nuclei, which was also counteracted by MSP. Hydrogen Peroxide 0-4 BCL2 apoptosis regulator Homo sapiens 49-54 24019973-3 2013 Here, we found that inhibition of EGFR by erlotinib stimulated phosphorylation and activation of STAT3 leading to increased Bcl2/Bcl-XL expression in head and neck cancer cells, which may dampen the therapeutic efficacy of erlotinib against head and neck cancer. Erlotinib Hydrochloride 42-51 BCL2 apoptosis regulator Homo sapiens 124-128 23685957-8 2013 Curcumin dose-dependently induced apoptosis of NTera-2 cells by reducing FasL expression and Bcl-2-to-Bax ratio, and activating caspase-9, -8 and -3. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 93-98 23684481-0 2013 Bcl-2 gene silence enhances the sensitivity toward 5-Fluorouracil in gastric adenocarcinoma cells. Fluorouracil 51-65 BCL2 apoptosis regulator Homo sapiens 0-5 23684481-2 2013 This study was to investigate whether downregulation of Bcl-2 expression by small interfering RNA (siRNA) against the Bcl-2 gene would enhance the apoptosis and sensitivity of gastric adenocarcinoma SGC-7901 cell to 5-Fluorouracil. Fluorouracil 216-230 BCL2 apoptosis regulator Homo sapiens 56-61 23684481-2 2013 This study was to investigate whether downregulation of Bcl-2 expression by small interfering RNA (siRNA) against the Bcl-2 gene would enhance the apoptosis and sensitivity of gastric adenocarcinoma SGC-7901 cell to 5-Fluorouracil. Fluorouracil 216-230 BCL2 apoptosis regulator Homo sapiens 118-123 23764197-7 2013 Lovastatin exposure induced lower RhoC, bcl-2, matrix metalloproteinase-9 (MMP-9), survivin, Akt, bcl-xL, vascular endothelial growth factor (VEGF), and p-p70s6k expression in OVCAR3 compared to the control, but higher caspase-3 and Bax expression. Lovastatin 0-10 BCL2 apoptosis regulator Homo sapiens 40-45 23984825-7 2013 Furthermore, real time RT-PCR and Western blot analysis showed that farrerol significantly decreased the expression of Bax mRNA, Bax, cleaved caspase-3, and phosph-p38 MAPK, while increasing the exporession of Bcl-2 mRNA and Bcl-2 in H2O2-induced EA.hy926 cells. farrerol 68-76 BCL2 apoptosis regulator Homo sapiens 210-215 23984825-7 2013 Furthermore, real time RT-PCR and Western blot analysis showed that farrerol significantly decreased the expression of Bax mRNA, Bax, cleaved caspase-3, and phosph-p38 MAPK, while increasing the exporession of Bcl-2 mRNA and Bcl-2 in H2O2-induced EA.hy926 cells. farrerol 68-76 BCL2 apoptosis regulator Homo sapiens 225-230 23984931-5 2013 After tBHP treatment, Bcl-2 protein expression decreased and Bax protein expression increased. tert-Butylhydroperoxide 6-10 BCL2 apoptosis regulator Homo sapiens 22-27 23984931-8 2013 Our results indicated that the JAK2-STAT pathway might mediate tBHP-induced HMC senescence through the Bcl-2-Bax pathway, and that probucol could attenuate HMC senescence by regulating STATs. tert-Butylhydroperoxide 63-67 BCL2 apoptosis regulator Homo sapiens 103-108 23359184-0 2013 Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR-21 regulation of BCL-2 expression. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 93-98 23359184-10 2013 Over-expression of miR-21 expression can reverse down-regulation of BCL-2 expression and apoptosis induced by resveratrol. Resveratrol 110-121 BCL2 apoptosis regulator Homo sapiens 68-73 23359184-11 2013 CONCLUSIONS: In this study, we demonstrated that the effect of resveratrol on apoptosis is due to inhibiting miR-21 regulation of BCL-2 expression. Resveratrol 63-74 BCL2 apoptosis regulator Homo sapiens 130-135 23764357-8 2013 Western blotting analysis showed that dioscin significantly down-regulated the expressions of Bcl-2 and Bcl-xl, and up-regulated the expressions of Bax, Bak and Bid. dioscin 38-45 BCL2 apoptosis regulator Homo sapiens 94-99 23706691-9 2013 The combination of S1 with PD98059 can inhibit Bcl-2 phosphorylation and enhance Bak release from Bcl-2. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 27-34 BCL2 apoptosis regulator Homo sapiens 47-52 23706691-9 2013 The combination of S1 with PD98059 can inhibit Bcl-2 phosphorylation and enhance Bak release from Bcl-2. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 27-34 BCL2 apoptosis regulator Homo sapiens 98-103 23856992-0 2013 miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2. Cisplatin 72-81 BCL2 apoptosis regulator Homo sapiens 95-100 23828460-9 2013 Forced overexpression of Bcl-2, Bcl-xL and catalase proteins reduced NiCl2-induced cell death; siRNA-mediated knockdown of their expression sensitized the cells to nickel-induced apoptosis, suggesting that Bcl-2, Bcl-xl and catalase protein expression plays a critical role in apoptosis resistance. nickel chloride 69-74 BCL2 apoptosis regulator Homo sapiens 25-30 23404339-8 2013 AMR-Me dose-dependently suppressed abnormal cell proliferation, induced apoptosis, up-regulated pro-apoptotic protein Bax and down-regulated antiapoptotic protein Bcl-2 in mammary tumors. methyl 25-hydroxy-3-oxoolean-12-en-28-oate 0-6 BCL2 apoptosis regulator Homo sapiens 163-168 23828460-9 2013 Forced overexpression of Bcl-2, Bcl-xL and catalase proteins reduced NiCl2-induced cell death; siRNA-mediated knockdown of their expression sensitized the cells to nickel-induced apoptosis, suggesting that Bcl-2, Bcl-xl and catalase protein expression plays a critical role in apoptosis resistance. Nickel 164-170 BCL2 apoptosis regulator Homo sapiens 25-30 23909904-9 2013 The results suggest that silymarin inhibits the Akt signaling pathway by increasing PTEN expression in FaDu cells and directly affects Bcl-2 family members. Silymarin 25-34 BCL2 apoptosis regulator Homo sapiens 135-140 23828460-9 2013 Forced overexpression of Bcl-2, Bcl-xL and catalase proteins reduced NiCl2-induced cell death; siRNA-mediated knockdown of their expression sensitized the cells to nickel-induced apoptosis, suggesting that Bcl-2, Bcl-xl and catalase protein expression plays a critical role in apoptosis resistance. Nickel 164-170 BCL2 apoptosis regulator Homo sapiens 206-211 23861345-7 2013 The reduction of BCL-2 expression in endocrine-resistant cells lowered their apoptotic threshold to antimitotic agents: nocodazole, paclitaxel, and the PLK1 inhibitor BI2536. Nocodazole 120-130 BCL2 apoptosis regulator Homo sapiens 17-22 23827970-5 2013 PAB was observed to activate a caspase-dependent apoptotic pathway in U937 cells through the regulation of the Bcl-2 family protein-mediated mitochondrial pathway. pseudolaric acid B 0-3 BCL2 apoptosis regulator Homo sapiens 111-116 23861345-7 2013 The reduction of BCL-2 expression in endocrine-resistant cells lowered their apoptotic threshold to antimitotic agents: nocodazole, paclitaxel, and the PLK1 inhibitor BI2536. Paclitaxel 132-142 BCL2 apoptosis regulator Homo sapiens 17-22 23861345-7 2013 The reduction of BCL-2 expression in endocrine-resistant cells lowered their apoptotic threshold to antimitotic agents: nocodazole, paclitaxel, and the PLK1 inhibitor BI2536. BI 2536 167-173 BCL2 apoptosis regulator Homo sapiens 17-22 23861345-8 2013 This phenomenon could be reversed with ectopic expression of BCL-2, and rescued with the BCL-2 inhibitor ABT-737. ABT-737 105-112 BCL2 apoptosis regulator Homo sapiens 89-94 23828170-10 2013 We found that HSP90AA1, one of the main modulators, interacted with HIF1A, AR and BCL2 in nickel-exposed cells. Nickel 90-96 BCL2 apoptosis regulator Homo sapiens 82-86 23974697-4 2013 The prototype BH3 mimetic ABT-737 selectively targets the three prosurvival proteins BCL-XL, BCL-2, and BCL-W (but not MCL-1 or A1) and its oral derivative ABT-263 has proved promising in clinical trials. BH 3 14-17 BCL2 apoptosis regulator Homo sapiens 93-98 23974697-4 2013 The prototype BH3 mimetic ABT-737 selectively targets the three prosurvival proteins BCL-XL, BCL-2, and BCL-W (but not MCL-1 or A1) and its oral derivative ABT-263 has proved promising in clinical trials. ABT-737 26-33 BCL2 apoptosis regulator Homo sapiens 93-98 23974697-4 2013 The prototype BH3 mimetic ABT-737 selectively targets the three prosurvival proteins BCL-XL, BCL-2, and BCL-W (but not MCL-1 or A1) and its oral derivative ABT-263 has proved promising in clinical trials. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 26-29 BCL2 apoptosis regulator Homo sapiens 93-98 23828170-11 2013 Interestingly, we found that HSP90AA1 was involved in the BCL2-associated apoptotic pathway in the nickel-only data, whereas this gene interacted with several genes functioning in CASP-associated apoptotic signaling in the cadmium-only data. Nickel 99-105 BCL2 apoptosis regulator Homo sapiens 58-62 23799623-8 2013 The antagonism of MTX efficacy caused by ASA was accompanied by altered expression of caspase-3, Bcl-2 and FAS but not dihydrofolate reductase (DHFR). Methotrexate 18-21 BCL2 apoptosis regulator Homo sapiens 97-102 23799623-8 2013 The antagonism of MTX efficacy caused by ASA was accompanied by altered expression of caspase-3, Bcl-2 and FAS but not dihydrofolate reductase (DHFR). Aspirin 41-44 BCL2 apoptosis regulator Homo sapiens 97-102 23799623-9 2013 This suggests that the alteration of caspase-3, Bcl-2 and FAS was involved in the antagonism between ASA and MTX. Aspirin 101-104 BCL2 apoptosis regulator Homo sapiens 48-53 23799623-9 2013 This suggests that the alteration of caspase-3, Bcl-2 and FAS was involved in the antagonism between ASA and MTX. Methotrexate 109-112 BCL2 apoptosis regulator Homo sapiens 48-53 23813634-9 2013 WJ25591-induced Bcl-2 down-regulation and activation of caspase-9, -8, and -3, suggesting apoptotic execution through both intrinsic and extrinsic apoptotic pathways. wj25591 0-7 BCL2 apoptosis regulator Homo sapiens 16-21 23881456-4 2013 Treatment with cudraflavone B triggered the mitochondrial apoptotic pathway (indicated by induction of the proapoptotic protein p53 and the p21 and p27 effector proteins), downregulation of cell cycle regulatory proteins (e.g., p-Rb, changing Bax/Bcl-2 ratios, cytochrome-c release), and caspase-3 activation. cudraflavone B 15-29 BCL2 apoptosis regulator Homo sapiens 247-252 23932824-6 2013 Furthermore, MAG-DPA treatments decreased NFkappaB activation leading to a reduction in Bcl-2, CyclinD1, c-myc, COX-2, MMP9 and VEGF expression levels in tumor tissue sections. 1-O-docosapentaenoylglycerol 13-20 BCL2 apoptosis regulator Homo sapiens 88-93 23975218-7 2013 The markers ERCC-1, XAF and anti-apoptotic proteins of the Bcl-2 family seem to represent the most promising biomarkers associated with response to adjuvant cisplatin-based chemotherapy. Cisplatin 157-166 BCL2 apoptosis regulator Homo sapiens 59-64 23726865-5 2013 When cells were incubated with inhibitors of p38 MAPK and JNK, ethanol-induced apoptosis was decreased while ROS generation was unaffected, and examination of pro-apoptotic Bax and anti-apoptotic Bcl-2 levels showed decrease of the former and increase of the latter. Ethanol 63-70 BCL2 apoptosis regulator Homo sapiens 196-201 23726866-3 2013 Furthermore, we showed that H2O2 could increase the apoptotic factors such as Bax/Bcl-2 ratio, caspase-3 level, and PARP activity in a time course manner. Hydrogen Peroxide 28-32 BCL2 apoptosis regulator Homo sapiens 82-87 24137498-6 2013 We therefore designed a peptide with two glycine "hinges" replacing residues I14 and V15, of the wild-type Bcl-2-BH4 domain (Bcl-2-BH4-IV/GG). Glycine 41-48 BCL2 apoptosis regulator Homo sapiens 107-112 23869083-4 2013 The proapoptotic small-molecule Bcl-2 inhibitor ABT-737 promoted mixed chimerism induction and reversed the antitolerogenic effect of calcineurin inhibitors by boosting the critical role of the proapoptotic Bcl-2 factor Bim. ABT-737 48-55 BCL2 apoptosis regulator Homo sapiens 32-37 23869083-4 2013 The proapoptotic small-molecule Bcl-2 inhibitor ABT-737 promoted mixed chimerism induction and reversed the antitolerogenic effect of calcineurin inhibitors by boosting the critical role of the proapoptotic Bcl-2 factor Bim. ABT-737 48-55 BCL2 apoptosis regulator Homo sapiens 207-212 24137498-6 2013 We therefore designed a peptide with two glycine "hinges" replacing residues I14 and V15, of the wild-type Bcl-2-BH4 domain (Bcl-2-BH4-IV/GG). sapropterin 113-116 BCL2 apoptosis regulator Homo sapiens 107-112 24137498-0 2013 Alpha-helical destabilization of the Bcl-2-BH4-domain peptide abolishes its ability to inhibit the IP3 receptor. sapropterin 43-46 BCL2 apoptosis regulator Homo sapiens 37-42 24137498-6 2013 We therefore designed a peptide with two glycine "hinges" replacing residues I14 and V15, of the wild-type Bcl-2-BH4 domain (Bcl-2-BH4-IV/GG). sapropterin 113-116 BCL2 apoptosis regulator Homo sapiens 125-130 24137498-4 2013 Moreover, the Bcl-2 homology domain 4 (Bcl-2-BH4) has been identified as essential and sufficient for this IP3R-mediated anti-apoptotic activity. sapropterin 45-48 BCL2 apoptosis regulator Homo sapiens 14-19 24137498-4 2013 Moreover, the Bcl-2 homology domain 4 (Bcl-2-BH4) has been identified as essential and sufficient for this IP3R-mediated anti-apoptotic activity. sapropterin 45-48 BCL2 apoptosis regulator Homo sapiens 39-44 24137498-6 2013 We therefore designed a peptide with two glycine "hinges" replacing residues I14 and V15, of the wild-type Bcl-2-BH4 domain (Bcl-2-BH4-IV/GG). sapropterin 131-134 BCL2 apoptosis regulator Homo sapiens 107-112 24137498-5 2013 In the present study, we investigated whether the reported inhibitory effect of a Bcl-2-BH4 peptide on the IP 3R1 was related to the distinctive alpha-helical conformation of the BH4 domain peptide. sapropterin 88-91 BCL2 apoptosis regulator Homo sapiens 82-87 24137498-5 2013 In the present study, we investigated whether the reported inhibitory effect of a Bcl-2-BH4 peptide on the IP 3R1 was related to the distinctive alpha-helical conformation of the BH4 domain peptide. sapropterin 179-182 BCL2 apoptosis regulator Homo sapiens 82-87 24137498-6 2013 We therefore designed a peptide with two glycine "hinges" replacing residues I14 and V15, of the wild-type Bcl-2-BH4 domain (Bcl-2-BH4-IV/GG). sapropterin 131-134 BCL2 apoptosis regulator Homo sapiens 125-130 24137498-7 2013 By comparing the structural and functional properties of the Bcl-2-BH4-IV/GG peptide with its native counterpart, we found that the variant contained reduced alpha-helicity, neither bound nor inhibited the IP 3R1 channel, and in turn lost its anti-apoptotic effect. sapropterin 67-70 BCL2 apoptosis regulator Homo sapiens 61-66 24137498-8 2013 Similar results were obtained with other substitutions in Bcl-2-BH4 that destabilized the alpha-helix with concomitant loss of IP3R inhibition. sapropterin 64-67 BCL2 apoptosis regulator Homo sapiens 58-63 24137498-9 2013 These results provide new insights for the further development of Bcl-2-BH4-derived peptides as specific inhibitors of the IP3R with significant pharmacological implications. sapropterin 72-75 BCL2 apoptosis regulator Homo sapiens 66-71 23027129-6 2013 Silencing of FGFR2 sensitized NB cells to cisplatin-induced apoptosis, which was regulated by the downregulation of the anti-apoptotic proteins BCL2 and BCLXL. Cisplatin 42-51 BCL2 apoptosis regulator Homo sapiens 144-148 24013456-5 2013 RESULTS: We found that CS-miR-Mimic, SS-miR-Mimic and siRNA, all down regulated the mRNA and protein levels of their cognate target BCL2 or AKT1 in a concentration-dependent manner. Cesium 23-25 BCL2 apoptosis regulator Homo sapiens 132-136 24009722-7 2013 Reversal of MYCN or BCL2 suppression reduces the potency of I-BET726-induced cytotoxicity in a cell line-specific manner; however, neither factor fully accounts for I-BET726 sensitivity. 4-(1-acetyl-4-((4-chlorophenyl)amino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoic acid 60-68 BCL2 apoptosis regulator Homo sapiens 20-24 24009722-8 2013 Oral administration of I-BET726 to mouse xenograft models of human neuroblastoma results in tumor growth inhibition and down-regulation MYCN and BCL2 expression, suggesting a potential role for these genes in tumor growth. 4-(1-acetyl-4-((4-chlorophenyl)amino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoic acid 23-31 BCL2 apoptosis regulator Homo sapiens 145-149 23973991-4 2013 A mechanistic analysis demonstrated that sinulariolide-induced apoptosis was activated through a mitochondria-related pathway, showing up-regulation of Bax, Bad and AIF, and down- regulation of Bcl-2, Bcl-xL, MCl-1 and p-Bad. sinulariolide 41-54 BCL2 apoptosis regulator Homo sapiens 194-199 23991130-0 2013 MicroRNA-650 was a prognostic factor in human lung adenocarcinoma and confers the docetaxel chemoresistance of lung adenocarcinoma cells via regulating Bcl-2/Bax expression. Docetaxel 82-91 BCL2 apoptosis regulator Homo sapiens 152-157 23769741-5 2013 Our results showed that simvastatin significantly enhanced proliferation and increased both mRNA and protein levels of cyclin D2, Bcl-2 and the ratio of Bcl-2 to Bax (Bcl-2/Bax). Simvastatin 24-35 BCL2 apoptosis regulator Homo sapiens 130-135 23769741-5 2013 Our results showed that simvastatin significantly enhanced proliferation and increased both mRNA and protein levels of cyclin D2, Bcl-2 and the ratio of Bcl-2 to Bax (Bcl-2/Bax). Simvastatin 24-35 BCL2 apoptosis regulator Homo sapiens 153-158 23791612-6 2013 The apoptosis of LX-2 cells was induced by wedelolactone accompanied with the decreasing expression of anti-apoptotic Bcl-2 and increasing expression of pro-apoptotic Bax. wedelolactone 43-56 BCL2 apoptosis regulator Homo sapiens 118-123 23766363-9 2013 The limonoid-treated xenografts exhibited significant downregulation in the expression of proteins involved in tumor cell survival (Bcl-2, Bcl-xL, c-IAP-1, survivin, and Mcl-1), proliferation (c-Myc and cyclin D1), invasion (MMP-9, ICAM-1), metastasis (CXCR4), and angiogenesis (VEGF). Limonins 4-12 BCL2 apoptosis regulator Homo sapiens 132-137 23769741-5 2013 Our results showed that simvastatin significantly enhanced proliferation and increased both mRNA and protein levels of cyclin D2, Bcl-2 and the ratio of Bcl-2 to Bax (Bcl-2/Bax). Simvastatin 24-35 BCL2 apoptosis regulator Homo sapiens 153-158 23791612-9 2013 In conclusion, wedelolactone could significantly inhibit the activation of LX-2 cells, the underlying mechanisms of which included inducing Bcl-2 family involved apoptosis, up-regulating phosphorylated status of ERK and JNK expressions, and inhibiting nuclear factor-kappaB (NF-kappaB) mediated activity. wedelolactone 15-28 BCL2 apoptosis regulator Homo sapiens 140-145 23769741-7 2013 Most importantly, treatment with ATP synthase blocker, oligomycin, significantly decreased both simvastatin-stimulated ATP content and cell proliferation, and completely reversed the simvastatin-induced up-regulation of cyclin D2 and Bcl-2 expression in hOBs. Oligomycins 55-65 BCL2 apoptosis regulator Homo sapiens 234-239 23769741-7 2013 Most importantly, treatment with ATP synthase blocker, oligomycin, significantly decreased both simvastatin-stimulated ATP content and cell proliferation, and completely reversed the simvastatin-induced up-regulation of cyclin D2 and Bcl-2 expression in hOBs. Simvastatin 96-107 BCL2 apoptosis regulator Homo sapiens 234-239 23769741-7 2013 Most importantly, treatment with ATP synthase blocker, oligomycin, significantly decreased both simvastatin-stimulated ATP content and cell proliferation, and completely reversed the simvastatin-induced up-regulation of cyclin D2 and Bcl-2 expression in hOBs. Adenosine Triphosphate 33-36 BCL2 apoptosis regulator Homo sapiens 234-239 23769741-7 2013 Most importantly, treatment with ATP synthase blocker, oligomycin, significantly decreased both simvastatin-stimulated ATP content and cell proliferation, and completely reversed the simvastatin-induced up-regulation of cyclin D2 and Bcl-2 expression in hOBs. Simvastatin 183-194 BCL2 apoptosis regulator Homo sapiens 234-239 23769741-9 2013 These results indicate that the up-regulation of cyclin D2 and Bcl-2/Bax by simvastatin depends on the intact function of ATP synthase in the mitochondria of hOBs. Simvastatin 76-87 BCL2 apoptosis regulator Homo sapiens 63-68 23769741-10 2013 It suggests that simvastatin may promote hOB proliferation, at least partly, via up-regulating mitochondrial function and subsequently cyclin D2 and Bcl-2/Bax expression. Simvastatin 17-28 BCL2 apoptosis regulator Homo sapiens 149-154 23850692-0 2013 LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2. Temozolomide 40-52 BCL2 apoptosis regulator Homo sapiens 130-135 23798675-0 2013 CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak. bakuchiol 146-149 BCL2 apoptosis regulator Homo sapiens 107-112 23850692-0 2013 LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2. Temozolomide 54-57 BCL2 apoptosis regulator Homo sapiens 130-135 23969976-0 2013 Ziyuglycoside II-induced apoptosis in human gastric carcinoma BGC-823 cells by regulating Bax/Bcl-2 expression and activating caspase-3 pathway. ziyuglycoside II 0-16 BCL2 apoptosis regulator Homo sapiens 94-99 23940835-5 2013 Moreover, LCA increased cleavage of Bid and Bax, down-regulation of Bcl-2, permeabilization of the mitochondrial outer membrane and activation of caspase-9. Lithocholic Acid 10-13 BCL2 apoptosis regulator Homo sapiens 68-73 23921797-6 2013 In addition, isoalantolactone triggers apoptosis in prostate cancer cells via up-regulation of Bax, down-regulation of Bcl-2, survivin, and significant activation of caspase-3. isoalantolactone 13-29 BCL2 apoptosis regulator Homo sapiens 119-124 23969976-4 2013 Our results revealed that ziyuglycoside II could inhibit the proliferation of BGC-823 cells by inducing apoptosis but not cell cycle arrest, which was associated with regulation of Bax/Bcl-2 expression, and activation of the caspase-3 pathway. ziyuglycoside II 26-42 BCL2 apoptosis regulator Homo sapiens 185-190 23794243-0 2013 Characterization of the stereochemical structures of 2H-thiazolo[3,2-a]pyrimidine compounds and their binding affinities for anti-apoptotic Bcl-2 family proteins. 2h-thiazolo[3,2-a]pyrimidine 53-81 BCL2 apoptosis regulator Homo sapiens 140-145 23794243-1 2013 In a previous study we reported a class of compounds with a 2H-thiazolo[3,2-a]pyrimidine core structure as general inhibitors of anti-apoptotic Bcl-2 family proteins. 2h-thiazolo[3,2-a]pyrimidine 60-88 BCL2 apoptosis regulator Homo sapiens 144-149 23893182-5 2013 Bax (Bcl2 associated X protein) was up-regulated and Bcl-2 (B cell linphoma gene-2) was down-regulated after Se treatment in both cells in a dose-dependent manner. Selenium 109-111 BCL2 apoptosis regulator Homo sapiens 53-58 23651505-0 2013 Resistance to BH3 mimetic S1 in SCLC cells that up-regulate and phosphorylate Bcl-2 through ERK1/2. BH 3 14-17 BCL2 apoptosis regulator Homo sapiens 78-83 23651505-2 2013 The purpose of this work was to study the key factors that determine the sensitivity of SCLC cells to Bcl-2 homology domain-3 (BH3) mimetic S1 and the mechanism underlying the resistance of BH3 mimetics. BH 3 127-130 BCL2 apoptosis regulator Homo sapiens 102-107 23651505-9 2013 The dual function of MAPK/ERK pathway in defining BH3 mimetics was illustrated; ERK1/2 activation leaded to Bcl-2 transcriptional up-regulation and sustained phosphorylation in naive and acquired resistant SCLC cells. BH 3 50-53 BCL2 apoptosis regulator Homo sapiens 108-113 23802633-4 2013 On the other hand, the amount of BCL2, an anti-apoptotic protein, was well correlated with paclitaxel resistance. Paclitaxel 91-101 BCL2 apoptosis regulator Homo sapiens 33-37 23802633-5 2013 Treatment of the paclitaxel-resistant cell lines with ABT-737, an inhibitor of BCL2 and BCLxL, or simultaneous knock-down of BCL2 and BCLxL dramatically increased the cells" sensitivity, while knock-down of MCL1, another member of the BCL2 family, had only a minimal effect. Paclitaxel 17-27 BCL2 apoptosis regulator Homo sapiens 79-83 23802633-5 2013 Treatment of the paclitaxel-resistant cell lines with ABT-737, an inhibitor of BCL2 and BCLxL, or simultaneous knock-down of BCL2 and BCLxL dramatically increased the cells" sensitivity, while knock-down of MCL1, another member of the BCL2 family, had only a minimal effect. Paclitaxel 17-27 BCL2 apoptosis regulator Homo sapiens 125-129 23802633-5 2013 Treatment of the paclitaxel-resistant cell lines with ABT-737, an inhibitor of BCL2 and BCLxL, or simultaneous knock-down of BCL2 and BCLxL dramatically increased the cells" sensitivity, while knock-down of MCL1, another member of the BCL2 family, had only a minimal effect. Paclitaxel 17-27 BCL2 apoptosis regulator Homo sapiens 125-129 23688861-6 2013 In addition, Brucine dose-dependently caused LoVo cells apoptosis evidenced by Annexin V/PI staining Brucine-induced apoptosis was mediated via up-regulation of Bax and down-regulation of Bcl-2. brucine 101-108 BCL2 apoptosis regulator Homo sapiens 188-193 23609007-7 2013 To provide insight into the functions of RASD1 signaling pathway in calycosin-induced apoptosis, the expression of Bcl-2, Bax, and RASD1 in calycosin-treated cells were determined by Western blot assay. 7,3'-dihydroxy-4'-methoxyisoflavone 140-149 BCL2 apoptosis regulator Homo sapiens 115-120 23609007-9 2013 Moreover, compared with control group, the expression of Bcl-2 decreased with calycosin in MCF-7 cells, while Bax increased, which was significantly correlated with elevated expression of RASD1. 7,3'-dihydroxy-4'-methoxyisoflavone 78-87 BCL2 apoptosis regulator Homo sapiens 57-62 23972240-5 2013 Results revealed that administration of LC-5C and LC-15C had little or no cytotoxic effect in normal peripheral blood mononuclear cells, but caused considerable cell death through apoptosis in cancer (HeLa) cells, which was evident from the induction of DNA fragmentation, the increases in the expressions of protein and mRNA of caspase 3 and Bax, and the decreases in the expressions of Bcl2 and Apaf and in the release of cytochrome-c. lc-5c 40-45 BCL2 apoptosis regulator Homo sapiens 388-392 23972240-5 2013 Results revealed that administration of LC-5C and LC-15C had little or no cytotoxic effect in normal peripheral blood mononuclear cells, but caused considerable cell death through apoptosis in cancer (HeLa) cells, which was evident from the induction of DNA fragmentation, the increases in the expressions of protein and mRNA of caspase 3 and Bax, and the decreases in the expressions of Bcl2 and Apaf and in the release of cytochrome-c. lc-15c 50-56 BCL2 apoptosis regulator Homo sapiens 388-392 23722043-7 2013 Our results showed that siBVR, blocking generation of bilirubin, reversed the effect of hypoxia on enhancing cell survival and apoptotic protein (Bcl-2, procasepase-9, procasepase-3) expression, preventing nuclear shrinkage, DNA fragmentation and mitochondrial depolarization in starved PASMCs, which were recovered by exogenous bilirubin. Bilirubin 54-63 BCL2 apoptosis regulator Homo sapiens 146-151 23597504-7 2013 Bile acid-induced proapoptotic signals were also decreased, as evidenced by a reduction in the expression ratios Bax-alpha/Bcl-2, Bcl-xS/Bcl-2, and Bcl-xS/Bcl-xL. Bile Acids and Salts 0-9 BCL2 apoptosis regulator Homo sapiens 123-128 23597504-7 2013 Bile acid-induced proapoptotic signals were also decreased, as evidenced by a reduction in the expression ratios Bax-alpha/Bcl-2, Bcl-xS/Bcl-2, and Bcl-xS/Bcl-xL. Bile Acids and Salts 0-9 BCL2 apoptosis regulator Homo sapiens 137-142 23688861-6 2013 In addition, Brucine dose-dependently caused LoVo cells apoptosis evidenced by Annexin V/PI staining Brucine-induced apoptosis was mediated via up-regulation of Bax and down-regulation of Bcl-2. brucine 13-20 BCL2 apoptosis regulator Homo sapiens 188-193 23991582-8 2013 The expression of Bcl-2, Bcl-XL in Celecoxib+VCR group, Celecoxib+VCR+PGE2 group and Celecoxib group were significantly lower than those in VCR group (P < 0.01). Celecoxib 35-44 BCL2 apoptosis regulator Homo sapiens 18-23 23893182-5 2013 Bax (Bcl2 associated X protein) was up-regulated and Bcl-2 (B cell linphoma gene-2) was down-regulated after Se treatment in both cells in a dose-dependent manner. Selenium 109-111 BCL2 apoptosis regulator Homo sapiens 60-82 23522452-10 2013 The pro-apoptotic effect of XRT/RSV correlated with decreased expression of the anti-apoptotic molecule FLIP, Bcl-2, and survivin. xrt 28-31 BCL2 apoptosis regulator Homo sapiens 110-115 23839278-6 2013 GSI-mediated antiproliferative effects were associated with significant reductions in the expression of Notch1, Jagged1, Jagged2, p-Akt and Bcl-2. 2-(5-Chlorothiophen-2-Yl)-N-[(3s)-1-(4-{2-[(Dimethylamino)methyl]-1h-Imidazol-1-Yl}-2-Fluorophenyl)-2-Oxopyrrolidin-3-Yl]ethanesulfonamide 0-3 BCL2 apoptosis regulator Homo sapiens 140-145 23522452-10 2013 The pro-apoptotic effect of XRT/RSV correlated with decreased expression of the anti-apoptotic molecule FLIP, Bcl-2, and survivin. Resveratrol 32-35 BCL2 apoptosis regulator Homo sapiens 110-115 23723123-2 2013 The BCL2 inhibitor ABT-263 (navitoclax) is active in clinical trials for lymphoid malignancies, yet resistance is expected on the basis of preclinical models. navitoclax 19-26 BCL2 apoptosis regulator Homo sapiens 4-8 23614795-5 2013 Dosing of navitoclax (ABT-263) was complicated by thrombocytopenia due to BCL-XL inhibition, but the BCL-2 specific inhibitor ABT-199 (GDC-0199) should avoid this issue, and may overcome stroma-mediated resistance to apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 126-129 BCL2 apoptosis regulator Homo sapiens 101-106 23614795-5 2013 Dosing of navitoclax (ABT-263) was complicated by thrombocytopenia due to BCL-XL inhibition, but the BCL-2 specific inhibitor ABT-199 (GDC-0199) should avoid this issue, and may overcome stroma-mediated resistance to apoptosis. venetoclax 135-143 BCL2 apoptosis regulator Homo sapiens 101-106 23666368-1 2013 UNLABELLED: We have developed a novel class (2-amino-4-phenyl-4H-chromene-3-carboxylate) of inhibitors of tubulin assembly by modifying HA14-1, which is a Bcl-2 inhibitor discovered by our group. 2-amino-4-phenyl-4h-chromene-3-carboxylate 45-87 BCL2 apoptosis regulator Homo sapiens 155-160 23666368-5 2013 Treatment of HL-60/Bcl-2 leukemia and CRL5908 lung cancer cells with these mHA compounds led to pronounced microtubule density decreases, G2/M cell cycle arrest, and apoptosis, as determined by immunofluorescence microscopy, flow cytometry, and DNA fragmentation analysis. mha compounds 75-88 BCL2 apoptosis regulator Homo sapiens 19-24 23708869-0 2013 Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo. gossypol acetic acid 96-112 BCL2 apoptosis regulator Homo sapiens 78-83 23732836-8 2013 Cyclin D1, CDK4 and Bcl-2 protein expression was inhibited by TOFA, while caspase-3 was cleaved and activated. 5-(tetradecyloxy)-2-furancarboxylic acid 62-66 BCL2 apoptosis regulator Homo sapiens 20-25 23708383-5 2013 Evodiamine-induced G0/G1 arrest and apoptosis were associated with a decrease in Bcl-2, cyclin D1 and cyclin-dependent kinase 6 (CDK6) expression and an increase in Bax and p27Kip1 expression. evodiamine 0-10 BCL2 apoptosis regulator Homo sapiens 81-86 23708869-2 2013 Recent studies revealed that gossypol is a non-peptidic small molecule inhibitor of Bcl-2/Bcl-xl. Gossypol 29-37 BCL2 apoptosis regulator Homo sapiens 84-89 23733203-4 2013 The apoptotic effect of SB365 was demonstrated by increased levels of cleaved caspase-3 and decreased Bcl-2 expression via mitochondrial membrane potential, as well as elevated numbers of terminal deoxynucleotidyl-transferase-mediated dUTP nick end labeling (TUNEL)-positive apoptotic cells. sb365 24-29 BCL2 apoptosis regulator Homo sapiens 102-107 23708869-7 2013 Bcl-2 and Bcl-xl expression was decreased by 86.5+-1.2% and 35.9+-3.6%, respectively, after treatment with gossypol acetate at 25 micromol/l for 24 h. Preliminary studies in vivo showed that a growth inhibition (T/C) of 30.9% (gossypol acetate 40 mg/kg) was obtained in Balb/C mice bearing Wus1 cells. gossypol acetic acid 107-123 BCL2 apoptosis regulator Homo sapiens 0-5 23708869-7 2013 Bcl-2 and Bcl-xl expression was decreased by 86.5+-1.2% and 35.9+-3.6%, respectively, after treatment with gossypol acetate at 25 micromol/l for 24 h. Preliminary studies in vivo showed that a growth inhibition (T/C) of 30.9% (gossypol acetate 40 mg/kg) was obtained in Balb/C mice bearing Wus1 cells. gossypol acetic acid 227-243 BCL2 apoptosis regulator Homo sapiens 0-5 23743572-11 2013 Finally, LY294002 was able to decrease the expression of MDR1/P-gp, Bcl-2 and XIAP, and upregulate expression of Bax and caspase-3, thereby enhancing chemosensitivity to VCR by inhibiting a drug pump and inducing apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 BCL2 apoptosis regulator Homo sapiens 68-73 23708869-10 2013 Gossypol acetate may represent a promising new anticancer agent with a novel molecular mechanism and warrants further investigation as a single agent, or in combination with other chemotherapeutics, for human multiple myeloma with Bcl-2 overexpression. gossypol acetic acid 0-16 BCL2 apoptosis regulator Homo sapiens 231-236 23784204-4 2013 We demonstrated that the constructed Bcl-2 siRNA vector effectively silenced Bcl-2 gene expression in the GBC-SD human gallbladder carcinoma cells, inhibited cell proliferation, induced cell apoptosis, increased chemotherapeutic sensitivity to 5-fluorouracil and inhibited tumor growth in vivo. Fluorouracil 244-258 BCL2 apoptosis regulator Homo sapiens 37-42 23936501-5 2013 TCN induces G0/G1 cell cycle arrest and apoptosis in cancer cells, activating pro-apoptotic proteins, including caspase-3, -8 and PARP-1, and decreasing the expression of anti-apoptotic proteins Bcl-2, Bcl-xL, and survivin. trichothecin 0-3 BCL2 apoptosis regulator Homo sapiens 195-200 23553948-5 2013 Higher BAX/BCL2 RMFI ratio was associated positively with CR rate (P = 0.03), but this study was unable to show that it translated into improved EFS or OS. Chromium 58-60 BCL2 apoptosis regulator Homo sapiens 11-15 23936432-0 2013 Inhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR-182 and p21. Atorvastatin 58-70 BCL2 apoptosis regulator Homo sapiens 133-137 23761079-9 2013 Treatment with HCPT increased the expression of glucose-regulated protein 78 (GRP78), phospho-PERK, activating transcription factor 6 (ATF6), phosphoinositol-requiring kinase 1 (IRE1), C/EBP homologous protein (CHOP), Bax, and phospho-c-Jun N-terminal kinase (JNK) and decreased the expression of Bcl-2. hydroxycamptothecinum 15-19 BCL2 apoptosis regulator Homo sapiens 297-302 23936432-10 2013 Bcl2 was downregulated and p21 was upregulated in PC3 cells exposed to ATO. Atorvastatin 71-74 BCL2 apoptosis regulator Homo sapiens 0-4 23900224-3 2013 After identifying the overexpressed resistance-related antiapoptotic genes (survivin and bcl-2) in cisplatin-resistant cells, the siRNA sequences were designed and screened to select the most efficacious candidates. Cisplatin 99-108 BCL2 apoptosis regulator Homo sapiens 89-94 23900225-0 2013 U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In Vivo. Oligonucleotides 11-27 BCL2 apoptosis regulator Homo sapiens 38-42 23887633-1 2013 ABT-263 and its structural analogues ABT-199 and ABT-737 inhibit B-cell lymphoma 2 (Bcl-2), BCL2L1 long isoform (Bcl-xL) and BCL2L2 (Bcl-w) proteins and promote cancer cell death. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 65-82 23887633-1 2013 ABT-263 and its structural analogues ABT-199 and ABT-737 inhibit B-cell lymphoma 2 (Bcl-2), BCL2L1 long isoform (Bcl-xL) and BCL2L2 (Bcl-w) proteins and promote cancer cell death. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 84-89 23887633-1 2013 ABT-263 and its structural analogues ABT-199 and ABT-737 inhibit B-cell lymphoma 2 (Bcl-2), BCL2L1 long isoform (Bcl-xL) and BCL2L2 (Bcl-w) proteins and promote cancer cell death. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 37-40 BCL2 apoptosis regulator Homo sapiens 65-82 23887633-1 2013 ABT-263 and its structural analogues ABT-199 and ABT-737 inhibit B-cell lymphoma 2 (Bcl-2), BCL2L1 long isoform (Bcl-xL) and BCL2L2 (Bcl-w) proteins and promote cancer cell death. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 37-40 BCL2 apoptosis regulator Homo sapiens 84-89 23887633-1 2013 ABT-263 and its structural analogues ABT-199 and ABT-737 inhibit B-cell lymphoma 2 (Bcl-2), BCL2L1 long isoform (Bcl-xL) and BCL2L2 (Bcl-w) proteins and promote cancer cell death. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 37-40 BCL2 apoptosis regulator Homo sapiens 65-82 23887633-1 2013 ABT-263 and its structural analogues ABT-199 and ABT-737 inhibit B-cell lymphoma 2 (Bcl-2), BCL2L1 long isoform (Bcl-xL) and BCL2L2 (Bcl-w) proteins and promote cancer cell death. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 37-40 BCL2 apoptosis regulator Homo sapiens 84-89 23887633-3 2013 In particular, we demonstrate that ABT-263 altered Bcl-xL interactions with Bcl-2 antagonist of cell death (Bad), Bcl-2-associated X protein (Bax), uveal autoantigen with coiled-coil domains and ankyrin repeats protein (UACA). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 35-38 BCL2 apoptosis regulator Homo sapiens 76-81 23880933-8 2013 Sinulariolide-induced apoptosis is relevant to mitochondrial-mediated apoptosis via caspase-dependent pathways, elucidated by the loss of mitochondrial membrane potential, release of cytochrome c, and activation of Bax, Bad and caspase-3/-9, as well as suppression of p-Bad, Bcl-xL and Bcl-2. sinulariolide 0-13 BCL2 apoptosis regulator Homo sapiens 286-291 23402819-7 2013 The high efficacy correlated to BimL interaction with all antiapoptotic Bcl-2 family members in melanoma cells, shown by co-immunoprecipitation analyses for Bcl-2, Bcl-xL, Mcl-1 and Bcl-w. biml 32-36 BCL2 apoptosis regulator Homo sapiens 72-77 23402819-7 2013 The high efficacy correlated to BimL interaction with all antiapoptotic Bcl-2 family members in melanoma cells, shown by co-immunoprecipitation analyses for Bcl-2, Bcl-xL, Mcl-1 and Bcl-w. biml 32-36 BCL2 apoptosis regulator Homo sapiens 157-162 23861973-11 2013 In addition, ATO treatment decreased the expression of Bcl-2 and Bcl-xL. Arsenic Trioxide 13-16 BCL2 apoptosis regulator Homo sapiens 55-60 23837445-0 2013 Induction of apoptosis in melanoma A375 cells by a chloroform fraction of Centratherum anthelminticum (L.) seeds involves NF-kappaB, p53 and Bcl-2-controlled mitochondrial signaling pathways. Chloroform 51-61 BCL2 apoptosis regulator Homo sapiens 141-146 23837445-15 2013 CACF treatment also resulted in higher reactive oxygen species (ROS) production and lower Bcl-2 expression, leading to decrease mitochondrial membrane potential (MMP). cacf 0-4 BCL2 apoptosis regulator Homo sapiens 90-95 23880928-6 2013 In addition, the authors found fucoidan-induced significantly attenuated in Bcl-2 overexpressing U937 cells, and pretreatment with fucoidan and HA 14-1, a small-molecule Bcl-2 inhibitor, markedly increased fucoidan-mediated apoptosis in Bcl-2 overexpressing U937 cells. fucoidan 31-39 BCL2 apoptosis regulator Homo sapiens 76-81 23845438-2 2013 In this issue of Cancer Cell, Vaillant and colleagues demonstrate that targeting BCL-2 with BH3 mimetics improves the response of xenografts from primary ER(+) breast tumors to endocrine therapy and reduces tamoxifen-induced endometrial hyperplasia, a strategy with potential clinical applicability. BH 3 92-95 BCL2 apoptosis regulator Homo sapiens 81-86 23845438-2 2013 In this issue of Cancer Cell, Vaillant and colleagues demonstrate that targeting BCL-2 with BH3 mimetics improves the response of xenografts from primary ER(+) breast tumors to endocrine therapy and reduces tamoxifen-induced endometrial hyperplasia, a strategy with potential clinical applicability. Tamoxifen 207-216 BCL2 apoptosis regulator Homo sapiens 81-86 23845444-0 2013 Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. BH 3 25-28 BCL2 apoptosis regulator Homo sapiens 10-15 23845444-0 2013 Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 37-40 BCL2 apoptosis regulator Homo sapiens 10-15 23628508-6 2013 Western blot analysis showed that aspidin BB suppressed Bcl-2 expression and enhanced Bax expression to desintegrate the outer mitochondrial membrane, then caused cytochrome c release which led to the activation of effector caspase-3, and further cleaved the poly ADP-ribose polymerase (PARP) in the nucleus, finally induced cell apoptosis. aspidin BB 34-41 BCL2 apoptosis regulator Homo sapiens 56-61 23660334-2 2013 Sanguinarine generated ROS, which was followed by a decrease in the mitochondrial membrane potential (MMP), the activation of caspase-9 and -3, and the down-regulation of anti-apoptotic proteins, such as Bcl2, XIAP and cIAP-1. sanguinarine 0-12 BCL2 apoptosis regulator Homo sapiens 204-208 23880928-6 2013 In addition, the authors found fucoidan-induced significantly attenuated in Bcl-2 overexpressing U937 cells, and pretreatment with fucoidan and HA 14-1, a small-molecule Bcl-2 inhibitor, markedly increased fucoidan-mediated apoptosis in Bcl-2 overexpressing U937 cells. fucoidan 31-39 BCL2 apoptosis regulator Homo sapiens 170-175 23660334-2 2013 Sanguinarine generated ROS, which was followed by a decrease in the mitochondrial membrane potential (MMP), the activation of caspase-9 and -3, and the down-regulation of anti-apoptotic proteins, such as Bcl2, XIAP and cIAP-1. Reactive Oxygen Species 23-26 BCL2 apoptosis regulator Homo sapiens 204-208 23880928-6 2013 In addition, the authors found fucoidan-induced significantly attenuated in Bcl-2 overexpressing U937 cells, and pretreatment with fucoidan and HA 14-1, a small-molecule Bcl-2 inhibitor, markedly increased fucoidan-mediated apoptosis in Bcl-2 overexpressing U937 cells. fucoidan 31-39 BCL2 apoptosis regulator Homo sapiens 170-175 23525071-9 2013 hnRNP A2/B1 siRNA combined with gemcitabine, 5-FU and oxaliplatin significantly increased (P<0.01) apoptosis of pancreatic cancer cell lines SW1990 and BxPC-3, increased the expression level of Bax mRNA, decreased Bcl-2 mRNA and MDR1 mRNA expression (P<0.01), and induced no change in p53, TRAIL, and Survivin mRNA expression in SW1990. Oxaliplatin 54-65 BCL2 apoptosis regulator Homo sapiens 217-222 23334251-13 2013 Survivin and beta-catenin expression were associated with intraperitoneal recurrence; high bcl-2 expression predicted longer DSS. dss 125-128 BCL2 apoptosis regulator Homo sapiens 91-96 23360981-0 2013 Non-apoptotic roles of Bcl-2 family: the calcium connection. Calcium 41-48 BCL2 apoptosis regulator Homo sapiens 23-28 23423712-12 2013 The SP600125 and U0126 neuroprotection appears related to NF-kappaB-regulated transcriptional control of Bcl-2 and XIAP. pyrazolanthrone 4-12 BCL2 apoptosis regulator Homo sapiens 105-110 23423712-12 2013 The SP600125 and U0126 neuroprotection appears related to NF-kappaB-regulated transcriptional control of Bcl-2 and XIAP. U 0126 17-22 BCL2 apoptosis regulator Homo sapiens 105-110 23463292-1 2013 Aquaporin-3 (AQP3), a water/glycerol-transporting protein that facilitates water, urea, and glycerol transport, can inhibit arsenite-induced apoptosis by up-regulating Bcl-2. Glycerol 28-36 BCL2 apoptosis regulator Homo sapiens 168-173 23463292-1 2013 Aquaporin-3 (AQP3), a water/glycerol-transporting protein that facilitates water, urea, and glycerol transport, can inhibit arsenite-induced apoptosis by up-regulating Bcl-2. arsenite 124-132 BCL2 apoptosis regulator Homo sapiens 168-173 23552471-10 2013 While investigating caspase activity and the expression of apoptosis-related proteins, fengycin was found to induce apoptosis in 95D cells through the mitochondrial pathway, evidenced by increased caspase activity, Bax expression, and cytochrome c release into the cytoplasm, as well as decreased Bcl-2 levels. fengycin 87-95 BCL2 apoptosis regulator Homo sapiens 297-302 23360981-6 2013 In particular, in these organelles Bcl-2 proteins seem to be involved in calcium homeostasis regulation although the mechanisms underlying this function are still misunderstood. Calcium 73-80 BCL2 apoptosis regulator Homo sapiens 35-40 23360981-9 2013 Here, we review the current knowledge on the control of calcium homeostasis by the Bcl-2 family at the endoplasmic reticulum and at the mitochondria. Calcium 56-63 BCL2 apoptosis regulator Homo sapiens 83-88 23582862-6 2013 The DOX-loaded unimolecular micelles up-regulated the cleavage of PARP and Caspase 3 proteins and increased the protein expression of Bax along with a concomitant decrease in Bcl2. Doxorubicin 4-7 BCL2 apoptosis regulator Homo sapiens 175-179 23788110-0 2013 Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy. ABT-737 63-70 BCL2 apoptosis regulator Homo sapiens 30-35 23815892-9 2013 The activity of intracellular antioxidants (superoxide dismutase and glutathione peroxidase) increased, as did mRNA and protein levels of the antiapoptotic gene Bcl-2 after the addition of geniposide. geniposide 189-199 BCL2 apoptosis regulator Homo sapiens 161-166 23815892-11 2013 CONCLUSIONS: Our results indicate that geniposide can protect SH-SY5Y cells against formaldehyde stress through modulating the expression of Bcl-2, P53, caspase 3 and caspase 9, and by increasing the activity of intracellular superoxide dismutase and glutathione peroxidase. geniposide 39-49 BCL2 apoptosis regulator Homo sapiens 141-146 23792647-10 2013 Combined CINK4 and paclitaxel produced synergistic anti-proliferative activity and increased apoptosis through reduced cyclin D1 and Bcl-2 in KRAS mutation-positive cancer cells. CINK4 9-14 BCL2 apoptosis regulator Homo sapiens 133-138 23792647-10 2013 Combined CINK4 and paclitaxel produced synergistic anti-proliferative activity and increased apoptosis through reduced cyclin D1 and Bcl-2 in KRAS mutation-positive cancer cells. Paclitaxel 19-29 BCL2 apoptosis regulator Homo sapiens 133-138 23773853-9 2013 An additional highlight of this study is the finding that Pho-s inhibits Bcl-2, inducing apoptosis through the mitochondrial pathway. phosphorylethanolamine 58-63 BCL2 apoptosis regulator Homo sapiens 73-78 23788110-2 2013 However, small-molecule inhibitors of Bcl-2 family members such as ABT-737 restore a functional apoptosis pathway in cancer cells, and its oral analog ABT-263 (Navitoclax) has entered clinical trials. ABT-737 67-74 BCL2 apoptosis regulator Homo sapiens 38-43 23792636-6 2013 Further, PXN mutants, through their interactions with BCL-2 and DRP-1, could regulate cisplatin drug resistance in human lung cancer cells. Cisplatin 86-95 BCL2 apoptosis regulator Homo sapiens 54-59 23792648-0 2013 Effect of doxorubicin, oxaliplatin, and methotrexate administration on the transcriptional activity of BCL-2 family gene members in stomach cancer cells. Doxorubicin 10-21 BCL2 apoptosis regulator Homo sapiens 103-108 23475945-7 2013 At molecular level, BMJ caused caspases activation, altered expression of Bcl-2 family members and cytochrome-c release into the cytosol. (12R)-12-methyltetradecanoic acid 20-23 BCL2 apoptosis regulator Homo sapiens 74-79 23792648-0 2013 Effect of doxorubicin, oxaliplatin, and methotrexate administration on the transcriptional activity of BCL-2 family gene members in stomach cancer cells. Oxaliplatin 23-34 BCL2 apoptosis regulator Homo sapiens 103-108 23792648-0 2013 Effect of doxorubicin, oxaliplatin, and methotrexate administration on the transcriptional activity of BCL-2 family gene members in stomach cancer cells. Methotrexate 40-52 BCL2 apoptosis regulator Homo sapiens 103-108 23579242-4 2013 Here we demonstrate that the beta-adrenoceptor/cAMP/PKA pathway triggers apoptosis through the transcriptional induction of the pro-apoptotic BH3-only Bcl-2 family member Bim in tissues such as the thymus and the heart. Cyclic AMP 47-51 BCL2 apoptosis regulator Homo sapiens 151-156 23612742-7 2013 Consistent with its anti-apoptotic target BCL2, miR-205 promoted apoptosis in prostate cancer cells in response to DNA damage by cisplatin and doxorubicin in the prostate cancer cell lines PC3 and LnCap. Cisplatin 129-138 BCL2 apoptosis regulator Homo sapiens 42-46 23410041-5 2013 The method was implemented with anticancer activity of Gossypol acetic acid against BCL2 target for colorectal cancer. gossypol acetic acid 55-75 BCL2 apoptosis regulator Homo sapiens 84-88 23410041-9 2013 The suggested compounds were further validated by docking study with Gossypol acetic acid and "Tetrahydroisoquinoline amide substituted phenyl pyrazole" cocrystallized with chimeric BCL2-XL (PDBID: 2W3L) protein. gossypol acetic acid 69-89 BCL2 apoptosis regulator Homo sapiens 182-186 23410041-9 2013 The suggested compounds were further validated by docking study with Gossypol acetic acid and "Tetrahydroisoquinoline amide substituted phenyl pyrazole" cocrystallized with chimeric BCL2-XL (PDBID: 2W3L) protein. tetrahydroisoquinoline amide 95-123 BCL2 apoptosis regulator Homo sapiens 182-186 23410041-9 2013 The suggested compounds were further validated by docking study with Gossypol acetic acid and "Tetrahydroisoquinoline amide substituted phenyl pyrazole" cocrystallized with chimeric BCL2-XL (PDBID: 2W3L) protein. phenyl pyrazole 136-151 BCL2 apoptosis regulator Homo sapiens 182-186 23674504-2 2013 Previously it was reported that miR-15/16 is the target of 13q14 deletions and plays a tumor suppressor role by suppressing Bcl-2. mir-15 32-38 BCL2 apoptosis regulator Homo sapiens 124-129 23607503-6 2013 H2O2 decreased the cellular levels of Bcl-2 and c-IAPs, cellular inhibitors of apoptosis proteins, but increased caspase-3 activation. Hydrogen Peroxide 0-4 BCL2 apoptosis regulator Homo sapiens 38-43 23539633-5 2013 In these women, physiological estradiol concentrations are able to induce an enhanced inflammatory response mediated by local chemokine production and to reinforce mechanisms of cell survival mediated by extracellular signal-regulated kinases and Bcl-2. Estradiol 30-39 BCL2 apoptosis regulator Homo sapiens 247-252 23670355-11 2013 In addition, nicorandil inhibited the enhancement of caspase-3 and -9 expression, and the increase in the Bax/Bcl-2 expression ratio, induced by hypoxia. Nicorandil 13-23 BCL2 apoptosis regulator Homo sapiens 110-115 23416365-2 2013 In this study, we utilize the copper-chelator drug ATN-224 (choline tetrathiomolybdate) to induce cell death in oxidative stress-resistant cells and cells overexpressing Bcl-2 by modulating the cellular redox environment and causing mitochondrial dysfunction. Copper 30-36 BCL2 apoptosis regulator Homo sapiens 170-175 23416365-2 2013 In this study, we utilize the copper-chelator drug ATN-224 (choline tetrathiomolybdate) to induce cell death in oxidative stress-resistant cells and cells overexpressing Bcl-2 by modulating the cellular redox environment and causing mitochondrial dysfunction. choline tetrathiomolybdate 60-86 BCL2 apoptosis regulator Homo sapiens 170-175 23677253-10 2013 Bufalin synergized with the JNK pathway to induce autophagy of hepatoma cells and is closely associated with the upregulation of TNF, BECN-1, MAPK and ATG8, together with the downregulation of Bcl-2 and Bid. bufalin 0-7 BCL2 apoptosis regulator Homo sapiens 193-198 23612742-7 2013 Consistent with its anti-apoptotic target BCL2, miR-205 promoted apoptosis in prostate cancer cells in response to DNA damage by cisplatin and doxorubicin in the prostate cancer cell lines PC3 and LnCap. Doxorubicin 143-154 BCL2 apoptosis regulator Homo sapiens 42-46 23386420-6 2013 Incubation with bleomycin (LD50 ) and H2O2 for 24 h increased Caspase-3, -8, -9 activities, Cyt-c and Bax levels and decreased Bcl-2 levels. Hydrogen Peroxide 38-42 BCL2 apoptosis regulator Homo sapiens 127-132 23386420-7 2013 The concurrent incubation of NT2 cells with bleomycin/H2O2 and NAC (5 mM) for 24 h abolished bleomycin/H2O2-dependent increases in Caspase-3, -8, -9 activities, Bax and Cyt-c levels and bleomycin/H2O2-dependent decrease in Bcl-2 level. Bleomycin 44-53 BCL2 apoptosis regulator Homo sapiens 223-228 23386420-6 2013 Incubation with bleomycin (LD50 ) and H2O2 for 24 h increased Caspase-3, -8, -9 activities, Cyt-c and Bax levels and decreased Bcl-2 levels. Bleomycin 16-25 BCL2 apoptosis regulator Homo sapiens 127-132 23386420-7 2013 The concurrent incubation of NT2 cells with bleomycin/H2O2 and NAC (5 mM) for 24 h abolished bleomycin/H2O2-dependent increases in Caspase-3, -8, -9 activities, Bax and Cyt-c levels and bleomycin/H2O2-dependent decrease in Bcl-2 level. Hydrogen Peroxide 54-58 BCL2 apoptosis regulator Homo sapiens 223-228 23386420-7 2013 The concurrent incubation of NT2 cells with bleomycin/H2O2 and NAC (5 mM) for 24 h abolished bleomycin/H2O2-dependent increases in Caspase-3, -8, -9 activities, Bax and Cyt-c levels and bleomycin/H2O2-dependent decrease in Bcl-2 level. Acetylcysteine 63-66 BCL2 apoptosis regulator Homo sapiens 223-228 23386420-7 2013 The concurrent incubation of NT2 cells with bleomycin/H2O2 and NAC (5 mM) for 24 h abolished bleomycin/H2O2-dependent increases in Caspase-3, -8, -9 activities, Bax and Cyt-c levels and bleomycin/H2O2-dependent decrease in Bcl-2 level. Bleomycin 93-102 BCL2 apoptosis regulator Homo sapiens 223-228 23386420-7 2013 The concurrent incubation of NT2 cells with bleomycin/H2O2 and NAC (5 mM) for 24 h abolished bleomycin/H2O2-dependent increases in Caspase-3, -8, -9 activities, Bax and Cyt-c levels and bleomycin/H2O2-dependent decrease in Bcl-2 level. Bleomycin 93-102 BCL2 apoptosis regulator Homo sapiens 223-228 23444126-7 2013 Treatment of fibroblast cell cultures with cisplatin induced a significant increase in beclin 1 and caspase 3 protein levels but a reduction in Bcl-2 expression. Cisplatin 43-52 BCL2 apoptosis regulator Homo sapiens 144-149 23361188-8 2013 In response to H(2)O(2)-induced apoptosis, Bax, acting as one of the pivotal pro-apoptotic members of Bcl-2 family, increased significantly, which directly resulted in an increased ratio of Bax to anti-apoptotic protein Bcl-2 (Bax/Bcl-2). Hydrogen Peroxide 15-23 BCL2 apoptosis regulator Homo sapiens 102-107 23361188-8 2013 In response to H(2)O(2)-induced apoptosis, Bax, acting as one of the pivotal pro-apoptotic members of Bcl-2 family, increased significantly, which directly resulted in an increased ratio of Bax to anti-apoptotic protein Bcl-2 (Bax/Bcl-2). Hydrogen Peroxide 15-23 BCL2 apoptosis regulator Homo sapiens 220-225 23361188-8 2013 In response to H(2)O(2)-induced apoptosis, Bax, acting as one of the pivotal pro-apoptotic members of Bcl-2 family, increased significantly, which directly resulted in an increased ratio of Bax to anti-apoptotic protein Bcl-2 (Bax/Bcl-2). Hydrogen Peroxide 15-23 BCL2 apoptosis regulator Homo sapiens 220-225 23734725-2 2013 Small molecule inhibitors such as AT-101 (a BH3-mimetic drug) have been developed to inhibit the antiapoptotic activity of Bcl-2 proteins, which proved effective in restoring radio- and chemo-sensitivity in head and neck cancer cells. gossypol acetic acid 34-40 BCL2 apoptosis regulator Homo sapiens 123-128 23700323-8 2013 Immunohistochemistry analysis of the tumor tissues showed a distinctive decrease in Bcl-2 staining in beta-elemene (56 %) and beta-elemene + methoxyamine (36 %) groups when compared with the negative control (77 %). beta-elemene 102-114 BCL2 apoptosis regulator Homo sapiens 84-89 23700323-8 2013 Immunohistochemistry analysis of the tumor tissues showed a distinctive decrease in Bcl-2 staining in beta-elemene (56 %) and beta-elemene + methoxyamine (36 %) groups when compared with the negative control (77 %). beta-elemene 126-138 BCL2 apoptosis regulator Homo sapiens 84-89 23700323-8 2013 Immunohistochemistry analysis of the tumor tissues showed a distinctive decrease in Bcl-2 staining in beta-elemene (56 %) and beta-elemene + methoxyamine (36 %) groups when compared with the negative control (77 %). methoxyamine 141-153 BCL2 apoptosis regulator Homo sapiens 84-89 23734725-2 2013 Small molecule inhibitors such as AT-101 (a BH3-mimetic drug) have been developed to inhibit the antiapoptotic activity of Bcl-2 proteins, which proved effective in restoring radio- and chemo-sensitivity in head and neck cancer cells. BH 3 44-47 BCL2 apoptosis regulator Homo sapiens 123-128 23734725-3 2013 However, high doses of AT-101 are associated with gastrointestinal, hepatic, and fertility side effects, which prompted the search for other Bcl-2 inhibitors. gossypol acetic acid 23-29 BCL2 apoptosis regulator Homo sapiens 141-146 23734725-6 2013 We report the development of degradable star-shaped polymers that proved to condense anti-Bcl-2 siRNA into "smart" pH-sensitive and membrane-destabilizing particles that shuttle their cargo past the endosomal membrane and into the cytoplasm of head and neck cancer cells. Polymers 52-60 BCL2 apoptosis regulator Homo sapiens 90-95 23792689-2 2013 The anti-apoptotic Bcl-2 family protein Bcl-xL also regulates neurotransmitter release and recovery in part by increasing ATP availability from mitochondria. Adenosine Triphosphate 122-125 BCL2 apoptosis regulator Homo sapiens 19-24 23734725-8 2013 Results also show that combining "smart" anti-Bcl-2 particles with the IC25 of AT-101 (inhibitory concentration responsible for killing 25% of the cells) synergistically inhibits cancer cell proliferation and increases cell apoptosis, which reduce the survival of UM-SCC-17B cancer cells compared to treatment with AT-101 alone. gossypol acetic acid 79-85 BCL2 apoptosis regulator Homo sapiens 46-51 23734725-8 2013 Results also show that combining "smart" anti-Bcl-2 particles with the IC25 of AT-101 (inhibitory concentration responsible for killing 25% of the cells) synergistically inhibits cancer cell proliferation and increases cell apoptosis, which reduce the survival of UM-SCC-17B cancer cells compared to treatment with AT-101 alone. gossypol acetic acid 315-321 BCL2 apoptosis regulator Homo sapiens 46-51 23611835-4 2013 Mechanistically, SB was shown to possess a microtubule destabilizing activity evidenced by hyperphosphorylation of Bcl2 and BclxL, suppression of microtubule polymerization and induction of a prometaphase arrest. SB 225002 17-19 BCL2 apoptosis regulator Homo sapiens 115-119 23624748-6 2013 We also found that overexpression of Bcl-2 completely blocked RU486-mediated apoptosis. Mifepristone 62-67 BCL2 apoptosis regulator Homo sapiens 37-42 23840351-2 2013 Furthermore, TCS down-regulated Bcl-2 expression was abrogated by a decoy oligonucleotide (OGN) to the cyclic AMP-responsive element (CRE). Oligonucleotides 74-89 BCL2 apoptosis regulator Homo sapiens 32-37 23840351-2 2013 Furthermore, TCS down-regulated Bcl-2 expression was abrogated by a decoy oligonucleotide (OGN) to the cyclic AMP-responsive element (CRE). Cyclic AMP 103-113 BCL2 apoptosis regulator Homo sapiens 32-37 23802572-15 2013 Furthermore, western blot and quantitative real time PCR assays demonstrated that the curcumin induced apoptosis in GBC-SD cells by regulating the ratio of Bcl-2/Bax and activating the expression of cleaved caspase-3. Curcumin 86-94 BCL2 apoptosis regulator Homo sapiens 156-161 23799362-9 2013 Additionally, NaHS increased Bcl-2 expression and decreased the expression of Bax, Caspase-3 and Caspase-9 in a dose-dependent way. sodium bisulfide 14-18 BCL2 apoptosis regulator Homo sapiens 29-34 23799118-11 2013 Desflurane preconditioning up-regulated the expression of c-IAP1 and Bcl-2, blocked the cleavage of caspase-3 and reduced SMAC release, and decreased the cell death of HUVECs after A/R. Desflurane 0-10 BCL2 apoptosis regulator Homo sapiens 69-74 23673431-6 2013 Compared to quercetin and 2-ME alone, combining quercetin with 2-ME at appropriate concentrations i) showed synergistic antiproliferative and proapoptotic activities; ii) increased G2/M phase population of cells; iii) decreased the ratio of Bcl-2/Bax significantly. Quercetin 48-57 BCL2 apoptosis regulator Homo sapiens 241-246 23673431-6 2013 Compared to quercetin and 2-ME alone, combining quercetin with 2-ME at appropriate concentrations i) showed synergistic antiproliferative and proapoptotic activities; ii) increased G2/M phase population of cells; iii) decreased the ratio of Bcl-2/Bax significantly. 2-Methoxyestradiol 63-67 BCL2 apoptosis regulator Homo sapiens 241-246 23673452-9 2013 Following treatment with sirtinol (inhibitor of SIRT1), the expression of the pro-survival protein Bcl-2 was markedly decreased in both MCF-7 and MDA-MB-231 cell lines, particularly in MDA-MB-231. sirtinol 25-33 BCL2 apoptosis regulator Homo sapiens 99-104 24079252-11 2013 RT-PCR test showed that curcumin can activate the expression of Bax and Caspase-3, inhibit the expression of Bcl-2 and Bcl-xL at the mRNA level. Curcumin 24-32 BCL2 apoptosis regulator Homo sapiens 109-114 23788190-4 2013 After treatment with fraxetin, the expression of ERalpha in MCF-7 cell was decreased, and estrogen genomic signaling pathway was inhibited by down-regulating the expression of cyclin D1 and Bcl-2 proteins. fraxetin 21-29 BCL2 apoptosis regulator Homo sapiens 190-195 23315866-0 2013 Ketamine used as an acesodyne in human breast cancer therapy causes an undesirable side effect, upregulating anti-apoptosis protein Bcl-2 expression. Ketamine 0-8 BCL2 apoptosis regulator Homo sapiens 132-137 23435476-1 2013 Boron complexes (dpp-bian)BCl2 (1) and (dpp-bian)BX (X = Cl, 2; Br, 3) (dpp-bian = 1,2-bis[(2,6-diisopropylphenyl)imino]acenaphthene) have been prepared by reacting mixtures dpp-bian-BX3 (1 : 1) with one (1) and two (2 and 3) equivalents of sodium correspondingly in toluene. Boron 0-5 BCL2 apoptosis regulator Homo sapiens 26-30 23435476-1 2013 Boron complexes (dpp-bian)BCl2 (1) and (dpp-bian)BX (X = Cl, 2; Br, 3) (dpp-bian = 1,2-bis[(2,6-diisopropylphenyl)imino]acenaphthene) have been prepared by reacting mixtures dpp-bian-BX3 (1 : 1) with one (1) and two (2 and 3) equivalents of sodium correspondingly in toluene. dpp-bian 17-25 BCL2 apoptosis regulator Homo sapiens 26-30 23453308-5 2013 Jacaric acid induced concentration- and time-depedent LNCaP cell death through activation of intrinsic and extrinsic apoptotic pathways resulting in cleavage of PARP-1, modulation of pro- and antiapoptotic Bcl-2 family of proteins and increased cleavage of caspase-3, -8 and -9. jacaric acid 0-12 BCL2 apoptosis regulator Homo sapiens 206-211 23688426-0 2013 Novel tamoxifen derivative Ridaifen-B induces Bcl-2 independent autophagy without estrogen receptor involvement. Tamoxifen 6-15 BCL2 apoptosis regulator Homo sapiens 46-51 23688426-0 2013 Novel tamoxifen derivative Ridaifen-B induces Bcl-2 independent autophagy without estrogen receptor involvement. ridaifen-B 27-37 BCL2 apoptosis regulator Homo sapiens 46-51 23485815-5 2013 PF pretreatment also inhibited NPC apoptosis induced by H2O2 by reversing the decreased level of Procaspase-3 and balancing Bcl-2 and Bax expression. Hydrogen Peroxide 56-60 BCL2 apoptosis regulator Homo sapiens 124-129 23315866-3 2013 We found that ketamine can upregulate the level of anti-apoptosis protein Bcl-2, which promotes breast cancer cell invasion and proliferation. Ketamine 14-22 BCL2 apoptosis regulator Homo sapiens 74-79 23315866-4 2013 Knockdown of Bcl-2 could inhibit the increase of Bcl-2 and reduce the invasion and proliferation caused by ketamine in human breast cancer cells. Ketamine 107-115 BCL2 apoptosis regulator Homo sapiens 13-18 23421409-11 2013 In addition, the two variants were resistant to CAFdA-induced apoptosis due to Bcl2 overexpression and decreased Bim. Clofarabine 48-53 BCL2 apoptosis regulator Homo sapiens 79-83 23755153-5 2014 Cisplatin treatment was shown to induce apoptosis, grossly observed by reduced tumor formation, through reduced Bcl-2 and survivin protein expression levels with an increase in caspase 3 expression compared to control tumors. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 112-117 23755153-6 2014 Tamoxifen treatment significantly altered the hormone receptor expression levels of the tumor, while additionally upregulating Bcl-2 and Cyclin D1. Tamoxifen 0-9 BCL2 apoptosis regulator Homo sapiens 127-132 23485012-6 2013 Expression of exogenous miR-138 suppressed PASMC apoptosis, prevented caspase activation and disrupted Bcl-2 signalling. mir-138 24-31 BCL2 apoptosis regulator Homo sapiens 103-108 23485394-0 2013 Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2. 9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- 20-26 BCL2 apoptosis regulator Homo sapiens 166-171 23575899-5 2013 Furthermore, CdCl2 also significantly stimulate the expression of Bcl-2 proteins in porcine granulosa cells than that in the control. Cadmium Chloride 13-18 BCL2 apoptosis regulator Homo sapiens 66-71 23582790-4 2013 The mechanism was at least partially due to DHA induced apoptosis by upregulating the expression of Bax, downregulating Bcl-2, Bcl-xL and Procaspase-3, and increasing caspase-9 activation, induced cell cycle arrest by downregulating cyclin E, CDK2 and CDK4. artenimol 44-47 BCL2 apoptosis regulator Homo sapiens 120-125 23496232-0 2013 Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2. Paclitaxel 11-21 BCL2 apoptosis regulator Homo sapiens 90-95 23745024-3 2013 Real time polymerase chain reaction and Western blotting were used to observe expression changes in p21, p53, Bax, Bcl-2, CDK2, and CyclinD1 in gastric cancer cells exposed to TSA. trichostatin A 176-179 BCL2 apoptosis regulator Homo sapiens 115-120 23745024-7 2013 p21, p53 and Bax gene expression levels in AGS cells were increased with TSA treatment duration; Bcl-2, CDK2, and CyclinD1 gene expression levels were decreased with TSA treatment duration. trichostatin A 166-169 BCL2 apoptosis regulator Homo sapiens 97-102 23543383-0 2013 Ruthenium (II) polypyridyl complexes stabilize the bcl-2 promoter quadruplex and induce apoptosis of Hela tumor cells. ruthenium (ii) polypyridyl complexes 0-36 BCL2 apoptosis regulator Homo sapiens 51-56 23543383-1 2013 In the present study, the interaction between GC-rich sequence of bcl-2 gene P1 promoter (Pu39) and two ruthenium (II) polypyridyl complexes, [Ru(bpy)2(tip)]2+ (1) and [Ru(phen)2(tip)]2+ (2), was investigated by UV-Visible, fluorescence spectroscopy, circular dichroism, fluorescence resonance energy transfer melting assay and polymerase chain reaction stop assay. Ruthenium 104-113 BCL2 apoptosis regulator Homo sapiens 66-71 23421409-12 2013 A Bcl2 inhibitor, ABT737, acted synergistically with CAFdA to inhibit the growth with combination index values of 0.27 in HL/CAFdA20 and 0.23 in HL/CAFdA80, compared with 0.65 in HL-60. ABT-737 18-24 BCL2 apoptosis regulator Homo sapiens 2-6 23421409-12 2013 A Bcl2 inhibitor, ABT737, acted synergistically with CAFdA to inhibit the growth with combination index values of 0.27 in HL/CAFdA20 and 0.23 in HL/CAFdA80, compared with 0.65 in HL-60. Clofarabine 53-58 BCL2 apoptosis regulator Homo sapiens 2-6 23620411-9 2013 Furthermore, exposure of cells to Japonicone A caused inactivation of the TNF-alpha-TAK1-IKK-NF-kappaB axis and inhibition of TNF-alpha-stimulated NF-kappaB activity and nuclear translocation, followed by downregulation of NF-kappaB target genes involved in cell apoptosis (Bcl-2, Bcl-xL, XIAP, TRAF2) and in the cell cycle and growth (cyclin D, c-Myc). japonicone 34-44 BCL2 apoptosis regulator Homo sapiens 274-279 23739004-4 2013 MAO-A mediates the induction of antiapoptotic bcl-2 and mao-a itself by rasagiline, whereas a different mechanism is associated with selegiline. rasagiline 72-82 BCL2 apoptosis regulator Homo sapiens 46-51 23393227-4 2013 We found that arenobufagin induced mitochondria-mediated apoptosis in HCC cells, with decreasing mitochondrial potential, as well as increasing Bax/Bcl-2 expression ratio, Bax translocation from cytosol to mitochondria. arenobufagin 14-26 BCL2 apoptosis regulator Homo sapiens 148-153 23661043-0 2013 Idebenone prevents human optic nerve head astrocytes from oxidative stress, apoptosis, and senescence by stabilizing BAX/Bcl-2 ratio. idebenone 0-9 BCL2 apoptosis regulator Homo sapiens 121-126 23588221-7 2013 In Bcl-2 siRNA-transfected cells, adding gefitinib further reduced the number of viable cells, induced apoptosis to a greater extent compared to either treatment alone. Gefitinib 41-50 BCL2 apoptosis regulator Homo sapiens 3-8 23588221-8 2013 These preclinical data suggested that downregulation of Bcl-2 by RNAi in the gefitinib-resistant H1975 lung cancer cell line with T790M mutation enhanced the effects of gefitinib and may offer a novel therapeutic strategy for the treatment of NSCLC. Gefitinib 77-86 BCL2 apoptosis regulator Homo sapiens 56-61 23588221-8 2013 These preclinical data suggested that downregulation of Bcl-2 by RNAi in the gefitinib-resistant H1975 lung cancer cell line with T790M mutation enhanced the effects of gefitinib and may offer a novel therapeutic strategy for the treatment of NSCLC. Gefitinib 169-178 BCL2 apoptosis regulator Homo sapiens 56-61 23787282-6 2013 Moreover, our study suggests that antiproliferative and apoptotic cell death effects of H2O2 took place via activation of caspase-3, affecting the expression of Bcl-2 and Bax (an antiapoptotic and a proapoptotic factor, respectively), and through deactivation of catalase enzyme, leading to accumulation of intracellular ROS and depletion of intracellular ATP level. Hydrogen Peroxide 88-92 BCL2 apoptosis regulator Homo sapiens 161-166 23787282-6 2013 Moreover, our study suggests that antiproliferative and apoptotic cell death effects of H2O2 took place via activation of caspase-3, affecting the expression of Bcl-2 and Bax (an antiapoptotic and a proapoptotic factor, respectively), and through deactivation of catalase enzyme, leading to accumulation of intracellular ROS and depletion of intracellular ATP level. Reactive Oxygen Species 321-324 BCL2 apoptosis regulator Homo sapiens 161-166 23787282-6 2013 Moreover, our study suggests that antiproliferative and apoptotic cell death effects of H2O2 took place via activation of caspase-3, affecting the expression of Bcl-2 and Bax (an antiapoptotic and a proapoptotic factor, respectively), and through deactivation of catalase enzyme, leading to accumulation of intracellular ROS and depletion of intracellular ATP level. Adenosine Triphosphate 356-359 BCL2 apoptosis regulator Homo sapiens 161-166 23832737-12 2013 An inhibitor ABT-737 (the Bcl-2 antagonist targets Bcl-2) against Bcl-2 suppressed cellular proliferation and promoted apoptosis induced by S100A4 re-expression in S100A4-siRNA-transfected ACHN cells. ABT-737 13-20 BCL2 apoptosis regulator Homo sapiens 26-31 23832737-12 2013 An inhibitor ABT-737 (the Bcl-2 antagonist targets Bcl-2) against Bcl-2 suppressed cellular proliferation and promoted apoptosis induced by S100A4 re-expression in S100A4-siRNA-transfected ACHN cells. ABT-737 13-20 BCL2 apoptosis regulator Homo sapiens 51-56 23832737-12 2013 An inhibitor ABT-737 (the Bcl-2 antagonist targets Bcl-2) against Bcl-2 suppressed cellular proliferation and promoted apoptosis induced by S100A4 re-expression in S100A4-siRNA-transfected ACHN cells. ABT-737 13-20 BCL2 apoptosis regulator Homo sapiens 51-56 23479448-0 2013 Bcl-2 proapoptotic proteins distribution in U-87 MG glioma cells before and after hypericin photodynamic action. hypericin 82-91 BCL2 apoptosis regulator Homo sapiens 0-5 23168911-6 2013 Besides, DHEA and EPEA treatment induced phosphorylation of Bcl-2 promoting its dissociation from beclin-1 which resulted in autophagy induction. Dehydroepiandrosterone 9-13 BCL2 apoptosis regulator Homo sapiens 60-65 23168911-6 2013 Besides, DHEA and EPEA treatment induced phosphorylation of Bcl-2 promoting its dissociation from beclin-1 which resulted in autophagy induction. Eicosapentaenoyl Ethanolamide 18-22 BCL2 apoptosis regulator Homo sapiens 60-65 23661043-10 2013 When ONHA cells were treated with idebenone and H2O2, real-time polymerase chain reaction and Western blot analysis yielded an increased expression of Bcl-2 and a decrease of BAX compared with those cells that were treated with H2O2 only. idebenone 34-43 BCL2 apoptosis regulator Homo sapiens 151-156 23771657-7 2013 The results showed that germacrone exposure decreased p-STAT3 and p-JAK2 and regulated expression of p53 and Bcl-2 family members at the same time. germacrone 24-34 BCL2 apoptosis regulator Homo sapiens 109-114 23661043-10 2013 When ONHA cells were treated with idebenone and H2O2, real-time polymerase chain reaction and Western blot analysis yielded an increased expression of Bcl-2 and a decrease of BAX compared with those cells that were treated with H2O2 only. Hydrogen Peroxide 48-52 BCL2 apoptosis regulator Homo sapiens 151-156 23661043-10 2013 When ONHA cells were treated with idebenone and H2O2, real-time polymerase chain reaction and Western blot analysis yielded an increased expression of Bcl-2 and a decrease of BAX compared with those cells that were treated with H2O2 only. Hydrogen Peroxide 228-232 BCL2 apoptosis regulator Homo sapiens 151-156 23882289-10 2013 The phosphorylation of p38 mitogen-activated protein (MAP) kinase and the release of Smac from mitochondria were suppressed and the expression levels of Bcl-2 and cAMP response element-binding protein (CREB), the transcription factor of Bcl-2, were recovered following TAT-survivin transduction, indicating that survivin had an anti-apoptotic effect against doxorubicin injury. Doxorubicin 358-369 BCL2 apoptosis regulator Homo sapiens 153-158 22959059-9 2013 EGCG caused apoptotic cell death accompanied by up-regulation of proapoptotic Bax and down-regulation of antiapoptotic protein Bcl2. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 127-131 23882289-11 2013 CONCLUSION: Our results suggest that survivin has a potentially cytoprotective effect against doxorubicin-induced cardiac myocyte apoptosis through mechanisms that involve a decrease in the phosphorylation of p38 MAP kinase, mitochondrial Smac release, and increased expression of Bcl-2 and CREB. Doxorubicin 94-105 BCL2 apoptosis regulator Homo sapiens 281-286 22899281-7 2013 2"-Hydroxy-4,4",5",6"-tetramethoxychalcone was found to be both cytotoxic and anticlonogenic at 20 microm in cell lines Cal51, MCF7 and MDAMB-468, and to act synergistically with the Bcl2 inhibitor ABT737 to enhance apoptosis in Cal51 breast cancer cells. 2"-hydroxy-4,4",5",6"-tetramethoxychalcone 0-42 BCL2 apoptosis regulator Homo sapiens 183-187 23318928-5 2013 Furthermore, by directly manipulating NF-kappaB signaling, we showed that the observed RNF11-enhanced 6-OHDA toxicity is mediated through inhibition of NF-kappaB-dependent transcription of TNF-alpha, antioxidants GSS and SOD1, and anti-apoptotic factor BCL2. Oxidopamine 102-108 BCL2 apoptosis regulator Homo sapiens 253-257 23607990-4 2013 BH3 profiling can be applied to any viable single cell suspension and provides a response from the sum total of all known and unknown interactions within the BCL2 family for each stimulus, and the pattern of response can provide both a cell"s propensity towards mitochondrial apoptosis, or "priming", as well as indicate dependencies on specific anti-apoptotic proteins. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 158-162 23833659-11 2013 In addition, the proteins caspase-3 and Bax in cells treated with flavopiridol were upregulated, while cyclin D1 and Bcl-2 were downregulated. alvocidib 66-78 BCL2 apoptosis regulator Homo sapiens 117-122 23737957-5 2013 YLT322 increased the expression of Bax, decreased the expression of Bcl-2, and induced the release of cytochrome c which activates the mitochondrial apoptotic pathway. 2-chloro-N-(2-(2-(5-methylpyridin-2-ylamino)-2-oxoethylthio)benzo(d)thiazol-6-yl) acetamide 0-6 BCL2 apoptosis regulator Homo sapiens 68-73 23980364-10 2013 CONCLUSION: Curcumin combined FOLFOX could significantly inhibit the proliferation of BGC-823 cells possibly via promoting Bax expression and Caspase-3 activity, inhibiting Bcl-2 expression, thus inducing apoptosis. Curcumin 12-20 BCL2 apoptosis regulator Homo sapiens 173-178 23980364-10 2013 CONCLUSION: Curcumin combined FOLFOX could significantly inhibit the proliferation of BGC-823 cells possibly via promoting Bax expression and Caspase-3 activity, inhibiting Bcl-2 expression, thus inducing apoptosis. Folfox protocol 30-36 BCL2 apoptosis regulator Homo sapiens 173-178 23665025-8 2013 We found that the combination of cisplatin and STAT3 siRNA resulted in the collapse of the mitochondrial membrane potential, attenuated the expression of Bcl-xL and Bcl-2, and increased the release of cytochrome C and expression of Bax. Cisplatin 33-42 BCL2 apoptosis regulator Homo sapiens 165-170 23705792-11 2013 With long-term I2, mammary tumor tissue became more sensitive to DOX, since a single injection of the lowest dose of DOX (4 mg/Kg) was enough to stop tumor progression and a second DOX4 injection on day 14 caused a significant and rapid decrease in tumor size, decreased the expression of chemoresistance markers (Bcl2 and survivin), and increased the expression of the apoptotic protein Bax and peroxisome proliferator-activated receptor type gamma. Doxorubicin 65-68 BCL2 apoptosis regulator Homo sapiens 314-318 23562496-9 2013 Xanthohumol and 2-hydroxychalcone induced apoptosis by Bcl-2 downregulation. xanthohumol 0-11 BCL2 apoptosis regulator Homo sapiens 55-60 23562496-9 2013 Xanthohumol and 2-hydroxychalcone induced apoptosis by Bcl-2 downregulation. 2'-hydroxychalcone 16-33 BCL2 apoptosis regulator Homo sapiens 55-60 23562504-5 2013 We also found that edaravone exhibited its neuroprotective roles by enhancing brain-derived neurotrophic factor (BDNF) and Bcl-2 expression, suppressing caspase-3 activity and promoting extracellular signal-regulated kinase1/2 (ERK1/2) activation. Edaravone 19-28 BCL2 apoptosis regulator Homo sapiens 123-128 21345578-8 2013 Consequently, the use of Celecoxib may be of specific value for the treatment of apoptosis-resistant tumors with overexpression of Bcl-2, Mcl-1, or survivin as single drug or in combination with radiotherapy, chemotherapy, or targeted pro-apoptotic drugs that are inhibited by survivin, Bcl-2 or Mcl-1. Celecoxib 25-34 BCL2 apoptosis regulator Homo sapiens 131-136 21345578-8 2013 Consequently, the use of Celecoxib may be of specific value for the treatment of apoptosis-resistant tumors with overexpression of Bcl-2, Mcl-1, or survivin as single drug or in combination with radiotherapy, chemotherapy, or targeted pro-apoptotic drugs that are inhibited by survivin, Bcl-2 or Mcl-1. Celecoxib 25-34 BCL2 apoptosis regulator Homo sapiens 287-292 22230093-4 2013 BH3 profiling has proven useful in identifying and understanding cellular dependence on individual anti-apoptotic proteins like BCL-2 or MCL-1. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 128-133 23628417-4 2013 In addition, both BLU and paclitaxel enhanced the expression of the pro-apoptotic protein Bax together with the suppression of anti-apoptotic protein Bcl-2, a protein which is well-known for its function as a regulator in protecting cells from apoptosis. Paclitaxel 26-36 BCL2 apoptosis regulator Homo sapiens 150-155 23847403-0 2013 Interaction studies to evaluate 2- carboxyphenolate analogues as inhibitor of anti-apoptotic protein Bcl-2. 2- carboxyphenolate 32-51 BCL2 apoptosis regulator Homo sapiens 101-106 23847403-6 2013 In this work we have applied an insilico approach to study the binding of 2-carboxyphenolate analogues as potent inhibitors of anti-apoptotic protein Bcl-2. Salicylates 74-92 BCL2 apoptosis regulator Homo sapiens 150-155 23847403-8 2013 From the docking results it was observed that zinc 2- carboxyphenolate showed strong inhibition with Bcl-2 with docking energy of -4.6 kcal/mol. zinc 2- carboxyphenolate 46-70 BCL2 apoptosis regulator Homo sapiens 101-106 25206431-6 2013 Curcumin is neuroprotective against gp120 V3 loop-induced neuronal damage by inhibiting the activation of L-type calcium currents, relieving intracellular Ca(2+) overload, promoting Bcl-2 expression, and inhibiting Bax activation. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 182-187 23703386-11 2013 Furthermore, SB203580 treatment reduced the expression of VEGF, Eotaxin-1, IL-12, MMP-9, Bcl-2 and c-Myc. SB 203580 13-21 BCL2 apoptosis regulator Homo sapiens 89-94 23705792-11 2013 With long-term I2, mammary tumor tissue became more sensitive to DOX, since a single injection of the lowest dose of DOX (4 mg/Kg) was enough to stop tumor progression and a second DOX4 injection on day 14 caused a significant and rapid decrease in tumor size, decreased the expression of chemoresistance markers (Bcl2 and survivin), and increased the expression of the apoptotic protein Bax and peroxisome proliferator-activated receptor type gamma. dox4 181-185 BCL2 apoptosis regulator Homo sapiens 314-318 23705845-0 2013 Optimization and validation of mitochondria-based functional assay as a useful tool to identify BH3-like molecules selectively targeting anti-apoptotic Bcl-2 proteins. BH 3 96-99 BCL2 apoptosis regulator Homo sapiens 152-157 23705845-11 2013 CONCLUSIONS: This method based on MOMP is a useful screening tool for identifying BH3 mimetics with selective toxicity against breast cancer cell mitochondria protected by the three major Bcl-2 anti-apoptotic proteins. BH 3 82-85 BCL2 apoptosis regulator Homo sapiens 188-193 23624503-8 2013 The sensitivity of CD44(+)CD24(+)p53wt cells to paclitaxel is associated with the downregulation of Bcl-2 expression, upregulation of Bax levels, and upregulation of caspase-3 activity. Paclitaxel 48-58 BCL2 apoptosis regulator Homo sapiens 100-105 23611778-1 2013 Small-molecule Bcl-2/Bcl-xL inhibitor Navitoclax represents a promising cancer therapeutic since preclinical and clinical studies with Navitoclax have demonstrated strong anticancer activity in several types of cancers. navitoclax 38-48 BCL2 apoptosis regulator Homo sapiens 15-20 23611778-1 2013 Small-molecule Bcl-2/Bcl-xL inhibitor Navitoclax represents a promising cancer therapeutic since preclinical and clinical studies with Navitoclax have demonstrated strong anticancer activity in several types of cancers. navitoclax 135-145 BCL2 apoptosis regulator Homo sapiens 15-20 23717386-2 2013 It was implicated in human pathology (Wolfram Syndrome 2) and in BCL-2 mediated antagonization of Beclin 1-dependent autophagy and depression of ER calcium stores. Calcium 148-155 BCL2 apoptosis regulator Homo sapiens 65-70 23624503-7 2013 The resistance of CD44(+)CD24(+)Cdx1(+) cells to paclitaxel is associated with upregulation of Cdx1 and Bcl-2 expression, caspase-3 activity, and the ratio of LC3-II/LC3-I. Paclitaxel 49-59 BCL2 apoptosis regulator Homo sapiens 104-109 23681233-9 2013 Taxol also induced c-Jun N-terminal kinase (JNK) activation and phosphorylation of its substrates B-cell CLL/lymphoma 2 (Bcl2) and BCL2-like 1 (BclXL) under normoxia and hypoxia very early after taxol exposure. Paclitaxel 0-5 BCL2 apoptosis regulator Homo sapiens 121-125 23700428-7 2013 Mechanistically, FK-16 activated nuclear p53 to upregulate Bax and downregulate Bcl-2. fk-16 17-22 BCL2 apoptosis regulator Homo sapiens 80-85 23700428-8 2013 Knockdown of p53, genetic ablation of Bax, or overexpression of Bcl-2 reversed FK-16-induced apoptosis and autophagy. fk-16 79-84 BCL2 apoptosis regulator Homo sapiens 64-69 23700428-10 2013 Collectively, FK-16 induces caspase-independent apoptosis and autophagy through the common p53-Bcl-2/Bax cascade in colon cancer cells. fk-16 14-19 BCL2 apoptosis regulator Homo sapiens 95-100 23681227-0 2013 IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2. sapropterin 127-130 BCL2 apoptosis regulator Homo sapiens 141-146 23681227-8 2013 Inhibiting or knocking down IP3R2 activity in SU-DHL-4-reduced TAT-IDP(S)-induced apoptosis, which is compatible with its ability to dissociate Bcl-2 from IP3R2 and to promote IP3-induced pro-apoptotic Ca(2+) signaling. su-dhl-4 46-54 BCL2 apoptosis regulator Homo sapiens 144-149 23681227-8 2013 Inhibiting or knocking down IP3R2 activity in SU-DHL-4-reduced TAT-IDP(S)-induced apoptosis, which is compatible with its ability to dissociate Bcl-2 from IP3R2 and to promote IP3-induced pro-apoptotic Ca(2+) signaling. Inositol 1,4,5-Trisphosphate 28-31 BCL2 apoptosis regulator Homo sapiens 144-149 23691145-8 2013 Therefore we sought to determine whether pharmacological inhibition of BCL-2/BCL-xL with ABT-263 could potentiate apoptosis in response to these agents. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 89-92 BCL2 apoptosis regulator Homo sapiens 71-76 23681233-9 2013 Taxol also induced c-Jun N-terminal kinase (JNK) activation and phosphorylation of its substrates B-cell CLL/lymphoma 2 (Bcl2) and BCL2-like 1 (BclXL) under normoxia and hypoxia very early after taxol exposure. Paclitaxel 195-200 BCL2 apoptosis regulator Homo sapiens 121-125 23681233-13 2013 In conclusion, the resistance against taxol-induced cell death observed under hypoxia can be explained by a more effective autophagic flow activated via the classical mTOR pathway and by a mechanism involving JNK, which could be dependent on Bcl2 and BclXL phosphorylation but independent of JNK-induced autophagy activation. Paclitaxel 38-43 BCL2 apoptosis regulator Homo sapiens 242-246 23680104-9 2013 Release of multi-domain Bak from its inhibitory binding to Bcl-2/Bcl-xL and Mcl-1 using JY-1-106 was detected via immunoprecipitation (IP) western blotting.At the cellular level, we compared the growth proliferation IC50s of JY-1-106 and ABT-737 in multiple cancer cell lines with various Bcl-xL and Mcl-1 expression levels. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 238-241 BCL2 apoptosis regulator Homo sapiens 59-64 23480852-2 2013 The BCL2 family of proteins and bioactive sphingolipids are intricately linked during apoptotic cell death. Sphingolipids 42-55 BCL2 apoptosis regulator Homo sapiens 4-8 23480852-4 2013 In the present study we demonstrate that direct inhibition of anti-apoptotic BCL2 proteins with ABT-263 is sufficient to induce C(16)-ceramide synthesis in multiple cell lines, including human leukaemia and myeloma cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 96-99 BCL2 apoptosis regulator Homo sapiens 77-81 23480852-4 2013 In the present study we demonstrate that direct inhibition of anti-apoptotic BCL2 proteins with ABT-263 is sufficient to induce C(16)-ceramide synthesis in multiple cell lines, including human leukaemia and myeloma cells. Palmitic Acid 128-133 BCL2 apoptosis regulator Homo sapiens 77-81 23480852-4 2013 In the present study we demonstrate that direct inhibition of anti-apoptotic BCL2 proteins with ABT-263 is sufficient to induce C(16)-ceramide synthesis in multiple cell lines, including human leukaemia and myeloma cells. Ceramides 134-142 BCL2 apoptosis regulator Homo sapiens 77-81 23640461-4 2013 By measuring the growth or adenosine triphosphate content of transformants co-expressing Bax with pro-survival Bcl-2 relatives, we found that the Bcl-2 antagonist drugs ABT-737 or ABT-263 abolished Bcl-2 or Bcl-xL function and reduced Bcl-w activity, but failed to inhibit Mcl-1, A1 or the poxvirus orthologs DPV022 and SPPV14. Adenosine Triphosphate 27-49 BCL2 apoptosis regulator Homo sapiens 146-151 23608371-2 2013 METHODS: The mechanism of EtAc-LME induced apoptosis was explored by analysing the activation of pro-caspases, PARP cleavage, expression of cytochrome-c (Cyt-c) was determined by western blotting, mRNA expression of Bcl-2, Bax by RT-PCR, loss of mitochondrial potential using DiOC6 dye, annexin binding assay and its influence on cell cycle arrest by flow cytometry. etac-lme 26-34 BCL2 apoptosis regulator Homo sapiens 216-221 23583394-9 2013 GM reduced expression of anti-apoptotic protein Bcl-2 and induced expression of Bax and cleaved caspase 3; these effects and GM-induced expression of COX-2 and iNOS were also attenuated by MSP. Gentamicins 0-2 BCL2 apoptosis regulator Homo sapiens 48-53 23667527-5 2013 Additionally, BCL-2 family antgonist ABT-737 increased the sensitivity of several DLBCL cell lines to vorinostat-induced apoptosis, including one cell line (SUDHL6) that is resistant to vorinostat alone. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 37-40 BCL2 apoptosis regulator Homo sapiens 14-19 23667527-5 2013 Additionally, BCL-2 family antgonist ABT-737 increased the sensitivity of several DLBCL cell lines to vorinostat-induced apoptosis, including one cell line (SUDHL6) that is resistant to vorinostat alone. Vorinostat 102-112 BCL2 apoptosis regulator Homo sapiens 14-19 23667527-5 2013 Additionally, BCL-2 family antgonist ABT-737 increased the sensitivity of several DLBCL cell lines to vorinostat-induced apoptosis, including one cell line (SUDHL6) that is resistant to vorinostat alone. Vorinostat 186-196 BCL2 apoptosis regulator Homo sapiens 14-19 23667527-6 2013 Moreover, two variants of the HDACi-sensitive SUDHL4 cell line that have decreased sensitivity to vorinostat showed up-regulation of BCL-2 family anti-apoptotic proteins such as BCL-XL and MCL-1, as well as decreased sensitivity to ABT-737. Vorinostat 98-108 BCL2 apoptosis regulator Homo sapiens 133-138 23667527-6 2013 Moreover, two variants of the HDACi-sensitive SUDHL4 cell line that have decreased sensitivity to vorinostat showed up-regulation of BCL-2 family anti-apoptotic proteins such as BCL-XL and MCL-1, as well as decreased sensitivity to ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 232-235 BCL2 apoptosis regulator Homo sapiens 133-138 23673539-0 2013 U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In Vivo. Oligonucleotides 11-27 BCL2 apoptosis regulator Homo sapiens 38-42 23640461-4 2013 By measuring the growth or adenosine triphosphate content of transformants co-expressing Bax with pro-survival Bcl-2 relatives, we found that the Bcl-2 antagonist drugs ABT-737 or ABT-263 abolished Bcl-2 or Bcl-xL function and reduced Bcl-w activity, but failed to inhibit Mcl-1, A1 or the poxvirus orthologs DPV022 and SPPV14. Adenosine Triphosphate 27-49 BCL2 apoptosis regulator Homo sapiens 146-151 23640461-4 2013 By measuring the growth or adenosine triphosphate content of transformants co-expressing Bax with pro-survival Bcl-2 relatives, we found that the Bcl-2 antagonist drugs ABT-737 or ABT-263 abolished Bcl-2 or Bcl-xL function and reduced Bcl-w activity, but failed to inhibit Mcl-1, A1 or the poxvirus orthologs DPV022 and SPPV14. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 169-172 BCL2 apoptosis regulator Homo sapiens 111-116 23640461-4 2013 By measuring the growth or adenosine triphosphate content of transformants co-expressing Bax with pro-survival Bcl-2 relatives, we found that the Bcl-2 antagonist drugs ABT-737 or ABT-263 abolished Bcl-2 or Bcl-xL function and reduced Bcl-w activity, but failed to inhibit Mcl-1, A1 or the poxvirus orthologs DPV022 and SPPV14. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 169-172 BCL2 apoptosis regulator Homo sapiens 146-151 23640461-4 2013 By measuring the growth or adenosine triphosphate content of transformants co-expressing Bax with pro-survival Bcl-2 relatives, we found that the Bcl-2 antagonist drugs ABT-737 or ABT-263 abolished Bcl-2 or Bcl-xL function and reduced Bcl-w activity, but failed to inhibit Mcl-1, A1 or the poxvirus orthologs DPV022 and SPPV14. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 169-172 BCL2 apoptosis regulator Homo sapiens 146-151 23640461-4 2013 By measuring the growth or adenosine triphosphate content of transformants co-expressing Bax with pro-survival Bcl-2 relatives, we found that the Bcl-2 antagonist drugs ABT-737 or ABT-263 abolished Bcl-2 or Bcl-xL function and reduced Bcl-w activity, but failed to inhibit Mcl-1, A1 or the poxvirus orthologs DPV022 and SPPV14. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 180-183 BCL2 apoptosis regulator Homo sapiens 111-116 23640461-4 2013 By measuring the growth or adenosine triphosphate content of transformants co-expressing Bax with pro-survival Bcl-2 relatives, we found that the Bcl-2 antagonist drugs ABT-737 or ABT-263 abolished Bcl-2 or Bcl-xL function and reduced Bcl-w activity, but failed to inhibit Mcl-1, A1 or the poxvirus orthologs DPV022 and SPPV14. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 180-183 BCL2 apoptosis regulator Homo sapiens 146-151 23640461-4 2013 By measuring the growth or adenosine triphosphate content of transformants co-expressing Bax with pro-survival Bcl-2 relatives, we found that the Bcl-2 antagonist drugs ABT-737 or ABT-263 abolished Bcl-2 or Bcl-xL function and reduced Bcl-w activity, but failed to inhibit Mcl-1, A1 or the poxvirus orthologs DPV022 and SPPV14. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 180-183 BCL2 apoptosis regulator Homo sapiens 146-151 23507259-4 2013 We have examined at the molecular level the crosstalk between these nuclear receptors from the point of view of their control of cell growth and show here that RA reverts estrogen-stimulated transcription of the pivotal anti-apoptotic bcl-2 gene by preventing demethylation of dimethyl lysine 9 in histone H3 (HeK9me2). Tretinoin 160-162 BCL2 apoptosis regulator Homo sapiens 235-240 23645731-6 2013 Curcumin reduced the expression and phosphorylation of anti-apoptotic Bcl-2, but did not affect the expressions of pro-apoptotic Bax and anti-apoptotic nuclear factor (NF-kappaB). Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 70-75 23645731-7 2013 CONCLUSION: These results suggest that curcumin induces G2/M arrest and apoptosis through multiple mechanisms involving enhanced mitogen-activated protein (MAP) kinase activity, reduced AKT-mTOR activity, and reduced Bcl-2 function. Curcumin 39-47 BCL2 apoptosis regulator Homo sapiens 217-222 23212307-7 2013 JNK inhibitor abolished the DPQZ-induced increase in the phosphorylation of Bcl-2 and the protein levels of proform caspase-3, caspase-8, and caspase-9, indicating that JNK is an upstream activator of Bcl-2 and caspase family members and plays a key role in DPQZ-induced HSC-3 cell apoptosis. 6-(N,N-dimethylamino)-2-(naphthalene-1-yl)-4-quinazolinone 28-32 BCL2 apoptosis regulator Homo sapiens 76-81 23212307-7 2013 JNK inhibitor abolished the DPQZ-induced increase in the phosphorylation of Bcl-2 and the protein levels of proform caspase-3, caspase-8, and caspase-9, indicating that JNK is an upstream activator of Bcl-2 and caspase family members and plays a key role in DPQZ-induced HSC-3 cell apoptosis. 6-(N,N-dimethylamino)-2-(naphthalene-1-yl)-4-quinazolinone 28-32 BCL2 apoptosis regulator Homo sapiens 201-206 23212307-7 2013 JNK inhibitor abolished the DPQZ-induced increase in the phosphorylation of Bcl-2 and the protein levels of proform caspase-3, caspase-8, and caspase-9, indicating that JNK is an upstream activator of Bcl-2 and caspase family members and plays a key role in DPQZ-induced HSC-3 cell apoptosis. 6-(N,N-dimethylamino)-2-(naphthalene-1-yl)-4-quinazolinone 258-262 BCL2 apoptosis regulator Homo sapiens 76-81 23507259-4 2013 We have examined at the molecular level the crosstalk between these nuclear receptors from the point of view of their control of cell growth and show here that RA reverts estrogen-stimulated transcription of the pivotal anti-apoptotic bcl-2 gene by preventing demethylation of dimethyl lysine 9 in histone H3 (HeK9me2). dimethyl lysine 277-292 BCL2 apoptosis regulator Homo sapiens 235-240 23058179-7 2013 Treatment with 0.1 and 1 muM of gallic acid also resulted in a significant increase in caspase-3 activity and regulated the productions of Bcl-2, Bax, p53 and pAkt. Gallic Acid 32-43 BCL2 apoptosis regulator Homo sapiens 139-144 23609470-8 2013 The tamoxifen-resistant cells displayed high phosphorylation of ERalpha at Ser118 in the presence of tamoxifen; however, treatment with U0126 neither affected the level of Ser118 phosphorylation nor expression of the ERalpha target Bcl-2, suggesting that ERK contributes to cell growth independently of ERalpha in our cell model. Tamoxifen 4-13 BCL2 apoptosis regulator Homo sapiens 232-237 23494867-10 2013 Altholactone also caused a decrease in bcl-2 and an increase in p53 expression. altholactone 0-12 BCL2 apoptosis regulator Homo sapiens 39-44 23315923-6 2013 RESULTS: In 24 and 48 h, glycoaldehyde elicited a decrease in apoptosis rate in comparison with the control condition concomitantly with a reduction in Bax/Bcl2 RNA ratio and in Nfkb1 RNA expression. glycolaldehyde 25-38 BCL2 apoptosis regulator Homo sapiens 156-160 23315923-7 2013 In contrast, after 72 and 96 h, glycoaldehyde promoted an increase in apoptosis rate concomitantly with an increase in Bax/Bcl2 RNA ratio and in Nfkb1 RNA expression. glycolaldehyde 32-45 BCL2 apoptosis regulator Homo sapiens 123-127 23467622-8 2013 Tritpolide-induced ERK activation modulated the expression of the Bcl-2 protein family member Bax but was not involved in the downregulation of Bcl-xL expression. tritpolide 0-10 BCL2 apoptosis regulator Homo sapiens 66-71 23129176-0 2013 Notch pathway is involved in high glucose-induced apoptosis in podocytes via Bcl-2 and p53 pathways. Glucose 34-41 BCL2 apoptosis regulator Homo sapiens 77-82 23129176-2 2013 Here we demonstrated that high glucose (HG) upregulated Notch pathway in podocytes accompanied with the alteration of Bcl-2 and p53 pathways, subsequently leading to podocytes apoptosis. Glucose 31-38 BCL2 apoptosis regulator Homo sapiens 118-123 23150431-0 2013 CREB-mediated Bcl-2 expression contributes to RCAN1 protection from hydrogen peroxide-induced neuronal death. Hydrogen Peroxide 68-85 BCL2 apoptosis regulator Homo sapiens 14-19 23429261-0 2013 pRb/E2F-1-mediated caspase-dependent induction of Noxa amplifies the apoptotic effects of the Bcl-2/Bcl-xL inhibitor ABT-737. ABT-737 117-124 BCL2 apoptosis regulator Homo sapiens 94-99 23429261-2 2013 We herein show that treatment with a potent inhibitor of Bcl-2 and Bcl-xL, ABT-737, triggers caspase-dependent induction of the BH3-only protein, Mcl-1 inhibitor, Noxa. ABT-737 75-82 BCL2 apoptosis regulator Homo sapiens 57-62 23601074-5 2013 The gefitinib/PI-103 combination also significantly induced caspase-3/7-mediated PARP cleavage and reduced two anti-apoptotic proteins, XIAP and Bcl-2 in the susceptible cell lines. Gefitinib 4-13 BCL2 apoptosis regulator Homo sapiens 145-150 23404459-5 2013 However, lower concentration GA significantly downregulated the expression of anti-apoptotic protein including Bcl-2, Bcl-xL, and Mcl-1, which also dramatically activated cleaved caspase-9 and -3 in a dose- and time-dependent manner. gambogic acid 29-31 BCL2 apoptosis regulator Homo sapiens 111-116 23545701-6 2013 NS-398 inhibited the NF-kappaB p65 protein levels and the expression of various NF-kappaB target genes, including cyclin D1, c-Myc, survivin and Bcl-2. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 0-6 BCL2 apoptosis regulator Homo sapiens 145-150 23483134-5 2013 A 50 micromol/l dose of ursonic acid decreased the mRNA expression levels of anti-apoptotic NF-kappaBp65 and Bcl-2 0.17 (8.9/52.6)-fold and 0.22 (9.5/42.3)-fold, respectively. Ursonic acid 24-36 BCL2 apoptosis regulator Homo sapiens 109-114 23688756-13 2013 CONCLUSION: Mechanisms underlying bone marrow damage by iron overload might be through the follows: (1)The increased ROS induced by excessive iron deposition affected the expressions of Caspase-3 and Bcl-2, which caused more BMMNC apoptosis; (2)The abnormal number and ratio of T lymphocytes caused by iron overload aggravated the abnormality of immunity of IRP; (3)Iron overload may increase the damage to erythrocytes and stem cells coated with auto-antibodies. Iron 56-60 BCL2 apoptosis regulator Homo sapiens 200-205 24016480-17 2013 However, after miR-135a inhibitor transfection, the expression level of bcl-2 protein was significantly higher than that in control group (0.92 +- 0.03 vs 0.76 +- 0.09, P = 0.037) and the activity of caspase-3 was significantly lower than that in control group (59.5 +- 4.1 vs 95.4 +- 2.1, P < 0.01). mir-135a 15-23 BCL2 apoptosis regulator Homo sapiens 72-77 23584140-6 2013 Further, incubation of cells with combinations of limonoids and curcumin resulted in elevation of total cellular caspase-3 activity by 3.5-4.0 fold along with a 2- to 4-fold increase in the Bax/Bcl-2 ratio. Limonins 50-59 BCL2 apoptosis regulator Homo sapiens 194-199 23584140-6 2013 Further, incubation of cells with combinations of limonoids and curcumin resulted in elevation of total cellular caspase-3 activity by 3.5-4.0 fold along with a 2- to 4-fold increase in the Bax/Bcl-2 ratio. Curcumin 64-72 BCL2 apoptosis regulator Homo sapiens 194-199 23440293-9 2013 During atorvastatin-triggered apoptosis, changes in the expression levels of mitochondrial outer membrane permeability regulatory proteins of the Bcl-2 family were also observed. Atorvastatin 7-19 BCL2 apoptosis regulator Homo sapiens 146-151 23688756-7 2013 The expressions of Bcl-2 on BMMNC, erythrocytes and stem cells of iron overloading IRP patients were significantly lower than those of non-iron overloading IRP ones (P < 0.05). Iron 66-70 BCL2 apoptosis regulator Homo sapiens 19-24 23688756-7 2013 The expressions of Bcl-2 on BMMNC, erythrocytes and stem cells of iron overloading IRP patients were significantly lower than those of non-iron overloading IRP ones (P < 0.05). Iron 139-143 BCL2 apoptosis regulator Homo sapiens 19-24 23435602-6 2013 An ethyl acetate (EtOAc) extract exhibited the highest cytotoxicity and resulted in an up-regulated expression of the pro-apoptotic protein Bax (bcl-2 associated X protein) and a down-regulated expression of the anti-apoptotic protein Bcl2 in both SW480 and MCF7 cells. ethyl acetate 3-16 BCL2 apoptosis regulator Homo sapiens 235-239 23435602-6 2013 An ethyl acetate (EtOAc) extract exhibited the highest cytotoxicity and resulted in an up-regulated expression of the pro-apoptotic protein Bax (bcl-2 associated X protein) and a down-regulated expression of the anti-apoptotic protein Bcl2 in both SW480 and MCF7 cells. ethyl acetate 18-23 BCL2 apoptosis regulator Homo sapiens 235-239 23688756-13 2013 CONCLUSION: Mechanisms underlying bone marrow damage by iron overload might be through the follows: (1)The increased ROS induced by excessive iron deposition affected the expressions of Caspase-3 and Bcl-2, which caused more BMMNC apoptosis; (2)The abnormal number and ratio of T lymphocytes caused by iron overload aggravated the abnormality of immunity of IRP; (3)Iron overload may increase the damage to erythrocytes and stem cells coated with auto-antibodies. ros 117-120 BCL2 apoptosis regulator Homo sapiens 200-205 23688756-13 2013 CONCLUSION: Mechanisms underlying bone marrow damage by iron overload might be through the follows: (1)The increased ROS induced by excessive iron deposition affected the expressions of Caspase-3 and Bcl-2, which caused more BMMNC apoptosis; (2)The abnormal number and ratio of T lymphocytes caused by iron overload aggravated the abnormality of immunity of IRP; (3)Iron overload may increase the damage to erythrocytes and stem cells coated with auto-antibodies. Iron 142-146 BCL2 apoptosis regulator Homo sapiens 200-205 23688756-13 2013 CONCLUSION: Mechanisms underlying bone marrow damage by iron overload might be through the follows: (1)The increased ROS induced by excessive iron deposition affected the expressions of Caspase-3 and Bcl-2, which caused more BMMNC apoptosis; (2)The abnormal number and ratio of T lymphocytes caused by iron overload aggravated the abnormality of immunity of IRP; (3)Iron overload may increase the damage to erythrocytes and stem cells coated with auto-antibodies. Iron 142-146 BCL2 apoptosis regulator Homo sapiens 200-205 23261425-0 2013 Stabilization of G-quadruplex DNA by C-5-methyl-cytosine in bcl-2 promoter: implications for epigenetic regulation. c-5-methyl-cytosine 37-56 BCL2 apoptosis regulator Homo sapiens 60-65 23626686-6 2013 Far-UV circular dichroism (CD) spectroscopy was used to detect direct Bcl-2-Bax-interactions in the presence of polyoxyethylene-(23)-lauryl-ether (Brij-35) detergent at a level below its critical micelle concentration (CMC). Brij 35 112-145 BCL2 apoptosis regulator Homo sapiens 70-75 23626686-9 2013 In addition, Bcl-2 was able to form mixed micelles with Triton X-100 solubilized neutral phospholipids in the presence of high concentrations of Brij-35 (above its CMC). Octoxynol 56-68 BCL2 apoptosis regulator Homo sapiens 13-18 23626686-9 2013 In addition, Bcl-2 was able to form mixed micelles with Triton X-100 solubilized neutral phospholipids in the presence of high concentrations of Brij-35 (above its CMC). Phospholipids 89-102 BCL2 apoptosis regulator Homo sapiens 13-18 23626686-9 2013 In addition, Bcl-2 was able to form mixed micelles with Triton X-100 solubilized neutral phospholipids in the presence of high concentrations of Brij-35 (above its CMC). Brij 35 145-152 BCL2 apoptosis regulator Homo sapiens 13-18 23261425-3 2013 In the present study, the results from CD spectrum and FRET assay showed that the methylation of cytosine in the CpG islands could induce a conformational change of the G-quadruplex in the P1 promoter of bcl-2, and greatly increase the thermal-stability of this DNA oligomer. Cadmium 39-41 BCL2 apoptosis regulator Homo sapiens 204-209 23261425-3 2013 In the present study, the results from CD spectrum and FRET assay showed that the methylation of cytosine in the CpG islands could induce a conformational change of the G-quadruplex in the P1 promoter of bcl-2, and greatly increase the thermal-stability of this DNA oligomer. Cytosine 97-105 BCL2 apoptosis regulator Homo sapiens 204-209 23363053-1 2013 Pro-survival members of the Bcl-2 protein family inhibit cell death by binding short helical BH3 motifs in pro-apoptotic proteins. BH 3 93-96 BCL2 apoptosis regulator Homo sapiens 28-33 23613775-7 2013 We speculated that the mechanism underlying might be that eugenol inhibited the oxidative stress and the activation of ERK1/2, p38MAPK and IKK/NF-kappaB pathways, subsequently inhibited the dissociation of Beclin1-Bcl2 heterodimer and autophagy, and finally impaired IAV replication. Eugenol 58-65 BCL2 apoptosis regulator Homo sapiens 214-218 23474389-0 2013 Synthesis and evaluation of 3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines as Bcl-2 inhibitory anticancer agents. 3-(benzylthio)-5-(1h-indol-3-yl)-1,2,4-triazol-4-amines 28-83 BCL2 apoptosis regulator Homo sapiens 87-92 23474389-1 2013 A series of substituted 3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines has been synthesised and tested in vitro as potential pro-apoptotic Bcl-2-inhibitory anticancer agents. 3-(benzylthio)-5-(1h-indol-3-yl)-4h-1,2,4-triazol-4-amines 24-82 BCL2 apoptosis regulator Homo sapiens 151-156 23566222-9 2013 In addition to increased B-cell lymphoma 2 (Bcl-2) phosphorylation through JNK signaling in response to docetaxel, si-Vav3 enhanced docetaxel-induced apoptosis, as characterized by the accumulation of sub-G1 phase cells and DNA fragmentation, through Bcl-xL/Bcl-2-associated death promoter (Bad) dephosphorylation, resulting in increased caspase-9, caspase-3, and cleaved poly(ADP-ribose) polymerase activation. Docetaxel 104-113 BCL2 apoptosis regulator Homo sapiens 25-42 23474389-3 2013 Active compounds, such as the nitrobenzyl analogue 6c, were found to exhibit sub-micromolar IC50 values in Bcl-2 expressing human cancer cell lines. nitrobenzyl 30-41 BCL2 apoptosis regulator Homo sapiens 107-112 23566222-9 2013 In addition to increased B-cell lymphoma 2 (Bcl-2) phosphorylation through JNK signaling in response to docetaxel, si-Vav3 enhanced docetaxel-induced apoptosis, as characterized by the accumulation of sub-G1 phase cells and DNA fragmentation, through Bcl-xL/Bcl-2-associated death promoter (Bad) dephosphorylation, resulting in increased caspase-9, caspase-3, and cleaved poly(ADP-ribose) polymerase activation. Docetaxel 104-113 BCL2 apoptosis regulator Homo sapiens 44-49 23403511-8 2013 Moreover, U0126 prevented the rapamycin-induced increase of Bcl-2 and VEGF-A levels. U 0126 10-15 BCL2 apoptosis regulator Homo sapiens 60-65 23559002-9 2013 Finally, we provide evidence for the involvement of the B-cell lymphoma protein 2 family, Bcl-2-interacting mediator (Bim), in a JNK-dependent manner, in the apoptosis-inducing activity of simvastatin. Simvastatin 189-200 BCL2 apoptosis regulator Homo sapiens 90-95 23593287-0 2013 PGPIPN, a therapeutic hexapeptide, suppressed human ovarian cancer growth by targeting BCL2. pgpipn 0-6 BCL2 apoptosis regulator Homo sapiens 87-91 23593287-5 2013 Further study demonstrated that the anti-tumor effect of PGPIPN is partially through promoting cell apoptosis by inhibiting BCL2 pathway. pgpipn 57-63 BCL2 apoptosis regulator Homo sapiens 124-128 23403511-9 2013 Under hypoxia, rapamycin effectively prevented the hypoxia-induced increase of pCREB, Bcl-2, and VEGF-A. Sirolimus 15-24 BCL2 apoptosis regulator Homo sapiens 86-91 23261849-0 2013 Anisomycin treatment enhances TRAIL-mediated apoptosis in renal carcinoma cells through the down-regulation of Bcl-2, c-FLIP(L) and Mcl-1. Anisomycin 0-10 BCL2 apoptosis regulator Homo sapiens 111-116 23426174-7 2013 Our study suggested that the apoptotic effect of 8-c can be attributed to the upregulation of p53, caspase-3, and cleaved poly(ADP-ribose) polymerase (PARP) and the downregulation of Bcl-2. 8-c 49-52 BCL2 apoptosis regulator Homo sapiens 183-188 23261849-7 2013 Cumulatively, our study demonstrates that anisomycin treatment enhances TRAIL-mediated apoptosis through the down-regulation of Bcl-2, c-FLIP(L) and Mcl-1 at the transcriptional or post-transcriptional level. Anisomycin 42-52 BCL2 apoptosis regulator Homo sapiens 128-133 23353698-2 2013 Since CLL is characterized by overexpression of pro-survival Bcl-2 family members, treatments with their antagonists, such as ABT-737, represent a promising new therapeutic strategy. ABT-737 126-133 BCL2 apoptosis regulator Homo sapiens 61-66 23353698-3 2013 ABT-737 is a BH3 mimetic agent which binds Bcl-2, Bcl-XL and Bcl-w with high affinity, while weakly interacts with Mcl-1 and Bfl-1. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 43-48 23353698-3 2013 ABT-737 is a BH3 mimetic agent which binds Bcl-2, Bcl-XL and Bcl-w with high affinity, while weakly interacts with Mcl-1 and Bfl-1. BH 3 13-16 BCL2 apoptosis regulator Homo sapiens 43-48 23338853-0 2013 Lanthanum induced primary neuronal apoptosis through mitochondrial dysfunction modulated by Ca2+ and Bcl-2 family. Lanthanum 0-9 BCL2 apoptosis regulator Homo sapiens 101-106 23338853-7 2013 Our results demonstrated that toxicity of lanthanum in cortical neurons perhaps partly attributed to enhanced mitochondrial apoptosis due to mitochondrial dysfunction modulated by Ca(2+) and Bcl-2 family. Lanthanum 42-51 BCL2 apoptosis regulator Homo sapiens 191-196 23320492-0 2013 Combination of guanine arabinoside and Bcl-2 inhibitor YC137 overcomes the cytarabine resistance in HL-60 leukemia cell line. YC137 55-60 BCL2 apoptosis regulator Homo sapiens 39-44 23320492-0 2013 Combination of guanine arabinoside and Bcl-2 inhibitor YC137 overcomes the cytarabine resistance in HL-60 leukemia cell line. Cytarabine 75-85 BCL2 apoptosis regulator Homo sapiens 39-44 23320492-4 2013 Here, we established a new ara-C-resistant acute myeloid leukemia cell line (HL-60/ara-C60) with dual resistance characteristics of the anti-antimetabolic character of decreased ara-CTP production and an increase in the antiapoptotic factors Bcl-2 and Bcl-XL. Cytarabine 27-32 BCL2 apoptosis regulator Homo sapiens 242-247 23320492-6 2013 A relatively new nucleoside analog, 9-beta-d-arabinofuranosylguanine (ara-G), and the small molecule Bcl-2 antagonist YC137 were used for this purpose. YC137 118-123 BCL2 apoptosis regulator Homo sapiens 101-106 23328493-8 2013 Finally, DSC inhibited H2O2-induced changes of Bcl-2, Bax, and caspase-3 expression, and all of these effects were reversed by HO-1 silencing. Hydrogen Peroxide 23-27 BCL2 apoptosis regulator Homo sapiens 47-52 23296903-0 2013 Dietary high fluorine induces apoptosis and alters Bcl-2, Bax, and caspase-3 protein expression in the cecal tonsil lymphocytes of broilers. Fluorine 13-21 BCL2 apoptosis regulator Homo sapiens 51-56 23296903-6 2013 Meanwhile, immunohistochemical tests showed that the Bcl-2 protein expression decreased, and the Bax and caspase-3 protein expression increased in the high-fluorine groups II and III. Fluorine 156-164 BCL2 apoptosis regulator Homo sapiens 53-58 23296903-7 2013 In conclusion, dietary fluorine in the range of 800-1,200 mg/kg increased lymphocyte apoptosis in the cecal tonsil of broilers, suggesting that the lymphocyte apoptosis in the cecal tonsil was mediated by direct effects of fluoride on the expression of Bcl-2, Bax, and caspase-3. Fluorine 23-31 BCL2 apoptosis regulator Homo sapiens 253-258 23320492-9 2013 HL-60/ara-C60 cells were also refractory to ara-C-induced apoptosis due to overexpression of Bcl-2 and Bcl-XL. Cytarabine 6-11 BCL2 apoptosis regulator Homo sapiens 93-98 23261849-4 2013 Anisomycin treatment led to the down-regulation of Bcl-2 expression at the transcriptional level, and the over-expression of Bcl-2 inhibited the apoptosis induced by the combination treatment of anisomycin and TRAIL. Anisomycin 0-10 BCL2 apoptosis regulator Homo sapiens 51-56 22955373-0 2013 The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond. sapropterin 14-17 BCL2 apoptosis regulator Homo sapiens 36-41 23261849-4 2013 Anisomycin treatment led to the down-regulation of Bcl-2 expression at the transcriptional level, and the over-expression of Bcl-2 inhibited the apoptosis induced by the combination treatment of anisomycin and TRAIL. Anisomycin 195-205 BCL2 apoptosis regulator Homo sapiens 125-130 22955373-6 2013 Furthermore, one amino acid critically different in the sequence of Bcl-2"s and Bcl-XL"s BH4 domains underpins their selective effect on Ca(2+) signaling and distinct biological properties of Bcl-2 versus Bcl-XL. sapropterin 89-92 BCL2 apoptosis regulator Homo sapiens 68-73 22955373-6 2013 Furthermore, one amino acid critically different in the sequence of Bcl-2"s and Bcl-XL"s BH4 domains underpins their selective effect on Ca(2+) signaling and distinct biological properties of Bcl-2 versus Bcl-XL. sapropterin 89-92 BCL2 apoptosis regulator Homo sapiens 192-197 23592899-0 2013 Gambogic acid induces mitochondria-dependent apoptosis by modulation of Bcl-2 and Bax in mantle cell lymphoma JeKo-1 cells. gambogic acid 0-13 BCL2 apoptosis regulator Homo sapiens 72-77 22955373-8 2013 Moreover, these insights open novel avenues to selectively suppress malignant Bcl-2 function in cancer cells by targeting its BH4 domain, while maintaining essential Bcl-XL functions in normal cells. sapropterin 126-129 BCL2 apoptosis regulator Homo sapiens 78-83 22955373-9 2013 Thus, IP3R-derived molecules that mimic the BH4 domain"s binding site on the IP3R may function synergistically with BH3-mimetic molecules selectivity suppressing Bcl-2"s proto-oncogenic activity. sapropterin 44-47 BCL2 apoptosis regulator Homo sapiens 162-167 22955373-9 2013 Thus, IP3R-derived molecules that mimic the BH4 domain"s binding site on the IP3R may function synergistically with BH3-mimetic molecules selectivity suppressing Bcl-2"s proto-oncogenic activity. BH 3 116-119 BCL2 apoptosis regulator Homo sapiens 162-167 23510470-5 2013 RESULTS: Quercetin intercalated with calf thymus cell DNA and HeLa cell DNA and inhibition of anti-apoptotic AKT and Bcl-2 expression were observed. Quercetin 9-18 BCL2 apoptosis regulator Homo sapiens 117-122 23592899-7 2013 GA induces apoptosis in JeKo-1 cells but not in normal bone marrow cells, which was involved in reducing the membrane potential of mitochondria, activating caspases-3, -8 and -9 and decreasing the ratio of Bcl-2 and Bax without cell cycle arresting. gambogic acid 0-2 BCL2 apoptosis regulator Homo sapiens 206-211 23592899-8 2013 CONCLUSIONS: GA induced apoptosis in human MCL JeKo-1 cells by regulating Bcl-2/Bax and activating caspase-3, -8 and -9 via mitochondrial pathway without affecting cell cycle. gambogic acid 13-15 BCL2 apoptosis regulator Homo sapiens 74-79 23395885-2 2013 Direct targeting of the antiapoptotic BCL2 members with GX15-070 (obatoclax), a BH3-mimetic currently in clinical development, is an attractive strategy to overcome antiestrogen resistance in some breast cancers. BH 3 80-83 BCL2 apoptosis regulator Homo sapiens 38-42 23291592-10 2013 The same H2O2-treated cells also showed activated ASK (P-ASK), increased Bax, lowered Bcl-2, cytochrome c release, and elevated caspase 3/7 activity. Hydrogen Peroxide 9-13 BCL2 apoptosis regulator Homo sapiens 86-91 22983795-7 2013 Moreover, quercetin caused a concentration-dependent loss of mitochondrial membrane potential and cytochrome c release to cytosol and also decreased Bcl-2/Bax ratio, indicating that quercetin-induced apoptosis is through mitochondrial pathway. Quercetin 10-19 BCL2 apoptosis regulator Homo sapiens 149-154 22983795-7 2013 Moreover, quercetin caused a concentration-dependent loss of mitochondrial membrane potential and cytochrome c release to cytosol and also decreased Bcl-2/Bax ratio, indicating that quercetin-induced apoptosis is through mitochondrial pathway. Quercetin 182-191 BCL2 apoptosis regulator Homo sapiens 149-154 23403953-9 2013 Expression of the anti-apoptotic mRNA BCL2 was induced by NaB in control cells, but this induction of BCL2 was inhibited by ID2 knockdown and strengthened by ID2 overexpression. nab 58-61 BCL2 apoptosis regulator Homo sapiens 38-42 23363047-10 2013 Furthermore, bcl-2 transcription was suppressed 1.58- and 1.86-fold at 10.0 and 20.0 nM SYUIQ-FM05, respectively, but 0.4 and 2.0 nM SYUIQ-FM05 had no effect. N'-(7-fluoro-5-N-methyl-10H-indolo(3,2-b)quinolin-5-ium)-N,N-dimethylpropane-1,3-diamine 88-98 BCL2 apoptosis regulator Homo sapiens 13-18 23481492-10 2013 Carvedilol could also preserve cardiac contractility via modulation of the tumor necrosis factor alpha and interleukin 8 mRNA expression and reduction of Bcl-2 and cytochrome c protein production and decrease the occurrence of apoptosis ex vivo. Carvedilol 0-10 BCL2 apoptosis regulator Homo sapiens 154-159 23376438-10 2013 Collectively, these results suggest that the activation of p53, JNK or p38 kinase by ZEN metabolites is the main upstream signal required for the mitochondrial alteration of Bcl-2/Bax signaling pathways and intracellular ROS generation, while MMP loss and nuclear translocation of AIF are the critical downstream events for ZEN metabolite-mediated apoptosis in macrophages. Zearalenone 85-88 BCL2 apoptosis regulator Homo sapiens 174-179 23337397-3 2013 Increased Bax/Bcl-2 ratio, increased caspase 3 and 9 activities, cleaved PARP, decreased VEGF, MMP-2 and MMP-9 activities were observed after NN-32 treatment of U937 cell. nn-32 142-147 BCL2 apoptosis regulator Homo sapiens 14-19 23352508-10 2013 However, pretreatment of cells with the autophagy inhibitor, 3-methyladenine (3MA), remarkably increased CPF toxicity in these cells; this with correlated with increased expression of Bax and decreased expression of Bcl-2 in mitochondria. 3-methyladenine 61-76 BCL2 apoptosis regulator Homo sapiens 216-221 23352508-10 2013 However, pretreatment of cells with the autophagy inhibitor, 3-methyladenine (3MA), remarkably increased CPF toxicity in these cells; this with correlated with increased expression of Bax and decreased expression of Bcl-2 in mitochondria. 3-methyladenine 78-81 BCL2 apoptosis regulator Homo sapiens 216-221 23376438-10 2013 Collectively, these results suggest that the activation of p53, JNK or p38 kinase by ZEN metabolites is the main upstream signal required for the mitochondrial alteration of Bcl-2/Bax signaling pathways and intracellular ROS generation, while MMP loss and nuclear translocation of AIF are the critical downstream events for ZEN metabolite-mediated apoptosis in macrophages. Reactive Oxygen Species 221-224 BCL2 apoptosis regulator Homo sapiens 174-179 23376438-10 2013 Collectively, these results suggest that the activation of p53, JNK or p38 kinase by ZEN metabolites is the main upstream signal required for the mitochondrial alteration of Bcl-2/Bax signaling pathways and intracellular ROS generation, while MMP loss and nuclear translocation of AIF are the critical downstream events for ZEN metabolite-mediated apoptosis in macrophages. Zearalenone 324-327 BCL2 apoptosis regulator Homo sapiens 174-179 23345014-0 2013 Adenosine induces cell cycle arrest and apoptosis via cyclinD1/Cdk4 and Bcl-2/Bax pathways in human ovarian cancer cell line OVCAR-3. Adenosine 0-9 BCL2 apoptosis regulator Homo sapiens 72-77 23554843-0 2013 Increased expression of the androgen receptor with p300 and interleukin-6 coactivators compensate for oligonucleotide suppression of bcl-2: no increased CREB binding protein or interleukin-4 expression. Oligonucleotides 102-117 BCL2 apoptosis regulator Homo sapiens 133-138 23233043-8 2013 Both safingol and PDTC (NF-kappaB inhibitor) could apparently rescue the effects of VIIa on expression of MMP-9, caspase-3, TF, and Bcl-2/bax in SW620 cells. safingol 5-13 BCL2 apoptosis regulator Homo sapiens 132-137 23188704-5 2013 From among a panel of apoptosis-related factors (p53, Bcl-2, Bcl-XL, BAX, and survivin), the expression of Livin was upregulated after cisplatin treatment in a dose-dependent manner. Cisplatin 135-144 BCL2 apoptosis regulator Homo sapiens 54-59 23345014-2 2013 Adenosine has been shown to inhibit cell growth and induce apoptosis in the several cancer cells via caspase activation and Bcl-2/Bax pathway. Adenosine 0-9 BCL2 apoptosis regulator Homo sapiens 124-129 23345014-9 2013 Moreover, down-regulation of Bcl-2 protein expression, up-regulation of Bax protein expression and activation of caspase-3 were observed in response to adenosine treatment. Adenosine 152-161 BCL2 apoptosis regulator Homo sapiens 29-34 23345014-10 2013 The results of this study suggest that extracellular adenosine induced G1 cell cycle arrest and apoptosis in ovarian cancer cells via cyclinD1/ Cdk4 and Bcl-2/Bax pathways and caspase-3 activation. Adenosine 53-62 BCL2 apoptosis regulator Homo sapiens 153-158 23833954-12 2013 Moreover, myricitrin pretreatment could up-regulate the expression of the anti-apoptotic protein Bcl-2, down-regulate the expression of the pro-apoptotic protein Bax, and decrease the expression of Caspase-3, 9. myricitrin 10-20 BCL2 apoptosis regulator Homo sapiens 97-102 23451794-0 2013 Flavanols from evening primrose (Oenothera paradoxa) defatted seeds inhibit prostate cells invasiveness and cause changes in Bcl-2/Bax mRNA ratio. flavanols 0-9 BCL2 apoptosis regulator Homo sapiens 125-130 23352978-7 2013 Both I3C and EGCG significantly increased caspase-3 activity, DNA fragmentation percentage, DR4 and DR5 protein expression as well as decreased Bcl-2 protein expression when compared to control groups. epigallocatechin gallate 13-17 BCL2 apoptosis regulator Homo sapiens 144-149 23415863-0 2013 Paclitaxel attenuates Bcl-2 resistance to apoptosis in breast cancer cells through an endoplasmic reticulum-mediated calcium release in a dosage dependent manner. Paclitaxel 0-10 BCL2 apoptosis regulator Homo sapiens 22-27 23262352-7 2013 Taken together, our results indicate that the JNK and ERK pathways, and modulation of Bcl-2 family proteins were key regulators of apoptosis in response to 7,8-DHF in U937 cells. 6,7-dihydroxyflavone 156-163 BCL2 apoptosis regulator Homo sapiens 86-91 23262352-0 2013 Apoptosis induction of human leukemia U937 cells by 7,8-dihydroxyflavone hydrate through modulation of the Bcl-2 family of proteins and the MAPKs signaling pathway. 6,7-dihydroxyflavone 52-72 BCL2 apoptosis regulator Homo sapiens 107-112 23262352-5 2013 Furthermore, it was found that Bcl-2 overexpression markedly protected U937 cells from 7,8-DHF-induced apoptosis by restoring activation of caspases. 6,7-dihydroxyflavone 87-94 BCL2 apoptosis regulator Homo sapiens 31-36 23403085-4 2013 Further investigation demonstrated that 8k reduced H2O2-induced activation of mitochondrial apoptosis by inhibiting the expression of Bax and elevating the expression of Bcl-2. Hydrogen Peroxide 51-55 BCL2 apoptosis regulator Homo sapiens 170-175 23415863-4 2013 However, Bcl-2 expression suppresses the cell"s pro-apoptotic response of endoplasmic reticulum calcium release, thus inhibiting susceptibility of cancer cells to undergo apoptosis. Calcium 96-103 BCL2 apoptosis regulator Homo sapiens 9-14 23415863-0 2013 Paclitaxel attenuates Bcl-2 resistance to apoptosis in breast cancer cells through an endoplasmic reticulum-mediated calcium release in a dosage dependent manner. Calcium 117-124 BCL2 apoptosis regulator Homo sapiens 22-27 23415863-5 2013 Depending upon dosage, a paclitaxel-induced stimulatory effect can overcome the Bcl-2-mediated inhibitory effect on endoplasmic reticulum calcium release, thus attenuating the resistance of Bcl-2 to apoptosis. Paclitaxel 25-35 BCL2 apoptosis regulator Homo sapiens 80-85 23415863-5 2013 Depending upon dosage, a paclitaxel-induced stimulatory effect can overcome the Bcl-2-mediated inhibitory effect on endoplasmic reticulum calcium release, thus attenuating the resistance of Bcl-2 to apoptosis. Paclitaxel 25-35 BCL2 apoptosis regulator Homo sapiens 190-195 23415863-1 2013 To address the controversy regarding efficacy of paclitaxel in the presence of the anti-apoptotic protein Bcl-2, we investigated calcium stored in the endoplasmic reticulum as a potential factor. Paclitaxel 49-59 BCL2 apoptosis regulator Homo sapiens 106-111 23415863-6 2013 Our finding is the first to demonstrate that endoplasmic reticulum calcium plays a key role in the efficacy of paclitaxel in the presence of Bcl-2, thus providing insight into the complex but crucial paclitaxel-calcium-Bcl-2 relationship, which may impact breast cancer treatment. Paclitaxel 111-121 BCL2 apoptosis regulator Homo sapiens 141-146 23415863-6 2013 Our finding is the first to demonstrate that endoplasmic reticulum calcium plays a key role in the efficacy of paclitaxel in the presence of Bcl-2, thus providing insight into the complex but crucial paclitaxel-calcium-Bcl-2 relationship, which may impact breast cancer treatment. Paclitaxel 111-121 BCL2 apoptosis regulator Homo sapiens 219-224 23415863-6 2013 Our finding is the first to demonstrate that endoplasmic reticulum calcium plays a key role in the efficacy of paclitaxel in the presence of Bcl-2, thus providing insight into the complex but crucial paclitaxel-calcium-Bcl-2 relationship, which may impact breast cancer treatment. Paclitaxel 200-210 BCL2 apoptosis regulator Homo sapiens 141-146 23415863-6 2013 Our finding is the first to demonstrate that endoplasmic reticulum calcium plays a key role in the efficacy of paclitaxel in the presence of Bcl-2, thus providing insight into the complex but crucial paclitaxel-calcium-Bcl-2 relationship, which may impact breast cancer treatment. Paclitaxel 200-210 BCL2 apoptosis regulator Homo sapiens 219-224 23415863-6 2013 Our finding is the first to demonstrate that endoplasmic reticulum calcium plays a key role in the efficacy of paclitaxel in the presence of Bcl-2, thus providing insight into the complex but crucial paclitaxel-calcium-Bcl-2 relationship, which may impact breast cancer treatment. Calcium 67-74 BCL2 apoptosis regulator Homo sapiens 141-146 23415863-6 2013 Our finding is the first to demonstrate that endoplasmic reticulum calcium plays a key role in the efficacy of paclitaxel in the presence of Bcl-2, thus providing insight into the complex but crucial paclitaxel-calcium-Bcl-2 relationship, which may impact breast cancer treatment. Calcium 67-74 BCL2 apoptosis regulator Homo sapiens 219-224 23415863-2 2013 Our results showed that the ER calcium store is a common target for both paclitaxel and Bcl-2 protein. Calcium 31-38 BCL2 apoptosis regulator Homo sapiens 88-93 23341456-1 2013 Members of the Bcl-2 family of proteins are important inhibitors of apoptosis in human cancer and are targets for novel anticancer agents such as the Bcl-2 antagonists, ABT-263 (Navitoclax), and its analog ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 169-172 BCL2 apoptosis regulator Homo sapiens 15-20 23287709-4 2013 Cisplatin induced apoptosis of HK-2 cells in which down-regulation of Bcl-2 and activation of caspase-3 were possibly involved. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 70-75 23313858-7 2013 Interestingly, silencing of Sirt1 significantly enhances sensitivity of porcine preadipocytes to camptothecin, which may be due to upregulation of p53, acetylated p53, Bax, cleaved caspase-3 and downregulation of Bcl-2. Camptothecin 97-109 BCL2 apoptosis regulator Homo sapiens 213-218 23333498-0 2013 Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation. epigallocatechin gallate 0-24 BCL2 apoptosis regulator Homo sapiens 144-149 23333498-0 2013 Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation. sulforaphane 29-41 BCL2 apoptosis regulator Homo sapiens 144-149 23333498-0 2013 Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation. Paclitaxel 84-94 BCL2 apoptosis regulator Homo sapiens 144-149 23333498-12 2013 Taken together, these results indicate that EGCG and SFN combination treatment can induce apoptosis by down-regulating of hTERT and Bcl-2 and promote DNA damage response specifically in paclitaxel-resistant ovarian cancer cell lines and suggest the use of these compounds for overcoming paclitaxel resistance in ovarian cancer treatment. epigallocatechin gallate 44-48 BCL2 apoptosis regulator Homo sapiens 132-137 23333498-12 2013 Taken together, these results indicate that EGCG and SFN combination treatment can induce apoptosis by down-regulating of hTERT and Bcl-2 and promote DNA damage response specifically in paclitaxel-resistant ovarian cancer cell lines and suggest the use of these compounds for overcoming paclitaxel resistance in ovarian cancer treatment. sulforaphane 53-56 BCL2 apoptosis regulator Homo sapiens 132-137 23333825-6 2013 The sorghum 3-deoxyanthocyanins induced apoptosis in MCF 7 was mediated by stimulation of the p(53) gene and down regulation of the (bcl) 2 gene. 3-deoxyanthocyanins 12-31 BCL2 apoptosis regulator Homo sapiens 133-139 23341456-1 2013 Members of the Bcl-2 family of proteins are important inhibitors of apoptosis in human cancer and are targets for novel anticancer agents such as the Bcl-2 antagonists, ABT-263 (Navitoclax), and its analog ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 206-209 BCL2 apoptosis regulator Homo sapiens 15-20 23341456-1 2013 Members of the Bcl-2 family of proteins are important inhibitors of apoptosis in human cancer and are targets for novel anticancer agents such as the Bcl-2 antagonists, ABT-263 (Navitoclax), and its analog ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 206-209 BCL2 apoptosis regulator Homo sapiens 150-155 23341456-5 2013 Using neuroblastoma cell lines, with a defined Bcl-2 family dependence, we found that BAG3 expression correlated with Mcl-1 dependence and ABT-737 resistance. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 139-142 BCL2 apoptosis regulator Homo sapiens 47-52 23341456-1 2013 Members of the Bcl-2 family of proteins are important inhibitors of apoptosis in human cancer and are targets for novel anticancer agents such as the Bcl-2 antagonists, ABT-263 (Navitoclax), and its analog ABT-737. navitoclax 178-188 BCL2 apoptosis regulator Homo sapiens 15-20 23333149-6 2013 Second, ROS-low LSCs aberrantly overexpress BCL-2. Reactive Oxygen Species 8-11 BCL2 apoptosis regulator Homo sapiens 44-49 23333149-8 2013 Based on these findings, we propose a model wherein the unique physiology of ROS-low LSCs provides an opportunity for selective targeting via disruption of BCL-2-dependent oxidative phosphorylation. Reactive Oxygen Species 77-80 BCL2 apoptosis regulator Homo sapiens 156-161 23333150-4 2013 Notably, sabutoclax, a pan-BCL2 inhibitor, renders marrow-niche-resident BC LSCs sensitive to TKIs at doses that spare normal progenitors. 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-N5-(2-phenylpropyl)-N5'-(2-phenylpropyl)-2,2'-binaphthyl-5,5'-dicarboxamide 9-19 BCL2 apoptosis regulator Homo sapiens 27-31 23497522-0 2013 Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensivity radiosensivity after radioembolization with yttrium-90 resin microspheres. Yttrium-90 174-184 BCL2 apoptosis regulator Homo sapiens 30-35 23560237-9 2013 In addition, caffeine up-regulated caspase-3 and down-regulated Bcl-2 at the protein level. Caffeine 13-21 BCL2 apoptosis regulator Homo sapiens 64-69 23452820-2 2013 Chemotherapy and targeted therapies, including the Bcl-2 inhibitor ABT-737, may induce tumor cell autophagy. ABT-737 67-74 BCL2 apoptosis regulator Homo sapiens 51-56 23234544-2 2013 In the present study we examined the effect of combining selumetinib with the BH3 [BCL2 (B-cell lymphoma 2) homology domain 3]-mimetic BCL2 inhibitor ABT-263. BH 3 78-81 BCL2 apoptosis regulator Homo sapiens 89-106 23234544-2 2013 In the present study we examined the effect of combining selumetinib with the BH3 [BCL2 (B-cell lymphoma 2) homology domain 3]-mimetic BCL2 inhibitor ABT-263. BH 3 78-81 BCL2 apoptosis regulator Homo sapiens 83-87 23100158-3 2013 The results demonstrated that beta-ionone-induced apoptosis in a dose-dependent manner in SGC-7901 cells treated with beta-ionone (25, 50, 100 and 200 mumol/L) for 24 h. beta-ionone was also shown to induce the expression of cleaved-caspase-3 and inhibit bcl-2 expression in SGC-7901 cells in a dose-dependent manner. beta-ionone 30-41 BCL2 apoptosis regulator Homo sapiens 255-260 23234544-2 2013 In the present study we examined the effect of combining selumetinib with the BH3 [BCL2 (B-cell lymphoma 2) homology domain 3]-mimetic BCL2 inhibitor ABT-263. BH 3 78-81 BCL2 apoptosis regulator Homo sapiens 135-139 23234544-2 2013 In the present study we examined the effect of combining selumetinib with the BH3 [BCL2 (B-cell lymphoma 2) homology domain 3]-mimetic BCL2 inhibitor ABT-263. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 150-153 BCL2 apoptosis regulator Homo sapiens 135-139 23234544-8 2013 Thus the combination of a BCL2 inhibitor and an ERK1/2 pathway inhibitor is synthetic lethal in ERK1/2-addicted tumour cells, delays the onset of acquired resistance and in some cases overcomes acquired resistance to selumetinib. AZD 6244 217-228 BCL2 apoptosis regulator Homo sapiens 26-30 23274910-4 2013 Although Mcl-1 dominance renders SCC cells resistant to the BH3-mimetic ABT-737, vorinostat primes them for sensitivity to ABT-737 by shuttling Bim from Mcl-1 to Bcl-2/Bcl-xl, resulting in dramatic synergy for this combination and sustained tumor regression in vivo. Vorinostat 81-91 BCL2 apoptosis regulator Homo sapiens 162-167 23245210-0 2013 Melatonin is involved in the apoptosis and necrosis of pancreatic cancer cell line SW-1990 via modulating of Bcl-2/Bax balance. Melatonin 0-9 BCL2 apoptosis regulator Homo sapiens 109-114 23245210-6 2013 RT-PCR and Western blot showed that Bcl-2 expression was downregulated, while Bax expression was upregulated, after melatonin treatment. Melatonin 116-125 BCL2 apoptosis regulator Homo sapiens 36-41 23245210-7 2013 Melatonin may be a pro-apoptotic and pro-necrotic agent for pancreatic cancer cells via its modulation of Bcl-2/Bax balance. Melatonin 0-9 BCL2 apoptosis regulator Homo sapiens 106-111 23302226-8 2013 We identified Noxa as the only Bcl-2 family protein to be highly correlated with Oct-4 status and cisplatin sensitivity. Cisplatin 98-107 BCL2 apoptosis regulator Homo sapiens 31-36 24648943-0 2013 Hedgehog signaling inhibitor cyclopamine induces apoptosis by decreasing Gli2 and Bcl2 expression in human salivary pleomorphic adenoma cells. cyclopamine 29-40 BCL2 apoptosis regulator Homo sapiens 82-86 24648943-8 2013 One-way ANOVA test results revealed a significantly greater decrease (P<0.01) of Gli2 and Bcl2 mRNA levels in the cyclopamine-treated group as compared to the blank control group and dimethyl sulfoxide (DMSO)-treated group. cyclopamine 117-128 BCL2 apoptosis regulator Homo sapiens 93-97 24648943-10 2013 Findings of this study showed that cyclopamine affected the mechanism of HSPA cell apoptosis, which may be associated with the downregulation of Gli2 and Bcl2 mRNA expression levels and the activation of the mitochondrial apoptotic pathways. cyclopamine 35-46 BCL2 apoptosis regulator Homo sapiens 154-158 23274910-3 2013 Treatment with the histone deacetylase (HDAC) inhibitor vorinostat regulates Bcl-2 family member expression to disable the Mcl-1 axis and thereby induce apoptosis in SCC cells. Vorinostat 56-66 BCL2 apoptosis regulator Homo sapiens 77-82 22926545-0 2013 Daidzein induced apoptosis via down-regulation of Bcl-2/Bax and triggering of the mitochondrial pathway in BGC-823 cells. daidzein 0-8 BCL2 apoptosis regulator Homo sapiens 50-55 23691440-9 2013 CCK8 assay showed that cell proliferation was significantly decreased and was significantly lower in miR-15a ODN combined with Bcl-2 siRNA plus MTX group than in miR-15a ODN with methotrexate group, Bcl-2 siRNA with MTX group, and single MTX group (P<0.05). Methotrexate 216-219 BCL2 apoptosis regulator Homo sapiens 127-132 23691440-9 2013 CCK8 assay showed that cell proliferation was significantly decreased and was significantly lower in miR-15a ODN combined with Bcl-2 siRNA plus MTX group than in miR-15a ODN with methotrexate group, Bcl-2 siRNA with MTX group, and single MTX group (P<0.05). Methotrexate 216-219 BCL2 apoptosis regulator Homo sapiens 127-132 23691440-12 2013 Among these groups, the apoptotic rate of miR-15a ODN combined with Bcl-2 siRNA plus MTX group was the highest; this apoptotic rate was also significantly different from that of miR-15a ODN or Bcl-2 siRNA plus MTX (P<0.05). Methotrexate 210-213 BCL2 apoptosis regulator Homo sapiens 68-73 23691440-13 2013 CONCLUSIONS: Bcl-2 siRNA combined with miR-15a ODN could enhance MTX-induced apoptosis in Raji cells. Methotrexate 65-68 BCL2 apoptosis regulator Homo sapiens 13-18 23691440-0 2013 Combined transfection of Bcl-2 siRNA and miR-15a oligonucleotides enhanced methotrexate-induced apoptosis in Raji cells. Methotrexate 75-87 BCL2 apoptosis regulator Homo sapiens 25-30 23691440-2 2013 This study aims to investigate whether Bcl-2 small interfering RNA (siRNA) combined with miR-15a oligonucleotides (ODN) could enhance methotrexate (MTX)-induced apoptosis in Raji cells. Methotrexate 134-146 BCL2 apoptosis regulator Homo sapiens 39-44 23691440-2 2013 This study aims to investigate whether Bcl-2 small interfering RNA (siRNA) combined with miR-15a oligonucleotides (ODN) could enhance methotrexate (MTX)-induced apoptosis in Raji cells. Methotrexate 148-151 BCL2 apoptosis regulator Homo sapiens 39-44 22926545-9 2013 Specifically, daidzein induced a change in the Bax/Bcl-2 ratios and activation of caspases-3 and -9 and the cleavage of PARP. daidzein 14-22 BCL2 apoptosis regulator Homo sapiens 51-56 23364875-0 2013 Pharmacological doses of melatonin induce alterations in mitochondrial mass and potential, bcl-2 levels and K+ currents in UVB-exposed U937 cells. Melatonin 25-34 BCL2 apoptosis regulator Homo sapiens 91-96 23161404-8 2013 Moreover, inhibition of GSK3 reduced etoposide-induced association of p53 with Bcl2 and Bax oligomerization. Etoposide 37-46 BCL2 apoptosis regulator Homo sapiens 79-83 23271435-6 2013 The purpose of this study was to prepare chitosan nanoparticles via ionic gelation of chitosan by tripolyphosphate for effective delivery of siRNA to silence the anti-apoptotic Bcl-2 gene in neoplastic cells. triphosphoric acid 98-114 BCL2 apoptosis regulator Homo sapiens 177-182 23750296-2 2013 Curiosity in BCL-2 family - mitochondrial interactions led to the identification that the sphingolipid pathway plays a crucial role in BCL-2 family function. Sphingolipids 90-102 BCL2 apoptosis regulator Homo sapiens 13-18 23271636-6 2013 Real time PCR analysis showed markedly up-regulated expression of prosurvival, proliferation and chondrogenic genes (BCL2L1, BCL2, AKT, PCNA, COL2A1, ACAN, SOX9 and BGN) and significantly down-regulated expression of pro-apoptotic genes (BAX, FADD) in the Lovastatin-treated group in comparison with injured cells. Lovastatin 256-266 BCL2 apoptosis regulator Homo sapiens 117-121 23083798-8 2013 Preclinical studies are under way for other Bcl-2 inhibitors including ABT-737, HA14-1, and Bcl-2 homology 3 inhibitors. ABT-737 71-78 BCL2 apoptosis regulator Homo sapiens 44-49 23787180-7 2013 Furthermore, several anti-apoptotic characteristics of adenine were determined, including the ability to inhibit caspase 3/7, upregulate B-cell lymphoma (Bcl-2) and downregulate Bcl-2- associated X (Bax), capase-9 gene expression in 4 Gy-irradiated AHH-1 cells. Adenine 55-62 BCL2 apoptosis regulator Homo sapiens 154-159 23750296-2 2013 Curiosity in BCL-2 family - mitochondrial interactions led to the identification that the sphingolipid pathway plays a crucial role in BCL-2 family function. Sphingolipids 90-102 BCL2 apoptosis regulator Homo sapiens 135-140 23404469-7 2013 Measuring the modulation of regulators in the cell cycle, apoptosis and signal transductions by western blot analysis showed that the effect of Dasatinib was due to suppression of the expression of Bax, Bcl-2, Caspase-3, and Caspase-8. Dasatinib 144-153 BCL2 apoptosis regulator Homo sapiens 203-208 23220614-6 2013 Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3. U 0126 13-18 BCL2 apoptosis regulator Homo sapiens 88-93 23404440-10 2013 Compared with the other experimental groups, the Rg3 and TAE group expressed significantly lower levels of CD31 and VEGF (P<0.05), significantly increased levels of the pro-apoptotic genes caspase-3 and Bax (P<0.05), and significantly reduced levels of anti-apoptotic Bcl-2 at the mRNA and protein levels (P<0.05). tae 57-60 BCL2 apoptosis regulator Homo sapiens 274-279 23965458-0 2013 Immunolocalization of Bcl-2 oncoprotein in amlodipine-induced gingival overgrowth. Amlodipine 43-53 BCL2 apoptosis regulator Homo sapiens 22-27 23422486-2 2013 We evaluated mono- and bispecific oligonucleotides which comparably suppressed expression of B-cell lymphoma-2 (BCL-2) in LNCaP cells. Oligonucleotides 34-50 BCL2 apoptosis regulator Homo sapiens 93-110 23266503-7 2013 We also showed that the down-regulation of Bcl-2 and concurrent increase in Bax and Bim levels contribute to the apoptosis induced by baicalein. baicalein 134-143 BCL2 apoptosis regulator Homo sapiens 43-48 23422486-2 2013 We evaluated mono- and bispecific oligonucleotides which comparably suppressed expression of B-cell lymphoma-2 (BCL-2) in LNCaP cells. Oligonucleotides 34-50 BCL2 apoptosis regulator Homo sapiens 112-117 23965458-4 2013 (ii) To compare and correlate the Bcl-2 expression in gingival samples from subjects on amlodipine therapy to the findings in healthy controls. Amlodipine 88-98 BCL2 apoptosis regulator Homo sapiens 34-39 23314035-7 2013 Mechanistically, resveratrol treatment downregulated the expression of Bcl-2 and hypoxia-inducible factor-1alpha (HIF-1alpha) proteins and upregulated the expression of caspase-3 protein. Resveratrol 17-28 BCL2 apoptosis regulator Homo sapiens 83-88 23253949-6 2013 Our results also suggest that expression of Bcl-2 and mitochondrial cytochrome c was dosedependently reduced following Jolkinolide B-treated THP-1 and HL-60 cells, whereas Jolkinolide B up-regulated the expression of Bax and cytosolic cytochrome c. jolkinolide B 119-132 BCL2 apoptosis regulator Homo sapiens 44-49 23253949-6 2013 Our results also suggest that expression of Bcl-2 and mitochondrial cytochrome c was dosedependently reduced following Jolkinolide B-treated THP-1 and HL-60 cells, whereas Jolkinolide B up-regulated the expression of Bax and cytosolic cytochrome c. jolkinolide B 172-185 BCL2 apoptosis regulator Homo sapiens 44-49 23292300-6 2013 In addition, cordycepin treatment resulted in an increase of the Bax/Bcl-2 (or Bcl-xL) ratio, downregulation of inhibitor of apoptosis protein (IAP) family members, Bax conformational changes, and release of cytochrome c from the mitochondria to the cytosol. cordycepin 13-23 BCL2 apoptosis regulator Homo sapiens 69-74 23292300-8 2013 However, the quenching of ROS generation with antioxidant N-acetyl-L-cysteine conferred significant protection against cordycepin-elicited ROS generation, disruption of the MMP, modulation of Bcl-2 and IAP family proteins, caspase-3 and -9 activation and apoptosis. Reactive Oxygen Species 26-29 BCL2 apoptosis regulator Homo sapiens 192-197 23253949-9 2013 Taken together, our study for the first time suggests that Jolkinolide B is able to enhance apoptosis of human leukemic HL-60 and THP-1 cells, at least in part, through downregulation of JAK2/STAT3 and bcl-2, and upregulation of Bax and cytosolic cytochrome c. jolkinolide B 59-72 BCL2 apoptosis regulator Homo sapiens 202-207 23292300-8 2013 However, the quenching of ROS generation with antioxidant N-acetyl-L-cysteine conferred significant protection against cordycepin-elicited ROS generation, disruption of the MMP, modulation of Bcl-2 and IAP family proteins, caspase-3 and -9 activation and apoptosis. Acetylcysteine 58-77 BCL2 apoptosis regulator Homo sapiens 192-197 22968599-2 2013 MAO-B inhibitors, rasagiline and selegiline [(-)deprenyl], protect neuronal cells by direct intervention in mitochondrial death signaling and induction of pro-survival Bcl-2 and neurotrophic factors. rasagiline 18-28 BCL2 apoptosis regulator Homo sapiens 168-173 23415873-8 2013 In PHA-activated T cells, curcumin further enhanced PHA-induced CHOP expression and reduced the expression of the anti-apoptotic protein Bcl-2. Curcumin 26-34 BCL2 apoptosis regulator Homo sapiens 137-142 22274877-4 2013 In particular, the results revealed statistically reduced cell viability after hFOB were exposed to the above 10% H20M (257 +- 37 nm) eluates for 48 h. The apoptotic cell death triggered by H20M treatment was proven by the analysis of molecular markers of apoptosis, that is, the Bcl-2 family of genes. hfob 79-83 BCL2 apoptosis regulator Homo sapiens 280-285 22274877-4 2013 In particular, the results revealed statistically reduced cell viability after hFOB were exposed to the above 10% H20M (257 +- 37 nm) eluates for 48 h. The apoptotic cell death triggered by H20M treatment was proven by the analysis of molecular markers of apoptosis, that is, the Bcl-2 family of genes. h20 114-117 BCL2 apoptosis regulator Homo sapiens 280-285 23387989-4 2013 Towards this end, we assessed the combination of the PI3K inhibitor LY 294002 and the Bcl-2 family inhibitor ABT-737 in RCC cell lines. ABT-737 109-116 BCL2 apoptosis regulator Homo sapiens 86-91 22968599-3 2013 Recently, type A MAO (MAO-A) was found to mediate the induction of anti-apoptotic Bcl-2 by rasagiline, whereas MAO-A increases in neuronal death and also serves as a target of neurotoxins. rasagiline 91-101 BCL2 apoptosis regulator Homo sapiens 82-87 22968599-2 2013 MAO-B inhibitors, rasagiline and selegiline [(-)deprenyl], protect neuronal cells by direct intervention in mitochondrial death signaling and induction of pro-survival Bcl-2 and neurotrophic factors. Selegiline 33-43 BCL2 apoptosis regulator Homo sapiens 168-173 23314756-6 2013 O-DMA caused the downregulation of Bcl-2 and upregulation of Bax, which led to cytochrome c release from the mitochondria and activation of caspase-3. O-desmethylangolensin 0-5 BCL2 apoptosis regulator Homo sapiens 35-40 22968599-2 2013 MAO-B inhibitors, rasagiline and selegiline [(-)deprenyl], protect neuronal cells by direct intervention in mitochondrial death signaling and induction of pro-survival Bcl-2 and neurotrophic factors. Selegiline 45-56 BCL2 apoptosis regulator Homo sapiens 168-173 23363601-0 2013 Regulation of apoptosis by Bcl-2 cysteine oxidation in human lung epithelial cells. Cysteine 33-41 BCL2 apoptosis regulator Homo sapiens 27-32 22957790-4 2013 Moreover, our results also suggest that induced p73, up-regulated Bax/Bcl-2 molecular ratio and subsequent activation of caspase-3 may contribute to a direct short-term cytotoxic effect of high doses of BIBR1532, independent of long-term substantial telomere erosion-mediated cell cycle arrest. BIBR 1532 203-211 BCL2 apoptosis regulator Homo sapiens 70-75 23106698-10 2013 Lastly, EPA attenuated an increase in the bax:bcl-2 ratio, and cytochrome c release. Eicosapentaenoic Acid 8-11 BCL2 apoptosis regulator Homo sapiens 46-51 23363601-3 2013 The present study investigates the direct effect of H2O2 on Bcl-2 cysteine oxidation as a potential mechanism of apoptosis regulation. Hydrogen Peroxide 52-56 BCL2 apoptosis regulator Homo sapiens 60-65 23808158-6 2013 EGCG decreased the Bcl-2/Bax expression stimulated by a high glucose. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 19-24 23363601-3 2013 The present study investigates the direct effect of H2O2 on Bcl-2 cysteine oxidation as a potential mechanism of apoptosis regulation. Cysteine 66-74 BCL2 apoptosis regulator Homo sapiens 60-65 23808158-6 2013 EGCG decreased the Bcl-2/Bax expression stimulated by a high glucose. Glucose 61-68 BCL2 apoptosis regulator Homo sapiens 19-24 22086675-7 2013 The protein levels of various NF-kappaB-regulated molecules such as Bcl-2, COX-2, iNOS, VEGF, and MMPs were also decreased by silibinin in both cell culture studies and xenograft analyses, suggesting its potential to alter NF-kappaB transcriptional activity. Silybin 126-135 BCL2 apoptosis regulator Homo sapiens 68-73 23808158-8 2013 These findings suggest that EGCG protects HLEB-3 cells from high glucose-induced apoptosis by regulating the gene expression of the Bcl-2 family, c-fos, c-myc and p53. epigallocatechin gallate 28-32 BCL2 apoptosis regulator Homo sapiens 132-137 23363601-4 2013 Exposure of human lung epithelial cells to H2O2 induces apoptosis concomitant with cysteine oxidation and down-regulation of Bcl-2. Hydrogen Peroxide 43-47 BCL2 apoptosis regulator Homo sapiens 125-130 23808158-8 2013 These findings suggest that EGCG protects HLEB-3 cells from high glucose-induced apoptosis by regulating the gene expression of the Bcl-2 family, c-fos, c-myc and p53. Glucose 65-72 BCL2 apoptosis regulator Homo sapiens 132-137 23363601-5 2013 Inhibition of Bcl-2 oxidation by antioxidants or by site-directed mutagenesis of Bcl-2 at Cys-158 and Cys-229 abrogates the effects of H2O2 on Bcl-2 and apoptosis. Cysteine 90-93 BCL2 apoptosis regulator Homo sapiens 14-19 23363601-5 2013 Inhibition of Bcl-2 oxidation by antioxidants or by site-directed mutagenesis of Bcl-2 at Cys-158 and Cys-229 abrogates the effects of H2O2 on Bcl-2 and apoptosis. Cysteine 90-93 BCL2 apoptosis regulator Homo sapiens 81-86 23363601-5 2013 Inhibition of Bcl-2 oxidation by antioxidants or by site-directed mutagenesis of Bcl-2 at Cys-158 and Cys-229 abrogates the effects of H2O2 on Bcl-2 and apoptosis. Cysteine 90-93 BCL2 apoptosis regulator Homo sapiens 81-86 23363601-5 2013 Inhibition of Bcl-2 oxidation by antioxidants or by site-directed mutagenesis of Bcl-2 at Cys-158 and Cys-229 abrogates the effects of H2O2 on Bcl-2 and apoptosis. Cysteine 102-105 BCL2 apoptosis regulator Homo sapiens 14-19 23363601-5 2013 Inhibition of Bcl-2 oxidation by antioxidants or by site-directed mutagenesis of Bcl-2 at Cys-158 and Cys-229 abrogates the effects of H2O2 on Bcl-2 and apoptosis. Hydrogen Peroxide 135-139 BCL2 apoptosis regulator Homo sapiens 14-19 23363601-5 2013 Inhibition of Bcl-2 oxidation by antioxidants or by site-directed mutagenesis of Bcl-2 at Cys-158 and Cys-229 abrogates the effects of H2O2 on Bcl-2 and apoptosis. Hydrogen Peroxide 135-139 BCL2 apoptosis regulator Homo sapiens 81-86 23363601-5 2013 Inhibition of Bcl-2 oxidation by antioxidants or by site-directed mutagenesis of Bcl-2 at Cys-158 and Cys-229 abrogates the effects of H2O2 on Bcl-2 and apoptosis. Hydrogen Peroxide 135-139 BCL2 apoptosis regulator Homo sapiens 81-86 23363601-6 2013 Immunoprecipitation and confocal microscopic studies show that Bcl-2 interacts with mitogen-activated protein kinase (extracellular signal-regulated kinase 1/2 [ERK1/2]) to suppress apoptosis and that this interaction is modulated by cysteine oxidation of Bcl-2. Cysteine 234-242 BCL2 apoptosis regulator Homo sapiens 63-68 23314115-7 2013 Deltonin treatment also resulted in Bax upregulation, Bcl-2 downregulation, activation of caspase-3 and -8 and poly (ADP ribose) polymerase cleavage. deltonin 0-8 BCL2 apoptosis regulator Homo sapiens 66-71 23363601-7 2013 The H2O2-induced Bcl-2 cysteine oxidation interferes with Bcl-2 and ERK1/2 interaction. Hydrogen Peroxide 4-8 BCL2 apoptosis regulator Homo sapiens 17-22 23325792-2 2013 We recently reported that clinically achievable concentrations of the Bcl-2/Bcl-xL inhibitor ABT-737 failed to induce apoptosis in glioma cells, with persistent expression of survivin and Mcl-1. ABT-737 93-100 BCL2 apoptosis regulator Homo sapiens 70-75 23363601-7 2013 The H2O2-induced Bcl-2 cysteine oxidation interferes with Bcl-2 and ERK1/2 interaction. Hydrogen Peroxide 4-8 BCL2 apoptosis regulator Homo sapiens 58-63 23363601-7 2013 The H2O2-induced Bcl-2 cysteine oxidation interferes with Bcl-2 and ERK1/2 interaction. Cysteine 23-31 BCL2 apoptosis regulator Homo sapiens 17-22 23363601-7 2013 The H2O2-induced Bcl-2 cysteine oxidation interferes with Bcl-2 and ERK1/2 interaction. Cysteine 23-31 BCL2 apoptosis regulator Homo sapiens 58-63 23363601-8 2013 Mutation of the cysteine residues inhibits the disruption of Bcl-2-ERK complex, as well as the induction of apoptosis by H2O2. Cysteine 16-24 BCL2 apoptosis regulator Homo sapiens 61-66 23363601-9 2013 Taken together, these results demonstrate the critical role of Bcl-2 cysteine oxidation in the regulation of apoptosis through ERK signaling. Cysteine 69-77 BCL2 apoptosis regulator Homo sapiens 63-68 23479509-0 2013 Removal of the BH4 domain from Bcl-2 protein triggers an autophagic process that impairs tumor growth. Sapropterin 15-18 BCL2 apoptosis regulator Homo sapiens 31-36 23479509-2 2013 Noteworthy, melanoma cells in vivo exhibit markedly increased autophagy, as response to expression of bcl-2 protein deleted of its BH4 domain. Sapropterin 131-134 BCL2 apoptosis regulator Homo sapiens 102-107 23479509-3 2013 This observation led to the identification of a novel gain of function for bcl-2 protein lacking the BH4 domain. Sapropterin 101-104 BCL2 apoptosis regulator Homo sapiens 75-80 23479509-4 2013 In particular, upon different autophagic stimuli in vitro, overexpression of bcl-2 protein deleted of BH4 domain induces autophagosome accumulation, conversion of microtubule-associated protein 1 light chain 3B-II, reduced expression of p62/SQSTM1 protein, and thereby enhanced autophagic flux. Sapropterin 102-105 BCL2 apoptosis regulator Homo sapiens 77-82 23479509-5 2013 The relevance of Beclin-1 is evidenced by the fact that 1) the autophagy-promoting and growth-inhibiting properties are partially rescued by Beclin-1 knockdown in cells expressing bcl-2 protein lacking the BH4 domain, 2) Beclin-1 only interacts with wild-type but not with deleted bcl-2, and 3) BH4 domain removal from bcl-2 protein does not influence in vitro and in vivo growth of tumor cells expressing low levels of endogenous Beclin-1. Sapropterin 295-298 BCL2 apoptosis regulator Homo sapiens 180-185 23261589-10 2013 Sal toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3beta, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling. sal 0-3 BCL2 apoptosis regulator Homo sapiens 96-101 23479509-6 2013 These results provide new insight into molecular mechanism of bcl-2 functions and represent a rationale for the development of agents interfering with the BH4 domain of bcl-2 protein. Sapropterin 155-158 BCL2 apoptosis regulator Homo sapiens 62-67 23479509-6 2013 These results provide new insight into molecular mechanism of bcl-2 functions and represent a rationale for the development of agents interfering with the BH4 domain of bcl-2 protein. Sapropterin 155-158 BCL2 apoptosis regulator Homo sapiens 169-174 22610911-5 2013 In addition, pretreatment with ferulate markedly protected cells against t-BHP-induced apoptosis, as evidenced by decreased nuclear condensation, cytochrome c release, and caspase-3 cleavage and an increased Bax/Bcl-2 ratio. ferulic acid 31-39 BCL2 apoptosis regulator Homo sapiens 212-217 21955141-0 2013 The Bcl-2/Bcl-XL inhibitor ABT-737 promotes death of retinoblastoma cancer cells. ABT-737 27-34 BCL2 apoptosis regulator Homo sapiens 4-9 23425861-8 2013 Western blot analysis also showed that TBMS1 induced apoptosis by regulation of the Bcl-2 gene family in BGC823 cells. tubeimoside I 39-44 BCL2 apoptosis regulator Homo sapiens 84-89 23426065-6 2013 A drug resistance assay revealed that SP cells have a high survival rate when exposed to the chemotherapy drug 5-fluorouracil; the results of western blot analysis suggest that this stems from the abundant expression of the chemoresistance-associated proteins ABCG2 and Bcl-2. Fluorouracil 111-125 BCL2 apoptosis regulator Homo sapiens 270-275 22585533-5 2013 beta-eudesmol-induced apoptosis was accompanied by cleavage of caspase-3, caspase-9, and poly (ADP-ribose) polymerase; downregulation of Bcl-2 expression; release of cytochrome c from mitochondria; and decrease in mitochondrial membrane potential (MMP). beta-eudesmol 0-13 BCL2 apoptosis regulator Homo sapiens 137-142 22585533-6 2013 Activation of c-Jun N-terminal kinases (JNK) mitogen-activated protein kinases was observed in beta-eudesmol-treated HL60 cells, and the inhibitor of JNK blocked the beta-eudesmol-induced apoptosis, downregulation of Bcl-2, and the loss of MMP. beta-eudesmol 95-108 BCL2 apoptosis regulator Homo sapiens 217-222 22610911-5 2013 In addition, pretreatment with ferulate markedly protected cells against t-BHP-induced apoptosis, as evidenced by decreased nuclear condensation, cytochrome c release, and caspase-3 cleavage and an increased Bax/Bcl-2 ratio. tert-Butylhydroperoxide 73-78 BCL2 apoptosis regulator Homo sapiens 212-217 22585533-6 2013 Activation of c-Jun N-terminal kinases (JNK) mitogen-activated protein kinases was observed in beta-eudesmol-treated HL60 cells, and the inhibitor of JNK blocked the beta-eudesmol-induced apoptosis, downregulation of Bcl-2, and the loss of MMP. beta-eudesmol 166-179 BCL2 apoptosis regulator Homo sapiens 217-222 22628241-8 2013 Furthermore, western blotting analysis indicated that curcumin induced the release of cytochrome c, a significant increase of Bax and p53 and a marked reduction of Bcl-2 and survivin in LoVo cells. Curcumin 54-62 BCL2 apoptosis regulator Homo sapiens 164-169 23345169-5 2013 In addition, 5-geranyloxy-7-methoxycoumarin arrested cells at the G0/G1 phase, and induction of apoptosis was demonstrated through the activation of tumour suppressor gene p53, caspase8/3, regulation of Bcl2, and inhibition of p38 MAPK phosphorylation. 5-geranyloxy-7-methoxycoumarin 13-43 BCL2 apoptosis regulator Homo sapiens 203-207 22986577-10 2013 Furthermore, ethanol in combination with TRAIL increased the expression of cyclin-dependent kinase inhibitor p21 and decreased the levels of Bcl-2 and phosphorylated-AKT. Ethanol 13-20 BCL2 apoptosis regulator Homo sapiens 141-146 23856142-14 2013 CONCLUSION: Targeting to inhibit antiapoptotic mitochondrial gene Bcl-2 expression in A549 cells specifically decreased the mRNA of ERCC1, TYMS, and TOP2alpha genes, and significantly increased the sensitivities of A549 cells to chemotherapeutic agents such as etoposide, cisplatin, paclitaxel and navelbine. Paclitaxel 283-293 BCL2 apoptosis regulator Homo sapiens 66-71 23117019-5 2013 Based on this knowledge, we propose that selected BCL-2 proteins coordinate mitochondria and nuclear activities via ROS to enable "synchronized" cell fate decisions. Reactive Oxygen Species 116-119 BCL2 apoptosis regulator Homo sapiens 50-55 23658956-4 2010 We developed a multiplexed bead-based flow cytometry high-throughput assay based on the disruption of the binding of a fluorescently labeled-BH3 peptide of Bim to the six anti-apoptotic Bcl-2 family members: Bcl-XL, Bcl-W, Bcl-B, Bfl-1, and Mcl-1 and Bcl-2 (the eponymous founding member of the Bcl-2 family). BH 3 141-144 BCL2 apoptosis regulator Homo sapiens 186-191 23319068-4 2013 Increased protein levels of Bax and cleaved caspase 3 coupled with decreased expression of Bcl-2 were also observed in NSCs with increasing dose or time of PA treatment, whereas caspase 3 expression remained relatively unaltered. Palmitic Acid 156-158 BCL2 apoptosis regulator Homo sapiens 91-96 23856142-2 2013 METHODS: The miRNA recombinant plasmid targeting to human Bcl-2 gene was designed, synthesized and stably transferred into A549 cells by lipofectin technique as the experiment group. 1,2-dielaidoylphosphatidylethanolamine 137-147 BCL2 apoptosis regulator Homo sapiens 58-63 23856142-3 2013 The transcription of Bcl-2 mRNA was detected by reverse transcription-polymerase chain reaction (RT-PCR) by agarose gel electrophoresis, real-time PCR, and the protein level of Bcl-2 was measured by Western blot to confirm the function of miRNA plasmid. Sepharose 108-115 BCL2 apoptosis regulator Homo sapiens 21-26 23856142-14 2013 CONCLUSION: Targeting to inhibit antiapoptotic mitochondrial gene Bcl-2 expression in A549 cells specifically decreased the mRNA of ERCC1, TYMS, and TOP2alpha genes, and significantly increased the sensitivities of A549 cells to chemotherapeutic agents such as etoposide, cisplatin, paclitaxel and navelbine. Etoposide 261-270 BCL2 apoptosis regulator Homo sapiens 66-71 23856142-14 2013 CONCLUSION: Targeting to inhibit antiapoptotic mitochondrial gene Bcl-2 expression in A549 cells specifically decreased the mRNA of ERCC1, TYMS, and TOP2alpha genes, and significantly increased the sensitivities of A549 cells to chemotherapeutic agents such as etoposide, cisplatin, paclitaxel and navelbine. Cisplatin 272-281 BCL2 apoptosis regulator Homo sapiens 66-71 23856142-14 2013 CONCLUSION: Targeting to inhibit antiapoptotic mitochondrial gene Bcl-2 expression in A549 cells specifically decreased the mRNA of ERCC1, TYMS, and TOP2alpha genes, and significantly increased the sensitivities of A549 cells to chemotherapeutic agents such as etoposide, cisplatin, paclitaxel and navelbine. Vinorelbine 298-307 BCL2 apoptosis regulator Homo sapiens 66-71 23246440-4 2013 We hypothesized that DETANONOate inhibits previously identified NF-kappaB-regulated resistant factors such as Yin Yang 1 (YY1) and Bcl-2/BclXL. 2,2'-(hydroxynitrosohydrazono)bis-ethanamine 21-32 BCL2 apoptosis regulator Homo sapiens 131-136 23246471-3 2013 Poly(ethylene glycol)-block-poly(epsilon-caprolactone) (PEG-b-PCL) micelles were loaded with paclitaxel (cytotoxic agent), cyclopamine (hedgehog inhibitor), and gossypol (Bcl-2 inhibitor). poly(ethylene glycol)-block-poly(epsilon-caprolactone) 0-54 BCL2 apoptosis regulator Homo sapiens 171-176 23449448-3 2013 In this study, we show that bortezomib induced apoptosis, which was demonstrated by the downregulation of antiapoptotic molecules (Bcl-2, Bcl-XL, p-Bad, and p-AKT) and the upregulation of proapoptotic proteins (p21, p27, and cleaved-Bid) in ovarian cancer cell lines. Bortezomib 28-38 BCL2 apoptosis regulator Homo sapiens 131-136 23322663-2 2013 There is a 25-nucleotide G-rich sequence in the 5"-untranslated region (5"-UTR) of the BCL2 mRNA, which can adopt a G-quadruplex structure. 25-nucleotide 11-24 BCL2 apoptosis regulator Homo sapiens 87-91 23322663-11 2013 The properties of these alkaloids revealed promising potentials to regulate the expression of the BCL2 protein from the posttranscriptional pathway. Alkaloids 24-33 BCL2 apoptosis regulator Homo sapiens 98-102 23376416-9 2013 Furthermore, Bcl-2 expression was decreased and the ratio of Bcl-2 to Bax was significantly decreased by isatin. Isatin 105-111 BCL2 apoptosis regulator Homo sapiens 13-18 23376416-9 2013 Furthermore, Bcl-2 expression was decreased and the ratio of Bcl-2 to Bax was significantly decreased by isatin. Isatin 105-111 BCL2 apoptosis regulator Homo sapiens 61-66 23449455-7 2013 Over 4200 genes responded differently to vorinostat in normal and transformed cells and gene ontology and pathway analyses identified a tumor-cell-selective pro-apoptotic gene-expression signature that consisted of BCL2 family genes. Vorinostat 41-51 BCL2 apoptosis regulator Homo sapiens 215-219 23445492-0 2013 Pentoxifylline and the proteasome inhibitor MG132 induce apoptosis in human leukemia U937 cells through a decrease in the expression of Bcl-2 and Bcl-XL and phosphorylation of p65. Pentoxifylline 0-14 BCL2 apoptosis regulator Homo sapiens 136-141 23445492-0 2013 Pentoxifylline and the proteasome inhibitor MG132 induce apoptosis in human leukemia U937 cells through a decrease in the expression of Bcl-2 and Bcl-XL and phosphorylation of p65. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 44-49 BCL2 apoptosis regulator Homo sapiens 136-141 22484426-5 2013 This humanized-MYC/BCL2-model (hMB) accurately recapitulates the histopathological and clinical aspects of steroid-, chemotherapy- and rituximab-resistant human "double-hit" lymphomas that involve the MYC and BCL2 loci. Steroids 107-114 BCL2 apoptosis regulator Homo sapiens 19-23 23445492-7 2013 In these cells, PTX and the MG132 proteasome inhibitor decrease p65 (NF-kappaB subunit) phosphorylation and the antiapoptotic proteins Bcl-2 and Bcl-XL. Pentoxifylline 16-19 BCL2 apoptosis regulator Homo sapiens 135-140 23274410-13 2013 In GBC-SD cells, icariin significantly inhibited both the constitutive and gemcitabine-induced NF-kappaB activity, enhanced caspase-3 activity, induced G(0)-G(1) phase arrest, and suppressed the expression of Bcl-2, Bcl-xL and surviving proteins. icariin 17-24 BCL2 apoptosis regulator Homo sapiens 209-214 23102022-2 2013 We have recently developed ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017), derived from a dual inhibitor of Bcl-2 and SERCA proteins, sHA 14-1, with selective cytotoxicity toward MDR cancer cell lines in vitro. ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate 27-114 BCL2 apoptosis regulator Homo sapiens 158-163 23102022-2 2013 We have recently developed ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017), derived from a dual inhibitor of Bcl-2 and SERCA proteins, sHA 14-1, with selective cytotoxicity toward MDR cancer cell lines in vitro. ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate 116-122 BCL2 apoptosis regulator Homo sapiens 158-163 23102022-8 2013 Given the well-established functions of Bcl-2 family proteins and ER calcium in drug resistance, our results suggest that the down-regulation of Mcl-1 and the up-regulation of Noxa and Bim along with the decrease in ER calcium content are likely responsible for CXL017-induced resensitization of MDR cancer cells. Calcium 219-226 BCL2 apoptosis regulator Homo sapiens 40-45 23243017-2 2013 Tetracycline-inducible Bcl-2 and Bcl-xL dual knockdown sharply increased PI3K/AKT/mTOR inhibitor lethality. Tetracycline 0-12 BCL2 apoptosis regulator Homo sapiens 23-28 23243017-3 2013 Conversely, inducible knockdown or dominant-negative AKT increased, whereas constitutively active AKT reduced lethality of the Bcl-2/Bcl-xL inhibitor ABT-737. ABT-737 150-157 BCL2 apoptosis regulator Homo sapiens 127-132 23243017-11 2013 In a systemic AML xenograft model, dual tetracycline-inducible knockdown of Bcl-2/Bcl-xL sharply increased BEZ235 antileukemic effects. Tetracycline 40-52 BCL2 apoptosis regulator Homo sapiens 76-81 23243017-11 2013 In a systemic AML xenograft model, dual tetracycline-inducible knockdown of Bcl-2/Bcl-xL sharply increased BEZ235 antileukemic effects. dactolisib 107-113 BCL2 apoptosis regulator Homo sapiens 76-81 23202800-11 2013 In Eca-109 cells, crotoxin induced apoptosis and G1 block, significantly upregulated the expression of p15 and caspase-3 p17 genes and downregulated the expression of Bcl-2 gene. Beclotiamine 18-26 BCL2 apoptosis regulator Homo sapiens 167-172 23243017-13 2013 Together, these findings suggest that antileukemic synergism between PI3K/AKT/mTOR inhibitors and BH3 mimetics involves multiple mechanisms, including Mcl-1 downregulation, release of Bim from Bcl-2/Bcl-xL as well as Bak and Bax from Mcl-1/Bcl-2/Bcl-xL, and GSK3alpha/beta, culminating in Bax/Bak activation and apoptosis. BH 3 98-101 BCL2 apoptosis regulator Homo sapiens 193-198 23243017-13 2013 Together, these findings suggest that antileukemic synergism between PI3K/AKT/mTOR inhibitors and BH3 mimetics involves multiple mechanisms, including Mcl-1 downregulation, release of Bim from Bcl-2/Bcl-xL as well as Bak and Bax from Mcl-1/Bcl-2/Bcl-xL, and GSK3alpha/beta, culminating in Bax/Bak activation and apoptosis. BH 3 98-101 BCL2 apoptosis regulator Homo sapiens 240-245 22430213-0 2013 N-(phosphonacetyl)-L-aspartate induces TAp73-dependent apoptosis by modulating multiple Bcl-2 proteins: potential for cancer therapy. sparfosic acid 0-30 BCL2 apoptosis regulator Homo sapiens 88-93 23410971-0 2013 ABT-199: taking dead aim at BCL-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 28-33 23410971-1 2013 ABT-199 is a new selective small molecule inhibitor of BCL-2 that appears to spare platelets while achieving potent antitumor activity. venetoclax 0-7 BCL2 apoptosis regulator Homo sapiens 55-60 23389088-4 2013 Alterations in the expression of apoptosis-associated proteins in response to clerosterol treatment included upregulation of Bax, downregulation of Bcl-2 and activation of caspases 3 and 9. clerosterol 78-89 BCL2 apoptosis regulator Homo sapiens 148-153 23274410-13 2013 In GBC-SD cells, icariin significantly inhibited both the constitutive and gemcitabine-induced NF-kappaB activity, enhanced caspase-3 activity, induced G(0)-G(1) phase arrest, and suppressed the expression of Bcl-2, Bcl-xL and surviving proteins. gemcitabine 75-86 BCL2 apoptosis regulator Homo sapiens 209-214 23154865-4 2013 The electrostatic potential of BH3 cleft of Bcl-2/mutants and their heterodimerization with Bcl-2 associated X protein (Bax) were computationally evaluated. BH 3 31-34 BCL2 apoptosis regulator Homo sapiens 44-49 23154865-4 2013 The electrostatic potential of BH3 cleft of Bcl-2/mutants and their heterodimerization with Bcl-2 associated X protein (Bax) were computationally evaluated. BH 3 31-34 BCL2 apoptosis regulator Homo sapiens 92-97 23392706-7 2013 Lastly, hydroquinone and NU7026 exhibited synergistic effects on promoting apoptosis by increasing the protein levels of pro-apoptotic proteins Bax and caspase-3 but decreasing the protein expression of anti-apoptotic protein Bcl-2. hydroquinone 8-20 BCL2 apoptosis regulator Homo sapiens 226-231 23059386-1 2013 Mebendazole (MBZ) was identified as a promising therapeutic on the basis of its ability to induce apoptosis in melanoma cell lines through a B-cell lymphoma 2 (BCL2)-dependent mechanism. Mebendazole 0-11 BCL2 apoptosis regulator Homo sapiens 141-158 23059386-1 2013 Mebendazole (MBZ) was identified as a promising therapeutic on the basis of its ability to induce apoptosis in melanoma cell lines through a B-cell lymphoma 2 (BCL2)-dependent mechanism. Mebendazole 0-11 BCL2 apoptosis regulator Homo sapiens 160-164 23059386-1 2013 Mebendazole (MBZ) was identified as a promising therapeutic on the basis of its ability to induce apoptosis in melanoma cell lines through a B-cell lymphoma 2 (BCL2)-dependent mechanism. Mebendazole 13-16 BCL2 apoptosis regulator Homo sapiens 141-158 23201009-2 2013 Apogossypolone (ApoG2), the most potent gossypol derivative, has been defined as a novel small-molecule inhibitor of anti-apoptotic Bcl-2 family proteins. apogossypolone 0-14 BCL2 apoptosis regulator Homo sapiens 132-137 23201009-2 2013 Apogossypolone (ApoG2), the most potent gossypol derivative, has been defined as a novel small-molecule inhibitor of anti-apoptotic Bcl-2 family proteins. Gossypol 3-11 BCL2 apoptosis regulator Homo sapiens 132-137 23448605-3 2013 The aim of our study was to detect the level of apoptosis, expression bcl-2 and p53, associated with the different doses of CsA. Cyclosporine 124-127 BCL2 apoptosis regulator Homo sapiens 70-75 23378584-5 2013 However, before apoptosis is induced, BCL-2 proteins have critical roles in normal cell physiology related to neuronal activity, autophagy, calcium handling, mitochondrial dynamics and energetics, and other processes of normal healthy cells. Calcium 140-147 BCL2 apoptosis regulator Homo sapiens 38-43 22710762-10 2013 Bcl-2 expression tended to be increased after addition of thalidomide. Thalidomide 58-69 BCL2 apoptosis regulator Homo sapiens 0-5 22830613-6 2013 We observed increased levels of both pro- and antiapoptotic BCL-2 proteins at the mitochondria following exposure to roscovitine. Roscovitine 117-128 BCL2 apoptosis regulator Homo sapiens 60-65 22830613-7 2013 These results suggest that roscovitine induces priming of cancer cells for death by binding antiapoptotic BCL-2 proteins to proapoptotic BH3-only proteins at the mitochondria, thereby decreasing the threshold for diverse proapoptotic stimuli. Roscovitine 27-38 BCL2 apoptosis regulator Homo sapiens 106-111 23291630-0 2013 ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. venetoclax 0-7 BCL2 apoptosis regulator Homo sapiens 32-37 23291630-3 2013 The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of navitoclax, a selective inhibitor of both BCL-2 and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers. navitoclax 107-117 BCL2 apoptosis regulator Homo sapiens 149-154 23291630-3 2013 The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of navitoclax, a selective inhibitor of both BCL-2 and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers. navitoclax 107-117 BCL2 apoptosis regulator Homo sapiens 159-164 23291630-5 2013 Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and BCL-2-selective inhibitor, ABT-199. venetoclax 126-133 BCL2 apoptosis regulator Homo sapiens 99-104 23291630-7 2013 A single dose of ABT-199 in three patients with refractory chronic lymphocytic leukemia resulted in tumor lysis within 24 h. These data indicate that selective pharmacological inhibition of BCL-2 shows promise for the treatment of BCL-2-dependent hematological cancers. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 17-20 BCL2 apoptosis regulator Homo sapiens 190-195 23291630-7 2013 A single dose of ABT-199 in three patients with refractory chronic lymphocytic leukemia resulted in tumor lysis within 24 h. These data indicate that selective pharmacological inhibition of BCL-2 shows promise for the treatment of BCL-2-dependent hematological cancers. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 17-20 BCL2 apoptosis regulator Homo sapiens 231-236 23059386-1 2013 Mebendazole (MBZ) was identified as a promising therapeutic on the basis of its ability to induce apoptosis in melanoma cell lines through a B-cell lymphoma 2 (BCL2)-dependent mechanism. Mebendazole 13-16 BCL2 apoptosis regulator Homo sapiens 160-164 23069790-11 2013 Our results indicate that the expression of the EP2 receptor and Bcl-2 was significantly increased, whereas that of Bax and cleaved caspase-3 was decreased in HepG2 and SMMC-7721 cells after stimulation by butaprost. butaprost 206-215 BCL2 apoptosis regulator Homo sapiens 65-70 23069790-12 2013 Paeoniflorin significantly decreased the expression of the EP2 receptor and Bcl-2 and increased Bax and caspase-3 activation in HepG2 and SMMC-7721 cells on addition of butaprost. peoniflorin 0-12 BCL2 apoptosis regulator Homo sapiens 76-81 23069790-14 2013 Paeoniflorin, which may be a promising agent in the treatment of liver cancer, induced apoptosis in hepatocellular carcinoma cells by downregulating EP2 expression and also increased the Bax-to-Bcl-2 ratio, thus upregulating the activation of caspase-3. peoniflorin 0-12 BCL2 apoptosis regulator Homo sapiens 194-199 23440052-6 2013 On the contrary, OLA restored the decreased levels of anti-apoptotic Bcl-2 family proteins (Bcl-2, Bcl-xL, and Mcl-1) in PAM-treated cells. Oleic Acid 17-20 BCL2 apoptosis regulator Homo sapiens 69-74 23440052-6 2013 On the contrary, OLA restored the decreased levels of anti-apoptotic Bcl-2 family proteins (Bcl-2, Bcl-xL, and Mcl-1) in PAM-treated cells. Oleic Acid 17-20 BCL2 apoptosis regulator Homo sapiens 92-97 23076534-6 2013 Periostin-overexpressing cells treated with cisplatin or 5-FU showed significantly (p < 0.05) decreased expression of Bax and p53 proteins and increased expression of Bcl-2 protein, when compared to drug-treated mock counterparts. Cisplatin 44-53 BCL2 apoptosis regulator Homo sapiens 170-175 23076534-6 2013 Periostin-overexpressing cells treated with cisplatin or 5-FU showed significantly (p < 0.05) decreased expression of Bax and p53 proteins and increased expression of Bcl-2 protein, when compared to drug-treated mock counterparts. Fluorouracil 57-61 BCL2 apoptosis regulator Homo sapiens 170-175 23233484-9 2013 Inhibition of the antiapoptotic proteins Bcl-2 and Bcl-X(L) with the pharmacologic inhibitor ABT-737 increased effector caspase activation and apoptosis, and reduced cell survival with PAK4 or PAK1 knockdown. ABT-737 93-100 BCL2 apoptosis regulator Homo sapiens 41-46 23072837-0 2013 Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder. Glutamic Acid 85-94 BCL2 apoptosis regulator Homo sapiens 0-5 23072837-2 2013 In bipolar disorder (BD), studies have shown a key role for a Bcl-2 gene single-nucleotide polymorphism (SNP) rs956572 in the regulation of intracellular calcium (Ca(2+)) dynamics, Bcl-2 expression/levels, and vulnerability to cellular apoptosis. Calcium 154-161 BCL2 apoptosis regulator Homo sapiens 62-67 23072837-2 2013 In bipolar disorder (BD), studies have shown a key role for a Bcl-2 gene single-nucleotide polymorphism (SNP) rs956572 in the regulation of intracellular calcium (Ca(2+)) dynamics, Bcl-2 expression/levels, and vulnerability to cellular apoptosis. Calcium 154-161 BCL2 apoptosis regulator Homo sapiens 181-186 23072837-3 2013 At the same time, Bcl-2 decreases glutamate (Glu) toxicity in neural cells. Glutamic Acid 34-43 BCL2 apoptosis regulator Homo sapiens 18-23 23072837-3 2013 At the same time, Bcl-2 decreases glutamate (Glu) toxicity in neural cells. Glutamic Acid 45-48 BCL2 apoptosis regulator Homo sapiens 18-23 23072837-12 2013 Also, Bcl-2 AA genotype, previously associated with lower Bcl-2 expression and increase intracellular Ca(2+), showed to be associated with increased ACC Glu and Glx levels in euthymic-BD subjects. Glutamic Acid 153-156 BCL2 apoptosis regulator Homo sapiens 6-11 23392706-7 2013 Lastly, hydroquinone and NU7026 exhibited synergistic effects on promoting apoptosis by increasing the protein levels of pro-apoptotic proteins Bax and caspase-3 but decreasing the protein expression of anti-apoptotic protein Bcl-2. 2-(morpholin-4-yl)benzo(h)chromen-4-one 25-31 BCL2 apoptosis regulator Homo sapiens 226-231 23281693-9 2013 CONCLUSION: The present study suggests that one of the actions of PUVA therapy in psoriasis might be exerted through induction of apoptosis especially of lymphocytes by suppression of Bcl-2 expression and of keratinocytes through P53 and Fas pathways leading to healing of psoriasis. puva 66-70 BCL2 apoptosis regulator Homo sapiens 184-189 23229564-8 2013 Moreover, CAUE-induced apoptosis was enhanced in the Bcl-2 knockdown condition induced by small interfering RNA. Caffeic acid undecyl ester 10-14 BCL2 apoptosis regulator Homo sapiens 53-58 22565822-7 2013 Computational modeling showed that emodin could directly bind to the BH3 domain of Bcl-2 through forming one hydrogen bond with Ala146 residue in Bcl-2. Hydrogen 109-117 BCL2 apoptosis regulator Homo sapiens 83-88 23135489-3 2013 Casticin downregulated cell survival proteins including Bcl-xL, Bcl-2, survivin, XIAP and cFLIP, and induced death receptor 5 (DR5), but had no effect on DR4 and decoy receptors (DcR1 or DcR2). casticin 0-8 BCL2 apoptosis regulator Homo sapiens 76-81 23420047-5 2013 Western blotting was used to investigate the effects of rAGAP on p27, Bcl-2/Bax and PTEN/PI3K/Akt cellular signal transduction. ragap 56-61 BCL2 apoptosis regulator Homo sapiens 70-75 23281693-3 2013 AIM: In this study, we evaluated the expression of pro-apoptotic (P53, Fas and Bax) and anti-apoptotic (Bcl-2) proteins correlating it with apoptotic index (AI) and epidermal thickness in psoriatic skin before and after PUVA therapy. puva 220-224 BCL2 apoptosis regulator Homo sapiens 104-109 23469687-0 2013 Zerumbone induces apoptosis in human renal cell carcinoma via Gli-1/Bcl-2 pathway. zerumbone 0-9 BCL2 apoptosis regulator Homo sapiens 68-73 24024133-5 2013 Senescent HDFs are more resistant to oxidative stress (exogenous H2O2)-induced apoptosis in comparison to non-senescent (control) HDFs; this is associated with constitutively high levels of the anti-apoptotic gene, Bcl-2, and low expression of the pro-apoptotic gene, Bax. Hydrogen Peroxide 65-69 BCL2 apoptosis regulator Homo sapiens 215-220 23469687-6 2013 Mechanically, treatment of RCC cells with zerumbone activated caspase-3 and caspase-9, and finally led to cleavage of PARR In addition, downregulation of Gli-1 and Bcl-2, which were closely related to the chemoresistance of RCC, was observed in zerumbone-treated RCC cells. zerumbone 42-51 BCL2 apoptosis regulator Homo sapiens 164-169 23469687-8 2013 The zerumbone-induced apoptosis might be related to the activation of the caspase cascade and deregulation of the Gli-1/Bcl-2 pathway. zerumbone 4-13 BCL2 apoptosis regulator Homo sapiens 120-125 23484696-0 2013 [Effect of homoharringtonine on expression of NF-kappaB and BCL-2 proteins in K562 cells]. Homoharringtonine 11-28 BCL2 apoptosis regulator Homo sapiens 60-65 23484700-10 2013 It is concluded that the oxaliplatin can induce apoptosis of RPMI-8226 cells, activating the death receptor pathway and arresting cell cycle may be two of the related mechanisms, Bcl-2 gene has unobservable effects in the process of oxaliplatin-induced cell apoptosis. Oxaliplatin 25-36 BCL2 apoptosis regulator Homo sapiens 179-184 23484700-10 2013 It is concluded that the oxaliplatin can induce apoptosis of RPMI-8226 cells, activating the death receptor pathway and arresting cell cycle may be two of the related mechanisms, Bcl-2 gene has unobservable effects in the process of oxaliplatin-induced cell apoptosis. Oxaliplatin 233-244 BCL2 apoptosis regulator Homo sapiens 179-184 23348995-6 2013 Exposure of T24 cells to costunolide was also associated with increased expression of Bax, down-regulation of Bcl-2, survivin and significant activation of caspase-3, and its downstream target PARP. costunolide 25-36 BCL2 apoptosis regulator Homo sapiens 110-115 22930531-2 2013 Four-arm poly(ethylene glycol) is co-conjugated with DOX and anti-bcl-2 oligonucleotide with reducible linkers and acid-cleavable linkers, respectively. poly 9-13 BCL2 apoptosis regulator Homo sapiens 66-71 22930531-2 2013 Four-arm poly(ethylene glycol) is co-conjugated with DOX and anti-bcl-2 oligonucleotide with reducible linkers and acid-cleavable linkers, respectively. Ethylene Glycol 14-29 BCL2 apoptosis regulator Homo sapiens 66-71 22930531-2 2013 Four-arm poly(ethylene glycol) is co-conjugated with DOX and anti-bcl-2 oligonucleotide with reducible linkers and acid-cleavable linkers, respectively. Oligonucleotides 72-87 BCL2 apoptosis regulator Homo sapiens 66-71 23270479-5 2013 Se-GTPs clearly triggered the mitochondrial apoptotic pathway, as indicated by an increase in Bax/Bcl-2 ratio and subsequent caspase-3 and caspase-9 activation. se-gtps 0-7 BCL2 apoptosis regulator Homo sapiens 98-103 23142241-11 2013 SIGNIFICANCE: As wogonin was effective in vitro in promotion of apoptosis of myeloma cell by Akt-modulated, Bax and Bcl-2 related intrinsic apoptotic pathway, wogonin may be a potential therapeutic agent against multiple myeloma. wogonin 17-24 BCL2 apoptosis regulator Homo sapiens 116-121 23142241-11 2013 SIGNIFICANCE: As wogonin was effective in vitro in promotion of apoptosis of myeloma cell by Akt-modulated, Bax and Bcl-2 related intrinsic apoptotic pathway, wogonin may be a potential therapeutic agent against multiple myeloma. wogonin 159-166 BCL2 apoptosis regulator Homo sapiens 116-121 23122111-5 2013 Our data further indicate reduction of DeltapsiM and increased [Ca(2+)](i) during apoptosis induction by neferine with increased expression of apoptotic proteins such as Bax, Bad, cleaved forms of caspase 3, caspase 9 and PARP, with the downregulation of anti-apoptotic protein Bcl2 in HepG2 cells. neferine 105-113 BCL2 apoptosis regulator Homo sapiens 278-282 23136001-8 2013 Both dDAVP and 8-cpt-cAMP increased phosphorylation of proapoptotic Bcl-2 family members Bad and Bok. 8-cpt 15-20 BCL2 apoptosis regulator Homo sapiens 68-73 23136001-8 2013 Both dDAVP and 8-cpt-cAMP increased phosphorylation of proapoptotic Bcl-2 family members Bad and Bok. Cyclic AMP 21-25 BCL2 apoptosis regulator Homo sapiens 68-73 23117090-5 2013 Hoechst 33258 and Annexin V/PI staining results showed that the total cell number in apoptosis associated with a dose-dependent up-regulation of Bax and down-regulation of Bcl-2/Bcl-xl was increased. hoechst 0-7 BCL2 apoptosis regulator Homo sapiens 172-177 23299493-5 2013 Mechanistically, we showed that fucoxanthin attenuated cisplatin-induced NFkappaB expression and enhanced the NFkappaB-regulated Bax/Bcl-2 mRNA ratio. fucoxanthin 32-43 BCL2 apoptosis regulator Homo sapiens 133-138 23321005-5 2013 MiR-125 targets a number of genes such as transcription factors, matrix-metalloprotease, members of Bcl-2 family and others, aberrance of which may lead to abnormal proliferation, metastasis and invasion of cells, even carcinomas. mir-125 0-7 BCL2 apoptosis regulator Homo sapiens 100-105 23178663-11 2013 Treatment of MCF-7 cells with DTN encouraged apoptosis with cell death-transducing signals that reduced MMP by down-regulation of Bcl-2 and up-regulation of Bax, triggering cytochrome c release from the mitochondria to the cytosol. dentatin 30-33 BCL2 apoptosis regulator Homo sapiens 130-135 24900652-0 2013 The role of the acidity of N-heteroaryl sulfonamides as inhibitors of bcl-2 family protein-protein interactions. n-heteroaryl sulfonamides 27-52 BCL2 apoptosis regulator Homo sapiens 70-75 23167995-6 2013 A zebularine concentration of 50 muM accounted for the inhibition of cell proliferation of 67% at 48 h. The treatment with zebularine upregulated Bax, and decreased Bcl-2 protein. pyrimidin-2-one beta-ribofuranoside 2-12 BCL2 apoptosis regulator Homo sapiens 165-170 23167995-6 2013 A zebularine concentration of 50 muM accounted for the inhibition of cell proliferation of 67% at 48 h. The treatment with zebularine upregulated Bax, and decreased Bcl-2 protein. pyrimidin-2-one beta-ribofuranoside 123-133 BCL2 apoptosis regulator Homo sapiens 165-170 23165478-4 2013 The adverse immunostimulatory responses were abrogated by selective B cell-targeted delivery and early endosomal compartmentalization of G3139-encapsulated RIT-INPs, resulting in reduced NF-kappaB activation, robust Bcl-2 down-regulation, and enhanced sensitivity to fludarabine-induced cytotoxicity. Ritonavir 156-159 BCL2 apoptosis regulator Homo sapiens 216-221 24014296-4 2013 The unravelling of the BCL2 story in CLL has led to the development of a whole new class of therapeutic agents-the BH3 mimetics-which are significantly more targeted than conventional chemo-immunotherapy and therefore promise potent clinical activity coupled with reduced toxicity. BH 3 115-118 BCL2 apoptosis regulator Homo sapiens 23-27 23316476-5 2012 For example overexpression of Bcl-2 has been shown to contribute to a pro-oxidant intracellular milieu and down-regulation of cellular superoxide levels enhanced death sensitivity of Bcl-2 overexpressing cells. Superoxides 135-145 BCL2 apoptosis regulator Homo sapiens 30-35 23316476-5 2012 For example overexpression of Bcl-2 has been shown to contribute to a pro-oxidant intracellular milieu and down-regulation of cellular superoxide levels enhanced death sensitivity of Bcl-2 overexpressing cells. Superoxides 135-145 BCL2 apoptosis regulator Homo sapiens 183-188 23610963-0 2013 Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides. Etoposide 16-25 BCL2 apoptosis regulator Homo sapiens 62-67 23610963-4 2013 The aim of the study was to investigate the effects of the combined use of antisense oligonucleotides (ASOs) targeting BCL-2 and C-RAF transcripts on the in vitro cancer cell cultures exposed to etoposide. Oligonucleotides 85-101 BCL2 apoptosis regulator Homo sapiens 119-124 23610963-4 2013 The aim of the study was to investigate the effects of the combined use of antisense oligonucleotides (ASOs) targeting BCL-2 and C-RAF transcripts on the in vitro cancer cell cultures exposed to etoposide. Oligonucleotides, Antisense 103-107 BCL2 apoptosis regulator Homo sapiens 119-124 23247593-7 2013 Meanwhile, berberine dose-dependently induced ROS generation, G(2)/M phase arrest and apoptosis in U266 cells, and decreased the levels of miR-21 and Bcl-2. Berberine 11-20 BCL2 apoptosis regulator Homo sapiens 150-155 23247593-12 2013 CONCLUSION: In U266 cells, berberine suppresses NF-kappaB nuclear translocation via Set9-mediated lysine methylation, leads to decrease in the levels miR21 and Bcl-2, which induces ROS generation and apoptosis. Berberine 27-36 BCL2 apoptosis regulator Homo sapiens 160-165 23247593-12 2013 CONCLUSION: In U266 cells, berberine suppresses NF-kappaB nuclear translocation via Set9-mediated lysine methylation, leads to decrease in the levels miR21 and Bcl-2, which induces ROS generation and apoptosis. ros 181-184 BCL2 apoptosis regulator Homo sapiens 160-165 23711145-7 2013 Furthermore, celastrol dramatically increased expression of Bax/Bcl-2, proteolytic cleavage of Caspase-3, -9, PARP, and decreased expression of FasR. celastrol 13-22 BCL2 apoptosis regulator Homo sapiens 64-69 23336515-7 2013 Oridonin triggered the reduction of Bcl-2/Bax ratio, caspase-8, NF-kappaB (p65), IKKalpha, IKKbeta, phospho-mTOR, and increased expression level of cleaved PARP, Fas and PPARgamma in a time-dependent manner. oridonin 0-8 BCL2 apoptosis regulator Homo sapiens 36-41 23295863-6 2013 First, CsA could upregulate Fas/Fas ligand, downregulate Bcl-2/Bcl-XL, and increase caspase-1 and caspase-3. Cyclosporine 7-10 BCL2 apoptosis regulator Homo sapiens 57-62 23152113-8 2013 THG213.29 increased mRNA expression of heme-oxygenase 1, Bcl2, and FGF-2 in renal cortex; correspondingly, in EP(4)-transfected HEK293 cells, THG213.29 augmented FGF-2 and abrogated EP(4)-dependent overexpression of inflammatory IL-6 and of apoptotic death domain-associated protein and BCL2-associated agonist of cell death. thg213 0-6 BCL2 apoptosis regulator Homo sapiens 57-61 24364474-0 2013 Impact of treatment with methimazole on the Bcl-2 expression in CD8+ peripheral blood lymphocytes in children with Graves" disease. Methimazole 25-36 BCL2 apoptosis regulator Homo sapiens 44-49 23152113-8 2013 THG213.29 increased mRNA expression of heme-oxygenase 1, Bcl2, and FGF-2 in renal cortex; correspondingly, in EP(4)-transfected HEK293 cells, THG213.29 augmented FGF-2 and abrogated EP(4)-dependent overexpression of inflammatory IL-6 and of apoptotic death domain-associated protein and BCL2-associated agonist of cell death. thg213 0-6 BCL2 apoptosis regulator Homo sapiens 287-291 23406595-9 2013 In contrast, expression of the antiapoptotic molecule Bcl-2 at the mRNA and protein levels was significantly lower in MTX-treated NPs than in nontreated NPs. Methotrexate 118-121 BCL2 apoptosis regulator Homo sapiens 54-59 24364474-4 2013 The aim of this study was evaluation of expression of Bcl-2 protein in peripheral blood T lymphocytes in hyperthyroid children due to Graves" disease (GD) before and after therapy with methimazole (MMI), in comparison with healthy controls. Methimazole 185-196 BCL2 apoptosis regulator Homo sapiens 54-59 23267129-11 2013 Furthermore, beta-elemene increased caspase-3/7/10 activity, up-regulated protein expression of BAX, and down-regulated the one of BCL-2, BCL-XL, and of X-linked inhibitor of apoptosis (XIAP) in the cells, suggesting that apoptotic signaling pathways are involved in the responses triggered by beta-elemene. beta-elemene 13-25 BCL2 apoptosis regulator Homo sapiens 131-136 24083726-5 2013 After inhibition of autophagy by chloroquine, the rates of cell apoptosis were increased to (30.16+-3.54)%, and the level of Caspase-3 and P53 protein were increased, and Bcl-2 protein was decreased. Chloroquine 33-44 BCL2 apoptosis regulator Homo sapiens 171-176 23267148-7 2013 Together, these results indicate the pivotal role ROS play in the antiproliferative- and apoptosis-inducing activity of CDDO-Me in ovarian cancer cells; however, the role of ROS in the down-regulation of prosurvival AKT, mTOR, NF-kappaB and antiapoptotic BCL-2, BCL-xL, c-IAP1 and survivin warrants further investigation. bardoxolone methyl 120-127 BCL2 apoptosis regulator Homo sapiens 255-260 24289612-10 2013 The results showed that RTHF up-regulated the Bax/Bcl-2 ratio and cle-caspase3/9, cle-PARP expression in a dose- dependent manner. rthf 24-28 BCL2 apoptosis regulator Homo sapiens 50-55 24175842-4 2013 Menadione treatment increased the expression of pro-apoptotic proteins, Bax and p53, with a concurrent decrease in anti-apoptotic proteins, Bcl-2 and p65. Vitamin K 3 0-9 BCL2 apoptosis regulator Homo sapiens 140-145 23621258-0 2013 Bcl-2 overexpression inhibits generation of intracellular reactive oxygen species and blocks adriamycin-induced apoptosis in bladder cancer cells. Reactive Oxygen Species 58-81 BCL2 apoptosis regulator Homo sapiens 0-5 24377552-10 2013 Therefore, bortezomib can enhance ATO actions to induce apoptosis in RPMI 8266 cells, with decrease in expression of bcl-2 and increase of caspase-3, caspase-8 and caspase-9 proteins. Bortezomib 11-21 BCL2 apoptosis regulator Homo sapiens 117-122 23725146-0 2013 Effect of Bcl-2 on apoptosis and transcription factor NF-kappaB activation induced by adriamycin in bladder carcinoma BIU87 cells. Doxorubicin 86-96 BCL2 apoptosis regulator Homo sapiens 10-15 24289612-12 2013 These results suggest that RTHF might exert anti-growth and apoptosis activity against lung cancer A549 cells through activation of caspases and Bcl-2 family proteins and the MAPK pathway, therefore presenting as a promising therapeutic agent for the treatment of lung cancer. rthf 27-31 BCL2 apoptosis regulator Homo sapiens 145-150 24460340-7 2013 RESULTS: We found that gambogenic acid suppressed breast tumor growth in vivo, in association with increased expression of Fas and cleaved caspase-3,-8,-9 and bax, as well as decrease in the anti-apoptotic protein bcl-2. neo-gambogic acid 23-38 BCL2 apoptosis regulator Homo sapiens 214-219 23621258-0 2013 Bcl-2 overexpression inhibits generation of intracellular reactive oxygen species and blocks adriamycin-induced apoptosis in bladder cancer cells. Doxorubicin 93-103 BCL2 apoptosis regulator Homo sapiens 0-5 23621258-9 2013 Enhanced expression of Bcl-2 inhibited intracellular ROS generation following ADR treatment. Reactive Oxygen Species 53-56 BCL2 apoptosis regulator Homo sapiens 23-28 23725146-9 2013 These results suggest that the overexpression of Bcl-2 renders human bladder carcinoma cells resistant to adriamycin -induced cytotoxicity and there is a link between Bcl-2 and the NF-kappaB signaling pathway in the suppression of apoptosis. Doxorubicin 106-116 BCL2 apoptosis regulator Homo sapiens 49-54 23621258-11 2013 The overexpression of Bcl-2 renders human bladder cancer cells resistant to ADR-induced apoptosis and ROS might act as an important secondary messenger in this process. Reactive Oxygen Species 102-105 BCL2 apoptosis regulator Homo sapiens 22-27 24195080-6 2013 Moreover, alpha -zearalanol downregulated proapoptotic protein Bax, upregulated antiapoptotic proteins Bcl-2 and Bcl-XL, and decreased the expression and activity of caspase-9. Zeranol 10-27 BCL2 apoptosis regulator Homo sapiens 103-108 24083709-0 2013 Curcumin inhibits human non-small cell lung cancer A549 cell proliferation through regulation of Bcl-2/Bax and cytochrome C. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 97-102 24083709-3 2013 And to further confirm the relative anti-cancer mechanism of curcumin, RT-PCR was carried out to analysis the expression of relative apoptotic proteins Bax, Bcl-2. Curcumin 61-69 BCL2 apoptosis regulator Homo sapiens 157-162 24083709-4 2013 We found that curcumin could up-regulate the expression of Bax but down-regulate the expression of Bcl-2 in A549 cells. Curcumin 14-22 BCL2 apoptosis regulator Homo sapiens 99-104 24083709-6 2013 These results suggested that curcumin inhibited cancer cell growth through the regulation of Bcl-2/Bax and affect the mitochondrial apoptosis pathway. Curcumin 29-37 BCL2 apoptosis regulator Homo sapiens 93-98 24088253-4 2013 Furthermore, sesamin suppressed the constitutive and interleukin (IL)-6-induced signal transducer and activator of transcription 3 (STAT3) signalling pathway in HepG2 cells, leading to regulate the downstream genes, including p53, p21, cyclin proteins and the Bcl-2 protein family. sesamin 13-20 BCL2 apoptosis regulator Homo sapiens 260-265 23992001-2 2013 METHODS: The mechanism of binding of hesperetin with NF-?B and other apoptotic proteins like BAX, BAD, BCL2 and BCLXL was analysed in silico using Schrodinger suite 2009. hesperetin 37-47 BCL2 apoptosis regulator Homo sapiens 103-107 24172207-0 2013 Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer. Tamoxifen 50-59 BCL2 apoptosis regulator Homo sapiens 8-13 23533997-7 2013 This alantolactone-induced apoptosis was found to be associated with GSH depletion, inhibition of STAT3 activation, ROS generation, mitochondrial transmembrane potential dissipation, and increased Bax/Bcl-2 ratio and caspase-3 activation. alantolactone 5-18 BCL2 apoptosis regulator Homo sapiens 201-206 22861820-14 2013 Notably, Bcl-2 activation was suppressed by the JAK2 inhibitor, tyrphostin AG490. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 64-80 BCL2 apoptosis regulator Homo sapiens 9-14 23206987-0 2013 3-Thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile (S1) derivatives as pan-Bcl-2-inhibitors of Bcl-2, Bcl-xL and Mcl-1. 3-thiomorpholin-8-oxo-8h-acenaphtho [1,2-b] pyrrole-9-carbonitrile 0-66 BCL2 apoptosis regulator Homo sapiens 91-96 23206987-0 2013 3-Thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile (S1) derivatives as pan-Bcl-2-inhibitors of Bcl-2, Bcl-xL and Mcl-1. 3-thiomorpholin-8-oxo-8h-acenaphtho [1,2-b] pyrrole-9-carbonitrile 0-66 BCL2 apoptosis regulator Homo sapiens 111-116 23206987-1 2013 Based on the binding mode of our previously discovered dual inhibitor of Bcl-2 and Mcl-1, 3-thiomorpholin-8-oxo-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile (3, S1), a library of 9-substituted 3 derivatives was synthesized to further probe the p4 pocket of the two targets. ,2-b]pyrrole-9-carbonitrile 127-154 BCL2 apoptosis regulator Homo sapiens 73-78 24172207-0 2013 Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 64-67 BCL2 apoptosis regulator Homo sapiens 8-13 24172207-3 2013 ABT-199 is a small molecule that selectively inhibits BCL-2, which is currently in clinical trials in lymphoid malignancies. venetoclax 0-7 BCL2 apoptosis regulator Homo sapiens 54-59 24172207-5 2013 Combining ABT-199 with tamoxifen, the standard endocrine therapy for estrogen receptor-positive breast cancers, 85% of which have BCL-2 expression, represents a new strategy to prime cancer cells for apoptosis and elicit better cancer cell death responses. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 10-13 BCL2 apoptosis regulator Homo sapiens 130-135 24172207-5 2013 Combining ABT-199 with tamoxifen, the standard endocrine therapy for estrogen receptor-positive breast cancers, 85% of which have BCL-2 expression, represents a new strategy to prime cancer cells for apoptosis and elicit better cancer cell death responses. Tamoxifen 23-32 BCL2 apoptosis regulator Homo sapiens 130-135 24217648-10 2013 Proapoptotic cleaved caspases-3 was upregulated and antiapoptotic Bcl-2 protein was reduced in doxorubicin-treated BMSCs. Doxorubicin 95-106 BCL2 apoptosis regulator Homo sapiens 66-71 23319320-4 2013 Western blotting showed a loss of NF-kappaB, Bcl-2 and p-Akt, and the accumulation of Bad and Akt in cytoplasm of ATRA-treated AML-I preadipocytes. Tretinoin 114-118 BCL2 apoptosis regulator Homo sapiens 45-50 24107594-10 2013 The expression of cyt c and Bax was decreased, while that of Bcl-2 was increased significantly in lacidipine treated group. lacidipine 98-108 BCL2 apoptosis regulator Homo sapiens 61-66 23064957-1 2013 PURPOSE: The combination of oblimersen, a bcl-2 antisense oligonucleotide, and dacarbazine lead to superior progression-free survival in advanced melanoma patients. Oligonucleotides 58-73 BCL2 apoptosis regulator Homo sapiens 42-47 23420486-4 2013 The combination mifepristone/LY294002, but not the individual drugs, killed ovarian cancer cells via apoptosis, as attested by genomic DNA fragmentation and cleavage of caspase-3, and the concomitant down-regulation of anti-apoptotic proteins Bcl-2 and XIAP. Mifepristone 16-28 BCL2 apoptosis regulator Homo sapiens 243-248 23420486-4 2013 The combination mifepristone/LY294002, but not the individual drugs, killed ovarian cancer cells via apoptosis, as attested by genomic DNA fragmentation and cleavage of caspase-3, and the concomitant down-regulation of anti-apoptotic proteins Bcl-2 and XIAP. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 29-37 BCL2 apoptosis regulator Homo sapiens 243-248 24335172-0 2013 The function role of miR-181a in chemosensitivity to adriamycin by targeting Bcl-2 in low-invasive breast cancer cells. Doxorubicin 53-63 BCL2 apoptosis regulator Homo sapiens 77-82 24335172-13 2013 CONCLUSIONS: At least in part, the detection of miR-181a may direct the clinical medication in patients with neoadjuvant chemotherapy because of miR-181a enhanced adriamycin-induced apoptosis via targeting Bcl-2. Doxorubicin 163-173 BCL2 apoptosis regulator Homo sapiens 206-211 23924452-0 2013 Antitumor effects of mutant endostatin are enhanced by Bcl-2 antisense oligonucleotides in UM-UC-3 bladder cancer cell line. Oligonucleotides 71-87 BCL2 apoptosis regulator Homo sapiens 55-60 24088696-5 2013 Investigations for the possible mechanism underlying the induction of apoptosis showed that CH2Cl2 fraction or compound 7 induced apoptosis through down-regulation of Bcl-2, up-regulation of Bax, cleavage of caspase-9, cleavage of caspase-3 and cleavage of poly(ADP-ribose) polymerase (PARP) in HL-60 cells. Methylene Chloride 92-98 BCL2 apoptosis regulator Homo sapiens 167-172 23924452-4 2013 METHODS: The artificially synthesized Bcl-2 ASODN (antisense oligonucleotides) included a translation-initiation site and was transfected into the bladder cancer cells by Lipofectamine. asodn 44-49 BCL2 apoptosis regulator Homo sapiens 38-43 24033949-11 2013 Meanwhile, CoCl2-induced Bcl-2 overexpression was down-regulated in the presence of cisplatin when NF-kappaB activity was inhibited. cobaltous chloride 11-16 BCL2 apoptosis regulator Homo sapiens 25-30 24112174-8 2013 CONCLUSIONS: Andrographolide inhibits BGC-823 cell growth and induces BGC-823 cell apoptosis by up-regulating Bax and caspase-3 expressions and down-regulating Bcl-2 expression. andrographolide 13-28 BCL2 apoptosis regulator Homo sapiens 160-165 24033949-11 2013 Meanwhile, CoCl2-induced Bcl-2 overexpression was down-regulated in the presence of cisplatin when NF-kappaB activity was inhibited. Cisplatin 84-93 BCL2 apoptosis regulator Homo sapiens 25-30 23924452-4 2013 METHODS: The artificially synthesized Bcl-2 ASODN (antisense oligonucleotides) included a translation-initiation site and was transfected into the bladder cancer cells by Lipofectamine. Oligonucleotides 61-77 BCL2 apoptosis regulator Homo sapiens 38-43 24033949-12 2013 CONCLUSION: Up-regulating Bcl-2 might be involved in NF-kappaB activation induced resistance to cisplatin in A549 cells under CoCl2-induced chemical hypoxia. Cisplatin 96-105 BCL2 apoptosis regulator Homo sapiens 26-31 23924452-4 2013 METHODS: The artificially synthesized Bcl-2 ASODN (antisense oligonucleotides) included a translation-initiation site and was transfected into the bladder cancer cells by Lipofectamine. Lipofectamine 171-184 BCL2 apoptosis regulator Homo sapiens 38-43 24033949-12 2013 CONCLUSION: Up-regulating Bcl-2 might be involved in NF-kappaB activation induced resistance to cisplatin in A549 cells under CoCl2-induced chemical hypoxia. cobaltous chloride 126-131 BCL2 apoptosis regulator Homo sapiens 26-31 23924452-12 2013 CONCLUSIONS: Our findings indicated that Bcl-2 antisense oligonucleotides enhance the antitumor effects of mutant endostatin both in vitro and in vivo. Oligonucleotides 57-73 BCL2 apoptosis regulator Homo sapiens 41-46 24020139-6 2013 Immunohistochemical investigation of Bcl-2 and KJ67 expression was undertaken on paraffin blocks and showed elevated expression in the cases with endometrial polyps and hyperplasia, in contrast to atrophic endometria. Paraffin 81-89 BCL2 apoptosis regulator Homo sapiens 37-42 23746270-5 2013 The attention is focused on Bcl-2 family protein modulators ranging from natural products to synthetic ones with particular interest in foldamers as BH3 alpha helix mimetics. BH 3 149-152 BCL2 apoptosis regulator Homo sapiens 28-33 24592121-0 2013 Expression of URG4/URGCP, Cyclin D1, Bcl-2, and Bax genes in retinoic acid treated SH-SY5Y human neuroblastoma cells. Tretinoin 61-74 BCL2 apoptosis regulator Homo sapiens 37-42 24592121-6 2013 In this study, the effects of RA treatment on URG4/URGCP, CCND1, Bcl-2 and Bax gene expression changes in undifferentiated and differentiated SHSY5Y neuroblastoma cells was analyzed. Tretinoin 30-32 BCL2 apoptosis regulator Homo sapiens 65-70 22573288-7 2013 Bax up-regulation and Bcl-2 down-regulation on mRNA level and NF-kappaB down-regulation on protein level was found in this study, suggesting that Bcl-2, Bax and NF-kappaB may be involved in the mechanism of the apoptotic effect of citral on NB4 cells. citral 231-237 BCL2 apoptosis regulator Homo sapiens 22-27 22573288-7 2013 Bax up-regulation and Bcl-2 down-regulation on mRNA level and NF-kappaB down-regulation on protein level was found in this study, suggesting that Bcl-2, Bax and NF-kappaB may be involved in the mechanism of the apoptotic effect of citral on NB4 cells. citral 231-237 BCL2 apoptosis regulator Homo sapiens 146-151 23956783-11 2013 The rapid NF kappa B activation by S-[6]-gingerol was associated with an increase in mRNA levels of NF kappa B-target genes: cIAP-2, XIAP, and Bcl-2 that encode antiapoptotic proteins. gingerol 35-49 BCL2 apoptosis regulator Homo sapiens 143-148 24008440-9 2013 Western blot showed that nicorandil could upregulate Bcl-2 levels and downregulate Bax and caspase-3 expression. Nicorandil 25-35 BCL2 apoptosis regulator Homo sapiens 53-58 23843871-4 2013 EA also induced caspase-3-mediated apoptosis by increasing the Bax : Bcl-2 ratio and restored anoikis in both cell lines. Ellagic Acid 0-2 BCL2 apoptosis regulator Homo sapiens 69-74 23220642-1 2013 Based on a known nanomolar Bcl-2 homology domain 3 (BH3) mimetic 3-thiomorpholin-8-oxo-8H-acenaphtho[1,2-b] pyrrole-9-carbonitrile (S1, MW: 331), we applied a fragment-based approach to obtain BH3 mimetics with improved affinity and improved solubility in a water-ethanol (9:1) cosolvent. BH 3 52-55 BCL2 apoptosis regulator Homo sapiens 27-32 23220642-1 2013 Based on a known nanomolar Bcl-2 homology domain 3 (BH3) mimetic 3-thiomorpholin-8-oxo-8H-acenaphtho[1,2-b] pyrrole-9-carbonitrile (S1, MW: 331), we applied a fragment-based approach to obtain BH3 mimetics with improved affinity and improved solubility in a water-ethanol (9:1) cosolvent. 3-thiomorpholin-8-oxo-8h-acenaphtho[1,2-b] pyrrole-9-carbonitrile 65-130 BCL2 apoptosis regulator Homo sapiens 27-32 23220642-1 2013 Based on a known nanomolar Bcl-2 homology domain 3 (BH3) mimetic 3-thiomorpholin-8-oxo-8H-acenaphtho[1,2-b] pyrrole-9-carbonitrile (S1, MW: 331), we applied a fragment-based approach to obtain BH3 mimetics with improved affinity and improved solubility in a water-ethanol (9:1) cosolvent. BH 3 193-196 BCL2 apoptosis regulator Homo sapiens 27-32 23220642-1 2013 Based on a known nanomolar Bcl-2 homology domain 3 (BH3) mimetic 3-thiomorpholin-8-oxo-8H-acenaphtho[1,2-b] pyrrole-9-carbonitrile (S1, MW: 331), we applied a fragment-based approach to obtain BH3 mimetics with improved affinity and improved solubility in a water-ethanol (9:1) cosolvent. Water 258-263 BCL2 apoptosis regulator Homo sapiens 27-32 23220642-1 2013 Based on a known nanomolar Bcl-2 homology domain 3 (BH3) mimetic 3-thiomorpholin-8-oxo-8H-acenaphtho[1,2-b] pyrrole-9-carbonitrile (S1, MW: 331), we applied a fragment-based approach to obtain BH3 mimetics with improved affinity and improved solubility in a water-ethanol (9:1) cosolvent. Ethanol 264-271 BCL2 apoptosis regulator Homo sapiens 27-32 23573140-4 2013 Additionally, subamolide B evoked cell death pathways mediated by FasL/Fas, mitochondria, and endoplasmic reticulum (ER) stress, as supported by subamolide B-induced FasL upregulation, BCL-2 suppression/cytosolic release of cytochrome c, and UPR activation/CHOP upregulation, respectively. subamolide B 14-26 BCL2 apoptosis regulator Homo sapiens 185-190 24223611-0 2013 Zeaxanthin Induces Apoptosis in Human Uveal Melanoma Cells through Bcl-2 Family Proteins and Intrinsic Apoptosis Pathway. Zeaxanthins 0-10 BCL2 apoptosis regulator Homo sapiens 67-72 24223611-5 2013 Western blot analysis demonstrated that zeaxanthin decreased the expression of antiapoptotic proteins (Bcl-2 and Bcl-xL) and increased the expression of proapoptotic proteins (Bak and Bax) in zeaxanthin-treated melanoma cells. Zeaxanthins 40-50 BCL2 apoptosis regulator Homo sapiens 103-108 23533492-4 2013 Gastrodin significantly and dose dependently protected dopaminergic neurons against neurotoxicity through regulating free radicals, Bax/Bcl-2 mRNA, caspase-3, and cleaved poly(ADP-ribose) polymerase (PARP) in SH-SY5Y cells stressed with MPP(+). gastrodin 0-9 BCL2 apoptosis regulator Homo sapiens 136-141 24204395-0 2013 Destruxin B Isolated from Entomopathogenic Fungus Metarhizium anisopliae Induces Apoptosis via a Bcl-2 Family-Dependent Mitochondrial Pathway in Human Nonsmall Cell Lung Cancer Cells. destruxin B 0-11 BCL2 apoptosis regulator Homo sapiens 97-102 24204395-10 2013 Taken together, our findings suggest that destruxin-B-induced apoptosis in human nonsmall cell lung cancer cells is via a Bcl-2 family-dependent mitochondrial pathway. destruxin B 42-53 BCL2 apoptosis regulator Homo sapiens 122-127 23533482-5 2013 5,7-Dihydroxyflavone up-regulated the expression of pro-apoptotic protein Bax, attenuated the expression of anti-apoptotic proteins Bcl-2, Mcl-1, and IAPs, and reduced the phosphorylation levels of Akt and STAT3, weakening the anti-apoptotic signals thus facilitating the process of apoptosis. chrysin 0-20 BCL2 apoptosis regulator Homo sapiens 132-137 23662112-5 2013 Apoptosis of honokiol-treated SP cells was evidenced by increased annexin V staining and cleaved caspase-3 as well as decreased Survivin and Bcl-2. honokiol 13-21 BCL2 apoptosis regulator Homo sapiens 141-146 23662112-5 2013 Apoptosis of honokiol-treated SP cells was evidenced by increased annexin V staining and cleaved caspase-3 as well as decreased Survivin and Bcl-2. sp 30-32 BCL2 apoptosis regulator Homo sapiens 141-146 23173842-6 2013 Structural similarity of the Bcl-2 family of proteins greatly favors development of inhibitors that target the BH3 domain, called BH3 mimetics. BH 3 111-114 BCL2 apoptosis regulator Homo sapiens 29-34 23579452-4 2013 Bcl-2 family proteins control these channels in a manner expected from their physiological function: anti-apoptotic proteins destabilize the channels whereas pro-apoptotic proteins act synergistically with ceramide to increase membrane permeability. Ceramides 206-214 BCL2 apoptosis regulator Homo sapiens 0-5 23063592-4 2013 It was observed that CPs caused the increased in Bax/Bcl-2 ratio and triggered the activation of Cleaved-caspase-3, p53 in HepG2 cells. cps 21-24 BCL2 apoptosis regulator Homo sapiens 53-58 23330014-6 2013 DHA down-regulates the protein expression of Bcl-2 and Bim mRNA level, and up-regulates caspase-3 activity and Bax expression level. Docosahexaenoic Acids 0-3 BCL2 apoptosis regulator Homo sapiens 45-50 23007808-8 2013 RESULTS: The secretions from PHA-stimulated IgAN TMCs significantly inhibited proliferation, promoted apoptosis, and down-regulated Bcl-2 in HK-2 cells (P < 0.05) in time- and concentration-dependent manners. trimethylsilyl chloride 49-53 BCL2 apoptosis regulator Homo sapiens 132-137 23007808-10 2013 CONCLUSIONS: The secretions from PHA-stimulated IgAN TMCs can cause the inhibition of proliferation, promotion of apoptosis, down-regulation of Bcl-2, and EMT effects in HK-2 TECs, which may reflect the in-vivo remote modulation of functions of renal TECs by tonsillar inflammation. trimethylsilyl chloride 53-57 BCL2 apoptosis regulator Homo sapiens 144-149 23138847-0 2013 Involvement of the mitochondrial pathway and Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human breast cancer in vitro. artenimol 66-84 BCL2 apoptosis regulator Homo sapiens 49-54 23843790-4 2013 In this study, we detected the function of puerarin on serum-free-induced cell apoptosis using ELISA and TUNEL arrays and then found that the mortality of hOBs was significantly decreased after exposure to 10(-10)-10(-6) M puerarin and reached the maximal antiapoptotic effect at the concentration of 10(-8) M. In addition, compared with the control group, puerarin notably increased the Bcl-2 protein levels while it decreased the Bax protein levels in the hOBs in a dose-dependent way. puerarin 43-51 BCL2 apoptosis regulator Homo sapiens 388-393 23843790-5 2013 10(-7) M puerarin decreased the Bax/Bcl-2 ratio with a maximal decrease to 0.08. puerarin 9-17 BCL2 apoptosis regulator Homo sapiens 36-41 23138847-5 2013 In addition, the apoptotic action of DHA was associated with the increased expression of the pro-apoptotic gene Bim and a decreased expression of the anti-apoptotic gene Bcl-2. artenimol 37-40 BCL2 apoptosis regulator Homo sapiens 194-199 23256441-5 2013 Bamboo salt (9x) significantly induced apoptosis in cancer cells (P<.05) by upregulating Bax, caspase-9, and caspase-3, and downregulating Bcl-2. bamboo salt 0-11 BCL2 apoptosis regulator Homo sapiens 142-147 24204136-0 2013 Bcl-2-functionalized ultrasmall superparamagnetic iron oxide nanoparticles coated with amphiphilic polymer enhance the labeling efficiency of islets for detection by magnetic resonance imaging. ferric oxide 50-60 BCL2 apoptosis regulator Homo sapiens 0-5 24204136-0 2013 Bcl-2-functionalized ultrasmall superparamagnetic iron oxide nanoparticles coated with amphiphilic polymer enhance the labeling efficiency of islets for detection by magnetic resonance imaging. Polymers 99-106 BCL2 apoptosis regulator Homo sapiens 0-5 24204136-2 2013 Here, we developed an innoxious and concise synthesis approach for a novel B-cell lymphoma (Bcl)-2 monoclonal antibody-functionalized USPIO nanoparticle coated with an amphiphilic polymer (carboxylated polyethylene glycol monooleyl ether [OE-PEG-COOH]). ferumoxtran-10 134-139 BCL2 apoptosis regulator Homo sapiens 75-98 24204136-2 2013 Here, we developed an innoxious and concise synthesis approach for a novel B-cell lymphoma (Bcl)-2 monoclonal antibody-functionalized USPIO nanoparticle coated with an amphiphilic polymer (carboxylated polyethylene glycol monooleyl ether [OE-PEG-COOH]). polyethylene glycol monooleyl ether 202-237 BCL2 apoptosis regulator Homo sapiens 75-98 24204136-2 2013 Here, we developed an innoxious and concise synthesis approach for a novel B-cell lymphoma (Bcl)-2 monoclonal antibody-functionalized USPIO nanoparticle coated with an amphiphilic polymer (carboxylated polyethylene glycol monooleyl ether [OE-PEG-COOH]). oe-peg 239-245 BCL2 apoptosis regulator Homo sapiens 75-98 24204136-2 2013 Here, we developed an innoxious and concise synthesis approach for a novel B-cell lymphoma (Bcl)-2 monoclonal antibody-functionalized USPIO nanoparticle coated with an amphiphilic polymer (carboxylated polyethylene glycol monooleyl ether [OE-PEG-COOH]). Carbonic Acid 246-250 BCL2 apoptosis regulator Homo sapiens 75-98 24204136-7 2013 The combined results point to the promising potential of the novel Bcl-2-functionalized PEG-USPIO as a molecular imaging agent for in vivo monitoring of islet cells or other cells. Polyethylene Glycols 88-91 BCL2 apoptosis regulator Homo sapiens 67-72 22674530-7 2013 Interestingly, we found that Pi strongly enhances doxorubicin-induced cytotoxicity in U2OS, and not in Saos and MG63 cells, by apoptosis induction, as revealed by a marked increase of sub-G1 population, Bcl-2 downregulation, caspase-3 activation, and PARP cleavage. Doxorubicin 50-61 BCL2 apoptosis regulator Homo sapiens 203-208 23165748-0 2013 Trichostatin A induces apoptotic cell death of HeLa cells in a Bcl-2 and oxidative stress-dependent manner. trichostatin A 0-14 BCL2 apoptosis regulator Homo sapiens 63-68 23165748-4 2013 In addition, the administration of Bcl-2 siRNA intensified TSA-induced HeLa cell death. trichostatin A 71-74 BCL2 apoptosis regulator Homo sapiens 35-40 23165748-9 2013 In conclusion, TSA inhibited the growth of HeLa cells via Bcl-2-mediated apoptosis, which was closely related to O2 - and GSH content levels. trichostatin A 27-30 BCL2 apoptosis regulator Homo sapiens 70-75 23165748-9 2013 In conclusion, TSA inhibited the growth of HeLa cells via Bcl-2-mediated apoptosis, which was closely related to O2 - and GSH content levels. Oxygen 137-139 BCL2 apoptosis regulator Homo sapiens 70-75 23165748-9 2013 In conclusion, TSA inhibited the growth of HeLa cells via Bcl-2-mediated apoptosis, which was closely related to O2 - and GSH content levels. Glutathione 146-149 BCL2 apoptosis regulator Homo sapiens 70-75 22953760-8 2013 Differential expressions of proteins such as p53, Bax, caspase-3, and caspase-9 were significantly up-regulated in PFOS-exposed hosts, whereas Bcl-2 expression was significantly down-regulated. perfluorooctane sulfonic acid 115-119 BCL2 apoptosis regulator Homo sapiens 143-148 23782641-10 2013 NAC also attenuated the ratio of sub-G1, the generation of DNA fragmentation and the expression of Bcl-2, Bax, caspase-3, and caspase-9. Acetylcysteine 0-3 BCL2 apoptosis regulator Homo sapiens 99-104 22892822-3 2013 In addition, rasagiline and (-)deprenyl increase the expression of anti-apoptotic Bcl-2 protein family and neurotrophic factors. rasagiline 13-23 BCL2 apoptosis regulator Homo sapiens 82-87 22892822-3 2013 In addition, rasagiline and (-)deprenyl increase the expression of anti-apoptotic Bcl-2 protein family and neurotrophic factors. Selegiline 31-39 BCL2 apoptosis regulator Homo sapiens 82-87 23665936-0 2013 Epigallocatechin gallate protects against nitric oxide-induced apoptosis via scavenging ROS and modulating the Bcl-2 family in human dental pulp cells. epigallocatechin gallate 0-24 BCL2 apoptosis regulator Homo sapiens 111-116 23665936-0 2013 Epigallocatechin gallate protects against nitric oxide-induced apoptosis via scavenging ROS and modulating the Bcl-2 family in human dental pulp cells. Nitric Oxide 42-54 BCL2 apoptosis regulator Homo sapiens 111-116 23665936-11 2013 These results suggest that EGCG has a protective effect against NO-induced apoptosis in HDPC by scavenging ROS and modulating the Bcl-2 family. epigallocatechin gallate 27-31 BCL2 apoptosis regulator Homo sapiens 130-135 23677569-0 2013 Oligonucleotide suppression of bcl-2 in LNCaP cells is compensated by increased androgen sensitivity, p53 and oncogene activity, and suppressed caspase-3. Oligonucleotides 0-15 BCL2 apoptosis regulator Homo sapiens 31-36 23962295-3 2013 The results suggested that GF4 can effectively inhibit the proliferation of the cells, and Bax expression increased gradually, but Bcl-2 expression reduced with the increase of GF4 concentration. ginsenoside F4 27-30 BCL2 apoptosis regulator Homo sapiens 131-136 23064738-5 2013 Baicalein inhibited Akt phosphorylation, downregulated Bcl-2 expression and upregulated Bax expression, which in turn increased the ratio of Bax/Bcl-2. baicalein 0-9 BCL2 apoptosis regulator Homo sapiens 55-60 23064738-5 2013 Baicalein inhibited Akt phosphorylation, downregulated Bcl-2 expression and upregulated Bax expression, which in turn increased the ratio of Bax/Bcl-2. baicalein 0-9 BCL2 apoptosis regulator Homo sapiens 145-150 23067223-5 2013 Correspondingly, anisomycin induced cleaved caspase-3 and up-regulation of pro-apoptotic proteins (BimEL and Bad), meanwhile down-regulation of anti-apoptotic proteins (Mcl-1 and Bcl-2), both in a dose- and time-dependent manner in GC resistant CEM-C1 cells. Anisomycin 17-27 BCL2 apoptosis regulator Homo sapiens 179-184 23412788-7 2013 One representative example is the high-level amplification of the BCL2 gene, which predicts a good response to pro-apoptotic BH3 mimetic drugs. BH 3 125-128 BCL2 apoptosis regulator Homo sapiens 66-70 23335846-8 2013 Axitinib, which inhibits lenticular cell autophosphorylation of its VEGF receptor, was employed to demonstrate a role for the VEGF-VEGFR2 receptor complex in regulating Bcl-2 expression. Axitinib 0-8 BCL2 apoptosis regulator Homo sapiens 169-174 23335846-16 2013 Axitinib also prevented the VEGF-mediated expression of Bcl-2. Axitinib 0-8 BCL2 apoptosis regulator Homo sapiens 56-61 23361001-5 2013 The escape of FKBP38 and Bcl-2 from the mitochondria is determined by the number of basic amino acids in their COOH-terminal signal sequences. Amino Acids, Basic 84-101 BCL2 apoptosis regulator Homo sapiens 25-30 23962295-3 2013 The results suggested that GF4 can effectively inhibit the proliferation of the cells, and Bax expression increased gradually, but Bcl-2 expression reduced with the increase of GF4 concentration. ginsenoside F4 177-180 BCL2 apoptosis regulator Homo sapiens 131-136 23441615-0 2013 Flavanols from Japanese quince (Chaenomeles japonica) fruit inhibit human prostate and breast cancer cell line invasiveness and cause favorable changes in Bax/Bcl-2 mRNA ratio. flavanols 0-9 BCL2 apoptosis regulator Homo sapiens 159-164 23022271-4 2013 CYT significantly inhibited the neuronal apoptosis induced by NMDA exposure by reversing intracellular Ca(2+) overload and balancing Bcl-2 and Bax expression levels. N-Methylaspartate 62-66 BCL2 apoptosis regulator Homo sapiens 133-138 22948038-12 2013 Further, E2 decreased Hcy-induced apoptotic death by upregulating the antiapoptotic protein Bcl-2, decreasing cytochrome c release from mitochondria, and attenuating apoptotic cascade activation (Bax, caspase-9, and caspase-3). Homocysteine 22-25 BCL2 apoptosis regulator Homo sapiens 92-97 23441611-0 2013 Deuterium depleted water effects on survival of lung cancer patients and expression of Kras, Bcl2, and Myc genes in mouse lung. Deuterium 0-9 BCL2 apoptosis regulator Homo sapiens 93-97 23441616-3 2013 Nobiletin induced the death of SNU-16 cells through apoptosis, as evidenced by the increased cell population in the sub-G1 phase, the appearance of fragmented nuclei, an increase in the Bax/Bcl-2 ratio, the proteolytic activation of caspase-9, an increase in caspase-3 activity, and the degradation of poly(ADP-ribose) polymerase (PARP) protein. nobiletin 0-9 BCL2 apoptosis regulator Homo sapiens 190-195 24053141-6 2013 Using real time PCR assay, lycopene also induced apoptosis in prostate cancer cells with altered gene expression of Bax and Bcl-2. Lycopene 27-35 BCL2 apoptosis regulator Homo sapiens 124-129 23909734-3 2013 Triticuside A-induced apoptosis was accompanied by a significant decrease of Mcl-1 and Bcl-2 proteins and by an increase of cleavage of caspases-3, -7, -9, and PARP. triticuside A 0-13 BCL2 apoptosis regulator Homo sapiens 87-92 23859040-5 2013 The presence of pifithrin, an inhibitor of p53 function, blocked ECG-induced apoptosis as was manifested by restored cell viability and caspase-3 activity to control values and reestablished the balance among Bcl-2 anti- and proapoptotic protein levels. pifithrin 16-25 BCL2 apoptosis regulator Homo sapiens 209-214 23859040-5 2013 The presence of pifithrin, an inhibitor of p53 function, blocked ECG-induced apoptosis as was manifested by restored cell viability and caspase-3 activity to control values and reestablished the balance among Bcl-2 anti- and proapoptotic protein levels. epicatechin gallate 65-68 BCL2 apoptosis regulator Homo sapiens 209-214 23924855-5 2013 Simvastatin inhibited the survival of A549 cells in a dose-dependent manner, decreased Bcl-2 protein expression, and increased Bax protein expression time and dose dependently. Simvastatin 0-11 BCL2 apoptosis regulator Homo sapiens 87-92 23076380-7 2013 The results showed that the expression levels of Bcl-2 mRNA and protein decreased, compared with either the pGenecil-1-NC or the untransfected cell group (P<0.05). pgenecil-1-nc 132-145 BCL2 apoptosis regulator Homo sapiens 61-66 23076380-10 2013 Bcl-2 protein expression in the untransfected and the pGenesil-1-NC group were markedly higher than that of the pGenesil-1-Bcl-2-1 and the pGenesil-1-Bcl-2 group by immunohistochemistry (both P<0.01) and the results using transmission electron microscopy showed that Bcl-2 shRNA significantly induced Raji cell apoptosis. pgenesil 66-74 BCL2 apoptosis regulator Homo sapiens 0-5 23076380-11 2013 Additionally, the inhibition effect of pGenesil-1-Bcl-2-1 was better than that of pGenesil-1-Bcl-2-2. pgenesil-1 39-49 BCL2 apoptosis regulator Homo sapiens 50-55 23117412-5 2013 Moreover, an increase in Bax protein and cytosol cytochrome c from mitochondria and a decrease in bcl-2 protein were observed following treatment with d-limonene. Limonene 163-173 BCL2 apoptosis regulator Homo sapiens 110-115 23255914-0 2013 Rapamycin induces autophagy in the melanoma cell line M14 via regulation of the expression levels of Bcl-2 and Bax. Sirolimus 0-9 BCL2 apoptosis regulator Homo sapiens 101-106 23255914-5 2013 We revealed that rapamycin induced autophagy and inhibited the proliferation of M14 cells in a concentration-dependent manner, Furthermore, western blot analysis revealed an upregulated expression of Bcl-2 and downregulated expression of Bax in M14 cells. Sirolimus 17-26 BCL2 apoptosis regulator Homo sapiens 200-205 24205431-6 2013 The apoptosis in rotenone-induced SK-N-SH cells was accompanied by the loss of mitochondrial membrane potential, increased ROS generation, the depletion of GSH, enhanced activities of enzymatic antioxidants, upregulation of Bax, cyt c, and caspases 3 and 9, and downregulation of Bcl-2, which were attenuated in the presence of hesperidin. Rotenone 17-25 BCL2 apoptosis regulator Homo sapiens 280-285 24762223-5 2013 Concomitant treatment with DHMEQ and the inhibitor of antiapoptotic Bcl-2 family proteins, GX15-070, triggered synergistic reduction of the viability and induced apoptosis of G361 cells. dehydroxymethylepoxyquinomicin 27-32 BCL2 apoptosis regulator Homo sapiens 68-73 23533654-9 2013 In combination with NVP-BEZ235 and CDDP, there was dramatic synergy in shrinking tumor volumes and inducing apoptosis through increasing Noxa, Bax and decreasing Mcl-1, Bcl-2. dactolisib 24-30 BCL2 apoptosis regulator Homo sapiens 169-174 24399733-7 2013 Consistently, western blotting revealed that ursolic acid effectively cleaved poly (ADP-ribose) polymerase (PARP), activated caspase-9 and -3, suppressed the expression of survival proteins such as Bcl-XL, Bcl-2 and Mcl-1, and upregulated the expression of Bax in PC-3 cells. ursolic acid 45-57 BCL2 apoptosis regulator Homo sapiens 206-211 23527236-0 2013 Apoptosis through Bcl-2/Bax and cleaved caspase up-regulation in melanoma treated by boron neutron capture therapy. Boron 85-90 BCL2 apoptosis regulator Homo sapiens 18-23 23395573-11 2013 Compared with control groups, Bax and E-cadherin were significantly upregulated, and Bcl-2 and PCNA were significantly downregulated in Sal-treated cells. salinomycin 136-139 BCL2 apoptosis regulator Homo sapiens 85-90 23590603-6 2013 The study results showed that doxorubicin increased the number of TUNEL positive cells, as well as the protein levels of cleaved caspase-3 and cytochrome c, and reduced the ratio of Bcl-2/Bax. Doxorubicin 30-41 BCL2 apoptosis regulator Homo sapiens 182-187 23533616-8 2013 Knockdown of CHOP attenuated MMC-induced apoptosis by increasing the ratio of BCL-2/BAX and decreasing BIM expression, suggesting that ER stress is involved in MMC-induced fibroblast apoptosis. Mitomycin 29-32 BCL2 apoptosis regulator Homo sapiens 78-83 23533654-9 2013 In combination with NVP-BEZ235 and CDDP, there was dramatic synergy in shrinking tumor volumes and inducing apoptosis through increasing Noxa, Bax and decreasing Mcl-1, Bcl-2. Cisplatin 35-39 BCL2 apoptosis regulator Homo sapiens 169-174 23457590-2 2013 Apogossypol, a putative broad spectrum BCL-2 family antagonist, was the prototype compound used to induce this ER membrane reorganization. apogossypol 0-11 BCL2 apoptosis regulator Homo sapiens 39-44 23536831-10 2013 Casticin downregulated the expression levels of the cell survival proteins cFLIP, Bcl-2, XIAP, and survivin. casticin 0-8 BCL2 apoptosis regulator Homo sapiens 82-87 23483946-6 2013 Immunofluorescence and Western blotting showed that H2O2 treatment increased the levels of p-JAK2, p-STAT3, Cytochrome c, Bax and Caspase3 and decreased the levels of Bcl2, whereas melatonin treatment partially reversed these effects. Hydrogen Peroxide 52-56 BCL2 apoptosis regulator Homo sapiens 167-171 23457590-9 2013 Although perturbation of Ca(2+) homeostasis was clearly one mechanism by which some agents induced ER membrane reorganization, influx of extracellular Na(+) but not Ca(2+) was required for ER membrane reorganization induced by apogossypol and the related BCL-2 family antagonist, TW37, in both human and yeast cells. apogossypol 227-238 BCL2 apoptosis regulator Homo sapiens 255-260 23437261-1 2013 BACKGROUND: Owing to their important function in regulating cell death, pharmacological inhibition of Bcl-2 proteins by dubbed BH3-mimetics is a promising strategy for apoptosis induction or sensitization to chemotherapy. BH 3 127-130 BCL2 apoptosis regulator Homo sapiens 102-107 23460874-0 2013 Molecular interactions of prodiginines with the BH3 domain of anti-apoptotic Bcl-2 family members. prodiginine 26-38 BCL2 apoptosis regulator Homo sapiens 77-82 23437193-11 2013 Increased of reactive oxygen species (ROS) production, coupled with downregulation of anti-apoptotic molecules (Bcl-2, Bcl-xL) led to reduction of mitochondrial membrane potential (MMP) and release of cytochrome c in both human breast cancer cells treated with vernodalin. vernodalin 261-271 BCL2 apoptosis regulator Homo sapiens 112-117 23390536-8 2013 And C646-induced growth inhibition on AE-positive AML cells was associated with reduced global histone H3 acetylation and declined c-kit and bcl-2 levels. C646 4-8 BCL2 apoptosis regulator Homo sapiens 141-146 23437345-6 2013 The growth inhibition of DPCs by 6-gingerol in vitro may reflect a decrease in the Bcl-2/Bax ratio. dpcs 25-29 BCL2 apoptosis regulator Homo sapiens 83-88 23437345-6 2013 The growth inhibition of DPCs by 6-gingerol in vitro may reflect a decrease in the Bcl-2/Bax ratio. gingerol 33-43 BCL2 apoptosis regulator Homo sapiens 83-88 23405080-5 2013 Cd also increased intracellular reactive oxygen species (ROS) generation and malondialdehyde (MDA) production and induced mitochondrial dysfunction (the loss of mitochondrial membrane potential (MMP) and the increase of cytosolic cytochrome c release), the decreased Bcl-2 expression, increased p53 expression, poly (ADP-ribose) polymerase (PARP) cleavage, and caspase cascades, which accompanied with intracellular Cd accumulation. Cadmium 0-2 BCL2 apoptosis regulator Homo sapiens 267-272 23342080-9 2013 Independent examination using 4 previously-reported microarray datasets of Tamoxifen-treated patient samples (n = 503) confirmed the potential of BCL2-CDKN1A. Tamoxifen 75-84 BCL2 apoptosis regulator Homo sapiens 146-150 23342165-10 2013 Taken together, our data suggest that combining inhibitors of anti-apoptotic BCL2-like proteins with drugs that alter the balance of bioactive sphingolipids will be a powerful combination for the treatment of human cancers. Sphingolipids 143-156 BCL2 apoptosis regulator Homo sapiens 77-81 23342165-0 2013 Inhibition of ceramide metabolism sensitizes human leukemia cells to inhibition of BCL2-like proteins. Ceramides 14-22 BCL2 apoptosis regulator Homo sapiens 83-87 23342165-5 2013 We conducted a screen to identify drugs that could be combined with an inhibitor of anti-apoptotic BCL2-like proteins, ABT-263, to kill human leukemia cells lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 119-122 BCL2 apoptosis regulator Homo sapiens 99-103 23320119-9 2013 Furthermore, although the proapoptotic protein Bax levels were not affected, the antiapoptotic protein Bcl-2 level was downregulated with zebularine treatment. pyrimidin-2-one beta-ribofuranoside 138-148 BCL2 apoptosis regulator Homo sapiens 103-108 23441183-0 2013 Pramanicin analog induces apoptosis in human colon cancer cells: critical roles for Bcl-2, Bim, and p38 MAPK signaling. pramanicin 0-10 BCL2 apoptosis regulator Homo sapiens 84-89 23326121-7 2012 After treatment with oridonin for 24 h, the effects of oridonin on expression of Apaf-1, Bcl-2, Bax, caspase-3 and cytochrome c were also analyzed using reverse-transcript polymerase chain reaction (RT-PCR) and Western blotting. oridonin 55-63 BCL2 apoptosis regulator Homo sapiens 89-94 24001324-9 2013 Activated caspase 3 and Bax/Bcl-2 ratio were significantly increased in Cisplatin-treated cells. Cisplatin 72-81 BCL2 apoptosis regulator Homo sapiens 28-33 24001324-10 2013 Oxygen pretreatment inhibited caspase 3 activation and decreased Bax/Bcl-2 ratio. Oxygen 0-6 BCL2 apoptosis regulator Homo sapiens 69-74 23200181-6 2013 Furthermore, the expression of p53, Fas, Bax and activated caspase-3 protein was significantly upregulated in cells treated with HMME-SDT and DOX, whereas Bcl-2 protein was downregulated. hmme-sdt 129-137 BCL2 apoptosis regulator Homo sapiens 155-160 23200181-6 2013 Furthermore, the expression of p53, Fas, Bax and activated caspase-3 protein was significantly upregulated in cells treated with HMME-SDT and DOX, whereas Bcl-2 protein was downregulated. Doxorubicin 142-145 BCL2 apoptosis regulator Homo sapiens 155-160 23249971-4 2012 Also, the sinulariolide-induced apoptosis is related to the mitochondrial-mediated apoptosis via caspase-dependent pathways, elucidated by the loss of mitochondrial membrane potential, release of cytochrome C, activation of caspase-3/-9, Bax and Bad, as well as suppression of Bcl-2/Bcl-xL/Mcl-1. sinulariolide 10-23 BCL2 apoptosis regulator Homo sapiens 277-282 23041154-8 2012 These events attenuated caspase-3 activity and bax/Bcl-2 ratio leading to higher viability of the H(2)O(2)-treated SK-N-MC cells. Hydrogen Peroxide 98-106 BCL2 apoptosis regulator Homo sapiens 51-56 23041154-8 2012 These events attenuated caspase-3 activity and bax/Bcl-2 ratio leading to higher viability of the H(2)O(2)-treated SK-N-MC cells. sk-n 115-119 BCL2 apoptosis regulator Homo sapiens 51-56 23041154-8 2012 These events attenuated caspase-3 activity and bax/Bcl-2 ratio leading to higher viability of the H(2)O(2)-treated SK-N-MC cells. Methylcholanthrene 120-122 BCL2 apoptosis regulator Homo sapiens 51-56 22576883-9 2013 In the three cell lines both forms of iodine activated the intrinsic apoptotic pathway (increasing the BAX/BCL-2 index and caspases). Iodine 38-44 BCL2 apoptosis regulator Homo sapiens 107-112 22674285-10 2013 Ardisianone dramatically induced mitochondrial damage, identified by downregulation of Bcl-2 family proteins, ROS production, and loss of DeltaPsi(m) . Ardisianone 0-11 BCL2 apoptosis regulator Homo sapiens 87-92 22674285-14 2013 CONCLUSIONS: The data suggest that the ardisianone induces apoptosis in human prostate cancers through mitochondrial damage stress, leading to the inhibition of mTOR/p70S6K pathway, downregulation of Bcl-2 family members, degradation of survivin, and activation of caspase cascades. Ardisianone 39-50 BCL2 apoptosis regulator Homo sapiens 200-205 23147571-5 2013 We discovered that G-TPP kills the U937 cells through the apoptotic pathway and the overexpression of Bcl-2 significantly inhibits U937 cell death to G-TPP. UNII-M6LC47TUG3 150-155 BCL2 apoptosis regulator Homo sapiens 102-107 23147571-7 2013 Importantly, G-TPP overcomes the apoptosis resistance conferred by Bcl-2 in Hep3B cells via necroptosis. UNII-M6LC47TUG3 13-18 BCL2 apoptosis regulator Homo sapiens 67-72 23147571-9 2013 We further found that whereas there is a Bcl-2-Beclin 1 interaction in response to G-TPP, silencing the beclin 1 gene failed to block LC3-II accumulation in the Hep3B cells, indicating that G-TPP triggers Beclin 1-independent protective autophagy in Hep3B cells. UNII-M6LC47TUG3 83-88 BCL2 apoptosis regulator Homo sapiens 41-46 23147571-10 2013 Taken together, these data reveal that G-TPP induces cell death through a combination of death pathways, including necroptosis and apoptosis, and overcomes the apoptosis resistance conferred by Bcl-2 in Hep3B cells via necroptosis. UNII-M6LC47TUG3 39-44 BCL2 apoptosis regulator Homo sapiens 194-199 23534290-6 2013 At the same time, the combined effect of radiation and Ptx enhanced antiapoptotic Bcl-2 phosphorylation, caspases activation and survivin expression. Paclitaxel 55-58 BCL2 apoptosis regulator Homo sapiens 82-87 23259599-0 2012 ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 82-87 23259599-3 2012 In the present study, we aimed to determine if ABT-737, a BH3-only mimic, could reverse the acquired radioresistance of the breast cancer cell line MDA-MB-231R by targeting Bcl-2 and Bcl-xL. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 47-50 BCL2 apoptosis regulator Homo sapiens 173-178 23259599-12 2012 Bcl-2 and Bcl-xL were down regulated in the MDA-MB-231R cells following treatment with ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 87-90 BCL2 apoptosis regulator Homo sapiens 0-5 23259599-13 2012 CONCLUSIONS: Targeting of the anti-apoptotic proteins Bcl-2 and Bcl-xL with ABT-737 may reverse the acquired radioresistance of MDA-MB-231R cells in vitro and in vivo. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 76-79 BCL2 apoptosis regulator Homo sapiens 54-59 23123629-11 2012 In addition, inhibition of JNK by SP600125 or silencing of the JNK scaffold protein JIP2 reduced phosphorylation of Bcl-2, which may help to promote anti-apoptotic pathways. pyrazolanthrone 34-42 BCL2 apoptosis regulator Homo sapiens 116-121 22980779-4 2012 The protective effect of WESP and their bioactive compounds in 0.2mM t-BHP-induced HepG2 cells may be associated with positive regulation of GSH levels and antioxidant enzymes, decrease in ROS formation and TBARS generation, increase in the mitochondria membrane potential and Bcl-2/Bax ratio, as well as decrease in caspase-3 activation. tert-Butylhydroperoxide 69-74 BCL2 apoptosis regulator Homo sapiens 277-282 22893484-2 2012 We investigated pharmacologic interaction between the DNA methyltransferase inhibitor 5-azacytidine (5-AZA) and the BCL-2 inhibitor ABT-737. Azacitidine 86-99 BCL2 apoptosis regulator Homo sapiens 116-121 24213508-5 2012 The apoptosis induced by AZM was partly through a caspase-dependent mechanism with an up-regulation of apoptotic protein cleavage PARP and caspase-3 products, as well as a down-regulation of anti-apoptotic proteins, Mcl-1, bcl-2 and bcl-X1. Azithromycin 25-28 BCL2 apoptosis regulator Homo sapiens 223-228 23211670-5 2012 BPB induced upregulation of Bax, Bad and Bak, downregulation of Bcl-2, Bid and Bcl-XL and dysfunction of mitochondria in chondrosarcoma. 1-benzyl-2-phenylbenzimidazole 0-3 BCL2 apoptosis regulator Homo sapiens 64-69 22893484-2 2012 We investigated pharmacologic interaction between the DNA methyltransferase inhibitor 5-azacytidine (5-AZA) and the BCL-2 inhibitor ABT-737. ABT-737 132-139 BCL2 apoptosis regulator Homo sapiens 116-121 23682426-10 2012 Decrease of Bcl-2 and increase of Bax in mRNA and/or protein expressions showed that the Bcl-2 family proteins were involved in berberine-induced apoptosis. Berberine 128-137 BCL2 apoptosis regulator Homo sapiens 12-17 23225433-6 2012 CONCLUSION: The observation that the expression of several genes [such as B-cell lymphoma-2 (BCL2), myelocytomatosis oncogene (MYC), caspases] is modulated midly-to-moderately, after 4OHT addition suggests that this combined approach in the clinical setting should be further investigated through appropriate trials. 4,17 beta-dihydroxy-4-androstene-3-one 183-187 BCL2 apoptosis regulator Homo sapiens 74-91 23225433-6 2012 CONCLUSION: The observation that the expression of several genes [such as B-cell lymphoma-2 (BCL2), myelocytomatosis oncogene (MYC), caspases] is modulated midly-to-moderately, after 4OHT addition suggests that this combined approach in the clinical setting should be further investigated through appropriate trials. 4,17 beta-dihydroxy-4-androstene-3-one 183-187 BCL2 apoptosis regulator Homo sapiens 93-97 23225437-6 2012 mRNA and protein expression levels of BCL2-associated X protein (BAX) and p53 were up-regulated and those of B-cell lymphoma-2 (BCL2) were down-regulated, while p21 mRNA levels were significantly increased in cells treated with (-)-epicatechin in a concentration-dependent manner. Catechin 228-243 BCL2 apoptosis regulator Homo sapiens 109-126 23225437-6 2012 mRNA and protein expression levels of BCL2-associated X protein (BAX) and p53 were up-regulated and those of B-cell lymphoma-2 (BCL2) were down-regulated, while p21 mRNA levels were significantly increased in cells treated with (-)-epicatechin in a concentration-dependent manner. Catechin 228-243 BCL2 apoptosis regulator Homo sapiens 38-42 23194187-5 2012 Furthermore, GA induced PARP cleavage, activation of caspase-3, caspase-8, and caspase-9, as well as an increased ratio of Bax/Bcl-2. gambogic acid 13-15 BCL2 apoptosis regulator Homo sapiens 127-132 22917577-0 2012 Resistance to butyrate impairs bile acid-induced apoptosis in human colon adenocarcinoma cells via up-regulation of Bcl-2 and inactivation of Bax. Butyrates 14-22 BCL2 apoptosis regulator Homo sapiens 116-121 22917577-0 2012 Resistance to butyrate impairs bile acid-induced apoptosis in human colon adenocarcinoma cells via up-regulation of Bcl-2 and inactivation of Bax. Bile Acids and Salts 31-40 BCL2 apoptosis regulator Homo sapiens 116-121 22917577-6 2012 Moreover, butyrate-resistant cells show higher Bcl-2 levels that confer resistance to bile acid-induced apoptosis sequestering Bax and avoiding Bax-dependent pore formation in the mitochondria. Butyrates 10-18 BCL2 apoptosis regulator Homo sapiens 47-52 22917577-6 2012 Moreover, butyrate-resistant cells show higher Bcl-2 levels that confer resistance to bile acid-induced apoptosis sequestering Bax and avoiding Bax-dependent pore formation in the mitochondria. Bile Acids and Salts 86-95 BCL2 apoptosis regulator Homo sapiens 47-52 22917577-7 2012 We have confirmed that this resistance is reverted using the Bcl-2 inhibitor ABT-263, thus demonstrating that the lower sensitivity of butyrate-resistant cells to the apoptotic effects of bile acids is mainly due to increased Bcl-2 levels. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 77-80 BCL2 apoptosis regulator Homo sapiens 61-66 22917577-7 2012 We have confirmed that this resistance is reverted using the Bcl-2 inhibitor ABT-263, thus demonstrating that the lower sensitivity of butyrate-resistant cells to the apoptotic effects of bile acids is mainly due to increased Bcl-2 levels. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 77-80 BCL2 apoptosis regulator Homo sapiens 226-231 22917577-7 2012 We have confirmed that this resistance is reverted using the Bcl-2 inhibitor ABT-263, thus demonstrating that the lower sensitivity of butyrate-resistant cells to the apoptotic effects of bile acids is mainly due to increased Bcl-2 levels. Butyrates 135-143 BCL2 apoptosis regulator Homo sapiens 61-66 22917577-7 2012 We have confirmed that this resistance is reverted using the Bcl-2 inhibitor ABT-263, thus demonstrating that the lower sensitivity of butyrate-resistant cells to the apoptotic effects of bile acids is mainly due to increased Bcl-2 levels. Butyrates 135-143 BCL2 apoptosis regulator Homo sapiens 226-231 22917577-7 2012 We have confirmed that this resistance is reverted using the Bcl-2 inhibitor ABT-263, thus demonstrating that the lower sensitivity of butyrate-resistant cells to the apoptotic effects of bile acids is mainly due to increased Bcl-2 levels. Bile Acids and Salts 188-198 BCL2 apoptosis regulator Homo sapiens 61-66 22917577-7 2012 We have confirmed that this resistance is reverted using the Bcl-2 inhibitor ABT-263, thus demonstrating that the lower sensitivity of butyrate-resistant cells to the apoptotic effects of bile acids is mainly due to increased Bcl-2 levels. Bile Acids and Salts 188-198 BCL2 apoptosis regulator Homo sapiens 226-231 22576985-4 2012 Treatment of cells with lithium resulted in a dose-dependent induction of p53, retinoblastoma (Rb) and bax expression which was accompanied by concomitant inhibition of bcl-2 expression as demonstrated using immunohistochemical microscopy. Lithium 24-31 BCL2 apoptosis regulator Homo sapiens 169-174 22576985-5 2012 These results seem to suggest that lithium induced cell death in these cells by inhibiting expression of anti-apoptotic protein, bcl-2, while inducing higher expression of its pro-apoptotic counterparts which include bax. Lithium 35-42 BCL2 apoptosis regulator Homo sapiens 129-134 23682426-10 2012 Decrease of Bcl-2 and increase of Bax in mRNA and/or protein expressions showed that the Bcl-2 family proteins were involved in berberine-induced apoptosis. Berberine 128-137 BCL2 apoptosis regulator Homo sapiens 89-94 23159854-12 2012 Doxorubicin-resistant MCF-7/Dox (R) cells were examined in these experiments as a control drug-resistant line; it displayed increased sensitivity to EGFR and Bcl-2 inhibitors compared with empty vector transduced MCF-7 cells. Doxorubicin 0-11 BCL2 apoptosis regulator Homo sapiens 159-164 22979990-8 2012 In vitro cytotoxicity, apoptosis and Western-blot analyses revealed significant cellular growth inhibition and decrease of Pokemon and Bcl-2 protein expression in HepG2 cells treated with Chol-siRNA-Pokemon-loaded rHDL nanoparticles (rHDL/Chol-siRNA-Pokemon complexes), respectively. chol 188-192 BCL2 apoptosis regulator Homo sapiens 135-140 23054864-7 2012 The results showed breast cancer cells respond in a diverse manner to LiCl, i.e., at lower concentrations (1, 5, and 10 mM), LiCl induces cell survival by inhibiting apoptosis through regulation of GSK-3beta, caspase-2, Bax, and cleaved caspase-7 and by activating anti-apoptotic proteins (Akt, beta-catenin, Bcl-2, and cyclin D1). Lithium Chloride 125-129 BCL2 apoptosis regulator Homo sapiens 309-314 22705850-1 2012 The proapoptotic B-cell lymphoma (Bcl)-2 protein Bcl-x(S) encloses the Bcl-2 homology (BH) domains BH3 and BH4 and triggers apoptosis via the multidomain protein Bak, however, the mechanism remained elusive. BH 3 99-102 BCL2 apoptosis regulator Homo sapiens 17-40 22705850-1 2012 The proapoptotic B-cell lymphoma (Bcl)-2 protein Bcl-x(S) encloses the Bcl-2 homology (BH) domains BH3 and BH4 and triggers apoptosis via the multidomain protein Bak, however, the mechanism remained elusive. sapropterin 107-110 BCL2 apoptosis regulator Homo sapiens 17-40 23027625-5 2012 Treatment with tectorigenin inhibited the nuclear translocation of NFkappaB and the expression of NFkappaB-dependent genes such as FLIP, XIAP, Bcl-2, Bcl-xL and COX-2, which are known to be associated with chemoresistance. tectorigenin 15-27 BCL2 apoptosis regulator Homo sapiens 143-148 23159854-12 2012 Doxorubicin-resistant MCF-7/Dox (R) cells were examined in these experiments as a control drug-resistant line; it displayed increased sensitivity to EGFR and Bcl-2 inhibitors compared with empty vector transduced MCF-7 cells. Doxorubicin 0-3 BCL2 apoptosis regulator Homo sapiens 159-164 22828872-7 2012 We further found that formononetin activated MAPK signaling pathway in a dose-dependent manner, which resulted in the increased ratio of Bax/Bcl-2, and induced apoptosis on MCF-7 cells. formononetin 22-34 BCL2 apoptosis regulator Homo sapiens 141-146 22249429-8 2012 Furthermore, we demonstrated that apoptosis induction by SQA occurs via caspase-3, -6, -8, -9 and -13 and was associated with down-regulation of Bcl-2. sargaquinoic acid 57-60 BCL2 apoptosis regulator Homo sapiens 145-150 22438101-3 2012 Further, perifosine and curcumin synergistically increase intracellular level of reactive oxygen species and ceramide, and downregulate the expression of cyclin D1 and Bcl-2 in colorectal cancer cells. perifosine 9-19 BCL2 apoptosis regulator Homo sapiens 168-173 22438101-3 2012 Further, perifosine and curcumin synergistically increase intracellular level of reactive oxygen species and ceramide, and downregulate the expression of cyclin D1 and Bcl-2 in colorectal cancer cells. Curcumin 24-32 BCL2 apoptosis regulator Homo sapiens 168-173 24808664-8 2012 CONCLUSION: The BCL2 protein of human origin showed a higher affinity toward the compound paclitaxel. Paclitaxel 90-100 BCL2 apoptosis regulator Homo sapiens 16-20 23151791-5 2012 Further results showed that swainsonine treatment up-regulated Bax, downregulated Bcl-2 expression, triggered Bax translocation to mitochondria, destructed mitochondria integrity and activated mitochondria-mediated apoptotic pathway, followed by the release of cytochrome c, which in turn activated caspase-9 and caspase-3, promoted the cleavage of PARP, resulting in Eca-109 cell apoptosis. Swainsonine 28-39 BCL2 apoptosis regulator Homo sapiens 82-87 22562160-8 2012 We found half of the lethal dose (LD(50)) of bleomycin on NCCIT cell viability as 120 mug/ml after incubation for 72 h. Incubation with bleomycin (LD(50)) induced increases in caspase-3, caspase-8, and caspase-9 activities and Cyt-c and Bax protein levels and a decrease in Bcl-2 level. Bleomycin 45-54 BCL2 apoptosis regulator Homo sapiens 274-279 22562160-8 2012 We found half of the lethal dose (LD(50)) of bleomycin on NCCIT cell viability as 120 mug/ml after incubation for 72 h. Incubation with bleomycin (LD(50)) induced increases in caspase-3, caspase-8, and caspase-9 activities and Cyt-c and Bax protein levels and a decrease in Bcl-2 level. Bleomycin 136-145 BCL2 apoptosis regulator Homo sapiens 274-279 22562160-9 2012 Co-incubation of NCCIT cells with bleomycin and 10 mM NAC abolished bleomycin-induced increases in caspase-3 and caspase-9 activities, Bax, and Cyt-c levels and bleomycin-induced decrease in Bcl-2 level. Bleomycin 34-43 BCL2 apoptosis regulator Homo sapiens 191-196 22562160-9 2012 Co-incubation of NCCIT cells with bleomycin and 10 mM NAC abolished bleomycin-induced increases in caspase-3 and caspase-9 activities, Bax, and Cyt-c levels and bleomycin-induced decrease in Bcl-2 level. Acetylcysteine 54-57 BCL2 apoptosis regulator Homo sapiens 191-196 22562160-9 2012 Co-incubation of NCCIT cells with bleomycin and 10 mM NAC abolished bleomycin-induced increases in caspase-3 and caspase-9 activities, Bax, and Cyt-c levels and bleomycin-induced decrease in Bcl-2 level. Bleomycin 68-77 BCL2 apoptosis regulator Homo sapiens 191-196 22562160-9 2012 Co-incubation of NCCIT cells with bleomycin and 10 mM NAC abolished bleomycin-induced increases in caspase-3 and caspase-9 activities, Bax, and Cyt-c levels and bleomycin-induced decrease in Bcl-2 level. Bleomycin 68-77 BCL2 apoptosis regulator Homo sapiens 191-196 22959511-3 2012 Furthermore, arsenic trioxide stimulation led to inhibition of P-glycoprotein and Bcl-2 expression. Arsenic Trioxide 13-29 BCL2 apoptosis regulator Homo sapiens 82-87 22743622-5 2012 Both pro-survival genes BCL2 and MCL1 are targeted by actinomycin D, in contrast to fludarabine the backbone of current treatment schedules. Dactinomycin 54-67 BCL2 apoptosis regulator Homo sapiens 24-28 23165709-4 2012 The results show that TCEP at 0.01 and 1 mg L(-1) significantly increased the phosphorylation of c-Jun-NH2-terminal kinase (JNK) (135.5 and 138.0% of the control, respectively), and significantly decreased the expression of Bcl-2 and cIAP-2 at all tested concentrations, except for a slight decrease of Bcl-2 at 0.01 mg L(-1). tris(chloroethyl)phosphate 22-26 BCL2 apoptosis regulator Homo sapiens 224-229 23165709-4 2012 The results show that TCEP at 0.01 and 1 mg L(-1) significantly increased the phosphorylation of c-Jun-NH2-terminal kinase (JNK) (135.5 and 138.0% of the control, respectively), and significantly decreased the expression of Bcl-2 and cIAP-2 at all tested concentrations, except for a slight decrease of Bcl-2 at 0.01 mg L(-1). tris(chloroethyl)phosphate 22-26 BCL2 apoptosis regulator Homo sapiens 303-308 22899171-7 2012 Salvigenin inhibited H(2)O(2)-induced caspase-3 which is a hallmark of apoptosis in addition to reducing Bax\Bcl-2 ratio by 1.45 fold. salvigenin 0-10 BCL2 apoptosis regulator Homo sapiens 109-114 22006341-0 2012 Role of STAT3/5 and Bcl-2/xL in 2-methoxyestradiol-induced endoreduplication of nasopharyngeal carcinoma cells. 2-Methoxyestradiol 32-50 BCL2 apoptosis regulator Homo sapiens 20-25 22993037-8 2012 Furthermore, swainsonine enhanced the apoptosis of MHCC97-H cells with the induction of the upregulation of Bax and the downregulation of Bcl-2, whereas the expressionof Fas and Fas-L remained almost unchanged. Swainsonine 13-24 BCL2 apoptosis regulator Homo sapiens 162-167 22878646-8 2012 Resveratrol also increased phosphorylation of cyclic AMP-response-element-binding protein and transcription of the anti-apoptotic gene Bcl-2. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 135-140 22965493-4 2012 Sanguinarine caused a dose-dependent decrease in Bcl-2 and NF-kappaB protein expression and a significant increase in Bax protein expression. sanguinarine 0-12 BCL2 apoptosis regulator Homo sapiens 49-54 23012246-7 2012 RSK2(Ser227) inhibition resulting from BI-D1870 treatment restored lenalidomide-induced direct cytotoxicity of myeloma cells from interleukin-6-mediated cell protection, showed no cross-resistance to bortezomib, and exerted additive/synergistic antiproliferative effects in conjunction with the mTOR, histone deacetylase, and BH3-mimicking BCL2/BCLX(L) inhibitors. Lenalidomide 67-79 BCL2 apoptosis regulator Homo sapiens 340-344 23241934-8 2012 Moreover the nucleoside potentiated the early increase in the phosphorylation of the anti-apoptotic kinase Akt and the increase in the expression of the anti-apoptotic Bcl-2 protein induced by 6-OHDA. Nucleosides 13-23 BCL2 apoptosis regulator Homo sapiens 168-173 23194063-6 2012 Curcumin and RL197 inhibited RKO and SW480 colon cancer cell growth and induced apoptosis, and this was accompanied by downregulation of specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4 and Sp-regulated genes including the epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (c-MET), survivin, bcl-2, cyclin D1 and NFkappaB (p65 and p50). Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 332-337 23108049-6 2012 5"-FU treatment dephosphorylated ERK in a DUSP6-dependent manner, resulting in destabilization of Bcl-2 and stabilization of Bad. Fluorouracil 0-5 BCL2 apoptosis regulator Homo sapiens 98-103 23241934-8 2012 Moreover the nucleoside potentiated the early increase in the phosphorylation of the anti-apoptotic kinase Akt and the increase in the expression of the anti-apoptotic Bcl-2 protein induced by 6-OHDA. Oxidopamine 193-199 BCL2 apoptosis regulator Homo sapiens 168-173 22974689-9 2012 Interestingly, even higher toxicity was measured by lactate dehydrogenase release and terminal deoxynucleotidyl transferase dUTP nick end labeling of targeted doxorubicin micelles in Bcl-2 overexpressing adriamycin-resistant spheroids. Doxorubicin 159-170 BCL2 apoptosis regulator Homo sapiens 183-188 22974689-9 2012 Interestingly, even higher toxicity was measured by lactate dehydrogenase release and terminal deoxynucleotidyl transferase dUTP nick end labeling of targeted doxorubicin micelles in Bcl-2 overexpressing adriamycin-resistant spheroids. Doxorubicin 204-214 BCL2 apoptosis regulator Homo sapiens 183-188 23036742-8 2012 These results suggest that phycocyanin might suppress d-galactose-induced hLEC apoptosis through two pathways: mitochondrial pathway, involving p53 and Bcl-2 family protein expression, and unfolded protein response pathway, involving GRP78 and CHOP expression. Galactose 54-65 BCL2 apoptosis regulator Homo sapiens 152-157 23176396-9 2012 RESULTS: In putative HNSCC stem cells, salinomycin was found to significantly inhibit cell viability, induce a 71.5% increase in levels of apoptosis, elevate the Bax/Bcl-2 ratio, and work synergistically with cisplatin and paclitaxel in inducing cell death. salinomycin 39-50 BCL2 apoptosis regulator Homo sapiens 166-171 23091012-0 2012 Hepatitis B virus X protein targets Bcl-2 proteins to increase intracellular calcium, required for virus replication and cell death induction. Calcium 77-84 BCL2 apoptosis regulator Homo sapiens 36-41 23151022-12 2012 In addition, metformin induced apoptosis in OSCC cells, significantly down-regulating the anti-apoptotic proteins Bcl-2 and Bcl-xL and up-regulating the pro-apoptotic protein Bax. Metformin 13-22 BCL2 apoptosis regulator Homo sapiens 114-119 23091012-7 2012 Our results suggest that HBx targets Bcl-2 proteins through its BH3-like motif to promote cytosolic calcium elevation, cell death, and viral replication during HBV pathogenesis, which presents an excellent therapeutic intervention point in treating patients with chronic HBV. Calcium 100-107 BCL2 apoptosis regulator Homo sapiens 37-42 23443086-7 2012 Mechanistically, BAY11-7082 increased the activity of caspase 3 and reduced the expression of anti-apoptotic protein Bcl-2, but did not influence the expression of pro-apoptotic protein Bax. 3-(4-methylphenylsulfonyl)-2-propenenitrile 17-27 BCL2 apoptosis regulator Homo sapiens 117-122 25368634-8 2012 Furthermore, puerarin treatment downregulated Bax expression, upregulated bcl-2 expression and attenuated the activation of caspase-3 and -9. puerarin 13-21 BCL2 apoptosis regulator Homo sapiens 74-79 23152056-5 2012 To determine if the anti-apoptotic BCL-2 repertoire established the cell death threshold and chemoresistance in melanoma, a novel treatment strategy was designed to inhibit the anti-apoptotic BCL-2 members with ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 211-214 BCL2 apoptosis regulator Homo sapiens 192-197 23152059-8 2012 miR-204 targeted Bcl-2 messenger RNA and increased responsiveness of GC cells to 5-fluorouracil and oxaliplatin treatment. Fluorouracil 81-95 BCL2 apoptosis regulator Homo sapiens 17-22 23152059-8 2012 miR-204 targeted Bcl-2 messenger RNA and increased responsiveness of GC cells to 5-fluorouracil and oxaliplatin treatment. Oxaliplatin 100-111 BCL2 apoptosis regulator Homo sapiens 17-22 23152059-9 2012 Ectopic expression of Bcl-2 protein counteracted miR-204 pro-apoptotic activity in response to 5-fluorouracil. Fluorouracil 95-109 BCL2 apoptosis regulator Homo sapiens 22-27 23073173-0 2012 Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance. bicalutamide 0-12 BCL2 apoptosis regulator Homo sapiens 56-61 23091012-4 2012 Importantly, mutations in the BH3-like motif that prevent HBx binding to Bcl-2 and Bcl-xL abrogate cytosolic calcium elevation and cell death induced by HBx expression in hepatocytes and severely impair HBV viral replication, which can be substantially rescued by restoring cytosolic calcium. BH 3 30-33 BCL2 apoptosis regulator Homo sapiens 73-78 23091012-4 2012 Importantly, mutations in the BH3-like motif that prevent HBx binding to Bcl-2 and Bcl-xL abrogate cytosolic calcium elevation and cell death induced by HBx expression in hepatocytes and severely impair HBV viral replication, which can be substantially rescued by restoring cytosolic calcium. Calcium 109-116 BCL2 apoptosis regulator Homo sapiens 73-78 23091012-4 2012 Importantly, mutations in the BH3-like motif that prevent HBx binding to Bcl-2 and Bcl-xL abrogate cytosolic calcium elevation and cell death induced by HBx expression in hepatocytes and severely impair HBV viral replication, which can be substantially rescued by restoring cytosolic calcium. Calcium 284-291 BCL2 apoptosis regulator Homo sapiens 73-78 22939973-7 2012 The over-expression of NFkbeta, AKT and Bcl2 genes in cancer cells was down-regulated by [6]-gingerol treatment. gingerol 93-101 BCL2 apoptosis regulator Homo sapiens 40-44 23091012-5 2012 These results suggest that HBx binding to Bcl-2 family members and subsequent elevation of cytosolic calcium are important for HBV viral replication. Calcium 101-108 BCL2 apoptosis regulator Homo sapiens 42-47 23091012-6 2012 Consistently, RNAi knockdown of Bcl-2 or Bcl-xL results in reduced calcium elevation by HBx and decreased viral replication in hepatocytes. Calcium 67-74 BCL2 apoptosis regulator Homo sapiens 32-37 22874569-4 2012 Deprivation of L-Arg induced EIF2S1 (eIF2alpha), MAPK8 (JNK), BCL2 (Bcl-2) phosphorylation, and displacement of BECN1 (Beclin 1) binding to BCL2, leading to autophagosome formation. Arginine 15-20 BCL2 apoptosis regulator Homo sapiens 68-73 22874569-4 2012 Deprivation of L-Arg induced EIF2S1 (eIF2alpha), MAPK8 (JNK), BCL2 (Bcl-2) phosphorylation, and displacement of BECN1 (Beclin 1) binding to BCL2, leading to autophagosome formation. Arginine 15-20 BCL2 apoptosis regulator Homo sapiens 62-66 22874569-4 2012 Deprivation of L-Arg induced EIF2S1 (eIF2alpha), MAPK8 (JNK), BCL2 (Bcl-2) phosphorylation, and displacement of BECN1 (Beclin 1) binding to BCL2, leading to autophagosome formation. Arginine 15-20 BCL2 apoptosis regulator Homo sapiens 140-144 22983094-7 2012 This regulates the mitochondrial cell death pathway and alters its sensitivity not only to TRAIL, but to ABT-737, a Bcl-2 inhibitor. ABT-737 105-112 BCL2 apoptosis regulator Homo sapiens 116-121 22895079-8 2012 Our results showed that oridonin inhibiting activations of LYN (one of SRC family kinases) and ABL and their downstream Akt/mTOR, Raf/MEK/ERK and STAT5 pathways, downregulated Bcl-2 but upregulated Bax protein and then induced apoptosis in Ph+ ALL cells. oridonin 24-32 BCL2 apoptosis regulator Homo sapiens 176-181 22689683-10 2012 CONCLUSIONS: Our data demonstrate that acute myeloid leukemia cells show a variable but overall good susceptibility to the innovative therapeutic combination of sorafenib+nutlin-3, which differentially involves the pro-apoptotic Bcl-2 family members Bax and Bak in p53(wild-type) and p53(deleted) cells. Sorafenib 161-170 BCL2 apoptosis regulator Homo sapiens 229-234 23181283-10 2012 After cells were treated with juglone at the different dose for 24 h, the expression of Bcl-2 was significantly down-regulated and the expression of Bax was significantly up-regulated compared with the control. juglone 30-37 BCL2 apoptosis regulator Homo sapiens 88-93 23336025-4 2012 While pan-Bcl-2 inhibitors such as AT-101 and obatoclax can be more toxic for inhibiting all members of the anti-apoptotic Bcl-2 family of proteins, resistance can quickly develop for ABT-263, a selective Bcl-2 inhibitor. navitoclax 184-191 BCL2 apoptosis regulator Homo sapiens 10-15 22262057-0 2012 Inactivation of Bcl-2 through IkappaB kinase (IKK)-dependent phosphorylation mediates apoptosis upon exposure to 4-hydroxynonenal (HNE). 4-hydroxy-2-nonenal 113-129 BCL2 apoptosis regulator Homo sapiens 16-21 22961366-6 2012 Low Bcl-2 expression was correlated with increased carboplatin response in the tamoxifen-resistant cell line MCF-7/TAMR-1 and overexpression of Bcl-2 in this cell line resulted in significantly reduced carboplatin sensitivity, confirming the anti-apoptotic role of Bcl-2. Carboplatin 63-74 BCL2 apoptosis regulator Homo sapiens 4-9 22961366-6 2012 Low Bcl-2 expression was correlated with increased carboplatin response in the tamoxifen-resistant cell line MCF-7/TAMR-1 and overexpression of Bcl-2 in this cell line resulted in significantly reduced carboplatin sensitivity, confirming the anti-apoptotic role of Bcl-2. Tamoxifen 91-100 BCL2 apoptosis regulator Homo sapiens 4-9 22961366-6 2012 Low Bcl-2 expression was correlated with increased carboplatin response in the tamoxifen-resistant cell line MCF-7/TAMR-1 and overexpression of Bcl-2 in this cell line resulted in significantly reduced carboplatin sensitivity, confirming the anti-apoptotic role of Bcl-2. Tamoxifen 91-100 BCL2 apoptosis regulator Homo sapiens 168-173 22961366-6 2012 Low Bcl-2 expression was correlated with increased carboplatin response in the tamoxifen-resistant cell line MCF-7/TAMR-1 and overexpression of Bcl-2 in this cell line resulted in significantly reduced carboplatin sensitivity, confirming the anti-apoptotic role of Bcl-2. Tamoxifen 91-100 BCL2 apoptosis regulator Homo sapiens 168-173 22961366-6 2012 Low Bcl-2 expression was correlated with increased carboplatin response in the tamoxifen-resistant cell line MCF-7/TAMR-1 and overexpression of Bcl-2 in this cell line resulted in significantly reduced carboplatin sensitivity, confirming the anti-apoptotic role of Bcl-2. Carboplatin 238-249 BCL2 apoptosis regulator Homo sapiens 4-9 22961366-6 2012 Low Bcl-2 expression was correlated with increased carboplatin response in the tamoxifen-resistant cell line MCF-7/TAMR-1 and overexpression of Bcl-2 in this cell line resulted in significantly reduced carboplatin sensitivity, confirming the anti-apoptotic role of Bcl-2. Carboplatin 238-249 BCL2 apoptosis regulator Homo sapiens 168-173 22961366-6 2012 Low Bcl-2 expression was correlated with increased carboplatin response in the tamoxifen-resistant cell line MCF-7/TAMR-1 and overexpression of Bcl-2 in this cell line resulted in significantly reduced carboplatin sensitivity, confirming the anti-apoptotic role of Bcl-2. Carboplatin 238-249 BCL2 apoptosis regulator Homo sapiens 168-173 22403019-4 2012 Overloading HK-2 with Lysine levels reproducing those observed in urine of patients affected by LPI (10 mM) increased apoptosis (+30%; p < 0.01 vs.C), as well as Bax and Apaf-1 expressions (+30-50% p < 0.05), while downregulated Bcl-2 (-40% p < 0.05). Lysine 22-28 BCL2 apoptosis regulator Homo sapiens 235-240 22711503-6 2012 Further mutagenesis of this motif shows that amino acid residue aspartic acid (D) 16 of BMRP is essential for the BMRP/Bcl-2 interaction. Aspartic Acid 64-77 BCL2 apoptosis regulator Homo sapiens 119-124 22895548-4 2012 Butein markedly induced the generation of reactive oxygen species (ROS), decreased the phosphorylation of extracellular signal-regulated kinase (ERK), increased p38 activity, diminished Bcl-2 expression, induced caspase 3 cleavage and was associated with poly(ADP-ribose) polymerase (PARP) cleavage. butein 0-6 BCL2 apoptosis regulator Homo sapiens 210-215 22865487-5 2012 Radicicol and geldanamycin induced a decrease in Bid, Bcl-2, Bcl-xL and survivin protein levels, an increase in Bax levels, the mitochondrial transmembrane potential loss, cytochrome c release, activation of caspases (-8, -9, and -3), cleavage of PARP-1, and an increase in the tumor suppressor p53 levels. monorden 0-9 BCL2 apoptosis regulator Homo sapiens 54-59 22865487-5 2012 Radicicol and geldanamycin induced a decrease in Bid, Bcl-2, Bcl-xL and survivin protein levels, an increase in Bax levels, the mitochondrial transmembrane potential loss, cytochrome c release, activation of caspases (-8, -9, and -3), cleavage of PARP-1, and an increase in the tumor suppressor p53 levels. geldanamycin 14-26 BCL2 apoptosis regulator Homo sapiens 54-59 22895655-0 2012 Dioscin sensitizes cells to TRAIL-induced apoptosis through downregulation of c-FLIP and Bcl-2. dioscin 0-7 BCL2 apoptosis regulator Homo sapiens 101-106 22976781-5 2012 Besides, we evidenced that EGCG at similar concentrations, increased sperm motility, viability, and phosphorylation of proteins controlling cell survival such as Bcl2, Akt, and Src, via ER. epigallocatechin gallate 27-31 BCL2 apoptosis regulator Homo sapiens 162-166 22750966-9 2012 In MiaPaCa-2 cells, rANX II supplementation resulted in suppression of caspase-3 activation associated with increased Bcl-2/Bax ratios. ranx ii 20-27 BCL2 apoptosis regulator Homo sapiens 118-123 22948973-6 2012 After treatment with 7-PEC, a significant increase of Bax protein expression and decrease of Bcl-2 protein expression were observed at the same time. 7-piperazinethylchrysin 21-26 BCL2 apoptosis regulator Homo sapiens 93-98 22948973-9 2012 These results demonstrate that 7-PEC-induced mitochondrial dysfunction in HCT-116 human colon cancer cells triggers events responsible for caspase-dependent apoptosis pathways, and the elevated ratio of Bax/Bcl-2 is likely involved in this effect. 7-piperazinethylchrysin 31-36 BCL2 apoptosis regulator Homo sapiens 207-212 22915474-7 2012 The melamine-stimulated overexpression of TGF-beta1 not only promotes fibronectin production but also leads to decreased antiapoptotic (bcl-2, bcl-xl)/proapoptotic (bad, bax) protein ratio, increased caspase-3 and caspase-9 activities, and eventually HK-2 cell apoptosis. melamine 4-12 BCL2 apoptosis regulator Homo sapiens 136-141 25045421-8 2012 Expressions of pro-apoptotic factors (cleaved caspase-3/-8/-9 and bax) were increased by the combinational treatment with PQ1 and cisplatin; whereas, the pro-survival factor, bcl-2, was decreased by the combinational treatment. Cisplatin 130-139 BCL2 apoptosis regulator Homo sapiens 175-180 23285810-0 2012 Neohesperidin induces cellular apoptosis in human breast adenocarcinoma MDA-MB-231 cells via activating the Bcl-2/Bax-mediated signaling pathway. neohesperidin 0-13 BCL2 apoptosis regulator Homo sapiens 108-113 23285810-2 2012 For the first time, our study indicated that neohesperidin also induces cell apoptosis in human breast adenocarcinoma MDA-MB-231 cells, which was possibly mediated by regulating the P53/Bcl-2/Bax pathway. neohesperidin 45-58 BCL2 apoptosis regulator Homo sapiens 186-191 23285810-10 2012 Our study suggested that neohesperidin could induce apoptosis of MDA-MB-231 cells, a process which was associated with the activation of the Bcl-2/Bax-mediated signaling pathway. neohesperidin 25-38 BCL2 apoptosis regulator Homo sapiens 141-146 22922982-11 2012 As2O3 significantly suppressed cell growth, caused G2/M arrest, enhanced cell death and apoptosis induced by 89SrCl2 and decreased expression of the Bcl-2 gene. Arsenic Trioxide 0-5 BCL2 apoptosis regulator Homo sapiens 149-154 22922982-12 2012 Since expression of Bax was unchanged following treatment, As2O3 effectively reduced the Bcl-2/Bax ratio. Arsenic Trioxide 59-64 BCL2 apoptosis regulator Homo sapiens 89-94 22922982-13 2012 As2O3 (1-2 microM) enhances the cytotoxic effects of 89SrCl2 on the MCF-7 human breast cancer cell line by inducing G2 phase delay and promoting apoptosis through the reduction of the Bcl-2/Bax ratio. Arsenic Trioxide 0-5 BCL2 apoptosis regulator Homo sapiens 184-189 22922982-13 2012 As2O3 (1-2 microM) enhances the cytotoxic effects of 89SrCl2 on the MCF-7 human breast cancer cell line by inducing G2 phase delay and promoting apoptosis through the reduction of the Bcl-2/Bax ratio. 89srcl2 53-60 BCL2 apoptosis regulator Homo sapiens 184-189 22389198-4 2012 Further studies showed that FBRA extract caused a significant elevation of Bax protein and a slight reduction of Bcl2 protein levels, and furthermore caused the activation of caspase-3 in the cells. fbra 28-32 BCL2 apoptosis regulator Homo sapiens 113-117 22407755-3 2012 XN induced a higher rate of apoptosis in glioblastoma cells than in normal astrocytes, which was associated with activation of p53 and an elevated Bax/Bcl-2 ratio in glioblastoma cells, indicating an intrinsic caspase-dependent apoptotic pathway. xanthohumol 0-2 BCL2 apoptosis regulator Homo sapiens 151-156 22999929-0 2012 Protection by silibinin against experimental ischemic stroke: up-regulated pAkt, pmTOR, HIF-1alpha and Bcl-2, down-regulated Bax, NF-kappaB expression. Silybin 14-23 BCL2 apoptosis regulator Homo sapiens 103-108 22999929-5 2012 We found that silibinin significantly alleviated neurological deficit, reduced infarct volume, and suppressed brain edema, which were accompanied with upregulation of pAkt, pmTOR, HIF-1alpha, Bcl-2 and downregulation of Bax, NF-kappaB in ischemic brain tissue after stroke. Silybin 14-23 BCL2 apoptosis regulator Homo sapiens 192-197 22895655-3 2012 Treatment of Caki cells with dioscin downregulated c-FLIPL and Bcl-2 proteins in a dose-dependent manner. dioscin 29-36 BCL2 apoptosis regulator Homo sapiens 75-80 22895655-5 2012 We also found that dioscin induced downregulation of Bcl-2 at the transcriptional level. dioscin 19-26 BCL2 apoptosis regulator Homo sapiens 53-58 22895655-7 2012 Taken together, the present study demonstrates that dioscin enhances TRAIL-induced apoptosis in human renal cancer cells by downregulation of c-FLIPL and Bcl-2. dioscin 64-71 BCL2 apoptosis regulator Homo sapiens 178-183 22579788-0 2012 The BH3 mimetic S1 induces autophagy through ER stress and disruption of Bcl-2/Beclin 1 interaction in human glioma U251 cells. BH 3 4-7 BCL2 apoptosis regulator Homo sapiens 73-78 23110625-10 2012 (4) During the process of bufalin-induced apoptosis in SW620 cells, transient activation of p-stat3 inhibited the activation of stat3, up-regulated Bax expression, down-regulated livin and Bcl-2 expression (P<0.01), and activated caspase-3. bufalin 26-33 BCL2 apoptosis regulator Homo sapiens 189-194 23110625-11 2012 Inhibition of Jak-stat3 signaling pathway by pre-treatment with AG490 significantly enhanced the bufalin-induced apoptosis (P<0.01), further up-regulated Bax protein expression, down-regulated livin and Bcl-2 protein expression and enhanced caspase-3 activation. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 64-69 BCL2 apoptosis regulator Homo sapiens 206-211 23110625-11 2012 Inhibition of Jak-stat3 signaling pathway by pre-treatment with AG490 significantly enhanced the bufalin-induced apoptosis (P<0.01), further up-regulated Bax protein expression, down-regulated livin and Bcl-2 protein expression and enhanced caspase-3 activation. bufalin 97-104 BCL2 apoptosis regulator Homo sapiens 206-211 23110625-13 2012 Activation of caspase-3, up-regulation of Bax, down-regulation of livin and Bcl-2, as well as inhibition of Jak-stat3 signaling pathway might be the important mechanisms for the bufalin-induced apoptosis. bufalin 178-185 BCL2 apoptosis regulator Homo sapiens 76-81 22995319-5 2012 Treatment of HUVECs with LPS increased the NHE1 activity in a time-dependent manner associated with the increased Ca(i)(2+), which resulted in enhanced calpain activity as well as HUVECs apoptosis via NHE1-dependent degradation of Bcl-2. carboxyamido-triazole 114-119 BCL2 apoptosis regulator Homo sapiens 231-236 22997623-0 2012 Removal notice to "Molecular mechanisms involved in resistance of CLL cells towards ABT-737, a specific BCL-2 inhibitor" [Toxicology 290 (December (2-3)) (2011) 111]. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 84-87 BCL2 apoptosis regulator Homo sapiens 104-109 25538758-5 2012 Quantitative real-time reverse transcription-PCR and western blot assay results revealed that ginsenoside Rb1 inhibited intermittent high glucose-upregulated Bax expression, but antagonized intermittent high glucose-downregulated Bcl-2 expression in Schwann cells. Glucose 208-215 BCL2 apoptosis regulator Homo sapiens 230-235 23063124-5 2012 BH3 profiling identified BCL-2 inhibition as a targeted strategy likely to have a useful therapeutic index. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 25-30 23030453-2 2012 We have previously reported the design of 4,5-diphenyl-1H-pyrrole-3-carboxylic acids as a class of potent Bcl-2/Bcl-xL inhibitors. 4,5-diphenyl-1h-pyrrole-3-carboxylic acids 42-84 BCL2 apoptosis regulator Homo sapiens 106-111 22939915-10 2012 In addition, dioscin inhibited APAP-induced activation and expression of CYP2E1, up-regulated the expression of Bcl-2 and Bid, and inhibited the expression of Bax, Bak and p53. dioscin 13-20 BCL2 apoptosis regulator Homo sapiens 112-117 22841670-6 2012 Bufotalin treatment also induced apoptosis which was accompanied by decrease in mitochondrial membrane potential, increases in intracellular calcium level and reactive oxygen species production, activations of caspase-9 and -3, cleavage of poly ADP-ribose polymerase (PARP) as well as changes in the expressions of bcl-2 and bax. bufotalin 0-9 BCL2 apoptosis regulator Homo sapiens 315-320 29623239-5 2012 Forskolin treatment for up to 72 h resulted in 80% syncytialization, increased expression of Bcl-2 protein (P < 0.01) and mRNA (P < 0.05), and significantly decreased expression of protein and mRNA for Bax, p53, and caspases 3 and 8. Colforsin 0-9 BCL2 apoptosis regulator Homo sapiens 93-98 22987068-0 2012 An efficient antigene activity and antiproliferative effect by targeting the Bcl-2 or survivin gene with triplex forming oligonucleotides containing a W-shaped nucleoside analogue (WNA-betaT). triplex forming oligonucleotides 105-137 BCL2 apoptosis regulator Homo sapiens 77-82 22987068-0 2012 An efficient antigene activity and antiproliferative effect by targeting the Bcl-2 or survivin gene with triplex forming oligonucleotides containing a W-shaped nucleoside analogue (WNA-betaT). Nucleosides 160-170 BCL2 apoptosis regulator Homo sapiens 77-82 22987068-6 2012 We designed the GU TFO (WNA) and GU TFO (natural) for targeting sequences of the Bcl-2 or survivin oncogene. tfo 36-39 BCL2 apoptosis regulator Homo sapiens 81-86 22987068-8 2012 Remarkably, the Bcl-2- or survivin-targeted TFO (WNA) inhibited the cell proliferation and induced a caspase-dependent apoptosis. tfo 44-47 BCL2 apoptosis regulator Homo sapiens 16-21 23017833-5 2012 Curcumin suppressed the activation of NF-kappaB via the inhibition of IkappaBalpha phosphorylation, and downregulated the expressions of Bcl-2 and CyclinD1 in ESCC cell lines. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 137-142 22982675-4 2012 Withaferin A also down-regulates the expression of STAT3 regulated genes such as Bcl-xL, Bcl-2, cyclin D1 and survivin. withaferin A 0-12 BCL2 apoptosis regulator Homo sapiens 89-94 22843330-4 2012 Focused gene expression array analysis followed by immunoblot detection revealed that DP rapidly activates the cytotoxic unfolded protein response (UPR; involving phospho-PERK, phospho-eIF2alpha, Grp78, CHOP, and Hsp70) and the mitochondrial pathway of apoptosis with p53 upregulation and modulation of Bcl-2 family members (involving Noxa, Mcl-1, and Bcl-2). dp 86-88 BCL2 apoptosis regulator Homo sapiens 303-308 22711176-8 2012 Suppression of survivin expression resulted in curcumin resistance via the modulation of Bcl-2 and Bax expression. Curcumin 47-55 BCL2 apoptosis regulator Homo sapiens 89-94 22843330-4 2012 Focused gene expression array analysis followed by immunoblot detection revealed that DP rapidly activates the cytotoxic unfolded protein response (UPR; involving phospho-PERK, phospho-eIF2alpha, Grp78, CHOP, and Hsp70) and the mitochondrial pathway of apoptosis with p53 upregulation and modulation of Bcl-2 family members (involving Noxa, Mcl-1, and Bcl-2). dp 86-88 BCL2 apoptosis regulator Homo sapiens 352-357 22711363-6 2012 Dracorhodin perchlorate-induced apoptosis is mediated via upregulation of p53, inhibiting the activation of PI3K/Akt, and NF-kappaB, thereby decreasing the expression of the anti-apoptotic proteins, Bcl-2 and Bcl-XL. dracorhodin 0-23 BCL2 apoptosis regulator Homo sapiens 199-204 22624727-2 2012 Navitoclax (ABT-263) is a potent inhibitor of Bcl-2, Bcl-x(L) and Bcl-w, which has demonstrated efficacy in haematological tumours alone and in combination with other agents. navitoclax 0-10 BCL2 apoptosis regulator Homo sapiens 46-51 22678742-4 2012 Here, we found that PQ significantly decreases cell viability, increases sub-G1 hypodiploids DNA contents and caspase 3/7 activity in lung alveolar epithelial cell-derived L2 cells, which also caused mitochondrial dysfunction, and decreased the mRNA expression of Bcl-2 and increased that of Bax, Bak, and p53. Primaquine 20-22 BCL2 apoptosis regulator Homo sapiens 264-269 22678742-10 2012 Cells transfected with Nrf-2 siRNA significantly reversed the PQ-induced toxicity, including depolarization of MMP, increased the Bax, Bak, p53 mRNAs expression, decreased the Bcl-2 mRNA expression, increased the caspase 3/7 activity, Grp78, CHOP, and caspase-12 mRNAs and protein expression, and decreased that of pro-caspase-3. Primaquine 62-64 BCL2 apoptosis regulator Homo sapiens 176-181 22796564-7 2012 Furthermore, treatment with ALA down-regulated the Bax expression and the release of cytochrome c and AIF translocation, but up-regulated the Bcl-2 expression in SCs. Thioctic Acid 28-31 BCL2 apoptosis regulator Homo sapiens 142-147 23060563-7 2012 Interference with ATF5 function in SW1990 cells resulted in down-regulation of BCL-2 and up-regulation of BAX, resulting in enhanced sensitivity to apoptosis induced by paclitaxel treatment. Paclitaxel 169-179 BCL2 apoptosis regulator Homo sapiens 79-84 22624727-2 2012 Navitoclax (ABT-263) is a potent inhibitor of Bcl-2, Bcl-x(L) and Bcl-w, which has demonstrated efficacy in haematological tumours alone and in combination with other agents. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 12-15 BCL2 apoptosis regulator Homo sapiens 46-51 22762853-8 2012 GA-Me down-regulated the expression of various NF-kappaB-regulated genes including genes involved in cell proliferation (c-Myc and cyclin D1), anti-apoptosis (Bcl-2), invasion (MMP-9) and angiogenesis (VEGF, interleukin (IL)-6 and -8). ganoderic acid Me 0-5 BCL2 apoptosis regulator Homo sapiens 159-164 22767649-7 2012 In addition, NX treatment also modulates the levels of Bax and Bcl-2 proteins along with cytochrome c release, cleavage and enhanced expression of poly (adenosine diphosphate-ribose) polymerase as well as catalytic activities of caspases 3 and 9 in both A431 and A375 cells. nx 13-15 BCL2 apoptosis regulator Homo sapiens 63-68 22895112-4 2012 While the BH3-proteins bound to Bcl-XL and Bcl-2, the BH3 mimetic ABT-737 inhibited binding of only Bad and tBid, but not Bim. BH 3 10-13 BCL2 apoptosis regulator Homo sapiens 43-48 22895112-7 2012 Furthermore, we show that mutation of a conserved residue in the BH3 region in Bad and tBid disrupted their interactions with Bcl-XL and Bcl-2, while the corresponding BimEL mutant showed no decrease in binding to these anti-apoptotic proteins. BH 3 65-68 BCL2 apoptosis regulator Homo sapiens 137-142 22895112-7 2012 Furthermore, we show that mutation of a conserved residue in the BH3 region in Bad and tBid disrupted their interactions with Bcl-XL and Bcl-2, while the corresponding BimEL mutant showed no decrease in binding to these anti-apoptotic proteins. tBID 87-91 BCL2 apoptosis regulator Homo sapiens 137-142 22710635-6 2012 NaBu induced expression of caspase-3, caspase-9, and Bcl-2 and increased Bax in U373-MG cells. sethoxydim 0-4 BCL2 apoptosis regulator Homo sapiens 53-58 22982119-1 2012 Obatoclax is a linear oligopyrrole compound which antagonizes the antiapoptotic effects of the Bcl-2 family. oligopyrrole 22-34 BCL2 apoptosis regulator Homo sapiens 95-100 22851565-0 2012 Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Doxorubicin 117-128 BCL2 apoptosis regulator Homo sapiens 33-37 22895528-0 2012 Etoposide induces a mixed type of programmed cell death and overcomes the resistance conferred by Bcl-2 in Hep3B hepatoma cells. Etoposide 0-9 BCL2 apoptosis regulator Homo sapiens 98-103 22895528-5 2012 Furthermore, this study was conducted to examine whether etoposide overcomes the resistance conferred by Bcl-2 in Hep3B hepatoma cells. Etoposide 57-66 BCL2 apoptosis regulator Homo sapiens 105-110 22895528-10 2012 Importantly, etoposide can effectively induce cell death in Bcl-2-overexpressing Hep3B cells. Etoposide 13-22 BCL2 apoptosis regulator Homo sapiens 60-65 22895528-14 2012 To this end, we observed that etoposide-induced mixed type of programmed cell death is associated with the dissociation of Bcl-2 from Beclin-1. Etoposide 30-39 BCL2 apoptosis regulator Homo sapiens 123-128 22895528-15 2012 Taken together, etoposide induces a mixed type of programmed cell death and overcomes the resistance conferred by Bcl-2 in Hep3B hepatoma cells. Etoposide 16-25 BCL2 apoptosis regulator Homo sapiens 114-119 22842544-0 2012 Antimycin A sensitizes cells to TRAIL-induced apoptosis through upregulation of DR5 and downregulation of c-FLIP and Bcl-2. Antimycin A 0-11 BCL2 apoptosis regulator Homo sapiens 117-122 22581694-6 2012 Furthermore, these BaP-treated HPDLCs fell into apoptotic cell death as evidenced by induction in annexin V and caspase-3/7 staining and reduction of total cell number and Bcl-2 mRNA expression. Benzo(a)pyrene 19-22 BCL2 apoptosis regulator Homo sapiens 172-177 23182046-6 2012 Quinuclidinone derivative 6 increased expression levels of p53 and Bax at both protein and mRNA levels and reduced expression level of Mdm2, Bcl2, Akt and Bcl-XL It also increased mitochondrial apoptotic pathways by activating release of cytochrome c which is consistent with activation of caspase-9 as confirmed by caspase-9 inhibitor LEHD-CHO. 1-azabicyclo[2.2.2]octan-2-one 0-14 BCL2 apoptosis regulator Homo sapiens 142-146 22851565-0 2012 Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Cyclophosphamide 99-115 BCL2 apoptosis regulator Homo sapiens 33-37 22851565-0 2012 Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Vincristine 130-141 BCL2 apoptosis regulator Homo sapiens 33-37 22851565-0 2012 Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Prednisone 147-157 BCL2 apoptosis regulator Homo sapiens 33-37 22982226-8 2012 Moreover, NaHS markedly suppressed radiation-induced phosphorylation of P53, decrease of Bcl-2/Bax, and activity of nuclear factor kappaB (NF-kappaB). sodium bisulfide 10-14 BCL2 apoptosis regulator Homo sapiens 89-94 24716146-5 2012 In depth investigation for the molecular mechanisms, revealed that eburicoic acid firstly promoted reactive oxygen species generation and ATP depletion, leading to endoplasmic reticulum stress, followed by elevated cytosolic calcium ion concentration and BiP expression, downregulated phosphorylation of DAPK, upregulated phosphorylation of Beclin-1, JNK, and Bcl-2, and finally induced autophagy in Hep 3B cells. eburicoic acid 67-81 BCL2 apoptosis regulator Homo sapiens 360-365 22766766-5 2012 In addition, angelicin dose-dependently downregulated the expression of anti-apoptotic proteins including Bcl-2, Bcl-xL, and Mcl-1 suggesting the involvement of the intrinsic mitochondria-mediated apoptotic pathway which did not participate in Fas/FasL-induced caspase-8-mediated extrinsic, MAP kinases, and PI3K/AKT/GSK-3beta pathway. angelicin 13-22 BCL2 apoptosis regulator Homo sapiens 106-111 22945467-7 2012 As for signaling, quercetin was completely effective in alleviating the cleaved caspase-3, being only partially effective in suppressing Bax and Bad, restoring Bcl-2, and rescuing DNA damage. Quercetin 18-27 BCL2 apoptosis regulator Homo sapiens 160-165 22784708-5 2012 Methylglyoxal suppressed the expression of antiapoptotic factors, X-linked inhibitor of apoptosis protein (XIAP), survivin, cIAP1, Bcl-2, and Bcl-xL, without affecting TRAIL receptors, DR4 and DR5. Pyruvaldehyde 0-13 BCL2 apoptosis regulator Homo sapiens 131-136 22982226-9 2012 In conclusion, our finding demonstrates that H(2)S/CSE pathway plays a radioprotection role by inhibiting radiation-induced ROS production, P53 phosphorylation, NF-kappaB activation and decrease of Bcl-2/Bax, indicating that modulation of H(2)S may be a novel protection strategy for liver radiation injury in radiotherapy. h(2) 45-49 BCL2 apoptosis regulator Homo sapiens 198-203 22982226-9 2012 In conclusion, our finding demonstrates that H(2)S/CSE pathway plays a radioprotection role by inhibiting radiation-induced ROS production, P53 phosphorylation, NF-kappaB activation and decrease of Bcl-2/Bax, indicating that modulation of H(2)S may be a novel protection strategy for liver radiation injury in radiotherapy. Hydrogen Sulfide 45-50 BCL2 apoptosis regulator Homo sapiens 198-203 22825128-5 2012 The expression of apoptosis related proteins was also affected in cells treated with the combination of OA and 5-FU, including activation of caspases-3 and the expression of Bcl-2/Bax, survivin and NF-kappaB. Fluorouracil 123-127 BCL2 apoptosis regulator Homo sapiens 198-203 23055042-6 2012 Bop would be constrained by pro-survival Bcl-2 proteins in resting cells, because Bop became released from phosphorylated Bcl-2 induced by microtubule-interfering agent like vincristine (VCR). Vincristine 174-185 BCL2 apoptosis regulator Homo sapiens 41-46 22609276-6 2012 Treatment with beta-eleostearic acid caused massive ROS accumulation and GSH decrease, which lead to activation of caspase-3 and down-regulation of Bcl-2 indicating induction of apoptosis. eleostearic acid 15-36 BCL2 apoptosis regulator Homo sapiens 148-153 23055042-6 2012 Bop would be constrained by pro-survival Bcl-2 proteins in resting cells, because Bop became released from phosphorylated Bcl-2 induced by microtubule-interfering agent like vincristine (VCR). Vincristine 174-185 BCL2 apoptosis regulator Homo sapiens 122-127 22877649-10 2012 Beta-catenin siRNA significantly inhibited the expression of Bax and Bcl-2 in celastrol-treated HT29 cells. celastrol 78-87 BCL2 apoptosis regulator Homo sapiens 69-74 22549660-5 2012 Results of apoptosis proteins assay showed a upgrade of p53 and a downgrade of Bcl-2 level by FLX-ADM or FLX-PTX combinations in both cells. flx-adm 94-101 BCL2 apoptosis regulator Homo sapiens 79-84 22549660-5 2012 Results of apoptosis proteins assay showed a upgrade of p53 and a downgrade of Bcl-2 level by FLX-ADM or FLX-PTX combinations in both cells. flx-ptx 105-112 BCL2 apoptosis regulator Homo sapiens 79-84 22549660-6 2012 Our findings indicated that by synergism with anticancer drugs, FLX modulation of apoptosis via targeting p53 and Bcl-2 expression, FLX reverse the breast cancer cell"s resistance and enhance the chemosensitivity to ADM and PTX. Fluoxetine 64-67 BCL2 apoptosis regulator Homo sapiens 114-119 22549660-6 2012 Our findings indicated that by synergism with anticancer drugs, FLX modulation of apoptosis via targeting p53 and Bcl-2 expression, FLX reverse the breast cancer cell"s resistance and enhance the chemosensitivity to ADM and PTX. Doxorubicin 216-219 BCL2 apoptosis regulator Homo sapiens 114-119 22549660-6 2012 Our findings indicated that by synergism with anticancer drugs, FLX modulation of apoptosis via targeting p53 and Bcl-2 expression, FLX reverse the breast cancer cell"s resistance and enhance the chemosensitivity to ADM and PTX. Paclitaxel 224-227 BCL2 apoptosis regulator Homo sapiens 114-119 22824464-8 2012 Moreover, it was found that antioxidant N-acetylcysteine (NAC) blocked the induction of apoptosis and partly reversed the activation of JNK and p38, up-regulation of Bax, down-regulation of Bcl-2 and the activation of caspase-3 in NG-treated cells. Acetylcysteine 40-56 BCL2 apoptosis regulator Homo sapiens 190-195 22824464-8 2012 Moreover, it was found that antioxidant N-acetylcysteine (NAC) blocked the induction of apoptosis and partly reversed the activation of JNK and p38, up-regulation of Bax, down-regulation of Bcl-2 and the activation of caspase-3 in NG-treated cells. Acetylcysteine 58-61 BCL2 apoptosis regulator Homo sapiens 190-195 22974127-8 2012 RESULTS: Data indicated that simvastatin inhibited intrinsic cell survival pathway in PC3 cells by enhancing phosphorylation of Bad, reducing the protein expression of Bcl-2, Bcl-xL and cleaved caspases 9/3. Simvastatin 29-40 BCL2 apoptosis regulator Homo sapiens 168-173 22967286-0 2012 Increased ratio of anti-apoptotic to pro-apoptotic Bcl2 gene-family members in lithium-responders one month after treatment initiation. Lithium 79-86 BCL2 apoptosis regulator Homo sapiens 51-55 22967286-8 2012 Closer examination of the time-course of changes among BCL2 related genes showed that in lithium-responders, one month after starting treatment with lithium, several anti-apoptotic genes including Bcl2 and insulin receptor substrate 2 (IRS2) were up-regulated, while pro-apoptotic genes, including BCL2-antagonist/killer 1 (BAK1) and BCL2-associated agonist of cell death (BAD), were down-regulated. Lithium 89-96 BCL2 apoptosis regulator Homo sapiens 55-59 22967286-8 2012 Closer examination of the time-course of changes among BCL2 related genes showed that in lithium-responders, one month after starting treatment with lithium, several anti-apoptotic genes including Bcl2 and insulin receptor substrate 2 (IRS2) were up-regulated, while pro-apoptotic genes, including BCL2-antagonist/killer 1 (BAK1) and BCL2-associated agonist of cell death (BAD), were down-regulated. Lithium 89-96 BCL2 apoptosis regulator Homo sapiens 197-201 22967286-8 2012 Closer examination of the time-course of changes among BCL2 related genes showed that in lithium-responders, one month after starting treatment with lithium, several anti-apoptotic genes including Bcl2 and insulin receptor substrate 2 (IRS2) were up-regulated, while pro-apoptotic genes, including BCL2-antagonist/killer 1 (BAK1) and BCL2-associated agonist of cell death (BAD), were down-regulated. Lithium 89-96 BCL2 apoptosis regulator Homo sapiens 298-302 22967286-8 2012 Closer examination of the time-course of changes among BCL2 related genes showed that in lithium-responders, one month after starting treatment with lithium, several anti-apoptotic genes including Bcl2 and insulin receptor substrate 2 (IRS2) were up-regulated, while pro-apoptotic genes, including BCL2-antagonist/killer 1 (BAK1) and BCL2-associated agonist of cell death (BAD), were down-regulated. Lithium 89-96 BCL2 apoptosis regulator Homo sapiens 298-302 22967286-8 2012 Closer examination of the time-course of changes among BCL2 related genes showed that in lithium-responders, one month after starting treatment with lithium, several anti-apoptotic genes including Bcl2 and insulin receptor substrate 2 (IRS2) were up-regulated, while pro-apoptotic genes, including BCL2-antagonist/killer 1 (BAK1) and BCL2-associated agonist of cell death (BAD), were down-regulated. Lithium 149-156 BCL2 apoptosis regulator Homo sapiens 55-59 22964015-0 2012 Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. Arsenic Trioxide 0-16 BCL2 apoptosis regulator Homo sapiens 54-58 22964015-0 2012 Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. Ascorbic Acid 21-34 BCL2 apoptosis regulator Homo sapiens 54-58 22964015-11 2012 CONCLUSIONS: These results represent the basis for a possible association of ATO with other biological compounds able to modify the apoptotic pathways, such as inhibitors of the BCL2 family. Arsenic Trioxide 77-80 BCL2 apoptosis regulator Homo sapiens 178-182 22824464-4 2012 Moreover, NG-induced apoptosis of HepG2 cells was characteristic of intracellular reactive oxygen species (ROS) generation, loss of mitochondrial membrane potential (Deltapsim) and enhanced Bax-to-Bcl-2 ratio. Nitroglycerin 10-12 BCL2 apoptosis regulator Homo sapiens 197-202 22967286-8 2012 Closer examination of the time-course of changes among BCL2 related genes showed that in lithium-responders, one month after starting treatment with lithium, several anti-apoptotic genes including Bcl2 and insulin receptor substrate 2 (IRS2) were up-regulated, while pro-apoptotic genes, including BCL2-antagonist/killer 1 (BAK1) and BCL2-associated agonist of cell death (BAD), were down-regulated. Lithium 149-156 BCL2 apoptosis regulator Homo sapiens 298-302 22967286-8 2012 Closer examination of the time-course of changes among BCL2 related genes showed that in lithium-responders, one month after starting treatment with lithium, several anti-apoptotic genes including Bcl2 and insulin receptor substrate 2 (IRS2) were up-regulated, while pro-apoptotic genes, including BCL2-antagonist/killer 1 (BAK1) and BCL2-associated agonist of cell death (BAD), were down-regulated. Lithium 149-156 BCL2 apoptosis regulator Homo sapiens 298-302 22967286-9 2012 In contrast, in lithium non-responders, BCL2 and IRS2 were down-regulated, while BAK1 and BAD up-regulated at the one-month time-point. Lithium 16-23 BCL2 apoptosis regulator Homo sapiens 40-44 22975379-6 2012 Notably, targeting Notch and Hedgehog signaling depleted this population through inhibition of the survival molecules AKT and Bcl-2, suggesting a therapeutic strategy for abrogating Docetaxel resistance in HRPC. Docetaxel 182-191 BCL2 apoptosis regulator Homo sapiens 126-131 22446899-9 2012 Moreover, shikonin causes catalase downregulation and SOD-1 upregulation as well as decreased Bcl-2 and increased Bax expression. shikonin 10-18 BCL2 apoptosis regulator Homo sapiens 94-99 22187147-7 2012 Interestingly, most of the differentially expressed genes in these pathways leading to nuclear factor kappaB (NF-kappaB) activation and those important inhibitors of pathways leading to apoptosis, including FLIP and Bcl-2, were up-regulated by nicotine. Nicotine 244-252 BCL2 apoptosis regulator Homo sapiens 216-221 22433057-4 2012 Geldanamycin induced a decrease in Bid, Bcl-2, Bcl-xL and survivin protein levels; an increase in Bax and tumour suppressor p53 levels; loss of the mitochondrial transmembrane potential; cytochrome c release; activation of caspases (-8, -9 and -3); cleavage of PARP-1; and increase in the reactive oxygen species formation. geldanamycin 0-12 BCL2 apoptosis regulator Homo sapiens 40-45 22343223-4 2012 Moreover, the DHMEQ-CLX combination was associated with induction of PARP cleavage and down-regulation of the anti-apoptotic proteins Bcl-2, Mcl-1 and survivin, as well as activated Akt. dhmeq-clx 14-23 BCL2 apoptosis regulator Homo sapiens 134-139 22717365-5 2012 Moreover, PTX and shRNA simultaneously delivered to SKOV-3 cells lead to efficient reduction in the survivin and Bcl-2 expression as well as synergistic cell apoptotic induction in the in vitro study. Paclitaxel 10-13 BCL2 apoptosis regulator Homo sapiens 113-118 22471974-11 2012 KEY RESULTS: Flavocoxid reduced prostate weight and hyperplasia, blunted inducible expression of COX-2 and 5-LOX as well as the increased production of PGE(2) and leukotriene B(4) (LTB(4) ), enhanced pro-apoptotic Bax and caspase-9 and decreased the anti-apoptotic Bcl-2 mRNA. flavocoxid 13-23 BCL2 apoptosis regulator Homo sapiens 267-272 22213394-2 2012 The aim of this study was to investigate the frequency and prognostic impact of BCL2, BCL6, and MYC rearrangements in cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP)-treated DLBCL cases. Cyclophosphamide 118-134 BCL2 apoptosis regulator Homo sapiens 80-84 22767021-5 2012 Decitabine-induced apoptosis in U937 and HL60 cells was correlated with the downregulation of anti-apoptotic Bcl-2, XIAP, cIAP-1 and cIAP-2 protein levels, the cleavage of Bid proteins, the activation of caspases and the collapse of mitochondrial membrane potential (MMP). Decitabine 0-10 BCL2 apoptosis regulator Homo sapiens 121-126 22213394-2 2012 The aim of this study was to investigate the frequency and prognostic impact of BCL2, BCL6, and MYC rearrangements in cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP)-treated DLBCL cases. Doxorubicin 136-147 BCL2 apoptosis regulator Homo sapiens 80-84 22213394-2 2012 The aim of this study was to investigate the frequency and prognostic impact of BCL2, BCL6, and MYC rearrangements in cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP)-treated DLBCL cases. Vincristine 149-160 BCL2 apoptosis regulator Homo sapiens 80-84 22213394-2 2012 The aim of this study was to investigate the frequency and prognostic impact of BCL2, BCL6, and MYC rearrangements in cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP)-treated DLBCL cases. Prednisone 166-176 BCL2 apoptosis regulator Homo sapiens 80-84 22609455-1 2012 Small-molecule cell-permeable Bcl-2/Bcl-xL antagonist ABT-737 has recently emerged as a novel cancer therapeutic agent because it potently induces apoptosis in certain cancer cells. ABT-737 54-61 BCL2 apoptosis regulator Homo sapiens 30-35 22751989-9 2012 The upregulation of Bax, downregulation of Bcl-2 and cytochrome c release into the cytoplasm, which are considered as mechanisms of apoptotic cell death, were observed in the MCF-7 cells treated with sirtinol. sirtinol 200-208 BCL2 apoptosis regulator Homo sapiens 43-48 22018604-7 2012 In addition, GCTI increased the expression of cell cycle inhibitory proteins (p21, p27 and p53) and the Bax-to-Bcl-2 ratio to induce apoptosis. gcti 13-17 BCL2 apoptosis regulator Homo sapiens 111-116 22038727-0 2012 Compensatory and non-compensatory effects on protein expression following BCL-2 suppression by antisense oligonucleotides. Oligonucleotides 105-121 BCL2 apoptosis regulator Homo sapiens 74-79 22453662-5 2012 The concept of BH3 mimetics was prompted by the fact that BH3-only proteins are specific antagonistic ligands of prosurvival Bcl-2 family members. BH 3 15-18 BCL2 apoptosis regulator Homo sapiens 125-130 22895144-2 2012 The Bcl-2 homology domain 3-only protein Noxa has been implicated as a key inducer of apoptosis by bortezomib. Bortezomib 99-109 BCL2 apoptosis regulator Homo sapiens 4-9 23019417-5 2012 In addition, apicidin and docetaxel co-treatment specifically stimulates apoptosis, characterized by an increased Bax/Bcl-2 ratio and caspase-8 activation. apicidin 13-21 BCL2 apoptosis regulator Homo sapiens 118-123 22985579-0 2012 [Hydroxycamptothecin inhibits proliferation of human lung carcinoma cell line A549 and down-regulates its Bcl-2 gene expression in vitro]. hydroxycamptothecinum 1-20 BCL2 apoptosis regulator Homo sapiens 106-111 22985579-9 2012 CONCLUSION: HCPT can significantly inhibit the proliferation, induce apoptosis, and down-regulate Bcl-2 gene expression in human lung carcinoma cell line A549, suggesting the involvement of Bcl-2 gene in the inhibitory effect of HCPT on A549 cells. hydroxycamptothecinum 12-16 BCL2 apoptosis regulator Homo sapiens 98-103 22985579-9 2012 CONCLUSION: HCPT can significantly inhibit the proliferation, induce apoptosis, and down-regulate Bcl-2 gene expression in human lung carcinoma cell line A549, suggesting the involvement of Bcl-2 gene in the inhibitory effect of HCPT on A549 cells. hydroxycamptothecinum 12-16 BCL2 apoptosis regulator Homo sapiens 190-195 22710478-8 2012 It is possible that upregulation of Bax/Bcl-2 and regulation of expression of specific miRNAs play a role in inhibition of proliferation and induction of apoptosis in waltonitone-treated cells. 28-hydroxy-3-oxo-12-ursene 191-202 BCL2 apoptosis regulator Homo sapiens 52-57 22710790-8 2012 Western blot analysis demonstrated that rapamycin downregulates the expression levels of Bcl-2, which leads to increased cytochrome c release from mitochondria and subsequent activation of caspase cascades. Sirolimus 52-61 BCL2 apoptosis regulator Homo sapiens 101-106 23019417-5 2012 In addition, apicidin and docetaxel co-treatment specifically stimulates apoptosis, characterized by an increased Bax/Bcl-2 ratio and caspase-8 activation. Docetaxel 26-35 BCL2 apoptosis regulator Homo sapiens 118-123 22733819-8 2012 PMCA1 knockdown augmented necrosis mediated by the Ca(2+) ionophore ionomycin, whereas apoptosis mediated by the Bcl-2 inhibitor ABT-263 was enhanced by PMCA4 silencing. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 129-132 BCL2 apoptosis regulator Homo sapiens 113-118 22766741-0 2012 Action of db-cAMP on the bystander effect and chemosensitivity through connexin 43 and Bcl-2-mediated pathways in medulloblastoma cells. Bucladesine 10-17 BCL2 apoptosis regulator Homo sapiens 99-104 22766741-9 2012 In addition, db-cAMP increased the cytotoxicity of temozolomide and teniposide, possibly by downregulating the Bcl-2 expression and inducing apoptosis. Bucladesine 13-20 BCL2 apoptosis regulator Homo sapiens 123-128 22766741-9 2012 In addition, db-cAMP increased the cytotoxicity of temozolomide and teniposide, possibly by downregulating the Bcl-2 expression and inducing apoptosis. Temozolomide 51-63 BCL2 apoptosis regulator Homo sapiens 123-128 22766741-9 2012 In addition, db-cAMP increased the cytotoxicity of temozolomide and teniposide, possibly by downregulating the Bcl-2 expression and inducing apoptosis. Teniposide 80-90 BCL2 apoptosis regulator Homo sapiens 123-128 22766741-10 2012 Taken together, we demonstrated the beneficial effect of db-cAMP in treating medulloblastoma depending on the upregulation of BE and chemosensitivity through Cx43 and Bcl-2-mediated pathways. Bucladesine 57-64 BCL2 apoptosis regulator Homo sapiens 179-184 22796323-10 2012 Western blot results showed that dryofragin inhibited Bcl-2 and induced Bax expression which led to an activation of caspases-9 and -3 in the cytosol, and further cleavage of poly ADP-ribose polymerase (PARP) in the nucleus, then induced cell apoptosis. ((4-(4-amidinophenoxy)butanoyl)aspartyl)valine 33-43 BCL2 apoptosis regulator Homo sapiens 54-59 22860996-8 2012 Using Western blotting, we observed that allicin decreased the level of cytoplasmic p53, the PI3K/mTOR signaling pathway, and the level of Bcl-2 and increased the expression of AMPK/TSC2 and Beclin-1 signaling pathways in Hep G2 cells. allicin 41-48 BCL2 apoptosis regulator Homo sapiens 139-144 22920753-0 2012 Knock-down of NDRG2 sensitizes cervical cancer Hela cells to cisplatin through suppressing Bcl-2 expression. Cisplatin 61-70 BCL2 apoptosis regulator Homo sapiens 91-96 22920753-15 2012 CONCLUSIONS: These data suggested that down-regulation of NDRG2 could enhance sensitivity of Hela cells to cisplatin through inhibiting Bcl-2 protein expression, which might be mediated by up-regulating miR-15b and miR-16. Cisplatin 107-116 BCL2 apoptosis regulator Homo sapiens 136-141 22766626-6 2012 We found that zinc(II) ions caused elevated expression of Ki-67, a marker of proliferation, extremely low expression of p53, high expression of Bcl-2 and no changes in the expression of p53. Zinc 14-22 BCL2 apoptosis regulator Homo sapiens 168-173 20884251-9 2012 Bcl-2 apoptotic pathway induction by BCG and sunitinib treatment was evaluated by Western blotting method. Sunitinib 45-54 BCL2 apoptosis regulator Homo sapiens 0-5 20884251-15 2012 Furthermore, the bcl-2 expression was significant reduced in T24 cells in metachronous BCG and sunitinib combination treatment than single agent. Sunitinib 95-104 BCL2 apoptosis regulator Homo sapiens 17-22 23236760-6 2012 RESULT: Compared with the model group, various concentrations of paeonol (1, 5, 10 micromol x L(-1)) significantly reduced the hippocampal neurons karyopycnosis, decreased the rate of SH-SY5Y cell apoptosis to 22.4%, 18.1% and 16.4%, respectively, and improved the expressions of BDNF and Bcl-2 mRNA. paeonol 65-72 BCL2 apoptosis regulator Homo sapiens 289-294 23236760-7 2012 CONCLUSION: Paeonol relieves Abeta1-42 oligomer-induced neuron injury by increasing BDNF and Bcl-2 expressions. paeonol 12-19 BCL2 apoptosis regulator Homo sapiens 93-98 22898329-1 2012 BH3 mimetics such as ABT-737 and navitoclax bind to the BCL-2 family of proteins and induce apoptosis through the intrinsic apoptosis pathway. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 56-61 22898329-5 2012 We discuss how the expression of BCL-2 family proteins regulates the sensitivity to ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 84-87 BCL2 apoptosis regulator Homo sapiens 33-38 22898329-1 2012 BH3 mimetics such as ABT-737 and navitoclax bind to the BCL-2 family of proteins and induce apoptosis through the intrinsic apoptosis pathway. ABT-737 21-28 BCL2 apoptosis regulator Homo sapiens 56-61 22898329-1 2012 BH3 mimetics such as ABT-737 and navitoclax bind to the BCL-2 family of proteins and induce apoptosis through the intrinsic apoptosis pathway. navitoclax 33-43 BCL2 apoptosis regulator Homo sapiens 56-61 22693249-6 2012 Mechanistic investigations revealed that flavopiridol inhibited Mcl-1 transcription but increased transcription of Bim and its binding to Bcl-2/Bcl-xL. alvocidib 41-53 BCL2 apoptosis regulator Homo sapiens 138-143 22689920-4 2012 The BH3 mimetic ABT-737 displaced PARP1 from BCL2 in a dose-dependent manner, reestablishing PARP1 activity and DNA repair and promoting nonapoptotic cell death. BH 3 4-7 BCL2 apoptosis regulator Homo sapiens 45-49 22580047-0 2012 Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells. LCL161 39-45 BCL2 apoptosis regulator Homo sapiens 14-19 22689920-4 2012 The BH3 mimetic ABT-737 displaced PARP1 from BCL2 in a dose-dependent manner, reestablishing PARP1 activity and DNA repair and promoting nonapoptotic cell death. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 16-19 BCL2 apoptosis regulator Homo sapiens 45-49 22689920-5 2012 This form of cell death was unaffected by resistance to single-agent ABT-737 that results from upregulation of antiapoptotic BCL2 family members. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 69-72 BCL2 apoptosis regulator Homo sapiens 125-129 22689920-7 2012 Strikingly, BCL2 expression reduced the survival of PARP inhibitor-sensitive breast cancer and lung cancer cells by 90% to 100%, and these effects were reversed by ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 164-167 BCL2 apoptosis regulator Homo sapiens 12-16 22693249-1 2012 BH3 mimetic drugs induce cell death by antagonizing the activity of antiapoptotic Bcl-2 family proteins. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 82-87 22739412-0 2012 Involvement of NF-kappaB and Bcl2/Bax signaling pathways in the apoptosis of MCF7 cells induced by a xanthone compound Pyranocycloartobiloxanthone A. xanthone 101-109 BCL2 apoptosis regulator Homo sapiens 29-33 22739412-0 2012 Involvement of NF-kappaB and Bcl2/Bax signaling pathways in the apoptosis of MCF7 cells induced by a xanthone compound Pyranocycloartobiloxanthone A. pyranocycloartobiloxanthone A 119-148 BCL2 apoptosis regulator Homo sapiens 29-33 22739412-11 2012 Treatment of MCF7 cells with PA induced apoptosis with cell death-transducing signals, that regulate the MMP by down-regulation of Bcl2 and up-regulation of Bax, triggering the cytochrome c release from mitochondria to cytosol. pyranocycloartobiloxanthone A 29-31 BCL2 apoptosis regulator Homo sapiens 131-135 22739412-14 2012 The results demonstrated that PA induced apoptosis of MCF7 cells through NF-kappaB and Bcl2/Bax signaling pathways with the involvement of caspases. pyranocycloartobiloxanthone A 30-32 BCL2 apoptosis regulator Homo sapiens 87-91 22843880-9 2012 Moreover, beta-elemene triggered apoptosis and irreversible cell death in both sensitive and resistant ovarian cancer cells via the activation of caspase-3, -8 and 9; the loss of mitochondrial membrane potential (deltaPsim); the release of cytochrome c into the cytosol; and changes in the expression of BCL-2 family proteins. beta-elemene 10-22 BCL2 apoptosis regulator Homo sapiens 304-309 22771858-7 2012 Furthermore, ameliorating of ERK, JNK and Bcl-2 family-related apoptotic signaling pathways were also involved in the neuroprotection of hyperoside. hyperoside 137-147 BCL2 apoptosis regulator Homo sapiens 42-47 22687606-6 2012 In SKOV-3 cells DMU-212 caused up-regulation of pro-apoptotic Bax, Apaf-1 and p53 genes, specific to intrinsic pathway of apoptosis, and a decrease in Bcl-2 and Bcl 2110 mRNA expressions. dmu 16-19 BCL2 apoptosis regulator Homo sapiens 151-156 22875003-1 2012 The novel anticancer drug ABT-737 is a Bcl-2 Homology 3 (BH3)-mimetic that induces apoptosis by inhibiting pro-survival Bcl-2 proteins. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 26-29 BCL2 apoptosis regulator Homo sapiens 39-44 22875003-1 2012 The novel anticancer drug ABT-737 is a Bcl-2 Homology 3 (BH3)-mimetic that induces apoptosis by inhibiting pro-survival Bcl-2 proteins. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 26-29 BCL2 apoptosis regulator Homo sapiens 120-125 22875003-1 2012 The novel anticancer drug ABT-737 is a Bcl-2 Homology 3 (BH3)-mimetic that induces apoptosis by inhibiting pro-survival Bcl-2 proteins. BH 3 57-60 BCL2 apoptosis regulator Homo sapiens 39-44 22875003-1 2012 The novel anticancer drug ABT-737 is a Bcl-2 Homology 3 (BH3)-mimetic that induces apoptosis by inhibiting pro-survival Bcl-2 proteins. BH 3 57-60 BCL2 apoptosis regulator Homo sapiens 120-125 22875003-2 2012 ABT-737 binds with equal affinity to Bcl-2, Bcl-xL and Bcl-w in vitro and is expected to overrule apoptosis resistance mediated by these Bcl-2 proteins in equal measure. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 37-42 22875003-2 2012 ABT-737 binds with equal affinity to Bcl-2, Bcl-xL and Bcl-w in vitro and is expected to overrule apoptosis resistance mediated by these Bcl-2 proteins in equal measure. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 137-142 22875003-3 2012 We have profiled ABT-737 specificity for all six pro-survival Bcl-2 proteins, in p53 wild-type or p53-mutant human T-leukemic cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 17-20 BCL2 apoptosis regulator Homo sapiens 62-67 22875003-5 2012 However, Bcl-2 proved a better ABT-737 target than Bcl-xL and Bcl-w. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 31-34 BCL2 apoptosis regulator Homo sapiens 9-14 22875003-9 2012 These data identify Bcl-B, Bfl-1 and Mcl-1, but also Bcl-xL and Bcl-w as potential mediators of ABT-737 resistance and indicate that target proteins can be differentially sensitive to BH3-mimetics, depending on the pro-apoptotic Bcl-2 proteins they are complexed with. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 96-99 BCL2 apoptosis regulator Homo sapiens 229-234 22484386-0 2012 Mood stabilizers commonly restore staurosporine-induced increase of p53 expression and following decrease of Bcl-2 expression in SH-SY5Y cells. Staurosporine 34-47 BCL2 apoptosis regulator Homo sapiens 109-114 22484386-8 2012 Therefore, p53 and Bcl-2 can be considered to mediate the common anti-apoptotic effects of Li, VPA, CBZ and LTG. Carbamazepine 100-103 BCL2 apoptosis regulator Homo sapiens 19-24 22395444-7 2012 Reactive oxygen species triggered a decrease in mitochondria membrane potential and an increase in the ratio of Bax/Bcl2 leading to mitochondria mediated pathway involved in apoptosis. Reactive Oxygen Species 0-23 BCL2 apoptosis regulator Homo sapiens 116-120 22607196-6 2012 The synergistic effect of 5-FU induced by oroxylin A was also found in the suppression of Bcl-2 and in the activation of P53, Bax, PARP, and procaspase-3 proteins in HT-29 cells. Fluorouracil 26-30 BCL2 apoptosis regulator Homo sapiens 90-95 22607196-6 2012 The synergistic effect of 5-FU induced by oroxylin A was also found in the suppression of Bcl-2 and in the activation of P53, Bax, PARP, and procaspase-3 proteins in HT-29 cells. 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one 42-52 BCL2 apoptosis regulator Homo sapiens 90-95 22648782-5 2012 Downregulation of TLR4 using small-interference RNA sensitized PC-3 cells to docetaxel-induced apoptosis as determined by annexin V staining and poly (ADP-ribose) polymerase cleavage, which was coupled with increased Bax expression and decreased Bcl-2. Docetaxel 77-86 BCL2 apoptosis regulator Homo sapiens 246-251 22684875-8 2012 We also observed higher BCL2 mRNA expression in 19 of 20 KCOT frozen samples and moderate to high Bcl-2 immunopositivity in the basal layer cells of 16 of 18 paraffin embedded KCOTs (median: 42.6 %). Paraffin 158-166 BCL2 apoptosis regulator Homo sapiens 98-103 22491967-0 2012 Differential effects of Bcl-2 and caspases on mitochondrial permeabilization during endogenous or exogenous reactive oxygen species-induced cell death: a comparative study of H2O2, paraquat, t-BHP, etoposide and TNF-alpha-induced cell death. Reactive Oxygen Species 108-131 BCL2 apoptosis regulator Homo sapiens 24-29 22491967-2 2012 Our aim was to characterize relationships that exist between ROS, mitochondrial perturbations, Bcl-2 and caspases, depending on source and identity of ROS. Reactive Oxygen Species 151-154 BCL2 apoptosis regulator Homo sapiens 95-113 22491967-5 2012 Second, we have highlighted that during etoposide or TNF-alpha treatments, intracellular ROS level, MMP and cell death are all regulated by caspases and Bcl-2, with caspases acting early in the process. Etoposide 40-49 BCL2 apoptosis regulator Homo sapiens 153-158 22491967-5 2012 Second, we have highlighted that during etoposide or TNF-alpha treatments, intracellular ROS level, MMP and cell death are all regulated by caspases and Bcl-2, with caspases acting early in the process. Reactive Oxygen Species 89-92 BCL2 apoptosis regulator Homo sapiens 153-158 22491967-8 2012 On the one hand, these results show that endogenous or exogenous ROS can trigger multiple cell death pathways with Bcl-2 and caspases acting differentially. Reactive Oxygen Species 65-68 BCL2 apoptosis regulator Homo sapiens 115-133 22573342-10 2012 RAP80 siRNA combined with gemcitabine significantly increased (P < 0.01) apoptosis of pancreatic cancer cell lines SW1990 and Capan-2, increased expression of Bax mRNA, reduced Bcl-2 mRNA expression (P < 0.01), and slightly increased TRAIL mRNA expression (P < 0.01). gemcitabine 26-37 BCL2 apoptosis regulator Homo sapiens 180-185 24750915-3 2012 The results demonstrated that C. kwangsiensis polysaccharides can significantly inhibit the proliferation of CNE-2 cells, which was possibly through the induction of apoptosis mediated by attenuating Bcl-2 expression and promoting p53 expression. Polysaccharides 46-61 BCL2 apoptosis regulator Homo sapiens 200-205 22465296-1 2012 The anti-cancer effects of bryostatin-1, a potent diacylglycerol analogue, have traditionally been attributed to its action on protein kinase C. However, we previously documented apoptosis in a B non-Hodgkin lymphoma cell line involving diacylglycerol analogue stimulation of Ras guanyl-releasing protein, a Ras activator, and Bim, a proapoptotic Bcl-2 family protein. bryostatin 1 27-39 BCL2 apoptosis regulator Homo sapiens 347-352 22931245-0 2012 Growth inhibition and chemosensitization of human carcinoma cells by human serum albumin-coated liposomal antisense oligodeoxyribonucleotide against bcl-2. Oligodeoxyribonucleotides 116-140 BCL2 apoptosis regulator Homo sapiens 149-154 22931245-1 2012 Previous study has shown human serum albumin (HSA) coated liposomes can deliver bcl-2 antisense oligodeoxyribonucleotide (ODN) into KB carcinoma cells, and decrease bcl-2 mRNA and protein expression level. Oligodeoxyribonucleotides 96-120 BCL2 apoptosis regulator Homo sapiens 80-85 22931245-1 2012 Previous study has shown human serum albumin (HSA) coated liposomes can deliver bcl-2 antisense oligodeoxyribonucleotide (ODN) into KB carcinoma cells, and decrease bcl-2 mRNA and protein expression level. Oligodeoxyribonucleotides 122-125 BCL2 apoptosis regulator Homo sapiens 80-85 22931245-3 2012 Liposomes composed of dimethyldioctadecyl ammonium bromide/egg phosphatidylcholine/alpha-tocopheryl polyethylene glycol 1000 succinate (58:40:2 molar ratio) complexed with bcl-2 antisense ODN and coated with HSA were examined for cell growth inhibition and sensitization to a commonly used chemotherapeutic drug, doxorubicin. dimethyldioctadecylammonium 22-58 BCL2 apoptosis regulator Homo sapiens 172-177 22931245-3 2012 Liposomes composed of dimethyldioctadecyl ammonium bromide/egg phosphatidylcholine/alpha-tocopheryl polyethylene glycol 1000 succinate (58:40:2 molar ratio) complexed with bcl-2 antisense ODN and coated with HSA were examined for cell growth inhibition and sensitization to a commonly used chemotherapeutic drug, doxorubicin. tocophersolan 83-134 BCL2 apoptosis regulator Homo sapiens 172-177 22673012-3 2012 It has been shown that resveratrol inhibits the activation of Nf-kappaB and subsequently down regulates the expression of Nf-kappaB regulated genes such as interleukin-2 and Bcl-2, leading to cell cycle arrest and increased apoptosis in multiple myeloma cells. Resveratrol 23-34 BCL2 apoptosis regulator Homo sapiens 174-179 21547369-6 2012 DHA exposure caused early upregulation of the BH3-only protein NOXA, a proapototic member of the Bcl2 family encoded by PMAIP1, and genetic antagonism (siRNA targeting PMAIP1) rescued melanoma cells from apoptosis indicating a causative role of NOXA-upregulation in DHA-induced melanoma cell death. artenimol 0-3 BCL2 apoptosis regulator Homo sapiens 97-101 22852476-0 2012 Regulation of c-Myc and Bcl-2 induced apoptosis of human bronchial epithelial cells by zinc oxide nanoparticles. Zinc Oxide 87-97 BCL2 apoptosis regulator Homo sapiens 24-29 22852476-5 2012 It demonstrated that following the exposure of 16HBE cells to ZnO NPs, both levels of mRNA and protein expression of c-Myc were significantly up-regulated, whereas the expressions of Bcl-2 mRNA and protein were down-regulated. Zinc Oxide 62-65 BCL2 apoptosis regulator Homo sapiens 183-188 22852476-6 2012 Our results suggested that apoptosis induced by ZnO NPs might primarily involve the regulations of c-Myc and Bcl-2 gene expressions besides decline of MMP in 16HBE cells. Zinc Oxide 48-51 BCL2 apoptosis regulator Homo sapiens 109-114 21850491-3 2012 From an initial analysis of MDMA analogues synthesized with a modified alpha-substituent, it was found that incorporating a phenyl group increased potency against sensitive, Bcl-2-deplete, Burkitt"s lymphoma (BL) cells 10-fold relative to MDMA. N-Methyl-3,4-methylenedioxyamphetamine 28-32 BCL2 apoptosis regulator Homo sapiens 174-179 21850491-11 2012 In conclusion, MDMA analogues have been discovered with enhanced cytotoxic efficacy against lymphoma subtypes amongst which high-level Bcl-2--often a barrier to drug performance for this indication--fails to protect. N-Methyl-3,4-methylenedioxyamphetamine 15-19 BCL2 apoptosis regulator Homo sapiens 135-140 22617428-9 2012 SL-01 also increased Bax/Bcl-2 ratio in cancer cells. dodecyl-3-((1-(3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamoyl)pyrazine-2-carboxylate 0-5 BCL2 apoptosis regulator Homo sapiens 25-30 22573016-9 2012 Using RT-PCR, EGCG treatment induced a significant anti-apoptotic effect in injured muscle tissues by normalizing the Bax/Bcl-2 ratio back to baseline levels and inhibiting overexpression of the p53 apoptotic gene at days 3 and 7 post-surgery. epigallocatechin gallate 14-18 BCL2 apoptosis regulator Homo sapiens 122-127 22342440-7 2012 The colchicine-induced loss of mitochondrial membrane potential, activation of caspase-3 and 9, up-regulation of Bax and down-regulation of Bcl-2 showed an evidence for the colchicine activity on apoptosis, at least, by acting via the intrinsic apoptotic pathway. Colchicine 4-14 BCL2 apoptosis regulator Homo sapiens 140-145 22342440-7 2012 The colchicine-induced loss of mitochondrial membrane potential, activation of caspase-3 and 9, up-regulation of Bax and down-regulation of Bcl-2 showed an evidence for the colchicine activity on apoptosis, at least, by acting via the intrinsic apoptotic pathway. Colchicine 173-183 BCL2 apoptosis regulator Homo sapiens 140-145 23015779-5 2012 It was found that the apoptosis induced by 11-dehydrosinulariolide is relevant to mitochondrial-mediated apoptosis via caspase-dependent pathways, elucidated by loss of mitochondrial membrane potential ( Psim), release of cytochrome C, activation of caspase-3/-9 and Bax as well as suppression of Bcl-2/Bcl-xL. 11-dehydrosinulariolide 43-66 BCL2 apoptosis regulator Homo sapiens 297-302 23167183-6 2012 EGCG could suppress the expression of Bcl-2 and induce expression of Bax, Caspase-3. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 38-43 22565596-9 2012 Gene clustering analysis by STRING showed that most of the glucose stress-modulated genes were components of the intrinsic/mitochondrial apoptotic pathway including Bcl-2, Caspases and apoptosis executors. Glucose 59-66 BCL2 apoptosis regulator Homo sapiens 165-170 22931640-11 2012 It is concluded that baicalin can significantly inhibit the proliferation of HL-60 cells and induce the apoptosis of HL-60 cells, which may occur through decreasing Bcl-2/Bax ratio by intrinsic pathway and through extrinsic pathway. baicalin 21-29 BCL2 apoptosis regulator Homo sapiens 165-170 22687635-5 2012 Further research revealed that Baohuoside I accelerated apoptosis through the mitochondrial apoptotic pathway, involving the increment of BAX/Bcl-2 ratio, dissipation of mitochondrial membrane potential, transposition of cytochrome c, caspase 3 and caspase 9 activation, degradation of poly (ADP-ribose) polymerase and the over-production of reactive oxygen species (ROS). baohuoside I 31-43 BCL2 apoptosis regulator Homo sapiens 142-147 22825467-3 2012 BIM (BCL-2-interacting mediator of cell death), a BCL-2 homology 3-only pro-apoptotic protein, is upregulated by dexamethasone (Dex) treatment in acute lymphoblastic leukemia cells and has an essential role in Dex-induced apoptosis. Dexamethasone 113-126 BCL2 apoptosis regulator Homo sapiens 5-10 22702834-0 2012 In silico and in vitro elucidation of BH3 binding specificity toward Bcl-2. BH 3 38-41 BCL2 apoptosis regulator Homo sapiens 69-74 22944278-7 2012 RESULTS: Curcumin reduced the FeNTA-induced hepatocytic apoptosis by 46.65% and significantly down-regulated the protein levels of Bcl-2 and Bcl-XL. Curcumin 9-17 BCL2 apoptosis regulator Homo sapiens 131-136 22704995-8 2012 Western blot assay showed that Bax, Bcl-2 and NF-kappaBp65 might be implicated in L-NNP-induced selective HepG2 cell death. l-nnp 82-87 BCL2 apoptosis regulator Homo sapiens 36-41 22833097-6 2012 U937Bcl-2 transfectants, highly expressing Bcl-2, were reluctant to undergo apoptosis even following treatment with 500 muM D(-)lentiginosine, whereas apoptosis by D(-)lentiginosine was induced also in U937 cells, naturally deficient in P53. lentiginosine 125-141 BCL2 apoptosis regulator Homo sapiens 4-9 22833097-6 2012 U937Bcl-2 transfectants, highly expressing Bcl-2, were reluctant to undergo apoptosis even following treatment with 500 muM D(-)lentiginosine, whereas apoptosis by D(-)lentiginosine was induced also in U937 cells, naturally deficient in P53. lentiginosine 125-141 BCL2 apoptosis regulator Homo sapiens 43-48 22833097-6 2012 U937Bcl-2 transfectants, highly expressing Bcl-2, were reluctant to undergo apoptosis even following treatment with 500 muM D(-)lentiginosine, whereas apoptosis by D(-)lentiginosine was induced also in U937 cells, naturally deficient in P53. lentiginosine 126-141 BCL2 apoptosis regulator Homo sapiens 4-9 22833097-6 2012 U937Bcl-2 transfectants, highly expressing Bcl-2, were reluctant to undergo apoptosis even following treatment with 500 muM D(-)lentiginosine, whereas apoptosis by D(-)lentiginosine was induced also in U937 cells, naturally deficient in P53. lentiginosine 126-141 BCL2 apoptosis regulator Homo sapiens 43-48 22825467-3 2012 BIM (BCL-2-interacting mediator of cell death), a BCL-2 homology 3-only pro-apoptotic protein, is upregulated by dexamethasone (Dex) treatment in acute lymphoblastic leukemia cells and has an essential role in Dex-induced apoptosis. Dexamethasone 128-131 BCL2 apoptosis regulator Homo sapiens 5-10 22825467-3 2012 BIM (BCL-2-interacting mediator of cell death), a BCL-2 homology 3-only pro-apoptotic protein, is upregulated by dexamethasone (Dex) treatment in acute lymphoblastic leukemia cells and has an essential role in Dex-induced apoptosis. Dexamethasone 210-213 BCL2 apoptosis regulator Homo sapiens 5-10 22825469-6 2012 Gx15-070, a pan-BCL2 inhibitor, induced autophagy-dependent necroptosis in TET cells via a mechanism involving mTOR pathways, and inhibited TET xenograft growth. obatoclax 0-8 BCL2 apoptosis regulator Homo sapiens 16-20 22825469-7 2012 ABT263, an inhibitor of BCL2/BCL-XL/BCL-W, reduced proliferation in TET cells when administered in combination with sorafenib, a tyrosine kinase inhibitor able to downregulate MCL1. navitoclax 0-6 BCL2 apoptosis regulator Homo sapiens 24-28 22825469-7 2012 ABT263, an inhibitor of BCL2/BCL-XL/BCL-W, reduced proliferation in TET cells when administered in combination with sorafenib, a tyrosine kinase inhibitor able to downregulate MCL1. Sorafenib 116-125 BCL2 apoptosis regulator Homo sapiens 24-28 22739087-0 2012 Structure-based design of rhodanine-based acylsulfonamide derivatives as antagonists of the anti-apoptotic Bcl-2 protein. Rhodanine 26-35 BCL2 apoptosis regulator Homo sapiens 107-112 22739413-10 2012 RESULTS: The results suggests that DADS decreases the survival rate of androgen independent prostate cancer cells by modulating the expression of IGF system, which leads to inhibition of phosphorylation of Akt, thereby inhibits cell cycle progression and survival by lowering the expression of cyclin D1, NFkB and anti-apoptotic Bcl-2 molecule and increasing the level of pro-apoptotic (Bad and Bax) signaling molecules which leads to apoptosis. diallyl disulfide 35-39 BCL2 apoptosis regulator Homo sapiens 329-334 22739087-0 2012 Structure-based design of rhodanine-based acylsulfonamide derivatives as antagonists of the anti-apoptotic Bcl-2 protein. acylsulfonamide 42-57 BCL2 apoptosis regulator Homo sapiens 107-112 22739087-1 2012 A series of novel rhodanine-based acylsulfonamide derivatives were designed, synthesized, and evaluated as small-molecule inhibitors of anti-apoptotic Bcl-2 protein. Rhodanine 18-27 BCL2 apoptosis regulator Homo sapiens 151-156 22739087-1 2012 A series of novel rhodanine-based acylsulfonamide derivatives were designed, synthesized, and evaluated as small-molecule inhibitors of anti-apoptotic Bcl-2 protein. acylsulfonamide 34-49 BCL2 apoptosis regulator Homo sapiens 151-156 22764103-0 2012 Granzyme B triggers a prolonged pressure to die in Bcl-2 overexpressing cells, defining a window of opportunity for effective treatment with ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 141-144 BCL2 apoptosis regulator Homo sapiens 51-56 22735663-11 2012 Western blot data revealed that EUE inhibited H(2)O(2)-induced up- or down-regulation of cleaved PARP, cleaved caspase-3, Bcl-2, and Bcl-xL. h(2)o 46-51 BCL2 apoptosis regulator Homo sapiens 122-127 22747598-2 2012 We have designed and optimized a class of small-molecule inhibitors of Bcl-2 and Bcl-xL containing a 4,5-diphenyl-1H-pyrrole-3-carboxylic acid core structure. 4,5-diphenyl-1H-pyrrole-3-carboxylic Acid 101-142 BCL2 apoptosis regulator Homo sapiens 71-76 22764103-2 2012 Drugs that neutralise Bcl-2 (e.g., ABT-737) may therefore be effective adjuvants for immunotherapeutic strategies that use CL to kill cancer cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 35-38 BCL2 apoptosis regulator Homo sapiens 22-27 22764103-3 2012 Consistent with this we found that ABT-737 effectively restored MOMP in Bcl-2 overexpressing cells treated with GraB or natural killer cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 35-38 BCL2 apoptosis regulator Homo sapiens 72-77 22112969-0 2012 Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. gossypol acetic acid 86-92 BCL2 apoptosis regulator Homo sapiens 117-122 22112969-1 2012 BACKGROUND: AT-101 (A), a small molecule oral inhibitor of the Bcl-2 family, has activity alone and in combination with docetaxel (Taxotere) and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC). gossypol acetic acid 12-18 BCL2 apoptosis regulator Homo sapiens 63-68 22758641-4 2012 The proapoptotic activity of quercetin in cell lines and B-CLL is related to the expression and activity of Mcl-1-antiapoptotic proteins belonging to the Bcl-2 family. Quercetin 29-38 BCL2 apoptosis regulator Homo sapiens 154-159 22526619-5 2012 We then found that both caspase-3 and caspase-9 were activated, the expression of Bcl-2 protein decreased, and the expression of Bax protein increased after treatment with oroxylin A. 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one 172-182 BCL2 apoptosis regulator Homo sapiens 82-87 22314265-9 2012 Thus, the results indicate that regulation of the antiapoptotic and proapoptotic Bcl-2 family members Noxa and Mcl-1 is predicative of the effectiveness of the combination of MG-132 with different anticancer agents on apoptosis induction in pancreatic cancer cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 175-181 BCL2 apoptosis regulator Homo sapiens 81-86 22469656-8 2012 The results of the assays on the action mechanism of COS show that it is capable of inhibiting the LPS-induced decrease of the Bcl-2/Bax ratio, increase of caspase-3 and activation of BKCa. carbonyl sulfide 53-56 BCL2 apoptosis regulator Homo sapiens 127-132 22562580-7 2012 In addition, siRNA against NOX3 reduced apoptosis as demonstrated by TUNEL staining, and prevented the increased expression of Bax and abrogated the decrease in Bcl2 expression following cisplatin administration. Cisplatin 187-196 BCL2 apoptosis regulator Homo sapiens 161-165 22822525-6 2012 In this study sclerotiorin has been found to induce apoptosis in colon cancer (HCT-116) cells through the activation of BAX, and down-regulation of BCL-2, those further activated cleaved caspase-3 causing apoptosis of cancer cells. sclerotiorin 14-26 BCL2 apoptosis regulator Homo sapiens 148-153 22395446-8 2012 NNM-25 inhibited the PARP-1 activity, AKT phosphorylation, up-regulated the protein expression of p53, Bad, and mTOR as well as down-regulating the protein expression of Bcl-2 and decreasing mitochondrial membrane potential. nnm-25 0-6 BCL2 apoptosis regulator Homo sapiens 170-175 22753740-5 2012 Molecular analysis suggested that DHS inhibited cathepsin-mediated pro-survival signaling [pAKT: phosphorylated protein kinase B; BCL-2: B-cell lymphoma 2 and cyclin D1] and induced pro-apoptotic markers such as BAX [BCL-2-associated X protein] and cleaved caspase-3. methyl 8-(3-furyl)-2a,4,5,5a,6,6a,8,9,9a,10a,10b,10c-dodecahydro-3-hydroxy-2a,5a,6a,7-tetramethyl-5-(3-methylbut-2-enoyloxy)-2H,3H-cyclopenta(4',5')furo(2',3'-6,5)benzo(cd)isobenzofuran-6-acetate 34-37 BCL2 apoptosis regulator Homo sapiens 130-135 22348919-8 2012 Additionally, 5-epi-sinuleptolide induced apoptosis by mitochondria-mediated cytochrome c and Bax up-expression, down-regulated Bcl-2, and activated caspase-9 and -3. 5-episinuleptolide 14-33 BCL2 apoptosis regulator Homo sapiens 128-133 22801507-10 2012 Furthermore, treatment of these cells with HO-3867 resulted in decreased expression of pTyr705 and its downstream targets cyclin D1, Bcl-2 and survivin. ptyr705 87-94 BCL2 apoptosis regulator Homo sapiens 133-138 21591240-4 2012 Safrole-induced apoptosis was accompanied with up-regulation of the protein expression of Bax and Bid and down-regulation of the protein levels of Bcl-2 (up-regulation of the ratio of Bax/Bcl-2), resulting in cytochrome c release, promoted Apaf-1 level and sequential activation of caspase-9 and caspase-3 in a time-dependent manner. Safrole 0-7 BCL2 apoptosis regulator Homo sapiens 147-152 21591240-4 2012 Safrole-induced apoptosis was accompanied with up-regulation of the protein expression of Bax and Bid and down-regulation of the protein levels of Bcl-2 (up-regulation of the ratio of Bax/Bcl-2), resulting in cytochrome c release, promoted Apaf-1 level and sequential activation of caspase-9 and caspase-3 in a time-dependent manner. Safrole 0-7 BCL2 apoptosis regulator Homo sapiens 188-193 21796625-5 2012 EGCG inhibited cell proliferation and induced apoptosis by inhibiting the expression of Bcl-2 and XIAP and activating caspase-3. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 88-93 22807981-0 2012 Enhanced therapeutic efficacy of vitamin K2 by silencing BCL-2 expression in SMMC-7721 hepatocellular carcinoma cells. Vitamin K 2 33-43 BCL2 apoptosis regulator Homo sapiens 57-62 21928346-4 2012 Suberoylanilide hydroxamic acid (SAHA)-induced mitochondrial elongation in both Hep3B and Bcl-2-overexpressing Hep3B cells, apart from its apoptosis induction function. Vorinostat 0-31 BCL2 apoptosis regulator Homo sapiens 90-95 21928346-4 2012 Suberoylanilide hydroxamic acid (SAHA)-induced mitochondrial elongation in both Hep3B and Bcl-2-overexpressing Hep3B cells, apart from its apoptosis induction function. Vorinostat 33-37 BCL2 apoptosis regulator Homo sapiens 90-95 21769948-6 2012 Activation of p38 kinase also mediates 2ME induced Bax phosphorylated at Thr(167) after a 6 h treatment of 2ME, which in turn prevents formation of the Bcl-2-Bax heterodimer. Threonine 73-76 BCL2 apoptosis regulator Homo sapiens 152-157 22555976-4 2012 Quercetin caused leukemia cells apoptosis by decreasing the protein expression of PI3K and Bax, the inhibitory phosphorylation of Akt, the decreased levels of Bcl-2 protein and increased activations of caspase-2 and -3, and increased poly(ADP-ribose) polymerase cleavage. Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 159-164 22555976-5 2012 Our results indicate that the apoptotic processes caused by quercetin are mediated by the decrease of pAkt and Bcl-2 levels, the increase of Bax level, and the activation of caspase families in HL-60 cells. Quercetin 60-69 BCL2 apoptosis regulator Homo sapiens 111-116 22467215-7 2012 Importantly, Bcl-2 silencing sensitizes these cells to chemotherapy (cisplatin) suggesting a potential new therapeutic approach for treating breast cancers with HER2(+)-status. Cisplatin 69-78 BCL2 apoptosis regulator Homo sapiens 13-18 22411600-2 2012 AT-101, an (-)-enantiomer of gossypol, is a potent anticancer agent that is shown to be an inhibitor of Bcl-2/Bcl-XL. gossypol acetic acid 0-6 BCL2 apoptosis regulator Homo sapiens 104-109 22411600-2 2012 AT-101, an (-)-enantiomer of gossypol, is a potent anticancer agent that is shown to be an inhibitor of Bcl-2/Bcl-XL. Gossypol 29-37 BCL2 apoptosis regulator Homo sapiens 104-109 22212487-5 2012 CAD cells overexpressing wild-type PINK1 and treated with C2-ceramide showed lower percentages of depolarized mitochondria, lower expressions of Bax and higher expressions of Bcl-2 than non-transfected cells. N-acetylsphingosine 58-69 BCL2 apoptosis regulator Homo sapiens 175-180 22415852-8 2012 Moreover, CXB up-regulated the cell cycle negative regulator p21(CIP/WAF1) and the cell cycle positive regulator Cyclin A, blocked ERK1/2 phosphorylation, induced apoptotic factors (Bax and caspase-3) and reduced Bcl-2. Celecoxib 10-13 BCL2 apoptosis regulator Homo sapiens 213-218 22904681-8 2012 We have determined that Bcl2 is both necessary and sufficient to make the cells resistant to carboplatin. Carboplatin 93-104 BCL2 apoptosis regulator Homo sapiens 24-28 22904681-9 2012 We have also shown that Smad3 acts upstream to regulate the expression of Bcl2 specifically and, thus, sensitivity of the cells to carboplatin. Carboplatin 131-142 BCL2 apoptosis regulator Homo sapiens 74-78 22904681-11 2012 Collectively, these data suggest that loss of Smad3 expression in CSC-treated cells induces resistance to carboplatin by upregulating the expression of Bcl2. Carboplatin 106-117 BCL2 apoptosis regulator Homo sapiens 152-156 22552631-6 2012 Additionally, TSA induces expression of the pro-apoptotic protein Bax and decreases the expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL in both cell lines. trichostatin A 26-29 BCL2 apoptosis regulator Homo sapiens 154-159 22562377-11 2012 Additionally, curcumin reduced the activation levels of NF-kappaB in KCP-4 cells, and suppressed the expression levels of Bcl-2, Bcl-xL and survivin, which are apoptosis-related proteins regulated by NF-kappaB. Curcumin 14-22 BCL2 apoptosis regulator Homo sapiens 122-127 22445428-3 2012 Here we show that cisplatin induced several platelet apoptotic events including up-regulation of Bax and Bak, down-regulation of Bcl-2 and Bcl-X(L), mitochondrial translocation of Bax, mitochondrial inner transmembrane potential depolarization, caspase-3 activation and phosphatidylserine (PS) exposure. Cisplatin 18-27 BCL2 apoptosis regulator Homo sapiens 129-134 22608188-3 2012 These effects were coupled with upregulation of IL-10, TGF-beta, and BCL-2 in asbestos-exposed patients. Asbestos 78-86 BCL2 apoptosis regulator Homo sapiens 69-74 22608188-6 2012 The establishment of a continuously exposed subline to CR (MT-2CR) revealed resistance against CR-induced apoptosis and upregulation of the BCL-2/BAX ratio similar to that recorded for MT-2CB. Asbestos, Crocidolite 55-57 BCL2 apoptosis regulator Homo sapiens 140-145 22608188-6 2012 The establishment of a continuously exposed subline to CR (MT-2CR) revealed resistance against CR-induced apoptosis and upregulation of the BCL-2/BAX ratio similar to that recorded for MT-2CB. Asbestos, Crocidolite 63-65 BCL2 apoptosis regulator Homo sapiens 140-145 22446485-0 2012 Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Sorafenib 73-82 BCL2 apoptosis regulator Homo sapiens 14-19 23252279-6 2012 The activity and expression level of Caspase-3 were significantly increased when treated with galactosylated artemisinin for 36 h and 72 h. The expression of BAX was also increased markedly, while BCL-2 was reduced after treatment with the drug. artemisinin 109-120 BCL2 apoptosis regulator Homo sapiens 197-202 23252279-8 2012 CONCLUSION: Galactosylated artemisinin exhibits great antitumor activities, which may be ralated to triggering cytochrome C apoptotic pathway which mediated by BCL-2 family. artemisinin 27-38 BCL2 apoptosis regulator Homo sapiens 160-165 22261340-3 2012 Fisetin enhanced caspase-3 activation, downregulation of Bcl-2 and Mcl-1(L), and upregulation of Bax, Bim and Bad. fisetin 0-7 BCL2 apoptosis regulator Homo sapiens 57-62 22578158-8 2012 When gadd34, bcl-2, or bcl-xl is knocked down, apoptosis occurs in PEG-PE-treated normal cells. dioleoyl-N-(monomethoxypolyethylene glycol succinyl)phosphatidylethanolamine 67-73 BCL2 apoptosis regulator Homo sapiens 13-18 22446485-3 2012 Sorafenib triggered rapid and pronounced Mcl-1 down-regulation accompanied by enhanced binding of Bim to Bcl-2 and Bcl-xL, effects that were abolished by obatoclax coadministration. Sorafenib 0-9 BCL2 apoptosis regulator Homo sapiens 105-110 22446485-8 2012 These findings suggest that combining sorafenib with agents that inhibit Mcl-1 and Bcl-2/Bcl-xL such as obatoclax may represent a novel and potentially effective strategy in AML. Sorafenib 38-47 BCL2 apoptosis regulator Homo sapiens 83-88 22525702-1 2012 ABT-737 is a small molecule Bcl-2 homology (BH)-3 domain mimetic that binds to the Bcl-2 family proteins Bcl-2 and Bcl-xL and is currently under investigation in the clinic. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 28-33 22505651-7 2012 To study drug-induced apoptosis, we exposed tumor cells to navitoclax (ABT-263), an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, both in vitro and in vivo. navitoclax 71-78 BCL2 apoptosis regulator Homo sapiens 97-102 22469513-0 2012 Mitochondrial superoxide mediates doxorubicin-induced keratinocyte apoptosis through oxidative modification of ERK and Bcl-2 ubiquitination. Superoxides 14-24 BCL2 apoptosis regulator Homo sapiens 119-124 22469513-0 2012 Mitochondrial superoxide mediates doxorubicin-induced keratinocyte apoptosis through oxidative modification of ERK and Bcl-2 ubiquitination. Doxorubicin 34-45 BCL2 apoptosis regulator Homo sapiens 119-124 22469513-6 2012 The mechanism by which superoxide mediates the apoptotic effect of DOX was shown to involve downregulation of Bcl-2 through ubiquitin-proteasomal degradation. Superoxides 23-33 BCL2 apoptosis regulator Homo sapiens 110-115 22469513-6 2012 The mechanism by which superoxide mediates the apoptotic effect of DOX was shown to involve downregulation of Bcl-2 through ubiquitin-proteasomal degradation. Doxorubicin 67-70 BCL2 apoptosis regulator Homo sapiens 110-115 22469513-7 2012 Superoxide induces dephosphorylation of Bcl-2 through MAP kinase ERK1/2 inactivation, which promotes ubiquitination of Bcl-2. Superoxides 0-10 BCL2 apoptosis regulator Homo sapiens 40-45 22469513-7 2012 Superoxide induces dephosphorylation of Bcl-2 through MAP kinase ERK1/2 inactivation, which promotes ubiquitination of Bcl-2. Superoxides 0-10 BCL2 apoptosis regulator Homo sapiens 119-124 22525702-1 2012 ABT-737 is a small molecule Bcl-2 homology (BH)-3 domain mimetic that binds to the Bcl-2 family proteins Bcl-2 and Bcl-xL and is currently under investigation in the clinic. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 83-88 22608393-0 2012 Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonists. pyrazole 0-8 BCL2 apoptosis regulator Homo sapiens 55-60 22525702-1 2012 ABT-737 is a small molecule Bcl-2 homology (BH)-3 domain mimetic that binds to the Bcl-2 family proteins Bcl-2 and Bcl-xL and is currently under investigation in the clinic. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 83-88 22538851-3 2012 In human non-Hodgkin lymphomas, high expression of Bcl-2 but not Bcl-x(L) predicted sensitivity to ABT-263. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 99-102 BCL2 apoptosis regulator Homo sapiens 51-56 22608393-0 2012 Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonists. pyrimidine phenylacylsulfonamides 13-46 BCL2 apoptosis regulator Homo sapiens 55-60 22608393-1 2012 5-Butyl-1,4-diphenyl pyrazole and 2-amino-5-chloro pyrimidine acylsulfonamides were developed as potent dual antagonists of Bcl-2 and Bcl-xL. 5-butyl-1,4-diphenyl pyrazole 0-29 BCL2 apoptosis regulator Homo sapiens 124-129 22608393-1 2012 5-Butyl-1,4-diphenyl pyrazole and 2-amino-5-chloro pyrimidine acylsulfonamides were developed as potent dual antagonists of Bcl-2 and Bcl-xL. 2-amino-5-chloro pyrimidine acylsulfonamides 34-78 BCL2 apoptosis regulator Homo sapiens 124-129 22608961-0 2012 Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists. phenylacylsulfonamide 20-41 BCL2 apoptosis regulator Homo sapiens 57-62 22608961-1 2012 A series of phenylacylsulfonamides has been prepared as antagonists of Bcl-2/Bcl-xL. phenylacylsulfonamides 12-34 BCL2 apoptosis regulator Homo sapiens 71-76 22387880-7 2012 The chemosensitivity of SGC7901 (BGC823) cells to cisplatin increased significantly following the downregulation of Akt1 expression, which might be associated with the inactivation of the PI3K/Akt1 signaling pathway, followed by the induced expression of the pro-apoptotic protein Bax and a concomitant decrease of Bcl-2 expression. cisplatin 50-59 BCL2 apoptosis regulator Homo sapiens 315-320 22311471-8 2012 Moreover, 2-DCB and PA also induced Bax up-regulation, the reduction in Bcl-2 expression level, Bid cleavage and the release of cytochrome c from the mitochondria to the cytosol. 2-dodecylcyclobutanone 10-15 BCL2 apoptosis regulator Homo sapiens 72-77 22634008-5 2012 Further research revealed that IFN-alpha and sorafenib collaboratively regulated the expression levels of cell cycle-related proteins Cyclin A and Cyclin B as well as the pro-survival Bcl-2 family proteins Mcl-1, Bcl-2 and Bcl-X(L). Sorafenib 45-54 BCL2 apoptosis regulator Homo sapiens 184-189 22634008-5 2012 Further research revealed that IFN-alpha and sorafenib collaboratively regulated the expression levels of cell cycle-related proteins Cyclin A and Cyclin B as well as the pro-survival Bcl-2 family proteins Mcl-1, Bcl-2 and Bcl-X(L). Sorafenib 45-54 BCL2 apoptosis regulator Homo sapiens 213-218 22703841-3 2012 Moreover, the effects of their combination with the pro-apoptotic pharmacologic inhibitor of Bcl-2/Bcl-xL, ABT-737, have never been evaluated. ABT-737 107-114 BCL2 apoptosis regulator Homo sapiens 93-98 22703841-8 2012 Moreover, combining GSIXII treatment with ABT-737, a BH3-mimetic inhibitor of additional antiapoptotic proteins, such as Bcl-2 and Bcl-xL, leads to both a synergistic apoptotic response in breast cancer cells and to an inhibitory effect on mammosphere formation. ABT-737 42-49 BCL2 apoptosis regulator Homo sapiens 121-126 22703841-8 2012 Moreover, combining GSIXII treatment with ABT-737, a BH3-mimetic inhibitor of additional antiapoptotic proteins, such as Bcl-2 and Bcl-xL, leads to both a synergistic apoptotic response in breast cancer cells and to an inhibitory effect on mammosphere formation. BH 3 53-56 BCL2 apoptosis regulator Homo sapiens 121-126 22112972-0 2012 Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. Doxorubicin 36-47 BCL2 apoptosis regulator Homo sapiens 90-95 22112972-11 2012 By repairing the apoptotic machinery, we were able to sensitize chondrosarcoma cells to doxorubicin and cisplatin, indicating an important role for BCL-2 family members in chemoresistance and a promising new treatment strategy for inoperable chondrosarcoma. Doxorubicin 88-99 BCL2 apoptosis regulator Homo sapiens 148-153 22112972-11 2012 By repairing the apoptotic machinery, we were able to sensitize chondrosarcoma cells to doxorubicin and cisplatin, indicating an important role for BCL-2 family members in chemoresistance and a promising new treatment strategy for inoperable chondrosarcoma. Cisplatin 104-113 BCL2 apoptosis regulator Homo sapiens 148-153 22311471-8 2012 Moreover, 2-DCB and PA also induced Bax up-regulation, the reduction in Bcl-2 expression level, Bid cleavage and the release of cytochrome c from the mitochondria to the cytosol. Palmitic Acid 20-22 BCL2 apoptosis regulator Homo sapiens 72-77 22538851-4 2012 Moreover, we show that increasing Bcl-2 sensitized normal and transformed lymphoid cells to ABT-737 by elevating proapoptotic Bim. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 92-95 BCL2 apoptosis regulator Homo sapiens 34-39 22538851-6 2012 Cell-based protein redistribution assays unexpectedly revealed that ABT-737 disrupts Bcl-2/Bim complexes more readily than Bcl-x(L)/Bim or Bcl-w/Bim complexes. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 68-71 BCL2 apoptosis regulator Homo sapiens 85-90 22504301-2 2012 Overexpression of PLD1 or PLD2 increased Bcl-2 expression and phosphatidic acid (PA), the product of PLDs, also upregulated Bcl-2 expression. Phosphatidic Acids 62-79 BCL2 apoptosis regulator Homo sapiens 124-129 22429871-8 2012 Signal transduction studies showed that Dox markedly decreased mitochondrial membrane potential, disturbed Bcl-2 family protein balance, enhanced cytochrome c release in the cytosol, increased levels of Apaf1, caspase-9/3/8, FAS, cleaved PARP protein and ultimately led to apoptotic cell death. Doxorubicin 40-43 BCL2 apoptosis regulator Homo sapiens 107-112 22504301-2 2012 Overexpression of PLD1 or PLD2 increased Bcl-2 expression and phosphatidic acid (PA), the product of PLDs, also upregulated Bcl-2 expression. Phosphatidic Acids 81-83 BCL2 apoptosis regulator Homo sapiens 124-129 22575451-2 2012 Recently, the cAMP signaling system was found to modulate DNA-damaging agent-induced apoptosis by regulating the expression of Bcl-2 family proteins and inhibitors of apoptosis. Cyclic AMP 14-18 BCL2 apoptosis regulator Homo sapiens 127-132 22504301-8 2012 When signal transducer and activator of transcription 3 (STAT3) activity was blocked by a STAT3 specific siRNA, PA-induced Bcl-2 expression was remarkably decreased, suggesting that STAT3 is an essential transcription factor linking PLD to Bcl-2 upregulation. Phosphatidic Acids 112-114 BCL2 apoptosis regulator Homo sapiens 123-128 22592527-7 2012 In line with this notion, the depletion of anti-apoptotic proteins of the BCL-2 family sensitized TP53 (-/-) cells to the toxic effects of high-dose reversine. 2-(4-morpholinoanilino)-6-cyclohexylaminopurine 150-159 BCL2 apoptosis regulator Homo sapiens 74-79 22504301-8 2012 When signal transducer and activator of transcription 3 (STAT3) activity was blocked by a STAT3 specific siRNA, PA-induced Bcl-2 expression was remarkably decreased, suggesting that STAT3 is an essential transcription factor linking PLD to Bcl-2 upregulation. Phosphatidic Acids 112-114 BCL2 apoptosis regulator Homo sapiens 240-245 22448708-7 2012 Signal transduction studies showed that Dox markedly decreased mitochondrial membrane potential, disturbed Bcl-2 family protein balance, enhanced cytochrome c release in the cytosol, increased levels of Apaf1, caspase-9/3, cleaved PARP protein and ultimately led to apoptotic cell death. Doxorubicin 40-43 BCL2 apoptosis regulator Homo sapiens 107-112 22496272-2 2012 Nativoclax (ABT-263) is a potent and selective inhibitor of Bcl-2 and Bcl-x(L). nativoclax 0-10 BCL2 apoptosis regulator Homo sapiens 60-65 22496272-2 2012 Nativoclax (ABT-263) is a potent and selective inhibitor of Bcl-2 and Bcl-x(L). navitoclax 12-19 BCL2 apoptosis regulator Homo sapiens 60-65 22652645-6 2012 p-AKT, Bcl-2, and Bax expression was increased upon treatment with KH901, whereas the expression of caspase-3 was not induced upon treatment with KH901 with or without 5-FU. kh901 67-72 BCL2 apoptosis regulator Homo sapiens 7-12 23359768-9 2012 Zinc-citrate compound increased the expression of P21(waf1) and P53, and reduced the expression of Bcl-2 and Bcl-xL proteins but induced the expression of Bax protein. Zinc citrate 0-12 BCL2 apoptosis regulator Homo sapiens 99-104 21859781-7 2012 Furthermore, capsaicin induced increases in the ratio of Bax/Bcl-2 and abundance of apoptosis-related protein levels. Capsaicin 13-22 BCL2 apoptosis regulator Homo sapiens 61-66 22213475-6 2012 AIB1 regulated the expression of Bcl-2 in CCA cells through activating the Akt pathway as well as suppressing intracellular reactive oxygen species (ROS). Reactive Oxygen Species 124-147 BCL2 apoptosis regulator Homo sapiens 33-38 22213475-6 2012 AIB1 regulated the expression of Bcl-2 in CCA cells through activating the Akt pathway as well as suppressing intracellular reactive oxygen species (ROS). Reactive Oxygen Species 149-152 BCL2 apoptosis regulator Homo sapiens 33-38 22367066-3 2012 Exposure to MEMC was found to result in growth inhibition by the induction of caspase-dependent apoptosis in NCI-H460 cells, which correlated with upregulated expression of death receptor (DR)4, DR5 and FasL, downregulation of anti-apoptotic Bcl-2 and Bcl-xL expression, cleavage of Bid, and loss of mitochondrial membrane potential. Mercury, chloro(2-methoxyethyl)- 12-16 BCL2 apoptosis regulator Homo sapiens 278-283 22145750-7 2012 Bortezomib arrested the cell cycles of three cell lines at the G2/M stage, decreased BCL2 mRNA expression, but did not affect MDR1 mRNA levels. Bortezomib 0-10 BCL2 apoptosis regulator Homo sapiens 85-89 22286278-7 2012 Finally, by the bimolecular fluorescence complementation-fluorescence resonance energy transfer and co-immunoprecipitation assays, we found that procyanidin could inhibit the formation of the Atg5-Atg12/Atg16 heterotrimer and the dissociation of the beclin1/bcl2 heterodimer. procyanidin 145-156 BCL2 apoptosis regulator Homo sapiens 258-262 21382956-7 2012 Furthermore, SFN and eugenol combinations at synergistic dose significantly downregulated the expression of Bcl-2, COX-2 and IL-beta but not the antagonistic combinations. sulforaphane 13-16 BCL2 apoptosis regulator Homo sapiens 108-113 21382956-7 2012 Furthermore, SFN and eugenol combinations at synergistic dose significantly downregulated the expression of Bcl-2, COX-2 and IL-beta but not the antagonistic combinations. Eugenol 21-28 BCL2 apoptosis regulator Homo sapiens 108-113 21424700-6 2012 Cell death ensued despite RU-38486 caused transient up-regulation of anti-apoptotic Bcl-2, ORG-31710 induced transient up-regulation of inhibitor of apoptosis XIAP, and CDB-2914 up-regulated both XIAP and Bcl-2. Mifepristone 26-34 BCL2 apoptosis regulator Homo sapiens 84-89 21424700-6 2012 Cell death ensued despite RU-38486 caused transient up-regulation of anti-apoptotic Bcl-2, ORG-31710 induced transient up-regulation of inhibitor of apoptosis XIAP, and CDB-2914 up-regulated both XIAP and Bcl-2. ulipristal 169-177 BCL2 apoptosis regulator Homo sapiens 205-210 22622039-4 2012 We harnessed the natural killing activity of BCL-2-interacting mediator of cell death (BIM), which contains one of the most potent BH3 death domains of the BCL-2 protein family, to restore BH3-dependent cell death in resistant hematologic cancers. BH 3 131-134 BCL2 apoptosis regulator Homo sapiens 45-50 22622039-5 2012 A hydrocarbon-stapled peptide modeled after the BIM BH3 helix broadly targeted BCL-2 family proteins with high affinity, blocked inhibitory antiapoptotic interactions, directly triggered proapoptotic activity, and induced dose-responsive and BH3 sequence-specific cell death of hematologic cancer cells. Hydrocarbons 2-13 BCL2 apoptosis regulator Homo sapiens 79-84 22622039-5 2012 A hydrocarbon-stapled peptide modeled after the BIM BH3 helix broadly targeted BCL-2 family proteins with high affinity, blocked inhibitory antiapoptotic interactions, directly triggered proapoptotic activity, and induced dose-responsive and BH3 sequence-specific cell death of hematologic cancer cells. bim bh3 48-55 BCL2 apoptosis regulator Homo sapiens 79-84 22622039-5 2012 A hydrocarbon-stapled peptide modeled after the BIM BH3 helix broadly targeted BCL-2 family proteins with high affinity, blocked inhibitory antiapoptotic interactions, directly triggered proapoptotic activity, and induced dose-responsive and BH3 sequence-specific cell death of hematologic cancer cells. BH 3 52-55 BCL2 apoptosis regulator Homo sapiens 79-84 22622043-1 2012 A promising approach to cancer therapy is to elicit apoptosis with "BH3 mimetic" drugs, which target proteins of the BCL-2 family. BH 3 68-71 BCL2 apoptosis regulator Homo sapiens 117-122 21312071-4 2012 In vitro, PTH1R silencing suppressed cell proliferation and apoptosis induced by high levels of glucose by regulating Bax/Bcl-2 expression. Glucose 96-103 BCL2 apoptosis regulator Homo sapiens 122-127 22393246-3 2012 To understand the molecular basis for variable and relatively modest sensitivity to the Bcl-2 homology domain 3 mimetic drug ABT-737, the abundance of Bcl-2 family members was assayed in a panel of glioma cell lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 125-128 BCL2 apoptosis regulator Homo sapiens 88-93 22393247-9 2012 The combination of diltiazem and lactacystin also up-regulated the levels of Bik and released Bak from Bcl-xL, indicating the involvement of the Bcl2 family pathway in this apoptosis. Diltiazem 19-28 BCL2 apoptosis regulator Homo sapiens 145-149 22393247-9 2012 The combination of diltiazem and lactacystin also up-regulated the levels of Bik and released Bak from Bcl-xL, indicating the involvement of the Bcl2 family pathway in this apoptosis. lactacystin 33-44 BCL2 apoptosis regulator Homo sapiens 145-149 22054286-0 2012 Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma. Bortezomib 0-10 BCL2 apoptosis regulator Homo sapiens 52-57 22054286-5 2012 We investigated the association between the expression of anti-apoptotic members of the Bcl-2 family and the efficacy of bortezomib in patients with relapsed/refractory MM. Bortezomib 121-131 BCL2 apoptosis regulator Homo sapiens 88-93 22054286-8 2012 The association between Bcl-2 expression levels and clinical response was negated in bortezomib-treated patients (p = 0.014), while not so in dexamethasone-treated patients (p = 0.92). Bortezomib 85-95 BCL2 apoptosis regulator Homo sapiens 24-29 22054286-12 2012 Our data suggest that bortezomib may overcome the prognostic effect conferred by overexpression of some of the anti-apoptotic Bcl-2 family of genes in patients with relapsed/refractory MM. Bortezomib 22-32 BCL2 apoptosis regulator Homo sapiens 126-131 21573974-0 2012 Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR. Oligonucleotides 105-121 BCL2 apoptosis regulator Homo sapiens 139-144 22699051-9 2012 Compared with tunicamycin and cisplatin alone, the combined treatment significantly increased Bax expression and decreased Bcl-2 expression in the cells; tunicamycin up-regulated the expression of GRP-78 and enhanced the activity of caspase-3. Cisplatin 30-39 BCL2 apoptosis regulator Homo sapiens 123-128 22469952-7 2012 Curcumin (20 microM), bleomycin (400 microg/ml) and H2O2 (400 microM) incubation for 24 h decreased the viability of NTera-2 cells, and increased caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreased Bcl-2 levels. Bleomycin 22-31 BCL2 apoptosis regulator Homo sapiens 233-238 22469952-7 2012 Curcumin (20 microM), bleomycin (400 microg/ml) and H2O2 (400 microM) incubation for 24 h decreased the viability of NTera-2 cells, and increased caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreased Bcl-2 levels. Hydrogen Peroxide 52-56 BCL2 apoptosis regulator Homo sapiens 233-238 22820570-0 2012 [Protective effect of lentivirus-mediated Bcl-2 gene transfection against phosphoramide mustard-induced apoptosis of human ovarian granulosa cells]. phosphoramide mustard 74-95 BCL2 apoptosis regulator Homo sapiens 42-47 22820570-1 2012 OBJECTIVE: To investigate the effect of lentivirus-mediated Bcl-2 gene transfection in protecting human primary ovarian granulosa cells against phosphoramide mustard (PM)-induced apoptosis. phosphoramide mustard 144-165 BCL2 apoptosis regulator Homo sapiens 60-65 22820570-1 2012 OBJECTIVE: To investigate the effect of lentivirus-mediated Bcl-2 gene transfection in protecting human primary ovarian granulosa cells against phosphoramide mustard (PM)-induced apoptosis. phosphoramide mustard 167-169 BCL2 apoptosis regulator Homo sapiens 60-65 22447039-0 2012 Quercetin inhibits human breast cancer cell proliferation and induces apoptosis via Bcl-2 and Bax regulation. Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 96-101 22447039-6 2012 Furthermore, following quercetin treatment Bcl-2 expression decreased significantly while Bax expression increased significantly (P<0.05). Quercetin 23-32 BCL2 apoptosis regulator Homo sapiens 43-48 22466256-4 2012 The concept of BH3 mimetics has led to the characterization of small molecules mimicking proapoptotic BH3-only members of the Bcl-2 family by their ability to bind and antagonize the prosurvival members. BH 3 15-18 BCL2 apoptosis regulator Homo sapiens 126-131 22469952-7 2012 Curcumin (20 microM), bleomycin (400 microg/ml) and H2O2 (400 microM) incubation for 24 h decreased the viability of NTera-2 cells, and increased caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreased Bcl-2 levels. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 233-238 22673830-10 2012 Significant increases in expression of bax/bcl2 and p53 proteins confirmed that volatile oil induces apoptosis. Oils, Volatile 80-92 BCL2 apoptosis regulator Homo sapiens 43-47 22388098-0 2012 Pseudolaric acid B induces apoptosis via proteasome-mediated Bcl-2 degradation in hormone-refractory prostate cancer DU145 cells. pseudolaric acid B 0-18 BCL2 apoptosis regulator Homo sapiens 61-66 22238053-0 2012 Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol. Cisplatin 164-173 BCL2 apoptosis regulator Homo sapiens 64-68 22238053-0 2012 Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol. Etoposide 175-184 BCL2 apoptosis regulator Homo sapiens 64-68 22238053-11 2012 Treatment of AGS cells with 10 muM cisplatin, 0.5 muM etoposide and 10 nM taxol affected the BCL2, BAX and BCL2L12 mRNA levels, compared to the untreated cells. Paclitaxel 74-79 BCL2 apoptosis regulator Homo sapiens 93-97 22238053-12 2012 Cisplatin and etoposide induced a major down-regulation in the BCL2 mRNA levels after 72 h of treatment, while the BAX mRNA levels were slightly up-regulated. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 63-67 22238053-0 2012 Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol. Paclitaxel 189-194 BCL2 apoptosis regulator Homo sapiens 64-68 22238053-12 2012 Cisplatin and etoposide induced a major down-regulation in the BCL2 mRNA levels after 72 h of treatment, while the BAX mRNA levels were slightly up-regulated. Etoposide 14-23 BCL2 apoptosis regulator Homo sapiens 63-67 22388098-7 2012 Western blotting and/or caspase activity data indicated that PAB downregulated anti-apoptotic Bcl-2 protein and activated caspase-9 and caspase-3, which were largely rescued by NAC or MG-132 (proteasome inhibitor). pseudolaric acid B 61-64 BCL2 apoptosis regulator Homo sapiens 94-99 22238053-13 2012 Moreover, taxol had an up-regulating effect on both BCL2 and BAX transcript levels after 48 h of incubation. Paclitaxel 10-15 BCL2 apoptosis regulator Homo sapiens 52-56 22238053-11 2012 Treatment of AGS cells with 10 muM cisplatin, 0.5 muM etoposide and 10 nM taxol affected the BCL2, BAX and BCL2L12 mRNA levels, compared to the untreated cells. Cisplatin 35-44 BCL2 apoptosis regulator Homo sapiens 93-97 22238053-11 2012 Treatment of AGS cells with 10 muM cisplatin, 0.5 muM etoposide and 10 nM taxol affected the BCL2, BAX and BCL2L12 mRNA levels, compared to the untreated cells. Etoposide 54-63 BCL2 apoptosis regulator Homo sapiens 93-97 22388098-7 2012 Western blotting and/or caspase activity data indicated that PAB downregulated anti-apoptotic Bcl-2 protein and activated caspase-9 and caspase-3, which were largely rescued by NAC or MG-132 (proteasome inhibitor). benzyloxycarbonylleucyl-leucyl-leucine aldehyde 184-190 BCL2 apoptosis regulator Homo sapiens 94-99 22739157-5 2012 It is concluded that clofarabine inhibits proliferation of NB4 cells, which may be related with the down-regulation of Bcl-2 and induction of apoptosis. Clofarabine 21-32 BCL2 apoptosis regulator Homo sapiens 119-124 22967375-10 2012 Oridonin inhibited activation of ABL kinase and its downstream Akt/mTOR, Raf/MEK/ERK and STAT5 signaling pathways, which were constitutively activated in SUP-B15 cell line, down-regulated the level of anti- apoptotic protein Bcl-2 and up-regulated the expression of pro-apoptotic protein Bax. oridonin 0-8 BCL2 apoptosis regulator Homo sapiens 225-230 22967375-11 2012 CONCLUSION: Oridonin exerted anti-leukemia effect in Ph(+)ALL cell line SUP-B15 by inhibiting the activation of ABL kinase and its downstream Akt/mTOR, Raf/MEK/ERK and STAT5 signaling pathways, down-regulating the expression of Bcl-2 and up-regulating the expression of BAX. oridonin 12-20 BCL2 apoptosis regulator Homo sapiens 228-233 22967442-8 2012 Bcl-2 was knocked down in T-MDA-MB-231 cells using SiRNA and their growth inhibition was evaluated by MTT assay to evaluate the reversing effect of Bcl-2-silencing on drug resistance. monooxyethylene trimethylolpropane tristearate 102-105 BCL2 apoptosis regulator Homo sapiens 0-5 22967442-13 2012 The IC(50(s)) of docetaxel of T-MDA-MB-231 cells after Bcl-2-knocked down by siRNA was (21.52 +- 0.68) micromol/L, significantly decreased and lower than that before Bcl-2 silencing (32.98 +- 1.48) micromol/L. Docetaxel 17-26 BCL2 apoptosis regulator Homo sapiens 55-60 22967442-13 2012 The IC(50(s)) of docetaxel of T-MDA-MB-231 cells after Bcl-2-knocked down by siRNA was (21.52 +- 0.68) micromol/L, significantly decreased and lower than that before Bcl-2 silencing (32.98 +- 1.48) micromol/L. Docetaxel 17-26 BCL2 apoptosis regulator Homo sapiens 166-171 22967442-15 2012 Downregulation of Bcl-2 increases the sensitivity of polyploid cells to docetaxel. Docetaxel 72-81 BCL2 apoptosis regulator Homo sapiens 18-23 21986940-0 2012 2-deoxyglucose-induced toxicity is regulated by Bcl-2 family members and is enhanced by antagonizing Bcl-2 in lymphoma cell lines. Deoxyglucose 0-14 BCL2 apoptosis regulator Homo sapiens 48-53 21986940-0 2012 2-deoxyglucose-induced toxicity is regulated by Bcl-2 family members and is enhanced by antagonizing Bcl-2 in lymphoma cell lines. Deoxyglucose 0-14 BCL2 apoptosis regulator Homo sapiens 101-106 21986940-5 2012 In contrast, overexpressing the anti-apoptotic protein Bcl-2 dramatically enhanced the survival of 2DG-treated cells that was negated by a Bcl-2 antagonist. Deoxyglucose 99-102 BCL2 apoptosis regulator Homo sapiens 55-60 21986940-5 2012 In contrast, overexpressing the anti-apoptotic protein Bcl-2 dramatically enhanced the survival of 2DG-treated cells that was negated by a Bcl-2 antagonist. Deoxyglucose 99-102 BCL2 apoptosis regulator Homo sapiens 139-144 21986940-10 2012 These results demonstrate that ER stress appears to be rate limiting in 2DG-induced cell death in lymphoma cells, and this cell killing is regulated by the Bcl-2 family of proteins. Deoxyglucose 72-75 BCL2 apoptosis regulator Homo sapiens 156-161 22642642-7 2012 Bcl-2 expression was significantly increased in the presence of adriamycin and SCF (p < 0.038) and decreased in the presence of adriamycin and anti-SCF. Doxorubicin 64-74 BCL2 apoptosis regulator Homo sapiens 0-5 22642642-7 2012 Bcl-2 expression was significantly increased in the presence of adriamycin and SCF (p < 0.038) and decreased in the presence of adriamycin and anti-SCF. Doxorubicin 131-141 BCL2 apoptosis regulator Homo sapiens 0-5 22642642-8 2012 When adriamycin, anti-SCF and SCF were combined or when adriamycin was used alone the decrease in Bcl-2 expression was insignificantly altered. Doxorubicin 5-15 BCL2 apoptosis regulator Homo sapiens 98-103 22642642-8 2012 When adriamycin, anti-SCF and SCF were combined or when adriamycin was used alone the decrease in Bcl-2 expression was insignificantly altered. Doxorubicin 56-66 BCL2 apoptosis regulator Homo sapiens 98-103 22642642-12 2012 Our results demonstrate that anti-SCF with low dose of adriamycin reduces Bcl-2 expression in MCF-7/AdrRes cells and increases annexin V expression in both MCF7/AdrRes and MCF-7 cells. Doxorubicin 55-65 BCL2 apoptosis regulator Homo sapiens 74-79 22182451-3 2012 SNX-2112 induced the degradation of multiple Hsp90 client proteins, activated both the mitochondrial-mediated and death receptor-mediated apoptotic pathways, downregulated Bcl-2 and Bcl-xL, upregulated Bid, cleaved caspase-9, caspase-7, caspase-3 and PARP, and activated caspase-8. SNX 2112 0-8 BCL2 apoptosis regulator Homo sapiens 172-177 22500024-6 2012 Nrf1 loss sensitized keratinocytes to UVB-induced apoptosis by up-regulating the expression of the proapoptotic Bcl-2 family member Bik through reducing glutathione levels. Glutathione 153-164 BCL2 apoptosis regulator Homo sapiens 112-117 22739157-2 2012 MTT method was used to detect proliferation of NB4 cells treated with clofarabine 0.01 - 0.1 micromol/L for 48 h. The treated with clofarabine 0.01 - 0.1 micromol/L for 24 h, apoptosis rate and Bcl-2 expression of NB4 cells were measured by flow cytometry and Western blot respectively. monooxyethylene trimethylolpropane tristearate 0-3 BCL2 apoptosis regulator Homo sapiens 194-199 22739157-4 2012 After treated with clofarabine for 24 h, apoptosis rate of NB4 cells increased and Bcl-2 expression in NB4 cells decreased obviously (P < 0.05). Clofarabine 19-30 BCL2 apoptosis regulator Homo sapiens 83-88 22457358-4 2012 ColI but not Fn also prevented doxorubicin from down-regulating the levels of the prosurvival Bcl-2 protein family member Mcl-1. Doxorubicin 31-42 BCL2 apoptosis regulator Homo sapiens 94-99 22433870-4 2012 In estrogen receptor alpha-positive (ER(+)) breast cancer cells, phosphorylation of caveolin-1 (CAV1) on Tyr-14 facilitates mitochondrial apoptosis by increasing BCL2 phosphorylation in response to low dose paclitaxel (10 nM). Paclitaxel 207-217 BCL2 apoptosis regulator Homo sapiens 162-166 22433870-0 2012 Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK). Tyrosine 0-8 BCL2 apoptosis regulator Homo sapiens 94-98 22433870-0 2012 Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK). Tyrosine 0-3 BCL2 apoptosis regulator Homo sapiens 94-98 22433870-0 2012 Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK). Paclitaxel 69-79 BCL2 apoptosis regulator Homo sapiens 94-98 22433870-4 2012 In estrogen receptor alpha-positive (ER(+)) breast cancer cells, phosphorylation of caveolin-1 (CAV1) on Tyr-14 facilitates mitochondrial apoptosis by increasing BCL2 phosphorylation in response to low dose paclitaxel (10 nM). Tyrosine 105-108 BCL2 apoptosis regulator Homo sapiens 162-166 22542944-6 2012 SKLB70326 treatment induced apoptotic cell death via the activation of PARP, caspase-3, caspase-9 and Bax as well as the downregulation of Bcl-2. 3-amino-6-(3-methoxyphenyl)thieno(2.3-b)pyridine-2-carboxamide 0-9 BCL2 apoptosis regulator Homo sapiens 139-144 22380599-3 2012 The BH3 (Bcl-2 homology 3)-only Bcl-2 protein Noxa was required for H(2)O(2)-induced cell death and was the single BH3-only Bcl-2 protein whose pro-apoptotic activity was completely antagonized by endogenous Bcl-xL. (2)o(2) 69-76 BCL2 apoptosis regulator Homo sapiens 9-14 22380599-3 2012 The BH3 (Bcl-2 homology 3)-only Bcl-2 protein Noxa was required for H(2)O(2)-induced cell death and was the single BH3-only Bcl-2 protein whose pro-apoptotic activity was completely antagonized by endogenous Bcl-xL. (2)o(2) 69-76 BCL2 apoptosis regulator Homo sapiens 32-37 22380599-3 2012 The BH3 (Bcl-2 homology 3)-only Bcl-2 protein Noxa was required for H(2)O(2)-induced cell death and was the single BH3-only Bcl-2 protein whose pro-apoptotic activity was completely antagonized by endogenous Bcl-xL. (2)o(2) 69-76 BCL2 apoptosis regulator Homo sapiens 32-37 22589275-5 2012 The Bcl-2/Bcl-xL/Bcl-w inhibitor ABT-737 showed single-agent activity against only Bim:Bcl-2 primed tumor xenografts. ABT-737 33-40 BCL2 apoptosis regulator Homo sapiens 4-9 22537679-5 2012 Further experiments indicated that apoptosis induced by these glycoconjugated bis(disulfides) in U937 cells corresponds to the Bcl-2-sensitive, intrinsic form of apoptotic cell death. bis(disulfides 78-92 BCL2 apoptosis regulator Homo sapiens 127-132 22589275-5 2012 The Bcl-2/Bcl-xL/Bcl-w inhibitor ABT-737 showed single-agent activity against only Bim:Bcl-2 primed tumor xenografts. ABT-737 33-40 BCL2 apoptosis regulator Homo sapiens 87-92 22559167-7 2012 The effects of rapamycin and/or bortezomib on the mRNA expression levels of p53, p27, p21 and Bcl-2 family in HCCLM3 cells were evaluated by RT-PCR. Sirolimus 15-24 BCL2 apoptosis regulator Homo sapiens 94-99 22465181-5 2012 In the OVCAR-3 and SK-OV-3 cell lines, licochalocone A induced a decrease in Bid, Bcl-2, Bcl-xL and survivin protein levels; an increase in Bax levels; loss of the mitochondrial transmembrane potential; cytochrome c release; activation of caspases (-8, -9 and -3); cleavage of PARP-1; and an increase in the tumor suppressor p53 levels. licochalocone a 39-54 BCL2 apoptosis regulator Homo sapiens 82-87 22578287-5 2012 In U937 cells, DATS-induced apoptosis was correlated with down-regulation of Bcl-2, XIAP, and cIAP-1 protein levels, cleavage of Bid proteins, activation of caspases, and collapse of mitochondrial membrane potential. diallyl trisulfide 15-19 BCL2 apoptosis regulator Homo sapiens 77-82 22381066-0 2012 The tetramethoxyflavone zapotin selectively activates protein kinase C epsilon, leading to its down-modulation accompanied by Bcl-2, c-Jun and c-Fos decrease. zapotin 24-31 BCL2 apoptosis regulator Homo sapiens 126-131 22381066-9 2012 Furthermore, zapotin significantly increased the fraction of apoptotic cells in doxycycline-induced (HeLaPKCepsilonA/E) cells after 24h and decreased the levels of Bcl-2, c-Jun, c-Fos. zapotin 13-20 BCL2 apoptosis regulator Homo sapiens 164-169 21967640-6 2012 In response to stress signals, traffic of pro- and antiapoptotic mitochondrial proteins in the intermembrane space (B-cell lymphoma-extra large, Bcl-2-associated death promoter, Bcl-2 associated X-protein and cytochrome c) is modulated by the redox condition determined by mitochondrial O2 utilization and mitochondrial nitric oxide metabolism. Oxygen 287-289 BCL2 apoptosis regulator Homo sapiens 145-150 21967640-6 2012 In response to stress signals, traffic of pro- and antiapoptotic mitochondrial proteins in the intermembrane space (B-cell lymphoma-extra large, Bcl-2-associated death promoter, Bcl-2 associated X-protein and cytochrome c) is modulated by the redox condition determined by mitochondrial O2 utilization and mitochondrial nitric oxide metabolism. Oxygen 287-289 BCL2 apoptosis regulator Homo sapiens 178-183 21967640-6 2012 In response to stress signals, traffic of pro- and antiapoptotic mitochondrial proteins in the intermembrane space (B-cell lymphoma-extra large, Bcl-2-associated death promoter, Bcl-2 associated X-protein and cytochrome c) is modulated by the redox condition determined by mitochondrial O2 utilization and mitochondrial nitric oxide metabolism. Nitric Oxide 320-332 BCL2 apoptosis regulator Homo sapiens 145-150 21967640-6 2012 In response to stress signals, traffic of pro- and antiapoptotic mitochondrial proteins in the intermembrane space (B-cell lymphoma-extra large, Bcl-2-associated death promoter, Bcl-2 associated X-protein and cytochrome c) is modulated by the redox condition determined by mitochondrial O2 utilization and mitochondrial nitric oxide metabolism. Nitric Oxide 320-332 BCL2 apoptosis regulator Homo sapiens 178-183 22381066-0 2012 The tetramethoxyflavone zapotin selectively activates protein kinase C epsilon, leading to its down-modulation accompanied by Bcl-2, c-Jun and c-Fos decrease. 3,5,6,7-Tetramethoxyflavone 4-23 BCL2 apoptosis regulator Homo sapiens 126-131 22559167-7 2012 The effects of rapamycin and/or bortezomib on the mRNA expression levels of p53, p27, p21 and Bcl-2 family in HCCLM3 cells were evaluated by RT-PCR. Bortezomib 32-42 BCL2 apoptosis regulator Homo sapiens 94-99 22593445-7 2012 Safrole enhanced the levels of the pro-apoptotic protein BAX, inhibited those of the anti-apoptotic protein BCL-2 and promoted the levels of apoptosis-inducing factor (AIF) and endonuclease G (Endo G) in HL-60 cells. Safrole 0-7 BCL2 apoptosis regulator Homo sapiens 108-113 22504904-7 2012 The genes downstream of STAT3 (ie, Survivin, Mcl-1, Bcl-2 and Cyclin D1) were significantly down-regulated after exposure to celecoxib (25 and 50 mumol/L). Celecoxib 125-134 BCL2 apoptosis regulator Homo sapiens 52-57 22043989-11 2012 The apoptotic effect of both extracts, especially GTPs, seems to be mediated by both P 53 and Bcl-2. Guanosine Triphosphate 50-54 BCL2 apoptosis regulator Homo sapiens 94-99 22323130-7 2012 In response to paclitaxel, Bcl-2 was highly phosphorylated in death-prone cells, whereas much less Bcl-2 was phosphorylated in death-reluctant cells. Paclitaxel 15-25 BCL2 apoptosis regulator Homo sapiens 27-32 22323130-8 2012 Cotreatment with SP600125, an inhibitor JNK, significantly reduced the phosphorylated Bcl-2 in death-prone cells and caused a significant reduction in cell death. pyrazolanthrone 17-25 BCL2 apoptosis regulator Homo sapiens 86-91 22342732-9 2012 Bcl-2 family proteins were also responsible for DHA-induced apoptosis. artenimol 48-51 BCL2 apoptosis regulator Homo sapiens 0-5 22344570-7 2012 Further studies revealed that HZ08 increased vincristine-induced apoptosis, characterized as an intrinsic apoptosis pathway with enhanced G2/M phase arrest, since HZ08 had an effect on the intrinsic apoptotic regulator Bcl-2 and Bax. hz08 30-34 BCL2 apoptosis regulator Homo sapiens 219-224 22344570-7 2012 Further studies revealed that HZ08 increased vincristine-induced apoptosis, characterized as an intrinsic apoptosis pathway with enhanced G2/M phase arrest, since HZ08 had an effect on the intrinsic apoptotic regulator Bcl-2 and Bax. hz08 163-167 BCL2 apoptosis regulator Homo sapiens 219-224 22246135-4 2012 Our results revealed that the treatment of SK-N-MC cells with H(2)O(2) led to a decrease in cell viability through phosphorylation and activation of extracellular signal-regulated kinases (ERKs) and c-Jun N-terminal kinases (JNKs) pathways followed by increase in Bax/Bcl2 ratio and initiation of caspase-dependent apoptotic pathways. sk-n-mc 43-50 BCL2 apoptosis regulator Homo sapiens 268-272 22246135-6 2012 Our results demonstrated that flavonoid baicalein protected against H(2)O(2)-induced cell death by inhibition of JNK/ERK pathways activation and other key molecules in apoptotic pathways, including blockage of Bax and caspase-9 activation, induction of Bcl-2 expression and prevention of cell death. Flavonoids 30-39 BCL2 apoptosis regulator Homo sapiens 253-258 22246135-6 2012 Our results demonstrated that flavonoid baicalein protected against H(2)O(2)-induced cell death by inhibition of JNK/ERK pathways activation and other key molecules in apoptotic pathways, including blockage of Bax and caspase-9 activation, induction of Bcl-2 expression and prevention of cell death. Hydrogen Peroxide 68-76 BCL2 apoptosis regulator Homo sapiens 253-258 22240609-5 2012 We blocked the anti-apoptotic proteins of the Bcl-2 family by using ABT-737, a Bcl-2 and Bcl-XL inhibitor. ABT-737 68-75 BCL2 apoptosis regulator Homo sapiens 46-51 22387354-5 2012 The increase in the Bax to Bcl-2 ratio suggests that Bcl-2 family involved in the control of MEHP-induced apoptosis in these two cell types. mono-(2-ethylhexyl)phthalate 93-97 BCL2 apoptosis regulator Homo sapiens 27-32 22387354-5 2012 The increase in the Bax to Bcl-2 ratio suggests that Bcl-2 family involved in the control of MEHP-induced apoptosis in these two cell types. mono-(2-ethylhexyl)phthalate 93-97 BCL2 apoptosis regulator Homo sapiens 53-58 22240609-5 2012 We blocked the anti-apoptotic proteins of the Bcl-2 family by using ABT-737, a Bcl-2 and Bcl-XL inhibitor. ABT-737 68-75 BCL2 apoptosis regulator Homo sapiens 79-84 22240609-6 2012 ABT-737 modified Bcl-2 protein interactions toward a pro-apoptotic phenotype. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 17-22 22326969-6 2012 Instead, the over expression of anti-apoptotic Bcl-2, anti-oxidative heme oxygenase-1 (HO-1) and cell cycle regulator p16INK4 seemed to be more important for the gaining of cisplatin in these human urothelial carcinoma cell. Cisplatin 173-182 BCL2 apoptosis regulator Homo sapiens 47-52 26434259-8 2012 In addition, results suggest that the change in Bax/Bcl2 ratio by apigenin and quercetagetin seems to be due to their ability to alter the expression of bax and bcl2 transcription. quercetagetin 79-92 BCL2 apoptosis regulator Homo sapiens 52-56 26434259-8 2012 In addition, results suggest that the change in Bax/Bcl2 ratio by apigenin and quercetagetin seems to be due to their ability to alter the expression of bax and bcl2 transcription. quercetagetin 79-92 BCL2 apoptosis regulator Homo sapiens 161-165 26434261-6 2012 A decrease in expression of Bcl-2 and the cleavage of poly ADP-ribose polymerase (PARP) were observed after exposure to curcumin. Curcumin 120-128 BCL2 apoptosis regulator Homo sapiens 28-33 22544719-9 2012 NaBu-treated SCNT embryos showed similar levels of Oct4, Bcl-2, and Dnmt3b as in IVF blastocysts. sethoxydim 0-4 BCL2 apoptosis regulator Homo sapiens 57-62 22386815-6 2012 Ellagic acid treatment also significantly inhibited the UVA-induced apoptosis of HaCaT cells, as measured by a reduction of DNA fragmentation, mitochondria dysfunction, ER stress, caspase-3 activation, and Bcl-2/Bax deregulation. Ellagic Acid 0-12 BCL2 apoptosis regulator Homo sapiens 206-211 22386815-6 2012 Ellagic acid treatment also significantly inhibited the UVA-induced apoptosis of HaCaT cells, as measured by a reduction of DNA fragmentation, mitochondria dysfunction, ER stress, caspase-3 activation, and Bcl-2/Bax deregulation. uva 56-59 BCL2 apoptosis regulator Homo sapiens 206-211 22201607-7 2012 Carbon monoxide mediated lung protection involves several signaling pathways including mitogen activated protein kinases, nuclear factor-kappaB, activator protein-1, Akt, peroxisome proliferating- activated receptor-gamma, early growth response-1, caveolin-1, hypoxia-inducible factor-1alpha, caspases, Bcl-2-family members, heat shock proteins, or molecules of the fibrinolytic axis. Carbon Monoxide 0-15 BCL2 apoptosis regulator Homo sapiens 303-308 21732363-6 2012 GRA induced an increase in Bax:Bcl-2 ratio along with a significant increase in the protein level of the BH3 protein Bim. 18alpha-glycyrrhetinic acid 0-3 BCL2 apoptosis regulator Homo sapiens 31-36 22344475-12 2012 The ODC specific inhibitor, DFMO, altered the apoptotic effects of ROSC by increasing the generation of reactive oxygen species, decreasing the PA intracellular pool and modulating pro-apoptotic and anti-apoptotic Bcl-2 family members. Eflornithine 28-32 BCL2 apoptosis regulator Homo sapiens 214-219 22386766-11 2012 Modulation of Bcl-2 protein induced by Resveratrol could be mediating this effect. Resveratrol 39-50 BCL2 apoptosis regulator Homo sapiens 14-19 22023517-5 2012 In patients" cells, both PP-2A activation and Bcl-2 dephosphorylation are statistically linked to enzastaurin-induced CLL death. enzastaurin 98-109 BCL2 apoptosis regulator Homo sapiens 46-51 22679728-10 2012 The protein expression of Bax was up-regulated and that of Bcl-2 down-regulated in the emodin group and the emodin combined gemcitabine group when compared with the control group (P < 0.05). gemcitabine 124-135 BCL2 apoptosis regulator Homo sapiens 59-64 22278385-5 2012 We found that pretreatment with AS-IV significantly reversed the loss of cell viability, nuclear condensation, the generation of intracellular reactive oxygen species (ROS), and the increase in Bax/Bcl-2 ratio and the activity of caspase-3 induced by MPP(+). astragaloside A 32-37 BCL2 apoptosis regulator Homo sapiens 198-203 22366766-0 2012 EBP50 gene transfection promotes 5-fluorouracil-induced apoptosis in gastric cancer cells through Bax- and Bcl-2-triggered mitochondrial pathways. Fluorouracil 33-47 BCL2 apoptosis regulator Homo sapiens 119-124 22252725-5 2012 Furthermore, Sal B down-regulated the HG-mediated Bax expression and AIF nuclear translocation and the release of cytochrome c, but up-regulated the HG-induced BcL-2 expression in SCs. salvianolic acid B 13-18 BCL2 apoptosis regulator Homo sapiens 160-165 22367117-13 2012 Additionally, Beclin-1 is involved in evodiamine-induced autophagy and the pro-apoptotic mechanisms of evodiamine may be associated with down-regulation of Bcl-2 and up-regulation of Bax expression. evodiamine 38-48 BCL2 apoptosis regulator Homo sapiens 180-185 22367117-13 2012 Additionally, Beclin-1 is involved in evodiamine-induced autophagy and the pro-apoptotic mechanisms of evodiamine may be associated with down-regulation of Bcl-2 and up-regulation of Bax expression. evodiamine 115-125 BCL2 apoptosis regulator Homo sapiens 180-185 22860469-9 2012 CONCLUSION: Above data demonstrates that PE can induce apoptosis in human hepatoma HepG2 cells, and indicate that PE-induced expression level changes of Bax and Bcl2 may be related to the apoptosis-induction effect. phaseoloideside E 114-116 BCL2 apoptosis regulator Homo sapiens 161-165 22679728-11 2012 Emodin combined with gemcitabine could significantly inhibit the growth of pancreatic xenograft tumors, increase the positive expression of Bax in tumor tissues, obviously decrease the positive expressions of Ki-67 and Bcl-2 (P < 0.05). gemcitabine 21-32 BCL2 apoptosis regulator Homo sapiens 219-224 22679728-13 2012 CONCLUSION: Emodin could potentiate the inhibition of pancreatic cancer growth induced by gemcitabine both in vitro and in vivo, which might be achieved by up-regulating the expression of Bax and down-regulating the expression of Bcl-2. gemcitabine 90-101 BCL2 apoptosis regulator Homo sapiens 230-235 22138435-0 2012 Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737. ABT-737 132-139 BCL2 apoptosis regulator Homo sapiens 109-114 22138435-0 2012 Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737. ABT-737 132-139 BCL2 apoptosis regulator Homo sapiens 10-15 22138435-2 2012 ABT-737, a small molecule inhibitor of Bcl-2, Bcl-X(L), and Bcl-w, significantly induced apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells, and synergistically enhanced the cytotoxicity and apoptosis induced by conventional cytotoxic drugs. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 39-44 22465013-0 2012 Xanthorrhizol induced DNA fragmentation in HepG2 cells involving Bcl-2 family proteins. xanthorrhizol 0-13 BCL2 apoptosis regulator Homo sapiens 65-70 22109831-8 2012 Furthermore, beta,beta-dimethylacrylshikonin down-regulated the mRNA and protein expression of Bcl-2 but up-regulated that of Bax. beta, beta-dimethylacrylshikonin 13-44 BCL2 apoptosis regulator Homo sapiens 95-100 25722681-5 2012 Real-time RT-PCR reaction results showed that DL-3-n-butylphthalide reduced apoptosis by inhibiting downregulation of pro-apoptotic gene caspase-3 mRNA expression and upregulation of apoptosis-executive protease bcl-2 mRNA expression; however, DL-3-n-butylphthalide had no protective effects on brain microvascular endothelial cells after knockdown of hypoxia inducible factor-1alpha by small interfering RNA. 3-n-butylphthalide 46-67 BCL2 apoptosis regulator Homo sapiens 212-217 25722681-6 2012 These findings suggest that DL-3-n-butylphthalide can protect brain microvascular endothelial cells against oxygen glucose deprivation-induced injury by upregulating bcl-2 expression and downregulating caspase-3 expression though hypoxia inducible factor-1alpha pathway. 3-n-butylphthalide 28-49 BCL2 apoptosis regulator Homo sapiens 166-171 22465013-4 2012 Apoptosis in xanthorrhizol-treated HepG2 cells as observed by scanning electron microscopy was accompanied by truncation of BID; reduction of both anti-apoptotic Bcl-2 and Bcl-X(L) expression; cleavage of PARP and DFF45/ICAD proteins and DNA fragmentation. xanthorrhizol 13-26 BCL2 apoptosis regulator Homo sapiens 162-167 22465013-5 2012 Taken together, these results suggest xanthorrhizol as a potent antiproliferative agent on HepG2 cells by inducing apoptosis via Bcl-2 family members. xanthorrhizol 38-51 BCL2 apoptosis regulator Homo sapiens 129-134 21618512-1 2012 Human carcinomas often show resistance to cisplatin and Bcl-2 is associated with resistance to cisplatin. Cisplatin 95-104 BCL2 apoptosis regulator Homo sapiens 56-61 21618512-2 2012 However, Bcl-2 regulation on cisplatin treatment in human cancers is unknown. Cisplatin 29-38 BCL2 apoptosis regulator Homo sapiens 9-14 21618512-3 2012 Here, we show a novel mechanism by which cisplatin treatment promotes resistance by increasing the expression of Bcl-2 mRNA. Cisplatin 41-50 BCL2 apoptosis regulator Homo sapiens 113-118 21618512-4 2012 Bcl-2 mRNA and protein expression was increased in cisplatin-resistant endometrial cancer cell lines (KLE and HEC-1-A), but not in cisplatin-sensitive cell line (Ishikawa). Cisplatin 51-60 BCL2 apoptosis regulator Homo sapiens 0-5 21618512-4 2012 Bcl-2 mRNA and protein expression was increased in cisplatin-resistant endometrial cancer cell lines (KLE and HEC-1-A), but not in cisplatin-sensitive cell line (Ishikawa). Cisplatin 131-140 BCL2 apoptosis regulator Homo sapiens 0-5 21618512-5 2012 Cisplatin-mediated increase in Bcl-2 expression was blocked by combination with either actinomycin D or cycloheximide. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 31-36 21618512-5 2012 Cisplatin-mediated increase in Bcl-2 expression was blocked by combination with either actinomycin D or cycloheximide. Dactinomycin 87-100 BCL2 apoptosis regulator Homo sapiens 31-36 21618512-5 2012 Cisplatin-mediated increase in Bcl-2 expression was blocked by combination with either actinomycin D or cycloheximide. Cycloheximide 104-117 BCL2 apoptosis regulator Homo sapiens 31-36 21618512-7 2012 Inhibition of protein kinase C (PKC) activity prevented cisplatin-dependant increase in Bcl-2 mRNA, and induced apoptosis in KLE cells. Cisplatin 56-65 BCL2 apoptosis regulator Homo sapiens 88-93 21618512-9 2012 Cells stably expressing shRNA for Akt isoforms revealed that Akt2 was involved in cisplatin-dependant increase in Bcl-2 and apoptosis. Cisplatin 82-91 BCL2 apoptosis regulator Homo sapiens 114-119 21618512-10 2012 Overexpression of Akt2 in Akt2-deficient cells led to increased Bcl-2 expression on cisplatin treatment. Cisplatin 84-93 BCL2 apoptosis regulator Homo sapiens 64-69 21618512-11 2012 Our data suggest a novel regulation pathway of Bcl-2 by cisplatin, via the activation of PKC and Akt2, which has a profound impact on resistance to cisplatin-induced apoptosis in endometrial cancer cells. Cisplatin 56-65 BCL2 apoptosis regulator Homo sapiens 47-52 22456335-6 2012 We report that higher expression levels of the anti-apoptotic BCL2 family members MCL1 and BCL(XL) were detectable in cells with high inhibitory concentration 50 (IC(50)) values for SAHA. Vorinostat 182-186 BCL2 apoptosis regulator Homo sapiens 62-66 21618512-11 2012 Our data suggest a novel regulation pathway of Bcl-2 by cisplatin, via the activation of PKC and Akt2, which has a profound impact on resistance to cisplatin-induced apoptosis in endometrial cancer cells. Cisplatin 148-157 BCL2 apoptosis regulator Homo sapiens 47-52 22343498-10 2012 Pravastatin increased the phosphorylation of BAD, activated the expression of Pim-1 kinase and Bcl-2, and maintained the caspase 3 concentration relative to that of the respective untreated controls. Pravastatin 0-11 BCL2 apoptosis regulator Homo sapiens 95-100 22329894-4 2012 Dl-PHPB partially reversed the decrease of B-cell CLL/lymphoma 2 (Bcl-2) protein level induced by H(2)O(2). 2-(1-hydroxypentyl)-benzoate 0-7 BCL2 apoptosis regulator Homo sapiens 43-64 22329894-4 2012 Dl-PHPB partially reversed the decrease of B-cell CLL/lymphoma 2 (Bcl-2) protein level induced by H(2)O(2). 2-(1-hydroxypentyl)-benzoate 0-7 BCL2 apoptosis regulator Homo sapiens 66-71 22329894-4 2012 Dl-PHPB partially reversed the decrease of B-cell CLL/lymphoma 2 (Bcl-2) protein level induced by H(2)O(2). Water 98-103 BCL2 apoptosis regulator Homo sapiens 43-64 22329894-4 2012 Dl-PHPB partially reversed the decrease of B-cell CLL/lymphoma 2 (Bcl-2) protein level induced by H(2)O(2). Water 98-103 BCL2 apoptosis regulator Homo sapiens 66-71 22343498-11 2012 CONCLUSIONS: Pravastatin, administered at reoxygenation, protected the human myocardium by preventing the mitochondrial permeability transition pore opening, phosphorylating BAD, activating nitric oxide synthase, Pim-1 kinase, and Bcl-2, and preserving the myocardium against the caspase 3 activation. Pravastatin 13-24 BCL2 apoptosis regulator Homo sapiens 231-236 22425181-6 2012 In addition, lobaplatin increased p53, Bax expression, caspase-3 and poly (ADP-ribose) polymerase (PARP) cleavage, and reduced Bcl-2 expression, which contributed to the apoptosis of CCA cells. lobaplatin 13-23 BCL2 apoptosis regulator Homo sapiens 127-132 22493348-0 2012 Physiological concentrations of genistein and 17beta-estradiol inhibit MDA-MB-231 breast cancer cell growth by increasing BAX/BCL-2 and reducing pERK1/2. Genistein 32-41 BCL2 apoptosis regulator Homo sapiens 126-131 22493348-0 2012 Physiological concentrations of genistein and 17beta-estradiol inhibit MDA-MB-231 breast cancer cell growth by increasing BAX/BCL-2 and reducing pERK1/2. Estradiol 46-62 BCL2 apoptosis regulator Homo sapiens 126-131 22493348-3 2012 RESULTS: Compared to the control, 1 muM genistein plus 1 nM 17beta-estradiol significantly increased apoptosis, and the BAX/BCL-2 ratio, with a concomitant decrease in ERK1/2 phosphorylation. Genistein 40-49 BCL2 apoptosis regulator Homo sapiens 124-129 22493348-3 2012 RESULTS: Compared to the control, 1 muM genistein plus 1 nM 17beta-estradiol significantly increased apoptosis, and the BAX/BCL-2 ratio, with a concomitant decrease in ERK1/2 phosphorylation. Estradiol 60-76 BCL2 apoptosis regulator Homo sapiens 124-129 22493348-4 2012 High concentrations of genistein (100 muM) both in the presence and absence of 17beta-estradiol also increased apoptosis; however, these changes were not correlated with the BAX/BCL-2 ratio or with phosphorylation of ERK1/2. Genistein 23-32 BCL2 apoptosis regulator Homo sapiens 178-183 22155216-4 2012 In this study we have identified BH3 domain of Bax (Bax BH3) as potentially the best Bcl-2 antagonist by performing docking of BH3 peptides (peptides representing BH3 domain of pro-apoptotic and BH3-only proteins) into the Bcl-2 hydrophobic groove formed by BH3, BH1 and BH2 domains (also referred as BH3 cleft). BH 3 33-36 BCL2 apoptosis regulator Homo sapiens 85-90 22171982-0 2012 Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. gossypol acetic acid 26-32 BCL2 apoptosis regulator Homo sapiens 18-22 22171982-0 2012 Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. Lenalidomide 70-82 BCL2 apoptosis regulator Homo sapiens 18-22 22171982-7 2012 This effect was further enhanced with pre-treatment of tumour cells with AT-101 (a BH3 mimetic that functions as BCL2 antagonist). gossypol acetic acid 73-79 BCL2 apoptosis regulator Homo sapiens 113-117 22171982-7 2012 This effect was further enhanced with pre-treatment of tumour cells with AT-101 (a BH3 mimetic that functions as BCL2 antagonist). BH 3 83-86 BCL2 apoptosis regulator Homo sapiens 113-117 22311585-5 2012 Mechanistic studies demonstrated that derivatives of AH-487 disrupt mitotic spindles by inhibiting microtubule polymerization and induce apoptosis via induction of Bcl-2 phosphorylation in tumor cells. 2-(4-methyl-N-(3-(trifluoromethyl)phenyl)phenylsulfonamido)-N-(pyridin-3-yl)acetamide 53-59 BCL2 apoptosis regulator Homo sapiens 164-169 22539317-8 2012 Increased expression of p53, cleaved-caspase-3, cleaved-caspase-8, cleaved-caspase-9, p21, and Bax and decreased expression of Bcl-2 in sinularin-treated melanoma cells suggest that the anti-tumor activities of sinularin against melanoma cells are particularly correlated with these pro-apoptotic factors. sinularin 136-145 BCL2 apoptosis regulator Homo sapiens 127-132 22015607-8 2012 These findings highlight the importance of BH3:groove interactions in apoptosis regulation by the Bcl-2 protein family. BH 3 43-46 BCL2 apoptosis regulator Homo sapiens 98-103 22155216-4 2012 In this study we have identified BH3 domain of Bax (Bax BH3) as potentially the best Bcl-2 antagonist by performing docking of BH3 peptides (peptides representing BH3 domain of pro-apoptotic and BH3-only proteins) into the Bcl-2 hydrophobic groove formed by BH3, BH1 and BH2 domains (also referred as BH3 cleft). BH 3 33-36 BCL2 apoptosis regulator Homo sapiens 223-228 22159556-11 2012 Emodin monotherapy or combination with gemcitabine both decreased the gene and protein expression levels of MDR-1 (P-gp), NF-kappaB and Bcl-2 and inhibited the function of P-gp, but increased the expression levels of Bax, cytochrome-C (cytosol), caspase-9 and -3, and promoted cell apoptosis. gemcitabine 39-50 BCL2 apoptosis regulator Homo sapiens 136-141 22086183-7 2012 Vitamin E treatment further blocked activation of caspase-9 and Bcl-2 down-regulation induced by PLEO. Vitamin E 0-9 BCL2 apoptosis regulator Homo sapiens 64-69 22134829-0 2012 Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Simvastatin 0-11 BCL2 apoptosis regulator Homo sapiens 129-134 22134829-5 2012 In this study, we have demonstrated that simvastatin, at a dose of 20 microM for 24-72 h, induced in cancer cells but not in normal cells precise features of apoptosis including increased DNA fragmentation while, at the molecular level simvastatin induced overexpression of the pro-apoptotic gene Bax together with an inhibition of BCL-2, the gene that has the well-known function of protecting cells from apoptosis. Simvastatin 41-52 BCL2 apoptosis regulator Homo sapiens 332-337 22139054-11 2012 Magnolol triggered the mitochondrial-mediated apoptosis pathway as shown by an increased ratio of Bax/Bcl-2, dissipation of mitochondrial membrane potential (DeltaPsim), and sequential activation of caspase-3 and inhibition of PI3K/Akt. magnolol 0-8 BCL2 apoptosis regulator Homo sapiens 114-119 22179060-5 2012 We found that treatment with aspirin inhibited cell growth and induced apoptosis involving both extrinsic and intrinsic pathways as measured by DNA ladder formation, alteration in the Bax/Bcl-2 ratio, activation of the caspase activities and related protein expressions. Aspirin 41-48 BCL2 apoptosis regulator Homo sapiens 224-229 22209977-14 2012 CONCLUSIONS: This study for the first time demonstrated that downregulation of miR-181a and upregulation of Bcl-2 in leukaemia cells confer resistance to Ara-C-based therapy. Cytarabine 154-159 BCL2 apoptosis regulator Homo sapiens 108-113 22246103-9 2012 Taken together, our studies indicate that alpinetin inhibited the proliferation of pancreatic cancer cells possibly through the regulation of the Bcl-2 family and XIAP expression, release of cytochrome c and the activation of caspases. alpinetin 42-51 BCL2 apoptosis regulator Homo sapiens 170-175 22225575-6 2012 Furthermore, down-regulation of COX-2 expression using the COX-2 inhibitor, celecoxib, increased tunicamycin-induced apoptosis concomitant with the up-regulation of pro-apoptotic transcription factor CHOP (GADD153) and down-regulation of B-cell lymphoma 2/Bcl-2-associated X protein (Bcl-2/Bax) ratio, suggesting that inhibition of COX-2 sensitized human hepatoma cells to ER stress-induced apoptosis. Celecoxib 76-85 BCL2 apoptosis regulator Homo sapiens 256-261 21543203-5 2012 Flavokawain B also down-regulate Bcl-2 with concomitant increase in Bax level, which resulted in release of cytochrome c. flavokawain B 0-13 BCL2 apoptosis regulator Homo sapiens 33-38 22065207-0 2012 Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase. rasagiline 82-92 BCL2 apoptosis regulator Homo sapiens 73-78 22065207-1 2012 Rasagiline and (-)deprenyl (selegiline), irreversible type B monoamine oxidase (MAO-B) inhibitors, protect neuronal cells through gene induction of pro-survival Bcl-2 and neurotrophic factors in the cellular models of neurodegenerative disorders. rasagiline 0-10 BCL2 apoptosis regulator Homo sapiens 161-166 22065207-1 2012 Rasagiline and (-)deprenyl (selegiline), irreversible type B monoamine oxidase (MAO-B) inhibitors, protect neuronal cells through gene induction of pro-survival Bcl-2 and neurotrophic factors in the cellular models of neurodegenerative disorders. Selegiline 18-26 BCL2 apoptosis regulator Homo sapiens 161-166 22065207-1 2012 Rasagiline and (-)deprenyl (selegiline), irreversible type B monoamine oxidase (MAO-B) inhibitors, protect neuronal cells through gene induction of pro-survival Bcl-2 and neurotrophic factors in the cellular models of neurodegenerative disorders. Selegiline 28-38 BCL2 apoptosis regulator Homo sapiens 161-166 22065207-3 2012 Rasagiline and (-)deprenyl, and also befloxatone, a reversible MAO-A inhibitor, increased Bcl-2 mRNA and protein in SH-SY5Y cells. rasagiline 0-10 BCL2 apoptosis regulator Homo sapiens 90-95 22065207-3 2012 Rasagiline and (-)deprenyl, and also befloxatone, a reversible MAO-A inhibitor, increased Bcl-2 mRNA and protein in SH-SY5Y cells. befloxatone 37-48 BCL2 apoptosis regulator Homo sapiens 90-95 22065207-4 2012 Silencing MAO-A expression with short interfering (si) RNA suppressed Bcl-2 induction by rasagiline, but not by (-)deprenyl. rasagiline 89-99 BCL2 apoptosis regulator Homo sapiens 70-75 22065207-5 2012 MAO-B overexpression inhibited Bcl-2 induction by rasagiline and befloxatone, but did not affect that by (-)deprenyl, suggesting the different mechanisms behind Bcl-2 gene induction by these MAO-B inhibitors. rasagiline 50-60 BCL2 apoptosis regulator Homo sapiens 31-36 22065207-5 2012 MAO-B overexpression inhibited Bcl-2 induction by rasagiline and befloxatone, but did not affect that by (-)deprenyl, suggesting the different mechanisms behind Bcl-2 gene induction by these MAO-B inhibitors. befloxatone 65-76 BCL2 apoptosis regulator Homo sapiens 31-36 22065207-6 2012 The novel role of MAO-A in Bcl-2 induction by rasagiline is discussed with regard to the molecular mechanism underlying neuroprotection by the MAO inhibitors. rasagiline 46-56 BCL2 apoptosis regulator Homo sapiens 27-32 22225575-7 2012 Interestingly, co-treatment with tunicamycin and melatonin also decreased the expression of COX-2 and significantly increased the rate of apoptosis by elevating the levels of CHOP and reducing the Bcl-2/Bax ratio. Tunicamycin 33-44 BCL2 apoptosis regulator Homo sapiens 197-202 22225575-7 2012 Interestingly, co-treatment with tunicamycin and melatonin also decreased the expression of COX-2 and significantly increased the rate of apoptosis by elevating the levels of CHOP and reducing the Bcl-2/Bax ratio. Melatonin 49-58 BCL2 apoptosis regulator Homo sapiens 197-202 22225575-8 2012 These results demonstrate that melatonin sensitizes human hepatoma cells to ER stress-induced apoptosis by down-regulating COX-2 expression, increasing the levels of CHOP and decreasing the Bcl-2/Bax ratio. Melatonin 31-40 BCL2 apoptosis regulator Homo sapiens 190-195 22143535-6 2012 All of the evidences above indicate that DATS derivatives suppressed proliferation of PC-3 cells which was associated with the induction of apoptosis regulated by Bax/Bcl-2. diallyl trisulfide 41-45 BCL2 apoptosis regulator Homo sapiens 167-172 21779797-0 2012 Arsenic trioxide induces human pulmonary fibroblast cell death via the regulation of Bcl-2 family and caspase-8. Arsenic Trioxide 0-16 BCL2 apoptosis regulator Homo sapiens 85-90 21779797-10 2012 In conclusion, HPF cells were resistant to ATO and higher doses of ATO induced the growth inhibition and death in HPF cells via the regulation of Bcl-2 family and caspase-8. Arsenic Trioxide 67-70 BCL2 apoptosis regulator Homo sapiens 146-151 22219388-1 2012 Prior studies demonstrated that resistance to the ERBB1/2 inhibitor lapatinib could be overcome by the B cell CLL/lymphoma-2 (BCL-2) family antagonist obatoclax (GX15-070). Lapatinib 68-77 BCL2 apoptosis regulator Homo sapiens 103-124 22219388-1 2012 Prior studies demonstrated that resistance to the ERBB1/2 inhibitor lapatinib could be overcome by the B cell CLL/lymphoma-2 (BCL-2) family antagonist obatoclax (GX15-070). Lapatinib 68-77 BCL2 apoptosis regulator Homo sapiens 126-131 22219388-6 2012 Lapatinib and obatoclax-initiated autophagy depended on NOXA-mediated displacement of the prosurvival BCL-2 family member, MCL-1, from beclin 1, which was essential for the initiation of autophagy. Lapatinib 0-9 BCL2 apoptosis regulator Homo sapiens 102-107 22160140-6 2012 Treatment with the HDAC inhibitor sodium butyrate increased the expression of caspase-3 and DAPK1/2 genes but decreased the expression of Bcl-2 in human gastric cancer cells. Butyric Acid 34-49 BCL2 apoptosis regulator Homo sapiens 162-167 22033489-4 2012 Inhibition of Bcl-2/Bcl-xL by ABT-737 in cells from patients with tyrosine kinase inhibitor (TKI)-resistant BC CML promoted apoptosis in quiescent CD34(+) progenitor cells with an efficacy similar to that in proliferating cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 30-33 BCL2 apoptosis regulator Homo sapiens 14-19 22064351-1 2012 Recently, strategies for acute myeloid leukemia (AML) therapy have been developed that target anti-apoptotic BCL2 family members using BH3-mimetic drugs such as ABT-737. BH 3 135-138 BCL2 apoptosis regulator Homo sapiens 109-113 22064351-1 2012 Recently, strategies for acute myeloid leukemia (AML) therapy have been developed that target anti-apoptotic BCL2 family members using BH3-mimetic drugs such as ABT-737. ABT-737 161-168 BCL2 apoptosis regulator Homo sapiens 109-113 22064351-7 2012 Collectively, results demonstrated unexpected anti-apoptotic interaction between the BCL2 family-targeted BH3-mimetic ABT-737 and mitogen-activated protein kinase signaling in AML cells: the BH3 mimetic is not only restrained in its activity by MCL-1, but also induces its expression. BH 3 106-109 BCL2 apoptosis regulator Homo sapiens 85-89 22064351-7 2012 Collectively, results demonstrated unexpected anti-apoptotic interaction between the BCL2 family-targeted BH3-mimetic ABT-737 and mitogen-activated protein kinase signaling in AML cells: the BH3 mimetic is not only restrained in its activity by MCL-1, but also induces its expression. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 118-121 BCL2 apoptosis regulator Homo sapiens 85-89 22064351-7 2012 Collectively, results demonstrated unexpected anti-apoptotic interaction between the BCL2 family-targeted BH3-mimetic ABT-737 and mitogen-activated protein kinase signaling in AML cells: the BH3 mimetic is not only restrained in its activity by MCL-1, but also induces its expression. BH 3 191-194 BCL2 apoptosis regulator Homo sapiens 85-89 22382680-9 2012 Under various doses of nicotine, a decrease in the anti-apoptotic protein Bcl-2, but an increase in p53 and cleaved caspase-3 protein levels, was detected in a dose-dependent manner. Nicotine 23-31 BCL2 apoptosis regulator Homo sapiens 74-79 22285700-10 2012 Based on our results, bufalin induces apoptotic cell death in T24 cells through suppressing AKT activity and anti-apoptotic Bcl-2 protein as well as inducing pro-apoptotic Bax protein. bufalin 22-29 BCL2 apoptosis regulator Homo sapiens 124-129 22245810-6 2012 Treatment with butein significantly increased intracellular reactive oxygen species (ROS)levels and reduced the Bcl-2/Bax ratio, triggering the cleavage of pro-caspase 3 and poly-(ADP-ribose) polymerase (PARP). butein 15-21 BCL2 apoptosis regulator Homo sapiens 112-117 22577154-4 2012 We generated AZA-resistant myeloid cell line (SKM1-R) that exhibited increased expression of BCL2L10 an anti-apoptotic Bcl-2 member. Azathioprine 13-16 BCL2 apoptosis regulator Homo sapiens 119-124 22741011-0 2012 Silencing Notch-1 induces apoptosis and increases the chemosensitivity of prostate cancer cells to docetaxel through Bcl-2 and Bax. Docetaxel 99-108 BCL2 apoptosis regulator Homo sapiens 117-122 22741011-7 2012 Docetaxel treatment was also accompanied by an upregulation of Bax and a downregulation of Bcl-2. Docetaxel 0-9 BCL2 apoptosis regulator Homo sapiens 91-96 22269384-4 2012 To this aim, we have monitored the effects of DON on (i) cellular morphological changes via optical and transmission electron microscopy, especially in regards to cell viability and mitochondria changes, and (ii) its effects on key regulators of cell apoptosis, including cytochrome c, caspase-9, caspase-3, Bcl-2, Bax, and Bid. deoxynivalenol 46-49 BCL2 apoptosis regulator Homo sapiens 308-313 22570942-0 2012 Virosecurinine induces apoptosis by affecting Bcl-2 and Bax expression in human colon cancer SW480 cells. virosecurinine 0-14 BCL2 apoptosis regulator Homo sapiens 46-51 22570942-5 2012 Mechanistically, virosecurinine was found to up-regulated the Bax gene expression and down-regulated the Bcl-2 expression in SW480, The ratio of Bcl-2 to Bax was significantly decreased. virosecurinine 17-31 BCL2 apoptosis regulator Homo sapiens 105-110 22570942-5 2012 Mechanistically, virosecurinine was found to up-regulated the Bax gene expression and down-regulated the Bcl-2 expression in SW480, The ratio of Bcl-2 to Bax was significantly decreased. virosecurinine 17-31 BCL2 apoptosis regulator Homo sapiens 145-150 22570942-6 2012 Hence, we suggest that virosecurinine induced apoptosis in SW480 cells by affecting the expression of bcl-2 and bax. virosecurinine 23-37 BCL2 apoptosis regulator Homo sapiens 102-107 22285236-8 2012 Based on the detection of protein expression (PARP, p53, Bcl-2/Bcl-xL, Bax, p38, pp38) we found that usnic acid and atranorin are activators of programmed cell death in A2780 and HT-29, probably through the mitochondrial pathway. usnic acid 101-111 BCL2 apoptosis regulator Homo sapiens 57-62 22285236-8 2012 Based on the detection of protein expression (PARP, p53, Bcl-2/Bcl-xL, Bax, p38, pp38) we found that usnic acid and atranorin are activators of programmed cell death in A2780 and HT-29, probably through the mitochondrial pathway. atranorin 116-125 BCL2 apoptosis regulator Homo sapiens 57-62 22266706-8 2012 Furthermore, treatment with SG511 alone or in combination with cisplatin resulted in reduced expression the anti-apoptotic Bcl-2 family member Mcl-1 in HeLa and HT-29 cells. Cisplatin 75-84 BCL2 apoptosis regulator Homo sapiens 147-152 22269384-7 2012 The relative expression profile of Bcl-2 was contrary to that of Bax and Bid, as Bcl-2 expression decreased as the concentrations DON increased, reaching a minimum at the highest concentration of DON. deoxynivalenol 130-133 BCL2 apoptosis regulator Homo sapiens 35-40 22269384-8 2012 We concluded that DON-induced apoptosis was caused by mitochondrial dysfunction and subsequent release of cytochrome c into the cytoplasm and successive activation of caspases, and this was likely regulated by Bcl-2 family proteins. deoxynivalenol 18-21 BCL2 apoptosis regulator Homo sapiens 210-215 22450683-6 2012 Xathatin also increased total p53 protein levels, decreased Bcl-2/Bax ratio and expression of the downstream factors procaspase-9 and procaspase-3, which triggered the intrinsic apoptosis pathway. xathatin 0-8 BCL2 apoptosis regulator Homo sapiens 60-65 22541073-11 2012 Data mining of expression profiling indicated that the anti-apoptotic factor Bcl-2 decreased in K562 cells treated with either NAMPT-siRNA or imatinib, which was confirmed by Western blot. Imatinib Mesylate 142-150 BCL2 apoptosis regulator Homo sapiens 77-82 22541073-16 2012 When expression of NAMPT decreases, the K562 cells are more sensitive to imatinib, this may be related with the decreased transcriptional activity of NF-kappaB and its downstream effector Bcl-2. Imatinib Mesylate 73-81 BCL2 apoptosis regulator Homo sapiens 188-193 22334654-0 2012 Carbon monoxide modulates apoptosis by reinforcing oxidative metabolism in astrocytes: role of Bcl-2. Carbon Monoxide 0-15 BCL2 apoptosis regulator Homo sapiens 95-100 22334654-8 2012 By silencing Bcl-2 expression with siRNA transfection, CO effects in astrocytes were prevented, namely: (i) inhibition of apoptosis, (ii) increase on ATP generation, (iii) stimulation of COX activity, and (iv) mitochondrial biogenesis. Adenosine Triphosphate 150-153 BCL2 apoptosis regulator Homo sapiens 13-18 22275372-4 2012 Exposure of mouse hepatoma (Hepa-1) and human hepatoblastoma (HepG2) cells to antioxidant tert-butylhydroquinone led to induction of Bcl-2. 2-tert-butylhydroquinone 90-112 BCL2 apoptosis regulator Homo sapiens 133-138 22275372-10 2012 Furthermore, the specific knockdown of Bcl-2 in Nrf2-activated tumor cells led to increased etoposide-induced apoptosis and decreased cell survival and growth/proliferation. Etoposide 92-101 BCL2 apoptosis regulator Homo sapiens 39-44 22285729-0 2012 miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. mir-181a 0-8 BCL2 apoptosis regulator Homo sapiens 99-104 22311987-3 2012 While ABT-737 and its orally active analog ABT-263 are the most potent and specific inhibitors to date that bind Bcl-2 and Bcl-X(L) with high affinity but have a much lower affinity for Mcl-1, they are not very effective as single agents in certain cancer types because of elevated levels of Mcl-1. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 43-46 BCL2 apoptosis regulator Homo sapiens 113-118 22324429-4 2012 Moreover, FKB treatment resulted in the induction of apoptosis, which was associated with DNA fragmentation, mitochondria dysfunction, cytochrome c and AIF release, caspase-3 and caspase-9 activation, and Bcl-2/Bax dysregulation. flavokawain B 10-13 BCL2 apoptosis regulator Homo sapiens 205-210 22311987-3 2012 While ABT-737 and its orally active analog ABT-263 are the most potent and specific inhibitors to date that bind Bcl-2 and Bcl-X(L) with high affinity but have a much lower affinity for Mcl-1, they are not very effective as single agents in certain cancer types because of elevated levels of Mcl-1. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 6-9 BCL2 apoptosis regulator Homo sapiens 113-118 22313388-6 2012 Consistent with the increased Fas/CD95 expression, a drastic decrease in the Tyr705 phosphorylation of STAT3, a known negative regulator of Fas/CD95 transcription, was shown within 15 min in the EGCG-treated cells, leading to downregulation of the target gene products of STAT3, such as bcl-2, vascular endothelial growth factor (VEGF), mcl-1, and cyclin D1. epigallocatechin gallate 195-199 BCL2 apoptosis regulator Homo sapiens 287-292 22285729-0 2012 miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. Daunorubicin 73-85 BCL2 apoptosis regulator Homo sapiens 99-104 22222560-7 2012 Additionally, gambogenic acid increased expression ratio of Bcl-2/Bax in mRNA levels, Western blotting analysis also further confirmed the reduced level of Bcl-2 and increase the expression level of Bax in HepG2 cells. neo-gambogic acid 14-29 BCL2 apoptosis regulator Homo sapiens 60-65 22383790-0 2012 Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Obatoclax mesylate 16-34 BCL2 apoptosis regulator Homo sapiens 68-73 21993663-8 2012 RESULTS: miR-200bc/429 cluster was downregulated, while BCL2 and XIAP were upregulated in both MDR SGC7901/VCR (vincristine) and A549/CDDP (cisplatin) cells, compared with the parental SGC7901 and A549 cells, respectively. Vincristine 112-123 BCL2 apoptosis regulator Homo sapiens 56-60 22037880-0 2012 ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 79-84 22037880-8 2012 RESULTS: In this study, we demonstrate that ABT-263, a potent and orally bioavailable inhibitor of the Bcl-2 family, was able to reverse the resistance of hepatocarcinoma cell lines to TRAIL-induced apoptosis, while sparing normal liver cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 44-47 BCL2 apoptosis regulator Homo sapiens 103-108 22037880-9 2012 The molecular mechanism of the reversal in resistance may be attributed to the inhibition by ABT-263 of anti-apoptosis proteins of the Bcl-2 family. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 93-96 BCL2 apoptosis regulator Homo sapiens 135-140 22222560-7 2012 Additionally, gambogenic acid increased expression ratio of Bcl-2/Bax in mRNA levels, Western blotting analysis also further confirmed the reduced level of Bcl-2 and increase the expression level of Bax in HepG2 cells. neo-gambogic acid 14-29 BCL2 apoptosis regulator Homo sapiens 156-161 22393942-4 2012 Studies that describe celecoxib"s properties as a BH3 mimic or as a direct inhibitor of Bcl-2 are not available. Celecoxib 22-31 BCL2 apoptosis regulator Homo sapiens 88-93 22393942-5 2012 The motivations for this review are: to provide the basis for the development of novel compounds that modulate Bcl-2 expression using celecoxib as a structural starting point and to encourage additional biological studies (such as binding and enzymatic assays) that would provide information regarding celecoxib"s role as a Bcl-2 antagonist. Celecoxib 134-143 BCL2 apoptosis regulator Homo sapiens 111-116 22393942-6 2012 The current review summarizes work that identifies the role of celecoxib in blocking the activity of Bcl-2. Celecoxib 63-72 BCL2 apoptosis regulator Homo sapiens 101-106 22134754-7 2012 Belinostat induced the expression of p21 and p27, acetylation of p53 and G2/M arrest associated with Bcl2 and Bcl-Xl downmodulation and significant reduction of survivin, IAPs and Akt/pAkt and increased caspase-8 and -9 expression/activity. belinostat 0-10 BCL2 apoptosis regulator Homo sapiens 113-117 21455989-7 2012 Accordingly, Bcl-2- and Bcl-x(L) -overexpressing Jurkat cells, as well as caspase-9-deficient Jurkat cells, were resistant to apoptosis induced by decitabine and zebularine. Decitabine 147-157 BCL2 apoptosis regulator Homo sapiens 13-18 21455989-7 2012 Accordingly, Bcl-2- and Bcl-x(L) -overexpressing Jurkat cells, as well as caspase-9-deficient Jurkat cells, were resistant to apoptosis induced by decitabine and zebularine. pyrimidin-2-one beta-ribofuranoside 162-172 BCL2 apoptosis regulator Homo sapiens 13-18 22038922-6 2012 Iron and BCL2-interacting mediator of cell death (BIM) protein were involved in LCN2-induced cell death sensitization, based on the studies using iron donor, chelator, siderophore, and short hairpin RNA (shRNA)-mediated knockdown of bim expression. Iron 146-150 BCL2 apoptosis regulator Homo sapiens 9-13 22008998-5 2012 We found that up-regulation of death receptor 5 (DR5; receptor for TRAIL ligand), and down-regulation of Bcl-2 and c-FLIP (caspase regulator) contributes to RU-486 induced TRAIL sensitization. Mifepristone 157-163 BCL2 apoptosis regulator Homo sapiens 105-110 22008998-11 2012 Taken together, RU486 enhances TRAIL-mediated apoptosis through down-regulation of Bcl-2 and c-FLIP(L) as well as CHOP-mediated DR5 up-regulation. Mifepristone 16-21 BCL2 apoptosis regulator Homo sapiens 83-88 22755028-5 2012 The specific modulatory effects of EGCG were demonstrated by significant alterations in the expression levels of the following genes that control the apoptosis pathway: the TNF receptor and its ligand family, the death effector domain family, the Bcl-2 family or TP73. epigallocatechin gallate 35-39 BCL2 apoptosis regulator Homo sapiens 247-252 22157722-5 2012 AZD0530 is a Src TKI, TSA is a histone deacetylase inhibitor, and ABT-263 is a Bcl-2 inhibitor. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 66-70 BCL2 apoptosis regulator Homo sapiens 79-84 22675938-3 2012 The expressions of iNOS and Bax, Bcl-2 was detected by immunohistochemical SABC method. sabc 75-79 BCL2 apoptosis regulator Homo sapiens 33-38 22331221-11 2012 NSCLC cells that were resistant because of dysregulation of Bcl-2 family members (H1650) showed mean reductions in (18)F-FLT uptake of 49% and 23% with high and low doses of erlotinib, respectively, whereas the addition of ABT-263 did not affect tracer uptake but significantly increased the percentage of apoptotic cells in tumor sections. Erlotinib Hydrochloride 174-183 BCL2 apoptosis regulator Homo sapiens 60-65 22331221-11 2012 NSCLC cells that were resistant because of dysregulation of Bcl-2 family members (H1650) showed mean reductions in (18)F-FLT uptake of 49% and 23% with high and low doses of erlotinib, respectively, whereas the addition of ABT-263 did not affect tracer uptake but significantly increased the percentage of apoptotic cells in tumor sections. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 223-226 BCL2 apoptosis regulator Homo sapiens 60-65 21929682-5 2012 Additionally, melatonin effectively suppressed PA-induced reactive oxygen species generation and prevented PA-induced apoptosis whereby the rise in Bax/Bcl-2 ratio and caspase-3 activation in astroglial cells was inhibited. Melatonin 14-23 BCL2 apoptosis regulator Homo sapiens 152-157 21929682-5 2012 Additionally, melatonin effectively suppressed PA-induced reactive oxygen species generation and prevented PA-induced apoptosis whereby the rise in Bax/Bcl-2 ratio and caspase-3 activation in astroglial cells was inhibited. Palmitic Acid 107-109 BCL2 apoptosis regulator Homo sapiens 152-157 22241218-2 2012 The importance of the prosurvival BCL-2 family member BCL-X(L) in BL cell survival suggests that antagonistic BH3-mimetic compounds may have therapeutic potential. BH 3 110-113 BCL2 apoptosis regulator Homo sapiens 34-39 22241218-9 2012 Furthermore, blocking c-MYC function using the inhibitor 10058-F4 also induced apoptosis synergistically with ABT-737, suggesting that maintenance of expression of BCL-2 family members and/or c-MYC by the PI3K/AKT/mTOR pathway could contribute to BL cell survival and resistance to ABT-737. 5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one 57-65 BCL2 apoptosis regulator Homo sapiens 164-169 22241218-9 2012 Furthermore, blocking c-MYC function using the inhibitor 10058-F4 also induced apoptosis synergistically with ABT-737, suggesting that maintenance of expression of BCL-2 family members and/or c-MYC by the PI3K/AKT/mTOR pathway could contribute to BL cell survival and resistance to ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 110-113 BCL2 apoptosis regulator Homo sapiens 164-169 22241218-9 2012 Furthermore, blocking c-MYC function using the inhibitor 10058-F4 also induced apoptosis synergistically with ABT-737, suggesting that maintenance of expression of BCL-2 family members and/or c-MYC by the PI3K/AKT/mTOR pathway could contribute to BL cell survival and resistance to ABT-737. ABT-737 110-117 BCL2 apoptosis regulator Homo sapiens 164-169 22267549-10 2012 The involvement of Bcl-XL inhibition in sensitization was corroborated by the use of the pan-Bcl-2 inhibitor 2MAM-3 whereby the treated cells were sensitive to both CDDP- and TRAIL-induced apoptosis. Cisplatin 165-169 BCL2 apoptosis regulator Homo sapiens 93-98 22245127-7 2012 Cell apoptosis triggered by nickel (II) was characterized by the reduced protein expression of Bcl-2 and Bcl-xL and the induced the protein expression of Bad, Bcl-Xs, Bax, cytochrome c and caspases 9, 3 and 6. Nickel(2+) 28-39 BCL2 apoptosis regulator Homo sapiens 95-100 21796706-4 2012 Advanced glycation end-products up-regulated the expression of Bad and Bax and down-regulated Bcl-2 proteins, and pretreatment with DMPC significantly down-regulated Bad and Bax while up-regulating Bcl-2 expressions. Dimyristoylphosphatidylcholine 132-136 BCL2 apoptosis regulator Homo sapiens 94-99 21796706-4 2012 Advanced glycation end-products up-regulated the expression of Bad and Bax and down-regulated Bcl-2 proteins, and pretreatment with DMPC significantly down-regulated Bad and Bax while up-regulating Bcl-2 expressions. Dimyristoylphosphatidylcholine 132-136 BCL2 apoptosis regulator Homo sapiens 198-203 22245848-9 2012 Our data demonstrated that silica nanoparticles induced apoptosis in human liver cells, which is ROS mediated and regulated through p53, bax/bcl-2 and caspase pathways. Silicon Dioxide 27-33 BCL2 apoptosis regulator Homo sapiens 141-146 22245848-9 2012 Our data demonstrated that silica nanoparticles induced apoptosis in human liver cells, which is ROS mediated and regulated through p53, bax/bcl-2 and caspase pathways. Reactive Oxygen Species 97-100 BCL2 apoptosis regulator Homo sapiens 141-146 22179765-7 2012 The changes in the expression of caspase-8, capsase-9, Bax and bcl-2 after VI-16 treatment suggested that the mitochondrial pathway was involved in the apoptosis induced by VI-16. vi-16 87-92 BCL2 apoptosis regulator Homo sapiens 75-80 22179765-7 2012 The changes in the expression of caspase-8, capsase-9, Bax and bcl-2 after VI-16 treatment suggested that the mitochondrial pathway was involved in the apoptosis induced by VI-16. vi-16 197-202 BCL2 apoptosis regulator Homo sapiens 75-80 22210268-6 2012 Conversely, Beas-2B cells exposed to equivalent concentrations of Ni(2+) did not show evident signs of apoptosis and DNA damage, hence showing increased expression and phosphorylation of both EGFR and Neu, increased Bcl-2 and reduced BAX expression. Nickel(2+) 66-72 BCL2 apoptosis regulator Homo sapiens 216-221 22222411-10 2012 A decrease in Bcl-2/Bax ratio with the increased expression of caspase-3 provides evidence that quercetin-induced apoptosis may be mediated via the mitochondrial pathway. Quercetin 96-105 BCL2 apoptosis regulator Homo sapiens 14-19 22245127-8 2012 The regulation of the expression of Bcl-2-family proteins, the release of cytochrome c and the activation of caspases 9, 3 and 6 were inhibited in the presence of NAC. Acetylcysteine 163-166 BCL2 apoptosis regulator Homo sapiens 36-41 22343435-12 2012 HIF activation by cobalt decreased the CsA-induced apoptosis in HK-2 cells, as judged by the decreases in the number of apoptotic cells, pro-apoptotic caspase-3 activity, and the expression level of cleaved caspase-3, together with the increase in the expression of anti-apoptotic bcl-2. Cobalt 18-24 BCL2 apoptosis regulator Homo sapiens 281-286 22343435-12 2012 HIF activation by cobalt decreased the CsA-induced apoptosis in HK-2 cells, as judged by the decreases in the number of apoptotic cells, pro-apoptotic caspase-3 activity, and the expression level of cleaved caspase-3, together with the increase in the expression of anti-apoptotic bcl-2. Cyclosporine 39-42 BCL2 apoptosis regulator Homo sapiens 281-286 22624338-6 2012 Western blot analysis demonstrated that oxaliplatin could induce apoptosis of L02 cells by reducing the Bcl-2/Bim ratio, stimulating the cytochrome c release, and activating caspase-3. Oxaliplatin 40-51 BCL2 apoptosis regulator Homo sapiens 104-109 22429577-10 2012 Immunohistochemical staining (SP) shows the positive expressions of Bcl-2 and MRP3 proteins in Anip973/NVB transplantation tumor, which were observed to be higher than those in the Anip973 transplantation tumor. TFF2 protein, human 30-32 BCL2 apoptosis regulator Homo sapiens 68-73 22227334-9 2012 Furthermore, genistein pretreatment restored the 6-OHDA-induced up-regulation of Bax and down-regulation of Bcl-2 mRNA and protein expression. Genistein 13-22 BCL2 apoptosis regulator Homo sapiens 108-113 22227334-9 2012 Furthermore, genistein pretreatment restored the 6-OHDA-induced up-regulation of Bax and down-regulation of Bcl-2 mRNA and protein expression. Oxidopamine 49-55 BCL2 apoptosis regulator Homo sapiens 108-113 21761401-0 2012 Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737. ABT-737 109-116 BCL2 apoptosis regulator Homo sapiens 92-97 22104727-8 2012 The levels of Stat3 target oncogenes such as Bcl-2 and c-Myc were decreased with DPP, a Stat3 inhibitor, treatment, while the expression of tumor suppressor p53 was increased. dipalmitoylphosphatidylserine 81-84 BCL2 apoptosis regulator Homo sapiens 45-50 21761401-4 2012 The small-molecule BCL-2 inhibitor ABT-737 induces apoptosis in a BAX-dependent and BCL-2 homologous antagonist-killer (BAK)-dependent manner. ABT-737 35-42 BCL2 apoptosis regulator Homo sapiens 19-24 21761401-4 2012 The small-molecule BCL-2 inhibitor ABT-737 induces apoptosis in a BAX-dependent and BCL-2 homologous antagonist-killer (BAK)-dependent manner. ABT-737 35-42 BCL2 apoptosis regulator Homo sapiens 84-89 21761401-4 2012 The small-molecule BCL-2 inhibitor ABT-737 induces apoptosis in a BAX-dependent and BCL-2 homologous antagonist-killer (BAK)-dependent manner. bakuchiol 120-123 BCL2 apoptosis regulator Homo sapiens 19-24 21761401-4 2012 The small-molecule BCL-2 inhibitor ABT-737 induces apoptosis in a BAX-dependent and BCL-2 homologous antagonist-killer (BAK)-dependent manner. bakuchiol 120-123 BCL2 apoptosis regulator Homo sapiens 84-89 22184378-0 2012 Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. navitoclax 109-119 BCL2 apoptosis regulator Homo sapiens 62-66 22264758-6 2012 A decrease in bcl-2 level, and increase in the level of bax, cytochrome c release into the cytosol, cleavage of caspase 3/7and PARP suggested that coumarin polysulfides induced the intrinsic pathway of apoptosis. coumarin polysulfides 147-168 BCL2 apoptosis regulator Homo sapiens 14-19 22399804-9 2012 The pro-apoptotic protein BIM (also known as BCL2L11) is recruited to mitochondria in response to vinorelbine, where it can inhibit the anti-apoptotic protein BCL2, suggesting that BIM mediates vinorelbine-induced cell death. Vinorelbine 98-109 BCL2 apoptosis regulator Homo sapiens 45-49 22399804-9 2012 The pro-apoptotic protein BIM (also known as BCL2L11) is recruited to mitochondria in response to vinorelbine, where it can inhibit the anti-apoptotic protein BCL2, suggesting that BIM mediates vinorelbine-induced cell death. Vinorelbine 194-205 BCL2 apoptosis regulator Homo sapiens 45-49 22240779-2 2012 Strategies to restore apoptosis have led to the development of BH3 mimetics, which inhibit anti-apoptotic Bcl-2 family members. BH 3 63-66 BCL2 apoptosis regulator Homo sapiens 106-111 22184378-2 2012 The novel BH3 mimetic navitoclax (ABT-263) specifically inhibits BCL2 and related proteins BCL-x(l) and BCL-w, potently inducing apoptosis of CLL cells in vitro. BH 3 10-13 BCL2 apoptosis regulator Homo sapiens 65-69 22184378-2 2012 The novel BH3 mimetic navitoclax (ABT-263) specifically inhibits BCL2 and related proteins BCL-x(l) and BCL-w, potently inducing apoptosis of CLL cells in vitro. navitoclax 22-32 BCL2 apoptosis regulator Homo sapiens 65-69 22184378-2 2012 The novel BH3 mimetic navitoclax (ABT-263) specifically inhibits BCL2 and related proteins BCL-x(l) and BCL-w, potently inducing apoptosis of CLL cells in vitro. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 34-37 BCL2 apoptosis regulator Homo sapiens 65-69 21901545-0 2012 2,5-Hexanedione induces human ovarian granulosa cell apoptosis through BCL-2, BAX, and CASPASE-3 signaling pathways. 2,5-hexanedione 0-15 BCL2 apoptosis regulator Homo sapiens 71-76 22305266-10 2012 Likewise, down-regulation of p65 expression enhanced the cytotoxic effect of DOX, due to a significant decrease of mRNA levels of anti-apoptotic genes, such as the cellular inhibitor of apoptosis-1 (c-IAP1), and the long isoform of B cell leukemia/lymphoma-2 (Bcl-2), leading to efficient induction of caspase-3 cleavage in the cells. Doxorubicin 77-80 BCL2 apoptosis regulator Homo sapiens 232-258 22305266-10 2012 Likewise, down-regulation of p65 expression enhanced the cytotoxic effect of DOX, due to a significant decrease of mRNA levels of anti-apoptotic genes, such as the cellular inhibitor of apoptosis-1 (c-IAP1), and the long isoform of B cell leukemia/lymphoma-2 (Bcl-2), leading to efficient induction of caspase-3 cleavage in the cells. Doxorubicin 77-80 BCL2 apoptosis regulator Homo sapiens 260-265 21809075-5 2012 Roscovitine induced apoptosis by activating mitochondrial pathway caspases and modulating the expression of Bcl-2 family members. Roscovitine 0-11 BCL2 apoptosis regulator Homo sapiens 108-113 22109882-0 2012 The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics. Lenalidomide 26-38 BCL2 apoptosis regulator Homo sapiens 164-169 22109882-10 2012 An apoptosis protein array showed that the 1,25-D3 and lenalidomide combination increased pro-apoptotic proteins (phosphorylated p53) and decreased BCL-2 expression. Calcitriol 43-50 BCL2 apoptosis regulator Homo sapiens 148-153 22109882-10 2012 An apoptosis protein array showed that the 1,25-D3 and lenalidomide combination increased pro-apoptotic proteins (phosphorylated p53) and decreased BCL-2 expression. Lenalidomide 55-67 BCL2 apoptosis regulator Homo sapiens 148-153 22002102-0 2012 p53-dependent regulation of Mcl-1 contributes to synergistic cell death by ionizing radiation and the Bcl-2/Bcl-XL inhibitor ABT-737. ABT-737 125-132 BCL2 apoptosis regulator Homo sapiens 102-107 22002102-1 2012 Treatment with the Bcl-2/Bcl-XL inhibitor ABT-737 is a promising novel strategy to therapeutically induce apoptotic cell death in malignant tumors such as glioblastomas. ABT-737 42-49 BCL2 apoptosis regulator Homo sapiens 19-24 22057391-7 2012 In contrast, the DR cells exhibited no cleaved caspase 3 expression and maintained expression of Bcl-2 following recovery from 24 h Cr(VI) exposure. chromium hexavalent ion 132-138 BCL2 apoptosis regulator Homo sapiens 97-102 21818117-7 2012 Although both BH4-Bcl-2 and BH4-Bcl-Xl had antiapoptotic activity, BH4-Bcl-2 was more potent than BH4-Bcl-Xl. sapropterin 14-17 BCL2 apoptosis regulator Homo sapiens 18-23 22138446-6 2012 We show that concurrent treatment with GA and TPT is able to reverse TPT induced up-regulation of the anti-apoptotic protein Bcl2 in both p53+/+ and p53-/- HCT116 cells. geldanamycin 39-41 BCL2 apoptosis regulator Homo sapiens 125-129 22138446-6 2012 We show that concurrent treatment with GA and TPT is able to reverse TPT induced up-regulation of the anti-apoptotic protein Bcl2 in both p53+/+ and p53-/- HCT116 cells. tpt 46-49 BCL2 apoptosis regulator Homo sapiens 125-129 22138446-6 2012 We show that concurrent treatment with GA and TPT is able to reverse TPT induced up-regulation of the anti-apoptotic protein Bcl2 in both p53+/+ and p53-/- HCT116 cells. tpt 69-72 BCL2 apoptosis regulator Homo sapiens 125-129 21818117-0 2012 Selective regulation of IP3-receptor-mediated Ca2+ signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl. sapropterin 82-85 BCL2 apoptosis regulator Homo sapiens 96-101 21818117-1 2012 Antiapoptotic B-cell lymphoma 2 (Bcl-2) targets the inositol 1,4,5-trisphosphate receptor (IP(3)R) via its BH4 domain, thereby suppressing IP(3)R Ca(2+)-flux properties and protecting against Ca(2+)-dependent apoptosis. sapropterin 107-110 BCL2 apoptosis regulator Homo sapiens 14-31 21818117-1 2012 Antiapoptotic B-cell lymphoma 2 (Bcl-2) targets the inositol 1,4,5-trisphosphate receptor (IP(3)R) via its BH4 domain, thereby suppressing IP(3)R Ca(2+)-flux properties and protecting against Ca(2+)-dependent apoptosis. sapropterin 107-110 BCL2 apoptosis regulator Homo sapiens 33-38 21818117-2 2012 Here, we directly compared IP(3)R inhibition by BH4-Bcl-2 and BH4-Bcl-Xl. sapropterin 48-51 BCL2 apoptosis regulator Homo sapiens 52-57 21818117-4 2012 We identified a critical residue in BH4-Bcl-2 (Lys17) not conserved in BH4-Bcl-Xl (Asp11). sapropterin 36-39 BCL2 apoptosis regulator Homo sapiens 40-45 21818117-5 2012 Changing Lys17 into Asp in BH4-Bcl-2 completely abolished its IP(3)R-binding and -inhibitory properties, whereas changing Asp11 into Lys in BH4-Bcl-Xl induced IP(3)R binding and inhibition. sapropterin 27-30 BCL2 apoptosis regulator Homo sapiens 31-36 22012578-8 2012 Moreover, andrographolide-treated RAFLSs displayed a significant decrease in the Bcl-2/Bax ratio compared to untreated cells. andrographolide 10-25 BCL2 apoptosis regulator Homo sapiens 81-86 21818117-9 2012 In agreement with the IP(3)R-binding properties, the antiapoptotic activity of BH4-Bcl-2 and BH4-Bcl-Xl was modulated by the Lys/Asp substitutions. sapropterin 79-82 BCL2 apoptosis regulator Homo sapiens 83-88 21818117-9 2012 In agreement with the IP(3)R-binding properties, the antiapoptotic activity of BH4-Bcl-2 and BH4-Bcl-Xl was modulated by the Lys/Asp substitutions. Lysine 125-128 BCL2 apoptosis regulator Homo sapiens 83-88 21818117-9 2012 In agreement with the IP(3)R-binding properties, the antiapoptotic activity of BH4-Bcl-2 and BH4-Bcl-Xl was modulated by the Lys/Asp substitutions. Aspartic Acid 129-132 BCL2 apoptosis regulator Homo sapiens 83-88 21818117-11 2012 A single amino-acid difference between BH4-Bcl-2 and BH4-Bcl-Xl therefore underlies differential regulation of IP(3)Rs and Ca(2+)-driven apoptosis by these functional domains. sapropterin 39-42 BCL2 apoptosis regulator Homo sapiens 43-48 22078465-1 2012 CYR61 over-expression promotes cell proliferation by inhibiting carboplatin-induced apoptosis, decreasing Bax expression, and increasing Bcl-xL, Mcl-1, and Bcl-2. cyr61 0-5 BCL2 apoptosis regulator Homo sapiens 156-161 22158856-3 2012 Thus, we hypothesized that BH3-mimetic drugs that antagonize Bcl-2 family proteins may exert a greater efficacy when dosed metronomically. BH 3 27-30 BCL2 apoptosis regulator Homo sapiens 61-66 22139440-5 2012 Fisetin-caused cell death was accompanied by decreased expression of survivin and an increase in cleaved levels of caspases-3 and -7 and poly-(ADP-ribose) polymerase along with an increased ratio of Bax to Bcl-2. fisetin 0-7 BCL2 apoptosis regulator Homo sapiens 206-211 21711158-5 2012 Instead, curcumin caused apoptosis by increasing Bax expression while decreasing the expression of Bcl-2 and Bcl-xL. Curcumin 9-17 BCL2 apoptosis regulator Homo sapiens 99-104 22173547-3 2012 ABT-737, a small-molecule BH3-mimetic, selectively inhibits BCL-2, BCL-XL, and BCL-w and shows promise for treating leukemia, lymphoma, and small-cell lung cancer. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 60-65 22173547-3 2012 ABT-737, a small-molecule BH3-mimetic, selectively inhibits BCL-2, BCL-XL, and BCL-w and shows promise for treating leukemia, lymphoma, and small-cell lung cancer. BH 3 26-29 BCL2 apoptosis regulator Homo sapiens 60-65 22280355-5 2012 Addition of sera obtained from patients treated with combination of radiotherapy and EGCG feeding for 2-8 weeks to in vitro cultures of highly-metastatic human MDA-MB-231 breast cancer cells resulted in the following significant changes: (1) suppression of cell proliferation and invasion; (2) arrest of cell cycles at the G0/G1 phase; (3) reduction of activation of MMP9/MMP2, expressions of Bcl-2/Bax, c-Met receptor, NF-kappaB, and the phosphorylation of Akt. epigallocatechin gallate 85-89 BCL2 apoptosis regulator Homo sapiens 393-398 22182776-5 2012 Wogonin-induced apoptosis was accompanied by a significant decrease of the Bcl-2 and survivin and increase of Bax and p53. wogonin 0-7 BCL2 apoptosis regulator Homo sapiens 75-80 22056335-7 2012 Increased levels of Bax and cytosolic cytochrome C and decreased levels of Bcl2 were also observed in MeOH:water (80:20) treated MCF-7 cells. Methanol 102-106 BCL2 apoptosis regulator Homo sapiens 75-79 22056335-7 2012 Increased levels of Bax and cytosolic cytochrome C and decreased levels of Bcl2 were also observed in MeOH:water (80:20) treated MCF-7 cells. Water 107-112 BCL2 apoptosis regulator Homo sapiens 75-79 21971569-7 2012 A decrease in Bcl-2/Bax ratio with increased expression of caspase-3, and intracellular Ca2+ provide compelling evidence that TBMS1-induced apoptosis is mediated by the mitochondrial pathway. tubeimoside I 126-131 BCL2 apoptosis regulator Homo sapiens 14-19 22040216-6 2012 On the basis of our results, it appears that ellipticine resistance in neuroblastoma is caused by a combination of overexpression of Bcl-2, efflux or degradation of the drug and downregulation of topoisomerases. ellipticine 45-56 BCL2 apoptosis regulator Homo sapiens 133-138 22052376-0 2012 The pleiotropic effects of statins in the prevention of atherosclerosis : Editorial to: "Simvastatin suppresses apoptosis in vulnerable atherosclerotic plaques through regulating the expression of p53, Bcl-2 en Bcl-xL" by Weiwei Qin et al. Simvastatin 89-100 BCL2 apoptosis regulator Homo sapiens 202-207 22076676-6 2012 The OXPHOS un-coupler oligomycin A altered the expression levels of the Bcl-2 family of proteins; treatment with pMU or pMC reversed this effect and induced mitochondrial outer membrane permeabilization. oligomycin A 34-46 BCL2 apoptosis regulator Homo sapiens 84-89 21793937-10 2012 Finally, Western blot showed that higher expressions of MRP1, LRP, and BCL2 and lower expression of TopoIIbeta were observed in SCC-15/cisplatin cells than in clinical samples. Cisplatin 135-144 BCL2 apoptosis regulator Homo sapiens 71-75 21997261-6 2012 Further investigation of the apoptotic mechanisms in the cells demonstrated that high glucose upregulated the ratio of Bax/Bcl-2 and activated caspase-3 and also increased the levels of reactive oxygen species and malondialdehyde while reducing superoxide dismutase activity. Glucose 86-93 BCL2 apoptosis regulator Homo sapiens 123-128 21442624-11 2012 High glucose increased the Bax/Bcl-2 ratio and levels of cleaved PARP, cleaved caspase-9 and caspase-3, and reduced cell viability. Glucose 5-12 BCL2 apoptosis regulator Homo sapiens 31-36 22051979-5 2012 In the present study, we reported for the first time that paeoniflorin at non-toxic concentrations may effectively modulate multidrug resistance (MDR) of the human gastric cancer cell line SGC7901/vincristine (VCR) via the inhibition of NF-kappaB activation and, at least partly, by subsequently downregulating its target genes MDR1, BCL-XL and BCL-2. peoniflorin 58-70 BCL2 apoptosis regulator Homo sapiens 345-350 22012179-7 2012 A significant, dose-dependent reduction in the expression of caspase-3 and caspase-9 protein induced by H2O2 in MG63 cells was observed in response to simvastatin and the Bcl-2 levels were increased. Hydrogen Peroxide 104-108 BCL2 apoptosis regulator Homo sapiens 171-176 22012179-8 2012 In conclusion, simvastatin protects MG63 cells from oxidative stress-induced apoptosis through downregulation of caspase-3 and caspase-9 activation and upregulation of Bcl-2 expression, suggesting a protective effect in osteoporosis. Simvastatin 15-26 BCL2 apoptosis regulator Homo sapiens 168-173 22086271-9 2012 In addition, p-Akt and Bcl-2, which can promote TMZ resistance, were markedly decreased by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 91-99 BCL2 apoptosis regulator Homo sapiens 23-28 22052344-2 2012 We identified the same bcl-2/IgH fusion gene in paraffin-embedded lymph node (LN) samples and BM samples using immunohistochemistry (IHC), immunocytochemistry (ICC), cytologic morphology and fluorescence in situ hybridization (FISH). Paraffin 60-68 BCL2 apoptosis regulator Homo sapiens 23-28 22052344-5 2012 Approximately 78.6% (44/56) of the paraffin-embedded LN tissue sections that underwent FISH analysis had a bcl-2/IgH translocation. Paraffin 47-55 BCL2 apoptosis regulator Homo sapiens 119-124 22130551-4 2012 Functional studies showed that AQP3 and AQP9 can inhibit cell apoptosis induced by arsenite through down-regulating p53 and up-regulating Bcl-2 and XIAP. arsenite 83-91 BCL2 apoptosis regulator Homo sapiens 138-143 22391169-1 2012 This study was purposed to investigate the changes of mitochondrial membrane potential (MMP) and apoptosis-related gene Bcl-2 expression of HL-60 cells treated with 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT). 5-amino levulinic acid 165-186 BCL2 apoptosis regulator Homo sapiens 120-125 22020779-8 2012 Silencing HERG inhibited the apoptosis induced by cisplatin both in vitro and in vivo, by attenuating the cisplatin effects on Bcl-2, Bax and active caspase-3. Cisplatin 62-71 BCL2 apoptosis regulator Homo sapiens 139-144 22020779-8 2012 Silencing HERG inhibited the apoptosis induced by cisplatin both in vitro and in vivo, by attenuating the cisplatin effects on Bcl-2, Bax and active caspase-3. Cisplatin 118-127 BCL2 apoptosis regulator Homo sapiens 139-144 21520296-7 2012 We also demonstrate that TSA suppresses the growth of CRC cells, and induces G1 cell cycle arrest and apoptosis through the regulation of downstream targets of JAK2/STAT3 signaling, including Bcl-2, survivin and p16(ink4a) . trichostatin A 25-28 BCL2 apoptosis regulator Homo sapiens 192-197 21656835-12 2012 Co-treatment with bicalutimide reducing cell growth, induced apoptosis, and reduced Bcl-2 and BclxL, caspase-3 and PARP. bicalutimide 18-30 BCL2 apoptosis regulator Homo sapiens 84-89 22391169-1 2012 This study was purposed to investigate the changes of mitochondrial membrane potential (MMP) and apoptosis-related gene Bcl-2 expression of HL-60 cells treated with 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT). Alanine 215-218 BCL2 apoptosis regulator Homo sapiens 120-125 22490358-12 2012 CONCLUSIONS: The combination of ABT-737 with docetaxel can synergistically inhibit the proliferation of PC-3 cells through inducing apoptosis, which may be associated with cell cycle arrest, down-regulation of Bcl-2, Bcl-xL and Mcl-1 expression and activation of caspase-3. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 32-35 BCL2 apoptosis regulator Homo sapiens 210-215 22490358-12 2012 CONCLUSIONS: The combination of ABT-737 with docetaxel can synergistically inhibit the proliferation of PC-3 cells through inducing apoptosis, which may be associated with cell cycle arrest, down-regulation of Bcl-2, Bcl-xL and Mcl-1 expression and activation of caspase-3. Docetaxel 45-54 BCL2 apoptosis regulator Homo sapiens 210-215 22391169-5 2012 The semi-quantitative RT-PCR and real-time PCR showed that the expression level of Bcl-2 was obviously down regulated at 2 h after ALA-PCT, further down-regulated at 4 h, and lasted in low level at 24 h. It is concluded that ALA-PDT-induced apoptosis of HL-60 cells is associated with its effect on MMP, that is ALA-PDT promotes cell apoptosis through effect on mitochondrial function. Alanine 131-134 BCL2 apoptosis regulator Homo sapiens 83-88 22391169-5 2012 The semi-quantitative RT-PCR and real-time PCR showed that the expression level of Bcl-2 was obviously down regulated at 2 h after ALA-PCT, further down-regulated at 4 h, and lasted in low level at 24 h. It is concluded that ALA-PDT-induced apoptosis of HL-60 cells is associated with its effect on MMP, that is ALA-PDT promotes cell apoptosis through effect on mitochondrial function. Alanine 225-228 BCL2 apoptosis regulator Homo sapiens 83-88 22391177-5 2012 Compared with the group treated with As(2)O(3) (10 micromol/L) alone, zVAD-fmk (20 micromol/L) combined with As(2)O(3) (10 micromol/L) treatment group showed significant increase of expressions of Caspase-3 and BCL-2. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 70-78 BCL2 apoptosis regulator Homo sapiens 211-216 22391177-5 2012 Compared with the group treated with As(2)O(3) (10 micromol/L) alone, zVAD-fmk (20 micromol/L) combined with As(2)O(3) (10 micromol/L) treatment group showed significant increase of expressions of Caspase-3 and BCL-2. Arsenic Trioxide 109-118 BCL2 apoptosis regulator Homo sapiens 211-216 22278289-7 2012 Interestingly, co-culturing of primary cancer-associated fibroblasts (CAFs) with 22Rv1 or PC3 cells protected the cancer cells from sorafenib-induced cell death, and this protection was largely overcome by co-administration of the Bcl-2 antagonist, ABT737. Sorafenib 132-141 BCL2 apoptosis regulator Homo sapiens 231-236 22138516-9 2012 CONCLUSIONS: The study showed that major active component in the ethanol extract of Glycosmis pentaphylla is a flavonoid which induces apoptosis on cancer cell line, Hep3 B, by increasing the expression ratio of Bax/Bcl2 genes in a time and dose dependent manner. Ethanol 65-72 BCL2 apoptosis regulator Homo sapiens 216-220 22138516-9 2012 CONCLUSIONS: The study showed that major active component in the ethanol extract of Glycosmis pentaphylla is a flavonoid which induces apoptosis on cancer cell line, Hep3 B, by increasing the expression ratio of Bax/Bcl2 genes in a time and dose dependent manner. Flavonoids 111-120 BCL2 apoptosis regulator Homo sapiens 216-220 22157011-7 2012 SEGA (3a) inhibits indomethacin-induced down-regulation of bcl-2 and up-regulation of bax genes in gastric mucosa. Indomethacin 19-31 BCL2 apoptosis regulator Homo sapiens 59-64 22033244-0 2012 Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells. Cisplatin 32-41 BCL2 apoptosis regulator Homo sapiens 15-20 22033244-5 2012 Our results demonstrate that inhibition of BCL-2 by small-hairpin RNA (shRNA) or the BCL-2 inhibitor YC137, synergizes cisplatin sensitivity in NPC cells that overexpress BCL-2. YC137 101-106 BCL2 apoptosis regulator Homo sapiens 85-90 22033244-5 2012 Our results demonstrate that inhibition of BCL-2 by small-hairpin RNA (shRNA) or the BCL-2 inhibitor YC137, synergizes cisplatin sensitivity in NPC cells that overexpress BCL-2. YC137 101-106 BCL2 apoptosis regulator Homo sapiens 85-90 22033244-5 2012 Our results demonstrate that inhibition of BCL-2 by small-hairpin RNA (shRNA) or the BCL-2 inhibitor YC137, synergizes cisplatin sensitivity in NPC cells that overexpress BCL-2. Cisplatin 119-128 BCL2 apoptosis regulator Homo sapiens 43-48 22033244-5 2012 Our results demonstrate that inhibition of BCL-2 by small-hairpin RNA (shRNA) or the BCL-2 inhibitor YC137, synergizes cisplatin sensitivity in NPC cells that overexpress BCL-2. Cisplatin 119-128 BCL2 apoptosis regulator Homo sapiens 85-90 22033244-5 2012 Our results demonstrate that inhibition of BCL-2 by small-hairpin RNA (shRNA) or the BCL-2 inhibitor YC137, synergizes cisplatin sensitivity in NPC cells that overexpress BCL-2. Cisplatin 119-128 BCL2 apoptosis regulator Homo sapiens 85-90 22033244-6 2012 We also show that YC137 enhance cisplatin-induced apoptosis in HK1 and CNE1 cells through suppression of BCL-2 protein expression, induction of mitochondrial depolarization and activation of caspase 9 and caspase 3/7. YC137 18-23 BCL2 apoptosis regulator Homo sapiens 105-110 22033244-6 2012 We also show that YC137 enhance cisplatin-induced apoptosis in HK1 and CNE1 cells through suppression of BCL-2 protein expression, induction of mitochondrial depolarization and activation of caspase 9 and caspase 3/7. Cisplatin 32-41 BCL2 apoptosis regulator Homo sapiens 105-110 22278289-7 2012 Interestingly, co-culturing of primary cancer-associated fibroblasts (CAFs) with 22Rv1 or PC3 cells protected the cancer cells from sorafenib-induced cell death, and this protection was largely overcome by co-administration of the Bcl-2 antagonist, ABT737. ABT-737 249-255 BCL2 apoptosis regulator Homo sapiens 231-236 22278289-9 2012 The combination of sorafenib with Bcl-2 antagonists, such as ABT737, may constitute a promising therapeutic strategy against prostate cancer. ABT-737 61-67 BCL2 apoptosis regulator Homo sapiens 34-39 22036624-8 2012 Furthermore, treatment with Sal B down-regulated the IHG-induced release of cytochrome c, AIF nuclear translocation and Bax expression, but mitigated the IHG-mediated down-regulation of BcL-2 expression in SCs. salvianolic acid B 28-33 BCL2 apoptosis regulator Homo sapiens 186-191 22139839-4 2012 BCL2 was post-transcriptionally regulated and the repressed BCL2 mRNA was associated with non-polysomal, but dense fractions on sucrose density gradients. Sucrose 128-135 BCL2 apoptosis regulator Homo sapiens 60-64 22258404-8 2012 In addition, serine 77 phosphorylation reduces Bmf pro-apoptotic activity likely through a mechanism independent of altering Bmf localization to the mitochondria and/or interactions with dynein light chain 2 and the pro-survival proteins, B-cell lymphoma extra large, Bcl-2 and Mcl-1. Serine 13-19 BCL2 apoptosis regulator Homo sapiens 268-273 22264378-9 2012 Baicalein antagonized rotenone-induced overproduction of ROS, loss of DeltaPsim, the increased expression of Bax, cleaved caspase-3 and phosphorylated ERK1/2 and the decreased expression of Bcl-2. baicalein 0-9 BCL2 apoptosis regulator Homo sapiens 190-195 22264378-9 2012 Baicalein antagonized rotenone-induced overproduction of ROS, loss of DeltaPsim, the increased expression of Bax, cleaved caspase-3 and phosphorylated ERK1/2 and the decreased expression of Bcl-2. Rotenone 22-30 BCL2 apoptosis regulator Homo sapiens 190-195 22139839-0 2012 miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells. mir-125b 0-8 BCL2 apoptosis regulator Homo sapiens 35-39 22128299-2 2012 The BH3 mimetic ABT-737 antagonizes the antiapoptotic proteins Bcl-X(L) and Bcl-2 but not Mcl-1 or Bfl-1. BH 3 4-7 BCL2 apoptosis regulator Homo sapiens 76-81 21749866-3 2012 Here, we showed that Chlorogenic acid suppressed reactive oxygen species increase by activation of Akt phosphorylation,and increased FOXO family genes and anti-apoptotic protein Bcl-2 expression in MSCs culturing under oxidative stress. Chlorogenic Acid 21-37 BCL2 apoptosis regulator Homo sapiens 178-183 21749866-4 2012 In addition, PI-3Kinase Inhibitor (2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one, LY294002) could suppress the Chlorogenic acid-induced: (1) the cellular protective role, (2) the increase of the FOXO family genes expression, (3) increased expression of Bcl-2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 35-83 BCL2 apoptosis regulator Homo sapiens 256-261 21749866-4 2012 In addition, PI-3Kinase Inhibitor (2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one, LY294002) could suppress the Chlorogenic acid-induced: (1) the cellular protective role, (2) the increase of the FOXO family genes expression, (3) increased expression of Bcl-2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 85-93 BCL2 apoptosis regulator Homo sapiens 256-261 21749866-4 2012 In addition, PI-3Kinase Inhibitor (2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one, LY294002) could suppress the Chlorogenic acid-induced: (1) the cellular protective role, (2) the increase of the FOXO family genes expression, (3) increased expression of Bcl-2. Chlorogenic Acid 114-130 BCL2 apoptosis regulator Homo sapiens 256-261 22128299-2 2012 The BH3 mimetic ABT-737 antagonizes the antiapoptotic proteins Bcl-X(L) and Bcl-2 but not Mcl-1 or Bfl-1. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 16-19 BCL2 apoptosis regulator Homo sapiens 76-81 22108589-5 2012 Analysis of DNA fragmentation and chromatin condensation showed that arecoline induced apoptosis of BCC-1/KMC cells in a dose-dependent manner, activated caspase-3, and decreased expression of the anti-apoptotic protein Bcl-2. Arecoline 69-78 BCL2 apoptosis regulator Homo sapiens 220-225 22197393-0 2012 Induction of microtubule-damage, mitotic arrest, Bcl-2 phosphorylation, Bak activation, and mitochondria-dependent caspase cascade is involved in human Jurkat T-cell apoptosis by aruncin B from Aruncus dioicus var. 2-(8'-ethoxy-8'-methylpropylidene)-5-hydroxy-3,6-dihydro-2H-pyran-4-carboxylic acid 179-188 BCL2 apoptosis regulator Homo sapiens 49-54 22197393-2 2012 Exposure of human Jurkat T cells to aruncin B, purified from Aruncus dioicus, caused apoptosis along with microtubule damage, G(2)/M-arrest, Bcl-2 phosphorylation, Bak activation, mitochondrial membrane potential (Deltapsim) loss, cytochrome c release, activation of multiple caspases, and PARP degradation. 2-(8'-ethoxy-8'-methylpropylidene)-5-hydroxy-3,6-dihydro-2H-pyran-4-carboxylic acid 36-45 BCL2 apoptosis regulator Homo sapiens 141-146 22231496-7 2012 Moreover, daphnoretin inhibited Bcl-2 expression and induced Bax expression to desintegrate the outer mitochondrial membrane and causing cytochrome c release. daphnoretin 10-21 BCL2 apoptosis regulator Homo sapiens 32-37 22197812-12 2012 In H9 cells treated with RA for 29 days, GRP78/Bip, XBP-1 and Bcl2 were all upregulated. Tretinoin 25-27 BCL2 apoptosis regulator Homo sapiens 62-66 22206670-5 2012 Moreover, we found that TQ enhanced the 5-FU-induced killing of gastric cancer cells by mediating the downregulation of the anti-apoptotic protein bcl-2, the upregulation of the pro-apoptotic protein bax, and the activation of both caspase-3 and caspase-9. Fluorouracil 40-44 BCL2 apoptosis regulator Homo sapiens 147-152 22233801-0 2012 Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1. Glutathione 0-11 BCL2 apoptosis regulator Homo sapiens 134-139 22177955-8 2012 Treatment with GW9662 followed by CGZ resulted in a down-regulation of Akt activity and the loss of mitochondrial membrane potential (MMP), which was accompanied by a decrease in Bcl-2 expression and an increase in Bid cleavage. 2-chloro-5-nitrobenzanilide 15-21 BCL2 apoptosis regulator Homo sapiens 179-184 22177955-8 2012 Treatment with GW9662 followed by CGZ resulted in a down-regulation of Akt activity and the loss of mitochondrial membrane potential (MMP), which was accompanied by a decrease in Bcl-2 expression and an increase in Bid cleavage. ciglitazone 34-37 BCL2 apoptosis regulator Homo sapiens 179-184 22217149-12 2012 On the other hand, pre-treatment of gammaT3 in H2O2-treated DS neurons have reduced Bcl-2/Bax ratio, which was not shown in euploid neurons. Hydrogen Peroxide 47-51 BCL2 apoptosis regulator Homo sapiens 84-89 22027180-5 2012 Conversely, increase in phospho-c-Jun and Bax/Bcl-2 ratio was observed in METH-treated cells. Methamphetamine 74-78 BCL2 apoptosis regulator Homo sapiens 46-51 22027180-6 2012 Calpastatin reversed the toxic effect of METH by increasing cell viability, reducing phospho-c-Jun and Bax/Bcl-2 ratio in METH-treated cells. Methamphetamine 41-45 BCL2 apoptosis regulator Homo sapiens 107-112 22027180-6 2012 Calpastatin reversed the toxic effect of METH by increasing cell viability, reducing phospho-c-Jun and Bax/Bcl-2 ratio in METH-treated cells. Methamphetamine 122-126 BCL2 apoptosis regulator Homo sapiens 107-112 21889572-4 2012 In primary human villous trophoblast, a known pseudo-tumorigenic tissue, melatonin promotes the survival through inhibition of the Bax/Bcl-2 pathway while in BeWo choriocarcinoma cell line melatonin induces permeabilization of the mitochondrial membrane leading to cellular death. Melatonin 73-82 BCL2 apoptosis regulator Homo sapiens 135-140 22298457-10 2012 Western blotting assay showed that dehydrocorydaline dose-dependently increased Bax protein expression and decreased Bcl-2 protein expression. dehydrocorydalin 35-52 BCL2 apoptosis regulator Homo sapiens 117-122 22298457-12 2012 These results showed that dehydrocorydaline inhibits MCF-7 cell proliferation by inducing apoptosis mediated by regulating Bax/Bcl-2, activating caspases as well as cleaving PARP. dehydrocorydalin 26-43 BCL2 apoptosis regulator Homo sapiens 127-132 26701419-0 2012 Regulating the Conformation of Methylazacalix[6]pyridine by Oligonucleotide BCL-2 2345 and Its Recognition of Hydroxymethylpiperazinofullerene. methylazacalix(6)pyridine 31-56 BCL2 apoptosis regulator Homo sapiens 76-81 26701419-0 2012 Regulating the Conformation of Methylazacalix[6]pyridine by Oligonucleotide BCL-2 2345 and Its Recognition of Hydroxymethylpiperazinofullerene. Oligonucleotides 60-75 BCL2 apoptosis regulator Homo sapiens 76-81 26701419-0 2012 Regulating the Conformation of Methylazacalix[6]pyridine by Oligonucleotide BCL-2 2345 and Its Recognition of Hydroxymethylpiperazinofullerene. hydroxymethylpiperazinofullerene 110-142 BCL2 apoptosis regulator Homo sapiens 76-81 22555068-12 2012 CONCLUSION: Collectively, the results from the present study revealed a new role for DAP5 in cisplatin-induced apoptosis: DAP5/p97 and DAP5/p86 enhanced the translation of the anti-apoptotic protein Bcl-2 and inhibited cisplatin-induced apoptosis. Cisplatin 93-102 BCL2 apoptosis regulator Homo sapiens 199-204 22555068-12 2012 CONCLUSION: Collectively, the results from the present study revealed a new role for DAP5 in cisplatin-induced apoptosis: DAP5/p97 and DAP5/p86 enhanced the translation of the anti-apoptotic protein Bcl-2 and inhibited cisplatin-induced apoptosis. Cisplatin 219-228 BCL2 apoptosis regulator Homo sapiens 199-204 23317278-6 2012 In addition, the combination of exemestane and aspirin exhibited a synergistic inhibition of cell proliferation, significantly arrested the cell cycle in the G0/G1 phase and produced a stronger inhibitory effect on COX-1 and Bcl-2 expression than control or individual drug treatment. exemestane 32-42 BCL2 apoptosis regulator Homo sapiens 225-230 21573987-1 2012 OBJECTIVE: To evaluate the effect of raloxifene on antigen expression of Ki-67 and Bcl-2 in normal breast tissue. Raloxifene Hydrochloride 37-47 BCL2 apoptosis regulator Homo sapiens 83-88 22297752-4 2012 We found that the inhibitory concentration 50% of isolancifolide was approximately 20 M. The time- and dose-dependent effects of isolancifolide on apoptosis were determined by DNA fragmentation and propidium iodide staining, and the involvement of caspases and the Bcl-2 family in isolancifolide-induced apoptosis was assessed by Western blotting. isolancifolide 129-143 BCL2 apoptosis regulator Homo sapiens 265-270 22297752-4 2012 We found that the inhibitory concentration 50% of isolancifolide was approximately 20 M. The time- and dose-dependent effects of isolancifolide on apoptosis were determined by DNA fragmentation and propidium iodide staining, and the involvement of caspases and the Bcl-2 family in isolancifolide-induced apoptosis was assessed by Western blotting. isolancifolide 129-143 BCL2 apoptosis regulator Homo sapiens 265-270 23317278-6 2012 In addition, the combination of exemestane and aspirin exhibited a synergistic inhibition of cell proliferation, significantly arrested the cell cycle in the G0/G1 phase and produced a stronger inhibitory effect on COX-1 and Bcl-2 expression than control or individual drug treatment. Aspirin 47-54 BCL2 apoptosis regulator Homo sapiens 225-230 22524836-9 2012 The increased apoptotic sensitivity of SGC7901/ DDP to cisplatin was due to the decreasing proportion of Bcl-2/Bax via down-regulating NF-kB. Cisplatin 55-64 BCL2 apoptosis regulator Homo sapiens 105-110 22502687-7 2012 Curcumin induces apoptosis in myofibroblasts by down-regulating the Bcl-2/ Bax ratio. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 68-73 23098449-10 2012 OD values of caspase-3 and caspase-9 were increased and expression of bcl-2 was increased and bax was decreased in protein levels in RL952 cells after 24 h of hyperin treatment, Moreover, intracellular calcium accumulation occurred in hyperin-treated cells. Calcium 202-209 BCL2 apoptosis regulator Homo sapiens 70-75 22994712-8 2012 Truncated-Bid (tBid) translocated to mitochondria and activated the mitochondrial pathway in conjunction with down-regulation of Bcl-2 protein expression. tBID 15-19 BCL2 apoptosis regulator Homo sapiens 129-134 22863969-3 2012 Fomitoside-K could induce a dose and time-dependent apoptosis in YD-10B cells as characterized by cell morphology, cell cycle arrest, inhibition of survivin, activation of poly(ADP-ribose) polymerase (PARP), caspase-3, -9 and an increased expression ratio of Bax/Bcl-2. fomitoside-K 0-12 BCL2 apoptosis regulator Homo sapiens 263-268 23464460-10 2012 Furthermore, our study demonstrated that vitexicarpin induction of PC-3 cell apoptosis was associated with upregulation of the proapoptotic protein Bax, and downregulation of antiapoptotic protein Bcl-2, release of Cytochrome c from mitochondria and decrease in mitochondrial membrane potential. casticin 41-53 BCL2 apoptosis regulator Homo sapiens 197-202 22791165-6 2012 HGF-induced cell survival in response to oridonin administration was associated with the activation of c-Met-NF-kappaB-COX-2 and c-Met-Bcl-2-caspase-3 signaling pathways. oridonin 41-49 BCL2 apoptosis regulator Homo sapiens 135-140 22791152-2 2012 Treatment of HT-29 cells with LS-1 resulted in ROS generation, which was accompanied by disruption of mitochondrial membrane potential, cytosolic release of cytochrome c, sub-G1 peak accumulation, activation of Bid, caspase-3, -8, and -9, and cleavage of poly(ADP-ribose) polymerase (PARP) along with the suppressive expression of B cell lymphoma-2 (Bcl-2). Reactive Oxygen Species 47-50 BCL2 apoptosis regulator Homo sapiens 331-348 22791152-2 2012 Treatment of HT-29 cells with LS-1 resulted in ROS generation, which was accompanied by disruption of mitochondrial membrane potential, cytosolic release of cytochrome c, sub-G1 peak accumulation, activation of Bid, caspase-3, -8, and -9, and cleavage of poly(ADP-ribose) polymerase (PARP) along with the suppressive expression of B cell lymphoma-2 (Bcl-2). Reactive Oxygen Species 47-50 BCL2 apoptosis regulator Homo sapiens 350-355 22130129-5 2012 Ophiobolin O also caused the activation of JNK (c-Jun NH(2)-terminal kinase), p38 MAPK (mitogen activated protein kinase) and ERK (extracellular signal-regulated kinase) as well as the degradation of Bcl-2 phosphorylation (Ser70). ophiobolin O 0-12 BCL2 apoptosis regulator Homo sapiens 200-205 22791165-0 2012 Interruption of hepatocyte growth factor signaling augmented oridonin-induced death in human non-small cell lung cancer A549 cells via c-met-nuclear factor-kappaB-cyclooxygenase-2 and c-Met-Bcl-2-caspase-3 pathways. oridonin 61-69 BCL2 apoptosis regulator Homo sapiens 190-195 22791165-2 2012 Oridonin induced decrease in Bcl-2/Bax ratio and activation of caspase-3, while these processes were reversed by HGF, suggesting that HGF played an anti-apoptotic role in oridonin-induced A549 cell death. oridonin 0-8 BCL2 apoptosis regulator Homo sapiens 29-34 22975518-11 2012 Magnolol downregulated expression of the antiapoptotic protein Bcl2, upregulated expression of pro-apoptotic protein p53 and Bax, and caused the release of mitochondrial cytochrome c. magnolol 0-8 BCL2 apoptosis regulator Homo sapiens 63-67 22975518-12 2012 Magnolol-induced p53 and Bcl2 expression was abolished in the presence of compound C. Magnolol inhibited migration and invasion of HCT-116 cells through AMPK activation. magnolol 0-8 BCL2 apoptosis regulator Homo sapiens 25-29 21993018-3 2012 Bortezomib treatment led to phosphorylation/activation of jun N-terminal kinase (JNK) enzymes and JNK-dependent phosphorylation of Bcl-2 on serine 70. Bortezomib 0-10 BCL2 apoptosis regulator Homo sapiens 131-136 21399894-8 2012 Quantitative PCR and western analysis confirmed decreased expression of two genes, BCL-2 and CCND1, in docetaxel-resistant cells, which are both targeted by miR-34a. Docetaxel 103-112 BCL2 apoptosis regulator Homo sapiens 83-88 21399894-12 2012 This serves as a mechanism of acquired docetaxel resistance in these cells, possibly through direct interactions with BCL-2 and CCND1, therefore presenting a potential therapeutic target for the treatment of docetaxel-resistant breast cancer. Docetaxel 39-48 BCL2 apoptosis regulator Homo sapiens 118-123 21399894-12 2012 This serves as a mechanism of acquired docetaxel resistance in these cells, possibly through direct interactions with BCL-2 and CCND1, therefore presenting a potential therapeutic target for the treatment of docetaxel-resistant breast cancer. Docetaxel 208-217 BCL2 apoptosis regulator Homo sapiens 118-123 22172701-4 2012 Unlike ABT-737, which is a selective inhibitor of anti-apoptotic members of the Bcl-2 protein family, the class A compounds showed broad-spectrum binding activity to target proteins similar to those of Bim BH3 peptide. ABT-737 7-14 BCL2 apoptosis regulator Homo sapiens 80-85 22172701-9 2012 This study suggests that it is feasible to design small-molecule inhibitors based on the structure of Bim BH3, which shows broad-spectrum binding to Bcl-x(L), Bcl-2, and Mcl-1 proteins. BH 3 106-109 BCL2 apoptosis regulator Homo sapiens 159-164 21993018-3 2012 Bortezomib treatment led to phosphorylation/activation of jun N-terminal kinase (JNK) enzymes and JNK-dependent phosphorylation of Bcl-2 on serine 70. Serine 140-146 BCL2 apoptosis regulator Homo sapiens 131-136 22236190-4 2012 Our results also suggest that induction of p21 and subsequent disturbance of Bax/Bcl-2 balanced ratio as well as decreased telomerase activity may be rational mechanisms for the potent/direct short-term cytotoxicity of high doses of BIBR1532 against NB4 cells. BIBR 1532 233-241 BCL2 apoptosis regulator Homo sapiens 81-86 22052464-4 2012 We propose a different approach: therapies that combine 2-deoxyglucose (2DG) with Bcl-2 antagonist such as ABT-263/737 (ABT). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 107-110 BCL2 apoptosis regulator Homo sapiens 82-87 23568006-1 2012 AIM: To investigate whether the inhibition of Bcl-2 and Cyclin D1 by lentivirus-mediated RNA interference enhances doxorubicin (DXR) cytotoxicity in the drug-resistant human osteosarcoma MG63 cells. Doxorubicin 115-126 BCL2 apoptosis regulator Homo sapiens 46-51 23568006-1 2012 AIM: To investigate whether the inhibition of Bcl-2 and Cyclin D1 by lentivirus-mediated RNA interference enhances doxorubicin (DXR) cytotoxicity in the drug-resistant human osteosarcoma MG63 cells. Doxorubicin 128-131 BCL2 apoptosis regulator Homo sapiens 46-51 23568006-2 2012 MATERIALS AND METHODS: Lentivirus-mediated RNAi were used to inhibit the expression of Bcl-2 or Cyclin D1 mRNA and protein; qRT-PCR, Western blotting, Flow cytometry and MTT assays were used to detect the expression of Bcl-2 and Cyclin D1 and the sensitivity to doxorubicin of MG63/DXR. Doxorubicin 262-273 BCL2 apoptosis regulator Homo sapiens 87-92 22052464-4 2012 We propose a different approach: therapies that combine 2-deoxyglucose (2DG) with Bcl-2 antagonist such as ABT-263/737 (ABT). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 120-123 BCL2 apoptosis regulator Homo sapiens 82-87 22415078-7 2012 Conversely, DHA treatment resulted in increase in acetylation of H3 and Bcl-2 levels and decrease in deacetylation, methylation, phosphorylation of H3 and caspase-3 levels, suggesting that DHA promotes gene expression and neuroprotection. dehydroacetic acid 12-15 BCL2 apoptosis regulator Homo sapiens 72-77 22994946-6 2012 In contrast, 25-OH-cholesterol promoted CMC apoptosis by a caspase 3-dependent mechanism that involved the transcriptional activation of the pro-apoptotic protein, Bax and post-translational degradation of the anti-apoptotic protein, Bcl-2. 25-oh-cholesterol 13-30 BCL2 apoptosis regulator Homo sapiens 234-239 22080570-0 2012 Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737. ABT-737 103-110 BCL2 apoptosis regulator Homo sapiens 80-85 22415078-7 2012 Conversely, DHA treatment resulted in increase in acetylation of H3 and Bcl-2 levels and decrease in deacetylation, methylation, phosphorylation of H3 and caspase-3 levels, suggesting that DHA promotes gene expression and neuroprotection. dehydroacetic acid 189-192 BCL2 apoptosis regulator Homo sapiens 72-77 22508043-6 2012 Furthermore, expression of the pro-apoptotic protein Bad was up-regulated and expression of the anti-apoptotic proteins Bcl-2 and Bcl-xl was down-regulated in cells that had been treated with trolox plus curcumin. 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid 192-198 BCL2 apoptosis regulator Homo sapiens 120-125 22739213-5 2012 Immunohistochemical staining and western blotting demonstrated upregulation of Bax, cytochrome c and caspase-3, and downregulation of Bcl-2 for both in vivo and in vitro cases after ALA-LIU treatment. ala-liu 182-189 BCL2 apoptosis regulator Homo sapiens 134-139 22508043-6 2012 Furthermore, expression of the pro-apoptotic protein Bad was up-regulated and expression of the anti-apoptotic proteins Bcl-2 and Bcl-xl was down-regulated in cells that had been treated with trolox plus curcumin. Curcumin 204-212 BCL2 apoptosis regulator Homo sapiens 120-125 22132896-12 2012 Surprisingly, only rapamycin preconditioning treatment increased anti-apoptotic Bcl2 levels (P < 0 001). Sirolimus 19-28 BCL2 apoptosis regulator Homo sapiens 80-84 22048238-11 2012 PAO augmented the expression of Bim and strengthened the interaction between Bim and Bcl-2. oxophenylarsine 0-3 BCL2 apoptosis regulator Homo sapiens 85-90 22343305-4 2012 RESULTS: DAC, VPA and suberoylanilide hydroxamic acid (SAHA) inhibited proliferation, induced cell cycle arrest and enhanced the apoptotic index in both cell lines, DAC, VPA and SAHA upregulated E-cadherin mRNA and protein levels and downregulated Bcl-2 mRNA levels in vitro. Valproic Acid 14-17 BCL2 apoptosis regulator Homo sapiens 248-253 22343305-4 2012 RESULTS: DAC, VPA and suberoylanilide hydroxamic acid (SAHA) inhibited proliferation, induced cell cycle arrest and enhanced the apoptotic index in both cell lines, DAC, VPA and SAHA upregulated E-cadherin mRNA and protein levels and downregulated Bcl-2 mRNA levels in vitro. Vorinostat 22-53 BCL2 apoptosis regulator Homo sapiens 248-253 22343305-4 2012 RESULTS: DAC, VPA and suberoylanilide hydroxamic acid (SAHA) inhibited proliferation, induced cell cycle arrest and enhanced the apoptotic index in both cell lines, DAC, VPA and SAHA upregulated E-cadherin mRNA and protein levels and downregulated Bcl-2 mRNA levels in vitro. Vorinostat 55-59 BCL2 apoptosis regulator Homo sapiens 248-253 22343305-4 2012 RESULTS: DAC, VPA and suberoylanilide hydroxamic acid (SAHA) inhibited proliferation, induced cell cycle arrest and enhanced the apoptotic index in both cell lines, DAC, VPA and SAHA upregulated E-cadherin mRNA and protein levels and downregulated Bcl-2 mRNA levels in vitro. Valproic Acid 170-173 BCL2 apoptosis regulator Homo sapiens 248-253 22343305-4 2012 RESULTS: DAC, VPA and suberoylanilide hydroxamic acid (SAHA) inhibited proliferation, induced cell cycle arrest and enhanced the apoptotic index in both cell lines, DAC, VPA and SAHA upregulated E-cadherin mRNA and protein levels and downregulated Bcl-2 mRNA levels in vitro. Vorinostat 178-182 BCL2 apoptosis regulator Homo sapiens 248-253 23091559-0 2012 Dentatin Induces Apoptosis in Prostate Cancer Cells via Bcl-2, Bcl-xL, Survivin Downregulation, Caspase-9, -3/7 Activation, and NF-kappaB Inhibition. dentatin 0-8 BCL2 apoptosis regulator Homo sapiens 56-61 21938469-5 2012 Incubation of HepG2 cells with carvacrol for 24 h induced apoptosis by the activation of caspase-3, cleavage of PARP and decreased Bcl-2 gene expression. carvacrol 31-40 BCL2 apoptosis regulator Homo sapiens 131-136 22414090-3 2012 SMIs of antiapoptotic Bcl-2 proteins are assumed to compete with proapoptotic Bcl-2s to occupy BH3 docking grooves on the surfaces of antiapoptotic family members. BH 3 95-98 BCL2 apoptosis regulator Homo sapiens 22-27 22414090-3 2012 SMIs of antiapoptotic Bcl-2 proteins are assumed to compete with proapoptotic Bcl-2s to occupy BH3 docking grooves on the surfaces of antiapoptotic family members. BH 3 95-98 BCL2 apoptosis regulator Homo sapiens 78-83 23091559-5 2012 We found that dentatin-mediated accumulation of reactive oxygen species (ROS) and downregulated expression levels of antiapoptotic molecules (Bcl-2, Bcl-xL, and Survivin), leading to disruption of mitochondrial membrane potential (MMP), cell membrane permeability, and release of cytochrome c from the mitochondria into the cytosol. dentatin 14-22 BCL2 apoptosis regulator Homo sapiens 142-147 22645629-6 2012 Furthermore, EDCL did not alter the expression of bax in HepG2 cells but did selectively downregulate the expression of bcl-2 and bcl-xl, resulting in an increase in the ratio of bax:bcl-2 and bax:bcl-xl. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 13-17 BCL2 apoptosis regulator Homo sapiens 120-125 22454688-3 2012 Both intracellular and mitochondrial reactive oxygen species were increased to lead to alterations of mitochondrial membrane permeability and Bcl-2 family including upregulation of Bid, tBid, and Bax and downregulation of Bcl-2. Reactive Oxygen Species 37-60 BCL2 apoptosis regulator Homo sapiens 142-147 22454688-3 2012 Both intracellular and mitochondrial reactive oxygen species were increased to lead to alterations of mitochondrial membrane permeability and Bcl-2 family including upregulation of Bid, tBid, and Bax and downregulation of Bcl-2. Reactive Oxygen Species 37-60 BCL2 apoptosis regulator Homo sapiens 222-227 22454688-3 2012 Both intracellular and mitochondrial reactive oxygen species were increased to lead to alterations of mitochondrial membrane permeability and Bcl-2 family including upregulation of Bid, tBid, and Bax and downregulation of Bcl-2. tBID 186-190 BCL2 apoptosis regulator Homo sapiens 142-147 21760828-5 2012 Elevation of the Bax/Bcl-2 ratio and a decrease in IAP family proteins XIAP and survivin were also observed following terpinen-4-ol treatment. terpinenol-4 118-131 BCL2 apoptosis regulator Homo sapiens 21-26 21785650-8 2012 ASMq ethanol extract possesses an inhibition effect on Caco-2 cells proliferation, induction of cell apoptosis, cell cycle arrest in sub-G1 phase, and downregulation of bcl-2 and upregulation of Bax gene expression. asmq ethanol 0-12 BCL2 apoptosis regulator Homo sapiens 169-174 21785650-10 2012 The anticancer mechanism of ASMq ethanol extract may be involved in antiproliferation, induction of apoptosis, cell cycle arrest, and regulation of apoptosis-related gene expression such as bcl-2 and Bax activity pathway. asmq ethanol 28-40 BCL2 apoptosis regulator Homo sapiens 190-195 22719792-5 2012 In the upstream, diosgenin increased the expression of Bax, decreased the expression of Bid and Bcl-2, and augmented the Bax/Bcl-2 ratio. Diosgenin 17-26 BCL2 apoptosis regulator Homo sapiens 96-101 22719792-5 2012 In the upstream, diosgenin increased the expression of Bax, decreased the expression of Bid and Bcl-2, and augmented the Bax/Bcl-2 ratio. Diosgenin 17-26 BCL2 apoptosis regulator Homo sapiens 125-130 22719792-8 2012 These results suggest that diosgenin-induced apoptosis in HepG2 cells through Bcl-2 protein family-mediated mitochndria/caspase-3-dependent pathway. Diosgenin 27-36 BCL2 apoptosis regulator Homo sapiens 78-83 22645629-6 2012 Furthermore, EDCL did not alter the expression of bax in HepG2 cells but did selectively downregulate the expression of bcl-2 and bcl-xl, resulting in an increase in the ratio of bax:bcl-2 and bax:bcl-xl. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 13-17 BCL2 apoptosis regulator Homo sapiens 183-188 21933852-5 2012 RESULTS: Results demonstrate that quercetin, a natural flavonoid, restores TRAIL-induced cell death in resistant transformed follicular lymphoma B-cell lines, despite high Bcl-2 expression levels due to the chromosomal translocation t(14;18). Quercetin 34-43 BCL2 apoptosis regulator Homo sapiens 172-177 22080086-6 2012 In addition, simvastatin markedly increased protein levels of Bax (proapoptotic, +53%) and Bcl-2 (antiapoptotic, +100%, P<0.05), mitochondrial PTP opening (+44%, P<0.05), and TUNEL-positive nuclei in human skeletal myotubes, demonstrating up-regulation of mitochondrial-mediated myonuclear apoptotic mechanisms. Simvastatin 13-24 BCL2 apoptosis regulator Homo sapiens 91-96 22919418-7 2012 PEITC induced G(0)/G(1) phase arrest through the effects of associated protein such as p53, p21, p17, CDK2 and cyclin E, and it triggered apoptosis through promotion of Bax and Bid expression and reduction of Bcl-2, leading to decrease the levels of mitochondrial membrane potential (DeltaPsi(m)), and followed the releases of cytochrome c, AIF and Endo G then for causing apoptosis in HSC-3 cells. phenethyl isothiocyanate 0-5 BCL2 apoptosis regulator Homo sapiens 209-214 22202031-6 2012 Bcl-2 inhibition with ABT-737 enhanced TRAIL-mediated apoptosis in all HB cells. ABT-737 22-29 BCL2 apoptosis regulator Homo sapiens 0-5 22481869-5 2012 In addition, Tet/pTRE-STGC3/CNE2+Dox xenografts showed an increase in the percentage of apoptotic cells, a decrease in Bcl-2 protein expression and an increase in Bax protein expression. tetramethylenedisulfotetramine 13-16 BCL2 apoptosis regulator Homo sapiens 119-124 22481869-5 2012 In addition, Tet/pTRE-STGC3/CNE2+Dox xenografts showed an increase in the percentage of apoptotic cells, a decrease in Bcl-2 protein expression and an increase in Bax protein expression. Doxycycline 33-36 BCL2 apoptosis regulator Homo sapiens 119-124 22032837-0 2012 The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin. Cisplatin 92-101 BCL2 apoptosis regulator Homo sapiens 4-8 22032837-1 2012 OBJECTIVE: To identify pathways that influence endometrial cancer (EC) cell sensitivity to cisplatin and to characterize the BCL2 antagonist of cell death (BAD) pathway as a therapeutic target to increase cisplatin sensitivity. Cisplatin 205-214 BCL2 apoptosis regulator Homo sapiens 125-129 22532787-5 2012 Western blot study showed that isoalantolactone increased the expression of phosphorylated p38 MAPK, Bax, and cleaved caspase-3 and decreased the expression of Bcl-2 in a dose-dependent manner. isoalantolactone 31-47 BCL2 apoptosis regulator Homo sapiens 160-165 21897270-10 2012 Furthermore, the increase in the expression of Bim was the most significant among the Bcl-2 family after oleanen treatment. 12-oleanene-3beta,6alpha-diol 105-112 BCL2 apoptosis regulator Homo sapiens 86-91 22949821-6 2012 Taken together, our findings provide evidence showing that the down-regulation of Notch-1 by arsenic trioxide could be an effective approach, to cause down-regulation of Bcl-2, and NF-kappaB, resulting in the inhibition of cell growth and invasion as well as induction of apoptosis. Arsenic Trioxide 93-109 BCL2 apoptosis regulator Homo sapiens 170-175 22888237-4 2012 Upon the codelivery of siRNA, targeting the Bcl-2 gene, and DOX, using the folate-targeted nanocarrier, DOX-induced apoptosis in the skov-3 cells overexpressing folate receptor was significantly enhanced through a mechanism of downregulating the antiapoptotic protein Bcl-2, while simultaneously upregulating the proapoptotic protein Bax. Folic Acid 75-81 BCL2 apoptosis regulator Homo sapiens 44-49 22888237-4 2012 Upon the codelivery of siRNA, targeting the Bcl-2 gene, and DOX, using the folate-targeted nanocarrier, DOX-induced apoptosis in the skov-3 cells overexpressing folate receptor was significantly enhanced through a mechanism of downregulating the antiapoptotic protein Bcl-2, while simultaneously upregulating the proapoptotic protein Bax. Folic Acid 75-81 BCL2 apoptosis regulator Homo sapiens 268-273 22888237-4 2012 Upon the codelivery of siRNA, targeting the Bcl-2 gene, and DOX, using the folate-targeted nanocarrier, DOX-induced apoptosis in the skov-3 cells overexpressing folate receptor was significantly enhanced through a mechanism of downregulating the antiapoptotic protein Bcl-2, while simultaneously upregulating the proapoptotic protein Bax. Doxorubicin 104-107 BCL2 apoptosis regulator Homo sapiens 44-49 22888237-4 2012 Upon the codelivery of siRNA, targeting the Bcl-2 gene, and DOX, using the folate-targeted nanocarrier, DOX-induced apoptosis in the skov-3 cells overexpressing folate receptor was significantly enhanced through a mechanism of downregulating the antiapoptotic protein Bcl-2, while simultaneously upregulating the proapoptotic protein Bax. Doxorubicin 104-107 BCL2 apoptosis regulator Homo sapiens 268-273 22408435-8 2012 Moreover, bufalin synergized with Akt inhibitor to induce the apoptosis of A549 cells and this was associated with the upregulation of Bax expression, the downregulation of Bcl-2 and livin expression, and the activation of Caspase-3. bufalin 10-17 BCL2 apoptosis regulator Homo sapiens 173-178 22802690-1 2012 Polyethylene glycol-grafted polyethylenimine (PEG-g-PEI) which was functionalized with a neuroblastoma cell-specific ligand, the GD2 single chain antibody (scAb(GD2)), was synthesized in order to effectively deliver Bcl-2 siRNA into neuroblastoma cells. Polyethylene Glycols 0-19 BCL2 apoptosis regulator Homo sapiens 216-221 22802690-1 2012 Polyethylene glycol-grafted polyethylenimine (PEG-g-PEI) which was functionalized with a neuroblastoma cell-specific ligand, the GD2 single chain antibody (scAb(GD2)), was synthesized in order to effectively deliver Bcl-2 siRNA into neuroblastoma cells. Polyethyleneimine 28-44 BCL2 apoptosis regulator Homo sapiens 216-221 22802690-1 2012 Polyethylene glycol-grafted polyethylenimine (PEG-g-PEI) which was functionalized with a neuroblastoma cell-specific ligand, the GD2 single chain antibody (scAb(GD2)), was synthesized in order to effectively deliver Bcl-2 siRNA into neuroblastoma cells. peg-g-pei 46-55 BCL2 apoptosis regulator Homo sapiens 216-221 22802690-2 2012 This polymer was complexed first with superparamagnetic iron oxide nanoparticle (SPION) to get a MRI-visible targeted non-viral vector (scAb(GD2)-PEG-g-PEI-SPION) and then with Bcl-2 siRNA to form nanoparticles showing low cytotoxicity. Polymers 5-12 BCL2 apoptosis regulator Homo sapiens 177-182 22430528-6 2012 In addition, pretreatment with XG countered the effect of Abeta on Bax and Bcl-2 expression and repressed Abeta-induced caspase-3 activation, suggesting that the neuroprotective effect of XG is associated with apoptosis regulation. xg 31-33 BCL2 apoptosis regulator Homo sapiens 75-80 22393286-7 2012 Both the mRNA and protein levels of tumor suppressor gene p53 and apoptotic gene bax were upregulated while the antiapoptotic gene bcl-2 was downregulated in ZnO NP-treated HepG2 cells. zno np 158-164 BCL2 apoptosis regulator Homo sapiens 131-136 22215411-0 2012 Sanguinarine induces apoptosis of HT-29 human colon cancer cells via the regulation of Bax/Bcl-2 ratio and caspase-9-dependent pathway. sanguinarine 0-12 BCL2 apoptosis regulator Homo sapiens 91-96 21956158-10 2012 Omeprazole treatment in human colon cancer cell lines HCT-116 and HCA-7 cells resulted in induction of p21waf1/cip1 and decreased the expression of anti-apoptotic proteins Bcl-2, Bcl-XL and survivin in a dose-dependent manner. Omeprazole 0-10 BCL2 apoptosis regulator Homo sapiens 208-213 22430528-6 2012 In addition, pretreatment with XG countered the effect of Abeta on Bax and Bcl-2 expression and repressed Abeta-induced caspase-3 activation, suggesting that the neuroprotective effect of XG is associated with apoptosis regulation. xg 188-190 BCL2 apoptosis regulator Homo sapiens 75-80 22517702-3 2012 We studied the role of B-cell lymphoma 2 (Bcl-2) expression in predicting the response to DCF combination chemotherapy in metastatic gastric carcinoma. dcf 90-93 BCL2 apoptosis regulator Homo sapiens 23-40 22517702-3 2012 We studied the role of B-cell lymphoma 2 (Bcl-2) expression in predicting the response to DCF combination chemotherapy in metastatic gastric carcinoma. dcf 90-93 BCL2 apoptosis regulator Homo sapiens 42-47 21836813-4 2012 The mechanisms by which DISS protected neuron cells from glutamate-induced excitotoxicity included the downregulation of proapoptotic gene Bax and the upregulation of antiapoptotic gene Bcl-2. Glutamic Acid 57-66 BCL2 apoptosis regulator Homo sapiens 186-191 21946416-10 2012 However, only inhibition of ERK reduced the ability of PEDF to protect neurons from H2O2-induced Bcl-2 decrease and neuronal death. Hydrogen Peroxide 84-88 BCL2 apoptosis regulator Homo sapiens 97-102 22971477-5 2012 ABT-737 disturbed the binding of B cell lymphoma (Bcl)-2 homologous antagonist killer and Bcl-extra large; ATO downregulated myeloid cell leukaemia (Mcl)-1 protein and upregulated Mcl-1short, the short splicing variant. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 33-56 22814102-1 2012 Mcl-1, an anti-apoptotic Bcl-2 homolog that has a structurally divergent BH3-binding pocket, non-redundant action model, and unique characteristic of short life confers complete resistance to the BH3 mimetic ABT-737. BH 3 73-76 BCL2 apoptosis regulator Homo sapiens 25-30 22814102-1 2012 Mcl-1, an anti-apoptotic Bcl-2 homolog that has a structurally divergent BH3-binding pocket, non-redundant action model, and unique characteristic of short life confers complete resistance to the BH3 mimetic ABT-737. BH 3 196-199 BCL2 apoptosis regulator Homo sapiens 25-30 22814102-1 2012 Mcl-1, an anti-apoptotic Bcl-2 homolog that has a structurally divergent BH3-binding pocket, non-redundant action model, and unique characteristic of short life confers complete resistance to the BH3 mimetic ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 208-211 BCL2 apoptosis regulator Homo sapiens 25-30 22850597-4 2012 In additional studies, treatment of QBC939 cells with different concentrations (10, 40, 80 muM) of berberine for 48 h resulted in a significant dose-dependent increase in apoptosis compared to the non-berberine-treated control, which was associated with an increased expression of pro-apoptotic protein Bax and decreased expression of anti-apoptotic proteins Bcl-2 and Bcl-xL. Berberine 99-108 BCL2 apoptosis regulator Homo sapiens 359-364 21964700-12 2012 In addition, CUS increased the protein expression of bax, but decreased the bcl-2 and procaspase-3 expression in HepG2 cells. cus 13-16 BCL2 apoptosis regulator Homo sapiens 76-81 21964700-13 2012 Our data indicate that CUS has potential anticancer activity for human hepatoma, which can be attributed in part to its inhibition of proliferation and apoptosis, induced by decreasing the bcl-2:bax ratio and caspase-3 activation. cus 23-26 BCL2 apoptosis regulator Homo sapiens 189-194 22262940-0 2012 The polyamidoamine-mediated inhibition of bcl-2 by small hairpin RNA to induce apoptosis in human lens epithelial cells. Poly(amidoamine) 4-18 BCL2 apoptosis regulator Homo sapiens 42-47 22262940-1 2012 PURPOSE: To investigate whether apoptosis of human lens epithelial cells (HLECs) can be induced with the polyamidoamine (PAMAM)-mediated inhibition of bcl-2 (b-cell lymphoma 2) by small hairpin RNA (shRNA). Poly(amidoamine) 105-119 BCL2 apoptosis regulator Homo sapiens 151-156 22262940-1 2012 PURPOSE: To investigate whether apoptosis of human lens epithelial cells (HLECs) can be induced with the polyamidoamine (PAMAM)-mediated inhibition of bcl-2 (b-cell lymphoma 2) by small hairpin RNA (shRNA). Poly(amidoamine) 121-126 BCL2 apoptosis regulator Homo sapiens 151-156 22262940-2 2012 METHODS: HLECs (SRA01/04) were transfected with the fifth generation of PAMAM (PAMAM G5) by bcl-2 shRNA. Poly(amidoamine) 72-77 BCL2 apoptosis regulator Homo sapiens 92-97 22262940-2 2012 METHODS: HLECs (SRA01/04) were transfected with the fifth generation of PAMAM (PAMAM G5) by bcl-2 shRNA. Poly(amidoamine) 79-84 BCL2 apoptosis regulator Homo sapiens 92-97 22262940-10 2012 RESULTS: At 24, 48, and 72 h after transfection, the rate of transfection of bcl-2 shRNA mediated by PAMAM was higher than in the liposome-mediated group (p<0.05). Poly(amidoamine) 101-106 BCL2 apoptosis regulator Homo sapiens 77-82 22262940-13 2012 Hoechst staining showed that bcl-2 shRNA transfected cells had a lower growth status with nuclear fragmentation. hoechst 0-7 BCL2 apoptosis regulator Homo sapiens 29-34 22262940-15 2012 CONCLUSIONS: PAMAM-mediated bcl-2 shRNA can downregulate the expression of bcl-2 and induce the apoptosis of HLECs by engaging the mitochondrial pathway, including catalytic activation of the caspases. Poly(amidoamine) 13-18 BCL2 apoptosis regulator Homo sapiens 28-33 22262940-15 2012 CONCLUSIONS: PAMAM-mediated bcl-2 shRNA can downregulate the expression of bcl-2 and induce the apoptosis of HLECs by engaging the mitochondrial pathway, including catalytic activation of the caspases. Poly(amidoamine) 13-18 BCL2 apoptosis regulator Homo sapiens 75-80 22293115-3 2012 We demonstrated that miR-125b significantly suppresses HCC cell proliferation and promotes apoptosis by inhibiting the gene expression of the anti-apoptotic protein, Bcl-2. mir-125b 21-29 BCL2 apoptosis regulator Homo sapiens 166-171 22293115-6 2012 We concluded that miR-125b acts as a tumor suppressor in hepatic tumor development by targeting Bcl-2 and inducing cancer cell apoptosis. mir-125b 18-26 BCL2 apoptosis regulator Homo sapiens 96-101 22355465-0 2012 BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. Cisplatin 87-96 BCL2 apoptosis regulator Homo sapiens 0-4 22355465-2 2012 Recently, it has been demonstrated that the phosphorylation status of the BCL2 antagonist of cell death (BAD) protein may influence ovarian cancer (OVCA) cell sensitivity to cisplatin. Cisplatin 174-183 BCL2 apoptosis regulator Homo sapiens 74-78 22466960-0 2012 Activation of ERK-p53 and ERK-mediated phosphorylation of Bcl-2 are involved in autophagic cell death induced by the c-Met inhibitor SU11274 in human lung cancer A549 cells. ((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide) 133-140 BCL2 apoptosis regulator Homo sapiens 58-63 22366014-1 2012 OBJECTIVE: To investigate the effect of tetrandrine (Tet) on the expression of bax, bcl-2, and transforming growth factor-beta2 (TGF-beta2) mRNA in cultured human fibroblasts of Tenon"s capsules (TCFS) and explore its possible mechanism. tetrandrine 40-51 BCL2 apoptosis regulator Homo sapiens 84-89 22366014-1 2012 OBJECTIVE: To investigate the effect of tetrandrine (Tet) on the expression of bax, bcl-2, and transforming growth factor-beta2 (TGF-beta2) mRNA in cultured human fibroblasts of Tenon"s capsules (TCFS) and explore its possible mechanism. tet 53-56 BCL2 apoptosis regulator Homo sapiens 84-89 22366014-3 2012 RESULTS: The expression level of bax mRNA was obviously higher, while bcl-2 and TGF-beta2 mRNA levels were significantly lower in Tet-treated TCFS than those in the control cells (P<0.05). tet 130-133 BCL2 apoptosis regulator Homo sapiens 70-75 22366014-4 2012 CONCLUSION: Tet can inhibit the proliferation of TCFS possibly by reducing the expressions of bcl-2 and TGF-beta2 mRNA, enhancing the expression of bax mRNA and inducing cell apoptosis, suggesting its potential in preventing fibrous scar formation after glaucoma filtration surgery. tet 12-15 BCL2 apoptosis regulator Homo sapiens 96-101 22862178-6 2012 HEAMQ-induced apoptosis was accompanied with up-regulation of the protein expression of Bax and down-regulation of the protein expression of Bcl-2, Mcl-1, XIAP, and survivin, resulting in cytochrome c release and activation of caspases. heamq 0-5 BCL2 apoptosis regulator Homo sapiens 141-146 22862178-7 2012 Inhibitors of JNK (SP600125) and p38 MAPK (SB203580) suppressed HEAMQ-induced apoptosis and G2/M phase arrest, attenuated the activation of Bax, and blocked down-regulation of Bcl-2, XIAP and survivin in HEAMQ-treated U937 cells. SB 203580 43-51 BCL2 apoptosis regulator Homo sapiens 176-181 22862178-7 2012 Inhibitors of JNK (SP600125) and p38 MAPK (SB203580) suppressed HEAMQ-induced apoptosis and G2/M phase arrest, attenuated the activation of Bax, and blocked down-regulation of Bcl-2, XIAP and survivin in HEAMQ-treated U937 cells. heamq 64-69 BCL2 apoptosis regulator Homo sapiens 176-181 21901250-7 2012 In addition, bufalin treatment resulted in an increase of the Bax/Bcl-2 (or Bcl-xL) ratio and caused down-regulation of inhibitor of apoptosis protein (IAP) family members. bufalin 25-32 BCL2 apoptosis regulator Homo sapiens 78-83 23061910-5 2012 Taken together, our data indicated that stevioside induces the ROS-mediated mitochondrial permeability transition and results in the increased expression of apoptotic proteins such as Bax, Bcl-2 and Caspase-9. stevioside 40-50 BCL2 apoptosis regulator Homo sapiens 189-194 21947091-13 2012 SB potently induced apoptosis, which was accompanied by DNA fragmentation, down-regulated Bcl-2 in LNCaP and PC-3 cells, Bcl-xL in DU145 cells, and down-regulated procaspase-3, but not procaspase-7, in these human prostate cancer cell lines. Butyric Acid 0-2 BCL2 apoptosis regulator Homo sapiens 102-107 22001761-6 2012 Compared to controls, neurons overexpressing mortalin also demonstrated superior intracellular free calcium regulation, lower mitochondrial reactive oxygen species generation, and decreased Bax/Bcl-2 ratios in response to Abeta treatment. UNII-042A8N37WH 222-227 BCL2 apoptosis regulator Homo sapiens 194-199 21993665-8 2012 Acacetin-induced apoptosis was also accompanied by upregulation of Bax, and downregulation of Bcl-2. acacetin 0-8 BCL2 apoptosis regulator Homo sapiens 106-111 23272207-2 2012 Structural studies of Bcl-2 revealed the presence of a flexible and natively disordered loop that bridges the Bcl-2 homology motifs, BH3 and BH4. BH 3 133-136 BCL2 apoptosis regulator Homo sapiens 22-27 23284640-9 2012 Sal induced apoptosis as characterized by an increase in the Bax/Bcl-2 ratio. salinomycin 0-3 BCL2 apoptosis regulator Homo sapiens 65-70 23180967-9 2012 In addition, mifepristone obviously upregulated bax and Fas expression and downregulated bcl-2 expression. Mifepristone 13-25 BCL2 apoptosis regulator Homo sapiens 89-94 22149883-10 2012 Consistent with STAT3 inactivation, H-geniposide downregulated the expressions of Bcl-2, Bcl-xL, survivin, and cyclin D1; this correlated with the accumulation of cells in the sub-G1 phase of the cell cycle and the induction of apoptosis. h-geniposide 36-48 BCL2 apoptosis regulator Homo sapiens 82-87 23285061-1 2012 ABT-737 is a BH3 mimetic small molecule inhibitor that can effectively inhibit the activity of antiapoptotic Bcl-2 family proteins including Bcl2, Bcl-xL and Bcl-w, and further enhances the effect of apoptosis by activating the proapoptotic proteins (t-Bid, Bad, Bim). ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 141-145 23285061-1 2012 ABT-737 is a BH3 mimetic small molecule inhibitor that can effectively inhibit the activity of antiapoptotic Bcl-2 family proteins including Bcl2, Bcl-xL and Bcl-w, and further enhances the effect of apoptosis by activating the proapoptotic proteins (t-Bid, Bad, Bim). BH 3 13-16 BCL2 apoptosis regulator Homo sapiens 141-145 23272207-2 2012 Structural studies of Bcl-2 revealed the presence of a flexible and natively disordered loop that bridges the Bcl-2 homology motifs, BH3 and BH4. BH 3 133-136 BCL2 apoptosis regulator Homo sapiens 110-115 23272207-2 2012 Structural studies of Bcl-2 revealed the presence of a flexible and natively disordered loop that bridges the Bcl-2 homology motifs, BH3 and BH4. sapropterin 141-144 BCL2 apoptosis regulator Homo sapiens 22-27 23272207-2 2012 Structural studies of Bcl-2 revealed the presence of a flexible and natively disordered loop that bridges the Bcl-2 homology motifs, BH3 and BH4. sapropterin 141-144 BCL2 apoptosis regulator Homo sapiens 110-115 23028726-5 2012 Doxorubicin treatment showed the following dose-dependent effects: increase in the secretion of tumor necrosis factor alpha; decrease in the expression of phosphorylated protein kinase A and Bcl-2; and increase in the expression of phosphorylated signal transducer and activator of transcription 3, phosphorylated extracellular signal-regulated kinase (ERK), and ATF3. Doxorubicin 0-11 BCL2 apoptosis regulator Homo sapiens 191-196 23226540-0 2012 Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression. Gossypol 25-33 BCL2 apoptosis regulator Homo sapiens 109-114 23226540-0 2012 Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression. gemcitabine 60-71 BCL2 apoptosis regulator Homo sapiens 109-114 23226540-2 2012 Overexpression of Bcl-2 has been associated with gemcitabine resistance. gemcitabine 49-60 BCL2 apoptosis regulator Homo sapiens 18-23 23226540-3 2012 The aim of this study is to determine whether gossypol can overcome gemcitabine resistance in cell lines with high level of Bcl-2 expression in combination drug therapy. Gossypol 46-54 BCL2 apoptosis regulator Homo sapiens 124-129 23226540-3 2012 The aim of this study is to determine whether gossypol can overcome gemcitabine resistance in cell lines with high level of Bcl-2 expression in combination drug therapy. gemcitabine 68-79 BCL2 apoptosis regulator Homo sapiens 124-129 23226540-4 2012 Our study demonstrated that in 10 cell lines derived from different cancers, high Bcl-2 baseline expression was observed in cell lines that were resistant to gemcitabine (GEM-R). gemcitabine 158-169 BCL2 apoptosis regulator Homo sapiens 82-87 23226540-4 2012 Our study demonstrated that in 10 cell lines derived from different cancers, high Bcl-2 baseline expression was observed in cell lines that were resistant to gemcitabine (GEM-R). gem-r 171-176 BCL2 apoptosis regulator Homo sapiens 82-87 23226540-5 2012 Furthermore, synergistic effect of combination therapy was observed in gemcitabine-resistant (GEM-R) cell lines with high Bcl-2 expression, but not in a gemcitabine-sensitive (GEM-S) cell lines regardless of Bcl-2 expression. gemcitabine 71-82 BCL2 apoptosis regulator Homo sapiens 122-127 23226540-6 2012 Gossypol treatment resulted in the decrease of anti-apoptotic genes such as Bcl-2 and Bcl-xl and an upregulation of the pro-apoptotic gene, Noxa. Gossypol 0-8 BCL2 apoptosis regulator Homo sapiens 76-81 23185240-0 2012 Pan-Bcl-2 inhibitor AT-101 enhances tumor cell killing by EGFR targeted T cells. gossypol acetic acid 20-26 BCL2 apoptosis regulator Homo sapiens 4-9 22880001-1 2012 Cells that exhibit an absolute dependence on the anti-apoptotic BCL-2 protein for survival are termed "primed for death" and are killed by the BCL-2 antagonist ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 160-163 BCL2 apoptosis regulator Homo sapiens 64-69 23029396-11 2012 Furthermore, SFN induced apoptosis by inhibition of BCL-2 and activation of caspases. sulforaphane 13-16 BCL2 apoptosis regulator Homo sapiens 52-57 22952775-6 2012 Pristimerin treatment also resulted in apoptotic cell death, cleavage of caspase-3, modulation in the expressions of Bcl-2 family proteins, inhibition of the translocation and DNA-binding activity of NF-kappaB. pristimerin 0-11 BCL2 apoptosis regulator Homo sapiens 117-122 22880001-1 2012 Cells that exhibit an absolute dependence on the anti-apoptotic BCL-2 protein for survival are termed "primed for death" and are killed by the BCL-2 antagonist ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 160-163 BCL2 apoptosis regulator Homo sapiens 143-148 22880001-3 2012 We show here that 1) stable BCL-2 overexpression alone can induce a primed for death state and 2) that an ABT-737-induced loss of functional cytochrome c from the electron transport chain causes a reduction in maximal respiration that is readily detectable by microplate-based respirometry. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 106-109 BCL2 apoptosis regulator Homo sapiens 28-33 22880001-4 2012 Stable BCL-2 overexpression sensitized non-tumorigenic MCF10A mammary epithelial cells to ABT-737-induced caspase-dependent apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 90-93 BCL2 apoptosis regulator Homo sapiens 7-12 22880001-5 2012 Mitochondria within permeabilized BCL-2 overexpressing cells were selectively vulnerable to ABT-737-induced cytochrome c release compared to those from control-transfected cells, consistent with a primed state. ABT-737 92-99 BCL2 apoptosis regulator Homo sapiens 34-39 22880001-6 2012 ABT-737 treatment caused a dose-dependent impairment of maximal O(2) consumption in MCF10A BCL-2 overexpressing cells but not in control-transfected cells or in immortalized mouse embryonic fibroblasts lacking both BAX and BAK. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 91-96 22880001-6 2012 ABT-737 treatment caused a dose-dependent impairment of maximal O(2) consumption in MCF10A BCL-2 overexpressing cells but not in control-transfected cells or in immortalized mouse embryonic fibroblasts lacking both BAX and BAK. o(2) 64-68 BCL2 apoptosis regulator Homo sapiens 91-96 22693649-2 2012 AMP showed the more potent activity in inhibiting the proliferation of androgen-sensitive LNCaP and, to less extent, androgen-independent PC-3 human prostate cancer cell lines in vitro, primarily by induction of apoptosis associated with down-regulation of bcl-2. ampelopsin 0-3 BCL2 apoptosis regulator Homo sapiens 257-262 22870247-8 2012 Meanwhile, SP600125 induces the apoptosis of SW116/HCPT cells by promoting the cleavage of PARP and suppressing the anti-apoptotic protein survivin and bcl-2, and increases the sensitivity of SW1116/HCPT to HCPT. pyrazolanthrone 11-19 BCL2 apoptosis regulator Homo sapiens 152-157 22815798-5 2012 Moreover, physalin F-mediated accumulation of reactive oxygen species (ROS) caused Bcl-2 family proteins, Bcl-2, and Bcl-xL degradation, which led to disruption of mitochondrial membrane potential and release of cytochrome c from the mitochondria into the cytosol. physalin F 10-20 BCL2 apoptosis regulator Homo sapiens 83-88 22815798-5 2012 Moreover, physalin F-mediated accumulation of reactive oxygen species (ROS) caused Bcl-2 family proteins, Bcl-2, and Bcl-xL degradation, which led to disruption of mitochondrial membrane potential and release of cytochrome c from the mitochondria into the cytosol. physalin F 10-20 BCL2 apoptosis regulator Homo sapiens 106-111 22815798-5 2012 Moreover, physalin F-mediated accumulation of reactive oxygen species (ROS) caused Bcl-2 family proteins, Bcl-2, and Bcl-xL degradation, which led to disruption of mitochondrial membrane potential and release of cytochrome c from the mitochondria into the cytosol. Reactive Oxygen Species 46-69 BCL2 apoptosis regulator Homo sapiens 83-88 22815798-5 2012 Moreover, physalin F-mediated accumulation of reactive oxygen species (ROS) caused Bcl-2 family proteins, Bcl-2, and Bcl-xL degradation, which led to disruption of mitochondrial membrane potential and release of cytochrome c from the mitochondria into the cytosol. Reactive Oxygen Species 46-69 BCL2 apoptosis regulator Homo sapiens 106-111 22815798-5 2012 Moreover, physalin F-mediated accumulation of reactive oxygen species (ROS) caused Bcl-2 family proteins, Bcl-2, and Bcl-xL degradation, which led to disruption of mitochondrial membrane potential and release of cytochrome c from the mitochondria into the cytosol. Reactive Oxygen Species 71-74 BCL2 apoptosis regulator Homo sapiens 83-88 22815798-5 2012 Moreover, physalin F-mediated accumulation of reactive oxygen species (ROS) caused Bcl-2 family proteins, Bcl-2, and Bcl-xL degradation, which led to disruption of mitochondrial membrane potential and release of cytochrome c from the mitochondria into the cytosol. Reactive Oxygen Species 71-74 BCL2 apoptosis regulator Homo sapiens 106-111 22666341-12 2012 Together, our results indicate the novel and multifunctional role of Bcl-2 in malignant transformation and tumorigenesis of human lung epithelial cells chronically exposed to Cr(VI). Chromium 175-177 BCL2 apoptosis regulator Homo sapiens 69-74 22629368-6 2012 The NO donor, sodium nitroprusside (SNP), down-regulates Bcl-2 S-denitrosylation, attenuates Bcl-2 ubiquitination and subsequently counteracts MDA-7/IL-24 induced cancer cell apoptosis, whereas NO inhibitor 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxy-3-oxide (PTIO) shows the opposite effect. Nitroprusside 14-34 BCL2 apoptosis regulator Homo sapiens 57-62 22629368-6 2012 The NO donor, sodium nitroprusside (SNP), down-regulates Bcl-2 S-denitrosylation, attenuates Bcl-2 ubiquitination and subsequently counteracts MDA-7/IL-24 induced cancer cell apoptosis, whereas NO inhibitor 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxy-3-oxide (PTIO) shows the opposite effect. Nitroprusside 14-34 BCL2 apoptosis regulator Homo sapiens 93-98 22629368-9 2012 iNOS-siRNA facilitates Bcl-2 S-denitrosylation and ubiquitin-degradation, whereas the TrxR1 inhibitor auranofin prevents Bcl-2 from denitrosylation and ubiquitination, thus restrains the caspase signal pathway activation and subsequent cancer cell apoptosis. Auranofin 102-111 BCL2 apoptosis regulator Homo sapiens 121-126 22720045-4 2012 Cord blood-derived mast cells and the mast cell line LAD-2 were activated through FcepsilonRI crosslinking, with or without addition of chemicals that inhibit the activity or expression of selected Bcl-2 family members (ABT-737; roscovitine). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 220-223 BCL2 apoptosis regulator Homo sapiens 198-203 22590594-4 2012 In this study, we found that genetic variants of Bcl-2 proteins exist among cisplatin-sensitive and -resistant ovarian cancer cells, and the responses of NOXA and Bax to cisplatin are regulated mainly by p53. Cisplatin 76-85 BCL2 apoptosis regulator Homo sapiens 49-54 22590507-8 2012 Cell lines transfected with cDNAs for catalase, thioredoxin, or the anti-apoptotic bcl-2 gene were more resistant to arsenic trioxide than mock vector transfected cells. Arsenic Trioxide 117-133 BCL2 apoptosis regulator Homo sapiens 83-88 22590594-4 2012 In this study, we found that genetic variants of Bcl-2 proteins exist among cisplatin-sensitive and -resistant ovarian cancer cells, and the responses of NOXA and Bax to cisplatin are regulated mainly by p53. Cisplatin 170-179 BCL2 apoptosis regulator Homo sapiens 49-54 22590561-8 2012 Moreover, siRNA-mediated knockdown of the CXCL8-target gene Bcl-2 increased the sensitivity of PC3 cells to 5-FU. Fluorouracil 108-112 BCL2 apoptosis regulator Homo sapiens 60-65 22431999-9 2012 In vitro studies demonstrated that MVs up-regulated in cisplatin-treated human tubular epithelial cells anti-apoptotic genes, such as Bcl-xL, Bcl2 and BIRC8 and down-regulated genes that have a central role in the execution-phase of cell apoptosis such as Casp1, Casp8 and LTA. Cisplatin 55-64 BCL2 apoptosis regulator Homo sapiens 142-146 22457823-9 2012 Puerarin-induced apoptosis in hypoxic HPASMCs was accompanied by reduced mitochondrial membrane potential, cytochrome c release from the mitochondria, caspase-9 activation, and Bcl-2 down-regulation with concurrent Bax up-regulation. puerarin 0-8 BCL2 apoptosis regulator Homo sapiens 177-182 22363450-5 2012 Furthermore, curcumin treatment induced apoptosis through caspase 3 activation, confirmed by an increase in the ratio of Bax to Bcl2. Curcumin 13-21 BCL2 apoptosis regulator Homo sapiens 128-132 22359675-11 2012 Interestingly, the BITC-treated MDA-MB-231 cells exhibited induction of Bcl-2 protein expression, and RNA interference of Bcl-2 in this cell line resulted in augmentation of BITC-induced apoptosis. benzyl isothiocyanate 19-23 BCL2 apoptosis regulator Homo sapiens 72-77 22359675-11 2012 Interestingly, the BITC-treated MDA-MB-231 cells exhibited induction of Bcl-2 protein expression, and RNA interference of Bcl-2 in this cell line resulted in augmentation of BITC-induced apoptosis. benzyl isothiocyanate 174-178 BCL2 apoptosis regulator Homo sapiens 122-127 22403704-7 2012 Our results show that DDT and BPA potentiate ER transcriptional activity, resulting in an increased expression of receptor target genes, including progesterone receptor, bcl-2, and trefoil factor 1. DDT 22-25 BCL2 apoptosis regulator Homo sapiens 170-175 22403704-7 2012 Our results show that DDT and BPA potentiate ER transcriptional activity, resulting in an increased expression of receptor target genes, including progesterone receptor, bcl-2, and trefoil factor 1. bisphenol A 30-33 BCL2 apoptosis regulator Homo sapiens 170-175 22685405-8 2012 In addition to Bim and Bid BH3 domains, BH3s of BOPs Bik, Bmf, Hrk, and Noxa also were found to bind BBD, while those of both pro- and anti-apoptotic multi-BH domain Bcl-2 proteins were not. BH 3 40-44 BCL2 apoptosis regulator Homo sapiens 166-171 22253748-10 2012 Furthermore, enzastaurin reduced the expression of antiapoptotic Bcl-2 and survivin in GNAQ mutant cells. enzastaurin 13-24 BCL2 apoptosis regulator Homo sapiens 65-70 22685405-8 2012 In addition to Bim and Bid BH3 domains, BH3s of BOPs Bik, Bmf, Hrk, and Noxa also were found to bind BBD, while those of both pro- and anti-apoptotic multi-BH domain Bcl-2 proteins were not. 5-tert-butyl-1,3-benzodioxole 101-104 BCL2 apoptosis regulator Homo sapiens 166-171 22253748-11 2012 Inhibition of Erk1/2 phosphorylation with a MEK specific inhibitor enhanced the sensitivity of GNAQ wild type cells to enzastaurin, accompanied by p27(Kip1) accumulation and/or inhibition of enzastaurin-induced survivin and Bcl-2 upregulation. enzastaurin 119-130 BCL2 apoptosis regulator Homo sapiens 224-229 23421021-23 2012 The most likely mechanisms involve down-regulation of BCL-2 expression and altered AL susceptibility to TNFalpha, mediated by imbalance between AL membrane expression of TNF receptor type 1 (death receptor) and type 2 (survival mediator). Aluminum 144-146 BCL2 apoptosis regulator Homo sapiens 54-59 21944661-5 2011 Exposure of HepG2 to SKLB703 also resulted in Bax upregulation, Bcl-2 downregulation, cytochrome c release and mitochondrial transmembrane potential change in mitochondrial apoptotic pathway. sklb703 21-28 BCL2 apoptosis regulator Homo sapiens 64-69 23023419-7 2012 The molecular mechanisms underlying the decrease in bcl-2, AP-N, and uPA expression involved suppression of protein prenylation through inhibition of the mevalonate pathway. Mevalonic Acid 154-164 BCL2 apoptosis regulator Homo sapiens 52-57 21963225-8 2011 Moreover, lunasin potentiated the effect of oxaliplatin in modifying expression of proteins involved in apoptosis and metastasis including Bax, Bcl-2, IKK-alpha and p-p65. LUNASINE 10-17 BCL2 apoptosis regulator Homo sapiens 144-149 21963225-8 2011 Moreover, lunasin potentiated the effect of oxaliplatin in modifying expression of proteins involved in apoptosis and metastasis including Bax, Bcl-2, IKK-alpha and p-p65. Oxaliplatin 44-55 BCL2 apoptosis regulator Homo sapiens 144-149 22177381-0 2011 Thymoquinone decreases F-actin polymerization and the proliferation of human multiple myeloma cells by suppressing STAT3 phosphorylation and Bcl2/Bcl-XL expression. thymoquinone 0-12 BCL2 apoptosis regulator Homo sapiens 141-145 21978530-5 2011 This is supported by the results that have shown that co-treatment with antioxidants, VC, L-GSH and MitoQ(10), decreased 2-ME-induced generation of ROS and the loss of the mitochondrial membrane potential, increased the Bcl-2/Bax ratio, decreased 2-ME-induced activation of caspase-9 and caspase-3 and the up-regulation of apoptosis-inducing factor (AIF), and prevented 2-ME-induced apoptosis in SK-N-SH and SH-SY5Y cells. l-gsh 90-95 BCL2 apoptosis regulator Homo sapiens 220-225 21978530-5 2011 This is supported by the results that have shown that co-treatment with antioxidants, VC, L-GSH and MitoQ(10), decreased 2-ME-induced generation of ROS and the loss of the mitochondrial membrane potential, increased the Bcl-2/Bax ratio, decreased 2-ME-induced activation of caspase-9 and caspase-3 and the up-regulation of apoptosis-inducing factor (AIF), and prevented 2-ME-induced apoptosis in SK-N-SH and SH-SY5Y cells. mitoquinone 100-105 BCL2 apoptosis regulator Homo sapiens 220-225 21978530-5 2011 This is supported by the results that have shown that co-treatment with antioxidants, VC, L-GSH and MitoQ(10), decreased 2-ME-induced generation of ROS and the loss of the mitochondrial membrane potential, increased the Bcl-2/Bax ratio, decreased 2-ME-induced activation of caspase-9 and caspase-3 and the up-regulation of apoptosis-inducing factor (AIF), and prevented 2-ME-induced apoptosis in SK-N-SH and SH-SY5Y cells. 2-Methoxyestradiol 121-125 BCL2 apoptosis regulator Homo sapiens 220-225 21978530-5 2011 This is supported by the results that have shown that co-treatment with antioxidants, VC, L-GSH and MitoQ(10), decreased 2-ME-induced generation of ROS and the loss of the mitochondrial membrane potential, increased the Bcl-2/Bax ratio, decreased 2-ME-induced activation of caspase-9 and caspase-3 and the up-regulation of apoptosis-inducing factor (AIF), and prevented 2-ME-induced apoptosis in SK-N-SH and SH-SY5Y cells. 2-Methoxyestradiol 247-251 BCL2 apoptosis regulator Homo sapiens 220-225 21978530-5 2011 This is supported by the results that have shown that co-treatment with antioxidants, VC, L-GSH and MitoQ(10), decreased 2-ME-induced generation of ROS and the loss of the mitochondrial membrane potential, increased the Bcl-2/Bax ratio, decreased 2-ME-induced activation of caspase-9 and caspase-3 and the up-regulation of apoptosis-inducing factor (AIF), and prevented 2-ME-induced apoptosis in SK-N-SH and SH-SY5Y cells. 2-Methoxyestradiol 247-251 BCL2 apoptosis regulator Homo sapiens 220-225 21978530-5 2011 This is supported by the results that have shown that co-treatment with antioxidants, VC, L-GSH and MitoQ(10), decreased 2-ME-induced generation of ROS and the loss of the mitochondrial membrane potential, increased the Bcl-2/Bax ratio, decreased 2-ME-induced activation of caspase-9 and caspase-3 and the up-regulation of apoptosis-inducing factor (AIF), and prevented 2-ME-induced apoptosis in SK-N-SH and SH-SY5Y cells. Nitrogen 399-400 BCL2 apoptosis regulator Homo sapiens 220-225 20832877-6 2011 This trend was similar as what bax protein, a pro-apoptosis protein, showed analyzed by Western blotting; whereas the bcl-2 protein, an anti-apoptosis protein, increased in atorvastatin treated cells. Atorvastatin 173-185 BCL2 apoptosis regulator Homo sapiens 118-123 22219597-16 2011 HOMA, BMI and uric acid, in that sequence, best predicted serum Bcl-2 concentrations. Uric Acid 14-23 BCL2 apoptosis regulator Homo sapiens 64-69 21911303-3 2011 DS/Cu inhibited Bcl-2 expression and enhanced Dox-induced apoptosis. Deuterium 0-2 BCL2 apoptosis regulator Homo sapiens 16-21 21911303-3 2011 DS/Cu inhibited Bcl-2 expression and enhanced Dox-induced apoptosis. Copper 3-5 BCL2 apoptosis regulator Homo sapiens 16-21 22115332-0 2011 Flavokawain B induces apoptosis of human oral adenoid cystic cancer ACC-2 cells via up-regulation of Bim and down-regulation of Bcl-2 expression. flavokawain B 0-13 BCL2 apoptosis regulator Homo sapiens 128-133 22000994-6 2011 Signal transduction mechanism studies showed that nano copper exposure reciprocally regulated Bcl-2 family protein expression, disturbed mitochondrial membrane potential and subsequently helped releasing cytochrome c from mitochondria to cytosol. Copper 55-61 BCL2 apoptosis regulator Homo sapiens 94-99 22013068-3 2011 Here we report that doxorubicin-induced SMAR1-dependent transcriptional repression and SMAR1-independent degradation of IkBalpha resulted in nuclear translocation of p65NFkappaB and its association with p300 histone acetylase and subsequent transcription of Bcl-2 to impart protective response in drug-resistant cells. Doxorubicin 20-31 BCL2 apoptosis regulator Homo sapiens 258-263 21911303-6 2011 This study suggested that DS/Cu complex may re-sensitize HL60/Dox cells to Dox through activating JNK/c-jun as well as inhibiting anti-apoptotic bcl-2 expression. Deuterium 26-28 BCL2 apoptosis regulator Homo sapiens 145-150 21911303-6 2011 This study suggested that DS/Cu complex may re-sensitize HL60/Dox cells to Dox through activating JNK/c-jun as well as inhibiting anti-apoptotic bcl-2 expression. Copper 29-31 BCL2 apoptosis regulator Homo sapiens 145-150 21933893-1 2011 PURPOSE: We have previously shown the prognostic significance of BCL2 expression in the activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) patients treated with cyclophosphamide-Adriamycin-vincristine-prednisone (CHOP) or CHOP-like therapy. Cyclophosphamide 174-190 BCL2 apoptosis regulator Homo sapiens 65-69 21933893-1 2011 PURPOSE: We have previously shown the prognostic significance of BCL2 expression in the activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) patients treated with cyclophosphamide-Adriamycin-vincristine-prednisone (CHOP) or CHOP-like therapy. Doxorubicin 191-201 BCL2 apoptosis regulator Homo sapiens 65-69 21933893-1 2011 PURPOSE: We have previously shown the prognostic significance of BCL2 expression in the activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) patients treated with cyclophosphamide-Adriamycin-vincristine-prednisone (CHOP) or CHOP-like therapy. vincristine-prednisone 202-224 BCL2 apoptosis regulator Homo sapiens 65-69 21850486-4 2011 In a previous work, we showed that both mRNA and protein expression levels of the antiapoptotic gene Bcl-2 are reduced in MCF-7 cancer cells by the effect of the natural diterpene ent-16beta-17alpha-dihydroxykaurane (DHK). diterpene ent-16beta-17alpha-dihydroxykaurane 170-215 BCL2 apoptosis regulator Homo sapiens 101-106 21850486-4 2011 In a previous work, we showed that both mRNA and protein expression levels of the antiapoptotic gene Bcl-2 are reduced in MCF-7 cancer cells by the effect of the natural diterpene ent-16beta-17alpha-dihydroxykaurane (DHK). ent-17,19-dihydroxy-16-H-kaurane 217-220 BCL2 apoptosis regulator Homo sapiens 101-106 21887696-5 2011 Moreover, curcumin significantly induced apoptosis of SCC-4 cells with a decrease of the Bcl-2 level, reduction of mitochondrial membrane potential (DeltaPsi(m) ), and promoted the active forms of caspase-3. Curcumin 10-18 BCL2 apoptosis regulator Homo sapiens 89-94 22011009-8 2011 Real time PCR revealed that expression of Bax and Bcl-2 was simultaneously elevated on combination of resveratrol with doxorubicin or docetaxel in all tested cell lines, whereas p53 exhibited marginal elevation in MCF-7 and HepG2 cells. Resveratrol 102-113 BCL2 apoptosis regulator Homo sapiens 50-55 22011009-8 2011 Real time PCR revealed that expression of Bax and Bcl-2 was simultaneously elevated on combination of resveratrol with doxorubicin or docetaxel in all tested cell lines, whereas p53 exhibited marginal elevation in MCF-7 and HepG2 cells. Doxorubicin 119-130 BCL2 apoptosis regulator Homo sapiens 50-55 22011009-8 2011 Real time PCR revealed that expression of Bax and Bcl-2 was simultaneously elevated on combination of resveratrol with doxorubicin or docetaxel in all tested cell lines, whereas p53 exhibited marginal elevation in MCF-7 and HepG2 cells. Docetaxel 134-143 BCL2 apoptosis regulator Homo sapiens 50-55 20686818-4 2011 Cancer cells treated with protoapigenone resulted in persistent activation of mitogen-activated protein kinase (MAPK) ERK, JNK, and p38, hyperphosphorylation of Bcl-2 and Bcl-xL, and loss of mitochondrial membrane potential (MMP). protoapigenone 26-40 BCL2 apoptosis regulator Homo sapiens 161-166 22340335-0 2011 Inhibition of Bcl-2 enhances the efficacy of epirubicin chemotherapy in PC-3 prostate cancer cells. Epirubicin 45-55 BCL2 apoptosis regulator Homo sapiens 14-19 22340335-2 2011 Bcl-2 antisense oligonucleotide (G3139) has shown its antitumor effects enhanced in preclinical models when combined with taxol-based chemotherapy. Oligonucleotides 16-31 BCL2 apoptosis regulator Homo sapiens 0-5 22340335-2 2011 Bcl-2 antisense oligonucleotide (G3139) has shown its antitumor effects enhanced in preclinical models when combined with taxol-based chemotherapy. Paclitaxel 122-127 BCL2 apoptosis regulator Homo sapiens 0-5 22340335-9 2011 A marked down-regulation of Bcl-2 mRNA and protein was observed after antisense and epirubicin cotreatment. Epirubicin 84-94 BCL2 apoptosis regulator Homo sapiens 28-33 22340335-10 2011 A statistically significantly higher fraction of apoptotic cells was detected by flow-cytometric analysis after epirubicin treatment with prior antisense Bcl-2 transfenction, as compared with mono antisense Bcl-2 or epirubicin treatment. Epirubicin 112-122 BCL2 apoptosis regulator Homo sapiens 154-159 21935568-0 2011 The potent peptide antagonist to angiogenesis, C16Y, and cisplatin act synergistically in the down-regulation of the Bcl-2/Bax ratio and the induction of apoptosis in human ovarian cancer cells. Cisplatin 57-66 BCL2 apoptosis regulator Homo sapiens 117-122 21935568-2 2011 We examined the effect of cisplatin alone and in combination with C16Y, a newly-identified anti-angiogenic peptide from the NH2-terminal domains of the gamma-chain of laminin-1, on the modulation of Bcl-2/Bax expression and induction of apoptosis in ovarian cancer cells (OVACAR3). Cisplatin 26-35 BCL2 apoptosis regulator Homo sapiens 199-204 21935568-8 2011 Furthermore, Bcl-2 protein expression levels were markedly reduced by C16Y alone and cisplatin alone in a dose-dependent manner. Cisplatin 85-94 BCL2 apoptosis regulator Homo sapiens 13-18 21935568-9 2011 The combination of C16Y and cisplatin resulted in a further dramatic reduction in Bcl-2, underscoring the pronounced synergy produced by cisplatin and C16Y together. Cisplatin 28-37 BCL2 apoptosis regulator Homo sapiens 82-87 21935568-9 2011 The combination of C16Y and cisplatin resulted in a further dramatic reduction in Bcl-2, underscoring the pronounced synergy produced by cisplatin and C16Y together. Cisplatin 137-146 BCL2 apoptosis regulator Homo sapiens 82-87 21935568-11 2011 These observations suggest that the suppression of the Bcl-2/Bax ratio may play an important role in mediating the synergistic effect of cisplatin and C16Y on the induction of apoptosis in OVACAR3 cells. Cisplatin 137-146 BCL2 apoptosis regulator Homo sapiens 55-60 21744078-6 2011 Gefitinib caused Bad dephosphorylation, particularly in serine-112, and increased its binding preference to Bcl-2 and Bcl-xL. Gefitinib 0-9 BCL2 apoptosis regulator Homo sapiens 108-113 21988238-6 2011 Similarly, treatment with AB or AC reduced the declines in p85aPI3K, phosphorylated Akt, phosphorylated GSK-3beta, heat-shock transcription factor-1, and Bcl-2 induced by H(2) O(2) , as well as the increases in cyclooxygenase-2, cytosolic cytochrome c, cleaved caspase 9, and cleaved caspase 3. Amlodipine 26-28 BCL2 apoptosis regulator Homo sapiens 154-159 21988238-6 2011 Similarly, treatment with AB or AC reduced the declines in p85aPI3K, phosphorylated Akt, phosphorylated GSK-3beta, heat-shock transcription factor-1, and Bcl-2 induced by H(2) O(2) , as well as the increases in cyclooxygenase-2, cytosolic cytochrome c, cleaved caspase 9, and cleaved caspase 3. Charcoal 32-34 BCL2 apoptosis regulator Homo sapiens 154-159 21945308-12 2011 Additionally, the antioxidant N-acetyl-L-cysteine (NAC) significantly attenuated the costunolide-induced production of ROS, activation of caspases, down-regulation of Bcl-2, and apoptosis in platinum-resistant ovarian cancer cells. costunolide 85-96 BCL2 apoptosis regulator Homo sapiens 167-172 21874222-0 2011 Multidrug resistance-associated protein 3 and Bcl-2 contribute to multidrug resistance by vinorelbine in lung adenocarcinoma. Vinorelbine 102-113 BCL2 apoptosis regulator Homo sapiens 46-51 22060185-2 2011 Our data showed that paclitaxel can down-regulate the increased MLK3, JNK3, c-Jun, Bcl-2, and caspase-3 phosphorylation induced by ischemia injury. Paclitaxel 21-31 BCL2 apoptosis regulator Homo sapiens 83-88 21914853-3 2011 We previously reported the discovery of ABT-263 (navitoclax), a potent small-molecule inhibitor of Bcl-2, Bcl-X(L), and Bcl-w. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 40-43 BCL2 apoptosis regulator Homo sapiens 99-104 21620511-0 2011 A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Obatoclax mesylate 20-38 BCL2 apoptosis regulator Homo sapiens 42-47 21705382-8 2011 Considering the reliance of female eggs on calcium-dependent proteins and calcium-regulated processes and the exceptional longevity of oocytes in the primate lineage, we propose that this microstructural variation may be an adaptive feature associated with high maternal expression of this Bcl-2 family member. Calcium 43-50 BCL2 apoptosis regulator Homo sapiens 290-295 21705382-8 2011 Considering the reliance of female eggs on calcium-dependent proteins and calcium-regulated processes and the exceptional longevity of oocytes in the primate lineage, we propose that this microstructural variation may be an adaptive feature associated with high maternal expression of this Bcl-2 family member. Calcium 74-81 BCL2 apoptosis regulator Homo sapiens 290-295 21798596-6 2011 In addition, methadone"s activity synergized with that of the anti-Bcl-2 agent ABT-737 and was characterized by the induction of distinct changes in tumor cell mitochondria. Methadone 13-22 BCL2 apoptosis regulator Homo sapiens 67-72 21798596-6 2011 In addition, methadone"s activity synergized with that of the anti-Bcl-2 agent ABT-737 and was characterized by the induction of distinct changes in tumor cell mitochondria. ABT-737 79-86 BCL2 apoptosis regulator Homo sapiens 67-72 22006676-0 2011 The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells. ABT-737 26-33 BCL2 apoptosis regulator Homo sapiens 10-15 22006676-5 2011 ABT-737 is a novel small-molecule inhibitor of Bcl-2 and Bcl-x(L) that is able to induce apoptosis in a range of tumor types. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 47-52 21914853-4 2011 While navitoclax exhibits single-agent activity in tumors dependent on Bcl-2 or Bcl-X(L) for survival, the expression of Mcl-1 has been shown to confer resistance to navitoclax, most notably in solid tumors. navitoclax 6-16 BCL2 apoptosis regulator Homo sapiens 71-76 21880625-6 2011 On the basis of this knowledge, we demonstrate how the loss of RASSF1A function in medulloblastoma cells might be overcome using the novel BH3-only mimetic ABT-737 in combination with chemotherapeutic agents to target the BCL-2 anti-apoptotic members. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 156-159 BCL2 apoptosis regulator Homo sapiens 222-227 21664489-0 2011 ZnO nanorod-induced apoptosis in human alveolar adenocarcinoma cells via p53, survivin and bax/bcl-2 pathways: role of oxidative stress. Zinc Oxide 0-3 BCL2 apoptosis regulator Homo sapiens 95-100 21664489-6 2011 Moreover, pro-apoptotic protein bax was upregulated and the antiapoptotic proteins, survivin and bcl-2, were downregulated in ZnO nanorod exposed cells. Zinc Oxide 126-129 BCL2 apoptosis regulator Homo sapiens 97-102 21664489-7 2011 In conclusion, our data demonstrates that ZnO nanorod induced apoptosis in A549 cells through ROS and oxidative stress via p53, survivin, bax/bcl-2 and caspase pathways. Zinc Oxide 42-45 BCL2 apoptosis regulator Homo sapiens 142-147 21452372-4 2011 Escin sodium activated the initiator caspase-8, -9, and the effector caspase-3, degraded poly (ADP-ribose) polymerase (PARP) and attenuated the expression of Bcl-2. escin sodium 0-12 BCL2 apoptosis regulator Homo sapiens 158-163 21771752-13 2011 HHE decreased the expression of Bcl-2, while it increased that of Bax, which was attenuated by the treatment of NF-kappaB inhibitor (Bay 11-7082) or N-acetyl-L-cysteine (NAC). 3-(4-methylphenylsulfonyl)-2-propenenitrile 133-144 BCL2 apoptosis regulator Homo sapiens 32-37 21771752-15 2011 CONCLUSIONS: HHE-induced tubular cell apoptosis is mediated by modulation of Bax and Bcl-2 via ROS generation. Reactive Oxygen Species 95-98 BCL2 apoptosis regulator Homo sapiens 85-90 21907236-0 2011 Fluazinam-induced apoptosis of SH-SY5Y cells is mediated by p53 and Bcl-2 family proteins. fluazinam 0-9 BCL2 apoptosis regulator Homo sapiens 68-73 21710341-0 2011 Liposomes containing (-)-gossypol-enriched cottonseed oil suppress Bcl-2 and Bcl-xL expression in breast cancer cells. Gossypol 21-33 BCL2 apoptosis regulator Homo sapiens 67-72 21710341-0 2011 Liposomes containing (-)-gossypol-enriched cottonseed oil suppress Bcl-2 and Bcl-xL expression in breast cancer cells. Cottonseed Oil 43-57 BCL2 apoptosis regulator Homo sapiens 67-72 21710341-1 2011 PURPOSE: We have demonstrated that (-)-gossypol-enriched cottonseed oil [(-)-GPCSO] can down-regulate Bcl-2 expression in MCF-7 and primary cultured human breast cancer epithelial cells (PCHBCECs). Gossypol 35-47 BCL2 apoptosis regulator Homo sapiens 102-107 21710341-1 2011 PURPOSE: We have demonstrated that (-)-gossypol-enriched cottonseed oil [(-)-GPCSO] can down-regulate Bcl-2 expression in MCF-7 and primary cultured human breast cancer epithelial cells (PCHBCECs). Cottonseed Oil 57-71 BCL2 apoptosis regulator Homo sapiens 102-107 21710341-1 2011 PURPOSE: We have demonstrated that (-)-gossypol-enriched cottonseed oil [(-)-GPCSO] can down-regulate Bcl-2 expression in MCF-7 and primary cultured human breast cancer epithelial cells (PCHBCECs). (-)-gpcso 73-82 BCL2 apoptosis regulator Homo sapiens 102-107 21963806-3 2011 Sappanchalcone-treated oral cancer cells showed an increased cytosolic level of cytochrome c, downregulated Bcl-2 expression, upregulated Bax and p53 expression, caspase-3 and -9 activation, and poly (ADP-ribose) polymerase cleavage. sappanchalcone 0-14 BCL2 apoptosis regulator Homo sapiens 108-113 22312705-0 2011 MiR-122 increases sensitivity of drug-resistant BEL-7402/5-FU cells to 5-fluorouracil via down-regulation of bcl-2 family proteins. Fluorouracil 71-85 BCL2 apoptosis regulator Homo sapiens 109-114 22164193-0 2011 In LNCaP cells enhanced expression of both androgen receptor and costimulatory protein p300 compensate for antisense oligonucleotide suppression of bcl-2. Oligonucleotides 117-132 BCL2 apoptosis regulator Homo sapiens 148-153 21958871-6 2011 Additionally, simvastatin-induced apoptosis was accompanied by diminished Bcl-2 protein expression, increased cytosolic cytochrome c level, and activation of caspase 9 and caspase 3. Simvastatin 14-25 BCL2 apoptosis regulator Homo sapiens 74-79 22169296-4 2011 The results showed that compared with cells treated with 2-ME2 or Bor alone, the proliferative potential of cells in combination group was significantly inhibited (p < 0.05), and apoptosis rate markedly increased (p < 0.05), cell cycle was arrested at G(1)-S phase, the mRNA expressive level of P21 and BAX increased, while the expression of BCL-2 decreased. 2-Methoxyestradiol 57-62 BCL2 apoptosis regulator Homo sapiens 348-353 22169296-4 2011 The results showed that compared with cells treated with 2-ME2 or Bor alone, the proliferative potential of cells in combination group was significantly inhibited (p < 0.05), and apoptosis rate markedly increased (p < 0.05), cell cycle was arrested at G(1)-S phase, the mRNA expressive level of P21 and BAX increased, while the expression of BCL-2 decreased. Bortezomib 66-69 BCL2 apoptosis regulator Homo sapiens 348-353 21946115-4 2011 In saline-treated stroke animals, an impairment in learning and memory occurred that, at day 11 after stroke, was associated with hippocampus up-regulation of tumor necrosis factor-alpha (TNF-alpha), BAX, activated extracellular signal-regulated kinases (ERK1/2), c-jun N-terminal kinases (JNK1/2) and caspase-3, down-regulation of Bcl-2, and neuronal loss. Sodium Chloride 3-9 BCL2 apoptosis regulator Homo sapiens 332-337 21951963-9 2011 In addition, western blot analysis revealed a significant augmentation in the protein expression of Bax and attenuation in Bcl-2, suggesting that the celastrol-induced apoptosis acts through both death receptor and mitochondrial pathways. celastrol 150-159 BCL2 apoptosis regulator Homo sapiens 123-128 21958871-8 2011 Additionally, inhibition of Chk1 expression enhanced simvastatin-induced downregulation of Bcl-2, caspase 9 cleavage and subsequent apoptosis. Simvastatin 53-64 BCL2 apoptosis regulator Homo sapiens 91-96 21795032-10 2011 We concluded that Cpv inhibited MCF-7 cells proliferation by inducing apoptosis mediated by increasing ROS formation, decreasing DeltaPsim, regulating Bcl-2 family proteins expression, and activating caspases. Cyclopropavir 18-21 BCL2 apoptosis regulator Homo sapiens 151-156 22340096-0 2011 [Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells]. ABT-737 17-24 BCL2 apoptosis regulator Homo sapiens 1-6 22340096-0 2011 [Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells]. Cisplatin 38-47 BCL2 apoptosis regulator Homo sapiens 1-6 22340096-12 2011 CONCLUSION: The Bcl-2 inhibitor ABT-737 can significantly enhance cisplatin-induced apoptosis in human breast cancer T47D cells in vitro. ABT-737 32-39 BCL2 apoptosis regulator Homo sapiens 16-21 22340096-12 2011 CONCLUSION: The Bcl-2 inhibitor ABT-737 can significantly enhance cisplatin-induced apoptosis in human breast cancer T47D cells in vitro. Cisplatin 66-75 BCL2 apoptosis regulator Homo sapiens 16-21 21914439-4 2011 In addition, kaempferol treatment improved the expression of anti-apoptotic proteins Akt and Bcl-2 that was significantly reduced in beta-cells and human islets chronically exposed to hyperglycemia. kaempferol 13-23 BCL2 apoptosis regulator Homo sapiens 93-98 21933888-0 2011 Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma. ABT-737 75-82 BCL2 apoptosis regulator Homo sapiens 44-49 21933888-2 2011 To identify possible synergistic drug combinations for future clinical trials, we determined whether ABT-737, a small-molecule BH3-mimetic that inhibits most proteins of the antiapoptotic Bcl-2 family, could enhance 4-HPR activity in neuroblastoma. ABT-737 101-108 BCL2 apoptosis regulator Homo sapiens 188-193 21953453-2 2011 Here, we employ Sabutoclax, a potent and effective Mcl-1 antagonist, as a competing agent to screen a randomized 12-residue phage display library for peptides that bind strongly to the Bcl-2 homology 3 (BH3) binding groove of Mcl-1. 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-N5-(2-phenylpropyl)-N5'-(2-phenylpropyl)-2,2'-binaphthyl-5,5'-dicarboxamide 16-26 BCL2 apoptosis regulator Homo sapiens 185-190 22036586-2 2011 We employed chimeric proteins composed of exogenous BH3 domains inserted into a tBID backbone that can activate the proapoptotic effectors BAX and BAK to permeabilize membranes without being universally sequestered by all antiapoptotic BCL-2 proteins. tBID 80-84 BCL2 apoptosis regulator Homo sapiens 236-241 22093145-6 2011 The potentiation of ATO cytotoxicity by DCA is correlated with strong suppression of the expression of c-Myc and HIF-1alpha, and decreased expression of the survival protein Bcl-2. Dichloroacetic Acid 40-43 BCL2 apoptosis regulator Homo sapiens 174-179 22071691-3 2011 Cisplatin exposure modulated the levels of target proteins (reduced BCL2, AKT1, ATG16L2, and ULK2, while activated MDM4) in cisplatin-sensitive wild type DeltaNp63alpha cells leading to distinct changes in cell viability. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 68-72 22071691-3 2011 Cisplatin exposure modulated the levels of target proteins (reduced BCL2, AKT1, ATG16L2, and ULK2, while activated MDM4) in cisplatin-sensitive wild type DeltaNp63alpha cells leading to distinct changes in cell viability. Cisplatin 124-133 BCL2 apoptosis regulator Homo sapiens 68-72 22071691-4 2011 Finally, miR-885-3p modulated the cisplatin-induced TP53-dependent mitochondrial apoptosis by up regulation of MDM4 levels and down regulation of BCL2 levels in mitochondria. Cisplatin 34-43 BCL2 apoptosis regulator Homo sapiens 146-150 21940819-7 2011 Indeed, overexpression of Bcl-xL is able to rescue the effects of Rac2 deficiency and MLL-AF9 cells are exquisitely sensitive to direct inhibition of Bcl-2 family proteins by the BH3-mimetic, ABT-737. BH 3 179-182 BCL2 apoptosis regulator Homo sapiens 150-155 21940819-7 2011 Indeed, overexpression of Bcl-xL is able to rescue the effects of Rac2 deficiency and MLL-AF9 cells are exquisitely sensitive to direct inhibition of Bcl-2 family proteins by the BH3-mimetic, ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 192-195 BCL2 apoptosis regulator Homo sapiens 150-155 21940819-8 2011 Furthermore, concurrent exposure to NSC23766, a small-molecule inhibitor of Rac activation, increases the apoptotic effect of ABT-737, indicating the Rac/Bcl-2 survival pathway may be targeted synergistically. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 126-129 BCL2 apoptosis regulator Homo sapiens 154-159 22038684-8 2011 In addition, several intracellular targets including cyclooxygenase-2, nuclear factor kappa B, peroxisome proliferator-activated receptor gamma, mitogen-activated protein kinase, AKT, and BCL-2/BAX are found to play an important role in DHA-mediated additive or synergistic interaction with anticancer drugs. Docosahexaenoic Acids 237-240 BCL2 apoptosis regulator Homo sapiens 188-193 21927014-11 2011 Moreover, satraplatin treatment induced apoptosis along with Bcl-2 protein down-regulation and abrogated the clonogenic formation of CRC cells in vitro. satraplatin 10-21 BCL2 apoptosis regulator Homo sapiens 61-66 21893020-8 2011 Previous studies showed that Mcl-1 knockdown cells are hypersensitive to ABT-737, a small-molecule inhibitor of Bcl-2, Bcl-X(L), and Bcl-w. ABT-737 73-80 BCL2 apoptosis regulator Homo sapiens 112-117 21784061-6 2011 Finally, our data demonstrate that downregulation of Mcl-1 by YM155 synergistically lowers the threshold of Bcl-2 family member inhibitor ABT-263-induced cell death. YM 155 62-67 BCL2 apoptosis regulator Homo sapiens 108-113 21784061-6 2011 Finally, our data demonstrate that downregulation of Mcl-1 by YM155 synergistically lowers the threshold of Bcl-2 family member inhibitor ABT-263-induced cell death. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 138-141 BCL2 apoptosis regulator Homo sapiens 108-113 22340174-14 2011 In addition, API promoted caspase-3, Bad mRNA expression and inhibited Bcl-2 mRNA expression in a time-dependent and concentration- dependent manner. Apigenin 13-16 BCL2 apoptosis regulator Homo sapiens 71-76 21854768-0 2011 Acrolein sensitizes human renal cancer Caki cells to TRAIL-induced apoptosis via ROS-mediated up-regulation of death receptor-5 (DR5) and down-regulation of Bcl-2. Acrolein 0-8 BCL2 apoptosis regulator Homo sapiens 157-162 22069261-5 2011 We also studied the Bcl-2 family molecules involved in killing by using high concentrations of reducing sugars such as glucose or ribose. Glucose 119-126 BCL2 apoptosis regulator Homo sapiens 20-25 22069261-5 2011 We also studied the Bcl-2 family molecules involved in killing by using high concentrations of reducing sugars such as glucose or ribose. Ribose 130-136 BCL2 apoptosis regulator Homo sapiens 20-25 22069261-5 2011 We also studied the Bcl-2 family molecules involved in killing by using high concentrations of reducing sugars such as glucose or ribose. Sugars 104-110 BCL2 apoptosis regulator Homo sapiens 20-25 20549612-0 2011 Molecular events involved in ochratoxin A induced mitochondrial pathway of apoptosis, modulation by Bcl-2 family members. ochratoxin A 29-41 BCL2 apoptosis regulator Homo sapiens 100-105 21854768-0 2011 Acrolein sensitizes human renal cancer Caki cells to TRAIL-induced apoptosis via ROS-mediated up-regulation of death receptor-5 (DR5) and down-regulation of Bcl-2. ros 81-84 BCL2 apoptosis regulator Homo sapiens 157-162 21854768-6 2011 We found that acrolein down-regulated the protein level of Bcl-2 and Bcl-2 overexpression inhibited the cell death induced by the combined treatment with acrolein and TRAIL. Acrolein 14-22 BCL2 apoptosis regulator Homo sapiens 59-64 21854768-6 2011 We found that acrolein down-regulated the protein level of Bcl-2 and Bcl-2 overexpression inhibited the cell death induced by the combined treatment with acrolein and TRAIL. Acrolein 14-22 BCL2 apoptosis regulator Homo sapiens 69-74 21854768-9 2011 Taken together, our results demonstrated that acrolein enhances TRAIL-induced apoptosis in Caki cells through down-regulation of Bcl-2 and ROS dependent up-regulation of DR5. Acrolein 46-54 BCL2 apoptosis regulator Homo sapiens 129-134 21785821-3 2011 We studied BCL-2 expression in vivo in prostate cancer tissues obtained from patients who underwent radical prostatectomy after neoadjuvant ADT, by Northern and Western blot analysis, and immunohistochemistry. adt 140-143 BCL2 apoptosis regulator Homo sapiens 11-16 21837363-0 2011 Activation of Akt/GSK3beta and Akt/Bcl-2 signaling pathways in nickel-transformed BEAS-2B cells. Nickel 63-69 BCL2 apoptosis regulator Homo sapiens 35-40 21704149-4 2011 Notably, cell death induced by both curcumin and andrographolide was associated with decreased NFkappaB activity and a reduction in Bcl-2 and Bcl-xL expression. Curcumin 36-44 BCL2 apoptosis regulator Homo sapiens 132-137 21704149-4 2011 Notably, cell death induced by both curcumin and andrographolide was associated with decreased NFkappaB activity and a reduction in Bcl-2 and Bcl-xL expression. andrographolide 49-64 BCL2 apoptosis regulator Homo sapiens 132-137 21785821-5 2011 We demonstrated an increase of BCL-2 mRNA expression in patients who underwent neoadjuvant ADT for 1 month in comparison to patients who had not received any therapy. adt 91-94 BCL2 apoptosis regulator Homo sapiens 31-36 21837363-8 2011 In addition, two major anti-apoptotic proteins of the Bcl family, Bcl-2 and Bcl-XL, were increased in nickel-transformed cells. Nickel 102-108 BCL2 apoptosis regulator Homo sapiens 66-71 21837363-9 2011 By employing the small interfering RNA technique (siRNA), our results showed that siRNA Akt attenuated the expression of Bcl-2 and Bcl-XL in nickel-transformed cells, indicating that induction of Bcl-2 and Bcl-XL was likely mediated through Akt. Nickel 141-147 BCL2 apoptosis regulator Homo sapiens 121-126 21837363-9 2011 By employing the small interfering RNA technique (siRNA), our results showed that siRNA Akt attenuated the expression of Bcl-2 and Bcl-XL in nickel-transformed cells, indicating that induction of Bcl-2 and Bcl-XL was likely mediated through Akt. Nickel 141-147 BCL2 apoptosis regulator Homo sapiens 196-201 21785821-7 2011 Furthermore, BCL-2 protein levels in patients who underwent neoadjuvant ADT for 1 month were upregulated in comparison to patients who had not received any therapy. adt 72-75 BCL2 apoptosis regulator Homo sapiens 13-18 21785821-10 2011 Our data show that short-term administration of ADT interferes with BCL-2 expression, suggesting that androgen-mediated mechanisms may act through BCL-2-mediated apoptotic pathways. adt 48-51 BCL2 apoptosis regulator Homo sapiens 68-73 21785821-10 2011 Our data show that short-term administration of ADT interferes with BCL-2 expression, suggesting that androgen-mediated mechanisms may act through BCL-2-mediated apoptotic pathways. adt 48-51 BCL2 apoptosis regulator Homo sapiens 147-152 21799188-0 2011 Calycosin stimulates proliferation of estrogen receptor-positive human breast cancer cells through downregulation of Bax gene expression and upregulation of Bcl-2 gene expression at low concentrations. 7,3'-dihydroxy-4'-methoxyisoflavone 0-9 BCL2 apoptosis regulator Homo sapiens 157-162 21799188-9 2011 Furthermore, at these concentrations, calycosin decreased the percentage of early apoptosis in MCF-7 cells, downregulated mRNA and protein levels of Bax, and upregulated those of Bcl-2 at low concentrations. 7,3'-dihydroxy-4'-methoxyisoflavone 38-47 BCL2 apoptosis regulator Homo sapiens 179-184 21878904-2 2011 However, 5-FU resistance, mainly caused by the overexpression of antiapoptotic proteins such as Bcl-2, often leads ultimately to treatment failure. Fluorouracil 9-13 BCL2 apoptosis regulator Homo sapiens 96-101 21837364-5 2011 Moreover, beta-elemene decreased bcl-2 expression, increased bax expression and caused the cleavage of PARP. beta-elemene 10-22 BCL2 apoptosis regulator Homo sapiens 33-38 21701487-5 2011 In accordance, primary samples from newly diagnosed CBF AML patients (n=23) also showed differential sensitivity to in vitro treatment with a Smac mimetic such as BV6, an antagonist of inhibitor of apoptosis (IAP) proteins, and ABT-737, a BCL2 inhibitor. smac 142-146 BCL2 apoptosis regulator Homo sapiens 239-243 21878904-3 2011 We here investigated the effect of Bcl-2 gene silencing, using small interfering RNA (siRNA) (siBcl-2), on the efficacy of 5-FU in CRC. Fluorouracil 123-127 BCL2 apoptosis regulator Homo sapiens 35-40 21878904-4 2011 Transfection of siBcl-2 by a Lipofectamine2000/siRNA lipoplex effectively downregulated Bcl-2 expression in the DLD-1 cell line (a CRC), resulting in significant cell growth inhibition in vitro upon treatment with 5-FU. Lipofectamine 29-46 BCL2 apoptosis regulator Homo sapiens 18-23 21878904-4 2011 Transfection of siBcl-2 by a Lipofectamine2000/siRNA lipoplex effectively downregulated Bcl-2 expression in the DLD-1 cell line (a CRC), resulting in significant cell growth inhibition in vitro upon treatment with 5-FU. Fluorouracil 214-218 BCL2 apoptosis regulator Homo sapiens 18-23 21611853-6 2011 To estimate anti-apoptosis effect of taurine, flow cytometry analysis as well as detection for caspase-3 and Bcl-2 expressions was performed after morphine exposure for 48 h. It was found that Bcl-2 expression was down regulated by morphine, whereas taurine could reverse morphine-induced decrease in Bcl-2 expression. Taurine 37-44 BCL2 apoptosis regulator Homo sapiens 193-198 21735136-6 2011 ABPP-E4 pretreatment also resulted in increase of Bcl-2/Bax ratio and inhibition of caspase-3 activation in the cells on exposure to serum deprivation. Bropirimine 0-4 BCL2 apoptosis regulator Homo sapiens 50-55 21611853-6 2011 To estimate anti-apoptosis effect of taurine, flow cytometry analysis as well as detection for caspase-3 and Bcl-2 expressions was performed after morphine exposure for 48 h. It was found that Bcl-2 expression was down regulated by morphine, whereas taurine could reverse morphine-induced decrease in Bcl-2 expression. Taurine 37-44 BCL2 apoptosis regulator Homo sapiens 193-198 21611853-6 2011 To estimate anti-apoptosis effect of taurine, flow cytometry analysis as well as detection for caspase-3 and Bcl-2 expressions was performed after morphine exposure for 48 h. It was found that Bcl-2 expression was down regulated by morphine, whereas taurine could reverse morphine-induced decrease in Bcl-2 expression. Morphine 147-155 BCL2 apoptosis regulator Homo sapiens 193-198 21611853-6 2011 To estimate anti-apoptosis effect of taurine, flow cytometry analysis as well as detection for caspase-3 and Bcl-2 expressions was performed after morphine exposure for 48 h. It was found that Bcl-2 expression was down regulated by morphine, whereas taurine could reverse morphine-induced decrease in Bcl-2 expression. Morphine 147-155 BCL2 apoptosis regulator Homo sapiens 193-198 21611853-6 2011 To estimate anti-apoptosis effect of taurine, flow cytometry analysis as well as detection for caspase-3 and Bcl-2 expressions was performed after morphine exposure for 48 h. It was found that Bcl-2 expression was down regulated by morphine, whereas taurine could reverse morphine-induced decrease in Bcl-2 expression. Morphine 232-240 BCL2 apoptosis regulator Homo sapiens 193-198 21611853-6 2011 To estimate anti-apoptosis effect of taurine, flow cytometry analysis as well as detection for caspase-3 and Bcl-2 expressions was performed after morphine exposure for 48 h. It was found that Bcl-2 expression was down regulated by morphine, whereas taurine could reverse morphine-induced decrease in Bcl-2 expression. Morphine 232-240 BCL2 apoptosis regulator Homo sapiens 193-198 21611853-6 2011 To estimate anti-apoptosis effect of taurine, flow cytometry analysis as well as detection for caspase-3 and Bcl-2 expressions was performed after morphine exposure for 48 h. It was found that Bcl-2 expression was down regulated by morphine, whereas taurine could reverse morphine-induced decrease in Bcl-2 expression. Taurine 250-257 BCL2 apoptosis regulator Homo sapiens 193-198 21611853-6 2011 To estimate anti-apoptosis effect of taurine, flow cytometry analysis as well as detection for caspase-3 and Bcl-2 expressions was performed after morphine exposure for 48 h. It was found that Bcl-2 expression was down regulated by morphine, whereas taurine could reverse morphine-induced decrease in Bcl-2 expression. Taurine 250-257 BCL2 apoptosis regulator Homo sapiens 193-198 21611853-6 2011 To estimate anti-apoptosis effect of taurine, flow cytometry analysis as well as detection for caspase-3 and Bcl-2 expressions was performed after morphine exposure for 48 h. It was found that Bcl-2 expression was down regulated by morphine, whereas taurine could reverse morphine-induced decrease in Bcl-2 expression. Morphine 232-240 BCL2 apoptosis regulator Homo sapiens 193-198 21611853-6 2011 To estimate anti-apoptosis effect of taurine, flow cytometry analysis as well as detection for caspase-3 and Bcl-2 expressions was performed after morphine exposure for 48 h. It was found that Bcl-2 expression was down regulated by morphine, whereas taurine could reverse morphine-induced decrease in Bcl-2 expression. Morphine 232-240 BCL2 apoptosis regulator Homo sapiens 193-198 21867723-7 2011 CYN induced changes in the mRNA expression of P53 and its downstream regulated DNA damage responsive genes MDM2, GADD45alpha and apoptosis genes, BCL-2 and BAX, as well as oxidative stress responsive genes (GPX1, SOD1, GSR, GCLC), while no changes in the expression of genes CDKN1A and CAT were observed. cylindrospermopsin 0-3 BCL2 apoptosis regulator Homo sapiens 146-151 22204135-9 2011 Moreover, LY333531 reduced the ratio of Bcl-2/Bax. ruboxistaurin 10-18 BCL2 apoptosis regulator Homo sapiens 40-45 22322845-12 2011 CONCLUSION: DHA could inhibit proliferation and induce apoptosis in HepG2 cell lines through increasing the intracellular production of ROS and [Ca2+]i. Endoplasmic reticulum stress-induced apoptosis may contribute to this effect by regulating the expression of GADD153, proapoptotic Bax, and antiapoptotic Bcl-2. artenimol 12-15 BCL2 apoptosis regulator Homo sapiens 307-312 22322845-10 2011 An increase in GADD153 and Bax expression and a decrease in Bcl-2 were observed in DHA-treated cells. artenimol 83-86 BCL2 apoptosis regulator Homo sapiens 60-65 21840388-9 2011 Annonacin (0.1 muM) increased apoptosis while decreasing Bcl-2 protein expression. annonacin 0-9 BCL2 apoptosis regulator Homo sapiens 57-62 21964380-5 2011 In addition, quercetin repressed the expression of the pro-apoptotic Bax gene and enhanced that of the anti-apoptotic Bcl-2 gene in SH-SY5Y cells. Quercetin 13-22 BCL2 apoptosis regulator Homo sapiens 118-123 21878650-0 2011 miR-497 and miR-302b regulate ethanol-induced neuronal cell death through BCL2 protein and cyclin D2. Ethanol 30-37 BCL2 apoptosis regulator Homo sapiens 74-78 21878650-11 2011 In conclusion, our studies have shown that ethanol-induced neuronal apoptosis follows both the mitochondria-mediated (miR-497- and BCL2-mediated) and non-mitochondria-mediated (miR-302b- and CCND2-mediated) pathway. Ethanol 43-50 BCL2 apoptosis regulator Homo sapiens 131-135 21840388-10 2011 The combination of annonacin (0.1 muM) and 4-hydroxytamoxifen (1 muM) decreased Bcl-2 protein expression and ERalpha transcriptional activity more than annonacin (0.1 muM) did alone. annonacin 19-28 BCL2 apoptosis regulator Homo sapiens 80-85 21840388-10 2011 The combination of annonacin (0.1 muM) and 4-hydroxytamoxifen (1 muM) decreased Bcl-2 protein expression and ERalpha transcriptional activity more than annonacin (0.1 muM) did alone. hydroxytamoxifen 43-61 BCL2 apoptosis regulator Homo sapiens 80-85 21840388-14 2011 Moreover, annonacin decreased ERalpha, cyclin D1 and Bcl-2 protein expression in the xenograft at 22 days. annonacin 10-19 BCL2 apoptosis regulator Homo sapiens 53-58 21835956-3 2011 ABT-737 is a cell-permeant compound that binds to Bcl-2 and Bcl-x(L) but not to Mcl-1. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 50-55 21892202-14 2011 Oridonin markedly increased Bax expression in mitochondria, and decreased Bcl-2 expression in both the cytosol and mitochondria. oridonin 0-8 BCL2 apoptosis regulator Homo sapiens 74-79 21892202-15 2011 Oridonin also markedly increased the phosphorylation of Bcl-2 in the cytosol. oridonin 0-8 BCL2 apoptosis regulator Homo sapiens 56-61 21835956-6 2011 We demonstrated that ABT-737-sensitive and ABT-737-resistant cell lines could be differentiated by the BCL2/MCL1 expression ratio. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 21-24 BCL2 apoptosis regulator Homo sapiens 103-107 21710254-0 2011 Withaferin A induces apoptosis in human melanoma cells through generation of reactive oxygen species and down-regulation of Bcl-2. withaferin A 0-12 BCL2 apoptosis regulator Homo sapiens 124-129 21835956-6 2011 We demonstrated that ABT-737-sensitive and ABT-737-resistant cell lines could be differentiated by the BCL2/MCL1 expression ratio. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 43-46 BCL2 apoptosis regulator Homo sapiens 103-107 21835956-8 2011 ABT-737 first induced the disruption of Bcl-2/Bax, Bcl-2/Bik, or Bcl-2/Puma complexes, followed by the disruption of Bcl-2 heterodimers with Bak and Bim. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 40-45 21835956-8 2011 ABT-737 first induced the disruption of Bcl-2/Bax, Bcl-2/Bik, or Bcl-2/Puma complexes, followed by the disruption of Bcl-2 heterodimers with Bak and Bim. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 51-56 21835956-8 2011 ABT-737 first induced the disruption of Bcl-2/Bax, Bcl-2/Bik, or Bcl-2/Puma complexes, followed by the disruption of Bcl-2 heterodimers with Bak and Bim. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 51-56 21835956-8 2011 ABT-737 first induced the disruption of Bcl-2/Bax, Bcl-2/Bik, or Bcl-2/Puma complexes, followed by the disruption of Bcl-2 heterodimers with Bak and Bim. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 51-56 21710254-5 2011 The susceptibility of cells toward WFA-induced apoptosis correlated with low Bcl-2/Bax and Bcl-2/Bim ratios. withaferin A 35-38 BCL2 apoptosis regulator Homo sapiens 77-82 21710254-5 2011 The susceptibility of cells toward WFA-induced apoptosis correlated with low Bcl-2/Bax and Bcl-2/Bim ratios. withaferin A 35-38 BCL2 apoptosis regulator Homo sapiens 91-96 21361874-8 2011 The bcl-2, p53 and cox-2 genes in both cell lines treated with ASA seem to exhibit different patterns of expression. Aspirin 63-66 BCL2 apoptosis regulator Homo sapiens 4-9 21561376-5 2011 The six antiapoptotic Bcl-2 family members were expressed as glutathione-S-transferase fusion proteins and bound individually to six glutathione bead sets, with each set having a different intensity of red fluorescence. Glutathione 61-72 BCL2 apoptosis regulator Homo sapiens 22-27 21561376-6 2011 A fluorescein-conjugated Bcl-2 homology region 3 (BH3) peptide from Bim was employed as a universal ligand. Fluorescein 2-13 BCL2 apoptosis regulator Homo sapiens 25-30 21469974-0 2011 Effects of drospirenone/estradiol on steroid receptors and Bcl-2 in the postmenopausal endometrium. drospirenone 11-23 BCL2 apoptosis regulator Homo sapiens 59-64 21939359-9 2011 In addition, the expression analysis of genes involved in apoptosis and inflammation revealed significant downregulation of Bcl-2, COX-2, and IL-1beta on treatment with eugenol. Eugenol 169-176 BCL2 apoptosis regulator Homo sapiens 124-129 21361874-4 2011 The mechanism of action of different concentrations of ASA were compared in K562 (non-MDR) and Lucena (MDR) cells by analysing cell viability, apoptosis and necrosis, intracellular ROS (reactive oxygen species) formation and bcl-2, p53 and cox-2 gene expression. Aspirin 55-58 BCL2 apoptosis regulator Homo sapiens 225-230 21469974-1 2011 OBJECTIVE: To evaluate the effect of drospirenone with 17beta-estradiol on the histology and expression of estrogen and progesterone receptors and of Bcl-2 protein, in endometrium of postmenopausal women. drospirenone 37-49 BCL2 apoptosis regulator Homo sapiens 150-155 21469974-1 2011 OBJECTIVE: To evaluate the effect of drospirenone with 17beta-estradiol on the histology and expression of estrogen and progesterone receptors and of Bcl-2 protein, in endometrium of postmenopausal women. Estradiol 55-71 BCL2 apoptosis regulator Homo sapiens 150-155 21469974-6 2011 The drospirenone/estradiol group showed higher expression of ER and PR in glandular epithelium compared to stroma, but the Bcl-2 protein was more immunoreactive in stroma than in glandular epithelium. drospirenone 4-16 BCL2 apoptosis regulator Homo sapiens 123-128 21469974-7 2011 Compared to controls, drospirenone/estradiol users showed higher immunoexpression of ER, PR and Bcl-2 in both glandular epithelium and endometrial stroma. drospirenone 22-34 BCL2 apoptosis regulator Homo sapiens 96-101 21469974-7 2011 Compared to controls, drospirenone/estradiol users showed higher immunoexpression of ER, PR and Bcl-2 in both glandular epithelium and endometrial stroma. Estradiol 35-44 BCL2 apoptosis regulator Homo sapiens 96-101 21959046-8 2011 CQ sensitized A549 cells to TPT and enhanced TPT-induced apoptosis in a Bcl-2 family protein-independent fashion. Chloroquine 0-2 BCL2 apoptosis regulator Homo sapiens 72-77 21864950-0 2011 Conjugation of substituted ferrocenyl to thiadiazine as apoptosis-inducing agents targeting the Bax/Bcl-2 pathway. ferrocenyl 27-37 BCL2 apoptosis regulator Homo sapiens 100-105 21864950-0 2011 Conjugation of substituted ferrocenyl to thiadiazine as apoptosis-inducing agents targeting the Bax/Bcl-2 pathway. Thiadiazines 41-52 BCL2 apoptosis regulator Homo sapiens 100-105 20349264-2 2011 The present study was designed to determine the maximum tolerated dose (MTD) of oblimersen (antisense Bcl-2) and gemcitabine when administered to patients with refractory malignancies. oblimersen 80-90 BCL2 apoptosis regulator Homo sapiens 102-107 21767511-0 2011 The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. entinostat 46-54 BCL2 apoptosis regulator Homo sapiens 120-125 21767511-8 2011 Combination studies demonstrated that two Bcl-2 inhibitors (ABT-737 and obatoclax) significantly enhanced the effect of SNDX-275. ABT-737 60-67 BCL2 apoptosis regulator Homo sapiens 42-47 21767511-8 2011 Combination studies demonstrated that two Bcl-2 inhibitors (ABT-737 and obatoclax) significantly enhanced the effect of SNDX-275. entinostat 120-128 BCL2 apoptosis regulator Homo sapiens 42-47 22230393-6 2011 On the contrary, capsaicin was found to produce only an up-regulation of BCL2, an anti-apoptotic gene and MMP9, whereas no significant changes were reported in genes involved in inflammatory and immune responses. Capsaicin 17-26 BCL2 apoptosis regulator Homo sapiens 73-77 21826535-9 2011 We developed a five-gene model composed of PgR, BCL2, ERBB4 JM-a, RERG, and CD34 that identified early-stage, ER+/PR+ breast cancers in patients treated with tamoxifen that relapsed, although they exhibited clinicopathologic features suggesting good prognosis. Tamoxifen 158-167 BCL2 apoptosis regulator Homo sapiens 48-52 21687933-11 2011 Furthermore, TBMS1 induced the up-regulation of Bcl-2 associated X protein (Bax) expression, down-regulation of Bcl-2 expression, inhibition of nuclear factor-kappa-B (NF-kappaB) function and impacted the phosphorylation of p38 mitogen-activated protein kinase (p38/MAPK), extracellular signal-regulated kinases (ERK)1/2 and protein kinase B (Akt). tbms1 13-18 BCL2 apoptosis regulator Homo sapiens 48-53 21687933-11 2011 Furthermore, TBMS1 induced the up-regulation of Bcl-2 associated X protein (Bax) expression, down-regulation of Bcl-2 expression, inhibition of nuclear factor-kappa-B (NF-kappaB) function and impacted the phosphorylation of p38 mitogen-activated protein kinase (p38/MAPK), extracellular signal-regulated kinases (ERK)1/2 and protein kinase B (Akt). tbms1 13-18 BCL2 apoptosis regulator Homo sapiens 112-117 20372971-4 2011 Atiprimod-induced cell growth inhibition of JAK2 (V617F)-positive cells was coupled with induction of apoptosis, as evidenced by heightened mitochondrial membrane potential and caspase-3 activity, as well as PARP cleavage, increased turnover of the anti-apoptotic X-linked mammalian inhibitor of apoptosis (XIAP) protein, and inhibition of the pro-apoptotic protein BCL-2 in a time- and dose-dependent manner. azaspirane 0-9 BCL2 apoptosis regulator Homo sapiens 366-371 21743969-7 2011 Significant de-phosphorylation of Akt, increased Bax expression, decreased Bcl-2 expression and cleavage of caspase-3 were also observed in resveratrol-induced apoptosis in glioblastoma cells. Resveratrol 140-151 BCL2 apoptosis regulator Homo sapiens 75-80 21728742-0 2011 Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. alvocidib 0-12 BCL2 apoptosis regulator Homo sapiens 21-26 21728742-3 2011 Here, we report that in vivo administration of flavopiridol induced expression of the BCL-2 anti-apoptotic gene in leukemic blasts from adult patients with refractory AML. alvocidib 47-59 BCL2 apoptosis regulator Homo sapiens 86-91 21743966-10 2011 EGCG also suppressed AKT kinase activity and protein levels and also altered the expression levels of Bcl-2 family-related proteins such as Bcl-2, Bax, BAD and p-BAD. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 102-107 21743966-10 2011 EGCG also suppressed AKT kinase activity and protein levels and also altered the expression levels of Bcl-2 family-related proteins such as Bcl-2, Bax, BAD and p-BAD. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 140-145 21327582-0 2011 17beta-estradiol protects dopaminergic neurons in organotypic slice of mesencephalon by MAPK-mediated activation of anti-apoptosis gene BCL2. Estradiol 0-16 BCL2 apoptosis regulator Homo sapiens 136-140 21327582-7 2011 Taken together, MAPK pathway-mediated BCL2 expression accounted for one of the key mechanisms involved in E2 neuroprotective effect on dopaminergic neurons against 6-OHDA insult. Oxidopamine 164-170 BCL2 apoptosis regulator Homo sapiens 38-42 21552169-7 2011 Moreover, dipyrone prevented ischemia-induced changes in Bcl-2 and tBid, and ameliorated oxygen/glucose deprivation-mediated loss of mitochondrial membrane potential. Dipyrone 10-18 BCL2 apoptosis regulator Homo sapiens 57-62 21821060-3 2011 Treatment with naphthalimide-based DNA intercalators, including M2-A and R16, generally leads to a decrease in Bcl-2 intracellular amounts. Naphthalimides 15-28 BCL2 apoptosis regulator Homo sapiens 111-116 21698669-0 2011 Modulating Bcl-2 family proteins and caspase-3 in induction of apoptosis by paeoniflorin in human cervical cancer cells. peoniflorin 76-88 BCL2 apoptosis regulator Homo sapiens 11-16 21698669-9 2011 In conclusion, PF can induce significantly the apoptosis of HeLa cells, which may be demonstrated by the down-regulation of anti-apoptosis gene Bcl-2 and the up-regulation of pro-apoptosis genes Bax and caspase-3. peoniflorin 15-17 BCL2 apoptosis regulator Homo sapiens 144-149 21394804-7 2011 Molecular dissection revealed that the antiapoptotic protein bcl-2 was down-regulated after cholangiocarcinoma cell lines were treated with beta-escin, while the protein levels of bax and p53 were unchanged. Escin 140-150 BCL2 apoptosis regulator Homo sapiens 61-66 21609759-0 2011 Thymoquinone from Nigella sativa was more potent than cisplatin in eliminating of SiHa cells via apoptosis with down-regulation of Bcl-2 protein. thymoquinone 0-12 BCL2 apoptosis regulator Homo sapiens 131-136 21609759-0 2011 Thymoquinone from Nigella sativa was more potent than cisplatin in eliminating of SiHa cells via apoptosis with down-regulation of Bcl-2 protein. Cisplatin 54-63 BCL2 apoptosis regulator Homo sapiens 131-136 21609759-9 2011 In conclusion, thymoquinone from N. sativa was more potent than cisplatin in elimination of SiHa cells via apoptosis with down-regulation of Bcl-2 protein. thymoquinone 15-27 BCL2 apoptosis regulator Homo sapiens 141-146 21609759-9 2011 In conclusion, thymoquinone from N. sativa was more potent than cisplatin in elimination of SiHa cells via apoptosis with down-regulation of Bcl-2 protein. Cisplatin 64-73 BCL2 apoptosis regulator Homo sapiens 141-146 21660566-3 2011 We now show that the combination (2-DG + 6-AN + 2Gy) induces significant alterations in mitochondrial membrane potential and oxidative damage to lipid and proteins selectively in malignant cells resulting in the release of cytochrome c from mitochondria and increase in Bax/Bcl-2 ratio stimulating intrinsic pathway of apoptosis, besides enhancing the mitotic death linked to cytogenetic damage. Deoxyglucose 34-38 BCL2 apoptosis regulator Homo sapiens 274-279 21660566-3 2011 We now show that the combination (2-DG + 6-AN + 2Gy) induces significant alterations in mitochondrial membrane potential and oxidative damage to lipid and proteins selectively in malignant cells resulting in the release of cytochrome c from mitochondria and increase in Bax/Bcl-2 ratio stimulating intrinsic pathway of apoptosis, besides enhancing the mitotic death linked to cytogenetic damage. 6-Aminonicotinamide 41-45 BCL2 apoptosis regulator Homo sapiens 274-279 21821060-5 2011 We report here that p53 contributes to Bcl-2 down-regulation induced by B1, a novel naphthalimide-based DNA intercalating agent. Naphthalimides 84-97 BCL2 apoptosis regulator Homo sapiens 39-44 21821060-10 2011 Our study strengthens the links between p53 and Bcl-2 at a transcriptional level, upon naphthalimide-based DNA intercalator treatment. Naphthalimides 87-100 BCL2 apoptosis regulator Homo sapiens 48-53 21499301-4 2011 Lapatinib induced apoptosis in association with upregulation of the pro-apoptotic protein Bcl-2 interacting mediator of cell death (BIM) through inhibition of the MEK-ERK signaling pathway in breast cancer cells with HER2 amplification. Lapatinib 0-9 BCL2 apoptosis regulator Homo sapiens 90-95 21699893-9 2011 Tanshinone A could arrest K562 cells in the G(0)/G(1) phase and induce apoptosis, decrease the mitochondrial transmembrane potential, decrease the expressions of bcl-2 and c-Myc proteins, increase the expression of bax protein and the activity of caspase-3. tanshinone 0-12 BCL2 apoptosis regulator Homo sapiens 162-167 22655238-4 2011 Compound (-) BI97D6 potently inhibits the binding of BH3 peptides to Bcl-X(L), Bcl-2, Mcl-1, and Bfl-1 with IC(50) values of 76 +- 5, 31 +- 2, 25 +- 8, and 122 +- 28 nM, respectively. BH 3 53-56 BCL2 apoptosis regulator Homo sapiens 79-84 21772052-0 2011 An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 104-107 BCL2 apoptosis regulator Homo sapiens 17-22 21772052-2 2011 The small molecule inhibitor ABT-737 binds with high affinity to BCL-2, BCL-XL, and BCL-W but with low affinity to MCL-1, BFL-1, and BCL-B. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 29-32 BCL2 apoptosis regulator Homo sapiens 65-70 21772052-4 2011 Here we used RT-PCR as a highly sensitive and quantitative assay to compare expression of antiapoptotic BCL-2 genes that are known to be targeted by ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 149-152 BCL2 apoptosis regulator Homo sapiens 104-109 21772052-5 2011 Our findings reveal that the relative ratio of MCL-1 and BFL-1 to BCL-2 expression provides a highly significant linear correlation with ABT-737 sensitivity (r = 0.6, P < .001). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 137-140 BCL2 apoptosis regulator Homo sapiens 66-71 21772052-9 2011 This study defines a highly significant BCL-2 expression index for predicting the response of CLL to ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 101-104 BCL2 apoptosis regulator Homo sapiens 40-45 21929745-8 2011 In responsive cell lines, the MI-319/sorafenib combination induced the disappearance of p53 from the nucleus, the down modulation of Bcl-2 and Bcl-xL, the translocation of p53 to the mitochondria and that of AIF to the nuclei. 2-methyl-4-isothiazolin-3-one 30-32 BCL2 apoptosis regulator Homo sapiens 133-138 21778226-0 2011 Allyl isothiocyanate arrests cancer cells in mitosis, and mitotic arrest in turn leads to apoptosis via Bcl-2 protein phosphorylation. allyl isothiocyanate 0-20 BCL2 apoptosis regulator Homo sapiens 104-109 21778226-8 2011 Moreover, we found that apoptosis induction by AITC depended entirely on mitotic arrest and was mediated via Bcl-2 phosphorylation at Ser-70. Serine 134-137 BCL2 apoptosis regulator Homo sapiens 109-114 21778226-9 2011 Pre-arresting cells in G(1) phase by hydroxyurea abrogated both AITC-induced mitotic arrest and Bcl-2 phosphorylation. Hydroxyurea 37-48 BCL2 apoptosis regulator Homo sapiens 96-101 21929745-8 2011 In responsive cell lines, the MI-319/sorafenib combination induced the disappearance of p53 from the nucleus, the down modulation of Bcl-2 and Bcl-xL, the translocation of p53 to the mitochondria and that of AIF to the nuclei. Sorafenib 37-46 BCL2 apoptosis regulator Homo sapiens 133-138 21929745-10 2011 These modulatory effects of GSK-3beta on the activities of the sorafenib/MI-319 combination were the exact reverse of its effects on the activities of sorafenib alone, which induced the down modulation of Bcl-2 and Bcl-xL and the nuclear translocation of AIF only in cells in which GSK-3beta activity was either down modulated or constitutively low. Sorafenib 63-72 BCL2 apoptosis regulator Homo sapiens 205-210 21929745-10 2011 These modulatory effects of GSK-3beta on the activities of the sorafenib/MI-319 combination were the exact reverse of its effects on the activities of sorafenib alone, which induced the down modulation of Bcl-2 and Bcl-xL and the nuclear translocation of AIF only in cells in which GSK-3beta activity was either down modulated or constitutively low. 2-methyl-4-isothiazolin-3-one 73-75 BCL2 apoptosis regulator Homo sapiens 205-210 21929745-10 2011 These modulatory effects of GSK-3beta on the activities of the sorafenib/MI-319 combination were the exact reverse of its effects on the activities of sorafenib alone, which induced the down modulation of Bcl-2 and Bcl-xL and the nuclear translocation of AIF only in cells in which GSK-3beta activity was either down modulated or constitutively low. Sorafenib 151-160 BCL2 apoptosis regulator Homo sapiens 205-210 21961478-4 2011 Most of the miRNA target genes that showed altered expression could be classified as apoptotic genes and were up-regulated by PUFA or temozolomide treatment, while similar treatments resulted in repression of the corresponding mRNAs, such as cox2, irs1, irs2, ccnd1, itgb3, bcl2, sirt1, tp53inp1 and k-ras. Fatty Acids, Unsaturated 126-130 BCL2 apoptosis regulator Homo sapiens 274-278 21929745-11 2011 In A375 xenografts, the antitumor effects of sorafenib and MI-319 were additive and associated with the down modulation of Bcl-2 and Bcl-xL, the nuclear translocation of AIF, and increased suppression of tumor angiogenesis. Sorafenib 45-54 BCL2 apoptosis regulator Homo sapiens 123-128 21961478-4 2011 Most of the miRNA target genes that showed altered expression could be classified as apoptotic genes and were up-regulated by PUFA or temozolomide treatment, while similar treatments resulted in repression of the corresponding mRNAs, such as cox2, irs1, irs2, ccnd1, itgb3, bcl2, sirt1, tp53inp1 and k-ras. Temozolomide 134-146 BCL2 apoptosis regulator Homo sapiens 274-278 21929745-11 2011 In A375 xenografts, the antitumor effects of sorafenib and MI-319 were additive and associated with the down modulation of Bcl-2 and Bcl-xL, the nuclear translocation of AIF, and increased suppression of tumor angiogenesis. MI 319 59-65 BCL2 apoptosis regulator Homo sapiens 123-128 21797225-2 2011 Recent efforts from the Abbott Laboratories resulted in the development of the acylsulfonamide compound and clinical candidate that targets selectively Bcl-2, Bcl-x(L), and Bcl-w while it is not active against Mcl-1 and Bfl-1. acylsulfonamide 79-94 BCL2 apoptosis regulator Homo sapiens 152-157 21821698-0 2011 ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 63-68 21821698-2 2011 ABT-737 is a BH3 mimetic that targets Bcl-2, which is overexpressed in MCL and implicated in drug resistance. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 38-43 21821698-2 2011 ABT-737 is a BH3 mimetic that targets Bcl-2, which is overexpressed in MCL and implicated in drug resistance. BH 3 13-16 BCL2 apoptosis regulator Homo sapiens 38-43 21821698-10 2011 ABT-737 induced a rapid disruption of both Bcl-2/Bax and Bcl-2/Bik complexes. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 43-48 21821698-10 2011 ABT-737 induced a rapid disruption of both Bcl-2/Bax and Bcl-2/Bik complexes. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 57-62 21821698-14 2011 CONCLUSIONS: The present work shows that ABT-737 induces strong apoptosis in MCL cells expressing a Bcl-2(high)/Mcl-1(low) profile. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 41-44 BCL2 apoptosis regulator Homo sapiens 100-105 21821698-16 2011 Our results strongly support the use of ABT-737 according to the Bcl-2/Mcl-1 tumor cell profiles in the treatment of MCL. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 40-43 BCL2 apoptosis regulator Homo sapiens 65-70 21460857-1 2011 The BH3 mimetic ABT737 induces autophagy by competitively disrupting the inhibitory interaction between the BH3 domain of Beclin 1 and the anti-apoptotic proteins Bcl-2 and Bcl-X(L), thereby stimulating the Beclin 1-dependent allosteric activation of the pro-autophagic lipid kinase VPS34. BH 3 4-7 BCL2 apoptosis regulator Homo sapiens 163-168 21460857-1 2011 The BH3 mimetic ABT737 induces autophagy by competitively disrupting the inhibitory interaction between the BH3 domain of Beclin 1 and the anti-apoptotic proteins Bcl-2 and Bcl-X(L), thereby stimulating the Beclin 1-dependent allosteric activation of the pro-autophagic lipid kinase VPS34. ABT-737 16-22 BCL2 apoptosis regulator Homo sapiens 163-168 22025972-6 2011 Vitamin D3 treatment decreased the level of mRNA expression of patched1, Gli1, cyclin D1, and Bcl2, suggesting the possibility that vitamin D3 may act through regulation of hedgehog signaling. Cholecalciferol 0-10 BCL2 apoptosis regulator Homo sapiens 94-98 21777666-11 2011 Western blot analysis demonstrated that barakol-induced apoptosis was mediated by the increase in expression ratio of Bax/Bcl-2. barakol 40-47 BCL2 apoptosis regulator Homo sapiens 122-127 21777666-13 2011 Pretreatment of cells with N-acetyl-l-cysteine (NAC) attenuated intracellular ROS generation, the Bax/Bcl-2 protein expression, and apoptosis. Acetylcysteine 27-46 BCL2 apoptosis regulator Homo sapiens 102-107 21777666-14 2011 CONCLUSIONS: The mechanism of barakol-mediated toxicity in P19 cells is mainly associated with the ROS generation, followed by the imbalance of the Bax/Bcl-2 ratio, and caspase-9 activation leading to apoptotic cell death. barakol 30-37 BCL2 apoptosis regulator Homo sapiens 152-157 21785112-5 2011 NGA could increase the expression of the apoptosis-related proteins FasL, caspase-3, caspase-8, caspase-9, and Bax and decrease the expression of anti-apoptotic protein Bcl-2 accompanied by the mitochondrial transmembrane damage. neo-gambogic acid 0-3 BCL2 apoptosis regulator Homo sapiens 169-174 21765100-7 2011 Pretreatment with phosphatidylinositide 3-kinase/Akt inhibitor (LY-294002) prior to Ucn2 led to downregulation of CREB phosphorylation and hence reduced Bcl-2 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 64-73 BCL2 apoptosis regulator Homo sapiens 153-158 22025972-6 2011 Vitamin D3 treatment decreased the level of mRNA expression of patched1, Gli1, cyclin D1, and Bcl2, suggesting the possibility that vitamin D3 may act through regulation of hedgehog signaling. Cholecalciferol 132-142 BCL2 apoptosis regulator Homo sapiens 94-98 22162984-7 2011 Proliferation assays were performed on cells treated with the Bcl-2 inhibitor ABT-737 in the absence or presence of Herceptin. ABT-737 78-85 BCL2 apoptosis regulator Homo sapiens 62-67 21669190-8 2011 Our results highlight the NF-kappaB inhibitor helenalin as a promising chemotherapeutic agent to overcome Bcl-2-induced cell death resistance. helenalin 46-55 BCL2 apoptosis regulator Homo sapiens 106-111 21868525-8 2011 In addition, GA also activated the death receptor-dependent pathway by enhancing the protein expressions of fatty acid synthase (FAS), FAS ligand (FASL), caspase-8 and BCL-2 interacting domain (BID). Gallic Acid 13-15 BCL2 apoptosis regulator Homo sapiens 168-173 21868527-5 2011 Finally, sanguinarine induced apoptotic cell death by activating caspase and altering the Bcl-2/Bax ratio. sanguinarine 9-21 BCL2 apoptosis regulator Homo sapiens 90-95 21669190-0 2011 Helenalin bypasses Bcl-2-mediated cell death resistance by inhibiting NF-kappaB and promoting reactive oxygen species generation. Reactive Oxygen Species 94-117 BCL2 apoptosis regulator Homo sapiens 19-24 21669190-3 2011 Helenalin, a sesquiterpene lactone (STL), induces cell death and abrogates clonal survival in a highly apoptosis-resistant Bcl-2 overexpressing Jurkat cell line as well as in two other Bcl-2 overexpressing solid tumor cell lines (mammary MCF-7; pancreatic L6.3pl). helenalin 0-9 BCL2 apoptosis regulator Homo sapiens 123-128 21669190-3 2011 Helenalin, a sesquiterpene lactone (STL), induces cell death and abrogates clonal survival in a highly apoptosis-resistant Bcl-2 overexpressing Jurkat cell line as well as in two other Bcl-2 overexpressing solid tumor cell lines (mammary MCF-7; pancreatic L6.3pl). helenalin 0-9 BCL2 apoptosis regulator Homo sapiens 185-190 21669190-3 2011 Helenalin, a sesquiterpene lactone (STL), induces cell death and abrogates clonal survival in a highly apoptosis-resistant Bcl-2 overexpressing Jurkat cell line as well as in two other Bcl-2 overexpressing solid tumor cell lines (mammary MCF-7; pancreatic L6.3pl). Resveratrol 36-39 BCL2 apoptosis regulator Homo sapiens 123-128 21669190-5 2011 Moreover, helenalin induces an atypical form of cell death with necrotic features in Bcl-2 overexpressing cells, neither activating classical mediators of apoptosis (caspases, AIF, Omi/HtrA2, Apaf/apoptosome) nor ER-stress mediators (BiP/GRP78 and CHOP/GADD153), nor autophagy pathways (LC3 conversion). helenalin 10-19 BCL2 apoptosis regulator Homo sapiens 85-90 21669190-6 2011 In contrast, helenalin was found to inhibit NF-kappaB activation that was considerably increased in Bcl-2 overexpressing Jurkat cells and promotes cell survival. helenalin 13-22 BCL2 apoptosis regulator Homo sapiens 100-105 21628070-1 2011 The Bcl-2 protein, best known for its ability to inhibit apoptosis, interacts with the inositol 1,4,5-trisphosphate receptor (IP(3)R) Ca(2+) channel to regulate IP(3)-mediated Ca(2+) release from the endoplasmic reticulum. Inositol 1,4,5-Trisphosphate 126-131 BCL2 apoptosis regulator Homo sapiens 4-9 21616659-5 2011 We then investigated the mechanisms associated with MMC/curcumin-induced cell death by examining the effect of MMC/curcumin treatment on apoptosis, the activation of caspase-3, 8 and 9 and the expression of bcl-2 and bax. Mitomycin 52-55 BCL2 apoptosis regulator Homo sapiens 207-212 21424274-7 2011 Bax at 24-h post and Bax/Bcl-2 ratio at 24- (P < 0.01) and 48-h post (P < 0.05) following DH1 were greater than PRE (P < 0.05). CHEMBL37520 96-99 BCL2 apoptosis regulator Homo sapiens 25-30 21616659-5 2011 We then investigated the mechanisms associated with MMC/curcumin-induced cell death by examining the effect of MMC/curcumin treatment on apoptosis, the activation of caspase-3, 8 and 9 and the expression of bcl-2 and bax. Curcumin 56-64 BCL2 apoptosis regulator Homo sapiens 207-212 21616659-8 2011 MMC and curcumin together synergistically enhanced apoptosis in MCF-7 cells and the apoptosis most likely resulted from both the activation of caspases and modulation of bcl-2/bax expression. Mitomycin 0-3 BCL2 apoptosis regulator Homo sapiens 170-175 21616659-8 2011 MMC and curcumin together synergistically enhanced apoptosis in MCF-7 cells and the apoptosis most likely resulted from both the activation of caspases and modulation of bcl-2/bax expression. Curcumin 8-16 BCL2 apoptosis regulator Homo sapiens 170-175 21689714-7 2011 Bcl2/Bax protein levels indicated pycnogenol"s anti-apoptotic effect against high glucose-induced apoptotic cell death. Glucose 82-89 BCL2 apoptosis regulator Homo sapiens 0-4 21684048-1 2011 Based on our previous discovery of a dual inhibitor of Mcl-1 and Bcl-2, 3-thiomorpholin-8-oxo-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile (1, S1), and guided by structure insight of 1 complex with Mcl-1 and Bcl-2, we exploited the spatial orientation of BH3 groove of the two proteins by a series of analogues of 1. CHEMBL595134 72-136 BCL2 apoptosis regulator Homo sapiens 206-211 21753125-0 2011 Effects of BCL-2 suppression by antisense oligonucleotides on additional regulators of apoptosis compensatory change in non-targeted protein expression. Oligonucleotides 42-58 BCL2 apoptosis regulator Homo sapiens 11-16 21741427-4 2011 After treatment of HT-29 cell with DHEC, we observed the accumulation of intracellular reactive oxygen species, the loss of mitochondrial membrane potential, the alteration of expression of the Bcl-2 family members, the releasing of cytochrome c, the cleavage of poly (ADP-ribose) polymerase (PARP), and the activation of caspase-3, -8, and -9. Dihydroergocristine 35-39 BCL2 apoptosis regulator Homo sapiens 194-199 21503959-8 2011 In addition, P2Y11 sensitized endothelial cells to cisplatin-induced cell death by down-regulation of the expression of Bcl-2. Cisplatin 51-60 BCL2 apoptosis regulator Homo sapiens 120-125 21799993-4 2011 In this review, we discuss intracellular binding targets of aminoglycosides, highlighting specific aminoglycoside-binding proteins (HSP73, calreticulin and CLIMP-63) and their potential for triggering caspases and Bcl-2 signalling cascades that are involved in aminoglycoside-induced cytotoxicity. Aminoglycosides 60-75 BCL2 apoptosis regulator Homo sapiens 214-219 21799993-4 2011 In this review, we discuss intracellular binding targets of aminoglycosides, highlighting specific aminoglycoside-binding proteins (HSP73, calreticulin and CLIMP-63) and their potential for triggering caspases and Bcl-2 signalling cascades that are involved in aminoglycoside-induced cytotoxicity. Aminoglycosides 60-74 BCL2 apoptosis regulator Homo sapiens 214-219 21799993-4 2011 In this review, we discuss intracellular binding targets of aminoglycosides, highlighting specific aminoglycoside-binding proteins (HSP73, calreticulin and CLIMP-63) and their potential for triggering caspases and Bcl-2 signalling cascades that are involved in aminoglycoside-induced cytotoxicity. Aminoglycosides 99-113 BCL2 apoptosis regulator Homo sapiens 214-219 21708241-9 2011 Subamolide A increased Bax/Bcl-2 ratios, the amount of cytochrome c released from the mitochondria, caspase-3 and PARP cleavage, activated p53 and ERK1/2 and ultimately led to apoptosis in NTUB1 cells. subamolide A 0-12 BCL2 apoptosis regulator Homo sapiens 27-32 21538480-5 2011 Meanwhile, rAGAP significantly decreases the production of NF-kappaB, BCL-2, p-p38, p-c-Jun, and p-Erk1/2 and further suppresses the activation of VEGF and MMP-9 in SHG-44 cells. ragap 11-16 BCL2 apoptosis regulator Homo sapiens 70-75 21251937-6 2011 Nilotinib induced apoptosis of HSCs, which was correlated with reduced bcl-2 expression, increased p53 expression, cleavage of PARP, as well as increased expression of PPARgamma and TRAIL-R. Nilotinib also induced cell cycle arrest, accompanied by increased expression of p27 and downregulation of cyclin D1. nilotinib 0-9 BCL2 apoptosis regulator Homo sapiens 71-76 21251937-12 2011 Nilotinib could induce HSC undergoing apoptosis in vivo, which was correlated with downregulation of bcl-2. nilotinib 0-9 BCL2 apoptosis regulator Homo sapiens 101-106 21185708-8 2011 We observed that docosahexaenoic acid (DHA) reverted the resistance of nr-HaCaT cells to UVR-induced apoptosis, increasing the Bax/Bcl-2 ratio and caspase-3 activity, and reduced COX-2 levels by inhibiting the expression of the human antigen R (HuR), a known COX-2 mRNA stabilizer in keratinocytes. Docosahexaenoic Acids 17-37 BCL2 apoptosis regulator Homo sapiens 131-136 21185708-8 2011 We observed that docosahexaenoic acid (DHA) reverted the resistance of nr-HaCaT cells to UVR-induced apoptosis, increasing the Bax/Bcl-2 ratio and caspase-3 activity, and reduced COX-2 levels by inhibiting the expression of the human antigen R (HuR), a known COX-2 mRNA stabilizer in keratinocytes. Docosahexaenoic Acids 39-42 BCL2 apoptosis regulator Homo sapiens 131-136 21805050-6 2011 Furthermore, we observed that quercetin induced the loss of mitochondrial membrane potential, upregulated the expression of the proapoptotic proteins, Bax and cytochrome C, and activated caspase-9 and caspase-3, and downregulated the expression of antiapoptotic protein, Bcl-2. Quercetin 30-39 BCL2 apoptosis regulator Homo sapiens 271-276 20422317-5 2011 LNCaP prostate tumor cells were initially incubated for 24 h in the presence of oligos (6.25 muM) directed against bcl-2 and compared to lipofectin containing controls. Oligonucleotides 80-86 BCL2 apoptosis regulator Homo sapiens 115-120 21880154-6 2011 Our results further demonstrated that miR-125b could promote leukemic cell proliferation and inhibit cell apoptosis by regulating the expression of tumor suppressor BCL2-antagonist/killer 1 (Bak1). mir-125b 38-46 BCL2 apoptosis regulator Homo sapiens 165-169 21617882-6 2011 Quercetin-induced apoptosis was accompanied by a significant reduction of mitochondrial membrane potential, release of mitochondrial cytochrome c to the cytosol, activation of caspase-3, down-regulation of Bcl-2, p-Bad and up-regulation of Bax. Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 206-211 21756550-7 2011 Meanwhile, H(2)O(2)-induced down-regulation of Bcl-2, up-regulation of Bax, and DNA damage and apoptosis were also inhibited in the presence of L-carnitine. Hydrogen Peroxide 11-19 BCL2 apoptosis regulator Homo sapiens 47-52 21756550-7 2011 Meanwhile, H(2)O(2)-induced down-regulation of Bcl-2, up-regulation of Bax, and DNA damage and apoptosis were also inhibited in the presence of L-carnitine. Carnitine 144-155 BCL2 apoptosis regulator Homo sapiens 47-52 21756550-8 2011 DISCUSSION: Taken together, these results suggest that L-carnitine may function as an anti-oxidant to inhibit H(2)O(2)-induced oxidative stress as well as regulation of Bcl-2 family and prevent the apoptotic death of neuronal cells, which might be beneficial for the treatment of oxidative stress in neurodegenerative diseases. Carnitine 55-66 BCL2 apoptosis regulator Homo sapiens 169-174 21663752-10 2011 Moreover, amisulpride effectively increased the levels of phospho-CREB, BDNF, and Bcl-2. Amisulpride 10-21 BCL2 apoptosis regulator Homo sapiens 82-87 21864799-1 2011 AIMS: The purpose of this study was to investigate the photoefficacies of protoporphyrin IX (PpIX) generated by drug precursor 5-aminolevulinic acid (ALA) and its hexyl ester (H-ALA) on two human non-small lung carcinoma cell lines (H460/Bcl-2 and H460/neo). h-ala 176-181 BCL2 apoptosis regulator Homo sapiens 238-243 21341336-3 2011 It was found that corosolic acid increased the Bax/Bcl-2 ratio by up-regulating Bax expression, disrupted mitochondrial membrane potential and triggered the release of cytochrome c from mitochondria into the cytoplasm. corosolic acid 18-32 BCL2 apoptosis regulator Homo sapiens 51-56 21864799-1 2011 AIMS: The purpose of this study was to investigate the photoefficacies of protoporphyrin IX (PpIX) generated by drug precursor 5-aminolevulinic acid (ALA) and its hexyl ester (H-ALA) on two human non-small lung carcinoma cell lines (H460/Bcl-2 and H460/neo). protoporphyrin IX 74-91 BCL2 apoptosis regulator Homo sapiens 238-243 21864799-1 2011 AIMS: The purpose of this study was to investigate the photoefficacies of protoporphyrin IX (PpIX) generated by drug precursor 5-aminolevulinic acid (ALA) and its hexyl ester (H-ALA) on two human non-small lung carcinoma cell lines (H460/Bcl-2 and H460/neo). protoporphyrin IX 93-97 BCL2 apoptosis regulator Homo sapiens 238-243 21864799-1 2011 AIMS: The purpose of this study was to investigate the photoefficacies of protoporphyrin IX (PpIX) generated by drug precursor 5-aminolevulinic acid (ALA) and its hexyl ester (H-ALA) on two human non-small lung carcinoma cell lines (H460/Bcl-2 and H460/neo). 5-amino levulinic acid 150-153 BCL2 apoptosis regulator Homo sapiens 238-243 21721047-1 2011 We carried out docking and molecular dynamics simulations on ABT-737 and obatoclax, which are inhibitors of the Bcl-2 family of proteins. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 61-64 BCL2 apoptosis regulator Homo sapiens 112-117 21721047-2 2011 We modeled the binding mode of ABT-737 with Bcl-x(L) , Bcl-2, and Mcl-1 and examined their dynamical behavior. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 31-34 BCL2 apoptosis regulator Homo sapiens 55-60 21721047-4 2011 However, the phenylpiperazine linker group was dramatically more mobile in Mcl-1 compared to either Bcl-x(L) or Bcl-2. phenylpiperazine 13-29 BCL2 apoptosis regulator Homo sapiens 112-117 21768356-0 2011 Fas-mediated neutrophil apoptosis is accelerated by Bid, Bak, and Bax and inhibited by Bcl-2 and Mcl-1. ammonium ferrous sulfate 0-3 BCL2 apoptosis regulator Homo sapiens 87-92 21570961-5 2011 When cells were treated with the combination of gemcitabine and ICI 118551, NF-kappaB activation was blocked; the expression of Bax protein was substantially increased; and Bcl-2 protein was downregulated. gemcitabine 48-59 BCL2 apoptosis regulator Homo sapiens 173-178 21563797-6 2011 Tat-Sab(KIM1) selectivity was also demonstrated in anisomycin-stressed HeLa cells where Tat-Sab(KIM1) prevented Bcl-2 phosphorylation, cell death, loss of mitochondrial membrane potential, and superoxide generation but not c-Jun phosphorylation. Anisomycin 51-61 BCL2 apoptosis regulator Homo sapiens 112-117 21707109-4 2011 In this work, a self-assembled peptide nanofibrous system is formed by mixing a cationic peptide amphiphile (PA) with Bcl-2 antisense oligodeoxynucleotide (ODN), G3139, through electrostatic interactions. Oligodeoxyribonucleotides 134-154 BCL2 apoptosis regulator Homo sapiens 118-123 21768356-5 2011 Increased Bcl-2 or Mcl-1 expression prevents efficient induction of apoptosis by Fas stimulation indicating that the Bcl-2-regulated apoptosis pathway can directly interfere with Fas-triggered apoptosis. ammonium ferrous sulfate 81-84 BCL2 apoptosis regulator Homo sapiens 10-15 21768356-5 2011 Increased Bcl-2 or Mcl-1 expression prevents efficient induction of apoptosis by Fas stimulation indicating that the Bcl-2-regulated apoptosis pathway can directly interfere with Fas-triggered apoptosis. ammonium ferrous sulfate 81-84 BCL2 apoptosis regulator Homo sapiens 117-122 21707109-10 2011 Furthermore, Bcl-2 mRNA amounts were lower in MCF-7 human breast cancer cells in the presence of PA-ODN complex compared to naked ODN and mismatch ODN evidenced by quantitative RT-PCR studies. pa-odn 97-103 BCL2 apoptosis regulator Homo sapiens 13-18 21340723-2 2011 Co-treatment with VPA and bortezomib on acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) cell lines resulted in marked inhibition of proliferation and induction of apoptosis, including a striking increase in mitochondrial injury, caspase cascade activation, and altered expression of Bcl-2 family proteins. Valproic Acid 18-21 BCL2 apoptosis regulator Homo sapiens 299-304 21659534-6 2011 Furthermore, the tMPT/superoxide flash served as a convergence point for pro- and anti-apoptotic regulation mediated by cyclophilin D and Bcl-2 proteins. trimethylolpropane trimethacrylate 17-21 BCL2 apoptosis regulator Homo sapiens 138-143 21659534-6 2011 Furthermore, the tMPT/superoxide flash served as a convergence point for pro- and anti-apoptotic regulation mediated by cyclophilin D and Bcl-2 proteins. Superoxides 22-32 BCL2 apoptosis regulator Homo sapiens 138-143 21659544-2 2011 ABT-737 is an antagonist of antiapoptotic Bcl-2 proteins and therefore is a good predictor of Bcl-x(L)/Bcl-2 dependence. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 42-47 21659544-2 2011 ABT-737 is an antagonist of antiapoptotic Bcl-2 proteins and therefore is a good predictor of Bcl-x(L)/Bcl-2 dependence. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 103-108 21659544-6 2011 Overall, these results suggest that complex interactions, and not simply expression patterns of Bcl-2 proteins, need to be investigated to understand Bcl-2 dependence and how to better use agents, such as ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 205-208 BCL2 apoptosis regulator Homo sapiens 96-101 21573972-0 2011 Hydroxyl radical mediates cisplatin-induced apoptosis in human hair follicle dermal papilla cells and keratinocytes through Bcl-2-dependent mechanism. Hydroxyl Radical 0-16 BCL2 apoptosis regulator Homo sapiens 124-129 21573972-0 2011 Hydroxyl radical mediates cisplatin-induced apoptosis in human hair follicle dermal papilla cells and keratinocytes through Bcl-2-dependent mechanism. Cisplatin 26-35 BCL2 apoptosis regulator Homo sapiens 124-129 21573972-7 2011 The mechanism by which hydroxyl radical mediates the apoptotic effect of cisplatin was shown to involve down-regulation of the anti-apoptotic protein Bcl-2 through ubiquitin-proteasomal degradation. Hydroxyl Radical 23-39 BCL2 apoptosis regulator Homo sapiens 150-155 21573972-7 2011 The mechanism by which hydroxyl radical mediates the apoptotic effect of cisplatin was shown to involve down-regulation of the anti-apoptotic protein Bcl-2 through ubiquitin-proteasomal degradation. Cisplatin 73-82 BCL2 apoptosis regulator Homo sapiens 150-155 21630016-4 2011 In addition, the levels of anti-apoptotic protein Bcl-2 (B-cell lymphoma protein-2) were restored by PD98059 or SB239063 in cells treated with H(2)O(2) or staurosporine, respectively. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 101-108 BCL2 apoptosis regulator Homo sapiens 50-55 21630016-4 2011 In addition, the levels of anti-apoptotic protein Bcl-2 (B-cell lymphoma protein-2) were restored by PD98059 or SB239063 in cells treated with H(2)O(2) or staurosporine, respectively. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 101-108 BCL2 apoptosis regulator Homo sapiens 57-82 21573972-8 2011 Bcl-2 was also shown to have a negative regulatory role on hydroxyl radical. Hydroxyl Radical 59-75 BCL2 apoptosis regulator Homo sapiens 0-5 21340723-2 2011 Co-treatment with VPA and bortezomib on acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) cell lines resulted in marked inhibition of proliferation and induction of apoptosis, including a striking increase in mitochondrial injury, caspase cascade activation, and altered expression of Bcl-2 family proteins. Bortezomib 26-36 BCL2 apoptosis regulator Homo sapiens 299-304 21573972-9 2011 Together, our results indicate an essential role of hydroxyl radical in cisplatin-induced cell death of hair follicle cells through Bcl-2 regulation. Hydroxyl Radical 52-68 BCL2 apoptosis regulator Homo sapiens 132-137 21573972-9 2011 Together, our results indicate an essential role of hydroxyl radical in cisplatin-induced cell death of hair follicle cells through Bcl-2 regulation. Cisplatin 72-81 BCL2 apoptosis regulator Homo sapiens 132-137 21630016-4 2011 In addition, the levels of anti-apoptotic protein Bcl-2 (B-cell lymphoma protein-2) were restored by PD98059 or SB239063 in cells treated with H(2)O(2) or staurosporine, respectively. SB 239063 112-120 BCL2 apoptosis regulator Homo sapiens 50-55 21630016-4 2011 In addition, the levels of anti-apoptotic protein Bcl-2 (B-cell lymphoma protein-2) were restored by PD98059 or SB239063 in cells treated with H(2)O(2) or staurosporine, respectively. SB 239063 112-120 BCL2 apoptosis regulator Homo sapiens 57-82 21630016-4 2011 In addition, the levels of anti-apoptotic protein Bcl-2 (B-cell lymphoma protein-2) were restored by PD98059 or SB239063 in cells treated with H(2)O(2) or staurosporine, respectively. Hydrogen Peroxide 143-151 BCL2 apoptosis regulator Homo sapiens 50-55 21630016-4 2011 In addition, the levels of anti-apoptotic protein Bcl-2 (B-cell lymphoma protein-2) were restored by PD98059 or SB239063 in cells treated with H(2)O(2) or staurosporine, respectively. Hydrogen Peroxide 143-151 BCL2 apoptosis regulator Homo sapiens 57-82 21630016-4 2011 In addition, the levels of anti-apoptotic protein Bcl-2 (B-cell lymphoma protein-2) were restored by PD98059 or SB239063 in cells treated with H(2)O(2) or staurosporine, respectively. Staurosporine 155-168 BCL2 apoptosis regulator Homo sapiens 50-55 22022968-6 2011 Mycobacterium tuberculosis H37Rv- and H37Ra-induced Bcl-2 production was reduced by specific inhibitors of mitogen-activated protein kinase kinase-1 (PD98059) and p38 (SB203580), but increased by nuclear factor kappaB (NF-kappaB) inhibitor (BAY 11-7082). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 150-157 BCL2 apoptosis regulator Homo sapiens 52-57 21630016-4 2011 In addition, the levels of anti-apoptotic protein Bcl-2 (B-cell lymphoma protein-2) were restored by PD98059 or SB239063 in cells treated with H(2)O(2) or staurosporine, respectively. Staurosporine 155-168 BCL2 apoptosis regulator Homo sapiens 57-82 21910059-6 2011 We also found that ursolic acid induced Bax up-regulation and Bcl-2 down-regulation and release of cytochrome C to the cytosol from mitochondria. ursolic acid 19-31 BCL2 apoptosis regulator Homo sapiens 62-67 21508685-4 2011 As a result, it has been thought that so-called BH3 mimetics, that is the pharmacological agents that occupy the hydrophobic cleft of Bcl-2, Bcl-XL and Mcl-1, would induce autophagy solely by disrupting the interaction between Beclin 1 and its inhibitors. BH 3 48-51 BCL2 apoptosis regulator Homo sapiens 134-139 21693166-2 2011 The effect of the natural polyamines on telomeric and some oncogenic G-quadruplexes including bcl-2, c-kit, and c-myc G-quadruplexes has been studied by using absorption, fluorescence, CD, and NMR methods. Polyamines 26-36 BCL2 apoptosis regulator Homo sapiens 94-99 21570448-6 2011 RESULTS AND CONCLUSIONS: A selectivity of quindoline 4-aminoproline oligomers for G-quadruplex and triplex structures was observed, especially for those quadruplex sequences found in telomeres and in the promoter regions of c-myc and bcl-2 oncogenes. quindoline 4-aminoproline 42-67 BCL2 apoptosis regulator Homo sapiens 234-239 21807395-1 2011 Di- and trimeric quinoline derivatives have been recently described as potential modulators of Bcl-2 family protein interactions. quinoline 17-26 BCL2 apoptosis regulator Homo sapiens 95-100 22022968-6 2011 Mycobacterium tuberculosis H37Rv- and H37Ra-induced Bcl-2 production was reduced by specific inhibitors of mitogen-activated protein kinase kinase-1 (PD98059) and p38 (SB203580), but increased by nuclear factor kappaB (NF-kappaB) inhibitor (BAY 11-7082). SB 203580 168-176 BCL2 apoptosis regulator Homo sapiens 52-57 22022968-6 2011 Mycobacterium tuberculosis H37Rv- and H37Ra-induced Bcl-2 production was reduced by specific inhibitors of mitogen-activated protein kinase kinase-1 (PD98059) and p38 (SB203580), but increased by nuclear factor kappaB (NF-kappaB) inhibitor (BAY 11-7082). 3-(4-methylphenylsulfonyl)-2-propenenitrile 241-252 BCL2 apoptosis regulator Homo sapiens 52-57 21670080-7 2011 The proapoptotic Bcl-2/Bcl-xL/Bcl-w inhibitor, ABT-737, shows clinical promise, but Mcl-1 upregulation can promote resistance. ABT-737 47-54 BCL2 apoptosis regulator Homo sapiens 17-22 21826595-5 2011 After SW480 cells were treated by UA at the concentrations of 0-40 mumol/L for 48 h, FCM showed that annexin V (AV) positive cells and hypodiploid peak ratio increased along with the increase in the drug"s concentrations; and Western blot found that expressions of Bcl-2, Bcl-xL and survivin decreased in a concentration-dependent manner. ursolic acid 34-36 BCL2 apoptosis regulator Homo sapiens 265-270 21640157-6 2011 Using ABT-263, an inhibitor for Bcl-2, and 10058-F4, an inhibitor for c-Myc, we found that both cell lines were more highly sensitive to cell death as a result of Bcl-2 inhibition than of c-Myc inhibition. 5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one 43-51 BCL2 apoptosis regulator Homo sapiens 163-168 21663587-7 2011 The addition of DHA and VP16, in comparison to VP16 added alone, resulted in marked suppression in the expression of several genes involved in DNA damage repair, cell proliferation, survival, invasion, and angiogenesis, including PRKDC, Survivin, PIK3R1, MAPK14, NFkappaB1, NFkappaBIA, BCL2, CD44, and MAT1. Docosahexaenoic Acids 16-19 BCL2 apoptosis regulator Homo sapiens 286-290 21617861-6 2011 Curcumin-induced apoptosis was accompanied with upregulation of the protein expression of Bax and downregulation of the protein levels of Bcl-2, resulting in dysfunction of mitochondria and subsequently led to cytochrome c release and sequential activation of caspase-9 and caspase-3 in NPC-TW 076 cells in a time-dependent manner. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 138-143 21545309-0 2011 Regulated hypoxia/reperfusion-dependent modulation of ERK1/2, cPLA2, and Bcl-2/Bax: a potential mechanism of neuroprotective effect of penehyclidine hydrochloride. Penequine hydrochloride 135-162 BCL2 apoptosis regulator Homo sapiens 73-78 21161674-2 2011 However, Bcl-2, a common target of STAT3 and NF-kappaB signaling, is distinctly up-regulated in resveratrol-treated medulloblastoma cells, indicating potential effects of NF-kappaB in Bcl-2 expression and anti-medulloblastoma efficiency of resveratrol. Resveratrol 96-107 BCL2 apoptosis regulator Homo sapiens 9-14 21791020-10 2011 Correlations between Ki-67 and Bcl-2 were positive in the EGJ (P > 0.001) and in the distal (P = 0.001) and proximal esophagus (P = 0.013). ki-67 21-26 BCL2 apoptosis regulator Homo sapiens 31-36 21823019-0 2011 miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. mir-125b 0-8 BCL2 apoptosis regulator Homo sapiens 92-97 21823019-0 2011 miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. Cisplatin 55-64 BCL2 apoptosis regulator Homo sapiens 92-97 21823021-0 2011 Effects of rapamycin on expression of Bcl-2 and Bax in human lens epithelial cells and cell cycle in rats. Sirolimus 11-20 BCL2 apoptosis regulator Homo sapiens 38-43 21823021-1 2011 The effects of rapamycin on the expression of Bcl-2 and Bax protein in in vitro cultured human lens epithelial cells (LECs) and cell cycle were investigated in order to provide the theoretical basis for the development of new inhibitory drugs for clinical prevention and treatment of after-cataract. Sirolimus 15-24 BCL2 apoptosis regulator Homo sapiens 46-51 21823021-12 2011 Western blot demonstrated that rapamycin could suppress the expression of Bcl-2 protein, but promote the expression of Bax protein. Sirolimus 31-40 BCL2 apoptosis regulator Homo sapiens 74-79 21062672-4 2011 G+Q+B combination was significantly more effective than individual compounds or their double combinations in increasing ER-beta, bax (mRNA expression); phospho-JNK, bax (protein levels); and in decreasing bcl-2, cyclin E, c-myc (mRNA expression); phospho-AKT, phospho-ERK, bcl-2, proliferating cell nuclear antigen (protein levels) in PC-3 cells. g+q+b 0-5 BCL2 apoptosis regulator Homo sapiens 205-210 21062672-4 2011 G+Q+B combination was significantly more effective than individual compounds or their double combinations in increasing ER-beta, bax (mRNA expression); phospho-JNK, bax (protein levels); and in decreasing bcl-2, cyclin E, c-myc (mRNA expression); phospho-AKT, phospho-ERK, bcl-2, proliferating cell nuclear antigen (protein levels) in PC-3 cells. g+q+b 0-5 BCL2 apoptosis regulator Homo sapiens 273-278 21161674-2 2011 However, Bcl-2, a common target of STAT3 and NF-kappaB signaling, is distinctly up-regulated in resveratrol-treated medulloblastoma cells, indicating potential effects of NF-kappaB in Bcl-2 expression and anti-medulloblastoma efficiency of resveratrol. Resveratrol 96-107 BCL2 apoptosis regulator Homo sapiens 184-189 21161674-2 2011 However, Bcl-2, a common target of STAT3 and NF-kappaB signaling, is distinctly up-regulated in resveratrol-treated medulloblastoma cells, indicating potential effects of NF-kappaB in Bcl-2 expression and anti-medulloblastoma efficiency of resveratrol. Resveratrol 240-251 BCL2 apoptosis regulator Homo sapiens 9-14 21161674-4 2011 The results revealed that resveratrol activated NF-kappaB signaling in both cell lines at the 4-h treatment point, and the treated cells sequentially exhibited Bcl-2 up-regulation, neuronal-like phenotype with synaptophisin expression, and, eventually, apoptosis. Resveratrol 26-37 BCL2 apoptosis regulator Homo sapiens 160-165 21161674-5 2011 Pyrrolidine dithiocarbamate (PDTC) treatment inhibited NF-kappaB activation and Bcl-2 expression and committed resveratrol-treated cells to apoptosis at the 8-h time point without the step of neuron-oriented differentiation. pyrrolidine dithiocarbamic acid 0-27 BCL2 apoptosis regulator Homo sapiens 80-85 21161674-5 2011 Pyrrolidine dithiocarbamate (PDTC) treatment inhibited NF-kappaB activation and Bcl-2 expression and committed resveratrol-treated cells to apoptosis at the 8-h time point without the step of neuron-oriented differentiation. pyrrolidine dithiocarbamic acid 29-33 BCL2 apoptosis regulator Homo sapiens 80-85 21161674-9 2011 Our in-vitro and in-vivo results thus demonstrate the dual effects of NF-kappaB signaling on medulloblastoma cells by delaying resveratrol-induced apoptosis by up-regulating Bcl-2 expression or by involvement in neuronal-like differentiation in the absence of resveratrol. Resveratrol 127-138 BCL2 apoptosis regulator Homo sapiens 174-179 21718292-6 2011 Moreover, persistent levels of reactive oxygen species caused translocation of Bax to mitochondria and Bcl-2 degradation, which led to loss of mitochondrial membrane potential and release of cytochrome c to the cytosol. Reactive Oxygen Species 31-54 BCL2 apoptosis regulator Homo sapiens 103-108 21699455-7 2011 Curcumin-ND decreased cyclin D1, pAkt, pIkappaBalpha, and Bcl(2) protein. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 58-63 22066458-6 2011 Furthermore, beta-sitosterul also induced HepG2 cells apoptosis, lost mitochondrial membrane potential, activated caspase-3, caspase-8 and caspase-9, up-regulate Bax, tBid protein, down-regulation Bcl-2 protein. beta-sitosterul 13-28 BCL2 apoptosis regulator Homo sapiens 197-202 21937802-8 2011 Oridonin down-regulated Bcl-2, up-regulated Bax protein, and activated caspase-3 in a concentration-dependent manner in the PC-3 cells. oridonin 0-8 BCL2 apoptosis regulator Homo sapiens 24-29 21868342-4 2011 The changes in Bax and Bcl-2 mRNA expressions in response to kaempferol treatment were determined by RT-PCR, and the caspase-3 and caspase-9 activities were evaluated using colorimetric assay. kaempferol 61-71 BCL2 apoptosis regulator Homo sapiens 23-28 21868342-6 2011 RT-PCR showed that after kaempferol treatment caused up-regulated Bax and down-regulated Bcl-2 mRNA expression. kaempferol 25-35 BCL2 apoptosis regulator Homo sapiens 89-94 21466843-9 2011 Celastrol also up-regulated the expression of pro-apoptotic Bax, down-regulated anti-apoptotic Bcl-2, and inhibited Akt phosphorylation. celastrol 0-9 BCL2 apoptosis regulator Homo sapiens 95-100 21906442-5 2011 The expression levels of caspase-3, -8, -9, c-FLIP, Bcl-2, p53, and p21 in the FLS changed after epirubicin treatment. Epirubicin 97-107 BCL2 apoptosis regulator Homo sapiens 52-57 21906442-6 2011 CONCLUSION: Epirubicin may coordinate with AD5-10 in inducing FLS apoptosis through affecting the levels of p53, p21, c-FLIP, and Bcl-2. Epirubicin 12-22 BCL2 apoptosis regulator Homo sapiens 130-135 21906442-6 2011 CONCLUSION: Epirubicin may coordinate with AD5-10 in inducing FLS apoptosis through affecting the levels of p53, p21, c-FLIP, and Bcl-2. ad5-10 43-49 BCL2 apoptosis regulator Homo sapiens 130-135 21798045-0 2011 Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft. oblimersen 70-75 BCL2 apoptosis regulator Homo sapiens 54-59 21628402-4 2011 Consequently, several lymphoma-related ERK substrates were down-regulated by AZD6244 including MCT-1, c-Myc, Bcl-2, Mcl-1, and CDK1/2. AZD 6244 77-84 BCL2 apoptosis regulator Homo sapiens 109-114 21796156-8 2011 The treatment of these cells with the Bcl-2-homology domain 3 mimetic ABT-737 disrupts Bax/Bcl-2 interaction and allows Bax activation by nutlin-3. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 70-73 BCL2 apoptosis regulator Homo sapiens 38-43 21796156-8 2011 The treatment of these cells with the Bcl-2-homology domain 3 mimetic ABT-737 disrupts Bax/Bcl-2 interaction and allows Bax activation by nutlin-3. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 70-73 BCL2 apoptosis regulator Homo sapiens 91-96 21798045-3 2011 In this study we evaluated whether electroporation could increase the delivery of antisense oligodeoxynucleotides against bcl-2 (G3139) as well as the efficacy of combination chemotherapy in human melanoma xenografts. Oligodeoxyribonucleotides 92-113 BCL2 apoptosis regulator Homo sapiens 122-127 21798045-10 2011 The efficacy of this treatment was due to the higher G3139 uptake in tumor cells which led to a marked down-regulation of bcl-2 protein expression. oblimersen 53-58 BCL2 apoptosis regulator Homo sapiens 122-127 21750559-12 2011 Gossypol, a small-molecule inhibitor of Bcl-2 family members, mimics the activity of quercetin by lowering Mcl-1 expression and sensitising U-937 cells to apoptosis induced by recombinant TRAIL and the Fas-ligand. Gossypol 0-8 BCL2 apoptosis regulator Homo sapiens 40-45 21708126-6 2011 In contrast, overexpression of the anti-apoptotic Bcl-2 protein protects Jurkat cells against HOCl-LDL-induced apoptosis and prevents accumulation of reactive oxygen species. Hypochlorous Acid 94-98 BCL2 apoptosis regulator Homo sapiens 50-55 21708126-6 2011 In contrast, overexpression of the anti-apoptotic Bcl-2 protein protects Jurkat cells against HOCl-LDL-induced apoptosis and prevents accumulation of reactive oxygen species. Reactive Oxygen Species 150-173 BCL2 apoptosis regulator Homo sapiens 50-55 21549799-5 2011 Meanwhile, the data showed that olaquindox triggered ROS-mediated apoptosis in HepG2 cells correlated with both the mitochondrial DNA damage and nuclear DNA damage, collapse of Deltapsi(m), opening of mPTP, down-regulation of Bcl-2 and up-regulation of Bax. olaquindox 32-42 BCL2 apoptosis regulator Homo sapiens 226-231 21549799-5 2011 Meanwhile, the data showed that olaquindox triggered ROS-mediated apoptosis in HepG2 cells correlated with both the mitochondrial DNA damage and nuclear DNA damage, collapse of Deltapsi(m), opening of mPTP, down-regulation of Bcl-2 and up-regulation of Bax. ros 53-56 BCL2 apoptosis regulator Homo sapiens 226-231 21549799-7 2011 In conclusion, olaquindox induced apoptosis of HepG2 cells through a caspase-9 and -3 dependent mitochondrial pathway, involving p53, Bcl-2 family protein expression, Deltapsi(m) disruption and mPTP opening. olaquindox 15-25 BCL2 apoptosis regulator Homo sapiens 134-139 21628457-1 2011 BH3 mimetics are small molecules designed or discovered to mimic the binding of BH3-only proteins to the hydrophobic groove of antiapoptotic BCL2 proteins. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 141-145 21628457-4 2011 We show that ABT-737 is the only BH3 mimetic that inhibits BCL2 as assessed by displacement of BAD and BIM from BCL2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 13-16 BCL2 apoptosis regulator Homo sapiens 59-63 21628457-4 2011 We show that ABT-737 is the only BH3 mimetic that inhibits BCL2 as assessed by displacement of BAD and BIM from BCL2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 13-16 BCL2 apoptosis regulator Homo sapiens 112-116 21628457-4 2011 We show that ABT-737 is the only BH3 mimetic that inhibits BCL2 as assessed by displacement of BAD and BIM from BCL2. BH 3 33-36 BCL2 apoptosis regulator Homo sapiens 59-63 21628457-4 2011 We show that ABT-737 is the only BH3 mimetic that inhibits BCL2 as assessed by displacement of BAD and BIM from BCL2. BH 3 33-36 BCL2 apoptosis regulator Homo sapiens 112-116 21628457-7 2011 However, by combining two BH3 mimetics, one that inhibits BCL2 and one that induces NOXA, apoptosis is induced within 6 h in a BAX/BAK-dependent manner. BH 3 26-29 BCL2 apoptosis regulator Homo sapiens 58-62 21628457-7 2011 However, by combining two BH3 mimetics, one that inhibits BCL2 and one that induces NOXA, apoptosis is induced within 6 h in a BAX/BAK-dependent manner. bakuchiol 131-134 BCL2 apoptosis regulator Homo sapiens 58-62 21750559-12 2011 Gossypol, a small-molecule inhibitor of Bcl-2 family members, mimics the activity of quercetin by lowering Mcl-1 expression and sensitising U-937 cells to apoptosis induced by recombinant TRAIL and the Fas-ligand. Quercetin 85-94 BCL2 apoptosis regulator Homo sapiens 40-45 21225866-9 2011 It is noteworthy that 150 nM cucurbitacin I effectively blocked STAT3 signaling and downstream survival targets, such as B-cell chronic lymphocytic leukemia/lymphoma 2 (Bcl-2) and Bcl-2-like 1 (Bcl-xL) expression and induced apoptosis in CD133-positive NSCLC cells. cucurbitacin I 29-43 BCL2 apoptosis regulator Homo sapiens 121-167 21519046-9 2011 The 2% isoflurane treatment also enhanced a hypoxia-induced decrease in Bcl-2 levels. Isoflurane 7-17 BCL2 apoptosis regulator Homo sapiens 72-77 21519046-10 2011 CONCLUSIONS: These results suggest a potential concept that isoflurane has dual effects (protection versus promotion) on hypoxia-induced toxicity, which may act through Bcl-2 family proteins. Isoflurane 60-70 BCL2 apoptosis regulator Homo sapiens 169-174 21225866-9 2011 It is noteworthy that 150 nM cucurbitacin I effectively blocked STAT3 signaling and downstream survival targets, such as B-cell chronic lymphocytic leukemia/lymphoma 2 (Bcl-2) and Bcl-2-like 1 (Bcl-xL) expression and induced apoptosis in CD133-positive NSCLC cells. cucurbitacin I 29-43 BCL2 apoptosis regulator Homo sapiens 169-174 21435102-7 2011 The inhibition of STAT3 by XZH-5 was confirmed by the inhibition of STAT3 DNA binding ability and the downregulation of STAT3 downstream genes, such as Bcl-2, Bcl-xL, Cyclin D1 and Survivin; we also demonstrated that blockade of STAT3 phosphorylation in human rhabdomyosarcoma cells with XZH-5 caused apoptosis and suppressed colony-forming ability and cell migration. XZH-5 27-32 BCL2 apoptosis regulator Homo sapiens 152-157 21455254-10 2011 Combined vorinostat and ad-TRAIL induced stronger apoptosis induction, suppression of NF-kappaB activation and breakdown of the anti-apoptotic molecule Bcl-2. Vorinostat 9-19 BCL2 apoptosis regulator Homo sapiens 152-157 21573491-8 2011 In conclusion, wogonin induced ROS production and intracellular Ca2+, and altered the levels of anti- (Bcl-2) and pro- (Bad and Bax) apoptotic proteins. wogonin 15-22 BCL2 apoptosis regulator Homo sapiens 103-108 21555370-6 2011 Disrupting the mitochondrial BCL-2/BCL-XL antiapoptotic machinery in early survivor cells using BCL-2 Homology Domain 3 (BH3) mimetic agents such as ABT-737, or by dual RNAi-mediated knockdown of BCL-2/BCL-XL, was sufficient to eradicate the early-resistant lung-tumor-cells evading targeted inhibitors. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 149-152 BCL2 apoptosis regulator Homo sapiens 29-34 21933621-4 2011 Sodium valproate-induced apoptosis in HepG2 cells was investigated with fluorescence microscopy to detect morphological changes; by flow cytometry to calculate DNA ploidy and apoptotic cell percentages; with Western blotting analyses to determine c-Jun N-terminal kinases (JNK), p-JNK, Bcl-2, Bax, and caspase-3 and -9 protein expression levels; and using JC-1 fluorescence microscopy to detect the membrane potential of mitochondria. Valproic Acid 0-16 BCL2 apoptosis regulator Homo sapiens 286-291 21773964-10 2011 Furthermore, we found that glargine downregulated the level of Bax protein and upregulated that of Bcl-2 (p <0.05). Insulin Glargine 27-35 BCL2 apoptosis regulator Homo sapiens 99-104 21269693-3 2011 This article describes that DMSO, being non-toxic to the normal lymphocytes, up regulated TNFalpha and p53, declined Bcl-2/Bax ratio, activated caspase 9 and PARP-1 cleavage and produced apoptotic pattern of DNA ladder in Dalton"s lymphoma (DL) in vivo. Dimethyl Sulfoxide 28-32 BCL2 apoptosis regulator Homo sapiens 117-122 21663495-6 2011 Additionally, the expression of the anti-apoptotic factor Bcl-2 was decreased, whereas that of the well-known apoptotic factor Bax was increased, thereby releasing cytochrome c into cytosol in amentoflavone-treated cervical cancer cells. amentoflavone 193-206 BCL2 apoptosis regulator Homo sapiens 58-63 21375586-10 2011 In addition, ghrelin reversed the 5-FU-induced Bcl-2/Bax protein ratio. Ghrelin 13-20 BCL2 apoptosis regulator Homo sapiens 47-52 21375586-10 2011 In addition, ghrelin reversed the 5-FU-induced Bcl-2/Bax protein ratio. Fluorouracil 34-38 BCL2 apoptosis regulator Homo sapiens 47-52 21375586-11 2011 CONCLUSION: Ghrelin inhibits 5-FU-induced apoptosis in colon cancer cells through the regulation of the Bcl-2/Bax protein ratio. Ghrelin 12-19 BCL2 apoptosis regulator Homo sapiens 104-109 21375586-11 2011 CONCLUSION: Ghrelin inhibits 5-FU-induced apoptosis in colon cancer cells through the regulation of the Bcl-2/Bax protein ratio. Fluorouracil 29-33 BCL2 apoptosis regulator Homo sapiens 104-109 21506127-7 2011 In vitro, Bay 11-7085 inhibited constitutively active NF-kappaB expression in a dose-dependent manner and inhibition of NF-kappaB also down-regulated expression of the downstream target gene products Bcl-2, Bcl-XL (BCL2L1), XIAP and Survivin, leading to apoptosis via activation of the mitochondrial apoptotic pathway. BAY 11-7085 10-21 BCL2 apoptosis regulator Homo sapiens 200-205 21537846-10 2011 The TBMS I-induced growth inhibition of L-02 cells was accompanied by the collapse of mitochondrial membrane potential, release of cyt-c from the mitochondria to the cytosol, activation of caspase-9 and -3, decrease of anti-apoptotic protein Bcl-2 levels and increase of the pro-apoptotic protein Bax levels, all indicative of apoptosis through the mitochondrial pathway. tubeimoside I 4-10 BCL2 apoptosis regulator Homo sapiens 242-247 21566062-1 2011 The Bcl-2 antagonist ABT-737 targets Bcl-2/Bcl-xL, but not Mcl-1, which may confer resistance to this agent in various cancers with high levels of Mcl-1. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 21-24 BCL2 apoptosis regulator Homo sapiens 4-9 21566062-1 2011 The Bcl-2 antagonist ABT-737 targets Bcl-2/Bcl-xL, but not Mcl-1, which may confer resistance to this agent in various cancers with high levels of Mcl-1. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 21-24 BCL2 apoptosis regulator Homo sapiens 37-42 21566062-6 2011 Taken together, our data first showed the synergistic anticancer capabilities achieved by combining gemcitabine and ABT-737 and, second, opened new opportunities to use antiapoptotic Bcl-2 family members, which drive tumor cell resistance in current anticancer therapies, therapeutically. gemcitabine 100-111 BCL2 apoptosis regulator Homo sapiens 183-188 21566062-6 2011 Taken together, our data first showed the synergistic anticancer capabilities achieved by combining gemcitabine and ABT-737 and, second, opened new opportunities to use antiapoptotic Bcl-2 family members, which drive tumor cell resistance in current anticancer therapies, therapeutically. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 116-119 BCL2 apoptosis regulator Homo sapiens 183-188 21481590-5 2011 In parallel, some Bcl-2 members also regulate glucose metabolism and beta-cell function. Glucose 46-53 BCL2 apoptosis regulator Homo sapiens 18-23 21093517-6 2011 Pretreatment with SCM198 significantly increased antioxidant enzyme superoxide dismutase activity, ameliorated intracellular reactive oxygen species generation, prevented the dissipation of mitochondrial membrane potential, decreased apoptotic cell death in Hoechst 33258 staining, as well as down-regulated Bax and up-regulated Bcl-2 in both mRNA and protein levels compared with 6-OHDA damaged cells. leonurine 18-24 BCL2 apoptosis regulator Homo sapiens 329-334 22088287-12 2011 Celecoxib combined with radiotherapy could inhibit the expression of the protein of Bcl-2. Celecoxib 0-9 BCL2 apoptosis regulator Homo sapiens 84-89 21701130-10 2011 The mRNA and protein expression levels of p53 and bax were increased in Sertoli cells treated with MC-LR at 10 microg/ml compared with the control group (P < 0.05), while the bcl-2 protein levels were decreased in cells treated with MC-LR at 10 microg/ml (P < 0.05). cyanoginosin LR 99-104 BCL2 apoptosis regulator Homo sapiens 178-183 19576799-5 2011 Interestingly, targeting Bcl-2 with ASO resulted in the inhibition of in vitro tube formation and inhibition of angiogenesis in Matrigel plugs similar to treatment with bevacizumab. 1,5-anhydroglucitol 36-39 BCL2 apoptosis regulator Homo sapiens 25-30 21527773-9 2011 Furthermore, unidentified Bcl-2- and mitochondria-independent pathways are induced by pronecrotic and not by proapoptotic concentrations of cisplatin. Cisplatin 140-149 BCL2 apoptosis regulator Homo sapiens 26-31 21527773-11 2011 Yet, Bcl-2-independent effects lead to cell death, which may pose potential targets for pharmacological intervention aimed at reducing cisplatin nephrotoxicity. Cisplatin 135-144 BCL2 apoptosis regulator Homo sapiens 5-10 21640710-8 2011 We further showed that transfection of miR-365 inhibitor partly restored Bcl-2 expression at both mRNA and protein levels, leading to a reduction of ox-LDL-mediated apoptosis in HUVECs. mir-365 39-46 BCL2 apoptosis regulator Homo sapiens 73-78 21697949-4 2011 Surprisingly, despite their resistance, spheroids also upregulated Bim and thereby acquired sensitivity to ABT-737, an inhibitor of anti-apoptotic Bcl-2 molecules. ABT-737 107-114 BCL2 apoptosis regulator Homo sapiens 147-152 21562047-0 2011 BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Calcium 62-69 BCL2 apoptosis regulator Homo sapiens 0-4 21562047-3 2011 ABT-263 (Navitoclax), a specific inhibitor of antiapoptotic BCL2 proteins, which is currently being evaluated in clinical trials for the treatment of leukemia and other malignancies, induces a dose-limiting thrombocytopenia. navitoclax 0-7 BCL2 apoptosis regulator Homo sapiens 60-64 21562047-3 2011 ABT-263 (Navitoclax), a specific inhibitor of antiapoptotic BCL2 proteins, which is currently being evaluated in clinical trials for the treatment of leukemia and other malignancies, induces a dose-limiting thrombocytopenia. navitoclax 9-19 BCL2 apoptosis regulator Homo sapiens 60-64 21562047-6 2011 Notably, ABT-263 induced an immediate calcium response in platelets and the depletion of intracellular calcium stores, indicating that on BCL2/BCL-X(L) inhibition platelet activation is abrogated because of a diminished calcium signaling. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 9-12 BCL2 apoptosis regulator Homo sapiens 138-142 21562047-7 2011 By comparing the effects of ABT-263 and its analog ABT-737 on platelets and leukemia cells from the same donor, we show, for the first time, that these BCL2/BCL-X(L) inhibitors do not offer any selective toxicity but induce apoptosis at similar concentrations in leukemia cells and platelets. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 28-31 BCL2 apoptosis regulator Homo sapiens 152-156 21562047-7 2011 By comparing the effects of ABT-263 and its analog ABT-737 on platelets and leukemia cells from the same donor, we show, for the first time, that these BCL2/BCL-X(L) inhibitors do not offer any selective toxicity but induce apoptosis at similar concentrations in leukemia cells and platelets. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 51-54 BCL2 apoptosis regulator Homo sapiens 152-156 21714853-0 2011 Oxymatrine induces human pancreatic cancer PANC-1 cells apoptosis via regulating expression of Bcl-2 and IAP families, and releasing of cytochrome c. oxymatrine 0-10 BCL2 apoptosis regulator Homo sapiens 95-100 21714853-9 2011 CONCLUSION: Oxymatrine can induce apoptotic cell death of human pancreatic cancer, which might be attributed to the regulation of Bcl-2 and IAP families, release of mitochondrial cytochrome c and activation of caspase-3. oxymatrine 12-22 BCL2 apoptosis regulator Homo sapiens 130-135 21561860-3 2011 Here we show that degradation of the Bcl-2 homology 3-only proapoptotic protein Bim plays an important role in cisplatin resistance in ovarian cancer. Cisplatin 111-120 BCL2 apoptosis regulator Homo sapiens 37-42 21640710-10 2011 MiR-365 potentiates ox-LDL-induced ECs apoptosis by regulating the expression of Bcl-2, suggesting potential novel therapeutic targets for atherosclerosis. mir-365 0-7 BCL2 apoptosis regulator Homo sapiens 81-86 21396949-6 2011 Furthermore, co-treatment of cells with hypoxanthine plus 3-HK or MPA, which caused a reduction of about 60% in the intracellular GTP levels, led to apoptosis and activation of mitochondrial pathways through inverse regulation of Bcl-2/Bax expression and activation of caspase-3. Hypoxanthine 40-52 BCL2 apoptosis regulator Homo sapiens 230-235 21656752-7 2011 Constitutively activated NF-kappaB was inhibited by cucurbitacin D in the nucleus, which resulted in accumulation of NF-kappaB in the cytoplasm, leading to down-regulation of the expression of antiapoptotic proteins Bcl-xL and Bcl-2. cucurbitacin D 52-66 BCL2 apoptosis regulator Homo sapiens 227-232 21621522-7 2011 ZL11n triggered the mitochondrial/caspase apoptotic pathway by decreasing mitochondrial membrane potential, cytochrome c release from mitochondrial, and reducing the Bcl-2-to-Bax ratio, in addition to activating the caspase cascade. zl11n 0-5 BCL2 apoptosis regulator Homo sapiens 166-171 21277758-4 2011 Resveratrol treatment resulted in a gradual time-dependent decrease in the expression of anti-apoptotic Bcl-2 and increase in that of Bax, annexin A1, growth arrest- and DNA damage-induced gene 45alpha (GADD45alpha), and cleaved caspase-3. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 104-109 21396949-6 2011 Furthermore, co-treatment of cells with hypoxanthine plus 3-HK or MPA, which caused a reduction of about 60% in the intracellular GTP levels, led to apoptosis and activation of mitochondrial pathways through inverse regulation of Bcl-2/Bax expression and activation of caspase-3. Guanosine Triphosphate 130-133 BCL2 apoptosis regulator Homo sapiens 230-235 21480667-3 2011 Moreover, expression of antiapoptotic protein BCL-2 and the hybrid gene bcr/abl in K562 cells contributes resistance to DOX. Doxorubicin 120-123 BCL2 apoptosis regulator Homo sapiens 46-51 21474673-2 2011 We recently showed that Bcl-2 overexpression inhibited apoptosis in leukemia cells by creating a pro-oxidant intracellular milieu, and that inhibiting intracellular superoxide production sensitized Bcl-2-overexpressing cells to apoptotic stimuli. Superoxides 165-175 BCL2 apoptosis regulator Homo sapiens 24-29 21474673-2 2011 We recently showed that Bcl-2 overexpression inhibited apoptosis in leukemia cells by creating a pro-oxidant intracellular milieu, and that inhibiting intracellular superoxide production sensitized Bcl-2-overexpressing cells to apoptotic stimuli. Superoxides 165-175 BCL2 apoptosis regulator Homo sapiens 198-203 21474673-3 2011 We report here that silencing and functional inhibition of Rac1 block Bcl-2-mediated increase in intracellular superoxide levels in tumor cells. Superoxides 111-121 BCL2 apoptosis regulator Homo sapiens 70-75 21474673-6 2011 That this interaction is functionally relevant is supported by the ability of the Bcl-2 BH3 peptide as well as the silencing and functional inhibition of Rac1 to inhibit intracellular superoxide production as well as overcome Bcl-2-mediated drug resistance in human leukemia cells and cervical cancer cells. Superoxides 184-194 BCL2 apoptosis regulator Homo sapiens 82-87 21600879-3 2011 Cleavage of caspase-3 and PARP and reduction of Bcl-2 could also be detected after asperlin treatment to the cells. asperlin 83-91 BCL2 apoptosis regulator Homo sapiens 48-53 21366344-1 2011 Antisense oligonucleotide G3139 is designed for Bcl-2 downregulation and is known to induce toll-like receptor activation. Oligonucleotides 10-25 BCL2 apoptosis regulator Homo sapiens 48-53 21366344-1 2011 Antisense oligonucleotide G3139 is designed for Bcl-2 downregulation and is known to induce toll-like receptor activation. oblimersen 26-31 BCL2 apoptosis regulator Homo sapiens 48-53 21437721-10 2011 Expression of Bcl-2 in either the mitochondria or the endoplasmic reticulum (ER) strongly inhibited Ino-C2-PAF- and Glc-PAF-induced apoptosis. c2-paf 104-110 BCL2 apoptosis regulator Homo sapiens 14-19 21289292-10 2011 Expression of BCL-2 in BAX-containing cells resulted in a subsequent loss of ATP measured, implying that, even under nonapoptotic conditions, an antagonistic interaction exists between the two proteins. Adenosine Triphosphate 77-80 BCL2 apoptosis regulator Homo sapiens 14-19 21442307-5 2011 Hence, many cancer cells undergo apoptosis when exposed to agents that inhibit anti-apoptotic Bcl-2 molecules, such as BH3 mimetics, while normal cells remain relatively insensitive to single agent treatments with the same class of molecules. BH 3 119-122 BCL2 apoptosis regulator Homo sapiens 94-99 21437721-10 2011 Expression of Bcl-2 in either the mitochondria or the endoplasmic reticulum (ER) strongly inhibited Ino-C2-PAF- and Glc-PAF-induced apoptosis. Glucose 116-119 BCL2 apoptosis regulator Homo sapiens 14-19 21437721-10 2011 Expression of Bcl-2 in either the mitochondria or the endoplasmic reticulum (ER) strongly inhibited Ino-C2-PAF- and Glc-PAF-induced apoptosis. Platelet Activating Factor 107-110 BCL2 apoptosis regulator Homo sapiens 14-19 21435358-4 2011 Moreover, induced reactive nitrogen species (RNS) significantly increased the expression of bax, cleaved caspase-3 and poly adenosine diphosphate (ADP)-ribose polymerase (PARP) via JNK activation, but the expression of bcl-2 was not altered. Reactive Nitrogen Species 18-43 BCL2 apoptosis regulator Homo sapiens 219-224 21435358-4 2011 Moreover, induced reactive nitrogen species (RNS) significantly increased the expression of bax, cleaved caspase-3 and poly adenosine diphosphate (ADP)-ribose polymerase (PARP) via JNK activation, but the expression of bcl-2 was not altered. Reactive Nitrogen Species 45-48 BCL2 apoptosis regulator Homo sapiens 219-224 21420390-4 2011 Here we have demonstrated that [Pt(O,O"-acac)(gamma-acac)(DMS)] was more effective than cisplatin in provoking apoptosis characterized by: (a) mitochondria depolarization, (b) decrease of Bcl-2 expression and increase of BAX expressions with cytosol-to-mitochondria translocation, (c) activation of caspase-7 and -9 and (d) generation of reactive oxygen species (ROS). pt(o,o"-acac) 32-45 BCL2 apoptosis regulator Homo sapiens 188-193 21420390-7 2011 [Pt(O,O"-acac)(gamma-acac)(DMS)]-induced mitochondrial apoptosis was blocked when p38MAPK and JNK1/2 were inhibited, whilst the effects on Bax/Bcl-2 mRNA and protein levels were blocked inhibiting NF-kappaB. dms 27-30 BCL2 apoptosis regulator Homo sapiens 143-148 21233846-0 2011 Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells. sapropterin 15-18 BCL2 apoptosis regulator Homo sapiens 29-34 20956097-5 2011 Further we analyzed the effect of sulforaphane on the expression of Bcl-2, COX-2 and IL-1beta by RT-PCR on HeLa cells. sulforaphane 34-46 BCL2 apoptosis regulator Homo sapiens 68-73 21420390-4 2011 Here we have demonstrated that [Pt(O,O"-acac)(gamma-acac)(DMS)] was more effective than cisplatin in provoking apoptosis characterized by: (a) mitochondria depolarization, (b) decrease of Bcl-2 expression and increase of BAX expressions with cytosol-to-mitochondria translocation, (c) activation of caspase-7 and -9 and (d) generation of reactive oxygen species (ROS). gamma-acac 46-56 BCL2 apoptosis regulator Homo sapiens 188-193 21420390-4 2011 Here we have demonstrated that [Pt(O,O"-acac)(gamma-acac)(DMS)] was more effective than cisplatin in provoking apoptosis characterized by: (a) mitochondria depolarization, (b) decrease of Bcl-2 expression and increase of BAX expressions with cytosol-to-mitochondria translocation, (c) activation of caspase-7 and -9 and (d) generation of reactive oxygen species (ROS). dms 58-61 BCL2 apoptosis regulator Homo sapiens 188-193 21420390-7 2011 [Pt(O,O"-acac)(gamma-acac)(DMS)]-induced mitochondrial apoptosis was blocked when p38MAPK and JNK1/2 were inhibited, whilst the effects on Bax/Bcl-2 mRNA and protein levels were blocked inhibiting NF-kappaB. pt(o,o"-acac) 1-14 BCL2 apoptosis regulator Homo sapiens 143-148 21420390-7 2011 [Pt(O,O"-acac)(gamma-acac)(DMS)]-induced mitochondrial apoptosis was blocked when p38MAPK and JNK1/2 were inhibited, whilst the effects on Bax/Bcl-2 mRNA and protein levels were blocked inhibiting NF-kappaB. gamma-acac) 15-26 BCL2 apoptosis regulator Homo sapiens 143-148 21492126-2 2011 Obatoclax, a BH3-mimetic, has been designed to specifically target and counteract anti-apoptotic Bcl-2 proteins. BH 3 13-16 BCL2 apoptosis regulator Homo sapiens 97-102 20956097-8 2011 Also, the expression analysis of genes involved in apoptosis and inflammation revealed significant downregulation of Bcl-2, COX-2 and IL-1beta upon treatment with sulforaphane. sulforaphane 163-175 BCL2 apoptosis regulator Homo sapiens 117-122 21233846-3 2011 Here, we report on the role of the BH4 domain in bcl-2 functions, by showing that removal of or mutations at the BH4 domain abrogate the ability of bcl-2 to induce VEGF protein expression and transcriptional activity under hypoxia in human melanoma cells. sapropterin 35-38 BCL2 apoptosis regulator Homo sapiens 49-54 21420233-6 2011 This results in combinatorial inhibition of NFkappaB activity by gallic acid, which results in potent inhibition of NFkappaB target genes involved in inflammation, metastasis, anti-apoptosis and angiogenesis, such as IL-6, IL-8, COX2, CXCR4, XIAP, bcl2, VEGF. Gallic Acid 65-76 BCL2 apoptosis regulator Homo sapiens 248-252 21233846-3 2011 Here, we report on the role of the BH4 domain in bcl-2 functions, by showing that removal of or mutations at the BH4 domain abrogate the ability of bcl-2 to induce VEGF protein expression and transcriptional activity under hypoxia in human melanoma cells. sapropterin 35-38 BCL2 apoptosis regulator Homo sapiens 148-153 21233846-3 2011 Here, we report on the role of the BH4 domain in bcl-2 functions, by showing that removal of or mutations at the BH4 domain abrogate the ability of bcl-2 to induce VEGF protein expression and transcriptional activity under hypoxia in human melanoma cells. sapropterin 113-116 BCL2 apoptosis regulator Homo sapiens 49-54 21233846-3 2011 Here, we report on the role of the BH4 domain in bcl-2 functions, by showing that removal of or mutations at the BH4 domain abrogate the ability of bcl-2 to induce VEGF protein expression and transcriptional activity under hypoxia in human melanoma cells. sapropterin 113-116 BCL2 apoptosis regulator Homo sapiens 148-153 21233846-6 2011 Moreover, we validated the role of the BH4 domain of bcl-2 in the regulation of HIF-1/VEGF axis, demonstrating that BH4 peptide is sufficient to increase HIF-1alpha protein half-life impairing HIF-1alpha protein ubiquitination, and to enhance VEGF secretion in melanoma cells exposed to hypoxia. sapropterin 39-42 BCL2 apoptosis regulator Homo sapiens 53-58 21233846-6 2011 Moreover, we validated the role of the BH4 domain of bcl-2 in the regulation of HIF-1/VEGF axis, demonstrating that BH4 peptide is sufficient to increase HIF-1alpha protein half-life impairing HIF-1alpha protein ubiquitination, and to enhance VEGF secretion in melanoma cells exposed to hypoxia. sapropterin 116-119 BCL2 apoptosis regulator Homo sapiens 53-58 21396424-3 2011 [6]-Gingerol pretreatment protected against Abeta(25-35)-induced cytotoxicity and apoptotic cell death such as DNA fragmentation, disruption of mitochondrial membrane potential, elevated Bax/Bcl-2 ratio, and activation of caspase-3. gingerol 4-12 BCL2 apoptosis regulator Homo sapiens 191-196 21811429-8 2011 This effect was due to up-regulation of TRAIL receptors and members of the pro-apoptotic BCL-2 family by MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 105-110 BCL2 apoptosis regulator Homo sapiens 89-94 24298334-8 2011 In western blots assay, SDF-1alpha over-expressing human SkM or treated with rSDF-1alpha induced marked expression of total Akt (1.2-fold) and phospho-Akt (2.7-fold), Bcl2 (1.6-fold) and VEGF (5.8-fold) after exposure to 6 h anoxia as compared with human SkM controls. rsdf 77-81 BCL2 apoptosis regulator Homo sapiens 167-171 21388661-4 2011 Modulation of protein expression of the Bcl-2 family after treatment with metformin and/or cisplatin was determined by Western blotting. Metformin 74-83 BCL2 apoptosis regulator Homo sapiens 40-45 21388661-4 2011 Modulation of protein expression of the Bcl-2 family after treatment with metformin and/or cisplatin was determined by Western blotting. Cisplatin 91-100 BCL2 apoptosis regulator Homo sapiens 40-45 21388661-6 2011 Moreover, we established that metformin can induce apoptosis in OVCAR-3 and OVCAR-4 cells by activating caspases 3/7, down-regulating Bcl-2 and Bcl-xL expression, and up-regulating Bax and Bad expression. Metformin 30-39 BCL2 apoptosis regulator Homo sapiens 134-139 21382959-6 2011 Furthermore, CEDLI activates p53 and Bax, reduces Bcl-2 expression, and causes mitochondrial stress and the release of apoptosis-inducing factor into the cytosol followed by its translocation into the nucleus, resulting in hepatoma cell apoptosis. cedli 13-18 BCL2 apoptosis regulator Homo sapiens 50-55 21360576-8 2011 Enzastaurin was effective at inhibiting PKC alpha phosphorylation and membrane localization in the AML cell lines and suppressed phosphorylation of BCL2. enzastaurin 0-11 BCL2 apoptosis regulator Homo sapiens 148-152 21468550-10 2011 BCL-2 up-regulation could be achieved by miR-21 overexpression, which prevented T24 cells from apoptosis induced by doxorubicin. Doxorubicin 116-127 BCL2 apoptosis regulator Homo sapiens 0-5 21473903-14 2011 CONCLUSIONS: These results indicate that DHURS-induced apoptogenic activity in Jurkat T cells, which was less potent in normal peripheral T cells, was mediated by Deltapsim loss, mitochondrial cytochrome c release, and subsequent activation of caspase-9 and -3, leading to activation of caspase-7 and -8, which could be regulated by Bcl-2. dhurs 41-46 BCL2 apoptosis regulator Homo sapiens 333-338 21067292-0 2011 Effect of L-arginine on the expression of Bcl-2 and Bax in the placenta of fetal growth restriction. Arginine 10-20 BCL2 apoptosis regulator Homo sapiens 42-47 21067292-1 2011 OBJECTIVE: To investigate the effect of l-arginine on fetal growth restriction (FGR) in terms of the expression of Bcl-2 and Bax in placenta. Arginine 40-50 BCL2 apoptosis regulator Homo sapiens 115-120 21067292-10 2011 Compared with L-arginine group, the Bax expression increased, but bcl-2 expression decreased in control group. Arginine 14-24 BCL2 apoptosis regulator Homo sapiens 66-71 21067292-11 2011 CONCLUSIONS: L-arginine could reduce the expression of Bax, and enhance the expression of bcl-2, which may be associated with reduced placental apoptosis and improved placental function and fetal development. Arginine 13-23 BCL2 apoptosis regulator Homo sapiens 90-95 21393385-0 2011 The Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 42-45 BCL2 apoptosis regulator Homo sapiens 4-9 21393385-0 2011 The Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 42-45 BCL2 apoptosis regulator Homo sapiens 119-124 21393385-5 2011 We report that ABT-737 increases the expression of Bcl-2-associated death promoter (Bad), a proapoptotic partner of the proteins Bcl-2 and Bcl-xL. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 15-18 BCL2 apoptosis regulator Homo sapiens 51-56 21393385-9 2011 Finally, our results shed light on the mode of action of ABT-737, currently the best characterized inhibitor of the antiapoptotic proteins of the Bcl-2 family, and bear important implications regarding its use as an anticancer drug. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 57-60 BCL2 apoptosis regulator Homo sapiens 146-151 21399877-6 2011 Moreover, the administration of Bcl-2 siRNA augmented HPF cell death by MG132 whereas p53, Bax, caspase-3 and -8 siRNAs did not strongly affect cell death. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 72-77 BCL2 apoptosis regulator Homo sapiens 32-37 21328612-5 2011 EGCG induced upregulation of Bax and Bak, downregulation of Bcl-2 and Bcl-XL, and dysfunction of mitochondria in chondrosarcoma. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 60-65 21671172-10 2011 As compared with the control group, the apoptosis rate of cardiomyocytes in three DOX-treated groups was obviously increased, the expression levels of Bax increased, and those of Bcl-2 decreased (P<0.01). Doxorubicin 82-85 BCL2 apoptosis regulator Homo sapiens 179-184 21671172-11 2011 However, the expression levels of Bax were decreased, those of Bcl-2 increased and the apoptosis rate of cardiomyocytes obviously decreased in EH-R+DOX group when compared with those in the DOX group and the PCN+DOX group (P<0.01 for each). Doxorubicin 148-151 BCL2 apoptosis regulator Homo sapiens 63-68 21671172-13 2011 They could ameliorate the DOX-induced cardiomyocytes apoptosis by selectively inhibiting the expression of sEH with RNAi and increasing the expression of Bcl-2. Doxorubicin 26-29 BCL2 apoptosis regulator Homo sapiens 154-159 21468038-4 2011 Omacetaxine inhibits synthesis of anti-apoptotic proteins of the Bcl-2 family, including (myeloid cell leukaemia) Mcl-1, leading to cell death. Homoharringtonine 0-11 BCL2 apoptosis regulator Homo sapiens 65-70 21468550-11 2011 Furthermore, the miR-21 induced BCL-2 up-regulation could be cancelled by the PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 93-101 BCL2 apoptosis regulator Homo sapiens 32-37 21333732-7 2011 Obacunone upregulated expression of tumor suppressor protein p53, pro-apoptotic protein Bax and downregulated anti-apoptotic protein Bcl2. obacunone 0-9 BCL2 apoptosis regulator Homo sapiens 133-137 21315822-7 2011 Presence of polyoxyethylene-(20)-cetyl-ether (Brij-58) in the reaction mixture and subsequently in the immobilized metal-affinity purification steps was crucial to keep Bcl-2(2) soluble. Cetomacrogol 12-44 BCL2 apoptosis regulator Homo sapiens 169-174 21315822-7 2011 Presence of polyoxyethylene-(20)-cetyl-ether (Brij-58) in the reaction mixture and subsequently in the immobilized metal-affinity purification steps was crucial to keep Bcl-2(2) soluble. Cetomacrogol 46-53 BCL2 apoptosis regulator Homo sapiens 169-174 21315822-7 2011 Presence of polyoxyethylene-(20)-cetyl-ether (Brij-58) in the reaction mixture and subsequently in the immobilized metal-affinity purification steps was crucial to keep Bcl-2(2) soluble. Metals 115-120 BCL2 apoptosis regulator Homo sapiens 169-174 21549092-9 2011 On the other hand, cytochrome C, Bax/Bcl2 ratio and caspase-3, known as proapoptotic factors, significantly increased in the presence of sodium selenite alone, but not in the presence of docetaxel in monotherapy or in combination with sodium selenite. Sodium Selenite 137-152 BCL2 apoptosis regulator Homo sapiens 37-41 21729550-7 2011 And RT-PCR showed, as compared with curcumin or bortezomib group, there was mRNA expression decrease of BCL-2, cyclin D1 but increase of BAX in combined group. Curcumin 36-44 BCL2 apoptosis regulator Homo sapiens 104-109 21729550-7 2011 And RT-PCR showed, as compared with curcumin or bortezomib group, there was mRNA expression decrease of BCL-2, cyclin D1 but increase of BAX in combined group. Bortezomib 48-58 BCL2 apoptosis regulator Homo sapiens 104-109 21446759-7 2011 alpha-Mangostin activated caspase-3, -8, -9 expression, decreased Bcl-2 and increased Bax. mangostin 0-15 BCL2 apoptosis regulator Homo sapiens 66-71 21527247-3 2011 In this study, we identified a conserved BH3 motif in C-terminal coiled coil (CC2) region of nCLU by sequence analysis and characterized the molecular interaction of the putative nCLU BH3 domain with anti-apoptotic Bcl-2 family proteins by nuclear magnetic resonance (NMR) spectroscopy. BH 3 41-44 BCL2 apoptosis regulator Homo sapiens 215-220 21527247-7 2011 Taken altogether, our results suggest a molecular basis for the pro-apoptotic function of nCLU by elucidating the residue specific interactions of the BH3 motif in nCLU with anti-apoptotic Bcl-2 family proteins. BH 3 151-154 BCL2 apoptosis regulator Homo sapiens 189-194 29147235-8 2011 Conclusions: These findings establish a mechanistic linkup or interaction between c-myc, Bax, Bad, Bcl-2, caspase cascades, PI3K/Akt pathway and curcumin- induced apoptosis of EJ cells, suggesting that c-myc and PI3K/Akt signaling pathway play important roles in curcumin-induced apoptosis of EJ bladder cancer cells. Curcumin 145-153 BCL2 apoptosis regulator Homo sapiens 99-104 21454712-0 2011 Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells. Bortezomib 46-56 BCL2 apoptosis regulator Homo sapiens 5-10 21454712-7 2011 When killing by bortezomib (an agent whose cytotoxicity in Jurkat T-cell leukemia cells is dependent on Noxa) was examined, apoptosis was enhanced by the Bcl-2/Bcl-x(L) antagonist ABT-737 or by Bcl-2 down-regulation and diminished by Bcl-2 overexpression. Bortezomib 16-26 BCL2 apoptosis regulator Homo sapiens 154-159 21454712-7 2011 When killing by bortezomib (an agent whose cytotoxicity in Jurkat T-cell leukemia cells is dependent on Noxa) was examined, apoptosis was enhanced by the Bcl-2/Bcl-x(L) antagonist ABT-737 or by Bcl-2 down-regulation and diminished by Bcl-2 overexpression. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 180-183 BCL2 apoptosis regulator Homo sapiens 154-159 21454712-8 2011 Collectively, these observations not only establish the ability of Noxa and Bcl-2 to interact but also identify Bcl-2 overexpression as a potential mechanism of bortezomib resistance. Bortezomib 161-171 BCL2 apoptosis regulator Homo sapiens 112-117 21417302-6 2011 In addition, BA treatment resulted in DNA fragmentation, caspase-9 and caspase-3 activations, poly(ADP-ribose)polymerase (PARP) degradation, down-regulation of Bcl-2 and Bcl-xL expressions, up-regulation of Bax expression, and disruption of the mitochondrial membrane potential (MMP) in Hep 3B cells. Barium 13-15 BCL2 apoptosis regulator Homo sapiens 160-165 21459798-8 2011 By comparison, overexpression of Bcl-2, which simultaneously antagonizes tBid and p53, significantly inhibits bortezomib- and TRAIL-induced apoptosis and even rescues clonogenic survival. tBID 73-77 BCL2 apoptosis regulator Homo sapiens 33-38 21459798-8 2011 By comparison, overexpression of Bcl-2, which simultaneously antagonizes tBid and p53, significantly inhibits bortezomib- and TRAIL-induced apoptosis and even rescues clonogenic survival. Bortezomib 110-120 BCL2 apoptosis regulator Homo sapiens 33-38 21376032-5 2011 Icaritin at concentrations of 4-5 muM, however, induced apoptotic cell death characterized by the accumulation of the annexin V- and propidium iodide-positive cells, cleavage of poly ADP-ribose polymerase (PARP) and down-regulation of the Bcl-2 expression. icaritin 0-8 BCL2 apoptosis regulator Homo sapiens 239-244 21595920-0 2011 Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 31-36 21595920-0 2011 Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells. Daunorubicin 62-74 BCL2 apoptosis regulator Homo sapiens 31-36 21595920-13 2011 Curcumin-induced apoptosis was associated with reduced expression of both Bcl-2 mRNA and protein, subsequent loss of MMP, and activation of caspase-3 followed by PARP degradation. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 74-79 21595920-14 2011 Curcumin synergistically enhanced the cytotoxic effect of DNR in DNR-insensitive KG1a and Kasumi-1 cells, consistent with decreased Bcl-2 expression. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 132-137 21595920-16 2011 More importantly, curcumin suppressed Bcl-2 expression, selectively inhibited proliferation and synergistically enhanced the cytotoxicity of DNR in primary CD34+ AML cells, while showing limited lethality in normal CD34+ hematopoietic progenitors. Curcumin 18-26 BCL2 apoptosis regulator Homo sapiens 38-43 21595920-17 2011 CONCLUSION: Curcumin down-regulates Bcl-2 and induces apoptosis in DNR-insensitive CD34+ AML cell lines and primary CD34+ AML cells. Curcumin 12-20 BCL2 apoptosis regulator Homo sapiens 36-41 21398407-2 2011 We have identified the apoptotic proteins and pathways necessary for synergistic tumor cell apoptosis and in vivo antitumor responses seen when the HDAC inhibitor vorinostat is combined with the BH3-mimetic ABT-737 in lymphomas overexpressing Bcl-2. Vorinostat 163-173 BCL2 apoptosis regulator Homo sapiens 243-248 21398407-2 2011 We have identified the apoptotic proteins and pathways necessary for synergistic tumor cell apoptosis and in vivo antitumor responses seen when the HDAC inhibitor vorinostat is combined with the BH3-mimetic ABT-737 in lymphomas overexpressing Bcl-2. ABT-737 207-214 BCL2 apoptosis regulator Homo sapiens 243-248 21398407-3 2011 Vorinostat "primes" tumors overexpressing Bcl-2 for rapid ABT-737-mediated apoptosis by inducing expression of the BH3-only gene bmf. Vorinostat 0-10 BCL2 apoptosis regulator Homo sapiens 42-47 21398407-3 2011 Vorinostat "primes" tumors overexpressing Bcl-2 for rapid ABT-737-mediated apoptosis by inducing expression of the BH3-only gene bmf. ABT-737 58-65 BCL2 apoptosis regulator Homo sapiens 42-47 21382431-8 2011 Quantitative real-time PCR analysis demonstrated that following the exposure of A549 cells to nickel ferrite nanoparticles, the level of mRNA expressions of cell cycle checkpoint protein p53 and apoptotic proteins (bax, caspase-3 and caspase-9) were significantly up-regulated, whereas the expression of anti-apoptotic proteins (survivin and bcl-2) were down-regulated. Nickel 94-100 BCL2 apoptosis regulator Homo sapiens 342-347 21562496-5 2011 Overexpression of Bcl-2 almost completely abolishes the MS-275-mediated chemosensitization, underlining the importance of the mitochondrial pathway for inducing apoptosis. entinostat 56-62 BCL2 apoptosis regulator Homo sapiens 18-23 21397656-6 2011 6-OHDA-induced nitrosative stress ultimately caused apoptotic cell death as determined by decreased Bcl-2/Bax ratio, activation of c-Jun N-terminal kinase (JNK), and cleavage of caspase-3 and poly(ADP-ribose)polymerase (PARP), which were attenuated by peroxynitrite decomposition catalyst, 5,10,15,20-tetrakis(4-sulfonatophenyl)prophyrinato iron(III) (FeTPPS). Oxidopamine 0-6 BCL2 apoptosis regulator Homo sapiens 100-105 21382431-10 2011 To the best of our knowledge this is the first report showing that nickel ferrite nanoparticles induced apoptosis in A549 cells through ROS generation and oxidative stress via p53, survivin, bax/bcl-2 and caspase pathways. Nickel 67-73 BCL2 apoptosis regulator Homo sapiens 195-200 21487404-9 2011 The increased Bax and Bcl2 protein expression ratio indicated that intrinsic apoptotic pathway may be involved in DS/Cu-induced apoptosis. Disulfiram 114-116 BCL2 apoptosis regulator Homo sapiens 22-26 21367858-6 2011 Furthermore, poly(I-C) down-regulated anti-apoptotic protein, B cell lymphoma 2 (Bcl-2), and up-regulated Noxa, a key Bcl-2 homology 3-only antagonist of Bcl-2, leading to the priming of the intrinsic pathway. Poly I-C 13-21 BCL2 apoptosis regulator Homo sapiens 62-79 21487404-9 2011 The increased Bax and Bcl2 protein expression ratio indicated that intrinsic apoptotic pathway may be involved in DS/Cu-induced apoptosis. Copper 117-119 BCL2 apoptosis regulator Homo sapiens 22-26 21514278-0 2011 The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 41-44 BCL2 apoptosis regulator Homo sapiens 4-21 21514278-0 2011 The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 41-44 BCL2 apoptosis regulator Homo sapiens 23-27 21514278-0 2011 The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 53-56 BCL2 apoptosis regulator Homo sapiens 4-21 21514278-0 2011 The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 53-56 BCL2 apoptosis regulator Homo sapiens 23-27 21367858-6 2011 Furthermore, poly(I-C) down-regulated anti-apoptotic protein, B cell lymphoma 2 (Bcl-2), and up-regulated Noxa, a key Bcl-2 homology 3-only antagonist of Bcl-2, leading to the priming of the intrinsic pathway. Poly I-C 13-21 BCL2 apoptosis regulator Homo sapiens 81-86 21514278-2 2011 Amongst the most specific BCL2-inhibitors identified are ABT-737 and ABT-263. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 57-60 BCL2 apoptosis regulator Homo sapiens 26-30 21514278-2 2011 Amongst the most specific BCL2-inhibitors identified are ABT-737 and ABT-263. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 69-72 BCL2 apoptosis regulator Homo sapiens 26-30 21367858-6 2011 Furthermore, poly(I-C) down-regulated anti-apoptotic protein, B cell lymphoma 2 (Bcl-2), and up-regulated Noxa, a key Bcl-2 homology 3-only antagonist of Bcl-2, leading to the priming of the intrinsic pathway. Poly I-C 13-21 BCL2 apoptosis regulator Homo sapiens 118-123 21514278-7 2011 Addition of tariquidar or verapamil sensitized the cells to BCL2-inhibitor treatment, resulting in higher apoptosis. tariquidar 12-22 BCL2 apoptosis regulator Homo sapiens 60-64 21367858-6 2011 Furthermore, poly(I-C) down-regulated anti-apoptotic protein, B cell lymphoma 2 (Bcl-2), and up-regulated Noxa, a key Bcl-2 homology 3-only antagonist of Bcl-2, leading to the priming of the intrinsic pathway. Poly I-C 13-21 BCL2 apoptosis regulator Homo sapiens 118-123 21514278-7 2011 Addition of tariquidar or verapamil sensitized the cells to BCL2-inhibitor treatment, resulting in higher apoptosis. Verapamil 26-35 BCL2 apoptosis regulator Homo sapiens 60-64 21514278-8 2011 Our data suggest that the BCL2-inhibitors ABT-737 and ABT-263 are substrates for P-glycoprotein. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 42-45 BCL2 apoptosis regulator Homo sapiens 26-30 21520420-0 2011 Discovery and development of thiazolo[3,2-a]pyrimidinone derivatives as general inhibitors of Bcl-2 family proteins. thiazolo[3,2-a]pyrimidinone 29-56 BCL2 apoptosis regulator Homo sapiens 94-99 21514278-8 2011 Our data suggest that the BCL2-inhibitors ABT-737 and ABT-263 are substrates for P-glycoprotein. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 54-57 BCL2 apoptosis regulator Homo sapiens 26-30 21569413-9 2011 RESULTS: We have observed that EPA and DHA induce cell apoptosis, a reduction of cell viability and the expression of Bcl2 and procaspase-8. dehydroacetic acid 39-42 BCL2 apoptosis regulator Homo sapiens 118-122 21520420-1 2011 A class of compounds with a common thiazolo[3,2-a]pyrimidinone motif has been developed as general inhibitors of Bcl-2 family proteins. thiazolo[3,2-a]pyrimidinone 35-62 BCL2 apoptosis regulator Homo sapiens 113-118 21106189-5 2011 RESULTS: Alpha-mangostin showed excellent apoptotic effects on HNSCC cell lines, which induced the down-regulation of bcl-2, but up-regulation of bax and p53 in HN-22, HN-30 and HN-31. mangostin 9-24 BCL2 apoptosis regulator Homo sapiens 118-123 21336967-8 2011 The Pgp effect on miR-16/Bcl-2 was suppressed by Pgp blocker verapamil indicating the importance of the efflux of Pgp substrates. Verapamil 61-70 BCL2 apoptosis regulator Homo sapiens 25-30 21499287-9 2011 MG-132 (18.5 mumol/L) suppressed the proteasome activity by about 70% at 3 h. It induced apoptosis via down-regulation of antiapoptotic proteins Bcl-2 and XIAP, up-regulation of pro-apoptotic protein Bax and caspase-3, and production of cleaved C-terminal 85 kDa PARP). Magnesium 0-2 BCL2 apoptosis regulator Homo sapiens 145-150 21106189-6 2011 CONCLUSION: The present study suggests that the induction of apoptosis by alpha-mangostin seemed to be modulated by bcl-2, bax and p53 level in HNSCC cell lines. mangostin 74-89 BCL2 apoptosis regulator Homo sapiens 116-121 21486225-4 2011 In contrast, the pro-apoptotic Bcl-2 proteins contain prototypic effector proteins such as Bax and Bak, and the BH3 (Bcl-2 homology)-only proteins comprising Bak, Bid, Bim, Puma and Noxa. bakuchiol 99-102 BCL2 apoptosis regulator Homo sapiens 31-36 21656365-0 2011 Induction of apoptosis by chelerythrine chloride through mitochondrial pathway and Bcl-2 family proteins in human hepatoma SMMC-7721 cell. smmc 123-127 BCL2 apoptosis regulator Homo sapiens 83-88 21656365-5 2011 These results indicated that CHE may play an important role in suppression of tumor growth by inducing apoptosis in human hepatoma cells via the activation of a mitochondrial pathway and regulating the expression of Bcl-2 family proteins. Chlorides 29-32 BCL2 apoptosis regulator Homo sapiens 216-221 21486225-7 2011 Overexpression of Bcl-2 increases mitochondrial oxygen consumption and in doing so generates a slight pro-oxidant intracellular milieu, which promotes genomic instability and blocks death signalling. Oxygen 48-54 BCL2 apoptosis regulator Homo sapiens 18-23 21486225-8 2011 However, in the wake of overt oxidative stress, Bcl-2 regulates cellular redox status thereby preventing excessive build-up of ROS (reactive oxygen species), which is detrimental to cells and tissues. Reactive Oxygen Species 127-130 BCL2 apoptosis regulator Homo sapiens 48-53 21198544-9 2011 gamma-Tocotrienol also down-regulated the expression of STAT3-regulated gene products, including cyclin D1, Bcl-2, Bcl-xL, survivin, Mcl-1 and vascular endothelial growth factor. plastochromanol 8 0-17 BCL2 apoptosis regulator Homo sapiens 108-113 21486225-8 2011 However, in the wake of overt oxidative stress, Bcl-2 regulates cellular redox status thereby preventing excessive build-up of ROS (reactive oxygen species), which is detrimental to cells and tissues. Reactive Oxygen Species 132-155 BCL2 apoptosis regulator Homo sapiens 48-53 21787711-12 2011 These findings demonstrate that tas41 can inhibit the proliferation of, and induce apoptosis in, Caco-2 cells by activating caspase-3, caspase-8 and caspase-9, downregulating the expressions of VEGF, upregulating the ratio of bax/bcl-2. tas41 32-37 BCL2 apoptosis regulator Homo sapiens 230-235 21354561-6 2011 MAIN OUTCOME MEASURE(S): The effect of ATRA was examined on the expression and phosphorylation of relevant RA, PI3K/Akt, and Bcl2 proteins (immunochemical analysis), cell proliferation, cell cycle distribution, and apoptosis. Tretinoin 39-43 BCL2 apoptosis regulator Homo sapiens 125-129 21542014-7 2011 Unlike 1,25(OH)(2)D(3), the antiapoptotic effects of 25(OH)D(3) on Bax and Bcl-2 were blocked by the P450 inhibitor ketoconazole. Ketoconazole 116-128 BCL2 apoptosis regulator Homo sapiens 75-80 21305255-7 2011 Taken together, our results suggest that emodin improved the anti-tumor effect of gemcitabine, even at a lower dose of gemcitabine which could decrease the toxicity of chemotherapy, on transplanted tumors of the SW1990 cell line through the enhancement of apoptosis induced by gemcitabine, the mechanism of which may be through down-regulation of the Bcl-2/Bax ratio and promoting release of CytC from the mitochondria into the cytoplasm. gemcitabine 82-93 BCL2 apoptosis regulator Homo sapiens 351-356 21331075-9 2011 The inhibitors strongly synergized with both vincristine and the Bcl-2 inhibitor, ABT-263. navitoclax 82-89 BCL2 apoptosis regulator Homo sapiens 65-70 21244482-6 2011 Consistently, combined treatment of melatonin and puromycin reduced the expression of anti-apoptotic proteins, such as bcl-2 and bcl-x(L) , and also induced caspase-3 activation and poly (ADP-ribose) polymerase (PARP) cleavage compared to puromycin treatment alone. Melatonin 36-45 BCL2 apoptosis regulator Homo sapiens 119-124 21244482-6 2011 Consistently, combined treatment of melatonin and puromycin reduced the expression of anti-apoptotic proteins, such as bcl-2 and bcl-x(L) , and also induced caspase-3 activation and poly (ADP-ribose) polymerase (PARP) cleavage compared to puromycin treatment alone. Puromycin 50-59 BCL2 apoptosis regulator Homo sapiens 119-124 21234653-9 2011 Mechanistically, DHA activated caspase-3, caspase-8, and caspase-9; upregulated the expression of Bax, FAS, and cyclin D1; downregulated the expression of Bcl-2, Cdc25B, and cyclin B1; and inhibited the activity of NF-kB. artenimol 17-20 BCL2 apoptosis regulator Homo sapiens 155-160 21372225-1 2011 (-)-Gossypol, a natural BH3-mimetic and small-molecule Bcl-2 inhibitor, shows promise in ongoing phase II clinical trials for human cancers. Gossypol 0-12 BCL2 apoptosis regulator Homo sapiens 55-60 21372225-3 2011 In this study, we showed that (-)-gossypol dose dependently inhibited the expression of VEGF, Bcl-2, and Bcl-xL in human prostate cancer cells (PC-3 and DU 145) and primary cultured human umbilical vascular endothelial cells (HUVEC) in vitro. Gossypol 30-42 BCL2 apoptosis regulator Homo sapiens 94-99 21331449-6 2011 Furthermore, we showed that GA treatment elevates the Bax/Bcl-2 ratio. gambogic acid 28-30 BCL2 apoptosis regulator Homo sapiens 58-63 21382360-6 2011 In addition, Z-FY(t-Bu)- DMK modulated the Bcl-2 family levels, and suppressed caspase-3 activation. z-fy 13-17 BCL2 apoptosis regulator Homo sapiens 43-48 21292036-4 2011 In contrast, Bcl-2 overexpression diminished the effects of HO-3814. Holmium 60-62 BCL2 apoptosis regulator Homo sapiens 13-18 21800541-0 2011 [Structure-activity relationship of diosgenin derivatives as Bcl-2 antagonists]. Diosgenin 36-45 BCL2 apoptosis regulator Homo sapiens 61-66 21800541-2 2011 Study has found that diosgenin can inhibit the reproduction of tumor cells by inducing apoptosis and the main target spot of this effect is Bcl-2. Diosgenin 21-30 BCL2 apoptosis regulator Homo sapiens 140-145 21800541-3 2011 Based on the characteristics of pharmacophoric points" of the three-dimensional pharmacophore for Bcl-2 inhibitors, we have docked lots of diosgenin derivatives with Bcl-2, then synthesized 31 compounds of them, finally assessed the anti-tumor activity of the diosgenin derivatives in vitro against A375, A549, HepG-2 and K562. Diosgenin 139-148 BCL2 apoptosis regulator Homo sapiens 98-103 21800541-3 2011 Based on the characteristics of pharmacophoric points" of the three-dimensional pharmacophore for Bcl-2 inhibitors, we have docked lots of diosgenin derivatives with Bcl-2, then synthesized 31 compounds of them, finally assessed the anti-tumor activity of the diosgenin derivatives in vitro against A375, A549, HepG-2 and K562. Diosgenin 139-148 BCL2 apoptosis regulator Homo sapiens 166-171 21559519-7 2011 Morphine caused a dramatic decrease in Bcl-2 level but increase in Bax level in wild type microglia, but not in TLR9 deficient microglia. Morphine 0-8 BCL2 apoptosis regulator Homo sapiens 39-44 21382360-6 2011 In addition, Z-FY(t-Bu)- DMK modulated the Bcl-2 family levels, and suppressed caspase-3 activation. t-bu 18-22 BCL2 apoptosis regulator Homo sapiens 43-48 21334318-4 2011 Cafestol-induced apoptosis is associated with the reduction of mitochondrial membrane potential (MMP), activation of caspase 3, cytochrome c release, and down-regulation of anti-apoptotic proteins (Bcl-2, Bcl-xL, Mcl-1 and cFLIP). cafestol 0-8 BCL2 apoptosis regulator Homo sapiens 198-203 21334318-6 2011 Ectopic expression of Bcl-2 or Mcl-1 in Caki cells attenuates cafestol-induced apoptosis. cafestol 62-70 BCL2 apoptosis regulator Homo sapiens 22-27 21444803-6 2011 A crystal structure of sjA bound to a BH3 peptide provides direct evidence for the feasibility of developing BH3 mimetics to target Bcl-2 prosurvival proteins in schistosomes, suggesting an alternative application for this class of drugs beyond cancer treatment. BH 3 109-112 BCL2 apoptosis regulator Homo sapiens 132-137 21439939-7 2011 The antiapoptotic activity of M11 was suppressed by coexpression of proapoptotic BH3-only protein tBid, indicating that M11 inhibits apoptosis likely by the same mechanism as cellular antiapoptotic proteins Bcl-2 or Bcl-XL. tBID 98-102 BCL2 apoptosis regulator Homo sapiens 207-212 21510902-1 2011 BACKGROUND: We previously demonstrated that the plant-derived agent alpha-bisabolol enters cells via lipid rafts, binds to the pro-apoptotic Bcl-2 family protein BID, and may induce apoptosis. alpha-Bisabolol 68-83 BCL2 apoptosis regulator Homo sapiens 141-146 21397587-8 2011 We found that genes downstream of STAT3 (BCL-2, survivin, cyclin D1) were downregulated with celecoxib. Celecoxib 93-102 BCL2 apoptosis regulator Homo sapiens 41-46 21526214-8 2011 Pretreatment of RA inhibited caspase-1 downstream signal pathway, such as the activation of caspase-3 and 9, release of cytochrome c, translocation of apoptosis-inducing factor, up-regulation of Bax, down-regulation of Bcl-2, generation of reactive oxygen species, and activation of nuclear factor-kappaB. rosmarinic acid 16-18 BCL2 apoptosis regulator Homo sapiens 219-224 21524306-13 2011 Treatment of tumor cells with maslinic acid also resulted in an increase in the expression of Bid and Bax, repression of Bcl-2, release of cytochrome-c and an increase in the expression of caspases -9, -3, and -7. maslinic acid 30-43 BCL2 apoptosis regulator Homo sapiens 121-126 21444773-0 2011 Arginine methylation of BCL-2 antagonist of cell death (BAD) counteracts its phosphorylation and inactivation by Akt. Arginine 0-8 BCL2 apoptosis regulator Homo sapiens 24-29 21291946-6 2011 Moreover, upon 24h exposure to 10mug/mL CdTe QDs, the apoptotic HUVECs dramatically increased by 402.01%, accompanied with alternative expression of apoptosis proteins, which were upregulation of Bax, downregulation of Bcl-2, release of mitochondrial cytochrome c and cleavage of caspase-9/caspase-3. cadmium telluride 40-44 BCL2 apoptosis regulator Homo sapiens 219-224 21508398-0 2011 Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation. Paclitaxel 54-64 BCL2 apoptosis regulator Homo sapiens 9-14 21303669-4 2011 The present study investigated the effects of LA on ethanol-treated fetal rhombencephalic neurons with regard to oxidative stress and up-regulation of the pro-survival genes Xiap and Bcl-2. Ethanol 52-59 BCL2 apoptosis regulator Homo sapiens 183-188 21303669-10 2011 NAC also up-regulated Bcl-2 and Xiap. Acetylcysteine 0-3 BCL2 apoptosis regulator Homo sapiens 22-27 21508398-8 2011 CONCLUSION: BCL-2 and MDR1 overexpression may predict the inefficacy of paclitaxel-based chemoradiotherapy. Paclitaxel 72-82 BCL2 apoptosis regulator Homo sapiens 12-17 20390378-5 2011 The NaAsO2 treatment resulted in a marked increase in p53 protein as early as 4 h and in Bcl-2 protein level by 12 h. In addition, p53 downregulation accompanied the combined treatment of NaAsO2 and Na2SeO3. sodium arsenite 4-10 BCL2 apoptosis regulator Homo sapiens 89-94 20390378-5 2011 The NaAsO2 treatment resulted in a marked increase in p53 protein as early as 4 h and in Bcl-2 protein level by 12 h. In addition, p53 downregulation accompanied the combined treatment of NaAsO2 and Na2SeO3. sodium arsenite 188-194 BCL2 apoptosis regulator Homo sapiens 89-94 21122809-6 2011 Here we provide a comprehensive view of the roles of the BCL-2 family of proteins in mediating the molecular crosstalk between the ER and mitochondria to initiate apoptosis, in addition to their emerging functions in adaptation to stress, including autophagy, UPR, calcium homeostasis and organelle morphogenesis. Calcium 265-272 BCL2 apoptosis regulator Homo sapiens 57-62 20390378-5 2011 The NaAsO2 treatment resulted in a marked increase in p53 protein as early as 4 h and in Bcl-2 protein level by 12 h. In addition, p53 downregulation accompanied the combined treatment of NaAsO2 and Na2SeO3. na2seo3 199-206 BCL2 apoptosis regulator Homo sapiens 89-94 20390378-6 2011 Thus, our results indicate upregulation of p53 and Bcl-2 play acrucial role in the NaAsO2-induced G1 arrest and apoptosis of A375 cells and that downregulation p53 appears to contribute to the inhibition by Na2SeO3 of the effects induced by NaAsO2. sodium arsenite 83-89 BCL2 apoptosis regulator Homo sapiens 51-56 21237235-8 2011 Western blot data revealed that LJ inhibited H(2)O(2)-induced up- and down-regulation of cleaved PARP, cleaved caspase-3, Bcl-2, and Bcl-xL. Hydrogen Peroxide 45-53 BCL2 apoptosis regulator Homo sapiens 122-127 21556211-7 2011 In NI-BPH, I-BPH, and PC, the overexpression of COX-2, Bcl-2, and VEGF gradually increased. ni-bph 3-9 BCL2 apoptosis regulator Homo sapiens 55-60 21682141-5 2011 The validated 3D structure of tubulin beta-1 chain and Bcl-2 protein was taken to study their interaction with paclitaxel. Paclitaxel 111-121 BCL2 apoptosis regulator Homo sapiens 55-60 21682141-8 2011 It was also observed that CID_9919057 had glide score of -9.0, as compared to -8.24 of paclitaxel with Bcl-2 protein. Paclitaxel 87-97 BCL2 apoptosis regulator Homo sapiens 103-108 21258766-4 2011 The dose- and time-dependent effect of H2O2 on Bax, p53 and Bcl-2 expression was assessed by Western blot analysis. Hydrogen Peroxide 39-43 BCL2 apoptosis regulator Homo sapiens 60-65 21258766-5 2011 Treatment of cells with 1 mM H2O2 for 1 h induced an increase in Bax and p53 expression, but the expression of Bcl-2 was not affected by H2O2 treatment. Hydrogen Peroxide 29-33 BCL2 apoptosis regulator Homo sapiens 111-116 21228225-3 2011 Here we demonstrate that HBx enhances cisplatin-induced hepatotoxicity by a mechanism involving degradation of Mcl-1, an antiapoptotic member of the Bcl-2 family. Cisplatin 38-47 BCL2 apoptosis regulator Homo sapiens 149-154 21598493-3 2011 Different particle size quantum dots fluorescent probes were applied to detect P53 protein and Bcl-2 protein simultaneously in paraffin-embedded tissue section of human tongue squamous cell carcinoma under fluorescent microscope. Paraffin 127-135 BCL2 apoptosis regulator Homo sapiens 95-100 21598493-4 2011 RESULTS: P53 protein and Bcl-2 protein can be combined with quantum dots fluorescent probes and specific fluorescene can be observed with ultraviolet light excited. fluorescene 105-116 BCL2 apoptosis regulator Homo sapiens 25-30 21598493-6 2011 P53 protein and Bcl-2 protein can be combined with different particle size quantum dots fluorescent probes respectively in the same paraffin-embedded tissue section of human tongue squamous cell carcinoma and two kinds of fluorescene can be observed. Paraffin 132-140 BCL2 apoptosis regulator Homo sapiens 16-21 21598493-6 2011 P53 protein and Bcl-2 protein can be combined with different particle size quantum dots fluorescent probes respectively in the same paraffin-embedded tissue section of human tongue squamous cell carcinoma and two kinds of fluorescene can be observed. fluorescene 222-233 BCL2 apoptosis regulator Homo sapiens 16-21 21289522-1 2011 BACKGROUND: AT-101 is an inhibitor of Bcl-2 family proteins including Bcl-2, Bcl-xL, Mcl-1, and Bcl-w. gossypol acetic acid 12-18 BCL2 apoptosis regulator Homo sapiens 38-43 21289522-1 2011 BACKGROUND: AT-101 is an inhibitor of Bcl-2 family proteins including Bcl-2, Bcl-xL, Mcl-1, and Bcl-w. gossypol acetic acid 12-18 BCL2 apoptosis regulator Homo sapiens 70-75 21289522-19 2011 AT-101 is the first oral, pan Bcl-2 family inhibitor to exhibit a possible survival benefit in a randomized study. gossypol acetic acid 0-6 BCL2 apoptosis regulator Homo sapiens 30-35 21358717-0 2011 The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia. spc2996 36-43 BCL2 apoptosis regulator Homo sapiens 20-25 21358717-1 2011 SPC2996 is a novel locked nucleic acid phosphorothioate antisense molecule targeting the mRNA of the Bcl-2 oncoprotein. acid phosphorothioate 34-55 BCL2 apoptosis regulator Homo sapiens 101-106 21556211-7 2011 In NI-BPH, I-BPH, and PC, the overexpression of COX-2, Bcl-2, and VEGF gradually increased. i-bph 4-9 BCL2 apoptosis regulator Homo sapiens 55-60 21515462-8 2011 Salidroside significantly inhibited the cell apoptosis, reversed the expressions of Bcl-2 and Bax, and attenuated the decrease in the protein expression of PI3K and phosphorylation level of AKT. rhodioloside 0-11 BCL2 apoptosis regulator Homo sapiens 84-89 21357440-7 2011 TRA-8 combined with AT-101 or BH3I-2", inhibitors of antiapoptotic Bcl-2 proteins, produced synergistic cytotoxicity against ZR-75-1, BT-474, and T47D cells. Tretinoin 0-3 BCL2 apoptosis regulator Homo sapiens 67-72 21357440-7 2011 TRA-8 combined with AT-101 or BH3I-2", inhibitors of antiapoptotic Bcl-2 proteins, produced synergistic cytotoxicity against ZR-75-1, BT-474, and T47D cells. gossypol acetic acid 20-26 BCL2 apoptosis regulator Homo sapiens 67-72 21357440-7 2011 TRA-8 combined with AT-101 or BH3I-2", inhibitors of antiapoptotic Bcl-2 proteins, produced synergistic cytotoxicity against ZR-75-1, BT-474, and T47D cells. BH3I-2' 30-36 BCL2 apoptosis regulator Homo sapiens 67-72 21448585-4 2011 These results showed that wogonin induced mitochondria and death-receptor-mediated apoptotic cell death, which was characterized by activation of several caspases, induction of PARP cleavage, change of antiapoptotic/proapoptotic Bcl-2 family member ratios and cleavage of Bid. wogonin 26-33 BCL2 apoptosis regulator Homo sapiens 229-234 21869905-0 2011 In LNCaP cells enhanced expression of the androgen receptor compensates for Bcl-2 suppression by antisense oligonucleotides. Oligonucleotides 107-123 BCL2 apoptosis regulator Homo sapiens 76-81 21320517-6 2011 Taken together, our results indicated that PQQ could protect primary cultured hippocampal neurons against glutamate-induced cell damage by scavenging ROS, reducing Ca2+ influx, and caspase-3 activity, and suggested that PQQ-activated PI3K/Akt signaling might be responsible for its neuroprotective action through modulation of glutamate-induced imbalance between Bcl-2 and Bax. PQQ Cofactor 43-46 BCL2 apoptosis regulator Homo sapiens 363-368 20717763-7 2011 After the CGNs were chronically exposed to IL-6, NMDA stimulation led to an increase in the expression of Bcl-2 mRNA and a decrease in the expression of Bax and caspase-3 mRNAs and proteins when compared with those neurons lacking IL-6 exposure. N-Methylaspartate 49-53 BCL2 apoptosis regulator Homo sapiens 106-111 21320517-3 2011 We found that glutamate-induced apoptosis in cultured hippocampal neurons was significantly attenuated by the ensuing PQQ treatment, which also inhibited the glutamate-induced increase in Ca2+ influx, caspase-3 activity, and ROS production, and reversed the glutamate-induced decrease in Bcl-2/Bax ratio. Glutamic Acid 14-23 BCL2 apoptosis regulator Homo sapiens 288-293 21320517-3 2011 We found that glutamate-induced apoptosis in cultured hippocampal neurons was significantly attenuated by the ensuing PQQ treatment, which also inhibited the glutamate-induced increase in Ca2+ influx, caspase-3 activity, and ROS production, and reversed the glutamate-induced decrease in Bcl-2/Bax ratio. PQQ Cofactor 118-121 BCL2 apoptosis regulator Homo sapiens 288-293 21496427-9 2011 CONCLUSIONS: Cisplatin resistance of lung cancer cells is associated with overexpression of GRP75 gene, which could regulate the expressions of p53 and bcl-2. Cisplatin 13-22 BCL2 apoptosis regulator Homo sapiens 152-157 21320517-3 2011 We found that glutamate-induced apoptosis in cultured hippocampal neurons was significantly attenuated by the ensuing PQQ treatment, which also inhibited the glutamate-induced increase in Ca2+ influx, caspase-3 activity, and ROS production, and reversed the glutamate-induced decrease in Bcl-2/Bax ratio. Glutamic Acid 158-167 BCL2 apoptosis regulator Homo sapiens 288-293 21320517-3 2011 We found that glutamate-induced apoptosis in cultured hippocampal neurons was significantly attenuated by the ensuing PQQ treatment, which also inhibited the glutamate-induced increase in Ca2+ influx, caspase-3 activity, and ROS production, and reversed the glutamate-induced decrease in Bcl-2/Bax ratio. Glutamic Acid 158-167 BCL2 apoptosis regulator Homo sapiens 288-293 21320517-5 2011 And inhibition of phosphatidylinositol-3-kinase (PI3K)/Akt cascade by LY294002 and wortmannin significantly blocked the protective effects of PQQ, and alleviated the increase in Bcl-2/Bax ratio. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 70-78 BCL2 apoptosis regulator Homo sapiens 178-183 21320517-5 2011 And inhibition of phosphatidylinositol-3-kinase (PI3K)/Akt cascade by LY294002 and wortmannin significantly blocked the protective effects of PQQ, and alleviated the increase in Bcl-2/Bax ratio. Wortmannin 83-93 BCL2 apoptosis regulator Homo sapiens 178-183 21338095-5 2011 Furthermore, reduction in the transcription ratio of bcl2/bax and induction of cytochrome c release from mitochondria to cytosol with treatment of limonoids confirm the activation of intrinsic apoptosis pathway. Limonins 147-156 BCL2 apoptosis regulator Homo sapiens 53-57 21239698-10 2011 Pharmacodynamically, flavopiridol inhibited mRNAs of multiple cell cycle regulators, but with uniform increases in bcl-2. alvocidib 21-33 BCL2 apoptosis regulator Homo sapiens 115-120 21447176-8 2011 Western blotting demonstrated that Osthole down-regulated the expressions of Cyclin B1, p-Cdc2 and Bcl-2 and up-regulated the expressions of Bax in A549 cells. osthol 35-42 BCL2 apoptosis regulator Homo sapiens 99-104 21366295-1 2011 ABT-737 and ABT-263 are potent inhibitors of the BH3 antiapoptotic proteins, Bcl-x(L) and Bcl-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 90-95 21366295-1 2011 ABT-737 and ABT-263 are potent inhibitors of the BH3 antiapoptotic proteins, Bcl-x(L) and Bcl-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 12-15 BCL2 apoptosis regulator Homo sapiens 90-95 21366295-3 2011 We have designed and synthesized a series of novel quinazoline-based inhibitors of Bcl-2 and Bcl-x(L) that contain a heterocyclic alternative to the acylsulfonamide. Quinazolines 51-62 BCL2 apoptosis regulator Homo sapiens 83-88 21366295-3 2011 We have designed and synthesized a series of novel quinazoline-based inhibitors of Bcl-2 and Bcl-x(L) that contain a heterocyclic alternative to the acylsulfonamide. acylsulfonamide 149-164 BCL2 apoptosis regulator Homo sapiens 83-88 21366295-6 2011 Additionally, these novel quinazolines comprise only the second known class of Bcl-2 family protein inhibitors to induce mechanism-based cell death. Quinazolines 26-38 BCL2 apoptosis regulator Homo sapiens 79-84 21338095-6 2011 The activity of Bax and Bcl2 was confirmed through analysis of mitochondrial membrane potential and intracellular calcium in the cells treated with limonin and LG; the net content of caspase-8 was not affected by limonoids. Calcium 114-121 BCL2 apoptosis regulator Homo sapiens 24-28 21317202-8 2011 While having no effect on FLIP(S) or caspase-8 expression, Raf265 strongly decreased Bcl-2 levels in those cell lines susceptible to its TRAIL-sensitizing action. RAF265 59-65 BCL2 apoptosis regulator Homo sapiens 85-90 21317202-0 2011 The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells. RAF265 24-30 BCL2 apoptosis regulator Homo sapiens 41-46 21148306-0 2011 The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner. BH 3 4-7 BCL2 apoptosis regulator Homo sapiens 54-59 21148306-4 2011 Using several approaches, we demonstrate that BH3-M6 is a pan-Bcl-2 antagonist that inhibits the binding of Bcl-X(L), Bcl-2, and Mcl-1 to multi-domain Bax or Bak, or BH3-only Bim or Bad in cell-free systems and in intact human cancer cells, freeing up pro-apoptotic proteins to induce apoptosis. bh3-m6 46-52 BCL2 apoptosis regulator Homo sapiens 62-67 21159314-3 2011 This study examined the correlation of BCL-2 gene polymorphism with the response to treatment with pegylated-IFN-alfa2b and ribavirin. Ribavirin 124-133 BCL2 apoptosis regulator Homo sapiens 39-44 21148306-4 2011 Using several approaches, we demonstrate that BH3-M6 is a pan-Bcl-2 antagonist that inhibits the binding of Bcl-X(L), Bcl-2, and Mcl-1 to multi-domain Bax or Bak, or BH3-only Bim or Bad in cell-free systems and in intact human cancer cells, freeing up pro-apoptotic proteins to induce apoptosis. bh3-m6 46-52 BCL2 apoptosis regulator Homo sapiens 118-123 21159314-8 2011 We conclude that BCL-2 gene polymorphism at codon 43 (127G/A) is a new biological marker to potentially identify responders and non-responders of HCV genotype 4 patients to achieving a sustained virological response to treatment with IFN in combination with ribavirin. Ribavirin 258-267 BCL2 apoptosis regulator Homo sapiens 17-22 21338134-0 2011 Structural conversion of intramolecular and intermolecular G-quadruplexes of bcl2mid: the effect of potassium concentration and ion exchange. Potassium 100-109 BCL2 apoptosis regulator Homo sapiens 77-81 21338134-4 2011 In addition, the use of the lithium cation to keep the same ionic strength in a K(+) solution favors the formation of the bcl2mid dimer. Lithium 28-35 BCL2 apoptosis regulator Homo sapiens 122-126 21338134-7 2011 Furthermore, the spectral changes of bcl2mid when transitioning from sodium form to potassium form take place upon K(+) titration. Sodium 69-75 BCL2 apoptosis regulator Homo sapiens 37-41 21338134-7 2011 Furthermore, the spectral changes of bcl2mid when transitioning from sodium form to potassium form take place upon K(+) titration. Potassium 84-93 BCL2 apoptosis regulator Homo sapiens 37-41 21220478-2 2011 EXPERIMENTAL DESIGN: We treated a panel of NSCLC lines with a dose matrix of paclitaxel and navitoclax (formerly ABT-263), an inhibitor of Bcl-2, Bcl-x(L), and Bcl-w (1), and evaluated synergy. navitoclax 92-102 BCL2 apoptosis regulator Homo sapiens 139-144 20615501-10 2011 rhCG also inhibited the expression of the proapoptotic Bax protein and up-regulated antiapoptotic Bcl-2 levels in decidualizing HESCs exposed to ROS. Reactive Oxygen Species 145-148 BCL2 apoptosis regulator Homo sapiens 98-103 21483469-4 2011 Enhanced toxicity by Tat and morphine was accompanied by increased numbers of TUNEL positive apoptotic neurons, elevated caspase-3 levels and decreased ratio of anti- and pro-apoptotic proteins, Bcl2/Bax. Morphine 29-37 BCL2 apoptosis regulator Homo sapiens 195-199 21036023-7 2011 The Bax/Bcl-2 ratio was also increased in GA-treated HeLa cells. ganoderic acid 42-44 BCL2 apoptosis regulator Homo sapiens 8-13 21256832-0 2011 Withaferin A enhances radiation-induced apoptosis in Caki cells through induction of reactive oxygen species, Bcl-2 downregulation and Akt inhibition. withaferin A 0-12 BCL2 apoptosis regulator Homo sapiens 110-115 21256832-4 2011 In addition, reactive oxygen species (ROS) generation was correlated with the enhancement of radiation-induced apoptosis by Wit A. Wit A downregulated Bcl-2 protein levels and ectopic expression of Bcl-2 in Caki cells attenuated the apoptosis induced by Wit A plus radiation. Reactive Oxygen Species 13-36 BCL2 apoptosis regulator Homo sapiens 151-156 21256832-4 2011 In addition, reactive oxygen species (ROS) generation was correlated with the enhancement of radiation-induced apoptosis by Wit A. Wit A downregulated Bcl-2 protein levels and ectopic expression of Bcl-2 in Caki cells attenuated the apoptosis induced by Wit A plus radiation. Reactive Oxygen Species 13-36 BCL2 apoptosis regulator Homo sapiens 198-203 21256832-4 2011 In addition, reactive oxygen species (ROS) generation was correlated with the enhancement of radiation-induced apoptosis by Wit A. Wit A downregulated Bcl-2 protein levels and ectopic expression of Bcl-2 in Caki cells attenuated the apoptosis induced by Wit A plus radiation. Reactive Oxygen Species 38-41 BCL2 apoptosis regulator Homo sapiens 151-156 21256832-4 2011 In addition, reactive oxygen species (ROS) generation was correlated with the enhancement of radiation-induced apoptosis by Wit A. Wit A downregulated Bcl-2 protein levels and ectopic expression of Bcl-2 in Caki cells attenuated the apoptosis induced by Wit A plus radiation. Reactive Oxygen Species 38-41 BCL2 apoptosis regulator Homo sapiens 198-203 21408143-5 2011 Icaritin treatment also induced expression of pro-apoptotic protein Bax with a concomitant decrease of Bcl-2 expression. icaritin 0-8 BCL2 apoptosis regulator Homo sapiens 103-108 21196599-8 2011 Collectively, our results support the notion that BAK functions as a direct effector of MOMP akin to BAX and also adds significantly to the growing evidence indicating that mitochondrial membrane lipids are actively implicated in BCL-2 protein family function. bakuchiol 50-53 BCL2 apoptosis regulator Homo sapiens 230-235 21193695-3 2011 One approach centers on agents (eg, ABT-737) that compete with proapoptotic members of the Bcl-2 protein family for binding in the hydrophobic groove formed by the BH1-BH3 domains of Bcl-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 36-39 BCL2 apoptosis regulator Homo sapiens 183-188 21193695-4 2011 Another region of Bcl-2, the BH4 domain, also contributes to the antiapoptotic activity of Bcl-2 by binding to the inositol 1,4,5-trisphosphate receptor (IP3R) Ca2(+) channel, inhibiting IP(3)-dependent Ca2(+) release from the endoplasmic reticulum. sapropterin 29-32 BCL2 apoptosis regulator Homo sapiens 18-23 21193695-4 2011 Another region of Bcl-2, the BH4 domain, also contributes to the antiapoptotic activity of Bcl-2 by binding to the inositol 1,4,5-trisphosphate receptor (IP3R) Ca2(+) channel, inhibiting IP(3)-dependent Ca2(+) release from the endoplasmic reticulum. sapropterin 29-32 BCL2 apoptosis regulator Homo sapiens 91-96 21193695-4 2011 Another region of Bcl-2, the BH4 domain, also contributes to the antiapoptotic activity of Bcl-2 by binding to the inositol 1,4,5-trisphosphate receptor (IP3R) Ca2(+) channel, inhibiting IP(3)-dependent Ca2(+) release from the endoplasmic reticulum. Inositol 1,4,5-Trisphosphate 187-192 BCL2 apoptosis regulator Homo sapiens 18-23 21193695-4 2011 Another region of Bcl-2, the BH4 domain, also contributes to the antiapoptotic activity of Bcl-2 by binding to the inositol 1,4,5-trisphosphate receptor (IP3R) Ca2(+) channel, inhibiting IP(3)-dependent Ca2(+) release from the endoplasmic reticulum. Inositol 1,4,5-Trisphosphate 187-192 BCL2 apoptosis regulator Homo sapiens 91-96 21193695-5 2011 We report that a novel synthetic peptide, modeled after the Bcl-2-interacting site on the IP3R, binds to the BH4 domain of Bcl-2 and functions as a competitive inhibitor of the Bcl-2-IP3R interaction. sapropterin 109-112 BCL2 apoptosis regulator Homo sapiens 60-65 21193695-5 2011 We report that a novel synthetic peptide, modeled after the Bcl-2-interacting site on the IP3R, binds to the BH4 domain of Bcl-2 and functions as a competitive inhibitor of the Bcl-2-IP3R interaction. sapropterin 109-112 BCL2 apoptosis regulator Homo sapiens 123-128 21193695-5 2011 We report that a novel synthetic peptide, modeled after the Bcl-2-interacting site on the IP3R, binds to the BH4 domain of Bcl-2 and functions as a competitive inhibitor of the Bcl-2-IP3R interaction. sapropterin 109-112 BCL2 apoptosis regulator Homo sapiens 123-128 21107834-7 2011 Rapamycin altered the phenotype of antigen-specific Vgamma2Vdelta2 cells by inducing a population shift from CD62L + CD69- to CD62L-CD69+, higher expression of CD25 or Bcl-2, lower levels of CCR5 and increased resistance to Fas-mediated cellular apoptosis. Sirolimus 0-9 BCL2 apoptosis regulator Homo sapiens 168-173 21186059-1 2011 Diblock copolymers (PEI-PCL) of poly(epsilon-caprolactone) (PCL) and linear poly(ethylene imine) (PEI) were synthesized and assembled to biodegradable nano-carriers for co-delivery of BCL-2 siRNA and doxorubicin (DOX). diblock copolymers 0-18 BCL2 apoptosis regulator Homo sapiens 184-189 21186059-1 2011 Diblock copolymers (PEI-PCL) of poly(epsilon-caprolactone) (PCL) and linear poly(ethylene imine) (PEI) were synthesized and assembled to biodegradable nano-carriers for co-delivery of BCL-2 siRNA and doxorubicin (DOX). pei-pcl 20-27 BCL2 apoptosis regulator Homo sapiens 184-189 21186059-1 2011 Diblock copolymers (PEI-PCL) of poly(epsilon-caprolactone) (PCL) and linear poly(ethylene imine) (PEI) were synthesized and assembled to biodegradable nano-carriers for co-delivery of BCL-2 siRNA and doxorubicin (DOX). polycaprolactone 24-27 BCL2 apoptosis regulator Homo sapiens 184-189 21186059-1 2011 Diblock copolymers (PEI-PCL) of poly(epsilon-caprolactone) (PCL) and linear poly(ethylene imine) (PEI) were synthesized and assembled to biodegradable nano-carriers for co-delivery of BCL-2 siRNA and doxorubicin (DOX). poly(ethylene imine) 20-23 BCL2 apoptosis regulator Homo sapiens 184-189 21186059-5 2011 Compared to non-specific delivery, the folate-targeted delivery of BCL-2 siRNA resulted in more significant gene suppression at both the BCL-2 mRNA and protein expression levels, inducing cancer cell apoptosis and improving the therapeutic efficacy of the co-administered DOX. Folic Acid 39-45 BCL2 apoptosis regulator Homo sapiens 67-72 21186059-5 2011 Compared to non-specific delivery, the folate-targeted delivery of BCL-2 siRNA resulted in more significant gene suppression at both the BCL-2 mRNA and protein expression levels, inducing cancer cell apoptosis and improving the therapeutic efficacy of the co-administered DOX. Folic Acid 39-45 BCL2 apoptosis regulator Homo sapiens 137-142 21186059-5 2011 Compared to non-specific delivery, the folate-targeted delivery of BCL-2 siRNA resulted in more significant gene suppression at both the BCL-2 mRNA and protein expression levels, inducing cancer cell apoptosis and improving the therapeutic efficacy of the co-administered DOX. Doxorubicin 272-275 BCL2 apoptosis regulator Homo sapiens 67-72 21052098-4 2011 We demonstrated that Ad-ING4 plus CDDP induced synergistic growth inhibition, enhanced apoptosis, and had an additive effect on upregulation of Fas, Bax, Bak, cleaved Bid, cleaved caspase-8, caspase-9, caspase-3 and cleaved PARP, and on downregulation of Bcl-2 and Bcl-X(L) in SMMC-7721 hepatocarcinoma cells. Cisplatin 34-38 BCL2 apoptosis regulator Homo sapiens 255-260 21148565-4 2011 Moreover, the ubiquitin-dependent degradation of Bcl-2 was found to be promoted after KA treatment, which could be suppressed by the proteasome inhibitor MG132 and the NO donors, sodium nitroprusside and S-nitrosoglutathione. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 154-159 BCL2 apoptosis regulator Homo sapiens 49-54 21148565-4 2011 Moreover, the ubiquitin-dependent degradation of Bcl-2 was found to be promoted after KA treatment, which could be suppressed by the proteasome inhibitor MG132 and the NO donors, sodium nitroprusside and S-nitrosoglutathione. Nitroprusside 179-199 BCL2 apoptosis regulator Homo sapiens 49-54 21148565-4 2011 Moreover, the ubiquitin-dependent degradation of Bcl-2 was found to be promoted after KA treatment, which could be suppressed by the proteasome inhibitor MG132 and the NO donors, sodium nitroprusside and S-nitrosoglutathione. S-Nitrosoglutathione 204-224 BCL2 apoptosis regulator Homo sapiens 49-54 21148565-6 2011 At the same time, it was found that the exogenous NO donor GSNO could protect neurons when Bcl-2 is targeted. S-Nitrosoglutathione 59-63 BCL2 apoptosis regulator Homo sapiens 91-96 21148565-8 2011 NS102, GSNO, sodium nitroprusside, and MG132 contribute to the survival of CA1 and CA3/DG pyramidal neurons by attenuating Bcl-2 denitrosylation. S-Nitrosoglutathione 7-11 BCL2 apoptosis regulator Homo sapiens 123-128 21148565-8 2011 NS102, GSNO, sodium nitroprusside, and MG132 contribute to the survival of CA1 and CA3/DG pyramidal neurons by attenuating Bcl-2 denitrosylation. Nitroprusside 13-33 BCL2 apoptosis regulator Homo sapiens 123-128 21148565-8 2011 NS102, GSNO, sodium nitroprusside, and MG132 contribute to the survival of CA1 and CA3/DG pyramidal neurons by attenuating Bcl-2 denitrosylation. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 39-44 BCL2 apoptosis regulator Homo sapiens 123-128 21368833-11 2011 Correspondingly, T-ALL cell lines with defective FBW7 are particularly sensitive to the multi-kinase inhibitor sorafenib but resistant to the BCL2 antagonist ABT-737. ABT-737 158-165 BCL2 apoptosis regulator Homo sapiens 142-146 21300543-0 2011 Anti-tumor pyrimidinylpiperazines bind to the prosurvival Bcl-2 protein family member Bcl-XL. pyrimidinylpiperazines 11-33 BCL2 apoptosis regulator Homo sapiens 58-63 21300543-3 2011 Here we describe the design, synthesis, and evaluation of pyrimidylpiperazines that were discovered to be inhibitors of the prosurvival Bcl-2 protein family member Bcl-XL. pyrimidylpiperazines 58-78 BCL2 apoptosis regulator Homo sapiens 136-141 20490799-7 2011 The treatment with noscapine upregulated Bax and Cytochrome c (Cyt-c) protein, downregulated Bcl-2 protein. Noscapine 19-28 BCL2 apoptosis regulator Homo sapiens 93-98 21198858-4 2011 The expression of apoptotic parameters was analyzed using the standard immunohistochemical method (antibodies against caspase-3, CD95, c-FLIP, XIAP, survivin, and bcl-2) on formalin-fixed and routinely processed paraffin-embedded lymph node specimens. Formaldehyde 173-181 BCL2 apoptosis regulator Homo sapiens 163-168 20865015-3 2011 The DGR domain of INrf2 interacts with the BH2 domain of Bcl-2 and facilitates INrf2:Cul3-Rbx1-mediated ubiquitination of Bcl-2 by the conjugation of ubiquitin molecules to lysine17 of Bcl-2. lysine17 173-181 BCL2 apoptosis regulator Homo sapiens 57-62 20865015-3 2011 The DGR domain of INrf2 interacts with the BH2 domain of Bcl-2 and facilitates INrf2:Cul3-Rbx1-mediated ubiquitination of Bcl-2 by the conjugation of ubiquitin molecules to lysine17 of Bcl-2. lysine17 173-181 BCL2 apoptosis regulator Homo sapiens 122-127 20865015-3 2011 The DGR domain of INrf2 interacts with the BH2 domain of Bcl-2 and facilitates INrf2:Cul3-Rbx1-mediated ubiquitination of Bcl-2 by the conjugation of ubiquitin molecules to lysine17 of Bcl-2. lysine17 173-181 BCL2 apoptosis regulator Homo sapiens 122-127 21247388-5 2011 One of the major mechanisms of bortezomib associated with its anticancer activity is through upregulation of NOXA, which is a proapoptotic protein, and NOXA may interact with the anti-apoptotic proteins of Bcl-2 subfamily Bcl-X(L) and Bcl-2, and result in apoptotic cell death in malignant cells. Bortezomib 31-41 BCL2 apoptosis regulator Homo sapiens 206-211 21247388-5 2011 One of the major mechanisms of bortezomib associated with its anticancer activity is through upregulation of NOXA, which is a proapoptotic protein, and NOXA may interact with the anti-apoptotic proteins of Bcl-2 subfamily Bcl-X(L) and Bcl-2, and result in apoptotic cell death in malignant cells. Bortezomib 31-41 BCL2 apoptosis regulator Homo sapiens 235-240 21359924-7 2011 Immunocytochemistry indicated that the expression of Bcl-2 protein decreased, while the expression of p53 and Bax proteins increased in A549 cells treated with Inotodiol, compared with the control cells (P<0.05). inotodiol 160-169 BCL2 apoptosis regulator Homo sapiens 53-58 21359924-8 2011 CONCLUSION: Inotodiol can inhibit proliferation and induce the apoptosis of A549 cells, and its molecular mechanism may be associated with the up-regulating expression of p53 and bax proteins and down-regulating expression of Bcl-2 protein, which arrested A549 cells in S phase. inotodiol 12-21 BCL2 apoptosis regulator Homo sapiens 226-231 21298709-5 2011 At this low concentration range, a fenitrothion-induced twofold elevation in B-cell leukemia/lymphoma-2 (BCL-2) and cytochrome P450 isoenzyme (CYP1A1) gene expressions was observed. Fenitrothion 35-47 BCL2 apoptosis regulator Homo sapiens 77-103 21298709-5 2011 At this low concentration range, a fenitrothion-induced twofold elevation in B-cell leukemia/lymphoma-2 (BCL-2) and cytochrome P450 isoenzyme (CYP1A1) gene expressions was observed. Fenitrothion 35-47 BCL2 apoptosis regulator Homo sapiens 105-110 21225911-1 2011 BACKGROUND: ABT-737 is a BH3 mimetic small-molecule inhibitor that binds with high affinity to Bcl-2 to induce apoptosis in malignant cells and has shown promise as an effective anti-leukemic agent in pediatric preclinical tests. ABT-737 12-19 BCL2 apoptosis regulator Homo sapiens 95-100 20824697-4 2011 Drug resistance of PC is allegedly linked with both constitutive and OxP-induced activation of NF-kappaB, and we found that inactivation of (nuclear factor kappa B) NF-kappaB by genistein before treatment of cells with OxP was required for cell killing, which was consistent with the downregulation of NF-kappaB and its downstream antiapoptotic genes (Bcl-2, XIAPs and survivin). Genistein 178-187 BCL2 apoptosis regulator Homo sapiens 352-357 21393866-3 2011 We have found that the compound ABT-737, a Bcl-2 homology domain 3 (BH-3) mimetic, promotes apoptotic cell death in human colorectal carcinoma and small cell lung cancer cell lines exposed to hypoxia. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 32-35 BCL2 apoptosis regulator Homo sapiens 43-48 21393866-4 2011 This hypoxic induction of apoptosis was mediated through downregulation of myeloid cell leukemia sequence 1 (Mcl-1), a Bcl-2 family protein that serves as a biomarker for ABT-737 resistance. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 171-174 BCL2 apoptosis regulator Homo sapiens 119-124 21047686-7 2011 The effect of the LEN and DEX combination on apoptotic induction was mainly through mitochondrial signaling pathways, as demonstrated by phosphorylation of bcl-2 and up-regulation of proapoptotic proteins Bax, Bad and Bim, and the subsequent activation of caspase-9, caspase-3, and cleavage of PARP. Dexamethasone 26-29 BCL2 apoptosis regulator Homo sapiens 156-161 21252285-6 2011 Treatment with cisplatin/TRAIL also inhibited the expression of EGFR, p63, survivin, Bcl-2, and Bcl-xL in TNBC cells. Cisplatin 15-24 BCL2 apoptosis regulator Homo sapiens 85-90 21241762-7 2011 Western blot data revealed that loganin inhibited the H(2)O(2)-induced up-regulation of cleaved poly (ADP-ribose) polymerase (PARP) and cleaved caspase-3, increased the H(2)O(2)-induced decrease in the Bcl-2/Bax ratio, and attenuated the H(2)O(2)-induced release of cytochrome c from mitochondria to the cytosol. loganin 32-39 BCL2 apoptosis regulator Homo sapiens 202-207 21241762-7 2011 Western blot data revealed that loganin inhibited the H(2)O(2)-induced up-regulation of cleaved poly (ADP-ribose) polymerase (PARP) and cleaved caspase-3, increased the H(2)O(2)-induced decrease in the Bcl-2/Bax ratio, and attenuated the H(2)O(2)-induced release of cytochrome c from mitochondria to the cytosol. Hydrogen Peroxide 54-62 BCL2 apoptosis regulator Homo sapiens 202-207 21206976-0 2011 ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 11-16 21206976-4 2011 We hypothesized that the addition of ABT-263, a potent Bcl-2 inhibitor, should significantly enhance the degree of anoikis in lung adenocarcinoma cells treated with Src inhibitors. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 37-40 BCL2 apoptosis regulator Homo sapiens 55-60 20683843-0 2011 Effects of taspine on proliferation and apoptosis by regulating caspase-3 expression and the ratio of Bax/Bcl-2 in A431 cells. taspine 11-18 BCL2 apoptosis regulator Homo sapiens 106-111 21115943-3 2011 The results showed that PFOS could reduce the cell viability significantly, and the cellular apoptosis induced by PFOS was closely accompanied with dissipation of mitochondria membrane potential, upregulation messenger RNAs (mRNAs) of p53, Bax, caspase 9, and caspase 3, and decreased expression of Bcl-2 mRNA. perfluorooctane sulfonic acid 24-28 BCL2 apoptosis regulator Homo sapiens 299-304 21115943-3 2011 The results showed that PFOS could reduce the cell viability significantly, and the cellular apoptosis induced by PFOS was closely accompanied with dissipation of mitochondria membrane potential, upregulation messenger RNAs (mRNAs) of p53, Bax, caspase 9, and caspase 3, and decreased expression of Bcl-2 mRNA. perfluorooctane sulfonic acid 114-118 BCL2 apoptosis regulator Homo sapiens 299-304 21282543-0 2011 Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. navitoclax 17-27 BCL2 apoptosis regulator Homo sapiens 47-52 21282543-0 2011 Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 29-32 BCL2 apoptosis regulator Homo sapiens 47-52 21282543-3 2011 A phase I study of navitoclax, a novel inhibitor of Bcl-2 family proteins, was conducted to evaluate safety, pharmacokinetics, and preliminary efficacy in patients with solid tumors. navitoclax 19-29 BCL2 apoptosis regulator Homo sapiens 52-57 21212792-6 2011 Furthermore, the combination of SNS-032 and Ara-C showed remarkable synergy that was associated with reduced mRNA levels of the antiapoptotic genes XIAP, BCL2 and MCL1. N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide 32-39 BCL2 apoptosis regulator Homo sapiens 154-158 21212792-6 2011 Furthermore, the combination of SNS-032 and Ara-C showed remarkable synergy that was associated with reduced mRNA levels of the antiapoptotic genes XIAP, BCL2 and MCL1. Cytarabine 44-49 BCL2 apoptosis regulator Homo sapiens 154-158 21212792-8 2011 Treatment with Ara-C alone significantly induced the transcription of the antiapoptotic genes BCL2 and XIAP. Cytarabine 15-20 BCL2 apoptosis regulator Homo sapiens 94-98 21212792-9 2011 In contrast, the combination of SNS-032 and Ara-C suppressed the transcription of BCL2, XIAP and MCL1. N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide 32-39 BCL2 apoptosis regulator Homo sapiens 82-86 21212792-9 2011 In contrast, the combination of SNS-032 and Ara-C suppressed the transcription of BCL2, XIAP and MCL1. Cytarabine 44-49 BCL2 apoptosis regulator Homo sapiens 82-86 21115635-6 2011 The induction of proapoptotic Bcl-2 family proteins Bax and Bak and a decrease of antiapoptotic Bcl-2 protein Bcl-2 were observed in GL-treated cells. guggulu extract 133-135 BCL2 apoptosis regulator Homo sapiens 30-35 21115635-6 2011 The induction of proapoptotic Bcl-2 family proteins Bax and Bak and a decrease of antiapoptotic Bcl-2 protein Bcl-2 were observed in GL-treated cells. guggulu extract 133-135 BCL2 apoptosis regulator Homo sapiens 96-101 21115635-6 2011 The induction of proapoptotic Bcl-2 family proteins Bax and Bak and a decrease of antiapoptotic Bcl-2 protein Bcl-2 were observed in GL-treated cells. guggulu extract 133-135 BCL2 apoptosis regulator Homo sapiens 96-101 21241762-9 2011 These results suggest that the protective effects of loganin against H(2)O(2)-induced apoptosis may be due to a decrease in the Bcl-2/Bax ratio expression due to the inhibition of the phosphorylation of JNK, p38, and ERK 1/2 MAPKs. Hydrogen Peroxide 69-77 BCL2 apoptosis regulator Homo sapiens 128-133 21608150-5 2011 On the other hand, Fbw7-deficient T-ALL cell lines are much more resistant to the Bcl-2 antagonist, ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 100-103 BCL2 apoptosis regulator Homo sapiens 82-87 21225911-1 2011 BACKGROUND: ABT-737 is a BH3 mimetic small-molecule inhibitor that binds with high affinity to Bcl-2 to induce apoptosis in malignant cells and has shown promise as an effective anti-leukemic agent in pediatric preclinical tests. BH 3 25-28 BCL2 apoptosis regulator Homo sapiens 95-100 21235240-0 2011 3-Thiomorpholin-8-oxo-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile (S1) based molecules as potent, dual inhibitors of B-cell lymphoma 2 (Bcl-2) and myeloid cell leukemia sequence 1 (Mcl-1): structure-based design and structure-activity relationship studies. CHEMBL595134 0-64 BCL2 apoptosis regulator Homo sapiens 116-133 21485553-6 2011 The protein expression of I(kappa)B(alpha) was obviously up-regulated and that of Bcl-2 down-regulated in all the solanine concentration groups. Solanine 114-122 BCL2 apoptosis regulator Homo sapiens 82-87 21485553-7 2011 CONCLUSION: Solanine has an anti-prostate cancer effect by inhibiting PC-3 cell proliferation, arresting the S phase, inducing cell apoptosis, up-regulating the protein expression of I(kappa)B(alpha) and down-regulating that of Bcl-2. Solanine 12-20 BCL2 apoptosis regulator Homo sapiens 228-233 21250700-5 2011 Western blot analysis in HL60 cells showed that poricotriol A activated caspases-3, -8, and -9, while increasing the ratio of Bax/Bcl-2. poricotriol A 48-61 BCL2 apoptosis regulator Homo sapiens 130-135 21235240-0 2011 3-Thiomorpholin-8-oxo-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile (S1) based molecules as potent, dual inhibitors of B-cell lymphoma 2 (Bcl-2) and myeloid cell leukemia sequence 1 (Mcl-1): structure-based design and structure-activity relationship studies. CHEMBL595134 0-64 BCL2 apoptosis regulator Homo sapiens 135-140 21250700-7 2011 On the other hand, poricotriol A did not activate caspases-3, -8, and -9, but induced translocation of apoptosis-inducing factor (AIF) from mitochondria and increased the ratio of Bax/Bcl-2 in A549. poricotriol A 19-32 BCL2 apoptosis regulator Homo sapiens 184-189 21130731-6 2011 Inhibition of AKT activation by phosphoinocitide 3-kinase (PI3K) inhibitor LY294002 resulted in reduced Bcl-2 expression and enhanced Bax expression and thus induced apoptosis in the resistant cells, whereas inhibition of ERK1/2 activation by mitogen-activated protein kinase (MEK) inhibitor U0126 did not induce apoptosis without affecting the expression of Bcl-2 and Bax but decreased cell growth. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 75-83 BCL2 apoptosis regulator Homo sapiens 104-109 21130780-4 2011 The work presented here considers the incorporation of BAD and its various modifications in a model of the tBID-induction of BAK (Bcl-2 homologous antagonist killer) or the tBID-induction of BAX (Bcl-2-associated X protein). tBID 107-111 BCL2 apoptosis regulator Homo sapiens 130-135 21130780-5 2011 Steady state equations are used to develop an explicit formula describing the total concentration level of tBID, guaranteed to trigger apoptosis, as a bilinear function of the total BAD concentration level and the total anti-apoptotic protein concentration level (usually Bcl-2 or Bcl-xL). tBID 107-111 BCL2 apoptosis regulator Homo sapiens 272-277 21130780-6 2011 In particular, the formula explains how the pro-apoptotic protein BAD lowers the threshold at which tBID induces BAK/BAX activation-reducing the level of total Bcl-2/Bcl-xL available to inhibit tBID signaling in the mitochondria. tBID 100-104 BCL2 apoptosis regulator Homo sapiens 160-165 21130780-6 2011 In particular, the formula explains how the pro-apoptotic protein BAD lowers the threshold at which tBID induces BAK/BAX activation-reducing the level of total Bcl-2/Bcl-xL available to inhibit tBID signaling in the mitochondria. tBID 194-198 BCL2 apoptosis regulator Homo sapiens 160-165 21130731-6 2011 Inhibition of AKT activation by phosphoinocitide 3-kinase (PI3K) inhibitor LY294002 resulted in reduced Bcl-2 expression and enhanced Bax expression and thus induced apoptosis in the resistant cells, whereas inhibition of ERK1/2 activation by mitogen-activated protein kinase (MEK) inhibitor U0126 did not induce apoptosis without affecting the expression of Bcl-2 and Bax but decreased cell growth. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 75-83 BCL2 apoptosis regulator Homo sapiens 359-364 21167259-9 2011 Taken together, these findings indicate that curcumin I protects dopaminergic neurons from 6-OHDA-induced toxicity via the reduction of ROS production, and subsequent attenuation of p53 phosphorylation and reduction of the Bax/Bcl-2 ratio. Curcumin 45-55 BCL2 apoptosis regulator Homo sapiens 227-232 21189001-5 2011 To further explore the mechanism of action, two other cell lines were examined: HeLa cells which are highly sensitive to Dox, and HeLa cells overexpressing Bcl-2 which show impaired apoptosis and Dox resistance. Doxorubicin 196-199 BCL2 apoptosis regulator Homo sapiens 156-161 21200020-8 2011 AE/N-Ras(G12D) cells were more sensitive to Bcl-2 inhibition with ABT-737 than parent AE cells. ABT-737 66-73 BCL2 apoptosis regulator Homo sapiens 44-49 21265562-6 2011 Docking of heme onto a high-resolution structure of the G-quadruplex fold of Bcl-2 promoter DNA, which both binds heme and transfers oxygen, suggests a relatively open active site for this class of ribozymes and deoxyribozymes. Heme 11-15 BCL2 apoptosis regulator Homo sapiens 77-82 21265562-6 2011 Docking of heme onto a high-resolution structure of the G-quadruplex fold of Bcl-2 promoter DNA, which both binds heme and transfers oxygen, suggests a relatively open active site for this class of ribozymes and deoxyribozymes. Heme 114-118 BCL2 apoptosis regulator Homo sapiens 77-82 21265562-6 2011 Docking of heme onto a high-resolution structure of the G-quadruplex fold of Bcl-2 promoter DNA, which both binds heme and transfers oxygen, suggests a relatively open active site for this class of ribozymes and deoxyribozymes. Oxygen 133-139 BCL2 apoptosis regulator Homo sapiens 77-82 21167476-0 2011 The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder. Calcium 118-125 BCL2 apoptosis regulator Homo sapiens 4-9 21118682-6 2011 Moreover, Gambogenic acid could result in a time and concentration-dependent decrease in Phospho-Akt expression, basal expression levels of Akt change was not obvious, In addition, we detected Bcl-2 family including Bcl-2, Bax and Bad expression in mRNA level. neo-gambogic acid 10-25 BCL2 apoptosis regulator Homo sapiens 193-198 21118682-6 2011 Moreover, Gambogenic acid could result in a time and concentration-dependent decrease in Phospho-Akt expression, basal expression levels of Akt change was not obvious, In addition, we detected Bcl-2 family including Bcl-2, Bax and Bad expression in mRNA level. neo-gambogic acid 10-25 BCL2 apoptosis regulator Homo sapiens 216-221 21118682-7 2011 This resulted in a decrease of Bcl-2 and Bad increased in CNE-1 cells after Gambogenic acid treatment. neo-gambogic acid 76-91 BCL2 apoptosis regulator Homo sapiens 31-36 21118682-8 2011 Overall, our results indicated that Gambogenic acid mediated apoptosis through inactivation of Akt, accompanied with mitochondrial oxidative stress and cross-talk with Bcl-2 family in the process of apoptosis. neo-gambogic acid 36-51 BCL2 apoptosis regulator Homo sapiens 168-173 20942457-10 2011 This system treats MDR by inhibiting the Warburg effect and promoting mitochondrial binding of pro-apoptotic Bcl-2 proteins (lonidamine), while hyperstabilizing microtubules (paclitaxel). lonidamine 125-135 BCL2 apoptosis regulator Homo sapiens 109-114 21320251-0 2011 Bcl-2 SNP rs956572 associates with disrupted intracellular calcium homeostasis in bipolar I disorder. Calcium 59-66 BCL2 apoptosis regulator Homo sapiens 0-5 21326627-5 2011 We then analyzed protein expression for PTEN, BCL2 and PDCD4 as miR-21 target genes by IHC, and finally correlated the results with patients" clinicopathological features.Significant overexpression of miR-21 in PABC tumors compared to normal adjacent tissue was found. 4-azidobenzylcarazolol 211-215 BCL2 apoptosis regulator Homo sapiens 46-50 21123735-11 2011 Relative levels of phosphorylated cAMP response element binding protein and phosphorylated Bcl-2 were decreased in CEC treated with 2HE or siRNA, suggesting that HCO(3)(-)-dependent endogenous sAC activity can mobilize antiapoptotic signal transduction. Bicarbonates 162-168 BCL2 apoptosis regulator Homo sapiens 91-96 20714724-4 2011 The results of our study revealed that resveratrol induced apoptosis in CLL cells in a tumor-specific manner but did not affect non-leukemic cells, and apoptosis was associated with a decreased BCL2/BAX ratio. Resveratrol 39-50 BCL2 apoptosis regulator Homo sapiens 194-198 21380817-6 2011 Docetaxel decreased Bcl-2 in HCT-116 cells, which have functionally active p53, according to luciferase reporter gene analyses, and docetaxel-induced cell death and changes in Bcl-2 and NAG-1 expression were blocked by PFT-alpha, a p53 inhibitor. Docetaxel 0-9 BCL2 apoptosis regulator Homo sapiens 20-25 21380817-6 2011 Docetaxel decreased Bcl-2 in HCT-116 cells, which have functionally active p53, according to luciferase reporter gene analyses, and docetaxel-induced cell death and changes in Bcl-2 and NAG-1 expression were blocked by PFT-alpha, a p53 inhibitor. Docetaxel 0-9 BCL2 apoptosis regulator Homo sapiens 176-181 21380817-6 2011 Docetaxel decreased Bcl-2 in HCT-116 cells, which have functionally active p53, according to luciferase reporter gene analyses, and docetaxel-induced cell death and changes in Bcl-2 and NAG-1 expression were blocked by PFT-alpha, a p53 inhibitor. Docetaxel 132-141 BCL2 apoptosis regulator Homo sapiens 176-181 21169413-3 2011 ABT-737 is an example of one of the first small-molecule inhibitors of Bcl-2/Bcl-x(L) that has been shown to increase the sensitivity of ovarian cancer cells to carboplatin. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 71-76 21078540-5 2011 The mechanism is at least partially due to the suppressive effect of genistein both on the proper and ATO-induced Akt activation, and on the activity of NF-kappaB, and the latter correlated with the suppression of NF-kappaB regulated gene products, including cyclin D1, Bcl-xL, Bcl-2, c-myc, COX-2, and VEGF. Genistein 69-78 BCL2 apoptosis regulator Homo sapiens 278-283 21169413-3 2011 ABT-737 is an example of one of the first small-molecule inhibitors of Bcl-2/Bcl-x(L) that has been shown to increase the sensitivity of ovarian cancer cells to carboplatin. Carboplatin 161-172 BCL2 apoptosis regulator Homo sapiens 71-76 20863277-7 2011 Lithium-mediated neurotroprotective and neurotrophic effects involve mechanisms highly relevant to the post-stroke population including the increased expression of brain-derived neurotrophic factor (BDNF) and Bcl-2, and inhibition of GSK-3beta. Lithium 0-7 BCL2 apoptosis regulator Homo sapiens 209-214 20863277-8 2011 Lithium-induced increases in human gray matter have been reported and occur within a time frame consistent with the known effects of lithium through increased expression of BDNF, Bcl-2 and GSK-3beta inhibition. Lithium 0-7 BCL2 apoptosis regulator Homo sapiens 179-184 20863277-8 2011 Lithium-induced increases in human gray matter have been reported and occur within a time frame consistent with the known effects of lithium through increased expression of BDNF, Bcl-2 and GSK-3beta inhibition. Lithium 133-140 BCL2 apoptosis regulator Homo sapiens 179-184 20665703-7 2011 The combination of ZD6474 with paclitaxel versus either agent alone also more potently down-regulated the antiapoptotic bcl-2 protein, up-regulated pro-apoptotic signaling events involving expression of bax, activation of caspase-3 and caspase-7 proteins, and induced poly(ADP-ribose) polymerase resulting in apoptosis. vandetanib 19-25 BCL2 apoptosis regulator Homo sapiens 120-125 21134410-7 2011 In addition, celastrol decreased the expression of anti-apoptotic Bcl-2 protein and increased expression of pro-apoptotic Bax protein. celastrol 13-22 BCL2 apoptosis regulator Homo sapiens 66-71 21115120-0 2011 Selective impairment of CD4+CD25+Foxp3+ regulatory T cells by paclitaxel is explained by Bcl-2/Bax mediated apoptosis. Paclitaxel 62-72 BCL2 apoptosis regulator Homo sapiens 89-94 21115120-7 2011 Treg cells exposed to paclitaxel displayed downregulation of Bcl-2 and upregulation of Bax. Paclitaxel 22-32 BCL2 apoptosis regulator Homo sapiens 61-66 21115120-8 2011 Blocking the Bcl-2 pathway eliminated the difference between Treg and Teff cells responding to paclitaxel. Paclitaxel 95-105 BCL2 apoptosis regulator Homo sapiens 13-18 21115120-9 2011 These results suggest that Bcl-2 rather than tubulin contributes to the distinctive effect of paclitaxel on Treg cells. Paclitaxel 94-104 BCL2 apoptosis regulator Homo sapiens 27-32 20665703-7 2011 The combination of ZD6474 with paclitaxel versus either agent alone also more potently down-regulated the antiapoptotic bcl-2 protein, up-regulated pro-apoptotic signaling events involving expression of bax, activation of caspase-3 and caspase-7 proteins, and induced poly(ADP-ribose) polymerase resulting in apoptosis. Paclitaxel 31-41 BCL2 apoptosis regulator Homo sapiens 120-125 21126963-6 2011 Immunohistochemically, CTM is positive for LhS28, bcl-2, PAX2 and p16(INK4A). cyclohexane-1,2,4-tris(methylenesulfonate) 23-26 BCL2 apoptosis regulator Homo sapiens 50-55 21068071-6 2011 Treatment of VSC4.1 motoneurons with PPT, DPN, or EST induced overexpression of ERalpha, ERbeta, or both, which contributed to neuroprotection by upregulating expression of anti-apoptotic proteins (p-AKT, p-CREB, Bcl-2, and p-Src). NAD 42-45 BCL2 apoptosis regulator Homo sapiens 213-218 21115411-0 2011 Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells. ABT-737 58-65 BCL2 apoptosis regulator Homo sapiens 42-47 20822476-6 2011 We found that 15-HETE enhanced cell survival, suppressed the expression of phosphatase and tensin homologue deleted on chromosome ten, upregulated X-linked inhibitor of apoptosis protein and Bcl-2 and attenuated mitochondrial depolarization in pulmonary artery muscle smooth cells (PASMCs) under serum-deprived conditions. 15-Hete 14-21 BCL2 apoptosis regulator Homo sapiens 191-196 21115411-10 2011 CONCLUSION: We provide the first preclinical evidence that Bcl-2/Bcl-x(L) inhibition with ABT-737 synergistically enhances imatinib-induced cytotoxicity via apoptosis, and that direct engagement of apoptotic cell death may be an effective approach to circumvent imatinib-resistance in GIST. ABT-737 90-97 BCL2 apoptosis regulator Homo sapiens 59-64 21115411-10 2011 CONCLUSION: We provide the first preclinical evidence that Bcl-2/Bcl-x(L) inhibition with ABT-737 synergistically enhances imatinib-induced cytotoxicity via apoptosis, and that direct engagement of apoptotic cell death may be an effective approach to circumvent imatinib-resistance in GIST. Imatinib Mesylate 123-131 BCL2 apoptosis regulator Homo sapiens 59-64 21115411-10 2011 CONCLUSION: We provide the first preclinical evidence that Bcl-2/Bcl-x(L) inhibition with ABT-737 synergistically enhances imatinib-induced cytotoxicity via apoptosis, and that direct engagement of apoptotic cell death may be an effective approach to circumvent imatinib-resistance in GIST. Imatinib Mesylate 262-270 BCL2 apoptosis regulator Homo sapiens 59-64 21362244-7 2011 Furthermore, apoptosis-related factor (bcl-2/bax) expression levels in low concentrations penicillin and streptomycin groups were higher than that in the control group. Penicillins 90-100 BCL2 apoptosis regulator Homo sapiens 39-44 21354931-7 2011 Exposure to nitidine chloride, as shown by Western blotting, resulted in increased expressions of cleaved caspase-3, cleaved caspase-9 and Bax and decreased expressions of pro-caspase-3, pro-caspase-9 and Bcl-2. nitidine 12-29 BCL2 apoptosis regulator Homo sapiens 205-210 21134408-6 2011 Meanwhile, we found that although 24h dopamine and SKF83959 treatments have not produced major apoptosis, they induced significant neuronal dendrite retraction as well as reduction of neurotrophic molecules such as phosphorylated AKT, ERK and Bcl-2 through PLC-sensitive pathways. 9-(3-hydroxy-2-phosphonomethoxypropyl)guanine 34-37 BCL2 apoptosis regulator Homo sapiens 243-248 21134408-6 2011 Meanwhile, we found that although 24h dopamine and SKF83959 treatments have not produced major apoptosis, they induced significant neuronal dendrite retraction as well as reduction of neurotrophic molecules such as phosphorylated AKT, ERK and Bcl-2 through PLC-sensitive pathways. Dopamine 38-46 BCL2 apoptosis regulator Homo sapiens 243-248 21134408-6 2011 Meanwhile, we found that although 24h dopamine and SKF83959 treatments have not produced major apoptosis, they induced significant neuronal dendrite retraction as well as reduction of neurotrophic molecules such as phosphorylated AKT, ERK and Bcl-2 through PLC-sensitive pathways. SK and F 83959 51-59 BCL2 apoptosis regulator Homo sapiens 243-248 21425580-5 2011 Moreover, Celastrol decreased the expressions of p-Akt, survivin and Bcl-2 in the Akt signaling pathway. celastrol 10-19 BCL2 apoptosis regulator Homo sapiens 69-74 20880994-4 2011 Here, we show that single-stranded DNA modeled from the template strand of the BCL2 MBR, forms secondary structures that migrate faster on native PAGE in the presence of potassium, due to the formation of intramolecular G-quadruplexes. Potassium 170-179 BCL2 apoptosis regulator Homo sapiens 79-83 20658471-6 2011 The apoptosis induction with liquiritigenin is associated with the up-regulation of p53 and Bax, along with down-regulation of Bcl-2 and survivin. liquiritigenin 29-43 BCL2 apoptosis regulator Homo sapiens 127-132 21542284-11 2011 Further study showed that the emodin with or without gemcitabine significantly down-regulates NF-kappaB and its regulated molecules such as Bcl-2 and Survivin proteins both in vitro and in vivo. gemcitabine 53-64 BCL2 apoptosis regulator Homo sapiens 140-145 21362244-7 2011 Furthermore, apoptosis-related factor (bcl-2/bax) expression levels in low concentrations penicillin and streptomycin groups were higher than that in the control group. Streptomycin 105-117 BCL2 apoptosis regulator Homo sapiens 39-44 21823485-7 2011 CONCLUSION: The mechanism of human hepatoma BEL-7404 cells apoptosis induced by Galic acid from leaves of Phyllanthus emblica may be blocking G2/M period in cell life cycle, up-regulating the expression of Bax and down-regulating the expression of Bcl-2, that can decrease membrane potential of mitochondria,and triggered the caspases of activation of cascade and induced cell death. galic acid 80-90 BCL2 apoptosis regulator Homo sapiens 248-253 21073944-0 2011 Progallin A isolated from the acetic ether part of the leaves of Phyllanthus emblica L. induces apoptosis of human hepatocellular carcinoma BEL-7404 cells by up-regulation of Bax expression and down-regulation of Bcl-2 expression. ethyl gallate 0-11 BCL2 apoptosis regulator Homo sapiens 213-218 21304978-9 2011 Resveratrol induces apoptosis by activating capase-3/7 and inhibiting the expression of Bcl-2 and XIAP in human CSCs. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 88-93 21073944-12 2011 CONCLUSIONS: These results indicate that Progallin A has low immune toxicity in vitro and induces apoptosis of human hepatocellular carcinoma BEL-7404 cells which is related to the G1/M and G2/M arrest, and it exerts its apoptotic effect by up-regulation of Bax expression and down-regulation of Bcl-2 expression. ethyl gallate 41-52 BCL2 apoptosis regulator Homo sapiens 296-301 21093431-8 2011 Additionally, DHF-18 decreased the expression of Bcl-2 protein, whereas the levels of Bax and Bak were found to increase after DHF-18 treatment. DHF 18 14-20 BCL2 apoptosis regulator Homo sapiens 49-54 21078664-9 2011 In addition, nimbolide down-regulated cell survival proteins, including I-FLICE, cIAP-1, cIAP-2, Bcl-2, Bcl-xL, survivin, and X-linked inhibitor of apoptosis protein, and up-regulated the pro-apoptotic proteins p53 and Bax. nimbolide 13-22 BCL2 apoptosis regulator Homo sapiens 97-102 21224352-6 2011 Various proteins of the Bcl-2 family and MAPK kinases were found to be involved in amiloride-induced apoptosis. Amiloride 83-92 BCL2 apoptosis regulator Homo sapiens 24-29 21084274-1 2011 ABT-737, a small molecule cell-permeable Bcl-2 antagonist that acts by mimicking BH3 proteins, induces apoptotic cell death in multiple cancer types. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 41-46 20965163-4 2011 The results demonstrated that pretreatment of honokiol inhibited the activation of caspase-3 and caspase-9 and downregulated the expression of Bcl-2. honokiol 46-54 BCL2 apoptosis regulator Homo sapiens 143-148 21126053-2 2011 This study investigated the roles of caspase cascades, ROS, DNA damage, mitochondrial disruption, and Bax and Bcl-2 proteins in danthron-induced apoptosis of SNU-1 human gastric cancer cells, a commonly used cell culture system for in vitro studies. danthron 128-136 BCL2 apoptosis regulator Homo sapiens 110-115 20868662-6 2011 Carnosine alleviated all these alterations induced by MDA, but NAC merely inhibited Bcl-2 family-related activation of JNK and ERK. Acetylcysteine 63-66 BCL2 apoptosis regulator Homo sapiens 84-89 21173056-0 2011 Quercetin induces apoptosis by activating caspase-3 and regulating Bcl-2 and cyclooxygenase-2 pathways in human HL-60 cells. Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 67-72 21214929-8 2011 RESULTS: Combination treatments of alpha-TEA plus DOXO or CDDP act cooperatively to induce apoptosis, caspase-8 and caspase-9 cleavage, p73, phospho-c-Ab1 and phospho-JNK protein expression, and increase expression of p53 downstream mediators; namely, death receptor-5, CD95/APO-1 (Fas), Bax and Noxa, as well as Yap nuclear translocation - plus reduce expression of Bcl-2. Cisplatin 58-62 BCL2 apoptosis regulator Homo sapiens 367-372 21214929-8 2011 RESULTS: Combination treatments of alpha-TEA plus DOXO or CDDP act cooperatively to induce apoptosis, caspase-8 and caspase-9 cleavage, p73, phospho-c-Ab1 and phospho-JNK protein expression, and increase expression of p53 downstream mediators; namely, death receptor-5, CD95/APO-1 (Fas), Bax and Noxa, as well as Yap nuclear translocation - plus reduce expression of Bcl-2. 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid 35-44 BCL2 apoptosis regulator Homo sapiens 367-372 21214929-8 2011 RESULTS: Combination treatments of alpha-TEA plus DOXO or CDDP act cooperatively to induce apoptosis, caspase-8 and caspase-9 cleavage, p73, phospho-c-Ab1 and phospho-JNK protein expression, and increase expression of p53 downstream mediators; namely, death receptor-5, CD95/APO-1 (Fas), Bax and Noxa, as well as Yap nuclear translocation - plus reduce expression of Bcl-2. Doxorubicin 50-54 BCL2 apoptosis regulator Homo sapiens 367-372 21173056-5 2011 Furthermore, quercetin down-regulated the expression of anti-apoptosis protein Bcl-2 and up-regulated the expression of pro-apoptosis protein Bax. Quercetin 13-22 BCL2 apoptosis regulator Homo sapiens 79-84 21173056-8 2011 Taken together, these findings suggested that quercetin induces apoptosis in a caspase-3-dependent pathway by inhibiting Cox-2 expression and regulates the expression of downstream apoptotic components, including Bcl-2 and Bax. Quercetin 46-55 BCL2 apoptosis regulator Homo sapiens 213-218 21151158-11 2011 The guanine nucleotide exchange activity of Vav1 was required for enhancing Bcl-2 promoter activity, and the Vav1 downstream substrate, small GTPase Rac2, was likely involved in the control of Bcl-2 expression. Guanine Nucleotides 4-22 BCL2 apoptosis regulator Homo sapiens 76-81 20963498-6 2011 Immunoblot analysis revealed that the expression of p53, caspase-7 and -9 as well as the ratio of Bax/Bcl-2 protein increased significantly with higher EGCG concentrations and longer incubation times. epigallocatechin gallate 152-156 BCL2 apoptosis regulator Homo sapiens 102-107 20881478-5 2011 In addition, sorafenib exposure reduced constitutive STAT3 phosphorylation in HL60 cells and repressed STAT3 DNA-binding activity and Mcl-1 and Bcl-2 expression. Sorafenib 13-22 BCL2 apoptosis regulator Homo sapiens 144-149 20881478-9 2011 Taken together, our study indicates that sorafenib blocks Src kinase-mediated STAT3 phosphorylation and decreases the expression of apoptosis regulatory proteins Mcl-1 and Bcl-2, which are associated with increased apoptosis in HL60 cells. Sorafenib 41-50 BCL2 apoptosis regulator Homo sapiens 172-177 21677430-10 2011 HP concentrations significantly decreased the anti-apoptotic Bcl-2/Bax ratio and increased caspase-3 activity. Hematoporphyrins 0-2 BCL2 apoptosis regulator Homo sapiens 61-66 21273598-4 2011 RESULTS: Renieramycin M treatment caused p53 activation, which subsequently down-regulated anti-apoptotic MCL-1 and BCL-2 proteins, while the level of pro-apoptotic BAX protein was not altered. renieramycin M 9-23 BCL2 apoptosis regulator Homo sapiens 116-121 21376256-8 2011 RESULTS: Upregulation of Bcl-2 expression was detected in cells transfected with miR-21 mimics, accompanied by downregulated Bax expression, less apoptosis, lower caspase-3 activity, decreased chemosensitivity to gemcitabine and increased proliferation compared with the control cells. gemcitabine 213-224 BCL2 apoptosis regulator Homo sapiens 25-30 21376258-8 2011 Moreover, the Bcl-2/Bax ratio was found to be increased in cells pretreated with amlodipine, indicating an enhanced anti-apoptosis potential. Amlodipine 81-91 BCL2 apoptosis regulator Homo sapiens 14-19 22164966-1 2011 The purpose of this research work was to prepare poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles for delivery of siRNA (small interfering RNA) for silencing anti-apoptotic Bcl-2 gene in cancerous cells by using the double emulsion solvent diffusion (DESE) method. Polylactic Acid-Polyglycolic Acid Copolymer 49-79 BCL2 apoptosis regulator Homo sapiens 176-181 21376258-10 2011 CONCLUSIONS: Our data demonstrate that amlodipine ameliorates Ang II-induced endothelial apoptosis, which is likely associated with the elevation of Bcl-2/Bax ratio and reduction of the LOX-1 expression. Amlodipine 39-49 BCL2 apoptosis regulator Homo sapiens 149-154 22164966-1 2011 The purpose of this research work was to prepare poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles for delivery of siRNA (small interfering RNA) for silencing anti-apoptotic Bcl-2 gene in cancerous cells by using the double emulsion solvent diffusion (DESE) method. dese 254-258 BCL2 apoptosis regulator Homo sapiens 176-181 20836993-0 2011 Anti-apoptotic Bcl-2 fails to form efficient complexes with pro-apoptotic Bak to protect from Celecoxib-induced apoptosis. Celecoxib 94-103 BCL2 apoptosis regulator Homo sapiens 15-20 22292626-0 2011 Curcumin induces apoptosis involving bax/bcl-2 in human hepatoma SMMC-7721 cells. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 41-46 22292626-4 2011 Annexin-V/PI double staining detected by flow cytometry and expression of the relative apoptotic proteins (Bax, Bcl-2 and caspase-3) revealed a strong apoptosis-inducing competent of curcumin in SMMC-7721 cells. Curcumin 183-191 BCL2 apoptosis regulator Homo sapiens 112-117 22292626-6 2011 The results suggest that curcumin induction of apoptosis involves modulation of bax/bcl-2 in SMMC-7721 cells and provide a molecular basis for the development of naturally compounds as novel anticancer agents for human hepatomas. Curcumin 25-33 BCL2 apoptosis regulator Homo sapiens 84-89 22292626-6 2011 The results suggest that curcumin induction of apoptosis involves modulation of bax/bcl-2 in SMMC-7721 cells and provide a molecular basis for the development of naturally compounds as novel anticancer agents for human hepatomas. smmc 93-97 BCL2 apoptosis regulator Homo sapiens 84-89 23569726-3 2011 H2O2-induced apoptosis in RCC-26 was assayed with the following parameters: cell viability (% apoptosis), nucleosomal damage and DNA fragmentation, bcl-2 levels and flow cytometery analysis (ROS production evaluation). Hydrogen Peroxide 0-4 BCL2 apoptosis regulator Homo sapiens 148-153 20836993-2 2011 Apart from its inhibitor function, Celecoxib induces apoptosis through the intrinsic pathway which is controlled by the Bcl-2 family members. Celecoxib 35-44 BCL2 apoptosis regulator Homo sapiens 120-125 20836993-3 2011 In Jurkat T lymphoma cells, treatment with Celecoxib results in a rapid decline of the anti-apoptotic Bcl-2-related protein Mcl-1. Celecoxib 43-52 BCL2 apoptosis regulator Homo sapiens 102-107 21532146-8 2011 We also proved that glycyrrhizin could profoundly attenuate salbutamol-induced early cellular apoptosis by regulating the expressions of B-cell lymphoma 2 (Bcl-2) family genes. Glycyrrhizic Acid 20-32 BCL2 apoptosis regulator Homo sapiens 137-154 21628880-7 2011 TBMS I induced cell shrinkage, nuclear condensation and fragmentation, cell cycle arrest at the G2/M phase, mitochondrial membrane disruption, release of cytochrome c from the mitochondria, activation of caspase 3 and 9, and shifting Bax/Bcl-2 ratio from being anti-apoptotic to pro-apoptotic, all indicative of initiation and progression of apoptosis involving mitochondrial dysfunction. tubeimoside I 0-6 BCL2 apoptosis regulator Homo sapiens 238-243 21532146-8 2011 We also proved that glycyrrhizin could profoundly attenuate salbutamol-induced early cellular apoptosis by regulating the expressions of B-cell lymphoma 2 (Bcl-2) family genes. Glycyrrhizic Acid 20-32 BCL2 apoptosis regulator Homo sapiens 156-161 21532146-8 2011 We also proved that glycyrrhizin could profoundly attenuate salbutamol-induced early cellular apoptosis by regulating the expressions of B-cell lymphoma 2 (Bcl-2) family genes. Albuterol 60-70 BCL2 apoptosis regulator Homo sapiens 137-154 21532146-8 2011 We also proved that glycyrrhizin could profoundly attenuate salbutamol-induced early cellular apoptosis by regulating the expressions of B-cell lymphoma 2 (Bcl-2) family genes. Albuterol 60-70 BCL2 apoptosis regulator Homo sapiens 156-161 20966084-0 2011 DNA damage, DNA repair rates and mRNA expression levels of cell cycle genes (TP53, p21(CDKN1A), BCL2 and BAX) with respect to occupational exposure to styrene. Styrene 151-158 BCL2 apoptosis regulator Homo sapiens 96-100 21804218-6 2011 Furthermore, inhibition of NF-kappa B by IkBalphaSR, which is a powerful inhibitor of NF-kappa B, restored the ability of delta-elemene to induce apoptosis in the cells transfected with Bcl-2. elemene 122-135 BCL2 apoptosis regulator Homo sapiens 186-191 21804218-7 2011 These data strongly indicated that the apoptotic effect of delta-elemene on NCI-H292 was closely associated with the activity of NF-kappa B, which was up-regulated by Bcl-2 and Bcl-xL. elemene 59-72 BCL2 apoptosis regulator Homo sapiens 167-172 21804218-9 2011 The apoptotic effect of delta-elemene could be significantly offset by over-expression of either Bcl-2 or Bcl-xL. elemene 24-37 BCL2 apoptosis regulator Homo sapiens 97-102 22123186-11 2011 With more complete HER2 blockade, resistance to L-containing regimens required the activation of a redundant survival pathway, ER, which was up-regulated and promoted survival via various Bcl2 family members. l 48-49 BCL2 apoptosis regulator Homo sapiens 188-192 21804218-0 2011 B-cell lymphoma-2 over-expression protects delta-elemene-induced apoptosis in human lung carcinoma mucoepidermoid cells via a nuclear factor kappa B-related pathway. elemene 43-56 BCL2 apoptosis regulator Homo sapiens 0-17 21804218-5 2011 The cells with Bcl-2 or Bcl-xL over-expression showed an elevation of nuclear factor kappa B (NF-kappa B) activity, accompanying a significant reduction of delta-elemene-induced apoptosis. elemene 156-169 BCL2 apoptosis regulator Homo sapiens 15-20 20577262-0 2011 A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum. BH 3 10-13 BCL2 apoptosis regulator Homo sapiens 94-99 20577262-1 2011 A natural BH3-mimetic, small-molecule inhibitor of Bcl-2, (-)-gossypol, shows promise in ongoing phase II and III clinical trials for human prostate cancer. BH 3 10-13 BCL2 apoptosis regulator Homo sapiens 51-56 20577262-1 2011 A natural BH3-mimetic, small-molecule inhibitor of Bcl-2, (-)-gossypol, shows promise in ongoing phase II and III clinical trials for human prostate cancer. Gossypol 58-70 BCL2 apoptosis regulator Homo sapiens 51-56 20577262-2 2011 In this study we show that (-)-gossypol preferentially induces autophagy in androgen-independent (AI) prostate cancer cells that have high levels of Bcl-2 and are resistant to apoptosis, both in vitro and in vivo, but not in androgen-dependent (AD) cells with low Bcl-2 and sensitive to apoptosis. Gossypol 27-39 BCL2 apoptosis regulator Homo sapiens 149-154 20577262-2 2011 In this study we show that (-)-gossypol preferentially induces autophagy in androgen-independent (AI) prostate cancer cells that have high levels of Bcl-2 and are resistant to apoptosis, both in vitro and in vivo, but not in androgen-dependent (AD) cells with low Bcl-2 and sensitive to apoptosis. Gossypol 27-39 BCL2 apoptosis regulator Homo sapiens 264-269 20577262-5 2011 Our results show for the first time that (-)-gossypol can also interrupt the interactions between Beclin1 and Bcl-2/Bcl-xL at endoplasmic reticulum, thus releasing the BH3-only pro-autophagic protein Beclin1, which in turn triggers the autophagic cascade. Gossypol 41-53 BCL2 apoptosis regulator Homo sapiens 110-115 20577262-6 2011 Oral administration of (-)-gossypol significantly inhibited the growth of AI prostate cancer xenografts, representing a promising new regimen for the treatment of human hormone-refractory prostate cancer with Bcl-2 overexpression. Gossypol 23-35 BCL2 apoptosis regulator Homo sapiens 209-214 20736132-11 2011 Vitamin D inhibited extracellular signal-regulated kinase activation and down-regulated the expression of BCL-2, BCL-w, CDK1, and PCNA. Vitamin D 0-9 BCL2 apoptosis regulator Homo sapiens 106-111 22130369-7 2011 Furthermore, fangchinoline increased the expression of the proapoptotic protein B cell lymphoma-2 associated X (Bax) and decreased the expression of the antiapoptotic protein B cell lymphoma-2 (Bcl-2). fangchinoline 13-26 BCL2 apoptosis regulator Homo sapiens 80-97 22130369-7 2011 Furthermore, fangchinoline increased the expression of the proapoptotic protein B cell lymphoma-2 associated X (Bax) and decreased the expression of the antiapoptotic protein B cell lymphoma-2 (Bcl-2). fangchinoline 13-26 BCL2 apoptosis regulator Homo sapiens 175-192 22130369-7 2011 Furthermore, fangchinoline increased the expression of the proapoptotic protein B cell lymphoma-2 associated X (Bax) and decreased the expression of the antiapoptotic protein B cell lymphoma-2 (Bcl-2). fangchinoline 13-26 BCL2 apoptosis regulator Homo sapiens 194-199 21273177-3 2011 The reverse sequence of docetaxel before bortezomib was associated with increased apoptosis, cleavage of caspase-3 and PARP (poly [ADP-ribose] polymerase), and reduction in Bcl-2. Docetaxel 24-33 BCL2 apoptosis regulator Homo sapiens 173-178 19815401-9 2011 After cells were treated with juglone at the same dose for 24h, the level of ROS was significantly higher, the expression of Bcl-2 was significantly down-regulated and the expression of Bax was significantly up-regulated compared to the control. juglone 30-37 BCL2 apoptosis regulator Homo sapiens 125-130 19815401-12 2011 In conclusion, juglone can induce apoptosis in SGC-7901 cells through a mitochondrial pathway that seems to be mediated by the generation of ROS and a reduction in the Bcl-2/Bax ratio. juglone 15-22 BCL2 apoptosis regulator Homo sapiens 168-173 22150312-6 2011 Targeting SALL4, particularly when combined with the use of ABT-737, a BCL2 antagonist, could lead to leukemic cell-specific apoptosis. ABT-737 60-67 BCL2 apoptosis regulator Homo sapiens 71-75 20957341-9 2011 Transfection of VSMC from non-diabetic patients with a plasmid containing COX-2 (also known as PTGS2) increased basal production of COX-2 and BCL2 and mimicked the resistance to apoptosis that occurs in diabetic patients. vsmc 16-20 BCL2 apoptosis regulator Homo sapiens 142-146 20933077-6 2011 These results suggest that expression of SAD mitochondrial genes in cybrids activates oxidative-stress-related signaling pathways and reduces viability, and that the protective effects of puerarin inhibit oxidative-stress-induced apoptosis through down-regulation of Bax/Bcl-2 ratio, which blocks the activation of JNK, p38 and caspase-3. puerarin 188-196 BCL2 apoptosis regulator Homo sapiens 271-276 20736132-14 2011 CONCLUSION(S): Vitamin D inhibits growth of HuLM cells through the down-regulation of PCNA, CDK1, and BCL-2 and suppresses COMT expression and activity in HuLM cells. Vitamin D 15-24 BCL2 apoptosis regulator Homo sapiens 102-107 20940027-6 2011 Increase of the Bax/Bcl-2 ratio and activation of caspase-3 might be due to intracellular polyamine depletion. Polyamines 90-99 BCL2 apoptosis regulator Homo sapiens 20-25 20720574-8 2011 Interestingly, the knockdown of bcl-2 sensitized cells to TK/GCV. Ganciclovir 61-64 BCL2 apoptosis regulator Homo sapiens 32-37 21196331-5 2011 SFN induced apoptosis by inhibiting the expression of Bcl-2 and XIAP, phosphorylation of FKHR, and activating caspase-3. sulforaphane 0-3 BCL2 apoptosis regulator Homo sapiens 54-59 22038216-1 2011 The aim of this study was to evaluate the expression of COX-2 and Bcl-2 in primary fallopian tube carcinoma (PFTC), as well as their correlations with clinicopathologic features. pftc 109-113 BCL2 apoptosis regulator Homo sapiens 66-71 21056612-6 2011 Our results suggest that the protective effects of AST on MPP+-induced apoptosis may be due to its anti-oxidative properties and anti-apoptotic activity via induction of expression of superoxide dismutase (SOD) and catalase and regulating the expression of Bcl-2 and Bax. mangion-purified polysaccharide (Candida albicans) 58-62 BCL2 apoptosis regulator Homo sapiens 257-262 22038216-12 2011 We conclude that COX-2 and Bcl-2 may potentially be useful prognostic markers for PFTC. pftc 82-86 BCL2 apoptosis regulator Homo sapiens 27-32 21720514-7 2011 Further study demonstrated that both DNR/Br Tet-MNPs and DNR/Br Tet-Sol reduced the gene transcriptions and protein expressions of bcl-2 and survivin and enhanced that of bax and caspase 3. tetramethylenedisulfotetramine 44-47 BCL2 apoptosis regulator Homo sapiens 131-136 21968975-7 2011 Further analyses indicated that anti-apoptotic factor Bcl2 might be a factor responsible for the fact that depleting intracellular GSH could not hyper-sensitize H69AR cells to daunomycin. Glutathione 131-134 BCL2 apoptosis regulator Homo sapiens 54-58 21968975-8 2011 We hypothesized that knocking down the expression of Bcl2 could hyper-sensitize H69AR cells to daunomycin. Daunorubicin 95-105 BCL2 apoptosis regulator Homo sapiens 53-57 21968975-9 2011 Interestingly, infection of H69AR cells with retroviral particles harboring Bcl2 interfering RNAi not only reduced the expression of Bcl2, but also many factors that contribute to MDR, such as Bcl-xl, MRP1 and ABCC3, etc., leading to the MDR H69AR cells more sensitive to daunomycin than the parental H69 cell. Daunorubicin 272-282 BCL2 apoptosis regulator Homo sapiens 76-80 21747710-8 2011 K562 cells in the tryptanthrin treated group exhibited an increase in cytosol cyt-c, Bax and activated caspase-3 expression while a decrease in Bcl-2, mito cyt-c and pro-caspase-3 contents. tryptanthrine 18-30 BCL2 apoptosis regulator Homo sapiens 144-149 21731431-4 2011 Here we show that the calpain activator dibucaine induced several platelet apoptotic events including depolarization of the mitochondrial inner transmembrane potential, up-regulation of Bax and Bak, down-regulation of Bcl-2 and Bcl-X(L), caspase-3 activation and phosphatidylserine exposure. Dibucaine 40-49 BCL2 apoptosis regulator Homo sapiens 218-223 21822380-6 2011 Our results also showed that treatment with the copolymer of MNPs-Fe(3)O(4) and ART increased the expression of bcl-2, bax, bcl-rambo, and caspase-3 proteins, and decreased the expression of survivin protein in K562 cells compared with ART treatment alone. fe(3)o 66-72 BCL2 apoptosis regulator Homo sapiens 112-117 21720514-7 2011 Further study demonstrated that both DNR/Br Tet-MNPs and DNR/Br Tet-Sol reduced the gene transcriptions and protein expressions of bcl-2 and survivin and enhanced that of bax and caspase 3. tetramethylenedisulfotetramine 64-67 BCL2 apoptosis regulator Homo sapiens 131-136 21122037-10 2011 The diketopiperazine disulfides were found to induce apoptosis in HCT116 cells based on cell morphology, DNA fragmentation observed by agarose gel electrophoresis, Annexin-V/PI staining using a flow cytometer and cleavage of poly (ADP-ribose) polymerase (PARP), caspase-3, caspase-8, caspase-9 and Bcl-2 family proteins (Bcl-2, Bcl-xL and Bax) using Western blotting analysis. diketopiperazine disulfides 4-31 BCL2 apoptosis regulator Homo sapiens 298-303 21963730-9 2011 CONCLUSION: Phytoestrogen gave protection against high glucose-induced pancreatic cell damage through estrogen receptor beta and Bcl-2 dependent pathways. Glucose 55-62 BCL2 apoptosis regulator Homo sapiens 129-134 22091435-1 2011 Mechanism of chemoprevention by daidzein (500 mug/g bwt) was examined by injecting it subcutaneously at 16th, 18th, and 20th day postpartum, followed by counting of terminal end buds (TEBs), terminal ducts (TDs), and lobules and immunohistochemistry of ER-alpha, Bcl2, Bax, and caspase-3. daidzein 32-40 BCL2 apoptosis regulator Homo sapiens 263-267 22091435-6 2011 The ratio of expression of Bcl-2 to Bax proteins increased at PND50 the same whereas, it decreased at PND50 due to daidzein. daidzein 115-123 BCL2 apoptosis regulator Homo sapiens 27-32 21325776-6 2011 The pro-apoptotic effect of EPA or ARA was completely blocked in U937/Bcl-2 cells. Eicosapentaenoic Acid 28-31 BCL2 apoptosis regulator Homo sapiens 70-75 21122037-10 2011 The diketopiperazine disulfides were found to induce apoptosis in HCT116 cells based on cell morphology, DNA fragmentation observed by agarose gel electrophoresis, Annexin-V/PI staining using a flow cytometer and cleavage of poly (ADP-ribose) polymerase (PARP), caspase-3, caspase-8, caspase-9 and Bcl-2 family proteins (Bcl-2, Bcl-xL and Bax) using Western blotting analysis. diketopiperazine disulfides 4-31 BCL2 apoptosis regulator Homo sapiens 321-326 21325776-6 2011 The pro-apoptotic effect of EPA or ARA was completely blocked in U937/Bcl-2 cells. Arachidonic Acid 35-38 BCL2 apoptosis regulator Homo sapiens 70-75 21716649-6 2011 UA activated caspase-3, -8, and -9 and down regulated expression of Bcl-2 in BGC-803 cells. ursolic acid 0-2 BCL2 apoptosis regulator Homo sapiens 68-73 20625998-8 2011 Our findings revealed that PPDE contains potent pro-apoptotic factors that regulate expression of GATA-4 and Bcl-2 families, inducing cultured cardiomyocyte apoptosis. ppde 27-31 BCL2 apoptosis regulator Homo sapiens 109-114 21403907-9 2011 Moreover, compared with 5-FU alone, the apoptosis of CRC cells treated with DCA and 5-FU was enhanced and demonstrated with the changes of Bcl-2, Bax, and caspase-3 proteins. Dichloroacetic Acid 76-79 BCL2 apoptosis regulator Homo sapiens 139-144 21403907-9 2011 Moreover, compared with 5-FU alone, the apoptosis of CRC cells treated with DCA and 5-FU was enhanced and demonstrated with the changes of Bcl-2, Bax, and caspase-3 proteins. Fluorouracil 84-88 BCL2 apoptosis regulator Homo sapiens 139-144 21628860-2 2011 It is considered that BCL2 translocation precedes MYC events in lymphomagenesis of DHL. Cysteamine 83-86 BCL2 apoptosis regulator Homo sapiens 22-26 21069738-8 2011 Furanodienone treatment inhibited E2-stimulation of estrogen response element (ERE)-driven reporter plasmid activity and ablated E2-targeted gene (e.g., c-Myc, Bcl-2, and cyclin D1) expression which resulted in the inhibition of cell cycle progression and cell proliferation, and in the induction of apoptosis. furanodienone 0-13 BCL2 apoptosis regulator Homo sapiens 160-165 20947636-3 2011 Using an iron-overloaded gerbil model, we show that increased cardiac iron is associated with reduced activation of Akt (Ser473 and Thr308), diminished phosphorylation of the proapoptotic regulator Bad (Ser136), and an increased Bax/Bcl-2 ratio. Iron 70-74 BCL2 apoptosis regulator Homo sapiens 233-238 20140889-8 2011 Elimination of the Ca(2+)-binding capacity by substitution of the respective aspartate residues in a D92N/D94N double-substituted variant reduces the Bcl-2 affinity of the FKBP38(35-153)/CaM complex to the same degree as the presence of Ca(2+) in the wild-type protein. Aspartic Acid 77-86 BCL2 apoptosis regulator Homo sapiens 150-155 20964705-6 2011 Antiapoptotic effects of melatonin were related to a reduced expression of Bax and cytosolic cytochrome c release, increased expression of Bcl-2 and Bcl-xL, and inhibition of caspase-9 activity. Melatonin 25-34 BCL2 apoptosis regulator Homo sapiens 139-144 21776258-6 2011 Finally, we determined that the antioxidative properties of 24-Epi lead to the inhibition of MPP(+)-induced apoptosis by reducing DNA fragmentation as well as the Bax/Bcl-2 protein ratio and cleaved caspase-3. mangion-purified polysaccharide (Candida albicans) 93-99 BCL2 apoptosis regulator Homo sapiens 167-172 21063685-6 2011 In addition, real-time PCR and western blot studies showed that Bcl-2 and Bcl-w expressions were decreased, and Bax expression was increased with H2O2 treatment. Hydrogen Peroxide 146-150 BCL2 apoptosis regulator Homo sapiens 64-69 21461558-0 2011 Tubeimoside-1 inhibits proliferation and induces apoptosis by increasing the Bax to Bcl-2 ratio and decreasing COX-2 expression in lung cancer A549 cells. tubeimoside I 0-13 BCL2 apoptosis regulator Homo sapiens 84-89 21063685-10 2011 L-NBP treatment at dose of 10 muM inhibited H2O2-induced down-regulation of Bcl-2, Bcl-w, and PKCalpha but also attenuated the overexpression of Bax. l-nbp 0-5 BCL2 apoptosis regulator Homo sapiens 76-81 21737576-4 2011 An ultrasensitive quantitative real-time polymerase chain reaction methodology for BCL2L12 and BCL2 mRNA quantification was developed using SYBR Green chemistry. sybr green 140-150 BCL2 apoptosis regulator Homo sapiens 83-87 21063685-10 2011 L-NBP treatment at dose of 10 muM inhibited H2O2-induced down-regulation of Bcl-2, Bcl-w, and PKCalpha but also attenuated the overexpression of Bax. Hydrogen Peroxide 44-48 BCL2 apoptosis regulator Homo sapiens 76-81 21919647-4 2011 In addition, ascorbic acid decreased expression of several Sp-regulated genes that are involved in cancer cell proliferation [hepatocyte growth factor receptor (c-Met), epidermal growth factor receptor and cyclin D1], survival (survivin and bcl-2), and angiogenesis [vascular endothelial growth factor (VEGF) and its receptors (VEGFR1 and VEGFR2)]. Ascorbic Acid 13-26 BCL2 apoptosis regulator Homo sapiens 241-246 21473291-5 2011 Our data indicates that ATO can inhibit the proliferation of BL cell lines through 1) arresting the cell cycle; 2) decreasing the respiratory function and transmembrane potential of mitochondrial; and 3) downregulating the expressions of Survivin, Bcl-2, MCL-1, and VEGF. Arsenic Trioxide 24-27 BCL2 apoptosis regulator Homo sapiens 248-253 21776823-5 2011 Metformin induced apoptosis by arresting cells in G1 phase and reducing cyclin D level and increasing the expression of p21 and cyclin E. Molecular and cellular studies indicated that metformin significantly elevated p53 and Bax levels and reduced STAT3 and Bcl-2. Metformin 184-193 BCL2 apoptosis regulator Homo sapiens 258-263 21776823-5 2011 Metformin induced apoptosis by arresting cells in G1 phase and reducing cyclin D level and increasing the expression of p21 and cyclin E. Molecular and cellular studies indicated that metformin significantly elevated p53 and Bax levels and reduced STAT3 and Bcl-2. Metformin 0-9 BCL2 apoptosis regulator Homo sapiens 258-263 21857083-7 2011 Furthermore, curcumin enhanced expression of H2O2-induced pro-apoptotic protein Bax expression and inhibited expression of anti-apoptotic proteins Bcl-2 and Bcl-xL. Curcumin 13-21 BCL2 apoptosis regulator Homo sapiens 147-152 22301921-9 2011 The expression of downstream target genes of the Hedgehog pathway such as Gli1, Ptc1, CCND1 and BCL-2 were significantly decreased after 12.5 muM resveratrol treatment, which demonstrated a similar change of gene expression when Gli1 was knocked down by the RNAi technique in PANC-1 cells. Resveratrol 146-157 BCL2 apoptosis regulator Homo sapiens 96-101 22301921-10 2011 Resveratrol also downregulated the expression of Gli1, Ptc1, CCND1 and BCL-2 in Gli1-overexpressed BxPC-3 cells. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 71-76 22087318-3 2011 Here, we report that grape seed proanthocyanidins (GSPs) induce apoptosis of NSCLC cells, A549 and H1299, in vitro which is mediated through increased expression of pro-apoptotic protein Bax, decreased expression of anti-apoptotic proteins Bcl2 and Bcl-xl, disruption of mitochondrial membrane potential, and activation of caspases 9, 3 and poly (ADP-ribose) polymerase (PARP). Proanthocyanidins 32-49 BCL2 apoptosis regulator Homo sapiens 240-244 22216150-0 2011 Induction of Bcl-2 expression by hepatitis B virus pre-S2 mutant large surface protein resistance to 5-fluorouracil treatment in Huh-7 cells. Fluorouracil 101-115 BCL2 apoptosis regulator Homo sapiens 13-18 22216150-8 2011 Induction of Bcl-2 expression by HBV pre-S2Delta protein resulted in resistance to 5-fluorouracil treatment in colony formation, caspase-3 assay, and cell apoptosis, and can enhance cell death by co-incubation with Bcl-2 inhibitor. Fluorouracil 83-97 BCL2 apoptosis regulator Homo sapiens 13-18 22216150-8 2011 Induction of Bcl-2 expression by HBV pre-S2Delta protein resulted in resistance to 5-fluorouracil treatment in colony formation, caspase-3 assay, and cell apoptosis, and can enhance cell death by co-incubation with Bcl-2 inhibitor. Fluorouracil 83-97 BCL2 apoptosis regulator Homo sapiens 215-220 22216150-10 2011 CONCLUSION/SIGNIFICANCE: Our result demonstrates that HBV pre-S2Delta increased Bcl-2 expression which plays an important role in resistance to 5-fluorouracil-caused cell death. Fluorouracil 144-158 BCL2 apoptosis regulator Homo sapiens 80-85 22087285-8 2011 Furthermore, Bcl-2 was down-regulated whereas TRAIL-R1/DR4 and TRAIL-R2/DR5 expression was increased following the treatment of CSCs with GDC-0449. HhAntag691 138-146 BCL2 apoptosis regulator Homo sapiens 13-18 22096572-6 2011 FE induces mitochondrial membrane permeabilization (MMP) through loss of mitochondrial membrane potential (DeltaPsim) and regulation of the expression of Bcl-2 family members. Iron 0-2 BCL2 apoptosis regulator Homo sapiens 154-159 22096572-11 2011 CONCLUSIONS/SIGNIFICANCE: These data suggest that FE activates a caspase-independent apoptotic pathway in MCF-7 cancer cells through activation of ROS-mediated MAP kinases and regulation of the Bcl-2 family protein-mediated mitochondrial pathway. Iron 50-52 BCL2 apoptosis regulator Homo sapiens 194-199 22087318-3 2011 Here, we report that grape seed proanthocyanidins (GSPs) induce apoptosis of NSCLC cells, A549 and H1299, in vitro which is mediated through increased expression of pro-apoptotic protein Bax, decreased expression of anti-apoptotic proteins Bcl2 and Bcl-xl, disruption of mitochondrial membrane potential, and activation of caspases 9, 3 and poly (ADP-ribose) polymerase (PARP). Grape Seed Proanthocyanidins 51-55 BCL2 apoptosis regulator Homo sapiens 240-244 21949692-1 2011 As single agents, ABT-263 and ABT-737 (ABT), molecular antagonists of the Bcl-2 family, bind tightly to Bcl-2, Bcl-xL and Bcl-w, but not to Mcl-1, and induce apoptosis only in limited cell types. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 18-21 BCL2 apoptosis regulator Homo sapiens 74-79 21991326-10 2011 Stearic acid increased Bcl-2 expression in PCMDS, whereas oleic and linoleic acids had no effects. stearic acid 0-12 BCL2 apoptosis regulator Homo sapiens 23-28 21991326-11 2011 In contrast, alpha-linolenic acid decreased the proliferation and the survival of CML cell lines as well as BCL-2 and OB-R expression. alpha-Linolenic Acid 13-33 BCL2 apoptosis regulator Homo sapiens 108-113 21991326-12 2011 The effect of alpha-linolenic acids seemed to be due to PI3K pathway and Bcl-2 inhibition. alpha-Linolenic Acid 14-35 BCL2 apoptosis regulator Homo sapiens 73-78 21991326-14 2011 In the presence of leptin, the effect of alpha-linolenic acid on proliferation, survival, OB-R and BCl-2 expression was reduced. alpha-Linolenic Acid 41-61 BCL2 apoptosis regulator Homo sapiens 99-104 22096607-10 2011 Mutating either S111 or S112 to alanine enhanced binding to Bcl-2, but the double mutant S111/112A bound better to Bcl-2. Alanine 32-39 BCL2 apoptosis regulator Homo sapiens 60-65 21949692-1 2011 As single agents, ABT-263 and ABT-737 (ABT), molecular antagonists of the Bcl-2 family, bind tightly to Bcl-2, Bcl-xL and Bcl-w, but not to Mcl-1, and induce apoptosis only in limited cell types. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 18-21 BCL2 apoptosis regulator Homo sapiens 104-109 21957481-3 2011 Despite high expression of resistance-inducing genes like MDR1, Bcl2 and Bcl-xl, 15d-PGJ(2) strongly induced apoptosis in doxorubicin-resistant (A2780/AD) cells similar to the wild-type (A2780). Doxorubicin 122-133 BCL2 apoptosis regulator Homo sapiens 64-68 21949692-1 2011 As single agents, ABT-263 and ABT-737 (ABT), molecular antagonists of the Bcl-2 family, bind tightly to Bcl-2, Bcl-xL and Bcl-w, but not to Mcl-1, and induce apoptosis only in limited cell types. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 30-33 BCL2 apoptosis regulator Homo sapiens 74-79 21949692-1 2011 As single agents, ABT-263 and ABT-737 (ABT), molecular antagonists of the Bcl-2 family, bind tightly to Bcl-2, Bcl-xL and Bcl-w, but not to Mcl-1, and induce apoptosis only in limited cell types. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 30-33 BCL2 apoptosis regulator Homo sapiens 104-109 21949692-1 2011 As single agents, ABT-263 and ABT-737 (ABT), molecular antagonists of the Bcl-2 family, bind tightly to Bcl-2, Bcl-xL and Bcl-w, but not to Mcl-1, and induce apoptosis only in limited cell types. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 30-33 BCL2 apoptosis regulator Homo sapiens 74-79 21949692-1 2011 As single agents, ABT-263 and ABT-737 (ABT), molecular antagonists of the Bcl-2 family, bind tightly to Bcl-2, Bcl-xL and Bcl-w, but not to Mcl-1, and induce apoptosis only in limited cell types. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 30-33 BCL2 apoptosis regulator Homo sapiens 104-109 21901118-9 2011 Furthermore, with GRP78 synthesis inhibitor momitoxin (VT) and PKR inhibitor 2-aminopurine (2-AP) treatment for blocking GRP78 expression and eIF2alpha phosphorylation, PKR/PERK may involve in eIF2alpha phosphorylation/CHOP upregulation pathway that enhances the downstream regulators Bcl-2 family proteins expression and increased cell survival. momitoxin 44-53 BCL2 apoptosis regulator Homo sapiens 285-290 21901143-4 2011 In this report, we showed that the replication and transcription activator (RTA) encoded by KSHV ORF 50, a key regulator for KSHV reactivation from latent to lytic infection, upregulates the mRNA and protein levels of Bcl-2 in 293 cells, and TPA-induced KSHV-infected cells. Tetradecanoylphorbol Acetate 242-245 BCL2 apoptosis regulator Homo sapiens 218-223 21897857-6 2011 Butenolide also induced apoptosis in HeLa cells, with the activation of c-Jun N-terminal kinases (JNK), Bcl-2 family proteins, and caspases and proteasomes/lysosomes involved in this process. butenolide 0-10 BCL2 apoptosis regulator Homo sapiens 104-109 21901118-9 2011 Furthermore, with GRP78 synthesis inhibitor momitoxin (VT) and PKR inhibitor 2-aminopurine (2-AP) treatment for blocking GRP78 expression and eIF2alpha phosphorylation, PKR/PERK may involve in eIF2alpha phosphorylation/CHOP upregulation pathway that enhances the downstream regulators Bcl-2 family proteins expression and increased cell survival. 2-Aminopurine 77-90 BCL2 apoptosis regulator Homo sapiens 285-290 21897876-4 2011 The BH3 mimetic ABT-737, which can induce apoptosis by targeting pro-survival Bcl-2 family members, has been found to enhance the efficacy of many conventional chemotherapeutic agents in multiple cancers. BH 3 4-7 BCL2 apoptosis regulator Homo sapiens 78-83 21897876-4 2011 The BH3 mimetic ABT-737, which can induce apoptosis by targeting pro-survival Bcl-2 family members, has been found to enhance the efficacy of many conventional chemotherapeutic agents in multiple cancers. ABT-737 16-23 BCL2 apoptosis regulator Homo sapiens 78-83 21901118-9 2011 Furthermore, with GRP78 synthesis inhibitor momitoxin (VT) and PKR inhibitor 2-aminopurine (2-AP) treatment for blocking GRP78 expression and eIF2alpha phosphorylation, PKR/PERK may involve in eIF2alpha phosphorylation/CHOP upregulation pathway that enhances the downstream regulators Bcl-2 family proteins expression and increased cell survival. 2-Aminopurine 92-96 BCL2 apoptosis regulator Homo sapiens 285-290 21829603-1 2011 Our study aims to study the therapeutic effects of a novel Bcl-2 inhibitor, ABT-263, on hepatocellular carcinoma (HCC) and to provide primary preclinical data for future clinical trial with ABT-263. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 76-79 BCL2 apoptosis regulator Homo sapiens 59-64 21829603-1 2011 Our study aims to study the therapeutic effects of a novel Bcl-2 inhibitor, ABT-263, on hepatocellular carcinoma (HCC) and to provide primary preclinical data for future clinical trial with ABT-263. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 190-193 BCL2 apoptosis regulator Homo sapiens 59-64 21695177-9 2011 The apoptosis induced by THA was evident by induction of DNA fragmentation, release of cytoplasmic Cytochrome c from mitochondria, activation of caspases, downregulation of Bcl-2 and upregulation of Bax. tha 25-28 BCL2 apoptosis regulator Homo sapiens 173-178 21720559-6 2011 Furthermore, honokiol treatment led to augmentation of Bax/Bcl-2 and Bax/Bcl-xL ratios to favor apoptosis in pancreatic cancer cells. honokiol 13-21 BCL2 apoptosis regulator Homo sapiens 59-64 21720561-10 2011 We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 3-deazaneplanocin 46-51 BCL2 apoptosis regulator Homo sapiens 19-24 21720561-10 2011 We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 3-deazaneplanocin 92-97 BCL2 apoptosis regulator Homo sapiens 19-24 21720561-10 2011 We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 3-deazaneplanocin 92-97 BCL2 apoptosis regulator Homo sapiens 113-118 21720561-10 2011 We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ABT-737 102-109 BCL2 apoptosis regulator Homo sapiens 19-24 21720561-10 2011 We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ABT-737 102-109 BCL2 apoptosis regulator Homo sapiens 113-118 21720561-10 2011 We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 3-deazaneplanocin 92-97 BCL2 apoptosis regulator Homo sapiens 19-24 21720561-10 2011 We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 3-deazaneplanocin 92-97 BCL2 apoptosis regulator Homo sapiens 113-118 21203485-5 2010 As current small organic antagonists of Bcl-2 do not target BHRF1, the structures of it in complex with Bim or Bak shown here will be useful to guide efforts to target BHRF1 in EBV-associated malignancies, which are usually associated with poor clinical outcomes. bim 104-107 BCL2 apoptosis regulator Homo sapiens 40-45 20880848-10 2010 Activation of AMPK by TMZ also inhibits mTOR complex 1 (mTORC1) signaling and promotes anti-apoptosis protein Bcl-2 down-regulation, which together mediate TMZ-induced pro-cell apoptosis effects. Temozolomide 22-25 BCL2 apoptosis regulator Homo sapiens 110-115 20880848-10 2010 Activation of AMPK by TMZ also inhibits mTOR complex 1 (mTORC1) signaling and promotes anti-apoptosis protein Bcl-2 down-regulation, which together mediate TMZ-induced pro-cell apoptosis effects. Temozolomide 156-159 BCL2 apoptosis regulator Homo sapiens 110-115 21963974-4 2011 The Western blot assay indicated that the expression of Bcl-2 was decreased more in A549 cells treated with N-(3-trifluoromethylphenyl) retinamide than that in A549 cells treated with ATRA. n-(3-trifluoromethylphenyl) retinamide 108-146 BCL2 apoptosis regulator Homo sapiens 56-61 21963974-4 2011 The Western blot assay indicated that the expression of Bcl-2 was decreased more in A549 cells treated with N-(3-trifluoromethylphenyl) retinamide than that in A549 cells treated with ATRA. Tretinoin 184-188 BCL2 apoptosis regulator Homo sapiens 56-61 21963974-7 2011 The apoptosis of A549 cells induced by N-(3-trifluoromethylphenyl) retinamide may be related to downregulating the expression of Bcl-2. n-(3-trifluoromethylphenyl) retinamide 39-77 BCL2 apoptosis regulator Homo sapiens 129-134 21278889-8 2010 This potentiation of cisplatin activity was associated with HDAC inhibitor-mediated down-regulation of Bcl-2 and XIAP. Cisplatin 21-30 BCL2 apoptosis regulator Homo sapiens 103-108 20732448-9 2010 Addition of sodium nitroprusside (SNP), a nitric oxide donor to cells irradiated in vitro inhibited the repair of DNA damage and enhanced apoptosis (increased Bax to Bcl-2 ratio). Nitroprusside 12-32 BCL2 apoptosis regulator Homo sapiens 166-171 21223758-5 2010 The expressions of Bcl-2, Bax and Caspase-3 in HeLa cells induced by paeoniflorin were detected by immunocytochemistry. peoniflorin 69-81 BCL2 apoptosis regulator Homo sapiens 19-24 21223758-10 2010 There was a lowered expression of Bcl-2 and an elevated expression of Bax and Caspase-3 genes versus the control group after a 48-hour paeoniflorin treatment (P < 0.05). peoniflorin 135-147 BCL2 apoptosis regulator Homo sapiens 34-39 21223758-11 2010 CONCLUSION: Paeoniflorin can significantly induce the apoptosis of HeLa cells through a down-regulation of anti-apoptotic gene Bcl-2 and an up-regulation of pro-apoptotic genes Bax and Caspase-3. peoniflorin 12-24 BCL2 apoptosis regulator Homo sapiens 127-132 21159167-4 2010 RESULTS: U0126 significantly modulated endogenous expression of several important drug resistance (BCL2, ABCB1, ABCC3), prosurvival (BCL2), DNA repair (BRCA1, BRCA2), hormone receptor (AR, ESR2, PPARgamma) and drug metabolism (CYP3A4) genes newly identified in MM cells. U 0126 9-14 BCL2 apoptosis regulator Homo sapiens 99-103 21074517-5 2010 Additionally, GB suppresses the activation of TNF-alpha/NF-kappaB and decreases XIAP expression levels and the ratio of Bcl-2/Bax, which in turn induces HeLa cell apoptosis. gambogic acid 14-16 BCL2 apoptosis regulator Homo sapiens 120-125 20930068-5 2010 Our data demonstrate that bortezomib is capable of killing B-NHL cells via multiple mechanisms, regardless of their basal apoptotic potential, and contributes to growing evidence that proteasome inhibitors can act via modulation of B-cell lymphoma 2 (Bcl-2) family proteins. Bortezomib 26-36 BCL2 apoptosis regulator Homo sapiens 232-249 20930068-5 2010 Our data demonstrate that bortezomib is capable of killing B-NHL cells via multiple mechanisms, regardless of their basal apoptotic potential, and contributes to growing evidence that proteasome inhibitors can act via modulation of B-cell lymphoma 2 (Bcl-2) family proteins. Bortezomib 26-36 BCL2 apoptosis regulator Homo sapiens 251-256 20868669-4 2010 Trichostatin A induced nuclear damage, decreased Bid and Bcl-2 protein levels, increased in Bax levels, induced cytochrome c release, activated caspase-8, -9 and -3, and increased tumor suppressor p53 levels. trichostatin A 0-14 BCL2 apoptosis regulator Homo sapiens 57-62 21168768-2 2010 To harness the robust binding affinity and selectivity of structured peptides for interactome discovery, we engineered photoreactive stapled BH3 peptide helices that covalently capture their physiologic BCL-2 family targets. BH 3 141-144 BCL2 apoptosis regulator Homo sapiens 203-208 21159167-4 2010 RESULTS: U0126 significantly modulated endogenous expression of several important drug resistance (BCL2, ABCB1, ABCC3), prosurvival (BCL2), DNA repair (BRCA1, BRCA2), hormone receptor (AR, ESR2, PPARgamma) and drug metabolism (CYP3A4) genes newly identified in MM cells. U 0126 9-14 BCL2 apoptosis regulator Homo sapiens 133-137 20674153-2 2010 Icariin triggered the mitochondrial/caspase apoptotic pathway indicated by enhanced Bax-to-Bcl-2 ratio, loss of mitochondrial membrane potential, cytochrome c release, and caspase cascade. icariin 0-7 BCL2 apoptosis regulator Homo sapiens 91-96 20920558-10 2010 The Bcl-2 mRNA and protein expressions were decreased in lung epithelial cells treated with PDTC/Cu complex, which could be reversed by SP600125. pyrazolanthrone 136-144 BCL2 apoptosis regulator Homo sapiens 4-9 21063407-11 2010 Small BH3 mimetic molecules should be considered for further apoptosis-based therapy in myeloma cells expressing endogenous Bik/Bcl-2 complexes. BH 3 6-9 BCL2 apoptosis regulator Homo sapiens 128-133 21104938-4 2010 FNQ-induced apoptosis was accompanied with Bax up-regulation and the down-regulation of Bcl-2, X-linked inhibitor of apoptosis (XIAP), and survivin, resulting in cytochrome c release and sequential activation of caspase-9 and caspase-3. furano-1,2-naphthoquinone 0-3 BCL2 apoptosis regulator Homo sapiens 88-93 21129193-6 2010 In addition, the autofluorescent drug monodansylcadaverine (MDC), a specific autophagolysosome marker, accumulated in vacuoles after C-DIM treatment, and western blot analysis of lysates from cells treated with C-DIMs showed that the Beclin 1/Bcl-2 protein ratio increased. monodansylcadaverine 38-58 BCL2 apoptosis regulator Homo sapiens 243-248 21129193-6 2010 In addition, the autofluorescent drug monodansylcadaverine (MDC), a specific autophagolysosome marker, accumulated in vacuoles after C-DIM treatment, and western blot analysis of lysates from cells treated with C-DIMs showed that the Beclin 1/Bcl-2 protein ratio increased. monodansylcadaverine 60-63 BCL2 apoptosis regulator Homo sapiens 243-248 21122152-0 2010 Boron neutron capture therapy induces apoptosis of glioma cells through Bcl-2/Bax. Boron 0-5 BCL2 apoptosis regulator Homo sapiens 72-77 21104938-6 2010 The combined treatment of FNQ with AG1478 (a specific EGFR inhibitor) significantly enhanced the G(2)/M arrest and apoptosis, and also led to up-regulation in Bax, p53, p21, p27, release of mitochondrial cytochrome c, and down-regulation of Bcl-2, XIAP, survivin, cyclin A, cyclin B, Cdk1, and Cdk2 in A549 cells. RTKI cpd 35-41 BCL2 apoptosis regulator Homo sapiens 241-246 21104938-6 2010 The combined treatment of FNQ with AG1478 (a specific EGFR inhibitor) significantly enhanced the G(2)/M arrest and apoptosis, and also led to up-regulation in Bax, p53, p21, p27, release of mitochondrial cytochrome c, and down-regulation of Bcl-2, XIAP, survivin, cyclin A, cyclin B, Cdk1, and Cdk2 in A549 cells. furano-1,2-naphthoquinone 26-29 BCL2 apoptosis regulator Homo sapiens 241-246 20638780-7 2010 We further show that JNK and p38 MAPK act upstream of Bcl-2 expression in Fas-treated DU145 cells, and that cryptotanshinone significantly blocked activation of these kinases. ammonium ferrous sulfate 74-77 BCL2 apoptosis regulator Homo sapiens 54-59 21102482-0 2010 Involvement of Bcl-2, Src, and ERalpha in gossypol-mediated growth inhibition and apoptosis in human uterine leiomyoma and myometrial cells. Gossypol 42-50 BCL2 apoptosis regulator Homo sapiens 15-20 20633010-6 2010 5-FU induced p53 and p21 accumulation together with a decrease in cyclin B1 and Bcl-2 levels in treated keloid fibroblasts. Fluorouracil 0-4 BCL2 apoptosis regulator Homo sapiens 80-85 20638780-0 2010 Cryptotanshinone sensitizes DU145 prostate cancer cells to Fas(APO1/CD95)-mediated apoptosis through Bcl-2 and MAPK regulation. cryptotanshinone 0-16 BCL2 apoptosis regulator Homo sapiens 101-106 20638780-0 2010 Cryptotanshinone sensitizes DU145 prostate cancer cells to Fas(APO1/CD95)-mediated apoptosis through Bcl-2 and MAPK regulation. ammonium ferrous sulfate 59-62 BCL2 apoptosis regulator Homo sapiens 101-106 21122152-13 2010 Upon BPA-BNCT treatment, the Bax level increased in glioma cells, whereas Bcl-2 expression decreased. bpa-bnct 5-13 BCL2 apoptosis regulator Homo sapiens 74-79 20638780-6 2010 Here we report that cryptotanshinone, the major tanshinone isolated from Salvia miltiorrhiza Bunge, can suppress Bcl-2 expression and augment Fas sensitivity in DU145 cells. cryptotanshinone 20-36 BCL2 apoptosis regulator Homo sapiens 113-118 20963488-8 2010 Bufalin induced the apoptosis and cell cycle arrest by affecting the protein expressions of Bcl-2/Bax, cytochrome c, caspase-3, PARP, p53, p21WAF1, cyclinD1, and COX-2 in A549 cells. bufalin 0-7 BCL2 apoptosis regulator Homo sapiens 92-97 20638780-6 2010 Here we report that cryptotanshinone, the major tanshinone isolated from Salvia miltiorrhiza Bunge, can suppress Bcl-2 expression and augment Fas sensitivity in DU145 cells. tanshinone 26-36 BCL2 apoptosis regulator Homo sapiens 113-118 20876285-5 2010 MCF-7/HER2Delta16 cells evade tamoxifen through upregulation of BCL-2, whereas mediated suppression of BCL-2 expression or treatment of MCF-7/HER2Delta16 cells with the BCL-2 family pharmacological inhibitor ABT-737 restores tamoxifen sensitivity. Tamoxifen 30-39 BCL2 apoptosis regulator Homo sapiens 64-69 20876285-5 2010 MCF-7/HER2Delta16 cells evade tamoxifen through upregulation of BCL-2, whereas mediated suppression of BCL-2 expression or treatment of MCF-7/HER2Delta16 cells with the BCL-2 family pharmacological inhibitor ABT-737 restores tamoxifen sensitivity. ABT-737 208-215 BCL2 apoptosis regulator Homo sapiens 64-69 20876285-5 2010 MCF-7/HER2Delta16 cells evade tamoxifen through upregulation of BCL-2, whereas mediated suppression of BCL-2 expression or treatment of MCF-7/HER2Delta16 cells with the BCL-2 family pharmacological inhibitor ABT-737 restores tamoxifen sensitivity. Tamoxifen 225-234 BCL2 apoptosis regulator Homo sapiens 64-69 20876285-6 2010 Tamoxifen-resistant MCF-7/HER2Delta16 cells upregulate BCL-2 protein levels in response to suppressed ERalpha signaling mediated by estrogen withdrawal, tamoxifen treatment or fulvestrant treatment. Tamoxifen 0-9 BCL2 apoptosis regulator Homo sapiens 55-60 20876285-6 2010 Tamoxifen-resistant MCF-7/HER2Delta16 cells upregulate BCL-2 protein levels in response to suppressed ERalpha signaling mediated by estrogen withdrawal, tamoxifen treatment or fulvestrant treatment. Tamoxifen 153-162 BCL2 apoptosis regulator Homo sapiens 55-60 20876285-8 2010 Reintroduction of miR-15a/16 reduced tamoxifen-induced BCL-2 expression and sensitized MCF-7/HER2Delta16 to tamoxifen. Tamoxifen 37-46 BCL2 apoptosis regulator Homo sapiens 55-60 20876285-9 2010 Conversely, inhibition of miR-15a/16 in tamoxifen-sensitive cells activated BCL-2 expression and promoted tamoxifen resistance. Tamoxifen 40-49 BCL2 apoptosis regulator Homo sapiens 76-81 20876285-11 2010 The mechanism of HER2Delta16 therapeutic evasion, involving tamoxifen-induced upregulation of BCL-2 and suppression of miR-15a/16, provides a template for unique therapeutic interventions combining tamoxifen with modulation of microRNAs and/or ABT-737-mediated BCL-2 inhibition and apoptosis. Tamoxifen 60-69 BCL2 apoptosis regulator Homo sapiens 94-99 20876285-11 2010 The mechanism of HER2Delta16 therapeutic evasion, involving tamoxifen-induced upregulation of BCL-2 and suppression of miR-15a/16, provides a template for unique therapeutic interventions combining tamoxifen with modulation of microRNAs and/or ABT-737-mediated BCL-2 inhibition and apoptosis. Tamoxifen 60-69 BCL2 apoptosis regulator Homo sapiens 261-266 20876285-11 2010 The mechanism of HER2Delta16 therapeutic evasion, involving tamoxifen-induced upregulation of BCL-2 and suppression of miR-15a/16, provides a template for unique therapeutic interventions combining tamoxifen with modulation of microRNAs and/or ABT-737-mediated BCL-2 inhibition and apoptosis. Tamoxifen 198-207 BCL2 apoptosis regulator Homo sapiens 94-99 20876285-11 2010 The mechanism of HER2Delta16 therapeutic evasion, involving tamoxifen-induced upregulation of BCL-2 and suppression of miR-15a/16, provides a template for unique therapeutic interventions combining tamoxifen with modulation of microRNAs and/or ABT-737-mediated BCL-2 inhibition and apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 244-247 BCL2 apoptosis regulator Homo sapiens 94-99 20876285-11 2010 The mechanism of HER2Delta16 therapeutic evasion, involving tamoxifen-induced upregulation of BCL-2 and suppression of miR-15a/16, provides a template for unique therapeutic interventions combining tamoxifen with modulation of microRNAs and/or ABT-737-mediated BCL-2 inhibition and apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 244-247 BCL2 apoptosis regulator Homo sapiens 261-266 21156254-4 2010 Here we report two cases of THL with MYC, BCL2, and BCL6 rearrangements and t(3;8)(q27;q24) diagnosed in one center in the last two years. Orlistat 28-31 BCL2 apoptosis regulator Homo sapiens 42-46 21164560-10 2010 Western blot analysis showed that cajanol inhibited Bcl-2 expression and induced Bax expression. cajanol 34-41 BCL2 apoptosis regulator Homo sapiens 52-57 20816953-6 2010 The cell cycle analyses showed that VO-salen complex enhanced taxol-induced G2/M arrest and also increased taxol-induced apoptosis through a decrease in the ratio of Bcl-2/Bax which might account for the decrease in the apoptosis threshold among the affected cells. vo-salen 36-44 BCL2 apoptosis regulator Homo sapiens 166-171 20162574-0 2010 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. mir-181b 0-8 BCL2 apoptosis regulator Homo sapiens 53-57 21250597-8 2010 After fluvastatin treatment, expression of Bcl-2 and procaspase-9 were downregulated, cytochrome c (cytosolic extract), Bax and cleaved-caspase-3 protein expression were increased. Fluvastatin 6-17 BCL2 apoptosis regulator Homo sapiens 43-48 20162574-3 2010 We found that miR-181b was downregulated in both multidrug-resistant human gastric cancer cell line SGC7901/vincristine (VCR) and multidrug-resistant human lung cancer cell line A549/cisplatin (CDDP), and the downregulation of miR-181b in SGC7901/VCR and A549/CDDP cells was concurrent with the upregulation of BCL2 protein, compared with the parental SGC7901 and A549 cell lines, respectively. mir-181b 14-22 BCL2 apoptosis regulator Homo sapiens 311-315 20922713-8 2010 Patients with M2-3/Bcl2- and M3/Bcl2+ (high risk) had a two- to three-fold increased risk of recurrence when treated with either adjuvant hormone therapy or anthracycline-based chemotherapy compared with those with M1/Bcl2 +- and M2/Bcl2+ (low risk) [HR = 3.4 (2.8-5.6); p < 0.0001 and HR = 2.3 (1.2-4.3); p = 0.0009]. Anthracyclines 157-170 BCL2 apoptosis regulator Homo sapiens 19-23 20800695-3 2010 Here, we have identified a long term survival function for Bcl2 targeted at ER in mammalian system compared to wild type Bcl2 that is mediated by enhanced phosphorylation of heat shock protein 27 at ser 15, 78 and 82 sites with inhibition of caspase9 activity. Serine 199-202 BCL2 apoptosis regulator Homo sapiens 59-63 20800695-3 2010 Here, we have identified a long term survival function for Bcl2 targeted at ER in mammalian system compared to wild type Bcl2 that is mediated by enhanced phosphorylation of heat shock protein 27 at ser 15, 78 and 82 sites with inhibition of caspase9 activity. Serine 199-202 BCL2 apoptosis regulator Homo sapiens 121-125 22811811-10 2010 CONCLUSION: These findings are the first to demonstrate that high Bax expression is a good prognosticator for patients who underwent surgery alone, and that patient with low Bax/Bcl-2 expression ratio benefit from 5-FU-based adjuvant therapies. Fluorouracil 214-218 BCL2 apoptosis regulator Homo sapiens 178-183 20922713-8 2010 Patients with M2-3/Bcl2- and M3/Bcl2+ (high risk) had a two- to three-fold increased risk of recurrence when treated with either adjuvant hormone therapy or anthracycline-based chemotherapy compared with those with M1/Bcl2 +- and M2/Bcl2+ (low risk) [HR = 3.4 (2.8-5.6); p < 0.0001 and HR = 2.3 (1.2-4.3); p = 0.0009]. Anthracyclines 157-170 BCL2 apoptosis regulator Homo sapiens 32-36 20922713-8 2010 Patients with M2-3/Bcl2- and M3/Bcl2+ (high risk) had a two- to three-fold increased risk of recurrence when treated with either adjuvant hormone therapy or anthracycline-based chemotherapy compared with those with M1/Bcl2 +- and M2/Bcl2+ (low risk) [HR = 3.4 (2.8-5.6); p < 0.0001 and HR = 2.3 (1.2-4.3); p = 0.0009]. Anthracyclines 157-170 BCL2 apoptosis regulator Homo sapiens 32-36 20922713-8 2010 Patients with M2-3/Bcl2- and M3/Bcl2+ (high risk) had a two- to three-fold increased risk of recurrence when treated with either adjuvant hormone therapy or anthracycline-based chemotherapy compared with those with M1/Bcl2 +- and M2/Bcl2+ (low risk) [HR = 3.4 (2.8-5.6); p < 0.0001 and HR = 2.3 (1.2-4.3); p = 0.0009]. Anthracyclines 157-170 BCL2 apoptosis regulator Homo sapiens 32-36 21311676-4 2010 Moreover, melatonin markedly activated Bax expression and decreased Bcl-2 expression in dose increments. Melatonin 10-19 BCL2 apoptosis regulator Homo sapiens 68-73 21094089-0 2010 Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. navitoclax 0-10 BCL2 apoptosis regulator Homo sapiens 50-55 21076048-0 2010 B1, a novel amonafide analogue, overcomes the resistance conferred by Bcl-2 in human promyelocytic leukemia HL60 cells. amonafide 12-21 BCL2 apoptosis regulator Homo sapiens 70-75 19937163-0 2010 Increased prostate-specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR. Oligonucleotides 117-133 BCL2 apoptosis regulator Homo sapiens 151-156 21159604-0 2010 Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family proteins. Isotretinoin 68-88 BCL2 apoptosis regulator Homo sapiens 122-127 19908170-0 2010 Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 35-40 19908170-3 2010 In our study, we confirmed that the expression of miR-15a and miR-16 was upregulated and that of Bcl-2 was downregulated in curcumin-treated MCF-7 cells. Curcumin 124-132 BCL2 apoptosis regulator Homo sapiens 97-102 19908170-5 2010 Thus, we concluded that curcumin can reduce the expression of Bcl-2 by upregulating the expression of miR-15a and miR-16 in MCF-7 cells. Curcumin 24-32 BCL2 apoptosis regulator Homo sapiens 62-67 19937163-0 2010 Increased prostate-specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR. bispecific 96-106 BCL2 apoptosis regulator Homo sapiens 151-156 21159604-7 2010 A small molecule inhibitor of the Bcl-2 family of proteins (ABT-737) restored mitochondrial membrane potential loss and apoptosis in response to cytotoxic agents in 13-cis-RA treated cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 60-63 BCL2 apoptosis regulator Homo sapiens 34-39 21299121-0 2010 Dioscorealide B from the traditional Thai medicine Hua-Khao-Yen induces apoptosis in MCF-7 human breast cancer cells via modulation of Bax, Bak and Bcl-2 protein expression. dioscorealide B 0-15 BCL2 apoptosis regulator Homo sapiens 148-153 21159604-9 2010 Thus, combining 13-cis-RA with cytotoxic chemotherapy significantly reduced the cytotoxicity for neuroblastoma in vitro, mediated at least in part via the antiapoptotic Bcl-2 family of proteins. Isotretinoin 16-25 BCL2 apoptosis regulator Homo sapiens 169-174 21159606-3 2010 ABT-737, a novel BH3 mimetic, was shown to block Bcl-2 and Bcl-xL and induce MM cell apoptosis. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 49-54 21159606-3 2010 ABT-737, a novel BH3 mimetic, was shown to block Bcl-2 and Bcl-xL and induce MM cell apoptosis. BH 3 17-20 BCL2 apoptosis regulator Homo sapiens 49-54 21299121-5 2010 Dioscorealide B-induced apoptosis was associated with modulation of the multidomain Bcl-2 family members Bax, Bak and Bcl-2. dioscorealide B 0-15 BCL2 apoptosis regulator Homo sapiens 84-89 21299121-5 2010 Dioscorealide B-induced apoptosis was associated with modulation of the multidomain Bcl-2 family members Bax, Bak and Bcl-2. dioscorealide B 0-15 BCL2 apoptosis regulator Homo sapiens 118-123 21299121-6 2010 After treatment with 3 microM dioscorealide B, acceleration of the level of proapoptotic proteins Bax and Bak were observed at 6 hours and 12 hours, respectively, while the decrease in the expression of antiapoptotic protein Bcl-2 was observed 3 hours after the treatment. dioscorealide B 30-45 BCL2 apoptosis regulator Homo sapiens 225-230 21199742-7 2010 Caffeic acid decreased levels of uncleaved caspase-3 and Bcl-2, and induced cleaved caspase-3 and p53. caffeic acid 0-12 BCL2 apoptosis regulator Homo sapiens 57-62 20888852-6 2010 Inmunohistochemistry showed that neopladines bind to SKBR3 cell surface inducing FasL and BcL-2 expression. neopladines 33-44 BCL2 apoptosis regulator Homo sapiens 90-95 21176348-5 2010 The expressions of anti-apoptotic protein BCL-2 and h-tert mRNA were significantly decreased while the pro-apoptotic protein BAX and caspase-3 activity increased after treatment with VPA. Valproic Acid 183-186 BCL2 apoptosis regulator Homo sapiens 42-47 20651072-7 2010 Furthermore, Hsp90 inhibitors 17-AAG [17-(allylamino)-17-demethoxygeldanamycin] and STA-9090 significantly reduced the growth of myeloid leukemia xenografts in vivo and effectively down-regulated the expression of WT1 and its downstream target proteins, c-Myc and Bcl-2. tanespimycin 30-36 BCL2 apoptosis regulator Homo sapiens 264-269 20651072-7 2010 Furthermore, Hsp90 inhibitors 17-AAG [17-(allylamino)-17-demethoxygeldanamycin] and STA-9090 significantly reduced the growth of myeloid leukemia xenografts in vivo and effectively down-regulated the expression of WT1 and its downstream target proteins, c-Myc and Bcl-2. tanespimycin 38-78 BCL2 apoptosis regulator Homo sapiens 264-269 20680965-4 2010 Interaction of ABT-737, a small-molecule inhibitor of Bcl-2, Bcl-xL, and Bcl-W with cytotoxic drugs was monitored in a proliferation assay. ABT-737 15-22 BCL2 apoptosis regulator Homo sapiens 54-59 21548369-5 2010 RESULTS: After 24 h ischemia and reperfusion in gerbils, the level of Bcl-2 and HSP70 expressions in puerarin solid lipid nanoparticle group increased (P < 0.01) compared with the ischemic-reperfusion model group, and the level of Caspase-3 expression decreased (P < 0.01). puerarin 101-109 BCL2 apoptosis regulator Homo sapiens 70-75 21548369-7 2010 CONCLUSIONS: Puerarin solid lipid nanoparticle group can protect the cerebral ischemia-reperfusion injury in gerbils, which may be related to the upregulation of Bcl-2 and HSP70 expression and downregulation of Caspase-3 expression. puerarin 13-21 BCL2 apoptosis regulator Homo sapiens 162-167 21118500-11 2010 In addition, GS treatment significantly reduced the expression of anti-apoptotic proteins, Bcl-2, xIAP, Mcl1, survivin, cyclin D1 and c-myc, thus committing cells to apoptosis. pregna-4,17-diene-3,16-dione 13-15 BCL2 apoptosis regulator Homo sapiens 91-96 21199742-8 2010 CONCLUSION: Caffeic acid induces apoptosis by inhibiting Bcl-2 activity, leading to release of cytochrome c and subsequent activation of caspase-3, indicating that caffeic acid induces apoptosis via the mitochondrial apoptotic pathway. caffeic acid 12-24 BCL2 apoptosis regulator Homo sapiens 57-62 21199742-8 2010 CONCLUSION: Caffeic acid induces apoptosis by inhibiting Bcl-2 activity, leading to release of cytochrome c and subsequent activation of caspase-3, indicating that caffeic acid induces apoptosis via the mitochondrial apoptotic pathway. caffeic acid 164-176 BCL2 apoptosis regulator Homo sapiens 57-62 20225320-7 2010 CPX also downregulated protein expression of Bcl-xL and survivin and enhanced cleavages of Bcl-2. Ciclopirox 0-3 BCL2 apoptosis regulator Homo sapiens 91-96 20841355-0 2010 Serine 59 phosphorylation of {alpha}B-crystallin down-regulates its anti-apoptotic function by binding and sequestering Bcl-2 in breast cancer cells. Serine 0-6 BCL2 apoptosis regulator Homo sapiens 120-125 20943386-6 2010 Ursolic acid modulated the upregulation of Bax (pro-apoptotic) as well as the downregulation of Bcl-2 (anti-apoptotic). ursolic acid 0-12 BCL2 apoptosis regulator Homo sapiens 96-101 20943401-7 2010 Mechanistic studies have shown that this quinoxalinyl-piperazine compound is a G2/M-specific cell cycle inhibitor and inhibits anti-apoptotic Bcl-2 protein with p21 induction. quinoxalinyl-piperazine 41-64 BCL2 apoptosis regulator Homo sapiens 142-147 20828541-6 2010 In addition, ATX inhibited Abeta(25-35)-induced lowered membrane potential, decreased Bcl-2/Bax ratio. astaxanthine 13-16 BCL2 apoptosis regulator Homo sapiens 86-91 20837473-5 2010 Gossypol also down-regulated cell survival proteins (Bcl-x(L), Bcl-2, survivin, XIAP, and cFLIP) and dramatically up-regulated TRAIL death receptor (DR)-5 expression but had no effect on DR4 and decoy receptors. Gossypol 0-8 BCL2 apoptosis regulator Homo sapiens 63-68 20828541-6 2010 In addition, ATX inhibited Abeta(25-35)-induced lowered membrane potential, decreased Bcl-2/Bax ratio. UNII-042A8N37WH 27-32 BCL2 apoptosis regulator Homo sapiens 86-91 20816946-6 2010 Akt1, CyclinD1, MMP-2, MMP-9 and Bcl-2 protein expression decreased, and p27 expression increased in a dose-dependent manner with miR-451 mimics oligonucleotides. Oligonucleotides 145-161 BCL2 apoptosis regulator Homo sapiens 33-38 20939604-2 2010 Incednine has been reported to exhibit significant inhibitory activity against the antiapoptotic oncoproteins Bcl-2 and Bcl-xL. incednine 0-9 BCL2 apoptosis regulator Homo sapiens 110-115 20727582-7 2010 Silica nanoparticles also activated c-Jun N-terminal kinase (JNK), c-Jun, p53, caspase-3 and NF-kappaB, increased Bax expression and suppressed Bcl-2 protein. Silicon Dioxide 0-6 BCL2 apoptosis regulator Homo sapiens 144-149 20818185-2 2010 Here we report a novel compound targeting the BH3 binding groove of Bcl-XL/Bcl-2, Z18, which efficiently induces autophagy-associated cell death in HeLa cells, without apparent apoptosis. BH 3 46-49 BCL2 apoptosis regulator Homo sapiens 75-80 20656893-8 2010 We also observed aberrant production of extracellular matrix proteins, eNOS expression, and nitric oxide production in bcl-2-/- lung EC, which could contribute to inability to undergo capillary morphogenesis. Nitric Oxide 92-104 BCL2 apoptosis regulator Homo sapiens 119-124 20499237-6 2010 Results of our study revealed that simvastatin induced apoptosis of CLL cells concurrently with lowering of BCL-2/BAX ratio, and its pro-apoptotic effect is tumor-specific, not affecting normal lymphocytes. Simvastatin 35-46 BCL2 apoptosis regulator Homo sapiens 108-113 20930561-0 2010 The Bcl-2-Beclin 1 interaction in (-)-gossypol-induced autophagy versus apoptosis in prostate cancer cells. Gossypol 34-46 BCL2 apoptosis regulator Homo sapiens 4-9 20930561-2 2010 The natural BH3-mimetic (-)-gossypol preferentially induces autophagy in androgen-independent (AI) prostate cancer cells that have high levels of Bcl-2 and are resistant to apoptosis, whereas apoptosis is preferentially induced in androgen-dependent or -independent cells with low Bcl-2. BH 3 12-15 BCL2 apoptosis regulator Homo sapiens 146-151 20930561-2 2010 The natural BH3-mimetic (-)-gossypol preferentially induces autophagy in androgen-independent (AI) prostate cancer cells that have high levels of Bcl-2 and are resistant to apoptosis, whereas apoptosis is preferentially induced in androgen-dependent or -independent cells with low Bcl-2. Gossypol 24-36 BCL2 apoptosis regulator Homo sapiens 146-151 20930561-2 2010 The natural BH3-mimetic (-)-gossypol preferentially induces autophagy in androgen-independent (AI) prostate cancer cells that have high levels of Bcl-2 and are resistant to apoptosis, whereas apoptosis is preferentially induced in androgen-dependent or -independent cells with low Bcl-2. Gossypol 24-36 BCL2 apoptosis regulator Homo sapiens 281-286 20930561-3 2010 (-)-Gossypol induces autophagy via blocking Bcl-2-Beclin 1 interaction at the endoplasmic reticulum (ER), together with downregulating Bcl-2, upregulating Beclin 1 and activating the autophagic pathway. Gossypol 0-12 BCL2 apoptosis regulator Homo sapiens 44-49 20930561-3 2010 (-)-Gossypol induces autophagy via blocking Bcl-2-Beclin 1 interaction at the endoplasmic reticulum (ER), together with downregulating Bcl-2, upregulating Beclin 1 and activating the autophagic pathway. Gossypol 0-12 BCL2 apoptosis regulator Homo sapiens 135-140 22545969-7 2010 beta-Elemene augmented the cisplatin-induced activation of caspase-3/7/10 and caspase-9, cleavage of caspase-3 and -9, suppression of Bcl-2 and Bcl-X(L) expression, and release of cytochrome c from mitochondria in these cells. beta-elemene 0-12 BCL2 apoptosis regulator Homo sapiens 134-139 20165849-0 2010 A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Obatoclax mesylate 19-37 BCL2 apoptosis regulator Homo sapiens 41-46 22545969-7 2010 beta-Elemene augmented the cisplatin-induced activation of caspase-3/7/10 and caspase-9, cleavage of caspase-3 and -9, suppression of Bcl-2 and Bcl-X(L) expression, and release of cytochrome c from mitochondria in these cells. Cisplatin 27-36 BCL2 apoptosis regulator Homo sapiens 134-139 20477830-7 2010 B-cell CCL/lymphoma 2 (BCL2)-like 1 (BCL2L1) exhibited significant upregulation, while BCL2 showed partial derepression in PDAM-silenced cells after cisplatin treatment, suggesting that alteration of anti-apoptotic genes contributed in part to cisplatin resistance. Cisplatin 244-253 BCL2 apoptosis regulator Homo sapiens 23-27 20629079-4 2010 Significance of beclin 1, AKT, and Bcl-2 in dasatinib-induced autophagy and growth inhibition was assayed by small interfering RNA (siRNA) silencing and/or overexpression of the gene of interest. Dasatinib 44-53 BCL2 apoptosis regulator Homo sapiens 35-40 20629079-11 2010 Dasatinib also reduced Bcl-2 expression and activity. Dasatinib 0-9 BCL2 apoptosis regulator Homo sapiens 23-28 20629079-12 2010 Overexpression of Bcl-2 partially prevented dasatinib-induced autophagy. Dasatinib 44-53 BCL2 apoptosis regulator Homo sapiens 18-23 20629079-13 2010 CONCLUSIONS: Dasatinib induces autophagic cell death in ovarian cancer that partially depends on beclin 1, AKT, and Bcl-2. Dasatinib 13-22 BCL2 apoptosis regulator Homo sapiens 116-121 20818182-3 2010 In this study, we examined the involvement of Bcl-2 proteins in apoptosis induced by the chemotherapeutic agent actinomycin D. Dactinomycin 112-125 BCL2 apoptosis regulator Homo sapiens 46-51 20818182-6 2010 We also explored the therapeutic potential of actinomycin D in combination with ABT-737, an experimental agent that inhibits anti-apoptotic Bcl-2 proteins. Dactinomycin 46-59 BCL2 apoptosis regulator Homo sapiens 140-145 20818182-6 2010 We also explored the therapeutic potential of actinomycin D in combination with ABT-737, an experimental agent that inhibits anti-apoptotic Bcl-2 proteins. ABT-737 80-87 BCL2 apoptosis regulator Homo sapiens 140-145 20401760-5 2010 All results indicate that KLF4 induces apoptosis in leukemia cells involving the bcl-2/bax pathway during H(2)O(2) stimulation, suggesting a potential mechanism for research on drug-induced apoptosis. Hydrogen Peroxide 106-114 BCL2 apoptosis regulator Homo sapiens 81-86 20935462-0 2010 Teaching an old drug new tricks: Actinomycin D synergistically enhances sensitivity to the Bcl-2 antagonist ABT-737. Dactinomycin 33-46 BCL2 apoptosis regulator Homo sapiens 91-96 20935462-0 2010 Teaching an old drug new tricks: Actinomycin D synergistically enhances sensitivity to the Bcl-2 antagonist ABT-737. ABT-737 108-115 BCL2 apoptosis regulator Homo sapiens 91-96 20401760-0 2010 KLF4 promotes hydrogen-peroxide-induced apoptosis of chronic myeloid leukemia cells involving the bcl-2/bax pathway. Hydrogen Peroxide 14-31 BCL2 apoptosis regulator Homo sapiens 98-103 20401760-3 2010 The results showed that H(2)O(2) treatment of cells resulted in an increase in KLF4 levels; KLF4 induced apoptosis and slowed cell growth, potentially resulting from up-regulation of bax and down-regulation of bcl-2. Hydrogen Peroxide 24-32 BCL2 apoptosis regulator Homo sapiens 210-215 20127862-8 2010 Inhibition of Bcl-2 sensitized cells to the cytotoxic activity of panobinostat. Panobinostat 66-78 BCL2 apoptosis regulator Homo sapiens 14-19 20187112-7 2010 Following an agar block, there was positive staining for p16 and Ki-67 in the abnormal groups whilst the benign TEM cells stained positive for bcl-2. Agar 13-17 BCL2 apoptosis regulator Homo sapiens 143-148 20801552-5 2010 Hydroxamic acid derivatives trigger a higher degree of apoptosis than carboxylic acid counterparts, increase bax/bcl-2 expression ratio and induce caspase 3/7 activation. Hydroxamic Acids 0-15 BCL2 apoptosis regulator Homo sapiens 113-118 20828598-7 2010 In addition, administration of Polyphenon-B increased the expression of Bax, tBid, Smac/Diablo, cytochrome C, Apaf-1, caspases, and IkappaB with PARP cleavage, and decreased the expression of Bcl-2, Bcl-xL, pBad, NF-kappaB, p-IkappaB-alpha, IKKbeta and Ub in both HepG2 cells and in DAB-treated animals. polyphenon B 31-43 BCL2 apoptosis regulator Homo sapiens 192-197 20675079-0 2010 Metronomic small molecule inhibitor of Bcl-2 (TW-37) is antiangiogenic and potentiates the antitumor effect of ionizing radiation. TW-37 46-51 BCL2 apoptosis regulator Homo sapiens 39-44 20675079-9 2010 CONCLUSIONS: These results demonstrate that metronomic TW-37 potentiates the antitumor effects of radiotherapy and suggest that patients with head and neck cancer might benefit from the combination of small molecule inhibitor of Bcl-2 and radiation therapy. TW-37 55-60 BCL2 apoptosis regulator Homo sapiens 229-234 20878071-8 2010 Cantharidin-induced apoptosis was accompanied with up-regulation of the protein expression of Bax and PARP, but down-regulation of the protein levels of Bcl-2, resulting in dysfunction of mitochondria then led to Endo G and AIF release for causing induction of apoptosis. Cantharidin 0-11 BCL2 apoptosis regulator Homo sapiens 153-158 20878062-9 2010 P53 staining was decreased, while PCNA and TGFbeta3 staining were increased by indomethacin in tumor areas with high presence of COX-2, which correlated to staining of BAX, TUNEL, Bcl-2, c-jun, p21, p27, p53 and NM23. Indomethacin 79-91 BCL2 apoptosis regulator Homo sapiens 180-185 20685081-4 2010 PolyI:C-induced anoikis in SGEC was associated with the upregulation of the pro-apoptotic Bmf, BimEL and Bax and the down-regulation of the pro-survival Bcl-2 (real-time PCR analyses). Poly I-C 0-7 BCL2 apoptosis regulator Homo sapiens 153-158 20878089-12 2010 Curcumin also down-regulates the protein expressions of TCTP, Mcl-1 and Bcl-2, in order to induce mitochondrial dysfunction. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 72-77 20506110-12 2010 Moreover, PA increased the Bax/Bcl-2 ratio, cleaved PARP, and caspase-3 levels. Palmitic Acid 10-12 BCL2 apoptosis regulator Homo sapiens 31-36 20738755-7 2010 Using the SK-N-SH dopaminergic cell line as our model system, we found that METH-induced autophagy by inhibiting dissociation of Bcl-2/Beclin 1 complex and its upstream pathway that thereby led to cell death. Methamphetamine 76-80 BCL2 apoptosis regulator Homo sapiens 129-134 20824291-6 2010 TZDs induce apoptosis through increased levels of apoptotic molecules, such as p53 and PTEN and/or decreased level of anti-apoptotic molecules, such as Bcl-2 and survivin. Thiazolidinediones 0-4 BCL2 apoptosis regulator Homo sapiens 152-157 20738755-10 2010 Furthermore, we demonstrated a novel role for melatonin in protecting cells from autophagic cell death triggered by the Bcl-2/Beclin 1 pathway by inhibiting the activation of the JNK 1, Bcl-2 upstream pathway. Melatonin 46-55 BCL2 apoptosis regulator Homo sapiens 120-125 20738755-10 2010 Furthermore, we demonstrated a novel role for melatonin in protecting cells from autophagic cell death triggered by the Bcl-2/Beclin 1 pathway by inhibiting the activation of the JNK 1, Bcl-2 upstream pathway. Melatonin 46-55 BCL2 apoptosis regulator Homo sapiens 186-191 20860495-11 2010 In THP-1, AMP kinase (AMPK), which is activated when ATP becomes limiting, was rapidly phosphorylated by 2-DG, and expression of Bcl-2 was augmented, which might result in resistance to 2-DG. Deoxyglucose 186-190 BCL2 apoptosis regulator Homo sapiens 129-134 20860495-12 2010 On the other hand, AMPK phosphorylation and augmentation of Bcl-2 expression by 2-DG were not observed in NB4, which is 2-DG sensitive. Deoxyglucose 80-84 BCL2 apoptosis regulator Homo sapiens 60-65 20652372-6 2010 SBHA-induced apoptosis was accompanied by the loss of mitochondrial membrane potential (MMP; DeltaPsi(m)), Bcl-2 decrease, Bax increase, and the activation of caspase-3. suberoyl bis-hydroxamic acid 0-4 BCL2 apoptosis regulator Homo sapiens 107-112 21062915-9 2010 Notably, 150 nmol/L cucurbitacin I effectively blocked STAT3 signaling and downstream survivin and Bcl-2 expression, and it induced apoptosis in HNSCC-CD44(+)ALDH1(+). cucurbitacin I 20-34 BCL2 apoptosis regulator Homo sapiens 99-104 20696281-3 2010 The cleavage of BID to t-BID and degradation of anti-apoptotic BCL-2 proteins by lysosomal cysteine cathepsins were identified as links to the mitochondrial cytochrome c release, which eventually leads to caspase activation. Cysteine 91-99 BCL2 apoptosis regulator Homo sapiens 63-68 20829195-0 2010 A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax). navitoclax 74-81 BCL2 apoptosis regulator Homo sapiens 59-63 20829195-0 2010 A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax). navitoclax 83-93 BCL2 apoptosis regulator Homo sapiens 59-63 20829195-3 2010 ABT-263 (navitoclax) is a first-in-class BCL2 family inhibitor that restores the ability of cancer cells to undergo apoptosis. navitoclax 0-7 BCL2 apoptosis regulator Homo sapiens 41-45 20829195-3 2010 ABT-263 (navitoclax) is a first-in-class BCL2 family inhibitor that restores the ability of cancer cells to undergo apoptosis. navitoclax 9-19 BCL2 apoptosis regulator Homo sapiens 41-45 20829195-4 2010 However, many cancer cells are resistant to ABT-263 due to high levels of a BCL2 family member, MCL1, which is not targeted by the drug. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 44-47 BCL2 apoptosis regulator Homo sapiens 76-80 20560114-6 2010 Consistent with apoptosis induction, icaritin increased the Bax/Bcl-2 ratio and caspase-3 activation in HepG2 cells. icaritin 37-45 BCL2 apoptosis regulator Homo sapiens 64-69 20708055-6 2010 6-OHDA-induced intracellular generation of reactive oxygen species (ROS), activation of p38 MAPK and ERK1/2, and mitochondrial dysfunctions, including the decrease of membrane potential, increase of intracellular free Ca2+, release of cytochrome c, imbalance of Bax/Bcl-2 ratio and activation of caspase-3 were strikingly attenuated by chrysotoxine pretreatment. Oxidopamine 0-6 BCL2 apoptosis regulator Homo sapiens 266-271 21031621-8 2010 Simultaneously, resveratrol regulated the expression of the antiapoptotic proteins Bcl-2, Bcl-xL and XIAP and the proapoptotic protein Bax. Resveratrol 16-27 BCL2 apoptosis regulator Homo sapiens 83-88 20340172-5 2010 Pretreatment with 17beta-estradiol (10 nM) attenuated the increased expression of antiapoptotic protein Bcl-2, proapoptotic protein Bax and activation of caspases linked to mitochondrial apoptotic pathway following Tat exposure. Estradiol 18-34 BCL2 apoptosis regulator Homo sapiens 104-109 20340172-6 2010 In addition, select components of apoptotic pathway signaling appear more sensitive to estrogen receptor (ER) activation, as the addition of ER antagonist ICI 182780 reversed estrogen downregulation of Bax and caspase 3, while estrogen effects on Tat-induced Bcl-2 and caspase 9 expression were maintained. Fulvestrant 155-165 BCL2 apoptosis regulator Homo sapiens 259-264 20633548-0 2010 Gossypol inhibits phosphorylation of Bcl-2 in human leukemia HL-60 cells. Gossypol 0-8 BCL2 apoptosis regulator Homo sapiens 37-42 21355282-12 2010 CONCLUSION: BA exerted potent effect on growth inhibition, G0 cell cycle arrest and induction of apoptosis in BxPC-3 cells in vitro, possibly associated with the down-regulation of Bcl-2 and up-regulation of Bax expression. betulinic acid 12-14 BCL2 apoptosis regulator Homo sapiens 181-186 20609361-7 2010 In addition, tenuigenin inhibited activation of caspase-3 and reversed down-regulation of the ratio of Bcl-2/Bax, both of which were induced by methylglyoxal stimulation. Pyruvaldehyde 144-157 BCL2 apoptosis regulator Homo sapiens 103-108 20659543-10 2010 Caspase-8, caspase-3, Bax, P53 and P21 mRNAs as well as proteins were increased while Bcl-2 mRNA and protein were decreased significantly by 24 h of PE treatment. pe 149-151 BCL2 apoptosis regulator Homo sapiens 86-91 20655907-14 2010 Those results of our studies demonstrated that Juglone-induced mitochondrial dysfunction in HL-60 cells trigger events responsible for mitochondrial-dependent apoptosis pathways and the elevated ratio of Bax/Bcl-2 was also probably involved in this effect. juglone 47-54 BCL2 apoptosis regulator Homo sapiens 208-213 20633548-3 2010 Here we investigate the alterations of Bcl-2/Bcl-xL/Mcl-1 protein levels and Bcl-2 phosphorylation in gossypol-induced apoptosis in human leukemia HL-60 cells. Gossypol 102-110 BCL2 apoptosis regulator Homo sapiens 77-82 20691179-8 2010 Western blotting with treated cells revealed that berberine induces apoptosis in MCF-7 cells through a mitochondria-dependent pathway by increasing levels of cytoplasmic cytochrome c, caspase-9 activity and cleavage of PARP while decreasing levels of Bcl-2. Berberine 50-59 BCL2 apoptosis regulator Homo sapiens 251-256 20633548-5 2010 Bcl-2/Bcl-xL/Mcl-1 protein levels were slightly reduced and phosphorylation of Bcl-2 at threonine 56 (phospho T56) was not altered. Threonine 88-97 BCL2 apoptosis regulator Homo sapiens 79-84 20633548-6 2010 However, phosphorylation of Bcl-2 at serine 70 (phospho S70) was strikingly down-regulated in gossypol-exposed cells. Serine 37-43 BCL2 apoptosis regulator Homo sapiens 28-33 20633548-6 2010 However, phosphorylation of Bcl-2 at serine 70 (phospho S70) was strikingly down-regulated in gossypol-exposed cells. Gossypol 94-102 BCL2 apoptosis regulator Homo sapiens 28-33 20633548-9 2010 Collectively, gossypol treatment can reduce phosphorylation of Bcl-2 at serine 70 in leukemia HL-60 cells and gossypol may be a promising therapeutical candidate for leukemia patients especially expressing phosphorylated Bcl-2 at Ser70. Gossypol 14-22 BCL2 apoptosis regulator Homo sapiens 63-68 20633548-9 2010 Collectively, gossypol treatment can reduce phosphorylation of Bcl-2 at serine 70 in leukemia HL-60 cells and gossypol may be a promising therapeutical candidate for leukemia patients especially expressing phosphorylated Bcl-2 at Ser70. Gossypol 14-22 BCL2 apoptosis regulator Homo sapiens 221-226 20633548-9 2010 Collectively, gossypol treatment can reduce phosphorylation of Bcl-2 at serine 70 in leukemia HL-60 cells and gossypol may be a promising therapeutical candidate for leukemia patients especially expressing phosphorylated Bcl-2 at Ser70. Serine 72-78 BCL2 apoptosis regulator Homo sapiens 63-68 20633548-9 2010 Collectively, gossypol treatment can reduce phosphorylation of Bcl-2 at serine 70 in leukemia HL-60 cells and gossypol may be a promising therapeutical candidate for leukemia patients especially expressing phosphorylated Bcl-2 at Ser70. Gossypol 110-118 BCL2 apoptosis regulator Homo sapiens 221-226 20654613-9 2010 The level of Bcl-2 protein was restored to the normal level by 17beta-estradiol pharmacological postconditioning. Estradiol 63-79 BCL2 apoptosis regulator Homo sapiens 13-18 20674558-6 2010 DP increased the levels of reactive oxygen species (ROS) in HepG2 cells, and antioxidant N-acetylcysteine (NAC) completely blocked DP-induced ROS accumulation and the disruption of the balance between Bax and Bcl-2 proteins, and effectively blocked the decreased MMP and apoptosis, but had no effect on the activation of caspase-8 and the up-regulations of DR4 and DR5 induced by DP. 1-(3',4',5'-trimethoxyphenyl)-3-(3'',4''-dimethoxy-2'-hydroxyphenyl)propane 0-2 BCL2 apoptosis regulator Homo sapiens 209-214 20851102-6 2010 Mechanistically, 2DG and GD enhanced surface levels for both death receptors (DR4 and DR5); which was accompanied by reductions in levels of Mcl-1, Bcl-2 and survivin. Deoxyglucose 17-20 BCL2 apoptosis regulator Homo sapiens 148-153 20691200-9 2010 In exploring the underlying mechanisms of ellagic acid action, we found that oxLDL decreased Akt and eNOS phosphorylation, which in turn activated NF-kappaB and downstream pro-apoptotic signaling events including calcium accumulation, destabilization of mitochondrial permeability, and disruption of the balance between pro- and anti-apoptotic Bcl-2 proteins. Ellagic Acid 42-54 BCL2 apoptosis regulator Homo sapiens 344-349 20828195-6 2010 The cellular antioxidant, glutathione, was depleted and the apoptotic protein, Bcl-2, was down-regulated by the stigmasterol oxides identified as apoptotic. stigmasterol oxides 112-131 BCL2 apoptosis regulator Homo sapiens 79-84 20638373-10 2010 Western blot analysis showed that cajanol inhibited Bcl-2 expression and induced Bax expression to desintegrate the outer mitochondrial membrane and causing cytochrome c release. cajanol 34-41 BCL2 apoptosis regulator Homo sapiens 52-57 20674558-6 2010 DP increased the levels of reactive oxygen species (ROS) in HepG2 cells, and antioxidant N-acetylcysteine (NAC) completely blocked DP-induced ROS accumulation and the disruption of the balance between Bax and Bcl-2 proteins, and effectively blocked the decreased MMP and apoptosis, but had no effect on the activation of caspase-8 and the up-regulations of DR4 and DR5 induced by DP. Acetylcysteine 89-105 BCL2 apoptosis regulator Homo sapiens 209-214 20674558-6 2010 DP increased the levels of reactive oxygen species (ROS) in HepG2 cells, and antioxidant N-acetylcysteine (NAC) completely blocked DP-induced ROS accumulation and the disruption of the balance between Bax and Bcl-2 proteins, and effectively blocked the decreased MMP and apoptosis, but had no effect on the activation of caspase-8 and the up-regulations of DR4 and DR5 induced by DP. 1-(3',4',5'-trimethoxyphenyl)-3-(3'',4''-dimethoxy-2'-hydroxyphenyl)propane 131-133 BCL2 apoptosis regulator Homo sapiens 209-214 20674558-6 2010 DP increased the levels of reactive oxygen species (ROS) in HepG2 cells, and antioxidant N-acetylcysteine (NAC) completely blocked DP-induced ROS accumulation and the disruption of the balance between Bax and Bcl-2 proteins, and effectively blocked the decreased MMP and apoptosis, but had no effect on the activation of caspase-8 and the up-regulations of DR4 and DR5 induced by DP. Acetylcysteine 107-110 BCL2 apoptosis regulator Homo sapiens 209-214 20674558-6 2010 DP increased the levels of reactive oxygen species (ROS) in HepG2 cells, and antioxidant N-acetylcysteine (NAC) completely blocked DP-induced ROS accumulation and the disruption of the balance between Bax and Bcl-2 proteins, and effectively blocked the decreased MMP and apoptosis, but had no effect on the activation of caspase-8 and the up-regulations of DR4 and DR5 induced by DP. 1-(3',4',5'-trimethoxyphenyl)-3-(3'',4''-dimethoxy-2'-hydroxyphenyl)propane 131-133 BCL2 apoptosis regulator Homo sapiens 209-214 20547138-3 2010 We found that cells treated with 200muM hydrogen peroxide (H(2)O(2)) for 24h exhibited decreased viability and became apoptotic with corresponding Bax up-regulation, Bcl-2 down-regulation, caspase 3 activation and mitochondrial cytochrome c leakage. Hydrogen Peroxide 40-57 BCL2 apoptosis regulator Homo sapiens 166-171 20922271-6 2010 In contrast to previous reports about the use of ODN, a heterogeneous and up to 80% sequence-specific Bcl-2 protein knockdown was observed in the SW2, H2171 and H69 SCLC cell lines, although without significant sequence-specific reduction of cell viability, cell growth, or sensitization to cisplatin. Cisplatin 291-300 BCL2 apoptosis regulator Homo sapiens 102-107 20600877-3 2010 Curcumin (Cur) is a promising natural anticancer agent that can specifically regulate the expression of NF-kappaB, bcl-2, and bax in leukemia cells. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 115-120 21036697-0 2010 Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response. Oligodeoxyribonucleotides 93-113 BCL2 apoptosis regulator Homo sapiens 14-19 21036697-0 2010 Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response. Oligodeoxyribonucleotides 93-113 BCL2 apoptosis regulator Homo sapiens 87-92 20610805-4 2010 Subsequently, a functional study was conducted for comparison of paclitaxel-induced cytotoxicity and apoptosis between the BCL2 variant and the wild type in vitro. Paclitaxel 65-75 BCL2 apoptosis regulator Homo sapiens 123-127 20610805-8 2010 In addition, HeLa cells expressing the BCL2 Ala43Thr (G127A), similar to the control cells, were more sensitive to paclitaxel-induced cytotoxicity and apoptosis than those expressing wild-type BCL2. Paclitaxel 115-125 BCL2 apoptosis regulator Homo sapiens 39-43 20610805-9 2010 Consistently, the cleaved PARP and p-BCL2 proteins were subsequently increased after paclitaxel treatment, as also predicted by the bioinformatics analysis. Paclitaxel 85-95 BCL2 apoptosis regulator Homo sapiens 37-41 20874716-5 2010 Blockage of PI3K/Akt pathway with wortmannin also seriously impaired the protective effect of fibroblasts on myoblasts and fibroblast-induced Bcl2 expression. Wortmannin 34-44 BCL2 apoptosis regulator Homo sapiens 142-146 19819432-13 2010 Western blot analysis confirmed that EGCG at >=50 muM significantly decreased the expression of PCNA, CDK4, and BCL2 as well as increased the expression of the proapoptotic BAX in a dose-dependent manner. epigallocatechin gallate 37-41 BCL2 apoptosis regulator Homo sapiens 115-119 21063838-4 2010 The expression of apoptosis related p53 and Bcl-2 protein and the second messenger calcium were detected respectively by Western blotting, patch clamp and confocal calcium imaging. Calcium 164-171 BCL2 apoptosis regulator Homo sapiens 44-49 20534884-6 2010 A further and converging mechanism of cell protection by this indoleamine described in different models seems to lie in the control of damage and signaling function of mitochondria that involves decreased production of reactive oxygen species and activation of the antiapoptotic and redox-sensitive element Bcl2. indolamine 62-73 BCL2 apoptosis regulator Homo sapiens 307-311 21229643-6 2010 RESULTS: gossypol caused radiosensitization of PC-3 cells that are known to be radioresistant, with high Bcl-2 levels. Gossypol 9-17 BCL2 apoptosis regulator Homo sapiens 105-110 21244764-7 2010 Dexamethasone can up-regulate survivin, and to a lesser extent Bcl-2, in mature cells but not in pre-osteoblasts. Dexamethasone 0-13 BCL2 apoptosis regulator Homo sapiens 63-68 21063845-5 2010 However, paclitaxel sensitivity assay showed that sensitivity to paclitaxel was reversed after the transfection in both cell lines in terms of number of cells arrested at G(2)/M phase and the expression of Bcl-2 was significantly changed. Paclitaxel 9-19 BCL2 apoptosis regulator Homo sapiens 206-211 21063845-5 2010 However, paclitaxel sensitivity assay showed that sensitivity to paclitaxel was reversed after the transfection in both cell lines in terms of number of cells arrested at G(2)/M phase and the expression of Bcl-2 was significantly changed. Paclitaxel 65-75 BCL2 apoptosis regulator Homo sapiens 206-211 20452611-4 2010 Small molecule inhibitors of BH-3-mediated binding of Bcl-2 have been recently developed, although no investigation has been conducted in pancreatic cancer, a malignancy characterized by extreme resistance to PCD. BH 3 29-33 BCL2 apoptosis regulator Homo sapiens 54-59 20546110-12 2010 The stimulation also caused increased caspase-3 activity, phosphatidylserine redistribution and bcl-2 down-regulation, suggesting butyrate-induced apoptosis. Butyrates 130-138 BCL2 apoptosis regulator Homo sapiens 96-101 20626591-8 2010 Administration of melatonin to the PANC-1 cells resulted in the stimulation of Bcl-2/Bax and caspase-9 proteins levels. Melatonin 18-27 BCL2 apoptosis regulator Homo sapiens 79-84 20626591-10 2010 Pretreatment with luzindole alone and prior to the addition of melatonin reversed the stimulatory effect of this indoloamine on Bcl-2/Bax and caspase-9 proteins expression in PANC-1 cells. luzindole 18-27 BCL2 apoptosis regulator Homo sapiens 128-133 20626591-10 2010 Pretreatment with luzindole alone and prior to the addition of melatonin reversed the stimulatory effect of this indoloamine on Bcl-2/Bax and caspase-9 proteins expression in PANC-1 cells. Melatonin 63-72 BCL2 apoptosis regulator Homo sapiens 128-133 20626591-10 2010 Pretreatment with luzindole alone and prior to the addition of melatonin reversed the stimulatory effect of this indoloamine on Bcl-2/Bax and caspase-9 proteins expression in PANC-1 cells. indoloamine 113-124 BCL2 apoptosis regulator Homo sapiens 128-133 20452611-12 2010 CONCLUSIONS: Disruption of Bcl-2 activity using the small molecule inhibitor A-779024 induces apoptotic but not autophagic PCD. a-779024 77-85 BCL2 apoptosis regulator Homo sapiens 27-32 20617337-4 2010 We found that the inhibitors of Bcl-2 protein interactions caused a slow and complete release of intracellular agonist-sensitive stores of calcium. Calcium 139-146 BCL2 apoptosis regulator Homo sapiens 32-37 20808253-1 2010 INTRODUCTION: AT-101 is an oral, pan Bcl-2 family protein inhibitor that has demonstrated activity in small cell lung cancer (SCLC) models. gossypol acetic acid 14-20 BCL2 apoptosis regulator Homo sapiens 37-42 20617337-7 2010 CICR induced by different doses of BH3I-2" in Bcl-2 overexpressing cells was markedly decreased compared with control. cicr 0-4 BCL2 apoptosis regulator Homo sapiens 46-51 20617337-8 2010 The results suggest that Bcl-2 proteins regulate calcium release from the intracellular stores and suggest that the spatial-temporal patterns of agonist-stimulated cytosolic [Ca(+2)] changes are regulated by differential cellular distribution of interacting pairs of prosurvival and proapoptotic Bcl-2 proteins. Calcium 49-56 BCL2 apoptosis regulator Homo sapiens 25-30 21223714-10 2010 Among 97 apoptosis-related genes, 25 genes were differently expressed and 13 expressions were up-regulated in fludarabine treated group, involving in Bcl-2 pro-apoptotic gene, tumor necrosis factor (TNF) and its receptor superfamily gene, and caspase recruitment domain family, 12 genes expression down-regulated, including Bcl-2 antiapoptotic gene, TNF superfamily and its receptor related factor gene and apoptosis inhibitor protein family. fludarabine 110-121 BCL2 apoptosis regulator Homo sapiens 150-155 20073575-10 2010 The pro-apoptotic effect of serotonin was associated to a decrease in the expression of the anti-apoptotic factor Bcl-2. Serotonin 28-37 BCL2 apoptosis regulator Homo sapiens 114-119 20885891-7 2010 In contrast, in lupulone-treated SW480 cells, p53 was translocated to the cytoplasm where it initiated a survival response associated with the up-regulation of antiapoptotic Bcl-2 and Mcl-1 proteins in an attempt to preserve mitochondrial integrity. lupulon 16-24 BCL2 apoptosis regulator Homo sapiens 174-179 20885891-8 2010 These prosurvival effects of p53 in lupulone-treated SW480 cells were reversed by pifithrin-alpha, an inhibitor of p53 function, which caused a blocking of p53 in the nucleus leading to the down-regulation of Bcl-2 and Mcl-1, the up-regulation of proapoptotic Bax protein and TRAIL-death receptors leading to enhanced cell death. lupulon 36-44 BCL2 apoptosis regulator Homo sapiens 209-214 21163061-8 2010 The bufalin-induced apoptosis was confirmed by increased expression of tumor suppressor protein p53, bax and decreased expression of bcl-2. bufalin 4-11 BCL2 apoptosis regulator Homo sapiens 133-138 20687223-12 2010 Thus, in PC3PR cells, reduced expression of miR-34a confers paclitaxel resistance via up-regulating SIRT1 and Bcl2 expression. Paclitaxel 60-70 BCL2 apoptosis regulator Homo sapiens 110-114 20687223-13 2010 CONCLUSIONS: MiR-34a and its downstream targets SIRT1 and Bcl2 play important roles in the development of paclitaxel resistance, all of which can be useful biomarkers and promising therapeutic targets for the drug resistance in hormone-refractory prostate cancer. Paclitaxel 106-116 BCL2 apoptosis regulator Homo sapiens 58-62 21348303-6 2010 Western blotting analysis revealed that in ethanol treated cells preconditioned with NaNO2, the HIF-1alpha and Bcl-2 increased obviously, while the expression of pro-apoptotic proteins, including Bax, Caspase-9, Caspase-3 decreased. Ethanol 43-50 BCL2 apoptosis regulator Homo sapiens 111-116 20726580-4 2010 We have identified a highly conserved 25-nucleotide G-rich sequence (BCL2Q), with potential to fold into a RNA G-quadruplex structure, located 42 nucleotides upstream of the translation start site of human BCL-2. 25-nucleotide 38-51 BCL2 apoptosis regulator Homo sapiens 206-211 21223714-10 2010 Among 97 apoptosis-related genes, 25 genes were differently expressed and 13 expressions were up-regulated in fludarabine treated group, involving in Bcl-2 pro-apoptotic gene, tumor necrosis factor (TNF) and its receptor superfamily gene, and caspase recruitment domain family, 12 genes expression down-regulated, including Bcl-2 antiapoptotic gene, TNF superfamily and its receptor related factor gene and apoptosis inhibitor protein family. fludarabine 110-121 BCL2 apoptosis regulator Homo sapiens 324-329 20877573-7 2010 CXCL12 producing carcinomas cultured on poly-HEMA displayed heightened Bim and loss of Mcl-1 and Bcl-2 preceding cytochrome c release, and caspase-9 activation. poly-hema 40-49 BCL2 apoptosis regulator Homo sapiens 97-102 20599920-6 2010 Subsequently, S phase arrest, caspase 9/3 activaton, p53 and Bax up-regulation, as well as Bcl-2 down-regulation were observed in bakuchiol-treated A549 cells. bakuchiol 130-139 BCL2 apoptosis regulator Homo sapiens 91-96 20367277-4 2010 Whereas overexpression of Bcl-2 increased mitochondrial oxygen consumption and complex IV activity, CEM/Bcl-2 cells responded to the increased mitochondrial oxidative stress induced by resveratrol by significantly reducing mitochondrial respiration, complex IV activity, and O(2)(-) production, and promoted cell survival. Resveratrol 185-196 BCL2 apoptosis regulator Homo sapiens 104-109 20633539-13 2010 Compared to control cells, cells treated with TMZ showed a significant increase in the Bax/Bcl-2 ratio and caspase-3 activity (P<0.01). Temozolomide 46-49 BCL2 apoptosis regulator Homo sapiens 91-96 20633539-15 2010 Taken together, these results suggested that over-express miR-21 could inhibit TMZ-induced apoptosis in U87MG cells, at least in part, by decreasing Bax/Bcl-2 ratio and caspase-3 activity, which highlighted the possibility of miR-21 overexpression in the clinical resistance to chemotherapeutic therapy of TMZ. Temozolomide 79-82 BCL2 apoptosis regulator Homo sapiens 153-158 20367277-0 2010 Bcl-2 modulates resveratrol-induced ROS production by regulating mitochondrial respiration in tumor cells. Resveratrol 16-27 BCL2 apoptosis regulator Homo sapiens 0-5 20633539-0 2010 MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Temozolomide 75-87 BCL2 apoptosis regulator Homo sapiens 124-129 20562294-6 2010 Data further show that MGO-induced imbalance in the VEGF/Ang II ratio significantly changes the levels of BAX and Bcl-2 in endothelial cells. Pyruvaldehyde 23-26 BCL2 apoptosis regulator Homo sapiens 114-119 20367277-0 2010 Bcl-2 modulates resveratrol-induced ROS production by regulating mitochondrial respiration in tumor cells. Reactive Oxygen Species 36-39 BCL2 apoptosis regulator Homo sapiens 0-5 20367277-4 2010 Whereas overexpression of Bcl-2 increased mitochondrial oxygen consumption and complex IV activity, CEM/Bcl-2 cells responded to the increased mitochondrial oxidative stress induced by resveratrol by significantly reducing mitochondrial respiration, complex IV activity, and O(2)(-) production, and promoted cell survival. Oxygen 56-62 BCL2 apoptosis regulator Homo sapiens 26-31 20367277-4 2010 Whereas overexpression of Bcl-2 increased mitochondrial oxygen consumption and complex IV activity, CEM/Bcl-2 cells responded to the increased mitochondrial oxidative stress induced by resveratrol by significantly reducing mitochondrial respiration, complex IV activity, and O(2)(-) production, and promoted cell survival. o(2) 275-279 BCL2 apoptosis regulator Homo sapiens 104-109 20367277-5 2010 The inhibitory effect of Bcl-2 on resveratrol-induced mitochondrial O(2)(-) production is further corroborated by the neutralization of this regulatory effect upon siRNA-mediated gene silencing of Bcl-2. Resveratrol 34-45 BCL2 apoptosis regulator Homo sapiens 25-30 20367277-5 2010 The inhibitory effect of Bcl-2 on resveratrol-induced mitochondrial O(2)(-) production is further corroborated by the neutralization of this regulatory effect upon siRNA-mediated gene silencing of Bcl-2. Resveratrol 34-45 BCL2 apoptosis regulator Homo sapiens 197-202 20367277-5 2010 The inhibitory effect of Bcl-2 on resveratrol-induced mitochondrial O(2)(-) production is further corroborated by the neutralization of this regulatory effect upon siRNA-mediated gene silencing of Bcl-2. o(2)( 68-73 BCL2 apoptosis regulator Homo sapiens 25-30 20367277-6 2010 These data provide evidence implicating mitochondrial metabolism in the anticancer activity of resveratrol, and underscore a novel regulatory role of Bcl-2 against exogenous oxidative stress through its ability to fine tune mitochondrial respiration, and by doing so maintaining mitochondrial O(2)(-) at a level optimal for survival. Resveratrol 95-106 BCL2 apoptosis regulator Homo sapiens 150-155 20367277-6 2010 These data provide evidence implicating mitochondrial metabolism in the anticancer activity of resveratrol, and underscore a novel regulatory role of Bcl-2 against exogenous oxidative stress through its ability to fine tune mitochondrial respiration, and by doing so maintaining mitochondrial O(2)(-) at a level optimal for survival. o(2) 293-297 BCL2 apoptosis regulator Homo sapiens 150-155 20584903-0 2010 Bcl-2 and Bax interact via the BH1-3 groove-BH3 motif interface and a novel interface involving the BH4 motif. BH 3 44-47 BCL2 apoptosis regulator Homo sapiens 0-5 20584903-0 2010 Bcl-2 and Bax interact via the BH1-3 groove-BH3 motif interface and a novel interface involving the BH4 motif. sapropterin 100-103 BCL2 apoptosis regulator Homo sapiens 0-5 20584903-3 2010 Here, we used site-specific photocross-linking to map the surfaces of Bax and Bcl-2 that interact in the hetero-complex formed in a Triton X-100 micelle as a membrane surrogate. Octoxynol 132-144 BCL2 apoptosis regulator Homo sapiens 78-83 20584903-6 2010 However, other interaction sites form a second interface that includes helix 6 of Bax and the BH4 region of Bcl-2. sapropterin 94-97 BCL2 apoptosis regulator Homo sapiens 108-113 20944105-6 2010 Induction of apoptosis by XN was associated with the inhibition of prosurvival Akt, NF-kappaB and mTOR signaling proteins and NF-kappaB-regulated anti-apoptotic Bcl-2 and survivin. xanthohumol 26-28 BCL2 apoptosis regulator Homo sapiens 161-166 20726007-4 2010 Curcumin up-regulates caspase family proteins and down-regulates anti-apoptotic genes (Bcl-2 and Bcl-X(L)). Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 87-92 20206442-4 2010 Lunasin-induced apoptosis as evidenced by a twofold increase in the percentage of cells undergoing apoptosis, decreased Bcl-2:Bax ratio from 8.5 to 0.4, increased caspase-3 activity by 77% and increased expression of pro-apoptotic nuclear clusterin by five fold when compared to untreated cells. LUNASINE 0-7 BCL2 apoptosis regulator Homo sapiens 120-125 20660371-3 2010 Small interfering RNA-mediated knockdown of TR3 or cell treatment with the TR3 antagonist 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) decreased proliferation, induced apoptosis, and decreased expression of antiapoptotic genes including Bcl-2 and survivin in pancreatic cancer cells. 1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane 90-136 BCL2 apoptosis regulator Homo sapiens 253-258 20660371-3 2010 Small interfering RNA-mediated knockdown of TR3 or cell treatment with the TR3 antagonist 1,1-bis(3"-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) decreased proliferation, induced apoptosis, and decreased expression of antiapoptotic genes including Bcl-2 and survivin in pancreatic cancer cells. 1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane 138-149 BCL2 apoptosis regulator Homo sapiens 253-258 20732961-1 2010 PURPOSE: ABT-737, which blocks the function of Bcl-2 and Bcl-X(L) but not Mcl-1, has shown single-agent activity in preclinical models of small cell lung cancer (SCLC). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 9-12 BCL2 apoptosis regulator Homo sapiens 47-52 20482488-6 2010 The progress of clinical application of two ASOs showing promise in treatment of human cancers--Oblimersen (G3139), targeting BCL2 for the treatment of metastatic melanoma, and Custirsen (OGX-11), targeting clusterin for the treatment of hormone refractory prostate cancer (HRPC)--is examined. Oligonucleotides, Antisense 44-48 BCL2 apoptosis regulator Homo sapiens 126-130 20519142-0 2010 Pamidronate inhibits antiapoptotic bcl-2 expression through inhibition of the mevalonate pathway in prostate cancer PC-3 cells. Pamidronate 0-11 BCL2 apoptosis regulator Homo sapiens 35-40 20519142-5 2010 First, we observed that bcl-2 mRNA expression in PC-3 was significantly inhibited to 12% of the control level by treatment with 100 microM pamidronate for 12h. Pamidronate 139-150 BCL2 apoptosis regulator Homo sapiens 24-29 20519142-7 2010 Simultaneous treatment with geranylgeraniol, an intermediate of the mevalonate pathway, significantly blocked inhibition by pamidronate, and treatment with geranylgeranyl transferase inhibitor GGTI-286 also suppressed bcl-2 mRNA expression. geranylgeraniol 28-43 BCL2 apoptosis regulator Homo sapiens 218-223 20519142-10 2010 These results strongly indicate that bcl-2 reduction in bisphosphonate-treated PC-3 cells is dependent on inhibition of the mevalonate pathway. Diphosphonates 56-70 BCL2 apoptosis regulator Homo sapiens 37-42 20519142-10 2010 These results strongly indicate that bcl-2 reduction in bisphosphonate-treated PC-3 cells is dependent on inhibition of the mevalonate pathway. Mevalonic Acid 124-134 BCL2 apoptosis regulator Homo sapiens 37-42 20519142-11 2010 The inhibitory effect of bisphosphonates on bcl-2 expression shown in prostate cancer cell line should be tested in animal experiments and clinical studies. Diphosphonates 25-40 BCL2 apoptosis regulator Homo sapiens 44-49 20580704-5 2010 We observed that alpha-lipoic acid is able to scavenge reactive oxygen species in MCF-7 cells and that the reduction of reactive oxygen species is followed by cell growth arrest in the G1 phase of the cell cycle, via the specific inhibition of Akt pathway and the up-regulation of the cyclin-dependent kinase inhibitor p27(kip1), and by apoptosis, via changes of the ratio of the apoptotic-related protein Bax/Bcl-2. Thioctic Acid 17-34 BCL2 apoptosis regulator Homo sapiens 410-415 20580704-5 2010 We observed that alpha-lipoic acid is able to scavenge reactive oxygen species in MCF-7 cells and that the reduction of reactive oxygen species is followed by cell growth arrest in the G1 phase of the cell cycle, via the specific inhibition of Akt pathway and the up-regulation of the cyclin-dependent kinase inhibitor p27(kip1), and by apoptosis, via changes of the ratio of the apoptotic-related protein Bax/Bcl-2. Reactive Oxygen Species 120-143 BCL2 apoptosis regulator Homo sapiens 410-415 19800779-7 2010 While genistein, resveratrol and glycitein all increased apoptosis and reduced the Bcl-2/Bax ratio, resveratrol reduced this ratio more than either genistein or glycitein. glycitein 33-42 BCL2 apoptosis regulator Homo sapiens 83-88 20095801-0 2010 Effects of diphencyprone on expression of Bcl-2 protein in patients with alopecia areata. diphenylcyclopropenone 11-24 BCL2 apoptosis regulator Homo sapiens 42-47 20095801-4 2010 We investigated the effects of treatment with DPCP on the expression of Bcl-2 protein in hair follicle epithelial cells of AA patients and its relation to clinical response to treatment. diphenylcyclopropenone 46-50 BCL2 apoptosis regulator Homo sapiens 72-77 20664932-9 2010 Overexpression of Bcl-2 and Akt significantly attenuated NVP-AEW541 and dasatinib-induced Bax activation and cell death. Dasatinib 72-81 BCL2 apoptosis regulator Homo sapiens 18-23 20095801-8 2010 RESULTS: Level of Bcl-2 expression in respondent patients (Group 1) was significantly higher after DPCP treatment (36.50 +/- 4.23) compared to pretreatment state (3.67 +/- 1.406, P < 0.001). diphenylcyclopropenone 99-103 BCL2 apoptosis regulator Homo sapiens 18-23 19800779-7 2010 While genistein, resveratrol and glycitein all increased apoptosis and reduced the Bcl-2/Bax ratio, resveratrol reduced this ratio more than either genistein or glycitein. Genistein 6-15 BCL2 apoptosis regulator Homo sapiens 83-88 19800779-9 2010 On knockdown analysis, genistein, resveratrol and glycitein all reduced the Bcl-2/Bax ratio in the presence of apoptosis-inducing stimuli, and estrogen receptor (ER) alpha silencing had no effect on these reductions. Genistein 23-32 BCL2 apoptosis regulator Homo sapiens 76-81 19800779-9 2010 On knockdown analysis, genistein, resveratrol and glycitein all reduced the Bcl-2/Bax ratio in the presence of apoptosis-inducing stimuli, and estrogen receptor (ER) alpha silencing had no effect on these reductions. Resveratrol 34-45 BCL2 apoptosis regulator Homo sapiens 76-81 19800779-9 2010 On knockdown analysis, genistein, resveratrol and glycitein all reduced the Bcl-2/Bax ratio in the presence of apoptosis-inducing stimuli, and estrogen receptor (ER) alpha silencing had no effect on these reductions. glycitein 50-59 BCL2 apoptosis regulator Homo sapiens 76-81 21090097-1 2010 OBJECTIVE: To study the effect of intranasal glucosteroid on the expression of PKC, Bcl-2 and Bax in nasal polyps. glucosteroid 45-57 BCL2 apoptosis regulator Homo sapiens 84-89 20543097-10 2010 Tadalafil attenuated DOX-induced apoptosis and depletion of prosurvival proteins, including Bcl-2 and GATA-4, in myocardium. Tadalafil 0-9 BCL2 apoptosis regulator Homo sapiens 92-97 20543097-10 2010 Tadalafil attenuated DOX-induced apoptosis and depletion of prosurvival proteins, including Bcl-2 and GATA-4, in myocardium. Doxorubicin 21-24 BCL2 apoptosis regulator Homo sapiens 92-97 20803769-0 2010 Cordycepin induces apoptosis by enhancing JNK and p38 kinase activity and increasing the protein expression of Bcl-2 pro-apoptotic molecules. cordycepin 0-10 BCL2 apoptosis regulator Homo sapiens 111-116 19533419-0 2010 Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2. Oligonucleotides 82-98 BCL2 apoptosis regulator Homo sapiens 153-158 21472325-9 2010 After treatment with 10 microM pipoxolan for 24 h, there was an increase in pro-apoptotic Bax and a decrease in anti-apoptotic Bcl-2 and Bcl-xL proteins. pipoxolan 31-40 BCL2 apoptosis regulator Homo sapiens 127-132 20663933-3 2010 Although the absence of FADD or caspase-8 did not alter apoptosis rates in Jurkat cells, overexpression of dominant-negative caspase-9 or of antiapoptotic Bcl-xL or Bcl-2 largely decreased the cytotoxicity of DHA, demonstrating a role of the intrinsic death pathway. artenimol 209-212 BCL2 apoptosis regulator Homo sapiens 165-170 20663933-4 2010 The proapoptotic Bcl-2 effector protein Bak and the Bcl-2 homology domain 3-only protein NOXA turned out to be important mediators of DHA-induced apoptosis in Jurkat cells. artenimol 134-137 BCL2 apoptosis regulator Homo sapiens 17-22 20663933-4 2010 The proapoptotic Bcl-2 effector protein Bak and the Bcl-2 homology domain 3-only protein NOXA turned out to be important mediators of DHA-induced apoptosis in Jurkat cells. artenimol 134-137 BCL2 apoptosis regulator Homo sapiens 52-57 20397191-7 2010 Moreover, treatment with z-DEVD-fmk (a specific caspase-3 inhibitor) and the overexpression of Bcl-2 prevented eupafolin-stimulated caspase-8 activation. eupafolin 111-120 BCL2 apoptosis regulator Homo sapiens 95-100 20397191-8 2010 Altogether, these results suggest that the eupafolin-induced apoptosis in HeLa cells is mediated by caspase-dependent pathways, involving caspases-3, -9, and -8, which are initiated by the Bcl-2-dependent loss of DeltaPsi(m). eupafolin 43-52 BCL2 apoptosis regulator Homo sapiens 189-194 21302442-1 2010 OBJECTIVE: To assess effects of proteasome inhibitor Bortezomib (Bor) in combination with Daunorubicin (DNR) on proliferation, apoptosis and the expression of Bcl-2 mRNA in primary leukemia cells in vitro. Bortezomib 53-63 BCL2 apoptosis regulator Homo sapiens 159-164 22966396-7 2010 Among the genes, Bcl-2/adenovirus E1B 19 kDa protein interacting protein 3 (BNIP3), a Bcl-2 family pro-apoptotic protein, was identified as being involved in CPT-11 resistance following methylation of its promoter. Irinotecan 158-164 BCL2 apoptosis regulator Homo sapiens 17-22 20012722-4 2010 As(2)O(3)-induced apoptosis was partially inhibited by caspase inhibitor and accompanied by changes in the expression of Bcl-2 family proteins, decrease of mitochondrial membrane potential (MMP), release of cytochrome C from mitochondria, activation of caspase-3, caspase-9, and cleavage of poly (ADP-ribose) polymerase (PARP). (2)o(3) 2-9 BCL2 apoptosis regulator Homo sapiens 121-126 20084480-0 2010 Antiproliferative effect of 13-cis-retinoic acid is associated with granulocyte differentiation and decrease in cyclin B1 and Bcl-2 protein levels in G0/G1 arrested HL-60 cells. Isotretinoin 28-48 BCL2 apoptosis regulator Homo sapiens 126-131 21302442-8 2010 Compared with control group and single drug (DNR or Bor) group, there were obvious increase of apoptosis ratio and obvious decrease of Bcl-2 in the group of DNR 100 nmol/L combined with Bor 20 nmol/L after 24 h or 48 h cultivation (P < 0.05). Daunorubicin 45-48 BCL2 apoptosis regulator Homo sapiens 135-140 21302442-8 2010 Compared with control group and single drug (DNR or Bor) group, there were obvious increase of apoptosis ratio and obvious decrease of Bcl-2 in the group of DNR 100 nmol/L combined with Bor 20 nmol/L after 24 h or 48 h cultivation (P < 0.05). Bortezomib 52-55 BCL2 apoptosis regulator Homo sapiens 135-140 21302442-8 2010 Compared with control group and single drug (DNR or Bor) group, there were obvious increase of apoptosis ratio and obvious decrease of Bcl-2 in the group of DNR 100 nmol/L combined with Bor 20 nmol/L after 24 h or 48 h cultivation (P < 0.05). Daunorubicin 157-160 BCL2 apoptosis regulator Homo sapiens 135-140 21302442-8 2010 Compared with control group and single drug (DNR or Bor) group, there were obvious increase of apoptosis ratio and obvious decrease of Bcl-2 in the group of DNR 100 nmol/L combined with Bor 20 nmol/L after 24 h or 48 h cultivation (P < 0.05). Bortezomib 186-189 BCL2 apoptosis regulator Homo sapiens 135-140 20615460-9 2010 LJGP induced the reduction of mitochondrial membrane potential with activation of the Bcl-2 family of proteins and caspase-9. ljgp 0-4 BCL2 apoptosis regulator Homo sapiens 86-91 20571027-11 2010 This suggests that the degradation of bcl-2 mRNA induced by AS1411 results from both interference with nucleolin protection of bcl-2 mRNA and recruitment of the exosome by AUF1. AGRO 100 60-66 BCL2 apoptosis regulator Homo sapiens 38-43 20656010-4 2010 We found that Bcl-2/Bax ratio was significantly decreased and cytochrome c was released from mitochondrion to cytosol, which indicated that the mitochondrial pathway was activated by berberine. Berberine 183-192 BCL2 apoptosis regulator Homo sapiens 14-19 20647040-7 2010 The down-expression of Bcl-2, up-regulation of Bax, caspase-3 and caspase-9 activities followed by above changes revealed that the cytotoxicity of SM was involved in a lysosomal-mitochondrial death pathway induced by SM. beta-solamarine 147-149 BCL2 apoptosis regulator Homo sapiens 23-28 20571027-11 2010 This suggests that the degradation of bcl-2 mRNA induced by AS1411 results from both interference with nucleolin protection of bcl-2 mRNA and recruitment of the exosome by AUF1. AGRO 100 60-66 BCL2 apoptosis regulator Homo sapiens 127-132 20808790-7 2010 Enforced translocation of cyclin B1 and Cdk1 into mitochondria with a mitochondrial-targeting-peptide increased levels of Ser-315 phosphorylation on mitochondrial p53, improved ATP production and decreased apoptosis by sequestering p53 from binding to Bcl-2 and Bcl-xL. Serine 122-125 BCL2 apoptosis regulator Homo sapiens 252-257 20804583-3 2010 Taurine exerts its neuroprotective functions against the glutamate induced excitotoxicity by reducing the glutamate-induced increase of intracellular calcium level, by shifting the ratio of Bcl-2 and Bad ratio in favor of cell survival and by reducing the ER stress. Taurine 0-7 BCL2 apoptosis regulator Homo sapiens 190-195 20804583-3 2010 Taurine exerts its neuroprotective functions against the glutamate induced excitotoxicity by reducing the glutamate-induced increase of intracellular calcium level, by shifting the ratio of Bcl-2 and Bad ratio in favor of cell survival and by reducing the ER stress. Glutamic Acid 57-66 BCL2 apoptosis regulator Homo sapiens 190-195 20718984-7 2010 EGCG induces apoptosis by activating capase-3/7 and inhibiting the expression of Bcl-2, survivin and XIAP in CSCs. (-)-Epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 81-86 20727180-4 2010 RESULTS: While low concentrations of nicotine induced activation of NF-kappaB, Akt, Bcl2, MAPKs, AP1 and IAPs in H1299, it failed to induce NF-kappaB in A549, and compared to H1299, almost 100 times higher concentration of nicotine was required to induce all other survival signals in A549. Nicotine 37-45 BCL2 apoptosis regulator Homo sapiens 84-88 20493836-6 2010 Serum deprivation of PASMCs resulted in mitochondrial membrane depolarization, decreased expression of Bcl-2 and enhanced expression of Bax, all effects were reversed by 8,9-EET analog (214) in a ROCK dependent manner. pasmcs 21-27 BCL2 apoptosis regulator Homo sapiens 103-108 20808946-4 2010 Furthermore, increased levels of Bcl-2 and Bcl-xL in association with a decrease in the autophagy-related protein LC3-II were noted in cytotrophoblastic cells treated with vitamins C and E under standard culture conditions. vitamins c and e 172-188 BCL2 apoptosis regulator Homo sapiens 33-38 20529838-0 2010 The Bcl-2 homology domain 3 mimetic gossypol induces both Beclin 1-dependent and Beclin 1-independent cytoprotective autophagy in cancer cells. Gossypol 36-44 BCL2 apoptosis regulator Homo sapiens 4-9 20601444-2 2010 However, ABT-737, a specific BCL2 inhibitor, is neither orally bioavailable nor metabolically stable. ABT-737 9-16 BCL2 apoptosis regulator Homo sapiens 29-33 20601444-11 2010 CONCLUSIONS: Our data indicate that the exquisite in vitro sensitivity of CLL cells to BCL2 inhibitors may be lost in vivo due to high cell densities and the albumin binding of ABT-263. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 177-180 BCL2 apoptosis regulator Homo sapiens 87-91 20601444-12 2010 Modification of ABT-263 may yield a BCL2 inhibitor with greater bioavailability and more favorable pharmacokinetics. navitoclax 16-23 BCL2 apoptosis regulator Homo sapiens 36-40 20639495-3 2010 In this study, we demonstrate that mast cells exhibit a high sensitivity to ABT-737, a BH3-only mimetic molecule that induces apoptosis through high-affinity binding to the prosurvival proteins, Bcl-2, Bcl-XL, and Bcl-w. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 76-79 BCL2 apoptosis regulator Homo sapiens 195-200 20529838-1 2010 Gossypol, a natural Bcl-2 homology domain 3 mimetic compound isolated from cottonseeds, is currently being evaluated in clinical trials. Gossypol 0-8 BCL2 apoptosis regulator Homo sapiens 20-25 20529838-3 2010 We first show that knockdown of the Bcl-2 homology domain 3-only protein Beclin 1 reduces gossypol-induced autophagy in MCF-7 cells, but not in HeLa cells. Gossypol 90-98 BCL2 apoptosis regulator Homo sapiens 36-41 20529838-4 2010 Gossypol inhibits the interaction between Beclin 1 and Bcl-2 (B-cell leukemia/lymphoma 2), antagonizes the inhibition of autophagy by Bcl-2, and hence stimulates autophagy. Gossypol 0-8 BCL2 apoptosis regulator Homo sapiens 55-60 20704765-5 2010 When 5-FU and LY were treated in single and sequential combinations, the expression of p-AKT, p-NFkB, p-p53 and bcl-2 was observed on different concentrations by Western blot analysis. Fluorouracil 5-9 BCL2 apoptosis regulator Homo sapiens 112-117 20529838-4 2010 Gossypol inhibits the interaction between Beclin 1 and Bcl-2 (B-cell leukemia/lymphoma 2), antagonizes the inhibition of autophagy by Bcl-2, and hence stimulates autophagy. Gossypol 0-8 BCL2 apoptosis regulator Homo sapiens 62-88 20704765-12 2010 In sequential combination of 5-FU and LY, the expression of p-p53 was increased and bcl-2 expression was diminished compared to 5-FU alone. Fluorouracil 29-33 BCL2 apoptosis regulator Homo sapiens 84-89 20529838-4 2010 Gossypol inhibits the interaction between Beclin 1 and Bcl-2 (B-cell leukemia/lymphoma 2), antagonizes the inhibition of autophagy by Bcl-2, and hence stimulates autophagy. Gossypol 0-8 BCL2 apoptosis regulator Homo sapiens 134-139 20803121-9 2010 Following incubation with quercetin for 48 h, MCF-7 cells showed apoptotic cell death by the decreased levels of Bcl-2 protein and DeltaPsi(m) and increased activations of caspase-6, -8 and -9. Quercetin 26-35 BCL2 apoptosis regulator Homo sapiens 113-118 20691103-12 2010 Respectively, the rate of inhibition of EADM,5- Fu, NVB and DDP were significantly higher in the BCL-2 negative cancer cells than in the BCL-2 positive cancer cells. eadm 40-44 BCL2 apoptosis regulator Homo sapiens 97-102 20691103-12 2010 Respectively, the rate of inhibition of EADM,5- Fu, NVB and DDP were significantly higher in the BCL-2 negative cancer cells than in the BCL-2 positive cancer cells. eadm 40-44 BCL2 apoptosis regulator Homo sapiens 137-142 20691103-12 2010 Respectively, the rate of inhibition of EADM,5- Fu, NVB and DDP were significantly higher in the BCL-2 negative cancer cells than in the BCL-2 positive cancer cells. Fluorouracil 45-50 BCL2 apoptosis regulator Homo sapiens 97-102 20550194-0 2010 Inclusion complex of a Bcl-2 inhibitor with cyclodextrin: characterization, cellular accumulation, and in vivo antitumor activity. Cyclodextrins 44-56 BCL2 apoptosis regulator Homo sapiens 23-28 20550194-7 2010 Disruption of Bcl-2/Bax heterodimerization in MCF-7 cells further revealed S1-gamma-CD could reach the subcellular function site. s1-gamma-cd 75-86 BCL2 apoptosis regulator Homo sapiens 14-19 20716276-5 2010 We have recently reported that ROS and RNS can regulate Bcl-2 expression levels, thereby impacting its function. ros 31-34 BCL2 apoptosis regulator Homo sapiens 56-61 20716276-6 2010 Superoxide anion (*O(2)(-)) plays a proapoptotic role by causing downregulation and degradation of Bcl-2 protein through the ubiquitin-proteasomal pathway. Superoxides 0-16 BCL2 apoptosis regulator Homo sapiens 99-104 20716276-7 2010 In contrast, nitric oxide (NO)-mediated S-nitrosylation of Bcl-2 prevents its ubiquitination and subsequent proteasomal degradation, leading to inhibition of apoptosis. Nitric Oxide 13-25 BCL2 apoptosis regulator Homo sapiens 59-64 20651843-12 2010 We also found that the apoptotic process triggered by adenosine was involved in G0-G1 cell-cycle arrest, enhanced the activity of caspase-3, upregulated p53 and NF-kappaB p65 expression, and downregulated Bcl-2 expression. Adenosine 54-63 BCL2 apoptosis regulator Homo sapiens 205-210 20168333-5 2010 Nevertheless, simultaneous disruption of the p38 MAPK pathway was required to suppress MCL-1 expression, thereby allowing tBID to activate the proapoptotic BCL-2 family member BAK and stimulate mitochondrial outer membrane permeabilization (MOMP). tBID 122-126 BCL2 apoptosis regulator Homo sapiens 156-161 20447425-8 2010 Comparative study between the expression of the bcl2 gene family induced by the wild type and E2F1 Ser/Ala403 mutant revealed a statistically different pattern between both conditions. Serine 99-102 BCL2 apoptosis regulator Homo sapiens 48-52 20456425-12 2010 Furthermore, 5 micromol/L AG490 and 10 micromol/L wortmannin treatment of A549 cells for 8 h resulted in upregulation of Bax and Bad and downregulation of Bcl-2, Bcl-X(L), XIAP and p-Bad. Wortmannin 50-60 BCL2 apoptosis regulator Homo sapiens 155-160 20538760-0 2010 The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. obatoclax 92-100 BCL2 apoptosis regulator Homo sapiens 60-65 19967402-6 2010 More importantly, BER significantly enhanced the anticancer activity of anticancer agents such as trichostatin A (the histone deacetylase inhibitor) and celecoxib (the inhibitor of cyclooxygenase-2) by strongly reducing the viability and/or the Bcl-2/Bax protein ratio in A549 cells. trichostatin A 98-112 BCL2 apoptosis regulator Homo sapiens 245-250 20709666-0 2010 Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Obatoclax mesylate 18-36 BCL2 apoptosis regulator Homo sapiens 66-71 20709666-2 2010 PATIENTS AND METHODS: We conducted a multicenter, open-label, noncomparative phase II study of obatoclax mesylate, a small-molecule pan-BCL-2 antagonist, in patients with MF. Obatoclax mesylate 95-113 BCL2 apoptosis regulator Homo sapiens 136-141 19967402-6 2010 More importantly, BER significantly enhanced the anticancer activity of anticancer agents such as trichostatin A (the histone deacetylase inhibitor) and celecoxib (the inhibitor of cyclooxygenase-2) by strongly reducing the viability and/or the Bcl-2/Bax protein ratio in A549 cells. Celecoxib 153-162 BCL2 apoptosis regulator Homo sapiens 245-250 20493187-8 2010 Treatment with GA and 17-AAG led to growth arrests in G1 and S phases, increased sub-G1 hypodipoid cell population, induced apoptotic cell death, and upregulated P53 and P21 expression, although the drug-induced Bcl-2 upregulation cannot prevent cell death. geldanamycin 15-17 BCL2 apoptosis regulator Homo sapiens 212-217 20591651-3 2010 HDM2 plays an important role in the expression of Noxa, a pro-apoptotic molecule of the Bcl-2 family, which induces NB cell apoptotic death after doxorubcin (Doxo) treatment. doxorubcin 146-156 BCL2 apoptosis regulator Homo sapiens 88-93 20591651-3 2010 HDM2 plays an important role in the expression of Noxa, a pro-apoptotic molecule of the Bcl-2 family, which induces NB cell apoptotic death after doxorubcin (Doxo) treatment. Desoxycorticosterone Acetate 158-162 BCL2 apoptosis regulator Homo sapiens 88-93 20435036-3 2010 Using arsenic trioxide-responsive KU7 and non-responsive 253JB-V bladder cancer cells as models, we show that in KU7 cells, < or =5 microM arsenic trioxide decreased Sp1, Sp3 and Sp4 and several Sp-dependent genes and responses including cyclin D1, epidermal growth factor receptor, bcl-2, survivin and vascular endothelial growth factor, whereas at concentrations up to 15 microM, minimal effects were observed in 253JB-V cells. Arsenic Trioxide 142-158 BCL2 apoptosis regulator Homo sapiens 286-291 20493187-8 2010 Treatment with GA and 17-AAG led to growth arrests in G1 and S phases, increased sub-G1 hypodipoid cell population, induced apoptotic cell death, and upregulated P53 and P21 expression, although the drug-induced Bcl-2 upregulation cannot prevent cell death. tanespimycin 22-28 BCL2 apoptosis regulator Homo sapiens 212-217 20375269-5 2010 The methylation status of 2 of these candidate genes, BCL-2 and retinoic acid-related orphan receptor alpha (RORA), was further confirmed by bisulfite sequencing and methylation-specific PCR, respectively. hydrogen sulfite 141-150 BCL2 apoptosis regulator Homo sapiens 54-59 20460269-6 2010 In cells, mouse and human spinal cord with SOD1 mutations, the binding to mutant SOD1 triggers a conformational change in Bcl-2 that results in the uncovering of its toxic BH3 domain and conversion of Bcl-2 into a toxic protein. BH 3 172-175 BCL2 apoptosis regulator Homo sapiens 122-127 20460269-7 2010 Bcl-2 carrying a mutagenized, non-toxic BH3 domain fails to support mutant SOD1 mitochondrial toxicity. BH 3 40-43 BCL2 apoptosis regulator Homo sapiens 0-5 20596669-11 2010 Likewise, MHY218-induced apoptosis through caspase-3 activation was confirmed by the increase in the release of cytochrome c and Bax/Bcl-2 ratio. N1-hydroxy-N8-(4-phenoxyphenyl)octanediamide 10-16 BCL2 apoptosis regulator Homo sapiens 133-138 20463006-0 2010 MJ-29 inhibits tubulin polymerization, induces mitotic arrest, and triggers apoptosis via cyclin-dependent kinase 1-mediated Bcl-2 phosphorylation in human leukemia U937 cells. 6-pyrrolidinyl-2-(2-hydroxyphenyl)-4-quinazolinone 0-5 BCL2 apoptosis regulator Homo sapiens 125-130 20589722-5 2010 Gossypol, a small molecule inhibitor of pro-survival Bcl-2 family proteins, has been demonstrated to inhibit AI prostate cancer growth. Gossypol 0-8 BCL2 apoptosis regulator Homo sapiens 53-58 20589722-8 2010 VCaP cells treated with AT-101 demonstrated an increase in apoptosis and downregulation of Bcl-2 pro-survival proteins. gossypol acetic acid 24-30 BCL2 apoptosis regulator Homo sapiens 91-96 20393484-6 2010 Curcumin decreased protein and mRNA expression levels of signal transducer and activator of transcription (STAT)-3, bcl-2, and survivin in three cell lines and in patients" PBMCs. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 116-121 20463006-6 2010 Furthermore, MJ-29-induced Bcl-2 phosphorylation was also significantly attenuated by CDK1 siRNA. 6-pyrrolidinyl-2-(2-hydroxyphenyl)-4-quinazolinone 13-18 BCL2 apoptosis regulator Homo sapiens 27-32 20663036-12 2010 Moreover, beta-elemene exposure resulted in a decreased Bcl-2 protein level, increased cytochrome c release, and activated PARP and caspase-3, -7, -9, and -10 in prostate cancer cells. beta-elemene 10-22 BCL2 apoptosis regulator Homo sapiens 56-61 20463006-11 2010 In conclusion, our results suggest that MJ-29 induces mitotic arrest and apoptosis in U937 cells via CDK1-mediated Bcl-2 phosphorylation and inhibits the in vivo tumor growth of U937 xenograft mice. 6-pyrrolidinyl-2-(2-hydroxyphenyl)-4-quinazolinone 40-45 BCL2 apoptosis regulator Homo sapiens 115-120 19896708-4 2010 miR-138 could significantly down-regulate the expression of P-glycoprotein, Bcl-2, and the transcription of the multidrug resistance gene 1. mir-138 0-7 BCL2 apoptosis regulator Homo sapiens 76-81 20647330-7 2010 Finally, we report that ABT-737, a compound that interacts with proteins of the BCL2 family and exhibits a BAD-like reactivity, sensitizes HCC cells toward sorafenib-induced apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 24-27 BCL2 apoptosis regulator Homo sapiens 80-84 20536712-4 2010 Using two-dimensional polyacrylamide gel electrophoresis coupled with matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF/MS) and immunoblot analysis, we found that cb-EPS dramatically induced Beclin-1 and GRP78, and affected Bcl-2 and Bak regulation. cb-eps 201-207 BCL2 apoptosis regulator Homo sapiens 262-267 20536712-5 2010 CONCLUSIONS: The results of this study indicate that cb-EPS are antitumourigenic against HT-29 colon cancer cells and that this activity is because of the activation of autophagic cell death promoted directly by the induction of Beclin-1 and GRP78, as well as indirectly through the induction of Bcl-2 and Bak. cb-eps 53-59 BCL2 apoptosis regulator Homo sapiens 296-301 20723300-6 2010 After treatment with 20 nmol/L BZM at different time point, a time-dependent reduction of procaspase-3 and BCL-2 protein expression in CA46 cells was found. Bortezomib 31-34 BCL2 apoptosis regulator Homo sapiens 107-112 20723291-6 2010 The BCL-2 expression level in Raji and Namalwa cell lines treated by RTX is down-regulated which may be one of the mechanisms sensitizing the cytotoxicity of Gemcitabine or Navelbine. gemcitabine 158-169 BCL2 apoptosis regulator Homo sapiens 4-9 23605383-7 2010 However, significant apoptotic cell death was observed after at least 30 h of ZEA exposure as a consequence of increased Bax expression, decreased Bcl-2 expression and mitochondrial membrane potential (Deltapsim)-released cytochrome c and activated caspase-3 and caspase-9. Zearalenone 78-81 BCL2 apoptosis regulator Homo sapiens 147-152 21090107-7 2010 We further proved fact that resveratrol can specifically promote the activity of sirt1; moreover, activated sirt1 modulates the activity of caspase-3 and bcl-2 family, involving in transcriptional regulation of p53 and NF-kappaB through antagonizing factor-induced acetylation. Resveratrol 28-39 BCL2 apoptosis regulator Homo sapiens 154-159 20723300-7 2010 It is concluded that the BZM can inhibit the proliferation and induce the apoptosis of CA46 cells, which relative mechanism may involve the reduction of BCL-2 and the activation of caspase 3. Bortezomib 25-28 BCL2 apoptosis regulator Homo sapiens 153-158 20723291-6 2010 The BCL-2 expression level in Raji and Namalwa cell lines treated by RTX is down-regulated which may be one of the mechanisms sensitizing the cytotoxicity of Gemcitabine or Navelbine. Vinorelbine 173-182 BCL2 apoptosis regulator Homo sapiens 4-9 20668721-0 2010 Minocycline is cytoprotective in human trabecular meshwork cells and optic nerve head astrocytes by increasing expression of XIAP, survivin, and Bcl-2. Minocycline 0-11 BCL2 apoptosis regulator Homo sapiens 145-150 20723295-2 2010 Cell apoptosis and cell cycle changes of HL-60 cells treated with As2O3 and/or TGFss1 were detected by cytomorphologic observation and flow cytometry, the protein expressions of P27(Kip1), TGF-ss1, cyclin E and BCL-2 were measured by immunohistochemistry. Arsenic Trioxide 66-71 BCL2 apoptosis regulator Homo sapiens 211-216 20825716-8 2010 The models treated with SB203580 could gradually elevate the sensitivity of HepG2/CDDP to cisplatin, block the detention of cell cycle, up-regulate the expression of Bax and down-regulate the expressions of Bcl-2 and P-gp. SB 203580 24-32 BCL2 apoptosis regulator Homo sapiens 207-212 20668552-7 2010 The bcl-2-induced HIF-1alpha stabilization in response to low oxygen tension conditions was achieved through the impairment of ubiquitin-dependent HIF-1alpha degradation involving the molecular chaperone HSP90, but it was not dependent on the prolyl hydroxylation of HIF-1alpha protein. Oxygen 62-68 BCL2 apoptosis regulator Homo sapiens 4-9 20663169-9 2010 For Western blot analysis, an increase in Bax expression and a decrease in Bcl-2 expression were observed in TXL-treated cells. Docetaxel 109-112 BCL2 apoptosis regulator Homo sapiens 75-80 21046756-12 2010 The increased Bax/Bcl-2 ratio is mechanistically linked to the gecko alcohol extract-induced tumor cell apoptosis. Alcohols 69-76 BCL2 apoptosis regulator Homo sapiens 18-23 20686688-5 2010 CONCLUSION: Taken together, ER stress plays an important role in alpha-TEA induced apoptosis by enhancing DR5/caspase-8 pro-apoptotic signaling and suppressing anti-apoptotic factors c-FLIP and Bcl-2 via ER stress mediated JNK/CHOP/DR5/caspase-8 signaling. 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid 65-74 BCL2 apoptosis regulator Homo sapiens 194-199 20668721-11 2010 RT-PCR and Western blotting yielded an overexpression of Bcl-2, XIAP, and survivin when TMC or ONHA were treated with minocycline 20-40 muM under conditions of oxidative stress and when additionally incubated with TGFbeta-2. tmc 88-91 BCL2 apoptosis regulator Homo sapiens 57-62 20668721-11 2010 RT-PCR and Western blotting yielded an overexpression of Bcl-2, XIAP, and survivin when TMC or ONHA were treated with minocycline 20-40 muM under conditions of oxidative stress and when additionally incubated with TGFbeta-2. Minocycline 118-129 BCL2 apoptosis regulator Homo sapiens 57-62 20668721-13 2010 Treatment with minocycline 20-40 muM led to increased viability and proliferation under oxidative stress and TGFbeta-2, as well as overexpression of Bcl-2, XIAP, and survivin. Minocycline 15-26 BCL2 apoptosis regulator Homo sapiens 149-154 20346922-5 2010 Preparation of mitochondrial/cytosol fraction followed with immunoblot analysis showed the release of chromosome c from mitochondria, down-regulated expression of Bcl-2 and translocation of Bax, Bak and Bid, suggesting the mitochondrial-related pathway might be involved in alpha-bisabolol-induced apoptosis either. alpha-Bisabolol 274-289 BCL2 apoptosis regulator Homo sapiens 163-168 20398749-5 2010 The up-regulation of GADD153 in flavokawain B-treated HCT116 cells is associated with mitochondrial dysfunction and altered expression of Bcl-2 family members. flavokawain B 32-45 BCL2 apoptosis regulator Homo sapiens 138-143 19908231-7 2010 Resveratrol inhibited the proliferation of 4 different human PaCa cell lines, synergized the apoptotic effects of gemcitabine, inhibited the constitutive activation of NF-kappaB and expression of bcl-2, bcl-xL, COX-2, cyclin D1 MMP-9 and VEGF. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 196-201 19937797-6 2010 Betulinic acid also downregulated the expression of STAT3-regulated gene products such as bcl-xL, bcl-2, cyclin D1 and survivin. betulinic acid 0-14 BCL2 apoptosis regulator Homo sapiens 98-103 20398749-9 2010 Taken together, our data provide evidence for a molecular mechanism to explain the apoptotic activity of Alpinia plants, showing that flavokawain B acts through ROS generation and GADD153 up-regulation to regulate the expression of Bcl-2 family members, thereby inducing mitochondrial dysfunction and apoptosis in HCT116 cells. flavokawain B 134-147 BCL2 apoptosis regulator Homo sapiens 232-237 20385117-5 2010 The NMR data indicate increasing lactate production during apoptosis, which implies involvement of the intrinsic mitochondrial pathway, a notion supported by down-regulation of Bcl-2 and up-regulation of Bax levels as detected by Western blotting. Lactic Acid 33-40 BCL2 apoptosis regulator Homo sapiens 177-182 20616035-3 2010 This "addiction" can be exploited therapeutically by combining aurora kinase inhibitors and the orally bioavailable BH3 mimetic, ABT-263, which inhibits Bcl-XL, Bcl-2, and Bcl-w. BH 3 116-119 BCL2 apoptosis regulator Homo sapiens 161-166 20616035-3 2010 This "addiction" can be exploited therapeutically by combining aurora kinase inhibitors and the orally bioavailable BH3 mimetic, ABT-263, which inhibits Bcl-XL, Bcl-2, and Bcl-w. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 129-132 BCL2 apoptosis regulator Homo sapiens 161-166 20562023-12 2010 Meanwhile, THP also inhibited the decrease of intracellular mitochondrial membrane potential (psim), caspase-3 activation, cytochrome-c release and reduced Bax/Bcl-2 ratio in THP pretreated, irradiated cells. tetrahydropalmatine 11-14 BCL2 apoptosis regulator Homo sapiens 160-165 20460378-0 2010 MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. Paclitaxel 63-73 BCL2 apoptosis regulator Homo sapiens 111-116 20460378-10 2010 Moreover, we demonstrated that the pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) is a direct target of miR-125b. mir-125b 104-112 BCL2 apoptosis regulator Homo sapiens 49-54 20562023-12 2010 Meanwhile, THP also inhibited the decrease of intracellular mitochondrial membrane potential (psim), caspase-3 activation, cytochrome-c release and reduced Bax/Bcl-2 ratio in THP pretreated, irradiated cells. tetrahydropalmatine 175-178 BCL2 apoptosis regulator Homo sapiens 160-165 20431351-2 2010 Recently, we have shown that by targeting the oncogene Bcl-2, PK11195 increases the [Ca ( 2+) ] in the Endoplasmic Reticulum ([Ca ( 2+) ]er) as well as IP3 induced mitochondrial ([Ca ( 2+) ]m) and cytosolic ([Ca ( 2+) ]c) Ca ( 2+) transients in HeLa cervix carcinoma cells. Inositol 1,4,5-Trisphosphate 152-155 BCL2 apoptosis regulator Homo sapiens 55-60 20217235-3 2010 In this study with the mitocan alpha-tocopheryl succinate (alpha-TOS) the role of the Bcl-2 family proteins in the mechanism of malignant cell apoptosis has been determined. alpha-Tocopherol 31-57 BCL2 apoptosis regulator Homo sapiens 86-91 20217235-3 2010 In this study with the mitocan alpha-tocopheryl succinate (alpha-TOS) the role of the Bcl-2 family proteins in the mechanism of malignant cell apoptosis has been determined. alpha-Tocopherol 59-68 BCL2 apoptosis regulator Homo sapiens 86-91 19782128-6 2010 We also found that the total level of Bcl-2 decreased after HI in vivo and after ionophore challenge in cultured human neuroblastoma (IMR-32) cells in vitro. hi 60-62 BCL2 apoptosis regulator Homo sapiens 38-43 20851287-0 2010 Expression of sonic hedgehog signaling components in hepatocellular carcinoma and cyclopamine-induced apoptosis through Bcl-2 downregulation in vitro. cyclopamine 82-93 BCL2 apoptosis regulator Homo sapiens 120-125 20851287-13 2010 Cyclopamine remarkably decreased cell viability, induced apoptosis and downregulated Bcl-2 expression in HCC cells. cyclopamine 0-11 BCL2 apoptosis regulator Homo sapiens 85-90 20851287-15 2010 Cyclopamine induces apoptosis through downregulating Bcl-2 in HCC. cyclopamine 0-11 BCL2 apoptosis regulator Homo sapiens 53-58 19782128-7 2010 Furthermore, the Bcl-2 reduction was calpain-dependent, because it could be prevented by the calpain inhibitor CX295 both in vivo and in vitro, suggesting cross-talk between excitotoxic and apoptotic mechanisms. AK 295 111-116 BCL2 apoptosis regulator Homo sapiens 17-22 20187987-6 2010 Other assays demonstrated that the protective effect of ME was mediated by its antioxidant and anti-apoptotic effects, regulating reactive oxygen species and NO generation, Bcl-2 and Bax proteins, mitochondrial membrane depolarisation and caspase-3 activation. methionylglutamic acid 56-58 BCL2 apoptosis regulator Homo sapiens 173-178 20606027-0 2010 Minocycline is cytoprotective in human corneal endothelial cells and induces anti-apoptotic B-cell CLL/lymphoma 2 (Bcl-2) and X-linked inhibitor of apoptosis (XIAP). Minocycline 0-11 BCL2 apoptosis regulator Homo sapiens 92-113 20606027-0 2010 Minocycline is cytoprotective in human corneal endothelial cells and induces anti-apoptotic B-cell CLL/lymphoma 2 (Bcl-2) and X-linked inhibitor of apoptosis (XIAP). Minocycline 0-11 BCL2 apoptosis regulator Homo sapiens 115-120 20606027-6 2010 Expression of B-cell CLL/lymphoma 2 (Bcl-2) and X-linked inhibitor of apoptosis (XIAP) and their mRNA were assessed by reverse transcriptase (RT)-PCR and western blot analysis after treatment with minocycline alone and consecutive incubation with 200 microM H(2)O(2) and TGF-beta2. Minocycline 197-208 BCL2 apoptosis regulator Homo sapiens 14-35 20094061-6 2010 In addition to this, the synthesis of reactive oxygen species induced by staurosporine was attenuated and antiapoptotic proteins of the Bcl-2 family accumulated in the presence of lipoxin. Lipoxins 180-187 BCL2 apoptosis regulator Homo sapiens 136-141 20606027-11 2010 When CECs were treated with minocycline and then consecutively with H(2)O(2) or TGF-beta2, RT-PCR and western blot analysis yielded an overexpression of Bcl-2 and XIAP. Minocycline 28-39 BCL2 apoptosis regulator Homo sapiens 153-158 20361964-6 2010 Quercetin treatment protected ARPE-19 cells from H(2)O(2)-induced oxidative injury, enhanced BCL-2 transcript levels, increased the BCL-2/BAX ratio, suppressed the transcription of pro-apoptotic factors such as BAX, FADD, CASPASE-3 and CASPASE-9, inhibited the transcription of inflammatory factors such as TNF-alpha, COX-2 and INOS, and decreased the levels of COX and NO in the culture medium. Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 93-98 20411565-5 2010 We found that HK434, a PKC agonist, in combination with calcium ionophore, can induce Nur77 and Nor-1 phosphorylation, translocation, Bcl-2 BH3 exposure and thymocyte apoptosis. hk434 14-19 BCL2 apoptosis regulator Homo sapiens 134-139 20479784-8 2010 Six of the Bcl-2 family members inhibited apoptosis induced by camptothecin in mammalian cells with HyBcl-2-like 4 showing an especially strong protective effect. Camptothecin 63-75 BCL2 apoptosis regulator Homo sapiens 11-16 20361964-6 2010 Quercetin treatment protected ARPE-19 cells from H(2)O(2)-induced oxidative injury, enhanced BCL-2 transcript levels, increased the BCL-2/BAX ratio, suppressed the transcription of pro-apoptotic factors such as BAX, FADD, CASPASE-3 and CASPASE-9, inhibited the transcription of inflammatory factors such as TNF-alpha, COX-2 and INOS, and decreased the levels of COX and NO in the culture medium. Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 132-137 20472713-12 2010 Xenon caused an increased expression of p-Akt, HIF-1alpha and Bcl-2, while the other noble gases did not modify protein expression. Xenon 0-5 BCL2 apoptosis regulator Homo sapiens 62-67 20397022-12 2010 Pro-apoptotic bcl-2 family member, bad is down-regulated in cell lines HCT116 and CaCo2 by bortezomib treatment, a neoplasia-promoting event that is reversed by combination treatment. caco2 82-87 BCL2 apoptosis regulator Homo sapiens 14-19 20668314-0 2010 Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of BCL-2 in LNCaP cells. Oligonucleotides 21-37 BCL2 apoptosis regulator Homo sapiens 108-113 20397022-12 2010 Pro-apoptotic bcl-2 family member, bad is down-regulated in cell lines HCT116 and CaCo2 by bortezomib treatment, a neoplasia-promoting event that is reversed by combination treatment. Bortezomib 91-101 BCL2 apoptosis regulator Homo sapiens 14-19 20378717-8 2010 beta-Escin also down-regulated the expression of STAT3-regulated gene products, such as cyclin D1, Bcl-2, Bcl-xL, survivin, Mcl-1, and vascular endothelial growth factor. Escin 0-10 BCL2 apoptosis regulator Homo sapiens 99-104 20043176-9 2010 The expressions of p-KIT, p-AKT, PCNA and BCL-2 were higher in the samples of imatinib-resistant GISTs than those of imatinib-responsive ones. Imatinib Mesylate 78-86 BCL2 apoptosis regulator Homo sapiens 42-47 20439934-3 2010 N-acetyl-L-Cysteine (NAC) abrogated mitochondrial injury, cytochrome c, AIF, and Smac release, and Bcl-2 and Bcl-xL suppression and Bax and Bad activation induced by butyric acid. Butyric Acid 166-178 BCL2 apoptosis regulator Homo sapiens 99-104 19757172-10 2010 Furthermore, real-time PCR and Western blot analysis revealed an upregulation of Bcl-2 and a downregulation of Bax in QBC939 after the pre-treatment of tamoxifen. Tamoxifen 152-161 BCL2 apoptosis regulator Homo sapiens 81-86 20528251-9 2010 The ratio of Bcl-2/Bax protein decreased, and the percentage of activated caspase-3 increased in myeloma cells treated by matrine for 48 h, but this matrine-induced activity of caspase-3 was completely canceled by the addition of Z-Asp(O-Me)-Glu(O-Me)-Val-Asp(O-Me) fluoromethyl ketone (Z-DEVD-FMK), a caspase-3 inhibitor. matrine 122-129 BCL2 apoptosis regulator Homo sapiens 13-18 20528251-9 2010 The ratio of Bcl-2/Bax protein decreased, and the percentage of activated caspase-3 increased in myeloma cells treated by matrine for 48 h, but this matrine-induced activity of caspase-3 was completely canceled by the addition of Z-Asp(O-Me)-Glu(O-Me)-Val-Asp(O-Me) fluoromethyl ketone (Z-DEVD-FMK), a caspase-3 inhibitor. matrine 149-156 BCL2 apoptosis regulator Homo sapiens 13-18 20528251-9 2010 The ratio of Bcl-2/Bax protein decreased, and the percentage of activated caspase-3 increased in myeloma cells treated by matrine for 48 h, but this matrine-induced activity of caspase-3 was completely canceled by the addition of Z-Asp(O-Me)-Glu(O-Me)-Val-Asp(O-Me) fluoromethyl ketone (Z-DEVD-FMK), a caspase-3 inhibitor. benzyloxycarbonyl-asparagine 230-235 BCL2 apoptosis regulator Homo sapiens 13-18 19757179-7 2010 In addition, beta-ionone upregulated Bax protein and downregulated Bcl2 protein which led to Bax translocation and cytochrome c release, subsequently activated Caspase 3, thus resulting in apoptosis. beta-ionone 13-24 BCL2 apoptosis regulator Homo sapiens 67-71 20157766-9 2010 These changes in GSI-treated HL60 cells correlated with the down-regulation of c-Myc and Bcl2, and the low phosphorylation of the Rb protein. 2-(5-Chlorothiophen-2-Yl)-N-[(3s)-1-(4-{2-[(Dimethylamino)methyl]-1h-Imidazol-1-Yl}-2-Fluorophenyl)-2-Oxopyrrolidin-3-Yl]ethanesulfonamide 17-20 BCL2 apoptosis regulator Homo sapiens 89-93 21472292-0 2010 Tanshinone IIA may inhibit the growth of small cell lung cancer H146 cells by up-regulating the Bax/Bcl-2 ratio and decreasing mitochondrial membrane potential. tanshinone 0-14 BCL2 apoptosis regulator Homo sapiens 100-105 20587533-0 2010 The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma. Gossypol 24-36 BCL2 apoptosis regulator Homo sapiens 8-13 20587533-3 2010 Glioma cells displayed only limited sensitivity to single-agent treatment with the BH3 mimetics HA14-1, BH3I-2", and ABT-737, whereas the pan-Bcl-2 inhibitor (-)-gossypol efficiently induced cell death. Gossypol 158-170 BCL2 apoptosis regulator Homo sapiens 142-147 20587533-8 2010 Our data suggest that pan-Bcl-2 inhibitors are promising drugs that induce caspase-independent, autophagic cell death in apoptosis-resistant malignant glioma cells and augment the action of TMZ. Temozolomide 190-193 BCL2 apoptosis regulator Homo sapiens 26-31 20213344-1 2010 The present study tests the hypothesis that hyperoxia results in increased tyrosine phosphorylation of apoptotic proteins Bcl-2, Bcl-xl, Bax & Bad in the mitochondrial fraction of the cerebral cortex of newborn piglets. Tyrosine 75-83 BCL2 apoptosis regulator Homo sapiens 122-127 21472297-5 2010 Moreover, kayadiol-treated HeLa cells showed activation of caspases-3 and -9, as well as an increase in the depolarization of mitochondrial membrane potential and the Bax/Bcl-2 ratio. KAYADIOL 10-18 BCL2 apoptosis regulator Homo sapiens 171-176 21472305-13 2010 Western blot analysis showed that cinobufagin up-regulated Bax expression and down-regulated Bcl-2 expression. cinobufagin 34-45 BCL2 apoptosis regulator Homo sapiens 93-98 20693713-6 2010 TUNEL showed that DADS enhanced the cell apoptosis and apoptosis-promoting protein caspase-3 expression, decreased apoptosis-inhibiting protein bcl-2 expression, and also inhibited proliferation associated protein PCNA expression. diallyl disulfide 18-22 BCL2 apoptosis regulator Homo sapiens 144-149 20929130-4 2010 CONCLUSION: PAB can inhibit the proliferation and induce the apoptosis of Hela cells in vitro, and its molecular mechanism may be associated with up-regulating bax mRNA expression and down-regulating bcl-2 mRNA expression. pseudolaric acid B 12-15 BCL2 apoptosis regulator Homo sapiens 200-205 21472287-5 2010 The combination of bortezomib and SAHA caused an increase in the ratio of bax/bcl-2 expression, inhibited the nuclear transportation of NF-kappaB, and down-regulated Akt expression and phosphorylation in HeLa cells. Bortezomib 19-29 BCL2 apoptosis regulator Homo sapiens 78-83 21472287-5 2010 The combination of bortezomib and SAHA caused an increase in the ratio of bax/bcl-2 expression, inhibited the nuclear transportation of NF-kappaB, and down-regulated Akt expression and phosphorylation in HeLa cells. Vorinostat 34-38 BCL2 apoptosis regulator Homo sapiens 78-83 20514446-6 2010 5-FU (400 microM) induced apoptosis in MCF-7 cell monolayer as determined by HO/PI staining, PARP cleavage, p53 induction, Bax induction, and Bcl-2 down-regulation. Fluorouracil 0-4 BCL2 apoptosis regulator Homo sapiens 142-147 20929126-3 2010 SP immunohistochemical method was used to detect the expressions of Bcl-2, Caspase-3 and survivin in the samples. TFF2 protein, human 0-2 BCL2 apoptosis regulator Homo sapiens 68-73 20213344-7 2010 The data show that during hyperoxia there is a significant increase in tyrosine phosphorylation of Bcl2 and Bcl-xl, while the phosphorylation of proapototic proteins Bax & Bad was not altered. Tyrosine 71-79 BCL2 apoptosis regulator Homo sapiens 99-103 20513407-11 2010 2-AP-labeled Bcl-2 promoter region quadruplexes show increased fluorescence of the 2-AP base on addition of TMPyP4. 2-Aminopurine 83-87 BCL2 apoptosis regulator Homo sapiens 13-18 20499891-9 2010 Upregulation of pro-apoptotic proteins such as p53 and Bax and downregulation of antiapoptotic protein Bcl-2 were observed in PBQ-treated A549 cells. 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo(a)quinolizine-2-spiro-3'-(1'-phenyl)succinimide 126-129 BCL2 apoptosis regulator Homo sapiens 103-108 20144642-6 2010 Both AG490 and wortmannin also led to up-regulation in Bax and Bad, and down-regulation of Bcl-2, Bcl-X(L), and survivin in MDA-MB-231 cells. Wortmannin 15-25 BCL2 apoptosis regulator Homo sapiens 91-96 20403343-8 2010 Our results collectively demonstrate that down-regulation of Bcl-2 and c-FLIP contributes to the sensitizing effect of kahweol on TRAIL-mediated apoptosis in cancer cells. kahweol 119-126 BCL2 apoptosis regulator Homo sapiens 61-66 20513407-4 2010 The parent oligonucleotide is a 27-mer with a wild-type (WT) G-rich sequence of the Bcl-2 P1 promoter mid-region (5"-d(CGG GCG CGG GAG GAA GGG GGC GGG AGC-3")). Oligonucleotides 11-26 BCL2 apoptosis regulator Homo sapiens 84-89 20513407-11 2010 2-AP-labeled Bcl-2 promoter region quadruplexes show increased fluorescence of the 2-AP base on addition of TMPyP4. 2-Aminopurine 0-4 BCL2 apoptosis regulator Homo sapiens 13-18 20061081-7 2010 MK886 (5-LOX activating protein inhibitor) mediated the induction of apoptosis by elevation of caspase-3 and Bax/Bcl2 ratio. MK-886 0-5 BCL2 apoptosis regulator Homo sapiens 113-117 20576107-2 2010 ABT-737 is a novel inhibitor of anti-apoptotic proteins of the Bcl-2 family that has shown promise in various preclinical tumour models. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 63-68 20188077-3 2010 We have analyzed the relative contribution of caspases and Bcl-2 family of proteins in the induction phase of apoptosis triggered by doxorubicin in two p53-deficient leukemia cell lines, Jurkat and U937. Doxorubicin 133-144 BCL2 apoptosis regulator Homo sapiens 59-64 20144638-6 2010 SB202190 (p38 MAPK inhibitor) and SP600125 (JNK inhibitor) suppressed CMS-9-induced dissipation of mitochondrial membrane potential, Bcl-2 down-regulation, Bax up-regulation and increased mitochondrial translocation of Bax. 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole 0-8 BCL2 apoptosis regulator Homo sapiens 133-138 20144638-6 2010 SB202190 (p38 MAPK inhibitor) and SP600125 (JNK inhibitor) suppressed CMS-9-induced dissipation of mitochondrial membrane potential, Bcl-2 down-regulation, Bax up-regulation and increased mitochondrial translocation of Bax. pyrazolanthrone 34-42 BCL2 apoptosis regulator Homo sapiens 133-138 20481493-0 2010 Turning off transcription of the bcl-2 gene by stabilizing the bcl-2 promoter quadruplex with quindoline derivatives. quindoline 94-104 BCL2 apoptosis regulator Homo sapiens 33-38 20481493-0 2010 Turning off transcription of the bcl-2 gene by stabilizing the bcl-2 promoter quadruplex with quindoline derivatives. quindoline 94-104 BCL2 apoptosis regulator Homo sapiens 63-68 20481493-4 2010 Quindoline derivatives, the highly active G-quadruplex ligands developed by our group, could significantly suppress bcl-2 transcriptional activation but had less effect on mutated bcl-2 transcription. quindoline 0-10 BCL2 apoptosis regulator Homo sapiens 116-121 20481493-4 2010 Quindoline derivatives, the highly active G-quadruplex ligands developed by our group, could significantly suppress bcl-2 transcriptional activation but had less effect on mutated bcl-2 transcription. quindoline 0-10 BCL2 apoptosis regulator Homo sapiens 180-185 20403343-0 2010 The coffee diterpene kahweol sensitizes TRAIL-induced apoptosis in renal carcinoma Caki cells through down-regulation of Bcl-2 and c-FLIP. Diterpenes 11-20 BCL2 apoptosis regulator Homo sapiens 121-126 20403343-0 2010 The coffee diterpene kahweol sensitizes TRAIL-induced apoptosis in renal carcinoma Caki cells through down-regulation of Bcl-2 and c-FLIP. kahweol 21-28 BCL2 apoptosis regulator Homo sapiens 121-126 20403343-6 2010 Kahweol-induced down-regulation of Bcl-2 and ectopic expression of Bcl-2 led to attenuation of kahweol plus TRAIL-mediated apoptosis, indicative of Bcl-2 involvement in the apoptotic process. kahweol 0-7 BCL2 apoptosis regulator Homo sapiens 35-40 20403343-6 2010 Kahweol-induced down-regulation of Bcl-2 and ectopic expression of Bcl-2 led to attenuation of kahweol plus TRAIL-mediated apoptosis, indicative of Bcl-2 involvement in the apoptotic process. kahweol 0-7 BCL2 apoptosis regulator Homo sapiens 67-72 20403343-6 2010 Kahweol-induced down-regulation of Bcl-2 and ectopic expression of Bcl-2 led to attenuation of kahweol plus TRAIL-mediated apoptosis, indicative of Bcl-2 involvement in the apoptotic process. kahweol 0-7 BCL2 apoptosis regulator Homo sapiens 67-72 20403343-6 2010 Kahweol-induced down-regulation of Bcl-2 and ectopic expression of Bcl-2 led to attenuation of kahweol plus TRAIL-mediated apoptosis, indicative of Bcl-2 involvement in the apoptotic process. kahweol 95-102 BCL2 apoptosis regulator Homo sapiens 67-72 20403343-6 2010 Kahweol-induced down-regulation of Bcl-2 and ectopic expression of Bcl-2 led to attenuation of kahweol plus TRAIL-mediated apoptosis, indicative of Bcl-2 involvement in the apoptotic process. kahweol 95-102 BCL2 apoptosis regulator Homo sapiens 67-72 20305694-6 2010 ARTN-stimulated resistance to tamoxifen and fulvestrant is mediated by increased BCL-2 expression. Tamoxifen 30-39 BCL2 apoptosis regulator Homo sapiens 81-86 20305694-6 2010 ARTN-stimulated resistance to tamoxifen and fulvestrant is mediated by increased BCL-2 expression. Fulvestrant 44-55 BCL2 apoptosis regulator Homo sapiens 81-86 20453870-10 2010 Flow cytometry analysis showed that SB203580, an inhibitor of p38, abolished ML-7-induced apoptosis, which resulted in the upregulation of Bcl-2 and survivin, and downregulation of caspase-9, suggesting that Bcl-2, survivin and caspase-9 are downstream effectors of p38. SB 203580 36-44 BCL2 apoptosis regulator Homo sapiens 139-144 20453870-10 2010 Flow cytometry analysis showed that SB203580, an inhibitor of p38, abolished ML-7-induced apoptosis, which resulted in the upregulation of Bcl-2 and survivin, and downregulation of caspase-9, suggesting that Bcl-2, survivin and caspase-9 are downstream effectors of p38. SB 203580 36-44 BCL2 apoptosis regulator Homo sapiens 208-213 20513407-11 2010 2-AP-labeled Bcl-2 promoter region quadruplexes show increased fluorescence of the 2-AP base on addition of TMPyP4. tetra(4-N-methylpyridyl)porphine 108-114 BCL2 apoptosis regulator Homo sapiens 13-18 19968497-5 2010 Additionally, the CC genotype of the BCL2-938C>A polymorphism was associated with higher GLDH serum activities (U/l; 29.8 +/- 7.1 vs. 11.4 +/- 4.3 vs. 5.6 +/- 1.7 comparing CC vs. CA vs. AA; p < .05). gldh 92-96 BCL2 apoptosis regulator Homo sapiens 37-41 20651335-9 2010 Furthermore, increased expression of Mcl-1 and decreased expression of NF-kappaB p65 suggested that bortezomib resistance associated with Y373C mutation and wild-type FGFR3 may be partly mediated through Bcl-2 and NF-kappaB signaling. Bortezomib 100-110 BCL2 apoptosis regulator Homo sapiens 204-209 20100468-8 2010 Inhibition of mitotic arrest in the presence of paclitaxel blocks the phosphorylation of BNIP3, Bcl-2 and Bcl-xL, demonstrating that these proteins are phosphorylated by a mitochondrially active mitotic kinase. Paclitaxel 48-58 BCL2 apoptosis regulator Homo sapiens 96-101 20651361-6 2010 After curcumin treatment, BAX and BAD were up-regulated, BCL-2, BCL-X(L) and XIAP were down-regulated. Curcumin 6-14 BCL2 apoptosis regulator Homo sapiens 57-62 20050848-3 2010 FLX-induced increase in mitochondrial Bax levels, decrease in cytosolic Bid and Bcl-2 levels, loss of the mitochondrial transmembrane potential, cytochrome c release, caspase-3 activation and up-regulation of p53. Fluoxetine 0-3 BCL2 apoptosis regulator Homo sapiens 80-85 20210794-9 2010 Rosiglitazone also induced apoptosis in cyst-lining epithelial cells, which was correlated with increased bax expression and decreased bcl-2 expression. Rosiglitazone 0-13 BCL2 apoptosis regulator Homo sapiens 135-140 20698159-2 2010 However, some studies have revealed that Fas (CD95/APO1) which mediates apoptotic signal and decrease of anti-apoptotic Bcl-2 are frequently observed in acute myeloid leukemia (AML) M4/M5 leukemic cells. ammonium ferrous sulfate 41-44 BCL2 apoptosis regulator Homo sapiens 120-125 20471514-5 2010 When bortezomib was added, some proapoptotic genes (CARD9, TRAIL) were upregulated, and some antiapoptotic genes (BCL2, BCL3, FLICE) were downregulated. Bortezomib 5-15 BCL2 apoptosis regulator Homo sapiens 114-118 20298150-7 2010 These terpenoids are able to inhibit tumor cell proliferation and induce tumor cell death by inhibiting multiple cancer-specific targets including the proteasome, NF-kappaB, and antiapoptotic protein Bcl-2. Terpenes 6-16 BCL2 apoptosis regulator Homo sapiens 200-205 20206622-11 2010 Bcl-2 and Bcl-X(L) but not p53 may contribute to doxorubicin-induced apoptosis through Etk pathway. Doxorubicin 49-60 BCL2 apoptosis regulator Homo sapiens 0-5 20070306-5 2010 In Bcl-2-overexpressing HeLa cells (HBD98-2-4), the induction of apoptosis, ROS production and mitochondrial dysfunction were significantly suppressed, whereas the numbers of invaded GAS was not different between HeLa (mock cells) and the HeLa HBD98-2-4 cells. Reactive Oxygen Species 76-79 BCL2 apoptosis regulator Homo sapiens 3-8 20206622-6 2010 Furthermore, the levels of Bcl-2 and Bcl-X(L) significantly increased in H446-Etk cells than that in H446 cells after doxorubicin treatment, and were positively associated with Etk expression. Doxorubicin 118-129 BCL2 apoptosis regulator Homo sapiens 27-32 20097879-7 2010 The synergistic interaction of resveratrol and TRAIL depends on the intrinsic apoptosis pathway and caspases, since Bcl-2 overexpression and the caspase inhibitor zVAD.fmk inhibit apoptosis, whereas knockdown of SIRT1 by RNA interference has no effect. Resveratrol 31-42 BCL2 apoptosis regulator Homo sapiens 116-121 20429769-6 2010 Altered expression of the Bcl-2 family of proteins, inhibition of NF-kappaB activation and over-expression of caspases and survivin provide compelling evidence that azadirachtin and nimbolide induce a shift of balance toward a pro-apoptotic phenotype. azadirachtin 165-177 BCL2 apoptosis regulator Homo sapiens 26-31 20429769-6 2010 Altered expression of the Bcl-2 family of proteins, inhibition of NF-kappaB activation and over-expression of caspases and survivin provide compelling evidence that azadirachtin and nimbolide induce a shift of balance toward a pro-apoptotic phenotype. nimbolide 182-191 BCL2 apoptosis regulator Homo sapiens 26-31 20369390-0 2010 Simvastatin stimulates production of the antiapoptotic protein Bcl-2 via endothelin-1 and NFATc3 in SH-SY5Y cells. Simvastatin 0-11 BCL2 apoptosis regulator Homo sapiens 63-68 19424877-8 2010 To further investigate the underlying mechanism by which aspirin exerts its apoptosis effects, we studied the ErbB2 downstream cell survival signaling pathways and the expression of anti-apoptosis gene Bcl-2. Aspirin 57-64 BCL2 apoptosis regulator Homo sapiens 202-207 20336762-7 2010 The results showed that DBDCT-mediated cell-cycle arrest might occur through the induction of p21 in a p53-dependent manner and that DBDCT induction of the mitochondrial apoptotic signaling pathway is perhaps mediated by increasing Bax/Bcl-2 ratios, which result in the loss of DeltaPsi(m), release of cytochrome c into the cytoplasm, activation of caspase-3 and -9, and increased reactive oxygen species (ROS) generation. dbdct 133-138 BCL2 apoptosis regulator Homo sapiens 236-241 20336762-7 2010 The results showed that DBDCT-mediated cell-cycle arrest might occur through the induction of p21 in a p53-dependent manner and that DBDCT induction of the mitochondrial apoptotic signaling pathway is perhaps mediated by increasing Bax/Bcl-2 ratios, which result in the loss of DeltaPsi(m), release of cytochrome c into the cytoplasm, activation of caspase-3 and -9, and increased reactive oxygen species (ROS) generation. Reactive Oxygen Species 381-404 BCL2 apoptosis regulator Homo sapiens 236-241 20336762-7 2010 The results showed that DBDCT-mediated cell-cycle arrest might occur through the induction of p21 in a p53-dependent manner and that DBDCT induction of the mitochondrial apoptotic signaling pathway is perhaps mediated by increasing Bax/Bcl-2 ratios, which result in the loss of DeltaPsi(m), release of cytochrome c into the cytoplasm, activation of caspase-3 and -9, and increased reactive oxygen species (ROS) generation. Reactive Oxygen Species 406-409 BCL2 apoptosis regulator Homo sapiens 236-241 20428776-4 2010 Paradoxically, Bcl-2 expression, as observed for other anticancer compounds belonging to the enediyne family of drugs, confers CalC-gamma1 susceptibility rather than resistance in HL60 cells. Enediynes 93-101 BCL2 apoptosis regulator Homo sapiens 15-20 20513026-10 2010 Finally, XRP6258 induced a greater level of bcl2 phosphorylation than docetaxel in HN12 cell line. XRP6258 9-16 BCL2 apoptosis regulator Homo sapiens 44-48 20515947-3 2010 In contrast, we show here that treatment of human cancer cells with the pan-Bcl-2 inhibitor ABT-737 alone led to upregulation of Mcl-1 protein expression. ABT-737 92-99 BCL2 apoptosis regulator Homo sapiens 76-81 20515947-5 2010 These data suggest that the ABT-737/ARC combination, which simultaneously targets Bcl-2 and Mcl-1, may be efficient against human cancer. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 28-31 BCL2 apoptosis regulator Homo sapiens 82-87 20369390-3 2010 Recently, we reported that simvastatin stimulated neuronal gene expression and protein levels of the major antiapoptotic protein Bcl-2 in vivo and in vitro; suppression of Bcl-2 in SH-SY5Y cells reduced simvastatin neuroprotection; effects were independent of cholesterol and other products of the 3-hydroxy-3-methylglutaryl-CoA reductase pathway. Simvastatin 27-38 BCL2 apoptosis regulator Homo sapiens 129-134 20369390-3 2010 Recently, we reported that simvastatin stimulated neuronal gene expression and protein levels of the major antiapoptotic protein Bcl-2 in vivo and in vitro; suppression of Bcl-2 in SH-SY5Y cells reduced simvastatin neuroprotection; effects were independent of cholesterol and other products of the 3-hydroxy-3-methylglutaryl-CoA reductase pathway. Simvastatin 27-38 BCL2 apoptosis regulator Homo sapiens 172-177 20369390-3 2010 Recently, we reported that simvastatin stimulated neuronal gene expression and protein levels of the major antiapoptotic protein Bcl-2 in vivo and in vitro; suppression of Bcl-2 in SH-SY5Y cells reduced simvastatin neuroprotection; effects were independent of cholesterol and other products of the 3-hydroxy-3-methylglutaryl-CoA reductase pathway. Simvastatin 203-214 BCL2 apoptosis regulator Homo sapiens 172-177 20369390-3 2010 Recently, we reported that simvastatin stimulated neuronal gene expression and protein levels of the major antiapoptotic protein Bcl-2 in vivo and in vitro; suppression of Bcl-2 in SH-SY5Y cells reduced simvastatin neuroprotection; effects were independent of cholesterol and other products of the 3-hydroxy-3-methylglutaryl-CoA reductase pathway. Cholesterol 260-271 BCL2 apoptosis regulator Homo sapiens 172-177 20369390-5 2010 We tested the hypothesis that simvastatin stimulation of Bcl-2 involves up-regulation of ET-1 and binding of NFATc to Bcl-2 promoter sites in SH-SY5Y human neuroblastoma cells. Simvastatin 30-41 BCL2 apoptosis regulator Homo sapiens 57-62 20369390-5 2010 We tested the hypothesis that simvastatin stimulation of Bcl-2 involves up-regulation of ET-1 and binding of NFATc to Bcl-2 promoter sites in SH-SY5Y human neuroblastoma cells. Simvastatin 30-41 BCL2 apoptosis regulator Homo sapiens 118-123 20369390-10 2010 Treatment of cells with simvastatin stimulated binding of NFATc3 to the Bcl-2 promoter. Simvastatin 24-35 BCL2 apoptosis regulator Homo sapiens 72-77 20307556-0 2010 Mitochondrial fragmentation and neuronal cell death in response to the Bcl-2/Bcl-x(L)/Bcl-w antagonist ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 103-106 BCL2 apoptosis regulator Homo sapiens 71-76 20369390-11 2010 We report novel findings showing that up-regulation of Bcl-2 by simvastatin involves ET-1 and the transcription factor NFATc3. Simvastatin 64-75 BCL2 apoptosis regulator Homo sapiens 55-60 20307556-3 2010 Here we investigate the action of ABT-737, a small molecule inhibitor which specifically targets the BH3-protein binding domain of pro-survival Bcl-2, Bcl-X(L) and Bcl-w. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 34-37 BCL2 apoptosis regulator Homo sapiens 144-149 20232120-2 2010 Previously, we showed that (-)-epigallocatechin-3-gallate (EGCG), the major polyphenolic antioxidant present in green tea, resulted in a significant decrease in the viability and growth of melanoma and induction of apoptosis via modulation of the cki-cdk-cyclin network and Bcl2 family proteins. epigallocatechin gallate 27-57 BCL2 apoptosis regulator Homo sapiens 274-278 20428827-2 2010 Our results showed that miR-16, miR-34a-c, miR-17-5p and miR-125 were up-regulated, and their associated oncogenes (BCL2, E2F1 and E2F3, respectively) were down-regulated after cisplatin treatment. Cisplatin 177-186 BCL2 apoptosis regulator Homo sapiens 116-120 20428827-6 2010 Similarly, BCL2 and E2F3 were down-regulated when P53 expression was elevated by ASO treatment. Oligonucleotides, Antisense 81-84 BCL2 apoptosis regulator Homo sapiens 11-15 20232120-2 2010 Previously, we showed that (-)-epigallocatechin-3-gallate (EGCG), the major polyphenolic antioxidant present in green tea, resulted in a significant decrease in the viability and growth of melanoma and induction of apoptosis via modulation of the cki-cdk-cyclin network and Bcl2 family proteins. epigallocatechin gallate 59-63 BCL2 apoptosis regulator Homo sapiens 274-278 20054820-9 2010 Inhibition of PAK6 caused a decrease in Ser(112) phosphorylation of BAD, a proapoptotic member of the Bcl-2 family, which led to enhanced binding of BAD to Bcl-2 and Bcl-X(L) and release of cytochrome c culminating into caspase activation and cell apoptosis. Serine 40-43 BCL2 apoptosis regulator Homo sapiens 102-107 20054820-9 2010 Inhibition of PAK6 caused a decrease in Ser(112) phosphorylation of BAD, a proapoptotic member of the Bcl-2 family, which led to enhanced binding of BAD to Bcl-2 and Bcl-X(L) and release of cytochrome c culminating into caspase activation and cell apoptosis. Serine 40-43 BCL2 apoptosis regulator Homo sapiens 156-161 20058240-7 2010 It potently downregulated the expression of Mcl-1 and showed synergistic combination effect with Bcl-2 inhibitor ABT-737. ABT-737 113-120 BCL2 apoptosis regulator Homo sapiens 97-102 20433247-0 2010 Isoniazid-induced apoptosis in HepG2 cells: generation of oxidative stress and Bcl-2 down-regulation. Isoniazid 0-9 BCL2 apoptosis regulator Homo sapiens 79-84 20584662-4 2010 Bortizomib significantly increased the mRNA expressions of caspases-3 and caspases-9 but decreased the expression of bcl-2. bortizomib 0-10 BCL2 apoptosis regulator Homo sapiens 117-122 21029589-1 2010 OBJECTIVE: To investigate the influence of di-(2-ethylexyl) phthalate (DEHP) on cell apoptosis and expression of Bcl-2 and bax in cultured human first trimester cytotrophoblasts. di-(2-ethylexyl) phthalate 43-69 BCL2 apoptosis regulator Homo sapiens 113-118 20200474-5 2010 Treatment with 10 micronM beta-lap for 4 h almost completely abrogated the radiation-induced increase in NF-kappaB activation and the transcription of NF-kappaB target genes such as bcl2, gadd45beta and cyclinD1. beta-lapachone 26-34 BCL2 apoptosis regulator Homo sapiens 182-186 21163055-8 2010 In 15 mm Hg CO2 pressure, bcl-2/bax expression (0.78 +- 0.05) was obviously lower than that in the control group (1.43 +- 0.15) (P < 0.05) and the apoptosis ratio (11.70 +- 0.12) was significantly higher than the control group (0.22 +- 0.07) (P < 0.01) before silencing HIF-1alpha. N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide 12-15 BCL2 apoptosis regulator Homo sapiens 26-31 24278513-6 2010 Bax, caspase-3, p53, p38, and JNK activation increased, but activation of Bcl-2, ERK, and HO-1 decreased with berberine treatment with or without irradiation. Berberine 110-119 BCL2 apoptosis regulator Homo sapiens 74-79 20819480-8 2010 The level of caspase-3 was significantly increased and the content of Bcl-2 mRNA was decreased significantly, while the content of Bax mRNA was significantly increased in the U251 cells after treatment with DHA compound. dehydroacetic acid 207-210 BCL2 apoptosis regulator Homo sapiens 70-75 20819480-9 2010 CONCLUSION: DHA compound can inhibit the growth of some types of tumors and the increase of caspase-3 and Bax mRNA and decrease of Bcl-2 mRNA may be involved in its mechanism of action. dehydroacetic acid 12-15 BCL2 apoptosis regulator Homo sapiens 131-136 21029589-1 2010 OBJECTIVE: To investigate the influence of di-(2-ethylexyl) phthalate (DEHP) on cell apoptosis and expression of Bcl-2 and bax in cultured human first trimester cytotrophoblasts. Diethylhexyl Phthalate 71-75 BCL2 apoptosis regulator Homo sapiens 113-118 19903580-5 2010 PG490 and 5-FU treatment induced activated caspase 3 and Bax expression and inhibited Bcl-2 expression. triptolide 0-5 BCL2 apoptosis regulator Homo sapiens 86-91 19903580-5 2010 PG490 and 5-FU treatment induced activated caspase 3 and Bax expression and inhibited Bcl-2 expression. Fluorouracil 10-14 BCL2 apoptosis regulator Homo sapiens 86-91 21029589-6 2010 RESULTS: (1) The expression of Bcl-2: when incubated with DEHP at concentration of 0, 25, 50 and 100 micromol/L, the expression of Bcl-2 were 1.00 +- 0.05, 1.03 +- 0.04, 1.04 +- 0.03, 1.04 +- 0.04, which did not show statistical difference (P > 0.05). Diethylhexyl Phthalate 58-62 BCL2 apoptosis regulator Homo sapiens 31-36 21029589-6 2010 RESULTS: (1) The expression of Bcl-2: when incubated with DEHP at concentration of 0, 25, 50 and 100 micromol/L, the expression of Bcl-2 were 1.00 +- 0.05, 1.03 +- 0.04, 1.04 +- 0.03, 1.04 +- 0.04, which did not show statistical difference (P > 0.05). Diethylhexyl Phthalate 58-62 BCL2 apoptosis regulator Homo sapiens 131-136 20405848-2 2010 We discovered a quinazoline-2(1H)-thione derivative (DCBL55) as a new Bcl-x(L), Bcl-2, and Mcl-1 inhibitor by virtual database screening. quinazoline-2(1h)-thione 16-40 BCL2 apoptosis regulator Homo sapiens 80-85 19942343-4 2010 Triptolide induced abundant apoptosis with a prominent decline of Bcl-2, Bcl-X(L), survivin and Mcl-1. triptolide 0-10 BCL2 apoptosis regulator Homo sapiens 66-71 20056218-7 2010 RESULT(S): Treatment with CDB4124 significantly decreased levels of the proliferation marker proliferating cell nuclear antigen, the number of viable LSM cells, and the antiapoptotic protein Bcl-2. telapristone acetate 26-33 BCL2 apoptosis regulator Homo sapiens 191-196 20346929-6 2010 The expression of anti-apoptotic protein Bcl-2 decreased, whereas the apoptotic protein Bax increased in a dose-dependent manner during butyrate-induced apoptosis. Butyrates 136-144 BCL2 apoptosis regulator Homo sapiens 41-46 20346929-9 2010 Butyrate triggered the caspase apoptotic pathway, indicated by an enhanced Bax-to-Bcl-2 expression ratio and caspase cascade reaction, which was blocked by SP600125. Butyrates 0-8 BCL2 apoptosis regulator Homo sapiens 82-87 20346929-9 2010 Butyrate triggered the caspase apoptotic pathway, indicated by an enhanced Bax-to-Bcl-2 expression ratio and caspase cascade reaction, which was blocked by SP600125. pyrazolanthrone 156-164 BCL2 apoptosis regulator Homo sapiens 82-87 20415419-8 2010 Western blot analysis revealed that 5HTP also markedly increased Bcl-2 expression and suppressed both p38MAPK and NF-kappaB activation in the t-BHP-treated human fibroblast cells. 5-Hydroxytryptophan 36-40 BCL2 apoptosis regulator Homo sapiens 65-70 20493813-7 2010 Such intact mitochondria underwent MOMP in response to treatment of cells with the Bcl-2 antagonist ABT-737, suggesting that the resistance of these mitochondria to MOMP lies at the point of Bax or Bak activation. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 100-103 BCL2 apoptosis regulator Homo sapiens 83-88 20071661-3 2010 We previously reported that miR-15/16 is a target of 13q14 deletions and plays a tumor suppressor role by targeting BCL2. mir-15 28-34 BCL2 apoptosis regulator Homo sapiens 116-120 19876716-9 2010 Consistent with growth inhibition and apoptosis induction, icaritin decreased cyclin D1 and CDK4 expression and increased Bax/Bcl-2 ratio in human PSMCs. icaritin 59-67 BCL2 apoptosis regulator Homo sapiens 126-131 20438634-6 2010 Interestingly, although withaferin A and quercetin treatments both decrease intracellular protein levels of Bcl2, Bim and P-Bad, only withaferin A decreases protein levels of cytoskeletal tubulin, concomitantly with potent PARP cleavage, caspase 3 activation and apoptosis, at least in part via a direct thiol oxidation mechanism. withaferin A 24-36 BCL2 apoptosis regulator Homo sapiens 108-112 20438634-6 2010 Interestingly, although withaferin A and quercetin treatments both decrease intracellular protein levels of Bcl2, Bim and P-Bad, only withaferin A decreases protein levels of cytoskeletal tubulin, concomitantly with potent PARP cleavage, caspase 3 activation and apoptosis, at least in part via a direct thiol oxidation mechanism. Quercetin 41-50 BCL2 apoptosis regulator Homo sapiens 108-112 20005259-10 2010 Consistent with this, tribbles-mediated dephosphorylation of Bcl-2 Ser70 was associated with subsequent apoptosis. tribbles 22-30 BCL2 apoptosis regulator Homo sapiens 61-66 19556603-0 2010 Nitric oxide-mediated bcl-2 stabilization potentiates malignant transformation of human lung epithelial cells. Nitric Oxide 0-12 BCL2 apoptosis regulator Homo sapiens 22-27 20081872-6 2010 Immunohistochemical analysis revealed that (-)-gossypol enhanced caspase-3 and caspase-8 expression and decreased the expression of PCNA, Bcl-2 and CD31 in tumour tissues. Gossypol 43-55 BCL2 apoptosis regulator Homo sapiens 138-143 19556603-6 2010 Cr(VI)-transformed cells evaded apoptosis by a mechanism involving S-nitrosylation and stabilization of Bcl-2 protein in a nitric oxide-dependent manner. Nitric Oxide 123-135 BCL2 apoptosis regulator Homo sapiens 104-109 20154224-7 2010 Bleomycin induced the expression of Bcl-2 and Bcl-x(L), Bcl-2 family member proteins that protect cells from the mitochondria-dependent intrinsic apoptosis. Bleomycin 0-9 BCL2 apoptosis regulator Homo sapiens 36-41 20154224-7 2010 Bleomycin induced the expression of Bcl-2 and Bcl-x(L), Bcl-2 family member proteins that protect cells from the mitochondria-dependent intrinsic apoptosis. Bleomycin 0-9 BCL2 apoptosis regulator Homo sapiens 56-61 20127174-0 2010 Curcumin sensitizes non-small cell lung cancer cell anoikis through reactive oxygen species-mediated Bcl-2 downregulation. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 101-106 20127174-0 2010 Curcumin sensitizes non-small cell lung cancer cell anoikis through reactive oxygen species-mediated Bcl-2 downregulation. Reactive Oxygen Species 68-91 BCL2 apoptosis regulator Homo sapiens 101-106 20127174-6 2010 Curcumin downregulated Bcl-2 protein during anoikis and sensitized the cells to detachment-induced apoptosis, whereas it had no significant effect on Cav-1 protein expression. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 23-28 20127174-7 2010 Bcl-2 down-regulation as well as anoikis enhancement by curcumin were inhibited by superoxide anion scavenger, Mn(III)tetrakis(4-benzoic acid) porphyrin chloride, but were unaffected by other ROS scavengers including catalase and deferoxamine, suggesting that superoxide anion is a key player in the downregulation of Bcl-2 by curcumin. Curcumin 56-64 BCL2 apoptosis regulator Homo sapiens 318-323 20127174-7 2010 Bcl-2 down-regulation as well as anoikis enhancement by curcumin were inhibited by superoxide anion scavenger, Mn(III)tetrakis(4-benzoic acid) porphyrin chloride, but were unaffected by other ROS scavengers including catalase and deferoxamine, suggesting that superoxide anion is a key player in the downregulation of Bcl-2 by curcumin. Superoxides 83-99 BCL2 apoptosis regulator Homo sapiens 0-5 20127174-7 2010 Bcl-2 down-regulation as well as anoikis enhancement by curcumin were inhibited by superoxide anion scavenger, Mn(III)tetrakis(4-benzoic acid) porphyrin chloride, but were unaffected by other ROS scavengers including catalase and deferoxamine, suggesting that superoxide anion is a key player in the downregulation of Bcl-2 by curcumin. mn(iii)tetrakis(4-benzoic acid) porphyrin chloride 111-161 BCL2 apoptosis regulator Homo sapiens 0-5 20127174-7 2010 Bcl-2 down-regulation as well as anoikis enhancement by curcumin were inhibited by superoxide anion scavenger, Mn(III)tetrakis(4-benzoic acid) porphyrin chloride, but were unaffected by other ROS scavengers including catalase and deferoxamine, suggesting that superoxide anion is a key player in the downregulation of Bcl-2 by curcumin. Reactive Oxygen Species 192-195 BCL2 apoptosis regulator Homo sapiens 0-5 20127174-7 2010 Bcl-2 down-regulation as well as anoikis enhancement by curcumin were inhibited by superoxide anion scavenger, Mn(III)tetrakis(4-benzoic acid) porphyrin chloride, but were unaffected by other ROS scavengers including catalase and deferoxamine, suggesting that superoxide anion is a key player in the downregulation of Bcl-2 by curcumin. Deferoxamine 230-242 BCL2 apoptosis regulator Homo sapiens 0-5 20127174-7 2010 Bcl-2 down-regulation as well as anoikis enhancement by curcumin were inhibited by superoxide anion scavenger, Mn(III)tetrakis(4-benzoic acid) porphyrin chloride, but were unaffected by other ROS scavengers including catalase and deferoxamine, suggesting that superoxide anion is a key player in the downregulation of Bcl-2 by curcumin. Superoxides 260-276 BCL2 apoptosis regulator Homo sapiens 0-5 20127174-7 2010 Bcl-2 down-regulation as well as anoikis enhancement by curcumin were inhibited by superoxide anion scavenger, Mn(III)tetrakis(4-benzoic acid) porphyrin chloride, but were unaffected by other ROS scavengers including catalase and deferoxamine, suggesting that superoxide anion is a key player in the downregulation of Bcl-2 by curcumin. Curcumin 327-335 BCL2 apoptosis regulator Homo sapiens 0-5 20127174-8 2010 Furthermore, we provided evidence that curcumin decreased Bcl-2 level through ubiquitin-proteasomal degradation which sensitized cells to detachment-induced apoptosis. Curcumin 39-47 BCL2 apoptosis regulator Homo sapiens 58-63 20127174-9 2010 These findings indicate a novel pathway for curcumin regulation of Bcl-2 and provide a key mechanism of anoikis regulation that may be exploited for metastatic cancer treatment. Curcumin 44-52 BCL2 apoptosis regulator Homo sapiens 67-72 20133021-6 2010 Treatment of HL-60 and 518A2 cells with doxorubicin or its heptadecanoyl, linolenoyl, (menthoxycarbonyl)undecanoyl or menthoxymalonyl hydrazones also led to diverging increases of the ratio of bax to bcl-2 mRNA expression, of reactive oxygen species and of mitochondrial membrane damage. Doxorubicin 40-51 BCL2 apoptosis regulator Homo sapiens 200-205 19893570-0 2010 BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 89-94 20138484-6 2010 We found that expression levels of HSP and Bcl-2 in fibroblasts were strongly dependent on the surface hydrophilicity and concentration of nitrogen-containing functional groups on the nanofiber matrices. Nitrogen 139-147 BCL2 apoptosis regulator Homo sapiens 43-48 20133021-6 2010 Treatment of HL-60 and 518A2 cells with doxorubicin or its heptadecanoyl, linolenoyl, (menthoxycarbonyl)undecanoyl or menthoxymalonyl hydrazones also led to diverging increases of the ratio of bax to bcl-2 mRNA expression, of reactive oxygen species and of mitochondrial membrane damage. heptadecanoyl 59-72 BCL2 apoptosis regulator Homo sapiens 200-205 20133021-6 2010 Treatment of HL-60 and 518A2 cells with doxorubicin or its heptadecanoyl, linolenoyl, (menthoxycarbonyl)undecanoyl or menthoxymalonyl hydrazones also led to diverging increases of the ratio of bax to bcl-2 mRNA expression, of reactive oxygen species and of mitochondrial membrane damage. linolenoyl 74-84 BCL2 apoptosis regulator Homo sapiens 200-205 20133021-6 2010 Treatment of HL-60 and 518A2 cells with doxorubicin or its heptadecanoyl, linolenoyl, (menthoxycarbonyl)undecanoyl or menthoxymalonyl hydrazones also led to diverging increases of the ratio of bax to bcl-2 mRNA expression, of reactive oxygen species and of mitochondrial membrane damage. (menthoxycarbonyl)undecanoyl 86-114 BCL2 apoptosis regulator Homo sapiens 200-205 20133021-6 2010 Treatment of HL-60 and 518A2 cells with doxorubicin or its heptadecanoyl, linolenoyl, (menthoxycarbonyl)undecanoyl or menthoxymalonyl hydrazones also led to diverging increases of the ratio of bax to bcl-2 mRNA expression, of reactive oxygen species and of mitochondrial membrane damage. menthoxymalonyl hydrazones 118-144 BCL2 apoptosis regulator Homo sapiens 200-205 20372819-6 2010 The investigation of the mechanism by which PMBE induced apoptosis in HepG2 cells indicated that activation of extrinsic and intrinsic caspase, inhibition of NF-kappaB activation and decrease of the antiapoptotic protein Bcl-2 and the intact Bid protein were involved. pmbe 44-48 BCL2 apoptosis regulator Homo sapiens 221-226 20225234-8 2010 The effect of atRA was mediated by an increased expression of Bcl-2 whereas the Epo treatment upregulated not only Bcl-2 but also Bcl-xL. Tretinoin 14-18 BCL2 apoptosis regulator Homo sapiens 62-67 20347499-1 2010 BACKGROUND & AIMS: Bcl-xL, an anti-apoptotic member of the Bcl-2 family, is over-expressed in human hepatocellular carcinoma, conferring a survival advantage to tumour cells. Adenosine Monophosphate 12-15 BCL2 apoptosis regulator Homo sapiens 63-68 20347499-11 2010 Finally, expression of let-7c enhanced apoptosis of hepatoma cells upon exposure to sorafenib, which downregulates expression of another anti-apoptotic Bcl-2 protein, Mcl-1. Sorafenib 84-93 BCL2 apoptosis regulator Homo sapiens 152-157 20175127-4 2010 Overexpression of the protective mitochondrial proteins Bcl-2 and Bcl-x(L) conferred partial resistance to THDF-induced apoptosis. 5,7,3'-trihydroxy-3,4'-dimethoxyflavone 107-111 BCL2 apoptosis regulator Homo sapiens 56-61 20395330-10 2010 The antiapoptotic marker Bcl-2 exhibited a biphasic pattern, with a maximum drop at 3 h, followed by return toward baseline levels at 6 h. CONCLUSION: These results define the time course of various biologic events taking place in this model of murine breast cancer after a proapoptotic insult (single-dose paclitaxel). Paclitaxel 307-317 BCL2 apoptosis regulator Homo sapiens 25-30 20354451-0 2010 AT-101, a pan-Bcl-2 inhibitor, leads to radiosensitization of non-small cell lung cancer. gossypol acetic acid 0-6 BCL2 apoptosis regulator Homo sapiens 14-19 19560836-0 2010 Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy. Cisplatin 106-115 BCL2 apoptosis regulator Homo sapiens 14-19 19560836-11 2010 CONCLUSIONS: High expression of Bcl-2 may be a useful prognostic factor in locally advanced NSCLC patients treated with cisplatin-based CCRT. Cisplatin 120-129 BCL2 apoptosis regulator Homo sapiens 32-37 20423994-5 2010 Apoptosis in EFT cells by EGCG correlated with altered expression of Bcl-2 family proteins, including increased expression of proapoptotic Bax and decreased expression of prosurvival Bcl2, Bcl-XL, and Mcl-1 proteins. epigallocatechin gallate 26-30 BCL2 apoptosis regulator Homo sapiens 69-74 20372863-8 2010 These novel findings collectively suggest that ARL6IP1 may play a key role in cisplatin-induced apoptosis in CaSki cervical cancer cells by regulating the expression of apoptosis-associated proteins such as caspase-3, -9, p53, NF-kappaB, MAPK, Bcl-2, Bcl-xl, and Bax. Cisplatin 78-87 BCL2 apoptosis regulator Homo sapiens 244-249 20501387-8 2010 CONCLUSION: The combined use of cyclopamine and hydroxycamptothecin significantly down-regulates the expression on of bcl-2 to induce the apoptosis of human OSCC cell line HSQ-89. cyclopamine 32-43 BCL2 apoptosis regulator Homo sapiens 118-123 20501387-8 2010 CONCLUSION: The combined use of cyclopamine and hydroxycamptothecin significantly down-regulates the expression on of bcl-2 to induce the apoptosis of human OSCC cell line HSQ-89. hydroxycamptothecinum 48-67 BCL2 apoptosis regulator Homo sapiens 118-123 20442315-7 2010 There was a significant reduction in STAT3 downstream target protein levels including Bcl-xL, Bcl-2, survivin, and vascular endothelial growth factor, suggesting that HO-3867 exposure disrupted the JAK/STAT3 signaling pathway. Holmium 167-169 BCL2 apoptosis regulator Homo sapiens 94-99 20372863-7 2010 Cisplatin treatment induced caspase-3, -9, p53, Bax, NF-kappaB and MAPK expression, and suppressed Bcl-2 and Bcl-xl expression, whereas cells transfected with pcDNA3.1-ARL6IP1 showed lower levels of cisplatin-induced caspase-3, -9, p53, Bax, NF-kappaB and MAPK up-regulation and higher levels of cisplatin-suppressed Bcl-2 and Bcl-xl down-regulation. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 99-104 20005955-5 2010 Thereupon, Dex not only mediates its anti-apoptotic effect via activation of phosphoinositide 3-kinase (PI3K)/Akt signalling but also includes an involvement of the Bcl-2 family protein Bcl(XL). Dexamethasone 11-14 BCL2 apoptosis regulator Homo sapiens 165-170 20372863-7 2010 Cisplatin treatment induced caspase-3, -9, p53, Bax, NF-kappaB and MAPK expression, and suppressed Bcl-2 and Bcl-xl expression, whereas cells transfected with pcDNA3.1-ARL6IP1 showed lower levels of cisplatin-induced caspase-3, -9, p53, Bax, NF-kappaB and MAPK up-regulation and higher levels of cisplatin-suppressed Bcl-2 and Bcl-xl down-regulation. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 317-322 22966344-4 2010 This study showed that the ectopic overexpression of miR-16 may be therapeutically beneficial as is evidenced by impaired cell survival with concomitant attenuation of anti-apoptotic protein Bcl-2. mir-16 53-59 BCL2 apoptosis regulator Homo sapiens 191-196 22966344-5 2010 Moreover, the luciferase reporter assay suggested that miR-16 post-transcriptionally regulates Bcl-2 expression in pancreatic cancer cells through the target sites of the 3" untranslated region of this gene. mir-16 55-61 BCL2 apoptosis regulator Homo sapiens 95-100 19938012-14 2010 CONCLUSIONS: Downmodulation of Bcl-2 in metastatic castrate-resistant LNCaP-LN3 cells led to apoptosis via a cytochrome c-dependent pathway that was enhanced with docetaxel treatment. Docetaxel 163-172 BCL2 apoptosis regulator Homo sapiens 31-36 21203962-7 2010 In addition, the cleavage of Beclin 1 resulted in abrogating the interaction between Bcl-2 with Beclin 1, which could be blocked by z-VAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 132-141 BCL2 apoptosis regulator Homo sapiens 85-90 20083129-0 2010 Arsenite induces apoptosis in human mesenchymal stem cells by altering Bcl-2 family proteins and by activating intrinsic pathway. arsenite 0-8 BCL2 apoptosis regulator Homo sapiens 71-76 20096282-4 2010 Carboplatin and Akt inhibitor induced nuclear damage, decreased Bid and Bcl-2 protein levels, induced cytochrome c release, activated caspase-3 and increased tumor suppressor p53 levels. Carboplatin 0-11 BCL2 apoptosis regulator Homo sapiens 72-77 20189983-9 2010 Bcl-2- and Mcl-1-mediated protection from apoptosis induced by staurosporine or etoposide was enhanced in cells expressing InsP(3)R, demonstrating that their interactions with InsP(3)R enable Bcl-2 and Mcl-1 to be fully efficacious anti-apoptotic mediators. Staurosporine 63-76 BCL2 apoptosis regulator Homo sapiens 0-5 20189983-9 2010 Bcl-2- and Mcl-1-mediated protection from apoptosis induced by staurosporine or etoposide was enhanced in cells expressing InsP(3)R, demonstrating that their interactions with InsP(3)R enable Bcl-2 and Mcl-1 to be fully efficacious anti-apoptotic mediators. Etoposide 80-89 BCL2 apoptosis regulator Homo sapiens 0-5 20197552-1 2010 ABT-737 is a small-molecule antagonist of BCL-2 currently under evaluation in clinical trials in the oral form of ABT-263. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 42-47 20197552-1 2010 ABT-737 is a small-molecule antagonist of BCL-2 currently under evaluation in clinical trials in the oral form of ABT-263. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 114-117 BCL2 apoptosis regulator Homo sapiens 42-47 20139705-7 2010 ZD6474 also downregulated anti-apoptotic markers including Bcl-2, upregulated pro-apoptotic signaling events involving expression of bax, activation of caspase-3, and induction of poly (ADP-ribose) polymerase during apoptosis. vandetanib 0-6 BCL2 apoptosis regulator Homo sapiens 59-64 19796866-4 2010 Although both compounds increase the expression of Bcl-2, a Bcl-2 inhibitor completely blocked the protective effects of BPA while only partially affecting those of estradiol. bisphenol A 121-124 BCL2 apoptosis regulator Homo sapiens 60-65 20403207-0 2010 The conformation change of Bcl-2 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in SGC7901 human gastric cancer cells. Arsenic Trioxide 48-64 BCL2 apoptosis regulator Homo sapiens 27-32 20403207-4 2010 As the role of Bcl-2 in arsenic trioxide-mediated cell apoptosis and conformation change of Bcl-2 in response to arsenic trioxide treatment has not been studied. Arsenic Trioxide 24-40 BCL2 apoptosis regulator Homo sapiens 15-20 20403207-4 2010 As the role of Bcl-2 in arsenic trioxide-mediated cell apoptosis and conformation change of Bcl-2 in response to arsenic trioxide treatment has not been studied. Arsenic Trioxide 113-129 BCL2 apoptosis regulator Homo sapiens 15-20 20403207-4 2010 As the role of Bcl-2 in arsenic trioxide-mediated cell apoptosis and conformation change of Bcl-2 in response to arsenic trioxide treatment has not been studied. Arsenic Trioxide 113-129 BCL2 apoptosis regulator Homo sapiens 92-97 20403207-5 2010 The aim of the present study was to determine whether conformation change of Bcl-2 is involved in the action of arsenic trioxide. Arsenic Trioxide 112-128 BCL2 apoptosis regulator Homo sapiens 77-82 20403207-13 2010 There were two Bcl-2 phenotypes coexisting in SGC7901 cells and the Bcl-2 cytoprotective phenotype could change into a cytodestructive phenotype following conformational change of Bcl-2, triggered by arsenic trioxide exposure. Arsenic Trioxide 200-216 BCL2 apoptosis regulator Homo sapiens 15-20 20403207-13 2010 There were two Bcl-2 phenotypes coexisting in SGC7901 cells and the Bcl-2 cytoprotective phenotype could change into a cytodestructive phenotype following conformational change of Bcl-2, triggered by arsenic trioxide exposure. Arsenic Trioxide 200-216 BCL2 apoptosis regulator Homo sapiens 68-73 20403207-13 2010 There were two Bcl-2 phenotypes coexisting in SGC7901 cells and the Bcl-2 cytoprotective phenotype could change into a cytodestructive phenotype following conformational change of Bcl-2, triggered by arsenic trioxide exposure. Arsenic Trioxide 200-216 BCL2 apoptosis regulator Homo sapiens 68-73 20403207-14 2010 Bax activation might also be involved in arsenic trioxide-induced Bcl-2 conformational change. Arsenic Trioxide 41-57 BCL2 apoptosis regulator Homo sapiens 66-71 20403207-16 2010 CONCLUSION: Arsenic trioxide induces apoptosis through induction of Bcl-2 conformational change, Bax activation and up-regulation of total Bax expression rather than affecting total Bcl-2 expression in human gastric cancer SGC7901 cells. Arsenic Trioxide 12-28 BCL2 apoptosis regulator Homo sapiens 68-73 20403207-17 2010 The conformational change of Bcl-2 may be a novel described mechanism of arsenic trioxide-induced apoptosis in cancer cells. Arsenic Trioxide 73-89 BCL2 apoptosis regulator Homo sapiens 29-34 20307495-8 2010 p38 inhibitor (SB203580) blocked hypoxia-induced Bcl-2 expression, whereas PKC, ERK1/2 and PI3K inhibitors did not. SB 203580 15-23 BCL2 apoptosis regulator Homo sapiens 49-54 20388787-9 2010 These changes were accompanied by a decrease in cellular mitochondria content, an increase in BCL2 phosphorylation at serine 70, caspase-3 activation, and poly(ADP-ribose) polymerase cleavage. Serine 118-124 BCL2 apoptosis regulator Homo sapiens 94-98 20093144-7 2010 Furthermore, mitochondrial dysfunction associated with cell apoptosis including membrane potential loss, down-regulation of Bcl-2 and up-regulation of Bax and the release of cytochrome c were abrogated in the presence of L-carnitine. Carnitine 221-232 BCL2 apoptosis regulator Homo sapiens 124-129 20109541-3 2010 Several key molecules, including caspase-3, Bcl-2, BAD and Bax, were modulated by l-THP treatment. tetrahydropalmatine 82-87 BCL2 apoptosis regulator Homo sapiens 44-49 20190558-4 2010 Morphine increases Beclin 1 expression and reduces the interaction between Beclin 1 and Bcl-2, thus releasing Beclin 1 for its pro-autophagic activity. Morphine 0-8 BCL2 apoptosis regulator Homo sapiens 88-93 20154087-3 2010 When examined for its mechanism, we found that the triterpene down-regulated the expression of cell survival proteins including cFLIP, IAP-1, Bcl-2, Bcl-xL, survivin, and XIAP and up-regulated Bax expression. Triterpenes 51-61 BCL2 apoptosis regulator Homo sapiens 142-147 20190558-5 2010 Bcl-2 overexpression inhibits morphine-induced autophagy, whereas knockdown of Beclin 1 or knockout of ATG5 prevents morphine-induced autophagy. Morphine 30-38 BCL2 apoptosis regulator Homo sapiens 0-5 20305374-6 2010 Moreover, the combination of celecoxib with MG132 synergistically inhibited cell viability and increased apoptosis, as documented by caspase 3 and 7 activation, PARP cleavage, and down-regulation of Bcl-2. Celecoxib 29-38 BCL2 apoptosis regulator Homo sapiens 199-204 19459041-5 2010 At high doses zebularine induced changes in apoptotic proteins in a cell line specific manner manifested by alteration in caspase-3, Bax, Bcl2 and PARP cleavage. pyrimidin-2-one beta-ribofuranoside 14-24 BCL2 apoptosis regulator Homo sapiens 138-142 20121705-7 2010 Notably, the adverse effects of spermine on BAX/BCL-2 ratio, cytochrome c release and caspase activation was fully attenuated by F1. Spermine 32-40 BCL2 apoptosis regulator Homo sapiens 48-53 20305374-6 2010 Moreover, the combination of celecoxib with MG132 synergistically inhibited cell viability and increased apoptosis, as documented by caspase 3 and 7 activation, PARP cleavage, and down-regulation of Bcl-2. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 44-49 BCL2 apoptosis regulator Homo sapiens 199-204 19781850-5 2010 The levels of p53 were increased in the EGCG-treated cells, with a corresponding decrease in Bcl-2 and Bid protein levels as well as an increase in the Bax level. epigallocatechin gallate 40-44 BCL2 apoptosis regulator Homo sapiens 93-98 20193962-0 2010 Cardiolipin, phosphatidylserine, and BH4 domain of Bcl-2 family regulate Ca2+/H+ antiporter activity of human Bax inhibitor-1. sapropterin 37-40 BCL2 apoptosis regulator Homo sapiens 51-56 20193962-6 2010 The peptide corresponding to the BH4 domain of Bcl-2 and Bcl-xL proteins stimulated the BI-1 activities in 100% PC membranes. Phosphatidylcholines 112-114 BCL2 apoptosis regulator Homo sapiens 47-52 20704577-0 2010 Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) exert their anti-proliferative activity by interfering with Akt-mTOR signaling and bax:bcl-2 ratio modulation in cells from chronic myeloid leukemic patients. pyrrolo[1,2-b][1,2,5]benzothiadiazepines 0-40 BCL2 apoptosis regulator Homo sapiens 136-141 20373469-4 2010 PD169316 also prevented the loss of Bcl-2 and Bcl-xL in PDT-treated HK-1 cells. 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole 0-8 BCL2 apoptosis regulator Homo sapiens 36-41 20410645-5 2010 The Bax/Bcl-2 ratio was significantly increased by albanol A treatment. mulberrofuran G 51-60 BCL2 apoptosis regulator Homo sapiens 8-13 20447057-8 2010 CONCLUSIONS: Raloxifene treatment significantly reduced Ki-67 antigen expression and increased Bcl-2 expression in breast carcinomas of post-menopausal women. Raloxifene Hydrochloride 13-23 BCL2 apoptosis regulator Homo sapiens 95-100 20704577-0 2010 Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) exert their anti-proliferative activity by interfering with Akt-mTOR signaling and bax:bcl-2 ratio modulation in cells from chronic myeloid leukemic patients. pbtds 42-47 BCL2 apoptosis regulator Homo sapiens 136-141 20447057-0 2010 Evaluation of Ki-67 and Bcl-2 antigen expression in breast carcinomas of women treated with raloxifene. Raloxifene Hydrochloride 92-102 BCL2 apoptosis regulator Homo sapiens 24-29 20704577-2 2010 The bax:bcl-2 ratio was increased as a consequence of down-regulation of bcl-2 and up-regulation of bax proteins in response to treatment with PBTDs. pbtds 143-148 BCL2 apoptosis regulator Homo sapiens 8-13 20447057-1 2010 OBJECTIVES: To evaluate the effect of raloxifene on Ki-67 and Bcl-2 antigen expression in operable, stage II, oestrogen-receptor-positive invasive ductal breast carcinomas. Raloxifene Hydrochloride 38-48 BCL2 apoptosis regulator Homo sapiens 62-67 20198322-7 2010 ROS induced by 9-HPbD-PDT directly led to downregulated expression of Bcl-2, loss of mitochondrial membrane potential, release of cytochrome c from mitochondria, elevation of intracellular calcium due to ER stress, as well as induction of CHOP and activation of caspase-3, -8, -9 and -12. Reactive Oxygen Species 0-3 BCL2 apoptosis regulator Homo sapiens 70-75 20163198-0 2010 The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Cisplatin 25-34 BCL2 apoptosis regulator Homo sapiens 85-90 20163198-0 2010 The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Cisplatin 109-118 BCL2 apoptosis regulator Homo sapiens 85-90 20163198-7 2010 This review focuses on the relationship between glutathione and BCL-2 and their protective role in cDDP-induced reactive oxygen species formation and cDDP resistance. Glutathione 48-59 BCL2 apoptosis regulator Homo sapiens 64-69 20163198-7 2010 This review focuses on the relationship between glutathione and BCL-2 and their protective role in cDDP-induced reactive oxygen species formation and cDDP resistance. Cisplatin 99-103 BCL2 apoptosis regulator Homo sapiens 64-69 20163198-7 2010 This review focuses on the relationship between glutathione and BCL-2 and their protective role in cDDP-induced reactive oxygen species formation and cDDP resistance. Reactive Oxygen Species 112-135 BCL2 apoptosis regulator Homo sapiens 64-69 20163198-7 2010 This review focuses on the relationship between glutathione and BCL-2 and their protective role in cDDP-induced reactive oxygen species formation and cDDP resistance. Cisplatin 150-154 BCL2 apoptosis regulator Homo sapiens 64-69 19723525-4 2010 Furthermore, the imbalance of calcium homeostasis increased the level of BAX, decreased the level of Bcl-2, induced cytochrome c release and activated caspase-3, leading to intranucleosomal DNA fragmentation and plasma membrane damage, eventually resulting in cell apoptosis. Calcium 30-37 BCL2 apoptosis regulator Homo sapiens 101-106 19810096-6 2010 Bax and Bcl-2 protein expressions in tumor tissue treated with 5-FU were associated with both 5-FU sensitivity and the apoptotic cell count. Fluorouracil 63-67 BCL2 apoptosis regulator Homo sapiens 8-13 19810096-6 2010 Bax and Bcl-2 protein expressions in tumor tissue treated with 5-FU were associated with both 5-FU sensitivity and the apoptotic cell count. Fluorouracil 94-98 BCL2 apoptosis regulator Homo sapiens 8-13 19810100-10 2010 Furthermore, in vitro studies examining the effects of the PI3K/mTOR inhibitor in tumor derived cell lines indicated that PI-103 induced the anti-apoptotic BH3 family proteins Mcl1, Bcl2 and Bcl(xL) favoring, the in vitro survival of sorafenib treated melanoma cells. PI103 122-128 BCL2 apoptosis regulator Homo sapiens 182-186 20182772-6 2010 RESULTS: Pharmacologic concentrations of PEITC augmented Docetaxel-induced apoptosis in PC-3 and DU145 cells in association with suppression of Bcl-2 and XIAP protein levels and induction of Bax and Bak. phenethyl isothiocyanate 41-46 BCL2 apoptosis regulator Homo sapiens 144-149 19626458-2 2010 Here we presented that blockade the binding site of CREB to Bcl-2 by a CRE decoy oligonucleotide abrogated the TCS-decreased Bcl-2 expression. Oligonucleotides 81-96 BCL2 apoptosis regulator Homo sapiens 60-65 19626458-2 2010 Here we presented that blockade the binding site of CREB to Bcl-2 by a CRE decoy oligonucleotide abrogated the TCS-decreased Bcl-2 expression. Oligonucleotides 81-96 BCL2 apoptosis regulator Homo sapiens 125-130 19823097-0 2010 Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells. apogossypolone 23-37 BCL2 apoptosis regulator Homo sapiens 64-69 19823097-2 2010 Apogossypolone (ApoG2) is an analogue of (-)-gossypol, exhibiting binding activity with Ki values of 35 nmol/L for Bcl-2 and 25 nmol/L for Mcl-1. apogossypolone 0-14 BCL2 apoptosis regulator Homo sapiens 115-120 19823097-2 2010 Apogossypolone (ApoG2) is an analogue of (-)-gossypol, exhibiting binding activity with Ki values of 35 nmol/L for Bcl-2 and 25 nmol/L for Mcl-1. Gossypol 41-53 BCL2 apoptosis regulator Homo sapiens 115-120 19823097-3 2010 The present study was designed to test our hypothesis whether inactivation of Bcl-2 family of proteins using ApoG2 could sensitize pancreatic cancer cells to the cytotoxic effect of gemcitabine. gemcitabine 182-193 BCL2 apoptosis regulator Homo sapiens 78-83 19823097-10 2010 CONCLUSIONS: Apogossypolone, which functions as a potent pan-Bcl-2 family inhibitor, seems therapeutically promising for future translational studies including the treatment of pancreatic cancer. apogossypolone 13-27 BCL2 apoptosis regulator Homo sapiens 61-66 19748259-0 2010 Diallyl trisulfide induces Bcl-2 and caspase-3-dependent apoptosis via downregulation of Akt phosphorylation in human T24 bladder cancer cells. diallyl trisulfide 0-18 BCL2 apoptosis regulator Homo sapiens 27-32 19748259-4 2010 Mechanistically, DATS inhibits phosphatidylinositol 3"-kinase/Akt activation that, in turn, results in modulation of Bcl-2 family proteins, leading to enhanced apoptosis of T24 cells. diallyl trisulfide 17-21 BCL2 apoptosis regulator Homo sapiens 117-122 20350212-10 2010 Interestingly, when BCL2 expression was tested with an alternative antibody, E17, the protein was detected in SU-DHL-6, suggesting that the "negativity" of SU-DHL-6 line for BCL2 using the standard antibody is spurious. su-dhl-6 110-118 BCL2 apoptosis regulator Homo sapiens 20-24 20350212-10 2010 Interestingly, when BCL2 expression was tested with an alternative antibody, E17, the protein was detected in SU-DHL-6, suggesting that the "negativity" of SU-DHL-6 line for BCL2 using the standard antibody is spurious. su-dhl-6 156-164 BCL2 apoptosis regulator Homo sapiens 20-24 20350212-10 2010 Interestingly, when BCL2 expression was tested with an alternative antibody, E17, the protein was detected in SU-DHL-6, suggesting that the "negativity" of SU-DHL-6 line for BCL2 using the standard antibody is spurious. su-dhl-6 156-164 BCL2 apoptosis regulator Homo sapiens 174-178 20415745-5 2010 A statistically significant difference was found in the bcl-2 level between control samples and MF patients" biopsies before (P value 0.02) and after PUVA therapy (P value 0.011). puva 150-154 BCL2 apoptosis regulator Homo sapiens 56-61 20060462-10 2010 In conclusion, ROS-mediated oxidative stress, the activation of p53 and up-regulation of Bax/Bcl-2 ratio are involved in mechanistic pathways of 21 nm SiO(2) induced apoptosis in L-02 cells. Reactive Oxygen Species 15-18 BCL2 apoptosis regulator Homo sapiens 93-98 20149610-3 2010 EGCG treatment (10-100 microg/ml for 24-72 hours) caused cell growth inhibition and dose-dependent apoptosis: after 100 microg/ml EGCG treatment for 24 hours, Bax expression increased and Bcl2 expression decreased (p<0.05). epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 188-192 20149610-3 2010 EGCG treatment (10-100 microg/ml for 24-72 hours) caused cell growth inhibition and dose-dependent apoptosis: after 100 microg/ml EGCG treatment for 24 hours, Bax expression increased and Bcl2 expression decreased (p<0.05). epigallocatechin gallate 130-134 BCL2 apoptosis regulator Homo sapiens 188-192 20005289-7 2010 In addition, MG132 reduced ERK phosphorylation, increased caspase-3 activation, Fas-L expression and Bcl-2 cleavage in evodiamine-treated A375-S2 cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 13-18 BCL2 apoptosis regulator Homo sapiens 101-106 20005289-7 2010 In addition, MG132 reduced ERK phosphorylation, increased caspase-3 activation, Fas-L expression and Bcl-2 cleavage in evodiamine-treated A375-S2 cells. evodiamine 119-129 BCL2 apoptosis regulator Homo sapiens 101-106 20416170-4 2010 The effects of beta-elemene on the expression of BCL-2, caspase-3, DR-4 and NF-kappaB P65 proteins were analyzed by Western blot. beta-elemene 15-27 BCL2 apoptosis regulator Homo sapiens 49-54 19800672-11 2010 CONCLUSIONS: Bortezomib increases radiation sensitivity in androgen-independent human DU145 prostate cancer cells through inhibition of Bcl-2 and induction of caspase-3 genes. Bortezomib 13-23 BCL2 apoptosis regulator Homo sapiens 136-141 20416158-0 2010 [Docetaxel induces apoptosis and influences the expression of P-gp, BCL-2 and BAX protein in HL-60/ADR cells]. Docetaxel 1-10 BCL2 apoptosis regulator Homo sapiens 68-73 20416170-7 2010 The expression of caspase-3 and DR-4 proteins in RPMI-8226 cells treated with beta-elemene increased in a time-dependent manner, while expressions of BCL-2 and NF-kappaB P65 proteins decreased. beta-elemene 78-90 BCL2 apoptosis regulator Homo sapiens 150-155 20416158-1 2010 This study was aimed to investigate the effect of Docetaxel on drug-resistant leukemia cell line HL-60/ADR and its influence on expression of P-pg, BCL-2 and BAX proteins so as to provide a new strategy and theoretical basis for clinical solution of leukemia drug-resistance. Docetaxel 50-59 BCL2 apoptosis regulator Homo sapiens 148-153 20158203-1 2010 The screening of a small focused library of rhodanine derivatives as inhibitors of Bcl-2 proteins led to the discovery of two structurally related compounds with different binding profiles against the Bcl-XL and the Mcl-1 proteins. Rhodanine 44-53 BCL2 apoptosis regulator Homo sapiens 83-88 20416158-5 2010 It is concluded that the Docetaxel induces apoptosis of HL-60/ADR cells, decreases the expression of BCL-2 protein and increases the expression of BAX protein. Docetaxel 25-34 BCL2 apoptosis regulator Homo sapiens 101-106 20646542-10 2010 (4) The expression level of NF-kappaB and the high expression rate of bcl-2 were: in HCE1/MCS of control group, 0.67 and 60%; in HCE1/MCS of cisplatin group, 0.85 and 83%; in HCE1/MCS of MG132 group, 0.39 and 20%; in HCE1/MCS of MG132+cisplatin group, 0.47 and 33%. Cisplatin 141-150 BCL2 apoptosis regulator Homo sapiens 70-75 20646542-10 2010 (4) The expression level of NF-kappaB and the high expression rate of bcl-2 were: in HCE1/MCS of control group, 0.67 and 60%; in HCE1/MCS of cisplatin group, 0.85 and 83%; in HCE1/MCS of MG132 group, 0.39 and 20%; in HCE1/MCS of MG132+cisplatin group, 0.47 and 33%. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 187-192 BCL2 apoptosis regulator Homo sapiens 70-75 20646542-10 2010 (4) The expression level of NF-kappaB and the high expression rate of bcl-2 were: in HCE1/MCS of control group, 0.67 and 60%; in HCE1/MCS of cisplatin group, 0.85 and 83%; in HCE1/MCS of MG132 group, 0.39 and 20%; in HCE1/MCS of MG132+cisplatin group, 0.47 and 33%. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 229-234 BCL2 apoptosis regulator Homo sapiens 70-75 20139069-7 2010 We showed that the overexpression of FKBP38 attenuates reduction rate of Bcl-2, thus resulting in an increment of the intracellular Bcl-2 level, contributing to the resistance of apoptotic cell death induced by the treatment of kinetin riboside, an anticancer drug. kinetin riboside 228-244 BCL2 apoptosis regulator Homo sapiens 73-78 20139069-7 2010 We showed that the overexpression of FKBP38 attenuates reduction rate of Bcl-2, thus resulting in an increment of the intracellular Bcl-2 level, contributing to the resistance of apoptotic cell death induced by the treatment of kinetin riboside, an anticancer drug. kinetin riboside 228-244 BCL2 apoptosis regulator Homo sapiens 132-137 20048149-5 2010 We demonstrate in vitro that the interaction of FKBP38 with Bcl-2 is regulated by Rheb in a GTP-dependent manner. Guanosine Triphosphate 92-95 BCL2 apoptosis regulator Homo sapiens 60-65 20450732-10 2010 Cells pretreated with higher concentrations of vitexicarpin expressed less c-Myc and Bcl-2 in Hs578T cells.In contrast, p21 decreased when cells were treated with the same conditions. casticin 47-59 BCL2 apoptosis regulator Homo sapiens 85-90 20450732-11 2010 When c-Myc transient transfection was performed in vitexicarpin-treated cells, the effect of p21 and Bcl-2 disappeared. casticin 51-63 BCL2 apoptosis regulator Homo sapiens 101-106 20215556-8 2010 The canonical antiapoptotic protein Bcl-2 was downregulated in vivo and in vitro after L-nil treatment, which was associated with increased susceptibility to cisplatin-mediated tumor death. L-NIL 87-92 BCL2 apoptosis regulator Homo sapiens 36-41 20215556-8 2010 The canonical antiapoptotic protein Bcl-2 was downregulated in vivo and in vitro after L-nil treatment, which was associated with increased susceptibility to cisplatin-mediated tumor death. Cisplatin 158-167 BCL2 apoptosis regulator Homo sapiens 36-41 20646542-10 2010 (4) The expression level of NF-kappaB and the high expression rate of bcl-2 were: in HCE1/MCS of control group, 0.67 and 60%; in HCE1/MCS of cisplatin group, 0.85 and 83%; in HCE1/MCS of MG132 group, 0.39 and 20%; in HCE1/MCS of MG132+cisplatin group, 0.47 and 33%. Cisplatin 235-244 BCL2 apoptosis regulator Homo sapiens 70-75 20646542-12 2010 (2) MG132 could induce the inhibition and apoptosis of HCE1/MCS cells and partially reverse the natural resistance of HCE1/MCS to cisplatin, of which partially reverse the natural resistance may be in relation to the down-regulation of NF-kappaB and bcl-2 expression. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 4-9 BCL2 apoptosis regulator Homo sapiens 250-255 20646542-12 2010 (2) MG132 could induce the inhibition and apoptosis of HCE1/MCS cells and partially reverse the natural resistance of HCE1/MCS to cisplatin, of which partially reverse the natural resistance may be in relation to the down-regulation of NF-kappaB and bcl-2 expression. Cisplatin 130-139 BCL2 apoptosis regulator Homo sapiens 250-255 20646665-11 2010 Western blot assay indicated that dihydroartemisinin downregulated expression of nuclear P65, and combined treatment not only downregulated the expression of Cyclin D1, Bcl-xL and Bcl-2 while upregulated Bax, thus reduced the Bcl-2/Bax ratio, but also increased the caspase-3 activation, all of which increased apoptosis in both BxPC-3 and Panc-1 cells. artenimol 34-52 BCL2 apoptosis regulator Homo sapiens 180-185 20646665-11 2010 Western blot assay indicated that dihydroartemisinin downregulated expression of nuclear P65, and combined treatment not only downregulated the expression of Cyclin D1, Bcl-xL and Bcl-2 while upregulated Bax, thus reduced the Bcl-2/Bax ratio, but also increased the caspase-3 activation, all of which increased apoptosis in both BxPC-3 and Panc-1 cells. artenimol 34-52 BCL2 apoptosis regulator Homo sapiens 226-231 20360986-8 2010 Finally immunoprecipatations indicated that ABT-737 induces Bax, Bak and Bim desequestration from Bcl-2 and Bcl-xL but not from Mcl-1L. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 44-47 BCL2 apoptosis regulator Homo sapiens 98-103 20141168-3 2010 While anti-apoptotic Bcl-2 proteins possess up to four BH sequence domains (BH1-BH4), the pro-apoptotic counterparts have either three BH (BH1-BH3) domains or only the BH3 domain. Bh 55-57 BCL2 apoptosis regulator Homo sapiens 21-26 20141168-3 2010 While anti-apoptotic Bcl-2 proteins possess up to four BH sequence domains (BH1-BH4), the pro-apoptotic counterparts have either three BH (BH1-BH3) domains or only the BH3 domain. bh1 76-79 BCL2 apoptosis regulator Homo sapiens 21-26 20141168-3 2010 While anti-apoptotic Bcl-2 proteins possess up to four BH sequence domains (BH1-BH4), the pro-apoptotic counterparts have either three BH (BH1-BH3) domains or only the BH3 domain. sapropterin 80-83 BCL2 apoptosis regulator Homo sapiens 21-26 20141168-3 2010 While anti-apoptotic Bcl-2 proteins possess up to four BH sequence domains (BH1-BH4), the pro-apoptotic counterparts have either three BH (BH1-BH3) domains or only the BH3 domain. Bh 76-78 BCL2 apoptosis regulator Homo sapiens 21-26 20112989-4 2010 Immunoblotting suggested a down-regulation of several antiapoptotic proteins, including Bcl-2 and Bcl-xL in the nickel compound-treated cells. Nickel 112-118 BCL2 apoptosis regulator Homo sapiens 88-93 19959756-6 2010 In contrast, overexpression of the prosurvival protein Bcl-2 or deficiency of the apoptosis initiating BH3-only proteins Bim or Puma, or the downstream apoptosis effector Bax, markedly reduced glucose- or ribose-induced killing of islets. Glucose 193-200 BCL2 apoptosis regulator Homo sapiens 55-60 20118770-16 2010 Familiarity with the morphologic and immunophenotypic spectrum of DHL is important in directing testing to detect concurrent IGH-BCL2 and MYC rearrangements when a karyotype is unavailable. Cysteamine 66-69 BCL2 apoptosis regulator Homo sapiens 129-133 20392997-7 2010 Induction of apoptosis by CDDO-Me was associated with the inhibition of pro-survival Akt, NF-kappaB and mTOR signaling proteins and NF-kappaB-regulated anti-apoptotic Bcl-2, Bcl-xL, Bad and survivin. bardoxolone methyl 26-33 BCL2 apoptosis regulator Homo sapiens 167-172 19834492-2 2010 On oxidative stress, Bcl-2 moderates mitochondrial respiration through cytochrome c oxidase (COX) activity to prevent an excessive buildup of reactive oxygen species (ROS) by-production from electron transport activities. Reactive Oxygen Species 142-165 BCL2 apoptosis regulator Homo sapiens 21-26 19834492-2 2010 On oxidative stress, Bcl-2 moderates mitochondrial respiration through cytochrome c oxidase (COX) activity to prevent an excessive buildup of reactive oxygen species (ROS) by-production from electron transport activities. Reactive Oxygen Species 167-170 BCL2 apoptosis regulator Homo sapiens 21-26 19834492-3 2010 However, the underlying molecular mechanism(s) of Bcl-2-mediated ROS regulation and its impact on carcinogenesis remain unclear. Reactive Oxygen Species 65-68 BCL2 apoptosis regulator Homo sapiens 50-55 19834492-7 2010 The unique manner in which Bcl-2 adjusted COX subunits during these physiological stress triggers had a profound impact on the resultant decrease in COX activity and maintenance of mitochondrial ROS levels, thus delineating a novel mechanism for the homeostatic role of Bcl-2 in the redox biology and metabolism of cancer cells. Reactive Oxygen Species 195-198 BCL2 apoptosis regulator Homo sapiens 27-32 19834492-7 2010 The unique manner in which Bcl-2 adjusted COX subunits during these physiological stress triggers had a profound impact on the resultant decrease in COX activity and maintenance of mitochondrial ROS levels, thus delineating a novel mechanism for the homeostatic role of Bcl-2 in the redox biology and metabolism of cancer cells. Reactive Oxygen Species 195-198 BCL2 apoptosis regulator Homo sapiens 270-275 20196847-8 2010 Cells treated with cytotoxic concentrations of SFN have reduced cell migration and increased apoptotic cell death via an increase in Bak/Bcl-2 ratio and cleavage of procaspase-9 and poly (ADP-ribose)-polymerase (PARP). sulforaphane 47-50 BCL2 apoptosis regulator Homo sapiens 137-142 19579145-4 2010 Dexamethasone treatment protected hair cells in organ of Corti explants exposed to an ototoxic level of an inflammatory cytokine, and gene expression studies showed that this protection was accomplished by increased expression levels of anti-apoptosis genes (e.g. Bcl-2) and decreased levels of pro-apoptosis genes (e.g. Bax). Dexamethasone 0-13 BCL2 apoptosis regulator Homo sapiens 264-269 19959756-6 2010 In contrast, overexpression of the prosurvival protein Bcl-2 or deficiency of the apoptosis initiating BH3-only proteins Bim or Puma, or the downstream apoptosis effector Bax, markedly reduced glucose- or ribose-induced killing of islets. Ribose 205-211 BCL2 apoptosis regulator Homo sapiens 55-60 19959756-8 2010 CONCLUSIONS: These results implicate the Bcl-2 regulated apoptotic pathway in glucose-induced islet cell killing and indicate points in the pathway at which interventional strategies can be designed. Glucose 78-85 BCL2 apoptosis regulator Homo sapiens 41-46 19937735-9 2010 Ad.mda-7 activated protein phosphatase 2A (PP2A) and promoted dephosphorylation of the anti-apoptotic molecule BCL-2, a downstream ceramide-mediated pathway of mda-7/IL-24 action. Ceramides 131-139 BCL2 apoptosis regulator Homo sapiens 111-116 20332764-7 2010 Immunocytochemical study of molecular profile of A2780 and MCF-7 cells after long-term cultivation with homocysteine has been carried out and has revealed that such treatment resulted in the induction of Bcl-2, P-gp, GST and E-cadherin expression. Homocysteine 104-116 BCL2 apoptosis regulator Homo sapiens 204-209 20097727-9 2010 Exposure to catechol at concentrations greater than 100 microM enhanced Bax levels, and a decrease in Bcl-2 level was observed after the exposure to 600 microM catechol for 48 hours. catechol 160-168 BCL2 apoptosis regulator Homo sapiens 102-107 20052671-0 2010 Ursolic acid overcomes Bcl-2-mediated resistance to apoptosis in prostate cancer cells involving activation of JNK-induced Bcl-2 phosphorylation and degradation. ursolic acid 0-12 BCL2 apoptosis regulator Homo sapiens 23-28 20052671-0 2010 Ursolic acid overcomes Bcl-2-mediated resistance to apoptosis in prostate cancer cells involving activation of JNK-induced Bcl-2 phosphorylation and degradation. ursolic acid 0-12 BCL2 apoptosis regulator Homo sapiens 123-128 20052671-5 2010 UA can overcome Bcl-2-mediated resistance to apoptosis in LNCaP-AI cells. ursolic acid 0-2 BCL2 apoptosis regulator Homo sapiens 16-21 19725066-7 2010 Our results also confirmed that the toxicity of ketamine is related to apoptosis via the Bax/Bcl-2 ratio pathway and caspase-3 in the differentiated neuronal cells. Ketamine 48-56 BCL2 apoptosis regulator Homo sapiens 93-98 20052671-6 2010 Intrinsic apoptotic pathways can be triggered by UA treatment because c-Jun N-terminal kinase (JNK) is activated and subsequently provokes Bcl-2 phosphorylation and degradation, inducing activation of caspase-9. ursolic acid 49-51 BCL2 apoptosis regulator Homo sapiens 139-144 19813266-0 2010 Genistein induces receptor and mitochondrial pathways and increases apoptosis during BCL-2 knockdown in human malignant neuroblastoma SK-N-DZ cells. Genistein 0-9 BCL2 apoptosis regulator Homo sapiens 85-90 19813266-3 2010 The present study sought to elucidate the molecular mechanism of genistein-induced apoptosis and also to examine the effect of genistein in increasing apoptosis during Bcl-2 knockdown in human malignant neuroblastoma SK-N-DZ cells. Genistein 127-136 BCL2 apoptosis regulator Homo sapiens 168-173 19813266-12 2010 Our study demonstrates that Bcl-2 knockdown during genistein treatment effectively induced apoptosis in neuroblastoma cells. Genistein 51-60 BCL2 apoptosis regulator Homo sapiens 28-33 20339233-7 2010 Regarding apoptosis, we found more BCL2(+) cells in the nifedipine group when compared to controls (P = 0.12). Nifedipine 56-66 BCL2 apoptosis regulator Homo sapiens 35-39 20038611-0 2010 The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 36-39 BCL2 apoptosis regulator Homo sapiens 4-9 20038611-5 2010 However, expression of the pro-apoptotic protein Bim, and the extent of its association with Bcl-2, significantly correlated with in vivo ABT-737 sensitivity. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 138-141 BCL2 apoptosis regulator Homo sapiens 93-98 20025076-7 2010 Consequently, apoptosis was triggered by curcumin through the mitochondrial pathway via downregulation of Bcl-2, a downstream anti-apoptotic effector of the Shh signaling. Curcumin 41-49 BCL2 apoptosis regulator Homo sapiens 106-111 20038611-2 2010 ABT-737, a Bcl-2 homology domain 3 mimetic (for structure, see Nature 435:677-681, 2005) inhibits the prosurvival function of Bcl-2, Bcl-X(L), and Bcl-w. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 11-16 20038611-2 2010 ABT-737, a Bcl-2 homology domain 3 mimetic (for structure, see Nature 435:677-681, 2005) inhibits the prosurvival function of Bcl-2, Bcl-X(L), and Bcl-w. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 126-131 20025893-2 2010 In human epidermal (HaCaT) keratinocytes, 17-COOH-7DA inhibited proliferation in a dose-dependent manner, starting at a dose as low as 10(-11) M. This inhibition was accompanied by decreased expression of epidermal growth factor receptor, bcl2 and cyclin E2 mRNAs and by increased expression of involucrin mRNA. 3-hydroxyandrosta-5,7-diene-17-carboxylic acid 42-53 BCL2 apoptosis regulator Homo sapiens 239-243 20197389-2 2010 We found that 2-ME(2) markedly reduced the BEAC cell proliferation through regulating apoptotic machinery such as Bcl-2 and Bax. Mercaptoethanol 14-18 BCL2 apoptosis regulator Homo sapiens 114-119 19866475-9 2010 This protective effect of CCL2 was associated with activation of the ERK/MAP kinase and PI3K/AKT, inhibition of docetaxel-induced Bcl2 phosphorylation at serine 70, phosphorylation of Bad, and activation of caspase-3. Docetaxel 112-121 BCL2 apoptosis regulator Homo sapiens 130-134 19866475-9 2010 This protective effect of CCL2 was associated with activation of the ERK/MAP kinase and PI3K/AKT, inhibition of docetaxel-induced Bcl2 phosphorylation at serine 70, phosphorylation of Bad, and activation of caspase-3. Serine 154-160 BCL2 apoptosis regulator Homo sapiens 130-134 20179162-0 2010 Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 103-106 BCL2 apoptosis regulator Homo sapiens 73-78 20179162-1 2010 ABT-263 inhibits the antiapoptotic proteins Bcl-2, Bcl-x(L), and Bcl-w and has single-agent efficacy in numerous small cell lung carcinoma (SCLC) and leukemia/lymphoma cell lines in vitro and in vivo. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 44-49 20179162-4 2010 We identified the expression of Bcl-2 family genes that correlated best with sensitivity to ABT-263 in a panel of 36 SCLC and 31 leukemia/lymphoma cell lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 92-95 BCL2 apoptosis regulator Homo sapiens 32-37 20179162-5 2010 In cells sensitive to ABT-263, expression of Bcl-2 and Noxa is elevated, whereas expression of Mcl-1 is higher in resistant cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 22-25 BCL2 apoptosis regulator Homo sapiens 45-50 20383943-9 2010 Above all, our data revealed that bortezomib triggered apoptosis by enhancing the caspase 3 activation and/or modulating the Bax/Bcl-2 balance, and also provided preliminary data for further researches of bortezomib on pediatric neuroblastoma. Bortezomib 34-44 BCL2 apoptosis regulator Homo sapiens 129-134 20026395-0 2010 Goniothalamin-induced oxidative stress, DNA damage and apoptosis via caspase-2 independent and Bcl-2 independent pathways in Jurkat T-cells. goniothalamin 0-13 BCL2 apoptosis regulator Homo sapiens 95-100 19786087-0 2010 Induction of apoptosis by esculetin in human leukemia U937 cells: roles of Bcl-2 and extracellular-regulated kinase signaling. esculetin 26-35 BCL2 apoptosis regulator Homo sapiens 75-80 19786087-1 2010 In the present study, we reported that apoptosis induced by esculetin, a phenolic compound with apoptotic activity in cancer cells, was markedly blocked by Bcl-2-overexpression, but restored by HA14-1, a small-molecule Bcl-2 inhibitor, in human leukemic U937 cells. esculetin 60-69 BCL2 apoptosis regulator Homo sapiens 156-161 19786087-1 2010 In the present study, we reported that apoptosis induced by esculetin, a phenolic compound with apoptotic activity in cancer cells, was markedly blocked by Bcl-2-overexpression, but restored by HA14-1, a small-molecule Bcl-2 inhibitor, in human leukemic U937 cells. esculetin 60-69 BCL2 apoptosis regulator Homo sapiens 219-224 19786087-2 2010 The combined use of esculetin and HA14-1 effectively induced Bid cleavage and loss of mitochondrial membrane potential (MMP, Deltapsi(m)) leading to the activation of caspases and cleavage of poly(ADP-ribose) polymerase (PARP) in Bcl-2-overexpressing (U937/Bcl-2) cells. esculetin 20-29 BCL2 apoptosis regulator Homo sapiens 230-235 19786087-2 2010 The combined use of esculetin and HA14-1 effectively induced Bid cleavage and loss of mitochondrial membrane potential (MMP, Deltapsi(m)) leading to the activation of caspases and cleavage of poly(ADP-ribose) polymerase (PARP) in Bcl-2-overexpressing (U937/Bcl-2) cells. esculetin 20-29 BCL2 apoptosis regulator Homo sapiens 257-262 19786087-5 2010 The results indicate that HA14-1-induced reversal of the anti-apoptotic effect of Bcl-2 confers apoptosis sensitivity to esculetin by a mitochondrial amplification step and through the ERK-dependent induction of DR4 expression in U937/Bcl-2 cells. esculetin 121-130 BCL2 apoptosis regulator Homo sapiens 82-87 19786087-6 2010 Thus, HA14-1 reversal of Bcl-2-mediated esculetin resistance suggests a novel strategy for increasing esculetin sensitivity in Bcl-2-overexpressing leukemia cells. esculetin 40-49 BCL2 apoptosis regulator Homo sapiens 25-30 19786087-6 2010 Thus, HA14-1 reversal of Bcl-2-mediated esculetin resistance suggests a novel strategy for increasing esculetin sensitivity in Bcl-2-overexpressing leukemia cells. esculetin 102-111 BCL2 apoptosis regulator Homo sapiens 25-30 19786087-6 2010 Thus, HA14-1 reversal of Bcl-2-mediated esculetin resistance suggests a novel strategy for increasing esculetin sensitivity in Bcl-2-overexpressing leukemia cells. esculetin 102-111 BCL2 apoptosis regulator Homo sapiens 127-132 20545205-1 2010 OBJECTIVE: To research the effect of anthraquinone extracted from rubiqmnone on growth inhibition, introduction apoptosis and expression of relative gene of bcl-2 of hepatocarcinoma cell SMMC 7721, and provide the effective target of gene therapy. Anthraquinones 37-50 BCL2 apoptosis regulator Homo sapiens 157-162 20545205-1 2010 OBJECTIVE: To research the effect of anthraquinone extracted from rubiqmnone on growth inhibition, introduction apoptosis and expression of relative gene of bcl-2 of hepatocarcinoma cell SMMC 7721, and provide the effective target of gene therapy. rubiqmnone 66-76 BCL2 apoptosis regulator Homo sapiens 157-162 20545205-4 2010 The effect of anthraquinone on bcl-2mRNA expression was analyzed by RT-PCR. Anthraquinones 14-27 BCL2 apoptosis regulator Homo sapiens 31-36 20545205-10 2010 Anthraquinone could decrease the expression of bcl-2mRNA by RT-PCR. Anthraquinones 0-13 BCL2 apoptosis regulator Homo sapiens 47-52 20178647-1 2010 BACKGROUND: To test the hypothesis that modulation of Bcl-2 with 13-cis retinoic acid (CRA)/interferon-alpha2b (IFN) with paclitaxel (TAX), or mitoxantrone, estramustine and vinorelbine (MEV) will have clinical activity in men with metastatic castrate-resistant prostate cancer (CRPC). Paclitaxel 122-132 BCL2 apoptosis regulator Homo sapiens 54-59 19962976-0 2010 Catalpol inhibits apoptosis in hydrogen peroxide-induced endothelium by activating the PI3K/Akt signaling pathway and modulating expression of Bcl-2 and Bax. catalpol 0-8 BCL2 apoptosis regulator Homo sapiens 143-148 20178647-1 2010 BACKGROUND: To test the hypothesis that modulation of Bcl-2 with 13-cis retinoic acid (CRA)/interferon-alpha2b (IFN) with paclitaxel (TAX), or mitoxantrone, estramustine and vinorelbine (MEV) will have clinical activity in men with metastatic castrate-resistant prostate cancer (CRPC). Isotretinoin 65-85 BCL2 apoptosis regulator Homo sapiens 54-59 20037155-8 2010 Moreover, expression of the VDAC1-based peptides in cells over-expressing Bcl-2 prevented Bcl-2-mediated protection against staurosporine-induced apoptotic cell death. Staurosporine 124-137 BCL2 apoptosis regulator Homo sapiens 74-79 20037155-8 2010 Moreover, expression of the VDAC1-based peptides in cells over-expressing Bcl-2 prevented Bcl-2-mediated protection against staurosporine-induced apoptotic cell death. Staurosporine 124-137 BCL2 apoptosis regulator Homo sapiens 90-95 19962976-0 2010 Catalpol inhibits apoptosis in hydrogen peroxide-induced endothelium by activating the PI3K/Akt signaling pathway and modulating expression of Bcl-2 and Bax. Hydrogen Peroxide 31-48 BCL2 apoptosis regulator Homo sapiens 143-148 19962976-11 2010 Taken together, these results suggest that pre-treatment of HUVECs with catalpol can block H(2)O(2)-induced apoptosis, and that the underlying mechanism involves reactive oxygen species scavenging, activation of the PI3K/Akt-Bad signaling pathway and increased Bcl-2 and decreased Bax expression. catalpol 72-80 BCL2 apoptosis regulator Homo sapiens 261-266 20025279-7 2010 Moreover, the ratio of the expression levels of pro- and anti-apoptotic Bcl-2 family members was changed after treatment with EEAP. eeap 126-130 BCL2 apoptosis regulator Homo sapiens 72-77 20178647-1 2010 BACKGROUND: To test the hypothesis that modulation of Bcl-2 with 13-cis retinoic acid (CRA)/interferon-alpha2b (IFN) with paclitaxel (TAX), or mitoxantrone, estramustine and vinorelbine (MEV) will have clinical activity in men with metastatic castrate-resistant prostate cancer (CRPC). Isotretinoin 87-90 BCL2 apoptosis regulator Homo sapiens 54-59 20178647-1 2010 BACKGROUND: To test the hypothesis that modulation of Bcl-2 with 13-cis retinoic acid (CRA)/interferon-alpha2b (IFN) with paclitaxel (TAX), or mitoxantrone, estramustine and vinorelbine (MEV) will have clinical activity in men with metastatic castrate-resistant prostate cancer (CRPC). Estramustine 157-169 BCL2 apoptosis regulator Homo sapiens 54-59 20178647-1 2010 BACKGROUND: To test the hypothesis that modulation of Bcl-2 with 13-cis retinoic acid (CRA)/interferon-alpha2b (IFN) with paclitaxel (TAX), or mitoxantrone, estramustine and vinorelbine (MEV) will have clinical activity in men with metastatic castrate-resistant prostate cancer (CRPC). Vinorelbine 174-185 BCL2 apoptosis regulator Homo sapiens 54-59 20178647-1 2010 BACKGROUND: To test the hypothesis that modulation of Bcl-2 with 13-cis retinoic acid (CRA)/interferon-alpha2b (IFN) with paclitaxel (TAX), or mitoxantrone, estramustine and vinorelbine (MEV) will have clinical activity in men with metastatic castrate-resistant prostate cancer (CRPC). 1-Methyl-2-nitro-5-vinyl-1H-imidazole 187-190 BCL2 apoptosis regulator Homo sapiens 54-59 20085765-3 2010 This effect was inhibited by overexpression of human Bcl-2, by silencing of cytochrome c, and by ablation of Bax/Bak, indicating that H(2)O(2)-induced apoptosis was mediated by the mitochondrial pathway in Jurkat cells. Hydrogen Peroxide 134-142 BCL2 apoptosis regulator Homo sapiens 53-58 19944674-7 2010 Curcumin inhibited cell growth, induced apoptosis and upregulated maspin gene expression in MCF-7 cells and these findings were further correlated with the upregulation of p53 protein and downregulation of Bcl-2, suggesting maspin mediated apoptosis in MCF-7 cells. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 206-211 20159606-1 2010 Expression of MCL-1 is frequently elevated in cancer and is implicated in the resistance to chemotherapy by the BCL-2 small molecule inhibitor ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 143-146 BCL2 apoptosis regulator Homo sapiens 112-117 19799874-10 2010 Whereas off-target effects of zVAD appear as upstream, Bcl-2 may exert its inhibitory activity downstream of ROS. Reactive Oxygen Species 109-112 BCL2 apoptosis regulator Homo sapiens 55-60 19676043-5 2010 Indeed, Western blot analysis indicated that miR-153 downregulated both Bcl-2 and Mcl-1 at the protein levels. mir-153 45-52 BCL2 apoptosis regulator Homo sapiens 72-77 20067268-7 2010 In addition, genistein increased nucleosomal DNA fragmentation, increased the expression levels of Bax and c-Myc, and decreased the expression levels of Bcl-2 and Bcl-xL in TNF-alpha-induced HASMCs. hasmcs 191-197 BCL2 apoptosis regulator Homo sapiens 153-158 20067268-7 2010 In addition, genistein increased nucleosomal DNA fragmentation, increased the expression levels of Bax and c-Myc, and decreased the expression levels of Bcl-2 and Bcl-xL in TNF-alpha-induced HASMCs. Genistein 13-22 BCL2 apoptosis regulator Homo sapiens 153-158 19954742-9 2010 Surfactin triggered the mitochondrial/caspase apoptotic pathway indicated by enhanced Bax-to-Bcl-2 expression ratio, loss of mitochondrial membrane potential, cytochrome c release, and caspase cascade reaction. surfactin peptide 0-9 BCL2 apoptosis regulator Homo sapiens 93-98 20025854-6 2010 Gene expression analysis revealed that EGCG prevented the QUIN-induced expression of the proapoptotic gene, caspase-9, and increased that of the antiapoptotic genes, Bcl-XL, Bcl-2, and Bcl-w. epigallocatechin gallate 39-43 BCL2 apoptosis regulator Homo sapiens 174-179 20025854-6 2010 Gene expression analysis revealed that EGCG prevented the QUIN-induced expression of the proapoptotic gene, caspase-9, and increased that of the antiapoptotic genes, Bcl-XL, Bcl-2, and Bcl-w. Quinolinic Acid 58-62 BCL2 apoptosis regulator Homo sapiens 174-179 19889614-5 2010 Furthermore, we showed that this daidzein-induced ROS generation was accompanied by disruption of mitochondrial transmembrane potential, down-regulation of bcl-2, and up-regulation of bax, which led to the release of cytochrome C from the mitochondria into the cytosol, which, in turn, resulted in the activation of caspase-9 and caspase-7, and ultimately in cell death. daidzein 33-41 BCL2 apoptosis regulator Homo sapiens 156-161 19738454-1 2010 PURPOSE: To determine the maximum tolerated dose of oblimersen, an antisense oligonucleotide directed to the Bcl-2 mRNA, in combination with cisplatin and 5-flourouracil in patients with advanced gastric and esophageal carcinoma. Oligonucleotides 77-92 BCL2 apoptosis regulator Homo sapiens 109-114 19889614-5 2010 Furthermore, we showed that this daidzein-induced ROS generation was accompanied by disruption of mitochondrial transmembrane potential, down-regulation of bcl-2, and up-regulation of bax, which led to the release of cytochrome C from the mitochondria into the cytosol, which, in turn, resulted in the activation of caspase-9 and caspase-7, and ultimately in cell death. Reactive Oxygen Species 50-53 BCL2 apoptosis regulator Homo sapiens 156-161 19936928-7 2010 We studied the regulation of Bcl-2 family members in aspirin-induced apoptosis. Aspirin 53-60 BCL2 apoptosis regulator Homo sapiens 29-34 19737541-7 2010 Therefore, the ability of ABT-737 to inhibit Bcl-2 renders previously resistant HL-60 cancer cells highly sensitive to doxorubicin-DNA adducts, leading to a classical apoptotic response. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 26-29 BCL2 apoptosis regulator Homo sapiens 45-50 19882354-4 2010 Increased cAMP levels also shifted the ratio of the death promoter to death repressor genes via alteration of Bcl-2 and Bax proteins expression. Cyclic AMP 10-14 BCL2 apoptosis regulator Homo sapiens 110-115 20332461-8 2010 Furthermore, curcumin down-regulated bcl-2 and bcl(x)l, leading to caspase-mediated cell death. Curcumin 13-21 BCL2 apoptosis regulator Homo sapiens 37-42 20332466-5 2010 Firstly, VPA induced cell growth inhibition and apoptotic activity, as demonstrated by sulforhodamine B protein assay, annexin V assay and by Western blot analysis for Bcl2 and Bax expression levels, in all three cell lines. Valproic Acid 9-12 BCL2 apoptosis regulator Homo sapiens 168-172 19737541-0 2010 ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 18-23 19737541-0 2010 ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts. Doxorubicin 47-58 BCL2 apoptosis regulator Homo sapiens 18-23 19851870-6 2010 Our results suggest that psoralidin inhibits constitutive and TNF-induced expression of TNF-alpha and its downstream prosurvival signaling molecules such as NF-kappaB and Bcl-2 in AIPC cells. psoralidin 25-35 BCL2 apoptosis regulator Homo sapiens 171-176 19737541-7 2010 Therefore, the ability of ABT-737 to inhibit Bcl-2 renders previously resistant HL-60 cancer cells highly sensitive to doxorubicin-DNA adducts, leading to a classical apoptotic response. Doxorubicin 119-130 BCL2 apoptosis regulator Homo sapiens 45-50 19737541-3 2010 However, the overexpression of Bcl-2 confers resistance to doxorubicin/AN-9 DNA adduct forming treatments, thus limiting the therapeutic potential of this drug combination. Doxorubicin 59-70 BCL2 apoptosis regulator Homo sapiens 31-36 19737541-4 2010 The small molecule inhibitor, ABT-737, which binds to and inhibits Bcl-2, Bcl-xL and Bcl-w, was used in combination with doxorubicin/AN-9 treatments to overcome resistance to doxorubicin-DNA adducts in Bcl-2 overexpressing HL-60 cells (HL-60/Bcl-2). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 30-33 BCL2 apoptosis regulator Homo sapiens 67-72 19737541-8 2010 In conclusion, the data obtained provides promising evidence that the anticancer activity of doxorubicin-DNA adducts can be substantially enhanced in Bcl-2 overexpressing cancers with the use of the small molecule Bcl-2 inhibitor, ABT-737. Doxorubicin 93-104 BCL2 apoptosis regulator Homo sapiens 150-155 19737541-4 2010 The small molecule inhibitor, ABT-737, which binds to and inhibits Bcl-2, Bcl-xL and Bcl-w, was used in combination with doxorubicin/AN-9 treatments to overcome resistance to doxorubicin-DNA adducts in Bcl-2 overexpressing HL-60 cells (HL-60/Bcl-2). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 30-33 BCL2 apoptosis regulator Homo sapiens 202-207 19737541-4 2010 The small molecule inhibitor, ABT-737, which binds to and inhibits Bcl-2, Bcl-xL and Bcl-w, was used in combination with doxorubicin/AN-9 treatments to overcome resistance to doxorubicin-DNA adducts in Bcl-2 overexpressing HL-60 cells (HL-60/Bcl-2). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 30-33 BCL2 apoptosis regulator Homo sapiens 202-207 19737541-8 2010 In conclusion, the data obtained provides promising evidence that the anticancer activity of doxorubicin-DNA adducts can be substantially enhanced in Bcl-2 overexpressing cancers with the use of the small molecule Bcl-2 inhibitor, ABT-737. Doxorubicin 93-104 BCL2 apoptosis regulator Homo sapiens 214-219 19737541-8 2010 In conclusion, the data obtained provides promising evidence that the anticancer activity of doxorubicin-DNA adducts can be substantially enhanced in Bcl-2 overexpressing cancers with the use of the small molecule Bcl-2 inhibitor, ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 231-234 BCL2 apoptosis regulator Homo sapiens 150-155 19737541-8 2010 In conclusion, the data obtained provides promising evidence that the anticancer activity of doxorubicin-DNA adducts can be substantially enhanced in Bcl-2 overexpressing cancers with the use of the small molecule Bcl-2 inhibitor, ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 231-234 BCL2 apoptosis regulator Homo sapiens 214-219 19777565-6 2010 The antiapoptotic protein, Bcl-2, was decreased, whereas the apoptotic protein, Bax, was increased in a time-dependent manner in rotenone-induced apoptosis. Rotenone 129-137 BCL2 apoptosis regulator Homo sapiens 27-32 20104024-2 2010 We determined whether the anticancer agent celecoxib, alone or combined with a small molecule Bcl-2/Bcl-x(L) antagonist (ABT-737), can induce autophagy in colon cancer cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 121-124 BCL2 apoptosis regulator Homo sapiens 94-99 20104024-4 2010 Celecoxib was shown to induce apoptosis that was attenuated by ectopic Bcl-2 or Bax knockout. Celecoxib 0-9 BCL2 apoptosis regulator Homo sapiens 71-76 20422978-4 2010 RESULT: Western blot and PCR results demonstrated that Stat3 ASODN could significantly increased the expression of Bax and decreased the expression of Bcl-2 and C-Myc when the concentration of antisense oligodeoxynucleotide were heightened. Oligodeoxyribonucleotides 203-223 BCL2 apoptosis regulator Homo sapiens 151-156 19585117-10 2010 Western blotting assay revealed oroxylin A enhanced 5-FU-induced apoptosis in HepG2 cells by elevating the expressions of apoptotic-inducing proteins P53 and cleaved PARP and decreasing the expression of apoptotic-inhibitory proteins COX-2, Bcl-2, and pro-caspase3. 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one 32-42 BCL2 apoptosis regulator Homo sapiens 241-246 19585117-10 2010 Western blotting assay revealed oroxylin A enhanced 5-FU-induced apoptosis in HepG2 cells by elevating the expressions of apoptotic-inducing proteins P53 and cleaved PARP and decreasing the expression of apoptotic-inhibitory proteins COX-2, Bcl-2, and pro-caspase3. Fluorouracil 52-56 BCL2 apoptosis regulator Homo sapiens 241-246 19269153-5 2010 miR-16 is one of the miRNAs up-regulated by EGCG and one of its target genes is confirmed to be the anti-apoptotic protein Bcl-2. epigallocatechin gallate 44-48 BCL2 apoptosis regulator Homo sapiens 123-128 19269153-6 2010 EGCG treatment induced apoptosis and down-regulated Bcl-2 in HepG2 cells. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 52-57 19269153-7 2010 Transfection with anti-miR-16 inhibitor suppressed miR-16 expression and counteracted the EGCG effects on Bcl-2 down-regulation and also induction of apoptosis in cells. epigallocatechin gallate 90-94 BCL2 apoptosis regulator Homo sapiens 106-111 20126473-10 2010 We also found that the cytosolic pool of Bcl-xL and Bcl-2 remained unaffected in the low-dose MMC treatment but decreased in the high-dose MMC treatment. Mitomycin 139-142 BCL2 apoptosis regulator Homo sapiens 52-57 20126473-12 2010 In the low-dose MMC treatment, the increased mitochondrial p53, Bcl-xL, and Bcl-2 could attenuate apoptosis. Mitomycin 16-19 BCL2 apoptosis regulator Homo sapiens 76-81 20300700-0 2010 [Nifedipine regulated expression of bcl-2 in human gingival epithelial cells in vitro]. Nifedipine 1-11 BCL2 apoptosis regulator Homo sapiens 36-41 20044024-4 2010 In addition, anti-apoptotic BCL-2 family proteins like BCL-2 and BCL-XL, and ROS scavengers including ascorbic acid and 2,2,6,6-tetramethyl-1-piperidinyloxy were not able to inhibit Cyt C release as well as apoptosis by PGA(2). Prostaglandins A 220-223 BCL2 apoptosis regulator Homo sapiens 28-33 20300700-1 2010 PURPOSE: To investigate the effect of nifedipine(NIF) on transcription of bcl-2 in human gingival epithelial cells(HGECs) in vitro and to study the pathogenesis of epithelial thickening in drug-induced gingival overgrowth(DGO). Nifedipine 38-48 BCL2 apoptosis regulator Homo sapiens 74-79 19747539-8 2010 Both SP600125 and PD98059 attenuated Bad up-regulation, and reversed down-regulation of Bcl-2, Bcl-X(L), survivin, cyclin A, cyclin B, and Cdk2 in NFD-treated cells. pyrazolanthrone 5-13 BCL2 apoptosis regulator Homo sapiens 88-93 19747539-8 2010 Both SP600125 and PD98059 attenuated Bad up-regulation, and reversed down-regulation of Bcl-2, Bcl-X(L), survivin, cyclin A, cyclin B, and Cdk2 in NFD-treated cells. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 18-25 BCL2 apoptosis regulator Homo sapiens 88-93 19994890-11 2010 Additionally, treatment with genistein (6) changed the ratio of expression levels of pro- and anti-apoptotic Bcl-2 family members and subsequently induced the activation of caspase-9 and caspase-3, which was followed by cleavage of poly(ADP-ribose) polymerase (PARP). Genistein 29-38 BCL2 apoptosis regulator Homo sapiens 109-114 19855432-5 2010 ROS generation was attributed to the suppression of B-cell lymphoma-2 (Bcl-2) phosphorylation, and resulted in DNA damage and p53 activation. Reactive Oxygen Species 0-3 BCL2 apoptosis regulator Homo sapiens 52-69 19855432-5 2010 ROS generation was attributed to the suppression of B-cell lymphoma-2 (Bcl-2) phosphorylation, and resulted in DNA damage and p53 activation. Reactive Oxygen Species 0-3 BCL2 apoptosis regulator Homo sapiens 71-76 19855432-9 2010 Altogether, our results showed that loss of JNK activity triggers a Bcl-2/ROS/DDR signaling cascade that ultimately leads to premature senescence, indicating that basal JNK activity is essential in preventing premature senescence. Reactive Oxygen Species 74-77 BCL2 apoptosis regulator Homo sapiens 68-73 20105315-7 2010 Despite caspase activation, the upregulation of the anti-apoptotic bcl-2 family member protein mcl-1 that resulted from nelfinavir treatment stabilized the mitochondrial membrane potential, resulting in primarily mitochondria-independent cell death. Nelfinavir 120-130 BCL2 apoptosis regulator Homo sapiens 67-72 19818742-7 2010 Finally, delphinidin can efficiently prevent the down-regulation of Bcl-2 protein and up-regulation of Bax protein. delphinidin 9-20 BCL2 apoptosis regulator Homo sapiens 68-73 19932626-0 2010 Down-regulation of Bcl-2 and Akt induced by combination of photoactivated hypericin and genistein in human breast cancer cells. hypericin 74-83 BCL2 apoptosis regulator Homo sapiens 19-24 19932626-0 2010 Down-regulation of Bcl-2 and Akt induced by combination of photoactivated hypericin and genistein in human breast cancer cells. Genistein 88-97 BCL2 apoptosis regulator Homo sapiens 19-24 19932626-2 2010 Since genistein is known to suppress Bcl-2 expression, we predicted that photodynamic therapy with hypericin might benefit from mutual therapeutic combination. Genistein 6-15 BCL2 apoptosis regulator Homo sapiens 37-42 19932626-2 2010 Since genistein is known to suppress Bcl-2 expression, we predicted that photodynamic therapy with hypericin might benefit from mutual therapeutic combination. hypericin 99-108 BCL2 apoptosis regulator Homo sapiens 37-42 19682434-9 2010 Curcumin abolished the constitutive activation of NF-kappaB in the tumor tissue; induced apoptosis, and decreased cyclin D1, VEGF, COX-2, c-myc and Bcl-2 expression in the bladder cancer tissue. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 148-153 20302733-6 2010 RESULTS: At 72 h after transfection, the combination with gemcitabine and p65 siRNA significantly decreased the cell viability index (P < 0.05), and down-regulated the expression of Bcl-2 and procaspase-3 and up-regulated the expression of Bax compared with other groups. gemcitabine 58-69 BCL2 apoptosis regulator Homo sapiens 185-190 19716852-1 2010 A multi-inlet microfluidic hydrodynamic focusing (MF) system to prepare lipopolyplex (LP) containing Bcl-2 antisense deoxyoligonucleotide (ODN) was developed and evaluated. lipopolyplex 72-84 BCL2 apoptosis regulator Homo sapiens 101-106 20062536-3 2010 YC137 inhibits BCL-W and BCL2 and restores ICI sensitivity in resistant cells. YC137 0-5 BCL2 apoptosis regulator Homo sapiens 25-29 19716852-1 2010 A multi-inlet microfluidic hydrodynamic focusing (MF) system to prepare lipopolyplex (LP) containing Bcl-2 antisense deoxyoligonucleotide (ODN) was developed and evaluated. leucylproline 86-88 BCL2 apoptosis regulator Homo sapiens 101-106 19716852-7 2010 MF LP nanoparticles had higher level of Bcl-2 antisense uptake and showed more efficient down-regulation of Bcl-2 protein level than BM LP nanoparticles. leucylproline 3-5 BCL2 apoptosis regulator Homo sapiens 40-45 19716852-7 2010 MF LP nanoparticles had higher level of Bcl-2 antisense uptake and showed more efficient down-regulation of Bcl-2 protein level than BM LP nanoparticles. leucylproline 3-5 BCL2 apoptosis regulator Homo sapiens 108-113 19966835-10 2010 Aspirin inhibits GSK-3beta activation and suppresses the expression of its downstream gene products (cyclin D1 and Bcl-2), which are implicated in proliferation, survival and chemoresistance of pancreatic cancer. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 115-120 20387232-7 2010 Our result showed that PGE-induced apoptosis was associated with activation of caspase-3, -8 and -9, down-regulation of Bcl-2, up-regulation of Bax and release of mitochondrial cytochrome c to cytosol. phenylglycidyl ether 23-26 BCL2 apoptosis regulator Homo sapiens 120-125 20919636-6 2010 Alternatively, BCL-2 family members are contained in other multiprotein complexes at the ER that are involved in the control of diverse cellular processes including calcium homeostasis, autophagy and ER morphogenesis. Calcium 165-172 BCL2 apoptosis regulator Homo sapiens 15-20 19665451-4 2010 Aim of the present study was to identify specific pro- and anti-apoptotic members of the Bcl-2 family involved in the regulation of Bak activation, and subsequent apoptosis upon treatment with Celecoxib in the Jurkat cell model. Celecoxib 193-202 BCL2 apoptosis regulator Homo sapiens 89-94 21061466-9 2010 ATO also significantly enhanced expression of Bax and cytochrome c proteins but suppressed those of Bcl-2. Arsenic Trioxide 0-3 BCL2 apoptosis regulator Homo sapiens 100-105 19346318-7 2010 Troglitazone blocked NNK-induced up-regulation of HO-1, Bcl-2, and c-IAP2, and recovered Bad activity that was suppressed by NNK. Troglitazone 0-12 BCL2 apoptosis regulator Homo sapiens 56-61 19475409-0 2010 Treatment of K562 cells with 1,25-dihydroxyvitamin D3 induces distinct alterations in the expression of apoptosis-related genes BCL2, BAX, BCLXL, and p21. Calcitriol 29-53 BCL2 apoptosis regulator Homo sapiens 128-132 20150614-0 2010 Disulfide-linked liposomes: effective delivery vehicle for Bcl-2 antisense oligodeoxyribonucleotide G3139. Disulfides 0-9 BCL2 apoptosis regulator Homo sapiens 59-64 20150614-0 2010 Disulfide-linked liposomes: effective delivery vehicle for Bcl-2 antisense oligodeoxyribonucleotide G3139. Oligodeoxyribonucleotides 75-99 BCL2 apoptosis regulator Homo sapiens 59-64 20150614-3 2010 Disulfide-linked ODN liposomes were characterized for their size, ODN intracellular delivery, Bcl-2 mRNA and protein expression, growth inhibition, and chemosensitization. Disulfides 0-9 BCL2 apoptosis regulator Homo sapiens 94-99 20150614-5 2010 Treatment of the cells with disulfide-linked ODN liposomes resulted in efficient Bcl-2 down-regulation greater than that with hydrophobized disulfide-linked ODN and consistent with that of cellular growth inhibition and the sensitization to daunorubicin in KB cells. Disulfides 28-37 BCL2 apoptosis regulator Homo sapiens 81-86 20150614-5 2010 Treatment of the cells with disulfide-linked ODN liposomes resulted in efficient Bcl-2 down-regulation greater than that with hydrophobized disulfide-linked ODN and consistent with that of cellular growth inhibition and the sensitization to daunorubicin in KB cells. Daunorubicin 241-253 BCL2 apoptosis regulator Homo sapiens 81-86 19665451-0 2010 Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on celecoxib-induced apoptosis. Celecoxib 88-97 BCL2 apoptosis regulator Homo sapiens 39-44 19665451-0 2010 Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on celecoxib-induced apoptosis. Celecoxib 88-97 BCL2 apoptosis regulator Homo sapiens 67-72 19665451-8 2010 Our data reveal an important role of the Mcl-1/Noxa axis for Celecoxib-induced apoptosis and suggest that Celecoxib may be of value for treatment of tumors addicted to Mcl-1 and for combined treatment approaches targeting anti-apoptotic Bcl-2 family members. Celecoxib 106-115 BCL2 apoptosis regulator Homo sapiens 237-242 20686221-9 2010 Moreover, curcumin induced the expression of cyclin dependent kinase inhibitor genes p21 and p27, while it inhibited the expression of numerous genes, including Bcl-2, cyclin D1, CDK2, CDK4 and CDK6. Curcumin 10-18 BCL2 apoptosis regulator Homo sapiens 161-166 20460760-5 2010 A significantly elicited hypodiploid cell population was found in cells treated with 2, 4, and 8microM shikonin for 24 h. Moreover, treatment with shikonin induced reactive oxygen species (ROS) generation, increased extracellular signal-regulated kinase (ERK) phosphorylation, decreased B-cell lymphoma-2 (Bcl2) expression, and was accompanied by poly(ADP-ribose) polymerase (PARP) cleavage. shikonin 103-111 BCL2 apoptosis regulator Homo sapiens 287-304 20460760-5 2010 A significantly elicited hypodiploid cell population was found in cells treated with 2, 4, and 8microM shikonin for 24 h. Moreover, treatment with shikonin induced reactive oxygen species (ROS) generation, increased extracellular signal-regulated kinase (ERK) phosphorylation, decreased B-cell lymphoma-2 (Bcl2) expression, and was accompanied by poly(ADP-ribose) polymerase (PARP) cleavage. shikonin 103-111 BCL2 apoptosis regulator Homo sapiens 306-310 20190405-9 2010 Induction of p53, the activation of caspase-3 by H(2)O(2) which accompanying downregulation of bcl-2, was blocked by CXC195. Hydrogen Peroxide 49-57 BCL2 apoptosis regulator Homo sapiens 95-100 20522977-6 2010 In addition, donepezil was found to cause the loss of mitochondrial membrane potential (DeltaPsi(m)), to increase the release of cytochrome c to the cytosol, and to alter the expressions of Bcl-2 family proteins. Donepezil 13-22 BCL2 apoptosis regulator Homo sapiens 190-195 20096139-6 2010 ABL-N treatment also resulted in an increase in the expression of pro-apoptotic members (Bax and Bad) with a concomitant decrease in Bcl-2. abl-n 0-5 BCL2 apoptosis regulator Homo sapiens 133-138 19238538-0 2010 Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells. Cisplatin 79-88 BCL2 apoptosis regulator Homo sapiens 19-24 19238538-0 2010 Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells. Cisplatin 79-88 BCL2 apoptosis regulator Homo sapiens 103-108 20823585-5 2010 Furthermore, IPA was found to induce the loss of mitochondrial membrane potential, the release of cytochrome c to the cytosol, and the increased ratio of mitochondrial Bax/Bcl-2. ipa 13-16 BCL2 apoptosis regulator Homo sapiens 172-177 20930370-7 2010 Berberine also markedly enhanced apoptosis in T98G cells through the induction of a higher ratio of Bax/Bcl-2 proteins, disruption of the mitochondrial membrane potential, activation of caspase-9 and -3, and cleavage of the poly(ADP-ribose) polymerase (PARP). Berberine 0-9 BCL2 apoptosis regulator Homo sapiens 104-109 19238538-4 2010 Furthermore, when we transiently silenced Bcl-2, both cisplatin and paclitaxel induced apoptosis more than parental cells. Cisplatin 54-63 BCL2 apoptosis regulator Homo sapiens 42-47 20048077-4 2010 Vanadate suppressed p53-associated apoptotic events at the mitochondria, including the loss of mitochondrial membrane potential, the conformational change of Bax and Bak, the mitochondrial translocation of p53, and the interaction of p53 with Bcl-2. Vanadates 0-8 BCL2 apoptosis regulator Homo sapiens 243-248 19238538-4 2010 Furthermore, when we transiently silenced Bcl-2, both cisplatin and paclitaxel induced apoptosis more than parental cells. Paclitaxel 68-78 BCL2 apoptosis regulator Homo sapiens 42-47 19238538-10 2010 Enforced Bcl-2 expression in MDA-MB-231 cells abrogated the sensitizing effect of HA14-1 in cisplatin induced apoptosis. Cisplatin 92-101 BCL2 apoptosis regulator Homo sapiens 9-14 20659323-8 2010 Sensitisation to the pro-apoptotic effects DIAs is mediated by decreased expression of BCL2, which we show here is a direct MYB target in breast cancer cells. dias 43-47 BCL2 apoptosis regulator Homo sapiens 87-91 20339300-8 2010 Real-time PCR indicated that the expression of Bcl-2, Pax3, Bmp4 and Slug was down-regulated in the nicotine group, while the expression of P53, Bax and Msx1 was up-regulated. Nicotine 100-108 BCL2 apoptosis regulator Homo sapiens 47-52 19798105-5 2010 Further observation indicated that TSA induced a substantial dissipation of mitochondrial transmembrane potential, release of cytochrome c into the cytosol, and proteolytic cleavage of caspases-3/9 in HeLa cells, which was apparently mediated by ubiquitylation and the subsequent degradation of mitochondrial membrane proteins including BCL-2 and MCL-1. trichostatin A 35-38 BCL2 apoptosis regulator Homo sapiens 337-342 20357441-8 2010 Furthermore, paclitaxel and pirarubicin suppressed the expression of PCNA, cyclin D1, cyclin E and Bcl-2, and increased Bax expression. Paclitaxel 13-23 BCL2 apoptosis regulator Homo sapiens 99-104 20110687-6 2010 YXQ-EQ also substantially repressed NF-kappaB activity, resulting in decreased expression of anti-apoptotic Bcl-2, Bcl-X(L), XIAP and survivin proteins. yxq-eq 0-6 BCL2 apoptosis regulator Homo sapiens 108-113 21063098-7 2010 Moreover, periplocin induced apoptosis by downregulating Bcl-2 and upregulating Bax, leading to activation of caspase-3 and caspase-9. periplocin 10-20 BCL2 apoptosis regulator Homo sapiens 57-62 20948210-0 2010 Antitumor effects of ginkgolic acid in human cancer cell occur via cell cycle arrest and decrease the Bcl-2/Bax ratio to induce apoptosis. ginkgolic acid 21-35 BCL2 apoptosis regulator Homo sapiens 102-107 20948210-9 2010 GA-treated activated caspase-3 downregulated the expression of anti-apoptotic Bcl-2 protein and upregulated the expression of pro-apoptotic Bax protein, eventually leading to a decrease in the Bcl-2/Bax ratio in tumor cells. ginkgolic acid 0-2 BCL2 apoptosis regulator Homo sapiens 78-83 20948210-9 2010 GA-treated activated caspase-3 downregulated the expression of anti-apoptotic Bcl-2 protein and upregulated the expression of pro-apoptotic Bax protein, eventually leading to a decrease in the Bcl-2/Bax ratio in tumor cells. ginkgolic acid 0-2 BCL2 apoptosis regulator Homo sapiens 193-198 20357441-9 2010 CONCLUSION: These results suggest that the G2/M or G0/G1 cell cycle arrest and apoptosis induced by paclitaxel and pirarubicin are Bcl-2/Bax dependent, suggesting favorable effects of combination therapy with paclitaxel and pirarubicin in the treatment of osteosarcoma. Paclitaxel 209-219 BCL2 apoptosis regulator Homo sapiens 131-136 20357441-8 2010 Furthermore, paclitaxel and pirarubicin suppressed the expression of PCNA, cyclin D1, cyclin E and Bcl-2, and increased Bax expression. pirarubicin 28-39 BCL2 apoptosis regulator Homo sapiens 99-104 20357441-9 2010 CONCLUSION: These results suggest that the G2/M or G0/G1 cell cycle arrest and apoptosis induced by paclitaxel and pirarubicin are Bcl-2/Bax dependent, suggesting favorable effects of combination therapy with paclitaxel and pirarubicin in the treatment of osteosarcoma. pirarubicin 224-235 BCL2 apoptosis regulator Homo sapiens 131-136 20357441-9 2010 CONCLUSION: These results suggest that the G2/M or G0/G1 cell cycle arrest and apoptosis induced by paclitaxel and pirarubicin are Bcl-2/Bax dependent, suggesting favorable effects of combination therapy with paclitaxel and pirarubicin in the treatment of osteosarcoma. Paclitaxel 100-110 BCL2 apoptosis regulator Homo sapiens 131-136 20357441-9 2010 CONCLUSION: These results suggest that the G2/M or G0/G1 cell cycle arrest and apoptosis induced by paclitaxel and pirarubicin are Bcl-2/Bax dependent, suggesting favorable effects of combination therapy with paclitaxel and pirarubicin in the treatment of osteosarcoma. pirarubicin 115-126 BCL2 apoptosis regulator Homo sapiens 131-136 20036937-8 2010 Furthermore, resveratrol also exhibits anti-apoptotic properties via regulation of apoptotic mediators such as Bax, Bcl-2, and caspase-3. Resveratrol 13-24 BCL2 apoptosis regulator Homo sapiens 116-121 20557688-9 2010 In conclusion, the release of ROS by PU- or PTFE-treated THP-1 cells may induce iNOS expression and cause apoptosis in HUVECs via the p53, Bax and Bcl-2 proteins. Reactive Oxygen Species 30-33 BCL2 apoptosis regulator Homo sapiens 147-152 20425394-6 2010 Oblimersen, obatoclax, and ABT-263 target the antiapoptotic protein Bcl-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 27-30 BCL2 apoptosis regulator Homo sapiens 68-73 19669391-0 2010 Calcium pyrophosphate dihydrate crystal-induced inhibition of neutrophil apoptosis: involvement of Bcl-2 family members. Calcium Pyrophosphate 0-31 BCL2 apoptosis regulator Homo sapiens 99-104 19956899-7 2010 The exposure of cells to PCC resulted in growth inhibition and induction of apoptosis, which was associated with the proteolytic activation of caspase-3 and down-regulation of anti-apoptotic Bcl-2 protein. pyridinium chlorochromate 25-28 BCL2 apoptosis regulator Homo sapiens 191-196 20557688-9 2010 In conclusion, the release of ROS by PU- or PTFE-treated THP-1 cells may induce iNOS expression and cause apoptosis in HUVECs via the p53, Bax and Bcl-2 proteins. Polyurethanes 37-39 BCL2 apoptosis regulator Homo sapiens 147-152 20557688-9 2010 In conclusion, the release of ROS by PU- or PTFE-treated THP-1 cells may induce iNOS expression and cause apoptosis in HUVECs via the p53, Bax and Bcl-2 proteins. Polytetrafluoroethylene 44-48 BCL2 apoptosis regulator Homo sapiens 147-152 19157829-7 2010 Concomitantly, it inhibited 7-KC-induced apoptosis, by limiting caspase-3 activation and the modulatory effects of 7-KC on AKT, Bcl-2, Bcl-xL and Bax. 7-ketocholesterol 28-32 BCL2 apoptosis regulator Homo sapiens 128-133 20038799-3 2010 Here we have demonstrated that pharmacologic inhibition of FAO with etomoxir or ranolazine inhibited proliferation and sensitized human leukemia cells--cultured alone or on bone marrow stromal cells--to apoptosis induction by ABT-737, a molecule that releases proapoptotic Bcl-2 proteins such as Bak from antiapoptotic family members. etomoxir 68-76 BCL2 apoptosis regulator Homo sapiens 273-278 20038799-3 2010 Here we have demonstrated that pharmacologic inhibition of FAO with etomoxir or ranolazine inhibited proliferation and sensitized human leukemia cells--cultured alone or on bone marrow stromal cells--to apoptosis induction by ABT-737, a molecule that releases proapoptotic Bcl-2 proteins such as Bak from antiapoptotic family members. Ranolazine 80-90 BCL2 apoptosis regulator Homo sapiens 273-278 19608275-7 2010 The enhanced cytotoxicity of ATO+bortezomib was associated with augmented STAT3 inhibition and JNK activation, up-regulation of Bim, p21, p27, p53 as well as down-regulation of Bcl-2. ato 29-32 BCL2 apoptosis regulator Homo sapiens 177-182 20700417-2 2010 Promoter regions of C-myc and Bcl2 forming G-quadruplex structures are chemically synthesized and G-quadruplex structure is formed in presence of 100 mM potassium ion. Potassium 153-162 BCL2 apoptosis regulator Homo sapiens 30-34 20816004-5 2010 In addition, bcl-2 phosphorylation and AKT cleavage, induced by all MIA tested, was not observed in response to non-MIA CEU further emphasizing the differential cell death mechanisms induced by MIA and non-MIA CEU. N4-Methyl-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine 210-213 BCL2 apoptosis regulator Homo sapiens 13-18 19931389-0 2010 Opposing actions of the progesterone metabolites, 5alpha-dihydroprogesterone (5alphaP) and 3alpha-dihydroprogesterone (3alphaHP) on mitosis, apoptosis, and expression of Bcl-2, Bax and p21 in human breast cell lines. 5-alpha-Dihydroprogesterone 50-76 BCL2 apoptosis regulator Homo sapiens 170-175 19931389-0 2010 Opposing actions of the progesterone metabolites, 5alpha-dihydroprogesterone (5alphaP) and 3alpha-dihydroprogesterone (3alphaHP) on mitosis, apoptosis, and expression of Bcl-2, Bax and p21 in human breast cell lines. 3-hydroxypregn-4-en-20-one 91-117 BCL2 apoptosis regulator Homo sapiens 170-175 19608275-7 2010 The enhanced cytotoxicity of ATO+bortezomib was associated with augmented STAT3 inhibition and JNK activation, up-regulation of Bim, p21, p27, p53 as well as down-regulation of Bcl-2. Bortezomib 33-43 BCL2 apoptosis regulator Homo sapiens 177-182 19608275-8 2010 Furthermore, the synergistically potentiated apoptosis by p38 MAPK inhibition was associated with the attenuation of ATO+bortezomib-mediated activation of Hsp27 as well as the enhancement of ATO+bortezomib-mediated JNK activation, p53 up-regulation, and Bcl-2 down-regulation. ato+bortezomib 191-205 BCL2 apoptosis regulator Homo sapiens 254-259 19676104-6 2010 Our results demonstrate that BME-induced cell death is (i) triggered in human myeloid leukemia cell that over-express Bcl-2 and Bcl-x(L), and (ii) associated with loss of inner mitochondrial membrane potential (DeltaPsim) and an increase in reactive oxygen species (ROS). betuletol 3-methyl ether 29-32 BCL2 apoptosis regulator Homo sapiens 118-123 19676105-10 2010 We conclude that p53-independent curcumin-induced apoptosis in ovarian carcinoma cells involves p38 MAPK activation, ablation of prosurvival Akt signaling, and reduced expression of the antiapoptotic proteins Bcl-2 and survivin. Curcumin 33-41 BCL2 apoptosis regulator Homo sapiens 209-214 19676105-0 2010 Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 156-161 19676105-8 2010 Bax expression was unchanged but Bcl-2, survivin, phosphorylated Akt (on serine 473), and total Akt were downregulated in curcumin-treated HEY cells. Curcumin 122-130 BCL2 apoptosis regulator Homo sapiens 33-38 20117988-10 2010 In cells treated with a low concentration of L-Arg, the expressions of VEGF and COX-2 were increased as compared with those in the control cells; higher concentrations of L-Arg obviously decreased the expressions of p53 and bcl-2 and increased the expression of bax. Arginine 45-50 BCL2 apoptosis regulator Homo sapiens 224-229 20117988-10 2010 In cells treated with a low concentration of L-Arg, the expressions of VEGF and COX-2 were increased as compared with those in the control cells; higher concentrations of L-Arg obviously decreased the expressions of p53 and bcl-2 and increased the expression of bax. Arginine 171-176 BCL2 apoptosis regulator Homo sapiens 224-229 20117988-13 2010 The mechanism of L-Arg- induced cell apoptosis may be related to the up-regulation of bax protein and the down-regulation of p53 and bcl-2 proteins. Arginine 17-22 BCL2 apoptosis regulator Homo sapiens 133-138 20358477-4 2010 These features were in concert with a time-dependent activation (starting at 15 min and maintained up to 18 h) of the AP-1/JNK pathway, which played an important role in the control of the cell death induced by the flavonoid and contributed to the regulation of survival/proliferation (AKT, ERK) and death (caspase-3, p38, unbalance of Bcl-2 proapoptotic and antiapoptotic proteins) signals. Flavonoids 215-224 BCL2 apoptosis regulator Homo sapiens 336-341 19597709-1 2010 The present study aims to investigate the mechanism of phosphorylation of apoptotic proteins and tests the hypothesis that the hypoxia-induced increased tyrosine phosphorylation of apoptotic proteins Bcl-2 and Bcl-xl is Ca(2+)-influx-dependent. Tyrosine 153-161 BCL2 apoptosis regulator Homo sapiens 200-205 20184042-4 2010 Mechanistic investigation revealed that SFE oil induced CNE cell death via induction of apoptosis by regulating the expression of the Bcl-2 family of proteins, resulting in the dysfunction of mitochondria, leading to the release of cytochrome c into the cytosol, which then activated caspase-9, and subsequently cleaved caspases-3 and -7. sfe oil 40-47 BCL2 apoptosis regulator Homo sapiens 134-139 19597709-9 2010 p-Bcl-2 density was 21.1 +/- 1.1 Nx, 58.9 +/- 9.6 Hx and 29.5 +/- 6.4 Clo + Hx (P < 0.05 vs. Hx). clo 70-73 BCL2 apoptosis regulator Homo sapiens 2-7 19597709-13 2010 Results showed that clonidine administration prior to hypoxia prevents the hypoxia-induced increased nuclear Ca(2+)-influx and increased phosphorylation of Bcl-2 and Bcl-xl while phosphorylation of Bad and Bax was not altered. Clonidine 20-29 BCL2 apoptosis regulator Homo sapiens 156-161 20661831-5 2010 Early stage of curcumin/carnosic acid-induced apoptosis was associated with cleavage (activation) of caspase-8, caspase-9, and caspase-3 and the proapoptotic protein Bid, but not with oxidative stress or altered levels of other Bcl-2 family proteins (Bcl-2, Bcl-xl, Mcl-1, Bax, and Bak). Curcumin 15-23 BCL2 apoptosis regulator Homo sapiens 228-233 20661831-5 2010 Early stage of curcumin/carnosic acid-induced apoptosis was associated with cleavage (activation) of caspase-8, caspase-9, and caspase-3 and the proapoptotic protein Bid, but not with oxidative stress or altered levels of other Bcl-2 family proteins (Bcl-2, Bcl-xl, Mcl-1, Bax, and Bak). Curcumin 15-23 BCL2 apoptosis regulator Homo sapiens 251-256 20661831-5 2010 Early stage of curcumin/carnosic acid-induced apoptosis was associated with cleavage (activation) of caspase-8, caspase-9, and caspase-3 and the proapoptotic protein Bid, but not with oxidative stress or altered levels of other Bcl-2 family proteins (Bcl-2, Bcl-xl, Mcl-1, Bax, and Bak). salvin 24-37 BCL2 apoptosis regulator Homo sapiens 228-233 20661831-5 2010 Early stage of curcumin/carnosic acid-induced apoptosis was associated with cleavage (activation) of caspase-8, caspase-9, and caspase-3 and the proapoptotic protein Bid, but not with oxidative stress or altered levels of other Bcl-2 family proteins (Bcl-2, Bcl-xl, Mcl-1, Bax, and Bak). salvin 24-37 BCL2 apoptosis regulator Homo sapiens 251-256 20432175-6 2010 SDG had a main effect in the reduction of PS2, BCL2, and IGF-1R mRNA expression, whereas FO had a main effect only in PAKT reduction. secoisolariciresinol diglucoside 0-3 BCL2 apoptosis regulator Homo sapiens 47-51 20432175-7 2010 SDG alone also lowered the ERalpha, ERbeta, EGFR, BCL2 mRNA, and PMAPK protein, indicating that its effect involves the modulation of the ER- and growth factor receptor-mediated signaling pathways. secoisolariciresinol diglucoside 0-3 BCL2 apoptosis regulator Homo sapiens 50-54 19818735-2 2009 The aim of this study was to investigate whether the inhibition of Bcl-2 by lentivirus-mediated RNA interference would enhance doxorubicin cytotoxicity in the drug-resistant human osteosarcoma MG63 cells. Doxorubicin 127-138 BCL2 apoptosis regulator Homo sapiens 67-72 20924970-5 2010 Treatment with allicin resulted in HCT-116 apoptotic cell death as demonstrated by enhanced hypodiploid DNA content, decreased levels of B-cell non-Hodgkin lymphoma-2 (Bcl-2), increased levels of bax and increased capability of releasing cytochrome c from mitochondria to the cytosol. allicin 15-22 BCL2 apoptosis regulator Homo sapiens 137-166 20924970-5 2010 Treatment with allicin resulted in HCT-116 apoptotic cell death as demonstrated by enhanced hypodiploid DNA content, decreased levels of B-cell non-Hodgkin lymphoma-2 (Bcl-2), increased levels of bax and increased capability of releasing cytochrome c from mitochondria to the cytosol. allicin 15-22 BCL2 apoptosis regulator Homo sapiens 168-173 20377131-4 2010 Flow cytometry analyses demonstrated an increase in apoptosis following combined treatment with As2O3 and Ad-PML for 24 h, which was correlated with increased p53 and decreased Bcl-2 expression. Arsenic Trioxide 96-101 BCL2 apoptosis regulator Homo sapiens 177-182 20369465-5 2010 RESULTS: The rSIFN-co demonstrated a efficiency of inhibiting the cell proliferation, induce apoptosis of both MCF-7 cells and MCF-7/ADR cells, which was stronger than that of infergen in the same concentration; rSIFN-co combined with epirubicin has a synergistic action in inhibiting cell proliferation, inducing apoptosis of both type of breast cancer cells; rSIFN-co can also decrease the expression level of P53 and CerbB-2, increase the expression of Bcl-2 in both cell lines. rsifn 13-18 BCL2 apoptosis regulator Homo sapiens 456-461 19539424-3 2009 Apoptosis microarray assay results showed BCL-2 family genes might especially play an important role in waltonitone-induced apoptosis. 28-hydroxy-3-oxo-12-ursene 104-115 BCL2 apoptosis regulator Homo sapiens 42-47 19835841-5 2009 Moreover, salinomycin is able to induce apoptosis in cancer cells that exhibit resistance to apoptosis and anticancer agents by overexpression of Bcl-2, P-glycoprotein or 26S proteasomes with enhanced proteolytic activity. salinomycin 10-21 BCL2 apoptosis regulator Homo sapiens 146-151 19818735-6 2009 Flow cytometry and MTT assays revealed that Bcl-2 knock-down increased cellular apoptosis and the MG63 cells became sensitive to doxorubicin. monooxyethylene trimethylolpropane tristearate 19-22 BCL2 apoptosis regulator Homo sapiens 44-49 19850739-12 2009 Targeting of Bcl-2 family members by drugs promoting Bim (re)-expression, or by BH3-mimetics such as obatoclax, may be an attractive therapy concept in SM. BH 3 80-83 BCL2 apoptosis regulator Homo sapiens 13-18 19818735-6 2009 Flow cytometry and MTT assays revealed that Bcl-2 knock-down increased cellular apoptosis and the MG63 cells became sensitive to doxorubicin. Doxorubicin 129-140 BCL2 apoptosis regulator Homo sapiens 44-49 19818735-8 2009 Therefore, lentivirus-mediated Bcl-2 knock-down may sensitize these human osteosarcoma cells to doxorubicin and provide a potential therapeutic strategy for osteosarcoma. Doxorubicin 96-107 BCL2 apoptosis regulator Homo sapiens 31-36 19747165-9 2009 Thus mesothelin can inhibit paclitaxel-induced cell death mainly by involving PI3K signalling in the regulation of Bcl-2 family expression. Paclitaxel 28-38 BCL2 apoptosis regulator Homo sapiens 115-120 19858392-0 2009 Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma. ibritumomab tiuxetan 64-95 BCL2 apoptosis regulator Homo sapiens 30-35 19908860-4 2009 Our laboratory has previously demonstrated that the polypurine-rich strand of the bcl-2 promoter can form a mixture of three different G-quadruplex structures. polypurine 52-62 BCL2 apoptosis regulator Homo sapiens 82-87 19885558-0 2009 A novel resveratrol analogue HS-1793 treatment overcomes the resistance conferred by Bcl-2 and is associated with the formation of mature PML nuclear bodies in renal clear cell carcinoma Caki-1 cells. Resveratrol 8-19 BCL2 apoptosis regulator Homo sapiens 85-90 19597759-7 2009 The results also showed that protein expression of Bax, caspase-9, and caspase-3 significantly increased, protein expression of Bcl-2 and Fas-L significantly decreased, and Fas protein expression was unchanged after SDT treatment. 3,4-Dihydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione 216-219 BCL2 apoptosis regulator Homo sapiens 128-133 19417623-8 2009 Thus, FOXP1 and/or BCL2 immunostaining of bone marrow trephine sections could serve as an immunohistochemical marker in B-CLL. trephine 54-62 BCL2 apoptosis regulator Homo sapiens 19-23 19002577-0 2009 Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERalpha. Tamoxifen 0-9 BCL2 apoptosis regulator Homo sapiens 35-40 19002577-4 2009 Antiestrogen (Tamoxifen and ICI 182,780) treatment increased Bcl-2 levels in both MCF-7 and -7B cells and led to the formation of acinar structures. Tamoxifen 14-23 BCL2 apoptosis regulator Homo sapiens 61-66 19466539-5 2009 We also demonstrated that resveratrol or quercetin modulates mRNA levels and protein expression of Bax, a pro-apoptotic gene, and Bcl-2, an anti-apoptotic gene. Resveratrol 26-37 BCL2 apoptosis regulator Homo sapiens 130-135 19466539-5 2009 We also demonstrated that resveratrol or quercetin modulates mRNA levels and protein expression of Bax, a pro-apoptotic gene, and Bcl-2, an anti-apoptotic gene. Quercetin 41-50 BCL2 apoptosis regulator Homo sapiens 130-135 20055834-0 2009 Diallyl trisulphide-induced apoptosis in human melanoma cells involves downregulation of Bcl-2 and Bcl-xL expression and activation of caspases. diallyl trisulfide 0-19 BCL2 apoptosis regulator Homo sapiens 89-94 19404643-2 2009 METHODS: Jurkat human acute lymphocytic leukemia cells and HeLa cells transfected with a tet-regulated Bcl-2 expression system were treated with ABT-737 or its less active stereoisomer. tetramethylenedisulfotetramine 89-92 BCL2 apoptosis regulator Homo sapiens 103-108 19404643-7 2009 CONCLUSIONS: These results demonstrate that inhibition of Bcl-2 causes a loss of GSH, an increase in ROS, caspase activation and subsequent apoptosis. Glutathione 81-84 BCL2 apoptosis regulator Homo sapiens 58-63 19404643-7 2009 CONCLUSIONS: These results demonstrate that inhibition of Bcl-2 causes a loss of GSH, an increase in ROS, caspase activation and subsequent apoptosis. Reactive Oxygen Species 101-104 BCL2 apoptosis regulator Homo sapiens 58-63 19404643-8 2009 Clinically, redox alterations as a consequence of Bcl-2 inhibition by ABT-737 should be considered in devising combination therapies with this novel agent or its derivatives. ABT-737 70-77 BCL2 apoptosis regulator Homo sapiens 50-55 19732843-7 2009 Moreover, genistein enhances the phosphorylation and activation of p53, while decreases the ratio of Bcl-2/Bax and Bcl-xL/Bax and the level of phosphorylated Akt, which result in cells undergoing apoptosis. Genistein 10-19 BCL2 apoptosis regulator Homo sapiens 101-106 19797069-8 2009 Furthermore, overexpression of the antiapoptotic proteins Bcl-2 and Bcl-X(L) significantly inhibited TcdA-induced cell death, as well as TcdA-induced MOMP. tcda 101-105 BCL2 apoptosis regulator Homo sapiens 58-63 19797069-8 2009 Furthermore, overexpression of the antiapoptotic proteins Bcl-2 and Bcl-X(L) significantly inhibited TcdA-induced cell death, as well as TcdA-induced MOMP. tcda 137-141 BCL2 apoptosis regulator Homo sapiens 58-63 19797069-10 2009 Overexpression of the antiapoptotic proteins Bcl-2 and Bcl-X(L) in T84 cells also inhibited TcdA-induced cell death. tcda 92-96 BCL2 apoptosis regulator Homo sapiens 45-50 19885558-3 2009 Previously we designed and synthesized the resveratrol analogue HS-1793 displaying stronger antitumor efficacy than resveratrol and further demonstrated the HS-1793 resistance conferred by Bcl-2 in human leukemic U937 cells. Resveratrol 43-54 BCL2 apoptosis regulator Homo sapiens 189-194 19885558-8 2009 Our findings show that the resveratrol analogue HS-1793 might provide a novel promising strategy for overcoming the resistance conferred by Bcl-2 via PML protein and the formation of mature PML-NBs. Resveratrol 27-38 BCL2 apoptosis regulator Homo sapiens 140-145 19746447-0 2009 Runx2-mediated bcl-2 gene expression contributes to nitric oxide protection against hydrogen peroxide-induced osteoblast apoptosis. Nitric Oxide 52-64 BCL2 apoptosis regulator Homo sapiens 15-20 19582475-0 2009 Gambogic acid reduced bcl-2 expression via p53 in human breast MCF-7 cancer cells. gambogic acid 0-13 BCL2 apoptosis regulator Homo sapiens 22-27 19582475-1 2009 PURPOSE: In this study, we investigated the correlation between p53 and bcl-2 in gambogic acid (GA)-induced apoptosis. gambogic acid 81-94 BCL2 apoptosis regulator Homo sapiens 72-77 19582475-1 2009 PURPOSE: In this study, we investigated the correlation between p53 and bcl-2 in gambogic acid (GA)-induced apoptosis. gambogic acid 96-98 BCL2 apoptosis regulator Homo sapiens 72-77 19582475-12 2009 CONCLUSIONS: Gambogic acid induced human breast cancer cells MCF-7 apoptosis by reducing bcl-2 expression via p53. gambogic acid 13-26 BCL2 apoptosis regulator Homo sapiens 89-94 19746447-0 2009 Runx2-mediated bcl-2 gene expression contributes to nitric oxide protection against hydrogen peroxide-induced osteoblast apoptosis. Hydrogen Peroxide 84-101 BCL2 apoptosis regulator Homo sapiens 15-20 19746447-5 2009 Treatment of human MG63 cells with hydrogen peroxide inhibited Bcl-2 mRNA and protein production, but pretreatment with 0.3 mM SNP significantly ameliorated such inhibition. Hydrogen Peroxide 35-52 BCL2 apoptosis regulator Homo sapiens 63-68 19780069-0 2009 Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Silicon Dioxide 57-63 BCL2 apoptosis regulator Homo sapiens 31-36 19994847-7 2009 Additionally, the Bcl-2 antiapoptotic protein is predicted to bind pargyline, and the antiapoptic p53 interacting protein MDM2 is suggested to bind clofazimine. Pargyline 67-76 BCL2 apoptosis regulator Homo sapiens 18-23 19994847-7 2009 Additionally, the Bcl-2 antiapoptotic protein is predicted to bind pargyline, and the antiapoptic p53 interacting protein MDM2 is suggested to bind clofazimine. Clofazimine 148-159 BCL2 apoptosis regulator Homo sapiens 18-23 19741006-7 2009 Furthermore, KU135 but not 17-AAG was found to be a potent inducer of mitochondria-mediated apoptosis as evidenced, in part, by the fact that cell death was inhibited to a similar extent by Bcl-2/Bcl-x(L) overexpression or the depletion of apoptotic protease-activating factor-1 (Apaf-1). KU135 13-18 BCL2 apoptosis regulator Homo sapiens 190-195 19820116-3 2009 Using circular dichroism (CD), thermal denaturation and dimethyl sulfate (DMS) footprinting, we found that a single-stranded oligonucleotide with the sequence of the BCL2 G-rich region forms a potassium-stabilized G-quadruplex. dimethyl sulfate 56-72 BCL2 apoptosis regulator Homo sapiens 166-170 19820116-3 2009 Using circular dichroism (CD), thermal denaturation and dimethyl sulfate (DMS) footprinting, we found that a single-stranded oligonucleotide with the sequence of the BCL2 G-rich region forms a potassium-stabilized G-quadruplex. dimethyl sulfate 74-77 BCL2 apoptosis regulator Homo sapiens 166-170 19820116-3 2009 Using circular dichroism (CD), thermal denaturation and dimethyl sulfate (DMS) footprinting, we found that a single-stranded oligonucleotide with the sequence of the BCL2 G-rich region forms a potassium-stabilized G-quadruplex. Oligonucleotides 125-140 BCL2 apoptosis regulator Homo sapiens 166-170 19820116-3 2009 Using circular dichroism (CD), thermal denaturation and dimethyl sulfate (DMS) footprinting, we found that a single-stranded oligonucleotide with the sequence of the BCL2 G-rich region forms a potassium-stabilized G-quadruplex. Potassium 193-202 BCL2 apoptosis regulator Homo sapiens 166-170 20037823-8 2009 Moreover, the apoptosis was found in the CAOV3 cells exposed to UA; the Bax expression was increased and the Bcl-2 expression decreased. ursolic acid 64-66 BCL2 apoptosis regulator Homo sapiens 109-114 19598250-10 2009 Collectively, these findings demonstrate that TK attenuates glutamate-induced apoptosis through an intracellular signaling pathway including activation of B2R, ERK1/2, and NF-kappaB and up-regulation of BDNF and Bcl-2 expression. Glutamic Acid 60-69 BCL2 apoptosis regulator Homo sapiens 212-217 20030922-1 2009 This study was purposed to investigate the effects of compound Zhe-Bei granule (CZBG) combined with doxorubicin (Dox) on the expression of BCL-2, BAX and cell apoptosis rate in K562/A02 multidrug resistant tumor xenografts. czbg 80-84 BCL2 apoptosis regulator Homo sapiens 139-144 20030922-1 2009 This study was purposed to investigate the effects of compound Zhe-Bei granule (CZBG) combined with doxorubicin (Dox) on the expression of BCL-2, BAX and cell apoptosis rate in K562/A02 multidrug resistant tumor xenografts. Doxorubicin 100-111 BCL2 apoptosis regulator Homo sapiens 139-144 20030922-1 2009 This study was purposed to investigate the effects of compound Zhe-Bei granule (CZBG) combined with doxorubicin (Dox) on the expression of BCL-2, BAX and cell apoptosis rate in K562/A02 multidrug resistant tumor xenografts. Doxorubicin 113-116 BCL2 apoptosis regulator Homo sapiens 139-144 20030922-6 2009 The results indicated that as compared with normal saline control group and Dox group, the high, middle, low dose of CZBG combined with Dox could increase the cell apoptosis rate of tumor xenografts with statistical significance (p < 0.05); and could decrease the IOD value of BCL-2 and increase the IOD value of BAX in xenografts with statistical significance (p < 0.05). czbg 117-121 BCL2 apoptosis regulator Homo sapiens 280-285 20193328-10 2009 The changes of expression of bcl-2 and bax and decreasing of the bcl-2/bax ratio may be an important mechanism of action of the intravesical instillation of THP for preventing recurrence of non-muscle invasive bladder cancer. pirarubicin 157-160 BCL2 apoptosis regulator Homo sapiens 29-34 20030922-6 2009 The results indicated that as compared with normal saline control group and Dox group, the high, middle, low dose of CZBG combined with Dox could increase the cell apoptosis rate of tumor xenografts with statistical significance (p < 0.05); and could decrease the IOD value of BCL-2 and increase the IOD value of BAX in xenografts with statistical significance (p < 0.05). Doxorubicin 136-139 BCL2 apoptosis regulator Homo sapiens 280-285 20193328-10 2009 The changes of expression of bcl-2 and bax and decreasing of the bcl-2/bax ratio may be an important mechanism of action of the intravesical instillation of THP for preventing recurrence of non-muscle invasive bladder cancer. pirarubicin 157-160 BCL2 apoptosis regulator Homo sapiens 65-70 20030922-7 2009 It is concluded that CZBG combined with Dox can enhance the apoptosis rate in K562/A02 cells, down-regulate the expression of BCL-2 and up-regulate the expression of BAX, thereby, can reverse the multidrug resistance of K562/A02 cells by decreasing the ratio of BCL-2/BAX. czbg 21-25 BCL2 apoptosis regulator Homo sapiens 126-131 20030922-7 2009 It is concluded that CZBG combined with Dox can enhance the apoptosis rate in K562/A02 cells, down-regulate the expression of BCL-2 and up-regulate the expression of BAX, thereby, can reverse the multidrug resistance of K562/A02 cells by decreasing the ratio of BCL-2/BAX. czbg 21-25 BCL2 apoptosis regulator Homo sapiens 262-267 20353020-10 2009 CONCLUSION: The growth inhibition of Protobioside on HepG2 cells is highly related to cell cycle arrest at G2/M phase which was well correlated with the down-regulation of expression of Cyclin B1, and the induction of apoptosis via up-regulating of Bax and down-regulating Bcl-2 expression. protobioside 37-49 BCL2 apoptosis regulator Homo sapiens 273-278 20030922-7 2009 It is concluded that CZBG combined with Dox can enhance the apoptosis rate in K562/A02 cells, down-regulate the expression of BCL-2 and up-regulate the expression of BAX, thereby, can reverse the multidrug resistance of K562/A02 cells by decreasing the ratio of BCL-2/BAX. Doxorubicin 40-43 BCL2 apoptosis regulator Homo sapiens 126-131 20030922-7 2009 It is concluded that CZBG combined with Dox can enhance the apoptosis rate in K562/A02 cells, down-regulate the expression of BCL-2 and up-regulate the expression of BAX, thereby, can reverse the multidrug resistance of K562/A02 cells by decreasing the ratio of BCL-2/BAX. Doxorubicin 40-43 BCL2 apoptosis regulator Homo sapiens 262-267 20723360-0 2009 [Trichostatin A Induced Bcl-2 Protein Level Decrease Mediated A549/CDDP Cells Apoptosis by Mitochondria Pathway.]. trichostatin A 1-15 BCL2 apoptosis regulator Homo sapiens 24-29 19523755-6 2009 However, whereas Bcl-2 overexpression was very potent in inhibiting apoptosis triggered by Dox, this anti-apoptotic protein was largely inefficient in preventing Dox-CPPs-induced apoptosis. Doxorubicin 91-94 BCL2 apoptosis regulator Homo sapiens 17-22 20723360-16 2009 Over expression of Bcl-2 can inhibit TSA-induced A549/CDDP cell apoptosis, while the decrease of Bcl-2 enhanced the sensitivity of A549/CDDP cell to TSA. trichostatin A 37-40 BCL2 apoptosis regulator Homo sapiens 19-24 20723360-16 2009 Over expression of Bcl-2 can inhibit TSA-induced A549/CDDP cell apoptosis, while the decrease of Bcl-2 enhanced the sensitivity of A549/CDDP cell to TSA. trichostatin A 149-152 BCL2 apoptosis regulator Homo sapiens 97-102 19580395-2 2009 The BCL-2 family of proteins regulate cell death in response to anoxia (0-0.5% O2). Oxygen 79-81 BCL2 apoptosis regulator Homo sapiens 4-9 19815708-6 2009 Here, we show that sirolimus and paclitaxel differentially induce self-digesting autophagy in vascular endothelial cells with changes in expression of LC3B, p53, and Bcl-2, considerably suppressing re-endothelialization and revascularization. Sirolimus 19-28 BCL2 apoptosis regulator Homo sapiens 166-171 19815708-6 2009 Here, we show that sirolimus and paclitaxel differentially induce self-digesting autophagy in vascular endothelial cells with changes in expression of LC3B, p53, and Bcl-2, considerably suppressing re-endothelialization and revascularization. Paclitaxel 33-43 BCL2 apoptosis regulator Homo sapiens 166-171 19815709-5 2009 Significantly increased phosphorylated CREB1 and mRNA levels of BCL2, c-FOS, MMP9, and MMP13 were also observed in MM cells in vitro, which were further augmented after addition of Doxorubicin (Dox). Doxorubicin 181-192 BCL2 apoptosis regulator Homo sapiens 64-68 19815709-5 2009 Significantly increased phosphorylated CREB1 and mRNA levels of BCL2, c-FOS, MMP9, and MMP13 were also observed in MM cells in vitro, which were further augmented after addition of Doxorubicin (Dox). Doxorubicin 181-184 BCL2 apoptosis regulator Homo sapiens 64-68 19912650-7 2009 Enforced expression of anti-apoptotic Bcl-2 protein provided protection against camptothecin-induced cell death and partly against khat toxicity. Camptothecin 80-92 BCL2 apoptosis regulator Homo sapiens 38-43 19775596-13 2009 Ethanol also shifted the Bcl-2/Bax balance towards apoptosis. Ethanol 0-7 BCL2 apoptosis regulator Homo sapiens 25-30 19605509-2 2009 We investigated effects of Bcl-2 down-regulation by the Bcl-2 antisense oligodeoxynucleotide oblimersen in breast tumor biopsies. Oligodeoxyribonucleotides 72-92 BCL2 apoptosis regulator Homo sapiens 27-32 19580395-4 2009 In this review, we discuss how mitochondria, BCL-2 proteins, and HIFs are crucial for cellular responses to low oxygen. Oxygen 112-118 BCL2 apoptosis regulator Homo sapiens 45-50 20853778-9 2009 Recent studies have demonstrated that asbestos acts on peripheral T cells as superantigen and that in malignant mesothelioma patients there is an overexpression of the Bcl-2 gene on peripheral CD4+ T cells. Asbestos 38-46 BCL2 apoptosis regulator Homo sapiens 168-173 19768546-4 2009 We show that kahweol induces apoptosis in association with the activation of caspase 3 and cytochrome c release from the mitochondria to the cytosol, as well as down-regulation of anti-apoptotic proteins (Bcl-2, Bcl-xL, Mcl-1 and XIAP). kahweol 13-20 BCL2 apoptosis regulator Homo sapiens 205-210 19768546-6 2009 Ectopic expression of Bcl-2 or constitutive active Akt (myr-Akt) in U937 cells attenuates kahweol-induced apoptosis. kahweol 90-97 BCL2 apoptosis regulator Homo sapiens 22-27 19473757-8 2009 Moreover, our results showed that overexpression of Bcl-2 inhibited oroxylin A-induced apoptosis. 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one 68-78 BCL2 apoptosis regulator Homo sapiens 52-57 19555669-0 2009 Transcriptional down-regulation of Bcl-2 by vinorelbine: identification of a novel binding site of p53 on Bcl-2 promoter. Vinorelbine 44-55 BCL2 apoptosis regulator Homo sapiens 35-40 19555669-0 2009 Transcriptional down-regulation of Bcl-2 by vinorelbine: identification of a novel binding site of p53 on Bcl-2 promoter. Vinorelbine 44-55 BCL2 apoptosis regulator Homo sapiens 106-111 19555669-3 2009 Treatment with microtubule-targeting agents, including taxanes and Vinca alkaloids, generally leads to a decrease in Bcl-2 intracellular amounts. Taxoids 55-62 BCL2 apoptosis regulator Homo sapiens 117-122 19555669-3 2009 Treatment with microtubule-targeting agents, including taxanes and Vinca alkaloids, generally leads to a decrease in Bcl-2 intracellular amounts. Vinca Alkaloids 67-82 BCL2 apoptosis regulator Homo sapiens 117-122 19555669-5 2009 We report here that p53 contributes to vinorelbine-induced Bcl-2 down-regulation. Vinorelbine 39-50 BCL2 apoptosis regulator Homo sapiens 59-64 19555669-6 2009 Indeed, the decrease in Bcl-2 protein levels observed during vinorelbine-induced apoptosis was correlated to the decrease in mRNA levels, as a result of the inhibition of Bcl-2 transcription and promoter activity. Vinorelbine 61-72 BCL2 apoptosis regulator Homo sapiens 24-29 19555669-6 2009 Indeed, the decrease in Bcl-2 protein levels observed during vinorelbine-induced apoptosis was correlated to the decrease in mRNA levels, as a result of the inhibition of Bcl-2 transcription and promoter activity. Vinorelbine 61-72 BCL2 apoptosis regulator Homo sapiens 171-176 19823037-7 2009 The results from semi-quantitative and real-time RT-PCR indicated that DATS-enhanced the expression levels of FAS and cyclin D1, but in contrast, downregulated the expression levels of Akt and Bcl-2. diallyl trisulfide 71-75 BCL2 apoptosis regulator Homo sapiens 193-198 19673886-6 2009 Induction of apoptosis by CPT-11 with and without celecoxib was associated with the up-regulation of Bax expression and the down-regulation of Bcl-2 expression. Irinotecan 26-32 BCL2 apoptosis regulator Homo sapiens 143-148 19673886-6 2009 Induction of apoptosis by CPT-11 with and without celecoxib was associated with the up-regulation of Bax expression and the down-regulation of Bcl-2 expression. Celecoxib 50-59 BCL2 apoptosis regulator Homo sapiens 143-148 19823038-3 2009 The BCL-2 family antagonist Obatoclax (GX15-070), that inhibits BCL-2/BCL-X(L)/MCL-1 function, enhanced Lapatinib toxicity in parental HCT116 and Lapatinib adapted HCT116 cells. Lapatinib 104-113 BCL2 apoptosis regulator Homo sapiens 4-9 19823038-3 2009 The BCL-2 family antagonist Obatoclax (GX15-070), that inhibits BCL-2/BCL-X(L)/MCL-1 function, enhanced Lapatinib toxicity in parental HCT116 and Lapatinib adapted HCT116 cells. Lapatinib 146-155 BCL2 apoptosis regulator Homo sapiens 4-9 19394692-3 2009 ZD6474 induces growth arrest and apoptosis of imatinib-resistant and parental K562 cells, as well as inhibition of Src activity and its downstream effectors, the anti-apoptotic Bcl-2 family. vandetanib 0-6 BCL2 apoptosis regulator Homo sapiens 177-182 19843160-7 2009 In addition, extracellular-regulated protein kinase 5, nuclear factor-kappaB and Bcl-2 protein expression was down-regulated by miR-143, and further reduced by exposure to 5-fluorouracil. Fluorouracil 172-186 BCL2 apoptosis regulator Homo sapiens 81-86 20183254-6 2009 Curcumin treatment also induced Bid cleavage and downregulated the expression of Bcl-2 protein. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 81-86 19763773-5 2009 Rasagiline and (-)deprenyl, type B MAO inhibitors of propagylamine-derivatives, bind to MAO-A to protect neuronal cells against apoptosis through induction of pro-survival Bcl-2 and neurotrophic factors. rasagiline 0-10 BCL2 apoptosis regulator Homo sapiens 172-177 19763773-5 2009 Rasagiline and (-)deprenyl, type B MAO inhibitors of propagylamine-derivatives, bind to MAO-A to protect neuronal cells against apoptosis through induction of pro-survival Bcl-2 and neurotrophic factors. Selegiline 18-26 BCL2 apoptosis regulator Homo sapiens 172-177 19763773-5 2009 Rasagiline and (-)deprenyl, type B MAO inhibitors of propagylamine-derivatives, bind to MAO-A to protect neuronal cells against apoptosis through induction of pro-survival Bcl-2 and neurotrophic factors. propagylamine 53-66 BCL2 apoptosis regulator Homo sapiens 172-177 19641525-2 2009 ABT-737 is a BH3 mimetic compound that selectively targets BCL2 and BCLX(L). ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 59-63 19233505-7 2009 Moreover, the higher cleavage of poly (ADP)-ribose polymerase (PARP), the increased of Bax concurrent with the decreased of Bcl-2 indicated that pyrogallol treatment resulted in apoptosis of lung cancer cells. Pyrogallol 145-155 BCL2 apoptosis regulator Homo sapiens 124-129 19641525-2 2009 ABT-737 is a BH3 mimetic compound that selectively targets BCL2 and BCLX(L). BH 3 13-16 BCL2 apoptosis regulator Homo sapiens 59-63 19285749-8 2009 Treatment with cisplatin revealed that the expression of anti-apoptotic protein, bcl-2, was down-regulated in SBC-3/NEO cells, while that of SBC-3/OPN cells was not altered. Cisplatin 15-24 BCL2 apoptosis regulator Homo sapiens 81-86 19285749-11 2009 Our results suggest that OPN enhances chemo-resistance of cisplatin in SBC-3 cells by suppressing bcl-2 protein down-regulation, thereby blocking the caspase-9- and caspase-3-dependent cell apoptosis. Cisplatin 58-67 BCL2 apoptosis regulator Homo sapiens 98-103 19641525-4 2009 In vitro sensitivity to ABT-737 could not be simply predicted by the patients" clinical features, including response to prior therapy or known prognostic markers (CD38 expression, 17p deletion), or the relative expression of BCL2 family proteins (BCL2, MCL1, BAX, BIM). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 24-27 BCL2 apoptosis regulator Homo sapiens 247-251 20079076-0 2009 [Adenovirus-mediated delivery of bcl-2 gene attenuates cisplatin-induced degeneration of cultured spiral ganglion cells.]. Cisplatin 55-64 BCL2 apoptosis regulator Homo sapiens 33-38 19713356-6 2009 Overexpression of bcl-2 or treatment with the pan-caspase inhibitor N-benzyloxycarbonyl-Val-Ala-dl-Asp-fluoromethylketone abolished caspase-2, -8, -9, and -3 activation as well as Bid cleavage in response to oxaliplatin, suggesting that Bid cleavage occurred downstream of mitochondrial permeabilization and was predominantly mediated by caspases. Oxaliplatin 208-219 BCL2 apoptosis regulator Homo sapiens 18-23 19777212-7 2009 Camptothecin and etoposide caused an increase of protein expression of several cell-cycle regulators and induced the cleavage of Bcl-2 family of proteins. Camptothecin 0-12 BCL2 apoptosis regulator Homo sapiens 129-134 19777212-7 2009 Camptothecin and etoposide caused an increase of protein expression of several cell-cycle regulators and induced the cleavage of Bcl-2 family of proteins. Etoposide 17-26 BCL2 apoptosis regulator Homo sapiens 129-134 19723537-4 2009 Ranitidine also prevented the down-regulation of B-cell CLL/lymphoma 2 (BCL2) and the up-regulation of BCL2-associated X protein (BAX) by rotenone. Ranitidine 0-10 BCL2 apoptosis regulator Homo sapiens 49-70 19723537-4 2009 Ranitidine also prevented the down-regulation of B-cell CLL/lymphoma 2 (BCL2) and the up-regulation of BCL2-associated X protein (BAX) by rotenone. Ranitidine 0-10 BCL2 apoptosis regulator Homo sapiens 72-76 19878585-11 2009 In the case of sorafenib treatment, cells harbouring BRAF(V600E) mutation showed increase levels of apoptosis due to a balance of the anti-apoptotic proteins Mcl-1 and Bcl-2. Sorafenib 15-24 BCL2 apoptosis regulator Homo sapiens 168-173 19878585-13 2009 We have shown that in thyroid cancer cells sorafenib induces apoptosis by affecting Mcl-1 and Bcl-2 in BRAF(V600E) mutated cells which was independent of BRAF. Sorafenib 43-52 BCL2 apoptosis regulator Homo sapiens 94-99 20079076-1 2009 OBJECTIVE: To assess the protection against cisplatin-induced ototoxicity by adenovirus-mediated overexpression of the bcl-2 gene in cultured spiral ganglion cells (SGC). Cisplatin 44-53 BCL2 apoptosis regulator Homo sapiens 119-124 19921575-13 2009 Apoptosis of MKN45 induced by oridonin may be associated with the up-regulated expression of Bax and the change of Bcl-2/Bax ratio, thus to activate the caspase pathway. oridonin 30-38 BCL2 apoptosis regulator Homo sapiens 115-120 20079076-10 2009 Expression of bcl-2 in the SGC provided a significant level of protection against cisplatin-induced SGC degeneration. Cisplatin 82-91 BCL2 apoptosis regulator Homo sapiens 14-19 20079076-12 2009 Adenovirus-mediated delivery of the bcl-2 gene attenuates cisplatin-induced SGC degeneration. Cisplatin 58-67 BCL2 apoptosis regulator Homo sapiens 36-41 19699263-7 2009 PQQ strikingly decreased Bax/Bcl-2 ratio, and suppressed the cleavage of caspase-3. PQQ Cofactor 0-3 BCL2 apoptosis regulator Homo sapiens 29-34 19481065-5 2009 Xyloketal B concentration-dependently attenuated oxLDL-induced ROS generation, peroxynitrite formation and decrease of Bcl-2 expression. xyloketal B 0-11 BCL2 apoptosis regulator Homo sapiens 119-124 19683563-7 2009 Consistently, miR-34a knockdown through antisense LNA oligonucleotides increased the level of bcl2 protein in SH-SY5Y cells, which was accompanied by a decrease of active caspase-3. Oligonucleotides 54-70 BCL2 apoptosis regulator Homo sapiens 94-98 19852810-0 2009 AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis. gossypol acetic acid 0-6 BCL2 apoptosis regulator Homo sapiens 53-58 19852810-1 2009 BACKGROUND: Gossypol, a naturally occurring polyphenolic compound has been identified as a small molecule inhibitor of anti-apoptotic Bcl-2 family proteins. Gossypol 12-20 BCL2 apoptosis regulator Homo sapiens 134-139 19726685-2 2009 Apoptosis is triggered when a peptide containing a BH3 motif or a small molecule BH3 peptidomimetic, such as ABT 737, binds to the relevant Bcl-2 family members. BH 3 51-54 BCL2 apoptosis regulator Homo sapiens 140-145 19726685-2 2009 Apoptosis is triggered when a peptide containing a BH3 motif or a small molecule BH3 peptidomimetic, such as ABT 737, binds to the relevant Bcl-2 family members. BH 3 81-84 BCL2 apoptosis regulator Homo sapiens 140-145 19726685-2 2009 Apoptosis is triggered when a peptide containing a BH3 motif or a small molecule BH3 peptidomimetic, such as ABT 737, binds to the relevant Bcl-2 family members. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 109-112 BCL2 apoptosis regulator Homo sapiens 140-145 19726685-3 2009 ABT-737 is an antagonist of Bcl-2, Bcl-x(L), and Bcl-w but not of Mcl-1. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 28-33 19726685-8 2009 Our structure of this new organic ligand provided insights into the structural transitions that occur within the BH3 binding groove, highlighting significant differences in the structural properties of members of the Bcl-2 pro-survival protein family. BH 3 113-116 BCL2 apoptosis regulator Homo sapiens 217-222 19812686-5 2009 Indeed, tumor-shed PGE2 down-regulates IL2Rgammac expression, reduces phosphorylation as well as activation of Janus kinase 3 (Jak-3)/signal transducer and activator of transcription 5 (Stat-5) and decreases Bcl-2/Bax ratio thereby leading to activation of intrinsic apoptotic pathway. Dinoprostone 19-23 BCL2 apoptosis regulator Homo sapiens 208-213 19398149-0 2009 Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl-2. myricetin 0-9 BCL2 apoptosis regulator Homo sapiens 124-129 19398149-6 2009 Furthermore, Myricetin down regulated the expression of the long and short isoform of c-FLIP and bcl-2 and over-expression of the short isoform of c-FLIP (S) and bcl-2 attenuated apoptosis induced by the combination of Myricetin and TRAIL. myricetin 13-22 BCL2 apoptosis regulator Homo sapiens 97-102 19398149-6 2009 Furthermore, Myricetin down regulated the expression of the long and short isoform of c-FLIP and bcl-2 and over-expression of the short isoform of c-FLIP (S) and bcl-2 attenuated apoptosis induced by the combination of Myricetin and TRAIL. myricetin 13-22 BCL2 apoptosis regulator Homo sapiens 162-167 19398149-6 2009 Furthermore, Myricetin down regulated the expression of the long and short isoform of c-FLIP and bcl-2 and over-expression of the short isoform of c-FLIP (S) and bcl-2 attenuated apoptosis induced by the combination of Myricetin and TRAIL. myricetin 219-228 BCL2 apoptosis regulator Homo sapiens 162-167 19435648-7 2009 On the other hand we observed the inhibition of NF-kappaB nuclear translocation, up-regulation of Bax and down-regulation of Bcl-2, the caspase -3, -9 activity increase in HL60 cells after treated with M(2)-A, which indicated that the mitochondrial pathway was involved in the apoptosis signal pathway. 2-methyladenosine 202-208 BCL2 apoptosis regulator Homo sapiens 125-130 19818125-0 2009 Differential protection by wildtype vs. organelle-specific Bcl-2 suggests a combined requirement of both the ER and mitochondria in ceramide-mediated caspase-independent programmed cell death. Ceramides 132-140 BCL2 apoptosis regulator Homo sapiens 59-64 19807907-4 2009 RESULTS: Here, we demonstrate that minocycline attenuates both in vitro (oxygen glucose deprivation) and in vivo (middle cerebral artery occlusion) experimentally induced ischemic deficits by direct inhibition of apoptotic-like neuronal cell death involving the anti-apoptotic Bcl-2/cytochrome c pathway. Minocycline 35-46 BCL2 apoptosis regulator Homo sapiens 277-282 19818125-7 2009 RESULTS: Only wildtype Bcl-2 had the ability to efficiently protect from ceramide-mediated ciPCD, whereas expression of Bcl-2 solely at mitochondria, the ER, or the cytosol/nucleus did not prevent ceramide-mediated ciPCD. Ceramides 73-81 BCL2 apoptosis regulator Homo sapiens 23-28 19846952-4 2009 Berberine-induced apoptosis was associated with a reduction of the mitochondrial membrane potential associated with changes in the Bax/Bcl-2 ratio, release of cytochrome c from mitochondria and activation of down stream caspase-3. Berberine 0-9 BCL2 apoptosis regulator Homo sapiens 135-140 19669889-5 2009 Moreover, treatment of cells with EGCG resulted in increase of caspase-3 and Bax and decrease of Bcl-2, enhancing I/R-induced apoptosis. epigallocatechin gallate 34-38 BCL2 apoptosis regulator Homo sapiens 97-102 19701793-0 2009 Oligomerization of membrane-bound Bcl-2 is involved in its pore formation induced by tBid. tBID 85-89 BCL2 apoptosis regulator Homo sapiens 34-39 19366737-3 2009 Using pharmacological and immunochemical methods, we tested the role of mitochondrial permeability transition (MPT) and the Bcl-2 proteins in oxygen-dependent radiosensitivity. Oxygen 142-148 BCL2 apoptosis regulator Homo sapiens 124-129 19801848-1 2009 The authors previously reported that costunolide, an active compound isolated from the stem bark of Magnolia sieboldii, induced apoptosis via reactive oxygen species (ROS) and Bcl-2-dependent mitochondrial permeability transition in human leukemia cells. costunolide 37-48 BCL2 apoptosis regulator Homo sapiens 176-181 19801848-8 2009 Pretreatment with SP600125 recovered the costunolide-suppressed Bcl-2 expression. pyrazolanthrone 18-26 BCL2 apoptosis regulator Homo sapiens 64-69 19801848-8 2009 Pretreatment with SP600125 recovered the costunolide-suppressed Bcl-2 expression. costunolide 41-52 BCL2 apoptosis regulator Homo sapiens 64-69 19801848-9 2009 These results indicate that costunolide-induced JNK activation acts downstream of ROS but upstream of Bcl-2, and suggest that ROS-mediated JNK activation plays a key role in costunolide-induced apoptosis. costunolide 28-39 BCL2 apoptosis regulator Homo sapiens 102-107 19366737-7 2009 Nor was evidence found for the modulation of oxygen-dependent radiosensitivity by Bax/Bcl-2 signalling, mitochondrial ATP-dependent potassium (mitoK(ATP)) channels or mitochondrial Ca(2+) uptake. Oxygen 45-51 BCL2 apoptosis regulator Homo sapiens 86-91 19801848-9 2009 These results indicate that costunolide-induced JNK activation acts downstream of ROS but upstream of Bcl-2, and suggest that ROS-mediated JNK activation plays a key role in costunolide-induced apoptosis. Reactive Oxygen Species 126-129 BCL2 apoptosis regulator Homo sapiens 102-107 19616639-5 2009 Both NaHS and SP600125 (specific JNK inhibitor) decreased the number of apoptotic cells, lowered cytochrome C release and enhanced Bcl-2 expression. sodium bisulfide 5-9 BCL2 apoptosis regulator Homo sapiens 131-136 19659469-0 2009 Altered p53 and Bcl-2 expression in keratinocytes of vulvar lichen sclerosus during pimecrolimus treatment. pimecrolimus 84-96 BCL2 apoptosis regulator Homo sapiens 16-21 19616639-5 2009 Both NaHS and SP600125 (specific JNK inhibitor) decreased the number of apoptotic cells, lowered cytochrome C release and enhanced Bcl-2 expression. pyrazolanthrone 14-22 BCL2 apoptosis regulator Homo sapiens 131-136 19672740-3 2009 Investigating the responsible signalling cascades, it was found that NaAsO(2) administration activates mitogen-activated protein kinases (MAPKs) and NF-kappaB in oxidative stress mediated renal dysfunction and induced apoptotic cell death by the reciprocal regulation of Bcl-2/Bad in association with reducing mitochondrial membrane potential and increased cytosolic cytochrome C as well. sodium arsenite 69-77 BCL2 apoptosis regulator Homo sapiens 271-276 19755862-0 2009 Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells. Cisplatin 43-52 BCL2 apoptosis regulator Homo sapiens 25-30 19755862-6 2009 In TOV112D cells, on the other hand, acquired cisplatin resistance is associated with increased levels of Bcl-2 protein. Cisplatin 46-55 BCL2 apoptosis regulator Homo sapiens 106-111 19755862-7 2009 By inhibiting the activity of Bcl-2 protein with its pharmacological inhibitor gossypol or knocking down Bcl-2 expression by siRNA, cisplatin-resistant TOV112D cells became cisplatin-sensitive and subsequently increased cisplatin-induced apoptosis. Gossypol 79-87 BCL2 apoptosis regulator Homo sapiens 30-35 19755862-7 2009 By inhibiting the activity of Bcl-2 protein with its pharmacological inhibitor gossypol or knocking down Bcl-2 expression by siRNA, cisplatin-resistant TOV112D cells became cisplatin-sensitive and subsequently increased cisplatin-induced apoptosis. Cisplatin 132-141 BCL2 apoptosis regulator Homo sapiens 30-35 19755862-7 2009 By inhibiting the activity of Bcl-2 protein with its pharmacological inhibitor gossypol or knocking down Bcl-2 expression by siRNA, cisplatin-resistant TOV112D cells became cisplatin-sensitive and subsequently increased cisplatin-induced apoptosis. Cisplatin 132-141 BCL2 apoptosis regulator Homo sapiens 105-110 19755862-7 2009 By inhibiting the activity of Bcl-2 protein with its pharmacological inhibitor gossypol or knocking down Bcl-2 expression by siRNA, cisplatin-resistant TOV112D cells became cisplatin-sensitive and subsequently increased cisplatin-induced apoptosis. Cisplatin 173-182 BCL2 apoptosis regulator Homo sapiens 30-35 19755862-7 2009 By inhibiting the activity of Bcl-2 protein with its pharmacological inhibitor gossypol or knocking down Bcl-2 expression by siRNA, cisplatin-resistant TOV112D cells became cisplatin-sensitive and subsequently increased cisplatin-induced apoptosis. Cisplatin 173-182 BCL2 apoptosis regulator Homo sapiens 105-110 19755862-7 2009 By inhibiting the activity of Bcl-2 protein with its pharmacological inhibitor gossypol or knocking down Bcl-2 expression by siRNA, cisplatin-resistant TOV112D cells became cisplatin-sensitive and subsequently increased cisplatin-induced apoptosis. Cisplatin 173-182 BCL2 apoptosis regulator Homo sapiens 30-35 19755862-7 2009 By inhibiting the activity of Bcl-2 protein with its pharmacological inhibitor gossypol or knocking down Bcl-2 expression by siRNA, cisplatin-resistant TOV112D cells became cisplatin-sensitive and subsequently increased cisplatin-induced apoptosis. Cisplatin 173-182 BCL2 apoptosis regulator Homo sapiens 105-110 19724907-5 2009 Also, the ratio of Bax/Bcl-2 was increased leading to changes in mitochondria membrane potential (DeltaPsim) and release of cytochrome c, whereas the baicalein-induced apoptosis was partially abrogated by pretreatment with the pan-caspase inhibitor z-VAD-fmk, the accumulation of G2/M cells remained. baicalein 150-159 BCL2 apoptosis regulator Homo sapiens 23-28 19724890-4 2009 In addition, schisandrin C-induced apoptosis was associated with down-regulation of expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL, proteolytic activation of caspase-3 and -9, and a concomitant degradation of poly(ADP-ribose) polymerase (PARP). schizandrin C 13-26 BCL2 apoptosis regulator Homo sapiens 126-131 19735878-9 2009 Curcumin also suppressed NF-kappaB-regulated gene products (Bcl-2, Bcl-x(L), inhibitor of apoptosis protein-2, cyclooxygenase-2, and cyclin D1). Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 60-65 19857057-7 2009 In addition, both octanoate and decanoate increased the expression of pro-apoptotic Bax with an accompanied decrease of anti-apoptotic Bcl-2. octanoic acid 18-27 BCL2 apoptosis regulator Homo sapiens 135-140 19473291-5 2009 We treated the cells with either 100 nM taxol or transfected with a plasmid vector expressing Bcl-2 siRNA or both agents together for 72 h. Knockdown of Bcl-2 potentiated efficacy of taxol for cell death. Paclitaxel 40-45 BCL2 apoptosis regulator Homo sapiens 153-158 19473291-5 2009 We treated the cells with either 100 nM taxol or transfected with a plasmid vector expressing Bcl-2 siRNA or both agents together for 72 h. Knockdown of Bcl-2 potentiated efficacy of taxol for cell death. Paclitaxel 183-188 BCL2 apoptosis regulator Homo sapiens 94-99 19473291-5 2009 We treated the cells with either 100 nM taxol or transfected with a plasmid vector expressing Bcl-2 siRNA or both agents together for 72 h. Knockdown of Bcl-2 potentiated efficacy of taxol for cell death. Paclitaxel 183-188 BCL2 apoptosis regulator Homo sapiens 153-158 19724896-9 2009 Our results indicate that SNPs in DNA repair genes (XRCC3241 and XPD751) influence the ICS and together with the expression of EGFR, Hsp70, Bax, and Bcl-2, they could predict the cisplatin sensitivity of head and neck cancer cell lines (r=0.614, p<or=0.001). Cisplatin 179-188 BCL2 apoptosis regulator Homo sapiens 149-154 19821098-6 2009 After cisplatin was added, the expression levels of Bcl-2 mRNA were reduced, and those of Bax, caspase-3, and survivin mRNA were increased in transfection group as compared with those in control group (P<0.05). Cisplatin 6-15 BCL2 apoptosis regulator Homo sapiens 52-57 19821098-7 2009 It was concluded that shRNA expression vector targeting Livin gene could inhibit the expression of Livin gene in HeLa cells and enhance the apoptosis induced by cisplatin, which was related to the decreased expression of Bcl-2 and activation of Bax and caspase-3. Cisplatin 161-170 BCL2 apoptosis regulator Homo sapiens 221-226 19857057-7 2009 In addition, both octanoate and decanoate increased the expression of pro-apoptotic Bax with an accompanied decrease of anti-apoptotic Bcl-2. Decanoates 32-41 BCL2 apoptosis regulator Homo sapiens 135-140 19195736-4 2009 Next, we observed that high BCL-2-expressing human H69 SCLC cells, that were approximately 160-fold more sensitive to Dox than their combined BCL-2 and MRP-over-expressing (H69AR) counterparts, were only approximately 5-fold more resistant to DMSP. Doxorubicin 118-121 BCL2 apoptosis regulator Homo sapiens 28-33 19458629-5 2009 Accordingly, inhibition of Bcl-2 by ABT-737 was synergistic with ARRY-520 in HL-60Bcl-2 cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 36-39 BCL2 apoptosis regulator Homo sapiens 27-32 19640984-2 2009 Apart from the tumor suppressor p53 and proapoptotic Bcl-2 family member Bak, many targets contain class 1 PDZ domains and are involved in cell junction stability and signaling. bakuchiol 73-76 BCL2 apoptosis regulator Homo sapiens 53-58 19195736-4 2009 Next, we observed that high BCL-2-expressing human H69 SCLC cells, that were approximately 160-fold more sensitive to Dox than their combined BCL-2 and MRP-over-expressing (H69AR) counterparts, were only approximately 5-fold more resistant to DMSP. dimethylpropiothetin 243-247 BCL2 apoptosis regulator Homo sapiens 28-33 19796390-9 2009 BER also has synergistic effects with anticancer agents trichostatin A, celecoxib and/or carmofur on reducing Bcl-2/Bax ratios and VEGF secretions in MDA-MB-231 cells. trichostatin A 56-70 BCL2 apoptosis regulator Homo sapiens 110-115 19363675-14 2009 Morevoer, ROS generation is associated with increased expression of p38, caspases 3 and 8, and decreased Bcl-2 expression. Reactive Oxygen Species 10-13 BCL2 apoptosis regulator Homo sapiens 105-110 19796390-9 2009 BER also has synergistic effects with anticancer agents trichostatin A, celecoxib and/or carmofur on reducing Bcl-2/Bax ratios and VEGF secretions in MDA-MB-231 cells. Celecoxib 72-81 BCL2 apoptosis regulator Homo sapiens 110-115 19796390-9 2009 BER also has synergistic effects with anticancer agents trichostatin A, celecoxib and/or carmofur on reducing Bcl-2/Bax ratios and VEGF secretions in MDA-MB-231 cells. carmofur 89-97 BCL2 apoptosis regulator Homo sapiens 110-115 19796390-13 2009 BER has synergistic effects with anticancer agents trichostatin A, celecoxib and carmofur on inhibiting the growth of MDA-MB-231 cells and reducing the ratio of Bcl-2/Bax and/or VEGF expressions in the cancer cells. Celecoxib 67-76 BCL2 apoptosis regulator Homo sapiens 161-166 19796390-13 2009 BER has synergistic effects with anticancer agents trichostatin A, celecoxib and carmofur on inhibiting the growth of MDA-MB-231 cells and reducing the ratio of Bcl-2/Bax and/or VEGF expressions in the cancer cells. carmofur 81-89 BCL2 apoptosis regulator Homo sapiens 161-166 20090882-1 2009 The apoptotic effect of bacteria-derived beta-glucan was investigated in human colon cancer cells SNU-C4 using terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) assay, reverse transcription-polymerase chain reaction (RT-PCR) expressions of Bcl-2, Bax, and Caspase-3 genes, and assay of caspase-3 enzyme activity. beta-Glucans 41-52 BCL2 apoptosis regulator Homo sapiens 274-279 19457711-0 2009 Tumor thickness, depth of invasion, and Bcl-2 expression are correlated with FDG-uptake in oral squamous cell carcinomas. Fluorodeoxyglucose F18 77-80 BCL2 apoptosis regulator Homo sapiens 40-45 20090882-3 2009 In addition, beta-glucan (100 microg/mL) decreased the expression of Bcl-2 by 0.6 times, whereas the expression of Bax and Caspase-3 were increased by 3.1 and 2.3 times, respectively, compared to untreated control group. beta-Glucans 13-24 BCL2 apoptosis regulator Homo sapiens 69-74 19654426-9 2009 Conversely mitochondria isolated from Bid(-/-) animals that lack this pro-apoptotic Bcl-2 family member were resistant to Az-LPAF depolarization. Az-LPAF 122-129 BCL2 apoptosis regulator Homo sapiens 84-89 19478553-8 2009 These results indicate that Bcl-2 suppresses apoptosis and SP600125-induced G2/M arrest and endoreduplication. pyrazolanthrone 59-67 BCL2 apoptosis regulator Homo sapiens 28-33 19654426-11 2009 Thus, phospholipid oxidation products physically interact with mitochondria to continually depolarize this organelle without permanent harm, and Bcl-2 family members modulate this interaction with full-length Bid acting as a co-factor for pro-apoptotic, oxidatively truncated phospholipids. Phospholipids 276-289 BCL2 apoptosis regulator Homo sapiens 145-150 19468714-8 2009 Differential expression of genes, such as p53, Bcl-2, caspase-9, was evident in PFOA or PFOS exposure groups. perfluorooctanoic acid 80-84 BCL2 apoptosis regulator Homo sapiens 47-52 19699753-4 2009 IQDMA-induced apoptosis was accompanied with up-regulation of the protein expression of Bax and down-regulation of the protein levels of Bcl-2, Mcl-1, X-linked inhibitor of apoptosis (XIAP), and survivin, resulting in cytochrome c release and sequential activation of caspase-9 and caspase-3. N'-(11H-indolo(3,2-c)quinolin-6-yl)-N,N-dimethylethane-1,2-diamine 0-5 BCL2 apoptosis regulator Homo sapiens 137-142 19699753-7 2009 Both SP600125 and SB203580 attenuated the activation of Bax and cytochrome c release, and reversed down-regulation of Bcl-2, XIAP, survivin, cyclin A, cyclin B, and Cdk1 in IQDMA-treated cells. pyrazolanthrone 5-13 BCL2 apoptosis regulator Homo sapiens 118-123 19699753-7 2009 Both SP600125 and SB203580 attenuated the activation of Bax and cytochrome c release, and reversed down-regulation of Bcl-2, XIAP, survivin, cyclin A, cyclin B, and Cdk1 in IQDMA-treated cells. SB 203580 18-26 BCL2 apoptosis regulator Homo sapiens 118-123 19539716-4 2009 The findings also show that H(2)O(2) induces the dephosphorylation of the mammalian target of rapamycin (mTOR) at Ser 2481 and the p70 ribosomal protein S6 kinase (p70S6K) at Thr389 in a Bcl-2/E1B 19kDa interacting protein 3 (BNIP3)-dependent manner. Hydrogen Peroxide 28-36 BCL2 apoptosis regulator Homo sapiens 187-192 19539716-4 2009 The findings also show that H(2)O(2) induces the dephosphorylation of the mammalian target of rapamycin (mTOR) at Ser 2481 and the p70 ribosomal protein S6 kinase (p70S6K) at Thr389 in a Bcl-2/E1B 19kDa interacting protein 3 (BNIP3)-dependent manner. Serine 114-117 BCL2 apoptosis regulator Homo sapiens 187-192 19588526-3 2009 RESULTS: In vitro, CTCE-9908 inhibited cellular proliferation in PC-3-Bcl-2 and PC-3-Neo cell lines Furthermore in our xenograft model, CTCE-9908 delivered via daily intraperitoneal injections resulted in a statistically significant reduction in tumor size compared to control (396 + 205 mm(3) vs. 1,010 + 215 mm(3) respectively, p < 0.05) in the Bcl-2 expressing tumors. CTCE-9908 19-28 BCL2 apoptosis regulator Homo sapiens 70-75 19588526-3 2009 RESULTS: In vitro, CTCE-9908 inhibited cellular proliferation in PC-3-Bcl-2 and PC-3-Neo cell lines Furthermore in our xenograft model, CTCE-9908 delivered via daily intraperitoneal injections resulted in a statistically significant reduction in tumor size compared to control (396 + 205 mm(3) vs. 1,010 + 215 mm(3) respectively, p < 0.05) in the Bcl-2 expressing tumors. CTCE-9908 19-28 BCL2 apoptosis regulator Homo sapiens 350-355 19588526-3 2009 RESULTS: In vitro, CTCE-9908 inhibited cellular proliferation in PC-3-Bcl-2 and PC-3-Neo cell lines Furthermore in our xenograft model, CTCE-9908 delivered via daily intraperitoneal injections resulted in a statistically significant reduction in tumor size compared to control (396 + 205 mm(3) vs. 1,010 + 215 mm(3) respectively, p < 0.05) in the Bcl-2 expressing tumors. ctce 19-23 BCL2 apoptosis regulator Homo sapiens 70-75 19588526-3 2009 RESULTS: In vitro, CTCE-9908 inhibited cellular proliferation in PC-3-Bcl-2 and PC-3-Neo cell lines Furthermore in our xenograft model, CTCE-9908 delivered via daily intraperitoneal injections resulted in a statistically significant reduction in tumor size compared to control (396 + 205 mm(3) vs. 1,010 + 215 mm(3) respectively, p < 0.05) in the Bcl-2 expressing tumors. ctce 19-23 BCL2 apoptosis regulator Homo sapiens 350-355 19667115-7 2009 Significantly, inhibition of glucose metabolism reduced Bcl-2 and Bcl-x(L) protein levels. Glucose 29-36 BCL2 apoptosis regulator Homo sapiens 56-61 19633198-5 2009 This observation was supported by in vivo data showing that a Bcl-2 family inhibitor, ABT-263, strikingly enhanced the activity of anti-CD79b-vcMMAE. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 86-89 BCL2 apoptosis regulator Homo sapiens 62-67 19705844-7 2009 Tricetin-induced apoptotic cell death is associated with changes in the expression of Bax and Bak, decreasing levels of Bcl-2 and Bcl-X(L), and subsequently triggering the mitochondrial apoptotic pathway. tricetin 0-8 BCL2 apoptosis regulator Homo sapiens 120-125 19711916-0 2009 Licorice and licochalcone-A induce autophagy in LNCaP prostate cancer cells by suppression of Bcl-2 expression and the mTOR pathway. licochalcone A 13-27 BCL2 apoptosis regulator Homo sapiens 94-99 19595669-5 2009 Moreover, the expression of STAT3 target genes such as Cyclin D1, XIAP, and Bcl-2 that are essential for cell growth and survival was apparently attenuated after aspirin treatment. Aspirin 162-169 BCL2 apoptosis regulator Homo sapiens 76-81 19631782-0 2009 SAHA treatment overcomes the anti-apoptotic effects of Bcl-2 and is associated with the formation of mature PML nuclear bodies in human leukemic U937 cells. Vorinostat 0-4 BCL2 apoptosis regulator Homo sapiens 55-60 19631782-4 2009 We undertook this study to examine whether SAHA (suberoylanilide hydroxamic acid) overcomes the resistance by Bcl-2 in human leukemic cells, with a specific focus on the involvement of PML-NBs. Vorinostat 43-47 BCL2 apoptosis regulator Homo sapiens 110-115 19631782-4 2009 We undertook this study to examine whether SAHA (suberoylanilide hydroxamic acid) overcomes the resistance by Bcl-2 in human leukemic cells, with a specific focus on the involvement of PML-NBs. Vorinostat 49-80 BCL2 apoptosis regulator Homo sapiens 110-115 19631782-6 2009 Since we previously demonstrated that overexpression of Bcl-2 attenuates resveratrol-induced apoptosis in human leukemic U937 cells, resveratrol-treated U937 cells were used as a negative control. Resveratrol 73-84 BCL2 apoptosis regulator Homo sapiens 56-61 19631782-7 2009 The present study indicates that SAHA at 1-7 microM, the dose range known to induce apoptosis in various cancer cells, overcomes the anti-apoptotic effects of Bcl-2 in Bcl-2-overexpressing human leukemic U937 cells. Vorinostat 33-37 BCL2 apoptosis regulator Homo sapiens 159-164 19631782-7 2009 The present study indicates that SAHA at 1-7 microM, the dose range known to induce apoptosis in various cancer cells, overcomes the anti-apoptotic effects of Bcl-2 in Bcl-2-overexpressing human leukemic U937 cells. Vorinostat 33-37 BCL2 apoptosis regulator Homo sapiens 168-173 19631782-8 2009 Notably, we observed that SAHA-induced formation of mature promyelocytic leukemia (PML) nuclear bodies (NBs) correlates with overcoming the anti-apoptotic effects of Bcl-2 in human leukemic U937 cells. Vorinostat 26-30 BCL2 apoptosis regulator Homo sapiens 166-171 19714620-13 2009 Furthermore, in the mitochondrial fraction, SIRT1 inhibition by siRNA for SIRT1 increased the amount of Bax but reduced the amount of Bcl-2, while resveratrol reduced the amount of Bax but increased the amount of Bcl-2. Resveratrol 147-158 BCL2 apoptosis regulator Homo sapiens 213-218 19667115-9 2009 CONCLUSIONS: These results suggest that oxLDL enhances macrophage survival in the absence of CSF-1 by inducing PI3K-dependent glucose uptake, which is metabolized to maintain Bcl-2 and Bcl-x(L) protein levels. Glucose 126-133 BCL2 apoptosis regulator Homo sapiens 175-180 19468714-8 2009 Differential expression of genes, such as p53, Bcl-2, caspase-9, was evident in PFOA or PFOS exposure groups. perfluorooctane sulfonic acid 88-92 BCL2 apoptosis regulator Homo sapiens 47-52 19578044-0 2009 Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 20-25 19545597-0 2009 Phosphorylation of Bcl-2 and activation of caspase-3 via the c-Jun N-terminal kinase pathway in ursolic acid-induced DU145 cells apoptosis. ursolic acid 96-108 BCL2 apoptosis regulator Homo sapiens 19-24 19545597-6 2009 UA-induced JNK activation could result in Bcl-2 phosphorylation (Ser70) and degradation in DU145 cells, which may be one of the molecular mechanisms by which it induces apoptosis. ursolic acid 0-2 BCL2 apoptosis regulator Homo sapiens 42-47 19633425-8 2009 Furthermore, Bcl-xl and Mcl-1 levels significantly decreased, whereas expression levels of the proteins bcl-2 and bax were unchanged in response to sorafenib treatment in SW982 and HS-SY-II cells. Sorafenib 148-157 BCL2 apoptosis regulator Homo sapiens 104-109 19524689-2 2009 In addition, stimulation of HepG2 cells with GHSC-74 induced a series of intracellular events: (1) loss of mitochondrial membrane potential; (2) sustained elevation of cytosolic [Ca2+]; and (3) downregulation of Bcl-2. ghsc 45-49 BCL2 apoptosis regulator Homo sapiens 212-217 19671798-0 2009 Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Paclitaxel 0-10 BCL2 apoptosis regulator Homo sapiens 29-34 19671798-1 2009 We reported previously that Bcl-2 is paradoxically down-regulated in paclitaxel-resistant cancer cells. Paclitaxel 69-79 BCL2 apoptosis regulator Homo sapiens 28-33 19671798-2 2009 We reveal here that paclitaxel directly targets Bcl-2 in the loop domain, thereby facilitating the initiation of apoptosis. Paclitaxel 20-30 BCL2 apoptosis regulator Homo sapiens 48-53 19578044-0 2009 Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation. bakuchiol 90-93 BCL2 apoptosis regulator Homo sapiens 20-25 19671798-3 2009 Molecular modeling revealed an extraordinary similarity between the paclitaxel binding sites in Bcl-2 and beta-tubulin, leading us to speculate that paclitaxel could be mimetic of an endogenous peptide ligand, which binds both proteins. Paclitaxel 68-78 BCL2 apoptosis regulator Homo sapiens 96-101 19671798-3 2009 Molecular modeling revealed an extraordinary similarity between the paclitaxel binding sites in Bcl-2 and beta-tubulin, leading us to speculate that paclitaxel could be mimetic of an endogenous peptide ligand, which binds both proteins. Paclitaxel 149-159 BCL2 apoptosis regulator Homo sapiens 96-101 19578044-3 2009 Here, we show that cisplatin triggers a Bak-dependent pathway to induce apoptosis in Bcl-2-overexpressing MCF-7 cells. Cisplatin 19-28 BCL2 apoptosis regulator Homo sapiens 85-90 19671798-4 2009 We tested the hypothesis that paclitaxel mimics Nur77, which, like paclitaxel, changes the function of Bcl-2. Paclitaxel 30-40 BCL2 apoptosis regulator Homo sapiens 103-108 19578044-3 2009 Here, we show that cisplatin triggers a Bak-dependent pathway to induce apoptosis in Bcl-2-overexpressing MCF-7 cells. bakuchiol 40-43 BCL2 apoptosis regulator Homo sapiens 85-90 19671798-4 2009 We tested the hypothesis that paclitaxel mimics Nur77, which, like paclitaxel, changes the function of Bcl-2. Paclitaxel 67-77 BCL2 apoptosis regulator Homo sapiens 103-108 19671798-5 2009 This premise was confirmed by Nur77 interacting with both paclitaxel targets (Bcl-2 and beta-tubulin) and a peptide sequence mimicking the Nur77 structural region, thus reproducing the paclitaxel-like effects of tubulin polymerization and opening the permeability transition pore channel in mitochondria. Paclitaxel 58-68 BCL2 apoptosis regulator Homo sapiens 78-83 19578044-8 2009 In conclusion, our findings suggest a novel mode of action for cisplatin to overcome Bcl-2-mediated protection against apoptosis, which requires preferential activation of Bak and p53-mediated upregulation of Noxa protein levels and lipid peroxidation. Cisplatin 63-72 BCL2 apoptosis regulator Homo sapiens 85-90 19671798-5 2009 This premise was confirmed by Nur77 interacting with both paclitaxel targets (Bcl-2 and beta-tubulin) and a peptide sequence mimicking the Nur77 structural region, thus reproducing the paclitaxel-like effects of tubulin polymerization and opening the permeability transition pore channel in mitochondria. Paclitaxel 185-195 BCL2 apoptosis regulator Homo sapiens 78-83 19578044-8 2009 In conclusion, our findings suggest a novel mode of action for cisplatin to overcome Bcl-2-mediated protection against apoptosis, which requires preferential activation of Bak and p53-mediated upregulation of Noxa protein levels and lipid peroxidation. bakuchiol 172-175 BCL2 apoptosis regulator Homo sapiens 85-90 20196786-5 2009 We demonstrate that 5-aza-dc suppresses growth of CRC cells, and induces G2 cell cycle arrest and apoptosis through regulation of downstream targets of JAK2/STAT3/STAT5 signalling including Bcl-2, p16(ink4a), p21(waf1/cip1) and p27(kip1). Azacitidine 20-25 BCL2 apoptosis regulator Homo sapiens 190-195 19568971-4 2009 Stimulation of cardiac myocytes with 0.2 mM H(2)O(2), which induces apoptosis, resulted in a marked down-regulation of Bcl-2 protein simultaneously with an increase in its phosphorylation. Hydrogen Peroxide 44-52 BCL2 apoptosis regulator Homo sapiens 119-124 20196784-5 2009 The mechanisms underlying the protective effect of autophagy apparently involved the interference with cisplatin-induced modulation of Bcl-2 family proteins, as inhibition of autophagy potentiated cisplatin-mediated up-regulation of proapoptotic Bax and down-regulation of anti-apoptotic Bcl-2. Cisplatin 103-112 BCL2 apoptosis regulator Homo sapiens 135-140 20196784-5 2009 The mechanisms underlying the protective effect of autophagy apparently involved the interference with cisplatin-induced modulation of Bcl-2 family proteins, as inhibition of autophagy potentiated cisplatin-mediated up-regulation of proapoptotic Bax and down-regulation of anti-apoptotic Bcl-2. Cisplatin 197-206 BCL2 apoptosis regulator Homo sapiens 135-140 19783968-6 2009 The exposure of MCF-7 cells to conventional form of doxorubicin resulted in the decrease of p53 expression and the increase of Bcl-2 expression. Doxorubicin 52-63 BCL2 apoptosis regulator Homo sapiens 127-132 20196784-5 2009 The mechanisms underlying the protective effect of autophagy apparently involved the interference with cisplatin-induced modulation of Bcl-2 family proteins, as inhibition of autophagy potentiated cisplatin-mediated up-regulation of proapoptotic Bax and down-regulation of anti-apoptotic Bcl-2. Cisplatin 197-206 BCL2 apoptosis regulator Homo sapiens 288-293 19373868-8 2009 Treatment of Hs578T and Her-2/neu-driven NF639 cells with 1,25-dihydroxyvitamin D3 decreased RelB/RELB gene expression and levels of pro-survival targets Survivin, MnSOD and Bcl-2, while increasing their sensitivity to gamma-irradiation. Calcitriol 58-82 BCL2 apoptosis regulator Homo sapiens 174-179 19737977-2 2009 Antiapoptotic Bcl-2 is frequently overexpressed in refractory prostate cancer and increased following standard hormonal therapy and chemotherapy; however, the rationally designed Bcl-2 antagonist, ABT-737, has not shown single agent apoptosis-promoting activity against human prostate cancer cell lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 197-200 BCL2 apoptosis regulator Homo sapiens 14-19 19723880-7 2009 In contrast to unspecific LipofectAMINE transfection, down-regulation of antiapoptotic bcl-2 using fusion protein complexed siRNA was strictly dependent on EpCAM binding and internalization. Lipofectamine 26-39 BCL2 apoptosis regulator Homo sapiens 87-92 19723880-8 2009 Inhibition of bcl-2 expression facilitated tumor cell apoptosis as shown by increased sensitivity to the anticancer agent doxorubicin. Doxorubicin 122-133 BCL2 apoptosis regulator Homo sapiens 14-19 19723881-4 2009 Immunoblot analysis confirmed that curcumin induced apoptosis and revealed caspase-3 processing, poly ADP ribose polymerase cleavage, reduced Bcl-2, and decreased basal phosphorylated signal transducers and activators of transcription 3 (STAT3). Curcumin 35-43 BCL2 apoptosis regulator Homo sapiens 142-147 19555448-8 2009 This reduced apoptosis by melatonin was associated with the increase of Bcl-2 expression and a reduction of Bax/Bcl-2 ratio through a relative decrease of p53 mRNA and protein. Melatonin 26-35 BCL2 apoptosis regulator Homo sapiens 72-77 19555448-8 2009 This reduced apoptosis by melatonin was associated with the increase of Bcl-2 expression and a reduction of Bax/Bcl-2 ratio through a relative decrease of p53 mRNA and protein. Melatonin 26-35 BCL2 apoptosis regulator Homo sapiens 112-117 19737977-2 2009 Antiapoptotic Bcl-2 is frequently overexpressed in refractory prostate cancer and increased following standard hormonal therapy and chemotherapy; however, the rationally designed Bcl-2 antagonist, ABT-737, has not shown single agent apoptosis-promoting activity against human prostate cancer cell lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 197-200 BCL2 apoptosis regulator Homo sapiens 179-184 19540902-5 2009 SB202190 (p38 MAPK inhibitor) and SP600125 (JNK inhibitor) attenuated mitochondrial depolarization, degradation of Bcl-2/Bcl-xL, and mitochondrial translocation of Bax. 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole 0-8 BCL2 apoptosis regulator Homo sapiens 115-120 19528263-3 2009 It was found that ghrelin, when given alone, increased the expression of proliferation-associated PCNA and MAPK/ERK1,2, decreased the accumulation of apoptosis-related substances caspase-3, BAX, BCL2, decreased P(4), and increased PGF and OXT release. Ghrelin 18-25 BCL2 apoptosis regulator Homo sapiens 195-199 19950582-1 2009 OBJECTIVE: To evaluate the effects of phosphorothioate antisense oligonucleotides (ASON) bcl-2/ bc-xl ASON and bcl-2 on the proliferation and apoptosis of breast cancer cells, MCF-7. Parathion 38-54 BCL2 apoptosis regulator Homo sapiens 89-94 19950582-1 2009 OBJECTIVE: To evaluate the effects of phosphorothioate antisense oligonucleotides (ASON) bcl-2/ bc-xl ASON and bcl-2 on the proliferation and apoptosis of breast cancer cells, MCF-7. Oligonucleotides 65-81 BCL2 apoptosis regulator Homo sapiens 89-94 19950582-5 2009 The fluorensence intensities of bcl-2 in groups of NA-D and NA-S, PA-S and PA-D, FB1 and FB2 were 1.92+/-0.08 and 2.83+/-0.16 (P=0.028); 4.20+/-0.18 and 2.85+/-0.57 (P=0.001); 5.70+/-1.16 and 4.35+/-0.11 (P=0.001), respectively. Deuterium 54-55 BCL2 apoptosis regulator Homo sapiens 32-37 19950582-5 2009 The fluorensence intensities of bcl-2 in groups of NA-D and NA-S, PA-S and PA-D, FB1 and FB2 were 1.92+/-0.08 and 2.83+/-0.16 (P=0.028); 4.20+/-0.18 and 2.85+/-0.57 (P=0.001); 5.70+/-1.16 and 4.35+/-0.11 (P=0.001), respectively. Protactinium 66-70 BCL2 apoptosis regulator Homo sapiens 32-37 19706527-0 2009 The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor. sapropterin 4-7 BCL2 apoptosis regulator Homo sapiens 18-23 19706527-0 2009 The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor. Calcium 36-43 BCL2 apoptosis regulator Homo sapiens 18-23 19706527-1 2009 Although the presence of a BH4 domain distinguishes the antiapoptotic protein Bcl-2 from its proapoptotic relatives, little is known about its function. sapropterin 27-30 BCL2 apoptosis regulator Homo sapiens 78-83 19706527-2 2009 BH4 deletion converts Bcl-2 into a proapoptotic protein, whereas a TAT-BH4 fusion peptide inhibits apoptosis and improves survival in models of disease due to accelerated apoptosis. sapropterin 0-3 BCL2 apoptosis regulator Homo sapiens 22-27 19706527-4 2009 Here we report that the BH4 domain mediates interaction of Bcl-2 with the inositol 1,4,5-trisphosphate (IP3) receptor, an IP3-gated Ca(2+) channel on the endoplasmic reticulum (ER). sapropterin 24-27 BCL2 apoptosis regulator Homo sapiens 59-64 19706527-6 2009 A peptide inhibitor of Bcl-2-IP3 receptor interaction prevents these BH4-mediated effects. sapropterin 69-72 BCL2 apoptosis regulator Homo sapiens 23-28 19626005-3 2009 In type I cells, such as lymphocytes, activation of "effector caspases" by FAS-induced activation of caspase-8 suffices for cell killing, whereas in type II cells, including hepatocytes and pancreatic beta-cells, caspase cascade amplification through caspase-8-mediated activation of the pro-apoptotic BCL-2 family member BID (BH3 interacting domain death agonist) is essential. ammonium ferrous sulfate 75-78 BCL2 apoptosis regulator Homo sapiens 302-307 19527683-3 2009 Recently, the pro-apoptotic activities of IMQ occurring via the modulation of bcl-2 family have been reported in several tumor cells. Imiquimod 42-45 BCL2 apoptosis regulator Homo sapiens 78-83 19540902-5 2009 SB202190 (p38 MAPK inhibitor) and SP600125 (JNK inhibitor) attenuated mitochondrial depolarization, degradation of Bcl-2/Bcl-xL, and mitochondrial translocation of Bax. pyrazolanthrone 34-42 BCL2 apoptosis regulator Homo sapiens 115-120 19671865-8 2009 A mixture of Vitexins EVn-50 and purified Vitexin compound 6-hydroxy-4-(4-hydroxy-3-methoxyphenyl)-3-hydroxymethyl-7-methoxy-3, 4-dihydro-2-naphthaldehyde have cytotoxic effect on breast, prostate, and ovarian cancer cells and induces apoptosis with cleavage in poly ADP ribose polymerase protein, up-regulation of Bax, and down-regulation of Bcl-2. 6-hydroxy-4-(4-hydroxy-3-methoxyphenyl)-3 59-100 BCL2 apoptosis regulator Homo sapiens 343-348 19795525-7 2009 The BH3:groove interaction within Bak homodimers supports a general model to explain the associations between Bcl-2 family members. BH 3 4-7 BCL2 apoptosis regulator Homo sapiens 110-115 19664237-14 2009 Western blotting revealed that the expression of cell cycle related protein p21 and cyclin D1 were not affected by the treatments, whereas apoptosis related protein bax, Bcl-2, and clusterin were significantly regulated by As2O3 and/or DDP treatments compared with controls. Arsenic Trioxide 223-228 BCL2 apoptosis regulator Homo sapiens 170-175 19520063-7 2009 Taken together, these results indicated that acteoside could protect SH-SY5Y cells against beta-amyloid-induced cell injury by the attenuating ROS production and the modulating apoptotic signal pathway through Bcl-2 family, cytochrome c, and caspase-3. acteoside 45-54 BCL2 apoptosis regulator Homo sapiens 210-215 19539006-3 2009 TA blocked the rotenone-induced phosphorylation of JNK and P38, the downregulation of BCL2 and the upregulation of BAX. Rotenone 15-23 BCL2 apoptosis regulator Homo sapiens 86-90 19410573-8 2009 Namely, bortezomib abrogated both etoposide-induced NF-kappaB activation and etoposide-induced bcl-2 up-regulation. Bortezomib 8-18 BCL2 apoptosis regulator Homo sapiens 95-100 19410573-8 2009 Namely, bortezomib abrogated both etoposide-induced NF-kappaB activation and etoposide-induced bcl-2 up-regulation. Etoposide 77-86 BCL2 apoptosis regulator Homo sapiens 95-100 19481559-4 2009 DMPS treatment led to the activation of caspase-9 and caspase-3, accompanied by the cleavage of poly(ADP-ribose) polymerase (PARP) and led to cytochrome c release, depolarization of the mitochondrial membrane potential, and downregulation of the anti-apoptotic members of the bcl-2 family. N,N-dimethylphytosphingosine 0-4 BCL2 apoptosis regulator Homo sapiens 276-281 19481559-5 2009 Ectopic expression of bcl-2 and bcl-xL conferred resistance of HL-60 cells to DMPS-induced cell death, suggesting that DMPS-induced apoptosis occurs predominantly through the activation of the intrinsic mitochondrial pathway. N,N-dimethylphytosphingosine 78-82 BCL2 apoptosis regulator Homo sapiens 22-27 19481559-5 2009 Ectopic expression of bcl-2 and bcl-xL conferred resistance of HL-60 cells to DMPS-induced cell death, suggesting that DMPS-induced apoptosis occurs predominantly through the activation of the intrinsic mitochondrial pathway. N,N-dimethylphytosphingosine 119-123 BCL2 apoptosis regulator Homo sapiens 22-27 19653337-10 2009 The relative expression level of Bcl-2 dropped to less than 50% of control cells at a sub-apoptotic concentration of chelidonine and subsequently increased to higher than 120% at LD(50). chelidonine 117-128 BCL2 apoptosis regulator Homo sapiens 33-38 19433130-5 2009 GA treatment downregulated the expression of SRC-3 and then inhibited the activity of Akt kinase and its downstream targets p70 S6 kinase 1 (S6K1) and glycogen synthase kinase 3beta (GSK3beta) without changes in total protein levels of these three proteins, which thus influenced the expression of the apoptosis related gene Bcl-2 in K562 cells. gambogic acid 0-2 BCL2 apoptosis regulator Homo sapiens 325-330 19671865-8 2009 A mixture of Vitexins EVn-50 and purified Vitexin compound 6-hydroxy-4-(4-hydroxy-3-methoxyphenyl)-3-hydroxymethyl-7-methoxy-3, 4-dihydro-2-naphthaldehyde have cytotoxic effect on breast, prostate, and ovarian cancer cells and induces apoptosis with cleavage in poly ADP ribose polymerase protein, up-regulation of Bax, and down-regulation of Bcl-2. -methoxy-3, 4-dihydro-2-naphthaldehyde 116-154 BCL2 apoptosis regulator Homo sapiens 343-348 19671865-11 2009 Consistent with in vitro data, EVn-50 treatment induced apoptosis, down-regulated of Bcl-2, and up-regulated Bax in tumor xenografts. evn-50 31-37 BCL2 apoptosis regulator Homo sapiens 85-90 19684859-3 2009 ABT-737, a small-molecule inhibitor of Bcl-2, Bcl-xl and Bcl-w, has demonstrated efficacy in several forms of leukemia, lymphoma as well as solid tumors. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 39-44 19661327-7 2009 CWC-8 treatment also caused a time-dependent increase in Fas/CD95, FADD, cytosolic cytochrome c, caspase-8/-9/-3 active form, Apaf-1, AIF, Bax protein levels, and decrease in Bcl-2 protein level. cwc-8 0-5 BCL2 apoptosis regulator Homo sapiens 175-180 19664330-11 2009 The protein level of Bcl-2 was the lowest in BEL-7402 cells treated with sorafenib after paclitaxel. Sorafenib 73-82 BCL2 apoptosis regulator Homo sapiens 21-26 19664330-11 2009 The protein level of Bcl-2 was the lowest in BEL-7402 cells treated with sorafenib after paclitaxel. Paclitaxel 89-99 BCL2 apoptosis regulator Homo sapiens 21-26 19661335-3 2009 Therefore, we hypothesized that a possible mechanism for developing Tam resistance could be the regulation of ER-alpha and Bcl-2 family proteins through modulation of Akt activity. Tamoxifen 68-71 BCL2 apoptosis regulator Homo sapiens 123-128 19723048-4 2009 It was found that the anthocyanins could inhibit cell growth by 75% at the concentration of 400 microg/mL for 48 h. Flow cytometric analysis showed that the anthocyanins increased the amount of DNA fragments (sub-G1 fraction) in a dose-dependent manner, which is closely related to mitochondrial dysfunction and reduction in antiapoptotic proteins (Bcl-2, xIAP, cIAP-1, and cIAP-2). Anthocyanins 22-34 BCL2 apoptosis regulator Homo sapiens 349-354 19723048-4 2009 It was found that the anthocyanins could inhibit cell growth by 75% at the concentration of 400 microg/mL for 48 h. Flow cytometric analysis showed that the anthocyanins increased the amount of DNA fragments (sub-G1 fraction) in a dose-dependent manner, which is closely related to mitochondrial dysfunction and reduction in antiapoptotic proteins (Bcl-2, xIAP, cIAP-1, and cIAP-2). Anthocyanins 157-169 BCL2 apoptosis regulator Homo sapiens 349-354 19723050-5 2009 We found that beta-carotene (100 micromol/L) induced apoptosis (determined by cell viability), DNA fragmentation, and the protein levels of p53 and Bcl-2 in AGS cells. beta Carotene 14-27 BCL2 apoptosis regulator Homo sapiens 148-153 19723050-7 2009 beta-Carotene-induced alterations, including an increase in DNA fragmentation and p53 levels and a decrease in nuclear ATM and cellular Bcl-2 levels, were inhibited in the cells transfected with full-length ATM cDNA compared to wild-type cells or the cells transfected with control vector plasmid control DNA vector (pcDNA). beta Carotene 0-13 BCL2 apoptosis regulator Homo sapiens 136-141 19723050-8 2009 In conclusion, beta-carotene induces apoptosis by increasing apoptotic protein p53 and decreasing anti-apoptotic Bcl-2 as well as nuclear ATM in AGS cells. beta Carotene 15-28 BCL2 apoptosis regulator Homo sapiens 113-118 19723066-7 2009 Our results indicate and support the hypothesis that the apoptosis-related genes BCL2 and BCL2L12 respond similarly to treatment of the human, acute, myelocytic leukemia HL60 cells with the anticancer drugs vincristine and taxol though in a drug-specific and time-dependent manner. Vincristine 207-218 BCL2 apoptosis regulator Homo sapiens 81-85 19652374-6 2009 These findings suggest that salidroside protects endothelial cells from cobalt chloride-induced apoptosis as an antioxidant and by regulating Bcl-2 family. rhodioloside 28-39 BCL2 apoptosis regulator Homo sapiens 142-147 19723066-7 2009 Our results indicate and support the hypothesis that the apoptosis-related genes BCL2 and BCL2L12 respond similarly to treatment of the human, acute, myelocytic leukemia HL60 cells with the anticancer drugs vincristine and taxol though in a drug-specific and time-dependent manner. Paclitaxel 223-228 BCL2 apoptosis regulator Homo sapiens 81-85 19412639-1 2009 Genetic mutations frequently observed in human follicular lymphoma (FL) B-cells result in aberrant expression of the anti-apoptotic protein bcl-2 and surface immunoglobulins (Igs) which display one or more novel variable (V) region N-glycosylation motifs. Nitrogen 232-233 BCL2 apoptosis regulator Homo sapiens 140-145 19022681-6 2009 Recent developments in the direct therapeutic manipulation of Bcl-2 proteins using BH3-mimicking agents, such as ABT-737 or GX15-070, for hematologic malignancies are also summarized. BH 3 83-86 BCL2 apoptosis regulator Homo sapiens 62-67 19440893-0 2009 Ursolic acid triggers apoptosis and Bcl-2 downregulation in MCF-7 breast cancer cells. ursolic acid 0-12 BCL2 apoptosis regulator Homo sapiens 36-41 19440893-2 2009 The UA-induced apoptosis (53 microM), the PARP cleavage, and the decrease in Bcl-2 protein (53 microM) support the notion that UA induces apoptosis through the intrinsic mitochondrial pathway. ursolic acid 127-129 BCL2 apoptosis regulator Homo sapiens 77-82 19556859-10 2009 Resistance to ABT-737, which targets Bcl2/-w/-x, was overcome by Mcl1 knockdown. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 14-17 BCL2 apoptosis regulator Homo sapiens 37-41 19022681-6 2009 Recent developments in the direct therapeutic manipulation of Bcl-2 proteins using BH3-mimicking agents, such as ABT-737 or GX15-070, for hematologic malignancies are also summarized. ABT-737 113-120 BCL2 apoptosis regulator Homo sapiens 62-67 19379733-3 2009 We show that DHEA transmits its signal via specific G protein-coupled, membrane binding sites and inhibits apoptosis, through prevention of mitochondrial disruption and altered balance of Bcl-2 proteins. Dehydroepiandrosterone 13-17 BCL2 apoptosis regulator Homo sapiens 188-193 18830972-2 2009 Our preliminary data suggested that nickel(II) induced apoptosis in Jurkat cells by mitochondrial pathway, specifically via mitochondrial membrane potential dissipation and antiapoptotic gene bcl-2 down-regulation. Nickel(2+) 36-46 BCL2 apoptosis regulator Homo sapiens 192-197 19486334-0 2009 Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-cell CLL/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element-binding protein in the sub-regions of the hippocampus. Olanzapine 45-55 BCL2 apoptosis regulator Homo sapiens 104-125 19486334-7 2009 Our results show that 4-week treatment with both olanzapine and lithium increases the levels of Bcl-2 and CREB in the dentate gyrus and hippocampal area CA1. Olanzapine 49-59 BCL2 apoptosis regulator Homo sapiens 96-101 19486334-7 2009 Our results show that 4-week treatment with both olanzapine and lithium increases the levels of Bcl-2 and CREB in the dentate gyrus and hippocampal area CA1. Lithium 64-71 BCL2 apoptosis regulator Homo sapiens 96-101 19486334-10 2009 These results suggest that the up-regulation of Bcl-2 and CREB may underlie the neuroplastic actions of olanzapine and lithium. Olanzapine 104-114 BCL2 apoptosis regulator Homo sapiens 48-53 19486334-10 2009 These results suggest that the up-regulation of Bcl-2 and CREB may underlie the neuroplastic actions of olanzapine and lithium. Lithium 119-126 BCL2 apoptosis regulator Homo sapiens 48-53 19358267-8 2009 Bax expression was increased, whereas Bcl-2 was decreased in cells treated with CAPE compared to vehicle. caffeic acid phenethyl ester 80-84 BCL2 apoptosis regulator Homo sapiens 38-43 19381674-3 2009 We demonstrate that gal-1 induced proteolytic cleavage of the death agonist Bid, a member of the Bcl-2/Bcl-xL family and a substrate of activated caspase-8, was inhibited by caspase-8 inhibitor II (Z-IETD-FMK). benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone 198-208 BCL2 apoptosis regulator Homo sapiens 97-102 19755441-9 2009 Quercetin increased abundance of the pro-apoptotic protein Bax and decreased the levels of anti-apoptotic protein Bcl-2. Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 114-119 20141615-2 2009 An earlier study from this laboratory demonstrated 17beta-oestradiol (E2) induced apoptosis in macrophages derived from human peripheral blood monocytes and THP-1 acute monocytic leukaemia cell line when Bcl-2 was down-regulated; however, the involvement of E2 receptor subtypes in the modulation of death pathways in these cells remain unknown. Estradiol 51-68 BCL2 apoptosis regulator Homo sapiens 204-209 19220580-5 2009 Sorafenib-induced growth suppression and apoptosis were associated with inhibition of angiogenesis, down-regulation of phospho-platelet-derived growth factor receptor beta Tyr1021, phospho-eIF4E Ser209, phospho-c-Raf Ser259, c-Raf, Mcl-1, Bcl-2, Bcl-x and positive cell cycle regulators, up-regulation of apoptosis signalling kinase-1, p27 and p21. Sorafenib 0-9 BCL2 apoptosis regulator Homo sapiens 239-244 19483104-9 2009 Sorafenib + vorinostat treatment activated the c-Jun NH(2)-terminal kinase pathway, which was causal in promoting dissociation of Beclin1 from BCL-2, and in promoting autophagy. Sorafenib 0-9 BCL2 apoptosis regulator Homo sapiens 143-148 19659784-9 2009 PAR-induced apoptosis was associated with intracellular events including the decline of mitochondrial potential, increased release of cytochrome C from the mitochondria, decreased expression of Bcl-2, increased expression of Bax, Bid and tBid and activation of caspase 3 and 8. parthenolide 0-3 BCL2 apoptosis regulator Homo sapiens 194-199 19557821-6 2009 In addition, we found for the first time that lower levels of Bcl-2 protein under HG conditions could be countered by the action of flavonoids. Flavonoids 132-142 BCL2 apoptosis regulator Homo sapiens 62-67 19549761-7 2009 Expression of Bcl-2 and caspase-3 activation increased in B cells treated with 10 mumol/L resveratrol compared with mitogen alone (P < 0.01), and trends for dose-responsive increases in Bcl-2 expression and caspase-3 activation were observed (P-trend < 0.0001). Resveratrol 90-101 BCL2 apoptosis regulator Homo sapiens 14-19 19549761-7 2009 Expression of Bcl-2 and caspase-3 activation increased in B cells treated with 10 mumol/L resveratrol compared with mitogen alone (P < 0.01), and trends for dose-responsive increases in Bcl-2 expression and caspase-3 activation were observed (P-trend < 0.0001). Resveratrol 90-101 BCL2 apoptosis regulator Homo sapiens 189-194 19549761-11 2009 These data show that human B lymphocyte proliferation and apoptosis are modified by physiological concentrations of resveratrol and suggest that exposure of human B cells to resveratrol may increase survival by upregulating Bcl-2. Resveratrol 174-185 BCL2 apoptosis regulator Homo sapiens 224-229 19522739-8 2009 In the presence of PD98059, caspase-3 activity increased, while levels of Bax/cytochrome c (Cyt c) and Bcl-2 decreased. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 19-26 BCL2 apoptosis regulator Homo sapiens 103-108 19507186-8 2009 Radiosensitization was achieved with a substantial elevation of cleaved PARP-1 in DETANONOate-HT-29-treated versus control cells, which was accompanied by elevation of p21, p27, and BAX, and a concomitant decrease in Bcl-2. 2,2'-(hydroxynitrosohydrazono)bis-ethanamine 82-93 BCL2 apoptosis regulator Homo sapiens 217-222 19885011-4 2009 Naringin also blocked rotenone-induced phosphorylation of Jun NH2-terminal protein kinase (JNK) and P38, and prevented changes in B-cell CLL/lymphoma 2 (BCL2) and BCL2-associated X protein (BAX) expression levels. naringin 0-8 BCL2 apoptosis regulator Homo sapiens 130-151 19885011-4 2009 Naringin also blocked rotenone-induced phosphorylation of Jun NH2-terminal protein kinase (JNK) and P38, and prevented changes in B-cell CLL/lymphoma 2 (BCL2) and BCL2-associated X protein (BAX) expression levels. naringin 0-8 BCL2 apoptosis regulator Homo sapiens 153-157 19483104-9 2009 Sorafenib + vorinostat treatment activated the c-Jun NH(2)-terminal kinase pathway, which was causal in promoting dissociation of Beclin1 from BCL-2, and in promoting autophagy. Vorinostat 12-22 BCL2 apoptosis regulator Homo sapiens 143-148 19483105-0 2009 BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Sorafenib 66-75 BCL2 apoptosis regulator Homo sapiens 0-5 19483105-10 2009 Our data demonstrate that pancreatic tumor cells are susceptible to sorafenib + HDACI lethality and that in tumor cells unable to signal death from CD95, use of a BCL-2 family antagonist facilitates sorafenib + HDACI killing via autophagy and the intrinsic pathway. Sorafenib 199-208 BCL2 apoptosis regulator Homo sapiens 163-168 19390557-3 2009 Using cells deficient either for Bax/Bak or caspase-9, we found that only ABT-737 specifically targeted BCL2 proteins and induced apoptosis by activation of caspase-9, as only ABT-737 induced apoptosis was completely inhibited in cells deficient for Bax/Bak or caspase-9. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 74-77 BCL2 apoptosis regulator Homo sapiens 104-108 19813621-6 2009 However, the mechanism of how H2-H3 inhibits the anti-apoptotic activity of Bcl-2 remains poorly understood. h2-h3 30-35 BCL2 apoptosis regulator Homo sapiens 76-81 19451193-9 2009 Our data provide the first evidence that H(2)O(2) induces autophagy through interference with the Beclin 1 and Akt/mTOR signaling pathways and is regulated by the anti-apoptotic gene Bcl-2 in glioma U251 cells. Hydrogen Peroxide 41-49 BCL2 apoptosis regulator Homo sapiens 183-188 19520857-0 2009 B cell lymphoma (Bcl)-2 protein is the major determinant in bcl-2 adenine-uridine-rich element turnover overcoming HuR activity. Adenine 66-73 BCL2 apoptosis regulator Homo sapiens 0-23 19520857-0 2009 B cell lymphoma (Bcl)-2 protein is the major determinant in bcl-2 adenine-uridine-rich element turnover overcoming HuR activity. Adenine 66-73 BCL2 apoptosis regulator Homo sapiens 60-65 19520857-0 2009 B cell lymphoma (Bcl)-2 protein is the major determinant in bcl-2 adenine-uridine-rich element turnover overcoming HuR activity. Uridine 74-81 BCL2 apoptosis regulator Homo sapiens 0-23 19520857-0 2009 B cell lymphoma (Bcl)-2 protein is the major determinant in bcl-2 adenine-uridine-rich element turnover overcoming HuR activity. Uridine 74-81 BCL2 apoptosis regulator Homo sapiens 60-65 19442964-7 2009 The results demonstrated that both PMP depolarization and Na,K-ATPase impairment induced by rotenone were regulated by mitochondrial H(2)O(2) and Bcl-2. pmp 35-38 BCL2 apoptosis regulator Homo sapiens 146-151 19442964-7 2009 The results demonstrated that both PMP depolarization and Na,K-ATPase impairment induced by rotenone were regulated by mitochondrial H(2)O(2) and Bcl-2. Rotenone 92-100 BCL2 apoptosis regulator Homo sapiens 146-151 19742123-7 2009 Moreover, Bcl-2 expression was significantly reduced by cyclopamine treatment. cyclopamine 56-67 BCL2 apoptosis regulator Homo sapiens 10-15 19297314-0 2009 Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Docetaxel 0-9 BCL2 apoptosis regulator Homo sapiens 34-39 19297314-0 2009 Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. oblimersen 15-32 BCL2 apoptosis regulator Homo sapiens 34-39 19395874-5 2009 Here we report that T119 phosphorylation also reduces the interaction between Beclin 1 and Bcl-2, in line with the high degree of structural homology between the BH3 binding pockets of Bcl-2 and Bcl-X(L) proteins. BH 3 162-165 BCL2 apoptosis regulator Homo sapiens 91-96 19395874-5 2009 Here we report that T119 phosphorylation also reduces the interaction between Beclin 1 and Bcl-2, in line with the high degree of structural homology between the BH3 binding pockets of Bcl-2 and Bcl-X(L) proteins. BH 3 162-165 BCL2 apoptosis regulator Homo sapiens 185-190 19283527-0 2009 Curcumin sensitizes lung cancer cells to cisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 103-108 19283527-0 2009 Curcumin sensitizes lung cancer cells to cisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation. Cisplatin 41-50 BCL2 apoptosis regulator Homo sapiens 103-108 19283527-0 2009 Curcumin sensitizes lung cancer cells to cisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation. Superoxides 77-93 BCL2 apoptosis regulator Homo sapiens 103-108 19283527-2 2009 Curcumin was shown to induce superoxide anion generation, down-regulate anti-apoptotic Bcl-2 protein, and subsequently sensitize cells to cisplatin-induced apoptosis. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 87-92 19283527-3 2009 Co-treatment of the cells with curcumin and cisplatin resulted in increased apoptosis and reversal of Bcl-2-mediated cisplatin resistance. Curcumin 31-39 BCL2 apoptosis regulator Homo sapiens 102-107 19283527-3 2009 Co-treatment of the cells with curcumin and cisplatin resulted in increased apoptosis and reversal of Bcl-2-mediated cisplatin resistance. Cisplatin 44-53 BCL2 apoptosis regulator Homo sapiens 102-107 19283527-3 2009 Co-treatment of the cells with curcumin and cisplatin resulted in increased apoptosis and reversal of Bcl-2-mediated cisplatin resistance. Cisplatin 117-126 BCL2 apoptosis regulator Homo sapiens 102-107 19283527-4 2009 The mechanism by which curcumin down-regulates Bcl-2 and sensitizes cells to cisplatin-induced apoptosis involves proteasomal degradation of Bcl-2. Curcumin 23-31 BCL2 apoptosis regulator Homo sapiens 47-52 19283527-4 2009 The mechanism by which curcumin down-regulates Bcl-2 and sensitizes cells to cisplatin-induced apoptosis involves proteasomal degradation of Bcl-2. Curcumin 23-31 BCL2 apoptosis regulator Homo sapiens 141-146 19283527-4 2009 The mechanism by which curcumin down-regulates Bcl-2 and sensitizes cells to cisplatin-induced apoptosis involves proteasomal degradation of Bcl-2. Cisplatin 77-86 BCL2 apoptosis regulator Homo sapiens 141-146 19283527-5 2009 These findings indicate a novel pathway for curcumin regulation of Bcl-2, which could benefit the development of a cisplatin sensitizing agent. Curcumin 44-52 BCL2 apoptosis regulator Homo sapiens 67-72 19283527-5 2009 These findings indicate a novel pathway for curcumin regulation of Bcl-2, which could benefit the development of a cisplatin sensitizing agent. Cisplatin 115-124 BCL2 apoptosis regulator Homo sapiens 67-72 19623560-0 2009 Regulation of survivin and Bcl-2 in HepG2 cell apoptosis induced by quercetin. Quercetin 68-77 BCL2 apoptosis regulator Homo sapiens 27-32 19623560-2 2009 However, the regulation of survivin and Bcl-2 on the quercetin-induced cell-growth inhibition and apoptosis in cancer cells remains unclear. Quercetin 53-62 BCL2 apoptosis regulator Homo sapiens 40-45 19623560-8 2009 These data clearly indicate that quercetin-induced apoptosis is associated with caspase activation, and the levels of survivin and Bcl-2. Quercetin 33-42 BCL2 apoptosis regulator Homo sapiens 131-136 19540934-3 2009 Here we show that H2O2 induced apoptosis in cardiomyocytes with a marked down-regulation of Bcl-2 protein. Hydrogen Peroxide 18-22 BCL2 apoptosis regulator Homo sapiens 92-97 19446247-5 2009 Thiosulfinates down-regulated the expression of the anti-apoptotic protein Bcl-2, and up-regulated the expression of the pro-apoptotic protein Bax. thiosulfinates 0-14 BCL2 apoptosis regulator Homo sapiens 75-80 19555126-0 2009 Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. apogossypol 0-11 BCL2 apoptosis regulator Homo sapiens 66-92 19555126-0 2009 Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. apogossypol 0-11 BCL2 apoptosis regulator Homo sapiens 94-99 19555126-1 2009 Guided by nuclear magnetic resonance (NMR) binding assays and computational docking studies, a series of 5,5" substituted apogossypol derivatives was synthesized that resulted in potent pan-active inhibitors of antiapoptotic Bcl-2 family proteins. apogossypol 122-133 BCL2 apoptosis regulator Homo sapiens 225-230 19555126-2 2009 Compound 8r inhibits the binding of BH3 peptides to Bcl-X(L), Bcl-2, Mcl-1, and Bfl-1 with IC(50) values of 0.76, 0.32, 0.28, and 0.73 microM, respectively. BH 3 36-39 BCL2 apoptosis regulator Homo sapiens 62-67 19719971-12 2009 Furthermore, 3-BrPA stimulation decreased the expressions of Bcl-2, c-Myc and mutant p53, which were strongly associated with the programmed cell death signal transduction pathway. bromopyruvate 13-19 BCL2 apoptosis regulator Homo sapiens 61-66 19719971-13 2009 CONCLUSION: 3-BrPA inhibits proliferation, induces S phase and G2/M phase arrest, and promotes apoptosis in MCF-7 cells, which processes might be mediated by the downregulation of the expressions of Bcl-2, c-Myc and mutant p53. bromopyruvate 12-18 BCL2 apoptosis regulator Homo sapiens 199-204 19393315-6 2009 Genistein and daidzein upregulated the estrogen receptor ERbeta and increased Bcl-2 expression. Genistein 0-9 BCL2 apoptosis regulator Homo sapiens 78-83 19393315-6 2009 Genistein and daidzein upregulated the estrogen receptor ERbeta and increased Bcl-2 expression. daidzein 14-22 BCL2 apoptosis regulator Homo sapiens 78-83 19393315-7 2009 Silencing of Bcl-2 with siRNA abolished the protection of genistein. Genistein 58-67 BCL2 apoptosis regulator Homo sapiens 13-18 19393315-9 2009 We conclude that oxidative stress-induced apoptosis and cell proliferation inhibition can be prevented by soy isoflavones via the regulation of ERbeta and Bcl-2/Bax expression and modulation of cell survival signaling, such as the PI3K pathway. Isoflavones 110-121 BCL2 apoptosis regulator Homo sapiens 155-160 19422808-0 2009 Demethoxycurcumin induces Bcl-2 mediated G2/M arrest and apoptosis in human glioma U87 cells. demethoxycurcumin 0-17 BCL2 apoptosis regulator Homo sapiens 26-31 19422808-1 2009 Docking analysis of curcumin (C1), demethoxycurcumin (C2) and bisdemethoxycurcumin (C3) with Bcl-2 illustrated that among the three curcuminoids, C2 binds more efficiently into its putative active site. Curcumin 20-28 BCL2 apoptosis regulator Homo sapiens 93-98 19422808-1 2009 Docking analysis of curcumin (C1), demethoxycurcumin (C2) and bisdemethoxycurcumin (C3) with Bcl-2 illustrated that among the three curcuminoids, C2 binds more efficiently into its putative active site. demethoxycurcumin 35-52 BCL2 apoptosis regulator Homo sapiens 93-98 19422808-1 2009 Docking analysis of curcumin (C1), demethoxycurcumin (C2) and bisdemethoxycurcumin (C3) with Bcl-2 illustrated that among the three curcuminoids, C2 binds more efficiently into its putative active site. A(2)C 54-56 BCL2 apoptosis regulator Homo sapiens 93-98 19422808-1 2009 Docking analysis of curcumin (C1), demethoxycurcumin (C2) and bisdemethoxycurcumin (C3) with Bcl-2 illustrated that among the three curcuminoids, C2 binds more efficiently into its putative active site. bisdemethoxycurcumin 62-82 BCL2 apoptosis regulator Homo sapiens 93-98 19422808-1 2009 Docking analysis of curcumin (C1), demethoxycurcumin (C2) and bisdemethoxycurcumin (C3) with Bcl-2 illustrated that among the three curcuminoids, C2 binds more efficiently into its putative active site. curcuminoids 132-144 BCL2 apoptosis regulator Homo sapiens 93-98 19422808-3 2009 Human glioma U87 cells treated with curcuminoids resulted in activation of Bcl-2 mediated G2 checkpoint, which was associated with the induction of G2/M arrest and apoptosis. curcuminoids 36-48 BCL2 apoptosis regulator Homo sapiens 75-80 19097992-7 2009 ABT-737, a small molecule that inhibits Bcl-2, but not Mcl-1, abolished the multicellular resistance of A549 spheroids to bortezomib plus TRAIL. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 40-45 19097992-7 2009 ABT-737, a small molecule that inhibits Bcl-2, but not Mcl-1, abolished the multicellular resistance of A549 spheroids to bortezomib plus TRAIL. Bortezomib 122-132 BCL2 apoptosis regulator Homo sapiens 40-45 19097992-10 2009 Our study suggests that the balance of Bcl-2 family proteins contributes to the acquired multicellular resistance of spheroids, and suggests a possible target for improving the response of lung cancer to bortezomib therapies. Bortezomib 204-214 BCL2 apoptosis regulator Homo sapiens 39-44 19447220-3 2009 Here we show that P-glycoprotein (P-gp) mediates cell-cycle arrest and autophagy induced by celecoxib in human MDR overexpressing hepatocellular carcinoma cell line by down-regulation of the HGF/MET autocrine loop and Bcl-2 expression. Celecoxib 92-101 BCL2 apoptosis regulator Homo sapiens 218-223 19447221-0 2009 Bcl-2 blocks 2-methoxyestradiol induced leukemia cell apoptosis by a p27(Kip1)-dependent G1/S cell cycle arrest in conjunction with NF-kappaB activation. 2-Methoxyestradiol 13-31 BCL2 apoptosis regulator Homo sapiens 0-5 19447221-1 2009 2-Methoxyestradiol (2-ME2) induces leukemia cells to undergo apoptosis in association with Bcl-2 inactivation but the mechanisms whereby Bcl-2 contributes to protection against programmed cell death in this context remain unclear. 2-Methoxyestradiol 0-18 BCL2 apoptosis regulator Homo sapiens 91-96 19447221-1 2009 2-Methoxyestradiol (2-ME2) induces leukemia cells to undergo apoptosis in association with Bcl-2 inactivation but the mechanisms whereby Bcl-2 contributes to protection against programmed cell death in this context remain unclear. 2-Methoxyestradiol 0-18 BCL2 apoptosis regulator Homo sapiens 137-142 19325567-2 2009 Through interactions with members of the Bcl-2 family of proteins, it drives calcium (Ca(2+)) transients from the endoplasmic reticulum (ER) to mitochondria, thereby establishing a functional and physical link between these organelles. Calcium 77-84 BCL2 apoptosis regulator Homo sapiens 41-46 19325567-4 2009 Here, we show that the IP(3)R antagonist xestospongin B induces autophagy by disrupting a molecular complex formed by the IP(3)R and Beclin 1, an interaction that is increased or inhibited by overexpression or knockdown of Bcl-2, respectively. xestospongin B 41-55 BCL2 apoptosis regulator Homo sapiens 223-228 19721888-2 2009 In a recent study, we found that GRs form a complex with B-cell lymphoma 2 (Bcl-2), trans- locate to mitochondria in response to corticosterone (CORT), and modulate mitochondrial calcium and oxidation in an inverted U-shaped manner. Corticosterone 129-143 BCL2 apoptosis regulator Homo sapiens 76-81 19721888-2 2009 In a recent study, we found that GRs form a complex with B-cell lymphoma 2 (Bcl-2), trans- locate to mitochondria in response to corticosterone (CORT), and modulate mitochondrial calcium and oxidation in an inverted U-shaped manner. Corticosterone 145-149 BCL2 apoptosis regulator Homo sapiens 57-74 19623560-10 2009 Together, concurrent down-regulated survivin and Bcl-2 play an important role in HepG2 cell apoptosis induced by quercetin. Quercetin 113-122 BCL2 apoptosis regulator Homo sapiens 49-54 19390557-4 2009 Our data show that only ABT-737 is a specific BCL2 inhibitor and all other compounds investigated were not specific for BCL2 proteins. ABT-737 24-31 BCL2 apoptosis regulator Homo sapiens 46-50 19721888-2 2009 In a recent study, we found that GRs form a complex with B-cell lymphoma 2 (Bcl-2), trans- locate to mitochondria in response to corticosterone (CORT), and modulate mitochondrial calcium and oxidation in an inverted U-shaped manner. Corticosterone 145-149 BCL2 apoptosis regulator Homo sapiens 76-81 19721888-2 2009 In a recent study, we found that GRs form a complex with B-cell lymphoma 2 (Bcl-2), trans- locate to mitochondria in response to corticosterone (CORT), and modulate mitochondrial calcium and oxidation in an inverted U-shaped manner. Calcium 179-186 BCL2 apoptosis regulator Homo sapiens 76-81 18923901-5 2009 Simultaneously, celecoxib resulted in significant reduction of Bcl-2 and significant increase of p21(WAF1) and p27(KIP1) in SAC and NC cells. Celecoxib 16-25 BCL2 apoptosis regulator Homo sapiens 63-68 18923901-6 2009 The present study shows that celecoxib causes growth inhibition of gastric carcinoma cells by decreasing Bcl-2 of cyclooxygenase-2-dependent pathway, and by increasing p21(WAF1) and p27(KIP1) of cyclooxygenase-2-independent pathway. Celecoxib 29-38 BCL2 apoptosis regulator Homo sapiens 105-110 19557638-0 2009 Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 162-165 BCL2 apoptosis regulator Homo sapiens 14-19 19403302-1 2009 BACKGROUND: Expression of the pro-apoptotic BCL-2-interacting mediator (BIM) has recently been implicated in imatinib-induced apoptosis of BCR-ABL1(+) cells. Imatinib Mesylate 109-117 BCL2 apoptosis regulator Homo sapiens 44-49 19331832-8 2009 Corroborating the results on mitochondria, Bcl-xL/Bcl-2 inhibitors induced DeltaPsim loss, ATP depletion and necrosis in pancreatic acinar cells, both untreated and hyperstimulated with CCK-8 (in vitro pancreatitis model). Adenosine Triphosphate 91-94 BCL2 apoptosis regulator Homo sapiens 50-55 19149911-7 2009 Furthermore, these agents prevented the Meth-induced reduction of mitochondrial cytochrome c, the mitochondrial anti-apoptotic Bcl-2/Bax ratio, and mitochondrial cytochrome oxidase (COX) activity. Methamphetamine 40-44 BCL2 apoptosis regulator Homo sapiens 127-132 19149911-9 2009 One of the genes, Bcl-2, is a common target for lithium and VPA. Lithium 48-55 BCL2 apoptosis regulator Homo sapiens 18-23 19149911-10 2009 Knock-down of Bcl-2 with specific Bcl-2 siRNA reduced the lithium- and VPA-induced increases in mitochondrial oxidation. Lithium 58-65 BCL2 apoptosis regulator Homo sapiens 14-19 19149911-10 2009 Knock-down of Bcl-2 with specific Bcl-2 siRNA reduced the lithium- and VPA-induced increases in mitochondrial oxidation. Lithium 58-65 BCL2 apoptosis regulator Homo sapiens 34-39 19149911-10 2009 Knock-down of Bcl-2 with specific Bcl-2 siRNA reduced the lithium- and VPA-induced increases in mitochondrial oxidation. Valproic Acid 71-74 BCL2 apoptosis regulator Homo sapiens 14-19 19149911-10 2009 Knock-down of Bcl-2 with specific Bcl-2 siRNA reduced the lithium- and VPA-induced increases in mitochondrial oxidation. Valproic Acid 71-74 BCL2 apoptosis regulator Homo sapiens 34-39 21783988-0 2009 Reactive oxygen species production and Bax/Bcl-2 regulation in honokiol-induced apoptosis in human hepatocellular carcinoma SMMC-7721 cells. honokiol 63-71 BCL2 apoptosis regulator Homo sapiens 43-48 21783988-6 2009 Up-regulation of Bax and down-regulation of Bcl-2 were observed, suggesting that honokiol-induced apoptosis was associated with reactive oxygen species (ROS) production and an increase of Bax/Bcl-2 ratios. honokiol 81-89 BCL2 apoptosis regulator Homo sapiens 44-49 21783988-6 2009 Up-regulation of Bax and down-regulation of Bcl-2 were observed, suggesting that honokiol-induced apoptosis was associated with reactive oxygen species (ROS) production and an increase of Bax/Bcl-2 ratios. honokiol 81-89 BCL2 apoptosis regulator Homo sapiens 192-197 19557638-0 2009 Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 162-165 BCL2 apoptosis regulator Homo sapiens 137-142 19557638-4 2009 ABT-737 is a small molecule that inhibits the Bcl-2 family of apoptosis regulators. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 46-51 19428819-7 2009 Glu+AA applied together had a synergistic effect on the levels of Caspase-3 gene expression, and Bcl-2 and Hsp70 protein. Glutamic Acid 0-3 BCL2 apoptosis regulator Homo sapiens 97-102 19169818-3 2009 The present study tests the hypothesis that cerebral hyperoxia will result in increased serine phosphorylation of apoptotic proteins Bcl-2, Bcl-xl, Bax, and Bad in the mitochondrial membranes of the cerebral cortex of newborn piglets. Serine 88-94 BCL2 apoptosis regulator Homo sapiens 133-138 19169818-12 2009 The data show that there is a significant increase in serine phosphorylation of Bcl-2 and Bcl-xl proteins while phosphorylation of Bad and Bax proteins were not altered during hyperoxia in the mitochondrial fraction of the cerebral cortex of newborn piglets. Serine 54-60 BCL2 apoptosis regulator Homo sapiens 80-85 19494271-0 2009 The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity. ABT-737 28-35 BCL2 apoptosis regulator Homo sapiens 4-9 19513519-5 2009 Consistent with these results, the protein levels of Bax and phospho-Bcl-2 increased and those of Bcl-2 and XIAP decreased in cells treated with beta-elemene in combination with cisplatin, compared with the levels in cells treated with either agent alone. beta-elemene 145-157 BCL2 apoptosis regulator Homo sapiens 69-74 19513519-5 2009 Consistent with these results, the protein levels of Bax and phospho-Bcl-2 increased and those of Bcl-2 and XIAP decreased in cells treated with beta-elemene in combination with cisplatin, compared with the levels in cells treated with either agent alone. beta-elemene 145-157 BCL2 apoptosis regulator Homo sapiens 98-103 19513519-5 2009 Consistent with these results, the protein levels of Bax and phospho-Bcl-2 increased and those of Bcl-2 and XIAP decreased in cells treated with beta-elemene in combination with cisplatin, compared with the levels in cells treated with either agent alone. Cisplatin 178-187 BCL2 apoptosis regulator Homo sapiens 69-74 19513519-5 2009 Consistent with these results, the protein levels of Bax and phospho-Bcl-2 increased and those of Bcl-2 and XIAP decreased in cells treated with beta-elemene in combination with cisplatin, compared with the levels in cells treated with either agent alone. Cisplatin 178-187 BCL2 apoptosis regulator Homo sapiens 98-103 19957812-9 2009 Western blot assay indicated that dihydroartemisinin up-regulates expression of proliferation-associated protein p21(WAF1) and down-regulates expression of PCNA, increases expression of apoptosis-associated protein Bax and decreases expression of Bcl-2 and activates caspase-9 in BxPC-3 cells. artenimol 34-52 BCL2 apoptosis regulator Homo sapiens 247-252 19441815-7 2009 The A549 and CH27 cell lines treated with resveratrol, MR-3, and HMDB showed a time-dependent reduction of mitochondrial membrane potential, and the Bax/Bcl-2 ratio increased gradually with a higher concentration of polyphenols. Resveratrol 42-53 BCL2 apoptosis regulator Homo sapiens 153-158 19441815-7 2009 The A549 and CH27 cell lines treated with resveratrol, MR-3, and HMDB showed a time-dependent reduction of mitochondrial membrane potential, and the Bax/Bcl-2 ratio increased gradually with a higher concentration of polyphenols. Polyphenols 216-227 BCL2 apoptosis regulator Homo sapiens 153-158 19456133-5 2009 Cells treated with different concentrations of beta-sitosterol also showed changes typical of apoptosis: morphological changes, DNA damage, increased expression of pro-caspase-3 and bax (p < 0.05), and activation of pro-caspase-3 and suppression of bcl-2 expression (p < 0.05). gamma-sitosterol 47-62 BCL2 apoptosis regulator Homo sapiens 252-257 19456133-7 2009 The decrease of the bcl-2/bax ratio and DNA damage may be the critical mechanisms of apoptosis induced by beta-sitosterol in SGC-7901 human stomach cancer cells. gamma-sitosterol 106-121 BCL2 apoptosis regulator Homo sapiens 20-25 19513519-7 2009 These observations suggest that beta-elemene sensitizes NSCLC cells to cisplatin via a mitochondria-mediated intrinsic apoptosis pathway involving Bcl-2 family proteins and IAPs (inhibitor of apoptosis proteins). beta-elemene 32-44 BCL2 apoptosis regulator Homo sapiens 147-152 19689068-5 2009 CONCLUSION: The results suggested that DON could induce apoptosis of SGC-7901, BGC-823 cells in vitro in a dose-dependent manner, and possible mechanisms may be increased formation of Bax-Bax homology dimer and decreased formationof Bax-Bcl-2 dimer by up-regulation of the expression of Bax and down-regulation of that Bcl-2. deoxynivalenol 39-42 BCL2 apoptosis regulator Homo sapiens 237-242 19689068-5 2009 CONCLUSION: The results suggested that DON could induce apoptosis of SGC-7901, BGC-823 cells in vitro in a dose-dependent manner, and possible mechanisms may be increased formation of Bax-Bax homology dimer and decreased formationof Bax-Bcl-2 dimer by up-regulation of the expression of Bax and down-regulation of that Bcl-2. deoxynivalenol 39-42 BCL2 apoptosis regulator Homo sapiens 319-324 19494271-2 2009 ABT-737, which was originally developed for oncology, is a potent inhibitor of Bcl-2, Bcl-x(L), and Bcl-w protein function. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 79-84 19494271-6 2009 Bcl-2 family antagonism by ABT-737 was efficacious in treating animal models of arthritis and lupus. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 27-30 BCL2 apoptosis regulator Homo sapiens 0-5 19056433-0 2009 Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor. sapropterin 48-51 BCL2 apoptosis regulator Homo sapiens 10-15 19056433-9 2009 This review summarizes what is currently known about the BH4 domain of Bcl-2, its interaction with the IP3R and other proteins, and the part it plays in Bcl-2"s anti-apoptotic function. sapropterin 57-60 BCL2 apoptosis regulator Homo sapiens 71-76 19508737-12 2009 CONCLUSION: The data suggest that eurycomanone was cytotoxic on HepG2 cells by inducing apoptosis through the up-regulation of p53 and Bax, and down-regulation of Bcl-2. eurycomanone 34-46 BCL2 apoptosis regulator Homo sapiens 163-168 19412666-9 2009 In combination with the drugs targeted to cytoskeleton (taxol, cytochalasin D) the mutants of TRAIL induced apoptosis in resistant Hela cells overexpressing Bcl-2. Paclitaxel 56-61 BCL2 apoptosis regulator Homo sapiens 157-162 19056433-5 2009 This function is mediated through interaction of the Bcl-2 BH4 domain with the inositol 1,4,5-trisphosphate receptor (IP3R) Ca2+ channel. sapropterin 59-62 BCL2 apoptosis regulator Homo sapiens 53-58 19194797-5 2009 Concurrently, PMS777 increased ratio of bcl-2 to bax mRNA, and inhibited both mRNA expression and activity of caspase-3 in SH-SY5Y cells after the exposure with Abeta. PMS 777 14-20 BCL2 apoptosis regulator Homo sapiens 40-45 19172392-7 2009 Analysis of Bcl-2/Bax ratio as "survival index" showed that both pretreatment of gammaT3 and alphaT followed by H(2)O(2) increase the "survival index" of Bcl-2/Bax ratio compared to H(2)O(2)-treated cells, while treatment of gammaT3 alone decrease the ratio compared to unchanged Bcl2/Bax ratio of similar treatment with alphaT alone. alpha-Tocopherol 93-99 BCL2 apoptosis regulator Homo sapiens 12-17 19172392-7 2009 Analysis of Bcl-2/Bax ratio as "survival index" showed that both pretreatment of gammaT3 and alphaT followed by H(2)O(2) increase the "survival index" of Bcl-2/Bax ratio compared to H(2)O(2)-treated cells, while treatment of gammaT3 alone decrease the ratio compared to unchanged Bcl2/Bax ratio of similar treatment with alphaT alone. alpha-Tocopherol 93-99 BCL2 apoptosis regulator Homo sapiens 154-159 19153211-7 2009 BCl2 antagonists, such as HA-14-1, enhanced the effects of azacitidine in these two prostate cancer models. ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate 26-33 BCL2 apoptosis regulator Homo sapiens 0-4 19172392-7 2009 Analysis of Bcl-2/Bax ratio as "survival index" showed that both pretreatment of gammaT3 and alphaT followed by H(2)O(2) increase the "survival index" of Bcl-2/Bax ratio compared to H(2)O(2)-treated cells, while treatment of gammaT3 alone decrease the ratio compared to unchanged Bcl2/Bax ratio of similar treatment with alphaT alone. alpha-Tocopherol 93-99 BCL2 apoptosis regulator Homo sapiens 280-284 19048182-6 2009 Exposure to 15 mmHg CO(2) pneumoperitoneum significantly enhanced the expression levels of HIF-1alpha and Bax, while it attenuated Bcl-2 expression levels. Carbon Dioxide 20-25 BCL2 apoptosis regulator Homo sapiens 131-136 19483343-2 2009 Other research revealed that licochalcone E modulats the nuclear factor (NF)-kB and Bcl-2 families to induce endothelial cell apoptosis. licochalcone 29-41 BCL2 apoptosis regulator Homo sapiens 84-89 19513945-0 2009 Small-molecule BH3 mimetics to antagonize Bcl-2-homolog survival functions in cancer. BH 3 15-18 BCL2 apoptosis regulator Homo sapiens 42-47 19153211-7 2009 BCl2 antagonists, such as HA-14-1, enhanced the effects of azacitidine in these two prostate cancer models. Azacitidine 59-70 BCL2 apoptosis regulator Homo sapiens 0-4 19482643-5 2009 The ability of Bcl-2 to promote, modulate and optimize mitochondrial respiration under different redox states highlights the importance of mitochondrial bioenergetics, ROS and the roles they might play in the onset and/or maintenance of oncogenesis. ros 168-171 BCL2 apoptosis regulator Homo sapiens 15-20 18996626-4 2009 Moreover, in this paper the cellular growth inhibitor 39-hydroxy-6-methoxy-gambogic acid methyl ester (10) was identified as a HepG2 cell apoptosis inhibitor through Annexin-V/PI double staining assay and the expression of the related apoptotic proteins (Bax and Bcl-2). 39-hydroxy-6-methoxy-gambogic acid methyl ester 54-101 BCL2 apoptosis regulator Homo sapiens 263-268 19550397-4 2009 Besides, it was shown that antiapoptotic mechanisms (decrease of Bcl-2 expression) and intracellular glutathione detoxifying system are involved in the process of cisplatin resistance development in MCF-7 cells. Cisplatin 163-172 BCL2 apoptosis regulator Homo sapiens 65-70 18719855-5 2009 A decrease in Bcl-2/Bax ratio with increased expression of Apaf-1 and caspase-3, and cleavage of poly(ADP-ribose) polymerase provide compelling evidence that nimbolide-induced apoptosis is mediated by the mitochondrial pathway. nimbolide 158-167 BCL2 apoptosis regulator Homo sapiens 14-19 19207580-6 2009 Subsequent addition of 15 microM resveratrol (LD(50) = 23.2 microM) significantly (P < 0.05) upregulated further these genes (alpha-SMA x 6.5; TGF-beta1 x 1.9; TIMP-1 x 2.2; CD95/Fas x 13.1, TNFR-1 x 2.1; Bcl-2 x 3.6; Mcl-1 x 1.9). Resveratrol 33-44 BCL2 apoptosis regulator Homo sapiens 208-213 19291371-7 2009 RESULTS: In vitro, Tf-LP-G3139 was more effective in inducing down regulation of Bcl-2 in K562 cells than non-targeted LP-G3139, free G3139 and mismatched control ODN-G4126 in the same formulation. leucylproline 22-24 BCL2 apoptosis regulator Homo sapiens 81-86 19543489-3 2009 RESULTS: Cilostazol protected HUVECs against LPS-induced apoptosis by suppressing the mitochondrial permeability transition, cytosolic release of cytochrome c, and subsequent activation of caspases, stimulating extracellullar signal-regulated kinase (ERK1/2) and p38 MAPK signaling, and increasing phosphorylated cAMP-responsive element-binding protein (CREB) and Bcl-2 expression, while suppressing Bax expression. Cilostazol 9-19 BCL2 apoptosis regulator Homo sapiens 364-369 19543489-6 2009 Activation of ERK1/2 and p38 MAPKs, and subsequent stimulation of CREB phosphorylation and Bcl-2 expression, may be responsible for the cellular signaling mechanism of cilostazol-mediated protection. Cilostazol 168-178 BCL2 apoptosis regulator Homo sapiens 91-96 19683213-11 2009 CONCLUSIONS: mTHPC-mediated photo-cytotoxicity can effectively induce early apoptotic responses in NPC/HK1 cells which might be modulated by mitochondrial damages and Bcl-2 inhibition. temoporfin 13-18 BCL2 apoptosis regulator Homo sapiens 167-172 19270084-9 2009 Metabolism of the glucose was required for the emulsion-stimulated survival as well as the increase of prosurvival Bcl-2 transcript levels and maintenance of Bcl-2 protein expression. Glucose 18-25 BCL2 apoptosis regulator Homo sapiens 115-120 19270084-9 2009 Metabolism of the glucose was required for the emulsion-stimulated survival as well as the increase of prosurvival Bcl-2 transcript levels and maintenance of Bcl-2 protein expression. Glucose 18-25 BCL2 apoptosis regulator Homo sapiens 158-163 19476546-9 2009 Furthermore, 6-OHDA-induced up-regulation of Bax and down-regulation of Bcl-2 mRNA and protein expression could be restored by Rg1 pre-treatment. Oxidopamine 13-19 BCL2 apoptosis regulator Homo sapiens 72-77 19429240-6 2009 Kahweol considerably inhibited the expression of Bcl-2 but increased that of Bax; it also stimulated the cleavage of caspase-3 and PARP (poly ADP-ribose polymerase). kahweol 0-7 BCL2 apoptosis regulator Homo sapiens 49-54 19771878-7 2009 CONCLUSION: Oxymatrine could notably inhibit the HepG2 cells proliferation probably via upregulating the expression of the Bax and downregulating the expression of Bcl-2 and P53. oxymatrine 12-22 BCL2 apoptosis regulator Homo sapiens 164-169 19347031-3 2009 We targeted Bcl-2 to mitochondria or endoplasmic reticulum (ER) and induced apoptosis using several apoptotic stimuli that initiate ER and/or mitochondrial signaling pathways (UV radiation, TNF and cycloheximide, staurosporine, thapsigargin and tunicamycin). Thapsigargin 228-240 BCL2 apoptosis regulator Homo sapiens 12-17 19347031-3 2009 We targeted Bcl-2 to mitochondria or endoplasmic reticulum (ER) and induced apoptosis using several apoptotic stimuli that initiate ER and/or mitochondrial signaling pathways (UV radiation, TNF and cycloheximide, staurosporine, thapsigargin and tunicamycin). Tunicamycin 245-256 BCL2 apoptosis regulator Homo sapiens 12-17 18952228-8 2009 CONCLUSIONS: Postoperative vitamin C treatment of septic abdominal surgery patients exerts an antiapoptotic effect on peripheral blood neutrophils, reducing caspase-3 and PARP levels, and increasing Bcl-2 levels. Ascorbic Acid 27-36 BCL2 apoptosis regulator Homo sapiens 199-204 19445670-5 2009 siRNA knockdown as well as pharmacologic inhibitors of cell survival proteins (Bcl-2, Bcl-xL and XIAP) enhanced apoptosis of chemoresistant chondrosarcoma cells by up to 5.5 fold at 0.1 micromol and 5.5 fold at 1 micromol doxorubicin. Doxorubicin 222-233 BCL2 apoptosis regulator Homo sapiens 79-84 19135778-6 2009 Apoptosis caused by honokiol was also concomitant with the cleavage of caspases (caspase-3, -8, and -9) and Bid along with the suppressive expression of Bcl-2, but it was independent on the expression of Bax and p53. honokiol 20-28 BCL2 apoptosis regulator Homo sapiens 153-158 19070610-10 2009 Apicidin-induced apoptosis through caspase-3 activation was confirmed by the increase in the release of cytochrome c and the decrease in the Bax/Bcl-2 ratio. apicidin 0-8 BCL2 apoptosis regulator Homo sapiens 145-150 19304943-4 2009 Therefore, these experiments tested the hypothesis that APC-induced ROS results in activation of NF-kappaB before I/R, with consequent increased expression of antiapoptotic proteins such as Bcl-2 and decreased apoptosis. Reactive Oxygen Species 68-71 BCL2 apoptosis regulator Homo sapiens 190-195 19201925-12 2009 In CF cells, SERCA2 interacted with Bcl-2, leading to its displacement from caveolae-related domains of endoplasmic reticulum membranes, as demonstrated in sucrose density gradient centrifugation and immunoprecipitation studies. Sucrose 156-163 BCL2 apoptosis regulator Homo sapiens 36-41 19234140-6 2009 Consistent with the intrinsic turnover rates of their transcripts and proteins, antiapoptotic proteins, such as Mcl-1 and X-linked inhibitor of apoptosis protein (XIAP), were rapidly reduced on exposure to SNS-032, whereas Bcl-2 protein was not affected. N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide 206-213 BCL2 apoptosis regulator Homo sapiens 223-228 19264955-6 2009 Fisetin induced a reduction in the protein levels of antiapoptotic Bcl-xL and Bcl-2 and an increase in the levels of proapoptotic Bak and Bim. fisetin 0-7 BCL2 apoptosis regulator Homo sapiens 78-83 19329314-0 2009 Diversity-oriented synthesis of a cytisine-inspired pyridone library leading to the discovery of novel inhibitors of Bcl-2. cytisine 34-42 BCL2 apoptosis regulator Homo sapiens 117-122 19442044-6 2009 Thereby, the cyclooxygenase-2/prostaglandin E(2)-dependent production of pro-angiogenic vascular endothelial growth factor and levels of anti-apoptotic bcl-2 and bcl-X(L) are decreased. Dinoprostone 30-48 BCL2 apoptosis regulator Homo sapiens 152-157 19337026-2 2009 Like amino acid starvation, ceramide triggers autophagy by interfering with the mTOR-signaling pathway, and by dissociating the Beclin 1:Bcl-2 complex in a c-Jun N-terminal kinase 1 (JNK1)-mediated Bcl-2 phosphorylation-dependent manner. Ceramides 28-36 BCL2 apoptosis regulator Homo sapiens 137-142 19337026-2 2009 Like amino acid starvation, ceramide triggers autophagy by interfering with the mTOR-signaling pathway, and by dissociating the Beclin 1:Bcl-2 complex in a c-Jun N-terminal kinase 1 (JNK1)-mediated Bcl-2 phosphorylation-dependent manner. Ceramides 28-36 BCL2 apoptosis regulator Homo sapiens 198-203 19337026-3 2009 Dissociation of the Beclin 1:Bcl-2 complex, and the subsequent stimulation of autophagy have been observed in various contexts in which the cellular level of long-chain ceramides was increased. Ceramides 169-178 BCL2 apoptosis regulator Homo sapiens 29-34 19337026-5 2009 The dissociation of the Beclin 1:Bcl-2 complex has also been observed in response to tamoxifen and PDMP (an inhibitor of the enzyme that converts ceramide to glucosylceramide), drugs that increase the intracellular level of long-chain ceramides. Tamoxifen 85-94 BCL2 apoptosis regulator Homo sapiens 33-38 19337026-5 2009 The dissociation of the Beclin 1:Bcl-2 complex has also been observed in response to tamoxifen and PDMP (an inhibitor of the enzyme that converts ceramide to glucosylceramide), drugs that increase the intracellular level of long-chain ceramides. RV 538 99-103 BCL2 apoptosis regulator Homo sapiens 33-38 19337026-5 2009 The dissociation of the Beclin 1:Bcl-2 complex has also been observed in response to tamoxifen and PDMP (an inhibitor of the enzyme that converts ceramide to glucosylceramide), drugs that increase the intracellular level of long-chain ceramides. Ceramides 146-154 BCL2 apoptosis regulator Homo sapiens 33-38 19337026-5 2009 The dissociation of the Beclin 1:Bcl-2 complex has also been observed in response to tamoxifen and PDMP (an inhibitor of the enzyme that converts ceramide to glucosylceramide), drugs that increase the intracellular level of long-chain ceramides. Glucosylceramides 158-174 BCL2 apoptosis regulator Homo sapiens 33-38 19337026-5 2009 The dissociation of the Beclin 1:Bcl-2 complex has also been observed in response to tamoxifen and PDMP (an inhibitor of the enzyme that converts ceramide to glucosylceramide), drugs that increase the intracellular level of long-chain ceramides. Ceramides 235-244 BCL2 apoptosis regulator Homo sapiens 33-38 19337026-7 2009 Whether this autophagy that is unchecked by forced dissociation of the Beclin 1:Bcl-2 complex is related to the ability of ceramide to trigger cell death remains an open question. Ceramides 123-131 BCL2 apoptosis regulator Homo sapiens 80-85 19211028-5 2009 Its inhibition of serum-starvation- or staurosporine-induced apoptosis was reflected by less apoptotic cells, reduced BAX expression and increased levels of Bcl-2 and Bcl-X. Staurosporine 39-52 BCL2 apoptosis regulator Homo sapiens 157-162 19424057-7 2009 Bcl-2 mRNA was reduced in all hippocampal regions by stress, an effect independent of DMI treatment. Desipramine 86-89 BCL2 apoptosis regulator Homo sapiens 0-5 19424057-8 2009 However, immunoblot from hippocampal extracts revealed that stress increased BCL-2 levels, an effect prevented by chronic DMI. Desipramine 122-125 BCL2 apoptosis regulator Homo sapiens 77-82 19329314-0 2009 Diversity-oriented synthesis of a cytisine-inspired pyridone library leading to the discovery of novel inhibitors of Bcl-2. Pyridones 52-60 BCL2 apoptosis regulator Homo sapiens 117-122 19329314-3 2009 Solid-phase diversification of the pyridone scaffolds yielded a diverse library of 15,000 compounds enabling the discovery of a novel class of Bcl-2 inhibitors. Pyridones 35-43 BCL2 apoptosis regulator Homo sapiens 143-148 19270531-0 2009 Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Bortezomib 48-58 BCL2 apoptosis regulator Homo sapiens 0-5 19366825-1 2009 PURPOSE: AT-101 binds and inhibits the antiapoptotic function of Bcl-2, Bcl-xL, Mcl-1, and Bcl-w and is a potent stimulator of proapoptotic proteins. Astatine 9-11 BCL2 apoptosis regulator Homo sapiens 65-70 19270531-8 2009 Collectively these findings indicate that small molecule Bcl-2 antagonists promote bortezomib-mediated mitochondrial injury and lethality in DLBCL cells in association with enhanced JNK activation and ER stress induction. Bortezomib 83-93 BCL2 apoptosis regulator Homo sapiens 57-62 19141121-8 2009 When Bcl-2 related survival was analyzed in the GC- and non-GC subgroups, a significant prognostic effect of Bcl-2 on FFS was seen only in the non-GC group of patients (positive 65% vs. negative 100%, P = 0.011). CHEMBL1198227 118-121 BCL2 apoptosis regulator Homo sapiens 109-114 19383915-7 2009 In these prostate cancer cells, reducing eIF4E expression with an eIF4E-specific antisense oligonucleotide currently in phase I clinical trials robustly induces apoptosis, regardless of cell cycle phase, and reduces expression of the eIF4E-regulated proteins BCL-2 and c-myc. Oligonucleotides 91-106 BCL2 apoptosis regulator Homo sapiens 259-264 19196496-9 2009 Moreover, cells treated with aripirazole effectively increased the levels of GSK-3beta phosphorylation and Bcl-2 at doses of five and 10 microM (30% and 58% and 31% and 80%, respectively, p<0.05 or p<0.01). aripirazole 29-40 BCL2 apoptosis regulator Homo sapiens 107-112 19206150-9 2009 SP600125-induced polyploidy could be blocked by the BCL-2 inhibitor YC137. pyrazolanthrone 0-8 BCL2 apoptosis regulator Homo sapiens 52-57 19372481-8 2009 RESULTS: (18)F-FBnTP cellular uptake in viable cells declined linearly with the increasing duration of paclitaxel treatment, from 3 to 24 h, and plateaued at 48 h. The extent of decrease of (18)F-FBnTP correlated strongly with the Bax-to-Bcl-2 ratio (R(2) = 0.83) and release of cytochrome c (R(2) = 0.92), but preceded in time the caspase-3 cleavage. Paclitaxel 103-113 BCL2 apoptosis regulator Homo sapiens 238-243 19360359-0 2009 Se-methylselenocysteine sensitized TRAIL-mediated apoptosis via down-regulation of Bcl-2 expression. selenomethylselenocysteine 0-23 BCL2 apoptosis regulator Homo sapiens 83-88 19206150-9 2009 SP600125-induced polyploidy could be blocked by the BCL-2 inhibitor YC137. YC137 68-73 BCL2 apoptosis regulator Homo sapiens 52-57 19191010-5 2009 Curcumin mediated apoptosis in these cells appears to be due to upregulation of proapoptotic Bax, AIF, release of cytochrome c and down regulation of antiapoptotic Bcl-2, Bcl-XL in HeLa and SiHa. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 164-169 19323979-5 2009 Treatment of HUVEC with ATN-224 caused increased superoxide levels, phospho-ERK signalling, nuclear NRF1 expression, HO-1 expression and induction of the anti-apoptotic proteins P21, BCL2 and BCLXL. tetrathiomolybdate 24-31 BCL2 apoptosis regulator Homo sapiens 183-187 19265712-9 2009 In addition, we document, for the first time, that acetaminophen increases expression of the anti-apoptotic protein Bcl2. Acetaminophen 51-64 BCL2 apoptosis regulator Homo sapiens 116-120 19265712-10 2009 Suppressing Bcl2 with siRNA blocks the pro-survival effect of acetaminophen. Acetaminophen 62-75 BCL2 apoptosis regulator Homo sapiens 12-16 19429088-0 2009 Daidzein overcomes TRAIL-resistance in malignant glioma cells by modulating the expression of the intrinsic apoptotic inhibitor, bcl-2. daidzein 0-8 BCL2 apoptosis regulator Homo sapiens 129-134 19383849-5 2009 DHE induces up-regulation of Bax and Bad, down-regulation of Bcl-2 and Bcl-XL, and nuclear relocation of the mitochondrial factors apoptosis-inducing factor and endonuclease G. We also found that DHE inhibits survival signaling through the Janus tyrosine kinase-signal transducer and activator of transcription-3 signaling by increasing the expression of suppressors of cytokine signaling (SOCS)-1 and SOCS-3. dehydrocostus lactone 0-3 BCL2 apoptosis regulator Homo sapiens 61-66 19385057-7 2009 KAAD-cyclopamine led to an upregulation of death receptor 4 and 5 and down-regulation of bcl-2 and c-FLIP. 3-keto-N-aminoethylaminoethylcaproyldihydrocinnamoyl cyclopamine 0-16 BCL2 apoptosis regulator Homo sapiens 89-94 19429088-7 2009 However, Daidzein down-regulated bcl-2 and over-expression of bcl-2 attenuated apoptosis induced by the combination of Daidzein and TRAIL. daidzein 9-17 BCL2 apoptosis regulator Homo sapiens 33-38 19385057-8 2009 Furthermore, overexpression of both bcl-2 and c-FLIP attenuated KAAD-cyclopamine facilitated TRAIL-mediated apoptosis. 3-keto-N-aminoethylaminoethylcaproyldihydrocinnamoyl cyclopamine 64-80 BCL2 apoptosis regulator Homo sapiens 36-41 19429088-7 2009 However, Daidzein down-regulated bcl-2 and over-expression of bcl-2 attenuated apoptosis induced by the combination of Daidzein and TRAIL. daidzein 9-17 BCL2 apoptosis regulator Homo sapiens 62-67 19429088-7 2009 However, Daidzein down-regulated bcl-2 and over-expression of bcl-2 attenuated apoptosis induced by the combination of Daidzein and TRAIL. daidzein 119-127 BCL2 apoptosis regulator Homo sapiens 62-67 19121919-11 2009 gamma-Tocotrienol-induced apoptosis in HT-29 cells was accompanied by downregulation of Bcl-2, upregulation of Bax, and activation of caspase-3. plastochromanol 8 0-17 BCL2 apoptosis regulator Homo sapiens 88-93 19188481-3 2009 DHE induces up-regulation of Bax and Bak, down-regulation of Bcl-2 and Bcl-XL, and nuclear relocation of the mitochondrial factors apoptosis-inducing factor (AIF) and endonuclease G (Endo G). Dihydroergotamine 0-3 BCL2 apoptosis regulator Homo sapiens 61-66 19121919-13 2009 CONCLUSION: The results indicated that gamma-tocotrienol inhibits cell proliferation and induces apoptosis in HT-29 cells in a time- and dose-dependent manner, and that this process is accompanied by cell-cycle arrest at G(0)/G(1), an increased Bax/Bcl-2 ratio, and activation of caspase-3. plastochromanol 8 39-56 BCL2 apoptosis regulator Homo sapiens 249-254 19264808-8 2009 siRNA knockdown of ER alpha blocked the E(2)-induced increase in Pdcd4, PTEN and Bcl-2. Estradiol 40-44 BCL2 apoptosis regulator Homo sapiens 81-86 18694296-6 2009 Both SAHA and MS-275 induced an arrest in the cell cycle along with the induction of apoptotic pathways as evidenced by flow cytometry, annexin assay, detection of activated caspase 9, and molecular analysis of Bax/Bcl-2 expression. Vorinostat 5-9 BCL2 apoptosis regulator Homo sapiens 215-220 19264808-9 2009 Transfection of MCF-7 cells with antisense (AS) to miR-21 mimicked the E(2)-induced increase in Pdcd4, PTEN and Bcl-2. Estradiol 71-75 BCL2 apoptosis regulator Homo sapiens 112-117 19627004-1 2009 OBJECTIVE: To investigate the apoptotic effect of iodine-125 seeds on gastric cancer cell line MKN45 and its changes, including the changes of cellular morphosis, early apoptotic rate and Bcl-2/Bax expression, and to provide further evidence for the clinical application of iodine-125 seeds on gastric cancer. Iodine-125 50-60 BCL2 apoptosis regulator Homo sapiens 188-193 22009832-8 2009 This curcumin-induced apoptosis in U2OS cells was accompanied by up-regulation of Bax, Bak, and p-Bad and down-regulation of Bcl-2, but no effect on the levels of Bcl-X(L) or Bad proteins was noted. Curcumin 5-13 BCL2 apoptosis regulator Homo sapiens 125-130 18694296-6 2009 Both SAHA and MS-275 induced an arrest in the cell cycle along with the induction of apoptotic pathways as evidenced by flow cytometry, annexin assay, detection of activated caspase 9, and molecular analysis of Bax/Bcl-2 expression. entinostat 14-20 BCL2 apoptosis regulator Homo sapiens 215-220 19426672-0 2009 A novel resveratrol derivative, HS1793, overcomes the resistance conferred by Bcl-2 in human leukemic U937 cells. Resveratrol 8-19 BCL2 apoptosis regulator Homo sapiens 78-83 19074726-8 2009 Cotreatment with the Bcl-2/Bcl-x(L) antagonist ABT-737 decreased resistance and synergistically induced apoptosis of human CTCL cells. ABT-737 47-54 BCL2 apoptosis regulator Homo sapiens 21-26 19412422-2 2009 We describe a strong synergistic proapoptotic effect of the Bcl-2 family inhibitor ABT-737 and the standard antimelanoma drugs, namely, dacarbazine and fotemustine, and the experimental agent, imiquimod. ABT-737 83-90 BCL2 apoptosis regulator Homo sapiens 60-65 19412422-2 2009 We describe a strong synergistic proapoptotic effect of the Bcl-2 family inhibitor ABT-737 and the standard antimelanoma drugs, namely, dacarbazine and fotemustine, and the experimental agent, imiquimod. Dacarbazine 136-147 BCL2 apoptosis regulator Homo sapiens 60-65 19412422-2 2009 We describe a strong synergistic proapoptotic effect of the Bcl-2 family inhibitor ABT-737 and the standard antimelanoma drugs, namely, dacarbazine and fotemustine, and the experimental agent, imiquimod. fotemustine 152-163 BCL2 apoptosis regulator Homo sapiens 60-65 19412422-9 2009 Studies of mitochondrial cytochrome c release using BH3 peptides confirmed that a main effect of dacarbazine, fotemustine, and imiquimod was to neutralize Mcl-1, thereby sensitizing mitochondria to the inhibition of other Bcl-2 family members through ABT-737. Dacarbazine 97-108 BCL2 apoptosis regulator Homo sapiens 222-227 19412422-9 2009 Studies of mitochondrial cytochrome c release using BH3 peptides confirmed that a main effect of dacarbazine, fotemustine, and imiquimod was to neutralize Mcl-1, thereby sensitizing mitochondria to the inhibition of other Bcl-2 family members through ABT-737. fotemustine 110-121 BCL2 apoptosis regulator Homo sapiens 222-227 19008458-1 2009 ABT-737 and its orally active analog, ABT-263, are rationally designed inhibitors of BCL2 and BCL-X(L). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 85-89 19008458-1 2009 ABT-737 and its orally active analog, ABT-263, are rationally designed inhibitors of BCL2 and BCL-X(L). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 38-41 BCL2 apoptosis regulator Homo sapiens 85-89 19008458-8 2009 Our data indicate that after therapy with ABT-737-related inhibitors, resistant CLL cells might develop in lymph nodes in vivo and that treatment strategies targeting multiple BCL2 antiapoptotic members simultaneously may have synergistic activity. ABT-737 42-49 BCL2 apoptosis regulator Homo sapiens 176-180 19379505-18 2009 Activation of Akt and Bcl-2 may play an important role in preventing cytochrome c release from mitochondria to the cytoplasm and may also be important in the carcinogenicity of metallic nickel particles. Nickel 186-192 BCL2 apoptosis regulator Homo sapiens 22-27 19380879-4 2009 Finally, endogenous Puma is involved in the apoptotic response of human colorectal cancer cells to the Bcl-2/Bcl-xL inhibitor ABT-737, even in conditions where the expression of Mcl-1 is down-regulated. ABT-737 126-133 BCL2 apoptosis regulator Homo sapiens 103-108 19351753-2 2009 G3139 is an 18-mer phosphorothioate oligonucleotide targeted to the initiation codon region of the Bcl-2 mRNA. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 99-104 19351753-2 2009 G3139 is an 18-mer phosphorothioate oligonucleotide targeted to the initiation codon region of the Bcl-2 mRNA. Phosphorothioate Oligonucleotides 19-51 BCL2 apoptosis regulator Homo sapiens 99-104 19228691-5 2009 A cyclophilin D inhibitor, cyclosporine A, disrupts the CypD-Bcl2 interaction. Cyclosporine 27-41 BCL2 apoptosis regulator Homo sapiens 61-65 19360919-0 2009 Exogenous phosphatidylethanolamine induces apoptosis of human hepatoma HepG2 cells via the bcl-2/Bax pathway. phosphatidylethanolamine 10-34 BCL2 apoptosis regulator Homo sapiens 91-96 19360919-4 2009 Immunocytochemical assay and Western blotting were used to examine Bcl-2, Bax and caspase-3 protein levels in HepG2 cells treated with PE. phosphatidylethanolamine 135-137 BCL2 apoptosis regulator Homo sapiens 67-72 19360919-11 2009 CONCLUSION: Exogenous PE induces apoptosis of human hepatoma HepG2 cells via the bcl-2/bax pathway. phosphatidylethanolamine 22-24 BCL2 apoptosis regulator Homo sapiens 81-86 19228691-6 2009 CypD enhances the limiting effect of Bcl2 on the tBid-induced release of cytochrome c from mitochondria, which is not mediated via the MPT. tBID 49-53 BCL2 apoptosis regulator Homo sapiens 37-41 19270722-11 2009 Berbamine-treated K562-r cells also exhibited down-regulated expression of the anti-apoptotic proteins Bcl-2 and Bcl-x(L), up-regulated expression of the apoptotic proteins Bax and cytoplasmic cyt C, and stimulated proteolytic cleavage of PARP. berbamine 0-9 BCL2 apoptosis regulator Homo sapiens 103-108 19179333-0 2009 HSF1-mediated BAG3 expression attenuates apoptosis in 4-hydroxynonenal-treated colon cancer cells via stabilization of anti-apoptotic Bcl-2 proteins. 4-hydroxy-2-nonenal 54-70 BCL2 apoptosis regulator Homo sapiens 134-139 19233129-0 2009 Inhibitory heterotrimeric GTP-binding proteins inhibit hydrogen peroxide-induced apoptosis by up-regulation of Bcl-2 via NF-kappaB in H1299 human lung cancer cells. Guanosine Triphosphate 26-29 BCL2 apoptosis regulator Homo sapiens 111-116 19233129-0 2009 Inhibitory heterotrimeric GTP-binding proteins inhibit hydrogen peroxide-induced apoptosis by up-regulation of Bcl-2 via NF-kappaB in H1299 human lung cancer cells. Hydrogen Peroxide 55-72 BCL2 apoptosis regulator Homo sapiens 111-116 19233129-7 2009 We conclude that Galphai1 inhibits hydrogen peroxide-induced apoptosis of H1299 lung cancer cells by up-regulating the transcription of Bcl-2 through a p50-mediated NF-kappaB activation. Hydrogen Peroxide 35-52 BCL2 apoptosis regulator Homo sapiens 136-141 19250936-3 2009 Here we found that leptin protects DCs from spontaneous, UVB and H(2)O(2)-induced apoptosis, by triggering the activation of nuclear factor-kappa B (NF-kappaB) and a parallel up-regulation of bcl-2 and bcl-XL gene expression and Akt activation. Hydrogen Peroxide 65-73 BCL2 apoptosis regulator Homo sapiens 192-197 19250936-4 2009 We found that leptin activates the PI3K-Akt signaling pathway as demonstrated by the suppression of the effect of leptin on DC survival by wortmannin and API-2, which suppress the leptin-induced activation of Akt, NF-kappaB, bcl-2, bcl-XL and protection from apoptosis. Wortmannin 139-149 BCL2 apoptosis regulator Homo sapiens 225-230 19270722-14 2009 Berbamine-induced apoptosis in K562-r cells appeared to occur through a mechanism involving Bcl-2 family proteins, as well as mdr-1 mRNA and P-gp protein. berbamine 0-9 BCL2 apoptosis regulator Homo sapiens 92-97 19317806-7 2009 Silymarin also decreased mitochondrial transmembrane potential of the cells, thereby increasing levels of cytosolic cytochrome c while up-regulating expression of pro-apoptotic proteins (such as p53, Bax, APAF-1 and caspase-3) with concomitant decrease in anti-apoptotic proteins (Bcl-2 and survivin) and proliferation-associated proteins (beta-catenin, cyclin D1, c-Myc and PCNA). Silymarin 0-9 BCL2 apoptosis regulator Homo sapiens 281-286 19174695-5 2009 UA-induced apoptosis was accompanied by a significant decrease in bcl-2 and survivin expression, with the corresponding ratio of bax/bcl-2 increased. ursolic acid 0-2 BCL2 apoptosis regulator Homo sapiens 66-71 19174695-5 2009 UA-induced apoptosis was accompanied by a significant decrease in bcl-2 and survivin expression, with the corresponding ratio of bax/bcl-2 increased. ursolic acid 0-2 BCL2 apoptosis regulator Homo sapiens 133-138 19407972-6 2009 The expression level of Bcl-2 was decreased and caspase-3 was activated by EGCG or EGC treatment. epigallocatechin gallate 75-79 BCL2 apoptosis regulator Homo sapiens 24-29 19407972-6 2009 The expression level of Bcl-2 was decreased and caspase-3 was activated by EGCG or EGC treatment. gallocatechol 75-78 BCL2 apoptosis regulator Homo sapiens 24-29 19407972-7 2009 The extent in decrease of Bcl-2 and activation caspase-3 were more extensively occurred in EGCG-treated cells than in EGC-treated cells. epigallocatechin gallate 91-95 BCL2 apoptosis regulator Homo sapiens 26-31 19407972-7 2009 The extent in decrease of Bcl-2 and activation caspase-3 were more extensively occurred in EGCG-treated cells than in EGC-treated cells. gallocatechol 91-94 BCL2 apoptosis regulator Homo sapiens 26-31 19259124-0 2009 Repression of PKR mediates palmitate-induced apoptosis in HepG2 cells through regulation of Bcl-2. Palmitates 27-36 BCL2 apoptosis regulator Homo sapiens 92-97 19259124-3 2009 Palmitate down-regulates the activity of PKR and thereby decreases the level of Bcl-2 protein, mediated in part by reduced activation of the NF-kappaB transcription factor. Palmitates 0-9 BCL2 apoptosis regulator Homo sapiens 80-85 19259124-5 2009 The decrease in the phosphorylation of Bcl-2 at Ser70 upon exposure to palmitate is mediated by inhibition of PKR and possibly by c-Jun N-terminal kinase (JNK), whereas the phosphorylation of Bcl-2 at Ser87 is unaffected by palmitate or PKR. Palmitates 71-80 BCL2 apoptosis regulator Homo sapiens 39-44 19259124-5 2009 The decrease in the phosphorylation of Bcl-2 at Ser70 upon exposure to palmitate is mediated by inhibition of PKR and possibly by c-Jun N-terminal kinase (JNK), whereas the phosphorylation of Bcl-2 at Ser87 is unaffected by palmitate or PKR. Palmitates 71-80 BCL2 apoptosis regulator Homo sapiens 192-197 19259124-6 2009 In summary, PKR mediates the regulation of the protein level and the phosphorylation status of Bcl-2, providing a novel mechanism of palmitate-induced apoptosis in HepG2 cells. Palmitates 133-142 BCL2 apoptosis regulator Homo sapiens 95-100 19414396-7 2009 The expression level of Bcl-2 was decreased and caspase-3 was activated by GTP treatment. Guanosine Triphosphate 75-78 BCL2 apoptosis regulator Homo sapiens 24-29 19414396-8 2009 CONCLUSION: GTPs revealed anti-proliferative and apoptosis-inducing activity against HL-60 cells through the down-regulation of Bcl-2 and activation of caspase-3. gtps 12-16 BCL2 apoptosis regulator Homo sapiens 128-133 19414399-7 2009 EGCG decreased the protein levels of Bcl-2, Bcl-xl, xIAP, cIAP, Hsp70 and Hsp90, but increased the protein expression of Bad, Bax, Fas/CD95, cytochrome c, Apaf-1, AIF, GADD153, GRP78, and caspase-3, -7,-8 and -9 as observed by Western blotting examination. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 37-42 19318573-0 2009 TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. TW-37 0-5 BCL2 apoptosis regulator Homo sapiens 37-42 19318573-2 2009 We have previously reported that TW-37, a small-molecule inhibitor of Bcl-2 family proteins, inhibited cell growth and induced apoptosis in pancreatic cancer. TW-37 33-38 BCL2 apoptosis regulator Homo sapiens 70-75 19649719-4 2009 Western blot analysis indicated that matrine dose-dependently down-regulated the expression of anti-apoptotic protein Bcl-2 and up-regulated the level of pro-apoptotic protein bax, eventually leading the reduction of ratios of Bcl-2/Bax proteins in A549 and SMMC-7721 cells. matrine 37-44 BCL2 apoptosis regulator Homo sapiens 118-123 19649719-4 2009 Western blot analysis indicated that matrine dose-dependently down-regulated the expression of anti-apoptotic protein Bcl-2 and up-regulated the level of pro-apoptotic protein bax, eventually leading the reduction of ratios of Bcl-2/Bax proteins in A549 and SMMC-7721 cells. matrine 37-44 BCL2 apoptosis regulator Homo sapiens 227-232 19649719-7 2009 More importantly, matrine markedly enhanced the anticancer activity of anticancer agent trichostatin A (the histone deacetylase inhibitor) by strongly reducing the viability and/or the ratio of Bcl-2/Bax protein in A549 cells. matrine 18-25 BCL2 apoptosis regulator Homo sapiens 194-199 19649719-7 2009 More importantly, matrine markedly enhanced the anticancer activity of anticancer agent trichostatin A (the histone deacetylase inhibitor) by strongly reducing the viability and/or the ratio of Bcl-2/Bax protein in A549 cells. trichostatin A 88-102 BCL2 apoptosis regulator Homo sapiens 194-199 19181434-9 2009 CONCLUSION: Methotrexate in lower concentrations induces apoptosis of human choriocarcinoma cells via mitochondrial-initiated pathways, including reduction of mitochondrial membrane potential, activation of caspase-9, and up-regulation of Bax/Bcl-2 expression. Methotrexate 12-24 BCL2 apoptosis regulator Homo sapiens 243-248 19288022-0 2009 Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NF-kappaBp65 expression in breast cancer MDA-MB-231 cells. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 71-76 19287956-7 2009 CsA also elevated the expressions of both Bcl-2 and ERK1/2. Cyclosporine 0-3 BCL2 apoptosis regulator Homo sapiens 42-47 19292871-6 2009 ROS-amplified JNK induced cytochrome c release and caspase-9/3 activation through enhancement of expression of the proapoptotic protein Bim and reduction of expression of the antiapoptotic protein Bcl-2. Reactive Oxygen Species 0-3 BCL2 apoptosis regulator Homo sapiens 197-202 19288022-8 2009 Curcumin increased the protein expressions of p21 and Bax, but decreased the protein expression of p53 and Bcl-2 in MDA-MB-231 cells. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 107-112 19287965-0 2009 Induction of apoptosis in human leukemia U937 cells by anthocyanins through down-regulation of Bcl-2 and activation of caspases. Anthocyanins 55-67 BCL2 apoptosis regulator Homo sapiens 95-100 19372630-9 2009 Furthermore, downregulation of anti-apoptotic Bcl-2 (P = 0.001) was observed in MCF-7 cells treated with CPA with or without RES when compared to untreated MCF-7. Cyclophosphamide 105-108 BCL2 apoptosis regulator Homo sapiens 46-51 19287965-5 2009 Apoptosis of U937 cells by anthocyanins was associated with modulation of expression of Bcl-2 and IAP family members. Anthocyanins 27-39 BCL2 apoptosis regulator Homo sapiens 88-93 19287965-7 2009 However, anthocyanin-induced growth inhibition and apoptosis were significantly attenuated in Bcl-2 overexpressing U937 cells. Anthocyanins 9-20 BCL2 apoptosis regulator Homo sapiens 94-99 19287965-9 2009 Taken together, these results show that Bcl-2 and caspases are key regulators of apoptosis in response to anthocyanins in human leukemia U937 cells. Anthocyanins 106-118 BCL2 apoptosis regulator Homo sapiens 40-45 18987671-2 2009 The BH3 mimetic ABT-737 is a potent small molecule inhibitor of the anti-apoptotic proteins Bcl-2/Bcl-X(L)/Bcl-w. BH 3 4-7 BCL2 apoptosis regulator Homo sapiens 92-97 18987671-2 2009 The BH3 mimetic ABT-737 is a potent small molecule inhibitor of the anti-apoptotic proteins Bcl-2/Bcl-X(L)/Bcl-w. ABT-737 16-23 BCL2 apoptosis regulator Homo sapiens 92-97 18951478-3 2009 We found that Bcl-2 was down-regulated while Bax was up-regulated by glutamate treatment, and these changes were prevented in the presence of taurine. Glutamic Acid 69-78 BCL2 apoptosis regulator Homo sapiens 14-19 18951478-3 2009 We found that Bcl-2 was down-regulated while Bax was up-regulated by glutamate treatment, and these changes were prevented in the presence of taurine. Taurine 142-149 BCL2 apoptosis regulator Homo sapiens 14-19 19220725-5 2009 Melatonin inhibits the important steps of indomethacin-induced activation of mitochondrial pathway of apoptosis such as upregulation of the expression of Bax and Bak, and the downregulation of Bcl-2 and BclxL. Melatonin 0-9 BCL2 apoptosis regulator Homo sapiens 193-198 19220725-5 2009 Melatonin inhibits the important steps of indomethacin-induced activation of mitochondrial pathway of apoptosis such as upregulation of the expression of Bax and Bak, and the downregulation of Bcl-2 and BclxL. Indomethacin 42-54 BCL2 apoptosis regulator Homo sapiens 193-198 19373661-5 2009 Furthermore, rapamycin and curcumin increased caspase 9, 3 and 7 activity, decreased anti-apoptotic bcl-2 levels, and increased the pro-apoptotic protein Bax. Sirolimus 13-22 BCL2 apoptosis regulator Homo sapiens 100-105 19373661-5 2009 Furthermore, rapamycin and curcumin increased caspase 9, 3 and 7 activity, decreased anti-apoptotic bcl-2 levels, and increased the pro-apoptotic protein Bax. Curcumin 27-35 BCL2 apoptosis regulator Homo sapiens 100-105 19885006-3 2009 Camptothecin caused apoptosis in SiHa cells by inducing mitochondrial membrane permeability changes that lead to the loss of mitochondrial membrane potential, decreased Bcl-2 levels, cytochrome c release, caspase-3 activation, formation of reactive oxygen species and depletion of GSH. Camptothecin 0-12 BCL2 apoptosis regulator Homo sapiens 169-174 19372569-4 2009 Curcumin also potentiated the apoptotic effects of thalidomide and bortezomib by down-regulating the constitutive activation of NF-kappaB and Akt, and this correlated with the suppression of NF-kappaB-regulated gene products, including cyclin D1, Bcl-xL, Bcl-2, TRAF1, cIAP-1, XIAP, survivin, and vascular endothelial growth factor. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 255-260 19372569-4 2009 Curcumin also potentiated the apoptotic effects of thalidomide and bortezomib by down-regulating the constitutive activation of NF-kappaB and Akt, and this correlated with the suppression of NF-kappaB-regulated gene products, including cyclin D1, Bcl-xL, Bcl-2, TRAF1, cIAP-1, XIAP, survivin, and vascular endothelial growth factor. Thalidomide 51-62 BCL2 apoptosis regulator Homo sapiens 255-260 19372569-4 2009 Curcumin also potentiated the apoptotic effects of thalidomide and bortezomib by down-regulating the constitutive activation of NF-kappaB and Akt, and this correlated with the suppression of NF-kappaB-regulated gene products, including cyclin D1, Bcl-xL, Bcl-2, TRAF1, cIAP-1, XIAP, survivin, and vascular endothelial growth factor. Bortezomib 67-77 BCL2 apoptosis regulator Homo sapiens 255-260 19288022-9 2009 Our results show that one molecular mechanism of curcumin inhibits the proliferation of MDA-MB-231 cells either through up-regulating p21 expression and then inducing apoptosis, or through up-regulating the Bax to Bcl-2 ratio and then inducing apoptosis. Curcumin 49-57 BCL2 apoptosis regulator Homo sapiens 214-219 19505399-10 2009 Signaling through alpha7 and alpha3 nAChRs also significantly (p<0.05) altered expression of the cell state regulators p21 and Bcl-2, respectively, suggesting that downregulation of inflammation via nAChRs includes effects on the T cell cycle progression and apoptosis. nachrs 36-42 BCL2 apoptosis regulator Homo sapiens 130-135 19240654-10 2009 bcl-2 (p = 0.021) and p63 (p = 0.025) were both found to be prognostic for improved disease-specific survival (DSS). dss 111-114 BCL2 apoptosis regulator Homo sapiens 0-5 19240654-11 2009 Multivariate analysis (using age and biomarker expression) revealed that bcl-2 expression is prognostic for improved OS (p = 0.005) and DSS (p = 0.021). Osmium 117-119 BCL2 apoptosis regulator Homo sapiens 73-78 19240654-11 2009 Multivariate analysis (using age and biomarker expression) revealed that bcl-2 expression is prognostic for improved OS (p = 0.005) and DSS (p = 0.021). dss 136-139 BCL2 apoptosis regulator Homo sapiens 73-78 19240654-12 2009 CONCLUSIONS: Our results suggest that bcl-2 expression is prognostic for improved OS and DSS in NSCLC. Osmium 82-84 BCL2 apoptosis regulator Homo sapiens 38-43 19240654-12 2009 CONCLUSIONS: Our results suggest that bcl-2 expression is prognostic for improved OS and DSS in NSCLC. dss 89-92 BCL2 apoptosis regulator Homo sapiens 38-43 19373653-2 2009 Oblimersen sodium is a bcl-2 antisense oligonucleotide complementary to the first six codons of the open-reading frame of bcl-2 mRNA that can decrease transcription of Bcl-2 protein and increase myeloma cell susceptibility to cytotoxic agents. Oligonucleotides 39-54 BCL2 apoptosis regulator Homo sapiens 23-28 19373653-2 2009 Oblimersen sodium is a bcl-2 antisense oligonucleotide complementary to the first six codons of the open-reading frame of bcl-2 mRNA that can decrease transcription of Bcl-2 protein and increase myeloma cell susceptibility to cytotoxic agents. Oligonucleotides 39-54 BCL2 apoptosis regulator Homo sapiens 122-127 19373653-2 2009 Oblimersen sodium is a bcl-2 antisense oligonucleotide complementary to the first six codons of the open-reading frame of bcl-2 mRNA that can decrease transcription of Bcl-2 protein and increase myeloma cell susceptibility to cytotoxic agents. Oligonucleotides 39-54 BCL2 apoptosis regulator Homo sapiens 168-173 19372561-2 2009 Elevated Noxa and Bcl-2 levels directly correlated with sensitivity to ABT-737, whereas Mcl-1 levels were similar in all cell lines tested regardless of sensitivity. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 71-74 BCL2 apoptosis regulator Homo sapiens 18-23 19372561-8 2009 However, despite failure to regulate Mcl-1 levels, Noxa blocked binding of Bim to Mcl-1 following its release from Bcl-2 by ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 124-127 BCL2 apoptosis regulator Homo sapiens 115-120 19372562-0 2009 TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis. TW-37 0-5 BCL2 apoptosis regulator Homo sapiens 37-42 19372562-4 2009 Here, we evaluated the effect of TW-37, a small-molecule inhibitor of Bcl-2, on the cell cycle and survival of endothelial cells and HNSCC and on the progression of xenografted tumors. TW-37 33-38 BCL2 apoptosis regulator Homo sapiens 70-75 19379560-2 2009 The apoptosis and cell cycle changes of APL cells treated with As(2)O(3) were detected by morphology and flow cytometry respectively, the protein and mRNA expressions of P27(Kip1), TGF-beta1, cyclin E and BCL-2 were measured by immunohistochemistry and RT-PCR. Arsenic 63-65 BCL2 apoptosis regulator Homo sapiens 205-210 19379569-10 2009 8 microg/ml, gambogic acid can inhibit the growth of MUTZ-1 cells by inducing their apoptosis and down-regulating the expression of bcl-2 gene, which may be one of the main mechanisms underlying its antitumor effects. gambogic acid 13-26 BCL2 apoptosis regulator Homo sapiens 132-137 19302811-9 2009 Bcl-2 declined in myotubes by 61% and 69% after 24 or 96 h of treatment in 4 mM H(2)O(2), respectively. Water 80-85 BCL2 apoptosis regulator Homo sapiens 0-5 19351510-9 2009 CONCLUSION: Cinobufacin can inhibit the proliferation of BIU87 cells by inducting apoptosis, which may be related with S- and G2-phase arrest, down-regulation of Bcl-2, and increasing caspase-3 expression and its activity. cinobufacin 12-23 BCL2 apoptosis regulator Homo sapiens 162-167 19639794-3 2009 RESULT: After treatment with resveratrol, MTT assay showed the growth of U251 cells was inhibited in dose-dependent and time-dependent manners, apoptosis of cells advanced stage was built up, immunohistochemical staining displayed decreased the expression of Bcl-2, Bcl-XL, STAT3 and CyclinD1 and Western blot showed that resveratrol decreased the expression of Bcl-2, Bcl-XL, STAT3 and CyclinD1, and built up Bax and Caspase-3. Resveratrol 29-40 BCL2 apoptosis regulator Homo sapiens 259-264 19639794-3 2009 RESULT: After treatment with resveratrol, MTT assay showed the growth of U251 cells was inhibited in dose-dependent and time-dependent manners, apoptosis of cells advanced stage was built up, immunohistochemical staining displayed decreased the expression of Bcl-2, Bcl-XL, STAT3 and CyclinD1 and Western blot showed that resveratrol decreased the expression of Bcl-2, Bcl-XL, STAT3 and CyclinD1, and built up Bax and Caspase-3. Resveratrol 29-40 BCL2 apoptosis regulator Homo sapiens 362-367 19429011-9 2009 Interestingly, exposure to H(2)O(2) induced a significant decrease of Bcl-2 mRNA transcript, while Sod1 and Bax mRNAs levels were unchanged in PBMCs derived from MCI and AD patients. h(2)o 27-32 BCL2 apoptosis regulator Homo sapiens 70-75 19056168-6 2009 The combination of NS-398 and rosiglitazone exerted synergistic effects on proliferation inhibition, and apoptosis induction in SW1990 cells, with down-regulation of Bcl-2 and up-regulation of Bax expression. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 19-25 BCL2 apoptosis regulator Homo sapiens 166-171 19056168-6 2009 The combination of NS-398 and rosiglitazone exerted synergistic effects on proliferation inhibition, and apoptosis induction in SW1990 cells, with down-regulation of Bcl-2 and up-regulation of Bax expression. Rosiglitazone 30-43 BCL2 apoptosis regulator Homo sapiens 166-171 19379569-8 2009 Gambogic acid could significantly down-regulate the expressions of bcl-2 gene in a dose dependent manner, however, it had no effects on bax gene. gambogic acid 0-13 BCL2 apoptosis regulator Homo sapiens 67-72 19164457-0 2009 Antisense oligonucleotide targeting Bcl-2 messenger RNA in cancer: bad drug, bad target, neither or both? Oligonucleotides 10-25 BCL2 apoptosis regulator Homo sapiens 36-41 19291322-11 2009 In addition, we document, for the first time, that acetaminophen increases expression of the anti-apoptotic protein Bcl2 in brain neurons and decreases the menadione-induced elevation of the proapoptotic protein, cleaved caspase 3. Acetaminophen 51-64 BCL2 apoptosis regulator Homo sapiens 116-120 19291322-12 2009 We show that blocking acetaminophen-induced expression of Bcl2 reduces the pro-survival effect of the drug. Acetaminophen 22-35 BCL2 apoptosis regulator Homo sapiens 58-62 19217289-1 2009 The separation of atropisomeric conformers of 1,2,3,4-tetrahydroisoquinoline amide Bcl-2 ligands allowed the identification of the bioactive conformer which was subsequently confirmed by X-ray crystallography. 1,2,3,4-tetrahydroisoquinoline amide 46-82 BCL2 apoptosis regulator Homo sapiens 83-88 19250643-4 2009 Indomethacin treatment was associated with the disruption of mitochondrial transmembrane potential, release of cytochrome c, down-regulation of Bcl-2 and Mcl-1, upregulation of Bax, and elevation of caspases activity. Indomethacin 0-12 BCL2 apoptosis regulator Homo sapiens 144-149 19223583-0 2009 Mechanism of Bcl-2 and Bcl-X(L) inhibition of NLRP1 inflammasome: loop domain-dependent suppression of ATP binding and oligomerization. Adenosine Triphosphate 103-106 BCL2 apoptosis regulator Homo sapiens 13-18 19223583-6 2009 Bcl-2 and Bcl-X(L) were also determined to inhibit ATP binding to NLRP1, which is required for oligomerization of NLRP1, and Bcl-X(L) was demonstrated to interfere with NLRP1 oligomerization. Adenosine Triphosphate 51-54 BCL2 apoptosis regulator Homo sapiens 0-5 19223583-7 2009 Deletion of the flexible loop regions of Bcl-2 and Bcl-X(L), which are located between the first and second alpha-helices of these anti-apoptotic proteins and which were previously shown to be required for binding NLRP1, abrogated ability to inhibit caspase-1 activation, ATP binding and oligomerization of NLRP1. Adenosine Triphosphate 272-275 BCL2 apoptosis regulator Homo sapiens 41-46 19266600-5 2009 Expression of cyclooxygenase-2 (COX-2), p21 and bcl-2 in cells incubated with AA or DHA was examined by real-time RT-PCR. Docosahexaenoic Acids 84-87 BCL2 apoptosis regulator Homo sapiens 48-53 19266600-8 2009 Furthermore, DHA down- regulated mRNA of bcl-2 and up-regulated p21. Docosahexaenoic Acids 13-16 BCL2 apoptosis regulator Homo sapiens 41-46 18618109-13 2009 The increased sensitivity to FAS-induced apoptosis was linked to alterations in the apoptotic mediators Bcl-2, Bax, Bcl-XL and Apaf-1. ammonium ferrous sulfate 29-32 BCL2 apoptosis regulator Homo sapiens 104-109 19240170-0 2009 Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Cisplatin 13-22 BCL2 apoptosis regulator Homo sapiens 0-5 19240170-1 2009 PURPOSE: This study aimed to test the hypothesis that elevated expression of antiapoptotic Bcl-2 family proteins predicts a poor therapeutic response of oropharyngeal squamous cell carcinoma (OPSCC) to concurrent platinum-based chemoradiation therapy. Platinum 213-221 BCL2 apoptosis regulator Homo sapiens 91-96 19240170-2 2009 EXPERIMENTAL DESIGN: Levels of Bcl-2, Bcl-XL, and Bcl-w were determined and correlated with resistance to cisplatin in a large panel of cell lines derived from squamous cell carcinoma of the head and neck (HNSCC). Cisplatin 106-115 BCL2 apoptosis regulator Homo sapiens 31-36 19240170-4 2009 RESULTS: In HNSCC cell lines, high endogenous Bcl-2 expression was associated with increased cisplatin resistance, and experimental overexpression of Bcl-2 promoted cisplatin resistance. Cisplatin 93-102 BCL2 apoptosis regulator Homo sapiens 46-51 19240170-4 2009 RESULTS: In HNSCC cell lines, high endogenous Bcl-2 expression was associated with increased cisplatin resistance, and experimental overexpression of Bcl-2 promoted cisplatin resistance. Cisplatin 165-174 BCL2 apoptosis regulator Homo sapiens 150-155 19240170-8 2009 CONCLUSIONS: Immunohistochemical assessment of Bcl-2 in pretreatment biopsy specimens can predict response of advanced OPSCC to concurrent platinum-based chemoradiation. Platinum 139-147 BCL2 apoptosis regulator Homo sapiens 47-52 19106104-1 2009 We found that several major chromosomal fragile sites in human lymphomas, including the bcl-2 major breakpoint region, bcl-1 major translocation cluster, and c-Myc exon 1-intron 1 boundary, contain distinctive sequences of consecutive cytosines exhibiting a high degree of reactivity with the structure-specific chemical probe bisulfite. hydrogen sulfite 327-336 BCL2 apoptosis regulator Homo sapiens 88-93 19118607-6 2009 BPB-PLA(2)-induced dissipation of mitochondrial membrane potential and down-regulation of Bcl-2 were suppressed by SB202190 (p38MAPK inhibitor). 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole 115-123 BCL2 apoptosis regulator Homo sapiens 90-95 18715146-3 2009 Oxidative stress induced by the neurotoxins MPTP, paraquat, maneb, and rotenone causes lipid peroxidation and protein misfolding that affects cell death through members of the Bcl-2 family. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 44-48 BCL2 apoptosis regulator Homo sapiens 176-181 18715146-3 2009 Oxidative stress induced by the neurotoxins MPTP, paraquat, maneb, and rotenone causes lipid peroxidation and protein misfolding that affects cell death through members of the Bcl-2 family. Paraquat 50-58 BCL2 apoptosis regulator Homo sapiens 176-181 18715146-3 2009 Oxidative stress induced by the neurotoxins MPTP, paraquat, maneb, and rotenone causes lipid peroxidation and protein misfolding that affects cell death through members of the Bcl-2 family. Maneb 60-65 BCL2 apoptosis regulator Homo sapiens 176-181 18715146-3 2009 Oxidative stress induced by the neurotoxins MPTP, paraquat, maneb, and rotenone causes lipid peroxidation and protein misfolding that affects cell death through members of the Bcl-2 family. Rotenone 71-79 BCL2 apoptosis regulator Homo sapiens 176-181 19242642-5 2009 Two interventions that similarly inhibit mitochondrial adenine nucleotide transport are Bcl-2 overexpression and GSK inhibition. Adenine Nucleotides 55-73 BCL2 apoptosis regulator Homo sapiens 88-93 18521604-11 2009 Western blot showed that cucurbitacin B inhibited STAT3 phosphorylation and down-regulated the expression of Bcl-2. cucurbitacin B 25-39 BCL2 apoptosis regulator Homo sapiens 109-114 19223576-6 2009 While dissecting the molecular events, both upstream and downstream of Akt, we found that psoralidin inhibits phosphatidylinositol 3-kinase activation and transcriptionally represses the activation of nuclear factor-kappaB and its target genes (Bcl-2, Survivin, and Bcl-xL, etc. psoralidin 90-100 BCL2 apoptosis regulator Homo sapiens 245-250 18806758-8 2009 Two notable exceptions are ABT-737 and a related orally active derivative, ABT-263, which bind with high affinity to Bcl-2, Bcl-X(L) and Bcl-w and may prove to be useful tools for mechanistic studies. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 27-30 BCL2 apoptosis regulator Homo sapiens 117-122 18806758-8 2009 Two notable exceptions are ABT-737 and a related orally active derivative, ABT-263, which bind with high affinity to Bcl-2, Bcl-X(L) and Bcl-w and may prove to be useful tools for mechanistic studies. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 75-78 BCL2 apoptosis regulator Homo sapiens 117-122 19160423-4 2009 Kaempferol treatment induced apoptosis by decreasing the expression of Bcl-2 and increasing the expressions of Bax. kaempferol 0-10 BCL2 apoptosis regulator Homo sapiens 71-76 19160423-9 2009 In conclusion our study shows that the oxidative stress induced by kaempferol in K562 and U937 cell lines causes the inactivation of Akt and the activation of the mitochondrial phase of the apoptotic program with an increase of Bax and SIRT3, decrease of Bcl-2, release of cytochrome c, caspase-3 activation, and cell death. kaempferol 67-77 BCL2 apoptosis regulator Homo sapiens 255-260 19066342-6 2009 Treatment with BEPP led to increased phosphorylation of PKR and eIF2alpha, increased expression of BAX, and decreased expression of Bcl-2. bepp 15-19 BCL2 apoptosis regulator Homo sapiens 132-137 19308266-6 2009 In addition, Western blot analysis revealed that 1alpha,25(OH)(2)D(3) and menthol cooperatively modulate the expression of bcl-2 and p21 which provides the insight into the molecular mechanisms underlying the enhanced 1alpha,25(OH)(2)D(3)-mediated growth inhibition by menthol. Menthol 74-81 BCL2 apoptosis regulator Homo sapiens 123-128 19308266-6 2009 In addition, Western blot analysis revealed that 1alpha,25(OH)(2)D(3) and menthol cooperatively modulate the expression of bcl-2 and p21 which provides the insight into the molecular mechanisms underlying the enhanced 1alpha,25(OH)(2)D(3)-mediated growth inhibition by menthol. Menthol 269-276 BCL2 apoptosis regulator Homo sapiens 123-128 19294490-9 2009 Moreover, the amount of Bcl-2 enhanced in the presence of 17beta-estradiol was repressed by the compound. Estradiol 58-74 BCL2 apoptosis regulator Homo sapiens 24-29 19157446-6 2009 MATERIALS AND METHODS: Antisense oligonucleotides targeting Bcl-2 and clusterin were used alone or combined with TRAIL and cytotoxicity was examined by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolim bromide) proliferation assay. Oligonucleotides 33-49 BCL2 apoptosis regulator Homo sapiens 60-65 19157446-9 2009 RESULTS: Although no direct correlation between TRAIL sensitivity and the relative expression levels of Bcl-2 and clusterin was found in the bladder transitional cell carcinoma cell lines examined, antisense oligonucleotide mediated the down-regulation of Bcl-2 and clusterin, increasing the sensitivity of the partially resistant cells to TRAIL. Oligonucleotides 208-223 BCL2 apoptosis regulator Homo sapiens 256-261 19157446-12 2009 CONCLUSIONS: This study provides proof of principle that TRAIL combined with antisense oligonucleotide-Bcl-2 may have potential as a novel future treatment strategy for bladder transitional cell carcinoma. Oligonucleotides 87-102 BCL2 apoptosis regulator Homo sapiens 103-108 19062038-7 2009 Finally, the effect of the ERK inhibitor (PD98059) on BCL-2 expression and induction of anoikis was examined. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 42-49 BCL2 apoptosis regulator Homo sapiens 54-59 18729103-5 2009 We found that treatment of cells with delphinidin (30-240 microM; 48 h) resulted in (i) decrease in cell viability (ii) induction of apoptosis, (iii) cleavage of PARP, (iv) activation of caspases-3, -8, and -9, (v) increase in Bax with a concomitant decrease in Bcl-2 protein, and (vi) G2/M phase cell cycle arrest. delphinidin 38-49 BCL2 apoptosis regulator Homo sapiens 262-267 19095301-5 2009 We have recently reported on the expression and function of two Bcl-2 family members in normal placental development, namely the pro-apoptotic Mtd/Bok, and its anti-apoptotic partner Mcl-1 and have found that their expression is upregulated by low oxygen, a key mediator of trophoblast cell proliferation in early placentation. Oxygen 248-254 BCL2 apoptosis regulator Homo sapiens 64-69 19298750-6 2009 CONCLUSION: On a molecular level, hyperbaric oxygen therapy leads to activation of ion channels, inhibition of hypoxia inducible factor-1alpha, up-regulation of Bcl-2, inhibition of MMP-9, decreased cyclooxygenase-2 activity, decreased myeloperoxidase activity, up-regulation of superoxide dismutase and inhibition of Nogo-A (an endogenous growth-inhibitory factor). Oxygen 45-51 BCL2 apoptosis regulator Homo sapiens 161-166 19212627-5 2009 To develop a strategy of inducing apoptosis of skin cancer cells, the current study was performed to investigate the apoptotic pathway, especially focused on Bcl2 family proteins, in curcumin or UVB-treated basal cell carcinoma cell lines. Curcumin 183-191 BCL2 apoptosis regulator Homo sapiens 158-162 19373993-8 2009 Western blot analysis and immunohistochemistry further demonstrated that preconditioning, in an NMDA-dependent manner, enhanced activation of the pro-survival factors, p-CREB and Bcl-2, while attenuating activation of putative pro-death factors, p-c-Jun and Fas-L in the hippocampus CA1. N-Methylaspartate 96-100 BCL2 apoptosis regulator Homo sapiens 179-184 19428505-4 2009 Both oxaliplatin and cisplatin induced a dose-dependent neuronal apoptosis, modulated by the proteins of Bcl-2 family. Oxaliplatin 5-16 BCL2 apoptosis regulator Homo sapiens 105-110 19428505-4 2009 Both oxaliplatin and cisplatin induced a dose-dependent neuronal apoptosis, modulated by the proteins of Bcl-2 family. Cisplatin 21-30 BCL2 apoptosis regulator Homo sapiens 105-110 19124070-0 2009 Naringenin-induced apoptosis is attenuated by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human leukemia U937 cells. naringenin 0-10 BCL2 apoptosis regulator Homo sapiens 46-51 19462899-7 2009 Immunohistochemistry test demonstrated that tanshinone A upregulate P53 expression in both cells and also weakly upregulate the CerBb-2 expression in MCF-7 (P < 0.05), whereas no influence on CerBb-2 expression of MDA-MB-231 and on Bcl-2 expression of both cells were demonstrated (P > 0.05). tanshinone 44-56 BCL2 apoptosis regulator Homo sapiens 235-240 19124070-0 2009 Naringenin-induced apoptosis is attenuated by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human leukemia U937 cells. naringenin 0-10 BCL2 apoptosis regulator Homo sapiens 87-92 19135140-4 2009 Studies of PI and Annexin V dual staining analysis demonstrated that 20 microM Cd-induced apoptosis as early as 18 h. A concomitant by the generation of ROS, the loss of mitochondrial membrane potential, cytochrome c (cyt c) release, activation of caspase-9, -3 and regulation of Bcl-2 and Bax were observed. Cadmium 79-81 BCL2 apoptosis regulator Homo sapiens 280-285 19124070-2 2009 In this study, the effect of ectopic Bcl-2 expression on naringenin-induced apoptosis was investigated. naringenin 57-67 BCL2 apoptosis regulator Homo sapiens 37-42 19135140-7 2009 The anti-apoptosis exerted by selenium involved the blocking of Cd-induced ROS generation, the inhibition of Cd-induced mitochondrial membrane potential collapse, the prevention of cyt c release, subsequent inhibition of caspase activation and the changed level of Bcl-2 and Bax. Selenium 30-38 BCL2 apoptosis regulator Homo sapiens 265-270 19124070-3 2009 We found that Bcl-2 overexpression markedly protected human leukemia U937 cells from time- and dose-dependent induction of apoptosis by naringenin, as did caspase-3 and caspase-9 inhibitors. naringenin 136-146 BCL2 apoptosis regulator Homo sapiens 14-19 19124070-4 2009 Additionally, Bcl-2 overexpression attenuated naringenin-induced Bax translocation and cytosolic release of cytochrome c. naringenin 46-56 BCL2 apoptosis regulator Homo sapiens 14-19 19124070-5 2009 Our results also indicated that co-administration of HA14-1 and naringenin increased apoptosis in Bcl-2 overexpressing U937 cells by restoring mitochondrial dysfunction and activation of caspase-9 and caspase-3, as well as by cleavage of poly (ADP-ribose) polymerase. naringenin 64-74 BCL2 apoptosis regulator Homo sapiens 98-103 19124070-6 2009 Taken together, these observations indicate that Bcl-2 confers apoptosis resistance to naringenin by inhibiting a mitochondrial amplification step in U937 cells. naringenin 87-97 BCL2 apoptosis regulator Homo sapiens 49-54 19195607-9 2009 After exenatide treatment, myocardial phosphorylated Akt and Bcl-2 expression levels were higher compared with those after PBS treatment, and active caspase 3 expression was lower. Exenatide 6-15 BCL2 apoptosis regulator Homo sapiens 61-66 19287190-0 2009 STAT3 is involved in phosphatidic acid-induced Bcl-2 expression in HeLa cells. Phosphatidic Acids 21-38 BCL2 apoptosis regulator Homo sapiens 47-52 19287190-2 2009 We found that Bcl-2 was upregulated by PA treatment in HeLa cells. Phosphatidic Acids 39-41 BCL2 apoptosis regulator Homo sapiens 14-19 19287190-3 2009 However, how PA upregulates Bcl-2 expression has not yet been studied. Phosphatidic Acids 13-15 BCL2 apoptosis regulator Homo sapiens 28-33 19287190-4 2009 In this study, we tried to discover the mechanisms of Bcl-2 up-regulation by PA treatment in HeLa cells. Phosphatidic Acids 77-79 BCL2 apoptosis regulator Homo sapiens 54-59 19287190-5 2009 Treatment with PA resulted in significantly increased expression of Bcl-2 in HeLa cells. Phosphatidic Acids 15-17 BCL2 apoptosis regulator Homo sapiens 68-73 19287190-6 2009 Moreover, PA-induced Bcl-2 expression was blocked by mepacrine, an inhibitor of PLA2, but not by propranolol, an inhibitor of PA phospholyhydrolase (PAP). Phosphatidic Acids 10-12 BCL2 apoptosis regulator Homo sapiens 21-26 19287190-6 2009 Moreover, PA-induced Bcl-2 expression was blocked by mepacrine, an inhibitor of PLA2, but not by propranolol, an inhibitor of PA phospholyhydrolase (PAP). Quinacrine 53-62 BCL2 apoptosis regulator Homo sapiens 21-26 19287190-7 2009 Treatment of 1,2-dipalmitoryl-sn-glycero-3- phosphate (DPPA) also increased Bcl-2 expression. 1,2-dipalmitoryl-sn-glycero-3- phosphate 13-53 BCL2 apoptosis regulator Homo sapiens 76-81 19287190-7 2009 Treatment of 1,2-dipalmitoryl-sn-glycero-3- phosphate (DPPA) also increased Bcl-2 expression. dppa 55-59 BCL2 apoptosis regulator Homo sapiens 76-81 19287190-8 2009 These results indicate that Bcl-2 expression is mediated by lysophosphatidic acid (LPA), not by arachidonic acid (AA). lysophosphatidic acid 60-81 BCL2 apoptosis regulator Homo sapiens 28-33 19287190-8 2009 These results indicate that Bcl-2 expression is mediated by lysophosphatidic acid (LPA), not by arachidonic acid (AA). lysophosphatidic acid 83-86 BCL2 apoptosis regulator Homo sapiens 28-33 19287190-9 2009 Thereafter, we used MEK1/2 inhibitor, PD98059 to investigate the relationship between ERK1/2 MAPK and PA-induced Bcl-2 expression. Phosphatidic Acids 102-104 BCL2 apoptosis regulator Homo sapiens 113-118 19287190-10 2009 PA-induced Bcl-2 expression was decreased when ERK1/2 was inhibited by PD98059. Phosphatidic Acids 0-2 BCL2 apoptosis regulator Homo sapiens 11-16 19287190-10 2009 PA-induced Bcl-2 expression was decreased when ERK1/2 was inhibited by PD98059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 71-78 BCL2 apoptosis regulator Homo sapiens 11-16 19287190-11 2009 The transcription factor such as STAT3 which is controlled by ERK1/2 MAPK was increased along with Bcl-2 expression when the cells were treated with PA. Phosphatidic Acids 149-151 BCL2 apoptosis regulator Homo sapiens 99-104 19287190-12 2009 Furthermore, STAT3 siRNA treatments inhibited PA-induced Bcl-2 expression, suggesting that STAT3 (Ser727) is involved in PA-induced Bcl-2 expression. Phosphatidic Acids 46-48 BCL2 apoptosis regulator Homo sapiens 57-62 19287190-12 2009 Furthermore, STAT3 siRNA treatments inhibited PA-induced Bcl-2 expression, suggesting that STAT3 (Ser727) is involved in PA-induced Bcl-2 expression. Phosphatidic Acids 46-48 BCL2 apoptosis regulator Homo sapiens 132-137 19287190-12 2009 Furthermore, STAT3 siRNA treatments inhibited PA-induced Bcl-2 expression, suggesting that STAT3 (Ser727) is involved in PA-induced Bcl-2 expression. Phosphatidic Acids 121-123 BCL2 apoptosis regulator Homo sapiens 57-62 19287190-12 2009 Furthermore, STAT3 siRNA treatments inhibited PA-induced Bcl-2 expression, suggesting that STAT3 (Ser727) is involved in PA-induced Bcl-2 expression. Phosphatidic Acids 121-123 BCL2 apoptosis regulator Homo sapiens 132-137 19287190-13 2009 Taken together, these findings indicate that PA acts as an important mediator for increasing Bcl-2 expression through STAT3 (Ser727) activation via the ERK1/2 MAPK pathway. Phosphatidic Acids 45-47 BCL2 apoptosis regulator Homo sapiens 93-98 19239902-6 2009 In certain cells such as hepatocytes, albeit not lymphocytes, FAS-induced apoptosis requires amplification through proteolytic activation of the proapoptotic BCL-2 family member BID. ammonium ferrous sulfate 62-65 BCL2 apoptosis regulator Homo sapiens 158-163 19115248-2 2009 The combined action of tamoxifen/all-trans retinoic acid was advantageous in MCF-7 cells, reducing cell proliferation, Bcl-2 and c-Myc protein levels and increasing E-Cadherin protein levels and Gap junctional Intercellular Communication. Tamoxifen 23-32 BCL2 apoptosis regulator Homo sapiens 119-124 19115248-2 2009 The combined action of tamoxifen/all-trans retinoic acid was advantageous in MCF-7 cells, reducing cell proliferation, Bcl-2 and c-Myc protein levels and increasing E-Cadherin protein levels and Gap junctional Intercellular Communication. 2-octenal 37-42 BCL2 apoptosis regulator Homo sapiens 119-124 19115248-2 2009 The combined action of tamoxifen/all-trans retinoic acid was advantageous in MCF-7 cells, reducing cell proliferation, Bcl-2 and c-Myc protein levels and increasing E-Cadherin protein levels and Gap junctional Intercellular Communication. Tretinoin 43-56 BCL2 apoptosis regulator Homo sapiens 119-124 19115248-5 2009 The co-incubation of bradykinin-MCF-7 cells with tamoxifen/all-trans retinoic acid reduced cell proliferation, ERK1/2 activity, as well as Bcl-2, c-Myc, and bradykinin receptor-2 levels, without altering the enhanced E-cadherin levels induced by tamoxifen/all-trans retinoic acid. Tamoxifen 49-58 BCL2 apoptosis regulator Homo sapiens 139-144 19115248-5 2009 The co-incubation of bradykinin-MCF-7 cells with tamoxifen/all-trans retinoic acid reduced cell proliferation, ERK1/2 activity, as well as Bcl-2, c-Myc, and bradykinin receptor-2 levels, without altering the enhanced E-cadherin levels induced by tamoxifen/all-trans retinoic acid. retinoic 69-77 BCL2 apoptosis regulator Homo sapiens 139-144 19115248-5 2009 The co-incubation of bradykinin-MCF-7 cells with tamoxifen/all-trans retinoic acid reduced cell proliferation, ERK1/2 activity, as well as Bcl-2, c-Myc, and bradykinin receptor-2 levels, without altering the enhanced E-cadherin levels induced by tamoxifen/all-trans retinoic acid. Tretinoin 69-82 BCL2 apoptosis regulator Homo sapiens 139-144 19060243-1 2009 The apoptotic and therapeutic activities of the histone deacetylase inhibitor (HDACi) vorinostat are blocked by overexpression of Bcl-2 or Bcl-X(L). Vorinostat 86-96 BCL2 apoptosis regulator Homo sapiens 130-135 19060243-2 2009 Herein, we used the small molecule inhibitor ABT-737 to restore sensitivity of Emu-myc lymphomas overexpressing Bcl-2 or Bcl-X(L) to vorinostat and valproic acid (VPA). ABT-737 45-52 BCL2 apoptosis regulator Homo sapiens 112-117 19060243-2 2009 Herein, we used the small molecule inhibitor ABT-737 to restore sensitivity of Emu-myc lymphomas overexpressing Bcl-2 or Bcl-X(L) to vorinostat and valproic acid (VPA). Vorinostat 133-143 BCL2 apoptosis regulator Homo sapiens 112-117 19060243-6 2009 Emu-myc lymphomas that expressed Bcl-2 throughout the tumorigenesis process were especially sensitive to ABT-737, while those forced to overexpress Mcl-1 were not. ABT-737 105-112 BCL2 apoptosis regulator Homo sapiens 33-38 19027226-2 2009 Here, we show that the naturally-occurring shikonin analogues (deoxyshikonin, acetylshikonin, isobutyrylshikonin, beta,beta-dimethylacrylshikonin, isovalerylshikonin, alpha-methyl-n-butylshikonin) could bypass drug resistance mediated by not only P-gp, Bcl-2, and Bcl-xL, but also two additional important drug-resistant factors MRP1 and BCRP1, by induction of necroptosis. shikonin 43-51 BCL2 apoptosis regulator Homo sapiens 253-258 19228717-4 2009 It is controversial whether some BH3-domain proteins (Bim or tBid) directly activate multidomain pro-apoptotic proteins (e.g., Bax and Bak) or act via inhibition of those anti-apoptotic Bcl-2 proteins (Bcl-2, Bcl-XL, Bcl-w, Mcl-1, Bfl1/A-1, and Bcl-B) that stabilize pro-apoptotic proteins. tBID 61-65 BCL2 apoptosis regulator Homo sapiens 186-191 19228717-4 2009 It is controversial whether some BH3-domain proteins (Bim or tBid) directly activate multidomain pro-apoptotic proteins (e.g., Bax and Bak) or act via inhibition of those anti-apoptotic Bcl-2 proteins (Bcl-2, Bcl-XL, Bcl-w, Mcl-1, Bfl1/A-1, and Bcl-B) that stabilize pro-apoptotic proteins. tBID 61-65 BCL2 apoptosis regulator Homo sapiens 202-207 19228717-6 2009 Clinical trials of several investigational drugs targeting the Bcl-2 family (oblimersen sodium, AT-101, ABT-263, GX15-070) are ongoing. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 104-107 BCL2 apoptosis regulator Homo sapiens 63-68 19060244-3 2009 ABT-737, a small-molecule inhibitor of Bcl-2, Bcl-X(L), and Bcl-W, induced apoptosis preferentially in JAK2V617F-high PV erythroid precursors as compared with JAK2V617F-low or normal erythroblasts. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 39-44 19204830-0 2009 Small hairpin RNA targeting at Bcl-2 increases cytarabine-induced apoptosis in Raji cells. Cytarabine 47-57 BCL2 apoptosis regulator Homo sapiens 31-36 19056458-8 2009 Furthermore, labedipinedilol-A triggered the mitochondrial apoptotic pathway, as indicated by increasing the expression of Bax, but decreasing the level of Bcl-2, resulting in mitochondrial membrane potential loss, cytochrome c release, and activation of caspase-9 and -3. labedipinedilol A 13-30 BCL2 apoptosis regulator Homo sapiens 156-161 19151744-5 2009 The mechanism by which BAG-1 affected the function of Bcl-2 was exploredby using the cycloheximide chase assay. Cycloheximide 85-98 BCL2 apoptosis regulator Homo sapiens 54-59 19204830-2 2009 In this study, we investigated whether small hairpin RNA (shRNA) targeting at Bcl-2 mRNA could enhance cytarabine (Ara-C)-induced apoptosis in Raji cells. Cytarabine 103-113 BCL2 apoptosis regulator Homo sapiens 78-83 19151744-11 2009 Furthermore, the cycloheximide chase assay indicated that the degradation of Bcl-2 protein was extended in the BAG-1 p50 and p46 transfected MCF-7 cells. Cycloheximide 17-30 BCL2 apoptosis regulator Homo sapiens 77-82 19204830-2 2009 In this study, we investigated whether small hairpin RNA (shRNA) targeting at Bcl-2 mRNA could enhance cytarabine (Ara-C)-induced apoptosis in Raji cells. Cytarabine 115-120 BCL2 apoptosis regulator Homo sapiens 78-83 19204830-11 2009 Apoptotic rates of Raji cells treated with Bcl-2 shRNA combined with Ara-C significantly increased (P < 0.05), compared with either control shRNA/Ara-C combination or Ara-C-treated cells alone. Cytarabine 69-74 BCL2 apoptosis regulator Homo sapiens 43-48 19204830-11 2009 Apoptotic rates of Raji cells treated with Bcl-2 shRNA combined with Ara-C significantly increased (P < 0.05), compared with either control shRNA/Ara-C combination or Ara-C-treated cells alone. Cytarabine 149-154 BCL2 apoptosis regulator Homo sapiens 43-48 19204830-11 2009 Apoptotic rates of Raji cells treated with Bcl-2 shRNA combined with Ara-C significantly increased (P < 0.05), compared with either control shRNA/Ara-C combination or Ara-C-treated cells alone. Cytarabine 149-154 BCL2 apoptosis regulator Homo sapiens 43-48 19204830-12 2009 Our results suggest that the shRNA against Bcl-2 mRNA could increase Ara-C-induced apoptosis in Raji cells. Cytarabine 69-74 BCL2 apoptosis regulator Homo sapiens 43-48 19197149-7 2009 Moreover, expression of the pro-apoptotic protein Bax was increased, with resultant skewing in the Bax/bcl-2 ratio, providing a mechanistic explanation for the observed DHA-induced increase in apoptosis. Docosahexaenoic Acids 169-172 BCL2 apoptosis regulator Homo sapiens 103-108 19250217-6 2009 Furthermore, curcumin or, more potently, the isoxazole analogue, produced early reductions in the amounts of relevant gene transcripts that were diverse (i.e., they were relative to Bcl-2 and Bcl-X(L) in MCF-7 and the inhibitory of apoptosis proteins and COX-2 in MCF-7R) in the two cell lines. Curcumin 13-21 BCL2 apoptosis regulator Homo sapiens 182-187 19250217-6 2009 Furthermore, curcumin or, more potently, the isoxazole analogue, produced early reductions in the amounts of relevant gene transcripts that were diverse (i.e., they were relative to Bcl-2 and Bcl-X(L) in MCF-7 and the inhibitory of apoptosis proteins and COX-2 in MCF-7R) in the two cell lines. Isoxazoles 45-54 BCL2 apoptosis regulator Homo sapiens 182-187 19513435-1 2009 Study of the glucocorticoid effects on the counts of Bcl-2-positive cells in various zones of the spleen showed that dexamethasone and prednisolone stimulated migration of apoptosis-resistant cells to the spleen, but their effects on cell distribution in various morphofunctional zones of the spleen were different. Dexamethasone 117-130 BCL2 apoptosis regulator Homo sapiens 53-58 19513435-1 2009 Study of the glucocorticoid effects on the counts of Bcl-2-positive cells in various zones of the spleen showed that dexamethasone and prednisolone stimulated migration of apoptosis-resistant cells to the spleen, but their effects on cell distribution in various morphofunctional zones of the spleen were different. Prednisolone 135-147 BCL2 apoptosis regulator Homo sapiens 53-58 19103299-0 2009 Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Docetaxel 0-9 BCL2 apoptosis regulator Homo sapiens 110-115 19103299-0 2009 Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Zoledronic Acid 10-25 BCL2 apoptosis regulator Homo sapiens 110-115 18930812-2 2009 These properties appear to depend on a specific mitochondrial signaling of melatonin which is associated with a lower generation of reactive oxygen species and a better control of redox-sensitive components such as the antiapoptotic protein Bcl-2. Melatonin 75-84 BCL2 apoptosis regulator Homo sapiens 241-246 18930812-6 2009 In this model we found that pharmacological concentrations of melatonin (1 mM) were able to decrease superoxide anion production, mitochondrial damage, and caspase-dependent apoptosis by improved Bcl-2 levels and decreased Cyt c release in the cytoplasm. Melatonin 62-71 BCL2 apoptosis regulator Homo sapiens 196-201 19200201-0 2009 Gambogic acid induces apoptosis by regulating the expression of Bax and Bcl-2 and enhancing caspase-3 activity in human malignant melanoma A375 cells. gambogic acid 0-13 BCL2 apoptosis regulator Homo sapiens 72-77 19148464-0 2009 Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Paclitaxel 14-24 BCL2 apoptosis regulator Homo sapiens 49-54 19148464-5 2009 We also investigated members of Bcl-2 family by Western blotting and RT-PCR to clarify their role in paclitaxel resistance both in ER-positive and in ER-negative cells. Paclitaxel 101-111 BCL2 apoptosis regulator Homo sapiens 32-37 19200201-10 2009 CONCLUSION: GA can inhibit the proliferation of A375 cells and induce their apoptosis, which may be related to the up-regulation of the Bax/Bcl-2 ratio and caspase-3 activity. gambogic acid 12-14 BCL2 apoptosis regulator Homo sapiens 140-145 19148464-12 2009 Activation of ER gene expression in ER-negative KPL-4 cells by 5-aza-2"-deoxycytidine resulted in up-regulation of Bcl-2 mRNA. Decitabine 63-85 BCL2 apoptosis regulator Homo sapiens 115-120 19148464-15 2009 These results suggest that ER influenced chemosensitivity to paclitaxel through regulation of Bcl-2 family and regulation of the pathway may be crucial to increase the efficacy of taxanes in ER-positive breast cancer. Paclitaxel 61-71 BCL2 apoptosis regulator Homo sapiens 94-99 19235267-4 2009 A decrease in expressions of Bcl-2, Bcl-xL and survivin was observed after exposure to 10 approximately 80 micromol/L curcumin, while the levels of Bax and Bad increased in the curcumin-treated cells. Curcumin 118-126 BCL2 apoptosis regulator Homo sapiens 29-34 19148464-15 2009 These results suggest that ER influenced chemosensitivity to paclitaxel through regulation of Bcl-2 family and regulation of the pathway may be crucial to increase the efficacy of taxanes in ER-positive breast cancer. Taxoids 180-187 BCL2 apoptosis regulator Homo sapiens 94-99 18677583-0 2009 Evidence for involvement of ERK, PI3K, and RSK in induction of Bcl-2 by valproate. Valproic Acid 72-81 BCL2 apoptosis regulator Homo sapiens 63-68 18677583-1 2009 Valproate, an anticonvulsant and mood stabilizer, up-regulates Bcl-2, a neurotrophic/neuroprotective protein. Valproic Acid 0-9 BCL2 apoptosis regulator Homo sapiens 63-68 18677583-2 2009 In this study, we investigated the molecular mechanism through which Bcl-2 is up-regulated by valproate using cultured human neuron-like cells. Valproic Acid 94-103 BCL2 apoptosis regulator Homo sapiens 69-74 18677583-3 2009 Valproate, within therapeutically relevant ranges, induced time- and concentration-dependent up-regulations of both Bcl-2 messenger RNA and protein implicating an underlying gene transcriptional-mediated mechanism. Valproic Acid 0-9 BCL2 apoptosis regulator Homo sapiens 116-121 18677583-5 2009 Valproate increased transcriptional activity of a human bcl-2 promoter-reporter gene construct. Valproic Acid 0-9 BCL2 apoptosis regulator Homo sapiens 56-61 18677583-8 2009 These data collectively suggest that valproate induces Bcl-2 regulation partially through activations of the ERK and PI3K cascades and their convergent kinase, RSK, although other unknown mechanism(s) are likely involved. Valproic Acid 37-46 BCL2 apoptosis regulator Homo sapiens 55-60 18677583-9 2009 Given the known roles of Bcl-2 in the central nervous system, the current findings offer a partial yet complex molecular mechanistic explanation for the known neurobiological effects of valproate including neurite growth, neuronal survival, and neurogenesis. Valproic Acid 186-195 BCL2 apoptosis regulator Homo sapiens 25-30 19235267-4 2009 A decrease in expressions of Bcl-2, Bcl-xL and survivin was observed after exposure to 10 approximately 80 micromol/L curcumin, while the levels of Bax and Bad increased in the curcumin-treated cells. Curcumin 177-185 BCL2 apoptosis regulator Homo sapiens 29-34 19091346-18 2009 CONCLUSIONS: Finasteride administered 30 days before surgery appears to decrease the apoptotic factors caspase-7 and IGFBP-3 in cancer cells, while having little to no effect on caspase-3, insulin growth factor-1, bcl-2, p53 and p21. Finasteride 13-24 BCL2 apoptosis regulator Homo sapiens 214-219 19029119-0 2009 Role of JNK1-dependent Bcl-2 phosphorylation in ceramide-induced macroautophagy. Ceramides 48-56 BCL2 apoptosis regulator Homo sapiens 23-28 19236748-9 2009 Application of 5-BrTet and magnetic nanoparticle of Fe(3)O(4) inhibited the expression of BCL-2 protein and up-regulated the expression of BAX, and Caspase-3 protein in K562/A02 cell xenograft tumor. fe(3)o(4) 52-61 BCL2 apoptosis regulator Homo sapiens 90-95 19029119-3 2009 Here we show that short-chain ceramides (C(2)-ceramide and C(6)-ceramide) and stimulation of the de novo ceramide synthesis by tamoxifen induce the dissociation of the complex formed between the autophagy protein Beclin 1 and the anti-apoptotic protein Bcl-2. Ceramides 30-39 BCL2 apoptosis regulator Homo sapiens 253-258 19029119-3 2009 Here we show that short-chain ceramides (C(2)-ceramide and C(6)-ceramide) and stimulation of the de novo ceramide synthesis by tamoxifen induce the dissociation of the complex formed between the autophagy protein Beclin 1 and the anti-apoptotic protein Bcl-2. N-acetylsphingosine 41-54 BCL2 apoptosis regulator Homo sapiens 253-258 19029119-3 2009 Here we show that short-chain ceramides (C(2)-ceramide and C(6)-ceramide) and stimulation of the de novo ceramide synthesis by tamoxifen induce the dissociation of the complex formed between the autophagy protein Beclin 1 and the anti-apoptotic protein Bcl-2. N-caproylsphingosine 59-72 BCL2 apoptosis regulator Homo sapiens 253-258 19029119-3 2009 Here we show that short-chain ceramides (C(2)-ceramide and C(6)-ceramide) and stimulation of the de novo ceramide synthesis by tamoxifen induce the dissociation of the complex formed between the autophagy protein Beclin 1 and the anti-apoptotic protein Bcl-2. Ceramides 30-38 BCL2 apoptosis regulator Homo sapiens 253-258 19029119-3 2009 Here we show that short-chain ceramides (C(2)-ceramide and C(6)-ceramide) and stimulation of the de novo ceramide synthesis by tamoxifen induce the dissociation of the complex formed between the autophagy protein Beclin 1 and the anti-apoptotic protein Bcl-2. Tamoxifen 127-136 BCL2 apoptosis regulator Homo sapiens 253-258 19029119-5 2009 Three potential phosphorylation sites, Thr(69), Ser(70), and Ser(87), located in the non-structural N-terminal loop of Bcl-2, play major roles in the dissociation of Bcl-2 from Beclin 1. Threonine 0-3 BCL2 apoptosis regulator Homo sapiens 119-124 19029119-5 2009 Three potential phosphorylation sites, Thr(69), Ser(70), and Ser(87), located in the non-structural N-terminal loop of Bcl-2, play major roles in the dissociation of Bcl-2 from Beclin 1. Threonine 0-3 BCL2 apoptosis regulator Homo sapiens 166-171 19029119-5 2009 Three potential phosphorylation sites, Thr(69), Ser(70), and Ser(87), located in the non-structural N-terminal loop of Bcl-2, play major roles in the dissociation of Bcl-2 from Beclin 1. Serine 48-51 BCL2 apoptosis regulator Homo sapiens 119-124 19029119-5 2009 Three potential phosphorylation sites, Thr(69), Ser(70), and Ser(87), located in the non-structural N-terminal loop of Bcl-2, play major roles in the dissociation of Bcl-2 from Beclin 1. Serine 48-51 BCL2 apoptosis regulator Homo sapiens 166-171 19029119-5 2009 Three potential phosphorylation sites, Thr(69), Ser(70), and Ser(87), located in the non-structural N-terminal loop of Bcl-2, play major roles in the dissociation of Bcl-2 from Beclin 1. Serine 61-64 BCL2 apoptosis regulator Homo sapiens 119-124 19029119-5 2009 Three potential phosphorylation sites, Thr(69), Ser(70), and Ser(87), located in the non-structural N-terminal loop of Bcl-2, play major roles in the dissociation of Bcl-2 from Beclin 1. Serine 61-64 BCL2 apoptosis regulator Homo sapiens 166-171 19029119-6 2009 We further show that activation of c-Jun N-terminal protein kinase 1 by ceramide is required both to phosphorylate Bcl-2 and to stimulate macroautophagy. Ceramides 72-80 BCL2 apoptosis regulator Homo sapiens 115-120 19013234-2 2009 The effect of IL-3 and exogenous hydrogen peroxide on cell viability seems to be mediated through inhibition of the cell death commitment, as shown by apoptotic markers such as caspase activities, apoptotic nuclei, and changes in the amount of proteins belonging to the Bcl-2 family. Hydrogen Peroxide 33-50 BCL2 apoptosis regulator Homo sapiens 270-275 19047048-3 2009 Both cell lines also displayed an anomalous response to oligomycin, with rapid onset of depolarization that was prevented by cyclosporin A and by overexpression of Bcl-2. Oligomycins 56-66 BCL2 apoptosis regulator Homo sapiens 164-169 19113979-3 2009 ROS production induced by complex 1 treatment activated apoptosis through mitochondrial membrane depolarization in all prostate cancer cells, with up-regulation of Bax and down-regulation of Bcl-2 proteins. ros 0-3 BCL2 apoptosis regulator Homo sapiens 191-196 18824293-4 2009 RAD001 in combination with cisplatin induced a significant increase in the number of apoptotic cells, downregulated the expression of pro-survival molecules, Bcl-2, survivin and cyclinD1, and increased the cleavage of PARP, compared to RAD001 or cisplatin alone. Cisplatin 27-36 BCL2 apoptosis regulator Homo sapiens 158-163 19489279-14 2009 Western blotting showed that the Bcl-2 expression was decreased and the expression of Bax increased after treatment of arsenic trioxide. Arsenic Trioxide 119-135 BCL2 apoptosis regulator Homo sapiens 33-38 19072631-4 2009 The downregulation efficiency of Bcl-2 mRNA level was similar to that mediated by Lipofectamine but higher than that induced by PEI. Lipofectamine 82-95 BCL2 apoptosis regulator Homo sapiens 33-38 19072631-7 2009 However, the size of the complexes was still below 250 nm after being incubated in PBS containing 10% serum for 4 h. On the other hand, PEGylated siRNA delivered by the nanoparticles downregulated Bcl-2 mRNA expression level in the cells as efficiently as unmodified siRNA. Lead 83-86 BCL2 apoptosis regulator Homo sapiens 197-202 19072631-0 2009 Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug. Polymers 58-65 BCL2 apoptosis regulator Homo sapiens 22-27 18845789-4 2009 By contrast, treatment of cells with C2-ceramide (a potent PP2A activator) or expression of the PP2A catalytic subunit (PP2A/C) inhibits Bcl2 phosphorylation, leading to increased p53/Bcl2 binding and apoptotic cell death. N-acetylsphingosine 37-48 BCL2 apoptosis regulator Homo sapiens 137-141 18782651-2 2009 We previously reported that racemic (+/-) Apogossypol, a semi-synthetic compound derived from the natural product Gossypol, binds and inhibits Bcl-2 and Bcl-X(L)in vitro and in cell. apogossypol 36-53 BCL2 apoptosis regulator Homo sapiens 143-148 18782651-2 2009 We previously reported that racemic (+/-) Apogossypol, a semi-synthetic compound derived from the natural product Gossypol, binds and inhibits Bcl-2 and Bcl-X(L)in vitro and in cell. Gossypol 114-122 BCL2 apoptosis regulator Homo sapiens 143-148 18794803-6 2009 The CRAF inhibitor sorafenib was found to induce a time-dependent reduction in both BAD phosphorylation and Bcl-2 expression in the D594G/G469E lines only. Sorafenib 19-28 BCL2 apoptosis regulator Homo sapiens 108-113 19041641-7 2009 Ginsenoside Rb(1) (100 fg, 10 pg, and 1 ng/ml) increased the Bcl-2 expression level in UVB-treated human keratinocytes. ginsenoside Rb1 0-17 BCL2 apoptosis regulator Homo sapiens 61-66 19032555-0 2009 Isoflurane attenuates dynorphin-induced cytotoxicity and downregulation of Bcl-2 expression in differentiated neuroblastoma SH-SY5Y cells. Isoflurane 0-10 BCL2 apoptosis regulator Homo sapiens 75-80 19173092-6 2009 However, high expression of PR as well as high expression of three different ER activity profiles; ER/PR/Bcl-2, ER/PR/IGF-IR and ER/PR/Bcl-2/IGF-IR identified letrozole treated patients with significantly longer TTP. Letrozole 159-168 BCL2 apoptosis regulator Homo sapiens 135-140 19173092-7 2009 The ER activity profile including ER, PR, Bcl-2 and IGF-IR showed a trend towards being a selection criterion for letrozole versus tamoxifen therapy. Letrozole 114-123 BCL2 apoptosis regulator Homo sapiens 42-47 19173092-9 2009 Furthermore, it seems that the "ER activity profile" with high PR, IGF-IR and Bcl-2 is a promising selection criterion, regarding prediction of response to letrozole versus tamoxifen. Letrozole 156-165 BCL2 apoptosis regulator Homo sapiens 78-83 19173092-9 2009 Furthermore, it seems that the "ER activity profile" with high PR, IGF-IR and Bcl-2 is a promising selection criterion, regarding prediction of response to letrozole versus tamoxifen. Tamoxifen 173-182 BCL2 apoptosis regulator Homo sapiens 78-83 18931344-0 2009 Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Obatoclax mesylate 17-35 BCL2 apoptosis regulator Homo sapiens 69-74 18931344-1 2009 Obatoclax mesylate is a small molecule pan-Bcl-2 antagonist with in vitro activity against chronic lymphocytic leukemia (CLL) cells. Obatoclax mesylate 0-18 BCL2 apoptosis regulator Homo sapiens 43-48 19128456-9 2009 MDR1 and Bcl-2 gene expression was downmodulated by HIPK2 overexpression in cobalt-treated cells. Cobalt 76-82 BCL2 apoptosis regulator Homo sapiens 9-14 18845789-4 2009 By contrast, treatment of cells with C2-ceramide (a potent PP2A activator) or expression of the PP2A catalytic subunit (PP2A/C) inhibits Bcl2 phosphorylation, leading to increased p53/Bcl2 binding and apoptotic cell death. N-acetylsphingosine 37-48 BCL2 apoptosis regulator Homo sapiens 184-188 19239147-5 2009 Prevention of glutamate-induced apoptosis via preventing glutamate-mediated down-regulation of Bcl-2; 4. Glutamic Acid 14-23 BCL2 apoptosis regulator Homo sapiens 95-100 18845789-6 2009 PP2A directly interacts with the BH4 domain of Bcl2 as a docking site to potentially "bridge" PP2A to Bcl2"s flexible loop domain containing the target serine 70 phosphorylation site. sapropterin 33-36 BCL2 apoptosis regulator Homo sapiens 47-51 19239147-5 2009 Prevention of glutamate-induced apoptosis via preventing glutamate-mediated down-regulation of Bcl-2; 4. Glutamic Acid 57-66 BCL2 apoptosis regulator Homo sapiens 95-100 19239147-8 2009 Based on these observations, we propose that taurine protects neurons against glutamate-induced neurotoxicity in part, by preventing glutamate-induced membrane depolarization, elevation of [Ca2+]i, activation of calpain, reduction of Bcl-2 and apoptosis. Taurine 45-52 BCL2 apoptosis regulator Homo sapiens 234-239 18845789-6 2009 PP2A directly interacts with the BH4 domain of Bcl2 as a docking site to potentially "bridge" PP2A to Bcl2"s flexible loop domain containing the target serine 70 phosphorylation site. sapropterin 33-36 BCL2 apoptosis regulator Homo sapiens 102-106 19239147-8 2009 Based on these observations, we propose that taurine protects neurons against glutamate-induced neurotoxicity in part, by preventing glutamate-induced membrane depolarization, elevation of [Ca2+]i, activation of calpain, reduction of Bcl-2 and apoptosis. Glutamic Acid 78-87 BCL2 apoptosis regulator Homo sapiens 234-239 19239147-8 2009 Based on these observations, we propose that taurine protects neurons against glutamate-induced neurotoxicity in part, by preventing glutamate-induced membrane depolarization, elevation of [Ca2+]i, activation of calpain, reduction of Bcl-2 and apoptosis. Glutamic Acid 133-142 BCL2 apoptosis regulator Homo sapiens 234-239 18845789-6 2009 PP2A directly interacts with the BH4 domain of Bcl2 as a docking site to potentially "bridge" PP2A to Bcl2"s flexible loop domain containing the target serine 70 phosphorylation site. Serine 152-158 BCL2 apoptosis regulator Homo sapiens 47-51 18845789-6 2009 PP2A directly interacts with the BH4 domain of Bcl2 as a docking site to potentially "bridge" PP2A to Bcl2"s flexible loop domain containing the target serine 70 phosphorylation site. Serine 152-158 BCL2 apoptosis regulator Homo sapiens 102-106 19082897-4 2009 The anti-apoptotic effect of genistein was associated with an enhanced expression of Bcl-2 protein and its promoter activity. Genistein 29-38 BCL2 apoptosis regulator Homo sapiens 85-90 19655415-5 2009 Magnolol also inhibited H2O2-induced expressions of caspase-9 and caspase-3 and reduction of Bcl-2/Bax ratio. magnolol 0-8 BCL2 apoptosis regulator Homo sapiens 93-98 19655415-5 2009 Magnolol also inhibited H2O2-induced expressions of caspase-9 and caspase-3 and reduction of Bcl-2/Bax ratio. Hydrogen Peroxide 24-28 BCL2 apoptosis regulator Homo sapiens 93-98 19331147-6 2009 The protein levels of Bcl-2 decreased and Bax increased in the mitochondrial fraction while the Bax protein decreased, and p53 and cytochrome c protein levels increased in the cytosolic fraction in HepG2 cells after capsaicin treatment for 24 h by Western blot. Capsaicin 216-225 BCL2 apoptosis regulator Homo sapiens 22-27 19331147-8 2009 The caspase-3 activity significantly increased after capsaicin treatment for 24 h. Our results indicated that the capsaicin-induced apoptosis in HepG2 cells may result from the elevation of intracellular Ca2+ production, ROS, disruption of alpha psi(m), regulation of Bcl-2 family protein expression and caspase-3 activity. Capsaicin 53-62 BCL2 apoptosis regulator Homo sapiens 268-273 19331147-8 2009 The caspase-3 activity significantly increased after capsaicin treatment for 24 h. Our results indicated that the capsaicin-induced apoptosis in HepG2 cells may result from the elevation of intracellular Ca2+ production, ROS, disruption of alpha psi(m), regulation of Bcl-2 family protein expression and caspase-3 activity. Capsaicin 114-123 BCL2 apoptosis regulator Homo sapiens 268-273 19082729-4 2009 We found that 15-HETE enhanced cell survival, suppressed the expression and activity of caspase-3, upregulated bcl-2 and attenuated mitochondrial depolarization, prevented chromatin condensation and partly reversed K(+) channel opener-induced apoptosis in PASMCs under serum-deprived conditions. 15-Hete 14-21 BCL2 apoptosis regulator Homo sapiens 111-116 19343001-5 2009 Bufalin increased the Bax/Bcl-2 ratio and activated caspase-3 during the apoptotic process of MGC803 cells. bufalin 0-7 BCL2 apoptosis regulator Homo sapiens 26-31 18983973-0 2009 E-cadherin decreased human breast cancer cells sensitivity to staurosporine by up-regulating Bcl-2 expression. Staurosporine 62-75 BCL2 apoptosis regulator Homo sapiens 93-98 18983973-5 2009 The resistance of E-cadherin over-expressing cells to staurosporine may due to the up-regulation of Bcl-2/Bax ratio. Staurosporine 54-67 BCL2 apoptosis regulator Homo sapiens 100-105 19889203-8 2009 RESULTS: Treatment with curcumin and resveratrol suppressed NF-kappaB-regulated gene products involved in inflammation (cyclooxygenase-2, matrix metalloproteinase (MMP)-3, MMP-9, vascular endothelial growth factor), inhibited apoptosis (Bcl-2, Bcl-xL, and TNF-alpha receptor-associated factor 1) and prevented activation of caspase-3. Resveratrol 37-48 BCL2 apoptosis regulator Homo sapiens 237-242 19052874-11 2009 Regulation of Fas and Bcl-2 may be regarded as protective measures of the cell in response to hyperbaric oxygen. Oxygen 105-111 BCL2 apoptosis regulator Homo sapiens 22-27 19889203-8 2009 RESULTS: Treatment with curcumin and resveratrol suppressed NF-kappaB-regulated gene products involved in inflammation (cyclooxygenase-2, matrix metalloproteinase (MMP)-3, MMP-9, vascular endothelial growth factor), inhibited apoptosis (Bcl-2, Bcl-xL, and TNF-alpha receptor-associated factor 1) and prevented activation of caspase-3. Curcumin 24-32 BCL2 apoptosis regulator Homo sapiens 237-242 19709444-12 2009 When cells were treated with LY294002, a potent phosphoinositide 3-kinase inhibitor, Akt phosphorylation and Bcl-2 levels were reduced and Hsp70 downregulation no longer had a cytoprotective effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 29-37 BCL2 apoptosis regulator Homo sapiens 109-114 19056280-6 2009 H6 increased the expression of Bax protein, whereas it decreased the expression of Bcl-2 protein. HS 6 0-2 BCL2 apoptosis regulator Homo sapiens 83-88 18534198-7 2009 The treatment of cells with the specific JNK inhibitor SP600125, but not the p38 MAPK inhibitor SB203580, revealed that the JNK-Bcl-2 signaling cascade is required for Lf-induced apoptosis. pyrazolanthrone 55-63 BCL2 apoptosis regulator Homo sapiens 128-133 19027294-0 2009 Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors. tetrahydroisoquinoline amide 0-28 BCL2 apoptosis regulator Homo sapiens 71-76 19027294-0 2009 Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors. phenyl pyrazoles 41-57 BCL2 apoptosis regulator Homo sapiens 71-76 19027294-2 2009 We describe a series of phenyl pyrazoles that have high affinity for Bcl-2 and rationalise the observed SAR by means of an X-ray crystal structure. phenyl pyrazoles 24-40 BCL2 apoptosis regulator Homo sapiens 69-74 19056280-9 2009 Furthermore, the decrease of Bcl-2 and activation of Bax, caspase-9/caspase-3 may be the effectors of H6-induced apoptosis. HS 6 102-104 BCL2 apoptosis regulator Homo sapiens 29-34 20069048-0 2009 The Impact of Adenosine Fast Induction of Myocardial Arrest during CABG on Myocardial Expression of Apoptosis-Regulating Genes Bax and Bcl-2. Adenosine 14-23 BCL2 apoptosis regulator Homo sapiens 135-140 18228136-12 2009 In conclusion, 2ME chemosensitizes resistant breast cancer cells to Dox cytotoxicity by down regulating expression of Bcl2 and Cyclin D1, augmenting caspase 3 activity as well as inducing cell cycle block in G(1) and S phases. Doxorubicin 68-71 BCL2 apoptosis regulator Homo sapiens 118-122 19117992-0 2009 PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Calpha-mediated Bcl-2 stabilization. Cisplatin 75-84 BCL2 apoptosis regulator Homo sapiens 142-147 19117992-8 2009 Consistently, Bcl-2 knockdown sensitized PCa cells to cisplatin treatment and, more importantly, reversed the cisplatin resistance of PCa cells expressing the mt-PCPH oncoprotein. Cisplatin 54-63 BCL2 apoptosis regulator Homo sapiens 14-19 19117992-8 2009 Consistently, Bcl-2 knockdown sensitized PCa cells to cisplatin treatment and, more importantly, reversed the cisplatin resistance of PCa cells expressing the mt-PCPH oncoprotein. Cisplatin 110-119 BCL2 apoptosis regulator Homo sapiens 14-19 19117992-9 2009 Moreover, reexpression of Bcl-2 in PCPH/mt-PCPH knockdown PCa cells reversed the cisplatin sensitization caused by PCPH or mt-PCPH down-regulation. Cisplatin 81-90 BCL2 apoptosis regulator Homo sapiens 26-31 18836097-3 2009 Because AT-101 binds to the BH3 motif of all Bcl-2-family antiapoptotic proteins, we hypothesized that this molecule could overcome resistance. gossypol acetic acid 8-14 BCL2 apoptosis regulator Homo sapiens 45-50 18836097-3 2009 Because AT-101 binds to the BH3 motif of all Bcl-2-family antiapoptotic proteins, we hypothesized that this molecule could overcome resistance. BH 3 28-31 BCL2 apoptosis regulator Homo sapiens 45-50 18228136-4 2009 RT(2) Profiler PCR Array was used to identify differentially expressed genes in Dox and/or 2ME treatment groups, based on significance of results 4 genes were selected: MDR1, Bcl2, P53 and Cyclin D1. Doxorubicin 80-83 BCL2 apoptosis regulator Homo sapiens 175-179 18228136-8 2009 The array and western blotting showed that Bcl2 and Cyclin D1 expression were down regulated; P53 expression was not affected while MDR1 was over expressed by combination of 2ME with Dox. Doxorubicin 183-186 BCL2 apoptosis regulator Homo sapiens 43-47 19028702-7 2009 Treatment with 3-keto-N-(aminoethyl-aminocaproyl-dihydrocinnamoyl)-cyclopamine induced cancer cell apoptosis, suppressed cell growth, mobility and invasiveness and induced cancer cell dedifferentiation with decreased expression of E-cadherin, cytokeratin 7, Snail, calretinin, vimentin, Bcl-2, caspases, beta1 integrin, MT1-MMP and VEGF. 3-keto-n-(aminoethyl-aminocaproyl-dihydrocinnamoyl)-cyclopamine 15-78 BCL2 apoptosis regulator Homo sapiens 287-292 20069048-2 2009 We studied the effect of fast induction of cardiac arrest with denosine on myocardial bax and bcl-2 expression. Ganciclovir 63-71 BCL2 apoptosis regulator Homo sapiens 94-99 20069048-10 2009 After the adenosine treatment, the expression of both bax (0.52 versus 0.59, P = .4) and bcl-2 (0.104 versus 0.107, P = .4) remained unaltered after the operation. Adenosine 10-19 BCL2 apoptosis regulator Homo sapiens 89-94 19255499-0 2009 HIP1R interacts with a member of Bcl-2 family, BCL2L10, and induces BAK-dependent cell death. bakuchiol 68-71 BCL2 apoptosis regulator Homo sapiens 33-38 19255499-8 2009 A member of proapoptotic Bcl-2 family, BAK, was required for HIP1R to induce cell death, while BAX was dispensable. bakuchiol 39-42 BCL2 apoptosis regulator Homo sapiens 25-30 19660176-7 2009 Tacrolimus reduced significantly all of them and restored baseline values of nucleosome and caspase-9 in both experiments and Bcl-2 and caspase-3 when IL-1 + gamma-IF was added. Tacrolimus 0-10 BCL2 apoptosis regulator Homo sapiens 126-131 18937971-1 2009 OBJECTIVE: In cell line studies, BCL-2 and BAX proteins interfere with cancer response to taxanes. Taxoids 90-97 BCL2 apoptosis regulator Homo sapiens 33-38 22059351-11 2009 Combination of Bcl-2 antisense oligonucleotide with conventional chemotherapeutic drugs may enhance the cytotoxicity of these drugs and induces apoptosis. Oligonucleotides 31-46 BCL2 apoptosis regulator Homo sapiens 15-20 18796561-1 2009 Buthionine sulfoximine (BSO) is a well-known inhibitor of glutathione synthesis, producing slow glutathione (GSH) depletion and oxidative stress; some "responder" cells avoid BSO-induced death by trans-activating the prosurvival protein Bcl-2. Buthionine Sulfoximine 0-22 BCL2 apoptosis regulator Homo sapiens 237-242 18796561-1 2009 Buthionine sulfoximine (BSO) is a well-known inhibitor of glutathione synthesis, producing slow glutathione (GSH) depletion and oxidative stress; some "responder" cells avoid BSO-induced death by trans-activating the prosurvival protein Bcl-2. Buthionine Sulfoximine 24-27 BCL2 apoptosis regulator Homo sapiens 237-242 18796561-5 2009 The late phase, coinciding with reactive oxygen species production, is responsible, probably via p38 activation, for nuclear targeting of the complex and trans-activation of Bcl-2. Reactive Oxygen Species 32-55 BCL2 apoptosis regulator Homo sapiens 174-179 20067883-15 2009 beta-carotene, lycopene and all-trans retinoic acid alone and in combination with docetaxel were found to influence the expression of bcl-2 and p53 antigen in the cells examined. beta Carotene 0-13 BCL2 apoptosis regulator Homo sapiens 134-139 20067883-15 2009 beta-carotene, lycopene and all-trans retinoic acid alone and in combination with docetaxel were found to influence the expression of bcl-2 and p53 antigen in the cells examined. Lycopene 15-23 BCL2 apoptosis regulator Homo sapiens 134-139 20067883-15 2009 beta-carotene, lycopene and all-trans retinoic acid alone and in combination with docetaxel were found to influence the expression of bcl-2 and p53 antigen in the cells examined. Tretinoin 38-51 BCL2 apoptosis regulator Homo sapiens 134-139 20067883-15 2009 beta-carotene, lycopene and all-trans retinoic acid alone and in combination with docetaxel were found to influence the expression of bcl-2 and p53 antigen in the cells examined. Docetaxel 82-91 BCL2 apoptosis regulator Homo sapiens 134-139 19007973-7 2009 Further, urinary levels of Bcl-2 were elevated in ovarian cancer patients regardless of tumor grade, stage, size, histologic subtype, creatinine levels or patient age, but appeared to complement CA125 measurements. Creatinine 134-144 BCL2 apoptosis regulator Homo sapiens 27-32 19352052-6 2009 Both ghrelin and des-acyl ghrelin increased the Bcl-2/Bax ratio, prevented cytochrome c release, and inhibited caspase-3 activation. Ghrelin 5-12 BCL2 apoptosis regulator Homo sapiens 48-53 19352052-6 2009 Both ghrelin and des-acyl ghrelin increased the Bcl-2/Bax ratio, prevented cytochrome c release, and inhibited caspase-3 activation. ghrelin, des-n-octanoyl 17-33 BCL2 apoptosis regulator Homo sapiens 48-53 18937971-7 2009 As in our previously published analysis on platinum-cyclophosphamide-treated group, complete remission showed a borderline negative (paradoxic) association with high BAX expression in the whole group (p=0.058) and with BCL-2 expression in the TP53(-) group (p=0.058). platinum-cyclophosphamide 43-68 BCL2 apoptosis regulator Homo sapiens 219-224 18937971-8 2009 CONCLUSION: Our results suggest that TP53, BCL-2 and BAX proteins carry some predictive potential in taxane-platinum-treated ovarian cancer patients, auxiliary to clinicopathological factors. taxane-platinum 101-116 BCL2 apoptosis regulator Homo sapiens 43-48 20011242-9 2009 The transcription of caspase-3 and bax gene in the group treated with GA and MNPs-Fe(3)O(4) was higher than that in the GA-alone group or MNPs-Fe(3)O(4)-alone group, but the transcription of bcl-2, nuclear factor-kappaB, and survivin degraded as did the expression of corresponding proteins in K562 cells. fe(3) 82-87 BCL2 apoptosis regulator Homo sapiens 191-196 19431020-0 2009 Effect of proliferation, cell cycle, and Bcl-2s of MCF-7 cells by resveratrol. Resveratrol 66-77 BCL2 apoptosis regulator Homo sapiens 41-46 19516889-10 2009 The effects may be associated with over-expression of MDR1, LRP, P-gp, and Bcl-2, which can increase the intracellular platinum accumulation and induce the cell apoptosis. Platinum 119-127 BCL2 apoptosis regulator Homo sapiens 75-80 20192119-0 2009 Inhibition of BCL2 expression and activity increases H460 sensitivity to the growth inhibitory effects of polyphenon E. polyphenon E 106-118 BCL2 apoptosis regulator Homo sapiens 14-18 20192119-6 2009 Inhibition of BCL2 expression and activity, using siRNA and the small molecule inhibitor HA14-1 respectively, restored sensitivity to Poly E and induced BCL2-related apoptosis by decreasing mitochondrial membrane potential and inducing PARP cleavage. polyphenon E 134-140 BCL2 apoptosis regulator Homo sapiens 14-18 20192119-7 2009 Our results suggest that increased BCL2 expression may contribute to H460 resistance to the growth inhibitory effects of Poly E. polyphenon E 121-127 BCL2 apoptosis regulator Homo sapiens 35-39 20192119-8 2009 If validated in additional laboratory and clinical models, BCL2 could ultimately be used as a marker of Poly E resistance. polyphenon E 104-110 BCL2 apoptosis regulator Homo sapiens 59-63 20011242-9 2009 The transcription of caspase-3 and bax gene in the group treated with GA and MNPs-Fe(3)O(4) was higher than that in the GA-alone group or MNPs-Fe(3)O(4)-alone group, but the transcription of bcl-2, nuclear factor-kappaB, and survivin degraded as did the expression of corresponding proteins in K562 cells. fe(3)o 82-88 BCL2 apoptosis regulator Homo sapiens 191-196 18459128-5 2009 The berberine-induced apoptosis of both the A549 and H1299 human lung cancer cells was associated with the disruption of mitochondrial membrane potential, reduction in the levels of Bcl-2, Bcl-xl while increase in Bax, Bak, and activation of caspase-3. Berberine 4-13 BCL2 apoptosis regulator Homo sapiens 182-187 19012752-8 2009 Finally, these deleterious effects of MGO on STAT3 signaling led to down-regulation of a STAT3 target gene, Bcl-2, and sensitized cellular toxicity induced by H(2)O(2) and etoposide. Pyruvaldehyde 38-41 BCL2 apoptosis regulator Homo sapiens 108-113 18715270-8 2009 In the mitochondrial pathway, arsenite-induced increases in Bcl-2 levels and cytosolic cytochrome c were reduced by melatonin. arsenite 30-38 BCL2 apoptosis regulator Homo sapiens 60-65 19084597-6 2009 Combining 2-ME(2) with eugenol (i) inhibited growth of prostate cancer cells and induced apoptosis at lower concentrations than either single agent alone; (ii) analysis of the data using combination index (CI) showed CI values of 0.4 indicating strong synergistic interaction; (iii) increased population of cells G(2)/M phase by 4.5-fold (p=0.01); (iv) significantly reduced expression of antiapoptotic protein Bcl-2 and enhanced expression of proapoptotic protein Bax. Mercaptoethanol 10-14 BCL2 apoptosis regulator Homo sapiens 411-416 19084597-6 2009 Combining 2-ME(2) with eugenol (i) inhibited growth of prostate cancer cells and induced apoptosis at lower concentrations than either single agent alone; (ii) analysis of the data using combination index (CI) showed CI values of 0.4 indicating strong synergistic interaction; (iii) increased population of cells G(2)/M phase by 4.5-fold (p=0.01); (iv) significantly reduced expression of antiapoptotic protein Bcl-2 and enhanced expression of proapoptotic protein Bax. Eugenol 23-30 BCL2 apoptosis regulator Homo sapiens 411-416 20077182-7 2009 Western-blot analysis showed an activation of caspase-8, Bid, BAX, and caspase-3 and a decrease of Bcl-2 in JB6 cells treated with TiO(2) particles. titanium dioxide 131-137 BCL2 apoptosis regulator Homo sapiens 99-104 18759062-9 2009 Bcl-2 protein has significantly decreased in DADS treated cells. diallyl disulfide 45-49 BCL2 apoptosis regulator Homo sapiens 0-5 20107586-4 2009 Biz-2 elicited a 2-fold increase in the mRNA of the anti-apoptotic gene Bcl2, with a 10-fold increase in that of the proapoptotic gene Bax. biz-2 0-5 BCL2 apoptosis regulator Homo sapiens 72-76 19441249-7 2009 Bcl-2 level increased in spiral ganglion neurons exposed to Neurobasal medium + 10 nmol/L ouabain at 6 h. CONCLUSION: Low dose of ouabain protects injury of spiral ganglion neurons evoked by trophic factors deprived in vitro. Ouabain 90-97 BCL2 apoptosis regulator Homo sapiens 0-5 18521846-5 2009 2-methoxyestradiol-induced JNK activation was associated with the induction of apoptosis through the mitochondrial pathways as a result of increased phosphorylation (inactivation) of the anti-apoptotic Bcl-2 and Bcl-xL proteins. 2-Methoxyestradiol 0-18 BCL2 apoptosis regulator Homo sapiens 202-207 19183107-0 2009 Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2. Oligodeoxyribonucleotides 79-103 BCL2 apoptosis regulator Homo sapiens 112-117 19183107-1 2009 Antisense oligonucleotide G3139-mediated down-regulation of Bcl-2 is a potential strategy for overcoming chemoresistance in leukemia. Oligonucleotides 10-25 BCL2 apoptosis regulator Homo sapiens 60-65 19183107-1 2009 Antisense oligonucleotide G3139-mediated down-regulation of Bcl-2 is a potential strategy for overcoming chemoresistance in leukemia. oblimersen 26-31 BCL2 apoptosis regulator Homo sapiens 60-65 19183107-10 2009 Furthermore, up-regulation of TfR expression in leukemia cells by iron chelator deferoxamine resulted in a further increase in antisense effect (up to 79% Bcl-2 reduction in K562 at the mRNA level) and in caspase-dependent apoptosis (by approximately 3-fold) by Tf-LN. Iron 66-70 BCL2 apoptosis regulator Homo sapiens 155-160 19183107-10 2009 Furthermore, up-regulation of TfR expression in leukemia cells by iron chelator deferoxamine resulted in a further increase in antisense effect (up to 79% Bcl-2 reduction in K562 at the mRNA level) and in caspase-dependent apoptosis (by approximately 3-fold) by Tf-LN. Deferoxamine 80-92 BCL2 apoptosis regulator Homo sapiens 155-160 18832435-5 2009 NaHS also prevented rotenone-induced p38- and c-Jun NH(2)-terminal kinase (JNK)-mitogen-activated protein kinase (MAPK) phosphorylation and rotenone-mediated changes in Bcl-2/Bax levels, mitochondrial membrane potential (DeltaPsi(m)) dissipation, cytochrome c release, caspase-9/3 activation and poly(ADP-ribose) polymerase cleavage. Rotenone 20-28 BCL2 apoptosis regulator Homo sapiens 169-174 18832435-5 2009 NaHS also prevented rotenone-induced p38- and c-Jun NH(2)-terminal kinase (JNK)-mitogen-activated protein kinase (MAPK) phosphorylation and rotenone-mediated changes in Bcl-2/Bax levels, mitochondrial membrane potential (DeltaPsi(m)) dissipation, cytochrome c release, caspase-9/3 activation and poly(ADP-ribose) polymerase cleavage. sodium bisulfide 0-4 BCL2 apoptosis regulator Homo sapiens 169-174 18832435-5 2009 NaHS also prevented rotenone-induced p38- and c-Jun NH(2)-terminal kinase (JNK)-mitogen-activated protein kinase (MAPK) phosphorylation and rotenone-mediated changes in Bcl-2/Bax levels, mitochondrial membrane potential (DeltaPsi(m)) dissipation, cytochrome c release, caspase-9/3 activation and poly(ADP-ribose) polymerase cleavage. Rotenone 140-148 BCL2 apoptosis regulator Homo sapiens 169-174 19544974-1 2009 Our previous study has shown that sodium selenite can cause apoptosis in acute promyelocytic leukemia-derived NB4 cells in a caspase-dependent manner involving Deltapsim disruption and cleavage of Bcl-2, but more detailed mechanism(s) remain unclear. Sodium Selenite 34-49 BCL2 apoptosis regulator Homo sapiens 197-202 18357521-0 2009 Bcl-2 siRNA augments taxol mediated apoptotic death in human glioblastoma U138MG and U251MG cells. Paclitaxel 21-26 BCL2 apoptosis regulator Homo sapiens 0-5 18357521-4 2009 In the current study, we knocked down Bcl-2 expression using cognate siRNA during low-dose taxol treatment to induce apoptosis in two human glioblastoma U138MG and U251MG cell lines. Paclitaxel 91-96 BCL2 apoptosis regulator Homo sapiens 38-43 18357521-9 2009 Our current study demonstrated that Bcl-2 siRNA significantly augmented taxol mediated apoptosis in different human glioblastoma cells through induction of calpain and caspase proteolytic activities. Paclitaxel 72-77 BCL2 apoptosis regulator Homo sapiens 36-41 19116882-8 2009 DHA and DHA-rich phosphatidylcholine decreased Bcl-2 level in HT-29 and Caco-2 cells. Docosahexaenoic Acids 0-3 BCL2 apoptosis regulator Homo sapiens 47-52 19116882-8 2009 DHA and DHA-rich phosphatidylcholine decreased Bcl-2 level in HT-29 and Caco-2 cells. Docosahexaenoic Acids 8-11 BCL2 apoptosis regulator Homo sapiens 47-52 19116882-8 2009 DHA and DHA-rich phosphatidylcholine decreased Bcl-2 level in HT-29 and Caco-2 cells. Phosphatidylcholines 17-36 BCL2 apoptosis regulator Homo sapiens 47-52 20098578-7 2009 Bcl-2 protein and mRNA expressions were also decreased in cells that were treated with alpha-lipoic acid (P < 0.05). Thioctic Acid 87-104 BCL2 apoptosis regulator Homo sapiens 0-5 19838939-8 2009 Cyclin D1, cyclin D3, bcl-2, and NFkappa B proteins were found to be downregulated following gamma-tocopherol treatment. gamma-Tocopherol 93-109 BCL2 apoptosis regulator Homo sapiens 22-27 19806784-0 2009 Hemin counteracts the repression of Bcl-2 and NrF2 genes and the cell killing induced by imatinib in human Bcr-Abl(+) CML cells. Hemin 0-5 BCL2 apoptosis regulator Homo sapiens 36-41 19806784-9 2009 These data clearly indicate that: (a) cellular heme resulted from de novo biosynthesis and hemin uptake alters the developmental stage of human Bcr-Abl(+) CML cells and their susceptibility to imatinib; (b) cellular heme counteracts the ability of imatinib to repress Bcl-2 and Nrf2 gene expression; and (c) inhibitors of de novo biosynthesis can be developed and combined with imatinib to enhance its antileukemic activity. Heme 47-51 BCL2 apoptosis regulator Homo sapiens 268-273 19806784-9 2009 These data clearly indicate that: (a) cellular heme resulted from de novo biosynthesis and hemin uptake alters the developmental stage of human Bcr-Abl(+) CML cells and their susceptibility to imatinib; (b) cellular heme counteracts the ability of imatinib to repress Bcl-2 and Nrf2 gene expression; and (c) inhibitors of de novo biosynthesis can be developed and combined with imatinib to enhance its antileukemic activity. Hemin 91-96 BCL2 apoptosis regulator Homo sapiens 268-273 19440006-3 2009 The aim of this study was to investigate the modulations in the BAX, BCL2 and BCL2L12 mRNA levels in gastric cancer cells, after their treatment with the anticancer drugs 5-fluorouracil and irinotecan as well as the antioxidant substance leucovorin. Irinotecan 190-200 BCL2 apoptosis regulator Homo sapiens 69-73 19164252-15 2009 The ratio of Bcl-2 to Bax expression was decreased in the 25 micromol/L and the 50 micromol/L 3,4-DGE-treated groups compared to control (p<0.05). 3,4-dideoxyglucosone-3-ene 94-101 BCL2 apoptosis regulator Homo sapiens 13-18 19440292-4 2009 The expression of Stat3-regulated proteins such as c-myc, cyclin D1, Bcl2, survivin and VEGF were reduced in response to avicin treatment. avicin 121-127 BCL2 apoptosis regulator Homo sapiens 69-73 19538862-9 2009 RT-PCR and Western blot test showed that after the treatment of colon cancer cells with resveratrol at different concentrations (25, 50, 100 and 200 micromol/L), the expression level of bcl-2 was decreased, while expression level of bax was increased. Resveratrol 88-99 BCL2 apoptosis regulator Homo sapiens 186-191 18977202-0 2008 Aranorosin and a novel derivative inhibit the anti-apoptotic functions regulated by Bcl-2. aranorosin 0-10 BCL2 apoptosis regulator Homo sapiens 84-89 18977202-3 2008 A microbial metabolite, aranorosin, was identified as an inhibitor of the anti-apoptotic function of Bcl-2. aranorosin 24-34 BCL2 apoptosis regulator Homo sapiens 101-106 18977202-8 2008 Thus, a novel aranorosin derivative, K050, could be a potent therapeutic agent against Bcl-2-overexpressing human malignancies. aranorosin 14-24 BCL2 apoptosis regulator Homo sapiens 87-92 18848838-9 2008 Finally, PPARalpha activation reduced the lidocaine-induced caspase-3 activity and apoptosis, which might be due to the VDUP-1-mediated regulation of the Bax/Bcl-2 ratio. Lidocaine 42-51 BCL2 apoptosis regulator Homo sapiens 158-163 19109899-4 2008 Interestingly, Bmf, a BH3-only Bcl-2 family member, is required for death-receptor-induced necroptosis. BMF 15-18 BCL2 apoptosis regulator Homo sapiens 31-36 19052265-3 2008 Oblimersen, an antisense oligonucleotide that stops the translation of Bcl-2 mRNA to protein, significantly improved progression-free survival when administered in combination with dacarbazine. Oligonucleotides 25-40 BCL2 apoptosis regulator Homo sapiens 71-76 18927073-4 2008 Cells stably overexpressing Bcl-2/Bcl-x(L) or stably depleted of Apaf-1 were equally resistant to apoptosis induced by the DNA-damaging anticancer drug etoposide as determined by phosphatidylserine externalization and caspase activation. Etoposide 152-161 BCL2 apoptosis regulator Homo sapiens 28-33 19484992-7 2009 The gene array results showed that resveratrol greatly downregulated expression levels of Bcl-2 and MDR1. Resveratrol 35-46 BCL2 apoptosis regulator Homo sapiens 90-95 19484992-8 2009 After treated with 100 micromol/L, 200 micromol/L resveratrol, the expression level of Bcl-2 and MDR1 in KBv200 cells were markedly decreased in comparison with those untreated (t were 2.98, 3.51 and 3.12, 4.56, P < 0.05). Resveratrol 50-61 BCL2 apoptosis regulator Homo sapiens 87-92 19088028-0 2008 Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. ABT-737 122-129 BCL2 apoptosis regulator Homo sapiens 98-103 18980240-0 2008 Plumbagin-induced apoptosis of human breast cancer cells is mediated by inactivation of NF-kappaB and Bcl-2. plumbagin 0-9 BCL2 apoptosis regulator Homo sapiens 102-107 18980240-10 2008 Bcl-2 over-expression resulted in attenuation of plumbagin-induced effects, suggesting that the inhibition of cell growth and induction of apoptosis by plumbagin is in part due to inactivation of NF-kappaB/Bcl-2 pathway. plumbagin 49-58 BCL2 apoptosis regulator Homo sapiens 0-5 18980240-10 2008 Bcl-2 over-expression resulted in attenuation of plumbagin-induced effects, suggesting that the inhibition of cell growth and induction of apoptosis by plumbagin is in part due to inactivation of NF-kappaB/Bcl-2 pathway. plumbagin 49-58 BCL2 apoptosis regulator Homo sapiens 206-211 19088028-2 2008 We determined the effects of ABT-737, a small-molecule inhibitor of Bcl-2/Bcl-xL but not Mcl-1, on apoptosis induction alone and in combination with CPT-11 and explored mechanisms underlying their cooperativity. ABT-737 29-36 BCL2 apoptosis regulator Homo sapiens 68-73 19088028-8 2008 ABT-737 unsequestered the BH3-only protein Bim from its complex with Bcl-xL or Bcl-2 and disrupted the interaction of Bcl-xL with Bak. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 79-84 18789369-11 2008 Recent advances in cellular and molecular biology have reported that lithium may represent an effective therapeutic strategy for treating neurodegenerative disorders like Alzheimer"s disease, due to its effects on neuroprotective proteins like Bcl-2 and its actions on regulators of apoptosis and cellular resilience, such as GSK-3. Lithium 69-76 BCL2 apoptosis regulator Homo sapiens 244-249 18818203-5 2008 Stabilization of p27 in G(0) in BCL2 or BCL-x(L) cells was due to phosphorylation of p27 at Ser(10) by the kinase Mirk. Serine 92-95 BCL2 apoptosis regulator Homo sapiens 32-36 19070581-2 2008 Using this database, we show that although the CpG dinucleotide constitutes only 1% of the human genome, it accounts for 40%-70% of breakpoints at pro-B/pre-B stage translocation regions-specifically, those near the bcl-2, bcl-1, and E2A genes. cytidylyl-3'-5'-guanosine 47-63 BCL2 apoptosis regulator Homo sapiens 216-221 18695675-5 2008 The histone deacetylase inhibitor, trichostatin A, repressed bcl-2 transcription and decreased the IgH enhancer-bcl-2 promoter region interactions. trichostatin A 35-49 BCL2 apoptosis regulator Homo sapiens 61-66 18695675-5 2008 The histone deacetylase inhibitor, trichostatin A, repressed bcl-2 transcription and decreased the IgH enhancer-bcl-2 promoter region interactions. trichostatin A 35-49 BCL2 apoptosis regulator Homo sapiens 112-117 18762177-2 2008 Accumulating evidence indicates that the natural product gossypol and its derivatives can kill tumor cells by targeting antiapoptotic BCL-2 family members in such a manner as to trigger MOMP. Gossypol 57-65 BCL2 apoptosis regulator Homo sapiens 134-139 19026166-0 2008 Synergistic antitumoral activity and induction of apoptosis by novel pan Bcl-2 proteins inhibitor apogossypolone with adriamycin in human hepatocellular carcinoma. apogossypolone 98-112 BCL2 apoptosis regulator Homo sapiens 73-78 19026166-0 2008 Synergistic antitumoral activity and induction of apoptosis by novel pan Bcl-2 proteins inhibitor apogossypolone with adriamycin in human hepatocellular carcinoma. Doxorubicin 118-128 BCL2 apoptosis regulator Homo sapiens 73-78 18840766-4 2008 However, the role of Bax and Bcl-2 in regulating palmitate-induced apoptosis has not been well studied. Palmitates 49-58 BCL2 apoptosis regulator Homo sapiens 29-34 18840766-5 2008 Therefore, the purpose of this study was to determine whether palmitate-induced apoptosis in C(2)C(12) myotubes is dependent on Bax to Bcl-2 binding. Palmitates 62-71 BCL2 apoptosis regulator Homo sapiens 135-140 18840766-6 2008 An additional purpose of this study was to determine whether the changes in Bax to Bcl-2 binding corresponded to decreases in Akt signaling in palmitate-treated myoblasts. Palmitates 143-152 BCL2 apoptosis regulator Homo sapiens 83-88 19099231-0 2008 Phenethyl isothiocyanate induced apoptosis via down regulation of Bcl-2/XIAP and triggering of the mitochondrial pathway in MCF-7 cells. phenethyl isothiocyanate 0-24 BCL2 apoptosis regulator Homo sapiens 66-71 19099231-6 2008 PEITC also caused a decrease in the levels of Bcl-2 with a concomitant increase in Bax levels, which resulted in the release of cytochrome c. phenethyl isothiocyanate 0-5 BCL2 apoptosis regulator Homo sapiens 46-51 19099231-10 2008 Specifically, PEITC induced a change in the Bax/Bcl-2 ratios, XIAP levels and Smac translocation that was conjunction with the release of cytochrome c and following caspase activation. phenethyl isothiocyanate 14-19 BCL2 apoptosis regulator Homo sapiens 48-53 18765235-8 2008 Trolox, CAPE and AA861, i.e., all treatments that abolish ROS increase and prevent Bcl-2 up-regulation, increase the rate of cell loss, whereas BSO, increasing Bcl-2, reduces cell loss and induces chemo-resistance. 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid 0-6 BCL2 apoptosis regulator Homo sapiens 83-88 18765235-8 2008 Trolox, CAPE and AA861, i.e., all treatments that abolish ROS increase and prevent Bcl-2 up-regulation, increase the rate of cell loss, whereas BSO, increasing Bcl-2, reduces cell loss and induces chemo-resistance. 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid 0-6 BCL2 apoptosis regulator Homo sapiens 160-165 18778689-4 2008 However, several Bcl-2 proteins have been described that do not fit into these models, due to their atypical domain structure or due to their ability to induce apoptosis independently of BH3. BH 3 187-190 BCL2 apoptosis regulator Homo sapiens 17-22 18762177-5 2008 First, using a reconstituted liposomal system that recapitulates basic aspects of the BCL-2-regulated MOMP pathway, we demonstrate that MCL-1 inhibits BAX permeabilizing function via a "dual-interaction" mechanism, while submicromolar concentrations of gossypol reverse MCL-1-mediated inhibition of functional BAX activation. Gossypol 253-261 BCL2 apoptosis regulator Homo sapiens 86-91 18765235-4 2008 On the one side, pharmacological glutathione depletion with BSO further increases ROS formation and Bcl-2 levels. Glutathione 33-44 BCL2 apoptosis regulator Homo sapiens 100-105 18765235-5 2008 On the other side, scavenging of ROS by Trolox prevents Bcl-2 up-regulation. Reactive Oxygen Species 33-36 BCL2 apoptosis regulator Homo sapiens 56-61 18765235-5 2008 On the other side, scavenging of ROS by Trolox prevents Bcl-2 up-regulation. 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid 40-46 BCL2 apoptosis regulator Homo sapiens 56-61 18765235-6 2008 Two lipoxygenase (LOX) inhibitors (CAPE or AA861) prevent ROS increase and, accordingly, also prevent Bcl-2 up-regulation. 2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone 43-48 BCL2 apoptosis regulator Homo sapiens 102-107 19043216-7 2008 Furthermore, we demonstrated that NP-OH nanoplex of bcl-2 siRNA significantly inhibited tumor growth compared with control siRNA, and the efficacy was comparable to commercial products. np-oh 34-39 BCL2 apoptosis regulator Homo sapiens 52-57 19067680-2 2008 We demonstrate here that gambogic acid also present powerful antileukaemic potency through both growth arrest and apoptosis induction in Jurkat cells, which was accompanied by typical apoptotic morphological changes and sharp decreased expression of Bcl-xL and Bcl-2. gambogic acid 25-38 BCL2 apoptosis regulator Homo sapiens 261-266 18798263-8 2008 Both carotenoids induced cell cycle arrest during G(1) phase by reducing the expression of cyclin D1, cyclin D2, CDK4 and CDK6, and inducing the expression of GADD45alpha, and induced apoptosis by reducing the expression of Bcl-2, XIAP, cIAP2 and survivin. Carotenoids 5-16 BCL2 apoptosis regulator Homo sapiens 224-229 18785266-7 2008 The procedures involving cells" fixation with 1% paraformaldehyde and permeabilization with digitonin, required for intracellular Bcl-2 immunostaining did not compromise the association of 7-ADD (nor Annexin V-FITC) previously incubated with SCLC cells. Digitonin 92-101 BCL2 apoptosis regulator Homo sapiens 130-135 19002586-5 2008 Exposure of AsPC-1 and BxPC-3 cells to capsaicin was also associated with increased expression of Bax, down-regulation of bcl-2, survivin and significant release of cytochrome c and AIF in the cytosol. Capsaicin 39-48 BCL2 apoptosis regulator Homo sapiens 122-127 19002588-6 2008 Furthermore, we have shown that overexpression of Bcl-2 and active Akt (myr-Akt) in U937 cells inhibited the induction of apoptosis, activation of caspase-3, and PLC-gamma1 cleavage by withaferin A. withaferin A 185-197 BCL2 apoptosis regulator Homo sapiens 50-55 19047121-0 2008 Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Oligonucleotides 43-58 BCL2 apoptosis regulator Homo sapiens 27-32 19047121-2 2008 We evaluated the efficacy and safety of a Bcl-2 antisense oligonucleotide, G3139, in combination with doxorubicin (A) and docetaxel (T) in patients with locally advanced breast cancer (LABC). Oligonucleotides 58-73 BCL2 apoptosis regulator Homo sapiens 42-47 19047121-2 2008 We evaluated the efficacy and safety of a Bcl-2 antisense oligonucleotide, G3139, in combination with doxorubicin (A) and docetaxel (T) in patients with locally advanced breast cancer (LABC). oblimersen 75-80 BCL2 apoptosis regulator Homo sapiens 42-47 18930780-4 2008 NGEN-induced apoptosis was accompanied by increased hyperpolarization of the mitochondrial membrane potential, downregulation of Bcl-2, upregulation of Bax, activation of caspases and subsequent poly(ADP-ribose)polymerase (PARP) cleavages. naringenin 0-4 BCL2 apoptosis regulator Homo sapiens 129-134 19020760-12 2008 The Bcl-2 level was induced by dexamethasone treatment but decreased after treatment with 2-methoxyestradiol or lactic acid. Dexamethasone 31-44 BCL2 apoptosis regulator Homo sapiens 4-9 18753253-6 2008 In vitro, high extracellular glucose led to decreased Bcl-2 expression, reduced Rap1b GTPase activity, and increased levels of both Bax and GTPase activating protein in a proximal tubular cell line (HK-2). Glucose 29-36 BCL2 apoptosis regulator Homo sapiens 54-59 19020760-12 2008 The Bcl-2 level was induced by dexamethasone treatment but decreased after treatment with 2-methoxyestradiol or lactic acid. 2-Methoxyestradiol 90-108 BCL2 apoptosis regulator Homo sapiens 4-9 19020760-12 2008 The Bcl-2 level was induced by dexamethasone treatment but decreased after treatment with 2-methoxyestradiol or lactic acid. Lactic Acid 112-123 BCL2 apoptosis regulator Homo sapiens 4-9 18753253-9 2008 Furthermore, the BH4 domain of Bcl-2 was found to be required for successful protein-protein interaction between Bcl-2 and Rap1b. sapropterin 17-20 BCL2 apoptosis regulator Homo sapiens 31-36 18753253-9 2008 Furthermore, the BH4 domain of Bcl-2 was found to be required for successful protein-protein interaction between Bcl-2 and Rap1b. sapropterin 17-20 BCL2 apoptosis regulator Homo sapiens 113-118 18780829-8 2008 Pharmacological inhibition of NF-kappaBorRNA interference-mediated suppression of Bcl-2 and survivin was also shown to sensitize AIPC cells to oxaliplatin. Oxaliplatin 143-154 BCL2 apoptosis regulator Homo sapiens 82-87 18507762-8 2008 Exposure of hepG2 cells to honokiol resulted in the downregulation of Bcl-X(L) and Bcl-2 expression and the release of mitochondrial cytochrome c to the cytosol. honokiol 27-35 BCL2 apoptosis regulator Homo sapiens 83-88 19074850-8 2008 Resveratrol has been shown to be an APE/Ref-1 inhibitor and significant decreases in AP-1/JunD, MMP-1, Bcl-2, and iNOS protein levels occurred after exposure to resveratrol. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 103-108 19074850-8 2008 Resveratrol has been shown to be an APE/Ref-1 inhibitor and significant decreases in AP-1/JunD, MMP-1, Bcl-2, and iNOS protein levels occurred after exposure to resveratrol. Resveratrol 161-172 BCL2 apoptosis regulator Homo sapiens 103-108 19043528-6 2008 Sampling areas with different residual cellularity scores fromboth the imatinib-treated and untreated patients showed biochemical and immunohistochemical evidence of high levels of proautophagy beclin1/PI3KIII and low levels of antiautophagy beclin1/bcl2 complexes, together with the presence of LC3-II detected by Western blot analysis, thus supporting the presence of autophagy. Imatinib Mesylate 71-79 BCL2 apoptosis regulator Homo sapiens 250-254 18663430-9 2008 Next, it caused Bcl-2 phosphorylation on Ser-70, downregulation of Mcl-1 expression, and activation of caspase-3, leading to apoptotic cell death. Serine 41-44 BCL2 apoptosis regulator Homo sapiens 16-21 19641500-6 2008 The BH3 mimetics are small molecule antagonists of the anti-apoptotic BCL-2 members that function as competitive inhibitors by binding to the hydrophobic cleft. BH 3 4-7 BCL2 apoptosis regulator Homo sapiens 70-75 19020740-6 2008 Interestingly, expression of proteins related to taxane resistance including P-glycoprotein, class III beta-tubulin and Bcl-2 increased in MKN45/F2R cells. taxane 49-55 BCL2 apoptosis regulator Homo sapiens 120-125 18573594-4 2008 Treatment of irradiated PC-3 cells with methyl jasmonate resulted in suppression of anti-apoptotic Bcl-2 protein and elevation of caspase-3 activity. methyl jasmonate 40-56 BCL2 apoptosis regulator Homo sapiens 99-104 18941459-4 2008 We have previously shown that treatment of PC3 cells with IP6 induces the transcription of a subset of nuclear factor-kappaB (NF-kappaB)-responsive and pro-apoptotic BCL-2 family genes. Phytic Acid 58-61 BCL2 apoptosis regulator Homo sapiens 166-171 18941459-6 2008 Treatment with IP6 also leads to increased protein levels of PUMA, BIK/NBK and NOXA between 4 and 8 h of treatment and decreased levels of MCL-1 and BCL-2 after 24 h. Although blocking transcription using actinomycin D does not modulate PC3 cell sensitivity to IP6, inhibition of protein translation using cycloheximide has a significant protective effect. Phytic Acid 15-18 BCL2 apoptosis regulator Homo sapiens 149-154 18941459-9 2008 The enhanced effect of combined MG132/IP6 treatment is almost completely inhibited by cycloheximide and correlates with changes in BCL-2 family protein levels. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 32-37 BCL2 apoptosis regulator Homo sapiens 131-136 18941459-9 2008 The enhanced effect of combined MG132/IP6 treatment is almost completely inhibited by cycloheximide and correlates with changes in BCL-2 family protein levels. Phytic Acid 38-41 BCL2 apoptosis regulator Homo sapiens 131-136 18941459-10 2008 Altogether these results suggest a role for BCL-2 family proteins in mediating the combined effect of IP6 and proteasome inhibitors and warrant further pre-clinical studies for the treatment of AIPCa. Phytic Acid 102-105 BCL2 apoptosis regulator Homo sapiens 44-49 18639976-1 2008 Isothiocyanates are a class of phytochemicals able to induce apoptosis in numerous cells including Jurkat T-lymphoma cells overexpressing the oncoprotein Bcl-2. Isothiocyanates 0-15 BCL2 apoptosis regulator Homo sapiens 154-159 18639976-5 2008 Isothiocyanates specifically target cysteine residues, therefore we tested the hypothesis that PEITC directly impairs Bcl-2 and Bcl-X(L) activity by interacting with their conserved cysteine residues. phenethyl isothiocyanate 95-100 BCL2 apoptosis regulator Homo sapiens 118-123 18639976-6 2008 Jurkat cells overexpressing double cysteine mutants of Bcl-2 were generated, but they remained sensitive to PEITC. Cysteine 35-43 BCL2 apoptosis regulator Homo sapiens 55-60 18639976-6 2008 Jurkat cells overexpressing double cysteine mutants of Bcl-2 were generated, but they remained sensitive to PEITC. phenethyl isothiocyanate 108-113 BCL2 apoptosis regulator Homo sapiens 55-60 18980325-6 2008 In the study of apoptosis-related protein in the naringenin-treated cells, anti-apoptotic proteins such as p-Akt, NF-kappaB, and Bcl-2 were decreased, and pro-apoptotic protein Bad was accumulated by Western blot analysis. naringenin 49-59 BCL2 apoptosis regulator Homo sapiens 129-134 18667267-4 2008 In the Bcl-2 family proteins, Bid protein (a substrate of caspase-8) was activated by furanodiene, but Bcl-2, Bax and Bcl-xL proteins were not influenced by furanodiene stimulation. furanodiene 86-97 BCL2 apoptosis regulator Homo sapiens 7-12 18729182-4 2008 TMECG treatment of melanoma cells resulted in the downregulation of antiapoptotic Bcl-2, the upregulation of proapoptotic Bax and the activation of caspase-3; however, it did not induce the expression of the apoptosis protease-activating factor-1 (Apaf-1). tmecg 0-5 BCL2 apoptosis regulator Homo sapiens 82-87 18573594-6 2008 In summary, methyl jasmonate suppressed the radiation-induced Bcl-2 expression and enhanced the radiation sensitivity of human prostate cancer cells. methyl jasmonate 12-28 BCL2 apoptosis regulator Homo sapiens 62-67 18663354-0 2008 Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. ABT-737 48-55 BCL2 apoptosis regulator Homo sapiens 93-98 18780185-4 2008 Up-regulation of Bax/Bcl-2 ratio and activation of caspase-3 induced by high glucose suggested that mitochondria apoptosis pathway was involved. Glucose 77-84 BCL2 apoptosis regulator Homo sapiens 21-26 18780185-8 2008 Moreover, elevated reactive oxygen species (ROS) generation, calcium overload, Bax/Bcl-2 ratio, caspase-3 activation in HUVEC induced by high glucose were reversed by pre-challenge with VEGF. Glucose 142-149 BCL2 apoptosis regulator Homo sapiens 83-88 19000447-12 2008 The inhibition rates of 5-fluorouracil (5-FU), VCR, epirubicin (EADM) and OXA on cancer cells were lower in the group with strong expression of bcl-2 than in that with weak expression of bcl-2 (P<0.05). Fluorouracil 24-38 BCL2 apoptosis regulator Homo sapiens 144-149 19000447-12 2008 The inhibition rates of 5-fluorouracil (5-FU), VCR, epirubicin (EADM) and OXA on cancer cells were lower in the group with strong expression of bcl-2 than in that with weak expression of bcl-2 (P<0.05). Fluorouracil 40-44 BCL2 apoptosis regulator Homo sapiens 144-149 19000447-12 2008 The inhibition rates of 5-fluorouracil (5-FU), VCR, epirubicin (EADM) and OXA on cancer cells were lower in the group with strong expression of bcl-2 than in that with weak expression of bcl-2 (P<0.05). Epirubicin 52-62 BCL2 apoptosis regulator Homo sapiens 144-149 19000447-12 2008 The inhibition rates of 5-fluorouracil (5-FU), VCR, epirubicin (EADM) and OXA on cancer cells were lower in the group with strong expression of bcl-2 than in that with weak expression of bcl-2 (P<0.05). eadm 64-68 BCL2 apoptosis regulator Homo sapiens 144-149 18832577-7 2008 Although flupirtine was shown previously to increase neuronal survival by Bcl-2 up-regulation, this mechanism does not appear to play a role in flupirtine-mediated protection of retinal ganglion cells either in vitro or in vivo. flupirtine 9-19 BCL2 apoptosis regulator Homo sapiens 74-79 19076369-5 2008 Neurotrophic factors may modify glutamate signaling directly, by changing the expression of glutamate receptor subunits and Ca(2+)-regulating proteins, and also indirectly by inducing the production of antioxidant enzymes, energy-regulating proteins, and antiapoptotic Bcl-2 family members. Glutamic Acid 32-41 BCL2 apoptosis regulator Homo sapiens 269-274 18819005-4 2008 The peroxynitrite generator SIN-1 promoted apoptosis in monocytes based on oligonucleosomal DNA fragmentation, caspase-3 and -9 activation, Bcl-2 depletion and accumulation of Bax and p53 proteins. Peroxynitrous Acid 4-17 BCL2 apoptosis regulator Homo sapiens 140-145 18827561-2 2008 Apogossypolone (ApoG2), the most potent gossypol derivative, has been classified as a novel small-molecule inhibitor of antiapoptotic Bcl-2 family proteins. apogossypolone 0-14 BCL2 apoptosis regulator Homo sapiens 134-139 18827561-2 2008 Apogossypolone (ApoG2), the most potent gossypol derivative, has been classified as a novel small-molecule inhibitor of antiapoptotic Bcl-2 family proteins. Gossypol 3-11 BCL2 apoptosis regulator Homo sapiens 134-139 18313257-4 2008 The sulforaphane-induced apoptosis in U937 cells correlated with the generation of intracellular ROS, collapse of MMP, activation of caspase-3, and down-regulation of anti-apoptotic Bcl-2 expression. sulforaphane 4-16 BCL2 apoptosis regulator Homo sapiens 182-187 18842418-8 2008 These pentacyclic triterpene inhibitors showed an important relationship between Hh/GLI signaling inhibition, the decrease of BCL2, and cytotoxicity against cancer cells. Triterpenes 18-28 BCL2 apoptosis regulator Homo sapiens 126-130 18804944-10 2008 The results of gene detection showed that the expression levels of MDR1 and Bcl-2 were decreased upon resveratrol treatment. Resveratrol 102-113 BCL2 apoptosis regulator Homo sapiens 76-81 18845435-1 2008 The cytotoxic macrolide kendomycin was identified as a ligand of Bcl-xl, an anti-apoptotic member of the Bcl-2 protein family. Macrolides 14-23 BCL2 apoptosis regulator Homo sapiens 105-110 18845435-1 2008 The cytotoxic macrolide kendomycin was identified as a ligand of Bcl-xl, an anti-apoptotic member of the Bcl-2 protein family. kendomycin 24-34 BCL2 apoptosis regulator Homo sapiens 105-110 18663354-2 2008 As glioblastomas are characterized by high expression levels of anti-apoptotic Bcl-2 family proteins, we studied the effects of the novel Bcl-2 inhibitor, ABT-737, on malignant glioma cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 155-158 BCL2 apoptosis regulator Homo sapiens 138-143 18663354-3 2008 ABT-737 treatment released the pro-apoptotic Bax protein from its binding partner Bcl-2 and potently induced apoptotic cell death in glioblastoma cells in vitro and in vivo. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 82-87 18663354-5 2008 Downregulation of Mcl-1 and overexpression of Bcl-2 sensitized the cells to ABT-737-mediated apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 76-79 BCL2 apoptosis regulator Homo sapiens 46-51 18600231-8 2008 Moreover, treatment of MVP knocked-down senescent HDFs with SP600125, a specific c-Jun NH(2)-terminal kinase (JNK) inhibitor, restored the level of Bcl-2 protein. pyrazolanthrone 60-68 BCL2 apoptosis regulator Homo sapiens 148-153 18158619-7 2008 Reduced Bax expression and enhanced Bcl-2 expression by Id-1 were also noted in the presence of taxol. Paclitaxel 96-101 BCL2 apoptosis regulator Homo sapiens 36-41 18158619-8 2008 Taken together, we present a molecular mechanism where Id-1 regulates p53 and NF-kappaB pathways, which in turn regulates Bax and Bcl-2 genes, thus providing a survival advantage under exogenous stress such as serum-free or taxol treatment in MCF-7 breast cancer cells. Paclitaxel 224-229 BCL2 apoptosis regulator Homo sapiens 130-135 19330074-5 2008 RT-PCR and Western blot analysis were used to detect survivin as well as Bax and Bcl-2 expressions after the cells were treated with different concentrations of ponicidin. ponicidin 161-170 BCL2 apoptosis regulator Homo sapiens 81-86 18980980-7 2008 Sulforaphane induced the expression of Bax, Bak, Bim, and Noxa and inhibited the expression of Bcl-2, Bcl-X(L), and Mcl-1. sulforaphane 0-12 BCL2 apoptosis regulator Homo sapiens 95-100 19330074-8 2008 Marked morphological changes of cell apoptosis were observed clearly after the cells were treated with ponicidin for 48 approximately 72 h. RT-PCR and Western blot analysis demonstrated that both survivin and Bcl-2 expressions were down-regulated remarkably while Bax expression remained constant before and after apoptosis occurred. ponicidin 103-112 BCL2 apoptosis regulator Homo sapiens 209-214 19330074-9 2008 We therefore conclude that ponicidin has significant anti-proliferation effects by inducing apoptosis on leukemia cells in vitro, downregulation of survivin as well as Bcl-2 expressions may be the important apoptosis inducing mechanisms. ponicidin 27-36 BCL2 apoptosis regulator Homo sapiens 168-173 19031258-3 2008 In the present study, we examined the potential roles of p53, bax, and bcl-2 in baicalin-triggered apoptosis in MCF-7 cells, a cell line derived from human breast cancer. baicalin 80-88 BCL2 apoptosis regulator Homo sapiens 71-76 18496567-0 2008 Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells. avicin D 0-8 BCL2 apoptosis regulator Homo sapiens 67-72 18496567-8 2008 Avicin D also decreased expression of the inhibitor of apoptosis protein survivin, the anti-apoptotic protein bcl-2, but not the pro-apoptotic protein bax in these CTCL cells. avicin D 0-8 BCL2 apoptosis regulator Homo sapiens 110-115 18496567-9 2008 In summary, avicin D selectively induced apoptosis, inhibited STAT-3 activation, and decreased apoptosis inhibitors (bcl-2 and survivin) in CTCL cell lines and SS patients" Sezary cells. avicin D 12-20 BCL2 apoptosis regulator Homo sapiens 117-122 19001435-8 2008 Also, expression of the antiapoptotic protein Mcl-1, a member of the Bcl-2 family, was decreased and correlated with apoptosis induced by sorafenib. Sorafenib 138-147 BCL2 apoptosis regulator Homo sapiens 69-74 19047834-5 2008 The results of this study demonstrated that streptochlorin mediates ROS production, and that this mediation is followed by a decrease in the mitochondrial membrane potential (MMP, m), activation of caspase-3, and downregulation of antiapoptotic Bcl-2 protein. streptochlorin 44-58 BCL2 apoptosis regulator Homo sapiens 245-250 19001439-12 2008 Other effects induced by kaempferol were suppression of X-linked inhibitor of apoptosis proteins as the antiapoptotic members of the Bcl-2 family, Bcl-2, Bcl-xL, and Mcl-1 in a concentration-dependent manner. kaempferol 25-35 BCL2 apoptosis regulator Homo sapiens 133-138 19001439-12 2008 Other effects induced by kaempferol were suppression of X-linked inhibitor of apoptosis proteins as the antiapoptotic members of the Bcl-2 family, Bcl-2, Bcl-xL, and Mcl-1 in a concentration-dependent manner. kaempferol 25-35 BCL2 apoptosis regulator Homo sapiens 147-152 18949393-6 2008 Bcl-2/MMR expression was significantly (p=0.030 for whole series; p=0.018 for the 5-FU-treated cases) related to the response to treatment; tumours with low levels of both Bcl-2 and MMR responded better (n=18/31, 58%) than those with high Bcl-2 and MMR (n=3/16, 18%). Fluorouracil 82-86 BCL2 apoptosis regulator Homo sapiens 0-5 18949058-6 2008 This treatment was successful because of both efficient antagonism of the prosurvival Bcl-2 family member Mcl-1 by Bim and inhibition of Bcl-2 and Bcl-x(L) by ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 159-162 BCL2 apoptosis regulator Homo sapiens 137-142 18978796-2 2008 Here we direct Bcl2-specific short interfering RNA (siRNA) with 5"-triphosphate ends (3p-siRNA) against melanoma. 5"-triphosphate 64-79 BCL2 apoptosis regulator Homo sapiens 15-19 18663729-4 2008 The functional interaction between the BCL-2 family members and regulation of calcium homeostasis in the ER provides a critical link to the life or death outcome of the cell. Calcium 78-85 BCL2 apoptosis regulator Homo sapiens 39-44 18840529-2 2008 In this study, we investigated whether the cottonseed polyphenol, -(-)gossypol, a BH3 mimetic, can reduce the expression of pro-survival, or increase the expression of pro-apoptotic, Bcl2 family proteins and thereby effectively sensitize otherwise resistant bladder cancer cells to the standard chemotherapeutic drugs gemcitabine, paclitaxel and carboplatin. Polyphenols 54-64 BCL2 apoptosis regulator Homo sapiens 183-187 18840529-2 2008 In this study, we investigated whether the cottonseed polyphenol, -(-)gossypol, a BH3 mimetic, can reduce the expression of pro-survival, or increase the expression of pro-apoptotic, Bcl2 family proteins and thereby effectively sensitize otherwise resistant bladder cancer cells to the standard chemotherapeutic drugs gemcitabine, paclitaxel and carboplatin. Gossypol 66-78 BCL2 apoptosis regulator Homo sapiens 183-187 18668529-0 2008 Combination of vitamin E and selenium causes an induction of apoptosis of human prostate cancer cells by enhancing Bax/Bcl-2 ratio. Vitamin E 15-24 BCL2 apoptosis regulator Homo sapiens 119-124 18668529-0 2008 Combination of vitamin E and selenium causes an induction of apoptosis of human prostate cancer cells by enhancing Bax/Bcl-2 ratio. Selenium 29-37 BCL2 apoptosis regulator Homo sapiens 119-124 18668529-4 2008 We also determined the involvement of Bcl-2 family proteins as a mechanism of the biological effects of vitamin E and selenium combination. Vitamin E 104-113 BCL2 apoptosis regulator Homo sapiens 38-43 18668529-4 2008 We also determined the involvement of Bcl-2 family proteins as a mechanism of the biological effects of vitamin E and selenium combination. Selenium 118-126 BCL2 apoptosis regulator Homo sapiens 38-43 18817775-3 2008 Sustained phosphorylation of Caveolin-1 is observed upon treatment and between Taxol and 10-DAB, the former shows phosphorylated Raf-1, ERK1/2 and hyperphosphorylated Bcl-2 while the later showed much less magnitude of the same. 10-deacetylbaccatine III 89-95 BCL2 apoptosis regulator Homo sapiens 167-172 18336939-4 2008 RESULTS: Whereas Bcl-2 cells were more resistant to gamma-rays (0.2keV/microm) and helium ions (16.2keV/microm) than Neo cells, heavy ions (76.3-1610keV/microm) yielded similar survival regardless of Bcl-2 overexpression. Helium 83-89 BCL2 apoptosis regulator Homo sapiens 17-22 18336939-5 2008 Carbon ions (108keV/microm) decreased the difference in the apoptotic incidence between Bcl-2 and Neo cells, and prolonged G(2)/M arrest that occurred more extensively in Bcl-2 cells than in Neo cells. Carbon 0-6 BCL2 apoptosis regulator Homo sapiens 88-93 18336939-5 2008 Carbon ions (108keV/microm) decreased the difference in the apoptotic incidence between Bcl-2 and Neo cells, and prolonged G(2)/M arrest that occurred more extensively in Bcl-2 cells than in Neo cells. Carbon 0-6 BCL2 apoptosis regulator Homo sapiens 171-176 18778687-1 2008 The selective cyclooxygenase-2 (COX-2) inhibitor celecoxib constitutes the prototype of pro-apoptotic agents acting through the intrinsic death pathway in a Bcl-2 independent manner. Celecoxib 49-58 BCL2 apoptosis regulator Homo sapiens 157-162 18778687-2 2008 To gain further insight into celecoxib-mediated apoptosis regulation at the level of the mitochondria we tested in how far the crucial pro-apoptotic Bcl-2 proteins Bak and Bax were involved using clones of the Bax-deficient Jurkat T-lymphoma cell model either expressing Bak (Jurkat Bak positive) or being negative for Bak (Jurkat Bak negative), or overexpressing Bcl-2 (Jurkat Bcl-2). Celecoxib 29-38 BCL2 apoptosis regulator Homo sapiens 149-154 18778687-2 2008 To gain further insight into celecoxib-mediated apoptosis regulation at the level of the mitochondria we tested in how far the crucial pro-apoptotic Bcl-2 proteins Bak and Bax were involved using clones of the Bax-deficient Jurkat T-lymphoma cell model either expressing Bak (Jurkat Bak positive) or being negative for Bak (Jurkat Bak negative), or overexpressing Bcl-2 (Jurkat Bcl-2). bakuchiol 164-167 BCL2 apoptosis regulator Homo sapiens 149-154 18778687-8 2008 Interestingly, in celecoxib-sensitive Bak-positive cells, celecoxib-treatment resulted in down-regulation of the anti-apoptotic Bcl-2 protein Mcl-1 which may contribute to celecoxib-mediated activation of Bak-dependent apoptosis. Celecoxib 18-27 BCL2 apoptosis regulator Homo sapiens 128-133 18778687-8 2008 Interestingly, in celecoxib-sensitive Bak-positive cells, celecoxib-treatment resulted in down-regulation of the anti-apoptotic Bcl-2 protein Mcl-1 which may contribute to celecoxib-mediated activation of Bak-dependent apoptosis. bakuchiol 38-41 BCL2 apoptosis regulator Homo sapiens 128-133 18778687-8 2008 Interestingly, in celecoxib-sensitive Bak-positive cells, celecoxib-treatment resulted in down-regulation of the anti-apoptotic Bcl-2 protein Mcl-1 which may contribute to celecoxib-mediated activation of Bak-dependent apoptosis. Celecoxib 58-67 BCL2 apoptosis regulator Homo sapiens 128-133 18778687-8 2008 Interestingly, in celecoxib-sensitive Bak-positive cells, celecoxib-treatment resulted in down-regulation of the anti-apoptotic Bcl-2 protein Mcl-1 which may contribute to celecoxib-mediated activation of Bak-dependent apoptosis. Celecoxib 58-67 BCL2 apoptosis regulator Homo sapiens 128-133 18778687-8 2008 Interestingly, in celecoxib-sensitive Bak-positive cells, celecoxib-treatment resulted in down-regulation of the anti-apoptotic Bcl-2 protein Mcl-1 which may contribute to celecoxib-mediated activation of Bak-dependent apoptosis. bakuchiol 205-208 BCL2 apoptosis regulator Homo sapiens 128-133 18638457-4 2008 Current pharmacological approaches are focused on the use of peptides, small inhibitory molecules or antisense oligonucleotides to neutralize antiapoptotic Bcl-2 proteins, lowering the threshold and facilitating apoptosis of cancer cells. Oligonucleotides 111-127 BCL2 apoptosis regulator Homo sapiens 156-161 18638462-8 2008 Furthermore, IQDMA up-regulated Bax, and down-regulated Bcl-2, Bcl-X(L), cyclin D1, and vascular endothelial growth factor (VEGF) as followed by growth arrest of HL-60 cells, but the expression of survivin did not change in the presence of IQDMA. N'-(11H-indolo(3,2-c)quinolin-6-yl)-N,N-dimethylethane-1,2-diamine 13-18 BCL2 apoptosis regulator Homo sapiens 56-61 18638462-9 2008 Taken together, these results indicate that IQDMA causes significant induction of apoptosis in HL-60 cells via down-regulation of Src, IL-6, and STAT5 signaling and modulation of Bcl-2 family, cyclin D1 and VEGF proteins. N'-(11H-indolo(3,2-c)quinolin-6-yl)-N,N-dimethylethane-1,2-diamine 44-49 BCL2 apoptosis regulator Homo sapiens 179-184 18922907-0 2008 IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis. Bortezomib 14-24 BCL2 apoptosis regulator Homo sapiens 34-39 18922907-4 2008 Bortezomib plus IFN-alpha was effective at inducing apoptosis in melanoma cells that overexpressed Bcl-2 or Mcl-1, suggesting that this treatment combination can overcome mitochondrial pathways of cell survival and resistance to apoptosis. Bortezomib 0-10 BCL2 apoptosis regulator Homo sapiens 99-104 18690538-5 2008 Stable overexpression of Ran also markedly inhibited the phosphorylation of Bcl-2 by paclitaxel, and inhibited the translocation of Bax, the release of cytochrome c and activation of caspase-3. Paclitaxel 85-95 BCL2 apoptosis regulator Homo sapiens 76-81 18835031-6 2008 NuBCP-9s act as molecular switches to dislodge the Bcl-2 BH4 domain, exposing its BH3 domain, which in turn blocks the activity of antiapoptotic Bcl-X(L). sapropterin 57-60 BCL2 apoptosis regulator Homo sapiens 51-56 18687309-2 2008 We generated a number of stable Jurkat cell lines expressing varying levels of Bcl-2, and showed a strong correlation between Bcl-2 levels and resistance to Fas-mediated apoptosis. ammonium ferrous sulfate 157-160 BCL2 apoptosis regulator Homo sapiens 79-84 18687309-2 2008 We generated a number of stable Jurkat cell lines expressing varying levels of Bcl-2, and showed a strong correlation between Bcl-2 levels and resistance to Fas-mediated apoptosis. ammonium ferrous sulfate 157-160 BCL2 apoptosis regulator Homo sapiens 126-131 18687309-4 2008 Cells transfected with Bcl-2 averaged 70% more glutathione than parental cells, but there was no correlation between glutathione and resistance to apoptosis. Glutathione 47-58 BCL2 apoptosis regulator Homo sapiens 23-28 18958418-5 2008 Moreover, treatment with quercetin increased Bax expression but decreased Bcl-2 expression. Quercetin 25-34 BCL2 apoptosis regulator Homo sapiens 74-79 18696228-0 2008 2,3,7,8-tetrachlorodibenzo-p-dioxin regulates bovine herpesvirus type 1 induced apoptosis by modulating Bcl-2 family members. Polychlorinated Dibenzodioxins 0-35 BCL2 apoptosis regulator Homo sapiens 104-109 18282575-6 2008 Bcl-2 overexpression prevented Bax translocation whereas it failed to prevent ROS generation indicating that ROS is an upstream signal for inducing mitochondrial apoptotic damages. Reactive Oxygen Species 109-112 BCL2 apoptosis regulator Homo sapiens 0-5 18696228-7 2008 Furthermore TCDD increased Bax and Bid levels, and decreased Bcl-2 and Bcl-XL levels. Polychlorinated Dibenzodioxins 12-16 BCL2 apoptosis regulator Homo sapiens 61-66 18696228-9 2008 These results showed that TCDD influences BHV-1 induced apoptosis through members of Bcl-2 family and up-regulating activation of caspases. Polychlorinated Dibenzodioxins 26-30 BCL2 apoptosis regulator Homo sapiens 85-90 18551131-8 2008 Structural comparison of F1L with other Bcl-2 family members reveals a novel sequence signature that redefines the BH4 domain as a structural motif present in both pro- and anti-apoptotic Bcl-2 members, including viral Bcl-2-like proteins. sapropterin 115-118 BCL2 apoptosis regulator Homo sapiens 188-193 18829556-4 2008 Our hypothesis is that changes in the intrinsic (or mitochondrial) cell death pathway controlled by the BCL-2 family are key to the development of acquired paclitaxel resistance. Paclitaxel 156-166 BCL2 apoptosis regulator Homo sapiens 104-109 18829556-5 2008 Here we show that paclitaxel activates the mitochondrial apoptosis pathway, which can be blocked by BCL-2 overexpression. Paclitaxel 18-28 BCL2 apoptosis regulator Homo sapiens 100-105 18829556-6 2008 Treatment with ABT-737, a small-molecule BCL-2 antagonist, restores sensitivity to paclitaxel in BCL-2-overexpressing cells. ABT-737 15-22 BCL2 apoptosis regulator Homo sapiens 41-46 18829556-6 2008 Treatment with ABT-737, a small-molecule BCL-2 antagonist, restores sensitivity to paclitaxel in BCL-2-overexpressing cells. ABT-737 15-22 BCL2 apoptosis regulator Homo sapiens 97-102 18829556-6 2008 Treatment with ABT-737, a small-molecule BCL-2 antagonist, restores sensitivity to paclitaxel in BCL-2-overexpressing cells. Paclitaxel 83-93 BCL2 apoptosis regulator Homo sapiens 41-46 18829556-6 2008 Treatment with ABT-737, a small-molecule BCL-2 antagonist, restores sensitivity to paclitaxel in BCL-2-overexpressing cells. Paclitaxel 83-93 BCL2 apoptosis regulator Homo sapiens 97-102 18829556-8 2008 In these lines, acquired resistance to paclitaxel is mediated either by increased antiapoptotic BCL-2 proteins or decreased proapoptotic BCL-2 proteins. Paclitaxel 39-49 BCL2 apoptosis regulator Homo sapiens 96-101 18829556-8 2008 In these lines, acquired resistance to paclitaxel is mediated either by increased antiapoptotic BCL-2 proteins or decreased proapoptotic BCL-2 proteins. Paclitaxel 39-49 BCL2 apoptosis regulator Homo sapiens 137-142 18829556-10 2008 In summary, these findings suggest that alterations in the intrinsic apoptotic pathway controlled by BCL-2 protein family members may be crucial to causing paclitaxel resistance. Paclitaxel 156-166 BCL2 apoptosis regulator Homo sapiens 101-106 18829556-11 2008 Furthermore, our results suggest that combining small-molecule BCL-2 antagonists with paclitaxel may offer benefit to patients with paclitaxel-resistant tumors, an oncologic problem of great prevalence. Paclitaxel 132-142 BCL2 apoptosis regulator Homo sapiens 63-68 18769121-3 2008 BrdU pretreatment and subsequent UV irradiation (10 J/m(2)) accelerated an early increase in the ratio of pro-apoptotic Bax to that of Bcl-2, increased apoptosis-associated PARP cleavage and potentiated DNA damage compared to irradiated unsensitized cells. Bromodeoxyuridine 0-4 BCL2 apoptosis regulator Homo sapiens 135-140 18551131-0 2008 Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. BH 3 117-120 BCL2 apoptosis regulator Homo sapiens 45-50 18551131-8 2008 Structural comparison of F1L with other Bcl-2 family members reveals a novel sequence signature that redefines the BH4 domain as a structural motif present in both pro- and anti-apoptotic Bcl-2 members, including viral Bcl-2-like proteins. sapropterin 115-118 BCL2 apoptosis regulator Homo sapiens 40-45 18566606-2 2008 Here we show that the worm Bcl-2 homology domain-3 (BH3)-only protein EGL-1 binds mammalian pro-survival proteins very poorly, but can be converted into a high-affinity ligand for Bcl-2 and Bcl-x(L) by subtle mutation of the cysteine residue at position 62 within the BH3 domain. BH 3 52-55 BCL2 apoptosis regulator Homo sapiens 27-32 18551131-8 2008 Structural comparison of F1L with other Bcl-2 family members reveals a novel sequence signature that redefines the BH4 domain as a structural motif present in both pro- and anti-apoptotic Bcl-2 members, including viral Bcl-2-like proteins. sapropterin 115-118 BCL2 apoptosis regulator Homo sapiens 188-193 18566606-2 2008 Here we show that the worm Bcl-2 homology domain-3 (BH3)-only protein EGL-1 binds mammalian pro-survival proteins very poorly, but can be converted into a high-affinity ligand for Bcl-2 and Bcl-x(L) by subtle mutation of the cysteine residue at position 62 within the BH3 domain. BH 3 52-55 BCL2 apoptosis regulator Homo sapiens 180-185 18566606-2 2008 Here we show that the worm Bcl-2 homology domain-3 (BH3)-only protein EGL-1 binds mammalian pro-survival proteins very poorly, but can be converted into a high-affinity ligand for Bcl-2 and Bcl-x(L) by subtle mutation of the cysteine residue at position 62 within the BH3 domain. Cysteine 225-233 BCL2 apoptosis regulator Homo sapiens 27-32 18309509-7 2008 Measuring the modulation of regulators in the cell cycle, apoptosis and signal transductions by Western blot analysis showed that the effect of cucurbitacin B was due to suppression of the expression of p-STAT3, Bcl-2, and cyclin B1. cucurbitacin B 144-158 BCL2 apoptosis regulator Homo sapiens 212-217 18573337-6 2008 In addition, pro-apoptotic proteins such as Bax were up-regulated, whereas anti-apoptotic proteins, such as Bcl-2, were down-regulated by treatment with both CLA and PCLA. Linoleic Acids, Conjugated 158-161 BCL2 apoptosis regulator Homo sapiens 108-113 18573337-6 2008 In addition, pro-apoptotic proteins such as Bax were up-regulated, whereas anti-apoptotic proteins, such as Bcl-2, were down-regulated by treatment with both CLA and PCLA. pcla 166-170 BCL2 apoptosis regulator Homo sapiens 108-113 18623129-8 2008 Treatment of AU-565 cells with delphinidin resulted in (i) induction of apoptosis, (ii) cleavage of PARP protein, (iii) activation of caspase-3 and (iv) downregulation of Bcl-2 with an increase in the expression of Bax. delphinidin 31-42 BCL2 apoptosis regulator Homo sapiens 171-176 18644882-7 2008 Overexpression of bcl2 almost completely inhibited cell death using CDT treatment in the presence of z-VAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 101-110 BCL2 apoptosis regulator Homo sapiens 18-22 18852136-0 2008 Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: a Bcl-2- and superoxide dismutase 2-dependent mechanism. Polyphenols 8-19 BCL2 apoptosis regulator Homo sapiens 105-110 18813781-2 2008 We have previously reported that PDT using some photosensitizers, such as phthalocyanine 4 (Pc 4) damages the anti-apoptotic protein Bcl-2, and that Bcl-2 is a molecular PDT target using a mitochondrion-targeting photosensitizer. phthalocyanine 4 74-90 BCL2 apoptosis regulator Homo sapiens 133-138 18813781-2 2008 We have previously reported that PDT using some photosensitizers, such as phthalocyanine 4 (Pc 4) damages the anti-apoptotic protein Bcl-2, and that Bcl-2 is a molecular PDT target using a mitochondrion-targeting photosensitizer. phthalocyanine 4 74-90 BCL2 apoptosis regulator Homo sapiens 149-154 18813781-2 2008 We have previously reported that PDT using some photosensitizers, such as phthalocyanine 4 (Pc 4) damages the anti-apoptotic protein Bcl-2, and that Bcl-2 is a molecular PDT target using a mitochondrion-targeting photosensitizer. pc 4 92-96 BCL2 apoptosis regulator Homo sapiens 133-138 18813781-2 2008 We have previously reported that PDT using some photosensitizers, such as phthalocyanine 4 (Pc 4) damages the anti-apoptotic protein Bcl-2, and that Bcl-2 is a molecular PDT target using a mitochondrion-targeting photosensitizer. pc 4 92-96 BCL2 apoptosis regulator Homo sapiens 149-154 18412143-8 2008 The As2O3-induced Bcl-2 phosphorylation was attenuated largely by JNK inhibition using SP600125 or si-JNK and to some extent by p38 MAPK inhibition with PD169316 or si-p38 MAPK. Arsenic Trioxide 4-9 BCL2 apoptosis regulator Homo sapiens 18-23 18412143-8 2008 The As2O3-induced Bcl-2 phosphorylation was attenuated largely by JNK inhibition using SP600125 or si-JNK and to some extent by p38 MAPK inhibition with PD169316 or si-p38 MAPK. pyrazolanthrone 87-95 BCL2 apoptosis regulator Homo sapiens 18-23 18412143-8 2008 The As2O3-induced Bcl-2 phosphorylation was attenuated largely by JNK inhibition using SP600125 or si-JNK and to some extent by p38 MAPK inhibition with PD169316 or si-p38 MAPK. 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole 153-161 BCL2 apoptosis regulator Homo sapiens 18-23 18412143-9 2008 In addition, N-acetyl-L-cystein (NAC), a thiol-containing anti-oxidant, completely blocked As2O3-induced p38 MAPK and JNK activations, mitochondria translocation of Bax, and phosphorylation of Bcl-2. Arsenic Trioxide 91-96 BCL2 apoptosis regulator Homo sapiens 193-198 18412143-10 2008 These results support a notion that ROS-mediated activations of p38 MAPK and JNK in response to As2O3 treatment signals activation of Bax and phosphorylation of Bcl-2, resulting in mitochondrial apoptotic cell death in human cervical cancer cells. Reactive Oxygen Species 36-39 BCL2 apoptosis regulator Homo sapiens 161-166 18412143-10 2008 These results support a notion that ROS-mediated activations of p38 MAPK and JNK in response to As2O3 treatment signals activation of Bax and phosphorylation of Bcl-2, resulting in mitochondrial apoptotic cell death in human cervical cancer cells. Arsenic Trioxide 96-101 BCL2 apoptosis regulator Homo sapiens 161-166 18577716-8 2008 If glucose uptake is limited, glycolytic flux decreases to a level that no longer sustains viability, and proapoptotic Bcl-2 family members become activated, promoting cell death. Glucose 3-10 BCL2 apoptosis regulator Homo sapiens 119-124 18615109-4 2008 Both WT-Bcl-2 and ER-targeted Bcl-2 prevented spontaneous and Fas-dependent apoptosis in MDS erythroid precursors. ammonium ferrous sulfate 62-65 BCL2 apoptosis regulator Homo sapiens 8-13 18615109-4 2008 Both WT-Bcl-2 and ER-targeted Bcl-2 prevented spontaneous and Fas-dependent apoptosis in MDS erythroid precursors. ammonium ferrous sulfate 62-65 BCL2 apoptosis regulator Homo sapiens 30-35 18615109-8 2008 The protective effect of ER-targeted Bcl-2 toward spontaneous and Fas-induced apoptosis correlated with inhibition of BAP31 cleavage. ammonium ferrous sulfate 66-69 BCL2 apoptosis regulator Homo sapiens 37-42 18852117-7 2008 Analysis of the lung cancer cell lines identified the bcl-2 pathway to be associated with cisplatin resistance and the AKT pathway enriched in cisplatin- and docetaxel-resistant cell lines. Cisplatin 90-99 BCL2 apoptosis regulator Homo sapiens 54-59 18813800-7 2008 A significant additive effect in reducing cyclin D1 and bcl-2 expression was found when gamma-tocotrienol was added with either EGCG or resveratrol. plastochromanol 8 88-105 BCL2 apoptosis regulator Homo sapiens 56-61 18813800-7 2008 A significant additive effect in reducing cyclin D1 and bcl-2 expression was found when gamma-tocotrienol was added with either EGCG or resveratrol. epigallocatechin gallate 128-132 BCL2 apoptosis regulator Homo sapiens 56-61 18813800-7 2008 A significant additive effect in reducing cyclin D1 and bcl-2 expression was found when gamma-tocotrienol was added with either EGCG or resveratrol. Resveratrol 136-147 BCL2 apoptosis regulator Homo sapiens 56-61 18412143-3 2008 As2O3-induced apoptotic cell death in HeLa cells was associated with activation and mitochondrial translocation of Bax, a marked phosphorylation of Bcl-2, reduction of Bcl-2 and Bax interaction, dissipation of mitochondrial membrane potential. Arsenic Trioxide 0-5 BCL2 apoptosis regulator Homo sapiens 148-153 18412143-3 2008 As2O3-induced apoptotic cell death in HeLa cells was associated with activation and mitochondrial translocation of Bax, a marked phosphorylation of Bcl-2, reduction of Bcl-2 and Bax interaction, dissipation of mitochondrial membrane potential. Arsenic Trioxide 0-5 BCL2 apoptosis regulator Homo sapiens 168-173 18412143-5 2008 Moreover, the phosphorylation of Bcl-2 induced by As2O3 diminished its ability to bind to Bax. Arsenic Trioxide 50-55 BCL2 apoptosis regulator Homo sapiens 33-38 18852130-1 2008 ABT-263 is a potent, orally bioavailable inhibitor of the antiapoptotic Bcl-2 family members Bcl-2, Bcl-x(L), and Bcl-w, which is currently in phase I clinical trials. navitoclax 0-7 BCL2 apoptosis regulator Homo sapiens 72-77 18852130-1 2008 ABT-263 is a potent, orally bioavailable inhibitor of the antiapoptotic Bcl-2 family members Bcl-2, Bcl-x(L), and Bcl-w, which is currently in phase I clinical trials. navitoclax 0-7 BCL2 apoptosis regulator Homo sapiens 93-98 18852136-9 2008 Antisense oligodeoxynucleotides to human superoxide dismutase 2 and/or ectopic bcl-2 overexpression avoided polyphenols and chemoradiotherapy-induced colorectal cancer elimination and showed that the mangano-type superoxide dismutase and Bcl-2 are key targets in the molecular mechanism activated by the combined application of t-PTER and QUER. Oligodeoxyribonucleotides 10-31 BCL2 apoptosis regulator Homo sapiens 238-243 18852136-9 2008 Antisense oligodeoxynucleotides to human superoxide dismutase 2 and/or ectopic bcl-2 overexpression avoided polyphenols and chemoradiotherapy-induced colorectal cancer elimination and showed that the mangano-type superoxide dismutase and Bcl-2 are key targets in the molecular mechanism activated by the combined application of t-PTER and QUER. Polyphenols 108-119 BCL2 apoptosis regulator Homo sapiens 79-84 18852136-9 2008 Antisense oligodeoxynucleotides to human superoxide dismutase 2 and/or ectopic bcl-2 overexpression avoided polyphenols and chemoradiotherapy-induced colorectal cancer elimination and showed that the mangano-type superoxide dismutase and Bcl-2 are key targets in the molecular mechanism activated by the combined application of t-PTER and QUER. Polyphenols 108-119 BCL2 apoptosis regulator Homo sapiens 238-243 18594829-0 2008 Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. Docetaxel 0-9 BCL2 apoptosis regulator Homo sapiens 38-43 18761399-6 2008 Genistein down-regulates Bcl-2 and up-regulates Bax. Genistein 0-9 BCL2 apoptosis regulator Homo sapiens 25-30 18761399-7 2008 NF-kappaB binding sites are present in the promoter of Bcl-2, suggesting that genistein might inhibit the expression of Bcl-2 through down-regulation of NF-kappaB. Genistein 78-87 BCL2 apoptosis regulator Homo sapiens 55-60 18761399-7 2008 NF-kappaB binding sites are present in the promoter of Bcl-2, suggesting that genistein might inhibit the expression of Bcl-2 through down-regulation of NF-kappaB. Genistein 78-87 BCL2 apoptosis regulator Homo sapiens 120-125 18594829-0 2008 Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. Docetaxel 0-9 BCL2 apoptosis regulator Homo sapiens 63-68 18928586-0 2008 [Inducing-apoptosis effect of bortezomib on acute monocytic leukemia cell SHI-1 and its influence on expressions of Bcl2l12, Bcl-2 and Bax genes]. Bortezomib 30-40 BCL2 apoptosis regulator Homo sapiens 125-130 18594829-0 2008 Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. Bortezomib 14-24 BCL2 apoptosis regulator Homo sapiens 38-43 18928586-4 2008 RT-PCR was used to analyze the levels of Bcl2l12, Bcl-2 and bax mRNA in SHI-1 cells treated with bortezomib for 0, 6, 12 and 24 hours. Bortezomib 97-107 BCL2 apoptosis regulator Homo sapiens 50-55 18594829-0 2008 Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. Bortezomib 14-24 BCL2 apoptosis regulator Homo sapiens 63-68 18928586-8 2008 It is concluded that bortezomib inhibits the proliferation of SHI-1 and induces apoptosis in which Bcl2l12 and Bcl-2 gene can be ones of the main genes taking part in. Bortezomib 21-31 BCL2 apoptosis regulator Homo sapiens 111-116 18594829-2 2008 Docetaxel not only inhibits microtubule formation but can also downregulate expression of Bcl-2, a known antiapoptotic oncogene. Docetaxel 0-9 BCL2 apoptosis regulator Homo sapiens 90-95 18928588-0 2008 [Relationship between apoptotic effect of Resveratrol on KG-1 cells and expression of bcl-2/bax]. Resveratrol 42-53 BCL2 apoptosis regulator Homo sapiens 86-91 18594829-3 2008 Furthermore, the 26S proteasome inhibitor bortezomib can downregulate Bcl-2 expression. Bortezomib 42-52 BCL2 apoptosis regulator Homo sapiens 70-75 18594829-5 2008 In this study, we investigated whether treating human prostate cancer cells with docetaxel, bortezomib, or both could modulate Bcl-2 expression and whether such modulation could render Bcl-2-overexpressing cells more susceptible to radiation. Docetaxel 81-90 BCL2 apoptosis regulator Homo sapiens 127-132 18594829-5 2008 In this study, we investigated whether treating human prostate cancer cells with docetaxel, bortezomib, or both could modulate Bcl-2 expression and whether such modulation could render Bcl-2-overexpressing cells more susceptible to radiation. Bortezomib 92-102 BCL2 apoptosis regulator Homo sapiens 127-132 18594829-8 2008 In addition, docetaxel, bortezomib, or radiation resulted in a G2M phase arrest in PC-3-Bcl-2, whereas only docetaxel or radiation did so in PC-3-Neo cells. Docetaxel 13-22 BCL2 apoptosis regulator Homo sapiens 88-93 19230406-4 2008 The cell cycle distribution was altered and ratio of S phase and G2/M phase cell increased following the treatment with Tet combined with Nap, with Bcl-2 gene expression down-regulated, and BAX gene expression up-regulated. tet 120-123 BCL2 apoptosis regulator Homo sapiens 148-153 18594829-8 2008 In addition, docetaxel, bortezomib, or radiation resulted in a G2M phase arrest in PC-3-Bcl-2, whereas only docetaxel or radiation did so in PC-3-Neo cells. Bortezomib 24-34 BCL2 apoptosis regulator Homo sapiens 88-93 19230406-4 2008 The cell cycle distribution was altered and ratio of S phase and G2/M phase cell increased following the treatment with Tet combined with Nap, with Bcl-2 gene expression down-regulated, and BAX gene expression up-regulated. nedaplatin 138-141 BCL2 apoptosis regulator Homo sapiens 148-153 18594829-10 2008 Furthermore, docetaxel and bortezomib-treated cells exhibited marked changes in the expression of Bcl-2 and Bcl-xL. Docetaxel 13-22 BCL2 apoptosis regulator Homo sapiens 98-103 18594829-10 2008 Furthermore, docetaxel and bortezomib-treated cells exhibited marked changes in the expression of Bcl-2 and Bcl-xL. Bortezomib 27-37 BCL2 apoptosis regulator Homo sapiens 98-103 18594829-11 2008 CONCLUSIONS: This is the first study to demonstrate that docetaxel and bortezomib in combination can effectively sensitize Bcl-2-overexpressing human prostate cancer cells to radiation effects by modulating the expression of key members of the Bcl-2 family. Docetaxel 57-66 BCL2 apoptosis regulator Homo sapiens 123-128 18594829-11 2008 CONCLUSIONS: This is the first study to demonstrate that docetaxel and bortezomib in combination can effectively sensitize Bcl-2-overexpressing human prostate cancer cells to radiation effects by modulating the expression of key members of the Bcl-2 family. Docetaxel 57-66 BCL2 apoptosis regulator Homo sapiens 244-249 18594829-11 2008 CONCLUSIONS: This is the first study to demonstrate that docetaxel and bortezomib in combination can effectively sensitize Bcl-2-overexpressing human prostate cancer cells to radiation effects by modulating the expression of key members of the Bcl-2 family. Bortezomib 71-81 BCL2 apoptosis regulator Homo sapiens 123-128 18594829-11 2008 CONCLUSIONS: This is the first study to demonstrate that docetaxel and bortezomib in combination can effectively sensitize Bcl-2-overexpressing human prostate cancer cells to radiation effects by modulating the expression of key members of the Bcl-2 family. Bortezomib 71-81 BCL2 apoptosis regulator Homo sapiens 244-249 18603276-6 2008 Whereas the 17alpha-E(2)-induced apoptosis was completely abrogated by overexpression of Bcl-2 or by pretreatment with the pan-caspase inhibitor z-VAD-fmk, the accumulation of G(2)/M cells significantly increased. 17alpha-e(2) 12-24 BCL2 apoptosis regulator Homo sapiens 89-94 19080641-12 2008 When the concentration of EGCG was over 200microg/ml, it down-regulated the expression of COX-2 and Bcl-2 in both cell lines, however, EGCG resulted in no significant changes of Bcl-xl, Bax, Bad, and Bid. epigallocatechin gallate 26-30 BCL2 apoptosis regulator Homo sapiens 100-105 19080641-13 2008 CONCLUSION: EGCG induces apoptosis in HCC cells through down-regulation of COX-2 and Bcl-2 and consequently activating caspase-9 and caspase-3. epigallocatechin gallate 12-16 BCL2 apoptosis regulator Homo sapiens 85-90 18611398-6 2008 The results showed that grape seed polyphenols catechin and Pc B(4) pretreatment would protect cardiomyocytes against doxorubicin-induced toxicity by decreasing reactive oxygen species generation as well as the number of apoptotic cells, preventing DNA fragmentation, regulating the expression levels of the pro-apoptotic protein Bax-alpha and the anti-apoptotic protein Bcl-2, and inhibiting apoptotic signaling pathways. Polyphenols 35-46 BCL2 apoptosis regulator Homo sapiens 371-376 18495333-9 2008 We also observed a weak but significant correlation between sensitivity to tetrandrine and cellular expression of bcl-2 (P=0.035, r=-0.364). tetrandrine 75-86 BCL2 apoptosis regulator Homo sapiens 114-119 18585380-3 2008 Interestingly in one cisplatin resistant cell line which expresses BCL2/BCLxL, treatment with mTOR inhibitor (CCI-779) results in decreased levels of these anti-apoptotic proteins and may contribute to increasing apoptosis. Cisplatin 21-30 BCL2 apoptosis regulator Homo sapiens 67-71 18585380-3 2008 Interestingly in one cisplatin resistant cell line which expresses BCL2/BCLxL, treatment with mTOR inhibitor (CCI-779) results in decreased levels of these anti-apoptotic proteins and may contribute to increasing apoptosis. temsirolimus 110-117 BCL2 apoptosis regulator Homo sapiens 67-71 18611398-6 2008 The results showed that grape seed polyphenols catechin and Pc B(4) pretreatment would protect cardiomyocytes against doxorubicin-induced toxicity by decreasing reactive oxygen species generation as well as the number of apoptotic cells, preventing DNA fragmentation, regulating the expression levels of the pro-apoptotic protein Bax-alpha and the anti-apoptotic protein Bcl-2, and inhibiting apoptotic signaling pathways. Catechin 47-55 BCL2 apoptosis regulator Homo sapiens 371-376 18611398-6 2008 The results showed that grape seed polyphenols catechin and Pc B(4) pretreatment would protect cardiomyocytes against doxorubicin-induced toxicity by decreasing reactive oxygen species generation as well as the number of apoptotic cells, preventing DNA fragmentation, regulating the expression levels of the pro-apoptotic protein Bax-alpha and the anti-apoptotic protein Bcl-2, and inhibiting apoptotic signaling pathways. 2,2'-dichlorobiphenyl 60-67 BCL2 apoptosis regulator Homo sapiens 371-376 18644421-3 2008 Rosmarinic acid effectively suppressed the up-regulation of Bax and down-regulation of Bcl-2. rosmarinic acid 0-15 BCL2 apoptosis regulator Homo sapiens 87-92 18625218-0 2008 Pinocembrin prevents glutamate-induced apoptosis in SH-SY5Y neuronal cells via decrease of bax/bcl-2 ratio. pinocembrin 0-11 BCL2 apoptosis regulator Homo sapiens 95-100 18625218-0 2008 Pinocembrin prevents glutamate-induced apoptosis in SH-SY5Y neuronal cells via decrease of bax/bcl-2 ratio. Glutamic Acid 21-30 BCL2 apoptosis regulator Homo sapiens 95-100 18625218-8 2008 Western blotting results indicated that pinocembrin treatment reduced the expression of Bax and had no effect on Bcl-2, thus decreased the Bax-Bcl-2 ratio, which is in consistent with the gene expression result. pinocembrin 40-51 BCL2 apoptosis regulator Homo sapiens 143-148 18625218-10 2008 Thus we conclude that pinocembrin exerts its neuroprotective effects in glutamate injury model partly by inhibiting p53 expression, thus Bax-Bcl-2 ratio, and the release of cytochrome c. pinocembrin 22-33 BCL2 apoptosis regulator Homo sapiens 141-146 18606222-5 2008 GC and epirubicin significantly reduced mRNA expression levels of human intestinal MDR1, MDR-associated protein (MRP)1, and MRP2; downregulated the MDR1 promoter region; suppressed the mRNA expression of Bcl-2; induced the mRNA expression of Bax; and significantly increased the Bax-to-Bcl-2 ratio and the mRNA levels of p53, caspase-9 and -3. Epirubicin 7-17 BCL2 apoptosis regulator Homo sapiens 204-209 18606222-5 2008 GC and epirubicin significantly reduced mRNA expression levels of human intestinal MDR1, MDR-associated protein (MRP)1, and MRP2; downregulated the MDR1 promoter region; suppressed the mRNA expression of Bcl-2; induced the mRNA expression of Bax; and significantly increased the Bax-to-Bcl-2 ratio and the mRNA levels of p53, caspase-9 and -3. Epirubicin 7-17 BCL2 apoptosis regulator Homo sapiens 286-291 18599488-1 2008 Because Bcl-2 family members inhibit the ability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis, we investigated whether ABT-737, a small molecule Bcl-2 inhibitor, enhances TRAIL killing. ABT-737 161-168 BCL2 apoptosis regulator Homo sapiens 8-13 18599488-10 2008 Combinations of ABT-737 and TRAIL can be exploited therapeutically where antiapoptotic Bcl-2 family members drive tumor cell resistance to current anticancer therapies. ABT-737 16-23 BCL2 apoptosis regulator Homo sapiens 87-92 18622705-4 2008 In vitro treatment of D-allose resulted in the alteration of Bcl-2/Bax ratio in favor of apoptosis (programmed cell death, PCD) in both the HRPC cell lines, which was associated with the lowering of mitochondrial transmembrane potential (Deltapsi(m)) and the release of cytochrome C (cyt C), the cleavage of caspase 3 and poly (ADP-ribose) polymerase (PARP), and the elevation of calcium concentration in cytosol ([Ca(2+)](c)). allose 22-30 BCL2 apoptosis regulator Homo sapiens 61-66 18837891-5 2008 The present study was designed to evaluate Bcl-2 protein expression in breast tumor paraffin-embedded fixed tissue and sought to investigate association with the Bcl-2 protein release in patient serum, as well as its relationship with clinicopathological features. Paraffin 84-92 BCL2 apoptosis regulator Homo sapiens 43-48 18215418-3 2008 Using either transient or stable transfection combined with doxycycline-inducible expression, we titrated the cellular concentration of Bcl-2. Doxycycline 60-71 BCL2 apoptosis regulator Homo sapiens 136-141 18215418-11 2008 We further observed that high levels of Bcl-2 expression caused lipid peroxidation and that the deleterious effects of Bcl-2 could be abrogated by the reactive oxygen species (ROS) scavenger Trolox. Reactive Oxygen Species 151-174 BCL2 apoptosis regulator Homo sapiens 119-124 18215418-11 2008 We further observed that high levels of Bcl-2 expression caused lipid peroxidation and that the deleterious effects of Bcl-2 could be abrogated by the reactive oxygen species (ROS) scavenger Trolox. Reactive Oxygen Species 176-179 BCL2 apoptosis regulator Homo sapiens 40-45 18215418-11 2008 We further observed that high levels of Bcl-2 expression caused lipid peroxidation and that the deleterious effects of Bcl-2 could be abrogated by the reactive oxygen species (ROS) scavenger Trolox. Reactive Oxygen Species 176-179 BCL2 apoptosis regulator Homo sapiens 119-124 18215418-11 2008 We further observed that high levels of Bcl-2 expression caused lipid peroxidation and that the deleterious effects of Bcl-2 could be abrogated by the reactive oxygen species (ROS) scavenger Trolox. 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid 191-197 BCL2 apoptosis regulator Homo sapiens 40-45 18215418-11 2008 We further observed that high levels of Bcl-2 expression caused lipid peroxidation and that the deleterious effects of Bcl-2 could be abrogated by the reactive oxygen species (ROS) scavenger Trolox. 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid 191-197 BCL2 apoptosis regulator Homo sapiens 119-124 18215418-14 2008 These data reveal that high cellular concentrations of Bcl-2 lead to a calcium- and ROS-dependent induction of death. Calcium 71-78 BCL2 apoptosis regulator Homo sapiens 55-60 18215418-14 2008 These data reveal that high cellular concentrations of Bcl-2 lead to a calcium- and ROS-dependent induction of death. Reactive Oxygen Species 84-87 BCL2 apoptosis regulator Homo sapiens 55-60 19035306-3 2008 MATERIALS AND METHODS: The effect of the synthetic sulfonate ester, p-methoxyphenyl p-toluenesulfonate on growth inhibitory activity depending upon the estrogen-receptor (ER), p53, bcl-2 and caspase-3 status of cells was investigated by comparing its effects on three distinct human breast cancer cell lines (MCF-7, MDA-MB-231 and MDA-MB-453) and on one normal human mammary epithelial cell line (MCF-10A). sulfonate ester 51-66 BCL2 apoptosis regulator Homo sapiens 181-186 19035306-3 2008 MATERIALS AND METHODS: The effect of the synthetic sulfonate ester, p-methoxyphenyl p-toluenesulfonate on growth inhibitory activity depending upon the estrogen-receptor (ER), p53, bcl-2 and caspase-3 status of cells was investigated by comparing its effects on three distinct human breast cancer cell lines (MCF-7, MDA-MB-231 and MDA-MB-453) and on one normal human mammary epithelial cell line (MCF-10A). P-methoxyphenyl p-toluenesulfonate 68-102 BCL2 apoptosis regulator Homo sapiens 181-186 18338171-6 2008 RESULTS: In human tumor cell lines of different tissue origins, sensitivity to neocarzinostatin is proportional to the product of the relative contents of Bcl-2 and caspase-3 (r (2) = 0.9; P < 0.01). Zinostatin 79-95 BCL2 apoptosis regulator Homo sapiens 155-160 18338171-7 2008 Neuroblastoma and brain tumor cell lines are particularly sensitive to neocarzinostatin; the sensitivity of brain tumor lines to neocarzinostatin is enhanced by transfection with an expression construct for Bcl-2 and is proportional in transfected cells to the product of the relative contents of Bcl-2 and caspase-3 (r (2) = 0.7). Zinostatin 129-145 BCL2 apoptosis regulator Homo sapiens 207-212 18338171-7 2008 Neuroblastoma and brain tumor cell lines are particularly sensitive to neocarzinostatin; the sensitivity of brain tumor lines to neocarzinostatin is enhanced by transfection with an expression construct for Bcl-2 and is proportional in transfected cells to the product of the relative contents of Bcl-2 and caspase-3 (r (2) = 0.7). Zinostatin 129-145 BCL2 apoptosis regulator Homo sapiens 297-302 18407350-0 2008 Bcl-2 suppresses Ca2+ release through inositol 1,4,5-trisphosphate receptors and inhibits Ca2+ uptake by mitochondria without affecting ER calcium store content. Calcium 139-146 BCL2 apoptosis regulator Homo sapiens 0-5 18407350-9 2008 Roderick, The cellular concentration of Bcl-2 determines its pro- or anti-apoptotic effect, Cell Calcium (2008)], we described that only stable expression of Bcl-2 allowed it to work in a pro-survival manner whereas transient expression did not. Calcium 97-104 BCL2 apoptosis regulator Homo sapiens 40-45 18407350-9 2008 Roderick, The cellular concentration of Bcl-2 determines its pro- or anti-apoptotic effect, Cell Calcium (2008)], we described that only stable expression of Bcl-2 allowed it to work in a pro-survival manner whereas transient expression did not. Calcium 97-104 BCL2 apoptosis regulator Homo sapiens 158-163 18215418-8 2008 Rather Bcl-2 itself caused a significant amount of spontaneous cell death, and sensitised the cells to apoptotic agents such as staurosporine or ceramide. Staurosporine 128-141 BCL2 apoptosis regulator Homo sapiens 7-12 18215418-8 2008 Rather Bcl-2 itself caused a significant amount of spontaneous cell death, and sensitised the cells to apoptotic agents such as staurosporine or ceramide. Ceramides 145-153 BCL2 apoptosis regulator Homo sapiens 7-12 18215418-10 2008 Expression of calbindin, a calcium buffering protein, or an enzyme that inhibited inositol 1,4,5-trisphosphate-mediated calcium release, significantly reduced cell death caused by Bcl-2 expression. Inositol 1,4,5-Trisphosphate 82-110 BCL2 apoptosis regulator Homo sapiens 180-185 18215418-10 2008 Expression of calbindin, a calcium buffering protein, or an enzyme that inhibited inositol 1,4,5-trisphosphate-mediated calcium release, significantly reduced cell death caused by Bcl-2 expression. Calcium 120-127 BCL2 apoptosis regulator Homo sapiens 180-185 18769131-0 2008 Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo. apogossypolone 0-14 BCL2 apoptosis regulator Homo sapiens 65-70 18695940-3 2008 Overexpression of the anti-apoptotic Bcl-2 protein significantly increased the level of endogenous reduced glutathione, thus preventing its oxidation after the metabolic stress. Glutathione 107-118 BCL2 apoptosis regulator Homo sapiens 37-42 18765530-5 2008 However, 24 h after exposure, sorafenib- and vorinostat-treated cells exhibited markedly diminished expression of c-FLIP-s, full-length BID, BCL-2, BCL-XL, MCL-1, XIAP, increased expression of BIM, and increased activation of BAX, BAK, and BAD. Sorafenib 30-39 BCL2 apoptosis regulator Homo sapiens 141-146 18765530-5 2008 However, 24 h after exposure, sorafenib- and vorinostat-treated cells exhibited markedly diminished expression of c-FLIP-s, full-length BID, BCL-2, BCL-XL, MCL-1, XIAP, increased expression of BIM, and increased activation of BAX, BAK, and BAD. Vorinostat 45-55 BCL2 apoptosis regulator Homo sapiens 141-146 18818743-5 2008 Taken together, we suggest that the forced expression of Bcl-2 in human hepatoma may cause the cells to become more glucose-dependent for survival. Glucose 116-123 BCL2 apoptosis regulator Homo sapiens 57-62 18440692-5 2008 RESULTS: Honokiol significantly inhibited proliferation and induced apoptosis, with alteration of Bcl-2 members and caspase-3. honokiol 9-17 BCL2 apoptosis regulator Homo sapiens 98-103 23506184-1 2008 BACKGROUND: The discovery of ABT-263, a rationally designed Bcl-2/Bcl-xL inhibitor at present in Phase I clinical trials for cancer, is described. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 29-32 BCL2 apoptosis regulator Homo sapiens 60-65 18695876-7 2008 Bax and p21 expression was found to be up-regulated, whereas ppRb and bcl-2 were down-regulated in momilactone B-treated cells under hypoxic conditions. momilactone B 99-112 BCL2 apoptosis regulator Homo sapiens 70-75 18818743-0 2008 Enhanced Glucose Requirement in Human Hepatoma-derived HuH-7 Cells by Forced Expression of the bcl-2 Gene. Glucose 9-16 BCL2 apoptosis regulator Homo sapiens 95-100 19051078-3 2008 With the same concentration of menadione, the Bcl-2/Bax ratio decreased and nuclei containing condensed chromatin were observed in myoblasts to a greater extent than in myotubes. Vitamin K 3 31-40 BCL2 apoptosis regulator Homo sapiens 46-51 19051078-7 2008 Both LY294002 and API-2, an Akt inhibitor, decreased the Bcl-2/Bax ratio in menadione-exposed myotubes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 5-13 BCL2 apoptosis regulator Homo sapiens 57-62 19051078-7 2008 Both LY294002 and API-2, an Akt inhibitor, decreased the Bcl-2/Bax ratio in menadione-exposed myotubes. Vitamin K 3 76-85 BCL2 apoptosis regulator Homo sapiens 57-62 18500755-6 2008 Supplementation of ALCAR also prevented apoptosis by down-regulating caspase-3 levels, cytochrome c release, and p-Bcl-2 expression. Acetylcarnitine 19-24 BCL2 apoptosis regulator Homo sapiens 115-120 18548102-4 2008 As caspase-9 acts as an initiator caspase and Bcl-2 and Bcl-xL overexpression suppress spongistatin 1-induced apoptosis, cell death is mediated through the mitochondrial apoptosis pathway. spongistatin 1 87-101 BCL2 apoptosis regulator Homo sapiens 46-51 18512759-12 2008 NAC reversed the A beta(25-35)-induced decrease in the expression of Bcl-2, which could be blocked by the MAPK kinase (MEK) inhibitor or Cdk5 inhibitors. Acetylcysteine 0-3 BCL2 apoptosis regulator Homo sapiens 69-74 18512759-13 2008 These results suggest that NAC-mediated neuroprotection against A beta toxicity is likely mediated by the p35/Cdk5-ERKs-Bcl-2 signal pathway. Acetylcysteine 27-30 BCL2 apoptosis regulator Homo sapiens 120-125 18596739-0 2008 BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. BH 3 51-54 BCL2 apoptosis regulator Homo sapiens 0-5 18596739-0 2008 BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Bortezomib 129-139 BCL2 apoptosis regulator Homo sapiens 0-5 18790782-8 2008 Whereas mitoxantrone increased the Fas-induced apoptotic response of all cultured prostate cells tested, docetaxel pretreatment was found to preferentially enhance the killing of bcl-2-expressing cells. Docetaxel 105-114 BCL2 apoptosis regulator Homo sapiens 179-184 18596739-4 2008 CLL cells showed lower sensitivity to GX15-070 than primary mantle cell lymphoma (MCL) ones, in correlation with higher levels of phosphorylated BCL-2 at serine 70 residue (pBCL-2(Ser70)) in CLL cells. Serine 154-160 BCL2 apoptosis regulator Homo sapiens 145-150 18596739-5 2008 Decrease in BCL-2 phosphorylation by extracellular signal-regulated kinase (ERK)1/2 inhibition increased CLL sensitivity to GX15-070, while blocking BCL-2 dephosphorylation using a PP2A antagonist reduced the activity of this BH3 mimetic. BH 3 226-229 BCL2 apoptosis regulator Homo sapiens 12-17 18596739-7 2008 However, as proteasome inhibition led to the accumulation of phosphorylated BCL-2, the degree of interaction between GX15-070 and bortezomib was regulated by basal pBCL-2(Ser70) levels. Bortezomib 130-140 BCL2 apoptosis regulator Homo sapiens 76-81 18596739-8 2008 These results support the role of BCL-2 phosphorylation as a mechanism of resistance to BH3 mimetic compounds, and demonstrate that combination approaches including ERK inhibitors could enhance BH3 mimetics activity both alone or in combination with proteasome inhibitors. BH 3 88-91 BCL2 apoptosis regulator Homo sapiens 34-39 18524889-12 2008 Overexpression of BCL-2 caused a significant attenuation of erlotinib-induced cell death, but no effect on BAX and BAK activation. Erlotinib Hydrochloride 60-69 BCL2 apoptosis regulator Homo sapiens 18-23 18575824-0 2008 Bcl-2 antisense oligonucleotide inhibits the proliferation of childhood leukemia/lymphoma cells of the B-cell lineage. Oligonucleotides 16-31 BCL2 apoptosis regulator Homo sapiens 0-5 18695917-6 2008 Pretreatment of PD169316, a p38 MAPK specific inhibitor, completely attenuated the combination treatment-induced mitochondrial relocalization of Bax, and altered Bcl-2 phosphorylation. 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole 16-24 BCL2 apoptosis regulator Homo sapiens 162-167 18695917-7 2008 Moreover, pretreatment of SP600125, JNK specific inhibitor, clearly attenuated Bcl-2 phosphorylation, but did not affect Bax translocation to the mitochondria. pyrazolanthrone 26-34 BCL2 apoptosis regulator Homo sapiens 79-84 18695917-9 2008 These results indicate that activation of p38 MAPK is specifically required for translocation of Bax to the mitochondria, and both JNK and p38 MAPK are involved in phosphorylation of Bcl-2 in response to combination treatment with gamma-radiation and As2O3, and that ROS is a critical regulator of p38 MAPK and JNK activations. Arsenic Trioxide 251-256 BCL2 apoptosis regulator Homo sapiens 183-188 18695917-9 2008 These results indicate that activation of p38 MAPK is specifically required for translocation of Bax to the mitochondria, and both JNK and p38 MAPK are involved in phosphorylation of Bcl-2 in response to combination treatment with gamma-radiation and As2O3, and that ROS is a critical regulator of p38 MAPK and JNK activations. ros 267-270 BCL2 apoptosis regulator Homo sapiens 183-188 18575824-1 2008 An 18-mer phosphorothioate bcl-2 antisense oligonucleotide (ASO) inhibited colony formation of three B-cell leukemia/lymphoma cell lines in a dose dependent manner in the range of 0.125-0.5 micromol/l. Parathion 10-26 BCL2 apoptosis regulator Homo sapiens 27-32 18575824-1 2008 An 18-mer phosphorothioate bcl-2 antisense oligonucleotide (ASO) inhibited colony formation of three B-cell leukemia/lymphoma cell lines in a dose dependent manner in the range of 0.125-0.5 micromol/l. Oligonucleotides 43-58 BCL2 apoptosis regulator Homo sapiens 27-32 18513234-0 2008 The Bcl-2 antagonist HA14-1 forms a fluorescent albumin complex that can be mistaken for several oxidized ROS probes. Reactive Oxygen Species 106-109 BCL2 apoptosis regulator Homo sapiens 4-9 18575824-1 2008 An 18-mer phosphorothioate bcl-2 antisense oligonucleotide (ASO) inhibited colony formation of three B-cell leukemia/lymphoma cell lines in a dose dependent manner in the range of 0.125-0.5 micromol/l. Oligonucleotides, Antisense 60-63 BCL2 apoptosis regulator Homo sapiens 27-32 18639625-7 2008 The increase in apoptosis that was induced by streptochlorin was correlated with down-regulation of anti-apoptotic Bcl-2 expression, up-regulation of pro-apoptotic Bax and FasL, a decrease in the mitochondrial membrane potential (MMP), activation of caspases and degradation of poly-(ADP-ribose)polymerase and phospholipase C-gamma1 protein. streptochlorin 46-60 BCL2 apoptosis regulator Homo sapiens 115-120 18639625-9 2008 Furthermore, Bcl-2 overexpression significantly reversed the streptochlorin-induced growth inhibitory effects via inhibition of the MMP collapse and caspases activation and effectively attenuated the apoptotic response to streptochlorin. streptochlorin 61-75 BCL2 apoptosis regulator Homo sapiens 13-18 18795123-7 2008 Mcl-1, among the Bcl-2 and IAP (inhibitor of apoptosis protein) antiapoptotic family proteins tested, was proved to be a major inhibitor of the MG132-induced apoptosis in MPM cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 144-149 BCL2 apoptosis regulator Homo sapiens 17-22 18639625-9 2008 Furthermore, Bcl-2 overexpression significantly reversed the streptochlorin-induced growth inhibitory effects via inhibition of the MMP collapse and caspases activation and effectively attenuated the apoptotic response to streptochlorin. streptochlorin 222-236 BCL2 apoptosis regulator Homo sapiens 13-18 19175987-7 2008 Bcl-2 positive cell rates decreased to (15.1 +/- 4.8)% and (7.3 +/- 2.9)% in NB4-R2 cells treated with 1 mg/ml CDA-II plus 100 micromol/L cAMP for 48 h and 72 h, respectively. Cyclic AMP 138-142 BCL2 apoptosis regulator Homo sapiens 0-5 19175987-8 2008 While 100 micromol/L of cAMP could decrease Bcl-2 positive NB4-R2 cells from (92.0 +/- 0.6)% to (75.3 +/- 2.0)%. Cyclic AMP 24-28 BCL2 apoptosis regulator Homo sapiens 44-49 18528859-6 2008 From these results, we conclude that TW-37 is a potent inhibitor of progression of pancreatic cancer cells, which could be due to attenuation of Bcl-2 cellular signaling processes. TW-37 37-42 BCL2 apoptosis regulator Homo sapiens 145-150 18602901-7 2008 Besides, apoptosis was associated with alterations in expression of pro-apoptotic Bax and anti-apoptotic Bcl-2 proteins resulting in an increase in Bax:Bcl-2 ratio, mitochondrial release of cytochrome c and Smac, downregulation of selective baculoviral inhibitor-of-apoptosis repeat containing (BIRC) molecules, an increase in intracellular free [Ca2+], and activation of calpain and caspase-3. birc 295-299 BCL2 apoptosis regulator Homo sapiens 105-110 18430509-8 2008 Besides, protoapigenone had an enhanced cytotoxicity on SKOV3 cells enriched at S and G2/M phases, and ability to induce apoptosis through decreasing the protein levels of Bcl-xL and Bcl-2 and increasing the cleaved PARP by activating caspase-3. protoapigenone 9-23 BCL2 apoptosis regulator Homo sapiens 183-188 18719108-5 2008 Quantitative binding studies revealed that binding of ASPP2(Ank-SH3) to the Bcl-2 family members is selective at two levels: (i) interaction with Bcl-2-derived peptides is the tightest compared to peptides from the other family members, and (ii) within Bcl-2, binding of ASPP2(Ank-SH3) to the BH4 domain is tightest. sapropterin 293-296 BCL2 apoptosis regulator Homo sapiens 76-81 18528859-0 2008 TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer. TW-37 0-5 BCL2 apoptosis regulator Homo sapiens 37-42 18501396-8 2008 Roscovitine also reduced BCL-2 Ser70 phosphorylation and protected against apoptosis, suggesting mitotic arrest caused by hyperactivation of CDK1 directly or indirectly leads to BCL-2 phosphorylation and apoptosis. Roscovitine 0-11 BCL2 apoptosis regulator Homo sapiens 25-30 18698039-0 2008 Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3. Gefitinib 0-9 BCL2 apoptosis regulator Homo sapiens 53-58 18698039-6 2008 RESULTS: Gefitinib increases accumulation of 99mTc-Sestamibi in Bcl-2-overexpressing cells and enhances the physical interaction of phosphorylated Bcl-2 with inositol trisphosphate receptor type 3 (IP3R3). Gefitinib 9-18 BCL2 apoptosis regulator Homo sapiens 64-69 18698039-6 2008 RESULTS: Gefitinib increases accumulation of 99mTc-Sestamibi in Bcl-2-overexpressing cells and enhances the physical interaction of phosphorylated Bcl-2 with inositol trisphosphate receptor type 3 (IP3R3). Gefitinib 9-18 BCL2 apoptosis regulator Homo sapiens 147-152 18698039-6 2008 RESULTS: Gefitinib increases accumulation of 99mTc-Sestamibi in Bcl-2-overexpressing cells and enhances the physical interaction of phosphorylated Bcl-2 with inositol trisphosphate receptor type 3 (IP3R3). Technetium Tc 99m Sestamibi 51-60 BCL2 apoptosis regulator Homo sapiens 64-69 18501396-8 2008 Roscovitine also reduced BCL-2 Ser70 phosphorylation and protected against apoptosis, suggesting mitotic arrest caused by hyperactivation of CDK1 directly or indirectly leads to BCL-2 phosphorylation and apoptosis. Roscovitine 0-11 BCL2 apoptosis regulator Homo sapiens 178-183 18458532-7 2008 Our data suggests that Bcl-2, persistent JNK phosphorylation and cleavage of anti-apoptotic Mcl-1 are key events controlling susceptibility to FNQ. napabucasin 143-146 BCL2 apoptosis regulator Homo sapiens 23-28 18705844-4 2008 The expression of Bcl-2 and Bax was assessed by immunochemistry on paraffin-embedded placental specimens. Paraffin 67-75 BCL2 apoptosis regulator Homo sapiens 18-23 18584328-0 2008 Resveratrol disrupts peroxynitrite-triggered mitochondrial apoptotic pathway: a role for Bcl-2. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 89-94 18584328-5 2008 Additionally, peroxynitrite increased intracellular levels of Bax without affecting those of Bcl-2, increasing consequently the Bax/Bcl-2 ratio. Peroxynitrous Acid 14-27 BCL2 apoptosis regulator Homo sapiens 132-137 18584328-6 2008 This ratio decreased when cells where pre-incubated with 10 and 50 muM resveratrol, mainly due to resveratrol ability per se to increase Bcl-2 intracellular levels without affecting Bax intracellular levels. Resveratrol 71-82 BCL2 apoptosis regulator Homo sapiens 137-142 18584328-6 2008 This ratio decreased when cells where pre-incubated with 10 and 50 muM resveratrol, mainly due to resveratrol ability per se to increase Bcl-2 intracellular levels without affecting Bax intracellular levels. Resveratrol 98-109 BCL2 apoptosis regulator Homo sapiens 137-142 18584328-7 2008 These results propose an additional mechanism whereby resveratrol may exert its cardioprotective effects and suggest a key role for Bcl-2 in the resveratrol anti-apoptotic action, especially in disrupting peroxynitrite-triggered mitochondrial pathway. Resveratrol 145-156 BCL2 apoptosis regulator Homo sapiens 132-137 18584328-7 2008 These results propose an additional mechanism whereby resveratrol may exert its cardioprotective effects and suggest a key role for Bcl-2 in the resveratrol anti-apoptotic action, especially in disrupting peroxynitrite-triggered mitochondrial pathway. Peroxynitrous Acid 205-218 BCL2 apoptosis regulator Homo sapiens 132-137 18543107-3 2008 Cobalt chloride induced dose dependent apoptosis in HCT116 cells (250-750 muM) which, at higher concentrations (500-750 muM), was associated with an increase in the expression of the Bcl-2-related Mcl-1 survival protein. cobaltous chloride 0-15 BCL2 apoptosis regulator Homo sapiens 183-188 18676864-8 2008 BCL-2 inhibition of tamoxifen-induced apoptosis and tamoxifen activation of BAK, independent of BAX, further supports a role for 4ICD during tamoxifen-induced apoptosis. Tamoxifen 20-29 BCL2 apoptosis regulator Homo sapiens 0-5 18544562-0 2008 Superoxide-mediated proteasomal degradation of Bcl-2 determines cell susceptibility to Cr(VI)-induced apoptosis. Superoxides 0-10 BCL2 apoptosis regulator Homo sapiens 47-52 18437166-1 2008 Bax is a member of the Bcl-2 family that, together with Bak, is required for permeabilisation of the outer mitochondrial membrane (OMM). bakuchiol 56-59 BCL2 apoptosis regulator Homo sapiens 23-28 18544562-0 2008 Superoxide-mediated proteasomal degradation of Bcl-2 determines cell susceptibility to Cr(VI)-induced apoptosis. chromium hexavalent ion 87-93 BCL2 apoptosis regulator Homo sapiens 47-52 18544562-7 2008 In agreement with this observation, we found that Cr(VI) induces apoptosis mainly through the mitochondrial death pathway via caspase-9 activation, which is negatively regulated by the antiapoptotic protein Bcl-2. chromium hexavalent ion 50-56 BCL2 apoptosis regulator Homo sapiens 207-212 18544562-8 2008 Furthermore, .O(-)(2) induced apoptosis in response to Cr(VI) exposure by downregulating and degrading Bcl-2 protein through the ubiquitin-proteasomal pathway. chromium hexavalent ion 55-61 BCL2 apoptosis regulator Homo sapiens 103-108 18544562-9 2008 This study reveals a novel mechanism linking .O(-)(2) with Bcl-2 stability and provides a new dimension to ROS-mediated Bcl-2 downregulation and apoptosis induction. Reactive Oxygen Species 107-110 BCL2 apoptosis regulator Homo sapiens 59-64 18544562-9 2008 This study reveals a novel mechanism linking .O(-)(2) with Bcl-2 stability and provides a new dimension to ROS-mediated Bcl-2 downregulation and apoptosis induction. Reactive Oxygen Species 107-110 BCL2 apoptosis regulator Homo sapiens 120-125 18367648-8 2008 All examined G alpha12Q229L variants reduced phosphorylation of Bcl-2 at Ser-70, while only mutants unable to bind RhoGEFs also decreased cellular levels of Bcl-2. Serine 73-76 BCL2 apoptosis regulator Homo sapiens 64-69 18670359-0 2008 Hydroxysafflor yellow A enhances survival of vascular endothelial cells under hypoxia via upregulation of the HIF-1 alpha-VEGF pathway and regulation of Bcl-2/Bax. hydroxysafflor yellow A 0-23 BCL2 apoptosis regulator Homo sapiens 153-158 18404675-9 2008 Docetaxel enhanced the PARP-1 cleavage and caspases activation by TRAIL especially in androgen-independent, metastatic C4-2B cell line, mainly by phosphorylation of Bcl-2 by JNK activation. Docetaxel 0-9 BCL2 apoptosis regulator Homo sapiens 165-170 18759927-9 2008 Bim, a pro-apoptotic Bcl-2 family member, exerts a positive regulatory effect on cell cycle entry, which is opposed by Bcl-2. bim 0-3 BCL2 apoptosis regulator Homo sapiens 21-26 18759927-9 2008 Bim, a pro-apoptotic Bcl-2 family member, exerts a positive regulatory effect on cell cycle entry, which is opposed by Bcl-2. bim 0-3 BCL2 apoptosis regulator Homo sapiens 119-124 18640498-0 2008 Flavopiridol potentiates the cytotoxic effects of radiation in radioresistant tumor cells in which p53 is mutated or Bcl-2 is overexpressed. alvocidib 0-12 BCL2 apoptosis regulator Homo sapiens 117-122 18640498-3 2008 The purpose of the present study is to clarify whether flavopiridol enhances the cytotoxic effects of radiation in tumor cells that contain dysfunction p53 or that overexpress Bcl-2. alvocidib 55-67 BCL2 apoptosis regulator Homo sapiens 176-181 18640498-10 2008 CONCLUSIONS: Flavopiridol enhanced the cytotoxic effect of radiation in radioresistant tumor cells that harbor p53 dysfunction or Bcl-2 overexpression. alvocidib 13-25 BCL2 apoptosis regulator Homo sapiens 130-135 18640498-11 2008 A combination treatment of flavopiridol with radiation has the potential to conquer the radioresistance of malignant tumors induced by the genetic alteration of p53 or bcl-2. alvocidib 27-39 BCL2 apoptosis regulator Homo sapiens 168-173 18704308-4 2008 The expression of bcl-2/bax protein was immunohistochemically detected by SABC method. sabc 74-78 BCL2 apoptosis regulator Homo sapiens 18-23 18704308-8 2008 It is concluded that the targeted magnetic nanoparticles containing 5-Fu can improve the chemotherapeutic effect of 5-Fu by decreasing bcl-2 expression, increasing bax expression and inducing apoptosis of the liver cancer cells. Fluorouracil 68-72 BCL2 apoptosis regulator Homo sapiens 135-140 18704308-8 2008 It is concluded that the targeted magnetic nanoparticles containing 5-Fu can improve the chemotherapeutic effect of 5-Fu by decreasing bcl-2 expression, increasing bax expression and inducing apoptosis of the liver cancer cells. Fluorouracil 116-120 BCL2 apoptosis regulator Homo sapiens 135-140 18752749-11 2008 Flow cytometry and Western blot analysis showed that Bcl-2 protein level was inhibited after treatment with C8. 1-octene 108-110 BCL2 apoptosis regulator Homo sapiens 53-58 18667591-0 2008 Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mebendazole 0-11 BCL2 apoptosis regulator Homo sapiens 34-39 18667591-7 2008 The intrinsic apoptotic response is mediated through phosphorylation of Bcl-2, which occurs rapidly after treatment with mebendazole in melanoma cells but not in melanocytes. Mebendazole 121-132 BCL2 apoptosis regulator Homo sapiens 72-77 18667591-9 2008 We further show that mebendazole-resistant melanocytes can be sensitized through reduction of Bcl-2 protein levels, showing the essential role of Bcl-2 in the cellular response to mebendazole-mediated tubulin disruption. Mebendazole 21-32 BCL2 apoptosis regulator Homo sapiens 94-99 18667591-9 2008 We further show that mebendazole-resistant melanocytes can be sensitized through reduction of Bcl-2 protein levels, showing the essential role of Bcl-2 in the cellular response to mebendazole-mediated tubulin disruption. Mebendazole 21-32 BCL2 apoptosis regulator Homo sapiens 146-151 18667591-9 2008 We further show that mebendazole-resistant melanocytes can be sensitized through reduction of Bcl-2 protein levels, showing the essential role of Bcl-2 in the cellular response to mebendazole-mediated tubulin disruption. Mebendazole 180-191 BCL2 apoptosis regulator Homo sapiens 94-99 18667591-9 2008 We further show that mebendazole-resistant melanocytes can be sensitized through reduction of Bcl-2 protein levels, showing the essential role of Bcl-2 in the cellular response to mebendazole-mediated tubulin disruption. Mebendazole 180-191 BCL2 apoptosis regulator Homo sapiens 146-151 18465755-0 2008 Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Dichloroacetic Acid 0-15 BCL2 apoptosis regulator Homo sapiens 68-73 18465755-0 2008 Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Dichloroacetic Acid 17-20 BCL2 apoptosis regulator Homo sapiens 68-73 18465755-3 2008 Recently, dichloroacetate (DCA) was proven to potentiate the apoptotic machinery by interacting with Bcl-2. Dichloroacetic Acid 10-25 BCL2 apoptosis regulator Homo sapiens 101-106 18465755-3 2008 Recently, dichloroacetate (DCA) was proven to potentiate the apoptotic machinery by interacting with Bcl-2. Dichloroacetic Acid 27-30 BCL2 apoptosis regulator Homo sapiens 101-106 18465755-9 2008 Treatment of PC-3-Bcl-2 or PC-3-Neo with DCA and irradiation resulted in marked changes in various members of the Bcl-2 family. 3-neo 30-35 BCL2 apoptosis regulator Homo sapiens 114-119 18465755-9 2008 Treatment of PC-3-Bcl-2 or PC-3-Neo with DCA and irradiation resulted in marked changes in various members of the Bcl-2 family. Dichloroacetic Acid 41-44 BCL2 apoptosis regulator Homo sapiens 18-23 18465755-9 2008 Treatment of PC-3-Bcl-2 or PC-3-Neo with DCA and irradiation resulted in marked changes in various members of the Bcl-2 family. Dichloroacetic Acid 41-44 BCL2 apoptosis regulator Homo sapiens 114-119 18465755-11 2008 CONCLUSIONS: This is the first study to demonstrate DCA can effectively sensitize wild-type and over expressing Bcl-2 human prostate cancer cells to radiation by modulating the expression of key members of the Bcl-2 family. Dichloroacetic Acid 52-55 BCL2 apoptosis regulator Homo sapiens 112-117 18465755-11 2008 CONCLUSIONS: This is the first study to demonstrate DCA can effectively sensitize wild-type and over expressing Bcl-2 human prostate cancer cells to radiation by modulating the expression of key members of the Bcl-2 family. Dichloroacetic Acid 52-55 BCL2 apoptosis regulator Homo sapiens 210-215 19112901-10 2008 The expression of bcl-2 gene was suppressed after the essential oil from pine needles treatement. Oils, Volatile 54-67 BCL2 apoptosis regulator Homo sapiens 18-23 19112901-11 2008 CONCLUSION: The essential oil extracted from pine needles can inhibit cell growth of HepG2 cell line and induce apoptosis, which may associate with inhibition of telomerase activity and bcl-2 may be involved in the regulation of telomerase activity. Oils, Volatile 16-29 BCL2 apoptosis regulator Homo sapiens 186-191 18469002-1 2008 The mitogen-activated protein kinase JNK1 suppresses interleukin-3 withdrawal-induced cell death through phosphorylation of the BH3-only pro-apoptotic Bcl-2 family protein Bad at Thr-201. BH 3 128-131 BCL2 apoptosis regulator Homo sapiens 151-156 18469002-1 2008 The mitogen-activated protein kinase JNK1 suppresses interleukin-3 withdrawal-induced cell death through phosphorylation of the BH3-only pro-apoptotic Bcl-2 family protein Bad at Thr-201. Threonine 179-182 BCL2 apoptosis regulator Homo sapiens 151-156 18589412-10 2008 Importantly, glutamate preconditioning increased Bcl-2 expression that was blocked by KN93, staurosporin and CRE-decoy oligonucleotide. Glutamic Acid 13-22 BCL2 apoptosis regulator Homo sapiens 49-54 18589412-10 2008 Importantly, glutamate preconditioning increased Bcl-2 expression that was blocked by KN93, staurosporin and CRE-decoy oligonucleotide. Staurosporine 92-104 BCL2 apoptosis regulator Homo sapiens 49-54 18589412-10 2008 Importantly, glutamate preconditioning increased Bcl-2 expression that was blocked by KN93, staurosporin and CRE-decoy oligonucleotide. Oligonucleotides 119-134 BCL2 apoptosis regulator Homo sapiens 49-54 18589412-11 2008 These results suggest that preconditioning with glutamate conferred neuroprotection against subsequent OGD by inducing p-CREB-mediated Bcl-2 expression. Glutamic Acid 48-57 BCL2 apoptosis regulator Homo sapiens 135-140 18652667-10 2008 Furthermore, treatment with 17beta-estradiol (E2) stimulated growth and up-regulated Bcl-2 expression in estrogen responsive breast epithelial cells; however, these carcinogenic effects were diminished by either CLA or 4-Hydroxytamoxifen (Tam) and were suppressed further by the combination of CLA and Tam. Estradiol 28-44 BCL2 apoptosis regulator Homo sapiens 85-90 18657507-0 2008 Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2"s inhibition of apoptotic calcium signals. Calcium 84-91 BCL2 apoptosis regulator Homo sapiens 10-15 18657507-0 2008 Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2"s inhibition of apoptotic calcium signals. Calcium 84-91 BCL2 apoptosis regulator Homo sapiens 52-57 18657507-4 2008 A peptide based on this IP3R sequence displaced Bcl-2 from the IP3R and reversed Bcl-2-mediated inhibition of IP3R channel activity in vitro, IP3-induced ER Ca2+ release in permeabilized cells, and cell-permeable IP3 ester-induced Ca2+ elevation in intact cells. Inositol 1,4,5-Trisphosphate 24-27 BCL2 apoptosis regulator Homo sapiens 48-53 18657507-4 2008 A peptide based on this IP3R sequence displaced Bcl-2 from the IP3R and reversed Bcl-2-mediated inhibition of IP3R channel activity in vitro, IP3-induced ER Ca2+ release in permeabilized cells, and cell-permeable IP3 ester-induced Ca2+ elevation in intact cells. Inositol 1,4,5-Trisphosphate 24-27 BCL2 apoptosis regulator Homo sapiens 81-86 18657507-4 2008 A peptide based on this IP3R sequence displaced Bcl-2 from the IP3R and reversed Bcl-2-mediated inhibition of IP3R channel activity in vitro, IP3-induced ER Ca2+ release in permeabilized cells, and cell-permeable IP3 ester-induced Ca2+ elevation in intact cells. ip3 ester 213-222 BCL2 apoptosis regulator Homo sapiens 48-53 18657507-4 2008 A peptide based on this IP3R sequence displaced Bcl-2 from the IP3R and reversed Bcl-2-mediated inhibition of IP3R channel activity in vitro, IP3-induced ER Ca2+ release in permeabilized cells, and cell-permeable IP3 ester-induced Ca2+ elevation in intact cells. ip3 ester 213-222 BCL2 apoptosis regulator Homo sapiens 81-86 18570428-0 2008 A mixture of trans, trans conjugated linoleic acid induces apoptosis in MCF-7 human breast cancer cells with reciprocal expression of Bax and Bcl-2. Linoleic Acid 37-50 BCL2 apoptosis regulator Homo sapiens 142-147 19099828-14 2008 (3) Significantly increased expression of Bax protein and ratio of Bax/Bcl-2 was only found in infant rats treated with PB, CNP or VPA compared with control (P < 0.05), the results of TUNEL was in accordance with immunohistochemistry. Phenobarbital 120-122 BCL2 apoptosis regulator Homo sapiens 71-76 19086645-0 2008 [Curcumin inhibits growth, induces G1 arrest and apoptosis on human prostatic stromal cells by regulating Bcl-2/Bax]. Curcumin 1-9 BCL2 apoptosis regulator Homo sapiens 106-111 19086645-7 2008 CONCLUSION: Curcumin can induce apoptosis in human prostatic stromal cells by down-regulation of Bcl-2/Bax. Curcumin 12-20 BCL2 apoptosis regulator Homo sapiens 97-102 18424910-9 2008 When combined with Bcl-2 siRNA, doxorubicin (IC(50)) enhanced autophagy as indicated by the increased number cells with GFP-LC3-II-stained autophagosomes (punctuated pattern positive). Doxorubicin 32-43 BCL2 apoptosis regulator Homo sapiens 19-24 18525315-2 2008 When MKN45 cells were treated with 30 micromol/l purvalanol A, mitochondrial dysfunction occurred before the induction of the apoptosis and the expression of antiapoptotic proteins survivin, Bcl-XL, and Bcl-2 was reduced. 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine 49-61 BCL2 apoptosis regulator Homo sapiens 203-208 18582466-3 2008 Lovastatin treatment down-regulates the expression of Bcl-2 and activates apoptosis through a mitochondria-operated, ErbB2- regulated mechanism. Lovastatin 0-10 BCL2 apoptosis regulator Homo sapiens 54-59 18583128-1 2008 A multi-component reaction strategy was used for the fast and efficient synthesis of amide isosteres of known Bcl-2 inhibitors capable of disrupting protein-protein interactions. Amides 85-90 BCL2 apoptosis regulator Homo sapiens 110-115 18636671-10 2008 After treatment with aspirin, SW480 cells displayed typically morphological features of apoptosis and necrosis under TEM, and increased the Bcl-2 expression in cells, but the expression of Bax was down regulated. Aspirin 21-28 BCL2 apoptosis regulator Homo sapiens 140-145 18469004-0 2008 Cysteine cathepsins trigger caspase-dependent cell death through cleavage of bid and antiapoptotic Bcl-2 homologues. Cysteine 0-8 BCL2 apoptosis regulator Homo sapiens 99-104 18469004-5 2008 Moreover, in vitro experiments showed that one or more of the cysteine cathepsins B, L, S, K, and H could cleave Bcl-2, Bcl-xL, Mcl-1, Bak, and BimEL, whereas no Bax cleavage was observed. Cysteine 62-70 BCL2 apoptosis regulator Homo sapiens 113-118 18497563-3 2008 This interaction involves a Bcl-2 homology 3 (BH3) domain in Beclin 1 and the BH3 binding groove of Bcl-2/Bcl-X(L). BH 3 46-49 BCL2 apoptosis regulator Homo sapiens 28-33 18077129-4 2008 We also found that 6-O-angeloylenolin could inhibit nuclear translocation of NF-kappaB and modulate the expression of Bcl-2 gene family. 6-O-angeloylenolin 19-37 BCL2 apoptosis regulator Homo sapiens 118-123 18497563-3 2008 This interaction involves a Bcl-2 homology 3 (BH3) domain in Beclin 1 and the BH3 binding groove of Bcl-2/Bcl-X(L). BH 3 46-49 BCL2 apoptosis regulator Homo sapiens 100-105 18077129-5 2008 These results indicated that 6-O-angeloylenolin induces apoptosis by inhibition of NF-kappaB activation, modulation of Bcl-2 gene family expression and destruction of mitochondrial function. 6-O-angeloylenolin 29-47 BCL2 apoptosis regulator Homo sapiens 119-124 18403180-0 2008 Zfra is an inhibitor of Bcl-2 expression and cytochrome c release from the mitochondria. zfra 0-4 BCL2 apoptosis regulator Homo sapiens 24-29 18593931-7 2008 In HCT 116 colon carcinoma cells, sagopilone-induced apoptosis was partly antagonized by the knockdown of proapoptotic members of the Bcl-2 family, including Bax, Bak, and Puma, whereas knockdown of Bcl-2, Bcl-X(L), or Chk1 sensitized cells to sagopilone-induced cell death. sagopilone 34-44 BCL2 apoptosis regulator Homo sapiens 134-139 18593931-7 2008 In HCT 116 colon carcinoma cells, sagopilone-induced apoptosis was partly antagonized by the knockdown of proapoptotic members of the Bcl-2 family, including Bax, Bak, and Puma, whereas knockdown of Bcl-2, Bcl-X(L), or Chk1 sensitized cells to sagopilone-induced cell death. sagopilone 34-44 BCL2 apoptosis regulator Homo sapiens 199-204 18593936-5 2008 Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and Sp4, we observed that curcumin-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, survivin, and cyclin D1, was also due, in part, to loss of Sp proteins. Curcumin 100-108 BCL2 apoptosis regulator Homo sapiens 192-197 18511169-7 2008 KTA treatment triggered the mitochondrial apoptotic pathway indicated by a change in Bax/Bcl-2 ratios, resulting in mitochondrial membrane potential loss and caspase-9 activation. kotomolide A 0-3 BCL2 apoptosis regulator Homo sapiens 89-94 18356276-10 2008 The progrowth signaling via AKT-mammalian target rapamycin-p70(S6K) and cyclin D1/cyclin-dependent kinase were inhibited, and proapoptotic activity of Bcl-2-associated death promoter was increased by LY294002 treatment. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 200-208 BCL2 apoptosis regulator Homo sapiens 151-156 18495315-0 2008 Bcl-2 expression and apoptosis induction in human HL60 leukaemic cells treated with a novel organotellurium(IV) compound RT-04. organotellurium 92-107 BCL2 apoptosis regulator Homo sapiens 0-5 18411291-9 2008 TxA-induced inflammatory signaling via p38 and apoptosis as measured by activation of BAK (Bcl-2 homologous antagonist/killer) and DNA fragmentation were decreased in gp96-deficient B cells. txa 0-3 BCL2 apoptosis regulator Homo sapiens 91-96 18433847-11 2008 This process involves disruption of mitochondrial potential and production of ROS by a Bcl-2-independent pathway. Reactive Oxygen Species 78-81 BCL2 apoptosis regulator Homo sapiens 87-92 18441044-4 2008 Pretreatment of HEp2-alpha(v)beta(3) integrin-expressing cells with an inhibitor of GSH synthesis, buthionine sulfoximine (BSO), decreased the level of GSH and partially reverted drug resistance to all above-mentioned drugs, but it did not influence the expression of Bcl-2. Buthionine Sulfoximine 99-121 BCL2 apoptosis regulator Homo sapiens 268-273 18386790-4 2008 Curcumin is incorporated into H-RS cells and acts inhibiting both NF-kappaB and STAT3 activation, leading to a decreased expression of proteins involved in cell proliferation and apoptosis, e.g. Bcl-2, Bcl-xL, cFLIP, XIAP, c-IAP1, survivin, c-myc and cyclin D1. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 195-200 18575753-6 2008 We found that RSVL-induced apoptosis correlates with sustained activation of ERK1/2 and suppression of Bcl-2 expression. Resveratrol 14-18 BCL2 apoptosis regulator Homo sapiens 103-108 18575753-7 2008 Inhibition of ERK1/2 activation by its specific inhibitor or small interfering RNA reverses the effect of RSVL on Bcl-2 suppression and inhibits apoptosis, while overexpression of MEK1, which is directly upstream of both ERK1 and ERK2, enhances apoptosis induced by RSVL. Resveratrol 106-110 BCL2 apoptosis regulator Homo sapiens 114-119 18645028-2 2008 (-)-Gossypol, a natural BH3 mimetic, is a small-molecule inhibitor of Bcl-2/Bcl-xL/Mcl-1 currently in phase II clinical trials as an adjuvant therapy for human prostate cancer. Gossypol 0-12 BCL2 apoptosis regulator Homo sapiens 70-75 18645028-9 2008 (-)-Gossypol significantly enhances the antitumor activity of chemotherapy in vitro and in vivo, representing a promising new regime for the treatment of human hormone-refractory prostate cancer with Bcl-2/Bcl-xL/Mcl-1 overexpression. Gossypol 0-12 BCL2 apoptosis regulator Homo sapiens 200-205 18486907-5 2008 The induction of apoptosis after treatment with (-)-syringaresinol for 24 h was demonstrated by morphological changes, DNA fragmentation, altered ratio of Bax/Bcl-2, cleavage of poly(ADP-ribose) polymerase and flow cytometry analysis. syringaresinol 48-66 BCL2 apoptosis regulator Homo sapiens 159-164 18648656-5 2008 We also found the signaling changes in mitochondria-mediated apoptosis, such as cytochrome c release and increased expression of Bcl-2, as well as a dose-dependent attenuation of mitochondrial membrane potential in the DHA-OOH treated cells. dehydroacetic acid 219-222 BCL2 apoptosis regulator Homo sapiens 129-134 18648656-5 2008 We also found the signaling changes in mitochondria-mediated apoptosis, such as cytochrome c release and increased expression of Bcl-2, as well as a dose-dependent attenuation of mitochondrial membrane potential in the DHA-OOH treated cells. OOH 223-226 BCL2 apoptosis regulator Homo sapiens 129-134 18507431-3 2008 We show that resveratrol induces apoptosis in Jeko-1 cells and modulates several key molecules, including cyclin D1 (CCND1), p53 (TP53), p21 (CDKN1A), BCL2, BAX, Bcl XL (BCL2L1), caspase 9 (CASP9) and p27 (CDKN1B). Resveratrol 13-24 BCL2 apoptosis regulator Homo sapiens 151-155 18441044-4 2008 Pretreatment of HEp2-alpha(v)beta(3) integrin-expressing cells with an inhibitor of GSH synthesis, buthionine sulfoximine (BSO), decreased the level of GSH and partially reverted drug resistance to all above-mentioned drugs, but it did not influence the expression of Bcl-2. Buthionine Sulfoximine 123-126 BCL2 apoptosis regulator Homo sapiens 268-273 18442812-6 2008 Measuring the modulation of regulators in the cell cycle, apoptosis and signal transductions by Western blot analysis showed that the combination effect of cucurbitacin B and docetaxel was due to suppress the expression of p-STAT3 (signal transducers and activators of transcription 3), Bcl-2, and cyclin B1. cucurbitacin B 156-170 BCL2 apoptosis regulator Homo sapiens 287-292 18592012-4 2008 The expression of STAT3 downstream genes, survivin, cyclin D1, Cox-2, and c-Myc, was suppressed but Bcl-2 was enhanced by resveratrol. Resveratrol 122-133 BCL2 apoptosis regulator Homo sapiens 100-105 18592012-10 2008 Enhanced leukemia inhibitory factor and Bcl-2 expressions in resveratrol-treated cells might reflect a compensatory response to the loss of STAT3 function. Resveratrol 61-72 BCL2 apoptosis regulator Homo sapiens 40-45 18314257-0 2008 beta-Sitosterol induces G2/M arrest, endoreduplication, and apoptosis through the Bcl-2 and PI3K/Akt signaling pathways. gamma-sitosterol 0-15 BCL2 apoptosis regulator Homo sapiens 82-87 18342436-4 2008 The anti-apoptotic Bcl-2 and Survivin protein was downregulated by the curcumin treatment together with enhancement of the Bax and p53 expression. Curcumin 71-79 BCL2 apoptosis regulator Homo sapiens 19-24 18343029-0 2008 Bcl-2 overexpression attenuates SP600125-induced apoptosis in human leukemia U937 cells. pyrazolanthrone 32-40 BCL2 apoptosis regulator Homo sapiens 0-5 18343029-4 2008 In contrast, overexpression of the antiapoptotic protein Bcl-2 rendered leukemia cells resistant to SP600125-induced apoptosis, but more sensitive to G2/M phase arrest and endoreduplication (>4N DNA). pyrazolanthrone 100-108 BCL2 apoptosis regulator Homo sapiens 57-62 18343029-5 2008 Overexpression of Bcl-2 significantly inhibited SP600125-induced caspase-3 activation and degradation of its substrates, and sustained expression levels of the IAP-2 proteins following SP600125 treatment. pyrazolanthrone 48-56 BCL2 apoptosis regulator Homo sapiens 18-23 18343029-5 2008 Overexpression of Bcl-2 significantly inhibited SP600125-induced caspase-3 activation and degradation of its substrates, and sustained expression levels of the IAP-2 proteins following SP600125 treatment. pyrazolanthrone 185-193 BCL2 apoptosis regulator Homo sapiens 18-23 18343029-7 2008 These data provide important mechanistic insights related to Bcl-2-mediated resistance to SP600125-induced apoptosis, and induction of G2/M phase arrest and endoreduplication. pyrazolanthrone 90-98 BCL2 apoptosis regulator Homo sapiens 61-66 18442812-6 2008 Measuring the modulation of regulators in the cell cycle, apoptosis and signal transductions by Western blot analysis showed that the combination effect of cucurbitacin B and docetaxel was due to suppress the expression of p-STAT3 (signal transducers and activators of transcription 3), Bcl-2, and cyclin B1. Docetaxel 175-184 BCL2 apoptosis regulator Homo sapiens 287-292 18547146-9 2008 However, the addition of tBid recruited molar excesses of either protein to membranes, indicating that tBid activates both pro- and antiapoptotic members of the Bcl-2 family. tBID 103-107 BCL2 apoptosis regulator Homo sapiens 161-166 18046541-5 2008 This sorbitol-induced apoptosis in human K562 cells was also accompanied by the up-regulation of Bax, and down-regulation of p-Bcl-2, but no effect on the levels of Bcl-X(L). Sorbitol 5-13 BCL2 apoptosis regulator Homo sapiens 127-132 18329683-0 2008 A179L, a viral Bcl-2 homologue, targets the core Bcl-2 apoptotic machinery and its upstream BH3 activators with selective binding restrictions for Bid and Noxa. BH 3 92-95 BCL2 apoptosis regulator Homo sapiens 15-20 18046541-8 2008 These results clearly demonstrate that the induction of apoptosis by sorbitol involves multiple cellular/molecular pathways and strongly suggest that pro- and anti-apoptotic Bcl-2 family proteins, mitochondrial membrane potential, mitochondrial cyt c, and caspase 3, they all participate in sorbitol-induced apoptotic process in human K562 cells. Sorbitol 69-77 BCL2 apoptosis regulator Homo sapiens 174-179 18081943-7 2008 The results suggest that key regulators in tocotrienol-induced apoptosis may be Bcl-2 families and caspase-3 in SGC-7901 cells through down regulation of the Raf-ERK signalling pathway. Tocotrienols 43-54 BCL2 apoptosis regulator Homo sapiens 80-85 18377980-3 2008 One of the biochemical alterations accompanying Bcl-2 overexpression is the increase in cellular glutathione (GSH) levels. Glutathione 97-108 BCL2 apoptosis regulator Homo sapiens 48-53 18377980-3 2008 One of the biochemical alterations accompanying Bcl-2 overexpression is the increase in cellular glutathione (GSH) levels. Glutathione 110-113 BCL2 apoptosis regulator Homo sapiens 48-53 18377980-4 2008 In this study, we hypothesize that such increase of GSH concentration will selectively enhance the transfection activity of redox-sensitive delivery systems in cells overexpressing Bcl-2. Glutathione 52-55 BCL2 apoptosis regulator Homo sapiens 181-186 18377980-6 2008 It was confirmed that Bcl-2 overexpression resulted in the expected increase in GSH concentration. Glutathione 80-83 BCL2 apoptosis regulator Homo sapiens 22-27 18519699-0 2008 WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth. WL 276 0-6 BCL2 apoptosis regulator Homo sapiens 30-35 18379194-8 2008 Taken together, these results suggest that Nobiletin could induce p53-mediated cell cycle arrest and apoptosis via modulated the Bax:Bcl-2 protein ratio, is effective as a potent antitumor agent on lung tumors. nobiletin 43-52 BCL2 apoptosis regulator Homo sapiens 133-138 18081943-4 2008 Furthermore, gamma-tocotrienol-induced apoptosis was accompanied by down regulation of Bcl-2, up regulation of Bax, activation of caspase-3, and subsequent poly (ADP-ribose) polymerase cleavage. plastochromanol 8 13-30 BCL2 apoptosis regulator Homo sapiens 87-92 18081943-5 2008 These results indicated that up or down regulation of Bcl-2 family proteins play a major role in the initiation of gamma-tocotrienol-induced apoptosis as an activator of caspase-3. plastochromanol 8 115-132 BCL2 apoptosis regulator Homo sapiens 54-59 18369371-0 2008 Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy? BH 3 51-54 BCL2 apoptosis regulator Homo sapiens 14-19 18519699-4 2008 WL-276 was developed as a small-molecule antagonist against antiapoptotic Bcl-2 family proteins, with binding potency comparable to (-)-gossypol. WL 276 0-6 BCL2 apoptosis regulator Homo sapiens 74-79 18497995-4 2008 Bcl-2 overexpression protected Jurkat T leukemia cells from CdA-induced apoptosis and loss of mitochondrial transmembrane potential (Delta Psi m). Cladribine 60-63 BCL2 apoptosis regulator Homo sapiens 0-5 18366039-6 2008 It was also found that the L1Pt(II)Cl(2) complex is an efficient regulator of the apoptotic genes Bcl-2 in the treated SK-BR-3 cells. l1pt(ii)cl(2) 27-40 BCL2 apoptosis regulator Homo sapiens 98-103 18324624-5 2008 Following transient expression of MDR-1 and MCJ, changes in the sensitivity of Sk-Ov-3 cells to paclitaxel were detected whereas expression of Src, Bcl-2 and Bcl-X(L) decreased the sensitivity of Sk-Ov-3 cells to carboplatin. Carboplatin 213-224 BCL2 apoptosis regulator Homo sapiens 148-153 18519752-0 2008 Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 39-42 BCL2 apoptosis regulator Homo sapiens 16-21 18519752-1 2008 PURPOSE: The purpose of this study was to characterize the activity of the Bcl-2 protein family inhibitor ABT-263 in a panel of small cell lung cancer (SCLC) xenograft models. navitoclax 106-113 BCL2 apoptosis regulator Homo sapiens 75-80 18519752-11 2008 CONCLUSIONS: ABT-263 is a potent, orally bioavailable inhibitor of Bcl-2 family proteins that has recently entered clinical trials. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 13-16 BCL2 apoptosis regulator Homo sapiens 67-72 18189268-0 2008 Sanguinarine-induced apoptosis: generation of ROS, down-regulation of Bcl-2, c-FLIP, and synergy with TRAIL. sanguinarine 0-12 BCL2 apoptosis regulator Homo sapiens 70-75 18266926-0 2008 Maneb potentiates paraquat neurotoxicity by inducing key Bcl-2 family members. Maneb 0-5 BCL2 apoptosis regulator Homo sapiens 57-62 18189268-6 2008 During sanguinarin-induced apoptosis, protein levels of pro-caspase-3, Bcl-2, cIAP2, XIAP, and c-FLIPs were reduced. sanguinarine 7-18 BCL2 apoptosis regulator Homo sapiens 71-76 18189268-7 2008 Sanguinarine-mediated apoptosis was substantially blocked by ectopic expression of Bcl-2 and cFLIPs. sanguinarine 0-12 BCL2 apoptosis regulator Homo sapiens 83-88 18189268-9 2008 Therefore, combinatory treatment of sanguinarine and TRAIL may overcome the resistance of breast cancer cells due to overexpression of Akt or Bcl-2. sanguinarine 36-48 BCL2 apoptosis regulator Homo sapiens 142-147 18628592-7 2008 Moreover, treatment with N-acetyl-L-cysteine prior to induction with TRAIL increased expression of the anti-apoptotic Bcl-2 protein. Acetylcysteine 25-44 BCL2 apoptosis regulator Homo sapiens 118-123 18323457-9 2008 However, the antioxidant N-acetylcysteine opposed MSFTZ-mediated mitochondrial dysfunction, caspase activation, Bcl-2/Bax modulation, and apoptosis, supporting the role of ROS in the apoptotic process. Acetylcysteine 25-41 BCL2 apoptosis regulator Homo sapiens 112-117 18083230-9 2008 Celecoxib-induced apoptosis of IR-K562 cells led to release of cytochrome c, PARP cleavage and decreased Bcl2/Bax ratio. Celecoxib 0-9 BCL2 apoptosis regulator Homo sapiens 105-109 18310471-7 2008 SAHA treatment leads to cytochrome c release from mitochondria, which is suppressed by Bcl-2 but not by VAD. Vorinostat 0-4 BCL2 apoptosis regulator Homo sapiens 87-92 18310471-8 2008 Bcl-2 consistently blocks SAHA-induced apoptosis. Vorinostat 26-30 BCL2 apoptosis regulator Homo sapiens 0-5 18310471-9 2008 During SAHA treatment, Bcl-2 and Bcl-XL decrease, and Bid is proteolytically cleaved, whereas Bax and Bak expression remains constant. Vorinostat 7-11 BCL2 apoptosis regulator Homo sapiens 23-28 18566235-0 2008 Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins. gambogic acid 0-13 BCL2 apoptosis regulator Homo sapiens 48-53 18058803-4 2008 AMR-Me induced DNA fragmentation and PARP degradation which were preceded by changing Bax/Bcl-2 ratios, cytochrome c release, and subsequent induction of pro-caspase-9 and -7 processing in breast carcinoma MCF-7 cells, but it did not act on Fas/Fas ligand pathways and the activation of caspase-8, suggesting AMR-Me triggered the mitochondrial apoptotic pathway. methyl 25-hydroxy-3-oxoolean-12-en-28-oate 0-6 BCL2 apoptosis regulator Homo sapiens 90-95 18566235-2 2008 Using the antiapoptotic Bcl-2 family protein, Bfl-1, as a target for screening of a library of natural products, we identified GA as a competitive inhibitor that displaced BH3 peptides from Bfl-1 in a fluorescence polarization assay. gambogic acid 127-129 BCL2 apoptosis regulator Homo sapiens 24-29 19383332-0 2008 Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy. Anthracyclines 77-90 BCL2 apoptosis regulator Homo sapiens 20-25 18566235-3 2008 Analysis of competition for BH3 peptide binding revealed that GA inhibits all six human Bcl-2 family proteins to various extents, with Mcl-1 and Bcl-B the most potently inhibited [concentrations required for 50% inhibition (IC(50)), < 1 micromol/L]. gambogic acid 62-64 BCL2 apoptosis regulator Homo sapiens 88-93 19383332-7 2008 We found that a high Bcl-2 expression had no predictive value but had prognostic value in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy. Anthracyclines 138-151 BCL2 apoptosis regulator Homo sapiens 21-26 18566235-5 2008 GA functionally inhibited the antiapoptotic Bcl-2 family proteins as shown by experiments using isolated mitochondria in which recombinant purified Bcl-2 family proteins suppress SMAC release in vitro, showing that GA neutralizes their suppressive effects on mitochondria in a concentration-dependent manner. gambogic acid 0-2 BCL2 apoptosis regulator Homo sapiens 44-49 18566235-5 2008 GA functionally inhibited the antiapoptotic Bcl-2 family proteins as shown by experiments using isolated mitochondria in which recombinant purified Bcl-2 family proteins suppress SMAC release in vitro, showing that GA neutralizes their suppressive effects on mitochondria in a concentration-dependent manner. gambogic acid 0-2 BCL2 apoptosis regulator Homo sapiens 148-153 18566235-5 2008 GA functionally inhibited the antiapoptotic Bcl-2 family proteins as shown by experiments using isolated mitochondria in which recombinant purified Bcl-2 family proteins suppress SMAC release in vitro, showing that GA neutralizes their suppressive effects on mitochondria in a concentration-dependent manner. gambogic acid 215-217 BCL2 apoptosis regulator Homo sapiens 44-49 18566235-7 2008 However, GA retained cytotoxic activity against bax-/-bak-/- cells in which antiapoptotic Bcl-2 family proteins lack a cytoprotective phenotype, implying that GA also has additional targets that contribute to its cytotoxic mechanism. gambogic acid 9-11 BCL2 apoptosis regulator Homo sapiens 90-95 18566235-8 2008 Altogether, the findings suggest that suppression of antiapoptotic Bcl-2 family proteins may be among the cytotoxic mechanisms by which GA kills tumor cells. gambogic acid 136-138 BCL2 apoptosis regulator Homo sapiens 67-72 18566236-2 2008 Molecular targeting of Bcl-X(L) and/or Bcl-2 in HNSCC cells has been shown to promote apoptosis signaling and to sensitize cells to chemotherapy drugs, including cisplatin, which is commonly used in the treatment of HNSCC. Cisplatin 162-171 BCL2 apoptosis regulator Homo sapiens 39-44 18566236-3 2008 We report that induction of HNSCC apoptosis by the proteasome inhibitor bortezomib is accompanied by up-regulation of the proapoptotic proteins Bik and Bim, natural cellular inhibitors of Bcl-X(L) and Bcl-2. Bortezomib 72-82 BCL2 apoptosis regulator Homo sapiens 201-206 18599993-4 2008 The activation of caspase-3 was increased, and the rate of bcl-2/bax was down-regulated in the HXO-RB(44) cells processed with arsenic trioxide. Arsenic Trioxide 127-143 BCL2 apoptosis regulator Homo sapiens 59-64 18085673-1 2008 BACKGROUND: ABT-263 is a potent (K(i) < 1 nM) small-molecule BH3 mimetic that inhibits the antiapoptotic proteins Bcl-2, Bcl-x(L) and Bcl-w. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 12-15 BCL2 apoptosis regulator Homo sapiens 117-122 18085673-2 2008 The structurally related Bcl-2 inhibitor ABT-737 exhibits single-agent preclinical activity against lymphoma, small-cell lung carcinoma, and chronic lymphocytic leukemia and displays synergistic cytotoxicity with chemotherapeutics and radiation. ABT-737 41-48 BCL2 apoptosis regulator Homo sapiens 25-30 18446845-7 2008 The induction of apoptotic cell death by ESS was associated with down-regulation of anti-apoptotic Bcl-2 and up-regulation of pro-apoptotic Bax expression. ESS 41-44 BCL2 apoptosis regulator Homo sapiens 99-104 18400355-6 2008 Moreover, ghrelin increased mitochondrial anti-apoptosis related gene protein expression such as bcl-2 and MnSOD, reduced cytoplasmic cytochrome C (Cyt C) release and strengthened the activation of NF-kappaB. Ghrelin 10-17 BCL2 apoptosis regulator Homo sapiens 97-102 18375387-3 2008 Lansoprazole prevents indomethacin-induced up-regulation of proapoptotic Bax and Bak and down-regulation of antiapoptotic Bcl-2 and Bcl(xL) to maintain the normal proapoptotic/antiapoptotic ratio and thereby arrests indomethacin-induced mitochondrial translocation of Bax and collapse of mitochondrial membrane potential followed by cytochrome c release and caspase-9 activation. Lansoprazole 0-12 BCL2 apoptosis regulator Homo sapiens 122-127 18375387-3 2008 Lansoprazole prevents indomethacin-induced up-regulation of proapoptotic Bax and Bak and down-regulation of antiapoptotic Bcl-2 and Bcl(xL) to maintain the normal proapoptotic/antiapoptotic ratio and thereby arrests indomethacin-induced mitochondrial translocation of Bax and collapse of mitochondrial membrane potential followed by cytochrome c release and caspase-9 activation. Indomethacin 22-34 BCL2 apoptosis regulator Homo sapiens 122-127 18258354-3 2008 Here, we demonstrated that the combination of AG-041R (a CCK-2 receptor antagonist) plus NS-398 (a selective COX-2 inhibitor) treatment had synergistic effects on proliferation inhibition, apoptosis induction, down-regulation of Bcl-2 and up-regulation of Bax expression in MKN-45 cells. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 89-95 BCL2 apoptosis regulator Homo sapiens 229-234 18471982-1 2008 The Bcl-2 relative Bak is thought to drive apoptosis by forming homo-oligomers that permeabilize mitochondria, but how it is activated and oligomerizes is unclear. bakuchiol 19-22 BCL2 apoptosis regulator Homo sapiens 4-9 18339304-5 2008 PFF (0.7+/-0.3Pa, 5Hz, 1h) upregulated Bcl-2 and downregulated caspase-3 expression in osteocytes. 5hz 18-21 BCL2 apoptosis regulator Homo sapiens 39-44 18339304-5 2008 PFF (0.7+/-0.3Pa, 5Hz, 1h) upregulated Bcl-2 and downregulated caspase-3 expression in osteocytes. Hydrogen 23-25 BCL2 apoptosis regulator Homo sapiens 39-44 18339304-9 2008 This suggests that PFF inhibits osteocyte apoptosis via alterations in Bcl-2 and caspase-3 gene expression, which is at least partially regulated by NO. p-Fluorophenylalanine 19-22 BCL2 apoptosis regulator Homo sapiens 71-76 18405886-0 2008 Selenium protects the hypoxia induced apoptosis in neuroblastoma cells through upregulation of Bcl-2. Selenium 0-8 BCL2 apoptosis regulator Homo sapiens 95-100 18405886-11 2008 This study suggests that Se supplementation prevented the cells from hypoxia induced apoptosis by triggering upregulation of Bcl-2 protein and reducing the oxidative stress. Selenium 25-27 BCL2 apoptosis regulator Homo sapiens 125-130 18630529-8 2008 Baicalein induced apoptosis in a time-dependent effect through the inhibition of Bcl-2 expression, increased the levels of Bax, reduced the level of deltapsim, and promoted the cytochrome c release and caspase-3 activation. baicalein 0-9 BCL2 apoptosis regulator Homo sapiens 81-86 18405923-3 2008 Treatment of A172 cells with capsaicin inhibited cell growth and induced apoptosis through down-regulation of Bcl-2 and activation of caspase-3. Capsaicin 29-38 BCL2 apoptosis regulator Homo sapiens 110-115 18392682-4 2008 The apoptotic effect of TA was associated with (i) the release of cytochrome c from mitochondria which was not accompanied by dissipation of the mitochondrial membrane potential (DeltaPsi(m)), (ii) the activation of the mitogen-activated protein kinases (MAPKs) pathway and (iii) abrogated by the over-expression of Bcl-2 or Bcl-x(L). trifolin acetate 24-26 BCL2 apoptosis regulator Homo sapiens 316-321 18190795-11 2008 On top of this, PA -- the product of PLDs, also resulted in upregulation of Bcl-2 in SNU 484. Phosphatidic Acids 16-18 BCL2 apoptosis regulator Homo sapiens 76-81 18190795-12 2008 Although PA-induced Bcl-2 expression was blocked by mepacrine, an inhibitor of phospholipase A(2) (PLA(2)), increased Bcl-2 expression by PA was not abrogated by propranolol, an inhibitor of PA phospholyhydrolase (PAP). Phosphatidic Acids 9-11 BCL2 apoptosis regulator Homo sapiens 20-25 18190795-12 2008 Although PA-induced Bcl-2 expression was blocked by mepacrine, an inhibitor of phospholipase A(2) (PLA(2)), increased Bcl-2 expression by PA was not abrogated by propranolol, an inhibitor of PA phospholyhydrolase (PAP). Quinacrine 52-61 BCL2 apoptosis regulator Homo sapiens 20-25 18262755-6 2008 Consistently, the blockade of Bax action by RNA interference or Bcl-2 overexpression abolished the activation of JNK induced after, but not before, the production of ROS. Reactive Oxygen Species 166-169 BCL2 apoptosis regulator Homo sapiens 64-69 18190795-12 2008 Although PA-induced Bcl-2 expression was blocked by mepacrine, an inhibitor of phospholipase A(2) (PLA(2)), increased Bcl-2 expression by PA was not abrogated by propranolol, an inhibitor of PA phospholyhydrolase (PAP). Quinacrine 52-61 BCL2 apoptosis regulator Homo sapiens 118-123 18190795-12 2008 Although PA-induced Bcl-2 expression was blocked by mepacrine, an inhibitor of phospholipase A(2) (PLA(2)), increased Bcl-2 expression by PA was not abrogated by propranolol, an inhibitor of PA phospholyhydrolase (PAP). Phosphatidic Acids 138-140 BCL2 apoptosis regulator Homo sapiens 118-123 18190795-13 2008 Taken together, PLD1 and PLD2 are closely related with Bcl-2 expression together with PLA(2), but not with PAP, during taxotere-induced apoptosis in SNU 484 cells. Docetaxel 119-127 BCL2 apoptosis regulator Homo sapiens 55-60 18451495-4 2008 Combined treatment with berberine and cisplatin acted in concert to induce loss of mitochondrial membrane potential (Delta Psi m), release of cytochrome-c from mitochondria, and decreased expression of antiapoptotic Bcl-2, Bcl-x/L, resulting in activation of caspases and apoptosis. Berberine 24-33 BCL2 apoptosis regulator Homo sapiens 216-221 18451495-4 2008 Combined treatment with berberine and cisplatin acted in concert to induce loss of mitochondrial membrane potential (Delta Psi m), release of cytochrome-c from mitochondria, and decreased expression of antiapoptotic Bcl-2, Bcl-x/L, resulting in activation of caspases and apoptosis. Cisplatin 38-47 BCL2 apoptosis regulator Homo sapiens 216-221 18078766-7 2008 Phosphoinositide-3-kinase (PI3K)/Akt, survivin, bcl-2 were significantly downregulated in cells treated with the combination of celecoxib and cisplatin, and decreased survivin and bcl-2 levels were found in cells with wortmannin, a specific PI3K inhibitor. Celecoxib 128-137 BCL2 apoptosis regulator Homo sapiens 48-53 18078766-7 2008 Phosphoinositide-3-kinase (PI3K)/Akt, survivin, bcl-2 were significantly downregulated in cells treated with the combination of celecoxib and cisplatin, and decreased survivin and bcl-2 levels were found in cells with wortmannin, a specific PI3K inhibitor. Celecoxib 128-137 BCL2 apoptosis regulator Homo sapiens 180-185 18078766-7 2008 Phosphoinositide-3-kinase (PI3K)/Akt, survivin, bcl-2 were significantly downregulated in cells treated with the combination of celecoxib and cisplatin, and decreased survivin and bcl-2 levels were found in cells with wortmannin, a specific PI3K inhibitor. Cisplatin 142-151 BCL2 apoptosis regulator Homo sapiens 48-53 18078766-7 2008 Phosphoinositide-3-kinase (PI3K)/Akt, survivin, bcl-2 were significantly downregulated in cells treated with the combination of celecoxib and cisplatin, and decreased survivin and bcl-2 levels were found in cells with wortmannin, a specific PI3K inhibitor. Cisplatin 142-151 BCL2 apoptosis regulator Homo sapiens 180-185 18078766-9 2008 Therefore, celecoxib exerts its anti-tumor activities through COX-2-independent mechanisms, which may be PI3K/Akt-dependent, and survivin and bcl-2-related. Celecoxib 11-20 BCL2 apoptosis regulator Homo sapiens 142-147 18454859-6 2008 RESULTS: Tetracycline regulated short term over expression of HER-2 in the MCF7 cell line increased the antiapoptotic proteins Bcl-2 and survivin levels. Tetracycline 9-21 BCL2 apoptosis regulator Homo sapiens 127-132 18309326-1 2008 Primary chronic lymphocytic leukemia (CLL) cells are exquisitely sensitive to ABT-737, a small molecule BCL2-antagonist, which induces many of the classical biochemical and ultrastructural features of apoptosis, including BAX/BAK oligomerization, cytochrome c release, caspase activation and chromatin condensation. ABT-737 78-85 BCL2 apoptosis regulator Homo sapiens 104-108 18078766-10 2008 PI3K may be at the center of the celecoxib effects, which play an essential role in the regulation of survivin and Bcl-2. Celecoxib 33-42 BCL2 apoptosis regulator Homo sapiens 115-120 18262755-7 2008 Bcl-2 overexpression also blocked the translocation of Bax from the cytosol to the mitochondria only after the induction of ROS. Reactive Oxygen Species 124-127 BCL2 apoptosis regulator Homo sapiens 0-5 18262755-10 2008 This role for ROS appears to allow Bcl-2 to block the signaling events, which are initially induced upstream. Reactive Oxygen Species 14-17 BCL2 apoptosis regulator Homo sapiens 35-40 18359761-5 2008 Fisetin treatment also resulted in induction of apoptosis, poly (ADP-ribose) polymerase (PARP) cleavage, modulation in the expressions of Bcl-2 family proteins, inhibition of phosphatidyl inositol 3-kinase and phosphorylation of Akt at Ser(473) and Thr(308). fisetin 0-7 BCL2 apoptosis regulator Homo sapiens 138-143 17692431-5 2008 Finally, assays of eight Bak peptide analogues on Bcl-2 allowed us to postulate that modulations at position 78 could afford peptides with a binding selectivity enhanced for Bcl-x(L). bakuchiol 25-28 BCL2 apoptosis regulator Homo sapiens 50-55 18451170-0 2008 ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. navitoclax 0-7 BCL2 apoptosis regulator Homo sapiens 42-47 18451170-2 2008 We previously reported the discovery of ABT-737, a potent, small-molecule Bcl-2 family protein inhibitor. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 40-43 BCL2 apoptosis regulator Homo sapiens 74-79 18451170-4 2008 Here we report the biological properties of ABT-263, a potent, orally bioavailable Bad-like BH3 mimetic (K(i)"s of <1 nmol/L for Bcl-2, Bcl-xL, and Bcl-w). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 44-47 BCL2 apoptosis regulator Homo sapiens 132-137 18451170-6 2008 ABT-263 disrupts Bcl-2/Bcl-xL interactions with pro-death proteins (e.g., Bim), leading to the initiation of apoptosis within 2 hours posttreatment. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 17-22 18451239-0 2008 A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors. Oligonucleotides 87-102 BCL2 apoptosis regulator Homo sapiens 81-86 18451239-2 2008 The effect of G3139 treatment on Bcl-2 expression in peripheral blood mononuclear cells (PBMC) and paired tumor biopsies was also determined. oblimersen 14-19 BCL2 apoptosis regulator Homo sapiens 33-38 18451239-14 2008 In addition, we show that achievable intratumoral G3139 concentrations can result in Bcl-2 down-regulation in solid tumors and PBMCs. oblimersen 50-55 BCL2 apoptosis regulator Homo sapiens 85-90 18221384-8 2008 CONCLUSIONS: These studies demonstrated that bortezomib mediates anti-tumor effects in EBV-associated lymphoproliferations both in vitro and in vivo, and that its anti-proliferative and apoptotic effects are synergistically enhanced in the presence of a Bcl-2 inhibitor. Bortezomib 45-55 BCL2 apoptosis regulator Homo sapiens 254-259 18346839-2 2008 R-(-)-gossypol (AT-101) is a small molecule that mimics the BH3 domain of cellular Bcl-2 inhibitors and interferes with the function of prosurvival Bcl-2 proteins. Gossypol 0-14 BCL2 apoptosis regulator Homo sapiens 83-88 18346839-2 2008 R-(-)-gossypol (AT-101) is a small molecule that mimics the BH3 domain of cellular Bcl-2 inhibitors and interferes with the function of prosurvival Bcl-2 proteins. Gossypol 0-14 BCL2 apoptosis regulator Homo sapiens 148-153 18346839-2 2008 R-(-)-gossypol (AT-101) is a small molecule that mimics the BH3 domain of cellular Bcl-2 inhibitors and interferes with the function of prosurvival Bcl-2 proteins. gossypol acetic acid 16-22 BCL2 apoptosis regulator Homo sapiens 83-88 18346839-2 2008 R-(-)-gossypol (AT-101) is a small molecule that mimics the BH3 domain of cellular Bcl-2 inhibitors and interferes with the function of prosurvival Bcl-2 proteins. gossypol acetic acid 16-22 BCL2 apoptosis regulator Homo sapiens 148-153 18346839-2 2008 R-(-)-gossypol (AT-101) is a small molecule that mimics the BH3 domain of cellular Bcl-2 inhibitors and interferes with the function of prosurvival Bcl-2 proteins. BH 3 60-63 BCL2 apoptosis regulator Homo sapiens 83-88 18346839-8 2008 Apoptosis was activated via the mitochondrial pathway in multiple myeloma cell lines treated with AT-101 as demonstrated by an increased Bax to Bcl-2 ratio, mitochondrial membrane depolarization, and caspase activation. gossypol acetic acid 98-104 BCL2 apoptosis regulator Homo sapiens 144-149 18484413-2 2008 This study reported that reactive oxygen species (ROS) and nitric oxide (NO) generations were induced by evodiamine time-dependently; while they acted in synergy to trigger mitochondria-dependent apoptosis by induction of mitochondrial membrane permeabilization (MMP) through increasing the Bax/Bcl-2 or Bcl-x(L) ratio. Reactive Oxygen Species 25-48 BCL2 apoptosis regulator Homo sapiens 295-300 18484413-2 2008 This study reported that reactive oxygen species (ROS) and nitric oxide (NO) generations were induced by evodiamine time-dependently; while they acted in synergy to trigger mitochondria-dependent apoptosis by induction of mitochondrial membrane permeabilization (MMP) through increasing the Bax/Bcl-2 or Bcl-x(L) ratio. evodiamine 105-115 BCL2 apoptosis regulator Homo sapiens 295-300 18452462-9 2008 The Bcl-2 expression in bladder cancer cells is decreased and caspase-3 expression increased after NaB treatment. nab 99-102 BCL2 apoptosis regulator Homo sapiens 4-9 18064628-4 2008 We found dose- and time-dependent upregulation of Bim protein, a pro-apoptotic Bcl-2 family member, with highest levels at 24-48 h for 1 microM Dex. Dexamethasone 144-147 BCL2 apoptosis regulator Homo sapiens 79-84 18088078-6 2008 RESULTS: Continuous high glucose increased reactive oxygen species, 8-OHdG, nitrotyrosine, caspase-3, and reduced Bcl-2 expression. Glucose 25-32 BCL2 apoptosis regulator Homo sapiens 114-119 18359018-5 2008 In neuron/microglial co-cultures, minocycline treatment prevented activation and proliferation of microglia and protected neurons as demonstrated by decreased neuronal cell death and a shift of Bcl-2 family proteins toward anti-apoptotic ratio. Minocycline 34-45 BCL2 apoptosis regulator Homo sapiens 194-199 18508575-4 2008 In this review, we discuss the multimodal effects of ladostigil in terms of neuroprotective molecular mechanism in vivo and in vitro, which include the amyloid precursor protein processing; activation of protein kinase C and mitogen-activated protein kinase pathways; regulation of the Bcl-2 family members; inhibition of cell death markers and up-regulation of neurotrophic factors. (N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate 53-63 BCL2 apoptosis regulator Homo sapiens 286-291 18478476-7 2008 Positive expression rate of Bcl-2 was 80% and the positive cells showed resistance to 5-FU, ADM and MMC. Fluorouracil 86-90 BCL2 apoptosis regulator Homo sapiens 28-33 18273635-14 2008 A down-regulating effect of lactate is observed for superoxide dismutase 2 (1 h, 0.5-fold; 24 h, 0.4-fold; 7 days, 0.32-fold) and BCL2-associated X protein (24 h, 0.42-fold; 7 days, 0.4-fold). Lactic Acid 28-35 BCL2 apoptosis regulator Homo sapiens 130-134 18444248-13 2008 The addition of progesterone (100 ng/mL) resulted in a striking increase in Bcl-2 protein expression in the cultured leiomyoma cells. Progesterone 16-28 BCL2 apoptosis regulator Homo sapiens 76-81 18444248-14 2008 However, the addition of SB (20 microg/mL) resulted in a significant reduction in Bcl-2 protein expression in the cells. Antimony 25-27 BCL2 apoptosis regulator Homo sapiens 82-87 18444248-15 2008 The results indicated that human uterine leiomyomal cells express Bcl-2 protein and progesterone enhances its expression, however, SB reduces the expression of Bcl-2 protein in human uterine leiomyoma cells. Antimony 131-133 BCL2 apoptosis regulator Homo sapiens 160-165 18646526-9 2008 The bcl-2 protein expressions treated with IP6 were reduced, and the bax protein expressions treated with IP6 were more than those of control groups in dose and time dependent manners. Phytic Acid 43-46 BCL2 apoptosis regulator Homo sapiens 4-9 18646526-10 2008 CONCLUSION: The proliferation of gastric carcinoma SGC-7901 cells inhibitited by IP6 could be associated with apoptosis of gene bax and bcl-2. Phytic Acid 81-84 BCL2 apoptosis regulator Homo sapiens 136-141 18652313-12 2008 CONCLUSION: Cucurbitacin B inhibited cell proliferation and induced apoptosis of Hep-2 cells by suppressing STAT3 signal pathway, down regulating the expression of cyclin B1 and Bcl-2 proteins. cucurbitacin B 12-26 BCL2 apoptosis regulator Homo sapiens 178-183 18702305-8 2008 In 3-3 cells, the elevated ROS increased the AP-1 activity, subsequently the expression of Bax increased, and the expression of Bcl2 was reduced. Reactive Oxygen Species 27-30 BCL2 apoptosis regulator Homo sapiens 128-132 18287248-7 2008 It is noteworthy that this flavone also suppressed TNF-induced activation of Akt, a cell survival kinase, and expression of various antiapoptotic proteins, such as IAP-1, IAP-2, XIAP, Bcl-2, Bcl-xL, and TRAF-1. flavone 27-34 BCL2 apoptosis regulator Homo sapiens 184-189 18717345-7 2008 It was observed that poly-(ADP-ribose) polymeras (PARP) were cleaved to smaller molecules and ARG induced upregulation of bax and downregulation of bcl-2 protein expression. arctigenin 94-97 BCL2 apoptosis regulator Homo sapiens 148-153 18717345-9 2008 Taken together, this study demonstrated that ARG is a potent inducer of apoptosis and this was accompanied by caspase-3 activation and upregulation of bax/bcl-2, which offers a potential mechanism for the apoptosis-inducing activity of ARG. arctigenin 45-48 BCL2 apoptosis regulator Homo sapiens 155-160 18717345-9 2008 Taken together, this study demonstrated that ARG is a potent inducer of apoptosis and this was accompanied by caspase-3 activation and upregulation of bax/bcl-2, which offers a potential mechanism for the apoptosis-inducing activity of ARG. arctigenin 236-239 BCL2 apoptosis regulator Homo sapiens 155-160 18727869-0 2008 [DMF-induced adult hepatocyte apoptosis and its effects on expression of Bcl-2, Bax and Caspase-3]. Dimethylformamide 1-4 BCL2 apoptosis regulator Homo sapiens 73-78 18398104-1 2008 BACKGROUND: ABT-737 is a pan-Bcl-2 inhibitor that has a wide range of single-agent activity against acute lymphoblastic leukemia (ALL) cell lines and xenografts. ABT-737 12-19 BCL2 apoptosis regulator Homo sapiens 29-34 18727869-4 2008 RESULTS: The increase in apoptotic rate of hepatocytes in concentration-manner was shown after DMF treatment for 12 h. After treatment the expression of Bcl-2 was decreased steadily and lower than the control group (P < 0.01), the expression of Bax showed no significant difference among the groups of different dosage by one-factor analysis of variance (P > 0.05), as the increase of the dosage of DMF. Dimethylformamide 95-98 BCL2 apoptosis regulator Homo sapiens 153-158 18727869-4 2008 RESULTS: The increase in apoptotic rate of hepatocytes in concentration-manner was shown after DMF treatment for 12 h. After treatment the expression of Bcl-2 was decreased steadily and lower than the control group (P < 0.01), the expression of Bax showed no significant difference among the groups of different dosage by one-factor analysis of variance (P > 0.05), as the increase of the dosage of DMF. Dimethylformamide 405-408 BCL2 apoptosis regulator Homo sapiens 153-158 18727869-5 2008 The ratio of Bcl-2/Bax dropped with the dosage of DMF increasing, and the ratio in 200 mmol/L of DMF was significantly lower than that of the control (P < 0.01). Dimethylformamide 50-53 BCL2 apoptosis regulator Homo sapiens 13-18 18727869-7 2008 CONCLUSION: DMF can induce apoptosis of cultured adult normal hepatocytes in vitro, and the mechanism might be related to the decrease of Bcl-2/Bax and the cleavage of Caspase-3. Dimethylformamide 12-15 BCL2 apoptosis regulator Homo sapiens 138-143 18304716-9 2008 We also observed that chronic arsenic exposure reduced Bcl-2/Bax ratio and also resulted in cell cycle arrest of PBMC in G0/G1 phase. Arsenic 30-37 BCL2 apoptosis regulator Homo sapiens 55-60 18222036-3 2008 Clitocine-induced cell death was characterized with the changes in cell morphology, DNA fragmentation, activation of caspase-3, -8, and -9 (like) activities, poly(ADP-ribose) polymerase (PARP) cleavage, release of cytochrome c (cyt c) into cytosol, and increase of Bax:Bcl-2 ratio. clitocine 0-9 BCL2 apoptosis regulator Homo sapiens 269-274 18222036-4 2008 These results indicated that the induction of apoptosis by clitocine involved the multiple pathway including death receptor and mitochondrial pathways, and strongly suggested that the mitochondrial pathways were mediated by down-regulation of Bcl-2 and up-regulation of Bax, release of cytochrome c and subsequent activation of caspase-3 followed by down stream events leading to apoptotic mode of cell death. clitocine 59-68 BCL2 apoptosis regulator Homo sapiens 243-248 18398104-2 2008 A relationship between expression of myeloid cell leukemia 1 (Mcl-1), an antiapoptotic member of the Bcl-2 family of proteins, and resistance to ABT-737 has been reported for various cancers. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 145-148 BCL2 apoptosis regulator Homo sapiens 101-106 18313654-12 2008 Additionally, apicidin significantly increased the bax/bcl-2 ratio in MCF-7 cells. apicidin 14-22 BCL2 apoptosis regulator Homo sapiens 55-60 18263880-4 2008 Exposure of cells to nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone results in accumulation of Bcl2 in the nucleus and interaction with APE1, which requires all of the BH domains of Bcl2. SCHEMBL420028 21-79 BCL2 apoptosis regulator Homo sapiens 107-111 18413764-2 2008 ABT-737 is a small-molecule BH3 mimetic that binds to and antagonizes Bcl-2/Bcl-x(L) but not Mcl-1. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 70-75 18413764-2 2008 ABT-737 is a small-molecule BH3 mimetic that binds to and antagonizes Bcl-2/Bcl-x(L) but not Mcl-1. BH 3 28-31 BCL2 apoptosis regulator Homo sapiens 70-75 18358005-10 2008 PLS3 and tBid may form a bidirectional positive feedback loop that is antagonized by Bcl-2. tBID 9-13 BCL2 apoptosis regulator Homo sapiens 85-90 18413764-7 2008 Furthermore, ABT-737 untethered the proapoptotic BH3-only protein Bim from its sequestration by Bcl-x(L) or Bcl-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 13-16 BCL2 apoptosis regulator Homo sapiens 108-113 18178565-2 2008 In this report, we compared the ability of the six human anti-apoptotic Bcl-2 family members to suppress apoptosis induced by overexpression of Bax or Bak, correlating findings with protein interactions measured by three different methods: co-immunoprecipitation, glutathione S-transferase pulldown, and fluorescence polarization assays employing synthetic BH3 peptides from Bax and Bak. Glutathione 264-275 BCL2 apoptosis regulator Homo sapiens 72-77 18263880-4 2008 Exposure of cells to nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone results in accumulation of Bcl2 in the nucleus and interaction with APE1, which requires all of the BH domains of Bcl2. SCHEMBL420028 21-79 BCL2 apoptosis regulator Homo sapiens 194-198 18296917-4 2008 In the present study, we found that, in vincristine-resistant human gastric cancer cell line SGC7901/VCR, proteasome inhibitor MG132 was an effective inducer of apoptosis, and also had the capacity of downregulating the expression of anti-apoptotic Bcl-2 and MDR1 (P-gp), by which MG132 resensitized tumor cells to the apoptosis induced by anticancer drugs. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 127-132 BCL2 apoptosis regulator Homo sapiens 249-254 18379040-6 2008 Berberine treatment also markedly enhanced apoptosis in T98G cells through the induction of a higher ratio of the Bax/Bcl-2 proteins, the disruption of mitochondrial membrane potential, and the activation of procaspase-9, caspase-9, caspase-3, and poly(ADP-ribose) polymerase (PARP). Berberine 0-9 BCL2 apoptosis regulator Homo sapiens 118-123 18379047-8 2008 Triptolide-induced apoptosis was accompanied by loss of mitochondrial membrane potential and release of cytochrome c (cyt-c) from the mitochondria to the cytosol and down-regulation of anti-apoptotic protein Bcl-2 levels with concurrent up-regulation in pro-apoptotic protein Bax levels and tumor suppressor protein p53 levels. triptolide 0-10 BCL2 apoptosis regulator Homo sapiens 208-213 18358086-9 2008 The ratio of Bax/Bcl-2 decreased in arterial duct VSMC after RA treatment due to the significant inhibition of Bax expression. Tretinoin 61-63 BCL2 apoptosis regulator Homo sapiens 17-22 18381443-2 2008 Furthermore, we examined the efficacy of the aptamer AS1411 in targeting nucleolin and inducing bcl-2 mRNA instability and cytotoxicity in these cells. AGRO 100 53-59 BCL2 apoptosis regulator Homo sapiens 96-101 18381439-0 2008 Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. ABT-737 24-31 BCL2 apoptosis regulator Homo sapiens 58-63 18381439-2 2008 We compared primary SCLC xenografts prepared from de novo human tumors with standard cell line-based xenografts in the evaluation of a novel and highly potent small molecule inhibitor of Bcl-2, ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 194-197 BCL2 apoptosis regulator Homo sapiens 187-192 18381408-2 2008 Here, we review recent findings that cancer cell sensitivity to TRAIL is greatly increased when the Bcl-2 family protein Mcl-1 is down-regulated by the Raf/vascular endothelial growth factor kinase inhibitor sorafenib, a Food and Drug Administration-approved cancer drug. Sorafenib 208-217 BCL2 apoptosis regulator Homo sapiens 100-105 18381443-6 2008 Similarly, AS1411 (10 micromol/L) decreased the half-life of bcl-2 mRNA in MCF-7 and MDA-MB-231 cells to 1.0 and 1.2 hours, respectively. AGRO 100 11-17 BCL2 apoptosis regulator Homo sapiens 61-66 18381443-8 2008 AS1411 also inhibited the binding of nucleolin to the instability element AU-rich element 1 of bcl-2 mRNA in a cell-free system and in MCF-7 cells. AGRO 100 0-6 BCL2 apoptosis regulator Homo sapiens 95-100 18418425-5 2008 Prolonged exposure of the isolated neonatal cardiomyocyte to medium containing insulin and high glucose led to increased susceptibility to angiotensin II-mediated apoptosis, an effect associated with reduced levels of phospho-Akt and an increased Bax/Bcl-2 ratio. Glucose 96-103 BCL2 apoptosis regulator Homo sapiens 251-256 18418425-7 2008 Because the beneficial effects of high glucose were associated with elevations in phospho-Akt and Bcl-2 content, the cardioprotective activity of high glucose resembles the actions of insulin. Glucose 39-46 BCL2 apoptosis regulator Homo sapiens 98-103 18381443-9 2008 Together, the results suggest that AS1411 acts as a molecular decoy by competing with bcl-2 mRNA for binding to cytoplasmic nucleolin in these breast cancer cell lines. AGRO 100 35-41 BCL2 apoptosis regulator Homo sapiens 86-91 18418425-7 2008 Because the beneficial effects of high glucose were associated with elevations in phospho-Akt and Bcl-2 content, the cardioprotective activity of high glucose resembles the actions of insulin. Glucose 151-158 BCL2 apoptosis regulator Homo sapiens 98-103 18381443-10 2008 This interferes with the stabilization of bcl-2 mRNA by nucleolin and may be one mechanism by which AS1411 induces tumor cell death. AGRO 100 100-106 BCL2 apoptosis regulator Homo sapiens 42-47 18428028-4 2008 RSV treatment to breast cancer cells inhibited Bcl-2 and Bcl-X(L) expression and induced mitochondrial membrane depolarization. Resveratrol 0-3 BCL2 apoptosis regulator Homo sapiens 47-52 18360719-0 2008 Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line. Finasteride 0-11 BCL2 apoptosis regulator Homo sapiens 34-39 18360719-6 2008 The immunoreactivity for pro-apoptotic Bax was markedly increased whereas antiapoptotic Bcl-2 and Bcl-xL expression was significantly reduced after incubation of cells with finasteride. Finasteride 173-184 BCL2 apoptosis regulator Homo sapiens 88-93 18360714-6 2008 Thiosulfinates decreased the expression of the anti-apoptotic protein Bcl-2, and increased the expression of the pro-apoptotic protein Bax. thiosulfinates 0-14 BCL2 apoptosis regulator Homo sapiens 70-75 18360719-7 2008 These findings suggest that finasteride induces apoptosis in LNCaP cells via proteins of the Bcl-2 and caspase family. Finasteride 28-39 BCL2 apoptosis regulator Homo sapiens 93-98 18058069-6 2008 We have also shown that vincristine and lomustine trigger apoptosis in all these cells through the mitochondrial pathway via decrease in the level of the anti-apoptosis proteins Bcl-2 and Bcl-xl, respectively. Vincristine 24-35 BCL2 apoptosis regulator Homo sapiens 178-183 17941088-5 2008 RA improved mitochondrial function by inhibiting the stretch- and Ang II-induced reduction in mitochondrial membrane potential, cytochrome c release and by increasing the Bcl2/Bax ratio. Tretinoin 0-2 BCL2 apoptosis regulator Homo sapiens 171-175 18339127-4 2008 Interestingly, we found that melatonin induces a strong re-localization of Bcl-2, the main Bax antagonist to mitochondria, suggesting that Bax activation may in fact be antagonized by Bcl-2 at the mitochondrial level. Melatonin 29-38 BCL2 apoptosis regulator Homo sapiens 75-80 18221360-0 2008 Fluvastatin reduces oxidative damage in human vascular endothelial cells by upregulating Bcl-2. Fluvastatin 0-11 BCL2 apoptosis regulator Homo sapiens 89-94 18221360-6 2008 The protective effect of fluvastatin was mediated by the upregulation of Bcl-2 expression as probed by real-time polymerase chain reaction and Western blotting. Fluvastatin 25-36 BCL2 apoptosis regulator Homo sapiens 73-78 18221360-7 2008 Using siRNA to knock down the expression of Bcl-2, the protective effect of fluvastatin was abolished. Fluvastatin 76-87 BCL2 apoptosis regulator Homo sapiens 44-49 18221360-9 2008 CONCLUSIONS: These results suggest that fluvastatin has a potent protective effect against H(2)O(2)-induced apoptosis via upregulation of Bcl-2 expression. Fluvastatin 40-51 BCL2 apoptosis regulator Homo sapiens 138-143 18058069-6 2008 We have also shown that vincristine and lomustine trigger apoptosis in all these cells through the mitochondrial pathway via decrease in the level of the anti-apoptosis proteins Bcl-2 and Bcl-xl, respectively. Lomustine 40-49 BCL2 apoptosis regulator Homo sapiens 178-183 18221360-9 2008 CONCLUSIONS: These results suggest that fluvastatin has a potent protective effect against H(2)O(2)-induced apoptosis via upregulation of Bcl-2 expression. Hydrogen Peroxide 91-99 BCL2 apoptosis regulator Homo sapiens 138-143 18339127-0 2008 Melatonin antagonizes the intrinsic pathway of apoptosis via mitochondrial targeting of Bcl-2. Melatonin 0-9 BCL2 apoptosis regulator Homo sapiens 88-93 18339127-4 2008 Interestingly, we found that melatonin induces a strong re-localization of Bcl-2, the main Bax antagonist to mitochondria, suggesting that Bax activation may in fact be antagonized by Bcl-2 at the mitochondrial level. Melatonin 29-38 BCL2 apoptosis regulator Homo sapiens 184-189 18339127-5 2008 Indeed, we inhibit the melatonin anti-apoptotic effect (i) by silencing Bcl-2 with small interfering RNAs, or with small-molecular inhibitors targeted at the BH3 binding pocket in Bcl-2 (i.e. the one interacting with Bax); and (ii) by inhibiting melatonin-induced Bcl-2 mitochondrial re-localization with the MT1/MT2 receptor antagonist luzindole. Melatonin 23-32 BCL2 apoptosis regulator Homo sapiens 72-77 18339127-5 2008 Indeed, we inhibit the melatonin anti-apoptotic effect (i) by silencing Bcl-2 with small interfering RNAs, or with small-molecular inhibitors targeted at the BH3 binding pocket in Bcl-2 (i.e. the one interacting with Bax); and (ii) by inhibiting melatonin-induced Bcl-2 mitochondrial re-localization with the MT1/MT2 receptor antagonist luzindole. Melatonin 23-32 BCL2 apoptosis regulator Homo sapiens 180-185 18339127-5 2008 Indeed, we inhibit the melatonin anti-apoptotic effect (i) by silencing Bcl-2 with small interfering RNAs, or with small-molecular inhibitors targeted at the BH3 binding pocket in Bcl-2 (i.e. the one interacting with Bax); and (ii) by inhibiting melatonin-induced Bcl-2 mitochondrial re-localization with the MT1/MT2 receptor antagonist luzindole. Melatonin 23-32 BCL2 apoptosis regulator Homo sapiens 180-185 18339127-5 2008 Indeed, we inhibit the melatonin anti-apoptotic effect (i) by silencing Bcl-2 with small interfering RNAs, or with small-molecular inhibitors targeted at the BH3 binding pocket in Bcl-2 (i.e. the one interacting with Bax); and (ii) by inhibiting melatonin-induced Bcl-2 mitochondrial re-localization with the MT1/MT2 receptor antagonist luzindole. BH 3 158-161 BCL2 apoptosis regulator Homo sapiens 180-185 18339127-5 2008 Indeed, we inhibit the melatonin anti-apoptotic effect (i) by silencing Bcl-2 with small interfering RNAs, or with small-molecular inhibitors targeted at the BH3 binding pocket in Bcl-2 (i.e. the one interacting with Bax); and (ii) by inhibiting melatonin-induced Bcl-2 mitochondrial re-localization with the MT1/MT2 receptor antagonist luzindole. BH 3 158-161 BCL2 apoptosis regulator Homo sapiens 180-185 18339127-5 2008 Indeed, we inhibit the melatonin anti-apoptotic effect (i) by silencing Bcl-2 with small interfering RNAs, or with small-molecular inhibitors targeted at the BH3 binding pocket in Bcl-2 (i.e. the one interacting with Bax); and (ii) by inhibiting melatonin-induced Bcl-2 mitochondrial re-localization with the MT1/MT2 receptor antagonist luzindole. Melatonin 246-255 BCL2 apoptosis regulator Homo sapiens 180-185 18339127-5 2008 Indeed, we inhibit the melatonin anti-apoptotic effect (i) by silencing Bcl-2 with small interfering RNAs, or with small-molecular inhibitors targeted at the BH3 binding pocket in Bcl-2 (i.e. the one interacting with Bax); and (ii) by inhibiting melatonin-induced Bcl-2 mitochondrial re-localization with the MT1/MT2 receptor antagonist luzindole. Melatonin 246-255 BCL2 apoptosis regulator Homo sapiens 180-185 18200035-7 2008 Combination of sorafenib with cytarabine or the novel small molecule Bcl-2 inhibitor ABT-737 synergistically induced cell death in AML cell lines. ABT-737 85-92 BCL2 apoptosis regulator Homo sapiens 69-74 18339127-5 2008 Indeed, we inhibit the melatonin anti-apoptotic effect (i) by silencing Bcl-2 with small interfering RNAs, or with small-molecular inhibitors targeted at the BH3 binding pocket in Bcl-2 (i.e. the one interacting with Bax); and (ii) by inhibiting melatonin-induced Bcl-2 mitochondrial re-localization with the MT1/MT2 receptor antagonist luzindole. luzindole 337-346 BCL2 apoptosis regulator Homo sapiens 180-185 18339127-5 2008 Indeed, we inhibit the melatonin anti-apoptotic effect (i) by silencing Bcl-2 with small interfering RNAs, or with small-molecular inhibitors targeted at the BH3 binding pocket in Bcl-2 (i.e. the one interacting with Bax); and (ii) by inhibiting melatonin-induced Bcl-2 mitochondrial re-localization with the MT1/MT2 receptor antagonist luzindole. luzindole 337-346 BCL2 apoptosis regulator Homo sapiens 180-185 19145825-2 2008 The reduction of CD34+ granulocytes number, normalization of CD95 cells, negative correlation between the number of CD95 and p53, Bcl-2 granulocytes in Imatinib treated patients in comparison with a control group was determined. Imatinib Mesylate 152-160 BCL2 apoptosis regulator Homo sapiens 130-135 18339127-6 2008 This evidence provides a mechanism that may explain how melatonin through interaction with the MT1/MT2 receptors, elicits a pathway that interferes with the Bcl-2 family, thus modulating the cell life/death balance. Melatonin 56-65 BCL2 apoptosis regulator Homo sapiens 157-162 18201741-7 2008 A critical difference between the two types of stress treatments was that only vincristine-induced JNK activation resulted in phosphorylation of Bcl-2 at threonine-56, a modification that can block its anti-apoptotic function. Vincristine 79-90 BCL2 apoptosis regulator Homo sapiens 145-150 18357382-0 2008 Induction of apoptosis by piceatannol in human leukemic U937 cells through down-regulation of Bcl-2 and activation of caspases. 3,3',4,5'-tetrahydroxystilbene 26-37 BCL2 apoptosis regulator Homo sapiens 94-99 18357382-5 2008 RT-PCR and immunoblotting data showed that treating the cells with piceatannol caused the down-regulation of anti-apoptotic Bcl-2 and cIAP-2 expression. 3,3',4,5'-tetrahydroxystilbene 67-78 BCL2 apoptosis regulator Homo sapiens 124-129 18470428-4 2008 Treated with 220 micromol/L genistein for 3 days, the expression level of bax protein was 3.43 folds of the control group (P<0.01),but the expression level of bcl-2 and survivin proteins was respectively 85%(P<0.05) and 35%(P<0.01) of the control group. Genistein 28-37 BCL2 apoptosis regulator Homo sapiens 162-167 18470428-5 2008 CONCLUSION: The cell apoptosis induced by genistein in human salivary adenoid cystic carcinoma cell line SACC-83 may be associated with the upregulation of bax protein expression,and the downregulations of bcl-2 and survivin proteins expression. Genistein 42-51 BCL2 apoptosis regulator Homo sapiens 206-211 18470430-4 2008 SABC immunohistochemistry was used to determine the expression of bcl-2 and survivin genes in vascular and endothelial cells,and 8 normal skin tissues were obtained from infants and children for control. sabc 0-4 BCL2 apoptosis regulator Homo sapiens 66-71 17957723-3 2008 DIM-C-pPhOCH(3) induced caspase-dependent apoptosis in RKO colon cancer cells through decreased mitochondrial membrane potential which is accompanied by increased mitochondrial bax/bcl-2 ratios and release of cytochrome c into the cytosol. dim-c-pphoch(3) 0-15 BCL2 apoptosis regulator Homo sapiens 181-186 18357392-11 2008 In contrast, Bcl-2 expression was decreased by combination treatment with bortezomib plus docetaxel in SNU638 cells. Bortezomib 74-84 BCL2 apoptosis regulator Homo sapiens 13-18 18357392-11 2008 In contrast, Bcl-2 expression was decreased by combination treatment with bortezomib plus docetaxel in SNU638 cells. Docetaxel 90-99 BCL2 apoptosis regulator Homo sapiens 13-18 18357392-14 2008 Further combination studies with other chemotherapeutic drugs, in particular docetaxel showing more tumor cell growth inhibition and apoptosis suggest that combining bortezomib with docetaxel might be more effective for displaying tumor cell growth inhibitory effects in gastric cancer cells through regulation of Bcl-2, Bax and p27 proteins in vitro. Docetaxel 77-86 BCL2 apoptosis regulator Homo sapiens 314-319 18357392-14 2008 Further combination studies with other chemotherapeutic drugs, in particular docetaxel showing more tumor cell growth inhibition and apoptosis suggest that combining bortezomib with docetaxel might be more effective for displaying tumor cell growth inhibitory effects in gastric cancer cells through regulation of Bcl-2, Bax and p27 proteins in vitro. Bortezomib 166-176 BCL2 apoptosis regulator Homo sapiens 314-319 18357392-14 2008 Further combination studies with other chemotherapeutic drugs, in particular docetaxel showing more tumor cell growth inhibition and apoptosis suggest that combining bortezomib with docetaxel might be more effective for displaying tumor cell growth inhibitory effects in gastric cancer cells through regulation of Bcl-2, Bax and p27 proteins in vitro. Docetaxel 182-191 BCL2 apoptosis regulator Homo sapiens 314-319 18357397-12 2008 The ectopic expression of the anti-apoptotic BCL-2 protein attenuated the cytotoxic effects of genistein. Genistein 95-104 BCL2 apoptosis regulator Homo sapiens 45-50 18055082-9 2008 Western blot analysis showed that olanzapine, but not haloperidol, prevented the serum withdrawal-induced decrease in levels of neuroprotective proteins such as p-GSK-3beta, beta-catenin, and Bcl-2 (p<0.01), whereas haloperidol robustly reduced the levels of these proteins at a 10 muM dose in serum-starved cells (p<0.05). Olanzapine 34-44 BCL2 apoptosis regulator Homo sapiens 192-197 18325696-3 2008 During apoptosis induction by sanguinarine and chelerythrine, reactive oxygen species (ROS) was rapidly generated and DeltaPsi(mt) dissipated, while Bax, Bcl-2 and Bcl-X((L/S)) proteins" content in the mitochondrial fraction did not change significantly. sanguinarine 30-42 BCL2 apoptosis regulator Homo sapiens 154-159 18325696-3 2008 During apoptosis induction by sanguinarine and chelerythrine, reactive oxygen species (ROS) was rapidly generated and DeltaPsi(mt) dissipated, while Bax, Bcl-2 and Bcl-X((L/S)) proteins" content in the mitochondrial fraction did not change significantly. chelerythrine 47-60 BCL2 apoptosis regulator Homo sapiens 154-159 18201741-7 2008 A critical difference between the two types of stress treatments was that only vincristine-induced JNK activation resulted in phosphorylation of Bcl-2 at threonine-56, a modification that can block its anti-apoptotic function. Threonine 154-163 BCL2 apoptosis regulator Homo sapiens 145-150 18683683-0 2008 [Roles of bcl-2/bax expression and oligodendrocyte apoptosis in the pathogenesis of heroin-induced spongiform leucoencephalopathy]. Heroin 84-90 BCL2 apoptosis regulator Homo sapiens 10-15 18756958-15 2008 The protein expression levels of the antiapoptotic proteins Bcl-2, survivin, and XIAP were of the HER-2 siRNA III + cisplatin group were significantly lower than those of the cisplatin group, and the protein expression level of the apoptotic protein Smac of the HER-2 siRNA III + cisplatin group significantly higher than that of the cisplatin group (all P < 0.05). Cisplatin 116-125 BCL2 apoptosis regulator Homo sapiens 60-65 18756958-15 2008 The protein expression levels of the antiapoptotic proteins Bcl-2, survivin, and XIAP were of the HER-2 siRNA III + cisplatin group were significantly lower than those of the cisplatin group, and the protein expression level of the apoptotic protein Smac of the HER-2 siRNA III + cisplatin group significantly higher than that of the cisplatin group (all P < 0.05). Cisplatin 175-184 BCL2 apoptosis regulator Homo sapiens 60-65 18756958-15 2008 The protein expression levels of the antiapoptotic proteins Bcl-2, survivin, and XIAP were of the HER-2 siRNA III + cisplatin group were significantly lower than those of the cisplatin group, and the protein expression level of the apoptotic protein Smac of the HER-2 siRNA III + cisplatin group significantly higher than that of the cisplatin group (all P < 0.05). Cisplatin 175-184 BCL2 apoptosis regulator Homo sapiens 60-65 18756958-15 2008 The protein expression levels of the antiapoptotic proteins Bcl-2, survivin, and XIAP were of the HER-2 siRNA III + cisplatin group were significantly lower than those of the cisplatin group, and the protein expression level of the apoptotic protein Smac of the HER-2 siRNA III + cisplatin group significantly higher than that of the cisplatin group (all P < 0.05). Cisplatin 175-184 BCL2 apoptosis regulator Homo sapiens 60-65 18756958-17 2008 The mechanism of induction of cell apoptosis by HER-2 siRNA III + cisplatin may be related to the downregulation of Bcl-2, survivin and XIAP protein and the up-regulation of Smac protein. Cisplatin 66-75 BCL2 apoptosis regulator Homo sapiens 116-121 18195012-1 2008 BIM and tBID are two BCL-2 homology 3 (BH3)-only proteins with a particularly strong capacity to trigger BAX-driven mitochondrial outer membrane permeabilization, a crucial event in mammalian apoptosis. bim 0-3 BCL2 apoptosis regulator Homo sapiens 21-26 18195012-1 2008 BIM and tBID are two BCL-2 homology 3 (BH3)-only proteins with a particularly strong capacity to trigger BAX-driven mitochondrial outer membrane permeabilization, a crucial event in mammalian apoptosis. tBID 8-12 BCL2 apoptosis regulator Homo sapiens 21-26 18192508-5 2008 Flavopiridol-induced mitochondrial depolarization was not blocked by caspase inhibitors or by the calcium chelator EGTA, but was reduced by Bcl-2 overexpression. alvocidib 0-12 BCL2 apoptosis regulator Homo sapiens 140-145 18683683-1 2008 OBJECTIVE: To investigate the role of oligodendrocyte apoptosis under the regulation of the bcl-2/bax protein expression in brain white matter in the pathogenesis of heroin-induced spongiform leucoencephalopathy (HSLE). Heroin 166-172 BCL2 apoptosis regulator Homo sapiens 92-97 18347187-9 2008 The amounts of nuclear factor kappaB, Bcl-2, and Bcl-X(L) proteins were reduced in the cells treated with alpha-TOS for 6 hours. alpha-tos 106-115 BCL2 apoptosis regulator Homo sapiens 38-43 18242171-4 2008 Furthermore, we demonstrated that ropinirole can reduce the rotenone-induced cleavages of caspase 9, caspase 3 and PARP and elevate the expression of anti-apoptotic proteins of p-Akt and bcl-2. ropinirole 34-44 BCL2 apoptosis regulator Homo sapiens 187-192 18242171-4 2008 Furthermore, we demonstrated that ropinirole can reduce the rotenone-induced cleavages of caspase 9, caspase 3 and PARP and elevate the expression of anti-apoptotic proteins of p-Akt and bcl-2. Rotenone 60-68 BCL2 apoptosis regulator Homo sapiens 187-192 18334118-6 2008 Along with the increase of ISA concentration, Bcl-2 expression was decreased, the ratio of Bcl-2 to Bax was significantly decreased (P<0.05). Isatin 27-30 BCL2 apoptosis regulator Homo sapiens 46-51 18334118-6 2008 Along with the increase of ISA concentration, Bcl-2 expression was decreased, the ratio of Bcl-2 to Bax was significantly decreased (P<0.05). Isatin 27-30 BCL2 apoptosis regulator Homo sapiens 91-96 18510170-6 2008 DHA-induced DNA fragmentation also induced the activation of caspase-3 and influenced the expression of Bcl-2 and Bax. artenimol 0-3 BCL2 apoptosis regulator Homo sapiens 104-109 18160625-8 2008 Expression of wild-type and mitochondrial Bcl-2 showed significant inhibitory effects on tubular cell apoptosis that was induced by cisplatin or ATP depletion; however, ER-Bcl-2 was much less effective. Cisplatin 132-141 BCL2 apoptosis regulator Homo sapiens 42-47 18160625-8 2008 Expression of wild-type and mitochondrial Bcl-2 showed significant inhibitory effects on tubular cell apoptosis that was induced by cisplatin or ATP depletion; however, ER-Bcl-2 was much less effective. Adenosine Triphosphate 145-148 BCL2 apoptosis regulator Homo sapiens 42-47 18160625-11 2008 Consistently, wild-type and mitochondrial Bcl-2, but not ER-Bcl-2, blocked Bax activation during ATP depletion, a critical event for mitochondrial outer membrane permeabilization and cytochrome c release. Adenosine Triphosphate 97-100 BCL2 apoptosis regulator Homo sapiens 42-47 18160625-12 2008 In contrast, ER-Bcl-2 protected against apoptosis during tunicamycin-induced ER stress. Tunicamycin 57-68 BCL2 apoptosis regulator Homo sapiens 16-21 18096567-5 2008 Responding bcl-2+ patients received ASCT as consolidation, and those without bcl-2 overexpression (bcl-2-) conventional chemotherapy. asct 36-40 BCL2 apoptosis regulator Homo sapiens 11-16 18160664-0 2008 Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. VX680 25-31 BCL2 apoptosis regulator Homo sapiens 46-51 17505826-0 2008 A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. obatoclax 45-53 BCL2 apoptosis regulator Homo sapiens 21-26 18323654-7 2008 Quercetin also increased the ratio of Bax/Bcl-2 in favor of apoptosis with such treatment. Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 42-47 18084318-10 2008 Celecoxib showed a pro-apoptotic effect, inducing Bax and BID but down-regulating Bcl-2. Celecoxib 0-9 BCL2 apoptosis regulator Homo sapiens 82-87 18298900-8 2008 Treated by GA, the expression of DIO-1 was upregulated, and that of Bcl-2 and NF-kappaB was downregulated, leading to the activation of pro-caspase 3. gambogic acid 11-13 BCL2 apoptosis regulator Homo sapiens 68-73 17505826-0 2008 A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cisplatin 86-95 BCL2 apoptosis regulator Homo sapiens 21-26 18361731-0 2008 Induction of apoptosis by linoleic acid is associated with the modulation of Bcl-2 family and Fas/FasL system and activation of caspases in AGS human gastric adenocarcinoma cells. Linoleic Acid 26-39 BCL2 apoptosis regulator Homo sapiens 77-82 18167132-9 2008 Ridaifen-B significantly reduced mitochondrial membrane potential, and overexpression of Bcl-2 inhibited ridaifen-B-induced apoptosis. ridaifen-B 105-115 BCL2 apoptosis regulator Homo sapiens 89-94 18093815-0 2008 Differentially expressed pro- and anti-apoptogenic genes in response to benzene exposure: Immunohistochemical localization of p53, Bag, Bad, Bax, Bcl-2, and Bcl-w in lung epithelia. Benzene 72-79 BCL2 apoptosis regulator Homo sapiens 146-151 18385940-7 2008 High glucose markedly elevated Bax, and decreased NF-kappaB and Bcl-2 expression. Glucose 5-12 BCL2 apoptosis regulator Homo sapiens 64-69 18288567-13 2008 In a word, HFCL cells could inhibit the proliferation, induce the monocytic differentiation of U937, HL-60 and HL-60/VCR cells, and prevent TPT-induced apoptosis in HL-60 and HL-60/VCR cells via modulation of Bcl-2 and active Caspase-3. 9 alpha,11 alpha,15 alpha-trihydroxy-16-phenoxy-17,18,19,20-tetranorprosta-4,5,13-trienoic acid 140-143 BCL2 apoptosis regulator Homo sapiens 209-214 18292936-8 2008 Western blot analysis of apoptosis-related proteins demonstrated that treatment with MZ-5-156 (10(-6) M) for 48 h significantly increased the protein levels of Fas, phospho-p53 (Ser46), p53AIP1 (p53-regulated Apoptosis-Inducing Protein 1), and caspase-8, -9, and -3, and decreased the protein level of Bcl-2. mz-5 85-89 BCL2 apoptosis regulator Homo sapiens 302-307 18388470-5 2008 Our investigation also showed that PPC-induced apoptosis of both cancer cells was associated with intracellular events including DNA fragmentation, activation of caspase-3, and modulation of Bcl-2 and Bax. ppc 35-38 BCL2 apoptosis regulator Homo sapiens 191-196 17714734-6 2008 Bcl-2 was repressed by bortezomib in both PANC-1 and BxPC-3 cells, while no changes induced in either cell by bortezomib were disclosed in all five members of nuclear factor-kappa B family. Bortezomib 23-33 BCL2 apoptosis regulator Homo sapiens 0-5 18388472-8 2008 In general, apoptosis signaling cascades were activated by the following events: release of cytochrome c, upregulation of Bax, downregulation of Bcl-2, and activation of caspase-3 and -8 in the treatment of genistein and irradiation. Genistein 207-216 BCL2 apoptosis regulator Homo sapiens 145-150 18287262-4 2008 An (111)In-labeled PNA complementary to the translational start site of bcl-2 messenger RNA was attached to Tyr(3)-octreotate for somatostatin receptor-mediated intracellular delivery. octreotate, Tyr(3)- 108-125 BCL2 apoptosis regulator Homo sapiens 72-77 18167055-4 2008 Furthermore, apoptosis in the Tca-8113 cells was accompanied by the activation of protease caspase-8, -9, -3 and low expression of Bcl-2 protein. Trichloroacetic Acid 30-33 BCL2 apoptosis regulator Homo sapiens 131-136 18080802-4 2008 YXQG-EQ treatment inhibited constitutive and epidermal growth factor-induced Akt phosphorylation, basal and TNF-alpha-induced NF-kappaB activation, and downregulated anti-apoptotic Bcl-2 and Bcl-xL expression. yxqg-eq 0-7 BCL2 apoptosis regulator Homo sapiens 181-186 18077176-5 2008 Additionally, pro-apoptotic proteins Bax and caspase-3 have been implemented in the oxidative modification of PtdSer resulting in subsequent asymmetric collapse, while anti-apoptotic protein Bcl-2 has been found to prevent this process. Phosphatidylserines 110-116 BCL2 apoptosis regulator Homo sapiens 191-196 18398703-3 2008 p53 and BCL-2 immunohistochemical expression was determined using paraffin blocks containing the tumor area. Paraffin 66-74 BCL2 apoptosis regulator Homo sapiens 8-13 18155347-5 2008 Chlorpyrifos-induced toxicity was characterized by the loss of mitochondrial potential, the appearance of nuclear condensation and fragmentation, down-regulation of Bcl-2 as well as up-regulation of TNFalpha and FAS mRNA. Chlorpyrifos 0-12 BCL2 apoptosis regulator Homo sapiens 165-170 18031783-6 2008 The z-DEVD-fmk caspase-3 inhibitor and the ectopic expression of anti-apoptotic Bcl-2 significantly inhibited esculetin-induced apoptosis, demonstrating the important role of caspase-3 and mitochondrial proteins in the observed cytotoxic effect. esculetin 110-119 BCL2 apoptosis regulator Homo sapiens 80-85 18237106-0 2008 Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins. acylpyrogallols 0-15 BCL2 apoptosis regulator Homo sapiens 47-52 18237106-1 2008 A series of acylpyrogallols were designed, synthesized, and evaluated as small-molecule inhibitors of antiapoptotic Bcl-2 proteins. acylpyrogallols 12-27 BCL2 apoptosis regulator Homo sapiens 116-121 17647258-6 2008 A clear, dose-dependent reduction of proteasomal activity was also seen in the presence of increasing doses of dopamine, which was accompanied by a slight dose-dependent increase of caspases activities and Bcl-2 levels. Dopamine 111-119 BCL2 apoptosis regulator Homo sapiens 206-211 18056841-6 2008 BH3 profiling, a mitochondrial assay that classifies blocks in the intrinsic apoptotic pathway, indicated a dependence on BCL-2 of both ALL cell lines and primary samples. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 122-127 18056841-9 2008 Finally, BH3 profiling and protein studies accurately predicted a relative degree of sensitivity to BCL-2 antagonism in cell lines. BH 3 9-12 BCL2 apoptosis regulator Homo sapiens 100-105 18313386-4 2008 Removal of the BH1 or BH4 domain abrogates the inhibitory effect of Bcl2 on Ku DNA binding, DNA-PK, and DNA end-joining activities, which results in the failure of Bcl2 to block DSB repair as well as V(D)J recombination. bh1 15-18 BCL2 apoptosis regulator Homo sapiens 68-72 18313386-4 2008 Removal of the BH1 or BH4 domain abrogates the inhibitory effect of Bcl2 on Ku DNA binding, DNA-PK, and DNA end-joining activities, which results in the failure of Bcl2 to block DSB repair as well as V(D)J recombination. bh1 15-18 BCL2 apoptosis regulator Homo sapiens 164-168 18313386-4 2008 Removal of the BH1 or BH4 domain abrogates the inhibitory effect of Bcl2 on Ku DNA binding, DNA-PK, and DNA end-joining activities, which results in the failure of Bcl2 to block DSB repair as well as V(D)J recombination. sapropterin 22-25 BCL2 apoptosis regulator Homo sapiens 68-72 18313386-4 2008 Removal of the BH1 or BH4 domain abrogates the inhibitory effect of Bcl2 on Ku DNA binding, DNA-PK, and DNA end-joining activities, which results in the failure of Bcl2 to block DSB repair as well as V(D)J recombination. sapropterin 22-25 BCL2 apoptosis regulator Homo sapiens 164-168 17828309-0 2008 BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Bortezomib 56-66 BCL2 apoptosis regulator Homo sapiens 0-5 18082672-7 2008 Mechanistic studies demonstrated that the 5-FU plus scFv23/TNF combination specifically resulted in a down-regulation of HER-2/neu, p-Akt and Bcl-2 and up-regulation of TNF-R1. Fluorouracil 42-46 BCL2 apoptosis regulator Homo sapiens 142-147 18085563-6 2008 Activation of glial cells exclusively in these compartments, which was abolished by the expression of Hu-bcl-2 in the double mutants, suggested that chronic inflammation is an indirect consequence of Dpl-induced PC death. dpl 200-203 BCL2 apoptosis regulator Homo sapiens 105-110 18085563-8 2008 Taken together, these data strongly support the involvement of BCL-2 family-dependent apoptotic pathways in Dpl neurotoxicity. dpl 108-111 BCL2 apoptosis regulator Homo sapiens 63-68 18085563-9 2008 The capacity of BCL-2 to compensate PrP(c) deficiency by rescuing PCs from Dpl-induced death suggests that the BCL-2-like property of PrP(c) may impair Dpl-like neurotoxic pathways in wild-type neurons. dpl 75-78 BCL2 apoptosis regulator Homo sapiens 16-21 18085563-9 2008 The capacity of BCL-2 to compensate PrP(c) deficiency by rescuing PCs from Dpl-induced death suggests that the BCL-2-like property of PrP(c) may impair Dpl-like neurotoxic pathways in wild-type neurons. dpl 75-78 BCL2 apoptosis regulator Homo sapiens 111-116 18085563-9 2008 The capacity of BCL-2 to compensate PrP(c) deficiency by rescuing PCs from Dpl-induced death suggests that the BCL-2-like property of PrP(c) may impair Dpl-like neurotoxic pathways in wild-type neurons. dpl 152-155 BCL2 apoptosis regulator Homo sapiens 16-21 18085563-9 2008 The capacity of BCL-2 to compensate PrP(c) deficiency by rescuing PCs from Dpl-induced death suggests that the BCL-2-like property of PrP(c) may impair Dpl-like neurotoxic pathways in wild-type neurons. dpl 152-155 BCL2 apoptosis regulator Homo sapiens 111-116 18205257-18 2008 By using SP immunohistochemical method the expression of Phospho-Stat3 (Tyr705) and Bcl-2 in WCA group and 5-FU group was significantly decreased compared with the control group respectively. TFF2 protein, human 9-11 BCL2 apoptosis regulator Homo sapiens 84-89 18250445-7 2008 Interestingly, rapamycin also blocked class I-induced Akt phosphorylation at Ser(473) and Bcl-2 expression. Sirolimus 15-24 BCL2 apoptosis regulator Homo sapiens 90-95 18275607-0 2008 Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model. apogossypolone 23-37 BCL2 apoptosis regulator Homo sapiens 89-94 18006146-5 2008 Actually, in MCF-7 cells, VPA induces apoptosis, down-regulates Bcl-2 and up-regulates Bak expression. Valproic Acid 26-29 BCL2 apoptosis regulator Homo sapiens 64-69 18163422-10 2008 Galiellalactone inhibited Stat3-mediated luciferase activity (IC(50) approximately 5 microM) and reduced the expression of Bcl-2, Bcl-x(L), c-myc, and cyclin D1. galiellalactone 0-15 BCL2 apoptosis regulator Homo sapiens 123-128 17647102-4 2008 Morroniside at 1-100 microM inhibited the formation of ROS and the activation of caspase-3 and 9, and the upregulation of Bcl-2, whereas no significant change occurred in Bax levels. morroniside 0-11 BCL2 apoptosis regulator Homo sapiens 122-127 18176116-4 2008 Vincristine upregulated the expression of Bax, Bak, PUMA, Noxa, p53 and p21 proteins, and downregulated and/or phosphorylated the Bcl-2 protein. Vincristine 0-11 BCL2 apoptosis regulator Homo sapiens 130-135 18176116-6 2008 In addition, vincristine induced phosphorylation and reduction in Bcl-2 was prevented by an inhibitor of JNK. Vincristine 13-24 BCL2 apoptosis regulator Homo sapiens 66-71 18199286-1 2008 The regulative BH4 domain of human Bcl-2 protein exerts its anti-apoptic activity via the mitochondrion. sapropterin 15-18 BCL2 apoptosis regulator Homo sapiens 35-40 18199286-3 2008 To model the overproduction of Bcl-2 found in cancer processes, we studied the impact of elevated concentrations of its regulative BH4 segment on these mitochondrial membranes from the peptide and lipid perspective. sapropterin 131-134 BCL2 apoptosis regulator Homo sapiens 31-36 18230052-3 2008 This review explores the relationship between cholesterol and cancer in light of a recent study that demonstrated that the hedgehog (Hh) antagonist cyclopamine blocked expression of the Hh pathway targets PTCH1 and GLI1, lowered Bcl2 levels and increased apoptosis in medulloblastoma cells. Cholesterol 46-57 BCL2 apoptosis regulator Homo sapiens 229-233 18230052-3 2008 This review explores the relationship between cholesterol and cancer in light of a recent study that demonstrated that the hedgehog (Hh) antagonist cyclopamine blocked expression of the Hh pathway targets PTCH1 and GLI1, lowered Bcl2 levels and increased apoptosis in medulloblastoma cells. cyclopamine 148-159 BCL2 apoptosis regulator Homo sapiens 229-233 18281755-8 2008 Recent studies in this area have demonstrated various mechanisms involved in the anti-tumor activity of docetaxel: (1) efflux (p-glycoprotein), (2) metabolism (CYP3A4), (3) beta-tubulin (isotype class I and III), (4) cell cycle (HER2, BRCA1), (5) apoptosis (p53, Bcl-2, thioredoxin), and (6) cell proliferation (MIB-1, nuclear grade). Docetaxel 104-113 BCL2 apoptosis regulator Homo sapiens 263-268 17935127-6 2008 Accumulation of dephospho-beta-catenin (nondegraded form) parallel with Bcl-2 and Cyclin D1 downregulation was also achieved after 2-ME(2) treatment. Mercaptoethanol 131-135 BCL2 apoptosis regulator Homo sapiens 72-77 17955488-7 2008 Overexpression of Bcl-2 in HN4 cells prevented loss of MMP, nuclear translocation of EndoG and protected cells from the delayed apoptosis induced by cisplatin in the presence of z-VAD-fmk. Cisplatin 149-158 BCL2 apoptosis regulator Homo sapiens 18-23 17955488-7 2008 Overexpression of Bcl-2 in HN4 cells prevented loss of MMP, nuclear translocation of EndoG and protected cells from the delayed apoptosis induced by cisplatin in the presence of z-VAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 178-187 BCL2 apoptosis regulator Homo sapiens 18-23 17955489-7 2008 Cells treated with p-DDAP were shown to undergo apoptosis, based on condensation nuclei, cytofluorimetric analysis, propidium iodide staining and the expression of bcl-2 and caspase 3. 4-dodecylaminophenol 19-25 BCL2 apoptosis regulator Homo sapiens 164-169 18237468-7 2008 Hoechst 33342 staining and flow cytometry analysis showed an increase of apoptosis rate and decrease of mitochondrial membrane potential after SMMC-7721 cells were exposed to TBIDOM for 24 h. Pretreatment of SMMC-7721 cells with TBIDOM significantly induced a decrease of Bcl-2 protein expression and an increase of caspase-3 activity and Bax protein expression. tbidom 175-181 BCL2 apoptosis regulator Homo sapiens 272-277 18237468-7 2008 Hoechst 33342 staining and flow cytometry analysis showed an increase of apoptosis rate and decrease of mitochondrial membrane potential after SMMC-7721 cells were exposed to TBIDOM for 24 h. Pretreatment of SMMC-7721 cells with TBIDOM significantly induced a decrease of Bcl-2 protein expression and an increase of caspase-3 activity and Bax protein expression. smmc 208-212 BCL2 apoptosis regulator Homo sapiens 272-277 18237468-7 2008 Hoechst 33342 staining and flow cytometry analysis showed an increase of apoptosis rate and decrease of mitochondrial membrane potential after SMMC-7721 cells were exposed to TBIDOM for 24 h. Pretreatment of SMMC-7721 cells with TBIDOM significantly induced a decrease of Bcl-2 protein expression and an increase of caspase-3 activity and Bax protein expression. tbidom 229-235 BCL2 apoptosis regulator Homo sapiens 272-277 18207033-4 2008 An important positive association was observed between bcl-2 and reduced glutathione levels in the tumor tissue of patients receiving neoadjuvant therapy. Glutathione 73-84 BCL2 apoptosis regulator Homo sapiens 55-60 17924059-6 2008 Treatment with TRAIL in combination with the specific Bcl-2 inhibitor HA14-1 and the Bcl-2/Bcl-xL inhibitor BH3I-2" potently enhanced apoptosis in TRAIL-sensitive U87 cells in a dose-dependent fashion. BH3I-2' 108-114 BCL2 apoptosis regulator Homo sapiens 85-90 17989353-0 2008 Impact of targeting the adenine- and uracil-rich element of bcl-2 mRNA with oligoribonucleotides on apoptosis, cell cycle, and neuronal differentiation in SHSY-5Y cells. Adenine 24-31 BCL2 apoptosis regulator Homo sapiens 60-65 17989353-0 2008 Impact of targeting the adenine- and uracil-rich element of bcl-2 mRNA with oligoribonucleotides on apoptosis, cell cycle, and neuronal differentiation in SHSY-5Y cells. Uracil 37-43 BCL2 apoptosis regulator Homo sapiens 60-65 17989939-11 2008 Also, reduction in endogenous GSH along with selenite treatment is associated with increased apoptosis, increased expression of p38 and JNK MAPK, decreased Bcl-2 expression, and increase in caspase-3 expression. Glutathione 30-33 BCL2 apoptosis regulator Homo sapiens 156-161 17989939-11 2008 Also, reduction in endogenous GSH along with selenite treatment is associated with increased apoptosis, increased expression of p38 and JNK MAPK, decreased Bcl-2 expression, and increase in caspase-3 expression. Selenious Acid 45-53 BCL2 apoptosis regulator Homo sapiens 156-161 17989353-2 2008 We have also described three contiguous 2"-O-methyl oligoribonucleotides (ORNs) in both sense and antisense orientation with respect to the bcl-2 ARE that are able to regulate the bcl-2 mRNA half-life and Bcl-2 protein level in two different cell lines. 2"-o-methyl oligoribonucleotides 40-72 BCL2 apoptosis regulator Homo sapiens 140-145 17989353-2 2008 We have also described three contiguous 2"-O-methyl oligoribonucleotides (ORNs) in both sense and antisense orientation with respect to the bcl-2 ARE that are able to regulate the bcl-2 mRNA half-life and Bcl-2 protein level in two different cell lines. 2"-o-methyl oligoribonucleotides 40-72 BCL2 apoptosis regulator Homo sapiens 180-185 17989353-2 2008 We have also described three contiguous 2"-O-methyl oligoribonucleotides (ORNs) in both sense and antisense orientation with respect to the bcl-2 ARE that are able to regulate the bcl-2 mRNA half-life and Bcl-2 protein level in two different cell lines. 2"-o-methyl oligoribonucleotides 40-72 BCL2 apoptosis regulator Homo sapiens 205-210 17989353-2 2008 We have also described three contiguous 2"-O-methyl oligoribonucleotides (ORNs) in both sense and antisense orientation with respect to the bcl-2 ARE that are able to regulate the bcl-2 mRNA half-life and Bcl-2 protein level in two different cell lines. Oligoribonucleotides 74-78 BCL2 apoptosis regulator Homo sapiens 140-145 17989353-2 2008 We have also described three contiguous 2"-O-methyl oligoribonucleotides (ORNs) in both sense and antisense orientation with respect to the bcl-2 ARE that are able to regulate the bcl-2 mRNA half-life and Bcl-2 protein level in two different cell lines. Oligoribonucleotides 74-78 BCL2 apoptosis regulator Homo sapiens 180-185 17989353-2 2008 We have also described three contiguous 2"-O-methyl oligoribonucleotides (ORNs) in both sense and antisense orientation with respect to the bcl-2 ARE that are able to regulate the bcl-2 mRNA half-life and Bcl-2 protein level in two different cell lines. Oligoribonucleotides 74-78 BCL2 apoptosis regulator Homo sapiens 205-210 17989353-3 2008 Here we show that treatment of neuronal cell line (SHSY-5Y) with antisense ORNs targeting the bcl-2 ARE (bcl-2 ARE asORNs) prevents bcl-2 down-regulation in response to apoptotic stimuli with glucose/growth factor starvation (Locke medium) or oxygen deprivation and enhances the apoptotic threshold as evaluated by time-lapse videomicroscopy, fluorescence-activated cell sorting analysis, and caspase-3 activation. Glucose 192-199 BCL2 apoptosis regulator Homo sapiens 94-99 17989353-3 2008 Here we show that treatment of neuronal cell line (SHSY-5Y) with antisense ORNs targeting the bcl-2 ARE (bcl-2 ARE asORNs) prevents bcl-2 down-regulation in response to apoptotic stimuli with glucose/growth factor starvation (Locke medium) or oxygen deprivation and enhances the apoptotic threshold as evaluated by time-lapse videomicroscopy, fluorescence-activated cell sorting analysis, and caspase-3 activation. Glucose 192-199 BCL2 apoptosis regulator Homo sapiens 105-110 17989353-3 2008 Here we show that treatment of neuronal cell line (SHSY-5Y) with antisense ORNs targeting the bcl-2 ARE (bcl-2 ARE asORNs) prevents bcl-2 down-regulation in response to apoptotic stimuli with glucose/growth factor starvation (Locke medium) or oxygen deprivation and enhances the apoptotic threshold as evaluated by time-lapse videomicroscopy, fluorescence-activated cell sorting analysis, and caspase-3 activation. Glucose 192-199 BCL2 apoptosis regulator Homo sapiens 105-110 17989353-3 2008 Here we show that treatment of neuronal cell line (SHSY-5Y) with antisense ORNs targeting the bcl-2 ARE (bcl-2 ARE asORNs) prevents bcl-2 down-regulation in response to apoptotic stimuli with glucose/growth factor starvation (Locke medium) or oxygen deprivation and enhances the apoptotic threshold as evaluated by time-lapse videomicroscopy, fluorescence-activated cell sorting analysis, and caspase-3 activation. Oxygen 243-249 BCL2 apoptosis regulator Homo sapiens 94-99 17989353-3 2008 Here we show that treatment of neuronal cell line (SHSY-5Y) with antisense ORNs targeting the bcl-2 ARE (bcl-2 ARE asORNs) prevents bcl-2 down-regulation in response to apoptotic stimuli with glucose/growth factor starvation (Locke medium) or oxygen deprivation and enhances the apoptotic threshold as evaluated by time-lapse videomicroscopy, fluorescence-activated cell sorting analysis, and caspase-3 activation. Oxygen 243-249 BCL2 apoptosis regulator Homo sapiens 105-110 18223655-1 2008 The proapoptotic BCL-2 family member BAD resides in a glucokinase-containing complex that regulates glucose-driven mitochondrial respiration. Glucose 100-107 BCL2 apoptosis regulator Homo sapiens 17-22 17989353-3 2008 Here we show that treatment of neuronal cell line (SHSY-5Y) with antisense ORNs targeting the bcl-2 ARE (bcl-2 ARE asORNs) prevents bcl-2 down-regulation in response to apoptotic stimuli with glucose/growth factor starvation (Locke medium) or oxygen deprivation and enhances the apoptotic threshold as evaluated by time-lapse videomicroscopy, fluorescence-activated cell sorting analysis, and caspase-3 activation. Oxygen 243-249 BCL2 apoptosis regulator Homo sapiens 105-110 18202802-0 2008 Induction of apoptosis by pectenotoxin-2 is mediated with the induction of DR4/DR5, Egr-1 and NAG-1, activation of caspases and modulation of the Bcl-2 family in p53-deficient Hep3B hepatocellular carcinoma cells. pectenotoxin 2 26-40 BCL2 apoptosis regulator Homo sapiens 146-151 18250043-6 2008 Combined treatment with 5-AZA-CdR and EGCG altered the expressions of Bcl-2 (Bcl-xl) and Bax in HL-60 and K562 cells, decreased the mitochondrial transmembrane potential and induced cell apoposis, and the two agents exhibited obvious synergistic effect. epigallocatechin gallate 38-42 BCL2 apoptosis regulator Homo sapiens 70-75 17920232-7 2008 Furthermore, HPS treatment increased the cytosolic level of cytochrome c and resulted in caspase-3 activation; this effect was correlated with Bax up-regulation and Bcl-2 down-regulation. hps 13-16 BCL2 apoptosis regulator Homo sapiens 165-170 17983597-4 2008 Therefore, 5,6-dichloro-benzimidazole 1-beta-D-ribofuranoside, an adenosine analogue to inhibit mRNA synthesis, was used to estimate the bcl-2 mRNA degradation rate. Dichlororibofuranosylbenzimidazole 11-61 BCL2 apoptosis regulator Homo sapiens 137-142 18361842-19 2008 1.5 h after the treatment with RAL the p- Bcl-2 expression increased remarkable, pretreatment with SB203580 inhibited the p- Bcl-2 expression induced by RAL, and however, PD98059 did not show such effect. SB 203580 99-107 BCL2 apoptosis regulator Homo sapiens 125-130 17959858-6 2008 A total of 19 patients with the lowest levels of BCL2 protein expression were biologically and clinically heterogeneous; 5 patients exhibited high-level BCL2 RNA expression and 4 were fludarabine resistant. fludarabine 184-195 BCL2 apoptosis regulator Homo sapiens 49-53 18199533-8 2008 The Bcl2 promoter contains binding sites for cyclic AMP-responsive element binding protein CREB/ATF1 transcription factors and using the electrophoretic mobility shift assay with a CREB response element, we detected a stronger binding in t-Darpp-expressing cells. Cyclic AMP 45-55 BCL2 apoptosis regulator Homo sapiens 4-8 17991738-7 2008 Sorafenib down-modulates the pro-apoptotic Bcl-2 family member Noxa in cells with high constitutive GSK-3beta activity. Sorafenib 0-9 BCL2 apoptosis regulator Homo sapiens 43-48 18334937-11 2008 EGCG inhibited the H(2)O(2)-stimulated increase of caspase-9 and caspase-3 expression and the decrease of the Bcl-2/Bax ratio. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 110-115 18334937-11 2008 EGCG inhibited the H(2)O(2)-stimulated increase of caspase-9 and caspase-3 expression and the decrease of the Bcl-2/Bax ratio. Hydrogen Peroxide 19-27 BCL2 apoptosis regulator Homo sapiens 110-115 18334937-13 2008 CONCLUSIONS: These findings suggest that EGCG protects HLE cells from the mitochondria-mediated apoptosis induced by H(2)O(2) through the modulation of caspases, the Bcl-2 family, and the MAPK and Akt pathways. epigallocatechin gallate 41-45 BCL2 apoptosis regulator Homo sapiens 166-171 18386569-6 2008 Moreover, allicin showed effects in up-regulating the protein expressions of apoptosis promoting gene Bax and apoptosis initiating gene Fas (P < 0.05, P < 0.01), and down-regulating that of anti-apoptosis gene Bcl-2 (P < 0.05). allicin 10-17 BCL2 apoptosis regulator Homo sapiens 216-221 18069112-0 2008 Involvement of both mitochondrial- and death receptor-dependent apoptotic pathways regulated by Bcl-2 family in sodium fluoride-induced apoptosis of the human gingival fibroblasts. Sodium Fluoride 112-127 BCL2 apoptosis regulator Homo sapiens 96-101 18022776-10 2008 Western blot showed that solanine decreased the expression of Bcl-2 protein. Solanine 25-33 BCL2 apoptosis regulator Homo sapiens 62-67 18022776-11 2008 Therefore, the target of solanine in inducing apoptosis in HepG(2) cells seems to be mediated by the inhibition in the expression of Bcl-2 protein. Solanine 25-33 BCL2 apoptosis regulator Homo sapiens 133-138 17983597-4 2008 Therefore, 5,6-dichloro-benzimidazole 1-beta-D-ribofuranoside, an adenosine analogue to inhibit mRNA synthesis, was used to estimate the bcl-2 mRNA degradation rate. Adenosine 66-75 BCL2 apoptosis regulator Homo sapiens 137-142 19271688-0 2008 Quantitative analysis of expression level of BCL2 and BAX genes in Hep-2 and HL-60 cells after treatment with etoposide. Etoposide 110-119 BCL2 apoptosis regulator Homo sapiens 45-49 18097489-7 2008 Reduction of 2/BCl3, in which additional phenyl groups on the diazadiene C-2 and C-3 atoms hinder the radical coupling observed in , gave predominantly diazaborole .BCl, (9a) contaminated with .BCl2, (9b) the first such stable radical diazadiene complex of boron. diazaborole 152-163 BCL2 apoptosis regulator Homo sapiens 194-198 17680735-0 2008 Bcl-2 protein family members: versatile regulators of calcium signaling in cell survival and apoptosis. Calcium 54-61 BCL2 apoptosis regulator Homo sapiens 0-5 18188926-8 2008 Also, DHA and PEDF synergistically activate anti-apoptotic protein expression and decreased pro-apoptotic Bcl-2 protein expression and caspase 3 activation during oxidative stress. dehydroacetic acid 6-9 BCL2 apoptosis regulator Homo sapiens 106-111 17680735-6 2008 Recent findings indicate that Bcl-2 interacts with inositol 1,4,5-trisphosphate (IP3) receptor Ca2+ channels on the ER, regulating their opening in response to IP3- and thus inhibiting IP3-mediated Ca2+ signals that induce apoptosis while enhancing Ca2+ signals that support cell survival. Inositol 1,4,5-Trisphosphate 81-84 BCL2 apoptosis regulator Homo sapiens 30-35 17680735-6 2008 Recent findings indicate that Bcl-2 interacts with inositol 1,4,5-trisphosphate (IP3) receptor Ca2+ channels on the ER, regulating their opening in response to IP3- and thus inhibiting IP3-mediated Ca2+ signals that induce apoptosis while enhancing Ca2+ signals that support cell survival. Inositol 1,4,5-Trisphosphate 51-79 BCL2 apoptosis regulator Homo sapiens 30-35 17680735-6 2008 Recent findings indicate that Bcl-2 interacts with inositol 1,4,5-trisphosphate (IP3) receptor Ca2+ channels on the ER, regulating their opening in response to IP3- and thus inhibiting IP3-mediated Ca2+ signals that induce apoptosis while enhancing Ca2+ signals that support cell survival. Inositol 1,4,5-Trisphosphate 160-163 BCL2 apoptosis regulator Homo sapiens 30-35 18023291-14 2008 The Bcl-2/Bax mRNA ratio was 0.11 in the absence of TP508 at 1h and 4.95 at 7microg/ml TP508; by 3h the ratio was approximately 1 in both groups. Hydrogen 61-63 BCL2 apoptosis regulator Homo sapiens 4-9 18023291-15 2008 The Bcl-2/Bax protein ratio also increased by 63% at 1h. Hydrogen 53-55 BCL2 apoptosis regulator Homo sapiens 4-9 17938578-3 2008 Recently, gossypol was found to bind to the BH3 binding groove of Bcl-xL and with lesser affinity to Bcl-2. Gossypol 10-18 BCL2 apoptosis regulator Homo sapiens 101-106 18028486-1 2008 The effect of ABT-737, a BH3-mimicking inhibitor for anti-apoptotic Bcl-2 and Bcl-X(L), but not Mcl-1, against Bcr-Abl-positive (Bcr-Abl(+)) leukaemic cells was examined. ABT-737 14-21 BCL2 apoptosis regulator Homo sapiens 68-73 18028486-3 2008 Higher expression of anti-apoptotic Bcl-2 proteins reduced cell killing by ABT-737 in each cell line, but there was no correlation between the sensitivities to ABT-737 and the specific expression patterns of Bcl-2 family proteins among cell lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 75-78 BCL2 apoptosis regulator Homo sapiens 36-41 18028486-4 2008 Thus, the cell killing effect of ABT-737 must be determined not only by the expression patterns of Bcl-2 family proteins but also by other mechanisms, such as high expression of Bcr-Abl, or a drug-efflux pump, in CML cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 33-36 BCL2 apoptosis regulator Homo sapiens 99-104 18928543-14 2008 CONCLUSIONS: We identified molecular markers including a BCL2/FOS signature associated with tamoxifen failure; these markers may have clinical potential in the management of ER-positive breast cancer. Tamoxifen 92-101 BCL2 apoptosis regulator Homo sapiens 57-61 18560221-0 2008 Sanguinarine-induced apoptosis in human leukemia U937 cells via Bcl-2 downregulation and caspase-3 activation. sanguinarine 0-12 BCL2 apoptosis regulator Homo sapiens 64-69 17712622-8 2008 Pretreatment with PMS777 also markedly inhibited intracellular Ca(2+) overload, down-regulation of anti-apoptotic bcl-2 mRNA, stimulation of pro-apoptotic bax mRNA expression and activation of caspase-3 pathway. PMS 777 18-24 BCL2 apoptosis regulator Homo sapiens 114-119 18196976-0 2008 NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. Cisplatin 107-116 BCL2 apoptosis regulator Homo sapiens 89-94 18196976-7 2008 Taken together, the results clearly suggested that NCX-4016 causes significant induction of cell cycle arrest and apoptosis in cisplatin-resistant human ovarian cancer cells via down-regulation of EGFR/PI3K/STAT3 signaling and modulation of Bcl-2 family proteins. Cisplatin 127-136 BCL2 apoptosis regulator Homo sapiens 241-246 17920946-0 2008 Novel anti-apoptotic effect of Bcl-2: prevention of polyamine depletion-induced cell death. Polyamines 52-61 BCL2 apoptosis regulator Homo sapiens 31-36 17920946-7 2008 The DENSPM-induced activation of the polyamine catabolic enzyme spermidine/spermine N(1)-acetyltransferase was reduced by Bcl-2 over-expression, partly preventing polyamine depletion. Polyamines 37-46 BCL2 apoptosis regulator Homo sapiens 122-127 17920946-7 2008 The DENSPM-induced activation of the polyamine catabolic enzyme spermidine/spermine N(1)-acetyltransferase was reduced by Bcl-2 over-expression, partly preventing polyamine depletion. Polyamines 163-172 BCL2 apoptosis regulator Homo sapiens 122-127 17936584-2 2008 Gamide controls apoptosis by regulation of proteins of the Bcl-2 family and by regulation of the activation of caspases. gamide 0-6 BCL2 apoptosis regulator Homo sapiens 59-64 17936584-8 2008 Gamide inhibits caspase 3 activation via redundant Bcl-2-like protein-mediated pathways which involve alternative activation of Rac/Cdc42/PAK and Rho/ROCK. gamide 0-6 BCL2 apoptosis regulator Homo sapiens 51-56 17936584-9 2008 Gamide and Ggly differentially activate members of Rho family G proteins which in turn regulate different proteins of the Bcl-2 family leading to changes in caspase 3 activity. gamide 0-6 BCL2 apoptosis regulator Homo sapiens 122-127 18560221-10 2008 Sanguinarine-induced caspase-3 activation and apoptosis were significantly attenuated in Bcl-2-overexpressing U937/Bcl-2 cells. sanguinarine 0-12 BCL2 apoptosis regulator Homo sapiens 115-120 18560221-12 2008 CONCLUSIONS: These results demonstrated that the induction of apoptosis by sanguinarine in U937 cells was associated with altering the balance of Bcl-2 and Bax protein expression and activation of the caspase-3 pathway. sanguinarine 75-87 BCL2 apoptosis regulator Homo sapiens 146-151 18560228-7 2008 Bcl-2 expression level decreased upon doxorubicin application in sensitive cells. Doxorubicin 38-49 BCL2 apoptosis regulator Homo sapiens 0-5 18560221-9 2008 Induction of apoptosis by sanguinarine was also accompanied by upregulation of pro-apoptotic Bax and downregulation of anti-apoptotic Bcl-2 expression. sanguinarine 26-38 BCL2 apoptosis regulator Homo sapiens 134-139 18560221-10 2008 Sanguinarine-induced caspase-3 activation and apoptosis were significantly attenuated in Bcl-2-overexpressing U937/Bcl-2 cells. sanguinarine 0-12 BCL2 apoptosis regulator Homo sapiens 89-94 18519232-4 2008 Cisplatin added to the culture medium leads to the significant increase of P53 expression and decrease of BCL-2 expression. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 106-111 18925930-17 2008 CONCLUSIONS: In early severe sepsis a gene expression pattern with induction of the pro-apoptotic Bcl-2 family members Bim, Bid and Bak and a downregulation of the anti-apoptotic Bcl-2 and Bcl-xl proteins was observed in peripheral blood. bakuchiol 132-135 BCL2 apoptosis regulator Homo sapiens 98-103 18637512-3 2008 Cytomegaloviruses (CMVs) encode a mitochondria-localized inhibitor of apoptosis, vMIA, and a viral inhibitor of caspase activation, vICA, the functional homologs of Bcl-2 related and c-FLIP proteins, respectively. vica 132-136 BCL2 apoptosis regulator Homo sapiens 165-170 17522976-9 2008 When pretreated with BIM, the concentration of phospho-ERK1/2 or bcl-2 in the BIM + 12-HETE-treated group was significantly (P < 0.05) lower than in that treated with 12-HETE only, and the concentration in the BIM + baicalein-treated group was significantly (P < 0.05) higher than in that treated with baicalein only. baicalein 308-317 BCL2 apoptosis regulator Homo sapiens 65-70 17522976-10 2008 On the basis of these data we conclude that, via its metabolite 12-HETE, 12-LOX abolishes proliferation of AGS cells and protect cells from apoptosis by activating the ERK1/2 pathway and, eventually, enhances expression of bcl-2. 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid 64-71 BCL2 apoptosis regulator Homo sapiens 223-228 19056541-0 2008 Assessment of expression of selected Bcl-2 family proteins in lymphoid infiltration in patients with B-cell chronic lymphocytic leukaemia treated with nucleoside analogues. Nucleosides 151-161 BCL2 apoptosis regulator Homo sapiens 37-42 19205434-3 2008 Several factors have been speculated to affect the induction of Bcl-2 in these cells, including progesterone, endoplasmic reticulum stress, and microRNAs. Progesterone 96-108 BCL2 apoptosis regulator Homo sapiens 64-69 17522976-6 2008 The expression level of bcl-2 was up-regulated and down-regulated after separate treatment with 12-HETE and baicalein, respectively, and both of these effects could be blocked by PD98059. 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid 96-103 BCL2 apoptosis regulator Homo sapiens 24-29 17522976-6 2008 The expression level of bcl-2 was up-regulated and down-regulated after separate treatment with 12-HETE and baicalein, respectively, and both of these effects could be blocked by PD98059. baicalein 108-117 BCL2 apoptosis regulator Homo sapiens 24-29 17522976-9 2008 When pretreated with BIM, the concentration of phospho-ERK1/2 or bcl-2 in the BIM + 12-HETE-treated group was significantly (P < 0.05) lower than in that treated with 12-HETE only, and the concentration in the BIM + baicalein-treated group was significantly (P < 0.05) higher than in that treated with baicalein only. bim 21-24 BCL2 apoptosis regulator Homo sapiens 65-70 17522976-9 2008 When pretreated with BIM, the concentration of phospho-ERK1/2 or bcl-2 in the BIM + 12-HETE-treated group was significantly (P < 0.05) lower than in that treated with 12-HETE only, and the concentration in the BIM + baicalein-treated group was significantly (P < 0.05) higher than in that treated with baicalein only. bim 78-81 BCL2 apoptosis regulator Homo sapiens 65-70 17522976-9 2008 When pretreated with BIM, the concentration of phospho-ERK1/2 or bcl-2 in the BIM + 12-HETE-treated group was significantly (P < 0.05) lower than in that treated with 12-HETE only, and the concentration in the BIM + baicalein-treated group was significantly (P < 0.05) higher than in that treated with baicalein only. 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid 84-91 BCL2 apoptosis regulator Homo sapiens 65-70 17522976-9 2008 When pretreated with BIM, the concentration of phospho-ERK1/2 or bcl-2 in the BIM + 12-HETE-treated group was significantly (P < 0.05) lower than in that treated with 12-HETE only, and the concentration in the BIM + baicalein-treated group was significantly (P < 0.05) higher than in that treated with baicalein only. bim 78-81 BCL2 apoptosis regulator Homo sapiens 65-70 17522976-9 2008 When pretreated with BIM, the concentration of phospho-ERK1/2 or bcl-2 in the BIM + 12-HETE-treated group was significantly (P < 0.05) lower than in that treated with 12-HETE only, and the concentration in the BIM + baicalein-treated group was significantly (P < 0.05) higher than in that treated with baicalein only. baicalein 219-228 BCL2 apoptosis regulator Homo sapiens 65-70 17981569-13 2008 The results suggest the involvement of bcl2 and Caspase-3 in SA induced apoptosis of human U937 cells. sa 61-63 BCL2 apoptosis regulator Homo sapiens 39-43 19056541-4 2008 The aim of the study was to assess expression of selected Bcl-2 family proteins in neoplastic infiltration in bone marrow in patients with B-CLL treated with nucleoside analogues. Nucleosides 158-168 BCL2 apoptosis regulator Homo sapiens 58-63 18191076-4 2008 Constant high glucose levels increased p47-phox, p67-phox, and p22-phox expression [components of the Nicotinamide adenine dinucleotide phosphate [NAD(P)H] oxidase complex]; endothelial nitric oxide synthase, nitric oxide, and O(2)(-) production; nitrotyrosine, 8-hydroxy-2"-deoxyguanosine, and caspase-3 expression; and reduced Bcl-2 expression. Glucose 14-21 BCL2 apoptosis regulator Homo sapiens 329-334 18003625-6 2008 Bcl2 mRNA content was correlated with protamine mRNA ratio (P = 0.0250 for TB; P = 0.0003 for E). Terbium 75-77 BCL2 apoptosis regulator Homo sapiens 0-4 18003625-7 2008 Infertile men exhibit a more than 10-fold (P = 0.0155 for TB; P = 7.0 x 10(-6) for E) higher Bcl2 mRNA content versus controls. Terbium 58-60 BCL2 apoptosis regulator Homo sapiens 93-97 18003625-10 2008 CONCLUSIONS: We found significantly aberrant protamine ratios and a higher Bcl2 content in TB and E of infertile men compared to controls, suggesting that these molecules may be useful biomarkers for predicting male infertility. Terbium 91-93 BCL2 apoptosis regulator Homo sapiens 75-79 18097549-5 2008 PTX-GEM molecular interactions on the apoptotic markers PARP, Bcl-2 and Bax were analyzed by immunoblotting procedures. Paclitaxel 0-3 BCL2 apoptosis regulator Homo sapiens 62-67 18097549-9 2008 DNA ladder and Western blotting results in the PTX followed by GEM sequence revealed a significant increase in the apoptotic cell death of breast cancer cells related to the Bax/Bcl-2 apoptotic pathway. Paclitaxel 47-50 BCL2 apoptosis regulator Homo sapiens 178-183 18097549-11 2008 This synergistic interaction on the PTXright curved arrow GEM schedule appears to be related to an increase in the Bcl-2-related mitochondrial apoptotic pathway. ptxright 36-44 BCL2 apoptosis regulator Homo sapiens 115-120 18058384-5 2008 Oridonin up-regulated the expression ratio of mitochondrial proteins, Bax/Bcl-2. oridonin 0-8 BCL2 apoptosis regulator Homo sapiens 74-79 17959232-8 2008 DPF suppressed Bcl-2 levels, enhanced Bax levels and Bax/Bcl-2 ratio, and simultaneously translocated Bax to mitochondria followed by mitochondrial release of cytochrome c into the cytosol and activation of effector caspase-3. diethyl phosphate 0-3 BCL2 apoptosis regulator Homo sapiens 15-20 17959232-8 2008 DPF suppressed Bcl-2 levels, enhanced Bax levels and Bax/Bcl-2 ratio, and simultaneously translocated Bax to mitochondria followed by mitochondrial release of cytochrome c into the cytosol and activation of effector caspase-3. diethyl phosphate 0-3 BCL2 apoptosis regulator Homo sapiens 57-62 20445773-3 2008 We found that among these 14 SNPs, R72P, intron 3 16-bp del/ins, and intron 6 G>A in p53, -938C>A in Bcl-2, and I522L in CASP10 were significant predictors of the BPDE-induced lymphocytic AC in single-locus analysis. 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide 169-173 BCL2 apoptosis regulator Homo sapiens 107-112 17995938-7 2008 As observed with PACAP-38, the adenylyl cyclase activator, forskolin, also induced an increase in the number of neurite-bearing cells and an up-regulation in the expression of Bcl-2 and GAP-43. Colforsin 59-68 BCL2 apoptosis regulator Homo sapiens 176-181 17890680-6 2008 Analysis of Bcl-2 family proteins revealed phosphorylation of Bad at serine 112 as well as ERK-dependent inhibition of Mcl-1 degradation. Serine 69-75 BCL2 apoptosis regulator Homo sapiens 12-17 17574594-5 2008 MATERIALS AND METHODS: Bcl-2 expression was analyzed in the HB cell lines HUH6 and HepT1 as well as in the HCC cell line HepG2 before and after treatment with cisplatin, doxorubicin, taxol, and etoposid. Doxorubicin 170-181 BCL2 apoptosis regulator Homo sapiens 23-28 18078454-2 2008 A previous report has revealed that melatonin suppresses nitric oxide (NO)-induced apoptosis via the induction of Bcl-2 expression in PGT-beta pineal cells. Melatonin 36-45 BCL2 apoptosis regulator Homo sapiens 114-119 18078454-2 2008 A previous report has revealed that melatonin suppresses nitric oxide (NO)-induced apoptosis via the induction of Bcl-2 expression in PGT-beta pineal cells. Nitric Oxide 57-69 BCL2 apoptosis regulator Homo sapiens 114-119 18078454-5 2008 In addition, decreased Bax expression, increased Bcl-2 expression and a decreased release of cytochrome c into the cytosol were observed in the melatonin-pretreated SK-N-MC cells. Melatonin 144-153 BCL2 apoptosis regulator Homo sapiens 49-54 18078454-5 2008 In addition, decreased Bax expression, increased Bcl-2 expression and a decreased release of cytochrome c into the cytosol were observed in the melatonin-pretreated SK-N-MC cells. sk-n 165-169 BCL2 apoptosis regulator Homo sapiens 49-54 17574594-5 2008 MATERIALS AND METHODS: Bcl-2 expression was analyzed in the HB cell lines HUH6 and HepT1 as well as in the HCC cell line HepG2 before and after treatment with cisplatin, doxorubicin, taxol, and etoposid. Paclitaxel 183-188 BCL2 apoptosis regulator Homo sapiens 23-28 17574594-5 2008 MATERIALS AND METHODS: Bcl-2 expression was analyzed in the HB cell lines HUH6 and HepT1 as well as in the HCC cell line HepG2 before and after treatment with cisplatin, doxorubicin, taxol, and etoposid. Etoposide 194-202 BCL2 apoptosis regulator Homo sapiens 23-28 17911532-0 2008 Peroxide is a key mediator of Bcl-2 down-regulation and apoptosis induction by cisplatin in human lung cancer cells. Peroxides 0-8 BCL2 apoptosis regulator Homo sapiens 30-35 19013355-6 2008 Generation of reactive oxygen species, accumulation of Ca(2+), upregulation of caspase-3, down regulation of bcl-2, and deficiency of p-53 lead to arsenic-induced apoptosis. Arsenic 147-154 BCL2 apoptosis regulator Homo sapiens 109-114 18196608-4 2008 Apoptosis induced by BBSKE is through Bcl-2/Bax and caspase-3 pathways. (1,2-bis(1,2-benzisoselenazolone-3(2H)-ketone))ethane 21-26 BCL2 apoptosis regulator Homo sapiens 38-43 17972023-0 2008 Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2. Oligonucleotides 80-96 BCL2 apoptosis regulator Homo sapiens 187-192 18603134-2 2008 Because the intermolecular handshakes of BCL-2 proteins are so critical to controlling cellular fate, we undertook the development of a toolbox of peptidic ligands that harness the natural potency and specificity of BH alpha-helices to interrogate and potentially medicate the deregulated apoptotic pathways of human disease. Bh 216-218 BCL2 apoptosis regulator Homo sapiens 41-46 18603135-4 2008 Stabilized Alpha-Helices of BCL-2 domains (SAHBs) are structurally reinforced, protease-resistant, and cell-permeable compounds that retain the specificity of native BH3 death ligands and, therefore, serve as ideal reagents to dissect BCL-2 family interactions in vitro and in vivo. sahbs 43-48 BCL2 apoptosis regulator Homo sapiens 28-33 18603135-4 2008 Stabilized Alpha-Helices of BCL-2 domains (SAHBs) are structurally reinforced, protease-resistant, and cell-permeable compounds that retain the specificity of native BH3 death ligands and, therefore, serve as ideal reagents to dissect BCL-2 family interactions in vitro and in vivo. sahbs 43-48 BCL2 apoptosis regulator Homo sapiens 235-240 18603135-4 2008 Stabilized Alpha-Helices of BCL-2 domains (SAHBs) are structurally reinforced, protease-resistant, and cell-permeable compounds that retain the specificity of native BH3 death ligands and, therefore, serve as ideal reagents to dissect BCL-2 family interactions in vitro and in vivo. BH 3 166-169 BCL2 apoptosis regulator Homo sapiens 28-33 18603135-4 2008 Stabilized Alpha-Helices of BCL-2 domains (SAHBs) are structurally reinforced, protease-resistant, and cell-permeable compounds that retain the specificity of native BH3 death ligands and, therefore, serve as ideal reagents to dissect BCL-2 family interactions in vitro and in vivo. BH 3 166-169 BCL2 apoptosis regulator Homo sapiens 235-240 17973028-5 2008 The Bcl-2/Bax ratio was decreased as a consequence of decreased bcl-2 mRNA levels in response to treatment with VPA. Valproic Acid 112-115 BCL2 apoptosis regulator Homo sapiens 4-9 17973028-5 2008 The Bcl-2/Bax ratio was decreased as a consequence of decreased bcl-2 mRNA levels in response to treatment with VPA. Valproic Acid 112-115 BCL2 apoptosis regulator Homo sapiens 64-69 17911532-5 2008 Apoptosis induced by cisplatin was mediated through the mitochondrial death pathway, which requires caspase-9 activation and is regulated by Bcl-2. Cisplatin 21-30 BCL2 apoptosis regulator Homo sapiens 141-146 17911532-6 2008 Cisplatin induced down-regulation of Bcl-2 through a process that involves dephosphorylation and ubiquitination of the protein, which facilitates its degradation by proteasome. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 37-42 17911532-15 2008 Together, our results indicate an essential role of H(2)O(2) in the regulation of Bcl-2 and apoptotic cell death induced by cisplatin. Cisplatin 124-133 BCL2 apoptosis regulator Homo sapiens 82-87 18097588-7 2008 This was confirmed by Western blot analysis, which revealed a Bax/Bcl-2-balance change in favor of Bax, the proapoptotic member, in UA-treated M4Beu cells. ursolic acid 132-134 BCL2 apoptosis regulator Homo sapiens 66-71 18357729-0 2008 In vitro arsenic trioxide induces apoptosis in T cells of asthmatic patients by a Bcl-2 related mechanism. Arsenic Trioxide 9-25 BCL2 apoptosis regulator Homo sapiens 82-87 17897817-5 2008 Examination of the expression of apoptosis-regulating genes indicated that hesperidin treatment decreased the expression of B-cell CLL/lymphoma 2 (BCL2) mRNA, and increased the expression of BCL2-associated X protein (BAX). Hesperidin 75-85 BCL2 apoptosis regulator Homo sapiens 124-145 17897817-5 2008 Examination of the expression of apoptosis-regulating genes indicated that hesperidin treatment decreased the expression of B-cell CLL/lymphoma 2 (BCL2) mRNA, and increased the expression of BCL2-associated X protein (BAX). Hesperidin 75-85 BCL2 apoptosis regulator Homo sapiens 147-151 19378430-7 2008 CsA inhibited the H/R-induced translocation of cytochrome c, increased bcl-2 expression and restored mitochondrial membrane potential. Cyclosporine 0-3 BCL2 apoptosis regulator Homo sapiens 71-76 18645262-9 2008 CONCLUSION: The ZNRD1 gene might be involved in the cisplatin resistance of EC109 cells by regulating the expression of ERCC1 and Bcl-2. Cisplatin 52-61 BCL2 apoptosis regulator Homo sapiens 130-135 18939359-0 2008 [Changes in etoposide-induced apoptosis of HeLa tumor cells transfected with antisense oligonucleotide for BCL-2 mRNA]. Etoposide 12-21 BCL2 apoptosis regulator Homo sapiens 107-112 18939359-0 2008 [Changes in etoposide-induced apoptosis of HeLa tumor cells transfected with antisense oligonucleotide for BCL-2 mRNA]. Oligonucleotides 87-102 BCL2 apoptosis regulator Homo sapiens 107-112 18939359-3 2008 The aim of the study was to induce silencing of BCL-2 gene expression in HeLa tumor cell line using antisense oligonucleotides (ASOs) technique. Oligonucleotides 110-126 BCL2 apoptosis regulator Homo sapiens 48-53 18939359-3 2008 The aim of the study was to induce silencing of BCL-2 gene expression in HeLa tumor cell line using antisense oligonucleotides (ASOs) technique. Oligonucleotides, Antisense 128-132 BCL2 apoptosis regulator Homo sapiens 48-53 18552516-13 2008 The mechanism of hyperoside protecting against ECV-304 cell apoptosis by TBHP is related with resuming mitochondrial function and regulating the expression of SIRT1 and Bcl-2 family members. hyperoside 17-27 BCL2 apoptosis regulator Homo sapiens 169-174 18552516-13 2008 The mechanism of hyperoside protecting against ECV-304 cell apoptosis by TBHP is related with resuming mitochondrial function and regulating the expression of SIRT1 and Bcl-2 family members. tert-Butylhydroperoxide 73-77 BCL2 apoptosis regulator Homo sapiens 169-174 18077169-3 2008 Different BCL-2-related proteins are also located in multiprotein complexes at the endoplasmic reticulum (ER), which are involved in the control of diverse cellular processes, including calcium homeostasis, autophagy, the unfolded protein response and ER morphogenesis. Calcium 186-193 BCL2 apoptosis regulator Homo sapiens 10-15 18357729-14 2008 These results suggest that arsenic trioxide induces T cell apoptosis and decreases interleukin-4 release in T cells of asthmatic patients in vitro and that down-regulation of Bcl-2 expression may be an important mechanism. Arsenic Trioxide 27-43 BCL2 apoptosis regulator Homo sapiens 175-180 18357729-11 2008 Arsenic trioxide treatment significantly decreased interleukin-4 release and down-regulated Bcl-2 expression in asthmatic patients, while it only slightly affected healthy controls. Arsenic Trioxide 0-16 BCL2 apoptosis regulator Homo sapiens 92-97 18939359-6 2008 Effects of BCL-2 silencing were determined by Real-Time RT-PCR, proliferation/cytotoxicity MTT [3-(4,5-dimethylthiazol-2-yl)-2-5-dipheryl tetrazolium bromide] test, and by microscopic detection of apoptotic cells. 3-(4,5-dimethylthiazol-2-yl)-2-5-dipheryl tetrazolium bromide 96-157 BCL2 apoptosis regulator Homo sapiens 11-16 18073527-4 2007 Here we demonstrate that the broad-acting kinase inhibitor staurosporine (STS) confers GC-sensitivity on GC-resistant T lymphoma cells expressing elevated levels of either Bcl-2 or Bcl-XL, but not on GC-resistant myelogenic leukemia cells expressing Mcl-1 in addition to Bcl-2 and/or Bcl-XL. Staurosporine 59-72 BCL2 apoptosis regulator Homo sapiens 271-276 18939359-7 2008 RESULTS: We showed a decrease in BCL-2 mRNA level in cells transfected with anti-BCL-2 ASO at concentration ranging from 50 to 1200 nM. Oligonucleotides, Antisense 87-90 BCL2 apoptosis regulator Homo sapiens 33-38 18939359-7 2008 RESULTS: We showed a decrease in BCL-2 mRNA level in cells transfected with anti-BCL-2 ASO at concentration ranging from 50 to 1200 nM. Oligonucleotides, Antisense 87-90 BCL2 apoptosis regulator Homo sapiens 81-86 18939359-13 2008 The use of the anti-BCL-2 oligonucleotide in combination with etoposide results in significant deacrease of proliferation in cell cultures and this phenomenon is a result of synergy between used chemotherapy and gene therapy. Oligonucleotides 26-41 BCL2 apoptosis regulator Homo sapiens 20-25 18939359-13 2008 The use of the anti-BCL-2 oligonucleotide in combination with etoposide results in significant deacrease of proliferation in cell cultures and this phenomenon is a result of synergy between used chemotherapy and gene therapy. Etoposide 62-71 BCL2 apoptosis regulator Homo sapiens 20-25 18073527-0 2007 Staurosporine sensitizes T lymphoma cells to glucocorticoid-induced apoptosis: role of Nur77 and Bcl-2. Staurosporine 0-13 BCL2 apoptosis regulator Homo sapiens 97-102 18073527-4 2007 Here we demonstrate that the broad-acting kinase inhibitor staurosporine (STS) confers GC-sensitivity on GC-resistant T lymphoma cells expressing elevated levels of either Bcl-2 or Bcl-XL, but not on GC-resistant myelogenic leukemia cells expressing Mcl-1 in addition to Bcl-2 and/or Bcl-XL. Staurosporine 59-72 BCL2 apoptosis regulator Homo sapiens 172-177 18089795-5 2007 Expanded leukemic stem cell (Lin(-)/Sca-1(+)/c-Kit(+)) populations and hBCL-2 in the increased RAS-GTP complex within the expanded Sca-1(+) compartment are described in both MDS/AML-like diseases. ras-gtp 95-102 BCL2 apoptosis regulator Homo sapiens 71-77 18089795-7 2007 When hBCL-2 is switched off with doxycycline in the MDS mice, partial reversal of the phenotype was observed with persistence of bone marrow blasts and tissue infiltration as RAS recruits endogenous mouse (m)BCL-2 to remain active, thus demonstrating the role of the complex in the disease. Doxycycline 33-44 BCL2 apoptosis regulator Homo sapiens 5-11 18089795-8 2007 This represents the first in vivo progression model of MDS/AML dependent on the formation of a BCL-2:RAS-GTP complex. ras-gtp 101-108 BCL2 apoptosis regulator Homo sapiens 95-100 18073527-4 2007 Here we demonstrate that the broad-acting kinase inhibitor staurosporine (STS) confers GC-sensitivity on GC-resistant T lymphoma cells expressing elevated levels of either Bcl-2 or Bcl-XL, but not on GC-resistant myelogenic leukemia cells expressing Mcl-1 in addition to Bcl-2 and/or Bcl-XL. Staurosporine 74-77 BCL2 apoptosis regulator Homo sapiens 172-177 18089817-5 2007 BCL-2 inhibits cell death induced by erlotinib, but BCL-2-protected cells are thus rendered BCL-2-dependent and sensitive to the BCL-2 antagonist ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 146-149 BCL2 apoptosis regulator Homo sapiens 52-57 18073527-4 2007 Here we demonstrate that the broad-acting kinase inhibitor staurosporine (STS) confers GC-sensitivity on GC-resistant T lymphoma cells expressing elevated levels of either Bcl-2 or Bcl-XL, but not on GC-resistant myelogenic leukemia cells expressing Mcl-1 in addition to Bcl-2 and/or Bcl-XL. Staurosporine 74-77 BCL2 apoptosis regulator Homo sapiens 271-276 18089817-5 2007 BCL-2 inhibits cell death induced by erlotinib, but BCL-2-protected cells are thus rendered BCL-2-dependent and sensitive to the BCL-2 antagonist ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 146-149 BCL2 apoptosis regulator Homo sapiens 52-57 18089817-5 2007 BCL-2 inhibits cell death induced by erlotinib, but BCL-2-protected cells are thus rendered BCL-2-dependent and sensitive to the BCL-2 antagonist ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 146-149 BCL2 apoptosis regulator Homo sapiens 52-57 18089817-5 2007 BCL-2 inhibits cell death induced by erlotinib, but BCL-2-protected cells are thus rendered BCL-2-dependent and sensitive to the BCL-2 antagonist ABT-737. Erlotinib Hydrochloride 37-46 BCL2 apoptosis regulator Homo sapiens 0-5 18089817-6 2007 BH3 profiling reveals that mitochondrial BCL-2 is primed by death signals after EGFR inhibition in these cells. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 41-46 18167185-5 2007 RESULTS: TSA could inhibit cell growth and induced apoptosis in gastric cancer SGC-7901 cells through the regulation of apoptosis-related genes, such as Bcl-2, Bax and survivin. trichostatin A 9-12 BCL2 apoptosis regulator Homo sapiens 153-158 18089817-7 2007 As this result implies, key death-signaling proteins of the BCL-2 family, including BIM, were found to be up-regulated after erlotinib treatment and intercepted by overexpressed BCL-2. Erlotinib Hydrochloride 125-134 BCL2 apoptosis regulator Homo sapiens 60-65 18089817-7 2007 As this result implies, key death-signaling proteins of the BCL-2 family, including BIM, were found to be up-regulated after erlotinib treatment and intercepted by overexpressed BCL-2. Erlotinib Hydrochloride 125-134 BCL2 apoptosis regulator Homo sapiens 178-183 18089824-8 2007 In addition, we showed that down-regulation of ERK2 or MKP-1 decreases the basal level of Bcl-2 protein and that inhibition of Bcl-2 activity sensitizes ovarian cancer cells to cisplatin. Cisplatin 177-186 BCL2 apoptosis regulator Homo sapiens 127-132 18028886-7 2007 Moreover, the lithium-induced neuroprotection was accompanied by down-regulation of pro-apoptotic p53 in the CA1 but up-regulation of anti-apoptotic Bcl-2 and heat shock protein 70 (HSP70) in the ischemic brain. Lithium 14-21 BCL2 apoptosis regulator Homo sapiens 149-154 18031600-9 2007 Moreover, incubation of cortical neurons with SF for 30 min inhibited the reduction of the Bcl-2 expression induced by glutamate. Glutamic Acid 119-128 BCL2 apoptosis regulator Homo sapiens 91-96 18040043-2 2007 Small molecule obatoclax (GX15-070), which is predicted to occupy a hydrophobic pocket within the BH3 binding groove of BCL-2, antagonizes these members and induces apoptosis, dependent on BAX and BAK. BH 3 98-101 BCL2 apoptosis regulator Homo sapiens 120-125 18040043-5 2007 MCL-1 has been shown to confer resistance to the BCL-2/BCL-XL/BCL-w-selective antagonist ABT-737 and to the proteasome inhibitor bortezomib. ABT-737 89-96 BCL2 apoptosis regulator Homo sapiens 49-54 17854276-5 2007 In this review, evidence is presented indicating that members of the BCL-2 protein family are contained in multiprotein complexes at the ER, regulating diverse cellular processes including autophagy, calcium homeostasis, the unfolded-protein response, ER membrane remodeling, and calcium-dependent cell death. Calcium 200-207 BCL2 apoptosis regulator Homo sapiens 69-74 17854276-5 2007 In this review, evidence is presented indicating that members of the BCL-2 protein family are contained in multiprotein complexes at the ER, regulating diverse cellular processes including autophagy, calcium homeostasis, the unfolded-protein response, ER membrane remodeling, and calcium-dependent cell death. Calcium 280-287 BCL2 apoptosis regulator Homo sapiens 69-74 17916909-8 2007 Silibinin strongly increased phospho-extracellular signal-regulated kinase 1/2 (ERK1/2), Cip1/p21 and Kip1/p27 (cyclin-dependent kinase inhibitors) levels but moderately decreased Bcl-2 and survivin levels. Silybin 0-9 BCL2 apoptosis regulator Homo sapiens 180-185 17764803-9 2007 NtBHA pre-treated cells showed significant inhibition of apoptotic features such as activation of caspase-3, up-regulation of Bax and p53, and down-regulation of Bcl-2 compared to control cells upon exposure to ionizing radiation. N-tert-butylhydroxylamine 0-5 BCL2 apoptosis regulator Homo sapiens 162-167 18077580-7 2007 In the mitochondrial pathway, NAC attenuated arsenite-induced elevation in Bcl-2 level and cytosolic cytochrome c, as well as arsenite-induced reduction in procaspase-3 levels. Acetylcysteine 30-33 BCL2 apoptosis regulator Homo sapiens 75-80 18077580-7 2007 In the mitochondrial pathway, NAC attenuated arsenite-induced elevation in Bcl-2 level and cytosolic cytochrome c, as well as arsenite-induced reduction in procaspase-3 levels. arsenite 45-53 BCL2 apoptosis regulator Homo sapiens 75-80 18057714-10 2007 In addition, the Lico-E treatment caused a change in the Bax/Bcl-2 ratio that favored apoptosis. lico-e 17-23 BCL2 apoptosis regulator Homo sapiens 61-66 18057714-11 2007 These results suggest that Lico-E induces endothelial cell apoptosis by modulating NF-kappaB and the Bcl-2 family. lico-e 27-33 BCL2 apoptosis regulator Homo sapiens 101-106 17916909-11 2007 At molecular level, silibinin increased IGFBP-3, Cip1/p21, Kip1/p27 levels and ERK1/2 activation and decreased Bcl-2, survivin and VEGF levels in tumors. Silybin 20-29 BCL2 apoptosis regulator Homo sapiens 111-116 18096507-5 2007 Our finding on the regulation of RNA splicing of members of the Bcl-2 family in response to emetine presents a potential target for cancer treatment. Emetine 92-99 BCL2 apoptosis regulator Homo sapiens 64-69 18059161-8 2007 Western blotting of MDA-MB-231 cell lysates from EGCG and GTP treated and untreated control revealed an increase in bax, reduction in bcl2 and PARP cleavage. epigallocatechin gallate 49-53 BCL2 apoptosis regulator Homo sapiens 134-138 18059161-8 2007 Western blotting of MDA-MB-231 cell lysates from EGCG and GTP treated and untreated control revealed an increase in bax, reduction in bcl2 and PARP cleavage. epigallocatechin gallate 58-61 BCL2 apoptosis regulator Homo sapiens 134-138 18056200-0 2007 The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. ABT-737 34-41 BCL2 apoptosis regulator Homo sapiens 4-9 18056200-0 2007 The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Carboplatin 77-88 BCL2 apoptosis regulator Homo sapiens 4-9 17960583-7 2007 Immunocytochemistry demonstrated co-localization of BCL-2 and AKT, which was abrogated by treatment with HA14-1, a small molecule inhibitor of BH-3-mediated protein interaction by BCL-2. ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate 105-111 BCL2 apoptosis regulator Homo sapiens 52-57 18289046-5 2007 One phosphorothioate oligodeoxynucleotide antisense against Bcl-2 mRNA, oblimersen (Genasense, G3139), has been used in a substantial number of clinical trials. phosphorothioate oligodeoxynucleotide 4-41 BCL2 apoptosis regulator Homo sapiens 60-65 17921043-4 2007 Recent studies have highlighted ABT-737, a bona fide BH3 mimetic and potent inhibitor of antiapoptotic Bcl-2 family members, as a promising anticancer agent. ABT-737 32-39 BCL2 apoptosis regulator Homo sapiens 103-108 18174961-8 2007 Lindane increased the ratio of Bcl-2:Bax, as did 17beta-estradiol (E(2)). Hexachlorocyclohexane 0-7 BCL2 apoptosis regulator Homo sapiens 31-36 18174961-10 2007 Treatment with a binary mixture of 10(-8) M B[a]P plus 10(-12) M lindane or 10(-10) M E(2) reversed B[a]P-induced reductions in the ratio of Bcl-2- to Bax-positive cells. Hexachlorocyclohexane 65-72 BCL2 apoptosis regulator Homo sapiens 141-146 19192636-7 2007 Furthermore, Surface Plasmon Resonance analysis indicates that alpha-bisabolol directly interacts with Bid protein, a member of the Bcl2 family deeply involved in apoptosis, suggesting a possibility that Bid, or similar protein(s), may be involved in a putative intracellular transport system of alpha-bisabolol from plasma membrane to mitochondria. alpha-Bisabolol 63-78 BCL2 apoptosis regulator Homo sapiens 132-136 17848408-6 2007 Bcl-2-overexpressing FRO cells were more resistant to conventional chemotherapeutic agents (such as doxorubicin) but significantly more sensitive to BH3I-1 than control cells and were found to overexpress caspase-9, caspase-8, Bmf, Bok, and Bik transcripts and express less A1, BRaf, and FLIP transcripts. Doxorubicin 100-111 BCL2 apoptosis regulator Homo sapiens 0-5 17848408-8 2007 Nevertheless, overexpression of Bcl-2 may result in "oncogene addiction" of the cancer cell, which can be exploited by using BH3-domain inhibitors alone or in combination with other agents, including conventional chemotherapeutics (such as doxorubicin) or novel targeted therapies (such as the proteasome inhibitor bortezomib), for the treatment of aggressive thyroid cancer, including the medullary and anaplastic types. Doxorubicin 240-251 BCL2 apoptosis regulator Homo sapiens 32-37 17848408-8 2007 Nevertheless, overexpression of Bcl-2 may result in "oncogene addiction" of the cancer cell, which can be exploited by using BH3-domain inhibitors alone or in combination with other agents, including conventional chemotherapeutics (such as doxorubicin) or novel targeted therapies (such as the proteasome inhibitor bortezomib), for the treatment of aggressive thyroid cancer, including the medullary and anaplastic types. Bortezomib 315-325 BCL2 apoptosis regulator Homo sapiens 32-37 18174961-11 2007 In contrast, treatments with PhIP (known to possess hormonelike properties) plus lindane or E(2) resulted in profound reductions in Bcl-2:Bax ratio. Hexachlorocyclohexane 81-88 BCL2 apoptosis regulator Homo sapiens 132-137 18048888-9 2007 Shenghe Powder reduced the expression level of P-gp and Bcl-2 in SGC-7901/ vincristine and increased the apoptotic percentage of tumor cells; Shenghe Powder had the more significant effect on apoptosis (P< .05). Vincristine 75-86 BCL2 apoptosis regulator Homo sapiens 56-61 18048888-10 2007 In conclusion, Shenghe Powder increases the intracellular concentration of vincristine, consistent with the down-regulation of the expression of P-gp and Bcl-2. Vincristine 75-86 BCL2 apoptosis regulator Homo sapiens 154-159 17471535-7 2007 Furthermore, overexpression of active PKB/Akt or Bcl-2 successfully blocked ceramide-induced neuronal cell death through inhibition of the translocation of apoptosis-inducing factor. Ceramides 76-84 BCL2 apoptosis regulator Homo sapiens 49-54 17960583-7 2007 Immunocytochemistry demonstrated co-localization of BCL-2 and AKT, which was abrogated by treatment with HA14-1, a small molecule inhibitor of BH-3-mediated protein interaction by BCL-2. ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate 105-111 BCL2 apoptosis regulator Homo sapiens 180-185 17868308-11 2007 Inhibition of p38 kinase signaling pathway by treatment with PD1693, a MKK3/6 inhibitor, abolished the expression of cleaved caspase-9, the increase in the bax/bcl-2 gene expression ratio, as well as the fragmentation of DNA that followed injury of 1321N1 cells. pd1693 61-67 BCL2 apoptosis regulator Homo sapiens 160-165 18231749-1 2007 To explore the effects of Tanshinone II A on the proliferation, apoptosis and gene expression of p53 and bcl-2 in human gastric carcinoma MKN-45 cells. tanshinone 26-41 BCL2 apoptosis regulator Homo sapiens 105-110 18231749-4 2007 Semi-quantitative RT-PCR was used to further verify the expression of p53 and bcl-2 gene after exposure to Tanshinone A in MKN-45 cells. tanshinone 107-119 BCL2 apoptosis regulator Homo sapiens 78-83 18231749-7 2007 This resulted in apoptosis of MKN-45 cells and the apoptosis rate was as high as 43.91% after treatment with 2.0 microg/mL Tanshinone II A for 96 h. It was also found that Tanshinone II A up-regulated expression of p53 gene and down-regulated expression of bcl-2 gene. tanshinone 123-138 BCL2 apoptosis regulator Homo sapiens 257-262 18231749-7 2007 This resulted in apoptosis of MKN-45 cells and the apoptosis rate was as high as 43.91% after treatment with 2.0 microg/mL Tanshinone II A for 96 h. It was also found that Tanshinone II A up-regulated expression of p53 gene and down-regulated expression of bcl-2 gene. tanshinone 172-187 BCL2 apoptosis regulator Homo sapiens 257-262 17883400-7 2007 STS treatment resulted in sustained activation of the mitogen-activated protein kinase pathway enzymes extracellular regulated kinase, c-jun terminal kinase and p38, and depletion of the anti-apoptotic protein Bcl-2. Staurosporine 0-3 BCL2 apoptosis regulator Homo sapiens 210-215 18021420-8 2007 Additionally, overexpression of anti-apoptotic protein Bcl-2 in H460 cells did not affect the proteasomal phenotype of H460 cells but did result in decreased bortezomib-induced apoptosis. Bortezomib 158-168 BCL2 apoptosis regulator Homo sapiens 55-60 17428536-7 2007 Of importance, small molecule Bcl-2 antagonist, HA14-1 and agonistic anti-Fas mAb significantly enhanced BFA-mediated cytotoxicity and apoptosis, revealing novel and previously unexplored means to enhance ER stress-mediated cell killing in follicular lymphoma cells. Brefeldin A 105-108 BCL2 apoptosis regulator Homo sapiens 30-35 18030663-7 2007 We also found downregulation of testosterone induced antiapoptotic proteins, Bcl-2 and Survivin expression by [6]-gingerol in both LNCaP cells and in mouse ventral prostate. Testosterone 32-44 BCL2 apoptosis regulator Homo sapiens 77-82 18030663-7 2007 We also found downregulation of testosterone induced antiapoptotic proteins, Bcl-2 and Survivin expression by [6]-gingerol in both LNCaP cells and in mouse ventral prostate. gingerol 110-122 BCL2 apoptosis regulator Homo sapiens 77-82 18084610-4 2007 Here, we investigated the efficacy of AT-101 (R-(-)-gossypol acetic acid; a pan small molecule inhibitor of Bcl-2, Bcl-x(L), and Mcl-1) in combination with surgical castration to delay the onset of androgen-independent growth in vivo. gossypol acetic acid 46-72 BCL2 apoptosis regulator Homo sapiens 108-113 18084610-7 2007 In addition, we demonstrate the induction of caspase-9-and caspase-3-dependent induction of apoptosis following AT-101 treatment in vitro which was accompanied by an AT-101-induced downregulation of Bcl-2 and Mcl-1 mRNA and protein expression. Astatine 112-114 BCL2 apoptosis regulator Homo sapiens 199-204 18084610-8 2007 CONCLUSIONS: We conclude that AT-101 in combination with surgical castration delays the onset of androgen-independent prostate cancer in vivo by disrupting the antiapoptotic activity of Bcl-2 upregulation during the transition to androgen independence. gossypol acetic acid 30-36 BCL2 apoptosis regulator Homo sapiens 186-191 17616812-8 2007 Combination of ATRA and IFN-gamma showed more efficacy than IFN-gamma alone in causing apoptosis that occurred due to increases in Bax:Bcl-2 ratio, mitochondrial release of cytochrome c, and caspase-3 activity. Tretinoin 15-19 BCL2 apoptosis regulator Homo sapiens 135-140 18089606-4 2007 Similarly, asoprisnil decreased Bcl-2 expression and increased cleaved caspase-3 and cleaved poly(adenosine 5"-diphosphate-ribose) polymerase in leiomyoma cells but not in normal myometrial cells. asoprisnil 11-21 BCL2 apoptosis regulator Homo sapiens 32-37 17652622-6 2007 This conclusion is supported by the fact that Bcl-2-overexpressing cells and Bax/Bak doubly-deficient MEFs were entirely resistant to paclitaxel-induced apoptosis. Paclitaxel 134-144 BCL2 apoptosis regulator Homo sapiens 46-51 17986867-5 2007 The BPDE-induced apoptosis in H460 cells correlated with up-regulation of pro-apoptotic protein Bak, downregulation of anti-apoptotic Bcl-2 family members Bcl-2 and Bcl-xL, release of cytochrome c from mitochondria to the cytosol without a change in mitochondrial membrane potential or mitochondrial morphology (electron microscopy), and cleavage of caspase-8, -9, and -3. 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide 4-8 BCL2 apoptosis regulator Homo sapiens 134-139 17986867-5 2007 The BPDE-induced apoptosis in H460 cells correlated with up-regulation of pro-apoptotic protein Bak, downregulation of anti-apoptotic Bcl-2 family members Bcl-2 and Bcl-xL, release of cytochrome c from mitochondria to the cytosol without a change in mitochondrial membrane potential or mitochondrial morphology (electron microscopy), and cleavage of caspase-8, -9, and -3. 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide 4-8 BCL2 apoptosis regulator Homo sapiens 155-160 17986867-9 2007 In conclusion, the present study reveals that BPDE-induced apoptosis in H460 cells is associated with Bak induction and caspase activation but independent of Bcl-2. 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide 46-50 BCL2 apoptosis regulator Homo sapiens 158-163 17825790-5 2007 Furthermore, TCS-mediated Bcl-2 protein was abrogated by the suppression of CREB expression with antisense treatment, and blocking the interaction between CREB-binding protein and the Bcl-2 cyclic AMP-responsive element (CRE) by a CRE decoy oligonucleotide. Cyclic AMP 190-200 BCL2 apoptosis regulator Homo sapiens 26-31 17825790-5 2007 Furthermore, TCS-mediated Bcl-2 protein was abrogated by the suppression of CREB expression with antisense treatment, and blocking the interaction between CREB-binding protein and the Bcl-2 cyclic AMP-responsive element (CRE) by a CRE decoy oligonucleotide. Cyclic AMP 190-200 BCL2 apoptosis regulator Homo sapiens 184-189 17825790-5 2007 Furthermore, TCS-mediated Bcl-2 protein was abrogated by the suppression of CREB expression with antisense treatment, and blocking the interaction between CREB-binding protein and the Bcl-2 cyclic AMP-responsive element (CRE) by a CRE decoy oligonucleotide. Oligonucleotides 241-256 BCL2 apoptosis regulator Homo sapiens 26-31 17825790-5 2007 Furthermore, TCS-mediated Bcl-2 protein was abrogated by the suppression of CREB expression with antisense treatment, and blocking the interaction between CREB-binding protein and the Bcl-2 cyclic AMP-responsive element (CRE) by a CRE decoy oligonucleotide. Oligonucleotides 241-256 BCL2 apoptosis regulator Homo sapiens 184-189 18087815-6 2007 Moreover, DDMP suppressed the NF-kappaB target anti-apoptotic genes (Bcl-2), whereas it induced the expression of the apoptotic genes (Bax, cleaved caspase-3 and cleaved PARP). metoprine 10-14 BCL2 apoptosis regulator Homo sapiens 69-74 17785460-6 2007 The induction of Bcl-2 inhibited apoptosis induced by serum starvation or etoposide, and PKCepsilon activation attenuated etoposide-induced caspase-3 cleavage. Etoposide 74-83 BCL2 apoptosis regulator Homo sapiens 17-22 17785460-6 2007 The induction of Bcl-2 inhibited apoptosis induced by serum starvation or etoposide, and PKCepsilon activation attenuated etoposide-induced caspase-3 cleavage. Etoposide 122-131 BCL2 apoptosis regulator Homo sapiens 17-22 17959036-7 2007 IFNalpha markedly upregulated p53, Bax, Mdm2, and p21, downregulated Bcl-2, and activated caspase-3 and PARP cleavage in response to doxorubicin in U2OS cells. Doxorubicin 133-144 BCL2 apoptosis regulator Homo sapiens 69-74 17989874-0 2007 Bcl-2 small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma A549/DDP cell to cisplatin and diallyl disulfide. Cisplatin 39-48 BCL2 apoptosis regulator Homo sapiens 0-5 17989874-0 2007 Bcl-2 small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma A549/DDP cell to cisplatin and diallyl disulfide. Cisplatin 102-111 BCL2 apoptosis regulator Homo sapiens 0-5 17989874-0 2007 Bcl-2 small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma A549/DDP cell to cisplatin and diallyl disulfide. diallyl disulfide 116-133 BCL2 apoptosis regulator Homo sapiens 0-5 17989874-2 2007 In this study, we investigated the inhibitory effect of the hairpin Bcl-2 small interfering (si)RNA on the expression of the Bcl-2 gene in the cisplatin (DDP)-resistant human lung adenocarcinoma cell line A549/DDP, and the effect of Bcl-2 siRNA on drug sensitization in A549/DDP cells. Cisplatin 143-152 BCL2 apoptosis regulator Homo sapiens 68-73 17989874-2 2007 In this study, we investigated the inhibitory effect of the hairpin Bcl-2 small interfering (si)RNA on the expression of the Bcl-2 gene in the cisplatin (DDP)-resistant human lung adenocarcinoma cell line A549/DDP, and the effect of Bcl-2 siRNA on drug sensitization in A549/DDP cells. Cisplatin 143-152 BCL2 apoptosis regulator Homo sapiens 125-130 17989874-2 2007 In this study, we investigated the inhibitory effect of the hairpin Bcl-2 small interfering (si)RNA on the expression of the Bcl-2 gene in the cisplatin (DDP)-resistant human lung adenocarcinoma cell line A549/DDP, and the effect of Bcl-2 siRNA on drug sensitization in A549/DDP cells. Cisplatin 143-152 BCL2 apoptosis regulator Homo sapiens 125-130 17989874-8 2007 MTT results indicated that Bcl-2 transfectants had a higher cell inhibition rate after treatment with 0.2-200 microg/ml DDP or 50-200 microM DADS. monooxyethylene trimethylolpropane tristearate 0-3 BCL2 apoptosis regulator Homo sapiens 27-32 17989874-8 2007 MTT results indicated that Bcl-2 transfectants had a higher cell inhibition rate after treatment with 0.2-200 microg/ml DDP or 50-200 microM DADS. diallyl disulfide 141-145 BCL2 apoptosis regulator Homo sapiens 27-32 17989874-10 2007 After the addition of 20 microg/ml DDP or 100 microM DADS, siRNA targeting of the Bcl-2 gene specifically down-regulated gene expression in A549/DDP cells, increased spontaneous apoptosis, and sensitized cells to DDP and DADS. diallyl disulfide 53-57 BCL2 apoptosis regulator Homo sapiens 82-87 17989878-4 2007 Further, it was shown that the level of Bcl-2 mRNA decreased and Bax mRNA increased after addition of tetrandrine by using reverse transcription-polymerase chain reaction. tetrandrine 102-113 BCL2 apoptosis regulator Homo sapiens 40-45 18225567-12 2007 Overexpression of BCRP and LRP genes and an increase in Bcl-2 gene expression may have roles in the development of zoledronic acid resistance in the MCF-7 cell line. Zoledronic Acid 115-130 BCL2 apoptosis regulator Homo sapiens 56-61 17996085-11 2007 Furthermore, Bcl-2 overexpressing cells exhibited less cytocrome c release during PBTDs-induced apoptosis. pbtds 82-87 BCL2 apoptosis regulator Homo sapiens 13-18 17868064-10 2007 Diannexin increased expression of HO-1/Bcl-2/Bcl-xl, and reduced Caspase-3/TUNEL+ apoptotic cells. diannexin 0-9 BCL2 apoptosis regulator Homo sapiens 39-44 17893514-5 2007 Noscapine increased the Bax/Bcl-2 ratio with a significant decrease of Bcl-2 expression accompanied with Bcl-2 phosphorylation. Noscapine 0-9 BCL2 apoptosis regulator Homo sapiens 28-33 17893514-5 2007 Noscapine increased the Bax/Bcl-2 ratio with a significant decrease of Bcl-2 expression accompanied with Bcl-2 phosphorylation. Noscapine 0-9 BCL2 apoptosis regulator Homo sapiens 71-76 17893514-5 2007 Noscapine increased the Bax/Bcl-2 ratio with a significant decrease of Bcl-2 expression accompanied with Bcl-2 phosphorylation. Noscapine 0-9 BCL2 apoptosis regulator Homo sapiens 71-76 18024393-0 2007 Dexamethasone-induced apoptosis in acute lymphoblastic leukemia involves differential regulation of Bcl-2 family members. Dexamethasone 0-13 BCL2 apoptosis regulator Homo sapiens 100-105 17979224-2 2007 Several other binding proteins of paclitaxel, such as Bcl-2, heat shock proteins, and NSC-1, have also been reported. Paclitaxel 34-44 BCL2 apoptosis regulator Homo sapiens 54-59 17681819-3 2007 Recombinant Bcl-2 shRNAs expression vector were transfected into A549 cells with Lipofectamine 2000. Lipofectamine 81-99 BCL2 apoptosis regulator Homo sapiens 12-17 16973256-11 2007 The bcl-2 expression was higher in both gosereline and raloxifene groups compared to control group (173.7 for gosereline versus 94.7 for control, 179.7 for raloxifene versus 94.7 for control, p = 0.001). Raloxifene Hydrochloride 55-65 BCL2 apoptosis regulator Homo sapiens 4-9 16973256-11 2007 The bcl-2 expression was higher in both gosereline and raloxifene groups compared to control group (173.7 for gosereline versus 94.7 for control, 179.7 for raloxifene versus 94.7 for control, p = 0.001). Raloxifene Hydrochloride 156-166 BCL2 apoptosis regulator Homo sapiens 4-9 18024393-2 2007 The aim of this study was to characterize the involvement of Bcl-2 family members and caspase activation in dexamethasone(Dex)-induced apoptosis in ALL. Dexamethasone 108-121 BCL2 apoptosis regulator Homo sapiens 61-66 18024393-2 2007 The aim of this study was to characterize the involvement of Bcl-2 family members and caspase activation in dexamethasone(Dex)-induced apoptosis in ALL. Dextromethorphan 122-125 BCL2 apoptosis regulator Homo sapiens 61-66 18024393-7 2007 RESULTS: Dex induced significant down-regulation of the anti-apoptotic Bcl-2 family members Bcl-2 and Bcl-xL, differential activation of the pro-apoptotic Bak and Bax, loss of Delta psi m and cytochrome c release. Dextromethorphan 9-12 BCL2 apoptosis regulator Homo sapiens 71-76 18210747-5 2007 Also, coumarin treatment gradually decreased the expression of G0/G1-associated proteins which may have led to the G0/G1 arrest, and the anti-apoptotic proteins Bcl-2 and Bcl-xL, and increased the expression of the pro-apoptotic protein Bax. coumarin 6-14 BCL2 apoptosis regulator Homo sapiens 161-166 18024393-7 2007 RESULTS: Dex induced significant down-regulation of the anti-apoptotic Bcl-2 family members Bcl-2 and Bcl-xL, differential activation of the pro-apoptotic Bak and Bax, loss of Delta psi m and cytochrome c release. Dextromethorphan 9-12 BCL2 apoptosis regulator Homo sapiens 92-97 18210755-4 2007 RESULTS: Our results showed that baicalein promoted the levels of p53, BAX, cytochrome c, capase-3 and -9 and reduced the level of BCL-2, which were associated with the induction of apoptotic cell death of SCC-4 cells. baicalein 33-42 BCL2 apoptosis regulator Homo sapiens 131-136 18024393-10 2007 In 12 primary ALL samples Dex-induced apoptosis was associated with activation of Bax (p=0.045) and down-regulation of Bcl-2 (p=0.016) and/or Bcl-xL (p=0.004). Dextromethorphan 26-29 BCL2 apoptosis regulator Homo sapiens 119-124 18024393-12 2007 INTERPRETATION AND CONCLUSIONS: The differential regulation of pro- and anti-apoptotic Bcl-2 family members appears to be a key event in the execution of Dex-induced apoptosis in ALL cell lines, and also indicates a role for these proteins in primary ALL cells. Dextromethorphan 154-157 BCL2 apoptosis regulator Homo sapiens 87-92 18055344-4 2007 BCL2 /IgH translocation was analyzed in paraffin-embedded tissues from follicular lymphoma patients by using polymerase chain reaction (PCR) analysis of the major breakpoint region (MBR), the intermediate cluster region (ICR), and the minor cluster region. Paraffin 40-48 BCL2 apoptosis regulator Homo sapiens 0-4 17785366-5 2007 It was proposed that growth enhancement of leiomyoma cells by progesterone was mediated via bcl-2 induction. Progesterone 62-74 BCL2 apoptosis regulator Homo sapiens 92-97 17785366-9 2007 Transient transfection with deletion mutants of bcl-2 promoter showed that the -1281/-258-bp region conferred responsiveness to progesterone induction in the presence of PR-A. Progesterone 128-140 BCL2 apoptosis regulator Homo sapiens 48-53 17619073-7 2007 Similar to function way of SM, cDDP causes cancer cell apoptosis though caspase-8/caspase-3 and Bax/cytochrome c pathways, but the resistance to cDDP is correlated with Bcl-2 and Bcl-xL overexpression. Cisplatin 145-149 BCL2 apoptosis regulator Homo sapiens 169-174 17619073-9 2007 The combined treatment of SM and cDDP significantly reduced Bcl-2 and Bcl-xL expressions, and enhanced Bax, cytochrome c, caspase-9 and -3 expressions in breast cancer cells. beta-solamarine 26-28 BCL2 apoptosis regulator Homo sapiens 60-65 17619073-9 2007 The combined treatment of SM and cDDP significantly reduced Bcl-2 and Bcl-xL expressions, and enhanced Bax, cytochrome c, caspase-9 and -3 expressions in breast cancer cells. Cisplatin 33-37 BCL2 apoptosis regulator Homo sapiens 60-65 17680997-5 2007 This survival effect is mediated by the Bcl-2 family members and involves inhibition of caspase-3 activation; reduction of cleaved poly-ADP ribose polymerase and phosphorylated H2A.X protein levels and elevation of tyrosine hydroxylase expression. Tyrosine 215-223 BCL2 apoptosis regulator Homo sapiens 40-45 17530176-7 2007 Also, TLBC lowered levels of anti-apoptotic Bcl-2 and/or Bcl-X(L) protein in several of the cell lines. tlbc 6-10 BCL2 apoptosis regulator Homo sapiens 44-49 17530176-10 2007 Immunohistochemical and western blot analysis showed that Bcl-2 protein levels were decreased and Bax protein levels were slightly increased in the tumors injected with 20 mg/kg TLBC compared with the control tumors. tlbc 178-182 BCL2 apoptosis regulator Homo sapiens 58-63 17879964-0 2007 Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2-independent apoptosis in human prostatic adenocarcinoma cells. Sphingolipids 0-13 BCL2 apoptosis regulator Homo sapiens 67-72 17562131-8 2007 Mutations caused by ROS to mitochondrial DNA, its inability to repair it completely and creation of a vicious cycle of mutations along with role of Bcl-2 family genes and proteins has been implicated in many diseases where mitochondrial dysfunctions play a key role. Reactive Oxygen Species 20-23 BCL2 apoptosis regulator Homo sapiens 148-153 17874842-0 2007 Ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H- chromene-3-carboxylate (HA 14-1), a prototype small-molecule antagonist against antiapoptotic Bcl-2 proteins, decomposes to generate reactive oxygen species that induce apoptosis. ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate 0-80 BCL2 apoptosis regulator Homo sapiens 152-157 17874842-2 2007 Ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4 H-chromene-3-carboxylate (HA 14-1) is one of the earliest small-molecule antagonists against antiapoptotic Bcl-2 proteins. ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate 0-80 BCL2 apoptosis regulator Homo sapiens 163-168 17904593-3 2007 Our results suggest that the protective effects of esculin (10(-7), 10(-6) and 10(-5) M) on DA-induced cytotoxicity may be ascribed to its anti-oxidative properties by reducing ROS level, and its anti-apoptotic effect via protecting mitochondrion membrane potential (DeltaPsim), enhancing superoxide dismutaese (SOD) activity and reduced glutathione (GSH) levels, and regulating P53, Bax and Bcl-2 expression. Esculin 51-58 BCL2 apoptosis regulator Homo sapiens 392-397 17904593-3 2007 Our results suggest that the protective effects of esculin (10(-7), 10(-6) and 10(-5) M) on DA-induced cytotoxicity may be ascribed to its anti-oxidative properties by reducing ROS level, and its anti-apoptotic effect via protecting mitochondrion membrane potential (DeltaPsim), enhancing superoxide dismutaese (SOD) activity and reduced glutathione (GSH) levels, and regulating P53, Bax and Bcl-2 expression. Dopamine 92-94 BCL2 apoptosis regulator Homo sapiens 392-397 17879964-2 2007 METHODS: We evaluated the effects of BCL-2 over-expression in human prostatic adenocarcinoma cells on their susceptibility to sphingolipids (SLs) and to the sphingosine kinase (SpK) inhibitor, SKI II. Sphingolipids 126-139 BCL2 apoptosis regulator Homo sapiens 37-42 17879964-2 2007 METHODS: We evaluated the effects of BCL-2 over-expression in human prostatic adenocarcinoma cells on their susceptibility to sphingolipids (SLs) and to the sphingosine kinase (SpK) inhibitor, SKI II. Sphingolipids 141-144 BCL2 apoptosis regulator Homo sapiens 37-42 18060755-3 2007 Also, DHA and PEDF synergistically activate NPD1 synthesis and antiapoptotic protein expression and decreased proapoptotic Bcl-2 protein expression and caspase 3 activation during oxidative stress. Docosahexaenoic Acids 6-9 BCL2 apoptosis regulator Homo sapiens 123-128 17879964-5 2007 DMSP-induced DNA fragmentation and loss of mitochondrial membrane potential were equivalent in BCL-2 transfectants and parental PC-3 cells and were not associated with BCL-2 downregulation. dimethylpropiothetin 0-4 BCL2 apoptosis regulator Homo sapiens 95-100 18021997-6 2007 METHOD: Bcl-2 expression was determined immunohistochemically by NP030 antibody (DAKO) and Envision-DAB. diazobenzenesulfonic acid 100-103 BCL2 apoptosis regulator Homo sapiens 8-13 17428807-1 2007 In cerebellar granule neurons, a BH3-only Bcl-2 family member, death protein 5/harakiri, is up-regulated in a JNK-dependent manner during apoptosis induced by potassium deprivation. Potassium 159-168 BCL2 apoptosis regulator Homo sapiens 42-47 17629615-4 2007 Reduced Bcl-2 protein level is also found in a tamoxifen resistant human breast tumor grown as a xenograft. Tamoxifen 47-56 BCL2 apoptosis regulator Homo sapiens 8-13 17629615-5 2007 We show that re-expression of Bcl-2 partially rescues antiestrogen resistant MCF-7 sublines from DMAT-induced cell death. 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole 97-101 BCL2 apoptosis regulator Homo sapiens 30-35 18047955-3 2007 Targeting bcl-2 and bcl-xL messenger ribonucleic acid with antisense oligodeoxynucleotides (AS-ODNs) may enhance the cytotoxic effects of chemotherapeutic agents. Oligodeoxyribonucleotides 69-90 BCL2 apoptosis regulator Homo sapiens 10-15 18047955-3 2007 Targeting bcl-2 and bcl-xL messenger ribonucleic acid with antisense oligodeoxynucleotides (AS-ODNs) may enhance the cytotoxic effects of chemotherapeutic agents. as-odns 92-99 BCL2 apoptosis regulator Homo sapiens 10-15 18047955-10 2007 After combined treatment with chemotherapy and bcl-2 or bcl-xL AS-ODNs, cell death rates were significantly higher (e.g., 30.3% vs. 87.2% in HT 1197 cells for monotreatment vs. the combination of paclitaxel and bcl-xL AS-ODNs). Paclitaxel 196-206 BCL2 apoptosis regulator Homo sapiens 47-52 17927446-5 2007 The process requires induction of the proapoptotic BH3-only BCL2 family member BIM (i.e., BCL2-like 11, or BCL2L11); erlotinib dramatically induces BIM levels in sensitive but not in resistant cell lines, and knockdown of BIM expression by RNA interference virtually eliminates drug-induced cell killing in vitro. Erlotinib Hydrochloride 117-126 BCL2 apoptosis regulator Homo sapiens 60-64 17692289-2 2007 The cleavage of the BH4 domain in Bcl-x(L) and Bcl-2 by caspase 1 or 3 converts the anti-apoptotic Bcl-x(L) and Bcl-2 into pro-apoptotic proteins that potently induce apoptosis. sapropterin 20-23 BCL2 apoptosis regulator Homo sapiens 47-52 17692289-2 2007 The cleavage of the BH4 domain in Bcl-x(L) and Bcl-2 by caspase 1 or 3 converts the anti-apoptotic Bcl-x(L) and Bcl-2 into pro-apoptotic proteins that potently induce apoptosis. sapropterin 20-23 BCL2 apoptosis regulator Homo sapiens 112-117 17825286-9 2007 However, in the presence of tBid, co-incubation of apoptosis-competent mitochondria with Bcl-2 microsomes, but not with Bcl-2 mitochondria, diminished the Bax-binding to Bcl-2 significantly, suggesting that Bcl-2 in ER is readily inactivated by tBid. tBID 28-32 BCL2 apoptosis regulator Homo sapiens 89-94 17825286-9 2007 However, in the presence of tBid, co-incubation of apoptosis-competent mitochondria with Bcl-2 microsomes, but not with Bcl-2 mitochondria, diminished the Bax-binding to Bcl-2 significantly, suggesting that Bcl-2 in ER is readily inactivated by tBid. tBID 245-249 BCL2 apoptosis regulator Homo sapiens 89-94 17825286-10 2007 Co-incubation assay further confirmed that Bcl-2 in the ER, but not Bcl-2 in the mitochondria, is potentially inactivated by tBid. tBID 125-129 BCL2 apoptosis regulator Homo sapiens 43-48 17825286-11 2007 Our quantitative in vitro studies indicate that Bcl-2 in mitochondria and ER are similarly potent in inhibiting Bax-associated apoptosis of other mitochondria, but are regulated by tBid differently. tBID 181-185 BCL2 apoptosis regulator Homo sapiens 48-53 17698840-0 2007 Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. Sorafenib 112-121 BCL2 apoptosis regulator Homo sapiens 35-40 17698840-0 2007 Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. Sorafenib 123-134 BCL2 apoptosis regulator Homo sapiens 35-40 17927446-5 2007 The process requires induction of the proapoptotic BH3-only BCL2 family member BIM (i.e., BCL2-like 11, or BCL2L11); erlotinib dramatically induces BIM levels in sensitive but not in resistant cell lines, and knockdown of BIM expression by RNA interference virtually eliminates drug-induced cell killing in vitro. bim 79-82 BCL2 apoptosis regulator Homo sapiens 60-64 17636381-5 2007 Persistent high levels of NO and ROS caused Bcl-2 cleavage and translocation of Bax to mitochondria, which lead to loss of mitochondrial membrane potential (Deltapsim) and release of cytochrome c, AIF, Smac/DIABLO to the cytosol. Reactive Oxygen Species 33-36 BCL2 apoptosis regulator Homo sapiens 44-49 17652152-9 2007 These results suggest that asoprisnil elicits ER stress-induced apoptosis in cultured leiomyoma cells and that GADD153 plays a role in asoprisnil-induced apoptosis by modulating the Bcl-2 family of proteins, GADD34, and TRB3. asoprisnil 135-145 BCL2 apoptosis regulator Homo sapiens 182-187 17681284-0 2007 GEA 3162, a peroxynitrite donor, induces Bcl-2-sensitive, p53-independent apoptosis in murine bone marrow cells. gea 0-3 BCL2 apoptosis regulator Homo sapiens 41-46 17845507-5 2007 In addition, chalcone increased the expression of Bax and Bak, but decreased the levels of Bcl-2 and Bcl-X(L) and subsequently triggered mitochondrial apoptotic pathway (release of cytochrome c and activation of caspase-9 and caspase-3). Chalcone 13-21 BCL2 apoptosis regulator Homo sapiens 91-96 17673978-4 2007 Treatment of SW620 cells with 50 microM berberine resulted in activation of the caspase 3 and caspase 8, cleavage of poly ADP-ribose polymerase (PARP) and the release of cytochrome c; whereas, the expression of BID and anti-apoptosis factor c-IAP1, Bcl-2, and Bcl-(XL) were decreased markedly. Berberine 40-49 BCL2 apoptosis regulator Homo sapiens 249-254 17681284-0 2007 GEA 3162, a peroxynitrite donor, induces Bcl-2-sensitive, p53-independent apoptosis in murine bone marrow cells. Peroxynitrous Acid 12-25 BCL2 apoptosis regulator Homo sapiens 41-46 17273826-10 2007 Antimycin A3, in combination with SN-38 recapitulated this phenotype in HCT 116 cells, suggesting a potential role for small molecule inhibitors of Bcl-xL/Bcl-2 in the treatment of colorectal cancer, potentially in combination with irinotecan. blastmycin 0-12 BCL2 apoptosis regulator Homo sapiens 155-160 17434928-0 2007 Bcl-2 over-expression promotes genomic instability by inhibiting apoptosis of cells exposed to hydrogen peroxide. Hydrogen Peroxide 95-112 BCL2 apoptosis regulator Homo sapiens 0-5 17493842-8 2007 This suggests that the apoptosis induced by MG132 in MG63 cells is caspase-8 dependent, p27 and bcl-2 family related. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 44-49 BCL2 apoptosis regulator Homo sapiens 96-101 17909043-9 2007 The proapoptotic effect of zoledronic acid and zoledronic acid in combination with 4-HC on tumor cells was associated with an increase in caspase-3 activity and a decrease in phosphorylated Bcl-2, Bcl-2, and Bcl-X(L) expression. Zoledronic Acid 27-42 BCL2 apoptosis regulator Homo sapiens 190-195 17909043-9 2007 The proapoptotic effect of zoledronic acid and zoledronic acid in combination with 4-HC on tumor cells was associated with an increase in caspase-3 activity and a decrease in phosphorylated Bcl-2, Bcl-2, and Bcl-X(L) expression. Zoledronic Acid 27-42 BCL2 apoptosis regulator Homo sapiens 197-202 17909043-9 2007 The proapoptotic effect of zoledronic acid and zoledronic acid in combination with 4-HC on tumor cells was associated with an increase in caspase-3 activity and a decrease in phosphorylated Bcl-2, Bcl-2, and Bcl-X(L) expression. Zoledronic Acid 47-62 BCL2 apoptosis regulator Homo sapiens 190-195 17909043-9 2007 The proapoptotic effect of zoledronic acid and zoledronic acid in combination with 4-HC on tumor cells was associated with an increase in caspase-3 activity and a decrease in phosphorylated Bcl-2, Bcl-2, and Bcl-X(L) expression. Zoledronic Acid 47-62 BCL2 apoptosis regulator Homo sapiens 197-202 17909043-9 2007 The proapoptotic effect of zoledronic acid and zoledronic acid in combination with 4-HC on tumor cells was associated with an increase in caspase-3 activity and a decrease in phosphorylated Bcl-2, Bcl-2, and Bcl-X(L) expression. 4-hydroxyperoxycyclophosphamide 83-87 BCL2 apoptosis regulator Homo sapiens 190-195 17909043-9 2007 The proapoptotic effect of zoledronic acid and zoledronic acid in combination with 4-HC on tumor cells was associated with an increase in caspase-3 activity and a decrease in phosphorylated Bcl-2, Bcl-2, and Bcl-X(L) expression. 4-hydroxyperoxycyclophosphamide 83-87 BCL2 apoptosis regulator Homo sapiens 197-202 17786319-2 2007 Genistein-induced apoptosis involves Bcl-2 downregulation. Genistein 0-9 BCL2 apoptosis regulator Homo sapiens 37-42 17656415-7 2007 Specifically, 0.1 and 1 nM DHT stimulated PI3K activity, whereas 10 nM DHT decreased PI3K activity and levels of p-AKT S473 and p-AKT T308, p-BCL2, and enhanced phosphatase and tensin homologue (PTEN) phosphorylation. Dihydrotestosterone 71-74 BCL2 apoptosis regulator Homo sapiens 142-146 17786319-6 2007 We found that genistein induces enhanced cytochrome c release and mitochondrial membrane depolarization in MCF-7/Bcl-2 cells, as compared to control. Genistein 14-23 BCL2 apoptosis regulator Homo sapiens 113-118 17786319-8 2007 Cell cycle analysis indicated that genistein induces G0/G1 arrest in MCF-7/PV cells but increases in G2/M arrest in MCF-7/Bcl-2 cells. Genistein 35-44 BCL2 apoptosis regulator Homo sapiens 122-127 17492397-0 2007 Modulation of tumor radiation response with G3139, a bcl-2 antisense oligonucleotide. oblimersen 44-49 BCL2 apoptosis regulator Homo sapiens 53-58 17786319-5 2007 Our results demonstrate that overexpression of Bcl-2 rendered MCF-7 cells more sensitive, rather than resistant, to genistein. Genistein 116-125 BCL2 apoptosis regulator Homo sapiens 47-52 17492397-0 2007 Modulation of tumor radiation response with G3139, a bcl-2 antisense oligonucleotide. Oligonucleotides 69-84 BCL2 apoptosis regulator Homo sapiens 53-58 17786326-0 2007 Cobalt chloride induces apoptosis and zinc chloride suppresses cobalt-induced apoptosis by Bcl-2 expression in human submandibular gland HSG cells. zinc chloride 38-51 BCL2 apoptosis regulator Homo sapiens 91-96 17786326-0 2007 Cobalt chloride induces apoptosis and zinc chloride suppresses cobalt-induced apoptosis by Bcl-2 expression in human submandibular gland HSG cells. Cobalt 63-69 BCL2 apoptosis regulator Homo sapiens 91-96 17492397-3 2007 The aim of this study was to investigate in vivo anti-tumor effects of a combined modality treatment scheme consisting of radiation and the bcl-2 targeted AS oligonucleotide (ODN) G3139 (Oblimersen Sodium). Oligonucleotides 158-173 BCL2 apoptosis regulator Homo sapiens 140-145 17878372-3 2007 The ratio of Bcl-2+ Gag-specific CD8+ T cells to caspase-3+ Gag-specific CD8+ T cells was higher in the vaccinated-protected animals compared with unprotected monkeys. Glycosaminoglycans 20-23 BCL2 apoptosis regulator Homo sapiens 13-18 17492397-5 2007 G3139 potentiated the radiation response of bcl-2 positive SW620 tumors, but had no significant effect on bcl-2 negative HT-29 tumors assayed by tumor growth delay. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 44-49 17508219-1 2007 PURPOSE: Oblimersen is an 18-base oligodeoxynucleotide encoding antisense to the gene for bcl-2, an anti-apoptotic protein that is upregulated in renal and other cancers. 18-base oligodeoxynucleotide 26-54 BCL2 apoptosis regulator Homo sapiens 90-95 17786326-5 2007 Cobalt chloride inhibited the expression of both Bcl-2 protein and mRNA in dose- and time-dependent manner. cobaltous chloride 0-15 BCL2 apoptosis regulator Homo sapiens 49-54 17786326-6 2007 Zinc chloride recovered the cobalt-suppressed Bcl-2 expression and protected against cobalt-induced apoptosis in HSG cells. zinc chloride 0-13 BCL2 apoptosis regulator Homo sapiens 46-51 17786326-6 2007 Zinc chloride recovered the cobalt-suppressed Bcl-2 expression and protected against cobalt-induced apoptosis in HSG cells. Cobalt 28-34 BCL2 apoptosis regulator Homo sapiens 46-51 17786326-8 2007 Our results also indicate that cobalt-induced apoptotic steps in HSG cells are related to the production of Bcl-2 protein. Cobalt 31-37 BCL2 apoptosis regulator Homo sapiens 108-113 18270395-1 2007 UNLABELLED: The change in expression of apoptotic markers (Bcl-2 and Bax proteins) brought about by various chemotherapeutic regimens is being used for its predictive value for assessing response to neoadjuvant chemotherapy (NACT) in locally advanced breast carcinoma (LABC). nact 225-229 BCL2 apoptosis regulator Homo sapiens 59-64 18270395-16 2007 CONCLUSIONS: This significant positive correlation between clinical and immunohistochemical responses highlights the importance of apoptotic marker Bcl-2 family protein in predicting the response of LABC to NACT. nact 207-211 BCL2 apoptosis regulator Homo sapiens 148-153 17689613-0 2007 Copper conjugates of nimesulide Schiff bases targeting VEGF, COX and Bcl-2 in pancreatic cancer cells. Copper 0-6 BCL2 apoptosis regulator Homo sapiens 69-74 17689613-0 2007 Copper conjugates of nimesulide Schiff bases targeting VEGF, COX and Bcl-2 in pancreatic cancer cells. nimesulide schiff bases 21-44 BCL2 apoptosis regulator Homo sapiens 69-74 17696989-5 2007 The protective effect of reelin includes activating the Src-family kinases/PI3 K/Akt pathway which then led to selective phosphorylation of Bcl-2/Bcl-XL associated death promoter (BAD) at serine-136, while the phosphorylation-incompetent mutation of BAD (S136A) suppressed this protection. Serine 188-194 BCL2 apoptosis regulator Homo sapiens 140-145 17635668-4 2007 We show that aminoindan (0.1-1 mumol/L) significantly reduced the apoptosis-associated phosphorylated protein, H2A.X (Ser139), decreased the cleavage of caspase 9 and caspase 3, while increasing the anti-apoptotic proteins, Bcl-2 and Bcl-xl. 1-aminoindan 13-23 BCL2 apoptosis regulator Homo sapiens 224-229 17997295-4 2007 Inhibition of PLA2 and LOX with prednisolone and nordihydroguaiaretic acid (NDGA) caused a semi-quantitative increase of utrophin and Bcl-2-, and a dose-dependent, quantitative increase of desmin expression, an effect that was augmented by hypo-osmotic treatment. Prednisolone 32-44 BCL2 apoptosis regulator Homo sapiens 134-139 17415780-7 2007 Bcl-2 expression coincided with increased nuclear beta-catenin levels (Pg-NES) or a decrease in the level of total and nuclear beta-catenin associated with N-cadherin and alpha-catenin (Pg-WT and -NLS) cells. pg-nes 71-77 BCL2 apoptosis regulator Homo sapiens 0-5 17918040-3 2007 Further study showed that Andro induced activation of mitogen-activated protein kinases (MAPKs) including p38 kinase, c-Jun N-terminal kinase (JNK) and extracellular signal-related kinases (ERK1/2), but had no significant effect on caspase-3, Bcl-xL and Bcl-2, which are apoptosis-related proteins. andrographolide 26-31 BCL2 apoptosis regulator Homo sapiens 254-259 17938270-7 2007 Moreover, epothilone B and D increased the expressions of NF-kappaB-dependent apoptotic cell death regulatory genes, i.e., Bax, p53, and the active form of caspase-3, but reduced Bcl-2 expression, and these actions were partially reversed by salicylic acid. epothilone B 10-22 BCL2 apoptosis regulator Homo sapiens 179-184 17938270-7 2007 Moreover, epothilone B and D increased the expressions of NF-kappaB-dependent apoptotic cell death regulatory genes, i.e., Bax, p53, and the active form of caspase-3, but reduced Bcl-2 expression, and these actions were partially reversed by salicylic acid. Deuterium 27-28 BCL2 apoptosis regulator Homo sapiens 179-184 17912675-4 2007 Bcl-2 over-expressing cells are less sensitive to emetine while caspase-8-deficient Jurkat T-cells react similarly to wild-type cells. Emetine 50-57 BCL2 apoptosis regulator Homo sapiens 0-5 17997295-4 2007 Inhibition of PLA2 and LOX with prednisolone and nordihydroguaiaretic acid (NDGA) caused a semi-quantitative increase of utrophin and Bcl-2-, and a dose-dependent, quantitative increase of desmin expression, an effect that was augmented by hypo-osmotic treatment. Masoprocol 49-74 BCL2 apoptosis regulator Homo sapiens 134-139 17997295-4 2007 Inhibition of PLA2 and LOX with prednisolone and nordihydroguaiaretic acid (NDGA) caused a semi-quantitative increase of utrophin and Bcl-2-, and a dose-dependent, quantitative increase of desmin expression, an effect that was augmented by hypo-osmotic treatment. Masoprocol 76-80 BCL2 apoptosis regulator Homo sapiens 134-139 18007085-0 2007 [Effect of melatonin on the proliferation, apoptosis, and expression of bcl-2 in oxidized low-density lipoprotein-induced endothelial progenitor cells]. Melatonin 11-20 BCL2 apoptosis regulator Homo sapiens 72-77 18007085-1 2007 OBJECTIVE: To explore the effect of melatonin(Mel) on the proliferation, apoptosis and expression of bcl-2 in oxidized low-density lipoprotein(ox-LDL)-induced endothelial progenitor cells (EPC) from human umbilical cord blood in vitro. Melatonin 36-45 BCL2 apoptosis regulator Homo sapiens 101-106 18007089-3 2007 Immunohistochemistry (SP method) was used to study the expression of Bcl-2 and TGFbeta1 in human trophoblasts. TFF2 protein, human 22-24 BCL2 apoptosis regulator Homo sapiens 69-74 17724801-8 2007 MS-275-induced apoptosis was characterized by activation of caspase-3, up-regulation of Bax and down-regulation of Bcl-2. entinostat 0-6 BCL2 apoptosis regulator Homo sapiens 115-120 17894887-3 2007 For example, miR-15 and miR-16 induce apoptosis by targeting Bcl2. mir-15 13-19 BCL2 apoptosis regulator Homo sapiens 61-65 17956674-7 2007 After treating U266 cells with 2 micromol/L As2O3 at different time points, a time-dependent reduction of procaspase-3, hTERT mRNA and protein was found without any change of bcl-2 expression. Arsenic Trioxide 44-49 BCL2 apoptosis regulator Homo sapiens 175-180 17685632-6 2007 The ratio of expression levels of pro- and anti-apoptotic Bcl-2 family members was changed by gallic acid treatment. Gallic Acid 94-105 BCL2 apoptosis regulator Homo sapiens 58-63 17958331-4 2007 TDB-induced apoptosis in the MCF-7 cells was closely linked with the down-regulation of Bcl-2 protein expression and the cleavage of caspase-3 substrates, with poly(ADP-ribose) polymerase cleavage occurring by TDB treatment. TDB 0-3 BCL2 apoptosis regulator Homo sapiens 88-93 17970084-3 2007 Berberine enhanced the apoptosis of Ca Ski cells with the induction of a higher ratio of p53 and Bax/Bcl-2 proteins, increased levels of reactive oxygen species (ROS) and Ca2+, disruption of the mitochondrial membrane potential, and promotion of caspase-3 activity. Berberine 0-9 BCL2 apoptosis regulator Homo sapiens 101-106 17572662-0 2007 Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 21-24 BCL2 apoptosis regulator Homo sapiens 103-108 17617736-2 2007 We found that the drug resistant cancer cell lines overexpressing P-gp, MRP1, BCRP, Bcl-2 and Bcl-xL are susceptible to shikonin, a necroptotic inducer, despite the fact that they are highly resistant to a variety of anticancer agents such as anthracycline antibiotics, vinca alkaloids, taxanes, epipodophylotoxins, etc. anthracycline antibiotics 243-268 BCL2 apoptosis regulator Homo sapiens 84-89 17617736-2 2007 We found that the drug resistant cancer cell lines overexpressing P-gp, MRP1, BCRP, Bcl-2 and Bcl-xL are susceptible to shikonin, a necroptotic inducer, despite the fact that they are highly resistant to a variety of anticancer agents such as anthracycline antibiotics, vinca alkaloids, taxanes, epipodophylotoxins, etc. Vinca Alkaloids 270-285 BCL2 apoptosis regulator Homo sapiens 84-89 17617736-2 2007 We found that the drug resistant cancer cell lines overexpressing P-gp, MRP1, BCRP, Bcl-2 and Bcl-xL are susceptible to shikonin, a necroptotic inducer, despite the fact that they are highly resistant to a variety of anticancer agents such as anthracycline antibiotics, vinca alkaloids, taxanes, epipodophylotoxins, etc. Taxoids 287-294 BCL2 apoptosis regulator Homo sapiens 84-89 17617736-2 2007 We found that the drug resistant cancer cell lines overexpressing P-gp, MRP1, BCRP, Bcl-2 and Bcl-xL are susceptible to shikonin, a necroptotic inducer, despite the fact that they are highly resistant to a variety of anticancer agents such as anthracycline antibiotics, vinca alkaloids, taxanes, epipodophylotoxins, etc. epipodophylotoxins 296-314 BCL2 apoptosis regulator Homo sapiens 84-89 17510660-4 2007 This is achieved through the moderation of mitochondrial respiration, depending on the ROS context within the organelle, with the main players being Bcl-2 and cytochrome c oxidase (COX). Reactive Oxygen Species 87-90 BCL2 apoptosis regulator Homo sapiens 149-154 17510660-5 2007 We report a higher level of COX activity, oxygen consumption and mitochondrial respiration in tumor cells overexpressing Bcl-2. Oxygen 42-48 BCL2 apoptosis regulator Homo sapiens 121-126 17542780-5 2007 Further studies showed that morphine inhibited ROS (reactive oxygen species) generation, and prevented DOX-mediated caspase-3 activation, cytochrome c release and changes of Bax and Bcl-2 protein expression. Morphine 28-36 BCL2 apoptosis regulator Homo sapiens 182-187 17542780-6 2007 The antioxidant NAC (N-acetylcysteine) also showed the same effects as morphine on DOX-induced ROS generation, caspase-3 activation and cytochrome c release and changes in Bax (Bcl-2-associated X protein) and Bcl-2 protein expression. Acetylcysteine 16-19 BCL2 apoptosis regulator Homo sapiens 177-182 17542780-6 2007 The antioxidant NAC (N-acetylcysteine) also showed the same effects as morphine on DOX-induced ROS generation, caspase-3 activation and cytochrome c release and changes in Bax (Bcl-2-associated X protein) and Bcl-2 protein expression. Acetylcysteine 21-37 BCL2 apoptosis regulator Homo sapiens 177-182 17510658-0 2007 Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. ABT-737 97-104 BCL2 apoptosis regulator Homo sapiens 136-141 17510658-3 2007 Here we demonstrate that INNO-406, a much more active Bcr-Abl tyrosine kinase inhibitor than imatinib, augments the activities of several proapoptotic Bcl-2 homology (BH)3-only proteins (Bim, Bad, Bmf and Bik) and induces apoptosis in Ph(+) leukemia cells via Bcl-2 family-regulated intrinsic apoptosis pathway. Imatinib Mesylate 93-101 BCL2 apoptosis regulator Homo sapiens 151-156 17510658-4 2007 ABT-737, an inhibitor of antiapoptotic Bcl-2 and Bcl-X(L), greatly enhanced the apoptosis by INNO-406, even in INNO-406-less sensitive cells with Bcr-Abl point mutations except T315I mutation. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 39-44 17510660-7 2007 Interestingly, Bcl-2 is also able to regulate mitochondrial respiration and COX activity in the face of mounting ROS levels, triggered by mitochondrial complex inhibitors. Reactive Oxygen Species 113-116 BCL2 apoptosis regulator Homo sapiens 15-20 17510660-8 2007 In this respect, it is plausible to suggest that Bcl-2 may be able to create an environment, most suited for survival by adjusting mitochondrial respiration accordingly to meet energy requirements, without incurring an overwhelming, detrimental increase in intracellular ROS. Reactive Oxygen Species 271-274 BCL2 apoptosis regulator Homo sapiens 49-54 17671737-5 2007 RT-PCR evaluations performed in MCF-7 and MCF-7R showed that curcumin or MR 39 produced early modifications in the amounts of relevant gene transcripts, which, however, were mostly diverse (i.e. represented by decreases in IAPs and COX-2 in MCF-7R versus reductions in Bcl-2 and Bcl-XL as well as increases in the Bcl-XS/Bcl-XL ratio in MCF-7) in the two cell lines. Curcumin 61-69 BCL2 apoptosis regulator Homo sapiens 269-274 17541428-8 2007 Based on these results, a combination treatment including (-)-gossypol, an inhibitor of Mcl-1/Bcl-2/Bcl-x(L), was designed and proven effective in vivo. Gossypol 58-70 BCL2 apoptosis regulator Homo sapiens 94-99 17590421-0 2007 Curcumin down-regulates Ets-1 and Bcl-2 expression in human endometrial carcinoma HEC-1-A cells. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 34-39 17590421-6 2007 RESULTS: Curcumin induced apoptosis-like morphological changes and DNA degradation and decreased basal levels of Ets-1 and Bcl-2 protein contents in HEC-1-A cells in a time- and dose-dependent manner. Curcumin 9-17 BCL2 apoptosis regulator Homo sapiens 123-128 17590421-8 2007 CONCLUSIONS: Curcumin down-regulates Ets-1 and Bcl-2 expression and induces apoptosis in HEC-1-A cells, suggesting a novel molecular mechanism for the anti-tumor activity of curcumin. Curcumin 13-21 BCL2 apoptosis regulator Homo sapiens 47-52 17590421-8 2007 CONCLUSIONS: Curcumin down-regulates Ets-1 and Bcl-2 expression and induces apoptosis in HEC-1-A cells, suggesting a novel molecular mechanism for the anti-tumor activity of curcumin. Curcumin 174-182 BCL2 apoptosis regulator Homo sapiens 47-52 17671742-4 2007 RT-PCR and immunoblotting showed that treating the cells with curcumin resulted in the down-regulation of anti-apoptotic Bcl-2 and the X-linked inhibitor of the apoptosis protein as well as the up-regulation of pro-apoptotic Bax expression in a concentration-dependent manner. Curcumin 62-70 BCL2 apoptosis regulator Homo sapiens 121-126 19190694-8 2007 Considering all patients with chronic HCV-infection, bcl-2 rearrangement was slightly more frequent in the non treated group than in those who underwent treatment with interferon plus ribavirin but the difference was not statistically significant, although treated patients showed biochemical and virologic response at the end of 6 months of antiviral therapy. Ribavirin 184-193 BCL2 apoptosis regulator Homo sapiens 53-58 17934335-8 2007 We also found that the triacsin C-mediated growth inhibition in Hep 3B cells results from the induction of apoptosis with evidence of Bcl-2 reduction. triacsin C 23-33 BCL2 apoptosis regulator Homo sapiens 134-139 17900403-8 2007 The dose-dependent inhibition of cell proliferation and induction of apoptosis by triptolide may involve upregulation of Bax and downregulation of Bcl-2. triptolide 82-92 BCL2 apoptosis regulator Homo sapiens 147-152 17895587-10 2007 In addition, manumycin A contributed to oridonin-induced decrease of mitochondrial membrane potential (Deltapsim), consistent with the upregulation of Bax/Bcl-2 ratio. manumycin 13-24 BCL2 apoptosis regulator Homo sapiens 155-160 17895587-10 2007 In addition, manumycin A contributed to oridonin-induced decrease of mitochondrial membrane potential (Deltapsim), consistent with the upregulation of Bax/Bcl-2 ratio. oridonin 40-48 BCL2 apoptosis regulator Homo sapiens 155-160 17895587-11 2007 In conclusion, Ras negatively regulated autophagy in oridonin-treated A431 cells, which might be associated with activation of class I PI3-K. Downregulation of Deltapsim and increasing of the ratio of Bax/Bcl-2 might also be partially responsible for the initiation of the autophagic process. oridonin 53-61 BCL2 apoptosis regulator Homo sapiens 205-210 17855663-9 2007 Ursolic acid down-regulated the expression of STAT3-regulated gene products such as cyclin D1, Bcl-2, Bcl-xL, survivin, Mcl-1, and vascular endothelial growth factor. ursolic acid 0-12 BCL2 apoptosis regulator Homo sapiens 95-100 17595328-7 2007 Finally, stable knockdown of Bcl-2-interacting mediator of cell death (Bim) with short hairpin RNA in K562 cells significantly diminished sorafenib lethality, arguing strongly for a functional role of this proapoptotic Bcl-2 family member in the lethality of this agent. Sorafenib 138-147 BCL2 apoptosis regulator Homo sapiens 29-34 18095570-7 2007 CONCLUSION: Lycopene can induce apoptosis of PC-3, change the cell cycle distribution and downregulate the expression of cyclin D1 and bcl-2 and upregulate the expression of bax and then restrain cell proliferation. Lycopene 12-20 BCL2 apoptosis regulator Homo sapiens 135-140 17597151-5 2007 Here, we present a method for introducing backbone flexibility into protein design calculations and apply it to the design of diverse helical BH3 ligands that bind to the anti-apoptotic protein Bcl-xL, a member of the Bcl-2 protein family. BH 3 142-145 BCL2 apoptosis regulator Homo sapiens 218-223 17846503-5 2007 Acacetin caused a reduction of Bcl-2 expression leading to an increase of the Bax:Bcl-2 ratio. acacetin 0-8 BCL2 apoptosis regulator Homo sapiens 31-36 17846503-5 2007 Acacetin caused a reduction of Bcl-2 expression leading to an increase of the Bax:Bcl-2 ratio. acacetin 0-8 BCL2 apoptosis regulator Homo sapiens 82-87 17696246-9 2007 A certain concentration of AZT could up-regulate the expression of caspase-3 mRNA (r = 0.9969, P < 0.01), which was positively related to apoptosis rate, and could down-regulate the expression of Bcl-2 mRNA, which was negatively related to apoptosis rate (r = 0.926, P < 0.01). Zidovudine 27-30 BCL2 apoptosis regulator Homo sapiens 199-204 17349740-3 2007 The current study showed that a camptothecin (CPT)-selected human leukemia cell line (CPT-K5) had remarkably higher expression levels of Bcl-2 than its drug sensitive parental cell (RPMI 8402). Camptothecin 32-44 BCL2 apoptosis regulator Homo sapiens 137-142 17699787-5 2007 Relative to indole-3-carbinol, OSU-A9 displays a striking qualitative similarity in its effects on the phosphorylation or expression of multiple signaling targets, including Akt, mitogen-activated protein kinases, Bcl-2 family members, survivin, nuclear factor-kappaB, cyclin D1, p21, and p27. osu-a9 31-37 BCL2 apoptosis regulator Homo sapiens 214-219 21122291-18 2007 Possible mechanism is that Gax can downregulate Bcl-2 protein expression and upregulate Bax protein expression, and A549 cells apoptosis is related to the Bcl-2/Bax ratio. 1-{3-[(4-Pyridin-2-Ylpiperazin-1-Yl)sulfonyl]phenyl}-3-(1,3-Thiazol-2-Yl)urea 27-30 BCL2 apoptosis regulator Homo sapiens 48-53 17483171-1 2007 Proapoptotic phosphorothioate oligonucleotides such as G3139 (an 18-mer) induce Bcl-2-independent apoptosis, perhaps partly via direct interaction with VDAC and reduction of metabolite flow across the mitochondrial outer membrane. Phosphorothioate Oligonucleotides 13-46 BCL2 apoptosis regulator Homo sapiens 80-85 17483171-1 2007 Proapoptotic phosphorothioate oligonucleotides such as G3139 (an 18-mer) induce Bcl-2-independent apoptosis, perhaps partly via direct interaction with VDAC and reduction of metabolite flow across the mitochondrial outer membrane. oblimersen 55-60 BCL2 apoptosis regulator Homo sapiens 80-85 17640567-5 2007 The reducing agent also counteracted the inhibitory effects of curcumin on TNF-induced NF-kappaB-regulated antiapoptotic (Bcl-2, Bcl-xL, IAP1), proliferative (cyclin D1), and proinflammatory (COX-2, iNOS, and MMP-9) gene products. Curcumin 63-71 BCL2 apoptosis regulator Homo sapiens 122-127 17675494-2 2007 The effect of estrogen on the survival of human macrophages is largely unknown, and in this study we demonstrate that 17beta-estradiol (E2) provokes a death response in human THP-1 macrophages by initiating Bax translocation from cytosol to the mitochondria; however, a concomitant up-regulation of Bcl-2 creates a Bax to Bcl-2 ratio favorable for Bcl-2, thus ensuring cell survival. Estradiol 118-134 BCL2 apoptosis regulator Homo sapiens 299-304 17675494-2 2007 The effect of estrogen on the survival of human macrophages is largely unknown, and in this study we demonstrate that 17beta-estradiol (E2) provokes a death response in human THP-1 macrophages by initiating Bax translocation from cytosol to the mitochondria; however, a concomitant up-regulation of Bcl-2 creates a Bax to Bcl-2 ratio favorable for Bcl-2, thus ensuring cell survival. Estradiol 118-134 BCL2 apoptosis regulator Homo sapiens 322-327 17675494-2 2007 The effect of estrogen on the survival of human macrophages is largely unknown, and in this study we demonstrate that 17beta-estradiol (E2) provokes a death response in human THP-1 macrophages by initiating Bax translocation from cytosol to the mitochondria; however, a concomitant up-regulation of Bcl-2 creates a Bax to Bcl-2 ratio favorable for Bcl-2, thus ensuring cell survival. Estradiol 118-134 BCL2 apoptosis regulator Homo sapiens 322-327 17675494-2 2007 The effect of estrogen on the survival of human macrophages is largely unknown, and in this study we demonstrate that 17beta-estradiol (E2) provokes a death response in human THP-1 macrophages by initiating Bax translocation from cytosol to the mitochondria; however, a concomitant up-regulation of Bcl-2 creates a Bax to Bcl-2 ratio favorable for Bcl-2, thus ensuring cell survival. Estradiol 136-138 BCL2 apoptosis regulator Homo sapiens 299-304 17675494-2 2007 The effect of estrogen on the survival of human macrophages is largely unknown, and in this study we demonstrate that 17beta-estradiol (E2) provokes a death response in human THP-1 macrophages by initiating Bax translocation from cytosol to the mitochondria; however, a concomitant up-regulation of Bcl-2 creates a Bax to Bcl-2 ratio favorable for Bcl-2, thus ensuring cell survival. Estradiol 136-138 BCL2 apoptosis regulator Homo sapiens 322-327 17675494-2 2007 The effect of estrogen on the survival of human macrophages is largely unknown, and in this study we demonstrate that 17beta-estradiol (E2) provokes a death response in human THP-1 macrophages by initiating Bax translocation from cytosol to the mitochondria; however, a concomitant up-regulation of Bcl-2 creates a Bax to Bcl-2 ratio favorable for Bcl-2, thus ensuring cell survival. Estradiol 136-138 BCL2 apoptosis regulator Homo sapiens 322-327 17675494-4 2007 This estrogen-induced Bcl-2 increase is crucial for the survival of THP-1 macrophages as well as that of human peripheral blood monocyte-derived macrophages, which is evident from E2-induced cell death under small interfering RNA-mediated Bcl-2 knockdown conditions. Estradiol 180-182 BCL2 apoptosis regulator Homo sapiens 22-27 17675494-4 2007 This estrogen-induced Bcl-2 increase is crucial for the survival of THP-1 macrophages as well as that of human peripheral blood monocyte-derived macrophages, which is evident from E2-induced cell death under small interfering RNA-mediated Bcl-2 knockdown conditions. Estradiol 180-182 BCL2 apoptosis regulator Homo sapiens 239-244 17675494-5 2007 Hence, this study demonstrates that E2-induced Bcl-2 up-regulation is a homeostatic survival mechanism necessary for the manifestation of immunomodulatory effect of estrogen on human macrophages. Estradiol 36-38 BCL2 apoptosis regulator Homo sapiens 47-52 17349740-3 2007 The current study showed that a camptothecin (CPT)-selected human leukemia cell line (CPT-K5) had remarkably higher expression levels of Bcl-2 than its drug sensitive parental cell (RPMI 8402). Camptothecin 46-49 BCL2 apoptosis regulator Homo sapiens 137-142 17553788-5 2007 Rapid and selective down-regulation of the anti-apoptotic BCL-2 family protein MCL-1 preceded the activation of BAX, BAK, and caspases. bakuchiol 117-120 BCL2 apoptosis regulator Homo sapiens 58-63 17670936-7 2007 Also, DHA and pigment epithelium-derived factor synergistically modify the expression of Bcl-2 family members, activating antiapoptotic proteins and decreasing proapoptotic proteins, and by attenuating caspase 3 activation during oxidative stress. Docosahexaenoic Acids 6-9 BCL2 apoptosis regulator Homo sapiens 89-94 17187253-9 2007 Flavopiridol treatment downregulated the expression of the proapoptotic members of the Bcl-2 family proteins (Bak, Bax and PUMA-alpha). alvocidib 0-12 BCL2 apoptosis regulator Homo sapiens 87-92 17581297-6 2007 Combination treatment of Bcl-2 small interfering RNA with cisplatin resulted in a synergistic activity. Cisplatin 58-67 BCL2 apoptosis regulator Homo sapiens 25-30 17581297-8 2007 Of note, docetaxel treatment resulted in Bcl-2 phosphorylation of nonsmall cell lung cancer cells, whereas cisplatin increased the Bcl-2 overall expression and abrogated Bcl-2 phosphorylation. Docetaxel 9-18 BCL2 apoptosis regulator Homo sapiens 41-46 17581297-8 2007 Of note, docetaxel treatment resulted in Bcl-2 phosphorylation of nonsmall cell lung cancer cells, whereas cisplatin increased the Bcl-2 overall expression and abrogated Bcl-2 phosphorylation. Cisplatin 107-116 BCL2 apoptosis regulator Homo sapiens 131-136 17581297-8 2007 Of note, docetaxel treatment resulted in Bcl-2 phosphorylation of nonsmall cell lung cancer cells, whereas cisplatin increased the Bcl-2 overall expression and abrogated Bcl-2 phosphorylation. Cisplatin 107-116 BCL2 apoptosis regulator Homo sapiens 131-136 17581297-9 2007 On the basis of our findings, a Bcl-2 silencing approach appears to be a suitable strategy for sensitizing nonsmall cell lung cancer to cisplatin, but not to docetaxel. Cisplatin 136-145 BCL2 apoptosis regulator Homo sapiens 32-37 17544220-8 2007 Etoposide decreased the expression of Bcl-2, which was reversed by LPA. Etoposide 0-9 BCL2 apoptosis regulator Homo sapiens 38-43 17544220-8 2007 Etoposide decreased the expression of Bcl-2, which was reversed by LPA. Lysophospholipids 67-70 BCL2 apoptosis regulator Homo sapiens 38-43 17666813-4 2007 We also observed that saucernetin-7 caused the activations of caspase-3, -8 and -9, and that it induced Bid cleavage, the mitochondrial translocation of Bax from the cytosol, and cytochrome c release from mitochondria, but it had no effect on Bcl-2 and Bcl-xL levels. saucernetin-7 22-35 BCL2 apoptosis regulator Homo sapiens 243-248 17640484-4 2007 RESULTS: This study demonstrated that ZD1839 induced apoptosis in leukemic U937 cells by the downregulation of Bcl-2, caspase activation and subsequent apoptotic features. Gefitinib 38-44 BCL2 apoptosis regulator Homo sapiens 111-116 17640484-7 2007 These results indicate that the downregulation of Bcl-2 plays a major role in the initiation of ZD1839-induced apoptosis, and that the activation of a caspase cascade is involved in the execution of apoptosis. Gefitinib 96-102 BCL2 apoptosis regulator Homo sapiens 50-55 17581297-0 2007 Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel. Cisplatin 67-76 BCL2 apoptosis regulator Homo sapiens 0-5 17581297-2 2007 Interestingly, docetaxel as a standard of care for treatment of nonsmall cell lung cancer has been shown to inactivate the Bcl-2 function by phosphorylation. Docetaxel 15-24 BCL2 apoptosis regulator Homo sapiens 123-128 17581297-3 2007 We investigated the Bcl-2 expression status of nonsmall cell lung cancer cells in response to cisplatin or docetaxel and its effect on sensitizing nonsmall cell lung cancer cells by Bcl-2 downregulation employing a small interfering RNA approach. Cisplatin 94-103 BCL2 apoptosis regulator Homo sapiens 20-25 17581297-3 2007 We investigated the Bcl-2 expression status of nonsmall cell lung cancer cells in response to cisplatin or docetaxel and its effect on sensitizing nonsmall cell lung cancer cells by Bcl-2 downregulation employing a small interfering RNA approach. Docetaxel 107-116 BCL2 apoptosis regulator Homo sapiens 20-25 17560963-8 2007 Levels of the anti-apoptotic protein Bcl-2 was highly elevated in CEM/dEpoB300 cells and in these cells, ABZ was more effective in lowering the Bcl-2 levels than PTX. Albendazole 105-108 BCL2 apoptosis regulator Homo sapiens 37-42 17560963-8 2007 Levels of the anti-apoptotic protein Bcl-2 was highly elevated in CEM/dEpoB300 cells and in these cells, ABZ was more effective in lowering the Bcl-2 levels than PTX. Albendazole 105-108 BCL2 apoptosis regulator Homo sapiens 144-149 17560963-8 2007 Levels of the anti-apoptotic protein Bcl-2 was highly elevated in CEM/dEpoB300 cells and in these cells, ABZ was more effective in lowering the Bcl-2 levels than PTX. Paclitaxel 162-165 BCL2 apoptosis regulator Homo sapiens 37-42 17379544-7 2007 When the HeLa cells stably expressing Bcl-2 were treated with tunicamycin, endogenous RTN3 increased in the cell microsomal fraction. Tunicamycin 62-73 BCL2 apoptosis regulator Homo sapiens 38-43 17187253-11 2007 CONCLUSION: Our data indicate that flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIP(L) and this synergistic effect is Bcl-2 family independent. alvocidib 35-47 BCL2 apoptosis regulator Homo sapiens 138-143 17554207-0 2007 Induction of apoptosis in MCF-7 and MDA-MB-231 breast cancer cells by Oligonol is mediated by Bcl-2 family regulation and MEK/ERK signaling. oligonol 70-78 BCL2 apoptosis regulator Homo sapiens 94-99 17692808-5 2007 BH3 profiling identifies cells that require BCL-2 for survival and predicts sensitivity to the BCL-2 antagonist ABT-737. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 44-49 17692808-5 2007 BH3 profiling identifies cells that require BCL-2 for survival and predicts sensitivity to the BCL-2 antagonist ABT-737. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 95-100 17692808-5 2007 BH3 profiling identifies cells that require BCL-2 for survival and predicts sensitivity to the BCL-2 antagonist ABT-737. ABT-737 112-119 BCL2 apoptosis regulator Homo sapiens 95-100 17554207-5 2007 Treatment with 25 microg/ml Oligonol resulted in an activation of caspase-7 and up-regulation of Bad on MCF-7 cells, while the Oligonol (20 microg/ml) induced up-regulation of Bcl-2 protein in a time-response manner on MDA-MB-231 cells. oligonol 28-36 BCL2 apoptosis regulator Homo sapiens 176-181 17554207-5 2007 Treatment with 25 microg/ml Oligonol resulted in an activation of caspase-7 and up-regulation of Bad on MCF-7 cells, while the Oligonol (20 microg/ml) induced up-regulation of Bcl-2 protein in a time-response manner on MDA-MB-231 cells. oligonol 127-135 BCL2 apoptosis regulator Homo sapiens 176-181 17554207-7 2007 Oligonol triggers apoptosis in MCF-7 and MDA-MB-231 cells through the modulation of pro-apoptotic Bcl-2 family proteins and MEK/ERK signaling pathway. oligonol 0-8 BCL2 apoptosis regulator Homo sapiens 98-103 17671898-3 2007 An observance of the high antitumor efficiency of SL-pMMC was a result of its preferential accumulation in the tumor by the enhanced permeability and retention (EPR) effect, suppression of multidrug resistance (MDR) associated with P-glycoprotein and MRP drug efflux pumps, activation of caspase-dependent apoptosis signaling pathways and suppression of antiapoptotic cellular defense by increasing the BAX/BCL2 ratio. sl-pmmc 50-57 BCL2 apoptosis regulator Homo sapiens 407-411 17092697-6 2007 The growth stimulation of DPCs by EGCG in vitro may be mediated through the upregulations of phosphorylated Erk and Akt and by an increase in the ratio of Bcl-2/Bax ratio. dpcs 26-30 BCL2 apoptosis regulator Homo sapiens 155-160 17901590-8 2007 MTT assay demonstrated a significant dose-dependent inhibition of OE-19 cell growth by simvastatin, which also caused a significant reduction in Bcl-2 expression and an increase in Bax expression. Simvastatin 87-98 BCL2 apoptosis regulator Homo sapiens 145-150 17901590-4 2007 The aim of the present study was to analyze: 1) the impact of HMG-CoAR inhibitor, simvastatin, on human BA cell growth and 2) effect of simvastatin on apoptosis related proteins Bax/Bcl-2 and cyclooxygenase-2. Simvastatin 136-147 BCL2 apoptosis regulator Homo sapiens 182-187 17901590-8 2007 MTT assay demonstrated a significant dose-dependent inhibition of OE-19 cell growth by simvastatin, which also caused a significant reduction in Bcl-2 expression and an increase in Bax expression. monooxyethylene trimethylolpropane tristearate 0-3 BCL2 apoptosis regulator Homo sapiens 145-150 17187856-4 2007 N-Benzyladriamycin-14-valerate (AD 198) is a novel antitumor PKC activating agent that triggers rapid apoptosis through PKC-delta activation and mitochondrial depolarization in a manner that is unaffected by Bcl-2 expression. ad 32-34 BCL2 apoptosis regulator Homo sapiens 208-213 17554384-0 2007 BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 114-118 17554384-0 2007 BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. ABT-737 12-19 BCL2 apoptosis regulator Homo sapiens 114-118 17092697-6 2007 The growth stimulation of DPCs by EGCG in vitro may be mediated through the upregulations of phosphorylated Erk and Akt and by an increase in the ratio of Bcl-2/Bax ratio. epigallocatechin gallate 34-38 BCL2 apoptosis regulator Homo sapiens 155-160 17618565-1 2007 AIM: To study the combinational effects of bcl-2 antisense oligodeoxynucleotide (bcl-2 ASODN) and Rituximab (anti-CD20 monoclonal antibody) on proliferation and apoptosis of B-lymphoma Raji cells in vitro and in vivo, and to explore the possible mechanisms. Oligodeoxyribonucleotides 59-79 BCL2 apoptosis regulator Homo sapiens 81-86 17520660-8 2007 Surprisingly, treatment with TRAIL increased the levels of Bcl-2 by 50% in LNCaP-Bic cells. imidazole mustard 81-84 BCL2 apoptosis regulator Homo sapiens 59-64 17537404-4 2007 However, tumor cells that adapt to oxidative stress by increasing manganese superoxide dismutase (MnSOD), Prx I, and Bcl-2 showed drug resistance to 5-FU. Fluorouracil 149-153 BCL2 apoptosis regulator Homo sapiens 117-122 17708791-9 2007 According to flow cytometric analysis, the hyperthermia and adriamycin used alone or in combination could obviously increase the apoptosis rate and down-regulate Bcl-2 and P-gp expression of K562/AO2 cells (p < 0.01). Doxorubicin 60-70 BCL2 apoptosis regulator Homo sapiens 162-167 17708791-10 2007 It is concluded that the adriamycin chemotherapy combined with hyperthermia for 60 minutes shows obvious inhibitory effect on K562/AO2 cells, which increases the apoptosis rate and down-regulates expression of Bcl-2 and P-gp. Doxorubicin 25-35 BCL2 apoptosis regulator Homo sapiens 210-215 17708798-6 2007 The expressions of mdr1 mRNA and bcl-2 mRNA were decreased significantly by 10 micromol/L sodium selenite. Sodium Selenite 90-105 BCL2 apoptosis regulator Homo sapiens 33-38 17708798-7 2007 It is concluded that sodium selenite can reverse the multidrug resistance in K562/ADR partially by down-regulating the expressions of mdr1 mRNA and bcl-2 mRNA, and increasing apoptosis rate of K562/ADR cells. Sodium Selenite 21-36 BCL2 apoptosis regulator Homo sapiens 148-153 17708799-0 2007 [Effect of curcumin on expression of survivin, Bcl-2 and Bax in human multiple myeloma cell line]. Curcumin 11-19 BCL2 apoptosis regulator Homo sapiens 47-52 17708799-4 2007 RT-PCR showed that RPMI8226 cells expressed survivin, Bcl-2 strongly and Bax slightly; while RPMI8226 cells were treated with curcumin 10 micromol/L for 24 hours, the expressions of survivin, Bcl-2 mRNA were apparently down-regulated, and the expression of Bax mRNA was markedly up-regulated. Curcumin 126-134 BCL2 apoptosis regulator Homo sapiens 54-59 17708799-4 2007 RT-PCR showed that RPMI8226 cells expressed survivin, Bcl-2 strongly and Bax slightly; while RPMI8226 cells were treated with curcumin 10 micromol/L for 24 hours, the expressions of survivin, Bcl-2 mRNA were apparently down-regulated, and the expression of Bax mRNA was markedly up-regulated. Curcumin 126-134 BCL2 apoptosis regulator Homo sapiens 192-197 17708799-6 2007 The mechanism of antitumous effect of curcumin may be related to down-regulation of survivin, Bcl-2 mRNA and up-regulation of Bax mRNA. Curcumin 38-46 BCL2 apoptosis regulator Homo sapiens 94-99 18078134-9 2007 After 10 micromol/L mifepristone treatment, the expression of bcl-2 protein was decreased from (56 +/- 9)% to (37 +/- 6)% (P < 0.05), Bax and caspase-3 proteins was increased from (40 +/- 5)% to (87 +/- 10)% (P < 0.01), and from (36 +/- 7)% to (89 +/- 6)% (P < 0.01) respectively. Mifepristone 20-32 BCL2 apoptosis regulator Homo sapiens 62-67 17552510-0 2007 Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteins. Flavonoids 26-35 BCL2 apoptosis regulator Homo sapiens 112-117 17552510-1 2007 Structure-based strategy was employed to design flavonoid compounds to mimic the Bim BH3 peptide as a new class of inhibitors of the anti-apoptotic Bcl-2 proteins. Flavonoids 48-57 BCL2 apoptosis regulator Homo sapiens 148-153 17600621-5 2007 PAN-811 (3-aminopyridine-2-carboxaldehyde thiosemicarbazone), a novel neuroprotectant, elicits its function in primary neuronal cultures by upregulating Bcl-2 expression. 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 0-7 BCL2 apoptosis regulator Homo sapiens 153-158 17223257-2 2007 The imatinib-resistant K562/R1, -R2 and -R3 cells showed profound declines of Bcr-Abl level and concurrently exhibited up-regulation of Bcl-2 and Ku70/80, and down-regulation of Bax, DNA-PKcs and BRCA1, suggesting that loss of Bcr-Abl after exposure to imatinib might be accompanied by other cell survival mechanism. Imatinib Mesylate 4-12 BCL2 apoptosis regulator Homo sapiens 136-141 17600621-5 2007 PAN-811 (3-aminopyridine-2-carboxaldehyde thiosemicarbazone), a novel neuroprotectant, elicits its function in primary neuronal cultures by upregulating Bcl-2 expression. 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 9-59 BCL2 apoptosis regulator Homo sapiens 153-158 17600621-12 2007 Our results demonstrate that glutamate-induced phosphorylation of JNK and p38 MAPK is suppressed by PAN-811, which might contribute to Bcl-2 upregulation and PAN-811 neuroprotection. Glutamic Acid 29-38 BCL2 apoptosis regulator Homo sapiens 135-140 17610718-7 2007 Oxidative stress response genes diminish the activity of cantharidin by inducing DNA strand breaks which may be subject to base excision repair and induce apoptosis in a p53- and Bcl2-dependent manner. Cantharidin 57-68 BCL2 apoptosis regulator Homo sapiens 179-183 17596340-8 2007 Compared with normal, PAH PASMC had decreased Kv current and Kv1.5 expression and increased [Ca(2+)](i), [K(+)](i), mitochondrial potential (Delta Psi m), and bcl-2 levels. pasmc 26-31 BCL2 apoptosis regulator Homo sapiens 159-164 17616686-0 2007 Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells. propeptide 73-83 BCL2 apoptosis regulator Homo sapiens 14-18 17588342-8 2007 Furthermore, DHA induced apoptosis and G2 cell cycle arrest, accompanied by a decrease of Bcl-xL and Bcl-2 and an increase of Bax and Bad. artenimol 13-16 BCL2 apoptosis regulator Homo sapiens 101-106 16896168-8 2007 Additionally, downregulation of the B-cell lymphoma/leukemia-2 (Bcl-2) and Bcl-X(L) expression with simultaneous activation of caspase-3, -8, and -9 was observed in ECSCs after treatment with BAY 11-7085. BAY 11-7085 192-203 BCL2 apoptosis regulator Homo sapiens 36-62 16896168-8 2007 Additionally, downregulation of the B-cell lymphoma/leukemia-2 (Bcl-2) and Bcl-X(L) expression with simultaneous activation of caspase-3, -8, and -9 was observed in ECSCs after treatment with BAY 11-7085. BAY 11-7085 192-203 BCL2 apoptosis regulator Homo sapiens 64-69 17396262-1 2007 A novel small molecule inhibitor, 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide (MNB), competes with the Bak BH3 peptide to bind Bcl-2 protein with a binding affinity of IC(50) = 0.70 microM, as assessed by a fluorescence polarization based binding assay. 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide 34-92 BCL2 apoptosis regulator Homo sapiens 142-147 17396262-1 2007 A novel small molecule inhibitor, 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide (MNB), competes with the Bak BH3 peptide to bind Bcl-2 protein with a binding affinity of IC(50) = 0.70 microM, as assessed by a fluorescence polarization based binding assay. 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide 94-97 BCL2 apoptosis regulator Homo sapiens 142-147 17396262-1 2007 A novel small molecule inhibitor, 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide (MNB), competes with the Bak BH3 peptide to bind Bcl-2 protein with a binding affinity of IC(50) = 0.70 microM, as assessed by a fluorescence polarization based binding assay. bakuchiol 118-121 BCL2 apoptosis regulator Homo sapiens 142-147 17695552-3 2007 Western blot analysis was used to study celecoxib effects on the expression of mitogen-activated protein kinases (MAPKs), p53, p21, 14-3-4sigma, Bcl-2 and Bax. Celecoxib 40-49 BCL2 apoptosis regulator Homo sapiens 145-150 17695552-6 2007 Celecoxib had no effects on expression of MAPKs, Bax, or p21; however, it increased expression of p53 and 14-3-4sigma, and reduced expression of Bcl-2. Celecoxib 0-9 BCL2 apoptosis regulator Homo sapiens 145-150 17695552-9 2007 CONCLUSION: The results suggest that celecoxib induced cytotoxicity and apoptosis in this line of glioma cells and that such effects might be related to activation of p53 and 14-3-3sigma, reduced Bcl-2 and Bcl-2/Bax ratio, and increased caspace-3 activity. Celecoxib 37-46 BCL2 apoptosis regulator Homo sapiens 196-201 17695552-9 2007 CONCLUSION: The results suggest that celecoxib induced cytotoxicity and apoptosis in this line of glioma cells and that such effects might be related to activation of p53 and 14-3-3sigma, reduced Bcl-2 and Bcl-2/Bax ratio, and increased caspace-3 activity. Celecoxib 37-46 BCL2 apoptosis regulator Homo sapiens 206-211 17396262-0 2007 A novel Bcl-2 small molecule inhibitor 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide (MNB)-induced apoptosis in leukemia cells. 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide 39-97 BCL2 apoptosis regulator Homo sapiens 8-13 17396262-0 2007 A novel Bcl-2 small molecule inhibitor 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide (MNB)-induced apoptosis in leukemia cells. 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide 99-102 BCL2 apoptosis regulator Homo sapiens 8-13 17404493-3 2007 The IP(3)R antagonist xestospongin B induces autophagy in human cells through a pathway that requires the obligate contribution of Beclin-1, Atg5, Atg10, Atg12 and hVps34, yet is inhibited by ER-targeted Bcl-2 or Bcl-XL, two proteins that physically interact with IP(3)R. xestospongin B 22-36 BCL2 apoptosis regulator Homo sapiens 204-209 17438366-0 2007 BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 117-122 17438366-3 2007 The BH3 domains of other BH3-only proteins such as Bad, as well as BH3-mimetic compounds such as ABT737, competitively disrupt the inhibitory interaction between Beclin 1 and Bcl-2/Bcl-X(L). BH 3 4-7 BCL2 apoptosis regulator Homo sapiens 175-180 17438366-3 2007 The BH3 domains of other BH3-only proteins such as Bad, as well as BH3-mimetic compounds such as ABT737, competitively disrupt the inhibitory interaction between Beclin 1 and Bcl-2/Bcl-X(L). ABT-737 97-103 BCL2 apoptosis regulator Homo sapiens 175-180 17603173-0 2007 Beta-sitosterol induces anti-proliferation and apoptosis in human leukemic U937 cells through activation of caspase-3 and induction of Bax/Bcl-2 ratio. gamma-sitosterol 0-15 BCL2 apoptosis regulator Homo sapiens 139-144 17603173-5 2007 The increase in apoptosis induced by beta-sitosterol was associated with down-regulation of Bcl-2, degradation of poly-(ADP-ribose) polymerase (PARP) and phospholipase C (PLC)-gamma1 protein, and activation of caspase-3. gamma-sitosterol 37-52 BCL2 apoptosis regulator Homo sapiens 92-97 17603173-9 2007 Bcl-2 overexpression also significantly blocked caspase-3 activation and the decrease in PARP cleavage by beta-sitosterol, and effectively attenuated the apoptotic response to beta-sitosterol. gamma-sitosterol 106-121 BCL2 apoptosis regulator Homo sapiens 0-5 17603173-9 2007 Bcl-2 overexpression also significantly blocked caspase-3 activation and the decrease in PARP cleavage by beta-sitosterol, and effectively attenuated the apoptotic response to beta-sitosterol. gamma-sitosterol 176-191 BCL2 apoptosis regulator Homo sapiens 0-5 17603173-10 2007 These results show that beta-sitosterol potently induces apoptosis in U937 cells and that beta-sitosterol-induced apoptosis is related to the selective activation of caspase-3 and induction of Bax/Bcl-2 ratio. gamma-sitosterol 90-105 BCL2 apoptosis regulator Homo sapiens 197-202 17568189-5 2007 Biochemical examination revealed that pretreatment or cotreatment of carboplatin inhibited paclitaxel-induced IkappaBalpha degradation and bcl-2 phosphorylation. Carboplatin 69-80 BCL2 apoptosis regulator Homo sapiens 139-144 17568189-5 2007 Biochemical examination revealed that pretreatment or cotreatment of carboplatin inhibited paclitaxel-induced IkappaBalpha degradation and bcl-2 phosphorylation. Paclitaxel 91-101 BCL2 apoptosis regulator Homo sapiens 139-144 17436081-4 2007 In contrast, "alpha1,3FucT-VII" cells facilitated the apoptosis induced by all-trans retinoic acid (ATRA), which was verified by the greater sub-G1 (apoptotic cells) peak in flow cytometry analysis, more expressions of active caspase-3 and pro-apoptotic protein Bax, as well as less expressions of anti-apoptotic proteins, Bcl-2 and Bcl-X(L). Tretinoin 85-98 BCL2 apoptosis regulator Homo sapiens 323-328 17637928-0 2007 Acquisition of apoptotic resistance in cadmium-transformed human prostate epithelial cells: Bcl-2 overexpression blocks the activation of JNK signal transduction pathway. Cadmium 39-46 BCL2 apoptosis regulator Homo sapiens 92-97 17637928-10 2007 Mutation of tyrosine to serine at the 21st amino acid of the Bcl-2 protein BH4 domain resulted in a loss both of suppression of JNK1/2 phosphorylation and its anti-apoptotic function. Tyrosine 12-20 BCL2 apoptosis regulator Homo sapiens 61-66 17637928-10 2007 Mutation of tyrosine to serine at the 21st amino acid of the Bcl-2 protein BH4 domain resulted in a loss both of suppression of JNK1/2 phosphorylation and its anti-apoptotic function. Serine 24-30 BCL2 apoptosis regulator Homo sapiens 61-66 17637928-10 2007 Mutation of tyrosine to serine at the 21st amino acid of the Bcl-2 protein BH4 domain resulted in a loss both of suppression of JNK1/2 phosphorylation and its anti-apoptotic function. sapropterin 75-78 BCL2 apoptosis regulator Homo sapiens 61-66 17637928-11 2007 CONCLUSIONS: CTPE cells become resistant to apoptosis during malignant transformation, and disruption of the JNK pathway and Bcl-2 overexpression play important roles in this resistance. ctpe 13-17 BCL2 apoptosis regulator Homo sapiens 125-130 17637928-12 2007 Bcl-2 BH4 domain is required for modulating JNK phosphorylation and anti-apoptotic function. sapropterin 6-9 BCL2 apoptosis regulator Homo sapiens 0-5 17436081-4 2007 In contrast, "alpha1,3FucT-VII" cells facilitated the apoptosis induced by all-trans retinoic acid (ATRA), which was verified by the greater sub-G1 (apoptotic cells) peak in flow cytometry analysis, more expressions of active caspase-3 and pro-apoptotic protein Bax, as well as less expressions of anti-apoptotic proteins, Bcl-2 and Bcl-X(L). Tretinoin 100-104 BCL2 apoptosis regulator Homo sapiens 323-328 17760840-7 2007 The survival signal was also demonstrated by increased phosphorylation of serine/threonine-protein kinase B (AKT) and enhanced induction of expression of Bcl-2 during Ang II PC and its reversal with NAC & apocynin treated heart. Acetylcysteine 199-202 BCL2 apoptosis regulator Homo sapiens 154-159 17516089-5 2007 RESULTS: Ursolic acid inhibited significantly the cell viability and induced apoptosis in PC-3 cells at 55 microM and in LNCaP cells at 45 microM associated with a downregulation of bcl-2 protein. ursolic acid 9-21 BCL2 apoptosis regulator Homo sapiens 182-187 17359293-7 2007 Immunoprecipitation and Western blot analysis were performed to evaluate the effects of doxorubicin on phosphorylation of Bcl-2 antagonist of cell death (Bad) and protein kinase B (Akt/PKB). Doxorubicin 88-99 BCL2 apoptosis regulator Homo sapiens 122-127 17516089-3 2007 Our main objective was to investigate the effects of ursolic acid on cell viability, apoptosis and bcl-2 protein, in human hormone refractory and androgen-sensitive prostate cancer cells. ursolic acid 53-65 BCL2 apoptosis regulator Homo sapiens 99-104 17516089-4 2007 METHODS: The ursolic acid-induced changes in cell viability, apoptosis and bcl-2 protein were examined in human hormone refractory prostate cancer PC-3 cells and androgen-sensitive LNCaP cells, by MTT assay, flow cytometry and western blot analysis, respectively. ursolic acid 13-25 BCL2 apoptosis regulator Homo sapiens 75-80 17760840-7 2007 The survival signal was also demonstrated by increased phosphorylation of serine/threonine-protein kinase B (AKT) and enhanced induction of expression of Bcl-2 during Ang II PC and its reversal with NAC & apocynin treated heart. Adenosine Monophosphate 204-207 BCL2 apoptosis regulator Homo sapiens 154-159 17760840-7 2007 The survival signal was also demonstrated by increased phosphorylation of serine/threonine-protein kinase B (AKT) and enhanced induction of expression of Bcl-2 during Ang II PC and its reversal with NAC & apocynin treated heart. acetovanillone 209-217 BCL2 apoptosis regulator Homo sapiens 154-159 17400763-3 2007 In this study, we found that in human glioblastoma cells hypoxia induces the phosphorylation of the Bcl-2 family protein Bad, thus protecting hypoxic cells from paclitaxel-induced apoptosis. Paclitaxel 161-171 BCL2 apoptosis regulator Homo sapiens 100-105 17460700-0 2007 ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 25-30 17460700-2 2007 ABT-737 is a BH3 mimetic small-molecule inhibitor that binds with high affinity to Bcl-2 and Bcl-xL, preventing the sequestration of proapoptotic molecules and shifting the cell survival/apoptosis balance toward apoptosis induction. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 83-88 17460700-2 2007 ABT-737 is a BH3 mimetic small-molecule inhibitor that binds with high affinity to Bcl-2 and Bcl-xL, preventing the sequestration of proapoptotic molecules and shifting the cell survival/apoptosis balance toward apoptosis induction. BH 3 13-16 BCL2 apoptosis regulator Homo sapiens 83-88 17596214-7 2007 Curcumin-sensitized glioma cells to several clinically utilized chemotherapeutic agents (cisplatin, etoposide, camptothecin, and doxorubicin) and radiation, effects correlated with reduced expression of bcl-2 and IAP family members as well as DNA repair enzymes (MGMT, DNA-PK, Ku70, Ku80, and ERCC-1). Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 203-208 17516614-8 2007 A direct statistical correlation was observed between Fas and Bcl-2 expression on CD19+ B cells and SLE Disease Activity Index score. ammonium ferrous sulfate 54-57 BCL2 apoptosis regulator Homo sapiens 62-67 17599036-5 2007 GLA decreased the anti-oxidant content of tumor cells, expression of oncogenes ras, and Bcl-2, enhanced the activity of p53, protected normal cells and tissues from the toxic actions of radiation and anti-cancer drugs, enhanced the cytotoxic action of anti-cancer drugs and reversed tumor cell drug resistance. gamma-Linolenic Acid 0-3 BCL2 apoptosis regulator Homo sapiens 88-93 17620430-4 2007 In the human ovarian cancer ET(A)R-positive cell lines HEY, OVCA 433, SKOV-3, and A-2780, ZD4054 effectively inhibited the basal and ET-1-induced cell proliferation, associated with the inhibition of AKT and p42/44MAPK phosphorylation, and with increased apoptosis, through the inhibition of bcl-2 and activation of caspase-3 and poly(ADP-ribose) polymerase proteins. ZD4054 90-96 BCL2 apoptosis regulator Homo sapiens 292-297 17470554-8 2007 Our data also revealed that Bcl-2 regulates N-methyl-N"-nitro-N"-nitrosoguanidine-induced necrosis. Methylnitronitrosoguanidine 44-81 BCL2 apoptosis regulator Homo sapiens 28-33 17475221-9 2007 Furthermore, 2-Phenyl-4-quinolone induced the Mcl-1 cleavage, the phosphorylation of Bcl-2 and Bcl-xL (12-h treatment), and the caspase activation including caspase-8, -2 and -3 (24-h treatment). 2-phenyl-4-oxohydroquinoline 13-33 BCL2 apoptosis regulator Homo sapiens 85-90 17401658-1 2007 The present study investigates the correlation between the hypoxia-induced phosphorylation of cyclic AMP response element binding protein and the expression of apoptotic proteins (proapoptotic proteins Bax and Bad and antiapoptotic proteins Bcl-2 and Bcl-xl) during hypoxia in the cerebral cortex of newborn piglets. Cyclic AMP 94-104 BCL2 apoptosis regulator Homo sapiens 241-246 17549355-5 2007 In the group of patients after chemotherapy positive correlation between primary tumors and lymph node metastases in case of Bcl-2 and Bak proteins (p<0.04, r=0.424; p<0.02, r=0.478, respectively) was observed. bakuchiol 135-138 BCL2 apoptosis regulator Homo sapiens 125-130 17603292-7 2007 Resveratrol pretreatment led to a decrease in cleavage of PARP, an increase in the Bcl-2 protein, and activation of caspase-3. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 83-88 17620439-5 2007 Enhancement of rhTRAIL-induced apoptosis by bortezomib was caspase dependent, implicating extrinsic as well as intrinsic apoptosis activation, as shown by increased processing of caspase-8 as well as caspase-9, and could be abrogated completely by overexpression of caspase-8 inhibitor cytokine response modifier A (CrmA), and partially by overexpression of Bcl-2. Bortezomib 44-54 BCL2 apoptosis regulator Homo sapiens 358-363 17475221-13 2007 Furthermore, participation of cell-cycle regulators, Bcl-2 family of proteins, activation of caspases and release of AIF may mutually cross-regulate the apoptotic signaling cascades induced by 2-phenyl-4-quinolone. 2-phenyl-4-oxohydroquinoline 193-213 BCL2 apoptosis regulator Homo sapiens 53-58 17396132-3 2007 Inhibition of the proteasome by lactacystin prevented ER stress-induced degradation of Bcl-2, release of cytochrome c, processing of effector caspase-3, and exposure of phosphatidylserine. lactacystin 32-43 BCL2 apoptosis regulator Homo sapiens 87-92 17182178-7 2007 An HLA-A*0201 restricted CTL epitope was deduced in silica from the amino acid sequence of the Bcl2 protein and its binding affinity for HLA-A*0201 was confirmed using a biochemical binding assay. Silicon Dioxide 52-58 BCL2 apoptosis regulator Homo sapiens 95-99 17349619-5 2007 The mechanisms by which salidroside protected neuron cells from oxidative stress included the induction of several antioxidant enzymes, thioredoxin, heme oxygenase-1, and peroxiredoxin-I; the downregulation of pro-apoptotic gene Bax and the upregulation of anti-apoptotic genes Bcl-2 and Bcl-X(L). rhodioloside 24-35 BCL2 apoptosis regulator Homo sapiens 278-283 17311906-10 2007 Preincubating cells with the proteasome inhibitor MG-132 or lactacystin not only restored cisplatin-induced loss of Mcl-1 but also resulted in an accumulation of Mcl-1 that exceeded basal levels; however, Bcl-2 and BclxL levels did not change in response to MG-132 or lactacystin. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 50-56 BCL2 apoptosis regulator Homo sapiens 205-210 17258915-5 2007 Furthermore, tea polyphenols transduced the apoptosis signal via generation of reactive oxygen species and decrease in the Bcl-2/Bax ratio thereby inducing mitochondrial permeability transition with consequent activation of caspase-3. Polyphenols 17-28 BCL2 apoptosis regulator Homo sapiens 123-128 17173063-0 2007 "Seed" analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. ABT-737 131-138 BCL2 apoptosis regulator Homo sapiens 108-113 17173063-1 2007 ABT-737 is a subnanomolar inhibitor of the antiapoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 66-71 17311906-10 2007 Preincubating cells with the proteasome inhibitor MG-132 or lactacystin not only restored cisplatin-induced loss of Mcl-1 but also resulted in an accumulation of Mcl-1 that exceeded basal levels; however, Bcl-2 and BclxL levels did not change in response to MG-132 or lactacystin. lactacystin 60-71 BCL2 apoptosis regulator Homo sapiens 205-210 17547520-4 2007 Results of a Phase I/II study have shown that reducing Bcl-2 with oblimersen coincident with the administration of dacarbazine may amplify apoptosis and improve therapeutic outcome. Dacarbazine 115-126 BCL2 apoptosis regulator Homo sapiens 55-60 17847938-6 2007 The value of bcl-2 showed a statistically significant increase in the group of patients treated with PUVA therapy (p = 0.001) and an increase in the control group, demonstrating enhanced keratinocyte apoptosis after treatment. puva 101-105 BCL2 apoptosis regulator Homo sapiens 13-18 17544840-4 2007 Intracellular galectin-3 in particular, which contains the NWGR anti-death motif of the Bcl-2 family, inhibits cell apoptosis induced by chemotherapeutic agent such as cisplatin and etoposide in some types of cancer cells. Cisplatin 168-177 BCL2 apoptosis regulator Homo sapiens 88-93 17544840-4 2007 Intracellular galectin-3 in particular, which contains the NWGR anti-death motif of the Bcl-2 family, inhibits cell apoptosis induced by chemotherapeutic agent such as cisplatin and etoposide in some types of cancer cells. Etoposide 182-191 BCL2 apoptosis regulator Homo sapiens 88-93 17545623-5 2007 Consequently, we investigated the role of Bcl-2 family members in bortezomib-induced apoptosis. Bortezomib 66-76 BCL2 apoptosis regulator Homo sapiens 42-47 17545631-5 2007 By treating CML cells with imatinib, we could show that the resulting inhibition of BCR-ABL leads to a decreased expression of tumor antigens, including survivin, adipophilin, hTERT, WT-1, Bcl-x(L), and Bcl-2 in correlation to a decreased development of CML-specific CTLs. Imatinib Mesylate 27-35 BCL2 apoptosis regulator Homo sapiens 203-208 17540004-7 2007 The suppressive effect of S/ER-targeted Bcl-2 was in part due to the depletion of S/ER calcium stores. Calcium 87-94 BCL2 apoptosis regulator Homo sapiens 40-45 17540004-9 2007 In cells expressing Bcl-2-ER, thapsigargin maximally reduced autophagic flux. Thapsigargin 30-42 BCL2 apoptosis regulator Homo sapiens 20-25 17540004-10 2007 Thus, our results demonstrate that Bcl-2 negatively regulated the autophagic response at the level of S/ER calcium content rather than via direct interaction with Beclin 1. Calcium 107-114 BCL2 apoptosis regulator Homo sapiens 35-40 17487378-0 2007 The interactive transcript abundance index [c-myc*p73alpha]/[p21*Bcl-2] correlates with baseline level of apoptosis and response to CPT-11 in human bronchogenic carcinoma cell lines. Irinotecan 132-138 BCL2 apoptosis regulator Homo sapiens 65-70 17487363-6 2007 4-PB induced increased expression of genes of DNA damage checkpoints and of apoptosis via the down-regulation of anti-apoptotic bcl-2 mRNA expression and up-regulation of the activity of the apoptosis-associated enzyme caspase-3/7. 4-phenylbutyric acid 0-4 BCL2 apoptosis regulator Homo sapiens 128-133 17487378-6 2007 In addition, the interactive transcript abundance index (ITAI) [c-myc*p73alpha]/[p21*Bcl-2] was directly correlated with baseline apoptosis (p<0.01) and CPT-11 response (p<0.05). Irinotecan 156-162 BCL2 apoptosis regulator Homo sapiens 85-90 17392282-0 2007 Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 74-79 17392282-6 2007 Curcumin down-regulated the Bax level while augmenting Bcl-2 expression in these cells, thereby protecting the immunocytes from tumor-induced apoptosis. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 55-60 17383050-6 2007 Taurolidine but not PVP-I treatment resulted in p53 activation in 2/3 MPM cell lines and a decrease in the protein levels of survivin, Bcl-2 and Mcl-1. taurolidine 0-11 BCL2 apoptosis regulator Homo sapiens 135-140 17671763-5 2007 DFO induced apoptosis of activated HSCs, which was associated with decreasing Bcl-2 expression and the release of cytochrome c from the mitochondria to the cytosol with enhanced caspase-3 activity. Deferoxamine 0-3 BCL2 apoptosis regulator Homo sapiens 78-83 17409148-0 2007 Bcl-2 blocks accretion or depletion of stored calcium but has no effect on the redistribution of IP3 receptor I mediated by glycoprotein E of herpes simplex virus 1. Calcium 46-53 BCL2 apoptosis regulator Homo sapiens 0-5 17409148-11 2007 (ii) Apoptosis, the calcium stores, and cytopathic effects are regulated by Bcl-2. Calcium 20-27 BCL2 apoptosis regulator Homo sapiens 76-81 17577773-9 2007 IPI score was similar in both BCL-2 positive and negative cases. diprotin A 0-3 BCL2 apoptosis regulator Homo sapiens 30-35 17575115-7 2007 Our data show that Bcl-2 can protect antiestrogen-resistant breast cancer cells from cisplatin-induced cell death, indicating that the reduced expression of Bcl-2 in the antiestrogen-resistant cells plays a role in sensitizing the cells to cisplatin treatment. Cisplatin 85-94 BCL2 apoptosis regulator Homo sapiens 19-24 17371841-4 2007 We show that increased glucose metabolism protected cells against the proapoptotic Bcl-2 family protein Bim and attenuated degradation of the antiapoptotic Bcl-2 family protein Mcl-1. Glucose 23-30 BCL2 apoptosis regulator Homo sapiens 83-88 17371841-4 2007 We show that increased glucose metabolism protected cells against the proapoptotic Bcl-2 family protein Bim and attenuated degradation of the antiapoptotic Bcl-2 family protein Mcl-1. Glucose 23-30 BCL2 apoptosis regulator Homo sapiens 156-161 17371841-8 2007 These data provide a novel nutrient-sensitive mechanism linking glucose metabolism and Bcl-2 family proteins via GSK-3 that may promote survival of cells with high rates of glucose utilization, such as growth factor-stimulated or cancerous cells. Glucose 64-71 BCL2 apoptosis regulator Homo sapiens 87-92 17371841-8 2007 These data provide a novel nutrient-sensitive mechanism linking glucose metabolism and Bcl-2 family proteins via GSK-3 that may promote survival of cells with high rates of glucose utilization, such as growth factor-stimulated or cancerous cells. Glucose 173-180 BCL2 apoptosis regulator Homo sapiens 87-92 17575115-7 2007 Our data show that Bcl-2 can protect antiestrogen-resistant breast cancer cells from cisplatin-induced cell death, indicating that the reduced expression of Bcl-2 in the antiestrogen-resistant cells plays a role in sensitizing the cells to cisplatin treatment. Cisplatin 240-249 BCL2 apoptosis regulator Homo sapiens 157-162 17575115-7 2007 Our data show that Bcl-2 can protect antiestrogen-resistant breast cancer cells from cisplatin-induced cell death, indicating that the reduced expression of Bcl-2 in the antiestrogen-resistant cells plays a role in sensitizing the cells to cisplatin treatment. Cisplatin 85-94 BCL2 apoptosis regulator Homo sapiens 157-162 17575115-7 2007 Our data show that Bcl-2 can protect antiestrogen-resistant breast cancer cells from cisplatin-induced cell death, indicating that the reduced expression of Bcl-2 in the antiestrogen-resistant cells plays a role in sensitizing the cells to cisplatin treatment. Cisplatin 240-249 BCL2 apoptosis regulator Homo sapiens 19-24 17446862-5 2007 The pharmacological BH3 mimetic ABT737 competitively inhibits the interaction between Beclin-1 and Bcl-2/Bcl-X(L), antagonizes autophagy inhibition by Bcl-2/Bcl-X(L) and hence stimulates autophagy. BH 3 20-23 BCL2 apoptosis regulator Homo sapiens 99-104 17520521-5 2007 Treatment with ATA caused a drastic prevention of apoptosis and the gypenosides-mediated mitochondrial Bcl-2 decrease and Bax increase, but failed to inhibit ROS generation and MPT dysfunction. Amitrole 15-18 BCL2 apoptosis regulator Homo sapiens 103-108 17520521-8 2007 Buffering of the intracellular Ca(2+) increase with a Ca(2+) chelator BAMTA/AM blocked the gypenosides-elicited ERK inactivation, ROS generation, Bcl-2/Bax redistribution, mitochondrial dysfunction, and apoptosis. bamta 70-75 BCL2 apoptosis regulator Homo sapiens 146-151 17672346-3 2007 RESULT: ASMq flavonoids significantly inhibited growth of HepG2 cells in vitro, arrested HepG2 in the sub-G, phase, induced cell apoptosis and significantly down-regulated expression level of Bcl-2 mRNA, and up-regulated expression of p53, p21, Bax gene mRNA expressions. asmq flavonoids 8-23 BCL2 apoptosis regulator Homo sapiens 192-197 17446862-5 2007 The pharmacological BH3 mimetic ABT737 competitively inhibits the interaction between Beclin-1 and Bcl-2/Bcl-X(L), antagonizes autophagy inhibition by Bcl-2/Bcl-X(L) and hence stimulates autophagy. BH 3 20-23 BCL2 apoptosis regulator Homo sapiens 151-156 17446862-5 2007 The pharmacological BH3 mimetic ABT737 competitively inhibits the interaction between Beclin-1 and Bcl-2/Bcl-X(L), antagonizes autophagy inhibition by Bcl-2/Bcl-X(L) and hence stimulates autophagy. ABT-737 32-38 BCL2 apoptosis regulator Homo sapiens 99-104 17446862-5 2007 The pharmacological BH3 mimetic ABT737 competitively inhibits the interaction between Beclin-1 and Bcl-2/Bcl-X(L), antagonizes autophagy inhibition by Bcl-2/Bcl-X(L) and hence stimulates autophagy. ABT-737 32-38 BCL2 apoptosis regulator Homo sapiens 151-156 17227835-3 2007 The new small-molecule pan-Bcl-2 inhibitor GX15-070 mimics BH3-only proteins by binding to multiple antiapoptotic Bcl-2 members. obatoclax 43-51 BCL2 apoptosis regulator Homo sapiens 27-32 17227835-3 2007 The new small-molecule pan-Bcl-2 inhibitor GX15-070 mimics BH3-only proteins by binding to multiple antiapoptotic Bcl-2 members. obatoclax 43-51 BCL2 apoptosis regulator Homo sapiens 114-119 17446862-9 2007 BH3-only proteins and pharmacological BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin-1 and Bcl-2 or Bcl-X(L). BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 133-138 17510419-7 2007 We further showed that honokiol induced a CypD-regulated death in primary human acute myelogenous leukemia cells, overcame Bcl-2 and Bcl-X(L)-mediated apoptotic resistance, and was effective against HL60 cells in a pilot in vivo study. honokiol 23-31 BCL2 apoptosis regulator Homo sapiens 123-128 17505005-8 2007 Capsaicin down-regulated the expression of the STAT3-regulated gene products, such as cyclin D1, Bcl-2, Bcl-xL, survivin, and vascular endothelial growth factor. Capsaicin 0-9 BCL2 apoptosis regulator Homo sapiens 97-102 17510421-5 2007 We found that 10 micromol/L celecoxib reduced P-glycoprotein, Bcl-x(L), and Bcl-2 expression, and induced translocation of Bax from cytosol to mitochondria and cytochrome c release into cytosol in MDR-positive hepatocellular carcinoma cells. Celecoxib 28-37 BCL2 apoptosis regulator Homo sapiens 76-81 17005319-0 2007 Sanguinarine induces apoptosis of human pancreatic carcinoma AsPC-1 and BxPC-3 cells via modulations in Bcl-2 family proteins. sanguinarine 0-12 BCL2 apoptosis regulator Homo sapiens 104-109 17442357-0 2007 Nitric oxide and bcl-2 mediated the apoptosis induced by nickel(II) in human T hybridoma cells. Nickel(2+) 57-67 BCL2 apoptosis regulator Homo sapiens 17-22 17442357-6 2007 Induction of apoptotic cell death by nickel was mediated by reduction of bcl-2 expression. Nickel 37-43 BCL2 apoptosis regulator Homo sapiens 73-78 17442357-8 2007 These results suggest that nickel(II) chloride induces jurkat cells apoptosis via nitric oxide generation, mitochondrial depolarization and bcl-2 suppression. nickel chloride 27-46 BCL2 apoptosis regulator Homo sapiens 140-145 17510430-7 2007 Cells treated with the combination of PDT and 17-AAG exhibited decreased expression of the Hsp-90 client proteins phosphorylated survivin, phosphorylated Akt, and Bcl-2. tanespimycin 46-52 BCL2 apoptosis regulator Homo sapiens 163-168 17005319-6 2007 Further, sanguinarine-treatment to AsPC-1 and BxPC-3 cells resulted in a dose dependent (i) increase in pro-apoptotic Bax, Bid and Bak proteins; (ii) decrease in anti-apoptotic Bcl-2 and Bcl-X(L) proteins; and (iii) decrease in p53 with an increase in its phosphorylation. sanguinarine 9-21 BCL2 apoptosis regulator Homo sapiens 177-182 17426447-5 2007 NG-18-induced tumor cell apoptosis was associated with up-regulation of pro-apoptotic Bcl-2 family member Bax, and downregulation of anti-apoptotic protein Bcl-2. ng-18 0-5 BCL2 apoptosis regulator Homo sapiens 86-91 17456670-2 2007 We tested the hypothesis that the potent, prototypical sigma(1)-receptor agonist, 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP), protects neurons by a mechanism involving the antiapoptotic protein bcl-2. 4-phenyl-1-(4-phenylbutyl)piperidine 82-119 BCL2 apoptosis regulator Homo sapiens 196-201 17456670-2 2007 We tested the hypothesis that the potent, prototypical sigma(1)-receptor agonist, 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP), protects neurons by a mechanism involving the antiapoptotic protein bcl-2. 4-phenyl-1-(4-phenylbutyl)piperidine 121-125 BCL2 apoptosis regulator Homo sapiens 196-201 17456670-10 2007 PPBP"s ability to preserve bcl-2 protein after OGD by PPBP was fully abolished by rimcazole. rimcazole 82-91 BCL2 apoptosis regulator Homo sapiens 27-32 17473426-9 2007 In addition, 3-MA application downregulated DNA ladder and Bax expression but upregulated Bcl-2 expression, compared with oridonin alone treatment. 3-methyladenine 13-17 BCL2 apoptosis regulator Homo sapiens 90-95 17387269-8 2007 Our results suggest that Bcl-2 and survivin are two important proteins that may determine cells" response to DTX/PS-341-induced apoptosis. Docetaxel 109-112 BCL2 apoptosis regulator Homo sapiens 25-30 17387269-8 2007 Our results suggest that Bcl-2 and survivin are two important proteins that may determine cells" response to DTX/PS-341-induced apoptosis. Bortezomib 113-119 BCL2 apoptosis regulator Homo sapiens 25-30 17313401-2 2007 The aims of this study were to (1) determine whether there are differences between AD patients and healthy subjects in SsAg-induced caspase-3 activation and SsAg-induced changes of anti-apoptotic protein Bcl-2 and Bcl-2 mRNA levels of CD4+ T cells; (2) investigate the effect of interleukin (IL)-4 on SsAg-induced caspase-3 activation and SsAg-induced changes of Bcl-2 and Bcl-2 mRNA levels of CD4+ T cells. ssag 157-161 BCL2 apoptosis regulator Homo sapiens 204-209 17313401-2 2007 The aims of this study were to (1) determine whether there are differences between AD patients and healthy subjects in SsAg-induced caspase-3 activation and SsAg-induced changes of anti-apoptotic protein Bcl-2 and Bcl-2 mRNA levels of CD4+ T cells; (2) investigate the effect of interleukin (IL)-4 on SsAg-induced caspase-3 activation and SsAg-induced changes of Bcl-2 and Bcl-2 mRNA levels of CD4+ T cells. ssag 157-161 BCL2 apoptosis regulator Homo sapiens 214-219 17313401-2 2007 The aims of this study were to (1) determine whether there are differences between AD patients and healthy subjects in SsAg-induced caspase-3 activation and SsAg-induced changes of anti-apoptotic protein Bcl-2 and Bcl-2 mRNA levels of CD4+ T cells; (2) investigate the effect of interleukin (IL)-4 on SsAg-induced caspase-3 activation and SsAg-induced changes of Bcl-2 and Bcl-2 mRNA levels of CD4+ T cells. ssag 157-161 BCL2 apoptosis regulator Homo sapiens 214-219 17313401-2 2007 The aims of this study were to (1) determine whether there are differences between AD patients and healthy subjects in SsAg-induced caspase-3 activation and SsAg-induced changes of anti-apoptotic protein Bcl-2 and Bcl-2 mRNA levels of CD4+ T cells; (2) investigate the effect of interleukin (IL)-4 on SsAg-induced caspase-3 activation and SsAg-induced changes of Bcl-2 and Bcl-2 mRNA levels of CD4+ T cells. ssag 157-161 BCL2 apoptosis regulator Homo sapiens 214-219 17452997-0 2007 Bcl-2 cleavages at two adjacent sites by different caspases promote cisplatin-induced apoptosis. Cisplatin 68-77 BCL2 apoptosis regulator Homo sapiens 0-5 17426447-5 2007 NG-18-induced tumor cell apoptosis was associated with up-regulation of pro-apoptotic Bcl-2 family member Bax, and downregulation of anti-apoptotic protein Bcl-2. ng-18 0-5 BCL2 apoptosis regulator Homo sapiens 156-161 17452997-3 2007 We report herein that Bcl-2 protein was cleaved to produce two fragments of around 23 kDa in human hepatocarcinoma BEL-7404 cells or in Bcl-2 overexpressing CHO cells induced by cisplatin. Cisplatin 178-187 BCL2 apoptosis regulator Homo sapiens 22-27 17452997-3 2007 We report herein that Bcl-2 protein was cleaved to produce two fragments of around 23 kDa in human hepatocarcinoma BEL-7404 cells or in Bcl-2 overexpressing CHO cells induced by cisplatin. Cisplatin 178-187 BCL2 apoptosis regulator Homo sapiens 136-141 17457195-8 2007 The 90 mM NaCl high saline medium notably increased release of cytochrome c and Smac/DIABLO from mitochondria; activated caspase-3, JNK and ERK; stimulated mRNA expression of interleukin-1-converting enzyme and Bax; and reduced Bcl2 expression. Sodium Chloride 10-14 BCL2 apoptosis regulator Homo sapiens 228-232 17452997-4 2007 Treating cells with the general caspase inhibitor z-VAD-fmk blocked the induced cleavage of Bcl-2. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 50-59 BCL2 apoptosis regulator Homo sapiens 92-97 17452997-7 2007 These results indicate that Bcl-2 can be cleaved into two close fragments by different caspases during cisplatin-induced apoptosis, both of which contribute to the acceleration of apoptotic process. Cisplatin 103-112 BCL2 apoptosis regulator Homo sapiens 28-33 17439414-10 2007 The MTT results demonstrated that Bcl-2 and Bcl-xl transfected cells exhibited increased sensitivity to 5-FU or HCPT. monooxyethylene trimethylolpropane tristearate 4-7 BCL2 apoptosis regulator Homo sapiens 34-39 17439414-10 2007 The MTT results demonstrated that Bcl-2 and Bcl-xl transfected cells exhibited increased sensitivity to 5-FU or HCPT. Fluorouracil 104-108 BCL2 apoptosis regulator Homo sapiens 34-39 17439414-10 2007 The MTT results demonstrated that Bcl-2 and Bcl-xl transfected cells exhibited increased sensitivity to 5-FU or HCPT. 10-hydroxycamptothecin 112-116 BCL2 apoptosis regulator Homo sapiens 34-39 18645600-6 2007 V(D)J RSS have also been identified in certain proto-oncogenes like bcl-2 that are involved in translocations associated with the development of human lymphomas and in other genes such as hypoxanthine-guainine phosphoribosyl transferase (HPRT) in which deletion mutations and intron rearrangements are a common phenomenon. RSS 6-9 BCL2 apoptosis regulator Homo sapiens 68-73 17457195-8 2007 The 90 mM NaCl high saline medium notably increased release of cytochrome c and Smac/DIABLO from mitochondria; activated caspase-3, JNK and ERK; stimulated mRNA expression of interleukin-1-converting enzyme and Bax; and reduced Bcl2 expression. Sodium Chloride 20-26 BCL2 apoptosis regulator Homo sapiens 228-232 17454142-4 2007 Enforced expression of Bcl-2 has no effect on 4-HPR-induced oxidative stress, but notably prevents mitochondrial alterations and apoptosis, indicating that Bcl-2 functions by regulating events downstream of ROS generation. Reactive Oxygen Species 207-210 BCL2 apoptosis regulator Homo sapiens 23-28 17454142-4 2007 Enforced expression of Bcl-2 has no effect on 4-HPR-induced oxidative stress, but notably prevents mitochondrial alterations and apoptosis, indicating that Bcl-2 functions by regulating events downstream of ROS generation. Reactive Oxygen Species 207-210 BCL2 apoptosis regulator Homo sapiens 156-161 17230521-5 2007 By comparison of the parental HNE1 and its derivative HNE1-T3 cell lines, we found that the resistance to taxol in HNE1-T3 cells was associated with suppression of taxol-induced apoptosis evidenced by decreased expression of Bak and Bax and increased Bcl-2, as well as inhibition of PARP and caspase cleavage and DNA ladder formation. Paclitaxel 106-111 BCL2 apoptosis regulator Homo sapiens 251-256 17220163-5 2007 In contrast, the percentage of TUNEL-positive cells was significantly increased and Bcl-2 protein expression was significantly decreased by treatment with 10(-9) M raloxifene, whereas they were not affected by treatment with either 10(-8) or 10(-7) M raloxifene. Raloxifene Hydrochloride 164-174 BCL2 apoptosis regulator Homo sapiens 84-89 17230521-5 2007 By comparison of the parental HNE1 and its derivative HNE1-T3 cell lines, we found that the resistance to taxol in HNE1-T3 cells was associated with suppression of taxol-induced apoptosis evidenced by decreased expression of Bak and Bax and increased Bcl-2, as well as inhibition of PARP and caspase cleavage and DNA ladder formation. Paclitaxel 164-169 BCL2 apoptosis regulator Homo sapiens 251-256 17390014-7 2007 Western blot analysis showed that the proliferating cell nuclear antigen (PCNA) and Bcl-XL with sequence homology to Bcl-2 were significantly suppressed by As4O6. Arsenic Trioxide 156-161 BCL2 apoptosis regulator Homo sapiens 117-122 17446929-7 2007 Thus, in response to treatment with cisplatin, but not other chemotherapeutic agents, TAp73 underwent c-Abl-dependent phosphorylation, which promoted dissociation of the DeltaNp63alpha/TAp73 protein complex, TAp73-dependent transcription of proapoptotic Bcl-2 family members, and apoptosis. Cisplatin 36-45 BCL2 apoptosis regulator Homo sapiens 254-259 17472673-0 2007 Apoptosis, P53 and Bcl-2 expression in response to topical calcipotriol therapy for psoriasis. calcipotriene 59-71 BCL2 apoptosis regulator Homo sapiens 19-24 17472673-6 2007 RESULTS: After topical calcipotriol therapy, keratinocytes of psoriatic skin showed significant decrease of P53 (P = 0.002) and increase of Bcl-2 (P = 0.01) expression. calcipotriene 23-35 BCL2 apoptosis regulator Homo sapiens 140-145 17437889-5 2007 RESULTS: P-27 (60% +/- 20.13), p-16 (62.00% +/- 10.85), and bcl-2 (46.00% +/- 42.47) were highly expressed in Spitz nevi, whereas Ki-67 (2.80% +/- 2.55), Rb (3.75% +/- 4.55), p-53 (2.30% +/- 0.10), cyclin A (0.70% +/- 1.56), B1 (0.20% +/- 0.34), and bax (2.65% +/- 6.37) demonstrated a limited expression. Rubidium 154-156 BCL2 apoptosis regulator Homo sapiens 60-65 17192846-0 2007 R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. tipifarnib 9-18 BCL2 apoptosis regulator Homo sapiens 154-159 17192846-0 2007 R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. Zoledronic Acid 20-35 BCL2 apoptosis regulator Homo sapiens 154-159 17192846-0 2007 R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. Zoledronic Acid 37-43 BCL2 apoptosis regulator Homo sapiens 154-159 17289836-9 2007 Because expression of antiapoptotic Bcl-2, Bcl-xL, and X-chromosome-linked inhibitor of apoptosis protein (XIAP) is regulated by NF-kappaB, both curcumin and SH-6 decreased the levels of these proteins in PC3 cells through inhibition of NF-kappaB. Curcumin 145-153 BCL2 apoptosis regulator Homo sapiens 36-41 17262823-0 2007 Pretreatment with low nitric oxide protects osteoblasts from high nitric oxide-induced apoptotic insults through regulation of c-Jun N-terminal kinase/c-Jun-mediated Bcl-2 gene expression and protein translocation. Nitric Oxide 22-34 BCL2 apoptosis regulator Homo sapiens 166-171 17262823-0 2007 Pretreatment with low nitric oxide protects osteoblasts from high nitric oxide-induced apoptotic insults through regulation of c-Jun N-terminal kinase/c-Jun-mediated Bcl-2 gene expression and protein translocation. Nitric Oxide 66-78 BCL2 apoptosis regulator Homo sapiens 166-171 17267584-6 2007 Pioglitazone (100 microM) induced apoptosis in human VSMC from diabetic and nondiabetic patients (NDP), analyzed by DNA fragmentation and by degradation of Bcl-2, in high-glucose-containing medium (15 and 25 mM). Pioglitazone 0-12 BCL2 apoptosis regulator Homo sapiens 156-161 17289836-11 2007 Collectively, these data define a pathway whereby curcumin sensitizes prostate cancer cells to TRAIL by inhibiting Akt-regulated NF-kappaB and NF-kappaB-dependent antiapoptotic Bcl-2, Bcl-xL, and XIAP. Curcumin 50-58 BCL2 apoptosis regulator Homo sapiens 177-182 17452531-0 2007 Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak. BH 3 41-44 BCL2 apoptosis regulator Homo sapiens 83-88 17428192-6 2007 The effect of LIUS on the apoptotic event was further demonstrated by changes in the expression of apoptosis/viability related genes of p53, bax, bcl-2, and PCNA. lius 14-18 BCL2 apoptosis regulator Homo sapiens 146-151 17378556-6 2007 An alternative route to borane-phosphinimide complexes involves Me3SiCl elimination, as exemplified by the reaction of BCl2Ph with n-Bu3PNSiMe3, which gives the product n-Bu3PNBCl(Ph) (9). borane-phosphinimide 24-44 BCL2 apoptosis regulator Homo sapiens 119-123 17378556-6 2007 An alternative route to borane-phosphinimide complexes involves Me3SiCl elimination, as exemplified by the reaction of BCl2Ph with n-Bu3PNSiMe3, which gives the product n-Bu3PNBCl(Ph) (9). n-bu3pnsime3 131-143 BCL2 apoptosis regulator Homo sapiens 119-123 17378556-6 2007 An alternative route to borane-phosphinimide complexes involves Me3SiCl elimination, as exemplified by the reaction of BCl2Ph with n-Bu3PNSiMe3, which gives the product n-Bu3PNBCl(Ph) (9). n-bu3pnbcl 169-179 BCL2 apoptosis regulator Homo sapiens 119-123 17097281-12 2007 After treatment with swainsonine at the concentrations of 0.5, 1.5 and 4.5 microg/ml for 24 h, the expression of apoptosis inhibiting gene p53 and bcl-2 decreases, and the apoptotic trigger gene c-myc increases markedly (p<0.05), as well as [Ca2+]i overloading, SGC-7901 cell is induced to apoptosis in the end. Swainsonine 21-32 BCL2 apoptosis regulator Homo sapiens 147-152 17571308-9 2007 The results of Western blot indicated that DMF induced the activation of caspase-3, increased the ratio of Bax/Bcl-2 and downregulated the expression of phosphate-p38. Dimethylformamide 43-46 BCL2 apoptosis regulator Homo sapiens 111-116 17350598-4 2007 Tetrocarcin A affected neither expression of Akt, PDK1, or PTEN, nor did it affect the expression of Bcl family members including Bcl-2, Bcl-X(L), and Bax. tetrocarcin A 0-13 BCL2 apoptosis regulator Homo sapiens 130-135 16963181-6 2007 Rugosin E increased in the expression of Bax, Bak, and Bcl-Xs, but decreased the levels of Bcl-2 and Bcl-X(L), and subsequently triggered mitochondria apoptotic pathway (release of cytochrome c, activation of caspase-9, and caspase-3). rugosin E 0-9 BCL2 apoptosis regulator Homo sapiens 91-96 16963181-9 2007 Furthermore, rugosin E also inhibited the TNF-alpha-activated NF-kappaB-dependent reporter gene expression of cyclin D1, c-Myc, XIAP, Bcl-2, and Bcl-X(L) were all downregulated by rugosin E. rugosin E 13-22 BCL2 apoptosis regulator Homo sapiens 134-139 17430582-0 2007 Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Doxorubicin 97-108 BCL2 apoptosis regulator Homo sapiens 27-32 17378545-0 2007 Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins. Pyrogallol 0-10 BCL2 apoptosis regulator Homo sapiens 69-74 17440101-7 2007 Conversely, loss of p53 and p21 alleles had a counter effect on both BAX and Bcl-2 expression and the p53-null and p21-null cells were significantly resistant to the antiproliferative and apoptotic effects of noscapine. Noscapine 209-218 BCL2 apoptosis regulator Homo sapiens 77-82 17442993-0 2007 Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children"s Oncology Group Study. Oligonucleotides 42-57 BCL2 apoptosis regulator Homo sapiens 26-31 17430582-0 2007 Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Cyclophosphamide 113-129 BCL2 apoptosis regulator Homo sapiens 27-32 17430582-0 2007 Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Paclitaxel 142-152 BCL2 apoptosis regulator Homo sapiens 27-32 17430582-13 2007 Moreover, OS was significantly affected by ER, bcl-2 and c-erbB2. Osmium 10-12 BCL2 apoptosis regulator Homo sapiens 47-52 17407577-0 2007 Zerumbone induced apoptosis in liver cancer cells via modulation of Bax/Bcl-2 ratio. zerumbone 0-9 BCL2 apoptosis regulator Homo sapiens 72-77 17016430-0 2007 A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. ABT-737 39-46 BCL2 apoptosis regulator Homo sapiens 8-13 17016430-2 2007 Here we characterized the effects of ABT-737, a potent small-molecule inhibitor of antiapoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w with markedly higher affinity than previously reported compounds, on human MM cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 37-40 BCL2 apoptosis regulator Homo sapiens 106-111 17016430-9 2007 Taken together, our study provides the rationale for clinical protocols evaluating ABT-737, alone and together with botezomib, mephalan or dexamethasone, to enhance MM cell killing, overcome drug resistance conferred by Bcl-2 and improve patient outcome in MM. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 83-86 BCL2 apoptosis regulator Homo sapiens 220-225 17407577-10 2007 CONCLUSION: Therefore, zerumbone was found to induce the apoptotic process in HepG2 cells through the up and down regulation of Bax/Bcl-2 protein independently of functional p53 activity. zerumbone 23-32 BCL2 apoptosis regulator Homo sapiens 132-137 17376296-10 2007 The anti-apoptotic protein (Bcl-2) expression in H460 cells altered by 39% with downregulation, and the p53 protein by 25% with upregulation after being cultured with 2.0 micromol/L AZ4 for 48 h. In a time-dependent manner, the expression of the p53 and p21 proteins were increased to the maximum at 24 h, and then decreased at 48. az4 182-185 BCL2 apoptosis regulator Homo sapiens 28-33 17430651-5 2007 The expression of Bcl-2 was measured by FCM using fluorescein isothiocyanate (FITC)-conjugated anti-bcl-2 antibodies. Fluorescein-5-isothiocyanate 50-76 BCL2 apoptosis regulator Homo sapiens 18-23 17409392-1 2007 ABT-737 targets Bcl-2/Bcl-xL but not Mcl-1, which confers resistance to this novel agent. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 16-21 17430651-5 2007 The expression of Bcl-2 was measured by FCM using fluorescein isothiocyanate (FITC)-conjugated anti-bcl-2 antibodies. Fluorescein-5-isothiocyanate 78-82 BCL2 apoptosis regulator Homo sapiens 18-23 17430651-5 2007 The expression of Bcl-2 was measured by FCM using fluorescein isothiocyanate (FITC)-conjugated anti-bcl-2 antibodies. Fluorescein-5-isothiocyanate 78-82 BCL2 apoptosis regulator Homo sapiens 100-105 17135295-1 2007 G3139, an antisense Bcl-2 phosphorothioate oligodeoxyribonucleotide, induces apoptosis in melanoma and other cancer cells. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 20-25 17135295-1 2007 G3139, an antisense Bcl-2 phosphorothioate oligodeoxyribonucleotide, induces apoptosis in melanoma and other cancer cells. Parathion 26-42 BCL2 apoptosis regulator Homo sapiens 20-25 17135295-1 2007 G3139, an antisense Bcl-2 phosphorothioate oligodeoxyribonucleotide, induces apoptosis in melanoma and other cancer cells. Oligodeoxyribonucleotides 43-67 BCL2 apoptosis regulator Homo sapiens 20-25 17019560-10 2007 TBT exposure alters neither pro-apoptotic proteins Bax and p53 nor anti-apoptotic protein Bcl-2 levels at any exposure studied. tributyltin 0-3 BCL2 apoptosis regulator Homo sapiens 90-95 17371290-5 2007 Seizures cause mitochondrial dysfunction and activate intrinsic pathway components including pro-apoptotic Bcl-2 family proteins and caspases, processes that may be partly calcium-induced. Calcium 172-179 BCL2 apoptosis regulator Homo sapiens 107-112 17454636-7 2007 SKY analysis also identified a translocation involving chromosome band 18q21, to which BCL2 and MALT1 genes were assigned, suggesting their implication in the development or progression of SMZL. smzl 189-193 BCL2 apoptosis regulator Homo sapiens 87-91 17241114-0 2007 Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. Simvastatin 0-11 BCL2 apoptosis regulator Homo sapiens 64-69 17241114-3 2007 Recent in vivo studies from our lab reported the novel finding that simvastatin increased expression levels of a gene encoding for a major cell survival protein, bcl-2 [Johnson-Anuna et al., J. Pharmacol. Simvastatin 68-79 BCL2 apoptosis regulator Homo sapiens 162-167 17241114-6 2007 The purpose of the present experiments was to determine if simvastatin could protect neurons from excitotoxicity by altering Bcl-2 levels. Simvastatin 59-70 BCL2 apoptosis regulator Homo sapiens 125-130 17241114-9 2007 In addition, chronic simvastatin treatment significantly increased Bcl-2 mRNA and protein levels while challenge resulted in a significant reduction in Bcl-2 protein abundance. Simvastatin 21-32 BCL2 apoptosis regulator Homo sapiens 67-72 17241114-9 2007 In addition, chronic simvastatin treatment significantly increased Bcl-2 mRNA and protein levels while challenge resulted in a significant reduction in Bcl-2 protein abundance. Simvastatin 21-32 BCL2 apoptosis regulator Homo sapiens 152-157 17241114-10 2007 G3139, an antisense oligonucleotide directed against Bcl-2, abolished the protective effects of simvastatin and eliminated simvastatin-induced up-regulation of Bcl-2 protein. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 53-58 17241114-10 2007 G3139, an antisense oligonucleotide directed against Bcl-2, abolished the protective effects of simvastatin and eliminated simvastatin-induced up-regulation of Bcl-2 protein. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 160-165 17241114-10 2007 G3139, an antisense oligonucleotide directed against Bcl-2, abolished the protective effects of simvastatin and eliminated simvastatin-induced up-regulation of Bcl-2 protein. Oligonucleotides 20-35 BCL2 apoptosis regulator Homo sapiens 53-58 17241114-10 2007 G3139, an antisense oligonucleotide directed against Bcl-2, abolished the protective effects of simvastatin and eliminated simvastatin-induced up-regulation of Bcl-2 protein. Simvastatin 96-107 BCL2 apoptosis regulator Homo sapiens 53-58 17241114-10 2007 G3139, an antisense oligonucleotide directed against Bcl-2, abolished the protective effects of simvastatin and eliminated simvastatin-induced up-regulation of Bcl-2 protein. Simvastatin 123-134 BCL2 apoptosis regulator Homo sapiens 53-58 17241114-10 2007 G3139, an antisense oligonucleotide directed against Bcl-2, abolished the protective effects of simvastatin and eliminated simvastatin-induced up-regulation of Bcl-2 protein. Simvastatin 123-134 BCL2 apoptosis regulator Homo sapiens 160-165 17241114-11 2007 These findings suggest that neuroprotection by simvastatin is dependent on the drug"s previously unexplored and important effect of up-regulating Bcl-2. Simvastatin 47-58 BCL2 apoptosis regulator Homo sapiens 146-151 17287256-2 2007 In particular, the overexpression of Bcl-2-family members interferes with apoptosis initiation by DNA-damaging agents (e.g., cisplatin) or soluble death ligands (e.g., TRAIL). Cisplatin 125-134 BCL2 apoptosis regulator Homo sapiens 37-42 17332930-0 2007 Involvement of Bcl-2 family members, phosphatidylinositol 3"-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Curcumin 97-105 BCL2 apoptosis regulator Homo sapiens 15-20 17332930-0 2007 Involvement of Bcl-2 family members, phosphatidylinositol 3"-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. diferulolylmethane 107-125 BCL2 apoptosis regulator Homo sapiens 15-20 17332930-4 2007 Curcumin downregulated the expression of Bcl-2, and Bcl-XL and upregulated the expression of p53, Bax, Bak, PUMA, Noxa, and Bim. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 41-46 17998729-8 2007 Western blotting showed a decrease in bcl-2 and an increase in Bax in A427 cell cultured with 5,7-dimethoxy-4-p-methoxylphenylcoumarin or 5,7-dimethoxy-4-phenylcoumarin. 5,7,4'-Trimethoxy-4-phenylcoumarin 94-134 BCL2 apoptosis regulator Homo sapiens 38-43 17998729-8 2007 Western blotting showed a decrease in bcl-2 and an increase in Bax in A427 cell cultured with 5,7-dimethoxy-4-p-methoxylphenylcoumarin or 5,7-dimethoxy-4-phenylcoumarin. 5,7-Dimethoxy-4-phenyl-chromen-2-one 138-168 BCL2 apoptosis regulator Homo sapiens 38-43 17449938-7 2007 In addition, minoxidil plus ATRA elevated phosphorylated Erk, phosphorylated Akt and the ratio of Bcl-2/Bax, but decreased the expressions of P53 and P21 more effectively than by minoxidil alone. Minoxidil 13-22 BCL2 apoptosis regulator Homo sapiens 98-103 17449938-7 2007 In addition, minoxidil plus ATRA elevated phosphorylated Erk, phosphorylated Akt and the ratio of Bcl-2/Bax, but decreased the expressions of P53 and P21 more effectively than by minoxidil alone. Tretinoin 28-32 BCL2 apoptosis regulator Homo sapiens 98-103 17449938-8 2007 Our results suggest that minoxidil plus ATRA would additively enhance hair growth by mediating dual functions: 1) the prolongation of cell survival by activating the Erk and Akt signaling pathways, and 2) the prevention of apoptosis of DPCs and epithelial cells by increasing the ratio of Bcl-2/Bax and downregulating the expressions of P53 and P21. Minoxidil 25-34 BCL2 apoptosis regulator Homo sapiens 289-294 17449938-8 2007 Our results suggest that minoxidil plus ATRA would additively enhance hair growth by mediating dual functions: 1) the prolongation of cell survival by activating the Erk and Akt signaling pathways, and 2) the prevention of apoptosis of DPCs and epithelial cells by increasing the ratio of Bcl-2/Bax and downregulating the expressions of P53 and P21. Tretinoin 40-44 BCL2 apoptosis regulator Homo sapiens 289-294 17545017-6 2007 The apoptosis rate of chondrocytes in BUT+ selenium group was significantly lower than that of BUT groups (P<0.05), as was the positivity rate of Bcl-2 and Bax expression (P<0.05). Selenium 43-51 BCL2 apoptosis regulator Homo sapiens 149-154 17426248-4 2007 A Bcl-2 antagonist, ABT-737, has recently been discovered and shown to induce regression of solid tumors, but its activity is limited to a fraction of small-cell lung carcinoma (SCLC) models tested. ABT-737 20-27 BCL2 apoptosis regulator Homo sapiens 2-7 17052885-7 2007 Furthermore, when cells were transfected with pcDNA3/Bcl-2 before exposed to CdCl(2), alleviated apoptosis was assessed by part of the apoptotic features in this study. cdcl 77-81 BCL2 apoptosis regulator Homo sapiens 53-58 17342322-6 2007 Nevertheless, celecoxib at both concentrations induced a strong NFkappaB activation, with increased expression of NFkappaB-dependent genes, such as bcl-2, bcl-XL and survivin. Celecoxib 14-23 BCL2 apoptosis regulator Homo sapiens 148-153 17259174-4 2007 Exposure of cells to nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone results in accumulation of Bcl2 in the nucleus, which interacts with hMSH6 but not hMSH2 via its BH4 domain. SCHEMBL420028 21-79 BCL2 apoptosis regulator Homo sapiens 107-111 17331842-9 2007 CONCLUSION: Rapamycin has significant anti-proliferation effect by induction of apoptosis via activation of caspase-3 and disruption of mitochondrial membrane potential, as well as by down-regulation of anti-apoptotic protein Bcl-2 and up-regulation of pro-apoptotic protein Bcl-xl on hepatocellular carcinoma cells. Sirolimus 12-21 BCL2 apoptosis regulator Homo sapiens 226-231 17461445-9 2007 Meanwhile, the expression of Bax and PPARgamma was up-regulated, while the expression of Bcl-2 was down regulated in HT-29 cells treated with rosiglitazone in a time-dependent manner. Rosiglitazone 142-155 BCL2 apoptosis regulator Homo sapiens 89-94 17461445-10 2007 However, the effect of rosiglitazone on Bcl-2 and Bax was blocked or diminished in the presence of GW9662. Rosiglitazone 23-36 BCL2 apoptosis regulator Homo sapiens 40-45 17461445-10 2007 However, the effect of rosiglitazone on Bcl-2 and Bax was blocked or diminished in the presence of GW9662. 2-chloro-5-nitrobenzanilide 99-105 BCL2 apoptosis regulator Homo sapiens 40-45 17335970-8 2007 Besides, 5-ALA-PDT caused increase in Bax:Bcl-2 ratio and mitochondrial release of cytochrome c and apoptosis-inducing factor (AIF). 5-amino levulinic acid 9-14 BCL2 apoptosis regulator Homo sapiens 42-47 17105820-5 2007 Overexpression of antiapoptosis protein Bcl-2 in AML cells was directly correlated with p53 expression and phosphorylation on serine residues 15, 46, and 392. Serine 126-132 BCL2 apoptosis regulator Homo sapiens 40-45 17259174-4 2007 Exposure of cells to nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone results in accumulation of Bcl2 in the nucleus, which interacts with hMSH6 but not hMSH2 via its BH4 domain. sapropterin 177-180 BCL2 apoptosis regulator Homo sapiens 107-111 17465228-0 2007 Regulation of p53-, Bcl-2- and caspase-dependent signaling pathway in xanthorrhizol-induced apoptosis of HepG2 hepatoma cells. xanthorrhizol 70-83 BCL2 apoptosis regulator Homo sapiens 20-25 17195091-4 2007 We show that Bcl-2 but not caspase inhibition prevented staurosporine-induced intracellular acidification. Staurosporine 56-69 BCL2 apoptosis regulator Homo sapiens 13-18 17465228-6 2007 The apoptosis mediated by xanthorrhizol in the HepG2 cells was associated with the activation of tumor suppressor p53 and down-regulation of antiapoptotic Bcl-2 protein expression, but not Bax. xanthorrhizol 26-39 BCL2 apoptosis regulator Homo sapiens 155-160 17465228-7 2007 The levels of Bcl-2 protein expression decreased 24-h after treatment with xanthorrhizol and remained lower than controls throughout the experiment, resulting in a shift in the Bax to Bcl-2 ratio thus favouring apoptosis. xanthorrhizol 75-88 BCL2 apoptosis regulator Homo sapiens 14-19 17465228-7 2007 The levels of Bcl-2 protein expression decreased 24-h after treatment with xanthorrhizol and remained lower than controls throughout the experiment, resulting in a shift in the Bax to Bcl-2 ratio thus favouring apoptosis. xanthorrhizol 75-88 BCL2 apoptosis regulator Homo sapiens 184-189 17359382-11 2007 Histamine also up-regulated the expression of Bcl-2 and Mcl-1, and inhibited the activation of caspase-3. Histamine 0-9 BCL2 apoptosis regulator Homo sapiens 46-51 17077328-5 2007 Finally, we identify disruption of Bcl-2-dependent mitochondrial homeostasis as a possible point of convergence for the proapoptotic synergism observed with retinoids and MEK inhibitors. Retinoids 157-166 BCL2 apoptosis regulator Homo sapiens 35-40 17471026-0 2007 Targeted therapies for epithelial cancers: in vivo efficacy of the BCL-2/BCL-XL inhibitor 2-MeAA. 2-methoxyantimycin 90-96 BCL2 apoptosis regulator Homo sapiens 67-72 17476138-9 2007 FK228 inhibited a variety of EGFR-related pathways including Src, RAF-MEK-extracellular signal-regulated kinase (ERK) 1/2 and phosphatidyl inositol-3 kinase (PI3K)/AKT, resulting in down-regulation of Bcl-2 and Bcl-xL and up-regulation of Bax. romidepsin 0-5 BCL2 apoptosis regulator Homo sapiens 201-206 17573055-3 2007 Corresponding to the opposite effects of Dex on granulocyte apoptosis, we demonstrate that in neutrophils and eosinophils Dex oppositely affects expression of the anti-apoptotic Bcl-2 family protein Mcl-1L. Dexamethasone 41-44 BCL2 apoptosis regulator Homo sapiens 178-183 17573055-3 2007 Corresponding to the opposite effects of Dex on granulocyte apoptosis, we demonstrate that in neutrophils and eosinophils Dex oppositely affects expression of the anti-apoptotic Bcl-2 family protein Mcl-1L. Dexamethasone 122-125 BCL2 apoptosis regulator Homo sapiens 178-183 17050058-10 2007 Baicalein-induced apoptosis were also accompanied by decreasing in Bcl-2 and proform of caspase-3 and increasing p53 and Bax protein levels. baicalein 0-9 BCL2 apoptosis regulator Homo sapiens 67-72 17138646-7 2007 Estradiol treatment increases basal phosphorylation of both ERK1 and ERK2 in hippocampal CA1 and prevents ischemia-induced dephosphorylation and inactivation of ERK1 and CREB, down-regulation of Bcl-2 and activation of the caspase death cascade. Estradiol 0-9 BCL2 apoptosis regulator Homo sapiens 195-200 17138646-8 2007 Whereas ERK/MAPK signaling is critical to CREB activation and neuronal survival, the impact of estradiol on Bcl-2 levels is ERK independent. Estradiol 95-104 BCL2 apoptosis regulator Homo sapiens 108-113 17050787-7 2007 In LNCaP and PC-3, the apoptosis induced by resveratrol was mediated by activation of caspases 9 and 3 and a change in the ratio of bax/bcl-2. Resveratrol 44-55 BCL2 apoptosis regulator Homo sapiens 136-141 17273761-7 2007 On the other hand, GA down-regulated anti-apoptosis proteins such as Bcl-2 and Xiap. Gallic Acid 19-21 BCL2 apoptosis regulator Homo sapiens 69-74 17378914-0 2007 bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells. gemcitabine 30-41 BCL2 apoptosis regulator Homo sapiens 0-5 17131386-4 2007 We further show that MG-induced apoptosis of osteoblasts involves specific apoptotic biochemical changes, including oxidative stress, c-Jun N-terminal kinase (JNK) activation, mitochondrial membrane potential changes, cytochrome C release, increased Bax/Bcl-2 protein ratios, and activation of caspases (caspase-9, caspase-3) and p21-activated protein kinase 2 (PAK2). Pyruvaldehyde 21-23 BCL2 apoptosis regulator Homo sapiens 254-259 17298978-4 2007 By contrast, Bax translocation, mitochondrial membrane damage and reactive oxygen species (ROS) production were inversely correlated with the changes of survivin and Bcl-2. Reactive Oxygen Species 66-89 BCL2 apoptosis regulator Homo sapiens 166-171 17298978-4 2007 By contrast, Bax translocation, mitochondrial membrane damage and reactive oxygen species (ROS) production were inversely correlated with the changes of survivin and Bcl-2. Reactive Oxygen Species 91-94 BCL2 apoptosis regulator Homo sapiens 166-171 17378914-1 2007 Gemcitabine has been shown to ameliorate disease related symptoms and to prolong overall survival in pancreatic cancer.Yet, resistance to Gemcitabine is commonly observed in this tumour entity and has been linked to increased expression of anti-apoptotic bcl-2. gemcitabine 0-11 BCL2 apoptosis regulator Homo sapiens 255-260 17378914-1 2007 Gemcitabine has been shown to ameliorate disease related symptoms and to prolong overall survival in pancreatic cancer.Yet, resistance to Gemcitabine is commonly observed in this tumour entity and has been linked to increased expression of anti-apoptotic bcl-2. gemcitabine 138-149 BCL2 apoptosis regulator Homo sapiens 255-260 17378914-2 2007 We therefore investigated if and to what extend silencing of bcl-2 by specific siRNAs (siBCL2) might enhance Gemcitabine effects in human pancreatic carcinoma cells. gemcitabine 109-120 BCL2 apoptosis regulator Homo sapiens 61-66 17286744-4 2007 Upregulation of Bax and downregulation of Bcl-2 was also observed upon melatonin treatment. Melatonin 71-80 BCL2 apoptosis regulator Homo sapiens 42-47 17367069-8 2007 In the animal model, irinotecan treatment led to a statistically significant decrease in tumor growth that was accompanied by a decrease in Bcl-2 and survivin levels and an increase in apoptotic cell death. Irinotecan 21-31 BCL2 apoptosis regulator Homo sapiens 140-145 17286744-6 2007 Together, our results suggest that melatonin reduces the viability of HL-60 cells via induction of apoptosis primarily through regulation of Bax/Bcl-2 expression. Melatonin 35-44 BCL2 apoptosis regulator Homo sapiens 145-150 17311012-6 2007 Using a similar assay, killing of A02 cells by the cytotoxic T-lymphocyte clone 1H3 was shown to be amplified by coexposure to the potent small-molecule Bcl-2 inhibitor ABT-737. ABT-737 169-176 BCL2 apoptosis regulator Homo sapiens 153-158 17339367-4 2007 Activation of apoptosis by sulforaphane in MDA-MB-231 cells seemed to be initiated through induction of Fas ligand, which resulted in activation of caspase-8, caspase-3, and poly(ADP-ribose) polymerase, whereas apoptosis in the other breast cancer cell lines was initiated by decreased Bcl-2 expression, release of cytochrome c into the cytosol, activation of caspase-9 and caspase-3, but not caspase-8, and poly(ADP-ribose) polymerase cleavage. sulforaphane 27-39 BCL2 apoptosis regulator Homo sapiens 286-291 17268850-6 2007 Furthermore, salsolinol decreased the levels of the anti-apoptotic protein Bcl-2, and increased pro-apoptotic protein Bax, while enhancing the release of cytochrome-c from mitochondria. salsolinol 13-23 BCL2 apoptosis regulator Homo sapiens 75-80 17311012-7 2007 Experiments with immune effectors preincubated with concanamycin-A suggested that sensitisation to perforin/granzyme-B may underlie enhanced target-cell killing observed in the presence of Bcl-2 inhibitors. concanamycin A 52-66 BCL2 apoptosis regulator Homo sapiens 189-194 17196186-0 2007 Effects of ex vivo transduction of mesencephalic reaggregates with bcl-2 on grafted dopamine neuron survival. Dopamine 84-92 BCL2 apoptosis regulator Homo sapiens 67-72 16909112-4 2007 Gene expression analysis identified the proapoptotic Bcl-2 family members, Bmf and Bim, as induced by TGFbeta, dependent on both Smad4 and p38 function and the generation of reactive oxygen species. Reactive Oxygen Species 174-197 BCL2 apoptosis regulator Homo sapiens 53-58 17317842-10 2007 Docetaxel-induced JNK activation was required for Bcl-2 phosphorylation as well as caspase-2-dependent activation of Bax and Bak and subsequent mitochondrial release of apoptosis-inducing factor and cytochrome c. Docetaxel 0-9 BCL2 apoptosis regulator Homo sapiens 50-55 17266988-4 2007 Our results suggested that the protective effects of rosiglitazone on MPP(+) induced apoptosis may be ascribed to its anti-oxidative properties, anti-apoptotic activity via inducing expression of SOD and catalase and regulating the expression of Bcl-2 and Bax. Rosiglitazone 53-66 BCL2 apoptosis regulator Homo sapiens 246-251 17203500-7 2007 We have discovered that C3, the meso-zinc(II) complex is an extremely efficient regulator of the cell cycle and anti-apoptosis genes bcl-2 and bcl-xL. meso-zinc(ii) 32-45 BCL2 apoptosis regulator Homo sapiens 133-138 17287517-2 2007 Here, we report that 17beta-estradiol (E2) selectively regulates neuronal expression of the Bcl-2 family (bcl-2, bcl-x, bcl-w, bax, bak, bad, bik, bnip3, bid, and bim). Estradiol 21-37 BCL2 apoptosis regulator Homo sapiens 92-97 17287517-2 2007 Here, we report that 17beta-estradiol (E2) selectively regulates neuronal expression of the Bcl-2 family (bcl-2, bcl-x, bcl-w, bax, bak, bad, bik, bnip3, bid, and bim). Estradiol 21-37 BCL2 apoptosis regulator Homo sapiens 106-111 17308121-8 2007 In immunoglobulin-high cells, bortezomib increased the levels of proapoptotic Bax while reducing antiapoptotic Bcl-2. Bortezomib 30-40 BCL2 apoptosis regulator Homo sapiens 111-116 17186423-6 2007 8-day boric acid pre-exposure enhanced the toxicity of ionizing radiation treatment, while dose-dependently decreasing the expression of anti-apoptotic protein Bcl-2. boric acid 6-16 BCL2 apoptosis regulator Homo sapiens 160-165 17283153-0 2007 Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 99-102 BCL2 apoptosis regulator Homo sapiens 13-18 17224645-4 2007 The purpose of this study is to evaluate the efficacy of bcl2/bcl-x(L) inhibitor, 2-methoxy antimycin A3, in inducing apoptosis and increasing chemo-sensitivity in vitro and in vivo. 2-methoxy antimycin a3 82-104 BCL2 apoptosis regulator Homo sapiens 57-61 17224645-11 2007 Together, these findings indicate that exposure of cancer cells to small molecule Bcl-2/x(L) inhibitors such as 2-methoxy antimycin A3 alone, or in the combination with other chemotherapeutics, may represent a novel therapeutic strategy in treatment of cancer, especially mesothelioma. 2-methoxy antimycin a3 112-134 BCL2 apoptosis regulator Homo sapiens 82-87 17283153-1 2007 ABT-737 is a novel and potent Bcl-2 antagonist with single-agent activity against small-cell lung cancer (SCLC) cell lines. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 30-35 17283153-2 2007 Here, we evaluated the contribution of Bcl-2 family members to the in vitro cellular response of several SCLC cell lines to ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 124-127 BCL2 apoptosis regulator Homo sapiens 39-44 17283153-4 2007 Conversely, a progressive decrease in the relative levels of Bcl-2 and Noxa and a progressive increase in Mcl-1 levels characterized the increased resistance of H146 cells following chronic exposure to ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 202-205 BCL2 apoptosis regulator Homo sapiens 61-66 17283153-8 2007 Thus, SCLC cells sensitive to ABT-737 expressed the target proteins Bcl-2 and Bcl-X(L), whereas Mcl-1 and factors regulating Mcl-1 function seem to contribute to the overall resistance of SCLC cells to ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 30-33 BCL2 apoptosis regulator Homo sapiens 68-73 17090688-8 2007 Collectively, these data indicate that Rac1 is critical in differentiation of CD4-SP from the DP cell line by preventing TCR-induced apoptosis via Bcl-2 up-regulation. dp 94-96 BCL2 apoptosis regulator Homo sapiens 147-152 17276336-0 2007 Bcl-2-regulated calcium signals as common mediators of both apoptosis and autophagy. Calcium 16-23 BCL2 apoptosis regulator Homo sapiens 0-5 17276336-1 2007 The calcium ion, a major intracellular second messenger, is a known mediator of apoptosis and is regulated by the antiapoptotic protein Bcl-2. Calcium 4-11 BCL2 apoptosis regulator Homo sapiens 136-141 17276336-3 2007 (2007) in the current issue of Molecular Cell indicates that calcium also mediates the induction of macroautophagy in a Bcl-2 regulated fashion and identifies a signaling pathway through which calcium exerts its action. Calcium 61-68 BCL2 apoptosis regulator Homo sapiens 120-125 17276336-3 2007 (2007) in the current issue of Molecular Cell indicates that calcium also mediates the induction of macroautophagy in a Bcl-2 regulated fashion and identifies a signaling pathway through which calcium exerts its action. Calcium 193-200 BCL2 apoptosis regulator Homo sapiens 120-125 17049940-11 2007 CONCLUSIONS: Ponicidin has significant anti-proliferation effects by inducing apoptosis on hepatocellular carcinoma cells in vitro, down regulation of Survivin and Bcl-2 as well as upregualation of Bax expressions may be the important apoptotic inducing mechanisms. ponicidin 13-22 BCL2 apoptosis regulator Homo sapiens 164-169 17046747-4 2007 Using a preclinical model of tamoxifen-resistant growth, we found overexpression of c-Myc in all (3/3) and of Bcl-2 in most (2/3) tamoxifen resistant-breast cancer variants. Tamoxifen 29-38 BCL2 apoptosis regulator Homo sapiens 110-115 17046747-4 2007 Using a preclinical model of tamoxifen-resistant growth, we found overexpression of c-Myc in all (3/3) and of Bcl-2 in most (2/3) tamoxifen resistant-breast cancer variants. Tamoxifen 130-139 BCL2 apoptosis regulator Homo sapiens 110-115 17357444-1 2007 HEK293 cell was chose to study the kidney damage of cadmium and to explore the significance of caspase 3,Bcl-2 and AIF (apoptosis inducing factor) in the apoptosis of cells induced by cadmium. Cadmium 184-191 BCL2 apoptosis regulator Homo sapiens 105-110 17203211-3 2007 In this study, we have demonstrated that As2O3, at clinically achievable therapeutic concentrations, induces apoptosis in Bcl-2 negative human B cell line Ramos. Arsenic Trioxide 41-46 BCL2 apoptosis regulator Homo sapiens 122-127 17077270-0 2007 Stabilization of cellular mRNAs and up-regulation of proteins by oligoribonucleotides homologous to the Bcl2 adenine-uridine rich element motif. adenine-uridine 109-124 BCL2 apoptosis regulator Homo sapiens 104-108 17030058-4 2007 A higher Bcl-2/Bax relative ratio in PCOSE and HPCOSE was observed, in absence of active Caspase-3 and scarce DNA fragmentation in the four groups of endometria studied. pcose 37-42 BCL2 apoptosis regulator Homo sapiens 9-14 17030058-4 2007 A higher Bcl-2/Bax relative ratio in PCOSE and HPCOSE was observed, in absence of active Caspase-3 and scarce DNA fragmentation in the four groups of endometria studied. hpcose 47-53 BCL2 apoptosis regulator Homo sapiens 9-14 17156797-2 2007 Using a co-immunoprecipitation assay, it was observed that the level of Bcl-X(L) protein bound to Bax was clearly lower than that of Bcl-2 protein at 5 micro M of gossypol treatment, and the level of Bim protein bound to Bcl-X(L) was lowered at 20 micro M of gossypol treatment for 24 h, implicating that gossypol inhibits the heterodimerization of Bcl-X(L) with Bax and Bim. Gossypol 163-171 BCL2 apoptosis regulator Homo sapiens 133-138 17262884-0 2007 Involvement of MAPK, Bcl-2 family, cytochrome c, and caspases in induction of apoptosis by 1,6-O,O-diacetylbritannilactone in human leukemia cells. O, O-diacetylbritannilactone 91-122 BCL2 apoptosis regulator Homo sapiens 21-26 17235304-1 2007 G3139 (Genasense), an 18mer phosphorothioate antisense oligonucleotide targeted to the initiation codon region of the Bcl-2 messenger RNA (mRNA), downregulates Bcl-2 protein and mRNA expression in many cell lines. Parathion 28-44 BCL2 apoptosis regulator Homo sapiens 160-165 17235304-1 2007 G3139 (Genasense), an 18mer phosphorothioate antisense oligonucleotide targeted to the initiation codon region of the Bcl-2 messenger RNA (mRNA), downregulates Bcl-2 protein and mRNA expression in many cell lines. Oligonucleotides 55-70 BCL2 apoptosis regulator Homo sapiens 118-123 17490524-0 2007 [Effect of bufalin-inducing apoptosis on Bcl-2 and PKC in HL-60 cells]. bufalin 11-18 BCL2 apoptosis regulator Homo sapiens 41-46 17490524-3 2007 The present study was designed to investigate the effects of bufalin-induced apoptosis on Bcl-2 and PKC in human leukemic HL-60 cells. bufalin 61-68 BCL2 apoptosis regulator Homo sapiens 90-95 17490524-9 2007 (3) compared with control, treatment with bufalin at concentration of 50 nmol/L for 6 - 24 hours resulted in downregulation of protein expression, decrease of phosphorylation, and cleavage of Bcl-2, simultaneously. bufalin 42-49 BCL2 apoptosis regulator Homo sapiens 192-197 17490525-6 2007 It is concluded that NMDP and Ara-C induce apoptosis of HL-60 cells, and the mechanism of apoptosis induced by them may down-regulate the expression of bcl-2 gene and up-regulate the expression of bax gene. Nimodipine 21-25 BCL2 apoptosis regulator Homo sapiens 152-157 17490525-6 2007 It is concluded that NMDP and Ara-C induce apoptosis of HL-60 cells, and the mechanism of apoptosis induced by them may down-regulate the expression of bcl-2 gene and up-regulate the expression of bax gene. Cytarabine 30-35 BCL2 apoptosis regulator Homo sapiens 152-157 17490525-7 2007 The mechanism of HL-60 cell apoptosis induced by Ara-C and NMDP is probably associated with the down-regulation of Bcl-2 protein expression. Cytarabine 49-54 BCL2 apoptosis regulator Homo sapiens 115-120 17490525-7 2007 The mechanism of HL-60 cell apoptosis induced by Ara-C and NMDP is probably associated with the down-regulation of Bcl-2 protein expression. Nimodipine 59-63 BCL2 apoptosis regulator Homo sapiens 115-120 17156797-6 2007 Gossypol-induced apoptosis is, at least, through inhibiting the heterodimerization of Bcl-X(L)/Bcl-2 with pro-apoptosis molecules, followed by a caspase-dependent and -independent process which involves the release of AIF from the mitochondria to cytosol. Gossypol 0-8 BCL2 apoptosis regulator Homo sapiens 95-100 17174019-4 2007 After cells were exposed to TBT at the concentrations of 1-4 microM for 2h, the results suggested that TBT could induce an early and typical apoptosis, moreover caspase-3, the modifications of cytoskeletal structure and the Bcl-2 family were involved in this process. tributyltin 28-31 BCL2 apoptosis regulator Homo sapiens 224-229 17116300-6 2007 Furthermore, the mRNA levels of the NF-kappaB regulated anti-apoptosis genes Bcl-2, Bcl-xL, cIAP-2 and XIAP were decreased in a dose-dependent manner after BBSKE treatment. (1,2-bis(1,2-benzisoselenazolone-3(2H)-ketone))ethane 156-161 BCL2 apoptosis regulator Homo sapiens 77-82 17203183-0 2007 Ethyl acetate extract of Chinese medicinal herb Sarcandra glabra induces growth inhibition on human leukemic HL-60 cells, associated with cell cycle arrest and up-regulation of pro-apoptotic Bax/Bcl-2 ratio. ethyl acetate 0-13 BCL2 apoptosis regulator Homo sapiens 195-200 17174019-4 2007 After cells were exposed to TBT at the concentrations of 1-4 microM for 2h, the results suggested that TBT could induce an early and typical apoptosis, moreover caspase-3, the modifications of cytoskeletal structure and the Bcl-2 family were involved in this process. tributyltin 103-106 BCL2 apoptosis regulator Homo sapiens 224-229 17234779-6 2007 In turn, leukemic cells growing in direct contact with bone marrow stromal elements induce activation of Akt, ERK1/2, and STAT3 signaling in MSC, accompanied by significant increase in Hes1 and Bcl-2 proteins, which were all suppressed by QLT0267 and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 251-259 BCL2 apoptosis regulator Homo sapiens 194-199 17666167-0 2007 Impaired kinetics of Bax-GFP and Smac/DIABLO-GFP in caspase-8- and bid-silenced and Bcl-2 overexpressed breast cancer MCF-7 cells exposed to camptothecin. Camptothecin 141-153 BCL2 apoptosis regulator Homo sapiens 84-89 17234790-1 2007 The Bcl-2 antagonist ABT-737 targets Bcl-2/Bcl-xL but not Mcl-1, which may confer resistance to this novel agent. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 21-24 BCL2 apoptosis regulator Homo sapiens 4-9 17234790-1 2007 The Bcl-2 antagonist ABT-737 targets Bcl-2/Bcl-xL but not Mcl-1, which may confer resistance to this novel agent. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 21-24 BCL2 apoptosis regulator Homo sapiens 37-42 16517065-0 2007 Pomolic acid may overcome multidrug resistance mediated by overexpression of anti-apoptotic Bcl-2 proteins. pomolic acid 0-12 BCL2 apoptosis regulator Homo sapiens 92-97 16860395-2 2007 We, here report that human astrocytes derived from on NTera-2 (NT2) cell line expressing a functional anti-apoptotic protein bcl-2 under the control of a tetracycline responsive promoter using the Tet-On and Tet-Off expression systems. Tetracycline 154-166 BCL2 apoptosis regulator Homo sapiens 125-130 16860395-2 2007 We, here report that human astrocytes derived from on NTera-2 (NT2) cell line expressing a functional anti-apoptotic protein bcl-2 under the control of a tetracycline responsive promoter using the Tet-On and Tet-Off expression systems. tetramethylenedisulfotetramine 197-200 BCL2 apoptosis regulator Homo sapiens 125-130 16860395-2 2007 We, here report that human astrocytes derived from on NTera-2 (NT2) cell line expressing a functional anti-apoptotic protein bcl-2 under the control of a tetracycline responsive promoter using the Tet-On and Tet-Off expression systems. tetramethylenedisulfotetramine 208-211 BCL2 apoptosis regulator Homo sapiens 125-130 16860395-6 2007 Furthermore, NT2 astrocytes expressing bcl-2 showed rapid response to doxycycline presence in the Tet On and Tet off system. Doxycycline 70-81 BCL2 apoptosis regulator Homo sapiens 39-44 16860395-6 2007 Furthermore, NT2 astrocytes expressing bcl-2 showed rapid response to doxycycline presence in the Tet On and Tet off system. tetramethylenedisulfotetramine 98-101 BCL2 apoptosis regulator Homo sapiens 39-44 16860395-6 2007 Furthermore, NT2 astrocytes expressing bcl-2 showed rapid response to doxycycline presence in the Tet On and Tet off system. tetramethylenedisulfotetramine 109-112 BCL2 apoptosis regulator Homo sapiens 39-44 16860395-7 2007 The inducible expression of bcl-2 was found to be tightly regulated by doxycycline concentration in the NT2 astrocytes. Doxycycline 71-82 BCL2 apoptosis regulator Homo sapiens 28-33 16860395-8 2007 We also showed that the induction of bcl-2 expression prevented NT2 astrocytes from camptothecin-induced cellular damage. Camptothecin 84-96 BCL2 apoptosis regulator Homo sapiens 37-42 16517065-2 2007 This paper investigated whether pomolic acid (PA) was able to overcome resistance mediated by overexpression of Bcl-2 or BcL-xL. pomolic acid 32-44 BCL2 apoptosis regulator Homo sapiens 112-117 16517065-2 2007 This paper investigated whether pomolic acid (PA) was able to overcome resistance mediated by overexpression of Bcl-2 or BcL-xL. pomolic acid 46-48 BCL2 apoptosis regulator Homo sapiens 112-117 16517065-4 2007 Since Bcl-2 transfected cell lines were shown to be quite resistant to a series of chemotherapeutic agents, the data presented call attention to the possible clinical significance of PA as an anti-MDR drug. pomolic acid 183-185 BCL2 apoptosis regulator Homo sapiens 6-11 17139689-11 2007 As a result, a derivative, S2 (8-oxo-3-[(thienylmethyl)amino]-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile, M(W) = 341) was identified that possessed a lower binding energy to Bcl-2, and demonstrated better antitumor potency, even on the Bcl-2-overexpressing human acute myeloid leukemia (HL-60) cells (IC50 = 1.3 microM) in vitro. s2 (8-oxo-3-[(thienylmethyl)amino]-8h-acenaphtho[1,2-b]pyrrole-9-carbonitrile 27-104 BCL2 apoptosis regulator Homo sapiens 174-179 17160181-1 2007 The reaction between [Pt(nbe)3] (nbe=norbornene), two equivalents of the phosphines PPh3, PMePh2 or PMe2Ph and 1 equivalent of BCl3 affords the platinum dichloroboryl species [PtCl(BCl2)(PPh3)2], [PtCl(BCl2)(PMePh2)2] and [PtCl(BCl2)(PMe2Ph)2]. pt(nbe)3] 22-31 BCL2 apoptosis regulator Homo sapiens 181-185 17160181-1 2007 The reaction between [Pt(nbe)3] (nbe=norbornene), two equivalents of the phosphines PPh3, PMePh2 or PMe2Ph and 1 equivalent of BCl3 affords the platinum dichloroboryl species [PtCl(BCl2)(PPh3)2], [PtCl(BCl2)(PMePh2)2] and [PtCl(BCl2)(PMe2Ph)2]. pt(nbe)3] 22-31 BCL2 apoptosis regulator Homo sapiens 202-206 17160181-1 2007 The reaction between [Pt(nbe)3] (nbe=norbornene), two equivalents of the phosphines PPh3, PMePh2 or PMe2Ph and 1 equivalent of BCl3 affords the platinum dichloroboryl species [PtCl(BCl2)(PPh3)2], [PtCl(BCl2)(PMePh2)2] and [PtCl(BCl2)(PMe2Ph)2]. pt(nbe)3] 22-31 BCL2 apoptosis regulator Homo sapiens 202-206 17160181-1 2007 The reaction between [Pt(nbe)3] (nbe=norbornene), two equivalents of the phosphines PPh3, PMePh2 or PMe2Ph and 1 equivalent of BCl3 affords the platinum dichloroboryl species [PtCl(BCl2)(PPh3)2], [PtCl(BCl2)(PMePh2)2] and [PtCl(BCl2)(PMe2Ph)2]. phenylhydroxylamine 25-28 BCL2 apoptosis regulator Homo sapiens 181-185 17160181-1 2007 The reaction between [Pt(nbe)3] (nbe=norbornene), two equivalents of the phosphines PPh3, PMePh2 or PMe2Ph and 1 equivalent of BCl3 affords the platinum dichloroboryl species [PtCl(BCl2)(PPh3)2], [PtCl(BCl2)(PMePh2)2] and [PtCl(BCl2)(PMe2Ph)2]. phenylhydroxylamine 25-28 BCL2 apoptosis regulator Homo sapiens 202-206 17160181-1 2007 The reaction between [Pt(nbe)3] (nbe=norbornene), two equivalents of the phosphines PPh3, PMePh2 or PMe2Ph and 1 equivalent of BCl3 affords the platinum dichloroboryl species [PtCl(BCl2)(PPh3)2], [PtCl(BCl2)(PMePh2)2] and [PtCl(BCl2)(PMe2Ph)2]. phenylhydroxylamine 25-28 BCL2 apoptosis regulator Homo sapiens 202-206 17160181-1 2007 The reaction between [Pt(nbe)3] (nbe=norbornene), two equivalents of the phosphines PPh3, PMePh2 or PMe2Ph and 1 equivalent of BCl3 affords the platinum dichloroboryl species [PtCl(BCl2)(PPh3)2], [PtCl(BCl2)(PMePh2)2] and [PtCl(BCl2)(PMe2Ph)2]. 2-norbornene 37-47 BCL2 apoptosis regulator Homo sapiens 181-185 17160181-1 2007 The reaction between [Pt(nbe)3] (nbe=norbornene), two equivalents of the phosphines PPh3, PMePh2 or PMe2Ph and 1 equivalent of BCl3 affords the platinum dichloroboryl species [PtCl(BCl2)(PPh3)2], [PtCl(BCl2)(PMePh2)2] and [PtCl(BCl2)(PMe2Ph)2]. 2-norbornene 37-47 BCL2 apoptosis regulator Homo sapiens 202-206 17160181-1 2007 The reaction between [Pt(nbe)3] (nbe=norbornene), two equivalents of the phosphines PPh3, PMePh2 or PMe2Ph and 1 equivalent of BCl3 affords the platinum dichloroboryl species [PtCl(BCl2)(PPh3)2], [PtCl(BCl2)(PMePh2)2] and [PtCl(BCl2)(PMe2Ph)2]. 2-norbornene 37-47 BCL2 apoptosis regulator Homo sapiens 202-206 17160181-1 2007 The reaction between [Pt(nbe)3] (nbe=norbornene), two equivalents of the phosphines PPh3, PMePh2 or PMe2Ph and 1 equivalent of BCl3 affords the platinum dichloroboryl species [PtCl(BCl2)(PPh3)2], [PtCl(BCl2)(PMePh2)2] and [PtCl(BCl2)(PMe2Ph)2]. Phosphines 73-83 BCL2 apoptosis regulator Homo sapiens 181-185 17160181-1 2007 The reaction between [Pt(nbe)3] (nbe=norbornene), two equivalents of the phosphines PPh3, PMePh2 or PMe2Ph and 1 equivalent of BCl3 affords the platinum dichloroboryl species [PtCl(BCl2)(PPh3)2], [PtCl(BCl2)(PMePh2)2] and [PtCl(BCl2)(PMe2Ph)2]. Phosphines 73-83 BCL2 apoptosis regulator Homo sapiens 202-206 17160181-1 2007 The reaction between [Pt(nbe)3] (nbe=norbornene), two equivalents of the phosphines PPh3, PMePh2 or PMe2Ph and 1 equivalent of BCl3 affords the platinum dichloroboryl species [PtCl(BCl2)(PPh3)2], [PtCl(BCl2)(PMePh2)2] and [PtCl(BCl2)(PMe2Ph)2]. Phosphines 73-83 BCL2 apoptosis regulator Homo sapiens 202-206 17160181-1 2007 The reaction between [Pt(nbe)3] (nbe=norbornene), two equivalents of the phosphines PPh3, PMePh2 or PMe2Ph and 1 equivalent of BCl3 affords the platinum dichloroboryl species [PtCl(BCl2)(PPh3)2], [PtCl(BCl2)(PMePh2)2] and [PtCl(BCl2)(PMe2Ph)2]. 2-((4-pyridyl)methyl)amino-N-(3-(trifluoromethyl)phenyl)benzamide 100-106 BCL2 apoptosis regulator Homo sapiens 181-185 17160181-1 2007 The reaction between [Pt(nbe)3] (nbe=norbornene), two equivalents of the phosphines PPh3, PMePh2 or PMe2Ph and 1 equivalent of BCl3 affords the platinum dichloroboryl species [PtCl(BCl2)(PPh3)2], [PtCl(BCl2)(PMePh2)2] and [PtCl(BCl2)(PMe2Ph)2]. 2-((4-pyridyl)methyl)amino-N-(3-(trifluoromethyl)phenyl)benzamide 100-106 BCL2 apoptosis regulator Homo sapiens 202-206 17160181-1 2007 The reaction between [Pt(nbe)3] (nbe=norbornene), two equivalents of the phosphines PPh3, PMePh2 or PMe2Ph and 1 equivalent of BCl3 affords the platinum dichloroboryl species [PtCl(BCl2)(PPh3)2], [PtCl(BCl2)(PMePh2)2] and [PtCl(BCl2)(PMe2Ph)2]. 2-((4-pyridyl)methyl)amino-N-(3-(trifluoromethyl)phenyl)benzamide 100-106 BCL2 apoptosis regulator Homo sapiens 202-206 17160181-1 2007 The reaction between [Pt(nbe)3] (nbe=norbornene), two equivalents of the phosphines PPh3, PMePh2 or PMe2Ph and 1 equivalent of BCl3 affords the platinum dichloroboryl species [PtCl(BCl2)(PPh3)2], [PtCl(BCl2)(PMePh2)2] and [PtCl(BCl2)(PMe2Ph)2]. platinum dichloroboryl 144-166 BCL2 apoptosis regulator Homo sapiens 181-185 17160181-1 2007 The reaction between [Pt(nbe)3] (nbe=norbornene), two equivalents of the phosphines PPh3, PMePh2 or PMe2Ph and 1 equivalent of BCl3 affords the platinum dichloroboryl species [PtCl(BCl2)(PPh3)2], [PtCl(BCl2)(PMePh2)2] and [PtCl(BCl2)(PMe2Ph)2]. platinum dichloroboryl 144-166 BCL2 apoptosis regulator Homo sapiens 202-206 17160181-1 2007 The reaction between [Pt(nbe)3] (nbe=norbornene), two equivalents of the phosphines PPh3, PMePh2 or PMe2Ph and 1 equivalent of BCl3 affords the platinum dichloroboryl species [PtCl(BCl2)(PPh3)2], [PtCl(BCl2)(PMePh2)2] and [PtCl(BCl2)(PMe2Ph)2]. platinum dichloroboryl 144-166 BCL2 apoptosis regulator Homo sapiens 202-206 17160181-3 2007 With PMe3 as the phosphine, the complex [PtCl(BCl2)(PMe3)2] is isolated in high yield as a white crystalline powder although crystals suitable for X-ray crystallography were not obtained. trimethyl phosphine 5-9 BCL2 apoptosis regulator Homo sapiens 46-50 17160181-3 2007 With PMe3 as the phosphine, the complex [PtCl(BCl2)(PMe3)2] is isolated in high yield as a white crystalline powder although crystals suitable for X-ray crystallography were not obtained. phosphine 17-26 BCL2 apoptosis regulator Homo sapiens 46-50 17160181-4 2007 Crystals were obtained of a product shown by X-ray crystallography to be the unusual dinuclear species [Pt2(BCl2)2(PMe3)4(micro-Cl)][BCl4] which reveals an arrangement in which two square planar platinum(II) centres are linked by a single bridging chloride which is trans to a BCl2 group on each platinum centre. platinum(ii) 195-207 BCL2 apoptosis regulator Homo sapiens 108-112 17160181-4 2007 Crystals were obtained of a product shown by X-ray crystallography to be the unusual dinuclear species [Pt2(BCl2)2(PMe3)4(micro-Cl)][BCl4] which reveals an arrangement in which two square planar platinum(II) centres are linked by a single bridging chloride which is trans to a BCl2 group on each platinum centre. Chlorides 248-256 BCL2 apoptosis regulator Homo sapiens 108-112 17160181-4 2007 Crystals were obtained of a product shown by X-ray crystallography to be the unusual dinuclear species [Pt2(BCl2)2(PMe3)4(micro-Cl)][BCl4] which reveals an arrangement in which two square planar platinum(II) centres are linked by a single bridging chloride which is trans to a BCl2 group on each platinum centre. Platinum 195-203 BCL2 apoptosis regulator Homo sapiens 108-112 17160181-5 2007 The reaction of [PtCl(BCl2)(PMe3)2] with NEt3 or pyridine (py) affords the adducts [PtCl{BCl2(NEt3)}(PMe3)2] and [PtCl{BCl2(py)}(PMe3)2], respectively, both characterised spectroscopically. pyridine 49-57 BCL2 apoptosis regulator Homo sapiens 22-26 17160181-5 2007 The reaction of [PtCl(BCl2)(PMe3)2] with NEt3 or pyridine (py) affords the adducts [PtCl{BCl2(NEt3)}(PMe3)2] and [PtCl{BCl2(py)}(PMe3)2], respectively, both characterised spectroscopically. pyridine 49-57 BCL2 apoptosis regulator Homo sapiens 89-93 17160181-5 2007 The reaction of [PtCl(BCl2)(PMe3)2] with NEt3 or pyridine (py) affords the adducts [PtCl{BCl2(NEt3)}(PMe3)2] and [PtCl{BCl2(py)}(PMe3)2], respectively, both characterised spectroscopically. pyridine 49-57 BCL2 apoptosis regulator Homo sapiens 89-93 17160181-6 2007 The reaction between [PtCl(BCl2)(PMe3)2] and either 4 equivalents of NHEt2 or piperidine (pipH) results in the mono-substituted boryl species [PtCl{BCl(NEt2)}(PMe3)2] and [PtCl{BCl(pip)}(PMe3)2], respectively, the former characterised by X-ray crystallography. piperidine 78-88 BCL2 apoptosis regulator Homo sapiens 27-31 17160181-6 2007 The reaction between [PtCl(BCl2)(PMe3)2] and either 4 equivalents of NHEt2 or piperidine (pipH) results in the mono-substituted boryl species [PtCl{BCl(NEt2)}(PMe3)2] and [PtCl{BCl(pip)}(PMe3)2], respectively, the former characterised by X-ray crystallography. piph 90-94 BCL2 apoptosis regulator Homo sapiens 27-31 17160181-6 2007 The reaction between [PtCl(BCl2)(PMe3)2] and either 4 equivalents of NHEt2 or piperidine (pipH) results in the mono-substituted boryl species [PtCl{BCl(NEt2)}(PMe3)2] and [PtCl{BCl(pip)}(PMe3)2], respectively, the former characterised by X-ray crystallography. mono-substituted boryl 111-133 BCL2 apoptosis regulator Homo sapiens 27-31 17139689-11 2007 As a result, a derivative, S2 (8-oxo-3-[(thienylmethyl)amino]-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile, M(W) = 341) was identified that possessed a lower binding energy to Bcl-2, and demonstrated better antitumor potency, even on the Bcl-2-overexpressing human acute myeloid leukemia (HL-60) cells (IC50 = 1.3 microM) in vitro. s2 (8-oxo-3-[(thienylmethyl)amino]-8h-acenaphtho[1,2-b]pyrrole-9-carbonitrile 27-104 BCL2 apoptosis regulator Homo sapiens 236-241 17569215-8 2007 Curcumin-mediated regulation of apoptosis involves caspases, Bcl2 family members, inhibitors of apoptosis proteins, and heat shock proteins. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 61-65 17106192-5 2007 It was found that their BCL2 and BAD expression was significantly different compared to the normal controls, and a lower BAD expression was associated with a better molecular response to imatinib treatment at 12 months. Imatinib Mesylate 187-195 BCL2 apoptosis regulator Homo sapiens 24-28 17569210-4 2007 Curcumin decreased the expression of antiapoptotic members of the Bcl-2 family and elevated the expression of p53, Bax, procaspases 3, 8, and 9. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 66-71 17569210-5 2007 Curcumin prevents the entry of nuclear factor KB (NF-KB) into the nucleus there by decreasing the expression of cell cycle regulatory proteins and survival factors such as Bcl-2 and survivin. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 172-177 17404055-6 2007 Immunoblotting revealed that treatment of MCF-7 cells with 10-50 microM EGCG caused increases in Bax protein levels and decreases in Bcl-2 protein levels, shifting the Bax-Bcl-2 ratio to favor apoptosis, while treatment with 100-400 microM EGCG had no such effect. epigallocatechin gallate 72-76 BCL2 apoptosis regulator Homo sapiens 133-138 17404012-7 2007 Western blotting has revealed that DMNQ S-64 effectively activates the expression of caspase 8, 9, and 3, cleaves poly (ADP-ribose) polymerase, and increases the ratio of Bax/Bcl-2. 2,3-dimethoxy-1,4-naphthoquinone 35-39 BCL2 apoptosis regulator Homo sapiens 175-180 17404013-5 2007 By means of immunohistochemistry we estimated the level of overexpression of bcl-2 proteins in a series of the 26 formalin fixed, paraffin-embedded samples of oral squamous cell carcinoma (OSCC). Formaldehyde 114-122 BCL2 apoptosis regulator Homo sapiens 77-82 17404013-5 2007 By means of immunohistochemistry we estimated the level of overexpression of bcl-2 proteins in a series of the 26 formalin fixed, paraffin-embedded samples of oral squamous cell carcinoma (OSCC). Paraffin 130-138 BCL2 apoptosis regulator Homo sapiens 77-82 17404015-3 2007 The drugs cisplatin, carboplatin, and doxorubicin exhibit anticancer activity, the mechanism of which is not yet completely clarified, although they are known to modulate the expression of several genes including apoptosis-related genes, such as members of the BCL2 (Bcl-2) family. Cisplatin 10-19 BCL2 apoptosis regulator Homo sapiens 261-265 17404061-9 2007 Jaceosidin treatment also increased the ratio of proapoptotic Bax to the antiapoptotic Bcl-2 and induced the cleavage of caspase-3 and poly(ADP-ribose)polymerase (PARP). jaceosidin 0-10 BCL2 apoptosis regulator Homo sapiens 87-92 17404015-3 2007 The drugs cisplatin, carboplatin, and doxorubicin exhibit anticancer activity, the mechanism of which is not yet completely clarified, although they are known to modulate the expression of several genes including apoptosis-related genes, such as members of the BCL2 (Bcl-2) family. Cisplatin 10-19 BCL2 apoptosis regulator Homo sapiens 267-272 17404055-6 2007 Immunoblotting revealed that treatment of MCF-7 cells with 10-50 microM EGCG caused increases in Bax protein levels and decreases in Bcl-2 protein levels, shifting the Bax-Bcl-2 ratio to favor apoptosis, while treatment with 100-400 microM EGCG had no such effect. epigallocatechin gallate 72-76 BCL2 apoptosis regulator Homo sapiens 172-177 17404015-3 2007 The drugs cisplatin, carboplatin, and doxorubicin exhibit anticancer activity, the mechanism of which is not yet completely clarified, although they are known to modulate the expression of several genes including apoptosis-related genes, such as members of the BCL2 (Bcl-2) family. Carboplatin 21-32 BCL2 apoptosis regulator Homo sapiens 261-265 17404015-3 2007 The drugs cisplatin, carboplatin, and doxorubicin exhibit anticancer activity, the mechanism of which is not yet completely clarified, although they are known to modulate the expression of several genes including apoptosis-related genes, such as members of the BCL2 (Bcl-2) family. Carboplatin 21-32 BCL2 apoptosis regulator Homo sapiens 267-272 17159504-10 2007 15-Deoxy-Delta-prostaglandin J2+docetaxel showed a significant increase in apoptosis associated with inhibition of the Bcl2 and cyclin D1 expression and overexpression of caspase and p53 pathway genes. 15-deoxy-delta-prostaglandin j2 0-31 BCL2 apoptosis regulator Homo sapiens 119-123 17404015-3 2007 The drugs cisplatin, carboplatin, and doxorubicin exhibit anticancer activity, the mechanism of which is not yet completely clarified, although they are known to modulate the expression of several genes including apoptosis-related genes, such as members of the BCL2 (Bcl-2) family. Doxorubicin 38-49 BCL2 apoptosis regulator Homo sapiens 261-265 17404015-3 2007 The drugs cisplatin, carboplatin, and doxorubicin exhibit anticancer activity, the mechanism of which is not yet completely clarified, although they are known to modulate the expression of several genes including apoptosis-related genes, such as members of the BCL2 (Bcl-2) family. Doxorubicin 38-49 BCL2 apoptosis regulator Homo sapiens 267-272 17352223-6 2007 Western blot demonstrated that baicalin promoted the levels of Gadd153, Bax, cytochrome c and caspase-3 and -12, but decreased the levels of Grp78 and Bcl-2 in HL-60 cells. baicalin 31-39 BCL2 apoptosis regulator Homo sapiens 151-156 17159502-6 2007 Western blot analysis further showed down-regulation of procaspase-3, X-linked inhibitor of apoptosis protein and poly(ADP-ribose) polymerase cleavage in Bel-7402 cells treated with 15 mumol/l fenretinide for 48 h. Overexpression of p53 was observed in a time-dependent manner, along with a decrease in the Bcl-2/Bax ratio. Fenretinide 193-204 BCL2 apoptosis regulator Homo sapiens 307-312 17159504-10 2007 15-Deoxy-Delta-prostaglandin J2+docetaxel showed a significant increase in apoptosis associated with inhibition of the Bcl2 and cyclin D1 expression and overexpression of caspase and p53 pathway genes. Docetaxel 32-41 BCL2 apoptosis regulator Homo sapiens 119-123 17352246-6 2007 RESULTS: Ascorbic acid was found to reduce the proliferation of cells and induce apoptosis by the modulation of p53, p21, Bcl-2 and Bax. Ascorbic Acid 9-22 BCL2 apoptosis regulator Homo sapiens 122-127 17136320-4 2007 Bcl-2 cleavage and down-regulation of the inhibitor of apoptosis proteins (IAPs) family including cIAP-1/2, XIAP, and survivin, occurred downstream of ROS production during sulindac-induced apoptosis. Reactive Oxygen Species 151-154 BCL2 apoptosis regulator Homo sapiens 0-5 17080328-7 2007 While the knock-down of Bcl-2/Bcl-X(L) sensitized to sorbitol-induced killing, overexpression of a Bcl-2 variant that specifically localizes to mitochondria (but not of the wild-type nor of a endoplasmic reticulum-targeted form) strongly inhibited sorbitol effects. Sorbitol 53-61 BCL2 apoptosis regulator Homo sapiens 24-29 17080328-7 2007 While the knock-down of Bcl-2/Bcl-X(L) sensitized to sorbitol-induced killing, overexpression of a Bcl-2 variant that specifically localizes to mitochondria (but not of the wild-type nor of a endoplasmic reticulum-targeted form) strongly inhibited sorbitol effects. Sorbitol 53-61 BCL2 apoptosis regulator Homo sapiens 99-104 17080328-7 2007 While the knock-down of Bcl-2/Bcl-X(L) sensitized to sorbitol-induced killing, overexpression of a Bcl-2 variant that specifically localizes to mitochondria (but not of the wild-type nor of a endoplasmic reticulum-targeted form) strongly inhibited sorbitol effects. Sorbitol 248-256 BCL2 apoptosis regulator Homo sapiens 99-104 17202653-4 2007 In addition, minoxidil plus retinol more effectively elevated phosphorylated Erk, phosphorylated Akt levels, and the Bcl-2/Bax ratio than minoxidil alone in DPCs and HaCaT. Minoxidil 13-22 BCL2 apoptosis regulator Homo sapiens 117-122 17202653-4 2007 In addition, minoxidil plus retinol more effectively elevated phosphorylated Erk, phosphorylated Akt levels, and the Bcl-2/Bax ratio than minoxidil alone in DPCs and HaCaT. Vitamin A 28-35 BCL2 apoptosis regulator Homo sapiens 117-122 17916949-0 2007 The impact of high-dose sodium selenite therapy on Bcl-2 expression in adult non-Hodgkin"s lymphoma patients: correlation with response and survival. Sodium Selenite 24-39 BCL2 apoptosis regulator Homo sapiens 51-56 17916949-1 2007 The present study was undertaken to explore the effect of administration of high doses of sodium selenite on the expression of Bcl-2 in patients with non-Hodgkin"s lymphoma (NHL). Sodium Selenite 90-105 BCL2 apoptosis regulator Homo sapiens 127-132 17916949-5 2007 Sodium selenite administration resulted in significant decline of Bcl-2 level after therapy in group A-II (8.6 +/- 6.9 ng/ml vs 3 6.9 +/- 7.9 ng/ml, P < 0.05). Sodium Selenite 0-15 BCL2 apoptosis regulator Homo sapiens 66-71 17916949-9 2007 It is concluded that sodium selenite administration at the dosage and duration chosen acts as a down regulator of Bcl-2 and improves clinical outcome. Sodium Selenite 21-36 BCL2 apoptosis regulator Homo sapiens 114-119 17202653-5 2007 We found that the significant hair shaft elongation demonstrated after minoxidil plus retinol treatment would depend on the dual kinetics associated with the activations of Erk- and Akt-dependent pathways and the prevention of apoptosis by increasing the Bcl-2/Bax ratio. Minoxidil 71-80 BCL2 apoptosis regulator Homo sapiens 255-260 17202653-5 2007 We found that the significant hair shaft elongation demonstrated after minoxidil plus retinol treatment would depend on the dual kinetics associated with the activations of Erk- and Akt-dependent pathways and the prevention of apoptosis by increasing the Bcl-2/Bax ratio. Vitamin A 86-93 BCL2 apoptosis regulator Homo sapiens 255-260 18057548-11 2007 The results indicate that queuine down regulates cell proliferation and expression of Bcl2 protein, suggesting that queuine promotes cell death and participates in the regulation of cell proliferation. queuine 26-33 BCL2 apoptosis regulator Homo sapiens 86-90 18057548-11 2007 The results indicate that queuine down regulates cell proliferation and expression of Bcl2 protein, suggesting that queuine promotes cell death and participates in the regulation of cell proliferation. queuine 116-123 BCL2 apoptosis regulator Homo sapiens 86-90 17136320-4 2007 Bcl-2 cleavage and down-regulation of the inhibitor of apoptosis proteins (IAPs) family including cIAP-1/2, XIAP, and survivin, occurred downstream of ROS production during sulindac-induced apoptosis. Sulindac 173-181 BCL2 apoptosis regulator Homo sapiens 0-5 17136320-5 2007 Forced expression of survivin and Bcl-2 blocked sulindac-induced apoptosis. Sulindac 48-56 BCL2 apoptosis regulator Homo sapiens 34-39 17561354-4 2007 RESULTS: The ala43ala genotype of BCL2 anti-apoptotic gene was significantly associated with risk of developing esophageal cancer (OR 2.1, 95%CI=1.0-4.4, P=0.03), more so in males (OR 2.6, 95%CI=P=0.03). ala43ala 13-21 BCL2 apoptosis regulator Homo sapiens 34-38 17975304-7 2007 Isoborneol prevented 6-OHDA from decreasing the Bax/Bcl-2 ratio. isoborneol 0-10 BCL2 apoptosis regulator Homo sapiens 52-57 17561354-8 2007 Association with clinical characteristics showed BCL2 ala43ala genotype to be at increased risk for developing tumors in the middle third location (OR 2.3, 95%CI=1.0-5.3, P=0.03), while patients with CCND1 870AA genotypes were at higher risk for the development of cancer in the upper third location (OR 3.8, 95%CI=1.6-9, P=0.002). ala43ala 54-62 BCL2 apoptosis regulator Homo sapiens 49-53 17975304-7 2007 Isoborneol prevented 6-OHDA from decreasing the Bax/Bcl-2 ratio. Oxidopamine 21-27 BCL2 apoptosis regulator Homo sapiens 52-57 17200714-0 2007 Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. ABT-737 112-119 BCL2 apoptosis regulator Homo sapiens 38-42 17356266-7 2007 RESULTS: Exposure of U937 cells to (Z)-stellettic acid C resulted in growth inhibition and induction of apoptosis in a dose-dependent manner, which was associated with the modulation of Bcl-2 family expression, activation of caspases and downregulation of IAPs family members. (Z)-Stellettic acid C 35-56 BCL2 apoptosis regulator Homo sapiens 186-191 17133181-0 2007 Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients. drotrecogin alpha 13-30 BCL2 apoptosis regulator Homo sapiens 76-81 17133181-12 2007 In contrast, 24 hrs later we observed a significant decrease in these ratios, indicating an antiapoptotic effect in the DAA+ group (Bax/Bcl-2, 0.39 +/- 0.27; Bax/Bcl-xl, 0.68 +/- 0.35) compared with the DAA- group (Bax/Bcl-2, 1.81 +/- 1.1; Bax/Bcl-xl, 1.22 +/- 0.92, p = .001 and p = .039, respectively). daa 120-123 BCL2 apoptosis regulator Homo sapiens 136-141 17133181-12 2007 In contrast, 24 hrs later we observed a significant decrease in these ratios, indicating an antiapoptotic effect in the DAA+ group (Bax/Bcl-2, 0.39 +/- 0.27; Bax/Bcl-xl, 0.68 +/- 0.35) compared with the DAA- group (Bax/Bcl-2, 1.81 +/- 1.1; Bax/Bcl-xl, 1.22 +/- 0.92, p = .001 and p = .039, respectively). daa 120-123 BCL2 apoptosis regulator Homo sapiens 219-224 17133181-13 2007 CONCLUSIONS: In vivo, in human septic shock, DAA has antiapoptotic effects on circulating mononuclear cells, assessed by a significant decrease of both the Bax/Bcl-2 and Bax/Bcl-xl ratios. daa 45-48 BCL2 apoptosis regulator Homo sapiens 160-165 17157194-7 2007 Both low glucose and AICAR also elevated the expression of BH3-domain-only Bcl-2 antagonists, and induced caspase-3 activation, causing caspase-dependent truncation of Bcl-2. Glucose 9-16 BCL2 apoptosis regulator Homo sapiens 75-80 17157194-7 2007 Both low glucose and AICAR also elevated the expression of BH3-domain-only Bcl-2 antagonists, and induced caspase-3 activation, causing caspase-dependent truncation of Bcl-2. Glucose 9-16 BCL2 apoptosis regulator Homo sapiens 168-173 17053024-11 2007 In addition, ghrelin-treated cells showed an increased Bcl-2/Bax ratio, prevention of cytochrome c release, and inhibition of caspase-3 activation. Ghrelin 13-20 BCL2 apoptosis regulator Homo sapiens 55-60 17161815-5 2007 Also, Bcl-2"s overexpression and a caspase-3 inhibitor z-DEVD-fmk significantly attenuated PD98059-induced apoptosis through the down-regulation of caspase-3 activity, but did not attenuate G1 phase arrest. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 91-98 BCL2 apoptosis regulator Homo sapiens 6-11 17161815-7 2007 Thus, our results imply that PD98059-induced apoptosis is significantly involved in down-regulation of Bcl-2, caspase-3 activity, the Akt pathway, and some of the biological functions in U937 cells. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 29-36 BCL2 apoptosis regulator Homo sapiens 103-108 17994574-6 2007 Pretreatment with the inhibitor protected against the decrease in Bcl-2 expression in oxidized low-density lipoprotein- and 7beta-hydroxycholesterol-treated U937 cells. cholest-5-en-3 beta,7 alpha-diol 124-148 BCL2 apoptosis regulator Homo sapiens 66-71 17200714-0 2007 Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. ABT-737 112-119 BCL2 apoptosis regulator Homo sapiens 96-100 17200714-3 2007 BH3 profiling accurately predicts sensitivity to BCL2 antagonist ABT-737 in primary chronic lymphocytic leukemia (CLL) cells. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 49-53 17200714-3 2007 BH3 profiling accurately predicts sensitivity to BCL2 antagonist ABT-737 in primary chronic lymphocytic leukemia (CLL) cells. ABT-737 65-72 BCL2 apoptosis regulator Homo sapiens 49-53 17200714-4 2007 BH3 profiling also accurately distinguishes myeloid cell leukemia sequence 1 (MCL1) from BCL2 dependence in myeloma cell lines. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 89-93 17200714-6 2007 ABT-737 displaced BIM from BCL2"s BH3-binding pocket, allowing BIM to activate BAX, induce mitochondrial permeabilization, and rapidly commit the CLL cell to death. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 27-31 17200714-6 2007 ABT-737 displaced BIM from BCL2"s BH3-binding pocket, allowing BIM to activate BAX, induce mitochondrial permeabilization, and rapidly commit the CLL cell to death. BH 3 34-37 BCL2 apoptosis regulator Homo sapiens 27-31 17200714-6 2007 ABT-737 displaced BIM from BCL2"s BH3-binding pocket, allowing BIM to activate BAX, induce mitochondrial permeabilization, and rapidly commit the CLL cell to death. bim 18-21 BCL2 apoptosis regulator Homo sapiens 27-31 17200714-8 2007 Instead, BCL2 complexed to BIM is the critical target for ABT-737 in CLL. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 58-61 BCL2 apoptosis regulator Homo sapiens 9-13 18204303-2 2007 Sodium butyrate-induced apoptosis has been reported to associate with the up-regulation of pro-apoptotic Bax expression, and the down-regulation of anti-apoptotic Bcl-2 and Bcl-XL expressions. Butyric Acid 0-15 BCL2 apoptosis regulator Homo sapiens 163-168 17982885-5 2007 At the same time, rasagiline induces anti-apoptotic pro-survival proteins, Bcl-2 and glial cell-line derived neurotrophic factor, which is mediated by activated ERK-NF-kappaB signal pathway. rasagiline 18-28 BCL2 apoptosis regulator Homo sapiens 75-80 17363184-1 2007 The antisense drug G3139 (oblimersen sodium, Genta, Inc.) is a phosphorothioate oligodeoxynucleotide (ODN) containing unmethylated CpG units, which is targeted to suppress Bcl-2. oblimersen 19-24 BCL2 apoptosis regulator Homo sapiens 172-177 17363184-1 2007 The antisense drug G3139 (oblimersen sodium, Genta, Inc.) is a phosphorothioate oligodeoxynucleotide (ODN) containing unmethylated CpG units, which is targeted to suppress Bcl-2. Sodium 37-43 BCL2 apoptosis regulator Homo sapiens 172-177 17363184-1 2007 The antisense drug G3139 (oblimersen sodium, Genta, Inc.) is a phosphorothioate oligodeoxynucleotide (ODN) containing unmethylated CpG units, which is targeted to suppress Bcl-2. genta 45-50 BCL2 apoptosis regulator Homo sapiens 172-177 17917084-1 2007 In previous studies we demonstrated that antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha [MR1]), its binding site the epidermal growth factor receptor (EGFR [MR2]), and the anti-apoptosis protein bcl-2 (MR4) are efficacious against prostate tumors. Oligonucleotides 51-67 BCL2 apoptosis regulator Homo sapiens 236-241 17848743-0 2007 Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors. Oligonucleotides 21-37 BCL2 apoptosis regulator Homo sapiens 118-123 17363184-1 2007 The antisense drug G3139 (oblimersen sodium, Genta, Inc.) is a phosphorothioate oligodeoxynucleotide (ODN) containing unmethylated CpG units, which is targeted to suppress Bcl-2. phosphorothioate oligodeoxynucleotide 63-100 BCL2 apoptosis regulator Homo sapiens 172-177 17363184-1 2007 The antisense drug G3139 (oblimersen sodium, Genta, Inc.) is a phosphorothioate oligodeoxynucleotide (ODN) containing unmethylated CpG units, which is targeted to suppress Bcl-2. Oligodeoxyribonucleotides 102-105 BCL2 apoptosis regulator Homo sapiens 172-177 17363184-10 2007 Specifically, the unmethylated CpG ODN (and/or the phosphorothioate group) activates the immune system, but this potentially important anti-cancer effect is lost when the immune cells undergo premature apoptosis apparently because their Bcl-2 levels have been lowered by the antisense effect of G3139. Parathion 51-67 BCL2 apoptosis regulator Homo sapiens 237-242 17050806-4 2007 In addition, the atypic apoptosis induced by Zol was independent of caspase activation, and it was characterized by nuclear alterations, increased Bax expression, and reduced Bcl-2 level. Zoledronic Acid 45-48 BCL2 apoptosis regulator Homo sapiens 175-180 16874461-0 2007 Suppression of IP3-mediated calcium release and apoptosis by Bcl-2 involves the participation of protein phosphatase 1. Inositol 1,4,5-Trisphosphate 15-18 BCL2 apoptosis regulator Homo sapiens 61-66 16874461-0 2007 Suppression of IP3-mediated calcium release and apoptosis by Bcl-2 involves the participation of protein phosphatase 1. Calcium 28-35 BCL2 apoptosis regulator Homo sapiens 61-66 16874461-2 2007 Here, we have explored the mechanism(s) of how Bcl-2 suppresses the IP3-sensitive Ca2+ release in MCF-7 cells focusing on the possible role of protein phosphatase 1 (PP1). Inositol 1,4,5-Trisphosphate 68-71 BCL2 apoptosis regulator Homo sapiens 47-52 16874461-4 2007 Using various experimental approaches including phosphatase inhibition and RNAi, we show that Bcl-2 by competing with IP3R1 for the binding of PP1 can reduce the IP3-mediated calcium signal and protect cells from mitochondrial dysfunction and cell death. Inositol 1,4,5-Trisphosphate 118-121 BCL2 apoptosis regulator Homo sapiens 94-99 16874461-4 2007 Using various experimental approaches including phosphatase inhibition and RNAi, we show that Bcl-2 by competing with IP3R1 for the binding of PP1 can reduce the IP3-mediated calcium signal and protect cells from mitochondrial dysfunction and cell death. Calcium 175-182 BCL2 apoptosis regulator Homo sapiens 94-99 17237270-0 2007 Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Oligodeoxyribonucleotides 33-54 BCL2 apoptosis regulator Homo sapiens 14-19 17237270-3 2007 Antisense Bcl-2 oligodeoxynucleotide (ODN) reagents have been shown to be effective in reducing Bcl-2 expression in a number of systems. Oligodeoxyribonucleotides 38-41 BCL2 apoptosis regulator Homo sapiens 10-15 17237270-3 2007 Antisense Bcl-2 oligodeoxynucleotide (ODN) reagents have been shown to be effective in reducing Bcl-2 expression in a number of systems. Oligodeoxyribonucleotides 38-41 BCL2 apoptosis regulator Homo sapiens 96-101 17541305-0 2007 Microenvironment effects on promoting upregulation of matrix metalloproteinases in Bcl-2-overexpressing renal cell carcinoma as a response to doxorubicin treatment inducing the production of metastasis. Doxorubicin 142-153 BCL2 apoptosis regulator Homo sapiens 83-88 17961046-10 2007 Moreover, an increase in the proapoptotic Bax/Bcl-2 protein ratio was demonstrated with the combination of imatinib and nelfinavir. Imatinib Mesylate 107-115 BCL2 apoptosis regulator Homo sapiens 46-51 17961046-10 2007 Moreover, an increase in the proapoptotic Bax/Bcl-2 protein ratio was demonstrated with the combination of imatinib and nelfinavir. Nelfinavir 120-130 BCL2 apoptosis regulator Homo sapiens 46-51 17913750-3 2007 The review highlights recent solution NMR-based G-quadruplex structures formed by the four-repeat human telomere in K(+) solution and the guanine-rich strands of c-myc, c-kit and variant bcl-2 oncogenic promoters, as well as a bimolecular G-quadruplex that targets HIV-1 integrase. Guanine 138-145 BCL2 apoptosis regulator Homo sapiens 187-192 17640170-5 2007 Western blot analysis showed that the expression of B cell lymphoma-2 (Bcl-2) protein, an apoptosis inhibitory protein, in both cell lines was decreased more significant by paclitaxel in combination with seal oil than by paclitaxel alone. Paclitaxel 173-183 BCL2 apoptosis regulator Homo sapiens 52-69 17640170-5 2007 Western blot analysis showed that the expression of B cell lymphoma-2 (Bcl-2) protein, an apoptosis inhibitory protein, in both cell lines was decreased more significant by paclitaxel in combination with seal oil than by paclitaxel alone. Paclitaxel 173-183 BCL2 apoptosis regulator Homo sapiens 71-76 17640170-5 2007 Western blot analysis showed that the expression of B cell lymphoma-2 (Bcl-2) protein, an apoptosis inhibitory protein, in both cell lines was decreased more significant by paclitaxel in combination with seal oil than by paclitaxel alone. Paclitaxel 221-231 BCL2 apoptosis regulator Homo sapiens 52-69 17640170-5 2007 Western blot analysis showed that the expression of B cell lymphoma-2 (Bcl-2) protein, an apoptosis inhibitory protein, in both cell lines was decreased more significant by paclitaxel in combination with seal oil than by paclitaxel alone. Paclitaxel 221-231 BCL2 apoptosis regulator Homo sapiens 71-76 16503348-11 2007 Results also displayed that CIZAR-induced apoptosis involves the up-regulation of p21(WAF1) and Bax protein and down-regulation of Bcl-2 which were accompanied by the activation of caspase-3. cizar 28-33 BCL2 apoptosis regulator Homo sapiens 131-136 17520804-7 2007 Addition of oridonin increased Bax/Bcl-2 expression ratio and cytochrome c, whereas the expression of SIRT-1 was decreased, and 3-MA pre-application enhanced these changes. oridonin 12-20 BCL2 apoptosis regulator Homo sapiens 35-40 17299580-7 2006 The bag-1 antisense oligonucleotide affected the expression of Bid, Bad, Bcl-2, JNK, and phosphorylated JNK, although expression of PTEN and Bcl-X did not change. Oligonucleotides 20-35 BCL2 apoptosis regulator Homo sapiens 73-78 17202837-5 2006 Catalytic activation of caspase-9 and decreased expression of anti-apoptotic Bcl-2 and Bcl-XL proteins were observed in TSA-treated cells. trichostatin A 120-123 BCL2 apoptosis regulator Homo sapiens 77-82 17090549-6 2006 Additionally, we examined the role of the Bcl-2 BH4 domain in mediating binding to FKBP38, the Bcl-2 mitochondrial chaperone. sapropterin 48-51 BCL2 apoptosis regulator Homo sapiens 95-100 17090549-7 2006 Our results demonstrate a novel, pro-apoptotic function for nuclear Bcl-2 and identify the Bcl-2 BH4 domain as a key regulator in mediating Bcl-2/FKBP38 binding. sapropterin 97-100 BCL2 apoptosis regulator Homo sapiens 91-96 17090549-7 2006 Our results demonstrate a novel, pro-apoptotic function for nuclear Bcl-2 and identify the Bcl-2 BH4 domain as a key regulator in mediating Bcl-2/FKBP38 binding. sapropterin 97-100 BCL2 apoptosis regulator Homo sapiens 91-96 17068343-8 2006 Further, WIN-55,212-2 treatment of cells resulted in a dose-dependent increase in Bax/Bcl-2 ratio in such a way that favors apoptosis. win-55 9-15 BCL2 apoptosis regulator Homo sapiens 86-91 17069758-7 2006 The pro-apoptotic activity of oroxylin A was attributed to its ability to modulate the concerted expression of Bcl-2, Bax, and pro-caspase-3 proteins. 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one 30-40 BCL2 apoptosis regulator Homo sapiens 111-116 17069758-8 2006 The expression of Bcl-2 protein and pro-caspase-3 protein was dramatically decreased after treatment with oroxylin A. 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one 106-116 BCL2 apoptosis regulator Homo sapiens 18-23 17133272-1 2006 HIV-1 protease inhibitor (PI), nelfinavir (NFV) induced growth arrest and apoptosis of NCI-H460 and -H520, A549, EBC-1 and ABC-1 non-small-cell lung cancer (NSCLC) cells in association with upregulation of p21waf1, p27kip1 and p53, and downregulation of Bcl-2 and matrix metalloproteinase (MMP)-2 proteins. Nelfinavir 31-41 BCL2 apoptosis regulator Homo sapiens 254-259 17484203-1 2007 OBJECTIVE: To deeply explore the effects of microcystins (MC-LR) on Bax and Bcl-2 during the course of MC-LR promoting liver tumor. cyanoginosin LR 58-63 BCL2 apoptosis regulator Homo sapiens 76-81 17484203-1 2007 OBJECTIVE: To deeply explore the effects of microcystins (MC-LR) on Bax and Bcl-2 during the course of MC-LR promoting liver tumor. cyanoginosin LR 103-108 BCL2 apoptosis regulator Homo sapiens 76-81 17484203-6 2007 (2) The intension and areas of the protein expression of Bcl-2 in DEN + pure toxin group were 0.0977 and 0.0315, and in DEN control group were 0.0460 and 0.0205, respectively. Diethylnitrosamine 66-69 BCL2 apoptosis regulator Homo sapiens 57-62 17484203-7 2007 The expression level of Bcl-2 protein in DEN + pure toxin group were significantly higher than in DEN control group (P < 0.05). Diethylnitrosamine 41-44 BCL2 apoptosis regulator Homo sapiens 24-29 17484203-7 2007 The expression level of Bcl-2 protein in DEN + pure toxin group were significantly higher than in DEN control group (P < 0.05). Diethylnitrosamine 98-101 BCL2 apoptosis regulator Homo sapiens 24-29 17484203-11 2007 The intension of Bcl-2 mRNA expression in DEN + pure toxin group was 2.244, being significantly higher than in the other groups (P < 0.05). Diethylnitrosamine 42-45 BCL2 apoptosis regulator Homo sapiens 17-22 17181155-0 2006 Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer. ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate 43-122 BCL2 apoptosis regulator Homo sapiens 166-171 17181155-1 2006 The structure-activity relationship studies of ethyl 2-amino-6-cyclopentyl-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (1, HA 14-1), an antagonist of the antiapoptotic Bcl-2 proteins, are reported. BDBM50200964 47-132 BCL2 apoptosis regulator Homo sapiens 182-187 17181155-8 2006 (In this study, the binding interactions of the small molecules to antiapoptotic Bcl-2 proteins were studied by assaying their abilities to compete against a Bak peptide binding to the antiapoptotic Bcl-2 proteins. bakuchiol 158-161 BCL2 apoptosis regulator Homo sapiens 81-86 17181155-8 2006 (In this study, the binding interactions of the small molecules to antiapoptotic Bcl-2 proteins were studied by assaying their abilities to compete against a Bak peptide binding to the antiapoptotic Bcl-2 proteins. bakuchiol 158-161 BCL2 apoptosis regulator Homo sapiens 199-204 17113925-6 2006 The protective mechanism mediated by the two stilbenes could be related to their effect on bcl-2 gene family expression. Stilbenes 45-54 BCL2 apoptosis regulator Homo sapiens 91-96 17113925-8 2006 Conversely, bcl-2, an anti-apoptotic gene, highly down-regulated by amyloid beta (1-42) treatment, resulted expressed in the presence of stilbenes similarly to that shown by control cells. Stilbenes 137-146 BCL2 apoptosis regulator Homo sapiens 12-17 17112418-12 2006 N-demethyl-clarithromycin upregulated the expression ratio of mitochondrial Bax/Bcl-2, and significantly increased the expression of the p53 protein. n-demethyl-clarithromycin 0-25 BCL2 apoptosis regulator Homo sapiens 80-85 16983347-0 2006 Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation. Imatinib Mesylate 0-8 BCL2 apoptosis regulator Homo sapiens 98-103 17166371-7 2006 The expression of apoptosis-associated gene Bcl-2 was detected by SP immunocytochemistry. TFF2 protein, human 66-68 BCL2 apoptosis regulator Homo sapiens 44-49 17052670-6 2006 Caspase-3 inhibitor, z-DEVD-fmk, was significantly capable of restoring cell viability and BV-induced apoptosis through caspase-3 activation was significantly attenuated in Bcl-2-overexpressing cells. benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone 21-31 BCL2 apoptosis regulator Homo sapiens 173-178 17257079-2 2006 Growth modification caused by FSC iron involves a diminished expression of Bcl-2 and an overexpression of p53 proto-oncogene, accompanied by an increased incidence of apoptosis. Iron 34-38 BCL2 apoptosis regulator Homo sapiens 75-80 17384250-0 2006 Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide. Etoposide 193-202 BCL2 apoptosis regulator Homo sapiens 58-62 17384250-3 2006 The aim of the present research approach to investigate the expression of the apoptosis-related genes BCL2 (Bcl-2), FAS, Caspase-3, BAX and the new member BCL2L12, cloned by our group, along with treatment of HL-60 leukemia cells with etoposide. Etoposide 235-244 BCL2 apoptosis regulator Homo sapiens 102-106 17142989-2 2006 In this study, we found that treatment with 30 microM magnolol exhibited growth inhibition partly by inducing apoptosis in cultured human leukemia U937 cells and that the apoptosis was induced via the sequential ordering of molecular events; 1) a transient decrease of phosphorylated extracelluar signal-requlated kinase (ERK), 2) translocation of apoptosis inducing factor (AIF) from mitochondria to cytosol concurrent with a decreased membrane potential, and 3) downregulation of bcl-2 protein. magnolol 54-62 BCL2 apoptosis regulator Homo sapiens 482-487 17054427-4 2006 These experiments showed that SP600125 activated caspase 8 and confirmed that D1 activated the intrinsic pathway of apoptosis, as caspase 8 was not affected while Bcl-2 was down-regulated following D1 administration. pyrazolanthrone 30-38 BCL2 apoptosis regulator Homo sapiens 163-168 17341597-5 2006 After ensuring that standard separation procedures do not alter per se lymphocytes redox equilibrium nor Bcl-2 levels in the first 24 h of culture, we show that BSO treatment promotes the upregulation of Bcl-2, with a mechanism involving the increased radical production consequent to GSH depletion. Glutathione 285-288 BCL2 apoptosis regulator Homo sapiens 204-209 17132110-0 2006 Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Topotecan 0-9 BCL2 apoptosis regulator Homo sapiens 75-79 17132110-0 2006 Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Methotrexate 14-26 BCL2 apoptosis regulator Homo sapiens 75-79 17132110-7 2006 Downregulation of BCL2L12, BCL2 and FAS was observed after treatment of HL-60 cells with topotecan, while treatment with methotrexate led to downregulation of BCL2 and FAS, with no change in BCL2L12 expression. Topotecan 89-98 BCL2 apoptosis regulator Homo sapiens 18-22 17132110-7 2006 Downregulation of BCL2L12, BCL2 and FAS was observed after treatment of HL-60 cells with topotecan, while treatment with methotrexate led to downregulation of BCL2 and FAS, with no change in BCL2L12 expression. Topotecan 89-98 BCL2 apoptosis regulator Homo sapiens 27-31 17172851-4 2006 We here investigate the potential therapeutic utility of combined targeting of Mdm2 by Nutlin-3a and Bcl-2 by ABT-737, recently developed inhibitors of protein-protein interactions. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 110-113 BCL2 apoptosis regulator Homo sapiens 101-106 17172851-7 2006 In contrast, ABT-737 induced apoptosis predominantly in G1, the cell cycle phase with the lowest Bcl-2 protein levels and Bcl-2/Bax ratios. ABT-737 13-20 BCL2 apoptosis regulator Homo sapiens 97-102 17172851-7 2006 In contrast, ABT-737 induced apoptosis predominantly in G1, the cell cycle phase with the lowest Bcl-2 protein levels and Bcl-2/Bax ratios. ABT-737 13-20 BCL2 apoptosis regulator Homo sapiens 122-127 17172851-8 2006 In addition, Bcl-2 phosphorylation on Ser70 was absent in G1 but detectable in G2/M, thus lower Bcl-2 levels and absence of Bcl-2 phosphorylation appeared to facilitate ABT-737-induced apoptosis of G1 cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 169-172 BCL2 apoptosis regulator Homo sapiens 13-18 17168655-8 2006 Our pre-clinical studies showed that ATO is capable to induce cell death in acute leukemia cells but the apoptotic function is limited since it can induce also a mechanism of cell defense by activating pro-survival molecules such as MEK-ERK, Bcl-xL, Bcl-2. Arsenic Trioxide 37-40 BCL2 apoptosis regulator Homo sapiens 250-255 17088977-5 2006 Therefore, Bcl-2 and cyclin D1 were chosen as putative targets for increasing cell death and growth arrest induced by cisplatin, thereby enhancing the drug sensitivity in MCF-7. Cisplatin 118-127 BCL2 apoptosis regulator Homo sapiens 11-16 17209525-2 2006 Antisense oligodeoxynucleotides and, more recently, small-molecule ligands for Bcl-2 and Bcl-x(L), sensitize cancer cells to cytotoxic therapies. Oligodeoxyribonucleotides 10-31 BCL2 apoptosis regulator Homo sapiens 79-84 16945458-5 2006 This increase in TS extracts- and gallic acid-induced apoptosis was also associated with a reduction in the levels of Bcl-2, a potent cell-death inhibitor, and an increase in those of the Bax protein, which heterodimerizes with and thereby inhibits Bcl-2. Gallic Acid 34-45 BCL2 apoptosis regulator Homo sapiens 118-123 16945458-5 2006 This increase in TS extracts- and gallic acid-induced apoptosis was also associated with a reduction in the levels of Bcl-2, a potent cell-death inhibitor, and an increase in those of the Bax protein, which heterodimerizes with and thereby inhibits Bcl-2. Gallic Acid 34-45 BCL2 apoptosis regulator Homo sapiens 249-254 17088977-0 2006 Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of Bcl-2 and cyclin D1. Cisplatin 10-19 BCL2 apoptosis regulator Homo sapiens 89-94 17088977-6 2006 RNA interference, using Bcl-2- and cyclin D1- siRNAs sensitized MCF-7 cells to cisplatin treatment and by simultaneous knockdown of both Bcl-2 and cyclin D1 further sensitization was seen. Cisplatin 79-88 BCL2 apoptosis regulator Homo sapiens 24-29 17011577-3 2006 The pro-survival members of the Bcl-2 family mediate their effects through heterodimerization with the BH3 region of the pro-apoptotic members. BH 3 103-106 BCL2 apoptosis regulator Homo sapiens 32-37 16987815-2 2006 Among the "BCL-2 homology (BH) 3-only" members of pro-apoptotic proteins, truncated BID (tBID) has been implicated in direct BAX activation, although an explicit molecular mechanism remains elusive. tBID 89-93 BCL2 apoptosis regulator Homo sapiens 11-16 17159184-0 2006 Anti-apoptotic Bcl-2 gene transfection of human articular chondrocytes protects against nitric oxide-induced apoptosis. Nitric Oxide 88-100 BCL2 apoptosis regulator Homo sapiens 15-20 17287894-5 2006 Reverse transcription-polymerase chain reaction analysis revealed that exposure to 5-FU downregulated both MDR1 and bcl-2 mRNA and simultaneously upregulated CE2 mRNA expression, suggesting enhancement of subsequent CPT-11 cytotoxicity. Fluorouracil 83-87 BCL2 apoptosis regulator Homo sapiens 116-121 16970802-4 2006 RESULTS: In this report, we demonstrate that BH3 mimetics, molecules that facilitate apoptosis by releasing pro-apoptotic Bax from its antiapoptotic partner Bcl-2, are able to promote coated-platelet formation as monitored by several different markers of these cells. BH 3 45-48 BCL2 apoptosis regulator Homo sapiens 157-162 17140955-2 2006 This study was designed to evaluate whether gossypol, a phytochemical compound with BH3-mimetic property that functions as an inhibitor of Bcl2/BclXL, would sensitize cultured thoracic cancer cells to this death-inducing ligand. Gossypol 44-52 BCL2 apoptosis regulator Homo sapiens 139-143 16990509-0 2006 Reactive oxygen species mediate caspase activation and apoptosis induced by lipoic acid in human lung epithelial cancer cells through Bcl-2 down-regulation. Reactive Oxygen Species 0-23 BCL2 apoptosis regulator Homo sapiens 134-139 16990509-0 2006 Reactive oxygen species mediate caspase activation and apoptosis induced by lipoic acid in human lung epithelial cancer cells through Bcl-2 down-regulation. Thioctic Acid 76-87 BCL2 apoptosis regulator Homo sapiens 134-139 16990509-8 2006 LA induced down-regulation of mitochondrial Bcl-2 protein through peroxide-dependent proteasomal degradation, and overexpression of the Bcl-2 protein prevented the apoptotic effect of LA. Peroxides 66-74 BCL2 apoptosis regulator Homo sapiens 44-49 17054996-8 2006 In addition, PD98059 regulated the level of phospho-Bcl-2. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 13-20 BCL2 apoptosis regulator Homo sapiens 52-57 17197368-7 2006 The current studies show that ladostigil significantly decreased apoptosis via inhibition of the cleavage and prevention of caspase-3 activation through a mechanism related to regulation of the Bcl-2 family proteins, resulting in reduced levels of Bad and Bax and induced levels of Bcl-2. (N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate 30-40 BCL2 apoptosis regulator Homo sapiens 194-199 16630656-4 2006 The treatment significantly modified expression of several apoptosis-regulating proteins, including upregulation of Bax or downregulation of Bcl-2 and Mcl-1 by BOR+RIT, as well as downregulation of Bcl-2 and XIAP by BOR+CAM. Bortezomib 160-163 BCL2 apoptosis regulator Homo sapiens 141-146 16630656-4 2006 The treatment significantly modified expression of several apoptosis-regulating proteins, including upregulation of Bax or downregulation of Bcl-2 and Mcl-1 by BOR+RIT, as well as downregulation of Bcl-2 and XIAP by BOR+CAM. Ritonavir 164-167 BCL2 apoptosis regulator Homo sapiens 141-146 17172421-4 2006 As anticancer agent, we encapsulated the previously described antisense oligonucleotide 4625 specific for both bcl-2 and bcl-xL. Oligonucleotides 72-87 BCL2 apoptosis regulator Homo sapiens 111-116 17089066-3 2006 All drugs used alone, and cladribine combinations with mafosfamide and/or mitoxantrone induced DNA fragmentation and the changes in expression/proteolysis level of caspase-3, caspase-9 precursors, PARP-1, lamin B, Bax and Bcl-2; however, each to a different degree. Cladribine 26-36 BCL2 apoptosis regulator Homo sapiens 222-227 17197368-7 2006 The current studies show that ladostigil significantly decreased apoptosis via inhibition of the cleavage and prevention of caspase-3 activation through a mechanism related to regulation of the Bcl-2 family proteins, resulting in reduced levels of Bad and Bax and induced levels of Bcl-2. (N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate 30-40 BCL2 apoptosis regulator Homo sapiens 282-287 17089066-3 2006 All drugs used alone, and cladribine combinations with mafosfamide and/or mitoxantrone induced DNA fragmentation and the changes in expression/proteolysis level of caspase-3, caspase-9 precursors, PARP-1, lamin B, Bax and Bcl-2; however, each to a different degree. mafosfamide 55-66 BCL2 apoptosis regulator Homo sapiens 222-227 17005564-0 2006 tBid elicits a conformational alteration in membrane-bound Bcl-2 such that it inhibits Bax pore formation. tBID 0-4 BCL2 apoptosis regulator Homo sapiens 59-64 17089066-3 2006 All drugs used alone, and cladribine combinations with mafosfamide and/or mitoxantrone induced DNA fragmentation and the changes in expression/proteolysis level of caspase-3, caspase-9 precursors, PARP-1, lamin B, Bax and Bcl-2; however, each to a different degree. Mitoxantrone 74-86 BCL2 apoptosis regulator Homo sapiens 222-227 16998806-0 2006 Absence of Bcl-2 expression favors response to the short-term administration of diethylstilbestrol diphosphate in prostate Cancer. fosfestrol 80-110 BCL2 apoptosis regulator Homo sapiens 11-16 17005564-3 2006 tBid also activates anti-apoptotic Bcl-2 in the mitochondrial outer membrane, changing it from a single-spanning to a multispanning conformation that binds the active Bax and inhibits cytochrome c release. tBID 0-4 BCL2 apoptosis regulator Homo sapiens 35-40 16984800-7 2006 Celastrol prevented not only LPS-induced mRNA expression of iNOS and TNF-alpha, but also TNF-alpha-induced Bfl-1/A1 expression, a prosurvival Bcl-2 homologue. celastrol 0-9 BCL2 apoptosis regulator Homo sapiens 142-147 17005564-4 2006 However, it is not known whether other mitochondrial proteins are required to elicit the tBid-induced Bcl-2 conformational alteration. tBID 89-93 BCL2 apoptosis regulator Homo sapiens 102-107 17005564-6 2006 We found that purified tBid was sufficient to induce a conformational alteration in the liposome-tethered, but not cytosolic Bcl-2, resulting in a multispanning form that is similar to the one found in the mitochondrial outer membrane of drug-treated cells. tBID 23-27 BCL2 apoptosis regulator Homo sapiens 125-130 17005564-7 2006 Mutations that abolished tBid/Bcl-2 interaction also abolished the conformational alteration, demonstrating that a direct tBid/Bcl-2 interaction at the membrane is both required and sufficient to elicit the conformational alteration. tBID 25-29 BCL2 apoptosis regulator Homo sapiens 127-132 17005564-7 2006 Mutations that abolished tBid/Bcl-2 interaction also abolished the conformational alteration, demonstrating that a direct tBid/Bcl-2 interaction at the membrane is both required and sufficient to elicit the conformational alteration. tBID 122-126 BCL2 apoptosis regulator Homo sapiens 30-35 17005564-7 2006 Mutations that abolished tBid/Bcl-2 interaction also abolished the conformational alteration, demonstrating that a direct tBid/Bcl-2 interaction at the membrane is both required and sufficient to elicit the conformational alteration. tBID 122-126 BCL2 apoptosis regulator Homo sapiens 127-132 17005564-10 2006 Thus, there is a strong correlation between the direct interaction of membrane-bound Bcl-2 and tBid with activation of Bcl-2 in vitro and in vivo. tBID 95-99 BCL2 apoptosis regulator Homo sapiens 85-90 17005564-10 2006 Thus, there is a strong correlation between the direct interaction of membrane-bound Bcl-2 and tBid with activation of Bcl-2 in vitro and in vivo. tBID 95-99 BCL2 apoptosis regulator Homo sapiens 119-124 16980304-5 2006 We report here that Bcl-2 undergoes S-nitrosylation by endogenous nitric oxide (NO) in response to multiple apoptotic mediators and that this modification inhibits ubiquitin-proteasomal degradation of Bcl-2. Nitric Oxide 66-78 BCL2 apoptosis regulator Homo sapiens 20-25 16979204-8 2006 Instead, we demonstrate that leflunomide (20 microM) inhibited the APAP-induced early (3 h) activation (phosphorylation) of JNK1/2, thus inhibiting phosphorylation of the anti-apoptotic protein Bcl-2 and preventing P-Bcl-2-mediated induction of the mPT. Leflunomide 29-40 BCL2 apoptosis regulator Homo sapiens 194-199 16979204-8 2006 Instead, we demonstrate that leflunomide (20 microM) inhibited the APAP-induced early (3 h) activation (phosphorylation) of JNK1/2, thus inhibiting phosphorylation of the anti-apoptotic protein Bcl-2 and preventing P-Bcl-2-mediated induction of the mPT. Leflunomide 29-40 BCL2 apoptosis regulator Homo sapiens 217-222 16979204-8 2006 Instead, we demonstrate that leflunomide (20 microM) inhibited the APAP-induced early (3 h) activation (phosphorylation) of JNK1/2, thus inhibiting phosphorylation of the anti-apoptotic protein Bcl-2 and preventing P-Bcl-2-mediated induction of the mPT. Acetaminophen 67-71 BCL2 apoptosis regulator Homo sapiens 194-199 16979204-8 2006 Instead, we demonstrate that leflunomide (20 microM) inhibited the APAP-induced early (3 h) activation (phosphorylation) of JNK1/2, thus inhibiting phosphorylation of the anti-apoptotic protein Bcl-2 and preventing P-Bcl-2-mediated induction of the mPT. Acetaminophen 67-71 BCL2 apoptosis regulator Homo sapiens 217-222 16980304-5 2006 We report here that Bcl-2 undergoes S-nitrosylation by endogenous nitric oxide (NO) in response to multiple apoptotic mediators and that this modification inhibits ubiquitin-proteasomal degradation of Bcl-2. Nitric Oxide 66-78 BCL2 apoptosis regulator Homo sapiens 201-206 16980304-6 2006 Inhibition of NO production by the NO scavenger 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide and by NO synthase inhibitor aminoguanidine effectively inhibited S-nitrosylation of Bcl-2, increased its ubiquitination, and promoted apoptotic cell death induced by chromium (VI). 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole 48-113 BCL2 apoptosis regulator Homo sapiens 199-204 16980304-9 2006 Mutational analysis of Bcl-2 further showed that the two cysteine residues of Bcl-2 (Cys158 and Cys229) are important in the S-nitrosylation process and that mutations of these cysteines completely inhibited Bcl-2 S-nitrosylation. Cysteine 57-65 BCL2 apoptosis regulator Homo sapiens 23-28 16980304-9 2006 Mutational analysis of Bcl-2 further showed that the two cysteine residues of Bcl-2 (Cys158 and Cys229) are important in the S-nitrosylation process and that mutations of these cysteines completely inhibited Bcl-2 S-nitrosylation. Cysteine 57-65 BCL2 apoptosis regulator Homo sapiens 78-83 16980304-9 2006 Mutational analysis of Bcl-2 further showed that the two cysteine residues of Bcl-2 (Cys158 and Cys229) are important in the S-nitrosylation process and that mutations of these cysteines completely inhibited Bcl-2 S-nitrosylation. Cysteine 57-65 BCL2 apoptosis regulator Homo sapiens 78-83 16980304-9 2006 Mutational analysis of Bcl-2 further showed that the two cysteine residues of Bcl-2 (Cys158 and Cys229) are important in the S-nitrosylation process and that mutations of these cysteines completely inhibited Bcl-2 S-nitrosylation. Cysteine 177-186 BCL2 apoptosis regulator Homo sapiens 23-28 16980304-9 2006 Mutational analysis of Bcl-2 further showed that the two cysteine residues of Bcl-2 (Cys158 and Cys229) are important in the S-nitrosylation process and that mutations of these cysteines completely inhibited Bcl-2 S-nitrosylation. Cysteine 177-186 BCL2 apoptosis regulator Homo sapiens 78-83 16980304-9 2006 Mutational analysis of Bcl-2 further showed that the two cysteine residues of Bcl-2 (Cys158 and Cys229) are important in the S-nitrosylation process and that mutations of these cysteines completely inhibited Bcl-2 S-nitrosylation. Cysteine 177-186 BCL2 apoptosis regulator Homo sapiens 78-83 16980304-10 2006 Treatment of the cells with other stress inducers, including Fas ligand and buthionine sulfoxide, also induced Bcl-2 S-nitrosylation, suggesting that this is a general phenomenon that regulates Bcl-2 stability and function under various stress conditions. buthionine sulfoxide 76-96 BCL2 apoptosis regulator Homo sapiens 111-116 16980304-10 2006 Treatment of the cells with other stress inducers, including Fas ligand and buthionine sulfoxide, also induced Bcl-2 S-nitrosylation, suggesting that this is a general phenomenon that regulates Bcl-2 stability and function under various stress conditions. buthionine sulfoxide 76-96 BCL2 apoptosis regulator Homo sapiens 194-199 17201167-0 2006 Histamine inhibits cell proliferation and modulates the expression of Bcl-2 family proteins via the H2 receptor in human pancreatic cancer cells. Histamine 0-9 BCL2 apoptosis regulator Homo sapiens 70-75 17049120-9 2006 Resveratrol down-regulated the expression of the antiapoptotic proteins Bcl-2, Bcl-x(L) and XIAP and up-regulated the expression of the proapoptotic protein Bax. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 72-77 17075313-5 2006 The molecular analysis of the apoptotic machinery involved in valproic acid action revealed a central role in Bcl-2 downmodulation. Valproic Acid 62-75 BCL2 apoptosis regulator Homo sapiens 110-115 17201156-8 2006 Western blot assay also revealed that curcumin increased the levels of Bax and the release of cytochrome c, and decreased the levels of Bcl-2 in the examined cells. Curcumin 38-46 BCL2 apoptosis regulator Homo sapiens 136-141 17201158-6 2006 Curcumin also promoted the expression of Bax, cytochrome C, p53 and p21 but inhibited the expression of Bcl-2. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 104-109 17201174-8 2006 These results, thereby, suggest that xanthorrhizol has antiproliferative effects on MCF-7 cells by inducing apoptosis through the modulation of bcl-2, p53 and PARP-1 protein levels. xanthorrhizol 37-50 BCL2 apoptosis regulator Homo sapiens 144-149 17097553-1 2006 In this issue of Cancer Cell, two groups present data on the function of an antagonist of BCL-2, ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 97-100 BCL2 apoptosis regulator Homo sapiens 90-95 17140381-0 2006 Changes in expression of genes encoding antioxidant enzymes, heme oxygenase-1, Bcl-2, and Bcl-xl and in level of reactive oxygen species in tumor cells resistant to doxorubicin. Doxorubicin 165-176 BCL2 apoptosis regulator Homo sapiens 79-84 17140381-1 2006 The relationship between expression of genes encoding key antioxidant enzymes, heme oxygenase-1, Bcl-2, and Bcl-xl and change in production of reactive oxygen species (ROS) resulting from development of resistance of cancer cells K562, MCF-7, and SKOV-3 to the prooxidant chemotherapeutic agent doxorubicin (DOX) has been studied. Reactive Oxygen Species 143-166 BCL2 apoptosis regulator Homo sapiens 97-102 17140381-1 2006 The relationship between expression of genes encoding key antioxidant enzymes, heme oxygenase-1, Bcl-2, and Bcl-xl and change in production of reactive oxygen species (ROS) resulting from development of resistance of cancer cells K562, MCF-7, and SKOV-3 to the prooxidant chemotherapeutic agent doxorubicin (DOX) has been studied. Reactive Oxygen Species 168-171 BCL2 apoptosis regulator Homo sapiens 97-102 17140381-5 2006 Particular features of development of adaptive antioxidant response as well as redox-dependent change in bcl-2 gene expression under formation of DOX resistance of cancer cells of different genesis are discussed. Doxorubicin 146-149 BCL2 apoptosis regulator Homo sapiens 105-110 16889987-0 2006 A forskolin derivative, FSK88, induces apoptosis in human gastric cancer BGC823 cells through caspase activation involving regulation of Bcl-2 family gene expression, dissipation of mitochondrial membrane potential and cytochrome c release. Colforsin 2-11 BCL2 apoptosis regulator Homo sapiens 137-142 16889987-0 2006 A forskolin derivative, FSK88, induces apoptosis in human gastric cancer BGC823 cells through caspase activation involving regulation of Bcl-2 family gene expression, dissipation of mitochondrial membrane potential and cytochrome c release. fsk88 24-29 BCL2 apoptosis regulator Homo sapiens 137-142 16889987-6 2006 FSK88-induced apoptosis in human gastric cancer BGC823 cells was also accompanied by the up-regulation of Bax, Bad and down-regulation of Bcl-2. fsk88 0-5 BCL2 apoptosis regulator Homo sapiens 138-143 16889987-7 2006 Theses results clearly demonstrated that the induction of apoptosis by FSK88 involved multiple cellular and molecular pathways and strongly suggest that pro- and anti-apoptotic Bcl-2 family genes, mitochondrial membrane potential (Deltapsi(m)), cytochrome c, and caspase-3, participate in the FSK88-induced apoptotic process in human gastric cancer BGC823 cells. fsk88 71-76 BCL2 apoptosis regulator Homo sapiens 177-182 17145575-8 2006 The sensitivity enhancement ratio(SER) of Hela cells transfected with bcl2 ASODN,c-myc ASODN and bcl2 + c-myc ASODNs was 1.20, 1.53 and 2.18 respectively. Serine 34-37 BCL2 apoptosis regulator Homo sapiens 70-74 17145575-8 2006 The sensitivity enhancement ratio(SER) of Hela cells transfected with bcl2 ASODN,c-myc ASODN and bcl2 + c-myc ASODNs was 1.20, 1.53 and 2.18 respectively. Serine 34-37 BCL2 apoptosis regulator Homo sapiens 97-101 17097553-2 2006 Both groups find that expression of MCL-1, an antiapoptotic protein related to BCL-2, is a key determinant of resistance to ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 124-127 BCL2 apoptosis regulator Homo sapiens 79-84 16485030-8 2006 Steady state tBid mitochondrial localization was prohibited by activation of the MAPK pathway, also when the Bcl-2 homology domain 3 (BH3) domain of tBid was disrupted. tBID 13-17 BCL2 apoptosis regulator Homo sapiens 109-114 16485030-8 2006 Steady state tBid mitochondrial localization was prohibited by activation of the MAPK pathway, also when the Bcl-2 homology domain 3 (BH3) domain of tBid was disrupted. tBID 149-153 BCL2 apoptosis regulator Homo sapiens 109-114 16549336-4 2006 The downstream events, decrease of Bcl-2 protein amount, depolarization of the mitochondria and activation of the caspase 9 and caspase 3 depend on production of ceramide. Ceramides 162-170 BCL2 apoptosis regulator Homo sapiens 35-40 17097560-4 2006 ABT-737 induced the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 0-7 BCL2 apoptosis regulator Homo sapiens 38-43 17097560-6 2006 Inhibition of BCL-2 phosphorylation and reduction of MCL-1 expression restored sensitivity to ABT-737. ABT-737 94-101 BCL2 apoptosis regulator Homo sapiens 14-19 17034587-8 2006 In lupus nephritis patients, glomerular expression of Bcl-2 and Fas was seen in mesangial cells (1.3 +/- 0.1 and 2.0 +/- 0.1 for Bcl-2 and Fas, respectively). ammonium ferrous sulfate 64-67 BCL2 apoptosis regulator Homo sapiens 129-134 17034587-9 2006 Similarly, a statistically significantly higher Bcl-2 (217.1 +/- 85.9) and Fas (767.9 +/- 271) serum levels were found in lupus patients compared to controls (148.6 +/- 87, 550.3 +/- 91 for Bcl-2 and Fas, P < 0.05). ammonium ferrous sulfate 200-203 BCL2 apoptosis regulator Homo sapiens 48-53 16877374-9 2006 Down-regulation of the B-cell lymphoma/leukaemia-2 (Bcl-2) expression with the activation of caspase-3, caspase-8 and caspase-9 was observed in ECSC after beta-HIVS treatment. beta-hydroxyisovalerylshikonin 155-164 BCL2 apoptosis regulator Homo sapiens 23-50 16877374-9 2006 Down-regulation of the B-cell lymphoma/leukaemia-2 (Bcl-2) expression with the activation of caspase-3, caspase-8 and caspase-9 was observed in ECSC after beta-HIVS treatment. beta-hydroxyisovalerylshikonin 155-164 BCL2 apoptosis regulator Homo sapiens 52-57 16897757-8 2006 Tyr/Phe restriction also inhibits Bcl-2 and Met restriction inhibits Bcl-XL in mitochondria. Tyrosine 0-3 BCL2 apoptosis regulator Homo sapiens 34-39 17016653-8 2006 Taken together, it is suggested that sodium butyrate can be a promising chemopreventive agent for leukemic cells and changes in Bcl-2 family expressions, as well as telomerase activity may, play critical roles in sodium butyrate-induced apoptosis in U937 cells. Butyric Acid 37-52 BCL2 apoptosis regulator Homo sapiens 128-133 17016653-8 2006 Taken together, it is suggested that sodium butyrate can be a promising chemopreventive agent for leukemic cells and changes in Bcl-2 family expressions, as well as telomerase activity may, play critical roles in sodium butyrate-induced apoptosis in U937 cells. Butyric Acid 213-228 BCL2 apoptosis regulator Homo sapiens 128-133 16897757-8 2006 Tyr/Phe restriction also inhibits Bcl-2 and Met restriction inhibits Bcl-XL in mitochondria. Phenylalanine 4-7 BCL2 apoptosis regulator Homo sapiens 34-39 17173243-14 2006 Bax/Bcl-2 production and caspase-3 activity were up-regulated in cultured HKCs treated with HOCM iodine 74 or 111 mg/mL meglumine diatrizoate. hocm 92-96 BCL2 apoptosis regulator Homo sapiens 4-9 17056790-0 2006 Quercetin induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI-3-kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2). Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 66-71 17173243-14 2006 Bax/Bcl-2 production and caspase-3 activity were up-regulated in cultured HKCs treated with HOCM iodine 74 or 111 mg/mL meglumine diatrizoate. Iodine 97-103 BCL2 apoptosis regulator Homo sapiens 4-9 17173243-14 2006 Bax/Bcl-2 production and caspase-3 activity were up-regulated in cultured HKCs treated with HOCM iodine 74 or 111 mg/mL meglumine diatrizoate. Diatrizoate Meglumine 120-141 BCL2 apoptosis regulator Homo sapiens 4-9 17173243-16 2006 The regulation of apoptosis induced by HOCM in HKCs may be regulated by Bax/Bcl-2 and caspase-3. hocm 39-43 BCL2 apoptosis regulator Homo sapiens 76-81 17409985-1 2006 BACKGROUND: In preclinical models, the proteasome inhibitor bortezomib (PS-341) inhibits the growth of small cell lung cancer (SCLC) by inhibiting the antiapoptotic Bcl-2 signaling pathway. Bortezomib 60-70 BCL2 apoptosis regulator Homo sapiens 165-170 17014693-8 2006 The results demonstrate the anti-proliferative and apoptosis-inducing effects of melatonin; these changes were associated with cell cycle arrest, upregulation of P53 and Bax and downregulation of Bcl-2. Melatonin 81-90 BCL2 apoptosis regulator Homo sapiens 196-201 17014693-10 2006 P53 and Bax/Bcl-2 expression changes may be involved in these actions of melatonin. Melatonin 73-82 BCL2 apoptosis regulator Homo sapiens 12-17 17409985-1 2006 BACKGROUND: In preclinical models, the proteasome inhibitor bortezomib (PS-341) inhibits the growth of small cell lung cancer (SCLC) by inhibiting the antiapoptotic Bcl-2 signaling pathway. Bortezomib 72-78 BCL2 apoptosis regulator Homo sapiens 165-170 16887394-4 2006 Tet-regulated expression of Apoptin from an adenoviral vector showed cytotoxicity in DU145, PC-3, and LNCaP tumor cells regardless of expression of p53, Bcl-2, Bcl-xL, Bax, survivin, FLIP(S), XIAP, or CIAP. tetramethylenedisulfotetramine 0-3 BCL2 apoptosis regulator Homo sapiens 153-158 17121918-9 2006 Combined treatment with 10 micromol/L celecoxib and MK886 could prevent this activation and had additive effects on inhibiting tumor cell proliferation, inducing cell apoptosis, decreasing Bcl-2 expression, increasing Bax expression, and determining mitochondrial depolarization in comparison with treatment with either inhibitor alone. Celecoxib 38-47 BCL2 apoptosis regulator Homo sapiens 189-194 17039455-9 2006 Western analysis indicated that treatment of quercetin markedly down-regulated PARP and Bcl-2 proteins, and activated caspase-3, Bax, and Bak proteins. Quercetin 45-54 BCL2 apoptosis regulator Homo sapiens 88-93 17121941-5 2006 The BITC-induced apoptosis correlated with induction of proapoptotic proteins Bax (MCF-7) and Bak (MDA-MB-231 and MCF-7) and down-regulation of antiapoptotic proteins Bcl-2 and Bcl-xL (MDA-MB-231). benzyl isothiocyanate 4-8 BCL2 apoptosis regulator Homo sapiens 167-172 17121929-0 2006 Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine. vinflunine 108-118 BCL2 apoptosis regulator Homo sapiens 0-5 17121929-10 2006 This down-regulation was related to resistance, as A2780-TC1 cells stably transfected with a Bcl-2 construct recovered a partial sensitivity to vinflunine. vinflunine 144-154 BCL2 apoptosis regulator Homo sapiens 93-98 17121929-11 2006 Lastly, we confirmed the role played by Bcl-2 by showing that the mitochondrial membrane potential was only disrupted by vinflunine in cells expressing Bcl-2. vinflunine 121-131 BCL2 apoptosis regulator Homo sapiens 40-45 17121929-11 2006 Lastly, we confirmed the role played by Bcl-2 by showing that the mitochondrial membrane potential was only disrupted by vinflunine in cells expressing Bcl-2. vinflunine 121-131 BCL2 apoptosis regulator Homo sapiens 152-157 17121918-9 2006 Combined treatment with 10 micromol/L celecoxib and MK886 could prevent this activation and had additive effects on inhibiting tumor cell proliferation, inducing cell apoptosis, decreasing Bcl-2 expression, increasing Bax expression, and determining mitochondrial depolarization in comparison with treatment with either inhibitor alone. MK-886 52-57 BCL2 apoptosis regulator Homo sapiens 189-194 17121929-13 2006 Especially, this study shows that a specific pool of tubulin subtypes and a down-regulation of Bcl-2 are associated with resistance of ovarian cancer cells to vinflunine. vinflunine 159-169 BCL2 apoptosis regulator Homo sapiens 95-100 16387422-6 2006 Following Casticin exposure, Bcl-2 depletion occurs in cancer cells, and a sub-G1 accumulation occurs in the cell cycle. casticin 10-18 BCL2 apoptosis regulator Homo sapiens 29-34 16957011-10 2006 Expression of p53 and p21WAF/CIP1 increased in cells incubated with Fe-S, but not with Fe-D. Bcl-2 expression was significantly down-regulated in cells incubated with Fe-S in comparison with Fe-D, while Bax expression was not modified by the iron compounds. Iron 167-171 BCL2 apoptosis regulator Homo sapiens 93-98 16957011-10 2006 Expression of p53 and p21WAF/CIP1 increased in cells incubated with Fe-S, but not with Fe-D. Bcl-2 expression was significantly down-regulated in cells incubated with Fe-S in comparison with Fe-D, while Bax expression was not modified by the iron compounds. Iron 242-246 BCL2 apoptosis regulator Homo sapiens 93-98 17260801-0 2006 [Change of Bcl-2 expression and telomerase during apoptosis induced by oridonin on human hepatocelluar carcinoma cells]. oridonin 71-79 BCL2 apoptosis regulator Homo sapiens 11-16 16957011-10 2006 Expression of p53 and p21WAF/CIP1 increased in cells incubated with Fe-S, but not with Fe-D. Bcl-2 expression was significantly down-regulated in cells incubated with Fe-S in comparison with Fe-D, while Bax expression was not modified by the iron compounds. Iron 68-72 BCL2 apoptosis regulator Homo sapiens 93-98 18221044-6 2006 In particular, a recent surge has occurred in the number of patent documents describing small molecule inhibitors and BH3 mimetic blockers of Bcl-2/Bcl-x(L) function as obvious and important targets for promoting mitochondrial induced cancer cell death and for enhancing the actions of other chemotherapeutic agents. BH 3 118-121 BCL2 apoptosis regulator Homo sapiens 142-147 17260801-1 2006 OBJECTIVE: To investigate the change of Bcl-2 expression and telomerase during the apoptosis induced by oridonin on human hepatocelluar carcinoma BEL7402 cells. oridonin 104-112 BCL2 apoptosis regulator Homo sapiens 40-45 17260801-7 2006 Marked morphological changes of cell apoptosis were observed very clearly by Hoechst 33258 staining after the cells exposed to oridonin for 60 hours; Western blotting showed that Bcl-2 expression was down-regulated and Bax expression up-regulated concurrently along with the apoptotic process, and the expression of hTERT mRNA as well as activity of telomerase were decreased concurrently. oridonin 127-135 BCL2 apoptosis regulator Homo sapiens 179-184 17260801-8 2006 CONCLUSION: Oridonin could decrease the expression of hTERT mRNA and telomerase activity as well as down-regulation of Bcl-2 and up-regulation of Bax expression during the apoptosis of BEL-7402 cells. oridonin 12-20 BCL2 apoptosis regulator Homo sapiens 119-124 16387422-7 2006 Moreover, following a transient transfection with Bcl-2, MN1 cells are resistant to Casticin. casticin 84-92 BCL2 apoptosis regulator Homo sapiens 50-55 17072976-4 2006 IND (0.1 mmol/L for 1 h) significantly up-regulated pro-apoptotic genes in four families: (1) TNF receptor and ligand, (2) Caspase, (3) Bcl-2 and (4) Caspase recruiting domain. Indomethacin 0-3 BCL2 apoptosis regulator Homo sapiens 136-141 16928686-5 2006 Importantly, the Bcl-2 homology domain 3-only (BH3-only) protein Noxa was found to be strongly induced in cisplatin-resistant SCC cells by PS-341 but not by cisplatin. Cisplatin 106-115 BCL2 apoptosis regulator Homo sapiens 17-22 17062688-3 2006 Taxane-induced (paclitaxel and its analogue docetaxel) phosphorylation of Bcl-2 abolishes the potential antiapoptotic effect of Bcl-2. Paclitaxel 16-26 BCL2 apoptosis regulator Homo sapiens 74-79 17062688-0 2006 Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. taxane 91-97 BCL2 apoptosis regulator Homo sapiens 0-5 16806341-0 2006 Methyl-beta-cyclodextrin enhances the susceptibility of human breast cancer cells to carboplatin and 5-fluorouracil: involvement of Akt, NF-kappaB and Bcl-2. methyl-beta-cyclodextrin 0-24 BCL2 apoptosis regulator Homo sapiens 151-156 17062688-3 2006 Taxane-induced (paclitaxel and its analogue docetaxel) phosphorylation of Bcl-2 abolishes the potential antiapoptotic effect of Bcl-2. Paclitaxel 16-26 BCL2 apoptosis regulator Homo sapiens 128-133 17062688-3 2006 Taxane-induced (paclitaxel and its analogue docetaxel) phosphorylation of Bcl-2 abolishes the potential antiapoptotic effect of Bcl-2. taxane 0-6 BCL2 apoptosis regulator Homo sapiens 74-79 17062688-3 2006 Taxane-induced (paclitaxel and its analogue docetaxel) phosphorylation of Bcl-2 abolishes the potential antiapoptotic effect of Bcl-2. taxane 0-6 BCL2 apoptosis regulator Homo sapiens 128-133 17062688-3 2006 Taxane-induced (paclitaxel and its analogue docetaxel) phosphorylation of Bcl-2 abolishes the potential antiapoptotic effect of Bcl-2. Docetaxel 44-53 BCL2 apoptosis regulator Homo sapiens 74-79 17062688-3 2006 Taxane-induced (paclitaxel and its analogue docetaxel) phosphorylation of Bcl-2 abolishes the potential antiapoptotic effect of Bcl-2. Docetaxel 44-53 BCL2 apoptosis regulator Homo sapiens 128-133 17062688-4 2006 We hypothesized that (a) survival benefit in HRPC patients treated with taxanes is determined by the presence of Bcl-2 protein and (b) altered expression of Bak and Bax protein caused by genetic mutation is associated with biological aggressiveness of prostate cancer. Taxoids 72-79 BCL2 apoptosis regulator Homo sapiens 113-118 17062688-9 2006 Multivariate analysis revealed that the level of Bcl-2 expression before treatment with taxane-based chemotherapy was an independent predictor for cause-specific survival (P < 0.01) and baseline prostate-specific antigen level was an independent predictor for progression-free survival (P < 0.01). taxane 88-94 BCL2 apoptosis regulator Homo sapiens 49-54 17062688-11 2006 CONCLUSIONS: Bcl-2 expression in addition to prostate-specific antigen measurement before treatment could identify HRPC patients who may benefit from taxane-based chemotherapy. taxane 150-156 BCL2 apoptosis regulator Homo sapiens 13-18 16850164-0 2006 Involvement of IL-10 and Bcl-2 in resistance against an asbestos-induced apoptosis of T cells. Asbestos 56-64 BCL2 apoptosis regulator Homo sapiens 25-30 16966688-2 2006 We evaluated whether targeting Bcl-2 using an antisense oligonucleotide (oblimersen sodium) could improve the efficacy of systemic chemotherapy in patients with advanced melanoma. Oligonucleotides 56-71 BCL2 apoptosis regulator Homo sapiens 31-36 16966688-2 2006 We evaluated whether targeting Bcl-2 using an antisense oligonucleotide (oblimersen sodium) could improve the efficacy of systemic chemotherapy in patients with advanced melanoma. oblimersen 73-90 BCL2 apoptosis regulator Homo sapiens 31-36 16969344-6 2006 Overexpressing Bcl-2 inhibited cerulenin-mediated cell death. Cerulenin 31-40 BCL2 apoptosis regulator Homo sapiens 15-20 16435155-0 2006 Trichostatin A sensitizes TRAIL-resistant myeloma cells by downregulation of the antiapoptotic Bcl-2 proteins. trichostatin A 0-14 BCL2 apoptosis regulator Homo sapiens 95-100 16435155-6 2006 TSA treatment repressed the transcription and downregulated the expression of the antiapoptotic Bcl-2 proteins; Bcl-2 and Bcl-XL. trichostatin A 0-3 BCL2 apoptosis regulator Homo sapiens 96-101 16435155-7 2006 Surprisingly, the effect of TSA on the proapoptotic Bcl-2 proteins was mixed, the two isoforms of PUMA (alpha, beta), Noxa, Bax were downregulated, while Bim was upregulated. trichostatin A 28-31 BCL2 apoptosis regulator Homo sapiens 52-57 16435155-9 2006 CONCLUSION: In conclusion, TSA sensitized TRAIL-resistant myeloma cells by downregulating the antiapoptotic Bcl-2 protein without altering FLIP(S) expression. trichostatin A 27-30 BCL2 apoptosis regulator Homo sapiens 108-113 16435155-6 2006 TSA treatment repressed the transcription and downregulated the expression of the antiapoptotic Bcl-2 proteins; Bcl-2 and Bcl-XL. trichostatin A 0-3 BCL2 apoptosis regulator Homo sapiens 112-117 16849420-9 2006 Sensitivity of thyroid carcinoma cells to bortezomib was partially decreased by overexpression of Bcl-2 or treatment with IGF-I, whereas the combination of bortezomib with chemotherapy (doxorubicin) was synergistic. Bortezomib 42-52 BCL2 apoptosis regulator Homo sapiens 98-103 17018621-2 2006 Among the Bcl-2 family, a BH3-only member, NOXA, functions in a specific mitochondrial-based cell death pathway when melanoma cells are exposed to a proteasome inhibitor (e.g., bortezomib). Bortezomib 177-187 BCL2 apoptosis regulator Homo sapiens 10-15 17018621-3 2006 Some therapeutic agents, such as bortezomib, not only induce proapoptotic Bcl-2 family members and active conformational changes in Bak and Bax but also are associated with undesirable effects, including accumulation of antiapoptotic proteins, such as Mcl-1. Bortezomib 33-43 BCL2 apoptosis regulator Homo sapiens 74-79 17018621-4 2006 To enhance the bortezomib-mediated killing of melanoma cells, the apoptotic pathway involving NOXA was further investigated, leading to identification of an important target (i.e., the labile Bcl-2 homologue Mcl-1 but not other survival proteins). Bortezomib 15-25 BCL2 apoptosis regulator Homo sapiens 192-197 16914308-8 2006 In contrast, the 5-ASA-mediated Colo205 cell death is preventable by Bcl-2 over-expression. Mesalamine 17-22 BCL2 apoptosis regulator Homo sapiens 69-74 16624386-14 2006 CIZAR reduced expression of Bcl-2 and Bcl-xL proteins but induced expression of Bax protein. cizar 0-5 BCL2 apoptosis regulator Homo sapiens 28-33 16624386-17 2006 CIZAR(R) prevents the proliferation of OVCAR-3 cells by inactivation of m-aconitase activity and induces apoptosis by induction of proapoptotic gene (Bax), repression of antiapoptotic genes (Bcl-2, Bcl-xL), and consequently activation of caspase-3. cizar 0-5 BCL2 apoptosis regulator Homo sapiens 191-196 16935943-4 2006 Ladostigil dose-dependently decreased cell death via inhibition of the cleavage and prevention of caspase-3 activation (IC50=1.05 microM) through a mechanism related to regulation of the Bcl-2 family proteins, which resulted in reduced levels of Bad and Bax and induced levels of Bcl-2 gene and protein expression. (N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate 0-10 BCL2 apoptosis regulator Homo sapiens 187-192 16935943-4 2006 Ladostigil dose-dependently decreased cell death via inhibition of the cleavage and prevention of caspase-3 activation (IC50=1.05 microM) through a mechanism related to regulation of the Bcl-2 family proteins, which resulted in reduced levels of Bad and Bax and induced levels of Bcl-2 gene and protein expression. (N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate 0-10 BCL2 apoptosis regulator Homo sapiens 280-285 16822680-6 2006 Further, LPS (1 microgml(-1))-induced decrease in Bcl-2 and increase in Bax protein expression were fully reversed by cilostazol (10 microM) and dibutyryl cAMP (100 microM), all of which were antagonized by Rp-cAMPs (200 microM). Cilostazol 118-128 BCL2 apoptosis regulator Homo sapiens 50-55 16998471-9 2006 Moreover, the co-delivery of paclitaxel with Bcl-2-targeted small interfering RNA (siRNA) increased cytotoxicity in MDA-MB-231 human breast cancer cells. Paclitaxel 29-39 BCL2 apoptosis regulator Homo sapiens 45-50 16679036-12 2006 Rotenone also increased Bcl-2 mRNA expression and protein synthesis. Rotenone 0-8 BCL2 apoptosis regulator Homo sapiens 24-29 16835749-8 2006 The BEP2D cells stimulated with the nitrosamines showed multifold increases of the transcription of the PCNA and Bcl-2 genes by both real-time polymerase chain reaction and in-cell western assays. Nitrosamines 36-48 BCL2 apoptosis regulator Homo sapiens 113-118 16822680-6 2006 Further, LPS (1 microgml(-1))-induced decrease in Bcl-2 and increase in Bax protein expression were fully reversed by cilostazol (10 microM) and dibutyryl cAMP (100 microM), all of which were antagonized by Rp-cAMPs (200 microM). Cyclic AMP 155-159 BCL2 apoptosis regulator Homo sapiens 50-55 16904648-0 2006 Arsenic trioxide induces gallbladder carcinoma cell apoptosis via downregulation of Bcl-2. Arsenic Trioxide 0-16 BCL2 apoptosis regulator Homo sapiens 84-89 17184117-13 2006 Bcl-2 family proteins, survivin and caspases family proteins might play a role in the apoptosis process induced by DMTCCI. 3,3'-diethyl-9-methylthiacarbocyanine iodide 115-121 BCL2 apoptosis regulator Homo sapiens 0-5 17096883-7 2006 It is concluded that ouabain may induce apoptosis of Jurkat cells due to the activation of caspase-3 resulting from regulation of Bax protein and Bcl-2 gene expressions. Ouabain 21-28 BCL2 apoptosis regulator Homo sapiens 146-151 16904648-2 2006 Here, we report for the first time the pro-apoptosis role of arsenic trioxide (As2O3) in gallbladder carcinoma and identify the contribution of Bcl-2 in the As2O3-induced apoptosis. Arsenic Trioxide 157-162 BCL2 apoptosis regulator Homo sapiens 144-149 16904648-3 2006 The treatment of As2O3 in gallbladder carcinoma cells could induce apoptosis in a dose-dependent manner and downregulate the expression of anti-apoptotic protein Bcl-2 at mRNA level. Arsenic Trioxide 17-22 BCL2 apoptosis regulator Homo sapiens 162-167 16904648-4 2006 Moreover, Bcl-2 overexpression could protect gallbladder carcinoma cells from As2O3-induced apoptosis, indicating the contribution of Bcl-2 in As2O3-induced apoptosis. Arsenic Trioxide 78-83 BCL2 apoptosis regulator Homo sapiens 10-15 16904648-4 2006 Moreover, Bcl-2 overexpression could protect gallbladder carcinoma cells from As2O3-induced apoptosis, indicating the contribution of Bcl-2 in As2O3-induced apoptosis. Arsenic Trioxide 143-148 BCL2 apoptosis regulator Homo sapiens 10-15 16904648-4 2006 Moreover, Bcl-2 overexpression could protect gallbladder carcinoma cells from As2O3-induced apoptosis, indicating the contribution of Bcl-2 in As2O3-induced apoptosis. Arsenic Trioxide 143-148 BCL2 apoptosis regulator Homo sapiens 134-139 16904648-5 2006 Taken together, these results suggest that arsenic trioxide induces gallbladder carcinoma cell apoptosis via downregulation of Bcl-2, which may have important therapeutic implications in gallbladder carcinoma patients. Arsenic Trioxide 43-59 BCL2 apoptosis regulator Homo sapiens 127-132 16316721-0 2006 Triptolide induces Bcl-2 cleavage and mitochondria dependent apoptosis in p53-deficient HL-60 cells. triptolide 0-10 BCL2 apoptosis regulator Homo sapiens 19-24 16636671-3 2006 We report here that enforced Bcl-2 expression in MCF7 cells stabilizes p53, induces phosphorylation of p53 serine 15 (p53pSer15) and inhibits MCF7 cell growth. Serine 107-113 BCL2 apoptosis regulator Homo sapiens 29-34 16316721-5 2006 Importantly, triptolide induced the appearance of a truncated 23kD Bcl-2 which was inhibited by the general caspase inhibitor Z-VAD-FMK. triptolide 13-23 BCL2 apoptosis regulator Homo sapiens 67-72 17156654-10 2006 CONCLUSION: The mechanism of Bortezomib to induce apoptosis of myeloid leukemia cells is associated with down-regulation of Bcl-2 protein expression and cleaved activation of Caspase-9, Caspase-3 and PARP proteins. Bortezomib 29-39 BCL2 apoptosis regulator Homo sapiens 124-129 16316721-5 2006 Importantly, triptolide induced the appearance of a truncated 23kD Bcl-2 which was inhibited by the general caspase inhibitor Z-VAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 126-135 BCL2 apoptosis regulator Homo sapiens 67-72 16316721-7 2006 On the other hand, transfected cells overexpressing the 28kD Bcl-2 became more resistant to triptolide and upon triptolide treatment accumulated in the G(1) instead of S phase. triptolide 92-102 BCL2 apoptosis regulator Homo sapiens 61-66 16316721-7 2006 On the other hand, transfected cells overexpressing the 28kD Bcl-2 became more resistant to triptolide and upon triptolide treatment accumulated in the G(1) instead of S phase. triptolide 112-122 BCL2 apoptosis regulator Homo sapiens 61-66 16316721-10 2006 Our data suggest that in the absence of an intact p53 and without altering Bax level triptolide induces apoptosis activates a positive amplification loop involving caspase-mediated Bcl-2 cleavage/activation, mitochondrial cytochrome c release and further activation of caspases. triptolide 85-95 BCL2 apoptosis regulator Homo sapiens 181-186 16784856-8 2006 Molecular changes explored through Western-blot staining showed Tubeimoside V (1) decreased the expression levels of Bcl-2 protein and increased the expression levels of Bax protein. tubeimoside V 64-77 BCL2 apoptosis regulator Homo sapiens 117-122 16938864-8 2006 Among proliferating clones, growth arrest was accompanied by cell death in populations deplete in antiapoptotic Bcl-2: resting lymphocytes escaping low micromolar dopamine toxicity. Dopamine 163-171 BCL2 apoptosis regulator Homo sapiens 112-117 16938864-9 2006 Dysregulated bcl-2 expression, although preventing oxidative-induced caspase-dependent apoptosis, by itself conferred only minor protection against dopamine cytostasis. Dopamine 148-156 BCL2 apoptosis regulator Homo sapiens 13-18 16673127-6 2006 Bcl-2(+)/p53(+) group was found to be associated with advanced stage (p=0.008) and higher IPI (p=0.001), compared with the other groups. diprotin A 90-93 BCL2 apoptosis regulator Homo sapiens 0-5 16903866-5 2006 Further, we analyzed the effects of benomyl on the signal transduction pathways in relation to mitotic block, bcl2 phosphorylation and induction of apoptosis. Benomyl 36-43 BCL2 apoptosis regulator Homo sapiens 110-114 16805818-8 2006 Various biological parameters have been studied clinically for their ability to predict response to docetaxel, such as parameters related to: (1) efflux (p-glycoprotein) and metabolism (CYP3A4); (2) beta-tubulin (somatic mutation of beta-tubulin and changes in beta-tubulin isotypes levels); (3) cell cycle (HER2, BRCA1 and Aurora-A); and (4) apoptosis (p53, BCL2 and thioredoxin). Docetaxel 100-109 BCL2 apoptosis regulator Homo sapiens 359-363 16951189-2 2006 We have previously reported the activity of ABT-737, a potent inhibitor of Bcl-2, Bcl-X(L), and Bcl-w, which exhibits monotherapy efficacy in xenograft models of small-cell lung cancer and lymphoma and potentiates the activity of numerous cytotoxic agents. ABT-737 44-51 BCL2 apoptosis regulator Homo sapiens 75-80 16720374-7 2006 Dox-induced apoptosis included decrease in Bcl-2 expression, increase in Bak expression and caspase-3 and -9 activation but appeared to be p53- and Bax-independent. Doxycycline 0-3 BCL2 apoptosis regulator Homo sapiens 43-48 16442262-9 2006 In addition, cisplatin-induced apoptosis is abrogated by the overexpression of either Bcl-2 or Bcl-x(L), which diminished changes of mitochondrial membrane potential and decreased the amount of cytochrome c released from mitochondria. Cisplatin 13-22 BCL2 apoptosis regulator Homo sapiens 86-91 16740972-7 2006 The inhibition of apoptosis by hCG and dbcAMP was via the intrinsic pathway because the cytochalasin-D-treated cells stained intensely for Bax, whereas the cells treated with hormones, hCG, or dbcAMP stained predominantly for Bcl-2. Bucladesine 39-45 BCL2 apoptosis regulator Homo sapiens 226-231 16740972-7 2006 The inhibition of apoptosis by hCG and dbcAMP was via the intrinsic pathway because the cytochalasin-D-treated cells stained intensely for Bax, whereas the cells treated with hormones, hCG, or dbcAMP stained predominantly for Bcl-2. Bucladesine 193-199 BCL2 apoptosis regulator Homo sapiens 226-231 16903866-6 2006 The results suggest that benomyl causes loss of tension across the kinetochores, blocks the cell cycle progression at mitosis and subsequently, induces apoptosis through the bcl2-bax pathway in a manner qualitatively similar to the powerful microtubule targeted anticancer drugs like the vinca alkaloids and paclitaxel. Benomyl 25-32 BCL2 apoptosis regulator Homo sapiens 174-178 16557594-6 2006 High dose 5-FU also induced a higher regulation of the mitochondrial death genes APAF1, BAK1 and BCL2, and induction of genes of the ID family. Fluorouracil 10-14 BCL2 apoptosis regulator Homo sapiens 97-101 16879316-0 2006 Melatonin protects against hydrogen peroxide-induced cell death signaling in SH-SY5Y cultured cells: involvement of nuclear factor kappa B, Bax and Bcl-2. Melatonin 0-9 BCL2 apoptosis regulator Homo sapiens 148-153 16923163-9 2006 DHA promoted the early expression of Bcl-2, decreased Bax expression and reduced caspase-3 activation in photoreceptors. Docosahexaenoic Acids 0-3 BCL2 apoptosis regulator Homo sapiens 37-42 16879316-0 2006 Melatonin protects against hydrogen peroxide-induced cell death signaling in SH-SY5Y cultured cells: involvement of nuclear factor kappa B, Bax and Bcl-2. Hydrogen Peroxide 27-44 BCL2 apoptosis regulator Homo sapiens 148-153 16879316-10 2006 In addition, induction of Bcl-2 and Bax proteins was demonstrated in SH-SY5Y cultured cells treated with H(2)O(2), whereas the induction of Bax but not Bcl-2 was diminished by melatonin. Hydrogen Peroxide 105-113 BCL2 apoptosis regulator Homo sapiens 26-31 16762377-7 2006 The phosphorylation of Akt, an effector of PI3K, and the expression level of Bcl-2, an anti-apoptotic protein, increased with donepezil and galanthamine treatment, but not with tacrine treatment. Donepezil 126-135 BCL2 apoptosis regulator Homo sapiens 77-82 16985074-7 2006 We next showed that evodiamine induced the substantial amount of apoptosis both in Bcl-2- and Akt-overexpressing U937 cells but not in human peripheral blood mononuclear cells. evodiamine 20-30 BCL2 apoptosis regulator Homo sapiens 83-88 16985074-8 2006 Although benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone inhibited caspase activity in Bcl-2-overexpressing U937 cells, it completely prevented neither the induction of apoptosis or the nuclear translocation of apoptosis-inducing factor, which suggests that evodiamine is, at least in part, able to bypass the resistance of leukemia cells via caspase-independent apoptotic pathways. Caspase Inhibitor VI 9-58 BCL2 apoptosis regulator Homo sapiens 89-94 16762377-7 2006 The phosphorylation of Akt, an effector of PI3K, and the expression level of Bcl-2, an anti-apoptotic protein, increased with donepezil and galanthamine treatment, but not with tacrine treatment. Galantamine 140-152 BCL2 apoptosis regulator Homo sapiens 77-82 18473975-5 2006 Oblimersen is a 18-mer phosphorothioate antisense oligonucleotide designed to bind to the first six codons of the human bcl-2 mRNA. Parathion 23-39 BCL2 apoptosis regulator Homo sapiens 120-125 16974115-0 2006 Expression of Bcl-2 and Ki-67 in tamoxifen-associated endometrial polyps: comparison with postmenopausal polyps. Tamoxifen 33-42 BCL2 apoptosis regulator Homo sapiens 14-19 16974115-1 2006 BACKGROUND: The aim of this study was to evaluate the expression of Bcl-2 and Ki-67 in tamoxifen (TAM)-associated endometrial polyps and postmenopausal polyps. Tamoxifen 87-96 BCL2 apoptosis regulator Homo sapiens 68-73 16974115-1 2006 BACKGROUND: The aim of this study was to evaluate the expression of Bcl-2 and Ki-67 in tamoxifen (TAM)-associated endometrial polyps and postmenopausal polyps. Tamoxifen 98-101 BCL2 apoptosis regulator Homo sapiens 68-73 18473975-5 2006 Oblimersen is a 18-mer phosphorothioate antisense oligonucleotide designed to bind to the first six codons of the human bcl-2 mRNA. Oligonucleotides 50-65 BCL2 apoptosis regulator Homo sapiens 120-125 16937526-4 2006 Overexpression of proapoptotic factors like caspases and gadds associated with a down-regulation of antiapoptotic factors like Bcl-2, Bcl-X(L) or jun D accounted for erlotinib"s potency to induce apoptosis. gadds 57-62 BCL2 apoptosis regulator Homo sapiens 127-132 16563693-4 2006 ERK1/2 inhibition with PD98059 promoted cell death via the down-regulation of Bcl-2 protein levels, together with increasing mitochondrial damage, including the collapse of mitochondrial membrane potential, the release of cytochrome c from mitochondria to cytoplasm and caspase activity. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 23-30 BCL2 apoptosis regulator Homo sapiens 78-83 17166419-5 2006 Western blotting analysis showed that the expression of Bax and Caspase-3 up-regulated by DON was markedly decreased, while the expression of Bcl-2 down-regulated by DON was increased by 25 micromol/L Vit C pretreatment (P < 0.05). deoxynivalenol 166-169 BCL2 apoptosis regulator Homo sapiens 142-147 16814256-5 2006 Our results suggest that the protective effects of adiponectin on acetaldehyde-induced apoptosis may be ascribed to ability to induce the expression of anti-oxidant enzymes and to regulate Bcl-2 and Bax expression. Acetaldehyde 66-78 BCL2 apoptosis regulator Homo sapiens 189-194 16928273-9 2006 RESULTS: We noted both qualitative and quantitative differences in the functional activity of these two anti-apoptotic proteins in cells: Bcl-2 localized to the endoplasmic reticulum inhibits apoptosis induced by ceramide and thapsigargin but not by doxorubicin or TNFalpha, while Bcl-XL at the endoplasmic reticulum is active against all four drugs. Ceramides 213-221 BCL2 apoptosis regulator Homo sapiens 138-143 16472964-5 2006 In addition, the mechanism whereby DON and NIV induced cytotoxicity is mainly via apoptosis as we observed phosphatidylserine externalization, mitochondrial release of cytochrome c, procaspase-3 degradation and Bcl-2 degradation. deoxynivalenol 35-38 BCL2 apoptosis regulator Homo sapiens 211-216 16472964-5 2006 In addition, the mechanism whereby DON and NIV induced cytotoxicity is mainly via apoptosis as we observed phosphatidylserine externalization, mitochondrial release of cytochrome c, procaspase-3 degradation and Bcl-2 degradation. nivalenol 43-46 BCL2 apoptosis regulator Homo sapiens 211-216 17086696-7 2006 Meanwhile, ceramide increased the expression of Bax, Bad and Bid mRNA, and decreased the expression of Bcl-2 and Bcl-xl mRNA. Ceramides 11-19 BCL2 apoptosis regulator Homo sapiens 103-108 16928273-9 2006 RESULTS: We noted both qualitative and quantitative differences in the functional activity of these two anti-apoptotic proteins in cells: Bcl-2 localized to the endoplasmic reticulum inhibits apoptosis induced by ceramide and thapsigargin but not by doxorubicin or TNFalpha, while Bcl-XL at the endoplasmic reticulum is active against all four drugs. Thapsigargin 226-238 BCL2 apoptosis regulator Homo sapiens 138-143 16937526-4 2006 Overexpression of proapoptotic factors like caspases and gadds associated with a down-regulation of antiapoptotic factors like Bcl-2, Bcl-X(L) or jun D accounted for erlotinib"s potency to induce apoptosis. Erlotinib Hydrochloride 166-175 BCL2 apoptosis regulator Homo sapiens 127-132 16928273-9 2006 RESULTS: We noted both qualitative and quantitative differences in the functional activity of these two anti-apoptotic proteins in cells: Bcl-2 localized to the endoplasmic reticulum inhibits apoptosis induced by ceramide and thapsigargin but not by doxorubicin or TNFalpha, while Bcl-XL at the endoplasmic reticulum is active against all four drugs. Doxorubicin 250-261 BCL2 apoptosis regulator Homo sapiens 138-143 16928273-11 2006 Finally in MCF-7 cells, Bcl-XL is approximately ten times more active than Bcl-2 in repressing apoptosis induced by doxorubicin. Doxorubicin 116-127 BCL2 apoptosis regulator Homo sapiens 75-80 16568081-0 2006 Bcl-2 is a key regulator for the retinoic acid-induced apoptotic cell death in neuroblastoma. Tretinoin 33-46 BCL2 apoptosis regulator Homo sapiens 0-5 16568081-10 2006 This may provide a new therapeutic strategy against the ATRA-resistant and aggressive neuroblastomas by combining treatment with ATRA and a Bcl-2 inhibitor. Tretinoin 56-60 BCL2 apoptosis regulator Homo sapiens 140-145 16568081-6 2006 Enforced expression of Bcl-2 significantly inhibited ATRA-mediated apoptosis in CHP134 cells. Tretinoin 53-57 BCL2 apoptosis regulator Homo sapiens 23-28 16568081-7 2006 In addition, treatment of RTBM1 cells with a Bcl-2 inhibitor, HA14-1, enhanced apoptotic response induced by ATRA. Tretinoin 109-113 BCL2 apoptosis regulator Homo sapiens 45-50 16878868-3 2006 Peptides selected for this study are the 35 amino acid transmembrane domain of the Neu/erbB-2 protein and its point mutated (V664E) analogue expressed in some cancers, the 25 amino acid BH4 domain from the Bcl-2 antiapoptotic protein and the 15 amino acid Catestatin segment from chromogranin A found to have antimicrobial capabilities. sapropterin 186-189 BCL2 apoptosis regulator Homo sapiens 206-211 16890185-6 2006 hGSTA1-1 overexpression also provided protection to cells from DOX-induced apoptosis by inhibiting phosphorylation of c-Jun-N-terminal kinases (JNK), caspase-3 activation, and by preserving the levels of anti-apoptotic protein Bcl-2. Doxorubicin 63-66 BCL2 apoptosis regulator Homo sapiens 227-232 16806159-5 2006 Several targets of caspases and Bcl-2 family of proteins were detected and the data demonstrated that bromovulone III induced the activation of caspase-8, -9 and -3, and Bid cleavage in which the caspase-8 activation occurred the first. bromovulone 102-113 BCL2 apoptosis regulator Homo sapiens 32-37 16965675-12 2006 Co-treatment with troglitazone and epirubicin further downregulated the expression level of Bcl-2 and inhibited cell migration simultaneously. Troglitazone 18-30 BCL2 apoptosis regulator Homo sapiens 92-97 16965675-12 2006 Co-treatment with troglitazone and epirubicin further downregulated the expression level of Bcl-2 and inhibited cell migration simultaneously. Epirubicin 35-45 BCL2 apoptosis regulator Homo sapiens 92-97 16806162-7 2006 Isoflurane exposure also increased the expression of early growth response gene 1 (Egr-1) and Bcl-2, proteins downstream of ERK. Isoflurane 0-10 BCL2 apoptosis regulator Homo sapiens 94-99 16806162-10 2006 The increased expression of Egr-1 and Bcl-2 by isoflurane was inhibited by ERK inhibition. Isoflurane 47-57 BCL2 apoptosis regulator Homo sapiens 38-43 16806162-11 2006 Thus, our results suggest a role of ERK/Egr-1/Bcl-2 pathway in the isoflurane preconditioning-induced protection in the human neuroblastoma SH-SY5Y cells. Isoflurane 67-77 BCL2 apoptosis regulator Homo sapiens 46-51 16699950-3 2006 Esculetin treatment induced an increase in expression of Bax with a concomitant decrease of Bcl-2 in a time-dependent manner. esculetin 0-9 BCL2 apoptosis regulator Homo sapiens 92-97 16895478-0 2006 Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS. Paclitaxel 30-35 BCL2 apoptosis regulator Homo sapiens 124-128 16761109-1 2006 The antiapoptotic BCL2 family member MCL1 is rapidly upregulated upon exposure of ML-1 myeloid leukemia cells to either differentiation-inducing phorbol 12"-myristate 13"-acetate (PMA) or chemotherapeutic microtubule disrupting agents (MTDAs). Tetradecanoylphorbol Acetate 145-178 BCL2 apoptosis regulator Homo sapiens 18-22 16761109-1 2006 The antiapoptotic BCL2 family member MCL1 is rapidly upregulated upon exposure of ML-1 myeloid leukemia cells to either differentiation-inducing phorbol 12"-myristate 13"-acetate (PMA) or chemotherapeutic microtubule disrupting agents (MTDAs). Tetradecanoylphorbol Acetate 180-183 BCL2 apoptosis regulator Homo sapiens 18-22 16880619-5 2006 The protein expression ratio of Bcl-xL/Bax and Bcl-2/Bax was down-regulated and uncarinic acid E-induced apoptosis involves the initial phase mediated by the balance among Bcl-xL, Bcl-2 and Bax proteins, resulting in cytochrome c release from the mitochondria. uncarinic acid-E 80-96 BCL2 apoptosis regulator Homo sapiens 47-52 16880619-5 2006 The protein expression ratio of Bcl-xL/Bax and Bcl-2/Bax was down-regulated and uncarinic acid E-induced apoptosis involves the initial phase mediated by the balance among Bcl-xL, Bcl-2 and Bax proteins, resulting in cytochrome c release from the mitochondria. uncarinic acid-E 80-96 BCL2 apoptosis regulator Homo sapiens 180-185 16971768-1 2006 The effects of 20 microg/mL exogenous prostaglandin A(2) (PGA(2)) were determined on Bax, Bcl-2 and proliferating cell nuclear antigen (PCNA) expression levels in MCF-7 cells. prostaglandin A2 38-56 BCL2 apoptosis regulator Homo sapiens 90-95 16880619-8 2006 Taken together, uncarinic acid E induces apoptosis in HepG2 cells via accumulation of p53, alters the Bax/Bcl-2 ratio, and activates caspases, resulting in cytochrome c release from the mitochondria. uncarinic acid-E 16-32 BCL2 apoptosis regulator Homo sapiens 106-111 16971768-6 2006 The Bax/Bcl-2 ratio for PGA(2)-exposed cells was 2.7. prostaglandin A2 24-30 BCL2 apoptosis regulator Homo sapiens 8-13 16971768-1 2006 The effects of 20 microg/mL exogenous prostaglandin A(2) (PGA(2)) were determined on Bax, Bcl-2 and proliferating cell nuclear antigen (PCNA) expression levels in MCF-7 cells. prostaglandin A2 58-64 BCL2 apoptosis regulator Homo sapiens 90-95 16895478-0 2006 Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS. Etoposide 40-49 BCL2 apoptosis regulator Homo sapiens 124-128 16872361-4 2006 The results here demonstrate evidence for approximately 25% apoptosis after treatment with calcium salicylate, which up-regulatd the expression of p53, p21 and Bax, and down-regulated Bcl-2 in HT-1080 cells. calcium salicylate 91-109 BCL2 apoptosis regulator Homo sapiens 184-189 16855376-7 2006 In addition, biochemical examinations revealed that pretreatment or cotreatment of gemcitabine inhibited paclitaxel-induced IkappaBalpha degradation and bcl-2 phosphorylation that are believed to play critical roles in the signal pathways leading to apoptotic cell death. gemcitabine 83-94 BCL2 apoptosis regulator Homo sapiens 153-158 16855376-7 2006 In addition, biochemical examinations revealed that pretreatment or cotreatment of gemcitabine inhibited paclitaxel-induced IkappaBalpha degradation and bcl-2 phosphorylation that are believed to play critical roles in the signal pathways leading to apoptotic cell death. Paclitaxel 105-115 BCL2 apoptosis regulator Homo sapiens 153-158 16735106-7 2006 Thus, sanguinarine may overcome the phenomenon of Pgp-mediated MDR by inducing apoptosis through increasing the Bax/Bcl-2 ratio and activating caspase-3, and oncosis, which involved neither. sanguinarine 6-18 BCL2 apoptosis regulator Homo sapiens 116-121 16631166-8 2006 AR over-expression also prevented the lipid aldehyde-induced activation of caspase-3, MAPK, JNK and the expression of Bcl-2 family of proteins in HLEC. Aldehydes 44-52 BCL2 apoptosis regulator Homo sapiens 118-123 16885381-7 2006 We also show that suppression of the estrogen-induced antiapoptotic protein Bcl-2 may be involved in the antiproliferative effects of androgens and letrozole. Letrozole 148-157 BCL2 apoptosis regulator Homo sapiens 76-81 16545898-7 2006 In addition, the results showed that FME-induced apoptosis was accompanied by up-regulation of Bax and Bad, and down-regulation of Bcl-2 and Bcl-XL. NF-kB Activation Inhibitor IV 37-40 BCL2 apoptosis regulator Homo sapiens 131-136 16632641-10 2006 SP6000125 also inhibited the phosphorylation of Bcl-2 (Ser70) induced by plumbagin. sp6000125 0-9 BCL2 apoptosis regulator Homo sapiens 48-53 18156740-0 2006 Modulation of telomerase activity and human telomerase reverse transcriptase expression by caspases and bcl-2 family proteins in Cisplatin-induced cell death. Cisplatin 129-138 BCL2 apoptosis regulator Homo sapiens 104-109 16966277-6 2006 Low concentrations of 0.1 microM arsenic induced expression of the anti-apoptotic bcl-2 gene in both cell lines HL-60 and K562. Arsenic 33-40 BCL2 apoptosis regulator Homo sapiens 82-87 18156740-7 2006 This finding suggests that Bcl-2-induced telomerase activity exerts an antiapoptotic effect in cisplatin-induced death. Cisplatin 95-104 BCL2 apoptosis regulator Homo sapiens 27-32 18156740-11 2006 CONCLUSIONS: Bcl-2-induced telomerase activity inhibits cisplatin-induced apoptosis in HeLa cells, and can be regulated via both caspases and the interaction of Bcl-2 and Bak. Cisplatin 56-65 BCL2 apoptosis regulator Homo sapiens 13-18 18156740-11 2006 CONCLUSIONS: Bcl-2-induced telomerase activity inhibits cisplatin-induced apoptosis in HeLa cells, and can be regulated via both caspases and the interaction of Bcl-2 and Bak. Cisplatin 56-65 BCL2 apoptosis regulator Homo sapiens 161-166 16111802-0 2006 Combination of thiol antioxidant Silibinin with Brostallicin is associated with increase in the anti-apoptotic protein Bcl-2 and decrease in caspase 3 activity. Sulfhydryl Compounds 15-20 BCL2 apoptosis regulator Homo sapiens 119-124 16682503-0 2006 Lithium inhibits ceramide- and etoposide-induced protein phosphatase 2A methylation, Bcl-2 dephosphorylation, caspase-2 activation, and apoptosis. Lithium 0-7 BCL2 apoptosis regulator Homo sapiens 85-90 16477627-0 2006 Systemic Bcl-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV+ nasopharyngeal carcinoma xenografts in SCID mice. Oligodeoxyribonucleotides 25-45 BCL2 apoptosis regulator Homo sapiens 9-14 16477627-4 2006 We have investigated the antitumor and chemosensitizing effects of the Bcl-2 antisense oligodeoxynucleotide G3139 (oblimersen, Genasense) in NPC. Oligodeoxyribonucleotides 87-107 BCL2 apoptosis regulator Homo sapiens 71-76 16477627-4 2006 We have investigated the antitumor and chemosensitizing effects of the Bcl-2 antisense oligodeoxynucleotide G3139 (oblimersen, Genasense) in NPC. oblimersen 108-113 BCL2 apoptosis regulator Homo sapiens 71-76 16477627-13 2006 Western blots of tumor extracts obtained during oligo treatment showed that Bcl-2 levels were significantly decreased in G3139-treated animals. oblimersen 121-126 BCL2 apoptosis regulator Homo sapiens 76-81 16477627-14 2006 Our studies have demonstrated that the Bcl-2 antisense oligodeoxynucleotide, G3139, has proapoptotic effects in C666-1, and in combination with CDDP, is curative in C666-1 NPC xenograft tumors in vivo. Oligodeoxyribonucleotides 55-75 BCL2 apoptosis regulator Homo sapiens 39-44 16477627-14 2006 Our studies have demonstrated that the Bcl-2 antisense oligodeoxynucleotide, G3139, has proapoptotic effects in C666-1, and in combination with CDDP, is curative in C666-1 NPC xenograft tumors in vivo. oblimersen 77-82 BCL2 apoptosis regulator Homo sapiens 39-44 16477627-14 2006 Our studies have demonstrated that the Bcl-2 antisense oligodeoxynucleotide, G3139, has proapoptotic effects in C666-1, and in combination with CDDP, is curative in C666-1 NPC xenograft tumors in vivo. Cisplatin 144-148 BCL2 apoptosis regulator Homo sapiens 39-44 16740251-0 2006 Critical role of pro-apoptotic Bcl-2 family members in andrographolide-induced apoptosis in human cancer cells. andrographolide 55-70 BCL2 apoptosis regulator Homo sapiens 31-36 16682503-5 2006 Lithium and OA abrogated ceramide- and etoposide-induced Bcl-2 dephosphorylation at serine 70. Lithium 0-7 BCL2 apoptosis regulator Homo sapiens 57-62 16682503-5 2006 Lithium and OA abrogated ceramide- and etoposide-induced Bcl-2 dephosphorylation at serine 70. Ceramides 25-33 BCL2 apoptosis regulator Homo sapiens 57-62 16682503-5 2006 Lithium and OA abrogated ceramide- and etoposide-induced Bcl-2 dephosphorylation at serine 70. Etoposide 39-48 BCL2 apoptosis regulator Homo sapiens 57-62 16682503-5 2006 Lithium and OA abrogated ceramide- and etoposide-induced Bcl-2 dephosphorylation at serine 70. Serine 84-90 BCL2 apoptosis regulator Homo sapiens 57-62 16682503-8 2006 Taken together, lithium exhibited an antiapoptotic effect by inhibiting Bcl-2 dephosphorylation and caspase-2 activation, which involved, at least in part, a mechanism of down-regulating PP2A methylation and PP2A activity. Lithium 16-23 BCL2 apoptosis regulator Homo sapiens 72-77 16890799-2 2006 Current understanding of the role of Bcl-2 family proteins and strategies and recent developments in drug inhibitors of these proteins, particularly antisense oligonucleotides and targeted small molecules, are reviewed. Oligonucleotides 159-175 BCL2 apoptosis regulator Homo sapiens 37-42 16500682-9 2006 Of note is that for sulforaphane only, ratios of pro- to anti-apoptotic Bcl-2 family protein levels directly correlated with apoptosis induction measured by PARP cleavage. sulforaphane 20-32 BCL2 apoptosis regulator Homo sapiens 72-77 16500682-10 2006 Taken together, we demonstrated that the glucosinolate breakdown products investigated in this study have distinct profiles of cell growth inhibition, potential to induce p53-independent apoptosis and to modulate Bcl-2 family protein expression in human colon cancer cell lines. Glucosinolates 41-54 BCL2 apoptosis regulator Homo sapiens 213-218 16055262-5 2006 We then investigated effects of puerarin on expression of apoptosis-associated genes and the results revealed an increase of bax and decreases of c-myc and bcl-2. puerarin 32-40 BCL2 apoptosis regulator Homo sapiens 156-161 16111802-0 2006 Combination of thiol antioxidant Silibinin with Brostallicin is associated with increase in the anti-apoptotic protein Bcl-2 and decrease in caspase 3 activity. Silybin 33-42 BCL2 apoptosis regulator Homo sapiens 119-124 16111802-0 2006 Combination of thiol antioxidant Silibinin with Brostallicin is associated with increase in the anti-apoptotic protein Bcl-2 and decrease in caspase 3 activity. brostallicin 48-60 BCL2 apoptosis regulator Homo sapiens 119-124 16111802-5 2006 The mechanism underlying the interaction involved the apoptotic pathway as we demonstrated an increase in Bcl-2 protein levels and decrease in caspase 3 activity with the Silibinin-Brostallicin combination. Silybin 171-180 BCL2 apoptosis regulator Homo sapiens 106-111 16111802-5 2006 The mechanism underlying the interaction involved the apoptotic pathway as we demonstrated an increase in Bcl-2 protein levels and decrease in caspase 3 activity with the Silibinin-Brostallicin combination. brostallicin 181-193 BCL2 apoptosis regulator Homo sapiens 106-111 16699961-12 2006 Bcl-2 over expressing PC-3 cells, which were resistant to cisplatin induced apoptosis, underwent apoptosis following treatment with all the titanocene compounds. Cisplatin 58-67 BCL2 apoptosis regulator Homo sapiens 0-5 16790636-7 2006 Propofol 50 microM attenuated TNF-alpha and H2O2-induced cell apoptosis, accompanied by decreases in malondialdehyde and LDH production and restoration of Bcl-2 expression. Propofol 0-8 BCL2 apoptosis regulator Homo sapiens 155-160 16699961-12 2006 Bcl-2 over expressing PC-3 cells, which were resistant to cisplatin induced apoptosis, underwent apoptosis following treatment with all the titanocene compounds. titanocene compounds 140-160 BCL2 apoptosis regulator Homo sapiens 0-5 16986488-9 2006 Immunohistochemical staining with avidin-biotin was performed by using cytokeratin, vimentin, SMA, p53, Bcl 2, EMA, and CD10. avidin-biotin 34-47 BCL2 apoptosis regulator Homo sapiens 104-109 16702990-0 2006 Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular-regulated kinase pathway. Moclobemide 0-11 BCL2 apoptosis regulator Homo sapiens 24-29 16818653-0 2006 Phenethyl isothiocyanate triggers apoptosis in Jurkat cells made resistant by the overexpression of Bcl-2. phenethyl isothiocyanate 0-24 BCL2 apoptosis regulator Homo sapiens 100-105 16497706-7 2006 Panduratin A treatment to cells was found to result in inhibition of procaspases 9, 8, 6 and 3 with significant increase in the ratio of Bax:Bcl-2, suggesting the involvement of a mitochondrial-dependent apoptotic pathway. panduratin A 0-12 BCL2 apoptosis regulator Homo sapiens 141-146 16818653-2 2006 In this study, we show that whereas overexpression of the oncoprotein Bcl-2 renders Jurkat T-lymphoma cells resistant to a range of cytotoxic agents, phenethyl isothiocyanate is able to overcome the inhibitory action of Bcl-2 and trigger apoptosis. phenethyl isothiocyanate 150-174 BCL2 apoptosis regulator Homo sapiens 220-225 16818653-3 2006 A 50-fold increase in Bcl-2 expression shifted the dose-response curve, with an increase in the phenethyl isothiocyanate LD(50) from 7 to 15 micromol/L, but there was still a complete loss in cell viability at doses in excess of 20 micromol/L. phenethyl isothiocyanate 96-120 BCL2 apoptosis regulator Homo sapiens 22-27 16818653-6 2006 A structure-activity analysis showed that the phenethyl and benzyl isothiocyanates were most effective at triggering apoptosis in cells overexpressing Bcl-2 whereas phenyl isothiocyanate and benzyl thiocyanate had no proapoptotic activity. phenethyl and benzyl isothiocyanates 46-82 BCL2 apoptosis regulator Homo sapiens 151-156 16822200-5 2006 Reverse transcription-polymerase chain reaction and immunoblotting results indicated that treatments of cells with beta-lapachone resulted in down-regulation of anti-apoptotic Bcl-2 and Bcl-X(L) and up-regulation of pro-apoptotic Bax expression. beta-lapachone 115-129 BCL2 apoptosis regulator Homo sapiens 176-181 16916750-8 2006 Furthermore, Matrigel induced bcl-2 family expression was dependent on the transactivation of the EGF receptor pathway since PD98059 and AG1478 inhibited Matrigel induced bcl-2 family expression and caused HSG cells to be sensitive to CD95-mediated apoptosis. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 125-132 BCL2 apoptosis regulator Homo sapiens 30-35 16916750-8 2006 Furthermore, Matrigel induced bcl-2 family expression was dependent on the transactivation of the EGF receptor pathway since PD98059 and AG1478 inhibited Matrigel induced bcl-2 family expression and caused HSG cells to be sensitive to CD95-mediated apoptosis. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 125-132 BCL2 apoptosis regulator Homo sapiens 171-176 16513327-3 2006 The present results suggest that paclitaxel can induce apoptosis of NB-1 cells, which may be mediated by down-regulation of Bcl-2 together with up-regulation of Bax. Paclitaxel 33-43 BCL2 apoptosis regulator Homo sapiens 124-129 16864463-5 2006 In addition, apoptosis induced with julibroside J8 was associated with an increase in expression of the apoptosis inducer Bax, and a significant reduction in expression of the apoptosis suppressor Bcl-2 in mitochondria. Julibroside J8 36-50 BCL2 apoptosis regulator Homo sapiens 197-202 16710755-6 2006 The methodology by which we devise these oligonucleotides is described, using oligonucleotides directed against the oncogene, Bcl-2.4. Oligonucleotides 41-57 BCL2 apoptosis regulator Homo sapiens 126-131 16710755-6 2006 The methodology by which we devise these oligonucleotides is described, using oligonucleotides directed against the oncogene, Bcl-2.4. Oligonucleotides 78-94 BCL2 apoptosis regulator Homo sapiens 126-131 16710755-8 2006 Oligonucleotides are designed which can inhibit Bcl-2 transcription and lead to decreased mRNA and protein in vitro. Oligonucleotides 0-16 BCL2 apoptosis regulator Homo sapiens 48-53 16805953-6 2006 Sal A at 10 microM induced cell apoptosis in PDGF-BB-incubated HSCs, together with a reduction of Bcl-2 protein expression, induction of cell cycle inhibitory proteins p21 and p27, and down-regulation of cyclins D1 and E, suppression of Akt phosphorylation, reduction in PDGF receptor phosphorylation, and an increase in caspase-3 activity. salvianolic acid A 0-5 BCL2 apoptosis regulator Homo sapiens 98-103 16891473-5 2006 Clioquinol exhibited a synergistic interaction with DHA in reducing nuclear factor-kappaB activity and inducing apoptosis, and the combination reduced the level of several molecules that promote cell survival, including Akt, p65, and Bcl-2. Clioquinol 0-10 BCL2 apoptosis regulator Homo sapiens 234-239 16854582-9 2006 Cell proliferation analysis indicated that tamoxifen or ICI 182,780 reduced cell viability in a dose-dependent manner; however, KGF prevented this inhibition, which further demonstrated KGF triggered anti-apoptotic machinery through activating Bcl-2 and phospho-Akt expression. Tamoxifen 43-52 BCL2 apoptosis regulator Homo sapiens 244-249 16909596-4 2006 RESULTS: Retinoids and TTNPB could up-regulate the expression of Bax and down-regulate the expression of Bcl-2. Retinoids 9-18 BCL2 apoptosis regulator Homo sapiens 105-110 16909596-4 2006 RESULTS: Retinoids and TTNPB could up-regulate the expression of Bax and down-regulate the expression of Bcl-2. 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid 23-28 BCL2 apoptosis regulator Homo sapiens 105-110 16621793-6 2006 Message levels of CRE-driven genes such as brain-derived neurotrophic factor and the survival factor Bcl-2 were decreased in 6-OHDA-treated cells, but message levels of genes lacking CRE sequences were not affected. Oxidopamine 125-131 BCL2 apoptosis regulator Homo sapiens 101-106 16806009-1 2006 AIM: To investigate effects of bcl-2 fully phosporothioated antisense oligodeoxynucleotide(bcl-2 ASODN) on proliferation and apoptosis of human melanoma A375 cell, and its possible mechanism. Oligodeoxyribonucleotides 70-90 BCL2 apoptosis regulator Homo sapiens 31-36 16806009-1 2006 AIM: To investigate effects of bcl-2 fully phosporothioated antisense oligodeoxynucleotide(bcl-2 ASODN) on proliferation and apoptosis of human melanoma A375 cell, and its possible mechanism. Oligodeoxyribonucleotides 70-90 BCL2 apoptosis regulator Homo sapiens 91-96 16806009-2 2006 METHODS: Proliferation and apoptosis of A375 cell with bcl-2 ASODN treatment were evaluated by MTT colorimetric assay, laser scanning confocal microscope (LSCM), TUNEL and Annexin V/propidium iodide(PI), and the level of bcl-2 mRNA expression in A375 cell was detected by RT-PCR before and after being treated by bcl-2 ASODN. Propidium 182-198 BCL2 apoptosis regulator Homo sapiens 55-60 16806009-3 2006 RESULTS: MTT assay demonstrated that bcl-2 ASODN could inhibit the proliferation of the cells in both time and concentration dependent manner. monooxyethylene trimethylolpropane tristearate 9-12 BCL2 apoptosis regulator Homo sapiens 37-42 16806009-4 2006 Characteristic morphologic apoptosis changes were observed by LSCM after incubated with bcl-2 ASODN for 48 h. Most nucleus were labeled in brown by TUNEL in ASODN group, but not markedly labeled both in SODN and control group. asodn 94-99 BCL2 apoptosis regulator Homo sapiens 88-93 17007374-1 2006 OBJECTIVE: To study the effect of erythromycin on apoptosis and expression of Bax and Bcl-2 of epithelial cell in nasal polyps. Erythromycin 34-46 BCL2 apoptosis regulator Homo sapiens 86-91 16413707-6 2006 RESULTS: Endometrial polyps from tamoxifen users had significantly lower oestrogen receptor but increased progesterone receptor and Bcl-2 expression. Tamoxifen 33-42 BCL2 apoptosis regulator Homo sapiens 132-137 17147112-8 2006 RESULTS: sulindac induced morphologic alterations in BGC-823 cells, inhibited cell proliferation, increased the proportion of cells in G0/G1 phase and decreased the proportion of cells in S phase, induced apoptosis of BGC-823 cells, and decreased expressions of COX-2, bcl-2, ki-67 in the cells. Sulindac 9-17 BCL2 apoptosis regulator Homo sapiens 269-274 17147112-11 2006 CONCLUSION: sulindac may inhibit the growth of gastric cancer BGC-823 cells in vitro and the anti-tumor mechanism may be related to changes in cell cycle distribution, induction of apoptosis and inhibition of expression of COX-2, bcl-2, and ki-67. Sulindac 12-20 BCL2 apoptosis regulator Homo sapiens 230-235 16804963-5 2006 RESULTS: Tumor growth inhibitory rate, the positive expression rate of PCNA, Bax and Bcl-2 were 49.3%, 58.2%, 65.2% and 59.2% in rhGH+L-OHP group respectively; 46.6%, 62.5%, 59.7% and 64.7% in L-OHP group; 5.0%, 82.7%, 23.2% and 82.2% in rhGH group and 0, 77.8%, 23.5% and 80.3% in control group. Oxaliplatin 134-139 BCL2 apoptosis regulator Homo sapiens 85-90 16730715-3 2006 Treatment of CCRF-CEM (T cell acute lymphoblastic leukemia) cells with the GC, dexamethasone (Dex), activates p38-mitogen activated protein kinase (p38-MAPK) and then induces mRNA transcription and synthesis levels of BIM, a BH3-only pro-apoptotic BCL-2 family member. Dexamethasone 79-92 BCL2 apoptosis regulator Homo sapiens 248-253 16730715-3 2006 Treatment of CCRF-CEM (T cell acute lymphoblastic leukemia) cells with the GC, dexamethasone (Dex), activates p38-mitogen activated protein kinase (p38-MAPK) and then induces mRNA transcription and synthesis levels of BIM, a BH3-only pro-apoptotic BCL-2 family member. Dexamethasone 94-97 BCL2 apoptosis regulator Homo sapiens 248-253 16009487-0 2006 Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cisplatin 41-50 BCL2 apoptosis regulator Homo sapiens 16-21 16773715-9 2006 Meanwhile, ceramide up-regulated or down-regulated the mRNA expression of Bcl-2 family gene members. Ceramides 11-19 BCL2 apoptosis regulator Homo sapiens 74-79 16773715-10 2006 CONCLUSION: Ceramide induces apoptosis of human colon carcinoma HT-29 cells by affecting the expression of Bcl-2 family gene members and impacting the mitochondrial function. Ceramides 12-20 BCL2 apoptosis regulator Homo sapiens 107-112 16009487-8 2006 In contrast, overexpressed Bcl-2 protein inhibited cisplatin-induced Bax translocation and its downstream events in T24R2. Cisplatin 51-60 BCL2 apoptosis regulator Homo sapiens 27-32 16009487-9 2006 Downregulation of Bcl-2 by RNAi potentiated the redistribution of Bax and cytochrome c and reversed cisplatin-resistance. Cisplatin 100-109 BCL2 apoptosis regulator Homo sapiens 18-23 16009487-10 2006 Our results indicate that upregulation of Bcl-2 contributes to the development of cisplatin-resistance and usage of siRNA which targets the Bcl-2 gene may offer a potential tool to reverse the resistance to cisplatin in bladder cancer. Cisplatin 82-91 BCL2 apoptosis regulator Homo sapiens 42-47 16009487-10 2006 Our results indicate that upregulation of Bcl-2 contributes to the development of cisplatin-resistance and usage of siRNA which targets the Bcl-2 gene may offer a potential tool to reverse the resistance to cisplatin in bladder cancer. Cisplatin 82-91 BCL2 apoptosis regulator Homo sapiens 140-145 16009487-10 2006 Our results indicate that upregulation of Bcl-2 contributes to the development of cisplatin-resistance and usage of siRNA which targets the Bcl-2 gene may offer a potential tool to reverse the resistance to cisplatin in bladder cancer. Cisplatin 207-216 BCL2 apoptosis regulator Homo sapiens 140-145 16642033-3 2006 In transfected cells and isolated mitochondria, Bcl-2, but not the inactive point mutants Bcl-2-G145A and Bcl-2-V159D, undergoes a conformation change in the mitochondrial membrane in response to apoptotic agonists such as tBid and Bax. tBID 223-227 BCL2 apoptosis regulator Homo sapiens 48-53 16574665-0 2006 Vinblastine-induced apoptosis is mediated by discrete alterations in subcellular location, oligomeric structure, and activation status of specific Bcl-2 family members. Vinblastine 0-11 BCL2 apoptosis regulator Homo sapiens 147-152 16574665-3 2006 Bcl-2 was located in the mitochondria, underwent multisite phosphorylation after vinblastine treatment, and was strictly monomeric under all conditions. Vinblastine 81-92 BCL2 apoptosis regulator Homo sapiens 0-5 16455111-7 2006 The apoptosis in SW 872 human liposarcoma cells induced by quercetin was mediated through the activation of caspase-3, Bax, and Bak and then cleavage of PARP and downregulation of Bcl-2. Quercetin 59-68 BCL2 apoptosis regulator Homo sapiens 180-185 16678157-3 2006 Pretreatment of SH-SY5Y cells for 7 days, but not 1 day, with 1 mM of lithium or 0.6 mM of valproate significantly reduced rotenone and H2O2-induced cytotoxicity, cytochrome c release and caspase-3 activation, and increased Bcl-2 levels. Lithium 70-77 BCL2 apoptosis regulator Homo sapiens 224-229 16642033-4 2006 A mutant Bcl-2 with two cysteines introduced at positions predicted to result in a disulfide bond that would inhibit the mobility of alpha5-alpha6 helices (Bcl-2-S105C/E152C) was only active in a reducing environment. Cysteine 24-33 BCL2 apoptosis regulator Homo sapiens 9-14 16678157-3 2006 Pretreatment of SH-SY5Y cells for 7 days, but not 1 day, with 1 mM of lithium or 0.6 mM of valproate significantly reduced rotenone and H2O2-induced cytotoxicity, cytochrome c release and caspase-3 activation, and increased Bcl-2 levels. Valproic Acid 91-100 BCL2 apoptosis regulator Homo sapiens 224-229 16642033-4 2006 A mutant Bcl-2 with two cysteines introduced at positions predicted to result in a disulfide bond that would inhibit the mobility of alpha5-alpha6 helices (Bcl-2-S105C/E152C) was only active in a reducing environment. Cysteine 24-33 BCL2 apoptosis regulator Homo sapiens 156-161 16642033-4 2006 A mutant Bcl-2 with two cysteines introduced at positions predicted to result in a disulfide bond that would inhibit the mobility of alpha5-alpha6 helices (Bcl-2-S105C/E152C) was only active in a reducing environment. Disulfides 83-92 BCL2 apoptosis regulator Homo sapiens 9-14 16642033-4 2006 A mutant Bcl-2 with two cysteines introduced at positions predicted to result in a disulfide bond that would inhibit the mobility of alpha5-alpha6 helices (Bcl-2-S105C/E152C) was only active in a reducing environment. Disulfides 83-92 BCL2 apoptosis regulator Homo sapiens 156-161 16642033-5 2006 Thus, Bcl-2 must change the conformation to inhibit tBid-induced oligomerization of integral membrane Bax monomers and small oligomers. tBID 52-56 BCL2 apoptosis regulator Homo sapiens 6-11 16572199-4 2006 The level of Bcl-2 protein is decreased by ATRA treatment in NB4, HL-60 and HL-60/Res cells. Tretinoin 43-47 BCL2 apoptosis regulator Homo sapiens 13-18 16547588-4 2006 Our data revealed that the positive rate of PDCD5 expression in the gastric tumor tissues was significantly less than that of the normal tissues (14 out of 102 vs 36 out of 51), whereas, the decreased expression of PDCD5 protein was well correlated with the up-regulated expression of Bcl-2 in these tissues, and the up-regulated expression and nuclear translocation of PDCD5 protein were verified in the apoptotic GC cells induced by Diallyl trisulfide (DATS). diallyl trisulfide 435-453 BCL2 apoptosis regulator Homo sapiens 285-290 16547588-4 2006 Our data revealed that the positive rate of PDCD5 expression in the gastric tumor tissues was significantly less than that of the normal tissues (14 out of 102 vs 36 out of 51), whereas, the decreased expression of PDCD5 protein was well correlated with the up-regulated expression of Bcl-2 in these tissues, and the up-regulated expression and nuclear translocation of PDCD5 protein were verified in the apoptotic GC cells induced by Diallyl trisulfide (DATS). diallyl trisulfide 455-459 BCL2 apoptosis regulator Homo sapiens 285-290 16686729-2 2006 MATERIALS AND METHODS: Inhibition of Bcl-2 and Bcl-xL expression by the bispecific ASO was evaluated using real-time reverse transcription-polymerase chain reaction and Western blotting, while growth inhibition and induction of apoptosis were analysed by a crystal violet assay, flow cytometry and Western blotting of apoptosis-relevant proteins. Oligonucleotides, Antisense 83-86 BCL2 apoptosis regulator Homo sapiens 37-42 16686729-2 2006 MATERIALS AND METHODS: Inhibition of Bcl-2 and Bcl-xL expression by the bispecific ASO was evaluated using real-time reverse transcription-polymerase chain reaction and Western blotting, while growth inhibition and induction of apoptosis were analysed by a crystal violet assay, flow cytometry and Western blotting of apoptosis-relevant proteins. Gentian Violet 257-271 BCL2 apoptosis regulator Homo sapiens 37-42 16686729-8 2006 Furthermore, the apoptotic induction by Bcl-2/Bcl-xL bispecific ASO was synergistically enhanced by siRNA-mediated inhibition of clusterin, a cytoprotective chaperone that interacts with and inhibits activated Bax. Oligonucleotides, Antisense 64-67 BCL2 apoptosis regulator Homo sapiens 40-45 16740725-4 2006 We report that treatment of GIST cells with the transcriptional inhibitor flavopiridol, initially down-regulates the antiapoptotic proteins bcl-2, mcl-1, and X-linked inhibitor of apoptosis protein which occurs as early as 4 hours after exposure. alvocidib 74-86 BCL2 apoptosis regulator Homo sapiens 140-145 16817903-9 2006 Caspase 1-dependent apoptosis induced by doxorubicin was also inhibited by Bcl2 and caspase 9s, but caspase 1 activation by activated Ipaf was not inhibited by Bcl2. Doxorubicin 41-52 BCL2 apoptosis regulator Homo sapiens 75-79 16638644-6 2006 Marked morphological changes of cell apoptosis were observed very clearly by Hoechst 33258 staining as well as DNA fragmentation analysis after the cells exposed to oridonin for 60h; Western blotting showed cleavage of the caspase-3 zymogen protein (32-kDa) with the appearance of its 20-kDa subunit; Along with the apoptotic process Bcl-2 expression was down-regulated and Bax expression up-regulated concurrently observed by Western blotting. oridonin 165-173 BCL2 apoptosis regulator Homo sapiens 334-339 16638644-7 2006 We therefore conclude that oridonin can inhibit cell growth by induction of apoptosis in BEL-7402 cells via activation of caspase-3 as well as down-regulation of Bcl-2 and up-regulation of Bax expression. oridonin 27-35 BCL2 apoptosis regulator Homo sapiens 162-167 16685442-5 2006 Pharmacologic scavenging study of reactive oxygen species (ROS) revealed that synergistic augmentation of cytotoxicity was achieved by generation of ROS, which might modulate the expression of Bcl-2 family proteins, the activity of caspase-3, and mitochondrial membrane potential transition. Reactive Oxygen Species 34-57 BCL2 apoptosis regulator Homo sapiens 193-198 16685442-5 2006 Pharmacologic scavenging study of reactive oxygen species (ROS) revealed that synergistic augmentation of cytotoxicity was achieved by generation of ROS, which might modulate the expression of Bcl-2 family proteins, the activity of caspase-3, and mitochondrial membrane potential transition. Reactive Oxygen Species 59-62 BCL2 apoptosis regulator Homo sapiens 193-198 16685442-5 2006 Pharmacologic scavenging study of reactive oxygen species (ROS) revealed that synergistic augmentation of cytotoxicity was achieved by generation of ROS, which might modulate the expression of Bcl-2 family proteins, the activity of caspase-3, and mitochondrial membrane potential transition. Reactive Oxygen Species 149-152 BCL2 apoptosis regulator Homo sapiens 193-198 16778213-0 2006 Nitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitination. Nitric Oxide 0-12 BCL2 apoptosis regulator Homo sapiens 113-118 16778213-0 2006 Nitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitination. Cisplatin 43-52 BCL2 apoptosis regulator Homo sapiens 113-118 16778213-7 2006 Cisplatin resistance in H-460 cells is mediated by Bcl-2, and NO up-regulates its expression by preventing the degradation of Bcl-2 via ubiquitin-proteasome pathway. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 51-56 16778213-7 2006 Cisplatin resistance in H-460 cells is mediated by Bcl-2, and NO up-regulates its expression by preventing the degradation of Bcl-2 via ubiquitin-proteasome pathway. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 126-131 16778213-8 2006 Cisplatin-induced generation of reactive oxygen species causes dephosphorylation and degradation of Bcl-2. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 100-105 16778213-8 2006 Cisplatin-induced generation of reactive oxygen species causes dephosphorylation and degradation of Bcl-2. Reactive Oxygen Species 32-55 BCL2 apoptosis regulator Homo sapiens 100-105 16778213-10 2006 These findings indicate a novel pathway for NO regulation of Bcl-2, which provides a key mechanism for cisplatin resistance and its potential modulation for improved cancer chemotherapy. Cisplatin 103-112 BCL2 apoptosis regulator Homo sapiens 61-66 16731130-5 2006 This study tested the hypotheses (1) that hypoxia, DFX, or CoCl2 preconditioning attenuates myocardial apoptosis during DHCA; and (2) that the protective mechanism involves the altered expression of apoptosis regulatory proteins pAkt (antiapoptotic), Bcl-2 (antiapoptotic), and Bax (proapoptotic). cobaltous chloride 59-64 BCL2 apoptosis regulator Homo sapiens 251-256 16731130-11 2006 The expression of Bcl-2 was also significantly higher in the CoCl2 group (0.15 +/- 0.02) versus control (0.11 +/- 0.01, p = 0.007), whereas Bax expression was lower (0.34 +/- 0.04 versus 0.54 +/- 0.03 for control, p < 0.001). cobaltous chloride 61-66 BCL2 apoptosis regulator Homo sapiens 18-23 16731130-12 2006 CONCLUSIONS: Preconditioning with CoCl2 before prolonged DHCA in neonatal piglets attenuates myocardial apoptosis by mechanisms involving phosphorylation of Akt, upregulation of the antiapoptotic protein Bcl-2, and decreased expression of the proapoptotic protein Bax. cobaltous chloride 34-39 BCL2 apoptosis regulator Homo sapiens 204-209 16686729-0 2006 Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. Oligonucleotides 123-138 BCL2 apoptosis regulator Homo sapiens 149-154 16686729-1 2006 OBJECTIVE: To determine whether a specifically designed bispecific (Bcl-2/Bcl-xL) antisense oligonucleotide (ASO) induces apoptosis and enhances chemosensitivity in human prostate cancer LNCaP cells, as Bcl-2 and Bcl-xL are both anti-apoptotic genes associated with treatment resistance and tumour progression in many malignancies, including prostate cancer. Oligonucleotides 92-107 BCL2 apoptosis regulator Homo sapiens 68-73 16686729-1 2006 OBJECTIVE: To determine whether a specifically designed bispecific (Bcl-2/Bcl-xL) antisense oligonucleotide (ASO) induces apoptosis and enhances chemosensitivity in human prostate cancer LNCaP cells, as Bcl-2 and Bcl-xL are both anti-apoptotic genes associated with treatment resistance and tumour progression in many malignancies, including prostate cancer. Oligonucleotides, Antisense 109-112 BCL2 apoptosis regulator Homo sapiens 68-73 16731829-8 2006 Pioglitazone suppressed high glucose-induced phosphorylation of p44/42 mitogen-activated protein kinase and reduced Bcl-2 and p27(Kip1) protein levels. Pioglitazone 0-12 BCL2 apoptosis regulator Homo sapiens 116-121 16731829-8 2006 Pioglitazone suppressed high glucose-induced phosphorylation of p44/42 mitogen-activated protein kinase and reduced Bcl-2 and p27(Kip1) protein levels. Glucose 29-36 BCL2 apoptosis regulator Homo sapiens 116-121 16728570-5 2006 Evidence indicates that troglitazone and ciglitazone block BH3 domain-mediated interactions between the anti apoptotic Bcl-2 (B-cell leukemia/lymphoma 2) members Bcl-2/Bcl-xL and proapoptotic Bcl-2 members. Troglitazone 24-36 BCL2 apoptosis regulator Homo sapiens 119-124 16728570-5 2006 Evidence indicates that troglitazone and ciglitazone block BH3 domain-mediated interactions between the anti apoptotic Bcl-2 (B-cell leukemia/lymphoma 2) members Bcl-2/Bcl-xL and proapoptotic Bcl-2 members. Troglitazone 24-36 BCL2 apoptosis regulator Homo sapiens 126-152 16728570-5 2006 Evidence indicates that troglitazone and ciglitazone block BH3 domain-mediated interactions between the anti apoptotic Bcl-2 (B-cell leukemia/lymphoma 2) members Bcl-2/Bcl-xL and proapoptotic Bcl-2 members. Troglitazone 24-36 BCL2 apoptosis regulator Homo sapiens 162-167 16728570-5 2006 Evidence indicates that troglitazone and ciglitazone block BH3 domain-mediated interactions between the anti apoptotic Bcl-2 (B-cell leukemia/lymphoma 2) members Bcl-2/Bcl-xL and proapoptotic Bcl-2 members. Troglitazone 24-36 BCL2 apoptosis regulator Homo sapiens 162-167 16728570-5 2006 Evidence indicates that troglitazone and ciglitazone block BH3 domain-mediated interactions between the anti apoptotic Bcl-2 (B-cell leukemia/lymphoma 2) members Bcl-2/Bcl-xL and proapoptotic Bcl-2 members. ciglitazone 41-52 BCL2 apoptosis regulator Homo sapiens 119-124 16728570-5 2006 Evidence indicates that troglitazone and ciglitazone block BH3 domain-mediated interactions between the anti apoptotic Bcl-2 (B-cell leukemia/lymphoma 2) members Bcl-2/Bcl-xL and proapoptotic Bcl-2 members. ciglitazone 41-52 BCL2 apoptosis regulator Homo sapiens 126-152 16728570-5 2006 Evidence indicates that troglitazone and ciglitazone block BH3 domain-mediated interactions between the anti apoptotic Bcl-2 (B-cell leukemia/lymphoma 2) members Bcl-2/Bcl-xL and proapoptotic Bcl-2 members. ciglitazone 41-52 BCL2 apoptosis regulator Homo sapiens 162-167 16728570-5 2006 Evidence indicates that troglitazone and ciglitazone block BH3 domain-mediated interactions between the anti apoptotic Bcl-2 (B-cell leukemia/lymphoma 2) members Bcl-2/Bcl-xL and proapoptotic Bcl-2 members. ciglitazone 41-52 BCL2 apoptosis regulator Homo sapiens 162-167 16728570-5 2006 Evidence indicates that troglitazone and ciglitazone block BH3 domain-mediated interactions between the anti apoptotic Bcl-2 (B-cell leukemia/lymphoma 2) members Bcl-2/Bcl-xL and proapoptotic Bcl-2 members. BH 3 59-62 BCL2 apoptosis regulator Homo sapiens 119-124 16728570-5 2006 Evidence indicates that troglitazone and ciglitazone block BH3 domain-mediated interactions between the anti apoptotic Bcl-2 (B-cell leukemia/lymphoma 2) members Bcl-2/Bcl-xL and proapoptotic Bcl-2 members. BH 3 59-62 BCL2 apoptosis regulator Homo sapiens 126-152 16728570-5 2006 Evidence indicates that troglitazone and ciglitazone block BH3 domain-mediated interactions between the anti apoptotic Bcl-2 (B-cell leukemia/lymphoma 2) members Bcl-2/Bcl-xL and proapoptotic Bcl-2 members. BH 3 59-62 BCL2 apoptosis regulator Homo sapiens 162-167 16728570-5 2006 Evidence indicates that troglitazone and ciglitazone block BH3 domain-mediated interactions between the anti apoptotic Bcl-2 (B-cell leukemia/lymphoma 2) members Bcl-2/Bcl-xL and proapoptotic Bcl-2 members. BH 3 59-62 BCL2 apoptosis regulator Homo sapiens 162-167 16243419-4 2006 Compared with untreated control group, polyphenols (100 microg/ml) reduced the expression of Bcl-2 whereas those of Bax and Caspase-3 were increased. Polyphenols 39-50 BCL2 apoptosis regulator Homo sapiens 93-98 16782027-4 2006 The specific role of Noxa became apparent during glucose limitation and involves interaction with the labile Bcl-2 homolog Mcl-1. Glucose 49-56 BCL2 apoptosis regulator Homo sapiens 109-114 16760868-6 2006 RESULTS: In the TEA+GA group, the Bcl-2 positive cardiomyocytes were distinctly statistically increased compared to the GA group (P<0.001). tea 16-19 BCL2 apoptosis regulator Homo sapiens 34-39 16818496-6 2006 Indeed, the inactivation of p53 may explain the relative resistance to 5-fluorouracil, whereas Bcl-2 overexpression is associated with reduced sensitivity to gemcitabine. gemcitabine 158-169 BCL2 apoptosis regulator Homo sapiens 95-100 16585941-6 2006 Culture of cells in the presence of 25 mM D-glucose (i) enhanced apoptosis stimulated by serum depletion, (ii) enhanced activation of caspase-3, (iii) inhibited NF-kappaB activation, and (iv) decreased Bcl-2:Bax ratio. Glucose 42-51 BCL2 apoptosis regulator Homo sapiens 202-207 16585941-8 2006 Addition of TGF-beta1 to mesangial cells mimicked the effect of high glucose reducing NF-kappaB expression and Bcl-2:Bax ratio. Glucose 69-76 BCL2 apoptosis regulator Homo sapiens 111-116 16685396-1 2006 G3139 is an 18-mer phosphorothioate oligodeoxynucleotide (ODN) which has been targeted on the initiation codon region of the bcl-2 gene. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 125-130 16685396-1 2006 G3139 is an 18-mer phosphorothioate oligodeoxynucleotide (ODN) which has been targeted on the initiation codon region of the bcl-2 gene. Parathion 19-35 BCL2 apoptosis regulator Homo sapiens 125-130 16685396-1 2006 G3139 is an 18-mer phosphorothioate oligodeoxynucleotide (ODN) which has been targeted on the initiation codon region of the bcl-2 gene. Oligodeoxyribonucleotides 36-56 BCL2 apoptosis regulator Homo sapiens 125-130 16685396-1 2006 G3139 is an 18-mer phosphorothioate oligodeoxynucleotide (ODN) which has been targeted on the initiation codon region of the bcl-2 gene. Oligodeoxyribonucleotides 58-61 BCL2 apoptosis regulator Homo sapiens 125-130 16645134-9 2006 CONCLUSIONS: Our results indicate that cilostazol exerts a brain-protective effect through the CREB phosphorylation pathway leading to upregulation of Bcl-2 and COX-2 expressions and suggest that cilostazol is potentially useful for the treatment of cognitive impairment in poststroke patients. Cilostazol 39-49 BCL2 apoptosis regulator Homo sapiens 151-156 16697099-7 2006 Moreover, PARP proteins and pro-caspase 3, Bcl-2 were significantly inhibited after cantharidin treatment in T 24 cells. Cantharidin 84-95 BCL2 apoptosis regulator Homo sapiens 43-48 16635542-6 2006 Consequently, high dose of Tiron led to apoptotic cell death, which showed the DNA fragmentation, the caspase activation and the unbalance between antiapoptotic (Bcl-2) and proapoptotic proteins (Bax). 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt 27-32 BCL2 apoptosis regulator Homo sapiens 162-167 16687129-5 2006 In the present study, we used quantitative real-time reverse transcriptase-polymerase chain reaction (RT-PCR) to determine the effects of 50mM ethanol and 100nM of ipsapirone, a 5-HT(1A) agonist, on the expression of several NF-kappaB-dependent antiapoptotic genes: X-linked inhibitor of apoptosis protein (XIAP), cIAP1, cIAP2, Bcl-2, and Bcl-xl. ipsapirone 164-174 BCL2 apoptosis regulator Homo sapiens 328-333 16687129-7 2006 The results demonstrate that ethanol reduces the expression of several prosurvival genes: XIAP, cIAP1, cIAP2, Bcl-2, and Bcl-xl. Ethanol 29-36 BCL2 apoptosis regulator Homo sapiens 110-115 16687129-11 2006 Although ipsapirone treatment decreased the expression of cIAP1, Bcl-2, and Bcl-xl in control neurons, our prior studies suggest that their survival is not reduced by ipsapirone. ipsapirone 9-19 BCL2 apoptosis regulator Homo sapiens 65-70 16630579-3 2006 As Bcl2, through its BH4 domain, was previously shown to bind both Calcineurin (Can) and Raf proteins, we hypothesized that CsA inhibited Can binding to Bcl2 allowing the latter to bind more Raf at the mitochondria thereby diverting it from activating the ERK cascade. sapropterin 21-24 BCL2 apoptosis regulator Homo sapiens 3-7 16630579-6 2006 Finally, introduction of a Bcl2 BH4 domain into Daudi cells augmented ERK phosphorylation in unstimulated cells and this augmentation was unsensitive to CsA. sapropterin 32-35 BCL2 apoptosis regulator Homo sapiens 27-31 16495003-5 2006 Exposure to H2O2 induced a time-dependent decrease of Bcl-2 and SOD1 in control lymphocytes. Hydrogen Peroxide 12-16 BCL2 apoptosis regulator Homo sapiens 54-59 16407826-0 2006 Overexpression of hRFI inhibits 5-fluorouracil-induced apoptosis in colorectal cancer cells via activation of NF-kappaB and upregulation of BCL-2 and BCL-XL. Fluorouracil 32-46 BCL2 apoptosis regulator Homo sapiens 140-145 16554306-5 2006 The Bcl2 BH4 domain (amino acids 6-31) was found to bind directly to c-Myc MBII domain (amino acids 106-143), and this interaction is required for Bcl2 to enhance c-Myc transcriptional activity and inhibit DNA repair. sapropterin 9-12 BCL2 apoptosis regulator Homo sapiens 4-8 16554306-5 2006 The Bcl2 BH4 domain (amino acids 6-31) was found to bind directly to c-Myc MBII domain (amino acids 106-143), and this interaction is required for Bcl2 to enhance c-Myc transcriptional activity and inhibit DNA repair. sapropterin 9-12 BCL2 apoptosis regulator Homo sapiens 147-151 16469868-0 2006 Bcr-Abl reduces endoplasmic reticulum releasable calcium levels by a Bcl-2-independent mechanism and inhibits calcium-dependent apoptotic signaling. Calcium 49-56 BCL2 apoptosis regulator Homo sapiens 69-74 15996812-2 2006 The present work reports the involvement of Bcl-2 in response to the exposure of HEp-2 and KB cells to Carb or 5-FU. Carboplatin 103-107 BCL2 apoptosis regulator Homo sapiens 44-49 15996812-2 2006 The present work reports the involvement of Bcl-2 in response to the exposure of HEp-2 and KB cells to Carb or 5-FU. Fluorouracil 111-115 BCL2 apoptosis regulator Homo sapiens 44-49 16051428-5 2006 Both DIM and 5,5"-diBrDIM induced apoptosis in MCF-7 cells and this was accompanied by decreased Bcl-2, release of mitochondrial cytochrome c, and decreased mitochondrial membrane potential as determined by the red/green fluorescence of JC-1. 1,4-dideoxy-1,4-iminomannitol 5-8 BCL2 apoptosis regulator Homo sapiens 97-102 16051428-5 2006 Both DIM and 5,5"-diBrDIM induced apoptosis in MCF-7 cells and this was accompanied by decreased Bcl-2, release of mitochondrial cytochrome c, and decreased mitochondrial membrane potential as determined by the red/green fluorescence of JC-1. 5,5"-dibrdim 13-25 BCL2 apoptosis regulator Homo sapiens 97-102 16396631-3 2006 Treatment of HL-60 cells with taxol or okadaic acid has been shown to induce destabilization of bcl-2 mRNA, which was associated with decreased binding of trans-acting factors to bcl-2 mRNA. Paclitaxel 30-35 BCL2 apoptosis regulator Homo sapiens 96-101 16396631-3 2006 Treatment of HL-60 cells with taxol or okadaic acid has been shown to induce destabilization of bcl-2 mRNA, which was associated with decreased binding of trans-acting factors to bcl-2 mRNA. Paclitaxel 30-35 BCL2 apoptosis regulator Homo sapiens 179-184 16396631-3 2006 Treatment of HL-60 cells with taxol or okadaic acid has been shown to induce destabilization of bcl-2 mRNA, which was associated with decreased binding of trans-acting factors to bcl-2 mRNA. Okadaic Acid 39-51 BCL2 apoptosis regulator Homo sapiens 96-101 16396631-3 2006 Treatment of HL-60 cells with taxol or okadaic acid has been shown to induce destabilization of bcl-2 mRNA, which was associated with decreased binding of trans-acting factors to bcl-2 mRNA. Okadaic Acid 39-51 BCL2 apoptosis regulator Homo sapiens 179-184 16469868-7 2006 This effect is independent of Bcl-2, which is a known modulator of ER calcium homeostasis. Calcium 70-77 BCL2 apoptosis regulator Homo sapiens 30-35 16648253-1 2006 G3139, an 18-mer phosphorothioate antisense oligonucleotide targeted to the initiation codon region of the Bcl-2 mRNA, can induce caspase-dependent apoptosis via the intrinsic mitochondrial pathway in 518A2 and other melanoma cells. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 107-112 16564596-0 2006 Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. Oligodeoxyribonucleotides 49-73 BCL2 apoptosis regulator Homo sapiens 24-29 16564596-0 2006 Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. oblimersen 75-80 BCL2 apoptosis regulator Homo sapiens 24-29 16564596-7 2006 Treatment with 2 microM G3139 in Tf-conjugated liposomes resulted in >80% reduction in Bcl-2 transcript. oblimersen 24-29 BCL2 apoptosis regulator Homo sapiens 90-95 15982805-3 2006 After treated with BBSKE, a good linear correlation coefficient (r>or=0.989) between TrxR activity and cell viability exists in each cell line together with cell growth/proliferation inhibition and apoptosis through Bcl-2/Bax and Caspase-3 pathways. (1,2-bis(1,2-benzisoselenazolone-3(2H)-ketone))ethane 19-24 BCL2 apoptosis regulator Homo sapiens 219-224 16648253-1 2006 G3139, an 18-mer phosphorothioate antisense oligonucleotide targeted to the initiation codon region of the Bcl-2 mRNA, can induce caspase-dependent apoptosis via the intrinsic mitochondrial pathway in 518A2 and other melanoma cells. Oligonucleotides 44-59 BCL2 apoptosis regulator Homo sapiens 107-112 16554029-5 2006 Our results suggest that the protective effects of adiponectin on MPP+-induced apoptosis may be ascribed to its anti-oxidative properties, anti-apoptotic activity via inducing expression of SOD and catalase, and regulation of Bcl-2 and Bax expression. mangion-purified polysaccharide (Candida albicans) 66-70 BCL2 apoptosis regulator Homo sapiens 226-231 16629767-8 2006 There was a significant positive correlation between serum levels of s.Fas and that of Bcl-2 and both were significantly increased in patients with uncontrolled epilepsy. ammonium ferrous sulfate 71-74 BCL2 apoptosis regulator Homo sapiens 87-92 16827126-5 2006 The effects of (-)-gossypol on the expression of apoptotic-regulated gene markers in both death receptor- and mitochondria-mediated apoptotic pathways, such as the Bcl-2 family and caspase, etc., were detected by RT-PCR and Western blot analysis. Gossypol 15-27 BCL2 apoptosis regulator Homo sapiens 164-169 16532269-8 2006 Bcl-2 over-expression, which reduced peroxide accumulation without affecting the intracellular GSH content, attenuated necrosis generation by cadmium/H2O2 but not by cadmium/BSO. Peroxides 37-45 BCL2 apoptosis regulator Homo sapiens 0-5 16532269-8 2006 Bcl-2 over-expression, which reduced peroxide accumulation without affecting the intracellular GSH content, attenuated necrosis generation by cadmium/H2O2 but not by cadmium/BSO. Glutathione 95-98 BCL2 apoptosis regulator Homo sapiens 0-5 16532269-8 2006 Bcl-2 over-expression, which reduced peroxide accumulation without affecting the intracellular GSH content, attenuated necrosis generation by cadmium/H2O2 but not by cadmium/BSO. Cadmium 142-149 BCL2 apoptosis regulator Homo sapiens 0-5 16532269-8 2006 Bcl-2 over-expression, which reduced peroxide accumulation without affecting the intracellular GSH content, attenuated necrosis generation by cadmium/H2O2 but not by cadmium/BSO. Hydrogen Peroxide 150-154 BCL2 apoptosis regulator Homo sapiens 0-5 16532269-8 2006 Bcl-2 over-expression, which reduced peroxide accumulation without affecting the intracellular GSH content, attenuated necrosis generation by cadmium/H2O2 but not by cadmium/BSO. Cadmium 166-173 BCL2 apoptosis regulator Homo sapiens 0-5 16634625-10 2006 The results suggest that the indole sulfonamides inhibit cell proliferation at mitosis by perturbing the assembly dynamics of spindle microtubules and that they can kill cancer cells by inducing apoptosis through the bcl-2-dependent pathway. indole sulfonamides 29-48 BCL2 apoptosis regulator Homo sapiens 217-222 16424381-10 2006 In addition, ROS induced the antiapoptotic factor Bcl-2 in a TK-dependent fashion. Reactive Oxygen Species 13-16 BCL2 apoptosis regulator Homo sapiens 50-55 16827117-4 2006 Down-regulation of bcl-2 and up-regulation of bax mRNA by beta-eleostearic acid were also greater than by alpha-eleostearic acid. eleostearic acid 106-128 BCL2 apoptosis regulator Homo sapiens 19-24 16827126-8 2006 (-)-Gossypol caused apoptosis in DU-145 cells through the down-regulation of Bcl-2 and Bcl-xL and the up-regulation of Bax at the mRNA and protein levels. Gossypol 0-12 BCL2 apoptosis regulator Homo sapiens 77-82 16856578-2 2006 We report a case of malignant pheochromocytoma which showed early intense uptake and immediate rapid washout of 99mTc-tetrofosmin characterizing the overexpression of anti-apoptotic Bcl-2 and which was refractory to 131I-MIBG therapy. 3-Iodobenzylguanidine 216-225 BCL2 apoptosis regulator Homo sapiens 182-187 16856578-0 2006 A case of malignant pheochromocytoma with early intense uptake and immediate rapid washout of 99mTc-tetrofosmin characterizing the overexpression of anti-apoptotic Bcl-2. technetium tc-99m tetrofosmin 94-111 BCL2 apoptosis regulator Homo sapiens 164-169 16856578-1 2006 Defective apoptotic program due to the overexpression of the anti-apoptotic Bcl-2 protein of the outer mitochondrial membrane may be a cause of the poor response of malignant pheochromocytoma to 131I-MIBG therapy. 3-Iodobenzylguanidine 195-204 BCL2 apoptosis regulator Homo sapiens 76-81 16827126-12 2006 CONCLUSION: Our results indicated that the apoptotic processes caused by (-)-gossypol are mediated by the regulation of the Bcl-2 and caspase families in human prostate cancer cells. Gossypol 73-85 BCL2 apoptosis regulator Homo sapiens 124-129 16827131-0 2006 Involvement of Bax, Bcl-2, Ca2+ and caspase-3 in capsaicin-induced apoptosis of human leukemia HL-60 cells. Capsaicin 49-58 BCL2 apoptosis regulator Homo sapiens 20-25 16611376-0 2006 In vitro folate deficiency induces apoptosis by a p53, Fas (Apo-1, CD95) independent, bcl-2 related mechanism in phytohaemagglutinin-stimulated human peripheral blood lymphocytes. Folic Acid 9-15 BCL2 apoptosis regulator Homo sapiens 86-91 16611376-5 2006 In addition, folate deficiency was also found to downregulate IL-2, Fas antigen and bcl-2 expression, in terms of either mRNA or protein levels. Folic Acid 13-19 BCL2 apoptosis regulator Homo sapiens 84-89 16282346-6 2006 This effect was due to a selective induction of apoptosis among activated T cells that was related to caspase activation and cleavage of the antiapoptotic bcl-2 protein and was partially abolished by the addition of the pancaspase inhibitor Z-VAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 241-250 BCL2 apoptosis regulator Homo sapiens 155-160 16175394-4 2006 The first is by increased calcium in mitochondria derived from endoplasmic reticulum (ER); this calcium increase is regulated by Bcl-2 and Bax through the ER-mitochondria connection and the unfolded protein response in the ER. Calcium 26-33 BCL2 apoptosis regulator Homo sapiens 129-134 16611376-9 2006 These results suggest that IL-2 depletion by folate deficiency in lymphocytes reduces the bcl-2 level, thereby triggering deoxynucleoside triphosphate pool imbalance and p53-independent apoptosis. Folic Acid 45-51 BCL2 apoptosis regulator Homo sapiens 90-95 16611376-9 2006 These results suggest that IL-2 depletion by folate deficiency in lymphocytes reduces the bcl-2 level, thereby triggering deoxynucleoside triphosphate pool imbalance and p53-independent apoptosis. deoxynucleoside triphosphate 122-150 BCL2 apoptosis regulator Homo sapiens 90-95 16175394-4 2006 The first is by increased calcium in mitochondria derived from endoplasmic reticulum (ER); this calcium increase is regulated by Bcl-2 and Bax through the ER-mitochondria connection and the unfolded protein response in the ER. Calcium 96-103 BCL2 apoptosis regulator Homo sapiens 129-134 16651453-8 2006 We have tested our hypothesis using multiple molecular approaches and found that 3,3"-diindolylmethane inhibited cell growth and induced apoptosis in MDA-MB-231 breast cancer cells by down-regulating survivin, Bcl-2, and cdc25A expression and also caused up-regulation of p21(WAF1) expression, which could be responsible for cell cycle arrest. 3,3'-diindolylmethane 81-102 BCL2 apoptosis regulator Homo sapiens 210-215 16627975-0 2006 Chemosensitizing multiple drug resistance of human carcinoma by Bicyclol involves attenuated p-glycoprotein, GST-P and Bcl-2. bicyclol 64-72 BCL2 apoptosis regulator Homo sapiens 119-124 16627975-8 2006 Both VinRKB and AdrRMCF-7 cells showed increased GSH contents, and AdrRMCF-7 cell showed increased GST activity and the overexpression of Bcl-2 protein, by which molecules are tightly related to the MDR formation besides Mdr-1 p-glycoprotein. Glutathione 49-52 BCL2 apoptosis regulator Homo sapiens 138-143 16627975-9 2006 Bicyclol reduced the GSH contents, GST activities and Bcl-2 expression. bicyclol 0-8 BCL2 apoptosis regulator Homo sapiens 54-59 16627975-10 2006 All these data demonstrate that, by modifying the expressions of Mdr-1, GSH/GST and Bcl-2, Bicyclol increases the intracellular drug concentration and sensitizes the resistant cells to the anti-carcinoma agents. bicyclol 91-99 BCL2 apoptosis regulator Homo sapiens 84-89 16582591-12 2006 The Het-1A cells stimulated with nitrosamines showed multifold increases of the mRNA transcripts encoding PCNA and Bcl-2, and upregulated expression of the transcription factors GATA3, nuclear factor-kappaB, and STAT-1. Nitrosamines 33-45 BCL2 apoptosis regulator Homo sapiens 115-120 16651442-5 2006 Apoptosis induced by doxorubicin-DNA adducts initiates a caspase cascade that can be blocked by overexpressed Bcl-2, suggesting that adducts induce a classic mode of apoptosis. Doxorubicin 21-32 BCL2 apoptosis regulator Homo sapiens 110-115 16644678-8 2006 Consistent with the above, we found that pretreatment of nondiabetic VSMCs with high glucose abolished the degradation of Bcl-2 induced by CRP. Glucose 85-92 BCL2 apoptosis regulator Homo sapiens 122-127 16675587-10 2006 CONCLUSION: The use of Bcl-2-directed therapy and a proteasome inhibitor sensitizes human lymphoma cells to cytotoxic drugs like cyclophosphamide. Cyclophosphamide 129-145 BCL2 apoptosis regulator Homo sapiens 23-28 16697956-4 2006 Sensitivity to the cell-permeable BCL-2 antagonist ABT-737 is also related to priming of BCL-2 by activator BH3-only molecules. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 51-54 BCL2 apoptosis regulator Homo sapiens 34-39 16697956-4 2006 Sensitivity to the cell-permeable BCL-2 antagonist ABT-737 is also related to priming of BCL-2 by activator BH3-only molecules. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 51-54 BCL2 apoptosis regulator Homo sapiens 89-94 16675587-0 2006 The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Cyclophosphamide 136-152 BCL2 apoptosis regulator Homo sapiens 63-68 16675587-1 2006 PURPOSE: To determine whether the combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen can sensitize human lymphoma to cyclophosphamide. Cyclophosphamide 161-177 BCL2 apoptosis regulator Homo sapiens 93-98 16675587-8 2006 The addition of bortezomib also seemed to increase the levels of intracellular oblimersen, which resulted in a marked reduction in Bcl-2. Bortezomib 16-26 BCL2 apoptosis regulator Homo sapiens 131-136 16749867-9 2006 HPMA copolymer-bound doxorubicin induced a time-dependent decrease in the expression of the anti-apoptotic Bcl-2 and Bcl-xL proteins, which control cell survival. copolymer 5-14 BCL2 apoptosis regulator Homo sapiens 107-112 16634840-11 2006 C5a significantly increased the expression of Bcl2 mRNA (P=0.028), which was time-dependent, peaking at 30 min, and was abrogated in the presence of either wortmannin or PD98059 (both P=0.028). Wortmannin 156-166 BCL2 apoptosis regulator Homo sapiens 46-50 16634840-11 2006 C5a significantly increased the expression of Bcl2 mRNA (P=0.028), which was time-dependent, peaking at 30 min, and was abrogated in the presence of either wortmannin or PD98059 (both P=0.028). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 170-177 BCL2 apoptosis regulator Homo sapiens 46-50 16771731-8 2006 Minodronate decreased bcl-2 expression and induced bax expression, caspase-3 activity and degradation of PARP in DU145 and PC-3 cells. YM 529 0-11 BCL2 apoptosis regulator Homo sapiens 22-27 16684279-2 2006 In the present study, we compared the effects of calcipotriol and methylprednisolone aseponate (MPA) treatments on bcl-2, p53 and ki-67 expressions in psoriatic patients in order to define a relationship between regulation of apoptosis and healing process in psoriasis. calcipotriene 49-61 BCL2 apoptosis regulator Homo sapiens 115-120 16684279-2 2006 In the present study, we compared the effects of calcipotriol and methylprednisolone aseponate (MPA) treatments on bcl-2, p53 and ki-67 expressions in psoriatic patients in order to define a relationship between regulation of apoptosis and healing process in psoriasis. methylprednisolone aseponate 66-94 BCL2 apoptosis regulator Homo sapiens 115-120 16684279-2 2006 In the present study, we compared the effects of calcipotriol and methylprednisolone aseponate (MPA) treatments on bcl-2, p53 and ki-67 expressions in psoriatic patients in order to define a relationship between regulation of apoptosis and healing process in psoriasis. mpa 96-99 BCL2 apoptosis regulator Homo sapiens 115-120 16684279-9 2006 Following calcipotriol and MPA treatments, there was a significant reduction in p53 and ki-67 positivity accompanied by an increase in bcl-2 positivity (P < 0.05 each). calcipotriene 10-22 BCL2 apoptosis regulator Homo sapiens 135-140 16242776-4 2006 Inhibition of ATRA-induced apoptosis by TGF-beta1 was associated with an increased level of Mcl-1 protein, an anti-apoptotic member of Bcl-2 family, but not with inhibition of mitochondrial membrane depolarization. Tretinoin 14-18 BCL2 apoptosis regulator Homo sapiens 135-140 16307839-6 2006 In addition, chalcone also triggered the mitochondrial apoptotic signaling by increasing the amount of Bax and Bak and reducing the level of Bcl-2 and Bcl-X(L), and subsequently activated caspase-9 in MCF-7 and MDA-MB-231 cells. Chalcone 13-21 BCL2 apoptosis regulator Homo sapiens 141-146 16368533-5 2006 The antiapoptotic members of Bcl2 family such as Bcl2/Bcl-xL/Mcl-1 are phosphorylated on specific serine/threonine residues within this unstructured loop in response to diverse stimuli including treatment with chemotherapeutic taxanes, survival factor addition or chemopreventive agents. Serine 98-104 BCL2 apoptosis regulator Homo sapiens 29-33 16368533-5 2006 The antiapoptotic members of Bcl2 family such as Bcl2/Bcl-xL/Mcl-1 are phosphorylated on specific serine/threonine residues within this unstructured loop in response to diverse stimuli including treatment with chemotherapeutic taxanes, survival factor addition or chemopreventive agents. Serine 98-104 BCL2 apoptosis regulator Homo sapiens 49-53 16368533-5 2006 The antiapoptotic members of Bcl2 family such as Bcl2/Bcl-xL/Mcl-1 are phosphorylated on specific serine/threonine residues within this unstructured loop in response to diverse stimuli including treatment with chemotherapeutic taxanes, survival factor addition or chemopreventive agents. Threonine 105-114 BCL2 apoptosis regulator Homo sapiens 29-33 16368533-5 2006 The antiapoptotic members of Bcl2 family such as Bcl2/Bcl-xL/Mcl-1 are phosphorylated on specific serine/threonine residues within this unstructured loop in response to diverse stimuli including treatment with chemotherapeutic taxanes, survival factor addition or chemopreventive agents. Threonine 105-114 BCL2 apoptosis regulator Homo sapiens 49-53 16368533-5 2006 The antiapoptotic members of Bcl2 family such as Bcl2/Bcl-xL/Mcl-1 are phosphorylated on specific serine/threonine residues within this unstructured loop in response to diverse stimuli including treatment with chemotherapeutic taxanes, survival factor addition or chemopreventive agents. Taxoids 227-234 BCL2 apoptosis regulator Homo sapiens 29-33 16368533-5 2006 The antiapoptotic members of Bcl2 family such as Bcl2/Bcl-xL/Mcl-1 are phosphorylated on specific serine/threonine residues within this unstructured loop in response to diverse stimuli including treatment with chemotherapeutic taxanes, survival factor addition or chemopreventive agents. Taxoids 227-234 BCL2 apoptosis regulator Homo sapiens 49-53 16385419-8 2006 Overexpression of Bcl-2 in HeLa cells substantially attenuated triptolide-induced apoptosis. triptolide 63-73 BCL2 apoptosis regulator Homo sapiens 18-23 16731767-0 2006 Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3"-kinase/Akt pathway and Bcl-2 family proteins. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 146-151 16731767-7 2006 Resveratrol treatment for LNCaP cells was also found to result in a significant (a) loss of mitochondrial membrane potential, (b) inhibition in the protein level of antiapoptotic Bcl-2, and (c) increase in proapoptotic members of the Bcl-2 family, i.e., Bax, Bak, Bid, and Bad. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 179-184 16731767-7 2006 Resveratrol treatment for LNCaP cells was also found to result in a significant (a) loss of mitochondrial membrane potential, (b) inhibition in the protein level of antiapoptotic Bcl-2, and (c) increase in proapoptotic members of the Bcl-2 family, i.e., Bax, Bak, Bid, and Bad. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 234-239 16731767-8 2006 Taken together, our data suggested that resveratrol causes an inhibition of phosphatidylinositol 3"-kinase/Akt activation that, in turn, results in modulations in Bcl-2 family proteins in such a way that the apoptosis of LNCaP cells is promoted. Resveratrol 40-51 BCL2 apoptosis regulator Homo sapiens 163-168 16596200-0 2006 hRFI overexpressed in HCT116 cells modulates Bcl-2 family proteins when treated with 5-fluorouracil. Fluorouracil 85-99 BCL2 apoptosis regulator Homo sapiens 45-50 16596200-5 2006 As a result, we identified four genes (Bcl-2, Bcl-XL, cIAP2, and CFLAR) whose expression was four or more times higher in HCT116/ hRFI cells than in HCT116/LacZ cells, and found that Bcl-2 and the ratio of Bcl-2/Bax or Bcl-2/Bak were upregulated when HCT116/hRFI cells were treated with 5-FU. Fluorouracil 287-291 BCL2 apoptosis regulator Homo sapiens 39-44 16596200-6 2006 Furthermore, we also validated the up-regulation of Bcl-2 and Bcl-XL in HCT116/hRFI cells treated with 5-FU by Western blot analysis. Fluorouracil 103-107 BCL2 apoptosis regulator Homo sapiens 52-57 16596182-6 2006 It was also found that CDDP can increase the ratio of pro-apoptotic/pro-survival Bcl-2 members. Cisplatin 23-27 BCL2 apoptosis regulator Homo sapiens 81-86 16749867-9 2006 HPMA copolymer-bound doxorubicin induced a time-dependent decrease in the expression of the anti-apoptotic Bcl-2 and Bcl-xL proteins, which control cell survival. Doxorubicin 21-32 BCL2 apoptosis regulator Homo sapiens 107-112 16596200-7 2006 Such evidence suggests that the modulation of Bcl-2 family proteins seen in 5-FU treatment plays an important role in the anti-apoptotic function of HCT116/hRFI cells. Fluorouracil 76-80 BCL2 apoptosis regulator Homo sapiens 46-51 16443926-0 2006 The apoptotic effect of brucine from the seed of Strychnos nux-vomica on human hepatoma cells is mediated via Bcl-2 and Ca2+ involved mitochondrial pathway. brucine 24-31 BCL2 apoptosis regulator Homo sapiens 110-115 16443926-8 2006 Finally, Bcl-2 was found to predominately control the whole event of cell apoptosis induced by brucine. brucine 95-102 BCL2 apoptosis regulator Homo sapiens 9-14 16443926-9 2006 The elevation of [Ca2+]i caused by brucine was also suppressed by overexpression of Bcl-2 protein in HepG2 cells. brucine 35-42 BCL2 apoptosis regulator Homo sapiens 84-89 16446371-10 2006 PS-341 activated the BH3-only proteins Bik and Bim and down-regulated Bcl-2 and Bcl-xL mRNA and protein expression. Bortezomib 0-6 BCL2 apoptosis regulator Homo sapiens 70-75 16641227-6 2006 Reducing the expression of the proapoptotic protein Bcl-2-associated death protein (BAD) by small interfering RNA rendered SH-SY5Y cells resistant to rotenone, implicating BAD in rotenone-induced cell death. Rotenone 150-158 BCL2 apoptosis regulator Homo sapiens 52-57 16520381-2 2006 This study provides evidence that inhibition of Bcl-xL/Bcl-2 function represents a major pathway whereby alpha-tocopheryl succinate mediates apoptosis induction in prostate cancer cells. alpha-Tocopherol 105-131 BCL2 apoptosis regulator Homo sapiens 55-60 16520381-3 2006 In vitro data indicate that alpha-tocopheryl succinate was able to disrupt the binding of Bak BH3 peptide to Bcl-xL and Bcl-2 with IC50 of 26 microm, in line with its potency in antiproliferation. alpha-Tocopherol 28-54 BCL2 apoptosis regulator Homo sapiens 120-125 16520381-0 2006 alpha-Tocopheryl succinate induces apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 function. alpha-Tocopherol 0-26 BCL2 apoptosis regulator Homo sapiens 107-112 16641227-6 2006 Reducing the expression of the proapoptotic protein Bcl-2-associated death protein (BAD) by small interfering RNA rendered SH-SY5Y cells resistant to rotenone, implicating BAD in rotenone-induced cell death. Rotenone 179-187 BCL2 apoptosis regulator Homo sapiens 52-57 16631524-7 2006 These results suggest that in Jurkat cells, DNIC-thiosulfate induces Bcl-2- and caspase-independent apoptosis, which is probably secondary to local nitrosative stress at the cell surface. dnic-thiosulfate 44-60 BCL2 apoptosis regulator Homo sapiens 69-74 16361073-0 2006 Ethyl acetate extract of Patrinia scabiosaefolia downregulates anti-apoptotic Bcl-2/Bcl-X(L) expression, and induces apoptosis in human breast carcinoma MCF-7 cells independent of caspase-9 activation. ethyl acetate 0-13 BCL2 apoptosis regulator Homo sapiens 78-83 16616141-1 2006 In the present study, we evidence how in breast cancer cells low doses of Taxol for 18 h determined the upregulation of p53 and p21 waf expression concomitantly with a decrease of the anti-apoptotic Bcl-2. Paclitaxel 74-79 BCL2 apoptosis regulator Homo sapiens 199-204 16618754-7 2006 Our results showed that the production of hydrogen peroxide derived from MnSOD dismutation activated caspase-8, which might down-regulate Bcl-2 expression and induce Bax translocation to mitochondria. Hydrogen Peroxide 42-59 BCL2 apoptosis regulator Homo sapiens 138-143 16631524-8 2006 We hypothesize that the local release of nonheme Fe-NO species by activated macrophages may play a role in the killing of malignant cells that have high Bcl-2 levels. flubendiamide 49-54 BCL2 apoptosis regulator Homo sapiens 153-158 16288206-4 2006 Here, we describe a novel Bcl-x splice product of 138 amino acids termed Bcl-xAK (Atypical Killer), which encloses the Bcl-2 homology domains BH2 and BH4 as well as the transmembrane domain, but lacks BH1 and BH3. bh2 142-145 BCL2 apoptosis regulator Homo sapiens 119-124 16481323-0 2006 The mitochondrial effects of small organic ligands of BCL-2: sensitization of BCL-2-overexpressing cells to apoptosis by a pyrimidine-2,4,6-trione derivative. pyrimidine-2,4,6-trione 123-146 BCL2 apoptosis regulator Homo sapiens 54-59 16481323-0 2006 The mitochondrial effects of small organic ligands of BCL-2: sensitization of BCL-2-overexpressing cells to apoptosis by a pyrimidine-2,4,6-trione derivative. pyrimidine-2,4,6-trione 123-146 BCL2 apoptosis regulator Homo sapiens 78-83 16481323-6 2006 EM20-25 neutralized the antiapoptotic activity of overexpressed BCL-2 toward staurosporine and sensitized BCL-2-expressing cells from leukemic patients to the killing effects of staurosporine, chlorambucil, and fludarabine. Staurosporine 77-90 BCL2 apoptosis regulator Homo sapiens 64-69 16481323-6 2006 EM20-25 neutralized the antiapoptotic activity of overexpressed BCL-2 toward staurosporine and sensitized BCL-2-expressing cells from leukemic patients to the killing effects of staurosporine, chlorambucil, and fludarabine. Chlorambucil 193-205 BCL2 apoptosis regulator Homo sapiens 64-69 16481323-6 2006 EM20-25 neutralized the antiapoptotic activity of overexpressed BCL-2 toward staurosporine and sensitized BCL-2-expressing cells from leukemic patients to the killing effects of staurosporine, chlorambucil, and fludarabine. fludarabine 211-222 BCL2 apoptosis regulator Homo sapiens 64-69 16288206-2 2006 Whereas antiapoptotic proteins of the family share all four Bcl-2 homology domains (BH1-BH4), proapoptotic members may lack some of these domains, but all so far described proapoptotic Bcl-2 proteins enclose BH3. BH 3 208-211 BCL2 apoptosis regulator Homo sapiens 185-190 16288206-4 2006 Here, we describe a novel Bcl-x splice product of 138 amino acids termed Bcl-xAK (Atypical Killer), which encloses the Bcl-2 homology domains BH2 and BH4 as well as the transmembrane domain, but lacks BH1 and BH3. bh1 201-204 BCL2 apoptosis regulator Homo sapiens 119-124 16288206-4 2006 Here, we describe a novel Bcl-x splice product of 138 amino acids termed Bcl-xAK (Atypical Killer), which encloses the Bcl-2 homology domains BH2 and BH4 as well as the transmembrane domain, but lacks BH1 and BH3. BH 3 209-212 BCL2 apoptosis regulator Homo sapiens 119-124 16613675-3 2006 This study was to investigate the effect of UA on COX-2, Bcl-2 and Bax expression in human gastric cancer cell line SGC7901, and explore its potential mechanisms of inhibiting proliferation and inducing apoptosis. ursolic acid 44-46 BCL2 apoptosis regulator Homo sapiens 57-62 16613675-9 2006 When treated with 20-40 micromol/L UA for 24 h, SGC7901 cells were arrested at G0/G1 phase, and the apoptosis rates were (9.10+/-2.39)%, (26.30+/-1.25)%, and (35.20+/-2.26)%, respectively; meanwhile, COX-2 expression and its catalysate PGE2 were decreased, Bcl-2 expression was also decreased, whereas Bax expression was unchanged. ursolic acid 35-37 BCL2 apoptosis regulator Homo sapiens 257-262 16613675-10 2006 CONCLUSION: UA could inhibit proliferation and induce apoptosis of SGC7901 cells through arresting cell cycle, inhibiting COX-2 expression to reduce PGE2 production and down-regulate Bcl-2 expression. ursolic acid 12-14 BCL2 apoptosis regulator Homo sapiens 183-188 16195754-1 2006 G3139 is a phosphorothioate oligodeoxyribonucleotide that is targeted to the initiation codon region of the Bcl-2 mRNA, which downregulates Bcl-2 protein and mRNA expression via an antisense mechanism. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 108-113 16609701-0 2006 ZNRD1 mediates resistance of gastric cancer cells to methotrexate by regulation of IMPDH2 and Bcl-2. Methotrexate 53-65 BCL2 apoptosis regulator Homo sapiens 94-99 16322093-7 2006 Moreover, Lbc expression confers increased resistance to genotoxic stress induced by doxorubicin, which is associated with upregulation of Bcl-2 and BAD phosphorylation, and this is reversed by a Rho inhibitor. Doxorubicin 85-96 BCL2 apoptosis regulator Homo sapiens 139-144 16528476-2 2006 In this study, we demonstrated that NAPS induces apoptosis of Jurkat cells by activating Bak, but not Bax, which are both members of a proapoptotic subfamily of the Bcl-2 proteins. N-acetylphytosphingosine 36-40 BCL2 apoptosis regulator Homo sapiens 165-170 16474974-8 2006 Western blot analysis revealed an apparent time-dependent reduction in Bcl-2 protein levels in ciglitazone-treated melanocytes. ciglitazone 95-106 BCL2 apoptosis regulator Homo sapiens 71-76 16195754-1 2006 G3139 is a phosphorothioate oligodeoxyribonucleotide that is targeted to the initiation codon region of the Bcl-2 mRNA, which downregulates Bcl-2 protein and mRNA expression via an antisense mechanism. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 140-145 16195754-1 2006 G3139 is a phosphorothioate oligodeoxyribonucleotide that is targeted to the initiation codon region of the Bcl-2 mRNA, which downregulates Bcl-2 protein and mRNA expression via an antisense mechanism. phosphorothioate oligodeoxyribonucleotide 11-52 BCL2 apoptosis regulator Homo sapiens 108-113 16518826-0 2006 Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. Imatinib Mesylate 127-144 BCL2 apoptosis regulator Homo sapiens 14-19 16518826-3 2006 To the authors" knowledge, the current study is the first to evaluate Bcl-2 expression in pre-imatinib GIST tissue samples as a prognostic marker of progression-free survival (PFS) time in patients treated with imatinib. Imatinib Mesylate 94-102 BCL2 apoptosis regulator Homo sapiens 70-75 16518826-3 2006 To the authors" knowledge, the current study is the first to evaluate Bcl-2 expression in pre-imatinib GIST tissue samples as a prognostic marker of progression-free survival (PFS) time in patients treated with imatinib. Imatinib Mesylate 211-219 BCL2 apoptosis regulator Homo sapiens 70-75 16195754-1 2006 G3139 is a phosphorothioate oligodeoxyribonucleotide that is targeted to the initiation codon region of the Bcl-2 mRNA, which downregulates Bcl-2 protein and mRNA expression via an antisense mechanism. phosphorothioate oligodeoxyribonucleotide 11-52 BCL2 apoptosis regulator Homo sapiens 140-145 16518826-11 2006 CONCLUSIONS: In contrast to studies performed in the preimatinib era, in which Bcl-2 was found to be a negative prognostic indicator, the current study suggests a trend toward better PFS with increasing Bcl-2 expression level in GISTs from patients subsequently treated with imatinib. Imatinib Mesylate 56-64 BCL2 apoptosis regulator Homo sapiens 203-208 16518826-12 2006 Larger studies may help elucidate the influence of Bcl-2 expression on PFS after therapy with imatinib. Imatinib Mesylate 94-102 BCL2 apoptosis regulator Homo sapiens 51-56 16195754-2 2006 In previous work, we have demonstrated that the phenotype observed in several prostate and melanoma cell lines after treatment with G3139 appears to be Bcl-2 independent. oblimersen 132-137 BCL2 apoptosis regulator Homo sapiens 152-157 16231322-4 2006 This study was undertaken to elucidate the effect of FHIT expression and the role of Bcl-2-caspase signaling in paclitaxel-induced apoptosis in lung cancer cells. Paclitaxel 112-122 BCL2 apoptosis regulator Homo sapiens 85-90 16396982-7 2006 We confirmed that wortmannin blocked Akt phosphorylation and the downstream targets of the PI3K/Akt cascade, such as BAD (Bcl-2-associated death protein) and nuclear factor-kappaB in vivo by immunohistochemical staining and Western blotting. Wortmannin 18-28 BCL2 apoptosis regulator Homo sapiens 122-127 16307838-0 2006 T-2 toxin induces apoptosis, and selenium partly blocks, T-2 toxin induced apoptosis in chondrocytes through modulation of the Bax/Bcl-2 ratio. Selenium 33-41 BCL2 apoptosis regulator Homo sapiens 131-136 16307838-8 2006 Selenium could partly block the apoptosis of chondrocytes induced by T-2 toxin through decreasing the Bax/Bcl-2 ratio. Selenium 0-8 BCL2 apoptosis regulator Homo sapiens 106-111 16615003-11 2006 Treatment of CRC with CLX resulted in a significant decrease in serum levels of progastrin and this was accompanied by an increment in tumor expression of COX-2 with a concomitant reduction in gastrin, Bcl-2, survivin, and NFkappa B expression. Celecoxib 22-25 BCL2 apoptosis regulator Homo sapiens 202-207 16523333-14 2006 In most patients, the BCL-2/BAX ratio was lower in cell cultures supplemented with mixture of lovastatin and thalidomide in comparison with cell cultures supplemented with lovastatin or thalidomide alone. Lovastatin 94-104 BCL2 apoptosis regulator Homo sapiens 22-27 16523333-14 2006 In most patients, the BCL-2/BAX ratio was lower in cell cultures supplemented with mixture of lovastatin and thalidomide in comparison with cell cultures supplemented with lovastatin or thalidomide alone. Thalidomide 109-120 BCL2 apoptosis regulator Homo sapiens 22-27 16523333-14 2006 In most patients, the BCL-2/BAX ratio was lower in cell cultures supplemented with mixture of lovastatin and thalidomide in comparison with cell cultures supplemented with lovastatin or thalidomide alone. Thalidomide 186-197 BCL2 apoptosis regulator Homo sapiens 22-27 16704097-0 2006 [Effect on apoptosis of Tca8113 of interference of Bcl-2 and HER-2 genes antisense oligodeoxynucleotides transfection]. tca8113 24-31 BCL2 apoptosis regulator Homo sapiens 51-56 16231322-11 2006 Bcl-2 and Bcl-xL expressions were down-regulated after paclitaxel treatment in FHIT-expressing cells, whereas Bax and Bad expressions were up-regulated. Paclitaxel 55-65 BCL2 apoptosis regulator Homo sapiens 0-5 16565407-10 2006 DHA, the retina major polyunsaturated fatty acid, which protects photoreceptors from oxidative stress-induced apoptosis, completely blocked C2-ceramide-induced photoreceptor death, simultaneously increasing Bcl-2 expression. Docosahexaenoic Acids 0-3 BCL2 apoptosis regulator Homo sapiens 207-212 16565407-10 2006 DHA, the retina major polyunsaturated fatty acid, which protects photoreceptors from oxidative stress-induced apoptosis, completely blocked C2-ceramide-induced photoreceptor death, simultaneously increasing Bcl-2 expression. Fatty Acids, Unsaturated 22-48 BCL2 apoptosis regulator Homo sapiens 207-212 16231322-13 2006 These results indicate that paclitaxel-induced apoptosis enhanced by FHIT expression in lung cancer cells might be associated with modulation of Bcl-2-caspase signaling. Paclitaxel 28-38 BCL2 apoptosis regulator Homo sapiens 145-150 16565407-13 2006 DHA prevented oxidative stress and ceramide damage by upregulating Bcl-2 expression and glucosylating ceramide, thus decreasing its intracellular concentration. Docosahexaenoic Acids 0-3 BCL2 apoptosis regulator Homo sapiens 67-72 16498393-1 2006 We compared antisense phosphorothioate oligonucleotides (PS-ODN) that target BCL-2 such as Genasense (G3139-PS), with other PS-ODN or phosphodiester-ODN (PO-ODN) in their relative capacity to induce apoptosis of chronic lymphocytic leukemia (CLL) B cells in vitro. Phosphorothioate Oligonucleotides 22-55 BCL2 apoptosis regulator Homo sapiens 77-82 16464945-8 2006 Asoprisnil increased the TUNEL-positive rate, cleaved caspase-3, and cleaved poly(adenosine 5"-diphosphate-ribose) polymerase expression and decreased Bcl-2 protein expression in cultured leiomyoma cells. asoprisnil 0-10 BCL2 apoptosis regulator Homo sapiens 151-156 16314959-6 2006 Treatment of cells with TV at 15 microM for 24 h resulted in an increase in the activity of caspase-3, evidenced by colorimetric assay, and a dramatic up-regulation of p53, accompanied with a significant increase of Bax/Bcl-2 ratio, as evidenced by immunofluorescence assay. tetrazolium violet 24-26 BCL2 apoptosis regulator Homo sapiens 220-225 16519769-6 2006 Furthermore, Bax expression increased together with p53 and p21(WAF1/CIP1), while the Bcl-2 expression decreased in the immortalized and malignant keratinocytes treated with DFO. Deferoxamine 174-177 BCL2 apoptosis regulator Homo sapiens 86-91 16162358-0 2006 Nocodazole, a microtubule de-polymerising agent, induces apoptosis of chronic lymphocytic leukaemia cells associated with changes in Bcl-2 phosphorylation and expression. Nocodazole 0-10 BCL2 apoptosis regulator Homo sapiens 133-138 16162358-6 2006 Nocodazole causes two patterns of change to Bcl-2 expression. Nocodazole 0-10 BCL2 apoptosis regulator Homo sapiens 44-49 16162358-7 2006 In one there is increase in expression of the serine-70 phosphorylated form of Bcl-2 and in the other total Bcl-2 expression is reduced. Serine 46-52 BCL2 apoptosis regulator Homo sapiens 79-84 16498393-1 2006 We compared antisense phosphorothioate oligonucleotides (PS-ODN) that target BCL-2 such as Genasense (G3139-PS), with other PS-ODN or phosphodiester-ODN (PO-ODN) in their relative capacity to induce apoptosis of chronic lymphocytic leukemia (CLL) B cells in vitro. ps-odn 57-63 BCL2 apoptosis regulator Homo sapiens 77-82 16498393-3 2006 All tested thimidine-containing PS-ODN, irrespective of their primary sequences, reduced the expression of Bcl-2 protein and increased the levels of the proapoptotic molecules p53, Bid, Bax in CLL cells. thimidine 11-20 BCL2 apoptosis regulator Homo sapiens 107-112 16498393-5 2006 We conclude that thymidine-containing PS-ODN can activate CLL cells and induce apoptosis via a mechanism that is independent of BCL-2 gene interference or CpG motifs. Thymidine 17-26 BCL2 apoptosis regulator Homo sapiens 128-133 16616063-7 2006 Therefore, miR-15 and miR-16 are natural antisense Bcl2 interactors that could be used for therapy of Bcl2-overexpressing tumors. mir-15 11-17 BCL2 apoptosis regulator Homo sapiens 51-55 15770638-2 2006 Microarray analysis by ATRA treatment for 48 hr in peripheral blood mononuclear cells (in vivo) and in cultured bone marrow mononuclear cells (in vitro) from a patient with APL revealed upregulation of CD11b, CD11c, CCAAT enhancer binding protein epsilon, Rb1, Mad, and tumor necrosis factor-related genes; and downregulation of hTERT, c-Myc, WT1, bcl-2, and eukaryotic translation elongation factor 1alpha2. Tretinoin 23-27 BCL2 apoptosis regulator Homo sapiens 348-353 16534555-0 2006 Rosmarinic acid failed to suppress hydrogen peroxide-mediated apoptosis but induced apoptosis of Jurkat cells which was suppressed by Bcl-2. rosmarinic acid 0-15 BCL2 apoptosis regulator Homo sapiens 134-139 16534555-6 2006 Overexpression of Bcl-2 protected Jurkat cells from both H2O2- and RosA-induced apoptosis by altering the ratio of anti- to pro-apoptotic members of the Bcl-2 family. Hydrogen Peroxide 57-61 BCL2 apoptosis regulator Homo sapiens 18-23 16525653-7 2006 Immunoblotting showed PARP cleavage in the presence of mifepristone 10(-4) M. Caspase-3 and bcl-2 expression was reduced by mifepristone 10(-4) and 10(-7) M. These results suggest that progesterone has a paradoxical effect on OVCAR-3 cell proliferation, stimulating it at low concentrations and inhibiting it at high concentrations, potentially through a caspase-independent non-apoptotic death pathway. Mifepristone 55-67 BCL2 apoptosis regulator Homo sapiens 92-97 16525653-7 2006 Immunoblotting showed PARP cleavage in the presence of mifepristone 10(-4) M. Caspase-3 and bcl-2 expression was reduced by mifepristone 10(-4) and 10(-7) M. These results suggest that progesterone has a paradoxical effect on OVCAR-3 cell proliferation, stimulating it at low concentrations and inhibiting it at high concentrations, potentially through a caspase-independent non-apoptotic death pathway. Mifepristone 124-136 BCL2 apoptosis regulator Homo sapiens 92-97 16525653-8 2006 Mifepristone seems to inhibit OVCAR-3 cell proliferation by down-regulating bcl-2 and up-regulating caspase-3 activity. Mifepristone 0-12 BCL2 apoptosis regulator Homo sapiens 76-81 16616063-7 2006 Therefore, miR-15 and miR-16 are natural antisense Bcl2 interactors that could be used for therapy of Bcl2-overexpressing tumors. mir-15 11-17 BCL2 apoptosis regulator Homo sapiens 102-106 16380382-4 2006 Here we show that NMDA- and K25-mediated neuroprotection is associated with an increase in the levels of Bcl-2, an inhibition of K5-mediated increase in Bax, and the inhibition of the release of apoptogenic factors from mitochondria such as Smac/DIABLO and cytochrome c. N-Methylaspartate 18-22 BCL2 apoptosis regulator Homo sapiens 105-110 16472763-8 2006 These results support the hypothesis that Abeta-induced neurotoxicity occurs via bax over-expression, bcl-2 down-regulation, and caspase-3 activation, first indicating that methionine 35 redox state may alter this cell death pathway. Methionine 173-183 BCL2 apoptosis regulator Homo sapiens 102-107 16446060-1 2006 Bid, BH3-interacting domain death agonist, was initially cloned based in its ability to interact with both Bcl-2 and Bax. BH 3 5-8 BCL2 apoptosis regulator Homo sapiens 107-112 16638347-4 2006 Immunohistochemical technique was used to determine the expression of bax, bcl-2 and vascular endothelial growth factor (VEGF) proteins after treatment with 10 micromol/L of mifepristone. Mifepristone 174-186 BCL2 apoptosis regulator Homo sapiens 75-80 16638347-8 2006 Immunohistochemical technique showed the expression of bcl-2 and VEGF in the DU-145 and PC-3 cells treated with 10 micromol/L of mifepristone were significantly decreased, and the expression of bax was increased. Mifepristone 129-141 BCL2 apoptosis regulator Homo sapiens 55-60 16638347-11 2006 Mifepristone could initiate a cell death command via apoptotic pathways decreasing the expression of VEGF protein, downregulating the expression of bcl-2 protein and increasing the expression of bax protein. Mifepristone 0-12 BCL2 apoptosis regulator Homo sapiens 148-153 16407243-0 2006 The inflammatory mediator leukotriene D4 induces beta-catenin signaling and its association with antiapoptotic Bcl-2 in intestinal epithelial cells. Leukotriene D4 26-40 BCL2 apoptosis regulator Homo sapiens 111-116 15876485-0 2006 Increased thromboxane B(2) levels are associated with lipid peroxidation and Bcl-2 expression in human lung carcinoma. thromboxane b 10-23 BCL2 apoptosis regulator Homo sapiens 77-82 16540661-7 2006 The expression of Gal-3 stimulated the phosphorylation of Ser(112) of Bcl-2-associated death (Bad) protein and down-regulated Bad expression after treatment with cis-diammine-dichloroplatinum. Serine 58-61 BCL2 apoptosis regulator Homo sapiens 70-75 16319070-10 2006 Knockdown of STAT3 by STAT3-small interfering RNA negated the inhibitory effect of PTP inhibitor on troglitazone, indicating that troglitazone uses a STAT3 inactivation mechanism that makes caspase-8/9 activities susceptible to cytotoxic agents in glioma cells and that PTP1B plays a critical role in the down-regulation of activated STAT3, as well as FLIP and Bcl-2. Troglitazone 130-142 BCL2 apoptosis regulator Homo sapiens 361-366 16407243-5 2006 We also show that in the presence of LTD4, free beta-catenin translocates to the mitochondria where it associates with the cell survival protein Bcl-2. Leukotriene D4 37-41 BCL2 apoptosis regulator Homo sapiens 145-150 16407243-6 2006 We hypothesize that LTD4 may enhance cell survival via activation of beta-catenin signaling, in particular, by promoting the association of beta-catenin with Bcl-2 in the mitochondria. Leukotriene D4 20-24 BCL2 apoptosis regulator Homo sapiens 158-163 16380382-4 2006 Here we show that NMDA- and K25-mediated neuroprotection is associated with an increase in the levels of Bcl-2, an inhibition of K5-mediated increase in Bax, and the inhibition of the release of apoptogenic factors from mitochondria such as Smac/DIABLO and cytochrome c. 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole 28-31 BCL2 apoptosis regulator Homo sapiens 105-110 16520894-5 2006 In addition, pioglitazone caused a down-regulation of the X chromosome-linked inhibitor of apoptosis (XIAP), Bcl-2, and cyclooxygenase-2 (COX-2) under conditions leading to PPARgamma down-regulation. Pioglitazone 13-25 BCL2 apoptosis regulator Homo sapiens 109-114 16354662-11 2006 Furthermore, DNCB and juglone were potent inducers of apoptosis also in Bcl2 overexpressing HeLa cells or in A549 cells. Dinitrochlorobenzene 13-17 BCL2 apoptosis regulator Homo sapiens 72-76 16354662-11 2006 Furthermore, DNCB and juglone were potent inducers of apoptosis also in Bcl2 overexpressing HeLa cells or in A549 cells. juglone 22-29 BCL2 apoptosis regulator Homo sapiens 72-76 16538384-0 2006 p38 Mitogen-activated protein kinases is required for counteraction of 2-methoxyestradiol to estradiol-stimulated cell proliferation and induction of apoptosis in ovarian carcinoma cells via phosphorylation Bcl-2. 2-Methoxyestradiol 71-89 BCL2 apoptosis regulator Homo sapiens 207-212 16520894-6 2006 These results suggest that pioglitazone may have therapeutic relevance or significance in the treatment of human CRC, and the down-regulation of XIAP, Bcl-2, and COX-2 may contribute to pioglitazone-induced apoptosis in these and other RB-deficient cell lines and tumors. Pioglitazone 186-198 BCL2 apoptosis regulator Homo sapiens 151-156 16538384-0 2006 p38 Mitogen-activated protein kinases is required for counteraction of 2-methoxyestradiol to estradiol-stimulated cell proliferation and induction of apoptosis in ovarian carcinoma cells via phosphorylation Bcl-2. Estradiol 80-89 BCL2 apoptosis regulator Homo sapiens 207-212 16520895-0 2006 Increasing ornithine decarboxylase activity is another way of prolactin preventing methotrexate-induced apoptosis: crosstalk between ODC and BCL-2. Methotrexate 83-95 BCL2 apoptosis regulator Homo sapiens 141-146 16520895-11 2006 However, Bcl-2 is further enhanced following prolactin stimulation for 4 h and this enhancement is blocked by DFMO. Eflornithine 110-114 BCL2 apoptosis regulator Homo sapiens 9-14 16520895-12 2006 Bcl-2 has no effect on ODC activity and protein levels, but ODC upregulates Bcl-2, which is inhibited by DFMO. Eflornithine 105-109 BCL2 apoptosis regulator Homo sapiens 76-81 16619505-3 2006 G3139, a phosphorothioate antisense ODN against human bcl2 mRNA, was evaluated in this study. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 54-58 16501812-4 2006 Bcl-2 expression decreased from a median fluorescence index (MFI) of 331.71 +/- 42.2 to 245.81 +/- 52.2 (P < 0.001) after fludarabine treatment, but there was no difference between viable cells (331.57 +/- 44.6 MFI) and apoptotic cells (331.71 +/- 42.2 MFI) before incubation (P = 0.859). fludarabine 125-136 BCL2 apoptosis regulator Homo sapiens 0-5 16444746-6 2006 In particular, the combination valproate-imatinib downregulated the expression of Bcr-Abl and the antiapoptotic protein Bcl-2, which is particularly overexpressed in imatinib-resistant clones. Valproic Acid 31-40 BCL2 apoptosis regulator Homo sapiens 120-125 16380381-3 2006 Here, we have identified the anti-apoptotic Bcl-2 family member Mcl-1 as a potent tBid-binding partner. tBID 82-86 BCL2 apoptosis regulator Homo sapiens 44-49 16380381-4 2006 Site-directed mutagenesis reveals that the Bcl-2 homology (BH)3 domain of tBid is essential for binding to Mcl-1, whereas all three BH domains (BH1, BH2, and BH3) of Mcl-1 are required for interaction with tBid. tBID 74-78 BCL2 apoptosis regulator Homo sapiens 43-48 16380381-4 2006 Site-directed mutagenesis reveals that the Bcl-2 homology (BH)3 domain of tBid is essential for binding to Mcl-1, whereas all three BH domains (BH1, BH2, and BH3) of Mcl-1 are required for interaction with tBid. tBID 206-210 BCL2 apoptosis regulator Homo sapiens 43-48 16510597-2 2006 We show here that ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA14-1), a small organic compound recently proposed to function as an inhibitor of Bcl-2, increases the sensitivity of human glioblastoma cells to radiotherapy and chemotherapy. ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate 18-97 BCL2 apoptosis regulator Homo sapiens 182-187 16444746-6 2006 In particular, the combination valproate-imatinib downregulated the expression of Bcr-Abl and the antiapoptotic protein Bcl-2, which is particularly overexpressed in imatinib-resistant clones. Imatinib Mesylate 41-49 BCL2 apoptosis regulator Homo sapiens 120-125 16376585-5 2006 A decrease in expression of Bcl-2, Bcl-X(L) and pro-caspase-3 was observed after exposure to 40 microM curcumin, while the levels of p53 and Bax were increased in the curcumin-treated cells. Curcumin 103-111 BCL2 apoptosis regulator Homo sapiens 28-33 16444746-6 2006 In particular, the combination valproate-imatinib downregulated the expression of Bcr-Abl and the antiapoptotic protein Bcl-2, which is particularly overexpressed in imatinib-resistant clones. Imatinib Mesylate 166-174 BCL2 apoptosis regulator Homo sapiens 120-125 16501812-0 2006 Fludarabine induces apoptosis in chronic lymphocytic leukemia--the role of P53, Bcl-2, Bax, Mcl-1, and Bag-1 proteins. fludarabine 0-11 BCL2 apoptosis regulator Homo sapiens 80-85 16167071-6 2006 Our results showed that VPA-induced ERK 1/2 phosphorylation in turn causes phosphorylation of the antiapoptotic protein Bcl-2 and inhibits serum starvation-induced HUVEC apoptosis and cytochrome c release from the mitochondria. Valproic Acid 24-27 BCL2 apoptosis regulator Homo sapiens 120-125 16169930-1 2006 We have shown previously that apoptosis induction by diallyl trisulfide (DATS), a constituent of processed garlic, in PC-3 and DU145 human prostate cancer cells is associated with c-Jun N-terminal kinase and extracellular signal-regulated kinase-mediated phosphorylation of Bcl-2. diallyl trisulfide 53-71 BCL2 apoptosis regulator Homo sapiens 274-279 16169930-1 2006 We have shown previously that apoptosis induction by diallyl trisulfide (DATS), a constituent of processed garlic, in PC-3 and DU145 human prostate cancer cells is associated with c-Jun N-terminal kinase and extracellular signal-regulated kinase-mediated phosphorylation of Bcl-2. diallyl trisulfide 73-77 BCL2 apoptosis regulator Homo sapiens 274-279 16614704-0 2006 beta-lapachone induces growth inhibition and apoptosis in bladder cancer cells by modulation of Bcl-2 family and activation of caspases. beta-lapachone 0-14 BCL2 apoptosis regulator Homo sapiens 96-101 16458489-2 2006 To investigate the possible mechanism of oxymatrine"s role on cancer cells, in the present study, we examined further the effects of oxymatrine on the growth, proliferation, apoptosis and expression of bcl-2 and p53 gene in human hepatoma SMMC-7721 cells in vitro. oxymatrine 41-51 BCL2 apoptosis regulator Homo sapiens 202-207 16458489-2 2006 To investigate the possible mechanism of oxymatrine"s role on cancer cells, in the present study, we examined further the effects of oxymatrine on the growth, proliferation, apoptosis and expression of bcl-2 and p53 gene in human hepatoma SMMC-7721 cells in vitro. oxymatrine 133-143 BCL2 apoptosis regulator Homo sapiens 202-207 16458489-6 2006 Oxymatrine induce apoptosis of SMMC-7721 cells and apoptotic rate amount to about 60% after treatment with 1.0 mg/ml oxymatrine for 48 h. We also find that oxymatrine down-regulate expression of bcl-2 gene while up-regulate expression of p53 gene. oxymatrine 0-10 BCL2 apoptosis regulator Homo sapiens 195-200 16458489-6 2006 Oxymatrine induce apoptosis of SMMC-7721 cells and apoptotic rate amount to about 60% after treatment with 1.0 mg/ml oxymatrine for 48 h. We also find that oxymatrine down-regulate expression of bcl-2 gene while up-regulate expression of p53 gene. oxymatrine 117-127 BCL2 apoptosis regulator Homo sapiens 195-200 16458489-6 2006 Oxymatrine induce apoptosis of SMMC-7721 cells and apoptotic rate amount to about 60% after treatment with 1.0 mg/ml oxymatrine for 48 h. We also find that oxymatrine down-regulate expression of bcl-2 gene while up-regulate expression of p53 gene. oxymatrine 156-166 BCL2 apoptosis regulator Homo sapiens 195-200 16458489-7 2006 These results demonstrate that oxymatrine inhibit the proliferation and induce apoptosis of human hepatoma SMMC-7721 cells, and suggest that this effect was mediated probably by a significant cell cycle blockage in G2/M and S phase, down-regulation of bcl-2 and up-regulation of p53. oxymatrine 31-41 BCL2 apoptosis regulator Homo sapiens 252-257 16614704-6 2006 Treatment of T24 cells with beta-lapachone resulted in a down-regulation of Bcl-2 expression and up-regulation of Bax expression. beta-lapachone 28-42 BCL2 apoptosis regulator Homo sapiens 76-81 16112192-8 2006 Anti-SCF has significantly enhanced the low dose cytarabine- and daunorubicin-induced bcl-2 reduction in KG1a CD34+ AML cells from 26.7+/-0.6 to 64.6+/-1.0% and from 59.8+/-3.1 to 80.1+/-7.9%, respectively, p<0.01. Cytarabine 49-59 BCL2 apoptosis regulator Homo sapiens 86-91 16450387-0 2006 G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 63-68 16450387-0 2006 G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line. Oligonucleotides 16-31 BCL2 apoptosis regulator Homo sapiens 63-68 16450387-0 2006 G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line. Doxorubicin 78-89 BCL2 apoptosis regulator Homo sapiens 63-68 16450387-5 2006 We hypothesized reducing Bcl-2 expression in SS should enhance doxorubicin cytotoxicity. Doxorubicin 63-74 BCL2 apoptosis regulator Homo sapiens 25-30 16450387-8 2006 Treatment of FU-SY-1 SS with G3139 reduced Bcl-2 mRNA and protein levels, which enhanced doxorubicin-induced cell killing. Doxorubicin 89-100 BCL2 apoptosis regulator Homo sapiens 43-48 16450387-10 2006 G3139 anti-Bcl-2 intervention sensitized the FU-SY-1 SS to doxorubicin, due to increased apoptosis. Doxorubicin 59-70 BCL2 apoptosis regulator Homo sapiens 11-16 16112192-8 2006 Anti-SCF has significantly enhanced the low dose cytarabine- and daunorubicin-induced bcl-2 reduction in KG1a CD34+ AML cells from 26.7+/-0.6 to 64.6+/-1.0% and from 59.8+/-3.1 to 80.1+/-7.9%, respectively, p<0.01. Daunorubicin 65-77 BCL2 apoptosis regulator Homo sapiens 86-91 16112192-10 2006 Anti-SCF has also significantly enhanced the low dose cytarabine- and daunorubicin-induced bcl-2 reduction in KG1a CD34+ AML cells in the presence of SCF, p<0.05. Cytarabine 54-64 BCL2 apoptosis regulator Homo sapiens 91-96 16112192-10 2006 Anti-SCF has also significantly enhanced the low dose cytarabine- and daunorubicin-induced bcl-2 reduction in KG1a CD34+ AML cells in the presence of SCF, p<0.05. Daunorubicin 70-82 BCL2 apoptosis regulator Homo sapiens 91-96 16411021-2 2006 In the study of the molecular mechanism of this phenomenon, it was found that GnTV-AS reduced the expressions of anti-apoptotic proteins, such as phosphorylated protein kinase B and phosphorylated Bad as well as Bcl-2 and Bcl-X (L), and elevated those of pro-apoptotic proteins, including Bax, full length caspase-3 and its activated fragments as well as anti-oncoprotein p53. gntv 78-82 BCL2 apoptosis regulator Homo sapiens 212-217 16213739-0 2006 Bcl-2 phosphorylation in the BH4 domain precedes caspase-3 activation and cell death after neonatal cerebral hypoxic-ischemic injury. sapropterin 29-32 BCL2 apoptosis regulator Homo sapiens 0-5 16546963-8 2006 Treatment of cells with cerulenin and LY294002 down-regulated the protein levels of X chromosome-linked inhibitor of apoptosis (XIAP), cellular inhibitor of apoptosis 1 (cIAP-1), and Akt, whereas the levels of mitogen-activated protein/extracellular signal-regulated kinase kinase and other antiapoptotic Bcl-2 family proteins (Bcl-2 and Bcl-xl) did not change. Cerulenin 24-33 BCL2 apoptosis regulator Homo sapiens 305-310 16546963-8 2006 Treatment of cells with cerulenin and LY294002 down-regulated the protein levels of X chromosome-linked inhibitor of apoptosis (XIAP), cellular inhibitor of apoptosis 1 (cIAP-1), and Akt, whereas the levels of mitogen-activated protein/extracellular signal-regulated kinase kinase and other antiapoptotic Bcl-2 family proteins (Bcl-2 and Bcl-xl) did not change. Cerulenin 24-33 BCL2 apoptosis regulator Homo sapiens 328-333 16546963-8 2006 Treatment of cells with cerulenin and LY294002 down-regulated the protein levels of X chromosome-linked inhibitor of apoptosis (XIAP), cellular inhibitor of apoptosis 1 (cIAP-1), and Akt, whereas the levels of mitogen-activated protein/extracellular signal-regulated kinase kinase and other antiapoptotic Bcl-2 family proteins (Bcl-2 and Bcl-xl) did not change. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 BCL2 apoptosis regulator Homo sapiens 305-310 16546963-8 2006 Treatment of cells with cerulenin and LY294002 down-regulated the protein levels of X chromosome-linked inhibitor of apoptosis (XIAP), cellular inhibitor of apoptosis 1 (cIAP-1), and Akt, whereas the levels of mitogen-activated protein/extracellular signal-regulated kinase kinase and other antiapoptotic Bcl-2 family proteins (Bcl-2 and Bcl-xl) did not change. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 BCL2 apoptosis regulator Homo sapiens 328-333 16546987-6 2006 The Bcl-2 cleavage could be inhibited by the Z-VAD.fmk caspase inhibitor. z-vad 45-50 BCL2 apoptosis regulator Homo sapiens 4-9 16213739-2 2006 In a model of neonatal hypoxic-ischemic (HI) brain injury, we characterized the spatial and temporal phosphorylation of Bcl-2 at serine-24 (PS24-Bcl-2), using a site-specific antibody. Serine 129-135 BCL2 apoptosis regulator Homo sapiens 120-125 16213739-5 2006 Phosphorylation of Bcl-2 at serine-24 coincided with cytochrome c release after hypoxia-ischemia and preceded caspase-3 activation. Serine 28-34 BCL2 apoptosis regulator Homo sapiens 19-24 16213739-7 2006 In conclusion, phosphorylation of Bcl-2 at serine 24 was induced by hypoxia-ischemia, presumably resulting in loss of its anti-apoptotic function. Serine 43-49 BCL2 apoptosis regulator Homo sapiens 34-39 16511341-2 2006 Al-though it belongs to the Bcl-2 family and can hetero-dimerize with Bcl-2, its pro-apoptotic activity is distinct from those of other members of the Bcl-2 family. Aluminum 0-2 BCL2 apoptosis regulator Homo sapiens 28-33 16465424-10 2006 The immunoblot study also showed that the glucan induced depletion of the antiapoptotic Bcl-2 protein, but not the proapoptotic Bax protein, so that the Bax/Bcl-2 ratio was elevated in the breast cancer cells at the time when the most prominent apoptosis was also observed. Glucans 42-48 BCL2 apoptosis regulator Homo sapiens 88-93 16465424-10 2006 The immunoblot study also showed that the glucan induced depletion of the antiapoptotic Bcl-2 protein, but not the proapoptotic Bax protein, so that the Bax/Bcl-2 ratio was elevated in the breast cancer cells at the time when the most prominent apoptosis was also observed. Glucans 42-48 BCL2 apoptosis regulator Homo sapiens 157-162 16302260-10 2006 DBPT also effectively induced apoptosis in Bcl-2-overexpressing DU145 cells. dbpt 0-4 BCL2 apoptosis regulator Homo sapiens 43-48 16610078-6 2006 After fludarabine treatment the mRNA expression of Bcl-2, Bax, survivin, XIAP, cIAP-1 and cIAP-2 was not changed, but the mitochondrial membrane potential (MMP) was decreased. fludarabine 6-17 BCL2 apoptosis regulator Homo sapiens 51-56 16722382-1 2006 OBJECTIVE: To observe the role of puerarin on the proliferation of vascular smooth muscle cells(VSMC) induced by thrombin (T) and the effect of puerarin on the c-fos and bcl-2 protein expression. puerarin 144-152 BCL2 apoptosis regulator Homo sapiens 170-175 16722382-3 2006 Western blot was used to indicate the changes of c-fos and bcl-2 protein after 24 h of treatment of T and puerarin. puerarin 106-114 BCL2 apoptosis regulator Homo sapiens 59-64 16722382-4 2006 RESULT: 1.5 x 10(-5) - 1.5 x 10(-3) mol x L(-1) puerarin could significantly suppress this stimulation of VSMC proliferation and DNA synthesis induced by T. Western blot demonstrated that after 24 hour of treatment with T and puerarin, T could significantly increase c-fos and bcl-2 protein and 1.5 x 10(-5) - 1.5 x 10(-3) mol x L(-1) puerain could significantly suppress this increase. puerarin 48-56 BCL2 apoptosis regulator Homo sapiens 277-282 16722382-5 2006 CONCLUSION: puerarin can suppress the proliferation and DNA synthesis of VSMC promoted by T. This inhibitory effects of puerarin are closely related with the suppression of c-fos and bcl-2 protein. puerarin 12-20 BCL2 apoptosis regulator Homo sapiens 183-188 16722382-5 2006 CONCLUSION: puerarin can suppress the proliferation and DNA synthesis of VSMC promoted by T. This inhibitory effects of puerarin are closely related with the suppression of c-fos and bcl-2 protein. vsmc 73-77 BCL2 apoptosis regulator Homo sapiens 183-188 16722382-5 2006 CONCLUSION: puerarin can suppress the proliferation and DNA synthesis of VSMC promoted by T. This inhibitory effects of puerarin are closely related with the suppression of c-fos and bcl-2 protein. puerarin 120-128 BCL2 apoptosis regulator Homo sapiens 183-188 16511341-2 2006 Al-though it belongs to the Bcl-2 family and can hetero-dimerize with Bcl-2, its pro-apoptotic activity is distinct from those of other members of the Bcl-2 family. Aluminum 0-2 BCL2 apoptosis regulator Homo sapiens 70-75 16511341-2 2006 Al-though it belongs to the Bcl-2 family and can hetero-dimerize with Bcl-2, its pro-apoptotic activity is distinct from those of other members of the Bcl-2 family. Aluminum 0-2 BCL2 apoptosis regulator Homo sapiens 70-75 16368107-3 2006 The X-ray crystal structure demonstrates the mutual exchange of carboxy-terminal regions including BH2 (Bcl-2 homology 2) between monomer subunits, with the hinge region occurring at the hairpin turn between the fifth and sixth alpha helices. bh2 99-102 BCL2 apoptosis regulator Homo sapiens 104-109 16269156-5 2006 Moreover, addition of Gl-PP also led to a reduction of Bcl-2 anti-apoptotic protein expression and an increase of Bax pro-apoptotic protein expression of HUVECs. gl-pp 22-27 BCL2 apoptosis regulator Homo sapiens 55-60 16152590-10 2006 Bcl-2 phosphorylation and activation of ERK and JNK and caspase 3-dependent cleavage of PARP were observed in MDA-MB-435 cells treated with CB694. CB694 140-145 BCL2 apoptosis regulator Homo sapiens 0-5 16360119-5 2006 Our results suggest that the protective effects of rosiglitazone on acetaldehyde-induced apoptosis may be ascribed to ability to induce the expression of anti-oxidant enzymes and to regulate Bcl-2 and Bax expression. Rosiglitazone 51-64 BCL2 apoptosis regulator Homo sapiens 191-196 16186795-8 2006 Moreover, by mutation analysis we found that the ability of Oct-2 to activate bcl-2 required C/EBP, Cdx, and TATA-binding sites. Cefadroxil 100-103 BCL2 apoptosis regulator Homo sapiens 78-83 16458114-0 2006 Bcl-2 switches the type of demise from apoptosis to necrosis via cyclooxygenase-2 upregulation in HeLa cell induced by hydrogen peroxide. Hydrogen Peroxide 119-136 BCL2 apoptosis regulator Homo sapiens 0-5 16458114-2 2006 The objective of this study was to investigate the effects of bcl-2 on the types of cell demise in the HeLa/bcl-2 cells induced by H2O2. Hydrogen Peroxide 131-135 BCL2 apoptosis regulator Homo sapiens 62-67 16458114-2 2006 The objective of this study was to investigate the effects of bcl-2 on the types of cell demise in the HeLa/bcl-2 cells induced by H2O2. Hydrogen Peroxide 131-135 BCL2 apoptosis regulator Homo sapiens 108-113 16458114-4 2006 MTT assay revealed that the HeLa/bcl-2 cells showed a shorter life span. monooxyethylene trimethylolpropane tristearate 0-3 BCL2 apoptosis regulator Homo sapiens 33-38 16458114-5 2006 BrdU incorporation assay indicated that the bcl-2 exerted anti-demise effect on the HeLa/bcl-2 cells at the low concentration of H2O2. Hydrogen Peroxide 129-133 BCL2 apoptosis regulator Homo sapiens 44-49 16458114-5 2006 BrdU incorporation assay indicated that the bcl-2 exerted anti-demise effect on the HeLa/bcl-2 cells at the low concentration of H2O2. Hydrogen Peroxide 129-133 BCL2 apoptosis regulator Homo sapiens 89-94 16458114-6 2006 However, at the high concentration of H2O2, the death of the HeLa/bcl-2 cells was more than that of the HeLa/vector cells. Hydrogen Peroxide 38-42 BCL2 apoptosis regulator Homo sapiens 66-71 16458114-7 2006 The flow cytometry demonstrated that H2O2 mainly induced apoptosis in the HeLa/vector cells and elicited necrosis in the HeLa/bcl-2 cells. Hydrogen Peroxide 37-41 BCL2 apoptosis regulator Homo sapiens 126-131 16458114-8 2006 The addition of celecoxib to the cells treated by H2O2 could increase apoptosis in the HeLa/vector cells and convert necrosis into apoptosis in the HeLa/bcl-2 cells. Celecoxib 16-25 BCL2 apoptosis regulator Homo sapiens 153-158 16360119-5 2006 Our results suggest that the protective effects of rosiglitazone on acetaldehyde-induced apoptosis may be ascribed to ability to induce the expression of anti-oxidant enzymes and to regulate Bcl-2 and Bax expression. Acetaldehyde 68-80 BCL2 apoptosis regulator Homo sapiens 191-196 16458114-9 2006 The higher levels of cellular free radical and GSH were found in the HeLa/bcl-2 cells, but not in the HeLa/vector cells. Glutathione 47-50 BCL2 apoptosis regulator Homo sapiens 74-79 16412276-0 2006 Inhibition of Bcl-2 expression by a novel tumor-specific RNA interference system increases chemosensitivity to 5-fluorouracil in Hela cells. Fluorouracil 111-125 BCL2 apoptosis regulator Homo sapiens 14-19 16412276-12 2006 Inhibition of Bcl-2 did not affect cell proliferation, but increased the chemosensitivity of HeLa cells to 5-fluorouracil. Fluorouracil 107-121 BCL2 apoptosis regulator Homo sapiens 14-19 16412276-14 2006 Suppression of Bcl-2 by using this system sensitized HeLa cells to 5-fluorouracil. Fluorouracil 67-81 BCL2 apoptosis regulator Homo sapiens 15-20 16452220-4 2006 BAY 43-9006 (sorafenib) down-modulates the levels of Bcl-2 and Bcl-X(L) in a MAPK-independent manner in A2058 and SKMEL5 melanoma cells but not in the more resistant A375 cells. Sorafenib 0-11 BCL2 apoptosis regulator Homo sapiens 53-58 16322117-1 2006 PURPOSE: To assess the feasibility and antitumor activity of oblimersen sodium, an antisense oligonucleotide directed to the Bcl-2 mRNA, combined with irinotecan in patients with advanced colorectal carcinoma, characterize the pharmacokinetic behavior of both oblimersen sodium and irinotecan, and examine Bcl-2 protein inhibition in peripheral blood mononuclear cells (PBMC). oblimersen 61-78 BCL2 apoptosis regulator Homo sapiens 125-130 16322117-1 2006 PURPOSE: To assess the feasibility and antitumor activity of oblimersen sodium, an antisense oligonucleotide directed to the Bcl-2 mRNA, combined with irinotecan in patients with advanced colorectal carcinoma, characterize the pharmacokinetic behavior of both oblimersen sodium and irinotecan, and examine Bcl-2 protein inhibition in peripheral blood mononuclear cells (PBMC). oblimersen 61-78 BCL2 apoptosis regulator Homo sapiens 306-311 16322117-1 2006 PURPOSE: To assess the feasibility and antitumor activity of oblimersen sodium, an antisense oligonucleotide directed to the Bcl-2 mRNA, combined with irinotecan in patients with advanced colorectal carcinoma, characterize the pharmacokinetic behavior of both oblimersen sodium and irinotecan, and examine Bcl-2 protein inhibition in peripheral blood mononuclear cells (PBMC). Sodium 72-78 BCL2 apoptosis regulator Homo sapiens 125-130 16452234-9 2006 We also found that sulforaphane can sensitize both Bcl-xL- and Bcl-2-overexpressing hepatoma cells to TRAIL-induced apoptosis, indicating that treatment with a combination of TRAIL and sulforaphane may be a safe strategy for treating resistant hepatomas. sulforaphane 19-31 BCL2 apoptosis regulator Homo sapiens 63-68 16452234-9 2006 We also found that sulforaphane can sensitize both Bcl-xL- and Bcl-2-overexpressing hepatoma cells to TRAIL-induced apoptosis, indicating that treatment with a combination of TRAIL and sulforaphane may be a safe strategy for treating resistant hepatomas. sulforaphane 185-197 BCL2 apoptosis regulator Homo sapiens 63-68 16432862-10 2006 We therefore conclude that oridonin has significant antiproliferation effects on HPB-ALL cells by induction of apoptosis as well as directly causing cell necrosis and that oridonin-induced apoptosis on HPB-ALL cells is mainly related to the disruption of delta psi m and activation of caspase-3 as well as downregulation of anti-apoptotic protein Bcl-2, Bcl-XL, and upregulation of pro-apoptotic proteins Bax and Bid. oridonin 172-180 BCL2 apoptosis regulator Homo sapiens 347-352 16189662-9 2006 These findings supported the fact that the inhibitors of caspases, DEVD-FMK, IETD-FMK and VAD-FMK, prevented apoptosis and restored the expression of Bcl-XL, Bcl-2 and Bid. devd-fmk 67-75 BCL2 apoptosis regulator Homo sapiens 158-163 16189662-9 2006 These findings supported the fact that the inhibitors of caspases, DEVD-FMK, IETD-FMK and VAD-FMK, prevented apoptosis and restored the expression of Bcl-XL, Bcl-2 and Bid. isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone 77-85 BCL2 apoptosis regulator Homo sapiens 158-163 16189662-9 2006 These findings supported the fact that the inhibitors of caspases, DEVD-FMK, IETD-FMK and VAD-FMK, prevented apoptosis and restored the expression of Bcl-XL, Bcl-2 and Bid. VAD-fmk 90-97 BCL2 apoptosis regulator Homo sapiens 158-163 16459021-0 2006 Anti-apoptotic activity of caffeic acid, ellagic acid and ferulic acid in normal human peripheral blood mononuclear cells: a Bcl-2 independent mechanism. caffeic acid 27-39 BCL2 apoptosis regulator Homo sapiens 125-130 16459021-0 2006 Anti-apoptotic activity of caffeic acid, ellagic acid and ferulic acid in normal human peripheral blood mononuclear cells: a Bcl-2 independent mechanism. ferulic acid 58-70 BCL2 apoptosis regulator Homo sapiens 125-130 16459021-12 2006 In conclusion, the anti-apoptotic effect of EA, CA and FA in PBMCs seems to be through the Bcl-2 independent mechanism. Ellagic Acid 44-46 BCL2 apoptosis regulator Homo sapiens 91-96 16490592-8 2006 Resveratrol also down-regulated the expression of NF-kappaB-regulated gene products by Western blot analysis, gelatin zymography, and enzyme-linked immunosorbent assay, including interleukin-6, Bcl-2, Bcl-xL, XIAP, c-IAP, vascular endothelial growth factor (VEGF), and matrix metalloproteinase-9 (MMP-9), which modulates an array of signals controlling cellular survival and proliferation and tumor promotion. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 194-199 16452220-4 2006 BAY 43-9006 (sorafenib) down-modulates the levels of Bcl-2 and Bcl-X(L) in a MAPK-independent manner in A2058 and SKMEL5 melanoma cells but not in the more resistant A375 cells. Sorafenib 13-22 BCL2 apoptosis regulator Homo sapiens 53-58 16391804-8 2006 Microarray analysis revealed that expressions of some apoptosis related genes such as Bcl-2 changed, and were correlated with sequence-dependent cytotoxicity of the 5-FU --> CPT-11 sequence. Fluorouracil 165-169 BCL2 apoptosis regulator Homo sapiens 86-91 16125830-0 2006 Involvement of proapoptotic Bcl-2 family members in terbinafine-induced mitochondrial dysfunction and apoptosis in HL60 cells. Terbinafine 52-63 BCL2 apoptosis regulator Homo sapiens 28-33 16399623-5 2006 Silymarin pre-treatment reversed the effect of UV irradiation on the expression of phosphorylated Akt and phosphorylated p53 (regulated by Akt activation), followed by down-regulation of Bax and up-regulated expressions of Bcl-2 and Bcl-xL proteins in UV-irradiated A375-S2 cells. Silymarin 0-9 BCL2 apoptosis regulator Homo sapiens 223-228 16271357-8 2006 Erybraedin C similarly affects the survival of HT29 (MMR +/+, p53 -/- and Bcl-2 +/+) and LoVo (MMR -/-, p53 +/+ and Bcl-2 -/-) cells (LD(50): 1.94 and 1.73 microg/ml, respectively). erybraedin C 0-12 BCL2 apoptosis regulator Homo sapiens 74-79 16271357-8 2006 Erybraedin C similarly affects the survival of HT29 (MMR +/+, p53 -/- and Bcl-2 +/+) and LoVo (MMR -/-, p53 +/+ and Bcl-2 -/-) cells (LD(50): 1.94 and 1.73 microg/ml, respectively). erybraedin C 0-12 BCL2 apoptosis regulator Homo sapiens 116-121 17193257-8 2006 Taken together, our study suggests that ginsenoside Rd (1) significantly inhibits HeLa cell proliferation, and induces cell apoptosis through down-regulating Bcl-2 expression, up-regulating Bax expression, lowering the mitochondrial transmembrane potential, and activating the caspase-3 pathway. Ginsenosides 40-51 BCL2 apoptosis regulator Homo sapiens 158-163 16254033-5 2006 Donor treatment with bilirubin up-regulated mRNA expression of protective genes such as HO-1 and bcl-2 and suppressed proinflammatory and proapoptotic genes including monocyte chemoattractant protein-1 and caspase-3 and -8 in the islet grafts before transplantation. Bilirubin 21-30 BCL2 apoptosis regulator Homo sapiens 97-102 16184340-0 2006 Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from multiple sclerosis patients. Glatiramer Acetate 0-18 BCL2 apoptosis regulator Homo sapiens 62-67 16046235-4 2006 Etodolac induced down-regulation of Bcl-2 protein and mRNA, activation of Caspase-9, -7 and -3, cIAP-1 and Survivin, and loss of mitochondrial membrane potential in a dose-dependent manner. Etodolac 0-8 BCL2 apoptosis regulator Homo sapiens 36-41 16505117-5 2006 These responses on UVB and/or sanguinarine treatments were associated with (a) decrease in Bcl-2 and Bcl-X(L) and (b) increase in Bax, Bid, and Bak protein levels. sanguinarine 30-42 BCL2 apoptosis regulator Homo sapiens 91-96 16505117-6 2006 Bax knockdown and Bcl-2 overexpression resulted in a rescue of HaCaT cells from sanguinarine-mediated apoptosis. sanguinarine 80-92 BCL2 apoptosis regulator Homo sapiens 18-23 16505103-5 2006 Berberine also significantly (P < 0.05-0.001) enhanced apoptosis of DU145 and LNCaP cells with induction of a higher ratio of Bax/Bcl-2 proteins, disruption of mitochondrial membrane potential, and activation of caspase-9, caspase-3, and poly(ADP-ribose) polymerase. Berberine 0-9 BCL2 apoptosis regulator Homo sapiens 133-138 16173037-9 2006 The ratio of bcl-2:bax was decreased in the cancer-derived cells treated with selenite. Selenious Acid 78-86 BCL2 apoptosis regulator Homo sapiens 13-18 16391871-11 2006 Furthermore, treatment with 100 microM celecoxib resulted in significant apoptosis in all three cell lines, which was associated with downregulation of Bcl-2. Celecoxib 39-48 BCL2 apoptosis regulator Homo sapiens 152-157 16391871-13 2006 Induction of apoptosis in all three cell lines by celecoxib was associated with downregulation of Bcl-2. Celecoxib 50-59 BCL2 apoptosis regulator Homo sapiens 98-103 16293228-4 2006 Collectively, the results presented in this study demonstrate that peroxynitrite, while committing U937 cells to necrosis, triggers a parallel signaling response leading to the cytosolic localization of two important members of the Bcl-2 family implicated in the onset of MPT. Peroxynitrous Acid 67-80 BCL2 apoptosis regulator Homo sapiens 232-237 16677505-8 2006 Treatment with proglumide and NS-398 significantly reduced the bcl-2 mRNA and protein expression in the MKN-45 cells (P < 0.05). Proglumide 15-25 BCL2 apoptosis regulator Homo sapiens 63-68 16677505-8 2006 Treatment with proglumide and NS-398 significantly reduced the bcl-2 mRNA and protein expression in the MKN-45 cells (P < 0.05). N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 30-36 BCL2 apoptosis regulator Homo sapiens 63-68 16297990-13 2006 The ratio Bcl-2/Bax was reduced in parental or mock-transfected PC-3 cells after treatment with etoposide. Etoposide 96-105 BCL2 apoptosis regulator Homo sapiens 10-15 16617673-9 2006 Moreover, after 3-AB administration overexpression of Bcl-2 protein was observed in mitochondrial membranes, rough endoplasmatic reticulum, Golgi complex, nuclear envelopes, and also in cytoplasm and in nucleus. 3-aminobenzamide 16-20 BCL2 apoptosis regulator Homo sapiens 54-59 17016043-0 2006 Absence of BH3 domain mutations in the proapoptotic Bcl-2 gene family in non-Hodgkin lymphomas. BH 3 11-14 BCL2 apoptosis regulator Homo sapiens 52-57 16640863-0 2006 [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP]. Cisplatin 63-72 BCL2 apoptosis regulator Homo sapiens 10-15 16640863-1 2006 OBJECTIVE: To evaluate the influence of bcl-2 antisense oligodeoxynucleotides (AODN) on reversing cisplatin (DDP) resistance in ovarian carcinoma cell lines. Cisplatin 98-107 BCL2 apoptosis regulator Homo sapiens 40-45 16424655-3 2006 We found that FK228 activated caspase-9 and a subsequent caspase cascade by perturbing the mitochondrial membrane to release cytochrome c, which was almost completely blocked by overexpression of Bcl-2. romidepsin 14-19 BCL2 apoptosis regulator Homo sapiens 196-201 16405747-0 2006 [Inhibitory effect of bcl-2 antisense oligodeoxynucleotides on growth of human lung carcinoma xenograft in nude mice]. Oligodeoxyribonucleotides 38-59 BCL2 apoptosis regulator Homo sapiens 22-27 16405747-1 2006 BACKGROUND & OBJECTIVE: Antisense oligodeoxynucleotides (ASODN) targeting bcl-2 have in vitro and in vivo antitumor activities. Adenosine Monophosphate 12-15 BCL2 apoptosis regulator Homo sapiens 78-83 16405747-1 2006 BACKGROUND & OBJECTIVE: Antisense oligodeoxynucleotides (ASODN) targeting bcl-2 have in vitro and in vivo antitumor activities. Oligodeoxyribonucleotides 38-59 BCL2 apoptosis regulator Homo sapiens 78-83 16405747-1 2006 BACKGROUND & OBJECTIVE: Antisense oligodeoxynucleotides (ASODN) targeting bcl-2 have in vitro and in vivo antitumor activities. asodn 61-66 BCL2 apoptosis regulator Homo sapiens 78-83 16552836-0 2006 Baicalin-induced apoptosis is mediated by Bcl-2-dependent, but not p53-dependent, pathway in human leukemia cell lines. baicalin 0-8 BCL2 apoptosis regulator Homo sapiens 42-47 16374552-6 2006 Treatment with a subtoxic concentration of a bispecific bcl-2/bcl xL antisense oligonucleotide cooperated with okadaic acid to down-regulate bcl-2 and sensitize cyclin D1-overexpressing cells to okadaic acid. Oligonucleotides 79-94 BCL2 apoptosis regulator Homo sapiens 56-61 16374552-6 2006 Treatment with a subtoxic concentration of a bispecific bcl-2/bcl xL antisense oligonucleotide cooperated with okadaic acid to down-regulate bcl-2 and sensitize cyclin D1-overexpressing cells to okadaic acid. Oligonucleotides 79-94 BCL2 apoptosis regulator Homo sapiens 141-146 16374552-6 2006 Treatment with a subtoxic concentration of a bispecific bcl-2/bcl xL antisense oligonucleotide cooperated with okadaic acid to down-regulate bcl-2 and sensitize cyclin D1-overexpressing cells to okadaic acid. Okadaic Acid 111-123 BCL2 apoptosis regulator Homo sapiens 56-61 16374552-6 2006 Treatment with a subtoxic concentration of a bispecific bcl-2/bcl xL antisense oligonucleotide cooperated with okadaic acid to down-regulate bcl-2 and sensitize cyclin D1-overexpressing cells to okadaic acid. Okadaic Acid 111-123 BCL2 apoptosis regulator Homo sapiens 141-146 16374552-6 2006 Treatment with a subtoxic concentration of a bispecific bcl-2/bcl xL antisense oligonucleotide cooperated with okadaic acid to down-regulate bcl-2 and sensitize cyclin D1-overexpressing cells to okadaic acid. Okadaic Acid 195-207 BCL2 apoptosis regulator Homo sapiens 56-61 16297852-3 2006 There was a dose-dependent accumulation of Clu/ApoJ and downregulation of Bcl-2 which correlated with C(2)-ceramide-induced apoptosis of MRC-5. N-acetylsphingosine 102-115 BCL2 apoptosis regulator Homo sapiens 74-79 16297852-0 2006 Bcl-2 but not clusterin/apolipoprotein J protected human diploid fibroblasts and immortalized keratinocytes from ceramide-induced apoptosis: role of p53 in the ceramide response. Ceramides 113-121 BCL2 apoptosis regulator Homo sapiens 0-5 16475721-9 2006 Bcl-2 and c-Fos may play important roles in arsenic-mediated carcinogenesis of the urothelium. Arsenic 44-51 BCL2 apoptosis regulator Homo sapiens 0-5 16297852-4 2006 While overexpression of Bcl-2 suppressed C(2)-ceramide-mediated apoptosis in both cell types, Clu/ApoJ failed to do so, accessed by morphological changes, DNA fragmentation and PARP cleavage. N-acetylsphingosine 41-54 BCL2 apoptosis regulator Homo sapiens 24-29 16297852-0 2006 Bcl-2 but not clusterin/apolipoprotein J protected human diploid fibroblasts and immortalized keratinocytes from ceramide-induced apoptosis: role of p53 in the ceramide response. Ceramides 160-168 BCL2 apoptosis regulator Homo sapiens 0-5 16297852-6 2006 However, mutant p53(143ala) increased the sensitivity of MRC-5 to C(2)-ceramide-induced apoptosis by markedly downregulating Bcl-2, pointing to a role for p53. A(2)C 66-70 BCL2 apoptosis regulator Homo sapiens 125-130 16297852-6 2006 However, mutant p53(143ala) increased the sensitivity of MRC-5 to C(2)-ceramide-induced apoptosis by markedly downregulating Bcl-2, pointing to a role for p53. Ceramides 71-79 BCL2 apoptosis regulator Homo sapiens 125-130 16297852-7 2006 These results suggested that whereas downregulation of Bcl-2 may be a crucial factor involved in C(2)-ceramide-induced apoptosis, accumulation of Clu/ApoJ may be a signal of stress response. N-acetylsphingosine 97-110 BCL2 apoptosis regulator Homo sapiens 55-60 16336351-7 2006 Elevated Bcl-2 expression was closely associated with AAT (P = 0.002), suggesting that Bcl-2 expression is induced on initial exposure to AAT. o-Aminoazotoluene 54-57 BCL2 apoptosis regulator Homo sapiens 9-14 16213738-0 2006 The lethal effect of bis-type azridinylnaphthoquinone derivative on oral cancer cells (OEC-M1) associated with anti-apoptotic protein bcl-2. bis-type azridinylnaphthoquinone 21-53 BCL2 apoptosis regulator Homo sapiens 134-139 16213738-8 2006 By using Western blot, both G2/M phase cell cycle arresting protein, cyclin B, and anti-apoptotic protein, bcl-2, were expressed in OEC-M1 cell when the concentrations of AZ-1 were increased from 0.125 to 0.5 microM and then decreased from 1 to 2 microM of AZ-1 treatment as compared with control for 24 h. Both proteins were expressed most abundantly at 0.5 microM AZ-1. 2-aziridin-1-yl-3-((2-((2-(3-aziridin-1-yl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)thio)ethoxy)ethyl)thio)naphthoquinone 171-175 BCL2 apoptosis regulator Homo sapiens 107-112 17012779-8 2006 Oligonol triggers apoptosis in the MCF-7 and MDA-MB-231 breast cancer cells through modulation of the pro-apoptotic Bcl-2 family of proteins and the MEK/ERK signaling pathway, an observation suggesting its important chemopreventive effects. oligonol 0-8 BCL2 apoptosis regulator Homo sapiens 116-121 16336351-7 2006 Elevated Bcl-2 expression was closely associated with AAT (P = 0.002), suggesting that Bcl-2 expression is induced on initial exposure to AAT. o-Aminoazotoluene 54-57 BCL2 apoptosis regulator Homo sapiens 87-92 16697692-5 2006 Heme oxygenase-1 induction by treatment with cobalt protoporphyrin IX resulted in resistance to apoptosis, activation of Akt, reduction in p21(Cip/WAF1) levels and modification of bcl2/bax ratio towards survival. cobaltiprotoporphyrin 45-69 BCL2 apoptosis regulator Homo sapiens 180-184 16454747-7 2006 Phase 1 and 2 studies have been performed with Bcl-2 antisense oligonucleotides and high dose simvastatin in combination with chemotherapy in heavily pre-treated myeloma patients. Oligonucleotides 63-79 BCL2 apoptosis regulator Homo sapiens 47-52 16472148-5 2006 Increase in cyclic AMP and decrease in TNF-alpha levels were identified in the ipsilateral cortex under treatment with cilostazol accompanied by decreased Bax formation and cytochrome c release with increased Bcl-2 production in the penumbral area as well as in the in vitro human umbilical endothelial cells. Cilostazol 119-129 BCL2 apoptosis regulator Homo sapiens 209-214 16357615-14 2006 Anti-apoptotic Bcl-2 is strongly expressed, probably reflecting an adaptive response to obesity or alcohol-related stress. Alcohols 99-106 BCL2 apoptosis regulator Homo sapiens 15-20 17008791-0 2006 In vitro induction of apoptosis in U937 cells by perillyl alcohol with sensitization by pentoxifylline: increased BCL-2 and BAX protein expression. perillyl alcohol 49-65 BCL2 apoptosis regulator Homo sapiens 114-119 17008791-0 2006 In vitro induction of apoptosis in U937 cells by perillyl alcohol with sensitization by pentoxifylline: increased BCL-2 and BAX protein expression. Pentoxifylline 88-102 BCL2 apoptosis regulator Homo sapiens 114-119 16337836-9 2006 Furthermore, the expression levels of apoptosis-suppressing protein Bcl-2 were decreased in HL-60 cells treated with halocynthiaxanthin and fucoxanthinol. halocynthiaxanthin 117-135 BCL2 apoptosis regulator Homo sapiens 68-73 16337836-9 2006 Furthermore, the expression levels of apoptosis-suppressing protein Bcl-2 were decreased in HL-60 cells treated with halocynthiaxanthin and fucoxanthinol. fucoxanthinol 140-153 BCL2 apoptosis regulator Homo sapiens 68-73 17219718-10 2006 Increased BCL-2 expression in AL was detected in IPF and sarcoidosis. Aluminum 30-32 BCL2 apoptosis regulator Homo sapiens 10-15 17219718-13 2006 Proportion of AL positive for IGF-I was significantly correlated with parameters reflecting AL and AM cell proliferation and BCL-2 expression (e.g. AL IGF-I+ vs AM in S phase of cell cycle: r(S) = +0.50, p = 0.001), but not with apoptosis. Aluminum 14-16 BCL2 apoptosis regulator Homo sapiens 125-130 16556548-1 2006 G3139 is an antisense oligonucleotide (ODN) that can down-regulate bcl-2, thus potentially acting as a potent anticancer drug. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 67-72 16603448-0 2006 Bcl-2 siRNA induced apoptosis and increased sensitivity to 5-fluorouracil and HCPT in HepG2 cells. Fluorouracil 59-73 BCL2 apoptosis regulator Homo sapiens 0-5 16603448-0 2006 Bcl-2 siRNA induced apoptosis and increased sensitivity to 5-fluorouracil and HCPT in HepG2 cells. 10-hydroxycamptothecin 78-82 BCL2 apoptosis regulator Homo sapiens 0-5 16603448-7 2006 Accordingly, Bax protein expression had no change and caspase-3 protein expression showed significantly be up regulated; (2) MTT results showed that Bcl-2 siRNA transfectants had higher cell inhibitory rates after treated with 5-FU or HCPT; (3) flow cytometry results demonstrated that sub G1 population increased in Bcl-2 siRNA transfected cells compared with negative siRNA or untreated cells. monooxyethylene trimethylolpropane tristearate 125-128 BCL2 apoptosis regulator Homo sapiens 149-154 16603448-7 2006 Accordingly, Bax protein expression had no change and caspase-3 protein expression showed significantly be up regulated; (2) MTT results showed that Bcl-2 siRNA transfectants had higher cell inhibitory rates after treated with 5-FU or HCPT; (3) flow cytometry results demonstrated that sub G1 population increased in Bcl-2 siRNA transfected cells compared with negative siRNA or untreated cells. Fluorouracil 227-231 BCL2 apoptosis regulator Homo sapiens 149-154 16603448-7 2006 Accordingly, Bax protein expression had no change and caspase-3 protein expression showed significantly be up regulated; (2) MTT results showed that Bcl-2 siRNA transfectants had higher cell inhibitory rates after treated with 5-FU or HCPT; (3) flow cytometry results demonstrated that sub G1 population increased in Bcl-2 siRNA transfected cells compared with negative siRNA or untreated cells. 10-hydroxycamptothecin 235-239 BCL2 apoptosis regulator Homo sapiens 149-154 16603448-8 2006 After addition 5-FU (1300 mg/l) and HCPT (0.72 mg/l), Bcl-2 siRNA cells showed higher sub G1 population than negative siRNA or untreated cells. Fluorouracil 15-19 BCL2 apoptosis regulator Homo sapiens 54-59 16603448-8 2006 After addition 5-FU (1300 mg/l) and HCPT (0.72 mg/l), Bcl-2 siRNA cells showed higher sub G1 population than negative siRNA or untreated cells. 10-hydroxycamptothecin 36-40 BCL2 apoptosis regulator Homo sapiens 54-59 16603448-9 2006 siRNA targeting Bcl-2 gene can specifically down-regulate Bcl-2 expression, increased Bax/Bcl-2 ratio expression and caspase-3 activity in HepG2 cells, which lead to increase cells spontaneous apoptosis and sensitize cells to 5-FU or HCPT. Fluorouracil 226-230 BCL2 apoptosis regulator Homo sapiens 16-21 16603448-9 2006 siRNA targeting Bcl-2 gene can specifically down-regulate Bcl-2 expression, increased Bax/Bcl-2 ratio expression and caspase-3 activity in HepG2 cells, which lead to increase cells spontaneous apoptosis and sensitize cells to 5-FU or HCPT. 10-hydroxycamptothecin 234-238 BCL2 apoptosis regulator Homo sapiens 16-21 16556548-1 2006 G3139 is an antisense oligonucleotide (ODN) that can down-regulate bcl-2, thus potentially acting as a potent anticancer drug. Oligonucleotides 22-37 BCL2 apoptosis regulator Homo sapiens 67-72 16556548-1 2006 G3139 is an antisense oligonucleotide (ODN) that can down-regulate bcl-2, thus potentially acting as a potent anticancer drug. odn 39-42 BCL2 apoptosis regulator Homo sapiens 67-72 16556548-10 2006 Western blots were used to confirm the specific activity of G3139 as an anti-bcl-2 antisense agent. oblimersen 60-65 BCL2 apoptosis regulator Homo sapiens 77-82 16374644-11 2006 Liposomal-mediated anti-bcl-2 siRNA transfer led to a significant improvement of cisplatin treatment in HUH6 cells. Cisplatin 81-90 BCL2 apoptosis regulator Homo sapiens 24-29 15843867-0 2006 N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. n-propargylamine 0-16 BCL2 apoptosis regulator Homo sapiens 195-200 15843867-0 2006 N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. salsoline 92-113 BCL2 apoptosis regulator Homo sapiens 195-200 15843867-5 2006 N-Propargylamine stabilized mitochondrial membrane potential and induced anti-apoptotic Bcl-2 at 1 microM-10 nM. n-propargylamine 0-16 BCL2 apoptosis regulator Homo sapiens 88-93 17447417-10 2006 Rasagiline and other MAO-B inhibitors prevent the activation of apoptotic cascade and induce prosurvival genes, such as bcl-2 and glial cell line-derived neurotrophic factor, in MAO-A-containing cells. rasagiline 0-10 BCL2 apoptosis regulator Homo sapiens 120-125 15948141-0 2006 Synthesis and secondary structure in membranes of the Bcl-2 anti-apoptotic domain BH4. sapropterin 82-85 BCL2 apoptosis regulator Homo sapiens 54-59 15948141-1 2006 Solid phase synthesis of BH4, the 26 amino-acid domain (6RTGYDNREIVMKYIHYKLSQRGYEWD31) of the anti-apoptotic Bcl-2 protein has been accomplished using Fmoc chemistry. sapropterin 25-28 BCL2 apoptosis regulator Homo sapiens 109-114 16977965-12 2006 LMC showed: CD 20 (+), bcl-2 (-), CD 10 (+/-), and bcl-6 (+) in the follicle, and bcl-2 (+), CD10 (-/+) and bcl-6 (-) in the interfollicular area. LMC 0-3 BCL2 apoptosis regulator Homo sapiens 23-28 16219908-0 2006 Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2. alvocidib 0-12 BCL2 apoptosis regulator Homo sapiens 133-138 16219908-2 2006 Coadministration of flavopiridol with HDAC inhibitors synergistically potentiated mitochondrial damage (cytochrome c, second mitochondria-derived activator of caspases/direct IAP binding protein with low pI, and apoptosis-inducing factor release), caspase activation, poly(ADP-ribose) polymerase degradation, and cell death in both wild type and Bcl-2- or Bcl-x(L)-overexpressing cells and induced a pronounced loss of clonogenicity. alvocidib 20-32 BCL2 apoptosis regulator Homo sapiens 346-351 16219908-3 2006 In contrast, Bcl-2 and Bcl-x(L) largely blocked these events in cells exposed to the cytotoxic agent 1-beta-d-arabinofuranosylcytosine (ara-C). Cytarabine 101-134 BCL2 apoptosis regulator Homo sapiens 13-18 16219908-3 2006 In contrast, Bcl-2 and Bcl-x(L) largely blocked these events in cells exposed to the cytotoxic agent 1-beta-d-arabinofuranosylcytosine (ara-C). Cytarabine 136-141 BCL2 apoptosis regulator Homo sapiens 13-18 16219908-5 2006 Ectopic expression of a phosphorylation loop-deleted Bcl-2 or Bcl-2 lacking the serine(70) phosphorylation site, which dramatically protected cells from ara-C lethality, delayed but did not prevent flavopiridol/HDAC inhibitor-induced mitochondrial injury, cell death, or loss of clonogenicity. Serine 80-86 BCL2 apoptosis regulator Homo sapiens 53-58 16219908-5 2006 Ectopic expression of a phosphorylation loop-deleted Bcl-2 or Bcl-2 lacking the serine(70) phosphorylation site, which dramatically protected cells from ara-C lethality, delayed but did not prevent flavopiridol/HDAC inhibitor-induced mitochondrial injury, cell death, or loss of clonogenicity. Serine 80-86 BCL2 apoptosis regulator Homo sapiens 62-67 16219908-5 2006 Ectopic expression of a phosphorylation loop-deleted Bcl-2 or Bcl-2 lacking the serine(70) phosphorylation site, which dramatically protected cells from ara-C lethality, delayed but did not prevent flavopiridol/HDAC inhibitor-induced mitochondrial injury, cell death, or loss of clonogenicity. Cytarabine 153-158 BCL2 apoptosis regulator Homo sapiens 53-58 16219908-5 2006 Ectopic expression of a phosphorylation loop-deleted Bcl-2 or Bcl-2 lacking the serine(70) phosphorylation site, which dramatically protected cells from ara-C lethality, delayed but did not prevent flavopiridol/HDAC inhibitor-induced mitochondrial injury, cell death, or loss of clonogenicity. Cytarabine 153-158 BCL2 apoptosis regulator Homo sapiens 62-67 16219908-5 2006 Ectopic expression of a phosphorylation loop-deleted Bcl-2 or Bcl-2 lacking the serine(70) phosphorylation site, which dramatically protected cells from ara-C lethality, delayed but did not prevent flavopiridol/HDAC inhibitor-induced mitochondrial injury, cell death, or loss of clonogenicity. alvocidib 198-210 BCL2 apoptosis regulator Homo sapiens 53-58 16219908-5 2006 Ectopic expression of a phosphorylation loop-deleted Bcl-2 or Bcl-2 lacking the serine(70) phosphorylation site, which dramatically protected cells from ara-C lethality, delayed but did not prevent flavopiridol/HDAC inhibitor-induced mitochondrial injury, cell death, or loss of clonogenicity. alvocidib 198-210 BCL2 apoptosis regulator Homo sapiens 62-67 16533421-7 2006 Fhit could also partially restore sensitivity to cisplatin in Bcl-2- and Bcl-x(L)-overexpressing H460 cells that are normally resistant to this drug. Cisplatin 49-58 BCL2 apoptosis regulator Homo sapiens 62-67 16898267-0 2006 Quercetin induces p53-independent apoptosis in human prostate cancer cells by modulating Bcl-2-related proteins: a possible mediation by IGFBP-3. Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 89-94 16898267-7 2006 In quercetin-treated PC-3 cells, an increase in Bax protein expression and a decrease in Bcl-x(L) protein and Bcl-2 protein were observed. Quercetin 3-12 BCL2 apoptosis regulator Homo sapiens 110-115 17119350-2 2006 We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel. Serine 117-123 BCL2 apoptosis regulator Homo sapiens 279-284 17119350-2 2006 We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel. Paclitaxel 378-388 BCL2 apoptosis regulator Homo sapiens 279-284 16189296-4 2006 LAQ824-induced lethality in U937 cells did not involve the extrinsic apoptotic pathway, nor was it associated with death receptor up-regulation; instead, it was markedly inhibited by ectopic expression of Bcl-2, Bcl-x(L), XIAP, and Mcl-1. LAQ824 0-6 BCL2 apoptosis regulator Homo sapiens 205-210 16420771-0 2006 [Effects of sp600125 on proliferation and protein expression of bcl-2 and c-myc in hepatic stellate cells]. pyrazolanthrone 12-20 BCL2 apoptosis regulator Homo sapiens 64-69 16472074-5 2006 Immunofluorescence analysis indicates that (DIPP-L-Leu)2-L-LysOCH3 induced upregulation of pro-apoptotic Bax and downregulation of anti-apoptotic Bcl-2 and Bcl-x(L). (DIPP-L-Leu)2-L-Lys-OCH3 43-66 BCL2 apoptosis regulator Homo sapiens 146-151 16931898-4 2006 Interestingly, bcl-2 protein expression was decreased in T- and 5alpha-DHT-treated cells, leading to an increase in the bax/bcl-2 ratio. Dihydrotestosterone 71-74 BCL2 apoptosis regulator Homo sapiens 15-20 16931898-4 2006 Interestingly, bcl-2 protein expression was decreased in T- and 5alpha-DHT-treated cells, leading to an increase in the bax/bcl-2 ratio. Dihydrotestosterone 71-74 BCL2 apoptosis regulator Homo sapiens 124-129 16732934-1 2006 OBJECTIVE: To investigate the expression of mitochondria-mediated apoptosis pathway related genes bcl-2, Bax, survivin and Smac/DIABLO in bufalin induced HL-60 cell apoptosis. bufalin 138-145 BCL2 apoptosis regulator Homo sapiens 98-103 16391524-1 2005 Bis (Bag-3, CAIR), a Bcl-2-interacting protein, promotes the anti-apoptotic activity of Bcl-2 and increased levels of Bis have been observed in several disease models. Bismuth 0-3 BCL2 apoptosis regulator Homo sapiens 21-26 16391524-1 2005 Bis (Bag-3, CAIR), a Bcl-2-interacting protein, promotes the anti-apoptotic activity of Bcl-2 and increased levels of Bis have been observed in several disease models. Bismuth 0-3 BCL2 apoptosis regulator Homo sapiens 88-93 16732934-7 2006 The active subunits of caspase-3 were displayed after treatment for 8 h till 48 h. CONCLUSION: Apoptosis induced by bufalin is related to downregulation of expressions of bcl-2 and survivin, decrease of Bcl-2/Bax ratio, mitochondrial release of Smac/DIABLO, and activation of caspase-3. bufalin 116-123 BCL2 apoptosis regulator Homo sapiens 171-176 16732934-7 2006 The active subunits of caspase-3 were displayed after treatment for 8 h till 48 h. CONCLUSION: Apoptosis induced by bufalin is related to downregulation of expressions of bcl-2 and survivin, decrease of Bcl-2/Bax ratio, mitochondrial release of Smac/DIABLO, and activation of caspase-3. bufalin 116-123 BCL2 apoptosis regulator Homo sapiens 203-208 16437677-7 2005 Moreover, treatment of AGS cells with pseudolaric acid B was also associated with decreased levels of the anti-apoptotic protein Bcl-2, activation of caspase-3, and proteolytic cleavage of PARP-1. pseudolaric acid B 38-56 BCL2 apoptosis regulator Homo sapiens 129-134 16437677-10 2005 The data also suggest that pseudolaric acid B can trigger apoptosis by decreasing Bcl-2 levels and activating caspase-3 protease. pseudolaric acid B 27-45 BCL2 apoptosis regulator Homo sapiens 82-87 16297711-0 2005 Involvement of Bcl-2 family, cytochrome c and caspase 3 in induction of apoptosis by beauvericin in human non-small cell lung cancer cells. beauvericin 85-96 BCL2 apoptosis regulator Homo sapiens 15-20 16326430-7 2005 Ethanol-mediated changes in proteins regulated apoptosis (p53 and bcl-2), antioxidant (vitamin E and catalase) activities, generation of reactive oxygen species (ROS), and oxidative DNA damage shown as 8-hydroxy-2"-deoxyguanosine (8-OHdG) were measured in embryonic midbrain cells. Ethanol 0-7 BCL2 apoptosis regulator Homo sapiens 66-71 16298689-0 2005 Role of Bcl-2 in the arachidonate-mediated survival signaling preventing mitochondrial permeability transition-dependent U937 cell necrosis induced by peroxynitrite. Arachidonic Acid 21-33 BCL2 apoptosis regulator Homo sapiens 8-13 16298689-0 2005 Role of Bcl-2 in the arachidonate-mediated survival signaling preventing mitochondrial permeability transition-dependent U937 cell necrosis induced by peroxynitrite. Peroxynitrous Acid 151-164 BCL2 apoptosis regulator Homo sapiens 8-13 16298689-3 2005 Several lines of evidence consistently indicate that these low concentrations of peroxynitrite nevertheless commit cells to MPT, which is, however, prevented by a survival signaling in which arachidonic acid, protein kinase Calpha (PKCalpha), and Bcl-2 are sequentially involved. Peroxynitrous Acid 81-94 BCL2 apoptosis regulator Homo sapiens 247-252 16298689-6 2005 This was due to depletion of GSH, an event leading to loss of the anti-MPT function of Bcl-2. Glutathione 29-32 BCL2 apoptosis regulator Homo sapiens 87-92 16298689-7 2005 Collectively, these results demonstrate a role of Bcl-2 in monocyte survival signaling preventing MPT-dependent necrosis induced by peroxynitrite, and provide an explanation for the reported observation that Bcl-2 fails to prevent necrosis mediated by intrinsically toxic levels of peroxynitrite. mpt 98-101 BCL2 apoptosis regulator Homo sapiens 50-55 16298689-7 2005 Collectively, these results demonstrate a role of Bcl-2 in monocyte survival signaling preventing MPT-dependent necrosis induced by peroxynitrite, and provide an explanation for the reported observation that Bcl-2 fails to prevent necrosis mediated by intrinsically toxic levels of peroxynitrite. Peroxynitrous Acid 132-145 BCL2 apoptosis regulator Homo sapiens 50-55 16298689-7 2005 Collectively, these results demonstrate a role of Bcl-2 in monocyte survival signaling preventing MPT-dependent necrosis induced by peroxynitrite, and provide an explanation for the reported observation that Bcl-2 fails to prevent necrosis mediated by intrinsically toxic levels of peroxynitrite. Peroxynitrous Acid 282-295 BCL2 apoptosis regulator Homo sapiens 50-55 16290312-7 2005 Although an overexpression of Bcl-2 protects cortical neurons against ceramide-induced apoptosis, our data indicate that the Bcl-2 protein level is not modulated during IGF-I, ceramide and/or LY294002 treatment. Ceramides 70-78 BCL2 apoptosis regulator Homo sapiens 30-35 16199534-0 2005 Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression. Aspirin 16-36 BCL2 apoptosis regulator Homo sapiens 139-144 16199534-6 2005 Most interestingly, at least 12 h of pretreatment with ASA was prerequisite for promoting TRAIL-induced apoptosis and was related to down-regulation of BCL-2. Aspirin 55-58 BCL2 apoptosis regulator Homo sapiens 152-157 16199534-7 2005 Biochemical analysis revealed that ASA inhibited NF-kappaB activity, which is known to regulate BCL-2 gene expression, by dephosphorylating IkappaB-alpha and inhibiting IKKbeta activity but not by affecting the HER-2/neu phosphatidylinositol 3-kinase-Akt signal pathway. Aspirin 35-38 BCL2 apoptosis regulator Homo sapiens 96-101 16199534-8 2005 Overexpression of BCL-2 suppressed the promotive effect of ASA on TRAIL-induced apoptosis and changes in mitochondrial membrane potential. Aspirin 59-62 BCL2 apoptosis regulator Homo sapiens 18-23 16199534-9 2005 Taken together, our studies suggested that ASA-promoted TRAIL cytotoxicity is mediated through down-regulating BCL-2 and by decreasing mitochondrial membrane potential. Aspirin 43-46 BCL2 apoptosis regulator Homo sapiens 111-116 16326430-9 2005 The levels of p53, bcl-2, and 8-OHdG were concomitantly changed by alcohol and acetaldehyde treatment in midbrain cells. Alcohols 67-74 BCL2 apoptosis regulator Homo sapiens 19-24 16326430-9 2005 The levels of p53, bcl-2, and 8-OHdG were concomitantly changed by alcohol and acetaldehyde treatment in midbrain cells. Acetaldehyde 79-91 BCL2 apoptosis regulator Homo sapiens 19-24 16215670-7 2005 Ectopic expression of Bcl-2 appeared to inhibit ceramide-, and Akt specific inhibitor (SH-6)-induced apoptosis by sustained Akt activation. Ceramides 48-56 BCL2 apoptosis regulator Homo sapiens 22-27 16278342-5 2005 We showed that 1) after 1 h of reoxygenation, fluorescence had risen and that ROS production was inhibited by desipramine, an inhibitor of sphingomyelinase, an enzyme responsible for ceramide production (126 +/- 7% vs. 48 +/- 12%, P < 0.05); 2) administration of ceramide (N-acetylsphingosine) per se (i.e., in the absence of H/R) induced ROS production (65 +/- 3%), which was inhibited by complex III inhibitor: antimycin A (24 +/- 3%, P < 0.0001), or stigmatellin (31 +/- 2%, P < 0.0001); 3) hypoxia/reoxygenation-induced ROS production was not affected by either ceramide-activated protein kinase inhibitor dimethyl aminopurine or mitochondrial permeability transition inhibitor cyclosporin A but was significantly inhibited by the antiapoptotic protein Bcl-2 (82 +/- 8%, P < 0.05); 4) ceramide-induced ROS production was also inhibited by Bcl-2 (41 +/- 4%, P < 0.0001). Reactive Oxygen Species 78-81 BCL2 apoptosis regulator Homo sapiens 766-771 16278342-5 2005 We showed that 1) after 1 h of reoxygenation, fluorescence had risen and that ROS production was inhibited by desipramine, an inhibitor of sphingomyelinase, an enzyme responsible for ceramide production (126 +/- 7% vs. 48 +/- 12%, P < 0.05); 2) administration of ceramide (N-acetylsphingosine) per se (i.e., in the absence of H/R) induced ROS production (65 +/- 3%), which was inhibited by complex III inhibitor: antimycin A (24 +/- 3%, P < 0.0001), or stigmatellin (31 +/- 2%, P < 0.0001); 3) hypoxia/reoxygenation-induced ROS production was not affected by either ceramide-activated protein kinase inhibitor dimethyl aminopurine or mitochondrial permeability transition inhibitor cyclosporin A but was significantly inhibited by the antiapoptotic protein Bcl-2 (82 +/- 8%, P < 0.05); 4) ceramide-induced ROS production was also inhibited by Bcl-2 (41 +/- 4%, P < 0.0001). Reactive Oxygen Species 78-81 BCL2 apoptosis regulator Homo sapiens 855-860 16278342-5 2005 We showed that 1) after 1 h of reoxygenation, fluorescence had risen and that ROS production was inhibited by desipramine, an inhibitor of sphingomyelinase, an enzyme responsible for ceramide production (126 +/- 7% vs. 48 +/- 12%, P < 0.05); 2) administration of ceramide (N-acetylsphingosine) per se (i.e., in the absence of H/R) induced ROS production (65 +/- 3%), which was inhibited by complex III inhibitor: antimycin A (24 +/- 3%, P < 0.0001), or stigmatellin (31 +/- 2%, P < 0.0001); 3) hypoxia/reoxygenation-induced ROS production was not affected by either ceramide-activated protein kinase inhibitor dimethyl aminopurine or mitochondrial permeability transition inhibitor cyclosporin A but was significantly inhibited by the antiapoptotic protein Bcl-2 (82 +/- 8%, P < 0.05); 4) ceramide-induced ROS production was also inhibited by Bcl-2 (41 +/- 4%, P < 0.0001). Desipramine 110-121 BCL2 apoptosis regulator Homo sapiens 766-771 16278342-5 2005 We showed that 1) after 1 h of reoxygenation, fluorescence had risen and that ROS production was inhibited by desipramine, an inhibitor of sphingomyelinase, an enzyme responsible for ceramide production (126 +/- 7% vs. 48 +/- 12%, P < 0.05); 2) administration of ceramide (N-acetylsphingosine) per se (i.e., in the absence of H/R) induced ROS production (65 +/- 3%), which was inhibited by complex III inhibitor: antimycin A (24 +/- 3%, P < 0.0001), or stigmatellin (31 +/- 2%, P < 0.0001); 3) hypoxia/reoxygenation-induced ROS production was not affected by either ceramide-activated protein kinase inhibitor dimethyl aminopurine or mitochondrial permeability transition inhibitor cyclosporin A but was significantly inhibited by the antiapoptotic protein Bcl-2 (82 +/- 8%, P < 0.05); 4) ceramide-induced ROS production was also inhibited by Bcl-2 (41 +/- 4%, P < 0.0001). Desipramine 110-121 BCL2 apoptosis regulator Homo sapiens 855-860 16278342-6 2005 These results demonstrate that in endothelial cells submitted to hypoxia and glucose depletion followed by reoxygenation with glucose, the pathway implicated in mitochondrial complex III ROS production is ceramide dependent and is decreased by the antiapoptotic protein Bcl-2. Glucose 77-84 BCL2 apoptosis regulator Homo sapiens 270-275 16278342-6 2005 These results demonstrate that in endothelial cells submitted to hypoxia and glucose depletion followed by reoxygenation with glucose, the pathway implicated in mitochondrial complex III ROS production is ceramide dependent and is decreased by the antiapoptotic protein Bcl-2. Glucose 126-133 BCL2 apoptosis regulator Homo sapiens 270-275 16278342-6 2005 These results demonstrate that in endothelial cells submitted to hypoxia and glucose depletion followed by reoxygenation with glucose, the pathway implicated in mitochondrial complex III ROS production is ceramide dependent and is decreased by the antiapoptotic protein Bcl-2. Reactive Oxygen Species 187-190 BCL2 apoptosis regulator Homo sapiens 270-275 16278342-6 2005 These results demonstrate that in endothelial cells submitted to hypoxia and glucose depletion followed by reoxygenation with glucose, the pathway implicated in mitochondrial complex III ROS production is ceramide dependent and is decreased by the antiapoptotic protein Bcl-2. Ceramides 205-213 BCL2 apoptosis regulator Homo sapiens 270-275 16215670-7 2005 Ectopic expression of Bcl-2 appeared to inhibit ceramide-, and Akt specific inhibitor (SH-6)-induced apoptosis by sustained Akt activation. sanguiin H 6 87-91 BCL2 apoptosis regulator Homo sapiens 22-27 16048438-0 2005 STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Polyamines 78-87 BCL2 apoptosis regulator Homo sapiens 32-37 16048438-8 2005 Polyamine depletion increased mRNA and protein levels for Bcl-2, Mcl-1 (myeloid cell leukaemia-1) and c-IAP2 (inhibitor of apoptosis protein-2). Polyamines 0-9 BCL2 apoptosis regulator Homo sapiens 58-63 16215673-3 2005 The BH3 inhibitors (BH3Is) function by disrupting the interactions mediated by the BH3 domain between pro- and anti-apoptotic members of the Bcl-2 family and liberating more Bax/Bak to induce mitochondrial membrane permeabilization. BH 3 4-7 BCL2 apoptosis regulator Homo sapiens 141-146 16048438-9 2005 Significantly higher levels of Bcl-2 and c-IAP2 proteins were observed in polyamine-depleted cells before and after 9 h of TNF-alpha treatment. Polyamines 74-83 BCL2 apoptosis regulator Homo sapiens 31-36 16215673-3 2005 The BH3 inhibitors (BH3Is) function by disrupting the interactions mediated by the BH3 domain between pro- and anti-apoptotic members of the Bcl-2 family and liberating more Bax/Bak to induce mitochondrial membrane permeabilization. bh3is 20-25 BCL2 apoptosis regulator Homo sapiens 141-146 16048438-11 2005 DN-STAT3 decreased mRNA and protein levels for Bcl-2, Mcl-1 and c-IAP2 in polyamine-depleted cells. Polyamines 74-83 BCL2 apoptosis regulator Homo sapiens 47-52 16048438-14 2005 These results suggest that activation of STAT3 in response to polyamine depletion increases the transcription and subsequent expression of anti-apoptotic Bcl-2 and IAP family proteins and thereby promotes survival of cells against TNF-alpha-induced apoptosis. Polyamines 62-71 BCL2 apoptosis regulator Homo sapiens 154-159 16215673-3 2005 The BH3 inhibitors (BH3Is) function by disrupting the interactions mediated by the BH3 domain between pro- and anti-apoptotic members of the Bcl-2 family and liberating more Bax/Bak to induce mitochondrial membrane permeabilization. BH 3 20-23 BCL2 apoptosis regulator Homo sapiens 141-146 16215673-5 2005 However, when Apo2L/TRAIL was combined with the Bcl-xL inhibitor, BH3I-2", it induced apoptosis synergistically through activation of Caspase-8 and the proapoptotic Bcl-2 family member Bid, resulting in the activation of effector Caspase-3 and proteolytic cleavage of Poly(ADP-ribose) polymerase, events that were blocked by the pan-caspase inhibitor zVAD-fmk. BH3I-2' 66-72 BCL2 apoptosis regulator Homo sapiens 165-170 16267611-9 2005 There were trends for reductions in ER and PgR and trends for increases in bcl-2 in normal and hyperplastic tissue in the tamoxifen-treated arm, though these changes did not reach statistical significance. Tamoxifen 122-131 BCL2 apoptosis regulator Homo sapiens 75-80 16302093-6 2005 An increase in expression of the pro-apoptotic factor Bax and a decrease in expression of the anti-apoptotic factor Bcl-2 were also observed in a time-dependent manner after exposure of 50 microM curcumin, while the expression of the anti-apoptotic factor Bcl-xL was unchanged. Curcumin 196-204 BCL2 apoptosis regulator Homo sapiens 116-121 16195739-3 2005 In addition, TAp73 beta induced expression of proapoptotic Bcl-2 family members and led to apoptosis via the mitochondrial pathway. tap73 beta 13-23 BCL2 apoptosis regulator Homo sapiens 59-64 16033772-7 2005 Moreover, sulforaphane-induced apoptotic cell death was accompanied by upregulation of Bax and downregulation of Bcl-2 and Bcl-X(l) protein. sulforaphane 10-22 BCL2 apoptosis regulator Homo sapiens 113-118 16322301-0 2005 The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Doxorubicin 102-113 BCL2 apoptosis regulator Homo sapiens 40-45 16033772-10 2005 Whereas at a higher concentration, sulforaphane is an effective apoptosis inducer in HepG(2) cells through regulation of Bcl-2 family molecular and activation of ICE/Ced-3 protease (caspase 3) cascade. sulforaphane 35-47 BCL2 apoptosis regulator Homo sapiens 121-126 16322301-11 2005 CONCLUSION: We conclude that nuclear localization of NF-kappaB correlates with bcl-2 and bax expression and that the NF-kappaB/bcl-2 pathway may be associated with a poor response to neoadjuvant doxorubicin-based chemotherapy. Doxorubicin 195-206 BCL2 apoptosis regulator Homo sapiens 127-132 16332175-2 2005 In the AD patients the increased levels of oxidized guanine were demonstrated in DNA, accompanied by the elevated expression of p53, Bax, PARP, and of a 85-kDa protein subunit as well as an augmented ratio of Bax:Bcl-2. Guanine 52-59 BCL2 apoptosis regulator Homo sapiens 213-218 16361157-1 2005 OBJECTIVE: To observe bcl-2 expression and its correlation with apoptosis antagonism and immune evasion of small cell lung cancer cell line and explore the application of bcl-2 antisense thio-oligonucleotide (bcl-2 SON) in gene therapy for lung cancer. thio-oligonucleotide 187-207 BCL2 apoptosis regulator Homo sapiens 171-176 16361157-1 2005 OBJECTIVE: To observe bcl-2 expression and its correlation with apoptosis antagonism and immune evasion of small cell lung cancer cell line and explore the application of bcl-2 antisense thio-oligonucleotide (bcl-2 SON) in gene therapy for lung cancer. thio-oligonucleotide 187-207 BCL2 apoptosis regulator Homo sapiens 171-176 16332177-0 2005 Enhanced sensitivity of human hepatoma cells to 5-fluorouracil by small interfering RNA targeting Bcl-2. Fluorouracil 48-62 BCL2 apoptosis regulator Homo sapiens 98-103 16332177-1 2005 This study was designed to reveal whether the apoptosis induced in human hepatocellular carcinoma (HCC) cell lines by 5-fluorouracil (5-FU) could be enhanced by transfecting Bcl-2 small interfering RNA (siRNA). Fluorouracil 118-132 BCL2 apoptosis regulator Homo sapiens 174-179 16298862-8 2005 PBN pre-treated cells showed significant inhibition of apoptotic features such as activation of caspase-3, up-regulation of Bax and p53, and down-regulation of Bcl-2 compared to control cells upon exposure to ionizing radiation. phenyl-N-tert-butylnitrone 0-3 BCL2 apoptosis regulator Homo sapiens 160-165 16332177-1 2005 This study was designed to reveal whether the apoptosis induced in human hepatocellular carcinoma (HCC) cell lines by 5-fluorouracil (5-FU) could be enhanced by transfecting Bcl-2 small interfering RNA (siRNA). Fluorouracil 134-138 BCL2 apoptosis regulator Homo sapiens 174-179 16332177-2 2005 Bcl-2 siRNA and control siRNA were transfected into cells following treatment with or without 5-FU. Fluorouracil 94-98 BCL2 apoptosis regulator Homo sapiens 0-5 16332177-5 2005 Incubation of all cell lines with Bcl-2 siRNA reduced cell viability 96 h after 5-FU treatment compared with all other controls: Huh-7 (P < 0.01), Huh-7 with hepatitis C replicon (P < 0.01), HepG2 (P < 0.01), HLE (P < 0.05). Fluorouracil 80-84 BCL2 apoptosis regulator Homo sapiens 34-39 16332177-7 2005 The Bcl-2 siRNA prior to 5-FU treatment group showed the strongest effect of inducing apoptosis. Fluorouracil 25-29 BCL2 apoptosis regulator Homo sapiens 4-9 16278099-4 2005 Caspase-independent excitotoxic mechanisms, such as NMDA-induced calpain I activation, with activation and translocation of the cell death-promoting Bcl-2 family member Bid from cytoplasm to mitochondria, and subsequent translocation of apoptosis-inducing factor and endonuclease G to nuclei (which cause large-scale and internucleosomal DNA cleavage, respectively), may be triggered by SE. N-Methylaspartate 52-56 BCL2 apoptosis regulator Homo sapiens 149-154 16316310-2 2005 Docetaxel has a higher affinity for the tubulin subunit and is associated with a 100-fold greater phosphorylation of BCL-2 inducing apoptosis. Docetaxel 0-9 BCL2 apoptosis regulator Homo sapiens 117-122 16169208-4 2005 High glucose causes activation of several proteins involved in apoptotic cell death, including members of the caspase and Bcl-2 families. Glucose 5-12 BCL2 apoptosis regulator Homo sapiens 122-127 16306793-9 2005 A mitochondrial permeability transition pore activator significantly abolished the anti-apoptotic effect of nicorandil in endothelial cells, indicating that the mechanism of protective effect of nicorandil is involved in the mitochondrial apoptotic pathway although it affects neither Bcl-2 nor Bax protein expression levels. Nicorandil 108-118 BCL2 apoptosis regulator Homo sapiens 285-290 16306793-9 2005 A mitochondrial permeability transition pore activator significantly abolished the anti-apoptotic effect of nicorandil in endothelial cells, indicating that the mechanism of protective effect of nicorandil is involved in the mitochondrial apoptotic pathway although it affects neither Bcl-2 nor Bax protein expression levels. Nicorandil 195-205 BCL2 apoptosis regulator Homo sapiens 285-290 16395645-5 2005 An increase of G (0)/G (1) phase cells from 51.88 % to 78.69 % was noted after andrographolide treatment for 36 h. The G (0)/G (1) phase arrest and apoptosis were associated with disappearance of mitochondrial cytochrome c and increased expression of Bax but decreased expression of Bcl-2 proteins in the inhibited cells. andrographolide 79-94 BCL2 apoptosis regulator Homo sapiens 283-288 16144975-9 2005 In contrast, the bcl-2 antagonist ethyl[2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)]-4H-chromene-3-carboxylate (HA 14-1) reversed the protective effects of the three AChE inhibitors and that of nicotine. ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate 34-114 BCL2 apoptosis regulator Homo sapiens 17-22 16144975-9 2005 In contrast, the bcl-2 antagonist ethyl[2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)]-4H-chromene-3-carboxylate (HA 14-1) reversed the protective effects of the three AChE inhibitors and that of nicotine. Nicotine 198-206 BCL2 apoptosis regulator Homo sapiens 17-22 16354403-3 2005 In parallel, the nuclear factor-kappaB (NF-kappaB) signaling pathway was significantly inhibited by ergolide, which was accompanied by down-regulation of cell survival molecules, such as X-chromosome-linked inhibitor of apoptosis and Bcl-2. ergolide 100-108 BCL2 apoptosis regulator Homo sapiens 234-239 16183855-0 2005 Apoptosis induced by a new member of saponin family is mediated through caspase-8-dependent cleavage of Bcl-2. Saponins 37-44 BCL2 apoptosis regulator Homo sapiens 104-109 16412349-9 2005 Before and after treatment with VPA the mean fluorescence index (MFI) of Bcl-2, Bax, Bcl-xl and the levels of caspase 8, 9 and 3 were also detected with the FCM. Valproic Acid 32-35 BCL2 apoptosis regulator Homo sapiens 73-78 16338422-2 2005 However, phase III trials incorporating G3139, a phosphorothioate oligomer targeted to the initiation codon region of the bcl-2 mRNA, have recently been completed in advanced melanoma, myeloma, and chronic lymphocytic leukemia (CLL). Parathion 49-65 BCL2 apoptosis regulator Homo sapiens 122-127 16015611-12 2005 Moreover, AS+RT resulted in significantly reduced clonogenic survival over MM+RT, which was dampened in the Bcl-2 overexpressing lines. as+rt 10-15 BCL2 apoptosis regulator Homo sapiens 108-113 16015611-13 2005 CONCLUSIONS: To our knowledge, these data demonstrate for the first time that a Bcl-2 specific AS oligonucleotide sensitizes prostate cancer cells to RT. Oligonucleotides 98-113 BCL2 apoptosis regulator Homo sapiens 80-85 15893350-9 2005 The levels of Bcl-2 transcripts at 24h incubation in FT-1 stimulated with doxorubicin (0.3mug/ml), prednisolone (0.2mug/ml) and vincristine (5ng/ml) were increased to about 41.0-, 62.0- and 11.1-fold to those in non-stimulated FT-1, respectively. Doxorubicin 74-85 BCL2 apoptosis regulator Homo sapiens 14-19 15893350-9 2005 The levels of Bcl-2 transcripts at 24h incubation in FT-1 stimulated with doxorubicin (0.3mug/ml), prednisolone (0.2mug/ml) and vincristine (5ng/ml) were increased to about 41.0-, 62.0- and 11.1-fold to those in non-stimulated FT-1, respectively. Prednisolone 99-111 BCL2 apoptosis regulator Homo sapiens 14-19 15893350-9 2005 The levels of Bcl-2 transcripts at 24h incubation in FT-1 stimulated with doxorubicin (0.3mug/ml), prednisolone (0.2mug/ml) and vincristine (5ng/ml) were increased to about 41.0-, 62.0- and 11.1-fold to those in non-stimulated FT-1, respectively. Vincristine 128-139 BCL2 apoptosis regulator Homo sapiens 14-19 16394140-1 2005 G3139 is an 18mer phosphorothioate oligonucleotide targeted to the initiation codon region of the Bcl-2 mRNA. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 98-103 16261247-1 2005 A 1 : 1 Lewis acid-base complex between CyN=C=NCy and PhBCl2 has been isolated and structurally characterized, heating of which in refluxing toluene results in the amidinate, [PhC{NCy}2]BCl2; the overall reaction has been modeled by DFT calculations. cylindrospermopsin 40-43 BCL2 apoptosis regulator Homo sapiens 56-60 16261247-1 2005 A 1 : 1 Lewis acid-base complex between CyN=C=NCy and PhBCl2 has been isolated and structurally characterized, heating of which in refluxing toluene results in the amidinate, [PhC{NCy}2]BCl2; the overall reaction has been modeled by DFT calculations. Carbon 40-41 BCL2 apoptosis regulator Homo sapiens 56-60 16261247-1 2005 A 1 : 1 Lewis acid-base complex between CyN=C=NCy and PhBCl2 has been isolated and structurally characterized, heating of which in refluxing toluene results in the amidinate, [PhC{NCy}2]BCl2; the overall reaction has been modeled by DFT calculations. Toluene 141-148 BCL2 apoptosis regulator Homo sapiens 56-60 16002567-2 2005 We examined the expression and regulation of the Bcl-2/adenovirus EIB 19-kDa-interacting protein 3 (BNIP3), a pro-apoptotic gene regulated by nitric oxide (NO) in hepatocytes, in NEC. Nitric Oxide 142-154 BCL2 apoptosis regulator Homo sapiens 49-54 16202388-0 2005 Minocycline up-regulates BCL-2 levels in mitochondria and attenuates male germ cell apoptosis. Minocycline 0-11 BCL2 apoptosis regulator Homo sapiens 25-30 16202388-4 2005 Minocycline-mediated protection occurred at the mitochondria, involving the restoration of the BCL-2 levels and, in turn, suppression of cytochrome c and DIABLO release. Minocycline 0-11 BCL2 apoptosis regulator Homo sapiens 95-100 16394140-1 2005 G3139 is an 18mer phosphorothioate oligonucleotide targeted to the initiation codon region of the Bcl-2 mRNA. Phosphorothioate Oligonucleotides 18-50 BCL2 apoptosis regulator Homo sapiens 98-103 16309197-5 2005 Western blot analysis indicated that the induction of apoptosis by GA and ursolic acid was accompanied with an activation of caspase-8 and a reduction in the anti-apoptotic proteins, Bcl-2 and Bcl-xL, although the pro-apoptotic proteins, Bax and Bak, remained unaffected. Glycyrrhetinic Acid 67-69 BCL2 apoptosis regulator Homo sapiens 183-188 16309197-5 2005 Western blot analysis indicated that the induction of apoptosis by GA and ursolic acid was accompanied with an activation of caspase-8 and a reduction in the anti-apoptotic proteins, Bcl-2 and Bcl-xL, although the pro-apoptotic proteins, Bax and Bak, remained unaffected. ursolic acid 74-86 BCL2 apoptosis regulator Homo sapiens 183-188 16275990-0 2005 A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Oligonucleotides 18-33 BCL2 apoptosis regulator Homo sapiens 67-72 15920535-3 2005 We found that apoptosis induced by 4625 oligonucleotide was associated with decreased Bcl-2 protein expression and telomerase activity, while HA14-1 triggered apoptosis without affecting both Bcl-2 and telomerase levels. 4625 oligonucleotide 35-55 BCL2 apoptosis regulator Homo sapiens 86-91 16148027-0 2005 Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. propargylamine 109-123 BCL2 apoptosis regulator Homo sapiens 14-19 16148027-5 2005 Real-time RT-PCR demonstrated that propargylamine elevated gene expression levels of Bcl-2, and the neurotrophic factors glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) and reduced Bax gene expression. propargylamine 35-49 BCL2 apoptosis regulator Homo sapiens 85-90 16148027-9 2005 These results indicate that both rasagiline and propargylamine possess neurorescue activity, associated with regulation of Bcl-2 family proteins, neurotrophic factors, and APP metabolism. rasagiline 33-43 BCL2 apoptosis regulator Homo sapiens 123-128 16148027-9 2005 These results indicate that both rasagiline and propargylamine possess neurorescue activity, associated with regulation of Bcl-2 family proteins, neurotrophic factors, and APP metabolism. propargylamine 48-62 BCL2 apoptosis regulator Homo sapiens 123-128 16363061-8 2005 The use of GSI to induce NOXA induction overcomes the apoptotic resistance of melanoma cells, which commonly express numerous cell survival proteins such as Mcl-1, Bcl-2, and survivin. 2-(5-Chlorothiophen-2-Yl)-N-[(3s)-1-(4-{2-[(Dimethylamino)methyl]-1h-Imidazol-1-Yl}-2-Fluorophenyl)-2-Oxopyrrolidin-3-Yl]ethanesulfonamide 11-14 BCL2 apoptosis regulator Homo sapiens 164-169 16260652-10 2005 Western blot showed that LPS in high glucose increased the levels of anti-apoptotic Bcl-2 and Bcl-X(L,) and did not change proapoptotic Bax. Glucose 37-44 BCL2 apoptosis regulator Homo sapiens 84-89 16211268-10 2005 EGCG recovered UV-induced loss of anti-apoptotic component, bcl-2, and inhibited UV-induced apoptotic component, Fas ligand, expression. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 60-65 16149076-2 2005 Treatment of HL-60 cells with docetaxel resulted in the production of reactive oxygen species (ROS), activation of caspase-3 (-like) protease, c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) activation, bcl-2 phosphorylation and apoptosis. Docetaxel 30-39 BCL2 apoptosis regulator Homo sapiens 222-227 16149076-5 2005 The caspase inhibitor acetyl-Asp-Glu-Val-Asp-aldehyde (Ac-DEVD-CHO) effectively inhibited JNK/SAPK activation, bcl-2 phosphorylation and partially attenuated the ROS production induced by docetaxel. acetyl-aspartyl-glutamyl-valyl-aspartal 22-53 BCL2 apoptosis regulator Homo sapiens 111-116 16149076-5 2005 The caspase inhibitor acetyl-Asp-Glu-Val-Asp-aldehyde (Ac-DEVD-CHO) effectively inhibited JNK/SAPK activation, bcl-2 phosphorylation and partially attenuated the ROS production induced by docetaxel. acetyl-aspartyl-glutamyl-valyl-aspartal 55-66 BCL2 apoptosis regulator Homo sapiens 111-116 16149076-6 2005 Docetaxel-induced bcl-2 phosphorylation was completely blocked by expression of dominant negative JNK or the JNK/SAPK inhibitor SP600125. Docetaxel 0-9 BCL2 apoptosis regulator Homo sapiens 18-23 16149076-6 2005 Docetaxel-induced bcl-2 phosphorylation was completely blocked by expression of dominant negative JNK or the JNK/SAPK inhibitor SP600125. pyrazolanthrone 128-136 BCL2 apoptosis regulator Homo sapiens 18-23 16149076-7 2005 Overexpression of bcl-2 partially prevented docetaxel-mediated ROS production and subsequent caspase-3 activation, thereby inhibiting apoptotic cell death. Docetaxel 44-53 BCL2 apoptosis regulator Homo sapiens 18-23 16149076-7 2005 Overexpression of bcl-2 partially prevented docetaxel-mediated ROS production and subsequent caspase-3 activation, thereby inhibiting apoptotic cell death. Reactive Oxygen Species 63-66 BCL2 apoptosis regulator Homo sapiens 18-23 16207299-8 2005 The results suggest that the apoptotic effect of melatonin is associated with cell-cycle arrest, downregulation of Bcl-2, mitochondrial membrane depolarization, cytochrome c release and activation of caspase-3. Melatonin 49-58 BCL2 apoptosis regulator Homo sapiens 115-120 16275996-4 2005 Guggulsterone-induced apoptosis was associated with induction of multidomain proapoptotic Bcl-2 family members Bax and Bak. pregna-4,17-diene-3,16-dione 0-13 BCL2 apoptosis regulator Homo sapiens 90-95 16275996-5 2005 Interestingly, the expression of antiapoptotic proteins Bcl-2 and Bcl-xL was initially increased in guggulsterone-treated PC-3 cells but declined markedly following a 16- to 24-hour treatment with guggulsterone. pregna-4,17-diene-3,16-dione 100-113 BCL2 apoptosis regulator Homo sapiens 56-61 16275996-5 2005 Interestingly, the expression of antiapoptotic proteins Bcl-2 and Bcl-xL was initially increased in guggulsterone-treated PC-3 cells but declined markedly following a 16- to 24-hour treatment with guggulsterone. pregna-4,17-diene-3,16-dione 197-210 BCL2 apoptosis regulator Homo sapiens 56-61 16099847-10 2005 In conclusion, without modifying MAO-B activity, selegiline augments the gene induction of Trx, leading to elevated expression of antioxidative MnSOD and antiapoptotic Bcl-2 proteins for protecting against MPP+-induced neurotoxicity. Selegiline 49-59 BCL2 apoptosis regulator Homo sapiens 168-173 16275990-2 2005 The objective of this study was to determine whether a novel bispecific antisense oligonucleotide targeting both Bcl-2 and Bcl-xL induces apoptosis and enhances chemosensitivity in androgen-independent PC3 prostate cancer cells. Oligonucleotides 82-97 BCL2 apoptosis regulator Homo sapiens 113-118 16275990-3 2005 An antisense oligonucleotide with complete sequence identity to Bcl-2 and three-base mismatches to Bcl-xL selected from five antisense oligonucleotides targeting various regions with high homology between Bcl-2 and Bcl-xL was found to be the most potent inhibitor of both Bcl-2 and Bcl-xL expression in PC3 cells. Oligonucleotides 13-28 BCL2 apoptosis regulator Homo sapiens 64-69 16275990-3 2005 An antisense oligonucleotide with complete sequence identity to Bcl-2 and three-base mismatches to Bcl-xL selected from five antisense oligonucleotides targeting various regions with high homology between Bcl-2 and Bcl-xL was found to be the most potent inhibitor of both Bcl-2 and Bcl-xL expression in PC3 cells. Oligonucleotides 13-28 BCL2 apoptosis regulator Homo sapiens 205-210 16275990-3 2005 An antisense oligonucleotide with complete sequence identity to Bcl-2 and three-base mismatches to Bcl-xL selected from five antisense oligonucleotides targeting various regions with high homology between Bcl-2 and Bcl-xL was found to be the most potent inhibitor of both Bcl-2 and Bcl-xL expression in PC3 cells. Oligonucleotides 13-28 BCL2 apoptosis regulator Homo sapiens 205-210 16390854-8 2005 The down-regulation of the cyclin A, Bcl-2, and Bcl-X(L) expression with the simultaneous up-regulation of the p21 and Bax expression, and caspase-9 activation was observed in ECSC after bufalin treatment. bufalin 187-194 BCL2 apoptosis regulator Homo sapiens 37-42 16275990-4 2005 This selected Bcl-2/Bcl-xL bispecific antisense oligonucleotide reduced mRNA and protein levels in a dose-dependent manner, reducing Bcl-2 and Bcl-xL protein levels to 12% and 19%, respectively. Oligonucleotides 48-63 BCL2 apoptosis regulator Homo sapiens 14-19 16275990-4 2005 This selected Bcl-2/Bcl-xL bispecific antisense oligonucleotide reduced mRNA and protein levels in a dose-dependent manner, reducing Bcl-2 and Bcl-xL protein levels to 12% and 19%, respectively. Oligonucleotides 48-63 BCL2 apoptosis regulator Homo sapiens 133-138 16275990-8 2005 This Bcl-2/Bcl-xL bispecific antisense oligonucleotide also enhanced paclitaxel chemosensitivity in PC3 cells, reducing the IC50 of paclitaxel by >90%. Oligonucleotides 39-54 BCL2 apoptosis regulator Homo sapiens 5-10 16275990-8 2005 This Bcl-2/Bcl-xL bispecific antisense oligonucleotide also enhanced paclitaxel chemosensitivity in PC3 cells, reducing the IC50 of paclitaxel by >90%. Paclitaxel 69-79 BCL2 apoptosis regulator Homo sapiens 5-10 16275990-8 2005 This Bcl-2/Bcl-xL bispecific antisense oligonucleotide also enhanced paclitaxel chemosensitivity in PC3 cells, reducing the IC50 of paclitaxel by >90%. Paclitaxel 132-142 BCL2 apoptosis regulator Homo sapiens 5-10 16275990-9 2005 These findings illustrate that combined suppression of antiapoptotic Bcl-2 family members using this antisense oligonucleotide could be an attractive strategy for inhibiting cancer progression through alteration of the apoptotic rheostat in androgen-independent prostate cancer. Oligonucleotides 111-126 BCL2 apoptosis regulator Homo sapiens 69-74 16213503-1 2005 A genome wide search for new BH3-containing Bcl-2 family members was conducted using position weight matrices (PWM) and identified a large (480kDa), novel BH3-only protein, originally called LASU1 (now also known as Ureb-1, E3(histone), ARF-BP1, and Mule). BH 3 29-32 BCL2 apoptosis regulator Homo sapiens 44-49 16499090-6 2005 Evodiamine inhibited PKC activity, down-regulated the expression of ERK, phospho-ERK and Bcl-2, and staurosporine was capable of augmenting these effects induced by evodiamine. evodiamine 0-10 BCL2 apoptosis regulator Homo sapiens 89-94 16282053-3 2005 The concentrations of keratin 13 and bcl-2 in cells exfoliated from tongue fur were detected by immunohistochemical method. fur 75-78 BCL2 apoptosis regulator Homo sapiens 37-42 16111926-0 2005 Characterization and quantification of Bcl-2 antisense G3139 and metabolites in plasma and urine by ion-pair reversed phase HPLC coupled with electrospray ion-trap mass spectrometry. oblimersen 55-60 BCL2 apoptosis regulator Homo sapiens 39-44 16111926-1 2005 A novel ion-pair reversed phase electrospray ionization (IP-RP-ESI) liquid chromatography-mass spectrometry (LC-MS) method has been developed for identification and quantification of Bcl-2 antisense phosphorothioate oligonucleotides G3139 and metabolites in plasma. Parathion 199-215 BCL2 apoptosis regulator Homo sapiens 183-188 16111926-1 2005 A novel ion-pair reversed phase electrospray ionization (IP-RP-ESI) liquid chromatography-mass spectrometry (LC-MS) method has been developed for identification and quantification of Bcl-2 antisense phosphorothioate oligonucleotides G3139 and metabolites in plasma. Oligonucleotides 216-232 BCL2 apoptosis regulator Homo sapiens 183-188 16419151-4 2005 By using Western blotting methods, capsaicin reduced the expression of Bcl-2, the antiapoptotic protein, in AGS cells in a concentration-dependent manner. Capsaicin 35-44 BCL2 apoptosis regulator Homo sapiens 71-76 16419151-9 2005 CONCLUSION: These results suggest that capsaicin-induced cell death might be via a Bcl-2 sensitive apoptotic pathway. Capsaicin 39-48 BCL2 apoptosis regulator Homo sapiens 83-88 16499090-7 2005 CONCLUSION: PKC lies upstream and exhibits regulatory effect on ERK and Bcl-2 in evodiamine-induced cell death. evodiamine 81-91 BCL2 apoptosis regulator Homo sapiens 72-77 16007134-0 2005 Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway. Arsenic Trioxide 0-16 BCL2 apoptosis regulator Homo sapiens 84-89 16007134-6 2005 Nevertheless, As2O3-induced cell death occurred in a regulated manner and was abrogated upon Bcl-2 overexpression. Arsenic Trioxide 14-19 BCL2 apoptosis regulator Homo sapiens 93-98 16243795-5 2005 EXPERIMENTAL DESIGN: An antibody specific against pSer70 Bcl-2 was generated for thorough immunohistochemical examination of paraffin-embedded tumor specimens, allowing detection of the endogenously expressed antigen among a range of Bcl-2-positive colorectal neoplasms, including 75 tubular adenomas, 114 adenocarcinomas, and 15 cases of cancer in adenomas. Paraffin 125-133 BCL2 apoptosis regulator Homo sapiens 57-62 16007148-4 2005 Treatment of A549 lung cancer cells with BAY 43-9006 diminished Mcl-1 levels in a time- and dose-dependent manner without affecting other Bcl-2 family members. Sorafenib 41-52 BCL2 apoptosis regulator Homo sapiens 138-143 16007152-1 2005 The antiapoptotic Bcl-2-family proteins, Bcl-2 and Bcl-xL, are recognized phototargets of photodynamic therapy (PDT) with the mitochondrion-targeting phthalocyanine photosensitizer Pc 4. phthalocyanine 150-164 BCL2 apoptosis regulator Homo sapiens 18-23 16007152-1 2005 The antiapoptotic Bcl-2-family proteins, Bcl-2 and Bcl-xL, are recognized phototargets of photodynamic therapy (PDT) with the mitochondrion-targeting phthalocyanine photosensitizer Pc 4. phthalocyanine 150-164 BCL2 apoptosis regulator Homo sapiens 41-46 16052512-9 2005 Furthermore, TUNEL assay showed that activation of PAR1 attenuated docetaxel induced apoptosis through the upregulation of the Bcl-2 family protein Bcl-xL. Docetaxel 67-76 BCL2 apoptosis regulator Homo sapiens 127-132 16007148-3 2005 In the present study, the effects of BAY 43-9006 on the antiapoptotic Bcl-2 family member Mcl-1 were examined. Sorafenib 37-48 BCL2 apoptosis regulator Homo sapiens 70-75 16186597-0 2005 Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. Sodium 46-52 BCL2 apoptosis regulator Homo sapiens 56-61 16186597-0 2005 Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. Oligonucleotides 72-87 BCL2 apoptosis regulator Homo sapiens 56-61 16243823-5 2005 Curcumin also suppressed the paclitaxel-induced expression of antiapoptotic (XIAP, IAP-1, IAP-2, Bcl-2, and Bcl-xL), proliferative (cyclooxygenase 2, c-Myc, and cyclin D1), and metastatic proteins (vascular endothelial growth factor, matrix metalloproteinase-9, and intercellular adhesion molecule-1). Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 97-102 16243823-5 2005 Curcumin also suppressed the paclitaxel-induced expression of antiapoptotic (XIAP, IAP-1, IAP-2, Bcl-2, and Bcl-xL), proliferative (cyclooxygenase 2, c-Myc, and cyclin D1), and metastatic proteins (vascular endothelial growth factor, matrix metalloproteinase-9, and intercellular adhesion molecule-1). Paclitaxel 29-39 BCL2 apoptosis regulator Homo sapiens 97-102 16162974-6 2005 Finally, the analysis of the molecular markers that might be implicated in the synergism between LY294002 and gemcitabine suggests that PI3K inhibition might aid chemotherapeutic treatment, leading to changes in the balance between anti- and pro-apoptotic molecules of the Bcl-2 family, Bcl-XL and Bax. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 97-105 BCL2 apoptosis regulator Homo sapiens 273-278 15976387-1 2005 This study was undertaken to determine whether the Bcl-2 family proteins and Smac are regulators of aspirin-mediated apoptosis in a gastric mucosal cell line known as AGS cells. Aspirin 100-107 BCL2 apoptosis regulator Homo sapiens 51-56 15976387-5 2005 ASA downregulated Bcl-2 protein expression and induced Bax translocation into the mitochondria and cleavage of Bid. Aspirin 0-3 BCL2 apoptosis regulator Homo sapiens 18-23 16162974-6 2005 Finally, the analysis of the molecular markers that might be implicated in the synergism between LY294002 and gemcitabine suggests that PI3K inhibition might aid chemotherapeutic treatment, leading to changes in the balance between anti- and pro-apoptotic molecules of the Bcl-2 family, Bcl-XL and Bax. gemcitabine 110-121 BCL2 apoptosis regulator Homo sapiens 273-278 16388709-7 2005 Low Bcl-2 expression and high inflammatory status were normalized by vitamin E both in vivo and in vitro. Vitamin E 69-78 BCL2 apoptosis regulator Homo sapiens 4-9 16234098-5 2005 Western blotting suggested that deoxycholate down-regulated Bcl-2 protein expression and up-regulated Bax expression, but Fas was negative in the cells before and after deoxycholate treatment. Deoxycholic Acid 32-44 BCL2 apoptosis regulator Homo sapiens 60-65 16234098-7 2005 Aaspase-3 activation, Bcl-2 protein down-regulation and Bax up-regulation are involved in deoxycholate-induced apoptosis, which does not involve Fas-L/Fas. Deoxycholic Acid 90-102 BCL2 apoptosis regulator Homo sapiens 22-27 15972445-7 2005 The B-cell lymphoma 2 (Bcl-2) protein level remained stable, although its mRNA was consistently reduced, suggesting that the outcome of transcriptional inhibition by flavopiridol is governed by the intrinsic stability of the individual transcripts and proteins. alvocidib 166-178 BCL2 apoptosis regulator Homo sapiens 4-21 15972445-7 2005 The B-cell lymphoma 2 (Bcl-2) protein level remained stable, although its mRNA was consistently reduced, suggesting that the outcome of transcriptional inhibition by flavopiridol is governed by the intrinsic stability of the individual transcripts and proteins. alvocidib 166-178 BCL2 apoptosis regulator Homo sapiens 23-28 16250931-5 2005 Bortezomib is a proteasome inhibitor that can decrease Bcl-2 expression through diminished IkappaB degradation. Bortezomib 0-10 BCL2 apoptosis regulator Homo sapiens 55-60 16315863-7 2005 Treatment of MKN-45 cells with AS Bcl-2 increased sensitivity to adriamycin (ADM), cisplatin (CDDP), and paclitaxel (PTX) in vitro and in vivo. Doxorubicin 65-75 BCL2 apoptosis regulator Homo sapiens 34-39 16315863-7 2005 Treatment of MKN-45 cells with AS Bcl-2 increased sensitivity to adriamycin (ADM), cisplatin (CDDP), and paclitaxel (PTX) in vitro and in vivo. Doxorubicin 77-80 BCL2 apoptosis regulator Homo sapiens 34-39 16315863-7 2005 Treatment of MKN-45 cells with AS Bcl-2 increased sensitivity to adriamycin (ADM), cisplatin (CDDP), and paclitaxel (PTX) in vitro and in vivo. Cisplatin 83-92 BCL2 apoptosis regulator Homo sapiens 34-39 16315863-7 2005 Treatment of MKN-45 cells with AS Bcl-2 increased sensitivity to adriamycin (ADM), cisplatin (CDDP), and paclitaxel (PTX) in vitro and in vivo. Cisplatin 94-98 BCL2 apoptosis regulator Homo sapiens 34-39 16315863-7 2005 Treatment of MKN-45 cells with AS Bcl-2 increased sensitivity to adriamycin (ADM), cisplatin (CDDP), and paclitaxel (PTX) in vitro and in vivo. Paclitaxel 105-115 BCL2 apoptosis regulator Homo sapiens 34-39 16315863-7 2005 Treatment of MKN-45 cells with AS Bcl-2 increased sensitivity to adriamycin (ADM), cisplatin (CDDP), and paclitaxel (PTX) in vitro and in vivo. Paclitaxel 117-120 BCL2 apoptosis regulator Homo sapiens 34-39 16315863-8 2005 Similarly, treatment of BT-474, ZR-75-1, and MDA-MB-231 cells with AS Bcl-2 increased chemosensitivity to ADM, mitomycin C (MMC), PTX, and docetaxel (DOC). Mitomycin 111-122 BCL2 apoptosis regulator Homo sapiens 70-75 16315863-8 2005 Similarly, treatment of BT-474, ZR-75-1, and MDA-MB-231 cells with AS Bcl-2 increased chemosensitivity to ADM, mitomycin C (MMC), PTX, and docetaxel (DOC). Mitomycin 124-127 BCL2 apoptosis regulator Homo sapiens 70-75 16315863-8 2005 Similarly, treatment of BT-474, ZR-75-1, and MDA-MB-231 cells with AS Bcl-2 increased chemosensitivity to ADM, mitomycin C (MMC), PTX, and docetaxel (DOC). Paclitaxel 130-133 BCL2 apoptosis regulator Homo sapiens 70-75 16315863-8 2005 Similarly, treatment of BT-474, ZR-75-1, and MDA-MB-231 cells with AS Bcl-2 increased chemosensitivity to ADM, mitomycin C (MMC), PTX, and docetaxel (DOC). Docetaxel 139-148 BCL2 apoptosis regulator Homo sapiens 70-75 16315863-8 2005 Similarly, treatment of BT-474, ZR-75-1, and MDA-MB-231 cells with AS Bcl-2 increased chemosensitivity to ADM, mitomycin C (MMC), PTX, and docetaxel (DOC). Docetaxel 150-153 BCL2 apoptosis regulator Homo sapiens 70-75 16142413-9 2005 Bcl-2 was also depleted at 72 h when there was the most prominent elevation of the apoptotic cells, suggesting that it participates during the exacerbation rather than the initiation phases of the CHL-induced apoptosis. chlorophyllin 197-200 BCL2 apoptosis regulator Homo sapiens 0-5 16215281-9 2005 It has been shown that lithium, valproate, and/or carbamazepine regulate numerous factors involved in cell survival pathways, including cyclic adenine monophospate response element-binding protein, brain-derived neurotrophic factor, bcl-2, and mitogen-activated protein kinases. Lithium 23-30 BCL2 apoptosis regulator Homo sapiens 233-238 16185262-5 2005 When these changes were prevented by overexpressing Bcl-2 or pharmacologically decreasing the ROS level, K10 upregulation was inhibited, implying that the differentiated phenotype and K10 expression require apoptotic mitochondria, ROS being the most likely differentiation-mediating factor. Reactive Oxygen Species 94-97 BCL2 apoptosis regulator Homo sapiens 52-57 16185262-5 2005 When these changes were prevented by overexpressing Bcl-2 or pharmacologically decreasing the ROS level, K10 upregulation was inhibited, implying that the differentiated phenotype and K10 expression require apoptotic mitochondria, ROS being the most likely differentiation-mediating factor. Reactive Oxygen Species 231-234 BCL2 apoptosis regulator Homo sapiens 52-57 16181427-9 2005 Transducible loop deleted Bcl-2 increases the survival of cortical neurons following trophic factor withdrawal and also rescues neural cell lines from staurosporine-induced death. Staurosporine 151-164 BCL2 apoptosis regulator Homo sapiens 26-31 16215281-9 2005 It has been shown that lithium, valproate, and/or carbamazepine regulate numerous factors involved in cell survival pathways, including cyclic adenine monophospate response element-binding protein, brain-derived neurotrophic factor, bcl-2, and mitogen-activated protein kinases. Valproic Acid 32-41 BCL2 apoptosis regulator Homo sapiens 233-238 16227396-6 2005 Coadministration of sulindac sulfide and the small-molecule Bcl-2 inhibitor HA14-1 increased apoptosis induction and enhanced caspase-8 and caspase-9 cleavage, Bax redistribution, and cytochrome c and second mitochondria-derived activator of caspase release. sulindac sulfide 20-36 BCL2 apoptosis regulator Homo sapiens 60-65 16215281-9 2005 It has been shown that lithium, valproate, and/or carbamazepine regulate numerous factors involved in cell survival pathways, including cyclic adenine monophospate response element-binding protein, brain-derived neurotrophic factor, bcl-2, and mitogen-activated protein kinases. Carbamazepine 50-63 BCL2 apoptosis regulator Homo sapiens 233-238 16227396-0 2005 Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2. sulindac sulfide 0-16 BCL2 apoptosis regulator Homo sapiens 67-72 16227396-0 2005 Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2. sulindac sulfide 0-16 BCL2 apoptosis regulator Homo sapiens 139-144 16227396-3 2005 We determined the effect of ectopic Bcl-2 expression upon sulindac-induced apoptotic signaling in SW480 human colon cancer cells. Sulindac 58-66 BCL2 apoptosis regulator Homo sapiens 36-41 15994315-8 2005 Inhibition of PP2A by okadaic acid: 1) increased Bad and Bcl-2 phosphorylation at Ser112 and Ser70, respectively; 2) increased ERK activity; 3) prevented JNK activation; 4) prevented cytochrome c release, and activation of caspases-9 and -3 in response to TNF-alpha. Okadaic Acid 22-34 BCL2 apoptosis regulator Homo sapiens 57-62 16201908-1 2005 G3139 is an antisense Bcl-2 phosphorothioate oligonucleotide that has been combined with DTIC in a phase III clinical trial in melanoma. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 22-27 16201908-1 2005 G3139 is an antisense Bcl-2 phosphorothioate oligonucleotide that has been combined with DTIC in a phase III clinical trial in melanoma. Phosphorothioate Oligonucleotides 28-60 BCL2 apoptosis regulator Homo sapiens 22-27 16320583-0 2005 [Effect of Bcl-2 antisense phosphorothioate oligodeoxynucleotides on bile duct carcinoma cell line QBC939]. phosphorothioate oligodeoxynucleotides 27-65 BCL2 apoptosis regulator Homo sapiens 11-16 16320583-1 2005 OBJECTIVE: To investigate the effect of Bcl-2 antisense oligodeoxynucleotides (ASODN) on the cell proliferation and Bcl-2 expression in bile duct carcinoma cell line QBC939. Oligodeoxyribonucleotides 56-77 BCL2 apoptosis regulator Homo sapiens 116-121 16320583-2 2005 METHODS: Bcl-2 ASODN and control sequence were transfected into cell line QBC939 by Lipofectamine 2000. Lipofectamine 84-102 BCL2 apoptosis regulator Homo sapiens 9-14 16320583-4 2005 The survival rate and colony formation rate of QBC939 cells incubating with Bcl-2 ASODN were evaluated by trypan blue staining assay and colony forming test. Trypan Blue 106-117 BCL2 apoptosis regulator Homo sapiens 76-81 16320583-6 2005 Both trypan blue staining assay and colony forming test demonstrated that Bcl-2 ASODN could partially inhibit the growth of QBC939 cells. Trypan Blue 5-16 BCL2 apoptosis regulator Homo sapiens 74-79 16166262-0 2005 miR-15 and miR-16 induce apoptosis by targeting BCL2. mir-15 0-6 BCL2 apoptosis regulator Homo sapiens 48-52 16166262-5 2005 Therefore, miR-15 and miR-16 are natural antisense Bcl2 interactors that could be used for therapy of Bcl2-overexpressing tumors. mir-15 11-17 BCL2 apoptosis regulator Homo sapiens 51-55 16166262-5 2005 Therefore, miR-15 and miR-16 are natural antisense Bcl2 interactors that could be used for therapy of Bcl2-overexpressing tumors. mir-15 11-17 BCL2 apoptosis regulator Homo sapiens 102-106 16083863-0 2005 Bcl-2 mediated inhibition of erucylphosphocholine-induced apoptosis depends on its subcellular localisation. erucylphosphocholine 29-49 BCL2 apoptosis regulator Homo sapiens 0-5 16166319-0 2005 Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Oligonucleotides 16-31 BCL2 apoptosis regulator Homo sapiens 0-5 16277846-6 2005 In ATRA and TPA group, the change of HSP70 had positive correlation with JWA, and negative correlation with Bcl-2. Tretinoin 3-7 BCL2 apoptosis regulator Homo sapiens 108-113 16277846-6 2005 In ATRA and TPA group, the change of HSP70 had positive correlation with JWA, and negative correlation with Bcl-2. Tetradecanoylphorbol Acetate 12-15 BCL2 apoptosis regulator Homo sapiens 108-113 16127738-13 2005 Activation of caspase-3, decreased Bcl-2 protein and increased Bax protein are involved in TC-induced apoptosis of Eca109 cells. Taurocholic Acid 91-93 BCL2 apoptosis regulator Homo sapiens 35-40 15994315-10 2005 These results indicate that polyamines regulate PP2A activity, and inhibition of PP2A in response to polyamine depletion increases steady state levels of Bad and Bcl-2 proteins and their phosphorylation and thereby prevents cytochrome c release, caspase-9, and caspase-3 activation. Polyamines 28-38 BCL2 apoptosis regulator Homo sapiens 162-167 15994315-10 2005 These results indicate that polyamines regulate PP2A activity, and inhibition of PP2A in response to polyamine depletion increases steady state levels of Bad and Bcl-2 proteins and their phosphorylation and thereby prevents cytochrome c release, caspase-9, and caspase-3 activation. Polyamines 28-37 BCL2 apoptosis regulator Homo sapiens 162-167 16052481-7 2005 The apoptotic dose of garcinol (20 microM) changed the ratio of the anti-apoptotic Bcl-2 and proapoptotic BAX proteins within 12 h, which correlated with a release of cytochrome c from the mitochondria to the cytosol, and with PARP cleavage. garcinol 22-30 BCL2 apoptosis regulator Homo sapiens 83-88 16104877-0 2005 Etodolac inhibits EBER expression and induces Bcl-2-regulated apoptosis in Burkitt"s lymphoma cells. Etodolac 0-8 BCL2 apoptosis regulator Homo sapiens 46-51 16104877-6 2005 For the pathway of etodolac-induced apoptosis, reduction of anti-apoptotic bcl-2 mRNA and Bcl-2 protein, activation of Caspase-9 and -3, down-regulation of caspase inhibitors, c-IAP-1 and Survivin were involved. Etodolac 19-27 BCL2 apoptosis regulator Homo sapiens 75-80 16104877-6 2005 For the pathway of etodolac-induced apoptosis, reduction of anti-apoptotic bcl-2 mRNA and Bcl-2 protein, activation of Caspase-9 and -3, down-regulation of caspase inhibitors, c-IAP-1 and Survivin were involved. Etodolac 19-27 BCL2 apoptosis regulator Homo sapiens 90-95 16104877-7 2005 Moreover, EBER-1 and -2 expression in Epstein-Barr virus positive Daudi and Raji cells were reduced to result in down-regulation of Bcl-2 by treatment with etodolac. Etodolac 156-164 BCL2 apoptosis regulator Homo sapiens 132-137 16104877-10 2005 In conclusion, our findings indicated etodolac inhibited EBERs expression and induced apoptosis via a Bcl-2-regulated pathway. Etodolac 38-46 BCL2 apoptosis regulator Homo sapiens 102-107 16244579-4 2005 RESULTS: It has been shown that the formation of the resistance to cisplatin in A2780/DDP8 cells is accompanied by the increase of expression of glutathione-S-transferase and Bcl-2, by the decrease of expression of CD95-antigene and proliferation potential of the cells, by appearance of EGF receptors and elevation of expression level of E-cadherin, alpha- and beta-catenins, proving the enhancement of adhesive properties of tumor cells. Cisplatin 67-76 BCL2 apoptosis regulator Homo sapiens 175-180 16244579-5 2005 CONCLUSION: Antiapoptotic program seems to be the leading mechanism of the development of the resistance to cisplatin in A2780/DDP8 cells and is realized via high expression of Bcl-2. Cisplatin 108-117 BCL2 apoptosis regulator Homo sapiens 177-182 16244580-0 2005 Expression of Bax, Bad and Bcl-2 proteins under x-radiation effect towards human breast carcinoma MCF-7 cells and their doxorubicin-resistant derivatives. Doxorubicin 120-131 BCL2 apoptosis regulator Homo sapiens 27-32 16244580-5 2005 Different pattern of Bcl-2 expression was shown in MCF-7(DOX/R) cells compared with MCF-7(wt) cells. Doxorubicin 57-60 BCL2 apoptosis regulator Homo sapiens 21-26 17022150-10 2005 There were significant correlations between the IC50 of CDDP and Bcl-2, BCRP, GST-pi, and between that of 5-FU and MRP 2. cddp 56-60 BCL2 apoptosis regulator Homo sapiens 65-70 16001965-5 2005 Cultured Nb cells were sensitized to alpha-TOS by pre-treatment with Bcl-2, Bcl-xL or Mcl-1 siRNAs, while the malignant cell line was more resistant to the vitamin E analogue when Bax was knocked down. alpha-Tocopherol 37-46 BCL2 apoptosis regulator Homo sapiens 69-74 16001965-6 2005 In contrast, overexpression of Bcl-2 in Nb cells rendered them more resistant to alpha-TOS-induced apoptosis. alpha-Tocopherol 81-90 BCL2 apoptosis regulator Homo sapiens 31-36 16045454-6 2005 Pharmacological inhibition of PI3K attenuated motoneuron survival and was important in the regulation of Bcl-2 serine phosphorylation, limited release of cytochrome c into the cytoplasm and caspase activation. Serine 111-117 BCL2 apoptosis regulator Homo sapiens 105-110 15878253-5 2005 Activation of PPAR-gamma by ciglitazone in growth plate chondrocytes inhibits T(3) induced terminal differentiation and promotes apoptosis through increased levels of caspase 3/7 activity and decreased expression of the anti-apoptotic protein Bcl-2. ciglitazone 28-39 BCL2 apoptosis regulator Homo sapiens 243-248 16187019-10 2005 BCNU chemotherapy combined with retinamide markedly down-regulated levels of both Bcl-xL and Bcl-2 proteins in glioblastoma and enhanced the incidence of apoptosis in U87 cells. Carmustine 0-4 BCL2 apoptosis regulator Homo sapiens 93-98 16187019-10 2005 BCNU chemotherapy combined with retinamide markedly down-regulated levels of both Bcl-xL and Bcl-2 proteins in glioblastoma and enhanced the incidence of apoptosis in U87 cells. retinamide 32-42 BCL2 apoptosis regulator Homo sapiens 93-98 16187019-0 2005 Retinamide-induced apoptosis in glioblastomas is associated with down-regulation of Bcl-xL and Bcl-2 proteins. retinamide 0-10 BCL2 apoptosis regulator Homo sapiens 95-100 16187019-8 2005 Based on Western blots the levels of Bcl-2 and Bcl-xL were decreased in glioblastoma cells after treatment with retinamide. retinamide 112-122 BCL2 apoptosis regulator Homo sapiens 37-42 16170037-5 2005 The evaluation of molecular pathways involved in apoptosis indicates that the Bcl-2 but not the caspases may be involved in the CDDP protection of paclitaxel-induced apoptosis. cddp 128-132 BCL2 apoptosis regulator Homo sapiens 78-83 16132718-3 2005 In this study, we measured the expression of two Bcl-2 family members, Bax and Bcl-2, in a human endothelial like cell-line overexpressing the organic hydroperoxide-scavenging enzyme glutathione peroxidase (GPX1), in the absence of any apoptotic/oxidant stimulus. Hydrogen Peroxide 151-164 BCL2 apoptosis regulator Homo sapiens 49-54 16132718-3 2005 In this study, we measured the expression of two Bcl-2 family members, Bax and Bcl-2, in a human endothelial like cell-line overexpressing the organic hydroperoxide-scavenging enzyme glutathione peroxidase (GPX1), in the absence of any apoptotic/oxidant stimulus. Hydrogen Peroxide 151-164 BCL2 apoptosis regulator Homo sapiens 79-84 16170037-5 2005 The evaluation of molecular pathways involved in apoptosis indicates that the Bcl-2 but not the caspases may be involved in the CDDP protection of paclitaxel-induced apoptosis. Paclitaxel 147-157 BCL2 apoptosis regulator Homo sapiens 78-83 16005485-11 2005 There are two distinct cGMP-mediated survival pathways: (i) the up-regulation of a redox protein thioredoxin (Trx) for elevating mitochondrial levels of antioxidant protein Mn superoxide dismutase (MnSOD) and antiapoptotic protein Bcl-2, and (ii) the activation of mitochondrial ATP-sensitive potassium channels [K(ATP)]. Cyclic GMP 23-27 BCL2 apoptosis regulator Homo sapiens 231-236 15995977-9 2005 Expression of anti-apoptotic Bcl-2 was down regulated when the cells were treated with XN for 48--72 h. We conclude that induction of apoptosis by downregulation of Bcl-2 and activation of the caspase cascade may contribute to the chemopreventive or therapeutic potential of XN. xanthohumol 87-89 BCL2 apoptosis regulator Homo sapiens 29-34 15995977-9 2005 Expression of anti-apoptotic Bcl-2 was down regulated when the cells were treated with XN for 48--72 h. We conclude that induction of apoptosis by downregulation of Bcl-2 and activation of the caspase cascade may contribute to the chemopreventive or therapeutic potential of XN. xanthohumol 87-89 BCL2 apoptosis regulator Homo sapiens 165-170 15995977-9 2005 Expression of anti-apoptotic Bcl-2 was down regulated when the cells were treated with XN for 48--72 h. We conclude that induction of apoptosis by downregulation of Bcl-2 and activation of the caspase cascade may contribute to the chemopreventive or therapeutic potential of XN. xanthohumol 275-277 BCL2 apoptosis regulator Homo sapiens 29-34 15955869-0 2005 Increased Bcl2 expression by antisense oligoribonucleotides targeting the adenine-uridine-rich element motif. adenine-uridine 74-89 BCL2 apoptosis regulator Homo sapiens 10-14 15955869-4 2005 The bcl2 (b)-ARE (adenine-uridine-rich element) in the 3"-untranslated region of the b-RNA that regulates the rate of RNA degradation has been targeted with three chemically modified oligoribonucleotides designed in the antisense orientation (asORNs). Adenine 18-25 BCL2 apoptosis regulator Homo sapiens 4-8 15955869-4 2005 The bcl2 (b)-ARE (adenine-uridine-rich element) in the 3"-untranslated region of the b-RNA that regulates the rate of RNA degradation has been targeted with three chemically modified oligoribonucleotides designed in the antisense orientation (asORNs). Uridine 26-33 BCL2 apoptosis regulator Homo sapiens 4-8 15987648-3 2005 Nitric oxide generated by nitric oxide synthase or released from an endogenous S-nitrosothiol, S-nitrosoglutathione may up-regulate antioxidative thioredoxin system and antiapototic Bcl-2 protein through a cGMP-dependent mechanism. Nitric Oxide 0-12 BCL2 apoptosis regulator Homo sapiens 182-187 15987648-3 2005 Nitric oxide generated by nitric oxide synthase or released from an endogenous S-nitrosothiol, S-nitrosoglutathione may up-regulate antioxidative thioredoxin system and antiapototic Bcl-2 protein through a cGMP-dependent mechanism. nitric 26-32 BCL2 apoptosis regulator Homo sapiens 182-187 15987648-3 2005 Nitric oxide generated by nitric oxide synthase or released from an endogenous S-nitrosothiol, S-nitrosoglutathione may up-regulate antioxidative thioredoxin system and antiapototic Bcl-2 protein through a cGMP-dependent mechanism. S-Nitrosothiols 79-93 BCL2 apoptosis regulator Homo sapiens 182-187 15987648-3 2005 Nitric oxide generated by nitric oxide synthase or released from an endogenous S-nitrosothiol, S-nitrosoglutathione may up-regulate antioxidative thioredoxin system and antiapototic Bcl-2 protein through a cGMP-dependent mechanism. S-Nitrosoglutathione 95-115 BCL2 apoptosis regulator Homo sapiens 182-187 15987648-3 2005 Nitric oxide generated by nitric oxide synthase or released from an endogenous S-nitrosothiol, S-nitrosoglutathione may up-regulate antioxidative thioredoxin system and antiapototic Bcl-2 protein through a cGMP-dependent mechanism. Cyclic GMP 206-210 BCL2 apoptosis regulator Homo sapiens 182-187 16085054-8 2005 Accordingly, PXR overexpression in HepG2 cells led to bcl-2 induction upon clotrimazole treatment and protects cells against Fas-induced apoptosis. Clotrimazole 75-87 BCL2 apoptosis regulator Homo sapiens 54-59 16202314-5 2005 RESULTS: The peritoneal fluid concentrations of PGE2 and bcl-2 in study group were significantly higher than that of control group, (1987 +/- 532) ng/L vs (386 +/- 215) ng/L, (177 +/- 53) U/L vs (86 +/- 21) U/L, (P < 0.05); and the PGE2 levels of severe endometriosis were significantly higher than that of mild endometriosis, (2221 +/- 1352) ng/L vs (1694 +/- 381) ng/L, (P < 0.01). Dinoprostone 235-239 BCL2 apoptosis regulator Homo sapiens 57-62 16329599-9 2005 CONCLUSION: Our results demonstrated that genistein inhibited the viability of human colon cancer HT-29 cell via induction of apoptosis mainly through regulation of PCNA and Bax/Bcl-2 expression. Genistein 42-51 BCL2 apoptosis regulator Homo sapiens 178-183 16086582-4 2005 Similarly, Bcl-2-C adopted a structure with a predominance of intermolecularly bound pleated beta-sheet in the absence of membranes, with alpha-helix as the main component in the presence of DMPC and POPG, but intermolecular beta-sheet in the presence of EYPC and cholesterol. Dimyristoylphosphatidylcholine 191-195 BCL2 apoptosis regulator Homo sapiens 11-18 16086582-4 2005 Similarly, Bcl-2-C adopted a structure with a predominance of intermolecularly bound pleated beta-sheet in the absence of membranes, with alpha-helix as the main component in the presence of DMPC and POPG, but intermolecular beta-sheet in the presence of EYPC and cholesterol. 1-palmitoyl-2-oleoylglycero-3-phosphoglycerol 200-204 BCL2 apoptosis regulator Homo sapiens 11-18 16086582-4 2005 Similarly, Bcl-2-C adopted a structure with a predominance of intermolecularly bound pleated beta-sheet in the absence of membranes, with alpha-helix as the main component in the presence of DMPC and POPG, but intermolecular beta-sheet in the presence of EYPC and cholesterol. eypc 255-259 BCL2 apoptosis regulator Homo sapiens 11-18 16086582-4 2005 Similarly, Bcl-2-C adopted a structure with a predominance of intermolecularly bound pleated beta-sheet in the absence of membranes, with alpha-helix as the main component in the presence of DMPC and POPG, but intermolecular beta-sheet in the presence of EYPC and cholesterol. Cholesterol 264-275 BCL2 apoptosis regulator Homo sapiens 11-18 15880691-6 2005 Furthermore, inhibition of ERK through addition of PD98059 stimulated p53 activation in MCF7 cells and also led to upregulation of p53 downstream targets, p21 and Bax, which is a proapototic member of Bcl-2 family triggering mitochondrial pore opening. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 51-58 BCL2 apoptosis regulator Homo sapiens 201-206 16103078-4 2005 We found that 24-hour hypoxia (<0.1% O2) alone (no serum deprivation) showed sustained activation of extracellular signal-regulated kinase 1/2 (ERK1/2) associated with bcl-2 up-regulation and resistance to etoposide-induced (5 mumol/L) apoptosis. Oxygen 40-42 BCL2 apoptosis regulator Homo sapiens 171-176 16115953-9 2005 The attenuation of cisplatin-induced cell death in cyclin D1-overexpressing cells was correlated with the up-regulation of nuclear factor-kappaB activity and maintenance of bcl-2 and bcl-xl protein levels. Cisplatin 19-28 BCL2 apoptosis regulator Homo sapiens 173-178 16133879-12 2005 Moreover, ODC overexpression prevented the decline of Bcl-2 that maintains DeltaPsim, the cytochrome c release and activations of caspase 9 and 3 following MTX treatment. Methotrexate 156-159 BCL2 apoptosis regulator Homo sapiens 54-59 16027529-6 2005 Ellipticine increased the expression of Bax, but decreased the level of Bcl-2, Bcl-XL and X-linked inhibitor of apoptosis protein (XIAP), and subsequently triggered the mitochondrial apoptotic pathway (release of cytochrome c, and activation of caspase-9 and -3). ellipticine 0-11 BCL2 apoptosis regulator Homo sapiens 72-77 16167050-0 2005 Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides. Oligonucleotides 95-111 BCL2 apoptosis regulator Homo sapiens 10-15 15964220-0 2005 Effects of coumarin and 7OH-coumarin on bcl-2 and Bax expression in two human lung cancer cell lines in vitro. coumarin 11-19 BCL2 apoptosis regulator Homo sapiens 40-45 15964220-0 2005 Effects of coumarin and 7OH-coumarin on bcl-2 and Bax expression in two human lung cancer cell lines in vitro. 7oh-coumarin 24-36 BCL2 apoptosis regulator Homo sapiens 40-45 15964220-6 2005 Western blotting showed a decrease in bcl-2 and an increase in Bax in A427 cells cultured with coumarin or 7-OHC. coumarin 95-103 BCL2 apoptosis regulator Homo sapiens 38-43 15964220-6 2005 Western blotting showed a decrease in bcl-2 and an increase in Bax in A427 cells cultured with coumarin or 7-OHC. 7-HYDROXYCHOLESTEROL 107-112 BCL2 apoptosis regulator Homo sapiens 38-43 16167050-1 2005 This review article focuses on the intrinsic (mitochondrial) pathway of apoptosis, the function of the Bcl-2 protein family that regulates this pathway, the background of the antisense oligonucleotide oblimersen, which targets Bcl-2 protein synthesis, and the implications for this agent in hematologic malignancies. Oligonucleotides 185-200 BCL2 apoptosis regulator Homo sapiens 227-232 16109552-0 2005 [Effects of all-trans-retinoic acid, acitretin and tazarotene on apoptosis and Bax/Bcl-2 expressions of human melanoma cells A375 and the significance]. tazarotene 51-61 BCL2 apoptosis regulator Homo sapiens 83-88 16109552-1 2005 OBJECTIVE: To investigate the effects of all-trans retinoic acid (ATRA), acitretin and tazarotene on apoptosis and Bax/Bcl-2 protein expressions of human melanoma A375 cells. Tretinoin 66-70 BCL2 apoptosis regulator Homo sapiens 119-124 16109552-4 2005 SABC immunocytochemistry was employed for detection of Bax/Bcl-2 protein expressions. sabc 0-4 BCL2 apoptosis regulator Homo sapiens 59-64 16109552-6 2005 In addition, all the three agents significantly increased the number of cells positive for Bax expression and decreased the number of cells expressing Bcl-2 (P<0.05), among which acitretin had the strongest effects. Acitretin 182-191 BCL2 apoptosis regulator Homo sapiens 151-156 16109560-1 2005 OBJECTIVE: To observe the expression of Bcl-2 and Bax proteins and cell apoptosis induced by preoperative lymphatic chemotherapy with epirubicin-activated carbon suspension (Epi-CH) in the cells of axillary metastatic lymph node of breast cancer and investigate the mechanism. Epirubicin 134-144 BCL2 apoptosis regulator Homo sapiens 40-45 16109560-1 2005 OBJECTIVE: To observe the expression of Bcl-2 and Bax proteins and cell apoptosis induced by preoperative lymphatic chemotherapy with epirubicin-activated carbon suspension (Epi-CH) in the cells of axillary metastatic lymph node of breast cancer and investigate the mechanism. Carbon 155-161 BCL2 apoptosis regulator Homo sapiens 40-45 16109560-6 2005 The expression of Bcl-2 and Bax proteins were examined by SP immunohistochemistry. TFF2 protein, human 58-60 BCL2 apoptosis regulator Homo sapiens 18-23 16010430-5 2005 Apoptosis of A549 cells by TSA was associated with a down-regulation of anti-apoptotic Bcl-2 protein and an up-regulation of pro-apoptotic Bax protein. trichostatin A 27-30 BCL2 apoptosis regulator Homo sapiens 87-92 16010437-5 2005 ATO activated the intrinsic (mitochondrial) pathway of apoptosis, which involved disrupting mitochondrial membrane potential, increased Bax/Bcl-2 ratio and caspase-9 activation, as well as the extrinsic (death receptor) pathway mediated by Fas and caspase-8 activation. Arsenic Trioxide 0-3 BCL2 apoptosis regulator Homo sapiens 140-145 16022909-0 2005 Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer. Bortezomib 60-70 BCL2 apoptosis regulator Homo sapiens 13-18 16138714-7 2005 As predicted, progesterone successfully downregulated anti-apoptotic Bcl-2 expression, and dose-dependently suppressed Bcl-2 expression in tumor cells. Progesterone 14-26 BCL2 apoptosis regulator Homo sapiens 69-74 16138714-7 2005 As predicted, progesterone successfully downregulated anti-apoptotic Bcl-2 expression, and dose-dependently suppressed Bcl-2 expression in tumor cells. Progesterone 14-26 BCL2 apoptosis regulator Homo sapiens 119-124 15978939-6 2005 Western blot results illustrated that in the same dosage and incubation time, DMC could down-regulate the level of Bcl-2 protein and did not influence the expression of Bax protein. 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone 78-81 BCL2 apoptosis regulator Homo sapiens 115-120 15978939-7 2005 The resulting net effect could thus lead to a lower ratio of Bcl-2/Bax, which might be responsible for the DMC-induced apoptosis in K562 cells. 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone 107-110 BCL2 apoptosis regulator Homo sapiens 61-66 15978942-6 2005 Furthermore, overexpression of Bcl-2 rendered the cells resistant to THC at early time points but not upon prolonged exposure. Dronabinol 69-72 BCL2 apoptosis regulator Homo sapiens 31-36 15979589-7 2005 When RGCs were cultured with glutamate or an NO-generating reagent, the survival of RGCs was compromised, and Bcl-2 expression was decreased in these cells. Glutamic Acid 29-38 BCL2 apoptosis regulator Homo sapiens 110-115 16129037-7 2005 It is concluded that Ara-c can effectively induce apoptosis of HL-60 cells and simultaneously decrease the level of expression of Bcl-2 protein and elevate the level of expression of Bax protein. Cytarabine 21-26 BCL2 apoptosis regulator Homo sapiens 130-135 16129037-8 2005 Decrease of expression ratio of Bcl-2/Bax proteins may be one of the main mechanisms in HL-60 apoptosis induced by Ara-C. Cytarabine 115-120 BCL2 apoptosis regulator Homo sapiens 32-37 16086273-3 2005 The in vitro cultured human umbilical vein endothelial cells with homocysteine at different concentrations were incubated for 24 h. The expressions of Bcl 2 and caspase 9 at mRNA and protein levels were analyzed by reverse transcription-polymerase chain reaction(RT-PCR) and Western blot. Homocysteine 66-78 BCL2 apoptosis regulator Homo sapiens 151-156 16086273-6 2005 CONCLUSION: Homocysteine could affect the formation of apoptosome through repressing the expression of Bcl 2 gene and release of cytochrome-c from mitochondria. Homocysteine 12-24 BCL2 apoptosis regulator Homo sapiens 103-108 16022909-4 2005 Treatment with bortezomib resulted in decreased transcription of the BCL-2 promoter, decreased BCL-2 levels, and induced apoptosis. Bortezomib 15-25 BCL2 apoptosis regulator Homo sapiens 69-74 16022909-4 2005 Treatment with bortezomib resulted in decreased transcription of the BCL-2 promoter, decreased BCL-2 levels, and induced apoptosis. Bortezomib 15-25 BCL2 apoptosis regulator Homo sapiens 95-100 16012738-8 2005 Experimentally, we found that anti-apoptotic Bcl-2 protein levels decreased after ursolic acid treatment, while Bax expression increased. ursolic acid 82-94 BCL2 apoptosis regulator Homo sapiens 45-50 16012738-9 2005 Our results indicated that ursolic acid induced apoptotic processes in these poorly differentiated endometrial cancer cells occurs through mechanisms involving mitochondrial pathways and Bcl-2 family proteins. ursolic acid 27-39 BCL2 apoptosis regulator Homo sapiens 187-192 15982930-7 2005 Thalidomide reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60. Thalidomide 0-11 BCL2 apoptosis regulator Homo sapiens 66-71 15941563-7 2005 Furthermore, the free radical scavenger ascorbic acid and N-acetylcysteine attenuated emodin-mediated ROS production, ERK and AKT inactivation, mitochondrial dysfunction, Bcl-2/Bax modulation, and apoptosis. Ascorbic Acid 40-53 BCL2 apoptosis regulator Homo sapiens 171-176 15913545-6 2005 PA-treatment decreased Bad phosphorylation, increased Bcl-2 phosphorylation, and activated caspases-9 and -3, suggesting that PA initiated apoptosis through mitochondria dysfunction. pachymic acid 0-2 BCL2 apoptosis regulator Homo sapiens 54-59 15941563-7 2005 Furthermore, the free radical scavenger ascorbic acid and N-acetylcysteine attenuated emodin-mediated ROS production, ERK and AKT inactivation, mitochondrial dysfunction, Bcl-2/Bax modulation, and apoptosis. Acetylcysteine 58-74 BCL2 apoptosis regulator Homo sapiens 171-176 15964311-0 2005 Cinnamaldehyde-induced apoptosis in human PLC/PRF/5 cells through activation of the proapoptotic Bcl-2 family proteins and MAPK pathway. cinnamaldehyde 0-14 BCL2 apoptosis regulator Homo sapiens 97-102 15964311-11 2005 These results conclude that Cin triggers apoptosis in PLC/PRF/5 cells could be through the activation of pro-apoptotic Bcl-2 family (Bax and Bid) proteins and MAPK signaling pathway. cinnamaldehyde 28-31 BCL2 apoptosis regulator Homo sapiens 119-124 16024633-6 2005 The results showed that Bcl-2 family molecules, such as Bid, Bak, and Bax, are involved in the parthenolide-induced apoptosis and that the defective expression of Bcl-X(L) might contribute to the higher parthenolide sensitivity in the SCK cells than in the other adenomatous cholangiocarcinoma cells. parthenolide 95-107 BCL2 apoptosis regulator Homo sapiens 24-29 16024633-6 2005 The results showed that Bcl-2 family molecules, such as Bid, Bak, and Bax, are involved in the parthenolide-induced apoptosis and that the defective expression of Bcl-X(L) might contribute to the higher parthenolide sensitivity in the SCK cells than in the other adenomatous cholangiocarcinoma cells. parthenolide 203-215 BCL2 apoptosis regulator Homo sapiens 24-29 15922856-4 2005 We observed that eugenol transduced the apoptotic signal via ROS generation, thereby inducing mitochondrial permeability transition (MPT), reducing anti-apoptotic protein bcl-2 level, inducing cytochrome c release to the cytosol, and subsequent apoptotic cell death. Eugenol 17-24 BCL2 apoptosis regulator Homo sapiens 171-176 15949801-3 2005 Here, we have suggested the formation of an active site by structurally conserved residues in BH1 (glycine, arginine) and BH2 (tryptophan) domains of Bcl-2 family members, which also accounts for the functional effect of known mutations in BH1 (G145A, G145E) and BH2 (W188A) domains of Bcl-2. bh1 94-97 BCL2 apoptosis regulator Homo sapiens 150-155 15944736-7 2005 TAp63alpha upregulates expression of proapoptotic Bcl-2 family members like Bax and BCL2L11 and the expression of RAD9, DAP3 and APAF1. tap63alpha 0-10 BCL2 apoptosis regulator Homo sapiens 50-55 15949801-3 2005 Here, we have suggested the formation of an active site by structurally conserved residues in BH1 (glycine, arginine) and BH2 (tryptophan) domains of Bcl-2 family members, which also accounts for the functional effect of known mutations in BH1 (G145A, G145E) and BH2 (W188A) domains of Bcl-2. bh1 94-97 BCL2 apoptosis regulator Homo sapiens 286-291 15949801-3 2005 Here, we have suggested the formation of an active site by structurally conserved residues in BH1 (glycine, arginine) and BH2 (tryptophan) domains of Bcl-2 family members, which also accounts for the functional effect of known mutations in BH1 (G145A, G145E) and BH2 (W188A) domains of Bcl-2. Glycine 99-106 BCL2 apoptosis regulator Homo sapiens 150-155 15949801-3 2005 Here, we have suggested the formation of an active site by structurally conserved residues in BH1 (glycine, arginine) and BH2 (tryptophan) domains of Bcl-2 family members, which also accounts for the functional effect of known mutations in BH1 (G145A, G145E) and BH2 (W188A) domains of Bcl-2. Glycine 99-106 BCL2 apoptosis regulator Homo sapiens 286-291 15949801-3 2005 Here, we have suggested the formation of an active site by structurally conserved residues in BH1 (glycine, arginine) and BH2 (tryptophan) domains of Bcl-2 family members, which also accounts for the functional effect of known mutations in BH1 (G145A, G145E) and BH2 (W188A) domains of Bcl-2. Arginine 108-116 BCL2 apoptosis regulator Homo sapiens 150-155 15949801-3 2005 Here, we have suggested the formation of an active site by structurally conserved residues in BH1 (glycine, arginine) and BH2 (tryptophan) domains of Bcl-2 family members, which also accounts for the functional effect of known mutations in BH1 (G145A, G145E) and BH2 (W188A) domains of Bcl-2. Arginine 108-116 BCL2 apoptosis regulator Homo sapiens 286-291 15949801-3 2005 Here, we have suggested the formation of an active site by structurally conserved residues in BH1 (glycine, arginine) and BH2 (tryptophan) domains of Bcl-2 family members, which also accounts for the functional effect of known mutations in BH1 (G145A, G145E) and BH2 (W188A) domains of Bcl-2. bh2 122-125 BCL2 apoptosis regulator Homo sapiens 150-155 15949801-3 2005 Here, we have suggested the formation of an active site by structurally conserved residues in BH1 (glycine, arginine) and BH2 (tryptophan) domains of Bcl-2 family members, which also accounts for the functional effect of known mutations in BH1 (G145A, G145E) and BH2 (W188A) domains of Bcl-2. bh2 122-125 BCL2 apoptosis regulator Homo sapiens 286-291 15949801-3 2005 Here, we have suggested the formation of an active site by structurally conserved residues in BH1 (glycine, arginine) and BH2 (tryptophan) domains of Bcl-2 family members, which also accounts for the functional effect of known mutations in BH1 (G145A, G145E) and BH2 (W188A) domains of Bcl-2. Tryptophan 127-137 BCL2 apoptosis regulator Homo sapiens 150-155 15949801-3 2005 Here, we have suggested the formation of an active site by structurally conserved residues in BH1 (glycine, arginine) and BH2 (tryptophan) domains of Bcl-2 family members, which also accounts for the functional effect of known mutations in BH1 (G145A, G145E) and BH2 (W188A) domains of Bcl-2. Tryptophan 127-137 BCL2 apoptosis regulator Homo sapiens 286-291 15949801-3 2005 Here, we have suggested the formation of an active site by structurally conserved residues in BH1 (glycine, arginine) and BH2 (tryptophan) domains of Bcl-2 family members, which also accounts for the functional effect of known mutations in BH1 (G145A, G145E) and BH2 (W188A) domains of Bcl-2. bh1 240-243 BCL2 apoptosis regulator Homo sapiens 150-155 15949801-3 2005 Here, we have suggested the formation of an active site by structurally conserved residues in BH1 (glycine, arginine) and BH2 (tryptophan) domains of Bcl-2 family members, which also accounts for the functional effect of known mutations in BH1 (G145A, G145E) and BH2 (W188A) domains of Bcl-2. bh1 240-243 BCL2 apoptosis regulator Homo sapiens 286-291 15949801-3 2005 Here, we have suggested the formation of an active site by structurally conserved residues in BH1 (glycine, arginine) and BH2 (tryptophan) domains of Bcl-2 family members, which also accounts for the functional effect of known mutations in BH1 (G145A, G145E) and BH2 (W188A) domains of Bcl-2. bh2 263-266 BCL2 apoptosis regulator Homo sapiens 150-155 15949801-3 2005 Here, we have suggested the formation of an active site by structurally conserved residues in BH1 (glycine, arginine) and BH2 (tryptophan) domains of Bcl-2 family members, which also accounts for the functional effect of known mutations in BH1 (G145A, G145E) and BH2 (W188A) domains of Bcl-2. bh2 263-266 BCL2 apoptosis regulator Homo sapiens 286-291 16080576-3 2005 The IHC method of streptavidin biotin peroxidase on paraffin tissue sections was used to detect bcl2 and p53 oncoproteins and PAR4 pro-apoptotic protein expression in surgical specimens. Paraffin 52-60 BCL2 apoptosis regulator Homo sapiens 96-100 15907805-5 2005 Jurkat/TP cells showed weak phosphorylation of Bcl-2, and kinase inhibitors staurosporine and genistein attenuated not only MIA-induced Bcl-2 phosphorylation but also cytotoxicity of MIA in Jurkat/CV, but not in Jurkat/TP. Staurosporine 76-89 BCL2 apoptosis regulator Homo sapiens 136-141 15907805-5 2005 Jurkat/TP cells showed weak phosphorylation of Bcl-2, and kinase inhibitors staurosporine and genistein attenuated not only MIA-induced Bcl-2 phosphorylation but also cytotoxicity of MIA in Jurkat/CV, but not in Jurkat/TP. Genistein 94-103 BCL2 apoptosis regulator Homo sapiens 136-141 15791457-0 2005 Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Bortezomib 118-128 BCL2 apoptosis regulator Homo sapiens 10-15 16029048-2 2005 A phosphorothioate oligonucleotide with the sequence of bcl-2 targeted Oblimersen by employing a modified 2"-amino-2"-desoxy-uridine nucleotide bearing a succinyl linker at the 2" position was prepared. Phosphorothioate Oligonucleotides 2-34 BCL2 apoptosis regulator Homo sapiens 56-61 16029048-2 2005 A phosphorothioate oligonucleotide with the sequence of bcl-2 targeted Oblimersen by employing a modified 2"-amino-2"-desoxy-uridine nucleotide bearing a succinyl linker at the 2" position was prepared. 2"-amino-2"-desoxy-uridine nucleotide 106-143 BCL2 apoptosis regulator Homo sapiens 56-61 15917659-6 2005 Treatment of HeP2 and Cal27 cells with 400 nM antisense oligonucleotides against Bcl-2, Bcl-X(L) and Survivin for 48 hrs decreased their expression both at the mRNA as well as at the protein level, resulting in the induction of apoptosis. Oligonucleotides 56-72 BCL2 apoptosis regulator Homo sapiens 81-86 15791457-6 2005 The effect of mutation of a NF-kappaB site in the BCL-2 promoter was determined, as was the effect of inhibition of NF-kappaB function using a 26S proteasome inhibitor (bortezomib) on both BCL-2 transcription and induction of apoptosis. Bortezomib 169-179 BCL2 apoptosis regulator Homo sapiens 189-194 15791457-12 2005 Finally, the apoptotic efficacy of proteasome inhibition with bortezomib paralleled the ability to inhibit NF-kappaB activity and decrease BCL-2 levels. Bortezomib 62-72 BCL2 apoptosis regulator Homo sapiens 139-144 31394710-7 2005 CONCLUSION: The superior activity of docetaxel in tumors with low Bcl-2 warrants further studies on biomarkers for drug sensitivity and investigation of docetaxel in combination with drugs that reduce Bcl-2 gene expression. Docetaxel 37-46 BCL2 apoptosis regulator Homo sapiens 66-71 31394710-7 2005 CONCLUSION: The superior activity of docetaxel in tumors with low Bcl-2 warrants further studies on biomarkers for drug sensitivity and investigation of docetaxel in combination with drugs that reduce Bcl-2 gene expression. Docetaxel 37-46 BCL2 apoptosis regulator Homo sapiens 201-206 16020667-8 2005 We tested a small-molecule BH3 mimetic, (-)-gossypol, which binds to the BH3 domain of Bcl-2 and Bcl-x(L), for activity against the parental and cisplatin-resistant cell lines. BH 3 27-30 BCL2 apoptosis regulator Homo sapiens 87-92 15902437-4 2005 Several internal cell factors modulate this uptake; for example, multidrug resistance membrane proteins (Pgp and MRP1) and anti-apoptotic BCl-2 protein of the outer mitochondrial membrane can limit retention of MIBI. 2-methoxyisobutylisonitrile 211-215 BCL2 apoptosis regulator Homo sapiens 138-143 16009171-11 2005 A significant difference in PCNA/TC and Bcl-2/Bax ratios was detected in leiomyoma tissue between the raloxifene group and controls. Raloxifene Hydrochloride 102-112 BCL2 apoptosis regulator Homo sapiens 40-45 16009178-12 2005 CONCLUSION(S): Mifepristone inhibited cell growth by arresting cell cycle progression at S phase, induced apoptosis through caspase-3 activation, and modulated apoptosis regulatory genes BCL2/BAX and FAS/FASLG in Ishikawa cells. Mifepristone 15-27 BCL2 apoptosis regulator Homo sapiens 187-191 16133992-6 2005 These findings may indicate that, during TB, predisposition of CD4 T-cells to apoptosis may involve both low expression of Bcl-2, and excessive expression of TGF-beta TNF-alpha and FasL. Terbium 41-43 BCL2 apoptosis regulator Homo sapiens 123-128 16020667-6 2005 Bcl-x(L) expression increased in the cisplatin-resistant lines relative to the parental lines, whereas Bcl-2 expression was high in the parental lines and decreased in the cisplatin-resistant lines. Cisplatin 172-181 BCL2 apoptosis regulator Homo sapiens 103-108 15907983-12 2005 Paclitaxel showed anti-proliferate activity through the membrane death receptor (DR)-mediated apoptotic pathway involving activation of caspase-8 with a TRAIL-dependent fashion as well as the mitochondrial-mediated pathway involving down-regulation of bcl-2 by cytochrome c release. Paclitaxel 0-10 BCL2 apoptosis regulator Homo sapiens 252-257 15849194-6 2005 Moreover, the mitochondrial translocation of Raf-1 and the interaction between Raf-1 and Bcl-2 are regulated by Raf-1 phosphorylation at Ser-338/Ser-339. Serine 137-140 BCL2 apoptosis regulator Homo sapiens 89-94 15849194-6 2005 Moreover, the mitochondrial translocation of Raf-1 and the interaction between Raf-1 and Bcl-2 are regulated by Raf-1 phosphorylation at Ser-338/Ser-339. Serine 145-148 BCL2 apoptosis regulator Homo sapiens 89-94 15978414-6 2005 In hair pegs, apoptosis was active in high Ki-67 expression area, like outer root sheath, hair follicle sheath, but spared dermal papilla with low Ki-67 and high bcl-2 expression. pegs 8-12 BCL2 apoptosis regulator Homo sapiens 162-167 15978414-7 2005 In bulbous pegs, apoptosis appeared in companion layer, precortical area, inner root sheath and outer root sheath, but spared bulge area with high bcl-2 expression. pegs 11-15 BCL2 apoptosis regulator Homo sapiens 147-152 15953346-2 2005 Removal of depolarizing potassium triggers CGN apoptosis that requires induction of Bim, a BH3-only Bcl-2 family member. Potassium 24-33 BCL2 apoptosis regulator Homo sapiens 100-105 15953346-8 2005 Similarly, apoptosis induced by either a structurally distinct Bcl-2/Bcl-x(L) inhibitor (compound 6) or Bcl-2 antisense oligonucleotides was diminished by glutathione. Oligonucleotides 120-136 BCL2 apoptosis regulator Homo sapiens 104-109 15953346-8 2005 Similarly, apoptosis induced by either a structurally distinct Bcl-2/Bcl-x(L) inhibitor (compound 6) or Bcl-2 antisense oligonucleotides was diminished by glutathione. Glutathione 155-166 BCL2 apoptosis regulator Homo sapiens 63-68 15953346-8 2005 Similarly, apoptosis induced by either a structurally distinct Bcl-2/Bcl-x(L) inhibitor (compound 6) or Bcl-2 antisense oligonucleotides was diminished by glutathione. Glutathione 155-166 BCL2 apoptosis regulator Homo sapiens 104-109 16020667-8 2005 We tested a small-molecule BH3 mimetic, (-)-gossypol, which binds to the BH3 domain of Bcl-2 and Bcl-x(L), for activity against the parental and cisplatin-resistant cell lines. Gossypol 40-52 BCL2 apoptosis regulator Homo sapiens 87-92 16020667-8 2005 We tested a small-molecule BH3 mimetic, (-)-gossypol, which binds to the BH3 domain of Bcl-2 and Bcl-x(L), for activity against the parental and cisplatin-resistant cell lines. Cisplatin 145-154 BCL2 apoptosis regulator Homo sapiens 87-92 15800030-6 2005 Levels of the anti-apoptotic Bcl-2 protein remained constant during TGHQ-induced apoptosis of HL-60 cells, but Bcl-2 S70 phosphorylation decreased. 2,3,5-(triglutathion-S-yl)hydroquinone 68-72 BCL2 apoptosis regulator Homo sapiens 29-34 15867202-0 2005 Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. oblimersen 18-23 BCL2 apoptosis regulator Homo sapiens 27-32 15817479-12 2005 Taken together, ceramide and etoposide induced mitochondria-mediated apoptosis by initiating caspase-2 activation, which was, at least in part, regulated by Bcl-2. Etoposide 29-38 BCL2 apoptosis regulator Homo sapiens 157-162 15817479-0 2005 Bcl-2 rescues ceramide- and etoposide-induced mitochondrial apoptosis through blockage of caspase-2 activation. Ceramides 14-22 BCL2 apoptosis regulator Homo sapiens 0-5 15817479-0 2005 Bcl-2 rescues ceramide- and etoposide-induced mitochondrial apoptosis through blockage of caspase-2 activation. Etoposide 28-37 BCL2 apoptosis regulator Homo sapiens 0-5 15817479-6 2005 Overexpression of Bcl-2 prevented ceramide- and etoposide-induced caspase-2 activation and mitochondrial apoptosis. Ceramides 34-42 BCL2 apoptosis regulator Homo sapiens 18-23 15817479-6 2005 Overexpression of Bcl-2 prevented ceramide- and etoposide-induced caspase-2 activation and mitochondrial apoptosis. Etoposide 48-57 BCL2 apoptosis regulator Homo sapiens 18-23 15817479-10 2005 Further studies showed that Bcl-2 was dephosphorylated at serine 70 after ceramide and etoposide treatment. Serine 58-64 BCL2 apoptosis regulator Homo sapiens 28-33 15817479-10 2005 Further studies showed that Bcl-2 was dephosphorylated at serine 70 after ceramide and etoposide treatment. Ceramides 74-82 BCL2 apoptosis regulator Homo sapiens 28-33 15817479-10 2005 Further studies showed that Bcl-2 was dephosphorylated at serine 70 after ceramide and etoposide treatment. Etoposide 87-96 BCL2 apoptosis regulator Homo sapiens 28-33 15817479-11 2005 A protein phosphatase inhibitor, okadaic acid, rescued Bcl-2 dephosphorylation and blocked caspase-2 activation, mitochondrial damage, and cell death. Okadaic Acid 33-45 BCL2 apoptosis regulator Homo sapiens 55-60 15817479-12 2005 Taken together, ceramide and etoposide induced mitochondria-mediated apoptosis by initiating caspase-2 activation, which was, at least in part, regulated by Bcl-2. Ceramides 16-24 BCL2 apoptosis regulator Homo sapiens 157-162 15840562-8 2005 We infer that an imperfect purine/purine/pyrimidine (R.R.Y) triplex likely forms at the bcl-2 Mbr in vitro, and in vivo recombination data favor this as the major DNA conformation in vivo as well. purine 27-33 BCL2 apoptosis regulator Homo sapiens 88-93 15840562-8 2005 We infer that an imperfect purine/purine/pyrimidine (R.R.Y) triplex likely forms at the bcl-2 Mbr in vitro, and in vivo recombination data favor this as the major DNA conformation in vivo as well. purine 34-40 BCL2 apoptosis regulator Homo sapiens 88-93 15867202-0 2005 Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. Oligonucleotides 43-58 BCL2 apoptosis regulator Homo sapiens 27-32 15867202-2 2005 Bcl-2 antisense oligonucleotide, G3139, targets Bcl-2 mRNA. Oligonucleotides 16-31 BCL2 apoptosis regulator Homo sapiens 0-5 15867202-2 2005 Bcl-2 antisense oligonucleotide, G3139, targets Bcl-2 mRNA. Oligonucleotides 16-31 BCL2 apoptosis regulator Homo sapiens 48-53 15814613-6 2005 Overexpression of Bcl-2 normalizes ER calcium homeostasis and prevents calcium-mediated apoptosis in RelA-deficient cells. Calcium 38-45 BCL2 apoptosis regulator Homo sapiens 18-23 15911099-11 2005 Celecoxib thus potentiates apoptosis as shown by MTT assay, cytochrome c leakage, PARP cleavage, DNA fragmentation, Bcl-2 downregulation and possibly by inhibiting NF-kB activation. Celecoxib 0-9 BCL2 apoptosis regulator Homo sapiens 116-121 15958577-2 2005 One of the underlying factors that contribute to cisplatin resistance is the elevated level of BCL-2 and/or BCL-XL, which promotes cell survival. Cisplatin 49-58 BCL2 apoptosis regulator Homo sapiens 95-100 15958577-10 2005 Moreover, Siva-1 augments cisplatin-mediated cell death in MCF7 cells stably expressing BCL-2. Cisplatin 26-35 BCL2 apoptosis regulator Homo sapiens 88-93 15814613-6 2005 Overexpression of Bcl-2 normalizes ER calcium homeostasis and prevents calcium-mediated apoptosis in RelA-deficient cells. Calcium 71-78 BCL2 apoptosis regulator Homo sapiens 18-23 15765100-10 2005 Western blot analysis indicated that ET-1 alleviated homocysteine (Hcy)-induced apoptosis, likely acting by antagonizing the Hcy-induced decreases in Akt, pAkt, pAkt-to-Akt, Bcl-2-to-Bax ratios and increases in Bax and caveolin-1 expression. Homocysteine 125-128 BCL2 apoptosis regulator Homo sapiens 174-179 15929186-4 2005 Protein and mRNA expression of bcl-2 oncogene were detected by labeled streptavidin biotin (LSAB) immunohistochemistry and in situ hybridization respectively. Biotin 84-90 BCL2 apoptosis regulator Homo sapiens 31-36 15929186-4 2005 Protein and mRNA expression of bcl-2 oncogene were detected by labeled streptavidin biotin (LSAB) immunohistochemistry and in situ hybridization respectively. lsab 92-96 BCL2 apoptosis regulator Homo sapiens 31-36 16011306-0 2005 Bax/Bcl-2 expression levels of 2-methoxyestradiol-exposed esophageal cancer cells. 2-Methoxyestradiol 31-49 BCL2 apoptosis regulator Homo sapiens 4-9 15865936-3 2005 This ganglioside triggers the activation of 12-Lox (12-lipoxygenase) leading to oxidative stress and apoptosis via the induction of the transcription factor Gadd153 and the Bcl-2-family member protein Bak. Gangliosides 5-16 BCL2 apoptosis regulator Homo sapiens 173-178 15902208-4 2005 Here, using nuclear magnetic resonance (NMR)-based screening, parallel synthesis and structure-based design, we have discovered ABT-737, a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compounds. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 128-131 BCL2 apoptosis regulator Homo sapiens 195-200 15916743-10 2005 Furthermore, high doses of TZD induced massive apoptosis in renal cancer cells, with increased Bax expression and decreased Bcl-2 expression. 2,4-thiazolidinedione 27-30 BCL2 apoptosis regulator Homo sapiens 124-129 15920191-0 2005 Propofol dose-dependently reduces tumor necrosis factor-alpha-Induced human umbilical vein endothelial cell apoptosis: effects on Bcl-2 and Bax expression and nitric oxide generation. Propofol 0-8 BCL2 apoptosis regulator Homo sapiens 130-135 15920191-7 2005 Propofol, at concentrations >/=12 muM, significantly (P < 0.001) and dose-dependently attenuated TNF-induced increase in AI and decrease in Bcl-2/Bax ratio. Propofol 0-8 BCL2 apoptosis regulator Homo sapiens 146-151 15930731-1 2005 We have reported that caspase cascade accompanied by the regulation of Bax/Bcl-2 and MAPK signaling were involved in evodiamine-induced A375-S2 cell death. evodiamine 117-127 BCL2 apoptosis regulator Homo sapiens 75-80 15930731-4 2005 Subsequently, IL-1Ra reduced evodiamine-induced DNA degradation, p53 activation and up-regulation of Bax/Bcl-2 ratio. evodiamine 29-39 BCL2 apoptosis regulator Homo sapiens 105-110 15930365-3 2005 EXPERIMENTAL DESIGN: Jurkat cells engineered to overexpress Bcl-2 were treated with proteasome inhibitors (MG132, epoxomicin, and bortezomib), anticancer drugs (etoposide and doxorubicin), TRAIL, or combinations of these compounds. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 107-112 BCL2 apoptosis regulator Homo sapiens 60-65 16226733-8 2005 Treatment with fluvastatin (10 microM) enhanced cytochrome c release and increased the Bax/Bcl-2 ratio in both resting and strongly activated CD4+ T cells. Fluvastatin 15-26 BCL2 apoptosis regulator Homo sapiens 91-96 15846373-5 2005 Overexpression of Bcl-2, which is able to interact with CPT-1, counteracts the effects exerted by tBid on beta-oxidation. tBID 98-102 BCL2 apoptosis regulator Homo sapiens 18-23 15930365-3 2005 EXPERIMENTAL DESIGN: Jurkat cells engineered to overexpress Bcl-2 were treated with proteasome inhibitors (MG132, epoxomicin, and bortezomib), anticancer drugs (etoposide and doxorubicin), TRAIL, or combinations of these compounds. epoxomicin 114-124 BCL2 apoptosis regulator Homo sapiens 60-65 15930365-3 2005 EXPERIMENTAL DESIGN: Jurkat cells engineered to overexpress Bcl-2 were treated with proteasome inhibitors (MG132, epoxomicin, and bortezomib), anticancer drugs (etoposide and doxorubicin), TRAIL, or combinations of these compounds. Bortezomib 130-140 BCL2 apoptosis regulator Homo sapiens 60-65 16110345-9 2005 The neuroprotective activity of these drugs has been demonstrated to be associated with the propargylamine moiety, which protects mitochondrial viability and mitochondrial permeability transition pore by activating Bcl-2 and downregulating the Bax family of proteins. propargylamine 92-106 BCL2 apoptosis regulator Homo sapiens 215-220 15955068-8 2005 Indeed, 7-ketocholesterol treatment of human monocytic THP-1 cells induces the release of Bim-LC8 from the microtubule-associated dynein motor complex, and its association with Bcl-2. 7-ketocholesterol 8-25 BCL2 apoptosis regulator Homo sapiens 177-182 15955068-8 2005 Indeed, 7-ketocholesterol treatment of human monocytic THP-1 cells induces the release of Bim-LC8 from the microtubule-associated dynein motor complex, and its association with Bcl-2. bim-lc8 90-97 BCL2 apoptosis regulator Homo sapiens 177-182 16156517-2 2005 Jadomycin S was most potent against HepG2, IM-9 and IM-9/Bcl-2 while jadomycin F was most potent against H460. jadomycin S 0-11 BCL2 apoptosis regulator Homo sapiens 57-62 15913739-5 2005 Bcl-2-overexpressing SKOV3 cells were modified to express a doxycycline-inducible anti-Bcl-2 single-chain antibody and the effects of Bcl-2 protein inhibition on cell proliferation and apoptosis were assessed. Doxycycline 60-71 BCL2 apoptosis regulator Homo sapiens 0-5 15913739-5 2005 Bcl-2-overexpressing SKOV3 cells were modified to express a doxycycline-inducible anti-Bcl-2 single-chain antibody and the effects of Bcl-2 protein inhibition on cell proliferation and apoptosis were assessed. Doxycycline 60-71 BCL2 apoptosis regulator Homo sapiens 87-92 15913739-5 2005 Bcl-2-overexpressing SKOV3 cells were modified to express a doxycycline-inducible anti-Bcl-2 single-chain antibody and the effects of Bcl-2 protein inhibition on cell proliferation and apoptosis were assessed. Doxycycline 60-71 BCL2 apoptosis regulator Homo sapiens 87-92 15913739-7 2005 The Bcl-2-overexpressing SKOV3 cell line proliferates markedly faster and shows delayed progression to G2M phase compared to its low Bcl-2-expressing counterpart SKOV3.ip1 cell line. Isopenicillin N 168-171 BCL2 apoptosis regulator Homo sapiens 4-9 15913739-9 2005 Treatment with cisplatin resulted in more cells accumulating in S phase in Bcl-2-overexpressing SKOV3 cells, while the inhibition of Bcl-2 abolished delayed entry into G2M phase without affecting cisplatin-induced apoptosis. Cisplatin 15-24 BCL2 apoptosis regulator Homo sapiens 75-80 15949686-7 2005 Detailed analysis of expression of selected genes in beta-carotene treated LNCaP cells at the level of mRNA and protein indicated that the observed increase of proliferation could have been the result of slight induction of a few genes affecting proliferation (c-myc, c-jun) and apoptosis (bcl-2) with no significant effect on major cell cycle control genes (cdk2, RB, E2F-1). beta Carotene 53-66 BCL2 apoptosis regulator Homo sapiens 290-295 15977640-4 2005 We have previously demonstrated that ethanol-induced neuron apoptosis is critically dependent on expression of Bax, a proapoptotic member of the Bcl-2 family. Ethanol 37-44 BCL2 apoptosis regulator Homo sapiens 145-150 15939077-2 2005 Preclinical data demonstrate that docetaxel is a potent inhibitor of bcl-2, an antiapoptotic gene implicated in the progression of HRPC and the development of chemotherapy resistance. Docetaxel 34-43 BCL2 apoptosis regulator Homo sapiens 69-74 16167175-2 2005 Bcl-2 inhibition of apoptosis is mediated by its binding to pro-apoptotic proteins, e.g., Bax and tBid, inhibition of their oligomerization, and thus inhibition of mitochondrial outer membrane pore formation, through which other pro-apoptotic proteins, e.g., cytochrome c, are released to the cytosol. tBID 98-102 BCL2 apoptosis regulator Homo sapiens 0-5 16167175-3 2005 Bcl-2 also exhibits an indirect antioxidant activity caused by a sub-toxic elevation of mitochondrial production of reactive oxygen species and a compensatory increase in expression of antioxidant gene products. Reactive Oxygen Species 116-139 BCL2 apoptosis regulator Homo sapiens 0-5 15902734-0 2005 Expression of bcl-2 protein in chronic hepatitis C: effect of interferon alpha 2b with ribavirin therapy. Ribavirin 87-96 BCL2 apoptosis regulator Homo sapiens 14-19 15688415-0 2005 Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 129-134 16117893-9 2005 Western blot assay showed that cantharidin increased the level of Bax expression and inhibited the level of bcl-2 and survivin expression. Cantharidin 31-42 BCL2 apoptosis regulator Homo sapiens 108-113 16117893-10 2005 CONCLUSION: Cantharidin can induce A549 cells apoptosis mainly via regulation of Bax, bcl-2 and survivin expression. Cantharidin 12-23 BCL2 apoptosis regulator Homo sapiens 86-91 15902734-8 2005 CONCLUSION: IFNalpha2b+RBV treatment, by bcl-2 protein expression decrease, enables apoptosis of hepatocytes and associated liver lymphocytes, which in turn eliminate hepatitis C viruses. Ribavirin 23-26 BCL2 apoptosis regulator Homo sapiens 41-46 15735709-1 2005 This study explores the roles of Bax and other Bcl-2 family members play in arsenic trioxide (As(2)O(3))-induced apoptosis. Arsenic Trioxide 76-92 BCL2 apoptosis regulator Homo sapiens 47-52 15830342-0 2005 Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells. Tamoxifen 14-23 BCL2 apoptosis regulator Homo sapiens 49-54 15830342-3 2005 AS Bcl-2 18-mer phosphorothioate oligonucleotide was applied. mer phosphorothioate oligonucleotide 12-48 BCL2 apoptosis regulator Homo sapiens 3-8 15830342-7 2005 Combination treatment with trastuzumab or AS Bcl-2 enhanced TAM sensitivity in ZR-75-1 cells, which showed 50% inhibitory concentration (IC50) values of 0.9 microM (7.2-fold increase) and 0.5 microM (13.0-fold), respectively. Tamoxifen 60-63 BCL2 apoptosis regulator Homo sapiens 45-50 15830342-10 2005 Modulation of TAM sensitivity by AS Bcl-2 was superior to modulation by trastuzumab in HER-2-expressing and Bcl-2-expressing breast carcinoma cells. Tamoxifen 14-17 BCL2 apoptosis regulator Homo sapiens 36-41 15897598-4 2005 In these models, both SAHA and m-carboxycinnamic acid bis-hydroxamide induced growth arrest and caspase-mediated apoptosis and increased p21 protein levels, retinoblastoma hypophosphorylation, BH3-interacting domain death agonist cleavage, Bax up-regulation, down-regulation of Bcl-2, A1, and Bcl-x(L) expression, and cleavage of poly(ADP-ribose) polymerase and caspase-8, -9, -3, -7, and -2. Vorinostat 22-26 BCL2 apoptosis regulator Homo sapiens 278-283 15897598-4 2005 In these models, both SAHA and m-carboxycinnamic acid bis-hydroxamide induced growth arrest and caspase-mediated apoptosis and increased p21 protein levels, retinoblastoma hypophosphorylation, BH3-interacting domain death agonist cleavage, Bax up-regulation, down-regulation of Bcl-2, A1, and Bcl-x(L) expression, and cleavage of poly(ADP-ribose) polymerase and caspase-8, -9, -3, -7, and -2. carboxycinnamic acid bishydroxamide 31-69 BCL2 apoptosis regulator Homo sapiens 278-283 15897598-5 2005 Transfection of Bcl-2 cDNA partially suppressed SAHA-induced cell death. Vorinostat 48-52 BCL2 apoptosis regulator Homo sapiens 16-21 15665116-4 2005 The potentiation of As2O3-provoked apoptosis involved the increased disruption of mitochondrial transmembrane potential, increased caspase-3 activation and cytochrome c release from mitochondria, increased Bax and Bid activation, and attenuation of 27-kDa heat shock protein (HSP27) expression; the potentiation was prevented by Bcl-2 overexpression. Arsenic Trioxide 20-25 BCL2 apoptosis regulator Homo sapiens 329-334 15735709-4 2005 Stable overexpression of Bcl-2 in IM-9 cells (IM-9/Bcl-2) inhibited As(2)O(3)-mediated Bax activation and apoptosis, and this inhibition could be partially averted by cell-permeable Bid-Bcl-2 homology (BH)3 peptide. (2)o(3) 70-77 BCL2 apoptosis regulator Homo sapiens 25-30 15735709-4 2005 Stable overexpression of Bcl-2 in IM-9 cells (IM-9/Bcl-2) inhibited As(2)O(3)-mediated Bax activation and apoptosis, and this inhibition could be partially averted by cell-permeable Bid-Bcl-2 homology (BH)3 peptide. (2)o(3) 70-77 BCL2 apoptosis regulator Homo sapiens 51-56 15735709-4 2005 Stable overexpression of Bcl-2 in IM-9 cells (IM-9/Bcl-2) inhibited As(2)O(3)-mediated Bax activation and apoptosis, and this inhibition could be partially averted by cell-permeable Bid-Bcl-2 homology (BH)3 peptide. (2)o(3) 70-77 BCL2 apoptosis regulator Homo sapiens 51-56 15735709-7 2005 These data suggest that As(2)O(3) might exert the cell killing in part by inducing Bax activation through a Bcl-2-suppressible pathway in hematopoietic cells that is caspase independent and intracellular ROS regulated. Reactive Oxygen Species 204-207 BCL2 apoptosis regulator Homo sapiens 108-113 15909122-4 2005 Flavone induces the activation of caspases 2, 3, 8, 9 and 10 and a decrease of mitochondrial anti-apoptotic Bcl(2) protein expression. flavone 0-7 BCL2 apoptosis regulator Homo sapiens 108-113 15965099-7 2005 Incubation of C6 glioma cells with thallium acetate upregulated the expression of proapoptotic proteins Bad and Apaf and downregulated the expression of anti-apoptotic proteins Bcl-xL and Bcl-2. thallium acetate 35-51 BCL2 apoptosis regulator Homo sapiens 188-193 15965087-11 2005 Preconditioning-induced adaptive tolerance may be signaling through a cGMP-dependent induction of cytosolic redox protein Trx1 and subsequently mitochondrial proteins such as Bcl-2, MnSOD, and perhaps Trx2 or HSP70. Cyclic GMP 70-74 BCL2 apoptosis regulator Homo sapiens 175-180 15909128-0 2005 Down-regulation of Bcl-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER(+) breast cancer cells. Estradiol 73-82 BCL2 apoptosis regulator Homo sapiens 19-24 15909119-14 2005 Furthermore, ODC prevents TNF-alpha -induced apoptosis by decreasing intracellular ROS to avoid Bcl-2 decline, maintain Delta psi(m), prevent cytochrome c release and deactivate the caspase cascade pathway. Reactive Oxygen Species 83-86 BCL2 apoptosis regulator Homo sapiens 96-101 15909128-6 2005 The functional role of Bcl-2 in estradiol-induced apoptosis was further studied by knockdown or decrease of Bcl-2 with siRNA. Estradiol 32-41 BCL2 apoptosis regulator Homo sapiens 23-28 15909128-6 2005 The functional role of Bcl-2 in estradiol-induced apoptosis was further studied by knockdown or decrease of Bcl-2 with siRNA. Estradiol 32-41 BCL2 apoptosis regulator Homo sapiens 108-113 16158945-8 2005 An undetectable expression of Bcl-2 protein in control and drug-treated HSC-2 cells may explain the relatively higher sensitivity of this cell line to stilbenes and flavonoids. Stilbenes 151-160 BCL2 apoptosis regulator Homo sapiens 30-35 15909128-11 2005 Therefore, down-regulation of Bcl-2 synergistically enhanced estradiol-induced apoptosis in ER(+) postmenopausal breast cancer cells. Estradiol 61-70 BCL2 apoptosis regulator Homo sapiens 30-35 16158945-8 2005 An undetectable expression of Bcl-2 protein in control and drug-treated HSC-2 cells may explain the relatively higher sensitivity of this cell line to stilbenes and flavonoids. Flavonoids 165-175 BCL2 apoptosis regulator Homo sapiens 30-35 15705600-8 2005 In a time- and concentration-dependent manner, evodiamine also promoted the phosphorylations of Raf-1 kinase and Bcl-2. evodiamine 47-57 BCL2 apoptosis regulator Homo sapiens 113-118 15975156-8 2005 In addition, immunochemical staining and Western blot analysis revealed that anti-apoptotic Bcl-2 expression was enhanced following treatment with these protective flavonoids. Flavonoids 164-174 BCL2 apoptosis regulator Homo sapiens 92-97 15975156-10 2005 The down-regulation of Bcl-2 and up-regulation of caspase-3 activation were reversed by the cytoprotective flavonoids, (-)-epigallocatechin gallate, quercetin and hesperetin, at >/=10 microm. Flavonoids 107-117 BCL2 apoptosis regulator Homo sapiens 23-28 15975156-10 2005 The down-regulation of Bcl-2 and up-regulation of caspase-3 activation were reversed by the cytoprotective flavonoids, (-)-epigallocatechin gallate, quercetin and hesperetin, at >/=10 microm. epigallocatechin gallate 119-147 BCL2 apoptosis regulator Homo sapiens 23-28 15975156-10 2005 The down-regulation of Bcl-2 and up-regulation of caspase-3 activation were reversed by the cytoprotective flavonoids, (-)-epigallocatechin gallate, quercetin and hesperetin, at >/=10 microm. Quercetin 149-158 BCL2 apoptosis regulator Homo sapiens 23-28 15826766-3 2005 Down-regulation of bcl-2 expression using antisense oligonucleotides (asON) has been shown to increase chemosensitivity in clinical phase I-III studies with various cancers. Oligonucleotides 52-68 BCL2 apoptosis regulator Homo sapiens 19-24 15975156-10 2005 The down-regulation of Bcl-2 and up-regulation of caspase-3 activation were reversed by the cytoprotective flavonoids, (-)-epigallocatechin gallate, quercetin and hesperetin, at >/=10 microm. hesperetin 163-173 BCL2 apoptosis regulator Homo sapiens 23-28 15975156-10 2005 The down-regulation of Bcl-2 and up-regulation of caspase-3 activation were reversed by the cytoprotective flavonoids, (-)-epigallocatechin gallate, quercetin and hesperetin, at >/=10 microm. at > 175-181 BCL2 apoptosis regulator Homo sapiens 23-28 15911246-0 2005 Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts. Oligonucleotides 78-93 BCL2 apoptosis regulator Homo sapiens 62-67 15826766-3 2005 Down-regulation of bcl-2 expression using antisense oligonucleotides (asON) has been shown to increase chemosensitivity in clinical phase I-III studies with various cancers. Oligonucleotides, Antisense 70-74 BCL2 apoptosis regulator Homo sapiens 19-24 15826766-15 2005 Only a minor increase of cisplatin effectivity was noted after asON preincubation of cells with lower bcl-2 expression. Cisplatin 25-34 BCL2 apoptosis regulator Homo sapiens 102-107 15898928-10 2005 There was a significant positive correlation between serum CsA level and level of bcl-2 expression, but serum CsA was not significantly correlated with level of apoptosis or level of p53 expression. Cyclosporine 59-62 BCL2 apoptosis regulator Homo sapiens 82-87 15746243-7 2005 Lymphocyte progenitors in mice bearing a human bcl-2 transgene were protected from dexamethasone treatment. Dexamethasone 83-96 BCL2 apoptosis regulator Homo sapiens 47-52 15731293-7 2005 In addition, AMPH also caused increased expression of p53 and Bax at both transcript and protein levels; in contrast, Bcl-2 levels were decreased after the AMPH injections. Amphetamine 156-160 BCL2 apoptosis regulator Homo sapiens 118-123 15898928-11 2005 CONCLUSION: The results indicate that the pathogenesis of CsA-induced GO might involve inhibition of apoptosis, and overexpression of bcl-2 in the setting of high serum CsA. Cyclosporine 58-61 BCL2 apoptosis regulator Homo sapiens 134-139 15898928-11 2005 CONCLUSION: The results indicate that the pathogenesis of CsA-induced GO might involve inhibition of apoptosis, and overexpression of bcl-2 in the setting of high serum CsA. Cyclosporine 169-172 BCL2 apoptosis regulator Homo sapiens 134-139 15829320-7 2005 Bcl-2 and Bax levels were increased in inflammatory pleural samples (394%, p=0.001 and 188%, p=ns, respectively) and in MMs (94%, p=ns and 88%, p=0.0163, respectively). Methyl Methanesulfonate 120-123 BCL2 apoptosis regulator Homo sapiens 0-5 15703383-0 2005 Cephalostatin 1 inactivates Bcl-2 by hyperphosphorylation independent of M-phase arrest and DNA damage. cephalostatin I 0-15 BCL2 apoptosis regulator Homo sapiens 28-33 16019514-8 2005 Bcl-2 expression was reduced by NBT (11% vs. 2%). Nabumetone 32-35 BCL2 apoptosis regulator Homo sapiens 0-5 15703383-2 2005 Here, we show that overexpression of the antiapoptotic protein Bcl-2 protects cells only partially against cephalostatin 1-induced apoptosis. cephalostatin I 107-122 BCL2 apoptosis regulator Homo sapiens 63-68 15703383-3 2005 The mechanism of Bcl-2 inactivation by cephalostatin 1 is based on hyperphosphorylation of Bcl-2 on Thr69 and Ser87 because Jurkat cells overexpressing a Bcl-2 protein with mutations on both phosphorylation sites were completely protected against cephalostatin 1. cephalostatin 39-52 BCL2 apoptosis regulator Homo sapiens 17-22 15829295-3 2005 Our present studies showed that taxol, not LPS, induced cell apoptosis in human monocytic THP-1 cells, as indicated by PARP cleavage, as well as bcl-2 phosphorylation. Paclitaxel 32-37 BCL2 apoptosis regulator Homo sapiens 145-150 15703383-3 2005 The mechanism of Bcl-2 inactivation by cephalostatin 1 is based on hyperphosphorylation of Bcl-2 on Thr69 and Ser87 because Jurkat cells overexpressing a Bcl-2 protein with mutations on both phosphorylation sites were completely protected against cephalostatin 1. cephalostatin 39-52 BCL2 apoptosis regulator Homo sapiens 91-96 15703383-3 2005 The mechanism of Bcl-2 inactivation by cephalostatin 1 is based on hyperphosphorylation of Bcl-2 on Thr69 and Ser87 because Jurkat cells overexpressing a Bcl-2 protein with mutations on both phosphorylation sites were completely protected against cephalostatin 1. cephalostatin 39-52 BCL2 apoptosis regulator Homo sapiens 91-96 15703383-3 2005 The mechanism of Bcl-2 inactivation by cephalostatin 1 is based on hyperphosphorylation of Bcl-2 on Thr69 and Ser87 because Jurkat cells overexpressing a Bcl-2 protein with mutations on both phosphorylation sites were completely protected against cephalostatin 1. cephalostatin 247-260 BCL2 apoptosis regulator Homo sapiens 17-22 15703383-3 2005 The mechanism of Bcl-2 inactivation by cephalostatin 1 is based on hyperphosphorylation of Bcl-2 on Thr69 and Ser87 because Jurkat cells overexpressing a Bcl-2 protein with mutations on both phosphorylation sites were completely protected against cephalostatin 1. cephalostatin 247-260 BCL2 apoptosis regulator Homo sapiens 91-96 15703383-3 2005 The mechanism of Bcl-2 inactivation by cephalostatin 1 is based on hyperphosphorylation of Bcl-2 on Thr69 and Ser87 because Jurkat cells overexpressing a Bcl-2 protein with mutations on both phosphorylation sites were completely protected against cephalostatin 1. cephalostatin 247-260 BCL2 apoptosis regulator Homo sapiens 91-96 15703383-4 2005 In search of the kinase responsible for Bcl-2 phosphorylation, c-Jun NH2-terminal kinase (JNK) was found to be activated by cephalostatin 1. cephalostatin I 124-139 BCL2 apoptosis regulator Homo sapiens 40-45 15703383-5 2005 Reduction of Bcl-2 phosphorylation by the specific JNK inhibitor (anthra(1,3-cd)pyrazol-6(2H)-one) SP600125 suggested a crucial role for JNK in this process. anthra(1,3-cd)pyrazol-6(2h)-one 66-97 BCL2 apoptosis regulator Homo sapiens 13-18 15703383-5 2005 Reduction of Bcl-2 phosphorylation by the specific JNK inhibitor (anthra(1,3-cd)pyrazol-6(2H)-one) SP600125 suggested a crucial role for JNK in this process. pyrazolanthrone 99-107 BCL2 apoptosis regulator Homo sapiens 13-18 15703383-9 2005 Together, cephalostatin 1 is shown to induce JNK activation with subsequent Bcl-2 phosphorylation and inactivation. cephalostatin I 10-25 BCL2 apoptosis regulator Homo sapiens 76-81 15703383-10 2005 Reported triggers, such as the induction of an M-phase arrest or DNA damage are not involved in this process, suggesting a novel mechanism for cephalostatin 1-mediated Bcl-2 hyperphosphorylation. cephalostatin I 143-158 BCL2 apoptosis regulator Homo sapiens 168-173 15985719-0 2005 Induction of caspase 3 activity, bcl-2 bax and p65 gene expression modulation in human acute promyelocytic leukemia HL-60 cells by doxorubicin with amifostine. Doxorubicin 131-142 BCL2 apoptosis regulator Homo sapiens 33-38 15985719-0 2005 Induction of caspase 3 activity, bcl-2 bax and p65 gene expression modulation in human acute promyelocytic leukemia HL-60 cells by doxorubicin with amifostine. Amifostine 148-158 BCL2 apoptosis regulator Homo sapiens 33-38 15985719-12 2005 Semiquantitative reverse transcriptase polymerase chain reaction showed a decrease in bcl-2 and an increase in bax and p65 expression in HL-60 cells treated with doxorubicin in combination with amifostine when compared with the cells treated only with doxorubicin. Doxorubicin 162-173 BCL2 apoptosis regulator Homo sapiens 86-91 15985719-12 2005 Semiquantitative reverse transcriptase polymerase chain reaction showed a decrease in bcl-2 and an increase in bax and p65 expression in HL-60 cells treated with doxorubicin in combination with amifostine when compared with the cells treated only with doxorubicin. Amifostine 194-204 BCL2 apoptosis regulator Homo sapiens 86-91 15940066-0 2005 Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients. Anthracyclines 126-139 BCL2 apoptosis regulator Homo sapiens 61-66 15486995-10 2005 The overexpression of Bcl-2 in LNCaP B10 cells reduced the apoptotic effects of apigenin. Apigenin 80-88 BCL2 apoptosis regulator Homo sapiens 22-27 15886792-5 2005 In HUVECs, TZDs" anti-apoptotic effects inversely correlated (r=-0.95, p<0.01) with increased (p<0.05) expression of the apoptosis-inhibitor bcl-2, whereas PGJ(2)-induced apoptosis was associated with upregulation of c-myc (+447%) and E2F-1 (+339%). Thiazolidinediones 11-15 BCL2 apoptosis regulator Homo sapiens 147-152 15886792-5 2005 In HUVECs, TZDs" anti-apoptotic effects inversely correlated (r=-0.95, p<0.01) with increased (p<0.05) expression of the apoptosis-inhibitor bcl-2, whereas PGJ(2)-induced apoptosis was associated with upregulation of c-myc (+447%) and E2F-1 (+339%). 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE 162-165 BCL2 apoptosis regulator Homo sapiens 147-152 15889622-8 2005 The Bax/Bcl-2 ratios for PGA2- and 2-ME-exposed cells were 2.06 and 1.87 respectively, normalised against Bcl-2 levels. prostaglandin A2 25-29 BCL2 apoptosis regulator Homo sapiens 8-13 15834587-7 2005 The recovery of DXR-induced growth inhibition was closely associated with an increase in Bcl-2 in the presence of <10 microM nitrite. Nitrites 128-135 BCL2 apoptosis regulator Homo sapiens 89-94 15834587-10 2005 HO-1 inhibition by HO-1 antisense S-oligodeoxynucleotide treatment increased NO-induced growth inhibition, and decreased Bcl-2 expression or VEGF secretion in the three cell lines. Oligodeoxyribonucleotides 36-56 BCL2 apoptosis regulator Homo sapiens 121-126 15877949-7 2005 Although the expression of the Bax was increased when HT-29 cells were stimulated with different concentrations of H2O2 for 24 hours, the expression of Bcl-2 was decreased. Hydrogen Peroxide 115-119 BCL2 apoptosis regulator Homo sapiens 152-157 15877949-8 2005 While HT-29 cells were stimulated with 500 micromol/L H2O2, the expression of the Bax was increased and that of Bcl-2 was decreased overtime. Hydrogen Peroxide 54-58 BCL2 apoptosis regulator Homo sapiens 112-117 15609335-10 2005 EGCG treatment of melanoma cells resulted in a downmodulation of anti-apoptotic protein Bcl2, upregulation of proapoptotic Bax and activation of caspases -3, -7 and -9. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 88-92 15609335-12 2005 Our data suggest that EGCG causes significant induction of cell cycle arrest and apoptosis of melanoma cells that is mediated via modulations in the cki-cyclin-cdk network and Bcl2 family proteins. epigallocatechin gallate 22-26 BCL2 apoptosis regulator Homo sapiens 176-180 15685605-11 2005 However, a pretreatment with 100 microM or 200 microM DXM protected T98G cells against TMZ-induced apoptosis, concomitantly decreasing Bax:Bcl-2 ratio, calpain activity, and caspase-3 activity. Dexamethasone 54-57 BCL2 apoptosis regulator Homo sapiens 139-144 15837754-0 2005 Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia. oblimersen 64-69 BCL2 apoptosis regulator Homo sapiens 48-53 15837754-1 2005 PURPOSE: Down-regulation of Bcl-2 by the antisense G3139, currently under clinical evaluations, could restore chemosensitivity in otherwise resistant malignant cells. oblimersen 51-56 BCL2 apoptosis regulator Homo sapiens 28-33 15728109-8 2005 Since apoptosis induced by rapamycin is blocked by BCL-2, strategies aimed at detecting human tumours that express BCL-2 and other anti-apoptotic proteins might allow identification of rapamycin-resistant tumours. Sirolimus 27-36 BCL2 apoptosis regulator Homo sapiens 115-120 15728109-8 2005 Since apoptosis induced by rapamycin is blocked by BCL-2, strategies aimed at detecting human tumours that express BCL-2 and other anti-apoptotic proteins might allow identification of rapamycin-resistant tumours. Sirolimus 185-194 BCL2 apoptosis regulator Homo sapiens 51-56 15728109-8 2005 Since apoptosis induced by rapamycin is blocked by BCL-2, strategies aimed at detecting human tumours that express BCL-2 and other anti-apoptotic proteins might allow identification of rapamycin-resistant tumours. Sirolimus 185-194 BCL2 apoptosis regulator Homo sapiens 115-120 15889622-0 2005 Influence of prostaglandin A2 and 2-methoxyestradiol on Bax and Bcl-2 expression levels in cervical carcinoma cells. prostaglandin A2 13-29 BCL2 apoptosis regulator Homo sapiens 64-69 15889622-0 2005 Influence of prostaglandin A2 and 2-methoxyestradiol on Bax and Bcl-2 expression levels in cervical carcinoma cells. 2-Methoxyestradiol 34-52 BCL2 apoptosis regulator Homo sapiens 64-69 15745423-7 2005 These data provide an explanation for recent studies on CPO-catalyzed photodamage to both ER and mitochondrial Bcl-2. cpo 56-59 BCL2 apoptosis regulator Homo sapiens 111-116 15810075-15 2005 The low dose 32P colloids may induce human pancreatic carcinoma Pc-3 implanted tumor cell apoptosis; Apo2.7, caspase-3, Bcl-2 and Bax protein participated in regulating the process of irradiation induced cell apoptosis. Phosphorus-32 13-16 BCL2 apoptosis regulator Homo sapiens 120-125 15889622-8 2005 The Bax/Bcl-2 ratios for PGA2- and 2-ME-exposed cells were 2.06 and 1.87 respectively, normalised against Bcl-2 levels. 2-Methoxyestradiol 35-39 BCL2 apoptosis regulator Homo sapiens 8-13 15850677-10 2005 Structure activity studies have shown that the neuroprotective activity is associated with the propargyl moiety of rasagiline which protects mitochondrial viability and MPTp by activating Bcl-2 and protein kinase C (PKC), and down regulating pro-apoptotic FAS and Bax. rasagiline 115-125 BCL2 apoptosis regulator Homo sapiens 188-193 16029531-4 2005 SP immunohistochemistry was used to detect the expression of Bcl-2 and Bax. TFF2 protein, human 0-2 BCL2 apoptosis regulator Homo sapiens 61-66 15805291-5 2005 Furthermore, DIM #34 transiently inhibited the phosphorylation and activity of the extracellular signal-regulated kinase and abrogated Bcl-2 phosphorylation. 1,1-bis(3'-(5-methoxyindolyl))-1-(p-t-butylphenyl)indolesmethane 13-20 BCL2 apoptosis regulator Homo sapiens 135-140 15538569-5 2005 With regard to the effects of QdNOs on molecules that regulate apoptosis and the G2 to M transition, both BPQ and AMQ inhibited the expression of cyclin B, while DCQ significantly decreased the levels of Bcl-2 and increased Bax expression. 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline-1,4-dioxide 162-165 BCL2 apoptosis regulator Homo sapiens 204-209 15876860-0 2005 Localization of phosphorylated forms of Bcl-2 in mitosis: co-localization with Ki-67 and nucleolin in nuclear structures and on mitotic chromosomes. KS I 79-81 BCL2 apoptosis regulator Homo sapiens 40-45 15945276-4 2005 The level of Bcl-2 was slightly decreased, in contrast, the level of Bax elevated markedly, which resulted in a significant decrease of Bcl-2/Bax ratio after PA treatment on HepG2 cells. Palmitic Acid 158-160 BCL2 apoptosis regulator Homo sapiens 13-18 15837158-3 2005 For instance, sustained expression of Bcl2 has been associated with an increased resistance to apoptosis, and recently, anti-sense-mediated reduction of Bcl2 levels was shown to chemosensitize patients to dacarbazine, dimethyl triazino imidazole carboxomide, or DTIC. Dacarbazine 205-216 BCL2 apoptosis regulator Homo sapiens 153-157 15837158-3 2005 For instance, sustained expression of Bcl2 has been associated with an increased resistance to apoptosis, and recently, anti-sense-mediated reduction of Bcl2 levels was shown to chemosensitize patients to dacarbazine, dimethyl triazino imidazole carboxomide, or DTIC. dimethyl triazino imidazole carboxomide 218-257 BCL2 apoptosis regulator Homo sapiens 38-42 15837158-3 2005 For instance, sustained expression of Bcl2 has been associated with an increased resistance to apoptosis, and recently, anti-sense-mediated reduction of Bcl2 levels was shown to chemosensitize patients to dacarbazine, dimethyl triazino imidazole carboxomide, or DTIC. dimethyl triazino imidazole carboxomide 218-257 BCL2 apoptosis regulator Homo sapiens 153-157 15837158-3 2005 For instance, sustained expression of Bcl2 has been associated with an increased resistance to apoptosis, and recently, anti-sense-mediated reduction of Bcl2 levels was shown to chemosensitize patients to dacarbazine, dimethyl triazino imidazole carboxomide, or DTIC. Dacarbazine 262-266 BCL2 apoptosis regulator Homo sapiens 38-42 15837158-3 2005 For instance, sustained expression of Bcl2 has been associated with an increased resistance to apoptosis, and recently, anti-sense-mediated reduction of Bcl2 levels was shown to chemosensitize patients to dacarbazine, dimethyl triazino imidazole carboxomide, or DTIC. Dacarbazine 262-266 BCL2 apoptosis regulator Homo sapiens 153-157 15945276-4 2005 The level of Bcl-2 was slightly decreased, in contrast, the level of Bax elevated markedly, which resulted in a significant decrease of Bcl-2/Bax ratio after PA treatment on HepG2 cells. Palmitic Acid 158-160 BCL2 apoptosis regulator Homo sapiens 136-141 15749390-6 2005 Activation of the cGMP/PKG pathway induced expression of thioredoxin and Bcl-2 that were beneficial to cortical neurons in antagonizing Abeta/ceramide toxicity. Cyclic GMP 18-22 BCL2 apoptosis regulator Homo sapiens 73-78 15749390-6 2005 Activation of the cGMP/PKG pathway induced expression of thioredoxin and Bcl-2 that were beneficial to cortical neurons in antagonizing Abeta/ceramide toxicity. Ceramides 142-150 BCL2 apoptosis regulator Homo sapiens 73-78 15795422-1 2005 We reported recently that (-)epigallocatechin gallate and quercetin inhibited H2O2-induced apoptosis through modulation of the expression of apoptosis-related Bcl-2 and Bax in endothelial cells. epigallocatechin gallate 26-53 BCL2 apoptosis regulator Homo sapiens 159-164 15795422-1 2005 We reported recently that (-)epigallocatechin gallate and quercetin inhibited H2O2-induced apoptosis through modulation of the expression of apoptosis-related Bcl-2 and Bax in endothelial cells. Quercetin 58-67 BCL2 apoptosis regulator Homo sapiens 159-164 15795422-1 2005 We reported recently that (-)epigallocatechin gallate and quercetin inhibited H2O2-induced apoptosis through modulation of the expression of apoptosis-related Bcl-2 and Bax in endothelial cells. Hydrogen Peroxide 78-82 BCL2 apoptosis regulator Homo sapiens 159-164 15821341-5 2005 The inhibition of the PI3-K/PKC survival pathway might be responsible for SIRT1 inactivation and increased Bax/Bcl-2 expression ratio in evodiamine-induced cell death. evodiamine 137-147 BCL2 apoptosis regulator Homo sapiens 111-116 15626723-9 2005 Moreover, U0126 and ERK siRNA inhibition completely suppressed asiatic acid-induced Bcl-2 phosphorylation and Bax up-regulation, and caspase-9 activation. U 0126 10-15 BCL2 apoptosis regulator Homo sapiens 84-89 15626723-9 2005 Moreover, U0126 and ERK siRNA inhibition completely suppressed asiatic acid-induced Bcl-2 phosphorylation and Bax up-regulation, and caspase-9 activation. asiatic acid 63-75 BCL2 apoptosis regulator Homo sapiens 84-89 15626723-5 2005 Asiatic acid treatment triggered the mitochondrial apoptotic pathway indicated by changing Bax/Bcl-2 ratios, cytochrome c release, and caspase-9 activation, but it did not act on Fas/Fas ligand pathways and the activation of caspase-8. asiatic acid 0-12 BCL2 apoptosis regulator Homo sapiens 95-100 15756452-6 2005 Moreover, staurosporine treatment decreased bcl-2 expression in the cells plated on fibronectin and laminin. Staurosporine 10-23 BCL2 apoptosis regulator Homo sapiens 44-49 15827331-3 2005 We explored effects of oridonin on antiapoptotic Bcl-2 family members and found that it down-regulated levels of Mcl-1 and BCL-x(L), but not Bcl-2 protein, in both MT-1 and RPMI8226 cells. oridonin 23-31 BCL2 apoptosis regulator Homo sapiens 141-146 15827335-9 2005 Furthermore, Jurkat T leukemia cells that overexpressed Bcl-2 were less sensitive to LfcinB-induced apoptosis, which was characterized by mitochondrial swelling and the release of cytochrome c from mitochondria into the cytosolic compartment. LFcinB 85-91 BCL2 apoptosis regulator Homo sapiens 56-61 15756438-9 2005 Bcl-2 expression was down-regulated while Bax expression up-regulated concurrently when the cells were treated with ponicidin for 24-48 h. Therefore, we conclude that ponicidin has significant anti-proliferation effects by induction of apoptosis on myeloid leukemia cells in vitro, down-regulation of Bcl-2, and up-regulation of Bax, and that activation of caspase-3 and PARP may be an important apoptosis-inducing mechanism. ponicidin 116-125 BCL2 apoptosis regulator Homo sapiens 301-306 16019488-8 2005 We concluded that oridoning has significant anti-proliferative and apoptosis-inducing effects on NB4 cells by activation of caspase-3 and cleavage of PARP as well as by down regulation of Bcl-2 and disruption of the delta(psi)m. Furthermore, oridonin demonstrated apparent cell growth inhibition effects on fresh APL cells in vitro. oridonin 18-26 BCL2 apoptosis regulator Homo sapiens 188-193 15827331-3 2005 We explored effects of oridonin on antiapoptotic Bcl-2 family members and found that it down-regulated levels of Mcl-1 and BCL-x(L), but not Bcl-2 protein, in both MT-1 and RPMI8226 cells. oridonin 23-31 BCL2 apoptosis regulator Homo sapiens 49-54 15881612-0 2005 Sphingosine 1-phosphate is involved in cytoprotective actions of calcitriol in human fibroblasts and enhances the intracellular Bcl-2/Bax rheostat. sphingosine 1-phosphate 0-23 BCL2 apoptosis regulator Homo sapiens 128-133 15881612-10 2005 In conclusion, calcitriol H was revealed to protect human fibroblasts from apoptosis by formation of S1P resulting in a changed Bcl-2/Bax ratio. calcitriol h 15-27 BCL2 apoptosis regulator Homo sapiens 128-133 15854294-9 2005 In conclusion, HFCL stromal cells can prevent TPT-induced apoptosis in HL-60 and HL-60/VCR cells via modulation of Bcl-2 and active caspase-3. tpt 46-49 BCL2 apoptosis regulator Homo sapiens 115-120 15748876-2 2005 We have demonstrated in vitro that the neuroimmunophilin, FK506 (10-100 nM), dose dependently and significantly restored the ROS production to the control level, increased the Bcl-2 protein level, partly inhibited the cytochrome C release from mitochondria and reduced the caspase-3 activation in SH-SY5Y cells. Tacrolimus 58-63 BCL2 apoptosis regulator Homo sapiens 176-181 15674333-3 2005 Here we show that three representative apoptotic stimuli, that is, serum starvation, a mitochondrial toxin, and a DNA-damaging agent (etoposide), rapidly induce several distinct classes of prosurvival molecules, in particular, Bcl-2/Bcl-X(L) and superoxide dismutase (SOD; including both MnSOD and Cu/ZnSOD). Etoposide 134-143 BCL2 apoptosis regulator Homo sapiens 227-232 15454489-0 2005 A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism. Celecoxib 8-17 BCL2 apoptosis regulator Homo sapiens 143-148 15454489-0 2005 A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism. OSU 03012 30-38 BCL2 apoptosis regulator Homo sapiens 143-148 16104505-4 2005 After treated with tanshinone II A for 48h, the level of mRNA of bcl-2 and C-myc in NCI-H460 was tested by RT-PCR method. tanshinone 19-34 BCL2 apoptosis regulator Homo sapiens 65-70 15793875-1 2005 AIM: To investigate the effects of mitomycin (MMC) combined with sulindac on cell viability, apoptotic induction and expression of apoptosis-related gene Bcl-2 and cyclooxygenase-2 (COX-2) in gastric cancer SGC-7901 cells. Mitomycin 35-44 BCL2 apoptosis regulator Homo sapiens 154-159 15793875-1 2005 AIM: To investigate the effects of mitomycin (MMC) combined with sulindac on cell viability, apoptotic induction and expression of apoptosis-related gene Bcl-2 and cyclooxygenase-2 (COX-2) in gastric cancer SGC-7901 cells. Mitomycin 46-49 BCL2 apoptosis regulator Homo sapiens 154-159 15793875-1 2005 AIM: To investigate the effects of mitomycin (MMC) combined with sulindac on cell viability, apoptotic induction and expression of apoptosis-related gene Bcl-2 and cyclooxygenase-2 (COX-2) in gastric cancer SGC-7901 cells. Sulindac 65-73 BCL2 apoptosis regulator Homo sapiens 154-159 15793875-10 2005 After exposure for 24 h to MMC, the expression of COX-2 and Bcl-2 protein was up-regulated, COX-2 levels were down-regulated but Bcl-2 gene expression was not changed significantly in combined treatment group. Mitomycin 27-30 BCL2 apoptosis regulator Homo sapiens 60-65 15793875-10 2005 After exposure for 24 h to MMC, the expression of COX-2 and Bcl-2 protein was up-regulated, COX-2 levels were down-regulated but Bcl-2 gene expression was not changed significantly in combined treatment group. Mitomycin 27-30 BCL2 apoptosis regulator Homo sapiens 129-134 15793875-12 2005 MMC combined with sulindac can suppress the growth of gastric cancer cells through induction of apoptosis mediated by down-regulation of apoptosis-related Bcl-2 and COX-2 gene. Mitomycin 0-3 BCL2 apoptosis regulator Homo sapiens 155-160 15793875-12 2005 MMC combined with sulindac can suppress the growth of gastric cancer cells through induction of apoptosis mediated by down-regulation of apoptosis-related Bcl-2 and COX-2 gene. Sulindac 18-26 BCL2 apoptosis regulator Homo sapiens 155-160 15786529-0 2005 Effects of folic acid on epithelial apoptosis and expression of Bcl-2 and p53 in premalignant gastric lesions. Folic Acid 11-21 BCL2 apoptosis regulator Homo sapiens 64-69 15786529-8 2005 In contrast, the expression of Bcl-2 oncogene protein decreased after folic acid therapy. Folic Acid 70-80 BCL2 apoptosis regulator Homo sapiens 31-36 15748703-4 2005 A reduction in mitochondrial functions characterized by a decrease in the Bcl-2/Bax protein ratio and translocation of cytochrome c (cyt c) from the mitochondria to the cytosol in accordance with a decrease in mitochondrial membrane potential were observed in ME-treated HL-60 cells. myricetin 260-262 BCL2 apoptosis regulator Homo sapiens 74-79 15748703-6 2005 A PKC activator, 12-O-tetradecaoylphorbol-13-acetate (TPA) significantly attenuated ME-induced apoptosis via preventing cytochrome c release to the cytosol and maintaining the mitochondrial membrane potential by inhibiting the decrease in the Bcl-2/Bax protein ratio; these effects were blocked by protein kinase C (PKC) inhibitors including GF-109203X, H7, and staurosporin. 12-o-tetradecaoylphorbol-13-acetate 17-52 BCL2 apoptosis regulator Homo sapiens 243-248 15748703-6 2005 A PKC activator, 12-O-tetradecaoylphorbol-13-acetate (TPA) significantly attenuated ME-induced apoptosis via preventing cytochrome c release to the cytosol and maintaining the mitochondrial membrane potential by inhibiting the decrease in the Bcl-2/Bax protein ratio; these effects were blocked by protein kinase C (PKC) inhibitors including GF-109203X, H7, and staurosporin. Tetradecanoylphorbol Acetate 54-57 BCL2 apoptosis regulator Homo sapiens 243-248 15748703-6 2005 A PKC activator, 12-O-tetradecaoylphorbol-13-acetate (TPA) significantly attenuated ME-induced apoptosis via preventing cytochrome c release to the cytosol and maintaining the mitochondrial membrane potential by inhibiting the decrease in the Bcl-2/Bax protein ratio; these effects were blocked by protein kinase C (PKC) inhibitors including GF-109203X, H7, and staurosporin. myricetin 84-86 BCL2 apoptosis regulator Homo sapiens 243-248 15740068-0 2005 Induction of apoptosis by the Anthocyanidins through regulation of Bcl-2 gene and activation of c-Jun N-terminal kinase cascade in hepatoma cells. Anthocyanins 30-44 BCL2 apoptosis regulator Homo sapiens 67-72 15788686-0 2005 4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members. hydroxytamoxifen 0-18 BCL2 apoptosis regulator Homo sapiens 155-160 15781649-9 2005 Geldanamyin and PS-341 synergistically block NFkappaB activation, suppress Akt/PKB pathway, and down-regulate Bcl-XL, Bcl-2, cIAP-1, and cyclin D1 expression. geldanamyin 0-11 BCL2 apoptosis regulator Homo sapiens 118-123 15781649-9 2005 Geldanamyin and PS-341 synergistically block NFkappaB activation, suppress Akt/PKB pathway, and down-regulate Bcl-XL, Bcl-2, cIAP-1, and cyclin D1 expression. Bortezomib 16-22 BCL2 apoptosis regulator Homo sapiens 118-123 15854348-9 2005 CONCLUSIONS: The combination of HSV-TK/GCV system with allitride can inhibit the proliferation of BIU87 cells congenerously through apoptosis, which may be correlated with S- and G(2)-phase arrest, down-regulation of bcl-2 and increased caspase-3 expression and its activity. Ganciclovir 39-42 BCL2 apoptosis regulator Homo sapiens 217-222 15854348-9 2005 CONCLUSIONS: The combination of HSV-TK/GCV system with allitride can inhibit the proliferation of BIU87 cells congenerously through apoptosis, which may be correlated with S- and G(2)-phase arrest, down-regulation of bcl-2 and increased caspase-3 expression and its activity. diallyl trisulfide 55-64 BCL2 apoptosis regulator Homo sapiens 217-222 15523687-5 2005 We demonstrated that UA-induced apoptosis was dependent on the mitochondrial intrinsic pathway, as shown by transmembrane potential collapse (DeltaPsim) and by alteration of the Bax-Bcl-2 balance, with a concomitant increase in Bax expression and decrease in Bcl-2 expression. ursolic acid 21-23 BCL2 apoptosis regulator Homo sapiens 182-187 15523687-5 2005 We demonstrated that UA-induced apoptosis was dependent on the mitochondrial intrinsic pathway, as shown by transmembrane potential collapse (DeltaPsim) and by alteration of the Bax-Bcl-2 balance, with a concomitant increase in Bax expression and decrease in Bcl-2 expression. ursolic acid 21-23 BCL2 apoptosis regulator Homo sapiens 259-264 15740068-6 2005 Moreover, delphinidin-induced apoptotic cell death was accompanied by up-regulation of Bax and down-regulation of Bcl-2 protein. delphinidin 10-21 BCL2 apoptosis regulator Homo sapiens 114-119 15740068-8 2005 Our experiments provide evidence that delphinidin is an effective apoptosis inducer in HepG(2) cells through regulation of Bcl-2 family moleculars and activation of c-Jun N-terminal kinase cascade. delphinidin 38-49 BCL2 apoptosis regulator Homo sapiens 123-128 15843896-5 2005 The mRNA expression for bcl-2 was reduced by fenofibrate. Fenofibrate 45-56 BCL2 apoptosis regulator Homo sapiens 24-29 15706098-4 2005 Bcl-2 expression increases cell resistance to oxidants, augments the expression of intracellular defenses against reactive oxygen species, and may affect mitochondrial generation of superoxide radicals and hydrogen peroxide. Reactive Oxygen Species 114-137 BCL2 apoptosis regulator Homo sapiens 0-5 15706098-4 2005 Bcl-2 expression increases cell resistance to oxidants, augments the expression of intracellular defenses against reactive oxygen species, and may affect mitochondrial generation of superoxide radicals and hydrogen peroxide. Superoxides 182-192 BCL2 apoptosis regulator Homo sapiens 0-5 15722787-0 2005 Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer. Oligonucleotides 60-75 BCL2 apoptosis regulator Homo sapiens 44-49 15722787-0 2005 Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer. oblimersen 77-82 BCL2 apoptosis regulator Homo sapiens 44-49 15706098-4 2005 Bcl-2 expression increases cell resistance to oxidants, augments the expression of intracellular defenses against reactive oxygen species, and may affect mitochondrial generation of superoxide radicals and hydrogen peroxide. Hydrogen Peroxide 206-223 BCL2 apoptosis regulator Homo sapiens 0-5 15722787-1 2005 G3139 is a BCL-2 antisense oligonucleotide whose antitumor effects in preclinical models are enhanced when combined with taxane-based chemotherapy. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 11-16 15843899-6 2005 The antiapoptotic Bcl-2 protein was found to be associated with mitochondria in both sensitive and resistant cells and the association did not change under iron deprivation. Iron 156-160 BCL2 apoptosis regulator Homo sapiens 18-23 15722787-1 2005 G3139 is a BCL-2 antisense oligonucleotide whose antitumor effects in preclinical models are enhanced when combined with taxane-based chemotherapy. Oligonucleotides 27-42 BCL2 apoptosis regulator Homo sapiens 11-16 15722787-1 2005 G3139 is a BCL-2 antisense oligonucleotide whose antitumor effects in preclinical models are enhanced when combined with taxane-based chemotherapy. taxane 121-127 BCL2 apoptosis regulator Homo sapiens 11-16 15794866-1 2005 Oblimersen sodium is an antisense oligonucleotide to the first 6 codons of the B-cell leukemia gene 2 (bcl-2) open reading frame. Sodium 11-17 BCL2 apoptosis regulator Homo sapiens 79-101 15756025-2 2005 Here, we evaluate the combined efficacy of two antisense oligonucleotides targeting bcl-2 mRNA (ODN bcl-2) and c-myc mRNA (ODN c-myc) in combination with cis-diammine dichloroplatinum (cisplatin, DDP) on three human melanoma lines (LM, NG, and M20). Oligonucleotides 57-73 BCL2 apoptosis regulator Homo sapiens 84-89 15868934-7 2005 Baicalein-induced apoptosis was also accompanied by a decrease in Bcl-2 and caspase-3 proform levels. baicalein 0-9 BCL2 apoptosis regulator Homo sapiens 66-71 15756025-2 2005 Here, we evaluate the combined efficacy of two antisense oligonucleotides targeting bcl-2 mRNA (ODN bcl-2) and c-myc mRNA (ODN c-myc) in combination with cis-diammine dichloroplatinum (cisplatin, DDP) on three human melanoma lines (LM, NG, and M20). Oligonucleotides 57-73 BCL2 apoptosis regulator Homo sapiens 100-105 15794866-1 2005 Oblimersen sodium is an antisense oligonucleotide to the first 6 codons of the B-cell leukemia gene 2 (bcl-2) open reading frame. Sodium 11-17 BCL2 apoptosis regulator Homo sapiens 103-108 15669024-4 2005 FCM panel included lambda/kappa/CD19/CD5, CD23/CD10/CD20/CD19, CD4/CD7/CD8/CD3 and Bcl-2/CD10/CD19/CD3 in fluorescein isothiocyanate, phycoerythrin, and peridinin chlorophyll protein or a tandem conjugate of R-phycoerythrin and indodicarbocyanine and allophycocyanin. Fluorescein-5-isothiocyanate 106-132 BCL2 apoptosis regulator Homo sapiens 83-88 15794866-1 2005 Oblimersen sodium is an antisense oligonucleotide to the first 6 codons of the B-cell leukemia gene 2 (bcl-2) open reading frame. Oligonucleotides 34-49 BCL2 apoptosis regulator Homo sapiens 79-101 15794866-1 2005 Oblimersen sodium is an antisense oligonucleotide to the first 6 codons of the B-cell leukemia gene 2 (bcl-2) open reading frame. Oligonucleotides 34-49 BCL2 apoptosis regulator Homo sapiens 103-108 15703842-6 2005 The data provide evidence that BCL-2 protein could protect HL-60 VCR from mitochondrial membrane depolarization and block ROS production in these cells. ros 122-125 BCL2 apoptosis regulator Homo sapiens 31-36 15763656-4 2005 Interestingly, overexpression of Bcl-2 or FADD-DN did not interfere with resveratrol-mediated cell cycle arrest or survivin depletion, but blocked release of cytochrome c and Smac from mitochondria into the cytosol, enhanced caspase activation and apoptosis upon combined treatment with resveratrol and TRAIL indicating that overexpression of Bcl-2 or FADD-DN decoupled the effect of resveratrol on the cell cycle and apoptosis. Resveratrol 287-298 BCL2 apoptosis regulator Homo sapiens 33-38 15763656-4 2005 Interestingly, overexpression of Bcl-2 or FADD-DN did not interfere with resveratrol-mediated cell cycle arrest or survivin depletion, but blocked release of cytochrome c and Smac from mitochondria into the cytosol, enhanced caspase activation and apoptosis upon combined treatment with resveratrol and TRAIL indicating that overexpression of Bcl-2 or FADD-DN decoupled the effect of resveratrol on the cell cycle and apoptosis. Resveratrol 287-298 BCL2 apoptosis regulator Homo sapiens 33-38 15796203-4 2005 Moxa smoke dose-dependently induced internucleosomal DNA fragmentation, activation of caspases 3, 8 and 9, and slightly modified the expression of apoptosis-related proteins (Bcl-2, Bad, Bax) in HL-60 cells, but to much lesser extents than attained by positive controls (UV irradiation, actinomycin D treatment). moxa smoke 0-10 BCL2 apoptosis regulator Homo sapiens 175-180 15720419-9 2005 In the high-risk IPI group, Bcl-2 positivity identified a subgroup with invariably fatal disease. diprotin A 17-20 BCL2 apoptosis regulator Homo sapiens 28-33 15703811-9 2005 Western blot analysis was used to determine the protein expression of cancer suppressor genes, p53 (wt) and Bax, and the proto-oncogene, Bcl-2 in LNCaP cells following treatment with oridonin. oridonin 183-191 BCL2 apoptosis regulator Homo sapiens 121-142 15703811-10 2005 Oridonin up-regulated p53 and Bax and down-regulated Bcl-2 expression in a dose-dependent manner. oridonin 0-8 BCL2 apoptosis regulator Homo sapiens 53-58 15703812-0 2005 Microtubule inhibitor D-24851 induces p53-independent apoptotic cell death in malignant glioma cells through Bcl-2 phosphorylation and Bax translocation. indibulin 22-29 BCL2 apoptosis regulator Homo sapiens 109-114 15713621-3 2005 In this study, we examined the effects of two structurally different HDAC inhibitors, trichostatin A (TSA) and sodium butyrate (NaB), on the cell cycle, apoptosis, and bcl-2 expression in t(14;18) lymphoma cells. trichostatin A 86-100 BCL2 apoptosis regulator Homo sapiens 168-173 15703812-10 2005 Our results indicated that D-24851 effectively induces apoptosis through Bcl-2 phosphorylation and Bax translocation in human malignant glioma cells in a p53-independent manner. indibulin 27-34 BCL2 apoptosis regulator Homo sapiens 73-78 15703816-6 2005 Combined treatment with TNP-470 and docetaxel synergistically inhibited PC-3 cell growth in vitro through the enhanced induction of apoptotic cell death compared with treatment with either agent alone, a result explained, at least in part, by the down-regulation as well as phosphorylation of potential anti-apoptotic genes, Bcl-2 and Bcl-XL. Docetaxel 36-45 BCL2 apoptosis regulator Homo sapiens 325-330 15741050-3 2005 In this study, we assessed quercetin regulation of HT-29 and SW480 cell apoptosis and the influence of quercetin on the protein expression of ErbB2, ErbB3, Akt, Bax and Bcl-2. Quercetin 103-112 BCL2 apoptosis regulator Homo sapiens 169-174 15741050-7 2005 Western blot analysis of cell lysates revealed that Bcl-2 levels decreased dose-dependently in cells treated with quercetin, but Bax remained unchanged. Quercetin 114-123 BCL2 apoptosis regulator Homo sapiens 52-57 15621834-0 2005 Selective cyclooxygenase 2 inhibitor NS-398 induces apoptosis in myeloma cells via a Bcl-2 independent pathway. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 37-43 BCL2 apoptosis regulator Homo sapiens 85-90 15767553-2 2005 Because apoptosis is often triggered by BH3-only proteins of the Bcl-2 family, we have explored the hypothesis that bortezomib contributes to the apoptosis by up-regulating their levels. Bortezomib 116-126 BCL2 apoptosis regulator Homo sapiens 65-70 15767553-3 2005 Indeed, bortezomib induced increases of Bik and/or Bim in multiple cell lines but not notably of two other BH3-only proteins (Puma and Bid) nor other family members (Bax, Bak, Bcl-2, and Bcl-xL). Bortezomib 8-18 BCL2 apoptosis regulator Homo sapiens 176-181 15713621-3 2005 In this study, we examined the effects of two structurally different HDAC inhibitors, trichostatin A (TSA) and sodium butyrate (NaB), on the cell cycle, apoptosis, and bcl-2 expression in t(14;18) lymphoma cells. trichostatin A 102-105 BCL2 apoptosis regulator Homo sapiens 168-173 15767553-7 2005 Further evidence that bortezomib acts through the mitochondrial pathway regulated by the Bcl-2 family is that deficiency for APAF-1, which acts downstream of Bcl-2, also blocked its apoptotic effect. Bortezomib 22-32 BCL2 apoptosis regulator Homo sapiens 89-94 15856947-0 2005 [Parameters of binding and transport of oligodeoxynucleotide, which includes BCL2 mRNA translation start, to the K562 cells]. Oligodeoxyribonucleotides 40-60 BCL2 apoptosis regulator Homo sapiens 77-81 15767553-7 2005 Further evidence that bortezomib acts through the mitochondrial pathway regulated by the Bcl-2 family is that deficiency for APAF-1, which acts downstream of Bcl-2, also blocked its apoptotic effect. Bortezomib 22-32 BCL2 apoptosis regulator Homo sapiens 158-163 15713621-3 2005 In this study, we examined the effects of two structurally different HDAC inhibitors, trichostatin A (TSA) and sodium butyrate (NaB), on the cell cycle, apoptosis, and bcl-2 expression in t(14;18) lymphoma cells. Butyric Acid 111-126 BCL2 apoptosis regulator Homo sapiens 168-173 15856947-1 2005 Interaction of oligodeoxynucleotides (ODN), 18-mer, which included sequence of BCL2 mRNA translation start, with K562 cells has been studied. Oligodeoxyribonucleotides 15-36 BCL2 apoptosis regulator Homo sapiens 79-83 15713621-3 2005 In this study, we examined the effects of two structurally different HDAC inhibitors, trichostatin A (TSA) and sodium butyrate (NaB), on the cell cycle, apoptosis, and bcl-2 expression in t(14;18) lymphoma cells. nab 128-131 BCL2 apoptosis regulator Homo sapiens 168-173 15713621-4 2005 We found that in addition to potent cell cycle arrest, TSA and NaB also dramatically induced apoptosis and down-regulated bcl-2 expression, and overexpression of bcl-2 inhibited TSA-induced apoptosis. trichostatin A 55-58 BCL2 apoptosis regulator Homo sapiens 122-127 15713621-4 2005 We found that in addition to potent cell cycle arrest, TSA and NaB also dramatically induced apoptosis and down-regulated bcl-2 expression, and overexpression of bcl-2 inhibited TSA-induced apoptosis. nab 63-66 BCL2 apoptosis regulator Homo sapiens 122-127 15713621-4 2005 We found that in addition to potent cell cycle arrest, TSA and NaB also dramatically induced apoptosis and down-regulated bcl-2 expression, and overexpression of bcl-2 inhibited TSA-induced apoptosis. trichostatin A 178-181 BCL2 apoptosis regulator Homo sapiens 162-167 15713621-7 2005 TSA treatment increased the acetylation of the transcription factors Sp1 and C/EBPalpha and decreased their binding as well as the binding of CBP and HDAC2 to the bcl-2 promoters. trichostatin A 0-3 BCL2 apoptosis regulator Homo sapiens 163-168 15713621-8 2005 Mutation of Sp1 and C/EBPalpha binding sites reduced the TSA-induced repression of bcl-2 promoter activity. trichostatin A 57-60 BCL2 apoptosis regulator Homo sapiens 83-88 15707758-5 2005 The expression of pro-apoptotic gene, Bax, was increased and the expression of anti-apoptotic gene, Bcl-2, was decreased by CR-treatment. Chromium 124-126 BCL2 apoptosis regulator Homo sapiens 100-105 15700967-5 2005 PPBH3-5 and PPBH3-6 bind Bcl-2 with nanomolar affinity and a DeltaDeltaG = 0.9-1.3 kcal.mol-1 preference for Bcl-2 over Bcl-XL. ppbh3-5 0-7 BCL2 apoptosis regulator Homo sapiens 25-30 15842830-0 2005 [Differential expression of osteopontin and bax, bcl-2 by fluoride]. Fluorides 58-66 BCL2 apoptosis regulator Homo sapiens 49-54 15842830-1 2005 OBJECTIVE: To study the differential expression of bax, bcl-2 and osteopontin by fluoride in the renal tubular cells in vitro. Fluorides 81-89 BCL2 apoptosis regulator Homo sapiens 56-61 15700967-5 2005 PPBH3-5 and PPBH3-6 bind Bcl-2 with nanomolar affinity and a DeltaDeltaG = 0.9-1.3 kcal.mol-1 preference for Bcl-2 over Bcl-XL. ppbh3-5 0-7 BCL2 apoptosis regulator Homo sapiens 109-114 15700967-5 2005 PPBH3-5 and PPBH3-6 bind Bcl-2 with nanomolar affinity and a DeltaDeltaG = 0.9-1.3 kcal.mol-1 preference for Bcl-2 over Bcl-XL. ppbh3-6 12-19 BCL2 apoptosis regulator Homo sapiens 25-30 15700967-5 2005 PPBH3-5 and PPBH3-6 bind Bcl-2 with nanomolar affinity and a DeltaDeltaG = 0.9-1.3 kcal.mol-1 preference for Bcl-2 over Bcl-XL. ppbh3-6 12-19 BCL2 apoptosis regulator Homo sapiens 109-114 15700967-7 2005 PPBH3-5 and PPBH3-6 may have unique applications as early examples of nonnatural ligands that interact selectively with Bcl-2 proteins. ppbh3-5 0-7 BCL2 apoptosis regulator Homo sapiens 120-125 15700967-7 2005 PPBH3-5 and PPBH3-6 may have unique applications as early examples of nonnatural ligands that interact selectively with Bcl-2 proteins. ppbh3-6 12-19 BCL2 apoptosis regulator Homo sapiens 120-125 15639222-4 2005 QN also significantly enhanced C1027-induced apoptosis in BJAB cells, and the inhibition of apoptosis was observed in BJAB cells transfected with Bcl-2 gene. SCHEMBL5971152 0-2 BCL2 apoptosis regulator Homo sapiens 146-151 15735033-5 2005 The increased cisplatin sensitivity in MAD2 transfectants was associated with mitotic arrest and activation of apoptosis pathway evidenced by the increased mitotic index and apoptosis rate as well as decreased Bcl-2 and Bax ratio and expression of cleaved poly(ADP-ribose) polymerase and caspase 3. Cisplatin 14-23 BCL2 apoptosis regulator Homo sapiens 210-215 15735046-7 2005 Treatment of PC-3 cells with troglitazone or Delta2-TG led to reduced association of Bcl-2 and Bcl-xL with Bak, leading to caspase-dependent apoptosis. delta2-tg 45-54 BCL2 apoptosis regulator Homo sapiens 85-90 15735046-0 2005 Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. thiazolidenediones 0-18 BCL2 apoptosis regulator Homo sapiens 99-104 15592511-6 2005 Whereas expression of Bax remained unaffected, in particular, GCV and also 5-FC caused a decline in the level of Bcl-2. Ganciclovir 62-65 BCL2 apoptosis regulator Homo sapiens 113-118 15735046-7 2005 Treatment of PC-3 cells with troglitazone or Delta2-TG led to reduced association of Bcl-2 and Bcl-xL with Bak, leading to caspase-dependent apoptosis. Troglitazone 29-41 BCL2 apoptosis regulator Homo sapiens 85-90 15735046-9 2005 Considering the pivotal role of Bcl-xL/Bcl-2 in regulating mitochondrial integrity, this new mode of mechanism provides a framework to account for the PPARgamma-independent action of thiazolidenediones in inducing apoptosis in cancer cells. thiazolidenediones 183-201 BCL2 apoptosis regulator Homo sapiens 39-44 15592511-9 2005 These data suggest that TK/GCV- and CD/5-FC-induced apoptosis does neither require p53 nor death receptors, but converges at a mitochondrial pathway triggered by different mechanisms of modulation of Bcl-2 proteins. Ganciclovir 27-30 BCL2 apoptosis regulator Homo sapiens 200-205 15592513-3 2005 Here, we demonstrate that hydrogen peroxide (H2O2) upregulates the expression of Bfl-1, an antiapoptotic member of the Bcl-2 family, and that this is responsible for the antiapoptotic activity of ROS. Hydrogen Peroxide 26-43 BCL2 apoptosis regulator Homo sapiens 119-124 15686411-11 2005 On the other hand, the results showed that acacetin-induced apoptosis was accompanied by up-regulation of Bax and p53, down-regulation of Bcl-2, and cleavage of Bad. acacetin 43-51 BCL2 apoptosis regulator Homo sapiens 138-143 15592513-3 2005 Here, we demonstrate that hydrogen peroxide (H2O2) upregulates the expression of Bfl-1, an antiapoptotic member of the Bcl-2 family, and that this is responsible for the antiapoptotic activity of ROS. Hydrogen Peroxide 45-49 BCL2 apoptosis regulator Homo sapiens 119-124 15592513-3 2005 Here, we demonstrate that hydrogen peroxide (H2O2) upregulates the expression of Bfl-1, an antiapoptotic member of the Bcl-2 family, and that this is responsible for the antiapoptotic activity of ROS. ros 196-199 BCL2 apoptosis regulator Homo sapiens 119-124 15592513-5 2005 An investigation of the expression patterns of Bcl-2 family genes revealed that H2O2 treatment induced Bfl-1 gene expression, but left other genes unchanged, and this Bfl-1 expression and H2O2 -induced antiapoptotic effect was inhibited by antioxidants or NF-kappaB inhibitor. Hydrogen Peroxide 80-84 BCL2 apoptosis regulator Homo sapiens 47-52 15592513-5 2005 An investigation of the expression patterns of Bcl-2 family genes revealed that H2O2 treatment induced Bfl-1 gene expression, but left other genes unchanged, and this Bfl-1 expression and H2O2 -induced antiapoptotic effect was inhibited by antioxidants or NF-kappaB inhibitor. Hydrogen Peroxide 188-192 BCL2 apoptosis regulator Homo sapiens 47-52 15592527-6 2005 Analysis by cDNA microarray, RT-PCR, and Western blot showed that cell death members of Bcl-2 family, Bcl-2/adenovirus E1B 19-kDa-interacting protein 3 (BNIP3) and its homologue BNIP3-like (BNIP3L), were upregulated in As(2)O(3)-induced autophagic cell death. (2)o(3) 221-228 BCL2 apoptosis regulator Homo sapiens 88-93 15672207-6 2005 Calculations for the chloro analogue lead to a structure similar to that for B8F12, but with the long core bond extended so that one of the bridging BCl2 groups may now be regarded as terminal. Sodium Hypochlorite 21-27 BCL2 apoptosis regulator Homo sapiens 149-153 15572421-0 2005 Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5"-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. cdb 32-35 BCL2 apoptosis regulator Homo sapiens 95-100 15667975-3 2005 Tetrocarcin A (TC-A) and bcl-2 antisense oligonucleotides exhibit antitumor activity by inhibiting Bcl-2 function and transcription, respectively. tetrocarcin A 0-13 BCL2 apoptosis regulator Homo sapiens 99-104 15667975-3 2005 Tetrocarcin A (TC-A) and bcl-2 antisense oligonucleotides exhibit antitumor activity by inhibiting Bcl-2 function and transcription, respectively. tetrocarcin A 15-19 BCL2 apoptosis regulator Homo sapiens 99-104 15667975-3 2005 Tetrocarcin A (TC-A) and bcl-2 antisense oligonucleotides exhibit antitumor activity by inhibiting Bcl-2 function and transcription, respectively. Oligonucleotides 41-57 BCL2 apoptosis regulator Homo sapiens 25-30 15667975-3 2005 Tetrocarcin A (TC-A) and bcl-2 antisense oligonucleotides exhibit antitumor activity by inhibiting Bcl-2 function and transcription, respectively. Oligonucleotides 41-57 BCL2 apoptosis regulator Homo sapiens 99-104 15667975-9 2005 At concentrations that are not inherently cytotoxic, both TC-A and bcl-2 antisense oligonucleotides increased the cytotoxic effects of radiation in HeLa/bcl-2 cells, but not in HeLa/wt cells. tetrocarcin A 58-62 BCL2 apoptosis regulator Homo sapiens 153-158 15667975-9 2005 At concentrations that are not inherently cytotoxic, both TC-A and bcl-2 antisense oligonucleotides increased the cytotoxic effects of radiation in HeLa/bcl-2 cells, but not in HeLa/wt cells. Oligonucleotides 83-99 BCL2 apoptosis regulator Homo sapiens 67-72 15667975-9 2005 At concentrations that are not inherently cytotoxic, both TC-A and bcl-2 antisense oligonucleotides increased the cytotoxic effects of radiation in HeLa/bcl-2 cells, but not in HeLa/wt cells. Oligonucleotides 83-99 BCL2 apoptosis regulator Homo sapiens 153-158 15667975-11 2005 CONCLUSIONS: The present results suggest that TC-A and bcl-2 antisense oligonucleotides reduce radioresistance of tumor cells overexpressing Bcl-2. tetrocarcin A 46-50 BCL2 apoptosis regulator Homo sapiens 141-146 15667975-11 2005 CONCLUSIONS: The present results suggest that TC-A and bcl-2 antisense oligonucleotides reduce radioresistance of tumor cells overexpressing Bcl-2. Oligonucleotides 71-87 BCL2 apoptosis regulator Homo sapiens 55-60 15667975-11 2005 CONCLUSIONS: The present results suggest that TC-A and bcl-2 antisense oligonucleotides reduce radioresistance of tumor cells overexpressing Bcl-2. Oligonucleotides 71-87 BCL2 apoptosis regulator Homo sapiens 141-146 15647742-3 2005 After preconditioning ischemia (30 minutes MCAO or 30 minutes OGD), phosphorylation of CREB was increased, and there was an increased interaction between the bcl-2 cyclic AMP-responsive element (CRE) promoter and nuclear proteins after preconditioning ischemia in vivo and in vitro. Cyclic AMP 164-174 BCL2 apoptosis regulator Homo sapiens 158-163 15647742-5 2005 Ischemic tolerance was blocked by a CRE decoy oligonucleotide, which also blocked Bcl-2 expression. Oligonucleotides 46-61 BCL2 apoptosis regulator Homo sapiens 82-87 15647742-7 2005 H89, KN62, and U0126 reduced CREB activation and Bcl-2 expression. U 0126 15-20 BCL2 apoptosis regulator Homo sapiens 49-54 15647429-10 2005 Chondrocyte [(3)H]thymidine uptake correlated positively with Bcl-2 (r(s) = 0.62, p = 0.009) and correlated inversely with p53 levels (r(s) = -0.55, p = 0.02). Thymidine 18-27 BCL2 apoptosis regulator Homo sapiens 62-67 15684474-4 2005 Dracorhodin perchlorate upregulated the expression ratio of Bax/Bcl-2 and significantly increased the expression of p53 and p21(WAF1) proteins. dracorhodin 0-23 BCL2 apoptosis regulator Homo sapiens 64-69 15684474-8 2005 Taken together, dracorhodin perchlorate induces apoptosis in A375-S2 cells via accumulation of p53, alters the Bax/Bcl-2 ratio, and activates caspases and p38/JNK MAPKs. dracorhodin 16-39 BCL2 apoptosis regulator Homo sapiens 115-120 15572421-8 2005 Western blot analysis revealed that treatment with CDB-2914 significantly decreased the expression of PCNA and Bcl-2 protein and increased the expression of cleaved caspase-3 and cleaved PARP in a dose-dependent manner compared with untreated control cultures. cdb 51-54 BCL2 apoptosis regulator Homo sapiens 111-116 15572421-9 2005 These results suggest that CDB-2914 inhibits the proliferation of cultured leiomyoma cells by down-regulating PCNA expression and induces apoptosis by up-regulating cleaved caspase-3 and PARP expression and down-regulating Bcl-2 protein expression in those cells. ulipristal 27-35 BCL2 apoptosis regulator Homo sapiens 223-228 15572423-6 2005 BXL-628 counteracted keratinocyte growth factor (KGF) and androgen-induced cell proliferation and stimulated apoptosis with a parallel reduced expression of the survival oncoprotein Bcl-2. BXL628 0-7 BCL2 apoptosis regulator Homo sapiens 182-187 15713891-3 2005 (-)-Gossypol, a natural polyphenol product from cottonseed, has recently been identified as a potent small molecule inhibitor of both Bcl-2 and Bcl-xL. Gossypol 0-12 BCL2 apoptosis regulator Homo sapiens 134-139 15659237-5 2005 Striatal cell death induced by QUIN is mediated by an increase in Bax and a decrease in Bcl-2 protein levels, leading to reduced levels of Bax:Bcl-2 heterodimers. Quinolinic Acid 31-35 BCL2 apoptosis regulator Homo sapiens 88-93 15659237-5 2005 Striatal cell death induced by QUIN is mediated by an increase in Bax and a decrease in Bcl-2 protein levels, leading to reduced levels of Bax:Bcl-2 heterodimers. Quinolinic Acid 31-35 BCL2 apoptosis regulator Homo sapiens 143-148 15751275-6 2005 Bcl-2 and Bcl-XL proteins were decreased by asiatic acid treatment. asiatic acid 44-56 BCL2 apoptosis regulator Homo sapiens 0-5 15713901-1 2005 In a previous study, we showed that G3139, an antisense phosphorothioate oligonucleotide that down-regulates the expression of Bcl-2 protein, did not cause chemosensitization of 518A2 melanoma cells. oblimersen 36-41 BCL2 apoptosis regulator Homo sapiens 127-132 15659237-4 2005 Our results also show that Bcl-2, Bcl-x(L) and Bax protein levels and heterodimerization are selectively regulated by NMDA and non-NMDA receptor stimulation. N-Methylaspartate 118-122 BCL2 apoptosis regulator Homo sapiens 27-32 15547111-7 2005 Co-incubation with pifithrin-alpha (PFT-alpha), a selective p53 inhibitor, restored GADD45, Bcl2, cyclin B1, and p21(WAF1) expression levels and almost completely reversed the growth inhibitory, cell cycle, and apoptotic effects of 5-aza-CR. pifithrin 19-28 BCL2 apoptosis regulator Homo sapiens 92-96 15621213-12 2005 The mechanism of neuroprotective activity has been attributed to the ability of propargylamines-inducing the antiapoptotic family proteins Bcl-2 and Bcl-xl, while decreasing Bad and Bax and preventing opening of mitochondrial permeability transition pore. propargylamine 80-95 BCL2 apoptosis regulator Homo sapiens 139-144 15713901-1 2005 In a previous study, we showed that G3139, an antisense phosphorothioate oligonucleotide that down-regulates the expression of Bcl-2 protein, did not cause chemosensitization of 518A2 melanoma cells. Phosphorothioate Oligonucleotides 56-88 BCL2 apoptosis regulator Homo sapiens 127-132 15713891-5 2005 Our data show that (-)-gossypol potently enhanced radiation-induced apoptosis and growth inhibition of human prostate cancer PC-3 cells, which have a high level of Bcl-2/Bcl-xL proteins. Gossypol 19-31 BCL2 apoptosis regulator Homo sapiens 164-169 15713891-9 2005 Our results show that the natural polyphenol inhibitor of Bcl-2/Bcl-xL, (-)-gossypol, can radiosensitize prostate cancer in vitro and in vivo without augmenting toxicity. Polyphenols 34-44 BCL2 apoptosis regulator Homo sapiens 58-63 15713891-9 2005 Our results show that the natural polyphenol inhibitor of Bcl-2/Bcl-xL, (-)-gossypol, can radiosensitize prostate cancer in vitro and in vivo without augmenting toxicity. Gossypol 72-84 BCL2 apoptosis regulator Homo sapiens 58-63 15713891-10 2005 (-)-Gossypol may improve the outcome of current prostate cancer radiotherapy and represents a promising novel anticancer regime for molecular targeted therapy of hormone-refractory prostate cancer with Bcl-2/Bcl-xL overexpression. Gossypol 0-12 BCL2 apoptosis regulator Homo sapiens 202-207 15713892-0 2005 Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome c release, and caspase activation. Silymarin 0-9 BCL2 apoptosis regulator Homo sapiens 80-85 15713892-7 2005 The constitutive expression of antiapoptotic proteins Bcl-2 and Bcl-xl were decreased after silymarin treatment, whereas the expression of the proapoptotic protein Bax was increased. Silymarin 92-101 BCL2 apoptosis regulator Homo sapiens 54-59 15681030-7 2005 Our results suggested that the protective effects of SA on MPP(+)-induced cytotoxicity may be ascribed to its antioxidative properties and anti-apoptotic activity via regulating the expression of Bcl-2 and Bax. 3,4-dihydroxyphenyllactic acid 53-55 BCL2 apoptosis regulator Homo sapiens 196-201 15700118-11 2005 Finally, paclitaxel- or HER-2-mediated alterations in the phosphorylation of MAP kinases p42/44, Stress-activated protein kinase/Jun-terminal kinase (SAPK/JNK), and p38, and effects on the activation of caspase-3, caspase-7, and bcl-2 are discussed. Paclitaxel 9-19 BCL2 apoptosis regulator Homo sapiens 229-234 15713892-8 2005 There was a shift in Bax/Bcl-2 ratio in favor of apoptotic signal in silymarin-treated cells, which resulted in increased levels of cytochrome c release, apoptotic protease-activating factor-1, and cleaved caspase-3 and poly(ADP-ribose) polymerase in JB6 C141 cells. Silymarin 69-78 BCL2 apoptosis regulator Homo sapiens 25-30 15643508-0 2005 Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer. Docetaxel 59-68 BCL2 apoptosis regulator Homo sapiens 0-5 15643508-5 2005 We examined the association between Bcl-2 and P-gp expression and in vitro chemosensitivity to DOC and CDDP. Docetaxel 95-98 BCL2 apoptosis regulator Homo sapiens 36-41 15714982-3 2005 Docetaxel is a semisynthetic taxane that inhibit tumor growth by induction of microtubule stabilization and promotion of bcl-2 inactivation, which induce apoptosis. Docetaxel 0-9 BCL2 apoptosis regulator Homo sapiens 121-126 15643508-5 2005 We examined the association between Bcl-2 and P-gp expression and in vitro chemosensitivity to DOC and CDDP. Cisplatin 103-107 BCL2 apoptosis regulator Homo sapiens 36-41 15714982-3 2005 Docetaxel is a semisynthetic taxane that inhibit tumor growth by induction of microtubule stabilization and promotion of bcl-2 inactivation, which induce apoptosis. taxane 29-35 BCL2 apoptosis regulator Homo sapiens 121-126 15643508-9 2005 Positive Bcl-2 expression may be a promising indicator in determining in vitro taxane sensitivity in NSCLCs. taxane 79-85 BCL2 apoptosis regulator Homo sapiens 9-14 15770300-4 2005 METHODS: The study was conducted in the year 2001 using polymerase chain reaction (PCR), to detect bcl-2 gene rearrangement in paraffin sections in 5 FL and 23 DLBCL cases diagnosed at the Department of Pathology at Jordan University of Science and Technology, Irbid, Jordan. Paraffin 127-135 BCL2 apoptosis regulator Homo sapiens 99-104 15531913-7 2005 Since rottlerin can sensitize Bcl-2- or Bcl-xL-overexpressing glioma cells but not human astrocytes to TRAIL-induced apoptosis, this combined treatment may offer an attractive strategy for safely treating resistant gliomas. rottlerin 6-15 BCL2 apoptosis regulator Homo sapiens 30-35 15685445-2 2005 Docetaxel is a potent in vitro inhibitor of Bcl-2, an antiapoptotic gene. Docetaxel 0-9 BCL2 apoptosis regulator Homo sapiens 44-49 15639548-6 2005 There is substantial evidence that these effects occur by upregulation of the protective protein bcl-2 and are mediated via alpha7 nicotinic acetylcholine receptors. Acetylcholine 141-154 BCL2 apoptosis regulator Homo sapiens 97-102 15367432-2 2005 Consequently, the Bcl-2 protein is an attractive target for drug design, and Bcl-2-specific antisense oligonucleotides or small-molecule Bcl-2 inhibitors have shown broad anticancer activities in preclinical models and are currently in several clinical trials. Oligonucleotides 102-118 BCL2 apoptosis regulator Homo sapiens 18-23 15367432-2 2005 Consequently, the Bcl-2 protein is an attractive target for drug design, and Bcl-2-specific antisense oligonucleotides or small-molecule Bcl-2 inhibitors have shown broad anticancer activities in preclinical models and are currently in several clinical trials. Oligonucleotides 102-118 BCL2 apoptosis regulator Homo sapiens 77-82 15367432-2 2005 Consequently, the Bcl-2 protein is an attractive target for drug design, and Bcl-2-specific antisense oligonucleotides or small-molecule Bcl-2 inhibitors have shown broad anticancer activities in preclinical models and are currently in several clinical trials. Oligonucleotides 102-118 BCL2 apoptosis regulator Homo sapiens 77-82 15633216-0 2005 Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 25-30 BCL2 apoptosis regulator Homo sapiens 95-100 15633216-6 2005 Furthermore, expression level of Bcl-2 was detected using Western blot in HepG2 after treated with NS-398. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 99-105 BCL2 apoptosis regulator Homo sapiens 33-38 15633216-11 2005 Bcl-2 protein level was inhibited after treated with NS-398. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 53-59 BCL2 apoptosis regulator Homo sapiens 0-5 15625106-6 2005 Bcl-2-HUVEC-lined vessels retain 70-kDa FITC-dextran, but not 3-kDa dextran; local histamine rapidly induces leak of 70-kDa FITC-dextran or India ink. KDA 36-39 BCL2 apoptosis regulator Homo sapiens 0-5 15531918-7 2005 PS-341 downregulated the expression of Bcl-2 and Bcl-xl in protein levels at an early time of treatment. Bortezomib 0-6 BCL2 apoptosis regulator Homo sapiens 39-44 15625106-6 2005 Bcl-2-HUVEC-lined vessels retain 70-kDa FITC-dextran, but not 3-kDa dextran; local histamine rapidly induces leak of 70-kDa FITC-dextran or India ink. fluorescein isothiocyanate dextran 40-52 BCL2 apoptosis regulator Homo sapiens 0-5 15625106-6 2005 Bcl-2-HUVEC-lined vessels retain 70-kDa FITC-dextran, but not 3-kDa dextran; local histamine rapidly induces leak of 70-kDa FITC-dextran or India ink. Histamine 83-92 BCL2 apoptosis regulator Homo sapiens 0-5 15625106-6 2005 Bcl-2-HUVEC-lined vessels retain 70-kDa FITC-dextran, but not 3-kDa dextran; local histamine rapidly induces leak of 70-kDa FITC-dextran or India ink. fluorescein isothiocyanate dextran 124-136 BCL2 apoptosis regulator Homo sapiens 0-5 15625106-6 2005 Bcl-2-HUVEC-lined vessels retain 70-kDa FITC-dextran, but not 3-kDa dextran; local histamine rapidly induces leak of 70-kDa FITC-dextran or India ink. chinese ink 140-149 BCL2 apoptosis regulator Homo sapiens 0-5 15671997-7 2005 In villous trophoblast, heparin increased Bcl-2 and cytokeratin 18 protein expression. Heparin 24-31 BCL2 apoptosis regulator Homo sapiens 42-47 15501827-4 2005 By analogy, it has been hypothesized the BCL-2 family proteins would unfold and insert into the lipid bilayer upon membrane association. Lipid Bilayers 96-109 BCL2 apoptosis regulator Homo sapiens 41-46 15531922-6 2005 In order to study the influence of Bcl-2 on TRAIL-induced cell death more detailed, we utilized a tetracycline-regulated Bcl-2 expression system in Jurkat T cells. Tetracycline 98-110 BCL2 apoptosis regulator Homo sapiens 121-126 15531923-0 2005 Characterization of vinblastine-induced Bcl-xL and Bcl-2 phosphorylation: evidence for a novel protein kinase and a coordinated phosphorylation/dephosphorylation cycle associated with apoptosis induction. Vinblastine 20-31 BCL2 apoptosis regulator Homo sapiens 51-56 15531923-2 2005 In this study, we investigated the characteristics of Bcl-xL and Bcl-2 phosphorylation in KB-3 carcinoma cells treated with vinblastine. Vinblastine 124-135 BCL2 apoptosis regulator Homo sapiens 65-70 15613866-6 2005 Moreover, fluorescence in situ hybridization performed on paraffin-embedded tissue sections demonstrated an immunoglobulin heavy chain (IGH)/BCL2 translocation signal in both follicular and diffuse components, but an IGH/c-MYC translocation signal in only the diffuse component. Paraffin 58-66 BCL2 apoptosis regulator Homo sapiens 141-145 15903240-0 2005 Enhanced human thrombopoietin production by sodium butyrate addition to serum-free suspension culture of bcl-2-overexpressing CHO cells. CAV protocol 126-129 BCL2 apoptosis regulator Homo sapiens 105-110 16929757-4 2005 After six months of iodine overload, apoptotic thyrocytes were ten times more numerous; CD34 positive endothelial cells were diminished by one half bcl-2 immunoreactivity disappeared in thyrocytes and a bax one appeared in thyroid follicular and endothelial cells. Iodine 20-26 BCL2 apoptosis regulator Homo sapiens 148-153 15816563-8 2005 In conclusion, sodium fluorosilicate induces apoptosis in HOS cells through decrease in Bcl-2, the release of cytochrome c to the cytosol and activation of caspase-3. hexafluorosilicate 15-36 BCL2 apoptosis regulator Homo sapiens 88-93 15742811-0 2005 Pseudolaric acid B induces apoptosis through p53 and Bax/Bcl-2 pathways in human melanoma A375-S2 cells. pseudolaric acid B 0-18 BCL2 apoptosis regulator Homo sapiens 57-62 15365767-9 2005 DHA markedly increased the inhibitory effect of 5-FU on the expression of the antiapoptotic proteins BCL-2 and BCL-XL, and induced overexpression of c-MYC which has recently been shown to drive apoptosis and, when overexpressed, to sensitize cancer cells to the action of proapoptotic agents, including 5-FU. Docosahexaenoic Acids 0-3 BCL2 apoptosis regulator Homo sapiens 101-106 16168113-9 2005 The sequence Dox-->Pacl-->48-h washout-->5-FU produced a synergistic and highly schedule-dependent interaction (combination index < 1), resulting in an induction of apoptosis in both experimental models regardless of hormonal, p53, bcl-2 or bax status. Doxorubicin 13-16 BCL2 apoptosis regulator Homo sapiens 244-249 16168113-9 2005 The sequence Dox-->Pacl-->48-h washout-->5-FU produced a synergistic and highly schedule-dependent interaction (combination index < 1), resulting in an induction of apoptosis in both experimental models regardless of hormonal, p53, bcl-2 or bax status. Fluorouracil 50-54 BCL2 apoptosis regulator Homo sapiens 244-249 16280040-6 2005 Treatment of BT-474, ZR-75-1, and MDA-MB-231 cells with AS Bcl-2 increased chemosensitivity to doxorubicin (DOX), mitomycin C (MMC), paclitaxel (TXL), and docetaxel (TXT). Doxorubicin 95-106 BCL2 apoptosis regulator Homo sapiens 59-64 16280040-6 2005 Treatment of BT-474, ZR-75-1, and MDA-MB-231 cells with AS Bcl-2 increased chemosensitivity to doxorubicin (DOX), mitomycin C (MMC), paclitaxel (TXL), and docetaxel (TXT). Doxorubicin 108-111 BCL2 apoptosis regulator Homo sapiens 59-64 16280040-6 2005 Treatment of BT-474, ZR-75-1, and MDA-MB-231 cells with AS Bcl-2 increased chemosensitivity to doxorubicin (DOX), mitomycin C (MMC), paclitaxel (TXL), and docetaxel (TXT). Mitomycin 114-125 BCL2 apoptosis regulator Homo sapiens 59-64 16280040-6 2005 Treatment of BT-474, ZR-75-1, and MDA-MB-231 cells with AS Bcl-2 increased chemosensitivity to doxorubicin (DOX), mitomycin C (MMC), paclitaxel (TXL), and docetaxel (TXT). Mitomycin 127-130 BCL2 apoptosis regulator Homo sapiens 59-64 16280040-6 2005 Treatment of BT-474, ZR-75-1, and MDA-MB-231 cells with AS Bcl-2 increased chemosensitivity to doxorubicin (DOX), mitomycin C (MMC), paclitaxel (TXL), and docetaxel (TXT). Paclitaxel 133-143 BCL2 apoptosis regulator Homo sapiens 59-64 16280040-6 2005 Treatment of BT-474, ZR-75-1, and MDA-MB-231 cells with AS Bcl-2 increased chemosensitivity to doxorubicin (DOX), mitomycin C (MMC), paclitaxel (TXL), and docetaxel (TXT). Docetaxel 145-148 BCL2 apoptosis regulator Homo sapiens 59-64 16280040-6 2005 Treatment of BT-474, ZR-75-1, and MDA-MB-231 cells with AS Bcl-2 increased chemosensitivity to doxorubicin (DOX), mitomycin C (MMC), paclitaxel (TXL), and docetaxel (TXT). Docetaxel 155-164 BCL2 apoptosis regulator Homo sapiens 59-64 16280040-7 2005 Transfection of the Bcl-2 gene into MDA-MB-453 cells decreased sensitivity to DOX and MMC. Doxorubicin 78-81 BCL2 apoptosis regulator Homo sapiens 20-25 15365767-9 2005 DHA markedly increased the inhibitory effect of 5-FU on the expression of the antiapoptotic proteins BCL-2 and BCL-XL, and induced overexpression of c-MYC which has recently been shown to drive apoptosis and, when overexpressed, to sensitize cancer cells to the action of proapoptotic agents, including 5-FU. Fluorouracil 48-52 BCL2 apoptosis regulator Homo sapiens 101-106 16280040-7 2005 Transfection of the Bcl-2 gene into MDA-MB-453 cells decreased sensitivity to DOX and MMC. Mitomycin 86-89 BCL2 apoptosis regulator Homo sapiens 20-25 16305985-4 2005 ERK1/2 inhibition with PD98059 promoted apoptotic cell death through the downregulation of ERK1/2 activity and Bcl-2 protein levels. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 23-30 BCL2 apoptosis regulator Homo sapiens 111-116 16121028-0 2005 Effect of sphingosine on Ca2+ entry and mitochondrial potential of Jurkat T cells--interaction with Bcl2. Sphingosine 10-21 BCL2 apoptosis regulator Homo sapiens 100-104 15779298-0 2005 [Protein bcl-2 expression in the secretory endometrium after oral estrogen-progesterone replacement]. Progesterone 75-87 BCL2 apoptosis regulator Homo sapiens 9-14 15779298-14 2005 CONCLUSION: The bcl-2 expression in the mid-secretory endometrium is significantly higher in the cycle with estrogen-progesterone substitution comparing to the natural cycle. estrogen-progesterone 108-129 BCL2 apoptosis regulator Homo sapiens 16-21 16121028-4 2005 The present experiments were performed to explore whether treatment of Jurkat T cells with sphingosine leads to apoptosis and reduced Ca2+ entry and whether those effects are sensitive to expression of the antiapoptotic protein Bcl2, localized in the outer mitochondrial membrane. Sphingosine 91-102 BCL2 apoptosis regulator Homo sapiens 228-232 16301817-7 2005 Choline/M(3)-mAChR activated several survival signaling molecules (antiapoptotic proteins Bcl-2 and ERKs), increased endogenous antioxidant reserve (SOD), and reduced apoptotic mediators (proapoptotic proteins Fas and p38 MAPK) and intracellular Ca2+ overload. Choline 0-7 BCL2 apoptosis regulator Homo sapiens 90-95 16121028-9 2005 Mitochondrial Bcl2 reverses the effect on mitochondria but not on Ca2+ entry and thus leads to dissociation of those two sequelae of sphingosine treatment. Sphingosine 133-144 BCL2 apoptosis regulator Homo sapiens 14-18 16266195-1 2005 The taxoid analogue docetaxel is a potent inhibitor of microtubular depolymerisation and, in hormone-refractory metastatic prostate cancer, it also counters the effects of the anti-apoptotic protein Bcl-2. Docetaxel 20-29 BCL2 apoptosis regulator Homo sapiens 199-204 16614737-9 2005 In addition to the direct effect of repinotan on neuronal hyperpolarization and suppression of glutamate release this compound affects the death-inhibiting protein Bcl-2, serotonergic glial growth factor S-100beta and Nerve Growth Factor. repinotan hydrochloride 36-45 BCL2 apoptosis regulator Homo sapiens 164-169 16101440-6 2005 For cancer chemotherapy, the Bcl-2 antisense oligonucleotide is currently in phase III clinical trials. Oligonucleotides 45-60 BCL2 apoptosis regulator Homo sapiens 29-34 15586245-4 2005 Since sodium butyrate affects both differentiation and apoptosis, we investigated expression of bcl-2-related genes in a human hepatocellular carcinoma cell line HCC-T. Butyric Acid 6-21 BCL2 apoptosis regulator Homo sapiens 96-101 15827887-6 2005 Hippocampal cultures pretreated with ZnCl2 before anoxia showed decreased immunoreactivity for p53 and BAX, connected with BCL-2 overexpression, whereas the cultures exposed to zinc chelating agent - TPEN or TPEN connected with anoxia showed significant increase of immunorectivity for p53 and BAX. zinc chloride 37-42 BCL2 apoptosis regulator Homo sapiens 123-128 15827887-7 2005 This strong immunoreactivity of proapototic proteins (p53 and BAX) in hippocampal cultures exposed to anoxia or/and TPEN correlated with previous ultrastructural evidences of anoxia- and TPEN-induced apoptosis, while the overexpression of anti-apoptotic protein (BCL-2 and BCL-X) in zinc-pretreated cultures evidenced the protective ability of this metal against apoptosis in model of anoxia in vitro. N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine 116-120 BCL2 apoptosis regulator Homo sapiens 263-268 15827887-7 2005 This strong immunoreactivity of proapototic proteins (p53 and BAX) in hippocampal cultures exposed to anoxia or/and TPEN correlated with previous ultrastructural evidences of anoxia- and TPEN-induced apoptosis, while the overexpression of anti-apoptotic protein (BCL-2 and BCL-X) in zinc-pretreated cultures evidenced the protective ability of this metal against apoptosis in model of anoxia in vitro. N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine 187-191 BCL2 apoptosis regulator Homo sapiens 263-268 15796162-1 2005 Micromolar concentrations of the five-lipoxygenase inhibitor, MK 886 induce a "type 1" (apoptotic, extrinsic, death domain, receptor-dependent, caspase-positive) form of programmed cell death in Bcl-2-positive U937 human monoblastoid and HL-60 myeloid leukemia cells. MK-886 62-68 BCL2 apoptosis regulator Homo sapiens 195-200 15796162-7 2005 Bcl-2-positive HeLa cervical cancer cells exhibited an acute MK 886-induced increase in Ca2+. MK-886 61-67 BCL2 apoptosis regulator Homo sapiens 0-5 15589371-4 2005 Selenite-induced apoptosis in LAPC-4 cells correlated with a decrease in the Bcl-2:Bax expression ratio. Selenious Acid 0-8 BCL2 apoptosis regulator Homo sapiens 77-82 15796192-4 2005 In SKMEL-28 cells, Bcl-2 expression was low after UVB irradiation, but it was increased when treated with glycyrrhizin. Glycyrrhizic Acid 106-118 BCL2 apoptosis regulator Homo sapiens 19-24 16196285-4 2005 Streptavidin-biotin complex (SABC) immunocytochemical assays were employed for the detections of Bax/Bcl-2 proteins expressions. sabc 29-33 BCL2 apoptosis regulator Homo sapiens 101-106 16393120-4 2005 Eupatilin induced the apoptosis of AGS cells as revealed by a decrease in the ratio of pro-apoptotic Bax and anti-apoptotic Bcl-2, as well as the cleavage of caspase-3 and poly(ADP-ribose)polymerase (PARP). eupatilin 0-9 BCL2 apoptosis regulator Homo sapiens 124-129 16196285-7 2005 10(-5) mol/L retinoids significantly induced apoptosis of Tca8113 cells (all P < 0.05), elevated the cells population with detectable active caspase-3 (P < 0.05 for all), increased the number of cells forming Bax and decreased the number of cells forming Bcl-2 significantly (all P < 0.05). Retinoids 13-22 BCL2 apoptosis regulator Homo sapiens 261-266 15492114-0 2005 Retinoid-induced apoptosis in HL-60 cells is associated with nucleolin down-regulation and destabilization of Bcl-2 mRNA. Retinoids 0-8 BCL2 apoptosis regulator Homo sapiens 110-115 16025880-13 2005 The observations also point to an imbalance in the expression of antiapoptotic (Bcl-2) and proapoptotic (Bax, caspase 3) proteins as a potential mechanism underlying adenosine-induced mesangial cell apoptosis. Adenosine 166-175 BCL2 apoptosis regulator Homo sapiens 80-85 15573406-10 2005 Their neuroprotective effect has been demonstrated to be associated directly with the propargylamine moiety, which protects mitochondrial viability and MTPp by activating Bcl-2 and protein kinase C (PKC) and by downregulating the proapoptotic FAS and Bax protein families. propargylamine 86-100 BCL2 apoptosis regulator Homo sapiens 171-176 15621789-3 2005 Our very preliminary results revealed that mononuclear cell nuclear fraction from blood of patients responding to the used therapy, i.e., cladribine alone or its combination with mitoxantrone and cyclophosphamide indicates decrease (or even loss) of transition at 93 degrees C concomitant with increase of transition at 76 degrees C. A complementary study showed that in mononuclear cells of patients who appeared to be sensitive to chemotherapy the decrease of antiapoptotic Bcl-2 protein expression and signs of apoptotic morphology were observed. Cladribine 138-148 BCL2 apoptosis regulator Homo sapiens 476-481 15621789-3 2005 Our very preliminary results revealed that mononuclear cell nuclear fraction from blood of patients responding to the used therapy, i.e., cladribine alone or its combination with mitoxantrone and cyclophosphamide indicates decrease (or even loss) of transition at 93 degrees C concomitant with increase of transition at 76 degrees C. A complementary study showed that in mononuclear cells of patients who appeared to be sensitive to chemotherapy the decrease of antiapoptotic Bcl-2 protein expression and signs of apoptotic morphology were observed. Mitoxantrone 179-191 BCL2 apoptosis regulator Homo sapiens 476-481 15621789-3 2005 Our very preliminary results revealed that mononuclear cell nuclear fraction from blood of patients responding to the used therapy, i.e., cladribine alone or its combination with mitoxantrone and cyclophosphamide indicates decrease (or even loss) of transition at 93 degrees C concomitant with increase of transition at 76 degrees C. A complementary study showed that in mononuclear cells of patients who appeared to be sensitive to chemotherapy the decrease of antiapoptotic Bcl-2 protein expression and signs of apoptotic morphology were observed. Cyclophosphamide 196-212 BCL2 apoptosis regulator Homo sapiens 476-481 15657356-6 2005 EGCG decreased the expression of antiapoptotic protein Bcl-2 but increased proapoptotic protein Bax in these cells. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 55-60 15657356-7 2005 The increased ratio of Bax/Bcl-2 proteins after EGCG treatment may have resulted in increased release of cytochrome c from mitochondria into cytosols, increased expression of Apaf-1, and activation of caspase-3 and poly(ADP-ribose) polymerase, which may lead to apoptosis in MDA-MB-468 cells. epigallocatechin gallate 48-52 BCL2 apoptosis regulator Homo sapiens 27-32 15606891-0 2005 Activated JNK brings about accelerated apoptosis of Bcl-2-overexpressing C6 glioma cells on treatment with tamoxifen. Tamoxifen 107-116 BCL2 apoptosis regulator Homo sapiens 52-57 15606891-3 2005 Low leaky Bcl-2 expression offered complete protection against tamoxifen-induced apoptosis. Tamoxifen 63-72 BCL2 apoptosis regulator Homo sapiens 10-15 15606891-4 2005 High Bcl-2 levels, on the other hand, accelerated the apoptosis, with Bcl-2-overexpressing clones dying within 48 h of tamoxifen treatment as compared to 6 days for parental C6 cells. Tamoxifen 119-128 BCL2 apoptosis regulator Homo sapiens 70-75 15606891-6 2005 Only a minor fraction of the overexpressed Bcl-2 gets phosphorylated in tamoxifen-treated cells and the phosphorylation does not affect its binding to Bax. Tamoxifen 72-81 BCL2 apoptosis regulator Homo sapiens 43-48 15606891-7 2005 Tamoxifen treatment of Bcl-2-overexpressing clones was found to result in activation of c-Jun N-terminal kinase (JNK) and p38 kinase. Tamoxifen 0-9 BCL2 apoptosis regulator Homo sapiens 23-28 16249809-7 2005 We also studied the IgH and bcl-2 (major breakpoint region=MBR) gene rearrangement on paraffin embedded samples with conventional PCR methods. Paraffin 86-94 BCL2 apoptosis regulator Homo sapiens 28-33 15607561-0 2005 Disparate forms of MK 886-induced programmed death in BCL-2 (+) blood and BCL-2 (-) solid cancer cells and a putative "nuclear" Ca2+ channel: "soil" trumps "seed"? MK-886 19-25 BCL2 apoptosis regulator Homo sapiens 54-59 15607561-0 2005 Disparate forms of MK 886-induced programmed death in BCL-2 (+) blood and BCL-2 (-) solid cancer cells and a putative "nuclear" Ca2+ channel: "soil" trumps "seed"? MK-886 19-25 BCL2 apoptosis regulator Homo sapiens 74-79 15607561-5 2005 Solid tumor-derived Bcl-2-positive HeLa cervical cancer cells exhibit an acute increase in Ca(2+) after challenge with MK 886. MK-886 119-125 BCL2 apoptosis regulator Homo sapiens 20-25 15657350-0 2005 (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. Gossypol 0-12 BCL2 apoptosis regulator Homo sapiens 59-64 15657350-4 2005 Recently gossypol has been found to bind to Bcl-X(L) and, with less affinity, to Bcl-2. Gossypol 9-17 BCL2 apoptosis regulator Homo sapiens 81-86 15657350-5 2005 Here we investigate the ability of the (-) enantiomer of gossypol, (-)-gossypol, to overcome the apoptosis resistance conferred by Bcl-2 or Bcl-X(L) overexpression in Jurkat T leukemia cells. Gossypol 57-65 BCL2 apoptosis regulator Homo sapiens 131-136 15657350-5 2005 Here we investigate the ability of the (-) enantiomer of gossypol, (-)-gossypol, to overcome the apoptosis resistance conferred by Bcl-2 or Bcl-X(L) overexpression in Jurkat T leukemia cells. Gossypol 67-79 BCL2 apoptosis regulator Homo sapiens 131-136 15657350-6 2005 (-)-Gossypol potently induced cell death in Jurkat cells overexpressing Bcl-2 (IC50, 18.1+/-2.6 micromol/L) or Bcl-X(L) (IC50, 22.9+/-3.7 micromol/L). Gossypol 4-12 BCL2 apoptosis regulator Homo sapiens 72-77 15657350-9 2005 Additionally, (-)-gossypol was more efficient than etoposide at inducing caspase-3 activation and phosphatidylserine externalization in the setting of Bcl-2 or Bcl-X(L) overexpression. Gossypol 14-26 BCL2 apoptosis regulator Homo sapiens 151-156 15657350-11 2005 Moreover, (-)-gossypol treatment of isolated mitochondria purified from Bcl-2-overexpressing cells also resulted in cytochrome c release, indicating a possible direct action on Bcl-2 present in the mitochondrial outer membrane. Gossypol 10-22 BCL2 apoptosis regulator Homo sapiens 72-77 15671246-2 2005 Members of the Bcl-2 family play pivotal roles in regulating apoptosis and possess at least one of four Bcl-2 homology (BH) domains, designated BH1 to BH4. sapropterin 151-154 BCL2 apoptosis regulator Homo sapiens 15-20 15671246-2 2005 Members of the Bcl-2 family play pivotal roles in regulating apoptosis and possess at least one of four Bcl-2 homology (BH) domains, designated BH1 to BH4. sapropterin 151-154 BCL2 apoptosis regulator Homo sapiens 104-109 15657350-11 2005 Moreover, (-)-gossypol treatment of isolated mitochondria purified from Bcl-2-overexpressing cells also resulted in cytochrome c release, indicating a possible direct action on Bcl-2 present in the mitochondrial outer membrane. Gossypol 10-22 BCL2 apoptosis regulator Homo sapiens 177-182 15492114-2 2005 Studies were done to address the question whether ATRA-induced apoptosis is a consequence of destabilization of bcl-2 mRNA and decreased cellular levels of the anti-apoptotic protein, bcl-2. Tretinoin 50-54 BCL2 apoptosis regulator Homo sapiens 184-189 15657350-12 2005 Taken together, these results suggest that (-)-gossypol is a potent and novel therapeutic able to overcome apoptosis resistance by specifically targeting the activity of antiapoptotic Bcl-2 family members. Gossypol 43-55 BCL2 apoptosis regulator Homo sapiens 184-189 15492114-3 2005 ATRA induced differentiation of HL-60 cells along the granulocytic pathway within 48 h. The half-lives of bcl-2 mRNA in HL-60 cells incubated with ATRA for 48 or 72 h were reduced to 39 and 7% of the corresponding untreated control values, respectively. Tretinoin 0-4 BCL2 apoptosis regulator Homo sapiens 106-111 15492114-3 2005 ATRA induced differentiation of HL-60 cells along the granulocytic pathway within 48 h. The half-lives of bcl-2 mRNA in HL-60 cells incubated with ATRA for 48 or 72 h were reduced to 39 and 7% of the corresponding untreated control values, respectively. Tretinoin 147-151 BCL2 apoptosis regulator Homo sapiens 106-111 15786722-11 2005 These results suggested that mevastatin induced apoptosis when it inhibited GGPP biosynthesis and consequently decreased the level of phosphorylated ERK, which was a survival signal; moreover, at that time, there was no influence on NF-kappaB, Akt, p38, and Bcl-2. mevastatin 29-39 BCL2 apoptosis regulator Homo sapiens 258-263 15797260-7 2005 An increased ratio of bax to bcl-2 mRNA level with subsequent activation of caspase-3 was observed in high-glucose- or H2O2-exposed pericytes, which was also completely prevented by PEDF. Glucose 107-114 BCL2 apoptosis regulator Homo sapiens 29-34 15797260-7 2005 An increased ratio of bax to bcl-2 mRNA level with subsequent activation of caspase-3 was observed in high-glucose- or H2O2-exposed pericytes, which was also completely prevented by PEDF. Hydrogen Peroxide 119-123 BCL2 apoptosis regulator Homo sapiens 29-34 15492114-5 2005 Binding of a bcl-2 mRNA instability element (AU-rich element-1) to nucleolin in S100 extracts from ATRA-treated cells was decreased to 15% of control within 72 h. The decay of 5" capped, polyadenylated bcl-2 mRNA transcripts containing ARE-1 was more rapid in S100 extracts from ATRA-treated cells compared with untreated cells. Tretinoin 99-103 BCL2 apoptosis regulator Homo sapiens 13-18 15492114-5 2005 Binding of a bcl-2 mRNA instability element (AU-rich element-1) to nucleolin in S100 extracts from ATRA-treated cells was decreased to 15% of control within 72 h. The decay of 5" capped, polyadenylated bcl-2 mRNA transcripts containing ARE-1 was more rapid in S100 extracts from ATRA-treated cells compared with untreated cells. Tretinoin 99-103 BCL2 apoptosis regulator Homo sapiens 202-207 15492114-5 2005 Binding of a bcl-2 mRNA instability element (AU-rich element-1) to nucleolin in S100 extracts from ATRA-treated cells was decreased to 15% of control within 72 h. The decay of 5" capped, polyadenylated bcl-2 mRNA transcripts containing ARE-1 was more rapid in S100 extracts from ATRA-treated cells compared with untreated cells. Tretinoin 279-283 BCL2 apoptosis regulator Homo sapiens 13-18 15492114-6 2005 However, when recombinant nucleolin was added to extracts of ATRA-treated cells, the rate of bcl-2 mRNA decay was similar to the rate in extracts of untreated cells. Tretinoin 61-65 BCL2 apoptosis regulator Homo sapiens 93-98 15492114-7 2005 These results provide evidence that ATRA-induced apoptosis is a consequence of cellular differentiation, which leads to nucleolin down-regulation and bcl-2 mRNA instability. Tretinoin 36-40 BCL2 apoptosis regulator Homo sapiens 150-155 15829155-0 2005 Insulin-like growth factor-I decreased etoposide-induced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity. Etoposide 39-48 BCL2 apoptosis regulator Homo sapiens 97-102 15800708-10 2005 A shorter CR duration was observed in bcl-2+ patients when compared with bcl-2- ones (571+/-50 versus 850+/-17 days)(p=0.0001). Chromium 10-12 BCL2 apoptosis regulator Homo sapiens 38-43 15829155-11 2005 IGF-I prevented etoposide-induced apoptosis by increasing the expression of bcl-2 and decreasing the activity of CPP32. Etoposide 16-25 BCL2 apoptosis regulator Homo sapiens 76-81 15829155-13 2005 CONCLUSIONS: IGF-I decreased etoposide-induced apoptosis in glioma cells by increasing the expression of bcl-2 and decreasing the activity of CPP32. Etoposide 29-38 BCL2 apoptosis regulator Homo sapiens 105-110 15583801-12 2005 After ursolic acid treatment, the anti-apoptotic Bcl-2 protein decreased and Bax expression was enhanced. ursolic acid 6-18 BCL2 apoptosis regulator Homo sapiens 49-54 16084648-0 2005 PAN-811 (3-aminopyridine-2-carboxaldehyde thiosemicarbazone), a novel neuroprotectant, elicits its function in primary neuronal cultures by up-regulating Bcl-2 expression. 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 0-7 BCL2 apoptosis regulator Homo sapiens 154-159 16084648-0 2005 PAN-811 (3-aminopyridine-2-carboxaldehyde thiosemicarbazone), a novel neuroprotectant, elicits its function in primary neuronal cultures by up-regulating Bcl-2 expression. 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 9-59 BCL2 apoptosis regulator Homo sapiens 154-159 16084648-4 2005 Pretreatment of neurons with PAN-811 produced a time-dependent increase in the protein level of Bcl-2, which was evident even after glutamate or H/H treatments. 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 29-36 BCL2 apoptosis regulator Homo sapiens 96-101 16084648-4 2005 Pretreatment of neurons with PAN-811 produced a time-dependent increase in the protein level of Bcl-2, which was evident even after glutamate or H/H treatments. Glutamic Acid 132-141 BCL2 apoptosis regulator Homo sapiens 96-101 16084648-6 2005 Functional inhibition of Bcl-2 by HA14-1 reduced the neuroprotective efficacy of PAN-811. 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 81-88 BCL2 apoptosis regulator Homo sapiens 25-30 15878643-7 2005 The anti-apoptotic protein bcl-2 was also increased in the co-cultured SH-SY5Y cells 3 h after treatment with 6-OHDA. Oxidopamine 110-116 BCL2 apoptosis regulator Homo sapiens 27-32 16088225-5 2005 These results indicate that the increased anoxic tolerance, which is induced by HP in cultured hippocampal cells, may be correlated with Bcl-2 overexpression and enhanced stability of MMP, which ultimately reduces apoptosis 24 h after reoxygenation. Hematoporphyrins 80-82 BCL2 apoptosis regulator Homo sapiens 137-142 15583801-13 2005 Our results indicated that ursolic acid induced apoptotic processes in the endometrial cancer SNG-II cell line through mechanisms involving mitochondrial pathways and Bcl-2 family proteins. ursolic acid 27-39 BCL2 apoptosis regulator Homo sapiens 167-172 15860445-7 2005 However, beta-carotene-induced expression changes of BAX and other BCL2 pathway genes did not lead to the predicted induction of apoptosis in the A375 cells. beta Carotene 9-22 BCL2 apoptosis regulator Homo sapiens 67-71 16190549-7 2005 IFNa2b+RBV therapy diminished bcl2 positive cell percentage, specifically in patients with eliminated HCV. Ribavirin 7-10 BCL2 apoptosis regulator Homo sapiens 30-34 15389812-9 2005 In addition, and compared to CDDP, DACH-Ac-Pt was more effective in inducing Bax and increasing the Bax/Bcl-2 ratios in both the tumor models. dach-ac-pt 35-45 BCL2 apoptosis regulator Homo sapiens 104-109 15714803-4 2005 Apoptotic bodies and DNA ladder were observed in 5 micromol x L(-1) pseudolaric acid B-treated A375-S2 cells for 36 h. The expression of Bcl-2, Bcl-xL and ICAD was reduced time dependently, whereas the expression of Bax was increased. pseudolaric acid B 68-86 BCL2 apoptosis regulator Homo sapiens 137-142 15389812-11 2005 The differential induction of p21(WAF1/CIP1) and increase in Bax/Bcl-2 ratios with CDDP and DACH-Ac-Pt in LNCaP-LN3 cells appear to be linked to the relative activity of the two agents against this model. cddp 83-87 BCL2 apoptosis regulator Homo sapiens 65-70 15389812-11 2005 The differential induction of p21(WAF1/CIP1) and increase in Bax/Bcl-2 ratios with CDDP and DACH-Ac-Pt in LNCaP-LN3 cells appear to be linked to the relative activity of the two agents against this model. dach-ac-pt 92-102 BCL2 apoptosis regulator Homo sapiens 65-70 16456730-1 2005 The aim of this study was to determine the expression of Bcl-2 gene and prognostic importance of Bcl-2 expression in paraffin embedded blocks of patients diagnosed with non-small cell lung cancer (NSCLC). Paraffin 117-125 BCL2 apoptosis regulator Homo sapiens 97-102 15862030-5 2005 RESULTS: Tea polyphenols and tea pigments induced the appearance of DNA-LADDER; Western blot analysis demonstrated that Bcl-2 expression was significantly inhibited and the expression of Bax was significantly induced by tea polyphenols and tea pigments. Polyphenols 13-24 BCL2 apoptosis regulator Homo sapiens 120-125 15862030-5 2005 RESULTS: Tea polyphenols and tea pigments induced the appearance of DNA-LADDER; Western blot analysis demonstrated that Bcl-2 expression was significantly inhibited and the expression of Bax was significantly induced by tea polyphenols and tea pigments. Polyphenols 224-235 BCL2 apoptosis regulator Homo sapiens 120-125 16438800-6 2005 Upon exposure to heat shock, NtBHA pre-treated cells showed significant inhibition of apoptotic features such as activation of caspase-3, up-regulation of Bax, and down-regulation of Bcl-2 compared to untreated cells. N-tert-butylhydroxylamine 29-34 BCL2 apoptosis regulator Homo sapiens 183-188 15665588-5 2004 In addition, Bcl-2 expression was down-regulated while Bax protein level was up-regulated.Caspase-3 inhibitor, z-DEVD-fmk, partially blocked pseudolaric acid B-induced cell death, and the expression of two classical caspase substrates,PARP and ICAD, were both decreased in a time-dependent manner, indicative of downstream cas-pase activation. benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone 111-121 BCL2 apoptosis regulator Homo sapiens 13-18 15471874-2 2004 A Bcl-2 mutant lacking its BH4 domain (Delta BH4) also inhibited transcription, whereas a Bcl-2 mutant lacking its transmembrane domain (Delta TM) was ineffective. sapropterin 27-30 BCL2 apoptosis regulator Homo sapiens 2-7 15471874-2 2004 A Bcl-2 mutant lacking its BH4 domain (Delta BH4) also inhibited transcription, whereas a Bcl-2 mutant lacking its transmembrane domain (Delta TM) was ineffective. sapropterin 45-48 BCL2 apoptosis regulator Homo sapiens 2-7 15665588-5 2004 In addition, Bcl-2 expression was down-regulated while Bax protein level was up-regulated.Caspase-3 inhibitor, z-DEVD-fmk, partially blocked pseudolaric acid B-induced cell death, and the expression of two classical caspase substrates,PARP and ICAD, were both decreased in a time-dependent manner, indicative of downstream cas-pase activation. pseudolaric acid B 141-159 BCL2 apoptosis regulator Homo sapiens 13-18 15471874-4 2004 Subcellular localization studies showed that under conditions of transient transfection, the active Bcl-2 forms (wild type and Delta BH4) were predominantly found in the nuclear fraction, whereas the non-active forms (Delta TM, MaoB, and cytochrome b(5)) were in the non-nuclear fraction. sapropterin 133-136 BCL2 apoptosis regulator Homo sapiens 100-105 15588281-0 2004 Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities. Dexamethasone 0-13 BCL2 apoptosis regulator Homo sapiens 110-115 15623615-2 2004 G3139 (Genasense) is a phosphorothioate anti-Bcl-2 antisense oligonucleotide, but its mechanism of action is uncertain. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 45-50 15623615-2 2004 G3139 (Genasense) is a phosphorothioate anti-Bcl-2 antisense oligonucleotide, but its mechanism of action is uncertain. Parathion 23-39 BCL2 apoptosis regulator Homo sapiens 45-50 15623615-2 2004 G3139 (Genasense) is a phosphorothioate anti-Bcl-2 antisense oligonucleotide, but its mechanism of action is uncertain. Oligonucleotides 61-76 BCL2 apoptosis regulator Homo sapiens 45-50 15623615-6 2004 A 518A2 melanoma cell line stably overexpressing Bcl-2 protein was constructed and treated with either these cytotoxic agents or G3139. oblimersen 129-134 BCL2 apoptosis regulator Homo sapiens 49-54 15623615-8 2004 In addition, in the Bcl-2-overexpressing cells, only a modest increment in chemoresistance was observed, and treatment with G3139 not only did not down-regulate Bcl-2 expression but produced essentially identical toxicity as was observed in the wild-type or mock-transfected cells. oblimersen 124-129 BCL2 apoptosis regulator Homo sapiens 161-166 15588281-7 2004 Western blot analyses showed alternations in the levels of Bax (pro-apoptotic) and Bcl-2 (anti-apoptotic) proteins resulting in increased Bax:Bcl-2 ratio in TMZ treated cells. Temozolomide 157-160 BCL2 apoptosis regulator Homo sapiens 142-147 15588281-9 2004 However, 1-h pretreatment of cells with 40 microM DXM dramatically decreased TMZ induced apoptosis, decreasing Bax:Bcl-2 ratio and SBDPs. Dexamethasone 50-53 BCL2 apoptosis regulator Homo sapiens 115-120 15585172-2 2004 Antisense oligodeoxynucleotides, and more recently small molecule ligands for BCL-2 and BCL-XL, are directly cytotoxic or synergistic with standard cytotoxic agents, and in some cases, may demonstrate selectivity for tumor cells. Oligodeoxyribonucleotides 10-31 BCL2 apoptosis regulator Homo sapiens 78-83 15588281-0 2004 Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities. Temozolomide 60-72 BCL2 apoptosis regulator Homo sapiens 110-115 15588281-7 2004 Western blot analyses showed alternations in the levels of Bax (pro-apoptotic) and Bcl-2 (anti-apoptotic) proteins resulting in increased Bax:Bcl-2 ratio in TMZ treated cells. Temozolomide 157-160 BCL2 apoptosis regulator Homo sapiens 83-88 15480664-4 2004 In this study, we demonstrated that sodium selenite could induce apoptosis in NB4 cells via the classic mitochondrial pathway involving caspase-3 activation and Bcl-2 cleavage. Sodium Selenite 36-51 BCL2 apoptosis regulator Homo sapiens 161-166 15489891-6 2004 Analysis of cytochrome c release also confirmed that in Bcl-2- or Bcl-x(L)-expressing cells apoptosis could be detected by terminal deoxynucleotidyl-transferase mediated dUTP nick-end labelling (TUNEL) assay before any evidence of mitochondrial membrane perturbation. deoxyuridine triphosphate 170-174 BCL2 apoptosis regulator Homo sapiens 56-61 15601545-11 2004 Bcl-2 phosphorylation levels were higher in the combination groups than in vincristine or asiaticoside alone groups. Vincristine 75-86 BCL2 apoptosis regulator Homo sapiens 0-5 15601545-11 2004 Bcl-2 phosphorylation levels were higher in the combination groups than in vincristine or asiaticoside alone groups. asiaticoside 90-102 BCL2 apoptosis regulator Homo sapiens 0-5 15536330-3 2004 Formalin-fixed, paraffin-embedded tissue was immunostained with antibodies to p53, p27, phospho-AKT, and bcl-2 using the avidin-biotin-peroxidase method and tissue microarray technique. Formaldehyde 0-8 BCL2 apoptosis regulator Homo sapiens 105-110 15659818-0 2004 Docosahexaenoic acid from a cultured microalga inhibits cell growth and induces apoptosis by upregulating Bax/Bcl-2 ratio in human breast carcinoma MCF-7 cells. Docosahexaenoic Acids 0-20 BCL2 apoptosis regulator Homo sapiens 110-115 15659818-6 2004 Results from this study suggest that DHA from the cultured microalga is also effective in controlling cancer cell growth and that downregulation of antiapoptotic Bcl-2 is an important step in the induced apoptosis. Docosahexaenoic Acids 37-40 BCL2 apoptosis regulator Homo sapiens 162-167 15659824-3 2004 This study examined genistein-induced apoptosis through the regulation of bcl-2 and bax expression in the presence of estrogen. Genistein 20-29 BCL2 apoptosis regulator Homo sapiens 74-79 15574790-1 2004 The addition of B-cell lymphoma 2 (Bcl-2) antisense to dacarbazine in the treatment of metastatic melanoma demonstrates improved response rates and progression-free survival when compared with dacarbazine alone. Dacarbazine 193-204 BCL2 apoptosis regulator Homo sapiens 16-33 15566355-6 2004 Downregulation of Bcl-2 by G3139 was associated with a higher degree of rituximab-associated, complement-mediated cytotoxicity and antibody dependent cellular cytotoxicity when compared with rituximab alone-treated controls. oblimersen 27-32 BCL2 apoptosis regulator Homo sapiens 18-23 15503311-3 2004 The down-regulation of Bcl-2 protein by the antisense (AS) Bcl-2 (oblimesen sodium) may be a useful method for targeting the antiapoptotic protein and thereby increasing the chemotherapeutic effect of anticancer drugs. oblimesen sodium 66-82 BCL2 apoptosis regulator Homo sapiens 23-28 15503311-3 2004 The down-regulation of Bcl-2 protein by the antisense (AS) Bcl-2 (oblimesen sodium) may be a useful method for targeting the antiapoptotic protein and thereby increasing the chemotherapeutic effect of anticancer drugs. oblimesen sodium 66-82 BCL2 apoptosis regulator Homo sapiens 59-64 15572177-5 2004 Accordingly, activation of this signaling by lithium or Wnt ligands in AD-experimental animal models or in primary hippocampal neurons attenuate A beta neurotoxicity by recovering beta-catenin levels and Wnt-target gene expression of survival genes such as bcl-2. Lithium 45-52 BCL2 apoptosis regulator Homo sapiens 257-262 15574790-1 2004 The addition of B-cell lymphoma 2 (Bcl-2) antisense to dacarbazine in the treatment of metastatic melanoma demonstrates improved response rates and progression-free survival when compared with dacarbazine alone. Dacarbazine 193-204 BCL2 apoptosis regulator Homo sapiens 35-40 15585074-0 2004 Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer. Tamoxifen 52-61 BCL2 apoptosis regulator Homo sapiens 30-35 15585074-4 2004 Bcl-2 expression was evaluated and correlated with response to adjuvant tamoxifen and survival. Tamoxifen 72-81 BCL2 apoptosis regulator Homo sapiens 0-5 15585074-10 2004 Despite its being a retrospective nonrandomized study with a relatively low number of patients, our results suggest that Bcl-2 deserves further evaluation as a predictive factor of sensitivity to tamoxifen. Tamoxifen 196-205 BCL2 apoptosis regulator Homo sapiens 121-126 15577317-2 2004 METHODS: The expression of p53 and Bcl-2 protein was assessed by immunohistochemistry from paraffin blocks. Paraffin 91-99 BCL2 apoptosis regulator Homo sapiens 35-40 15571967-4 2004 Western blots for Bcl-2 and c-IAP1 showed increased levels of these anti-apoptotic proteins in cells incubated with doxorubicin, in accordance with NF-kappaB/Rel activation, while rapamycin clearly downmodulated these proteins, in line with its pro-apoptotic ability. Doxorubicin 116-127 BCL2 apoptosis regulator Homo sapiens 18-23 15571967-4 2004 Western blots for Bcl-2 and c-IAP1 showed increased levels of these anti-apoptotic proteins in cells incubated with doxorubicin, in accordance with NF-kappaB/Rel activation, while rapamycin clearly downmodulated these proteins, in line with its pro-apoptotic ability. Sirolimus 180-189 BCL2 apoptosis regulator Homo sapiens 18-23 15627060-5 2004 Bcl-2 expression was lower in non-sclerosing non-encapsulated (NSNE) (25%) cases of PMCs than in non-sclerosing encapsulated (NSE) (57.15%) cases of PTMCs (p < 0.05). nsne 63-67 BCL2 apoptosis regulator Homo sapiens 0-5 15627060-5 2004 Bcl-2 expression was lower in non-sclerosing non-encapsulated (NSNE) (25%) cases of PMCs than in non-sclerosing encapsulated (NSE) (57.15%) cases of PTMCs (p < 0.05). ptmcs 149-154 BCL2 apoptosis regulator Homo sapiens 0-5 15582135-9 2004 Finally, gefitinib suppressed the expression of antiapoptotic Bcl-2 and Bcl-X(L), further rendering HCC cells prone to apoptosis. Gefitinib 9-18 BCL2 apoptosis regulator Homo sapiens 62-67 15569266-5 2004 The effects of C2-ceramide and PACAP on Bax and Bcl-2 were blocked, respectively, by the JNK inhibitor L-JNKI1 and the MEK inhibitor U0126. N-acetylsphingosine 15-26 BCL2 apoptosis regulator Homo sapiens 48-53 15569266-5 2004 The effects of C2-ceramide and PACAP on Bax and Bcl-2 were blocked, respectively, by the JNK inhibitor L-JNKI1 and the MEK inhibitor U0126. L-JNKI-1 103-110 BCL2 apoptosis regulator Homo sapiens 48-53 15569266-5 2004 The effects of C2-ceramide and PACAP on Bax and Bcl-2 were blocked, respectively, by the JNK inhibitor L-JNKI1 and the MEK inhibitor U0126. U 0126 133-138 BCL2 apoptosis regulator Homo sapiens 48-53 15569266-8 2004 U0126 blocked PACAP-induced Bcl-2 expression, abrogated the inhibitory effect of PACAP on ceramide-induced caspase-9 activity, and promoted granule cell death. U 0126 0-5 BCL2 apoptosis regulator Homo sapiens 28-33 15569266-9 2004 The present study reveals that C2-ceramide and PACAP exert opposite effects on Bax and Bcl-2 through, respectively, JNK- and ERK-dependent mechanisms. N-acetylsphingosine 31-42 BCL2 apoptosis regulator Homo sapiens 87-92 15513900-8 2004 Our data suggest that the inhibitory effect of phthalates on TAM-induced apoptosis involves an increase in intracellular Bcl-2 to Bax ratio. Tamoxifen 61-64 BCL2 apoptosis regulator Homo sapiens 121-126 15634664-3 2004 Antisense oligonucleotides (AS-ODNs) that down-regulate BCL-2 expression induce apoptosis and chemosensitize B-cell lymphoma cells. Oligonucleotides 10-26 BCL2 apoptosis regulator Homo sapiens 56-61 15638966-3 2004 Bortezomib targets pathways relevant to tumor progression and therapy resistance and can directly modulate expression of cyclins, p27kip1, p53, nuclear factor-kB, Bcl-2, and Bax. Bortezomib 0-10 BCL2 apoptosis regulator Homo sapiens 163-168 15528043-0 2004 Bcl-2 family proteins regulate mitochondrial reactive oxygen production and protect against oxidative stress. reactive oxygen 45-60 BCL2 apoptosis regulator Homo sapiens 0-5 15528043-7 2004 Our results indicate that chronic and mild elevations in H(2)O(2) release from Bcl-2, Bcl-xL, and Mcl-1 overexpressing mitochondria lead to enhanced cellular antioxidant defense and protection against death caused by acute oxidative stress. Hydrogen Peroxide 57-65 BCL2 apoptosis regulator Homo sapiens 79-84 15547708-8 2004 Furthermore, bax mRNA level was up-regulated whereas a decline in Bcl-2 both protein and mRNA levels were detected in NaBu-treated cells. sethoxydim 118-122 BCL2 apoptosis regulator Homo sapiens 66-71 15844663-0 2004 Effect of arsenic trioxide (ATO) on human lung carcinoma PG cell line: ATO induced apoptosis of PG cells and decreased expression of Bcl-2, Pgp. Arsenic Trioxide 10-26 BCL2 apoptosis regulator Homo sapiens 133-138 15844663-0 2004 Effect of arsenic trioxide (ATO) on human lung carcinoma PG cell line: ATO induced apoptosis of PG cells and decreased expression of Bcl-2, Pgp. Arsenic Trioxide 71-74 BCL2 apoptosis regulator Homo sapiens 133-138 15844663-7 2004 ATO significantly inhibited Bcl-2 and Pgp expression of PG cells by SABC immunohistochemistry and FCM analysis. Arsenic Trioxide 0-3 BCL2 apoptosis regulator Homo sapiens 28-33 15844663-8 2004 In conclusion, our findings indicated that ATO induced apoptosis of PG cells and down-regulation of Bcl-2 and Pgp expressions, and these data might provide some theoretical basis for its clinical use in treating lung carcinoma. Arsenic Trioxide 43-46 BCL2 apoptosis regulator Homo sapiens 100-105 15634644-0 2004 The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. alvocidib 73-85 BCL2 apoptosis regulator Homo sapiens 19-24 15634644-0 2004 The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. Free Radicals 164-176 BCL2 apoptosis regulator Homo sapiens 19-24 15634644-1 2004 Interactions between the cyclin-dependent kinase inhibitor flavopiridol and the small-molecule Bcl-2 antagonist HA14-1 were examined in human multiple myeloma cells. alvocidib 59-71 BCL2 apoptosis regulator Homo sapiens 95-100 15504352-8 2004 In addition, exogenous expression of Bcl-2 desensitized SK-N-SH-MJD78 cells to poly-Q toxicity. polyglutamine 79-85 BCL2 apoptosis regulator Homo sapiens 37-42 15539052-5 2004 The protein expressions of cytochrome c and Bcl-2 were analyzed by Western blotting after the EGCG treatment. epigallocatechin gallate 94-98 BCL2 apoptosis regulator Homo sapiens 44-49 15539052-7 2004 EGCG raised the activities of caspase-9, enhanced the releasing of cytochrome c from the mitochondria, and suppressed the protein expression of Bcl-2. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 144-149 15631654-0 2004 [A novel bcl-2 antisense oligodeoxynucleotide F951 increases sensitivity of HL-60 cells to Ara-C]. Oligodeoxyribonucleotides 25-45 BCL2 apoptosis regulator Homo sapiens 9-14 15631654-0 2004 [A novel bcl-2 antisense oligodeoxynucleotide F951 increases sensitivity of HL-60 cells to Ara-C]. Cytarabine 91-96 BCL2 apoptosis regulator Homo sapiens 9-14 15454307-0 2004 Polychlorinated biphenyl mixtures (Aroclors) induce apoptosis via Bcl-2, Bax and caspase-3 proteins in neuronal cell cultures. polychlorinated biphenyl mixtures 0-33 BCL2 apoptosis regulator Homo sapiens 66-71 15454307-0 2004 Polychlorinated biphenyl mixtures (Aroclors) induce apoptosis via Bcl-2, Bax and caspase-3 proteins in neuronal cell cultures. Aroclors 35-43 BCL2 apoptosis regulator Homo sapiens 66-71 15454307-10 2004 The results indicate that the increase in Aroclor-induced apoptosis correlates with a reduction in the expression of antiapoptotic Bcl-2 and an increase in the expression of proapoptotic Bax. Aroclors 42-49 BCL2 apoptosis regulator Homo sapiens 131-136 15454307-11 2004 These results suggest that, with our experimental conditions, Aroclors induce apoptosis in primary cultures of cortical neurons via proteins of the Bcl-2 and caspase families. Aroclors 62-70 BCL2 apoptosis regulator Homo sapiens 148-153 15799240-6 2004 In this article we discuss how this may be achieved by lowering Bcl-2 anti-apoptotic protein expression using antisense oligonucleotides or, alternatively, by functionally antagonizing Bcl-2 using ligands of the mitochondrial benzodiazepine receptor. Oligonucleotides 120-136 BCL2 apoptosis regulator Homo sapiens 64-69 15504352-10 2004 In our cellular model, full-length expanded ataxin-3 that leads to neurodegenerative disorders significantly impaired the expression of Bcl-2 protein, which may be, at least in part, responsible for the weak tolerance to polyglutamine toxicity at the early stage of disease and ultimately resulted in an increase of stress-induced cell death upon apoptotic stress. polyglutamine 221-234 BCL2 apoptosis regulator Homo sapiens 136-141 15570010-3 2004 (-)-Gossypol, the levorotatory isomer of a natural product isolated from cottonseeds and roots, was recently discovered to bind to the BH3 binding groove of Bcl-xL and Bcl-2. Gossypol 0-12 BCL2 apoptosis regulator Homo sapiens 168-173 15663230-8 2004 CONCLUSION: PA may induce cell death on hepatocytes via mitochondria-mediated apoptosis by reducing the level of Bcl-2/Bax. Palmitic Acid 12-14 BCL2 apoptosis regulator Homo sapiens 113-118 15556132-4 2004 The antiapoptotic action of echinacoside was partially dependent on antioxidative stress effects, maintenance of mitochondria function, inhibition of caspase-3 activity and was also associated with increasing the expression of the antiapoptotic protein Bcl2. echinacoside 28-40 BCL2 apoptosis regulator Homo sapiens 253-257 15480430-5 2004 In resveratrol-treated cells, tumor necrosis factor (TNF), anti-CD95 antibodies and TNF-related apoptosis-inducing ligand (TRAIL) activate a caspase-dependent death pathway that escapes Bcl-2-mediated inhibition. Resveratrol 3-14 BCL2 apoptosis regulator Homo sapiens 186-191 15488634-6 2004 Our results demonstrated that genistein inhibited the viability of human colon cancer HT-29 cell via induction of apoptosis mainly through regulation of p21WAF1 and Bax/Bcl-2 expression. Genistein 30-39 BCL2 apoptosis regulator Homo sapiens 169-174 15535974-5 2004 Fucoxanthin suppressed the level of Bcl-2 protein. fucoxanthin 0-11 BCL2 apoptosis regulator Homo sapiens 36-41 15476281-2 2004 METHODS: AS bcl-2 was used with 18-mer phosphorothiated oligonucleotides in the MKN-45 gastric carcinoma cell line. Oligonucleotides 56-72 BCL2 apoptosis regulator Homo sapiens 12-17 15476281-5 2004 AS bcl-2 in vitro was treated with lipofectin, whereas it was administered intraperitoneally for 6 consecutive days twice every 2 weeks in vivo. 1,2-dielaidoylphosphatidylethanolamine 35-45 BCL2 apoptosis regulator Homo sapiens 3-8 15476281-7 2004 RESULTS: bcl-2 was down-regulated to 60% of its initial value after treatment with 1.0 muM AS bcl-2 compared with the controls of random and mismatched oligonucleotides. Oligonucleotides 152-168 BCL2 apoptosis regulator Homo sapiens 9-14 15476281-8 2004 Drug sensitivity to doxorubicin, cisplatin, and paclitaxel (TXL) was increased 3-4-fold when used in combination with AS bcl-2, which was determined with 50% inhibitory concentration values, compared with the control group. Doxorubicin 20-31 BCL2 apoptosis regulator Homo sapiens 121-126 15476281-8 2004 Drug sensitivity to doxorubicin, cisplatin, and paclitaxel (TXL) was increased 3-4-fold when used in combination with AS bcl-2, which was determined with 50% inhibitory concentration values, compared with the control group. Cisplatin 33-42 BCL2 apoptosis regulator Homo sapiens 121-126 15476281-8 2004 Drug sensitivity to doxorubicin, cisplatin, and paclitaxel (TXL) was increased 3-4-fold when used in combination with AS bcl-2, which was determined with 50% inhibitory concentration values, compared with the control group. Paclitaxel 48-58 BCL2 apoptosis regulator Homo sapiens 121-126 15476281-10 2004 The antitumor effect of cisplatin and TXL in vivo was enhanced significantly in combination with AS bcl-2. Cisplatin 24-33 BCL2 apoptosis regulator Homo sapiens 100-105 15476281-12 2004 CONCLUSIONS: Combination treatment with AS bcl-2 and anticancer drugs, including cisplatin and TXL, may be a new strategy for enhancing chemotherapeutic effects in the treatment of gastric carcinoma. Cisplatin 81-90 BCL2 apoptosis regulator Homo sapiens 43-48 15569999-2 2004 Reducing Bcl-2 protein levels by using antisense oligonucleotides targeting the gene message can increase the sensitivity of cancer cells to cytotoxic agents. Oligonucleotides 49-65 BCL2 apoptosis regulator Homo sapiens 9-14 15569999-3 2004 The objective of this work was to investigate the antitumor efficacy of the Bcl-2 antisense oligonucleotide oblimersen (Genasense; G3139), alone and in combination with vinorelbine (VNB), in an ectopic and orthotopic xenograft model of NCI-H460 human non-small-cell lung cancer. Oligonucleotides 92-107 BCL2 apoptosis regulator Homo sapiens 76-81 15570009-0 2004 Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells. Oligonucleotides 117-133 BCL2 apoptosis regulator Homo sapiens 83-88 15389877-7 2004 Indeed, 1,25(OH)2D3 treatment increased levels of the anti-apoptotic protein Bcl-2 and decreased levels of the pro-apoptotic proteins Bax and Bad in a time- and dose-dependent way. Calcitriol 8-19 BCL2 apoptosis regulator Homo sapiens 77-82 15389877-8 2004 Induction of Bcl-2 by 1,25(OH)2D3 was further shown to be mediated by ERK and, to a lesser extent, by Akt. Calcitriol 22-33 BCL2 apoptosis regulator Homo sapiens 13-18 15389877-9 2004 In conclusion, 1,25(OH)2D3 clearly protects keratinocytes against apoptosis (1) by activating the MEK/ERK and the PI-3K/Akt survival pathways and (2) by increasing the Bcl-2 to Bax and Bad ratio. Calcitriol 15-26 BCL2 apoptosis regulator Homo sapiens 168-173 15570009-7 2004 AS-4625 treatment of BT474 cells decreased both Bcl-2 and Bcl-XL expression, resulting in a 21 +/- 7% net apoptosis induction; the combination of AS-4625 followed by trastuzumab resulted in a significantly stronger induction of apoptosis (37 +/- 6%, P <0.01) that was not observed with the reverse treatment sequence (trastuzumab followed by AS-4625). as-4625 0-7 BCL2 apoptosis regulator Homo sapiens 48-53 15570010-3 2004 (-)-Gossypol, the levorotatory isomer of a natural product isolated from cottonseeds and roots, was recently discovered to bind to the BH3 binding groove of Bcl-xL and Bcl-2. BH 3 135-138 BCL2 apoptosis regulator Homo sapiens 168-173 15570009-7 2004 AS-4625 treatment of BT474 cells decreased both Bcl-2 and Bcl-XL expression, resulting in a 21 +/- 7% net apoptosis induction; the combination of AS-4625 followed by trastuzumab resulted in a significantly stronger induction of apoptosis (37 +/- 6%, P <0.01) that was not observed with the reverse treatment sequence (trastuzumab followed by AS-4625). Arsenic 0-2 BCL2 apoptosis regulator Homo sapiens 48-53 15474552-3 2004 In this study, GFP-Bax over-expression system showed that Bax, pro-apoptotic Bcl-2 family protein, was translocated to mitochondria by the presence of GJBRH. gjbrh 151-156 BCL2 apoptosis regulator Homo sapiens 77-82 15525476-9 2004 The expression levels of protein p53 and Bcl-2 decreased following 2-methoxyestradiol treatment in CNE2 cells, whereas Bax and p21(WAF1) protein expression were unaffected after treatment with 2-methoxyestradiol. 2-Methoxyestradiol 67-85 BCL2 apoptosis regulator Homo sapiens 41-46 15514848-0 2004 Suppression of bcl-2 gene by RNA interference increases chemosensitivity to cisplatin in nasopharyngeal carcinoma cell line CNE1. Cisplatin 76-85 BCL2 apoptosis regulator Homo sapiens 15-20 15514848-4 2004 The results showed that: stable transfection of CNE1 cells with vectors expressing shRNAs against bcl-2 decreased the expression of BCL-2 protein; suppression of BCL-2 expression did not affect cell proliferation but could increase the chemosensitivity to cisplatin in CNE1 cells. Cisplatin 256-265 BCL2 apoptosis regulator Homo sapiens 98-103 15514848-4 2004 The results showed that: stable transfection of CNE1 cells with vectors expressing shRNAs against bcl-2 decreased the expression of BCL-2 protein; suppression of BCL-2 expression did not affect cell proliferation but could increase the chemosensitivity to cisplatin in CNE1 cells. Cisplatin 256-265 BCL2 apoptosis regulator Homo sapiens 162-167 15525476-10 2004 CONCLUSION: These results suggest that 2-methoxyestradiol induced cell cycle arrest at G2/M phase and apoptosis of CNE2 cells which was associated to Bcl-2 down-regulation. 2-Methoxyestradiol 39-57 BCL2 apoptosis regulator Homo sapiens 150-155 15450950-0 2004 Cadmium induces apoptotic cell death in WI 38 cells via caspase-dependent Bid cleavage and calpain-mediated mitochondrial Bax cleavage by Bcl-2-independent pathway. Cadmium 0-7 BCL2 apoptosis regulator Homo sapiens 138-143 15505422-6 2004 Bcl-2/bclxL-specific antisense oligonucleotides restored the sensitivity of SK-OV-3 cells to apoptosis induction by rapamycin and RAD001. Oligonucleotides 31-47 BCL2 apoptosis regulator Homo sapiens 0-5 15505422-6 2004 Bcl-2/bclxL-specific antisense oligonucleotides restored the sensitivity of SK-OV-3 cells to apoptosis induction by rapamycin and RAD001. Sirolimus 116-125 BCL2 apoptosis regulator Homo sapiens 0-5 15505422-7 2004 These results indicate that baseline Bcl-2 expression and therapy-induced downexpression of CCND1 and CDK4 may be regarded as molecular markers enabling the prediction and follow-up of the cellular effects on cell cycle and apoptosis induction of rapamycin in ovarian cancer. Sirolimus 247-256 BCL2 apoptosis regulator Homo sapiens 37-42 15450950-9 2004 Cd induced the upregulation of Bcl-2 and the degradation of p53 protein. Cadmium 0-2 BCL2 apoptosis regulator Homo sapiens 31-36 15576332-0 2004 mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Carboplatin 165-176 BCL2 apoptosis regulator Homo sapiens 98-102 15576332-0 2004 mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Doxorubicin 181-192 BCL2 apoptosis regulator Homo sapiens 98-102 15576332-10 2004 In the case of carboplatin-induced apoptosis we detected down-regulation of BAX , BCL2 and caspase-9, whereas in the case of doxorubicin, BAX and BCL2 remained at control levels and caspase-9 was increased. Carboplatin 15-26 BCL2 apoptosis regulator Homo sapiens 82-86 15576332-10 2004 In the case of carboplatin-induced apoptosis we detected down-regulation of BAX , BCL2 and caspase-9, whereas in the case of doxorubicin, BAX and BCL2 remained at control levels and caspase-9 was increased. Carboplatin 15-26 BCL2 apoptosis regulator Homo sapiens 146-150 15546508-5 2004 Both ASA and indomethacin reduced the protein levels of Bcl-2 and Bcl-xl, but upregulated those of Bax and Bcl-xs. Aspirin 5-8 BCL2 apoptosis regulator Homo sapiens 56-61 15543656-9 2004 HMBA,used at cytostatic concentrations, reduced the ratio be-tween antiapoptotic (Bcl-2, Bcl-XL) and proapoptotic(Bax) members of the Bcl-2 family of proteins, thus lowering the threshold for MM cell death commitment. Polysorbates 61-66 BCL2 apoptosis regulator Homo sapiens 82-87 15543656-9 2004 HMBA,used at cytostatic concentrations, reduced the ratio be-tween antiapoptotic (Bcl-2, Bcl-XL) and proapoptotic(Bax) members of the Bcl-2 family of proteins, thus lowering the threshold for MM cell death commitment. Polysorbates 61-66 BCL2 apoptosis regulator Homo sapiens 134-139 15520199-7 2004 Cells overexpressing Bcl-2 were markedly resistant to CDDO-induced apoptosis. 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid 54-58 BCL2 apoptosis regulator Homo sapiens 21-26 15520201-3 2004 We have designed and synthesized a small molecule inhibitor of Bcl-2, named YC137, and studied its role in cancer cells. YC137 76-81 BCL2 apoptosis regulator Homo sapiens 63-68 15520201-4 2004 In vitro studies showed that YC137 inhibits the binding of the Bid BH3 peptide to Bcl-2, thus disrupting an interaction essential for the antiapoptotic activity of Bcl-2. YC137 29-34 BCL2 apoptosis regulator Homo sapiens 82-87 15546508-5 2004 Both ASA and indomethacin reduced the protein levels of Bcl-2 and Bcl-xl, but upregulated those of Bax and Bcl-xs. Indomethacin 13-25 BCL2 apoptosis regulator Homo sapiens 56-61 15520201-4 2004 In vitro studies showed that YC137 inhibits the binding of the Bid BH3 peptide to Bcl-2, thus disrupting an interaction essential for the antiapoptotic activity of Bcl-2. YC137 29-34 BCL2 apoptosis regulator Homo sapiens 164-169 15566391-9 2004 Cinnamaldehyde also upregulated the expression of pro-apoptotic protein (Bax) and down-regulated the levels of anti-apoptotic proteins, such as Bcl-2 and the inhibitor of apoptosis protein family (X-linked inhibitor of apoptosis protein (XIAP), cellular inhibitor of apoptosis protein (cIAP)-1 and cIAP-2). cinnamaldehyde 0-14 BCL2 apoptosis regulator Homo sapiens 144-149 15566391-15 2004 The expression of apoptotic inhibitors (XIAP, cIAP-1, cIAP-2) and anti-apoptotic (Bcl-2) and pro-apoptotic (Bax) proteins was affected by vitamin E pretreatment. Vitamin E 138-147 BCL2 apoptosis regulator Homo sapiens 82-87 15566391-18 2004 Pretreatment with vitamin E markedly prevented cinnamaldehyde-mediated apoptosis, which was associated with the modulation of XIAP, cIAP-1, cIAP-2, Bcl-2 and Bax protein activity. Vitamin E 18-27 BCL2 apoptosis regulator Homo sapiens 148-153 15578915-7 2004 The release of cytochrome c from mitochondria to the cytosol during apoptosis is mediated by the mitochondrial permeability transition pore, which is a protein complex formed by the voltage-dependent anion channel, members of the pro- and anti- apoptotic Bax-Bcl-2 protein family, cyclophilin D, and adenine nucleotide (ADP/ATP) translocators. Adenine Nucleotides 300-318 BCL2 apoptosis regulator Homo sapiens 259-264 19791424-4 2004 Proteasome inhibition seems to be able to overcome Bcl-2-mediated suppression of apoptosis, P-glycoprotein-mediated multidrug resistance, and inducible resistance through nuclear factor kappa B. Preclinical studies with bortezomib and other agents have provided evidence of sensitization to several classes of chemotherapeutics that are used against multiple myeloma. Bortezomib 220-230 BCL2 apoptosis regulator Homo sapiens 51-56 15578915-7 2004 The release of cytochrome c from mitochondria to the cytosol during apoptosis is mediated by the mitochondrial permeability transition pore, which is a protein complex formed by the voltage-dependent anion channel, members of the pro- and anti- apoptotic Bax-Bcl-2 protein family, cyclophilin D, and adenine nucleotide (ADP/ATP) translocators. Adenosine Diphosphate 320-323 BCL2 apoptosis regulator Homo sapiens 259-264 15578915-7 2004 The release of cytochrome c from mitochondria to the cytosol during apoptosis is mediated by the mitochondrial permeability transition pore, which is a protein complex formed by the voltage-dependent anion channel, members of the pro- and anti- apoptotic Bax-Bcl-2 protein family, cyclophilin D, and adenine nucleotide (ADP/ATP) translocators. Adenosine Triphosphate 324-327 BCL2 apoptosis regulator Homo sapiens 259-264 15479684-11 2004 Sulphasalazine induced T lymphocyte apoptosis was independent of the Fas pathway but associated with marked downregulation of antiapoptotic bcl-xl and bcl2, activation of the mitochondrial apoptosis signalling pathway, and subsequent activation of caspase-9 and caspase-3. Sulfasalazine 0-14 BCL2 apoptosis regulator Homo sapiens 151-155 15501771-3 2004 Initially, we observed that infection of UECs with gentamicin-killed gonococci increased the expression of the antiapoptotic Bcl-2 family member, bfl-1. Gentamicins 51-61 BCL2 apoptosis regulator Homo sapiens 125-130 15651175-4 2004 In vitro, the Bcl-2 antisense drug oblimersen sodium (Genasense, previously known as G3139) enhances the apoptotic response in CLL cells to fludarabine (Fludara), corticosteroids, alemtuzumab (Campath), and rituximab (Rituxan). fludarabine 140-151 BCL2 apoptosis regulator Homo sapiens 14-19 15542778-9 2004 In addition, the combination of bcl-2 antisense oligonucleotides with FR901228 enhanced FR901228-induced caspase-3 activity and cytotoxicity. romidepsin 70-78 BCL2 apoptosis regulator Homo sapiens 32-37 15542778-9 2004 In addition, the combination of bcl-2 antisense oligonucleotides with FR901228 enhanced FR901228-induced caspase-3 activity and cytotoxicity. romidepsin 88-96 BCL2 apoptosis regulator Homo sapiens 32-37 15542778-11 2004 Considering the possible contributions of BCL-2 and BCL-XL to multidrug resistance, FR901228 is a promising agent in the treatment of refractory as well as primary SCLC tumors. romidepsin 84-92 BCL2 apoptosis regulator Homo sapiens 42-47 15651173-1 2004 Most malignant plasma cells overexpress Bcl-2, which contributes to resistance against apoptosis induced by dexamethasone and other anticancer agents. Dexamethasone 108-121 BCL2 apoptosis regulator Homo sapiens 40-45 15492778-8 2004 In addition, it is generally accepted that cytotoxicity of cisplatin is mediated through induction of apoptosis and arrest of cell cycle resulting from its interaction with DNA, such as the formation of cisplatin-DNA adducts, which activates multiple signaling pathways, including those involving p53, Bcl-2 family, caspases, cyclins, CDKs, pRb, PKC, MAPK and PI3K/Akt. Cisplatin 59-68 BCL2 apoptosis regulator Homo sapiens 302-307 15492778-8 2004 In addition, it is generally accepted that cytotoxicity of cisplatin is mediated through induction of apoptosis and arrest of cell cycle resulting from its interaction with DNA, such as the formation of cisplatin-DNA adducts, which activates multiple signaling pathways, including those involving p53, Bcl-2 family, caspases, cyclins, CDKs, pRb, PKC, MAPK and PI3K/Akt. Cisplatin 203-212 BCL2 apoptosis regulator Homo sapiens 302-307 15651173-2 2004 Oblimersen sodium (Genasense, previously known as G3139), an antisense oligonucleotide that specifically binds to bcl-2 messenger RNA, decreases production of Bcl-2 protein in both human myeloma cell lines, as well as in ex vivo purified myeloma cells, and enhances the cytotoxicity of dexamethasone and doxorubicin. oblimersen 0-17 BCL2 apoptosis regulator Homo sapiens 114-119 15651173-2 2004 Oblimersen sodium (Genasense, previously known as G3139), an antisense oligonucleotide that specifically binds to bcl-2 messenger RNA, decreases production of Bcl-2 protein in both human myeloma cell lines, as well as in ex vivo purified myeloma cells, and enhances the cytotoxicity of dexamethasone and doxorubicin. oblimersen 0-17 BCL2 apoptosis regulator Homo sapiens 159-164 15651173-2 2004 Oblimersen sodium (Genasense, previously known as G3139), an antisense oligonucleotide that specifically binds to bcl-2 messenger RNA, decreases production of Bcl-2 protein in both human myeloma cell lines, as well as in ex vivo purified myeloma cells, and enhances the cytotoxicity of dexamethasone and doxorubicin. oblimersen 19-28 BCL2 apoptosis regulator Homo sapiens 114-119 15651173-2 2004 Oblimersen sodium (Genasense, previously known as G3139), an antisense oligonucleotide that specifically binds to bcl-2 messenger RNA, decreases production of Bcl-2 protein in both human myeloma cell lines, as well as in ex vivo purified myeloma cells, and enhances the cytotoxicity of dexamethasone and doxorubicin. oblimersen 19-28 BCL2 apoptosis regulator Homo sapiens 159-164 15651173-2 2004 Oblimersen sodium (Genasense, previously known as G3139), an antisense oligonucleotide that specifically binds to bcl-2 messenger RNA, decreases production of Bcl-2 protein in both human myeloma cell lines, as well as in ex vivo purified myeloma cells, and enhances the cytotoxicity of dexamethasone and doxorubicin. oblimersen 50-55 BCL2 apoptosis regulator Homo sapiens 114-119 15651173-2 2004 Oblimersen sodium (Genasense, previously known as G3139), an antisense oligonucleotide that specifically binds to bcl-2 messenger RNA, decreases production of Bcl-2 protein in both human myeloma cell lines, as well as in ex vivo purified myeloma cells, and enhances the cytotoxicity of dexamethasone and doxorubicin. oblimersen 50-55 BCL2 apoptosis regulator Homo sapiens 159-164 15651173-2 2004 Oblimersen sodium (Genasense, previously known as G3139), an antisense oligonucleotide that specifically binds to bcl-2 messenger RNA, decreases production of Bcl-2 protein in both human myeloma cell lines, as well as in ex vivo purified myeloma cells, and enhances the cytotoxicity of dexamethasone and doxorubicin. Oligonucleotides 71-86 BCL2 apoptosis regulator Homo sapiens 114-119 15557816-3 2004 In this study, the cellular mechanism of Delta(12)-PGJ(2)- induced apoptosis in HeLa cells, specifically, the role of two mitochondrial factors; bcl-2 and apoptosis-inducing factor (AIF) was investigated. delta(12)-prostaglandin J(2) 41-57 BCL2 apoptosis regulator Homo sapiens 145-150 15651175-4 2004 In vitro, the Bcl-2 antisense drug oblimersen sodium (Genasense, previously known as G3139) enhances the apoptotic response in CLL cells to fludarabine (Fludara), corticosteroids, alemtuzumab (Campath), and rituximab (Rituxan). fludarabine 153-160 BCL2 apoptosis regulator Homo sapiens 14-19 15630525-6 2004 Bcl-2 was expressed in all stromal Wilms tumors (11 of 11), all synovial sarcomas (4 of 4), some CCSKs (4 of 9), and none of the cellular mesoblastic nephromas (0 of 12). ccsks 97-102 BCL2 apoptosis regulator Homo sapiens 0-5 15557816-6 2004 One of the earliest events observed in Delta(12)-PGJ(2)-induced apoptotic events was dissipation of Deltapsi(m), the process known to be inhibited by bcl-2. delta(12) 39-48 BCL2 apoptosis regulator Homo sapiens 150-155 15557816-6 2004 One of the earliest events observed in Delta(12)-PGJ(2)-induced apoptotic events was dissipation of Deltapsi(m), the process known to be inhibited by bcl-2. 9-deoxy-delta-9-prostaglandin D2 49-55 BCL2 apoptosis regulator Homo sapiens 150-155 15496290-4 2004 Caseamembrin C induced down-regulation of Bcl-2 and Bcl-xL expression, while up-regulation of proapoptotic protein Mcl-1S (short chain), suggesting that these Bcl-2 family member proteins may play a role on arbitrating the apoptotic cell death. CASEAMEMBRIN C 0-14 BCL2 apoptosis regulator Homo sapiens 42-47 15486085-1 2004 The "BH3-only" proapoptotic BCL-2 family members initiate the intrinsic apoptotic pathway. BH 3 5-8 BCL2 apoptosis regulator Homo sapiens 28-33 15467752-0 2004 Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Fluorouracil 99-103 BCL2 apoptosis regulator Homo sapiens 12-17 15496290-7 2004 Taken together, it is suggested that caseamembrin C-induced apoptosis is predominantly through the activation of intrinsic apoptosis pathways by causing the down-regulation of Bcl-2 and Bcl-xL expression, up-regulation of Mcl-1S protein and activation of caspase-9 and caspase-3. CASEAMEMBRIN C 37-51 BCL2 apoptosis regulator Homo sapiens 176-181 15496290-4 2004 Caseamembrin C induced down-regulation of Bcl-2 and Bcl-xL expression, while up-regulation of proapoptotic protein Mcl-1S (short chain), suggesting that these Bcl-2 family member proteins may play a role on arbitrating the apoptotic cell death. CASEAMEMBRIN C 0-14 BCL2 apoptosis regulator Homo sapiens 159-164 15476743-0 2004 Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. gemcitabine 98-109 BCL2 apoptosis regulator Homo sapiens 53-58 15476743-4 2004 Here, we found that gemcitabine induced an apoptotic cell death via a Bcl-2-dependent caspase-9 activation pathway. gemcitabine 20-31 BCL2 apoptosis regulator Homo sapiens 70-75 15488156-5 2004 Lithium-induced regulation of anti- and pro-apoptotic pathways alters a wide variety of downstream effectors, including beta-catenin, heat shock factor 1, activator protein 1, cAMP-response-element-binding protein, and the Bcl-2 protein family. Lithium 0-7 BCL2 apoptosis regulator Homo sapiens 223-228 15245329-11 2004 The interaction of Bcl-2D21 with SERCA resulted in a conformational transition of SERCA, assessed through a Bcl-2-dependent increase in SERCA thiols available for the labelling with a fluorescent reagent. Sulfhydryl Compounds 142-148 BCL2 apoptosis regulator Homo sapiens 19-24 15245329-11 2004 The interaction of Bcl-2D21 with SERCA resulted in a conformational transition of SERCA, assessed through a Bcl-2-dependent increase in SERCA thiols available for the labelling with a fluorescent reagent. Sulfhydryl Compounds 142-148 BCL2 apoptosis regulator Homo sapiens 108-113 15245329-13 2004 Our results suggest that the direct interaction of Bcl-2 with SERCA may be involved in the regulation of apoptotic processes in vivo through modulation of cytoplasmic and/or endoplasmic reticulum calcium levels required for the execution of apoptosis. Calcium 196-203 BCL2 apoptosis regulator Homo sapiens 51-56 15292226-8 2004 UVA induced expression of the anti-apoptotic Bcl-2 family member, Bcl-XL, with abrogation of expression by using the p38 MAPK inhibitor SB202190. uva 0-3 BCL2 apoptosis regulator Homo sapiens 45-50 15292226-8 2004 UVA induced expression of the anti-apoptotic Bcl-2 family member, Bcl-XL, with abrogation of expression by using the p38 MAPK inhibitor SB202190. 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole 136-144 BCL2 apoptosis regulator Homo sapiens 45-50 15292252-9 2004 Bcl-2 expression was markedly elevated in VEGF-treated HDMECs, and it was significantly inhibited by the PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 120-128 BCL2 apoptosis regulator Homo sapiens 0-5 15197489-9 2004 Paclitaxel slightly decreased the expression of Bcl-2 protein, but antioxidants induced Bcl-2 protein. Paclitaxel 0-10 BCL2 apoptosis regulator Homo sapiens 48-53 15294893-4 2004 The specificity of the CA repeats in terms of destabilizing bcl-2 mRNA was proven by the substituting the CA repeats with other alternative repeats of purine/pyrimidine, but this had no effect on the stability of bcl-2 mRNA. purine 151-157 BCL2 apoptosis regulator Homo sapiens 60-65 15294893-4 2004 The specificity of the CA repeats in terms of destabilizing bcl-2 mRNA was proven by the substituting the CA repeats with other alternative repeats of purine/pyrimidine, but this had no effect on the stability of bcl-2 mRNA. pyrimidine 158-168 BCL2 apoptosis regulator Homo sapiens 60-65 15345651-7 2004 These data are consistent with Bcl-2-mediated inhibition of consumption of glycolytic ATP. Adenosine Triphosphate 86-89 BCL2 apoptosis regulator Homo sapiens 31-36 15453709-0 2004 Induction of apoptosis by shikonin through coordinative modulation of the Bcl-2 family, p27, and p53, release of cytochrome c, and sequential activation of caspases in human colorectal carcinoma cells. shikonin 26-34 BCL2 apoptosis regulator Homo sapiens 74-79 15453709-6 2004 Here, we found that shikonin-induced apoptotic cell death was accompanied by upregulation of p27, p53, and Bad and down-regulation of Bcl-2 and Bcl-X(L), while shikonin had little effect on the levels of Bax protein. shikonin 20-28 BCL2 apoptosis regulator Homo sapiens 134-139 15467450-0 2004 JNK is associated with Bcl-2 and PP1 in mitochondria: paclitaxel induces its activation and its association with the phosphorylated form of Bcl-2. Paclitaxel 54-64 BCL2 apoptosis regulator Homo sapiens 23-28 15466208-2 2004 Rituximab treatment of Bcl-2-deficient Ramos cells and Bcl-2-expressing Daudi cells selectively decreases Bcl-(xL) expression and sensitizes the cells to paclitaxel-induced apoptosis. Paclitaxel 154-164 BCL2 apoptosis regulator Homo sapiens 23-28 15466208-2 2004 Rituximab treatment of Bcl-2-deficient Ramos cells and Bcl-2-expressing Daudi cells selectively decreases Bcl-(xL) expression and sensitizes the cells to paclitaxel-induced apoptosis. Paclitaxel 154-164 BCL2 apoptosis regulator Homo sapiens 55-60 15467449-5 2004 Unexpectedly, enforced expression of p21(Cip1/WAF1) diminished paclitaxel-mediated inactivation of ERK, and reduced paclitaxel-induced activation of JNK as well as Bcl-2 phosphorylation. Paclitaxel 116-126 BCL2 apoptosis regulator Homo sapiens 164-169 15467450-0 2004 JNK is associated with Bcl-2 and PP1 in mitochondria: paclitaxel induces its activation and its association with the phosphorylated form of Bcl-2. Paclitaxel 54-64 BCL2 apoptosis regulator Homo sapiens 140-145 15467450-1 2004 It has been shown that the activation of JNK after paclitaxel-induced microtubule damage is parallel to Bcl-2 phosphorylation, cell cycle arrest in mitosis and apoptosis. Paclitaxel 51-61 BCL2 apoptosis regulator Homo sapiens 104-109 15467450-3 2004 Furthermore, whereas the JNK protein is present in a tripartite complex with the anti-apoptotic Bcl-2 protein and the PP1 phosphatase in mitochondria isolated from control cells, the activated form of JNK was associated with the phosphorylated form of Bcl-2, but devoid of PP1, in mitochondria isolated from paclitaxel-treated cells. Paclitaxel 308-318 BCL2 apoptosis regulator Homo sapiens 96-101 15538973-0 2004 Ectopic expression of clusterin/apolipoprotein J or Bcl-2 decreases the sensitivity of HaCaT cells to toxic effects of ropivacaine. Ropivacaine 119-130 BCL2 apoptosis regulator Homo sapiens 52-57 15467450-6 2004 Bcl-2 phosphorylation was inhibited by CEP 11004, a JNK pathway inhibitor and by immunodepletion of JNK. CEP-11004 39-48 BCL2 apoptosis regulator Homo sapiens 0-5 15538973-7 2004 Ectopic overexpression of the secreted form of clusterin/apoliporotein J or Bcl-2 decreased the sensitivity of HaCaT cells to toxic effects of ropivacaine as demonstrated by DNA fragmentation, the proteolytic cleavage of PARP and by a reduction in procaspase-3 expression. Ropivacaine 143-154 BCL2 apoptosis regulator Homo sapiens 76-81 20368823-8 2004 A significant decrease in Bcl-2 expression and a mild up-regulation of Bax were also observed in both phenylacetate-treated cell lines. phenylacetic acid 102-115 BCL2 apoptosis regulator Homo sapiens 26-31 15467450-7 2004 Taken together, these data show that JNK activation provides a molecular linkage from microtubule damages to the mitochondrial apoptotic machinery and also point to a pivotal role for the JNK/Bcl-2/PP1 complex in the control of apoptosis following paclitaxel treatment. Paclitaxel 248-258 BCL2 apoptosis regulator Homo sapiens 192-197 15390206-11 2004 Further investigation showed that SCCHN cells expressing predominantly mutant p53 and decreased Bcl-2 were more susceptible to cisplatin-induced apoptosis than vector-transfected controls (p < .0001). Cisplatin 127-136 BCL2 apoptosis regulator Homo sapiens 96-101 15485790-0 2004 [Apoptosis and regulation of expressions of apoptosis-related gene Bcl-2 and p53 induced by selenium dioxide in three leukemia cell lines]. Selenium Oxides 92-108 BCL2 apoptosis regulator Homo sapiens 67-72 15485790-1 2004 OBJECTIVE: To investigate the mechanisms underlying the effect of selenium dioxide (SeO(2)) on the proliferation, apoptosis, and apoptosis-related gene expressions of Bcl-2 and p53 in 3 leukemia cell lines NB4, K562 and HL-60. Selenium Oxides 66-82 BCL2 apoptosis regulator Homo sapiens 167-172 15485790-1 2004 OBJECTIVE: To investigate the mechanisms underlying the effect of selenium dioxide (SeO(2)) on the proliferation, apoptosis, and apoptosis-related gene expressions of Bcl-2 and p53 in 3 leukemia cell lines NB4, K562 and HL-60. seo(2) 84-90 BCL2 apoptosis regulator Homo sapiens 167-172 15485790-4 2004 SeO(2) treatment at 30 mmol/L for 48 h induced an apoptosis rate of 54.0 %, 46.5 %, 49.6 % in NB4, K562, and HL-60 cells respectively, and down-regulated Bcl-2 expression in NB4 and K562 but not in HL-60 cells. seo(2) 0-6 BCL2 apoptosis regulator Homo sapiens 154-159 15485790-5 2004 CONCLUSION: SeO(2) can induce apoptosis in NB4, K562 and HL-60 leukemia cells, involving the down-regulation of Bcl-2 and up-regulation of p53. seo(2) 12-18 BCL2 apoptosis regulator Homo sapiens 112-117 15289449-0 2004 Glutathione depletion up-regulates Bcl-2 in BSO-resistant cells. Glutathione 0-11 BCL2 apoptosis regulator Homo sapiens 35-40 15379893-5 2004 Activation of P2Y2 receptors was also coupled to the phosphorylation of cyclic AMP responsive element binding protein that positively regulates bcl-2 and bcl-xl gene expression. Cyclic AMP 72-82 BCL2 apoptosis regulator Homo sapiens 144-149 15375570-4 2004 The knockdown was accomplished by second-generation chimeric antisense oligonucleotides: Bcl-2 and Bcl-xL levels were strongly and reproducibly reduced, as revealed by real-time RT-PCR and Western blot analyses. Oligonucleotides 71-87 BCL2 apoptosis regulator Homo sapiens 89-94 15379893-6 2004 Cyclic AMP responsive element decoy oligonucleotides markedly attenuated the UTP-induced increase in bcl-2 and bcl-xl mRNA levels. Cyclic AMP 0-10 BCL2 apoptosis regulator Homo sapiens 101-106 15379893-6 2004 Cyclic AMP responsive element decoy oligonucleotides markedly attenuated the UTP-induced increase in bcl-2 and bcl-xl mRNA levels. Oligonucleotides 36-52 BCL2 apoptosis regulator Homo sapiens 101-106 15379893-6 2004 Cyclic AMP responsive element decoy oligonucleotides markedly attenuated the UTP-induced increase in bcl-2 and bcl-xl mRNA levels. Uridine Triphosphate 77-80 BCL2 apoptosis regulator Homo sapiens 101-106 15486188-0 2004 Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase. Temozolomide 53-65 BCL2 apoptosis regulator Homo sapiens 101-106 15486192-10 2004 In Bcl-2-overexpressing chronic lymphocytic leukemia cells, the small-molecule Bcl-2 inhibitor HA14-1 sensitized these cells to 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid-induced apoptosis. 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid 128-173 BCL2 apoptosis regulator Homo sapiens 3-8 15486192-10 2004 In Bcl-2-overexpressing chronic lymphocytic leukemia cells, the small-molecule Bcl-2 inhibitor HA14-1 sensitized these cells to 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid-induced apoptosis. 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid 128-173 BCL2 apoptosis regulator Homo sapiens 79-84 15486188-5 2004 Attenuation of Bcl-2 expression can be affected by treatment of cells with the antisense oligonucleotide, oblimersen sodium (Genasense), currently in phase III clinical trials in combination with the methylating agent dacarbazine. Oligonucleotides 89-104 BCL2 apoptosis regulator Homo sapiens 15-20 15486197-7 2004 In addition, paclitaxel, at cytostatic concentrations, early initiates an apoptotic signaling pathway associated with increases in the mitochondrial reducing potential, mitochondrial membrane potential, p53 expression, and Bax/Bcl-2 ratio. Paclitaxel 13-23 BCL2 apoptosis regulator Homo sapiens 227-232 15486188-5 2004 Attenuation of Bcl-2 expression can be affected by treatment of cells with the antisense oligonucleotide, oblimersen sodium (Genasense), currently in phase III clinical trials in combination with the methylating agent dacarbazine. oblimersen 106-123 BCL2 apoptosis regulator Homo sapiens 15-20 15338110-7 2004 Exposure of HUVEC to a high glucose concentration (30 mM) for 48 h markedly increased LDH release and MDA content in the medium and induced apoptosis and Bcl-2 protein expression in HUVEC. Glucose 28-35 BCL2 apoptosis regulator Homo sapiens 154-159 15486188-5 2004 Attenuation of Bcl-2 expression can be affected by treatment of cells with the antisense oligonucleotide, oblimersen sodium (Genasense), currently in phase III clinical trials in combination with the methylating agent dacarbazine. oblimersen 125-134 BCL2 apoptosis regulator Homo sapiens 15-20 15338110-8 2004 Pretreatment with 3,4,5,6-tetrahydroxyxanthone (1, 3 or 10 microM) or probucol (10 microM) significantly decreased the level of LDH and MDA in the medium, reduced apoptosis and increased the expression of Bcl-2 protein in HUVEC. 3,4,5,6-tetrahydroxyxanthone 18-46 BCL2 apoptosis regulator Homo sapiens 205-210 15486188-5 2004 Attenuation of Bcl-2 expression can be affected by treatment of cells with the antisense oligonucleotide, oblimersen sodium (Genasense), currently in phase III clinical trials in combination with the methylating agent dacarbazine. Dacarbazine 218-229 BCL2 apoptosis regulator Homo sapiens 15-20 15338110-8 2004 Pretreatment with 3,4,5,6-tetrahydroxyxanthone (1, 3 or 10 microM) or probucol (10 microM) significantly decreased the level of LDH and MDA in the medium, reduced apoptosis and increased the expression of Bcl-2 protein in HUVEC. Probucol 70-78 BCL2 apoptosis regulator Homo sapiens 205-210 15338110-9 2004 These results suggest that 3,4,5,6-tetrahydroxyxanthone inhibits high-glucose-induced endothelial cell apoptosis by increasing Bcl-2 protein expression in HUVEC. 3,4,5,6-tetrahydroxyxanthone 27-55 BCL2 apoptosis regulator Homo sapiens 127-132 15486188-9 2004 These results suggest that targeting both Bcl-2 with oblimersen and MGMT with PaTrin-2 would markedly enhance the antitumor activity of temozolomide and merits testing in clinical trials. Temozolomide 136-148 BCL2 apoptosis regulator Homo sapiens 42-47 15338110-9 2004 These results suggest that 3,4,5,6-tetrahydroxyxanthone inhibits high-glucose-induced endothelial cell apoptosis by increasing Bcl-2 protein expression in HUVEC. Glucose 70-77 BCL2 apoptosis regulator Homo sapiens 127-132 15544062-8 2004 HEM 30 microM significantly decreased Bcl-2 protein expression to 58.7% in SMMC-7721 and to 57.6% in HO-8910 cells. smmc 75-79 BCL2 apoptosis regulator Homo sapiens 38-43 15560086-3 2004 Here we described binding sense BCL2 oligodeoxynucleotide targeted to translation start of BCL2 mRNA (ODN) with K562 cells. Oligodeoxyribonucleotides 37-57 BCL2 apoptosis regulator Homo sapiens 32-36 15560086-3 2004 Here we described binding sense BCL2 oligodeoxynucleotide targeted to translation start of BCL2 mRNA (ODN) with K562 cells. Oligodeoxyribonucleotides 37-57 BCL2 apoptosis regulator Homo sapiens 91-95 15544062-9 2004 While HCPT 0.5 microM significantly decreased Bcl-2 protein expression to 64.3% in SMMC-7721 and to 70.0% in HO-8910 cells. smmc 83-87 BCL2 apoptosis regulator Homo sapiens 46-51 15498114-7 2004 N, N-dimethylsphingosine, a sphingosine kinase inhibitor, depleted intracellular sphingosine-1-phosphate production, also abrogated Bcl-2 protein expression in K562TC cells, while Bcl-2 protein level in K562 cells was up-regulated by exogenous sphingosine-1-phosphate. N,N-dimethylsphingosine 0-24 BCL2 apoptosis regulator Homo sapiens 180-185 15498114-10 2004 This is the first evidence that mitochondrial ceramidase, through its sphingoid metabolite sphingosine-1-phosphate, up-regulates Bcl-2 protein expression in K562 cells. Sphingosine 70-79 BCL2 apoptosis regulator Homo sapiens 129-134 15498114-0 2004 mitochondrial ceramidase overexpression up-regulates Bcl-2 protein level in K562 cells, probably through its metabolite sphingosine-1-phosphate. sphingosine 1-phosphate 120-143 BCL2 apoptosis regulator Homo sapiens 53-58 15498114-10 2004 This is the first evidence that mitochondrial ceramidase, through its sphingoid metabolite sphingosine-1-phosphate, up-regulates Bcl-2 protein expression in K562 cells. sphingosine 1-phosphate 91-114 BCL2 apoptosis regulator Homo sapiens 129-134 15498114-6 2004 Inhibition of mitochondrial ceramidase expression in K562TC cells by its specific antisense oligodeoxynucleotide was correlated with a decrease in Bcl-2 protein level. Oligodeoxyribonucleotides 92-112 BCL2 apoptosis regulator Homo sapiens 147-152 15498114-7 2004 N, N-dimethylsphingosine, a sphingosine kinase inhibitor, depleted intracellular sphingosine-1-phosphate production, also abrogated Bcl-2 protein expression in K562TC cells, while Bcl-2 protein level in K562 cells was up-regulated by exogenous sphingosine-1-phosphate. N,N-dimethylsphingosine 0-24 BCL2 apoptosis regulator Homo sapiens 132-137 15363891-0 2004 Glutamate mediates cell death and increases the Bax to Bcl-2 ratio in a differentiated neuronal cell line. Glutamic Acid 0-9 BCL2 apoptosis regulator Homo sapiens 55-60 15363891-3 2004 Recent evidence has shown that exposure to excitatory amino acids regulates the expression of the antiapoptotic protein, Bcl-2, and the proapoptotic protein, Bax, in neurons. Excitatory Amino Acids 43-65 BCL2 apoptosis regulator Homo sapiens 121-126 15363891-4 2004 Since it has been suggested that the ratio of Bax to Bcl-2 is an important determinant of neuronal survival, the reciprocal regulation of these Bcl-2 family proteins may play a role in the neurotoxicity mediated by glutamate. Glutamic Acid 215-224 BCL2 apoptosis regulator Homo sapiens 53-58 15363891-4 2004 Since it has been suggested that the ratio of Bax to Bcl-2 is an important determinant of neuronal survival, the reciprocal regulation of these Bcl-2 family proteins may play a role in the neurotoxicity mediated by glutamate. Glutamic Acid 215-224 BCL2 apoptosis regulator Homo sapiens 144-149 15363891-10 2004 Examination of Bcl-2 and Bax following glutamate treatment revealed that the expression of these proteins was inversely regulated. Glutamic Acid 39-48 BCL2 apoptosis regulator Homo sapiens 15-20 15363891-13 2004 Furthermore, a significant decrease in Bcl-2 levels was observed at 1 mM and 10 mM glutamate (32.1%+/-4.8 and 33.7+/-12.8%, respectively) while a significant upregulation of Bax expression (88.2+/-17.9%) was observed at 10 mM glutamate. Glutamic Acid 83-92 BCL2 apoptosis regulator Homo sapiens 39-44 15363891-13 2004 Furthermore, a significant decrease in Bcl-2 levels was observed at 1 mM and 10 mM glutamate (32.1%+/-4.8 and 33.7+/-12.8%, respectively) while a significant upregulation of Bax expression (88.2+/-17.9%) was observed at 10 mM glutamate. Glutamic Acid 226-235 BCL2 apoptosis regulator Homo sapiens 39-44 15363891-14 2004 Interestingly, Bcl-2 and Bax levels in cells treated with glutamate from 12-24 h were not significantly different from those of control. Glutamic Acid 58-67 BCL2 apoptosis regulator Homo sapiens 15-20 15363891-15 2004 Taken together, these findings provide additional evidence for the reciprocal regulation of Bcl-2 and Bax expression by glutamate and suggest that neuronal excitotoxicity may, in part, result from the inverse regulation of these proteins. Glutamic Acid 120-129 BCL2 apoptosis regulator Homo sapiens 92-97 15325238-4 2004 One of those potential mechanisms exhibited by Bcl-2 is its ability to counteract the detrimental effects of cell damage caused by free radicals, thereby gaining its well-known property of being an antioxidant. Free Radicals 131-144 BCL2 apoptosis regulator Homo sapiens 47-52 15210690-0 2004 Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation. SCHEMBL420028 17-75 BCL2 apoptosis regulator Homo sapiens 111-115 15210690-4 2004 We report here that NNK simultaneously stimulates Bcl2 phosphorylation exclusively at Ser(70) and c-Myc at Thr(58) and Ser(62) through activation of both ERK1/2 and PKCalpha, which is required for NNK-induced survival and proliferation of human lung cancer cells. Serine 86-89 BCL2 apoptosis regulator Homo sapiens 50-54 15210690-5 2004 Treatment of cells with staurosporine or PD98059 blocks both Bcl2 and c-Myc phosphorylation and results in suppression of NNK-induced proliferation. Staurosporine 24-37 BCL2 apoptosis regulator Homo sapiens 61-65 15210690-5 2004 Treatment of cells with staurosporine or PD98059 blocks both Bcl2 and c-Myc phosphorylation and results in suppression of NNK-induced proliferation. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 41-48 BCL2 apoptosis regulator Homo sapiens 61-65 15210690-7 2004 Phosphorylation of Bcl2 at Ser(70) promotes a direct interaction between Bcl2 and c-Myc in the nucleus and on the outer mitochondrial membrane that significantly enhances the half-life of the c-Myc protein. Serine 27-30 BCL2 apoptosis regulator Homo sapiens 19-23 15210690-7 2004 Phosphorylation of Bcl2 at Ser(70) promotes a direct interaction between Bcl2 and c-Myc in the nucleus and on the outer mitochondrial membrane that significantly enhances the half-life of the c-Myc protein. Serine 27-30 BCL2 apoptosis regulator Homo sapiens 73-77 15313391-8 2004 The effect of theophylline in induction of apoptosis involved reduction of intracellular levels of Bcl2. Theophylline 14-26 BCL2 apoptosis regulator Homo sapiens 99-103 15353804-4 2004 The stapled peptides, called "stabilized alpha-helix of BCL-2 domains" (SAHBs), proved to be helical, protease-resistant, and cell-permeable molecules that bound with increased affinity to multidomain BCL-2 member pockets. sahbs 72-77 BCL2 apoptosis regulator Homo sapiens 56-61 15353804-4 2004 The stapled peptides, called "stabilized alpha-helix of BCL-2 domains" (SAHBs), proved to be helical, protease-resistant, and cell-permeable molecules that bound with increased affinity to multidomain BCL-2 member pockets. sahbs 72-77 BCL2 apoptosis regulator Homo sapiens 201-206 15517864-1 2004 BACKGROUND: MK 886, a 5-lipoxygenase inhibitor, induces a type 1 "apoptotic" form of programmed cell death in Bcl-2-positive U937 monoblastoid cells. MK-886 12-18 BCL2 apoptosis regulator Homo sapiens 110-115 15314285-4 2004 Firstly, we found that VPA induced apoptosis in two of the four human melanoma cell lines, while both TSA and SAHA exhibited an antiproliferative and apoptotic effects in all four cell lines, a different expression of Bcl-2 and BclX(L/S) occurred. trichostatin A 102-105 BCL2 apoptosis regulator Homo sapiens 218-223 15314285-4 2004 Firstly, we found that VPA induced apoptosis in two of the four human melanoma cell lines, while both TSA and SAHA exhibited an antiproliferative and apoptotic effects in all four cell lines, a different expression of Bcl-2 and BclX(L/S) occurred. Vorinostat 110-114 BCL2 apoptosis regulator Homo sapiens 218-223 15517864-7 2004 Two chemicals that inhibit the function of Bcl-2, HA14-1 and 2-methyl-antimycin A3, reduced the Ca2+ response to MK 886, if pre-incubated with the Bcl-2-positive U937 cells at 37 degrees C for several hours. 2-methyl-antimycin a3 61-82 BCL2 apoptosis regulator Homo sapiens 43-48 15517879-2 2004 Since the cellular mechanisms mediating this effect are not well defined, we investigated the activity of LA, also in combination with DHT or with cyproterone acetate (CA), on the expression of genes (bcl-2, bax, c-myc) which may contribute to the proliferative behaviour of LNCaP cells. Cyproterone Acetate 147-166 BCL2 apoptosis regulator Homo sapiens 201-206 15517864-7 2004 Two chemicals that inhibit the function of Bcl-2, HA14-1 and 2-methyl-antimycin A3, reduced the Ca2+ response to MK 886, if pre-incubated with the Bcl-2-positive U937 cells at 37 degrees C for several hours. 2-methyl-antimycin a3 61-82 BCL2 apoptosis regulator Homo sapiens 147-152 15517879-6 2004 RESULTS: Both the mRNA and protein of the anti-apoptotic gene bcl-2 were induced (30-125%) by DHT after 24-144 h. LA decreased bcl-2 mRNA (10-40%), while it did not unequivocally affect protein expression. Dihydrotestosterone 94-97 BCL2 apoptosis regulator Homo sapiens 62-67 15517864-7 2004 Two chemicals that inhibit the function of Bcl-2, HA14-1 and 2-methyl-antimycin A3, reduced the Ca2+ response to MK 886, if pre-incubated with the Bcl-2-positive U937 cells at 37 degrees C for several hours. MK-886 113-119 BCL2 apoptosis regulator Homo sapiens 43-48 15517885-3 2004 The growth-inhibitory effects of resveratrol are mediated through cell-cycle arrest; upregulation of p21Cip1/WAF1, p53 and Bax; down-regulation of survivin, cyclin D1, cyclin E, Bcl-2, Bcl-xL and clAPs; and activation of caspases. Resveratrol 33-44 BCL2 apoptosis regulator Homo sapiens 178-183 15517864-7 2004 Two chemicals that inhibit the function of Bcl-2, HA14-1 and 2-methyl-antimycin A3, reduced the Ca2+ response to MK 886, if pre-incubated with the Bcl-2-positive U937 cells at 37 degrees C for several hours. MK-886 113-119 BCL2 apoptosis regulator Homo sapiens 147-152 15517890-0 2004 Carboxyamido-triazole (CAI), a signal transduction inhibitor induces growth inhibition and apoptosis in bladder cancer cells by modulation of Bcl-2. carboxyamido-triazole 0-21 BCL2 apoptosis regulator Homo sapiens 142-147 15517890-0 2004 Carboxyamido-triazole (CAI), a signal transduction inhibitor induces growth inhibition and apoptosis in bladder cancer cells by modulation of Bcl-2. carboxyamido-triazole 23-26 BCL2 apoptosis regulator Homo sapiens 142-147 15517864-8 2004 MK 886 was previously shown to induce reactive oxygen species and a fall in mitochondrial membrane potential in both Bcl-2-positive U937 and in Bcl-2-negative PC-3 prostate and panc-1 pancreatic cancer cells. MK-886 0-6 BCL2 apoptosis regulator Homo sapiens 117-122 15517890-7 2004 Under the same conditions under which CAI treatment augmented Fas-mediated apoptosis, it was shown to reduce intracellular bcl-2 quantity. ammonium ferrous sulfate 62-65 BCL2 apoptosis regulator Homo sapiens 123-128 15517864-8 2004 MK 886 was previously shown to induce reactive oxygen species and a fall in mitochondrial membrane potential in both Bcl-2-positive U937 and in Bcl-2-negative PC-3 prostate and panc-1 pancreatic cancer cells. MK-886 0-6 BCL2 apoptosis regulator Homo sapiens 144-149 15517864-8 2004 MK 886 was previously shown to induce reactive oxygen species and a fall in mitochondrial membrane potential in both Bcl-2-positive U937 and in Bcl-2-negative PC-3 prostate and panc-1 pancreatic cancer cells. Reactive Oxygen Species 38-61 BCL2 apoptosis regulator Homo sapiens 117-122 15517864-11 2004 These events may involve Bcl-2 participating in some form of Ca2+ channel and nuclear Ca2+ binding proteins undergoing conformational changes due to reactive oxygen species. Reactive Oxygen Species 149-172 BCL2 apoptosis regulator Homo sapiens 25-30 15517865-7 2004 Within 24 h of treatment with paclitaxel, Bcl-2 formed a doublet at 26 kilodaltons and the expression was abrogated with daunorubicin and the combination of the two drugs as determined by Western blots. Paclitaxel 30-40 BCL2 apoptosis regulator Homo sapiens 42-47 15517865-7 2004 Within 24 h of treatment with paclitaxel, Bcl-2 formed a doublet at 26 kilodaltons and the expression was abrogated with daunorubicin and the combination of the two drugs as determined by Western blots. Daunorubicin 121-133 BCL2 apoptosis regulator Homo sapiens 42-47 15235941-0 2004 Involvement of histone hypoacetylation in Ni2+-induced bcl- 2 down-regulation and human hepatoma cell apoptosis. Nickel(2+) 42-46 BCL2 apoptosis regulator Homo sapiens 55-61 15377153-11 2004 Our findings revealed that arsenic enhances UVB-induced keratinocyte apoptosis via suppression of Bcl-2 expression and stimulation of caspase-8 activity. Arsenic 27-34 BCL2 apoptosis regulator Homo sapiens 98-103 15231731-4 2004 Simultaneously, FUS downregulated cellular survival components (e.g., bcl-2, SOD). fusarubin 16-19 BCL2 apoptosis regulator Homo sapiens 70-75 15314279-6 2004 Interestingly, ROS have effects on both intrinsic and extrinsic apoptosis pathways through modulation of expression of the major molecules in these pathways, Bcl-2 and FasL. Reactive Oxygen Species 15-18 BCL2 apoptosis regulator Homo sapiens 158-163 15353307-3 2004 PGE2 induced by COX-2 exerts several biological properties that may be advantageous for tumorigenesis: 1) Promoting angiogenesis (increased VEGF, bFGF, and PDGF production), 2) Anti-apoptosis mechanism (via increased bcl-2 and Akt activity), 3) Stimulating tumor metastasis (by increasing matrix metalloproteinases) and 4) Decreased immune surveillance (decreased cytokine production and NK activity). Dinoprostone 0-4 BCL2 apoptosis regulator Homo sapiens 217-222 15235941-6 2004 At the same time, Ni(2+) induced a significant decrease in bcl- 2 expression and histone acetylation; the decrease of histone H4 acetylation in nucleosomes associated with the bcl- 2 promoter region was also proven by a chromatin immunoprecipitation assay, indicating the involvement of histone hypoacetylation in Ni(2+)-induced bcl- 2 down-regulation. Nickel(2+) 18-24 BCL2 apoptosis regulator Homo sapiens 59-65 15235941-6 2004 At the same time, Ni(2+) induced a significant decrease in bcl- 2 expression and histone acetylation; the decrease of histone H4 acetylation in nucleosomes associated with the bcl- 2 promoter region was also proven by a chromatin immunoprecipitation assay, indicating the involvement of histone hypoacetylation in Ni(2+)-induced bcl- 2 down-regulation. Nickel(2+) 18-24 BCL2 apoptosis regulator Homo sapiens 176-182 15235941-6 2004 At the same time, Ni(2+) induced a significant decrease in bcl- 2 expression and histone acetylation; the decrease of histone H4 acetylation in nucleosomes associated with the bcl- 2 promoter region was also proven by a chromatin immunoprecipitation assay, indicating the involvement of histone hypoacetylation in Ni(2+)-induced bcl- 2 down-regulation. Nickel(2+) 18-24 BCL2 apoptosis regulator Homo sapiens 176-182 15235941-6 2004 At the same time, Ni(2+) induced a significant decrease in bcl- 2 expression and histone acetylation; the decrease of histone H4 acetylation in nucleosomes associated with the bcl- 2 promoter region was also proven by a chromatin immunoprecipitation assay, indicating the involvement of histone hypoacetylation in Ni(2+)-induced bcl- 2 down-regulation. Nickel(2+) 314-320 BCL2 apoptosis regulator Homo sapiens 176-182 15235941-6 2004 At the same time, Ni(2+) induced a significant decrease in bcl- 2 expression and histone acetylation; the decrease of histone H4 acetylation in nucleosomes associated with the bcl- 2 promoter region was also proven by a chromatin immunoprecipitation assay, indicating the involvement of histone hypoacetylation in Ni(2+)-induced bcl- 2 down-regulation. Nickel(2+) 314-320 BCL2 apoptosis regulator Homo sapiens 176-182 15235941-7 2004 Further studies showed that increasing histone acetylation by either 100 nM of trichostatin A or over-expressing histone acetyltranferase p300 in Hep3B cells obviously attenuated the bcl- 2 down-regulation and cell apoptosis caused by Ni(2+). trichostatin A 79-93 BCL2 apoptosis regulator Homo sapiens 183-189 15235941-8 2004 Considering the importance of bcl- 2 in determining cell survival and apoptosis, the data presented here suggest that histone hypoacetylation may represent one unrevealed pathway in Ni(2+)-induced cell apoptosis, where bcl- 2 is one of its targets. Nickel(2+) 182-188 BCL2 apoptosis regulator Homo sapiens 30-36 15235941-8 2004 Considering the importance of bcl- 2 in determining cell survival and apoptosis, the data presented here suggest that histone hypoacetylation may represent one unrevealed pathway in Ni(2+)-induced cell apoptosis, where bcl- 2 is one of its targets. Nickel(2+) 182-188 BCL2 apoptosis regulator Homo sapiens 219-225 15322250-9 2004 Bax was up-regulated and translocated to mitochondria at the IC(50) and IC(70) concentrations, whereas Bcl-2 was phosphorylated only at the highest vinflunine concentration examined (500 nM). vinflunine 148-158 BCL2 apoptosis regulator Homo sapiens 103-108 15481605-5 2004 The Bcl-2/ Bax mRNA expression ratio increased progressively from the control to the heat preconditioned and ATP depleted cells (control; 100%, ATP depletion; 154 +/- 6%, heat preconditioning; 212 +/- 6%, heat preconditioning and ATP depletion; 421 +/- 8%). Adenosine Triphosphate 109-112 BCL2 apoptosis regulator Homo sapiens 4-9 15481605-5 2004 The Bcl-2/ Bax mRNA expression ratio increased progressively from the control to the heat preconditioned and ATP depleted cells (control; 100%, ATP depletion; 154 +/- 6%, heat preconditioning; 212 +/- 6%, heat preconditioning and ATP depletion; 421 +/- 8%). Adenosine Triphosphate 144-147 BCL2 apoptosis regulator Homo sapiens 4-9 15481605-5 2004 The Bcl-2/ Bax mRNA expression ratio increased progressively from the control to the heat preconditioned and ATP depleted cells (control; 100%, ATP depletion; 154 +/- 6%, heat preconditioning; 212 +/- 6%, heat preconditioning and ATP depletion; 421 +/- 8%). Adenosine Triphosphate 144-147 BCL2 apoptosis regulator Homo sapiens 4-9 15481605-8 2004 CONCLUSION: There may be a possibility that the preservation of cytolytic damage and an increase in the Bcl-2/Bax mRNA expression ratio is related to the increase of HSP72 in ATP depletion as a hypoxia model. Adenosine Triphosphate 175-178 BCL2 apoptosis regulator Homo sapiens 104-109 15143129-2 2004 In this study, we describe how the novel pyrrolo-1,5-benzoxazepine compound 7-[[dimethylcarbamoyl]oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) selectively induces apoptosis in Bcl-2-overexpressing cancer cells, whereas it shows no cytotoxic effect on normal peripheral blood mononuclear cells. pyrrolo-1,5-benzoxazepine 41-66 BCL2 apoptosis regulator Homo sapiens 195-200 15143129-2 2004 In this study, we describe how the novel pyrrolo-1,5-benzoxazepine compound 7-[[dimethylcarbamoyl]oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) selectively induces apoptosis in Bcl-2-overexpressing cancer cells, whereas it shows no cytotoxic effect on normal peripheral blood mononuclear cells. 7-[[dimethylcarbamoyl]oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (pbox-6) 76-161 BCL2 apoptosis regulator Homo sapiens 195-200 15143129-4 2004 PBOX-6 also induces Bcl-2 phosphorylation and apoptosis in wild-type T leukemia CEM cells and cells overexpressing Bcl-2. PBOX-6 0-6 BCL2 apoptosis regulator Homo sapiens 20-25 15143129-4 2004 PBOX-6 also induces Bcl-2 phosphorylation and apoptosis in wild-type T leukemia CEM cells and cells overexpressing Bcl-2. PBOX-6 0-6 BCL2 apoptosis regulator Homo sapiens 115-120 15143129-5 2004 This is in contrast to chemotherapeutic agents such as etoposide, actinomycin D, and ultraviolet irradiation, whereby overexpression of Bcl-2 confers resistance against apoptosis. Etoposide 55-64 BCL2 apoptosis regulator Homo sapiens 136-141 15143129-5 2004 This is in contrast to chemotherapeutic agents such as etoposide, actinomycin D, and ultraviolet irradiation, whereby overexpression of Bcl-2 confers resistance against apoptosis. Dactinomycin 66-79 BCL2 apoptosis regulator Homo sapiens 136-141 15143129-6 2004 In addition, PBOX-6 induces Bcl-2 phosphorylation and apoptosis in wild-type Jurkat acute lymphoblastic leukemia cells and cells overexpressing Bcl-2. PBOX-6 13-19 BCL2 apoptosis regulator Homo sapiens 28-33 15143129-6 2004 In addition, PBOX-6 induces Bcl-2 phosphorylation and apoptosis in wild-type Jurkat acute lymphoblastic leukemia cells and cells overexpressing Bcl-2. PBOX-6 13-19 BCL2 apoptosis regulator Homo sapiens 144-149 15143129-7 2004 However, Jurkat cells containing a Bcl-2 triple mutant, whereby the principal Bcl-2 phosphorylation sites are mutated to alanine, demonstrate resistance against Bcl-2 phosphorylation and apoptosis. Alanine 121-128 BCL2 apoptosis regulator Homo sapiens 35-40 15288519-8 2004 Moreover, genistein was able to prevent the down-regulation of the anti-apoptotic protein bcl-2 that was caused by t-BuOOH treatment. Genistein 10-19 BCL2 apoptosis regulator Homo sapiens 90-95 15367705-3 2004 DHL-4, a bcl-2 overexpressing lymphoid line, was the most sensitive (IC50, 5.2 micromol/L) and the cervical cancer cell line, SiHa, was the most resistant (IC50, >300 micromol/L). dhl-4 0-5 BCL2 apoptosis regulator Homo sapiens 9-14 16120427-24 2004 Inhibition of complex I with rotenone increases the expression and synthesis of Bcl-2 and Cox-2, both effects are similar effects to produced by IL-1 in human chondrocytes. Rotenone 29-37 BCL2 apoptosis regulator Homo sapiens 80-85 15288519-9 2004 These results indicate that genistein may have neuroprotective effect in cortical cells, which may be mediated by its regulation of the anti-apoptotic protein bcl-2. Genistein 28-37 BCL2 apoptosis regulator Homo sapiens 159-164 14996703-7 2004 Moreover, EGCG suppressed the proteins B-cell leukemia/lymphoma-2 protein (Bcl-2), X-linked inhibitor of apoptosis protein (XIAP), and myeloid cell leukemia-1 (Mcl-1) in CLL B cells. epigallocatechin gallate 10-14 BCL2 apoptosis regulator Homo sapiens 75-80 15548374-9 2004 In other studies, IP6 caused a dose- and a time-dependent apoptotic death of LNCaP cells, and a decrease in Bcl2 levels, causing a strong increase in Bax versus Bcl2 ratio, as well as an inhibition of constitutively active AKT phosphorylation. Phytic Acid 18-21 BCL2 apoptosis regulator Homo sapiens 108-112 15548374-9 2004 In other studies, IP6 caused a dose- and a time-dependent apoptotic death of LNCaP cells, and a decrease in Bcl2 levels, causing a strong increase in Bax versus Bcl2 ratio, as well as an inhibition of constitutively active AKT phosphorylation. Phytic Acid 18-21 BCL2 apoptosis regulator Homo sapiens 161-165 15300917-0 2004 Detection of BCL2-IGH rearrangement on paraffin-embedded tissue sections obtained from a small submucosal tumor of the rectum in a patient with recurrent follicular lymphoma. Paraffin 39-47 BCL2 apoptosis regulator Homo sapiens 13-17 15300917-5 2004 Fluorescence in situ hybridization on paraffin-embedded tissue sections (T-FISH) identified a translocation of BCL2 with IGH gene. Paraffin 38-46 BCL2 apoptosis regulator Homo sapiens 111-115 15358141-3 2004 The efficacious induction of apoptosis was observed at 45 microM for 24 h. Molecular data showed that EA induced the truncation of Bid protein and reduction of Bcl-2 protein. echinocystic acid 102-104 BCL2 apoptosis regulator Homo sapiens 160-165 15184368-9 2004 Knockdown of bcl-2 expression by siRNA in cardiac fibroblasts increased their apoptotic response to staurosporine, serum, and glucose deprivation and to simulated ischemia. Staurosporine 100-113 BCL2 apoptosis regulator Homo sapiens 13-18 15246562-4 2004 We report here that cisplatin-resistant cell lines overexpress Bcl-2 family protein Bcl-2-related gene expressed in fetal liver (Bfl-1)/A1 as compared with their parental cell. Cisplatin 20-29 BCL2 apoptosis regulator Homo sapiens 63-68 15246562-4 2004 We report here that cisplatin-resistant cell lines overexpress Bcl-2 family protein Bcl-2-related gene expressed in fetal liver (Bfl-1)/A1 as compared with their parental cell. Cisplatin 20-29 BCL2 apoptosis regulator Homo sapiens 84-89 15175350-0 2004 A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. Imatinib Mesylate 45-53 BCL2 apoptosis regulator Homo sapiens 125-130 15175350-3 2004 Whereas basal expression of Bcl-2 protein was very low in parental cells, imatinib-resistant cells displayed a marked increase in Bcl-2 mRNA and/or protein levels. Imatinib Mesylate 74-82 BCL2 apoptosis regulator Homo sapiens 130-135 15175350-6 2004 Ectopic expression of Bcl-2 protected K562 and LAMA84 cells from imatinib mesylate- and PP2-mediated lethality. Imatinib Mesylate 65-82 BCL2 apoptosis regulator Homo sapiens 22-27 15175350-7 2004 Conversely, interference with Bcl-2 function by co-administration of the small molecule Bcl-2 inhibitor HA14-1 or down-regulation of Bcl-2 expression by small interfering RNA or antisense strategies significantly increased mitochondrial dysfunction and apoptosis induced by imatinib mesylate and the topoisomerase inhibitor VP-16 in LAMA-R cells. Imatinib Mesylate 274-291 BCL2 apoptosis regulator Homo sapiens 30-35 15175350-7 2004 Conversely, interference with Bcl-2 function by co-administration of the small molecule Bcl-2 inhibitor HA14-1 or down-regulation of Bcl-2 expression by small interfering RNA or antisense strategies significantly increased mitochondrial dysfunction and apoptosis induced by imatinib mesylate and the topoisomerase inhibitor VP-16 in LAMA-R cells. Etoposide 324-329 BCL2 apoptosis regulator Homo sapiens 30-35 15219941-0 2004 Involvement of proapoptotic Bcl-2 family members in parthenolide-induced mitochondrial dysfunction and apoptosis. parthenolide 52-64 BCL2 apoptosis regulator Homo sapiens 28-33 15219941-3 2004 In the present study, we attempted to examine parthenolide-mediated cell death signaling pathway by focusing on the involvement of Bcl-2 family members. parthenolide 46-58 BCL2 apoptosis regulator Homo sapiens 131-136 15219941-9 2004 Therefore, the proapoptotic Bcl-2 family members are important mediators relaying the cell death signaling elicited by parthenolide from caspase 8 to downstream effector caspases such as caspase 3, and eventually to cell death. parthenolide 119-131 BCL2 apoptosis regulator Homo sapiens 28-33 15178684-4 2004 Bcl-2 overexpression and quenching of reactive oxygen species, which prevent arsenic trioxide-induced apoptosis, also prevent the formation of topoisomerase I-DNA complexes, whereas enhancement of reactive oxygen species accumulation promotes these complexes. Reactive Oxygen Species 38-61 BCL2 apoptosis regulator Homo sapiens 0-5 15178684-4 2004 Bcl-2 overexpression and quenching of reactive oxygen species, which prevent arsenic trioxide-induced apoptosis, also prevent the formation of topoisomerase I-DNA complexes, whereas enhancement of reactive oxygen species accumulation promotes these complexes. Arsenic Trioxide 77-93 BCL2 apoptosis regulator Homo sapiens 0-5 15178684-4 2004 Bcl-2 overexpression and quenching of reactive oxygen species, which prevent arsenic trioxide-induced apoptosis, also prevent the formation of topoisomerase I-DNA complexes, whereas enhancement of reactive oxygen species accumulation promotes these complexes. Reactive Oxygen Species 197-220 BCL2 apoptosis regulator Homo sapiens 0-5 15212811-6 2004 Western blot analysis revealed a modified expression of Bax, BCl-2, c-Jun, c-Fos and Raf-1 proteins in the human cord blood cells after direct exposure to styrene, whereas p53 expression did not change. Styrene 155-162 BCL2 apoptosis regulator Homo sapiens 61-66 15277270-2 2004 G3139 [oblimersen sodium (Genasense)] is a phosphorothioate antisense oligodeoxynucleotide that targets Bcl-2 mRNA, downregulates Bcl-2 protein translation, and enhances the antitumor effects of subtherapeutic doses of docetaxel (Taxotere). oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 104-109 15277270-2 2004 G3139 [oblimersen sodium (Genasense)] is a phosphorothioate antisense oligodeoxynucleotide that targets Bcl-2 mRNA, downregulates Bcl-2 protein translation, and enhances the antitumor effects of subtherapeutic doses of docetaxel (Taxotere). oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 130-135 15277270-2 2004 G3139 [oblimersen sodium (Genasense)] is a phosphorothioate antisense oligodeoxynucleotide that targets Bcl-2 mRNA, downregulates Bcl-2 protein translation, and enhances the antitumor effects of subtherapeutic doses of docetaxel (Taxotere). oblimersen 26-35 BCL2 apoptosis regulator Homo sapiens 104-109 15277270-2 2004 G3139 [oblimersen sodium (Genasense)] is a phosphorothioate antisense oligodeoxynucleotide that targets Bcl-2 mRNA, downregulates Bcl-2 protein translation, and enhances the antitumor effects of subtherapeutic doses of docetaxel (Taxotere). oblimersen 26-35 BCL2 apoptosis regulator Homo sapiens 130-135 15277270-2 2004 G3139 [oblimersen sodium (Genasense)] is a phosphorothioate antisense oligodeoxynucleotide that targets Bcl-2 mRNA, downregulates Bcl-2 protein translation, and enhances the antitumor effects of subtherapeutic doses of docetaxel (Taxotere). Parathion 43-59 BCL2 apoptosis regulator Homo sapiens 104-109 15277270-2 2004 G3139 [oblimersen sodium (Genasense)] is a phosphorothioate antisense oligodeoxynucleotide that targets Bcl-2 mRNA, downregulates Bcl-2 protein translation, and enhances the antitumor effects of subtherapeutic doses of docetaxel (Taxotere). Oligodeoxyribonucleotides 70-90 BCL2 apoptosis regulator Homo sapiens 104-109 15258617-0 2004 A mechanism for the proapoptotic activity of ursodeoxycholic acid: effects on Bcl-2 conformation. Ursodeoxycholic Acid 45-65 BCL2 apoptosis regulator Homo sapiens 78-83 15105834-4 2004 Elevated extracellular glucose causes rapid mitochondrial enlargement coupled with an increase in the mitochondrial membrane potential (Delta Psi(M)) followed by mitochondrial membrane depolarization (MMD), uncoupling protein 3 (UCP3) downregulation, caspase-3 activation and decreased Bcl-2. Glucose 23-30 BCL2 apoptosis regulator Homo sapiens 286-291 15105836-5 2004 This 7-ketocholesterol-induced apoptosis appears to be associated with the dephosphorylation of serine 75 and serine 99 of the proapoptotic protein Bcl-2 antagonist of cell death (BAD). 7-ketocholesterol 5-22 BCL2 apoptosis regulator Homo sapiens 148-153 15105836-5 2004 This 7-ketocholesterol-induced apoptosis appears to be associated with the dephosphorylation of serine 75 and serine 99 of the proapoptotic protein Bcl-2 antagonist of cell death (BAD). Serine 110-116 BCL2 apoptosis regulator Homo sapiens 148-153 15258617-1 2004 Ursodeoxycholic acid (UDCA), a relatively nontoxic bile acid, enhanced the apoptotic response of tumor cells to both photosensitizers that cause photodamage to Bcl-2 and to the nonpeptidic Bcl-2/Bcl-x(L) antagonist HA14-1. Ursodeoxycholic Acid 0-20 BCL2 apoptosis regulator Homo sapiens 160-165 15298963-15 2004 Furthermore, diosgenin induced apoptosis in HT-29 cells at least in part by inhibition of bcl-2 and by induction of caspase-3 protein expression. Diosgenin 13-22 BCL2 apoptosis regulator Homo sapiens 90-95 15298726-0 2004 Reactive oxygen species (ROS) control the expression of Bcl-2 family proteins by regulating their phosphorylation and ubiquitination. Reactive Oxygen Species 0-23 BCL2 apoptosis regulator Homo sapiens 56-61 15298726-0 2004 Reactive oxygen species (ROS) control the expression of Bcl-2 family proteins by regulating their phosphorylation and ubiquitination. Reactive Oxygen Species 25-28 BCL2 apoptosis regulator Homo sapiens 56-61 15258617-1 2004 Ursodeoxycholic acid (UDCA), a relatively nontoxic bile acid, enhanced the apoptotic response of tumor cells to both photosensitizers that cause photodamage to Bcl-2 and to the nonpeptidic Bcl-2/Bcl-x(L) antagonist HA14-1. Ursodeoxycholic Acid 0-20 BCL2 apoptosis regulator Homo sapiens 189-194 15298726-1 2004 We examined the influence of ROS on the phosphorylation and complex formation of Bcl-2 family proteins in Mn-superoxide dismutase (SOD) antisense-transfected squamous cell carcinoma cells, OSC-4 cells. Reactive Oxygen Species 29-32 BCL2 apoptosis regulator Homo sapiens 81-86 15298726-4 2004 After treatment with these agents, the phosphorylation of protein kinase A, Bcl-2 (Thr56) and Bad (Ser155) was increased, especially in antioxidant (N-acetylcysteine and pyrrolidine dithiocarbamate)-pretreated control cells, but the phosphorylation levels were very low in the antisense-transfected cells. Acetylcysteine 149-165 BCL2 apoptosis regulator Homo sapiens 76-81 15258617-1 2004 Ursodeoxycholic acid (UDCA), a relatively nontoxic bile acid, enhanced the apoptotic response of tumor cells to both photosensitizers that cause photodamage to Bcl-2 and to the nonpeptidic Bcl-2/Bcl-x(L) antagonist HA14-1. Ursodeoxycholic Acid 22-26 BCL2 apoptosis regulator Homo sapiens 160-165 15298726-4 2004 After treatment with these agents, the phosphorylation of protein kinase A, Bcl-2 (Thr56) and Bad (Ser155) was increased, especially in antioxidant (N-acetylcysteine and pyrrolidine dithiocarbamate)-pretreated control cells, but the phosphorylation levels were very low in the antisense-transfected cells. pyrrolidine dithiocarbamic acid 170-197 BCL2 apoptosis regulator Homo sapiens 76-81 15258617-1 2004 Ursodeoxycholic acid (UDCA), a relatively nontoxic bile acid, enhanced the apoptotic response of tumor cells to both photosensitizers that cause photodamage to Bcl-2 and to the nonpeptidic Bcl-2/Bcl-x(L) antagonist HA14-1. Ursodeoxycholic Acid 22-26 BCL2 apoptosis regulator Homo sapiens 189-194 15298726-6 2004 These results reveal that ROS induce apoptosis by regulating the phosphorylation and ubiquitination of Bcl-2 family proteins, resulting in increased proapoptotic protein levels and decreased antiapoptotic protein expression. Reactive Oxygen Species 26-29 BCL2 apoptosis regulator Homo sapiens 103-108 15265716-11 2004 The combination of cisplatin/freezing resulted in a 4-fold increase in the ratio of Bax to Bcl-2 when compared to controls, which represented a 2-fold increase over the 5-FU/freezing-combination model. Cisplatin 19-28 BCL2 apoptosis regulator Homo sapiens 91-96 15324812-5 2004 These compounds represent the first antiapoptotic small molecules targeting a Bcl-2 protein as shown by their ability to inhibit tBid-induced SMAC release, caspase-3 activation, and cell death. tBID 129-133 BCL2 apoptosis regulator Homo sapiens 78-83 15324812-5 2004 These compounds represent the first antiapoptotic small molecules targeting a Bcl-2 protein as shown by their ability to inhibit tBid-induced SMAC release, caspase-3 activation, and cell death. smac 142-146 BCL2 apoptosis regulator Homo sapiens 78-83 15297406-1 2004 PURPOSE: To assess the feasibility of administering oblimersen sodium, a phosphorothioate antisense oligonucleotide directed to the Bcl-2 mRNA, with docetaxel to patients with hormone-refractory prostate cancer; to characterize the pertinent pharmacokinetic parameters, Bcl-2 protein inhibition in peripheral blood mononuclear cell(s) (PBMC) and tumor; and to seek preliminary evidence of antitumor activity. Oligonucleotides 100-115 BCL2 apoptosis regulator Homo sapiens 132-137 15254726-0 2004 Expression profiles of p53, p21, bax and bcl-2 proteins in all-trans-retinoic acid treated primary and metastatic melanoma cells. 2-octenal 63-69 BCL2 apoptosis regulator Homo sapiens 41-46 15242775-3 2004 Overexpression of Bcl-2 inhibited carbachol-induced ROCK-I cleavage, indicating a mitochondrial apoptotic pathway. Carbachol 34-43 BCL2 apoptosis regulator Homo sapiens 18-23 15254726-5 2004 Expression of p53, p21 and bax was increased, and bcl-2 was decreased in melanoma cells after exposure to atRA at different concentrations for various periods of time. Tretinoin 106-110 BCL2 apoptosis regulator Homo sapiens 50-55 15254726-8 2004 These data indicate that p53, p21, bax and bcl-2 proteins were involved in atRA-induced apoptosis in melanoma cells. Tretinoin 75-79 BCL2 apoptosis regulator Homo sapiens 43-48 15254743-6 2004 Furthermore, we show that SU5416-induced apoptosis is associated with a decrease in the expression of the apoptosis inhibitors, MDM2 and Bcl-2, and an increase in the level of NF-kappaB inhibitor, IkappaBalpha. Semaxinib 26-32 BCL2 apoptosis regulator Homo sapiens 137-142 15254726-0 2004 Expression profiles of p53, p21, bax and bcl-2 proteins in all-trans-retinoic acid treated primary and metastatic melanoma cells. Tretinoin 69-82 BCL2 apoptosis regulator Homo sapiens 41-46 15254726-3 2004 In this study, we used a similar cell culture model system of matched primary and metastatic melanoma cells from the same patient to investigate whether p53 and bcl-2 family proteins were involved in atRA-induced apoptosis. Tretinoin 200-204 BCL2 apoptosis regulator Homo sapiens 161-166 15260130-3 2004 H2O2 increased both the ratio of bax/bcl-2 and the p53 mRNA expression. Hydrogen Peroxide 0-4 BCL2 apoptosis regulator Homo sapiens 37-42 15377870-10 2004 Antideath mitochondrial proteins of the Bcl-2 family also confer cellular resistance to oxidative stress, paradoxically through stimulation of mitochondrial free radical generation and secondary upregulation of antioxidant gene expression. Free Radicals 157-169 BCL2 apoptosis regulator Homo sapiens 40-45 15254790-5 2004 Patients treated with L-Dopa and dopamine agonists showed the lowest values of Bcl-2, coupled with the highest density of PBRs, while increased levels of Cu/Zn SOD were found in the group under monotherapy with L-Dopa. Levodopa 22-28 BCL2 apoptosis regulator Homo sapiens 79-84 15254790-5 2004 Patients treated with L-Dopa and dopamine agonists showed the lowest values of Bcl-2, coupled with the highest density of PBRs, while increased levels of Cu/Zn SOD were found in the group under monotherapy with L-Dopa. Dopamine 33-41 BCL2 apoptosis regulator Homo sapiens 79-84 15254790-5 2004 Patients treated with L-Dopa and dopamine agonists showed the lowest values of Bcl-2, coupled with the highest density of PBRs, while increased levels of Cu/Zn SOD were found in the group under monotherapy with L-Dopa. Levodopa 211-217 BCL2 apoptosis regulator Homo sapiens 79-84 15254709-7 2004 NS-398 was found to reduce the proliferation of monolayer cell cultures in a dose- and time-dependent manner and to induce apoptosis and lower bcl-2 protein levels. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 0-6 BCL2 apoptosis regulator Homo sapiens 143-148 15260130-5 2004 GPI1046 also reduced the ratio of bax/bcl-2 to the normal level. GPI 1046 0-7 BCL2 apoptosis regulator Homo sapiens 38-43 15208671-2 2004 Damaged microtubules induce phosphorylation of the Bcl-2 protein and lower the threshold of programmed cell death, both of which are inhibited by rapamycin. Sirolimus 146-155 BCL2 apoptosis regulator Homo sapiens 51-56 15363128-0 2004 [Change of Bcl-2, Bax proteins and mitochondrial membrane protein on nitric oxide induced apoptosis in HL-60 cells]. Nitric Oxide 69-81 BCL2 apoptosis regulator Homo sapiens 11-16 15148322-5 2004 p15 tBid is potently apoptotic and activates the multidomain Bcl-2 protein, Bax, resulting in release of cytochrome c from mitochondria. tBID 4-8 BCL2 apoptosis regulator Homo sapiens 61-66 15193998-7 2004 Interestingly, Bcl-2 overexpression that blocked cytochrome c release by LMB effectively attenuated the apoptotic response to LMB, suggesting that LMB-induced apoptosis is mediated through the mitochondrial pathway. leptomycin B 73-76 BCL2 apoptosis regulator Homo sapiens 15-20 15138279-1 2004 BCL-2 homology 3 (BH3)-only proteins of the BCL-2 family such as tBID and BIM(EL) assist BAX-type proteins to breach the permeability barrier of the outer mitochondrial membrane, thereby allowing cytoplasmic release of cytochrome c and other active inducers of cell death normally confined to the mitochondrial inter-membrane space. tBID 65-69 BCL2 apoptosis regulator Homo sapiens 0-5 15138279-1 2004 BCL-2 homology 3 (BH3)-only proteins of the BCL-2 family such as tBID and BIM(EL) assist BAX-type proteins to breach the permeability barrier of the outer mitochondrial membrane, thereby allowing cytoplasmic release of cytochrome c and other active inducers of cell death normally confined to the mitochondrial inter-membrane space. tBID 65-69 BCL2 apoptosis regulator Homo sapiens 44-49 15184882-0 2004 Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2. diallyl trisulfide 0-18 BCL2 apoptosis regulator Homo sapiens 171-176 15184882-4 2004 DATS-induced apoptosis in PC-3 cells was associated with phosphorylation of Bcl-2, reduced Bcl-2 : Bax interaction, and cleavage of procaspase-9 and -3. diallyl trisulfide 0-4 BCL2 apoptosis regulator Homo sapiens 76-81 15184882-4 2004 DATS-induced apoptosis in PC-3 cells was associated with phosphorylation of Bcl-2, reduced Bcl-2 : Bax interaction, and cleavage of procaspase-9 and -3. diallyl trisulfide 0-4 BCL2 apoptosis regulator Homo sapiens 91-96 15184882-7 2004 Phosphorylation of Bcl-2 in DATS-treated PC-3 cells was fully blocked in the presence of JNK-specific inhibitor SP600125. pyrazolanthrone 112-120 BCL2 apoptosis regulator Homo sapiens 19-24 15184882-9 2004 DATS-induced Bcl-2 phosphorylation and apoptosis were partially attenuated by pharmacological inhibition of ERK1/2 using PD98059 or U0126. diallyl trisulfide 0-4 BCL2 apoptosis regulator Homo sapiens 13-18 15184882-9 2004 DATS-induced Bcl-2 phosphorylation and apoptosis were partially attenuated by pharmacological inhibition of ERK1/2 using PD98059 or U0126. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 121-128 BCL2 apoptosis regulator Homo sapiens 13-18 15184882-9 2004 DATS-induced Bcl-2 phosphorylation and apoptosis were partially attenuated by pharmacological inhibition of ERK1/2 using PD98059 or U0126. U 0126 132-137 BCL2 apoptosis regulator Homo sapiens 13-18 15184882-11 2004 In conclusion, our data point towards important roles for Bcl-2, JNK and ERK in DATS-induced apoptosis in human prostate cancer cells. diallyl trisulfide 80-84 BCL2 apoptosis regulator Homo sapiens 58-63 15193998-7 2004 Interestingly, Bcl-2 overexpression that blocked cytochrome c release by LMB effectively attenuated the apoptotic response to LMB, suggesting that LMB-induced apoptosis is mediated through the mitochondrial pathway. leptomycin B 126-129 BCL2 apoptosis regulator Homo sapiens 15-20 15193998-7 2004 Interestingly, Bcl-2 overexpression that blocked cytochrome c release by LMB effectively attenuated the apoptotic response to LMB, suggesting that LMB-induced apoptosis is mediated through the mitochondrial pathway. leptomycin B 126-129 BCL2 apoptosis regulator Homo sapiens 15-20 15237427-14 2004 CONCLUSION: Tanshinone II-A could inhibit the growth and proliferation of HCC cell effectively in vitro by apoptosis induction, which was associated with up-regulation of fas, p53, bax, expression and down-regulation of bcl-2 and c-myc. tanshinone 12-27 BCL2 apoptosis regulator Homo sapiens 220-225 15207719-7 2004 Further, silibinin treatment prior to or immediately after UVB exposure altered Bcl-2, Bax, Bak, and cytochrome c levels in mitochondria and cytosol in favor of or against apoptosis, respectively. Silybin 9-18 BCL2 apoptosis regulator Homo sapiens 80-85 15251463-2 2004 Inhibition of AR by sorbinil or tolrestat prevented TNF-alpha-induced increase in Bax and Bak and the downregulation of Bcl-2. sorbinil 20-28 BCL2 apoptosis regulator Homo sapiens 120-125 15269161-9 2004 In addition, biochemical examinations revealed that gamma-radiation inhibited paclitaxel-induced IkappaBalpha degradation and bcl-2 phosphorylation and increased the protein levels of cyclin B1 and inhibitory phosphorylation of p34(cdc2). Paclitaxel 78-88 BCL2 apoptosis regulator Homo sapiens 126-131 15233914-5 2004 We also demonstrate that in mice and humans, Bcl-2 binds to high molecular weight SDS-resistant mutant SOD1 containing aggregates that are present in mitochondria from spinal cord but not liver. Sodium Dodecyl Sulfate 82-85 BCL2 apoptosis regulator Homo sapiens 45-50 15123638-8 2004 Thus, the IRES-mediated translation of BCL-2 may enable the cell to replenish levels of this critical protein during cell stress, when cap-dependent translation is repressed, thereby maintaining the balance between pro- and anti-apoptotic BCL-2 family members in the cell and preventing unwarranted induction of apoptosis. cap 135-138 BCL2 apoptosis regulator Homo sapiens 39-44 15123718-1 2004 The proapoptotic Bcl-2 family protein Bid is cleaved by caspase-8 to release the C-terminal fragment tBid, which translocates to the outer mitochondrial membrane and induces massive cytochrome c release and cell death. tBID 101-105 BCL2 apoptosis regulator Homo sapiens 17-22 15142860-6 2004 HOCl rapidly decreased endothelial Bcl-2 and induced cytochrome-C release, indicating that HOCl activates apoptotic EC death, partially via mitochondrial damage. Hypochlorous Acid 0-4 BCL2 apoptosis regulator Homo sapiens 35-40 15188008-4 2004 In this study, we examined G3139, a novel antisense compound targeting Bcl-2, in combination with IFNalpha. oblimersen 27-32 BCL2 apoptosis regulator Homo sapiens 71-76 15188008-11 2004 G3139 induced a specific downregulation of Bcl-2 in SK-RC-07 cells, which were then sensitised to anti-Fas after treatment with IFNalpha. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 43-48 15188008-12 2004 Taken together, these results suggest that Fas-dependent pathways as well as alternative pathways, which can be inhibited by Bcl-2, exist in renal cell carcinoma. ammonium ferrous sulfate 43-46 BCL2 apoptosis regulator Homo sapiens 125-130 15142860-6 2004 HOCl rapidly decreased endothelial Bcl-2 and induced cytochrome-C release, indicating that HOCl activates apoptotic EC death, partially via mitochondrial damage. Hypochlorous Acid 91-95 BCL2 apoptosis regulator Homo sapiens 35-40 15044368-7 2004 Low doses of Taxol enhanced Bcl2 phosphorylation and led to its degradation observed on the background of a sustained or increasing Bax level and accumulation of survivin and X-chromosome-linked inhibitor of apoptosis. Paclitaxel 13-18 BCL2 apoptosis regulator Homo sapiens 28-32 15256729-0 2004 Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells. gambogic acid 0-13 BCL2 apoptosis regulator Homo sapiens 69-74 15256734-3 2004 The results showed that ME induced oligonucleosomal fragmentation of DNA in HeLa cells and activated caspase-3, followed by the degradation of the inhibitor of caspase-activated DNase, decreased the expression of anti-apoptotic mitochondrial proteins Bcl-2 and Bcl-(XL), and increased that of proapoptotic Bax. mansonone E 24-26 BCL2 apoptosis regulator Homo sapiens 251-256 15256735-3 2004 Activities of caspase-9 and caspase-3 in UV-irradiated A375-S2 cells were effectively reduced by silymarin in a dose-dependent manner, while the expression of the inhibitor of caspase-activated DNase (ICAD), protein expression of Bcl-x(L) (Bcl-2 family member), and the activity of extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) were increased simultaneously. Silymarin 97-106 BCL2 apoptosis regulator Homo sapiens 240-245 15256740-4 2004 The activation of caspase-9 and -3, but not caspase-8, together with the down-regulation of anti-apoptotic Bcl-2 protein, demonstrated that the apoptotic signaling triggered by dioscin was mediated through the intrinsic mitochondria-dependent pathway. dioscin 177-184 BCL2 apoptosis regulator Homo sapiens 107-112 15070854-8 2004 However, treatment of the cells with 1-50 microm ciglitazone (cig), induced apoptosis and reverted the antiapoptotic effects of GH by increasing the programmed cell death up to 3.5-fold at 30 min and up to 1.7-fold at 24 h. Expression of Bcl-2 and TNF-related apoptosis-induced ligand was not affected by either GH or cig treatment, whereas GH reduced the expression of Bax, which was increased by cig treatment. ciglitazone 49-60 BCL2 apoptosis regulator Homo sapiens 238-243 15070854-8 2004 However, treatment of the cells with 1-50 microm ciglitazone (cig), induced apoptosis and reverted the antiapoptotic effects of GH by increasing the programmed cell death up to 3.5-fold at 30 min and up to 1.7-fold at 24 h. Expression of Bcl-2 and TNF-related apoptosis-induced ligand was not affected by either GH or cig treatment, whereas GH reduced the expression of Bax, which was increased by cig treatment. ciglitazone 49-52 BCL2 apoptosis regulator Homo sapiens 238-243 15070854-8 2004 However, treatment of the cells with 1-50 microm ciglitazone (cig), induced apoptosis and reverted the antiapoptotic effects of GH by increasing the programmed cell death up to 3.5-fold at 30 min and up to 1.7-fold at 24 h. Expression of Bcl-2 and TNF-related apoptosis-induced ligand was not affected by either GH or cig treatment, whereas GH reduced the expression of Bax, which was increased by cig treatment. ciglitazone 62-65 BCL2 apoptosis regulator Homo sapiens 238-243 15070854-8 2004 However, treatment of the cells with 1-50 microm ciglitazone (cig), induced apoptosis and reverted the antiapoptotic effects of GH by increasing the programmed cell death up to 3.5-fold at 30 min and up to 1.7-fold at 24 h. Expression of Bcl-2 and TNF-related apoptosis-induced ligand was not affected by either GH or cig treatment, whereas GH reduced the expression of Bax, which was increased by cig treatment. ciglitazone 62-65 BCL2 apoptosis regulator Homo sapiens 238-243 15213601-3 2004 The expression of ER and bcl-2 was weaker in the adenomyotic endometrium treated with danazol than in that treated with gonadotro-pin-releasing hormone agonist (GnRHa), whereas bcl-2 phosphorylated on serine-87 was more intensely expressed in danazol-treated adenomyotic endometrium than in the GnRHa-treated one. Danazol 86-93 BCL2 apoptosis regulator Homo sapiens 25-30 15203082-6 2004 (2) The expression levels of Bcl-xL and Mcl-1, members of the anti-apoptotic Bcl-2 family, were sequentially determined by western blot analysis after treatment with PGE2R-A. pge2r-a 166-173 BCL2 apoptosis regulator Homo sapiens 77-82 15213601-3 2004 The expression of ER and bcl-2 was weaker in the adenomyotic endometrium treated with danazol than in that treated with gonadotro-pin-releasing hormone agonist (GnRHa), whereas bcl-2 phosphorylated on serine-87 was more intensely expressed in danazol-treated adenomyotic endometrium than in the GnRHa-treated one. Danazol 86-93 BCL2 apoptosis regulator Homo sapiens 177-182 15332326-3 2004 Down-regulation of Bcl-xL and Bcl-2 with DNA antisense oligonucleotides promotes cell death in glioblastoma cells. Oligonucleotides 55-71 BCL2 apoptosis regulator Homo sapiens 30-35 15156398-8 2004 CONCLUSION: We conclude that overexpression of antiapoptotic proteins Bcl-2 and Bcl-X(L) and down-regulation of caspase-3 activity may be associated with cisplatin resistance in human ovarian cancer. Cisplatin 154-163 BCL2 apoptosis regulator Homo sapiens 70-75 15332326-13 2004 Down-regulation of Bcl-xL and Bcl-2 resulted in reversal of the ratio of Bax/Bcl-xL and Bax/Bcl-2 and enhanced cell death after treatment with BCNU. Carmustine 143-147 BCL2 apoptosis regulator Homo sapiens 30-35 15332326-13 2004 Down-regulation of Bcl-xL and Bcl-2 resulted in reversal of the ratio of Bax/Bcl-xL and Bax/Bcl-2 and enhanced cell death after treatment with BCNU. Carmustine 143-147 BCL2 apoptosis regulator Homo sapiens 92-97 15158086-8 2004 More significantly, ajoene profoundly enhanced the apoptotic effect of the two chemotherapeutic drugs: cytarabine and fludarabine in human CD34-positive resistant myeloid leukaemia cells through enhancing their bcl-2 inhibitory and caspase-3 activation activities. ajoene 20-26 BCL2 apoptosis regulator Homo sapiens 211-216 15158086-8 2004 More significantly, ajoene profoundly enhanced the apoptotic effect of the two chemotherapeutic drugs: cytarabine and fludarabine in human CD34-positive resistant myeloid leukaemia cells through enhancing their bcl-2 inhibitory and caspase-3 activation activities. fludarabine 118-129 BCL2 apoptosis regulator Homo sapiens 211-216 15158086-11 2004 The apoptosis inducing activity of ajoene is via the mitochondria-dependent caspase cascade through a significant reduction of the anti-apoptotic bcl-2 that results in release of cytochrome c and the activation of caspase-3. ajoene 35-41 BCL2 apoptosis regulator Homo sapiens 146-151 15493834-12 2004 Bcl-2 phosphorylation became visible, in Western blot, within 6 h in CEM cells treated with JIMB01 at 0.15 micromol x L(-1) or higher for 24 h. JIMB01 increased the activities of caspase-3, -8 and -9 in CEM cells; DEVD-fmk, a caspase-3 inhibitor, inhibited the cytotoxicity of JIMB01 in CEM leukemia cells. devd-fmk 214-222 BCL2 apoptosis regulator Homo sapiens 0-5 15116122-10 2004 Similar to many other therapeutic targets, MS-275-mediated apoptosis is reduced by overexpression of Bcl-2, justifying strategies to combine HDAC inhibitors with Bcl-2 antagonists. entinostat 43-49 BCL2 apoptosis regulator Homo sapiens 101-106 15116122-10 2004 Similar to many other therapeutic targets, MS-275-mediated apoptosis is reduced by overexpression of Bcl-2, justifying strategies to combine HDAC inhibitors with Bcl-2 antagonists. entinostat 43-49 BCL2 apoptosis regulator Homo sapiens 162-167 15158365-2 2004 In the present study, we investigated the effect of armepavines and atherosperminine on the cell survival rate and expression of bcl-2 and caspase-3 in CCRF-CEM cells. armepavine 52-63 BCL2 apoptosis regulator Homo sapiens 129-134 15205081-9 2004 The expression levels of Bcl-2 protein on lymphoblasts were lower at the first hour than at 0 and 2 h in 10- and 20-U/mL heparin concentrations (p <.001). Heparin 121-128 BCL2 apoptosis regulator Homo sapiens 25-30 15205081-10 2004 The lowest expression of Bcl-2 protein was detected in the 20-U/mL heparin concentration at the first hour. Heparin 67-74 BCL2 apoptosis regulator Homo sapiens 25-30 15503780-5 2004 The expression of Bcl-2 was decreased in STT treated cells as compared with untreated control cells. SCHEMBL22553698 41-44 BCL2 apoptosis regulator Homo sapiens 18-23 15048072-8 2004 In addition, DETANONOate downregulated the expression of Bcl-2 related gene (Bcl-(xL)) which is under the transcriptional regulation of NF-kappa B. 2,2'-(hydroxynitrosohydrazono)bis-ethanamine 13-24 BCL2 apoptosis regulator Homo sapiens 57-62 15196944-3 2004 However, the relationship between ganglioside GD3 and B-cell/CLL lymphoma 2 (Bcl-2) is not fully understood. Gangliosides 34-45 BCL2 apoptosis regulator Homo sapiens 54-75 15196944-3 2004 However, the relationship between ganglioside GD3 and B-cell/CLL lymphoma 2 (Bcl-2) is not fully understood. Gangliosides 34-45 BCL2 apoptosis regulator Homo sapiens 77-82 15196944-4 2004 In this study, we have demonstrated that the downregulation of Bcl-2 by overexpression of CMP-NeuAc:GM3 alpha-2,8-sialyltransferase (GD3 synthase) results in an accelerated apoptosis in vascular endothelial cells (ECV304), as evidenced by DNA fragmentation and caspase-3 activation. N-Acetylneuraminic Acid 94-99 BCL2 apoptosis regulator Homo sapiens 63-68 15158365-2 2004 In the present study, we investigated the effect of armepavines and atherosperminine on the cell survival rate and expression of bcl-2 and caspase-3 in CCRF-CEM cells. atherospermine 68-84 BCL2 apoptosis regulator Homo sapiens 129-134 15158365-6 2004 The expression of bcl-2 protein in CCRF-CEM cells treated with 30 microM armepavine oxalate was significantly decreased in western blotting analysis. armepavine oxalate 73-91 BCL2 apoptosis regulator Homo sapiens 18-23 15158365-8 2004 These findings indicate the involvement of bcl-2 and caspase-3 in the apoptotic process of CCRF-CEM cells induced by armepavine oxalate. armepavine oxalate 117-135 BCL2 apoptosis regulator Homo sapiens 43-48 14764521-6 2004 Up-regulation of interleukin-2 (IL-2) and Bcl-2 were dependent on phosphatidylinositol-3-kinase signal transduction, given that it was down-regulated by Wortmanin treatment. Wortmannin 153-162 BCL2 apoptosis regulator Homo sapiens 42-47 15158365-9 2004 The increased expression of active caspase-3 as well as decreased expression of bcl-2 support the assumption the armepavine oxalate-treated cells may be capable to complete the entire apoptotic process ending in cell fragmentation. armepavine oxalate 113-131 BCL2 apoptosis regulator Homo sapiens 80-85 15217967-2 2004 Oblimersen sodium is an antisense oligonucleotide compound designed to specifically bind to human bcl-2 mRNA, resulting in catalytic degradation of bcl-2 mRNA and subsequent decrease in bcl-2 protein translation. Sodium 11-17 BCL2 apoptosis regulator Homo sapiens 98-103 15163549-7 2004 Simvastatin reduced the protein content and mRNA expression for bcl-2 without affecting bax mRNA expression. Simvastatin 0-11 BCL2 apoptosis regulator Homo sapiens 64-69 15217967-2 2004 Oblimersen sodium is an antisense oligonucleotide compound designed to specifically bind to human bcl-2 mRNA, resulting in catalytic degradation of bcl-2 mRNA and subsequent decrease in bcl-2 protein translation. Sodium 11-17 BCL2 apoptosis regulator Homo sapiens 148-153 15217967-2 2004 Oblimersen sodium is an antisense oligonucleotide compound designed to specifically bind to human bcl-2 mRNA, resulting in catalytic degradation of bcl-2 mRNA and subsequent decrease in bcl-2 protein translation. Sodium 11-17 BCL2 apoptosis regulator Homo sapiens 148-153 15217967-2 2004 Oblimersen sodium is an antisense oligonucleotide compound designed to specifically bind to human bcl-2 mRNA, resulting in catalytic degradation of bcl-2 mRNA and subsequent decrease in bcl-2 protein translation. Oligonucleotides 34-49 BCL2 apoptosis regulator Homo sapiens 98-103 15217967-2 2004 Oblimersen sodium is an antisense oligonucleotide compound designed to specifically bind to human bcl-2 mRNA, resulting in catalytic degradation of bcl-2 mRNA and subsequent decrease in bcl-2 protein translation. Oligonucleotides 34-49 BCL2 apoptosis regulator Homo sapiens 148-153 15217967-2 2004 Oblimersen sodium is an antisense oligonucleotide compound designed to specifically bind to human bcl-2 mRNA, resulting in catalytic degradation of bcl-2 mRNA and subsequent decrease in bcl-2 protein translation. Oligonucleotides 34-49 BCL2 apoptosis regulator Homo sapiens 148-153 15024582-4 2004 Furthermore, FK228 treatment also reduced the anti-apoptotic protein Bcl-xL in all GM cells and anti-apoptotic Bcl-2 in U87MG cells, thereby shifting the cellular equilibrium from life to death. romidepsin 13-18 BCL2 apoptosis regulator Homo sapiens 111-116 15188493-10 2004 After 96 h of incubation with mifepristone 10 micromol/L, a concentration close to plasma concentrations achievable in human, the expression of Bcl-2 protein was decreased to (9.21+/-0.65)% from (25.32+/-1.44)%, whereas the expression of Bax protein was increased to (19.69+/-1.13)% from (1.24+/-0.78)% (P<0.01). Mifepristone 30-42 BCL2 apoptosis regulator Homo sapiens 144-149 15188493-11 2004 Additionally, the effects of mifepristone on the expression of Bcl-2 and Bax proteins in SGC7901/VCR cells were further demonstrated by Western blotting analysis. Mifepristone 29-41 BCL2 apoptosis regulator Homo sapiens 63-68 15188493-12 2004 CONCLUSION: Mifepristone has potent reversal effect on MDR in SGC7901/VCR via inhibiting the function of MRP and P-gp, modulating the expression of Bcl-2 and Bax proteins, and enhancing the sensitivity to anticancer agent VCR. Mifepristone 12-24 BCL2 apoptosis regulator Homo sapiens 148-153 15174162-0 2004 A novel bis-aziridinylnaphthoquinone with anti-solid tumor activity in which induced apoptosis is associated with altered expression of Bcl-2 protein. bis-aziridinylnaphthoquinone 8-36 BCL2 apoptosis regulator Homo sapiens 136-141 15126114-5 2004 Further analyses showed that both PPT and DPN enhanced Bcl-2 expression in hippocampal neurons, with an efficacy comparable to their neuroprotective capacity. NAD 42-45 BCL2 apoptosis regulator Homo sapiens 55-60 15177426-0 2004 Chemosensitization of breast carcinoma cells with the use of bcl-2 antisense oligodeoxynucleotide. Oligodeoxyribonucleotides 77-97 BCL2 apoptosis regulator Homo sapiens 61-66 15135300-8 2004 Genistein reduced Bcl-2 phosphorylation triggered by paclitaxel and vincristine without changing Bax protein expression. Genistein 0-9 BCL2 apoptosis regulator Homo sapiens 18-23 15135300-8 2004 Genistein reduced Bcl-2 phosphorylation triggered by paclitaxel and vincristine without changing Bax protein expression. Paclitaxel 53-63 BCL2 apoptosis regulator Homo sapiens 18-23 15135300-8 2004 Genistein reduced Bcl-2 phosphorylation triggered by paclitaxel and vincristine without changing Bax protein expression. Vincristine 68-79 BCL2 apoptosis regulator Homo sapiens 18-23 15135300-11 2004 In conclusion, genistein inversely affected tubulin-binding agent-induced apoptosis via down-regulation of cyclin B1/CDC2 kinase expression resulting in reduced Bcl-2 phosphorylation. Genistein 15-24 BCL2 apoptosis regulator Homo sapiens 161-166 14742319-8 2004 In addition, the fact that the taxol-induced apoptosis rate, down-regulation of Bcl-2 and up-regulation of Bax were suppressed by PD098059 treatment in Id-1 expressing cells indicates that the Id-1 induced cellular protection against apoptosis is mediated through Raf/MEK signalling pathways. Paclitaxel 31-36 BCL2 apoptosis regulator Homo sapiens 80-85 15188515-8 2004 Immunohistochemical staining showed that after the treatment of primary gastric cancer cells with genistein for 24 to 96 h, the positivity rates of Bcl-2 proteins were apparently reduced with time and the positivity rates of Bax proteins were apparently increased with time. Genistein 98-107 BCL2 apoptosis regulator Homo sapiens 148-153 15188515-9 2004 After exposed to genistein at 20 micromol/L for 24, 48, 72 and 96 respectively, the density of bcl-2 mRNA decreased progressively and the density of bax mRNA increased progressively with elongation of time. Genistein 17-26 BCL2 apoptosis regulator Homo sapiens 95-100 15182386-6 2004 Since the bcl-2 promoter contained two ORE, and ORE-driven transcriptional activity and Bcl-2 mRNA expression were increased by treatment with 10 microm-quercetin or kaempferol, it is possible that quercetin and kaempferol might up-regulate Bcl-2 expression through OR transactivation in MCF-7 cells. Quercetin 153-162 BCL2 apoptosis regulator Homo sapiens 10-15 15182386-6 2004 Since the bcl-2 promoter contained two ORE, and ORE-driven transcriptional activity and Bcl-2 mRNA expression were increased by treatment with 10 microm-quercetin or kaempferol, it is possible that quercetin and kaempferol might up-regulate Bcl-2 expression through OR transactivation in MCF-7 cells. Quercetin 153-162 BCL2 apoptosis regulator Homo sapiens 88-93 15182386-6 2004 Since the bcl-2 promoter contained two ORE, and ORE-driven transcriptional activity and Bcl-2 mRNA expression were increased by treatment with 10 microm-quercetin or kaempferol, it is possible that quercetin and kaempferol might up-regulate Bcl-2 expression through OR transactivation in MCF-7 cells. Quercetin 153-162 BCL2 apoptosis regulator Homo sapiens 241-246 15182386-6 2004 Since the bcl-2 promoter contained two ORE, and ORE-driven transcriptional activity and Bcl-2 mRNA expression were increased by treatment with 10 microm-quercetin or kaempferol, it is possible that quercetin and kaempferol might up-regulate Bcl-2 expression through OR transactivation in MCF-7 cells. kaempferol 166-176 BCL2 apoptosis regulator Homo sapiens 10-15 15182386-6 2004 Since the bcl-2 promoter contained two ORE, and ORE-driven transcriptional activity and Bcl-2 mRNA expression were increased by treatment with 10 microm-quercetin or kaempferol, it is possible that quercetin and kaempferol might up-regulate Bcl-2 expression through OR transactivation in MCF-7 cells. kaempferol 166-176 BCL2 apoptosis regulator Homo sapiens 88-93 15182386-6 2004 Since the bcl-2 promoter contained two ORE, and ORE-driven transcriptional activity and Bcl-2 mRNA expression were increased by treatment with 10 microm-quercetin or kaempferol, it is possible that quercetin and kaempferol might up-regulate Bcl-2 expression through OR transactivation in MCF-7 cells. kaempferol 166-176 BCL2 apoptosis regulator Homo sapiens 241-246 15182386-6 2004 Since the bcl-2 promoter contained two ORE, and ORE-driven transcriptional activity and Bcl-2 mRNA expression were increased by treatment with 10 microm-quercetin or kaempferol, it is possible that quercetin and kaempferol might up-regulate Bcl-2 expression through OR transactivation in MCF-7 cells. Quercetin 198-207 BCL2 apoptosis regulator Homo sapiens 10-15 15182386-6 2004 Since the bcl-2 promoter contained two ORE, and ORE-driven transcriptional activity and Bcl-2 mRNA expression were increased by treatment with 10 microm-quercetin or kaempferol, it is possible that quercetin and kaempferol might up-regulate Bcl-2 expression through OR transactivation in MCF-7 cells. Quercetin 198-207 BCL2 apoptosis regulator Homo sapiens 88-93 15182386-6 2004 Since the bcl-2 promoter contained two ORE, and ORE-driven transcriptional activity and Bcl-2 mRNA expression were increased by treatment with 10 microm-quercetin or kaempferol, it is possible that quercetin and kaempferol might up-regulate Bcl-2 expression through OR transactivation in MCF-7 cells. kaempferol 212-222 BCL2 apoptosis regulator Homo sapiens 10-15 15177426-1 2004 This study was designed to observe whether the rates of apoptosis induced in the breast cancer cell line MCF-7 by 5-fluorouracil (5-FU) could be enhanced by transfecting bcl-2 antisense oligonucleotide (ASODN). Fluorouracil 114-128 BCL2 apoptosis regulator Homo sapiens 170-175 15177426-1 2004 This study was designed to observe whether the rates of apoptosis induced in the breast cancer cell line MCF-7 by 5-fluorouracil (5-FU) could be enhanced by transfecting bcl-2 antisense oligonucleotide (ASODN). Fluorouracil 130-134 BCL2 apoptosis regulator Homo sapiens 170-175 15177426-1 2004 This study was designed to observe whether the rates of apoptosis induced in the breast cancer cell line MCF-7 by 5-fluorouracil (5-FU) could be enhanced by transfecting bcl-2 antisense oligonucleotide (ASODN). Oligonucleotides 186-201 BCL2 apoptosis regulator Homo sapiens 170-175 15177426-1 2004 This study was designed to observe whether the rates of apoptosis induced in the breast cancer cell line MCF-7 by 5-fluorouracil (5-FU) could be enhanced by transfecting bcl-2 antisense oligonucleotide (ASODN). asodn 203-208 BCL2 apoptosis regulator Homo sapiens 170-175 15177426-5 2004 Moreover, incubation of MCF-7 with bcl-2 ASODN prior to 5-FU treatment caused remarkable loss of viable cells compared with all other control ODNs (P < 0.01). Fluorouracil 56-60 BCL2 apoptosis regulator Homo sapiens 35-40 15242250-4 2004 All-trans retinoic acid, taxol and okadiac acid induce downregulation or inactivation of nucleolin, which destabilizes bcl-2 mRNA and triggers apoptosis. Tretinoin 10-23 BCL2 apoptosis regulator Homo sapiens 119-124 15173074-1 2004 PURPOSE: G3139 is an antisense bcl-2 phosphorothioate oligodeoxyribonucleotide that is currently being evaluated in Phase III clinical trials in several human cancers. oblimersen 9-14 BCL2 apoptosis regulator Homo sapiens 31-36 15173074-1 2004 PURPOSE: G3139 is an antisense bcl-2 phosphorothioate oligodeoxyribonucleotide that is currently being evaluated in Phase III clinical trials in several human cancers. phosphorothioate oligodeoxyribonucleotide 37-78 BCL2 apoptosis regulator Homo sapiens 31-36 15242250-4 2004 All-trans retinoic acid, taxol and okadiac acid induce downregulation or inactivation of nucleolin, which destabilizes bcl-2 mRNA and triggers apoptosis. Paclitaxel 25-30 BCL2 apoptosis regulator Homo sapiens 119-124 15242250-4 2004 All-trans retinoic acid, taxol and okadiac acid induce downregulation or inactivation of nucleolin, which destabilizes bcl-2 mRNA and triggers apoptosis. okadiac acid 35-47 BCL2 apoptosis regulator Homo sapiens 119-124 15138626-7 2004 Although the expression of mRNA and protein of Bcl-2 decreased in 2008 cells after treatment with cisplatin, the expression of Bcl-2 remained unchanged in 2008 C-13 cells. Cisplatin 98-107 BCL2 apoptosis regulator Homo sapiens 47-52 15085157-0 2004 G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 9-14 15239399-5 2004 Results of immunohistochemical analysis of paraffin-embedded specimens were positive for cyclin D1 and Bcl2 in the tumor cells. Paraffin 43-51 BCL2 apoptosis regulator Homo sapiens 103-107 15153524-3 2004 Using digitonin-based subcellular fractionation and Western blotting, we found that spontaneous apoptosis of human neutrophils (after approximately 20 h of culture) was associated with translocation of two proapoptotic Bcl-2 homologues, Bid and Bax, to the mitochondria and truncation of Bid, with subsequent release of Omi/HtrA2 and Smac/DIABLO into the cytosol. Digitonin 6-15 BCL2 apoptosis regulator Homo sapiens 219-224 15157940-0 2004 Caffeine suppresses the expression of the Bcl-2 mRNA in BeWo cell culture and rat placenta. Caffeine 0-8 BCL2 apoptosis regulator Homo sapiens 42-47 15157940-3 2004 We found that the expression of the B-cell CLL/lymphoma 2 (Bcl-2) gene in BeWo cells was down-regulated by caffeine, suggesting that chronic exposure during the gestational period could exert an influence on embryogenesis. Caffeine 107-115 BCL2 apoptosis regulator Homo sapiens 36-57 15157940-3 2004 We found that the expression of the B-cell CLL/lymphoma 2 (Bcl-2) gene in BeWo cells was down-regulated by caffeine, suggesting that chronic exposure during the gestational period could exert an influence on embryogenesis. Caffeine 107-115 BCL2 apoptosis regulator Homo sapiens 59-64 15157940-5 2004 We found a significantly decreased level of Bcl-2 mRNA expression, which demonstrated the influence of caffeine on placental function. Caffeine 103-111 BCL2 apoptosis regulator Homo sapiens 44-49 15008459-7 2004 In addition, oridonin increased the expression of the apoptosis inducer, Bax, promoted the release of cytochrome c without affecting Bcl-2 expression, and activated down-stream caspase-9 in the mitochondrial pathway. oridonin 13-21 BCL2 apoptosis regulator Homo sapiens 133-138 15008459-8 2004 These observations indicated that an appropriate dose of oridonin gave an initial premitochondrial phase that involved the Bcl-2 family of the pro-apoptotic protein Bax that required the participation of caspase-9 and caspase-3. oridonin 57-65 BCL2 apoptosis regulator Homo sapiens 123-128 15085157-0 2004 G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma. Oligodeoxyribonucleotides 25-45 BCL2 apoptosis regulator Homo sapiens 9-14 15085157-3 2004 G3139 is an antisense oligodeoxynucleotide targeted to the first six codons of the Bcl-2 mRNA open reading frame. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 83-88 15085157-3 2004 G3139 is an antisense oligodeoxynucleotide targeted to the first six codons of the Bcl-2 mRNA open reading frame. Oligodeoxyribonucleotides 22-42 BCL2 apoptosis regulator Homo sapiens 83-88 15228663-5 2004 In addition, mevastatin caused the collapse of mitochondrial transmembrane potential (Deltapsim), induced DNA fragmentation, and down-regulated the mRNA expression of bcl-2. mevastatin 13-23 BCL2 apoptosis regulator Homo sapiens 167-172 15120582-7 2004 Over-expression of bcl-2 blunted low glucose-induced apoptosis and up-regulated IGF-I receptor, with the effect of IGF-I addition being negligible on apoptosis, while significantly enhancing mitochondrial activity. Glucose 37-44 BCL2 apoptosis regulator Homo sapiens 19-24 15120582-11 2004 The potent anti-apoptotic systems IGF-I and bcl-2 are both thus able to enhance cell survival in a glucose-deprived human neuronal model. Glucose 99-106 BCL2 apoptosis regulator Homo sapiens 44-49 15102520-8 2004 It also profoundly caused an increase in polymerized tubulin levels and Bcl-2 phosphorylation on serine 70 in these cells. Serine 97-103 BCL2 apoptosis regulator Homo sapiens 72-77 15102520-12 2004 Furthermore, several biological events including the Bcl-2 phosphorylation, Bax up-regulation and increase of caspase-3 activity could explain evodiamine-induced cell apoptosis. evodiamine 143-153 BCL2 apoptosis regulator Homo sapiens 53-58 15149601-1 2004 In healthy cells the antiapoptotic protein Bcl-2 adopts a topology typical of tail-anchored proteins with only the hydrophobic carboxyl terminus inserted into the membrane, as shown by labeling cell lysates with a membrane-impermeant sulfhydryl-specific reagent. Sulfhydryl Compounds 234-244 BCL2 apoptosis regulator Homo sapiens 43-48 15149601-2 2004 Induction of apoptosis in cells triggered a change in the conformation of Bcl-2 such that cysteine 158 near the base of helix 5 inserted into the lipid bilayer of both endoplasmic reticulum and mitochondria where it was protected from labeling. Cysteine 90-98 BCL2 apoptosis regulator Homo sapiens 74-79 15138474-5 2004 A combination of histological grade plus immunochemical staining for BCL-2, p27 and Cyclin D1, generated a useful prognostic index for tamoxifen-treated patients but not for those treated by surgery alone. Tamoxifen 135-144 BCL2 apoptosis regulator Homo sapiens 69-74 15183012-4 2004 Exposure to dieldrin (30-100 microM) produced significant cytotoxicity and caspase-3 activation within 3h in vector-transfected PC12 cells, whereas human Bcl-2-transfected PC12 cells were almost completely resistant to dieldrin-induced cytotoxicity and caspase-3 activation. Dieldrin 219-227 BCL2 apoptosis regulator Homo sapiens 154-159 15170083-4 2004 The neuroprotective effects of pramipexole seemed to be derived from several mechanisms: stimulation of D(2) autoreceptor, stimulation of D(3) receptor, inhibition of oxidative reaction and following radical production, increase of Bcl-2 protein and inhibition of apoptotic cell death, and production of neurotrophic factor. Pramipexole 31-42 BCL2 apoptosis regulator Homo sapiens 232-237 15120608-7 2004 Carboplatin inhibited NF-kappaB binding to its response element present in Bcl-2 promoter resulting in downregulation of antiapoptotic Bcl-2 protein. Carboplatin 0-11 BCL2 apoptosis regulator Homo sapiens 75-80 15120608-7 2004 Carboplatin inhibited NF-kappaB binding to its response element present in Bcl-2 promoter resulting in downregulation of antiapoptotic Bcl-2 protein. Carboplatin 0-11 BCL2 apoptosis regulator Homo sapiens 135-140 15142674-8 2004 A decrease in expression of p53, bcl-2, and bcl-X(L) was observed after 12 h exposure of 40 microM curcumin. Curcumin 99-107 BCL2 apoptosis regulator Homo sapiens 33-38 15024023-5 2004 Depletion of cellular polyamines by alpha-difluoromethylornithine induced levels of phosphorylated Akt and increased Akt kinase activity, although it had no effect on expression of total Akt, pERK, p38, and Bcl-2 proteins. Polyamines 22-32 BCL2 apoptosis regulator Homo sapiens 207-212 15102525-4 2004 The anti-apoptotic activity was confirmed with some of (-)-BPAP analogues, and the mechanism was found to be due to the direct stabilization of mitochondrial membrane potential and the induction of anti-apoptotic Bcl-2. (-)-bpap 55-63 BCL2 apoptosis regulator Homo sapiens 213-218 15228663-7 2004 It is concluded that mevastatin suppresses proliferation by inducing G(0)/G(1) phase arrest and triggering apoptosis via down-regulation of bcl-2 and reduction of Deltapsim, which may be attributed to the inhibition of MVA pathway by mevastatin. mevastatin 21-31 BCL2 apoptosis regulator Homo sapiens 140-145 14988393-7 2004 ZVAD, the pancaspase inhibitor, and Bcl-2 annulled the effect of Act D on SK1, demonstrating a role for cysteine proteases downstream of Bcl-2 in the down-regulation of SK1. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 0-4 BCL2 apoptosis regulator Homo sapiens 137-142 14766748-6 2004 We suggest that Bax is regulated by phosphorylation of Ser(184) in an Akt-dependent manner and that phosphorylation inhibits Bax effects on the mitochondria by maintaining the protein in the cytoplasm, heterodimerized with antiapoptotic Bcl-2 family members. Serine 55-58 BCL2 apoptosis regulator Homo sapiens 237-242 14988393-9 2004 Inhibition of cathepsin B, a lysosomal protease, produced a significant reversal of SK1 decline by Act D, suggesting that a multitude of ZVAD-sensitive cysteine proteases downstream of Bcl-2 mediated the SK1 decrease. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 137-141 BCL2 apoptosis regulator Homo sapiens 185-190 15132839-0 2004 Oridonin induces apoptosis of HeLa cells via altering expression of Bcl-2/Bax and activating caspase-3/ICAD pathway. oridonin 0-8 BCL2 apoptosis regulator Homo sapiens 68-73 15004018-0 2004 Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. Minocycline 0-11 BCL2 apoptosis regulator Homo sapiens 25-30 15004018-5 2004 We further show that Bcl-2 is a key molecular determinant of minocycline protection. Minocycline 61-72 BCL2 apoptosis regulator Homo sapiens 21-26 15004018-8 2004 Minocycline induced Bcl-2, which accumulated in mitochondria and interacted with death-promoting molecules including Bax, Bak, and Bid. Minocycline 0-11 BCL2 apoptosis regulator Homo sapiens 20-25 15004018-9 2004 Down-regulation of Bcl-2 by specific antisense oligonucleotides abolished the cytoprotective effects of minocycline. Oligonucleotides 47-63 BCL2 apoptosis regulator Homo sapiens 19-24 15004018-9 2004 Down-regulation of Bcl-2 by specific antisense oligonucleotides abolished the cytoprotective effects of minocycline. Minocycline 104-115 BCL2 apoptosis regulator Homo sapiens 19-24 15004018-11 2004 One mechanism for minocycline protection involves the induction of Bcl-2, an antiapoptotic protein. Minocycline 18-29 BCL2 apoptosis regulator Homo sapiens 67-72 15274354-10 2004 Induction of apoptosis in HMJ-38-treated HL-60 cells was accompanied by an apparent increase of cytosolic cytochrome c, down-regulation of Bcl-2, up-regulation of Bax and cleavage of pro-caspase-9, -3 and poly(ADP)ribosylpolymerase (PARP). 2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone 26-32 BCL2 apoptosis regulator Homo sapiens 139-144 15142122-7 2004 In addition, the PI-3K inhibitor partially blocked the effects of H(2)O(2) on up-regulation of Bcl-2 and Bcl-X(L) protein expression, down-regulation of Bax protein expression, and phosphorylation of Bcl-2 and IkappaBalpha. Hydrogen Peroxide 66-74 BCL2 apoptosis regulator Homo sapiens 95-100 15142122-7 2004 In addition, the PI-3K inhibitor partially blocked the effects of H(2)O(2) on up-regulation of Bcl-2 and Bcl-X(L) protein expression, down-regulation of Bax protein expression, and phosphorylation of Bcl-2 and IkappaBalpha. Hydrogen Peroxide 66-74 BCL2 apoptosis regulator Homo sapiens 200-205 15031723-2 2004 The aim of this study was to investigate if downregulation of bcl-2 or xIAP by RNA interference (RNAi) would sensitize MCF-7 cells to etoposide and doxorubicin. Etoposide 134-143 BCL2 apoptosis regulator Homo sapiens 62-67 15031723-2 2004 The aim of this study was to investigate if downregulation of bcl-2 or xIAP by RNA interference (RNAi) would sensitize MCF-7 cells to etoposide and doxorubicin. Doxorubicin 148-159 BCL2 apoptosis regulator Homo sapiens 62-67 15031723-6 2004 Therefore, downregulation of bcl-2 or xIAP by RNAi enhances the effects of etoposide and doxorubicin. Etoposide 75-84 BCL2 apoptosis regulator Homo sapiens 29-34 15031723-6 2004 Therefore, downregulation of bcl-2 or xIAP by RNAi enhances the effects of etoposide and doxorubicin. Doxorubicin 89-100 BCL2 apoptosis regulator Homo sapiens 29-34 14960579-7 2004 Whereas overexpression of Bcl-2 significantly attenuated IL-18-induced endothelial cell apoptosis, Bcl-2/Bcl-X(L) chimeric phosphorothioated 2"-MOE-modified antisense oligonucleotides potentiated the proapoptotic effects of IL-18. Oligonucleotides 167-183 BCL2 apoptosis regulator Homo sapiens 26-31 14748742-0 2004 Bcl2-low-expressing MCF7 cells undergo necrosis rather than apoptosis upon staurosporine treatment. Staurosporine 75-88 BCL2 apoptosis regulator Homo sapiens 0-4 14748742-3 2004 Rz-bcl2-expressing cells were more sensitive to staurosporine than control cells. Staurosporine 48-61 BCL2 apoptosis regulator Homo sapiens 3-7 14741615-0 2004 Effect of cobalt and chromium ions on bcl-2, bax, caspase-3, and caspase-8 expression in human U937 macrophages. Chromium 21-29 BCL2 apoptosis regulator Homo sapiens 38-43 14741615-2 2004 The purpose of this study was to analyze the effect of Co(2+) and Cr(3+) ions on the expression of bcl-2, bax, caspase-3 and caspase-8 to better understand the mechanisms leading to ion-induced apoptosis in macrophages. Cobalt(2+) 55-61 BCL2 apoptosis regulator Homo sapiens 99-104 14741615-7 2004 In conclusion, our results suggest that the modulation of the expression of proteins from the bcl-2 and the caspase families of proteins are implicated in the induction of macrophage apoptosis by Co(2+) and Cr(3+) ions. Cobalt(2+) 196-202 BCL2 apoptosis regulator Homo sapiens 94-99 15132839-10 2004 In addition, oridonin-induced apoptosis was associated with an increase in the expression of the apoptosis inducer Bax, and a significant reduction in expression of the apoptosis suppressor Bcl-2 in mitochondria. oridonin 13-21 BCL2 apoptosis regulator Homo sapiens 190-195 15326375-6 2004 4HPR-induced apoptosis in these cells was associated with stimulation of reactive oxygen species generation, decreased levels of Bcl-2 protein, release of cytochrome c into the cytosol, increased caspase-3 activity, and poly(ADP-ribose) polymerase cleavage. Fenretinide 0-4 BCL2 apoptosis regulator Homo sapiens 129-134 14688022-14 2004 The results suggest that in addition to inactivation of Akt-1 and alteration in the expression of the Bcl-2 family of proteins, activation of MEK-ERK is required for quercetin-induced apoptosis in A549 lung carcinoma cells. Quercetin 166-175 BCL2 apoptosis regulator Homo sapiens 102-107 15132839-11 2004 CONCLUSION: Oridonin induces HeLa cells apoptosis by altering balance of Bcl-2 and Bax protein expression and activation of caspase-3/ICAD pathway. oridonin 12-20 BCL2 apoptosis regulator Homo sapiens 73-78 15131061-2 2004 G3139, a phosphorothioate antisense oligonucleotide targeted to the initiation codon region of the bcl-2 mRNA, is currently being evaluated in several Phase II and Phase III clinical trials. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 99-104 14729592-3 2004 The phenomenon was observed in the Fas-resistant T24 bladder carcinoma cell line and in Jurkat T cells overexpressing the anti-apoptotic protein Bcl-2. ammonium ferrous sulfate 35-38 BCL2 apoptosis regulator Homo sapiens 145-150 15124184-7 2004 We also detected the active form of caspase-3 and Bid in apoptotic leukemia cells after treatment with 5-FU and/or anti-CD8 antibody, indicating that the drug and antibody induced cell death through caspase-3 and the signal pathway may involve the Bcl-2 protein family. Fluorouracil 103-107 BCL2 apoptosis regulator Homo sapiens 248-253 15131061-2 2004 G3139, a phosphorothioate antisense oligonucleotide targeted to the initiation codon region of the bcl-2 mRNA, is currently being evaluated in several Phase II and Phase III clinical trials. Parathion 9-25 BCL2 apoptosis regulator Homo sapiens 99-104 15131061-2 2004 G3139, a phosphorothioate antisense oligonucleotide targeted to the initiation codon region of the bcl-2 mRNA, is currently being evaluated in several Phase II and Phase III clinical trials. Oligonucleotides 36-51 BCL2 apoptosis regulator Homo sapiens 99-104 15131061-7 2004 CONCLUSIONS: These results strongly suggest that bcl-2 expression in DU145 cells is not strongly associated with the prolife phenotype and that the mechanism by which G3139 produces its cytostatic effects in this cell line is bcl-2 independent. oblimersen 167-172 BCL2 apoptosis regulator Homo sapiens 226-231 15131062-9 2004 PS-341 not only inhibited nuclear localization of NF-kappaB but also activated the caspase cascade, increased p21 and Bax levels, and decreased Bcl-2 levels. Bortezomib 0-6 BCL2 apoptosis regulator Homo sapiens 144-149 14736733-10 2004 In addition, ET-A receptor antagonists BQ123 and BQ485 partially blocked nonmyocyte-conditioned media-mediated antiapoptotic effect, ERK and CREB phosphorylation, and Bcl-2 protein increase. cyclo(Trp-Asp-Pro-Val-Leu) 39-44 BCL2 apoptosis regulator Homo sapiens 167-172 14736733-10 2004 In addition, ET-A receptor antagonists BQ123 and BQ485 partially blocked nonmyocyte-conditioned media-mediated antiapoptotic effect, ERK and CREB phosphorylation, and Bcl-2 protein increase. BQ 485 49-54 BCL2 apoptosis regulator Homo sapiens 167-172 15067355-6 2004 The functionality of the increased Bcl-2 protein was examined using resistance to bile salt-induced apoptosis as the endpoint. Bile Acids and Salts 82-91 BCL2 apoptosis regulator Homo sapiens 35-40 15140868-5 2004 17beta-Estradiol up-regulates epidermal growth factor (EGF) receptor, but down-regulates p53 protein in leiomyoma cells, whereas progesterone augments EGF and Bcl-2 protein, but inhibits insulin-like growth factor (IGF-I) and tumour necrosis factor (TNFalpha). Progesterone 129-141 BCL2 apoptosis regulator Homo sapiens 159-164 15291359-5 2004 Western blotting showed that 0.1 microM PAO downregulated the expression of both Bcl-2 and Bcl-X(L) proteins, whereas I microM As2O3 downregulated only Bcl-2 expression. Arsenic Trioxide 127-132 BCL2 apoptosis regulator Homo sapiens 152-157 15113961-12 2004 Estrogen-responsive pS2 mRNA expression in tumors did not differ among groups, but expression of the antiapoptotic marker B-cell lymphoma/leukemia-2 (bcl-2) in tumors from the E(2) + MC group was downregulated, compared to that of the E(2) treatment group. Methylcholanthrene 183-185 BCL2 apoptosis regulator Homo sapiens 150-155 15114276-2 2004 LCPUFAs suppress the production of tumor necrosis factor-alpha (TNF-alpha) (and so also of OX40, since it belongs to the family of TNFR) and the expression of Bcl-2, suggesting that these fatty acids have the ability to prevent/suppress autoimmune diseases. Fatty Acids 188-199 BCL2 apoptosis regulator Homo sapiens 159-164 15110811-7 2004 The cardioprotective abilities of PC were abolished with desipramine, which also downregulated a PC-mediated increase in antiapoptotic protein Bcl-2. pc 34-36 BCL2 apoptosis regulator Homo sapiens 143-148 15110811-7 2004 The cardioprotective abilities of PC were abolished with desipramine, which also downregulated a PC-mediated increase in antiapoptotic protein Bcl-2. Desipramine 57-68 BCL2 apoptosis regulator Homo sapiens 143-148 15110811-7 2004 The cardioprotective abilities of PC were abolished with desipramine, which also downregulated a PC-mediated increase in antiapoptotic protein Bcl-2. pc 97-99 BCL2 apoptosis regulator Homo sapiens 143-148 15110811-9 2004 CONCLUSIONS: The results suggested for the first time that sphingolipid can induce the expression of Bcl-2 warranting its clinical use as a pharmacologic PC agent. Sphingolipids 59-71 BCL2 apoptosis regulator Homo sapiens 101-106 15291359-5 2004 Western blotting showed that 0.1 microM PAO downregulated the expression of both Bcl-2 and Bcl-X(L) proteins, whereas I microM As2O3 downregulated only Bcl-2 expression. oxophenylarsine 40-43 BCL2 apoptosis regulator Homo sapiens 81-86 15291359-7 2004 PAO-induced apoptosis seems to be related to the activation of the mitochondrial pathway and downregulation of both Bcl-2 and Bcl-X(L). oxophenylarsine 0-3 BCL2 apoptosis regulator Homo sapiens 116-121 15291360-0 2004 Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells. Bryostatins 0-10 BCL2 apoptosis regulator Homo sapiens 91-96 15291360-5 2004 This resistance was associated with an early up-regulation of the anti-apoptotic protein Mcl-1 and post-translational phosphorylation of Bcl-2 at serine 70. Serine 146-152 BCL2 apoptosis regulator Homo sapiens 137-142 15271313-0 2004 Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides. Cisplatin 16-25 BCL2 apoptosis regulator Homo sapiens 88-93 15271313-0 2004 Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides. Oligonucleotides 104-120 BCL2 apoptosis regulator Homo sapiens 88-93 15271313-1 2004 BACKGROUND: The aim of our study was to examine the effects of the combined application of cisplatin and bcl-2 antisense oligonucleotide on human bladder cancer cell lines to determine the possible synergistic effects in cytotoxicity and to estimate its potential value for subsequent in vivo trials. Oligonucleotides 121-136 BCL2 apoptosis regulator Homo sapiens 105-110 14966123-3 2004 In this study, we investigated the upstream mechanism of cytochrome c release induced by ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA14-1), a recently discovered small molecule inhibitor of Bcl-2. ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate 89-168 BCL2 apoptosis regulator Homo sapiens 229-234 15070698-7 2004 Low doses of CDDO-Im and bortezomib overcome the cytoprotective effects of antiapoptotic proteins Bcl2 and heat shock protein-27 (Hsp27) as well as nuclear factor-kappa B (NF-kappaB)-mediated growth/survival and drug resistance. 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole 13-20 BCL2 apoptosis regulator Homo sapiens 98-102 14991574-7 2004 2-MeOE2 bis-sulfamate and 2-EtE2 sulfamate both induced BCL-2 phosphorylation, p53 protein expression and apoptosis in HUVECs. 2-meoe2 bis-sulfamate 0-21 BCL2 apoptosis regulator Homo sapiens 56-61 14991574-7 2004 2-MeOE2 bis-sulfamate and 2-EtE2 sulfamate both induced BCL-2 phosphorylation, p53 protein expression and apoptosis in HUVECs. 2-ete2 sulfamate 26-42 BCL2 apoptosis regulator Homo sapiens 56-61 15077178-4 2004 Treatment of 2F7 cells with Rituximab or the p38 inhibitor SB203580 inhibited the constitutive p38 MAPK activity and resulted in the inhibition of Sp1, IL-10, STAT3, and Bcl-2. SB 203580 59-67 BCL2 apoptosis regulator Homo sapiens 170-175 15070698-7 2004 Low doses of CDDO-Im and bortezomib overcome the cytoprotective effects of antiapoptotic proteins Bcl2 and heat shock protein-27 (Hsp27) as well as nuclear factor-kappa B (NF-kappaB)-mediated growth/survival and drug resistance. Bortezomib 25-35 BCL2 apoptosis regulator Homo sapiens 98-102 14726674-8 2004 In addition, STI571 treatment affected the balance of the Bcl-2 family of apoptosis regulators on favor of a pro-apoptotic phenotype. Imatinib Mesylate 13-19 BCL2 apoptosis regulator Homo sapiens 58-63 15068807-6 2004 Finally, while Bcl-2 and Bcl-x(L), negative regulators of mitochondrial-regulated apoptosis, could effectively block O(6)MeG/MutSalpha-dependent apoptosis, they were unable to prevent the cells from ultimately dying. o(6) 117-121 BCL2 apoptosis regulator Homo sapiens 15-20 15064360-3 2004 Both types were at least as effective as G3139 (Genta, Inc.) in reducing the level of Bcl-2 protein in T24 cells following a 4 h transfection at a dose of 0.1 micro M. Circular dichroism spectra showed that both types formed A-form duplexes with the complementary RNA, and the melting temperatures were in the order of Me-S-ODN.RNA > normal DNA.RNA > S-ODN.RNA. oblimersen 41-46 BCL2 apoptosis regulator Homo sapiens 86-91 15064360-3 2004 Both types were at least as effective as G3139 (Genta, Inc.) in reducing the level of Bcl-2 protein in T24 cells following a 4 h transfection at a dose of 0.1 micro M. Circular dichroism spectra showed that both types formed A-form duplexes with the complementary RNA, and the melting temperatures were in the order of Me-S-ODN.RNA > normal DNA.RNA > S-ODN.RNA. genta 48-53 BCL2 apoptosis regulator Homo sapiens 86-91 14961568-7 2004 Celecoxib, in a dose- and time-dependent manner, induced MM cell apoptosis, which involved decreased Akt phosphorylation, loss of Bcl-2 and Survivin protein expression and caspase-3 activation. Celecoxib 0-9 BCL2 apoptosis regulator Homo sapiens 130-135 15077150-3 2004 But currently a controversy exists regarding reported effects of Bcl-2 on the calcium concentration within the lumen of the endoplasmic reticulum. Calcium 78-85 BCL2 apoptosis regulator Homo sapiens 65-70 15077150-4 2004 Although several prominent reports indicate that Bcl-2 overexpression is associated with a decrease in luminal calcium, there are a large number of reports indicating that Bcl-2 either does not decrease luminal calcium or actually increases luminal calcium. Calcium 111-118 BCL2 apoptosis regulator Homo sapiens 49-54 15039212-7 2004 In cases of LOH, there was a preferential loss of the proline allele, which was associated with an up-regulation of Bcl2 and lack of co-expression of Fas/FasL and, thus, impaired apoptosis (P < 0.001). Proline 54-61 BCL2 apoptosis regulator Homo sapiens 116-120 15059137-9 2004 BCL-2, BCL-XL and MCL-1 showed decreased expression in depsipeptide-treated samples. Depsipeptides 55-67 BCL2 apoptosis regulator Homo sapiens 0-5 14666386-0 2004 Bcl-2 overexpression prevents 99mTc-MIBI uptake in breast cancer cell lines. 2-methoxyisobutylisonitrile 35-40 BCL2 apoptosis regulator Homo sapiens 0-5 14688026-10 2004 Low dose lindane (10(-12)-10(-10) M) significantly elevated the percentage of MCF-7 cells staining positive for Bcl-2 and of PC-3 cells staining positive for Bax. Hexachlorocyclohexane 9-16 BCL2 apoptosis regulator Homo sapiens 112-117 14666386-1 2004 We have previously shown a correlation between the absence of technetium-99m methoxyisobutylisonitrile ((99m)Tc-MIBI) uptake and overexpression of the anti-apoptotic protein Bcl-2 in human breast carcinoma. 2-methoxyisobutylisonitrile 77-102 BCL2 apoptosis regulator Homo sapiens 174-179 14666386-1 2004 We have previously shown a correlation between the absence of technetium-99m methoxyisobutylisonitrile ((99m)Tc-MIBI) uptake and overexpression of the anti-apoptotic protein Bcl-2 in human breast carcinoma. Technetium 62-72 BCL2 apoptosis regulator Homo sapiens 174-179 14666386-1 2004 We have previously shown a correlation between the absence of technetium-99m methoxyisobutylisonitrile ((99m)Tc-MIBI) uptake and overexpression of the anti-apoptotic protein Bcl-2 in human breast carcinoma. Technetium Tc 99m Sestamibi 109-116 BCL2 apoptosis regulator Homo sapiens 174-179 14666386-2 2004 To establish a direct cause-effect relationship between Bcl-2 overexpression and reduced (99m)Tc-MIBI uptake, MCF-7 and T47D breast cancer cell lines were stably transfected with the human Bcl-2 gene to increase intracellular protein levels and tested for (99m)Tc-MIBI uptake. Technetium Tc 99m Sestamibi 94-101 BCL2 apoptosis regulator Homo sapiens 56-61 14666386-3 2004 All clones overexpressing Bcl-2 showed a dramatic reduction of (99m)Tc-MIBI uptake as compared with mock transfected control cells. Technetium Tc 99m Sestamibi 68-75 BCL2 apoptosis regulator Homo sapiens 26-31 15075075-9 2004 The effect of LAQ824 was due to increased apoptosis accompanied by activation of caspase-3 and caspase-9, cleavage of poly(ADP-ribose)-polymerase (PARP) as well as by down-regulation of Bcl-2 and disruption of the mitochondrial membrane potential. LAQ824 14-20 BCL2 apoptosis regulator Homo sapiens 186-191 14666386-5 2004 After 4.5 h of staurosporine treatment, a tenfold increase in (99m)Tc-MIBI uptake was observed in treated as compared with untreated Bcl-2 overexpressing cells. Staurosporine 15-28 BCL2 apoptosis regulator Homo sapiens 133-138 14666386-5 2004 After 4.5 h of staurosporine treatment, a tenfold increase in (99m)Tc-MIBI uptake was observed in treated as compared with untreated Bcl-2 overexpressing cells. Technetium Tc 99m Sestamibi 67-74 BCL2 apoptosis regulator Homo sapiens 133-138 14739660-6 2004 Our results demonstrated that high concentrations of MTBITC can also induce apoptosis, through an increase of p53 and bax, but not bcl-2, protein expression. 4-methylthiobutyl isothiocyanate 53-59 BCL2 apoptosis regulator Homo sapiens 131-136 15120184-5 2004 Pretreatment of EC with the PI3K inhibitor wortmannin blocked class I-mediated expression of Bcl-2, but not Bcl-xL, suggesting a role for the PI3K/Akt signaling pathway in regulation of class I-induced Bcl-2 expression. Wortmannin 43-53 BCL2 apoptosis regulator Homo sapiens 93-98 15120184-5 2004 Pretreatment of EC with the PI3K inhibitor wortmannin blocked class I-mediated expression of Bcl-2, but not Bcl-xL, suggesting a role for the PI3K/Akt signaling pathway in regulation of class I-induced Bcl-2 expression. Wortmannin 43-53 BCL2 apoptosis regulator Homo sapiens 202-207 15010857-0 2004 Staurosporine-induced apoptosis in Chang liver cells is associated with down-regulation of Bcl-2 and Bcl-XL. Staurosporine 0-13 BCL2 apoptosis regulator Homo sapiens 91-96 15037574-8 2004 RESULTS: Tbeta(4) treatment decreased deleterious mitochondrial alterations, significantly decreased cytochrome c release from mitochondria, and increased Bcl-2 expression in ethanol-exposed human corneal epithelial cells. Ethanol 175-182 BCL2 apoptosis regulator Homo sapiens 155-160 15051014-7 2004 RESULTS: Both the chemotherapeutic agents gemcitabine and paclitaxel activated NF-kappaB and stimulated BCL-2 gene promoter activity. gemcitabine 42-53 BCL2 apoptosis regulator Homo sapiens 104-109 15051014-7 2004 RESULTS: Both the chemotherapeutic agents gemcitabine and paclitaxel activated NF-kappaB and stimulated BCL-2 gene promoter activity. Paclitaxel 58-68 BCL2 apoptosis regulator Homo sapiens 104-109 15121343-6 2004 Studies have revealed that both VPA and lithium altered the expression of several early inducible genes belonging to the AP-1 family of transcription factors; this family is responsible for controlling the expression of a number of genes including cytoprotective proteins such as the anti-apoptotic protein, bcl-2. Lithium 40-47 BCL2 apoptosis regulator Homo sapiens 308-313 15121343-7 2004 Evidence shows that chronic administration of VPA or lithium can stimulate bcl-2 expression as well as inhibit GSK-3 beta activity, which renders a cell less susceptible to apoptosis. Valproic Acid 46-49 BCL2 apoptosis regulator Homo sapiens 75-80 15121343-7 2004 Evidence shows that chronic administration of VPA or lithium can stimulate bcl-2 expression as well as inhibit GSK-3 beta activity, which renders a cell less susceptible to apoptosis. Lithium 53-60 BCL2 apoptosis regulator Homo sapiens 75-80 15034938-5 2004 While treatment of cells with taxol resulted in bcl-2 phosphorylation and mitochondrial depolarization, cytochrome c was not released and pro-caspase-3 was not activated. Paclitaxel 30-35 BCL2 apoptosis regulator Homo sapiens 48-53 15033191-8 2004 1.0 microM of minoxidil increased Bcl-2 expression over 150%, while 1.0 microM of minoxidil decreased Bax expression by more than 50%. Minoxidil 14-23 BCL2 apoptosis regulator Homo sapiens 34-39 15033191-10 2004 CONCLUSION: Minoxidil promotes the survival of human DPCs by activating both ERK and Akt and by preventing cell death by increasing the ratio of Bcl-2/Bax. Minoxidil 12-21 BCL2 apoptosis regulator Homo sapiens 145-150 15010857-6 2004 Western blotting analysis showed that in Chang liver cells staurosporine induced a marked decrease in the levels of the antiapoptotic factors Bcl-2 (-75%) and Bcl-XL (-50%). Staurosporine 59-72 BCL2 apoptosis regulator Homo sapiens 142-147 15010857-11 2004 We conclude that staurosporine induced apoptosis in Chang liver cells by a mitochondria-caspase-dependent pathway which was closely correlated with a decrease in Bcl-2 and Bcl-XL levels, while in HuH-6 and HepG2 hepatoma cells the drug caused only an antiproliferative effect. Staurosporine 17-30 BCL2 apoptosis regulator Homo sapiens 162-167 15052673-7 2004 CONCLUSION: Treatment with 10.0 mmol/L of HMBA can significantly inhibit the growth and induce apoptosis of human hepatocellular carcinoma SMMC-7721 cells by decreasing the ratio of Bcl-2 to Bax. hexamethylene bisacetamide 42-46 BCL2 apoptosis regulator Homo sapiens 182-187 15051039-7 2004 Bcl-2 expression was investigated by immunohistochemistry from paraffin-embedded tissue. Paraffin 63-71 BCL2 apoptosis regulator Homo sapiens 0-5 15078986-6 2004 SBHA down-regulated several key antiapoptotic proteins including X-linked inhibitor of apoptosis and the Bcl-2 family proteins, Bcl-XL and Mcl-1. suberic bishydroxamate 0-4 BCL2 apoptosis regulator Homo sapiens 105-110 15078986-8 2004 In addition, SBHA induced relocation of the protein Bim to mitochondria and its association with Bcl-2. suberic bishydroxamate 13-17 BCL2 apoptosis regulator Homo sapiens 97-102 15179620-5 2004 Downstream proangiogenic actions of these eicosanoid products include: (1) production of vascular endothelial growth factor; (2) promotion of vascular sprouting, migration, and tube formation; (3) enhanced endothelial cell survival via Bcl-2 expression and Akt signaling; (4) induction of matrix metalloproteinases; (5) activation of epidermal growth factor receptor-mediated angiogenesis; and (6) suppression of interleukin-12 production. Eicosanoids 42-52 BCL2 apoptosis regulator Homo sapiens 236-241 15186734-3 2004 Our data also show that FL in synergy with TPO may inhibit apoptosis in megakaryocyte development by up-regulating bcl-2 and inducing conformational changes of p53, in MK progenitors. fl 24-26 BCL2 apoptosis regulator Homo sapiens 115-120 15030396-4 2004 This death pathway can be blocked by anti-apoptotic members of the Bcl-2 protein family that might shift redox potential to a more reduced state, preventing free radical-mediated damage. Free Radicals 157-169 BCL2 apoptosis regulator Homo sapiens 67-72 15078983-0 2004 N"-(phenyl-pyridin-2-yl-methylene)-hydrazine carbodithioic acid methyl ester enhances radiation-induced cell death by targeting Bcl-2 against human lung carcinoma cells. N'-(phenylpyridin-2-ylmethylene)hydrazine carbodithioic acid methyl ester 0-76 BCL2 apoptosis regulator Homo sapiens 128-133 15052690-13 2004 After being treated with octreotide, the expressions of both mutant-type p53 and bcl-2 decreased considering the percentage of positive cells (P<0.05). Octreotide 25-35 BCL2 apoptosis regulator Homo sapiens 81-86 15052690-15 2004 The reduction of mutant-type p53 and bcl-2 expressions may be associated with the apoptosis induced by octreotide. Octreotide 103-113 BCL2 apoptosis regulator Homo sapiens 37-42 15046727-4 2004 We further demonstrate that odorant stimuli rescue OSNs in a cAMP-dependent manner by activating the MAPK/CREB-dependent transcriptional pathway, possibly as a result of expression of Bcl-2. Cyclic AMP 61-65 BCL2 apoptosis regulator Homo sapiens 184-189 15003505-2 2004 Bak, a member of the Bcl-2 protein family, accelerates apoptosis by an unknown mechanism. bakuchiol 0-3 BCL2 apoptosis regulator Homo sapiens 21-26 15006371-0 2004 Synthesis and helical structure of lactam bridged BH3 peptides derived from pro-apoptotic Bcl-2 family proteins. Lactams 35-41 BCL2 apoptosis regulator Homo sapiens 90-95 15020613-0 2004 Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. Oligonucleotides 42-57 BCL2 apoptosis regulator Homo sapiens 26-31 14699151-6 2004 The data presented here demonstrate that the bcl-2 homology 4 (BH4) domain, specifically amino acids 17-31, is necessary for the bcl-2 interaction with paxillin. Sapropterin 63-66 BCL2 apoptosis regulator Homo sapiens 45-50 14699151-6 2004 The data presented here demonstrate that the bcl-2 homology 4 (BH4) domain, specifically amino acids 17-31, is necessary for the bcl-2 interaction with paxillin. Sapropterin 63-66 BCL2 apoptosis regulator Homo sapiens 129-134 14699151-7 2004 Paxillin also associated with the BH4 domains of more closely related bcl-2 family members, bcl-xL and bcl-w, compared with that from the non-mammalian homologue ced9. Sapropterin 34-37 BCL2 apoptosis regulator Homo sapiens 70-75 14699151-8 2004 Tyrosines 21 and 28 in the bcl-2 BH4 domain were essential for interaction with paxillin. Tyrosine 0-9 BCL2 apoptosis regulator Homo sapiens 27-32 14699151-9 2004 In embryonic kidney organ culture, incubation with the bcl-2 BH4 domain resulted in inhibition of ureteric bud branching. Sapropterin 61-64 BCL2 apoptosis regulator Homo sapiens 55-60 15004148-8 2004 The ability of the Bcl-2 transgene to protect Jurkat cells from RelA degradation, caspase activation, and apoptosis implicates the mitochondria in these SK-RC-45 ganglioside-mediated effects. Gangliosides 162-173 BCL2 apoptosis regulator Homo sapiens 19-24 15026354-9 2004 Moreover, the spontaneous phosphorylation of antiapoptotic Bcl-2 in the G(2)-M synchronized cells was enhanced synergistically by the BITC treatment. benzyl isothiocyanate 134-138 BCL2 apoptosis regulator Homo sapiens 59-64 14679209-2 2004 Our earlier studies indicated that taxol- or okadaic acid-induced bcl-2 mRNA destabilization in HL-60 cells is associated with decreased binding of trans-acting factors to the ARE. Paclitaxel 35-40 BCL2 apoptosis regulator Homo sapiens 66-71 14679209-2 2004 Our earlier studies indicated that taxol- or okadaic acid-induced bcl-2 mRNA destabilization in HL-60 cells is associated with decreased binding of trans-acting factors to the ARE. Okadaic Acid 45-57 BCL2 apoptosis regulator Homo sapiens 66-71 14679209-8 2004 Taxol or okadaic acid treatment of HL-60 cells results in proteolysis of nucleolin in a similar time frame as drug-induced bcl-2 mRNA down-regulation. Paclitaxel 0-5 BCL2 apoptosis regulator Homo sapiens 123-128 14679209-8 2004 Taxol or okadaic acid treatment of HL-60 cells results in proteolysis of nucleolin in a similar time frame as drug-induced bcl-2 mRNA down-regulation. Okadaic Acid 9-21 BCL2 apoptosis regulator Homo sapiens 123-128 14679209-9 2004 These findings suggest that nucleolin functions as a bcl-2-stabilizing factor and that taxol and okadaic acid treatment induces apoptosis in HL-60 cells through a process that involves down-regulation of nucleolin and destabilization of bcl-2 mRNA. Paclitaxel 87-92 BCL2 apoptosis regulator Homo sapiens 237-242 14679209-9 2004 These findings suggest that nucleolin functions as a bcl-2-stabilizing factor and that taxol and okadaic acid treatment induces apoptosis in HL-60 cells through a process that involves down-regulation of nucleolin and destabilization of bcl-2 mRNA. Okadaic Acid 97-109 BCL2 apoptosis regulator Homo sapiens 237-242 15026354-0 2004 A link between benzyl isothiocyanate-induced cell cycle arrest and apoptosis: involvement of mitogen-activated protein kinases in the Bcl-2 phosphorylation. benzyl isothiocyanate 15-36 BCL2 apoptosis regulator Homo sapiens 134-139 15026354-7 2004 We reported here for the first time that the antiapoptotic Bcl-2 protein was phosphorylated by the BITC treatment without significant alteration of the Bcl-2 total protein amount. benzyl isothiocyanate 99-103 BCL2 apoptosis regulator Homo sapiens 59-64 15020613-2 2004 Bcl-2 suppression by G3139 (oblimersen sodium), a phosphorothioate oligonucleotide complementary to the bcl-2 mRNA, has the potential to enhance the antitumor efficacy of standard cytotoxic chemotherapy. Phosphorothioate Oligonucleotides 50-82 BCL2 apoptosis regulator Homo sapiens 0-5 14996496-4 2004 Both pro- and anti-apoptotic Bcl-2 family members can regulate endoplasmic reticulum calcium, cellular pH and endoplasmic reticulum resident proteins. Calcium 85-92 BCL2 apoptosis regulator Homo sapiens 29-34 14759493-6 2004 These results suggest that HP enhances the hypoxic tolerance of hypothalamic neurons, and the underlying mechanisms may be related to the increased stability of MMP and the overexpression of Bcl-2 induced by HP. Hematoporphyrins 27-29 BCL2 apoptosis regulator Homo sapiens 191-196 14759493-6 2004 These results suggest that HP enhances the hypoxic tolerance of hypothalamic neurons, and the underlying mechanisms may be related to the increased stability of MMP and the overexpression of Bcl-2 induced by HP. Hematoporphyrins 208-210 BCL2 apoptosis regulator Homo sapiens 191-196 15152945-6 2004 CONCLUSION: Although some resistant sublines express a variant pattern of suppressor/oncogenes with low bcl-2, resistance is substantially reversed by paclitaxel treatment. Paclitaxel 151-161 BCL2 apoptosis regulator Homo sapiens 104-109 14975768-0 2004 Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells. Paclitaxel 52-62 BCL2 apoptosis regulator Homo sapiens 0-5 14975768-5 2004 Instead, SNU-398 cells express high levels of the anti-apoptotic Bcl-2 and Bcl-x(L) proteins and the level of Bcl-x(L) could be further induced upon paclitaxel treatment. Paclitaxel 149-159 BCL2 apoptosis regulator Homo sapiens 65-70 14975768-7 2004 Therefore, these results strongly suggest that Bcl-2 and Bcl-x(L) play an important role in mediating resistance to paclitaxel. Paclitaxel 116-126 BCL2 apoptosis regulator Homo sapiens 47-52 14726646-7 2004 In contrast, paclitaxel-induced apoptosis MM depolarization, cytochrome C release and activation of caspase 9 were all blocked by Bcl-2. Paclitaxel 13-23 BCL2 apoptosis regulator Homo sapiens 130-135 14610615-15 2004 Bcl-2 phosphorylation occurred after exposure to DTX at a concentration equivalent to the clinical dose, but did not occur after exposure to PTX in KFTx cells. Docetaxel 49-52 BCL2 apoptosis regulator Homo sapiens 0-5 15016329-1 2004 The anti-apoptotic protein, Bcl-2 was phosphorylated at the Ser-87 residue in normal human blood cells, while it was not phosphorylated in tumor cells. Serine 60-63 BCL2 apoptosis regulator Homo sapiens 28-33 14996734-9 2004 PCDGF/GP88 blocked tamoxifen-induced apoptosis by preventing down-regulation of bcl-2 expression and poly(ADP-ribose) polymerase cleavage. Tamoxifen 19-28 BCL2 apoptosis regulator Homo sapiens 80-85 14996748-6 2004 IL-10 inhibition by AS101 results in dephosphorylation of Stat3, followed by reduced expression of Bcl-2. ammonium trichloro(dioxoethylene-O,O'-)tellurate 20-25 BCL2 apoptosis regulator Homo sapiens 99-104 14726646-5 2004 ATO rapidly induced Apo2/TRAIL, activation of caspase 8, cleavage of BID, depolarization of mitochondrial membrane (MM) and release of AIF from mitochondria in a Bcl-2 independent fashion. Arsenic Trioxide 0-3 BCL2 apoptosis regulator Homo sapiens 162-167 15123268-3 2004 Our compound, Apogossypol, is capable of binding and inhibiting Bcl-2 and Bcl-X(L) with high affinity and induces apoptosis of tumor cell lines. apogossypol 14-25 BCL2 apoptosis regulator Homo sapiens 64-69 15032666-12 2004 For example, Herceptin trade mark inhibits ErbB2 function and anti-sense oligonucleotides against Bcl-2 reduce Bcl-2 expression. Oligonucleotides 73-89 BCL2 apoptosis regulator Homo sapiens 98-103 15032666-12 2004 For example, Herceptin trade mark inhibits ErbB2 function and anti-sense oligonucleotides against Bcl-2 reduce Bcl-2 expression. Oligonucleotides 73-89 BCL2 apoptosis regulator Homo sapiens 111-116 15013030-4 2004 Valproate also markedly increased Bcl-2 mRNA levels by 260%, but only in hNT neurons. Valproic Acid 0-9 BCL2 apoptosis regulator Homo sapiens 34-39 15016329-3 2004 Treatment of the tumor cells with a PP2A inhibitor resulted in the appearance of Bcl-2 phosphorylation at Ser-87. Serine 106-109 BCL2 apoptosis regulator Homo sapiens 81-86 15016329-5 2004 Phosphorylation of Bcl-2 protein at the Ser-87 residue resulted in a reduction in anti-apoptotic function in human tumor cell lines. Serine 40-43 BCL2 apoptosis regulator Homo sapiens 19-24 14712481-5 2004 These effects, associated with an up-regulation of p53, p21 and bax, a shuttling of p53 protein into the nucleus and a down-regulation of bcl-2, survivin and p27 protein, were reversed by the simultaneous addition of guanine or guanosine and were more evident using nondialysed serum containing hypoxanthine. Guanosine 228-237 BCL2 apoptosis regulator Homo sapiens 138-143 15037411-9 2004 Bcl-2 expression decreased in 12 of 15, increased in 2 of 15, and remained unchanged in 1 of 15 subjects in the tibolone group, compared with 5 of 19, 9 of 19, and 5 of 19 subjects, respectively, in the CEE-MPA group. tibolone 112-120 BCL2 apoptosis regulator Homo sapiens 0-5 14712481-5 2004 These effects, associated with an up-regulation of p53, p21 and bax, a shuttling of p53 protein into the nucleus and a down-regulation of bcl-2, survivin and p27 protein, were reversed by the simultaneous addition of guanine or guanosine and were more evident using nondialysed serum containing hypoxanthine. Hypoxanthine 295-307 BCL2 apoptosis regulator Homo sapiens 138-143 14712481-5 2004 These effects, associated with an up-regulation of p53, p21 and bax, a shuttling of p53 protein into the nucleus and a down-regulation of bcl-2, survivin and p27 protein, were reversed by the simultaneous addition of guanine or guanosine and were more evident using nondialysed serum containing hypoxanthine. Guanine 217-224 BCL2 apoptosis regulator Homo sapiens 138-143 15094967-6 2004 Pretreatment of cells with the PPAR-gamma ligand pioglitazone blocked TNF-alpha-mediated apoptosis, caspase-3 activation, expression of Bcl-2, and lipid peroxidation (P <.01 vs TNF-alpha alone). Pioglitazone 49-61 BCL2 apoptosis regulator Homo sapiens 136-141 14966372-4 2004 In our present study, we showed that A1, a constitutive and inducible Bcl-2 homologue expressed in mature circulating human neutrophils, might confer the protection from hydrogen peroxide (H(2)O(2))- and peroxynitrite (ONOO)-induced cell death. Hydrogen Peroxide 170-187 BCL2 apoptosis regulator Homo sapiens 70-75 14966372-4 2004 In our present study, we showed that A1, a constitutive and inducible Bcl-2 homologue expressed in mature circulating human neutrophils, might confer the protection from hydrogen peroxide (H(2)O(2))- and peroxynitrite (ONOO)-induced cell death. Hydrogen Peroxide 189-198 BCL2 apoptosis regulator Homo sapiens 70-75 14966372-4 2004 In our present study, we showed that A1, a constitutive and inducible Bcl-2 homologue expressed in mature circulating human neutrophils, might confer the protection from hydrogen peroxide (H(2)O(2))- and peroxynitrite (ONOO)-induced cell death. Peroxynitrous Acid 204-217 BCL2 apoptosis regulator Homo sapiens 70-75 14966372-4 2004 In our present study, we showed that A1, a constitutive and inducible Bcl-2 homologue expressed in mature circulating human neutrophils, might confer the protection from hydrogen peroxide (H(2)O(2))- and peroxynitrite (ONOO)-induced cell death. onoo 219-223 BCL2 apoptosis regulator Homo sapiens 70-75 15001646-9 2004 Upon estradiol exposure, we observed an enhanced phosphorylation of the proteins involved in the phosphatidylinositol-3-OH kinase (PI3K)/Akt pathway like PDK1, Akt, GSK-3, Bcl-2, together with ERK1/2, which was also involved in cell survival signals. Estradiol 5-14 BCL2 apoptosis regulator Homo sapiens 172-177 15094967-8 2004 The PPAR-gamma ligand pioglitazone modulates lipid peroxidation, alters Bcl-2 expression and caspase-3 activation, and finally reduces apoptosis. Pioglitazone 22-34 BCL2 apoptosis regulator Homo sapiens 72-77 14602088-6 2004 On the other hand, roscovitine modified the expression of cytochrome c (Cyt c), Bcl-2 and Bax, which are involved in the apoptotic intrinsic pathway induced by S/K deprivation. Roscovitine 19-30 BCL2 apoptosis regulator Homo sapiens 80-85 15031604-4 2004 The BH4 domain of the Bcl-2 family members is responsible for their antiapoptotic activity. sapropterin 4-7 BCL2 apoptosis regulator Homo sapiens 22-27 15031604-5 2004 The BH4 domains of Bcl-2 and Bcl-xl inhibit cytochrome c release and the loss of mitochondrial membrane potential. sapropterin 4-7 BCL2 apoptosis regulator Homo sapiens 19-24 15031604-6 2004 METHODS AND RESULTS: The purpose of this project was to study the antiapoptotic effect of cell-permeant derivative of Bcl-2 (BH4 peptide) on endothelial cells exposed to stress conditions. sapropterin 125-128 BCL2 apoptosis regulator Homo sapiens 118-123 15078907-10 2004 However, the Bax/Bcl-2 ratio showed a significant association with the CR rate (P = 0.0289). Chromium 71-73 BCL2 apoptosis regulator Homo sapiens 17-22 15026553-0 2004 Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells. Cisplatin 44-53 BCL2 apoptosis regulator Homo sapiens 19-24 15026553-2 2004 In the present study, we have investigated if Bcl-2 contributes to the emergence of cisplatin resistance in SCLC H69 cells. Cisplatin 84-93 BCL2 apoptosis regulator Homo sapiens 46-51 15026553-6 2004 Bcl-2 was constitutively phosphorylated at serine 70 in H69 cells but not in H69/CP cells and cisplatin had little effect on Bcl-2 phosphorylation. Serine 43-49 BCL2 apoptosis regulator Homo sapiens 0-5 14767525-3 2004 The Bax/Bcl-2 ratio values were changed in B-CLL cells originated from blood samples of patients treated by the three therapy protocols, and was the most elevated in the case of CMC treatment. cmc 178-181 BCL2 apoptosis regulator Homo sapiens 8-13 15072449-5 2004 In particular, as demonstrated by densitometric analysis, after exposure to both platinum compounds the total amount of the anti-apoptotic protein Bcl-2 was significantly reduced. Platinum 81-89 BCL2 apoptosis regulator Homo sapiens 147-152 15120425-7 2004 Oxysterol-resistant cells demonstrated no significant difference in the expression of several genes previously implicated in oxysterol resistance, but expressed the bcl-2 gene at significantly lower levels than those observed in control cells. Oxysterols 0-9 BCL2 apoptosis regulator Homo sapiens 165-170 14767525-0 2004 Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells. Cladribine 40-50 BCL2 apoptosis regulator Homo sapiens 147-152 14767525-0 2004 Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells. Cyclophosphamide 102-118 BCL2 apoptosis regulator Homo sapiens 147-152 14757322-4 2004 Apoptosis was reduced by the addition of pifithrin (PFT) alpha and enhanced by transient transfection with bcl-2 antisense-oligonucleotide in Bcl-2-overexpressing cells. Oligonucleotides 123-138 BCL2 apoptosis regulator Homo sapiens 107-112 14757322-4 2004 Apoptosis was reduced by the addition of pifithrin (PFT) alpha and enhanced by transient transfection with bcl-2 antisense-oligonucleotide in Bcl-2-overexpressing cells. Oligonucleotides 123-138 BCL2 apoptosis regulator Homo sapiens 142-147 14660675-3 2004 In particular, an increase in uPAR protein and mRNA expression was found in melanoma bcl-2 transfectants grown under hypoxia when compared with control cells, and a decrease of uPAR protein expression was induced by treatment of cells with specific bcl-2 antisense oligonucleotides. Oligonucleotides 265-281 BCL2 apoptosis regulator Homo sapiens 249-254 15038405-5 2004 PATIENTS AND METHODS: Bcl-2 expression was investigated using immunohistochemical techniques on paraffin-embedded tissue from 21 patients with uterine LMS. Paraffin 96-104 BCL2 apoptosis regulator Homo sapiens 22-27 14660675-5 2004 Treatment of cells with mitramycin A, an inhibitor of Sp1 activity, confirmed the role of Sp1 transcriptional activity in uPAR induction by Bcl-2. mitramycin a 24-36 BCL2 apoptosis regulator Homo sapiens 140-145 14660675-7 2004 In fact, ERK kinase activation was induced in Bcl-2-overexpressing cells exposed to hypoxia, and the ERK kinase inhibitor UO126 was able to down-regulate Sp1 phosphorylation and DNA binding activity. U 0126 122-127 BCL2 apoptosis regulator Homo sapiens 46-51 15075671-2 2004 MEN15658 induces p53 accumulation, and activation of gadd-45, p21, c-fos and bcl-2 family genes in human ovarian carcinoma A2780 cell line. 2-((1,10)phenanthrolin-2-ylhydrazono)-3,4-dihydro-2H-naphthalen-1-one 0-8 BCL2 apoptosis regulator Homo sapiens 77-82 14647451-2 2004 Here, we show that clinically relevant doses of As(2)O(3) can induce typical apoptosis in IM-9, a multiple myeloma cell line, in a Bcl-2 inhibitable manner. Arsenic Trioxide 48-57 BCL2 apoptosis regulator Homo sapiens 131-136 14647451-7 2004 Finally, we found that As(2)O(3) induced the increased expression and homodimerization of VDAC in IM-9 cells, but not in Bcl-2 overexpressing cells, suggesting that VDAC homodimerization could potentially determine its gating capacity to cyto c, and Bcl-2 blockage of VDAC homodimerization represents a novel mechanism for its inhibition of apoptosis. (2)o(3) 25-32 BCL2 apoptosis regulator Homo sapiens 250-255 14965369-3 2004 In this study, we found that PS-341 induced growth arrest and apoptosis of NCI-H520 and -H460 non-small cell lung cancer (NSCLC) cells in conjunction with markedly up-regulated levels of p21(waf1) and p53, and down-regulation of bcl-2 protein in these cells. Bortezomib 29-35 BCL2 apoptosis regulator Homo sapiens 229-234 12920017-0 2004 The phosphoserine-585-dependent pathway of the GM-CSF/IL-3/IL-5 receptors mediates hematopoietic cell survival through activation of NF-kappaB and induction of bcl-2. Phosphoserine 4-17 BCL2 apoptosis regulator Homo sapiens 160-165 12920017-6 2004 These results demonstrate that both serine and tyrosine phosphorylation pathways play a role in hematopoietic cell survival, are initially independent of each other, and converge on NF-kappaB to promote bcl-2 expression. Serine 36-42 BCL2 apoptosis regulator Homo sapiens 203-208 12920017-6 2004 These results demonstrate that both serine and tyrosine phosphorylation pathways play a role in hematopoietic cell survival, are initially independent of each other, and converge on NF-kappaB to promote bcl-2 expression. Tyrosine 47-55 BCL2 apoptosis regulator Homo sapiens 203-208 14712090-0 2004 Tocotrienol-rich fraction of palm oil activates p53, modulates Bax/Bcl2 ratio and induces apoptosis independent of cell cycle association. Tocotrienols 0-11 BCL2 apoptosis regulator Homo sapiens 67-71 14712090-0 2004 Tocotrienol-rich fraction of palm oil activates p53, modulates Bax/Bcl2 ratio and induces apoptosis independent of cell cycle association. Palm Oil 29-37 BCL2 apoptosis regulator Homo sapiens 67-71 15101720-2 2004 We reviewed the diagnosis of 48 patients with FL and investigated the type of bcl-2 gene rearrangement using DNA from paraffin-embedded tumor samples obtained at the time of diagnosis. Paraffin 118-126 BCL2 apoptosis regulator Homo sapiens 78-83 14745797-6 2004 The solid-state NMR spectra of Bcl-2 and FXYD proteins, in uniaxially oriented lipid bilayers, give the first view of their membrane-associated architectures. Lipid Bilayers 79-93 BCL2 apoptosis regulator Homo sapiens 31-36 14610217-3 2004 Because the majority of colon carcinomas are known to overexpress antiapoptotic proteins such as survivin and Bcl-2 and show only limited ability to undergo apoptosis, we hypothesized that the ability of sulindac to cause regression of adenomas and to inhibit colon carcinogenesis is mediated, at least in part, by down-regulation of one or more of these antiapoptotic proteins. Sulindac 204-212 BCL2 apoptosis regulator Homo sapiens 110-115 15013368-9 2004 VEGF and Bcl-2 immunoreactivity increased with prolonged exposure and increased extent of oxygen/metabolite deprivation. Oxygen 90-96 BCL2 apoptosis regulator Homo sapiens 9-14 14767488-11 2004 Notably, phospho-Akt (Ser-473) was increased in FL (Bcl-2+ or -) (P<0.03) with increased phospho-Bad (Ser-136), as compared with levels in FH. Serine 22-25 BCL2 apoptosis regulator Homo sapiens 52-57 14767488-11 2004 Notably, phospho-Akt (Ser-473) was increased in FL (Bcl-2+ or -) (P<0.03) with increased phospho-Bad (Ser-136), as compared with levels in FH. Serine 105-108 BCL2 apoptosis regulator Homo sapiens 52-57 14715264-5 2004 Of the apoptotic mediators tested, the anti-apoptotic protein Bcl-x(L) was strongly down-regulated by combined treatment of the cells with SBHA and TRAIL but not by the HDAC inhibitor alone, while little or no change in the expression of other Bcl-2 family members highly expressed in MM cells, including Mcl-1 and Bax, was observed. suberoyl bis-hydroxamic acid 139-143 BCL2 apoptosis regulator Homo sapiens 244-249 14737118-8 2004 G110R substitution confers on Bcl-2(1) substantially increased binding affinity to Bak, Bad and Bax BH3 peptides, demonstrating that R110 is a key contributor to the BH3 binding affinity of Bcl-2. BH 3 100-103 BCL2 apoptosis regulator Homo sapiens 30-35 14737118-8 2004 G110R substitution confers on Bcl-2(1) substantially increased binding affinity to Bak, Bad and Bax BH3 peptides, demonstrating that R110 is a key contributor to the BH3 binding affinity of Bcl-2. BH 3 100-103 BCL2 apoptosis regulator Homo sapiens 190-195 14710235-12 2004 Apoptosis was associated with downregulation of Bcl-2 by gefitinib in MDA-MB-231 cells. Gefitinib 57-66 BCL2 apoptosis regulator Homo sapiens 48-53 14744787-8 2004 Consistent with resveratrol"s ability to kill cells via nonapoptotic processes, cells transfected to express high levels of the antiapoptotic proteins Bcl-x(L) and Bcl-2 are equally sensitive as control cells to resveratrol. Resveratrol 16-27 BCL2 apoptosis regulator Homo sapiens 164-169 14709013-5 2004 The change in the expression of Bcl-2, Bcl-X(L), and Bax in response to hop bitter acids was studied, and the Bcl-2 protein level slightly decreased; however, the Bcl-X(L) protein level was obviously decreased, whereas the Bax protein level was dramatically increased, indicating that the control of Bcl-2 family proteins by hop bitter acids might participate in the disruption of mitochondrial integrity. bitter acids 76-88 BCL2 apoptosis regulator Homo sapiens 32-37 14709013-5 2004 The change in the expression of Bcl-2, Bcl-X(L), and Bax in response to hop bitter acids was studied, and the Bcl-2 protein level slightly decreased; however, the Bcl-X(L) protein level was obviously decreased, whereas the Bax protein level was dramatically increased, indicating that the control of Bcl-2 family proteins by hop bitter acids might participate in the disruption of mitochondrial integrity. bitter acids 329-341 BCL2 apoptosis regulator Homo sapiens 32-37 14760103-10 2004 ZD1839 promoted paclitaxel-induced Bcl-2 down-regulation resulting in promoting apoptosis by blocking paclitaxel-induced activation of the EGFR-extracellular signal-regulated kinase antiapoptotic pathway independent of Akt activity in SKRC-49. Gefitinib 0-6 BCL2 apoptosis regulator Homo sapiens 35-40 14760103-10 2004 ZD1839 promoted paclitaxel-induced Bcl-2 down-regulation resulting in promoting apoptosis by blocking paclitaxel-induced activation of the EGFR-extracellular signal-regulated kinase antiapoptotic pathway independent of Akt activity in SKRC-49. Paclitaxel 16-26 BCL2 apoptosis regulator Homo sapiens 35-40 14760103-10 2004 ZD1839 promoted paclitaxel-induced Bcl-2 down-regulation resulting in promoting apoptosis by blocking paclitaxel-induced activation of the EGFR-extracellular signal-regulated kinase antiapoptotic pathway independent of Akt activity in SKRC-49. Paclitaxel 102-112 BCL2 apoptosis regulator Homo sapiens 35-40 14724571-10 2004 All three inhibitors reversed Taxotere-induced phosphorylation of Bcl-2. Docetaxel 30-38 BCL2 apoptosis regulator Homo sapiens 66-71 14724573-3 2004 Roscovitine could sensitize Bcl-2- or Bcl-xL-overexpressing glioma cells, but not human astrocytes, to TRAIL-induced apoptosis, offering an attractive strategy for safely treating resistant gliomas. Roscovitine 0-11 BCL2 apoptosis regulator Homo sapiens 28-33 14715531-3 2004 Activation of these signaling pathways along with generation of reactive oxygen species leads to alterations in the activity of key mitochondrial proteins such as mitochondrial ATP-sensitive K(+) channels, the mitochondrial permeability transition pore, and bcl-2 family members. Reactive Oxygen Species 64-87 BCL2 apoptosis regulator Homo sapiens 258-263 14712225-5 2004 On the other hand, p16 sensitized cells to cisplatin-mediated apoptosis through Bcl-2 decline. Cisplatin 43-52 BCL2 apoptosis regulator Homo sapiens 80-85 14720367-1 2004 BACKGROUND & OBJECTIVE: Bcl-2/E1B 19kDa interacting protein3-like (BNIP3L) gene is a tumor suppressor gene cloned from a human fetal liver cDNA library, which is located at 8p21, one of the high frequent regions of loss of heterozygosity (LOH) in lung carcinoma. Adenosine Monophosphate 12-15 BCL2 apoptosis regulator Homo sapiens 28-33 15032596-7 2004 This pathway involves members of the Bcl-2 family, in particular Bcl-2, Bcl-xl, Bim, and probably Bak. bakuchiol 98-101 BCL2 apoptosis regulator Homo sapiens 37-42 14972016-2 2004 Mechanisms of resistance include altered glutathione handling that accompanies up-regulation of Bcl-2 and its relatives. Glutathione 41-52 BCL2 apoptosis regulator Homo sapiens 96-101 15124691-0 2004 G3139, a BCL-2 antisense oligo-nucleotide, in AML. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 9-14 15124691-0 2004 G3139, a BCL-2 antisense oligo-nucleotide, in AML. Oligonucleotides 25-41 BCL2 apoptosis regulator Homo sapiens 9-14 14555614-7 2004 In other studies, silibinin caused a moderate increase in phospho-Bcl-2, without any noticeable changes in total Bcl-2 levels, and down-regulated bax levels moderately. Silybin 18-27 BCL2 apoptosis regulator Homo sapiens 66-71 14514658-3 2004 SFN-induced apoptosis was associated with up-regulation of Bax, down-regulation of Bcl-2 and activation of caspases-3, -9 and -8. sulforaphane 0-3 BCL2 apoptosis regulator Homo sapiens 83-88 15199607-13 2004 In contrast, lack of Bcl-2 expression was associated with a higher probability of complete pathological response to doxorubicin-based chemotherapy. Doxorubicin 116-127 BCL2 apoptosis regulator Homo sapiens 21-26 15566959-11 2004 However, anti-apoptotic Bcl-2 and Bcl-X(L) were elevated and the cell cycle regulator cyclin D1 was slightly upregulated with both 1 and 5 microM cisplatin treatment. Cisplatin 146-155 BCL2 apoptosis regulator Homo sapiens 24-29 15129760-10 2004 RT-PCR and Western blot analysis of the islets indicated that Bcl-2 levels increased by 2.5-fold and BAX levels decreased by twofold in cultures supplemented with polyphenol. Polyphenols 163-173 BCL2 apoptosis regulator Homo sapiens 62-67 15129760-11 2004 This resulted in BAX/Bcl-2 ratios that were lower in polyphenol-supplemented cultures than with control cultures. Polyphenols 53-63 BCL2 apoptosis regulator Homo sapiens 21-26 15134489-0 2004 Inhibition of anti-apoptotic Bcl-2 family proteins by natural polyphenols: new avenues for cancer chemoprevention and chemotherapy. Polyphenols 62-73 BCL2 apoptosis regulator Homo sapiens 29-34 14711563-7 2004 The Bcl-2 concentration was similar in endometrial homogenates obtained throughout the menstrual cycle, but L-Arg decreased Bcl-2 only in endometrium from the proliferative phase. Arginine 108-113 BCL2 apoptosis regulator Homo sapiens 124-129 15544507-5 2004 In addition, we have recently found that galanthamine has neuroprotective effects by inducing calcium signals and the induction of the antiapoptotic protein Bcl-2. Galantamine 41-53 BCL2 apoptosis regulator Homo sapiens 157-162 15315167-0 2004 Difference in expression of Bcl-2 and Bcl-xl genes in cisplatin-sensitive and cisplatin-resistant human in ovarian cancer cell lines. Cisplatin 54-63 BCL2 apoptosis regulator Homo sapiens 28-33 14654975-8 2004 In addition, silibinin treatment caused a change in the ratio of Bax/Bcl-2 in a manner that favors apoptosis. Silybin 13-22 BCL2 apoptosis regulator Homo sapiens 69-74 14654975-10 2004 These results suggest that silibinin may exert, at least partly, its anti-cancer effect by inhibiting angiogenesis through induction of endothelial apoptosis via modulation of NF-kappaB, Bcl-2 family and caspases. Silybin 27-36 BCL2 apoptosis regulator Homo sapiens 187-192 15165116-4 2004 The protein expression levels of bcl-2, p53 and MDM2 in cancer cells were examined by SP immunohistochemistry. TFF2 protein, human 86-88 BCL2 apoptosis regulator Homo sapiens 33-38 15167912-12 2004 Additionally, a dramatic decrease in Bcl-2 expression with s-thalidomide suggests a possible enhancement of cytotoxic effect if combined with other cytotoxic agents. Thalidomide 59-72 BCL2 apoptosis regulator Homo sapiens 37-42 14605879-7 2004 Decreased phosphorylated-Akt by LY294002 treatment led to a down-regulation of Mcl-2 and phosphorylated Bad proteins, which are anti-apoptotic factors and belong to the Bcl-2 family. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 BCL2 apoptosis regulator Homo sapiens 169-174 14605879-8 2004 On the other hand, expression levels of the other anti-apoptotic factors, such as FLICE-inhibitory protein (FLIP), Bcl-2 and Bcl-XL, which are associated with the Fas-mediated apoptotic signal pathway, did not change after LY294002 treatment. ammonium ferrous sulfate 163-166 BCL2 apoptosis regulator Homo sapiens 115-120 15315167-2 2004 Our results showed that (1) "DNA ladder" was observed in A2780 and AD6 after cisplatin treatment; (2) after 3.0, 6.0, 9.9 microg/ml of cisplatin treatment, a significant difference was noted in the rate of apoptosis between in A2780 and AD6 (P<0.05); (3) Bcl-2 and Bcl-xl genes were overexpressed in AD6. Cisplatin 135-144 BCL2 apoptosis regulator Homo sapiens 258-263 15315167-3 2004 After cisplatin treatment, the expression of Bcl-2 and Bcl-xl genes was down-regulated in A2780 and AD6. Cisplatin 6-15 BCL2 apoptosis regulator Homo sapiens 45-50 15315167-0 2004 Difference in expression of Bcl-2 and Bcl-xl genes in cisplatin-sensitive and cisplatin-resistant human in ovarian cancer cell lines. Cisplatin 78-87 BCL2 apoptosis regulator Homo sapiens 28-33 14654930-0 2004 Synergistic action of piroxicam on the eicosapentaenoic acid-induced apoptosis is associated with enhanced down-regulation of anti-apoptotic Bcl-2 expression but not promoted activation of pro-apoptotic Bid protein. Piroxicam 22-31 BCL2 apoptosis regulator Homo sapiens 141-146 14975502-1 2004 Chloroquine and related anti-malarial drugs appear to promote apoptosis in T-cells by suppressing NF-kappa-B, which enhances the expression of anti-apoptotic proteins (e.g., Bcl-2). Chloroquine 0-11 BCL2 apoptosis regulator Homo sapiens 174-179 14975502-14 2004 Currently, an antisense drug targeting Bcl-2 (G3139/Genasense(TM), Genta, Inc.) is in late-stage cancer trials and may be on the market for those indications in months. genta 67-72 BCL2 apoptosis regulator Homo sapiens 39-44 14654102-6 2004 Incubation of the cells for 48 h with 300 nM galantamine doubled the density of alpha7 nicotinic receptors and tripled the expression of the antiapoptotic protein Bcl-2. Galantamine 45-56 BCL2 apoptosis regulator Homo sapiens 163-168 14654102-7 2004 These results strongly suggest that galantamine can prevent apoptotic cell death by inducing neuroprotection through a mechanism related to that described for nicotine, i.e. activation of nAChRs and upregulation of Bcl-2. Galantamine 36-47 BCL2 apoptosis regulator Homo sapiens 215-220 15671682-10 2004 In addition, immunocytochemical data and Western blot analysis revealed that, unlike flavonol derivatives, the expression of Bcl-2 was markedly up-regulated, and that the expression of Bax and activation of caspase-3 were strongly inhibited by this flavanone derivative, thereby implicating antioxidant activity-related anti-apoptotic mechanisms of 2",4",7-trihydroxyflavanone. flavanone 249-258 BCL2 apoptosis regulator Homo sapiens 125-130 15671682-10 2004 In addition, immunocytochemical data and Western blot analysis revealed that, unlike flavonol derivatives, the expression of Bcl-2 was markedly up-regulated, and that the expression of Bax and activation of caspase-3 were strongly inhibited by this flavanone derivative, thereby implicating antioxidant activity-related anti-apoptotic mechanisms of 2",4",7-trihydroxyflavanone. 2",4",7-trihydroxyflavanone 349-376 BCL2 apoptosis regulator Homo sapiens 125-130 14701745-4 2004 Here we show that growth factor deprivation induced proteolytic cleavage of the proapoptotic Bcl-2 family member BID to yield its active truncated form, tBID. tBID 153-157 BCL2 apoptosis regulator Homo sapiens 93-98 15161985-6 2004 Docetaxel also appears to have direct antitumoral activity via an apoptotic effect mediated by bcl-2 phosphorylation. Docetaxel 0-9 BCL2 apoptosis regulator Homo sapiens 95-100 14654930-0 2004 Synergistic action of piroxicam on the eicosapentaenoic acid-induced apoptosis is associated with enhanced down-regulation of anti-apoptotic Bcl-2 expression but not promoted activation of pro-apoptotic Bid protein. Eicosapentaenoic Acid 39-60 BCL2 apoptosis regulator Homo sapiens 141-146 14654930-7 2004 This synergistic action of PRX on the EPA-induced apoptosis was associated with enhanced down-regulation of anti-apoptotic Bcl-2 protein expression, but not promoted activation of pro-apoptotic Bid protein. Eicosapentaenoic Acid 38-41 BCL2 apoptosis regulator Homo sapiens 123-128 14637145-0 2003 Hydrogen peroxide increases a 55-kDa tyrosinase concomitantly with induction of p53-dependent p21 waf1 expression and a greater Bax/Bcl-2 ratio in pigmented melanoma. Hydrogen Peroxide 0-17 BCL2 apoptosis regulator Homo sapiens 132-137 15625915-0 2004 A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis. Oligonucleotides 54-69 BCL2 apoptosis regulator Homo sapiens 79-84 15625915-1 2004 We previously reported the Bcl-2/Bcl-xL-bispecific activity of the 2"-O-(2-methoxy)ethyl (2"-MOE)-modified gapmer antisense oligonucleotide 4625. 2"-o-(2-methoxy)ethyl (2"-moe) 67-97 BCL2 apoptosis regulator Homo sapiens 27-32 15625915-1 2004 We previously reported the Bcl-2/Bcl-xL-bispecific activity of the 2"-O-(2-methoxy)ethyl (2"-MOE)-modified gapmer antisense oligonucleotide 4625. Oligonucleotides 124-139 BCL2 apoptosis regulator Homo sapiens 27-32 15625915-2 2004 This oligonucleotide has 100% complementarity to Bcl-2 and three mismatches to Bcl-xL. Oligonucleotides 5-20 BCL2 apoptosis regulator Homo sapiens 49-54 15124003-5 2004 Chronic exposure to casodex resulted in differentiation of both LNCaP-R and -UR cells to the NE-type morphology accompanied by a marked downregulation of Bcl-2 protein, while Bax protein levels were unchanged. bicalutamide 20-27 BCL2 apoptosis regulator Homo sapiens 154-159 15124003-6 2004 Downregulation of Bcl-2 was post-transcriptional since Bcl-2 message levels were unchanged in LNCaP cells treated with casodex. bicalutamide 119-126 BCL2 apoptosis regulator Homo sapiens 18-23 14647446-7 2003 The overexpression of Bcl-x(L) or Bcl-2 strongly inhibited calicheamicin-induced apoptosis. calicheamicin T 59-72 BCL2 apoptosis regulator Homo sapiens 34-39 15033810-4 2003 In addition, patients taking l-Dopa + dopamine agonists showed marked decrease in Bcl-2 levels and increased PBR expression, which seems in keeping with the hypothesis that PBR may be functionally related to Bcl-2. Levodopa 29-35 BCL2 apoptosis regulator Homo sapiens 82-87 14657380-0 2003 Control of Bcl-2 expression by reactive oxygen species. Reactive Oxygen Species 31-54 BCL2 apoptosis regulator Homo sapiens 11-16 14657380-5 2003 Culture with MnTBAP revealed a tight inverse correlation between the levels of Bcl-2 and ROS within T cells. Reactive Oxygen Species 89-92 BCL2 apoptosis regulator Homo sapiens 79-84 14657380-9 2003 Taken together, our results suggest that ROS sensitize T cells to apoptosis by decreasing expression of Bcl-2. Reactive Oxygen Species 41-44 BCL2 apoptosis regulator Homo sapiens 104-109 21310133-4 2003 Cisplatin could obviously down-regulate telomerase activity, decrease S phase cells, increase G0/G1 phase cells, decline the expressions of bcl-2 and PCNA proteins and induce the expression of p53 protein of SLC-89 cells in a concentration-dependent fashion. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 140-145 21310133-5 2003 CONCLUSIONS: Cisplatin can obviously inhibit the proliferation of SLC-89, change the distribution of cell cycle, decline telomerase activity and expressions of bcl-2 and PCNA proteins, and induce expression of p53 protein, which may be the important mechanisms of cisplatin"s anticancer action. Cisplatin 13-22 BCL2 apoptosis regulator Homo sapiens 160-165 15033810-4 2003 In addition, patients taking l-Dopa + dopamine agonists showed marked decrease in Bcl-2 levels and increased PBR expression, which seems in keeping with the hypothesis that PBR may be functionally related to Bcl-2. Levodopa 29-35 BCL2 apoptosis regulator Homo sapiens 208-213 15033810-4 2003 In addition, patients taking l-Dopa + dopamine agonists showed marked decrease in Bcl-2 levels and increased PBR expression, which seems in keeping with the hypothesis that PBR may be functionally related to Bcl-2. Dopamine 38-46 BCL2 apoptosis regulator Homo sapiens 82-87 15033711-0 2003 Cisplatin-induced apoptosis in HL-60 human promyelocytic leukemia cells: differential expression of BCL2 and novel apoptosis-related gene BCL2L12. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 100-104 14751826-4 2003 The oligonucleotide targeting Bcl-2 and Bcl-xL was used in the 2"-MOE or LNA-modified gapmer format, the survivin siRNA was derived from the sequence of an effective first generation antisense oligonucleotide. Oligonucleotides 4-19 BCL2 apoptosis regulator Homo sapiens 30-35 15033810-4 2003 In addition, patients taking l-Dopa + dopamine agonists showed marked decrease in Bcl-2 levels and increased PBR expression, which seems in keeping with the hypothesis that PBR may be functionally related to Bcl-2. Dopamine 38-46 BCL2 apoptosis regulator Homo sapiens 208-213 15033711-3 2003 In the present study, the expression of BCL2 and BCL2L12 genes during cisplatin-induced apoptosis in HL-60 leukemic cells was investigated. Cisplatin 70-79 BCL2 apoptosis regulator Homo sapiens 40-44 15033711-7 2003 Gradual, time-dependent downregulation of BCL2 gene was observed during cisplatin treatment. Cisplatin 72-81 BCL2 apoptosis regulator Homo sapiens 42-46 15033812-5 2003 Overexpression of human Bcl-2 in PC12 cells completely suppressed dieldrin-induced caspase-3 activation and DNA fragmentation. Dieldrin 66-74 BCL2 apoptosis regulator Homo sapiens 24-29 15033814-2 2003 When apoptosis is inhibited by Bcl-2 overexpression, oxLDL may trigger necrosis through a calcium-dependent pathway. Calcium 90-97 BCL2 apoptosis regulator Homo sapiens 31-36 14710848-4 2003 Loss of 19 kDa Bcl-2 in adriamycin-induced apoptotic cells underlines this. Doxorubicin 24-34 BCL2 apoptosis regulator Homo sapiens 15-20 14609739-5 2003 DHAc also showed significant effects on the gene expression of the house-keeping genes GAP-DH and beta-actin, as well as on NF-ATc, p65, I-kappa B alpha, bcl-2, and cyclin D1. DHAC 0-4 BCL2 apoptosis regulator Homo sapiens 154-159 14679005-6 2003 17-AAG/SAHA-treated cells also displayed down-regulation of the antiapoptotic protein Mcl-1 and evidence of Bcl-2 cleavage. tanespimycin 0-6 BCL2 apoptosis regulator Homo sapiens 108-113 14679005-6 2003 17-AAG/SAHA-treated cells also displayed down-regulation of the antiapoptotic protein Mcl-1 and evidence of Bcl-2 cleavage. Vorinostat 7-11 BCL2 apoptosis regulator Homo sapiens 108-113 14671432-3 2003 We recently demonstrated statistically significantly reduced growth activity and elevated cellular GSH levels in exponentially growing rat CC531 colon carcinoma cells overexpressing the full-length human Bcl-2 protein (CCbcl2#A3). Glutathione 99-102 BCL2 apoptosis regulator Homo sapiens 204-209 12960011-6 2003 Increased de novo ceramide formation is probably the most damaging lipid and is a cause of lipoapoptosis, abetted by a decline in tissue Bcl-2. Ceramides 18-26 BCL2 apoptosis regulator Homo sapiens 137-142 14678967-6 2003 Ectopic expression of Bcl-2 and Bcl-x(L) inhibits mitochondrial changes, ROS production, and apoptosis providing additional support for an association between mitochondrial dysfunction and Ad.mda-7 action. Reactive Oxygen Species 73-76 BCL2 apoptosis regulator Homo sapiens 22-27 12894216-1 2003 The interactions between B-cell lymphoma 2 (BCL-2) family members are known to be mediated through the binding of the BH3 domain of a proapoptotic member to the BH3-binding groove of an antiapoptotic member. BH 3 118-121 BCL2 apoptosis regulator Homo sapiens 25-42 12894216-1 2003 The interactions between B-cell lymphoma 2 (BCL-2) family members are known to be mediated through the binding of the BH3 domain of a proapoptotic member to the BH3-binding groove of an antiapoptotic member. BH 3 118-121 BCL2 apoptosis regulator Homo sapiens 44-49 12894216-1 2003 The interactions between B-cell lymphoma 2 (BCL-2) family members are known to be mediated through the binding of the BH3 domain of a proapoptotic member to the BH3-binding groove of an antiapoptotic member. BH 3 161-164 BCL2 apoptosis regulator Homo sapiens 25-42 12894216-1 2003 The interactions between B-cell lymphoma 2 (BCL-2) family members are known to be mediated through the binding of the BH3 domain of a proapoptotic member to the BH3-binding groove of an antiapoptotic member. BH 3 161-164 BCL2 apoptosis regulator Homo sapiens 44-49 14710848-5 2003 G2/M-phase accumulation of cells by nocodazole-treatment also results in loss of 19 kDa Bcl-2. Nocodazole 36-46 BCL2 apoptosis regulator Homo sapiens 88-93 14636829-9 2003 Overexpression of Bcl-2 significantly protected bufadienolide-treated cells from phosphatidylserine translocation, transmembrane potential disruption, and internucleosomal DNA fragmentation. bufadienolide 48-61 BCL2 apoptosis regulator Homo sapiens 18-23 14675202-0 2003 17beta-estradiol inhibits oxidative stress-induced apoptosis in keratinocytes by promoting Bcl-2 expression. Estradiol 0-16 BCL2 apoptosis regulator Homo sapiens 91-96 14612938-5 2003 In addition, beta-sitosterol-induced apoptosis in HT116 cells was associated with a decreased expression of the anti-apototic Bcl-2 protein and mRNA and a concomitant increase of the pro-apototic Bax protein and mRNA, and with release of cytochrome c from the mitochondria into the cytosol. gamma-sitosterol 13-28 BCL2 apoptosis regulator Homo sapiens 126-131 14675187-9 2003 DMF, but not MHF, led to a concentration-dependent decrease of Bcl-2 expression in interleukin-2-stimulated T cells. Dimethyl Fumarate 0-3 BCL2 apoptosis regulator Homo sapiens 63-68 14675202-3 2003 H2O2 decreased, whereas 17beta-estradiol increased Bcl-2 protein and mRNA levels in keratinocytes, and H2O2 plus 17beta-estradiol led to basal levels. Estradiol 24-40 BCL2 apoptosis regulator Homo sapiens 51-56 14675202-9 2003 H-89, an inhibitor of cAMP-dependent protein kinase A, suppressed basal and 17beta-estradiol-induced cAMP response element-binding protein phosphorylation, cAMP response element-dependent transcriptional activity, Bcl-2 expression, and apoptosis resistance. N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide 0-4 BCL2 apoptosis regulator Homo sapiens 214-219 14675202-4 2003 Overexpression of Bcl-2 protected keratinocytes against H2O2-induced apoptosis, indicating the anti-apoptotic effect of Bcl-2. Hydrogen Peroxide 56-60 BCL2 apoptosis regulator Homo sapiens 18-23 14675202-9 2003 H-89, an inhibitor of cAMP-dependent protein kinase A, suppressed basal and 17beta-estradiol-induced cAMP response element-binding protein phosphorylation, cAMP response element-dependent transcriptional activity, Bcl-2 expression, and apoptosis resistance. Estradiol 76-92 BCL2 apoptosis regulator Homo sapiens 214-219 14675202-5 2003 H2O2 suppressed, whereas 17beta-estradiol enhanced bcl-2 promoter activity, and H2O2 plus 17beta-estradiol led to basal activity. Estradiol 25-41 BCL2 apoptosis regulator Homo sapiens 51-56 14675202-14 2003 These results suggest that 17beta-estradiol may enhance Bcl-2 expression and prevent H2O2-induced apoptosis by phosphorylating cAMP response element-binding protein via cAMP/protein kinase A pathway in keratinocytes. Estradiol 27-43 BCL2 apoptosis regulator Homo sapiens 56-61 14675202-6 2003 Cyclic adenosine monophosphate (cAMP) response element on bcl-2 promoter was responsible for the effects of 17beta-estradiol and H2O2. Cyclic AMP 0-30 BCL2 apoptosis regulator Homo sapiens 58-63 14675202-6 2003 Cyclic adenosine monophosphate (cAMP) response element on bcl-2 promoter was responsible for the effects of 17beta-estradiol and H2O2. Estradiol 108-124 BCL2 apoptosis regulator Homo sapiens 58-63 14675202-6 2003 Cyclic adenosine monophosphate (cAMP) response element on bcl-2 promoter was responsible for the effects of 17beta-estradiol and H2O2. Hydrogen Peroxide 129-133 BCL2 apoptosis regulator Homo sapiens 58-63 14675202-7 2003 Bcl-2 expression was enhanced by membrane-impermeable bovine serum albumin-conjugated 17beta-estradiol, indicating the effects via membrane 17beta-estradiol-binding sites. Estradiol 86-102 BCL2 apoptosis regulator Homo sapiens 0-5 14675202-7 2003 Bcl-2 expression was enhanced by membrane-impermeable bovine serum albumin-conjugated 17beta-estradiol, indicating the effects via membrane 17beta-estradiol-binding sites. 17beta 86-92 BCL2 apoptosis regulator Homo sapiens 0-5 14675202-7 2003 Bcl-2 expression was enhanced by membrane-impermeable bovine serum albumin-conjugated 17beta-estradiol, indicating the effects via membrane 17beta-estradiol-binding sites. Estradiol 93-102 BCL2 apoptosis regulator Homo sapiens 0-5 14645670-5 2003 Coadministration of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or TNF-alpha substantially increased MEK inhibitors (e.g., PD184352 or U0126)/UCN-01-induced mitochondrial dysfunction, activation of procaspase-8 and Bid, and apoptosis in Bcl-2- and Bcl-xL-overexpressing cells but not in those in which the extrinsic pathway was interrupted. 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide 149-157 BCL2 apoptosis regulator Homo sapiens 263-268 14674700-3 2003 NaCN-induced chemical hypoxia increased iNOs and HSP-70 mRNA in both types of cells, whereas p53 and Bcl-2 mRNA were singularly induced in T84 cells and Jurkat T cells, respectively. Sodium Cyanide 0-4 BCL2 apoptosis regulator Homo sapiens 101-106 14674700-4 2003 In both cell types, treatment of hypoxic cells with a reversible selective iNOs inhibitor, Now-nitro-L-arginine (LNNA), blocked iNOs, Bcl-2, and HSP-70 mRNA, but increased p53. now-nitro-l-arginine 91-111 BCL2 apoptosis regulator Homo sapiens 134-139 14645667-2 2003 The stress-inducible transcription factor known as growth and DNA damage (GADD)-inducible transcription factor 153 is induced in response to fenretinide and in other cell types modulates apoptosis via pro- and antiapoptotic members of the BCL2 family. gadd 74-78 BCL2 apoptosis regulator Homo sapiens 239-243 14707277-16 2003 At 30 micro M, genistein inhibited the growth significantly, induced G(2)-M arrest, increased Bax:Bcl-2 ratio, decreased NF-kappaB DNA binding, and induced apoptosis. Genistein 15-24 BCL2 apoptosis regulator Homo sapiens 98-103 14645670-5 2003 Coadministration of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or TNF-alpha substantially increased MEK inhibitors (e.g., PD184352 or U0126)/UCN-01-induced mitochondrial dysfunction, activation of procaspase-8 and Bid, and apoptosis in Bcl-2- and Bcl-xL-overexpressing cells but not in those in which the extrinsic pathway was interrupted. U 0126 161-166 BCL2 apoptosis regulator Homo sapiens 263-268 14645667-2 2003 The stress-inducible transcription factor known as growth and DNA damage (GADD)-inducible transcription factor 153 is induced in response to fenretinide and in other cell types modulates apoptosis via pro- and antiapoptotic members of the BCL2 family. Fenretinide 141-152 BCL2 apoptosis regulator Homo sapiens 239-243 14645667-3 2003 Because BCL2-family proteins are important in apoptosis induced by chemotherapeutic drugs, GADD153 may be a key mediator of synergy between fenretinide and chemotherapeutic drugs. Fenretinide 140-151 BCL2 apoptosis regulator Homo sapiens 8-12 14669326-6 2003 The anti-apoptosis proteins Bcl-2 and Mcl-1 were decreased in parallel and Bax increased, indicating that Bcl-2 family proteins-mitochondria-caspase cascade was responsible for oil-induced apoptosis. Oils 177-180 BCL2 apoptosis regulator Homo sapiens 28-33 14716145-3 2003 Oblimersen (Genasense, Aventis Pharmaceuticals / Genta Inc) is a 18mer antisense-oligonucleotide (ASO), which specifically binds to the first 6 codons of the human bcl-2 mRNA, resulting in degradation and destruction of the mRNA by RNAse H. Subsequently there is a significant decrease of bcl-2 translation. genta 49-54 BCL2 apoptosis regulator Homo sapiens 164-169 14716145-3 2003 Oblimersen (Genasense, Aventis Pharmaceuticals / Genta Inc) is a 18mer antisense-oligonucleotide (ASO), which specifically binds to the first 6 codons of the human bcl-2 mRNA, resulting in degradation and destruction of the mRNA by RNAse H. Subsequently there is a significant decrease of bcl-2 translation. Oligonucleotides 81-96 BCL2 apoptosis regulator Homo sapiens 164-169 14716145-3 2003 Oblimersen (Genasense, Aventis Pharmaceuticals / Genta Inc) is a 18mer antisense-oligonucleotide (ASO), which specifically binds to the first 6 codons of the human bcl-2 mRNA, resulting in degradation and destruction of the mRNA by RNAse H. Subsequently there is a significant decrease of bcl-2 translation. Oligonucleotides 81-96 BCL2 apoptosis regulator Homo sapiens 289-294 14716145-3 2003 Oblimersen (Genasense, Aventis Pharmaceuticals / Genta Inc) is a 18mer antisense-oligonucleotide (ASO), which specifically binds to the first 6 codons of the human bcl-2 mRNA, resulting in degradation and destruction of the mRNA by RNAse H. Subsequently there is a significant decrease of bcl-2 translation. Oligonucleotides, Antisense 98-101 BCL2 apoptosis regulator Homo sapiens 164-169 14716145-3 2003 Oblimersen (Genasense, Aventis Pharmaceuticals / Genta Inc) is a 18mer antisense-oligonucleotide (ASO), which specifically binds to the first 6 codons of the human bcl-2 mRNA, resulting in degradation and destruction of the mRNA by RNAse H. Subsequently there is a significant decrease of bcl-2 translation. Oligonucleotides, Antisense 98-101 BCL2 apoptosis regulator Homo sapiens 289-294 14669326-6 2003 The anti-apoptosis proteins Bcl-2 and Mcl-1 were decreased in parallel and Bax increased, indicating that Bcl-2 family proteins-mitochondria-caspase cascade was responsible for oil-induced apoptosis. Oils 177-180 BCL2 apoptosis regulator Homo sapiens 106-111 14627985-3 2003 In the present study, we demonstrated that the bcl-2/bcl-xL bispecific antisense oligonucleotide 4625 inhibits bcl-2 expression and angiogenesis in two bcl-2 overexpressing clones derived from the M14 human melanoma cell line. Oligonucleotides 81-96 BCL2 apoptosis regulator Homo sapiens 111-116 14612913-9 2003 Treatment of cultures of nontumorigenic cells with l-deprenyl or clorgyline significantly increased the levels of the protein Bcl-2 following irradiation, but there was no such effect on the already-elevated levels of this protein in the tumour samples. Selegiline 51-61 BCL2 apoptosis regulator Homo sapiens 126-131 14612913-9 2003 Treatment of cultures of nontumorigenic cells with l-deprenyl or clorgyline significantly increased the levels of the protein Bcl-2 following irradiation, but there was no such effect on the already-elevated levels of this protein in the tumour samples. Clorgyline 65-75 BCL2 apoptosis regulator Homo sapiens 126-131 14612913-10 2003 Since the Bcl-2 has been shown to be an inhibitor of apoptosis or programmed cell death, this would imply that the protective effects of l-deprenyl and clorgyline involve activation of antiapoptotic pathways within the normal cell. l-deprenyl and clorgyline 137-162 BCL2 apoptosis regulator Homo sapiens 10-15 14627984-2 2003 It has previously been shown that the BH4 domain of Bcl-2/Bcl-xL is essential for the prevention of apoptotic mitochondrial changes, including the release of cytochrome c and apoptotic cell death. sapropterin 38-41 BCL2 apoptosis regulator Homo sapiens 52-57 14627985-3 2003 In the present study, we demonstrated that the bcl-2/bcl-xL bispecific antisense oligonucleotide 4625 inhibits bcl-2 expression and angiogenesis in two bcl-2 overexpressing clones derived from the M14 human melanoma cell line. Oligonucleotides 81-96 BCL2 apoptosis regulator Homo sapiens 111-116 14627985-0 2003 Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. Oligonucleotides 58-73 BCL2 apoptosis regulator Homo sapiens 35-40 14627985-3 2003 In the present study, we demonstrated that the bcl-2/bcl-xL bispecific antisense oligonucleotide 4625 inhibits bcl-2 expression and angiogenesis in two bcl-2 overexpressing clones derived from the M14 human melanoma cell line. Oligonucleotides 81-96 BCL2 apoptosis regulator Homo sapiens 47-52 14607914-6 2003 Conversely, overexpression of Bcl-2 or Bcl-x(L) completely inhibits the initiation of apoptosis, indicating that 15d-PGJ(2)-mediated apoptosis involves activation of the mitochondrial pathway. 15d-pgj 113-120 BCL2 apoptosis regulator Homo sapiens 30-35 14576343-3 2003 Indeed, an emerging hypothesis is that, during apoptosis, the Bcl-2 family regulates ER-to-mitochondrion communication by BH3-only proteins and calcium ions and thereby triggers mitochondrial dysfunction and cell death. Calcium 144-151 BCL2 apoptosis regulator Homo sapiens 62-67 14506750-7 2003 The combination treatment of docetaxel plus PD98059 also increased cellular apoptosis, which was in part due to the inactivation of Bcl-2 by increasing phosphorylated Bcl-2 by more than 6-fold and Bax expression by 3-fold over each agent alone. Docetaxel 29-38 BCL2 apoptosis regulator Homo sapiens 132-137 14561532-7 2003 Expression of anti-apoptotic protein, Bcl-2, in BJAB cells drastically inhibited DeltaPsim change and DNA ladder formation but not H2O2 generation, confirming the participation of mitochondrial dysfunction in apoptosis. Hydrogen Peroxide 131-135 BCL2 apoptosis regulator Homo sapiens 38-43 14506747-10 2003 Quantitative Western blots showed a shift of the bax:bcl-2 ratio toward proapoptotic bax in ADA-treated cells. Adapalene 92-95 BCL2 apoptosis regulator Homo sapiens 53-58 14506750-7 2003 The combination treatment of docetaxel plus PD98059 also increased cellular apoptosis, which was in part due to the inactivation of Bcl-2 by increasing phosphorylated Bcl-2 by more than 6-fold and Bax expression by 3-fold over each agent alone. Docetaxel 29-38 BCL2 apoptosis regulator Homo sapiens 167-172 14506750-7 2003 The combination treatment of docetaxel plus PD98059 also increased cellular apoptosis, which was in part due to the inactivation of Bcl-2 by increasing phosphorylated Bcl-2 by more than 6-fold and Bax expression by 3-fold over each agent alone. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 44-51 BCL2 apoptosis regulator Homo sapiens 132-137 14506750-7 2003 The combination treatment of docetaxel plus PD98059 also increased cellular apoptosis, which was in part due to the inactivation of Bcl-2 by increasing phosphorylated Bcl-2 by more than 6-fold and Bax expression by 3-fold over each agent alone. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 44-51 BCL2 apoptosis regulator Homo sapiens 167-172 14506750-8 2003 At these dosages, docetaxel alone caused only marginal phosphorylation of Bcl-2 (10%). Docetaxel 18-27 BCL2 apoptosis regulator Homo sapiens 74-79 14506750-9 2003 Docetaxel plus U0126 had only 20% added effect on Bcl-2 phosphorylation compared to docetaxel alone. Docetaxel 0-9 BCL2 apoptosis regulator Homo sapiens 50-55 14506750-9 2003 Docetaxel plus U0126 had only 20% added effect on Bcl-2 phosphorylation compared to docetaxel alone. U 0126 15-20 BCL2 apoptosis regulator Homo sapiens 50-55 12876069-6 2003 IGF-1R survival signals targeted the Bcl-2 family of proteins to protect against glucose-induced apoptosis and oxidative stress. Glucose 81-88 BCL2 apoptosis regulator Homo sapiens 37-42 14600398-4 2003 Furthermore, evodiamine-induced activation of caspase-3 resulted in the down-regulation of anti-apoptotic Bcl-2 expression and up-regulation of proapoptotic Bax expression. evodiamine 13-23 BCL2 apoptosis regulator Homo sapiens 106-111 14563488-0 2003 Bcl-2 overexpression prevents daunorubicin-induced apoptosis through inhibition of XIAP and Akt degradation. Daunorubicin 30-42 BCL2 apoptosis regulator Homo sapiens 0-5 14758732-4 2003 These results suggested that the inhibition of Bcl-2 expression in HL-60 cells might account for the mechanism of 6-gingerol-induced apoptosis. gingerol 114-124 BCL2 apoptosis regulator Homo sapiens 47-52 14624621-9 2003 Using modifications of this synthetic strategy, the ri-PTD-4-G conjugate of bcl-2 antisense PNA was prepared using a lysine derivative of tetramethylrhodamine (TMR) for fluorescence microscopy. tetramethylrhodamine 138-158 BCL2 apoptosis regulator Homo sapiens 76-81 14624621-9 2003 Using modifications of this synthetic strategy, the ri-PTD-4-G conjugate of bcl-2 antisense PNA was prepared using a lysine derivative of tetramethylrhodamine (TMR) for fluorescence microscopy. tetramethylrhodamine 160-163 BCL2 apoptosis regulator Homo sapiens 76-81 14624621-10 2003 Plasma stability studies showed that (111)In-DOTA-labeled ri-PTD-4-G-anti-bcl-2 PNA was stable for 168 h at 37 degrees C, unlike the conjugate containing the parent peptide sequence. 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid 45-49 BCL2 apoptosis regulator Homo sapiens 74-79 14624621-10 2003 Plasma stability studies showed that (111)In-DOTA-labeled ri-PTD-4-G-anti-bcl-2 PNA was stable for 168 h at 37 degrees C, unlike the conjugate containing the parent peptide sequence. ri-ptd-4-g 58-68 BCL2 apoptosis regulator Homo sapiens 74-79 14624621-11 2003 Scanning confocal fluorescence microscopy of TMR-labeled ri-PTD-4-G-anti-bcl-2 PNA in Raji lymphoma cells demonstrated that the retro-inverso peptide was active in membrane permeation and mediated cellular internalization of the antisense PNA into the cytoplasm, where high concentrations of bcl-2 mRNA are expected to be present. tetramethylrhodamine 45-48 BCL2 apoptosis regulator Homo sapiens 73-78 14624621-11 2003 Scanning confocal fluorescence microscopy of TMR-labeled ri-PTD-4-G-anti-bcl-2 PNA in Raji lymphoma cells demonstrated that the retro-inverso peptide was active in membrane permeation and mediated cellular internalization of the antisense PNA into the cytoplasm, where high concentrations of bcl-2 mRNA are expected to be present. tetramethylrhodamine 45-48 BCL2 apoptosis regulator Homo sapiens 292-297 14624621-11 2003 Scanning confocal fluorescence microscopy of TMR-labeled ri-PTD-4-G-anti-bcl-2 PNA in Raji lymphoma cells demonstrated that the retro-inverso peptide was active in membrane permeation and mediated cellular internalization of the antisense PNA into the cytoplasm, where high concentrations of bcl-2 mRNA are expected to be present. ri-ptd-4-g 57-67 BCL2 apoptosis regulator Homo sapiens 73-78 14624621-11 2003 Scanning confocal fluorescence microscopy of TMR-labeled ri-PTD-4-G-anti-bcl-2 PNA in Raji lymphoma cells demonstrated that the retro-inverso peptide was active in membrane permeation and mediated cellular internalization of the antisense PNA into the cytoplasm, where high concentrations of bcl-2 mRNA are expected to be present. ri-ptd-4-g 57-67 BCL2 apoptosis regulator Homo sapiens 292-297 14624621-9 2003 Using modifications of this synthetic strategy, the ri-PTD-4-G conjugate of bcl-2 antisense PNA was prepared using a lysine derivative of tetramethylrhodamine (TMR) for fluorescence microscopy. Lysine 117-123 BCL2 apoptosis regulator Homo sapiens 76-81 12894215-0 2003 Decrease in intracellular superoxide sensitizes Bcl-2-overexpressing tumor cells to receptor and drug-induced apoptosis independent of the mitochondria. Superoxides 26-36 BCL2 apoptosis regulator Homo sapiens 48-53 12894215-3 2003 Moreover, Bcl-2 overexpression resulted in a slightly elevated constitutive level of superoxide anion and pH in CEM leukemia cells. Superoxides 85-101 BCL2 apoptosis regulator Homo sapiens 10-15 12894215-4 2003 Interestingly, decreasing intracellular superoxide concentration with an inhibitor of the beta-nicotinamide adenine dinucleotide phosphate oxidase or by transient transfection with a dominant-negative form of the guanosine triphosphate-binding protein Rac1 resulted in a significant increase in the sensitivity of CEM/Bcl-2 cells to CD95- or merocil-induced apoptosis. Superoxides 40-50 BCL2 apoptosis regulator Homo sapiens 318-323 12966153-7 2003 Consistent with the induction of apoptosis, 15-deoxy-PGJ2 increased the expression of proapoptotic proteins caspase 3, caspase 9, and Bax but down-regulated antiapoptotic protein Bcl-2. 15-deoxy-delta(12,14)-prostaglandin J2 44-57 BCL2 apoptosis regulator Homo sapiens 179-184 12882997-3 2003 Using antisense oligonucleotides, we achieved a block of iNOS protein formation, accompanied by a strong decrease in the expression of the protective stress response genes bcl-2, vascular endothelial growth factor, and heme oxygenase-1 (HO-1). Oligonucleotides 16-32 BCL2 apoptosis regulator Homo sapiens 172-177 14587026-1 2003 All-trans retinoic acid (ATRA) can down regulate the anti-apoptotic protein Bcl-2 and the cell cycle proteins cyclin D1 and cdk2 in estrogen receptor-positive breast cancer cells. Tretinoin 0-23 BCL2 apoptosis regulator Homo sapiens 76-81 14587026-1 2003 All-trans retinoic acid (ATRA) can down regulate the anti-apoptotic protein Bcl-2 and the cell cycle proteins cyclin D1 and cdk2 in estrogen receptor-positive breast cancer cells. Tretinoin 25-29 BCL2 apoptosis regulator Homo sapiens 76-81 14686729-9 2003 In addition, apoptosis occurred in both cell lines treated with either PGZ or ATRA, which was associated with a downregulation of bcl-2 and an upregulation of bax proteins. Pioglitazone 71-74 BCL2 apoptosis regulator Homo sapiens 130-135 14686729-9 2003 In addition, apoptosis occurred in both cell lines treated with either PGZ or ATRA, which was associated with a downregulation of bcl-2 and an upregulation of bax proteins. Tretinoin 78-82 BCL2 apoptosis regulator Homo sapiens 130-135 14686729-11 2003 Furthermore, treatment of fresh glioblastoma tissue from patients with PGZ, either alone or in combination with ATRA, induced a significant level of tumor cell apoptosis together with a downregulation of bcl-2 protein level as compared with untreated control brain tissue. Pioglitazone 71-74 BCL2 apoptosis regulator Homo sapiens 204-209 14686729-11 2003 Furthermore, treatment of fresh glioblastoma tissue from patients with PGZ, either alone or in combination with ATRA, induced a significant level of tumor cell apoptosis together with a downregulation of bcl-2 protein level as compared with untreated control brain tissue. Tretinoin 112-116 BCL2 apoptosis regulator Homo sapiens 204-209 14532826-0 2003 Re: Enhancement of diethylstilbestrol induced cytotoxicity by bcl-2 antisense oligodeoxynucleotides and a glutathione depletor for prostate cancer. Diethylstilbestrol 19-37 BCL2 apoptosis regulator Homo sapiens 62-67 14532826-0 2003 Re: Enhancement of diethylstilbestrol induced cytotoxicity by bcl-2 antisense oligodeoxynucleotides and a glutathione depletor for prostate cancer. Oligodeoxyribonucleotides 78-99 BCL2 apoptosis regulator Homo sapiens 62-67 14738153-0 2003 Cellular pharmacology of P-ethoxy antisense oligonucleotides targeted to Bcl-2 in a follicular lymphoma cell line. p-ethoxy 25-33 BCL2 apoptosis regulator Homo sapiens 73-78 12931228-8 2003 Importantly, low-concentration HA14-1 (5 muM) was nontoxic to normal colony-forming cells, whereas it enhanced the cytotoxicity of the antileukemia drug cytarabine in Bcl-2-positive lymphoblastic leukemia cells. Cytarabine 153-163 BCL2 apoptosis regulator Homo sapiens 167-172 14738153-0 2003 Cellular pharmacology of P-ethoxy antisense oligonucleotides targeted to Bcl-2 in a follicular lymphoma cell line. Oligonucleotides 44-60 BCL2 apoptosis regulator Homo sapiens 73-78 14738153-1 2003 A P-ethoxy oligonucleotide (oligo), 20 bases long and specific for the translation initiation site of human Bcl-2 mRNA, was incorporated into liposomes to increase its intracellular delivery. p-ethoxy oligonucleotide 2-26 BCL2 apoptosis regulator Homo sapiens 108-113 14738153-1 2003 A P-ethoxy oligonucleotide (oligo), 20 bases long and specific for the translation initiation site of human Bcl-2 mRNA, was incorporated into liposomes to increase its intracellular delivery. Oligonucleotides 11-16 BCL2 apoptosis regulator Homo sapiens 108-113 14738153-8 2003 Our results indicate that the Bcl-2 inhibitory activity is maintained with P-ethoxy antisense oligos ranging from 7 to 20 bases. p-ethoxy 75-83 BCL2 apoptosis regulator Homo sapiens 30-35 14511771-6 2003 It is also shown that PGE2 promoted both in keratinocytes and KB cells expression of Bcl-2, which was accompanied in the first case by increase in its mitochondrial level. Dinoprostone 22-26 BCL2 apoptosis regulator Homo sapiens 85-90 14566405-9 2003 Infusion of pergolide could induce the expression of bcl-2 and reduce the expression of bax. Pergolide 12-21 BCL2 apoptosis regulator Homo sapiens 53-58 14566405-11 2003 All these results indicate that pergolide plays an important role in the protection of hippocampal neurons from apotosis through upregulating the expression of bcl-2 protein and reducing the expression of bax protein. Pergolide 32-41 BCL2 apoptosis regulator Homo sapiens 160-165 14521916-7 2003 Inhibition of CsA- but not lactacytin-induced apoptosis by overexpression of Bcl-2 in Jurkat T cells revealed that CsA and proteasome inhibitors activate different apoptotic pathways, while both CsA- and lactacystin-induced apoptosis were found to be dependent on caspase activation and independent of the FasL/Fas system. Cyclosporine 14-17 BCL2 apoptosis regulator Homo sapiens 77-82 14521916-7 2003 Inhibition of CsA- but not lactacytin-induced apoptosis by overexpression of Bcl-2 in Jurkat T cells revealed that CsA and proteasome inhibitors activate different apoptotic pathways, while both CsA- and lactacystin-induced apoptosis were found to be dependent on caspase activation and independent of the FasL/Fas system. Cyclosporine 115-118 BCL2 apoptosis regulator Homo sapiens 77-82 14521916-7 2003 Inhibition of CsA- but not lactacytin-induced apoptosis by overexpression of Bcl-2 in Jurkat T cells revealed that CsA and proteasome inhibitors activate different apoptotic pathways, while both CsA- and lactacystin-induced apoptosis were found to be dependent on caspase activation and independent of the FasL/Fas system. Cyclosporine 115-118 BCL2 apoptosis regulator Homo sapiens 77-82 14521916-7 2003 Inhibition of CsA- but not lactacytin-induced apoptosis by overexpression of Bcl-2 in Jurkat T cells revealed that CsA and proteasome inhibitors activate different apoptotic pathways, while both CsA- and lactacystin-induced apoptosis were found to be dependent on caspase activation and independent of the FasL/Fas system. lactacystin 204-215 BCL2 apoptosis regulator Homo sapiens 77-82 14555211-6 2003 Thus, bcl-2-overexpressing cells exhibit elevated expression of antioxidant enzymes and higher levels of cellular GSH compared with the control cells transfected with the vector alone. Glutathione 114-117 BCL2 apoptosis regulator Homo sapiens 6-11 14555213-3 2003 A correlation between the expression of Bcl-2 protein and protection against apoptosis induced by DEX was found in granulosa cell lines expressing various levels of Bcl-2. Dexamethasone 98-101 BCL2 apoptosis regulator Homo sapiens 40-45 14555213-3 2003 A correlation between the expression of Bcl-2 protein and protection against apoptosis induced by DEX was found in granulosa cell lines expressing various levels of Bcl-2. Dexamethasone 98-101 BCL2 apoptosis regulator Homo sapiens 165-170 14555232-10 2003 Treatment with SBHA also resulted in down-regulation of antiapoptotic members of the Bcl-2 family, Bcl-X(L) and Mcl-1, and the IAP member, XIAP. suberic bishydroxamate 15-19 BCL2 apoptosis regulator Homo sapiens 85-90 14555233-7 2003 For methylating agents inducing O(6)-methylguanine, an additional requirement is mismatch repair provoking DSB formation that triggers Bcl-2 decline and caspase-9/-3 activation. O-(6)-methylguanine 32-50 BCL2 apoptosis regulator Homo sapiens 135-140 14555244-0 2003 The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. rasagiline 148-158 BCL2 apoptosis regulator Homo sapiens 20-25 14555244-3 2003 Specifically rasagiline activates Bcl-2, Bcl-xl, protein kinase C (PKC) and reduces Bax in a variety of cells including PC-12 and neuroblastoma human dopamine derived SH-SY5Y cells. rasagiline 13-23 BCL2 apoptosis regulator Homo sapiens 34-39 14555244-5 2003 This pharmacological action of rasagiline is also associated with the prevention of the neurotoxin induced fall in mitochondrial membrane potential, opening of mitochondria permeability transition pore, activation of proteasome-ubiquitin complex, inhibition of cytochrome c release and prevention of caspase 3 activation, similar to the actions of cyclosporin A or Bcl-2 over expression in SH-SY5Y cells. rasagiline 31-41 BCL2 apoptosis regulator Homo sapiens 365-370 14556859-0 2003 Protection conferred by Bcl-2 expression involves reduced oxidative stress and increased glutathione production during hypothermia-induced apoptosis in AK-5 tumor cells. Glutathione 89-100 BCL2 apoptosis regulator Homo sapiens 24-29 14556859-2 2003 Introduction of Bcl-2 gene in BC-8 cells inhibited hypothermia-induced apoptotic process, which is ascribed to reduced ROS generation and higher glutathione production. ros 119-122 BCL2 apoptosis regulator Homo sapiens 16-21 14556859-2 2003 Introduction of Bcl-2 gene in BC-8 cells inhibited hypothermia-induced apoptotic process, which is ascribed to reduced ROS generation and higher glutathione production. Glutathione 145-156 BCL2 apoptosis regulator Homo sapiens 16-21 12927354-7 2003 These results suggest that MEHP can induce apoptosis in U937 cells through modulation of the balance of bcl-2/bax in part by PPARgamma activation. mono-(2-ethylhexyl)phthalate 27-31 BCL2 apoptosis regulator Homo sapiens 104-109 14515361-12 2003 The data suggest that the ratio of Bcl-2/Bad in astrocytes following ActD and CHX treatment does not decrease as much in untreated cells during ischemia. Cycloheximide 78-81 BCL2 apoptosis regulator Homo sapiens 35-40 12820987-7 2003 In this work, we found that Bcl-2 levels in K5 cells did not show any change during 2-7 days in vitro (DIV); but cells grown with NMDA and K25 displayed an increase (55% approximately) of Bcl-2 from 4 DIV, as compared to control. N-Methylaspartate 130-134 BCL2 apoptosis regulator Homo sapiens 28-33 12820987-7 2003 In this work, we found that Bcl-2 levels in K5 cells did not show any change during 2-7 days in vitro (DIV); but cells grown with NMDA and K25 displayed an increase (55% approximately) of Bcl-2 from 4 DIV, as compared to control. N-Methylaspartate 130-134 BCL2 apoptosis regulator Homo sapiens 188-193 14636445-5 2003 The expression of Bcl-2 in SMMC-7721 cells treated by 3 mmol/L or 10 mmol/L aspirin decreased markedly, but no effect on Bax. smmc 27-31 BCL2 apoptosis regulator Homo sapiens 18-23 14636445-5 2003 The expression of Bcl-2 in SMMC-7721 cells treated by 3 mmol/L or 10 mmol/L aspirin decreased markedly, but no effect on Bax. Aspirin 76-83 BCL2 apoptosis regulator Homo sapiens 18-23 14636445-6 2003 CONCLUSION: The cooperative anti-tumor effect of aspirin and TRAIL may be related to the inhibition of the expression of Bcl-2 by aspirin Aspirin 49-56 BCL2 apoptosis regulator Homo sapiens 121-126 14636445-6 2003 CONCLUSION: The cooperative anti-tumor effect of aspirin and TRAIL may be related to the inhibition of the expression of Bcl-2 by aspirin Aspirin 130-137 BCL2 apoptosis regulator Homo sapiens 121-126 12925958-12 2003 These results suggest that HCV NS5A as a Bcl-2 homologue interacts with Bax to protect p53-negative HCC cells from NaPB-induced apoptosis. 4-phenylbutylamine 115-119 BCL2 apoptosis regulator Homo sapiens 41-46 14581372-1 2003 In recent studies, we found that sulindac sulfide (SS), exisulind, CP248, and CP461 induce growth inhibition and apoptosis in a series of human prostate cancer cell lines, irrespective of cyclooxygenase expression, p53 mutations, or bcl-2 overexpression. sulindac sulfide 33-49 BCL2 apoptosis regulator Homo sapiens 233-238 14581372-1 2003 In recent studies, we found that sulindac sulfide (SS), exisulind, CP248, and CP461 induce growth inhibition and apoptosis in a series of human prostate cancer cell lines, irrespective of cyclooxygenase expression, p53 mutations, or bcl-2 overexpression. sulindac sulfide 51-53 BCL2 apoptosis regulator Homo sapiens 233-238 14581372-1 2003 In recent studies, we found that sulindac sulfide (SS), exisulind, CP248, and CP461 induce growth inhibition and apoptosis in a series of human prostate cancer cell lines, irrespective of cyclooxygenase expression, p53 mutations, or bcl-2 overexpression. (5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride 78-83 BCL2 apoptosis regulator Homo sapiens 233-238 14515361-0 2003 Cycloheximide and actinomycin D delay death and affect bcl-2, bax, and Ice gene expression in astrocytes under in vitro ischemia. Cycloheximide 0-13 BCL2 apoptosis regulator Homo sapiens 55-60 14515361-0 2003 Cycloheximide and actinomycin D delay death and affect bcl-2, bax, and Ice gene expression in astrocytes under in vitro ischemia. Dactinomycin 18-31 BCL2 apoptosis regulator Homo sapiens 55-60 14505794-0 2003 Taxol- and okadaic acid-induced destabilization of bcl-2 mRNA is associated with decreased binding of proteins to a bcl-2 instability element. Paclitaxel 0-5 BCL2 apoptosis regulator Homo sapiens 51-56 13679234-12 2003 These results suggest that YM529, the new bisphosphonate, induced apoptosis when inhibit GGPP synthase and consequently decreased the levels of phosphorylated ERK, which is a survival signal; moreover, during this process, there is no influence on NF-kappaB, Akt, p38, and Bcl-2. Diphosphonates 42-56 BCL2 apoptosis regulator Homo sapiens 273-278 14505458-0 2003 Ins(1,4,5)P3-mediated calcium signals and apoptosis: is there a role for Bcl-2? Inositol 1,4,5-Trisphosphate 0-12 BCL2 apoptosis regulator Homo sapiens 73-78 14505458-1 2003 In this review we speculate that the anti-apoptotic protein Bcl-2 may regulate calcium signals involved in mediating cell death. Calcium 79-86 BCL2 apoptosis regulator Homo sapiens 60-65 14505458-3 2003 Also, we review evidence that Bcl-2 regulates calcium release from the endoplasmic reticulum, and speculate that Bcl-2 may interact either functionally or physically with Ins(1,4,5)P(3) receptors to modulate calcium signals that determine life or death decisions. Calcium 46-53 BCL2 apoptosis regulator Homo sapiens 30-35 14505458-3 2003 Also, we review evidence that Bcl-2 regulates calcium release from the endoplasmic reticulum, and speculate that Bcl-2 may interact either functionally or physically with Ins(1,4,5)P(3) receptors to modulate calcium signals that determine life or death decisions. Calcium 208-215 BCL2 apoptosis regulator Homo sapiens 113-118 14505794-0 2003 Taxol- and okadaic acid-induced destabilization of bcl-2 mRNA is associated with decreased binding of proteins to a bcl-2 instability element. Paclitaxel 0-5 BCL2 apoptosis regulator Homo sapiens 116-121 14505794-0 2003 Taxol- and okadaic acid-induced destabilization of bcl-2 mRNA is associated with decreased binding of proteins to a bcl-2 instability element. Okadaic Acid 11-23 BCL2 apoptosis regulator Homo sapiens 51-56 14505794-0 2003 Taxol- and okadaic acid-induced destabilization of bcl-2 mRNA is associated with decreased binding of proteins to a bcl-2 instability element. Okadaic Acid 11-23 BCL2 apoptosis regulator Homo sapiens 116-121 14505794-2 2003 We report here that taxol or okadaic acid (OA) treatment of HL-60 cells reduced bcl-2 mRNA steady state levels to 50% of control cell levels in 20-24hr of treatment. Paclitaxel 20-25 BCL2 apoptosis regulator Homo sapiens 80-85 14505794-2 2003 We report here that taxol or okadaic acid (OA) treatment of HL-60 cells reduced bcl-2 mRNA steady state levels to 50% of control cell levels in 20-24hr of treatment. Okadaic Acid 29-41 BCL2 apoptosis regulator Homo sapiens 80-85 14505794-8 2003 Collectively, these results suggest a novel action of taxol and OA on bcl-2 expression, which involves bcl-2 mRNA downregulation through inactivation of bcl-2 mRNA stabilizing factors. Paclitaxel 54-59 BCL2 apoptosis regulator Homo sapiens 70-75 14505794-8 2003 Collectively, these results suggest a novel action of taxol and OA on bcl-2 expression, which involves bcl-2 mRNA downregulation through inactivation of bcl-2 mRNA stabilizing factors. Paclitaxel 54-59 BCL2 apoptosis regulator Homo sapiens 103-108 14505794-8 2003 Collectively, these results suggest a novel action of taxol and OA on bcl-2 expression, which involves bcl-2 mRNA downregulation through inactivation of bcl-2 mRNA stabilizing factors. Paclitaxel 54-59 BCL2 apoptosis regulator Homo sapiens 103-108 14570617-0 2003 Effects of magnesium sulfate on neuron apoptosis and expression of caspase-3, bax and bcl-2 after cerebral ischemia-reperfusion injury. Magnesium Sulfate 11-28 BCL2 apoptosis regulator Homo sapiens 86-91 14511363-2 2003 In the present study, we explored the relation of hydrogen peroxide (H2O2) generation by polymorphonuclear cells (PMNs) to the cytosolic expression of Bax and Bcl2 proteins and apoptosis in haemodialysis (HD) patients. Hydrogen Peroxide 50-67 BCL2 apoptosis regulator Homo sapiens 159-163 14627349-10 2003 Treatment of GC patients with Vioxx resulted in a significant decrease in plasma and tumor contents of both progastrin and gastrin, and this was accompanied by the increment in tumor expression of COX-2, PPARy, Bax, and caspase-3 with a concomitant reduction in Bcl-2 and survivin expression. rofecoxib 30-35 BCL2 apoptosis regulator Homo sapiens 262-267 14627349-14 2003 (4) COX-2, PPARgamma, Bcl-2, and survivin were overexpressed in gastric tumor, but the inhibition of COX-2 activity by Vioxx resulted in a significant reduction in serum and tumor levels of progastrin and gastrin and serum IL-8 and TNF-alpha levels, suggesting that gastrin and proinflammatory cytokines could mediate the up-regulation of COX-2 in gastric cancerogenesis. rofecoxib 119-124 BCL2 apoptosis regulator Homo sapiens 22-27 14627349-15 2003 (5) Vioxx also enhanced expression of COX-2, PPARy, Bax, and caspase-3, while inhibiting the expression of Bcl-2 and survivin, suggesting that COX-2 blockade might be useful in chemoprevention against gastric cancer possibly due to enhancement of the PPARy- and proapoptotic proteins-dependent apoptosis and the reduction in progastrin/gastrin-induced promotion of tumor growth. rofecoxib 4-9 BCL2 apoptosis regulator Homo sapiens 107-112 14499628-0 2003 Bcl-2 prevents abnormal mitochondrial proliferation during etoposide-induced apoptosis. Etoposide 59-68 BCL2 apoptosis regulator Homo sapiens 0-5 14511363-0 2003 Quantification of Bax and Bcl2 in polymorphonuclear leukocytes from haemodialysis patients: relation to hydrogen peroxide. Hydrogen Peroxide 104-121 BCL2 apoptosis regulator Homo sapiens 26-30 14511363-2 2003 In the present study, we explored the relation of hydrogen peroxide (H2O2) generation by polymorphonuclear cells (PMNs) to the cytosolic expression of Bax and Bcl2 proteins and apoptosis in haemodialysis (HD) patients. Hydrogen Peroxide 69-73 BCL2 apoptosis regulator Homo sapiens 159-163 14511363-4 2003 Bax and Bcl2 expression was detected by flow cytometry using FITC-conjugated antibodies. Fluorescein-5-isothiocyanate 61-65 BCL2 apoptosis regulator Homo sapiens 8-12 14511363-11 2003 In the HD patients with detectable cytosolic Bax and Bcl2 proteins, the Bax to Bcl2 ratio inversely correlated with H2O2 levels (P<0.0001). Hydrogen Peroxide 116-120 BCL2 apoptosis regulator Homo sapiens 53-57 14511363-11 2003 In the HD patients with detectable cytosolic Bax and Bcl2 proteins, the Bax to Bcl2 ratio inversely correlated with H2O2 levels (P<0.0001). Hydrogen Peroxide 116-120 BCL2 apoptosis regulator Homo sapiens 79-83 14511363-12 2003 Finally, brief exposure of PMNs to 0.1-100 microM of H2O2 resulted in a marked increase in Bcl2 expression (P=0.001), which was prevented by catalase (P=0.05). Hydrogen Peroxide 53-57 BCL2 apoptosis regulator Homo sapiens 91-95 14511363-14 2003 CONCLUSIONS: This study demonstrates that in HD patients, high-resting cytosolic H2O2 production by PMNs is not associated with accelerated in vitro apoptosis, and that the Bax/Bcl2 system may counter-balance the deleterious effects of reactive oxygen species in human PMNs. Reactive Oxygen Species 236-259 BCL2 apoptosis regulator Homo sapiens 177-181 12897059-7 2003 Furthermore, EGCG increased Bcl-2 expression but decreased Bax expression, causing an increase in the Bcl-2-to-Bax ratio. epigallocatechin gallate 13-17 BCL2 apoptosis regulator Homo sapiens 28-33 14514777-6 2003 RESULTS: TMA expression of CD10, CD20, bcl-2, and bcl-6 showed 100% concordance with results from conventional sections in 60 cases. tma 9-12 BCL2 apoptosis regulator Homo sapiens 39-44 12897059-7 2003 Furthermore, EGCG increased Bcl-2 expression but decreased Bax expression, causing an increase in the Bcl-2-to-Bax ratio. epigallocatechin gallate 13-17 BCL2 apoptosis regulator Homo sapiens 102-107 12897059-9 2003 In conclusion, this study demonstrates that EGCG promotes keratinocyte survival and inhibits the UV-induced apoptosis via two mechanisms: by phosphorylating Ser112 and Ser136 of Bad protein through Erk and Akt pathways, respectively, and by increasing the Bcl-2-to-Bax ratio. epigallocatechin gallate 44-48 BCL2 apoptosis regulator Homo sapiens 256-261 14599092-5 2003 Gemtuzumab ozogamicin (Mylotarg) for the treatment of patients with CD33-positive acute myeloid leukemia, selective FLT3 inhibitors currently in advanced development (e.g., SU11248, PKC412, CT53518 and CEP-710) and other targeted compounds (e.g., farnesyl transferase inhibitors, BCL-2 inhibitors and interleukin-2) may present initial opportunities to achieve improved outcomes. OZOGAMICIN 11-21 BCL2 apoptosis regulator Homo sapiens 280-285 14564359-0 2003 Endogenous nitric oxide downregulates the Bcl-2 expression of eosinophils through mitogen-activated protein kinase in bronchial asthma. Nitric Oxide 11-23 BCL2 apoptosis regulator Homo sapiens 42-47 14564359-12 2003 After incubation for 16 hours, the expression of Bcl-2 on eosinophils from patients with asthma was significantly enhanced by L-NAME. NG-Nitroarginine Methyl Ester 126-132 BCL2 apoptosis regulator Homo sapiens 49-54 13130506-9 2003 Expression of antisense bcl-2 in glioma cells resulted in significantly increased cytotoxicity of cisplatin. Cisplatin 98-107 BCL2 apoptosis regulator Homo sapiens 24-29 14517609-3 2003 It has been previously shown that phosphorylation of Ser 70 located in this loop region regulates the anti-apoptotic activity of Bcl-2. Serine 53-56 BCL2 apoptosis regulator Homo sapiens 129-134 13130506-10 2003 In conclusion, antisense bcl-2 expression can effectively reduce glioma survival, including retarding in vitro growth, complete loss of tumorigenicity, and significantly enhanced cisplatin cytotoxicity. Cisplatin 179-188 BCL2 apoptosis regulator Homo sapiens 25-30 14512787-2 2003 To gain insight into the molecular mechanisms underlying chemotherapeutic drug resistance, we examined the role of the Bcl-2 family members Bcl-2 and Bax in cell death in the melanoma cell line G361 following stimulation with cisplatin (CDDP) or dacarbazine (DTIC). Cisplatin 226-235 BCL2 apoptosis regulator Homo sapiens 119-124 14513055-0 2003 The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Bortezomib 25-35 BCL2 apoptosis regulator Homo sapiens 110-115 14512787-7 2003 CDDP-induced apoptosis and secondary necrosis were accompanied by activation of caspase-3 and modulation of Bcl-2 family members Bcl-2 and Bax. Cisplatin 0-4 BCL2 apoptosis regulator Homo sapiens 108-113 14512787-7 2003 CDDP-induced apoptosis and secondary necrosis were accompanied by activation of caspase-3 and modulation of Bcl-2 family members Bcl-2 and Bax. Cisplatin 0-4 BCL2 apoptosis regulator Homo sapiens 129-134 14512787-9 2003 Flow cytometry, which enables measurement of protein at the single-cell level, revealed that Bcl-2+/Bax- cells were decreased, with a slight concomitant rise in Bcl-2-/Bax+ cells on stimulation with CDDP. Cisplatin 199-203 BCL2 apoptosis regulator Homo sapiens 93-98 14512787-9 2003 Flow cytometry, which enables measurement of protein at the single-cell level, revealed that Bcl-2+/Bax- cells were decreased, with a slight concomitant rise in Bcl-2-/Bax+ cells on stimulation with CDDP. Cisplatin 199-203 BCL2 apoptosis regulator Homo sapiens 161-166 14512787-10 2003 These findings suggest that the chemotherapeutic agents CDDP and DTIC induce apoptosis and/or secondary necrosis depending on dose, probably involving the modulation of Bcl-2 family proteins. Cisplatin 56-60 BCL2 apoptosis regulator Homo sapiens 169-174 14512787-10 2003 These findings suggest that the chemotherapeutic agents CDDP and DTIC induce apoptosis and/or secondary necrosis depending on dose, probably involving the modulation of Bcl-2 family proteins. Dacarbazine 65-69 BCL2 apoptosis regulator Homo sapiens 169-174 13678665-0 2003 Targeted expression of BCL-2 attenuates MPP+ but not 6-OHDA induced cell death in dopaminergic neurons. mangion-purified polysaccharide (Candida albicans) 40-44 BCL2 apoptosis regulator Homo sapiens 23-28 14578468-1 2003 G3139 is an 18-mer phosphorothioate oligodeoxyribonucleotide, which is targeted to the initiation codon region of the bcl-2mRNA. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 118-123 14578468-1 2003 G3139 is an 18-mer phosphorothioate oligodeoxyribonucleotide, which is targeted to the initiation codon region of the bcl-2mRNA. Parathion 19-35 BCL2 apoptosis regulator Homo sapiens 118-123 14578468-1 2003 G3139 is an 18-mer phosphorothioate oligodeoxyribonucleotide, which is targeted to the initiation codon region of the bcl-2mRNA. Oligodeoxyribonucleotides 36-60 BCL2 apoptosis regulator Homo sapiens 118-123 14578468-7 2003 A series of mismatched G3139-related oligomers were synthesized that could also substantially down-regulate bcl-2 protein expression, but only if the CpG motifs were preserved, demonstrating the presence of additional non-antisense mechanisms. oblimersen 23-28 BCL2 apoptosis regulator Homo sapiens 108-113 13678665-5 2003 Although both staurosporine and 6-OHDA induced apoptosis, overexpression of Bcl-2 only rescued cells from programmed cell death induced by staurosporine. Staurosporine 14-27 BCL2 apoptosis regulator Homo sapiens 76-81 13678665-5 2003 Although both staurosporine and 6-OHDA induced apoptosis, overexpression of Bcl-2 only rescued cells from programmed cell death induced by staurosporine. Staurosporine 139-152 BCL2 apoptosis regulator Homo sapiens 76-81 14728868-11 2003 Mifepristone up-regulated significantly the expression of p53 protein, but down-regulated the expression of bcl-2 protein (P < 0.01). Mifepristone 0-12 BCL2 apoptosis regulator Homo sapiens 108-113 12950722-10 2003 The combined treatment with genistein and cisplatin significantly reduced bcl-2 and bcl-xL protein and increased Apaf-1 protein expression. Genistein 28-37 BCL2 apoptosis regulator Homo sapiens 74-79 12950722-10 2003 The combined treatment with genistein and cisplatin significantly reduced bcl-2 and bcl-xL protein and increased Apaf-1 protein expression. Cisplatin 42-51 BCL2 apoptosis regulator Homo sapiens 74-79 14613035-0 2003 Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancer. Oligonucleotides 16-32 BCL2 apoptosis regulator Homo sapiens 0-5 14613035-6 2003 Downregulation of bcl-2 by antisense oligonucleotides has been shown to improve the efficacy of chemotherapy in experimental models. Oligonucleotides 37-53 BCL2 apoptosis regulator Homo sapiens 18-23 12972297-4 2003 Overexpression of osVDAC4 induces apoptosis, which can be blocked by Bcl-2 and the VDAC inhibitor DIDS. osvdac4 18-25 BCL2 apoptosis regulator Homo sapiens 69-74 12972300-6 2003 Bcl-2 over-expression did not prevent apoptosis after gemcitabine-treatment, but protected dexamethasone-treated cells from apoptosis, without fully preventing the decline of respiration and cell size. Dexamethasone 91-104 BCL2 apoptosis regulator Homo sapiens 0-5 13679861-0 2003 The chemopreventive agent N-(4-hydroxyphenyl)retinamide induces apoptosis through a mitochondrial pathway regulated by proteins from the Bcl-2 family. Fenretinide 26-55 BCL2 apoptosis regulator Homo sapiens 137-142 12957653-6 2003 Moreover, the degree of HOCl-oxLDL-induced caspase-3 and -8 activation, and apoptosis was significantly reduced in U937/Bcl-2 cells, with no activation of caspase-9. Hypochlorous Acid 24-28 BCL2 apoptosis regulator Homo sapiens 120-125 12957653-10 2003 The interference of Bcl-2 overexpression with HOCl-oxLDL-induced apoptosis suggests the importance of mitochondrial involvement in this apoptotic mechanism. Hypochlorous Acid 46-50 BCL2 apoptosis regulator Homo sapiens 20-25 14575542-7 2003 In conclusion, the combination of Z-LLL-CHO and VP16 enhanced their individual cytotoxic effect by inducing apoptosis, in which increase of S + G2/M fraction in cell cycle as well as the enhanced cleavage of Bcl-2 are the possible mechanism of the additive effect on leukemic cells by Z-LLL-CHO and VP16. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 34-43 BCL2 apoptosis regulator Homo sapiens 208-213 14575542-7 2003 In conclusion, the combination of Z-LLL-CHO and VP16 enhanced their individual cytotoxic effect by inducing apoptosis, in which increase of S + G2/M fraction in cell cycle as well as the enhanced cleavage of Bcl-2 are the possible mechanism of the additive effect on leukemic cells by Z-LLL-CHO and VP16. Etoposide 48-52 BCL2 apoptosis regulator Homo sapiens 208-213 13679861-8 2003 Altogether, these data indicate that 4-HPR induces MMP through an ROS-mediated pathway that involves the obligatory contribution of the proapopotic Bcl-2 family members Bax and/or Bak. Reactive Oxygen Species 66-69 BCL2 apoptosis regulator Homo sapiens 148-153 14728868-12 2003 The expressive rates of p53 and bcl-2 proteins were (54.8 +/- 4.0)% and (10.1 +/- 1.2)%, respectively, when 3AO cells was cultured with mifepristone of 10 micro mol/L for 24 h. Compared with the expression rates of control group (27.1 +/- 3.3)% and (17.6 +/- 1.0)%, the difference was significant (P < 0.01). Mifepristone 136-148 BCL2 apoptosis regulator Homo sapiens 32-37 12927789-7 2003 Inasmuch as Bcl-2 suppresses while Bax accelerates apoptosis, treatment of cells with morphine reduced the expression of Bax and enhanced the expression of Bcl-2. Morphine 86-94 BCL2 apoptosis regulator Homo sapiens 12-17 14519654-2 2003 G3139 (Genasense, oblimersen; Genta Inc.), a Bcl-2 antisense oligonucleotide, has been shown to down-regulate the Bcl-2 protein and induce apoptosis in myeloid leukemia cells from treated patients. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 45-50 14519654-2 2003 G3139 (Genasense, oblimersen; Genta Inc.), a Bcl-2 antisense oligonucleotide, has been shown to down-regulate the Bcl-2 protein and induce apoptosis in myeloid leukemia cells from treated patients. oblimersen 0-5 BCL2 apoptosis regulator Homo sapiens 114-119 14519654-2 2003 G3139 (Genasense, oblimersen; Genta Inc.), a Bcl-2 antisense oligonucleotide, has been shown to down-regulate the Bcl-2 protein and induce apoptosis in myeloid leukemia cells from treated patients. genta 30-35 BCL2 apoptosis regulator Homo sapiens 45-50 14519654-2 2003 G3139 (Genasense, oblimersen; Genta Inc.), a Bcl-2 antisense oligonucleotide, has been shown to down-regulate the Bcl-2 protein and induce apoptosis in myeloid leukemia cells from treated patients. genta 30-35 BCL2 apoptosis regulator Homo sapiens 114-119 14519654-2 2003 G3139 (Genasense, oblimersen; Genta Inc.), a Bcl-2 antisense oligonucleotide, has been shown to down-regulate the Bcl-2 protein and induce apoptosis in myeloid leukemia cells from treated patients. Oligonucleotides 61-76 BCL2 apoptosis regulator Homo sapiens 45-50 12821677-10 2003 In PC-3 prostate carcinoma cells (with overexpression of Bcl-2), a reduction of bortezomib-induced ROS generation, Delta psi m increase was correlated with cellular resistance to bortezomib and the attenuation of drug-induced apoptosis. Bortezomib 80-90 BCL2 apoptosis regulator Homo sapiens 57-62 12821677-10 2003 In PC-3 prostate carcinoma cells (with overexpression of Bcl-2), a reduction of bortezomib-induced ROS generation, Delta psi m increase was correlated with cellular resistance to bortezomib and the attenuation of drug-induced apoptosis. Reactive Oxygen Species 99-102 BCL2 apoptosis regulator Homo sapiens 57-62 12821677-10 2003 In PC-3 prostate carcinoma cells (with overexpression of Bcl-2), a reduction of bortezomib-induced ROS generation, Delta psi m increase was correlated with cellular resistance to bortezomib and the attenuation of drug-induced apoptosis. Bortezomib 179-189 BCL2 apoptosis regulator Homo sapiens 57-62 14519627-6 2003 The role of SK-RC-45-stimulated caspase activation in degrading T-cell Bcl-2 was assessed using a pan-caspase inhibitor, as well as a specific inhibitor of caspase-9. sk-rc-45 12-20 BCL2 apoptosis regulator Homo sapiens 71-76 14519627-8 2003 The SK-RC-45-induced modulation of lymphocyte Bcl-2 levels was largely caspase independent because pretreatment of T cells with pan-caspase inhibitor III or an inhibitor of caspase-9 had minimal or no effect on stabilizing the protein, although it did provide protection against apoptosis. sk-rc-45 4-12 BCL2 apoptosis regulator Homo sapiens 46-51 12970736-6 2003 The 3" region contained the Cdx site, which mediates the effect of A-Myb on the bcl-2 promoter. Cefadroxil 28-31 BCL2 apoptosis regulator Homo sapiens 80-85 12899928-5 2003 In addition, DOX treatment also upregulated Bax and downregulated Bcl-2 levels in the cells. Doxorubicin 13-16 BCL2 apoptosis regulator Homo sapiens 66-71 12927789-7 2003 Inasmuch as Bcl-2 suppresses while Bax accelerates apoptosis, treatment of cells with morphine reduced the expression of Bax and enhanced the expression of Bcl-2. Morphine 86-94 BCL2 apoptosis regulator Homo sapiens 156-161 12950415-3 2003 The putative chemopreventive actions include the inhibition of inflammatory cascades and/or reactions involved in cell growth and proliferation, such as cyclo-oxygenase (COX-1 and COX-2), which regulate cell proliferation through the formation of prostaglandins; lipoxygenase; nuclear factor kappaB (NFkappaB), responsible for the subsequent expression of pro-inflammatory molecules; MAP kinases and Bcl-2, as well as the activation of apoptotic processes, such as the stimulation of intestinal sphingomyelinase. Prostaglandins 247-261 BCL2 apoptosis regulator Homo sapiens 400-405 12951476-6 2003 Transfection efficiency of ganglioside-containing liposomes was also assessed by the effects of antisense oligonucleotides (AS-ODN) for bcl-2 gene, which suppresses apoptotic cell death. Oligonucleotides 106-122 BCL2 apoptosis regulator Homo sapiens 136-141 12748063-9 2003 Additionally, ethanol-exposed cells display a blunting of TNF-alpha-induced Akt activation and Bcl-2 antagonist of cell death phosphorylation that may account, in part, for the increased sensitivity of the mitochondria to Bax-mediated damage. Ethanol 14-21 BCL2 apoptosis regulator Homo sapiens 95-100 12951476-7 2003 Western blotting analysis revealed that the expression of Bcl-2 was decreased by AS-ODN, and the reduction of protein expression in cells treated with GA(1)-containing liposomes was more remarkable than that with GM(1a)-containing liposomes. G(A1) ganglioside 151-156 BCL2 apoptosis regulator Homo sapiens 58-63 12951476-7 2003 Western blotting analysis revealed that the expression of Bcl-2 was decreased by AS-ODN, and the reduction of protein expression in cells treated with GA(1)-containing liposomes was more remarkable than that with GM(1a)-containing liposomes. gm(1a) 213-219 BCL2 apoptosis regulator Homo sapiens 58-63 12953308-6 2003 Western blot analysis of the expression of various Bcl-2 family members in betulinic acid-treated cells showed, surprisingly, a suppression of the expression of the proapoptotic protein Bax but no changes in Mcl-1 or Bcl-2 expression. betulinic acid 75-89 BCL2 apoptosis regulator Homo sapiens 51-56 14505758-10 2003 A higher bcl-2/bax relative ratio in PCOSE was observed. pcose 37-42 BCL2 apoptosis regulator Homo sapiens 9-14 12937219-15 2003 CONCLUSIONS: TNF-alpha directs HPMCs to commit apoptosis via the Fas/Fas ligand pathway through a modulation of Fas and bcl-2. hpmcs 31-36 BCL2 apoptosis regulator Homo sapiens 120-125 12911627-7 2003 Further research showed that co-incubation of green tea polyphenols and SNP caused loss of mitochondrial membrane potential, depletion of intracellular GSH and accumulation of reactive oxygen species, and exacerbated NO-induced neuronal apoptosis via a Bcl-2 sensitive pathway. Polyphenols 56-67 BCL2 apoptosis regulator Homo sapiens 253-258 12967636-0 2003 Hsp10 and Hsp60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin in cardiac muscle cells. Doxorubicin 86-97 BCL2 apoptosis regulator Homo sapiens 25-30 12967636-8 2003 These findings indicate that overexpression of Hsp10 and Hsp60 differentially modulated Bcl-2 family and in turn attenuate doxorubicin-induced cardiac muscle death. Doxorubicin 123-134 BCL2 apoptosis regulator Homo sapiens 88-93 12935767-10 2003 The pyruvate-related redox manipulation inhibited the H2O2-induced p53 activation, restored the downregulated bcl-2 and the upregulated bax, and hence enhanced the bcl-2/bax expression ratio. Pyruvic Acid 4-12 BCL2 apoptosis regulator Homo sapiens 110-115 12935767-10 2003 The pyruvate-related redox manipulation inhibited the H2O2-induced p53 activation, restored the downregulated bcl-2 and the upregulated bax, and hence enhanced the bcl-2/bax expression ratio. Pyruvic Acid 4-12 BCL2 apoptosis regulator Homo sapiens 164-169 12935767-10 2003 The pyruvate-related redox manipulation inhibited the H2O2-induced p53 activation, restored the downregulated bcl-2 and the upregulated bax, and hence enhanced the bcl-2/bax expression ratio. Hydrogen Peroxide 54-58 BCL2 apoptosis regulator Homo sapiens 110-115 12935767-10 2003 The pyruvate-related redox manipulation inhibited the H2O2-induced p53 activation, restored the downregulated bcl-2 and the upregulated bax, and hence enhanced the bcl-2/bax expression ratio. Hydrogen Peroxide 54-58 BCL2 apoptosis regulator Homo sapiens 164-169 12938158-2 2003 This study tested the hypothesis that shear stress induced nitric oxide is associated with altered expression of regulatory onco-proteins, bcl-2, and Fas (APO-1/CD95) and apoptosis in primary human osteoarthritic chondrocyte cultures. Nitric Oxide 59-71 BCL2 apoptosis regulator Homo sapiens 139-144 12938158-7 2003 Inhibition of shear stress induced nitric oxide release by L-NAME coincided with a 2.7-fold increase of bcl-2, when compared to chondrocytes exposed to shear stress in the absence of L-NAME. Nitric Oxide 35-47 BCL2 apoptosis regulator Homo sapiens 104-109 12938158-7 2003 Inhibition of shear stress induced nitric oxide release by L-NAME coincided with a 2.7-fold increase of bcl-2, when compared to chondrocytes exposed to shear stress in the absence of L-NAME. NG-Nitroarginine Methyl Ester 59-65 BCL2 apoptosis regulator Homo sapiens 104-109 12925222-5 2003 In search of the molecular mechanism responsible for the antiapoptotic effect of ginsenoside F1, we find that protection from ultraviolet-B-induced apoptosis is tightly correlated with ginsenoside-F1-mediated inhibition of ultraviolet-B-induced downregulation of Bcl-2 and Brn-3a expression. Ginsenosides 81-92 BCL2 apoptosis regulator Homo sapiens 263-268 12883741-8 2003 In addition, up-regulation of Bax and down-regulation of Bcl-2 was also observed indicating that these two apoptotic regulators may play important roles in terazosin-mediated cell death pathway. Terazosin 156-165 BCL2 apoptosis regulator Homo sapiens 57-62 12941797-0 2003 Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. lonafarnib 103-111 BCL2 apoptosis regulator Homo sapiens 40-45 15169668-12 2003 CONCLUSION: Insulin could inhibit apoptosis of human trophoblasts cells induced by H2O2, which be may through decreased caspase-3 activity and increased Bcl-2 protein expression. Hydrogen Peroxide 83-87 BCL2 apoptosis regulator Homo sapiens 153-158 12788915-6 2003 On the other hand, Bcl-2 overexpression albeit preventing doxorubicin-induced apoptosis, has no effect on p53-mediated CD95 up-regulation in breast tumor cells. Doxorubicin 58-69 BCL2 apoptosis regulator Homo sapiens 19-24 12915131-5 2003 These results indicate that Ras, Bcl-2, as well as Raf-1 and PI3K pathways play pivotal roles in 5-FU-induced apoptosis under Ha-ras-overexpressed condition. Fluorouracil 97-101 BCL2 apoptosis regulator Homo sapiens 33-38 12915131-8 2003 Through understanding the mechanism of 5-FU induced apoptosis in tumor cells, a new direction toward the treatment of Ha-ras oncogene-related cancers with 5-FU at more optimal dosages is possible and combinational therapy with other drugs that suppress PI3K and Bcl-2 activities can also be considered. Fluorouracil 39-43 BCL2 apoptosis regulator Homo sapiens 262-267 12805375-12 2003 Overexpression of Bcl-2 family members blocked palmitate-induced apoptosis. Palmitates 47-56 BCL2 apoptosis regulator Homo sapiens 18-23 12800189-4 2003 Preferential downregulation of either Bcl-xL alone or of Bcl-xL and Bcl-2 simultaneously was achieved by treatment with antisense oligonucleotides 4259 and 4625, respectively, whereas the expression of other apoptosis-relevant genes remained unaffected. Oligonucleotides 130-146 BCL2 apoptosis regulator Homo sapiens 68-73 12800189-7 2003 Our results demonstrate that Bcl-2 and Bcl-xL antisense treatment facilitates apoptosis in mesothelioma cells and suggest the use of Bcl-2/Bcl-xL bispecific antisense treatment in combination with cisplatin or gemcitabine for therapy of malignant pleural mesothelioma. Cisplatin 197-206 BCL2 apoptosis regulator Homo sapiens 29-34 12800189-7 2003 Our results demonstrate that Bcl-2 and Bcl-xL antisense treatment facilitates apoptosis in mesothelioma cells and suggest the use of Bcl-2/Bcl-xL bispecific antisense treatment in combination with cisplatin or gemcitabine for therapy of malignant pleural mesothelioma. gemcitabine 210-221 BCL2 apoptosis regulator Homo sapiens 29-34 12867996-8 2003 Bcl-2 overexpression reduced the generation of necrosis by H(2)O(2), but not by BSO plus cisplatin. Water 59-64 BCL2 apoptosis regulator Homo sapiens 0-5 12794765-7 2003 These results suggest that the reduction of mdr-1 and bcl-2 expression by salvicine possibly contributes to its cytotoxicity and apoptotic induction in this system. salvicine 74-83 BCL2 apoptosis regulator Homo sapiens 54-59 12815279-3 2003 Diethylmaleate (DEM)-induced apoptotic damage in Jurkat cells was blocked by the anti-apoptotic protein Bcl-2, whereas, a peptide inhibitor of caspase-3 but not caspase-9 blocked DEM-induced mitochondrial damage. diethyl maleate 0-14 BCL2 apoptosis regulator Homo sapiens 104-109 12815279-3 2003 Diethylmaleate (DEM)-induced apoptotic damage in Jurkat cells was blocked by the anti-apoptotic protein Bcl-2, whereas, a peptide inhibitor of caspase-3 but not caspase-9 blocked DEM-induced mitochondrial damage. diethyl maleate 16-19 BCL2 apoptosis regulator Homo sapiens 104-109 12689928-4 2003 UO126 modulated the levels of several intracellular proteins including B-cell lymphoma protein 2 (Bcl-2), myeloid cell leukemia-1 (Mcl-1) and caspase 8 homolog FLICE-inhibitory protein (cFLIP), and induced G2M cell-cycle arrest or apoptosis. U 0126 0-5 BCL2 apoptosis regulator Homo sapiens 71-96 12689928-4 2003 UO126 modulated the levels of several intracellular proteins including B-cell lymphoma protein 2 (Bcl-2), myeloid cell leukemia-1 (Mcl-1) and caspase 8 homolog FLICE-inhibitory protein (cFLIP), and induced G2M cell-cycle arrest or apoptosis. U 0126 0-5 BCL2 apoptosis regulator Homo sapiens 98-103 12898509-7 2003 Elevated levels of BCL-2 expression results in N-terminal cleavage of BCL-2 at a novel site different from a previously identified caspase cleavage site at Asp 34 by a non-caspase protease. Aspartic Acid 156-159 BCL2 apoptosis regulator Homo sapiens 19-24 12898509-7 2003 Elevated levels of BCL-2 expression results in N-terminal cleavage of BCL-2 at a novel site different from a previously identified caspase cleavage site at Asp 34 by a non-caspase protease. Aspartic Acid 156-159 BCL2 apoptosis regulator Homo sapiens 70-75 12768320-1 2003 PURPOSE: Based on prior studies demonstrating the effect of 13- cis-retinoic acid and interferon alpha (CRA/IFN) in decreasing the expression of the antiapoptotic protein bcl-2, our prior clinical study of CRA/IFN with paclitaxel (TAX) administered every 3 weeks, and data demonstrating increased activity of weekly TAX against prostate cancer, we designed a phase I study of weekly TAX in combination with CRA/IFN in patients with prostate cancer and other advanced malignancies. Isotretinoin 60-81 BCL2 apoptosis regulator Homo sapiens 171-176 12768320-1 2003 PURPOSE: Based on prior studies demonstrating the effect of 13- cis-retinoic acid and interferon alpha (CRA/IFN) in decreasing the expression of the antiapoptotic protein bcl-2, our prior clinical study of CRA/IFN with paclitaxel (TAX) administered every 3 weeks, and data demonstrating increased activity of weekly TAX against prostate cancer, we designed a phase I study of weekly TAX in combination with CRA/IFN in patients with prostate cancer and other advanced malignancies. Paclitaxel 219-229 BCL2 apoptosis regulator Homo sapiens 171-176 12907619-4 2003 HDACI-induced mitochondrial membrane damage and apoptosis were inhibited by overexpression of Bcl-2, but not by the polycaspase inhibitor N-tert-butoxy-carbonyl-Val-Ala-Asp-fluoromethylketone (zVAD-fmk). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 193-201 BCL2 apoptosis regulator Homo sapiens 94-99 12907654-13 2003 Our data indicate that the combined treatment of Apo2L/TRAIL and CPT-11 achieves tumor control in prostate cancer tumors through regulation of Bcl-2 family proteins and potent activation of caspases. Irinotecan 65-71 BCL2 apoptosis regulator Homo sapiens 143-148 12912970-0 2003 Activation of prodeath Bcl-2 family proteins and mitochondrial apoptosis pathway by sanguinarine in immortalized human HaCaT keratinocytes. sanguinarine 84-96 BCL2 apoptosis regulator Homo sapiens 23-28 12912970-9 2003 Sanguinarine also resulted in significant increases in the proapoptotic members of Bcl-2 family proteins, i.e., Bak and Bid. bakuchiol 112-115 BCL2 apoptosis regulator Homo sapiens 83-88 12974619-6 2003 Stable overexpression of human Bcl-2 could reduce the apoptosis of TC-treated cells by blocking the translocation of Bax and the release of cytochrome c. tripchlorolide 67-69 BCL2 apoptosis regulator Homo sapiens 31-36 12912970-8 2003 As shown by the immunoblot analysis, our data clearly demonstrated that sanguinarine treatment to HaCaT cells resulted in a dose-dependent (a) increase in the level of Bax with a concomitant decrease in Bcl-2 levels and (b) increase in Bax/Bcl-2 ratio. sanguinarine 72-84 BCL2 apoptosis regulator Homo sapiens 203-208 12912970-11 2003 Taken together, our data showed the involvement of mitochondrial pathway and Bcl-2 family proteins during sanguinarine-mediated apoptosis of immortalized keratinocytes. sanguinarine 106-118 BCL2 apoptosis regulator Homo sapiens 77-82 12912970-8 2003 As shown by the immunoblot analysis, our data clearly demonstrated that sanguinarine treatment to HaCaT cells resulted in a dose-dependent (a) increase in the level of Bax with a concomitant decrease in Bcl-2 levels and (b) increase in Bax/Bcl-2 ratio. sanguinarine 72-84 BCL2 apoptosis regulator Homo sapiens 240-245 12912970-9 2003 Sanguinarine also resulted in significant increases in the proapoptotic members of Bcl-2 family proteins, i.e., Bak and Bid. sanguinarine 0-12 BCL2 apoptosis regulator Homo sapiens 83-88 14578676-0 2003 The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation. Docetaxel 27-36 BCL2 apoptosis regulator Homo sapiens 86-91 12952249-3 2003 It was assessed whether CsA-induced inhibition of the late asthmatic reaction was associated with apoptosis of BALF T-lymphocytes and other cell types, as well as expression of the antiapoptotic protein B-cell leukaemia/lymphoma 2 gene product (Bcl-2). Cyclosporine 24-27 BCL2 apoptosis regulator Homo sapiens 245-250 12952249-6 2003 The numbers of Bcl-2-positive cells were significantly reduced in the CsA but not the placebo group. Cyclosporine 70-73 BCL2 apoptosis regulator Homo sapiens 15-20 12824303-10 2003 In conclusion, Celecoxib induces apoptosis via a novel apoptosome-dependent but Bcl-2-independent mitochondrial pathway. Celecoxib 15-24 BCL2 apoptosis regulator Homo sapiens 80-85 14578676-0 2003 The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation. Docetaxel 38-46 BCL2 apoptosis regulator Homo sapiens 86-91 14578676-2 2003 Previous studies have shown that in vitro treatment of specific human tumor lines with docetaxel is associated with the phosphorylation and inactivation of the bcl-2 protein and the occurrence of apoptosis. Docetaxel 87-96 BCL2 apoptosis regulator Homo sapiens 160-165 14578676-3 2003 The goal of this study was to examine whether bcl-2 expression is truly required for in vivo responsiveness to docetaxel. Docetaxel 111-120 BCL2 apoptosis regulator Homo sapiens 46-51 14578676-4 2003 The expression and state of phosphorylation of bcl-2 was examined in human MX-1 breast or DU-145 prostate tumors explanted from nu/nu mice treated with docetaxel. Docetaxel 152-161 BCL2 apoptosis regulator Homo sapiens 47-52 14578676-5 2003 The MX-1 cells accumulated in the G2/M phase of the cell cycle and exhibited phosphorylation of bcl-2 after treatment with docetaxel. Docetaxel 123-132 BCL2 apoptosis regulator Homo sapiens 96-101 14598907-0 2003 Gallic acid, an antioxidant, exhibits antiapoptotic potential in normal human lymphocytes: A Bcl-2 independent mechanism. Gallic Acid 0-11 BCL2 apoptosis regulator Homo sapiens 93-98 12974082-3 2003 The effects of sodium butyrate on transcription of Bax and Bcl-2 was analyzed by RT-PCR. Butyric Acid 15-30 BCL2 apoptosis regulator Homo sapiens 59-64 12939460-0 2003 Arsenic trioxide induces apoptosis in peripheral blood T lymphocyte subsets by inducing oxidative stress: a role of Bcl-2. Arsenic Trioxide 0-16 BCL2 apoptosis regulator Homo sapiens 116-121 12879014-7 2003 In contrast, treatment of cells with LY294002, to inhibit phosphoinositide 3-kinase (PI3K), caused downregulation of Bcl-2 and Mcl-1 and allowed deltaMEKK1:ER* to elicit a robust apoptotic response characterized by activation of Bax and caspases. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 BCL2 apoptosis regulator Homo sapiens 117-122 12939460-9 2003 Furthermore, overexpression of Bcl-2 inhibited As(2)O(3)-induced apoptosis and blocked depolarization of deltapsi(m), generation of ROS, and release of both cytochrome c and AIF. (2)o(3) 49-56 BCL2 apoptosis regulator Homo sapiens 31-36 12939460-9 2003 Furthermore, overexpression of Bcl-2 inhibited As(2)O(3)-induced apoptosis and blocked depolarization of deltapsi(m), generation of ROS, and release of both cytochrome c and AIF. Reactive Oxygen Species 132-135 BCL2 apoptosis regulator Homo sapiens 31-36 12918120-8 2003 NADH could not only eliminate the apoptosis induced by X-ray irradiation, but also up-regulate expression of bcl-2 protein and down-regulate expression of p53, bax, fas and fasL proteins (P<0.05). NAD 0-4 BCL2 apoptosis regulator Homo sapiens 109-114 12918120-10 2003 CONCLUSION: NADH has marked anti-radiation effect, its mechanism may be associated with up-regulation of bcl-2 expression and down-regulation of p53, bax fas and fasL expression, as well as decline of intracellular ROS. NAD 12-16 BCL2 apoptosis regulator Homo sapiens 105-110 12894226-5 2003 Thus, EGCG had a concurrent effect on two important transcription factors p53 and NF-kappaB, causing a change in the ratio of Bax/Bcl-2 in a manner that favors apoptosis. epigallocatechin gallate 6-10 BCL2 apoptosis regulator Homo sapiens 130-135 12921638-8 2003 he expression rate of bcl-2 were (18 +/- 3)%, (36 +/- 9)%, and (33 +/- 7)% respectively in the control, 15d-PGJ(2), and ciglitazone groups with a very significant difference between the control group and any of the agonist-treated groups (all P < 0.01) and without significant difference between the two treated groups. 15d-pgj 104-111 BCL2 apoptosis regulator Homo sapiens 22-27 12740907-5 2003 In both HBE and MCF-7 cells, we found that estradiol (E2) induced an increase in Bcl-2 mRNA levels. Estradiol 43-52 BCL2 apoptosis regulator Homo sapiens 81-86 12853972-5 2003 AraC, but not TNF or ceramide was able to induce apoptosis in these cells as detected by assays for lipid peroxidation, reactive oxygen intermediates generation, caspase activation, cytotoxicity, Bcl-2 degradation, and DNA fragmentation. Cytarabine 0-4 BCL2 apoptosis regulator Homo sapiens 196-201 12921638-8 2003 he expression rate of bcl-2 were (18 +/- 3)%, (36 +/- 9)%, and (33 +/- 7)% respectively in the control, 15d-PGJ(2), and ciglitazone groups with a very significant difference between the control group and any of the agonist-treated groups (all P < 0.01) and without significant difference between the two treated groups. ciglitazone 120-131 BCL2 apoptosis regulator Homo sapiens 22-27 12815459-8 2003 Taken together, these data support the hypothesis that Casodex induces cell death by a pathway that is independent of changes in DeltaPsim and Bcl-2 actions and results in an extended lag phase of cell survival that may promote the induction of an invasive phenotype after treatment. bicalutamide 55-62 BCL2 apoptosis regulator Homo sapiens 143-148 12926066-10 2003 Using Western blot, the phosphorylation of Bcl-2 protein was found in palictaxel analog-treated cells in a time-dependent manner similar to that of mitotic arrest, thereby indicating that there existed a close correlation between Bcl-2 phosphorylation and mitotic arrest that preceded apoptosis. palictaxel 70-80 BCL2 apoptosis regulator Homo sapiens 43-48 12926066-10 2003 Using Western blot, the phosphorylation of Bcl-2 protein was found in palictaxel analog-treated cells in a time-dependent manner similar to that of mitotic arrest, thereby indicating that there existed a close correlation between Bcl-2 phosphorylation and mitotic arrest that preceded apoptosis. palictaxel 70-80 BCL2 apoptosis regulator Homo sapiens 230-235 12807727-6 2003 Curcumin causes dose-dependent apoptosis and DNA fragmentation of Caki cells, which is preceded by the sequential dephosphorylation of Akt, down-regulation of the anti-apoptotic Bcl-2, Bcl-XL and IAP proteins, release of cytochrome c and activation of caspase 3. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 178-183 12721291-2 2003 Here, we have initiated these steps in isolated mitochondria derived from control and BCL-2-overexpressing cells using synthetic BH3 peptides and subsequently analyzed the BCL members by chemical cross-linking. Peptides 133-141 BCL2 apoptosis regulator Homo sapiens 86-91 12721291-5 2003 Induction of the open conformation of BAK occurs even in the presence of excess BCL-2, but BCL-2 selectively interacts with this open conformer and blocks BAK oligomerization and cytochrome c release, dependent on the ratio of BID BH3 and BCL-2. BH 3 231-234 BCL2 apoptosis regulator Homo sapiens 91-96 12721291-5 2003 Induction of the open conformation of BAK occurs even in the presence of excess BCL-2, but BCL-2 selectively interacts with this open conformer and blocks BAK oligomerization and cytochrome c release, dependent on the ratio of BID BH3 and BCL-2. BH 3 231-234 BCL2 apoptosis regulator Homo sapiens 91-96 12721291-6 2003 This mechanism of inhibition by BCL-2 also occurs in intact cells stimulated with Fas or expressing tBID. tBID 100-104 BCL2 apoptosis regulator Homo sapiens 32-37 12721291-7 2003 Although BID BH3 interacts with both BCL-2 and BAK, the results indicate that when BCL-2 is in excess it can sequester the BID BH3-induced activated conformer of BAK, effectively blocking downstream events. BH 3 13-16 BCL2 apoptosis regulator Homo sapiens 37-42 12721291-7 2003 Although BID BH3 interacts with both BCL-2 and BAK, the results indicate that when BCL-2 is in excess it can sequester the BID BH3-induced activated conformer of BAK, effectively blocking downstream events. BH 3 13-16 BCL2 apoptosis regulator Homo sapiens 83-88 12721291-7 2003 Although BID BH3 interacts with both BCL-2 and BAK, the results indicate that when BCL-2 is in excess it can sequester the BID BH3-induced activated conformer of BAK, effectively blocking downstream events. BH 3 127-130 BCL2 apoptosis regulator Homo sapiens 83-88 12721291-8 2003 This model suggests that the primary mechanism for BCL-2 blockade targets activated BAK rather than sequestering tBID. tBID 113-117 BCL2 apoptosis regulator Homo sapiens 51-56 14508087-4 2003 BCL2-specific antisense oligonucleotides have shown broad anti-cancer activities in pre-clinical models and are currently in several phase III trials. Oligonucleotides 24-40 BCL2 apoptosis regulator Homo sapiens 0-4 12769775-9 2003 Alternative approaches to achieve the functional knock-out of Bcl-2 include the use of either peptides mimicking the BH3 domain of Bcl-2-related proteins or more stable, non peptidic BH3 mimetics and the pharmacological modulation of the post-translational modifications of the protein. BH 3 117-120 BCL2 apoptosis regulator Homo sapiens 62-67 12855657-7 2003 SL11144 decreased Bcl-2 and increased Bax protein levels in MDA-MB-231 cells. SL11144 0-7 BCL2 apoptosis regulator Homo sapiens 18-23 12769774-8 2003 One may assume that taxanes are able to induce the phosphorylation of Bcl-X(L)/Bcl-2 members and thus inactivate their anti-apoptotic capacities. Taxoids 20-27 BCL2 apoptosis regulator Homo sapiens 79-84 12769774-9 2003 The down-regulation of Bcl-2 and/or the upregulation of p53 and p21/WAF-1 are certainly one of the important modes of apoptosis induction by taxanes. Taxoids 141-148 BCL2 apoptosis regulator Homo sapiens 23-28 12823982-0 2003 1,25-dihydroxyvitamin D3-induced apoptosis of retinoblastoma cells is associated with reciprocal changes of Bcl-2 and bax. Calcitriol 0-24 BCL2 apoptosis regulator Homo sapiens 108-113 12943815-7 2003 Bortezomib treatment led to accumulation of p21(WAF1/CIP1) and p27(KIP1) and decreased BCL-2; gemcitabine decreased p27(KIP1), induced BCL-2 and had no effect on p21(WAF1/CIP1). Bortezomib 0-10 BCL2 apoptosis regulator Homo sapiens 87-92 12834450-8 2003 Moreover, Bcl-2 expression in healing psoriasis epidermis after MEL treatment is significantly decreased compared with untreated skin and the TUNEL (TdT-mediated dUTP-biotin nick end labelling) technique revealed the presence of relevant apoptotic keratinocytes in the irradiated epidermis. mel 64-67 BCL2 apoptosis regulator Homo sapiens 10-15 12943815-7 2003 Bortezomib treatment led to accumulation of p21(WAF1/CIP1) and p27(KIP1) and decreased BCL-2; gemcitabine decreased p27(KIP1), induced BCL-2 and had no effect on p21(WAF1/CIP1). gemcitabine 94-105 BCL2 apoptosis regulator Homo sapiens 135-140 12890888-6 2003 Pretreatment with phorbol-12-myristate-13-acetate, which induces the expression of antiapoptotic Bcl-2, inhibited thapsigargin-induced degradation of caspases-9 and -3, but not caspase-12-like protein degradation. Tetradecanoylphorbol Acetate 18-49 BCL2 apoptosis regulator Homo sapiens 97-102 12890888-6 2003 Pretreatment with phorbol-12-myristate-13-acetate, which induces the expression of antiapoptotic Bcl-2, inhibited thapsigargin-induced degradation of caspases-9 and -3, but not caspase-12-like protein degradation. Thapsigargin 114-126 BCL2 apoptosis regulator Homo sapiens 97-102 12929741-0 2003 Association between the photodynamic loss of Bcl-2 and the sensitivity to apoptosis caused by phthalocyanine photodynamic therapy. phthalocyanine 94-108 BCL2 apoptosis regulator Homo sapiens 45-50 12815160-0 2003 Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Paclitaxel 46-56 BCL2 apoptosis regulator Homo sapiens 0-5 12815160-6 2003 CPM values after Bcl-2 immunoprecipitation was 62.8-fold higher than those of the control antibody, thereby indicating the involvement of Bcl-2 in paclitaxel binding. Paclitaxel 147-157 BCL2 apoptosis regulator Homo sapiens 17-22 12815160-6 2003 CPM values after Bcl-2 immunoprecipitation was 62.8-fold higher than those of the control antibody, thereby indicating the involvement of Bcl-2 in paclitaxel binding. Paclitaxel 147-157 BCL2 apoptosis regulator Homo sapiens 138-143 12815160-9 2003 When A2780TC cells were stably transfected with a Bcl-2 construct, paclitaxel sensitivity was partially restored, thereby supporting a direct role of Bcl-2 down-regulation in the maintenance of drug-resistance. Paclitaxel 67-77 BCL2 apoptosis regulator Homo sapiens 50-55 12815160-9 2003 When A2780TC cells were stably transfected with a Bcl-2 construct, paclitaxel sensitivity was partially restored, thereby supporting a direct role of Bcl-2 down-regulation in the maintenance of drug-resistance. Paclitaxel 67-77 BCL2 apoptosis regulator Homo sapiens 150-155 12815160-10 2003 Finally, we examined Bcl-2 by immunohistochemistry in a small subset of ovarian cancer paclitaxel-resistant patients and we noticed that the protein is down-regulated in this clinical setting with respect to the expression levels found in drug-sensitive tumors. Paclitaxel 87-97 BCL2 apoptosis regulator Homo sapiens 21-26 12815160-11 2003 These findings demonstrate that Bcl-2 is an additional intracellular target of taxanes and that its down-regulation is involved in taxane resistance. Taxoids 79-86 BCL2 apoptosis regulator Homo sapiens 32-37 12815160-11 2003 These findings demonstrate that Bcl-2 is an additional intracellular target of taxanes and that its down-regulation is involved in taxane resistance. taxane 79-85 BCL2 apoptosis regulator Homo sapiens 32-37 12883037-3 2003 We demonstrated that Dox and Taxol induced apoptosis through down-regulation of XIAP and phosphorylation of Bcl-2 in a concentration-dependent manner without changing expression of Bcl-xL in H460 cells. Doxorubicin 21-24 BCL2 apoptosis regulator Homo sapiens 108-113 12883037-3 2003 We demonstrated that Dox and Taxol induced apoptosis through down-regulation of XIAP and phosphorylation of Bcl-2 in a concentration-dependent manner without changing expression of Bcl-xL in H460 cells. Paclitaxel 29-34 BCL2 apoptosis regulator Homo sapiens 108-113 12929741-1 2003 We have reported that photodynamic therapy (PDT) using the photosensitizer phthalocyanine (Pc) 4 and red light damages the antiapoptotic protein Bcl-2. phthalocyanine 75-89 BCL2 apoptosis regulator Homo sapiens 145-150 12929741-1 2003 We have reported that photodynamic therapy (PDT) using the photosensitizer phthalocyanine (Pc) 4 and red light damages the antiapoptotic protein Bcl-2. pc) 4 91-96 BCL2 apoptosis regulator Homo sapiens 145-150 12921557-4 2003 The expression of bcl-2 protein decreased and p53 protein increased in BGC-823 cells treated with D-limonene, compared with the control cells. Limonene 98-108 BCL2 apoptosis regulator Homo sapiens 18-23 12730627-0 2003 Reversal of Bcl-2-mediated resistance of the EW36 human B-cell lymphoma cell line to arsenite- and pesticide-induced apoptosis by PK11195, a ligand of the mitochondrial benzodiazepine receptor. arsenite 85-93 BCL2 apoptosis regulator Homo sapiens 12-17 12730627-3 2003 Specifically, antagonistic ligands of the mBzR, such as 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline-carboxamide (PK11195), have been shown to sensitize Bcl-2 overexpressing cells to apoptosis induction by facilitating the opening of the PT pore and the subsequent loss of mitochondrial membrane potential (Deltapsim). PK 11195 56-129 BCL2 apoptosis regulator Homo sapiens 170-175 14758801-1 2003 The article highlighted in this issue is "Reversal of Bcl-2 Mediated Resistance of the EW36 Human B-Cell Lymphoma Cell Line to Arsenite and Pesticide-Induced Apoptosis by PK11195, a Ligand of the Mitochondrial Benzodiazepine Receptor" by Donna E. Muscarella, Kerry A. O"Brien, Ann T. Lemley, and Stephen E Bloom from Cornell University in Ithaca, NY (pp. arsenite 127-135 BCL2 apoptosis regulator Homo sapiens 54-59 12804759-2 2003 We show herein that Bcl-2 overexpression in a prototypic type I cell line (SKW6.4) promotes mitochondrial generation of ATP and blocks Fas-triggered plasma membrane externalization of phosphatidylserine (PS). Adenosine Triphosphate 120-123 BCL2 apoptosis regulator Homo sapiens 20-25 12702730-0 2003 Bcl-2 protein is required for the adenine/uridine-rich element (ARE)-dependent degradation of its own messenger. Adenine 34-41 BCL2 apoptosis regulator Homo sapiens 0-5 12702730-0 2003 Bcl-2 protein is required for the adenine/uridine-rich element (ARE)-dependent degradation of its own messenger. Uridine 42-49 BCL2 apoptosis regulator Homo sapiens 0-5 12804759-2 2003 We show herein that Bcl-2 overexpression in a prototypic type I cell line (SKW6.4) promotes mitochondrial generation of ATP and blocks Fas-triggered plasma membrane externalization of phosphatidylserine (PS). ammonium ferrous sulfate 135-138 BCL2 apoptosis regulator Homo sapiens 20-25 12576296-6 2003 Ceramide-mediated apoptosis was blocked by a general caspase inhibitor, Boc-d-fluoromethylketone, and by overexpression of the antiapoptotic protein Bcl-2. Ceramides 0-8 BCL2 apoptosis regulator Homo sapiens 149-154 12763612-1 2003 It has recently been demonstrated that valproic acid (VPA) robustly promotes neurite outgrowth, activates the extracellular signal regulated kinase pathway, and increases growth cone-associated protein 43 and bcl-2 levels in cultured human neuroblastoma SH-SY5Y cells. Valproic Acid 39-52 BCL2 apoptosis regulator Homo sapiens 209-214 12763612-1 2003 It has recently been demonstrated that valproic acid (VPA) robustly promotes neurite outgrowth, activates the extracellular signal regulated kinase pathway, and increases growth cone-associated protein 43 and bcl-2 levels in cultured human neuroblastoma SH-SY5Y cells. Valproic Acid 54-57 BCL2 apoptosis regulator Homo sapiens 209-214 12702731-2 2003 Here we report the identification of chelerythrine as an inhibitor of BclXL-Bak Bcl-2 homology 3 (BH3) domain binding through a high throughput screening of 107,423 extracts derived from natural products. chelerythrine 37-50 BCL2 apoptosis regulator Homo sapiens 80-85 12702731-8 2003 Our data suggest that chelerythrine triggers apoptosis through a mechanism that involves direct targeting of Bcl-2 family proteins. chelerythrine 22-35 BCL2 apoptosis regulator Homo sapiens 109-114 12948406-18 2003 The onset of apoptosis in ovarian carcinoma cell is related to the up-regulation of bax and down-regulation of bcl-2 in mRNA and protein level induced by Genistein. Genistein 154-163 BCL2 apoptosis regulator Homo sapiens 111-116 12810650-10 2003 Characteristic of agents that disrupt microtubules, the taccalonolides caused G(2)-M accumulation, Bcl-2 phosphorylation, and initiation of apoptosis. taccalonolides 56-70 BCL2 apoptosis regulator Homo sapiens 99-104 12767928-2 2003 Bcl-2 family proteins modulate the mitochondrial permeability through interaction with adenine nucleotide translocator (ANT), voltage-dependent anion channel (VDAC), ADP/ATP exchange, or oxidative phosphorylation during apoptosis. Adenosine Diphosphate 166-169 BCL2 apoptosis regulator Homo sapiens 0-5 12767928-2 2003 Bcl-2 family proteins modulate the mitochondrial permeability through interaction with adenine nucleotide translocator (ANT), voltage-dependent anion channel (VDAC), ADP/ATP exchange, or oxidative phosphorylation during apoptosis. Adenosine Triphosphate 170-173 BCL2 apoptosis regulator Homo sapiens 0-5 12663669-6 2003 In contrast, overexpression of Bcl-2 protects EC treated with cytokine plus LY294002 but not EC treated with cytokine plus cycloheximide. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 76-84 BCL2 apoptosis regulator Homo sapiens 31-36 12576296-7 2003 Notably, overexpression of Bcl-2 reduced the basal cellular levels of ceramide and prevented the induction of ceramide generation by C(6)-ceramide, which implies ceramide generation as a possible target for the antiapoptotic effects of Bcl-2. Ceramides 70-78 BCL2 apoptosis regulator Homo sapiens 27-32 12576296-7 2003 Notably, overexpression of Bcl-2 reduced the basal cellular levels of ceramide and prevented the induction of ceramide generation by C(6)-ceramide, which implies ceramide generation as a possible target for the antiapoptotic effects of Bcl-2. Ceramides 110-118 BCL2 apoptosis regulator Homo sapiens 27-32 12576296-7 2003 Notably, overexpression of Bcl-2 reduced the basal cellular levels of ceramide and prevented the induction of ceramide generation by C(6)-ceramide, which implies ceramide generation as a possible target for the antiapoptotic effects of Bcl-2. N-caproylsphingosine 133-146 BCL2 apoptosis regulator Homo sapiens 27-32 12576296-7 2003 Notably, overexpression of Bcl-2 reduced the basal cellular levels of ceramide and prevented the induction of ceramide generation by C(6)-ceramide, which implies ceramide generation as a possible target for the antiapoptotic effects of Bcl-2. Ceramides 110-118 BCL2 apoptosis regulator Homo sapiens 27-32 12773170-3 2003 The binding of the anti-tumour agent Taxol to the anti-apoptosis protein Bcl-2 [Rodi, Janes, Sanganee, Holton, Wallace and Makowski (1999) J. Mol. Paclitaxel 37-42 BCL2 apoptosis regulator Homo sapiens 73-78 12560233-1 2003 Tetrocarcin-A (TC-A), an antibiotic agent isolated from actinomycetes, has recently been described to antagonize Bcl-2 functions, thereby sensitizing tumor cells to cell death signals under control of Bcl-2. tetrocarcin A 0-13 BCL2 apoptosis regulator Homo sapiens 201-206 12560233-0 2003 Tetrocarcin-A--induced ER stress mediates apoptosis in B-CLL cells via a Bcl-2--independent pathway. tetrocarcin A 0-13 BCL2 apoptosis regulator Homo sapiens 73-78 12560233-1 2003 Tetrocarcin-A (TC-A), an antibiotic agent isolated from actinomycetes, has recently been described to antagonize Bcl-2 functions, thereby sensitizing tumor cells to cell death signals under control of Bcl-2. tetrocarcin A 0-13 BCL2 apoptosis regulator Homo sapiens 113-118 12560233-1 2003 Tetrocarcin-A (TC-A), an antibiotic agent isolated from actinomycetes, has recently been described to antagonize Bcl-2 functions, thereby sensitizing tumor cells to cell death signals under control of Bcl-2. tetrocarcin A 15-19 BCL2 apoptosis regulator Homo sapiens 113-118 12560233-1 2003 Tetrocarcin-A (TC-A), an antibiotic agent isolated from actinomycetes, has recently been described to antagonize Bcl-2 functions, thereby sensitizing tumor cells to cell death signals under control of Bcl-2. tetrocarcin A 15-19 BCL2 apoptosis regulator Homo sapiens 201-206 12768189-0 2003 Methioninase gene therapy with selenomethionine induces apoptosis in bcl-2-overproducing lung cancer cells. Selenomethionine 31-47 BCL2 apoptosis regulator Homo sapiens 69-74 12709826-0 2003 Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line. Paclitaxel 28-38 BCL2 apoptosis regulator Homo sapiens 76-81 12709826-0 2003 Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line. Cisplatin 43-52 BCL2 apoptosis regulator Homo sapiens 76-81 12709826-0 2003 Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line. Cisplatin 103-112 BCL2 apoptosis regulator Homo sapiens 76-81 12768189-6 2003 Staurosporine-induced apoptosis was inhibited in the bcl-2-overproducing clones as well as in the parental cell line. Staurosporine 0-13 BCL2 apoptosis regulator Homo sapiens 53-58 12721767-0 2003 Inhibition of early 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma. technetium 99m methoxyisobutylisonitrile 20-30 BCL2 apoptosis regulator Homo sapiens 41-46 12709826-13 2003 CONCLUSIONS: These results indicate that exposure to TXL prior to CDDP plays a key role in circumventing CDDP resistance by phosphorylating Bcl-2 protein in the human epidermoid carcinoma cell line A431/CDDP2. Cisplatin 105-109 BCL2 apoptosis regulator Homo sapiens 140-145 12807754-7 2003 Interestingly, inhibition of JNK strongly reduced Bcl-2 phosphorylation by 2-ME as well as p53 induction, and almost completely suppressed 2-ME-induced apoptosis. 2-Methoxyestradiol 75-79 BCL2 apoptosis regulator Homo sapiens 50-55 12807754-9 2003 The results suggest that not only p53 induction through p38/JNK-dependent NFkappaB/AP-1 activation but also JNK-dependent Bcl-2 phosphorylation are required for 2-ME-induced apoptosis; moreover, inhibition of these pathways may be involved in androgen-mediated resistance to apoptosis. 2-Methoxyestradiol 161-165 BCL2 apoptosis regulator Homo sapiens 122-127 12718798-5 2003 Antisense oligonucleotides directed against Bcl-2 are effective in vitro and are being evaluated in clinical trials in CLL. Oligonucleotides 10-26 BCL2 apoptosis regulator Homo sapiens 44-49 12749011-10 2003 However, bcl-2 expression was found to be unfavorably associated with the OS (P = 0.0054) in a confined group with low (n = 51) or low intermediate (n = 22) IPI scores. diprotin A 157-160 BCL2 apoptosis regulator Homo sapiens 9-14 12721767-9 2003 In MIBI-positive lesions, an inverse significant correlation was found between T/B ratios and Bcl-2 levels ( r=-0.50, P<0.01). 2-methoxyisobutylisonitrile 3-7 BCL2 apoptosis regulator Homo sapiens 94-99 12721767-11 2003 High levels of Bcl-2, despite the stabilisation of mitochondrial membrane potentials, prevent accumulation of (99m)Tc-MIBI in tumour cells. Technetium Tc 99m Sestamibi 115-122 BCL2 apoptosis regulator Homo sapiens 15-20 12868490-8 2003 These results indicate that hyperthermia and AAPH induce enhanced apoptosis and subsequent cell killing via two pathways; a pathway dependenton increase in LPO and [Ca2+]i, and a pathway associated with cytochrome c release and subsequent caspase activation without changes of mitochondrial membrane potential and Bax/Bcl-2 expression in these cell lines. aaph 45-49 BCL2 apoptosis regulator Homo sapiens 318-323 12721767-12 2003 In conclusion, absent or reduced early (99m)Tc-MIBI uptake in large tumours may indicate a Bcl-2-mediated resistance to chemo- and radiotherapy. Technetium Tc 99m Sestamibi 44-51 BCL2 apoptosis regulator Homo sapiens 91-96 12696066-10 2003 Immunohistochemical staining of paraffin sections from six cases demonstrated expression of JUNB protein in five cases and BCL2 in three cases. Paraffin 32-40 BCL2 apoptosis regulator Homo sapiens 123-127 12777976-6 2003 Exposure of cells to high flavopiridol concentrations (>100 nM) resulted in decreased expression of genes downstream in the normal p16 cell cycle control pathway (Rb and E2F) and the anti-apoptotic gene BCL2. alvocidib 26-38 BCL2 apoptosis regulator Homo sapiens 206-210 12736725-5 2003 The Bcl-2 antisense was introduced into 8305C cells by using a 18-mer phosphorothioate oligonucleotide by lipopolyamine-mediated transfection twice for 12 h. The expression of apoptosis genes was assessed by Western blotting. Phosphorothioate Oligonucleotides 70-102 BCL2 apoptosis regulator Homo sapiens 4-9 12736725-5 2003 The Bcl-2 antisense was introduced into 8305C cells by using a 18-mer phosphorothioate oligonucleotide by lipopolyamine-mediated transfection twice for 12 h. The expression of apoptosis genes was assessed by Western blotting. lipopolyamine 106-119 BCL2 apoptosis regulator Homo sapiens 4-9 12736725-11 2003 Susceptibility in apoptotic cell death following treatment with anticancer drugs was associated with induction of apoptosis-related genes in undifferentiated thyroid carcinoma cells, and induction of apoptosis was enhanced by pretreatment with Bcl-2 antisense oligonucleotide. Oligonucleotides 260-275 BCL2 apoptosis regulator Homo sapiens 244-249 12736725-12 2003 These results imply a potential new strategy targeting an antiapoptotic protein, Bcl-2, by its antisense oligonucleotide for enhancement of chemotherapeutic efficacy in undifferentiated thyroid carcinomas. Oligonucleotides 105-120 BCL2 apoptosis regulator Homo sapiens 81-86 12626642-3 2003 KR-31372 and diazoxide enhanced DNA fragmentation associated with increase in phosphatase and tensin homolog deleted from chromosome 10 (PTEN) and decrease in serine/threonine kinase phosphorylation, which were accompanied by augmented Bax and cytochrome c release, and suppressed Bcl-2 in HUVECs. Diazoxide 13-22 BCL2 apoptosis regulator Homo sapiens 281-286 12955881-6 2003 Retinoic acid also modulates c-myc and Bcl-2 expression. Tretinoin 0-13 BCL2 apoptosis regulator Homo sapiens 39-44 12782109-9 2003 Also, t-BuOOH treatment caused an elevation in the levels of the pro-apoptotic proteins p53 and p21/WAF-1 and a reduction in the levels of the anti-apoptotic protein bcl-2 compared to their levels in control HCN1-A cells, while pretreatment with nicotinamide reduced p53 and p21/WAF-1 levels even in the presence of t-BuOOH. di-tert-butyl peroxide 6-13 BCL2 apoptosis regulator Homo sapiens 166-171 12590938-2 2003 The phosphorylation status of BAD, a member of the Bcl-2 protein family, is an important checkpoint governing life-or-death decisions: Phosphorylation of serine residues 112, 136 and 155 on BAD prevents apoptosis. Serine 154-160 BCL2 apoptosis regulator Homo sapiens 51-56 12802789-6 2003 Similarly, downregulation of Bcl-2 was reversed by inducible TS expression in TDX, but not 5-FU-treated cells. raltitrexed 78-81 BCL2 apoptosis regulator Homo sapiens 29-34 12817893-8 2003 It was found that the LHRH-BH3 peptide induced apoptosis by simultaneous inhibition of the antiapoptotic function of BCL-2 protein family and activation of caspase-dependent signaling pathway. BH 3 27-30 BCL2 apoptosis regulator Homo sapiens 117-122 14763159-11 2003 For example, phosphorylation of BCL-2 through a JNK-dependent mechanism has been postulated to contribute to apoptosis induced by the taxane class of cytotoxic agents. taxane 134-140 BCL2 apoptosis regulator Homo sapiens 32-37 12882693-4 2003 RESULTS: ASPO could down regulate the expression of bcl-2 resulting in both inhibition of growth and induction of apoptosis in treated HL-60 cells, which failed to develop leukemia in SCID mice at all. aspo 9-13 BCL2 apoptosis regulator Homo sapiens 52-57 12882693-0 2003 [Bcl-2 antisense oligonucleotides suppress HL-60 cell growth in a SCID mouse mode]. Oligonucleotides 17-33 BCL2 apoptosis regulator Homo sapiens 1-6 12644466-2 2003 Cytochrome c release, caspase-3-(-like) protease activation, and apoptosis induced by antitumor drugs were accelerated by overexpression of Bcl-2 lacking a Bcl-2 homology (BH) 1 domain (Bcl-2/ DeltaBH1), but not by that of BH2, BH3, or BH4 domain-deleted Bcl-2. sapropterin 236-239 BCL2 apoptosis regulator Homo sapiens 140-145 12882693-1 2003 OBJECTIVE: To study the effects of bcl-2 antisense phosphorothioate oligonucleotides (ASPO) on suppression of HL-60 cell growth in SCID mice and to investigate the feasibility of purging leukemia cells plus bcl-2 ASPO used in vitro. aspo 86-90 BCL2 apoptosis regulator Homo sapiens 35-40 12882693-2 2003 METHODS: 1 x 10(7) viable HL-60 cells were treated with 10 micro mol/L bcl-2 ASPO seven days before the intraperitoneal (IP) inoculation to the SCID mice, Treatment with sense oligonucleotides (SPO) was similar as for the controls. aspo 77-81 BCL2 apoptosis regulator Homo sapiens 71-76 12644466-2 2003 Cytochrome c release, caspase-3-(-like) protease activation, and apoptosis induced by antitumor drugs were accelerated by overexpression of Bcl-2 lacking a Bcl-2 homology (BH) 1 domain (Bcl-2/ DeltaBH1), but not by that of BH2, BH3, or BH4 domain-deleted Bcl-2. bh2 223-226 BCL2 apoptosis regulator Homo sapiens 140-145 12644474-4 2003 We observed growth arrest and apoptosis, upon decreasing Bcl-2 protein and transcript in the high Bcl-2-expressing, androgen-independent prostate cancer cell line, by all-trans-retinoic acid treatment (ATRA), but this did not occur in the androgen-dependent cell line expressing low levels of Bcl-2. 2-octenal 171-177 BCL2 apoptosis regulator Homo sapiens 57-62 12644474-4 2003 We observed growth arrest and apoptosis, upon decreasing Bcl-2 protein and transcript in the high Bcl-2-expressing, androgen-independent prostate cancer cell line, by all-trans-retinoic acid treatment (ATRA), but this did not occur in the androgen-dependent cell line expressing low levels of Bcl-2. 2-octenal 171-177 BCL2 apoptosis regulator Homo sapiens 98-103 12644474-4 2003 We observed growth arrest and apoptosis, upon decreasing Bcl-2 protein and transcript in the high Bcl-2-expressing, androgen-independent prostate cancer cell line, by all-trans-retinoic acid treatment (ATRA), but this did not occur in the androgen-dependent cell line expressing low levels of Bcl-2. 2-octenal 171-177 BCL2 apoptosis regulator Homo sapiens 98-103 12644474-4 2003 We observed growth arrest and apoptosis, upon decreasing Bcl-2 protein and transcript in the high Bcl-2-expressing, androgen-independent prostate cancer cell line, by all-trans-retinoic acid treatment (ATRA), but this did not occur in the androgen-dependent cell line expressing low levels of Bcl-2. Tretinoin 177-190 BCL2 apoptosis regulator Homo sapiens 57-62 12644474-4 2003 We observed growth arrest and apoptosis, upon decreasing Bcl-2 protein and transcript in the high Bcl-2-expressing, androgen-independent prostate cancer cell line, by all-trans-retinoic acid treatment (ATRA), but this did not occur in the androgen-dependent cell line expressing low levels of Bcl-2. Tretinoin 177-190 BCL2 apoptosis regulator Homo sapiens 98-103 12644474-4 2003 We observed growth arrest and apoptosis, upon decreasing Bcl-2 protein and transcript in the high Bcl-2-expressing, androgen-independent prostate cancer cell line, by all-trans-retinoic acid treatment (ATRA), but this did not occur in the androgen-dependent cell line expressing low levels of Bcl-2. Tretinoin 177-190 BCL2 apoptosis regulator Homo sapiens 98-103 12644474-6 2003 In stable clones expressing ectopic Par-4 and in ATRA-treated cells, we observed decreased Bcl-2 protein and transcript. Tretinoin 49-53 BCL2 apoptosis regulator Homo sapiens 91-96 12777847-6 2003 Basiliximab and cyclosporine had little effect on apoptosis, but did alter Bcl-2 and Fas expression. Cyclosporine 16-28 BCL2 apoptosis regulator Homo sapiens 75-80 12637494-3 2003 The anti-apoptotic Bcl-2 family protein Bcl-x(L) is induced by dexamethasone at the transcriptional level at all stages of fibrosarcoma development. Dexamethasone 63-76 BCL2 apoptosis regulator Homo sapiens 19-24 12531792-4 2003 In a subset of CLL patients, B-cell lymphoma 2 (Bcl-2)-associated death promoter homolog (Bad), a proapoptotic Bcl-2 family member that when phosphorylated on specific serine residues is sequestered in the cytosol by 14-3-3, was dephosphorylated at Ser112 following rolipram/forskolin treatment of leukemic cells. Serine 168-174 BCL2 apoptosis regulator Homo sapiens 29-46 12521996-0 2003 Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells. Dexamethasone 16-29 BCL2 apoptosis regulator Homo sapiens 77-82 12756268-9 2003 The single knockout of Bax or Bak (but not Bid) or the transfection-enforced expression of mitochondrion-targeted (but not endoplasmic reticulum-targeted) Bcl-2 conferred protection against CPX (but not NFX*)-induced MMP and death. Ciprofloxacin 190-193 BCL2 apoptosis regulator Homo sapiens 155-160 12521996-0 2003 Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells. Paclitaxel 32-42 BCL2 apoptosis regulator Homo sapiens 77-82 12531792-4 2003 In a subset of CLL patients, B-cell lymphoma 2 (Bcl-2)-associated death promoter homolog (Bad), a proapoptotic Bcl-2 family member that when phosphorylated on specific serine residues is sequestered in the cytosol by 14-3-3, was dephosphorylated at Ser112 following rolipram/forskolin treatment of leukemic cells. Colforsin 275-284 BCL2 apoptosis regulator Homo sapiens 29-46 12531792-4 2003 In a subset of CLL patients, B-cell lymphoma 2 (Bcl-2)-associated death promoter homolog (Bad), a proapoptotic Bcl-2 family member that when phosphorylated on specific serine residues is sequestered in the cytosol by 14-3-3, was dephosphorylated at Ser112 following rolipram/forskolin treatment of leukemic cells. Serine 168-174 BCL2 apoptosis regulator Homo sapiens 48-53 12531792-4 2003 In a subset of CLL patients, B-cell lymphoma 2 (Bcl-2)-associated death promoter homolog (Bad), a proapoptotic Bcl-2 family member that when phosphorylated on specific serine residues is sequestered in the cytosol by 14-3-3, was dephosphorylated at Ser112 following rolipram/forskolin treatment of leukemic cells. Colforsin 275-284 BCL2 apoptosis regulator Homo sapiens 48-53 12531792-4 2003 In a subset of CLL patients, B-cell lymphoma 2 (Bcl-2)-associated death promoter homolog (Bad), a proapoptotic Bcl-2 family member that when phosphorylated on specific serine residues is sequestered in the cytosol by 14-3-3, was dephosphorylated at Ser112 following rolipram/forskolin treatment of leukemic cells. Colforsin 275-284 BCL2 apoptosis regulator Homo sapiens 111-116 12521996-1 2003 Overexpression of Bcl-2 in myeloma cells results in resistance to drugs such as dexamethasone (DEX), adenovirus-mediated delivery of p53 (Ad-p53), and paclitaxel (TAX), which work through the intrinsic apoptotic pathway. Dexamethasone 80-93 BCL2 apoptosis regulator Homo sapiens 18-23 12521996-1 2003 Overexpression of Bcl-2 in myeloma cells results in resistance to drugs such as dexamethasone (DEX), adenovirus-mediated delivery of p53 (Ad-p53), and paclitaxel (TAX), which work through the intrinsic apoptotic pathway. Dexamethasone 95-98 BCL2 apoptosis regulator Homo sapiens 18-23 12521996-1 2003 Overexpression of Bcl-2 in myeloma cells results in resistance to drugs such as dexamethasone (DEX), adenovirus-mediated delivery of p53 (Ad-p53), and paclitaxel (TAX), which work through the intrinsic apoptotic pathway. Paclitaxel 151-161 BCL2 apoptosis regulator Homo sapiens 18-23 12531792-4 2003 In a subset of CLL patients, B-cell lymphoma 2 (Bcl-2)-associated death promoter homolog (Bad), a proapoptotic Bcl-2 family member that when phosphorylated on specific serine residues is sequestered in the cytosol by 14-3-3, was dephosphorylated at Ser112 following rolipram/forskolin treatment of leukemic cells. Serine 168-174 BCL2 apoptosis regulator Homo sapiens 111-116 12521996-2 2003 Bcl-2 antisense oligodeoxynucleotides (Bcl-2-ASO) have been shown to induce apoptosis in cancer cells, as a single agent or, better, in combination with chemotherapy. Oligodeoxyribonucleotides 16-37 BCL2 apoptosis regulator Homo sapiens 0-5 12521996-2 2003 Bcl-2 antisense oligodeoxynucleotides (Bcl-2-ASO) have been shown to induce apoptosis in cancer cells, as a single agent or, better, in combination with chemotherapy. Oligodeoxyribonucleotides 16-37 BCL2 apoptosis regulator Homo sapiens 39-44 12531799-5 2003 We also detected cleavage of Bid, suggesting a role for Bcl-2 family members in regulation of SAHA-induced cell death. Vorinostat 94-98 BCL2 apoptosis regulator Homo sapiens 56-61 12531799-6 2003 Transfection of Bcl-2 cDNA into MM.1S cells completely abrogated SAHA-induced apoptosis, confirming its protective role. Vorinostat 65-69 BCL2 apoptosis regulator Homo sapiens 16-21 12531792-4 2003 In a subset of CLL patients, B-cell lymphoma 2 (Bcl-2)-associated death promoter homolog (Bad), a proapoptotic Bcl-2 family member that when phosphorylated on specific serine residues is sequestered in the cytosol by 14-3-3, was dephosphorylated at Ser112 following rolipram/forskolin treatment of leukemic cells. Rolipram 266-274 BCL2 apoptosis regulator Homo sapiens 29-46 12531792-4 2003 In a subset of CLL patients, B-cell lymphoma 2 (Bcl-2)-associated death promoter homolog (Bad), a proapoptotic Bcl-2 family member that when phosphorylated on specific serine residues is sequestered in the cytosol by 14-3-3, was dephosphorylated at Ser112 following rolipram/forskolin treatment of leukemic cells. Rolipram 266-274 BCL2 apoptosis regulator Homo sapiens 48-53 12531792-4 2003 In a subset of CLL patients, B-cell lymphoma 2 (Bcl-2)-associated death promoter homolog (Bad), a proapoptotic Bcl-2 family member that when phosphorylated on specific serine residues is sequestered in the cytosol by 14-3-3, was dephosphorylated at Ser112 following rolipram/forskolin treatment of leukemic cells. Rolipram 266-274 BCL2 apoptosis regulator Homo sapiens 111-116 12754095-0 2003 N-Acetylcysteine enhances UV-mediated caspase-3 activation, fragmentation of E2F-4, and apoptosis in human C8161 melanoma: inhibition by ectopic Bcl-2 expression. Acetylcysteine 0-16 BCL2 apoptosis regulator Homo sapiens 145-150 12729794-0 2003 Transmembrane domain of Bcl-2 is required for inhibition of ceramide synthesis, but not cytochrome c release in the pathway of inostamycin-induced apoptosis. Ceramides 60-68 BCL2 apoptosis regulator Homo sapiens 24-29 12729794-0 2003 Transmembrane domain of Bcl-2 is required for inhibition of ceramide synthesis, but not cytochrome c release in the pathway of inostamycin-induced apoptosis. inostamycin 127-138 BCL2 apoptosis regulator Homo sapiens 24-29 12729794-3 2003 In the present study, we found that overexpression of Bcl-2 in human small cell lung carcinoma Ms-1 cells inhibited not only the release of cytochrome c from mitochondria into cytosol but also de novo ceramide synthesis induced by inostamycin, a phosphatidylinositol turnover inhibitor. Ceramides 201-209 BCL2 apoptosis regulator Homo sapiens 54-59 12729794-3 2003 In the present study, we found that overexpression of Bcl-2 in human small cell lung carcinoma Ms-1 cells inhibited not only the release of cytochrome c from mitochondria into cytosol but also de novo ceramide synthesis induced by inostamycin, a phosphatidylinositol turnover inhibitor. inostamycin 231-242 BCL2 apoptosis regulator Homo sapiens 54-59 12729794-3 2003 In the present study, we found that overexpression of Bcl-2 in human small cell lung carcinoma Ms-1 cells inhibited not only the release of cytochrome c from mitochondria into cytosol but also de novo ceramide synthesis induced by inostamycin, a phosphatidylinositol turnover inhibitor. Phosphatidylinositols 246-266 BCL2 apoptosis regulator Homo sapiens 54-59 12729794-4 2003 To investigate the correlation between the structure of Bcl-2 and its inhibitory function in inostamycin-induced apoptosis, Ms-1 cells that stably overexpress domain-deletional mutants of Bcl-2 were established. inostamycin 93-104 BCL2 apoptosis regulator Homo sapiens 56-61 12726919-6 2003 These data are the first report showing CED-9 has cytoprotective effects against oxidative stress, and add CED-9 to the list of Bcl-2 protein family members that modulate ROS-mediated programmed cell death. Reactive Oxygen Species 171-174 BCL2 apoptosis regulator Homo sapiens 128-133 12754095-6 2003 These effects of joint NAC-UV radiation treatment were counteracted by the overexpression of the bcl-2 gene. Acetylcysteine 23-26 BCL2 apoptosis regulator Homo sapiens 97-102 12729794-6 2003 Thus, the deletion mutant of tarnsmembrane domain of Bcl-2 can suppress inostamycin-induced apoptosis by inhibiting cytochrome c release, a downstream event of ceramide synthesis in the pathway of inostamycin-induced apoptosis. inostamycin 72-83 BCL2 apoptosis regulator Homo sapiens 53-58 12754095-7 2003 To our knowledge, this report is the first to: (i) demonstrate a synergy between DNA-damaging agents, like UV radiation, and antioxidants, like NAC, and (ii) show that a Bcl-2-inhibitable E2F-4 fragmentation occurs concurrently with caspase-3 activation and apoptosis. Acetylcysteine 144-147 BCL2 apoptosis regulator Homo sapiens 170-175 12729794-6 2003 Thus, the deletion mutant of tarnsmembrane domain of Bcl-2 can suppress inostamycin-induced apoptosis by inhibiting cytochrome c release, a downstream event of ceramide synthesis in the pathway of inostamycin-induced apoptosis. Ceramides 160-168 BCL2 apoptosis regulator Homo sapiens 53-58 12729794-6 2003 Thus, the deletion mutant of tarnsmembrane domain of Bcl-2 can suppress inostamycin-induced apoptosis by inhibiting cytochrome c release, a downstream event of ceramide synthesis in the pathway of inostamycin-induced apoptosis. inostamycin 197-208 BCL2 apoptosis regulator Homo sapiens 53-58 12704800-8 2003 From these results, we propose that BHV-1 has one or more genes encoding apoptosis-inhibiting factors which interfere with the involvement of bcl-2 gene family members and apoptotic pathway, depending upon caspase-3, triggered by sorbitol. Sorbitol 230-238 BCL2 apoptosis regulator Homo sapiens 142-147 12729794-7 2003 We also found that the BH3 and BH4 domains of Bcl-2 were necessary for inhibition of inostamycin-induced apoptosis, and deletion of BH1 or BH2 did not affect the inhibitory effect of Bcl-2 to inostamycin-induced apoptotic events. inostamycin 85-96 BCL2 apoptosis regulator Homo sapiens 46-51 12729794-7 2003 We also found that the BH3 and BH4 domains of Bcl-2 were necessary for inhibition of inostamycin-induced apoptosis, and deletion of BH1 or BH2 did not affect the inhibitory effect of Bcl-2 to inostamycin-induced apoptotic events. inostamycin 192-203 BCL2 apoptosis regulator Homo sapiens 46-51 12853327-0 2003 The role of caspase III inhibition in methamphetamine-induced alterations in p53 and bcl-2 expression: correlation with dopaminergic neurotoxicity. Methamphetamine 38-53 BCL2 apoptosis regulator Homo sapiens 85-90 12771938-10 2003 Over expression of Bcl-2 blocked TRAIL-induced apoptosis in the presence of U0126. U 0126 76-81 BCL2 apoptosis regulator Homo sapiens 19-24 12785737-7 2003 These results indicate that DDN exerts antitumor activity, which appears to be related to the induction of apoptosis by regulating Bcl-2 family proteins. 2,3-dichloro-5,8-dihydroxy-1,4-naphthoquinone 28-31 BCL2 apoptosis regulator Homo sapiens 131-136 12522001-8 2003 Collectively, these findings indicate that in U937 cells, bryostatin 1 promotes paclitaxel-mediated mitochondrial injury and apoptosis, and circumvents resistance to cell death conferred by loss of the Bcl-2 phosphorylation domain, through the PKC-dependent induction of TNF-alpha. bryostatin 1 58-70 BCL2 apoptosis regulator Homo sapiens 202-207 12894543-6 2003 Western blot analysis demonstrated that codeinone enhanced the Pro-apoptotic Bax protein expression, but reduced the anti-apoptotic Bcl-2 protein expression. 6-codeinone 40-49 BCL2 apoptosis regulator Homo sapiens 132-137 12624108-10 2003 Alkaline treatment stripped off tBid from the membrane-bound organellar fraction of Bid plus Bcl-2-co-transfected cells, but not from cells transfected with only Bid, suggesting inhibition of tBid insertion into mitochondrial membranes by Bcl-2. tBID 32-36 BCL2 apoptosis regulator Homo sapiens 93-98 12624108-14 2003 Critical steps blocked by Bcl-2 included tBid insertion, Bax translocation, and Bax/Bak oligomerization in the mitochondrial membranes. tBID 41-45 BCL2 apoptosis regulator Homo sapiens 26-31 12712458-11 2003 The combination of a PKC inhibitor with CPT-11 or SN-38 led to decreased expression of the antiapoptotic protein bcl-2, and increased expression of the proapoptotic protein bax. Irinotecan 40-46 BCL2 apoptosis regulator Homo sapiens 113-118 12736759-9 2003 CONCLUSIONS: The ATRA-induced increase in cytotoxicity of ara-C was, in part, the result of an increase in the functional expression of nucleoside transporters, and a role for bcl-2 was also indicated. Tretinoin 17-21 BCL2 apoptosis regulator Homo sapiens 176-181 12712458-11 2003 The combination of a PKC inhibitor with CPT-11 or SN-38 led to decreased expression of the antiapoptotic protein bcl-2, and increased expression of the proapoptotic protein bax. Irinotecan 50-55 BCL2 apoptosis regulator Homo sapiens 113-118 12731064-7 2003 All TGF-beta 1-mediated effects, but Bcl2 up-regulation, can be reproduced by the LY294002 phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor but not by inhibitors of the MAPK/ERK (MEK) and Janus kinase (Jak)/STAT pathways, which promote cell death. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 82-90 BCL2 apoptosis regulator Homo sapiens 37-41 12738752-3 2003 We previously examined the antitumor effects of a fully phosphorothioated Bcl-2 antisense oligonucleotide, G3139, in EBV(+) lymphoproliferative disease in vitro and in vivo using the human/severe combined immunodeficient (SCID) chimeric model of PTLD. Oligonucleotides 90-105 BCL2 apoptosis regulator Homo sapiens 74-79 12738752-4 2003 These studies showed that G3139 treatment decreased Bcl-2 protein levels in association with antiproliferative and proapoptotic effects in lymphoblastoid cell lines (LCLs) in vitro. oblimersen 26-31 BCL2 apoptosis regulator Homo sapiens 52-57 12738752-14 2003 Bcl-2 antisense oligonucleotide therapy in combination with rituximab may represent a promising nontoxic and effective targeted therapy for EBV-associated lymphoproliferative diseases such as PTLD and ARL. Oligonucleotides 16-31 BCL2 apoptosis regulator Homo sapiens 0-5 12769779-6 2003 In several cases, these ligands (e.g., HA14-1, 2-methoxy antimycin A) induce apoptosis even under conditions of Bcl2 overexpression and if developed preclinically will be promising anticancer agents. ha14-1, 2-methoxy antimycin a 39-68 BCL2 apoptosis regulator Homo sapiens 112-116 12878863-6 2003 Lastly, we have found that Bis IX can override the apoptosis-inhibitory effects of Bcl-2 overexpression. bisindolylmaleimide IX 27-33 BCL2 apoptosis regulator Homo sapiens 83-88 12731064-9 2003 Altogether, our findings suggest that TGF-beta1 prevents Fas-induced apoptosis of pre-B lines by inhibiting PI3K pathway and by enhancing expression of Bcl2. ammonium ferrous sulfate 57-60 BCL2 apoptosis regulator Homo sapiens 152-156 12684678-3 2003 In the present studies, we determined the effect of high intracellular levels of the anti-apoptosis Bcl-2 protein on caspase 3 activation and cyctochrome c release during phorbol ester 12-myristate 13-acetate (PMA)-induced apoptosis. phorbol ester 12-myristate 13-acetate 171-208 BCL2 apoptosis regulator Homo sapiens 100-105 12626434-4 2003 High toxic concentration of DA (500 microM), R-APO (50 microM), melatonin (50 microM), and EGCG (50 microM) exhibited a similar profile of proapoptotic gene expression, increasing the level of bax, caspase-6, fas ligand, and the cell-cycle inhibitor gadd45 genes, while decreasing antiapoptotic bcl-2 and bcl-xL. Dopamine 28-30 BCL2 apoptosis regulator Homo sapiens 295-300 12626434-4 2003 High toxic concentration of DA (500 microM), R-APO (50 microM), melatonin (50 microM), and EGCG (50 microM) exhibited a similar profile of proapoptotic gene expression, increasing the level of bax, caspase-6, fas ligand, and the cell-cycle inhibitor gadd45 genes, while decreasing antiapoptotic bcl-2 and bcl-xL. Apomorphine 45-50 BCL2 apoptosis regulator Homo sapiens 295-300 12626434-4 2003 High toxic concentration of DA (500 microM), R-APO (50 microM), melatonin (50 microM), and EGCG (50 microM) exhibited a similar profile of proapoptotic gene expression, increasing the level of bax, caspase-6, fas ligand, and the cell-cycle inhibitor gadd45 genes, while decreasing antiapoptotic bcl-2 and bcl-xL. Melatonin 64-73 BCL2 apoptosis regulator Homo sapiens 295-300 12626434-4 2003 High toxic concentration of DA (500 microM), R-APO (50 microM), melatonin (50 microM), and EGCG (50 microM) exhibited a similar profile of proapoptotic gene expression, increasing the level of bax, caspase-6, fas ligand, and the cell-cycle inhibitor gadd45 genes, while decreasing antiapoptotic bcl-2 and bcl-xL. epigallocatechin gallate 91-95 BCL2 apoptosis regulator Homo sapiens 295-300 12706124-3 2003 An MTT assay revealed that BCL-2-overexpressing cells (HCA2/bcl-2) showed more severe growth suppression due to hydrogen peroxide or doxorubicin treatment than vector control cells (HCA2/vector). monooxyethylene trimethylolpropane tristearate 3-6 BCL2 apoptosis regulator Homo sapiens 27-32 12706124-3 2003 An MTT assay revealed that BCL-2-overexpressing cells (HCA2/bcl-2) showed more severe growth suppression due to hydrogen peroxide or doxorubicin treatment than vector control cells (HCA2/vector). monooxyethylene trimethylolpropane tristearate 3-6 BCL2 apoptosis regulator Homo sapiens 60-65 12706124-3 2003 An MTT assay revealed that BCL-2-overexpressing cells (HCA2/bcl-2) showed more severe growth suppression due to hydrogen peroxide or doxorubicin treatment than vector control cells (HCA2/vector). Hydrogen Peroxide 112-129 BCL2 apoptosis regulator Homo sapiens 27-32 12706124-3 2003 An MTT assay revealed that BCL-2-overexpressing cells (HCA2/bcl-2) showed more severe growth suppression due to hydrogen peroxide or doxorubicin treatment than vector control cells (HCA2/vector). Hydrogen Peroxide 112-129 BCL2 apoptosis regulator Homo sapiens 60-65 12706124-3 2003 An MTT assay revealed that BCL-2-overexpressing cells (HCA2/bcl-2) showed more severe growth suppression due to hydrogen peroxide or doxorubicin treatment than vector control cells (HCA2/vector). Doxorubicin 133-144 BCL2 apoptosis regulator Homo sapiens 27-32 12706124-3 2003 An MTT assay revealed that BCL-2-overexpressing cells (HCA2/bcl-2) showed more severe growth suppression due to hydrogen peroxide or doxorubicin treatment than vector control cells (HCA2/vector). Doxorubicin 133-144 BCL2 apoptosis regulator Homo sapiens 60-65 12684678-3 2003 In the present studies, we determined the effect of high intracellular levels of the anti-apoptosis Bcl-2 protein on caspase 3 activation and cyctochrome c release during phorbol ester 12-myristate 13-acetate (PMA)-induced apoptosis. Tetradecanoylphorbol Acetate 210-213 BCL2 apoptosis regulator Homo sapiens 100-105 12684678-7 2003 Treatment with 20 nM PMA for 24 h produced morphological features of apoptosis and DNA fragmentation in U937 and U937/Bcl-2 cells, but not in R-U937 cells. Tetradecanoylphorbol Acetate 21-24 BCL2 apoptosis regulator Homo sapiens 118-123 12719730-7 2003 BH3-only molecules, often working in concert, compete for downstream multidomain pro- and anti-apoptotic BCL-2 members to control serial stages of lymphocyte development and homeostasis. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 105-110 12480939-6 2003 Both RA and antisense Bcl-2 oligonucleotide decreased Bcl-2 protein levels and markedly increased caspase activity and apoptosis in cyclin D1-infected cells. Oligonucleotides 28-43 BCL2 apoptosis regulator Homo sapiens 22-27 12686415-2 2003 Here we describe a set of novel apoptotic phenomena--stimulation of the mitochondrial potassium uptake preceding cytochrome c release and regulation of such potassium uptake by bcl-2 family proteins. Potassium 86-95 BCL2 apoptosis regulator Homo sapiens 177-182 12686415-2 2003 Here we describe a set of novel apoptotic phenomena--stimulation of the mitochondrial potassium uptake preceding cytochrome c release and regulation of such potassium uptake by bcl-2 family proteins. Potassium 157-166 BCL2 apoptosis regulator Homo sapiens 177-182 12686415-4 2003 Overexpression of bcl-2 protein prevented the mitochondrial potassium uptake as well as cytochrome c release in apoptosis. Potassium 60-69 BCL2 apoptosis regulator Homo sapiens 18-23 12686415-5 2003 Bcl-2 was found to upregulate the mitochondrial potassium efflux mechanism--the K/H exchanger. Potassium 48-57 BCL2 apoptosis regulator Homo sapiens 0-5 12686415-8 2003 The described counter-regulation of mitochondrial potassium transport by bcl-2 and Bid suggests a novel view of a mechanism of cytochrome c release from mitochondria in apoptosis. Potassium 50-59 BCL2 apoptosis regulator Homo sapiens 73-78 12480939-6 2003 Both RA and antisense Bcl-2 oligonucleotide decreased Bcl-2 protein levels and markedly increased caspase activity and apoptosis in cyclin D1-infected cells. Oligonucleotides 28-43 BCL2 apoptosis regulator Homo sapiens 54-59 12670922-8 2003 The ganglioside-synthesizing SK-RC-45 line stimulated the TUNEL (terminal deoxynucleotidyl transferase-mediated nick end labeling) positivity of cocultured T cells by a mechanism that involved decreasing lymphocyte expression levels of Bcl-2 and Bcl-(XL), inducing cytochrome c release from their mitochondria and activating caspases 9 and 3. Gangliosides 4-15 BCL2 apoptosis regulator Homo sapiens 236-241 12700662-4 2003 Here, we show that Cidofovir induces a downregulation of the EBV oncoprotein LMP1 associated with a decrease of the antiapoptotic Bcl-2 and an increase of the proapoptotic Bax protein in Raji (BL) and C15 (NPC) cells. Cidofovir 19-28 BCL2 apoptosis regulator Homo sapiens 130-135 12681495-2 2003 Overexpression of Bcl-2 inhibited UVB-induced apoptosis by blocking the early generation of reactive oxygen species, mitochondrial cardiolipin degradation and cytochrome c release, without affecting Fas ligand (FasL)-induced cell death. Reactive Oxygen Species 92-115 BCL2 apoptosis regulator Homo sapiens 18-23 12681495-5 2003 Our results suggest that Bcl-2 overexpression, by preventing reactive oxygen species production, helps indirectly to maintain the integrity of lysosomal membranes, and therefore inhibits the release of cathepsins, which contribute to the cytosolic activation of procaspase-8 in UVB-irradiated keratinocytes. Reactive Oxygen Species 61-84 BCL2 apoptosis regulator Homo sapiens 25-30 12556448-8 2003 We provide evidences that translocation into the mitochondria of the Bcl-2 family member Bid depends on caspase-9 and that this translocation is a late event during TSA-induced apoptosis. trichostatin A 165-168 BCL2 apoptosis regulator Homo sapiens 69-74 12694257-2 2003 BH3-containing peptides induce apoptosis by binding to the hydrophobic pocket of the anti-apoptotic proteins, such as Bcl-2 or Bcl-XL. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 118-123 12694257-4 2003 BH3I-2" induces apoptosis by disrupting interactions mediated by the BH3 domain, between pro-apoptotic and anti-apoptotic members of the Bcl-2 family. BH3I-2' 0-6 BCL2 apoptosis regulator Homo sapiens 137-142 12694257-4 2003 BH3I-2" induces apoptosis by disrupting interactions mediated by the BH3 domain, between pro-apoptotic and anti-apoptotic members of the Bcl-2 family. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 137-142 12670922-8 2003 The ganglioside-synthesizing SK-RC-45 line stimulated the TUNEL (terminal deoxynucleotidyl transferase-mediated nick end labeling) positivity of cocultured T cells by a mechanism that involved decreasing lymphocyte expression levels of Bcl-2 and Bcl-(XL), inducing cytochrome c release from their mitochondria and activating caspases 9 and 3. sk-rc-45 29-37 BCL2 apoptosis regulator Homo sapiens 236-241 12645082-4 2003 Like MPP(+), DETA-NO caused an early decrease in Bcl-2 mRNA, did not increase Bax protein in rho(0) cells and caused caspase- and cycloheximide-dependent apoptosis and caspase-independent cell death. DETA-NO 13-20 BCL2 apoptosis regulator Homo sapiens 49-54 26680929-11 2003 Bax, as a proapoptotic factor, was increased in the SaOS2cells, but the Bcl-xL and Bcl-2 were decreased when the cells were exposed to 10miceoM Taxol. Paclitaxel 144-149 BCL2 apoptosis regulator Homo sapiens 83-88 12684432-9 2003 Interestingly, LDFRT treatment in both cell lines with or without Paclitaxel down-regulated nuclear factor kappa B activity and BCL-2 protein expression and simultaneously up-regulated BAX protein. Paclitaxel 66-76 BCL2 apoptosis regulator Homo sapiens 128-133 12684432-10 2003 These findings strongly suggest that LDFRT (at these doses, HRS phenomenon is observed) can be used in combination with Paclitaxel to overcome the antiapoptotic effects of BCL-2 and nuclear factor kappa B. Paclitaxel 120-130 BCL2 apoptosis regulator Homo sapiens 172-177 12594179-3 2003 Bcl-2 expressing cells were found to have higher intracellular levels of GSH and to produce lower amounts of virus than Bcl-2 negative cells. Glutathione 73-76 BCL2 apoptosis regulator Homo sapiens 0-5 12594179-4 2003 Two different steps in the virus life-cycle were involved in Bcl-2/GSH mediated viral inhibition: 1) expression of late viral proteins (in particular hemagglutinin and matrix); and 2) nuclear-cytoplasmic translocation of viral ribonucleoproteins (vRNPs). Glutathione 67-70 BCL2 apoptosis regulator Homo sapiens 61-66 12632082-5 2003 An enhanced drug-sensitivity to MMC and TXL upon pretreatment with antisense Bcl-2 ODN was observed, with the IC50 values increasing 1.9- and 2.0-fold, respectively. Mitomycin 32-35 BCL2 apoptosis regulator Homo sapiens 77-82 12672908-8 2003 The antioxidants, (-)epigallocatechin gallate and quercetin, inhibited endothelial apoptosis, enhanced the expression of bcl-2 protein and inhibited the expression of bax protein and the cleavage and activation of caspase-3. epigallocatechin gallate 18-45 BCL2 apoptosis regulator Homo sapiens 121-126 12672908-8 2003 The antioxidants, (-)epigallocatechin gallate and quercetin, inhibited endothelial apoptosis, enhanced the expression of bcl-2 protein and inhibited the expression of bax protein and the cleavage and activation of caspase-3. Quercetin 50-59 BCL2 apoptosis regulator Homo sapiens 121-126 12803240-9 2003 The present findings suggest that Fas/Fas-L and Bcl-2 protein expression participate in the regulation of apoptosis in EVT along the invasion to the decidua, and that the increased occurrence of apoptosis in the invasive phenotype of EVT may be attributable to the increased expressions of Fas and Fas-L and decreased expression of Bcl-2 protein in those cells in term placentas. EVT 119-122 BCL2 apoptosis regulator Homo sapiens 48-53 12803240-9 2003 The present findings suggest that Fas/Fas-L and Bcl-2 protein expression participate in the regulation of apoptosis in EVT along the invasion to the decidua, and that the increased occurrence of apoptosis in the invasive phenotype of EVT may be attributable to the increased expressions of Fas and Fas-L and decreased expression of Bcl-2 protein in those cells in term placentas. EVT 119-122 BCL2 apoptosis regulator Homo sapiens 332-337 12594179-5 2003 Buthionine-sulfoximine-induced inhibition of GSH synthesis in Bcl-2 expressing cells caused an increase in the expression of late viral proteins but did not restore vRNP export to the cytoplasm. buthionine 0-10 BCL2 apoptosis regulator Homo sapiens 62-67 12594179-5 2003 Buthionine-sulfoximine-induced inhibition of GSH synthesis in Bcl-2 expressing cells caused an increase in the expression of late viral proteins but did not restore vRNP export to the cytoplasm. sulfoximine 11-22 BCL2 apoptosis regulator Homo sapiens 62-67 12594179-5 2003 Buthionine-sulfoximine-induced inhibition of GSH synthesis in Bcl-2 expressing cells caused an increase in the expression of late viral proteins but did not restore vRNP export to the cytoplasm. Glutathione 45-48 BCL2 apoptosis regulator Homo sapiens 62-67 12632069-8 2003 The cell lysates were analyzed by immunoblotting techniques for the expression of key genes targeted by ciprofloxacin (p21WAF1, Bax and Bcl-2). Ciprofloxacin 104-117 BCL2 apoptosis regulator Homo sapiens 136-141 12632069-16 2003 These effects of ciprofloxacin were mediated by cell cycle arrest at S-G2/M phase of the cell cycle, Bax translocation to mitochondrial membrane and by increasing the Bax/Bcl-2 ratio in PC3 prostate cancer cells. Ciprofloxacin 17-30 BCL2 apoptosis regulator Homo sapiens 171-176 12672908-10 2003 The antiapoptotic activity of flavonoids appears to be mediated at the mitochondrial bcl-2 and bax gene level. Flavonoids 30-40 BCL2 apoptosis regulator Homo sapiens 85-90 12690294-8 2003 Furthermore, examination of the levels of apoptosis regulatory proteins showed that, while levels of p53, Bax and p21 are higher, that of anti-apoptotic Bcl-2 is undetectable in cells treated with 2-ME compared with untreated controls. 2-Methoxyestradiol 197-201 BCL2 apoptosis regulator Homo sapiens 153-158 12629413-0 2003 Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. Dihydrotestosterone 34-53 BCL2 apoptosis regulator Homo sapiens 14-19 12629413-8 2003 RESULTS: Cells cultured in charcoal stripped serum in the presence of DHT resulted in down-regulation of bcl-2 protein. Charcoal 27-35 BCL2 apoptosis regulator Homo sapiens 105-110 12531222-3 2003 All-trans retinoic acid (ATRA) down-regulates bcl-2 expression and heightens AML sensitivity to cytosine arabinoside (ara-C)-induced apoptosis in vitro. Tretinoin 0-23 BCL2 apoptosis regulator Homo sapiens 46-51 12531222-3 2003 All-trans retinoic acid (ATRA) down-regulates bcl-2 expression and heightens AML sensitivity to cytosine arabinoside (ara-C)-induced apoptosis in vitro. Tretinoin 25-29 BCL2 apoptosis regulator Homo sapiens 46-51 12769332-9 2003 Various strategies have been proposed also to directly inhibit Bcl-2 and related anti-apoptotic proteins, including antisense oligonucleotides (e.g. Genasense, currently tested in phase III trials), small molecules that mimic the BH3 dimerization domain of these proteins and kinase inhibitors. Oligonucleotides 126-142 BCL2 apoptosis regulator Homo sapiens 63-68 12769332-9 2003 Various strategies have been proposed also to directly inhibit Bcl-2 and related anti-apoptotic proteins, including antisense oligonucleotides (e.g. Genasense, currently tested in phase III trials), small molecules that mimic the BH3 dimerization domain of these proteins and kinase inhibitors. BH 3 230-233 BCL2 apoptosis regulator Homo sapiens 63-68 12769332-10 2003 Ligands of the mitochondrial benzodiazepine receptor such as the isoquinolone carboxamide derivative PK11195 also overcome the membrane-stabilizing effect of Bcl-2, whereas the adenosine nucleotide translocator (ANT) and the mitochondrial DNA are two other potential cellular targets for cytotoxic agents. isoquinolone carboxamide 65-89 BCL2 apoptosis regulator Homo sapiens 158-163 12629413-8 2003 RESULTS: Cells cultured in charcoal stripped serum in the presence of DHT resulted in down-regulation of bcl-2 protein. Dihydrotestosterone 70-73 BCL2 apoptosis regulator Homo sapiens 105-110 12629413-9 2003 Down-regulation of bcl-2 protein and mRNA by DHT was inhibited by coincubation with the antiandrogen bicalutamide, an agent that competitively inhibits binding of DHT to androgen receptor. Dihydrotestosterone 45-48 BCL2 apoptosis regulator Homo sapiens 19-24 12629413-9 2003 Down-regulation of bcl-2 protein and mRNA by DHT was inhibited by coincubation with the antiandrogen bicalutamide, an agent that competitively inhibits binding of DHT to androgen receptor. bicalutamide 101-113 BCL2 apoptosis regulator Homo sapiens 19-24 12629413-9 2003 Down-regulation of bcl-2 protein and mRNA by DHT was inhibited by coincubation with the antiandrogen bicalutamide, an agent that competitively inhibits binding of DHT to androgen receptor. Dihydrotestosterone 163-166 BCL2 apoptosis regulator Homo sapiens 19-24 12629413-11 2003 Bcl-2 mRNA was also down-regulated by DHT and this down-regulation could not be abolished by cycloheximide. Dihydrotestosterone 38-41 BCL2 apoptosis regulator Homo sapiens 0-5 12629413-12 2003 CONCLUSIONS: Together these results suggest that the suppression of bcl-2 expression by DHT in hormone sensitive LNCaP-FGC prostate cancer cells occurs directly. Dihydrotestosterone 88-91 BCL2 apoptosis regulator Homo sapiens 68-73 12663772-11 2003 Induction of apoptosis by M protein, actinomycin D, and DRB was inhibited in stably transfected HeLa cell lines that overexpress Bcl-2, an antiapoptotic protein that inhibits the caspase-9 pathway. Dactinomycin 37-50 BCL2 apoptosis regulator Homo sapiens 129-134 12663772-11 2003 Induction of apoptosis by M protein, actinomycin D, and DRB was inhibited in stably transfected HeLa cell lines that overexpress Bcl-2, an antiapoptotic protein that inhibits the caspase-9 pathway. Dichlororibofuranosylbenzimidazole 56-59 BCL2 apoptosis regulator Homo sapiens 129-134 12690298-3 2003 We also investigated the relationship between Fas-mediated apoptosis and the expression of the bcl-2 family, measured using Western blotting. ammonium ferrous sulfate 46-49 BCL2 apoptosis regulator Homo sapiens 95-100 12510025-2 2003 trans-Resveratrol reverses phosphorylation of Bcl-2 induced by paclitaxel and concomitantly blocks Raf-1 phosphorylation, also observed after paclitaxel exposure, thus suggesting that Bcl-2 inactivation may be dependent on the activation of the Raf/Ras cascade. Paclitaxel 63-73 BCL2 apoptosis regulator Homo sapiens 46-51 12727447-7 2003 Although Bcl-2 did not have a dramatic effect on AP-1 or Egr-1 induction within the first 3 h, it caused a lowering of steady-state redox levels with a concomitant increase in cellular glutathione. Glutathione 185-196 BCL2 apoptosis regulator Homo sapiens 9-14 12727447-8 2003 We propose that the lowering of cellular redox and the upregulation of glutathione are responsible in part for the protective properties of Bcl-2. Glutathione 71-82 BCL2 apoptosis regulator Homo sapiens 140-145 12510025-2 2003 trans-Resveratrol reverses phosphorylation of Bcl-2 induced by paclitaxel and concomitantly blocks Raf-1 phosphorylation, also observed after paclitaxel exposure, thus suggesting that Bcl-2 inactivation may be dependent on the activation of the Raf/Ras cascade. Paclitaxel 142-152 BCL2 apoptosis regulator Homo sapiens 184-189 12510025-2 2003 trans-Resveratrol reverses phosphorylation of Bcl-2 induced by paclitaxel and concomitantly blocks Raf-1 phosphorylation, also observed after paclitaxel exposure, thus suggesting that Bcl-2 inactivation may be dependent on the activation of the Raf/Ras cascade. Resveratrol 0-17 BCL2 apoptosis regulator Homo sapiens 46-51 12510025-2 2003 trans-Resveratrol reverses phosphorylation of Bcl-2 induced by paclitaxel and concomitantly blocks Raf-1 phosphorylation, also observed after paclitaxel exposure, thus suggesting that Bcl-2 inactivation may be dependent on the activation of the Raf/Ras cascade. Resveratrol 0-17 BCL2 apoptosis regulator Homo sapiens 184-189 12510025-3 2003 trans-Resveratrol also reverses the sustained phosphorylation of JNK/SAPK, which specifically occurs after paclitaxel exposure.Overall, our observations demonstrate that (a) the toxic action of paclitaxel on neuronal-like cells is not only related to the effect of the drug on tubulin, but also to its capacity to activate several intracellular pathways leading to inactivation of Bcl-2, thus causing cells to die by apoptosis, (b) trans-resveratrol significantly reduces paclitaxel-induced apoptosis by modulating the cellular signaling pathways which commit the cell to apoptosis. Resveratrol 0-17 BCL2 apoptosis regulator Homo sapiens 381-386 12510025-3 2003 trans-Resveratrol also reverses the sustained phosphorylation of JNK/SAPK, which specifically occurs after paclitaxel exposure.Overall, our observations demonstrate that (a) the toxic action of paclitaxel on neuronal-like cells is not only related to the effect of the drug on tubulin, but also to its capacity to activate several intracellular pathways leading to inactivation of Bcl-2, thus causing cells to die by apoptosis, (b) trans-resveratrol significantly reduces paclitaxel-induced apoptosis by modulating the cellular signaling pathways which commit the cell to apoptosis. Paclitaxel 194-204 BCL2 apoptosis regulator Homo sapiens 381-386 12510025-3 2003 trans-Resveratrol also reverses the sustained phosphorylation of JNK/SAPK, which specifically occurs after paclitaxel exposure.Overall, our observations demonstrate that (a) the toxic action of paclitaxel on neuronal-like cells is not only related to the effect of the drug on tubulin, but also to its capacity to activate several intracellular pathways leading to inactivation of Bcl-2, thus causing cells to die by apoptosis, (b) trans-resveratrol significantly reduces paclitaxel-induced apoptosis by modulating the cellular signaling pathways which commit the cell to apoptosis. Paclitaxel 194-204 BCL2 apoptosis regulator Homo sapiens 381-386 12657361-6 2003 However, other proteins including Bcl-2 family members, heat shock proteins, caspase-like decoy, calpains and proteases, and lipid moieties in the form of phosphoinositides also can function as caspase inhibitors. Phosphatidylinositols 155-172 BCL2 apoptosis regulator Homo sapiens 34-39 12720156-0 2003 Modulation of the activity of Bcl-2 in Waldenstrom"s macroglobulinemia using antisense oligonucleotides. Oligonucleotides 87-103 BCL2 apoptosis regulator Homo sapiens 30-35 12720156-5 2003 We have shown that Bcl-2 is expressed in WM cells in vitro and that downregulation of Bcl-2 may be achieved by treatment with G3139. oblimersen 126-131 BCL2 apoptosis regulator Homo sapiens 86-91 12720156-7 2003 Bcl-2 downregulation via G3139 antisense treatment may have potential anticancer efficacy in WM and further studies to address its effects on clinical specimens are warranted, in anticipation of using this agent in WM clinical trials. oblimersen 25-30 BCL2 apoptosis regulator Homo sapiens 0-5 12720157-3 2003 Oblimersen sodium (G3139, Genasense, Genta Inc, Berkeley Heights, NJ) is an antisense oligonucleotide compound designed to specifically bind to the first six codons of the human bcl-2 mRNA sequence, resulting in degradation of bcl-2 mRNA and subsequent decrease in Bcl-2 protein translation. Oligonucleotides 86-101 BCL2 apoptosis regulator Homo sapiens 178-183 12720157-4 2003 Oblimersen is the first oligonucleotide to demonstrate proof of principle of an antisense effect in human tumors by the documented downregulation of the target Bcl-2 protein. Oligonucleotides 24-39 BCL2 apoptosis regulator Homo sapiens 160-165 12885364-3 2003 Expression of bcl-2 and bax was detected by immunohistochemistry streptomycin-avidin-biotin-peroxidase complex (SABC) method, and correlation between them was analyzed. Streptomycin 65-77 BCL2 apoptosis regulator Homo sapiens 14-19 12715170-23 2003 The increase in number of Bcl-2 positive cells after combined treatment and the consistently negative p21 status after any treatment in GLC4-CDDP may protect these tumor cells from apoptosis as a part of their resistance mechanism to cisplatin. Cisplatin 234-243 BCL2 apoptosis regulator Homo sapiens 26-31 12679905-11 2003 After 48 hours incubation with tributyrin at 2 mmol/L(-1), the level of Bcl-2 protein was lowered, and the level of Bax protein was increased in SGC-7901, accompanied by PARP cleavage. tributyrin 31-41 BCL2 apoptosis regulator Homo sapiens 72-77 12679905-12 2003 CONCLUSION: Tributyrin could inhibit the growth of gastric cancer cells effectively in vitro by inhibiting DNA synthesis and inducing apoptosis, which was associated with the down-regulated Bcl-2 expression and the up-regulated Bax expression. tributyrin 12-22 BCL2 apoptosis regulator Homo sapiens 190-195 12889121-12 2003 The study showed that 0.5 mumol.L-1 cisplatin or 1 x 10(-4) mumol.L-1 lidamycin alone decreased Bcl-2 protein level, while lidamycin in combination with cisplatin strongly inhibited expression of Bcl-2 proteins in BEL-7402 cells. l-1 cisplatin 32-45 BCL2 apoptosis regulator Homo sapiens 96-101 12889121-12 2003 The study showed that 0.5 mumol.L-1 cisplatin or 1 x 10(-4) mumol.L-1 lidamycin alone decreased Bcl-2 protein level, while lidamycin in combination with cisplatin strongly inhibited expression of Bcl-2 proteins in BEL-7402 cells. l-1 cisplatin 32-45 BCL2 apoptosis regulator Homo sapiens 196-201 12540838-3 2003 We found that CREB activity, including its DNA binding ability and phosphorylation on residue Ser-133, was strongly inhibited by Cpd 5, followed by suppression of CRE-mediated transcription of cyclin D1 and Bcl-2 genes. Serine 94-97 BCL2 apoptosis regulator Homo sapiens 207-212 12538580-7 2003 The mechanism of protection afforded by muscarinic receptor activation from camptothecin-induced apoptotic signaling involved blockade of mitochondrial cytochrome c release associated with a bolstering of mitochondrial bcl-2 levels and blockade of the translocation of Bax to mitochondria. Camptothecin 76-88 BCL2 apoptosis regulator Homo sapiens 219-224 12889121-12 2003 The study showed that 0.5 mumol.L-1 cisplatin or 1 x 10(-4) mumol.L-1 lidamycin alone decreased Bcl-2 protein level, while lidamycin in combination with cisplatin strongly inhibited expression of Bcl-2 proteins in BEL-7402 cells. C 1027 70-79 BCL2 apoptosis regulator Homo sapiens 96-101 12889121-12 2003 The study showed that 0.5 mumol.L-1 cisplatin or 1 x 10(-4) mumol.L-1 lidamycin alone decreased Bcl-2 protein level, while lidamycin in combination with cisplatin strongly inhibited expression of Bcl-2 proteins in BEL-7402 cells. C 1027 70-79 BCL2 apoptosis regulator Homo sapiens 196-201 12889121-12 2003 The study showed that 0.5 mumol.L-1 cisplatin or 1 x 10(-4) mumol.L-1 lidamycin alone decreased Bcl-2 protein level, while lidamycin in combination with cisplatin strongly inhibited expression of Bcl-2 proteins in BEL-7402 cells. Cisplatin 36-45 BCL2 apoptosis regulator Homo sapiens 96-101 12889121-12 2003 The study showed that 0.5 mumol.L-1 cisplatin or 1 x 10(-4) mumol.L-1 lidamycin alone decreased Bcl-2 protein level, while lidamycin in combination with cisplatin strongly inhibited expression of Bcl-2 proteins in BEL-7402 cells. Cisplatin 36-45 BCL2 apoptosis regulator Homo sapiens 196-201 12889121-13 2003 CONCLUSION: The results suggest that lidamycin enhancement of cisplatin-induced apoptosis associates with decrease of Bcl-2 protein expression, which may be useful for cancer chemotherapy. C 1027 37-46 BCL2 apoptosis regulator Homo sapiens 118-123 12889121-13 2003 CONCLUSION: The results suggest that lidamycin enhancement of cisplatin-induced apoptosis associates with decrease of Bcl-2 protein expression, which may be useful for cancer chemotherapy. Cisplatin 62-71 BCL2 apoptosis regulator Homo sapiens 118-123 12424199-10 2003 Indeed, within this subset of 147 pts, higher bax/bcl-2 ratio was significantly associated both with a higher CR rate (86% versus 42%; P <.000 01) and a longer OS (P =.0016). Chromium 110-112 BCL2 apoptosis regulator Homo sapiens 50-55 12525482-4 2003 We have shown previously that a tyrosine-deficient IL-2Rbeta chain paired with wild type gammac stimulated enhancement of bcl-2 mRNA in IL-2-dependent T cells, but it was not determined which region of the IL-2R or which pathway was activated to direct this signaling response. Tyrosine 32-40 BCL2 apoptosis regulator Homo sapiens 122-127 12525482-5 2003 Here we show that up-regulation of Bcl-2 by an IL-2R lacking IL-2Rbeta tyrosine residues leads to increased cell survival after cytokine deprivation; strikingly, this survival signal does not occur in the absence of gammac tyrosine residues. Tyrosine 71-79 BCL2 apoptosis regulator Homo sapiens 35-40 12525482-5 2003 Here we show that up-regulation of Bcl-2 by an IL-2R lacking IL-2Rbeta tyrosine residues leads to increased cell survival after cytokine deprivation; strikingly, this survival signal does not occur in the absence of gammac tyrosine residues. Tyrosine 223-231 BCL2 apoptosis regulator Homo sapiens 35-40 12644821-1 2003 In cell line studies, BCL-2, BAX, as well as novel MEK1 protein levels have strong influence on ovarian cancer response to cisplatin-based chemotherapy. Cisplatin 123-132 BCL2 apoptosis regulator Homo sapiens 22-27 12644821-8 2003 Another novel finding is that CR was negatively influenced by high BAX expression in all patients group (P=0.047) and by BCL2 expression in the TP53(-) group (P=0.05). Chromium 30-32 BCL2 apoptosis regulator Homo sapiens 121-125 12644821-12 2003 BCL-2 and BAX, but not MEK1 expressions have predictive value in ovarian cancer patients treated with platinum-based chemotherapy. Platinum 102-110 BCL2 apoptosis regulator Homo sapiens 0-5 12591950-0 2003 JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. bim 23-26 BCL2 apoptosis regulator Homo sapiens 50-54 12604350-0 2003 Regulation of leukotriene-dependent induction of cyclooxygenase-2 and Bcl-2. Leukotrienes 14-25 BCL2 apoptosis regulator Homo sapiens 70-75 12628337-0 2003 Remarkable induction of apoptosis in cancer cells by a novel cationic liposome complexed with a bcl-2 antisense oligonucleotide. Oligonucleotides 112-127 BCL2 apoptosis regulator Homo sapiens 96-101 12628337-3 2003 Bcl-2 antisense phosphorothioate oligonucleotides (AS-ODNs) were complexed with the cationic liposomes with the derivative (I) and they were introduced into human cervix epithelial carcinoma cell lines HeLa, and mouse fibroblast NIH3T3 cells. Phosphorothioate Oligonucleotides 16-49 BCL2 apoptosis regulator Homo sapiens 0-5 12628337-3 2003 Bcl-2 antisense phosphorothioate oligonucleotides (AS-ODNs) were complexed with the cationic liposomes with the derivative (I) and they were introduced into human cervix epithelial carcinoma cell lines HeLa, and mouse fibroblast NIH3T3 cells. Oligonucleotides, Antisense 51-58 BCL2 apoptosis regulator Homo sapiens 0-5 12628337-4 2003 An AS-ODNs targeting/bcl-2 gene induced probably apoptosis (including necrosis in some cases) in HeLa and NIH3T3 cells, however, nonsense oligonucleotides (NS-ODNs) corresponding to a scrambled-sequence control hardly induced apoptosis. Oligonucleotides 138-154 BCL2 apoptosis regulator Homo sapiens 21-26 12628337-6 2003 Fluorescence intensities of FITC-conjugated bcl-2 AS-ODNs were specifically found in the nucleus. Fluorescein-5-isothiocyanate 28-32 BCL2 apoptosis regulator Homo sapiens 44-49 12604781-6 2003 These findings provide a mechanism of E(2)-induced neuronal survival by attenuation of excitotoxic glutamate [Ca(2+)](i) rise via increased mitochondrial sequestration of cytosolic Ca(2+) coupled with an increase in Bcl-2 expression to sustain mitochondrial Ca(2+) load tolerance and function. Estradiol 38-42 BCL2 apoptosis regulator Homo sapiens 216-221 12820386-5 2003 When compared with undifferentiated controls, ATRA induced Bcl-2 expression, while loss of Bax expression was observed only in cells differentiated by ATRA + BMP-6. Tretinoin 46-50 BCL2 apoptosis regulator Homo sapiens 59-64 12419773-7 2003 The genetic program for glucose-induced mesangial cell apoptosis was characterized by an upregulation of the Bax/Bcl-2 ratio. Glucose 24-31 BCL2 apoptosis regulator Homo sapiens 113-118 12618753-3 2003 Serum withdrawal promoted the rapid, de novo accumulation of Bim(EL), a proapoptotic "BH3-only" member of the Bcl-2 protein family. bim 61-64 BCL2 apoptosis regulator Homo sapiens 110-115 12614281-8 2003 Addition of antioxidants (deferoxamine or 2-methyaminochroman) to the storage solution suppressed mitochondrial pore opening and swelling, Bcl-2 to Bax ratio increase, cytochrome C translocation, caspase-3 activation as well as rewarming-induced apoptosis. Deferoxamine 26-38 BCL2 apoptosis regulator Homo sapiens 139-144 12614281-8 2003 Addition of antioxidants (deferoxamine or 2-methyaminochroman) to the storage solution suppressed mitochondrial pore opening and swelling, Bcl-2 to Bax ratio increase, cytochrome C translocation, caspase-3 activation as well as rewarming-induced apoptosis. 2-methyaminochroman 42-61 BCL2 apoptosis regulator Homo sapiens 139-144 12820386-6 2003 The high Bcl-2/Bax ratio in cells differentiated by ATRA and ATRA + BMP-6, respectively, correlated with the survival of these cells in serum-free media. Tretinoin 52-56 BCL2 apoptosis regulator Homo sapiens 9-14 12820386-6 2003 The high Bcl-2/Bax ratio in cells differentiated by ATRA and ATRA + BMP-6, respectively, correlated with the survival of these cells in serum-free media. Tretinoin 61-65 BCL2 apoptosis regulator Homo sapiens 9-14 12684271-14 2003 Expression of Bcl-2 protein on progenitor cells of asthma was downregulated by theophylline, salbutamol, db-cAMP and rolipram. Theophylline 79-91 BCL2 apoptosis regulator Homo sapiens 14-19 12611458-5 2003 Tamoxifen can induce ER-dependent apoptosis in human breast tumor cells by a mechanism involving the Bcl2/mitochondrial arm of the apoptotic machinery. Tamoxifen 0-9 BCL2 apoptosis regulator Homo sapiens 101-105 12684271-14 2003 Expression of Bcl-2 protein on progenitor cells of asthma was downregulated by theophylline, salbutamol, db-cAMP and rolipram. Albuterol 93-103 BCL2 apoptosis regulator Homo sapiens 14-19 12684271-14 2003 Expression of Bcl-2 protein on progenitor cells of asthma was downregulated by theophylline, salbutamol, db-cAMP and rolipram. Bucladesine 105-112 BCL2 apoptosis regulator Homo sapiens 14-19 12684271-14 2003 Expression of Bcl-2 protein on progenitor cells of asthma was downregulated by theophylline, salbutamol, db-cAMP and rolipram. Rolipram 117-125 BCL2 apoptosis regulator Homo sapiens 14-19 12684271-16 2003 Theophylline and rolipram decreased colony formation committed to the eosinophil lineage, together with an increase in apoptosis through an inhibition of Bcl-2 expression effects that may occur through cAMP. Rolipram 17-25 BCL2 apoptosis regulator Homo sapiens 154-159 12684271-16 2003 Theophylline and rolipram decreased colony formation committed to the eosinophil lineage, together with an increase in apoptosis through an inhibition of Bcl-2 expression effects that may occur through cAMP. Cyclic AMP 202-206 BCL2 apoptosis regulator Homo sapiens 154-159 12751376-8 2003 Following treatment with either tamoxifen or letrozole, variable effects were observed on the apoptotic index and expression of Bcl-2. Tamoxifen 32-41 BCL2 apoptosis regulator Homo sapiens 128-133 12631622-6 2003 Overexpression of Bcl-2 increased resistance of MCF-7 cells to doxorubicin in 2-day, 5-day, and 8-week assays. Doxorubicin 63-74 BCL2 apoptosis regulator Homo sapiens 18-23 12631622-7 2003 Analysis of doxorubicin sensitivity of individual MCF/Bcl-2 clones showed that doxorubicin resistance was positively correlated with level of Bcl-2 overexpression. Doxorubicin 12-23 BCL2 apoptosis regulator Homo sapiens 54-59 12631622-7 2003 Analysis of doxorubicin sensitivity of individual MCF/Bcl-2 clones showed that doxorubicin resistance was positively correlated with level of Bcl-2 overexpression. Doxorubicin 12-23 BCL2 apoptosis regulator Homo sapiens 142-147 12631622-7 2003 Analysis of doxorubicin sensitivity of individual MCF/Bcl-2 clones showed that doxorubicin resistance was positively correlated with level of Bcl-2 overexpression. Doxorubicin 79-90 BCL2 apoptosis regulator Homo sapiens 54-59 12631622-7 2003 Analysis of doxorubicin sensitivity of individual MCF/Bcl-2 clones showed that doxorubicin resistance was positively correlated with level of Bcl-2 overexpression. Doxorubicin 79-90 BCL2 apoptosis regulator Homo sapiens 142-147 12631622-9 2003 Induction of Raf-1 activity in MCF-7 cells overexpressing Bcl-2 resulted in greater doxorubicin resistance than induction of Raf-1 activity in MCF-7 cells lacking Bcl-2 overexpression. Doxorubicin 84-95 BCL2 apoptosis regulator Homo sapiens 58-63 12631622-12 2003 These observations suggest both independent and overlapping roles for Raf-1 and Bcl-2 oncogenes in the resistance to growth inhibition by doxorubicin. Doxorubicin 138-149 BCL2 apoptosis regulator Homo sapiens 80-85 12631623-6 2003 RESULTS: In a synergistic fashion, Gem231 and HCPT induced growth arrest, apoptosis, and changes in cell morphology; down-regulated RIalpha expression; down-regulated Bcl-2 and promoted its hyperphosphorylation; up-regulated the proapoptotic proteins Bax and Bad; and promoted hypophosphorylation of Bad. GEM231 35-41 BCL2 apoptosis regulator Homo sapiens 167-172 12631623-6 2003 RESULTS: In a synergistic fashion, Gem231 and HCPT induced growth arrest, apoptosis, and changes in cell morphology; down-regulated RIalpha expression; down-regulated Bcl-2 and promoted its hyperphosphorylation; up-regulated the proapoptotic proteins Bax and Bad; and promoted hypophosphorylation of Bad. hydroxycamptothecinum 46-50 BCL2 apoptosis regulator Homo sapiens 167-172 12700632-4 2003 Exogenous ROS and caspase-3 induced deltapsi(m) drop and cytochrome c release from mitochondria, which could be prevented by molecular (dominant-negative caspase-9) and pharmacologic (zVAD-fmk) caspase inhibitors and overexpression of Bcl-2. Reactive Oxygen Species 10-13 BCL2 apoptosis regulator Homo sapiens 235-240 12700632-4 2003 Exogenous ROS and caspase-3 induced deltapsi(m) drop and cytochrome c release from mitochondria, which could be prevented by molecular (dominant-negative caspase-9) and pharmacologic (zVAD-fmk) caspase inhibitors and overexpression of Bcl-2. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 184-192 BCL2 apoptosis regulator Homo sapiens 235-240 12631622-4 2003 In this study we investigated effects of Bcl-2 and Raf-1 on doxorubicin-induced growth inhibition of MCF-7 breast cancer cells. Doxorubicin 60-71 BCL2 apoptosis regulator Homo sapiens 41-46 12606514-8 2003 In addition, palmitic acid decreased Bcl-2 expression and induced release of cytochrome c from the mitochondria into the cytosol, which was prevented by fumonisin B1 and by oleic acid. Palmitic Acid 13-26 BCL2 apoptosis regulator Homo sapiens 37-42 12606514-11 2003 The deleterious effect of palmitic acid is mediated via formation of ceramide and activation of the apoptotic mitochondrial pathway, whereas Bcl-2 may contribute to the protective effect of monounsaturated fatty acids. Fatty Acids, Monounsaturated 190-217 BCL2 apoptosis regulator Homo sapiens 141-146 12751376-8 2003 Following treatment with either tamoxifen or letrozole, variable effects were observed on the apoptotic index and expression of Bcl-2. Letrozole 45-54 BCL2 apoptosis regulator Homo sapiens 128-133 12669953-3 2003 Doxorubicin (DOX) and antisense oligonucleotides (ASO) targeted to MDR1 and BCL-2 mRNA were combined in a solution within one liposomal drug delivery system (LDDS) in different combination series. Oligonucleotides 32-48 BCL2 apoptosis regulator Homo sapiens 76-81 12603597-8 2003 Ethanol decreased Jurkat cell expression of Bcl-2, whereas ethanol increased Jurkat cell expression of Bax. Ethanol 0-7 BCL2 apoptosis regulator Homo sapiens 44-49 12579337-0 2003 Telomerase activity, expression of Bcl-2 and cell cycle regulation in doxorubicin resistant gastric carcinoma cell lines. Doxorubicin 70-81 BCL2 apoptosis regulator Homo sapiens 35-40 12579337-4 2003 Bcl-2 protein expression, which is known to regulate telomerase activity, did not change in doxorubicin resistant cell lines but decreased in parent cell lines by doxorubicin treatment. Doxorubicin 163-174 BCL2 apoptosis regulator Homo sapiens 0-5 12579337-10 2003 Therefore, relative resistance to doxorubicin may be related to high levels of bcl-2 or intact cell cycle and consequently high telomerase activity. Doxorubicin 34-45 BCL2 apoptosis regulator Homo sapiens 79-84 12822513-1 2003 We studied the possibility of increasing sensitization of drug-resistant MDA435/LCC6 multidrug-resistant (MDR) human breast cancer cells to doxorubicin (DOX) by increasing cellular drug retention with P-glycoprotein (P-gp) inhibitor PSC833 in combination with induction of cell death through down-regulation of Bcl-2 protein using Bcl-2 antisense (G3139). Doxorubicin 140-151 BCL2 apoptosis regulator Homo sapiens 311-316 12822513-1 2003 We studied the possibility of increasing sensitization of drug-resistant MDA435/LCC6 multidrug-resistant (MDR) human breast cancer cells to doxorubicin (DOX) by increasing cellular drug retention with P-glycoprotein (P-gp) inhibitor PSC833 in combination with induction of cell death through down-regulation of Bcl-2 protein using Bcl-2 antisense (G3139). Doxorubicin 140-151 BCL2 apoptosis regulator Homo sapiens 331-336 12822513-1 2003 We studied the possibility of increasing sensitization of drug-resistant MDA435/LCC6 multidrug-resistant (MDR) human breast cancer cells to doxorubicin (DOX) by increasing cellular drug retention with P-glycoprotein (P-gp) inhibitor PSC833 in combination with induction of cell death through down-regulation of Bcl-2 protein using Bcl-2 antisense (G3139). Doxorubicin 153-156 BCL2 apoptosis regulator Homo sapiens 311-316 12822513-1 2003 We studied the possibility of increasing sensitization of drug-resistant MDA435/LCC6 multidrug-resistant (MDR) human breast cancer cells to doxorubicin (DOX) by increasing cellular drug retention with P-glycoprotein (P-gp) inhibitor PSC833 in combination with induction of cell death through down-regulation of Bcl-2 protein using Bcl-2 antisense (G3139). Doxorubicin 153-156 BCL2 apoptosis regulator Homo sapiens 331-336 12576871-10 2003 In bcl-2 over expressing prostate cancer cells there was significant suppression of doxazosin induced anoikis and cell invasion compared with neocontrol transfectants (p <0.05). Doxazosin 84-93 BCL2 apoptosis regulator Homo sapiens 3-8 12576871-13 2003 Furthermore, bcl-2 resulted in partial reversion of the doxazosin induced VEGF decrease. Doxazosin 56-65 BCL2 apoptosis regulator Homo sapiens 13-18 12576871-14 2003 CONCLUSIONS: These findings demonstrate that the quinazoline derived alpha1-antagonists doxazosin and terazosin but not sulfonamide based tamsulosin induce anoikis and inhibit prostate cancer cell invasion, an effect that is antagonized by bcl-2. Quinazolines 49-60 BCL2 apoptosis regulator Homo sapiens 240-245 12576871-14 2003 CONCLUSIONS: These findings demonstrate that the quinazoline derived alpha1-antagonists doxazosin and terazosin but not sulfonamide based tamsulosin induce anoikis and inhibit prostate cancer cell invasion, an effect that is antagonized by bcl-2. Doxazosin 88-97 BCL2 apoptosis regulator Homo sapiens 240-245 12576871-14 2003 CONCLUSIONS: These findings demonstrate that the quinazoline derived alpha1-antagonists doxazosin and terazosin but not sulfonamide based tamsulosin induce anoikis and inhibit prostate cancer cell invasion, an effect that is antagonized by bcl-2. Terazosin 102-111 BCL2 apoptosis regulator Homo sapiens 240-245 12630918-9 2003 Increased apoptosis after dexamethasone treatment was accompanied by increased immunoreactivity for caspase-3 and decreased immunoreactivity for the anti-apoptotic proteins Bcl-2 and Bcl-x, which further supports our apoptosis results. Dexamethasone 26-39 BCL2 apoptosis regulator Homo sapiens 173-178 12669953-0 2003 Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Oligonucleotides 120-136 BCL2 apoptosis regulator Homo sapiens 95-100 12669953-0 2003 Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Doxorubicin 173-184 BCL2 apoptosis regulator Homo sapiens 95-100 12669953-3 2003 Doxorubicin (DOX) and antisense oligonucleotides (ASO) targeted to MDR1 and BCL-2 mRNA were combined in a solution within one liposomal drug delivery system (LDDS) in different combination series. Oligonucleotides, Antisense 50-53 BCL2 apoptosis regulator Homo sapiens 76-81 12669953-6 2003 RESULTS: The combination of DOX and ASO targeted to MDR1 and BCL-2 mRNA in one LDDS exhibited a dramatic increase in the anticancer action of DOX. Doxorubicin 28-31 BCL2 apoptosis regulator Homo sapiens 61-66 12669953-6 2003 RESULTS: The combination of DOX and ASO targeted to MDR1 and BCL-2 mRNA in one LDDS exhibited a dramatic increase in the anticancer action of DOX. Oligonucleotides, Antisense 36-39 BCL2 apoptosis regulator Homo sapiens 61-66 12926551-9 2003 Semi-quantitative RT-PCR showed a decrease in bcl-2 and an increase in bax, c-myc and p65 expression in HL-60 cells treated with carboplatin in combination with amifostine as compared to the cells treated only with carboplatin. Carboplatin 129-140 BCL2 apoptosis regulator Homo sapiens 46-51 12926551-9 2003 Semi-quantitative RT-PCR showed a decrease in bcl-2 and an increase in bax, c-myc and p65 expression in HL-60 cells treated with carboplatin in combination with amifostine as compared to the cells treated only with carboplatin. Amifostine 161-171 BCL2 apoptosis regulator Homo sapiens 46-51 12669953-6 2003 RESULTS: The combination of DOX and ASO targeted to MDR1 and BCL-2 mRNA in one LDDS exhibited a dramatic increase in the anticancer action of DOX. Doxorubicin 142-145 BCL2 apoptosis regulator Homo sapiens 61-66 12566069-4 2003 However, expression of Bcl-2 or Bcl-x(L) prevents ROS production and subsequent loss of deltapsi(m), thereby inhibiting apoptotic cell death. Reactive Oxygen Species 50-53 BCL2 apoptosis regulator Homo sapiens 23-28 12632486-8 2003 Immunohistochemical staining showed that after the treatment of EC-9706 cells with resveratrol (10 mmol/L) for 24 to 96 hours, the PRs of Bcl-2 proteins were apparently reduced with treated time (P<0.05) and the PRs of Bax proteins were apparently increased with treated time (P<0.05). Resveratrol 83-94 BCL2 apoptosis regulator Homo sapiens 138-143 12632493-7 2003 Paclitaxel could reduce the expression of apoptosis-regulated gene Bcl-2, and improve the expression of apoptosis-regulated gene Bax. Paclitaxel 0-10 BCL2 apoptosis regulator Homo sapiens 67-72 12477721-0 2003 Bcl-2, via its BH4 domain, blocks apoptotic signaling mediated by mitochondrial Ras. sapropterin 15-18 BCL2 apoptosis regulator Homo sapiens 0-5 12566077-2 2003 This study explored the potential of irofulven (hydroxymethylacylfulvene, HMAF, MGI 114, NSC 683863), a novel DNA- and protein-reactive anticancer drug, to overcome the anti-apoptotic properties of Bcl-2 in HeLa cells with controlled Bcl-2 overexpression. irofulven 37-46 BCL2 apoptosis regulator Homo sapiens 198-203 12566077-2 2003 This study explored the potential of irofulven (hydroxymethylacylfulvene, HMAF, MGI 114, NSC 683863), a novel DNA- and protein-reactive anticancer drug, to overcome the anti-apoptotic properties of Bcl-2 in HeLa cells with controlled Bcl-2 overexpression. irofulven 37-46 BCL2 apoptosis regulator Homo sapiens 234-239 12566077-2 2003 This study explored the potential of irofulven (hydroxymethylacylfulvene, HMAF, MGI 114, NSC 683863), a novel DNA- and protein-reactive anticancer drug, to overcome the anti-apoptotic properties of Bcl-2 in HeLa cells with controlled Bcl-2 overexpression. irofulven 48-72 BCL2 apoptosis regulator Homo sapiens 198-203 12566077-5 2003 Both Bcl-2-dependent and -independent responses to irofulven were abrogated by a broad-spectrum caspase inhibitor. irofulven 51-60 BCL2 apoptosis regulator Homo sapiens 5-10 12566077-7 2003 In comparison, Bcl-2 overexpression drastically reduced apoptotic DNA fragmentation by etoposide, acting via topoisomerase II-mediated DNA damage, but had no effect on apoptotic DNA fragmentation by helenalin A, which reacts with proteins but not DNA. Etoposide 87-96 BCL2 apoptosis regulator Homo sapiens 15-20 12566077-8 2003 Irofulven retains its pro-apoptotic and growth inhibitory potential in cell lines that have naturally high Bcl-2 expression. irofulven 0-9 BCL2 apoptosis regulator Homo sapiens 107-112 12566077-9 2003 Collectively, the results implicate multiple mechanisms of apoptosis induction by irofulven, which may differ in time course and Bcl-2 dependence. irofulven 82-91 BCL2 apoptosis regulator Homo sapiens 129-134 12628584-5 2003 Western blot analysis demonstrated that p53 and Bax expression were dramatically increased at the same time points, whereas Bcl-2 expression was significantly reduced at all time points after deltamethrin treatment. decamethrin 192-204 BCL2 apoptosis regulator Homo sapiens 124-129 12628584-6 2003 Further, we found that nitric oxide synthase inhibitor N(G)-nitro-L-arginine prevented deltamethrin-induced neuronal apoptosis and altered expression of p53, Bax, and Bcl-2. Nitric Oxide 23-35 BCL2 apoptosis regulator Homo sapiens 167-172 12431997-0 2003 BCL-2 improves oxidative phosphorylation and modulates adenine nucleotide translocation in mitochondria of cells harboring mutant mtDNA. Adenine Nucleotides 55-73 BCL2 apoptosis regulator Homo sapiens 0-5 12431997-1 2003 Members of the BCL-2-related antiapoptotic family of proteins have been shown previously to regulate ATP/ADP exchange across the mitochondrial membranes and to prevent the loss of coupled mitochondrial respiration during apoptosis. Adenosine Triphosphate 101-104 BCL2 apoptosis regulator Homo sapiens 15-20 12431997-1 2003 Members of the BCL-2-related antiapoptotic family of proteins have been shown previously to regulate ATP/ADP exchange across the mitochondrial membranes and to prevent the loss of coupled mitochondrial respiration during apoptosis. Adenosine Diphosphate 105-108 BCL2 apoptosis regulator Homo sapiens 15-20 12431997-3 2003 The effect of BCL-2 overexpression in mutated cells was independent from apoptosis and was presumably associated with a modulation of adenine nucleotide exchange between mitochondria and cytosol. Adenine Nucleotides 134-152 BCL2 apoptosis regulator Homo sapiens 14-19 12431997-4 2003 These results suggest that BCL-2 can regulate respiratory functions in response to mitochondrial distress by regulating the levels of adenine nucleotides. Adenine Nucleotides 134-153 BCL2 apoptosis regulator Homo sapiens 27-32 12628584-6 2003 Further, we found that nitric oxide synthase inhibitor N(G)-nitro-L-arginine prevented deltamethrin-induced neuronal apoptosis and altered expression of p53, Bax, and Bcl-2. Nitroarginine 55-76 BCL2 apoptosis regulator Homo sapiens 167-172 12628584-6 2003 Further, we found that nitric oxide synthase inhibitor N(G)-nitro-L-arginine prevented deltamethrin-induced neuronal apoptosis and altered expression of p53, Bax, and Bcl-2. decamethrin 87-99 BCL2 apoptosis regulator Homo sapiens 167-172 12536078-4 2003 Cisplatin upregulated the expression of both death and decoy TRAIL receptors, as well as of TRAF5 and -6, downregulated the anti-apoptotic proteins, Bcl-2, and induced activation of caspases-3, -8 and -9. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 149-154 12446691-10 2003 Interestingly, the cytosolic calcium chelator BAPTA-AM and K-201 protected RA-treated chondrocytes from undergoing apoptotic changes, as indicated by higher bcl-2 gene expression, reduced caspase-3 activity, and the percentage of TUNEL-positive cells. Calcium 29-36 BCL2 apoptosis regulator Homo sapiens 157-162 12446691-10 2003 Interestingly, the cytosolic calcium chelator BAPTA-AM and K-201 protected RA-treated chondrocytes from undergoing apoptotic changes, as indicated by higher bcl-2 gene expression, reduced caspase-3 activity, and the percentage of TUNEL-positive cells. 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester 46-54 BCL2 apoptosis regulator Homo sapiens 157-162 12446691-10 2003 Interestingly, the cytosolic calcium chelator BAPTA-AM and K-201 protected RA-treated chondrocytes from undergoing apoptotic changes, as indicated by higher bcl-2 gene expression, reduced caspase-3 activity, and the percentage of TUNEL-positive cells. K201 compound 59-64 BCL2 apoptosis regulator Homo sapiens 157-162 12446691-10 2003 Interestingly, the cytosolic calcium chelator BAPTA-AM and K-201 protected RA-treated chondrocytes from undergoing apoptotic changes, as indicated by higher bcl-2 gene expression, reduced caspase-3 activity, and the percentage of TUNEL-positive cells. Tretinoin 75-77 BCL2 apoptosis regulator Homo sapiens 157-162 12464623-9 2003 Our study also provides evidence for p90(S6) ribosomal kinase as a point of convergence between the two signaling pathways resulting in the phosphorylation of the pro-apoptotic Bcl-2 family member Bad at serine 112. Serine 204-210 BCL2 apoptosis regulator Homo sapiens 177-182 12536078-6 2003 Cisplatin/Apo2L/TRAIL combination resulted in further downregulation of expression of anti-apoptotic proteins, Bcl-2 and Bcl-xL, as well as an increase in mitochondrial permeability transition and activation of caspases-3, -8, and -10. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 111-116 12393461-5 2003 Curcumin also down-regulated the expression of NF-kappaB-regulated gene products, including IkappaBalpha, Bcl-2, Bcl-x(L), cyclin D1, and interleukin-6. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 106-111 12576925-2 2003 Docetaxel has been shown to be more potent than paclitaxel in inducing bcl-2 phosphorylation and apoptosis and is clinically active in some paclitaxel-resistant breast tumors. Docetaxel 0-9 BCL2 apoptosis regulator Homo sapiens 71-76 12576925-2 2003 Docetaxel has been shown to be more potent than paclitaxel in inducing bcl-2 phosphorylation and apoptosis and is clinically active in some paclitaxel-resistant breast tumors. Paclitaxel 48-58 BCL2 apoptosis regulator Homo sapiens 71-76 12546725-12 2003 The expression of bcl-2 protein was down-regulated after treatment with AraC in combination with EGCG. epigallocatechin gallate 97-101 BCL2 apoptosis regulator Homo sapiens 18-23 12576463-14 2003 In addition, Bcl-2/Bax interaction was diminished after addition of phytosphingosine. phytosphingosine 68-84 BCL2 apoptosis regulator Homo sapiens 13-18 12700646-3 2003 Database searches revealed Bfk, an unusual novel member of the Bcl-2 family that contains a BH2 and BH3 region but not BH1 or BH4. bh2 92-95 BCL2 apoptosis regulator Homo sapiens 63-68 12700646-3 2003 Database searches revealed Bfk, an unusual novel member of the Bcl-2 family that contains a BH2 and BH3 region but not BH1 or BH4. BH 3 100-103 BCL2 apoptosis regulator Homo sapiens 63-68 12536201-8 2003 Combined RNAi for c-raf and bcl-2 induced apoptosis in HL-60, U937, and THP-1 cells and increased chemosensitivity to etoposide and daunorubicin. Etoposide 118-127 BCL2 apoptosis regulator Homo sapiens 28-33 12536201-8 2003 Combined RNAi for c-raf and bcl-2 induced apoptosis in HL-60, U937, and THP-1 cells and increased chemosensitivity to etoposide and daunorubicin. Daunorubicin 132-144 BCL2 apoptosis regulator Homo sapiens 28-33 12667305-0 2003 Targeting bcl-2 by triplex-forming oligonucleotide--a promising carrier for gene-radiotherapy. triplex-forming oligonucleotide 19-50 BCL2 apoptosis regulator Homo sapiens 10-15 12667305-3 2003 Here, we attempted to apply this antigen strategy using a TFO incorporated with a Conversion-electron-emitter, (99m)technetium, to target bcl-2 gene, the prototypical inhibitor of apoptosis. tfo 58-61 BCL2 apoptosis regulator Homo sapiens 138-143 12667305-3 2003 Here, we attempted to apply this antigen strategy using a TFO incorporated with a Conversion-electron-emitter, (99m)technetium, to target bcl-2 gene, the prototypical inhibitor of apoptosis. Technetium 116-126 BCL2 apoptosis regulator Homo sapiens 138-143 12667305-4 2003 In the bcl-2 promoter region, we found two TFO binding sites which bind corresponding TFOs with very high specificity and affinity. tfo 43-46 BCL2 apoptosis regulator Homo sapiens 7-12 12667305-4 2003 In the bcl-2 promoter region, we found two TFO binding sites which bind corresponding TFOs with very high specificity and affinity. tfos 86-90 BCL2 apoptosis regulator Homo sapiens 7-12 12667305-7 2003 In addition, (99m)technetium-conjugated TFOs were found to form a stable triplex and to inhibit bcl-2 gene transcription in vitro. Technetium 18-28 BCL2 apoptosis regulator Homo sapiens 96-101 12667305-7 2003 In addition, (99m)technetium-conjugated TFOs were found to form a stable triplex and to inhibit bcl-2 gene transcription in vitro. tfos 40-44 BCL2 apoptosis regulator Homo sapiens 96-101 12667305-8 2003 Our results suggest a promising application of this triplex-forming oligonucleotide based Conversion-electron-emitter mediated gene radiotherapy in diseases related to bcl-2 overexpression. triplex-forming oligonucleotide 52-83 BCL2 apoptosis regulator Homo sapiens 168-173 12700646-0 2003 Bfk: a novel weakly proapoptotic member of the Bcl-2 protein family with a BH3 and a BH2 region. bh2 85-88 BCL2 apoptosis regulator Homo sapiens 47-52 12604404-12 2003 INTERPRETATION AND CONCLUSIONS: B-cells from a considerable proportion of CLL cases studied (11/20) are more prone to fludarabine-induced apoptosis after CD40 triggering; accordingly Bcl-2 expression was lower in activated cells. fludarabine 118-129 BCL2 apoptosis regulator Homo sapiens 183-188 12574204-7 2003 To investigate a cause and effect relationship between these two phenomena, we evaluated the effects of RU486 treatment on the expression of two apoptosis-related genes, bax and bcl-2, known to be regulated through NF-kappa B binding on their promoter. Mifepristone 104-109 BCL2 apoptosis regulator Homo sapiens 178-183 12527942-6 2003 Furthermore, methionine restriction resulted in cleavage of BID and reduction in Bcl-2 levels in both cell lines. Methionine 13-23 BCL2 apoptosis regulator Homo sapiens 81-86 12527942-9 2003 Cleavage of BID and decreased expression of Bcl-2 upon methionine deprivation may be the underlying mechanism to stimulate release of cytochrome c from mitochondria. Methionine 55-65 BCL2 apoptosis regulator Homo sapiens 44-49 12644056-0 2003 Bcl-2 prevents doxorubicin-induced apoptosis of human liver cancer cells. Doxorubicin 15-26 BCL2 apoptosis regulator Homo sapiens 0-5 12644056-7 2003 These results suggest that the overexpression of Bcl-2 renders human HCC cells resistant to doxorubicin-induced cytotoxicity. Doxorubicin 92-103 BCL2 apoptosis regulator Homo sapiens 49-54 12574204-8 2003 RT-PCR demonstrated that RU486 significantly induced bax mRNA levels, while suppressing mRNA of bcl-2. Mifepristone 25-30 BCL2 apoptosis regulator Homo sapiens 96-101 12574204-11 2003 This study demonstrates that the inhibition of growth and apoptosis of human endometrial cells by RU486 involves stimulation of NF-kappa B binding with subsequent modulation of apoptosis regulatory genes bax and bcl-2. Mifepristone 98-103 BCL2 apoptosis regulator Homo sapiens 212-217 12591359-0 2003 Apoptosis and expression of BCL-2 and BAX in cyclosporine-induced experimental renal fibrosis. Cyclosporine 45-57 BCL2 apoptosis regulator Homo sapiens 28-33 12581565-4 2003 We chose to study the pathology of patients in this specific trial because both docetaxel and vinorelbine phosphorylate bcl-2 and we hypothesized that this mechanism may affect clinical outcome. Docetaxel 80-89 BCL2 apoptosis regulator Homo sapiens 120-125 12581565-4 2003 We chose to study the pathology of patients in this specific trial because both docetaxel and vinorelbine phosphorylate bcl-2 and we hypothesized that this mechanism may affect clinical outcome. Vinorelbine 94-105 BCL2 apoptosis regulator Homo sapiens 120-125 12542519-5 2003 Staurosporine, a potent inhibitor of phospholipid Ca2+-dependent protein kinase, increased externalized phosphatidylserine levels on SZ95 sebocytes, detected by annexin V/propidium iodide flow cytometry, as early as after 1 h, whereas dose-dependent reduction of bcl-2 mRNA and protein expression, enhanced DNA fragmentation, and increased caspase 3 levels, detected by caspase 3 inhibitor/propidium iodide flow cytometry, were found after 6 h of treatment. Staurosporine 0-13 BCL2 apoptosis regulator Homo sapiens 263-268 12544353-0 2003 Enhancement of diethylstilbestrol induced cytotoxicity by bcl-2 antisense oligodeoxynucleotides and a glutathione depletor for prostate cancer. Diethylstilbestrol 15-33 BCL2 apoptosis regulator Homo sapiens 58-63 12544353-0 2003 Enhancement of diethylstilbestrol induced cytotoxicity by bcl-2 antisense oligodeoxynucleotides and a glutathione depletor for prostate cancer. Oligodeoxyribonucleotides 74-95 BCL2 apoptosis regulator Homo sapiens 58-63 12544353-1 2003 PURPOSE: Bcl-2 has been shown to prolong cancer cell survival by blocking apoptosis and have the function of scavenging reactive oxygen species. Reactive Oxygen Species 120-143 BCL2 apoptosis regulator Homo sapiens 9-14 12544353-12 2003 CONCLUSIONS: Antisense bcl-2 oligodeoxynucleotides significantly enhanced DES induced cytotoxicity in hormone independent prostate cancer cells through the apoptotic pathway independent of augmented reactive oxygen species generation, whereas the glutathione depletor augmented cytotoxicity and reactive oxygen species generation. Diethylstilbestrol 74-77 BCL2 apoptosis regulator Homo sapiens 23-28 12544353-12 2003 CONCLUSIONS: Antisense bcl-2 oligodeoxynucleotides significantly enhanced DES induced cytotoxicity in hormone independent prostate cancer cells through the apoptotic pathway independent of augmented reactive oxygen species generation, whereas the glutathione depletor augmented cytotoxicity and reactive oxygen species generation. Reactive Oxygen Species 199-222 BCL2 apoptosis regulator Homo sapiens 23-28 12544353-12 2003 CONCLUSIONS: Antisense bcl-2 oligodeoxynucleotides significantly enhanced DES induced cytotoxicity in hormone independent prostate cancer cells through the apoptotic pathway independent of augmented reactive oxygen species generation, whereas the glutathione depletor augmented cytotoxicity and reactive oxygen species generation. Glutathione 247-258 BCL2 apoptosis regulator Homo sapiens 23-28 12544353-12 2003 CONCLUSIONS: Antisense bcl-2 oligodeoxynucleotides significantly enhanced DES induced cytotoxicity in hormone independent prostate cancer cells through the apoptotic pathway independent of augmented reactive oxygen species generation, whereas the glutathione depletor augmented cytotoxicity and reactive oxygen species generation. Reactive Oxygen Species 295-318 BCL2 apoptosis regulator Homo sapiens 23-28 12783683-1 2003 OBJECTIVE: To evaluate the chemotherapeutic sensitivity of uveal melanoma in vitro and reverse its drug resistance by the delivery of bcl-2 antisense oligodeoxynucleotide (AS-ODN). Oligodeoxyribonucleotides 150-170 BCL2 apoptosis regulator Homo sapiens 134-139 12667288-0 2003 [Design of antisense oligodeoxynucleotide targeting at bcl-2 mRNA and observation on its effect on the sensitivity of leukemia cells to arabinosyl cytosine]. Oligodeoxyribonucleotides 21-41 BCL2 apoptosis regulator Homo sapiens 55-60 12667288-0 2003 [Design of antisense oligodeoxynucleotide targeting at bcl-2 mRNA and observation on its effect on the sensitivity of leukemia cells to arabinosyl cytosine]. Cytarabine 136-155 BCL2 apoptosis regulator Homo sapiens 55-60 12667288-1 2003 The effective target sites for antisense oligodeoxynucleotides (AS-ODN) on bcl-2 mRNA, except its start region, were looked for and their effects on the sensitivity of HL-60 and K562 leukemia cells to arabinosyl cytosine (Ara-C) were observed. Oligodeoxyribonucleotides 41-62 BCL2 apoptosis regulator Homo sapiens 75-80 12667288-1 2003 The effective target sites for antisense oligodeoxynucleotides (AS-ODN) on bcl-2 mRNA, except its start region, were looked for and their effects on the sensitivity of HL-60 and K562 leukemia cells to arabinosyl cytosine (Ara-C) were observed. Cytarabine 201-220 BCL2 apoptosis regulator Homo sapiens 75-80 12667288-1 2003 The effective target sites for antisense oligodeoxynucleotides (AS-ODN) on bcl-2 mRNA, except its start region, were looked for and their effects on the sensitivity of HL-60 and K562 leukemia cells to arabinosyl cytosine (Ara-C) were observed. Cytarabine 222-227 BCL2 apoptosis regulator Homo sapiens 75-80 12667288-2 2003 The secondary structure of bcl-2 mRNA was simulated with RNAstructure microsoftware, and AS-ODNs, targeting at some sites, were designed and synthesizd with phosphorothioate modifying. Parathion 157-173 BCL2 apoptosis regulator Homo sapiens 27-32 12667288-4 2003 The results showed that 10 micro mol/L bcl-2 AS-ODN combined with Ara-C inhibited the expression of bcl-2 protein, increased apoptosis in HL-60 and K562 cells and decresed IC(50) of Ara-C significantly. Cytarabine 66-71 BCL2 apoptosis regulator Homo sapiens 39-44 12667288-4 2003 The results showed that 10 micro mol/L bcl-2 AS-ODN combined with Ara-C inhibited the expression of bcl-2 protein, increased apoptosis in HL-60 and K562 cells and decresed IC(50) of Ara-C significantly. Cytarabine 66-71 BCL2 apoptosis regulator Homo sapiens 100-105 12667288-4 2003 The results showed that 10 micro mol/L bcl-2 AS-ODN combined with Ara-C inhibited the expression of bcl-2 protein, increased apoptosis in HL-60 and K562 cells and decresed IC(50) of Ara-C significantly. Cytarabine 182-187 BCL2 apoptosis regulator Homo sapiens 39-44 12667289-7 2003 It is concluded that PDE inhibitor aminophylline may induce Raji cell growth inhibition, S phase arrest, apoptosis via down-regulation of Bcl-2 and reduction of mitochondrial transmembrane potential. Aminophylline 35-48 BCL2 apoptosis regulator Homo sapiens 138-143 12490308-0 2003 The combined treatment of aspirin and radiation induces apoptosis by the regulation of bcl-2 and caspase-3 in human cervical cancer cell. Aspirin 26-33 BCL2 apoptosis regulator Homo sapiens 87-92 12490308-11 2003 We have demonstrated that combined treatment of aspirin and radiation induces the antitumor effect mediated by bcl-2 and caspase-3 pathway in cervical cancer cells. Aspirin 48-55 BCL2 apoptosis regulator Homo sapiens 111-116 12697099-1 2003 OBJECTIVE: To study the in vitro antitumor activity of bcl-2 fully phosporothioated antisense oligodeoxynucleotide (bcl-2 ASODN) to malignant lymphoblastic cells. Oligodeoxyribonucleotides 94-114 BCL2 apoptosis regulator Homo sapiens 55-60 12697099-1 2003 OBJECTIVE: To study the in vitro antitumor activity of bcl-2 fully phosporothioated antisense oligodeoxynucleotide (bcl-2 ASODN) to malignant lymphoblastic cells. Oligodeoxyribonucleotides 94-114 BCL2 apoptosis regulator Homo sapiens 116-121 12697099-2 2003 METHODS: Proliferation and apoptosis of Raji cells incubated with bcl-2 ASODN were evaluated by MTT assay, flow cytometry (FCM) and electron microscopy, and the level of bcl-2 protein and mRNA expression were assessed by FCM and RT-PCR, respectively. monooxyethylene trimethylolpropane tristearate 96-99 BCL2 apoptosis regulator Homo sapiens 66-71 12697099-3 2003 RESULTS: MTT assay demonstrated that bcl-2 ASODN could partially inhibit the growth of Raji cells. monooxyethylene trimethylolpropane tristearate 9-12 BCL2 apoptosis regulator Homo sapiens 37-42 12783683-1 2003 OBJECTIVE: To evaluate the chemotherapeutic sensitivity of uveal melanoma in vitro and reverse its drug resistance by the delivery of bcl-2 antisense oligodeoxynucleotide (AS-ODN). as-odn 172-178 BCL2 apoptosis regulator Homo sapiens 134-139 12783701-7 2003 (2) The result of detecting apoptosis gene and proliferating cell nuclear antigen (PCNA) by immunohistochemical method showed that the expression of bcl-2, Fas and PCNA in the CAG rates induced by high-salt hot water was much higher than that of normal gastric mucosa (P < 0.05). Salts 202-206 BCL2 apoptosis regulator Homo sapiens 149-154 12783701-9 2003 After being given high-salt hot water intragastrically for 4, 8, 12 weeks, the bcl-2 protein expression rates were 12.5%, 16.7%, 76.5%, the Fas protein expression rates were 18.7%, 22.2% and 64.7%. Water 32-37 BCL2 apoptosis regulator Homo sapiens 79-84 12393493-0 2003 Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. oblimersen 39-44 BCL2 apoptosis regulator Homo sapiens 48-53 12393493-11 2003 This study demonstrates that G3139 can be administered safely with FLAG chemotherapy and down-regulate its target, Bcl-2. oblimersen 29-34 BCL2 apoptosis regulator Homo sapiens 115-120 12393493-0 2003 Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Oligonucleotides 64-79 BCL2 apoptosis regulator Homo sapiens 48-53 12543781-0 2003 Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Glutathione 14-25 BCL2 apoptosis regulator Homo sapiens 45-50 12421819-5 2003 Here we report that nicotine can induce Bcl2 phosphorylation exclusively at the serine 70 site in association with prolonged survival of SCLC H82 cells expressing wild-type but not the phosphorylation-deficient S70A mutant Bcl2 after treatment with chemotherapeutic agents (i.e. cisplatin or VP-16). Serine 80-86 BCL2 apoptosis regulator Homo sapiens 40-44 12421819-5 2003 Here we report that nicotine can induce Bcl2 phosphorylation exclusively at the serine 70 site in association with prolonged survival of SCLC H82 cells expressing wild-type but not the phosphorylation-deficient S70A mutant Bcl2 after treatment with chemotherapeutic agents (i.e. cisplatin or VP-16). Cisplatin 279-288 BCL2 apoptosis regulator Homo sapiens 40-44 12421819-6 2003 Nicotine induces activation of PKC alpha and the MAPKs ERK1 and ERK2, which are physiological Bcl2 kinases. Nicotine 0-8 BCL2 apoptosis regulator Homo sapiens 94-98 12421819-7 2003 Furthermore, ET-18-OCH3, a specific phospholipase C (PLC) inhibitor, blocks nicotine-stimulated Bcl2 phosphorylation and promotes apoptosis, suggesting that PLC may be involved in nicotine activation of Bcl2 kinases. edelfosine 13-23 BCL2 apoptosis regulator Homo sapiens 96-100 12421819-7 2003 Furthermore, ET-18-OCH3, a specific phospholipase C (PLC) inhibitor, blocks nicotine-stimulated Bcl2 phosphorylation and promotes apoptosis, suggesting that PLC may be involved in nicotine activation of Bcl2 kinases. edelfosine 13-23 BCL2 apoptosis regulator Homo sapiens 203-207 12421819-7 2003 Furthermore, ET-18-OCH3, a specific phospholipase C (PLC) inhibitor, blocks nicotine-stimulated Bcl2 phosphorylation and promotes apoptosis, suggesting that PLC may be involved in nicotine activation of Bcl2 kinases. Nicotine 76-84 BCL2 apoptosis regulator Homo sapiens 96-100 12421819-7 2003 Furthermore, ET-18-OCH3, a specific phospholipase C (PLC) inhibitor, blocks nicotine-stimulated Bcl2 phosphorylation and promotes apoptosis, suggesting that PLC may be involved in nicotine activation of Bcl2 kinases. Nicotine 76-84 BCL2 apoptosis regulator Homo sapiens 203-207 12421819-7 2003 Furthermore, ET-18-OCH3, a specific phospholipase C (PLC) inhibitor, blocks nicotine-stimulated Bcl2 phosphorylation and promotes apoptosis, suggesting that PLC may be involved in nicotine activation of Bcl2 kinases. Nicotine 180-188 BCL2 apoptosis regulator Homo sapiens 96-100 12421819-7 2003 Furthermore, ET-18-OCH3, a specific phospholipase C (PLC) inhibitor, blocks nicotine-stimulated Bcl2 phosphorylation and promotes apoptosis, suggesting that PLC may be involved in nicotine activation of Bcl2 kinases. Nicotine 180-188 BCL2 apoptosis regulator Homo sapiens 203-207 12421819-9 2003 Thus, nicotine-induced cell survival results, at least in part, from a mechanism that involves Bcl2 phosphorylation. Nicotine 6-14 BCL2 apoptosis regulator Homo sapiens 95-99 12421819-10 2003 Therefore, novel therapeutic strategies for lung cancer in which Bcl2 is expressed may be used to abrogate the anti-apoptotic activity of Bcl2 by inhibiting multiple upstream nicotine-activated pathways. Nicotine 175-183 BCL2 apoptosis regulator Homo sapiens 65-69 12421819-10 2003 Therefore, novel therapeutic strategies for lung cancer in which Bcl2 is expressed may be used to abrogate the anti-apoptotic activity of Bcl2 by inhibiting multiple upstream nicotine-activated pathways. Nicotine 175-183 BCL2 apoptosis regulator Homo sapiens 138-142 12543781-7 2003 Treatment of MCF-7 lines with buthionine sulfoximine, an inhibitor of glutathione synthesis, normalized glutathione levels in Bcl-2 and control transfectants and completely abrogated Bcl-2-mediated cisplatin resistance without affecting Bcl-2 expression. Glutathione 70-81 BCL2 apoptosis regulator Homo sapiens 183-188 12543781-7 2003 Treatment of MCF-7 lines with buthionine sulfoximine, an inhibitor of glutathione synthesis, normalized glutathione levels in Bcl-2 and control transfectants and completely abrogated Bcl-2-mediated cisplatin resistance without affecting Bcl-2 expression. Glutathione 70-81 BCL2 apoptosis regulator Homo sapiens 183-188 12543781-7 2003 Treatment of MCF-7 lines with buthionine sulfoximine, an inhibitor of glutathione synthesis, normalized glutathione levels in Bcl-2 and control transfectants and completely abrogated Bcl-2-mediated cisplatin resistance without affecting Bcl-2 expression. Glutathione 104-115 BCL2 apoptosis regulator Homo sapiens 126-131 12543781-7 2003 Treatment of MCF-7 lines with buthionine sulfoximine, an inhibitor of glutathione synthesis, normalized glutathione levels in Bcl-2 and control transfectants and completely abrogated Bcl-2-mediated cisplatin resistance without affecting Bcl-2 expression. Cisplatin 198-207 BCL2 apoptosis regulator Homo sapiens 183-188 12543781-7 2003 Treatment of MCF-7 lines with buthionine sulfoximine, an inhibitor of glutathione synthesis, normalized glutathione levels in Bcl-2 and control transfectants and completely abrogated Bcl-2-mediated cisplatin resistance without affecting Bcl-2 expression. Cisplatin 198-207 BCL2 apoptosis regulator Homo sapiens 183-188 12543781-9 2003 These results suggest that Bcl-2-mediated cisplatin resistance in MCF-7 cells is dependent on up-regulation of glutathione production, which contributes to cell survival by mechanisms independent of cisplatin inactivation or inhibition of DNA adduct formation. Cisplatin 42-51 BCL2 apoptosis regulator Homo sapiens 27-32 12543781-9 2003 These results suggest that Bcl-2-mediated cisplatin resistance in MCF-7 cells is dependent on up-regulation of glutathione production, which contributes to cell survival by mechanisms independent of cisplatin inactivation or inhibition of DNA adduct formation. Glutathione 111-122 BCL2 apoptosis regulator Homo sapiens 27-32 12543781-9 2003 These results suggest that Bcl-2-mediated cisplatin resistance in MCF-7 cells is dependent on up-regulation of glutathione production, which contributes to cell survival by mechanisms independent of cisplatin inactivation or inhibition of DNA adduct formation. Cisplatin 199-208 BCL2 apoptosis regulator Homo sapiens 27-32 12543781-10 2003 A similar dependence on glutathione for Bcl-2-mediated inhibition of cisplatin toxicity was confirmed in a second cell line, the lymphocytic precursor FL5.12. Glutathione 24-35 BCL2 apoptosis regulator Homo sapiens 40-45 12543781-10 2003 A similar dependence on glutathione for Bcl-2-mediated inhibition of cisplatin toxicity was confirmed in a second cell line, the lymphocytic precursor FL5.12. Cisplatin 69-78 BCL2 apoptosis regulator Homo sapiens 40-45 12421819-0 2003 A functional role for nicotine in Bcl2 phosphorylation and suppression of apoptosis. Nicotine 22-30 BCL2 apoptosis regulator Homo sapiens 34-38 12421819-4 2003 It is possible that nicotine may regulate Bcl2 to stimulate cell survival. Nicotine 20-28 BCL2 apoptosis regulator Homo sapiens 42-46 12421819-5 2003 Here we report that nicotine can induce Bcl2 phosphorylation exclusively at the serine 70 site in association with prolonged survival of SCLC H82 cells expressing wild-type but not the phosphorylation-deficient S70A mutant Bcl2 after treatment with chemotherapeutic agents (i.e. cisplatin or VP-16). Nicotine 20-28 BCL2 apoptosis regulator Homo sapiens 40-44 12421819-5 2003 Here we report that nicotine can induce Bcl2 phosphorylation exclusively at the serine 70 site in association with prolonged survival of SCLC H82 cells expressing wild-type but not the phosphorylation-deficient S70A mutant Bcl2 after treatment with chemotherapeutic agents (i.e. cisplatin or VP-16). Nicotine 20-28 BCL2 apoptosis regulator Homo sapiens 223-227 12504798-8 2003 Ap(4)A also induced a profound decrease in the level of the Bcl-2 protein. diadenosine tetraphosphate 0-6 BCL2 apoptosis regulator Homo sapiens 60-65 12543814-0 2003 Bcl-2 and Bax modulate adenine nucleotide translocase activity. Adenine Nucleotides 23-41 BCL2 apoptosis regulator Homo sapiens 0-5 12543814-1 2003 Bcl-2 is a prosurvival factor that reportedly prevents the nonspecific permeabilization of mitochondrial membranes, yet enhances specific ADP/ATP exchange by these organelles. Adenosine Diphosphate 138-141 BCL2 apoptosis regulator Homo sapiens 0-5 12543814-1 2003 Bcl-2 is a prosurvival factor that reportedly prevents the nonspecific permeabilization of mitochondrial membranes, yet enhances specific ADP/ATP exchange by these organelles. Adenosine Triphosphate 142-145 BCL2 apoptosis regulator Homo sapiens 0-5 12543814-2 2003 Here, we show that Bcl-2 enhances the ADP/ATP exchange in proteoliposomes containing the purified adenine nucleotide translocase (ANT) in isolated mitochondria and mitoplasts, as well as in intact cells in which mitochondrial matrix ATP was monitored continuously using a specific luciferase-based assay system. Adenosine Diphosphate 38-41 BCL2 apoptosis regulator Homo sapiens 19-24 12543814-2 2003 Here, we show that Bcl-2 enhances the ADP/ATP exchange in proteoliposomes containing the purified adenine nucleotide translocase (ANT) in isolated mitochondria and mitoplasts, as well as in intact cells in which mitochondrial matrix ATP was monitored continuously using a specific luciferase-based assay system. Adenosine Triphosphate 42-45 BCL2 apoptosis regulator Homo sapiens 19-24 12543814-2 2003 Here, we show that Bcl-2 enhances the ADP/ATP exchange in proteoliposomes containing the purified adenine nucleotide translocase (ANT) in isolated mitochondria and mitoplasts, as well as in intact cells in which mitochondrial matrix ATP was monitored continuously using a specific luciferase-based assay system. Adenine Nucleotides 98-116 BCL2 apoptosis regulator Homo sapiens 19-24 12543814-2 2003 Here, we show that Bcl-2 enhances the ADP/ATP exchange in proteoliposomes containing the purified adenine nucleotide translocase (ANT) in isolated mitochondria and mitoplasts, as well as in intact cells in which mitochondrial matrix ATP was monitored continuously using a specific luciferase-based assay system. Adenosine Triphosphate 233-236 BCL2 apoptosis regulator Homo sapiens 19-24 12543814-3 2003 Conversely, Bax, which displaces Bcl-2 from ANT in apoptotic cells, inhibits ADP/ATP exchange through a direct action on ANT. Adenosine Diphosphate 77-80 BCL2 apoptosis regulator Homo sapiens 33-38 12543814-3 2003 Conversely, Bax, which displaces Bcl-2 from ANT in apoptotic cells, inhibits ADP/ATP exchange through a direct action on ANT. Adenosine Triphosphate 81-84 BCL2 apoptosis regulator Homo sapiens 33-38 12543781-12 2003 Inhibition of glutathione synthesis or modulation of glutathione stores in tumors that overexpress Bcl-2 may comprise a novel anticancer strategy. Glutathione 14-25 BCL2 apoptosis regulator Homo sapiens 99-104 12543781-12 2003 Inhibition of glutathione synthesis or modulation of glutathione stores in tumors that overexpress Bcl-2 may comprise a novel anticancer strategy. Glutathione 53-64 BCL2 apoptosis regulator Homo sapiens 99-104 12543781-0 2003 Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cisplatin 60-69 BCL2 apoptosis regulator Homo sapiens 45-50 12543781-6 2003 Bcl-2 overexpression in MCF-7 cells was associated with a nearly 3-fold increase in cellular glutathione levels and with increased resistance to cell death after cisplatin exposure. Glutathione 93-104 BCL2 apoptosis regulator Homo sapiens 0-5 12543781-6 2003 Bcl-2 overexpression in MCF-7 cells was associated with a nearly 3-fold increase in cellular glutathione levels and with increased resistance to cell death after cisplatin exposure. Cisplatin 162-171 BCL2 apoptosis regulator Homo sapiens 0-5 12403774-11 2003 Most significantly, Bcl-2 overexpression prevents the staurosporine-induced hypersensitivity of the outer membrane to digitonin. Staurosporine 54-67 BCL2 apoptosis regulator Homo sapiens 20-25 12543781-7 2003 Treatment of MCF-7 lines with buthionine sulfoximine, an inhibitor of glutathione synthesis, normalized glutathione levels in Bcl-2 and control transfectants and completely abrogated Bcl-2-mediated cisplatin resistance without affecting Bcl-2 expression. Buthionine Sulfoximine 30-52 BCL2 apoptosis regulator Homo sapiens 126-131 12403774-11 2003 Most significantly, Bcl-2 overexpression prevents the staurosporine-induced hypersensitivity of the outer membrane to digitonin. Digitonin 118-127 BCL2 apoptosis regulator Homo sapiens 20-25 12543781-7 2003 Treatment of MCF-7 lines with buthionine sulfoximine, an inhibitor of glutathione synthesis, normalized glutathione levels in Bcl-2 and control transfectants and completely abrogated Bcl-2-mediated cisplatin resistance without affecting Bcl-2 expression. Buthionine Sulfoximine 30-52 BCL2 apoptosis regulator Homo sapiens 183-188 12543781-7 2003 Treatment of MCF-7 lines with buthionine sulfoximine, an inhibitor of glutathione synthesis, normalized glutathione levels in Bcl-2 and control transfectants and completely abrogated Bcl-2-mediated cisplatin resistance without affecting Bcl-2 expression. Buthionine Sulfoximine 30-52 BCL2 apoptosis regulator Homo sapiens 183-188 12495814-5 2003 Moreover, DA induced apoptotic cell death, which was observed by nuclear and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) staining and measurement of caspase-3 activity; this compound up-regulated apoptotic factor p53 while down-regulating anti-apoptotic factor Bcl-2. Dopamine 10-12 BCL2 apoptosis regulator Homo sapiens 295-300 12527913-0 2003 MAD2-induced sensitization to vincristine is associated with mitotic arrest and Raf/Bcl-2 phosphorylation in nasopharyngeal carcinoma cells. Vincristine 30-41 BCL2 apoptosis regulator Homo sapiens 84-89 12527913-6 2003 In addition, increased phosphorylation of Raf, MEK1/2 and Bcl-2 was observed in MAD2-overexpressing cells in response to vincristine. Vincristine 121-132 BCL2 apoptosis regulator Homo sapiens 58-63 12527913-7 2003 Furthermore, inhibition of phosphorylation of MEK1/2 by its inhibitor PD098059 led to reduced sensitivity to vincristine, which was associated with decreased Bcl-2 phosphorylation. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 70-78 BCL2 apoptosis regulator Homo sapiens 158-163 12527913-7 2003 Furthermore, inhibition of phosphorylation of MEK1/2 by its inhibitor PD098059 led to reduced sensitivity to vincristine, which was associated with decreased Bcl-2 phosphorylation. Vincristine 109-120 BCL2 apoptosis regulator Homo sapiens 158-163 15314975-0 2003 Expression of p21 and bcl-2 proteins in paraffin-embedded preparations of non-small cell lung cancer in stage IIIA after Etoposide and Cisplatin induced chemotherapy. Paraffin 40-48 BCL2 apoptosis regulator Homo sapiens 22-27 12488311-0 2003 Comment on "A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer", by C. M. Rudin et al. Oligonucleotides 54-69 BCL2 apoptosis regulator Homo sapiens 38-43 15314975-0 2003 Expression of p21 and bcl-2 proteins in paraffin-embedded preparations of non-small cell lung cancer in stage IIIA after Etoposide and Cisplatin induced chemotherapy. Cisplatin 135-144 BCL2 apoptosis regulator Homo sapiens 22-27 12522090-4 2003 Overexpression of Bcl-2 protected CH27 cells against magnolol-triggered apoptosis. magnolol 53-61 BCL2 apoptosis regulator Homo sapiens 18-23 12522090-9 2003 6 These results indicate that regulation of the Bcl-2 family, accumulation of cytosolic cytochrome c, and activation of caspase-9 and caspase-3 may be the effector mechanisms of magnolol-induced apoptosis. magnolol 178-186 BCL2 apoptosis regulator Homo sapiens 48-53 12455053-0 2003 An association of Bcl-2 phosphorylation and Bax localization with their functions after hyperthermia and paclitaxel treatment. Paclitaxel 105-115 BCL2 apoptosis regulator Homo sapiens 18-23 12708481-5 2003 In addition, evodiamine increased the expression of the apoptosis inducer Bax, but decreased the expression of the apoptosis suppressor Bcl-2 in mitochondria. evodiamine 13-23 BCL2 apoptosis regulator Homo sapiens 136-141 12708481-6 2003 Taken together, our data indicated that evodiamine alters the balance of Bcl-2 and Bax gene expression and induces apoptosis through the caspase pathway in HeLa cells. evodiamine 40-50 BCL2 apoptosis regulator Homo sapiens 73-78 12787726-3 2003 The cytotoxicity of DOX, Ant-BH3 and Ant-BH3 mixed in with DOX, mitochondrial transmembrane potential, expression of genes encoding pro- and antiapoptotic members of BCL-2 protein family and caspases, caspases activity, apoptosis induction were assessed in human ovarian carcinoma cells. ant-bh3 37-44 BCL2 apoptosis regulator Homo sapiens 166-171 12572700-13 2003 The balance of bax-bcl2 is important in the control of apoptosis as well as loss of fragile histidine triad expression. Histidine 92-101 BCL2 apoptosis regulator Homo sapiens 19-23 12764351-4 2003 RESULTS: The results showed that the two antisense oligodeoxynucleotides significantly reduced IC(50) levels for VP-16, Ara-c, DNA and As(2)O(3), inhibited bcl-2 gene expression and induced apoptosis of leukemic cells. Oligodeoxyribonucleotides 51-72 BCL2 apoptosis regulator Homo sapiens 156-161 14642526-0 2003 Bcl-2 antisense oligodeoxynucleotide increases the sensitivity of leukemic cells to arsenic trioxide. Oligodeoxyribonucleotides 16-36 BCL2 apoptosis regulator Homo sapiens 0-5 14642526-0 2003 Bcl-2 antisense oligodeoxynucleotide increases the sensitivity of leukemic cells to arsenic trioxide. Arsenic Trioxide 84-100 BCL2 apoptosis regulator Homo sapiens 0-5 14642526-1 2003 Cell culture, tissue chemistry and flow cytometry were used to determine whether antisense bcl-2 oligodeoxynucleotides enhanced the sensitivity of leukemia cells to arsenic trioxide. Arsenic Trioxide 165-181 BCL2 apoptosis regulator Homo sapiens 91-96 14642526-2 2003 A combination of arsenic trioxide with antisense bcl-2 oligodeoxynucleotides inhibited cell growth, induced apoptosis and induced bcl-2 protein expression in K562 and NB4 leukemic cells more significantly than either arsenic trioxide or the oligodeoxynucleotides on their own (P<0.01). Arsenic Trioxide 17-33 BCL2 apoptosis regulator Homo sapiens 130-135 14642526-2 2003 A combination of arsenic trioxide with antisense bcl-2 oligodeoxynucleotides inhibited cell growth, induced apoptosis and induced bcl-2 protein expression in K562 and NB4 leukemic cells more significantly than either arsenic trioxide or the oligodeoxynucleotides on their own (P<0.01). Arsenic Trioxide 217-233 BCL2 apoptosis regulator Homo sapiens 49-54 14642526-2 2003 A combination of arsenic trioxide with antisense bcl-2 oligodeoxynucleotides inhibited cell growth, induced apoptosis and induced bcl-2 protein expression in K562 and NB4 leukemic cells more significantly than either arsenic trioxide or the oligodeoxynucleotides on their own (P<0.01). Oligodeoxyribonucleotides 55-76 BCL2 apoptosis regulator Homo sapiens 49-54 14642526-2 2003 A combination of arsenic trioxide with antisense bcl-2 oligodeoxynucleotides inhibited cell growth, induced apoptosis and induced bcl-2 protein expression in K562 and NB4 leukemic cells more significantly than either arsenic trioxide or the oligodeoxynucleotides on their own (P<0.01). Oligodeoxyribonucleotides 55-76 BCL2 apoptosis regulator Homo sapiens 130-135 14642526-3 2003 Thus, bcl-2 antisense oligodeoxynucleotides increase the sensitivity of leukemic cells to arsenic trioxide. Oligodeoxyribonucleotides 22-43 BCL2 apoptosis regulator Homo sapiens 6-11 14642526-3 2003 Thus, bcl-2 antisense oligodeoxynucleotides increase the sensitivity of leukemic cells to arsenic trioxide. Arsenic Trioxide 90-106 BCL2 apoptosis regulator Homo sapiens 6-11 14633785-13 2003 Similar clinical trials with Bcl-2 ASO molecules alone and in combination with doxorubicin and dexamethasone or thalidomide showed promising results. 1,5-anhydroglucitol 35-38 BCL2 apoptosis regulator Homo sapiens 29-34 14633785-13 2003 Similar clinical trials with Bcl-2 ASO molecules alone and in combination with doxorubicin and dexamethasone or thalidomide showed promising results. Dexamethasone 95-108 BCL2 apoptosis regulator Homo sapiens 29-34 12469194-0 2003 Determination of the in vivo effects of prednisone on Bcl-2 family protein expression in childhood acute lymphoblastic leukemia. Prednisone 40-50 BCL2 apoptosis regulator Homo sapiens 54-59 12469194-2 2003 In 30 consecutive children with ALL treated with prednisone we determined changes in the expression of Bcl-2, Bax and Bcl-xl proteins in leukemic lymphoblasts and related these to clinical features and rate of prednisone-induced apoptosis. Prednisone 49-59 BCL2 apoptosis regulator Homo sapiens 103-108 12469194-2 2003 In 30 consecutive children with ALL treated with prednisone we determined changes in the expression of Bcl-2, Bax and Bcl-xl proteins in leukemic lymphoblasts and related these to clinical features and rate of prednisone-induced apoptosis. Prednisone 210-220 BCL2 apoptosis regulator Homo sapiens 103-108 12469194-5 2003 Prednisone treatment induced a decrease in Bcl-2 and Bcl-xl levels in 17 and 16 of the 28 patients, respectively, while Bax protein increased in 14 of the 21 patients. Prednisone 0-10 BCL2 apoptosis regulator Homo sapiens 43-48 12469198-12 2003 And Bcl-2 over-expression attenuates NPPA-induced apoptosis by inhibiting caspase-3 activation, and subsequently inhibits calpain autolysis and Bax cleavage. N-phenethyl-2-phenylacetamide 37-41 BCL2 apoptosis regulator Homo sapiens 4-9 12469202-1 2003 Bcl-2 in cancer cells was shown to be a potent indicator of 5-FU efficacy, but the protein in normal tissue cells appeared not to be a marker of 5-FU toxicity probably due to the functional alteration of Bcl-2 associated with cell senescence. Fluorouracil 60-64 BCL2 apoptosis regulator Homo sapiens 0-5 12455053-3 2003 Therefore, we focused on the localization and phosphorylation of Bcl-2 and Bax, key mediators of the apoptotic pathway, after hyperthermia and paclitaxel treatment of PC-10 squamous cell carcinoma cells that excessively expressed Bcl-2 and Bax in the cytoplasm. Paclitaxel 143-153 BCL2 apoptosis regulator Homo sapiens 65-70 12469202-0 2003 Bcl-2 in cancer and normal tissue cells as a prediction marker of response to 5-fluorouracil. Fluorouracil 78-92 BCL2 apoptosis regulator Homo sapiens 0-5 12455053-4 2003 Paclitaxel treatment markedly induced qualitative changes in Bcl-2, whereas hyperthermia did only quantitative changes in Bax. Paclitaxel 0-10 BCL2 apoptosis regulator Homo sapiens 61-66 12455053-6 2003 On the other hand, paclitaxel treatment induced dose- and time-dependent phosphorylation of Bcl-2. Paclitaxel 19-29 BCL2 apoptosis regulator Homo sapiens 92-97 12455053-11 2003 Our results suggest that the subcellular redistribution of Bax and the phosphorylation of Bcl-2 depend on the type of apoptosis inducers, such as hyperthermia and paclitaxel, and Bcl-2 has a central role in the decision of apoptotic outcome. Paclitaxel 163-173 BCL2 apoptosis regulator Homo sapiens 90-95 12618894-11 2003 The amount of Bcl-2 in TYK-nu cells was reduced by vitamin K(2), but not by GGO. Vitamin K 51-60 BCL2 apoptosis regulator Homo sapiens 14-19 12558990-3 2003 Down-regulation of both bcl-2 and bcl-xL expression in glioblastoma cell lines U87 and NS008 with bcl-2/bcl-xL bispecific antisense oligonucleotide resulted in spontaneous cell death. Oligonucleotides 132-147 BCL2 apoptosis regulator Homo sapiens 24-29 12724857-1 2003 Taxanes are known to activate several cellular signals including mitogen-activated protein kinase (MAPK) and nuclear factor kappa B (NF-kappa B), tyrosine phosphorylation of Shc, and serine phosphorylation of Bcl-2. Taxoids 0-7 BCL2 apoptosis regulator Homo sapiens 209-214 16233383-11 2003 The cytochrome P-450 activity per culture of 3-methyl-cholanthrene-treated HepG2-Bcl2 was double that of treated HepG2-mock. Methylcholanthrene 45-66 BCL2 apoptosis regulator Homo sapiens 81-85 12720479-3 2003 It is thus noteworthy that lithium and valproate have recently been demonstrated to robustly increase the expression of the cytoprotective protein bcl-2 (an abbreviation for the B-cell lymphoma/leukemia-2 gene) in the CNS in vivo and in cells of human neuronal origin. Lithium 27-34 BCL2 apoptosis regulator Homo sapiens 147-152 12720479-3 2003 It is thus noteworthy that lithium and valproate have recently been demonstrated to robustly increase the expression of the cytoprotective protein bcl-2 (an abbreviation for the B-cell lymphoma/leukemia-2 gene) in the CNS in vivo and in cells of human neuronal origin. Valproic Acid 39-48 BCL2 apoptosis regulator Homo sapiens 147-152 12518171-0 2003 H1-A extracted from Cordyceps sinensis suppresses the proliferation of human mesangial cells and promotes apoptosis, probably by inhibiting the tyrosine phosphorylation of Bcl-2 and Bcl-XL. Tyrosine 144-152 BCL2 apoptosis regulator Homo sapiens 172-177 12558990-3 2003 Down-regulation of both bcl-2 and bcl-xL expression in glioblastoma cell lines U87 and NS008 with bcl-2/bcl-xL bispecific antisense oligonucleotide resulted in spontaneous cell death. Oligonucleotides 132-147 BCL2 apoptosis regulator Homo sapiens 98-103 12558990-9 2003 These findings support a potential role of bcl-2/bcl-xL bispecifc antisense oligonucleotide therapy as a treatment strategy to enhance caspase-dependent cell death in patients with glioblastoma. Oligonucleotides 76-91 BCL2 apoptosis regulator Homo sapiens 43-48 12529680-1 2003 An antisense oligodeoxynucleotide (ODN) complementary to the first six codons of the Bcl-2 mRNA, G3139 (oblimersen sodium; Genasense), has been shown to downregulate Bcl-2 and produce responses in a variety of malignancies including drug-resistant lymphoma. Oligodeoxyribonucleotides 13-33 BCL2 apoptosis regulator Homo sapiens 85-90 12529680-1 2003 An antisense oligodeoxynucleotide (ODN) complementary to the first six codons of the Bcl-2 mRNA, G3139 (oblimersen sodium; Genasense), has been shown to downregulate Bcl-2 and produce responses in a variety of malignancies including drug-resistant lymphoma. Oligodeoxyribonucleotides 13-33 BCL2 apoptosis regulator Homo sapiens 166-171 12407771-0 2003 Induction of programmed cell death with an antisense Bcl-2 oligonucleotide. Oligonucleotides 59-74 BCL2 apoptosis regulator Homo sapiens 53-58 14716031-0 2003 Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer. gemcitabine 81-92 BCL2 apoptosis regulator Homo sapiens 21-26 14716031-0 2003 Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer. Cisplatin 97-106 BCL2 apoptosis regulator Homo sapiens 21-26 12617962-5 2003 Calcineuin-Bcl-2 interactions increased after exposure in vitro to excitotoxic agents and conditions of hypoxia/aglycia. calcineuin 0-10 BCL2 apoptosis regulator Homo sapiens 11-16 12488556-2 2003 Whereas bryostatin 1 and UCN-01 both markedly enhanced ara-C-induced mitochondrial injury (e.g., cytochrome c and Smac/DIABLO release, loss of mitochondrial membrane potential), caspase activation, and apoptosis, ectopic expression of an N-terminal loop-deleted Bcl-2 mutant protein protected cells from ara-C/UCN-01- but not ara-C/bryostatin 1-mediated lethality. bryostatin 1 8-20 BCL2 apoptosis regulator Homo sapiens 262-267 12488556-2 2003 Whereas bryostatin 1 and UCN-01 both markedly enhanced ara-C-induced mitochondrial injury (e.g., cytochrome c and Smac/DIABLO release, loss of mitochondrial membrane potential), caspase activation, and apoptosis, ectopic expression of an N-terminal loop-deleted Bcl-2 mutant protein protected cells from ara-C/UCN-01- but not ara-C/bryostatin 1-mediated lethality. 7-hydroxystaurosporine 25-31 BCL2 apoptosis regulator Homo sapiens 262-267 12488556-2 2003 Whereas bryostatin 1 and UCN-01 both markedly enhanced ara-C-induced mitochondrial injury (e.g., cytochrome c and Smac/DIABLO release, loss of mitochondrial membrane potential), caspase activation, and apoptosis, ectopic expression of an N-terminal loop-deleted Bcl-2 mutant protein protected cells from ara-C/UCN-01- but not ara-C/bryostatin 1-mediated lethality. Cytarabine 55-60 BCL2 apoptosis regulator Homo sapiens 262-267 14689061-1 2003 The aim of this study was to assess the possible relationship between the silver stained nucleolar organizer regions (AgNOR) and immunocytochemically detected p53 and bcl-2 proteins in ALL, AML, B-CLL and CML patients (adults and children) at the initial presentation. Silver 74-80 BCL2 apoptosis regulator Homo sapiens 167-172 12488548-0 2003 Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines. FTI 277 55-62 BCL2 apoptosis regulator Homo sapiens 72-77 12559097-11 2003 Higher levels of phosphorylated CREB and CRE-responsive genes such as bcl-2 may be responsible for lithium"s reported effects on neuronal survival. Lithium 99-106 BCL2 apoptosis regulator Homo sapiens 70-75 12617962-7 2003 A specific calcineurin inhibitor, FK-520, attenuated insult-induced increases in calcineurin-Bcl-2 interactions and augmented caspase-3 like activity. immunomycin 34-40 BCL2 apoptosis regulator Homo sapiens 93-98 14535829-4 2003 More importantly, we show that in both cell lines, Bcl-2 inhibits mitochondrial respiration and causes a decrease of the ATP/ADP ratio. Adenosine Triphosphate 121-124 BCL2 apoptosis regulator Homo sapiens 51-56 12759537-2 2003 The expression of the markers examined - Bcl-2, c-erbB-2, p53 - was detected in paraffin sections of the tumors by the streptavidin-biotin peroxidase method following heat-induced antigen retrieval, and the apoptosis rate was determined by the TUNEL method. Paraffin 80-88 BCL2 apoptosis regulator Homo sapiens 41-46 12791511-6 2003 In addition, isoflavone cytotoxicity correlated with downregulation of Bcl-2 and Bcl-XL expression. Isoflavones 13-23 BCL2 apoptosis regulator Homo sapiens 71-76 15000830-8 2003 However, if siRNA compounds targeting Bcl-2 were combined with the apoptosis-inducing chemotherapeutic agent cisplatin, a massive increase in apoptotic cell death compared with controls was observed. Cisplatin 109-118 BCL2 apoptosis regulator Homo sapiens 38-43 14535829-4 2003 More importantly, we show that in both cell lines, Bcl-2 inhibits mitochondrial respiration and causes a decrease of the ATP/ADP ratio. Adenosine Diphosphate 125-128 BCL2 apoptosis regulator Homo sapiens 51-56 14535829-6 2003 Based on this observation, we propose that the outcome of Bcl-2 expression is determined by the type of cellular ATP synthesis, namely that Bcl-2 causes apoptosis in cells relying on oxidative phosphorylation. Adenosine Triphosphate 113-116 BCL2 apoptosis regulator Homo sapiens 58-63 14535829-6 2003 Based on this observation, we propose that the outcome of Bcl-2 expression is determined by the type of cellular ATP synthesis, namely that Bcl-2 causes apoptosis in cells relying on oxidative phosphorylation. Adenosine Triphosphate 113-116 BCL2 apoptosis regulator Homo sapiens 140-145 16985955-5 2003 This article reviews the development of antisense oligonucleotides that inhibit the anti-apoptotic bcL-2 protein. Oligonucleotides 50-66 BCL2 apoptosis regulator Homo sapiens 99-104 12795055-3 2003 COX-2 appears to: (a) play a key role in the release and activity of proangiogenic proteins; (b) result in the production of eicosanoid products TXA2, PGI2, PGE2 that directly stimulate endothelial cell migration and angiogenesis in vivo, and (c) result in enhanced tumor cell, and possibly, vascular endothelial cell survival by upregulation of the antiapoptotic proteins Bcl-2 and/or activation of PI3K-Akt. Eicosanoids 125-135 BCL2 apoptosis regulator Homo sapiens 373-378 12795055-3 2003 COX-2 appears to: (a) play a key role in the release and activity of proangiogenic proteins; (b) result in the production of eicosanoid products TXA2, PGI2, PGE2 that directly stimulate endothelial cell migration and angiogenesis in vivo, and (c) result in enhanced tumor cell, and possibly, vascular endothelial cell survival by upregulation of the antiapoptotic proteins Bcl-2 and/or activation of PI3K-Akt. Dinoprostone 157-161 BCL2 apoptosis regulator Homo sapiens 373-378 12701214-22 2003 This lithium protection was correlated with up-regulation of cytoprotective Bcl-2 and down-regulation of apoptotic proteins p53 and Bax, and neurons showing DNA damage and caspase-3 activation. Lithium 5-12 BCL2 apoptosis regulator Homo sapiens 76-81 12518226-6 2003 Furthermore, carbachol also stimulated Bcl-2 promoter-driven luciferase gene expression in transfected SH-SY5Y cells. Carbachol 13-22 BCL2 apoptosis regulator Homo sapiens 39-44 12518226-4 2003 In the present study, it was found that carbachol not only activated MEK/ERK-1/2 signaling pathways, but also increased the expression levels of Bcl-2 and phospho-Bad proteins in human neuroblastoma SH-SY5Y cells. Carbachol 40-49 BCL2 apoptosis regulator Homo sapiens 145-150 12531556-6 2002 When apoptosis is blocked by overexpression of Bcl-2, oxLDL trigger necrosis through a calcium-dependent pathway. Calcium 87-94 BCL2 apoptosis regulator Homo sapiens 47-52 12566829-0 2003 Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy. Anthralin 132-141 BCL2 apoptosis regulator Homo sapiens 32-37 12566829-8 2003 Bcl-2 was detected only in basal layers of psoriatic epidermis following both petrolatum and anthralin application. Anthralin 93-102 BCL2 apoptosis regulator Homo sapiens 0-5 12531534-5 2002 Further evaluation of the apoptotic process revealed that NDGA and BFA induced a rapid dephosphorylation of BAD and decrease expression of Bcl-2. Brefeldin A 67-70 BCL2 apoptosis regulator Homo sapiens 139-144 12520732-8 2002 CONCLUSIONS: Cisplatin-resistance in human ovarian cancer cell lines may associated with the overexpression of anti-apoptotic protein bcl-2 and downregulation of caspase-3 activity, but not associated with the expression of bax and bcl-xs. Cisplatin 13-22 BCL2 apoptosis regulator Homo sapiens 134-139 12466961-5 2002 Janus kinase inhibitor AG490 inhibits Stat3 activation with a concomitant reduction in steady-state levels of Bcl-X(L), Bcl-2 and Mcl-1 proteins and induces apoptosis in U251 cells as revealed by Poly (ADP-ribose) polymerase cleavage and Annexin-V staining. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 23-28 BCL2 apoptosis regulator Homo sapiens 120-125 12482581-8 2002 Bcl-2 phosphorylation was increased by hydroxytyrosol and pyrrolidine dithiocarbamate and not by resveratrol. 3,4-dihydroxyphenylethanol 39-53 BCL2 apoptosis regulator Homo sapiens 0-5 12482581-8 2002 Bcl-2 phosphorylation was increased by hydroxytyrosol and pyrrolidine dithiocarbamate and not by resveratrol. pyrrolidine dithiocarbamic acid 58-85 BCL2 apoptosis regulator Homo sapiens 0-5 12454767-10 2002 In conclusion, tumour stage, node stage, p53 gene status, and bcl-2 expression are independent predictors of tumour response to platin-fluorouracil in patients with squamous-cell carcinomas of the head and neck. platin-fluorouracil 128-147 BCL2 apoptosis regulator Homo sapiens 62-67 12520735-0 2002 [Bcl-2 antisense oligodeoxynucleotide enhances araninosyl cytosine-induced apoptosis of primary leukemia cells]. Oligodeoxyribonucleotides 17-37 BCL2 apoptosis regulator Homo sapiens 1-6 12520735-0 2002 [Bcl-2 antisense oligodeoxynucleotide enhances araninosyl cytosine-induced apoptosis of primary leukemia cells]. araninosyl cytosine 47-66 BCL2 apoptosis regulator Homo sapiens 1-6 12520735-1 2002 BACKGROUND & OBJECTIVE: The previous study has identified two novel antisense oligonucleotides (AS-ODN) of new target point in the translation initiation and the coding region of bcl-2 mRNA that could increase the sensitivity of HL-60 and K562 cells lines to etoposide, daunorubicin, and araninosyl cytosine (Ara-C). Adenosine Monophosphate 12-15 BCL2 apoptosis regulator Homo sapiens 183-188 12562045-8 2002 As a result of these biochemical effects on the mevalonate pathway, bisphosphonates appear to modulate the expression of bcl-2 leading to caspase-dependent apoptosis, inhibit matrix metalloproteinases, downregulate alphavbeta3 and alphavbeta5 integrins, and increase expression of osteoprotegerin, thereby antagonizing osteoclastogenesis. Mevalonic Acid 48-58 BCL2 apoptosis regulator Homo sapiens 121-126 12520735-1 2002 BACKGROUND & OBJECTIVE: The previous study has identified two novel antisense oligonucleotides (AS-ODN) of new target point in the translation initiation and the coding region of bcl-2 mRNA that could increase the sensitivity of HL-60 and K562 cells lines to etoposide, daunorubicin, and araninosyl cytosine (Ara-C). Oligonucleotides 82-98 BCL2 apoptosis regulator Homo sapiens 183-188 12520735-1 2002 BACKGROUND & OBJECTIVE: The previous study has identified two novel antisense oligonucleotides (AS-ODN) of new target point in the translation initiation and the coding region of bcl-2 mRNA that could increase the sensitivity of HL-60 and K562 cells lines to etoposide, daunorubicin, and araninosyl cytosine (Ara-C). Etoposide 263-272 BCL2 apoptosis regulator Homo sapiens 183-188 12520735-1 2002 BACKGROUND & OBJECTIVE: The previous study has identified two novel antisense oligonucleotides (AS-ODN) of new target point in the translation initiation and the coding region of bcl-2 mRNA that could increase the sensitivity of HL-60 and K562 cells lines to etoposide, daunorubicin, and araninosyl cytosine (Ara-C). Daunorubicin 274-286 BCL2 apoptosis regulator Homo sapiens 183-188 12520735-1 2002 BACKGROUND & OBJECTIVE: The previous study has identified two novel antisense oligonucleotides (AS-ODN) of new target point in the translation initiation and the coding region of bcl-2 mRNA that could increase the sensitivity of HL-60 and K562 cells lines to etoposide, daunorubicin, and araninosyl cytosine (Ara-C). araninosyl cytosine 292-311 BCL2 apoptosis regulator Homo sapiens 183-188 12520735-1 2002 BACKGROUND & OBJECTIVE: The previous study has identified two novel antisense oligonucleotides (AS-ODN) of new target point in the translation initiation and the coding region of bcl-2 mRNA that could increase the sensitivity of HL-60 and K562 cells lines to etoposide, daunorubicin, and araninosyl cytosine (Ara-C). Cytarabine 313-318 BCL2 apoptosis regulator Homo sapiens 183-188 12520735-2 2002 This study was designed to investigate whether the two novel bcl-2 AS-ODNs could increase Ara-C-induced apoptosis of cultured primary acute leukemia (AL) and chronic lymphocytic leukemia (CLL) Cells. Cytarabine 90-95 BCL2 apoptosis regulator Homo sapiens 61-66 12520735-4 2002 The expression levels of bcl-2 protein were assayed by immunofluorescence using fluorescein isothiocyanate label. Fluorescein-5-isothiocyanate 80-106 BCL2 apoptosis regulator Homo sapiens 25-30 12520735-8 2002 It was found that the two AS-ODNs respectively combined with Ara-C could significantly downregulate bcl-2 protein expression (P < 0.05). Cytarabine 61-66 BCL2 apoptosis regulator Homo sapiens 100-105 12520735-11 2002 CONCLUSIONS: The two novel AS-ODNs of new target point in the translation initiation and the coding region of bcl-2 mRNA could enhance Ara-C induced apoptosis of AL and CLL cells. Cytarabine 135-140 BCL2 apoptosis regulator Homo sapiens 110-115 12370489-5 2002 Pro-apoptotic Bcl-2 family members such as bax or bak are clearly required to initiate cytochrome c/apaf-1/caspase-9 mediated cell death during oxygen deprivation. Oxygen 144-150 BCL2 apoptosis regulator Homo sapiens 14-19 12370489-6 2002 Here we review what is currently known oxygen deprivation induced cell death and speculate about initiating mechanisms resulting in the activation of pro-apoptotic Bcl-2 family members. Oxygen 39-45 BCL2 apoptosis regulator Homo sapiens 164-169 12562045-8 2002 As a result of these biochemical effects on the mevalonate pathway, bisphosphonates appear to modulate the expression of bcl-2 leading to caspase-dependent apoptosis, inhibit matrix metalloproteinases, downregulate alphavbeta3 and alphavbeta5 integrins, and increase expression of osteoprotegerin, thereby antagonizing osteoclastogenesis. Diphosphonates 68-83 BCL2 apoptosis regulator Homo sapiens 121-126 12462380-8 2002 In addition, immunoblotting revealed that EGC treatment was correlated with a decrease in Bcl-2 and an increase in Bax level. gallocatechol 42-45 BCL2 apoptosis regulator Homo sapiens 90-95 12568310-1 2002 The Bcl-2 antisense oligonucleotide (AS-ODN) G3139 chemosensitizes human malignancies by downregulating the antiapoptotic protein Bcl-2. Oligonucleotides 20-35 BCL2 apoptosis regulator Homo sapiens 4-9 12568310-1 2002 The Bcl-2 antisense oligonucleotide (AS-ODN) G3139 chemosensitizes human malignancies by downregulating the antiapoptotic protein Bcl-2. Oligonucleotides 20-35 BCL2 apoptosis regulator Homo sapiens 130-135 12568310-1 2002 The Bcl-2 antisense oligonucleotide (AS-ODN) G3139 chemosensitizes human malignancies by downregulating the antiapoptotic protein Bcl-2. Oligonucleotides, Antisense 37-43 BCL2 apoptosis regulator Homo sapiens 4-9 12568310-1 2002 The Bcl-2 antisense oligonucleotide (AS-ODN) G3139 chemosensitizes human malignancies by downregulating the antiapoptotic protein Bcl-2. Oligonucleotides, Antisense 37-43 BCL2 apoptosis regulator Homo sapiens 130-135 12433696-0 2002 BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. ABVD protocol 135-139 BCL2 apoptosis regulator Homo sapiens 0-5 12433696-10 2002 We conclude that BCL-2 is frequently expressed by HRS cells in cHD and is associated with inferior FFS in patients treated with ABVD or equivalent regimens. ABVD protocol 128-132 BCL2 apoptosis regulator Homo sapiens 17-22 12444550-2 2002 In the present study, it is shown that release of cytochrome c and apoptosis induced by tumor necrosis factor alpha (TNF) in HeLa cells can be inhibited by (i) overexpression of an oncoprotein Bcl-2, (ii) Cyclosporin A, an inhibitor of the mitochondrial permeability transition pore (PTP) or (iii) oligomycin, an inhibitor of H+- ATP-synthase. Cyclosporine 205-218 BCL2 apoptosis regulator Homo sapiens 193-198 12537668-6 2002 These data suggest a potentially important therapeutic approach for enhancing radiosensitivity in prostate tumors via antisense oligonucleotide or other drug therapies that down-regulate Bcl2. Oligonucleotides 128-143 BCL2 apoptosis regulator Homo sapiens 187-191 12460791-6 2002 Moreover, while bcl-2 overexpression does not induce changes in P-170 glycoprotein expression, it did induce a reduction of the adenosine triphosphate (ATP) levels and basal protein kinase C (PKC) activity, both of which have a crucial role in the regulation of the MDR phenotype. Adenosine Triphosphate 128-150 BCL2 apoptosis regulator Homo sapiens 16-21 12460791-6 2002 Moreover, while bcl-2 overexpression does not induce changes in P-170 glycoprotein expression, it did induce a reduction of the adenosine triphosphate (ATP) levels and basal protein kinase C (PKC) activity, both of which have a crucial role in the regulation of the MDR phenotype. Adenosine Triphosphate 152-155 BCL2 apoptosis regulator Homo sapiens 16-21 12570053-2 2002 The Bcl-2 family member Bcl-xL has been demonstrated to provide resistance to chemotherapeutic agents including CBDCA. Carboplatin 112-117 BCL2 apoptosis regulator Homo sapiens 4-9 12476423-3 2002 Semi-quantitative reverse transcription-PCR was performed to detect the mRNA expression of bcl-2 c-myc survivin bax s100A(2) TNFalpha TGFbeta(1) and IL-6 in the small-cell lung cancer cell line NCI-H446 treated with antisense bcl-2 oligodeoxynucliotide. oligodeoxynucliotide 232-252 BCL2 apoptosis regulator Homo sapiens 91-96 12473608-8 2002 Cryptophycin 52 induced phosphorylation of c-raf1 and bcl-2 and/or bcl-x(L) to comparable levels in all cell lines studied, and LNCaP cells overexpressing bcl-2 were more resistant to cryptophycin 52-induced apoptosis. cryptophycin 0-12 BCL2 apoptosis regulator Homo sapiens 54-59 12473608-8 2002 Cryptophycin 52 induced phosphorylation of c-raf1 and bcl-2 and/or bcl-x(L) to comparable levels in all cell lines studied, and LNCaP cells overexpressing bcl-2 were more resistant to cryptophycin 52-induced apoptosis. cryptophycin 0-12 BCL2 apoptosis regulator Homo sapiens 155-160 12473608-11 2002 We conclude that apoptosis induced by cryptophycin 52 in prostate cancer cells is androgen status independent, cell type specific for caspase requirement, modulated by the bcl-2 family, linked to but not dependent on p53, and strongly correlated with c-Jun NH(2)-terminal kinase phosphorylation. cryptophycin 38-50 BCL2 apoptosis regulator Homo sapiens 172-177 12495472-5 2002 Furthermore, overexpression of Bcl-2 also significantly attenuated the effects of costunolide. costunolide 82-93 BCL2 apoptosis regulator Homo sapiens 31-36 12495472-7 2002 Taken together, the present study demonstrates that the costunolide-induced apoptosis depends on intracellular thiols contents, which are modulated by Bcl-2. costunolide 56-67 BCL2 apoptosis regulator Homo sapiens 151-156 12495472-7 2002 Taken together, the present study demonstrates that the costunolide-induced apoptosis depends on intracellular thiols contents, which are modulated by Bcl-2. Sulfhydryl Compounds 111-117 BCL2 apoptosis regulator Homo sapiens 151-156 12409140-0 2002 23-Hydroxybetulinic acid-mediated apoptosis is accompanied by decreases in bcl-2 expression and telomerase activity in HL-60 Cells. 23-hydroxybetulinic acid 0-24 BCL2 apoptosis regulator Homo sapiens 75-80 12609062-0 2002 [Effects of antisense bcl-2 or survivin on the growth of human neuroblastoma cell line SK-N-MC]. sk-n-mc 87-94 BCL2 apoptosis regulator Homo sapiens 22-27 12444550-2 2002 In the present study, it is shown that release of cytochrome c and apoptosis induced by tumor necrosis factor alpha (TNF) in HeLa cells can be inhibited by (i) overexpression of an oncoprotein Bcl-2, (ii) Cyclosporin A, an inhibitor of the mitochondrial permeability transition pore (PTP) or (iii) oligomycin, an inhibitor of H+- ATP-synthase. Oligomycins 298-308 BCL2 apoptosis regulator Homo sapiens 193-198 12412180-8 2002 Troglitazone induced apoptosis by caspase-dependent (mitchondrial transmembrane potential decrease, cleavage of poly [adenosine diphosphate ribose] polymerase, 7A6 antigen exposure, Bcl-2 decrease, and activation of caspase 3) and caspase-independent (phosphatidylserine externalization) mechanisms. Troglitazone 0-12 BCL2 apoptosis regulator Homo sapiens 182-187 12444550-3 2002 Staurosporine-induced apoptosis is sensitive to Bcl-2 but insensitive to Cyclosporin A and oligomycin. Staurosporine 0-13 BCL2 apoptosis regulator Homo sapiens 48-53 12417302-2 2002 Here, we report that 2-methoxyestradiol (2-ME), an endogenous metabolite of estrogen that does not bind to nuclear estrogen receptors, effectively induces apoptosis in Bcl-2-expressing human prostate and breast carcinoma cells in vitro and in a rat prostate tumor model in vivo. 2-Methoxyestradiol 21-39 BCL2 apoptosis regulator Homo sapiens 168-173 12417302-2 2002 Here, we report that 2-methoxyestradiol (2-ME), an endogenous metabolite of estrogen that does not bind to nuclear estrogen receptors, effectively induces apoptosis in Bcl-2-expressing human prostate and breast carcinoma cells in vitro and in a rat prostate tumor model in vivo. 2-Methoxyestradiol 41-45 BCL2 apoptosis regulator Homo sapiens 168-173 12417302-3 2002 In several cell lines derived from prostate, breast, liver and colorectal carcinomas, 2-ME treatment led to an activation of c-Jun N-terminal kinase (JNK) and phosphorylation of Bcl-2, which preceded the induction of apoptosis. 2-Methoxyestradiol 86-90 BCL2 apoptosis regulator Homo sapiens 178-183 12417302-4 2002 In summary, our data suggest that 2-ME induces apoptosis in epithelial carcinomas by causing phosphorylation of JNK, which appears to be correlated with phosphorylation of Bcl-2. 2-Methoxyestradiol 34-38 BCL2 apoptosis regulator Homo sapiens 172-177 12381674-10 2002 Sulfasalazine-induced DeltaPsi(m) loss, AIF redistribution, and cell death are fully prevented by overexpression of Bcl-2. Sulfasalazine 0-13 BCL2 apoptosis regulator Homo sapiens 116-121 12194522-6 2002 Based on the genes studied, we could propose a general pathway for the cell reaction according to the surface treatments used: (1) metal ion release changes the time course of gene expression in the FAK pathway; (2) once the accumulation of metal ions released from the Ti surface exceeds a threshold value, cell growth is diminished and apoptosis may be activated; (3) PTK up-regulation is also induced by metal ion release; (4) the expression of Bcl-2 family and Bax may suggest that metal ions induce apoptosis. Metals 131-136 BCL2 apoptosis regulator Homo sapiens 448-453 12526221-1 2002 BACKGROUND & OBJECTIVE: Insulin-like growth factor II (IGF-II) can stimulate cell proliferation; B cell lymphoma 2 (bcl-2) protein can strongly inhabit cell apoptosis. Adenosine Monophosphate 12-15 BCL2 apoptosis regulator Homo sapiens 101-118 12526221-1 2002 BACKGROUND & OBJECTIVE: Insulin-like growth factor II (IGF-II) can stimulate cell proliferation; B cell lymphoma 2 (bcl-2) protein can strongly inhabit cell apoptosis. Adenosine Monophosphate 12-15 BCL2 apoptosis regulator Homo sapiens 120-125 12553008-3 2002 After 4 days incubation, all CLA-treated cells displayed an increase in caspase 3 (27-34%) and caspase 9 activities (37-47%), cleavage of pro-caspase 3 (32 kDa) to 17 and 12 kDa subunits, increased membrane annexin V levels and reduced expression of bcl-2 compared with untreated controls. Linoleic Acids, Conjugated 29-32 BCL2 apoptosis regulator Homo sapiens 250-255 12440850-0 2002 Radiometal-labeled peptide-PNA conjugates for targeting bcl-2 expression: preparation, characterization, and in vitro mRNA binding. peptide-pna 19-30 BCL2 apoptosis regulator Homo sapiens 56-61 12440850-5 2002 Northern blot analysis showed that (90)Y-PTD-4-K(DOTA)-anti-bcl-2-PNA bound specifically to as little as 50 fmol of bcl-2 mRNA, a result equivalent to that obtained with the analogous (32)P-labeled DNA antisense oligonucleotide. Oligonucleotides 212-227 BCL2 apoptosis regulator Homo sapiens 60-65 12194522-6 2002 Based on the genes studied, we could propose a general pathway for the cell reaction according to the surface treatments used: (1) metal ion release changes the time course of gene expression in the FAK pathway; (2) once the accumulation of metal ions released from the Ti surface exceeds a threshold value, cell growth is diminished and apoptosis may be activated; (3) PTK up-regulation is also induced by metal ion release; (4) the expression of Bcl-2 family and Bax may suggest that metal ions induce apoptosis. Metals 241-246 BCL2 apoptosis regulator Homo sapiens 448-453 12426281-3 2002 In this study, we investigated the effect of dexamethasone (DEX) on the apoptosis and B-cell lymphoma (Bcl)-2 expression of peripheral blood T lymphocytes as well as the soluble form of Fas (sFas) in allergic asthmatic patients. Dexamethasone 45-58 BCL2 apoptosis regulator Homo sapiens 86-109 12194522-6 2002 Based on the genes studied, we could propose a general pathway for the cell reaction according to the surface treatments used: (1) metal ion release changes the time course of gene expression in the FAK pathway; (2) once the accumulation of metal ions released from the Ti surface exceeds a threshold value, cell growth is diminished and apoptosis may be activated; (3) PTK up-regulation is also induced by metal ion release; (4) the expression of Bcl-2 family and Bax may suggest that metal ions induce apoptosis. Metals 241-246 BCL2 apoptosis regulator Homo sapiens 448-453 12194522-6 2002 Based on the genes studied, we could propose a general pathway for the cell reaction according to the surface treatments used: (1) metal ion release changes the time course of gene expression in the FAK pathway; (2) once the accumulation of metal ions released from the Ti surface exceeds a threshold value, cell growth is diminished and apoptosis may be activated; (3) PTK up-regulation is also induced by metal ion release; (4) the expression of Bcl-2 family and Bax may suggest that metal ions induce apoptosis. Metals 241-246 BCL2 apoptosis regulator Homo sapiens 448-453 12452453-0 2002 Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Doxorubicin 81-92 BCL2 apoptosis regulator Homo sapiens 0-5 12452453-0 2002 Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Paclitaxel 94-104 BCL2 apoptosis regulator Homo sapiens 0-5 12452453-0 2002 Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Cyclophosphamide 109-125 BCL2 apoptosis regulator Homo sapiens 0-5 12452453-2 2002 Here we describe the use of the bcl-2/bcl-xL bispecific antisense oligonucleotide 4625 to sensitize breast carcinoma cells to anti-cancer drugs routinely used in breast cancer therapy. Oligonucleotides 66-81 BCL2 apoptosis regulator Homo sapiens 32-37 12426281-3 2002 In this study, we investigated the effect of dexamethasone (DEX) on the apoptosis and B-cell lymphoma (Bcl)-2 expression of peripheral blood T lymphocytes as well as the soluble form of Fas (sFas) in allergic asthmatic patients. Dexamethasone 60-63 BCL2 apoptosis regulator Homo sapiens 86-109 12445555-1 2002 The example of Bcl-2 antisense oligonucleotides. Oligonucleotides 31-47 BCL2 apoptosis regulator Homo sapiens 15-20 12543086-7 2002 Anti-apoptotic regulators of apoptosis such as Bcl-2 may act by reducing the ebb and flow of Ca(2+) through the ER/mitochondrial couple. O-(4-ethoxybutyl)berbamine 77-80 BCL2 apoptosis regulator Homo sapiens 47-52 12423325-11 2002 After treatment with ASA, down-regulation of Bcl2 and CD44v6 expression and up-regulation of nm23 expression were observed in SW480 cells. Aspirin 21-24 BCL2 apoptosis regulator Homo sapiens 45-49 12423325-14 2002 Down-regulation of Bcl2 expression might represent a potential mechanism by which ASA induces apoptosis in this COX-2 negative colon cancer cell line. Aspirin 82-85 BCL2 apoptosis regulator Homo sapiens 19-23 12445555-5 2002 In addition, the role of one oligonucleotide, G3139, which is targeted to the coding region of bcl-2 messenger RNA, in inhibiting tumor progression in vitro and in clinical trials, is described. Oligonucleotides 29-44 BCL2 apoptosis regulator Homo sapiens 95-100 12421364-8 2002 However, it did so without reducing levels of superoxide, hydrogen peroxide or lipid peroxidation; (iii) Bcl-2 protected against permanent anoxia, an insult likely to involve little to no ROS generation. Reactive Oxygen Species 188-191 BCL2 apoptosis regulator Homo sapiens 105-110 12198119-6 2002 Overexpression of bcl-2 by gene transfer abrogated ET-743-induced apoptosis, but cells underwent cell cycle arrest. Trabectedin 51-57 BCL2 apoptosis regulator Homo sapiens 18-23 12198119-7 2002 ET-743 triggered cytochrome c release from mitochondria that was inhibited by Bcl-2 overexpression. Trabectedin 0-6 BCL2 apoptosis regulator Homo sapiens 78-83 12425431-10 2002 High glucose-mediated apoptosis was associated with a decrease in the expression of Bcl-2 (-87%) and a twofold increase in the expression of Bax protein. Glucose 5-12 BCL2 apoptosis regulator Homo sapiens 84-89 12421364-3 2002 There is evidence that these additional actions may be antioxidant in nature, in that Bcl-2 has been reported to protect against generators of reactive oxygen species (ROS), to increase antioxidant defenses and to decrease levels of ROS and of oxidative damage. Reactive Oxygen Species 143-166 BCL2 apoptosis regulator Homo sapiens 86-91 12421364-3 2002 There is evidence that these additional actions may be antioxidant in nature, in that Bcl-2 has been reported to protect against generators of reactive oxygen species (ROS), to increase antioxidant defenses and to decrease levels of ROS and of oxidative damage. Reactive Oxygen Species 168-171 BCL2 apoptosis regulator Homo sapiens 86-91 12421364-3 2002 There is evidence that these additional actions may be antioxidant in nature, in that Bcl-2 has been reported to protect against generators of reactive oxygen species (ROS), to increase antioxidant defenses and to decrease levels of ROS and of oxidative damage. Reactive Oxygen Species 233-236 BCL2 apoptosis regulator Homo sapiens 86-91 12421364-5 2002 We have examined these issues in neuron-enriched primary hippocampal cultures, with overexpression of bcl-2 driven by a herpes simplex virus amplicon: (i) Bcl-2 protected strongly against glutamate, whose toxicity is at least partially ROS-dependent. Glutamic Acid 188-197 BCL2 apoptosis regulator Homo sapiens 155-160 12421364-5 2002 We have examined these issues in neuron-enriched primary hippocampal cultures, with overexpression of bcl-2 driven by a herpes simplex virus amplicon: (i) Bcl-2 protected strongly against glutamate, whose toxicity is at least partially ROS-dependent. Reactive Oxygen Species 236-239 BCL2 apoptosis regulator Homo sapiens 155-160 12421364-7 2002 Despite that, Bcl-2 had no effect on levels of lipid peroxidation, which is thought to be the primary locus of glutamate-induced oxidative damage; (ii) Bcl-2 was also mildly protective against the pro-oxidant adriamycin. Doxorubicin 209-219 BCL2 apoptosis regulator Homo sapiens 152-157 12421364-9 2002 These findings suggest that Bcl-2 can have antioxidant actions that may nonetheless not be central to its protective effects, can protect against an ROS generator without targeting steps specific to oxidative biochemistry, and can protect in the absence of ROS generation. Reactive Oxygen Species 149-152 BCL2 apoptosis regulator Homo sapiens 28-33 12421364-9 2002 These findings suggest that Bcl-2 can have antioxidant actions that may nonetheless not be central to its protective effects, can protect against an ROS generator without targeting steps specific to oxidative biochemistry, and can protect in the absence of ROS generation. Reactive Oxygen Species 257-260 BCL2 apoptosis regulator Homo sapiens 28-33 12421372-2 2002 This cell death can be blocked by genetic deletion of Bax, a member of the pro-apoptotic Bcl-2 family, cycloheximide an inhibitor of macromolecular synthesis or expression of dominant-negative c-jun. Cycloheximide 103-116 BCL2 apoptosis regulator Homo sapiens 89-94 12533044-4 2002 JM-1, SUP-B 15 and RS4 leukemic cell lines cleaved Bcl-2 to its 23 kDa form when exposed to the chemotherapeutic agents 1-beta-D-arabinofuranosyl-cytosine (Ara-C) or etoposide (VP-16). Cytarabine 120-154 BCL2 apoptosis regulator Homo sapiens 51-56 12421878-2 2002 Molecular mechanisms postulated to contribute to the multiple benefits of omega-3 fatty acids include 1) suppressing the expression of cyclooxygenase-2 in tumors, thus decreasing proliferation of cancer cells and reducing angiogenesis in the tumor; 2) decreasing the expression of AP-1 and ras, two oncogenes implicated in tumor promotion; 3) inducing differentiation of cancer cells; 4) suppressing nuclear factor-kappaB activation and bcl-2 expression, thus allowing apoptosis of cancer cells; and 5) reducing cancer-induced cachexia. Fatty Acids, Omega-3 74-93 BCL2 apoptosis regulator Homo sapiens 437-442 12533044-4 2002 JM-1, SUP-B 15 and RS4 leukemic cell lines cleaved Bcl-2 to its 23 kDa form when exposed to the chemotherapeutic agents 1-beta-D-arabinofuranosyl-cytosine (Ara-C) or etoposide (VP-16). Cytarabine 156-161 BCL2 apoptosis regulator Homo sapiens 51-56 12533044-4 2002 JM-1, SUP-B 15 and RS4 leukemic cell lines cleaved Bcl-2 to its 23 kDa form when exposed to the chemotherapeutic agents 1-beta-D-arabinofuranosyl-cytosine (Ara-C) or etoposide (VP-16). Etoposide 166-175 BCL2 apoptosis regulator Homo sapiens 51-56 12709297-8 2002 Moreover, our studies indicate that nicotinamide is able to prevent the up-regulation of the pro-apoptotic proteins p53 and p21/WAF-1, and the down-regulation of the anti-apoptotic protein bcl-2 that is induced by t-BuOOH in HCN2 cells. Niacinamide 36-48 BCL2 apoptosis regulator Homo sapiens 189-194 21174810-3 2002 bcl-2 was transfected into cardiomyocytes with Lipofectamine transfection methods. Lipofectamine 47-60 BCL2 apoptosis regulator Homo sapiens 0-5 12391322-7 2002 Stimulation with IGF-1, as well as overexpression of Bcl-2 or constitutively active Akt in MM cells also modestly attenuates PS-341-induced cell death, whereas inhibitors of the BH3 domain of Bcl-2 family members or the heat-shock protein 90 enhance tumor cell sensitivity to proteasome inhibition. Bortezomib 125-131 BCL2 apoptosis regulator Homo sapiens 53-58 12490120-0 2002 [Arsenic trioxide induced apoptosis and expression of p53 and bcl-2 genes in human small cell lung cancer cells]. Arsenic Trioxide 1-17 BCL2 apoptosis regulator Homo sapiens 62-67 12101183-0 2002 Phosphorylation of Bcl-2 in G2/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis. hypericin 90-99 BCL2 apoptosis regulator Homo sapiens 19-24 12384529-4 2002 Surprisingly, however, cell cycle analysis revealed that CP461 caused G(2)-M arrest with an EC(50) of 1.1 micro M. G(2)-M arrest was associated with phosphorylation of Bcl2 (but not BAD, Bax, or Bcl-XL): both of these end points were abrogated by treatment with a calcium chelator. (5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride 57-62 BCL2 apoptosis regulator Homo sapiens 168-172 12384529-6 2002 Because microtubule-active drugs such as vincristine also induced G(2)-M arrest and Bcl2 phosphorylation in WSU-CLL, whereas the genotoxic drugs etoposide and doxorubicin did not, we examined the effect of CP461 on microtubules by indirect immunofluoresence microscopy. Vincristine 41-52 BCL2 apoptosis regulator Homo sapiens 84-88 12101183-3 2002 Here we show that, in HeLa cells, photoactivated hypericin does not cause Bcl-2 degradation but induces Bcl-2 phosphorylation in a dose- and time-dependent manner. hypericin 49-58 BCL2 apoptosis regulator Homo sapiens 104-109 12366500-8 2002 Propofol treatment resulted in activation of caspase-3, -6, -8 and -9, thereby suggesting that cell surface death receptor activation of the caspase cascade mediates propofol-induced apoptosis with consequent formation of the cleaved product of Bid (a pro-apoptotic Bcl-2 family member protein) and activation of the mitochondrial pathway with cytosolic release of cytochrome c. Propofol 0-8 BCL2 apoptosis regulator Homo sapiens 266-271 12151395-5 2002 Moreover, the role of p53 in activation of this pathway was demonstrated by the fact that inhibition of p53 activity by pifithrin-alpha reduced the sensitivity of HCT116/p21(-/-) cells to daunomycin-induced apoptosis and restored a Bax/Bcl-2 ratio similar to that observed in HCT116p21(+/+) cells. pifithrin 120-135 BCL2 apoptosis regulator Homo sapiens 236-241 12151395-5 2002 Moreover, the role of p53 in activation of this pathway was demonstrated by the fact that inhibition of p53 activity by pifithrin-alpha reduced the sensitivity of HCT116/p21(-/-) cells to daunomycin-induced apoptosis and restored a Bax/Bcl-2 ratio similar to that observed in HCT116p21(+/+) cells. Daunorubicin 188-198 BCL2 apoptosis regulator Homo sapiens 236-241 12366500-8 2002 Propofol treatment resulted in activation of caspase-3, -6, -8 and -9, thereby suggesting that cell surface death receptor activation of the caspase cascade mediates propofol-induced apoptosis with consequent formation of the cleaved product of Bid (a pro-apoptotic Bcl-2 family member protein) and activation of the mitochondrial pathway with cytosolic release of cytochrome c. Propofol 166-174 BCL2 apoptosis regulator Homo sapiens 266-271 12508651-7 2002 RESULTS: Antisense alpha 1, 4Gal-T oligonucleotide signifantly inhibited cell growth (P < 0.01), induced the apoptosis (P < 0.05), downregulated expression of bcl-2 protein (P < 0.01) and upregulated expressions of fas and bax protein (P < 0.01), but did not influence p53 expression in glioma cell line SWO-38. alpha 1, 4gal-t oligonucleotide 19-50 BCL2 apoptosis regulator Homo sapiens 165-170 12508653-4 2002 Immunohistochemistry was used to examine the expression of Bax, Bcl-2 after treatment of triptolide and celastrol. triptolide 89-99 BCL2 apoptosis regulator Homo sapiens 64-69 12508653-4 2002 Immunohistochemistry was used to examine the expression of Bax, Bcl-2 after treatment of triptolide and celastrol. celastrol 104-113 BCL2 apoptosis regulator Homo sapiens 64-69 12508651-8 2002 CONCLUSIONS: Antisense alpha 1, 4Gal-T oligonucleotide can significantly inhibit proliferation and induce apoptosis in human gliomas cell line SWO-38, which maybe due to the interactions of fas, bax, and bcl-2. alpha 1, 4gal-t oligonucleotide 23-54 BCL2 apoptosis regulator Homo sapiens 204-209 12431242-2 2002 ATRA induced apoptosis in all the B-CLL samples tested, and this was accompanied by a specific reduction in Bcl-2 and Mcl-1 protein expression in the apoptotic cells. Tretinoin 0-4 BCL2 apoptosis regulator Homo sapiens 108-113 12508651-8 2002 CONCLUSIONS: Antisense alpha 1, 4Gal-T oligonucleotide can significantly inhibit proliferation and induce apoptosis in human gliomas cell line SWO-38, which maybe due to the interactions of fas, bax, and bcl-2. swo-38 143-149 BCL2 apoptosis regulator Homo sapiens 204-209 12207177-4 2002 Bcl-2 located at the ER was shown to interfere with apoptosis induction by Bax, ceramides, ionising radiation, serum withdrawal and c-myc expression. Ceramides 80-89 BCL2 apoptosis regulator Homo sapiens 0-5 12207177-6 2002 For instance, Bcl-2 at the ER may regulate calcium fluxes between the ER and the mitochondria. Calcium 43-50 BCL2 apoptosis regulator Homo sapiens 14-19 12207177-9 2002 Current data on the function of Bcl-2 at the ER, its role for the modulation of calcium fluxes and its influence on caspase activation at the ER are reviewed. Calcium 80-87 BCL2 apoptosis regulator Homo sapiens 32-37 12508653-7 2002 CONCLUSION: Triptolide and celastrol inhibit the proliferation of glioma cells in vitro, which was associated with promoting the expression of Bax and inhibiting the expression of Bcl-2 and accelerating cell apotosis. triptolide 12-22 BCL2 apoptosis regulator Homo sapiens 180-185 12508653-7 2002 CONCLUSION: Triptolide and celastrol inhibit the proliferation of glioma cells in vitro, which was associated with promoting the expression of Bax and inhibiting the expression of Bcl-2 and accelerating cell apotosis. celastrol 27-36 BCL2 apoptosis regulator Homo sapiens 180-185 12297835-9 2002 Apoptosis after COX-2 inhibition with SC-58635 (50 micromol/L) was independent of BCL-2, BAX, and the phosphorylation status of AKT/PKB and BAD, but correlated with activation of caspase-9, caspase-3, and caspase-6. Celecoxib 38-46 BCL2 apoptosis regulator Homo sapiens 82-87 12239620-12 2002 The induction of apoptosis by GEN was associated with a 52.8% decrease (p=0.001) in the immunoreactivity to antiapoptotic Bcl-2 and with a 195.9% (p=0.001) increase in the immunoreactivity to proapoptotic Bax. Genistein 30-33 BCL2 apoptosis regulator Homo sapiens 122-127 12239620-13 2002 Thus, preventive efficacy of GEN in HER-2/neu+/ER- 184-B5/HER cells may be due to its ability to down-regulate HER-2/neu mediated signal transduction, increase the expression of the cyclin dependent kinase inhibitor p16INK4, and induce Bcl-2 dependent apoptosis. Genistein 29-32 BCL2 apoptosis regulator Homo sapiens 236-241 12481898-8 2002 Polyphenol-driven apoptosis in chronic leukemic B cells was shown to correlate with an activation of caspase 3, a drop in the mitochondrial transmembrane potential, a reduction in the expression of the anti-apoptotic protein bcl-2, as well as a reduction in the expression of the inducible nitric oxide synthase (iNOS). Polyphenols 0-10 BCL2 apoptosis regulator Homo sapiens 225-230 12220328-0 2002 Melatonin suppresses NO-induced apoptosis via induction of Bcl-2 expression in PGT-beta immortalized pineal cells. Melatonin 0-9 BCL2 apoptosis regulator Homo sapiens 59-64 12220328-8 2002 Pretreatment with melatonin (0.1 mm) induced the expression of Bcl-2 and suppressed the release of cytochrome c into the cytosol, thereby arresting NO-induced apoptotic cell death. Melatonin 18-27 BCL2 apoptosis regulator Homo sapiens 63-68 12220328-9 2002 These results suggest that the antiapoptotic effect of melatonin is associated with induction of Bcl-2 expression in PGT-beta cells, which in turn blocks caspase-3 activation and inhibits cytochrome c release into the cytosol. Melatonin 55-64 BCL2 apoptosis regulator Homo sapiens 97-102 12481899-5 2002 Furthermore, these changes were independent of Bcl-2 expression suggesting that the previously observed increase in Bax expression following exposure of B-CLL cells to Bcl-2 antisense oligonucleotides was probably caused by the induction of apoptosis rather than a rheostatic response to the reduction in Bcl-2 protein expression. Oligonucleotides 184-200 BCL2 apoptosis regulator Homo sapiens 168-173 12481899-0 2002 Antisense oligonucleotides complementary to Bax transcripts reduce the susceptibility of B-cell chronic lymphocytic leukaemia cells to apoptosis in a bcl-2 independent manner. Oligonucleotides 10-26 BCL2 apoptosis regulator Homo sapiens 150-155 12481899-5 2002 Furthermore, these changes were independent of Bcl-2 expression suggesting that the previously observed increase in Bax expression following exposure of B-CLL cells to Bcl-2 antisense oligonucleotides was probably caused by the induction of apoptosis rather than a rheostatic response to the reduction in Bcl-2 protein expression. Oligonucleotides 184-200 BCL2 apoptosis regulator Homo sapiens 168-173 12481899-1 2002 Our previous work demonstrated that antisense oligonucleotides complementary to Bcl-2 mRNA sequences were able to reduce Bcl-2 protein expression in B-cell chronic lymphocytic leukaemia (B-CLL) cells. Oligonucleotides 46-62 BCL2 apoptosis regulator Homo sapiens 80-85 12481899-1 2002 Our previous work demonstrated that antisense oligonucleotides complementary to Bcl-2 mRNA sequences were able to reduce Bcl-2 protein expression in B-cell chronic lymphocytic leukaemia (B-CLL) cells. Oligonucleotides 46-62 BCL2 apoptosis regulator Homo sapiens 121-126 12513735-0 2002 [Study on telomerase activity and expression of hTERT, c-myc and bcl-2 during terminal differentiation of HL-60 cells induced by retinoic acid]. Tretinoin 129-142 BCL2 apoptosis regulator Homo sapiens 65-70 12242728-0 2002 Bcl-2 antagonizes the combined apoptotic effect of transforming growth factor-beta and dihydrotestosterone in prostate cancer cells. Dihydrotestosterone 87-106 BCL2 apoptosis regulator Homo sapiens 0-5 12242728-3 2002 The previously cloned TGF-RbetaII receptor LNCaP cells, responsive to both TGF-beta and androgens, were engineered to overexpress the bcl-2 oncoprotein and the profile of apoptosis induction was analyzed in response to TGF-beta alone (5.0 ng/ml) or in combination with DHT (1 nM). Dihydrotestosterone 269-272 BCL2 apoptosis regulator Homo sapiens 134-139 12242728-4 2002 RESULTS: Biological characterization of cloned LNCaP TbetaRII hygromycin/bcl-2 transfectants demonstrated that bcl-2 overexpression resulted in a significant inhibition of the combined TGF-beta and DHT apoptotic effect in prostate cancer cells (P < 0.01). hygromycin A 62-72 BCL2 apoptosis regulator Homo sapiens 111-116 12242728-4 2002 RESULTS: Biological characterization of cloned LNCaP TbetaRII hygromycin/bcl-2 transfectants demonstrated that bcl-2 overexpression resulted in a significant inhibition of the combined TGF-beta and DHT apoptotic effect in prostate cancer cells (P < 0.01). Dihydrotestosterone 198-201 BCL2 apoptosis regulator Homo sapiens 111-116 12242728-5 2002 Furthermore, molecular analysis indicated that this antagonistic effect of bcl-2 on apoptosis was due to partial suppression of TGF-beta and DHT-mediated induction of caspase-1 expression and activation in LNCaP TbetaRII-hygro/bcl-2 transfectants. Dihydrotestosterone 141-144 BCL2 apoptosis regulator Homo sapiens 75-80 12242728-5 2002 Furthermore, molecular analysis indicated that this antagonistic effect of bcl-2 on apoptosis was due to partial suppression of TGF-beta and DHT-mediated induction of caspase-1 expression and activation in LNCaP TbetaRII-hygro/bcl-2 transfectants. Dihydrotestosterone 141-144 BCL2 apoptosis regulator Homo sapiens 227-232 12389115-4 2002 Furthermore, the phosphorylation of Bcl-2 and Bcl-X(L) proteins in Taxol treated cells was detected at 8 h. In contrast, Taxol had no effect on the levels of Fas and FasL proteins and neither antagonistic, anti-Fas antibody affected Taxol-induced apoptosis. Paclitaxel 67-72 BCL2 apoptosis regulator Homo sapiens 36-41 12389115-5 2002 These results suggest that, following the phosphorylation of Bcl-2 and Bcl-X(L)proteins, Taxol-induced apoptosis is induced through the mitochondria-dependent pathway in T24 cells. Paclitaxel 89-94 BCL2 apoptosis regulator Homo sapiens 61-66 12357364-10 2002 Although caspases can also collaborate in DeltaPsi(m) loss, proapoptotic proteins from the Bcl-2 superfamily may be the key inducers of DeltaPsi(m) loss and apoptosis in B-CLL cells sensitive to 2CdA. 2'-chloro-2'-deoxyadenosine 195-199 BCL2 apoptosis regulator Homo sapiens 91-96 12513735-4 2002 It is concluded that the telomerase activity is related to decrease expression of hTERT, c-myc and bcl-2 mRNA during HL-60 cell differentiation induced by ATRA. Tretinoin 155-159 BCL2 apoptosis regulator Homo sapiens 99-104 12508535-4 2002 The immunohistochemical SP staining was used to determine the expressions of bcl-2 protein and p53 protein. TFF2 protein, human 24-26 BCL2 apoptosis regulator Homo sapiens 77-82 12214265-6 2002 Induction of G2 arrest with sequential abrogation of a p53-independent checkpoint allows pharmacological manipulation of Raf-1/Bcl-2 hyperphosphorylation, PARP and Rb cleavage and cell death caused by PTX in p53-deficient cells. ptx 201-204 BCL2 apoptosis regulator Homo sapiens 127-132 12362319-4 2002 bcl-2 mRNA expression level in Burkitt"s lymphoma pre-and post-treated with bcl-2 antisense phosphothioate oligodeoxynucleotides (AS-PS-ODN) was determined with real-time quantitative RT-PCR, also with semi-quantitative RT-PCR. phosphothioate oligodeoxynucleotides 92-128 BCL2 apoptosis regulator Homo sapiens 0-5 12362319-4 2002 bcl-2 mRNA expression level in Burkitt"s lymphoma pre-and post-treated with bcl-2 antisense phosphothioate oligodeoxynucleotides (AS-PS-ODN) was determined with real-time quantitative RT-PCR, also with semi-quantitative RT-PCR. as-ps-odn 130-139 BCL2 apoptosis regulator Homo sapiens 0-5 12362319-4 2002 bcl-2 mRNA expression level in Burkitt"s lymphoma pre-and post-treated with bcl-2 antisense phosphothioate oligodeoxynucleotides (AS-PS-ODN) was determined with real-time quantitative RT-PCR, also with semi-quantitative RT-PCR. as-ps-odn 130-139 BCL2 apoptosis regulator Homo sapiens 76-81 12496485-0 2002 Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3. 3,4-dihydroxybenzohydroxamic acid 0-5 BCL2 apoptosis regulator Homo sapiens 61-66 12529982-6 2002 Deferoxamine mesylate induced a small increase in the endogenous expression of both the bcl-2 and bax genes in the MCF-7 cells and this can be prevented by ferric chloride. Deferoxamine 0-21 BCL2 apoptosis regulator Homo sapiens 88-93 12529982-6 2002 Deferoxamine mesylate induced a small increase in the endogenous expression of both the bcl-2 and bax genes in the MCF-7 cells and this can be prevented by ferric chloride. ferric chloride 156-171 BCL2 apoptosis regulator Homo sapiens 88-93 12181745-4 2002 DEX increases the expression of anti-apoptotic Bcl-2 and Bcl-x(L) proteins, decreases the expression of pro-apoptotic Bax and inhibits Bad translocation thereby preventing the release of cytochrome c, the activation of caspases, and cell death. Dexamethasone 0-3 BCL2 apoptosis regulator Homo sapiens 47-52 12496485-1 2002 In this study, we investigated the influence of Bcl-2 overexpression on the radiosensitizing potential of Didox (DX; 3,4-Dihydroxybenzohydroxamic acid), a novel ribonucleotide reductase inhibitor, in p53-null prostate cancer cell line PC-3. 3,4-dihydroxybenzohydroxamic acid 106-111 BCL2 apoptosis regulator Homo sapiens 48-53 12168105-8 2002 It is known that in contrary to phospho Bcl2, native Bcl2 (non-phosphoform) is unable to associate with cis-trans peptidyl prolyl isomerase Pin1-a key factor to regulate the fate of phosphoforms of Bcl2 and apoptosis. phosphoform 63-74 BCL2 apoptosis regulator Homo sapiens 53-57 12215338-10 2002 CONCLUSION(S): The induction of DNA fragmentation by L-arginine on proliferative endometria suggests that NO may be involved in the endometrial apoptotic process, whose control may be related predominantly to the changes of Bcl-2 expression. Arginine 53-63 BCL2 apoptosis regulator Homo sapiens 224-229 12168105-8 2002 It is known that in contrary to phospho Bcl2, native Bcl2 (non-phosphoform) is unable to associate with cis-trans peptidyl prolyl isomerase Pin1-a key factor to regulate the fate of phosphoforms of Bcl2 and apoptosis. phosphoform 63-74 BCL2 apoptosis regulator Homo sapiens 53-57 12168106-6 2002 Bcl-2 overexpression attenuates arsenic trioxide-induced apoptosis in U937 cells by inhibition of caspase 3 activity, but not inhibition of Akt. Arsenic Trioxide 32-48 BCL2 apoptosis regulator Homo sapiens 0-5 12200198-7 2002 Rasagiline prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF). rasagiline 0-10 BCL2 apoptosis regulator Homo sapiens 108-113 12358775-0 2002 Nitric oxide regulates cGMP-dependent cAMP-responsive element binding protein phosphorylation and Bcl-2 expression in cerebellar neurons: implication for a survival role of nitric oxide. Nitric Oxide 0-12 BCL2 apoptosis regulator Homo sapiens 98-103 12210368-4 2002 Bcl-2 expression increased significantly in hypothyroid myopathy, correlating with high serum TSH levels, and not with either triiodothyronine (T3) or thyroxine (T4) serum levels. Thyrotropin 94-97 BCL2 apoptosis regulator Homo sapiens 0-5 12168083-0 2002 Quantitative analysis of expression levels of bax, bcl-2, and survivin in cancer cells during cisplatin treatment. Cisplatin 94-103 BCL2 apoptosis regulator Homo sapiens 51-56 12168083-7 2002 The changes in expression levels of three genes (bax, bcl-2, and survivin) during CDDP treatment were evaluated by real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Cisplatin 82-86 BCL2 apoptosis regulator Homo sapiens 54-59 12168083-11 2002 Also, in LoVo cells, the expression level of bcl-2 mRNA decreased after 24 h treatment with CDDP. Cisplatin 92-96 BCL2 apoptosis regulator Homo sapiens 45-50 12168083-12 2002 On the other hand, during CDDP treatment, the expression levels of bcl-2 and survivin mRNA significantly increased in PANC-1 cells. Cisplatin 26-30 BCL2 apoptosis regulator Homo sapiens 67-72 12199864-5 2002 Overexpression of bcl-2 protected pEC against apoptosis induced by staurosporine or actinomycin D, but failed to prevent hNK cell-mediated lysis. Staurosporine 67-80 BCL2 apoptosis regulator Homo sapiens 18-23 12199864-5 2002 Overexpression of bcl-2 protected pEC against apoptosis induced by staurosporine or actinomycin D, but failed to prevent hNK cell-mediated lysis. Dactinomycin 84-97 BCL2 apoptosis regulator Homo sapiens 18-23 12231068-5 2002 Calcitriol induces poly (adenosine diphosphate-ribose) polymerase cleavage, increases bax/bcl-2 ratio, reduces levels of phosphorylated mitogen-activated protein kinases (P-MAPKs; also known as extracellular signal-related kinase [ERK] 1/2) and phosphorylated Akt, induces caspase-dependent mitogen-activated protein kinase kinase (MEK) cleavage and upregulation of MEK kinase-1, all potential markers of the apoptotic pathway. Calcitriol 0-10 BCL2 apoptosis regulator Homo sapiens 90-95 12068015-10 2002 Expression of the antiapoptotic protein, Bcl-2, in BJAB cells drastically inhibited TAS-103-induced apoptosis, confirming that H(2)O(2) generation occurs upstream of mitochondrial permeability transition. 6-((2-(dimethylamino)ethyl)amino)-3-hydroxy-7H-indeno(2,1-c)quinolin-7-one 84-91 BCL2 apoptosis regulator Homo sapiens 41-46 12567892-9 2002 CONCLUSION: DADAG-induced apoptosis in HL-60 cells required caspase-3 activation and caspase-3 activation was related with Bcl-2 family members. dianhydro-3,4-diacetylgalactitol 12-17 BCL2 apoptosis regulator Homo sapiens 123-128 12189556-0 2002 Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax. Retinoids 0-9 BCL2 apoptosis regulator Homo sapiens 107-112 12189556-3 2002 An involvement of the Bcl-2 family of proteins was shown, such that 9-cis-retinoic acid causes a decrease in the Bcl-2/Bax ratio. Alitretinoin 68-87 BCL2 apoptosis regulator Homo sapiens 22-27 12189556-3 2002 An involvement of the Bcl-2 family of proteins was shown, such that 9-cis-retinoic acid causes a decrease in the Bcl-2/Bax ratio. Alitretinoin 68-87 BCL2 apoptosis regulator Homo sapiens 113-118 12189556-4 2002 Overexpression of Bcl-2 also resulted in inhibition of apoptosis induced by 9-cis-retinoic acid. Alitretinoin 76-95 BCL2 apoptosis regulator Homo sapiens 18-23 12058035-8 2002 In addition, gene expression analysis revealed that EGCG prevented both the 6-OHDA-induced expression of several mRNAs, such as Bax, Bad, and Mdm2, and the decrease in Bcl-2, Bcl-w, and Bcl-x(L). epigallocatechin gallate 52-56 BCL2 apoptosis regulator Homo sapiens 168-173 12068015-10 2002 Expression of the antiapoptotic protein, Bcl-2, in BJAB cells drastically inhibited TAS-103-induced apoptosis, confirming that H(2)O(2) generation occurs upstream of mitochondrial permeability transition. h(2) 127-131 BCL2 apoptosis regulator Homo sapiens 41-46 12160929-8 2002 The levels of p53 and Bax proteins were elevated, while Bcl-2 protein was downregulated in TCE- or PERC-treated p53-WT H460 cells. Trichloroethylene 91-94 BCL2 apoptosis regulator Homo sapiens 56-61 12403069-6 2002 The increase in Bax mRNA to Bcl-2 mRNA ratio after treatment with CDDP was suppressed in MDR1-overexpressing cells. Cisplatin 66-70 BCL2 apoptosis regulator Homo sapiens 28-33 12160929-8 2002 The levels of p53 and Bax proteins were elevated, while Bcl-2 protein was downregulated in TCE- or PERC-treated p53-WT H460 cells. Tetrachloroethylene 99-103 BCL2 apoptosis regulator Homo sapiens 56-61 12147221-9 2002 Our results thus indicate that pierisin-1-induced apoptosis is mediated primarily via a mitochondrial pathway involving Bcl-2 and caspases. pierisin-1 31-41 BCL2 apoptosis regulator Homo sapiens 120-125 12042324-8 2002 TAT-BH4 attenuated CK release and loss of TTC staining, demonstrating the role of mitochondria and a pro-apoptotic Bcl-2 family member in the process leading to cell death. sapropterin 4-7 BCL2 apoptosis regulator Homo sapiens 115-120 12139741-6 2002 Treatment with all-trans retinoic acid (ATRA) reduced Bcl-2 and Bcl-X(L) expression in the leukaemic Q cells, and enhanced their chemosensitivity to cytosine arabinoside (ara-C). Tretinoin 15-38 BCL2 apoptosis regulator Homo sapiens 54-59 12023951-7 2002 The pro-apoptotic BCL-2 family member, BAX, is also activated faster in cells expressing normal CFTR than in those with mutant CFTR under these conditions, and artificial glutathione depletion increases the extent of BAX activation. Glutathione 171-182 BCL2 apoptosis regulator Homo sapiens 18-23 12147221-0 2002 Bcl-2 blocks apoptosis caused by pierisin-1, a guanine-specific ADP-ribosylating toxin from the cabbage butterfly. pierisin-1 33-43 BCL2 apoptosis regulator Homo sapiens 0-5 12147221-0 2002 Bcl-2 blocks apoptosis caused by pierisin-1, a guanine-specific ADP-ribosylating toxin from the cabbage butterfly. Guanine 47-54 BCL2 apoptosis regulator Homo sapiens 0-5 12139741-6 2002 Treatment with all-trans retinoic acid (ATRA) reduced Bcl-2 and Bcl-X(L) expression in the leukaemic Q cells, and enhanced their chemosensitivity to cytosine arabinoside (ara-C). Tretinoin 40-44 BCL2 apoptosis regulator Homo sapiens 54-59 12060676-0 2002 Glutathione depletion enforces the mitochondrial permeability transition and causes cell death in Bcl-2 overexpressing HL60 cells. Glutathione 0-11 BCL2 apoptosis regulator Homo sapiens 98-103 12174089-9 2002 1,25(OH)2D3 may induce apoptosis either indirectly through effects on the insulin-like growth receptor and tumour necrosis factor-alpha or more directly via the Bcl-2 family system, the ceramide pathway, the death receptors (e.g. Fas) and the stress-activated protein kinase pathways (Jun N terminal kinase and p38). Calcitriol 0-11 BCL2 apoptosis regulator Homo sapiens 161-166 12154028-3 2002 This study was designed to determine whether, and how, the cyclic Arg-Gly-Asp peptide Cilengitide (EMD 121974), which targets the alpha(v)beta(3) integrin receptor expressed on neovasculature, could increase systemic RIT efficacy of therapy in a human breast cancer tumor model having mutant p53 and expressing bcl-2. peptide cilengitide 78-97 BCL2 apoptosis regulator Homo sapiens 311-316 12212968-4 2002 The administration of agonistic anti-Fas antibody (CH-11) or cycloheximide alone did not induce apoptosis, whereas the co-administration of CH-11 with cycloheximide induced apoptosis in WI-38 cells, in which caspase-8 and -3, but not -9, were activated, and X chromosome-linked inhibitor of apoptosis (ILP) and FLICE-like inhibitor protein (FLIP(L)), but not bcl-xL and bcl-2, were remarkably down regulated. 4-dimethylamino-3',4'-dimethoxychalcone 140-145 BCL2 apoptosis regulator Homo sapiens 370-375 12212968-4 2002 The administration of agonistic anti-Fas antibody (CH-11) or cycloheximide alone did not induce apoptosis, whereas the co-administration of CH-11 with cycloheximide induced apoptosis in WI-38 cells, in which caspase-8 and -3, but not -9, were activated, and X chromosome-linked inhibitor of apoptosis (ILP) and FLICE-like inhibitor protein (FLIP(L)), but not bcl-xL and bcl-2, were remarkably down regulated. Cycloheximide 151-164 BCL2 apoptosis regulator Homo sapiens 370-375 12165276-0 2002 Glutamine protects activated human T cells from apoptosis by up-regulating glutathione and Bcl-2 levels. Glutamine 0-9 BCL2 apoptosis regulator Homo sapiens 91-96 12165276-7 2002 Meanwhile, glutamine down-regulated CD95 and CD95L expression, but up-regulated CD45RO and Bcl-2 expression in activated T cells. Glutamine 11-20 BCL2 apoptosis regulator Homo sapiens 91-96 12165276-11 2002 Studying normal peripheral lymphoproliferation, we also found that the presence of glutamine increased lymphoproliferation as well as Bcl-2 and CD95 expression; but decreased CD95L and activation-induced T-cell death. Glutamine 83-92 BCL2 apoptosis regulator Homo sapiens 134-139 12060676-1 2002 Bcl-2, a protein that blocks apoptosis by inhibiting the mitochondrial permeability transition (MPT) and release of cytochrome c appears to affect normal mitochondrial function by altering electron flow and increasing rates of reactive oxygen species (ROS) production. Reactive Oxygen Species 227-250 BCL2 apoptosis regulator Homo sapiens 0-5 12060676-1 2002 Bcl-2, a protein that blocks apoptosis by inhibiting the mitochondrial permeability transition (MPT) and release of cytochrome c appears to affect normal mitochondrial function by altering electron flow and increasing rates of reactive oxygen species (ROS) production. Reactive Oxygen Species 252-255 BCL2 apoptosis regulator Homo sapiens 0-5 12126962-0 2002 Bcl-2 phosphorylation and proteasome-dependent degradation induced by paclitaxel treatment: consequences on sensitivity of isolated mitochondria to Bid. Paclitaxel 70-80 BCL2 apoptosis regulator Homo sapiens 0-5 12060676-2 2002 In this study, we show that glutathione (GSH) depletion induces ROS production and selective toxicity in HL60 cells that overexpress Bcl-2 compared with neomycin vector control cells. Glutathione 28-39 BCL2 apoptosis regulator Homo sapiens 133-138 12126962-1 2002 Several studies have suggested that Bcl-2 phosphorylation, which occurs during mitotic arrest induced by paclitaxel, inhibits its antiapoptotic function. Paclitaxel 105-115 BCL2 apoptosis regulator Homo sapiens 36-41 12126962-4 2002 In HeLa cells, in which paclitaxel induces apoptosis, the nonphosphorylated form of Bcl-2 is degraded by a proteasome-dependent degradation pathway, whereas the phosphorylated forms of mitochondrial Bcl-2 appear to be resistant to proteasome-induced degradation. Paclitaxel 24-34 BCL2 apoptosis regulator Homo sapiens 84-89 12126962-4 2002 In HeLa cells, in which paclitaxel induces apoptosis, the nonphosphorylated form of Bcl-2 is degraded by a proteasome-dependent degradation pathway, whereas the phosphorylated forms of mitochondrial Bcl-2 appear to be resistant to proteasome-induced degradation. Paclitaxel 24-34 BCL2 apoptosis regulator Homo sapiens 199-204 12126962-8 2002 Indeed, in response to paclitaxel treatment, the level of Bcl-2 expression in mitochondria rather than its phosphorylation state could regulate the sensitivity of mitochondria to cytochrome c releasing agents in vitro. Paclitaxel 23-33 BCL2 apoptosis regulator Homo sapiens 58-63 12060676-2 2002 In this study, we show that glutathione (GSH) depletion induces ROS production and selective toxicity in HL60 cells that overexpress Bcl-2 compared with neomycin vector control cells. Glutathione 41-44 BCL2 apoptosis regulator Homo sapiens 133-138 12060676-2 2002 In this study, we show that glutathione (GSH) depletion induces ROS production and selective toxicity in HL60 cells that overexpress Bcl-2 compared with neomycin vector control cells. Reactive Oxygen Species 64-67 BCL2 apoptosis regulator Homo sapiens 133-138 12060676-2 2002 In this study, we show that glutathione (GSH) depletion induces ROS production and selective toxicity in HL60 cells that overexpress Bcl-2 compared with neomycin vector control cells. Neomycin 153-161 BCL2 apoptosis regulator Homo sapiens 133-138 12118331-0 2002 7-hydroxystaurosporine (UCN-01) and ionizing radiation combine to inhibit the growth of Bcl-2-overexpressing U937 leukemia cells through a non-apoptotic mechanism. 7-hydroxystaurosporine 0-22 BCL2 apoptosis regulator Homo sapiens 88-93 12144824-14 2002 Bcl-2 phosphorylation appeared after exposure to IC(50) PTX in all cells. Paclitaxel 56-59 BCL2 apoptosis regulator Homo sapiens 0-5 12358797-0 2002 Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. n-propargyl-1(r)-aminoindan 159-186 BCL2 apoptosis regulator Homo sapiens 137-142 12358797-2 2002 NM(R)Sal reduced mitochondrial membrane potential, DeltaPsim, in the early phase of apoptosis, which was not suppressed by a pan-caspase inhibitor, but was antagonized by Bcl-2 and cyclosporin A, suggesting the involvement of the PT in NM(R)Sal-induced loss of DeltaPsim. sal 5-8 BCL2 apoptosis regulator Homo sapiens 171-176 12358797-3 2002 NM(R)Sal-induced apoptosis was completely inhibited not only by Bcl-2 and a pan-caspase inhibitor, but also by cyclosporin A, suggesting the essential role of the PT in NM(R)Sal-induced apoptosis. sal 5-8 BCL2 apoptosis regulator Homo sapiens 64-69 12135371-13 2002 Bcl-2 BH3 failed to induce cytochrome c release, even in wild-type cells. BH 3 6-9 BCL2 apoptosis regulator Homo sapiens 0-5 12513765-3 2002 It was concluded that PTPase pathway might be implicated in the regulation of cell proliferation, cell cycle and apoptosis, and PTPase specific inhibitor Na(3)VO(4) could induce Raji cell growth inhibition, G(2)/M arrest and apoptosis via down-regulation of Bcl-2 and cyclin B1, and reduction of mitochondrial transmembrane potential. na(3) 154-159 BCL2 apoptosis regulator Homo sapiens 258-263 12492117-0 2002 PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Bortezomib 0-6 BCL2 apoptosis regulator Homo sapiens 46-51 12492117-1 2002 Treatment with the proteasome inhibitor, PS-341 resulted in concentration- and time-dependent effects on Bcl-2 phosphorylation and cleavage in H460 cells that coincided with the PS-341-induced G2-M phase arrest. Bortezomib 41-47 BCL2 apoptosis regulator Homo sapiens 105-110 12492117-2 2002 The observed Bcl-2 cleavage paralleled the degree of PS-341-induced apoptosis but was detected to a similar extent with comparable concentrations of two other proteasome inhibitors (MG-132 and PSI). Bortezomib 53-59 BCL2 apoptosis regulator Homo sapiens 13-18 12492117-2 2002 The observed Bcl-2 cleavage paralleled the degree of PS-341-induced apoptosis but was detected to a similar extent with comparable concentrations of two other proteasome inhibitors (MG-132 and PSI). Magnesium 182-184 BCL2 apoptosis regulator Homo sapiens 13-18 12492117-4 2002 Exposure to PS-341 resulted in an additional Mr 25,000 cleavage fragment of Bcl-2, whereas only a Mr 23,000 fragment was observed with other anticancer agents. Bortezomib 12-18 BCL2 apoptosis regulator Homo sapiens 76-81 12170431-5 2002 PS-341 is a specific, selective inhibitor of the 26S proteasome which induces apoptosis and has activity in cell types characterized by overexpression of Bcl-2. Bortezomib 0-6 BCL2 apoptosis regulator Homo sapiens 154-159 12135371-7 2002 Bax BH3 peptide (20-amino acids) potently inhibited both Bax/Bcl-2 and Bax/Bcl-x(L) interactions, exhibiting IC(50) values of 15 and 9.5 microM, respectively. 20-amino acids 17-31 BCL2 apoptosis regulator Homo sapiens 61-66 12135371-9 2002 Bcl-2 BH3 peptide (20-amino acids) was inactive toward Bax/Bcl-2 and had only a weak inhibitory effect on Bax/Bcl-x(L) heterodimerization. BH 3 6-9 BCL2 apoptosis regulator Homo sapiens 0-5 12135371-9 2002 Bcl-2 BH3 peptide (20-amino acids) was inactive toward Bax/Bcl-2 and had only a weak inhibitory effect on Bax/Bcl-x(L) heterodimerization. 20-amino acids 19-33 BCL2 apoptosis regulator Homo sapiens 0-5 12135371-15 2002 In cells overexpressing Bcl-2, the potency of Bax BH3 peptide was similar to that seen in wild-type cells, while the efficacy of Bad BH3 peptide was reduced. BH 3 50-53 BCL2 apoptosis regulator Homo sapiens 24-29 12135371-15 2002 In cells overexpressing Bcl-2, the potency of Bax BH3 peptide was similar to that seen in wild-type cells, while the efficacy of Bad BH3 peptide was reduced. BH 3 133-136 BCL2 apoptosis regulator Homo sapiens 24-29 11994280-1 2002 In this study we found that Tat protected vincristine-treated Kaposi"s sarcoma cells from apoptosis and from down-regulation of several anti-apoptotic genes such as AKT-1, AKT-2, BCL2, BCL-XL, and insulin-like growth factor I and induced the de novo expression of the interleukin-3 gene. Vincristine 42-53 BCL2 apoptosis regulator Homo sapiens 179-183 12119354-5 2002 Instead, ROS were produced by integrin-induced changes in mitochondrial function, which were inhibited by Bcl-2 and involved transient membrane potential loss. Reactive Oxygen Species 9-12 BCL2 apoptosis regulator Homo sapiens 106-111 12000759-10 2002 We conclude that ionomycin-induced calpain activation promotes decrease of Bcl-2 proteins thereby triggering the intrinsic apoptotic pathway. Ionomycin 17-26 BCL2 apoptosis regulator Homo sapiens 75-80 12114539-10 2002 In addition, SB203580 effectively inhibited Ad.mda-7-mediated induction of the GADD family of genes in a time- and dose-dependent manner, and it effectively blocked Ad.mda-7-mediated down-regulation of the antiapoptotic protein BCL-2. SB 203580 13-21 BCL2 apoptosis regulator Homo sapiens 228-233 12086721-2 2002 Effect of concentration and time on incorporation of free and lipid associated (lipoplexes) [3H]Bcl-2 AO (25-600 ng/ml) into normolipidemic human plasma lipoproteins was determined by density gradient ultracentrifugation after incubation at 37 degrees C for 5, 30, 60 and 120 min. Tritium 93-95 BCL2 apoptosis regulator Homo sapiens 96-101 12150944-0 2002 Arginine antimetabolite L-canavanine induces apoptotic cell death in human Jurkat T cells via caspase-3 activation regulated by Bcl-2 or Bcl-xL. Arginine 0-8 BCL2 apoptosis regulator Homo sapiens 128-133 12150944-0 2002 Arginine antimetabolite L-canavanine induces apoptotic cell death in human Jurkat T cells via caspase-3 activation regulated by Bcl-2 or Bcl-xL. Canavanine 24-36 BCL2 apoptosis regulator Homo sapiens 128-133 12150944-6 2002 These results demonstrate that the cytotoxic effect of L-canavanine on Jurkat T cells is attributable to the induced apoptosis and that L-canavanine-induced apoptosis is mediated by a cytochrome c-independent caspase-3 activation pathway that can be interrupted by Bcl-2 or Bcl-xL. Canavanine 136-148 BCL2 apoptosis regulator Homo sapiens 265-270 12086721-10 2002 These findings suggest that the majority of [3H]Bcl-2 AO is plasma protein bound with little lipoprotein association and no significant movement between different lipoprotein and LPDP fractions. Tritium 45-47 BCL2 apoptosis regulator Homo sapiens 48-53 12070027-4 2002 Each antisense oligonucleotide (ASO; Bcl-2, Bcl-x(L), or Mcl-1 ASO) introduced into human myeloma cell lines by electroporation induced a marked reduction in the level of the corresponding protein. Oligonucleotides 15-30 BCL2 apoptosis regulator Homo sapiens 37-42 12091252-5 2002 In room air, cells without supplemental Gln (Gln-) survived with BCL-2 levels similar to those of Gln+ cells, but cell growth was minimal. Glutamine 45-48 BCL2 apoptosis regulator Homo sapiens 65-70 12091252-5 2002 In room air, cells without supplemental Gln (Gln-) survived with BCL-2 levels similar to those of Gln+ cells, but cell growth was minimal. Glutamine 45-48 BCL2 apoptosis regulator Homo sapiens 65-70 12070027-8 2002 Finally, although Bcl-2 ASO treatment alone has no effect, it can sensitize myeloma cell lines to dexamethasone (Dex), whereas Bcl-x(L) ASO in combination with Dex still had no effect. Dexamethasone 98-111 BCL2 apoptosis regulator Homo sapiens 18-23 12141825-6 2002 Immunohistochemical bcl-2 expression was assessed using the streptavidin-biotin method and the presence of apoptotic cells was evaluated by TUNEL method. Biotin 73-79 BCL2 apoptosis regulator Homo sapiens 20-25 12081782-2 2002 MATERIALS AND METHODS: In the cisplatin-resistant bladder tumour cell lines T24R1 and T24R2, the expression of Bcl2 was determined by reverse transcription-polymerase chain reaction and Western blot assay, and antisense oligonucleotide targeting of the Bcl2 coding sequence was administered with lipofectin. Oligonucleotides 220-235 BCL2 apoptosis regulator Homo sapiens 111-115 12081782-2 2002 MATERIALS AND METHODS: In the cisplatin-resistant bladder tumour cell lines T24R1 and T24R2, the expression of Bcl2 was determined by reverse transcription-polymerase chain reaction and Western blot assay, and antisense oligonucleotide targeting of the Bcl2 coding sequence was administered with lipofectin. 1,2-dielaidoylphosphatidylethanolamine 296-306 BCL2 apoptosis regulator Homo sapiens 111-115 12081782-4 2002 Short-term exposure to cisplatin up-regulated Bcl2 mRNA and protein expression in parent T24 cells. Cisplatin 23-32 BCL2 apoptosis regulator Homo sapiens 46-50 12081782-5 2002 Treatment with antisense oligonucleotide down-regulated Bcl2 protein expression and significantly enhanced the cytotoxicity of cisplatin. Oligonucleotides 25-40 BCL2 apoptosis regulator Homo sapiens 56-60 12081782-5 2002 Treatment with antisense oligonucleotide down-regulated Bcl2 protein expression and significantly enhanced the cytotoxicity of cisplatin. Cisplatin 127-136 BCL2 apoptosis regulator Homo sapiens 56-60 12081782-6 2002 CONCLUSIONS: Up-regulation of Bcl2 protein expression might be one of the mechanisms of cisplatin resistance in bladder cancer cells, and antisense Bcl2 oligonucleotide may be helpful in chemotherapy for bladder cancer by reversing cisplatin resistance. Cisplatin 88-97 BCL2 apoptosis regulator Homo sapiens 30-34 12081782-6 2002 CONCLUSIONS: Up-regulation of Bcl2 protein expression might be one of the mechanisms of cisplatin resistance in bladder cancer cells, and antisense Bcl2 oligonucleotide may be helpful in chemotherapy for bladder cancer by reversing cisplatin resistance. Oligonucleotides 153-168 BCL2 apoptosis regulator Homo sapiens 148-152 12081782-6 2002 CONCLUSIONS: Up-regulation of Bcl2 protein expression might be one of the mechanisms of cisplatin resistance in bladder cancer cells, and antisense Bcl2 oligonucleotide may be helpful in chemotherapy for bladder cancer by reversing cisplatin resistance. Cisplatin 232-241 BCL2 apoptosis regulator Homo sapiens 30-34 12081782-6 2002 CONCLUSIONS: Up-regulation of Bcl2 protein expression might be one of the mechanisms of cisplatin resistance in bladder cancer cells, and antisense Bcl2 oligonucleotide may be helpful in chemotherapy for bladder cancer by reversing cisplatin resistance. Cisplatin 232-241 BCL2 apoptosis regulator Homo sapiens 148-152 12106610-8 2002 In MCF-7 cells, a reduction of bcl-2 protein expression by TAM treatment was abolished by a combination of TAM with PBR ligands. Tamoxifen 59-62 BCL2 apoptosis regulator Homo sapiens 31-36 12106610-8 2002 In MCF-7 cells, a reduction of bcl-2 protein expression by TAM treatment was abolished by a combination of TAM with PBR ligands. Tamoxifen 107-110 BCL2 apoptosis regulator Homo sapiens 31-36 12186376-5 2002 However, only MCF-7, MDA-MB-231, and ZR-75-1 cells, which expressed a high level of bcl-2 protein, underwent apoptosis when exposed to the combination of TGZ and either ATRA or 9-cis-RA. (2~{s},3~{r},4~{s},5~{r},6~{r})-2-[(2~{s},3~{r},4~{s},5~{r},6~{r})-4-[4-(3-Fluorophenyl)-1,2,3-Triazol-1-Yl]-6-(Hydroxymethyl)-3,5-Bis(Oxidanyl)oxan-2-Yl]sulfanyl-6-(Hydroxymethyl)oxane-3,4,5-Triol 154-157 BCL2 apoptosis regulator Homo sapiens 84-89 12186376-5 2002 However, only MCF-7, MDA-MB-231, and ZR-75-1 cells, which expressed a high level of bcl-2 protein, underwent apoptosis when exposed to the combination of TGZ and either ATRA or 9-cis-RA. Tretinoin 169-173 BCL2 apoptosis regulator Homo sapiens 84-89 12186376-5 2002 However, only MCF-7, MDA-MB-231, and ZR-75-1 cells, which expressed a high level of bcl-2 protein, underwent apoptosis when exposed to the combination of TGZ and either ATRA or 9-cis-RA. Tretinoin 177-185 BCL2 apoptosis regulator Homo sapiens 84-89 12081782-0 2002 Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines. Oligonucleotides 15-30 BCL2 apoptosis regulator Homo sapiens 10-14 12081782-0 2002 Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines. Cisplatin 34-43 BCL2 apoptosis regulator Homo sapiens 10-14 12081782-1 2002 OBJECTIVE: To determine the change of expression of Bcl2 in cisplatin-resistant bladder cancer cell lines and the reversibility of chemoresistance to cisplatin with antisense oligonucleotide against Bcl2, as higher expression of Bcl2 is associated with drug resistance in many different cancer cell lines. Cisplatin 60-69 BCL2 apoptosis regulator Homo sapiens 52-56 12081782-1 2002 OBJECTIVE: To determine the change of expression of Bcl2 in cisplatin-resistant bladder cancer cell lines and the reversibility of chemoresistance to cisplatin with antisense oligonucleotide against Bcl2, as higher expression of Bcl2 is associated with drug resistance in many different cancer cell lines. Cisplatin 150-159 BCL2 apoptosis regulator Homo sapiens 199-203 12081782-1 2002 OBJECTIVE: To determine the change of expression of Bcl2 in cisplatin-resistant bladder cancer cell lines and the reversibility of chemoresistance to cisplatin with antisense oligonucleotide against Bcl2, as higher expression of Bcl2 is associated with drug resistance in many different cancer cell lines. Cisplatin 150-159 BCL2 apoptosis regulator Homo sapiens 199-203 12081782-1 2002 OBJECTIVE: To determine the change of expression of Bcl2 in cisplatin-resistant bladder cancer cell lines and the reversibility of chemoresistance to cisplatin with antisense oligonucleotide against Bcl2, as higher expression of Bcl2 is associated with drug resistance in many different cancer cell lines. Oligonucleotides 175-190 BCL2 apoptosis regulator Homo sapiens 52-56 12081782-1 2002 OBJECTIVE: To determine the change of expression of Bcl2 in cisplatin-resistant bladder cancer cell lines and the reversibility of chemoresistance to cisplatin with antisense oligonucleotide against Bcl2, as higher expression of Bcl2 is associated with drug resistance in many different cancer cell lines. Oligonucleotides 175-190 BCL2 apoptosis regulator Homo sapiens 199-203 12081782-1 2002 OBJECTIVE: To determine the change of expression of Bcl2 in cisplatin-resistant bladder cancer cell lines and the reversibility of chemoresistance to cisplatin with antisense oligonucleotide against Bcl2, as higher expression of Bcl2 is associated with drug resistance in many different cancer cell lines. Oligonucleotides 175-190 BCL2 apoptosis regulator Homo sapiens 199-203 12081782-2 2002 MATERIALS AND METHODS: In the cisplatin-resistant bladder tumour cell lines T24R1 and T24R2, the expression of Bcl2 was determined by reverse transcription-polymerase chain reaction and Western blot assay, and antisense oligonucleotide targeting of the Bcl2 coding sequence was administered with lipofectin. Cisplatin 30-39 BCL2 apoptosis regulator Homo sapiens 111-115 12100143-8 2002 Finally, over-expression of Bcl-2 and its homologue Bcl-xL was observed in manumycin-treated cells as well as in control myeloma cells, implying that the Bcl-2 family is not involved. manumycin 75-84 BCL2 apoptosis regulator Homo sapiens 28-33 12063559-11 2002 Similarly, the two retinoids caused almost a 50% (p=0.01) down-regulation of Bcl-2 immunoreactivity. Retinoids 19-28 BCL2 apoptosis regulator Homo sapiens 77-82 12063559-13 2002 These data demonstrate that ATRA and 9cisRA may inhibit HER-2/neu induced aberrant proliferation in part by retarding cell cycle progression, down-regulating HER-2/neu-mediated signal transduction and inducing Bcl-2-dependent apoptosis through a retinoid receptor-mediated mechanism. Tretinoin 28-32 BCL2 apoptosis regulator Homo sapiens 210-215 12063550-4 2002 Overexpression of Bcl-2, however, prevented the dissipation of mitochondrial membrane potential, subsequently protecting the cells from As2O3-induced apoptosis. Arsenic Trioxide 136-141 BCL2 apoptosis regulator Homo sapiens 18-23 12063559-13 2002 These data demonstrate that ATRA and 9cisRA may inhibit HER-2/neu induced aberrant proliferation in part by retarding cell cycle progression, down-regulating HER-2/neu-mediated signal transduction and inducing Bcl-2-dependent apoptosis through a retinoid receptor-mediated mechanism. Alitretinoin 37-43 BCL2 apoptosis regulator Homo sapiens 210-215 12063570-9 2002 Further studies in this area are warranted as the roles of p21WAF1, Bax/Bcl-2 and NF-kappaB may be important molecular events in mediating the antiproliferative and apoptosis inducing effect of etoposide in combination with ciprofloxacin in HRPC cells. Etoposide 194-203 BCL2 apoptosis regulator Homo sapiens 72-77 12101266-1 2002 Inhibition of bcl-2 expression by antisense oligodeoxynucleotides (ODN) might render bcl-2 overexpressing malignant B cells more susceptible to chemotherapy. Oligodeoxyribonucleotides 44-65 BCL2 apoptosis regulator Homo sapiens 14-19 12107264-8 2002 Endogenous levels of the survival gene protein Bcl-2 were significantly elevated in all cultures treated with Dex compared with either nonstimulated cultures or cultures stimulated with LH and forskolin. Luteinizing Hormone 186-188 BCL2 apoptosis regulator Homo sapiens 47-52 12107264-8 2002 Endogenous levels of the survival gene protein Bcl-2 were significantly elevated in all cultures treated with Dex compared with either nonstimulated cultures or cultures stimulated with LH and forskolin. Colforsin 193-202 BCL2 apoptosis regulator Homo sapiens 47-52 12107264-8 2002 Endogenous levels of the survival gene protein Bcl-2 were significantly elevated in all cultures treated with Dex compared with either nonstimulated cultures or cultures stimulated with LH and forskolin. Dexamethasone 110-113 BCL2 apoptosis regulator Homo sapiens 47-52 12101266-1 2002 Inhibition of bcl-2 expression by antisense oligodeoxynucleotides (ODN) might render bcl-2 overexpressing malignant B cells more susceptible to chemotherapy. Oligodeoxyribonucleotides 44-65 BCL2 apoptosis regulator Homo sapiens 85-90 12101266-1 2002 Inhibition of bcl-2 expression by antisense oligodeoxynucleotides (ODN) might render bcl-2 overexpressing malignant B cells more susceptible to chemotherapy. Oligodeoxyribonucleotides 67-70 BCL2 apoptosis regulator Homo sapiens 14-19 12101266-1 2002 Inhibition of bcl-2 expression by antisense oligodeoxynucleotides (ODN) might render bcl-2 overexpressing malignant B cells more susceptible to chemotherapy. Oligodeoxyribonucleotides 67-70 BCL2 apoptosis regulator Homo sapiens 85-90 12118096-5 2002 Quantitative analysis of apoptosis and the apoptosis regulatory genes Bcl-2, Bcl-xL, and Bax were performed by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-digoxigenin nick-end labeling staining and real-time PCR, respectively. deoxyuridine triphosphate 158-183 BCL2 apoptosis regulator Homo sapiens 70-75 12106882-6 2002 Components associated with Fas-dependent apoptosis (caspase-3, bcl-2 and bax) were characterized using western immunoblot following exposure to serum-derived membrane fragments. ammonium ferrous sulfate 27-30 BCL2 apoptosis regulator Homo sapiens 63-68 12097652-8 2002 The highest expression of Bcl-2 was observed in control Caco-2 cells, and expression decreased with increasing butyrate concentration. Butyrates 111-119 BCL2 apoptosis regulator Homo sapiens 26-31 12118096-5 2002 Quantitative analysis of apoptosis and the apoptosis regulatory genes Bcl-2, Bcl-xL, and Bax were performed by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-digoxigenin nick-end labeling staining and real-time PCR, respectively. Digoxigenin 184-195 BCL2 apoptosis regulator Homo sapiens 70-75 12075113-7 2002 Importantly, we found that EW36 cells, which overexpress the Bcl-2 protein, can be substantially sensitized to arsenite-induced apoptosis by prior exposure to nonlethal hyperthermia. arsenite 111-119 BCL2 apoptosis regulator Homo sapiens 61-66 12142991-0 2002 Inhibition of telomerase activity and bcl-2 expression in berbamine-induced apoptosis in HL-60 cells. berbamine 58-67 BCL2 apoptosis regulator Homo sapiens 38-43 12142991-5 2002 The telomerase activity was inhibited in a time-dependent manner during the berbamine-induced apoptosis of HL-60 cells, and the expression of bcl-2 was progressively down-regulated by berbamine. berbamine 184-193 BCL2 apoptosis regulator Homo sapiens 142-147 12142991-7 2002 The present results indicate that inhibition of telomerase and reduced bcl-2 gene expression may play a role in the berbamine-induced apoptosis of HL-60 cells. berbamine 116-125 BCL2 apoptosis regulator Homo sapiens 71-76 12127261-8 2002 Both of the antioxidants vitamin C and vitamin E prevented the dysregulation of Bcl-2 and Bax in HA-treated endothelial cells. Ascorbic Acid 25-34 BCL2 apoptosis regulator Homo sapiens 80-85 12127261-8 2002 Both of the antioxidants vitamin C and vitamin E prevented the dysregulation of Bcl-2 and Bax in HA-treated endothelial cells. Vitamin E 39-48 BCL2 apoptosis regulator Homo sapiens 80-85 12408761-3 2002 The effect of curcumin on the expression of c-myc, bcl-2, mutant-type p53 and Fas protein and mRNA was studied by flow cytometry (FCM) and reverse transcription-polymerase chain reaction (RT-PCR). Curcumin 14-22 BCL2 apoptosis regulator Homo sapiens 51-56 12408761-8 2002 The expression of c-myc, bcl-2, mutant-type p53 protein and mRNA was decreased sharply in CA46 cells treated with curcumin, while Fas protein and mRNA was increased. Curcumin 114-122 BCL2 apoptosis regulator Homo sapiens 25-30 12411207-0 2002 [The effects of carotenoids on the proliferation of human breast cancer cell and gene expression of bcl-2]. Carotenoids 16-27 BCL2 apoptosis regulator Homo sapiens 100-105 12408761-9 2002 CONCLUSION: Curcumin is able to inhibit the proliferation of CA46 cells and induce the cell apoptosis by down-regulating the expression of c-myc, bcl-2, mutant-type p53 and up-regulating the expression of Fas. Curcumin 12-20 BCL2 apoptosis regulator Homo sapiens 146-151 12411207-1 2002 OBJECTIVE: To investigate the effects of various carotenoids on the proliferation, cell cycle, apoptosis and expression of bcl-2 gene in breast cancer cell MCF-7. Carotenoids 49-60 BCL2 apoptosis regulator Homo sapiens 123-128 12411207-9 2002 Carotenoids down regulated bcl-2 gene expression. Carotenoids 0-11 BCL2 apoptosis regulator Homo sapiens 27-32 12057839-0 2002 An anti-Parkinson"s disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. n-propargyl-1(r)-aminoindan 34-61 BCL2 apoptosis regulator Homo sapiens 114-119 12057839-0 2002 An anti-Parkinson"s disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. rasagiline 63-73 BCL2 apoptosis regulator Homo sapiens 114-119 12057839-3 2002 In this paper, the effects of rasagiline on the levels of anti-apoptotic bcl-2 gene family were studied. rasagiline 30-40 BCL2 apoptosis regulator Homo sapiens 73-78 12057839-4 2002 Rasagiline increased the levels of bcl-2 and bcl-x(l) mRNA at 100-10 nM and 100-10 pM, but not the level of pro-apoptotic bax mRNA. rasagiline 0-10 BCL2 apoptosis regulator Homo sapiens 35-40 12057839-5 2002 Enhanced expression of bcl-2 family indicates the ability of rasagiline to adjust the apoptotic threshold and protect degenerating neurons in PD. rasagiline 61-71 BCL2 apoptosis regulator Homo sapiens 23-28 11929874-0 2002 A functional role for the B56 alpha-subunit of protein phosphatase 2A in ceramide-mediated regulation of Bcl2 phosphorylation status and function. Ceramides 73-81 BCL2 apoptosis regulator Homo sapiens 105-109 11929874-1 2002 Recently it has been shown that the potent apoptotic agent ceramide activates a mitochondrial protein phosphatase 2A (PP2A) and promotes dephosphorylation of the anti-apoptotic molecule Bcl2 (Ruvolo, P. P., Deng, X., Ito, T., Carr, B. K., and May, W. S. (1999) J. Biol. Ceramides 59-67 BCL2 apoptosis regulator Homo sapiens 186-190 11929874-4 2002 In cells expressing Bcl2, dephosphorylation of Bcl2 appears to be required for ceramide-induced cell death because treatment of cells with low doses of the PP2A inhibitor okadaic acid blocks Bcl2 dephosphorylation and promotes cell survival. Ceramides 79-87 BCL2 apoptosis regulator Homo sapiens 20-24 11929874-4 2002 In cells expressing Bcl2, dephosphorylation of Bcl2 appears to be required for ceramide-induced cell death because treatment of cells with low doses of the PP2A inhibitor okadaic acid blocks Bcl2 dephosphorylation and promotes cell survival. Ceramides 79-87 BCL2 apoptosis regulator Homo sapiens 47-51 11929874-4 2002 In cells expressing Bcl2, dephosphorylation of Bcl2 appears to be required for ceramide-induced cell death because treatment of cells with low doses of the PP2A inhibitor okadaic acid blocks Bcl2 dephosphorylation and promotes cell survival. Ceramides 79-87 BCL2 apoptosis regulator Homo sapiens 47-51 11929874-4 2002 In cells expressing Bcl2, dephosphorylation of Bcl2 appears to be required for ceramide-induced cell death because treatment of cells with low doses of the PP2A inhibitor okadaic acid blocks Bcl2 dephosphorylation and promotes cell survival. Okadaic Acid 171-183 BCL2 apoptosis regulator Homo sapiens 20-24 11929874-4 2002 In cells expressing Bcl2, dephosphorylation of Bcl2 appears to be required for ceramide-induced cell death because treatment of cells with low doses of the PP2A inhibitor okadaic acid blocks Bcl2 dephosphorylation and promotes cell survival. Okadaic Acid 171-183 BCL2 apoptosis regulator Homo sapiens 47-51 11929874-4 2002 In cells expressing Bcl2, dephosphorylation of Bcl2 appears to be required for ceramide-induced cell death because treatment of cells with low doses of the PP2A inhibitor okadaic acid blocks Bcl2 dephosphorylation and promotes cell survival. Okadaic Acid 171-183 BCL2 apoptosis regulator Homo sapiens 47-51 11929874-5 2002 Furthermore, the non-phosphorylatable (i.e. PP2A-resistant) gain-of-function S70E mutant Bcl2 can protect cells from ceramide-induced apoptosis. Ceramides 117-125 BCL2 apoptosis regulator Homo sapiens 89-93 11929874-11 2002 Thus, understanding the mechanism of how PP2A regulates Bcl2 phosphorylation status and how ceramide might regulate this process requires identification of the regulatory B-subunit of PP2A that comprises the Bcl2 phosphatase. Ceramides 92-100 BCL2 apoptosis regulator Homo sapiens 208-212 11929874-12 2002 Results indicate that the B56 alpha-subunit is a candidate regulatory subunit of the physiologic Bcl2 phosphatase since (a) B56 alpha associates with Bcl2 as evidenced by pull-down experiments, (b) B56 alpha co-localizes with Bcl2 in mitochondrial membranes, (c) ceramide promotes translocation of B56 alpha to mitochondrial membranes, and (d) overexpression of B56 alpha promotes mitochondrial PP2A activity and Bcl2 dephosphorylation and potentiates cell killing with ceramide. Ceramides 263-271 BCL2 apoptosis regulator Homo sapiens 97-101 11929874-12 2002 Results indicate that the B56 alpha-subunit is a candidate regulatory subunit of the physiologic Bcl2 phosphatase since (a) B56 alpha associates with Bcl2 as evidenced by pull-down experiments, (b) B56 alpha co-localizes with Bcl2 in mitochondrial membranes, (c) ceramide promotes translocation of B56 alpha to mitochondrial membranes, and (d) overexpression of B56 alpha promotes mitochondrial PP2A activity and Bcl2 dephosphorylation and potentiates cell killing with ceramide. Ceramides 263-271 BCL2 apoptosis regulator Homo sapiens 150-154 11929874-12 2002 Results indicate that the B56 alpha-subunit is a candidate regulatory subunit of the physiologic Bcl2 phosphatase since (a) B56 alpha associates with Bcl2 as evidenced by pull-down experiments, (b) B56 alpha co-localizes with Bcl2 in mitochondrial membranes, (c) ceramide promotes translocation of B56 alpha to mitochondrial membranes, and (d) overexpression of B56 alpha promotes mitochondrial PP2A activity and Bcl2 dephosphorylation and potentiates cell killing with ceramide. Ceramides 263-271 BCL2 apoptosis regulator Homo sapiens 150-154 11929874-12 2002 Results indicate that the B56 alpha-subunit is a candidate regulatory subunit of the physiologic Bcl2 phosphatase since (a) B56 alpha associates with Bcl2 as evidenced by pull-down experiments, (b) B56 alpha co-localizes with Bcl2 in mitochondrial membranes, (c) ceramide promotes translocation of B56 alpha to mitochondrial membranes, and (d) overexpression of B56 alpha promotes mitochondrial PP2A activity and Bcl2 dephosphorylation and potentiates cell killing with ceramide. Ceramides 263-271 BCL2 apoptosis regulator Homo sapiens 150-154 11929874-12 2002 Results indicate that the B56 alpha-subunit is a candidate regulatory subunit of the physiologic Bcl2 phosphatase since (a) B56 alpha associates with Bcl2 as evidenced by pull-down experiments, (b) B56 alpha co-localizes with Bcl2 in mitochondrial membranes, (c) ceramide promotes translocation of B56 alpha to mitochondrial membranes, and (d) overexpression of B56 alpha promotes mitochondrial PP2A activity and Bcl2 dephosphorylation and potentiates cell killing with ceramide. Ceramides 470-478 BCL2 apoptosis regulator Homo sapiens 97-101 11929874-12 2002 Results indicate that the B56 alpha-subunit is a candidate regulatory subunit of the physiologic Bcl2 phosphatase since (a) B56 alpha associates with Bcl2 as evidenced by pull-down experiments, (b) B56 alpha co-localizes with Bcl2 in mitochondrial membranes, (c) ceramide promotes translocation of B56 alpha to mitochondrial membranes, and (d) overexpression of B56 alpha promotes mitochondrial PP2A activity and Bcl2 dephosphorylation and potentiates cell killing with ceramide. Ceramides 470-478 BCL2 apoptosis regulator Homo sapiens 150-154 11929874-12 2002 Results indicate that the B56 alpha-subunit is a candidate regulatory subunit of the physiologic Bcl2 phosphatase since (a) B56 alpha associates with Bcl2 as evidenced by pull-down experiments, (b) B56 alpha co-localizes with Bcl2 in mitochondrial membranes, (c) ceramide promotes translocation of B56 alpha to mitochondrial membranes, and (d) overexpression of B56 alpha promotes mitochondrial PP2A activity and Bcl2 dephosphorylation and potentiates cell killing with ceramide. Ceramides 470-478 BCL2 apoptosis regulator Homo sapiens 150-154 11929874-12 2002 Results indicate that the B56 alpha-subunit is a candidate regulatory subunit of the physiologic Bcl2 phosphatase since (a) B56 alpha associates with Bcl2 as evidenced by pull-down experiments, (b) B56 alpha co-localizes with Bcl2 in mitochondrial membranes, (c) ceramide promotes translocation of B56 alpha to mitochondrial membranes, and (d) overexpression of B56 alpha promotes mitochondrial PP2A activity and Bcl2 dephosphorylation and potentiates cell killing with ceramide. Ceramides 470-478 BCL2 apoptosis regulator Homo sapiens 150-154 12031489-0 2002 Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide. Oligonucleotides 81-96 BCL2 apoptosis regulator Homo sapiens 58-63 12056831-7 2002 At 4 and 6 h ischemia, U0126-treated astrocytes expressed a lower level of Bcl-2 than controls. U 0126 23-28 BCL2 apoptosis regulator Homo sapiens 75-80 12056831-8 2002 In contrast, LY294002-treated astrocytes expressed a higher level of Bcl-2 than controls as shown by Western blots. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 BCL2 apoptosis regulator Homo sapiens 69-74 11934900-8 2002 Thus, we propose that H-Ras signals followed by Raf-1/MAPK pathway but not PI3K not only reduces beta(1)-mediated adhesion of osteoblasts to matrix proteins but induces apoptosis presumably via the Fas up-regulation and Bcl-2 down-regulation. beta(1) 97-104 BCL2 apoptosis regulator Homo sapiens 220-225 12037671-5 2002 The results presented here indicated that the cell lines responsive to 2-ME could undergo apoptosis either by G2-M arrest (PANC-1) with Bcl-x(L) phosphorylation or by the accumulation of tetraploid cells in G1-S region (MIA PaCa-2) without Bcl-2/ Bcl-x(L) phosphorylation. 2-Methoxyestradiol 71-75 BCL2 apoptosis regulator Homo sapiens 240-245 12031489-5 2002 Only oligonucleotide 4625 exhibited a potent bispecific antisense activity against bcl-2 and bcl-xL, which effectively reduced tumor cell viability. Oligonucleotides 5-20 BCL2 apoptosis regulator Homo sapiens 83-88 12031489-6 2002 The other antisense oligonucleotides were either uniquely active against bcl-2 or completely inactive. Oligonucleotides 20-36 BCL2 apoptosis regulator Homo sapiens 73-78 12031489-2 2002 The ability of the 2"-O-(2-methoxyethylribose) (2"-MOE)-modified phosphorothioate gapmer oligonucleotide 4625, which matches the bcl-2 mRNA and has three base-mismatches to bcl-xL, to inhibit bcl-2 and bcl-xL expression and induce tumor cell apoptosis has been described. 2"-o-(2-methoxyethylribose) 19-46 BCL2 apoptosis regulator Homo sapiens 129-134 12031489-2 2002 The ability of the 2"-O-(2-methoxyethylribose) (2"-MOE)-modified phosphorothioate gapmer oligonucleotide 4625, which matches the bcl-2 mRNA and has three base-mismatches to bcl-xL, to inhibit bcl-2 and bcl-xL expression and induce tumor cell apoptosis has been described. 2"-o-(2-methoxyethylribose) 19-46 BCL2 apoptosis regulator Homo sapiens 192-197 12031489-2 2002 The ability of the 2"-O-(2-methoxyethylribose) (2"-MOE)-modified phosphorothioate gapmer oligonucleotide 4625, which matches the bcl-2 mRNA and has three base-mismatches to bcl-xL, to inhibit bcl-2 and bcl-xL expression and induce tumor cell apoptosis has been described. Parathion 65-81 BCL2 apoptosis regulator Homo sapiens 129-134 12051739-0 2002 PP1 phosphatase is involved in Bcl-2 dephosphorylation after prolonged mitotic arrest induced by paclitaxel. Paclitaxel 97-107 BCL2 apoptosis regulator Homo sapiens 31-36 12051739-1 2002 During mitotic arrest induced by paclitaxel, most of the mitochondrial Bcl-2 is phosphorylated. Paclitaxel 33-43 BCL2 apoptosis regulator Homo sapiens 71-76 12031489-2 2002 The ability of the 2"-O-(2-methoxyethylribose) (2"-MOE)-modified phosphorothioate gapmer oligonucleotide 4625, which matches the bcl-2 mRNA and has three base-mismatches to bcl-xL, to inhibit bcl-2 and bcl-xL expression and induce tumor cell apoptosis has been described. Parathion 65-81 BCL2 apoptosis regulator Homo sapiens 192-197 12051739-6 2002 Depletion of these cytosol extracts by microcystin-Sepharose maintained Bcl-2 phosphorylated forms, indicating that this cytosol possessed phosphatase activity. microcystin 39-50 BCL2 apoptosis regulator Homo sapiens 72-77 12031489-2 2002 The ability of the 2"-O-(2-methoxyethylribose) (2"-MOE)-modified phosphorothioate gapmer oligonucleotide 4625, which matches the bcl-2 mRNA and has three base-mismatches to bcl-xL, to inhibit bcl-2 and bcl-xL expression and induce tumor cell apoptosis has been described. Oligonucleotides 89-104 BCL2 apoptosis regulator Homo sapiens 129-134 12051739-6 2002 Depletion of these cytosol extracts by microcystin-Sepharose maintained Bcl-2 phosphorylated forms, indicating that this cytosol possessed phosphatase activity. Sepharose 51-60 BCL2 apoptosis regulator Homo sapiens 72-77 12051739-7 2002 Furthermore, the dephosphorylation of Bcl-2 by cytosol prepared from cells exiting mitotic block was inhibited by okadaic acid, at a dose known to inhibit PP1, and by inhibitor 2, a specific inhibitor of PP1 and by immunodepletion of PP1. Okadaic Acid 114-126 BCL2 apoptosis regulator Homo sapiens 38-43 12031489-2 2002 The ability of the 2"-O-(2-methoxyethylribose) (2"-MOE)-modified phosphorothioate gapmer oligonucleotide 4625, which matches the bcl-2 mRNA and has three base-mismatches to bcl-xL, to inhibit bcl-2 and bcl-xL expression and induce tumor cell apoptosis has been described. Oligonucleotides 89-104 BCL2 apoptosis regulator Homo sapiens 192-197 12126940-6 2002 Similarly the bcl-2 -transfected cells were more resistant to mitochondrial DNA damage after H(2)O(2) treatment than the other groups and suffered 50% less damage after exposure to 200 microM H(2)O(2), as assayed by quantitative polymerase chain reaction assays. Hydrogen Peroxide 192-200 BCL2 apoptosis regulator Homo sapiens 14-19 11997667-6 2002 Over-expression of the anti-apoptotic gene bcl-2 suppressed cell death initiated by all or single vitamin (either DCaP, CC or Rb) deprivation. Pantothenic Acid 114-118 BCL2 apoptosis regulator Homo sapiens 43-48 11997667-6 2002 Over-expression of the anti-apoptotic gene bcl-2 suppressed cell death initiated by all or single vitamin (either DCaP, CC or Rb) deprivation. Riboflavin 126-128 BCL2 apoptosis regulator Homo sapiens 43-48 11997667-7 2002 The involvement of bcl-2 activity, established a close association between small vitamin molecules particularly DCaP, CC or Rb and the biochemical activation of apoptosis. Pantothenic Acid 112-116 BCL2 apoptosis regulator Homo sapiens 19-24 12162702-3 2002 Oblimersen sodium (G3139, Genasense, Genta Inc., Berkeley Heights, NJ) is an antisense oligonucleotide (AS-ON) compound designed to specifically bind to the first 6 codons of the human bcl-2 mRNA sequence, resulting in degradation of bcl-2 mRNA and subsequent decrease in Bcl-2 protein translation. Oligonucleotides 87-102 BCL2 apoptosis regulator Homo sapiens 185-190 12162702-4 2002 Oblimersen is the first oligonucleotide to demonstrate proof of principle of an antisense effect in human tumors by the documented downregulation of the target Bcl-2 protein. Oligonucleotides 24-39 BCL2 apoptosis regulator Homo sapiens 160-165 12060119-6 2002 In addition, Bcl-2 expression was also inhibited by resveratrol. Resveratrol 52-63 BCL2 apoptosis regulator Homo sapiens 13-18 12060119-7 2002 Thus, downregulation of the two anti-apoptotic proteins iNOS and Bcl-2 can contribute to the apoptotic effects of resveratrol in leukaemic B cells from chronic leukaemia. Resveratrol 114-125 BCL2 apoptosis regulator Homo sapiens 65-70 12297471-9 2002 CONCLUSION: I/R might induce apoptosis in L02 cells by up-regulating the expression of p16, p21, p53 and down-regulating the expression of Bcl-2, and the protective effect of NADH against I/R-induced apoptosis may lie in the expression regulation of the proteins concerned. NAD 175-179 BCL2 apoptosis regulator Homo sapiens 139-144 12126940-6 2002 Similarly the bcl-2 -transfected cells were more resistant to mitochondrial DNA damage after H(2)O(2) treatment than the other groups and suffered 50% less damage after exposure to 200 microM H(2)O(2), as assayed by quantitative polymerase chain reaction assays. Hydrogen Peroxide 93-101 BCL2 apoptosis regulator Homo sapiens 14-19 12049842-7 2002 We further demonstrated that activation of c-jun N-terminal kinase (JNK) signaling pathway may play an important role in the PDP-induced Bcl-2 phosphorylation and apoptosis in HL 60 cells as evidenced by the JNK specific anti-sense oligonucleotide experiment. Oligonucleotides 232-247 BCL2 apoptosis regulator Homo sapiens 137-142 12136520-0 2002 Liposomal delivery of antisense oligonucleotides for efficient downregulation of Bcl-2 and induction of apoptosis. Oligonucleotides 32-48 BCL2 apoptosis regulator Homo sapiens 81-86 12012012-5 2002 Bcl-2 over-expression inhibited both delay in S-phase exit and CDDP-induced apoptosis in ATRA-pretreated cells. cddp 63-67 BCL2 apoptosis regulator Homo sapiens 0-5 12012012-5 2002 Bcl-2 over-expression inhibited both delay in S-phase exit and CDDP-induced apoptosis in ATRA-pretreated cells. Tretinoin 89-93 BCL2 apoptosis regulator Homo sapiens 0-5 12011972-5 2002 Bcl-2 expression in lymphocytes infiltrating into the liver was investigated by immunohistochemistry using a monoclonal antibody to Bcl-2 with an avidin-biotin complex system. Biotin 153-159 BCL2 apoptosis regulator Homo sapiens 0-5 11987151-12 2002 Overexpression of FADD-DN and Bcl-2 affected the activation of caspase-3 and PARP cleavage differently: FADD-DN attenuated the activation of caspase-3 and PARP cleavage whereas Bcl-2 overexpression prevented caspase-3 activation and completely blocked cleavage of PARP. fadd-dn 18-25 BCL2 apoptosis regulator Homo sapiens 177-182 11987151-12 2002 Overexpression of FADD-DN and Bcl-2 affected the activation of caspase-3 and PARP cleavage differently: FADD-DN attenuated the activation of caspase-3 and PARP cleavage whereas Bcl-2 overexpression prevented caspase-3 activation and completely blocked cleavage of PARP. fadd-dn 104-111 BCL2 apoptosis regulator Homo sapiens 30-35 12579792-7 2002 Combination of CA-Na and MMC synergistically inhibited Bcl-2 expression and enhanced caspase-3 expression of the cells. ca-na 15-20 BCL2 apoptosis regulator Homo sapiens 55-60 12138400-3 2002 Antisense oligonucleotides directed toward the open reading frame of the bcl-2 gene have been used to inhibit Bcl-2 expression. Oligonucleotides 10-26 BCL2 apoptosis regulator Homo sapiens 73-78 12138400-3 2002 Antisense oligonucleotides directed toward the open reading frame of the bcl-2 gene have been used to inhibit Bcl-2 expression. Oligonucleotides 10-26 BCL2 apoptosis regulator Homo sapiens 110-115 12138400-5 2002 However, it remains to be determined whether Bcl-2 antisense oligonucleotides will have a beneficial effect in solid tumors, such as breast cancer. Oligonucleotides 61-77 BCL2 apoptosis regulator Homo sapiens 45-50 12138400-8 2002 We will discuss the paradoxical role of Bcl-2 and the potential therapeutic application of Bcl-2 antisense oligonucleotides in breast cancer. Oligonucleotides 107-123 BCL2 apoptosis regulator Homo sapiens 91-96 12046067-7 2002 RESULTS: Treatment of MGC80-3 cells with TPA and VP-16 resulted in apoptosis, accompanied by the repression of Bcl-2 protein in a time-dependent manner. Tetradecanoylphorbol Acetate 41-44 BCL2 apoptosis regulator Homo sapiens 111-116 12579792-7 2002 Combination of CA-Na and MMC synergistically inhibited Bcl-2 expression and enhanced caspase-3 expression of the cells. Mitomycin 25-28 BCL2 apoptosis regulator Homo sapiens 55-60 11986784-5 2002 Forced expression of the anti-apoptotic protein bcl-2 attenuated bisphosphonate-induced loss of cell viability and induction of DNA fragmentation in MDA-MB-231 cells. Diphosphonates 65-79 BCL2 apoptosis regulator Homo sapiens 48-53 12173346-6 2002 RESULTS: Under aerobic culture conditions (5% CO2 plus 21% O2) HTDEC expressed less Bcl-2 and were more susceptible to IFN-gamma-induced apoptosis with significant reductions in both cell proliferation and capillary tube formation, when compared with normal human macrovascular and microvascular EC. N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide 46-49 BCL2 apoptosis regulator Homo sapiens 84-89 11986787-7 2002 Furthermore, aspirin treatment is associated with an increase in bcl-2 expression, which persists in the presence of the anticancer drugs. Aspirin 13-20 BCL2 apoptosis regulator Homo sapiens 65-70 11986224-7 2002 Finally, antisense bcl-x(L) and bcl-2 knockdown in T and B cells, respectively, and induction of Bcl-x(S) expression in granulocytes through antisense oligonucleotide-mediated redirection of bcl-x pre-mRNA splicing were sufficient to induce significant apoptosis in these cells. Oligonucleotides 151-166 BCL2 apoptosis regulator Homo sapiens 32-37 12019181-8 2002 Functional studies indicate that Bimgamma inhibits clonal growth in prostate cancer cells and promotes apoptosis, which is inhibited by overexpressing Bcl-2. bimgamma 33-41 BCL2 apoptosis regulator Homo sapiens 151-156 12076958-5 2002 As well as MnSOD expression, the *NO-cGMP-PKG pathway mediated the preconditioning-induced upregulation of antiapoptotic protein Bcl-2 and the downregulation of adaptor protein p66(shc). Cyclic GMP 37-41 BCL2 apoptosis regulator Homo sapiens 129-134 12229934-2 2002 For that purpose, heating for 10 min by microwave (MW) up t o 100 degrees C in citrate buffer, pH 6.0, prior to immunostaining is often used to retrieve Bcl-2 antigens in archival formalin-fixed, paraffin-embedded tissue. Formaldehyde 180-188 BCL2 apoptosis regulator Homo sapiens 153-158 12168872-9 2002 The presence of bcl-2 mRNA was assessed on paraffin-embedded, 4 microm-thick sections, using a standard in situ hybridization method with a commercially available bcl-2 probe (Maxim Biotech, USA), while the streptavidin-biotin immunohistochemical technique was employed to detect bcl-2 protein expression using the monoclonal anti-bcl-2 antibody (DAKO, USA). Paraffin 43-51 BCL2 apoptosis regulator Homo sapiens 16-21 12168872-9 2002 The presence of bcl-2 mRNA was assessed on paraffin-embedded, 4 microm-thick sections, using a standard in situ hybridization method with a commercially available bcl-2 probe (Maxim Biotech, USA), while the streptavidin-biotin immunohistochemical technique was employed to detect bcl-2 protein expression using the monoclonal anti-bcl-2 antibody (DAKO, USA). Biotin 220-226 BCL2 apoptosis regulator Homo sapiens 16-21 12148244-7 2002 In contrast, both E1B 55K and Bcl-2 allowed cell survival and prevented the typical features of programmed cell death, such as phosphatidyl-serine exposure, loss of mitochondrial membrane potential, and chromatin condensation and fragmentation. Phosphatidylserines 127-146 BCL2 apoptosis regulator Homo sapiens 30-35 11964319-3 2002 In AML cell lines with constitutively activated MAPK, MAPK kinase (MEK) blockade by PD184352 strikingly potentiated the apoptosis induced by the small-molecule Bcl-2 inhibitor HA14-1 or by Bcl-2 antisense oligonucleotides. 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide 84-92 BCL2 apoptosis regulator Homo sapiens 160-165 11964319-3 2002 In AML cell lines with constitutively activated MAPK, MAPK kinase (MEK) blockade by PD184352 strikingly potentiated the apoptosis induced by the small-molecule Bcl-2 inhibitor HA14-1 or by Bcl-2 antisense oligonucleotides. 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide 84-92 BCL2 apoptosis regulator Homo sapiens 189-194 12229934-2 2002 For that purpose, heating for 10 min by microwave (MW) up t o 100 degrees C in citrate buffer, pH 6.0, prior to immunostaining is often used to retrieve Bcl-2 antigens in archival formalin-fixed, paraffin-embedded tissue. Paraffin 196-204 BCL2 apoptosis regulator Homo sapiens 153-158 12111453-5 2002 In addition, a series of propargylamines were found to prevent apoptosis through stabilization of mitochondrial membrane potential, which also involved Bcl-2. propargylamine 25-40 BCL2 apoptosis regulator Homo sapiens 152-157 11978640-0 2002 Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Fatty Acids, Nonesterified 22-38 BCL2 apoptosis regulator Homo sapiens 204-209 11956588-7 2002 The combination treatment with DOX and TRAIL resulted in a synergistic cytotoxic effect on LNCaP, LNCaP-Bcl-2, PC-3, and PC93 human prostate cancer cell lines, but not on normal human prostatic stromal cells. Doxorubicin 31-34 BCL2 apoptosis regulator Homo sapiens 104-109 12065643-3 2002 In this study, the roles of endogenous Bcl-2 proteins in cyanide-induced apoptosis were investigated. Cyanides 57-64 BCL2 apoptosis regulator Homo sapiens 39-44 12065643-4 2002 After cyanide (100-500 microm) treatment for 24 h, two pro-apoptotic Bcl-2 proteins, Bcl-X(S) and Bax were up-regulated as shown by western blot and RT-PCR analysis. Cyanides 6-13 BCL2 apoptosis regulator Homo sapiens 69-74 12065643-5 2002 The expression levels of two antiapoptotic Bcl-2 proteins, Bcl-2 and Bcl-X(L), remained unchanged after cyanide treatment, whereas the mRNA levels of Bcl-X(S) and Bax began to increase within 2 h and their protein levels increased 6 h after treatment. Cyanides 104-111 BCL2 apoptosis regulator Homo sapiens 43-48 12133541-13 2002 Hispidus Hoo polysaccharides selectively inhibited the proliferation, the colony forming ability, and the viability and function of human gastric cancer cells through the low protein expression of c-myc, bcl-2 and the high protein expression of p53, fas, fas-L and the cell factor TGF beta(1). hispidus hoo polysaccharides 0-28 BCL2 apoptosis regulator Homo sapiens 204-209 14612291-2 2002 METHODS: The s-p immunohistochemistry assay was used to detect the expression of the bcl-2 gene on paraffin-embedded sections from 97 cases of primary pancreatic carcinoma, 32 cases of pancreatitis, and 21 cases of normal pancreas. Paraffin 99-107 BCL2 apoptosis regulator Homo sapiens 85-90 12148891-0 2002 Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2/bax/ratio. Hydroxychloroquine 0-18 BCL2 apoptosis regulator Homo sapiens 120-125 12009392-9 2002 Treatment of both cell lines with dmPGE(2) resulted in dose-dependently higher expression of COX-2, Bcl-2, and bax mRNA compared with untreated cells. dmpge 34-39 BCL2 apoptosis regulator Homo sapiens 100-105 12036455-8 2002 In addition, 697/DEX and 697/Bcl-2 had higher levels of glutathione (GSH) than 697/Neo. Glutathione 56-67 BCL2 apoptosis regulator Homo sapiens 29-34 12036455-8 2002 In addition, 697/DEX and 697/Bcl-2 had higher levels of glutathione (GSH) than 697/Neo. Glutathione 69-72 BCL2 apoptosis regulator Homo sapiens 29-34 12036455-9 2002 In the presence of L-buthionine-(S, R)-sulfoximine (BSO), an inhibitor of GSH synthesis, both 697/DEX and 697/Bcl-2 recovered their sensitivity to DEX. l-buthionine-(s, r)-sulfoximine 19-50 BCL2 apoptosis regulator Homo sapiens 110-115 12036455-9 2002 In the presence of L-buthionine-(S, R)-sulfoximine (BSO), an inhibitor of GSH synthesis, both 697/DEX and 697/Bcl-2 recovered their sensitivity to DEX. Buthionine Sulfoximine 52-55 BCL2 apoptosis regulator Homo sapiens 110-115 12036455-9 2002 In the presence of L-buthionine-(S, R)-sulfoximine (BSO), an inhibitor of GSH synthesis, both 697/DEX and 697/Bcl-2 recovered their sensitivity to DEX. Glutathione 74-77 BCL2 apoptosis regulator Homo sapiens 110-115 12036455-9 2002 In the presence of L-buthionine-(S, R)-sulfoximine (BSO), an inhibitor of GSH synthesis, both 697/DEX and 697/Bcl-2 recovered their sensitivity to DEX. Dexamethasone 147-150 BCL2 apoptosis regulator Homo sapiens 110-115 12162425-9 2002 These metabolic and topographical changes in PS arrangement in plasma membrane appear to be early responses to antisense bcl-2 exposure that trigger a PS-dependent apoptotic signaling pathway. Phosphatidylserines 45-47 BCL2 apoptosis regulator Homo sapiens 121-126 12162425-9 2002 These metabolic and topographical changes in PS arrangement in plasma membrane appear to be early responses to antisense bcl-2 exposure that trigger a PS-dependent apoptotic signaling pathway. Phosphatidylserines 151-153 BCL2 apoptosis regulator Homo sapiens 121-126 12162425-0 2002 Depletion of Bcl-2 by an antisense oligonucleotide induces apoptosis accompanied by oxidation and externalization of phosphatidylserine in NCI-H226 lung carcinoma cells. Oligonucleotides 35-50 BCL2 apoptosis regulator Homo sapiens 13-18 12162425-0 2002 Depletion of Bcl-2 by an antisense oligonucleotide induces apoptosis accompanied by oxidation and externalization of phosphatidylserine in NCI-H226 lung carcinoma cells. Phosphatidylserines 117-135 BCL2 apoptosis regulator Homo sapiens 13-18 11988841-4 2002 Pin1 and its homologues are known to target the proline residue carboxyl terminal to the phosphorylated threonine or serine residue of mitotic phosphoproteins, such as Bcl2. Proline 48-55 BCL2 apoptosis regulator Homo sapiens 168-172 12162425-6 2002 We found a decrease in Bcl-2 was associated with a selective oxidation of PS in a sub-population of the cells with externalized PS. Phosphatidylserines 74-76 BCL2 apoptosis regulator Homo sapiens 23-28 12162425-6 2002 We found a decrease in Bcl-2 was associated with a selective oxidation of PS in a sub-population of the cells with externalized PS. Phosphatidylserines 128-130 BCL2 apoptosis regulator Homo sapiens 23-28 11988841-2 2002 Phosphorylation of Bcl2 predominantly occurs on two serine residues (70 and 87) in cells arrested at G2-M phase by microtubule disarraying agents. Serine 52-58 BCL2 apoptosis regulator Homo sapiens 19-23 11988841-4 2002 Pin1 and its homologues are known to target the proline residue carboxyl terminal to the phosphorylated threonine or serine residue of mitotic phosphoproteins, such as Bcl2. Threonine 104-113 BCL2 apoptosis regulator Homo sapiens 168-172 11988841-4 2002 Pin1 and its homologues are known to target the proline residue carboxyl terminal to the phosphorylated threonine or serine residue of mitotic phosphoproteins, such as Bcl2. Serine 117-123 BCL2 apoptosis regulator Homo sapiens 168-172 11988841-7 2002 Interestingly, proteasomal degradation of Pin1 facilitates dephosphorylation of phospho Bcl2 due to longer exposure of Taxol. Paclitaxel 119-124 BCL2 apoptosis regulator Homo sapiens 88-92 12100521-3 2002 Staining scores for Bcl-2 in the dEM, endometrial hyperplasia (EMH) and endometrioid cancer (ECA) groups were higher than in the pEM group (P = 0.004; P = 0.036 and P = 0.020, respectively). 3-(2-phenylethyl)-4-methylsydnone 129-132 BCL2 apoptosis regulator Homo sapiens 20-25 12086014-8 2002 Immunoblot analysis with an antibody against Bcl-2 phosphorylated at serine 70 demonstrated that taxol induced the phosphorylation of Bcl-2 with its enhancement in the presence of CsA. Paclitaxel 97-102 BCL2 apoptosis regulator Homo sapiens 134-139 12081204-1 2002 BAG-1 (BCL-2 athanogene-1), a multifunctional protein which associates with steroid hormone receptors (including the oestrogen receptor) and the anti-apoptotic BCL-2 protein, regulates steroid hormone-dependent transcription and apoptosis. Steroids 76-91 BCL2 apoptosis regulator Homo sapiens 7-12 12086014-8 2002 Immunoblot analysis with an antibody against Bcl-2 phosphorylated at serine 70 demonstrated that taxol induced the phosphorylation of Bcl-2 with its enhancement in the presence of CsA. Serine 69-75 BCL2 apoptosis regulator Homo sapiens 45-50 12086014-10 2002 These results suggest that the enhancement of taxol-induced apoptosis by immunosuppressive drugs is at least partly due to the inhibition of calcineurin activity and the loss of the antiapoptotic function of Bcl-2 via the enhancement of phosphorylation and the reduction of expression. Paclitaxel 46-51 BCL2 apoptosis regulator Homo sapiens 208-213 12086014-8 2002 Immunoblot analysis with an antibody against Bcl-2 phosphorylated at serine 70 demonstrated that taxol induced the phosphorylation of Bcl-2 with its enhancement in the presence of CsA. Serine 69-75 BCL2 apoptosis regulator Homo sapiens 134-139 12033780-4 2002 Comparisons of the amino acid sequence of VP5 with well-known Bcl-2 family member proteins showed that the VP5 protein contains Bcl-2 homology (BH) domains BH1, BH2, BH3, and BH4 but without the transmembrane region. bh2 161-164 BCL2 apoptosis regulator Homo sapiens 62-67 12086014-8 2002 Immunoblot analysis with an antibody against Bcl-2 phosphorylated at serine 70 demonstrated that taxol induced the phosphorylation of Bcl-2 with its enhancement in the presence of CsA. Paclitaxel 97-102 BCL2 apoptosis regulator Homo sapiens 45-50 11996879-5 2002 An immunohistochemical assay and western immunoblot analysis showed down-regulation of the bcl-2 gene and up-regulation of the bax and c-myc genes in the acutiaporberine-treated cells. acutiaporberine 154-169 BCL2 apoptosis regulator Homo sapiens 91-96 11971188-7 2002 Cells expressing BCL-2 or treated with the pan caspase inhibitor, zVAD-fmk, allowed accumulation of high levels of cytotoxic BIK compared to control cells. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 66-74 BCL2 apoptosis regulator Homo sapiens 17-22 12033780-4 2002 Comparisons of the amino acid sequence of VP5 with well-known Bcl-2 family member proteins showed that the VP5 protein contains Bcl-2 homology (BH) domains BH1, BH2, BH3, and BH4 but without the transmembrane region. BH 3 166-169 BCL2 apoptosis regulator Homo sapiens 62-67 12033780-4 2002 Comparisons of the amino acid sequence of VP5 with well-known Bcl-2 family member proteins showed that the VP5 protein contains Bcl-2 homology (BH) domains BH1, BH2, BH3, and BH4 but without the transmembrane region. sapropterin 175-178 BCL2 apoptosis regulator Homo sapiens 62-67 12033780-4 2002 Comparisons of the amino acid sequence of VP5 with well-known Bcl-2 family member proteins showed that the VP5 protein contains Bcl-2 homology (BH) domains BH1, BH2, BH3, and BH4 but without the transmembrane region. sapropterin 175-178 BCL2 apoptosis regulator Homo sapiens 128-133 12056703-4 2002 Suppression of Bcl-2 levels through the use of G3139, an antisense oligonucleotide complementary to the mRNA encoding Bcl-2, might increase the antitumor efficacy of cytotoxic therapy. oblimersen 47-52 BCL2 apoptosis regulator Homo sapiens 15-20 11921051-9 2002 Flupirtine upregulates Bcl-2, increases glutathione levels, activates an inwardly rectifying potassium channel, and delays loss of intermitochondrial membrane calcium retention capacity. flupirtine 0-10 BCL2 apoptosis regulator Homo sapiens 23-28 11815602-0 2002 Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis. Etoposide 140-149 BCL2 apoptosis regulator Homo sapiens 74-79 12056703-0 2002 A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Oligonucleotides 42-57 BCL2 apoptosis regulator Homo sapiens 26-31 12056703-4 2002 Suppression of Bcl-2 levels through the use of G3139, an antisense oligonucleotide complementary to the mRNA encoding Bcl-2, might increase the antitumor efficacy of cytotoxic therapy. oblimersen 47-52 BCL2 apoptosis regulator Homo sapiens 118-123 12056703-4 2002 Suppression of Bcl-2 levels through the use of G3139, an antisense oligonucleotide complementary to the mRNA encoding Bcl-2, might increase the antitumor efficacy of cytotoxic therapy. Oligonucleotides 67-82 BCL2 apoptosis regulator Homo sapiens 15-20 11971816-7 2002 Both IGFBP-3 and TNF-alpha treatment increased the levels of the inactive, serine phosphorylated form of the survival protein Bcl-2. Serine 75-81 BCL2 apoptosis regulator Homo sapiens 126-131 11895790-6 2002 In turn, Hsp90 modulated Bcl-2 expression, as shown by a complete blockage of VEGF-induced Bcl-2 expression and binding to Hsp90 by the Hsp90-specific inhibitor geldanamycin (GA). geldanamycin 161-173 BCL2 apoptosis regulator Homo sapiens 25-30 11895790-6 2002 In turn, Hsp90 modulated Bcl-2 expression, as shown by a complete blockage of VEGF-induced Bcl-2 expression and binding to Hsp90 by the Hsp90-specific inhibitor geldanamycin (GA). geldanamycin 161-173 BCL2 apoptosis regulator Homo sapiens 91-96 11895790-6 2002 In turn, Hsp90 modulated Bcl-2 expression, as shown by a complete blockage of VEGF-induced Bcl-2 expression and binding to Hsp90 by the Hsp90-specific inhibitor geldanamycin (GA). geldanamycin 175-177 BCL2 apoptosis regulator Homo sapiens 25-30 11895790-6 2002 In turn, Hsp90 modulated Bcl-2 expression, as shown by a complete blockage of VEGF-induced Bcl-2 expression and binding to Hsp90 by the Hsp90-specific inhibitor geldanamycin (GA). geldanamycin 175-177 BCL2 apoptosis regulator Homo sapiens 91-96 11971816-8 2002 The effect of TNF-alpha on Bcl-2 serine phosphorylation was blocked by IGFBP-3 antisense oligomers. Serine 33-39 BCL2 apoptosis regulator Homo sapiens 27-32 11971816-9 2002 These findings confirm that IGFBP-3 is essential for TNF-alpha-induced apoptosis in PC-3 cells and that this IGFBP-3 effect includes the inactivation of Bcl-2 through serine phosphorylation. Serine 167-173 BCL2 apoptosis regulator Homo sapiens 153-158 11948143-3 2002 Bcl-2 antisense oligonucleotides (ODNs) down-regulate Bcl-2 expression and inhibit growth of the follicular lymphoma cell line WSU-FSCCL. Oligonucleotides 16-32 BCL2 apoptosis regulator Homo sapiens 0-5 11948143-3 2002 Bcl-2 antisense oligonucleotides (ODNs) down-regulate Bcl-2 expression and inhibit growth of the follicular lymphoma cell line WSU-FSCCL. Oligonucleotides 16-32 BCL2 apoptosis regulator Homo sapiens 54-59 11948143-9 2002 Phosphorothioate ODNs against the translation initiation site of bcl-2 mRNA in the antisense and mismatched antisense sequences were administered i.v. Parathion 0-16 BCL2 apoptosis regulator Homo sapiens 65-70 12390742-5 2002 CONCLUSION: Mifepristone may act to enhance the sensitivity of COC1/DDP cells to cisplatin, possibly through regulating Bcl-2 and Bax protein expressions. Mifepristone 12-24 BCL2 apoptosis regulator Homo sapiens 120-125 12018387-0 2002 7,8-Dihydroneopterin induces apoptosis of Jurkat T-lymphocytes via a Bcl-2-sensitive pathway. 7,8-dihydroneopterin 0-20 BCL2 apoptosis regulator Homo sapiens 69-74 12018387-4 2002 Results suggest that 7,8-dihydroneopterin-induced apoptosis of T-lymphocytes is mediated by a Bcl-2-sensitive pathway. 7,8-dihydroneopterin 21-41 BCL2 apoptosis regulator Homo sapiens 94-99 11960288-6 2002 Cooperation between TRAIL and TK/GCV depended both on caspase activation and on mitochondrial apoptogenic function because both the broad-spectrum caspase inhibitor zVAD.fmk and overexpression of Bcl-2 decreased enhancement of cell kill by TRAIL. Ganciclovir 33-36 BCL2 apoptosis regulator Homo sapiens 196-201 11920608-0 2002 Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Fluorouracil 46-60 BCL2 apoptosis regulator Homo sapiens 109-114 11920608-6 2002 In addition, we found that high levels of anti-apoptotic Bcl-2 and Bcl-x(L) proteins combined with a low level of Bax were correlated to high 5-FU resistance of wild-type p53 cell lines. Fluorouracil 142-146 BCL2 apoptosis regulator Homo sapiens 57-62 11920608-8 2002 In conclusion, the relative levels of Bcl-2, Bcl-x(L) and Bax may altogether contribute to determine the resistance of a majority of colon tumor cells to long-term 5-FU treatment, whatever their p53 status. Fluorouracil 164-168 BCL2 apoptosis regulator Homo sapiens 38-43 12390742-5 2002 CONCLUSION: Mifepristone may act to enhance the sensitivity of COC1/DDP cells to cisplatin, possibly through regulating Bcl-2 and Bax protein expressions. Cisplatin 81-90 BCL2 apoptosis regulator Homo sapiens 120-125 11988851-5 2002 Furthermore, the mitochondrial Bcl-2 protein represented a dramatic change in response to baicalein treatment. baicalein 90-99 BCL2 apoptosis regulator Homo sapiens 31-36 11907198-10 2002 Our results demonstrated that SIV Nef inhibited Fas-induced apoptosis in these cells and that the mechanism involved upregulation of the Bcl-2 protein. ammonium ferrous sulfate 48-51 BCL2 apoptosis regulator Homo sapiens 137-142 11951081-6 2002 It is suggested that free radicals and lipid peroxides suppress the expression of Bcl-2, activate caspases and shorten telomere, and thus inducing apoptosis of tumor cells. Free Radicals 21-34 BCL2 apoptosis regulator Homo sapiens 82-87 11951081-6 2002 It is suggested that free radicals and lipid peroxides suppress the expression of Bcl-2, activate caspases and shorten telomere, and thus inducing apoptosis of tumor cells. Lipid Peroxides 39-54 BCL2 apoptosis regulator Homo sapiens 82-87 11927338-3 2002 METHODS: The expression of p53, mdm2, and bcl-2 protein was studied by immunohistochemical methods in paraffin-embedded nephrectomy specimens from 112 patients whose clinicopathologic data confirmed renal cell carcinoma. Paraffin 102-110 BCL2 apoptosis regulator Homo sapiens 42-47 12054916-0 2002 Increased cytosol Ca(2+) and type 1 programmed cell death in Bcl-2-positive U937 but not in Bcl-2-negative PC-3 and Panc-1 cells induced by the 5-lipoxygenase inhibitor MK 886. MK-886 169-175 BCL2 apoptosis regulator Homo sapiens 61-66 12419161-0 2002 Effects of tetracycline-controlled antisense bcl-2 expression on the growth and apoptosis of human neuroblastoma cell line SK-N-MC. Tetracycline 11-23 BCL2 apoptosis regulator Homo sapiens 45-50 11779855-8 2002 Finally, Dox triggered Bcl-2 down-regulation, cytochrome c release from mitochondria, and the activation of caspases 9 and 3, suggesting the involvement of a mitochondrially operated pathway of apoptosis. Doxorubicin 9-12 BCL2 apoptosis regulator Homo sapiens 23-28 12419161-0 2002 Effects of tetracycline-controlled antisense bcl-2 expression on the growth and apoptosis of human neuroblastoma cell line SK-N-MC. sk-n-mc 123-130 BCL2 apoptosis regulator Homo sapiens 45-50 12419161-1 2002 OBJECTIVE: To study the effects of tetracycline-controlled antisense bcl-2 expression on the growth and apoptosis of human neuroblastoma cell line SK-N-MC and the related mechanisms. Tetracycline 35-47 BCL2 apoptosis regulator Homo sapiens 69-74 12419161-2 2002 METHODS: The tetracycline-controlled antisense bcl-2 expressing vector PUCCOMB1(CMV)/Asbcl-2 was constructed by inserting a 0.6 kb fragment antisense bcl-2 cDNA sequence into the plasmid PUCCOMB1(CMV). Tetracycline 13-25 BCL2 apoptosis regulator Homo sapiens 47-52 12419161-2 2002 METHODS: The tetracycline-controlled antisense bcl-2 expressing vector PUCCOMB1(CMV)/Asbcl-2 was constructed by inserting a 0.6 kb fragment antisense bcl-2 cDNA sequence into the plasmid PUCCOMB1(CMV). Tetracycline 13-25 BCL2 apoptosis regulator Homo sapiens 87-92 12419161-4 2002 The transfectant cells were further studied for growth viability and apoptosis induced by antisense bcl-2 expression controlled by tetracycline. Tetracycline 131-143 BCL2 apoptosis regulator Homo sapiens 100-105 11948397-0 2002 Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and caspase-9 activation. Ganciclovir 0-11 BCL2 apoptosis regulator Homo sapiens 103-108 11948397-9 2002 Caspase-9 mediated cleavage of Bcl-2 accelerates the apoptotic process and may explain the high potential of GCV to induce apoptosis. Ganciclovir 109-112 BCL2 apoptosis regulator Homo sapiens 31-36 11960374-4 2002 Ceramide-induced apoptosis is accompanied by accumulation of p53 followed by an increase of Bax and decrease of Bcl-2 levels. Ceramides 0-8 BCL2 apoptosis regulator Homo sapiens 112-117 11948397-4 2002 GCV-provoked DNA instability was likely to be responsible for the observed initial decline in Bcl-2 level and caspase-9/-3 activation. Ganciclovir 0-3 BCL2 apoptosis regulator Homo sapiens 94-99 11960369-3 2002 When added to isolated mitochondria, BaxBH3 and Bcl2BH3 induced MMP, which was inhibited by CsA. Cyclosporine 92-95 BCL2 apoptosis regulator Homo sapiens 48-55 12419161-8 2002 CONCLUSIONS: The results suggested that tetracycline-controlled expression of antisense bcl-2 can effectively inhibit the cell viability of SK-N-MC cells, increase the sensitivity to apoptosis-inducing factor, as well as facilitate cell apoptosis after treatment of culture without FBS. Tetracycline 40-52 BCL2 apoptosis regulator Homo sapiens 88-93 11960374-5 2002 Inhibition of p53 expression with p53 antisense oligonucleotides inhibits apoptosis and prevents the increase in Bax and decrease in Bcl-2. Oligonucleotides 48-64 BCL2 apoptosis regulator Homo sapiens 133-138 11960374-7 2002 These results suggest that p53 regulates the ratio Bcl-2/Bax and the expression/activation of caspases during ceramide-induced apoptosis in SKN-SH cells. Ceramides 110-118 BCL2 apoptosis regulator Homo sapiens 51-56 12419161-8 2002 CONCLUSIONS: The results suggested that tetracycline-controlled expression of antisense bcl-2 can effectively inhibit the cell viability of SK-N-MC cells, increase the sensitivity to apoptosis-inducing factor, as well as facilitate cell apoptosis after treatment of culture without FBS. sk-n-mc 140-147 BCL2 apoptosis regulator Homo sapiens 88-93 11960374-9 2002 Thus ceramide-induced reduction in the Bcl-2/Bax ratio, increase in caspase activity, and apoptosis is dependent upon increases in cellular p53 levels which play a critical role in the regulation of apoptotic cell death. Ceramides 5-13 BCL2 apoptosis regulator Homo sapiens 39-44 11886382-1 2002 Recently, it was disclosed that all-trans retinoic acid (ATRA) inhibits myeloma cell growth by downregulating the interleukin 6 (IL-6)/IL-6 receptor (IL-6R) auto/paracrine loop, and upregulating p21/Cip1 cyclin-dependent kinase inhibitor (CDK-I), thereby inducing apoptosis with a decrease in Bcl-2 protein expression. Tretinoin 42-55 BCL2 apoptosis regulator Homo sapiens 293-298 11741880-5 2002 Our results demonstrate that the effects of the "multidomain" proapoptotic BCL-2 family members Bak and Bax involve direct effects on the endoplasmic reticular Ca(2+) pool with subsequent sensitization of mitochondria to calcium-mediated fluxes and cytochrome c release. Calcium 221-228 BCL2 apoptosis regulator Homo sapiens 75-80 11866437-6 2002 Thus 2-deoxy-D-ribose-modulated suppression of HIF-1 alpha expression could prevent the hypoxia-induced decrease of the anti-apoptotic Bcl-2 and Bcl-x(L) on the mitochondria. Deoxyribose 5-21 BCL2 apoptosis regulator Homo sapiens 135-140 11886382-1 2002 Recently, it was disclosed that all-trans retinoic acid (ATRA) inhibits myeloma cell growth by downregulating the interleukin 6 (IL-6)/IL-6 receptor (IL-6R) auto/paracrine loop, and upregulating p21/Cip1 cyclin-dependent kinase inhibitor (CDK-I), thereby inducing apoptosis with a decrease in Bcl-2 protein expression. Tretinoin 57-61 BCL2 apoptosis regulator Homo sapiens 293-298 11920601-0 2002 ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Gefitinib 0-6 BCL2 apoptosis regulator Homo sapiens 90-95 11920601-0 2002 ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Gefitinib 8-14 BCL2 apoptosis regulator Homo sapiens 90-95 11920601-0 2002 ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. taxane 71-77 BCL2 apoptosis regulator Homo sapiens 90-95 11920601-1 2002 Constitutive bcl-2 overexpression increases the tumorigenic and metastatic potential of doxorubicin-resistant, estrogen-independent, MCF-7 ADR human breast cancer cells. Doxorubicin 88-99 BCL2 apoptosis regulator Homo sapiens 13-18 11931841-0 2002 Bcl-2 family-mediated apoptotic effects of 3,3"-diindolylmethane (DIM) in human breast cancer cells. 3,3'-diindolylmethane 43-64 BCL2 apoptosis regulator Homo sapiens 0-5 11882313-0 2002 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atorvastatin 61-73 BCL2 apoptosis regulator Homo sapiens 161-166 11882313-0 2002 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Simvastatin 78-89 BCL2 apoptosis regulator Homo sapiens 161-166 11882313-2 2002 In this work, we demonstrate that treatment of VSMCs with simvastatin and atorvastatin inhibited Bcl-2 expression in a time and dose-dependent manner, while Bax expression was not modified. vsmcs 47-52 BCL2 apoptosis regulator Homo sapiens 97-102 11882313-2 2002 In this work, we demonstrate that treatment of VSMCs with simvastatin and atorvastatin inhibited Bcl-2 expression in a time and dose-dependent manner, while Bax expression was not modified. Simvastatin 58-69 BCL2 apoptosis regulator Homo sapiens 97-102 11882313-2 2002 In this work, we demonstrate that treatment of VSMCs with simvastatin and atorvastatin inhibited Bcl-2 expression in a time and dose-dependent manner, while Bax expression was not modified. Atorvastatin 74-86 BCL2 apoptosis regulator Homo sapiens 97-102 11895917-9 2002 Decreased expression of additional proteins (Apaf-1, cIAP-1, cIAP-2, and XIAP) paralleled apoptosis detected at 24 h. CONCLUSIONS: These findings show that the selective down-regulation of Bcl-2 by rituximab leading to apoptosis in ARL cells by cisplatin is through the mitochondria-dependent caspase pathway. Cisplatin 245-254 BCL2 apoptosis regulator Homo sapiens 189-194 12170773-0 2002 Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis. alvocidib 103-115 BCL2 apoptosis regulator Homo sapiens 12-17 12170773-2 2002 A 3-fold increase in full-length Bcl-2 protein conferred substantial resistance to ara-C-associated lethality, but not to FP-mediated cytochrome c release, caspase-3 and-9 activation and apoptosis. Cytarabine 83-88 BCL2 apoptosis regulator Homo sapiens 33-38 11895895-0 2002 Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Oligonucleotides 33-48 BCL2 apoptosis regulator Homo sapiens 17-22 11895895-0 2002 Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. oblimersen 50-55 BCL2 apoptosis regulator Homo sapiens 17-22 12390773-4 2002 RESULT: NADH not only inhibited the apoptosis induced by UVB irradiation, but also up-regulated the expression of Bcl-2 protein and down-regulated expressions of p53 and Bax proteins (P<0.01). NAD 8-12 BCL2 apoptosis regulator Homo sapiens 114-119 11895895-1 2002 PURPOSE: To evaluate the safety and pharmacokinetics of BCL-2 antisense oligonucleotide (G3139) administered by prolonged i.v. Oligonucleotides 72-87 BCL2 apoptosis regulator Homo sapiens 56-61 11895895-1 2002 PURPOSE: To evaluate the safety and pharmacokinetics of BCL-2 antisense oligonucleotide (G3139) administered by prolonged i.v. oblimersen 89-94 BCL2 apoptosis regulator Homo sapiens 56-61 11895895-3 2002 EXPERIMENTAL DESIGN: A total of 35 patients was treated in cohorts of 3-6 with 0.6-6.9 mg/kg/day of BCL-2 antisense oligonucleotide as a continuous infusion for 14 or 21 days. Oligonucleotides 116-131 BCL2 apoptosis regulator Homo sapiens 100-105 12390773-6 2002 CONCLUSION: NADH significantly inhibits apoptosis induced by UVB irradiation possibly by the mechanism of up-regulating Bcl-2 expression and down-regulating p53 and Bax expressions. NAD 12-16 BCL2 apoptosis regulator Homo sapiens 120-125 11739380-7 2002 Interestingly, the survival of the neuroblastoma cells treated with retinoic acid was partly dependent on the expression of RAGE, and inhibition of RAGE function partially blocked the increase in anti-apoptotic protein Bcl-2 following retinoic acid treatment. Tretinoin 68-81 BCL2 apoptosis regulator Homo sapiens 219-224 21782589-5 2002 NaF treatment also gradually decreased the expression of the anti-apoptotic protein Bcl-2, and increased activation of caspase-3 and cleavage of poly (ADP-ribose) polymerase. Sodium Fluoride 0-3 BCL2 apoptosis regulator Homo sapiens 84-89 11739380-7 2002 Interestingly, the survival of the neuroblastoma cells treated with retinoic acid was partly dependent on the expression of RAGE, and inhibition of RAGE function partially blocked the increase in anti-apoptotic protein Bcl-2 following retinoic acid treatment. Tretinoin 235-248 BCL2 apoptosis regulator Homo sapiens 219-224 11874491-3 2002 Primary cell cultures derived from 17 melanomas, the cell line A375, and normal melanocytes from healthy donors were treated with antisense oligonucleotides targeting either the bcl-xL mRNA or the bcl-2 and the bcl-xL mRNAs simultaneously. Oligonucleotides 140-156 BCL2 apoptosis regulator Homo sapiens 197-202 11867687-6 2002 Analysis of the expression of Bcl-2-family proteins after 48 h of fludarabine treatment revealed that Bcl-xL levels were significantly higher (P<0.05) for cells cultured on H89 than on polylysine and correlated (r=0.56, P<0.05) with the increased cell viability observed on H89 cultures. fludarabine 66-77 BCL2 apoptosis regulator Homo sapiens 30-35 11874491-8 2002 As shown in A375 cells and the stage III melanoma cells 0513, both the bcl-xL monospecific oligonucleotide 4259 and the bcl-2/bcl-xL bispecific oligonucleotide 4625 effectively reduced tumor cell viability by induction of apoptosis with IC50 values ranging from 200 to 350 nM. Oligonucleotides 144-159 BCL2 apoptosis regulator Homo sapiens 120-125 11867687-6 2002 Analysis of the expression of Bcl-2-family proteins after 48 h of fludarabine treatment revealed that Bcl-xL levels were significantly higher (P<0.05) for cells cultured on H89 than on polylysine and correlated (r=0.56, P<0.05) with the increased cell viability observed on H89 cultures. Polylysine 188-198 BCL2 apoptosis regulator Homo sapiens 30-35 11861801-5 2002 The overexpression of Bcl-2 gene prevented FTY720- and etoposide-mediated apoptosis, but not Fas-mediated apoptosis. Etoposide 55-64 BCL2 apoptosis regulator Homo sapiens 22-27 11927016-6 2002 With YCU-N861 cells, ATRA also caused a decrease in Bcl-2 and Bcl-X(L) and an increase in Bax. Tretinoin 21-25 BCL2 apoptosis regulator Homo sapiens 52-57 11832715-1 2002 PURPOSE: In our earlier series we showed that ciprofloxacin inhibits bladder tumor cell growth with concomitant S/G2M cell cycle arrest and reported an increased Bax-to-Bcl-2 ratio in cells undergoing cell death. Ciprofloxacin 46-59 BCL2 apoptosis regulator Homo sapiens 169-174 11832715-11 2002 Our findings also showed Bcl-2 dependent subcellular redistribution of Bax to the mitochondrial membrane in ciprofloxacin treated bladder tumor cells. Ciprofloxacin 108-121 BCL2 apoptosis regulator Homo sapiens 25-30 11854432-6 2002 Paclitaxel-induced apoptosis resulted in the phosphorylation of Bcl-2 that was suppressed by the addition of ET-1. Paclitaxel 0-10 BCL2 apoptosis regulator Homo sapiens 64-69 11792416-7 2002 Although, flavopiridol did not affect cyclin D1 and cyclin A levels, it inhibited Mcl-1 and Bcl-2 protein levels and cyclin-dependent kinase 2 activity. alvocidib 10-22 BCL2 apoptosis regulator Homo sapiens 92-97 11854432-11 2002 These results establish a novel role for ET-1 in determining protection of ovarian carcinoma cells against paclitaxel-induced apoptosis through Bcl-2-dependent and PI3-K-mediated Akt pathways and suggest that ET-1 and ET(A)R could represent important targets for anticancer therapy. Paclitaxel 107-117 BCL2 apoptosis regulator Homo sapiens 144-149 11992642-13 2002 We conclude that docetaxel is able to activate caspase-3, induce Bcl-2 phosphorylation and apoptosis in cells that show a prolonged G2/M arrest, but cells may also die by a caspase-3-independent cell death mechanism. Docetaxel 17-26 BCL2 apoptosis regulator Homo sapiens 65-70 11830458-7 2002 Expression of bcl-2 in the intermediate IPI group identified a further 28% of patients with an overall survival comparable to the high IPI group. diprotin A 40-43 BCL2 apoptosis regulator Homo sapiens 14-19 11830458-7 2002 Expression of bcl-2 in the intermediate IPI group identified a further 28% of patients with an overall survival comparable to the high IPI group. diprotin A 135-138 BCL2 apoptosis regulator Homo sapiens 14-19 11830458-8 2002 In the intermediate IPI, bcl-2(-) group, the presence of a GC phenotype improved overall survival to levels approaching the IPI low group. diprotin A 124-127 BCL2 apoptosis regulator Homo sapiens 25-30 11807783-6 2002 In accord with these findings, in undifferentiated cells, beta-carotene was more effective in decreasing cyclin A and Bcl-2 expression and in increasing p21 and p27 expression. beta Carotene 58-71 BCL2 apoptosis regulator Homo sapiens 118-123 11773707-3 2002 In the present study, we examined the role of phosphotidylinositol 3 (PI3) kinase signaling in okadaic acid-induced apoptosis by pre-treating normal rat kidney renal epithelial cells expressing human bcl-2 with the PI3 kinase inhibitors, LY294002 and wortmannin, followed by apoptosis-inducing concentrations of okadaic acid. Okadaic Acid 95-107 BCL2 apoptosis regulator Homo sapiens 200-205 11829627-0 2002 Novel polyphenol molecule isolated from licorice root (Glycrrhiza glabra) induces apoptosis, G2/M cell cycle arrest, and Bcl-2 phosphorylation in tumor cell lines. Polyphenols 6-16 BCL2 apoptosis regulator Homo sapiens 121-126 11829627-9 2002 Only one molecule was responsible for Bcl-2 phosphorylation; it was identified as 1-(2,4-dihydroxyphenyl)-3-hydroxy-3-(4"-hydroxyphenyl) 1-propanone (beta-hydroxy-DHP). 1-(2,4-dihydroxyphenyl)-3-hydroxy-3-(4"-hydroxyphenyl) 1-propanone 82-148 BCL2 apoptosis regulator Homo sapiens 38-43 11829627-10 2002 The effect on Bcl-2 was structure specific, because alpha-hydroxy-DHP, 1-(2,4-dihydroxyphenyl)-2-hydroxy-3-(4"-hydroxyphenyl) 1-propanone, in contrast to beta-hydroxy-DHP, was not capable of Bcl-2 phosphorylation. 1-(2,4-dihydroxyphenyl)-2-hydroxy-3-(4"-hydroxyphenyl) 1-propanone 71-137 BCL2 apoptosis regulator Homo sapiens 14-19 11866879-11 2002 CONCLUSION: Heparin and ADM appear to interact in a synergistic manner, which may be related to the over-expression of p53 and p21 mRNA and the elevated ratio of Bax/Bcl-2 mRNA. Heparin 12-19 BCL2 apoptosis regulator Homo sapiens 166-171 11866879-11 2002 CONCLUSION: Heparin and ADM appear to interact in a synergistic manner, which may be related to the over-expression of p53 and p21 mRNA and the elevated ratio of Bax/Bcl-2 mRNA. Doxorubicin 24-27 BCL2 apoptosis regulator Homo sapiens 166-171 12022947-3 2002 Among the various PTPC components, the adenine nucleotide translocator (ANT) appears to act as a bi-functional protein which, on the one hand, contributes to a crucial step of aerobic energy metabolism, the ADP/ATP translocation, and on the other hand, can be converted into a pro-apoptotic pore under the control of onco- and anti-oncoproteins from the Bax/Bcl-2 family. Adenine Nucleotides 39-57 BCL2 apoptosis regulator Homo sapiens 358-363 11843726-4 2002 The activity of paclitaxel was correlated with an elevation of cyclin B1/CDC2 activity, prolonged mitotic arrest, and Bcl-2 phosphorylation. Paclitaxel 16-26 BCL2 apoptosis regulator Homo sapiens 118-123 12022947-3 2002 Among the various PTPC components, the adenine nucleotide translocator (ANT) appears to act as a bi-functional protein which, on the one hand, contributes to a crucial step of aerobic energy metabolism, the ADP/ATP translocation, and on the other hand, can be converted into a pro-apoptotic pore under the control of onco- and anti-oncoproteins from the Bax/Bcl-2 family. Adenosine Diphosphate 207-210 BCL2 apoptosis regulator Homo sapiens 358-363 11875716-0 2002 Src tyrosine kinase augments taxotere-induced apoptosis through enhanced expression and phosphorylation of Bcl-2. Docetaxel 29-37 BCL2 apoptosis regulator Homo sapiens 107-112 12022947-3 2002 Among the various PTPC components, the adenine nucleotide translocator (ANT) appears to act as a bi-functional protein which, on the one hand, contributes to a crucial step of aerobic energy metabolism, the ADP/ATP translocation, and on the other hand, can be converted into a pro-apoptotic pore under the control of onco- and anti-oncoproteins from the Bax/Bcl-2 family. Adenosine Triphosphate 211-214 BCL2 apoptosis regulator Homo sapiens 358-363 12022950-0 2002 A role for calcium in Bcl-2 action? Calcium 11-18 BCL2 apoptosis regulator Homo sapiens 22-27 11875716-6 2002 Treatment of HAG/src3-1 cells with taxotere resulted in phosphorylation of Bcl-2 and subsequent induction of apoptotic cell death, whereas neither Bcl-2 phosphorylation nor apoptosis occurred in parental or c-H-ras-transfected HAG-1 cells. Docetaxel 35-43 BCL2 apoptosis regulator Homo sapiens 75-80 11875716-8 2002 Treatment of HAG/src3-1 cells with herbimycin A significantly reduced the expression and phosphorylation of Bcl-2, and abrogated taxotere-induced apoptosis, suggesting a potential role for Src protein tyrosine kinase in the taxotere-induced apoptotic events. herbimycin 35-47 BCL2 apoptosis regulator Homo sapiens 108-113 11875716-10 2002 These data indicate that the ability of activated Src to increase taxotere sensitivity would be mediated by apoptotic events occurring through Src to downstream signal transduction pathways toward Bcl-2 phosphorylation, but not by activated Ras, PI-3 kinase or protein kinase C. Docetaxel 66-74 BCL2 apoptosis regulator Homo sapiens 197-202 11802204-11 2002 This corresponded with suppression of Bcl-2 and Bcl-X/L expression in wt-p53 cells exposed to gemcitabine whereas Bcl-2 levels remained stable and Bcl-X/L levels increased in mut-p53 cells exposed to gemcitabine. gemcitabine 94-105 BCL2 apoptosis regulator Homo sapiens 38-43 11820937-7 2002 On the addition of a plant-specific peptide, phytochelatin [PC(7), (gammaGlu-Cys)(7)-Gly], to the medium, the detoxification of Cd(2+) and cooperation with Bcl-2 were more intense than in the cases of GSH and NAC. Glutathione 201-204 BCL2 apoptosis regulator Homo sapiens 156-161 11820937-7 2002 On the addition of a plant-specific peptide, phytochelatin [PC(7), (gammaGlu-Cys)(7)-Gly], to the medium, the detoxification of Cd(2+) and cooperation with Bcl-2 were more intense than in the cases of GSH and NAC. gamma-glutamylcysteine 67-80 BCL2 apoptosis regulator Homo sapiens 156-161 11820937-7 2002 On the addition of a plant-specific peptide, phytochelatin [PC(7), (gammaGlu-Cys)(7)-Gly], to the medium, the detoxification of Cd(2+) and cooperation with Bcl-2 were more intense than in the cases of GSH and NAC. Acetylcysteine 209-212 BCL2 apoptosis regulator Homo sapiens 156-161 11805214-5 2002 Incubation with LPS markedly decreased the Bcl-2 level, which was totally reversed by KR-31378 and to a lesser degree by KR-31612 and by alpha-tocopherol. Krypton 86-88 BCL2 apoptosis regulator Homo sapiens 43-48 11820937-7 2002 On the addition of a plant-specific peptide, phytochelatin [PC(7), (gammaGlu-Cys)(7)-Gly], to the medium, the detoxification of Cd(2+) and cooperation with Bcl-2 were more intense than in the cases of GSH and NAC. 7)-gly 82-88 BCL2 apoptosis regulator Homo sapiens 156-161 11805214-5 2002 Incubation with LPS markedly decreased the Bcl-2 level, which was totally reversed by KR-31378 and to a lesser degree by KR-31612 and by alpha-tocopherol. Krypton 121-123 BCL2 apoptosis regulator Homo sapiens 43-48 11805237-5 2002 Incubation with LPS caused a marked decrease in Bcl-2 protein, which was significantly reversed by cilostazol and its analogs. Cilostazol 99-109 BCL2 apoptosis regulator Homo sapiens 48-53 11805214-5 2002 Incubation with LPS markedly decreased the Bcl-2 level, which was totally reversed by KR-31378 and to a lesser degree by KR-31612 and by alpha-tocopherol. alpha-Tocopherol 137-153 BCL2 apoptosis regulator Homo sapiens 43-48 11805237-7 2002 In conclusion, cilostazol and its analogs exert a strong protection against apoptotic cell death by scavenging hydroxyl radicals and intracellular ROS with reduction in TNF-alpha formation and by increasing Bcl-2 protein expression and decreasing Bax protein and cytochrome c release. Cilostazol 15-25 BCL2 apoptosis regulator Homo sapiens 207-212 11840333-7 2002 Further, the DNA cross-linking drugs BCNU and cisplatin, but not the microtubule poison vincristine, induced significant cell death in U87MG/hDkk cells, and this was accompanied by altered Bcl-2/Bax expression and a reduction in the amount of telomere DNA as visualized by fluorescence in situ hybridization. Carmustine 37-41 BCL2 apoptosis regulator Homo sapiens 189-194 11883704-7 2002 The expression levels of protein bcl-2, bax have no change in response to squamocin treatment in HL-60 cells, whereas stress-activated protein kinase (SAPK/JNK) was activated after treatment with squamocin in HL-60 cells. squamocin 196-205 BCL2 apoptosis regulator Homo sapiens 33-38 16120290-0 2002 Bcl-2 sensitive mitochondrial potassium accumulation and swelling in apoptosis. Potassium 30-39 BCL2 apoptosis regulator Homo sapiens 0-5 16120290-3 2002 Potassium uptake and swelling of mitochondria were blocked by bcl-2 overexpression. Potassium 0-9 BCL2 apoptosis regulator Homo sapiens 62-67 16120290-6 2002 This study suggests several novel aspects of apoptotic signaling: (1) potassium related swelling of mitochondria; (2) inhibition of mitochondrial potassium uptake by bcl-2; (3) co-existence within one system of multiple mechanisms of cytochrome c release: mitochondrial swelling and swelling-independent permeabilization of the outer mitochondrial membrane. Potassium 146-155 BCL2 apoptosis regulator Homo sapiens 166-171 11840333-7 2002 Further, the DNA cross-linking drugs BCNU and cisplatin, but not the microtubule poison vincristine, induced significant cell death in U87MG/hDkk cells, and this was accompanied by altered Bcl-2/Bax expression and a reduction in the amount of telomere DNA as visualized by fluorescence in situ hybridization. Cisplatin 46-55 BCL2 apoptosis regulator Homo sapiens 189-194 11782377-7 2002 Synergistic potentiation of STI571-mediated lethality by PD184352 was associated with multiple perturbations in signaling and apoptotic regulatory pathways, including caspase-dependent down-regulation of Bcr-Abl and Bcl-2; caspase-independent down-regulation of Bcl-x(L) and Mcl-1; activation of JNK, p38 MAPK, and p34(cdc2); and diminished phosphorylation of Stat5 and CREB. Imatinib Mesylate 28-34 BCL2 apoptosis regulator Homo sapiens 216-221 11791174-4 2002 Expression of both anti-apoptotic (such as Bcl-2 and Bcl-x(L)) and proapoptotic (such as Bax) proteins is markedly elevated in the liver of human ALD and chronically ethanol-fed IL-6 (+/+) mice. Ethanol 166-173 BCL2 apoptosis regulator Homo sapiens 43-48 11899739-6 2002 We analyzed clinical and pathological parameters including bcl-2 expression in paraffin-embedded tumor samples using immunohistochemical technique. Paraffin 79-87 BCL2 apoptosis regulator Homo sapiens 59-64 12237565-9 2002 In conclusion, reduction of BCL-2 makes cells more sensitive to death induced by ROS and leads to shortening of the culture"s life span. Reactive Oxygen Species 81-84 BCL2 apoptosis regulator Homo sapiens 28-33 11756188-6 2002 Furthermore, CDDO-Me inhibited the activation of ERK1/2, as determined by the inhibition of mitochondrial ERK1/2 phosphorylation, and it blocked Bcl-2 phosphorylation, rendering Bcl-2 less anti-apoptotic. bardoxolone methyl 13-20 BCL2 apoptosis regulator Homo sapiens 145-150 11756188-6 2002 Furthermore, CDDO-Me inhibited the activation of ERK1/2, as determined by the inhibition of mitochondrial ERK1/2 phosphorylation, and it blocked Bcl-2 phosphorylation, rendering Bcl-2 less anti-apoptotic. bardoxolone methyl 13-20 BCL2 apoptosis regulator Homo sapiens 178-183 11756218-0 2002 Induction of cell cycle arrest and apoptosis in human colon adenocarcinoma cell lines by beta-carotene through down-regulation of cyclin A and Bcl-2 family proteins. beta Carotene 89-102 BCL2 apoptosis regulator Homo sapiens 143-148 11855753-1 2002 PURPOSE: To evaluate the pharmacokinetic (PK) properties of Bcl-2 antisense oligodeoxynucleotide G3139 when combined with the anthracycline anticancer drug doxorubicin (DOX) in a model of MDA435/LCC6 human breast cancer in severely compromised immunodeficient (SCID) mice. Oligodeoxyribonucleotides 76-96 BCL2 apoptosis regulator Homo sapiens 60-65 11855753-1 2002 PURPOSE: To evaluate the pharmacokinetic (PK) properties of Bcl-2 antisense oligodeoxynucleotide G3139 when combined with the anthracycline anticancer drug doxorubicin (DOX) in a model of MDA435/LCC6 human breast cancer in severely compromised immunodeficient (SCID) mice. oblimersen 97-102 BCL2 apoptosis regulator Homo sapiens 60-65 11777344-6 2002 Pretreatment of THP-1 cells with MEK inhibitors (U0126 and PD98059) prior to bryo1 induction blocked the expression of both XIAP and the c-fms product (M-CSF receptor), a hallmark of monocytic differentiation, but not Bcl-2. U 0126 49-54 BCL2 apoptosis regulator Homo sapiens 218-223 11777344-6 2002 Pretreatment of THP-1 cells with MEK inhibitors (U0126 and PD98059) prior to bryo1 induction blocked the expression of both XIAP and the c-fms product (M-CSF receptor), a hallmark of monocytic differentiation, but not Bcl-2. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 59-66 BCL2 apoptosis regulator Homo sapiens 218-223 11782377-7 2002 Synergistic potentiation of STI571-mediated lethality by PD184352 was associated with multiple perturbations in signaling and apoptotic regulatory pathways, including caspase-dependent down-regulation of Bcr-Abl and Bcl-2; caspase-independent down-regulation of Bcl-x(L) and Mcl-1; activation of JNK, p38 MAPK, and p34(cdc2); and diminished phosphorylation of Stat5 and CREB. 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide 57-65 BCL2 apoptosis regulator Homo sapiens 216-221 12674762-8 2002 These findings suggested that the Bcl-2 gene family indeed participated in the regulatory process of apoptosis induced by curcumin in HL-60 cells and AML cells. Curcumin 122-130 BCL2 apoptosis regulator Homo sapiens 34-39 11756235-0 2002 Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 160-165 11756235-0 2002 Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Curcumin 10-27 BCL2 apoptosis regulator Homo sapiens 160-165 11756235-3 2002 The apoptotic intermediates through which curcumin exhibits its cytotoxic effects against tumor cells are not known, and the participation of antiapoptotic proteins Bcl-2 or Bcl-xl in the curcumin-induced apoptosis pathway is not established. Curcumin 188-196 BCL2 apoptosis regulator Homo sapiens 165-170 11756235-12 2002 Our results also suggest that Bcl-2 and Bcl-xl are critical negative regulators of curcumin-induced apoptosis. Curcumin 83-91 BCL2 apoptosis regulator Homo sapiens 30-35 11709494-6 2002 High concentration of H2O2 increased an apoptotic signal molecule, ASK1, which resulted in Bcl-2 down-regulation, membrane potential disruption, decreased ATP and glucose uptake, and activation of caspases. Hydrogen Peroxide 22-26 BCL2 apoptosis regulator Homo sapiens 91-96 11958592-6 2002 Furthermore, rifampicin down-regulated the expression of Bax and CD95L and up-regulated the expression of Bcl-2, Bcl-xL, and Flice-inhibitory protein-L (FLIPL); however, rifampicin had no effect on CD95 or XIAP expression. Rifampin 13-23 BCL2 apoptosis regulator Homo sapiens 106-111 12323098-8 2002 For that, antisense oligonucleotides addressed to the coding region of bcl2 mRNA were synthesized and administered to the MCF7 human cell line. Oligonucleotides 20-36 BCL2 apoptosis regulator Homo sapiens 71-75 11748660-6 2002 The effect of LMP1 on the balance of Bcl-2 and Bax ratio may play a role in inducing susceptibility to cisplatin-induced cell death. Cisplatin 103-112 BCL2 apoptosis regulator Homo sapiens 37-42 11796751-5 2002 Stable over-expression of Bcl-2 in SH-SY5Y protected cells from death at doses of staurosporine up to 1 microm. Staurosporine 82-95 BCL2 apoptosis regulator Homo sapiens 26-31 11867266-8 2002 Bcl-2 family proteins are expressed in leiomyomas and myometrium in different phases related to and influenced by gonadal steroids. Steroids 122-130 BCL2 apoptosis regulator Homo sapiens 0-5 12025892-2 2002 Because ATRA has effects (increase in apoptosis, suppression of bcl-2), it has also been used for the treatment of other French-American-British (FAB) subtypes of acute myelogenous leukemia (AML). Tretinoin 8-12 BCL2 apoptosis regulator Homo sapiens 64-69 12025892-10 2002 Logistic regression analysis revealed that ATRA administration was the important factor in CR, among other potential factors including age, white blood count, bcl-2 expression, and the uptake and efflux of Rh123 (p = 0.05). Tretinoin 43-47 BCL2 apoptosis regulator Homo sapiens 159-164 11986995-6 2002 It is thus noteworthy that mood stabilizers, such as lithium and valproate, indirectly regulate a number of factors involved in cell survival pathways--including cAMP response element binding protein, brain derived neurotrophic factor, bcl-2 and mitogen-activated protein kinases--and may thus bring about some of their delayed long-term beneficial effects via under-appreciated neurotrophic effects. Lithium 53-60 BCL2 apoptosis regulator Homo sapiens 236-241 11986995-6 2002 It is thus noteworthy that mood stabilizers, such as lithium and valproate, indirectly regulate a number of factors involved in cell survival pathways--including cAMP response element binding protein, brain derived neurotrophic factor, bcl-2 and mitogen-activated protein kinases--and may thus bring about some of their delayed long-term beneficial effects via under-appreciated neurotrophic effects. Valproic Acid 65-74 BCL2 apoptosis regulator Homo sapiens 236-241 12465754-7 2002 Calcitriol induces PARP cleavage, increases the bax/bcl-2 ratio, reduces levels of phosphorylated mitogen-activated protein kinases (P-MAPKs, P-Erk-1/2) and phosphorylated Akt (P-Akt), induces caspase-dependent MEK cleavage and up-regulation of MEKK-1, all potential markers of the apoptotic pathway. Calcitriol 0-10 BCL2 apoptosis regulator Homo sapiens 52-57 11930666-0 2002 Overexpression of bcl-2 protects hepatoma cell line HCC-9204 from ethanol-induced apoptosis. Ethanol 66-73 BCL2 apoptosis regulator Homo sapiens 18-23 11930666-1 2002 OBJECTIVE: To investigate the effect of overexpression of bcl-2 on ethanol-induced apoptosis of primary hepatocellular carcinoma (HCC) cells. Ethanol 67-74 BCL2 apoptosis regulator Homo sapiens 58-63 11930666-10 2002 CONCLUSION: Overexpression of Bcl-2 protein suppresses ethanol-induced apoptosis of the HCC cell line HCC-9204. Ethanol 55-62 BCL2 apoptosis regulator Homo sapiens 30-35 11751611-9 2002 Progesterone and 19-norprogesterone, alone or in combination with estrogen, increased Bcl-2 expression. Progesterone 0-12 BCL2 apoptosis regulator Homo sapiens 86-91 11751611-9 2002 Progesterone and 19-norprogesterone, alone or in combination with estrogen, increased Bcl-2 expression. 19-norprogesterone 17-35 BCL2 apoptosis regulator Homo sapiens 86-91 12658808-2 2002 The expression of bcl-2 in the colorectal carcinoma and incisional edge tissue of tumor was detected by using SABC method. sabc 110-114 BCL2 apoptosis regulator Homo sapiens 18-23 12674762-1 2002 To investigate whether the Bcl-2 gene family is involved in modulating mechanism of apoptosis and change of cell cycle protein induced by curcumin in acute myeloid leukemia HL-60 cell line and primary acute myelogenous leukemic cells, the Bcl-2 family member Mcl-1, Bax and Bak and cell cycle proteins including P27kipl, P21wafl, cyclin D3 and pRbp- were selected and their expression detected by SABC immuno-histochemical stain method. Curcumin 138-146 BCL2 apoptosis regulator Homo sapiens 27-32 12674762-1 2002 To investigate whether the Bcl-2 gene family is involved in modulating mechanism of apoptosis and change of cell cycle protein induced by curcumin in acute myeloid leukemia HL-60 cell line and primary acute myelogenous leukemic cells, the Bcl-2 family member Mcl-1, Bax and Bak and cell cycle proteins including P27kipl, P21wafl, cyclin D3 and pRbp- were selected and their expression detected by SABC immuno-histochemical stain method. sabc 397-401 BCL2 apoptosis regulator Homo sapiens 27-32 12241083-1 2002 Independent of apoptosis, dexamethasone induced and a decrease of respiration and citrate synthase activity per cell in cells with and without transgenic Bcl-2 expression. Dexamethasone 26-39 BCL2 apoptosis regulator Homo sapiens 154-159 12088100-0 2002 Changes in apoptosis, mitosis, Her-2, p53 and Bcl2 expression in breast carcinomas after short-term tamoxifen treatment. Tamoxifen 100-109 BCL2 apoptosis regulator Homo sapiens 46-50 12088100-2 2002 Following tamoxifen treatment expression of HER-2 and p53 decreased but Bcl2 remained unchanged. Tamoxifen 10-19 BCL2 apoptosis regulator Homo sapiens 72-76 12903196-3 2002 Pierisin-1 induced apoptosis in mammalian cells accompanied by a release of cytochrome c and activation of a variety of caspases, and this apoptosis was inhibited by overexpression of Bcl-2. pierisin-1 0-10 BCL2 apoptosis regulator Homo sapiens 184-189 12138244-3 2002 METHODS: The cytotoxic effects of 5-FU and gemcitabine in AsPC-1, Capan-1, Mia-PaCa-2 and T3M4 pancreatic cancer cell lines were assessed by growth assays, and mRNA expression levels of pro-apoptotic and anti-apoptotic genes of the Bcl-2 family were analyzed by RNAse protection assays. Fluorouracil 34-38 BCL2 apoptosis regulator Homo sapiens 232-237 12138244-8 2002 The bax/bcl-2 ratio maintained relatively stable following 5-FU/gemcitabine treatment and reflected the chemotherapeutic sensitivity of these cell lines. Fluorouracil 59-63 BCL2 apoptosis regulator Homo sapiens 8-13 12138244-8 2002 The bax/bcl-2 ratio maintained relatively stable following 5-FU/gemcitabine treatment and reflected the chemotherapeutic sensitivity of these cell lines. gemcitabine 64-75 BCL2 apoptosis regulator Homo sapiens 8-13 12533967-4 2002 Formalin-fixed, paraffin embedded tissues were treated with ant-Bcl-2 antibody (Dako No M 0887). Formaldehyde 0-8 BCL2 apoptosis regulator Homo sapiens 64-69 12533968-5 2002 The immunolocalization of Bcl-2 was performed using the Labelled Streptavidin Biotin (LSAB) method. Biotin 78-84 BCL2 apoptosis regulator Homo sapiens 26-31 11755820-3 2002 To gain some insights into the association of CBDCA resistance with Bcl-2 family level or p53 status, we established eight carcinoma cell lines, consisting of two resistant (MIT8, MIT16), two sensitive (MIT6, MIT7), and four intermediate lines. Carboplatin 46-51 BCL2 apoptosis regulator Homo sapiens 68-73 11754643-6 2002 Pentoxifylline also prevented the radiation-induced decreases in [3H]thymidine uptake and BCL2 and PTHrP receptor mRNA levels in chondrocytes. Pentoxifylline 0-14 BCL2 apoptosis regulator Homo sapiens 90-94 12903200-6 2002 Furthermore, HeLa cells which were transiently transfected with the siRNA expression vector against bcl-2 and were subsequently treated with doxorubicin efficiently underwent apoptosis, concomitant with the repression of the bcl-2 gene. Doxorubicin 141-152 BCL2 apoptosis regulator Homo sapiens 100-105 12903200-6 2002 Furthermore, HeLa cells which were transiently transfected with the siRNA expression vector against bcl-2 and were subsequently treated with doxorubicin efficiently underwent apoptosis, concomitant with the repression of the bcl-2 gene. Doxorubicin 141-152 BCL2 apoptosis regulator Homo sapiens 225-230 11744329-4 2001 Bcl-2 transfectants of both cell lines were more resistant to H(2)O(2) and showed increases in GSH level and Cu/Zn-superoxide dismutase (SOD1) activity, but not in Mn-superoxide dismutase, glutathione peroxidase, or glutathione reductase activities. Glutathione 95-98 BCL2 apoptosis regulator Homo sapiens 0-5 11739184-0 2001 Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Arsenic Trioxide 0-16 BCL2 apoptosis regulator Homo sapiens 145-150 21106154-2 2001 METHODS: DNA gel electrophoresis, terminal deoxynucleotidyl transferase nick end labeling (TUNEL) and immunocytochemistry were used to detect the apoptosis induced by As2O3 with different doses and time and the expression of Bcl-2 or PCNA. Arsenic Trioxide 167-172 BCL2 apoptosis regulator Homo sapiens 225-230 11744329-0 2001 Effect of overexpression of BCL-2 on cellular oxidative damage, nitric oxide production, antioxidant defenses, and the proteasome. Nitric Oxide 64-76 BCL2 apoptosis regulator Homo sapiens 28-33 11744329-3 2001 We therefore examined parameters of antioxidant defense and oxidative damage in two different cell lines, NT-2/D1 (NT-2) and SK-N-MC, overexpressing Bcl-2 as compared with vector-only controls. sk-n-mc 125-132 BCL2 apoptosis regulator Homo sapiens 149-154 11751388-8 2001 Examination of pathways common to Taxol and retinoid signaling revealed that this synergy was related in part to effects on Bcl-2 expression/phosphorylation as well as the activity of the c-Jun NH(2)-terminal kinase and activator protein-1. Paclitaxel 34-39 BCL2 apoptosis regulator Homo sapiens 124-129 11744329-6 2001 Overexpression of Bcl-2 did not significantly decrease levels of oxidative DNA damage (measured as 8-hydroxyguanine) or lipid peroxidation, but it decreased levels of 3-nitrotyrosine in both cell lines and protein carbonyls in SK-N-MC cells only. 3-nitrotyrosine 167-182 BCL2 apoptosis regulator Homo sapiens 18-23 11751388-8 2001 Examination of pathways common to Taxol and retinoid signaling revealed that this synergy was related in part to effects on Bcl-2 expression/phosphorylation as well as the activity of the c-Jun NH(2)-terminal kinase and activator protein-1. Retinoids 44-52 BCL2 apoptosis regulator Homo sapiens 124-129 11744329-4 2001 Bcl-2 transfectants of both cell lines were more resistant to H(2)O(2) and showed increases in GSH level and Cu/Zn-superoxide dismutase (SOD1) activity, but not in Mn-superoxide dismutase, glutathione peroxidase, or glutathione reductase activities. Water 62-67 BCL2 apoptosis regulator Homo sapiens 0-5 11744329-6 2001 Overexpression of Bcl-2 did not significantly decrease levels of oxidative DNA damage (measured as 8-hydroxyguanine) or lipid peroxidation, but it decreased levels of 3-nitrotyrosine in both cell lines and protein carbonyls in SK-N-MC cells only. sk-n-mc 227-234 BCL2 apoptosis regulator Homo sapiens 18-23 11744329-9 2001 The ability of Bcl-2 overexpression to decrease 3-nitrotyrosine levels suggests that it may decrease formation of peroxynitrite or other reactive nitrogen species; this was confirmed as decreased production of NO(2)(-)/NO(3)(-) in the transfected cells and a fall in the level of nNOS protein. 3-nitrotyrosine 48-63 BCL2 apoptosis regulator Homo sapiens 15-20 11744329-9 2001 The ability of Bcl-2 overexpression to decrease 3-nitrotyrosine levels suggests that it may decrease formation of peroxynitrite or other reactive nitrogen species; this was confirmed as decreased production of NO(2)(-)/NO(3)(-) in the transfected cells and a fall in the level of nNOS protein. Peroxynitrous Acid 114-127 BCL2 apoptosis regulator Homo sapiens 15-20 11744329-9 2001 The ability of Bcl-2 overexpression to decrease 3-nitrotyrosine levels suggests that it may decrease formation of peroxynitrite or other reactive nitrogen species; this was confirmed as decreased production of NO(2)(-)/NO(3)(-) in the transfected cells and a fall in the level of nNOS protein. reactive nitrogen 137-154 BCL2 apoptosis regulator Homo sapiens 15-20 11579094-9 2001 Treatment with antioxidants restored the levels of antiapoptotic proteins (Hsp70 and Bcl-2) in DOX-treated BAEC. Doxorubicin 95-98 BCL2 apoptosis regulator Homo sapiens 85-90 11592958-0 2001 Nitric oxide suppresses the expression of Bcl-2 binding protein BNIP3 in hepatocytes. Nitric Oxide 0-12 BCL2 apoptosis regulator Homo sapiens 42-47 11747348-5 2001 Western blot analysis indicated that Tyrphostin AG 1024-induced apoptosis was associated with a downregulation of expression of phospho-Akt1, increased expression of Bax, p53 and p21, and a decreased expression of bcl-2 expression, especially when combined with irradiation. Tyrphostins 37-47 BCL2 apoptosis regulator Homo sapiens 214-219 11720765-9 2001 The neurotoxic cell death induced by manganese was significantly reduced in the Bcl-2-overexpressing DA cell lines. Manganese 37-46 BCL2 apoptosis regulator Homo sapiens 80-85 11728179-4 2001 Herein, we describe the discovery of novel classes of small-molecule inhibitors targeted at the BH3 binding pocket in Bcl-2. BH 3 96-99 BCL2 apoptosis regulator Homo sapiens 118-123 11728179-6 2001 A structure-based computer screening approach has been employed to search the National Cancer Institute 3D database of 206 876 organic compounds to identify potential Bcl-2 small-molecule inhibitors that bind to the BH3 binding site of Bcl-2. BH 3 216-219 BCL2 apoptosis regulator Homo sapiens 167-172 11728179-6 2001 A structure-based computer screening approach has been employed to search the National Cancer Institute 3D database of 206 876 organic compounds to identify potential Bcl-2 small-molecule inhibitors that bind to the BH3 binding site of Bcl-2. BH 3 216-219 BCL2 apoptosis regulator Homo sapiens 236-241 11728179-17 2001 Our results suggest that the structure-based computer screening strategy employed in the study is effective for identifying novel, structurally diverse, nonpeptide small-molecule inhibitors that target the BH3 binding site of Bcl-2. BH 3 206-209 BCL2 apoptosis regulator Homo sapiens 226-231 11720765-10 2001 Our findings suggest that manganese-induced neurotoxicity is mediated in part by ER stress and considerably ameliorated by Bcl-2 overexpression in DA cells. Manganese 26-35 BCL2 apoptosis regulator Homo sapiens 123-128 11759062-1 2001 The authors recently showed variable subcellular immunoreactivity of the Bcl-2 and Bax proteins after fixation of cell monolayers with acetone, methanol, or paraformaldehyde (PF) followed by methanol (PF/methanol). Acetone 135-142 BCL2 apoptosis regulator Homo sapiens 73-78 11813903-3 2001 In this study we wanted to determine the influence of different NSAIDs (indomethacin, ibuprofen and sodium salicylate) and hydrocortisone on Bcl-2 expression and the apoptotic behavior of head and neck tumor cell lines and normal oral keratinocytes. Indomethacin 72-84 BCL2 apoptosis regulator Homo sapiens 141-146 11813903-3 2001 In this study we wanted to determine the influence of different NSAIDs (indomethacin, ibuprofen and sodium salicylate) and hydrocortisone on Bcl-2 expression and the apoptotic behavior of head and neck tumor cell lines and normal oral keratinocytes. Ibuprofen 86-95 BCL2 apoptosis regulator Homo sapiens 141-146 11813903-3 2001 In this study we wanted to determine the influence of different NSAIDs (indomethacin, ibuprofen and sodium salicylate) and hydrocortisone on Bcl-2 expression and the apoptotic behavior of head and neck tumor cell lines and normal oral keratinocytes. Sodium Salicylate 100-117 BCL2 apoptosis regulator Homo sapiens 141-146 11813903-3 2001 In this study we wanted to determine the influence of different NSAIDs (indomethacin, ibuprofen and sodium salicylate) and hydrocortisone on Bcl-2 expression and the apoptotic behavior of head and neck tumor cell lines and normal oral keratinocytes. Hydrocortisone 123-137 BCL2 apoptosis regulator Homo sapiens 141-146 11813903-6 2001 Indomethacin (1 mM) and ibuprofen (1 mM) significantly reduced Bcl-2 expression in the cancer cell lines tested and might be thought responsible for the observed increase in apoptosis. Indomethacin 0-12 BCL2 apoptosis regulator Homo sapiens 63-68 11813903-6 2001 Indomethacin (1 mM) and ibuprofen (1 mM) significantly reduced Bcl-2 expression in the cancer cell lines tested and might be thought responsible for the observed increase in apoptosis. Ibuprofen 24-33 BCL2 apoptosis regulator Homo sapiens 63-68 11813903-7 2001 At all concentrations tested the influence of sodium salicylate and hydrocortisone on Bcl-2 expression was not significant. Hydrocortisone 68-82 BCL2 apoptosis regulator Homo sapiens 86-91 11759062-1 2001 The authors recently showed variable subcellular immunoreactivity of the Bcl-2 and Bax proteins after fixation of cell monolayers with acetone, methanol, or paraformaldehyde (PF) followed by methanol (PF/methanol). Methanol 144-152 BCL2 apoptosis regulator Homo sapiens 73-78 11759062-1 2001 The authors recently showed variable subcellular immunoreactivity of the Bcl-2 and Bax proteins after fixation of cell monolayers with acetone, methanol, or paraformaldehyde (PF) followed by methanol (PF/methanol). paraform 157-173 BCL2 apoptosis regulator Homo sapiens 73-78 11759062-1 2001 The authors recently showed variable subcellular immunoreactivity of the Bcl-2 and Bax proteins after fixation of cell monolayers with acetone, methanol, or paraformaldehyde (PF) followed by methanol (PF/methanol). paraform 175-177 BCL2 apoptosis regulator Homo sapiens 73-78 11759062-1 2001 The authors recently showed variable subcellular immunoreactivity of the Bcl-2 and Bax proteins after fixation of cell monolayers with acetone, methanol, or paraformaldehyde (PF) followed by methanol (PF/methanol). Methanol 191-199 BCL2 apoptosis regulator Homo sapiens 73-78 11759062-1 2001 The authors recently showed variable subcellular immunoreactivity of the Bcl-2 and Bax proteins after fixation of cell monolayers with acetone, methanol, or paraformaldehyde (PF) followed by methanol (PF/methanol). paraform 201-203 BCL2 apoptosis regulator Homo sapiens 73-78 11759062-1 2001 The authors recently showed variable subcellular immunoreactivity of the Bcl-2 and Bax proteins after fixation of cell monolayers with acetone, methanol, or paraformaldehyde (PF) followed by methanol (PF/methanol). Methanol 191-199 BCL2 apoptosis regulator Homo sapiens 73-78 11751518-5 2001 Oncol., 16: 333-338, 2000) that genistein induces cell cycle arrest and apoptosis by up-regulating p21(WAF1) and Bax, and down-regulating cyclin B1 and Bcl-2 in a head and neck cancer cell line. Genistein 32-41 BCL2 apoptosis regulator Homo sapiens 152-157 11751483-0 2001 A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Oligonucleotides 75-90 BCL2 apoptosis regulator Homo sapiens 69-74 11751483-2 2001 Genasense is a phosphorothioate antisense oligonucleotide complementary to the bcl-2 mRNA open reading frame that in preclinical studies has shown significant activity in inhibiting expression of Bcl-2, delaying androgen independence, and improving chemosensitivity in prostate and other cancer models. oblimersen 0-9 BCL2 apoptosis regulator Homo sapiens 79-84 11751483-2 2001 Genasense is a phosphorothioate antisense oligonucleotide complementary to the bcl-2 mRNA open reading frame that in preclinical studies has shown significant activity in inhibiting expression of Bcl-2, delaying androgen independence, and improving chemosensitivity in prostate and other cancer models. oblimersen 0-9 BCL2 apoptosis regulator Homo sapiens 196-201 11728380-11 2001 The data also suggest that DW2282 triggered apoptosis by decreasing Bcl-2 levels and activating caspase-3 protease. DW 2282 27-33 BCL2 apoptosis regulator Homo sapiens 68-73 11751523-7 2001 EGCG also caused a decrease in the Bcl-2 and Bcl-X(L) proteins, an increase in the Bax protein, and activation of caspase 9, suggesting that EGCG induces apoptosis via a mitochondrial pathway. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 35-40 11751483-2 2001 Genasense is a phosphorothioate antisense oligonucleotide complementary to the bcl-2 mRNA open reading frame that in preclinical studies has shown significant activity in inhibiting expression of Bcl-2, delaying androgen independence, and improving chemosensitivity in prostate and other cancer models. Parathion 15-31 BCL2 apoptosis regulator Homo sapiens 79-84 11751483-2 2001 Genasense is a phosphorothioate antisense oligonucleotide complementary to the bcl-2 mRNA open reading frame that in preclinical studies has shown significant activity in inhibiting expression of Bcl-2, delaying androgen independence, and improving chemosensitivity in prostate and other cancer models. Parathion 15-31 BCL2 apoptosis regulator Homo sapiens 196-201 11751523-7 2001 EGCG also caused a decrease in the Bcl-2 and Bcl-X(L) proteins, an increase in the Bax protein, and activation of caspase 9, suggesting that EGCG induces apoptosis via a mitochondrial pathway. epigallocatechin gallate 141-145 BCL2 apoptosis regulator Homo sapiens 35-40 11751483-2 2001 Genasense is a phosphorothioate antisense oligonucleotide complementary to the bcl-2 mRNA open reading frame that in preclinical studies has shown significant activity in inhibiting expression of Bcl-2, delaying androgen independence, and improving chemosensitivity in prostate and other cancer models. Oligonucleotides 42-57 BCL2 apoptosis regulator Homo sapiens 79-84 11751483-2 2001 Genasense is a phosphorothioate antisense oligonucleotide complementary to the bcl-2 mRNA open reading frame that in preclinical studies has shown significant activity in inhibiting expression of Bcl-2, delaying androgen independence, and improving chemosensitivity in prostate and other cancer models. Oligonucleotides 42-57 BCL2 apoptosis regulator Homo sapiens 196-201 11787776-5 2001 Western blot analysis showed that levels of bcl-2, bax and c-myc were significantly overexpressed by treatment with the increase of heparin concentrations. Heparin 132-139 BCL2 apoptosis regulator Homo sapiens 44-49 11751483-13 2001 Peripheral blood lymphocyte Bcl-2 protein expression decreased in five of five patients given Genasense at 5mg/kg/day (mean change from baseline, -12.8%; SD, 16.4%) as assessed by flow cytometry. oblimersen 94-103 BCL2 apoptosis regulator Homo sapiens 28-33 11723234-7 2001 Conversely, overexpression of the mitochondrial antiapoptotic factor Bcl-2 blocked caspase 9 activation, leading to an inhibition of drug-induced plasma membrane permeability and blebbing, terminal deoxynucleotidyl transferase dUTP nick-end labeling positivity, PARP cleavage, Annexin V positivity, and drug-induced cell death. deoxyuridine triphosphate 227-231 BCL2 apoptosis regulator Homo sapiens 69-74 11829192-4 2001 In the present study p53 and bcl-2 expression in paraffin sections from 50 cases of laryngeal squamous cell carcinoma were analysed and correlated with routine clinico-pathological parameters. Paraffin 49-57 BCL2 apoptosis regulator Homo sapiens 29-34 11805418-0 2001 Antisense Bcl-2 oligonucleotide uptake in human transitional cell carcinoma. Oligonucleotides 16-31 BCL2 apoptosis regulator Homo sapiens 10-15 11805418-1 2001 OBJECTIVES: Antisense oligonucleotides (AO) downregulate Bcl-2 protein expression in various tumours if good target cell uptake is achieved. Oligonucleotides 22-38 BCL2 apoptosis regulator Homo sapiens 57-62 11805418-2 2001 In this study, uptake of FITC labelled AO (FITC-AO) directed at Bcl-2 was examined in: (1) the RT4 bladder tumour cell line; (2) normal pig urothelium, and (3) human superficial bladder tumours. Fluorescein-5-isothiocyanate 25-29 BCL2 apoptosis regulator Homo sapiens 64-69 11805418-2 2001 In this study, uptake of FITC labelled AO (FITC-AO) directed at Bcl-2 was examined in: (1) the RT4 bladder tumour cell line; (2) normal pig urothelium, and (3) human superficial bladder tumours. Oligonucleotides, Antisense 39-41 BCL2 apoptosis regulator Homo sapiens 64-69 11805418-2 2001 In this study, uptake of FITC labelled AO (FITC-AO) directed at Bcl-2 was examined in: (1) the RT4 bladder tumour cell line; (2) normal pig urothelium, and (3) human superficial bladder tumours. fitc-ao 43-50 BCL2 apoptosis regulator Homo sapiens 64-69 11726273-0 2001 Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2. Serine 81-87 BCL2 apoptosis regulator Homo sapiens 27-32 11726273-0 2001 Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2. Serine 81-87 BCL2 apoptosis regulator Homo sapiens 94-99 11726273-2 2001 The phosphorylation of serine 70 of Bcl-2 (pS70-Bcl-2) peaks 24 to 48 h after paclitaxel treatment and accelerates apoptosis. Serine 23-29 BCL2 apoptosis regulator Homo sapiens 36-41 11726273-2 2001 The phosphorylation of serine 70 of Bcl-2 (pS70-Bcl-2) peaks 24 to 48 h after paclitaxel treatment and accelerates apoptosis. Serine 23-29 BCL2 apoptosis regulator Homo sapiens 43-53 11726273-2 2001 The phosphorylation of serine 70 of Bcl-2 (pS70-Bcl-2) peaks 24 to 48 h after paclitaxel treatment and accelerates apoptosis. Paclitaxel 78-88 BCL2 apoptosis regulator Homo sapiens 36-41 11726273-2 2001 The phosphorylation of serine 70 of Bcl-2 (pS70-Bcl-2) peaks 24 to 48 h after paclitaxel treatment and accelerates apoptosis. Paclitaxel 78-88 BCL2 apoptosis regulator Homo sapiens 43-53 11726273-3 2001 Phosphorylation is effectively inhibited in the presence of actinomycin D or cycloheximide, which restore cell viability to the same level as control cells not expressing Bcl-2. Dactinomycin 60-73 BCL2 apoptosis regulator Homo sapiens 171-176 11726273-3 2001 Phosphorylation is effectively inhibited in the presence of actinomycin D or cycloheximide, which restore cell viability to the same level as control cells not expressing Bcl-2. Cycloheximide 77-90 BCL2 apoptosis regulator Homo sapiens 171-176 11726273-4 2001 These results indicate that paclitaxel-induced kinase(s) and/or its activator(s) are synthesized de novo and play an important role in paclitaxel-induced apoptosis by phosphorylating Bcl-2. Paclitaxel 28-38 BCL2 apoptosis regulator Homo sapiens 183-188 11726273-4 2001 These results indicate that paclitaxel-induced kinase(s) and/or its activator(s) are synthesized de novo and play an important role in paclitaxel-induced apoptosis by phosphorylating Bcl-2. Paclitaxel 135-145 BCL2 apoptosis regulator Homo sapiens 183-188 11726273-5 2001 In binding assays using the phosphorylation-specific antibody against pS70-Bcl-2, the induction of serine 70 phosphorylation 70 results in a loss of the binding ability of Bcl-2 to Bax, a pro-apoptotic partner, and induces subsequent cell death. Serine 99-105 BCL2 apoptosis regulator Homo sapiens 70-80 11726273-5 2001 In binding assays using the phosphorylation-specific antibody against pS70-Bcl-2, the induction of serine 70 phosphorylation 70 results in a loss of the binding ability of Bcl-2 to Bax, a pro-apoptotic partner, and induces subsequent cell death. Serine 99-105 BCL2 apoptosis regulator Homo sapiens 75-80 11726273-6 2001 When the pS70-Bcl-2 antibody was added to human breast cancer tissue, serine 70 phosphorylation was also detected, even prior to treatment with anticancer agents. Serine 70-76 BCL2 apoptosis regulator Homo sapiens 9-19 11726273-7 2001 Further study of breast cancers revealed 83% of tumors with high pS70-Bcl-2 expression responded to paclitaxel or docetaxel treatment, whereas 57% of those with low expression not respond. Paclitaxel 100-110 BCL2 apoptosis regulator Homo sapiens 65-75 11726273-7 2001 Further study of breast cancers revealed 83% of tumors with high pS70-Bcl-2 expression responded to paclitaxel or docetaxel treatment, whereas 57% of those with low expression not respond. Docetaxel 114-123 BCL2 apoptosis regulator Homo sapiens 65-75 11726273-8 2001 These findings suggest that pS70-Bcl-2 might be a predictive factor for prognosis and sensitivity to paclitaxel treatment for breast cancer. Paclitaxel 101-111 BCL2 apoptosis regulator Homo sapiens 28-38 11723234-8 2001 Although Bcl-2 thus blocked the cytotoxic effects of activated CPA, it did not inhibit the drug"s cytostatic effects. Cyclophosphamide 63-66 BCL2 apoptosis regulator Homo sapiens 9-14 11723234-9 2001 CPA induced S-phase cell cycle arrest followed by conversion to an apoptotic pre-G1 state in wild-type 9L cells; by contrast, Bcl-2-expressing 9L cells accumulated in G2/M in response to CPA treatment. Cyclophosphamide 187-190 BCL2 apoptosis regulator Homo sapiens 126-131 11723234-10 2001 Intratumoral expression of Bcl-2 and related family members, including both apoptotic and antiapoptotic factors, is thus an important determinant of the responsiveness of tumor cells to CPA and ifosfamide, both in the context of conventional chemotherapy and in patients sensitized to these oxazaphosphorine drugs by the use of cytochrome P450-based gene therapy. Cyclophosphamide 186-189 BCL2 apoptosis regulator Homo sapiens 27-32 11723234-10 2001 Intratumoral expression of Bcl-2 and related family members, including both apoptotic and antiapoptotic factors, is thus an important determinant of the responsiveness of tumor cells to CPA and ifosfamide, both in the context of conventional chemotherapy and in patients sensitized to these oxazaphosphorine drugs by the use of cytochrome P450-based gene therapy. Ifosfamide 194-204 BCL2 apoptosis regulator Homo sapiens 27-32 11723234-10 2001 Intratumoral expression of Bcl-2 and related family members, including both apoptotic and antiapoptotic factors, is thus an important determinant of the responsiveness of tumor cells to CPA and ifosfamide, both in the context of conventional chemotherapy and in patients sensitized to these oxazaphosphorine drugs by the use of cytochrome P450-based gene therapy. oxazaphosphorine 291-307 BCL2 apoptosis regulator Homo sapiens 27-32 11723237-0 2001 Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells. Parathion 126-142 BCL2 apoptosis regulator Homo sapiens 112-117 11723237-1 2001 Isis 3521 and G3139 are 20- and 18-mer phosphorothioate oligonucleotides, respectively, targeted to the protein kinase C (PKC)-alpha and bcl-2 mRNAs. Phosphorothioate Oligonucleotides 39-72 BCL2 apoptosis regulator Homo sapiens 137-142 11854904-7 2001 After 24 hours incubation with sulindac at 2mmol x L(-1) and 4mmol x L(-1), the level of COX-2 and Bcl-2 protein were lowered in MKN45, SMMC7721 and HepG(2) cells but not in MKN28 cells. Sulindac 31-39 BCL2 apoptosis regulator Homo sapiens 99-104 11723237-8 2001 When the carrier Eufectin 5 is employed, only bcl-2 is down-regulated in both T24 and PC3 cells at 50 nM oligonucleotide concentration. Oligonucleotides 105-120 BCL2 apoptosis regulator Homo sapiens 46-51 11723237-9 2001 At 100 nM, both bcl-2 and PKC-alpha expression are down-regulated, and only at this concentration can "chemosensitization" to paclitaxel and carboplatin be observed. Paclitaxel 126-136 BCL2 apoptosis regulator Homo sapiens 16-21 11723237-9 2001 At 100 nM, both bcl-2 and PKC-alpha expression are down-regulated, and only at this concentration can "chemosensitization" to paclitaxel and carboplatin be observed. Carboplatin 141-152 BCL2 apoptosis regulator Homo sapiens 16-21 11903930-8 2001 We conclude that: (1) the presence of C-Jun and Bcl-2 within the glucose polymer mass of CAm may be related to mitochondrial damage and/or a transient overload of proteolytic systems during cellular injury; and (2) repetitive cellular stress during life may cause the age-related increase of CAm in elderly subjects. Glucose 65-72 BCL2 apoptosis regulator Homo sapiens 48-53 11903930-8 2001 We conclude that: (1) the presence of C-Jun and Bcl-2 within the glucose polymer mass of CAm may be related to mitochondrial damage and/or a transient overload of proteolytic systems during cellular injury; and (2) repetitive cellular stress during life may cause the age-related increase of CAm in elderly subjects. cafestol palmitate 89-92 BCL2 apoptosis regulator Homo sapiens 48-53 11854904-8 2001 CONCLUSION: Sulindac could inhibit the growth of gastric cancer cells and HCC cells effectively in vitro by apoptosis induction, which was associated with regression of COX-2 and Bcl-2 expression. Sulindac 12-20 BCL2 apoptosis regulator Homo sapiens 179-184 11767000-3 2001 The PTK inhibitor genistein (GEN) and PKC inhibitor staurosporine (STP) down-regulated Mcl-1 and Bcl-2 expression, and induced growth inhibition by blocking at the G2/M phase of cell cycle, followed by apoptosis, leading to chromatin condensation and DNA fragmentation. Genistein 18-27 BCL2 apoptosis regulator Homo sapiens 97-102 11749792-1 2001 AIM: To explore the effect of cationic lipid 1,3-di-oleoyloxy-2-(6-carboxy-spermyl)-propylamid (DOSPER) on cellular uptake and activity of bcl-2 antisense oligodeoxynucleotide G3139 in HL-60 cells. 1,3-di-oleoyloxy-2-(6-carboxy-spermyl)-propylamid 45-94 BCL2 apoptosis regulator Homo sapiens 139-144 11713097-2 2001 Sodium butyrate (NaB) is a histone deacetylase inhibitor capable of alteration of bcl-2 family protein expression in other tumor types. Butyric Acid 0-15 BCL2 apoptosis regulator Homo sapiens 82-87 11713097-2 2001 Sodium butyrate (NaB) is a histone deacetylase inhibitor capable of alteration of bcl-2 family protein expression in other tumor types. nab 17-20 BCL2 apoptosis regulator Homo sapiens 82-87 11709009-9 2001 Following exposure to camptothecin, keratocytes from patients with Fuchs dystrophy responded with an increased level of Bax and a low level of Bcl-2. Camptothecin 22-34 BCL2 apoptosis regulator Homo sapiens 143-148 11555660-4 2001 Nitric oxide causes release of cytochrome c from mitochondria, and Bcl-2 protects the neural progenitor cells against nitric oxide-induced death, consistent with a pivotal role for mitochondrial changes in controlling the cell death process. Nitric Oxide 118-130 BCL2 apoptosis regulator Homo sapiens 67-72 11555660-6 2001 The anti-apoptotic protein Bcl-2 protected NPC against nitric oxide-induced apoptosis and suppressed activation of p38 MAP kinase. Nitric Oxide 55-67 BCL2 apoptosis regulator Homo sapiens 27-32 11753638-9 2001 Curcumin alone induced apoptosis in both cell types, which correlated with the downregulation of the expression of Bcl-2 and Bcl-xL and the activation of procaspase-3 and procaspase-8. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 115-120 11514546-9 2001 Antisense oligonucleotides to Bcl-2 significantly down-regulated Bcl-2 protein expression in VHL-positive cells and rendered them sensitive to apoptosis. Oligonucleotides 10-26 BCL2 apoptosis regulator Homo sapiens 30-35 11514546-9 2001 Antisense oligonucleotides to Bcl-2 significantly down-regulated Bcl-2 protein expression in VHL-positive cells and rendered them sensitive to apoptosis. Oligonucleotides 10-26 BCL2 apoptosis regulator Homo sapiens 65-70 11720482-1 2001 The effects of vinorelbine and paclitaxel on the activity of extracellular signal-regulated protein kinase2 (ERK2), a member of MAP kinase, and its role in the induction of bcl-2 phosphorylation and apoptosis were evaluated in MCF-7 cells. Vinorelbine 15-26 BCL2 apoptosis regulator Homo sapiens 173-178 11720482-1 2001 The effects of vinorelbine and paclitaxel on the activity of extracellular signal-regulated protein kinase2 (ERK2), a member of MAP kinase, and its role in the induction of bcl-2 phosphorylation and apoptosis were evaluated in MCF-7 cells. Paclitaxel 31-41 BCL2 apoptosis regulator Homo sapiens 173-178 11720482-5 2001 We also demonstrated that elevated bcl-2 phosphorylation induced by vinorelbine is paralleled by decrease of a complex formation between bcl-2 and bax, cleavage of poly (ADP) ribose polymerase (PARP) protein, activation of caspase-7, and apoptosis. Vinorelbine 68-79 BCL2 apoptosis regulator Homo sapiens 35-40 11720482-5 2001 We also demonstrated that elevated bcl-2 phosphorylation induced by vinorelbine is paralleled by decrease of a complex formation between bcl-2 and bax, cleavage of poly (ADP) ribose polymerase (PARP) protein, activation of caspase-7, and apoptosis. Vinorelbine 68-79 BCL2 apoptosis regulator Homo sapiens 137-142 11720482-7 2001 Thus, our data suggest that the apoptosis induced by vinorelbine in MCF-7 cells is mediated through the bcl-2 phosphorylation/bax/caspases pathways, and that activation of ERK2 by vinorelbine does not directly lead to the drug-mediated apoptosis. Vinorelbine 53-64 BCL2 apoptosis regulator Homo sapiens 104-109 11595647-4 2001 Stable high glucose induced apoptosis in human umbilical vein endothelial cells, a phenomenon accompanied by a significant decrease of Bcl-2 and a simultaneous increase of Bax expression. Glucose 12-19 BCL2 apoptosis regulator Homo sapiens 135-140 11767000-6 2001 The MEK inhibitor U0126 (U0) decreased Bcl-2 expression but not Mcl-1 expression, inhibited cells growth and induced G1/G0 arrest. U 0126 18-23 BCL2 apoptosis regulator Homo sapiens 39-44 11767000-6 2001 The MEK inhibitor U0126 (U0) decreased Bcl-2 expression but not Mcl-1 expression, inhibited cells growth and induced G1/G0 arrest. U 0126 18-20 BCL2 apoptosis regulator Homo sapiens 39-44 11687888-4 2001 Moreover, monoglyceride-mediated apoptosis was suppressed either by Bcl-2 overexpression, treatment with a broad inhibitor of caspases, or RNA and protein synthesis inhibitors. Monoglycerides 10-23 BCL2 apoptosis regulator Homo sapiens 68-73 11767000-3 2001 The PTK inhibitor genistein (GEN) and PKC inhibitor staurosporine (STP) down-regulated Mcl-1 and Bcl-2 expression, and induced growth inhibition by blocking at the G2/M phase of cell cycle, followed by apoptosis, leading to chromatin condensation and DNA fragmentation. Genistein 29-32 BCL2 apoptosis regulator Homo sapiens 97-102 11767000-3 2001 The PTK inhibitor genistein (GEN) and PKC inhibitor staurosporine (STP) down-regulated Mcl-1 and Bcl-2 expression, and induced growth inhibition by blocking at the G2/M phase of cell cycle, followed by apoptosis, leading to chromatin condensation and DNA fragmentation. Staurosporine 52-65 BCL2 apoptosis regulator Homo sapiens 97-102 11767000-3 2001 The PTK inhibitor genistein (GEN) and PKC inhibitor staurosporine (STP) down-regulated Mcl-1 and Bcl-2 expression, and induced growth inhibition by blocking at the G2/M phase of cell cycle, followed by apoptosis, leading to chromatin condensation and DNA fragmentation. Staurosporine 67-70 BCL2 apoptosis regulator Homo sapiens 97-102 11767000-4 2001 LY294002 (LY)-mediated inhibition of P13-K activity down-regulated Bcl-2 but not Mcl-1 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 BCL2 apoptosis regulator Homo sapiens 67-72 11767000-4 2001 LY294002 (LY)-mediated inhibition of P13-K activity down-regulated Bcl-2 but not Mcl-1 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-2 BCL2 apoptosis regulator Homo sapiens 67-72 11714368-6 2001 Treatment with CAPE caused rapid activation of caspase-3 after 4 h, down-regulation of Bcl-2 expression after 6 h, and up-regulation of Bax expression after 16 h. These results suggest that CAPE is a potent apoptosis-inducing agent; its action is accompanied by activation of caspase-3, down-regulation of Bcl-2, and up-regulation of Bax in human leukemic HL-60 cells. caffeic acid phenethyl ester 15-19 BCL2 apoptosis regulator Homo sapiens 87-92 11745284-8 2001 DEM preincubation restored sensitivity to Fas antibody and radiation-induced apoptosis in cells from the LNCaP-bcl-2 transfectant cell line that, normally, are resistant to these apoptotic stimuli. diethyl maleate 0-3 BCL2 apoptosis regulator Homo sapiens 111-116 11761456-4 2001 In the present study, we expanded our investigations to examine the effect of cisplatin-induced ERK activation on the expression of p53-targeted genes that have been shown to be important in the cellular response to DNA damage including Bax, Bcl-2, Bcl-x1, Cyclin G, Gadd45, p21WAF1, and Mdm2. Cisplatin 78-87 BCL2 apoptosis regulator Homo sapiens 242-247 11597394-0 2001 Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect. Sirolimus 0-9 BCL2 apoptosis regulator Homo sapiens 54-59 11605012-5 2001 Tamoxifen induces the anti-apoptotic gene, Bcl-2, by its effect on estradiol (E2), via an E2-response element in the promotor region of Bcl-2. Tamoxifen 0-9 BCL2 apoptosis regulator Homo sapiens 43-48 11605012-5 2001 Tamoxifen induces the anti-apoptotic gene, Bcl-2, by its effect on estradiol (E2), via an E2-response element in the promotor region of Bcl-2. Tamoxifen 0-9 BCL2 apoptosis regulator Homo sapiens 136-141 11605012-10 2001 The possible reasons that the chemotherapy benefit in receptor-positive patients is small and marginal are the following: i) concurrent treatment or pretreatment with tamoxifen can increase plasma E2 levels in premenopausal patients, thereby inducing Bcl-2 in residual cancer cells, which might decrease drug-sensitivity in combination with chemotherapy; ii) induction of Bcl-2 might be involved predominantly in the resistance to taxanes, the cytotoxic action of which targets Bcl-2. Tamoxifen 167-176 BCL2 apoptosis regulator Homo sapiens 251-256 11605012-10 2001 The possible reasons that the chemotherapy benefit in receptor-positive patients is small and marginal are the following: i) concurrent treatment or pretreatment with tamoxifen can increase plasma E2 levels in premenopausal patients, thereby inducing Bcl-2 in residual cancer cells, which might decrease drug-sensitivity in combination with chemotherapy; ii) induction of Bcl-2 might be involved predominantly in the resistance to taxanes, the cytotoxic action of which targets Bcl-2. Tamoxifen 167-176 BCL2 apoptosis regulator Homo sapiens 372-377 11605012-10 2001 The possible reasons that the chemotherapy benefit in receptor-positive patients is small and marginal are the following: i) concurrent treatment or pretreatment with tamoxifen can increase plasma E2 levels in premenopausal patients, thereby inducing Bcl-2 in residual cancer cells, which might decrease drug-sensitivity in combination with chemotherapy; ii) induction of Bcl-2 might be involved predominantly in the resistance to taxanes, the cytotoxic action of which targets Bcl-2. Tamoxifen 167-176 BCL2 apoptosis regulator Homo sapiens 372-377 11605012-11 2001 Co-treatment or pretreatment with tamoxifen for adjuvant therapy might decrease the efficacy of anticancer drugs, an effect that is mediated by induction of Bcl-2, especially in premenopausal patients with node-positive breast cancer. Tamoxifen 34-43 BCL2 apoptosis regulator Homo sapiens 157-162 11733941-7 2001 For Bcl-2-transfected cells, the release of Ca2+ was incomplete as determined by a further [Ca2+]i transient produced by the addition of the Ca2+ ionophore ionomycin after PDT. Ionomycin 156-165 BCL2 apoptosis regulator Homo sapiens 4-9 12188882-1 2001 D-RNAi (Messenger RNA-antisense DNA interference), a novel posttranscriptional phenomenon of silencing gene expression by transfection of mRNA-aDNA hybrids, was originally observed in the effects of bcl-2 on phorbol ester-induced apoptosis in human prostate cancer LNCaP cells. Phorbol Esters 208-221 BCL2 apoptosis regulator Homo sapiens 199-204 11714368-6 2001 Treatment with CAPE caused rapid activation of caspase-3 after 4 h, down-regulation of Bcl-2 expression after 6 h, and up-regulation of Bax expression after 16 h. These results suggest that CAPE is a potent apoptosis-inducing agent; its action is accompanied by activation of caspase-3, down-regulation of Bcl-2, and up-regulation of Bax in human leukemic HL-60 cells. caffeic acid phenethyl ester 15-19 BCL2 apoptosis regulator Homo sapiens 306-311 11714368-6 2001 Treatment with CAPE caused rapid activation of caspase-3 after 4 h, down-regulation of Bcl-2 expression after 6 h, and up-regulation of Bax expression after 16 h. These results suggest that CAPE is a potent apoptosis-inducing agent; its action is accompanied by activation of caspase-3, down-regulation of Bcl-2, and up-regulation of Bax in human leukemic HL-60 cells. caffeic acid phenethyl ester 190-194 BCL2 apoptosis regulator Homo sapiens 87-92 11714368-6 2001 Treatment with CAPE caused rapid activation of caspase-3 after 4 h, down-regulation of Bcl-2 expression after 6 h, and up-regulation of Bax expression after 16 h. These results suggest that CAPE is a potent apoptosis-inducing agent; its action is accompanied by activation of caspase-3, down-regulation of Bcl-2, and up-regulation of Bax in human leukemic HL-60 cells. caffeic acid phenethyl ester 190-194 BCL2 apoptosis regulator Homo sapiens 306-311 11703590-10 2001 Cisplatin-induced Akt/PKB activation was associated with Bad phosphorylation, suggesting induction of a cell survival signal mediated by the Bcl-2 family member, Bad. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 141-146 11738551-3 2001 The role of Bcl-2 in MCF-7 cell survival was confirmed by stable overexpression of Bcl-2 which resulted in suppression of apoptosis induced by doxorubicin (DOX), paclitaxel (TAX) and TNF as compared to vector-control cells. Doxorubicin 143-154 BCL2 apoptosis regulator Homo sapiens 12-17 11738551-3 2001 The role of Bcl-2 in MCF-7 cell survival was confirmed by stable overexpression of Bcl-2 which resulted in suppression of apoptosis induced by doxorubicin (DOX), paclitaxel (TAX) and TNF as compared to vector-control cells. Doxorubicin 143-154 BCL2 apoptosis regulator Homo sapiens 83-88 11738551-3 2001 The role of Bcl-2 in MCF-7 cell survival was confirmed by stable overexpression of Bcl-2 which resulted in suppression of apoptosis induced by doxorubicin (DOX), paclitaxel (TAX) and TNF as compared to vector-control cells. Doxorubicin 156-159 BCL2 apoptosis regulator Homo sapiens 83-88 11738551-3 2001 The role of Bcl-2 in MCF-7 cell survival was confirmed by stable overexpression of Bcl-2 which resulted in suppression of apoptosis induced by doxorubicin (DOX), paclitaxel (TAX) and TNF as compared to vector-control cells. Paclitaxel 162-172 BCL2 apoptosis regulator Homo sapiens 12-17 11738551-3 2001 The role of Bcl-2 in MCF-7 cell survival was confirmed by stable overexpression of Bcl-2 which resulted in suppression of apoptosis induced by doxorubicin (DOX), paclitaxel (TAX) and TNF as compared to vector-control cells. Paclitaxel 162-172 BCL2 apoptosis regulator Homo sapiens 83-88 11694645-0 2001 Short-chain fatty acids inhibit invasive human colon cancer by modulating uPA, TIMP-1, TIMP-2, mutant p53, Bcl-2, Bax, p21 and PCNA protein expression in an in vitro cell culture model. Fatty Acids, Volatile 0-23 BCL2 apoptosis regulator Homo sapiens 107-112 11587529-4 2001 The caspase inhibitor Z-VAD-fmk strongly attenuates both bcl-2 mRNA decay and bcl-2 AUBP pattern changes elicited by apoptotic stimuli, indicating the involvement of bcl-2 AUBPs in bcl-2 mRNA stability control. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 22-31 BCL2 apoptosis regulator Homo sapiens 78-83 11774038-3 2001 Comparison of a variety of pharmacological inhibitors of serine/threonine-specific protein kinases demonstrated that the cyclin-dependent kinase inhibitor, flavopiridol, selectively blocks Bcl-2 phosphorylation induced by antimicrotubule drugs. alvocidib 156-168 BCL2 apoptosis regulator Homo sapiens 189-194 11774038-5 2001 Examination of several serine-->alanine substitution mutants of Bcl-2 suggested that serine 70 and serine 87 represent major sites of Bcl-2 phosphorylation induced in response to microtubule-targeting drugs. Serine 23-29 BCL2 apoptosis regulator Homo sapiens 67-72 11774038-5 2001 Examination of several serine-->alanine substitution mutants of Bcl-2 suggested that serine 70 and serine 87 represent major sites of Bcl-2 phosphorylation induced in response to microtubule-targeting drugs. Alanine 35-42 BCL2 apoptosis regulator Homo sapiens 67-72 11774038-5 2001 Examination of several serine-->alanine substitution mutants of Bcl-2 suggested that serine 70 and serine 87 represent major sites of Bcl-2 phosphorylation induced in response to microtubule-targeting drugs. Serine 88-94 BCL2 apoptosis regulator Homo sapiens 67-72 11774038-5 2001 Examination of several serine-->alanine substitution mutants of Bcl-2 suggested that serine 70 and serine 87 represent major sites of Bcl-2 phosphorylation induced in response to microtubule-targeting drugs. Serine 88-94 BCL2 apoptosis regulator Homo sapiens 137-142 11774038-5 2001 Examination of several serine-->alanine substitution mutants of Bcl-2 suggested that serine 70 and serine 87 represent major sites of Bcl-2 phosphorylation induced in response to microtubule-targeting drugs. Serine 88-94 BCL2 apoptosis regulator Homo sapiens 67-72 11774038-5 2001 Examination of several serine-->alanine substitution mutants of Bcl-2 suggested that serine 70 and serine 87 represent major sites of Bcl-2 phosphorylation induced in response to microtubule-targeting drugs. Serine 88-94 BCL2 apoptosis regulator Homo sapiens 137-142 11774038-9 2001 Since the region in Bcl-2 containing serine 70 and serine 87 represents a proline-rich loop that has been associated with autorepression of its antiapoptotic activity, the discovery of Pin1 interactions with phosphorylated Bcl-2 raises the possibility that Pin1 alters the conformation of Bcl-2 and thereby modulates its function in cells arrested with antimicrotubule drugs. Serine 37-43 BCL2 apoptosis regulator Homo sapiens 20-25 11774038-9 2001 Since the region in Bcl-2 containing serine 70 and serine 87 represents a proline-rich loop that has been associated with autorepression of its antiapoptotic activity, the discovery of Pin1 interactions with phosphorylated Bcl-2 raises the possibility that Pin1 alters the conformation of Bcl-2 and thereby modulates its function in cells arrested with antimicrotubule drugs. Proline 74-81 BCL2 apoptosis regulator Homo sapiens 20-25 11495898-5 2001 Apoptosis induced by NGF neutralization could be blocked by the specific p38 MAPK inhibitor SB203580 or by Bcl-2 mutations in Ser-87 or Thr-56. Serine 126-129 BCL2 apoptosis regulator Homo sapiens 107-112 11495898-5 2001 Apoptosis induced by NGF neutralization could be blocked by the specific p38 MAPK inhibitor SB203580 or by Bcl-2 mutations in Ser-87 or Thr-56. Threonine 136-139 BCL2 apoptosis regulator Homo sapiens 107-112 11591753-3 2001 The report of a PKC activatable cAMP response element (CRE) in the bcl-2 promoter and a role for PKC in bcl-2 expression in B cells led us to the hypothesis that PKC phosphorylation activates transcription factor CREB after IL-3R engagement. Cyclic AMP 32-36 BCL2 apoptosis regulator Homo sapiens 67-72 11774038-2 2001 Phosphorylation of the Bcl-2 protein is induced on serine residues in tumor cells arrested by microtubule-targeting drugs (paclitaxel, vincristine, nocodazole) and has been associated with inactivation of antiapoptotic function through an unknown mechanism. Serine 51-57 BCL2 apoptosis regulator Homo sapiens 23-28 11774038-2 2001 Phosphorylation of the Bcl-2 protein is induced on serine residues in tumor cells arrested by microtubule-targeting drugs (paclitaxel, vincristine, nocodazole) and has been associated with inactivation of antiapoptotic function through an unknown mechanism. Paclitaxel 123-133 BCL2 apoptosis regulator Homo sapiens 23-28 11774038-2 2001 Phosphorylation of the Bcl-2 protein is induced on serine residues in tumor cells arrested by microtubule-targeting drugs (paclitaxel, vincristine, nocodazole) and has been associated with inactivation of antiapoptotic function through an unknown mechanism. Vincristine 135-146 BCL2 apoptosis regulator Homo sapiens 23-28 11774038-2 2001 Phosphorylation of the Bcl-2 protein is induced on serine residues in tumor cells arrested by microtubule-targeting drugs (paclitaxel, vincristine, nocodazole) and has been associated with inactivation of antiapoptotic function through an unknown mechanism. Nocodazole 148-158 BCL2 apoptosis regulator Homo sapiens 23-28 11489892-3 2001 The release of endogenous cytochrome c from mitochondria into the cytoplasm was detected in Bcl-2-negative cells treated with the kinase inhibitor staurosporine or the calcium-ATPase inhibitor thapsigargin. Staurosporine 147-160 BCL2 apoptosis regulator Homo sapiens 92-97 11489892-3 2001 The release of endogenous cytochrome c from mitochondria into the cytoplasm was detected in Bcl-2-negative cells treated with the kinase inhibitor staurosporine or the calcium-ATPase inhibitor thapsigargin. Thapsigargin 193-205 BCL2 apoptosis regulator Homo sapiens 92-97 11596021-14 2001 Further studies are warranted to determine whether pharmacogenomic assessment of topoisomerase II, MRP, or bcl-2 may predict for response to mitoxantrone. Mitoxantrone 141-153 BCL2 apoptosis regulator Homo sapiens 107-112 11597122-10 2001 Moreover, it blocked Taxol-induced phosphorylation of p38 and Bcl-2, and prevented a Taxol-induced change in relative mobility of the apoptosis signal-regulating kinase 1 (Ask1). Paclitaxel 21-26 BCL2 apoptosis regulator Homo sapiens 62-67 11587529-4 2001 The caspase inhibitor Z-VAD-fmk strongly attenuates both bcl-2 mRNA decay and bcl-2 AUBP pattern changes elicited by apoptotic stimuli, indicating the involvement of bcl-2 AUBPs in bcl-2 mRNA stability control. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 22-31 BCL2 apoptosis regulator Homo sapiens 57-62 11587529-4 2001 The caspase inhibitor Z-VAD-fmk strongly attenuates both bcl-2 mRNA decay and bcl-2 AUBP pattern changes elicited by apoptotic stimuli, indicating the involvement of bcl-2 AUBPs in bcl-2 mRNA stability control. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 22-31 BCL2 apoptosis regulator Homo sapiens 78-83 11587529-4 2001 The caspase inhibitor Z-VAD-fmk strongly attenuates both bcl-2 mRNA decay and bcl-2 AUBP pattern changes elicited by apoptotic stimuli, indicating the involvement of bcl-2 AUBPs in bcl-2 mRNA stability control. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 22-31 BCL2 apoptosis regulator Homo sapiens 78-83 11483855-1 2001 Survival factors activate kinases which, in turn, phosphorylate the proapoptotic Bcl-xl/Bcl-2-associated death promoter homolog (BAD) protein at key serine residues. Serine 149-155 BCL2 apoptosis regulator Homo sapiens 88-93 11641782-2 2001 Nonetheless, both mock- and bcl-2-transfected MCF-7 cells undergo apoptosis after treatment with a variety of stimuli, including the DNA-cleaving antimitotic agent, neocarzinostatin (NCS). Zinostatin 165-181 BCL2 apoptosis regulator Homo sapiens 28-33 11641782-2 2001 Nonetheless, both mock- and bcl-2-transfected MCF-7 cells undergo apoptosis after treatment with a variety of stimuli, including the DNA-cleaving antimitotic agent, neocarzinostatin (NCS). Zinostatin 183-186 BCL2 apoptosis regulator Homo sapiens 28-33 11642314-6 2001 Tectorigenin also inhibited autophosphorylation of epidermal growth factor (EGF) receptor by EGF and decreased the expression of Bcl-2 protein, with less activity than genistein. tectorigenin 0-12 BCL2 apoptosis regulator Homo sapiens 129-134 11592071-2 2001 Previously, we have shown ADAC in CD8+ populations to be Fas independent, TNF-alpha receptor 2 (TNFR2) mediated, caspase dependent, and accompanied by a decrease in Bcl-2. adenosine amine congener 26-30 BCL2 apoptosis regulator Homo sapiens 165-170 11577002-0 2001 Bcl-2 overexpression attenuates resveratrol-induced apoptosis in U937 cells by inhibition of caspase-3 activity. Resveratrol 32-43 BCL2 apoptosis regulator Homo sapiens 0-5 11577002-2 2001 In the present study, we determined the effect of high intracellular levels of the anti-apoptosis protein Bcl-2 on caspase-3 activation, PLC-gamma1 degradation and cytochrome c release during resveratrol-induced apoptosis. Resveratrol 192-203 BCL2 apoptosis regulator Homo sapiens 106-111 11577002-7 2001 In contrast, resveratrol-induced caspase-3 activation and PLC-gamma1 degradation and apoptosis were significantly inhibited in U937/Bcl-2 cells. Resveratrol 13-24 BCL2 apoptosis regulator Homo sapiens 132-137 11577002-8 2001 Bcl-2 overexpressing cells exhibited less cytochrome c release and sustained expression levels of the IAP proteins during resveratrol-induced apoptosis. Resveratrol 122-133 BCL2 apoptosis regulator Homo sapiens 0-5 11577002-9 2001 In addition, these findings indicate that Bcl-2 inhibits resveratrol-induced apoptosis by a mechanism that interferes with cytochrome c release and activity of caspase-3 that is involved in the execution of apoptosis. Resveratrol 57-68 BCL2 apoptosis regulator Homo sapiens 42-47 11740051-3 2001 Immunohistochemical staining method was used for detecting p53 and bcl-2 expression on paraffin blocks of three pure insular, five follicular or papillary thyroid carcinomas with a major insular component (more than 50%) and six with a minor insular component (20-50%). Paraffin 87-95 BCL2 apoptosis regulator Homo sapiens 67-72 11606022-0 2001 17-beta-estradiol alters Jurkat lymphocyte cell cycling and induces apoptosis through suppression of Bcl-2 and cyclin A. Estradiol 0-17 BCL2 apoptosis regulator Homo sapiens 101-106 11692156-0 2001 Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model. Oligonucleotides 16-32 BCL2 apoptosis regulator Homo sapiens 0-5 11692156-1 2001 We used Bcl-2 antisense oligonucleotides (G3139) to chemosensitize human gastric cancer by downregulation of Bcl-2 expression in vivo. Oligonucleotides 24-40 BCL2 apoptosis regulator Homo sapiens 8-13 11677264-0 2001 Iodoacetate protects hippocampal neurons against excitotoxic and oxidative injury: involvement of heat-shock proteins and Bcl-2. Iodoacetates 0-11 BCL2 apoptosis regulator Homo sapiens 122-127 11692156-1 2001 We used Bcl-2 antisense oligonucleotides (G3139) to chemosensitize human gastric cancer by downregulation of Bcl-2 expression in vivo. Oligonucleotides 24-40 BCL2 apoptosis regulator Homo sapiens 109-114 11677264-6 2001 Levels of the stress heat-shock proteins HSP70 and HSP90, and of the anti-apoptotic protein Bcl-2, were increased in neurons exposed to IAA. Iodoacetic Acid 136-139 BCL2 apoptosis regulator Homo sapiens 92-97 11692156-6 2001 Treatment with Bcl-2 antisense oligonucleotides is thus a promising novel approach to enhance antitumor activity of cisplatin or other drugs used in gastric cancer therapy and warrants further evaluation in clinical trials. Oligonucleotides 31-47 BCL2 apoptosis regulator Homo sapiens 15-20 11692156-6 2001 Treatment with Bcl-2 antisense oligonucleotides is thus a promising novel approach to enhance antitumor activity of cisplatin or other drugs used in gastric cancer therapy and warrants further evaluation in clinical trials. Cisplatin 116-125 BCL2 apoptosis regulator Homo sapiens 15-20 11587214-6 2001 Second, rolipram suppresses the expression of anti-apoptotic members of the Bcl-2 family and induces the pro-apoptotic protein Bax, thereby shifting the balance between pro- and anti-apoptotic members of the Bcl-2 family towards a pro-apoptotic direction. Rolipram 8-16 BCL2 apoptosis regulator Homo sapiens 76-81 11587214-6 2001 Second, rolipram suppresses the expression of anti-apoptotic members of the Bcl-2 family and induces the pro-apoptotic protein Bax, thereby shifting the balance between pro- and anti-apoptotic members of the Bcl-2 family towards a pro-apoptotic direction. Rolipram 8-16 BCL2 apoptosis regulator Homo sapiens 208-213 11740418-7 2001 RESULTS: Treated lymphocytes exhibit a significantly enhanced expression of Fas/FssL system associated with a decrease of Bcl2 expression at both 5 and 50 mg/ml propofol concentrations (p<0.05). Propofol 161-169 BCL2 apoptosis regulator Homo sapiens 122-126 11740418-9 2001 CONCLUSIONS: Propofol impairs, in vitro, both Fas/FasL and Bcl2 expressions on lymphocytes at clinically relevant concentrations but fails to induce apoptotic cell death. Propofol 13-21 BCL2 apoptosis regulator Homo sapiens 59-63 11593425-4 2001 Rapamycin did not affect bcl-2 mRNA although it increased cellular BCL-2 concentration by inhibiting phosphorylation, a mechanism initiating the decay process. Sirolimus 0-9 BCL2 apoptosis regulator Homo sapiens 67-72 11593425-5 2001 To add new insight, we combined rapamycin treatment with treatment by taxol, which, by damaging microtubules, can phosphorylate BCL-2 and activate apoptosis. Paclitaxel 70-75 BCL2 apoptosis regulator Homo sapiens 128-133 11552982-10 2001 In the model cell line used, conditional bcl-2 expression delayed glucocorticoid-induced apoptosis by protecting against loss of mitochondrial membrane potential; bcl-2 expression delayed the increase in lactate production and had no effect on the pre-apoptotic drop in lactate production. Lactic Acid 204-211 BCL2 apoptosis regulator Homo sapiens 163-168 11513800-8 2001 Therapeutic efficacy of PFV-encapsulated antisense ODN against two proto-oncogenes, c-myc and bcl-2, was examined in various cell lines. pfv 24-27 BCL2 apoptosis regulator Homo sapiens 94-99 11513800-10 2001 However, treatment of 518A2 melanoma cells with PFV-encapsulated antisense targeting bcl-2 at concentrations of 0.5 microM and 1.0 microM resulted in reduced bcl-2 mRNA level by about 20% and 25% after 48 h incubation. pfv 48-51 BCL2 apoptosis regulator Homo sapiens 85-90 11513800-10 2001 However, treatment of 518A2 melanoma cells with PFV-encapsulated antisense targeting bcl-2 at concentrations of 0.5 microM and 1.0 microM resulted in reduced bcl-2 mRNA level by about 20% and 25% after 48 h incubation. pfv 48-51 BCL2 apoptosis regulator Homo sapiens 158-163 11535817-6 2001 SAHA-induced Bid cleavage was not blocked by caspase inhibitors or the overexpression of Bcl-2 but did require the transcriptional regulatory activity of SAHA. Vorinostat 0-4 BCL2 apoptosis regulator Homo sapiens 89-94 11472266-3 2001 The mechanism of anticancer activity of the cryptophycins has been associated with their destabilization of microtubules and with their induction of bcl-2 phosphorylation leading to apoptosis. Depsipeptides 44-57 BCL2 apoptosis regulator Homo sapiens 149-154 11522452-6 2001 The level of Bcl-2 protein was not affected by glutathione depletion even upon curcumin treatment. Curcumin 79-87 BCL2 apoptosis regulator Homo sapiens 13-18 11848518-7 2001 MATERIALS AND METHODS: The aim of the present study was to investigate the effect of ajoene on changes in the expression of apoptosis-related proteins: bcl-2 and caspase-3, induced by two principal drugs used in treatment of AML, cytarabine and fludarabine, in KGI human myeloid leukaemia CD34-positive-resistant cells. ajoene 85-91 BCL2 apoptosis regulator Homo sapiens 152-157 11848518-9 2001 RESULTS: Quantitative ELISA measurement of bcl-2 (units per million cells) showed treatment of KG1-resistant leukaemia cells with 40 microM ajoene alone to significantly reduce the bcl-2-expression from 239.5 +/- 1.5 in control cultures to only 22.0 +/- 4.0 in ajoene-treated cultures. ajoene 140-146 BCL2 apoptosis regulator Homo sapiens 43-48 11848518-9 2001 RESULTS: Quantitative ELISA measurement of bcl-2 (units per million cells) showed treatment of KG1-resistant leukaemia cells with 40 microM ajoene alone to significantly reduce the bcl-2-expression from 239.5 +/- 1.5 in control cultures to only 22.0 +/- 4.0 in ajoene-treated cultures. ajoene 140-146 BCL2 apoptosis regulator Homo sapiens 181-186 11848518-10 2001 Fludarabine had significantly more inhibitory effect on bcl-2-expression than cytarabine in KGI-resistant myeloid leukaemia cells. fludarabine 0-11 BCL2 apoptosis regulator Homo sapiens 56-61 11848518-11 2001 Ajoene significantly enhanced the inhibitory effect of the two chemotherapeutic drugs, cytarabine and fludarabine, on bcl-2-expression in KGI cells. ajoene 0-6 BCL2 apoptosis regulator Homo sapiens 118-123 11848518-11 2001 Ajoene significantly enhanced the inhibitory effect of the two chemotherapeutic drugs, cytarabine and fludarabine, on bcl-2-expression in KGI cells. Cytarabine 87-97 BCL2 apoptosis regulator Homo sapiens 118-123 11848518-11 2001 Ajoene significantly enhanced the inhibitory effect of the two chemotherapeutic drugs, cytarabine and fludarabine, on bcl-2-expression in KGI cells. fludarabine 102-113 BCL2 apoptosis regulator Homo sapiens 118-123 11683923-0 2001 Caspase-3 activity and expression of Bcl-2 family in human neutrophils by Helicobacter pylori water-soluble proteins. Water 94-99 BCL2 apoptosis regulator Homo sapiens 37-42 11571575-10 2001 Importantly, LNCaP cells stably transfected to overexpress Bcl-2 showed similar patterns of cell death when infected with Ad/ARR(2)PB.Bax.GFP, an 82% reduction in cell viability seen 48 h after infection. (2)pb 128-133 BCL2 apoptosis regulator Homo sapiens 59-64 11774739-5 2001 Western blot analysis using murine monoclonal anti-Bcl-2 antibody showed more than 5-fold Bcl-2 overexpression in Pt-resistant cells in response to cisplatin treatment. Cisplatin 148-157 BCL2 apoptosis regulator Homo sapiens 51-56 11774739-5 2001 Western blot analysis using murine monoclonal anti-Bcl-2 antibody showed more than 5-fold Bcl-2 overexpression in Pt-resistant cells in response to cisplatin treatment. Cisplatin 148-157 BCL2 apoptosis regulator Homo sapiens 90-95 11774740-6 2001 An interaction of Bax and Bcl-2 is very important to decide cell life or death, and Bcl-2 phosphorylation may control this interaction: Paclitaxel treatment induced Bcl-2 phosphorylation and typical apoptosis, whereas hyperthermia induced not Bcl-2 phosphorylation but nuclear translocation and failed to induce apoptosis. Paclitaxel 136-146 BCL2 apoptosis regulator Homo sapiens 26-31 11774740-6 2001 An interaction of Bax and Bcl-2 is very important to decide cell life or death, and Bcl-2 phosphorylation may control this interaction: Paclitaxel treatment induced Bcl-2 phosphorylation and typical apoptosis, whereas hyperthermia induced not Bcl-2 phosphorylation but nuclear translocation and failed to induce apoptosis. Paclitaxel 136-146 BCL2 apoptosis regulator Homo sapiens 84-89 11774740-6 2001 An interaction of Bax and Bcl-2 is very important to decide cell life or death, and Bcl-2 phosphorylation may control this interaction: Paclitaxel treatment induced Bcl-2 phosphorylation and typical apoptosis, whereas hyperthermia induced not Bcl-2 phosphorylation but nuclear translocation and failed to induce apoptosis. Paclitaxel 136-146 BCL2 apoptosis regulator Homo sapiens 84-89 11774740-6 2001 An interaction of Bax and Bcl-2 is very important to decide cell life or death, and Bcl-2 phosphorylation may control this interaction: Paclitaxel treatment induced Bcl-2 phosphorylation and typical apoptosis, whereas hyperthermia induced not Bcl-2 phosphorylation but nuclear translocation and failed to induce apoptosis. Paclitaxel 136-146 BCL2 apoptosis regulator Homo sapiens 84-89 11683923-8 2001 Western blot for Bcl-2 family also performed in neutrophilic differentiated HL-60 cells by all-trans-retinoic acid. Tretinoin 91-114 BCL2 apoptosis regulator Homo sapiens 17-22 11718220-4 2001 Dox 50 ng/ml - IFN alpha 2b 500 IU/ml treatment inhibited cell proliferation (47.2 +/- 1.4%, p < 0.0001; MTT assay: 40.6 +/- 1.2%, p < 0.0001) and augmented the expression of P-170, Bcl-2 and HLA-ABC, while it didn"t exert apoptosis, producing a slight G2/M arrest. Doxorubicin 0-3 BCL2 apoptosis regulator Homo sapiens 188-193 11516199-4 2001 The effect of PS-341 on BCL-2 gene transcription was examined using a BCL-2 promoter/luciferase reporter construct. Bortezomib 14-20 BCL2 apoptosis regulator Homo sapiens 24-29 11509621-8 2001 Although Fas-mediated apoptosis involved changes in Bcl-2, Bax, and Bad regulatory proteins, such alterations were not observed with Tat. ammonium ferrous sulfate 9-12 BCL2 apoptosis regulator Homo sapiens 52-57 11490306-2 2001 We determined Bcl-2 down-regulation after antisense oligonucleotide therapy and synergism with mitomycin C in transitional cell carcinoma of the bladder. Oligonucleotides 52-67 BCL2 apoptosis regulator Homo sapiens 14-19 11490306-8 2001 There was only evidence in 1 cell line, T24/83, that Bcl-2 protein expression down-regulation enhanced mitomycin C induced apoptotic cell death. Mitomycin 103-114 BCL2 apoptosis regulator Homo sapiens 53-58 11490306-10 2001 Therefore, antisense oligonucleotides represent a viable strategy for Bcl-2 protein down-regulation. Oligonucleotides 21-37 BCL2 apoptosis regulator Homo sapiens 70-75 11571709-3 2001 METHODS AND RESULTS: We report an accurate method for quantitative detection of the bcl-2/IgH translocation marker of follicular lymphoma in a series of patients in various stages of remission and relapse who had been treated with a combination of ifosfamide, mitoxantrone, and etoposide (MINE) chemotherapy and monoclonal anti-CD20 antibody (Rituximab). Ifosfamide 248-258 BCL2 apoptosis regulator Homo sapiens 84-89 11571709-3 2001 METHODS AND RESULTS: We report an accurate method for quantitative detection of the bcl-2/IgH translocation marker of follicular lymphoma in a series of patients in various stages of remission and relapse who had been treated with a combination of ifosfamide, mitoxantrone, and etoposide (MINE) chemotherapy and monoclonal anti-CD20 antibody (Rituximab). Mitoxantrone 260-272 BCL2 apoptosis regulator Homo sapiens 84-89 11571709-3 2001 METHODS AND RESULTS: We report an accurate method for quantitative detection of the bcl-2/IgH translocation marker of follicular lymphoma in a series of patients in various stages of remission and relapse who had been treated with a combination of ifosfamide, mitoxantrone, and etoposide (MINE) chemotherapy and monoclonal anti-CD20 antibody (Rituximab). Etoposide 278-287 BCL2 apoptosis regulator Homo sapiens 84-89 11520058-0 2001 Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Arsenic Trioxide 0-16 BCL2 apoptosis regulator Homo sapiens 89-94 11583631-4 2001 Comparison of wild-type versus mutant BCL-2, BCL-X(L) indicates these antiapoptotics sequester BH3 domain-only molecules in stable mitochondrial complexes, preventing the activation of BAX, BAK. BH 3 95-98 BCL2 apoptosis regulator Homo sapiens 38-43 11516199-8 2001 The downregulation of BCL-2 by PS-341 appears to be transcriptionally mediated. Bortezomib 31-37 BCL2 apoptosis regulator Homo sapiens 22-27 11483246-0 2001 The cyclic AMP response element in the Bcl-2 promoter confers inducibility by hypoxia in neuronal cells. Cyclic AMP 4-14 BCL2 apoptosis regulator Homo sapiens 39-44 11517326-2 2001 In some cell lines d120-induced apoptosis, manifested by the release of cytochrome c, activation of caspase 3, and fragmentation of cellular DNA, is blocked by the overexpression of Bcl-2. d120 19-23 BCL2 apoptosis regulator Homo sapiens 182-187 11596115-1 2001 The aim of this study was to evaluate the role of bcl-2 in 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) sensitivity of the ADFS human glioblastoma cell line in vitro and in vivo. Carmustine 59-95 BCL2 apoptosis regulator Homo sapiens 50-55 11596115-1 2001 The aim of this study was to evaluate the role of bcl-2 in 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) sensitivity of the ADFS human glioblastoma cell line in vitro and in vivo. Carmustine 97-101 BCL2 apoptosis regulator Homo sapiens 50-55 11596115-6 2001 The ability of the catalase inhibitor, sodium azide, to increase the BCNU sensitivity of the bcl-2 transfectants to levels of the BCNU-treated control clone substantiated the role of the catalase activity. Sodium Azide 39-51 BCL2 apoptosis regulator Homo sapiens 93-98 11596115-8 2001 Xenografts of bcl-2 overexpressing tumors were less sensitive to BCNU treatment than xenografts originating from control cells. Carmustine 65-69 BCL2 apoptosis regulator Homo sapiens 14-19 11483246-2 2001 We show here that this effect is dependent upon the cyclic AMP response element (CRE) in the Bcl-2 promoter since mutation of this element abolishes the response and the isolated CRE can confer the response on a heterologous promoter. Cyclic AMP 52-62 BCL2 apoptosis regulator Homo sapiens 93-98 11483246-4 2001 Despite the lack of cyclic AMP responsiveness, activation of the Bcl-2 promoter via the CRE in response to hypoxia requires the CREB transcription factor and is associated with the enhanced phosphorylation of CREB on serine 133 and enhanced transcriptional activation by the CREB-binding protein, CBP, in response to hypoxia. Serine 217-223 BCL2 apoptosis regulator Homo sapiens 65-70 11513935-4 2001 One antisense drug has been approved for local treatment of cytomegalovirus-induced retinitis, and several antisense oligonucleotides are in clinical trials, including oligonucleotides that target the mRNA of BCL2, protein-kinase-C alpha, and RAF kinase. Oligonucleotides 117-133 BCL2 apoptosis regulator Homo sapiens 209-213 11513935-4 2001 One antisense drug has been approved for local treatment of cytomegalovirus-induced retinitis, and several antisense oligonucleotides are in clinical trials, including oligonucleotides that target the mRNA of BCL2, protein-kinase-C alpha, and RAF kinase. Oligonucleotides 168-184 BCL2 apoptosis regulator Homo sapiens 209-213 11395480-9 2001 The proapoptotic effect of BMP-2 is PKC-dependent, because BMP-2 increases PKC activity, and the selective PKC inhibitor calphostin C blocks the BMP-2-induced increased Bax/Bcl-2, caspase activity, and apoptosis. calphostin C 121-133 BCL2 apoptosis regulator Homo sapiens 173-178 11534770-5 2001 Curcumin-induced cell death was mainly due to apoptosis in which a prominent downregulation of Bcl-2 and upregulation of Bax were involved. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 95-100 11489837-5 2001 In fact, oligonucleotides antisense bcl-2 have shown antitumor activity in animal models and have successfully completed early clinical trials. Oligonucleotides 9-25 BCL2 apoptosis regulator Homo sapiens 36-41 11468182-4 2001 Recent data indicate that arsenic trioxide (As(2)O(3)) induces remission of refractory acute promyelocytic leukemia and apoptosis of cell lines overexpressing Bcl-2 family members; therefore, it was hypothesized that chemorefractory MM cells would be sensitive to As(2)O(3). Arsenic Trioxide 26-42 BCL2 apoptosis regulator Homo sapiens 159-164 11468182-4 2001 Recent data indicate that arsenic trioxide (As(2)O(3)) induces remission of refractory acute promyelocytic leukemia and apoptosis of cell lines overexpressing Bcl-2 family members; therefore, it was hypothesized that chemorefractory MM cells would be sensitive to As(2)O(3). Arsenic Trioxide 44-53 BCL2 apoptosis regulator Homo sapiens 159-164 11479221-13 2001 Thus, helenalin is a promising experimental cytotoxic agent that possibly points to new strategies to overcome apoptosis resistance attributable to overexpression of antiapoptotic Bcl-2 proteins. helenalin 6-15 BCL2 apoptosis regulator Homo sapiens 180-185 11479221-4 2001 We show here that the sesquiterpene lactone helenalin (10-50 microM) induces apoptosis in leukemia Jurkat T cells even if they lack the CD95 death receptor or overexpress the antiapoptotic proteins Bcl-x(L) or Bcl-2. sesquiterpene lactone 22-43 BCL2 apoptosis regulator Homo sapiens 210-215 11479221-4 2001 We show here that the sesquiterpene lactone helenalin (10-50 microM) induces apoptosis in leukemia Jurkat T cells even if they lack the CD95 death receptor or overexpress the antiapoptotic proteins Bcl-x(L) or Bcl-2. helenalin 44-53 BCL2 apoptosis regulator Homo sapiens 210-215 11502101-0 2001 Bax, Bcl-2, and NF-kappaB expression in sanguinarine induced bimodal cell death. sanguinarine 40-52 BCL2 apoptosis regulator Homo sapiens 5-10 11505395-2 2001 This combination also enhanced sensitivity to paclitaxel in a bcl-2 and mutant p53 expressing renal carcinoma cell line. Paclitaxel 46-56 BCL2 apoptosis regulator Homo sapiens 62-67 11459807-9 2001 A Western blot analysis showed the apoptosis of the granulosa cells induced by palmitic acid to be accompanied by the down-regulation of an apoptosis inhibitor, Bcl-2, and the up-regulation of an apoptosis effector, Bax. Palmitic Acid 79-92 BCL2 apoptosis regulator Homo sapiens 161-166 11502101-1 2001 The apoptosis related proteins Bax, Bcl-2, and NF-kappaB were analyzed in sanguinarine induced apoptosis and blister cell death (BCD) of K562 erythroleukemia cells and in sanguinarine treated high Bcl-2 expressing JM1 pre-B lymphoblastic cells, utilizing immunofluorescence-flow cytometry. sanguinarine 74-86 BCL2 apoptosis regulator Homo sapiens 36-41 11506966-4 2001 The protection was dose- and time-dependent -- maximal protection requiring pre-incubation with 100 ng/ml HGF for 48 h. Western blotting analysis and flow cytometric studies revealed that HGF inhibited doxorubicin- and etoposide-induced decreases in the levels of the anti-apoptotic proteins Bcl-X(L), and to a lesser extent Bcl-2, without inducing changes in the pro-apoptotic Bax protein. Doxorubicin 202-213 BCL2 apoptosis regulator Homo sapiens 325-330 11502101-1 2001 The apoptosis related proteins Bax, Bcl-2, and NF-kappaB were analyzed in sanguinarine induced apoptosis and blister cell death (BCD) of K562 erythroleukemia cells and in sanguinarine treated high Bcl-2 expressing JM1 pre-B lymphoblastic cells, utilizing immunofluorescence-flow cytometry. sanguinarine 74-86 BCL2 apoptosis regulator Homo sapiens 197-202 11561905-9 2001 Furthermore, treating Bcl-2 cultures with ceramide (10 microM), a second messenger mediating the RA-initiated death signal in parental cells, no longer caused DNA laddering. Ceramides 42-50 BCL2 apoptosis regulator Homo sapiens 22-27 11502101-3 2001 In contrast, high Bcl-2 expressing JM1 cells, when exposed to the same concentrations (and duration) of sanguinarine that induced PCD and BCD in K562 cells, failed to show the respective morphologies while showing a concomitant increase in Bcl-2. sanguinarine 104-116 BCL2 apoptosis regulator Homo sapiens 18-23 11561905-9 2001 Furthermore, treating Bcl-2 cultures with ceramide (10 microM), a second messenger mediating the RA-initiated death signal in parental cells, no longer caused DNA laddering. Tretinoin 97-99 BCL2 apoptosis regulator Homo sapiens 22-27 11502101-3 2001 In contrast, high Bcl-2 expressing JM1 cells, when exposed to the same concentrations (and duration) of sanguinarine that induced PCD and BCD in K562 cells, failed to show the respective morphologies while showing a concomitant increase in Bcl-2. sanguinarine 104-116 BCL2 apoptosis regulator Homo sapiens 240-245 11476900-4 2001 Here we report that DP cells that were treated with PMA and ionomycin up-regulated bcl-2 and down-regulated CD1 expression. Tetradecanoylphorbol Acetate 52-55 BCL2 apoptosis regulator Homo sapiens 83-88 11585319-8 2001 We further obtained evidence of the upregulation of the intracellular apoptotic signalling cascade, represented by bcl-2 and bax, the transcription factor p53 and the active form of caspase 3, after pretreatment with mitomycin C. Mitomycin 217-228 BCL2 apoptosis regulator Homo sapiens 115-120 11476900-4 2001 Here we report that DP cells that were treated with PMA and ionomycin up-regulated bcl-2 and down-regulated CD1 expression. Ionomycin 60-69 BCL2 apoptosis regulator Homo sapiens 83-88 11466337-7 2001 Ceramide-induced apoptosis is also completely prevented by Bcl-2 overexpression. Ceramides 0-8 BCL2 apoptosis regulator Homo sapiens 59-64 11763419-0 2001 Induction of apoptosis by estramustine phosphate mediated by phosphorylation of bcl-2. Estramustine 26-48 BCL2 apoptosis regulator Homo sapiens 80-85 11520893-0 2001 Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. salsoline 206-227 BCL2 apoptosis regulator Homo sapiens 22-27 11520893-6 2001 Overexpression of Bcl-2 prevented the decline in DeltaPsim and also apoptotic DNA damage induced by N-methyl(R)salsolinol. salsoline 100-121 BCL2 apoptosis regulator Homo sapiens 18-23 11511312-0 2001 The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. ammonium ferrous sulfate 82-85 BCL2 apoptosis regulator Homo sapiens 8-13 11511312-6 2001 The Bax/Bcl-2 ratio was also in clear correlation with sensitivity to another cell death inducer, N-acetylsphingosine. N-acetylsphingosine 98-117 BCL2 apoptosis regulator Homo sapiens 8-13 11523059-2 2001 Sennosides alter colonic crypt length, proliferative activity, and bcl-2 expression 18 h after administration. senokot 0-10 BCL2 apoptosis regulator Homo sapiens 67-72 11547546-1 2001 In this study we show that overexpression of Bcl-2 in PC60R1R2 cells reveals a caspase-dependent mechanism of cytochrome c release following photodynamic therapy (PDT) with hypericin. hypericin 173-182 BCL2 apoptosis regulator Homo sapiens 45-50 11480555-13 2001 Ceramide activation of protein phosphatases has been shown to promote inactivation of a number of pro-growth cellular regulators including the kinases PKC alpha and Akt, Bcl2 and the retinoblastoma protein. Ceramides 0-8 BCL2 apoptosis regulator Homo sapiens 170-174 11547546-4 2001 Hypericin-induced mitochondrial depolarization coincided with cytochrome c release in PC60R1R2 cells while it precedes massive cytochrome c efflux in PC60R1R2/Bcl-2 cells. hypericin 0-9 BCL2 apoptosis regulator Homo sapiens 159-164 11547546-6 2001 In contrast, in PC60R1R2/Bcl-2 cells cytochrome c release and apoptosis were suppressed by addition of zVAD-fmk or cyclosporin A. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 103-111 BCL2 apoptosis regulator Homo sapiens 25-30 11547546-6 2001 In contrast, in PC60R1R2/Bcl-2 cells cytochrome c release and apoptosis were suppressed by addition of zVAD-fmk or cyclosporin A. Cyclosporine 115-128 BCL2 apoptosis regulator Homo sapiens 25-30 11525264-0 2001 Susceptibility of thyroid cancer cells to 7-hydroxystaurosporine-induced apoptosis correlates with Bcl-2 protein level. 7-hydroxystaurosporine 42-64 BCL2 apoptosis regulator Homo sapiens 99-104 11685722-5 2001 Taxane-induced microtubule stabilization arrests cells in the G(2)M phase of the cell cycle and induces bcl-2 phosphorylation, thereby promoting a cascade of events that ultimately leads to apoptotic cell death. taxane 0-6 BCL2 apoptosis regulator Homo sapiens 104-109 11685722-6 2001 In preclinical studies, docetaxel had a higher affinity for tubulin and was shown to be a more potent inducer of bcl-2 phosphorylation than paclitaxel. Docetaxel 24-33 BCL2 apoptosis regulator Homo sapiens 113-118 11685732-0 2001 Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. oblimersen 31-36 BCL2 apoptosis regulator Homo sapiens 38-43 11685732-0 2001 Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Oligonucleotides 54-69 BCL2 apoptosis regulator Homo sapiens 38-43 11685732-3 2001 Reduction of Bcl-2 expression in hormone-refractory prostate cancer (HRPC) preclinical models markedly increases the antitumor efficacy of docetaxel both in vitro and in vivo. Docetaxel 139-148 BCL2 apoptosis regulator Homo sapiens 13-18 11685732-4 2001 Thus, a phase I/II pharmacokinetic and biologic correlative study has been initiated in patients with HRPC to examine whether docetaxel therapy can be enhanced with a therapeutic antisense oligodeoxynucleotide (G3139) directed at bcl-2 gene expression. Oligodeoxyribonucleotides 189-209 BCL2 apoptosis regulator Homo sapiens 230-235 11685722-4 2001 Docetaxel is believed to have a twofold mechanism of antineoplastic activity: (1) inhibition of microtubular depolymerization, and (2) attenuation of the effects of bcl-2 and bcl-xL gene expression. Docetaxel 0-9 BCL2 apoptosis regulator Homo sapiens 165-170 11525264-8 2001 Furthermore, upregulating of Bcl-2 by 1alpha,25-dihydroxyvitamin D3 (VD3) could protect primary thyroid cell from death induced by UCN-01. Calcitriol 38-67 BCL2 apoptosis regulator Homo sapiens 29-34 11494156-0 2001 Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells. Cisplatin 34-43 BCL2 apoptosis regulator Homo sapiens 12-17 11333270-6 2001 Furthermore, Ras mediates this up-regulation of bcl-2 by activating the phosphatidylinositol 3-kinase-AKT pathway. Phosphatidylinositols 72-92 BCL2 apoptosis regulator Homo sapiens 48-53 11494156-3 2001 In the present study we have investigated the role of Bcl-2 in cellular response to oxidative stress (hydrogen peroxide) and cisplatin using a clone of human metastatic melanoma, which, in spite of Bcl-2 (over)expression, exhibited a moderate chemosensitivity. Hydrogen Peroxide 102-119 BCL2 apoptosis regulator Homo sapiens 54-59 11494156-5 2001 In the floating apoptotic cells generated by either hydrogen peroxide or cisplatin, along with morphological and biochemical features of apoptosis, we detected a significant Bcl-2 cleavage, yielding the Bax-like fragment of 23 kDa. Hydrogen Peroxide 52-69 BCL2 apoptosis regulator Homo sapiens 174-179 11494156-5 2001 In the floating apoptotic cells generated by either hydrogen peroxide or cisplatin, along with morphological and biochemical features of apoptosis, we detected a significant Bcl-2 cleavage, yielding the Bax-like fragment of 23 kDa. Cisplatin 73-82 BCL2 apoptosis regulator Homo sapiens 174-179 11494156-6 2001 Preincubation of cells with the caspase-3/-7 inhibitor DEVD-CHO completely suppressed Bcl-2 cleavage, thus confirming that such a specific proteolysis requires activation of caspase-3/-7. aspartyl-glutamyl-valyl-aspartal 55-63 BCL2 apoptosis regulator Homo sapiens 86-91 11494156-7 2001 The oxidant- and cisplatin-induced processing of Bcl-2 documented in the present study may represent a regulatory mechanism to circumvent the survival function of Bcl-2 upon apoptosis triggering and to enhance apoptotic response. Cisplatin 17-26 BCL2 apoptosis regulator Homo sapiens 49-54 11494156-7 2001 The oxidant- and cisplatin-induced processing of Bcl-2 documented in the present study may represent a regulatory mechanism to circumvent the survival function of Bcl-2 upon apoptosis triggering and to enhance apoptotic response. Cisplatin 17-26 BCL2 apoptosis regulator Homo sapiens 163-168 11592526-5 2001 New protein synthesis induced by the alpha-2 agonist, brimonidine, prevents decreases in the levels of BCL-2 and thereby reduces mitochondrially-dependent apoptosis. Brimonidine Tartrate 54-65 BCL2 apoptosis regulator Homo sapiens 103-108 11472347-0 2001 Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. alvocidib 0-12 BCL2 apoptosis regulator Homo sapiens 25-30 11472347-2 2001 In this study, we examined the in vitro effects of flavopiridol and fludarabine on B-CLL cells from 64 patients (36 treated and 28 untreated) in terms of apoptosis induction and Bcl-2 family expression. alvocidib 51-63 BCL2 apoptosis regulator Homo sapiens 178-183 11472347-2 2001 In this study, we examined the in vitro effects of flavopiridol and fludarabine on B-CLL cells from 64 patients (36 treated and 28 untreated) in terms of apoptosis induction and Bcl-2 family expression. fludarabine 68-79 BCL2 apoptosis regulator Homo sapiens 178-183 11472347-5 2001 Bcl-2 and Mcl-1 expression were downregulated in both flavopiridol and fludarabine-induced apoptotic cells, but the increase in Bax expression that accompanied fludarabine-induced apoptosis was not evident in flavopiridol-treated cells. alvocidib 54-66 BCL2 apoptosis regulator Homo sapiens 0-5 11472347-5 2001 Bcl-2 and Mcl-1 expression were downregulated in both flavopiridol and fludarabine-induced apoptotic cells, but the increase in Bax expression that accompanied fludarabine-induced apoptosis was not evident in flavopiridol-treated cells. fludarabine 71-82 BCL2 apoptosis regulator Homo sapiens 0-5 11472347-6 2001 In addition, Bcl-2:Bax ratios were not predictive of flavopiridol cytotoxicity (P = 0.82), whereas they were highly predictive of in vitro responsiveness to fludarabine (P = 0.001). fludarabine 157-168 BCL2 apoptosis regulator Homo sapiens 13-18 11427503-0 2001 Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 121-126 11466611-5 2001 ANT-dependent, NO-, peroxynitrite- or HNE-induced permeabilization is at least partially inhibited by recombinant Bcl-2 protein, as well as the antioxidants trolox and butylated hydroxytoluene. Peroxynitrous Acid 20-33 BCL2 apoptosis regulator Homo sapiens 114-119 11401838-8 2001 Blockade of Kv channels in control cells (-bcl-2) by 4-aminopyridine also inhibited the ST-induced increase in I(Kv) and apoptosis. 4-Aminopyridine 53-68 BCL2 apoptosis regulator Homo sapiens 43-48 11724334-11 2001 We also found up-regulation of p21WAF1 expression and down-regulation of Bcl-2 in hypericin treated cells. hypericin 82-91 BCL2 apoptosis regulator Homo sapiens 73-78 11465719-12 2001 Up-regulation of the Bax:Bcl-2 ratio in SSc fibroblasts by Bcl-2 antisense oligonucleotides restored their susceptibility to Fas-mediated apoptosis. Oligonucleotides 75-91 BCL2 apoptosis regulator Homo sapiens 25-30 11465719-12 2001 Up-regulation of the Bax:Bcl-2 ratio in SSc fibroblasts by Bcl-2 antisense oligonucleotides restored their susceptibility to Fas-mediated apoptosis. Oligonucleotides 75-91 BCL2 apoptosis regulator Homo sapiens 59-64 11465719-12 2001 Up-regulation of the Bax:Bcl-2 ratio in SSc fibroblasts by Bcl-2 antisense oligonucleotides restored their susceptibility to Fas-mediated apoptosis. ammonium ferrous sulfate 125-128 BCL2 apoptosis regulator Homo sapiens 25-30 11465719-12 2001 Up-regulation of the Bax:Bcl-2 ratio in SSc fibroblasts by Bcl-2 antisense oligonucleotides restored their susceptibility to Fas-mediated apoptosis. ammonium ferrous sulfate 125-128 BCL2 apoptosis regulator Homo sapiens 59-64 11688516-10 2001 Conversely, reduction of Bcl-2 by antisense transfection make MCF-7 cells more sensitive to ICI-induced growth inhibition and apoptosis. ici 92-95 BCL2 apoptosis regulator Homo sapiens 25-30 11431352-10 2001 Additionally, piceatannol, an inhibitor of STAT3 activation, down-regulates the expression of Bcl-2. 3,3',4,5'-tetrahydroxystilbene 14-25 BCL2 apoptosis regulator Homo sapiens 94-99 11431360-7 2001 In vivo footprint analysis revealed that a CRE site and a Cdx site in the bcl-2 promoter were occupied on the translocated alleles but not on the normal alleles in both the follicular and transformed lymphomas. Cefadroxil 58-61 BCL2 apoptosis regulator Homo sapiens 74-79 11413108-8 2001 In PBT, Bax expression was highly and significantly correlated with both Bcl-2 and Bcl-x(L), but correlation with Bcl-2 was absent in LPT. (E)-2-(pent-3-en-1-yn-1-yl)thiophene 3-6 BCL2 apoptosis regulator Homo sapiens 73-78 11592526-6 2001 CONCLUSIONS: Brimonidine appears to maintain BCL-2 levels by supporting the activity of an intrinsic anti-apoptosis signalling system that involves phosphorylation of protein kinase B. Brimonidine Tartrate 13-24 BCL2 apoptosis regulator Homo sapiens 45-50 11461956-3 2001 Overexpression of Bcl-2 rendered cells more resistant to apoptosis induced by serum withdrawal, H2O2 or 4-hydroxy-2-trans-nonenal (HNE). Hydrogen Peroxide 96-100 BCL2 apoptosis regulator Homo sapiens 18-23 11391617-8 2001 These findings suggest that isobutyramide therapy could be a novel therapeutic strategy for patients with bladder cancer if docetaxel is combined according to the Bcl-2 expression status. isobutyramide 28-41 BCL2 apoptosis regulator Homo sapiens 163-168 11425893-4 2001 Data from non-neuronal cells indicate that taxol-induced apoptosis requires activation of N-terminal c-Jun protein kinase (JNK) that phosphorylates and inactivates Bcl-2. Paclitaxel 43-48 BCL2 apoptosis regulator Homo sapiens 164-169 11425893-7 2001 In contrast to human embryonic kidney 293 cells, expression of wild-type Bcl-2 in cortical neurons protected against taxol-induced apoptosis, and taxol did not induce Bcl-2 phosphorylation. Paclitaxel 117-122 BCL2 apoptosis regulator Homo sapiens 73-78 11461956-3 2001 Overexpression of Bcl-2 rendered cells more resistant to apoptosis induced by serum withdrawal, H2O2 or 4-hydroxy-2-trans-nonenal (HNE). 4-hydroxy-2-nonenal 131-134 BCL2 apoptosis regulator Homo sapiens 18-23 11461956-5 2001 Serum withdrawal or H2O2 raised levels of protein carbonyls, lipid peroxidation, 8-OHG and 3-nitrotyrosine, changes that were attenuated in cells overexpressing Bcl-2. Hydrogen Peroxide 20-24 BCL2 apoptosis regulator Homo sapiens 161-166 11461956-3 2001 Overexpression of Bcl-2 rendered cells more resistant to apoptosis induced by serum withdrawal, H2O2 or 4-hydroxy-2-trans-nonenal (HNE). 4-hydroxy-2-nonenal 104-129 BCL2 apoptosis regulator Homo sapiens 18-23 11461956-5 2001 Serum withdrawal or H2O2 raised levels of protein carbonyls, lipid peroxidation, 8-OHG and 3-nitrotyrosine, changes that were attenuated in cells overexpressing Bcl-2. 8-ohg 81-86 BCL2 apoptosis regulator Homo sapiens 161-166 11455981-3 2001 To investigate the discrepancy between apoptosis- and differentiation-inductions of leukemia cells by VK2 treatment, we used bcl-2 gene transfected HL-60 cells (HL-60-bcl-2) which resulted in five-fold over-expression of BCL-2 protein, and then compared the effects of MK4 to the control HL-60-neo cells. menatetrenone 269-272 BCL2 apoptosis regulator Homo sapiens 125-130 11461956-5 2001 Serum withdrawal or H2O2 raised levels of protein carbonyls, lipid peroxidation, 8-OHG and 3-nitrotyrosine, changes that were attenuated in cells overexpressing Bcl-2. 3-nitrotyrosine 91-106 BCL2 apoptosis regulator Homo sapiens 161-166 11391617-0 2001 Overexpression of Bcl-2 regulates sodium butyrate- and/or docetaxel-induced apoptosis in human bladder cancer cells both in vitro and in vivo. Butyric Acid 34-49 BCL2 apoptosis regulator Homo sapiens 18-23 11391617-0 2001 Overexpression of Bcl-2 regulates sodium butyrate- and/or docetaxel-induced apoptosis in human bladder cancer cells both in vitro and in vivo. Docetaxel 58-67 BCL2 apoptosis regulator Homo sapiens 18-23 11391617-1 2001 Sodium butyrate (NaBt), a physiologically occurring short-chain fatty acid, induces differentiation as well as apoptosis in numerous cell types, and this induction is partially regulated by Bcl-2 expression. Butyric Acid 0-15 BCL2 apoptosis regulator Homo sapiens 190-195 11391617-1 2001 Sodium butyrate (NaBt), a physiologically occurring short-chain fatty acid, induces differentiation as well as apoptosis in numerous cell types, and this induction is partially regulated by Bcl-2 expression. NABT 17-21 BCL2 apoptosis regulator Homo sapiens 190-195 11391617-5 2001 An amount of 5 mM NaBt induced apoptosis, accompanied by up-regulation of Bak in KoTCC-1/C cells but failed to induce apoptosis in KoTCC-1/BH cells despite substantial down-regulation of Bcl-2. NABT 18-22 BCL2 apoptosis regulator Homo sapiens 187-192 11455981-4 2001 Seventy-two hours of exposure to various concentrations of MK4 resulted in growth inhibition of these cells in a dose-dependent manner (0.1-50 microM), however, HL-60-bcl-2 was less sensitive against MK4. menatetrenone 59-62 BCL2 apoptosis regulator Homo sapiens 167-172 11391617-7 2001 Furthermore, docetaxel induced Bcl-2 phosphorylation in KoTCC-1/BH cells and combined treatment with isobutyramide and docetaxel synergistically inhibited the growth of KoTCC-1/BH cells both in vitro and in vivo. Docetaxel 13-22 BCL2 apoptosis regulator Homo sapiens 31-36 11391617-7 2001 Furthermore, docetaxel induced Bcl-2 phosphorylation in KoTCC-1/BH cells and combined treatment with isobutyramide and docetaxel synergistically inhibited the growth of KoTCC-1/BH cells both in vitro and in vivo. isobutyramide 101-114 BCL2 apoptosis regulator Homo sapiens 31-36 11699414-0 2001 Bcl-2 antisense oligonucleotides enhance the cytotoxicity of chlorambucil in B-cell chronic lymphocytic leukaemia cells. Oligonucleotides 16-32 BCL2 apoptosis regulator Homo sapiens 0-5 11455981-4 2001 Seventy-two hours of exposure to various concentrations of MK4 resulted in growth inhibition of these cells in a dose-dependent manner (0.1-50 microM), however, HL-60-bcl-2 was less sensitive against MK4. menatetrenone 200-203 BCL2 apoptosis regulator Homo sapiens 167-172 11699414-0 2001 Bcl-2 antisense oligonucleotides enhance the cytotoxicity of chlorambucil in B-cell chronic lymphocytic leukaemia cells. Chlorambucil 61-73 BCL2 apoptosis regulator Homo sapiens 0-5 11391617-7 2001 Furthermore, docetaxel induced Bcl-2 phosphorylation in KoTCC-1/BH cells and combined treatment with isobutyramide and docetaxel synergistically inhibited the growth of KoTCC-1/BH cells both in vitro and in vivo. Docetaxel 119-128 BCL2 apoptosis regulator Homo sapiens 31-36 11699414-1 2001 We have previously shown that the Bcl-2 antisense oligonucleotide ODN 2009 can induce apoptosis in B-cell chronic lymphocytic leukaemia (B-CLL) cells. Oligonucleotides 50-65 BCL2 apoptosis regulator Homo sapiens 34-39 11571630-7 2001 Coexpression of Bcl-2 and N-Myc supports growth in low serum conditions and anchorage-independent growth in soft agar. Agar 113-117 BCL2 apoptosis regulator Homo sapiens 16-21 11699414-3 2001 Bcl-2 antisense in combination with Chlorambucil resulted in a more marked reduction in Bcl-2 protein expression (p = 0.003), enhanced Bax expression (p < 0.0001) and increased apoptosis when compared to cells incubated with Chlorambucil alone (p = 0.03). Chlorambucil 36-48 BCL2 apoptosis regulator Homo sapiens 88-93 11699414-3 2001 Bcl-2 antisense in combination with Chlorambucil resulted in a more marked reduction in Bcl-2 protein expression (p = 0.003), enhanced Bax expression (p < 0.0001) and increased apoptosis when compared to cells incubated with Chlorambucil alone (p = 0.03). Chlorambucil 228-240 BCL2 apoptosis regulator Homo sapiens 0-5 11699414-4 2001 This increased in vitro cytotoxicity demonstrates a proof of the concept that a combination of Bcl-2 antisense oligonucleotides with conventional chemotherapeutic drugs may elicit an enhanced therapeutic effect in B-CLL and should therefore be considered for further investigation in the form of a clinical trial. Oligonucleotides 111-127 BCL2 apoptosis regulator Homo sapiens 95-100 11690551-0 2001 Antitumor effect of bcl-2 antisense phosphorothioate oligodeoxynucleotides on human renal-cell carcinoma cells in vitro and in mice. Parathion 36-52 BCL2 apoptosis regulator Homo sapiens 20-25 11323415-1 2001 Interleukin (IL)-3-induced Bcl2 phosphorylation at Ser(70) may be required for its full and potent antiapoptotic activity. Serine 51-54 BCL2 apoptosis regulator Homo sapiens 27-31 11323415-4 2001 Results indicate that anisomycin, a potent activator of the stress kinase JNK/SAPK, can induce Bcl2 phosphorylation at Ser(70) and that JNK1 can be latently activated following IL-3 withdrawal to mediate Bcl2 phosphorylation. Anisomycin 22-32 BCL2 apoptosis regulator Homo sapiens 95-99 11323415-4 2001 Results indicate that anisomycin, a potent activator of the stress kinase JNK/SAPK, can induce Bcl2 phosphorylation at Ser(70) and that JNK1 can be latently activated following IL-3 withdrawal to mediate Bcl2 phosphorylation. Anisomycin 22-32 BCL2 apoptosis regulator Homo sapiens 204-208 11323415-4 2001 Results indicate that anisomycin, a potent activator of the stress kinase JNK/SAPK, can induce Bcl2 phosphorylation at Ser(70) and that JNK1 can be latently activated following IL-3 withdrawal to mediate Bcl2 phosphorylation. Serine 119-122 BCL2 apoptosis regulator Homo sapiens 95-99 11423992-6 2001 PDT-induced Bcl-2 loss occurred in MCF-7 cells that do not express caspase-3 or in the presence of protease inhibitors, but was prevented, along with the induction of apoptosis, by the singlet oxygen scavenger L-histidine. Singlet Oxygen 185-199 BCL2 apoptosis regulator Homo sapiens 12-17 11323415-7 2001 Furthermore, low dose okadaic acid (OA), a potent protein phosphatase 1 and 2A inhibitor, can activate the mitogen-activated protein kinases JNK1 and ERK1/2, but not p38 kinase, to induce Bcl2 phosphorylation and prolong cell survival in factor-deprived cells. Okadaic Acid 22-34 BCL2 apoptosis regulator Homo sapiens 188-192 11323415-7 2001 Furthermore, low dose okadaic acid (OA), a potent protein phosphatase 1 and 2A inhibitor, can activate the mitogen-activated protein kinases JNK1 and ERK1/2, but not p38 kinase, to induce Bcl2 phosphorylation and prolong cell survival in factor-deprived cells. Okadaic Acid 36-38 BCL2 apoptosis regulator Homo sapiens 188-192 11323415-8 2001 Since PD98059, a specific MEK inhibitor, can only partially inhibit OA-induced Bcl2 phosphorylation but completely blocks OA-induced Bcl2 phosphorylation in cells expressing DN-JNK1, this supports the conclusion that OA may stimulate Bcl2 phosphorylation via a mechanism involving both JNK1 and ERK1/2. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 6-13 BCL2 apoptosis regulator Homo sapiens 79-83 11323415-8 2001 Since PD98059, a specific MEK inhibitor, can only partially inhibit OA-induced Bcl2 phosphorylation but completely blocks OA-induced Bcl2 phosphorylation in cells expressing DN-JNK1, this supports the conclusion that OA may stimulate Bcl2 phosphorylation via a mechanism involving both JNK1 and ERK1/2. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 6-13 BCL2 apoptosis regulator Homo sapiens 133-137 11323415-8 2001 Since PD98059, a specific MEK inhibitor, can only partially inhibit OA-induced Bcl2 phosphorylation but completely blocks OA-induced Bcl2 phosphorylation in cells expressing DN-JNK1, this supports the conclusion that OA may stimulate Bcl2 phosphorylation via a mechanism involving both JNK1 and ERK1/2. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 6-13 BCL2 apoptosis regulator Homo sapiens 133-137 11406564-7 2001 In vitro down-regulation of bcl-2 with antisense oligonucleotides allowed the release of cytochrome c from mitochondria and the activation of caspases 8 and 3 upon Fas activation as well as sensitized neuroblastoma cells to Fas-mediated apoptosis. Oligonucleotides 49-65 BCL2 apoptosis regulator Homo sapiens 28-33 11406564-7 2001 In vitro down-regulation of bcl-2 with antisense oligonucleotides allowed the release of cytochrome c from mitochondria and the activation of caspases 8 and 3 upon Fas activation as well as sensitized neuroblastoma cells to Fas-mediated apoptosis. ammonium ferrous sulfate 164-167 BCL2 apoptosis regulator Homo sapiens 28-33 11406564-9 2001 However, combined treatment with bcl-2 and FLIP antisense oligonucleotides had a statistically significant synergistic effect reversing Fas-resistance in neuroblastoma cells in vitro. ammonium ferrous sulfate 136-139 BCL2 apoptosis regulator Homo sapiens 33-38 11423992-0 2001 Photochemical destruction of the Bcl-2 oncoprotein during photodynamic therapy with the phthalocyanine photosensitizer Pc 4. phthalocyanine 88-102 BCL2 apoptosis regulator Homo sapiens 33-38 11429697-8 2001 Retinoic acid markedly decreased the Bcl-2 levels in MCF-7 and ZR-75 cells. Tretinoin 0-13 BCL2 apoptosis regulator Homo sapiens 37-42 11429697-9 2001 Accordingly, coexpression of Bcl-2 and cyclin D1 rendered the cells resistant to retinoic acid-induced apoptosis. Tretinoin 81-94 BCL2 apoptosis regulator Homo sapiens 29-34 11423992-6 2001 PDT-induced Bcl-2 loss occurred in MCF-7 cells that do not express caspase-3 or in the presence of protease inhibitors, but was prevented, along with the induction of apoptosis, by the singlet oxygen scavenger L-histidine. Histidine 210-221 BCL2 apoptosis regulator Homo sapiens 12-17 11384110-7 2001 We conclude that ATRA synergistically enhances docetaxel toxicity by down-regulating Bcl-2 expression and partially reverses the docetaxel-induced G2/M arrest by inhibiting docetaxel-induced cdc2 phosphorylation in a pathway that is dependent on MAPK. Tretinoin 17-21 BCL2 apoptosis regulator Homo sapiens 85-90 11384110-2 2001 Docetaxel-induced apoptotic cell death was associated with phosphorylation and hence inactivation of Bcl-2. Docetaxel 0-9 BCL2 apoptosis regulator Homo sapiens 101-106 11459200-1 2001 PURPOSE: Arsenic compounds have been found to be effective in the treatment of acute promyelocytic leukemia through the downregulation of bcl-2 expression. Arsenic 9-16 BCL2 apoptosis regulator Homo sapiens 138-143 11384110-3 2001 ATRA enhanced docetaxel-induced apoptosis and combined treatment with ATRA and docetaxel resulted in down-regulation of Bcl-2. Tretinoin 70-74 BCL2 apoptosis regulator Homo sapiens 120-125 11384110-3 2001 ATRA enhanced docetaxel-induced apoptosis and combined treatment with ATRA and docetaxel resulted in down-regulation of Bcl-2. Docetaxel 79-88 BCL2 apoptosis regulator Homo sapiens 120-125 11356682-0 2001 Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Estradiol 0-9 BCL2 apoptosis regulator Homo sapiens 37-42 11484935-2 2001 We found that four anticancer agents: etoposide, doxorubicin, bleomycin and paclitaxel induced apoptosis in human umbilical vein endothelial cells (HUVECs) (as judged by DNA fragmentation) with a time- and concentration-dependent decrease in bcl-2 protein but without the involvement of p53. Etoposide 38-47 BCL2 apoptosis regulator Homo sapiens 242-247 11387204-0 2001 The Ca2+ concentration of the endoplasmic reticulum is a key determinant of ceramide-induced apoptosis: significance for the molecular mechanism of Bcl-2 action. Ceramides 76-84 BCL2 apoptosis regulator Homo sapiens 148-153 11387204-4 2001 All conditions that lowered [Ca2+]er protected HeLa cells from ceramide, a Bcl-2-sensitive apoptotic stimulus, while treatments that increased [Ca2+]er had the opposite effect. Ceramides 63-71 BCL2 apoptosis regulator Homo sapiens 75-80 11484935-2 2001 We found that four anticancer agents: etoposide, doxorubicin, bleomycin and paclitaxel induced apoptosis in human umbilical vein endothelial cells (HUVECs) (as judged by DNA fragmentation) with a time- and concentration-dependent decrease in bcl-2 protein but without the involvement of p53. Doxorubicin 49-60 BCL2 apoptosis regulator Homo sapiens 242-247 11484935-2 2001 We found that four anticancer agents: etoposide, doxorubicin, bleomycin and paclitaxel induced apoptosis in human umbilical vein endothelial cells (HUVECs) (as judged by DNA fragmentation) with a time- and concentration-dependent decrease in bcl-2 protein but without the involvement of p53. Bleomycin 62-71 BCL2 apoptosis regulator Homo sapiens 242-247 11484935-2 2001 We found that four anticancer agents: etoposide, doxorubicin, bleomycin and paclitaxel induced apoptosis in human umbilical vein endothelial cells (HUVECs) (as judged by DNA fragmentation) with a time- and concentration-dependent decrease in bcl-2 protein but without the involvement of p53. Paclitaxel 76-86 BCL2 apoptosis regulator Homo sapiens 242-247 16120269-11 2001 Using a stable transfected CEM cell line, we show that Bcl-2 suppressed caspase processing in both cytosolic and mitochondrial compartments in response to both staurosporine and Fas ligation. Staurosporine 160-173 BCL2 apoptosis regulator Homo sapiens 55-60 11387307-4 2001 By means of immunohistochemistry and a computerized image analysis, bcl-2 immunostaining was localized and quantified in 36 randomly selected paraffin-embedded ectopic trophoblast tissue specimens collected from women undergoing surgery for ruptured (n = 18) and non-ruptured (n = 18) tubal ectopic pregnancies. Paraffin 142-150 BCL2 apoptosis regulator Homo sapiens 68-73 11351249-0 2001 Bcl-2 modulates Fas-mediated apoptosis in human renal cell carcinoma cell lines. ammonium ferrous sulfate 16-19 BCL2 apoptosis regulator Homo sapiens 0-5 11351249-5 2001 Furthermore, Bcl-2 expression was found only in three cell lines which were all susceptible to CH11, and the downregulation of Bcl-2 protein by treatment with antisense oligodeoxynucleotide targeting Bcl-2 gene resulted in an enhancement of cell death induced by CH11. Oligodeoxyribonucleotides 169-189 BCL2 apoptosis regulator Homo sapiens 13-18 11351249-5 2001 Furthermore, Bcl-2 expression was found only in three cell lines which were all susceptible to CH11, and the downregulation of Bcl-2 protein by treatment with antisense oligodeoxynucleotide targeting Bcl-2 gene resulted in an enhancement of cell death induced by CH11. Oligodeoxyribonucleotides 169-189 BCL2 apoptosis regulator Homo sapiens 127-132 11351249-5 2001 Furthermore, Bcl-2 expression was found only in three cell lines which were all susceptible to CH11, and the downregulation of Bcl-2 protein by treatment with antisense oligodeoxynucleotide targeting Bcl-2 gene resulted in an enhancement of cell death induced by CH11. Oligodeoxyribonucleotides 169-189 BCL2 apoptosis regulator Homo sapiens 127-132 11356894-4 2001 CaN changes were paralleled by increased activation, but not expression, of CaN-regulated protein phosphatase 1 and a reduction in the phosphorylation state of CaN substrates involved in cell survival (i.e., Bcl-2-associated death protein and cAMP response element-binding protein). Cyclic AMP 243-247 BCL2 apoptosis regulator Homo sapiens 208-213 11340567-3 2001 We have shown that irradiation of the human myeloma cell line RPMI-8226 induced apoptosis as determined by DNA degradation, cytochrome c release into cytoplasm and BCL-2 caspase-mediated cleavage. rpmi-8226 62-71 BCL2 apoptosis regulator Homo sapiens 164-169 11340567-8 2001 Our findings show that in irradiated RPMI-8226 cells the formation of BCL-2/BAX heterodimers correlates with apoptosis. rpmi 37-41 BCL2 apoptosis regulator Homo sapiens 70-75 11351258-8 2001 The model we developed here will allow further studies on the role of post-translational events involving bcl-2 (such as translocation and/or phosphorylation) in the cellular response to ara-C treatment. Cytarabine 187-192 BCL2 apoptosis regulator Homo sapiens 106-111 11262395-8 2001 Thus, Bcl-rambo constitutes a novel type of pro-apoptotic Bcl-2 member that triggers cell death independently of its BH motifs. Bh 117-119 BCL2 apoptosis regulator Homo sapiens 58-63 11391701-8 2001 Furthermore, 17beta-estradiol induced phosphorylation of the cAMP response element binding protein (CREB) at Ser(133) within 15 min and then upregulated Bcl-2 in a PI3-K/Akt-dependent manner. Estradiol 13-29 BCL2 apoptosis regulator Homo sapiens 153-158 11391701-9 2001 Because CREB is known to be a transcription factor for Bcl-2, these results suggest that 17beta-estradiol exerts its antiapoptotic effects by CREB phosphorylation and Bcl-2 upregulation via nongenomic activation of the PI3-K/Akt pathway in cultured cortical neurons. Estradiol 89-105 BCL2 apoptosis regulator Homo sapiens 55-60 11391701-9 2001 Because CREB is known to be a transcription factor for Bcl-2, these results suggest that 17beta-estradiol exerts its antiapoptotic effects by CREB phosphorylation and Bcl-2 upregulation via nongenomic activation of the PI3-K/Akt pathway in cultured cortical neurons. Estradiol 89-105 BCL2 apoptosis regulator Homo sapiens 167-172 11340162-1 2001 In a panel of four human melanoma cell lines, equitoxic doses of cisplatin induced the proapoptotic conformation of the Bcl-2 family protein Bak prior to the execution phase of apoptosis. Cisplatin 65-74 BCL2 apoptosis regulator Homo sapiens 120-125 12578613-7 2001 By comparison, these results showed that the leukemic cell line M-07e and KG-1a, which both express bcl-2 at a relative high level, had different susceptibility to undergo apoptosis induced by Z-LLL-CHO, which possibly due to their different levels of expression and activation of caspase-3 precursor, as well as their different degree of bcl-2 cleavage after treated by Z-LLL-CHO. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 193-202 BCL2 apoptosis regulator Homo sapiens 100-105 11866980-0 2001 [Overexpression of bcl-2 protects HCC-9204 hepatoma cells from ethanol-induced apoptosis]. Ethanol 63-70 BCL2 apoptosis regulator Homo sapiens 19-24 11866980-1 2001 OBJECTIVE: To explore the effect of apoptosis-associated gene bcl-2 overexpression on ethanol-induced apoptosis in hepatocellular carcinoma (HCC) cells. Ethanol 86-93 BCL2 apoptosis regulator Homo sapiens 62-67 12578613-7 2001 By comparison, these results showed that the leukemic cell line M-07e and KG-1a, which both express bcl-2 at a relative high level, had different susceptibility to undergo apoptosis induced by Z-LLL-CHO, which possibly due to their different levels of expression and activation of caspase-3 precursor, as well as their different degree of bcl-2 cleavage after treated by Z-LLL-CHO. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 193-202 BCL2 apoptosis regulator Homo sapiens 339-344 11866980-8 2001 After being treated with 6% ethanol, the optical absorbance data of HCC-bcl-2 cells and non-transfected HCC-9204 cells detected by MTT assay were 0.519 +/- 0.053 and 0.366 +/- 0.046, respectively, the former was significantly higher than the latter (P < 0.01). Ethanol 28-35 BCL2 apoptosis regulator Homo sapiens 72-77 12578613-7 2001 By comparison, these results showed that the leukemic cell line M-07e and KG-1a, which both express bcl-2 at a relative high level, had different susceptibility to undergo apoptosis induced by Z-LLL-CHO, which possibly due to their different levels of expression and activation of caspase-3 precursor, as well as their different degree of bcl-2 cleavage after treated by Z-LLL-CHO. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 371-380 BCL2 apoptosis regulator Homo sapiens 100-105 11866980-8 2001 After being treated with 6% ethanol, the optical absorbance data of HCC-bcl-2 cells and non-transfected HCC-9204 cells detected by MTT assay were 0.519 +/- 0.053 and 0.366 +/- 0.046, respectively, the former was significantly higher than the latter (P < 0.01). monooxyethylene trimethylolpropane tristearate 131-134 BCL2 apoptosis regulator Homo sapiens 72-77 11866980-10 2001 CONCLUSION: Overexpression of bcl-2 protein can suppress ethanol-induced apoptosis in HCC-9204 hepatoma cells. Ethanol 57-64 BCL2 apoptosis regulator Homo sapiens 30-35 12578617-0 2001 [The Antisense Oligodeoxynucleotides of bcl-2 Oncogene Enhances the Sensitivity of K562 Leukemic Cells to As(2)O(3)] The biological reaction, changes of cellular DNA and bcl-2 protein content of K562 cells to bcl-2 ASODN or As(2)O(3) alone or bcl-2 ASODN associated with As(2)O(3) were investigated by cellular microculture, immunological tissue-chemistry method, and flow cytometry. Oligodeoxyribonucleotides 15-36 BCL2 apoptosis regulator Homo sapiens 40-45 12578617-0 2001 [The Antisense Oligodeoxynucleotides of bcl-2 Oncogene Enhances the Sensitivity of K562 Leukemic Cells to As(2)O(3)] The biological reaction, changes of cellular DNA and bcl-2 protein content of K562 cells to bcl-2 ASODN or As(2)O(3) alone or bcl-2 ASODN associated with As(2)O(3) were investigated by cellular microculture, immunological tissue-chemistry method, and flow cytometry. Oligodeoxyribonucleotides 15-36 BCL2 apoptosis regulator Homo sapiens 170-175 12578617-0 2001 [The Antisense Oligodeoxynucleotides of bcl-2 Oncogene Enhances the Sensitivity of K562 Leukemic Cells to As(2)O(3)] The biological reaction, changes of cellular DNA and bcl-2 protein content of K562 cells to bcl-2 ASODN or As(2)O(3) alone or bcl-2 ASODN associated with As(2)O(3) were investigated by cellular microculture, immunological tissue-chemistry method, and flow cytometry. Oligodeoxyribonucleotides 15-36 BCL2 apoptosis regulator Homo sapiens 170-175 12578617-0 2001 [The Antisense Oligodeoxynucleotides of bcl-2 Oncogene Enhances the Sensitivity of K562 Leukemic Cells to As(2)O(3)] The biological reaction, changes of cellular DNA and bcl-2 protein content of K562 cells to bcl-2 ASODN or As(2)O(3) alone or bcl-2 ASODN associated with As(2)O(3) were investigated by cellular microculture, immunological tissue-chemistry method, and flow cytometry. Oligodeoxyribonucleotides 15-36 BCL2 apoptosis regulator Homo sapiens 170-175 11368946-1 2001 This study tests the hypothesis that administration of magnesium sulfate, an antagonist of the NMDA receptor ion-channel, will prevent the hypoxia-induced alteration in the expression and the ratio of Bax and Bcl-2 proteins in cerebral cortical neuronal nuclear membranes. Magnesium Sulfate 55-72 BCL2 apoptosis regulator Homo sapiens 209-214 11377415-0 2001 Overexpression of Bcl-2 suppresses the calcium activation of a mitochondrial megachannel. Calcium 39-46 BCL2 apoptosis regulator Homo sapiens 18-23 11377415-2 2001 Bcl-2 suppresses apoptosis by inhibiting calcium activation of the permeability transition of mitochondria. Calcium 41-48 BCL2 apoptosis regulator Homo sapiens 0-5 11377415-3 2001 In this patch-clamp study, overexpression of Bcl-2 in mitochondria of cultured cells suppressed calcium activation of a high conductance channel that may underlie the permeability transition. Calcium 96-103 BCL2 apoptosis regulator Homo sapiens 45-50 11355954-0 2001 Bcl-2 resistant mitochondrial toxicity mediated by the isoquinoline carboxamide PK11195 involves de novo generation of reactive oxygen species. isoquinoline-1-carboxamide 55-79 BCL2 apoptosis regulator Homo sapiens 0-5 11368946-9 2001 However, in the magnesium sulfate-treated group the Bax:Bcl-2 ratio was similar to normoxic controls. Magnesium Sulfate 16-33 BCL2 apoptosis regulator Homo sapiens 56-61 11355954-0 2001 Bcl-2 resistant mitochondrial toxicity mediated by the isoquinoline carboxamide PK11195 involves de novo generation of reactive oxygen species. Reactive Oxygen Species 119-142 BCL2 apoptosis regulator Homo sapiens 0-5 11368946-10 2001 The data demonstrate that magnesium sulfate treatment prevents both the hypoxia-induced increase in Bax protein expression and the alteration of Bax:Bcl-2 protein ratios. Magnesium Sulfate 26-43 BCL2 apoptosis regulator Homo sapiens 149-154 11355956-2 2001 In both the uninvolved MIN mouse colonic epithelium and HT-29 colon cancer cells, nabumetone downregulated the anti-apoptotic protein, Bcl-2, with concomitant induction of apoptosis, suggesting a potential mechanism for colon cancer chemoprevention. Nabumetone 82-92 BCL2 apoptosis regulator Homo sapiens 135-140 11368946-11 2001 We suggest that magnesium sulfate treatment before and during hypoxia may decrease hypoxia-induced programmed cell death by maintaining the normal ratio of Bax to Bcl-2 proteins. Magnesium Sulfate 16-33 BCL2 apoptosis regulator Homo sapiens 163-168 11426834-10 2001 These results suggest that the increased ratio of Bax/Bcl-2 and the decreased mitochondrial membrane potential might be involved in the mechanisms of alisol B-induced cell apoptosis. alisol B 150-158 BCL2 apoptosis regulator Homo sapiens 54-59 11278482-8 2001 These differences in responses to oligonucleotide treatment were analyzed in the context of expression of Bcl-x(L), Bcl-x(S), and Bcl-2 proteins. Oligonucleotides 34-49 BCL2 apoptosis regulator Homo sapiens 130-135 11432453-0 2001 bcl-2 protects HL-60 cells from apoptosis by stabilizing their intracellular calcium pools. Calcium 77-84 BCL2 apoptosis regulator Homo sapiens 0-5 11432453-6 2001 Our results showed that overexpression of bcl-2 significantly blocked TG- and Br-A23187-induced apoptosis in calcium containing buffer. Calcimycin 81-87 BCL2 apoptosis regulator Homo sapiens 42-47 11350916-4 2001 Loss of cell viability, bcl-2 down-regulation, and poly(ADP-ribose) polymerase cleavage, indicative of apoptosis, also occurred in wt p53 C8161 cells on treatment with oligonucleotide 4625. Oligonucleotides 168-183 BCL2 apoptosis regulator Homo sapiens 24-29 11432453-6 2001 Our results showed that overexpression of bcl-2 significantly blocked TG- and Br-A23187-induced apoptosis in calcium containing buffer. Calcium 109-116 BCL2 apoptosis regulator Homo sapiens 42-47 11432453-7 2001 Measurement of intracellular calcium showed that bcl-2 overexpression could reduce sustained elevation of cytosolic Ca2+ induced by these agents. Calcium 29-36 BCL2 apoptosis regulator Homo sapiens 49-54 11432453-8 2001 However, in calcium-free medium, bcl-2 overexpression maintained Ca2+ uptake in ER of both TG- and Br-A23187-treated cells. Calcium 12-19 BCL2 apoptosis regulator Homo sapiens 33-38 11432453-9 2001 Moreover, the depletion of Ca2+ by EGTA enhanced TG- and Br-A23187-induced apoptosis, and reduced the anti-apoptotic action of bcl-2, suggesting that cytosolic Ca2+ elevation may be required for optimal ER pool refilling. Egtazic Acid 35-39 BCL2 apoptosis regulator Homo sapiens 127-132 11432453-10 2001 These findings suggest that bcl-2 facilitates and maintains the replenishment of Ca2+ in intracellular stores and, as a result, influences the intracellular calcium, thus protecting the cells from death. Calcium 157-164 BCL2 apoptosis regulator Homo sapiens 28-33 11278320-1 2001 Antisense Bcl-2 oligonucleotide sensitizes RIF 1 cells to photodynamic therapy apoptosis. Oligonucleotides 16-31 BCL2 apoptosis regulator Homo sapiens 10-15 11278320-8 2001 This treatment also resulted in oligonucleotide concentration-dependent decrease in cell viability and down-regulation of Bcl-2 protein with a concomitant increase in apoptosis. Oligonucleotides 32-47 BCL2 apoptosis regulator Homo sapiens 122-127 11497278-2 2001 We studied the mechanism of the growth-inhibitory effect of cisplatin (CDDP) on human pancreatic cancer cells in connection with the status of the p53 gene and expression of the bcl-2 family. Cisplatin 60-69 BCL2 apoptosis regulator Homo sapiens 178-183 11497278-2 2001 We studied the mechanism of the growth-inhibitory effect of cisplatin (CDDP) on human pancreatic cancer cells in connection with the status of the p53 gene and expression of the bcl-2 family. Cisplatin 71-75 BCL2 apoptosis regulator Homo sapiens 178-183 11497278-7 2001 Increased expression of bax and reduced expression of bcl-2 are involved in the growth-inhibitory effect of CDDP on pancreatic cancer cells with wild-type p53 gene. Cisplatin 108-112 BCL2 apoptosis regulator Homo sapiens 54-59 11350916-0 2001 p53-Independent induction of apoptosis in human melanoma cells by a bcl-2/bcl-xL bispecific antisense oligonucleotide. Oligonucleotides 102-117 BCL2 apoptosis regulator Homo sapiens 68-73 11350916-3 2001 Upon treatment with oligonucleotide 4625, p53-mut C8161 cells showed earlier DNA damage, which occurred concomitantly with the reduction of bcl-2 and bcl-xL expression and the increase in the expression of proapoptotic bax. Oligonucleotides 20-35 BCL2 apoptosis regulator Homo sapiens 140-145 11350916-6 2001 In contrast to many other anticancer agents to which the apoptotic response is decreased because of p53 mutations, our data suggest that the bcl-2/bcl-xL bispecific antisense oligonucleotide 4625 effectively induces p53-independent apoptosis in human C8161 melanoma cells. Oligonucleotides 175-190 BCL2 apoptosis regulator Homo sapiens 141-146 11393587-0 2001 Butein, a plant polyphenol, induces apoptosis concomitant with increased caspase-3 activity, decreased Bcl-2 expression and increased Bax expression in HL-60 cells. butein 0-6 BCL2 apoptosis regulator Homo sapiens 103-108 11316580-2 2001 beta-Carotene inhibited the growth of human WiDr colon adenocarcinoma cells in a dose- and time-dependent manner, induced apoptosis, and blocked Bcl-2 expression. beta Carotene 0-13 BCL2 apoptosis regulator Homo sapiens 145-150 11316564-6 2001 In terms of changes in expression of p53-related proteins, increase in expression of Bax and decrease in that of Bcl-2 were observed in TE-2 but not in TE-1, suggesting that the main mode of cell death induced by genistein in a cell line with wild type p53 differed from that with mutant p53. Genistein 213-222 BCL2 apoptosis regulator Homo sapiens 113-118 11393587-6 2001 Furthermore, the treatment of HL-60 cells with butein decreased the expression of Bcl-2 protein, but increased the expression of Bax protein. butein 47-53 BCL2 apoptosis regulator Homo sapiens 82-87 11393587-7 2001 These results suggest that butein-induced apoptosis is mediated through the activation of caspase-3 and it is associated with changed expression of Bcl-2 and Bax proteins. butein 27-33 BCL2 apoptosis regulator Homo sapiens 148-153 11278378-4 2001 Levels of phosphorylated Akt, an effector of PI3K, and Bcl-2 were increased by nicotine. Nicotine 79-87 BCL2 apoptosis regulator Homo sapiens 55-60 11783084-5 2001 The expression of bcl-2 was decreased in beta-elemene treated cells as compared with the untreated control cells. beta-elemene 41-53 BCL2 apoptosis regulator Homo sapiens 18-23 11326099-2 2001 tBID, the caspase-activated form of a "BH3-domain-only" BCL-2 family member, triggers the homooligomerization of "multidomain" conserved proapoptotic family members BAK or BAX, resulting in the release of cytochrome c from mitochondria. tBID 0-4 BCL2 apoptosis regulator Homo sapiens 56-61 11295216-7 2001 A more pronounced degree of caspase activation and apoptosis after the action of P(GFLG)-DOX depended on the inhibition of bcl-2-encoded cellular defensive mechanisms and a more significant activation of Apaf-1. Doxorubicin 89-92 BCL2 apoptosis regulator Homo sapiens 123-128 11402324-7 2001 We have shown that the high levels of Bcl-2 expression in FV-P-induced erythroleukemic cells inhibited apoptosis induced by etoposide, low serum and p53 expression. Etoposide 124-133 BCL2 apoptosis regulator Homo sapiens 38-43 11305906-0 2001 Biophysical characterization of recombinant human Bcl-2 and its interactions with an inhibitory ligand, antimycin A. Antimycin A 104-115 BCL2 apoptosis regulator Homo sapiens 50-55 11305906-7 2001 The optimal binding conformation of antimycin A was predicted from molecular docking of antimycin A with the hBcl-2 model created by homology modeling. Antimycin A 36-47 BCL2 apoptosis regulator Homo sapiens 109-115 11305906-7 2001 The optimal binding conformation of antimycin A was predicted from molecular docking of antimycin A with the hBcl-2 model created by homology modeling. Antimycin A 88-99 BCL2 apoptosis regulator Homo sapiens 109-115 11305906-8 2001 Antimycin A selectively induces apoptosis in cells overexpressing Bcl-2, suggesting that hydrophobic groove-binding compounds may act as selective apoptotic triggers in tumor cells. Antimycin A 0-11 BCL2 apoptosis regulator Homo sapiens 66-71 11275362-0 2001 Capsaicin-induced apoptosis in SK-Hep-1 hepatocarcinoma cells involves Bcl-2 downregulation and caspase-3 activation. Capsaicin 0-9 BCL2 apoptosis regulator Homo sapiens 71-76 11275362-5 2001 Furthermore, capsaicin prominently reduced the ratio of anti-apoptotic Bcl-2 to pro-apoptotic Bax and consequently increased caspase-3 activity. Capsaicin 13-22 BCL2 apoptosis regulator Homo sapiens 71-76 11402324-8 2001 Similarly, ectopic Bcl-2 expression within these cells also provided protection from apoptosis induced by etoposide and growth in low serum. Etoposide 106-115 BCL2 apoptosis regulator Homo sapiens 19-24 11347653-4 2001 By contrast, the CCh-stimulated initial [Ca2+]i increase was reduced at 0.5 and 4 h post-irradiation in all cell types and remained decreased at 24 h in wild-type and control-transfected cells, but recovered in Bcl-2- and Bcl-XL-transfectants. Carbachol 17-20 BCL2 apoptosis regulator Homo sapiens 211-216 11278284-6 2001 Blocking cytochrome c release by Bcl-2 overexpression rendered LNCaP cells resistant to TRAIL plus wortmannin treatment but did not affect caspase 8 or BID processing. Wortmannin 99-109 BCL2 apoptosis regulator Homo sapiens 33-38 11257620-11 2001 Bcl-2 was expressed focally in MACs, diffusely in sBCCs, and in scattered cells in dTEs. dtes 83-87 BCL2 apoptosis regulator Homo sapiens 0-5 11566020-1 2001 Genasense (formerly known as G-3139), an antisense oligonucleotide specific for Bcl-2, is under development by Genta as an iv drip infusion for the potential treatment of various cancers including melanoma, prostate, breast and colon cancer [3083751. oblimersen 0-9 BCL2 apoptosis regulator Homo sapiens 80-85 11380606-0 2001 Doxorubicin and a butyric acid derivative effectively reduce levels of BCL-2 protein in the cells of chronic lymphocytic leukemia patient. Doxorubicin 0-11 BCL2 apoptosis regulator Homo sapiens 71-76 11380606-0 2001 Doxorubicin and a butyric acid derivative effectively reduce levels of BCL-2 protein in the cells of chronic lymphocytic leukemia patient. Butyric Acid 18-30 BCL2 apoptosis regulator Homo sapiens 71-76 11294384-0 2001 Synthesis of tetrocarcin derivatives with specific inhibitory activity towards Bcl-2 functions. tetrocarcin 13-24 BCL2 apoptosis regulator Homo sapiens 79-84 11294384-1 2001 Tetrocarcin A was recently identified as an inhibitor of the anti-apoptotic function of Bcl-2. tetrocarcin A 0-13 BCL2 apoptosis regulator Homo sapiens 88-93 11294384-2 2001 We synthesized novel tetrocarcin derivatives in order to increase their selective inhibitory activity against Bcl-2. tetrocarcin 21-32 BCL2 apoptosis regulator Homo sapiens 110-115 11780464-5 2001 bcl-2 gene expression of BIU-87 cells was observed by strept avidin-biotin complex (SABC) immunohistochemical method. biu 25-28 BCL2 apoptosis regulator Homo sapiens 0-5 11780464-5 2001 bcl-2 gene expression of BIU-87 cells was observed by strept avidin-biotin complex (SABC) immunohistochemical method. Biotin 67-74 BCL2 apoptosis regulator Homo sapiens 0-5 11780464-5 2001 bcl-2 gene expression of BIU-87 cells was observed by strept avidin-biotin complex (SABC) immunohistochemical method. sabc 84-88 BCL2 apoptosis regulator Homo sapiens 0-5 11780464-10 2001 CONCLUSION: As2O3 can significantly induce apoptosis in bladder cancer cells by down-regulating the expression of the bcl-2 gene and inhibiting DNA synthesis. Arsenic Trioxide 12-17 BCL2 apoptosis regulator Homo sapiens 118-123 11566020-1 2001 Genasense (formerly known as G-3139), an antisense oligonucleotide specific for Bcl-2, is under development by Genta as an iv drip infusion for the potential treatment of various cancers including melanoma, prostate, breast and colon cancer [3083751. oblimersen 29-35 BCL2 apoptosis regulator Homo sapiens 80-85 11566020-1 2001 Genasense (formerly known as G-3139), an antisense oligonucleotide specific for Bcl-2, is under development by Genta as an iv drip infusion for the potential treatment of various cancers including melanoma, prostate, breast and colon cancer [3083751. Oligonucleotides 51-66 BCL2 apoptosis regulator Homo sapiens 80-85 11380606-7 2001 The combination of low concentrations of AN-9 and doxorubicin more than additively enhanced apoptosis and reduced bcl-2 levels in B-CLL cultures which were resistant to AN-9. Doxorubicin 50-61 BCL2 apoptosis regulator Homo sapiens 114-119 11276013-0 2001 Differential expression of cell death regulators in response to thapsigargin and adriamycin in Bcl-2 transfected DU145 prostatic cancer cells. Thapsigargin 64-76 BCL2 apoptosis regulator Homo sapiens 95-100 11279616-6 2001 Over-expression of bcl-2 in cx43-transfected cells partially confers the resistance to apoptosis induced by etoposide, suggesting that the cx43-mediated apoptosis to chemotherapeutic agents is regulated in part through the down-regulation of bcl-2 expression. Etoposide 108-117 BCL2 apoptosis regulator Homo sapiens 19-24 11276013-0 2001 Differential expression of cell death regulators in response to thapsigargin and adriamycin in Bcl-2 transfected DU145 prostatic cancer cells. Doxorubicin 81-91 BCL2 apoptosis regulator Homo sapiens 95-100 11276013-10 2001 In the presence of thapsigargin or adriamycin, levels of Bcl-2 and its heterodimeric partner Bax were elevated approximately two-fold with no change in Bak in Bcl-2 transfectants in contrast to controls, where Bak was increased (two-fold). Thapsigargin 19-31 BCL2 apoptosis regulator Homo sapiens 57-62 11276013-10 2001 In the presence of thapsigargin or adriamycin, levels of Bcl-2 and its heterodimeric partner Bax were elevated approximately two-fold with no change in Bak in Bcl-2 transfectants in contrast to controls, where Bak was increased (two-fold). Doxorubicin 35-45 BCL2 apoptosis regulator Homo sapiens 57-62 11276013-12 2001 Moreover, Bcl-2 overexpression conferred a significant cytotoxic chemoresistance and altered the balance of expression of death promoters (from Bak, a dominant death promoter in controls, to Bax) in response to thapsigargin and adriamycin. Thapsigargin 211-223 BCL2 apoptosis regulator Homo sapiens 10-15 11276013-12 2001 Moreover, Bcl-2 overexpression conferred a significant cytotoxic chemoresistance and altered the balance of expression of death promoters (from Bak, a dominant death promoter in controls, to Bax) in response to thapsigargin and adriamycin. Doxorubicin 228-238 BCL2 apoptosis regulator Homo sapiens 10-15 12761970-1 2001 OBJECTIVE: To investigate the protein expression of B-cell lymphoma/leukemia-2(Bcl-2) and B-cell lymphoma/leukemia-x long(Bcl-x1) in eosinophils in nasal polyps and the influence of beclomethasone dipropionate on the expression. Beclomethasone 182-209 BCL2 apoptosis regulator Homo sapiens 79-84 11368354-11 2001 In addition, multisite Bcl2 phosphorylation induced by anti-mitotic drugs like paclitaxel may inhibit Bcl2 indicating the potential wide range of functional consequences that this post-translational modification may have on function. Paclitaxel 79-89 BCL2 apoptosis regulator Homo sapiens 23-27 11368354-11 2001 In addition, multisite Bcl2 phosphorylation induced by anti-mitotic drugs like paclitaxel may inhibit Bcl2 indicating the potential wide range of functional consequences that this post-translational modification may have on function. Paclitaxel 79-89 BCL2 apoptosis regulator Homo sapiens 102-106 12397885-4 2001 Antidepressants, lithium, and valproate indirectly regulate a number of factors involved in cell survival pathways, including CREB, BDNF, Bcl-2, and MAP kinases, and may thus bring about some of their delayed long term beneficial effects via underappreciated neurotrophic effects. Lithium 17-24 BCL2 apoptosis regulator Homo sapiens 138-143 12397885-4 2001 Antidepressants, lithium, and valproate indirectly regulate a number of factors involved in cell survival pathways, including CREB, BDNF, Bcl-2, and MAP kinases, and may thus bring about some of their delayed long term beneficial effects via underappreciated neurotrophic effects. Valproic Acid 30-39 BCL2 apoptosis regulator Homo sapiens 138-143 11802967-7 2001 SP immunohistological staining method was performed to detect the changes of expressions of p53, Bcl-2 and Bax gene. TFF2 protein, human 0-2 BCL2 apoptosis regulator Homo sapiens 97-102 12761970-2 2001 METHODS: Using May-Grunwald-Giemsa (MGG) method and immunohistochemical method, the protein expression of Bcl-x1 and Bcl-2 in eosinophils in nasal polyps from patients treated with beclomethasone dipropionate treatment and patients without any treatment was compared. Beclomethasone 181-208 BCL2 apoptosis regulator Homo sapiens 117-122 11259472-0 2001 Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. Oligonucleotides 54-69 BCL2 apoptosis regulator Homo sapiens 20-25 11313919-9 2001 APO-BRDU assay demonstrated that polyamine analogs induced apoptosis, with a loss of the anti-apoptotic protein Bcl-2. Polyamines 33-42 BCL2 apoptosis regulator Homo sapiens 112-117 11282109-6 2001 Moreover, esculetin application reduced Bcl-2 protein expression to 58% after 9 h as compared with that time at 0. esculetin 10-19 BCL2 apoptosis regulator Homo sapiens 40-45 11259472-2 2001 We recently reported that the bcl-2/bcl-xL-bispecific antisense oligonucleotide 4625 induces apoptosis in lung carcinoma cells. bispecific 43-53 BCL2 apoptosis regulator Homo sapiens 30-35 11259472-2 2001 We recently reported that the bcl-2/bcl-xL-bispecific antisense oligonucleotide 4625 induces apoptosis in lung carcinoma cells. Oligonucleotides 64-79 BCL2 apoptosis regulator Homo sapiens 30-35 11259472-4 2001 METHODS: Oligonucleotide 4625-mediated inhibition of bcl-2 and bcl-xL expression in vitro was measured in breast carcinoma cells with the use of reverse transcription-polymerase chain reaction (PCR), real-time PCR, and western blotting. Oligonucleotides 9-24 BCL2 apoptosis regulator Homo sapiens 53-58 11259472-9 2001 RESULTS: In breast carcinoma cells, oligonucleotide 4625 treatment reduced bcl-2 and bcl-xL messenger RNA levels in a dose-dependent manner. Oligonucleotides 36-51 BCL2 apoptosis regulator Homo sapiens 75-80 11259472-10 2001 At 600 nM:, oligonucleotide 4625 reduced Bcl-2 and Bcl-xL protein levels to 25% (95% confidence interval [CI] = 16% to 34%) and 20% (95% CI = 14% to 26%), respectively, of the levels in untreated cells and it decreased viability in all cell lines mainly by inducing apoptosis. Oligonucleotides 12-27 BCL2 apoptosis regulator Homo sapiens 41-46 11259472-11 2001 In vivo, oligonucleotide 4625 statistically significantly inhibited the growth of breast and colorectal carcinoma xenografts by 51% (95% CI = 28% to 74%) and 59% (95% CI = 44% to 74%), respectively, relative to those treated with control oligonucleotide 4626; it also reduced Bcl-2 and Bcl-xL protein levels and induced tumor cell apoptosis. Oligonucleotides 9-24 BCL2 apoptosis regulator Homo sapiens 276-281 11259472-12 2001 CONCLUSION: The bcl-2/bcl-xL-bispecific antisense oligonucleotide 4625 merits further study as a novel compound for cancer therapy. Oligonucleotides 50-65 BCL2 apoptosis regulator Homo sapiens 16-21 11307620-4 2001 BCL-2 gene transfer inhibits apoptosis induced by lovastatin but not apoptosis induced by phenylacetate. Lovastatin 50-60 BCL2 apoptosis regulator Homo sapiens 0-5 11292287-0 2001 Nitric oxide-mediated expression of Bcl-2 and Bcl-xl and protection from tumor necrosis factor-alpha-mediated apoptosis in porcine endothelial cells after exposure to low concentrations of xenoreactive natural antibody. Nitric Oxide 0-12 BCL2 apoptosis regulator Homo sapiens 36-41 11292287-5 2001 RESULTS: The cells acquired resistance to tumor necrosis factor-alpha-mediated apoptosis (50-100% reduction at 6 hr) and up-regulated expression of Bcl-2 and Bcl-xl; sustained expression was accompanied by inducible nitric oxide (NO) synthase expression and by enhanced production of NO by EC. Nitric Oxide 216-228 BCL2 apoptosis regulator Homo sapiens 148-153 11292287-8 2001 Second, an NO synthase inhibitor NG-monomethyl-L-arginine.monoacetate was able to specifically inhibit the anti-pig antibody-mediated expression of Bcl-2 or Bcl-xl. omega-N-Methylarginine 33-57 BCL2 apoptosis regulator Homo sapiens 148-153 11292287-8 2001 Second, an NO synthase inhibitor NG-monomethyl-L-arginine.monoacetate was able to specifically inhibit the anti-pig antibody-mediated expression of Bcl-2 or Bcl-xl. Acetates 58-69 BCL2 apoptosis regulator Homo sapiens 148-153 11237391-5 2001 The importance of Bcl-2 for response to EB1089 is supported by our observation that oestradiol abrogates the effect of EB1089 in cell lines which increase Bcl-2 in response to oestradiol treatment. Estradiol 84-94 BCL2 apoptosis regulator Homo sapiens 18-23 11237391-5 2001 The importance of Bcl-2 for response to EB1089 is supported by our observation that oestradiol abrogates the effect of EB1089 in cell lines which increase Bcl-2 in response to oestradiol treatment. Estradiol 84-94 BCL2 apoptosis regulator Homo sapiens 155-160 11237391-5 2001 The importance of Bcl-2 for response to EB1089 is supported by our observation that oestradiol abrogates the effect of EB1089 in cell lines which increase Bcl-2 in response to oestradiol treatment. Estradiol 176-186 BCL2 apoptosis regulator Homo sapiens 18-23 11237391-5 2001 The importance of Bcl-2 for response to EB1089 is supported by our observation that oestradiol abrogates the effect of EB1089 in cell lines which increase Bcl-2 in response to oestradiol treatment. Estradiol 176-186 BCL2 apoptosis regulator Homo sapiens 155-160 11237705-4 2001 The addition of bcl-2 antisense oligonucleotides, however, restored apoptosis. Oligonucleotides 32-48 BCL2 apoptosis regulator Homo sapiens 16-21 11275990-2 2001 We recently reported that antisense Bcl-2 oligodeoxynucleotides (ODNs) delay progression to androgen independence in the androgen-dependent (AD) human LNCaP prostate tumor model. Oligodeoxyribonucleotides 65-69 BCL2 apoptosis regulator Homo sapiens 36-41 11275990-4 2001 Semi-quantitative reverse transcriptast-polymerase chain reaction revealed that treatment of LNCaP cells with antisense Bcl-2 ODN decreased Bcl-2 expression in a dose-dependent and sequence-specific manner, whereas Bcl-2 expression was not affected by paclitaxel treatment. Paclitaxel 252-262 BCL2 apoptosis regulator Homo sapiens 120-125 11231287-6 2001 The sensitivity of the cells to thapsigargin-induced apoptosis was evaluated by cell viability and nuclear fragmentation (Hoechst 33258) and compared with pro-(Bcl-2, Bcl-x(L)) and anti-apoptotic (Bax, Bak) protein expression of the Bcl-2 family. Thapsigargin 32-44 BCL2 apoptosis regulator Homo sapiens 233-238 11277419-0 2001 Routine formaldehyde fixation irreversibly reduces immunoreactivity of Bcl-2 in the nuclear compartment of breast cancer cells, but not in the cytoplasm. Formaldehyde 8-20 BCL2 apoptosis regulator Homo sapiens 71-76 11277419-4 2001 In their experience, nuclear or mitotic staining of Bcl-2, in contrast with cytoplasmic Bcl-2 immunoreactivity, is rarely observed in formaldehyde-fixed, paraffin-embedded breast cancer specimens. Formaldehyde 134-146 BCL2 apoptosis regulator Homo sapiens 52-57 11280732-6 2001 On the contrary, bcl-2 expression was associated with a high CR rate. Chromium 61-63 BCL2 apoptosis regulator Homo sapiens 17-22 11280732-11 2001 Modulation of PDT response with bioreductive drugs and/or drugs targeting bcl-2 (i.e., taxanes) may prove of significant therapeutic importance in a subgroup of patients with high HIF expression. Taxoids 87-94 BCL2 apoptosis regulator Homo sapiens 74-79 11462152-6 2001 Also, the expression of bcl-2 in cells treated with 200 microM H2O2 was diminished, whereas expression of p53 and p21waf-1 was increased compared to the controls. Hydrogen Peroxide 63-67 BCL2 apoptosis regulator Homo sapiens 24-29 11277419-4 2001 In their experience, nuclear or mitotic staining of Bcl-2, in contrast with cytoplasmic Bcl-2 immunoreactivity, is rarely observed in formaldehyde-fixed, paraffin-embedded breast cancer specimens. Paraffin 154-162 BCL2 apoptosis regulator Homo sapiens 52-57 11277419-5 2001 Therefore, the authors wondered if nuclear and mitotic Bcl-2 immunoreactivity could be irreversibly reduced by certain fixation procedures, including formaldehyde fixation. Formaldehyde 150-162 BCL2 apoptosis regulator Homo sapiens 55-60 11277419-7 2001 Whereas nuclear and mitotic immunoreactivity for Bcl-2 was clearly present after formaldehyde and methanol fixation, it was completely absent in cells fixed in acetone, methanol, or formaldehyde alone. Formaldehyde 81-93 BCL2 apoptosis regulator Homo sapiens 49-54 11277419-7 2001 Whereas nuclear and mitotic immunoreactivity for Bcl-2 was clearly present after formaldehyde and methanol fixation, it was completely absent in cells fixed in acetone, methanol, or formaldehyde alone. Methanol 98-106 BCL2 apoptosis regulator Homo sapiens 49-54 11277419-7 2001 Whereas nuclear and mitotic immunoreactivity for Bcl-2 was clearly present after formaldehyde and methanol fixation, it was completely absent in cells fixed in acetone, methanol, or formaldehyde alone. Acetone 160-167 BCL2 apoptosis regulator Homo sapiens 49-54 11277419-7 2001 Whereas nuclear and mitotic immunoreactivity for Bcl-2 was clearly present after formaldehyde and methanol fixation, it was completely absent in cells fixed in acetone, methanol, or formaldehyde alone. Methanol 169-177 BCL2 apoptosis regulator Homo sapiens 49-54 11277419-7 2001 Whereas nuclear and mitotic immunoreactivity for Bcl-2 was clearly present after formaldehyde and methanol fixation, it was completely absent in cells fixed in acetone, methanol, or formaldehyde alone. Formaldehyde 182-194 BCL2 apoptosis regulator Homo sapiens 49-54 11277419-8 2001 In addition, it was found that in particular nuclear and mitotic Bcl-2, and to a lesser extent cytoplasmic Bcl-2 immunoreactivity, decreased after prolonged formaldehyde fixation, whereas Bax immunoreactivity diminished only slightly. Formaldehyde 157-169 BCL2 apoptosis regulator Homo sapiens 65-70 11277419-8 2001 In addition, it was found that in particular nuclear and mitotic Bcl-2, and to a lesser extent cytoplasmic Bcl-2 immunoreactivity, decreased after prolonged formaldehyde fixation, whereas Bax immunoreactivity diminished only slightly. Formaldehyde 157-169 BCL2 apoptosis regulator Homo sapiens 107-112 11319611-4 2001 Moreover, DEX treatment increased the expression of anti-apoptotic Bcl-2 and Bcl-xL proteins in human and rat hepatocytes, respectively, whereas the expression of pro-apoptotic proteins Bcl-xS or Bad was not detected or remained unchanged. Dexamethasone 10-13 BCL2 apoptosis regulator Homo sapiens 67-72 11177741-4 2001 Preliminary data suggest that gene expression levels of topoisomerase I, p21, bcl-2, and ICE may be predictive of response to therapy with CPT-11. Irinotecan 139-145 BCL2 apoptosis regulator Homo sapiens 78-83 11231287-10 2001 Bcl-2 expression was strongly increased by PMA and drastically decreased by staurosporine as was Bcl-x(L) expression. Staurosporine 76-89 BCL2 apoptosis regulator Homo sapiens 0-5 11231287-13 2001 Furthermore, the expression of Bcl-2 was reduced by toxin B from Clostridium difficile and, to a lesser extent, by wortmannin suggesting a role of small G-protein RhoA and PtdIns3 kinase in the control of Bcl-2 expression. Wortmannin 115-125 BCL2 apoptosis regulator Homo sapiens 31-36 11231287-13 2001 Furthermore, the expression of Bcl-2 was reduced by toxin B from Clostridium difficile and, to a lesser extent, by wortmannin suggesting a role of small G-protein RhoA and PtdIns3 kinase in the control of Bcl-2 expression. Wortmannin 115-125 BCL2 apoptosis regulator Homo sapiens 205-210 11401436-1 2001 Members of the Bcl-2 family of apoptosis-regulating proteins contain at least one of the four evolutionarily conserved domains, termed BH1, BH2, BH3, or BH4. bh1 135-138 BCL2 apoptosis regulator Homo sapiens 15-20 11264898-0 2001 Iron induces Bcl-2 expression in human dermal microvascular endothelial cells. Iron 0-4 BCL2 apoptosis regulator Homo sapiens 13-18 11264898-4 2001 Using immunohistochemistry and Western Blot analysis, we found that the extended cellular life span induced by iron was paralleled by an increase of Bcl-2 protein expression. Iron 111-115 BCL2 apoptosis regulator Homo sapiens 149-154 11401436-1 2001 Members of the Bcl-2 family of apoptosis-regulating proteins contain at least one of the four evolutionarily conserved domains, termed BH1, BH2, BH3, or BH4. bh2 140-143 BCL2 apoptosis regulator Homo sapiens 15-20 11401436-1 2001 Members of the Bcl-2 family of apoptosis-regulating proteins contain at least one of the four evolutionarily conserved domains, termed BH1, BH2, BH3, or BH4. BH 3 145-148 BCL2 apoptosis regulator Homo sapiens 15-20 11401436-1 2001 Members of the Bcl-2 family of apoptosis-regulating proteins contain at least one of the four evolutionarily conserved domains, termed BH1, BH2, BH3, or BH4. sapropterin 153-156 BCL2 apoptosis regulator Homo sapiens 15-20 11207265-2 2001 The proteasome inhibitor lactacystin differentially regulated the protein levels of proapoptotic Bcl-2 family members and Bik was accumulated at the mitochondria. lactacystin 25-36 BCL2 apoptosis regulator Homo sapiens 97-102 11312881-10 2001 The level of expression of Bcl-2 slightly decreased, while the levels of Bad and Bax were dramatically increased in cells treated with garcinol. garcinol 135-143 BCL2 apoptosis regulator Homo sapiens 27-32 11239649-10 2001 Control cells and cells treated with the lowest concentration of ASA exhibited 2% apoptosis and more than 60% of the population expressed bcl-2. Aspirin 65-68 BCL2 apoptosis regulator Homo sapiens 138-143 11222695-5 2001 We show that wt HSV-1, but not the mutant viruses, maintains bcl-2 RNA and protein levels during infection and protects from the cisplatin-induced decrease in bcl-2 RNA; our data suggest that both ICP27 and ICP4 are required for this function. Cisplatin 129-138 BCL2 apoptosis regulator Homo sapiens 159-164 11238733-9 2001 Levels of the anti-apoptotic protein Bcl-2 were increased in neurons grown on laminin and decreased by wortmanin, suggesting a mechanism for the neuroprotective effect of integrin-mediated signaling. Wortmannin 103-112 BCL2 apoptosis regulator Homo sapiens 37-42 11181062-6 2001 We also show that caspase-9/-3-mediated cleavage of Bcl-2 occurs in vivo during apoptosis in CHO-HSV-TK cells after exposure to the antiviral drug ganciclovir. Ganciclovir 147-158 BCL2 apoptosis regulator Homo sapiens 52-57 11222086-14 2001 High intrinsic levels of Bcl-2 and Bcl-x(L) may prevent apoptotic death of keratinocytes at lower levels of JP-8, while perturbation of the balance between pro- and antiapoptotic Bcl-2 family members at higher levels may ultimately play a role in necrotic cell death in human keratinocytes. JP-8 108-112 BCL2 apoptosis regulator Homo sapiens 25-30 12536628-5 2001 CONCLUSION: bcl-2 and c-myc genes play an important role in pathogenesis and the development of AL. Aluminum 96-98 BCL2 apoptosis regulator Homo sapiens 12-17 11098049-7 2001 Treatment of hypertrophic chondrocytes by PTH or by p38 MAPK inhibitor SB203580 up-regulates Bcl-2, suggesting that Bcl-2 lies downstream of p38 MAPK in the PTH signaling pathway. SB 203580 71-79 BCL2 apoptosis regulator Homo sapiens 93-98 11342237-0 2001 SeO(2) induces apoptosis with down-regulation of Bcl-2 and up-regulation of P53 expression in both immortal human hepatic cell line and hepatoma cell line. seo(2) 0-6 BCL2 apoptosis regulator Homo sapiens 49-54 11342237-3 2001 SeO(2) could also down-regulate the Bcl-2 level, greatly in HL-7702 and slightly in SMMC-7721 cells, but up-regulate wild type P53 level a little in HL-7702 and significantly in SMMC-7721 cells. seo(2) 0-6 BCL2 apoptosis regulator Homo sapiens 36-41 11342237-4 2001 The Bcl-2/P53 value was closely correlated with the apoptotic rate as well as SeO(2) concentrations. seo(2) 78-84 BCL2 apoptosis regulator Homo sapiens 4-9 11098049-7 2001 Treatment of hypertrophic chondrocytes by PTH or by p38 MAPK inhibitor SB203580 up-regulates Bcl-2, suggesting that Bcl-2 lies downstream of p38 MAPK in the PTH signaling pathway. SB 203580 71-79 BCL2 apoptosis regulator Homo sapiens 116-121 11245455-12 2001 A-105972 caused a mobility shift of bcl-2 on SDS-PAGE, suggesting that A-105972 induced bcl-2 phosphorylation. Sodium Dodecyl Sulfate 45-48 BCL2 apoptosis regulator Homo sapiens 36-41 11181702-0 2001 Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-2. Adenine Nucleotides 54-72 BCL2 apoptosis regulator Homo sapiens 130-135 11245455-12 2001 A-105972 caused a mobility shift of bcl-2 on SDS-PAGE, suggesting that A-105972 induced bcl-2 phosphorylation. Sodium Dodecyl Sulfate 45-48 BCL2 apoptosis regulator Homo sapiens 88-93 11162629-3 2001 Using functional and spectrophotometric measurements in an inducible PC12-Tet-on-bcl-2 cell line we demonstrate that induction of Bcl-2 overexpression rapidly reduced cytochrome b and c levels as well as complex I activity. tetramethylenedisulfotetramine 74-77 BCL2 apoptosis regulator Homo sapiens 81-86 11341981-5 2001 This contrasted with the capacity of NAC to prevent the alterations caused by BSO/200 microM cadmium in other proteins, namely the suppression of Bax expression and the increase in Bcl-2 and HSP-60 expression. Cadmium 93-100 BCL2 apoptosis regulator Homo sapiens 181-186 11162629-3 2001 Using functional and spectrophotometric measurements in an inducible PC12-Tet-on-bcl-2 cell line we demonstrate that induction of Bcl-2 overexpression rapidly reduced cytochrome b and c levels as well as complex I activity. tetramethylenedisulfotetramine 74-77 BCL2 apoptosis regulator Homo sapiens 130-135 11162629-4 2001 To confirm that these changes were specific for Bcl-2 we generated a bcl-2 antisense construct under the control of the tetracycline responsive promotor. Tetracycline 120-132 BCL2 apoptosis regulator Homo sapiens 48-53 11162629-4 2001 To confirm that these changes were specific for Bcl-2 we generated a bcl-2 antisense construct under the control of the tetracycline responsive promotor. Tetracycline 120-132 BCL2 apoptosis regulator Homo sapiens 69-74 11166763-4 2001 Incubation of ECs with high levels of nitric oxide (NO) released by N-ethyl-2-[1-ethyl-2-hydroxy-2-nitrosohydrazino]-ethanamine, a NO releasing agent, resulted in apoptosis in association with decreased levels of Bcl-2, and increased levels of Bax, an accelerator of aoptosis. Nitric Oxide 38-50 BCL2 apoptosis regulator Homo sapiens 213-218 11245415-2 2001 Light-activated verteporfin-induced apoptosis was abolished by transfection with Bcl-2, a procedure reported to inhibit the mitochondrial permeability transition pore complex (PTPC). Verteporfin 16-27 BCL2 apoptosis regulator Homo sapiens 81-86 11245415-5 2001 Verteporfin phototoxicity on ANT proteoliposomes was mediated by reactive oxygen species and was prevented by recombinant Bcl-2 or the adenine nucleotides ATP and ADP. Verteporfin 0-11 BCL2 apoptosis regulator Homo sapiens 122-127 11166763-4 2001 Incubation of ECs with high levels of nitric oxide (NO) released by N-ethyl-2-[1-ethyl-2-hydroxy-2-nitrosohydrazino]-ethanamine, a NO releasing agent, resulted in apoptosis in association with decreased levels of Bcl-2, and increased levels of Bax, an accelerator of aoptosis. n-ethyl-2-[1-ethyl-2-hydroxy-2-nitrosohydrazino]-ethanamine 68-127 BCL2 apoptosis regulator Homo sapiens 213-218 11512155-4 2001 Recently developed antisense oligonucleotides with the ability to inhibit the expression of anti-apoptotic proteins, including Bcl-2, Bcl-xL, FLIP and surviving, have been shown to facilitate tumor cell apoptosis and sensitize tumor cells to cytotoxic treatments. Oligonucleotides 29-45 BCL2 apoptosis regulator Homo sapiens 127-132 11159853-14 2001 Incubation of the cells with Dex dramatically reduced Bcl-2 levels to 15% of control at 37 C (P: < 0.01) or 32 C in the presence or absence of forskolin (P: < 0.01). Dexamethasone 29-32 BCL2 apoptosis regulator Homo sapiens 54-59 11428715-3 2001 This study was carried out to evaluate changes in expression of cell death promoters, P53 and bax, and cell death repressor, bcl-2, in cAMP-treated granulosa cells. Cyclic AMP 135-139 BCL2 apoptosis regulator Homo sapiens 125-130 11234887-7 2001 Cotreatment with UCN-01 also increased F-ara-A-mediated apoptosis and loss of delta psi(m) in U937 cells ectopically expressing Bcl-2, although not to the same extent as that observed in empty-vector controls. fludarabine 39-46 BCL2 apoptosis regulator Homo sapiens 128-133 11234896-0 2001 Efficacy of treatment with antisense oligonucleotides complementary to immunoglobulin sequences of bcl-2/immunoglobulin fusion transcript in a t(14;18) human lymphoma-scid mouse model. Oligonucleotides 37-53 BCL2 apoptosis regulator Homo sapiens 99-104 11234896-2 2001 We reported previously that antisense oligodeoxyribonucleotides directed at the bcl-2 translational start site, as well as those targeted to immunoglobulin sequences 3" of the translocation breakpoint, down-regulate bcl-2 and inhibit growth of the t(14;18)-positive lymphoma line WSU-FSCCL in vitro. Oligodeoxyribonucleotides 38-63 BCL2 apoptosis regulator Homo sapiens 80-85 11234896-2 2001 We reported previously that antisense oligodeoxyribonucleotides directed at the bcl-2 translational start site, as well as those targeted to immunoglobulin sequences 3" of the translocation breakpoint, down-regulate bcl-2 and inhibit growth of the t(14;18)-positive lymphoma line WSU-FSCCL in vitro. Oligodeoxyribonucleotides 38-63 BCL2 apoptosis regulator Homo sapiens 216-221 11234896-3 2001 We have developed a scid mouse model with this human cell line and demonstrate that antisense oligodeoxyribonucleotides targeted to immunoglobulin c(mu) sequences down-regulate bcl-2 protein expression and induce apoptosis of WSU-FSCCL cells in vivo. Oligodeoxyribonucleotides 94-119 BCL2 apoptosis regulator Homo sapiens 177-182 11171373-1 2001 Previous studies have shown that overexpression of Bcl2 protects cells from glucose deprivation-induced cell death in multidrug-resistant human breast carcinoma, MCF-7/ADR cells. Glucose 76-83 BCL2 apoptosis regulator Homo sapiens 51-55 11171373-2 2001 In this study, we further investigated the protective role of Bcl2 in glucose deprivation-induced cytotoxicity. Glucose 70-77 BCL2 apoptosis regulator Homo sapiens 62-66 11152530-5 2001 As cells expressed bcl-2 at higher levels, they became more capable of growing in soft agarose and became resistant to apoptosis. Sepharose 87-94 BCL2 apoptosis regulator Homo sapiens 19-24 11171373-3 2001 Although Bcl2 did not prevent a 3.2-fold increase in the level of hydroperoxide during glucose deprivation, it led to a compartmentalization of hydroperoxide molecules in the mitochondria. Hydrogen Peroxide 144-157 BCL2 apoptosis regulator Homo sapiens 9-13 11171373-5 2001 It is possible that overexpression of Bcl2 prevents glucose deprivation-induced ceramide generation, probably by preventing the leakage of hydroperoxide from the mitochondria. Glucose 52-59 BCL2 apoptosis regulator Homo sapiens 38-42 11171373-5 2001 It is possible that overexpression of Bcl2 prevents glucose deprivation-induced ceramide generation, probably by preventing the leakage of hydroperoxide from the mitochondria. Ceramides 80-88 BCL2 apoptosis regulator Homo sapiens 38-42 11171373-5 2001 It is possible that overexpression of Bcl2 prevents glucose deprivation-induced ceramide generation, probably by preventing the leakage of hydroperoxide from the mitochondria. Hydrogen Peroxide 139-152 BCL2 apoptosis regulator Homo sapiens 38-42 11171373-7 2001 Overexpression of Bcl2 suppressed an increase in oxidized glutathione content and thiol precursor content. Glutathione 58-69 BCL2 apoptosis regulator Homo sapiens 18-22 11171373-7 2001 Overexpression of Bcl2 suppressed an increase in oxidized glutathione content and thiol precursor content. Sulfhydryl Compounds 82-87 BCL2 apoptosis regulator Homo sapiens 18-22 11171373-8 2001 Our results indicate that Bcl2 protects cells from metabolic oxidative stress-induced damage by inhibiting the leakage of hydroperoxide from the mitochondria and subsequently preventing ceramide generation. Hydrogen Peroxide 122-135 BCL2 apoptosis regulator Homo sapiens 26-30 11171373-8 2001 Our results indicate that Bcl2 protects cells from metabolic oxidative stress-induced damage by inhibiting the leakage of hydroperoxide from the mitochondria and subsequently preventing ceramide generation. Ceramides 186-194 BCL2 apoptosis regulator Homo sapiens 26-30 11181829-0 2001 Antisense inhibition of BCL-2 expression induces retinoic acid-mediated cell death during differentiation of human NT2N neurons. Tretinoin 49-62 BCL2 apoptosis regulator Homo sapiens 24-29 11181829-5 2001 This concentration of retinoic acid was not toxic to undifferentiated NT2/D1 cells but was sufficient to up-regulate the BCL-2 protein in 6 days. Tretinoin 22-35 BCL2 apoptosis regulator Homo sapiens 121-126 11181829-7 2001 Inhibition of the accumulation of endogenous BCL-2 with vectors expressing the antisense mRNA of Bcl-2 caused extensive apoptosis after 3 weeks of the retinoic acid treatment. Tretinoin 151-164 BCL2 apoptosis regulator Homo sapiens 45-50 11181829-7 2001 Inhibition of the accumulation of endogenous BCL-2 with vectors expressing the antisense mRNA of Bcl-2 caused extensive apoptosis after 3 weeks of the retinoic acid treatment. Tretinoin 151-164 BCL2 apoptosis regulator Homo sapiens 97-102 11181829-10 2001 The ability of BCL-2 to prevent retinoic acid-induced cell death was also confirmed in undifferentiated NT2/D1 cells that were transfected with a vector containing Bcl-2 cDNA in sense orientation and exposed to toxic doses (40-80 microM) of retinoic acid. Tretinoin 32-45 BCL2 apoptosis regulator Homo sapiens 15-20 11181829-10 2001 The ability of BCL-2 to prevent retinoic acid-induced cell death was also confirmed in undifferentiated NT2/D1 cells that were transfected with a vector containing Bcl-2 cDNA in sense orientation and exposed to toxic doses (40-80 microM) of retinoic acid. Tretinoin 241-254 BCL2 apoptosis regulator Homo sapiens 15-20 11181829-11 2001 Furthermore, down-regulation of BCL-2 levels by an antisense oligonucleotide in neuronally differentiated NT2/D1 cells increased their susceptibility to retinoic acid-induced apoptosis. Oligonucleotides 61-76 BCL2 apoptosis regulator Homo sapiens 32-37 11181829-11 2001 Furthermore, down-regulation of BCL-2 levels by an antisense oligonucleotide in neuronally differentiated NT2/D1 cells increased their susceptibility to retinoic acid-induced apoptosis. Tretinoin 153-166 BCL2 apoptosis regulator Homo sapiens 32-37 11181829-12 2001 These results indicate that one function of the up-regulation of endogenous BCL-2 during neuronal differentiation is to regulate the sensitivity of young post-mitotic neurons to retinoic acid-mediated apoptosis. Tretinoin 178-191 BCL2 apoptosis regulator Homo sapiens 76-81 11166656-8 2001 This increased ROS production was associated with changes in the expression of the antiapoptotic/antioxidant compounds Bcl-2 and thioredoxin along the course of the disease. Reactive Oxygen Species 15-18 BCL2 apoptosis regulator Homo sapiens 119-124 11160861-3 2001 Overexpression of a dominant-negative mutant, mitogen-activated protein kinase kinase 1 (MEKK1-DN) or treatment with JNK-specific antisense oligonucleotide prevented paclitaxel-induced JNK activation, Bcl-2 phosphorylation and apoptosis. Oligonucleotides 140-155 BCL2 apoptosis regulator Homo sapiens 201-206 11158311-7 2001 Restoration of Bcl2 expression in Gadd153-overexpressing cells led to replenishment of glutathione and a reduction in levels of reactive oxygen species, and it protected cells from ER stress-induced cell death. Glutathione 87-98 BCL2 apoptosis regulator Homo sapiens 15-19 11158311-7 2001 Restoration of Bcl2 expression in Gadd153-overexpressing cells led to replenishment of glutathione and a reduction in levels of reactive oxygen species, and it protected cells from ER stress-induced cell death. Reactive Oxygen Species 128-151 BCL2 apoptosis regulator Homo sapiens 15-19 11160861-0 2001 Involvement of Asp-Glu-Val-Asp-directed, caspase-mediated mitogen-activated protein kinase kinase 1 Cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells. Aspartic Acid 15-18 BCL2 apoptosis regulator Homo sapiens 161-166 11160861-0 2001 Involvement of Asp-Glu-Val-Asp-directed, caspase-mediated mitogen-activated protein kinase kinase 1 Cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells. Glutamic Acid 19-22 BCL2 apoptosis regulator Homo sapiens 161-166 11160861-0 2001 Involvement of Asp-Glu-Val-Asp-directed, caspase-mediated mitogen-activated protein kinase kinase 1 Cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells. Valine 23-26 BCL2 apoptosis regulator Homo sapiens 161-166 11160861-3 2001 Overexpression of a dominant-negative mutant, mitogen-activated protein kinase kinase 1 (MEKK1-DN) or treatment with JNK-specific antisense oligonucleotide prevented paclitaxel-induced JNK activation, Bcl-2 phosphorylation and apoptosis. Paclitaxel 166-176 BCL2 apoptosis regulator Homo sapiens 201-206 11160861-0 2001 Involvement of Asp-Glu-Val-Asp-directed, caspase-mediated mitogen-activated protein kinase kinase 1 Cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells. Aspartic Acid 27-30 BCL2 apoptosis regulator Homo sapiens 161-166 11160861-0 2001 Involvement of Asp-Glu-Val-Asp-directed, caspase-mediated mitogen-activated protein kinase kinase 1 Cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells. Paclitaxel 187-197 BCL2 apoptosis regulator Homo sapiens 161-166 11160861-6 2001 The caspase inhibitor Ac-Asp-Glu-Val-Asp-CHO (DEVD-CHO), but not Ac-Tyr-Val-Ala-Asp-CHO (Ac-YVAD-CHO), effectively blocked MEKK1 cleavage, JNK activation, Bcl-2 phosphorylation, and subsequent apoptosis. ac-asp-glu-val-asp-cho 22-44 BCL2 apoptosis regulator Homo sapiens 155-160 11175750-1 2001 To study the role of the BH3 domain in mediating pro-apoptotic and anti-apoptotic activities of Bcl-2 family members, we identified a series of novel small molecules (BH3Is) that inhibit the binding of the Bak BH3 peptide to Bcl-xL. BH 3 25-28 BCL2 apoptosis regulator Homo sapiens 96-101 11160861-9 2001 Taken together, our results suggest that disruption of cytoarchitecture by paclitaxel triggers a novel apoptosis-signaling pathway, wherein an active DEVD-directed caspase (DEVDase) initially cleaves MEKK1to generate a proapoptotic kinase fragment that is able to activate JNK and subsequent Bcl-2 phosphorylation, finally eliciting cell death. cytoarchitecture 55-71 BCL2 apoptosis regulator Homo sapiens 292-297 11175750-4 2001 Our results indicate that BH3-dependent heterodimerization is the key function of anti-apoptotic Bcl-2 family members and is required for the maintenance of cellular homeostasis. BH 3 26-29 BCL2 apoptosis regulator Homo sapiens 97-102 11175751-0 2001 Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Antimycin A 0-11 BCL2 apoptosis regulator Homo sapiens 41-46 11175751-3 2001 Computational molecular docking analysis predicted that antimycin A interacts with the Bcl-2 homology domain 3 (BH3)-binding hydrophobic groove of Bcl-xL. Antimycin A 56-67 BCL2 apoptosis regulator Homo sapiens 87-92 11160861-9 2001 Taken together, our results suggest that disruption of cytoarchitecture by paclitaxel triggers a novel apoptosis-signaling pathway, wherein an active DEVD-directed caspase (DEVDase) initially cleaves MEKK1to generate a proapoptotic kinase fragment that is able to activate JNK and subsequent Bcl-2 phosphorylation, finally eliciting cell death. Paclitaxel 75-85 BCL2 apoptosis regulator Homo sapiens 292-297 11175751-4 2001 We demonstrate that antimycin A and a Bak BH3 peptide bind competitively to recombinant Bcl-2. Antimycin A 20-31 BCL2 apoptosis regulator Homo sapiens 88-93 11139401-6 2001 Overexpression of the apoptosis-inhibitory proto-oncogene Bcl-2, which encodes an inhibitor of the mitochondrial permeability transition (PT) pore, delayed both the DeltaPsi(m) disruption and the depletion of NAD(P)H. nad(p)h 209-216 BCL2 apoptosis regulator Homo sapiens 58-63 11175751-7 2001 Finally, antimycin A inhibits the pore-forming activity of Bcl-x L in synthetic liposomes, demonstrating that a small non-peptide ligand can directly inhibit the function of Bcl-2-related proteins. Antimycin A 9-20 BCL2 apoptosis regulator Homo sapiens 174-179 11139341-4 2001 To investigate the mechanism of action of Bcl-2-mediated inhibition of cyanide m-chlorophenylhydrazone-induced apoptosis, we measured the mitochondrial transmembrane potential (DeltaPsi(m)) after uncoupling mitochondrial electron transport and found that both HL-60 wild-type and Bcl-2-overexpressing cells similarly depolarize following cyanide m-chlorophenylhydrazone exposure. cyanide m-chlorophenylhydrazone 71-102 BCL2 apoptosis regulator Homo sapiens 42-47 11139341-4 2001 To investigate the mechanism of action of Bcl-2-mediated inhibition of cyanide m-chlorophenylhydrazone-induced apoptosis, we measured the mitochondrial transmembrane potential (DeltaPsi(m)) after uncoupling mitochondrial electron transport and found that both HL-60 wild-type and Bcl-2-overexpressing cells similarly depolarize following cyanide m-chlorophenylhydrazone exposure. cyanide m-chlorophenylhydrazone 338-369 BCL2 apoptosis regulator Homo sapiens 42-47 11139341-7 2001 Depletion of mitochondrial (but not cytosolic) glutathione induced apoptosis in Bcl-2-overexpressing cells and negated the protective effect of Bcl-2. Glutathione 47-58 BCL2 apoptosis regulator Homo sapiens 80-85 11139341-8 2001 Furthermore, following glutathione depletion, Bcl-2-overexpressing cells were sensitized to undergo cyanide m-chlorophenylhydrazone-induced apoptosis. Glutathione 23-34 BCL2 apoptosis regulator Homo sapiens 46-51 11139341-8 2001 Furthermore, following glutathione depletion, Bcl-2-overexpressing cells were sensitized to undergo cyanide m-chlorophenylhydrazone-induced apoptosis. cyanide m-chlorophenylhydrazone 100-131 BCL2 apoptosis regulator Homo sapiens 46-51 11299823-13 2001 Studies on PDT combination with agents targeting bcl-2 (i.e. taxanes) are on going to eventually assess a super-additive effect. Taxoids 61-68 BCL2 apoptosis regulator Homo sapiens 49-54 11313951-7 2001 Treatment of K562 cells with the histone deacetylase inhibitor, trichostatin A, resulted in an increase in bcl-2 promoter activity whether p53 was present or not. trichostatin A 64-78 BCL2 apoptosis regulator Homo sapiens 107-112 11313951-9 2001 Similar results were obtained when endogenous bcl-2 mRNA or protein levels were measured in response to either p53 or trichostatin A, and p53 expression resulted in enhanced apoptosis. trichostatin A 118-132 BCL2 apoptosis regulator Homo sapiens 46-51 11299723-6 2001 Moreover, the data imply that upregulation of bcl-2 is critical in the development of resistance to ara-C and ASNase in these leukemic lines. Cytarabine 100-105 BCL2 apoptosis regulator Homo sapiens 46-51 11299782-9 2001 CONCLUSIONS: The results indicated that the octreotide triggered an apoptosis-induction in a human pancreatic cancer xenograft, coupled with the increased dephosphorylation state in the tumors, but the mitotic activity was not affected and bcl-2 expression has not been induced. Octreotide 44-54 BCL2 apoptosis regulator Homo sapiens 240-245 11269744-0 2001 Cryptophycin-induced hyperphosphorylation of Bcl-2, cell cycle arrest and growth inhibition in human H460 NSCLC cells. cryptophycin 0-12 BCL2 apoptosis regulator Homo sapiens 45-50 11133770-5 2001 As(2)O(3)-induced apoptosis was decreased by tRA pretreatment of NB4 cells but not of R4 cells and was associated with a strong induction of Bfl-1/A1 expression, a Bcl-2 protein family member. (2)o(3) 2-9 BCL2 apoptosis regulator Homo sapiens 164-169 11908866-0 2001 Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Butyric Acid 39-54 BCL2 apoptosis regulator Homo sapiens 118-123 11908866-0 2001 Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. trichostatin A 59-73 BCL2 apoptosis regulator Homo sapiens 118-123 11716782-0 2001 The pro-apoptotic Bcl-2 family member tBid localizes to mitochondrial contact sites. tBID 38-42 BCL2 apoptosis regulator Homo sapiens 18-23 11716782-9 2001 These findings link these sites with cardiolipin in tBid targeting and suggest a role for Bcl-2 family members in regulating the activity of contact sites in relation to apoptosis. tBID 52-56 BCL2 apoptosis regulator Homo sapiens 90-95 11261829-0 2001 Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer. Tamoxifen 54-63 BCL2 apoptosis regulator Homo sapiens 28-33 11261829-3 2001 This study has tested the hypothesis that the degree of down-regulation of ER and the ER-regulated marker bcl-2 are associated with the quality and duration of tamoxifen response. Tamoxifen 160-169 BCL2 apoptosis regulator Homo sapiens 106-111 11261829-9 2001 This study demonstrates that greater down-regulation of ER and the ER-regulated protein bcl-2 on primary tamoxifen are significantly associated with a better quality of response and bcl-2 and the proliferation marker MIB1 a longer duration of response in ER+ve breast cancer. Tamoxifen 105-114 BCL2 apoptosis regulator Homo sapiens 88-93 11261829-9 2001 This study demonstrates that greater down-regulation of ER and the ER-regulated protein bcl-2 on primary tamoxifen are significantly associated with a better quality of response and bcl-2 and the proliferation marker MIB1 a longer duration of response in ER+ve breast cancer. Tamoxifen 105-114 BCL2 apoptosis regulator Homo sapiens 182-187 11269744-6 2001 Western blot analysis for Bcl-2 phosphorylation was carried out after 4 h and 24 h of exposure to cryptophycin 52, cryptophycin 55, paclitaxel or vinblastine. cryptophycin 98-110 BCL2 apoptosis regulator Homo sapiens 26-31 11269744-6 2001 Western blot analysis for Bcl-2 phosphorylation was carried out after 4 h and 24 h of exposure to cryptophycin 52, cryptophycin 55, paclitaxel or vinblastine. cryptophycin 115-127 BCL2 apoptosis regulator Homo sapiens 26-31 11531015-6 2001 Overexpression of the antiapoptotic Bcl-2 protein synergized with activation of the Raf/MEK/ERK cascade and increased the efficiency of transformation of FDC-PI and TF-1 cells. fdc-pi 154-160 BCL2 apoptosis regulator Homo sapiens 36-41 11269744-6 2001 Western blot analysis for Bcl-2 phosphorylation was carried out after 4 h and 24 h of exposure to cryptophycin 52, cryptophycin 55, paclitaxel or vinblastine. Paclitaxel 132-142 BCL2 apoptosis regulator Homo sapiens 26-31 11269744-6 2001 Western blot analysis for Bcl-2 phosphorylation was carried out after 4 h and 24 h of exposure to cryptophycin 52, cryptophycin 55, paclitaxel or vinblastine. Vinblastine 146-157 BCL2 apoptosis regulator Homo sapiens 26-31 11269744-7 2001 Cryptophycin 52 and cryptophycin 55 were very potent inducers of Bcl-2 phosphorylation. cryptophycin 0-12 BCL2 apoptosis regulator Homo sapiens 65-70 11269744-7 2001 Cryptophycin 52 and cryptophycin 55 were very potent inducers of Bcl-2 phosphorylation. cryptophycin 20-32 BCL2 apoptosis regulator Homo sapiens 65-70 11269744-8 2001 After 4 h of exposure, Bcl-2 phosphorylation was evident with 0.05 nM cryptophycin 52, 0.25 nM cryptophycin 55, 5 nM vinblastine and 50 nM paclitaxel. cryptophycin 70-82 BCL2 apoptosis regulator Homo sapiens 23-28 11352500-0 2001 Taxol induced Bcl-2 protein phosphorylation in human hepatocellular carcinoma QGY-7703 cell line. Paclitaxel 0-5 BCL2 apoptosis regulator Homo sapiens 14-19 11269744-8 2001 After 4 h of exposure, Bcl-2 phosphorylation was evident with 0.05 nM cryptophycin 52, 0.25 nM cryptophycin 55, 5 nM vinblastine and 50 nM paclitaxel. cryptophycin 95-107 BCL2 apoptosis regulator Homo sapiens 23-28 11352500-2 2001 Treatment of a human hepatocellular carcinoma cell line, QGY-7703, with Taxol induced apoptosis and Bcl-2 protein phosphorylation. Paclitaxel 72-77 BCL2 apoptosis regulator Homo sapiens 100-105 11269744-8 2001 After 4 h of exposure, Bcl-2 phosphorylation was evident with 0.05 nM cryptophycin 52, 0.25 nM cryptophycin 55, 5 nM vinblastine and 50 nM paclitaxel. Vinblastine 117-128 BCL2 apoptosis regulator Homo sapiens 23-28 11352500-4 2001 Bcl-2 protein was phosphorylated in Taxol-treated QGY cells within 3 h of treatment, and continued gradually up to 24 h. By 48 h, the protein was unphosphorylated. Paclitaxel 36-41 BCL2 apoptosis regulator Homo sapiens 0-5 11352500-7 2001 The inactivation of Bcl-2 protein phosphorylation could be one of the key mechanisms needed for the induction of apoptosis in Taxol-treated QGY cells. Paclitaxel 126-131 BCL2 apoptosis regulator Homo sapiens 20-25 11787859-0 2001 Role of Bcl-2 family proteins and caspase-3 in sanguinarine-induced bimodal cell death. sanguinarine 47-59 BCL2 apoptosis regulator Homo sapiens 8-13 11787859-2 2001 We previously demonstrated that sanguinarine treatment at a low level induced apoptosis or programmed cell death (PCD) in the Bcl-2 low-expressing K562 human erythroleukemia cells, and that a high level induced blister cell death (BCD); whereas Bcl-2 overexpressing, sanguinarine-treated JM1 pre-B lymphoblastic cells displayed neither apoptosis nor BCD morphologies. sanguinarine 32-44 BCL2 apoptosis regulator Homo sapiens 126-131 11787859-2 2001 We previously demonstrated that sanguinarine treatment at a low level induced apoptosis or programmed cell death (PCD) in the Bcl-2 low-expressing K562 human erythroleukemia cells, and that a high level induced blister cell death (BCD); whereas Bcl-2 overexpressing, sanguinarine-treated JM1 pre-B lymphoblastic cells displayed neither apoptosis nor BCD morphologies. sanguinarine 32-44 BCL2 apoptosis regulator Homo sapiens 245-250 11269744-8 2001 After 4 h of exposure, Bcl-2 phosphorylation was evident with 0.05 nM cryptophycin 52, 0.25 nM cryptophycin 55, 5 nM vinblastine and 50 nM paclitaxel. Paclitaxel 139-149 BCL2 apoptosis regulator Homo sapiens 23-28 11269744-9 2001 The hyperphosphorylated form of Bcl-2 was evident after 24 h exposure of H460 cells to 0.25 nM cryptophycin 52 or cryptophycin 55 and 50 nM vinblastine or paclitaxel. cryptophycin 95-107 BCL2 apoptosis regulator Homo sapiens 32-37 11269744-9 2001 The hyperphosphorylated form of Bcl-2 was evident after 24 h exposure of H460 cells to 0.25 nM cryptophycin 52 or cryptophycin 55 and 50 nM vinblastine or paclitaxel. cryptophycin 114-126 BCL2 apoptosis regulator Homo sapiens 32-37 11269744-9 2001 The hyperphosphorylated form of Bcl-2 was evident after 24 h exposure of H460 cells to 0.25 nM cryptophycin 52 or cryptophycin 55 and 50 nM vinblastine or paclitaxel. Vinblastine 140-151 BCL2 apoptosis regulator Homo sapiens 32-37 11269744-9 2001 The hyperphosphorylated form of Bcl-2 was evident after 24 h exposure of H460 cells to 0.25 nM cryptophycin 52 or cryptophycin 55 and 50 nM vinblastine or paclitaxel. Paclitaxel 155-165 BCL2 apoptosis regulator Homo sapiens 32-37 11269744-12 2001 In Bcl-2-negative Calu-6 NSCLC cells, 90% cell killing was obtained with 0.03 nM cryptophycin 52, 0.1 nM cryptophycin 55, 11 nM paclitaxel and 0.5 nM vinblastine using the same experimental design. cryptophycin 81-93 BCL2 apoptosis regulator Homo sapiens 3-8 11269744-13 2001 Thus, cryptophycins are potent inducers of Bcl-2 phosphorylation. Depsipeptides 6-19 BCL2 apoptosis regulator Homo sapiens 43-48 11269744-14 2001 The cryptophycins were more potent cytotoxic agents in Bcl-2-negative Calu-6 cells than in Bcl-2-positive H460 cells indicating that pathways triggered by Bcl-2 phosphorylation are involved in cryptophycin-induced lethality. Depsipeptides 4-17 BCL2 apoptosis regulator Homo sapiens 55-60 11269744-14 2001 The cryptophycins were more potent cytotoxic agents in Bcl-2-negative Calu-6 cells than in Bcl-2-positive H460 cells indicating that pathways triggered by Bcl-2 phosphorylation are involved in cryptophycin-induced lethality. Depsipeptides 4-17 BCL2 apoptosis regulator Homo sapiens 91-96 11269744-14 2001 The cryptophycins were more potent cytotoxic agents in Bcl-2-negative Calu-6 cells than in Bcl-2-positive H460 cells indicating that pathways triggered by Bcl-2 phosphorylation are involved in cryptophycin-induced lethality. Depsipeptides 4-17 BCL2 apoptosis regulator Homo sapiens 91-96 11269744-14 2001 The cryptophycins were more potent cytotoxic agents in Bcl-2-negative Calu-6 cells than in Bcl-2-positive H460 cells indicating that pathways triggered by Bcl-2 phosphorylation are involved in cryptophycin-induced lethality. cryptophycin 4-16 BCL2 apoptosis regulator Homo sapiens 55-60 11269744-14 2001 The cryptophycins were more potent cytotoxic agents in Bcl-2-negative Calu-6 cells than in Bcl-2-positive H460 cells indicating that pathways triggered by Bcl-2 phosphorylation are involved in cryptophycin-induced lethality. cryptophycin 4-16 BCL2 apoptosis regulator Homo sapiens 91-96 11269744-14 2001 The cryptophycins were more potent cytotoxic agents in Bcl-2-negative Calu-6 cells than in Bcl-2-positive H460 cells indicating that pathways triggered by Bcl-2 phosphorylation are involved in cryptophycin-induced lethality. cryptophycin 4-16 BCL2 apoptosis regulator Homo sapiens 91-96 11530860-1 2001 PURPOSE: To study the immunolocalization of the Bcl-2 protein in formalin-fixed placental tissue collected from uncomplicated term pregnancies. Formaldehyde 65-73 BCL2 apoptosis regulator Homo sapiens 48-53 11120600-0 2001 Differential effects of bcl-2 on cell death triggered under ATP-depleting conditions. Adenosine Triphosphate 60-63 BCL2 apoptosis regulator Homo sapiens 24-29 11120600-2 2001 Bcl-2 can block apoptotic demise, which occurs preferably under conditions of high cellular ATP levels. Adenosine Triphosphate 92-95 BCL2 apoptosis regulator Homo sapiens 0-5 11120600-6 2001 Thus, the antiapoptotic protein Bcl-2 can reduce the overall amount of cell death in ATP-depleted cells regardless whether it occurs by apoptosis or necrosis. Adenosine Triphosphate 85-88 BCL2 apoptosis regulator Homo sapiens 32-37 11120600-9 2001 Therefore, the mechanisms whereby Bcl-2 prevents cell death and favors retention of cytochrome c in the mitochondria require neither the maintenance of mitochondrial DeltaPsi nor the maintenance of normal ATP levels. Adenosine Triphosphate 205-208 BCL2 apoptosis regulator Homo sapiens 34-39 11722998-4 2001 In Section I Dr. Richard Klasa presents preclinical data on the use of antisense oligonucleotides directed at the bcl-2 gene message to specifically downregulate Bcl-2 protein expression in non-Hodgkin"s lymphomas and render the cells more susceptible to the induction of apoptosis. Oligonucleotides 81-97 BCL2 apoptosis regulator Homo sapiens 114-119 11855781-11 2001 DXM and GM-CSF-driven apoptosis was reversibly associated with bcl-2-expression (bcl-2-dependent mechanism). Dexamethasone 0-3 BCL2 apoptosis regulator Homo sapiens 63-68 11722998-4 2001 In Section I Dr. Richard Klasa presents preclinical data on the use of antisense oligonucleotides directed at the bcl-2 gene message to specifically downregulate Bcl-2 protein expression in non-Hodgkin"s lymphomas and render the cells more susceptible to the induction of apoptosis. Oligonucleotides 81-97 BCL2 apoptosis regulator Homo sapiens 162-167 11855781-11 2001 DXM and GM-CSF-driven apoptosis was reversibly associated with bcl-2-expression (bcl-2-dependent mechanism). Dexamethasone 0-3 BCL2 apoptosis regulator Homo sapiens 81-86 11329613-7 2001 Actually, cycloheximide alone was able to induce hepatoma cell BEL7404 to death that could also be inhibited by over-expressing Bcl-2. Cycloheximide 10-23 BCL2 apoptosis regulator Homo sapiens 128-133 11165716-7 2001 Transfection of Jurkat cells with Bcl-2 prevented DMA-2,4-D-induced disruption of the mitochondrial transmembrane potential and led to a complete blockage of apoptosis. dma-2 50-55 BCL2 apoptosis regulator Homo sapiens 34-39 11165716-7 2001 Transfection of Jurkat cells with Bcl-2 prevented DMA-2,4-D-induced disruption of the mitochondrial transmembrane potential and led to a complete blockage of apoptosis. 4-d 56-59 BCL2 apoptosis regulator Homo sapiens 34-39 11135048-0 2001 Expression of CD34 and bcl-2 in phyllodes tumours, fibroadenomas and spindle cell lesions of the breast. phyllodes 32-41 BCL2 apoptosis regulator Homo sapiens 23-28 11147815-7 2001 The overexpression of human Bcl-2 suppressed apoptosis, indicating that the cytosol from concanamycin A-treated HS-72 cells induces apoptosis by a Bcl-2-inhibiting mechanism. concanamycin A 89-103 BCL2 apoptosis regulator Homo sapiens 28-33 11935678-5 2001 Expression of bcl-2 gene was measured with a reverse transcription method by a synthesis of cDNA and amplification of gene fragment with specific oligonucleotides in polymerase chain reaction (RT-PCR). Oligonucleotides 146-162 BCL2 apoptosis regulator Homo sapiens 14-19 11158204-2 2001 Phosphorylation of Bcl2 at serine 70 is required for suppression of apoptosis in interleukin 3 (IL-3)-dependent myeloid cells deprived of IL-3 or treated with antileukemic drugs and can result from agonist activation of mitochondrial protein kinase C alpha (PKCalpha). Serine 27-33 BCL2 apoptosis regulator Homo sapiens 19-23 11158204-3 2001 However, we have recently found that high concentrations of staurosporine up to 1 microM: can only partially inhibit IL-3-stimulated Bcl2 phosphorylation but completely block PKCalpha-mediated Bcl2 phosphorylation in vitro, indicating the existence of a non-PKC, staurosporine-resistant Bcl2 kinase (SRK). Staurosporine 60-73 BCL2 apoptosis regulator Homo sapiens 133-137 11158204-3 2001 However, we have recently found that high concentrations of staurosporine up to 1 microM: can only partially inhibit IL-3-stimulated Bcl2 phosphorylation but completely block PKCalpha-mediated Bcl2 phosphorylation in vitro, indicating the existence of a non-PKC, staurosporine-resistant Bcl2 kinase (SRK). Staurosporine 60-73 BCL2 apoptosis regulator Homo sapiens 193-197 11158204-7 2001 These findings indicate a novel role for ERK1 and 2 as molecular links between proliferative and survival signaling and may, at least in part, explain the apparent paradox by which Bcl2 may suppress staurosporine-induced apoptosis. Staurosporine 199-212 BCL2 apoptosis regulator Homo sapiens 181-185 11497100-2 2001 Available data suggest that there are at least three main pathways by which sphingosine and its metabolites affect Ca2+ fluxes in different cell types: (1) indirect action on Ca2+ stores, mediated by other transduction pathways; (2) direct action on the receptors of Ca2+ channels and Ca2+ pumps which are localized at the membranes of Ca2+ stores; (3) indirect action mediated by the regulation of expression of the channel-forming protein Bcl-2, which incorporates into membranes of Ca2+ stores. Sphingosine 76-87 BCL2 apoptosis regulator Homo sapiens 441-446 11358275-5 2001 The results show an increased level of serine/tyrosine phosphorylated Bcl-2 in nuclear membranes of hypoxic animals. Serine 39-45 BCL2 apoptosis regulator Homo sapiens 70-75 11358275-5 2001 The results show an increased level of serine/tyrosine phosphorylated Bcl-2 in nuclear membranes of hypoxic animals. Tyrosine 46-54 BCL2 apoptosis regulator Homo sapiens 70-75 11326318-2 2001 Phosphorylation of the Bcl-2 protein is induced on serine residues in tumor cells arrested by microtubule-targeting drugs (paclitaxel, vincristine, nocodazole) and has been associated with inactivation of antiapoptotic function through an unknown mechanism. Serine 51-57 BCL2 apoptosis regulator Homo sapiens 23-28 11326318-2 2001 Phosphorylation of the Bcl-2 protein is induced on serine residues in tumor cells arrested by microtubule-targeting drugs (paclitaxel, vincristine, nocodazole) and has been associated with inactivation of antiapoptotic function through an unknown mechanism. Paclitaxel 123-133 BCL2 apoptosis regulator Homo sapiens 23-28 11326318-2 2001 Phosphorylation of the Bcl-2 protein is induced on serine residues in tumor cells arrested by microtubule-targeting drugs (paclitaxel, vincristine, nocodazole) and has been associated with inactivation of antiapoptotic function through an unknown mechanism. Vincristine 135-146 BCL2 apoptosis regulator Homo sapiens 23-28 11326318-2 2001 Phosphorylation of the Bcl-2 protein is induced on serine residues in tumor cells arrested by microtubule-targeting drugs (paclitaxel, vincristine, nocodazole) and has been associated with inactivation of antiapoptotic function through an unknown mechanism. Nocodazole 148-158 BCL2 apoptosis regulator Homo sapiens 23-28 11326318-3 2001 Comparison of a variety of pharmacological inhibitors of serine/threonine-specific protein kinases demonstrated that the cyclin-dependent kinase inhibitor, flavopiridol, selectively blocks Bcl-2 phosphorylation induced by antimicrotubule drugs. alvocidib 156-168 BCL2 apoptosis regulator Homo sapiens 189-194 11326318-5 2001 Examination of several serine-->alanine substitution mutants of Bcl-2 suggested that serine 70 and serine 87 represent major sites of Bcl-2 phosphorylation induced in response to microtubule-targeting drugs. Serine 23-29 BCL2 apoptosis regulator Homo sapiens 67-72 11326318-5 2001 Examination of several serine-->alanine substitution mutants of Bcl-2 suggested that serine 70 and serine 87 represent major sites of Bcl-2 phosphorylation induced in response to microtubule-targeting drugs. Alanine 35-42 BCL2 apoptosis regulator Homo sapiens 67-72 11326318-5 2001 Examination of several serine-->alanine substitution mutants of Bcl-2 suggested that serine 70 and serine 87 represent major sites of Bcl-2 phosphorylation induced in response to microtubule-targeting drugs. Serine 88-94 BCL2 apoptosis regulator Homo sapiens 67-72 11326318-5 2001 Examination of several serine-->alanine substitution mutants of Bcl-2 suggested that serine 70 and serine 87 represent major sites of Bcl-2 phosphorylation induced in response to microtubule-targeting drugs. Serine 88-94 BCL2 apoptosis regulator Homo sapiens 137-142 11326318-5 2001 Examination of several serine-->alanine substitution mutants of Bcl-2 suggested that serine 70 and serine 87 represent major sites of Bcl-2 phosphorylation induced in response to microtubule-targeting drugs. Serine 88-94 BCL2 apoptosis regulator Homo sapiens 67-72 11326318-5 2001 Examination of several serine-->alanine substitution mutants of Bcl-2 suggested that serine 70 and serine 87 represent major sites of Bcl-2 phosphorylation induced in response to microtubule-targeting drugs. Serine 88-94 BCL2 apoptosis regulator Homo sapiens 137-142 11326318-9 2001 Since the region in Bcl-2 containing serine 70 and serine 87 represents a proline-rich loop that has been associated with autorepression of its antiapoptotic activity, the discovery of Pin1 interactions with phosphorylated Bcl-2 raises the possibility that Pin1 alters the conformation of Bcl-2 and thereby modulates its function in cells arrested with antimicrotubule drugs. Serine 37-43 BCL2 apoptosis regulator Homo sapiens 20-25 11326318-9 2001 Since the region in Bcl-2 containing serine 70 and serine 87 represents a proline-rich loop that has been associated with autorepression of its antiapoptotic activity, the discovery of Pin1 interactions with phosphorylated Bcl-2 raises the possibility that Pin1 alters the conformation of Bcl-2 and thereby modulates its function in cells arrested with antimicrotubule drugs. Proline 74-81 BCL2 apoptosis regulator Homo sapiens 20-25 11377843-0 2001 Enhanced axonal growth from fetal human bcl-2 transgenic mouse dopamine neurons transplanted to the adult rat striatum. Dopamine 63-71 BCL2 apoptosis regulator Homo sapiens 40-45 11574780-6 2001 Tumour response to in vivo drug treatment was associated with an early down-regulation of Bcl-2, which was somewhat more marked for the aza compound. Azathioprine 136-139 BCL2 apoptosis regulator Homo sapiens 90-95 11346685-2 2001 These agents include the epidermal growth factor tyrosine kinase inhibitors, the farnesyl transferase inhibitors, and bcl-2 antisense oligonucleotides. Oligonucleotides 134-150 BCL2 apoptosis regulator Homo sapiens 118-123 11641617-0 2001 Differential effects of sex steroids on T and B cells: modulation of cell cycle phase distribution, apoptosis and bcl-2 protein levels. Steroids 28-36 BCL2 apoptosis regulator Homo sapiens 114-119 11770015-1 2001 Our previous studies with low Bcl-2-expressing K562 cells have shown that, when treated with the putative anti-cancer drug sanguinarine, concentrations of 1.5 microg/ml induced the morphology of apoptosis or programmed cell death (PCD), while concentrations of 12.5 microg/ml induced a morphology of blister formation or blister cell death (BCD). sanguinarine 123-135 BCL2 apoptosis regulator Homo sapiens 30-35 11770015-4 2001 Thus, the over-expression of anti-apoptotic Bcl-2 may have prevented sanguinarine from inducing PCD and BCD in JM1 cells. sanguinarine 69-81 BCL2 apoptosis regulator Homo sapiens 44-49 11770015-5 2001 These results indicate that the resistance of JM1 cells to the alkaloid sanguinarine may have been due to an anti-BCD role played by Bcl-2, in addition to its widely reported anti-apoptotic role. sanguinarine 72-84 BCL2 apoptosis regulator Homo sapiens 133-138 12050821-0 2001 Effects of Cyclosporine A and Highly Expressed Bcl-2 on Apoptosis of HL-60 Cells Induced by EGTA. Egtazic Acid 92-96 BCL2 apoptosis regulator Homo sapiens 47-52 11865975-0 2001 BCL-2 is involved in preventing oxidant-induced cell death and in decreasing oxygen radical production. Reactive Oxygen Species 77-91 BCL2 apoptosis regulator Homo sapiens 0-5 11865975-2 2001 Furthermore, it has been proposed that BCL-2 acts to inhibit cell death by interfering with the production of oxygen-derived free radicals induced by a wide variety of stimuli. Oxygen 110-116 BCL2 apoptosis regulator Homo sapiens 39-44 11865975-2 2001 Furthermore, it has been proposed that BCL-2 acts to inhibit cell death by interfering with the production of oxygen-derived free radicals induced by a wide variety of stimuli. derived free radicals 117-138 BCL2 apoptosis regulator Homo sapiens 39-44 11865975-4 2001 Compared to Neo control cells, BCL-2-expressing cells are more resistant to the killing and growth retardation induced by hydrogen peroxide, superoxide, or by the oxygen radical-generating quinone-containing compounds menadione, diaziquone and adriamycin. Hydrogen Peroxide 122-139 BCL2 apoptosis regulator Homo sapiens 31-36 11865975-4 2001 Compared to Neo control cells, BCL-2-expressing cells are more resistant to the killing and growth retardation induced by hydrogen peroxide, superoxide, or by the oxygen radical-generating quinone-containing compounds menadione, diaziquone and adriamycin. Superoxides 141-151 BCL2 apoptosis regulator Homo sapiens 31-36 11865975-4 2001 Compared to Neo control cells, BCL-2-expressing cells are more resistant to the killing and growth retardation induced by hydrogen peroxide, superoxide, or by the oxygen radical-generating quinone-containing compounds menadione, diaziquone and adriamycin. Reactive Oxygen Species 163-177 BCL2 apoptosis regulator Homo sapiens 31-36 11865975-4 2001 Compared to Neo control cells, BCL-2-expressing cells are more resistant to the killing and growth retardation induced by hydrogen peroxide, superoxide, or by the oxygen radical-generating quinone-containing compounds menadione, diaziquone and adriamycin. quinone 189-196 BCL2 apoptosis regulator Homo sapiens 31-36 11865975-4 2001 Compared to Neo control cells, BCL-2-expressing cells are more resistant to the killing and growth retardation induced by hydrogen peroxide, superoxide, or by the oxygen radical-generating quinone-containing compounds menadione, diaziquone and adriamycin. Vitamin K 3 218-227 BCL2 apoptosis regulator Homo sapiens 31-36 11865975-4 2001 Compared to Neo control cells, BCL-2-expressing cells are more resistant to the killing and growth retardation induced by hydrogen peroxide, superoxide, or by the oxygen radical-generating quinone-containing compounds menadione, diaziquone and adriamycin. diaziquone 229-239 BCL2 apoptosis regulator Homo sapiens 31-36 11865975-4 2001 Compared to Neo control cells, BCL-2-expressing cells are more resistant to the killing and growth retardation induced by hydrogen peroxide, superoxide, or by the oxygen radical-generating quinone-containing compounds menadione, diaziquone and adriamycin. Doxorubicin 244-254 BCL2 apoptosis regulator Homo sapiens 31-36 11865975-7 2001 Hydroxyl radical levels generated by the quinone-containing agents were low in BCL-2-expressing JB6 cells compared to control Neo cells. Hydroxyl Radical 0-16 BCL2 apoptosis regulator Homo sapiens 79-84 11865975-7 2001 Hydroxyl radical levels generated by the quinone-containing agents were low in BCL-2-expressing JB6 cells compared to control Neo cells. quinone 41-48 BCL2 apoptosis regulator Homo sapiens 79-84 11865975-9 2001 On the other hand, the glutathione concentrations increased in BCL-2 overexpressing cells after oxidative challenge, while the opposite was true for control cells. Glutathione 23-34 BCL2 apoptosis regulator Homo sapiens 63-68 11865975-10 2001 Thus, our results suggest that BCL-2 inhibition of oxidant-induced cell death is mediated, at least in part, through an antioxidant pathway, and that this pathway involves glutathione. Glutathione 172-183 BCL2 apoptosis regulator Homo sapiens 31-36 12050821-1 2001 Effects of mitochondrial permeability transition pore-specific inhibitor cyclosporine A (CsA) and highly expressed Bcl-2 on the apoptosis of HL-60 cells induced by EGTA were studied. Egtazic Acid 164-168 BCL2 apoptosis regulator Homo sapiens 115-120 11785103-0 2001 [Role of the antioxidant system and redox-dependent regulation of transcription factors bcl-2 and p53 in forming resistance of human K562 erythroleukemia cells to doxorubicin]. Doxorubicin 163-174 BCL2 apoptosis regulator Homo sapiens 88-93 11669559-7 2001 Immunolocalization of the bcl-2 oncoprotein was performed using the labeled streptavidin biotin (LSAB) method. Biotin 89-95 BCL2 apoptosis regulator Homo sapiens 26-31 11669559-6 2001 Formalin-fixed, paraffin-embedded tissues were treated with anti-bcl-2 antibody (Dako No M0887). Formaldehyde 0-8 BCL2 apoptosis regulator Homo sapiens 65-70 10993881-5 2000 It appears that LIGHT and IFN-gamma act synergistically to activate caspase-3, with the resultant cleavage of Bcl-2, removal of the BH4 domain, leading to conversion of Bcl-2 from an antiapoptotic to a proapoptotic form in p53-deficient hepatocellular carcinoma Hep3BT2 cells. sapropterin 132-135 BCL2 apoptosis regulator Homo sapiens 169-174 10993881-7 2000 Although benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethylketone and benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone can prevent the cleavage of Bcl-2 by LIGHT/IFN-gamma, they only partially inhibit apoptosis in Hep3BT2 cells that are overexpressing Bcl-2. benzyloxycarbonyl-asp-glu-val-asp-fluoromethylketone 9-61 BCL2 apoptosis regulator Homo sapiens 143-148 10993881-7 2000 Although benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethylketone and benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone can prevent the cleavage of Bcl-2 by LIGHT/IFN-gamma, they only partially inhibit apoptosis in Hep3BT2 cells that are overexpressing Bcl-2. benzyloxycarbonyl-asp-glu-val-asp-fluoromethylketone 9-61 BCL2 apoptosis regulator Homo sapiens 248-253 10993881-7 2000 Although benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethylketone and benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone can prevent the cleavage of Bcl-2 by LIGHT/IFN-gamma, they only partially inhibit apoptosis in Hep3BT2 cells that are overexpressing Bcl-2. Caspase Inhibitor VI 66-114 BCL2 apoptosis regulator Homo sapiens 143-148 10993881-7 2000 Although benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethylketone and benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone can prevent the cleavage of Bcl-2 by LIGHT/IFN-gamma, they only partially inhibit apoptosis in Hep3BT2 cells that are overexpressing Bcl-2. Caspase Inhibitor VI 66-114 BCL2 apoptosis regulator Homo sapiens 248-253 11716437-0 2000 A model for the interaction of paclitaxel with the Bcl-2 loop domain: a chemical approach to induce conformation-dependent phosphorylation. Paclitaxel 31-41 BCL2 apoptosis regulator Homo sapiens 51-56 11716437-2 2000 Paclitaxel and baccatin III were individually docked into the Bcl-2 loop domain. Paclitaxel 0-10 BCL2 apoptosis regulator Homo sapiens 62-67 11716437-2 2000 Paclitaxel and baccatin III were individually docked into the Bcl-2 loop domain. baccatin III 15-27 BCL2 apoptosis regulator Homo sapiens 62-67 11716437-5 2000 It was found that both paclitaxel"s core skeleton and its C-13 side chain contribute significantly to its interaction with Bcl-2. Paclitaxel 23-33 BCL2 apoptosis regulator Homo sapiens 123-128 11716437-6 2000 A portion of the Bcl-2 loop domain was found to be locked by the bound paclitaxel and baccatin III in a similar conformation. Paclitaxel 71-81 BCL2 apoptosis regulator Homo sapiens 17-22 11716437-6 2000 A portion of the Bcl-2 loop domain was found to be locked by the bound paclitaxel and baccatin III in a similar conformation. baccatin III 86-98 BCL2 apoptosis regulator Homo sapiens 17-22 11139434-4 2000 Levamisole increased in ECs integrin-dependent matrix adhesion, inhibited proliferation (-70%), reduced expression of survival factors such as clusterin (-30%), endothelin-1 (-43%), bcl-2 (-34%), endothelial NO-synthase (-32%) and pRb (Retinoblastoma protein: -89%), and increased that of growth arrest/death signals such as p21 (+73%) and bak (+50%). Levamisole 0-10 BCL2 apoptosis regulator Homo sapiens 182-187 11090099-0 2000 Effect of saikosaponin, a triterpene saponin, on apoptosis in lymphocytes: association with c-myc, p53, and bcl-2 mRNA. saikosaponin D 10-22 BCL2 apoptosis regulator Homo sapiens 108-113 11090099-0 2000 Effect of saikosaponin, a triterpene saponin, on apoptosis in lymphocytes: association with c-myc, p53, and bcl-2 mRNA. Saponins 15-22 BCL2 apoptosis regulator Homo sapiens 108-113 11078807-5 2000 In contrast, 5 mM NaBt-induced apoptotic cell death in ACHN cells, accompanied by up-regulation of BaK and down-regulation of Bcl-2. NABT 18-22 BCL2 apoptosis regulator Homo sapiens 126-131 11090099-21 2000 It is suggested that the apoptotic effect of saikosaponin-d may be partly mediated by increases in c-myc and p53 mRNA levels accompanied by a decrease in bcl-2 mRNA level. saikosaponin D 45-59 BCL2 apoptosis regulator Homo sapiens 154-159 11175264-1 2000 To understand the roles of bcl-2 for the survival of leukemic cells, we constructed human leukemic HL60 transformant lines in which full length bcl-2 antisense message was conditionally expressed by a tetracycline-regulatable expression system. Tetracycline 201-213 BCL2 apoptosis regulator Homo sapiens 144-149 11156256-15 2000 One possible mechanism may be the modulatory effects of bryostatin 1 on the Bax:Bcl-2 family of apoptosis-regulatory proteins. bryostatin 1 56-68 BCL2 apoptosis regulator Homo sapiens 80-85 11153146-6 2000 CONCLUSIONS: This data indicates that in high-risk breast cancer patients the immunohistochemical evaluation of p53 and bcl-2 may be of clinical value in distinguishing different responses to adjuvant anthracycline-based chemotherapy. Anthracyclines 201-214 BCL2 apoptosis regulator Homo sapiens 120-125 11080180-8 2000 Bcl-2 is a stronger inhibitor of cytochrome c release than zVAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 59-67 BCL2 apoptosis regulator Homo sapiens 0-5 11153146-0 2000 Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy. Anthracyclines 80-93 BCL2 apoptosis regulator Homo sapiens 16-21 11426618-5 2000 Increased expression of the leukocyte integrins CD11b and CD18 as well as down-regulation of the anti-apoptotic gene bcl-2 are associated with late stage differentiation of the myeloid lineage and retinoic acid induced maturation of acute myeloid leukemic cells. Tretinoin 197-210 BCL2 apoptosis regulator Homo sapiens 117-122 11110847-8 2000 Therefore, the mechanism of genistein-induced apoptosis at this concentration might rely largely on the stress pathway rather than the pathway mediated by the Bcl-2 family of proteins. Genistein 28-37 BCL2 apoptosis regulator Homo sapiens 159-164 11426618-7 2000 Following 24 hrs exposure to 20 microM lovastatin, all 7 acute myeloid leukemia cell lines tested showed a decrease in bcl-2 mRNA expression while only 1/5 acute lymphocytic leukemia cell lines showed a similar response. Lovastatin 39-49 BCL2 apoptosis regulator Homo sapiens 119-124 11426618-8 2000 A role for bcl-2 in the apoptotic response of acute myeloid leukemia cells to lovastatin was demonstrated as exogenous constitutive expression of bcl-2 in the AML-5 cell line inhibited apoptosis in a time and dose dependent manner. Lovastatin 78-88 BCL2 apoptosis regulator Homo sapiens 11-16 11426618-8 2000 A role for bcl-2 in the apoptotic response of acute myeloid leukemia cells to lovastatin was demonstrated as exogenous constitutive expression of bcl-2 in the AML-5 cell line inhibited apoptosis in a time and dose dependent manner. Lovastatin 78-88 BCL2 apoptosis regulator Homo sapiens 146-151 11095980-5 2000 NGF withdrawal induces p38 MAPK, but not JNK, activation in CESS cells, and SB203580, a specific inhibitor of p38 MAPK, is able to prevent both Bcl-2 phosphorylation and apoptosis, indicating that p38 MAPK is the enzyme responsible for these events. SB 203580 76-84 BCL2 apoptosis regulator Homo sapiens 144-149 11866947-8 2000 bcl-2 oncoprotein expression rate was significantly lower in cerulenin-treated group in comparing with the control group. Cerulenin 61-70 BCL2 apoptosis regulator Homo sapiens 0-5 11778475-0 2000 [Bcl-2 antisense oligodeoxyribonucleotide increases apoptosis of lung carcinoma cells induced by cisplatin]. Oligodeoxyribonucleotides 17-41 BCL2 apoptosis regulator Homo sapiens 1-6 11778475-0 2000 [Bcl-2 antisense oligodeoxyribonucleotide increases apoptosis of lung carcinoma cells induced by cisplatin]. Cisplatin 97-106 BCL2 apoptosis regulator Homo sapiens 1-6 11778475-1 2000 OBJECTIVE: To study the effect of antisense oligodeoxyribonucleotide (ODN) to apoptotic suppress gene bcl-2 on apoptosis of lung carcinoma cells induced by cisplatin. Oligodeoxyribonucleotides 44-68 BCL2 apoptosis regulator Homo sapiens 102-107 11135700-3 2000 RESULTS: Arsenic trioxide could strongly inhibit the growth of human hepatocarcinoma cells QGY-7701 and QGY-7703 with the cell cycle arrested on S phase, and induce the apoptosis of the cells with bcl-2 gene expression down-regulated and bax and Fas gene expression up-regulated. Arsenic Trioxide 9-25 BCL2 apoptosis regulator Homo sapiens 197-202 11866947-11 2000 The mechanism of cell death may be correlated with apoptosis, and bcl-2 and bax gene may play an important role in regulating cerulenin-induced apoptosis. Cerulenin 126-135 BCL2 apoptosis regulator Homo sapiens 66-71 12578669-6 2000 At the same time, the high concentration of As(2)O(3) downregulated expression of bcl-2 and resulted in karyopyknosis and cytoplasm condensation; low concentration generated similar effect on expression of bcl-2 and cell morphology in high-risk group, but did not affect in low-risk. Arsenic Trioxide 44-53 BCL2 apoptosis regulator Homo sapiens 82-87 12578669-6 2000 At the same time, the high concentration of As(2)O(3) downregulated expression of bcl-2 and resulted in karyopyknosis and cytoplasm condensation; low concentration generated similar effect on expression of bcl-2 and cell morphology in high-risk group, but did not affect in low-risk. Arsenic Trioxide 44-53 BCL2 apoptosis regulator Homo sapiens 206-211 11778475-1 2000 OBJECTIVE: To study the effect of antisense oligodeoxyribonucleotide (ODN) to apoptotic suppress gene bcl-2 on apoptosis of lung carcinoma cells induced by cisplatin. Oligodeoxyribonucleotides 70-73 BCL2 apoptosis regulator Homo sapiens 102-107 11778475-1 2000 OBJECTIVE: To study the effect of antisense oligodeoxyribonucleotide (ODN) to apoptotic suppress gene bcl-2 on apoptosis of lung carcinoma cells induced by cisplatin. Cisplatin 156-165 BCL2 apoptosis regulator Homo sapiens 102-107 11778475-14 2000 CONCLUSION: Antisense oligodeoxyribonucleotide to bcl-2 can inhibit significantly the expression of bcl-2 of lung cancer cells and increase apoptosis of cancer cells induced by cisplatin. Oligodeoxyribonucleotides 22-46 BCL2 apoptosis regulator Homo sapiens 50-55 11044365-0 2000 Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status. Fluorouracil 33-47 BCL2 apoptosis regulator Homo sapiens 0-5 11778475-14 2000 CONCLUSION: Antisense oligodeoxyribonucleotide to bcl-2 can inhibit significantly the expression of bcl-2 of lung cancer cells and increase apoptosis of cancer cells induced by cisplatin. Oligodeoxyribonucleotides 22-46 BCL2 apoptosis regulator Homo sapiens 100-105 11778475-14 2000 CONCLUSION: Antisense oligodeoxyribonucleotide to bcl-2 can inhibit significantly the expression of bcl-2 of lung cancer cells and increase apoptosis of cancer cells induced by cisplatin. Cisplatin 177-186 BCL2 apoptosis regulator Homo sapiens 50-55 11102893-8 2000 SDNA was greater in p53-positive and bcl-2-negative cases; SDNP was greater in p53-positive cases; SHF was lower in p53- and c-myc-positive cases. sdna 0-4 BCL2 apoptosis regulator Homo sapiens 37-42 11020446-0 2000 Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01). Cytarabine 16-49 BCL2 apoptosis regulator Homo sapiens 140-145 11020446-0 2000 Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01). 7-hydroxystaurosporine 170-192 BCL2 apoptosis regulator Homo sapiens 140-145 11020446-5 2000 Examination of cells at later intervals revealed that ectopic expression of Bcl-2 or Bcl-2Delta(32-80) could only delay, but not prevent, mitochondrial damage, caspase activation, and cell death induced by ara-C/UCN-01 treatment. Cytarabine 206-211 BCL2 apoptosis regulator Homo sapiens 76-81 11020446-5 2000 Examination of cells at later intervals revealed that ectopic expression of Bcl-2 or Bcl-2Delta(32-80) could only delay, but not prevent, mitochondrial damage, caspase activation, and cell death induced by ara-C/UCN-01 treatment. Cytarabine 206-211 BCL2 apoptosis regulator Homo sapiens 85-90 11072095-5 2000 Under this condition, bcl-2 mRNA levels were significantly increased over time by retinoid treatment, whereas bax mRNA levels were not affected. Retinoids 82-90 BCL2 apoptosis regulator Homo sapiens 22-27 11205313-3 2000 RESULTS: The techniques used herein determined accumulation of paclitaxel/PSC 833 induced apoptotic cells with sub-G0 (hypodiploid) DNA content and blocked in the G2/M phase of the cell cycle, internucleosomal DNA fragmentation, poly (ADP-ribose) polymerase cleavage, Bcl-2 modulation and Bax up-regulation, without any significant alterations in the levels of Bcl-xL, CD95/Fas or Fas-L proteins. Paclitaxel 63-73 BCL2 apoptosis regulator Homo sapiens 268-273 11044365-9 2000 Moreover, after 5-FU exposure, Bax and Bcl-2 proteins regulation was under p53 protein control and a statistically significant relationship (r = 0.880, P = 0.0097) was observed between Bcl-2/Bax ratio and 5-FU sensitivity. Fluorouracil 16-20 BCL2 apoptosis regulator Homo sapiens 39-44 11044365-9 2000 Moreover, after 5-FU exposure, Bax and Bcl-2 proteins regulation was under p53 protein control and a statistically significant relationship (r = 0.880, P = 0.0097) was observed between Bcl-2/Bax ratio and 5-FU sensitivity. Fluorouracil 16-20 BCL2 apoptosis regulator Homo sapiens 185-190 11044365-9 2000 Moreover, after 5-FU exposure, Bax and Bcl-2 proteins regulation was under p53 protein control and a statistically significant relationship (r = 0.880, P = 0.0097) was observed between Bcl-2/Bax ratio and 5-FU sensitivity. Fluorouracil 205-209 BCL2 apoptosis regulator Homo sapiens 39-44 11044365-9 2000 Moreover, after 5-FU exposure, Bax and Bcl-2 proteins regulation was under p53 protein control and a statistically significant relationship (r = 0.880, P = 0.0097) was observed between Bcl-2/Bax ratio and 5-FU sensitivity. Fluorouracil 205-209 BCL2 apoptosis regulator Homo sapiens 185-190 11044365-10 2000 In conclusion, whatever p53 status, Bcl-2 or Bax induction and Bcl-2/Bax protein ratio were correlated to 5-FU sensitivity. Fluorouracil 106-110 BCL2 apoptosis regulator Homo sapiens 36-41 11044365-10 2000 In conclusion, whatever p53 status, Bcl-2 or Bax induction and Bcl-2/Bax protein ratio were correlated to 5-FU sensitivity. Fluorouracil 106-110 BCL2 apoptosis regulator Homo sapiens 63-68 11095261-17 2000 INTERPRETATION: Systemic administration of augmerosen downregulated the target BCL2 protein in metastatic cancer. oblimersen 43-53 BCL2 apoptosis regulator Homo sapiens 79-83 11080152-2 2000 We found that dexamethasone-activated endogenous and exogenous GR inhibit p53-dependent functions, including transactivation, up- (Bax and p21(WAF1/CIP1)) and down- (Bcl2) regulation of endogenous genes, cell cycle arrest and apoptosis. Dexamethasone 14-27 BCL2 apoptosis regulator Homo sapiens 166-170 11103805-0 2000 Modulation of mitogen-activated protein kinases and phosphorylation of Bcl-2 by vinblastine represent persistent forms of normal fluctuations at G2-M1. Vinblastine 80-91 BCL2 apoptosis regulator Homo sapiens 71-76 11103805-5 2000 We show that Bcl-2 phosphorylation and JNK activation, as well as extracellular response kinase and p38 inactivation, occur not only in response to vinblastine but also as discrete transient events at G2-M phase in untreated synchronized KB-3 cells. Vinblastine 148-159 BCL2 apoptosis regulator Homo sapiens 13-18 11087334-6 2000 5"-Thiol derivatized phosphorothioate-ODNs directed against the protooncogene bcl-2 were conjugated to this maleimido-modified peptide. 5"-thiol 0-8 BCL2 apoptosis regulator Homo sapiens 78-83 11087334-6 2000 5"-Thiol derivatized phosphorothioate-ODNs directed against the protooncogene bcl-2 were conjugated to this maleimido-modified peptide. Parathion 21-37 BCL2 apoptosis regulator Homo sapiens 78-83 11023998-5 2000 In addition to inhibiting caspase-3 through a dithiothreitol-sensitive S-nitrosylation process, preconditioning stress concomitantly up-regulated the expression of the anti-apoptotic bcl-2 protein and down-regulated the p66shc adaptor protein. Dithiothreitol 46-60 BCL2 apoptosis regulator Homo sapiens 183-188 11064002-13 2000 In addition, the expression of the bcl-2/bax protein decreased significantly in these two cell lines treated with TCHQ but not PCP. 2,3,5,6-tetrachlorohydroquinone 114-118 BCL2 apoptosis regulator Homo sapiens 35-40 11139286-12 2000 Activation of the Fas pathway in the Bcl-2 and Bcl-xL transfectants by antibody also inhibited carbachol and EGF responsiveness (i.e., Ca2+ mobilization and/or influx) by 50-60%. Carbachol 95-104 BCL2 apoptosis regulator Homo sapiens 37-42 11085527-5 2000 The first strategy used CS-propynylated phosphorothioate-phosphodiester oligonucleotides and co-down-regulated both Bcl-xL and Bcl-2; the second strategy used isosequential "gap-mer" phosphorothioate oligonucleotides containing 2"-O-methyl oligoribonucleotides at the 3" and 5" termini. Cesium 24-26 BCL2 apoptosis regulator Homo sapiens 127-132 11085527-5 2000 The first strategy used CS-propynylated phosphorothioate-phosphodiester oligonucleotides and co-down-regulated both Bcl-xL and Bcl-2; the second strategy used isosequential "gap-mer" phosphorothioate oligonucleotides containing 2"-O-methyl oligoribonucleotides at the 3" and 5" termini. Oligonucleotides 72-88 BCL2 apoptosis regulator Homo sapiens 127-132 11196462-4 2000 At the same time, however, expression of bcl-2, which has a cAMP response element (CRE), was not affected. Cyclic AMP 60-64 BCL2 apoptosis regulator Homo sapiens 41-46 11186002-0 2000 [Suppression of expression of bcl-2 and bcl-xL genes using antisense oligonucleotides: a new approach to cancer therapy]. Oligonucleotides 69-85 BCL2 apoptosis regulator Homo sapiens 30-35 12214088-5 2000 H2O2-treatment resulted in dose-dependent increases in cell death due to genomic and mitochondrial DNA damage associated with increased levels of 8-OHdG and the p53 and CD95 pro-apoptosis genes, reduced levels of the Bcl-2 survival gene, activation of JNK and p38 stress kinases, and inhibition of PI3 kinase survival signaling. Hydrogen Peroxide 0-4 BCL2 apoptosis regulator Homo sapiens 217-222 11090257-7 2000 DHA treatment decreased bcl-2 levels in association with apoptosis, whereas bax levels remained unchanged. dehydroacetic acid 0-3 BCL2 apoptosis regulator Homo sapiens 24-29 11040047-7 2000 When treated with an anticancer drug (etoposide or cisplatin) or the kinase inhibitor staurosporin, the cells containing a high G(1) population and a high Bcl-2 protein level were much more resistant to the induced apoptosis than the cells containing a high S phase population and a low Bcl-2 protein level. Etoposide 38-47 BCL2 apoptosis regulator Homo sapiens 155-160 11040047-7 2000 When treated with an anticancer drug (etoposide or cisplatin) or the kinase inhibitor staurosporin, the cells containing a high G(1) population and a high Bcl-2 protein level were much more resistant to the induced apoptosis than the cells containing a high S phase population and a low Bcl-2 protein level. Etoposide 38-47 BCL2 apoptosis regulator Homo sapiens 287-292 11040047-7 2000 When treated with an anticancer drug (etoposide or cisplatin) or the kinase inhibitor staurosporin, the cells containing a high G(1) population and a high Bcl-2 protein level were much more resistant to the induced apoptosis than the cells containing a high S phase population and a low Bcl-2 protein level. Cisplatin 51-60 BCL2 apoptosis regulator Homo sapiens 155-160 11040047-7 2000 When treated with an anticancer drug (etoposide or cisplatin) or the kinase inhibitor staurosporin, the cells containing a high G(1) population and a high Bcl-2 protein level were much more resistant to the induced apoptosis than the cells containing a high S phase population and a low Bcl-2 protein level. Cisplatin 51-60 BCL2 apoptosis regulator Homo sapiens 287-292 11040047-7 2000 When treated with an anticancer drug (etoposide or cisplatin) or the kinase inhibitor staurosporin, the cells containing a high G(1) population and a high Bcl-2 protein level were much more resistant to the induced apoptosis than the cells containing a high S phase population and a low Bcl-2 protein level. Staurosporine 86-98 BCL2 apoptosis regulator Homo sapiens 155-160 11040047-7 2000 When treated with an anticancer drug (etoposide or cisplatin) or the kinase inhibitor staurosporin, the cells containing a high G(1) population and a high Bcl-2 protein level were much more resistant to the induced apoptosis than the cells containing a high S phase population and a low Bcl-2 protein level. Staurosporine 86-98 BCL2 apoptosis regulator Homo sapiens 287-292 11126389-5 2000 It is noteworthy that lithium, valproate and antidepressants indirectly regulate a number of factors involved in cell survival pathways including CREB, BDNF, bcl-2 and MAP kinases, and may thus bring about some of their delayed long-term beneficial effects via underappreciated neurotrophic effects. Lithium 22-29 BCL2 apoptosis regulator Homo sapiens 158-163 11126389-5 2000 It is noteworthy that lithium, valproate and antidepressants indirectly regulate a number of factors involved in cell survival pathways including CREB, BDNF, bcl-2 and MAP kinases, and may thus bring about some of their delayed long-term beneficial effects via underappreciated neurotrophic effects. Valproic Acid 31-40 BCL2 apoptosis regulator Homo sapiens 158-163 11090257-8 2000 These results suggest that decreased expression of bcl-2 by DHA might increase the sensitivity of cells to lipid peroxidation and to programmed cell death. dehydroacetic acid 60-63 BCL2 apoptosis regulator Homo sapiens 51-56 11006574-5 2000 Treatment of Y79 cells with sodium butyrate alone lowered the levels of p53, E2F-1 and Bcl-2. Butyric Acid 28-43 BCL2 apoptosis regulator Homo sapiens 87-92 11050287-8 2000 Penclomedine killed glioma cells via an apoptotic, but death receptor-, bcl-2- and caspase-independent pathway, but did not inhibit telomerase and did not act synergistically with cytotoxic drugs. penclomedine 0-12 BCL2 apoptosis regulator Homo sapiens 72-77 11235561-0 2000 [The role of bcl-2 gene family in taxol-mediated apoptosis in BJAB B cell lymphoma cell line]. Paclitaxel 34-39 BCL2 apoptosis regulator Homo sapiens 13-18 11235561-7 2000 The expression of bcl-2 at mRNA and protion level was decreased while that of bcl-xs transcription was increased after taxol treatment. Paclitaxel 119-124 BCL2 apoptosis regulator Homo sapiens 18-23 11235561-9 2000 Bcl-2 and bcl-xs are involved in the regulation of taxol-induced apoptosis. Paclitaxel 51-56 BCL2 apoptosis regulator Homo sapiens 0-5 11235565-0 2000 [Bcl-2 anti-sense oligonucleotide sensitizes Fas-mediated apoptosis of gastric cancer cells]. Oligonucleotides 18-33 BCL2 apoptosis regulator Homo sapiens 1-6 11235565-0 2000 [Bcl-2 anti-sense oligonucleotide sensitizes Fas-mediated apoptosis of gastric cancer cells]. ammonium ferrous sulfate 45-48 BCL2 apoptosis regulator Homo sapiens 1-6 11235565-1 2000 OBJECTIVE: To study the effect of bcl-2 anti-sense oligonucleotide on the sensitivity of gastric cancer cells to Fas-mediated apoptosis. Oligonucleotides 51-66 BCL2 apoptosis regulator Homo sapiens 34-39 11235565-2 2000 METHODS: Gastric cancer cell line MKN45 was transfected with bcl-2 anti-sense oligonucleotide, and expression of bcl-2 was examined by Western blotting. Oligonucleotides 78-93 BCL2 apoptosis regulator Homo sapiens 61-66 11235565-4 2000 RESULTS: Bcl-2 expression in MKN45 cells transfected with bcl-2 anti-sense oligonucleotide was markedly inhibited. Oligonucleotides 75-90 BCL2 apoptosis regulator Homo sapiens 9-14 11235565-4 2000 RESULTS: Bcl-2 expression in MKN45 cells transfected with bcl-2 anti-sense oligonucleotide was markedly inhibited. Oligonucleotides 75-90 BCL2 apoptosis regulator Homo sapiens 58-63 11235565-6 2000 CONCLUSION: Expression of bcl-2 in gastric cancer cells may antagonize Fas-mediated apoptosis. ammonium ferrous sulfate 71-74 BCL2 apoptosis regulator Homo sapiens 26-31 11236678-0 2000 [Effect of hyperbaric oxygen on the expression of proteins Bcl-2 and Bax in the gerbil hippocampus CA1 following forebrain ischemia reperfusion]. Oxygen 22-28 BCL2 apoptosis regulator Homo sapiens 59-64 11236678-2 2000 METHODS: Changes of the expression of protein Bcl-2 or Bax were observed in CA1 region of gerbil hippocampus following HBOT on ischemia reperfusion 3 days using the method of labelled streptavidin biotin (LSAB) immunohistochemistry staining. Biotin 197-203 BCL2 apoptosis regulator Homo sapiens 46-51 11236678-2 2000 METHODS: Changes of the expression of protein Bcl-2 or Bax were observed in CA1 region of gerbil hippocampus following HBOT on ischemia reperfusion 3 days using the method of labelled streptavidin biotin (LSAB) immunohistochemistry staining. lsab 205-209 BCL2 apoptosis regulator Homo sapiens 46-51 11342340-8 2000 When Bcl-2 expression was downregulated in WSU-CLL cells using gene specific antisense oligonucleotides, the susceptibility of WSU-CLL cells to the cytotoxicity of chemotherapeutic agent Fludarabine was increased. Oligonucleotides 87-103 BCL2 apoptosis regulator Homo sapiens 5-10 11342340-8 2000 When Bcl-2 expression was downregulated in WSU-CLL cells using gene specific antisense oligonucleotides, the susceptibility of WSU-CLL cells to the cytotoxicity of chemotherapeutic agent Fludarabine was increased. fludarabine 187-198 BCL2 apoptosis regulator Homo sapiens 5-10 11236678-6 2000 CONCLUSION: HBO can induce the expression of Bcl-2, which is the mechanism of neuronal protecting effect of HBOT. 2,4-dihydroxy-7-methoxy-1,4-benzoxazin-3-one 12-15 BCL2 apoptosis regulator Homo sapiens 45-50 11105982-6 2000 Using Western blotting analysis, we found that the gossypol-induced apoptosis may not be involved in the regulation of p53 but possibly associated with the regulation of bcl-2 and Bax expression. Gossypol 51-59 BCL2 apoptosis regulator Homo sapiens 170-175 11027659-0 2000 Analysis of the role of conserved cysteine residues in the bcl-2 oncoprotein. Cysteine 34-42 BCL2 apoptosis regulator Homo sapiens 59-64 11059778-0 2000 Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. O-(6)-methylguanine 32-48 BCL2 apoptosis regulator Homo sapiens 52-57 11059778-13 2000 Overall, the data indicate that O6MeG induces apoptosis via secondary lesions that trigger Bcl-2 decline, cytochrome c release, and caspase-9 and caspase-3 activation independently of Fas/Fas ligand and p53, for which the cells are mutated. O-(6)-methylguanine 32-37 BCL2 apoptosis regulator Homo sapiens 91-96 11063971-2 2000 It is thus noteworthy that lithium and valproate have recently been demonstrated to robustly increase the expression of the cytoprotective protein bcl-2 in the central nervous system. Lithium 27-34 BCL2 apoptosis regulator Homo sapiens 147-152 11063971-2 2000 It is thus noteworthy that lithium and valproate have recently been demonstrated to robustly increase the expression of the cytoprotective protein bcl-2 in the central nervous system. Valproic Acid 39-48 BCL2 apoptosis regulator Homo sapiens 147-152 10896673-0 2000 Bcl-2 independence of flavopiridol-induced apoptosis. alvocidib 22-34 BCL2 apoptosis regulator Homo sapiens 0-5 10896673-6 2000 In human lung carcinoma cells, which contain high levels of endogenous Bcl-2 and lack procaspase 8, flavopiridol treatment leads to mitochondrial depolarization in the absence of cytochrome c release, followed by the activation of caspase 3 and cell death. alvocidib 100-112 BCL2 apoptosis regulator Homo sapiens 71-76 11027659-3 2000 Two cysteine residues are found in Bcl-2 and these residues are well-conserved across species. Cysteine 4-12 BCL2 apoptosis regulator Homo sapiens 35-40 11027659-8 2000 Together, the data indicate that the cysteine residues in Bcl-2 contribute, but are not absolutely essential, to the ability of Bcl-2 to homodimerize, heterodimerize with Bax, and suppress apoptosis. Cysteine 37-45 BCL2 apoptosis regulator Homo sapiens 58-63 11027659-8 2000 Together, the data indicate that the cysteine residues in Bcl-2 contribute, but are not absolutely essential, to the ability of Bcl-2 to homodimerize, heterodimerize with Bax, and suppress apoptosis. Cysteine 37-45 BCL2 apoptosis regulator Homo sapiens 128-133 11129738-3 2000 It showed that HCPT at a dose of 0.1 microg/ml increased the expression of P53, c-Myc and Bax protein, and decreased the expression of Bcl-2 and AFP. 10-hydroxycamptothecin 15-19 BCL2 apoptosis regulator Homo sapiens 135-140 11227216-12 2000 Moreover, we tested TZT-1027 for its ability to induce Bcl-2 phosphorylation in human cancer cell lines. triazinate 20-23 BCL2 apoptosis regulator Homo sapiens 55-60 11024552-3 2000 An increase in BCL-2 expression is observed upon incubation with steroids. Steroids 65-73 BCL2 apoptosis regulator Homo sapiens 15-20 11110054-0 2000 Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression. oblimersen 33-38 BCL2 apoptosis regulator Homo sapiens 11-16 11227216-13 2000 TZT-1027 and other agents which interacted with microtubules induced Bcl-2 phosphorylation, whereas DNA-damaging agents did not. soblidotin 0-8 BCL2 apoptosis regulator Homo sapiens 69-74 11227216-14 2000 The present results suggested an association of the growth-inhibitory effect of TZT-1027 with the induction of apoptosis and indicated that the apoptosis induced by TZT-1027 was followed by G2/M arrest even if there was no Caspase-3 or Bcl-2. soblidotin 80-88 BCL2 apoptosis regulator Homo sapiens 236-241 11227216-14 2000 The present results suggested an association of the growth-inhibitory effect of TZT-1027 with the induction of apoptosis and indicated that the apoptosis induced by TZT-1027 was followed by G2/M arrest even if there was no Caspase-3 or Bcl-2. soblidotin 165-173 BCL2 apoptosis regulator Homo sapiens 236-241 11034086-10 2000 Like other antimicrotubule agents, the sulfamoylated estrone derivatives induced BCL-2 and BCL-XL phosphorylation and increased p53 expression. Estrone 53-60 BCL2 apoptosis regulator Homo sapiens 81-86 11110059-1 2000 Apoptosis induction by the pure antiestrogen faslodex, also known as ICI 182780 (ICI), is associated with an effective down-regulation of Bcl-2 expression in the human breast cancer cell line MCF-7. Fulvestrant 45-53 BCL2 apoptosis regulator Homo sapiens 138-143 11110059-5 2000 In contrast, Bcl-2 expression was strongly decreased following administration of ICI but only weakly after administration of Tam. Tamoxifen 125-128 BCL2 apoptosis regulator Homo sapiens 13-18 11110054-0 2000 Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression. Oligonucleotides 49-64 BCL2 apoptosis regulator Homo sapiens 11-16 11110054-1 2000 We have investigated the effects of transient Bcl-2 down-regulation induced by the Bcl-2 antisense oligodeoxynucleotide (ODN) G3139 (Genta Incorporated) in high Bcl-2 protein expressing, estrogen receptor (ER) positive MCF-7 and low Bcl-2 expressing, ER negative MDA435/LCC6 human breast cancer cells. Oligodeoxyribonucleotides 99-119 BCL2 apoptosis regulator Homo sapiens 46-51 11110054-1 2000 We have investigated the effects of transient Bcl-2 down-regulation induced by the Bcl-2 antisense oligodeoxynucleotide (ODN) G3139 (Genta Incorporated) in high Bcl-2 protein expressing, estrogen receptor (ER) positive MCF-7 and low Bcl-2 expressing, ER negative MDA435/LCC6 human breast cancer cells. genta 133-138 BCL2 apoptosis regulator Homo sapiens 46-51 11051254-2 2000 Furthermore, posttranslational modification of moderately expressed endogenous Bcl-2 has been correlated with susceptibility to paclitaxel treatment in vitro. Paclitaxel 128-138 BCL2 apoptosis regulator Homo sapiens 79-84 11055326-6 2000 The mode by which Bcl-2 regulates IkappaBalpha was related to the N-terminal phosphorylation and degradation of IkappaBalpha by the proteasome since an N-terminal deletion mutant of IkappaBalpha or the proteasome inhibitor lactacystin abrogated Bcl-2"s inhibitory effects on IkappaBalpha and prevented NFkappaB activation. lactacystin 223-234 BCL2 apoptosis regulator Homo sapiens 18-23 11051254-8 2000 The median survival time from initiation of paclitaxel therapy for patients with low Bcl-2 expression was 663 days (95% CI, 456-1119 days) and was not significantly different than the 450 days (95% CI, 239-1058 days) observed for patients with high Bcl-2 expression. Paclitaxel 44-54 BCL2 apoptosis regulator Homo sapiens 85-90 11899648-1 2000 This study assesses the potential value of the tumor markers p53, HER2, and Bcl-2 in predicting the clinical response to doxorubicin and paclitaxel as single agents in the treatment of metastatic breast cancer. Doxorubicin 121-132 BCL2 apoptosis regulator Homo sapiens 76-81 11899648-1 2000 This study assesses the potential value of the tumor markers p53, HER2, and Bcl-2 in predicting the clinical response to doxorubicin and paclitaxel as single agents in the treatment of metastatic breast cancer. Paclitaxel 137-147 BCL2 apoptosis regulator Homo sapiens 76-81 11775848-0 2000 Co-transfection of MRP and bcl-2 antisense S-oligodeoxynucleotides reduces drug resistance in cisplatin-resistant lung cancer cells. Oligodeoxyribonucleotides 45-66 BCL2 apoptosis regulator Homo sapiens 27-32 11078056-11 2000 This effect may due to induction of apoptosis through uncoupling of oxidative phosphorylation and down-regulation of Bcl-2, as has been demonstrated for some nonselective NSAIDs, for instance, flurbiprofen. Flurbiprofen 193-205 BCL2 apoptosis regulator Homo sapiens 117-122 11775848-0 2000 Co-transfection of MRP and bcl-2 antisense S-oligodeoxynucleotides reduces drug resistance in cisplatin-resistant lung cancer cells. Cisplatin 94-103 BCL2 apoptosis regulator Homo sapiens 27-32 11775848-7 2000 Resistance to cisplatin in the cells treated with bcl-2 or/and MRP antisense S-ODN decreased by 60.6% (6.5 times), 56.4% (7.2 times) and 71.0% (4.8 times), respectively, which paralleled the decrease of bcl-2 and MRP expression. Cisplatin 14-23 BCL2 apoptosis regulator Homo sapiens 50-55 11775848-7 2000 Resistance to cisplatin in the cells treated with bcl-2 or/and MRP antisense S-ODN decreased by 60.6% (6.5 times), 56.4% (7.2 times) and 71.0% (4.8 times), respectively, which paralleled the decrease of bcl-2 and MRP expression. Cisplatin 14-23 BCL2 apoptosis regulator Homo sapiens 203-208 11775848-10 2000 Statistically significant dose- and concentration-dependent increases of apoptotic cells were observed in the groups exposed to 100 mumol/L cisplatin for 48 h after treatment by bcl-2 or/and MRP antisense. Cisplatin 140-149 BCL2 apoptosis regulator Homo sapiens 178-183 11775848-11 2000 CONCLUSION: Bcl-2 and MRP were at least additive and possibly synergistic in conferring drug resistance in a cisplatin-resistant lung adenocarcinoma cell line. Cisplatin 109-118 BCL2 apoptosis regulator Homo sapiens 12-17 11899648-0 2000 A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. Doxorubicin 78-89 BCL2 apoptosis regulator Homo sapiens 39-44 11068922-11 2000 Our results demonstrate that HgCl2 induces a significant elevation in the Bcl-2 content of T-cells; in contrast, T-cells treated with MeHgCl did not exhibit altered levels of this anti-apoptotic protein. Mercuric Chloride 29-34 BCL2 apoptosis regulator Homo sapiens 74-79 11057740-2 2000 A dose of 2 Gy IR was selected for further analyses to determine if subsequent exposure to 10nM bryostatin- would overcome the resistance to IR-induced apoptosis conferred by Bcl-2 over expression. Bryostatins 96-106 BCL2 apoptosis regulator Homo sapiens 175-180 11023989-9 2000 These results show that mitochondria are a key destination for apoptogenic GD3 ganglioside along the lipid pathway to programmed cell death and indicate that relevant GD3 targets are under bcl-2 control. Gangliosides 79-90 BCL2 apoptosis regulator Homo sapiens 189-194 10995888-9 2000 We also found a significant down-regulation of Bcl-2 in flavopiridol-treated cells. alvocidib 56-68 BCL2 apoptosis regulator Homo sapiens 47-52 10995888-10 2000 These findings suggest that down-regulation of Bcl-2 may be one of the molecular mechanisms through which flavopiridol induces apoptosis and inhibits cell growth, suggesting that flavopiridol may be an effective chemotherapeutic agent against prostate cancer. alvocidib 106-118 BCL2 apoptosis regulator Homo sapiens 47-52 10995888-10 2000 These findings suggest that down-regulation of Bcl-2 may be one of the molecular mechanisms through which flavopiridol induces apoptosis and inhibits cell growth, suggesting that flavopiridol may be an effective chemotherapeutic agent against prostate cancer. alvocidib 179-191 BCL2 apoptosis regulator Homo sapiens 47-52 10996199-7 2000 Chlorambucil produced almost identical changes in Bcl-2 and Bax expression in normal T-cells and leukaemic B-cells triggered to die by apoptosis, which together with the correlation between Bcl-2 and chemosensitivity confirms a pivotal role for Bcl-2 in regulating a distal step in the apoptotic pathway following cytotoxic cellular damage. Chlorambucil 0-12 BCL2 apoptosis regulator Homo sapiens 190-195 10996199-4 2000 The chlorambucil ID(50) values for T-cells from B-CLL patients showed a direct correlation with Bcl-2 expression (P=0.002) and an inverse correlation with CD3 cell count (P<0.0001), suggesting a trend of increasing chemosensitivity and decreasing Bcl-2 expression with an elevated T-cell count. Chlorambucil 4-16 BCL2 apoptosis regulator Homo sapiens 96-101 10996199-4 2000 The chlorambucil ID(50) values for T-cells from B-CLL patients showed a direct correlation with Bcl-2 expression (P=0.002) and an inverse correlation with CD3 cell count (P<0.0001), suggesting a trend of increasing chemosensitivity and decreasing Bcl-2 expression with an elevated T-cell count. Chlorambucil 4-16 BCL2 apoptosis regulator Homo sapiens 250-255 10996199-6 2000 We found correlations in the leukaemic B-cells between chlorambucil ID(50) values and both Bcl-2 expression (P=0.006), and Bcl-2/Bax ratios (P=0.002), suggesting a role for the Bcl-2/Bax ratio in predicting the response of untreated CLL patients to cytotoxic treatment. Chlorambucil 55-67 BCL2 apoptosis regulator Homo sapiens 91-96 10996199-6 2000 We found correlations in the leukaemic B-cells between chlorambucil ID(50) values and both Bcl-2 expression (P=0.006), and Bcl-2/Bax ratios (P=0.002), suggesting a role for the Bcl-2/Bax ratio in predicting the response of untreated CLL patients to cytotoxic treatment. Chlorambucil 55-67 BCL2 apoptosis regulator Homo sapiens 123-128 10996199-6 2000 We found correlations in the leukaemic B-cells between chlorambucil ID(50) values and both Bcl-2 expression (P=0.006), and Bcl-2/Bax ratios (P=0.002), suggesting a role for the Bcl-2/Bax ratio in predicting the response of untreated CLL patients to cytotoxic treatment. Chlorambucil 55-67 BCL2 apoptosis regulator Homo sapiens 123-128 10996199-7 2000 Chlorambucil produced almost identical changes in Bcl-2 and Bax expression in normal T-cells and leukaemic B-cells triggered to die by apoptosis, which together with the correlation between Bcl-2 and chemosensitivity confirms a pivotal role for Bcl-2 in regulating a distal step in the apoptotic pathway following cytotoxic cellular damage. Chlorambucil 0-12 BCL2 apoptosis regulator Homo sapiens 50-55 11074606-4 2000 Physiologic concentrations of genistein (< or = 20 microM) decreased LNCaP viable cell number in a dose-dependent manner, induced a G(1) cell-cycle block, decreased prostate-specific antigen mRNA expression, and increased p27(KIP1) and p21(WAF1) (mRNA and protein) but had no effect on apoptosis or the mRNA expression of the apoptosis- and cell-cycle-related markers bcl-2, bax, Rb, and proliferating cell nuclear antigen. Genistein 30-39 BCL2 apoptosis regulator Homo sapiens 371-376 11063051-4 2000 Furthermore, alteration of expression of bcl-2 family genes using transgenic approaches, viral vectors, or anti-sense oligonucleotides modifies neuronal cell death and neurological outcome after injury. Oligonucleotides 118-134 BCL2 apoptosis regulator Homo sapiens 41-46 10996199-7 2000 Chlorambucil produced almost identical changes in Bcl-2 and Bax expression in normal T-cells and leukaemic B-cells triggered to die by apoptosis, which together with the correlation between Bcl-2 and chemosensitivity confirms a pivotal role for Bcl-2 in regulating a distal step in the apoptotic pathway following cytotoxic cellular damage. Chlorambucil 0-12 BCL2 apoptosis regulator Homo sapiens 190-195 11095401-0 2000 Survival mechanisms induced by 12-O-tetradecanoylphorbol-13-acetate in normal human melanocytes include inhibition of apoptosis and increased Bcl-2 expression. Tetradecanoylphorbol Acetate 31-67 BCL2 apoptosis regulator Homo sapiens 142-147 11095401-7 2000 Following withdrawal of TPA from melanocytes, the expression of Bcl-2 decreased steadily. Tetradecanoylphorbol Acetate 24-27 BCL2 apoptosis regulator Homo sapiens 64-69 11095401-9 2000 These results suggest that TPA plays an important role in stimulating the growth of melanocytes by promoting anti-apoptotic mechanisms associated with high levels of Bcl-2. Tetradecanoylphorbol Acetate 27-30 BCL2 apoptosis regulator Homo sapiens 166-171 11057740-8 2000 Moreover, U937/Bcl-2 cells were more susceptible to the growth-inhibitory effects of IR/bryostatin-1 than U937/pCEP4 cells. bryostatin 1 88-100 BCL2 apoptosis regulator Homo sapiens 15-20 11057740-9 2000 CONCLUSIONS: Bryostatin-1 increased the radiosensitivity of U937 transfectant cell lines without enhancing apoptosis; furthermore, U937/Bcl-2 cells were more susceptible to IR/bryostatin-1-mediated antiproliferative effects than their empty-vector counterparts. bryostatin 1 176-188 BCL2 apoptosis regulator Homo sapiens 136-141 10913135-6 2000 In addition, AS-JNK1/2 inhibited vinblastine-induced phosphorylation of Bcl-2 by 85% and that of Bcl-X(L) by 65%. Vinblastine 33-44 BCL2 apoptosis regulator Homo sapiens 72-77 11819674-4 2000 Flow cytometry was used to assay cell-DNA distribution and the protein expression of Bcl-2 and Bax detected by immunocytochemical method.RESULTS:The cell growth was significantly inhibited by varying concentrations of arsenic trioxide as revealed by cell counting and cell-growth curve, which was dose- and time-dependent. Arsenic Trioxide 218-234 BCL2 apoptosis regulator Homo sapiens 85-90 11819674-9 2000 High expressions of Bcl-2 and Bax were detected in 1 and 2&mgr;mol/L arsenic trioxide-treated cells, these were 46%, 87.33% and 83.08%, 95.83% respectively, among which that of Bax was more significant. Adenosine Monophosphate 59-62 BCL2 apoptosis regulator Homo sapiens 20-25 11819674-9 2000 High expressions of Bcl-2 and Bax were detected in 1 and 2&mgr;mol/L arsenic trioxide-treated cells, these were 46%, 87.33% and 83.08%, 95.83% respectively, among which that of Bax was more significant. Arsenic Trioxide 73-89 BCL2 apoptosis regulator Homo sapiens 20-25 11819674-10 2000 Arsenic trioxide treatment at 0.5&mgr;mol/L resulted in a higher expression level of Bcl-2 and lower expression level of Bax,which were 8.81% and 3.83% respectively, as compared with that of the control group (15.33%) (P(1)<0.01, P(2)<0.01).CONCLUSION:Arsenic trioxide not only inhibited proliferation but also induced apoptosis of human hepatoma cell line BEL-7402. Arsenic Trioxide 0-16 BCL2 apoptosis regulator Homo sapiens 89-94 11819674-11 2000 The induced-apoptosis effect of 1,2&mgr;mol/L arsenic trioxide was related to the expression level of Bcl-2 and Bax. 1,2& 32-39 BCL2 apoptosis regulator Homo sapiens 106-111 11819674-11 2000 The induced-apoptosis effect of 1,2&mgr;mol/L arsenic trioxide was related to the expression level of Bcl-2 and Bax. Arsenic Trioxide 50-66 BCL2 apoptosis regulator Homo sapiens 106-111 11048643-0 2000 Effects of allyl sulfur compounds and garlic extract on the expression of Bcl-2, Bax, and p53 in non small cell lung cancer cell lines. Sulfur 17-23 BCL2 apoptosis regulator Homo sapiens 74-79 10913135-0 2000 Vinblastine-induced phosphorylation of Bcl-2 and Bcl-XL is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade. Vinblastine 0-11 BCL2 apoptosis regulator Homo sapiens 39-44 10913135-2 2000 Because microtubule inhibitors activate JNK, we sought to determine whether JNK was responsible for Bcl-2/Bcl-X(L) phosphorylation in KB-3 cells treated with vinblastine. Vinblastine 158-169 BCL2 apoptosis regulator Homo sapiens 100-105 10956385-8 2000 In addition, when paclitaxel-induced apoptosis was inhibited by Bcl-2 over-expression, cdc2 up-regulation did not occur, leading to a lower level of activation of the cyclin B/cdc2 complex. Paclitaxel 18-28 BCL2 apoptosis regulator Homo sapiens 64-69 11030151-7 2000 Our study further showed that rhVEGF or hypoxia induced ERK phosphorylation in serum-deprived cells, and that a specific inhibitor of MAPK/ERK, PD98059 eliminated the anti-apoptotic activity of rhVEGF or hypoxia by increasing Bax/Bcl-2 ratio and caspase-3 activity. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 144-151 BCL2 apoptosis regulator Homo sapiens 230-235 11029754-10 2000 Finally, Bcl-2 overexpression inhibited etoposide-induced calpain activation, Bax cleavage, cytochrome c release, and apoptosis. Etoposide 40-49 BCL2 apoptosis regulator Homo sapiens 9-14 11016650-5 2000 This initiation process of MT-21-induced apoptosis was suppressed by overexpression of Bcl-2, which is known to prevent cells from undergoing apoptosis in response to a variety of stimuli. MT 21 27-32 BCL2 apoptosis regulator Homo sapiens 87-92 10996309-2 2000 Overexpression of Bcl-2 in S. pombe inhibits cell growth independently of rad9, but enhances resistance of rad9-null cells to methyl methanesulfonate, ultraviolet and ionizing radiation. Methyl Methanesulfonate 126-149 BCL2 apoptosis regulator Homo sapiens 18-23 11000289-0 2000 Bcl-2 transfected HaCaT keratinocytes resist apoptotic signals of ceramides, tumor necrosis factor alpha and 1 alpha, 25-dihydroxyvitamin D(3). Ceramides 66-75 BCL2 apoptosis regulator Homo sapiens 0-5 11000289-0 2000 Bcl-2 transfected HaCaT keratinocytes resist apoptotic signals of ceramides, tumor necrosis factor alpha and 1 alpha, 25-dihydroxyvitamin D(3). 1,25-dihydroxyvitamin D 109-139 BCL2 apoptosis regulator Homo sapiens 0-5 11062697-1 2000 In this report, we demonstrate the down-regulation of telomerase activity and c-Myc and Bcl-2 expression during 9-nitrocamptothecin (9NC)-induced regression of human DU145 prostate tumors grown as xenografts in immunodeficient mice. rubitecan 112-131 BCL2 apoptosis regulator Homo sapiens 88-93 11000289-10 2000 This indicates the important role of bcl-2 in the regulation of ceramide-mediated signalling pathways in human keratinocytes and supports the involvement of ceramide as a signalling molecule in 1 alpha,25-dihydroxyvitamin D(3)-induced biological responses. Ceramides 64-72 BCL2 apoptosis regulator Homo sapiens 37-42 11000289-10 2000 This indicates the important role of bcl-2 in the regulation of ceramide-mediated signalling pathways in human keratinocytes and supports the involvement of ceramide as a signalling molecule in 1 alpha,25-dihydroxyvitamin D(3)-induced biological responses. alpha,25-dihydroxyvitamin d(3) 196-226 BCL2 apoptosis regulator Homo sapiens 37-42 11042671-7 2000 In contrast, the increase in ceramide level by an inhibitor of ceramide glucosyltransferase-1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol caused elevation of the Bax/Bcl-2 ratio and potentiation of caspase-3 activation, thereby resulting in enhancement of etoposide-induced apoptosis. decanoylamino-3-morpholino-1-propanol 114-151 BCL2 apoptosis regulator Homo sapiens 180-185 10961874-3 2000 U937 cells constitutively express the antiapoptotic protein Bcl-2; but during differentiation, in response to the phorbol ester PMA (phorbol 12 beta-myristate 13 alpha-acetate), Mcl-1 is transiently induced. Phorbol Esters 114-127 BCL2 apoptosis regulator Homo sapiens 60-65 10961874-3 2000 U937 cells constitutively express the antiapoptotic protein Bcl-2; but during differentiation, in response to the phorbol ester PMA (phorbol 12 beta-myristate 13 alpha-acetate), Mcl-1 is transiently induced. Tetradecanoylphorbol Acetate 128-131 BCL2 apoptosis regulator Homo sapiens 60-65 10975859-3 2000 The NO generator, sodium nitroprusside (SNP), promoted chondrocyte death in association with DNA fragmentation, caspase-3 activation, and down-regulation of Bcl-2. Nitroprusside 18-38 BCL2 apoptosis regulator Homo sapiens 157-162 10971319-0 2000 Ceramide 2 (N-acetyl sphingosine) is associated with reduction in Bcl-2 protein levels by Western blotting and with apoptosis in cultured human keratinocytes. ceramide 2 0-10 BCL2 apoptosis regulator Homo sapiens 66-71 10971319-0 2000 Ceramide 2 (N-acetyl sphingosine) is associated with reduction in Bcl-2 protein levels by Western blotting and with apoptosis in cultured human keratinocytes. N-acetylsphingosine 12-32 BCL2 apoptosis regulator Homo sapiens 66-71 11032173-0 2000 Effect of Bcl-2 and caspase-3 on calcium distribution in apoptosis of HL-60 cells. Calcium 33-40 BCL2 apoptosis regulator Homo sapiens 10-15 11032173-3 2000 Calcium, an important intracellular signal element in cells, is also observed to have changes during apoptosis, which maybe affected by Bcl-2 protein. Calcium 0-7 BCL2 apoptosis regulator Homo sapiens 136-141 11032173-7 2000 The results indicate that activated caspase-3 can promote the movement of intracellular calcium from Golgi"s apparatus to nucleus, and the process is inhibited by Ac-DEVD-CHO (inhibitor of caspase-3), and that Bcl-2 can inhibit the movement and accumulation of intracellular calcium in nucleus through its inhibition on caspase-3. acetyl-aspartyl-glutamyl-valyl-aspartal 163-174 BCL2 apoptosis regulator Homo sapiens 210-215 11032173-7 2000 The results indicate that activated caspase-3 can promote the movement of intracellular calcium from Golgi"s apparatus to nucleus, and the process is inhibited by Ac-DEVD-CHO (inhibitor of caspase-3), and that Bcl-2 can inhibit the movement and accumulation of intracellular calcium in nucleus through its inhibition on caspase-3. Calcium 275-282 BCL2 apoptosis regulator Homo sapiens 210-215 11032173-7 2000 The results indicate that activated caspase-3 can promote the movement of intracellular calcium from Golgi"s apparatus to nucleus, and the process is inhibited by Ac-DEVD-CHO (inhibitor of caspase-3), and that Bcl-2 can inhibit the movement and accumulation of intracellular calcium in nucleus through its inhibition on caspase-3. Calcium 88-95 BCL2 apoptosis regulator Homo sapiens 210-215 11042671-8 2000 Furthermore, cell-permeable exogenous ceramides (C2- and C6-ceramide) induced downregulation of Bcl-2, leading to an increase in the Bax/Bcl-2 ratio and subsequent activation of caspases-9 and -3. Ceramides 38-47 BCL2 apoptosis regulator Homo sapiens 96-101 11032175-7 2000 These results suggested that Fas-mediated apoptosis in human hepatoma cells is possibly regulated by Bcl-2 family proteins via mitochondria pathway. ammonium ferrous sulfate 29-32 BCL2 apoptosis regulator Homo sapiens 101-106 11042671-8 2000 Furthermore, cell-permeable exogenous ceramides (C2- and C6-ceramide) induced downregulation of Bcl-2, leading to an increase in the Bax/Bcl-2 ratio and subsequent activation of caspases-9 and -3. Ceramides 38-47 BCL2 apoptosis regulator Homo sapiens 137-142 11042671-0 2000 Ordering of ceramide formation, caspase activation, and Bax/Bcl-2 expression during etoposide-induced apoptosis in C6 glioma cells. Etoposide 84-93 BCL2 apoptosis regulator Homo sapiens 60-65 11042671-4 2000 In addition, exposure of cells to etoposide resulted in decreased expression of Bcl-2 with reciprocal increase in Bax protein. Etoposide 34-43 BCL2 apoptosis regulator Homo sapiens 80-85 11042671-8 2000 Furthermore, cell-permeable exogenous ceramides (C2- and C6-ceramide) induced downregulation of Bcl-2, leading to an increase in the Bax/Bcl-2 ratio and subsequent activation of caspases-9 and -3. Ceramides 38-46 BCL2 apoptosis regulator Homo sapiens 96-101 11042671-6 2000 Reduced glutathione or N-acetylcysteine, which could reduce ceramide formation by inhibiting sphingomyelinase activity, prevented C6 cells from etoposide-induced apoptosis through blockage of caspase-3 activation and change of the Bax/Bcl-2 ratio. Glutathione 8-19 BCL2 apoptosis regulator Homo sapiens 235-240 11042671-8 2000 Furthermore, cell-permeable exogenous ceramides (C2- and C6-ceramide) induced downregulation of Bcl-2, leading to an increase in the Bax/Bcl-2 ratio and subsequent activation of caspases-9 and -3. Ceramides 38-46 BCL2 apoptosis regulator Homo sapiens 137-142 11042671-6 2000 Reduced glutathione or N-acetylcysteine, which could reduce ceramide formation by inhibiting sphingomyelinase activity, prevented C6 cells from etoposide-induced apoptosis through blockage of caspase-3 activation and change of the Bax/Bcl-2 ratio. Acetylcysteine 23-39 BCL2 apoptosis regulator Homo sapiens 235-240 11042671-9 2000 Taken together, these results suggest that ceramide may function as a mediator of etoposide-induced apoptosis of C6 glioma cells, which induces increase in the Bax/Bcl-2 ratio followed by release of cytochrome c leading to caspases-9 and -3 activation. Ceramides 43-51 BCL2 apoptosis regulator Homo sapiens 164-169 11042671-6 2000 Reduced glutathione or N-acetylcysteine, which could reduce ceramide formation by inhibiting sphingomyelinase activity, prevented C6 cells from etoposide-induced apoptosis through blockage of caspase-3 activation and change of the Bax/Bcl-2 ratio. Etoposide 144-153 BCL2 apoptosis regulator Homo sapiens 235-240 11042671-9 2000 Taken together, these results suggest that ceramide may function as a mediator of etoposide-induced apoptosis of C6 glioma cells, which induces increase in the Bax/Bcl-2 ratio followed by release of cytochrome c leading to caspases-9 and -3 activation. Etoposide 82-91 BCL2 apoptosis regulator Homo sapiens 164-169 11042671-7 2000 In contrast, the increase in ceramide level by an inhibitor of ceramide glucosyltransferase-1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol caused elevation of the Bax/Bcl-2 ratio and potentiation of caspase-3 activation, thereby resulting in enhancement of etoposide-induced apoptosis. Ceramides 29-37 BCL2 apoptosis regulator Homo sapiens 180-185 11042671-7 2000 In contrast, the increase in ceramide level by an inhibitor of ceramide glucosyltransferase-1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol caused elevation of the Bax/Bcl-2 ratio and potentiation of caspase-3 activation, thereby resulting in enhancement of etoposide-induced apoptosis. threo 97-102 BCL2 apoptosis regulator Homo sapiens 180-185 11056329-9 2000 We could demonstrate that these pro-apoptotic actions of tibolone and its Delta4 isomer were mediated at least partially through the bcl-2-family of proteins. tibolone 57-65 BCL2 apoptosis regulator Homo sapiens 133-138 10999771-7 2000 In addition, biochemical examinations revealed that docetaxel could induce phosphorylation of both bcl-2 and c-raf-1, but these changes were inhibited when tumor cells were pretreated or simultaneously treated with doxorubicin. Docetaxel 52-61 BCL2 apoptosis regulator Homo sapiens 99-104 10999771-7 2000 In addition, biochemical examinations revealed that docetaxel could induce phosphorylation of both bcl-2 and c-raf-1, but these changes were inhibited when tumor cells were pretreated or simultaneously treated with doxorubicin. Doxorubicin 215-226 BCL2 apoptosis regulator Homo sapiens 99-104 11125544-7 2000 Effect of Bcl-2 overexpression on induction of Bax in response to butyrate pretreatment was studied in cells transfected with Bcl-2. Butyrates 66-74 BCL2 apoptosis regulator Homo sapiens 10-15 11125544-7 2000 Effect of Bcl-2 overexpression on induction of Bax in response to butyrate pretreatment was studied in cells transfected with Bcl-2. Butyrates 66-74 BCL2 apoptosis regulator Homo sapiens 126-131 11125544-10 2000 Treatment of cells over expressing Bcl-2 with BA did not show induction of Bax suggesting that higher levels of Bcl-2 can block butyrate induced increase in levels of Bax. Butyrates 46-48 BCL2 apoptosis regulator Homo sapiens 35-40 11125544-10 2000 Treatment of cells over expressing Bcl-2 with BA did not show induction of Bax suggesting that higher levels of Bcl-2 can block butyrate induced increase in levels of Bax. Butyrates 128-136 BCL2 apoptosis regulator Homo sapiens 35-40 11125544-10 2000 Treatment of cells over expressing Bcl-2 with BA did not show induction of Bax suggesting that higher levels of Bcl-2 can block butyrate induced increase in levels of Bax. Butyrates 128-136 BCL2 apoptosis regulator Homo sapiens 112-117 11125544-11 2000 CONCLUSIONS: Use of BA at lower than toxic doses to upregulate the proapoptotic potential of cancer cells may be useful in an adjuvant or neoadjuvant setting but its success may depend upon the intrinsic Bcl-2 levels in the tumor. Butyrates 20-22 BCL2 apoptosis regulator Homo sapiens 204-209 11775943-3 2000 bcl-2 expression in these paraffin embraced specimens was examined by immunohistochemical technique with specific monoclonal antibodies. Paraffin 26-34 BCL2 apoptosis regulator Homo sapiens 0-5 10956420-8 2000 Because Bcl-2 has been shown to block cytochrome C release potently, we exposed human neuroblastoma cells (SH-SY5Y) to TPEN. N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine 119-123 BCL2 apoptosis regulator Homo sapiens 8-13 10956420-9 2000 Whereas Bcl-2 overexpression completely blocked both cytochrome C release and apoptosis induced by staurosporine, it attenuated neither induced by TPEN. Staurosporine 99-112 BCL2 apoptosis regulator Homo sapiens 8-13 10964950-10 2000 Moreover, the caspase inhibitor zVAD-fluoromethylketone as well as expression of bcl-2 or bcl-xL inhibited cortical neuron apoptosis induced by arsenite or by constitutive activation of JNK or p38. arsenite 144-152 BCL2 apoptosis regulator Homo sapiens 81-86 10964950-11 2000 These data indicate that both JNK and p38 contribute to arsenite-induced apoptosis in primary CNS neurons, and this apoptosis requires the bcl-2-caspase pathway. arsenite 56-64 BCL2 apoptosis regulator Homo sapiens 139-144 10976921-6 2000 As targets for participation in apoptosis, Bcl-2 and Bcl-xl were phosphorylated in response to JNK activation by taxol or UV; this was prevented by E2. Paclitaxel 113-118 BCL2 apoptosis regulator Homo sapiens 43-48 10962335-9 2000 Coexpression of Ki-67 with bcl-2 was noted in 3 of the 24 RCCs with bcl-2 expression. ki-67 16-21 BCL2 apoptosis regulator Homo sapiens 27-32 10962335-9 2000 Coexpression of Ki-67 with bcl-2 was noted in 3 of the 24 RCCs with bcl-2 expression. ki-67 16-21 BCL2 apoptosis regulator Homo sapiens 68-73 10960601-2 2000 The expression of Bcl-2-family proteins as a function of sensitivity to 1, 3-dinitrobenzene (DNB)-induced mitochondrial permeability transition (MPT) was examined in C6 glioma and SY5Y neuroblastoma cells. 3-dinitrobenzene 72-91 BCL2 apoptosis regulator Homo sapiens 18-23 10960601-2 2000 The expression of Bcl-2-family proteins as a function of sensitivity to 1, 3-dinitrobenzene (DNB)-induced mitochondrial permeability transition (MPT) was examined in C6 glioma and SY5Y neuroblastoma cells. 3-dinitrobenzene 93-96 BCL2 apoptosis regulator Homo sapiens 18-23 10969777-0 2000 Bcl-2 overexpression results in enhanced capacitative calcium entry and resistance to SKF-96365-induced apoptosis. Calcium 54-61 BCL2 apoptosis regulator Homo sapiens 0-5 10969781-3 2000 Apoptosis in THP-1 cells induced by Z-LLL-CHO involved a cytochrome c-dependent pathway, which included the release of mitochondrial cytochrome c, activation of caspase-9 and -3, and cleavage of Bcl-2 into a shortened 22-kDa fragment. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 36-45 BCL2 apoptosis regulator Homo sapiens 195-200 10969777-0 2000 Bcl-2 overexpression results in enhanced capacitative calcium entry and resistance to SKF-96365-induced apoptosis. 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole 86-95 BCL2 apoptosis regulator Homo sapiens 0-5 10969781-8 2000 Likewise, differentiated THP-1 cells were refractory to Z-LLL-CHO-induced cytochrome c release, caspase activation, and Bcl-2 cleavage. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 56-61 BCL2 apoptosis regulator Homo sapiens 120-125 10972198-5 2000 Ginsenoside Rg3 induced classic apoptotic morphology and interfered with the expression of apoptosis-related genes, bcl-2 and caspase-3, in LNCaP cells, as demonstrated by fluorescence microscopy, flow cytometry and reverse transcriptase-polymerase chain reaction. Ginsenosides 0-11 BCL2 apoptosis regulator Homo sapiens 116-121 11798838-0 2000 [The toxic effects of high-dose Bcl-2 antisense phosphorothioate oligodeoxynucleotides incubation on cell line]. phosphorothioate oligodeoxynucleotides 48-86 BCL2 apoptosis regulator Homo sapiens 32-37 11798838-1 2000 OBJECTIVE: To investigate the toxic effects of high-dose Bcl-2 antisense phosphorothioate oligodeoxynucleotides (AS-PS-ODN, ASPO) incubation on HL60 cells and to understand the relationship between the dose of ASPO and the toxicity. phosphorothioate oligodeoxynucleotides 73-111 BCL2 apoptosis regulator Homo sapiens 57-62 11798838-1 2000 OBJECTIVE: To investigate the toxic effects of high-dose Bcl-2 antisense phosphorothioate oligodeoxynucleotides (AS-PS-ODN, ASPO) incubation on HL60 cells and to understand the relationship between the dose of ASPO and the toxicity. as-ps-odn 113-122 BCL2 apoptosis regulator Homo sapiens 57-62 11798838-1 2000 OBJECTIVE: To investigate the toxic effects of high-dose Bcl-2 antisense phosphorothioate oligodeoxynucleotides (AS-PS-ODN, ASPO) incubation on HL60 cells and to understand the relationship between the dose of ASPO and the toxicity. aspo 124-128 BCL2 apoptosis regulator Homo sapiens 57-62 11798838-12 2000 The expression of Bcl-2 protein in the groups of HL60 which were passaged after incubation with ASPO or SPO was reinereased to 99.6% and 97.8%, respectively. aspo 96-100 BCL2 apoptosis regulator Homo sapiens 18-23 11798838-13 2000 CONCLUSION: Although ASPO is a kind of low-toxic drug, the toxic effects of Bcl-2 ASPO seem to be dependent on the dose increasing to a certain extent. aspo 21-25 BCL2 apoptosis regulator Homo sapiens 76-81 11798838-13 2000 CONCLUSION: Although ASPO is a kind of low-toxic drug, the toxic effects of Bcl-2 ASPO seem to be dependent on the dose increasing to a certain extent. aspo 82-86 BCL2 apoptosis regulator Homo sapiens 76-81 11798838-15 2000 Our results may also provide some referring concentrations of Bcl-2 ASPO for the pharmacodynamic and toxicological study in vivo in future. aspo 68-72 BCL2 apoptosis regulator Homo sapiens 62-67 10910950-4 2000 However, those cell lines that overexpressed both v-myc and human bcl-2 showed varying ability to form colonies in soft agar, which did not correlate with their human bcl-2 expression level. Agar 120-124 BCL2 apoptosis regulator Homo sapiens 66-71 10891529-0 2000 Theophylline and cisplatin synergize in down regulation of BCL-2 induction of apoptosis in human granulosa cells transformed by a mutated p53 (p53 val135) and Ha-ras oncogene. Theophylline 0-12 BCL2 apoptosis regulator Homo sapiens 59-64 11006007-0 2000 The downregulation of Bcl-2 expression is necessary for theophylline-induced apoptosis of eosinophil. Theophylline 56-68 BCL2 apoptosis regulator Homo sapiens 22-27 11006007-7 2000 Bcl-2 expression was augmented by IL-5 stimulation, yet it was considerably inhibited by theophylline treatment. Theophylline 89-101 BCL2 apoptosis regulator Homo sapiens 0-5 11006007-8 2000 These data suggest that intracellular cAMP levels and Bcl-2 expression are involved in the suppression of eosinophil survival by theophylline. Theophylline 129-141 BCL2 apoptosis regulator Homo sapiens 54-59 11051041-10 2000 Overall, from numerous studies, the data indicate that in addition to ERalpha bcl-2 is a potential candidate to help further improve our ability to predict response to tamoxifen. Tamoxifen 168-177 BCL2 apoptosis regulator Homo sapiens 78-83 11051041-11 2000 ER and bcl-2 are the most useful molecular markers to better identify breast cancer patients who will respond to tamoxifen and who will have prolonged survival. Tamoxifen 113-122 BCL2 apoptosis regulator Homo sapiens 7-12 10997587-5 2000 Whereas empty-vector control cells exposed to 50 nM ara-C exhibited a decline in Bcl-2 expression, dephosphorylation of pRb, and an initial accumulation in S-phase, antisense-expressing cells did not. Cytarabine 52-57 BCL2 apoptosis regulator Homo sapiens 81-86 11041231-0 2000 Bcl-2, Fas and caspase 3 expression in endometrium from levonorgestrel implant users with and without breakthrough bleeding. Levonorgestrel 56-70 BCL2 apoptosis regulator Homo sapiens 0-5 10891529-0 2000 Theophylline and cisplatin synergize in down regulation of BCL-2 induction of apoptosis in human granulosa cells transformed by a mutated p53 (p53 val135) and Ha-ras oncogene. Cisplatin 17-26 BCL2 apoptosis regulator Homo sapiens 59-64 10891529-2 2000 We have examined the effect of cisplatin alone and in combination with theophylline, a phoshodiesterase inhibitor, on modulation of Bcl-2/Bax expression and induction of apoptosis in human granulosa cells transformed by stable transfection with mutant p53 plus Ha-ras. Cisplatin 31-40 BCL2 apoptosis regulator Homo sapiens 132-137 10891529-2 2000 We have examined the effect of cisplatin alone and in combination with theophylline, a phoshodiesterase inhibitor, on modulation of Bcl-2/Bax expression and induction of apoptosis in human granulosa cells transformed by stable transfection with mutant p53 plus Ha-ras. Theophylline 71-83 BCL2 apoptosis regulator Homo sapiens 132-137 10891529-9 2000 In contrast Bcl-2 protein expression levels were markedly reduced by theophylline and cisplatin in a dose-dependent manner. Theophylline 69-81 BCL2 apoptosis regulator Homo sapiens 12-17 10891529-9 2000 In contrast Bcl-2 protein expression levels were markedly reduced by theophylline and cisplatin in a dose-dependent manner. Cisplatin 86-95 BCL2 apoptosis regulator Homo sapiens 12-17 11043771-11 2000 Anti-Ig treatment of a Fas-sensitive line, A20.2J, activated a number of genes whose products may block apoptosis proximally (like FLICE-inhibitory protein (FLIP1)) or at late points, such as bcl-2-family members. ammonium ferrous sulfate 23-26 BCL2 apoptosis regulator Homo sapiens 192-197 10891529-10 2000 The combination of theophylline and cisplatin resulted in a further dramatic reduction in Bcl-2, under-scoring the pronounced synergy of these two drugs. Theophylline 19-31 BCL2 apoptosis regulator Homo sapiens 90-95 10891529-10 2000 The combination of theophylline and cisplatin resulted in a further dramatic reduction in Bcl-2, under-scoring the pronounced synergy of these two drugs. Cisplatin 36-45 BCL2 apoptosis regulator Homo sapiens 90-95 10891529-11 2000 These observations suggest that suppression of Bcl-2 expression may play an important role in mediating the synergistic effect of cisplatin and theophylline on induction of apoptosis in ovarian cancer cells. Cisplatin 130-139 BCL2 apoptosis regulator Homo sapiens 47-52 10891529-11 2000 These observations suggest that suppression of Bcl-2 expression may play an important role in mediating the synergistic effect of cisplatin and theophylline on induction of apoptosis in ovarian cancer cells. Theophylline 144-156 BCL2 apoptosis regulator Homo sapiens 47-52 10924254-5 2000 We propose that NGF-deprivation promotes dephosphorylation of BAD while hBcl-2 facilitates its release into the cytoplasm where it is degraded by noncaspase, Boc.Asp(O-Me)fmk-inhibitable proteases. asp(o-me 162-170 BCL2 apoptosis regulator Homo sapiens 72-78 10915219-9 2000 Octreotide (10(-6) and 10(-7) M) significantly decreased (P<0.001) forskolin-induced but not basal cAMP accumulation; at both doses for 72 h it inhibited cell growth (20 and 55% respectively), and induced apoptosis (20 and 40%), and abolished Bcl-2 protein in cell lysates. Octreotide 0-10 BCL2 apoptosis regulator Homo sapiens 246-251 10915219-9 2000 Octreotide (10(-6) and 10(-7) M) significantly decreased (P<0.001) forskolin-induced but not basal cAMP accumulation; at both doses for 72 h it inhibited cell growth (20 and 55% respectively), and induced apoptosis (20 and 40%), and abolished Bcl-2 protein in cell lysates. Colforsin 70-79 BCL2 apoptosis regulator Homo sapiens 246-251 10930016-11 2000 Furthermore, low concentrations of etoposide also induced apoptosis in the T-98G/p53 cells by enhancing the expression of transfected wild-type p53, decreasing the expression of bcl-2, and activating CPP32 activity. Etoposide 35-44 BCL2 apoptosis regulator Homo sapiens 178-183 10930016-14 2000 CONCLUSIONS: These findings indicate that wild-type p53, CPP32, and bcl-2 may mediate apoptosis induced by etoposide. Etoposide 107-116 BCL2 apoptosis regulator Homo sapiens 68-73 10908276-10 2000 In summary, these results suggest that the opposite actions of L-Arg and HCG on human corpus luteum viability may, in part, be mediated by changes in the level of the anti-apoptotic activities caused by oestradiol and Bcl-2 protein. Arginine 63-68 BCL2 apoptosis regulator Homo sapiens 218-223 10932011-2 2000 METHODS: The mRNA expressions of Bcl-2 gene in a series of 137 pulmonary tissues collected at various sites and with different properties were studied with Northern hybridization and non-radioactive digoxigenin labeling and detection system. Digoxigenin 199-210 BCL2 apoptosis regulator Homo sapiens 33-38 10951621-1 2000 OBJECTIVE: To evaluate the role of Bcl-2 family proteins in hepatocytic apoptosis caused by ethanol. Ethanol 92-99 BCL2 apoptosis regulator Homo sapiens 35-40 10951621-4 2000 We also observed the expression of Bcl-2 protein in HepG(2) cells infected with Bcl-2 adenovirus vector and its protection against hepatocytic apoptosis caused by ethanol. Ethanol 163-170 BCL2 apoptosis regulator Homo sapiens 35-40 10951621-4 2000 We also observed the expression of Bcl-2 protein in HepG(2) cells infected with Bcl-2 adenovirus vector and its protection against hepatocytic apoptosis caused by ethanol. Ethanol 163-170 BCL2 apoptosis regulator Homo sapiens 80-85 10898955-5 2000 Caspase inhibitors prevented Pa-induced apoptosis, Bcl-2 depletion, and DNase activation. Protactinium 29-31 BCL2 apoptosis regulator Homo sapiens 51-56 10951621-6 2000 CONCLUSION: The overexpression of Bax, Bak proteins may play a role in HepG(2) cell apoptosis induced by ethanol and can be blocked effectively by Bcl-2 adenovirus vector. Ethanol 105-112 BCL2 apoptosis regulator Homo sapiens 147-152 10822135-0 2000 Caspase involved synergistic cytotoxicity of bcl-2 antisense oligonucleotides and adriamycin on transitional cell cancer cells. Oligonucleotides 61-77 BCL2 apoptosis regulator Homo sapiens 45-50 10822135-1 2000 We have previously shown that Bcl-2 expression was negative prognostic factor in transitional cell cancer (TCC), and that TCC cell lines expressing high levels of Bcl-2 are resistant to Adriamycin triggered apoptosis. Doxorubicin 186-196 BCL2 apoptosis regulator Homo sapiens 163-168 10822135-2 2000 Here we examined antisense oligonucleotide-mediated downregulation of Bcl-2 expression and its effect on sensitivity to Adriamycin (ADM) treatment in T24 cells. Oligonucleotides 27-42 BCL2 apoptosis regulator Homo sapiens 70-75 10822135-2 2000 Here we examined antisense oligonucleotide-mediated downregulation of Bcl-2 expression and its effect on sensitivity to Adriamycin (ADM) treatment in T24 cells. Doxorubicin 120-130 BCL2 apoptosis regulator Homo sapiens 70-75 10822135-2 2000 Here we examined antisense oligonucleotide-mediated downregulation of Bcl-2 expression and its effect on sensitivity to Adriamycin (ADM) treatment in T24 cells. Doxorubicin 132-135 BCL2 apoptosis regulator Homo sapiens 70-75 10822135-3 2000 Treatment of T24 cells with 20 microM of bcl-2 antisense phosphorothioate oligodeoxynucleotide (PODN) reduced the Bcl-2 protein level. phosphorothioate oligodeoxynucleotide 57-94 BCL2 apoptosis regulator Homo sapiens 41-46 10822135-3 2000 Treatment of T24 cells with 20 microM of bcl-2 antisense phosphorothioate oligodeoxynucleotide (PODN) reduced the Bcl-2 protein level. phosphorothioate oligodeoxynucleotide 57-94 BCL2 apoptosis regulator Homo sapiens 114-119 10898955-3 2000 In addition, Bcl-2 protein levels were downregulated during Pa-induced cell death. Protactinium 60-62 BCL2 apoptosis regulator Homo sapiens 13-18 10918609-0 2000 Influence of Bax or Bcl-2 overexpression on the ceramide-dependent apoptotic pathway in glioma cells. Ceramides 48-56 BCL2 apoptosis regulator Homo sapiens 20-25 10918609-2 2000 In the present study, the effects of Bcl-2 and Bax on the ceramide-mediated apoptotic pathways were examined in glioma cells overexpressing Bcl-2 or Bax. Ceramides 58-66 BCL2 apoptosis regulator Homo sapiens 37-42 10918609-8 2000 In contrast, Bcl-2 overexpression resulted in a retardation of the apoptotic process via prevention of cytochrome c release and caspases activation, and ceramide formation was also blocked when Bcl-2 was highly overexpressed in glioma cells. Ceramides 153-161 BCL2 apoptosis regulator Homo sapiens 13-18 10918609-8 2000 In contrast, Bcl-2 overexpression resulted in a retardation of the apoptotic process via prevention of cytochrome c release and caspases activation, and ceramide formation was also blocked when Bcl-2 was highly overexpressed in glioma cells. Ceramides 153-161 BCL2 apoptosis regulator Homo sapiens 194-199 10918609-10 2000 These results indicate that Bax promotes apoptosis regardless of ceramide formation and that Bcl-2 or Bcl-xL prevents ceramide formation by repressing neutral sphingomyelinase as well as ceramide-induced cytochrome c release. Ceramides 118-126 BCL2 apoptosis regulator Homo sapiens 93-98 10918609-10 2000 These results indicate that Bax promotes apoptosis regardless of ceramide formation and that Bcl-2 or Bcl-xL prevents ceramide formation by repressing neutral sphingomyelinase as well as ceramide-induced cytochrome c release. Ceramides 118-126 BCL2 apoptosis regulator Homo sapiens 93-98 10887097-4 2000 Flavopiridol (0.1 mcmol/L) and UCN-01 (1 mcmol/L) also induced striking decreases in the levels of the antiapoptosis proteins Mcl-1, X-linked inhibitor of apoptosis (XIAP), and BAG-1 in nearly all cases of B-CLL and of Bcl-2 in approximately half of B-CLL specimens evaluated. alvocidib 0-12 BCL2 apoptosis regulator Homo sapiens 219-224 10880354-2 2000 A variety of survival signals are reported to induce the phosphorylation of BAD at Ser(112) or Ser(136), triggering its dissociation from Bcl-2/Bcl-X(L). Serine 83-86 BCL2 apoptosis regulator Homo sapiens 138-143 10880354-2 2000 A variety of survival signals are reported to induce the phosphorylation of BAD at Ser(112) or Ser(136), triggering its dissociation from Bcl-2/Bcl-X(L). Serine 95-98 BCL2 apoptosis regulator Homo sapiens 138-143 10766756-3 2000 When CDC2 was activated by okadaic acid in HL-60 cells, Bcl-2 phosphorylation was readily induced. Okadaic Acid 27-39 BCL2 apoptosis regulator Homo sapiens 56-61 10873618-2 2000 To look at this more closely, we examined the changes in the levels of Bcl-2 family proteins during 8-Cl-cAMP-induced apoptosis of SH-SY5Y human neuroblastoma cells. 8-chloro-cyclic adenosine monophosphate 100-109 BCL2 apoptosis regulator Homo sapiens 71-76 10873618-3 2000 Following the treatment with 8-Cl-cAMP, Bcl-2 was transiently down-regulated and Bad was increased continuously up to day 5. 8-chloro-cyclic adenosine monophosphate 29-38 BCL2 apoptosis regulator Homo sapiens 40-45 10873618-4 2000 In addition, overexpression of Bcl-2 efficiently blocked the 8-Cl-cAMP-induced apoptosis, suggesting Bcl-2 family proteins may be involved in the 8-Cl-cAMP-induced apoptosis. 8-chloro-cyclic adenosine monophosphate 61-70 BCL2 apoptosis regulator Homo sapiens 31-36 10873618-4 2000 In addition, overexpression of Bcl-2 efficiently blocked the 8-Cl-cAMP-induced apoptosis, suggesting Bcl-2 family proteins may be involved in the 8-Cl-cAMP-induced apoptosis. 8-chloro-cyclic adenosine monophosphate 61-70 BCL2 apoptosis regulator Homo sapiens 101-106 10873618-4 2000 In addition, overexpression of Bcl-2 efficiently blocked the 8-Cl-cAMP-induced apoptosis, suggesting Bcl-2 family proteins may be involved in the 8-Cl-cAMP-induced apoptosis. 8-cl 61-65 BCL2 apoptosis regulator Homo sapiens 31-36 10873618-4 2000 In addition, overexpression of Bcl-2 efficiently blocked the 8-Cl-cAMP-induced apoptosis, suggesting Bcl-2 family proteins may be involved in the 8-Cl-cAMP-induced apoptosis. 8-cl 61-65 BCL2 apoptosis regulator Homo sapiens 101-106 10873618-4 2000 In addition, overexpression of Bcl-2 efficiently blocked the 8-Cl-cAMP-induced apoptosis, suggesting Bcl-2 family proteins may be involved in the 8-Cl-cAMP-induced apoptosis. 8-chloro-cyclic adenosine monophosphate 66-70 BCL2 apoptosis regulator Homo sapiens 31-36 10873618-4 2000 In addition, overexpression of Bcl-2 efficiently blocked the 8-Cl-cAMP-induced apoptosis, suggesting Bcl-2 family proteins may be involved in the 8-Cl-cAMP-induced apoptosis. 8-chloro-cyclic adenosine monophosphate 66-70 BCL2 apoptosis regulator Homo sapiens 101-106 10873618-5 2000 The contribution of the apoptotic cell death and the inhibition of cell proliferation in the 8-Cl-cAMP-induced growth inhibition was closely monitored in the Bcl-2-overexpressing cells. 8-chloro-cyclic adenosine monophosphate 93-102 BCL2 apoptosis regulator Homo sapiens 158-163 10953339-12 2000 The modulation of bcl-2 may be dependent on specific structural differences between LA and the parent compound chalcone and independent of LA estrogenicity. Chalcone 111-119 BCL2 apoptosis regulator Homo sapiens 18-23 10953339-0 2000 Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. licochalcone A 40-54 BCL2 apoptosis regulator Homo sapiens 14-19 10953339-0 2000 Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Flavonoids 75-84 BCL2 apoptosis regulator Homo sapiens 14-19 10766756-7 2000 Using synthetic peptides and mutant cell lines, we identified threonine 56, one of two consensus sites for CDC2 within the Bcl-2 sequence, as a residue phosphorylated by CDC2. Threonine 62-71 BCL2 apoptosis regulator Homo sapiens 123-128 10766756-8 2000 Mutation at threonine 56 abrogated the cell cycle inhibitory effect of Bcl-2 without affecting anti-apoptotic function. Threonine 12-21 BCL2 apoptosis regulator Homo sapiens 71-76 10913502-0 2000 Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2"s neurotrophic effects? Lithium 0-7 BCL2 apoptosis regulator Homo sapiens 88-93 10807947-5 2000 A comparison of effects of drugs belonging to the same class but endowed with a different antitumor activity (i.e. cisplatin versus a novel multinuclear platinum complex and doxorubicin versus a disaccharide analogue) showed a correlation between drug efficacy, apoptotic response, and Bcl-2 phosphorylation. Cisplatin 115-124 BCL2 apoptosis regulator Homo sapiens 286-291 10807947-5 2000 A comparison of effects of drugs belonging to the same class but endowed with a different antitumor activity (i.e. cisplatin versus a novel multinuclear platinum complex and doxorubicin versus a disaccharide analogue) showed a correlation between drug efficacy, apoptotic response, and Bcl-2 phosphorylation. Platinum 153-161 BCL2 apoptosis regulator Homo sapiens 286-291 10807947-5 2000 A comparison of effects of drugs belonging to the same class but endowed with a different antitumor activity (i.e. cisplatin versus a novel multinuclear platinum complex and doxorubicin versus a disaccharide analogue) showed a correlation between drug efficacy, apoptotic response, and Bcl-2 phosphorylation. Doxorubicin 174-185 BCL2 apoptosis regulator Homo sapiens 286-291 10913502-0 2000 Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2"s neurotrophic effects? N-acetylaspartate 18-36 BCL2 apoptosis regulator Homo sapiens 88-93 10930993-5 2000 Good responders to initial prednisone therapy ("prednisone response") revealed significantly higher Bcl-2 expression levels [5.4 +/- 3.4 relative fluorescence intensity (RFI), n = 68] than poor responders (3.7 +/- 2.6 RFI, n = 42; P = 0.002). Prednisone 27-37 BCL2 apoptosis regulator Homo sapiens 100-105 10930993-5 2000 Good responders to initial prednisone therapy ("prednisone response") revealed significantly higher Bcl-2 expression levels [5.4 +/- 3.4 relative fluorescence intensity (RFI), n = 68] than poor responders (3.7 +/- 2.6 RFI, n = 42; P = 0.002). Prednisone 48-58 BCL2 apoptosis regulator Homo sapiens 100-105 10889510-5 2000 Transfection with Bcl-2 (SHEP/Bcl-2 cells) prevents serum withdrawal and mannitol induced apoptosis and caspase-3 activation. Mannitol 73-81 BCL2 apoptosis regulator Homo sapiens 18-23 10861090-5 2000 Paclitaxel, a microtubule-stabilizing drug known to inhibit Bcl-2 antiapoptotic activity and to be highly effective in the treatment of certain neoplasms, has recently been found to be active also in patients with advanced HIV-associated KS. Paclitaxel 0-10 BCL2 apoptosis regulator Homo sapiens 60-65 10889510-5 2000 Transfection with Bcl-2 (SHEP/Bcl-2 cells) prevents serum withdrawal and mannitol induced apoptosis and caspase-3 activation. Mannitol 73-81 BCL2 apoptosis regulator Homo sapiens 30-35 10962206-5 2000 These alterations were delayed in MCF-7/ADR cells transfected with bcl-2 and completely suppressed by treatment with an antioxidant, N-acetyl-L-cysteine. Acetylcysteine 133-152 BCL2 apoptosis regulator Homo sapiens 67-72 10937688-9 2000 In contrast, patients drinking lesser amounts of ethanol had lower rates of hepatocyte apoptosis and more frequent bcl-2 expression. Ethanol 49-56 BCL2 apoptosis regulator Homo sapiens 115-120 10937688-12 2000 The precise role of apoptosis in the pathogenesis of hepatitis C-related liver injury remains unclear, but its induction may be related to downregulation of bcl-2 expression associated with ethanol consumption. Ethanol 190-197 BCL2 apoptosis regulator Homo sapiens 157-162 10910051-4 2000 Growth arrest prevented paclitaxel-induced Bcl-2 phosphorylation and apoptosis without affecting paclitaxel-induced tubulin polymerization. Paclitaxel 24-34 BCL2 apoptosis regulator Homo sapiens 43-48 10910051-6 2000 Unlike MCF-7 cells, MCF-10A cells were arrested by epidermal growth factor withdrawal, precluding paclitaxel-induced Bcl-2 phosphorylation. Paclitaxel 98-108 BCL2 apoptosis regulator Homo sapiens 117-122 10914739-0 2000 Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Oligonucleotides 93-108 BCL2 apoptosis regulator Homo sapiens 77-82 10914739-2 2000 This study investigated the activity of the Bcl-2 antisense oligodeoxynucleotide (AS ODN) G3139 combined with free doxorubicin (F-DOX) or sterically stabilized liposomal doxorubicin (SL-DOX) to determine the role that drug pharmacodistribution properties may have on antitumor activity using a Bcl-2-expressing human breast solid tumor xenograft model. Oligodeoxyribonucleotides 60-80 BCL2 apoptosis regulator Homo sapiens 44-49 10914739-2 2000 This study investigated the activity of the Bcl-2 antisense oligodeoxynucleotide (AS ODN) G3139 combined with free doxorubicin (F-DOX) or sterically stabilized liposomal doxorubicin (SL-DOX) to determine the role that drug pharmacodistribution properties may have on antitumor activity using a Bcl-2-expressing human breast solid tumor xenograft model. sl-dox 183-189 BCL2 apoptosis regulator Homo sapiens 44-49 11100818-11 2000 Bcl-2 overexpressing and control human glioma cell clones (T98MG line) were treated in culture with the cytotoxic drugs carmustine (BCNU), paclitaxel, vincristine, and doxorubicin. Carmustine 120-130 BCL2 apoptosis regulator Homo sapiens 0-5 11100818-11 2000 Bcl-2 overexpressing and control human glioma cell clones (T98MG line) were treated in culture with the cytotoxic drugs carmustine (BCNU), paclitaxel, vincristine, and doxorubicin. Doxorubicin 168-179 BCL2 apoptosis regulator Homo sapiens 0-5 11100818-11 2000 Bcl-2 overexpressing and control human glioma cell clones (T98MG line) were treated in culture with the cytotoxic drugs carmustine (BCNU), paclitaxel, vincristine, and doxorubicin. Carmustine 132-136 BCL2 apoptosis regulator Homo sapiens 0-5 11100818-12 2000 In addition, bcl-2-overexpressing and control cells were infected with a retrovirus carrying the herpes-simplex-virus thymidine kinase gene (HSV-tk), and then treated with ganciclovir (GCV). Ganciclovir 172-183 BCL2 apoptosis regulator Homo sapiens 13-18 11100818-11 2000 Bcl-2 overexpressing and control human glioma cell clones (T98MG line) were treated in culture with the cytotoxic drugs carmustine (BCNU), paclitaxel, vincristine, and doxorubicin. Paclitaxel 139-149 BCL2 apoptosis regulator Homo sapiens 0-5 11100818-12 2000 In addition, bcl-2-overexpressing and control cells were infected with a retrovirus carrying the herpes-simplex-virus thymidine kinase gene (HSV-tk), and then treated with ganciclovir (GCV). Ganciclovir 185-188 BCL2 apoptosis regulator Homo sapiens 13-18 11100818-13 2000 Bcl-2 overexpression significantly increased tumor cell resistance against all of the above cytotoxic drugs, and also against HSV-TK/GCV mediated gene therapy. Ganciclovir 133-136 BCL2 apoptosis regulator Homo sapiens 0-5 10949026-3 2000 When BAD is bound to prosurvival Bcl-2 family members, BAD Ser-155 phosphorylation requires the prior phosphorylation of Ser-136, which recruits 14-3-3 proteins that then function to increase the accessibility of Ser-155 to survival-promoting kinases. Serine 59-62 BCL2 apoptosis regulator Homo sapiens 33-38 10949026-2 2000 We report that survival factors trigger the phosphorylation of the proapoptotic Bcl-2 family member BAD at a site (Ser-155) within the BAD BH3 domain. Serine 115-118 BCL2 apoptosis regulator Homo sapiens 80-85 10949026-3 2000 When BAD is bound to prosurvival Bcl-2 family members, BAD Ser-155 phosphorylation requires the prior phosphorylation of Ser-136, which recruits 14-3-3 proteins that then function to increase the accessibility of Ser-155 to survival-promoting kinases. Serine 121-124 BCL2 apoptosis regulator Homo sapiens 33-38 10949026-3 2000 When BAD is bound to prosurvival Bcl-2 family members, BAD Ser-155 phosphorylation requires the prior phosphorylation of Ser-136, which recruits 14-3-3 proteins that then function to increase the accessibility of Ser-155 to survival-promoting kinases. Serine 121-124 BCL2 apoptosis regulator Homo sapiens 33-38 10949026-4 2000 Ser-155 phosphorylation disrupts the binding of BAD to prosurvival Bcl-2 proteins and thereby promotes cell survival. Serine 0-3 BCL2 apoptosis regulator Homo sapiens 67-72 11776191-10 2000 Analysis on expression of intracellular bcl-2 protein showed that progesterone could down-regulate bcl-2 protein and at concentration of 1 x 10(-5) mol/L it could almost block bcl-2 expression. Progesterone 66-78 BCL2 apoptosis regulator Homo sapiens 40-45 11776191-10 2000 Analysis on expression of intracellular bcl-2 protein showed that progesterone could down-regulate bcl-2 protein and at concentration of 1 x 10(-5) mol/L it could almost block bcl-2 expression. Progesterone 66-78 BCL2 apoptosis regulator Homo sapiens 99-104 11776191-10 2000 Analysis on expression of intracellular bcl-2 protein showed that progesterone could down-regulate bcl-2 protein and at concentration of 1 x 10(-5) mol/L it could almost block bcl-2 expression. Progesterone 66-78 BCL2 apoptosis regulator Homo sapiens 99-104 11778549-0 2000 [The effects of RA538 and antisense c-myc on cervical cancer cell lines with high expression of bcl-2 gene]. ra538 16-21 BCL2 apoptosis regulator Homo sapiens 96-101 11877007-4 2000 Higher concentration of As(2)O(3) induced apoptosis in HL-60 or NB4 cells accompanied by more rapid down regulation of telomerase activity and bcl-2 expression. Arsenic Trioxide 24-33 BCL2 apoptosis regulator Homo sapiens 143-148 10866313-5 2000 Inhibition of TK/GCV-induced mitochondrial perturbations by Bcl-2 overexpression or by the mitochondrion-specific inhibitor bongkrekic acid also strongly inhibited TK/GCV-induced activation of caspases and apoptosis. Ganciclovir 17-20 BCL2 apoptosis regulator Homo sapiens 60-65 10866313-5 2000 Inhibition of TK/GCV-induced mitochondrial perturbations by Bcl-2 overexpression or by the mitochondrion-specific inhibitor bongkrekic acid also strongly inhibited TK/GCV-induced activation of caspases and apoptosis. Ganciclovir 167-170 BCL2 apoptosis regulator Homo sapiens 60-65 10866313-7 2000 Perturbation of mitochondrial function mediated accumulation of wild-type p53 protein, since Bcl-2 overexpression, bongkrekic acid, or inhibition of mitochondrial protein synthesis with chloramphenicol strongly reduced TK/GCV-induced accumulation of wild-type p53 protein. Ganciclovir 222-225 BCL2 apoptosis regulator Homo sapiens 93-98 10866313-8 2000 These findings suggest that TK/GCV therapy may be less efficient in tumors in which the mitochondrial amplification of TK/GCV-induced apoptosis is blocked, e.g., by Bcl-2 overexpression. Ganciclovir 31-34 BCL2 apoptosis regulator Homo sapiens 165-170 10866313-8 2000 These findings suggest that TK/GCV therapy may be less efficient in tumors in which the mitochondrial amplification of TK/GCV-induced apoptosis is blocked, e.g., by Bcl-2 overexpression. Ganciclovir 122-125 BCL2 apoptosis regulator Homo sapiens 165-170 10751382-0 2000 Bcl-2 inhibits a Fas-induced conformational change in the Bax N terminus and Bax mitochondrial translocation. ammonium ferrous sulfate 17-20 BCL2 apoptosis regulator Homo sapiens 0-5 10845930-0 2000 Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Oligonucleotides 26-42 BCL2 apoptosis regulator Homo sapiens 10-15 10845930-0 2000 Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Cytarabine 102-122 BCL2 apoptosis regulator Homo sapiens 10-15 10845930-4 2000 Down-regulation of Bcl-2 by Bcl-2-AS reduced the viability of HL-60 cells and, less effectively, HL-60-DOX cells and increased ara-C cytotoxicity in both cell lines. Doxorubicin 103-106 BCL2 apoptosis regulator Homo sapiens 19-24 10845930-4 2000 Down-regulation of Bcl-2 by Bcl-2-AS reduced the viability of HL-60 cells and, less effectively, HL-60-DOX cells and increased ara-C cytotoxicity in both cell lines. Cytarabine 127-132 BCL2 apoptosis regulator Homo sapiens 19-24 10845930-4 2000 Down-regulation of Bcl-2 by Bcl-2-AS reduced the viability of HL-60 cells and, less effectively, HL-60-DOX cells and increased ara-C cytotoxicity in both cell lines. Cytarabine 127-132 BCL2 apoptosis regulator Homo sapiens 28-33 10845930-5 2000 Incubation of primary AML blasts with Bcl-2-AS decreased Bcl-2 expression in CD34(+) blast cells after induction of apoptosis and enhancement of ara-C cytotoxicity in 11 of 19 primary AML samples. Cytarabine 145-150 BCL2 apoptosis regulator Homo sapiens 38-43 10861861-3 2000 For example, the well-known lectin, galectin-3, a lactose-binding protein, can act inside the nucleus in splicing events, and at the plasma membrane in adhesion, and it was demonstrated that galectin-3 interacts in the cytoplasm with Bcl-2, an antiapoptotic protein. Lactose 50-57 BCL2 apoptosis regulator Homo sapiens 234-239 10816444-0 2000 Bcl-2 accelerates retinoic acid-induced growth arrest and recovery in human gastric cancer cells. Tretinoin 18-31 BCL2 apoptosis regulator Homo sapiens 0-5 10862921-10 2000 Gene expression was defined with the method of reverse transcription by cDNA synthesis and amplification of bcl-2 gene fragment with specific oligonucleotides in reverse transcriptase polymerase chain reaction (RT-PCR). Oligonucleotides 142-158 BCL2 apoptosis regulator Homo sapiens 108-113 10911913-11 2000 The "Bcl-2 rheostat" may be pitched against apoptosis in colon cancer, inasmuch as overexpression of Bcl-2, downregulation of Bak, and mutation of Bax are common defects in colon tumors. bakuchiol 126-129 BCL2 apoptosis regulator Homo sapiens 5-10 10751558-9 2000 Moreover, our results demonstrate that tocopherols may exert their antiatherogenic effects at least in part via reduction of the MAPK and JunK cascade together with a protective profile of apoptotic genes of the Bcl-2 family. Tocopherols 39-50 BCL2 apoptosis regulator Homo sapiens 212-217 10816444-12 2000 In a search for the mechanism by which Bcl-2 affects growth regulation, we found that p21 gene expression was more prominent in SC-M1/Bcl2 cells than in SC-M1/neo cells in the presence of RA, but when RA was removed, p21 gene expression levels in SC-M1/Bcl2 cells were also reduced earlier than in SC-M1/neo cells. Tretinoin 201-203 BCL2 apoptosis regulator Homo sapiens 39-44 10843893-9 2000 These data suggest that glucose treatment renders the cardiomyocyte resistant to hypoxia-induced apoptosis and necrosis by preventing the accumulation of Ca(2+) during hypoxia, promoting the upregulation of Bcl-2, and enhancing the inactivation of Bad. Glucose 24-31 BCL2 apoptosis regulator Homo sapiens 207-212 10816444-6 2000 In this study, when treated with RA, SC-M1/Bcl2 cells, which were generated by transfecting SC-M1 cells with bcl-2 DNA, were growth-arrested two days earlier than SC-M1/neo cells, which were generated by transfecting SC-M1 cells with vector DNA. Tretinoin 33-35 BCL2 apoptosis regulator Homo sapiens 43-47 10816444-6 2000 In this study, when treated with RA, SC-M1/Bcl2 cells, which were generated by transfecting SC-M1 cells with bcl-2 DNA, were growth-arrested two days earlier than SC-M1/neo cells, which were generated by transfecting SC-M1 cells with vector DNA. Tretinoin 33-35 BCL2 apoptosis regulator Homo sapiens 109-114 10816444-7 2000 This indicates that Bcl-2 accelerates RA-induced growth arrest. Tretinoin 38-40 BCL2 apoptosis regulator Homo sapiens 20-25 10816444-8 2000 In addition to the accelerated growth arrest, RA-treated SC-M1/Bcl2 cells also recovered from growth arrest two days faster than SC-M1/neo cells after the removal of RA. Tretinoin 46-48 BCL2 apoptosis regulator Homo sapiens 63-67 10816444-12 2000 In a search for the mechanism by which Bcl-2 affects growth regulation, we found that p21 gene expression was more prominent in SC-M1/Bcl2 cells than in SC-M1/neo cells in the presence of RA, but when RA was removed, p21 gene expression levels in SC-M1/Bcl2 cells were also reduced earlier than in SC-M1/neo cells. Tretinoin 188-190 BCL2 apoptosis regulator Homo sapiens 39-44 10822281-5 2000 The overall responses were qualitatively similar in both cell types, but MCF-7 cells treated with Taxol showed a significant delay in apoptosis, correlating with early up-regulation of Bcl-2 and delayed release of cytochrome c. Paclitaxel 98-103 BCL2 apoptosis regulator Homo sapiens 185-190 10868686-7 2000 Down-regulation of bcl-2 by aspirin was found in the two cell lines tested. Aspirin 28-35 BCL2 apoptosis regulator Homo sapiens 19-24 10822274-1 2000 Calphostin C-mediated apoptosis in glioma cells was reported previously to be associated with down-regulation of Bcl-2 and Bcl-xL. calphostin C 0-12 BCL2 apoptosis regulator Homo sapiens 113-118 10822275-7 2000 Moreover, the ability of Ro-31-8220 to induce apoptotic activation was completely inhibited by the over-expression of the apoptotic suppressor gene, Bcl-2, in the cells. ro-31 25-30 BCL2 apoptosis regulator Homo sapiens 149-154 10850456-9 2000 Tumor cells overexpressing Bcl-2 or Bcl-xL become resistant to apoptosis induced by the chemotherapeutic drug etoposide. Etoposide 110-119 BCL2 apoptosis regulator Homo sapiens 27-32 10874212-0 2000 Spicamycin and KRN5500 induce apoptosis in myeloid and lymphoid cell lines with down-regulation of bcl-2 expression and modulation of promyelocytic leukemia protein. septacidin 0-10 BCL2 apoptosis regulator Homo sapiens 99-104 10873104-2 2000 If the level of Bcl-2 protein can be reduced sufficiently using antisense oligonucleotides (ASOs) targeting the gene message, then cytotoxic agents may be rendered more effective in eliminating disease and increasing cure rate. Oligonucleotides 74-90 BCL2 apoptosis regulator Homo sapiens 16-21 10873104-2 2000 If the level of Bcl-2 protein can be reduced sufficiently using antisense oligonucleotides (ASOs) targeting the gene message, then cytotoxic agents may be rendered more effective in eliminating disease and increasing cure rate. Oligonucleotides, Antisense 92-96 BCL2 apoptosis regulator Homo sapiens 16-21 10873104-4 2000 These data confirm that a combination of an ASO (5 mg/kg) targeting bcl-2 and a low dose of cyclophosphamide (35 mg/kg) was an effective strategy, leading to the eradication of the DoHH2 cells in vivo and cure of the animals. Oligonucleotides, Antisense 44-47 BCL2 apoptosis regulator Homo sapiens 68-73 10873111-0 2000 A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Oligonucleotides 29-44 BCL2 apoptosis regulator Homo sapiens 61-66 10873111-4 2000 To test the possibility that oligonucleotides targeting this region have the potential to down-regulate bcl-2 and bcl-xL expression simultaneously, three 2"-O-methoxy-ethoxy-modified phosphorothioate oligonucleotides were designed. Oligonucleotides 29-45 BCL2 apoptosis regulator Homo sapiens 104-109 10873111-5 2000 These oligonucleotides differed in the number of mismatches to bcl-2 and bcl-xL and in the number of nucleotides to which the modifications were made. Oligonucleotides 6-22 BCL2 apoptosis regulator Homo sapiens 63-68 10873111-9 2000 This is the first report of a bcl-2/bcl-xL bispecific antisense oligonucleotide that deserves attention as a therapeutic compound in lung cancer and other malignancies in which bcl-2 and/or bcl-xL are overexpressed. Oligonucleotides 64-79 BCL2 apoptosis regulator Homo sapiens 30-35 10873111-9 2000 This is the first report of a bcl-2/bcl-xL bispecific antisense oligonucleotide that deserves attention as a therapeutic compound in lung cancer and other malignancies in which bcl-2 and/or bcl-xL are overexpressed. Oligonucleotides 64-79 BCL2 apoptosis regulator Homo sapiens 177-182 10841223-1 2000 OBJECTIVES: To elucidate the pattern of expression of four members of the Bcl-2 family of proteins and to correlate this with terminal deoxynucleotidyl transferase [TdT]-mediated dUTP nick end labelling (TUNEL) and DNA fragmentation. deoxyuridine triphosphate 179-183 BCL2 apoptosis regulator Homo sapiens 74-79 10811458-7 2000 Various mechanisms have been proposed for the As2O3-induced changes in NB4 (including modulation of promyelocytic leukemia proteins (PML) and Bcl-2, modification of the glutathione redox system, caspase activation, and cell cycle arrest) and are currently under investigation in the megakaryocytic leukemia cell lines. Arsenic Trioxide 46-51 BCL2 apoptosis regulator Homo sapiens 142-147 10811458-8 2000 Recent preliminary results indicate that As2O3 downregulates Bcl-2 expression and induces cell cycle arrest in megakaryocytic cell lines. Arsenic Trioxide 41-46 BCL2 apoptosis regulator Homo sapiens 61-66 10857791-6 2000 The phosphorylation and/or recruitment of these proteins to the snoRNP complex is induced by multiple apoptotic stimuli (e.g., Fas ligation, anisomycin, or ultraviolet irradiation), an effect that is blocked by overexpression of Bcl-2. Anisomycin 141-151 BCL2 apoptosis regulator Homo sapiens 229-234 10874212-0 2000 Spicamycin and KRN5500 induce apoptosis in myeloid and lymphoid cell lines with down-regulation of bcl-2 expression and modulation of promyelocytic leukemia protein. KRN 5500 15-22 BCL2 apoptosis regulator Homo sapiens 99-104 11776172-4 2000 RESULTS: In NTP group apoptosis index(AI) of cytotrophoblasts(CT) and syncytiophoblasts(ST) in placenta was (1.1 +/- 0.9)% and (41.8 +/- 1.5)%; bax positive rate was (1.0 +/- 0.9)% and (28.9 +/- 9.7)%; bcl-2 was (2.2 +/- 0.8)% and (22.9 +/- 0.7)% respectively; bax/bcl-2 was 0.7-1.7. ntp 12-15 BCL2 apoptosis regulator Homo sapiens 202-207 12578696-4 2000 Compare with previously untreated AL, relapse/refractory AL patients had higher Bcl-2 and P53 protein level, lower marrow complete remission, and was easy to relapse. Aluminum 57-59 BCL2 apoptosis regulator Homo sapiens 80-85 10823933-7 2000 Analysis of the kinetics of Ca(2+) store depletion in response to the Ca(2+)-ATPase inhibitor thapsigargin revealed that Bcl-2 increased the permeability of the ER membrane. Thapsigargin 94-106 BCL2 apoptosis regulator Homo sapiens 121-126 10825137-0 2000 Induction of apoptosis in leukemic cells by the reversible microtubule-disrupting agent 2-methoxy-5-(2",3",4"-trimethoxyphenyl)-2,4,6-cycloheptatrien-1 -one: protection by Bcl-2 and Bcl-X(L) and cell cycle arrest. 2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone 88-156 BCL2 apoptosis regulator Homo sapiens 172-177 10825137-9 2000 Overexpression of bcl-2 or bcl-xL by gene transfer in human erythroleukemic HEL cells abrogated MTC-induced apoptosis, but cells remained arrested in G2-M, suggesting that bcl-2 and bcl-xL block the signaling pathway between G2-M arrest and triggering of apoptosis. 2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone 96-99 BCL2 apoptosis regulator Homo sapiens 18-23 10825137-10 2000 MTC-treated bcl-2 and bcl-xL-transfected HEL cells recovered their capacity to proliferate after MTC removal. 2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone 0-3 BCL2 apoptosis regulator Homo sapiens 12-17 10825137-10 2000 MTC-treated bcl-2 and bcl-xL-transfected HEL cells recovered their capacity to proliferate after MTC removal. 2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone 97-100 BCL2 apoptosis regulator Homo sapiens 12-17 11776172-4 2000 RESULTS: In NTP group apoptosis index(AI) of cytotrophoblasts(CT) and syncytiophoblasts(ST) in placenta was (1.1 +/- 0.9)% and (41.8 +/- 1.5)%; bax positive rate was (1.0 +/- 0.9)% and (28.9 +/- 9.7)%; bcl-2 was (2.2 +/- 0.8)% and (22.9 +/- 0.7)% respectively; bax/bcl-2 was 0.7-1.7. ntp 12-15 BCL2 apoptosis regulator Homo sapiens 265-270 10813710-0 2000 Medroxyprogesterone acetate inhibits human pancreatic carcinoma cell growth by inducing apoptosis in association with Bcl-2 phosphorylation. Medroxyprogesterone Acetate 0-27 BCL2 apoptosis regulator Homo sapiens 118-123 10822379-6 2000 Surprisingly, cytochrome c release by BFA is not only blocked by wild-type Bcl-2 but also by a Bcl-2 variant that is exclusively targeted to the ER (Bcl-2/cb5). Brefeldin A 38-41 BCL2 apoptosis regulator Homo sapiens 75-80 10822379-6 2000 Surprisingly, cytochrome c release by BFA is not only blocked by wild-type Bcl-2 but also by a Bcl-2 variant that is exclusively targeted to the ER (Bcl-2/cb5). Brefeldin A 38-41 BCL2 apoptosis regulator Homo sapiens 95-100 10822379-6 2000 Surprisingly, cytochrome c release by BFA is not only blocked by wild-type Bcl-2 but also by a Bcl-2 variant that is exclusively targeted to the ER (Bcl-2/cb5). Brefeldin A 38-41 BCL2 apoptosis regulator Homo sapiens 95-100 10832914-5 2000 RESULTS: Ethanol-treated PNET2 neuronal cells exhibited increased apoptosis mediated by increased levels of p53 and phospho-amino-terminal c-jun kinase (phospho-JNK), and reduced levels of Bcl-2, phosphoinositol 3-kinase (PI3 K), and intact (approximately 116 kD) poly (ADP ribose) polymerase (PARP), a deoxyribonucleic acid repair enzyme and important substrate for caspase 3. Ethanol 9-16 BCL2 apoptosis regulator Homo sapiens 189-194 10773101-12 2000 These findings indicated that Fas-mediated apoptosis was inhibited by the Bcl-2 family in the development of teeth. ammonium ferrous sulfate 30-33 BCL2 apoptosis regulator Homo sapiens 74-79 10807870-11 2000 The importance of NF-kappaB in endothelial apoptosis was confirmed by the observation that pyrrolidine dithiocarbamate, a potent NF-kappaB inhibitor, prevented endothelial apoptosis, caspase 3-like activity, and bcl-2 downregulation induced by hypoxia. pyrrolidine dithiocarbamic acid 91-118 BCL2 apoptosis regulator Homo sapiens 212-217 10784621-0 2000 Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin"s lymphoma. Oligonucleotides 62-77 BCL2 apoptosis regulator Homo sapiens 46-51 10785588-2 2000 We have previously reported that decreased expression of Bcl-2 and/or Ki-S1 were associated with tumour response to neo-adjuvant tamoxifen in 50 elderly women with oestrogen receptor (ER)-positive breast cancer. Tamoxifen 129-138 BCL2 apoptosis regulator Homo sapiens 57-62 10785588-6 2000 These data suggest there are at least two mechanisms for effective tamoxifen therapy: increased apoptosis as a consequence of reduced Bcl-2 expression, and decreased proliferation. Tamoxifen 67-76 BCL2 apoptosis regulator Homo sapiens 134-139 10784621-1 2000 PURPOSE: To evaluate the pharmacokinetics and toxicity of an antisense oligonucleotide targeting bcl-2 in patients with non-Hodgkin"s lymphoma (NHL) and to determine efficacy using clinical and biologic end points. Oligonucleotides 71-86 BCL2 apoptosis regulator Homo sapiens 97-102 10779771-5 2000 However, compared with EGFP-transduced HUVEC, the Bcl-2-transduced cells are resistant to the apoptotic effects of serum and growth factor withdrawal and are also resistant to the induction of apoptosis by staurosporine or by ceramide, with or without TNF. Staurosporine 206-219 BCL2 apoptosis regulator Homo sapiens 50-55 10771474-7 2000 Notably, despite the induction of apoptosis, analysis of the expression of Bcl-2 family members in betulinic-acid-treated cells revealed that expression of the anti-apoptotic protein Mcl-1 was induced. betulinic acid 99-113 BCL2 apoptosis regulator Homo sapiens 75-80 10779771-5 2000 However, compared with EGFP-transduced HUVEC, the Bcl-2-transduced cells are resistant to the apoptotic effects of serum and growth factor withdrawal and are also resistant to the induction of apoptosis by staurosporine or by ceramide, with or without TNF. Ceramides 226-234 BCL2 apoptosis regulator Homo sapiens 50-55 10811013-7 2000 Bak and bfl-1 mRNA levels were largely increased during DMSO-induced differentiation of HL-60 cells, and these genes were the bcl-2 family members that were expressed most abundantly in mature neutrophils. Dimethyl Sulfoxide 56-60 BCL2 apoptosis regulator Homo sapiens 126-131 10811013-5 2000 After DMSO treatment, bak, bcl-w, bfl-1, fas, and caspases 1 and 9 were up-regulated, whereas bik, bcl-2, and caspases 2, 3, and 10 were down-regulated at different degrees, achieving mRNA expression levels that correlated with those detected in peripheral blood neutrophils. Dimethyl Sulfoxide 6-10 BCL2 apoptosis regulator Homo sapiens 99-104 10767713-2 2000 Immunohistochemical analysis using a monoclonal mouse antibody to the bcl-2 protein and in situ hybridization using a digoxigenin-labelled bcl-2 cRNA probe were carried out on formalin-fixed and paraffin-embedded specimens from 53 colorectal adenocarcinomas, 27 liver secondaries, and 60 adenomas with various degrees of dysplasia. Digoxigenin 118-129 BCL2 apoptosis regulator Homo sapiens 139-144 10777712-8 2000 Sulfasalazine, a potent and specific inhibitor of NF-kappaB, induced Bax at the expense of Bcl-2, in a p53-dependent manner. Sulfasalazine 0-13 BCL2 apoptosis regulator Homo sapiens 91-96 11042529-9 2000 In conclusion, As(2) O(3) might become a new therapeutic tool in the treatment of ATL as As(2) O(3) induces apoptosis by destruction of the bcl-2 protein and enhancement of the bak protein production proceeding to activate caspases, and also induces G(1) phase accumulation by enhancement of p53, Cip1/p21, Kip1/p27 and dephosphorylation of pRb to HTLV-I infected T-cell lines. (2) o(3) 17-25 BCL2 apoptosis regulator Homo sapiens 140-145 10754212-0 2000 Deoxycholic acid-induced apoptosis is switched to necrosis by bcl-2 and calphostin C. We previously demonstrated that the cytotoxicity associated with exposure of HCT116 cells to deoxycholic acid was due to the induction of apoptosis. Deoxycholic Acid 0-16 BCL2 apoptosis regulator Homo sapiens 62-67 10754212-0 2000 Deoxycholic acid-induced apoptosis is switched to necrosis by bcl-2 and calphostin C. We previously demonstrated that the cytotoxicity associated with exposure of HCT116 cells to deoxycholic acid was due to the induction of apoptosis. Deoxycholic Acid 179-195 BCL2 apoptosis regulator Homo sapiens 62-67 10754212-3 2000 Hence, DCA-induced apoptosis requires caspase activity and both bcl-2 and PKC can determine the type of cell death induced by deoxycholic acid. Dichloroacetic Acid 7-10 BCL2 apoptosis regulator Homo sapiens 64-69 10777712-5 2000 Pretreatment of fATII cells with l-buthionine-(S,R)-sulfoximine, an irreversible inhibitor of gamma-glutamylcysteine synthetase, the rate-limiting enzyme in the biosynthesis of glutathione (GSH), enhanced Bax and p53 expression over Bcl-2. l-buthionine sulfoximine 33-63 BCL2 apoptosis regulator Homo sapiens 233-238 10738115-9 2000 Interestingly, 9-cis-RA induced transiently the expression of p21(Waf1/Cip1), p27(Kip1), p300, CBP, BAX, Bak and bcl-2 proteins, respectively. Alitretinoin 15-23 BCL2 apoptosis regulator Homo sapiens 113-118 10777712-6 2000 The GSH analogue, gamma-glutamylcysteinyl-ethyl ester, down-regulated Bax/p53 abundance but restored that of Bcl-2, thereby increasing Bcl-2/Bax. Glutathione 4-7 BCL2 apoptosis regulator Homo sapiens 109-114 10777712-6 2000 The GSH analogue, gamma-glutamylcysteinyl-ethyl ester, down-regulated Bax/p53 abundance but restored that of Bcl-2, thereby increasing Bcl-2/Bax. Glutathione 4-7 BCL2 apoptosis regulator Homo sapiens 135-140 10777712-6 2000 The GSH analogue, gamma-glutamylcysteinyl-ethyl ester, down-regulated Bax/p53 abundance but restored that of Bcl-2, thereby increasing Bcl-2/Bax. N-gamma-glutamylcysteine ethyl ester 18-53 BCL2 apoptosis regulator Homo sapiens 109-114 10777712-6 2000 The GSH analogue, gamma-glutamylcysteinyl-ethyl ester, down-regulated Bax/p53 abundance but restored that of Bcl-2, thereby increasing Bcl-2/Bax. N-gamma-glutamylcysteine ethyl ester 18-53 BCL2 apoptosis regulator Homo sapiens 135-140 10777712-7 2000 The antioxidant and GSH precursor N-acetyl-l-cysteine favored Bcl-2 at the expense of Bax/p53, whereas pyrrolidine dithiocarbamate induced Bax against Bcl-2, with mild effect on p53. Glutathione 20-23 BCL2 apoptosis regulator Homo sapiens 62-67 10777712-7 2000 The antioxidant and GSH precursor N-acetyl-l-cysteine favored Bcl-2 at the expense of Bax/p53, whereas pyrrolidine dithiocarbamate induced Bax against Bcl-2, with mild effect on p53. Acetylcysteine 34-53 BCL2 apoptosis regulator Homo sapiens 62-67 10777712-7 2000 The antioxidant and GSH precursor N-acetyl-l-cysteine favored Bcl-2 at the expense of Bax/p53, whereas pyrrolidine dithiocarbamate induced Bax against Bcl-2, with mild effect on p53. pyrrolidine dithiocarbamic acid 103-130 BCL2 apoptosis regulator Homo sapiens 151-156 10738248-7 2000 Overexpression of bcl-2 by gene transfer prevented DeltaPsi(m) collapse, ROS generation, caspase activation and apoptosis in ET-18-OCH(3)-treated leukemic T cells. Reactive Oxygen Species 73-76 BCL2 apoptosis regulator Homo sapiens 18-23 10738248-7 2000 Overexpression of bcl-2 by gene transfer prevented DeltaPsi(m) collapse, ROS generation, caspase activation and apoptosis in ET-18-OCH(3)-treated leukemic T cells. edelfosine 125-137 BCL2 apoptosis regulator Homo sapiens 18-23 10754212-3 2000 Hence, DCA-induced apoptosis requires caspase activity and both bcl-2 and PKC can determine the type of cell death induced by deoxycholic acid. Deoxycholic Acid 126-142 BCL2 apoptosis regulator Homo sapiens 64-69 11832064-4 2000 RESULTS: Steroid could induce apoptosis of different fibroblasts in vitro in correspondence with increasing ratio of Bax/Bcl-2 proteins. Steroids 9-16 BCL2 apoptosis regulator Homo sapiens 121-126 10733510-6 2000 The HMBA-induced death pathway was marked by release of cytochrome c from the mitochondria and reduction of Bcl-2 protein levels. hexamethylene bisacetamide 4-8 BCL2 apoptosis regulator Homo sapiens 108-113 10753955-0 2000 The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. Celecoxib 31-40 BCL2 apoptosis regulator Homo sapiens 134-139 10753955-7 2000 In an effort to delineate the underlying mechanism, we examined the effect of celecoxib on the expression of Bcl-2 as well as the activation of the key anti-apoptotic kinase Akt. Celecoxib 78-87 BCL2 apoptosis regulator Homo sapiens 109-114 10766421-6 2000 In addition, we have shown that both the cell death and expression of p27(kip1) protein induced by ceramide were significantly decreased in HL-60 cells overexpressing bcl-2. Ceramides 99-107 BCL2 apoptosis regulator Homo sapiens 167-172 10766421-8 2000 These findings indicate that p27(kip1) may play important roles in mediating ceramide-induced apoptosis and its expression can be regulated by Bax and Bcl-2. Ceramides 77-85 BCL2 apoptosis regulator Homo sapiens 151-156 14731708-13 2000 By contrast, however, tamoxifen induced a significant, early increase in the prevalence of apoptosis associated with inhibition of tumour growth and an inverse relationship in both mitosis and bcl-2 expression, suggesting that apoptosis may be an accurate and sensitive early marker of even a moderate response to tamoxifen. Tamoxifen 22-31 BCL2 apoptosis regulator Homo sapiens 193-198 10766196-7 2000 To determine one potential reason for the greater potentiation of the effects of paclitaxel than those of Adriamycin, we determined the effects of preincubation of MCF-7 cells on paclitaxel-induced phosphorylation of Bcl-2. Paclitaxel 179-189 BCL2 apoptosis regulator Homo sapiens 217-222 10773822-7 2000 From these results, we concluded that Bcl-2 and SMN proteins bound with each other at the amino-terminal region near the BH4 domain of Bcl-2 and the region encoded by exon 6 of SMN, both regions known to be important for their function. sapropterin 121-124 BCL2 apoptosis regulator Homo sapiens 38-43 10773822-7 2000 From these results, we concluded that Bcl-2 and SMN proteins bound with each other at the amino-terminal region near the BH4 domain of Bcl-2 and the region encoded by exon 6 of SMN, both regions known to be important for their function. sapropterin 121-124 BCL2 apoptosis regulator Homo sapiens 135-140 10778958-12 2000 In summary, we found that sequential treatment with Bryo-1 and 2-CdA caused a significant reduction in peripheral blood lymphocytes (CLL cells) with simultaneous induction of differentiation and the initiation of the Bax: Bcl-2 apoptotic pathway. bryostatin 1 52-58 BCL2 apoptosis regulator Homo sapiens 222-227 10766196-8 2000 Pretreatment of MCF-7 cells with either 1,25(OH)2D3 or ATRA increased the phosphorylation of Bcl-2 by variable concentrations of paclitaxel. Calcitriol 40-51 BCL2 apoptosis regulator Homo sapiens 93-98 10766196-8 2000 Pretreatment of MCF-7 cells with either 1,25(OH)2D3 or ATRA increased the phosphorylation of Bcl-2 by variable concentrations of paclitaxel. Tretinoin 55-59 BCL2 apoptosis regulator Homo sapiens 93-98 10766196-8 2000 Pretreatment of MCF-7 cells with either 1,25(OH)2D3 or ATRA increased the phosphorylation of Bcl-2 by variable concentrations of paclitaxel. Paclitaxel 129-139 BCL2 apoptosis regulator Homo sapiens 93-98 10773818-6 2000 Mutating specific BH3 residues needed for binding Bcl2 does not prevent synergy with oligomycin, implying that no such binding is required. BH 3 18-21 BCL2 apoptosis regulator Homo sapiens 50-54 10782891-5 2000 Further, cPrG.HCl treatment up-regulated Bax and Bak expression, down-regulated Bcl-2 expression, and activated caspase-3. Hydrochloric Acid 14-17 BCL2 apoptosis regulator Homo sapiens 80-85 10728603-6 2000 P(GFLG)-DOX effectively killed both types of tumors inducing apoptosis and necrosis through the activation of p53, Apaf-1, caspase 9, c-fos, or c-jun pathways, and the downregulation of the bcl-2 gene. Doxorubicin 8-11 BCL2 apoptosis regulator Homo sapiens 190-195 10744622-1 2000 We have previously demonstrated that bcl-2 overexpression enhances the metastatic potential of the MCF7 ADR human breast cancer cell line resistant to adriamycin by inducing metastasis-associated properties. Doxorubicin 151-161 BCL2 apoptosis regulator Homo sapiens 37-42 10733592-0 2000 17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Estradiol 0-16 BCL2 apoptosis regulator Homo sapiens 61-66 10713328-7 2000 Down-regulation of Bcl-2 protein expression was evident in NB4 cells treated with ATRA and ATRA in combination with Iso-Q or 1,25 D(3), but not in cells treated with a classic chemotherapeutic agent, arabinosycytosine, suggesting that Bcl-2 down-regulation is neither necessary, nor specific for apoptosis in this model. Tretinoin 82-86 BCL2 apoptosis regulator Homo sapiens 235-240 10713328-7 2000 Down-regulation of Bcl-2 protein expression was evident in NB4 cells treated with ATRA and ATRA in combination with Iso-Q or 1,25 D(3), but not in cells treated with a classic chemotherapeutic agent, arabinosycytosine, suggesting that Bcl-2 down-regulation is neither necessary, nor specific for apoptosis in this model. Tretinoin 91-95 BCL2 apoptosis regulator Homo sapiens 19-24 10713328-7 2000 Down-regulation of Bcl-2 protein expression was evident in NB4 cells treated with ATRA and ATRA in combination with Iso-Q or 1,25 D(3), but not in cells treated with a classic chemotherapeutic agent, arabinosycytosine, suggesting that Bcl-2 down-regulation is neither necessary, nor specific for apoptosis in this model. Tretinoin 91-95 BCL2 apoptosis regulator Homo sapiens 235-240 10713328-7 2000 Down-regulation of Bcl-2 protein expression was evident in NB4 cells treated with ATRA and ATRA in combination with Iso-Q or 1,25 D(3), but not in cells treated with a classic chemotherapeutic agent, arabinosycytosine, suggesting that Bcl-2 down-regulation is neither necessary, nor specific for apoptosis in this model. iso-q 116-121 BCL2 apoptosis regulator Homo sapiens 19-24 10737619-6 2000 AMPA (3 microM) increased the number of apoptotic nuclei to 60% of control in wild-type cultures, and human Bcl-2 significantly decreased the number of apoptotic nuclei to 30% of AMPA-treated cultures. alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid 179-183 BCL2 apoptosis regulator Homo sapiens 108-113 10737619-7 2000 Human Bcl-2 only provided significant neuroprotection against neuronal injury induced by low concentrations of staurosporine (1-10 nM) and H2O2 (0.1-30 microM) and where neuronal death was by apoptosis, but not against H2O2-induced necrosis. Staurosporine 111-124 BCL2 apoptosis regulator Homo sapiens 6-11 10737619-7 2000 Human Bcl-2 only provided significant neuroprotection against neuronal injury induced by low concentrations of staurosporine (1-10 nM) and H2O2 (0.1-30 microM) and where neuronal death was by apoptosis, but not against H2O2-induced necrosis. Hydrogen Peroxide 139-143 BCL2 apoptosis regulator Homo sapiens 6-11 10737619-7 2000 Human Bcl-2 only provided significant neuroprotection against neuronal injury induced by low concentrations of staurosporine (1-10 nM) and H2O2 (0.1-30 microM) and where neuronal death was by apoptosis, but not against H2O2-induced necrosis. Hydrogen Peroxide 219-223 BCL2 apoptosis regulator Homo sapiens 6-11 10713328-7 2000 Down-regulation of Bcl-2 protein expression was evident in NB4 cells treated with ATRA and ATRA in combination with Iso-Q or 1,25 D(3), but not in cells treated with a classic chemotherapeutic agent, arabinosycytosine, suggesting that Bcl-2 down-regulation is neither necessary, nor specific for apoptosis in this model. Tretinoin 82-86 BCL2 apoptosis regulator Homo sapiens 19-24 10733592-1 2000 We have found that 17beta-estradiol induces bcl-2 transcription in human breast cancer MCF-7 cells. Estradiol 19-35 BCL2 apoptosis regulator Homo sapiens 44-49 10733592-6 2000 Moreover, the identified elements were able to mediate up-regulation of bcl-2 expression by 17beta-estradiol, since exogenous bcl-2 mRNA was induced by hormone challenge of MCF-7 cells transiently transfected with a vector containing the bcl-2 coding sequence cloned under the control of a non-estrogen-responsive promoter. Estradiol 92-108 BCL2 apoptosis regulator Homo sapiens 72-77 10733592-6 2000 Moreover, the identified elements were able to mediate up-regulation of bcl-2 expression by 17beta-estradiol, since exogenous bcl-2 mRNA was induced by hormone challenge of MCF-7 cells transiently transfected with a vector containing the bcl-2 coding sequence cloned under the control of a non-estrogen-responsive promoter. Estradiol 92-108 BCL2 apoptosis regulator Homo sapiens 126-131 10733592-6 2000 Moreover, the identified elements were able to mediate up-regulation of bcl-2 expression by 17beta-estradiol, since exogenous bcl-2 mRNA was induced by hormone challenge of MCF-7 cells transiently transfected with a vector containing the bcl-2 coding sequence cloned under the control of a non-estrogen-responsive promoter. Estradiol 92-108 BCL2 apoptosis regulator Homo sapiens 126-131 10733592-7 2000 Finally, we show that hormone prevention of apoptosis, induced by incubating MCF-7 cells with hydrogen peroxide, was strictly related to bcl-2 up-regulation. Hydrogen Peroxide 94-111 BCL2 apoptosis regulator Homo sapiens 137-142 10825522-2 2000 We tested whether antisense oligonucleotides to the bcl-2 gene would affect glioma cell viability. Oligonucleotides 28-44 BCL2 apoptosis regulator Homo sapiens 52-57 10747202-3 2000 The Bcl-2 proteins can be divided into three subgroups: 1) antiapoptotic proteins with multiple Bcl-2 homology (BH) domains and a transmembrane region, 2) proapoptotic proteins with the same structure but missing the BH4 domain, and 3) proapoptotic ligands with only the BH3 domain. sapropterin 217-220 BCL2 apoptosis regulator Homo sapiens 4-9 10825522-3 2000 METHODS: Antisense oligonucleotides directed to the first six codons of the human bcl-2 gene, and nonsense oligonucleotides as a control, were transfected into malignant glioma cells. Oligonucleotides 19-35 BCL2 apoptosis regulator Homo sapiens 82-87 10825522-6 2000 RESULTS: There was up to a log-fold decrease in cell growth of the bcl-2 AS treated cells compared to the NS transfected cells for both Roc (p = 0.007 and p = 0.004) and Jon52 (p = 0.02 and p = 0.004) at 5 and 24 hr of transfection. Saquinavir 136-139 BCL2 apoptosis regulator Homo sapiens 67-72 10877050-4 2000 In vitro studies of human chronic lymphocytic leukemia cells incubated with theophylline, a phosphodiesterase inhibitor, resulted in downregulation of bcl-2 concomitant with induction of apoptosis. Theophylline 76-88 BCL2 apoptosis regulator Homo sapiens 151-156 10692111-10 2000 Furthermore, camptothecin treatment reduced bcl-2 and P-glycoprotein expression in wild-type p53 MMAN cells, but not cells overexpressing mutant p53. Camptothecin 13-25 BCL2 apoptosis regulator Homo sapiens 44-49 11789265-6 2000 CONCLUSION: FCNNAV could induce apoptosis of human leukemia cells and this effect is related to down-regulation of Bcl-2 gene expression level. fcnnav 12-18 BCL2 apoptosis regulator Homo sapiens 115-120 10737788-0 2000 BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death. sapropterin 0-3 BCL2 apoptosis regulator Homo sapiens 28-33 10737788-5 2000 Furthermore, BH4 oligopeptides of Bcl-2 and Bcl-x(L), but not mutant peptides, were able to inhibit both VDAC activity on liposomes even in the presence of Bax and apoptotic Deltapsi loss in isolated mitochondria. sapropterin 13-16 BCL2 apoptosis regulator Homo sapiens 34-39 10737788-7 2000 These results indicate that the BH4 of Bcl-2/Bcl-x(L) is essential and sufficient for inhibiting VDAC activity, which in turn prevents apoptotic mitochondrial changes, and for preventing apoptotic cell death. sapropterin 32-35 BCL2 apoptosis regulator Homo sapiens 39-44 10749111-2 2000 To test the possibility of modulating Bcl-2 function as an anticancer strategy, a cell permeable Bcl-2 binding peptide, cell permeable moiety (cpm)-1285, was designed by chemically attaching a fatty acid to a peptide derived from the proapoptotic protein Bad. Fatty Acids 193-203 BCL2 apoptosis regulator Homo sapiens 97-102 10728681-0 2000 Tetrocarcin A inhibits mitochondrial functions of Bcl-2 and suppresses its anti-apoptotic activity. tetrocarcin A 0-13 BCL2 apoptosis regulator Homo sapiens 50-55 10728681-4 2000 A microbial secondary metabolite, Tetrocarcin A (TC-A), was identified as an inhibitor of the anti-apoptotic function of Bcl-2. tetrocarcin A 34-47 BCL2 apoptosis regulator Homo sapiens 121-126 10728681-4 2000 A microbial secondary metabolite, Tetrocarcin A (TC-A), was identified as an inhibitor of the anti-apoptotic function of Bcl-2. tetrocarcin A 49-53 BCL2 apoptosis regulator Homo sapiens 121-126 10728681-5 2000 Apoptosis could be induced in cell lines that overexpressed Bcl-2 or Bcl-XL when the cells were treated with anti-Fas antibody, tumor necrosis factor alpha, staurosporine, or Bax, in addition to TC-A. Staurosporine 157-170 BCL2 apoptosis regulator Homo sapiens 60-65 10728681-5 2000 Apoptosis could be induced in cell lines that overexpressed Bcl-2 or Bcl-XL when the cells were treated with anti-Fas antibody, tumor necrosis factor alpha, staurosporine, or Bax, in addition to TC-A. tetrocarcin A 195-199 BCL2 apoptosis regulator Homo sapiens 60-65 10762061-0 2000 Regulation of bcl-2 family in hydrogen peroxide-induced apoptosis in human leukemia HL-60 cells. Hydrogen Peroxide 30-47 BCL2 apoptosis regulator Homo sapiens 14-19 11324420-14 2000 CONCLUSION: Ceramide induces apoptosis in Bel7402 cells, related to Bcl-2 down-regulation. Ceramides 12-20 BCL2 apoptosis regulator Homo sapiens 68-73 10728681-9 2000 Thus, TC-A should serve as an archetype for specific inhibitors of Bcl-2 functions. tetrocarcin A 6-10 BCL2 apoptosis regulator Homo sapiens 67-72 10675481-2 2000 By systematic site directed mutagenesis studies, we have previously mapped taxol induced phosphorylation sites to be Ser-70 and 87 residues of Bcl2 protein. Paclitaxel 75-80 BCL2 apoptosis regulator Homo sapiens 143-147 10675494-17 2000 Treatment of HOK-16B-BaP with antisense bcl-2 oligonucleotide rendered the cells more sensitive to CH-11-induced apoptosis. hok-16b-bap 13-24 BCL2 apoptosis regulator Homo sapiens 40-45 10675494-17 2000 Treatment of HOK-16B-BaP with antisense bcl-2 oligonucleotide rendered the cells more sensitive to CH-11-induced apoptosis. Oligonucleotides 46-61 BCL2 apoptosis regulator Homo sapiens 40-45 10675494-17 2000 Treatment of HOK-16B-BaP with antisense bcl-2 oligonucleotide rendered the cells more sensitive to CH-11-induced apoptosis. 4-dimethylamino-3',4'-dimethoxychalcone 99-104 BCL2 apoptosis regulator Homo sapiens 40-45 10733098-8 2000 These results suggest that the difference of susceptibility to Fas-mediated apoptosis among cell populations depends on the expression of Fas Ag, Bcl-2, and caspases. ammonium ferrous sulfate 63-66 BCL2 apoptosis regulator Homo sapiens 146-151 10839193-0 2000 Differential responses of Bcl-2 family genes to etoposide in chronic myeloid leukemia K562 cells. Etoposide 48-57 BCL2 apoptosis regulator Homo sapiens 26-31 10752575-5 2000 The present results suggest that a diminished calcium binding capacity of MSA Purkinje cells might lead to a change in the regulation of proteins of the bcl-2 family that could favor the pathologic initiation of apoptosis. Calcium 46-53 BCL2 apoptosis regulator Homo sapiens 153-158 10669763-10 2000 Furthermore, MAP kinase triggers phosphorylation of Bcl-2, whereas a reduction in Bcl-2 phosphorylation was observed in the presence of MAP kinase-specific phosphatases or the MAP kinase-specific inhibitor PD98059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 206-213 BCL2 apoptosis regulator Homo sapiens 52-57 10669763-10 2000 Furthermore, MAP kinase triggers phosphorylation of Bcl-2, whereas a reduction in Bcl-2 phosphorylation was observed in the presence of MAP kinase-specific phosphatases or the MAP kinase-specific inhibitor PD98059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 206-213 BCL2 apoptosis regulator Homo sapiens 82-87 10816097-2 2000 Survival factors such as insulin-like growth factor-I (IGF-I) initiate a signalling cascade that starts by tyrosine phosphorylation of substrates leading to the activation of serine kinases that modulate the activity of members of the Bcl-2 family, which regulates the apoptotic machinery in most cells. Tyrosine 107-115 BCL2 apoptosis regulator Homo sapiens 235-240 10657030-0 2000 Bcl-2 overexpression attenuates dopamine-induced apoptosis in an immortalized neural cell line by suppressing the production of reactive oxygen species. Dopamine 32-40 BCL2 apoptosis regulator Homo sapiens 0-5 10657030-0 2000 Bcl-2 overexpression attenuates dopamine-induced apoptosis in an immortalized neural cell line by suppressing the production of reactive oxygen species. Oxygen 137-143 BCL2 apoptosis regulator Homo sapiens 0-5 10657030-3 2000 The antiapoptic agent, bcl-2, has been shown to protect cells against the toxic effects of reactive oxygen species (ROS). Reactive Oxygen Species 91-114 BCL2 apoptosis regulator Homo sapiens 23-28 10657030-3 2000 The antiapoptic agent, bcl-2, has been shown to protect cells against the toxic effects of reactive oxygen species (ROS). Reactive Oxygen Species 116-119 BCL2 apoptosis regulator Homo sapiens 23-28 10657030-4 2000 Thus, we tested whether bcl-2 could attenuate the toxic effects of DA on immortalized neural cells. Dopamine 67-69 BCL2 apoptosis regulator Homo sapiens 24-29 10657030-8 2000 Furthermore, overexpression of bcl-2 caused significant protection against DA-induced apoptosis. Dopamine 75-77 BCL2 apoptosis regulator Homo sapiens 31-36 11776633-6 2000 In addition, transfection with antisense bcl-2 did not induce marked apoptosis whereas treatment of the transfectant with low concentration (0.2 mmol/L) of DFMO resulted in enhanced expression inhibition of bcl-2 protein, inhibition of cell growth and induction of apoptosis. Eflornithine 156-160 BCL2 apoptosis regulator Homo sapiens 207-212 10696460-2 2000 STUDY DESIGN: We analyzed the differential expression of different apoptosis modulators, Bcl-2, Bax, p53 and Fas, for their potential role in PB-induced apoptosis using relative quantitative flow cytometry (FCM). Phenylbutyrates 142-144 BCL2 apoptosis regulator Homo sapiens 89-94 10696460-7 2000 FCM revealed a heterogeneous stimulatory effect on the expression of Bax and Bcl-2 in PC3-PF cells at 0.5-2.5 mM PB. Phenylbutyrates 113-115 BCL2 apoptosis regulator Homo sapiens 77-82 10696460-9 2000 CONCLUSION: Our data show that PB-induced PCa apoptosis is associated with the relative repression of Bcl-2 and with up-regulation of Bax and Fas proteins and that this PB-induced apoptosis is independent of p53 and androgen-dependency status of PCa cell lines. Phenylbutyrates 31-33 BCL2 apoptosis regulator Homo sapiens 102-107 10648417-0 2000 Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Arsenic 0-7 BCL2 apoptosis regulator Homo sapiens 124-129 10671672-1 2000 Expression of the Bcl-2 family members in a human hepatocellular carcinoma cell line (HCC-T) after sodium butyrate-treatment was investigated. Butyric Acid 99-114 BCL2 apoptosis regulator Homo sapiens 18-23 10671672-3 2000 Since sodium butyrate has effects on both differentiation and apoptosis, we investigated the expression profile of bcl-2 related genes in HCC-T. Butyric Acid 6-21 BCL2 apoptosis regulator Homo sapiens 115-120 10679755-0 2000 Heterogeneous apoptotic responses of prostate cancer cell lines identify an association between sensitivity to staurosporine-induced apoptosis, expression of Bcl-2 family members, and caspase activation. Staurosporine 111-124 BCL2 apoptosis regulator Homo sapiens 158-163 10699926-6 2000 Comparable microtubule targeting was demonstrated in HL60 and in K562 cell lines, as bcl-2 and raf-1 were phosphorylated following treatment with taxanes. Taxoids 146-153 BCL2 apoptosis regulator Homo sapiens 85-90 10699926-10 2000 These results extend to taxol and taxotere the notion that drug-induced apoptosis is delayed upstream of caspase-3 activation in K562 cells, that such kinetics is independent of drug concentration and exposure time, and that it is linked to intrinsic cellular characteristics mapping between bcl-2 phosphorylation and cytochrome c release. Paclitaxel 24-29 BCL2 apoptosis regulator Homo sapiens 292-297 10699926-10 2000 These results extend to taxol and taxotere the notion that drug-induced apoptosis is delayed upstream of caspase-3 activation in K562 cells, that such kinetics is independent of drug concentration and exposure time, and that it is linked to intrinsic cellular characteristics mapping between bcl-2 phosphorylation and cytochrome c release. Docetaxel 34-42 BCL2 apoptosis regulator Homo sapiens 292-297 10677502-1 2000 Bcl2 phosphorylation at Ser-70 may be required for the full and potent suppression of apoptosis in IL-3-dependent myeloid cells and can result from agonist activation of mitochondrial protein kinase C (PKC). Serine 24-27 BCL2 apoptosis regulator Homo sapiens 0-4 10677502-2 2000 Paradoxically, expression of exogenous Bcl2 can protect parental cells from apoptosis induced by the potent PKC inhibitor, staurosporine (stauro). Staurosporine 123-136 BCL2 apoptosis regulator Homo sapiens 39-43 10677502-2 2000 Paradoxically, expression of exogenous Bcl2 can protect parental cells from apoptosis induced by the potent PKC inhibitor, staurosporine (stauro). Staurosporine 123-129 BCL2 apoptosis regulator Homo sapiens 39-43 10677502-3 2000 High concentrations of stauro of up to 1 microM only partially inhibit IL-3-stimulated Bcl2 phosphorylation but completely block PKC-mediated Bcl2 phosphorylation in vitro. Staurosporine 23-29 BCL2 apoptosis regulator Homo sapiens 87-91 10677502-3 2000 High concentrations of stauro of up to 1 microM only partially inhibit IL-3-stimulated Bcl2 phosphorylation but completely block PKC-mediated Bcl2 phosphorylation in vitro. Staurosporine 23-29 BCL2 apoptosis regulator Homo sapiens 142-146 10677502-5 2000 We show that aurintricarboxylic acid (ATA), a nonpeptide activator of cellular MEK/mitogen-activated protein kinase (MAPK) kinase, can induce Ser-70 phosphorylation of Bcl2 and support survival of cells expressing wild-type but not the phosphorylation-incompetent S70A mutant Bcl2. Aurintricarboxylic Acid 13-36 BCL2 apoptosis regulator Homo sapiens 168-172 10677502-5 2000 We show that aurintricarboxylic acid (ATA), a nonpeptide activator of cellular MEK/mitogen-activated protein kinase (MAPK) kinase, can induce Ser-70 phosphorylation of Bcl2 and support survival of cells expressing wild-type but not the phosphorylation-incompetent S70A mutant Bcl2. Aurintricarboxylic Acid 13-36 BCL2 apoptosis regulator Homo sapiens 276-280 10677502-5 2000 We show that aurintricarboxylic acid (ATA), a nonpeptide activator of cellular MEK/mitogen-activated protein kinase (MAPK) kinase, can induce Ser-70 phosphorylation of Bcl2 and support survival of cells expressing wild-type but not the phosphorylation-incompetent S70A mutant Bcl2. Aurintricarboxylic Acid 38-41 BCL2 apoptosis regulator Homo sapiens 168-172 10677502-5 2000 We show that aurintricarboxylic acid (ATA), a nonpeptide activator of cellular MEK/mitogen-activated protein kinase (MAPK) kinase, can induce Ser-70 phosphorylation of Bcl2 and support survival of cells expressing wild-type but not the phosphorylation-incompetent S70A mutant Bcl2. Aurintricarboxylic Acid 38-41 BCL2 apoptosis regulator Homo sapiens 276-280 10677502-5 2000 We show that aurintricarboxylic acid (ATA), a nonpeptide activator of cellular MEK/mitogen-activated protein kinase (MAPK) kinase, can induce Ser-70 phosphorylation of Bcl2 and support survival of cells expressing wild-type but not the phosphorylation-incompetent S70A mutant Bcl2. Serine 142-145 BCL2 apoptosis regulator Homo sapiens 168-172 10677502-5 2000 We show that aurintricarboxylic acid (ATA), a nonpeptide activator of cellular MEK/mitogen-activated protein kinase (MAPK) kinase, can induce Ser-70 phosphorylation of Bcl2 and support survival of cells expressing wild-type but not the phosphorylation-incompetent S70A mutant Bcl2. Serine 142-145 BCL2 apoptosis regulator Homo sapiens 276-280 10677502-6 2000 A role for a MEK/MAPK as a responsible SRK was implicated because the highly specific MEK/MAPK inhibitor, PD98059, also can only partially inhibit IL-3-induced Bcl2 phosphorylation, whereas the combination of PD98059 and stauro completely blocks phosphorylation and synergistically enhances apoptosis. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 106-113 BCL2 apoptosis regulator Homo sapiens 160-164 10677502-7 2000 p44MAPK/extracellular signal-regulated kinase 1 (ERK1) and p42 MAPK/ERK2 are activated by IL-3, colocalize with mitochondrial Bcl2, and can directly phosphorylate Bcl2 on Ser-70 in a stauro-resistant manner both in vitro and in vivo. Serine 171-174 BCL2 apoptosis regulator Homo sapiens 126-130 10677502-7 2000 p44MAPK/extracellular signal-regulated kinase 1 (ERK1) and p42 MAPK/ERK2 are activated by IL-3, colocalize with mitochondrial Bcl2, and can directly phosphorylate Bcl2 on Ser-70 in a stauro-resistant manner both in vitro and in vivo. Serine 171-174 BCL2 apoptosis regulator Homo sapiens 163-167 10648421-1 2000 When bcl-2 is immunoprecipitated from (32)P-labeled cell extracts of all-trans retinoic acid (ATRA)-treated acute myeloblastic leukemia (AML) blasts, a phosphorylated protein of approximately 30 kd is coprecipitated. Phosphorus-32 38-43 BCL2 apoptosis regulator Homo sapiens 5-10 10648421-1 2000 When bcl-2 is immunoprecipitated from (32)P-labeled cell extracts of all-trans retinoic acid (ATRA)-treated acute myeloblastic leukemia (AML) blasts, a phosphorylated protein of approximately 30 kd is coprecipitated. Tretinoin 79-92 BCL2 apoptosis regulator Homo sapiens 5-10 10648421-1 2000 When bcl-2 is immunoprecipitated from (32)P-labeled cell extracts of all-trans retinoic acid (ATRA)-treated acute myeloblastic leukemia (AML) blasts, a phosphorylated protein of approximately 30 kd is coprecipitated. Tretinoin 94-98 BCL2 apoptosis regulator Homo sapiens 5-10 10713737-8 2000 This suggests that Bcl-2 cleavage might contribute to the late cyto c release, which results in mitochondrial dysfunction manifested by the decrease of ATP and Deltapsim. Adenosine Triphosphate 152-155 BCL2 apoptosis regulator Homo sapiens 19-24 11775534-10 2000 CONCLUSIONS: 1,25(OH)2D3 can inhibit cell growth with G0/G1 arrest, enhance the proliferation inhibition action of adriamycin, and induce apoptosis which may result from the down-regulation of the anti-apoptotic bcl-2 protein. Calcitriol 13-24 BCL2 apoptosis regulator Homo sapiens 212-217 10656697-4 2000 The present studies demonstrate that the impact of Bcl-2 on glutathione (GSH) metabolism is cell line-dependent. Glutathione 60-71 BCL2 apoptosis regulator Homo sapiens 51-56 10639596-0 2000 Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line, Reh. bryostatin 1 0-12 BCL2 apoptosis regulator Homo sapiens 66-71 10639596-2 2000 In the present study, we investigated the novelty and potential role of bryostatin 1, a macrocyclic lactone isolated from the marine bryozoan, Bugula neritina, in inducing the ubiquitin-mediated proteolysis of the oncoprotein Bcl-2. bryostatin 1 72-84 BCL2 apoptosis regulator Homo sapiens 226-231 10639596-3 2000 Immunoprecipitation and immunoblotting analyses revealed that Bcl-2 is ubiquitinated following exposure of the acute lymphoblastic leukemia (ALL) cell line Reh to 1 nM bryostatin 1. bryostatin 1 168-180 BCL2 apoptosis regulator Homo sapiens 62-67 10639596-4 2000 Bcl-2 protein rapidly decreases to 50% of that recorded in the control after 24 h of bryostatin 1 treatment. bryostatin 1 85-97 BCL2 apoptosis regulator Homo sapiens 0-5 10639596-5 2000 In the subsequent 24 h, Bcl-2 protein again rapidly decreases to 6% of its pre-bryostatin 1 level at which time a plateau is reached and maintained for another 72 h. Furthermore, ubiquitin-Bcl-2 conjugates are detected in untreated as well as bryostatin 1 treated cells, indicating that ubiquitin-dependent proteolysis plays a role in the normal turnover of Bcl-2. bryostatin 1 79-91 BCL2 apoptosis regulator Homo sapiens 24-29 10639596-5 2000 In the subsequent 24 h, Bcl-2 protein again rapidly decreases to 6% of its pre-bryostatin 1 level at which time a plateau is reached and maintained for another 72 h. Furthermore, ubiquitin-Bcl-2 conjugates are detected in untreated as well as bryostatin 1 treated cells, indicating that ubiquitin-dependent proteolysis plays a role in the normal turnover of Bcl-2. bryostatin 1 79-91 BCL2 apoptosis regulator Homo sapiens 189-194 10639596-5 2000 In the subsequent 24 h, Bcl-2 protein again rapidly decreases to 6% of its pre-bryostatin 1 level at which time a plateau is reached and maintained for another 72 h. Furthermore, ubiquitin-Bcl-2 conjugates are detected in untreated as well as bryostatin 1 treated cells, indicating that ubiquitin-dependent proteolysis plays a role in the normal turnover of Bcl-2. bryostatin 1 79-91 BCL2 apoptosis regulator Homo sapiens 189-194 10639596-5 2000 In the subsequent 24 h, Bcl-2 protein again rapidly decreases to 6% of its pre-bryostatin 1 level at which time a plateau is reached and maintained for another 72 h. Furthermore, ubiquitin-Bcl-2 conjugates are detected in untreated as well as bryostatin 1 treated cells, indicating that ubiquitin-dependent proteolysis plays a role in the normal turnover of Bcl-2. bryostatin 1 243-255 BCL2 apoptosis regulator Homo sapiens 24-29 10639596-5 2000 In the subsequent 24 h, Bcl-2 protein again rapidly decreases to 6% of its pre-bryostatin 1 level at which time a plateau is reached and maintained for another 72 h. Furthermore, ubiquitin-Bcl-2 conjugates are detected in untreated as well as bryostatin 1 treated cells, indicating that ubiquitin-dependent proteolysis plays a role in the normal turnover of Bcl-2. bryostatin 1 243-255 BCL2 apoptosis regulator Homo sapiens 189-194 10639596-5 2000 In the subsequent 24 h, Bcl-2 protein again rapidly decreases to 6% of its pre-bryostatin 1 level at which time a plateau is reached and maintained for another 72 h. Furthermore, ubiquitin-Bcl-2 conjugates are detected in untreated as well as bryostatin 1 treated cells, indicating that ubiquitin-dependent proteolysis plays a role in the normal turnover of Bcl-2. bryostatin 1 243-255 BCL2 apoptosis regulator Homo sapiens 189-194 10639596-6 2000 However, ubiquitin-Bcl-2 conjugates increase in a time-dependent manner following bryostatin 1 treatment. bryostatin 1 82-94 BCL2 apoptosis regulator Homo sapiens 19-24 10639596-7 2000 Lactacystin, which inhibits the proteinase activities of the proteasome, inhibited the bryostatin 1-induced decrease of Bcl-2 protein. lactacystin 0-11 BCL2 apoptosis regulator Homo sapiens 120-125 10639596-7 2000 Lactacystin, which inhibits the proteinase activities of the proteasome, inhibited the bryostatin 1-induced decrease of Bcl-2 protein. bryostatin 1 87-99 BCL2 apoptosis regulator Homo sapiens 120-125 10639596-10 2000 In addition, bryostatin 1 treatment of the Reh cell line decreased expression of bcl-2 mRNA within 3 h. However, bcl-2 mRNA expression returned after 24 h. We speculate that this decrease in mRNA together with increased 26S proteolytic activity accounts for the initial rapid decrease recorded in Bcl-2 protein. bryostatin 1 13-25 BCL2 apoptosis regulator Homo sapiens 81-86 10639596-10 2000 In addition, bryostatin 1 treatment of the Reh cell line decreased expression of bcl-2 mRNA within 3 h. However, bcl-2 mRNA expression returned after 24 h. We speculate that this decrease in mRNA together with increased 26S proteolytic activity accounts for the initial rapid decrease recorded in Bcl-2 protein. bryostatin 1 13-25 BCL2 apoptosis regulator Homo sapiens 297-302 10639596-11 2000 These findings indicate that bryostatin 1 treatment of Reh ALL cells decreases Bcl-2 expression through two processes: a) enhanced Bcl-2 protein degradation through the activation of the ubiquitin-proteasome pathway and b) decreased bcl-2 mRNA expression. bryostatin 1 29-41 BCL2 apoptosis regulator Homo sapiens 79-84 10639596-11 2000 These findings indicate that bryostatin 1 treatment of Reh ALL cells decreases Bcl-2 expression through two processes: a) enhanced Bcl-2 protein degradation through the activation of the ubiquitin-proteasome pathway and b) decreased bcl-2 mRNA expression. bryostatin 1 29-41 BCL2 apoptosis regulator Homo sapiens 131-136 10639596-11 2000 These findings indicate that bryostatin 1 treatment of Reh ALL cells decreases Bcl-2 expression through two processes: a) enhanced Bcl-2 protein degradation through the activation of the ubiquitin-proteasome pathway and b) decreased bcl-2 mRNA expression. bryostatin 1 29-41 BCL2 apoptosis regulator Homo sapiens 233-238 10821422-14 2000 We also examined whether this occurred by the down regulation of bcl-2 protein expression that is likely to increase the susceptibility of Jurkat cells to endosulfan toxicity. Endosulfan 155-165 BCL2 apoptosis regulator Homo sapiens 65-70 10821422-15 2000 Paradoxically, the intracellular expression of bcl-2 protein was elevated in a dose dependent manner suggesting endosulfan-induced apoptosis occurred by a non-bcl-2 pathway. Endosulfan 112-122 BCL2 apoptosis regulator Homo sapiens 47-52 10821422-15 2000 Paradoxically, the intracellular expression of bcl-2 protein was elevated in a dose dependent manner suggesting endosulfan-induced apoptosis occurred by a non-bcl-2 pathway. Endosulfan 112-122 BCL2 apoptosis regulator Homo sapiens 159-164 10656697-0 2000 Cell line dependence of Bcl-2-induced alteration of glutathione handling. Glutathione 52-63 BCL2 apoptosis regulator Homo sapiens 24-29 10656697-2 2000 Moreover, despite evidence that Bcl-2 is antiapoptotic by virtue of its effect on reactive oxygen species and their scavengers, Bcl-2 exerts its antiapoptotic effects even under anaerobic conditions. Reactive Oxygen Species 82-105 BCL2 apoptosis regulator Homo sapiens 32-37 10656697-3 2000 The reasons for the variable relationship between Bcl-2 and reactive oxygen species are not clear. Reactive Oxygen Species 60-83 BCL2 apoptosis regulator Homo sapiens 50-55 10683383-4 2000 Doxorubicin treatment prevented mitotic arrest, Bcl-2 phosphorylation, and cell death caused by paclitaxel, epothilones, and vinblastine. Doxorubicin 0-11 BCL2 apoptosis regulator Homo sapiens 48-53 10731694-6 2000 MK enhanced the expression of Bcl-2, but not that of Bcl-x(L), in G401 cells in a dose-dependent manner, and it prevented the Bcl-2 reduction due to CDDP. Cisplatin 149-153 BCL2 apoptosis regulator Homo sapiens 126-131 11809111-1 2000 OBJECTIVE: To study the therapeutic effect of bcl-2 antisense oligodeoxynucleotide (ODN)/RNA human cervical carcinoma in vitro. Oligodeoxyribonucleotides 62-82 BCL2 apoptosis regulator Homo sapiens 46-51 11876963-8 2000 Further study showed that TB could gradually down-regulated bcl-2 expression. tributyrin 26-28 BCL2 apoptosis regulator Homo sapiens 60-65 10656697-4 2000 The present studies demonstrate that the impact of Bcl-2 on glutathione (GSH) metabolism is cell line-dependent. Glutathione 73-76 BCL2 apoptosis regulator Homo sapiens 51-56 10656697-7 2000 These findings indicate that the effects of Bcl-2 on GSH handling are millieu-dependent. Glutathione 53-56 BCL2 apoptosis regulator Homo sapiens 44-49 10623473-6 2000 Employing bcl-2-overexpressing HL-60 cells permitted demonstration of nuclear lobulation, ELCS formation, and centrosome-MT movement concomitantly during RA-induced differentiation, implying independence between the cellular reorganization and apoptotic programs. Tretinoin 154-156 BCL2 apoptosis regulator Homo sapiens 10-15 10940651-8 2000 On the basis of these results, ATRA-induced apoptosis in these AML cell lines is independent of the p53 pathway, although it is associated with the down-regulation of bcl-2. Tretinoin 31-35 BCL2 apoptosis regulator Homo sapiens 167-172 10645010-0 2000 Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Sulfhydryl Compounds 24-29 BCL2 apoptosis regulator Homo sapiens 86-91 10645010-8 2000 Concomitantly, a series of different thiol crosslinking agents (diamide, DTDP, and BMH, phenylarsine oxide) but not tert-butylhydroperoxide or arsenite induce mitochondrial membrane permeabilization and cell death irrespective of the expression level of Bcl-2. Sulfhydryl Compounds 37-42 BCL2 apoptosis regulator Homo sapiens 254-259 10645010-8 2000 Concomitantly, a series of different thiol crosslinking agents (diamide, DTDP, and BMH, phenylarsine oxide) but not tert-butylhydroperoxide or arsenite induce mitochondrial membrane permeabilization and cell death irrespective of the expression level of Bcl-2. bmh 83-86 BCL2 apoptosis regulator Homo sapiens 254-259 10645010-8 2000 Concomitantly, a series of different thiol crosslinking agents (diamide, DTDP, and BMH, phenylarsine oxide) but not tert-butylhydroperoxide or arsenite induce mitochondrial membrane permeabilization and cell death irrespective of the expression level of Bcl-2. oxophenylarsine 88-106 BCL2 apoptosis regulator Homo sapiens 254-259 10645010-9 2000 These data indicate that thiol crosslinkers cause a covalent modification of ANT which, beyond any control by Bcl-2, leads to mitochondrial membrane permeabilization and cell death. Sulfhydryl Compounds 25-30 BCL2 apoptosis regulator Homo sapiens 110-115 11291028-3 2000 To overcome this cytotoxic effect of NaBu, a survival protein, human Bcl-2, was overexpressed in recombinant Chinese hamster ovary (CHO) cells (SH2-0.32), producing a humanized antibody directed against the S surface antigen of hepatitis B virus. sethoxydim 37-41 BCL2 apoptosis regulator Homo sapiens 69-74 10644513-7 2000 When a human bcl-2 gene was transfected in SC2G cells and overexpressed, SC2G cells seemed to acquire tolerance for HMA. herbimycin 116-119 BCL2 apoptosis regulator Homo sapiens 13-18 10678579-9 2000 COX-2 synthesizes prostaglandin E2 (PGE2) which stimulates bcl-2 and inhibits apoptosis, and induces interleukin-6 (IL-6) which enhances haptoglobin synthesis. Dinoprostone 18-34 BCL2 apoptosis regulator Homo sapiens 59-64 10678579-9 2000 COX-2 synthesizes prostaglandin E2 (PGE2) which stimulates bcl-2 and inhibits apoptosis, and induces interleukin-6 (IL-6) which enhances haptoglobin synthesis. Dinoprostone 36-40 BCL2 apoptosis regulator Homo sapiens 59-64 10769646-13 2000 Three cell lines resistant to ara-C (CEM/ara-C/B, CEM/ara-C/D and CEM/ara-C/I) showed an important increased expression of bcl-2 protein after treatment with 1 microM ara-C, but not after 10 microM. Cytarabine 30-35 BCL2 apoptosis regulator Homo sapiens 123-128 10769646-13 2000 Three cell lines resistant to ara-C (CEM/ara-C/B, CEM/ara-C/D and CEM/ara-C/I) showed an important increased expression of bcl-2 protein after treatment with 1 microM ara-C, but not after 10 microM. 2-chloroethyl methyl sulfide 37-40 BCL2 apoptosis regulator Homo sapiens 123-128 10769646-13 2000 Three cell lines resistant to ara-C (CEM/ara-C/B, CEM/ara-C/D and CEM/ara-C/I) showed an important increased expression of bcl-2 protein after treatment with 1 microM ara-C, but not after 10 microM. Cytarabine 41-46 BCL2 apoptosis regulator Homo sapiens 123-128 10769646-13 2000 Three cell lines resistant to ara-C (CEM/ara-C/B, CEM/ara-C/D and CEM/ara-C/I) showed an important increased expression of bcl-2 protein after treatment with 1 microM ara-C, but not after 10 microM. 2-chloroethyl methyl sulfide 50-53 BCL2 apoptosis regulator Homo sapiens 123-128 10769646-13 2000 Three cell lines resistant to ara-C (CEM/ara-C/B, CEM/ara-C/D and CEM/ara-C/I) showed an important increased expression of bcl-2 protein after treatment with 1 microM ara-C, but not after 10 microM. Cytarabine 41-46 BCL2 apoptosis regulator Homo sapiens 123-128 10769646-13 2000 Three cell lines resistant to ara-C (CEM/ara-C/B, CEM/ara-C/D and CEM/ara-C/I) showed an important increased expression of bcl-2 protein after treatment with 1 microM ara-C, but not after 10 microM. 2-chloroethyl methyl sulfide 50-53 BCL2 apoptosis regulator Homo sapiens 123-128 10769646-13 2000 Three cell lines resistant to ara-C (CEM/ara-C/B, CEM/ara-C/D and CEM/ara-C/I) showed an important increased expression of bcl-2 protein after treatment with 1 microM ara-C, but not after 10 microM. Cytarabine 41-46 BCL2 apoptosis regulator Homo sapiens 123-128 10769646-13 2000 Three cell lines resistant to ara-C (CEM/ara-C/B, CEM/ara-C/D and CEM/ara-C/I) showed an important increased expression of bcl-2 protein after treatment with 1 microM ara-C, but not after 10 microM. Cytarabine 41-46 BCL2 apoptosis regulator Homo sapiens 123-128 10769646-18 2000 It is apparent that selection for ara-C resistance confers cross-resistance to many other classes of drugs and gamma radiation, probably due to bcl-2 protein overexpression or P-gp and MRP expression, as independent mechanisms. Cytarabine 34-39 BCL2 apoptosis regulator Homo sapiens 144-149 10646901-5 2000 Overexpression of BCL-2 in A2780 cells led to resistance to cisplatin compared to the vector control when assayed at 48 h post-drug incubation but a significant increase in sensitivity at 96 h. Relative rates of apoptosis at 48- and 96-h post-cisplatin exposure mirrored the growth inhibition. Cisplatin 60-69 BCL2 apoptosis regulator Homo sapiens 18-23 10646901-5 2000 Overexpression of BCL-2 in A2780 cells led to resistance to cisplatin compared to the vector control when assayed at 48 h post-drug incubation but a significant increase in sensitivity at 96 h. Relative rates of apoptosis at 48- and 96-h post-cisplatin exposure mirrored the growth inhibition. Cisplatin 243-252 BCL2 apoptosis regulator Homo sapiens 18-23 11052631-9 2000 CONCLUSIONS: These results suggest that the exposure duration, DT, and expression of MDR-1, bcl-2 and bax each contribute to paclitaxel sensitivity of human colorectal carcinoma cells. Paclitaxel 125-135 BCL2 apoptosis regulator Homo sapiens 92-97 11191059-3 2000 The contributions of COX-2 in tumor angiogenesis include: (a) the increased expression of the proangiogenic growth factor VEGF; (b) the production of the eicosanoid products thromboxane A2, PGE2 and PGI2 that can directly stimulate endothelial cell migration and growth factor-induced angiogenesis; and potentially, (c) the inhibition of endothelial cell apoptosis by stimulation of Bcl-2 or Akt activation. Eicosanoids 154-164 BCL2 apoptosis regulator Homo sapiens 383-388 11052631-11 2000 There may be a therapeutic window for taxanes in colon cancer by optimizing pharmacokinetics and modulating MDR-1 and bcl-2 resistance factors. Taxoids 38-45 BCL2 apoptosis regulator Homo sapiens 118-123 11059564-6 2000 Moreover, proadifen weakened ATRA-induced downregulation of the Bcl-2 protein. Proadifen 10-19 BCL2 apoptosis regulator Homo sapiens 64-69 11059564-6 2000 Moreover, proadifen weakened ATRA-induced downregulation of the Bcl-2 protein. Tretinoin 29-33 BCL2 apoptosis regulator Homo sapiens 64-69 10975289-4 2000 Significant inhibition of Bcl-2 oncogene protein expression by the same concentration of FNQ3 also was demonstrated by an immunohistochemical staining method to visualize the expressed cells and Western blot in polyacrylamide gel electrophoresis. polyacrylamide 211-225 BCL2 apoptosis regulator Homo sapiens 26-31 11191059-3 2000 The contributions of COX-2 in tumor angiogenesis include: (a) the increased expression of the proangiogenic growth factor VEGF; (b) the production of the eicosanoid products thromboxane A2, PGE2 and PGI2 that can directly stimulate endothelial cell migration and growth factor-induced angiogenesis; and potentially, (c) the inhibition of endothelial cell apoptosis by stimulation of Bcl-2 or Akt activation. Thromboxane A2 174-188 BCL2 apoptosis regulator Homo sapiens 383-388 10713725-7 2000 High level overexpression of the anti-apoptotic protein Bcl-2 prevented Bax redistribution to the mitochondria, caspase activation and apoptosis following exposure to staurosporine or etoposide. Staurosporine 167-180 BCL2 apoptosis regulator Homo sapiens 56-61 10713725-7 2000 High level overexpression of the anti-apoptotic protein Bcl-2 prevented Bax redistribution to the mitochondria, caspase activation and apoptosis following exposure to staurosporine or etoposide. Etoposide 184-193 BCL2 apoptosis regulator Homo sapiens 56-61 10713727-9 2000 As diamide was non-toxic, we used diamide as a Bcl-2 activator to protect MC against a subsequent toxic dose of NO. Diamide 34-41 BCL2 apoptosis regulator Homo sapiens 47-52 10826769-4 2000 Analysis of flow cytometry indicates that H2O2 decreases the level of Bcl-2. Hydrogen Peroxide 42-46 BCL2 apoptosis regulator Homo sapiens 70-75 11191059-3 2000 The contributions of COX-2 in tumor angiogenesis include: (a) the increased expression of the proangiogenic growth factor VEGF; (b) the production of the eicosanoid products thromboxane A2, PGE2 and PGI2 that can directly stimulate endothelial cell migration and growth factor-induced angiogenesis; and potentially, (c) the inhibition of endothelial cell apoptosis by stimulation of Bcl-2 or Akt activation. Epoprostenol 199-203 BCL2 apoptosis regulator Homo sapiens 383-388 10601800-8 2000 Our results indicate that the reduction of apoptosis was one of the CDDP-resistant mechanisms, and that reduced apoptosis in CDDP-resistant cells was influenced by Bcl-2 and CPP32 proteins. Cisplatin 125-129 BCL2 apoptosis regulator Homo sapiens 164-169 10613922-10 2000 There were differences in the expression of c-fos, c-jun, and bcl-2 genes after the incubation of OVCAR-3 cells with free and HPMA copolymer-bound ADR indicating differences in activation of cell death signaling pathways. hpma copolymer 126-140 BCL2 apoptosis regulator Homo sapiens 62-67 11775218-0 2000 Overexpression of Bcl-2 partly inhibits apoptosis of human cervical cancer SiHa cells induced by arsenic trioxide. Arsenic Trioxide 97-113 BCL2 apoptosis regulator Homo sapiens 18-23 11775218-1 2000 OBJECTIVE: To study the biological effect of arsenic trioxide (As2O3) on human cervical cancer SiHa cells and SiHa cells overexpressing bcl-2 gene. Arsenic Trioxide 63-68 BCL2 apoptosis regulator Homo sapiens 136-141 11775218-7 2000 Nevertheless, As2O3 at a high concentration could still induce apoptosis of SiHa-Bcl2 cells mainly via decreasing Bcl-2 expression and slightly inhibiting viral gene expression. Arsenic Trioxide 14-19 BCL2 apoptosis regulator Homo sapiens 114-119 11775218-8 2000 CONCLUSION: As2O3 is an inducer of the apoptosis of human cervical carcinoma cells and the cells overexpressing Bcl-2 can partly resist As2O3 induced apoptosis, but the exact mechanism is unclear. Arsenic Trioxide 136-141 BCL2 apoptosis regulator Homo sapiens 112-117 10611712-0 2000 Bcl-2, Bax, and c-Fos expression correlates to RPE cell apoptosis induced by UV-light and daunorubicin. Daunorubicin 90-102 BCL2 apoptosis regulator Homo sapiens 0-5 10614618-0 2000 Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Calcitriol 0-10 BCL2 apoptosis regulator Homo sapiens 76-81 10614618-5 2000 The calcitriol-induced apoptosis is accompanied by a down-regulation of Bcl-2 and Bcl-X(L) proteins, both of which protect cells from undergoing apoptosis. Calcitriol 4-14 BCL2 apoptosis regulator Homo sapiens 72-77 10614618-7 2000 We find that overexpression of Bcl-2 blocks calcitriol-induced apoptosis and reduces, but does not eliminate, calcitriol-induced growth inhibition. Calcitriol 44-54 BCL2 apoptosis regulator Homo sapiens 31-36 10614618-7 2000 We find that overexpression of Bcl-2 blocks calcitriol-induced apoptosis and reduces, but does not eliminate, calcitriol-induced growth inhibition. Calcitriol 110-120 BCL2 apoptosis regulator Homo sapiens 31-36 10627292-0 2000 A conserved AU-rich element in the 3" untranslated region of bcl-2 mRNA is endowed with a destabilizing function that is involved in bcl-2 down-regulation during apoptosis. Gold 12-14 BCL2 apoptosis regulator Homo sapiens 61-66 10601800-0 2000 Regulation of apoptosis reduction in the cisplatin-resistant A431 cell line by Bcl-2 and CPP32. Cisplatin 41-50 BCL2 apoptosis regulator Homo sapiens 79-84 11125490-0 2000 B cell production and turnover in CBA/Ca, CBA/N and CBA/N-bcl-2 transgenic mice: xid-mediated failure among pre B cells is unaltered by bcl-2 overexpression. Nitrogen 56-57 BCL2 apoptosis regulator Homo sapiens 58-63 10627292-0 2000 A conserved AU-rich element in the 3" untranslated region of bcl-2 mRNA is endowed with a destabilizing function that is involved in bcl-2 down-regulation during apoptosis. Gold 12-14 BCL2 apoptosis regulator Homo sapiens 133-138 10642312-12 2000 The increase in bax/bcl-2 ratio in DHA-stimulated cells was not affected by ET-1. Docosahexaenoic Acids 35-38 BCL2 apoptosis regulator Homo sapiens 20-25 10627292-4 2000 Here we demonstrate that bcl-2 mRNA is endowed with an adenine- and uracil-rich element (ARE) characterized by high evolutionary conservation not only among all chordates examined, but even between chordates and the nematode Caenorhabditis elegans (ced-9 gene). Adenine 55-62 BCL2 apoptosis regulator Homo sapiens 25-30 10627292-4 2000 Here we demonstrate that bcl-2 mRNA is endowed with an adenine- and uracil-rich element (ARE) characterized by high evolutionary conservation not only among all chordates examined, but even between chordates and the nematode Caenorhabditis elegans (ced-9 gene). Uracil 68-74 BCL2 apoptosis regulator Homo sapiens 25-30 10627292-6 2000 This possibility is corroborated by the fact that the pathway leading to the modulating activity of bcl-2 ARE is influenced by PKC, since the addition of DAG and TPA markedly attenuated the bcl-2 ARE destabilizing potential. dag 154-157 BCL2 apoptosis regulator Homo sapiens 100-105 10627292-6 2000 This possibility is corroborated by the fact that the pathway leading to the modulating activity of bcl-2 ARE is influenced by PKC, since the addition of DAG and TPA markedly attenuated the bcl-2 ARE destabilizing potential. dag 154-157 BCL2 apoptosis regulator Homo sapiens 190-195 10627292-6 2000 This possibility is corroborated by the fact that the pathway leading to the modulating activity of bcl-2 ARE is influenced by PKC, since the addition of DAG and TPA markedly attenuated the bcl-2 ARE destabilizing potential. Tetradecanoylphorbol Acetate 162-165 BCL2 apoptosis regulator Homo sapiens 100-105 10627292-6 2000 This possibility is corroborated by the fact that the pathway leading to the modulating activity of bcl-2 ARE is influenced by PKC, since the addition of DAG and TPA markedly attenuated the bcl-2 ARE destabilizing potential. Tetradecanoylphorbol Acetate 162-165 BCL2 apoptosis regulator Homo sapiens 190-195 10627292-7 2000 Conversely, it is noteworthy that when C(2)-ceramide is added to the culture medium as the apoptotic agent, the beta-globin transcript harboring the bcl-2 ARE undergoes a dramatic increase in decay. N-acetylsphingosine 39-52 BCL2 apoptosis regulator Homo sapiens 149-154 10627292-9 2000 The half-life of the mRNA of bcl-2 in Jurkat cells is prolonged by PKC stimulation and shortened by C(2)-ceramide addition, strongly supporting the view that bcl-2 mRNA stability plays a physiological role in modulating bcl-2 expression, particularly in its down-regulation during apoptosis. N-acetylsphingosine 100-113 BCL2 apoptosis regulator Homo sapiens 29-34 10627292-9 2000 The half-life of the mRNA of bcl-2 in Jurkat cells is prolonged by PKC stimulation and shortened by C(2)-ceramide addition, strongly supporting the view that bcl-2 mRNA stability plays a physiological role in modulating bcl-2 expression, particularly in its down-regulation during apoptosis. N-acetylsphingosine 100-113 BCL2 apoptosis regulator Homo sapiens 158-163 10627292-9 2000 The half-life of the mRNA of bcl-2 in Jurkat cells is prolonged by PKC stimulation and shortened by C(2)-ceramide addition, strongly supporting the view that bcl-2 mRNA stability plays a physiological role in modulating bcl-2 expression, particularly in its down-regulation during apoptosis. N-acetylsphingosine 100-113 BCL2 apoptosis regulator Homo sapiens 158-163 10695937-0 2000 Immunolocalizaiton of c-Myc and bcl-2 proto-oncogene products in gingival hyperplasia induced by nifedipine and phenytoin. Nifedipine 97-107 BCL2 apoptosis regulator Homo sapiens 32-37 10826666-0 2000 Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. Lithium 0-7 BCL2 apoptosis regulator Homo sapiens 48-53 11202219-6 2000 The results demonstrate that estradiol exerts profound protective effects against ischemic brain injury induced by cerebral artery occlusion and that this protective action correlates with changes in the level of gene expression of estradiol receptors and members of the Bcl-2 family. Estradiol 29-38 BCL2 apoptosis regulator Homo sapiens 271-276 10695937-3 2000 METHODS: We immunohistochemically examined the expression of both c-Myc and bcl-2 oncoprotein, which can exert influence on the epithelial morphogenesis and homeostasis, in 12 hyperplastic gingival tissues induced by nifedipine and phenytoin as well as 5 control tissues using avidin-biotin-peroxidase complex methods. Nifedipine 217-227 BCL2 apoptosis regulator Homo sapiens 76-81 10695937-3 2000 METHODS: We immunohistochemically examined the expression of both c-Myc and bcl-2 oncoprotein, which can exert influence on the epithelial morphogenesis and homeostasis, in 12 hyperplastic gingival tissues induced by nifedipine and phenytoin as well as 5 control tissues using avidin-biotin-peroxidase complex methods. Phenytoin 232-241 BCL2 apoptosis regulator Homo sapiens 76-81 10695937-7 2000 CONCLUSIONS: The results of our present study indicate that the synergistic overexpression of c-Myc and bcl-2 oncoprotein may be related to the pathogenesis of gingival hyperplasia induced by nifedipine and phenytoin, especially to the morphogenesis of hyperplastic epithelia. Nifedipine 192-202 BCL2 apoptosis regulator Homo sapiens 104-109 10695937-7 2000 CONCLUSIONS: The results of our present study indicate that the synergistic overexpression of c-Myc and bcl-2 oncoprotein may be related to the pathogenesis of gingival hyperplasia induced by nifedipine and phenytoin, especially to the morphogenesis of hyperplastic epithelia. Phenytoin 207-216 BCL2 apoptosis regulator Homo sapiens 104-109 10695937-0 2000 Immunolocalizaiton of c-Myc and bcl-2 proto-oncogene products in gingival hyperplasia induced by nifedipine and phenytoin. Phenytoin 112-121 BCL2 apoptosis regulator Homo sapiens 32-37 11776601-1 2000 OBJECTIVE: To study the effect of estradiol (E2) and tamoxifen (TAM) on the apoptosis regulatory genes (bax, bcl-2) and mdr-1 in MCF-7 cells. Estradiol 34-43 BCL2 apoptosis regulator Homo sapiens 109-114 11188937-5 2000 New therapeutic modalities aimed to affect BCL2 such as the antiidiotype vaccines or antisense oligonucleotides against BCL2 have motivated great expectancy. Oligonucleotides 95-111 BCL2 apoptosis regulator Homo sapiens 43-47 11188937-5 2000 New therapeutic modalities aimed to affect BCL2 such as the antiidiotype vaccines or antisense oligonucleotides against BCL2 have motivated great expectancy. Oligonucleotides 95-111 BCL2 apoptosis regulator Homo sapiens 120-124 10870682-7 2000 Tamoxifen has multiple influence on the rate of growth of cancer cells: depends on estrogen receptor (ER), conducts reduction of proliferation rate; depends on ER and other mechanisms conducts to suppressions of Bcl-2 protein expression and induction of cell death through apoptotic pathway. Tamoxifen 0-9 BCL2 apoptosis regulator Homo sapiens 212-217 10870682-8 2000 Estradiol prevents the apoptotic influence of tamoxifen probably by enhancement of Bcl-2 protein expression and does not prevent the inhibition of proliferation rate. Estradiol 0-9 BCL2 apoptosis regulator Homo sapiens 83-88 10870682-8 2000 Estradiol prevents the apoptotic influence of tamoxifen probably by enhancement of Bcl-2 protein expression and does not prevent the inhibition of proliferation rate. Tamoxifen 46-55 BCL2 apoptosis regulator Homo sapiens 83-88 11173657-11 2000 There was a trend of negative correlation of Bcl2 with Ki67 (p=0.062). ki67 55-59 BCL2 apoptosis regulator Homo sapiens 45-49 10637471-8 2000 Serine/threonine phosphorylation is also involved in the regulation of the apoptosis-controlling Bcl-2 protein, as certain phosphorylation events induced by cytokines such as IL-3 are anti-apoptotic, whereas other phosphorylation events triggered by chemotherapeutic drugs such as Paclitaxel are associated with cell death. Serine 0-6 BCL2 apoptosis regulator Homo sapiens 97-102 10637471-8 2000 Serine/threonine phosphorylation is also involved in the regulation of the apoptosis-controlling Bcl-2 protein, as certain phosphorylation events induced by cytokines such as IL-3 are anti-apoptotic, whereas other phosphorylation events triggered by chemotherapeutic drugs such as Paclitaxel are associated with cell death. Threonine 7-16 BCL2 apoptosis regulator Homo sapiens 97-102 10637471-8 2000 Serine/threonine phosphorylation is also involved in the regulation of the apoptosis-controlling Bcl-2 protein, as certain phosphorylation events induced by cytokines such as IL-3 are anti-apoptotic, whereas other phosphorylation events triggered by chemotherapeutic drugs such as Paclitaxel are associated with cell death. Paclitaxel 281-291 BCL2 apoptosis regulator Homo sapiens 97-102 11050805-0 2000 Bcl-2 molecular analysis in paraffin-embedded biopsies from diffuse large B-cell lymphomas. Paraffin 28-36 BCL2 apoptosis regulator Homo sapiens 0-5 11831985-2 2000 METHODS: Immunohistochemical SABC method was used to detect the expression of proto-oncogene bcl-2 and MTS1/p16 in 51 paraffin-embedded primary transitional cell carcinoma of bladder specimens and 5 normal bladder mucosa specimens. sabc 29-33 BCL2 apoptosis regulator Homo sapiens 93-98 11831985-2 2000 METHODS: Immunohistochemical SABC method was used to detect the expression of proto-oncogene bcl-2 and MTS1/p16 in 51 paraffin-embedded primary transitional cell carcinoma of bladder specimens and 5 normal bladder mucosa specimens. Paraffin 118-126 BCL2 apoptosis regulator Homo sapiens 93-98 11776601-1 2000 OBJECTIVE: To study the effect of estradiol (E2) and tamoxifen (TAM) on the apoptosis regulatory genes (bax, bcl-2) and mdr-1 in MCF-7 cells. Tamoxifen 53-62 BCL2 apoptosis regulator Homo sapiens 109-114 11776601-1 2000 OBJECTIVE: To study the effect of estradiol (E2) and tamoxifen (TAM) on the apoptosis regulatory genes (bax, bcl-2) and mdr-1 in MCF-7 cells. Tamoxifen 64-67 BCL2 apoptosis regulator Homo sapiens 109-114 10581168-1 1999 Previous studies have shown that bryostatin 1 induces a decrease in the expression of the antiapoptotic protooncogene Bcl-2 in the human acute lymphoblastic leukemia (ALL) cell line Reh. bryostatin 1 33-45 BCL2 apoptosis regulator Homo sapiens 118-123 10585263-11 1999 Overexpression of Bcl-2 not only suppressed apoptosis but also completely prevented induction of p21 and Bax caused by ceramide in SK-Hep-1 cells. Ceramides 119-127 BCL2 apoptosis regulator Homo sapiens 18-23 10585263-13 1999 These results suggest that p21 promotes ceramide-induced apoptosis by enhancing the expression of Bax, thereby modulating the molecular ratio of Bcl-2:Bax in human hepatocarcinoma cells. Ceramides 40-48 BCL2 apoptosis regulator Homo sapiens 145-150 10597196-0 1999 p21Waf1/Cip1 acts in synergy with bcl-2 to confer multidrug resistance in a camptothecin-selected human lung-cancer cell line. Camptothecin 76-88 BCL2 apoptosis regulator Homo sapiens 34-39 10597196-6 1999 Furthermore, the co-treatment of p21Waf1/Cip1 and bcl-2 anti-sense oligodeoxy-nucleotides restored drug susceptibility in A549/CPT cells more effectively than either one of them alone. Oligodeoxyribonucleotides 67-89 BCL2 apoptosis regulator Homo sapiens 50-55 10583267-4 1999 In this study we evaluated the cellular responses to a Bcl-2 antisense oligonucleotide in terms of Bcl-2 mRNA and protein expression and the induction of apoptosis. Oligonucleotides 71-86 BCL2 apoptosis regulator Homo sapiens 55-60 10583267-4 1999 In this study we evaluated the cellular responses to a Bcl-2 antisense oligonucleotide in terms of Bcl-2 mRNA and protein expression and the induction of apoptosis. Oligonucleotides 71-86 BCL2 apoptosis regulator Homo sapiens 99-104 10583267-7 1999 Therefore Bcl-2 antisense oligonucleotides might be useful in the treatment of B-CLL. Oligonucleotides 26-42 BCL2 apoptosis regulator Homo sapiens 10-15 11139839-8 1999 New agents such as the staurosporine analogue UCN-01 and bryostatin are thought to affect apoptosis induction by altering BCL-2 phosphorylation. Staurosporine 23-36 BCL2 apoptosis regulator Homo sapiens 122-127 10660093-8 1999 These results indicate that clofilium exerts antiproliferative action and growth inhibition on HL-60 through induction of apoptosis which is mediated via Bcl-2-insensitive activation of caspase-3, and suggest chemotherapeutic and cytostatic potentials of this compound in human leukemias. clofilium 28-37 BCL2 apoptosis regulator Homo sapiens 154-159 10660093-0 1999 Clofilium, a potassium channel blocker, induces apoptosis of human promyelocytic leukemia (HL-60) cells via Bcl-2-insensitive activation of caspase-3. clofilium 0-9 BCL2 apoptosis regulator Homo sapiens 108-113 10579309-7 1999 Amino acid sequence analysis revealed that rat and human Mcl-1 showed a complete conservation of the Bcl-2 homology domains BH1, BH2, and BH3. bh2 129-132 BCL2 apoptosis regulator Homo sapiens 101-106 10579309-7 1999 Amino acid sequence analysis revealed that rat and human Mcl-1 showed a complete conservation of the Bcl-2 homology domains BH1, BH2, and BH3. BH 3 138-141 BCL2 apoptosis regulator Homo sapiens 101-106 11139839-8 1999 New agents such as the staurosporine analogue UCN-01 and bryostatin are thought to affect apoptosis induction by altering BCL-2 phosphorylation. 7-hydroxystaurosporine 46-52 BCL2 apoptosis regulator Homo sapiens 122-127 11139839-8 1999 New agents such as the staurosporine analogue UCN-01 and bryostatin are thought to affect apoptosis induction by altering BCL-2 phosphorylation. Bryostatins 57-67 BCL2 apoptosis regulator Homo sapiens 122-127 10597302-0 1999 Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Vorinostat 55-86 BCL2 apoptosis regulator Homo sapiens 142-147 10569615-0 1999 Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2. Cisplatin 41-50 BCL2 apoptosis regulator Homo sapiens 122-127 10569615-1 1999 PURPOSE: The objective of this study was to characterize the effect of mutant-type p53 and Bcl-2 expression on the sensitivity to cisplatin in a human bladder cancer cell line both in vitro and in vivo. Cisplatin 130-139 BCL2 apoptosis regulator Homo sapiens 91-96 10569615-3 1999 The effects of the overexpression of mutant-type p53, Bcl-2, or both on the sensitivity to cisplatin and the apoptotic features in vitro were evaluated by the MTT assay, staining with Hoechst 33258 and a DNA fragmentation assay. Cisplatin 91-100 BCL2 apoptosis regulator Homo sapiens 54-59 10569615-5 1999 RESULTS: The introduction of mutant-type p53 or Bcl-2 conferred resistance to cisplatin on KoTCC-1 cells through the inhibition of apoptosis. Cisplatin 78-87 BCL2 apoptosis regulator Homo sapiens 48-53 10569615-7 1999 Furthermore, the KoTCC-1 cells transfected with both mutant-type p53 and Bcl-2 exhibited significantly higher resistance to cisplatin treatment than cells transfected with mutant-type p53 or Bcl-2 alone in experimental models in vivo. Cisplatin 124-133 BCL2 apoptosis regulator Homo sapiens 73-78 10569615-7 1999 Furthermore, the KoTCC-1 cells transfected with both mutant-type p53 and Bcl-2 exhibited significantly higher resistance to cisplatin treatment than cells transfected with mutant-type p53 or Bcl-2 alone in experimental models in vivo. Cisplatin 124-133 BCL2 apoptosis regulator Homo sapiens 191-196 10569615-8 1999 CONCLUSIONS: These findings suggest that the overexpression of both mutant-type p53 and Bcl-2 in bladder cancer cells synergistically interferes with the therapeutic effect of cisplatin through the inhibition of the apoptotic pathway. Cisplatin 176-185 BCL2 apoptosis regulator Homo sapiens 88-93 10567572-3 1999 Changing these sites to alanine conferred more antiapoptotic activity on BCL-2 following physiologic death signals as well as paclitaxel, indicating that phosphorylation is inactivating. Alanine 24-31 BCL2 apoptosis regulator Homo sapiens 73-78 10567572-8 1999 Moreover, the combination of dominant negative ASK1, (dnASK1), dnMKK7, and dnJNK1 inhibited paclitaxel-induced BCL-2 phosphorylation. Paclitaxel 92-102 BCL2 apoptosis regulator Homo sapiens 111-116 10705995-11 1999 After 24 h of exposure of T47-D cells to either 1 or 10 microM progesterone, we observed a marked down-regulation of protooncogene bcl-2 protein and mRNA levels. Progesterone 63-75 BCL2 apoptosis regulator Homo sapiens 131-136 10597302-0 1999 Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Vorinostat 88-92 BCL2 apoptosis regulator Homo sapiens 142-147 10597302-4 1999 Enforced expression of Bcl-2 or Bcl-XL inhibited SAHA-induced apoptosis, but only modestly potentiated differentiation. Vorinostat 49-53 BCL2 apoptosis regulator Homo sapiens 23-28 10597302-9 1999 These findings indicate that SAHA potently induces apoptosis in human leukemia cells via a pathway that is p53-independent but at least partially regulated by Bcl-2/Bcl-XL, p21CIP1, and the c-Jun/AP-1 signaling cascade. Vorinostat 29-33 BCL2 apoptosis regulator Homo sapiens 159-164 10564080-3 1999 Depletion of ANs was significantly greater in BCL-2 (66.7 +/- 2%) than in WT (38.8 +/- 2%) cells. 1-anilino-8-naphthalenesulfonate 13-16 BCL2 apoptosis regulator Homo sapiens 46-51 10559201-4 1999 Overexpression of the anti-apoptosis protein Bcl-2 led to increased Ca(m) load, increased mitochondrial membrane potential (DeltaPsi(m)), and inhibition of staurosporine-induced apoptosis. ca(m) 68-73 BCL2 apoptosis regulator Homo sapiens 45-50 10559201-4 1999 Overexpression of the anti-apoptosis protein Bcl-2 led to increased Ca(m) load, increased mitochondrial membrane potential (DeltaPsi(m)), and inhibition of staurosporine-induced apoptosis. Staurosporine 156-169 BCL2 apoptosis regulator Homo sapiens 45-50 10551883-0 1999 Tyrosine phosphorylation of the Bcl-2-associated protein BNIP-2 by fibroblast growth factor receptor-1 prevents its binding to Cdc42GAP and Cdc42. Tyrosine 0-8 BCL2 apoptosis regulator Homo sapiens 32-37 10542244-0 1999 Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. Estradiol 69-85 BCL2 apoptosis regulator Homo sapiens 44-49 10542244-1 1999 bcl-2 gene expression is induced by 17beta-estradiol (E2) in T47D and MCF-7 human breast cancer cells, and the mechanism of E2 responsiveness was further investigated by analysis of the bcl-2 gene promoter. Estradiol 36-52 BCL2 apoptosis regulator Homo sapiens 0-5 10542244-6 1999 These data coupled with results of transient transfection studies demonstrated that transcriptional activation by E2 of the -1578 to -1534 region of the bcl-2 gene promoter was dependent on induction of cAMP and subsequent activation through a cAMP response element. Cyclic AMP 203-207 BCL2 apoptosis regulator Homo sapiens 153-158 10542244-6 1999 These data coupled with results of transient transfection studies demonstrated that transcriptional activation by E2 of the -1578 to -1534 region of the bcl-2 gene promoter was dependent on induction of cAMP and subsequent activation through a cAMP response element. Cyclic AMP 244-248 BCL2 apoptosis regulator Homo sapiens 153-158 18726487-0 1999 Mechanisms of arsenic trioxide induced apoptosis of human cervical cancer HeLa cells and protection by Bcl-2. Arsenic Trioxide 14-30 BCL2 apoptosis regulator Homo sapiens 103-108 18726487-6 1999 However, it was found that As(2)O(3) at a high concentration could also induce apoptosis of HeLa cells overexpressing Bcl-2 possibly mainly via downregulating Bcl-2 expression and slightly inhibiting viral gene expression. (2)o(3) 29-36 BCL2 apoptosis regulator Homo sapiens 118-123 18726487-6 1999 However, it was found that As(2)O(3) at a high concentration could also induce apoptosis of HeLa cells overexpressing Bcl-2 possibly mainly via downregulating Bcl-2 expression and slightly inhibiting viral gene expression. (2)o(3) 29-36 BCL2 apoptosis regulator Homo sapiens 159-164 10597253-8 1999 Apoptosis and activation of caspase-3 by cisplatin, but not DCVC, was prevented by bcl-2. Cisplatin 41-50 BCL2 apoptosis regulator Homo sapiens 83-88 10544027-1 1999 Here, we show that Bcl-2 is phosphorylated on serine upon treatment of CEM T cells with normal IgG and that the overexpression of Bcl-2 in stable transfectants of CEM T cells prevents IgG-induced cell death. Serine 46-52 BCL2 apoptosis regulator Homo sapiens 19-24 10544027-1 1999 Here, we show that Bcl-2 is phosphorylated on serine upon treatment of CEM T cells with normal IgG and that the overexpression of Bcl-2 in stable transfectants of CEM T cells prevents IgG-induced cell death. Serine 46-52 BCL2 apoptosis regulator Homo sapiens 130-135 10597216-5 1999 DNA transfection experiments indicated that Bis itself exerted only weak anti-apoptotic activity, but was synergistic with Bcl-2 in preventing Bax-induced and Fas-mediated apoptosis. ammonium ferrous sulfate 159-162 BCL2 apoptosis regulator Homo sapiens 123-128 10597216-6 1999 These results suggest that Bis is a novel modulator of cellular anti-apoptotic activity that functions through its interaction with Bcl-2. Bismuth 27-30 BCL2 apoptosis regulator Homo sapiens 132-137 10564080-4 1999 Proliferation of both lines decreased, averaging 63 +/- 17% of control by 48 h. Exposure to 5 mM H(2)O(2) caused no further change in ANs in BCL-2 cells but in WT cells decreased the EC to 0.45 +/- 0.08 and depleted ANs to 41 +/- 9% of control; after 24 h, WT cells became pyknotic and showed DNA fragmentation but no chromatin condensation, whereas BCL-2 cells died by delayed necrosis. Hydrogen Peroxide 97-105 BCL2 apoptosis regulator Homo sapiens 350-355 10697578-6 1999 The expression of primary tumor bcl-2 protein was immunohistochemically evaluated by antihuman bcl-2 monoclonal antibody (diluted 1:100, Dako, Copenhagen, Denmark) on formalin-fixed paraffin-embedded tissue. Formaldehyde 167-175 BCL2 apoptosis regulator Homo sapiens 32-37 10697531-8 1999 On the other hand, antisense oligodeoxynucleotides against Bcl-2 mRNA showed a growth inhibitory effect on PLC/PRF/5 cells, but did not show an additive effect on the DBcAMP-induced growth inhibition. Oligodeoxyribonucleotides 29-50 BCL2 apoptosis regulator Homo sapiens 59-64 10697531-8 1999 On the other hand, antisense oligodeoxynucleotides against Bcl-2 mRNA showed a growth inhibitory effect on PLC/PRF/5 cells, but did not show an additive effect on the DBcAMP-induced growth inhibition. Bucladesine 167-173 BCL2 apoptosis regulator Homo sapiens 59-64 10697578-6 1999 The expression of primary tumor bcl-2 protein was immunohistochemically evaluated by antihuman bcl-2 monoclonal antibody (diluted 1:100, Dako, Copenhagen, Denmark) on formalin-fixed paraffin-embedded tissue. Paraffin 182-190 BCL2 apoptosis regulator Homo sapiens 32-37 10697531-9 1999 DBcAMP itself inhibited bcl-2 protein expression. Bucladesine 0-6 BCL2 apoptosis regulator Homo sapiens 24-29 10697613-6 1999 CONCLUSION: The present results suggest that TP is important for remodeling the existing vasculature early in tumor development and intraductal extension, expressions of TP and Bcl-2 are tightly linked and TP status can not generally predict chemotherapeutic sensitivity for 5-FU as a single molecular marker. Fluorouracil 275-279 BCL2 apoptosis regulator Homo sapiens 177-182 10554039-6 1999 Sodium butyrate also decreased the Bcl-2 level, whereas it increased the Bax level and stimulated the release of cytochrome c from the mitochondria, an event that was most likely responsible for the activation of caspase-3. Butyric Acid 0-15 BCL2 apoptosis regulator Homo sapiens 35-40 10554018-3 1999 Neomycin-resistant LNCaP cells that overexpress bcl-2 (LNCaP(bcl-2/neo-r)) were cocultured with hygromycin-resistant LNCaP cells (LNCaP(hygr-r)). Neomycin 0-8 BCL2 apoptosis regulator Homo sapiens 48-53 10554018-3 1999 Neomycin-resistant LNCaP cells that overexpress bcl-2 (LNCaP(bcl-2/neo-r)) were cocultured with hygromycin-resistant LNCaP cells (LNCaP(hygr-r)). Neomycin 0-8 BCL2 apoptosis regulator Homo sapiens 61-66 10544182-5 1999 Bcl-2 overexpression partially protected stably transfected CCRF-CEM sublines from butyrate-induced apoptosis, but showed no effect on butyrate-induced growth inhibition, further distinguishing these two butyrate effects. Butyrates 83-91 BCL2 apoptosis regulator Homo sapiens 0-5 10554028-12 1999 AZT-sensitive BL cells transfected with BCL-2 became resistant. Zidovudine 0-3 BCL2 apoptosis regulator Homo sapiens 40-45 10674872-7 1999 Administration of Tam also initially decreased the expression of BCL-2. Tamoxifen 18-21 BCL2 apoptosis regulator Homo sapiens 65-70 10674872-8 1999 In contrast to ZM treatment, BCL-2 expression increased again after 8 h of incubation with Tam. Tamoxifen 91-94 BCL2 apoptosis regulator Homo sapiens 29-34 10674872-9 1999 After 96 h Tam treated cells expressed BCL-2 levels nearly as high as untreated cells. Tamoxifen 11-14 BCL2 apoptosis regulator Homo sapiens 39-44 10518116-10 1999 The opposite alteration of Bcl-2 (anti-apoptotic) and p53 (apoptotic) contents in SH-SY5Y cells with retinoic acid and staurosporine are attributed to the changes in cell vulnerability. Tretinoin 101-114 BCL2 apoptosis regulator Homo sapiens 27-32 10757037-6 1999 The altered cell cycle progression may trigger the cell"s apoptotic potential, as indicated by the reduced amount of Bcl-2 synthesized inside heptachlor-treated cells. Heptachlor 142-152 BCL2 apoptosis regulator Homo sapiens 117-122 10518116-8 1999 The expression of the proteins of the protooncogene Bcl-2 and the tumor suppressor gene p53 following staurosporine or retinoic acid treatment was assessed by Western blot and immunocytochemistry. Staurosporine 102-115 BCL2 apoptosis regulator Homo sapiens 52-57 10569627-5 1999 Here new relationships between the cellular redox state and the apoptotic regulatory protein BCL-2 will be described with emphasis on potential mechanisms by which GSH can alter cellular physiology in addition to its role in detoxification. Glutathione 164-167 BCL2 apoptosis regulator Homo sapiens 93-98 10534572-11 1999 Moreover, up-regulation of p53 and down-regulation of Bcl-2 was observed only in HPAC cells treated with Taxol. Paclitaxel 105-110 BCL2 apoptosis regulator Homo sapiens 54-59 10518116-8 1999 The expression of the proteins of the protooncogene Bcl-2 and the tumor suppressor gene p53 following staurosporine or retinoic acid treatment was assessed by Western blot and immunocytochemistry. Tretinoin 119-132 BCL2 apoptosis regulator Homo sapiens 52-57 10518116-10 1999 The opposite alteration of Bcl-2 (anti-apoptotic) and p53 (apoptotic) contents in SH-SY5Y cells with retinoic acid and staurosporine are attributed to the changes in cell vulnerability. Staurosporine 119-132 BCL2 apoptosis regulator Homo sapiens 27-32 10518116-9 1999 Retinoic acid increased Bcl-2 and decreased p53 levels, whereas staurosporine decreased Bcl-2 and increased p53 levels. Tretinoin 0-13 BCL2 apoptosis regulator Homo sapiens 24-29 10537063-0 1999 Activation of Akt kinase inhibits apoptosis and changes in Bcl-2 and Bax expression induced by nitric oxide in primary hippocampal neurons. Nitric Oxide 95-107 BCL2 apoptosis regulator Homo sapiens 59-64 10518116-9 1999 Retinoic acid increased Bcl-2 and decreased p53 levels, whereas staurosporine decreased Bcl-2 and increased p53 levels. Staurosporine 64-77 BCL2 apoptosis regulator Homo sapiens 88-93 10521923-10 1999 At higher doses of radiation, ascorbate decreased apoptosis and restored the level of BCL2 in the cells. Ascorbic Acid 30-39 BCL2 apoptosis regulator Homo sapiens 86-90 10557066-0 1999 Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Tretinoin 101-114 BCL2 apoptosis regulator Homo sapiens 14-19 10557066-10 1999 Downregulation of Bcl-2 mRNA and protein was observed by ATRA and the combination of Ara-C, followed by ATRA, resulted in markedly increased cytotoxicity in HL-60 cells, as compared to Ara-C alone or ATRA followed by Ara-C. Cytarabine 85-90 BCL2 apoptosis regulator Homo sapiens 18-23 10557066-10 1999 Downregulation of Bcl-2 mRNA and protein was observed by ATRA and the combination of Ara-C, followed by ATRA, resulted in markedly increased cytotoxicity in HL-60 cells, as compared to Ara-C alone or ATRA followed by Ara-C. Tretinoin 57-61 BCL2 apoptosis regulator Homo sapiens 18-23 10557066-10 1999 Downregulation of Bcl-2 mRNA and protein was observed by ATRA and the combination of Ara-C, followed by ATRA, resulted in markedly increased cytotoxicity in HL-60 cells, as compared to Ara-C alone or ATRA followed by Ara-C. Cytarabine 185-190 BCL2 apoptosis regulator Homo sapiens 18-23 10557066-10 1999 Downregulation of Bcl-2 mRNA and protein was observed by ATRA and the combination of Ara-C, followed by ATRA, resulted in markedly increased cytotoxicity in HL-60 cells, as compared to Ara-C alone or ATRA followed by Ara-C. Tretinoin 104-108 BCL2 apoptosis regulator Homo sapiens 18-23 10557066-10 1999 Downregulation of Bcl-2 mRNA and protein was observed by ATRA and the combination of Ara-C, followed by ATRA, resulted in markedly increased cytotoxicity in HL-60 cells, as compared to Ara-C alone or ATRA followed by Ara-C. Cytarabine 185-190 BCL2 apoptosis regulator Homo sapiens 18-23 10559795-0 1999 Induction of apoptosis by S-nitrosoglutathione and Cu2+ or Ni2+ ion through modulation of bax, bad, and bcl-2 proteins in human colon adenocarcinoma cells. S-Nitrosoglutathione 26-46 BCL2 apoptosis regulator Homo sapiens 104-109 10559795-0 1999 Induction of apoptosis by S-nitrosoglutathione and Cu2+ or Ni2+ ion through modulation of bax, bad, and bcl-2 proteins in human colon adenocarcinoma cells. cupric ion 51-55 BCL2 apoptosis regulator Homo sapiens 104-109 10559795-0 1999 Induction of apoptosis by S-nitrosoglutathione and Cu2+ or Ni2+ ion through modulation of bax, bad, and bcl-2 proteins in human colon adenocarcinoma cells. Nickel(2+) 59-63 BCL2 apoptosis regulator Homo sapiens 104-109 10559795-8 1999 We also found that copper ions modulated the expression of bad, bax, and bcl-2 in GSNO-treated HT 29 cells. Copper 19-25 BCL2 apoptosis regulator Homo sapiens 73-78 10559795-8 1999 We also found that copper ions modulated the expression of bad, bax, and bcl-2 in GSNO-treated HT 29 cells. S-Nitrosoglutathione 82-86 BCL2 apoptosis regulator Homo sapiens 73-78 10559795-10 1999 On the other hand, significant inhibition of bcl-2 occurred in HT 29 cells with simultaneous treatment of GSNO with Cu(2+) (or Ni(2+)). S-Nitrosoglutathione 106-110 BCL2 apoptosis regulator Homo sapiens 45-50 10559795-10 1999 On the other hand, significant inhibition of bcl-2 occurred in HT 29 cells with simultaneous treatment of GSNO with Cu(2+) (or Ni(2+)). cupric ion 116-122 BCL2 apoptosis regulator Homo sapiens 45-50 10567879-5 1999 At constant Bax protein levels, stable sense and antisense gene-transfected QGY-7703 cells showed that constitutive expression of Bcl-2 could render the cells more resistant to Taxol and doxorubicin. Paclitaxel 177-182 BCL2 apoptosis regulator Homo sapiens 130-135 10567879-5 1999 At constant Bax protein levels, stable sense and antisense gene-transfected QGY-7703 cells showed that constitutive expression of Bcl-2 could render the cells more resistant to Taxol and doxorubicin. Doxorubicin 187-198 BCL2 apoptosis regulator Homo sapiens 130-135 10544235-3 1999 Here, we show that Z-VAD-fmk, a caspase inhibitor, can suppress the Bcl-2-dependent cell survival at 39.5 degrees C. This result suggests that a caspase-like activity can act as an inhibitor of apoptosis in this model, downstream of Bcl-2. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 19-28 BCL2 apoptosis regulator Homo sapiens 233-238 10567879-7 1999 As Bcl-2 levels are directly proportional to the resistance of QGY-7703 cells to Taxol and doxorubicin, manipulation of Bcl-2 could be performed to enhance the sensitivity of liver cancer to chemotherapeutic agents. Paclitaxel 81-86 BCL2 apoptosis regulator Homo sapiens 3-8 10567879-7 1999 As Bcl-2 levels are directly proportional to the resistance of QGY-7703 cells to Taxol and doxorubicin, manipulation of Bcl-2 could be performed to enhance the sensitivity of liver cancer to chemotherapeutic agents. Paclitaxel 81-86 BCL2 apoptosis regulator Homo sapiens 120-125 10567879-7 1999 As Bcl-2 levels are directly proportional to the resistance of QGY-7703 cells to Taxol and doxorubicin, manipulation of Bcl-2 could be performed to enhance the sensitivity of liver cancer to chemotherapeutic agents. Doxorubicin 91-102 BCL2 apoptosis regulator Homo sapiens 3-8 10567879-7 1999 As Bcl-2 levels are directly proportional to the resistance of QGY-7703 cells to Taxol and doxorubicin, manipulation of Bcl-2 could be performed to enhance the sensitivity of liver cancer to chemotherapeutic agents. Doxorubicin 91-102 BCL2 apoptosis regulator Homo sapiens 120-125 10557088-0 1999 Bax membrane insertion during Fas(CD95)-induced apoptosis precedes cytochrome c release and is inhibited by Bcl-2. ammonium ferrous sulfate 30-33 BCL2 apoptosis regulator Homo sapiens 108-113 11776616-10 1999 CONCLUSION: Bcl-2 and MRP genes are responsible for the induced resistance of A549DDP cells to cisplatin. Cisplatin 95-104 BCL2 apoptosis regulator Homo sapiens 12-17 10544235-3 1999 Here, we show that Z-VAD-fmk, a caspase inhibitor, can suppress the Bcl-2-dependent cell survival at 39.5 degrees C. This result suggests that a caspase-like activity can act as an inhibitor of apoptosis in this model, downstream of Bcl-2. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 19-28 BCL2 apoptosis regulator Homo sapiens 68-73 10502406-0 1999 Paclitaxel induces apoptosis in Saos-2 cells with CD95L upregulation and Bcl-2 phosphorylation. Paclitaxel 0-10 BCL2 apoptosis regulator Homo sapiens 73-78 10557088-8 1999 In addition, our findings indicate that prevention of Bax insertion into the mitochondria represents a novel mechanism by which Bcl-2 inhibits Fas-induced apoptosis. ammonium ferrous sulfate 143-146 BCL2 apoptosis regulator Homo sapiens 128-133 10529398-5 1999 A triplex-forming bis-PNA was targeted to a homopurine sequence on the coding strand of the bcl-2 cDNA. triplex-forming bis-pna 2-25 BCL2 apoptosis regulator Homo sapiens 92-97 10529398-5 1999 A triplex-forming bis-PNA was targeted to a homopurine sequence on the coding strand of the bcl-2 cDNA. homopurine 44-54 BCL2 apoptosis regulator Homo sapiens 92-97 10471519-5 1999 For example, serine protein phosphorylation, which occurs during mitotic arrest or meiosis, explains paclitaxel-induced hyperphosphorylation of Bcl-2 and Bcl-xL. Serine 13-19 BCL2 apoptosis regulator Homo sapiens 144-149 10521466-3 1999 Our data show that PS1 and Bcl-2 assemble into a macromolecular complex, and that they are released from this complex in response to an apoptotic stimulus induced by staurosporine. Staurosporine 166-179 BCL2 apoptosis regulator Homo sapiens 27-32 10530765-0 1999 Induction of apoptosis in HL-60 cells by eicosapentaenoic acid (EPA) is associated with downregulation of bcl-2 expression. Eicosapentaenoic Acid 41-62 BCL2 apoptosis regulator Homo sapiens 106-111 10530765-0 1999 Induction of apoptosis in HL-60 cells by eicosapentaenoic acid (EPA) is associated with downregulation of bcl-2 expression. Eicosapentaenoic Acid 64-67 BCL2 apoptosis regulator Homo sapiens 106-111 10530765-5 1999 Also, bcl-2 protein expression was downregulated in much greater extent than that of bax showing that depression of bcl-2 might be an important step during the EPA-induced apoptosis in HL-60 cells. Eicosapentaenoic Acid 160-163 BCL2 apoptosis regulator Homo sapiens 6-11 10530765-5 1999 Also, bcl-2 protein expression was downregulated in much greater extent than that of bax showing that depression of bcl-2 might be an important step during the EPA-induced apoptosis in HL-60 cells. Eicosapentaenoic Acid 160-163 BCL2 apoptosis regulator Homo sapiens 116-121 10514462-4 1999 We evaluated for the first time the effect of Bcl-2 expression on the intracellular distribution and production of hydrogen peroxide, under basal conditions and after treatment with apoptosis inducing agents, ceramide analogs and tumor necrosis factor (TNF)-alpha. Hydrogen Peroxide 115-132 BCL2 apoptosis regulator Homo sapiens 46-51 10514462-4 1999 We evaluated for the first time the effect of Bcl-2 expression on the intracellular distribution and production of hydrogen peroxide, under basal conditions and after treatment with apoptosis inducing agents, ceramide analogs and tumor necrosis factor (TNF)-alpha. Ceramides 209-217 BCL2 apoptosis regulator Homo sapiens 46-51 10514462-5 1999 Increased availability of mitochondrial NAD(P)H was detected in Bcl-2-expressing cells and was correlated with an increased constitutive mitochondrial production of hydrogen peroxide. Hydrogen Peroxide 165-182 BCL2 apoptosis regulator Homo sapiens 64-69 10514462-6 1999 Although production of hydrogen peroxide was increased by either C(6)-ceramide or TNF-alpha in Bcl-2 negative Daudi cells commensurate with the early phases of apoptosis, this increase did not occur in Bcl-2-expressing cells. Hydrogen Peroxide 23-40 BCL2 apoptosis regulator Homo sapiens 95-100 10514462-6 1999 Although production of hydrogen peroxide was increased by either C(6)-ceramide or TNF-alpha in Bcl-2 negative Daudi cells commensurate with the early phases of apoptosis, this increase did not occur in Bcl-2-expressing cells. N-caproylsphingosine 65-78 BCL2 apoptosis regulator Homo sapiens 95-100 10471519-5 1999 For example, serine protein phosphorylation, which occurs during mitotic arrest or meiosis, explains paclitaxel-induced hyperphosphorylation of Bcl-2 and Bcl-xL. Paclitaxel 101-111 BCL2 apoptosis regulator Homo sapiens 144-149 10506215-0 1999 Linkage of the BH4 domain of Bcl-2 and the nuclear factor kappaB signaling pathway for suppression of apoptosis. sapropterin 15-18 BCL2 apoptosis regulator Homo sapiens 29-34 10502041-8 1999 Although expression of Bcl-2 protein was found in 6 of 12 (50%) grade II ependymomas, 5 of 15 (33%) grade II oligodendrogliomas, and 6 of 8 (75%) grade III oligodendrogliomas, no correlation between Fas/FasL co-expression and Bcl-2 production could be demonstrated, indicating that protection from Fas-mediated apoptosis probably involves other mechanisms. ammonium ferrous sulfate 199-202 BCL2 apoptosis regulator Homo sapiens 23-28 10506215-7 1999 In view of the growing evidence that the conserved N-terminal BH4 domain of Bcl-2 plays a critical role in suppressing apoptosis, we ascertained whether this region accounts for the underlying effects of Bcl-2 on IkappaBalpha activity. sapropterin 62-65 BCL2 apoptosis regulator Homo sapiens 76-81 10506215-12 1999 Furthermore, adenovirus-mediated delivery of an IkappaBalpha mutant to prevent NFkappaB activation impaired the ability of Bcl-2 to suppress apoptosis provoked by TNFalpha plus cycloheximide in ventricular myocytes. Cycloheximide 177-190 BCL2 apoptosis regulator Homo sapiens 123-128 10506215-13 1999 The data provide the first evidence for the regulation of IkappaBalpha by Bcl-2 through a mechanism that requires the conserved BH4 domain that links Bcl-2 to the NFkappaB signaling pathway for suppression of apoptosis. sapropterin 128-131 BCL2 apoptosis regulator Homo sapiens 74-79 10506215-13 1999 The data provide the first evidence for the regulation of IkappaBalpha by Bcl-2 through a mechanism that requires the conserved BH4 domain that links Bcl-2 to the NFkappaB signaling pathway for suppression of apoptosis. sapropterin 128-131 BCL2 apoptosis regulator Homo sapiens 150-155 10518159-6 1999 Chronic lithium treatment also robustly increases the expression of the neuroprotective protein Bcl-2, raising the intriguing possibility that some of lithium"s effects are mediated through underappreciated neurotrophic/neuroprotective effects. Lithium 8-15 BCL2 apoptosis regulator Homo sapiens 96-101 10518159-6 1999 Chronic lithium treatment also robustly increases the expression of the neuroprotective protein Bcl-2, raising the intriguing possibility that some of lithium"s effects are mediated through underappreciated neurotrophic/neuroprotective effects. Lithium 151-158 BCL2 apoptosis regulator Homo sapiens 96-101 14634334-6 1999 These data, in continuation with the observations that Apoptin is specifically stimulated by Bcl-2 in tumor cells, does not need p53, and is not inhibited by Bcr-Abl in these cells, imply that Apoptin is a potential anti-tumor therapy. apoptin 55-62 BCL2 apoptosis regulator Homo sapiens 93-98 10484067-8 1999 Therefore, sulindac derivatives can cause growth inhibition and induce apoptosis in human prostate cancer cells by a COX-1 and -2 independent mechanism, and this occurs irrespective of androgen sensitivity or increased expression of bcl-2. Sulindac 11-19 BCL2 apoptosis regulator Homo sapiens 233-238 10509176-3 1999 Similar lithium-induced increases in bcl-2 are also observed in cells of human neuronal origin, and are observed in rat frontal cortex at lithium levels as low as approximately 0.3 mmol/L. Lithium 8-15 BCL2 apoptosis regulator Homo sapiens 37-42 10509176-3 1999 Similar lithium-induced increases in bcl-2 are also observed in cells of human neuronal origin, and are observed in rat frontal cortex at lithium levels as low as approximately 0.3 mmol/L. Lithium 138-145 BCL2 apoptosis regulator Homo sapiens 37-42 10519395-0 1999 Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Vitamin D 21-30 BCL2 apoptosis regulator Homo sapiens 80-85 10509176-6 1999 Consistent with the increases in bcl-2 levels and inhibition of GSK-3 beta, lithium has been demonstrated to exert robust protective effects against diverse insults both in vitro and in vivo. Lithium 76-83 BCL2 apoptosis regulator Homo sapiens 33-38 10509176-8 1999 To date, lithium remains the only medication demonstrated to markedly increase bcl-2 levels in several brain areas; in the absence of other adequate treatments, the potential efficacy of lithium in the long term treatment of certain neurodegenerative disorders may be warranted. Lithium 9-16 BCL2 apoptosis regulator Homo sapiens 79-84 10507761-0 1999 Paradoxical regulation of Bcl-2 family proteins by 17beta-oestradiol in human breast cancer cells MCF-7. Estradiol 51-68 BCL2 apoptosis regulator Homo sapiens 26-31 10507761-4 1999 Using multi-probe RNAase protection assays, we found changes in the mRNA levels of several Bcl-2 family proteins upon treatment of MCF-7 cells with 17beta-oestradiol. Estradiol 148-165 BCL2 apoptosis regulator Homo sapiens 91-96 10507761-5 1999 Unexpectedly, we found a paradoxical effects of 17beta-oestradiol on two anti-apoptotic proteins Bcl-2 and Bcl-x. Estradiol 48-65 BCL2 apoptosis regulator Homo sapiens 97-102 10507761-6 1999 Treatment with 17beta-oestradiol resulted in up-regulation of Bcl-2 mRNA and protein, but down-regulated Bcl-x(L) mRNA and protein. Estradiol 15-32 BCL2 apoptosis regulator Homo sapiens 62-67 10507761-10 1999 We speculate that different members of the Bcl-2 family proteins may be regulated through different pathway and these pathways may be modulated by 17beta-oestradiol. Estradiol 147-164 BCL2 apoptosis regulator Homo sapiens 43-48 10519395-7 1999 Contrary to CrmA, overexpression of an antiapoptotic protein Bcl-2 in MCF-7 cells conferred a nearly complete protection from apoptosis induced by vitamin D compounds. Vitamin D 147-156 BCL2 apoptosis regulator Homo sapiens 61-66 10519395-8 1999 Taken together, these data indicate that vitamin D compounds induce apoptosis via a novel caspase- and p53-independent pathway that can be inhibited by Bcl-2. Vitamin D 41-50 BCL2 apoptosis regulator Homo sapiens 152-157 11180782-2 1999 Bax, a pro-apoptotic protein from the Bcl-2 family of proteins, has a microsatellite composed of an eight deoxyguanine [(G)8] tract located in exon 3. deoxyguanine 106-118 BCL2 apoptosis regulator Homo sapiens 38-43 10537367-3 1999 In this study, we investigated the effects of TAM on bcl-2 family gene products bcl-2, bax, and bcl-X(L) and on p53 levels in estrogen receptor-positive MCF-7 breast cancer cells. Tamoxifen 46-49 BCL2 apoptosis regulator Homo sapiens 53-58 10537367-0 1999 Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels. Tamoxifen 0-9 BCL2 apoptosis regulator Homo sapiens 81-86 10525261-10 1999 Bcl-2 had only a minor effect on TBT-triggered caspase activation or cell death. tributyltin 33-36 BCL2 apoptosis regulator Homo sapiens 0-5 10537367-3 1999 In this study, we investigated the effects of TAM on bcl-2 family gene products bcl-2, bax, and bcl-X(L) and on p53 levels in estrogen receptor-positive MCF-7 breast cancer cells. Tamoxifen 46-49 BCL2 apoptosis regulator Homo sapiens 80-85 10537367-4 1999 We found that TAM induced time- and concentration-dependent down-regulation of bcl-2 at both the mRNA and protein level. Tamoxifen 14-17 BCL2 apoptosis regulator Homo sapiens 79-84 10537367-5 1999 Down-regulation of bcl-2 correlated with TAM-induced apoptosis. Tamoxifen 41-44 BCL2 apoptosis regulator Homo sapiens 19-24 10537367-6 1999 In addition, estradiol treatment significantly increased bcl-2 protein expression and blocked the reduction of bcl-2 by TAM. Estradiol 13-22 BCL2 apoptosis regulator Homo sapiens 57-62 10537367-6 1999 In addition, estradiol treatment significantly increased bcl-2 protein expression and blocked the reduction of bcl-2 by TAM. Estradiol 13-22 BCL2 apoptosis regulator Homo sapiens 111-116 10537367-6 1999 In addition, estradiol treatment significantly increased bcl-2 protein expression and blocked the reduction of bcl-2 by TAM. Tamoxifen 120-123 BCL2 apoptosis regulator Homo sapiens 111-116 10537367-8 1999 Our results demonstrate that TAM can induce apoptosis in a time- and dose-dependent manner by modulating bcl-2 levels in breast cancer cells, and down-regulation of bcl-2 induced by TAM was not accompanied by alterations in p53 levels. Tamoxifen 29-32 BCL2 apoptosis regulator Homo sapiens 105-110 10493941-4 1999 The simultaneous apoptosis with Bcl2 phosphorylation was evident in cancer cells challenged with the proteasome inhibitor, MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 123-128 BCL2 apoptosis regulator Homo sapiens 32-36 10493941-5 1999 Our studies suggest that the proteasome inhibitor MG132 induced tumor cell killing is mediated through Bcl2 phosphorylation. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 50-55 BCL2 apoptosis regulator Homo sapiens 103-107 10534122-7 1999 Morphine-treated Jurkat cells also showed a decreased expression of bcl-2 and an enhanced expression of bax. Morphine 0-8 BCL2 apoptosis regulator Homo sapiens 68-73 10604264-0 1999 A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Docetaxel 20-29 BCL2 apoptosis regulator Homo sapiens 134-139 10573132-0 1999 Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh. bryostatin 1 30-42 BCL2 apoptosis regulator Homo sapiens 4-9 10573132-3 1999 Treatment with bryostatin 1 induced a down-regulation in Bcl-2 protein that was not accompanied by an obvious Bax protein induction or apoptosis. bryostatin 1 15-27 BCL2 apoptosis regulator Homo sapiens 57-62 10573132-7 1999 Western blots revealed that dolastatin 10-induced apoptosis was accompanied by the induction of Bax protein and the reduction in Bcl-2 protein. dolastatin 10 28-41 BCL2 apoptosis regulator Homo sapiens 129-134 10573132-8 1999 Auristatin PE and vincristine induced both Bax and Bcl-2 protein, leaving the Bax:Bcl-2 ratio constant. soblidotin 0-13 BCL2 apoptosis regulator Homo sapiens 51-56 10573132-8 1999 Auristatin PE and vincristine induced both Bax and Bcl-2 protein, leaving the Bax:Bcl-2 ratio constant. Vincristine 18-29 BCL2 apoptosis regulator Homo sapiens 51-56 10573132-8 1999 Auristatin PE and vincristine induced both Bax and Bcl-2 protein, leaving the Bax:Bcl-2 ratio constant. Vincristine 18-29 BCL2 apoptosis regulator Homo sapiens 82-87 10573132-9 1999 Reh cells pretreated for 24 h with bryostatin 1 followed by dolastatin 10, auristatin PE or vincristine showed significant apoptosis which was accompanied by Bcl-2 protein down regulation and Bax protein up regulation. bryostatin 1 35-47 BCL2 apoptosis regulator Homo sapiens 158-163 10573132-9 1999 Reh cells pretreated for 24 h with bryostatin 1 followed by dolastatin 10, auristatin PE or vincristine showed significant apoptosis which was accompanied by Bcl-2 protein down regulation and Bax protein up regulation. Vincristine 92-103 BCL2 apoptosis regulator Homo sapiens 158-163 10510942-3 1999 RESULTS: Initially, we asked whether paclitaxel-induced bcl-2 phosphorylation is triggered by the spindle assembly checkpoint via an active cdc2 kinase-dependent pathway and whether phosphorylation of endogenous bcl-2 is the signal that activates cell death machinery. Paclitaxel 37-47 BCL2 apoptosis regulator Homo sapiens 56-61 10530711-3 1999 One such new therapeutic approach based on the "silencing" of genes involved in the prevention of apoptosis is Bcl-2 antisense oligonucleotide (AO) therapy. Oligonucleotides 127-142 BCL2 apoptosis regulator Homo sapiens 111-116 10530711-3 1999 One such new therapeutic approach based on the "silencing" of genes involved in the prevention of apoptosis is Bcl-2 antisense oligonucleotide (AO) therapy. Oligonucleotides, Antisense 144-146 BCL2 apoptosis regulator Homo sapiens 111-116 10510942-4 1999 Paclitaxel-induced G2/M cell cycle arrest correlated with cdc2 kinase activity and bcl-2 phosphorylation. Paclitaxel 0-10 BCL2 apoptosis regulator Homo sapiens 83-88 10604264-0 1999 A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Docetaxel 31-39 BCL2 apoptosis regulator Homo sapiens 134-139 10604265-4 1999 Of several agents recently shown to reduce prostate-specific antigen levels in phase II studies, 13-cis-retinoic acid and interferon-alpha can reduce the expression of bcl-2 and overcome bcl-2-mediated resistance to paclitaxel in resistant cell lines. Isotretinoin 97-117 BCL2 apoptosis regulator Homo sapiens 168-173 10604265-4 1999 Of several agents recently shown to reduce prostate-specific antigen levels in phase II studies, 13-cis-retinoic acid and interferon-alpha can reduce the expression of bcl-2 and overcome bcl-2-mediated resistance to paclitaxel in resistant cell lines. Isotretinoin 97-117 BCL2 apoptosis regulator Homo sapiens 187-192 10604265-4 1999 Of several agents recently shown to reduce prostate-specific antigen levels in phase II studies, 13-cis-retinoic acid and interferon-alpha can reduce the expression of bcl-2 and overcome bcl-2-mediated resistance to paclitaxel in resistant cell lines. Paclitaxel 216-226 BCL2 apoptosis regulator Homo sapiens 187-192 10604265-5 1999 For these reasons, our current studies test the hypothesis that reducing the expression of bcl-2 with 13-cis-retinoic acid and interferon-alpha in combination with taxanes will improve clinical results. Isotretinoin 102-122 BCL2 apoptosis regulator Homo sapiens 91-96 11477803-4 1999 17-beta-estradiol stimulated a concentration-dependent increase in bcl-2 mRNA level, while tamoxifen lead to a concentration-dependent decrease in bcl-2 mRNA level. Estradiol 0-17 BCL2 apoptosis regulator Homo sapiens 67-72 11477803-4 1999 17-beta-estradiol stimulated a concentration-dependent increase in bcl-2 mRNA level, while tamoxifen lead to a concentration-dependent decrease in bcl-2 mRNA level. Tamoxifen 91-100 BCL2 apoptosis regulator Homo sapiens 147-152 11477803-0 1999 [The regulation of estrogen and tamoxifen to bcl-2 oncogene in endometrial carcinoma]. Tamoxifen 32-41 BCL2 apoptosis regulator Homo sapiens 45-50 11477803-6 1999 Estrogen may up-regulate the cell bcl-2 level to inhibit cell apoptosis, while tamoxifen may down-regulate the cell bcl-2 level and induce apoptosis. Tamoxifen 79-88 BCL2 apoptosis regulator Homo sapiens 116-121 11477803-2 1999 METHODS: A reverse transcription-polymerase chain reaction (RT-PCR) method was utilized to quantitate bcl-2 mRNA levels which regulated by estrogen(17-beta-estradiol) and tamoxifen in estrogen receptor (ER)(+) RL-952 endometrial carcinoma cells. Estradiol 148-165 BCL2 apoptosis regulator Homo sapiens 102-107 10446449-11 1999 Thus, it is concluded that during carcinogenesis the hydroperoxide-reducing capacity of the uterine cervix tissue is enhanced, possibly mediated by bcl-2 protein, and in turn metabolically suppresses the 12-lipoxygenase activity. Hydrogen Peroxide 53-66 BCL2 apoptosis regulator Homo sapiens 148-153 11477803-2 1999 METHODS: A reverse transcription-polymerase chain reaction (RT-PCR) method was utilized to quantitate bcl-2 mRNA levels which regulated by estrogen(17-beta-estradiol) and tamoxifen in estrogen receptor (ER)(+) RL-952 endometrial carcinoma cells. Tamoxifen 171-180 BCL2 apoptosis regulator Homo sapiens 102-107 10496350-2 1999 However, little is known about other mechanisms of resistance, such as a possible protection against Tomudex-induced apoptosis mediated by bcl-2. raltitrexed 101-108 BCL2 apoptosis regulator Homo sapiens 139-144 10471409-1 1999 Treatment of NIH-OVCAR-3 cells with paclitaxel, a microtubule-stabilizing agent, induces mitotic arrest and apoptosis, but also Bcl-2 phosphorylation. Paclitaxel 36-46 BCL2 apoptosis regulator Homo sapiens 128-133 10471409-3 1999 Indeed, when paclitaxel-treated cells were induced to exit mitosis in the presence of 2-aminopurine, Bcl-2 phosphorylation and Bcl-2 down-regulation were both inhibited. Paclitaxel 13-23 BCL2 apoptosis regulator Homo sapiens 101-106 10471409-3 1999 Indeed, when paclitaxel-treated cells were induced to exit mitosis in the presence of 2-aminopurine, Bcl-2 phosphorylation and Bcl-2 down-regulation were both inhibited. Paclitaxel 13-23 BCL2 apoptosis regulator Homo sapiens 127-132 10471409-3 1999 Indeed, when paclitaxel-treated cells were induced to exit mitosis in the presence of 2-aminopurine, Bcl-2 phosphorylation and Bcl-2 down-regulation were both inhibited. 2-Aminopurine 86-99 BCL2 apoptosis regulator Homo sapiens 101-106 10471409-5 1999 Furthermore, we show that Bcl-2 is degraded in mitosis by the proteasome-dependent pathway since Bcl-2 down-regulation is inhibited by proteasome inhibitors such as MG132, Lactacystin and LLnL. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 165-170 BCL2 apoptosis regulator Homo sapiens 26-31 10471409-5 1999 Furthermore, we show that Bcl-2 is degraded in mitosis by the proteasome-dependent pathway since Bcl-2 down-regulation is inhibited by proteasome inhibitors such as MG132, Lactacystin and LLnL. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 165-170 BCL2 apoptosis regulator Homo sapiens 97-102 10471409-5 1999 Furthermore, we show that Bcl-2 is degraded in mitosis by the proteasome-dependent pathway since Bcl-2 down-regulation is inhibited by proteasome inhibitors such as MG132, Lactacystin and LLnL. lactacystin 172-183 BCL2 apoptosis regulator Homo sapiens 26-31 10471409-5 1999 Furthermore, we show that Bcl-2 is degraded in mitosis by the proteasome-dependent pathway since Bcl-2 down-regulation is inhibited by proteasome inhibitors such as MG132, Lactacystin and LLnL. lactacystin 172-183 BCL2 apoptosis regulator Homo sapiens 97-102 10628356-10 1999 2-AP treatment decreased the ratio of anti-apoptotic Bcl-2 to the death stimulating protein Bax, which may account for the molecular basis of apoptosis-inducing activity of this chemopreventive organosulfur derivative. 2-(allylthio)pyrazine 0-4 BCL2 apoptosis regulator Homo sapiens 53-58 10520003-4 1999 Apoptosis resistance was associated with CD40L- and Bryostatin-induced elevations in the anti-apoptotic Bcl-2 family protein Mcl-1. Bryostatins 52-62 BCL2 apoptosis regulator Homo sapiens 104-109 10628333-7 1999 In KB cells, Bcl-2 expression decreased only after treatment with paclitaxel. Paclitaxel 66-76 BCL2 apoptosis regulator Homo sapiens 13-18 10499633-8 1999 In addition, biochemical examination revealed that 5-FU and HU blocked the antimitotic agent-induced increase of p21WAF1/CIP1 protein levels, as well as prevented the hyperphosphorylation of the bcl-2 and c-raf-1 proteins. Fluorouracil 51-55 BCL2 apoptosis regulator Homo sapiens 195-200 10619494-0 1999 Participation of Bcl-2/Bax-alpha in glutamate-induced apoptosis of human glioblastoma cells. Glutamic Acid 36-45 BCL2 apoptosis regulator Homo sapiens 17-22 10477451-7 1999 RESULTS: The IC(50) of fludarabine and gemcitabine on CLL cells was 550 and 1,100 microg/mL, respectively, in our series of samples; the cytotoxicity of either drug was not influenced by the percentage of BCL-2 positive cells in the same sample. fludarabine 23-34 BCL2 apoptosis regulator Homo sapiens 205-210 10477451-7 1999 RESULTS: The IC(50) of fludarabine and gemcitabine on CLL cells was 550 and 1,100 microg/mL, respectively, in our series of samples; the cytotoxicity of either drug was not influenced by the percentage of BCL-2 positive cells in the same sample. gemcitabine 39-50 BCL2 apoptosis regulator Homo sapiens 205-210 10458408-0 1999 Calcium ionophore, ionomycin inhibits growth of human bladder cancer cells both in vitro and in vivo with alteration of Bcl-2 and Bax expression levels. Calcium 0-7 BCL2 apoptosis regulator Homo sapiens 120-125 10458408-0 1999 Calcium ionophore, ionomycin inhibits growth of human bladder cancer cells both in vitro and in vivo with alteration of Bcl-2 and Bax expression levels. Ionomycin 19-28 BCL2 apoptosis regulator Homo sapiens 120-125 10458408-4 1999 Bcl-2 and Bax expression levels in HT1376 after ionomycin treatment were examined by Northern and Western blot analyses. Ionomycin 48-57 BCL2 apoptosis regulator Homo sapiens 0-5 10458408-8 1999 Ionomycin treatment caused a marked decrease in the ratios of Bcl-2 to Bax mRNA and protein in HT1376 cells. Ionomycin 0-9 BCL2 apoptosis regulator Homo sapiens 62-67 10458408-11 1999 CONCLUSIONS: These findings suggest that ionomycin-based therapy could be used as a novel therapeutic strategy for advanced bladder cancer through the effective induction of apoptosis by decreasing the ratio of Bcl-2 to Bax. Ionomycin 41-50 BCL2 apoptosis regulator Homo sapiens 211-216 10638174-0 1999 The role of apoptosis and bcl-2 protein in topical treatment of oral leukoplakia with isotretinoin. Isotretinoin 86-98 BCL2 apoptosis regulator Homo sapiens 26-31 10638174-1 1999 BACKGROUND: This study evaluates the role of bcl-2 protein, as well as, of apoptotic bodies in the topical treatment of oral leucoplakia with 13-cis-retinoic acid (isotretinoin). Isotretinoin 142-162 BCL2 apoptosis regulator Homo sapiens 45-50 10582655-4 1999 On the other hand, BCL-2 prevented apoptosis induced by these long-chain fatty acids, where as n-3 fatty acids suppressed ras expression leading to suppression of development of overt neoplasia. long-chain fatty acids 62-84 BCL2 apoptosis regulator Homo sapiens 19-24 10582655-4 1999 On the other hand, BCL-2 prevented apoptosis induced by these long-chain fatty acids, where as n-3 fatty acids suppressed ras expression leading to suppression of development of overt neoplasia. Fatty Acids, Omega-3 95-110 BCL2 apoptosis regulator Homo sapiens 19-24 10582655-7 1999 Based on these results, it is suggested that long-chain fatty acids induce apoptosis by enhancing lipid peroxidation, suppressing BCL-2 expression possibly by phosphorylation and augmentation of P450 activity. long-chain fatty acids 45-67 BCL2 apoptosis regulator Homo sapiens 130-135 10619494-5 1999 The glutamate-induced apoptosis appears to involve the modulation of Bcl-2 family gene products such as Bcl-2, Bcl-xL, and Bax-alpha. Glutamic Acid 4-13 BCL2 apoptosis regulator Homo sapiens 69-74 10619494-5 1999 The glutamate-induced apoptosis appears to involve the modulation of Bcl-2 family gene products such as Bcl-2, Bcl-xL, and Bax-alpha. Glutamic Acid 4-13 BCL2 apoptosis regulator Homo sapiens 104-109 10619494-6 1999 Both Bcl-2 and Bcl-xL were down-regulated by glutamate at 24 h and further at 48 h. The apoptosis-promoting product p21 Bax-alpha was also down-regulated in GB-12 but slightly up-regulated in GB-4, accompanied by generation of variant form of p18 Bax-alpha in both cell lines. Glutamic Acid 45-54 BCL2 apoptosis regulator Homo sapiens 5-10 10619494-6 1999 Both Bcl-2 and Bcl-xL were down-regulated by glutamate at 24 h and further at 48 h. The apoptosis-promoting product p21 Bax-alpha was also down-regulated in GB-12 but slightly up-regulated in GB-4, accompanied by generation of variant form of p18 Bax-alpha in both cell lines. gb-12 157-162 BCL2 apoptosis regulator Homo sapiens 5-10 10619494-6 1999 Both Bcl-2 and Bcl-xL were down-regulated by glutamate at 24 h and further at 48 h. The apoptosis-promoting product p21 Bax-alpha was also down-regulated in GB-12 but slightly up-regulated in GB-4, accompanied by generation of variant form of p18 Bax-alpha in both cell lines. GB-4 192-196 BCL2 apoptosis regulator Homo sapiens 5-10 10619494-7 1999 These findings suggest that glutamate toxicity results in cellular death via an apoptotic mechanism which appears to involve the Bcl-2/Bax-alpha molecular complex. Glutamic Acid 28-37 BCL2 apoptosis regulator Homo sapiens 129-134 10424768-7 1999 p53 and p21 protein content also increased markedly during paclitaxel exposure, accompanied by phosphorylation of Bcl-2. Paclitaxel 59-69 BCL2 apoptosis regulator Homo sapiens 114-119 10438583-2 1999 When treated with anti-Fas or staurosporine, only three of the four clones showed resistance to apoptosis that correlated with the level of Bcl-2 expression. Staurosporine 30-43 BCL2 apoptosis regulator Homo sapiens 140-145 10438583-5 1999 However, with staurosporine treatment the processing of all the caspases examined was inhibited to a similar degree by the different levels of Bcl-2 expression in the resistant clones. Staurosporine 14-27 BCL2 apoptosis regulator Homo sapiens 143-148 10438583-6 1999 These results suggest that Bcl-2 blocked Fas-mediated cell death by acting downstream of caspase-8, which is in contrast to staurosporine-induced apoptosis where Bcl-2 is acting upstream of caspase-8. Staurosporine 124-137 BCL2 apoptosis regulator Homo sapiens 162-167 10463770-0 1999 Bcl-2 plays a key role instead of mdr1 in the resistance to hexadecylphosphocholine in human epidermoid tumor cell line KB. miltefosine 60-83 BCL2 apoptosis regulator Homo sapiens 0-5 10521575-4 1999 The temporal profile of p53, c-Myc, Bcl-2, Bax expression and caspases activation after glutamate treatment suggest that Bcl-2, c-Myc and caspase-3 play important roles in the excitotoxic neuronal cell death. Glutamic Acid 88-97 BCL2 apoptosis regulator Homo sapiens 121-126 10521575-8 1999 The antiapoptotic potential of bFGF may result from its attenuating effect on the down-regulation of Bcl-2 induced by glutamate and, subsequently, blockade of apoptosis cascade. Glutamic Acid 118-127 BCL2 apoptosis regulator Homo sapiens 101-106 10463617-10 1999 In summary, although Bcl-2 at a low level of expression was antiapoptotic, Bcl-2 at a high level of expression was proapoptotic to Fas-mediated apoptosis. ammonium ferrous sulfate 131-134 BCL2 apoptosis regulator Homo sapiens 75-80 10402233-14 1999 Little changes in expression of PCNA, Rb, p53, and bcl-2 were observed in the five cell types treated with resveratrol, compared to untreated cells. Resveratrol 107-118 BCL2 apoptosis regulator Homo sapiens 51-56 10428509-10 1999 ATRA-induced apoptosis caused actin cleavage, which was not affected by G-CSF, and Bcl-2 downregulation. Tretinoin 0-4 BCL2 apoptosis regulator Homo sapiens 83-88 10428509-11 1999 Etoposide induced a caspase-dependent cleavage of Bcl-2, while actin remained intact. Etoposide 0-9 BCL2 apoptosis regulator Homo sapiens 50-55 10473109-6 1999 Lovastatin treatment resulted in decreased expression of the antiapoptotic protein bcl-2 and increased the expression of the proapoptotic protein bax. Lovastatin 0-10 BCL2 apoptosis regulator Homo sapiens 83-88 10615232-1 1999 This retrospective study of ovarian cancer aimed to elucidate whether expression of apoptosis-related proteins, bcl-2, p53 or MDM-2, is associated with resistance to chemotherapy, especially cisplatin (CDDP) based chemotherapy. Cisplatin 191-200 BCL2 apoptosis regulator Homo sapiens 112-117 10615232-1 1999 This retrospective study of ovarian cancer aimed to elucidate whether expression of apoptosis-related proteins, bcl-2, p53 or MDM-2, is associated with resistance to chemotherapy, especially cisplatin (CDDP) based chemotherapy. Cisplatin 202-206 BCL2 apoptosis regulator Homo sapiens 112-117 10402233-15 1999 Noted exceptions included reduced expression of Rb protein and increased expression of p53 in 2beta and 2Tbeta cells, and increased expression of bcl-2 in 2beta cells, treated with resveratrol. Resveratrol 181-192 BCL2 apoptosis regulator Homo sapiens 146-151 10453946-3 1999 The aim of our study was to evaluate whether Bcl-2 protects hepatoma cells from Fas-mediated apoptosis. ammonium ferrous sulfate 80-83 BCL2 apoptosis regulator Homo sapiens 45-50 10423518-5 1999 Moreover, overexpression of bcl-2 in human leukemia HL60 cells that had been transfected with cDNA for bcl-2 prevented bufalin-induced apoptosis but had no significant effect on the change in plasma membrane potential induced by bufalin. bufalin 119-126 BCL2 apoptosis regulator Homo sapiens 28-33 10423518-5 1999 Moreover, overexpression of bcl-2 in human leukemia HL60 cells that had been transfected with cDNA for bcl-2 prevented bufalin-induced apoptosis but had no significant effect on the change in plasma membrane potential induced by bufalin. bufalin 119-126 BCL2 apoptosis regulator Homo sapiens 103-108 10423518-5 1999 Moreover, overexpression of bcl-2 in human leukemia HL60 cells that had been transfected with cDNA for bcl-2 prevented bufalin-induced apoptosis but had no significant effect on the change in plasma membrane potential induced by bufalin. bufalin 229-236 BCL2 apoptosis regulator Homo sapiens 28-33 10423518-6 1999 Since bufalin specifically inhibits the Na+,K(+)-ATPase of human but not murine tumor cells, and since this inhibition leads to a change in intracellular concentration of Na+ ions, our findings suggest that bufalin induces apoptosis in human tumor cells selectively via inhibition of the Na+,K(+)-ATPase, which acts upstream of the bcl-2 protein. bufalin 207-214 BCL2 apoptosis regulator Homo sapiens 332-337 10453946-12 1999 Inhibition of Bcl-2 expression by transfection of antisense oligodeoxynucleotides caused spontaneous apoptosis in HCC-T, but not in HepG2 cells, suggesting that Bcl-2 is essential for survival of HCC-T cells, whereas other proteins may substitute for it in HepG2 cells. Oligodeoxyribonucleotides 60-81 BCL2 apoptosis regulator Homo sapiens 14-19 10453946-12 1999 Inhibition of Bcl-2 expression by transfection of antisense oligodeoxynucleotides caused spontaneous apoptosis in HCC-T, but not in HepG2 cells, suggesting that Bcl-2 is essential for survival of HCC-T cells, whereas other proteins may substitute for it in HepG2 cells. Oligodeoxyribonucleotides 60-81 BCL2 apoptosis regulator Homo sapiens 161-166 10453946-13 1999 Following LZBC infection, 10% HepG2 cells were beta-galactosidase-positive by X-gal staining and Bcl-2-positive. lzbc 10-14 BCL2 apoptosis regulator Homo sapiens 97-102 10453946-14 1999 In cells surviving after anti-Fas treatment, the proportion of beta-galactosidase-positive cells increased to 50% and the beta-galactosidase activity increased 6-fold, indicating that Bcl-2 expression protected the cells from Fas-mediated apoptosis. ammonium ferrous sulfate 30-33 BCL2 apoptosis regulator Homo sapiens 184-189 10453946-14 1999 In cells surviving after anti-Fas treatment, the proportion of beta-galactosidase-positive cells increased to 50% and the beta-galactosidase activity increased 6-fold, indicating that Bcl-2 expression protected the cells from Fas-mediated apoptosis. ammonium ferrous sulfate 226-229 BCL2 apoptosis regulator Homo sapiens 184-189 10453946-15 1999 In the cloned HepG2 cells stably expressing Bcl-2, the extent of Fas-mediated apoptosis was inversely related to the level of Bcl-2 expression. ammonium ferrous sulfate 65-68 BCL2 apoptosis regulator Homo sapiens 44-49 10453946-15 1999 In the cloned HepG2 cells stably expressing Bcl-2, the extent of Fas-mediated apoptosis was inversely related to the level of Bcl-2 expression. ammonium ferrous sulfate 65-68 BCL2 apoptosis regulator Homo sapiens 126-131 10453946-16 1999 CONCLUSION: Bcl-2 confers protection to human hepatoma cells against Fas-mediated apoptosis, and is essential for survival of some, but not all, hepatoma cells. ammonium ferrous sulfate 69-72 BCL2 apoptosis regulator Homo sapiens 12-17 10455888-11 1999 CONCLUSIONS: Treatment with CPT effectively inhibited the growth of the human gastric cancer SIIA; the mechanism involved was induction of apoptosis mediated by up-regulation of p53, p21Waf1/Cip1, and p27Kip1 and the down-regulation of Bcl-2 and Bcl-XL. Camptothecin 28-31 BCL2 apoptosis regulator Homo sapiens 236-241 10456672-0 1999 Effect of all-trans retinoic acid on chemotherapy induced apoptosis and down-regulation of Bcl-2 in human myeloid leukaemia CD34 positive cells. 2-octenal 14-19 BCL2 apoptosis regulator Homo sapiens 91-96 10456672-0 1999 Effect of all-trans retinoic acid on chemotherapy induced apoptosis and down-regulation of Bcl-2 in human myeloid leukaemia CD34 positive cells. Tretinoin 20-33 BCL2 apoptosis regulator Homo sapiens 91-96 10456672-4 1999 Recently, all-trans retinoic acid (RA) has been reported to enhance cytarabine-induced apoptosis and downregulate Bcl-2 in several human myeloid leukaemia CD34 negative cells. Tretinoin 10-33 BCL2 apoptosis regulator Homo sapiens 114-119 10456672-4 1999 Recently, all-trans retinoic acid (RA) has been reported to enhance cytarabine-induced apoptosis and downregulate Bcl-2 in several human myeloid leukaemia CD34 negative cells. Tretinoin 35-37 BCL2 apoptosis regulator Homo sapiens 114-119 10456672-11 1999 As single agents, RA, cytarabine and fludarabine reduced Bcl-2 expression in a dose dependent manner in both cell types. Tretinoin 18-20 BCL2 apoptosis regulator Homo sapiens 57-62 10456672-11 1999 As single agents, RA, cytarabine and fludarabine reduced Bcl-2 expression in a dose dependent manner in both cell types. Cytarabine 22-32 BCL2 apoptosis regulator Homo sapiens 57-62 10456672-11 1999 As single agents, RA, cytarabine and fludarabine reduced Bcl-2 expression in a dose dependent manner in both cell types. fludarabine 37-48 BCL2 apoptosis regulator Homo sapiens 57-62 10456672-12 1999 Using a quantitative ELISA assay, the Bcl-2 protein concentration was reduced by 86 or 100%, after 72 h of treatment with 10 microM cytarabine or fludarabine, respectively, in both CD34 positive leukaemia cell types. Cytarabine 132-142 BCL2 apoptosis regulator Homo sapiens 38-43 10456672-12 1999 Using a quantitative ELISA assay, the Bcl-2 protein concentration was reduced by 86 or 100%, after 72 h of treatment with 10 microM cytarabine or fludarabine, respectively, in both CD34 positive leukaemia cell types. fludarabine 146-157 BCL2 apoptosis regulator Homo sapiens 38-43 10456672-13 1999 The addition of RA to cytarabine enhanced its induced reduction of Bcl-2 in KG1 CD34+CD7- but not in KGla CD34+CD7+ human myeloid leukaemia cells. Tretinoin 16-18 BCL2 apoptosis regulator Homo sapiens 67-72 10456672-13 1999 The addition of RA to cytarabine enhanced its induced reduction of Bcl-2 in KG1 CD34+CD7- but not in KGla CD34+CD7+ human myeloid leukaemia cells. Cytarabine 22-32 BCL2 apoptosis regulator Homo sapiens 67-72 10409755-0 1999 Bcl-2 and Bcl-X(L) block thapsigargin-induced nitric oxide generation, c-Jun NH(2)-terminal kinase activity, and apoptosis. Thapsigargin 25-37 BCL2 apoptosis regulator Homo sapiens 0-5 10409755-0 1999 Bcl-2 and Bcl-X(L) block thapsigargin-induced nitric oxide generation, c-Jun NH(2)-terminal kinase activity, and apoptosis. Nitric Oxide 46-58 BCL2 apoptosis regulator Homo sapiens 0-5 10409755-2 1999 We examined the role of Bcl-2 and Bcl-X(L) in the regulation of cytosolic Ca(2+), nitric oxide production (NO), c-Jun NH(2)-terminal kinase (JNK) activation, and apoptosis in Jurkat T cells. Nitric Oxide 82-94 BCL2 apoptosis regulator Homo sapiens 24-29 10409755-11 1999 Overexpression of Bcl-2 or Bcl-X(L) inhibited TG-induced loss in mitochondrial membrane potential, release of cytochrome c, and activation of caspase-3 and JNK. Thapsigargin 46-48 BCL2 apoptosis regulator Homo sapiens 18-23 10409755-16 1999 JT/Bcl-2 and JT/Bcl-X(L) cells are susceptible to NO-mediated apoptosis, but Bcl-2 and Bcl-X(L) protect the cells against TG-induced apoptosis by negatively regulating Ca(2+)-sensitive NO synthase activity or expression. Thapsigargin 122-124 BCL2 apoptosis regulator Homo sapiens 77-82 11869536-0 1999 [Apoptosis of HL60 cells induced by inhibition of bcl-2 with antisense phosphorothioate oligodeoxynucleotides]. phosphorothioate oligodeoxynucleotides 71-109 BCL2 apoptosis regulator Homo sapiens 50-55 10409669-3 1999 The Bcl-2 protein, which inhibits apoptosis, is cleaved at Asp-34 by caspases during apoptosis and by recombinant caspase-3 in vitro. Aspartic Acid 59-62 BCL2 apoptosis regulator Homo sapiens 4-9 10409669-10 1999 However, transient transfection of caspase-3 into MCF-7 cells restores Bcl-2 cleavage after staurosporine treatment. Staurosporine 92-105 BCL2 apoptosis regulator Homo sapiens 71-76 10400650-0 1999 Ceramide induces Bcl2 dephosphorylation via a mechanism involving mitochondrial PP2A. Ceramides 0-8 BCL2 apoptosis regulator Homo sapiens 17-21 10400650-1 1999 Phosphorylation of Bcl2 at serine 70 is required for its potent anti-apoptotic function. Serine 27-33 BCL2 apoptosis regulator Homo sapiens 19-23 10400650-7 1999 The potent apoptotic agent ceramide can activate a PP2A, suggesting that one potential component of the ceramide-induced death signal may involve the inactivation of Bcl2. Ceramides 27-35 BCL2 apoptosis regulator Homo sapiens 166-170 10400650-7 1999 The potent apoptotic agent ceramide can activate a PP2A, suggesting that one potential component of the ceramide-induced death signal may involve the inactivation of Bcl2. Ceramides 104-112 BCL2 apoptosis regulator Homo sapiens 166-170 10400650-8 1999 Results indicate that C2-ceramide but not inactive C2-dihydroceramide, was found to specifically activate a mitochondrial PP2A, which rapidly and completely induced Bcl2 dephosphorylation and correlated closely with ceramide-induced cell death. N-acetylsphingosine 22-33 BCL2 apoptosis regulator Homo sapiens 165-169 10400650-8 1999 Results indicate that C2-ceramide but not inactive C2-dihydroceramide, was found to specifically activate a mitochondrial PP2A, which rapidly and completely induced Bcl2 dephosphorylation and correlated closely with ceramide-induced cell death. Ceramides 25-33 BCL2 apoptosis regulator Homo sapiens 165-169 10400650-9 1999 Using a genetic approach, the gain-of-function S70E Bcl2 mutation, which mimics phosphorylation, fails to undergo apoptosis even with the addition of high doses of ceramide (IC50 > 50 microM). Ceramides 164-172 BCL2 apoptosis regulator Homo sapiens 52-56 10400650-10 1999 In contrast, cells overexpressing exogenous wild-type Bcl2 were sensitive to ceramide at dosages where PP2A is fully active and Bcl2 would be expected to be dephosphorylated (IC50 = 14 microM). Ceramides 77-85 BCL2 apoptosis regulator Homo sapiens 54-58 10432288-5 1999 We have found that Bcl-2 overexpression leads to the prevention of chemotherapy (paclitaxel)-induced expression of FasL and blocks paclitaxel-induced apoptosis. Paclitaxel 81-91 BCL2 apoptosis regulator Homo sapiens 19-24 10400650-11 1999 These findings indicate that in cells expressing functional Bcl2, the mechanism of death action for ceramide may involve, at least in part, a mitochondrial PP2A that dephosphorylates and inactivates Bcl2. Ceramides 100-108 BCL2 apoptosis regulator Homo sapiens 60-64 10432288-5 1999 We have found that Bcl-2 overexpression leads to the prevention of chemotherapy (paclitaxel)-induced expression of FasL and blocks paclitaxel-induced apoptosis. Paclitaxel 131-141 BCL2 apoptosis regulator Homo sapiens 19-24 10400650-11 1999 These findings indicate that in cells expressing functional Bcl2, the mechanism of death action for ceramide may involve, at least in part, a mitochondrial PP2A that dephosphorylates and inactivates Bcl2. Ceramides 100-108 BCL2 apoptosis regulator Homo sapiens 199-203 10432288-6 1999 The mechanism of this effect is that Bcl-2 prevents the nuclear translocation of NFAT (nuclear factor of activated T lymphocytes, a transcription factor activated by microtubule damage) by binding and sequestering calcineurin, a calcium-dependent phosphatase that must dephosphorylate NFAT to move to the nucleus. Calcium 229-236 BCL2 apoptosis regulator Homo sapiens 37-42 10403841-3 1999 Here we report that in cells treated with butyric acid, the cleavage of DNA-PKcs was paralleled or preceded by the induction of activation of caspase-3, and these events were inhibited by Bcl-2 overexpression. Butyric Acid 42-54 BCL2 apoptosis regulator Homo sapiens 188-193 10406804-9 1999 Moreover, WT1 expressing cells displaying upregulated Bcl-2 were found to be resistant to apoptosis induced by staurosporine, vincristine and doxorubicine. Staurosporine 111-124 BCL2 apoptosis regulator Homo sapiens 54-59 10406804-9 1999 Moreover, WT1 expressing cells displaying upregulated Bcl-2 were found to be resistant to apoptosis induced by staurosporine, vincristine and doxorubicine. Vincristine 126-137 BCL2 apoptosis regulator Homo sapiens 54-59 10406804-9 1999 Moreover, WT1 expressing cells displaying upregulated Bcl-2 were found to be resistant to apoptosis induced by staurosporine, vincristine and doxorubicine. Doxorubicin 142-154 BCL2 apoptosis regulator Homo sapiens 54-59 10652602-7 1999 At higher doses of lovastatin (50 mM, 100 mM, 200 mM), a significant apoptosis was observed as evidenced by FACS analysis with annexin V staining, which was associated with downregulation of Bcl-2 protein. Lovastatin 19-29 BCL2 apoptosis regulator Homo sapiens 191-196 10360831-0 1999 bcl-2 inhibits mitochondrial metabolism and lonidamine-induced apoptosis in adriamycin-resistant MCF7 cells. lonidamine 44-54 BCL2 apoptosis regulator Homo sapiens 0-5 10360831-0 1999 bcl-2 inhibits mitochondrial metabolism and lonidamine-induced apoptosis in adriamycin-resistant MCF7 cells. Doxorubicin 76-86 BCL2 apoptosis regulator Homo sapiens 0-5 10360831-7 1999 We demonstrated that over-expression of bcl-2 inhibited LND-induced apoptosis, while reducing 14CO2 production, oxygen uptake and ATP content, whereas aerobic lactate production was essentially unaffected. 14co2 94-99 BCL2 apoptosis regulator Homo sapiens 40-45 10360831-7 1999 We demonstrated that over-expression of bcl-2 inhibited LND-induced apoptosis, while reducing 14CO2 production, oxygen uptake and ATP content, whereas aerobic lactate production was essentially unaffected. Oxygen 112-118 BCL2 apoptosis regulator Homo sapiens 40-45 10360831-7 1999 We demonstrated that over-expression of bcl-2 inhibited LND-induced apoptosis, while reducing 14CO2 production, oxygen uptake and ATP content, whereas aerobic lactate production was essentially unaffected. Adenosine Triphosphate 130-133 BCL2 apoptosis regulator Homo sapiens 40-45 10403783-2 1999 However, recent reports have also demonstrated that long-term exposure of MCF-7 human breast cancer cells to estradiol results in estrogen receptor- and estradiol dose-dependent overexpression of the antiapoptosis gene, bcl-2. Estradiol 109-118 BCL2 apoptosis regulator Homo sapiens 220-225 10403783-2 1999 However, recent reports have also demonstrated that long-term exposure of MCF-7 human breast cancer cells to estradiol results in estrogen receptor- and estradiol dose-dependent overexpression of the antiapoptosis gene, bcl-2. Estradiol 153-162 BCL2 apoptosis regulator Homo sapiens 220-225 10403783-7 1999 This bcl-2-mediated indirect effect of estradiol is accompanied by prevention of apoptosis in MCF-7 cells. Estradiol 39-48 BCL2 apoptosis regulator Homo sapiens 5-10 10403800-4 1999 Interestingly, chronic treatment with clinical concentrations of cyclosporin A (0.5-2.5 microM for 8 days) led to a significant increase in Bcl-2 expression, while nucleosomes were similar to control level. Cyclosporine 65-78 BCL2 apoptosis regulator Homo sapiens 140-145 10470656-8 1999 However, in the p53 negative subgroup (n = 36), AI and BAX scores were higher and BCL-2 scores lower in the 5"-DFUR group than in the control group (P = 0.006, 0.008 and 0.050, respectively). 5"-dfur 108-115 BCL2 apoptosis regulator Homo sapiens 82-87 10397248-8 1999 Bcl-2 and Bcl-xL proteins remained relatively unchanged in expression for over 48 h after exposure to cisplatin in the A2780 cell lines. Cisplatin 102-111 BCL2 apoptosis regulator Homo sapiens 0-5 10394957-11 1999 AG1478 induced expression of Bak and down-regulated Bcl-2. RTKI cpd 0-6 BCL2 apoptosis regulator Homo sapiens 52-57 10561278-1 1999 PURPOSE: Recent studies demonstrate that retinoids decrease expression of the anti-apoptotic protein bcl-2, enhance the effect of chemotherapy, and act synergistically with interferon alfa (IFNalpha) to inhibit tumor cell growth in vitro. Retinoids 41-50 BCL2 apoptosis regulator Homo sapiens 101-106 10470656-10 1999 The BCL-2/BAX mRNA ratio was decreased in response to 5-FU in IMR90. Fluorouracil 54-58 BCL2 apoptosis regulator Homo sapiens 4-9 10400418-1 1999 Raf-1 activation and Bcl-2 hyperphosphorylation following treatment with paclitaxel (Taxol) or other microtubule-active drugs is associated with mitotic arrest. Paclitaxel 73-83 BCL2 apoptosis regulator Homo sapiens 21-26 10400418-1 1999 Raf-1 activation and Bcl-2 hyperphosphorylation following treatment with paclitaxel (Taxol) or other microtubule-active drugs is associated with mitotic arrest. Paclitaxel 85-90 BCL2 apoptosis regulator Homo sapiens 21-26 10400420-8 1999 Enforced expression of Bcl-2 partially protected cells from fludarabine-related apoptosis, an effect that was overcome, in part, by subsequent exposure of cells to bryostatin 1. fludarabine 60-71 BCL2 apoptosis regulator Homo sapiens 23-28 10400420-8 1999 Enforced expression of Bcl-2 partially protected cells from fludarabine-related apoptosis, an effect that was overcome, in part, by subsequent exposure of cells to bryostatin 1. bryostatin 1 164-176 BCL2 apoptosis regulator Homo sapiens 23-28 10470656-12 1999 CONCLUSIONS: Preoperative treatment with 5"-DFUR induced apoptosis and changes in BCL-2 and BAX expression in p53 negative breast cancers. 5"-dfur 41-48 BCL2 apoptosis regulator Homo sapiens 82-87 10400420-9 1999 Interestingly, Bcl-2-overexpressing cells were as or in some cases, more susceptible to differentiation induction by fludarabine (+/- bryostatin 1) than their empty vector-containing counterparts. fludarabine 117-128 BCL2 apoptosis regulator Homo sapiens 15-20 10400418-4 1999 Simultaneously with PARP cleavage, paclitaxel induces cleavage of Bcl-2 protein yielding a potentially pro-apoptotic 22 kDa product. Paclitaxel 35-45 BCL2 apoptosis regulator Homo sapiens 66-71 10400418-5 1999 In comparison, the stimulation of Raf-1 by phorbol ester (TPA) activates the MAPK pathway, causes MAPK-dependent p21WAF1/CIP1 induction, Rb dephosphorylation and growth arrest without Bcl-2 phosphorylation or apoptosis. Phorbol Esters 43-56 BCL2 apoptosis regulator Homo sapiens 184-189 11776807-12 1999 CONCLUSION: Antisense oligodeoxynucleotide of bcl-2 decreases bcl-2 gene expression and induces apoptosis of human gastric cancer cells in vitro. Oligodeoxyribonucleotides 22-42 BCL2 apoptosis regulator Homo sapiens 46-51 10400418-5 1999 In comparison, the stimulation of Raf-1 by phorbol ester (TPA) activates the MAPK pathway, causes MAPK-dependent p21WAF1/CIP1 induction, Rb dephosphorylation and growth arrest without Bcl-2 phosphorylation or apoptosis. Tetradecanoylphorbol Acetate 58-61 BCL2 apoptosis regulator Homo sapiens 184-189 12532785-1 1999 In this study, the biological effects and molecular mechanism of recombinant RA538 and antisense c-myc adenovirus on human gastric, esophageal, 2BS and high-expression bcl-2 gene cancer cell lines were studied in vitro and in vivo. ra538 77-82 BCL2 apoptosis regulator Homo sapiens 168-173 11829877-1 1999 OBJECTIVE: To study the effects of bcl-2 antisense oligonucleotides (ODN) on the expression of bcl-2 and apoptosis in MCF-7 cell line. Oligonucleotides 51-67 BCL2 apoptosis regulator Homo sapiens 95-100 11776807-12 1999 CONCLUSION: Antisense oligodeoxynucleotide of bcl-2 decreases bcl-2 gene expression and induces apoptosis of human gastric cancer cells in vitro. Oligodeoxyribonucleotides 22-42 BCL2 apoptosis regulator Homo sapiens 62-67 10359585-4 1999 In addition, the mutation of the potential ubiquitin-acceptor amino acids of Bcl-2 provides protection against TNF-alpha- and staurosporine-induced degradation in vitro and in vivo. Staurosporine 126-139 BCL2 apoptosis regulator Homo sapiens 77-82 10366441-5 1999 In contrast, Bcl-2 expression induced by gene transfer prevents all hallmarks of arsenite-induced cell death, including the Delta Psim collapse. arsenite 81-89 BCL2 apoptosis regulator Homo sapiens 13-18 10366441-10 1999 Arsenite also opens the purified, reconstituted PT pore in vitro in a cyclosporin A- and Bcl-2-inhibitible fashion. arsenite 0-8 BCL2 apoptosis regulator Homo sapiens 89-94 10381376-4 1999 We found that (1) apoptosis, but not mitotic arrest, was inhibited in cells with constitutive expression of Bcl-2; (2) pretreatment of cells with the DNA synthesis inhibitor hydroxyurea blocked the mitotic arrest but not the apoptosis mediated by okadaic acid; (3) down-regulation of c-myc gene was associated with apoptosis, but not with mitotic arrest; and (4) inhibition of protein synthesis abrogated mitotic arrest, but not apoptosis. Okadaic Acid 247-259 BCL2 apoptosis regulator Homo sapiens 108-113 10381557-9 1999 Downregulation of Bcl-2 by an antisense oligonucleotide in the differentiated cells, however, increased their susceptibility to S100beta-related cytotoxicity. Oligonucleotides 40-55 BCL2 apoptosis regulator Homo sapiens 18-23 10366429-11 1999 In contrast to uv-irradiated cells, curcumin-treated Jurkat cells considerably increased the level of Bcl-2. Curcumin 36-44 BCL2 apoptosis regulator Homo sapiens 102-107 10359739-7 1999 Furthermore, H2O2 elicited translocation of Bax and Bad from cytosol to mitochondria, where these factors formed heterodimers with Bcl-2, which was followed by the release of cytochrome c, activation of CPP32, and cleavage of poly(ADP-ribose) polymerase. Hydrogen Peroxide 13-17 BCL2 apoptosis regulator Homo sapiens 131-136 10376521-2 1999 Taxol-induced apoptosis was associated with phosphorylation of both c-Raf-1 and Bcl-2 and activation of ERK and JNK MAP kinases. Paclitaxel 0-5 BCL2 apoptosis regulator Homo sapiens 80-85 10376521-4 1999 TPCK treatment also prevented phosphorylation of c-Raf-1 and Bcl-2 in response to Taxol treatment. Paclitaxel 82-87 BCL2 apoptosis regulator Homo sapiens 61-66 10376521-8 1999 Thus, while the Taxol-induced phosphorylations of c-Raf-1 and Bcl-2 proteins appear to be coupled, these events can be disassociated from ERK1/2 activation. Paclitaxel 16-21 BCL2 apoptosis regulator Homo sapiens 62-67 10376521-9 1999 In summary, these findings suggest that phosphorylation of c-Raf-1 and Bcl-2, but not ERK1/2, are important signaling events in Taxol-induced apoptosis of MCF-7 breast cancer cells and that a TPCK inhibitable protease(s) is required for these processes. Paclitaxel 128-133 BCL2 apoptosis regulator Homo sapiens 71-76 10359585-5 1999 Moreover, mimicking phosphorylation of the putative mitogen-activated protein (MAP) kinase sites of the Bcl-2 protein (Thr 56, Thr 74, and Ser 87) abolishes its degradation, suggesting a link between the MAP kinase pathway to the proteasome pathway. Threonine 119-122 BCL2 apoptosis regulator Homo sapiens 104-109 10359585-5 1999 Moreover, mimicking phosphorylation of the putative mitogen-activated protein (MAP) kinase sites of the Bcl-2 protein (Thr 56, Thr 74, and Ser 87) abolishes its degradation, suggesting a link between the MAP kinase pathway to the proteasome pathway. Threonine 127-130 BCL2 apoptosis regulator Homo sapiens 104-109 10359585-5 1999 Moreover, mimicking phosphorylation of the putative mitogen-activated protein (MAP) kinase sites of the Bcl-2 protein (Thr 56, Thr 74, and Ser 87) abolishes its degradation, suggesting a link between the MAP kinase pathway to the proteasome pathway. Serine 139-142 BCL2 apoptosis regulator Homo sapiens 104-109 10333483-5 1999 Pironetin also induced the rapid phosphorylation of Bcl-2 before formation of the DNA ladder in HL-60 cells, as seen with several tubulin binders. pironetin 0-9 BCL2 apoptosis regulator Homo sapiens 52-57 10403535-6 1999 Resveratrol treatment resulted in a gradual decrease in the expression of anti-apoptotic Bcl-2. Resveratrol 0-11 BCL2 apoptosis regulator Homo sapiens 89-94 11713806-1 1999 G-3139 is an antisense phosphorothioate oligodeoxynucleotide (AS PS ON) which suppresses bcl-2 expression and is being developed by Genta Inc for the potential treatment of various cancers [308375]. oblimersen 0-6 BCL2 apoptosis regulator Homo sapiens 89-94 10554162-0 1999 Synthesis of Bcl-2 in response to anthracycline treatment may contribute to an apoptosis-resistant phenotype in leukemic cell lines. Anthracyclines 34-47 BCL2 apoptosis regulator Homo sapiens 13-18 10554162-2 1999 Therefore, we evaluated the Bcl-2 content and synthesis in relation with the apoptotic potential in leukemic cell lines after anthracycline treatment. Anthracyclines 126-139 BCL2 apoptosis regulator Homo sapiens 28-33 10391670-0 1999 Effects of lisinopril administration on blood bcl-2 concentrations in patients with immunoglobulin A nephropathy. Lisinopril 11-21 BCL2 apoptosis regulator Homo sapiens 46-51 10391670-3 1999 A 6-month course of 5 mg/day lisinopril given to subjects with proteinuria significantly reduced blood bcl-2 concentrations and caused a reduction in proteinuria. Lisinopril 29-39 BCL2 apoptosis regulator Homo sapiens 103-108 11713806-1 1999 G-3139 is an antisense phosphorothioate oligodeoxynucleotide (AS PS ON) which suppresses bcl-2 expression and is being developed by Genta Inc for the potential treatment of various cancers [308375]. phosphorothioate oligodeoxynucleotide 23-60 BCL2 apoptosis regulator Homo sapiens 89-94 10554162-7 1999 IDA induced a concentration-dependent increase in Bcl-2 content in all cell lines as long as they do not perform apoptosis. Idarubicin 0-3 BCL2 apoptosis regulator Homo sapiens 50-55 10554162-8 1999 Enhanced Bcl-2 expression was inhibited by cycloheximide, actinomycin D, or antisense oligonucleotide directed against bcl-2 mRNA. Cycloheximide 43-56 BCL2 apoptosis regulator Homo sapiens 9-14 10424444-4 1999 Analysis of cell survival in etoposide-treated cultures indicated that IL-15 was also more potent than IL-2 as a survival factor for CD56+ cells by virtue of its greater ability to up-regulate bcl-2 expression. Etoposide 29-38 BCL2 apoptosis regulator Homo sapiens 193-198 10554162-8 1999 Enhanced Bcl-2 expression was inhibited by cycloheximide, actinomycin D, or antisense oligonucleotide directed against bcl-2 mRNA. Dactinomycin 58-71 BCL2 apoptosis regulator Homo sapiens 9-14 10554162-8 1999 Enhanced Bcl-2 expression was inhibited by cycloheximide, actinomycin D, or antisense oligonucleotide directed against bcl-2 mRNA. Oligonucleotides 86-101 BCL2 apoptosis regulator Homo sapiens 9-14 10554162-8 1999 Enhanced Bcl-2 expression was inhibited by cycloheximide, actinomycin D, or antisense oligonucleotide directed against bcl-2 mRNA. Oligonucleotides 86-101 BCL2 apoptosis regulator Homo sapiens 119-124 10554162-9 1999 Bcl-2 expression was also increased in the resistant U937 variant after serum deprivation or C2-ceramide treatment. N-acetylsphingosine 93-104 BCL2 apoptosis regulator Homo sapiens 0-5 10554162-11 1999 CONCLUSIONS: These data suggest that exposure to IDA induces Bcl-2 expression in leukemic cell lines, and that this mechanism could contribute to apoptosis resistance and participate in the acquisition of chemoresistance. Idarubicin 49-52 BCL2 apoptosis regulator Homo sapiens 61-66 10374780-3 1999 This study retrospectively evaluates bcl-2 and bcl-x immunostaining in paraffin-embedded materials in gangliogliomas. Paraffin 71-79 BCL2 apoptosis regulator Homo sapiens 37-42 10341297-6 1999 Western blot analysis showed that auristatin-PE up-regulated the expression of wt-p53, p21WAF1 and Bax, and down-regulated Bcl-2 and cyclin B in HPAC cells, while only up-regulation of p21WAF1 and Bax was observed in PANC-1 cells. auristatin 34-44 BCL2 apoptosis regulator Homo sapiens 123-128 10341297-6 1999 Western blot analysis showed that auristatin-PE up-regulated the expression of wt-p53, p21WAF1 and Bax, and down-regulated Bcl-2 and cyclin B in HPAC cells, while only up-regulation of p21WAF1 and Bax was observed in PANC-1 cells. pe 45-47 BCL2 apoptosis regulator Homo sapiens 123-128 10341297-7 1999 These results suggest that auristatin-PE may induce apoptosis and p21WAF1 expression through p53-dependent or independent pathways, and that up-regulation of p21WAF1 and Bax and down-regulation of Bcl-2 may be the molecular mechanism through which auristatin-PE inhibits cell growth and induces apoptosis. soblidotin 27-40 BCL2 apoptosis regulator Homo sapiens 197-202 10394541-1 1999 OBJECTIVE: To compare the immunohistochemical expression of Bcl-2 in uterine leiomyomas in patients undergoing myomectomy or hysterectomy with and without preoperative treatment with the gonadotropin-releasing hormone receptor agonist (GnRH-a) leuprolide acetate (LA). gnrh-a 236-242 BCL2 apoptosis regulator Homo sapiens 60-65 10321832-7 1999 However, ECM prevented p21 and Bcl-2 down-regulation induced by taxol or etoposide. Paclitaxel 64-69 BCL2 apoptosis regulator Homo sapiens 31-36 10321832-7 1999 However, ECM prevented p21 and Bcl-2 down-regulation induced by taxol or etoposide. Etoposide 73-82 BCL2 apoptosis regulator Homo sapiens 31-36 10336521-7 1999 Ectopic expression of BCL-2 prevents BA-induced caspase activation, DNA fragmentation, and cell death. betulinic acid 37-39 BCL2 apoptosis regulator Homo sapiens 22-27 10336521-9 1999 The generation of reactive oxygen species is blocked by BCL-2 and requires new protein synthesis but is unaffected by caspase inhibitors, suggesting that BA toxicity sequentially involves new protein synthesis, formation of reactive oxygen species, and activation of crm-A-insensitive caspases. Reactive Oxygen Species 18-41 BCL2 apoptosis regulator Homo sapiens 56-61 10336521-9 1999 The generation of reactive oxygen species is blocked by BCL-2 and requires new protein synthesis but is unaffected by caspase inhibitors, suggesting that BA toxicity sequentially involves new protein synthesis, formation of reactive oxygen species, and activation of crm-A-insensitive caspases. betulinic acid 154-156 BCL2 apoptosis regulator Homo sapiens 56-61 10354271-10 1999 Compared with ATP-depleted controls, prior heat stress inhibited the pro-apoptotic changes in the ratio of Bcl2 to BAX, proteins known to regulate the apoptotic set point in renal cells. Adenosine Triphosphate 14-17 BCL2 apoptosis regulator Homo sapiens 107-111 10233914-8 1999 The enhanced H2O2 production by monocytes from asymptomatic untreated patients with CD4(+) cell counts above 500/microliter was associated with a decrease in the levels of Bcl-2 and thioredoxin. Hydrogen Peroxide 13-17 BCL2 apoptosis regulator Homo sapiens 172-177 10354271-15 1999 Novel interactions between HSP 72 and Bcl2 may be responsible, at least in part, for the protection afforded by prior heat stress against ATP depletion injury. Adenosine Triphosphate 138-141 BCL2 apoptosis regulator Homo sapiens 38-42 12548776-0 1999 [Effect of PIC-BE on the expression of MDR-1 and bcl-2 genes in a multidrug resistance cell variant K562/ADM]. pic-be 11-17 BCL2 apoptosis regulator Homo sapiens 49-54 10429663-3 1999 We next established stable transfectants of Bcl-2 in the gastric cancer cell line AZ521 and found that Bcl-2 blocked TAS-103-induced apoptosis. 6-((2-(dimethylamino)ethyl)amino)-3-hydroxy-7H-indeno(2,1-c)quinolin-7-one 117-124 BCL2 apoptosis regulator Homo sapiens 103-108 12548776-1 1999 The effect of PIC-BE on the expression of mdr-1, bcl-2 and bax genes and their protein products (P-gp, Bcl-2 and Bax) was observed respectively in a multidrug resistance (MDR) cell variant K562/ADM. pic-be 14-20 BCL2 apoptosis regulator Homo sapiens 103-108 10429663-3 1999 We next established stable transfectants of Bcl-2 in the gastric cancer cell line AZ521 and found that Bcl-2 blocked TAS-103-induced apoptosis. 6-((2-(dimethylamino)ethyl)amino)-3-hydroxy-7H-indeno(2,1-c)quinolin-7-one 117-124 BCL2 apoptosis regulator Homo sapiens 44-49 12548776-1 1999 The effect of PIC-BE on the expression of mdr-1, bcl-2 and bax genes and their protein products (P-gp, Bcl-2 and Bax) was observed respectively in a multidrug resistance (MDR) cell variant K562/ADM. pic-be 14-20 BCL2 apoptosis regulator Homo sapiens 49-54 12548776-2 1999 The results showed that PIC-BE could significantly inhibit the expression of mdr-1 and bcl-2 genes at both mRNA and protein levels in K562/ADM cell line, and the effect was dose- and time-dependent within limited range. pic-be 24-30 BCL2 apoptosis regulator Homo sapiens 87-92 10229667-5 1999 The cleavage of Bcl-2 was inhibited by a caspase-3 (CPP32)-specific inhibitor [acetyl-Asp-Glu-Val-Asp-CHO (DEVD-CHO)] but not caspase 1 inhibitor (acetyl-Tyr-Val-Ala-Asp-CHO), suggesting that Bcl-2 is a proteolytic substrate of a caspase-3-like protease activated during apoptosis. acetyl-aspartyl-glutamyl-valyl-aspartal 79-105 BCL2 apoptosis regulator Homo sapiens 192-197 10403664-7 1999 Lethal MMS treatment also increased Bax, but not Bcl-2 expression, whereas in H2O2 induced apoptosis, the level of both Bcl-2 and Bax declined. Hydrogen Peroxide 78-82 BCL2 apoptosis regulator Homo sapiens 120-125 10334917-0 1999 Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis. Paclitaxel 101-111 BCL2 apoptosis regulator Homo sapiens 12-17 10334917-1 1999 The impact of ectopic expression of an N-terminal phosphorylation loop deletant Bcl-2 protein (Bcl-2Delta32-80) on the response of U937 monoblastic leukemia cells to paclitaxel was examined. Paclitaxel 166-176 BCL2 apoptosis regulator Homo sapiens 80-85 10334917-3 1999 58, 3202, 1998), U937 cells overexpressing Bcl-2Delta32-80 were significantly more resistant than those overexpressing full-length protein to caspase-3 and -9 activation, PARP degradation, and apoptosis induced by paclitaxel (500 nM; 18 h). Paclitaxel 214-224 BCL2 apoptosis regulator Homo sapiens 43-48 10334917-5 1999 Enhanced resistance of U937/Bcl-2Delta32-80 cells to paclitaxel was observed primarily in the G2M population. Paclitaxel 53-63 BCL2 apoptosis regulator Homo sapiens 28-33 10334917-6 1999 Together, these findings demonstrate that deletion of the Bcl-2 phosphorylation loop domain increases resistance of U937 leukemia cells to paclitaxel-mediated mitochondrial damage and apoptosis and suggest that factors other than, or in addition to, phosphorylation contribute to Bcl-2-related cytoprotectivity against paclitaxel in this model system. Paclitaxel 139-149 BCL2 apoptosis regulator Homo sapiens 58-63 10334917-6 1999 Together, these findings demonstrate that deletion of the Bcl-2 phosphorylation loop domain increases resistance of U937 leukemia cells to paclitaxel-mediated mitochondrial damage and apoptosis and suggest that factors other than, or in addition to, phosphorylation contribute to Bcl-2-related cytoprotectivity against paclitaxel in this model system. Paclitaxel 319-329 BCL2 apoptosis regulator Homo sapiens 58-63 10229667-4 1999 Treatment of M-07e cells with benzyloxycarbonyl-Leu-Leu-l-leucinal (Z-LLL-CHO; MG-132), a reversible ubiquitin-proteasome inhibitor, markedly accelerated the cleavage of Bcl-2 and promoted cell death through the apoptotic pathway. CAV protocol 74-77 BCL2 apoptosis regulator Homo sapiens 170-175 10229667-4 1999 Treatment of M-07e cells with benzyloxycarbonyl-Leu-Leu-l-leucinal (Z-LLL-CHO; MG-132), a reversible ubiquitin-proteasome inhibitor, markedly accelerated the cleavage of Bcl-2 and promoted cell death through the apoptotic pathway. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 79-85 BCL2 apoptosis regulator Homo sapiens 170-175 10229667-5 1999 The cleavage of Bcl-2 was inhibited by a caspase-3 (CPP32)-specific inhibitor [acetyl-Asp-Glu-Val-Asp-CHO (DEVD-CHO)] but not caspase 1 inhibitor (acetyl-Tyr-Val-Ala-Asp-CHO), suggesting that Bcl-2 is a proteolytic substrate of a caspase-3-like protease activated during apoptosis. acetyl-aspartyl-glutamyl-valyl-aspartal 79-105 BCL2 apoptosis regulator Homo sapiens 16-21 10426457-3 1999 In vitro analyses demonstrate docetaxel (Taxotere; Rhone-Poulenc Rorer, Collegeville, PA) to be 100-fold more potent than paclitaxel in bcl-2 phosphorylation and apoptotic cell death. Docetaxel 30-39 BCL2 apoptosis regulator Homo sapiens 136-141 10426457-3 1999 In vitro analyses demonstrate docetaxel (Taxotere; Rhone-Poulenc Rorer, Collegeville, PA) to be 100-fold more potent than paclitaxel in bcl-2 phosphorylation and apoptotic cell death. Docetaxel 41-49 BCL2 apoptosis regulator Homo sapiens 136-141 10426457-3 1999 In vitro analyses demonstrate docetaxel (Taxotere; Rhone-Poulenc Rorer, Collegeville, PA) to be 100-fold more potent than paclitaxel in bcl-2 phosphorylation and apoptotic cell death. Paclitaxel 122-132 BCL2 apoptosis regulator Homo sapiens 136-141 10229667-5 1999 The cleavage of Bcl-2 was inhibited by a caspase-3 (CPP32)-specific inhibitor [acetyl-Asp-Glu-Val-Asp-CHO (DEVD-CHO)] but not caspase 1 inhibitor (acetyl-Tyr-Val-Ala-Asp-CHO), suggesting that Bcl-2 is a proteolytic substrate of a caspase-3-like protease activated during apoptosis. aspartyl-glutamyl-valyl-aspartal 107-115 BCL2 apoptosis regulator Homo sapiens 16-21 10229667-5 1999 The cleavage of Bcl-2 was inhibited by a caspase-3 (CPP32)-specific inhibitor [acetyl-Asp-Glu-Val-Asp-CHO (DEVD-CHO)] but not caspase 1 inhibitor (acetyl-Tyr-Val-Ala-Asp-CHO), suggesting that Bcl-2 is a proteolytic substrate of a caspase-3-like protease activated during apoptosis. L 709049 147-173 BCL2 apoptosis regulator Homo sapiens 16-21 10229667-6 1999 The simultaneous addition of recombinant human GM-CSF (rhGM-CSF) to M-07e cultures delayed the activation of caspase 3 and Bcl-2 cleavage triggered by Z-LLL-CHO, suggesting that the activation of the GM-CSF signalling pathway can partly overcome the apoptotic effect induced by Z-LLL-CHO. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 151-160 BCL2 apoptosis regulator Homo sapiens 123-128 10229667-8 1999 Lactacystin-induced apoptosis in M-07e cells was remarkably similar to that induced by Z-LLL-CHO, which included caspase 3 activation, cleavage of Bcl-2 into a 22 kDa fragment and, ultimately, cell death. lactacystin 0-11 BCL2 apoptosis regulator Homo sapiens 147-152 10229667-9 1999 These results showed that inhibition of the ubiquitin-proteasome pathways can lead to the activation of a DEVD-CHO-sensitive caspase and induces Bcl-2 cleavage, which might have a role in mediating apoptosis in M-07e cells. aspartyl-glutamyl-valyl-aspartal 106-114 BCL2 apoptosis regulator Homo sapiens 145-150 11230808-0 1999 Changes in the generation of reactive oxygen species and in mitochondrial membrane potential during apoptosis induced by the antidepressants imipramine, clomipramine, and citalopram and the effects on these changes by Bcl-2 and Bcl-X(L). Reactive Oxygen Species 29-52 BCL2 apoptosis regulator Homo sapiens 218-223 10344753-10 1999 These results suggest that cisplatin blocks paclitaxel-induced apoptosis at a point downstream of Bcl-2 degradation and independent of microtubule stabilization. Cisplatin 27-36 BCL2 apoptosis regulator Homo sapiens 98-103 10344753-10 1999 These results suggest that cisplatin blocks paclitaxel-induced apoptosis at a point downstream of Bcl-2 degradation and independent of microtubule stabilization. Paclitaxel 44-54 BCL2 apoptosis regulator Homo sapiens 98-103 10216101-5 1999 Overexpression of bcl-2 in ARP-1 cells prevents Dex-mediated repression of NF-kappaB activity and apoptosis. Dexamethasone 48-51 BCL2 apoptosis regulator Homo sapiens 18-23 10318846-5 1999 Both effector caspase processing and cytochrome c release were inhibited in the resistant variant cells as well as in Bcl-2 transfectants, suggesting that, in Jurkat cells, the apoptosis signaling pathways activated by CD95, etoposide, and gamma-radiation are under common mitochondrial control. Etoposide 225-234 BCL2 apoptosis regulator Homo sapiens 118-123 10318846-7 1999 Exogenous ceramide bypassed apoptosis resistance in the variant cells, but not in Bcl-2-transfected cells, suggesting that apoptosis signaling induced by CD95, etoposide, and gamma-radiation is subject to common regulation at a level different from that targeted by Bcl-2. Ceramides 10-18 BCL2 apoptosis regulator Homo sapiens 266-271 10321921-5 1999 Further studies have shown that IL-6, c-fos, and Bcl-2 are all elevated in Paget"s disease--all of these factors can be activated by virally induced ROS. ros 149-152 BCL2 apoptosis regulator Homo sapiens 49-54 10216101-6 1999 Sustained NF-kappaB DNA binding is also observed in two previously characterized Dex-resistant MM cell lines (RPMI8226 and ARH-77) that express moderate levels of endogenous bcl-2 and IkappaBalpha proteins. Dexamethasone 81-84 BCL2 apoptosis regulator Homo sapiens 174-179 10481938-4 1999 In this study we investigated regulation of BAX and BCL-2 expression by VP-16 and cyclophosphamide as a potential mechanism for the induction of breast cancer cell death induced by this regimen. Cyclophosphamide 82-98 BCL2 apoptosis regulator Homo sapiens 52-57 10472781-2 1999 Our results showed that: (1) Treatment of MCF-7 cells with Adriamycin resulted in time- and concentration-dependent decreases in Bcl-2 and increases in Bax mRNA and protein levels. Doxorubicin 59-69 BCL2 apoptosis regulator Homo sapiens 129-134 10220568-0 1999 Suppression of apoptosis by Bcl-2 to enhance benzene metabolites-induced oxidative DNA damage and mutagenesis: A possible mechanism of carcinogenesis. Benzene 45-52 BCL2 apoptosis regulator Homo sapiens 28-33 10472781-3 1999 (2) Camptothecin elicited similar trends on Bcl-2 and Bax as Adriamycin, while etoposide, at 50-100 fold (1-5 microM) the effective concentration of Adriamycin and camptothecin, only resulted in an increase in Bax mRNA levels. Camptothecin 4-16 BCL2 apoptosis regulator Homo sapiens 44-49 10472781-4 1999 (3) Adriamycin and camptothecin, but not etoposide, were effective in suppressing estradiol-stimulated increases in Bcl-2 mRNA levels. Doxorubicin 4-14 BCL2 apoptosis regulator Homo sapiens 116-121 10472781-4 1999 (3) Adriamycin and camptothecin, but not etoposide, were effective in suppressing estradiol-stimulated increases in Bcl-2 mRNA levels. Camptothecin 19-31 BCL2 apoptosis regulator Homo sapiens 116-121 10472781-4 1999 (3) Adriamycin and camptothecin, but not etoposide, were effective in suppressing estradiol-stimulated increases in Bcl-2 mRNA levels. Estradiol 82-91 BCL2 apoptosis regulator Homo sapiens 116-121 10340400-7 1999 Induction of apoptosis in arsenic-treated Meg-01 and UT7 cells was accompanied by a dose-response decrease of Bcl-2 protein, whereas As2O3 had no effect on this measurement in HL60, ZR75, and MCF7 cell lines. Arsenic 26-33 BCL2 apoptosis regulator Homo sapiens 110-115 10381635-0 1999 Manganese induces apoptosis of human B cells: caspase-dependent cell death blocked by bcl-2. Manganese 0-9 BCL2 apoptosis regulator Homo sapiens 86-91 10381635-14 1999 Moreover, Bcl-2 overexpression in BL-CL effectively protected cells from apoptosis and cell death induced by manganese. Manganese 109-118 BCL2 apoptosis regulator Homo sapiens 10-15 10381635-15 1999 This is the first report showing the involvement of Mn2+ in the regulation of B lymphocyte death presumably via a caspase-dependent process with a death-protective effect of Bcl-2. Manganese(2+) 52-56 BCL2 apoptosis regulator Homo sapiens 174-179 10200346-2 1999 Our previous studies indicate that bryostatin 1 (Bryo 1) induces differentiation of WSU-CLL and increases the ratio of dCK/5"-NT activity and Bax/Bcl-2. bryostatin 1 35-47 BCL2 apoptosis regulator Homo sapiens 146-151 10374876-4 1999 Etoposide treatment of these cells triggered a time-dependent activation of type II and type III caspases and cleavage of Bcl-2 yielding a 23 kDa cleavage fragment. Etoposide 0-9 BCL2 apoptosis regulator Homo sapiens 122-127 10374876-7 1999 While evidence for cleavage of Bcl-2 in several subcellular compartments of etoposide-treated cells was obtained, this cleavage was detected predominantly in the mitochondrial fraction, thus providing further support for the central role of mitochondria in apoptosis. Etoposide 76-85 BCL2 apoptosis regulator Homo sapiens 31-36 10374876-8 1999 Caspase-mediated cleavage following etoposide treatment of these myeloid leukemic cells may represent a means for the attenuation of Bcl-2 function upon apoptosis induction. Etoposide 36-45 BCL2 apoptosis regulator Homo sapiens 133-138 10220568-3 1999 This study demonstrates that ectopic expression of Bcl-2 effectively suppresses benzene-active metabolites, 1,4-hydroquinone- and 1, 4-benzoquinone-induced apoptosis in human leukemic HL-60 cells, as evidenced by morphological changes and DNA fragmentation. Benzene 80-87 BCL2 apoptosis regulator Homo sapiens 51-56 10349985-4 1999 bcl-2 and p53 protein expression were demonstrated by immunohistochemical methods, using formalin-fixed, paraffin-embedded biopsy tissues. Formaldehyde 89-97 BCL2 apoptosis regulator Homo sapiens 0-5 10349985-4 1999 bcl-2 and p53 protein expression were demonstrated by immunohistochemical methods, using formalin-fixed, paraffin-embedded biopsy tissues. Paraffin 105-113 BCL2 apoptosis regulator Homo sapiens 0-5 10220568-3 1999 This study demonstrates that ectopic expression of Bcl-2 effectively suppresses benzene-active metabolites, 1,4-hydroquinone- and 1, 4-benzoquinone-induced apoptosis in human leukemic HL-60 cells, as evidenced by morphological changes and DNA fragmentation. 1,4-hydroquinone 108-124 BCL2 apoptosis regulator Homo sapiens 51-56 10220568-3 1999 This study demonstrates that ectopic expression of Bcl-2 effectively suppresses benzene-active metabolites, 1,4-hydroquinone- and 1, 4-benzoquinone-induced apoptosis in human leukemic HL-60 cells, as evidenced by morphological changes and DNA fragmentation. quinone 130-147 BCL2 apoptosis regulator Homo sapiens 51-56 10220568-5 1999 These data suggest that Bcl-2 prevents benzene metabolites-induced apoptosis at the downstream of oxidative damage events. Benzene 39-46 BCL2 apoptosis regulator Homo sapiens 24-29 10220568-6 1999 This study also determines the level of 8-hydroxydeoxyguanosine (8-OH-dGua), an indicator for oxidative DNA damage, in neo- and Bcl-2-overexpressing HL-60 cells after treating with 1,4-hydroquinone or 1,4-benzoquinone. 8-ohdg 40-63 BCL2 apoptosis regulator Homo sapiens 128-133 10220568-6 1999 This study also determines the level of 8-hydroxydeoxyguanosine (8-OH-dGua), an indicator for oxidative DNA damage, in neo- and Bcl-2-overexpressing HL-60 cells after treating with 1,4-hydroquinone or 1,4-benzoquinone. 1,4-hydroquinone 181-197 BCL2 apoptosis regulator Homo sapiens 128-133 10203579-0 1999 Bcl-2 protects against beta-lapachone-mediated caspase 3 activation and apoptosis in human myeloid leukemia (HL-60) cells. beta-lapachone 23-37 BCL2 apoptosis regulator Homo sapiens 0-5 10220568-8 1999 The above findings suggest that Bcl-2 may retain benzene metabolites-induced oxidative DNA damage in surviving cells. Benzene 49-56 BCL2 apoptosis regulator Homo sapiens 32-37 10220568-9 1999 Indeed, the failure of repairing 8-OH-dGua and thymine glycol in benzene metabolites-treated Bcl-2 survivors increases the number of mutation frequencies at the hprt locus. 8-oh-dgua 33-42 BCL2 apoptosis regulator Homo sapiens 93-98 10220568-9 1999 Indeed, the failure of repairing 8-OH-dGua and thymine glycol in benzene metabolites-treated Bcl-2 survivors increases the number of mutation frequencies at the hprt locus. thymine glycol 47-61 BCL2 apoptosis regulator Homo sapiens 93-98 10220568-9 1999 Indeed, the failure of repairing 8-OH-dGua and thymine glycol in benzene metabolites-treated Bcl-2 survivors increases the number of mutation frequencies at the hprt locus. Benzene 65-72 BCL2 apoptosis regulator Homo sapiens 93-98 10220568-10 1999 Results in this study thus provide a novel benzene-induced carcinogenesis mechanism by which up-regulation of Bcl-2 protein may promote the susceptibility to benzene metabolites-induced mutagenesis by overriding apoptosis and attenuating DNA repair capacity. Benzene 43-50 BCL2 apoptosis regulator Homo sapiens 110-115 10621853-0 1999 bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study. Isotretinoin 41-61 BCL2 apoptosis regulator Homo sapiens 0-5 10220568-10 1999 Results in this study thus provide a novel benzene-induced carcinogenesis mechanism by which up-regulation of Bcl-2 protein may promote the susceptibility to benzene metabolites-induced mutagenesis by overriding apoptosis and attenuating DNA repair capacity. Benzene 158-165 BCL2 apoptosis regulator Homo sapiens 110-115 10621853-0 1999 bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study. Isotretinoin 63-75 BCL2 apoptosis regulator Homo sapiens 0-5 10417679-12 1999 Overexpression of bcl-2 was recognized in 57% of VA, 33% of mucosal components of CIVA, and 7% of invasive components of CIVA. civa 82-86 BCL2 apoptosis regulator Homo sapiens 18-23 10353597-0 1999 Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. lonidamine 0-10 BCL2 apoptosis regulator Homo sapiens 44-49 10417679-12 1999 Overexpression of bcl-2 was recognized in 57% of VA, 33% of mucosal components of CIVA, and 7% of invasive components of CIVA. civa 121-125 BCL2 apoptosis regulator Homo sapiens 18-23 10319729-5 1999 Inhibition of the MAPK pathway by use of the specific MEK1/2 inhibitor (10 microM PD98059) in both HL60/pCEP4 and HL60/Bcl-2 cells prior to irradiation permitted a similar prolonged radiation-induced activation of JNK1. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 82-89 BCL2 apoptosis regulator Homo sapiens 119-124 10367343-11 1999 Bcl-2 levels were found, in resting cells, to be low in the presence or absence of mercury. Mercury 83-90 BCL2 apoptosis regulator Homo sapiens 0-5 10367343-13 1999 The relationship between mercury-induced apoptosis in human T cells, mitochondrial dysfunction, and intracellular levels of bcl-2 are discussed. Mercury 25-32 BCL2 apoptosis regulator Homo sapiens 124-129 10333765-2 1999 Meanwhile, it has been shown that bcl-2 antisense oligonucleotide can induce apoptosis or increase toxicity of the treatment in tumors in vivo and in vitro. Oligonucleotides 50-65 BCL2 apoptosis regulator Homo sapiens 34-39 10333765-4 1999 Here we investigated the effect of an antisense bcl-2 RNA retrovirus vector transfer on the sensitivity of 2-butylamino-2-demethoxy-hypocrellin A (2-BA-2-DMHA) photosensitization in a human gastric adenocarcinoma MGC803 cell line. 2-butylamino-2-demethoxy-hypocrellin A 107-145 BCL2 apoptosis regulator Homo sapiens 48-53 10333765-4 1999 Here we investigated the effect of an antisense bcl-2 RNA retrovirus vector transfer on the sensitivity of 2-butylamino-2-demethoxy-hypocrellin A (2-BA-2-DMHA) photosensitization in a human gastric adenocarcinoma MGC803 cell line. 2-butylamino-2-demethoxy-hypocrellin A 147-158 BCL2 apoptosis regulator Homo sapiens 48-53 10333765-6 1999 The decreased expression of bcl-2 protein was accompanied by increased phototoxicity and susceptibility to apoptosis induced by 2-BA-2-DMHA PDT. 2-butylamino-2-demethoxy-hypocrellin A 128-139 BCL2 apoptosis regulator Homo sapiens 28-33 10353597-6 1999 Accordingly, the cell death-inducing effect of LND is amplified by simultaneous addition of PK11195, an isoquinoline ligand of the peripheral benzodiazepine receptor which antagonizes the cytoprotective effect of Bcl-2. isoquinoline 104-116 BCL2 apoptosis regulator Homo sapiens 213-218 10194425-1 1999 Preclinical data suggest that retinoids, eg, all-trans retinoic acid (ATRA), lower concentrations of antiapoptotic proteins such as bcl-2, possibly thereby improving the outcome of anti-acute myeloid leukemia (AML) chemotherapy. Retinoids 30-39 BCL2 apoptosis regulator Homo sapiens 132-137 10194425-1 1999 Preclinical data suggest that retinoids, eg, all-trans retinoic acid (ATRA), lower concentrations of antiapoptotic proteins such as bcl-2, possibly thereby improving the outcome of anti-acute myeloid leukemia (AML) chemotherapy. Tretinoin 45-68 BCL2 apoptosis regulator Homo sapiens 132-137 10196212-0 1999 The role of antiapoptotic Bcl-2 family members in endothelial apoptosis elucidated with antisense oligonucleotides. Oligonucleotides 98-114 BCL2 apoptosis regulator Homo sapiens 26-31 10194425-1 1999 Preclinical data suggest that retinoids, eg, all-trans retinoic acid (ATRA), lower concentrations of antiapoptotic proteins such as bcl-2, possibly thereby improving the outcome of anti-acute myeloid leukemia (AML) chemotherapy. Tretinoin 70-74 BCL2 apoptosis regulator Homo sapiens 132-137 10196170-8 1999 Overexpression of anti-apoptotic Bcl2 blocked MEKK1 and taxol-induced apoptosis but did not block the caspase-dependent cleavage of MEKK1 in response to etoposide. Paclitaxel 56-61 BCL2 apoptosis regulator Homo sapiens 33-37 10340887-0 1999 Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. gemcitabine 0-11 BCL2 apoptosis regulator Homo sapiens 101-106 10323270-3 1999 We found that the addition of serum from patients treated with fluvastatin for 6 days caused a significant reduction in cell proliferation, increased cell apoptosis and reduced the B cell leukemia-2 (bcl-2) concentration. Fluvastatin 63-74 BCL2 apoptosis regulator Homo sapiens 181-198 10323270-3 1999 We found that the addition of serum from patients treated with fluvastatin for 6 days caused a significant reduction in cell proliferation, increased cell apoptosis and reduced the B cell leukemia-2 (bcl-2) concentration. Fluvastatin 63-74 BCL2 apoptosis regulator Homo sapiens 200-205 10189371-6 1999 EM showed that cells overexpressing Bcl-2 displayed near-normal morphology and viability in response to vincristine or etoposide. Vincristine 104-115 BCL2 apoptosis regulator Homo sapiens 36-41 10189371-6 1999 EM showed that cells overexpressing Bcl-2 displayed near-normal morphology and viability in response to vincristine or etoposide. Etoposide 119-128 BCL2 apoptosis regulator Homo sapiens 36-41 10340887-3 1999 We determined whether induction of apoptosis by gemcitabine in pancreatic carcinoma is associated with cellular Bcl-2 content. gemcitabine 48-59 BCL2 apoptosis regulator Homo sapiens 112-117 10340887-7 1999 RESULTS: Pancreatic cancer cell lines expressed varying amounts of Bcl-2, and the 50% lethal dose for gemcitabine-induced apoptosis was correlated with Bcl-2 content. gemcitabine 102-113 BCL2 apoptosis regulator Homo sapiens 67-72 14634285-3 1999 However, the mitochondrial and nuclear effects of palmitate are inhibited by overexpression of anti-apoptotic proto-oncogene product Bcl-2 and exacerbated by 2-bromo-palmitate as well as by carnitine. Palmitates 50-59 BCL2 apoptosis regulator Homo sapiens 133-138 10340887-7 1999 RESULTS: Pancreatic cancer cell lines expressed varying amounts of Bcl-2, and the 50% lethal dose for gemcitabine-induced apoptosis was correlated with Bcl-2 content. gemcitabine 102-113 BCL2 apoptosis regulator Homo sapiens 152-157 14634285-4 1999 The cytoprotective actions of Bcl-2, respectively, is not antagonized by etomoxir, an inhibitor of carnitine palmitoyl transferase 1 (CPT1), suggesting that the recently described physical interaction between CPT1 and Bcl-2 is irrelevant to Bcl-2-mediated inhibition of palmitate-induce apoptosis. Palmitates 270-279 BCL2 apoptosis regulator Homo sapiens 30-35 10340887-8 1999 Furthermore, Bcl-2 overexpression was associated with a significant increase in the 50% lethal dose for gemcitabine-induced apoptosis. gemcitabine 104-115 BCL2 apoptosis regulator Homo sapiens 13-18 14634285-4 1999 The cytoprotective actions of Bcl-2, respectively, is not antagonized by etomoxir, an inhibitor of carnitine palmitoyl transferase 1 (CPT1), suggesting that the recently described physical interaction between CPT1 and Bcl-2 is irrelevant to Bcl-2-mediated inhibition of palmitate-induce apoptosis. Palmitates 270-279 BCL2 apoptosis regulator Homo sapiens 218-223 10340887-9 1999 CONCLUSIONS: Cellular Bcl-2 content was directly correlated with the cytotoxicity of gemcitabine in pancreatic carcinoma. gemcitabine 85-96 BCL2 apoptosis regulator Homo sapiens 22-27 14634285-4 1999 The cytoprotective actions of Bcl-2, respectively, is not antagonized by etomoxir, an inhibitor of carnitine palmitoyl transferase 1 (CPT1), suggesting that the recently described physical interaction between CPT1 and Bcl-2 is irrelevant to Bcl-2-mediated inhibition of palmitate-induce apoptosis. Palmitates 270-279 BCL2 apoptosis regulator Homo sapiens 218-223 10340887-11 1999 Furthermore, the effectiveness of gemcitabine and other chemotherapeutic agents may be increased by gene therapy-mediated alteration of bcl-2 gene family members. gemcitabine 34-45 BCL2 apoptosis regulator Homo sapiens 136-141 14634285-6 1999 Mitochondria purified from Bcl-2 over-expressing cells are protected against the palmitate-stimulated release of such factors. Palmitates 81-90 BCL2 apoptosis regulator Homo sapiens 27-32 10075088-8 1999 Flow cytometry studies showed that exposure of HL-60 cells to 150 microM H2O2 resulted in decreased Bcl-2 expression that was associated with enhanced apoptosis (up to 33.6 +/- 2.6%). Hydrogen Peroxide 73-77 BCL2 apoptosis regulator Homo sapiens 100-105 10381626-5 1999 Exposure of TPA-differentiated U937 cells to 0.8 microg/ml cycloheximide for 24 h, that triggers apoptosis in 50% cells, activates procaspase-2L, -3 and -8, induces the mitochondrial release of cytochrome c and decreases Bcl-xL expression without modifying Bcl-2, Mcl-1 and Bax protein levels. Tetradecanoylphorbol Acetate 12-15 BCL2 apoptosis regulator Homo sapiens 257-262 10361685-4 1999 During the induction of apoptosis by phloretin, the expression of Bax protein in B16 cells increased and the levels of p53, Bcl-2, and Bcl-XL proteins did not change. Phloretin 37-46 BCL2 apoptosis regulator Homo sapiens 124-129 10090950-4 1999 In addition, the expression of MCL-1, an antiapoptotic member of the BCL-2 family, is downregulated during Na-Sal-induced cell death, whereas the expression of BCL-2, BAX, and BCL-XL is unchanged. Sodium Salicylate 107-113 BCL2 apoptosis regulator Homo sapiens 69-74 10233386-8 1999 However, both of the cell lines showed progressive down-regulation of bcl-2, which began after 12-24 h exposure of the cells to ATRA as determined by ELISA, Western blotting and flow cytometry. Tretinoin 128-132 BCL2 apoptosis regulator Homo sapiens 70-75 10233386-9 1999 The present results show that mitochondria have a role in ATRA-induced apoptosis in AML cells and down-regulation of bcl-2 is related to it. Tretinoin 58-62 BCL2 apoptosis regulator Homo sapiens 117-122 10381626-2 1999 Exposure of undifferentiated U937 cells to 50 microM etoposide for 6 h, that triggers apoptosis in 80% cells, activates procaspase-2L, -3 and -8, induces the mitochondrial release of cytochrome c and decreases Mcl-1 expression without modifying Bcl-2, Bcl-xL and Bax protein levels. Etoposide 53-62 BCL2 apoptosis regulator Homo sapiens 245-250 10381626-5 1999 Exposure of TPA-differentiated U937 cells to 0.8 microg/ml cycloheximide for 24 h, that triggers apoptosis in 50% cells, activates procaspase-2L, -3 and -8, induces the mitochondrial release of cytochrome c and decreases Bcl-xL expression without modifying Bcl-2, Mcl-1 and Bax protein levels. Cycloheximide 59-72 BCL2 apoptosis regulator Homo sapiens 257-262 10199796-6 1999 Moreover, down-regulation of Bcl-2 protein and up-regulation of RAR beta suggest that retinoid may act on the genetic defect responsible for prostate cancer progression. Retinoids 86-94 BCL2 apoptosis regulator Homo sapiens 29-34 10194469-7 1999 Bcl-2 overexpression abrogated the Cer response to etoposide and IR and reduced CD95-induced Cer accumulation. Etoposide 51-60 BCL2 apoptosis regulator Homo sapiens 0-5 10098499-0 1999 1Alpha,25-dihydroxyvitamin D3 up-regulates Bcl-2 expression and protects normal human thyrocytes from programmed cell death. Calcitriol 0-29 BCL2 apoptosis regulator Homo sapiens 43-48 10098499-7 1999 The increase in Bcl-2 expression, mediated by VD3, correlated with protection of thyrocytes against the induction of apoptosis by either staurosporine or UV irradiation. Staurosporine 137-150 BCL2 apoptosis regulator Homo sapiens 16-21 10097113-0 1999 Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Paclitaxel 55-65 BCL2 apoptosis regulator Homo sapiens 31-36 10210536-12 1999 On a molecular level, taxanes activate a number of genes, but it appears that their effects are mainly p53-independent and primarily involve phosphorylation of the Bcl-2 gene. Taxoids 22-29 BCL2 apoptosis regulator Homo sapiens 164-169 10097113-10 1999 Thus, our data show that the antiapoptotic effects of Bcl-2 can be overcome by phosphorylation of Ser-70; forms of Bcl-2 lacking the loop region are much more effective at preventing apoptosis than wild-type Bcl-2 because they cannot be phosphorylated. Serine 98-101 BCL2 apoptosis regulator Homo sapiens 54-59 10097113-1 1999 At high concentrations, the tubule poison paclitaxel is able to kill cancer cells that express Bcl-2; it inhibits the antiapoptotic activity of Bcl-2 by inducing its phosphorylation. Paclitaxel 42-52 BCL2 apoptosis regulator Homo sapiens 95-100 10097113-10 1999 Thus, our data show that the antiapoptotic effects of Bcl-2 can be overcome by phosphorylation of Ser-70; forms of Bcl-2 lacking the loop region are much more effective at preventing apoptosis than wild-type Bcl-2 because they cannot be phosphorylated. Serine 98-101 BCL2 apoptosis regulator Homo sapiens 115-120 10097113-10 1999 Thus, our data show that the antiapoptotic effects of Bcl-2 can be overcome by phosphorylation of Ser-70; forms of Bcl-2 lacking the loop region are much more effective at preventing apoptosis than wild-type Bcl-2 because they cannot be phosphorylated. Serine 98-101 BCL2 apoptosis regulator Homo sapiens 115-120 10097113-1 1999 At high concentrations, the tubule poison paclitaxel is able to kill cancer cells that express Bcl-2; it inhibits the antiapoptotic activity of Bcl-2 by inducing its phosphorylation. Paclitaxel 42-52 BCL2 apoptosis regulator Homo sapiens 144-149 10097113-11 1999 JNK, but not ERK or p38 MAPK, appear to be involved in the phosphorylation of Bcl-2 induced by paclitaxel. Paclitaxel 95-105 BCL2 apoptosis regulator Homo sapiens 78-83 10097113-3 1999 Mutant forms of Bcl-2 with an alteration in serine at amino acid 70 (S70A) or with deletion of a 60-aa loop region between the alpha1 and alpha2 helices (Deltaloop Bcl-2, which also deletes amino acid 70) were unable to be phosphorylated by paclitaxel treatment of MDA-MB-231 cells into which the genes for the mutant proteins were transfected. Serine 44-50 BCL2 apoptosis regulator Homo sapiens 16-21 10097113-3 1999 Mutant forms of Bcl-2 with an alteration in serine at amino acid 70 (S70A) or with deletion of a 60-aa loop region between the alpha1 and alpha2 helices (Deltaloop Bcl-2, which also deletes amino acid 70) were unable to be phosphorylated by paclitaxel treatment of MDA-MB-231 cells into which the genes for the mutant proteins were transfected. Paclitaxel 241-251 BCL2 apoptosis regulator Homo sapiens 16-21 10097113-5 1999 In cells expressing the S70A mutant, paclitaxel induced about one-third the level of apoptosis seen with wild-type Bcl-2. Paclitaxel 37-47 BCL2 apoptosis regulator Homo sapiens 115-120 10097113-7 1999 Paclitaxel-induced apoptosis was associated with phosphorylation of Bcl-2 and activation of ERK and JNK MAPKs. Paclitaxel 0-10 BCL2 apoptosis regulator Homo sapiens 68-73 10037682-0 1999 Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. Lithium 10-17 BCL2 apoptosis regulator Homo sapiens 76-81 10100870-0 1999 Change in lactate production in Myc-transformed cells precedes apoptosis and can be inhibited by Bcl-2 overexpression. Lactic Acid 10-17 BCL2 apoptosis regulator Homo sapiens 97-102 10100870-3 1999 In this report we demonstrate that the overexpression of the anti-apoptotic protein Bcl-2 in Rat1-Myc cells (Rat1-Myc-Bcl-2) reduces the molar ratio of lactate production to glucose consumption (Y(L/G)). Lactic Acid 152-159 BCL2 apoptosis regulator Homo sapiens 84-89 10100870-3 1999 In this report we demonstrate that the overexpression of the anti-apoptotic protein Bcl-2 in Rat1-Myc cells (Rat1-Myc-Bcl-2) reduces the molar ratio of lactate production to glucose consumption (Y(L/G)). Lactic Acid 152-159 BCL2 apoptosis regulator Homo sapiens 118-123 10100870-11 1999 By abolishing the reduction in LPR, Bcl-2 may protect Rat1-Myc cells from staurosporine-induced apoptosis. Staurosporine 74-87 BCL2 apoptosis regulator Homo sapiens 36-41 10037696-0 1999 Nitric oxide fully protects against UVA-induced apoptosis in tight correlation with Bcl-2 up-regulation. Nitric Oxide 0-12 BCL2 apoptosis regulator Homo sapiens 84-89 10085086-4 1999 Treatment of neurons with an antisense oligonucleotide to bcl-2 mRNA or that to bcl-x mRNA blocked the up-regulation of Bcl-2 or Bcl-x expression, respectively, and partially inhibited the neuroprotective effect induced by TNF. Oligonucleotides 39-54 BCL2 apoptosis regulator Homo sapiens 58-63 10085086-4 1999 Treatment of neurons with an antisense oligonucleotide to bcl-2 mRNA or that to bcl-x mRNA blocked the up-regulation of Bcl-2 or Bcl-x expression, respectively, and partially inhibited the neuroprotective effect induced by TNF. Oligonucleotides 39-54 BCL2 apoptosis regulator Homo sapiens 120-125 10085086-5 1999 Moreover, adenovirus-mediated overexpression of Bcl-2 significantly inhibited hypoxia- or nitric oxide-induced neuronal death. Nitric Oxide 90-102 BCL2 apoptosis regulator Homo sapiens 48-53 10085086-8 1999 These findings indicate that induction of Bcl-2 and Bcl-x expression through NFkappaB activation is involved in the neuroprotective action of TNF against hypoxia- or nitric oxide-induced injury. Nitric Oxide 166-178 BCL2 apoptosis regulator Homo sapiens 42-47 10075725-6 1999 Our data indicate that: (i) activated JNK/SAPK acts upstream of membrane changes and caspase-3 activation in paclitaxel-initiated apoptotic pathways, independently of cell cycle stage, (ii) activated JNK/SAPK is not responsible for paclitaxel-induced phosphorylation of Bcl-2, and (iii) apoptosis resulting from microtubule damage may comprise multiple mechanisms, including a JNK/SAPK-dependent early phase and a JNK/SAPK-independent late phase. Paclitaxel 109-119 BCL2 apoptosis regulator Homo sapiens 270-275 10037682-3 1999 Long term, but not acute, treatment of cultured cerebellar granule cells with LiCl induces a concentration-dependent decrease in mRNA and protein levels of proapoptotic p53 and Bax; conversely, mRNA and protein levels of cytoprotective Bcl-2 are remarkably increased. Lithium Chloride 78-82 BCL2 apoptosis regulator Homo sapiens 236-241 10037682-4 1999 The ratios of Bcl-2/Bax protein levels increase by approximately 5-fold after lithium treatment for 5-7 days. Lithium 78-85 BCL2 apoptosis regulator Homo sapiens 14-19 10037682-6 1999 Pretreatment with LiCl for 7 days prevents glutamate-induced increase in p53 and Bax expression and maintains Bcl-2 in an elevated state. Lithium Chloride 18-22 BCL2 apoptosis regulator Homo sapiens 110-115 10037682-6 1999 Pretreatment with LiCl for 7 days prevents glutamate-induced increase in p53 and Bax expression and maintains Bcl-2 in an elevated state. Glutamic Acid 43-52 BCL2 apoptosis regulator Homo sapiens 110-115 10037682-9 1999 These results strongly suggest that lithium-induced Bcl-2 up-regulation and p53 and Bax down-regulation play a prominent role in neuroprotection against excitotoxicity. Lithium 36-43 BCL2 apoptosis regulator Homo sapiens 52-57 10086798-0 1999 Chlorambucil resistance in B-cell chronic lymphocytic leukaemia is mediated through failed Bax induction and selection of high Bcl-2-expressing subclones. Chlorambucil 0-12 BCL2 apoptosis regulator Homo sapiens 127-132 10089878-4 1999 It appears two criteria must be met for proapoptotic function within the BCL2 family: targeting of molecules to intracellular membranes, and exposure of the BH3 death domain. BH 3 157-160 BCL2 apoptosis regulator Homo sapiens 73-77 10037739-3 1999 Similarly, in MCF7 cells stably expressing either Bcl-2 or Bcl-2(DeltaTM), nuclear levels of p53 protein were up-regulated upon treatment with the DNA-damaging agents doxorubicin and UV radiation, whereas p53-responsive promoter activity and expression of p21(CIP1/WAF1) were strongly reduced in MCF7-Bcl-2 cells but not in MCF7-Bcl-2(DeltaTM) or control MCF7 cells. Doxorubicin 167-178 BCL2 apoptosis regulator Homo sapiens 50-55 10037739-3 1999 Similarly, in MCF7 cells stably expressing either Bcl-2 or Bcl-2(DeltaTM), nuclear levels of p53 protein were up-regulated upon treatment with the DNA-damaging agents doxorubicin and UV radiation, whereas p53-responsive promoter activity and expression of p21(CIP1/WAF1) were strongly reduced in MCF7-Bcl-2 cells but not in MCF7-Bcl-2(DeltaTM) or control MCF7 cells. Doxorubicin 167-178 BCL2 apoptosis regulator Homo sapiens 59-64 10037739-3 1999 Similarly, in MCF7 cells stably expressing either Bcl-2 or Bcl-2(DeltaTM), nuclear levels of p53 protein were up-regulated upon treatment with the DNA-damaging agents doxorubicin and UV radiation, whereas p53-responsive promoter activity and expression of p21(CIP1/WAF1) were strongly reduced in MCF7-Bcl-2 cells but not in MCF7-Bcl-2(DeltaTM) or control MCF7 cells. Doxorubicin 167-178 BCL2 apoptosis regulator Homo sapiens 59-64 10037739-3 1999 Similarly, in MCF7 cells stably expressing either Bcl-2 or Bcl-2(DeltaTM), nuclear levels of p53 protein were up-regulated upon treatment with the DNA-damaging agents doxorubicin and UV radiation, whereas p53-responsive promoter activity and expression of p21(CIP1/WAF1) were strongly reduced in MCF7-Bcl-2 cells but not in MCF7-Bcl-2(DeltaTM) or control MCF7 cells. Doxorubicin 167-178 BCL2 apoptosis regulator Homo sapiens 59-64 10089890-0 1999 In vitro treatment with retinoids decreases bcl-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells. Retinoids 24-33 BCL2 apoptosis regulator Homo sapiens 44-49 10205001-7 1999 Moreover, incubation of activated macrophages with CsA and FK506 contributed to maintain higher levels of Bcl-2 than in LPS/IFN-gamma treated cells. Tacrolimus 59-64 BCL2 apoptosis regulator Homo sapiens 106-111 10200572-5 1999 BCL-2, on the other hand, effectively inhibited actinomycin D-induced DNA fragmentation, the appearance of PS at the cells outer leaflet and the decrease in deltapsi[m]. Dactinomycin 48-61 BCL2 apoptosis regulator Homo sapiens 0-5 10355747-3 1999 Exposure of "variant" small cell lung carcinoma (SCLC) and non-SCLC cells, which secrete low concentrations (< 0.01 pmol/mg protein) of bombesin, to nanomolar concentrations of methadone resulted in increased levels of mitogen-activated protein (MAP) kinase phosphatases and inactivation of MAP kinase, suppression of the bcl-2 protein, and induction of apoptosis. Methadone 180-189 BCL2 apoptosis regulator Homo sapiens 325-330 10390076-5 1999 In oncohematology, a number of trials have been initiated with antisense oligonucleotides directed against molecular targets, including the bcl-2, c-myc, bcr-abl, c-myb or p53 oncogenes and tumor suppressor genes. Oligonucleotides 73-89 BCL2 apoptosis regulator Homo sapiens 140-145 10089890-8 1999 This effect may be mediated by a reduced intracellular expression of BCL-2 protein, which indeed observed after prolonged in vitro treatment with retinoids. Retinoids 146-155 BCL2 apoptosis regulator Homo sapiens 69-74 10089890-9 1999 It has been described recently that an enhanced expression of BCL-2 protein can contribute to the occurrence of early chemoresistance; the downregulation of BCL-2 protein induced by retinoids could thus be exploited, by means of novel chemotherapy plus retinoids combinations, in order to improve the efficacy of conventional chemotherapy in MM. Retinoids 182-191 BCL2 apoptosis regulator Homo sapiens 62-67 10089890-9 1999 It has been described recently that an enhanced expression of BCL-2 protein can contribute to the occurrence of early chemoresistance; the downregulation of BCL-2 protein induced by retinoids could thus be exploited, by means of novel chemotherapy plus retinoids combinations, in order to improve the efficacy of conventional chemotherapy in MM. Retinoids 182-191 BCL2 apoptosis regulator Homo sapiens 157-162 10089890-9 1999 It has been described recently that an enhanced expression of BCL-2 protein can contribute to the occurrence of early chemoresistance; the downregulation of BCL-2 protein induced by retinoids could thus be exploited, by means of novel chemotherapy plus retinoids combinations, in order to improve the efficacy of conventional chemotherapy in MM. Retinoids 253-262 BCL2 apoptosis regulator Homo sapiens 62-67 10089890-9 1999 It has been described recently that an enhanced expression of BCL-2 protein can contribute to the occurrence of early chemoresistance; the downregulation of BCL-2 protein induced by retinoids could thus be exploited, by means of novel chemotherapy plus retinoids combinations, in order to improve the efficacy of conventional chemotherapy in MM. Retinoids 253-262 BCL2 apoptosis regulator Homo sapiens 157-162 10024685-0 1999 Taxol-induced bcl-2 phosphorylation in ovarian cancer cell monolayer and spheroids. Paclitaxel 0-5 BCL2 apoptosis regulator Homo sapiens 14-19 10064615-7 1999 Conversely, a sustained calcium influx elicited by the calcium ionophore A23187 induced necrosis in cells expressing high Bcl-2 levels and apoptosis in cells expressing low Bcl-2 levels. Calcium 24-31 BCL2 apoptosis regulator Homo sapiens 122-127 10064615-7 1999 Conversely, a sustained calcium influx elicited by the calcium ionophore A23187 induced necrosis in cells expressing high Bcl-2 levels and apoptosis in cells expressing low Bcl-2 levels. Calcium 24-31 BCL2 apoptosis regulator Homo sapiens 173-178 10064615-7 1999 Conversely, a sustained calcium influx elicited by the calcium ionophore A23187 induced necrosis in cells expressing high Bcl-2 levels and apoptosis in cells expressing low Bcl-2 levels. Calcium 55-62 BCL2 apoptosis regulator Homo sapiens 122-127 10064615-7 1999 Conversely, a sustained calcium influx elicited by the calcium ionophore A23187 induced necrosis in cells expressing high Bcl-2 levels and apoptosis in cells expressing low Bcl-2 levels. Calcimycin 73-79 BCL2 apoptosis regulator Homo sapiens 122-127 10064615-8 1999 This suggests that Bcl-2 acts downstream from the calcium peak and inhibits only the apoptotic pathway, not the necrosis pathway, thus explaining the apparent shift from oxLDL-induced apoptosis toward necrosis when Bcl-2 is overexpressed. Calcium 50-57 BCL2 apoptosis regulator Homo sapiens 19-24 10024685-4 1999 Taxol treatment of monolayers resulted in the characteristic phosphorylation of Bcl-2, which was not demonstrated in spheroid cultures. Paclitaxel 0-5 BCL2 apoptosis regulator Homo sapiens 80-85 10023011-5 1999 The IC50 of cytarabine and fludarabine were significantly higher in CD34 positive cells with high Bcl-2 than in CD34 negative cells with low Bcl-2. Cytarabine 12-22 BCL2 apoptosis regulator Homo sapiens 98-103 9989782-6 1999 The inhibition of BAEC apoptosis by stable transfection of bcl-2 prevented the involution of the network. baec 18-22 BCL2 apoptosis regulator Homo sapiens 59-64 10434946-1 1999 It is likely that the changes which occur in the endometrium throughout the menstrual cycle involve apoptosis, and that expression of associated genes, such as the bcl-2 family, are regulated by sex steroids. Steroids 199-207 BCL2 apoptosis regulator Homo sapiens 164-169 10434946-4 1999 After administration of mifepristone on day 2 after the LH surge, a significant increase in bcl-2 immunoreactivity was observed in glandular and surface epithelium. Mifepristone 24-36 BCL2 apoptosis regulator Homo sapiens 92-97 10434946-8 1999 These data indicate that antiprogestin administration inhibits progesterone downregulation of steroid receptors in endometrial glands, resulting in persistence of a proliferative endometrium and accompanying bcl-2 secretion. Progesterone 63-75 BCL2 apoptosis regulator Homo sapiens 208-213 10023011-5 1999 The IC50 of cytarabine and fludarabine were significantly higher in CD34 positive cells with high Bcl-2 than in CD34 negative cells with low Bcl-2. fludarabine 27-38 BCL2 apoptosis regulator Homo sapiens 141-146 10023011-7 1999 Both cytarabine and fludarabine have reduced Bcl-2 concentrations in both cell types. Cytarabine 5-15 BCL2 apoptosis regulator Homo sapiens 45-50 10023011-7 1999 Both cytarabine and fludarabine have reduced Bcl-2 concentrations in both cell types. fludarabine 20-31 BCL2 apoptosis regulator Homo sapiens 45-50 10023011-5 1999 The IC50 of cytarabine and fludarabine were significantly higher in CD34 positive cells with high Bcl-2 than in CD34 negative cells with low Bcl-2. Cytarabine 12-22 BCL2 apoptosis regulator Homo sapiens 141-146 10023011-5 1999 The IC50 of cytarabine and fludarabine were significantly higher in CD34 positive cells with high Bcl-2 than in CD34 negative cells with low Bcl-2. fludarabine 27-38 BCL2 apoptosis regulator Homo sapiens 98-103 10026138-1 1999 Apoptosis was induced in human glioma cell lines by exposure to 100 nM calphostin C, a specific inhibitor of protein kinase C. Calphostin C-induced apoptosis was associated with synchronous down-regulation of Bcl-2 and Bcl-xL as well as activation of caspase-3 but not caspase-1. calphostin C 71-83 BCL2 apoptosis regulator Homo sapiens 209-214 10075008-9 1999 We thus characterized the cytotoxic mechanism as apoptotic in nature, and we measured the expression of several members of the Bcl-2 family in PC3 cells upon treatment with CeReS-18. ceres-18 173-181 BCL2 apoptosis regulator Homo sapiens 127-132 10049671-1 1999 This report describes the cloning of recombinant human Bcl-2, in which the putative disordered loop region has been replaced with a flexible linker and the hydrophobic C-terminus has been replaced with a 6xHis tag (Bcl-2(6-32)-AAAA-Bcl-2(86-206)-HHHHHH, abbreviation rhBcl-2; amino acid numbering excludes the initiating methionine). Methionine 321-331 BCL2 apoptosis regulator Homo sapiens 55-60 11601243-9 1999 Tripterine could upregulate Bax, c-myc expression and downregulate bcl-2 expression at protein level. celastrol 0-10 BCL2 apoptosis regulator Homo sapiens 67-72 11601243-10 1999 CONCLUSION: Tripterine can efficiently induce HMC-1 cell apoptosis, occurring mainly in S phase, which is correlated with upregulating Bax, c-myc expression and downregulating bcl-2 expression. celastrol 12-22 BCL2 apoptosis regulator Homo sapiens 176-181 10026138-1 1999 Apoptosis was induced in human glioma cell lines by exposure to 100 nM calphostin C, a specific inhibitor of protein kinase C. Calphostin C-induced apoptosis was associated with synchronous down-regulation of Bcl-2 and Bcl-xL as well as activation of caspase-3 but not caspase-1. calphostin C 127-139 BCL2 apoptosis regulator Homo sapiens 209-214 10021389-7 1999 Addition of dATP (which stimulates the procaspase-processing factor Apaf-1 [8] [9]) overcame inhibition of caspase activation by Bcl-2, but did not prevent the control of cytochrome c release from mitochondria by Bcl-2. 2'-deoxyadenosine triphosphate 12-16 BCL2 apoptosis regulator Homo sapiens 129-134 14634295-3 1999 In time, treatment with 1 microM paclitaxel successively induced formation of bundles, then pseudo-asters concomitantly with mitotic block and phosphorylation of bcl-2 (48 h), then phosphorylation of tau and externalization of phosphatidylserine at the early phase of apoptosis (72 h) and finally DNA fragmentation (96 h). Paclitaxel 33-43 BCL2 apoptosis regulator Homo sapiens 162-167 9949233-0 1999 [Inhibition of Bcl-2 expression in HL60 cells by incubation with antisense phosphorothioate oligodeoxynucleotides]. phosphorothioate oligodeoxynucleotides 75-113 BCL2 apoptosis regulator Homo sapiens 15-20 9949233-1 1999 OBJECTIVE: To observe whether the expression of Bcl-2 mRNA and protein in HL60 cells could be decreased by incubation with antisense phosphorothioate oligodeoxnucleotides (ASPO) at different concentrations (5micromol/L,10micromol/L,and 20micromol/L). phosphorothioate oligodeoxnucleotides 133-170 BCL2 apoptosis regulator Homo sapiens 48-53 9949233-1 1999 OBJECTIVE: To observe whether the expression of Bcl-2 mRNA and protein in HL60 cells could be decreased by incubation with antisense phosphorothioate oligodeoxnucleotides (ASPO) at different concentrations (5micromol/L,10micromol/L,and 20micromol/L). aspo 172-176 BCL2 apoptosis regulator Homo sapiens 48-53 9949233-6 1999 CONCLUSION: The data suggested that ASPO could inhibit the expression of Bcl-2 mRNA and protein in HL60 cells and the inhibitory effect depended on the specific sequences, the concentration and the time of incubation, but it could not last very long. aspo 36-40 BCL2 apoptosis regulator Homo sapiens 73-78 10021389-7 1999 Addition of dATP (which stimulates the procaspase-processing factor Apaf-1 [8] [9]) overcame inhibition of caspase activation by Bcl-2, but did not prevent the control of cytochrome c release from mitochondria by Bcl-2. 2'-deoxyadenosine triphosphate 12-16 BCL2 apoptosis regulator Homo sapiens 213-218 10064072-0 1999 Granulocyte-macrophage colony-stimulating factor protects dendritic cells from liposome-encapsulated dichloromethylene diphosphonate-induced apoptosis through a Bcl-2-mediated pathway. Clodronic Acid 101-132 BCL2 apoptosis regulator Homo sapiens 161-166 9925744-6 1999 More importantly, Z-VAD survival effects on immortalized brown adipocytes concur with a downregulation of Bcl-xS mRNA/protein and an upregulation of Bcl-2 protein content. z-vad 18-23 BCL2 apoptosis regulator Homo sapiens 149-154 10021463-7 1999 Using deletion mutants of Bcl-2, the NF-kappaB inhibitory function of Bcl-2 was mapped to bcl homology domains BH2 and BH4, whereas all BH domains were required for the antiapoptotic function. bh2 111-114 BCL2 apoptosis regulator Homo sapiens 70-75 10048784-10 1999 Overexpression of bcl-2 in the mitochondrial membrane inhibits calcium efflux, but the underlying mechanisms are not clearly known. Calcium 63-70 BCL2 apoptosis regulator Homo sapiens 18-23 10021463-7 1999 Using deletion mutants of Bcl-2, the NF-kappaB inhibitory function of Bcl-2 was mapped to bcl homology domains BH2 and BH4, whereas all BH domains were required for the antiapoptotic function. sapropterin 119-122 BCL2 apoptosis regulator Homo sapiens 70-75 10067009-1 1999 OBJECTIVE: To study whether interleukin-6 (IL-6) changes the expression of the anti-apoptic Bcl-2 protein in the prevention of cis-diaminedichloroplatinum (II) (CDDP)-induced apoptosis of human ovarian cancer cells. Cisplatin 127-159 BCL2 apoptosis regulator Homo sapiens 92-97 9889250-12 1999 The retention of bcl-2 on chromosomes in unfixed, permeabilized preparations was influenced by protease treatment, phosphate, and pH. Phosphates 115-124 BCL2 apoptosis regulator Homo sapiens 17-22 10067009-1 1999 OBJECTIVE: To study whether interleukin-6 (IL-6) changes the expression of the anti-apoptic Bcl-2 protein in the prevention of cis-diaminedichloroplatinum (II) (CDDP)-induced apoptosis of human ovarian cancer cells. Cisplatin 161-165 BCL2 apoptosis regulator Homo sapiens 92-97 10217615-8 1999 Cells were then exposed to synthetic antisense bcl-2 oligonucleotide treatment, after which programmed cell death was determined, as evidenced by DNA fragmentation. Oligonucleotides 53-68 BCL2 apoptosis regulator Homo sapiens 47-52 9891071-2 1999 HL-60 cells that stably overexpressed a bcl-2 cDNA transgene (Bcl-2:HL-60 cells) contained mitochondria and a cytosol that were resistant to exogenous Cif and that lacked detectable endogenous Cif activity, respectively. cif 151-154 BCL2 apoptosis regulator Homo sapiens 40-45 9891071-2 1999 HL-60 cells that stably overexpressed a bcl-2 cDNA transgene (Bcl-2:HL-60 cells) contained mitochondria and a cytosol that were resistant to exogenous Cif and that lacked detectable endogenous Cif activity, respectively. cif 193-196 BCL2 apoptosis regulator Homo sapiens 40-45 9891071-4 1999 The addition of purified caspase 3, caspase 7, or caspase 8 to the cytosolic extract from Bcl-2:HL-60 cells, however, restored Cif activity, demonstrating that the inhibition of Cif by Bcl-2 overexpression could be overcome by activated caspases. cif 178-181 BCL2 apoptosis regulator Homo sapiens 90-95 9891071-4 1999 The addition of purified caspase 3, caspase 7, or caspase 8 to the cytosolic extract from Bcl-2:HL-60 cells, however, restored Cif activity, demonstrating that the inhibition of Cif by Bcl-2 overexpression could be overcome by activated caspases. cif 178-181 BCL2 apoptosis regulator Homo sapiens 185-190 9891071-7 1999 Finally, we demonstrate that the activation of Cif correlated with the activation of the Bcl-2 family member Bid by caspases and that Cif activity was selectively neutralized by anti-Bid antibodies. cif 47-50 BCL2 apoptosis regulator Homo sapiens 89-94 9891071-8 1999 Taken together, these results indicate that Cif is identical to Bid and that it can be inhibited by Bcl-2 and activated by caspases. cif 44-47 BCL2 apoptosis regulator Homo sapiens 100-105 9928762-5 1999 RESULTS: The frequency of Bcl-2 positive cells was higher in HCCs that had undergone TAE (TAE HCC) than that in HCCs that had not undergone TAE (41.75+/-15.06 vs. 1.01+/-0.79 cells/1000 cells, p = 0.0173). tae 85-88 BCL2 apoptosis regulator Homo sapiens 26-31 9928762-5 1999 RESULTS: The frequency of Bcl-2 positive cells was higher in HCCs that had undergone TAE (TAE HCC) than that in HCCs that had not undergone TAE (41.75+/-15.06 vs. 1.01+/-0.79 cells/1000 cells, p = 0.0173). tae 90-93 BCL2 apoptosis regulator Homo sapiens 26-31 9928762-10 1999 Furthermore, the VEGF staining intensity in Bcl-2 positive areas of TAE HCCs was higher than in Bcl-2 negative areas (1.296+/-0.126 vs. 1.066+/-0.024, p = 0.0186), while in HCCs that had not undergone TAE the staining intensity was similar. tae 68-71 BCL2 apoptosis regulator Homo sapiens 44-49 10217615-11 1999 Synthetic antisense bcl-2 oligonucleotide treatment resulted in decreased Bcl-2 levels, reduced cell proliferation, decreased cell viability, and increased levels of spontaneous PCD. Oligonucleotides 26-41 BCL2 apoptosis regulator Homo sapiens 20-25 10217615-11 1999 Synthetic antisense bcl-2 oligonucleotide treatment resulted in decreased Bcl-2 levels, reduced cell proliferation, decreased cell viability, and increased levels of spontaneous PCD. Oligonucleotides 26-41 BCL2 apoptosis regulator Homo sapiens 74-79 10205784-6 1999 The activation of caspases can be inhibited by several molecules, including peptide aldehydes (caspase-1 and or caspase-3 inhibitors) and crmA that target the active-site cysteine of caspase family members, Bcl-2, IAP (inhibitor of apoptosis protein) and NAIP (neuronal apoptosis inhibitory protein). Aldehydes 84-93 BCL2 apoptosis regulator Homo sapiens 207-212 10205784-6 1999 The activation of caspases can be inhibited by several molecules, including peptide aldehydes (caspase-1 and or caspase-3 inhibitors) and crmA that target the active-site cysteine of caspase family members, Bcl-2, IAP (inhibitor of apoptosis protein) and NAIP (neuronal apoptosis inhibitory protein). crma 138-142 BCL2 apoptosis regulator Homo sapiens 207-212 10205784-6 1999 The activation of caspases can be inhibited by several molecules, including peptide aldehydes (caspase-1 and or caspase-3 inhibitors) and crmA that target the active-site cysteine of caspase family members, Bcl-2, IAP (inhibitor of apoptosis protein) and NAIP (neuronal apoptosis inhibitory protein). Cysteine 171-179 BCL2 apoptosis regulator Homo sapiens 207-212 10437153-0 1999 Elemene induces apoptosis and regulates expression of bcl-2 protein in human leukemia K562 cells. elemene 0-7 BCL2 apoptosis regulator Homo sapiens 54-59 10436692-6 1999 Immunohistochemical gene Bcl-2 protein expression was determined in paraffin included pathological slices. Paraffin 68-76 BCL2 apoptosis regulator Homo sapiens 25-30 10190792-8 1999 Bcl-2 can be inactivated by phosphorylation as occurs with taxanes. Taxoids 59-66 BCL2 apoptosis regulator Homo sapiens 0-5 10190792-9 1999 The retinoids, as a class, can inhibit the growth of resistant cell lines that overexpress bcl-2, and the combination of interferon (IFN) and cis-retinoic acid (CRA) demonstrated increased antitumor activity. Retinoids 4-13 BCL2 apoptosis regulator Homo sapiens 91-96 9989825-7 1999 Overexpression of Bcl-2 and the viral anti-apoptotic proteins BHRF-1 and E1B 19K counteracted H2O2-induced apoptosis. Hydrogen Peroxide 94-98 BCL2 apoptosis regulator Homo sapiens 18-23 11798633-3 1999 RESULTS: Compared with inactive SLE patients and normal controls, a proposition of T cells (including CD(3)(+), CD(4)(+) and CD(8)(+) subgroups) expressing Bcl-2 protein increased significantly in active SLE patients. Cadmium 102-104 BCL2 apoptosis regulator Homo sapiens 156-161 9873048-4 1999 In the presence of IL-3, constitutively expressed Bcl-2 was phosphorylated on serine residue(s), and phosphorylated Bcl-2 lost its capacity to heterodimerize with Bax. Serine 78-84 BCL2 apoptosis regulator Homo sapiens 50-55 9988115-0 1999 Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone. gemcitabine 0-11 BCL2 apoptosis regulator Homo sapiens 86-91 9988115-7 1999 Ectopic expression of BCL-2 moderately attenuated gemcitabine-induced cell death. gemcitabine 50-61 BCL2 apoptosis regulator Homo sapiens 22-27 9892691-11 1999 This study demonstrates the receptor-specific cytotoxic effect of 2-pyrrolinodoxorubicin conjugated to [D-Lys6] LH-RH, exerted through induction of apoptosis and modulation of Bax, Bcl-2, and DNA fragmentation. AN 204 66-88 BCL2 apoptosis regulator Homo sapiens 181-186 9927186-6 1999 Furthermore, Bcl-2 protein was shown to specifically suppress the p53-mediated transactivation of p21CIP1/WAF1 and PG13-CAT, which is a typical p53-binding-site reporter construct. pg13-cat 115-123 BCL2 apoptosis regulator Homo sapiens 13-18 9927186-7 1999 Similarly, the inhibitory effect of Bcl-2 protein was seen in a GADD45 promoter reporter construct after treatment with methylmethane sulfonate or UV-radiation. Methyl Methanesulfonate 120-143 BCL2 apoptosis regulator Homo sapiens 36-41 9878399-4 1999 However, a subset of the peptides was identified that exhibits significant similarity to a non-conserved region of the anti-apoptotic human protein Bcl-2: ELISA assays confirmed binding of paclitaxel to Bcl-2, and circular dichroism spectroscopy demonstrated that a substantial conformational change accompanies this binding. Paclitaxel 189-199 BCL2 apoptosis regulator Homo sapiens 148-153 9880563-2 1999 The MCL1 member of the BCL2 family is up-regulated during the induction of monocytic differentiation (approximately 10-fold with 12-O-tetradecanoylphorbol 13-acetate (TPA)). Tetradecanoylphorbol Acetate 129-165 BCL2 apoptosis regulator Homo sapiens 23-27 9880563-2 1999 The MCL1 member of the BCL2 family is up-regulated during the induction of monocytic differentiation (approximately 10-fold with 12-O-tetradecanoylphorbol 13-acetate (TPA)). Tetradecanoylphorbol Acetate 167-170 BCL2 apoptosis regulator Homo sapiens 23-27 9878399-4 1999 However, a subset of the peptides was identified that exhibits significant similarity to a non-conserved region of the anti-apoptotic human protein Bcl-2: ELISA assays confirmed binding of paclitaxel to Bcl-2, and circular dichroism spectroscopy demonstrated that a substantial conformational change accompanies this binding. Paclitaxel 189-199 BCL2 apoptosis regulator Homo sapiens 203-208 9878399-5 1999 In vivo, treatment with paclitaxel has been shown to lead to Bcl-2 inactivation with concomitant phosphorylation of residues in a disordered, regulatory loop region of the protein. Paclitaxel 24-34 BCL2 apoptosis regulator Homo sapiens 61-66 9878399-6 1999 Similarity between paclitaxel-selected peptides and this loop region implicate these residues in drug binding, and suggest that the apoptotic action of paclitaxel may involve the binding of paclitaxel to Bcl-2. Paclitaxel 19-29 BCL2 apoptosis regulator Homo sapiens 204-209 9878399-6 1999 Similarity between paclitaxel-selected peptides and this loop region implicate these residues in drug binding, and suggest that the apoptotic action of paclitaxel may involve the binding of paclitaxel to Bcl-2. Paclitaxel 152-162 BCL2 apoptosis regulator Homo sapiens 204-209 9878399-6 1999 Similarity between paclitaxel-selected peptides and this loop region implicate these residues in drug binding, and suggest that the apoptotic action of paclitaxel may involve the binding of paclitaxel to Bcl-2. Paclitaxel 152-162 BCL2 apoptosis regulator Homo sapiens 204-209 10075388-0 1999 Reduced bcl-2 concentrations in hypertensive patients after lisinopril or nifedipine administration. Lisinopril 60-70 BCL2 apoptosis regulator Homo sapiens 8-13 9878060-5 1999 Boo also has an N-terminal region with strong homology to the BH4 domain found to be important for the function of some anti-apoptotic Bcl-2 homologues. sapropterin 62-65 BCL2 apoptosis regulator Homo sapiens 135-140 10500808-3 1999 In this study we evaluated the relation between bcl-2 expression, spontaneous and dexamethasone (DXM) induced apoptosis, and in vitro resistance to DXM, prednisolone (PRD) and cytarabine (ARA) determined using the total cell kill colorimetric methyl-thiazol-tetrazolium salt (MTT) assay, in childhood acute lymphoblastic leukemia (ALL). Dexamethasone 97-100 BCL2 apoptosis regulator Homo sapiens 48-53 10500808-3 1999 In this study we evaluated the relation between bcl-2 expression, spontaneous and dexamethasone (DXM) induced apoptosis, and in vitro resistance to DXM, prednisolone (PRD) and cytarabine (ARA) determined using the total cell kill colorimetric methyl-thiazol-tetrazolium salt (MTT) assay, in childhood acute lymphoblastic leukemia (ALL). Dexamethasone 148-151 BCL2 apoptosis regulator Homo sapiens 48-53 10500808-3 1999 In this study we evaluated the relation between bcl-2 expression, spontaneous and dexamethasone (DXM) induced apoptosis, and in vitro resistance to DXM, prednisolone (PRD) and cytarabine (ARA) determined using the total cell kill colorimetric methyl-thiazol-tetrazolium salt (MTT) assay, in childhood acute lymphoblastic leukemia (ALL). Cytarabine 176-186 BCL2 apoptosis regulator Homo sapiens 48-53 10500808-3 1999 In this study we evaluated the relation between bcl-2 expression, spontaneous and dexamethasone (DXM) induced apoptosis, and in vitro resistance to DXM, prednisolone (PRD) and cytarabine (ARA) determined using the total cell kill colorimetric methyl-thiazol-tetrazolium salt (MTT) assay, in childhood acute lymphoblastic leukemia (ALL). methyl-thiazol-tetrazolium salt 243-274 BCL2 apoptosis regulator Homo sapiens 48-53 10500808-3 1999 In this study we evaluated the relation between bcl-2 expression, spontaneous and dexamethasone (DXM) induced apoptosis, and in vitro resistance to DXM, prednisolone (PRD) and cytarabine (ARA) determined using the total cell kill colorimetric methyl-thiazol-tetrazolium salt (MTT) assay, in childhood acute lymphoblastic leukemia (ALL). monooxyethylene trimethylolpropane tristearate 276-279 BCL2 apoptosis regulator Homo sapiens 48-53 10500809-0 1999 Comparison of BCL-2 and BAX protein expression with in vitro sensitivity to ARA-C and 6TG in AML. Cytarabine 76-81 BCL2 apoptosis regulator Homo sapiens 14-19 10500809-0 1999 Comparison of BCL-2 and BAX protein expression with in vitro sensitivity to ARA-C and 6TG in AML. Thioguanine 86-89 BCL2 apoptosis regulator Homo sapiens 14-19 10500809-5 1999 One of 7 patients (14%) whose cells were sensitive to ara-C expressed BCL-2 compared to 4/4 patients (100%) whose cells were resistant to ara-C in vitro (p = 0.05). Cytarabine 54-59 BCL2 apoptosis regulator Homo sapiens 70-75 10075388-0 1999 Reduced bcl-2 concentrations in hypertensive patients after lisinopril or nifedipine administration. Nifedipine 74-84 BCL2 apoptosis regulator Homo sapiens 8-13 10075388-4 1999 Treatment of hypertensive patients with hypotensive drugs caused a reduction in bcl-2 concentrations, which was more marked after administration of lisinopril than of nifedipine. Lisinopril 148-158 BCL2 apoptosis regulator Homo sapiens 80-85 10075388-4 1999 Treatment of hypertensive patients with hypotensive drugs caused a reduction in bcl-2 concentrations, which was more marked after administration of lisinopril than of nifedipine. Nifedipine 167-177 BCL2 apoptosis regulator Homo sapiens 80-85 10075388-6 1999 Moreover, lisinopril and nifedipine appear to be capable of reducing bcl-2 concentrations, with potentially beneficial effects on vascular modifications in patients with hypertension. Lisinopril 10-20 BCL2 apoptosis regulator Homo sapiens 69-74 10075388-6 1999 Moreover, lisinopril and nifedipine appear to be capable of reducing bcl-2 concentrations, with potentially beneficial effects on vascular modifications in patients with hypertension. Nifedipine 25-35 BCL2 apoptosis regulator Homo sapiens 69-74 10367743-10 1999 However, inhibition of etoposide-induced apoptosis by Bcl-2 resulted in the accumulation of giant, multinucleated cells that eventually lost the ability to exclude trypan blue without apoptotic morphology or DNA degradation. Trypan Blue 164-175 BCL2 apoptosis regulator Homo sapiens 54-59 10226594-0 1999 Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2. Docetaxel 16-25 BCL2 apoptosis regulator Homo sapiens 132-137 10226594-3 1999 We further show that this increase in cell death is due to an increase in apoptosis, and that this sensitization coincides with a docetaxel induced G2-M arrest and phosphorylation of the bcl-2 oncoprotein. Docetaxel 130-139 BCL2 apoptosis regulator Homo sapiens 187-192 10226594-4 1999 We speculate that this phosphorylation of the apoptosis blocker bcl-2 might be responsible for the sensitization, and we suggest a clinical study comparing a 24 hour docetaxel pretreatment to the current simultaneous schedules. Docetaxel 166-175 BCL2 apoptosis regulator Homo sapiens 64-69 10695052-4 1999 In addition, the expression patterns of Bcl-2 family members during taxol or Dox treatment were investigated. Paclitaxel 68-73 BCL2 apoptosis regulator Homo sapiens 40-45 10695052-4 1999 In addition, the expression patterns of Bcl-2 family members during taxol or Dox treatment were investigated. Doxorubicin 77-80 BCL2 apoptosis regulator Homo sapiens 40-45 10321512-0 1999 Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification. dolastatin 10 12-25 BCL2 apoptosis regulator Homo sapiens 106-111 10321512-9 1999 Immunoblot analysis revealed that 1.3 nM dolastatin 10 altered the electrophoretic mobility of bcl-2 in NCI-H69 and -H510 cells within 16 h of treatment. dolastatin 10 41-54 BCL2 apoptosis regulator Homo sapiens 95-100 10367743-3 1999 PURPOSE: The purpose of this study was to identify the point at which Bcl-2 interrupts the apoptotic cascade initiated following exposure of human tumor cells to etoposide. Etoposide 162-171 BCL2 apoptosis regulator Homo sapiens 70-75 10367743-10 1999 However, inhibition of etoposide-induced apoptosis by Bcl-2 resulted in the accumulation of giant, multinucleated cells that eventually lost the ability to exclude trypan blue without apoptotic morphology or DNA degradation. Etoposide 23-32 BCL2 apoptosis regulator Homo sapiens 54-59 10321512-10 1999 Incubation of protein extract from dolastatin 10-treated NCI-H69 and -H510 cells with calcineurin resulted in the disappearance of the altered mobility species, suggesting dolastatin 10-induced bcl-2 phosphorylation. dolastatin 10 35-48 BCL2 apoptosis regulator Homo sapiens 194-199 10200551-0 1999 Dexamethasone induces apoptosis in human T cell clones expressing low levels of Bcl-2. Dexamethasone 0-13 BCL2 apoptosis regulator Homo sapiens 80-85 10321512-10 1999 Incubation of protein extract from dolastatin 10-treated NCI-H69 and -H510 cells with calcineurin resulted in the disappearance of the altered mobility species, suggesting dolastatin 10-induced bcl-2 phosphorylation. dolastatin 10 172-185 BCL2 apoptosis regulator Homo sapiens 194-199 9886853-4 1999 DHT caused a marked down-regulation of Bcl-2 protein and messenger RNA levels in both the presence and absence of 17beta-estradiol. Dihydrotestosterone 0-3 BCL2 apoptosis regulator Homo sapiens 39-44 9886853-4 1999 DHT caused a marked down-regulation of Bcl-2 protein and messenger RNA levels in both the presence and absence of 17beta-estradiol. Estradiol 114-130 BCL2 apoptosis regulator Homo sapiens 39-44 9933116-5 1999 Further, as a result of Bcl-2 overexpression, we found that hGH greatly depressed Fas-induced activation of the cysteine protease caspase-3 (CPP32), which in turn affected the cleavage of poly(ADP-ribose) polymerase. ammonium ferrous sulfate 82-85 BCL2 apoptosis regulator Homo sapiens 24-29 9888267-10 1999 Furthermore, vitamin D compounds, although not able to induce apoptosis when used alone, potentiate apoptosis induced by 9-cis RA in HL-60 cells and differentially regulate the expression of the apoptosis-related gene products bcl-2 and bax. Vitamin D 13-22 BCL2 apoptosis regulator Homo sapiens 227-232 10200551-4 1999 The results show that the amount of Bcl-2 expression, that changes during cell cycle phases, determines susceptibility or resistance to apoptosis induced by Dex. Dextromethorphan 157-160 BCL2 apoptosis regulator Homo sapiens 36-41 10200551-5 1999 In fact, undetectable expression of Bcl-2 in sensitive cells favors Dex-mediated apoptosis while high expression of Bcl-2 in proliferating cells counterbalances apoptosis induction. Dextromethorphan 68-71 BCL2 apoptosis regulator Homo sapiens 36-41 10573189-8 1999 Overexpression of bcl-2 inhibited STS and C2-ceramide induced cytochrome c redistribution, caspase-3 activation and apoptosis. N-acetylsphingosine 42-53 BCL2 apoptosis regulator Homo sapiens 18-23 9934688-4 1999 Butyrate induces much higher levels of multiple class II and class III transcripts than does TPA, including v-MIPI, v-IL-6, v-Bcl-2, vGPCR and ORF26. Butyrates 0-8 BCL2 apoptosis regulator Homo sapiens 126-131 10720200-6 1999 Bcl-2 works by rendering gliomas resistant to Fas-mediated apoptosis. ammonium ferrous sulfate 46-49 BCL2 apoptosis regulator Homo sapiens 0-5 10757447-0 1999 Sodium butyrate modulates p53 and Bcl-2 expression in human retinoblastoma cell lines. Butyric Acid 0-15 BCL2 apoptosis regulator Homo sapiens 34-39 10063313-0 1999 The relationship between cisplatin-induced apoptosis and p53, bcl-2 and bax expression in human lung cancer cells. Cisplatin 25-34 BCL2 apoptosis regulator Homo sapiens 62-67 10063313-8 1999 Cancer cells with the natural expression of bcl-2 and p53 mutation may be more resistant to cisplatin and less susceptible to apoptosis. Cisplatin 92-101 BCL2 apoptosis regulator Homo sapiens 44-49 10757447-6 1999 Up to 12 h after 1 mM SB treatment, p53 and Bcl-2 expressions were similar to control levels, then gradually decreased to very low levels at 5 days. Butyric Acid 22-24 BCL2 apoptosis regulator Homo sapiens 44-49 10757447-9 1999 SB-induced modulation of p53 and Bcl-2 expression may have implications for controlling Rb growth, particularly in combination with chemotherapy drugs, which are increasingly used in the treatment of Rb. Butyric Acid 0-2 BCL2 apoptosis regulator Homo sapiens 33-38 10222499-3 1999 Bcl-2-related proteins are the principal regulators of apoptosis, acting through the control of ions (K+, H+, Cl-, Ca2+) and reactive oxygen species fluxes, the release of apoptogenic factors from mitochondria (AIF, cytochrome c) and the activation of the executors of apoptosis (caspases, DNases). Reactive Oxygen Species 125-148 BCL2 apoptosis regulator Homo sapiens 0-5 10393368-7 1999 In the PZX-5 carcinoma line that was originally negative, the one month Sandostatin treatment induced the strong expression of bcl-2 protein suggesting a development of an acquired resistance against programmed cell death in this tumor. Octreotide 72-83 BCL2 apoptosis regulator Homo sapiens 127-132 9850070-0 1998 3-(Iodoacetamido)-benzoylurea: a novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells. 3-(iodoacetamido)-benzoylurea 0-29 BCL2 apoptosis regulator Homo sapiens 124-129 10030664-12 1998 In contrast, cells expressing Bcl-2 had functional mitochondria and remained viable during reoxygenation even without glucose. Glucose 118-125 BCL2 apoptosis regulator Homo sapiens 30-35 9841888-0 1998 Distinct sites of action of Bcl-2 and Bcl-xL in the ceramide pathway of apoptosis. Ceramides 52-60 BCL2 apoptosis regulator Homo sapiens 28-33 9841888-1 1998 We studied the inhibition of tumour necrosis factor alpha (TNFalpha)- and camptothecin-induced apoptosis by Bcl-2 and Bcl-xL as they relate to the ceramide pathway. Camptothecin 74-86 BCL2 apoptosis regulator Homo sapiens 108-113 9841888-1 1998 We studied the inhibition of tumour necrosis factor alpha (TNFalpha)- and camptothecin-induced apoptosis by Bcl-2 and Bcl-xL as they relate to the ceramide pathway. Ceramides 147-155 BCL2 apoptosis regulator Homo sapiens 108-113 9841888-2 1998 Expression of either Bcl-2 or Bcl-xL provided significant protection from the apoptotic effects of TNFalpha or camptothecin. Camptothecin 111-123 BCL2 apoptosis regulator Homo sapiens 21-26 9841888-6 1998 These results identify a different mechanism of action for Bcl-xL compared with Bcl-2 and they demonstrate that Bcl-xL targets a point upstream of ceramide generation, whereas Bcl-2 functions downstream of ceramide in the TNFalpha- and camptothecin-activated pathways of apoptosis. Ceramides 206-214 BCL2 apoptosis regulator Homo sapiens 176-181 9843949-5 1998 Proapoptotic Bax- and Bak-BH3 (Bcl-2 homology) peptides, but not a mutant BH3 peptide nor a mutant Bak lacking BH3, induced the mitochondrial changes, indicating an essential role of the BH3 region. BH 3 26-29 BCL2 apoptosis regulator Homo sapiens 31-36 9881701-6 1998 Thus, BH3 of Bcl-2 encodes binding specificity but not the apoptotic propensity. BH 3 6-9 BCL2 apoptosis regulator Homo sapiens 13-18 9881701-9 1998 Thus, BH3 controls the binding specificity among Bcl-2 family members, and direct interaction between pro-apoptotic and anti-apoptotic proteins is a mechanism to regulate mitochondrial membrane potential and apoptosis. BH 3 6-9 BCL2 apoptosis regulator Homo sapiens 49-54 9879997-4 1998 We found up-regulation of p21WAF1 and Bax expressions, however, the expressions of p53 and Bcl-2 genes remained unchanged in TPA-treated cells. Tetradecanoylphorbol Acetate 125-128 BCL2 apoptosis regulator Homo sapiens 91-96 9850096-0 1998 Bcl-2-mediated resistance to apoptosis is associated with glutathione-induced inhibition of AP24 activation of nuclear DNA fragmentation. Glutathione 58-69 BCL2 apoptosis regulator Homo sapiens 0-5 9850096-5 1998 Bcl-2-overexpressing cells that were nutritionally depleted of glutathione (GSH) became sensitive to tumor necrosis factor- or UV light-induced activation of AP24 and underwent apoptotic cell death. Glutathione 63-74 BCL2 apoptosis regulator Homo sapiens 0-5 9850096-5 1998 Bcl-2-overexpressing cells that were nutritionally depleted of glutathione (GSH) became sensitive to tumor necrosis factor- or UV light-induced activation of AP24 and underwent apoptotic cell death. Glutathione 76-79 BCL2 apoptosis regulator Homo sapiens 0-5 9850096-6 1998 Moreover, nuclei isolated from Bcl-2-overexpressing cells that were depleted of GSH became sensitive to AP24-induced DNA fragmentation. Glutathione 80-83 BCL2 apoptosis regulator Homo sapiens 31-36 9850096-9 1998 Furthermore, agents that deplete intracellular levels of GSH may have therapeutic use in the sensitization of Bcl-2-overexpressing cancer cells to apoptotic cell death. Glutathione 57-60 BCL2 apoptosis regulator Homo sapiens 110-115 11263312-2 1999 METHODS: We investigated the expression of bcl-2 in 38 samples of hemangioma (19 cases of capillary hemangioma, 10 cases of cavernous hemangioma, 9 cases of racemose hemangioma) and 6 samples of normal skin by immunohistochemical SP method. TFF2 protein, human 230-232 BCL2 apoptosis regulator Homo sapiens 43-48 9842975-2 1998 Here, we asked whether alterations in the p53 and RB pathways and the expression of six BCL-2 family proteins predicted acute cytotoxicity and clonogenic cell death induced by BCNU, vincristine, cytarabine, teniposide, doxorubicin, camptothecin or beta-lapachone in 12 human malignant glioma cell lines. Carmustine 176-180 BCL2 apoptosis regulator Homo sapiens 88-93 9842975-2 1998 Here, we asked whether alterations in the p53 and RB pathways and the expression of six BCL-2 family proteins predicted acute cytotoxicity and clonogenic cell death induced by BCNU, vincristine, cytarabine, teniposide, doxorubicin, camptothecin or beta-lapachone in 12 human malignant glioma cell lines. Vincristine 182-193 BCL2 apoptosis regulator Homo sapiens 88-93 9842975-2 1998 Here, we asked whether alterations in the p53 and RB pathways and the expression of six BCL-2 family proteins predicted acute cytotoxicity and clonogenic cell death induced by BCNU, vincristine, cytarabine, teniposide, doxorubicin, camptothecin or beta-lapachone in 12 human malignant glioma cell lines. Cytarabine 195-205 BCL2 apoptosis regulator Homo sapiens 88-93 9842975-2 1998 Here, we asked whether alterations in the p53 and RB pathways and the expression of six BCL-2 family proteins predicted acute cytotoxicity and clonogenic cell death induced by BCNU, vincristine, cytarabine, teniposide, doxorubicin, camptothecin or beta-lapachone in 12 human malignant glioma cell lines. Teniposide 207-217 BCL2 apoptosis regulator Homo sapiens 88-93 9842975-2 1998 Here, we asked whether alterations in the p53 and RB pathways and the expression of six BCL-2 family proteins predicted acute cytotoxicity and clonogenic cell death induced by BCNU, vincristine, cytarabine, teniposide, doxorubicin, camptothecin or beta-lapachone in 12 human malignant glioma cell lines. Doxorubicin 219-230 BCL2 apoptosis regulator Homo sapiens 88-93 9842975-2 1998 Here, we asked whether alterations in the p53 and RB pathways and the expression of six BCL-2 family proteins predicted acute cytotoxicity and clonogenic cell death induced by BCNU, vincristine, cytarabine, teniposide, doxorubicin, camptothecin or beta-lapachone in 12 human malignant glioma cell lines. Camptothecin 232-244 BCL2 apoptosis regulator Homo sapiens 88-93 9842975-2 1998 Here, we asked whether alterations in the p53 and RB pathways and the expression of six BCL-2 family proteins predicted acute cytotoxicity and clonogenic cell death induced by BCNU, vincristine, cytarabine, teniposide, doxorubicin, camptothecin or beta-lapachone in 12 human malignant glioma cell lines. beta-lapachone 248-262 BCL2 apoptosis regulator Homo sapiens 88-93 9829980-5 1998 Significantly, Diva lacks critical residues in the conserved BH3 region that mediate the interaction between BH3-containing proapoptotic Bcl-2 homologues and their prosurvival binding partners. BH 3 61-64 BCL2 apoptosis regulator Homo sapiens 137-142 9829980-5 1998 Significantly, Diva lacks critical residues in the conserved BH3 region that mediate the interaction between BH3-containing proapoptotic Bcl-2 homologues and their prosurvival binding partners. BH 3 109-112 BCL2 apoptosis regulator Homo sapiens 137-142 9894610-4 1998 Here we report that Bcl-2 and benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD-fmk), a broad spectrum caspase inhibitor, prevent loss of mitochondrial membrane potential (delta psi m) and the production of reactive oxygen species (ROS) caused by GC, while acetyl-Asp-Glu-Val-Asp-aldehyde (Ac-DEVD-CHO), an inhibitor of the caspase-3 family proteases, does not. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 85-93 BCL2 apoptosis regulator Homo sapiens 20-25 9894610-4 1998 Here we report that Bcl-2 and benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD-fmk), a broad spectrum caspase inhibitor, prevent loss of mitochondrial membrane potential (delta psi m) and the production of reactive oxygen species (ROS) caused by GC, while acetyl-Asp-Glu-Val-Asp-aldehyde (Ac-DEVD-CHO), an inhibitor of the caspase-3 family proteases, does not. Reactive Oxygen Species 217-240 BCL2 apoptosis regulator Homo sapiens 20-25 9894610-4 1998 Here we report that Bcl-2 and benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD-fmk), a broad spectrum caspase inhibitor, prevent loss of mitochondrial membrane potential (delta psi m) and the production of reactive oxygen species (ROS) caused by GC, while acetyl-Asp-Glu-Val-Asp-aldehyde (Ac-DEVD-CHO), an inhibitor of the caspase-3 family proteases, does not. Reactive Oxygen Species 242-245 BCL2 apoptosis regulator Homo sapiens 20-25 9894610-4 1998 Here we report that Bcl-2 and benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD-fmk), a broad spectrum caspase inhibitor, prevent loss of mitochondrial membrane potential (delta psi m) and the production of reactive oxygen species (ROS) caused by GC, while acetyl-Asp-Glu-Val-Asp-aldehyde (Ac-DEVD-CHO), an inhibitor of the caspase-3 family proteases, does not. acetyl-aspartyl-glutamyl-valyl-aspartal 267-298 BCL2 apoptosis regulator Homo sapiens 20-25 9894610-4 1998 Here we report that Bcl-2 and benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD-fmk), a broad spectrum caspase inhibitor, prevent loss of mitochondrial membrane potential (delta psi m) and the production of reactive oxygen species (ROS) caused by GC, while acetyl-Asp-Glu-Val-Asp-aldehyde (Ac-DEVD-CHO), an inhibitor of the caspase-3 family proteases, does not. acetyl-aspartyl-glutamyl-valyl-aspartal 300-311 BCL2 apoptosis regulator Homo sapiens 20-25 9894613-2 1998 We report here that a novel dipeptidyl proteasome inhibitor, CEP1612, at low concentrations rapidly induces apoptosis in human Jurkat T cells overexpressing Bcl-2 and also in all human prostate, breast, tongue and brain tumor cell lines we have tested to date, without exception. CEP 1612 61-68 BCL2 apoptosis regulator Homo sapiens 157-162 9850070-9 1998 The phosphorylated bcl-2 representative of an inactivated form of the oncoprotein was found in the cells 12 h after treatment with 3-IAABU. 3-iaabu 131-138 BCL2 apoptosis regulator Homo sapiens 19-24 9865905-9 1998 The second finding that drug-induced apoptosis was equal or higher in tumors that expressed Pgp, p53, and Bcl-2 compared to tumors that did not express these proteins supports the use of paclitaxel in treating Pgp-, p53- and Bcl-2-positive tumors. Paclitaxel 187-197 BCL2 apoptosis regulator Homo sapiens 106-111 9865905-9 1998 The second finding that drug-induced apoptosis was equal or higher in tumors that expressed Pgp, p53, and Bcl-2 compared to tumors that did not express these proteins supports the use of paclitaxel in treating Pgp-, p53- and Bcl-2-positive tumors. Paclitaxel 187-197 BCL2 apoptosis regulator Homo sapiens 225-230 9885901-6 1998 Both the transgenic Bcl-2 and zVAD-fmk, an inhibitor of caspases, affected all features of Dex-induced apoptosis in a similar fashion, by inhibiting cell death and PARP cleavage, and by stabilizing AP-1, NF-kappaB p50-p50 and NUR-77 levels. Dexamethasone 91-94 BCL2 apoptosis regulator Homo sapiens 20-25 9850737-8 1998 These results demonstrate that prolonged in vitro treatment of H9 lymphoma cells with AZT results in the development of resistance to antitumor agents in association with inhibition of apoptosis and increased expression of bcl-2. Zidovudine 86-89 BCL2 apoptosis regulator Homo sapiens 223-228 9885901-7 1998 Furthermore, Bcl-2 prevented Dex-induced RelA-p50 activation. Dexamethasone 29-32 BCL2 apoptosis regulator Homo sapiens 13-18 9885901-8 1998 However, a higher gene dosage of the transgenic Bcl-2 was required for protection against Dex, compared to the PMA and/or ionomycin-induced apoptosis. Dexamethasone 90-93 BCL2 apoptosis regulator Homo sapiens 48-53 9855633-7 1998 Similarly, pramipexole pretreatment increased Bcl-2 and inhibited MPP+-induced apoptosis. Pramipexole 11-22 BCL2 apoptosis regulator Homo sapiens 46-51 9855631-11 1998 Overexpression of bcl-2 decreased the toxicity and DNA fragmentation produced by the combination of CYP2E1 plus Fe-NTA, as did a peptide inhibitor of caspase 3. ferric nitrilotriacetate 112-118 BCL2 apoptosis regulator Homo sapiens 18-23 9855633-9 1998 On the other hand, N6,2"-O-dibutyryl cAMP or calphostin C induced a decreased Bcl-2 level and enhanced MPP+-induced cell death. Bucladesine 19-41 BCL2 apoptosis regulator Homo sapiens 78-83 9855633-5 1998 The talipexole pretreatment induced an increase in antiapoptotic Bcl-2 protein level but had no effect on levels of proapoptotic Bax, Bak, and Bad. talipexole 4-14 BCL2 apoptosis regulator Homo sapiens 65-70 9855633-9 1998 On the other hand, N6,2"-O-dibutyryl cAMP or calphostin C induced a decreased Bcl-2 level and enhanced MPP+-induced cell death. calphostin C 45-57 BCL2 apoptosis regulator Homo sapiens 78-83 9855633-10 1998 These results suggest that talipexole has dual actions: (1) it directly scavenges ROS, affording slight protection against MPP+-induced apoptosis, and (2) it induces Bcl-2 expression, thereby affording more potent protection, if it is administrated before MPP+. talipexole 27-37 BCL2 apoptosis regulator Homo sapiens 166-171 9840183-8 1998 Furthermore, the protective effect of overexpression of BCL2 was more pronounced after ara-C treatment than with radiation. Cytarabine 87-92 BCL2 apoptosis regulator Homo sapiens 56-60 12579733-0 1998 [Expression of bcl-2 gene in human trabecular cells induced by dexamethasone]. Dexamethasone 63-76 BCL2 apoptosis regulator Homo sapiens 15-20 12579733-1 1998 PURPOSE: To investigate the influence of dexamethasone on expression of bcl-2 gene in human trabecular cells. Dexamethasone 41-54 BCL2 apoptosis regulator Homo sapiens 72-77 12579733-4 1998 RESULTS: The positive cells of the bcl-2 protein could be identified after dexamethasone effected for 6 hours and the positive cell increased with time going on. Dexamethasone 75-88 BCL2 apoptosis regulator Homo sapiens 35-40 12579733-5 1998 CONCLUSION: The expression of bcl-2 gene can be induced by dexamethasone, it may be related with glaucomatic pathogenesis. Dexamethasone 59-72 BCL2 apoptosis regulator Homo sapiens 30-35 9840917-4 1998 Jurkat cell transformants that overexpress Bcl-2 were partially but not completely resistant to the Fas-induced apoptosis. ammonium ferrous sulfate 100-103 BCL2 apoptosis regulator Homo sapiens 43-48 10081494-0 1998 EAT/mcl-1, a member of the bcl-2 related genes, confers resistance to apoptosis induced by cis-diammine dichloroplatinum (II) via a p53-independent pathway. Cisplatin 91-120 BCL2 apoptosis regulator Homo sapiens 27-32 9828101-0 1998 Brefeldin A-mediated apoptosis requires the activation of caspases and is inhibited by Bcl-2. Brefeldin A 0-11 BCL2 apoptosis regulator Homo sapiens 87-92 9828101-9 1998 Furthermore, Jurkat cells transfected with the proto-oncoprotein Bcl-2, which is able to block various apoptotic conditions, showed remarkable resistance to the apoptotic effect of BFA. Brefeldin A 181-184 BCL2 apoptosis regulator Homo sapiens 65-70 9828101-10 1998 Thus, the data indicate that BFA-induced apoptosis requires caspase(s) activation, primarily the activation of caspase-3, and is inhibited by overexpression of Bcl-2. Brefeldin A 29-32 BCL2 apoptosis regulator Homo sapiens 160-165 9813055-0 1998 Nitric oxide suppression of apoptosis occurs in association with an inhibition of Bcl-2 cleavage and cytochrome c release. Nitric Oxide 0-12 BCL2 apoptosis regulator Homo sapiens 82-87 9813055-5 1998 Both Bcl-2 cleavage and cytochrome c release were inhibited in tumor necrosis factor alpha- and actinomycin D-treated MCF-7 cells exposed to NO donors. Dactinomycin 96-109 BCL2 apoptosis regulator Homo sapiens 5-10 9840917-7 1998 These results suggest that Bcl-2 inhibits Fas-induced apoptosis by preventing the formation of the death-inducing signaling complex that is composed of Fas, FADD/MORT1, and caspase 8. ammonium ferrous sulfate 42-45 BCL2 apoptosis regulator Homo sapiens 27-32 9891541-0 1998 p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy. Platinum 89-97 BCL2 apoptosis regulator Homo sapiens 8-13 9808574-1 1998 Flavopiridol has been reported to induce apoptosis in lymphoid cell lines via downregulation of bcl-2. alvocidib 0-12 BCL2 apoptosis regulator Homo sapiens 96-101 9804769-0 1998 A splicing variant of the Bcl-2 member Bok with a truncated BH3 domain induces apoptosis but does not dimerize with antiapoptotic Bcl-2 proteins in vitro. BH 3 60-63 BCL2 apoptosis regulator Homo sapiens 26-31 9929161-1 1998 bcl-2 expression was examined on paraffin-embedded specimens in proliferative, hyperplastic, and neoplastic human endometrium by immunohistochemistry. Paraffin 33-41 BCL2 apoptosis regulator Homo sapiens 0-5 9806739-2 1998 Bronchial submucosa from steroid- untreated asthmatics showed an increase in the number of eosinophils and a decrease in that of apoptotic cells compared with that of control subjects, but no significant changes in the number of T lymphocytes or in that of cells expressing Bcl-2, Fas, or FasL. Steroids 25-32 BCL2 apoptosis regulator Homo sapiens 274-279 9806739-4 1998 Compared with control subjects or untreated patients, steroid-treated asthmatics exhibited increased expression of Bcl-2, Fas, FasL, and of proliferating cell nuclear antigen (PCNA) in their bronchial epithelium, without changes in the number of apoptotic cells. Steroids 54-61 BCL2 apoptosis regulator Homo sapiens 115-120 9806739-7 1998 Treatment with steroids may also augment survival and proliferation of epithelial cells, possibly via the expression of Bcl-2 and PCNA. Steroids 15-23 BCL2 apoptosis regulator Homo sapiens 120-125 9804855-0 1998 Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. Paclitaxel 74-79 BCL2 apoptosis regulator Homo sapiens 27-32 9804855-4 1998 We found that paclitaxel (Taxol(R)) treatment of epithelial tumor cells induced a prolonged mitotic arrest, elevated levels of mitotic kinase activity, hyperphosphorylation of Bcl-2, and subsequent cell death. Paclitaxel 14-24 BCL2 apoptosis regulator Homo sapiens 176-181 9804855-4 1998 We found that paclitaxel (Taxol(R)) treatment of epithelial tumor cells induced a prolonged mitotic arrest, elevated levels of mitotic kinase activity, hyperphosphorylation of Bcl-2, and subsequent cell death. Paclitaxel 26-31 BCL2 apoptosis regulator Homo sapiens 176-181 9804855-5 1998 The Taxol-induced Bcl-2 phosphorylation was dose-dependent. Paclitaxel 4-9 BCL2 apoptosis regulator Homo sapiens 18-23 9804855-6 1998 Furthermore, phosphorylated Bcl-2 remained complexed with Bax in Taxol-treated cells undergoing apoptosis. Paclitaxel 65-70 BCL2 apoptosis regulator Homo sapiens 28-33 9846203-0 1998 Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53. Progesterone 0-12 BCL2 apoptosis regulator Homo sapiens 94-99 9846632-15 1998 In MCF-7 cell cultures treated with 1,25(OH)2D3 or EB1089 (1 x 10(-8) M), bcl-2 protein levels were decreased in a time-dependent manner relative to control levels. Calcitriol 36-47 BCL2 apoptosis regulator Homo sapiens 74-79 9809975-3 1998 However, we have found that several early paclitaxel-mediated events are enhanced in SW626 transfectants that overexpress BAX, including G2-M-phase arrest, tubulin polymerization, and BCL-2 phosphorylation. Paclitaxel 42-52 BCL2 apoptosis regulator Homo sapiens 184-189 9846632-17 1998 Densitometric analyses indicate that the vitamin D compounds lower the bcl-2/bax ratio favouring increased susceptibility of MCF-7 cells to undergo apoptosis. Vitamin D 41-50 BCL2 apoptosis regulator Homo sapiens 71-76 9829730-14 1998 In contrast, low expression of the apoptosis inhibitor Bcl-2 was associated with response to TPT therapy. Topotecan 93-96 BCL2 apoptosis regulator Homo sapiens 55-60 9829750-12 1998 The correlation between drug efficacy and Bcl-2 phosphorylation may underly a peculiar feature related to improvement of efficacy of the disaccharide analogue. Disaccharides 137-149 BCL2 apoptosis regulator Homo sapiens 42-47 9808050-8 1998 In TF1-bcl2 cells, this protein was not detected after GM-CSF depletion or MMS treatment, but was observed after sphingosine treatment. Sphingosine 113-124 BCL2 apoptosis regulator Homo sapiens 3-11 19003419-12 1998 However, the bcl-2 transfected cells exhibited resistance to the osmotic stress resulting in long term adaptation to a high salt environment. Salts 124-128 BCL2 apoptosis regulator Homo sapiens 13-18 9808050-10 1998 These results suggest that sphingosine is a unique reagent for apoptosis and that it can overcome bcl-2 gene expression. Sphingosine 27-38 BCL2 apoptosis regulator Homo sapiens 98-103 9808050-0 1998 Analysis of bax protein in sphingosine-induced apoptosis in the human leukemic cell line TF1 and its bcl-2 transfectants. Sphingosine 27-38 BCL2 apoptosis regulator Homo sapiens 101-106 9808050-2 1998 In this study, we examined the effect of sphingosine in bcl-2-overexpressing cells compared with cells that do not express the bcl-2 gene. Sphingosine 41-52 BCL2 apoptosis regulator Homo sapiens 56-61 9808050-12 1998 Sphingosine, but not ceramide, may prove applicable as a reagent for future cytotoxic drugs used to treat intractable tumors overexpressing bcl-2. Sphingosine 0-11 BCL2 apoptosis regulator Homo sapiens 140-145 9808050-4 1998 In contrast, bcl-2 transfectants of TF1 (TF1-bcl2), which we established, were resistant to most of these treatments but remained sensitive to sphingosine. Sphingosine 143-154 BCL2 apoptosis regulator Homo sapiens 13-18 9808050-4 1998 In contrast, bcl-2 transfectants of TF1 (TF1-bcl2), which we established, were resistant to most of these treatments but remained sensitive to sphingosine. Sphingosine 143-154 BCL2 apoptosis regulator Homo sapiens 41-49 9766529-7 1998 Activation of CPP32 activity, PARP (a DNA repair enzyme) degradation, and release of cytochrome c from mitochondria to the cytosol are involved in arsenite-induced apoptosis, and Bcl-2 antagonize arsenite-induced apoptosis by a mechanism that interferes in the activity of CPP32. arsenite 147-155 BCL2 apoptosis regulator Homo sapiens 179-184 10023317-0 1998 Genistein inactivates bcl-2, delays the G2/M phase of the cell cycle, and induces apoptosis of human breast adenocarcinoma MCF-7 cells. Genistein 0-9 BCL2 apoptosis regulator Homo sapiens 22-27 9804146-14 1998 Treatment of RPE cells with 100 microM flupirtine gluconate for 72 hours caused an upregulation of the proto-oncogene protein Bcl-2 and a decrease in TIAR and ICH-1L proteins compared with that in control cells. Flupirtine gluconate 39-59 BCL2 apoptosis regulator Homo sapiens 126-131 9766529-7 1998 Activation of CPP32 activity, PARP (a DNA repair enzyme) degradation, and release of cytochrome c from mitochondria to the cytosol are involved in arsenite-induced apoptosis, and Bcl-2 antagonize arsenite-induced apoptosis by a mechanism that interferes in the activity of CPP32. arsenite 196-204 BCL2 apoptosis regulator Homo sapiens 179-184 9779827-0 1998 Evidence of a direct role for Bcl-2 in the regulation of articular chondrocyte apoptosis under the conditions of serum withdrawal and retinoic acid treatment. Tretinoin 134-147 BCL2 apoptosis regulator Homo sapiens 30-35 9779827-2 1998 Here we demonstrate the importance of Bcl-2 in regulating articular chondrocyte apoptosis in response to both serum withdrawal and retinoic acid treatment. Tretinoin 131-144 BCL2 apoptosis regulator Homo sapiens 38-43 9840719-0 1998 Bcl-2 expression correlates with apoptosis induction but not loss of clonogenic survival in small cell lung cancer cell lines treated with etoposide. Etoposide 139-148 BCL2 apoptosis regulator Homo sapiens 0-5 9779827-8 1998 In contrast, chondrocytes overexpressing Bcl-2 were resistant to apoptosis induced by both serum withdrawal and retinoic acid treatment. Tretinoin 112-125 BCL2 apoptosis regulator Homo sapiens 41-46 9823934-8 1998 Bcl-2 was constitutively expressed on unstimulated PBLs, but its expression was significantly augmented by IL-2 or PMA plus ionomycin. Ionomycin 124-133 BCL2 apoptosis regulator Homo sapiens 0-5 9823934-11 1998 The resistance of these activated PBLs to Fas-mediated apoptosis may be due to the augmented Bcl-2 expression or the presence of Bcl-2:Bax heterodimers on these cells. ammonium ferrous sulfate 42-45 BCL2 apoptosis regulator Homo sapiens 93-98 9783811-0 1998 Further characterization of cyclophosphamide resistance: expression of CD95 and of bcl-2 in a CML cell line. Cyclophosphamide 28-44 BCL2 apoptosis regulator Homo sapiens 83-88 9788433-3 1998 In particular, the relation between Bcl-2 and the endoplasmic reticulum (ER) calcium store is not well-understood. Calcium 77-84 BCL2 apoptosis regulator Homo sapiens 36-41 9823951-0 1998 Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression. ammonium ferrous sulfate 15-18 BCL2 apoptosis regulator Homo sapiens 137-142 9823951-3 1998 We therefore investigated the relationship between sensitivity to Fas-mediated apoptosis and (1) Fas expression, (2) p53 status, and (3) Bcl-2 protein levels in pediatric ALL cell lines and primary leukemic cells. ammonium ferrous sulfate 66-69 BCL2 apoptosis regulator Homo sapiens 137-142 9823951-13 1998 Sensitivity to Fas-mediated apoptosis was associated with a mt-p53 phenotype and absence of Bcl-2 expression. ammonium ferrous sulfate 15-18 BCL2 apoptosis regulator Homo sapiens 92-97 9825701-6 1998 The elimination of cyclobutane pyrimidine dimers through photoreactivation 24 h after irradiation in cells overexpressing Bcl-2 did not affect apoptosis. cyclobutane pyrimidine 19-41 BCL2 apoptosis regulator Homo sapiens 122-127 9825701-7 1998 This indicates that irreversible events in the signaling pathway of apoptosis occur in the period between irradiation and photoreactivation even in the presence of high levels of Bcl-2 protein can delay the onset of UV-induced apoptosis in these marsupial cells, early events triggered by the pyrimidine dimers, upstream from the Bcl-2 action, lead the cell to a state committed to die. pyrimidine 293-303 BCL2 apoptosis regulator Homo sapiens 179-184 10437144-0 1998 Quercetin down-regulated bcl-2 gene expression in human leukemia HL-60 cells. Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 25-30 10437144-1 1998 AIM: To study the effect of quercetin (Que) on bcl-2 gene expression in human leukemia HL-60 cells. Quercetin 28-37 BCL2 apoptosis regulator Homo sapiens 47-52 10437144-1 1998 AIM: To study the effect of quercetin (Que) on bcl-2 gene expression in human leukemia HL-60 cells. Quercetin 39-42 BCL2 apoptosis regulator Homo sapiens 47-52 9811453-0 1998 Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity. GL 331 42-47 BCL2 apoptosis regulator Homo sapiens 0-5 9811453-6 1998 The fact that Bcl-2 has been found to antagonize cell death induced by a wide variety of agents, accounts for why we examined whether if Bcl-2 could antagonize GL331 effects. GL 331 160-165 BCL2 apoptosis regulator Homo sapiens 137-142 9811453-7 1998 Interestingly, ectopic overexpression of Bcl-2 in either HL-60 or U937 cells caused in resistance towards GL331-elicited DNA fragmentation and cytotoxic effect. GL 331 106-111 BCL2 apoptosis regulator Homo sapiens 41-46 9811453-8 1998 Additionally, Bcl-2 also attenuated the poly(ADP-ribosyl)ation of PARP itself as well as Histone H1 at the early period of drug treatment. poly(adp-ribosyl) 40-57 BCL2 apoptosis regulator Homo sapiens 14-19 9790773-3 1998 BH3 is required for BID to interact with BCL-2 and BAX, as well as for its function as a death agonist. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 41-46 9756506-0 1998 Glutathione depletion is associated with decreased Bcl-2 expression and increased apoptosis in cholangiocytes. Glutathione 0-11 BCL2 apoptosis regulator Homo sapiens 51-56 9756506-10 1998 Maintenance of GSH levels by addition of glutathione ethyl ester in the presence of BSO blocked the BSO-associated increase in apoptosis in BSO-treated cholangiocytes and also prevented the decrease in Bcl-2 protein. Glutathione 15-18 BCL2 apoptosis regulator Homo sapiens 202-207 9756506-10 1998 Maintenance of GSH levels by addition of glutathione ethyl ester in the presence of BSO blocked the BSO-associated increase in apoptosis in BSO-treated cholangiocytes and also prevented the decrease in Bcl-2 protein. S-ethyl glutathione 41-64 BCL2 apoptosis regulator Homo sapiens 202-207 9756506-13 1998 Our results using a human cholangiocyte cell line demonstrate that reduction in the cellular levels of an antioxidant such as GSH results in increased degradation of Bcl-2 protein and an increase in apoptosis. Glutathione 126-129 BCL2 apoptosis regulator Homo sapiens 166-171 9840719-1 1998 The influence of bcl-2 oncogene expression on etoposide-induced apoptosis and clonogenic survival was investigated in five small cell lung cancer (SCLC) cell lines, three of which were bcl-2-expressing and two of which were non-bcl-2-expressing. Etoposide 46-55 BCL2 apoptosis regulator Homo sapiens 17-22 9840719-3 1998 When bcl-2-expressing cells were incubated in cystine/ methionine-free (CMF) medium, etoposide-induced apoptosis was restored to levels comparable to those seen in non-bcl-2-expressing lines. Cystine 46-53 BCL2 apoptosis regulator Homo sapiens 5-10 9840719-3 1998 When bcl-2-expressing cells were incubated in cystine/ methionine-free (CMF) medium, etoposide-induced apoptosis was restored to levels comparable to those seen in non-bcl-2-expressing lines. Methionine 55-65 BCL2 apoptosis regulator Homo sapiens 5-10 9840719-3 1998 When bcl-2-expressing cells were incubated in cystine/ methionine-free (CMF) medium, etoposide-induced apoptosis was restored to levels comparable to those seen in non-bcl-2-expressing lines. Etoposide 85-94 BCL2 apoptosis regulator Homo sapiens 5-10 9820586-0 1998 Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5"-NT and Bax/Bcl-2. bryostatin 1 51-63 BCL2 apoptosis regulator Homo sapiens 186-191 9792140-0 1998 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Fluorouracil 0-14 BCL2 apoptosis regulator Homo sapiens 85-90 9792140-3 1998 We sought to determine the roles played by the p53 and Bcl-2 family of proteins in 5-fluorouracil (5-FU)-induced apoptosis of human colon cancer cell lines. Fluorouracil 83-97 BCL2 apoptosis regulator Homo sapiens 55-60 9792140-3 1998 We sought to determine the roles played by the p53 and Bcl-2 family of proteins in 5-fluorouracil (5-FU)-induced apoptosis of human colon cancer cell lines. Fluorouracil 99-103 BCL2 apoptosis regulator Homo sapiens 55-60 9792140-11 1998 In cells containing wild-type p53 (e.g. LoVo), 5-FU-induced apoptosis was accompanied by increased expression of Bax and Bak without consistent modulation of other bcl-2 family proteins. Fluorouracil 47-51 BCL2 apoptosis regulator Homo sapiens 164-169 9792140-14 1998 In conclusion, these results suggest that some members of the Bcl-2 family of proteins, in human colon cancer cell lines, are modulated by 5-FU and that the ratio of Bcl-X(L) to Bax may be related to chemosensitivity to 5-FU. Fluorouracil 139-143 BCL2 apoptosis regulator Homo sapiens 62-67 9792140-14 1998 In conclusion, these results suggest that some members of the Bcl-2 family of proteins, in human colon cancer cell lines, are modulated by 5-FU and that the ratio of Bcl-X(L) to Bax may be related to chemosensitivity to 5-FU. Fluorouracil 220-224 BCL2 apoptosis regulator Homo sapiens 62-67 9820586-8 1998 WSU-CLL cells treated with bryostatin 1 showed a significant increase in the ratio of Bax to Bcl-2. bryostatin 1 27-39 BCL2 apoptosis regulator Homo sapiens 93-98 9820586-12 1998 The bryostatin 1-induced increased ratio of dCK/5"-NT activity and an increased ratio of Bax/Bcl-2 are at least two mechanisms through which this natural compound is able to potentiate the anti-tumor activity of 2-CdA in otherwise resistant CLL cells. bryostatin 1 4-16 BCL2 apoptosis regulator Homo sapiens 93-98 9840719-3 1998 When bcl-2-expressing cells were incubated in cystine/ methionine-free (CMF) medium, etoposide-induced apoptosis was restored to levels comparable to those seen in non-bcl-2-expressing lines. Etoposide 85-94 BCL2 apoptosis regulator Homo sapiens 168-173 9792147-0 1998 Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Oligodeoxyribonucleotides 44-65 BCL2 apoptosis regulator Homo sapiens 28-33 9792147-0 1998 Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Doxorubicin 81-92 BCL2 apoptosis regulator Homo sapiens 28-33 9840719-5 1998 In addition, treatment of the two bcl-2-expressing cell lines with etoposide in CMF medium did not modify their clonogenic survival curves compared to treatment in regular medium. Etoposide 67-76 BCL2 apoptosis regulator Homo sapiens 34-39 9792147-2 1998 In the present study, the interactions between the bcl-2 antisense oligodeoxynucleotide 2009 and the chemotherapeutic agents etoposide, doxorubicin and cisplatin were investigated on small-cell lung cancer cell lines to search for synergistic combinations. Oligodeoxyribonucleotides 67-87 BCL2 apoptosis regulator Homo sapiens 51-56 9840719-6 1998 These results are consistent with the idea that bcl-2 expression modulates etoposide-induced apoptosis but not clonogenic survival. Etoposide 75-84 BCL2 apoptosis regulator Homo sapiens 48-53 9792147-2 1998 In the present study, the interactions between the bcl-2 antisense oligodeoxynucleotide 2009 and the chemotherapeutic agents etoposide, doxorubicin and cisplatin were investigated on small-cell lung cancer cell lines to search for synergistic combinations. Etoposide 125-134 BCL2 apoptosis regulator Homo sapiens 51-56 9792147-2 1998 In the present study, the interactions between the bcl-2 antisense oligodeoxynucleotide 2009 and the chemotherapeutic agents etoposide, doxorubicin and cisplatin were investigated on small-cell lung cancer cell lines to search for synergistic combinations. Doxorubicin 136-147 BCL2 apoptosis regulator Homo sapiens 51-56 9766678-2 1998 We investigated the sequence of these events in SHEP neuroblastoma cells transfected with Bcl-2 or Bcl-X(L) using two different drugs, namely, doxorubicin (Doxo), which activates the CD95/CD95 ligand (CD95-L) system, and betulinic acid (Bet A), which does not enhance the expression of CD95 or CD95-L and which, as shown here, directly targets mitochondria. Doxorubicin 143-154 BCL2 apoptosis regulator Homo sapiens 90-95 9792147-2 1998 In the present study, the interactions between the bcl-2 antisense oligodeoxynucleotide 2009 and the chemotherapeutic agents etoposide, doxorubicin and cisplatin were investigated on small-cell lung cancer cell lines to search for synergistic combinations. Cisplatin 152-161 BCL2 apoptosis regulator Homo sapiens 51-56 9792147-3 1998 The cell lines NCI-H69, SW2 and NCI-H82 express high, intermediate-high and low basal levels of Bcl-2, respectively, which are inversely correlated with the sensitivities of the cell lines to treatment with oligodeoxynucleotide 2009 and the chemotherapeutic agents alone. Oligodeoxyribonucleotides 207-227 BCL2 apoptosis regulator Homo sapiens 96-101 9835862-8 1998 In the cases associated with the t(14;18) (q32;q21) chromosomal translocation, the bcl-2/JH junctional regions are amplified by PCR in approximately equal to 50% of cases and then sequenced in order to synthesize an anti-junction oligonucleotide probe specific for each patient"s malignant clone (clonospecific probe). Oligonucleotides 230-245 BCL2 apoptosis regulator Homo sapiens 83-88 9766645-0 1998 NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 0-5 BCL2 apoptosis regulator Homo sapiens 84-89 9766645-4 1998 Treatment with 100 microM NS398 caused a down-regulation in bcl-2 protein expression, followed by chromatin condensation, chromosomal DNA fragmentation, and changes in nuclear morphology detected by 4,6-diamidino-2-phenylindole staining, DNA fragmentation assay, and terminal deoxynucleotidyl transferase-mediated UTP-biotin nick end-labeling assay. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 26-31 BCL2 apoptosis regulator Homo sapiens 60-65 9766678-2 1998 We investigated the sequence of these events in SHEP neuroblastoma cells transfected with Bcl-2 or Bcl-X(L) using two different drugs, namely, doxorubicin (Doxo), which activates the CD95/CD95 ligand (CD95-L) system, and betulinic acid (Bet A), which does not enhance the expression of CD95 or CD95-L and which, as shown here, directly targets mitochondria. Doxorubicin 156-160 BCL2 apoptosis regulator Homo sapiens 90-95 9762907-0 1998 Okadaic acid-induced apoptosis of HL60 leukemia cells is preceded by destabilization of bcl-2 mRNA and downregulation of bcl-2 protein. Okadaic Acid 0-12 BCL2 apoptosis regulator Homo sapiens 88-93 10203695-3 1998 Here, we report that caspase 8 and 3 activation, poly(ADP-ribose)polymerase cleavage and apoptosis are inhibited by the lipoxygenase inhibitor, nordihydroguaretic acid (NDGA), or ectopic expression of crm-A or bcl-2. Masoprocol 144-167 BCL2 apoptosis regulator Homo sapiens 210-215 10203695-3 1998 Here, we report that caspase 8 and 3 activation, poly(ADP-ribose)polymerase cleavage and apoptosis are inhibited by the lipoxygenase inhibitor, nordihydroguaretic acid (NDGA), or ectopic expression of crm-A or bcl-2. Masoprocol 169-173 BCL2 apoptosis regulator Homo sapiens 210-215 10203695-5 1998 Apoptosis induced by exogenous ceramide resembles CD95-mediated apoptosis in that bcl-2 is protective but differs in that NDGA and crm-A have no effect and in that cycloheximide (CHX) inhibits rather than potentiates ceramide-induced cell death. Ceramides 31-39 BCL2 apoptosis regulator Homo sapiens 82-87 9735392-0 1998 Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein. Serine 97-103 BCL2 apoptosis regulator Homo sapiens 37-41 9735392-0 1998 Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein. Serine 97-103 BCL2 apoptosis regulator Homo sapiens 133-137 9735392-0 1998 Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein. Serine 111-117 BCL2 apoptosis regulator Homo sapiens 37-41 9735392-0 1998 Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein. Serine 111-117 BCL2 apoptosis regulator Homo sapiens 133-137 9735392-1 1998 Specifically anti-microtubule agents such as taxol, vincristine, vinblastine and dolastatin can trigger Bcl2 phosphorylation at G2-M phase of the cell cycle in malignant cells derived from a variety of human cancers. Paclitaxel 45-50 BCL2 apoptosis regulator Homo sapiens 104-108 9735392-1 1998 Specifically anti-microtubule agents such as taxol, vincristine, vinblastine and dolastatin can trigger Bcl2 phosphorylation at G2-M phase of the cell cycle in malignant cells derived from a variety of human cancers. Vincristine 52-63 BCL2 apoptosis regulator Homo sapiens 104-108 9735392-1 1998 Specifically anti-microtubule agents such as taxol, vincristine, vinblastine and dolastatin can trigger Bcl2 phosphorylation at G2-M phase of the cell cycle in malignant cells derived from a variety of human cancers. Vinblastine 65-76 BCL2 apoptosis regulator Homo sapiens 104-108 9735392-1 1998 Specifically anti-microtubule agents such as taxol, vincristine, vinblastine and dolastatin can trigger Bcl2 phosphorylation at G2-M phase of the cell cycle in malignant cells derived from a variety of human cancers. 2-[[2-(dimethylamino)-3-methylbutanoyl]amino]-N-[4-methoxy-6-[2-[1-methoxy-2-methyl-3-oxo-3-[[2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-2-methyl-6-oxohexan-3-yl]-N,3-dimethylbutanamide 81-91 BCL2 apoptosis regulator Homo sapiens 104-108 9735392-2 1998 In this study, the status of Bcl2 phosphorylation was investigated in response to more antimicrotubule agents such as colchicine, colcemid or podophyllotoxin. Colchicine 118-128 BCL2 apoptosis regulator Homo sapiens 29-33 9735392-2 1998 In this study, the status of Bcl2 phosphorylation was investigated in response to more antimicrotubule agents such as colchicine, colcemid or podophyllotoxin. Demecolcine 130-138 BCL2 apoptosis regulator Homo sapiens 29-33 9735392-2 1998 In this study, the status of Bcl2 phosphorylation was investigated in response to more antimicrotubule agents such as colchicine, colcemid or podophyllotoxin. Podophyllotoxin 142-157 BCL2 apoptosis regulator Homo sapiens 29-33 9735392-5 1998 Studies reported here clearly indicate that serine-87 residue along with serine-70 of Bcl2 protein are necessary for microtubule damaging drug induced phosphorylation. Serine 44-50 BCL2 apoptosis regulator Homo sapiens 86-90 9735392-5 1998 Studies reported here clearly indicate that serine-87 residue along with serine-70 of Bcl2 protein are necessary for microtubule damaging drug induced phosphorylation. Serine 73-79 BCL2 apoptosis regulator Homo sapiens 86-90 9735415-0 1998 Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Paclitaxel 54-64 BCL2 apoptosis regulator Homo sapiens 0-5 9735415-15 1998 GEM and TAX act synergistically, at low doses (IC50 of 0.5 microM for GEM and 0.025 microM for TAX), to effectively kill bcl-2 overexpressing cells that are resistant to higher doses (0.25 microM) of TAX alone. gemcitabine 0-3 BCL2 apoptosis regulator Homo sapiens 121-126 11819336-1 1998 AIM:To compare the expression level of Fas gene and Bcl-2 gene in gastric cancer cells SGC7901 and gastric cancer MDR (multidrug resistant) cells SGC7901/VCR,to transduce Fas cDNA and Bcl-2 antisense nucleic acid into SGC7901/VCR cells respectively, and to observe the expression of two genes in transfectants and non-transfectants as well as their drug sensitivity.METHODS:Eukaryotic expression vector pBK-Fas cDNA and pDOR-anti Bcl-2 were constructed and transfected into SGC7901/VCR cells by lipofectamine,respectively.Northern blot and Western blot were used to detect the expression of mRNA and protein in SGC7901/VCR and SGC7901 cells and transfectants, and drug sensitivity of transfectants for VCR, CDDP and 5-FU was analyzed with MTT assay.RESULTS:After gene transfection, 80 for Fas and 120 for antisense Bcl-2 drug-resistant clones were selected from 2 X10(5) cells, transfection rate being 0.04% and 0.06%. ammonium ferrous sulfate 39-42 BCL2 apoptosis regulator Homo sapiens 184-189 11819336-1 1998 AIM:To compare the expression level of Fas gene and Bcl-2 gene in gastric cancer cells SGC7901 and gastric cancer MDR (multidrug resistant) cells SGC7901/VCR,to transduce Fas cDNA and Bcl-2 antisense nucleic acid into SGC7901/VCR cells respectively, and to observe the expression of two genes in transfectants and non-transfectants as well as their drug sensitivity.METHODS:Eukaryotic expression vector pBK-Fas cDNA and pDOR-anti Bcl-2 were constructed and transfected into SGC7901/VCR cells by lipofectamine,respectively.Northern blot and Western blot were used to detect the expression of mRNA and protein in SGC7901/VCR and SGC7901 cells and transfectants, and drug sensitivity of transfectants for VCR, CDDP and 5-FU was analyzed with MTT assay.RESULTS:After gene transfection, 80 for Fas and 120 for antisense Bcl-2 drug-resistant clones were selected from 2 X10(5) cells, transfection rate being 0.04% and 0.06%. ammonium ferrous sulfate 39-42 BCL2 apoptosis regulator Homo sapiens 184-189 11819336-1 1998 AIM:To compare the expression level of Fas gene and Bcl-2 gene in gastric cancer cells SGC7901 and gastric cancer MDR (multidrug resistant) cells SGC7901/VCR,to transduce Fas cDNA and Bcl-2 antisense nucleic acid into SGC7901/VCR cells respectively, and to observe the expression of two genes in transfectants and non-transfectants as well as their drug sensitivity.METHODS:Eukaryotic expression vector pBK-Fas cDNA and pDOR-anti Bcl-2 were constructed and transfected into SGC7901/VCR cells by lipofectamine,respectively.Northern blot and Western blot were used to detect the expression of mRNA and protein in SGC7901/VCR and SGC7901 cells and transfectants, and drug sensitivity of transfectants for VCR, CDDP and 5-FU was analyzed with MTT assay.RESULTS:After gene transfection, 80 for Fas and 120 for antisense Bcl-2 drug-resistant clones were selected from 2 X10(5) cells, transfection rate being 0.04% and 0.06%. ammonium ferrous sulfate 39-42 BCL2 apoptosis regulator Homo sapiens 184-189 9893665-6 1998 TBZ seems to act in the presence of P-glycoprotein and Bcl-2 and in the absence of p53 and is able to circumvent the mechanisms of drug resistance and anti-apoptosis present in HL60R cells. 1-(2',6'-difluorophenyl)-1H,3H-thiazolo(3,4-a)benzimidazole 0-3 BCL2 apoptosis regulator Homo sapiens 55-60 9796922-8 1998 The observed protection from Dex-induced apoptosis correlated with an increase in bcl-2 protein levels. Dexamethasone 29-32 BCL2 apoptosis regulator Homo sapiens 82-87 9821074-5 1998 The constant expression of bcl-2 i early dysplastic cells of BD and the earliest expression of P53 in the basal cells of perilesional normal skin indicate that the initial step of arsenic-induced carcinogenesis is from the basal germinative cells. Arsenic 180-187 BCL2 apoptosis regulator Homo sapiens 27-32 9751192-5 1998 Inhibition of NO production in astrocytes by N(G)-monomethyl-L-arginine, an inhibitor of NOS, significantly inhibited neuronal death together with changes in Bcl-2 and Bax protein levels and in caspase-3-like activity. omega-N-Methylarginine 45-71 BCL2 apoptosis regulator Homo sapiens 158-163 9771754-3 1998 We have reported that transgenic mice expressing human Bcl-2 in their hepatocytes are protected from Fas/CD95-mediated liver apoptosis. ammonium ferrous sulfate 101-104 BCL2 apoptosis regulator Homo sapiens 55-60 11819336-1 1998 AIM:To compare the expression level of Fas gene and Bcl-2 gene in gastric cancer cells SGC7901 and gastric cancer MDR (multidrug resistant) cells SGC7901/VCR,to transduce Fas cDNA and Bcl-2 antisense nucleic acid into SGC7901/VCR cells respectively, and to observe the expression of two genes in transfectants and non-transfectants as well as their drug sensitivity.METHODS:Eukaryotic expression vector pBK-Fas cDNA and pDOR-anti Bcl-2 were constructed and transfected into SGC7901/VCR cells by lipofectamine,respectively.Northern blot and Western blot were used to detect the expression of mRNA and protein in SGC7901/VCR and SGC7901 cells and transfectants, and drug sensitivity of transfectants for VCR, CDDP and 5-FU was analyzed with MTT assay.RESULTS:After gene transfection, 80 for Fas and 120 for antisense Bcl-2 drug-resistant clones were selected from 2 X10(5) cells, transfection rate being 0.04% and 0.06%. Lipofectamine 495-508 BCL2 apoptosis regulator Homo sapiens 52-57 11819336-1 1998 AIM:To compare the expression level of Fas gene and Bcl-2 gene in gastric cancer cells SGC7901 and gastric cancer MDR (multidrug resistant) cells SGC7901/VCR,to transduce Fas cDNA and Bcl-2 antisense nucleic acid into SGC7901/VCR cells respectively, and to observe the expression of two genes in transfectants and non-transfectants as well as their drug sensitivity.METHODS:Eukaryotic expression vector pBK-Fas cDNA and pDOR-anti Bcl-2 were constructed and transfected into SGC7901/VCR cells by lipofectamine,respectively.Northern blot and Western blot were used to detect the expression of mRNA and protein in SGC7901/VCR and SGC7901 cells and transfectants, and drug sensitivity of transfectants for VCR, CDDP and 5-FU was analyzed with MTT assay.RESULTS:After gene transfection, 80 for Fas and 120 for antisense Bcl-2 drug-resistant clones were selected from 2 X10(5) cells, transfection rate being 0.04% and 0.06%. cddp 707-711 BCL2 apoptosis regulator Homo sapiens 52-57 11819336-1 1998 AIM:To compare the expression level of Fas gene and Bcl-2 gene in gastric cancer cells SGC7901 and gastric cancer MDR (multidrug resistant) cells SGC7901/VCR,to transduce Fas cDNA and Bcl-2 antisense nucleic acid into SGC7901/VCR cells respectively, and to observe the expression of two genes in transfectants and non-transfectants as well as their drug sensitivity.METHODS:Eukaryotic expression vector pBK-Fas cDNA and pDOR-anti Bcl-2 were constructed and transfected into SGC7901/VCR cells by lipofectamine,respectively.Northern blot and Western blot were used to detect the expression of mRNA and protein in SGC7901/VCR and SGC7901 cells and transfectants, and drug sensitivity of transfectants for VCR, CDDP and 5-FU was analyzed with MTT assay.RESULTS:After gene transfection, 80 for Fas and 120 for antisense Bcl-2 drug-resistant clones were selected from 2 X10(5) cells, transfection rate being 0.04% and 0.06%. Fluorouracil 716-720 BCL2 apoptosis regulator Homo sapiens 52-57 11819336-1 1998 AIM:To compare the expression level of Fas gene and Bcl-2 gene in gastric cancer cells SGC7901 and gastric cancer MDR (multidrug resistant) cells SGC7901/VCR,to transduce Fas cDNA and Bcl-2 antisense nucleic acid into SGC7901/VCR cells respectively, and to observe the expression of two genes in transfectants and non-transfectants as well as their drug sensitivity.METHODS:Eukaryotic expression vector pBK-Fas cDNA and pDOR-anti Bcl-2 were constructed and transfected into SGC7901/VCR cells by lipofectamine,respectively.Northern blot and Western blot were used to detect the expression of mRNA and protein in SGC7901/VCR and SGC7901 cells and transfectants, and drug sensitivity of transfectants for VCR, CDDP and 5-FU was analyzed with MTT assay.RESULTS:After gene transfection, 80 for Fas and 120 for antisense Bcl-2 drug-resistant clones were selected from 2 X10(5) cells, transfection rate being 0.04% and 0.06%. monooxyethylene trimethylolpropane tristearate 739-742 BCL2 apoptosis regulator Homo sapiens 52-57 11819336-1 1998 AIM:To compare the expression level of Fas gene and Bcl-2 gene in gastric cancer cells SGC7901 and gastric cancer MDR (multidrug resistant) cells SGC7901/VCR,to transduce Fas cDNA and Bcl-2 antisense nucleic acid into SGC7901/VCR cells respectively, and to observe the expression of two genes in transfectants and non-transfectants as well as their drug sensitivity.METHODS:Eukaryotic expression vector pBK-Fas cDNA and pDOR-anti Bcl-2 were constructed and transfected into SGC7901/VCR cells by lipofectamine,respectively.Northern blot and Western blot were used to detect the expression of mRNA and protein in SGC7901/VCR and SGC7901 cells and transfectants, and drug sensitivity of transfectants for VCR, CDDP and 5-FU was analyzed with MTT assay.RESULTS:After gene transfection, 80 for Fas and 120 for antisense Bcl-2 drug-resistant clones were selected from 2 X10(5) cells, transfection rate being 0.04% and 0.06%. ammonium ferrous sulfate 171-174 BCL2 apoptosis regulator Homo sapiens 52-57 11819336-1 1998 AIM:To compare the expression level of Fas gene and Bcl-2 gene in gastric cancer cells SGC7901 and gastric cancer MDR (multidrug resistant) cells SGC7901/VCR,to transduce Fas cDNA and Bcl-2 antisense nucleic acid into SGC7901/VCR cells respectively, and to observe the expression of two genes in transfectants and non-transfectants as well as their drug sensitivity.METHODS:Eukaryotic expression vector pBK-Fas cDNA and pDOR-anti Bcl-2 were constructed and transfected into SGC7901/VCR cells by lipofectamine,respectively.Northern blot and Western blot were used to detect the expression of mRNA and protein in SGC7901/VCR and SGC7901 cells and transfectants, and drug sensitivity of transfectants for VCR, CDDP and 5-FU was analyzed with MTT assay.RESULTS:After gene transfection, 80 for Fas and 120 for antisense Bcl-2 drug-resistant clones were selected from 2 X10(5) cells, transfection rate being 0.04% and 0.06%. ammonium ferrous sulfate 171-174 BCL2 apoptosis regulator Homo sapiens 184-189 11819336-1 1998 AIM:To compare the expression level of Fas gene and Bcl-2 gene in gastric cancer cells SGC7901 and gastric cancer MDR (multidrug resistant) cells SGC7901/VCR,to transduce Fas cDNA and Bcl-2 antisense nucleic acid into SGC7901/VCR cells respectively, and to observe the expression of two genes in transfectants and non-transfectants as well as their drug sensitivity.METHODS:Eukaryotic expression vector pBK-Fas cDNA and pDOR-anti Bcl-2 were constructed and transfected into SGC7901/VCR cells by lipofectamine,respectively.Northern blot and Western blot were used to detect the expression of mRNA and protein in SGC7901/VCR and SGC7901 cells and transfectants, and drug sensitivity of transfectants for VCR, CDDP and 5-FU was analyzed with MTT assay.RESULTS:After gene transfection, 80 for Fas and 120 for antisense Bcl-2 drug-resistant clones were selected from 2 X10(5) cells, transfection rate being 0.04% and 0.06%. ammonium ferrous sulfate 171-174 BCL2 apoptosis regulator Homo sapiens 184-189 11819336-1 1998 AIM:To compare the expression level of Fas gene and Bcl-2 gene in gastric cancer cells SGC7901 and gastric cancer MDR (multidrug resistant) cells SGC7901/VCR,to transduce Fas cDNA and Bcl-2 antisense nucleic acid into SGC7901/VCR cells respectively, and to observe the expression of two genes in transfectants and non-transfectants as well as their drug sensitivity.METHODS:Eukaryotic expression vector pBK-Fas cDNA and pDOR-anti Bcl-2 were constructed and transfected into SGC7901/VCR cells by lipofectamine,respectively.Northern blot and Western blot were used to detect the expression of mRNA and protein in SGC7901/VCR and SGC7901 cells and transfectants, and drug sensitivity of transfectants for VCR, CDDP and 5-FU was analyzed with MTT assay.RESULTS:After gene transfection, 80 for Fas and 120 for antisense Bcl-2 drug-resistant clones were selected from 2 X10(5) cells, transfection rate being 0.04% and 0.06%. ammonium ferrous sulfate 171-174 BCL2 apoptosis regulator Homo sapiens 184-189 9727009-8 1998 The Bcl-2-mediated loss of IkappaBalpha could be prevented by the proteasome inhibitor lactacystin, consistent with the notion that the targeted degradation of IkappaBalpha consequent to overexpression of Bcl-2 utilizes the ubiquitin-proteasome pathway. lactacystin 87-98 BCL2 apoptosis regulator Homo sapiens 4-9 9727009-8 1998 The Bcl-2-mediated loss of IkappaBalpha could be prevented by the proteasome inhibitor lactacystin, consistent with the notion that the targeted degradation of IkappaBalpha consequent to overexpression of Bcl-2 utilizes the ubiquitin-proteasome pathway. lactacystin 87-98 BCL2 apoptosis regulator Homo sapiens 205-210 9771966-3 1998 IL-2-induced DNA binding activity for these transcription factors is sensitive to phosphatidylinositol 3 kinase inhibitor wortmannin and to Rho inhibitor Clostridium difficile toxin B, which inhibit IL-2-induced Bcl-2 expression. Wortmannin 122-132 BCL2 apoptosis regulator Homo sapiens 212-217 9762907-0 1998 Okadaic acid-induced apoptosis of HL60 leukemia cells is preceded by destabilization of bcl-2 mRNA and downregulation of bcl-2 protein. Okadaic Acid 0-12 BCL2 apoptosis regulator Homo sapiens 121-126 9734474-8 1998 The levels of Bcl-2-associated Bax were increased after serum withdrawal and incubation with doxorubicin and were reduced by IGF I. Doxorubicin 93-104 BCL2 apoptosis regulator Homo sapiens 14-19 9762907-1 1998 We have studied the actions of the protein phosphatase inhibitor okadaic acid (OA) on the expression of bcl-2 in HL60 human leukemia cells. Okadaic Acid 65-77 BCL2 apoptosis regulator Homo sapiens 104-109 9762907-1 1998 We have studied the actions of the protein phosphatase inhibitor okadaic acid (OA) on the expression of bcl-2 in HL60 human leukemia cells. Okadaic Acid 79-81 BCL2 apoptosis regulator Homo sapiens 104-109 9716607-0 1998 Phosphorylation of BCL-2 after exposure of human leukemic cells to retinoic acid. Tretinoin 67-80 BCL2 apoptosis regulator Homo sapiens 19-24 9716607-3 1998 Two-dimension gels (isoelectric focusing followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis [SDS-PAGE]) disclosed a novel acidic isoform of bcl-2 in ATRA-treated blast cells from a continuous line and from two AML patients; when the cell lysates were digested with lambda-phosphatase, bcl-2 reverted to the control position, indicating that it was phosphorylated. Sodium Dodecyl Sulfate 112-115 BCL2 apoptosis regulator Homo sapiens 159-164 9716607-1 1998 Serine phosphorylation of bcl-2 has been reported after treatment of cells with protein kinase C, okadaic acid, taxol, and other chemotherapeutic agents that attack microtubules. Serine 0-6 BCL2 apoptosis regulator Homo sapiens 26-31 9716607-4 1998 Metabolic labeling experiments using 32Pi showed that, while control bcl-2 was labeled, incorporation was greatly increased when cells were treated with ATRA. Tretinoin 153-157 BCL2 apoptosis regulator Homo sapiens 69-74 9716607-5 1998 A comparison of bcl-2 from blasts treated with ATRA or taxol showed that bcl-2 was phosphorylated on serine in cells treated with either agent; however, both qualitative and quantitative differences were seen. Tretinoin 47-51 BCL2 apoptosis regulator Homo sapiens 16-21 9716607-5 1998 A comparison of bcl-2 from blasts treated with ATRA or taxol showed that bcl-2 was phosphorylated on serine in cells treated with either agent; however, both qualitative and quantitative differences were seen. Tretinoin 47-51 BCL2 apoptosis regulator Homo sapiens 73-78 9716607-1 1998 Serine phosphorylation of bcl-2 has been reported after treatment of cells with protein kinase C, okadaic acid, taxol, and other chemotherapeutic agents that attack microtubules. Okadaic Acid 98-110 BCL2 apoptosis regulator Homo sapiens 26-31 9716607-5 1998 A comparison of bcl-2 from blasts treated with ATRA or taxol showed that bcl-2 was phosphorylated on serine in cells treated with either agent; however, both qualitative and quantitative differences were seen. Paclitaxel 55-60 BCL2 apoptosis regulator Homo sapiens 73-78 9716607-5 1998 A comparison of bcl-2 from blasts treated with ATRA or taxol showed that bcl-2 was phosphorylated on serine in cells treated with either agent; however, both qualitative and quantitative differences were seen. Serine 101-107 BCL2 apoptosis regulator Homo sapiens 16-21 9716607-5 1998 A comparison of bcl-2 from blasts treated with ATRA or taxol showed that bcl-2 was phosphorylated on serine in cells treated with either agent; however, both qualitative and quantitative differences were seen. Serine 101-107 BCL2 apoptosis regulator Homo sapiens 73-78 9716607-1 1998 Serine phosphorylation of bcl-2 has been reported after treatment of cells with protein kinase C, okadaic acid, taxol, and other chemotherapeutic agents that attack microtubules. Paclitaxel 112-117 BCL2 apoptosis regulator Homo sapiens 26-31 9716607-6 1998 Qualitatively, the phosphorylated isoform from taxol-treated cells was slightly larger than the native isoform and could be distinguished on 10% to 20% SDS-polyacrylamide gradient gels, while the phosphorylated bcl-2 after ATRA ran as a single band on gradient gels at the same position as control bcl-2. Paclitaxel 47-52 BCL2 apoptosis regulator Homo sapiens 211-216 9716607-6 1998 Qualitatively, the phosphorylated isoform from taxol-treated cells was slightly larger than the native isoform and could be distinguished on 10% to 20% SDS-polyacrylamide gradient gels, while the phosphorylated bcl-2 after ATRA ran as a single band on gradient gels at the same position as control bcl-2. Paclitaxel 47-52 BCL2 apoptosis regulator Homo sapiens 298-303 9716607-7 1998 Quantitatively, all bcl-2 from ATRA-treated cells was in the phosphorylated isoform, while after taxol, both phosphorylated and native bcl-2 was present; incorporation of 32Pi into bcl-2 was stimulated to greater extent in ATRA-treated compared with taxol-treated cells. Tretinoin 31-35 BCL2 apoptosis regulator Homo sapiens 20-25 9783732-5 1998 Following exposure of cells to taxol, the Bcl-2 protein displayed an alteration in mobility that was not modified appreciably by bryostatin 1 treatment. Paclitaxel 31-36 BCL2 apoptosis regulator Homo sapiens 42-47 9783732-6 1998 The mobility shift in Bcl-2 protein from cells exposed to taxol followed by bryostatin 1 was eliminated by treatment of lysates with the protein phosphatase 2A (PP2A); the latter effect was blocked by okadaic acid. Paclitaxel 58-63 BCL2 apoptosis regulator Homo sapiens 22-27 9783732-6 1998 The mobility shift in Bcl-2 protein from cells exposed to taxol followed by bryostatin 1 was eliminated by treatment of lysates with the protein phosphatase 2A (PP2A); the latter effect was blocked by okadaic acid. bryostatin 1 76-88 BCL2 apoptosis regulator Homo sapiens 22-27 9783732-6 1998 The mobility shift in Bcl-2 protein from cells exposed to taxol followed by bryostatin 1 was eliminated by treatment of lysates with the protein phosphatase 2A (PP2A); the latter effect was blocked by okadaic acid. Okadaic Acid 201-213 BCL2 apoptosis regulator Homo sapiens 22-27 9716607-7 1998 Quantitatively, all bcl-2 from ATRA-treated cells was in the phosphorylated isoform, while after taxol, both phosphorylated and native bcl-2 was present; incorporation of 32Pi into bcl-2 was stimulated to greater extent in ATRA-treated compared with taxol-treated cells. 32pi 171-175 BCL2 apoptosis regulator Homo sapiens 20-25 9716607-8 1998 We used immunoprecipitation experiments to ask if bcl-2 phosphorylated after ATRA or taxol had altered capacity to dimerize with bax. Tretinoin 77-81 BCL2 apoptosis regulator Homo sapiens 50-55 9716607-2 1998 We report here that bcl-2 is phosphorylated on serine in acute myeloblastic leukemia (AML) blasts exposed to all trans retinoic acid (ATRA). Serine 47-53 BCL2 apoptosis regulator Homo sapiens 20-25 9716607-8 1998 We used immunoprecipitation experiments to ask if bcl-2 phosphorylated after ATRA or taxol had altered capacity to dimerize with bax. Paclitaxel 85-90 BCL2 apoptosis regulator Homo sapiens 50-55 9716607-10 1998 We conclude that: bcl-2 is phosphorylated on serine after treatment of AML blasts with ATRA; bcl-2 phosphorylation after ATRA is different from that seen after taxol; bcl-2 phosphorylated after either agent retains capacity to dimerize with bax. Serine 45-51 BCL2 apoptosis regulator Homo sapiens 18-23 9716607-10 1998 We conclude that: bcl-2 is phosphorylated on serine after treatment of AML blasts with ATRA; bcl-2 phosphorylation after ATRA is different from that seen after taxol; bcl-2 phosphorylated after either agent retains capacity to dimerize with bax. Tretinoin 87-91 BCL2 apoptosis regulator Homo sapiens 18-23 9716607-2 1998 We report here that bcl-2 is phosphorylated on serine in acute myeloblastic leukemia (AML) blasts exposed to all trans retinoic acid (ATRA). Tretinoin 119-132 BCL2 apoptosis regulator Homo sapiens 20-25 9716607-10 1998 We conclude that: bcl-2 is phosphorylated on serine after treatment of AML blasts with ATRA; bcl-2 phosphorylation after ATRA is different from that seen after taxol; bcl-2 phosphorylated after either agent retains capacity to dimerize with bax. Tretinoin 121-125 BCL2 apoptosis regulator Homo sapiens 18-23 9716607-10 1998 We conclude that: bcl-2 is phosphorylated on serine after treatment of AML blasts with ATRA; bcl-2 phosphorylation after ATRA is different from that seen after taxol; bcl-2 phosphorylated after either agent retains capacity to dimerize with bax. Tretinoin 121-125 BCL2 apoptosis regulator Homo sapiens 93-98 9716607-10 1998 We conclude that: bcl-2 is phosphorylated on serine after treatment of AML blasts with ATRA; bcl-2 phosphorylation after ATRA is different from that seen after taxol; bcl-2 phosphorylated after either agent retains capacity to dimerize with bax. Tretinoin 121-125 BCL2 apoptosis regulator Homo sapiens 93-98 9716607-11 1998 The ATRA or taxol-induced phosphorylation of bcl-2 can also be seen in blast cells obtained from AML patients. Tretinoin 4-8 BCL2 apoptosis regulator Homo sapiens 45-50 9716607-11 1998 The ATRA or taxol-induced phosphorylation of bcl-2 can also be seen in blast cells obtained from AML patients. Paclitaxel 12-17 BCL2 apoptosis regulator Homo sapiens 45-50 9734656-3 1998 CEM induced to overexpress bcl-2, and REH) displayed parallel sensitivity to four antileukaemia drugs with different mechanisms of action, with K562 generally being the least sensitive and REH being the most sensitive. 2-chloroethyl methyl sulfide 0-3 BCL2 apoptosis regulator Homo sapiens 27-32 9734658-0 1998 Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein. Arsenic 0-7 BCL2 apoptosis regulator Homo sapiens 113-118 9734658-6 1998 We concluded that combined activation of the caspases and down-regulation of Bcl-2 could determine the fate of B-cell leukaemic cells in response to arsenic. Arsenic 149-156 BCL2 apoptosis regulator Homo sapiens 77-82 9716607-2 1998 We report here that bcl-2 is phosphorylated on serine in acute myeloblastic leukemia (AML) blasts exposed to all trans retinoic acid (ATRA). Tretinoin 134-138 BCL2 apoptosis regulator Homo sapiens 20-25 9716607-3 1998 Two-dimension gels (isoelectric focusing followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis [SDS-PAGE]) disclosed a novel acidic isoform of bcl-2 in ATRA-treated blast cells from a continuous line and from two AML patients; when the cell lysates were digested with lambda-phosphatase, bcl-2 reverted to the control position, indicating that it was phosphorylated. Sodium Dodecyl Sulfate 53-75 BCL2 apoptosis regulator Homo sapiens 159-164 9716607-3 1998 Two-dimension gels (isoelectric focusing followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis [SDS-PAGE]) disclosed a novel acidic isoform of bcl-2 in ATRA-treated blast cells from a continuous line and from two AML patients; when the cell lysates were digested with lambda-phosphatase, bcl-2 reverted to the control position, indicating that it was phosphorylated. polyacrylamide 76-90 BCL2 apoptosis regulator Homo sapiens 159-164 9770327-6 1998 Bcl-2 protein expression was uupregulated by IL-7 with or without dexamethasone, but Bc1-2 was expressed at a much lower level than BclxL in these cells. Dexamethasone 66-79 BCL2 apoptosis regulator Homo sapiens 0-5 9879777-5 1998 The effect of a combination of mifepristone and 4-hydroxytamoxifen on cell growth inhibition, on the increase in DNA fragmentation, bcl2 downregulation, and induction of TGFbeta1 protein was additive and significantly different (P < 0.05) from the effect of monotherapy. Mifepristone 31-43 BCL2 apoptosis regulator Homo sapiens 132-136 9879777-5 1998 The effect of a combination of mifepristone and 4-hydroxytamoxifen on cell growth inhibition, on the increase in DNA fragmentation, bcl2 downregulation, and induction of TGFbeta1 protein was additive and significantly different (P < 0.05) from the effect of monotherapy. hydroxytamoxifen 48-66 BCL2 apoptosis regulator Homo sapiens 132-136 9877027-5 1998 Increased expression of p21CiP1, phosphorylation of Bcl-2, and activation of p33 MBP kinase may play part of the key mechanism for FR-induced apoptosis. romidepsin 131-133 BCL2 apoptosis regulator Homo sapiens 52-57 9737686-6 1998 As2O3 induced apoptosis and down-regulated bcl-2 expression in NB4, NOP-1 and NKM-1 cells. Arsenic Trioxide 0-5 BCL2 apoptosis regulator Homo sapiens 43-48 9741594-10 1998 After 24 h incubation in the presence of copper, the levels of Bcl-2 and Bcl-XL reduced about 33.8% and 51.1% compared with untreated cells, respectively. Copper 41-47 BCL2 apoptosis regulator Homo sapiens 63-68 9868803-0 1998 Expression kinetics of the (proto) oncogenes c-myc and bcl-2 following photodynamic treatment of normal and transformed human fibroblasts with 5-aminolaevulinic acid-stimulated endogenous protoporphyrin IX. Aminolevulinic Acid 143-165 BCL2 apoptosis regulator Homo sapiens 55-60 9868803-0 1998 Expression kinetics of the (proto) oncogenes c-myc and bcl-2 following photodynamic treatment of normal and transformed human fibroblasts with 5-aminolaevulinic acid-stimulated endogenous protoporphyrin IX. protoporphyrin IX 188-205 BCL2 apoptosis regulator Homo sapiens 55-60 9868803-4 1998 In this study, therefore, quantitative determination of the expression of the (proto) oncogenes c-myc and bcl-2 in normal and transformed human fibroblasts at different times following photodynamic treatment with 5-aminolaevulinic acid-stimulated endogenous protoporphyrin IX and low-dose irradiation has been carried out by quantitative reverse transcriptase polymerase chain reaction (RT-PCR). Aminolevulinic Acid 213-235 BCL2 apoptosis regulator Homo sapiens 106-111 9818030-2 1998 We found that treatment of cells with vinblastine induced phosphorylation of Bcl-2, resulting in the dissociation of Bcl-2 and Bax. Vinblastine 38-49 BCL2 apoptosis regulator Homo sapiens 77-82 9818030-2 1998 We found that treatment of cells with vinblastine induced phosphorylation of Bcl-2, resulting in the dissociation of Bcl-2 and Bax. Vinblastine 38-49 BCL2 apoptosis regulator Homo sapiens 117-122 9818030-6 1998 Thus, vinblastine-induced apoptosis might be mediated by the phosphorylation of Bcl-2, resulting in Bcl-2 inactivation, and by subsequent activation of caspase-3. Vinblastine 6-17 BCL2 apoptosis regulator Homo sapiens 80-85 9818030-6 1998 Thus, vinblastine-induced apoptosis might be mediated by the phosphorylation of Bcl-2, resulting in Bcl-2 inactivation, and by subsequent activation of caspase-3. Vinblastine 6-17 BCL2 apoptosis regulator Homo sapiens 100-105 9737698-2 1998 Its activity is regulated through association with bcl-2 homologous and nonhomologous proteins and also by serine phosphorylation. Serine 107-113 BCL2 apoptosis regulator Homo sapiens 51-56 9737698-4 1998 Moreover, bcl-2 proteins mutated for Asp residues at positions 31 and 34 were efficiently cleaved by RL-7 cell lysates, indicating that this proteolytic activity is distinct from the caspase-3 that cleaves bcl-2 at Asp 34. Aspartic Acid 37-40 BCL2 apoptosis regulator Homo sapiens 10-15 9758366-4 1998 Therefore, we performed a survey of bcl-2 expression in 778 cases of NHL using immunohistochemical techniques applied to routinely processed and paraffin-embedded tissues. Paraffin 145-153 BCL2 apoptosis regulator Homo sapiens 36-41 9737698-4 1998 Moreover, bcl-2 proteins mutated for Asp residues at positions 31 and 34 were efficiently cleaved by RL-7 cell lysates, indicating that this proteolytic activity is distinct from the caspase-3 that cleaves bcl-2 at Asp 34. Aspartic Acid 215-218 BCL2 apoptosis regulator Homo sapiens 10-15 9737698-8 1998 The N-terminus of bcl-2 which contains the BH4 domain that binds the kinase Raf-1 and the phosphatase calcineurin is essential for anti-apoptotic activity. sapropterin 43-46 BCL2 apoptosis regulator Homo sapiens 18-23 10921033-3 1998 A monoclonal antibody to the bcl-2 gene product was used, the signal was detected using a streptavidin-biotin complex with aminoethylcarbazole. Biotin 103-109 BCL2 apoptosis regulator Homo sapiens 29-34 10445257-2 1998 The data on bcl-2 action in preventing calcium signal and apoptosis in lymphoid cells are presented. Calcium 39-46 BCL2 apoptosis regulator Homo sapiens 12-17 9769126-1 1998 We have analysed the expression of bcl-2 protein retrospectively in 34 primary male breast carcinomas (MBC), using the monoclonal antibody bcl-2 in formalin-fixed, paraffin-embedded tissues. Paraffin 164-172 BCL2 apoptosis regulator Homo sapiens 35-40 10921033-3 1998 A monoclonal antibody to the bcl-2 gene product was used, the signal was detected using a streptavidin-biotin complex with aminoethylcarbazole. UNII-VDT1WE1IVQ 123-142 BCL2 apoptosis regulator Homo sapiens 29-34 9699642-0 1998 "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. Paclitaxel 115-120 BCL2 apoptosis regulator Homo sapiens 83-88 21781879-8 1998 The level of expression of bcl-2 was dramatically decreased in cells treated with SIN-1 or GSNO, while the expression level of bax, the heterodimer of bcl-2, did not significant change. S-Nitrosoglutathione 91-95 BCL2 apoptosis regulator Homo sapiens 27-32 9699642-0 1998 "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. Paclitaxel 31-36 BCL2 apoptosis regulator Homo sapiens 83-88 9699642-1 1998 Taxol, 1-beta-D-arabinofuranosylcytosine (ara-C), and etoposide induce apoptosis in HL-60 cells that is blocked by overexpression of Bcl-2 or Bcl-xL.A 60-amino acid "loop" domain of Bcl-2 and Bcl-xL that contains phosphorylation sites is known to negatively regulate their antiapoptotic function. Paclitaxel 0-5 BCL2 apoptosis regulator Homo sapiens 133-138 9664115-3 1998 Treatment with cisplatin and carboplatin also provoked an increase in the level of p53 and p21, and a lowering in Bcl-2. Carboplatin 29-40 BCL2 apoptosis regulator Homo sapiens 114-119 9699642-1 1998 Taxol, 1-beta-D-arabinofuranosylcytosine (ara-C), and etoposide induce apoptosis in HL-60 cells that is blocked by overexpression of Bcl-2 or Bcl-xL.A 60-amino acid "loop" domain of Bcl-2 and Bcl-xL that contains phosphorylation sites is known to negatively regulate their antiapoptotic function. Paclitaxel 0-5 BCL2 apoptosis regulator Homo sapiens 182-187 9699642-1 1998 Taxol, 1-beta-D-arabinofuranosylcytosine (ara-C), and etoposide induce apoptosis in HL-60 cells that is blocked by overexpression of Bcl-2 or Bcl-xL.A 60-amino acid "loop" domain of Bcl-2 and Bcl-xL that contains phosphorylation sites is known to negatively regulate their antiapoptotic function. Cytarabine 7-40 BCL2 apoptosis regulator Homo sapiens 133-138 9699642-1 1998 Taxol, 1-beta-D-arabinofuranosylcytosine (ara-C), and etoposide induce apoptosis in HL-60 cells that is blocked by overexpression of Bcl-2 or Bcl-xL.A 60-amino acid "loop" domain of Bcl-2 and Bcl-xL that contains phosphorylation sites is known to negatively regulate their antiapoptotic function. Cytarabine 7-40 BCL2 apoptosis regulator Homo sapiens 182-187 9699642-1 1998 Taxol, 1-beta-D-arabinofuranosylcytosine (ara-C), and etoposide induce apoptosis in HL-60 cells that is blocked by overexpression of Bcl-2 or Bcl-xL.A 60-amino acid "loop" domain of Bcl-2 and Bcl-xL that contains phosphorylation sites is known to negatively regulate their antiapoptotic function. Cytarabine 42-47 BCL2 apoptosis regulator Homo sapiens 133-138 9699642-1 1998 Taxol, 1-beta-D-arabinofuranosylcytosine (ara-C), and etoposide induce apoptosis in HL-60 cells that is blocked by overexpression of Bcl-2 or Bcl-xL.A 60-amino acid "loop" domain of Bcl-2 and Bcl-xL that contains phosphorylation sites is known to negatively regulate their antiapoptotic function. Cytarabine 42-47 BCL2 apoptosis regulator Homo sapiens 182-187 9699642-1 1998 Taxol, 1-beta-D-arabinofuranosylcytosine (ara-C), and etoposide induce apoptosis in HL-60 cells that is blocked by overexpression of Bcl-2 or Bcl-xL.A 60-amino acid "loop" domain of Bcl-2 and Bcl-xL that contains phosphorylation sites is known to negatively regulate their antiapoptotic function. Etoposide 54-63 BCL2 apoptosis regulator Homo sapiens 133-138 9699642-1 1998 Taxol, 1-beta-D-arabinofuranosylcytosine (ara-C), and etoposide induce apoptosis in HL-60 cells that is blocked by overexpression of Bcl-2 or Bcl-xL.A 60-amino acid "loop" domain of Bcl-2 and Bcl-xL that contains phosphorylation sites is known to negatively regulate their antiapoptotic function. Etoposide 54-63 BCL2 apoptosis regulator Homo sapiens 182-187 9699642-11 1998 In association with Taxol-induced apoptosis, the levels of Bcl-2 that were coimmunoprecipitated with APAF-1 declined in HL-60/neo and HL-60/Bcl-2delta cells. Paclitaxel 20-25 BCL2 apoptosis regulator Homo sapiens 59-64 9699642-11 1998 In association with Taxol-induced apoptosis, the levels of Bcl-2 that were coimmunoprecipitated with APAF-1 declined in HL-60/neo and HL-60/Bcl-2delta cells. Paclitaxel 20-25 BCL2 apoptosis regulator Homo sapiens 140-145 9699642-13 1998 Previous studies have demonstrated that Taxol induces phosphorylation of Bcl-2 in association with Taxol-induced apoptosis of HL-60/neo cells. Paclitaxel 40-45 BCL2 apoptosis regulator Homo sapiens 73-78 9699642-13 1998 Previous studies have demonstrated that Taxol induces phosphorylation of Bcl-2 in association with Taxol-induced apoptosis of HL-60/neo cells. Paclitaxel 99-104 BCL2 apoptosis regulator Homo sapiens 73-78 9699642-14 1998 Immunoblot analysis demonstrated a Taxol-induced mobility shift of Bcl-2 but not p19Bcl-2delta. Paclitaxel 35-40 BCL2 apoptosis regulator Homo sapiens 67-72 9699642-15 1998 Taxol also increased [32P]Pi incorporation in p26Bcl-2, but not in p19Bcl-2delta or p18Bcl-xL. Paclitaxel 0-5 BCL2 apoptosis regulator Homo sapiens 49-54 9699642-15 1998 Taxol also increased [32P]Pi incorporation in p26Bcl-2, but not in p19Bcl-2delta or p18Bcl-xL. Phosphorus-32 22-25 BCL2 apoptosis regulator Homo sapiens 49-54 9699642-16 1998 These findings indicate that the loop domain is necessary for the Taxol-induced mobility shift and phosphorylation of Bcl-2. Paclitaxel 66-71 BCL2 apoptosis regulator Homo sapiens 118-123 9699642-17 1998 Loop domain also seems to be necessary for the antiapoptotic effect of Bcl-2 against Taxol-induced apoptosis but not ara-C- or etoposide-induced apoptosis. Paclitaxel 85-90 BCL2 apoptosis regulator Homo sapiens 71-76 9664139-0 1998 Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells. Dexamethasone 54-67 BCL2 apoptosis regulator Homo sapiens 0-5 9664139-8 1998 While DEX-induced apoptosis was dependent on the level of bcl-2 expression, MEL-induced apoptosis was independent of bcl-2 levels. Dexamethasone 6-9 BCL2 apoptosis regulator Homo sapiens 58-63 9664139-9 1998 Treatment with DEX of the low bcl-2-expressing cells (DEX-sensitive) resulted in a rapid apoptosis from all phases of the cell cycle. Dexamethasone 15-18 BCL2 apoptosis regulator Homo sapiens 30-35 9664139-9 1998 Treatment with DEX of the low bcl-2-expressing cells (DEX-sensitive) resulted in a rapid apoptosis from all phases of the cell cycle. Dexamethasone 54-57 BCL2 apoptosis regulator Homo sapiens 30-35 9664139-11 1998 Major differences between DEX and MEL were also observed with respect to their effects on the levels of bcl-2 and p53. Dexamethasone 26-29 BCL2 apoptosis regulator Homo sapiens 104-109 9664139-12 1998 Whereas DEX induced an early (day 1) downregulation of bcl-2 (only in the cells with low bcl-2), treatment with MEL did not affect bcl-2 levels. Dexamethasone 8-11 BCL2 apoptosis regulator Homo sapiens 55-60 9664139-14 1998 These results, taken together, suggest that the two drugs target different cellular components and induce apoptosis by different pathways, and that resistance to DEX is associated with low levels of bcl-2, whereas resistance to MEL is independent of bcl-2, and therefore, in vivo resistance to MEL, observed in MM patients, might involve other mechanisms rather than bcl-2. Dexamethasone 162-165 BCL2 apoptosis regulator Homo sapiens 199-204 10200525-7 1998 mRNA expression of BAX, BCL2, MDR1, MRP, ERCC1 and ERCC2, putatively associated with cisplatin resistance to apoptotic death was unchanged. cisplatin 85-94 BCL2 apoptosis regulator Homo sapiens 24-28 11245018-6 1998 In CR group the expression of Bcl-2 mRNA was obviously lower than that of NR one (P < 0.01). Chromium 3-5 BCL2 apoptosis regulator Homo sapiens 30-35 9707172-2 1998 Here we show that in U937 and HL60 myeloid leukemia cells and in normal skin fibroblasts, cell-permeant ceramides can trigger neutral sphingomyelinase activation, sphingomyelin hydrolysis, and endogenous ceramide generation regardless of Bcl2 overexpression. Ceramides 104-113 BCL2 apoptosis regulator Homo sapiens 238-242 9707172-2 1998 Here we show that in U937 and HL60 myeloid leukemia cells and in normal skin fibroblasts, cell-permeant ceramides can trigger neutral sphingomyelinase activation, sphingomyelin hydrolysis, and endogenous ceramide generation regardless of Bcl2 overexpression. Ceramides 104-112 BCL2 apoptosis regulator Homo sapiens 238-242 9664115-3 1998 Treatment with cisplatin and carboplatin also provoked an increase in the level of p53 and p21, and a lowering in Bcl-2. Cisplatin 15-24 BCL2 apoptosis regulator Homo sapiens 114-119 9728339-6 1998 An alternative method of protection from oxygen radicals is employed by complex I-deficient cell types that do not induce MnSOD in that they show induction of the bcl-2 protein. Reactive Oxygen Species 41-56 BCL2 apoptosis regulator Homo sapiens 163-168 9699542-16 1998 CONCLUSIONS: High levels of glucose and rapid reduction of glucose modulate the expression of bcl-2 family genes in retinal pericytes. Glucose 28-35 BCL2 apoptosis regulator Homo sapiens 94-99 9699542-16 1998 CONCLUSIONS: High levels of glucose and rapid reduction of glucose modulate the expression of bcl-2 family genes in retinal pericytes. Glucose 59-66 BCL2 apoptosis regulator Homo sapiens 94-99 9701342-3 1998 We show here that an inhibitor of proteolytic process of apoptosis, N-tosyl-L-phenylalanyl chloromethyl ketone (TPCK), protected hippocampal neuronal damage by inhibition of the DNA fragmentation in a dose-dependent manner and that TPCK induced an apoptosis-regulating molecule, Bcl-2 protein, in the surviving neurons. Nitrogen 68-69 BCL2 apoptosis regulator Homo sapiens 279-284 9701342-3 1998 We show here that an inhibitor of proteolytic process of apoptosis, N-tosyl-L-phenylalanyl chloromethyl ketone (TPCK), protected hippocampal neuronal damage by inhibition of the DNA fragmentation in a dose-dependent manner and that TPCK induced an apoptosis-regulating molecule, Bcl-2 protein, in the surviving neurons. -l-phenylalanyl chloromethyl ketone 75-110 BCL2 apoptosis regulator Homo sapiens 279-284 9733629-14 1998 HCL stimulated NB to overexpress bcl-2 and presumably become resistant to apoptosis. Hydrochloric Acid 0-3 BCL2 apoptosis regulator Homo sapiens 33-38 9703946-0 1998 Expression of Bcl-2 increases intracellular glutathione by inhibiting methionine-dependent GSH efflux. Glutathione 44-55 BCL2 apoptosis regulator Homo sapiens 14-19 9707513-6 1998 Immunoblot analysis demonstrated that both BaP and its 7,8-dihydrodiol metabolite affected a pathway involving Bcl-2 and Bax cytosolic proteins. Benzo(a)pyrene 43-46 BCL2 apoptosis regulator Homo sapiens 111-116 9707513-6 1998 Immunoblot analysis demonstrated that both BaP and its 7,8-dihydrodiol metabolite affected a pathway involving Bcl-2 and Bax cytosolic proteins. 7,8-dihydrodiol 55-70 BCL2 apoptosis regulator Homo sapiens 111-116 9707513-7 1998 Daudi cells undergoing apoptosis at 36 h in response to 10 microM BaP, the parent compound, expressed moderately reduced amounts of Bcl-2 (78% of vehicle controls). Benzo(a)pyrene 66-69 BCL2 apoptosis regulator Homo sapiens 132-137 9707513-8 1998 At the same time point, the 7,8-dihydrodiol and BDPE metabolites at 3 microM resulted in Bcl-2 protein expression that was 52% of that seen in vehicle controls. 7,8-dihydrodiol 28-43 BCL2 apoptosis regulator Homo sapiens 89-94 9707513-8 1998 At the same time point, the 7,8-dihydrodiol and BDPE metabolites at 3 microM resulted in Bcl-2 protein expression that was 52% of that seen in vehicle controls. 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide 48-52 BCL2 apoptosis regulator Homo sapiens 89-94 9707513-15 1998 Bcl-2 expression was most responsive to ANF at later time points following PAH exposure (18 and 36 h); however, Bcl-2 appeared to be more sensitive to the effects of ANF alone. Polycyclic Aromatic Hydrocarbons 75-78 BCL2 apoptosis regulator Homo sapiens 0-5 9707513-16 1998 Taken together, these data suggest that modulation of Bcl-2 family proteins, perhaps secondary to altered Ca2+ homeostasis, plays an important role in human B cell apoptosis induced by BaP. Benzo(a)pyrene 185-188 BCL2 apoptosis regulator Homo sapiens 54-59 9677421-7 1998 Furthermore, TCDD decreases the Bcl-2 protein level in these cell lines. Polychlorinated Dibenzodioxins 13-17 BCL2 apoptosis regulator Homo sapiens 32-37 9703946-0 1998 Expression of Bcl-2 increases intracellular glutathione by inhibiting methionine-dependent GSH efflux. Methionine 70-80 BCL2 apoptosis regulator Homo sapiens 14-19 9703946-0 1998 Expression of Bcl-2 increases intracellular glutathione by inhibiting methionine-dependent GSH efflux. Glutathione 91-94 BCL2 apoptosis regulator Homo sapiens 14-19 9703946-1 1998 Overexpression of Bcl-2 and related anti-apoptotic gene products has been shown to increase the intracellular concentration of the antioxidant tripeptide glutathione in neuronal and hematopoietic cells. tripeptide K-26 143-153 BCL2 apoptosis regulator Homo sapiens 18-23 9703946-1 1998 Overexpression of Bcl-2 and related anti-apoptotic gene products has been shown to increase the intracellular concentration of the antioxidant tripeptide glutathione in neuronal and hematopoietic cells. Glutathione 154-165 BCL2 apoptosis regulator Homo sapiens 18-23 9703946-2 1998 A similar examination of HeLa cells that stably overexpress Bcl-2 (Bcl-2/HeLa) demonstrated that the reduced form of glutathione (GSH) was increased by 60% compared to control cells (80 nmol GSH/mg protein compared to 50 nmol GSH/mg). Glutathione 117-128 BCL2 apoptosis regulator Homo sapiens 60-65 9703946-2 1998 A similar examination of HeLa cells that stably overexpress Bcl-2 (Bcl-2/HeLa) demonstrated that the reduced form of glutathione (GSH) was increased by 60% compared to control cells (80 nmol GSH/mg protein compared to 50 nmol GSH/mg). Glutathione 117-128 BCL2 apoptosis regulator Homo sapiens 67-72 9703946-2 1998 A similar examination of HeLa cells that stably overexpress Bcl-2 (Bcl-2/HeLa) demonstrated that the reduced form of glutathione (GSH) was increased by 60% compared to control cells (80 nmol GSH/mg protein compared to 50 nmol GSH/mg). Glutathione 130-133 BCL2 apoptosis regulator Homo sapiens 60-65 9668078-2 1998 We studied the correlation between Bcl-2 phosphorylation, mitotic arrest, and apoptosis induced by the anti-tubulin agent paclitaxel. Paclitaxel 122-132 BCL2 apoptosis regulator Homo sapiens 35-40 9668078-11 1998 However, a continuous exposure to nocodazole resulted in a pattern of Bcl-2 phosphorylation, M phase arrest, and apoptosis similar to that observed with paclitaxel. Nocodazole 34-44 BCL2 apoptosis regulator Homo sapiens 70-75 9668078-12 1998 The phosphatase inhibitor okadaic acid was found to inhibit the dephosphorylation of phosphorylated Bcl-2 and to delay the progression of nocodazole M phase-arrested cells into interphase. Okadaic Acid 26-38 BCL2 apoptosis regulator Homo sapiens 100-105 9703946-2 1998 A similar examination of HeLa cells that stably overexpress Bcl-2 (Bcl-2/HeLa) demonstrated that the reduced form of glutathione (GSH) was increased by 60% compared to control cells (80 nmol GSH/mg protein compared to 50 nmol GSH/mg). Glutathione 130-133 BCL2 apoptosis regulator Homo sapiens 67-72 9668078-13 1998 In contrast, the serine/threonine kinase inhibitor staurosporine, but not the tyrosine kinase inhibitor genistein, led to rapid dephosphorylation of phosphorylated Bcl-2 and accelerated the progression of nocodazole M phase-arrested cells into interphase. Staurosporine 51-64 BCL2 apoptosis regulator Homo sapiens 164-169 9668078-8 1998 Similar results were obtained with SKOV3 cells, indicating that the association of paclitaxel-induced M phase arrest and Bcl-2 phosphorylation is not restricted to HeLa cells. Paclitaxel 83-93 BCL2 apoptosis regulator Homo sapiens 121-126 9668078-14 1998 Immune complex kinase assays in cell-free systems demonstrated that Bcl-2 protein can be a substrate of Cdc2/cyclin B1 kinase isolated from paclitaxel-treated cells arrested in M phase. Paclitaxel 140-150 BCL2 apoptosis regulator Homo sapiens 68-73 9703946-2 1998 A similar examination of HeLa cells that stably overexpress Bcl-2 (Bcl-2/HeLa) demonstrated that the reduced form of glutathione (GSH) was increased by 60% compared to control cells (80 nmol GSH/mg protein compared to 50 nmol GSH/mg). Glutathione 191-194 BCL2 apoptosis regulator Homo sapiens 60-65 9703946-2 1998 A similar examination of HeLa cells that stably overexpress Bcl-2 (Bcl-2/HeLa) demonstrated that the reduced form of glutathione (GSH) was increased by 60% compared to control cells (80 nmol GSH/mg protein compared to 50 nmol GSH/mg). Glutathione 191-194 BCL2 apoptosis regulator Homo sapiens 60-65 9703946-8 1998 Consistent with expression of sinusoidal activity, DTT was found to stimulate GSH efflux while the amino acid methionine inhibited efflux in both HeLa and Bcl-2/HeLa cells. amino acid methionine 99-120 BCL2 apoptosis regulator Homo sapiens 155-160 9703946-9 1998 However, methionine-dependent inhibition of efflux was found to be significantly increased by expression of Bcl-2. Methionine 9-19 BCL2 apoptosis regulator Homo sapiens 108-113 9703946-10 1998 To test the prediction that the increase in GSH observed in Bcl-2/HeLa cells was mediated by methionine; Bcl-2/HeLa cells were cultured for 24 hrs in methionine-free growth medium. Glutathione 44-47 BCL2 apoptosis regulator Homo sapiens 60-65 9703946-10 1998 To test the prediction that the increase in GSH observed in Bcl-2/HeLa cells was mediated by methionine; Bcl-2/HeLa cells were cultured for 24 hrs in methionine-free growth medium. Methionine 93-103 BCL2 apoptosis regulator Homo sapiens 60-65 9703946-11 1998 Under these conditions, the GSH concentration of the Bcl-2/HeLa cells dropped to the level observed in HeLa cells (50 nmol GSH/mg protein). Glutathione 28-31 BCL2 apoptosis regulator Homo sapiens 53-58 9703946-11 1998 Under these conditions, the GSH concentration of the Bcl-2/HeLa cells dropped to the level observed in HeLa cells (50 nmol GSH/mg protein). Glutathione 123-126 BCL2 apoptosis regulator Homo sapiens 53-58 9703946-12 1998 These studies suggest that overexpression of Bcl-2 increases GSH levels by altering methionine-dependent GSH efflux, an activity associated in HeLa cells with expression of the RsGshT transporter. Glutathione 61-64 BCL2 apoptosis regulator Homo sapiens 45-50 9703946-12 1998 These studies suggest that overexpression of Bcl-2 increases GSH levels by altering methionine-dependent GSH efflux, an activity associated in HeLa cells with expression of the RsGshT transporter. Methionine 84-94 BCL2 apoptosis regulator Homo sapiens 45-50 9703946-12 1998 These studies suggest that overexpression of Bcl-2 increases GSH levels by altering methionine-dependent GSH efflux, an activity associated in HeLa cells with expression of the RsGshT transporter. Glutathione 105-108 BCL2 apoptosis regulator Homo sapiens 45-50 9642262-8 1998 In addition, RA-induced suppression of Bcl-2 expression was abrogated by overexpression of BAG-1. Tretinoin 13-15 BCL2 apoptosis regulator Homo sapiens 39-44 9671760-5 1998 TGZ (10(-5) M, 4 days) reversibly inhibits clonal growth of MCF7 breast cancer cells and the combination of TGZ (10(-5) M) and ATRA (10(-6) M, 4 days) synergistically and irreversibly inhibits growth and induces apoptosis of MCF7 cells, associated with a dramatic decrease of their bcl-2 protein levels. Troglitazone 0-3 BCL2 apoptosis regulator Homo sapiens 282-287 9671760-5 1998 TGZ (10(-5) M, 4 days) reversibly inhibits clonal growth of MCF7 breast cancer cells and the combination of TGZ (10(-5) M) and ATRA (10(-6) M, 4 days) synergistically and irreversibly inhibits growth and induces apoptosis of MCF7 cells, associated with a dramatic decrease of their bcl-2 protein levels. Troglitazone 108-111 BCL2 apoptosis regulator Homo sapiens 282-287 9671760-7 1998 The observed apoptosis mediated by TGZ and ATRA may be related to the striking down-regulation of bcl-2, because forced over-expression of bcl-2 in MCF7 cells cultured with TGZ and ATRA blocks their cell death. Troglitazone 35-38 BCL2 apoptosis regulator Homo sapiens 98-103 9671760-7 1998 The observed apoptosis mediated by TGZ and ATRA may be related to the striking down-regulation of bcl-2, because forced over-expression of bcl-2 in MCF7 cells cultured with TGZ and ATRA blocks their cell death. Troglitazone 35-38 BCL2 apoptosis regulator Homo sapiens 139-144 9671760-7 1998 The observed apoptosis mediated by TGZ and ATRA may be related to the striking down-regulation of bcl-2, because forced over-expression of bcl-2 in MCF7 cells cultured with TGZ and ATRA blocks their cell death. Tretinoin 43-47 BCL2 apoptosis regulator Homo sapiens 98-103 9671760-7 1998 The observed apoptosis mediated by TGZ and ATRA may be related to the striking down-regulation of bcl-2, because forced over-expression of bcl-2 in MCF7 cells cultured with TGZ and ATRA blocks their cell death. Tretinoin 43-47 BCL2 apoptosis regulator Homo sapiens 139-144 9671760-7 1998 The observed apoptosis mediated by TGZ and ATRA may be related to the striking down-regulation of bcl-2, because forced over-expression of bcl-2 in MCF7 cells cultured with TGZ and ATRA blocks their cell death. Troglitazone 173-176 BCL2 apoptosis regulator Homo sapiens 98-103 9671760-7 1998 The observed apoptosis mediated by TGZ and ATRA may be related to the striking down-regulation of bcl-2, because forced over-expression of bcl-2 in MCF7 cells cultured with TGZ and ATRA blocks their cell death. Troglitazone 173-176 BCL2 apoptosis regulator Homo sapiens 139-144 9671760-7 1998 The observed apoptosis mediated by TGZ and ATRA may be related to the striking down-regulation of bcl-2, because forced over-expression of bcl-2 in MCF7 cells cultured with TGZ and ATRA blocks their cell death. Tretinoin 181-185 BCL2 apoptosis regulator Homo sapiens 98-103 9671760-7 1998 The observed apoptosis mediated by TGZ and ATRA may be related to the striking down-regulation of bcl-2, because forced over-expression of bcl-2 in MCF7 cells cultured with TGZ and ATRA blocks their cell death. Tretinoin 181-185 BCL2 apoptosis regulator Homo sapiens 139-144 9651399-7 1998 Apoptosis induced by adenovirus vectors expressing elevated levels of BCL-2 can be readily inhibited by the caspase inhibitor z-VAD-fmk, suggesting that high levels of BCL-2 expression induce apoptosis via the caspase cascade. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 126-135 BCL2 apoptosis regulator Homo sapiens 70-75 9651399-7 1998 Apoptosis induced by adenovirus vectors expressing elevated levels of BCL-2 can be readily inhibited by the caspase inhibitor z-VAD-fmk, suggesting that high levels of BCL-2 expression induce apoptosis via the caspase cascade. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 126-135 BCL2 apoptosis regulator Homo sapiens 168-173 9657968-8 1998 Overexpression of the anti-apoptotic protein Bcl-2 significantly decreased the apoptosis seen after treatment with H2O2 without altering ERK or JNK/SAPK activities. Hydrogen Peroxide 115-119 BCL2 apoptosis regulator Homo sapiens 45-50 9657968-10 1998 Bcl-2 acts independently and downstream of ERK and JNK/SAPK to enhance the survival of H2O2-treated cells. Hydrogen Peroxide 87-91 BCL2 apoptosis regulator Homo sapiens 0-5 9651311-5 1998 This calcium-dependent regulation of the Bcl-xl channel provides new insights into the roles of calcium and Bcl-2-related proteins in the programmed cell death pathway. Calcium 5-12 BCL2 apoptosis regulator Homo sapiens 108-113 9639400-10 1998 In GLC4, increased Bcl-2 expression was found, a protein described to confer TNF-resistance. glucose tetrasaccharide 3-7 BCL2 apoptosis regulator Homo sapiens 19-24 9703910-0 1998 An exogenous cdk inhibitor, butyrolactone-I, induces apoptosis with increased Bax/Bcl-2 ratio in p53-mutated pancreatic cancer cells. butyrolactone I 28-43 BCL2 apoptosis regulator Homo sapiens 82-87 9739439-1 1998 PURPOSE: Paclitaxel and gemcitabine possess broad spectra of clinical activity, distinct mechanisms of cytotoxicity, and are differentially affected by mutations in cell-cycle regulatory proteins, such as bcl-2. Paclitaxel 9-19 BCL2 apoptosis regulator Homo sapiens 205-210 9739439-1 1998 PURPOSE: Paclitaxel and gemcitabine possess broad spectra of clinical activity, distinct mechanisms of cytotoxicity, and are differentially affected by mutations in cell-cycle regulatory proteins, such as bcl-2. gemcitabine 24-35 BCL2 apoptosis regulator Homo sapiens 205-210 9703910-5 1998 In butyrolactone-I-treated PANC-1 cells, expression of p53 protein was unchanged, but Bax expression was slightly upregulated and Bcl-2 expression was predominantly down-regulated. butyrolactone I 3-18 BCL2 apoptosis regulator Homo sapiens 130-135 9661878-0 1998 Unsymmetrically substituted polyamine analogue induces caspase-independent programmed cell death in Bcl-2-overexpressing cells. Polyamines 28-37 BCL2 apoptosis regulator Homo sapiens 100-105 9713486-10 1998 Increased apoptotic responses were generally observed in cell lines that were sensitive to etoposide and this correlated with low ratios of Bcl-2/Bax protein. Etoposide 91-100 BCL2 apoptosis regulator Homo sapiens 140-145 9670994-7 1998 Expression of BCl-2 in a PC12 mutant that has a normal dopamine content allowed partial NGF-induced differentiation suggesting that the apoptotic pathway might be involved in the failure of differentiation when the de novo pathway of purine synthesis is partially inhibited. Dopamine 55-63 BCL2 apoptosis regulator Homo sapiens 14-19 9688289-4 1998 These results not only suggested that both arsenite and arsenate induced apoptosis of NB4 cells through 2 different mechanisms--at low doses, arsenical might directly induce apoptosis through regulation of cell cycle checkpoint, while at high doses they might directly induce it, but also indicated that bcl-2 might not play an important role in arsenite or arsenate-induced apoptosis of NB4 cells, whereas chemical valence of As in a compound might be related to efficiency in arsenical induction of apoptosis. arsenite 43-51 BCL2 apoptosis regulator Homo sapiens 304-309 9688289-4 1998 These results not only suggested that both arsenite and arsenate induced apoptosis of NB4 cells through 2 different mechanisms--at low doses, arsenical might directly induce apoptosis through regulation of cell cycle checkpoint, while at high doses they might directly induce it, but also indicated that bcl-2 might not play an important role in arsenite or arsenate-induced apoptosis of NB4 cells, whereas chemical valence of As in a compound might be related to efficiency in arsenical induction of apoptosis. arsenic acid 56-64 BCL2 apoptosis regulator Homo sapiens 304-309 9670994-7 1998 Expression of BCl-2 in a PC12 mutant that has a normal dopamine content allowed partial NGF-induced differentiation suggesting that the apoptotic pathway might be involved in the failure of differentiation when the de novo pathway of purine synthesis is partially inhibited. purine 234-240 BCL2 apoptosis regulator Homo sapiens 14-19 10920987-3 1998 RESULTS: In 9 different malignant lymphoma cell lines, Su-DHL-4 and Su-DHL-6 were shown bcl-2(MBR)/JH rearrangement, the sensitivity of PCR was 1:10(5). su-dhl-4 55-63 BCL2 apoptosis regulator Homo sapiens 88-93 9738982-2 1998 In a study designed to elucidate the reason for this efficacy, two cell lines derived from lymphomas with BCL2 gene rearrangement (SU-DHL-4 and SU-DHL-6) showed remarkable growth inhibition and cell-death, and two other cell lines derived from a diffuse lymphoma (RC-K8) and a mantle cell lymphoma (SP-49) showed moderate growth inhibition, but neither a CD20 weakly positive cell line (NALL-1) nor a negative cell line (MOLT-4) showed any growth inhibition. su-dhl-4 131-139 BCL2 apoptosis regulator Homo sapiens 106-110 9738982-2 1998 In a study designed to elucidate the reason for this efficacy, two cell lines derived from lymphomas with BCL2 gene rearrangement (SU-DHL-4 and SU-DHL-6) showed remarkable growth inhibition and cell-death, and two other cell lines derived from a diffuse lymphoma (RC-K8) and a mantle cell lymphoma (SP-49) showed moderate growth inhibition, but neither a CD20 weakly positive cell line (NALL-1) nor a negative cell line (MOLT-4) showed any growth inhibition. su-dhl-6 144-152 BCL2 apoptosis regulator Homo sapiens 106-110 9738982-2 1998 In a study designed to elucidate the reason for this efficacy, two cell lines derived from lymphomas with BCL2 gene rearrangement (SU-DHL-4 and SU-DHL-6) showed remarkable growth inhibition and cell-death, and two other cell lines derived from a diffuse lymphoma (RC-K8) and a mantle cell lymphoma (SP-49) showed moderate growth inhibition, but neither a CD20 weakly positive cell line (NALL-1) nor a negative cell line (MOLT-4) showed any growth inhibition. rc-k8 264-269 BCL2 apoptosis regulator Homo sapiens 106-110 9713967-2 1998 A dose-dependent decrease in Bcl-2 protein expression was observed in the different lymphomas incubated with lipid-incorporated bcl-2 antisense oligonucleotides (L-bcl-2). Oligonucleotides 144-160 BCL2 apoptosis regulator Homo sapiens 29-34 9713967-2 1998 A dose-dependent decrease in Bcl-2 protein expression was observed in the different lymphomas incubated with lipid-incorporated bcl-2 antisense oligonucleotides (L-bcl-2). Oligonucleotides 144-160 BCL2 apoptosis regulator Homo sapiens 128-133 9713967-2 1998 A dose-dependent decrease in Bcl-2 protein expression was observed in the different lymphomas incubated with lipid-incorporated bcl-2 antisense oligonucleotides (L-bcl-2). Oligonucleotides 144-160 BCL2 apoptosis regulator Homo sapiens 164-169 10920987-3 1998 RESULTS: In 9 different malignant lymphoma cell lines, Su-DHL-4 and Su-DHL-6 were shown bcl-2(MBR)/JH rearrangement, the sensitivity of PCR was 1:10(5). su-dhl-6 68-76 BCL2 apoptosis regulator Homo sapiens 88-93 9647742-0 1998 2-Methoxyestradiol-induced phosphorylation of Bcl-2: uncoupling from JNK/SAPK activation. 2-Methoxyestradiol 0-18 BCL2 apoptosis regulator Homo sapiens 46-51 9671389-5 1998 BFL-1 shares four conserved domains, BH1, BH2, BH3 and BH4 with other BCL-2 family proteins. sapropterin 55-58 BCL2 apoptosis regulator Homo sapiens 70-75 9632706-4 1998 SB202190 stimulated the activity of CPP32-like caspases, and its apoptotic effect was completely blocked by the protease inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone and expression of bcl-2. 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole 0-8 BCL2 apoptosis regulator Homo sapiens 199-204 9637784-12 1998 However, control and Bcl-2-overexpressing mitochondria respond equally well to a combination of atractyloside and PK11195. Atractyloside 96-109 BCL2 apoptosis regulator Homo sapiens 21-26 9671409-6 1998 Nuclear run-on experiments demonstrate that etoposide increases CASP gene transcription in U937 cells, an effect that is prevented by Bcl-2 overexpression. Etoposide 44-53 BCL2 apoptosis regulator Homo sapiens 134-139 9620283-7 1998 Flow cytometry analysis revealed that the mean fluorescence intensity of bcl-2 protein was slightly decreased in cells treated with ATRA. Tretinoin 132-136 BCL2 apoptosis regulator Homo sapiens 73-78 9637556-11 1998 Treatment with 5-azaC or butyrate affected the expression levels of proteins of the Bcl-2 family. Azacitidine 15-21 BCL2 apoptosis regulator Homo sapiens 84-89 9637556-11 1998 Treatment with 5-azaC or butyrate affected the expression levels of proteins of the Bcl-2 family. Butyrates 25-33 BCL2 apoptosis regulator Homo sapiens 84-89 9649124-9 1998 This regimen of melatonin followed by atRA induced cytocidal effects on MCF-7 cells by activating pathways leading to apoptosis (programmed cell death) as evidenced by decreased ER and Bcl-2 and increased Bax and transforming growth factor beta 1 (TGF-beta1) expression. Tretinoin 38-42 BCL2 apoptosis regulator Homo sapiens 185-190 9671409-5 1998 This effect of etoposide is not observed in K562 cells and bcl-2-transfected U937 cells which are less sensitive to drug-induced apoptosis. Etoposide 15-24 BCL2 apoptosis regulator Homo sapiens 59-64 9660542-8 1998 In addition, cells overexpressing bcl-2 or bcl-xL proteins were as sensitive to 1,2-naphthoquinones as were control cells. 1,2-naphthoquinone 80-99 BCL2 apoptosis regulator Homo sapiens 34-39 9649124-9 1998 This regimen of melatonin followed by atRA induced cytocidal effects on MCF-7 cells by activating pathways leading to apoptosis (programmed cell death) as evidenced by decreased ER and Bcl-2 and increased Bax and transforming growth factor beta 1 (TGF-beta1) expression. Melatonin 16-25 BCL2 apoptosis regulator Homo sapiens 185-190 9620283-8 1998 These results indicate that in U266B1 cells, combined treatment with anti-Fas mAb and ATRA enhances the induction of apoptosis by modulating the expression of Fas and bcl-2 by ATRA. Tretinoin 86-90 BCL2 apoptosis regulator Homo sapiens 167-172 9671115-8 1998 Rbcl2-2, a Bcl-2 overexpressing clone, suppressed DNA fragmentation and U1-70kDa digestion in response to GSNO, although allowing delayed but complete poly(ADP-ribose) polymerase degradation. S-Nitrosoglutathione 106-110 BCL2 apoptosis regulator Homo sapiens 11-16 9584191-2 1998 In this study, the microtubule-damaging drugs paclitaxel, vincristine, and vinblastine induced Bcl2 hyperphosphorylation and apoptosis in MCF-7 and MDA-MB-231 cells and reduced Bcl2-Bax dimerization. Paclitaxel 46-56 BCL2 apoptosis regulator Homo sapiens 95-99 9584191-2 1998 In this study, the microtubule-damaging drugs paclitaxel, vincristine, and vinblastine induced Bcl2 hyperphosphorylation and apoptosis in MCF-7 and MDA-MB-231 cells and reduced Bcl2-Bax dimerization. Paclitaxel 46-56 BCL2 apoptosis regulator Homo sapiens 177-181 9584191-2 1998 In this study, the microtubule-damaging drugs paclitaxel, vincristine, and vinblastine induced Bcl2 hyperphosphorylation and apoptosis in MCF-7 and MDA-MB-231 cells and reduced Bcl2-Bax dimerization. Vincristine 58-69 BCL2 apoptosis regulator Homo sapiens 95-99 9584191-2 1998 In this study, the microtubule-damaging drugs paclitaxel, vincristine, and vinblastine induced Bcl2 hyperphosphorylation and apoptosis in MCF-7 and MDA-MB-231 cells and reduced Bcl2-Bax dimerization. Vincristine 58-69 BCL2 apoptosis regulator Homo sapiens 177-181 9584191-2 1998 In this study, the microtubule-damaging drugs paclitaxel, vincristine, and vinblastine induced Bcl2 hyperphosphorylation and apoptosis in MCF-7 and MDA-MB-231 cells and reduced Bcl2-Bax dimerization. Vinblastine 75-86 BCL2 apoptosis regulator Homo sapiens 95-99 9584191-2 1998 In this study, the microtubule-damaging drugs paclitaxel, vincristine, and vinblastine induced Bcl2 hyperphosphorylation and apoptosis in MCF-7 and MDA-MB-231 cells and reduced Bcl2-Bax dimerization. Vinblastine 75-86 BCL2 apoptosis regulator Homo sapiens 177-181 9584191-3 1998 Paclitaxel or vincristine induced increased expression of Bax, while overexpression of Bcl2 in these cell lines counteracted the effects of low doses of these drugs. Paclitaxel 0-10 BCL2 apoptosis regulator Homo sapiens 87-91 9584191-4 1998 In addition, paclitaxel- and vincristine-induced activation of cyclic AMP (cAMP)-dependent protein kinase (protein kinase A [PKA]) induced Bcl2 hyperphosphorylation and apoptosis, which were blocked by the PKA inhibitor Rp diastereomers of cAMP (Rp-cAMP). Paclitaxel 13-23 BCL2 apoptosis regulator Homo sapiens 139-143 9584191-4 1998 In addition, paclitaxel- and vincristine-induced activation of cyclic AMP (cAMP)-dependent protein kinase (protein kinase A [PKA]) induced Bcl2 hyperphosphorylation and apoptosis, which were blocked by the PKA inhibitor Rp diastereomers of cAMP (Rp-cAMP). Vincristine 29-40 BCL2 apoptosis regulator Homo sapiens 139-143 9584191-4 1998 In addition, paclitaxel- and vincristine-induced activation of cyclic AMP (cAMP)-dependent protein kinase (protein kinase A [PKA]) induced Bcl2 hyperphosphorylation and apoptosis, which were blocked by the PKA inhibitor Rp diastereomers of cAMP (Rp-cAMP). Cyclic AMP 63-73 BCL2 apoptosis regulator Homo sapiens 139-143 9584191-4 1998 In addition, paclitaxel- and vincristine-induced activation of cyclic AMP (cAMP)-dependent protein kinase (protein kinase A [PKA]) induced Bcl2 hyperphosphorylation and apoptosis, which were blocked by the PKA inhibitor Rp diastereomers of cAMP (Rp-cAMP). Cyclic AMP 75-79 BCL2 apoptosis regulator Homo sapiens 139-143 9584191-4 1998 In addition, paclitaxel- and vincristine-induced activation of cyclic AMP (cAMP)-dependent protein kinase (protein kinase A [PKA]) induced Bcl2 hyperphosphorylation and apoptosis, which were blocked by the PKA inhibitor Rp diastereomers of cAMP (Rp-cAMP). Cyclic AMP 240-244 BCL2 apoptosis regulator Homo sapiens 139-143 9584191-4 1998 In addition, paclitaxel- and vincristine-induced activation of cyclic AMP (cAMP)-dependent protein kinase (protein kinase A [PKA]) induced Bcl2 hyperphosphorylation and apoptosis, which were blocked by the PKA inhibitor Rp diastereomers of cAMP (Rp-cAMP). Cyclic AMP 240-244 BCL2 apoptosis regulator Homo sapiens 139-143 9584191-8 1998 Interestingly, paclitaxel or vincristine induced activation of caspase 3 and cleavage of poly(ADP-ribose) polymerase downstream of Bcl2 hyperphosphorylation. Paclitaxel 15-25 BCL2 apoptosis regulator Homo sapiens 131-135 9584191-8 1998 Interestingly, paclitaxel or vincristine induced activation of caspase 3 and cleavage of poly(ADP-ribose) polymerase downstream of Bcl2 hyperphosphorylation. Vincristine 29-40 BCL2 apoptosis regulator Homo sapiens 131-135 11825416-2 1998 METHOD: We detected the apoptotic status and the expression of apoptotic related gene bcl-2 and bax protein in 48 cases of RCC with TdT-mediated dUTP-biotin nick end labeling (TUNEL) and immunohistochemistry methods. dutp-biotin 145-156 BCL2 apoptosis regulator Homo sapiens 86-91 9626159-3 1998 We recently showed that Bcl-2 protein, an apoptosis-inhibiting gene product, was abundantly expressed in leiomyoma relative to its expression in the normal myometrium and that Bcl-2 protein expression in cultured leiomyoma cells was up-regulated by P4, but down-regulated by 17 beta-estradiol (E2). Estradiol 278-292 BCL2 apoptosis regulator Homo sapiens 24-29 9626159-3 1998 We recently showed that Bcl-2 protein, an apoptosis-inhibiting gene product, was abundantly expressed in leiomyoma relative to its expression in the normal myometrium and that Bcl-2 protein expression in cultured leiomyoma cells was up-regulated by P4, but down-regulated by 17 beta-estradiol (E2). Estradiol 278-292 BCL2 apoptosis regulator Homo sapiens 176-181 9678718-9 1998 Furthermore, HL-60 cells transduced with a bcl-2 expression vector showed the same differentiation response to retinoids as did parental HL-60 cells even though apoptosis was inhibited in these bcl-2-transduced cells, suggesting that differentiation and apoptosis are regulated independently in myeloid leukemic cells. Retinoids 111-120 BCL2 apoptosis regulator Homo sapiens 43-48 9638703-3 1998 Immunohistochemical analysis with monoclonal antibodies to bcl-2 oncoprotein in formalin-fixed paraffin-embedded tissue sections revealed that severe epithelial dysplasias had a higher percentage of immunoreactivity than did mild and moderate dysplasias and squamous cell carcinomas. Formaldehyde 80-88 BCL2 apoptosis regulator Homo sapiens 59-64 9638703-3 1998 Immunohistochemical analysis with monoclonal antibodies to bcl-2 oncoprotein in formalin-fixed paraffin-embedded tissue sections revealed that severe epithelial dysplasias had a higher percentage of immunoreactivity than did mild and moderate dysplasias and squamous cell carcinomas. Paraffin 95-103 BCL2 apoptosis regulator Homo sapiens 59-64 9593754-8 1998 Finally, cells overexpressing both Cdxs showed strongly decreased Bcl-2 expression, which could account for their increased sensitivity to apoptosis. cdxs 35-39 BCL2 apoptosis regulator Homo sapiens 66-71 9610364-0 1998 Zinc suppresses apoptosis of U937 cells induced by hydrogen peroxide through an increase of the Bcl-2/Bax ratio. Hydrogen Peroxide 51-68 BCL2 apoptosis regulator Homo sapiens 96-101 9610364-3 1998 Hydrogen peroxide treatment for 1h with or without zinc increased both Bcl-2 and Bax proteins. Hydrogen Peroxide 0-17 BCL2 apoptosis regulator Homo sapiens 71-76 9610364-3 1998 Hydrogen peroxide treatment for 1h with or without zinc increased both Bcl-2 and Bax proteins. Hydrogen 32-34 BCL2 apoptosis regulator Homo sapiens 71-76 9610364-7 1998 These results indicate that the suppression of H2O2-induced apoptosis by zinc is mediated through an increase of the Bcl-2/Bax ratio, which occurs upstream from the activation of CPP32. Hydrogen Peroxide 47-51 BCL2 apoptosis regulator Homo sapiens 117-122 9619871-6 1998 These results suggest that upregulation of bcl-2 in 4-pp-R cells is related to the resistance to CPT-11 as well as to A23187 or dexamethasone. 4-pp 52-56 BCL2 apoptosis regulator Homo sapiens 43-48 9575197-12 1998 These results suggest that BNIP3 is a member of the BH3-contaning BCL-2 family of pro-apoptotic proteins and functions in mitochondria. BH 3 52-55 BCL2 apoptosis regulator Homo sapiens 66-71 9619871-6 1998 These results suggest that upregulation of bcl-2 in 4-pp-R cells is related to the resistance to CPT-11 as well as to A23187 or dexamethasone. Irinotecan 97-103 BCL2 apoptosis regulator Homo sapiens 43-48 9619871-6 1998 These results suggest that upregulation of bcl-2 in 4-pp-R cells is related to the resistance to CPT-11 as well as to A23187 or dexamethasone. Calcimycin 118-124 BCL2 apoptosis regulator Homo sapiens 43-48 9619871-6 1998 These results suggest that upregulation of bcl-2 in 4-pp-R cells is related to the resistance to CPT-11 as well as to A23187 or dexamethasone. Dexamethasone 128-141 BCL2 apoptosis regulator Homo sapiens 43-48 9565547-4 1998 Bcl-2, a protein that protects against apoptosis and blocks cytochrome c release, prevents superoxide production when it is overexpressed. Superoxides 91-101 BCL2 apoptosis regulator Homo sapiens 0-5 9576963-0 1998 Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. Oxidopamine 73-90 BCL2 apoptosis regulator Homo sapiens 33-38 9576963-0 1998 Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 95-140 BCL2 apoptosis regulator Homo sapiens 33-38 9635829-0 1998 Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines. Cisplatin 36-45 BCL2 apoptosis regulator Homo sapiens 19-24 9558392-6 1998 ATRA treatment also led to downregulation of bcl-2 and endogenous RARalpha in PML-RARalpha-expressing cells, but had little effect on the level of exogenously expressed PML-RARalpha. Tretinoin 0-4 BCL2 apoptosis regulator Homo sapiens 45-50 9558392-7 1998 We conclude that (1) subtle differences exist in the biologic activities of the L and S isoforms of PML-RARalpha, and (2) both isoforms are capable of transducing an ATRA-mediated signal that leads to downregulation of bcl-2 and induction of programmed cell death. Tretinoin 166-170 BCL2 apoptosis regulator Homo sapiens 219-224 9635834-2 1998 The bcl-2 oncoprotein is thought to make cells resistant to a variety of insults, including cytotoxic drugs, by the suppression of apoptosis, which appears to involve the repartitioning of intracellular calcium. Calcium 203-210 BCL2 apoptosis regulator Homo sapiens 4-9 9652754-0 1998 Nitrogen mustard up-regulates Bcl-2 and GSH and increases NTP and PCr in HT-29 colon cancer cells. Mechlorethamine 0-16 BCL2 apoptosis regulator Homo sapiens 30-35 10200493-6 1998 We found Bcl-2 over-expression and ZVAD.FMK-sensitive caspase inhibition were able to prevent chromatin condensation and cellular fragmentation. FMK 40-43 BCL2 apoptosis regulator Homo sapiens 9-14 9652754-1 1998 We hypothesized that unexplained increases in nucleoside triphosphates (NTP) observed by 31P magnetic resonance spectroscopy (MRS) after treatment of tumours by DNA-damaging agents were related to chemotherapy-induced up-regulation of the bcl-2 gene and DNA damage prevention and repair processes. nucleoside triphosphates 46-70 BCL2 apoptosis regulator Homo sapiens 239-244 9652754-1 1998 We hypothesized that unexplained increases in nucleoside triphosphates (NTP) observed by 31P magnetic resonance spectroscopy (MRS) after treatment of tumours by DNA-damaging agents were related to chemotherapy-induced up-regulation of the bcl-2 gene and DNA damage prevention and repair processes. ntp 72-75 BCL2 apoptosis regulator Homo sapiens 239-244 9652754-4 1998 Increased cell division was noted at 4 h. Two high-energy interconvertible phosphates, NTP (P < or = 0.006) and phosphocreatine (PCr) (P < or = 0.0002), increased at 2 h concurrently with increased levels of bcl-2 protein and glutathione. Phosphates 75-85 BCL2 apoptosis regulator Homo sapiens 214-219 9652754-5 1998 This study demonstrates that bcl-2 and glutathione are up-regulated by HN2 and links this to a previously unexplained 31P MRS phenomenon: increased NTP after chemotherapy. ntp 148-151 BCL2 apoptosis regulator Homo sapiens 29-34 9596995-0 1998 A phosphatidylcholine phospholipase C inhibitor, D609, blocks interleukin-3 (IL-3)-induced bcl-2 expression but not c-myc expression in human IL-3-dependent cells. tricyclodecane-9-yl-xanthogenate 49-53 BCL2 apoptosis regulator Homo sapiens 91-96 9596995-4 1998 Using human IL-3-dependent TF-1 cells, we have found that the tyrosine kinase inhibitor genistein blocks both the IL-3 suppression of apoptosis and the expression of the cell survival gene bcl-2. Genistein 88-97 BCL2 apoptosis regulator Homo sapiens 189-194 9596995-5 1998 In addition, we have found that D609, a specific inhibitor of phosphatidylcholine-specific phospholipase C, also inhibits IL-3-induced expression of the bcl-2 gene without affecting IL-3-induced tyrosine phosphorylation. tricyclodecane-9-yl-xanthogenate 32-36 BCL2 apoptosis regulator Homo sapiens 153-158 9596995-5 1998 In addition, we have found that D609, a specific inhibitor of phosphatidylcholine-specific phospholipase C, also inhibits IL-3-induced expression of the bcl-2 gene without affecting IL-3-induced tyrosine phosphorylation. Phosphatidylcholines 62-81 BCL2 apoptosis regulator Homo sapiens 153-158 9596995-7 1998 Significantly, genistein inhibited the IL-3 induction of both bcl-2 and c-myc gene. Genistein 15-24 BCL2 apoptosis regulator Homo sapiens 62-67 9556624-11 1998 Evidence is provided to demonstrate that depletion of GSH is dependent on activity of interleukin-1beta-converting enzyme-like proteases but is upstream of the site of action of Bcl-2 and of the execution phase caspases. Glutathione 54-57 BCL2 apoptosis regulator Homo sapiens 178-183 9581676-0 1998 Loss of butyrate-induced apoptosis in human hepatoma cell lines HCC-M and HCC-T having substantial Bcl-2 expression. Butyrates 8-16 BCL2 apoptosis regulator Homo sapiens 99-104 9581676-7 1998 Western blot analysis showed that Bcl-2 was expressed in the HCC-T and HCC-M cells, and its expression was increased after exposure to sodium butyrate. Butyric Acid 135-150 BCL2 apoptosis regulator Homo sapiens 34-39 9581676-8 1998 Antisense oligodeoxynucleotide against bcl-2 easily caused apoptosis. Oligodeoxyribonucleotides 10-30 BCL2 apoptosis regulator Homo sapiens 39-44 9581676-9 1998 These results indicate that sodium butyrate hardly induces apoptotic change in the human hepatoma cell lines, HCC-T and HCC-M, with the increase of Bcl-2 expression. Butyric Acid 28-43 BCL2 apoptosis regulator Homo sapiens 148-153 9576258-8 1998 Exogenous IGF-I stimulated WITG3 cell proliferation and significantly (p < 0.05) antagonized the cytotoxic effects of TAM in a dose-dependent fashion; IGF-I, but not TAM, enhanced expression of bcl-2 and bcl-xL proteins; however, bax protein expression was unchanged by either treatment. Tamoxifen 121-124 BCL2 apoptosis regulator Homo sapiens 197-202 9584207-1 1998 We investigated the roles of p53 and Bcl-2 homologues in the induction of apoptosis by cisplatin and paclitaxel in wild-type p53-expressing human ovarian carcinoma cells and cisplatin-resistant derivatives that have lost p53 function. Cisplatin 87-96 BCL2 apoptosis regulator Homo sapiens 37-42 9584207-1 1998 We investigated the roles of p53 and Bcl-2 homologues in the induction of apoptosis by cisplatin and paclitaxel in wild-type p53-expressing human ovarian carcinoma cells and cisplatin-resistant derivatives that have lost p53 function. Paclitaxel 101-111 BCL2 apoptosis regulator Homo sapiens 37-42 9553057-8 1998 Furthermore, their autocatalytic and apoptotic activities were inhibited by the pancaspase inhibitor z-VAD-fluoromethylketone, but not by CrmA or Bcl-2, thus directly demonstrating that the targets of inhibition of apoptosis by CrmA and Bcl-2 are upstream of caspases-3 and -6. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 101-125 BCL2 apoptosis regulator Homo sapiens 237-242 9682214-0 1998 Bcl-2 regulates nonapoptotic signal transduction: inhibition of c-Jun N-terminal kinase (JNK) activation by IL-1 beta and hydrogen peroxide. Hydrogen Peroxide 122-139 BCL2 apoptosis regulator Homo sapiens 0-5 9682214-5 1998 Treatment with nonlethal concentrations of H2O2, which resulted in the simultaneous stimulation of mitogen-activated protein kinase (MAPK) and JNK, demonstrated that bcl-2 appeared to alter the balance of activation of these two kinase cascades. Hydrogen Peroxide 43-47 BCL2 apoptosis regulator Homo sapiens 166-171 9682214-7 1998 In contrast, the reduction in JNK activity in cells expressing bcl-2 can be restored by costimulation with a calcium ionophore. Calcium 109-116 BCL2 apoptosis regulator Homo sapiens 63-68 9621361-2 1998 We have reported that PPF induced apoptosis in human glioma cells and as its mechanism, up-regulation of NGF, Fas, Bax beta and down-regulation of Bcl-2 were assumed. propentofylline 22-25 BCL2 apoptosis regulator Homo sapiens 147-152 11243121-0 1998 [Fas mediated apoptosis inhibited by human bcl-2 gene in lymphoma cell line Jurkat]. ammonium ferrous sulfate 1-4 BCL2 apoptosis regulator Homo sapiens 43-48 9588215-7 1998 This increase of Bcl-2 in MDR cells could be due to the selection process as vincristine enhances Bcl-2 phosphorylation and expression in HL60 sensitive cells. Vincristine 77-88 BCL2 apoptosis regulator Homo sapiens 17-22 9588215-7 1998 This increase of Bcl-2 in MDR cells could be due to the selection process as vincristine enhances Bcl-2 phosphorylation and expression in HL60 sensitive cells. Vincristine 77-88 BCL2 apoptosis regulator Homo sapiens 98-103 9588215-8 1998 MDR HL60-Vincristine cells therefore display a resistance to apoptosis induced by non-MDR drugs, possibly by Bcl-2 overexpression and inability of these drugs to mediate intracellular pH changes in these drug-resistant cells. Vincristine 9-20 BCL2 apoptosis regulator Homo sapiens 109-114 9563480-16 1998 This age-dependent nature of initiation, together with the differential responses of Bcl-2+ and Bcl-2- lesions, may be responsible for the apparently contradictory outcomes of PB treatment in infant and adult B6C3F1 mice. Phenobarbital 176-178 BCL2 apoptosis regulator Homo sapiens 85-90 9581775-7 1998 TNFalpha plus NAC treatment resulted in a marked decrease in Bcl-2 protein levels in HIV-1-infected cells, coupled with an increase in Bax protein compared to uninfected cells, suggesting that the difference in susceptibility to TNFalpha-induced apoptosis may relate to the differences in relative levels of Bcl-2 and Bax. Acetylcysteine 14-17 BCL2 apoptosis regulator Homo sapiens 61-66 9581775-7 1998 TNFalpha plus NAC treatment resulted in a marked decrease in Bcl-2 protein levels in HIV-1-infected cells, coupled with an increase in Bax protein compared to uninfected cells, suggesting that the difference in susceptibility to TNFalpha-induced apoptosis may relate to the differences in relative levels of Bcl-2 and Bax. Acetylcysteine 14-17 BCL2 apoptosis regulator Homo sapiens 308-313 9563469-0 1998 Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Serine 0-6 BCL2 apoptosis regulator Homo sapiens 56-60 9563469-1 1998 Taxoids and other microtubule-damaging drugs are known to induce Bcl2 phosphorylation at the G2-M phase of the cell cycle, with concomitant apoptosis in malignant cells derived from a variety of human malignancies, including leukemia, lymphoma, and breast and prostate cancer. Taxoids 0-7 BCL2 apoptosis regulator Homo sapiens 65-69 9547337-6 1998 Although calcium, prooxidants, and several recombinant caspases (caspases 1, 2, 3, 4, and 6) enhance the permeability of PT pore-containing liposomes, recombinant Bcl-2 or Bcl-XL augment the resistance of the reconstituted PT pore complex to pore opening. Calcium 9-16 BCL2 apoptosis regulator Homo sapiens 163-168 9563480-16 1998 This age-dependent nature of initiation, together with the differential responses of Bcl-2+ and Bcl-2- lesions, may be responsible for the apparently contradictory outcomes of PB treatment in infant and adult B6C3F1 mice. Phenobarbital 176-178 BCL2 apoptosis regulator Homo sapiens 96-101 9563469-2 1998 We have investigated the ability of another antineoplastic drug, dolastatin 10, in inducing Bcl2 phosphorylation and apoptosis. dolastatin 10 65-78 BCL2 apoptosis regulator Homo sapiens 92-96 9563469-3 1998 We also investigated the effects of a phosphatase inhibitor okadaic acid in the regulation of Bcl2 phosphorylation, cell cycle arrest, and programmed cell death. Okadaic Acid 60-72 BCL2 apoptosis regulator Homo sapiens 94-98 9610615-5 1998 Nuclear staining of bcl-2 was observed in 50% of AGC, 30% of EGC, and 10% of TA; cytoplasmic staining, on the other hand, was observed in all TA, 5% of EGC, and 10% of AGC. gallocatechol 61-64 BCL2 apoptosis regulator Homo sapiens 20-25 9563469-4 1998 Moreover, site-directed mutagenesis studies were performed to determine the specific serine residue(s) responsible for drug-induced Bcl2 phosphorylation. Serine 85-91 BCL2 apoptosis regulator Homo sapiens 132-136 9563469-5 1998 Our results indicate that these antimicrotubule agents or okadaic acid can induce posttranslational modification (phosphorylation) of Bcl2 protein at multiple serine residues. Okadaic Acid 58-70 BCL2 apoptosis regulator Homo sapiens 134-138 9563469-5 1998 Our results indicate that these antimicrotubule agents or okadaic acid can induce posttranslational modification (phosphorylation) of Bcl2 protein at multiple serine residues. Serine 159-165 BCL2 apoptosis regulator Homo sapiens 134-138 9535847-2 1998 Sequence analysis revealed that Mtd is a member of the Bcl-2 family of proteins containing conserved BH1, BH2, BH3, and BH4 regions and a carboxyl-terminal hydrophobic domain. bh1 101-104 BCL2 apoptosis regulator Homo sapiens 55-60 9535847-2 1998 Sequence analysis revealed that Mtd is a member of the Bcl-2 family of proteins containing conserved BH1, BH2, BH3, and BH4 regions and a carboxyl-terminal hydrophobic domain. bh2 106-109 BCL2 apoptosis regulator Homo sapiens 55-60 9535847-2 1998 Sequence analysis revealed that Mtd is a member of the Bcl-2 family of proteins containing conserved BH1, BH2, BH3, and BH4 regions and a carboxyl-terminal hydrophobic domain. BH 3 111-114 BCL2 apoptosis regulator Homo sapiens 55-60 9535847-2 1998 Sequence analysis revealed that Mtd is a member of the Bcl-2 family of proteins containing conserved BH1, BH2, BH3, and BH4 regions and a carboxyl-terminal hydrophobic domain. sapropterin 120-123 BCL2 apoptosis regulator Homo sapiens 55-60 9607633-3 1998 We hypothesize that (1) chemotherapeutic agents induce mitochondrial changes and apoptosis through mechanisms associated with reactive oxidant species production; (2) the anti-apoptotic protein Bcl-2 prevents drug-induced mitochondrial changes, reactive oxygen species (ROS) production, and apoptosis; and (3) the assay of drug-induced mitochondrial changes can reflect drug-specific chemoresistance in a given cancer cell line. Reactive Oxygen Species 245-268 BCL2 apoptosis regulator Homo sapiens 194-199 9607633-3 1998 We hypothesize that (1) chemotherapeutic agents induce mitochondrial changes and apoptosis through mechanisms associated with reactive oxidant species production; (2) the anti-apoptotic protein Bcl-2 prevents drug-induced mitochondrial changes, reactive oxygen species (ROS) production, and apoptosis; and (3) the assay of drug-induced mitochondrial changes can reflect drug-specific chemoresistance in a given cancer cell line. Reactive Oxygen Species 270-273 BCL2 apoptosis regulator Homo sapiens 194-199 9607633-10 1998 RESULTS: Both SKBr3 and SKBr3/Bcl2-2 cells show cell cycle arrest after Herbimycin treatment. herbimycin 72-82 BCL2 apoptosis regulator Homo sapiens 30-34 9607633-13 1998 By contrast, Herbimycin-treated SKBr3/Bcl2-2 cells show no change in mitochondrial mass or deltapsi(m). herbimycin 13-23 BCL2 apoptosis regulator Homo sapiens 38-42 9607633-16 1998 Bcl-2 transfection prevents these changes because it prevents apoptosis and induces chemoresistance to Herbimycin in SKBr3. herbimycin 103-113 BCL2 apoptosis regulator Homo sapiens 0-5 9607633-16 1998 Bcl-2 transfection prevents these changes because it prevents apoptosis and induces chemoresistance to Herbimycin in SKBr3. skbr3 117-122 BCL2 apoptosis regulator Homo sapiens 0-5 9600337-2 1998 The present study provides evidence that nicotine (a) activates the mitogen-activated protein (MAP) kinase signalling pathway in lung cancer cells, specifically extracellular signal-regulated kinase (ERK2), resulting in increased expression of the bcl-2 protein and inhibition of apoptosis in these cells; and (b) blocks the inhibition of protein kinase C (PKC) and ERK2 activity in lung cancer cells by anti-cancer agents, such as therapeutic opioid drugs, and thus can adversely affect cancer therapy. Nicotine 41-49 BCL2 apoptosis regulator Homo sapiens 248-253 9528999-1 1998 1,25-Dihydroxyvitamin D3 [1,25-(OH)2D3] and its synthetic analog EB1089 induce characteristic morphological features of apoptosis in MCF-7 cells in vitro that coincide with up-regulation of clusterin and cathepsin B, proteins associated with apoptosis in the mammary gland, and with down-regulation of Bcl-2, an antiapoptotic protein. Calcitriol 0-24 BCL2 apoptosis regulator Homo sapiens 302-307 9528999-1 1998 1,25-Dihydroxyvitamin D3 [1,25-(OH)2D3] and its synthetic analog EB1089 induce characteristic morphological features of apoptosis in MCF-7 cells in vitro that coincide with up-regulation of clusterin and cathepsin B, proteins associated with apoptosis in the mammary gland, and with down-regulation of Bcl-2, an antiapoptotic protein. Calcitriol 26-38 BCL2 apoptosis regulator Homo sapiens 302-307 9615758-0 1998 Dolastatin 15 induces apoptosis and BCL-2 phosphorylation in small cell lung cancer cell lines. dolastatin 15 0-13 BCL2 apoptosis regulator Homo sapiens 36-41 9695733-8 1998 Pulse BrdU uptake showed an increased G1/G0 fraction in Bcl-2(+) cells. Bromodeoxyuridine 6-10 BCL2 apoptosis regulator Homo sapiens 56-61 9695733-9 1998 Doxorubicin-induced apoptosis occurred in Bcl-2(-) but not in Bcl-2(+) cell lines. Doxorubicin 0-11 BCL2 apoptosis regulator Homo sapiens 42-47 9547353-6 1998 The antioxidants vitamin E, vitamin C, or trolox prevented the lipid peroxidation as well as the cytotoxicity and apoptosis, as did transfection with plasmid containing antisense CYP2E1 or overexpression of Bcl-2. Vitamin E 17-26 BCL2 apoptosis regulator Homo sapiens 207-212 9592822-0 1998 [Neural protective agents, propentofylline (PPF) could induce apoptotic cell death in the human glioma cells: analysis of Bcl-2 and Bax alpha/Bax beta expressions]. propentofylline 27-42 BCL2 apoptosis regulator Homo sapiens 122-127 9592822-0 1998 [Neural protective agents, propentofylline (PPF) could induce apoptotic cell death in the human glioma cells: analysis of Bcl-2 and Bax alpha/Bax beta expressions]. propentofylline 44-47 BCL2 apoptosis regulator Homo sapiens 122-127 9592822-4 1998 Recently, we have found that propentofylline could modulate some apoptosis related genes products in the glioma cell lines, i.e. NGF, trk A mRNA levels and Fas protein expressions were increased, whereas bcl-2 mRNA level was decreased. propentofylline 29-44 BCL2 apoptosis regulator Homo sapiens 204-209 9579023-0 1998 Bcl-2 and Bcl-xL in peroxide-resistant A549 and U87MG cells. Peroxides 20-28 BCL2 apoptosis regulator Homo sapiens 0-5 9579023-4 1998 When examined 7 to 32 days after cessation of peroxide exposure (times when peroxide resistance was maintained), bcl-2 protein levels were significantly increased in most peroxide-resistant U87MG cells. Peroxides 46-54 BCL2 apoptosis regulator Homo sapiens 113-118 9579023-4 1998 When examined 7 to 32 days after cessation of peroxide exposure (times when peroxide resistance was maintained), bcl-2 protein levels were significantly increased in most peroxide-resistant U87MG cells. Peroxides 76-84 BCL2 apoptosis regulator Homo sapiens 113-118 9579023-4 1998 When examined 7 to 32 days after cessation of peroxide exposure (times when peroxide resistance was maintained), bcl-2 protein levels were significantly increased in most peroxide-resistant U87MG cells. Peroxides 76-84 BCL2 apoptosis regulator Homo sapiens 113-118 9579023-10 1998 Although the increased bcl-2 protein in peroxide-resistant U87MG cells may contribute to their oxidant tolerance, the lack of a dose-response relationship, the failure to induce bcl-xL protein, and the absence of any bcl-2 or bcl-xL protein induction in peroxide-resistant A549 cells suggest these genes are not primary factors in oxidant resistance. Peroxides 40-48 BCL2 apoptosis regulator Homo sapiens 23-28 9579023-10 1998 Although the increased bcl-2 protein in peroxide-resistant U87MG cells may contribute to their oxidant tolerance, the lack of a dose-response relationship, the failure to induce bcl-xL protein, and the absence of any bcl-2 or bcl-xL protein induction in peroxide-resistant A549 cells suggest these genes are not primary factors in oxidant resistance. Peroxides 254-262 BCL2 apoptosis regulator Homo sapiens 23-28 9579691-3 1998 The proto-oncogene bcl-2 is involved in the regulation of cell death and is able to block apoptosis in motoneurones. motoneurones 103-115 BCL2 apoptosis regulator Homo sapiens 19-24 9547353-6 1998 The antioxidants vitamin E, vitamin C, or trolox prevented the lipid peroxidation as well as the cytotoxicity and apoptosis, as did transfection with plasmid containing antisense CYP2E1 or overexpression of Bcl-2. Ascorbic Acid 28-37 BCL2 apoptosis regulator Homo sapiens 207-212 9547353-6 1998 The antioxidants vitamin E, vitamin C, or trolox prevented the lipid peroxidation as well as the cytotoxicity and apoptosis, as did transfection with plasmid containing antisense CYP2E1 or overexpression of Bcl-2. 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid 42-48 BCL2 apoptosis regulator Homo sapiens 207-212 9501197-0 1998 Bcl-2 expression causes redistribution of glutathione to the nucleus. Glutathione 42-53 BCL2 apoptosis regulator Homo sapiens 0-5 9501197-1 1998 In this study we used HeLa cells transfected with a conditional Bcl-2 expression construct to study the effects of Bcl-2 on reduced glutathione (GSH) metabolism. Glutathione 132-143 BCL2 apoptosis regulator Homo sapiens 115-120 9501197-1 1998 In this study we used HeLa cells transfected with a conditional Bcl-2 expression construct to study the effects of Bcl-2 on reduced glutathione (GSH) metabolism. Glutathione 145-148 BCL2 apoptosis regulator Homo sapiens 115-120 9501197-2 1998 Our previous work demonstrated that depletion of GSH by culturing cells in tissue culture medium lacking the amino acids cysteine and methionine, essential for GSH biosynthesis, caused cells overexpressing Bcl-2 to become sensitized to apoptotic induction. Glutathione 49-52 BCL2 apoptosis regulator Homo sapiens 206-211 9501197-2 1998 Our previous work demonstrated that depletion of GSH by culturing cells in tissue culture medium lacking the amino acids cysteine and methionine, essential for GSH biosynthesis, caused cells overexpressing Bcl-2 to become sensitized to apoptotic induction. amino acids cysteine 109-129 BCL2 apoptosis regulator Homo sapiens 206-211 9501197-2 1998 Our previous work demonstrated that depletion of GSH by culturing cells in tissue culture medium lacking the amino acids cysteine and methionine, essential for GSH biosynthesis, caused cells overexpressing Bcl-2 to become sensitized to apoptotic induction. Methionine 134-144 BCL2 apoptosis regulator Homo sapiens 206-211 9501197-2 1998 Our previous work demonstrated that depletion of GSH by culturing cells in tissue culture medium lacking the amino acids cysteine and methionine, essential for GSH biosynthesis, caused cells overexpressing Bcl-2 to become sensitized to apoptotic induction. Glutathione 160-163 BCL2 apoptosis regulator Homo sapiens 206-211 9501197-3 1998 Here we report that Bcl-2 also dramatically alters GSH compartmentalization. Glutathione 51-54 BCL2 apoptosis regulator Homo sapiens 20-25 9501197-4 1998 Cellular distribution of GSH, assayed by confocal microscopy, revealed that when Bcl-2 expression was suppressed GSH was uniformly distributed primarily in the cytosol, whereas overexpression of Bcl-2 led to a relocalization of GSH into the nucleus. Glutathione 25-28 BCL2 apoptosis regulator Homo sapiens 81-86 9501197-4 1998 Cellular distribution of GSH, assayed by confocal microscopy, revealed that when Bcl-2 expression was suppressed GSH was uniformly distributed primarily in the cytosol, whereas overexpression of Bcl-2 led to a relocalization of GSH into the nucleus. Glutathione 25-28 BCL2 apoptosis regulator Homo sapiens 195-200 9501197-4 1998 Cellular distribution of GSH, assayed by confocal microscopy, revealed that when Bcl-2 expression was suppressed GSH was uniformly distributed primarily in the cytosol, whereas overexpression of Bcl-2 led to a relocalization of GSH into the nucleus. Glutathione 113-116 BCL2 apoptosis regulator Homo sapiens 81-86 9501197-4 1998 Cellular distribution of GSH, assayed by confocal microscopy, revealed that when Bcl-2 expression was suppressed GSH was uniformly distributed primarily in the cytosol, whereas overexpression of Bcl-2 led to a relocalization of GSH into the nucleus. Glutathione 113-116 BCL2 apoptosis regulator Homo sapiens 81-86 9501197-7 1998 Our results indicate that one of the functions of Bcl-2 is to promote sequestration of GSH into the nucleus, thereby altering nuclear redox and blocking caspase activity as well as other nuclear alterations characteristic of apoptosis. Glutathione 87-90 BCL2 apoptosis regulator Homo sapiens 50-55 9506361-10 1998 bcl-2 expression and resistance to SNP toxicity both were decreased by the introduction of PKCalpha antisense oligonucleotides into U343 cells. Oligonucleotides 110-126 BCL2 apoptosis regulator Homo sapiens 0-5 9506361-13 1998 The susceptibility of these glioma cells to nitroprusside-induced killing appears to be correlated inversely with bcl-2 and PKC activity. Nitroprusside 44-57 BCL2 apoptosis regulator Homo sapiens 114-119 9514052-0 1998 Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)all-trans retinamide. Oligonucleotides 71-86 BCL2 apoptosis regulator Homo sapiens 55-60 9514052-0 1998 Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)all-trans retinamide. n-(2-hydroxyphenyl) 102-121 BCL2 apoptosis regulator Homo sapiens 55-60 9615758-9 1998 Immunoblot analysis of dolastatin 15-treated cells which overexpressed bcl-2 revealed a pattern consistent with bcl-2 phosphorylation. dolastatin 15 23-36 BCL2 apoptosis regulator Homo sapiens 71-76 9514052-0 1998 Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)all-trans retinamide. retinamide 131-141 BCL2 apoptosis regulator Homo sapiens 55-60 9514052-5 1998 Cell growth in liquid culture was significantly inhibited by antisense Bcl-2 oligonucleotides compared with control sense oligonucleotides; inhibition by these oligonucleotides was significantly enhanced on combination with the synthetic retinoid N-(2-hydroxyphenyl)all-trans-retinamide (2-HPR). Oligonucleotides 77-93 BCL2 apoptosis regulator Homo sapiens 71-76 9514052-5 1998 Cell growth in liquid culture was significantly inhibited by antisense Bcl-2 oligonucleotides compared with control sense oligonucleotides; inhibition by these oligonucleotides was significantly enhanced on combination with the synthetic retinoid N-(2-hydroxyphenyl)all-trans-retinamide (2-HPR). Oligonucleotides 122-138 BCL2 apoptosis regulator Homo sapiens 71-76 9514052-5 1998 Cell growth in liquid culture was significantly inhibited by antisense Bcl-2 oligonucleotides compared with control sense oligonucleotides; inhibition by these oligonucleotides was significantly enhanced on combination with the synthetic retinoid N-(2-hydroxyphenyl)all-trans-retinamide (2-HPR). Oligonucleotides 122-138 BCL2 apoptosis regulator Homo sapiens 71-76 9514052-5 1998 Cell growth in liquid culture was significantly inhibited by antisense Bcl-2 oligonucleotides compared with control sense oligonucleotides; inhibition by these oligonucleotides was significantly enhanced on combination with the synthetic retinoid N-(2-hydroxyphenyl)all-trans-retinamide (2-HPR). Retinoids 238-246 BCL2 apoptosis regulator Homo sapiens 71-76 9615758-9 1998 Immunoblot analysis of dolastatin 15-treated cells which overexpressed bcl-2 revealed a pattern consistent with bcl-2 phosphorylation. dolastatin 15 23-36 BCL2 apoptosis regulator Homo sapiens 112-117 9514052-5 1998 Cell growth in liquid culture was significantly inhibited by antisense Bcl-2 oligonucleotides compared with control sense oligonucleotides; inhibition by these oligonucleotides was significantly enhanced on combination with the synthetic retinoid N-(2-hydroxyphenyl)all-trans-retinamide (2-HPR). n-(2-hydroxyphenyl)all-trans-retinamide 247-286 BCL2 apoptosis regulator Homo sapiens 71-76 9514052-8 1998 The use of Bcl-2 antisense oligonucleotides plus 2-HPR may provide a novel approach to therapy of hormone-resistant prostate cancer. Oligonucleotides 27-43 BCL2 apoptosis regulator Homo sapiens 11-16 9559879-8 1998 Furthermore, ectopic overexpression of Bcl-2 in HL-60 cells also attenuated beta-lapachone-induced H2O2 and conferred resistance to beta-lapachone-induced cell death. beta-lapachone 76-90 BCL2 apoptosis regulator Homo sapiens 39-44 9580328-4 1998 Overexpression of Bcl-2 and pretreatment with either the immunosuppressant cyclosporin A or the glutathione precursor N-acetyl-L-cysteine blocked deltapsi(m) disruption and apoptosis, but not the generation of ROS induced by these compounds. Cyclosporine 75-88 BCL2 apoptosis regulator Homo sapiens 18-23 9580328-4 1998 Overexpression of Bcl-2 and pretreatment with either the immunosuppressant cyclosporin A or the glutathione precursor N-acetyl-L-cysteine blocked deltapsi(m) disruption and apoptosis, but not the generation of ROS induced by these compounds. Glutathione 96-107 BCL2 apoptosis regulator Homo sapiens 18-23 9580328-4 1998 Overexpression of Bcl-2 and pretreatment with either the immunosuppressant cyclosporin A or the glutathione precursor N-acetyl-L-cysteine blocked deltapsi(m) disruption and apoptosis, but not the generation of ROS induced by these compounds. Acetylcysteine 118-137 BCL2 apoptosis regulator Homo sapiens 18-23 9580328-4 1998 Overexpression of Bcl-2 and pretreatment with either the immunosuppressant cyclosporin A or the glutathione precursor N-acetyl-L-cysteine blocked deltapsi(m) disruption and apoptosis, but not the generation of ROS induced by these compounds. Reactive Oxygen Species 210-213 BCL2 apoptosis regulator Homo sapiens 18-23 9559879-8 1998 Furthermore, ectopic overexpression of Bcl-2 in HL-60 cells also attenuated beta-lapachone-induced H2O2 and conferred resistance to beta-lapachone-induced cell death. Hydrogen Peroxide 99-103 BCL2 apoptosis regulator Homo sapiens 39-44 9559879-8 1998 Furthermore, ectopic overexpression of Bcl-2 in HL-60 cells also attenuated beta-lapachone-induced H2O2 and conferred resistance to beta-lapachone-induced cell death. beta-lapachone 132-146 BCL2 apoptosis regulator Homo sapiens 39-44 9519879-0 1998 The thiol crosslinking agent diamide overcomes the apoptosis-inhibitory effect of Bcl-2 by enforcing mitochondrial permeability transition. Sulfhydryl Compounds 4-9 BCL2 apoptosis regulator Homo sapiens 82-87 9591207-11 1998 An inverse, but not statistically significant (p = 0.06) correlation was observed between the percentage of bcl-2 positive cells and serum calcium level in parathyroid adenomas. Calcium 139-146 BCL2 apoptosis regulator Homo sapiens 108-113 9592841-5 1998 Although the expression of Bcl-2 varied widely from 7 to 80 x 10(3) MESF units, no significant difference was found in the mean value between the patients with acute lymphoblastic leukemia and those with acute myeloblastic leukemia. mesf 68-72 BCL2 apoptosis regulator Homo sapiens 27-32 9619919-0 1998 Taxol can induce phosphorylation of BCL-2 in multiple myeloma cells and potentiate dexamethasone-induced apoptosis. Paclitaxel 0-5 BCL2 apoptosis regulator Homo sapiens 36-41 9619919-5 1998 Only concentrations of taxol that phosphorylated BCL-2 interacted with dexamethasone for enhanced apoptotic death. Paclitaxel 23-28 BCL2 apoptosis regulator Homo sapiens 49-54 9619919-5 1998 Only concentrations of taxol that phosphorylated BCL-2 interacted with dexamethasone for enhanced apoptotic death. Dexamethasone 71-84 BCL2 apoptosis regulator Homo sapiens 49-54 9619919-6 1998 Geldanamycin, which prevented taxol-induced BCL-2 phosphorylation, also prevented the potentiated cytotoxicity. geldanamycin 0-12 BCL2 apoptosis regulator Homo sapiens 44-49 9619919-6 1998 Geldanamycin, which prevented taxol-induced BCL-2 phosphorylation, also prevented the potentiated cytotoxicity. Paclitaxel 30-35 BCL2 apoptosis regulator Homo sapiens 44-49 10682484-3 1998 The expression of bcl-2 mRNA was also determined by northern blotting in GC of developing follicle after sex steroids addition. Steroids 109-117 BCL2 apoptosis regulator Homo sapiens 18-23 9519879-0 1998 The thiol crosslinking agent diamide overcomes the apoptosis-inhibitory effect of Bcl-2 by enforcing mitochondrial permeability transition. Diamide 29-36 BCL2 apoptosis regulator Homo sapiens 82-87 9519879-1 1998 In several different cell lines, Bcl-2 prevents the induction of apoptosis (DNA fragmentation, PARP cleavage, phosphatidylserine exposure) by the pro-oxidant ter-butylhydroperoxide (t-BHP) but has no cytoprotective effect when apoptosis is induced by the thiol crosslinking agent diazenedicarboxylic acid his 5N,N-dimethylamide (diamide). ter-butylhydroperoxide 158-180 BCL2 apoptosis regulator Homo sapiens 33-38 9519879-1 1998 In several different cell lines, Bcl-2 prevents the induction of apoptosis (DNA fragmentation, PARP cleavage, phosphatidylserine exposure) by the pro-oxidant ter-butylhydroperoxide (t-BHP) but has no cytoprotective effect when apoptosis is induced by the thiol crosslinking agent diazenedicarboxylic acid his 5N,N-dimethylamide (diamide). t-bhp 182-187 BCL2 apoptosis regulator Homo sapiens 33-38 9519879-1 1998 In several different cell lines, Bcl-2 prevents the induction of apoptosis (DNA fragmentation, PARP cleavage, phosphatidylserine exposure) by the pro-oxidant ter-butylhydroperoxide (t-BHP) but has no cytoprotective effect when apoptosis is induced by the thiol crosslinking agent diazenedicarboxylic acid his 5N,N-dimethylamide (diamide). Sulfhydryl Compounds 255-260 BCL2 apoptosis regulator Homo sapiens 33-38 9519879-1 1998 In several different cell lines, Bcl-2 prevents the induction of apoptosis (DNA fragmentation, PARP cleavage, phosphatidylserine exposure) by the pro-oxidant ter-butylhydroperoxide (t-BHP) but has no cytoprotective effect when apoptosis is induced by the thiol crosslinking agent diazenedicarboxylic acid his 5N,N-dimethylamide (diamide). diazenedicarboxylic acid his 5n 280-311 BCL2 apoptosis regulator Homo sapiens 33-38 9484785-1 1998 To investigate the effects of the expression of Bcl-2 protein in bladder cancer on the apoptosis induced by cisplatin or adenoviral-mediated p53 gene (Ad5CMV-p53) transfer, we transfected the bcl-2 gene into KoTCC-1, a human bladder cancer cell line that does not express the Bcl-2 protein. Cisplatin 108-117 BCL2 apoptosis regulator Homo sapiens 48-53 9519879-1 1998 In several different cell lines, Bcl-2 prevents the induction of apoptosis (DNA fragmentation, PARP cleavage, phosphatidylserine exposure) by the pro-oxidant ter-butylhydroperoxide (t-BHP) but has no cytoprotective effect when apoptosis is induced by the thiol crosslinking agent diazenedicarboxylic acid his 5N,N-dimethylamide (diamide). n-dimethylamide 312-327 BCL2 apoptosis regulator Homo sapiens 33-38 9519879-1 1998 In several different cell lines, Bcl-2 prevents the induction of apoptosis (DNA fragmentation, PARP cleavage, phosphatidylserine exposure) by the pro-oxidant ter-butylhydroperoxide (t-BHP) but has no cytoprotective effect when apoptosis is induced by the thiol crosslinking agent diazenedicarboxylic acid his 5N,N-dimethylamide (diamide). Diamide 329-336 BCL2 apoptosis regulator Homo sapiens 33-38 9519879-3 1998 Bcl-2 stabilizes the delta psi(m) of t-BHP-treated cells but has no inhibitory effect on the delta psi(m) collapse induced by diamide. t-bhp 37-42 BCL2 apoptosis regulator Homo sapiens 0-5 9519879-4 1998 As compared to normal controls, isolated mitochondria from Bcl-2 overexpressing cells are relatively resistant to the induction of delta psi(m) disruption by t-BHP in vitro. t-bhp 158-163 BCL2 apoptosis regulator Homo sapiens 59-64 9519879-5 1998 Such Bcl-2 overexpressing mitochondria also fail to release apoptosis-inducing factor (AIF) and cytochrome c from the intermembrane space, whereas control mitochondria not overexpressing Bcl-2 do liberate AIF and cytochrome c in response to t-BHP. t-bhp 241-246 BCL2 apoptosis regulator Homo sapiens 5-10 9519879-7 1998 This indicates that Bcl-2 suppresses the permeability transition (PT) and the associated release of intermembrane proteins induced by t-BHP but not by diamide. t-bhp 134-139 BCL2 apoptosis regulator Homo sapiens 20-25 9519879-9 1998 Recombinant Bcl-2 or Bcl-X(L) proteins augment the resistance of reconstituted PT pore complexes to pore opening induced by t-BHP. t-bhp 124-129 BCL2 apoptosis regulator Homo sapiens 12-17 9613987-0 1998 BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine. fludarabine 122-133 BCL2 apoptosis regulator Homo sapiens 0-5 9485014-2 1998 U937 human leukemic cells treated with 1,25-dihydroxyvitamin D3 [1,25(OH)2D3; 10(-8) M] become resistant to TNF, an effect that is independent of cell cycle status and expression of TNF receptors or BCL-2. 1,25-dihydroxyvitamin d3 [1,25(oh)2d3 39-76 BCL2 apoptosis regulator Homo sapiens 199-204 9484802-13 1998 Ectopic expression of bcl-2 did not alter basal glutathione levels but attenuated glutathione depletion induced by BSO. Glutathione 82-93 BCL2 apoptosis regulator Homo sapiens 22-27 9465036-3 1998 Although Bcl-2 had no effect on the respiration rate of isolated mitochondria, it prevented both Deltapsi loss and the permeability transition (PT) induced by various reagents, including Ca2+, H2O2, and tert-butyl hydroperoxide. Hydrogen Peroxide 193-197 BCL2 apoptosis regulator Homo sapiens 9-14 9465036-3 1998 Although Bcl-2 had no effect on the respiration rate of isolated mitochondria, it prevented both Deltapsi loss and the permeability transition (PT) induced by various reagents, including Ca2+, H2O2, and tert-butyl hydroperoxide. tert-Butylhydroperoxide 203-227 BCL2 apoptosis regulator Homo sapiens 9-14 9465036-8 1998 Furthermore, Bcl-2 enhanced H+ efflux but not K+ flux after treatment of mitochondria with Ca2+ or tert-butyl hydroperoxide. tert-Butylhydroperoxide 99-123 BCL2 apoptosis regulator Homo sapiens 13-18 9553660-5 1998 AML patients with high bcl-2 mRNA expression achieved lower CR rates than those with no or low expression. Chromium 60-62 BCL2 apoptosis regulator Homo sapiens 23-28 9543700-0 1998 Effects of 2-chlorodeoxyadenosine and gold sodium thiomalate on human bcl-2 gene expression. Cladribine 11-33 BCL2 apoptosis regulator Homo sapiens 70-75 9543700-0 1998 Effects of 2-chlorodeoxyadenosine and gold sodium thiomalate on human bcl-2 gene expression. Gold Sodium Thiomalate 38-60 BCL2 apoptosis regulator Homo sapiens 70-75 9613987-0 1998 BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine. Cladribine 138-162 BCL2 apoptosis regulator Homo sapiens 0-5 9461199-4 1998 In the present study we demonstrate that bcl-2 antisense oligonucleotide treatment improves the chemosensitivity of human melanoma grown in severe combined immunodeficient (SCID) mice. Oligonucleotides 57-72 BCL2 apoptosis regulator Homo sapiens 41-46 9457899-2 1998 In this study we investigated what effect the differentiation agent butyrate had on the cellular levels of the apoptosis regulators BCL2, BCLX(L) and BAX and on radiation-induced apoptosis. Butyrates 68-76 BCL2 apoptosis regulator Homo sapiens 132-136 9430630-2 1998 An expression screen for proteins that bind to Bcl-2 yielded a small novel protein, denoted Bim, whose only similarity to any known protein is the short (nine amino acid) BH3 motif shared by most Bcl-2 homologues. BH 3 171-174 BCL2 apoptosis regulator Homo sapiens 47-52 9430630-2 1998 An expression screen for proteins that bind to Bcl-2 yielded a small novel protein, denoted Bim, whose only similarity to any known protein is the short (nine amino acid) BH3 motif shared by most Bcl-2 homologues. BH 3 171-174 BCL2 apoptosis regulator Homo sapiens 196-201 9443419-9 1998 Treatment of UKF-NB-2AD169 cells with ganciclovir, abolishing virus production, reestablished sensitivity to chemotherapy, lowered Bcl-2 expression, and facilitated inducibility of apoptosis to the level of the parental cell line. Ganciclovir 38-49 BCL2 apoptosis regulator Homo sapiens 131-136 9443418-0 1998 Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Dinoprostone 48-64 BCL2 apoptosis regulator Homo sapiens 28-33 9492297-8 1998 The apoptosis inhibitor Bcl-2 specifically acts on the ceramide-activated pathway to block caspase-3 activation and apoptosis. Ceramides 55-63 BCL2 apoptosis regulator Homo sapiens 24-29 9443418-6 1998 Additionally, PGE2 inhibits programmed cell death caused by SC-58125 and induces Bcl-2 expression, but did not affect Bcl-x or Bax expression in human colon cancer (HCA-7) cells. Dinoprostone 14-18 BCL2 apoptosis regulator Homo sapiens 81-86 9457825-16 1998 It remains to prove that this immediate efficacy has an impact on long-term disease-free survival in such patients, and to understand how the LD-TBI works (direct and/or indirect induction of apoptosis; relationship with t(14;18) translocation and overexpression of bcl-2). ld-tbi 142-148 BCL2 apoptosis regulator Homo sapiens 266-271 9419346-0 1998 Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells. hexamethylene bisacetamide 0-26 BCL2 apoptosis regulator Homo sapiens 88-93 9457054-0 1998 U937 apoptotic cell death by nitric oxide: Bcl-2 downregulation and caspase activation. Nitric Oxide 29-41 BCL2 apoptosis regulator Homo sapiens 43-48 9419346-7 1998 Overexpression of BCL-2 protein in ARP-1 cells confers resistance to HMBA-induced apoptosis. hexamethylene bisacetamide 69-73 BCL2 apoptosis regulator Homo sapiens 18-23 9419346-8 1998 Taken together, these data suggest that HMBA is a potent inducer of apoptosis in human myeloma cells, which may act through suppressing the anti-apoptotic function of the bcl-2 gene. hexamethylene bisacetamide 40-44 BCL2 apoptosis regulator Homo sapiens 171-176 9472635-0 1998 Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest. Paclitaxel 0-5 BCL2 apoptosis regulator Homo sapiens 111-116 9338077-6 1998 The latter process is influenced by components of various signal transduction pathways (e.g., PKC) and expression of oncogenes (e.g., bcl-2, c-Jun), perturbations in which may significantly alter ara-C sensitivity. Cytarabine 196-201 BCL2 apoptosis regulator Homo sapiens 134-139 9699002-1 1998 Raf-1 kinase was shown to bind via its catalytic domain (Cat) to Bcl-2 in a BH4 domain-dependent manner. sapropterin 76-79 BCL2 apoptosis regulator Homo sapiens 65-70 11367733-5 1998 RESULTS: The morphological and biochemical changes characteristic of apoptosis were partially restored after treatment with sodium ferulate, Immunofluorescence assay showed a decrease in BCL-2 and an increase in Bax oncogene proteins in lymphocytes treated with H2O2 and an improvement of cell apoptosis was found after sodium ferulate treatment. ferulic acid 124-139 BCL2 apoptosis regulator Homo sapiens 187-192 11498881-0 1998 [Inhibitive effect of bcl-2 antisense oligodeoxynucleotide on Bcl-2 protein synthesis and cell proliferation in human laryngocarcinoma Hep-2 cells]. Oligodeoxyribonucleotides 38-58 BCL2 apoptosis regulator Homo sapiens 22-27 11498881-0 1998 [Inhibitive effect of bcl-2 antisense oligodeoxynucleotide on Bcl-2 protein synthesis and cell proliferation in human laryngocarcinoma Hep-2 cells]. Oligodeoxyribonucleotides 38-58 BCL2 apoptosis regulator Homo sapiens 62-67 11498881-5 1998 RESULTS: Bcl-2 antisense oligodeoxynucleotide had an obvious effect on bcl-2 mRNA, but inhibited Bcl-2 protein synthesis significantly, the inhibitive rate had positive correlation with concentration of antisense oligodeoxynucleotide and time of action. Oligodeoxyribonucleotides 25-45 BCL2 apoptosis regulator Homo sapiens 9-14 11498881-5 1998 RESULTS: Bcl-2 antisense oligodeoxynucleotide had an obvious effect on bcl-2 mRNA, but inhibited Bcl-2 protein synthesis significantly, the inhibitive rate had positive correlation with concentration of antisense oligodeoxynucleotide and time of action. Oligodeoxyribonucleotides 25-45 BCL2 apoptosis regulator Homo sapiens 71-76 11498881-5 1998 RESULTS: Bcl-2 antisense oligodeoxynucleotide had an obvious effect on bcl-2 mRNA, but inhibited Bcl-2 protein synthesis significantly, the inhibitive rate had positive correlation with concentration of antisense oligodeoxynucleotide and time of action. Oligodeoxyribonucleotides 25-45 BCL2 apoptosis regulator Homo sapiens 97-102 11498881-5 1998 RESULTS: Bcl-2 antisense oligodeoxynucleotide had an obvious effect on bcl-2 mRNA, but inhibited Bcl-2 protein synthesis significantly, the inhibitive rate had positive correlation with concentration of antisense oligodeoxynucleotide and time of action. Oligodeoxyribonucleotides 213-233 BCL2 apoptosis regulator Homo sapiens 9-14 11498881-7 1998 CONCLUSIONS: It is suggested that bcl-2 antisense oligodeoxynucleotide might specifically inhibit bcl-2 protein synthesis and cell proliferation in Hep-2 cells at translation level. Oligodeoxyribonucleotides 50-70 BCL2 apoptosis regulator Homo sapiens 34-39 11498881-7 1998 CONCLUSIONS: It is suggested that bcl-2 antisense oligodeoxynucleotide might specifically inhibit bcl-2 protein synthesis and cell proliferation in Hep-2 cells at translation level. Oligodeoxyribonucleotides 50-70 BCL2 apoptosis regulator Homo sapiens 98-103 9472635-8 1998 However, taxol induced a mobility shift of the bcl-2 protein on immunoblot analysis, indicative of bcl-2 phosphorylation. Paclitaxel 9-14 BCL2 apoptosis regulator Homo sapiens 47-52 9472635-8 1998 However, taxol induced a mobility shift of the bcl-2 protein on immunoblot analysis, indicative of bcl-2 phosphorylation. Paclitaxel 9-14 BCL2 apoptosis regulator Homo sapiens 99-104 9472635-9 1998 Bcl-2 phosphorylation on serine was confirmed by immunoprecipitation and phosphoserine immunoblot analysis. Serine 25-31 BCL2 apoptosis regulator Homo sapiens 0-5 9472635-9 1998 Bcl-2 phosphorylation on serine was confirmed by immunoprecipitation and phosphoserine immunoblot analysis. Phosphoserine 73-86 BCL2 apoptosis regulator Homo sapiens 0-5 9472635-10 1998 Considering (1) that phosphorylation of bcl-2 interferes with its heterodimerization with bax and (2) the inhibition of CD95-mediated apoptosis by bcl-2, we propose that taxol sensitizes malignant glioma cells to CD95 ligand by increasing the functional bax/bcl-2 rheostat in favour of bax and thus cell death. Paclitaxel 170-175 BCL2 apoptosis regulator Homo sapiens 40-45 9472635-10 1998 Considering (1) that phosphorylation of bcl-2 interferes with its heterodimerization with bax and (2) the inhibition of CD95-mediated apoptosis by bcl-2, we propose that taxol sensitizes malignant glioma cells to CD95 ligand by increasing the functional bax/bcl-2 rheostat in favour of bax and thus cell death. Paclitaxel 170-175 BCL2 apoptosis regulator Homo sapiens 147-152 9472635-10 1998 Considering (1) that phosphorylation of bcl-2 interferes with its heterodimerization with bax and (2) the inhibition of CD95-mediated apoptosis by bcl-2, we propose that taxol sensitizes malignant glioma cells to CD95 ligand by increasing the functional bax/bcl-2 rheostat in favour of bax and thus cell death. Paclitaxel 170-175 BCL2 apoptosis regulator Homo sapiens 147-152 9472640-7 1998 In the breast carcinoma MX-1, hypersensitive to cisplatin and to the lonidamine+cisplatin combination, the efficacy of drug treatment was associated with phosphorylation of bcl-2 followed by down-regulation of the protein. Cisplatin 48-57 BCL2 apoptosis regulator Homo sapiens 173-178 9554589-0 1998 Expression of Bcl-2 in human epithelial tumor (HeLa) cells enhances clonogenic survival following exposure to 5-fluoro-2"-deoxyuridine or staurosporine, but not following exposure to etoposide or doxorubicin. 5-fluoro-2'-deoxyuridine 110-134 BCL2 apoptosis regulator Homo sapiens 14-19 9472640-7 1998 In the breast carcinoma MX-1, hypersensitive to cisplatin and to the lonidamine+cisplatin combination, the efficacy of drug treatment was associated with phosphorylation of bcl-2 followed by down-regulation of the protein. lonidamine 69-79 BCL2 apoptosis regulator Homo sapiens 173-178 9554589-0 1998 Expression of Bcl-2 in human epithelial tumor (HeLa) cells enhances clonogenic survival following exposure to 5-fluoro-2"-deoxyuridine or staurosporine, but not following exposure to etoposide or doxorubicin. Staurosporine 138-151 BCL2 apoptosis regulator Homo sapiens 14-19 9554589-0 1998 Expression of Bcl-2 in human epithelial tumor (HeLa) cells enhances clonogenic survival following exposure to 5-fluoro-2"-deoxyuridine or staurosporine, but not following exposure to etoposide or doxorubicin. Doxorubicin 196-207 BCL2 apoptosis regulator Homo sapiens 14-19 9472640-7 1998 In the breast carcinoma MX-1, hypersensitive to cisplatin and to the lonidamine+cisplatin combination, the efficacy of drug treatment was associated with phosphorylation of bcl-2 followed by down-regulation of the protein. Cisplatin 80-89 BCL2 apoptosis regulator Homo sapiens 173-178 9554589-3 1998 Stable expression of Bcl-2 in the human epithelial tumor (HeLa) cell line results in inhibition of apoptosis following exposure to the topoisomerase II poison, etoposide. Etoposide 160-169 BCL2 apoptosis regulator Homo sapiens 21-26 9554589-5 1998 PURPOSE: The purpose of this study was to further investigate the role of Bcl-2 in human epithelial tumor cell drug resistance using 5-fluoro-2"-deoxyuridine, staurosporine, and doxorubicin, in addition to etoposide. 5-fluoro-2'-deoxyuridine 133-157 BCL2 apoptosis regulator Homo sapiens 74-79 9472640-8 1998 Lonidamine itself caused a delayed phosphorylation of bcl-2. lonidamine 0-10 BCL2 apoptosis regulator Homo sapiens 54-59 9554589-5 1998 PURPOSE: The purpose of this study was to further investigate the role of Bcl-2 in human epithelial tumor cell drug resistance using 5-fluoro-2"-deoxyuridine, staurosporine, and doxorubicin, in addition to etoposide. Etoposide 206-215 BCL2 apoptosis regulator Homo sapiens 74-79 9443038-5 1998 In all 52 cases identified as carrying BCL2/JH fusion by conventional Southern blot analysis, LD-PCR successfully amplified fragments encompassing the junctions, which were readily identifiable on ethidium bromide-stained gel. Ethidium 197-213 BCL2 apoptosis regulator Homo sapiens 39-43 9554589-8 1998 RESULTS: Despite profound inhibition to loss of plasma membrane integrity for all agents tested, Bcl-2 was only able to significantly increase clonogenic survival following exposure to 5-fluoro-2"-deoxyuridine and staurosporine, but not following exposure to etoposide or doxorubicin. 5-fluoro-2'-deoxyuridine 185-209 BCL2 apoptosis regulator Homo sapiens 97-102 9554589-8 1998 RESULTS: Despite profound inhibition to loss of plasma membrane integrity for all agents tested, Bcl-2 was only able to significantly increase clonogenic survival following exposure to 5-fluoro-2"-deoxyuridine and staurosporine, but not following exposure to etoposide or doxorubicin. Staurosporine 214-227 BCL2 apoptosis regulator Homo sapiens 97-102 9554589-8 1998 RESULTS: Despite profound inhibition to loss of plasma membrane integrity for all agents tested, Bcl-2 was only able to significantly increase clonogenic survival following exposure to 5-fluoro-2"-deoxyuridine and staurosporine, but not following exposure to etoposide or doxorubicin. Etoposide 259-268 BCL2 apoptosis regulator Homo sapiens 97-102 9554589-8 1998 RESULTS: Despite profound inhibition to loss of plasma membrane integrity for all agents tested, Bcl-2 was only able to significantly increase clonogenic survival following exposure to 5-fluoro-2"-deoxyuridine and staurosporine, but not following exposure to etoposide or doxorubicin. Doxorubicin 272-283 BCL2 apoptosis regulator Homo sapiens 97-102 17092816-0 1998 Reversing drug resistance in bcl-2-expressing tumor cells by depleting glutathione. Glutathione 71-82 BCL2 apoptosis regulator Homo sapiens 29-34 17092816-6 1998 Additionally, recent evidence points to bcl-2 involvement in the regulation of antioxidant pathways mediated by glutathione. Glutathione 112-123 BCL2 apoptosis regulator Homo sapiens 40-45 9436618-0 1998 Bcl-2 overexpression in the HaCaT cell line is associated with a different membrane fatty acid composition and sensitivity to oxidative stress. Fatty Acids 84-94 BCL2 apoptosis regulator Homo sapiens 0-5 9436618-5 1998 Following peroxide treatment, the formation of reactive oxygen species was lower in Bcl-2 expressing cells, suggesting a better capacity to counter oxidative stress. Peroxides 10-18 BCL2 apoptosis regulator Homo sapiens 84-89 9436618-5 1998 Following peroxide treatment, the formation of reactive oxygen species was lower in Bcl-2 expressing cells, suggesting a better capacity to counter oxidative stress. Reactive Oxygen Species 47-70 BCL2 apoptosis regulator Homo sapiens 84-89 9436618-6 1998 Total Superoxide Dismutase activity was induced by oxidative t-BOOH treatment in bcl-2 transfected cells, which also accumulated less damage to membrane lipids and proteins, as assessed by TBA-RS and carbonyl formation respectively. booh 63-67 BCL2 apoptosis regulator Homo sapiens 81-86 9436618-6 1998 Total Superoxide Dismutase activity was induced by oxidative t-BOOH treatment in bcl-2 transfected cells, which also accumulated less damage to membrane lipids and proteins, as assessed by TBA-RS and carbonyl formation respectively. tba 189-192 BCL2 apoptosis regulator Homo sapiens 81-86 27420332-10 1998 In these cases bcl-2 expression was found to be significantly reduced after heparin incubation when comparing to bcl-2 level before incubation. Heparin 76-83 BCL2 apoptosis regulator Homo sapiens 15-20 9436618-7 1998 On the other hand, the formation of 4-hydroxy-nonenal, a more specific marker of peroxidative damage to polyunsaturated fatty acids, was higher in bcl-2 transfected cells than in control cells. 4-hydroxy-2-nonenal 36-53 BCL2 apoptosis regulator Homo sapiens 147-152 9436618-7 1998 On the other hand, the formation of 4-hydroxy-nonenal, a more specific marker of peroxidative damage to polyunsaturated fatty acids, was higher in bcl-2 transfected cells than in control cells. Fatty Acids, Unsaturated 104-131 BCL2 apoptosis regulator Homo sapiens 147-152 9436618-8 1998 Bcl-2 over-expression was also associated with significant changes in the fatty acid composition of cell membranes. Fatty Acids 74-84 BCL2 apoptosis regulator Homo sapiens 0-5 9436618-10 1998 Changes in protein kinase C activity were also associated to bcl-2 expression, possibly resulting from the differences in membrane fatty acid composition. Fatty Acids 131-141 BCL2 apoptosis regulator Homo sapiens 61-66 9678489-8 1998 TGF-beta treatment increased intracellular peroxide production and suppressed the expression of glutathione-S-transferase in the Hep3B cells, and these effects were partially suppressed by the overexpression of Bcl-2. Peroxides 43-51 BCL2 apoptosis regulator Homo sapiens 211-216 9852210-0 1998 Bcl-2- and CrmA-inhibitable dephosphorylation and cleavage of retinoblastoma protein during etoposide-induced apoptosis. Etoposide 92-101 BCL2 apoptosis regulator Homo sapiens 0-5 9852210-5 1998 Here, we report that expression of the Bcl-2 oncoprotein, an inhibitor of caspases (interleukin 1 -converting enzyme-like proteases), blocked RB dephosphorylation, RB cleavage and apoptosis in etoposide-treated human Jurkat T cells. Etoposide 193-202 BCL2 apoptosis regulator Homo sapiens 39-44 9454907-3 1998 Forced expression of bcl-2 in 8226 and ARP-1 multiple myeloma (MM) cell lines expressing relatively low levels of bcl-2, resulted in 1-2 log increase in resistance to dexamethasone (DEX)-induced apoptosis. Dexamethasone 167-180 BCL2 apoptosis regulator Homo sapiens 21-26 9454907-3 1998 Forced expression of bcl-2 in 8226 and ARP-1 multiple myeloma (MM) cell lines expressing relatively low levels of bcl-2, resulted in 1-2 log increase in resistance to dexamethasone (DEX)-induced apoptosis. Dexamethasone 182-185 BCL2 apoptosis regulator Homo sapiens 21-26 9454907-5 1998 The increased sensitivity to anti-FAS-induced apoptosis in 8226 cells was due to the increase in FAS expression in the bcl-2 transfected cells and was proportionate to the increase in FAS expression. ammonium ferrous sulfate 34-37 BCL2 apoptosis regulator Homo sapiens 119-124 9678489-9 1998 These results suggest that Bcl-2 may protect cell from TGF-beta-F-induced apoptosis by interfering TGF-beta generated signals leading to induce reactive oxygen species production. Reactive Oxygen Species 144-167 BCL2 apoptosis regulator Homo sapiens 27-32 9585084-4 1998 Significantly, HL-60/BCL-2 cells retained greater long-term proliferative capacity than HL-60 cells when treated with low doses of doxorubicin. Doxorubicin 131-142 BCL2 apoptosis regulator Homo sapiens 21-26 9517506-7 1998 The Bcl-2/Bax was significantly greater in the cell fractions resistant to chlorambucil-induced apoptosis. Chlorambucil 75-87 BCL2 apoptosis regulator Homo sapiens 4-9 9460707-0 1998 Nitric oxide donor-induced p53-sensitive cell death is enhanced by Bcl-2 reduction in human neuroblastoma cells. Nitric Oxide 0-12 BCL2 apoptosis regulator Homo sapiens 67-72 9510008-6 1998 Localization of BAX to the steroid-secreting cells of the corpus luteum implies a functional role and BAX may interact with other members of the BCL-2 family to affect luteal function. Steroids 27-34 BCL2 apoptosis regulator Homo sapiens 145-150 9460707-3 1998 Protein level of Bcl-2 was decreased by pretreatment with diBu-cAMP or staurosporine, and, on the contrary, the level was increased by pretreatment with PMA. Bucladesine 58-67 BCL2 apoptosis regulator Homo sapiens 17-22 9460707-3 1998 Protein level of Bcl-2 was decreased by pretreatment with diBu-cAMP or staurosporine, and, on the contrary, the level was increased by pretreatment with PMA. Staurosporine 71-84 BCL2 apoptosis regulator Homo sapiens 17-22 9460707-3 1998 Protein level of Bcl-2 was decreased by pretreatment with diBu-cAMP or staurosporine, and, on the contrary, the level was increased by pretreatment with PMA. Tetradecanoylphorbol Acetate 153-156 BCL2 apoptosis regulator Homo sapiens 17-22 10223618-7 1998 CD40 stimulation enhanced Bcl-2 expression, and antisense oligonucleotide against bcl-2 canceled the inhibition of HTC/C3 cell growth caused by CD40 stimulation. Oligonucleotides 58-73 BCL2 apoptosis regulator Homo sapiens 82-87 9459175-0 1997 Relationship between nitrogen mustard drug resistance in B-cell chronic lymphocytic leukemia (B-CLL) and protein expression of Bcl-2, Bax, Bcl-X and p53. Nitrogen 21-29 BCL2 apoptosis regulator Homo sapiens 127-132 10731954-3 1998 Using monoclonal FITC-conjugated antibody, antigen BCL-2 was found in peripheral blood cells in children with both lymphoblastic (ALL) and non-lymphoblastic leukemia (NLL). Fluorescein-5-isothiocyanate 17-21 BCL2 apoptosis regulator Homo sapiens 51-56 9587934-2 1998 In this study a monospecific anti-human bcl-2 antibody that is reactive in formalin-fixed tissues was used with an avidin-biotin complex immunoperoxidase method to evaluate 41 cases of lymphoproliferative disorders of the salivary gland. Formaldehyde 75-83 BCL2 apoptosis regulator Homo sapiens 40-45 9587934-2 1998 In this study a monospecific anti-human bcl-2 antibody that is reactive in formalin-fixed tissues was used with an avidin-biotin complex immunoperoxidase method to evaluate 41 cases of lymphoproliferative disorders of the salivary gland. avidin-biotin 115-128 BCL2 apoptosis regulator Homo sapiens 40-45 10923408-1 1998 OBJECTIVE: To investigate the effects of Arg-Gly-Asp-Ser (RGDS) tetrapeptide on the expressions of apoptosis-related genes interleukin-1 beta-converting enzyme (ICE) and bcl-2 in human glomerular mesangial cells, so as to provide experimental evidence for regulating proliferation and apoptosis of mesangial cells with RGD-containing polypeptide. arginyl-glycyl-aspartyl-serine 41-56 BCL2 apoptosis regulator Homo sapiens 170-175 9459177-4 1997 In stable Bcl-2 transfectants, G-Rh2 also induced DNA fragmentation, while staurosporine-induced DNA fragmentation was totally blocked. Staurosporine 75-88 BCL2 apoptosis regulator Homo sapiens 10-15 9421304-13 1997 Furthermore, we performed the time-course analysis of Bcl-2 protein expression in phenylephrine (10 microM)-stimulated VSMCs. Phenylephrine 82-95 BCL2 apoptosis regulator Homo sapiens 54-59 9428650-4 1997 7Beta-hydroxycholesterol and 7-ketocholesterol induced nuclear condensation and/or fragmentation, internucleosomal DNA fragmentation, and IL-1beta secretion, which were partially inhibited by Bcl-2 overexpression. cholest-5-en-3 beta,7 alpha-diol 0-24 BCL2 apoptosis regulator Homo sapiens 192-197 9428650-4 1997 7Beta-hydroxycholesterol and 7-ketocholesterol induced nuclear condensation and/or fragmentation, internucleosomal DNA fragmentation, and IL-1beta secretion, which were partially inhibited by Bcl-2 overexpression. 7-ketocholesterol 29-46 BCL2 apoptosis regulator Homo sapiens 192-197 9373241-0 1997 The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. alvocidib 44-56 BCL2 apoptosis regulator Homo sapiens 71-76 9373241-8 1997 The results showed that flavopiridol downregulates bcl-2 mRNA and bcl-2 protein expression within 24 hours. alvocidib 24-36 BCL2 apoptosis regulator Homo sapiens 51-56 9373241-8 1997 The results showed that flavopiridol downregulates bcl-2 mRNA and bcl-2 protein expression within 24 hours. alvocidib 24-36 BCL2 apoptosis regulator Homo sapiens 66-71 9373250-10 1997 p53-specific antisense oligonucleotide treatment recapitulated the effects of Tpo treatment on the levels of Bax, Mdm-2, and Bcl-2. Oligonucleotides 23-38 BCL2 apoptosis regulator Homo sapiens 125-130 9393748-2 1997 Here, we demonstrate that expression of galectin-3 in human breast carcinoma BT549 cells inhibits cis-diamminedichloroplatinum (cisplatin)-induced poly(ADP-ribose) polymerase degradation and apoptosis, without altering Bcl-2, Bcl-X(L), or Bax expressions. Cisplatin 128-137 BCL2 apoptosis regulator Homo sapiens 219-224 9470903-7 1997 In melanocyte cultures, stimulation of the dopa-oxidase pool, a key enzyme in melanin synthesis, paralleled Bcl-2 down-regulation and Bax up-regulation. Melanins 78-85 BCL2 apoptosis regulator Homo sapiens 108-113 9432028-0 1997 Alterations in Bcl-2/Bax protein levels in platelets form part of an ionomycin-induced process that resembles apoptosis. Ionomycin 69-78 BCL2 apoptosis regulator Homo sapiens 15-20 9432028-4 1997 A side-scatter shift and a decrease in the Bcl-2/Bax protein ratio were observed by flow cytometry analysis after stimulation with ionomycin. Ionomycin 131-140 BCL2 apoptosis regulator Homo sapiens 43-48 9393748-3 1997 Galectin-3 contains the NWGR amino acid sequence highly conserved in the BH1 domain of the bcl-2 gene family, and a substitution of glycine to alanine in this motif abrogated its antiapoptotic activity. Glycine 132-139 BCL2 apoptosis regulator Homo sapiens 91-96 9393748-3 1997 Galectin-3 contains the NWGR amino acid sequence highly conserved in the BH1 domain of the bcl-2 gene family, and a substitution of glycine to alanine in this motif abrogated its antiapoptotic activity. Alanine 143-150 BCL2 apoptosis regulator Homo sapiens 91-96 9815616-5 1997 In addition, the survival factor Bcl-2, which has demonstrated inconsistent protective effects against Fas signaling in other systems, was inhibitory to Fas-induced apoptosis in colon carcinoma cells after adenoviral transduction. ammonium ferrous sulfate 103-106 BCL2 apoptosis regulator Homo sapiens 33-38 9447823-7 1997 In particular, CR was achieved in 86% of patients with a bcl-2 MFI <14, but only in 57% of patients with a MFI >14 (P = 0.008). Chromium 15-17 BCL2 apoptosis regulator Homo sapiens 57-62 9464838-0 1997 Ectopic expression of Bcl-2, but not Bcl-xL rescues Ramos B cells from Fas-mediated apoptosis. ammonium ferrous sulfate 71-74 BCL2 apoptosis regulator Homo sapiens 22-27 9464838-3 1997 We have previously shown that protection from calcium ionophore- and macromolecular synthesis inhibitor-induced apoptosis by CD40 ligation is associated with a rapid up-regulation of Bcl-xL followed by a more moderate and delayed up-regulation of Bcl-2. Calcium 46-53 BCL2 apoptosis regulator Homo sapiens 247-252 9464838-4 1997 We show here that overexpression of Bcl-xL, like Bcl-2, protects Ramos cells from apoptosis induction in response to calcium ionophore, anti-Ig and macromolecular synthesis inhibition. Calcium 117-124 BCL2 apoptosis regulator Homo sapiens 49-54 9464838-6 1997 Thus, in Ramos B cells, the Fas apoptotic pathway exhibits differential sensitivity to inhibition by Bcl-2 family members. ammonium ferrous sulfate 28-31 BCL2 apoptosis regulator Homo sapiens 101-106 9428700-0 1997 Apoptotic cell death induced by inhibitors of energy conservation--Bcl-2 inhibits apoptosis downstream of a fall of ATP level. Adenosine Triphosphate 116-119 BCL2 apoptosis regulator Homo sapiens 67-72 9428700-4 1997 Bcl-2 does not antagonize the inhibitory potential of mitochondrial inhibitors, and cannot prevent or delay the decrease of the cellular ATP level subsequent to metabolic inhibition. Adenosine Triphosphate 137-140 BCL2 apoptosis regulator Homo sapiens 0-5 9406817-6 1997 We found that both K252 and anti-NGF antibody strikingly downregulate bcl-2 expression, starting at 72 h. Furthermore, HaCat keratinocytes stably transfected with a plasmid containing bcl-2 cDNA fail to undergo apoptosis when treated with K252. staurosporine aglycone 19-23 BCL2 apoptosis regulator Homo sapiens 70-75 9406817-6 1997 We found that both K252 and anti-NGF antibody strikingly downregulate bcl-2 expression, starting at 72 h. Furthermore, HaCat keratinocytes stably transfected with a plasmid containing bcl-2 cDNA fail to undergo apoptosis when treated with K252. staurosporine aglycone 19-23 BCL2 apoptosis regulator Homo sapiens 184-189 9396780-0 1997 Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2. Cytarabine 79-112 BCL2 apoptosis regulator Homo sapiens 172-177 9447823-8 1997 A further decrease of CR rate to 41% was observed in patients in whom a higher bcl-2 MFI was coupled with the presence of CD34 antigen on their blasts. Chromium 22-24 BCL2 apoptosis regulator Homo sapiens 79-84 9396780-3 1997 After exposure to an equimolar concentration of ara-C (10 microM for 6 hr), HL-60/Bcl-2 cells were significantly less susceptible to apoptosis, DNA fragmentation, and loss of clonogenicity than HL-60/pCEP4 cells. Cytarabine 48-53 BCL2 apoptosis regulator Homo sapiens 82-87 9396780-4 1997 The protective effect of increased Bcl-2 expression was manifested by a failure of ara-C to induce activation/cleavage of the Yama protease (CPP32; caspase-3) and degradation of one of its substrates, poly(ADP-ribose)polymerase to an 85-kDa cleavage product. Cytarabine 83-88 BCL2 apoptosis regulator Homo sapiens 35-40 9436964-4 1997 Expression of bcl-2 protein was seen in the proliferative zone in BE and showed a significant increase in RA but was essentially absent in HGD. Radium 106-108 BCL2 apoptosis regulator Homo sapiens 14-19 9396780-7 1997 Western analysis of Bcl-2 protein obtained from overexpressing cells treated with bryostatin 1, staurosporine, or UCN-01 revealed the appearance of a slowly migrating species and a general broadening of the protein band, effects that were insensitive to the protein synthesis inhibitor cycloheximide. bryostatin 1 82-94 BCL2 apoptosis regulator Homo sapiens 20-25 9396780-7 1997 Western analysis of Bcl-2 protein obtained from overexpressing cells treated with bryostatin 1, staurosporine, or UCN-01 revealed the appearance of a slowly migrating species and a general broadening of the protein band, effects that were insensitive to the protein synthesis inhibitor cycloheximide. Staurosporine 96-109 BCL2 apoptosis regulator Homo sapiens 20-25 9396780-7 1997 Western analysis of Bcl-2 protein obtained from overexpressing cells treated with bryostatin 1, staurosporine, or UCN-01 revealed the appearance of a slowly migrating species and a general broadening of the protein band, effects that were insensitive to the protein synthesis inhibitor cycloheximide. 7-hydroxystaurosporine 114-120 BCL2 apoptosis regulator Homo sapiens 20-25 9396780-7 1997 Western analysis of Bcl-2 protein obtained from overexpressing cells treated with bryostatin 1, staurosporine, or UCN-01 revealed the appearance of a slowly migrating species and a general broadening of the protein band, effects that were insensitive to the protein synthesis inhibitor cycloheximide. Cycloheximide 286-299 BCL2 apoptosis regulator Homo sapiens 20-25 9396780-8 1997 Alterations in Bcl-2 protein mobility on sodium dodecyl sulfate-polyacrylamide gel electrophoresis were reversed by treatment of lysates with alkaline phosphatase or protein phosphatase 2A; actions of the latter were blocked by the specific phosphatase inhibitor okadaic acid. Sodium Dodecyl Sulfate 41-63 BCL2 apoptosis regulator Homo sapiens 15-20 9396780-8 1997 Alterations in Bcl-2 protein mobility on sodium dodecyl sulfate-polyacrylamide gel electrophoresis were reversed by treatment of lysates with alkaline phosphatase or protein phosphatase 2A; actions of the latter were blocked by the specific phosphatase inhibitor okadaic acid. polyacrylamide 64-78 BCL2 apoptosis regulator Homo sapiens 15-20 9396780-8 1997 Alterations in Bcl-2 protein mobility on sodium dodecyl sulfate-polyacrylamide gel electrophoresis were reversed by treatment of lysates with alkaline phosphatase or protein phosphatase 2A; actions of the latter were blocked by the specific phosphatase inhibitor okadaic acid. Okadaic Acid 263-275 BCL2 apoptosis regulator Homo sapiens 15-20 9396780-9 1997 In vivo labeling studies of Bcl-2 protein demonstrated increased incorporation of [32PO4]orthophosphate in drug-treated cells. [32po4]orthophosphate 82-103 BCL2 apoptosis regulator Homo sapiens 28-33 9396780-11 1997 Collectively, these findings indicate that bryostatin 1, which down-regulates PKC, and staurosporine and UCN-01, which directly inhibit the enzyme, circumvent resistance of Bcl-2-overexpressing leukemic cells to ara-C-induced apoptosis and activation of the protease cascade. bryostatin 1 43-55 BCL2 apoptosis regulator Homo sapiens 173-178 9396780-11 1997 Collectively, these findings indicate that bryostatin 1, which down-regulates PKC, and staurosporine and UCN-01, which directly inhibit the enzyme, circumvent resistance of Bcl-2-overexpressing leukemic cells to ara-C-induced apoptosis and activation of the protease cascade. Cytarabine 212-217 BCL2 apoptosis regulator Homo sapiens 173-178 9436964-6 1997 We noted a positive correlation between Ki-67 and bcl-2 in the proliferative zone of BE and RA, whereas a negative correlation was present on the surface of RA. Beryllium 85-87 BCL2 apoptosis regulator Homo sapiens 50-55 9436964-6 1997 We noted a positive correlation between Ki-67 and bcl-2 in the proliferative zone of BE and RA, whereas a negative correlation was present on the surface of RA. Radium 92-94 BCL2 apoptosis regulator Homo sapiens 50-55 9409814-0 1997 Differential activity of bcl-2 and ICE enzyme family protease inhibitors on Fas and puromycin-induced apoptosis of glioma cells. ammonium ferrous sulfate 76-79 BCL2 apoptosis regulator Homo sapiens 25-30 9398050-6 1997 LN-229 cells which have partial p53-wild-type activity show enhanced expression of p53, p21 and bax protein, whereas bcl-2 levels decrease, after exposure to camptothecin. Camptothecin 158-170 BCL2 apoptosis regulator Homo sapiens 117-122 9427965-0 1997 Expression of Bax and Bcl-2 protein in the gerbil hippocampus following transient forebrain ischemia and its modification by phencyclidine. Phencyclidine 125-138 BCL2 apoptosis regulator Homo sapiens 22-27 9427965-1 1997 To determine the effect of phencyclidine (a noncompetitive NMDA receptor antagonist) on expression of Bax and Bcl-2 (apoptosis-regulating proteins) in gerbil hippocampus after transient forebrain ischemia, brain sections were immunohistochemically evaluated 48, 72, 96 h and 7 days following ischemia. Phencyclidine 27-40 BCL2 apoptosis regulator Homo sapiens 110-115 9444671-9 1997 Within 5-10 hr after start of paracetamol exposure, a marked downregulation of both c-myc and bcl-2 mRNA was observed. Acetaminophen 30-41 BCL2 apoptosis regulator Homo sapiens 94-99 9409814-0 1997 Differential activity of bcl-2 and ICE enzyme family protease inhibitors on Fas and puromycin-induced apoptosis of glioma cells. Puromycin 84-93 BCL2 apoptosis regulator Homo sapiens 25-30 9409814-8 1997 Bcl-2 which protects glioma cells from Fas ligand-induced cell death, was shown to have only a small protective effect on puromycin-induced apoptosis. Puromycin 122-131 BCL2 apoptosis regulator Homo sapiens 0-5 9494534-9 1997 Expression of bcl-2 family members (bax, bcl-x) was modulated by fotemustine, etoposide and cisplatin. fotemustine 65-76 BCL2 apoptosis regulator Homo sapiens 14-19 9403032-0 1997 Modulation of NF-kappa B, and Bcl-2 in apoptosis induced by cisplatin in HeLa cells. Cisplatin 60-69 BCL2 apoptosis regulator Homo sapiens 30-35 9494534-9 1997 Expression of bcl-2 family members (bax, bcl-x) was modulated by fotemustine, etoposide and cisplatin. Etoposide 78-87 BCL2 apoptosis regulator Homo sapiens 14-19 9494534-9 1997 Expression of bcl-2 family members (bax, bcl-x) was modulated by fotemustine, etoposide and cisplatin. Cisplatin 92-101 BCL2 apoptosis regulator Homo sapiens 14-19 22358876-0 1997 Reinforcing apoptosis-resistance of COS and myeloma cells by transfecting with bcl-2 gene. carbonyl sulfide 36-39 BCL2 apoptosis regulator Homo sapiens 79-84 9581540-10 1997 Interestingly, we found that TGF-beta1 prevented the C2-ceramide-caused decrease of Bcl-2 protein. N-acetylsphingosine 53-64 BCL2 apoptosis regulator Homo sapiens 84-89 9581540-11 1997 We thus propose that TGF-beta1 rescues ceramide-induced cell death, possibly by maintaining the constant level of Bcl-2, thereby abolishing CPP32/Yama protease activation. Ceramides 39-47 BCL2 apoptosis regulator Homo sapiens 114-119 9354463-7 1997 Overexpression of Bcl-2 and Bcl-XL conferred resistance to BA at the level of mitochondrial dysfunction, protease activation, and nuclear fragmentation. betulinic acid 59-61 BCL2 apoptosis regulator Homo sapiens 18-23 9354463-9 1997 Furthermore, Bax and Bcl-xs, two death-promoting proteins of the Bcl-2 family, were up-regulated following BA treatment. betulinic acid 107-109 BCL2 apoptosis regulator Homo sapiens 65-70 9815594-7 1997 The expression of Bcl-2 relative to Bax decreased more after combined treatment with cisplatin and ATRA than after either drug alone. Cisplatin 85-94 BCL2 apoptosis regulator Homo sapiens 18-23 9815594-7 1997 The expression of Bcl-2 relative to Bax decreased more after combined treatment with cisplatin and ATRA than after either drug alone. Tretinoin 99-103 BCL2 apoptosis regulator Homo sapiens 18-23 9815595-5 1997 Treatment of LNCaP cells with 10 nm Taxol led, after 24 h, to relatively specific and almost total down-regulation of bcl-xL protein in the absence of alteration of bax, bak, or bcl-2 levels. Paclitaxel 36-41 BCL2 apoptosis regulator Homo sapiens 178-183 21590211-2 1997 Cells expressing Bcl-2 (COLO320) and those that did not (DLD-1), underwent apoptosis after 24 h exposure to 1 mu M taxol. Paclitaxel 115-120 BCL2 apoptosis regulator Homo sapiens 17-22 9470815-10 1997 Our results suggest the existence of a p53-independent pathway of oestradiol regulation of growth and proliferation in this human endometrial adenocarcinoma, resulting in accumulation of cells in G0/G1 through p21WAF1/Cip1 induction and, after prolonged treatment, downregulation of bcl-2 protein. Estradiol 66-76 BCL2 apoptosis regulator Homo sapiens 283-288 9367385-7 1997 Furthermore, co-expression of LMP-1 and Bcl-2 in RHEK-1 cells enabled the cells to grow under low-serum conditions and to form colonies in semi-soft agar medium. Agar 149-153 BCL2 apoptosis regulator Homo sapiens 40-45 21590211-4 1997 The molecular weight of Bcl-2 was increased to above 26 kDa in COLO320 and LoVo cells after a 4 h exposure to taxol. Paclitaxel 110-115 BCL2 apoptosis regulator Homo sapiens 24-29 9396083-2 1997 After incubation of HL-60 cells with 100 microM 3-deazaadenosine for 45 min., a schedule known to perturb transmethylation metabolites and initiate apoptosis in these cells, a 50% decrease in c-myc and a 50% increase in bcl-2 RNA steady-state levels compared to control cells were observed. 3-deazaadenosine 48-64 BCL2 apoptosis regulator Homo sapiens 220-225 9396083-10 1997 It is concluded that 3-deazaadenosine initiated apoptosis affects c-myc, bcl-2, bax and bcl-x1 mRNA levels. 3-deazaadenosine 21-37 BCL2 apoptosis regulator Homo sapiens 73-78 21590211-5 1997 Incubating the cells with genistein, a protein tyrosine kinase inhibitor, inhibited the taxol-induced modified Bcl-2 expression and apoptosis. Genistein 26-35 BCL2 apoptosis regulator Homo sapiens 111-116 21590211-5 1997 Incubating the cells with genistein, a protein tyrosine kinase inhibitor, inhibited the taxol-induced modified Bcl-2 expression and apoptosis. Paclitaxel 88-93 BCL2 apoptosis regulator Homo sapiens 111-116 21590211-6 1997 These results suggest that taxol induces apoptosis in cells arrested in G(2)/M phase which might be partly explained by Bcl-2 inactivation by phosphorylation in human colon carcinoma cell lines. Paclitaxel 27-32 BCL2 apoptosis regulator Homo sapiens 120-125 9342186-4 1997 The levels of the apoptosis effector proteins Bak and Bad were enhanced, whereas there was a slight down-regulation of the apoptosis suppressor protein Bcl-2 after treatment of the cells with PDBu and DMSO. Phorbol 12,13-Dibutyrate 192-196 BCL2 apoptosis regulator Homo sapiens 152-157 9402847-0 1997 In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts. Tretinoin 58-71 BCL2 apoptosis regulator Homo sapiens 28-33 9402847-1 1997 Using flow cytometry, we have investigated the effects of 0.5 microM all-trans-retinoic acid (ATRA) on bcl-2 expression in the blast cells of 25 acute myeloblastic leukemia (AML) patients and the HL-60 cell line after incubation for 6 days. Tretinoin 69-92 BCL2 apoptosis regulator Homo sapiens 103-108 9402847-1 1997 Using flow cytometry, we have investigated the effects of 0.5 microM all-trans-retinoic acid (ATRA) on bcl-2 expression in the blast cells of 25 acute myeloblastic leukemia (AML) patients and the HL-60 cell line after incubation for 6 days. Tretinoin 94-98 BCL2 apoptosis regulator Homo sapiens 103-108 9402847-2 1997 We observed a significant decrease of bcl-2 expression after treatment with ATRA in 12 of 25 AML samples and the HL-60 cells. Tretinoin 76-80 BCL2 apoptosis regulator Homo sapiens 38-43 9402847-3 1997 The mean fluorescence intensity (MFI) ratio for the bcl-2 levels of the ATRA responders (n = 12) was reduced to 7.9 +/- 4.8 following incubation with ATRA compared with 10.9 +/- 6.5 (mean +/- SD) for control samples incubated without ATRA (p = 0.011). Tretinoin 72-76 BCL2 apoptosis regulator Homo sapiens 52-57 9402847-9 1997 Because many chemotherapeutic agents also operate through the activation of programmed cell death and bcl-2 levels are positively associated with resistance to apoptosis, ATRA can be used in combination chemotherapy to increase the chemosensitivity of some patients with AML. Tretinoin 171-175 BCL2 apoptosis regulator Homo sapiens 102-107 9359515-0 1997 Fludarabine ability to down-regulate Bcl-2 gene product in CD5+ leukaemic B cells: in vitro/in vivo correlations. fludarabine 0-11 BCL2 apoptosis regulator Homo sapiens 37-42 9359515-3 1997 This study aimed to determine whether F-ara-A-induced apoptosis might be related to Bcl-2 modifications and to evaluate in vitro/in vivo correlations. fludarabine 38-45 BCL2 apoptosis regulator Homo sapiens 84-89 9359515-5 1997 F-ara-A down-regulated the expression of Bcl-2 in 5/12 cases. fludarabine 0-7 BCL2 apoptosis regulator Homo sapiens 41-46 9359515-9 1997 The in vivo outcome after treatment with three to six courses of F-ara-A was evaluable in 10 patients: 4/5 cases, whose cells had shown in vitro Bcl-2 down-regulation and prominent apoptosis after exposure to F-ara-A, had a complete response (CR) and a partial response (PR) was observed in the remaining patient. fludarabine 65-72 BCL2 apoptosis regulator Homo sapiens 145-150 9326614-3 1997 Both BAX and BCL-2 insert into KCl-loaded vesicles in a pH-dependent fashion and demonstrate macroscopic ion efflux. Potassium Chloride 31-34 BCL2 apoptosis regulator Homo sapiens 13-18 9342186-4 1997 The levels of the apoptosis effector proteins Bak and Bad were enhanced, whereas there was a slight down-regulation of the apoptosis suppressor protein Bcl-2 after treatment of the cells with PDBu and DMSO. Dimethyl Sulfoxide 201-205 BCL2 apoptosis regulator Homo sapiens 152-157 9328309-12 1997 An 18 mer bcl-2 antisense oligonucleotide reduced expression of Bcl-2 protein by 50% and increased the rate of beauvericin-induced apoptosis more than threefold in the malignant cells. Oligonucleotides 26-41 BCL2 apoptosis regulator Homo sapiens 10-15 9328309-12 1997 An 18 mer bcl-2 antisense oligonucleotide reduced expression of Bcl-2 protein by 50% and increased the rate of beauvericin-induced apoptosis more than threefold in the malignant cells. Oligonucleotides 26-41 BCL2 apoptosis regulator Homo sapiens 64-69 9328309-12 1997 An 18 mer bcl-2 antisense oligonucleotide reduced expression of Bcl-2 protein by 50% and increased the rate of beauvericin-induced apoptosis more than threefold in the malignant cells. beauvericin 111-122 BCL2 apoptosis regulator Homo sapiens 10-15 9414036-3 1997 Treatment with herbimycin A or wortmannin also enhanced Bcl-2 expression, but the BB type of platelet-derived growth factor decreased the level. herbimycin 15-27 BCL2 apoptosis regulator Homo sapiens 56-61 9312165-9 1997 In eosinophils, the expression of bcl-2 protein decreased after incubation with theophylline. Theophylline 80-92 BCL2 apoptosis regulator Homo sapiens 34-39 9317114-8 1997 In this system, Fas ligation also triggers Bcl-2/Bcl-x down-regulation, an effect inhibited by sIgG cross-linking, the cysteine protease inhibitor acetyl-Tyr-Val-Ala-Asp-chloromethyl ketone, and PMA treatment. N-acetyl-tyrosyl-valyl-alanyl-aspartyl chloromethyl ketone 147-189 BCL2 apoptosis regulator Homo sapiens 43-48 9317114-8 1997 In this system, Fas ligation also triggers Bcl-2/Bcl-x down-regulation, an effect inhibited by sIgG cross-linking, the cysteine protease inhibitor acetyl-Tyr-Val-Ala-Asp-chloromethyl ketone, and PMA treatment. Tetradecanoylphorbol Acetate 195-198 BCL2 apoptosis regulator Homo sapiens 43-48 9317114-0 1997 B cell receptor cross-linking prevents Fas-induced cell death by inactivating the IL-1 beta-converting enzyme protease and regulating Bcl-2/Bcl-x expression. ammonium ferrous sulfate 39-42 BCL2 apoptosis regulator Homo sapiens 134-139 9390034-0 1997 Variation of bcl-2 expression in breast ducts and lobules in relation to plasma progesterone levels: overexpression and absence of variation in fibroadenomas. Progesterone 80-92 BCL2 apoptosis regulator Homo sapiens 13-18 9390034-9 1997 This was further supported by a statistical link (P = 5 x 10(-3) between high levels of circulating progesterone and weak bcl-2 staining in lobules and ducts. Progesterone 100-112 BCL2 apoptosis regulator Homo sapiens 122-127 9414036-3 1997 Treatment with herbimycin A or wortmannin also enhanced Bcl-2 expression, but the BB type of platelet-derived growth factor decreased the level. Wortmannin 31-41 BCL2 apoptosis regulator Homo sapiens 56-61 9311611-0 1997 bcl-2 and bak may play a pivotal role in sodium butyrate-induced apoptosis in colonic epithelial cells; however overexpression of bcl-2 does not protect against bak-mediated apoptosis. Butyric Acid 41-56 BCL2 apoptosis regulator Homo sapiens 0-5 9329022-0 1997 Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53. hypericin 0-9 BCL2 apoptosis regulator Homo sapiens 95-100 9364213-4 1997 bcl-2 overexpression in JB6 clone41 cells caused a TPA-induced soft-agar growth fivefold greater than the growth of nontransfected or vector-transfected (neo control) cells. Tetradecanoylphorbol Acetate 51-54 BCL2 apoptosis regulator Homo sapiens 0-5 9364213-7 1997 When compared with control cells, bcl-2-transfected cells expressed significantly more c-fos but not c-jun after TPA treatment. Tetradecanoylphorbol Acetate 113-116 BCL2 apoptosis regulator Homo sapiens 34-39 9364213-8 1997 Furthermore, the levels of AP-1 and AP-1-induced transactivation of TRE-CAT were greater in bcl-2-transfected cells than in control cells after TPA treatment. Tetradecanoylphorbol Acetate 144-147 BCL2 apoptosis regulator Homo sapiens 92-97 9295281-5 1997 We found that Bcl-2 levels were increased by treatment of HL-60 cells with exogenous DAG or 12-O-tetradecanoylphorbol-13-acetate (TPA). Diglycerides 85-88 BCL2 apoptosis regulator Homo sapiens 14-19 9295281-5 1997 We found that Bcl-2 levels were increased by treatment of HL-60 cells with exogenous DAG or 12-O-tetradecanoylphorbol-13-acetate (TPA). Tetradecanoylphorbol Acetate 92-128 BCL2 apoptosis regulator Homo sapiens 14-19 9295281-5 1997 We found that Bcl-2 levels were increased by treatment of HL-60 cells with exogenous DAG or 12-O-tetradecanoylphorbol-13-acetate (TPA). Tetradecanoylphorbol Acetate 130-133 BCL2 apoptosis regulator Homo sapiens 14-19 9295281-6 1997 In contrast, exogenous ceramide treatment caused a decrease in cellular Bcl-2 levels. Ceramides 23-31 BCL2 apoptosis regulator Homo sapiens 72-77 9295281-7 1997 Thus, ara-C stimulates the synthesis of two second messengers with opposing effects on Bcl-2. Cytarabine 6-11 BCL2 apoptosis regulator Homo sapiens 87-92 9295281-11 1997 ET-18-OCH3 also inhibited stimulation of Bcl-2 by TPA and enhanced the decrease in Bcl-2 observed in ara-C-treated cells. edelfosine 0-10 BCL2 apoptosis regulator Homo sapiens 41-46 9295281-11 1997 ET-18-OCH3 also inhibited stimulation of Bcl-2 by TPA and enhanced the decrease in Bcl-2 observed in ara-C-treated cells. edelfosine 0-10 BCL2 apoptosis regulator Homo sapiens 83-88 9295281-11 1997 ET-18-OCH3 also inhibited stimulation of Bcl-2 by TPA and enhanced the decrease in Bcl-2 observed in ara-C-treated cells. Tetradecanoylphorbol Acetate 50-53 BCL2 apoptosis regulator Homo sapiens 41-46 9295281-11 1997 ET-18-OCH3 also inhibited stimulation of Bcl-2 by TPA and enhanced the decrease in Bcl-2 observed in ara-C-treated cells. Cytarabine 101-106 BCL2 apoptosis regulator Homo sapiens 83-88 9295281-12 1997 These data indicate that ara-C-induced apoptosis is limited by ara-C-stimulated PKCbetaII through effects on Bcl-2. Cytarabine 25-30 BCL2 apoptosis regulator Homo sapiens 109-114 9295281-12 1997 These data indicate that ara-C-induced apoptosis is limited by ara-C-stimulated PKCbetaII through effects on Bcl-2. Cytarabine 63-68 BCL2 apoptosis regulator Homo sapiens 109-114 9307264-4 1997 Exposure of Ewing"s sarcoma cells to lactacystin resulted in accumulation of ubiquitinated proteins and activation of a Bcl-2-sensitive apoptotic pathways. lactacystin 37-48 BCL2 apoptosis regulator Homo sapiens 120-125 9294614-3 1997 The role of caspases in mediating TG-induced apoptosis was investigated in the Bcl-2-negative human breast cancer cell line, MDA-MB-468. Thapsigargin 34-36 BCL2 apoptosis regulator Homo sapiens 79-84 9294614-4 1997 Apoptosis developed in MDA-MB-468 cells over a period of 24-72 h following treatment with 100 nM TG, and was prevented by Bcl-2 overexpression. Thapsigargin 97-99 BCL2 apoptosis regulator Homo sapiens 122-127 9294614-7 1997 These findings indicate that TG-induced apoptosis of MDA-MB-468 breast cancer cells is subject to inhibition by Bcl-2 and is mediated by caspase activity. Thapsigargin 29-31 BCL2 apoptosis regulator Homo sapiens 112-117 9380411-3 1997 Consequently, the E1B 19K and Bcl-2 proteins bind to and inhibit the cellular death-inducing proteins Bax, Bak and Nbk/Bik. bakuchiol 107-110 BCL2 apoptosis regulator Homo sapiens 30-35 9311611-3 1997 RG/C2 and BH/C1 cells express p-26-bcl-2 and butyrate treatment decreased p26-bcl-2 levels in association with apoptosis, whereas bax and bak levels remained constant. Butyrates 45-53 BCL2 apoptosis regulator Homo sapiens 78-83 9311611-8 1997 Furthermore, butyrate also induced apoptosis and increased bak levels in AA/C1 cells transfected with a bcl-2 expression vector which expressed high levels of p26-bcl-2. Butyrates 13-21 BCL2 apoptosis regulator Homo sapiens 104-109 9311611-8 1997 Furthermore, butyrate also induced apoptosis and increased bak levels in AA/C1 cells transfected with a bcl-2 expression vector which expressed high levels of p26-bcl-2. Butyrates 13-21 BCL2 apoptosis regulator Homo sapiens 163-168 9311611-10 1997 bcl-2 protected against apoptosis in one transfectant in which bak levels were not elevated in response to butyrate, whereas it did not protect in the other transfectant in which bak levels were increased after butyrate treatment. Butyrates 107-115 BCL2 apoptosis regulator Homo sapiens 0-5 9311611-11 1997 The results suggest that expression of constitutively high levels of p26-bcl-2 only conferred protection against apoptosis when bak levels were not elevated in response to butyrate and that expression of constitutively high levels of p26-bcl-2 does not counter the effects of bak. Butyrates 172-180 BCL2 apoptosis regulator Homo sapiens 73-78 9311611-12 1997 Different mechanisms appear to be involved in cell death signalling in different tumours since butyrate may induce apoptosis via elevated levels of bak or reduced levels of p26-bcl-2. Butyrates 95-103 BCL2 apoptosis regulator Homo sapiens 177-182 9372267-4 1997 The catecholamine-dependent inhibition of T- and B-lymphocyte activity is mediated via an induction of a Bcl-2/Bax and Fas/FasL involved apoptosis. Catecholamines 4-17 BCL2 apoptosis regulator Homo sapiens 105-110 9297974-7 1997 Bcl-2-type molecules, being able to modulate the permeability transition pores by interaction with adenosine nucleotide translocators, may have played an essential role in conferring a means of controlling apoptosis. adenosine nucleotide 99-119 BCL2 apoptosis regulator Homo sapiens 0-5 9368670-0 1997 Calphostin C synergistically induces apoptosis with VP-16 in lymphoma cells which express abundant phosphorylated Bcl-2 protein. calphostin C 0-12 BCL2 apoptosis regulator Homo sapiens 114-119 9368670-4 1997 Simultaneous immunoblot analysis revealed that this induction of apoptosis coincided with the downregulation of serine-phosphorylated Bcl-2 (13% of control cells). Serine 112-118 BCL2 apoptosis regulator Homo sapiens 134-139 9354939-3 1997 The effect of treatment with hyperthermia and verapamil on the expression of apoptosis-associated proteins including Bcl-2, p53, bax, and c-Myc was studied by Western blot analysis. Verapamil 46-55 BCL2 apoptosis regulator Homo sapiens 117-122 9345852-3 1997 In this review Yves Sagot, Richard Vejsada and Ann C. Kato focus on the effects of neurotrophic factors and Bcl-2, both of which have been shown to prevent cell death in various experimental paradigms. sagot 20-25 BCL2 apoptosis regulator Homo sapiens 108-113 9288183-14 1997 For the high-bcl-2-expressing variant, however, it did restore the ability to genetically respond to a secondary apoptotic agent, phorbol ester, as evidenced by the renewed ability of phorbol ester to induce NGF1A mRNA in these cells. Phorbol Esters 130-143 BCL2 apoptosis regulator Homo sapiens 13-18 9288183-14 1997 For the high-bcl-2-expressing variant, however, it did restore the ability to genetically respond to a secondary apoptotic agent, phorbol ester, as evidenced by the renewed ability of phorbol ester to induce NGF1A mRNA in these cells. Phorbol Esters 184-197 BCL2 apoptosis regulator Homo sapiens 13-18 9299422-0 1997 Bcl-2 completely blocks Fas-mediated apoptosis in mtDNA-depleted HeLa cells. ammonium ferrous sulfate 24-27 BCL2 apoptosis regulator Homo sapiens 0-5 9268320-0 1997 Bcl-2 and the outer mitochondrial membrane in the inactivation of cytochrome c during Fas-mediated apoptosis. ammonium ferrous sulfate 86-89 BCL2 apoptosis regulator Homo sapiens 0-5 9268320-4 1997 Because Bcl-2 projects into the mitochondrial intermembrane space and cytochrome c is located in the intermembrane space, we considered the possibility that Bcl-2 might protect cytochrome c from inactivation during Fas-mediated apoptosis. ammonium ferrous sulfate 215-218 BCL2 apoptosis regulator Homo sapiens 157-162 9299422-4 1997 These findings suggest that the Fas-mediated apoptotic pathway is directly linked to Bcl-2 protection in the cells with an accompanying mitochondrial dysfunction. ammonium ferrous sulfate 32-35 BCL2 apoptosis regulator Homo sapiens 85-90 9305631-6 1997 The binding of BAG-1 to one of its known cellular targets, Bcl-2, in cell lysates was found to be dependent on ATP, consistent with the possible involvement of Hsp/Hsc70 in complex formation. Adenosine Triphosphate 111-114 BCL2 apoptosis regulator Homo sapiens 59-64 9281370-3 1997 We show here that treatment of human leukemia cells HL60 with 1,25-dihydroxyvitamin D3 (1,25D3) results in progressive increases in the levels of cellular antiapoptotic protein Mcl-1, a transient increase in Al protein level, but no increases in Bcl-2 or Bcl-XL proteins. Calcitriol 62-86 BCL2 apoptosis regulator Homo sapiens 246-251 9242431-0 1997 Bcl-2 protein inhibits bufalin-induced apoptosis through inhibition of mitogen-activated protein kinase activation in human leukemia U937 cells. bufalin 23-30 BCL2 apoptosis regulator Homo sapiens 0-5 9242435-2 1997 High levels of the antiapoptotic Bcl-x(L) or Bcl-2, relative to the proapoptotic Bax, have been shown to inhibit HIDAC-induced cleavage and activity of caspase-3 and apoptosis of the human acute myeloid leukemia HL-60 cells. hidac 113-118 BCL2 apoptosis regulator Homo sapiens 45-50 9242435-6 1997 HIDAC treatment for 4 h also modestly increased the intracellular levels of free Bax relative to Bax bound to Bcl-2 and Bcl-x(L) in HL-60/neo but not in HL-60/Bcl-x(L) cells. hidac 0-5 BCL2 apoptosis regulator Homo sapiens 110-115 9276475-6 1997 Differential Bcl-2 and ICE mRNA expression was also found when granulocytic differentiation was stimulated by DMSO. Dimethyl Sulfoxide 110-114 BCL2 apoptosis regulator Homo sapiens 13-18 9242431-2 1997 Here, we report the effect of overexpression of bcl-2 in U937 cells on the signaling pathway of apoptosis that is induced by bufalin. bufalin 125-132 BCL2 apoptosis regulator Homo sapiens 48-53 9242431-4 1997 No significant difference was detected in the activation of MAPK kinase-1 that is induced by bufalin in wild-type or Bcl-2-overexpressed U937 cells; however, the activation of MAPK by bufalin was significantly attenuated in the cells overexpressing Bcl-2. bufalin 184-191 BCL2 apoptosis regulator Homo sapiens 249-254 9242431-5 1997 Bufalin treatment activated activator protein-1 transcriptional activity; however, this activation was decreased to 40% in bcl-2-overexpressed U937 cells. bufalin 0-7 BCL2 apoptosis regulator Homo sapiens 123-128 9297559-0 1997 Bcl-2 blocks peroxynitrite-induced apoptosis in HL-60 cells, an association with reactive oxygen species. Peroxynitrous Acid 13-26 BCL2 apoptosis regulator Homo sapiens 0-5 16465270-6 1997 Interestingly, enforced expression of BCL-2 also inhibited the ability of VP-16 to generate oxy-radicals and to depress intracellular glutathione levels. oxy-radicals 92-104 BCL2 apoptosis regulator Homo sapiens 38-43 16465270-6 1997 Interestingly, enforced expression of BCL-2 also inhibited the ability of VP-16 to generate oxy-radicals and to depress intracellular glutathione levels. Glutathione 134-145 BCL2 apoptosis regulator Homo sapiens 38-43 9260915-2 1997 Moreover, ectopic expression of bcl-2 can impair apoptosis signaling by most of the cell stresses that activate the ceramide/JNK pathway. Ceramides 116-124 BCL2 apoptosis regulator Homo sapiens 32-37 9260915-3 1997 Here we show that enforced expression of bcl-2 protects prostate carcinoma cells against the induction of apoptosis by exogenous C2-ceramide. N-acetylsphingosine 129-140 BCL2 apoptosis regulator Homo sapiens 41-46 9260915-4 1997 Moreover, enforced bcl-2 expression blocked the capacity of C2-ceramide to activate JNK1, indicating bcl-2 functions at the level of JNK1 or upstream of JNK1 in the ceramide/JNK pathway. N-acetylsphingosine 60-71 BCL2 apoptosis regulator Homo sapiens 19-24 9260915-4 1997 Moreover, enforced bcl-2 expression blocked the capacity of C2-ceramide to activate JNK1, indicating bcl-2 functions at the level of JNK1 or upstream of JNK1 in the ceramide/JNK pathway. N-acetylsphingosine 60-71 BCL2 apoptosis regulator Homo sapiens 101-106 9260915-4 1997 Moreover, enforced bcl-2 expression blocked the capacity of C2-ceramide to activate JNK1, indicating bcl-2 functions at the level of JNK1 or upstream of JNK1 in the ceramide/JNK pathway. Ceramides 63-71 BCL2 apoptosis regulator Homo sapiens 19-24 9260915-4 1997 Moreover, enforced bcl-2 expression blocked the capacity of C2-ceramide to activate JNK1, indicating bcl-2 functions at the level of JNK1 or upstream of JNK1 in the ceramide/JNK pathway. Ceramides 63-71 BCL2 apoptosis regulator Homo sapiens 101-106 9260915-6 1997 Our results indicate bcl-2 can protect cells against diminished availability of arachidonic acid, 12-HETE, and 15-HETE. Arachidonic Acid 80-96 BCL2 apoptosis regulator Homo sapiens 21-26 9260915-6 1997 Our results indicate bcl-2 can protect cells against diminished availability of arachidonic acid, 12-HETE, and 15-HETE. 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid 98-105 BCL2 apoptosis regulator Homo sapiens 21-26 9260915-6 1997 Our results indicate bcl-2 can protect cells against diminished availability of arachidonic acid, 12-HETE, and 15-HETE. 15-hydroxy-5,8,11,13-eicosatetraenoic acid 111-118 BCL2 apoptosis regulator Homo sapiens 21-26 9297559-0 1997 Bcl-2 blocks peroxynitrite-induced apoptosis in HL-60 cells, an association with reactive oxygen species. Reactive Oxygen Species 81-104 BCL2 apoptosis regulator Homo sapiens 0-5 9380798-8 1997 However, overexpression of human bcl-2 inhibited diclofenac-mediated apoptosis by 90%, demonstrating directly that bcl-2 expression can regulate nonsteroidal antiinflammatory drug induction of cell death. Diclofenac 49-59 BCL2 apoptosis regulator Homo sapiens 33-38 9306964-0 1997 Down-regulation of bcl-2 expression is closely related to squamous differentiation and progesterone therapy in endometrial carcinomas. Progesterone 87-99 BCL2 apoptosis regulator Homo sapiens 19-24 9306964-7 1997 In addition, bcl-2 expression appears to be down-regulated by progesterone therapy through tumour cell maturation, indicating that bcl-2 may be a clinically useful marker of hormone therapy effects. Progesterone 62-74 BCL2 apoptosis regulator Homo sapiens 13-18 9306964-7 1997 In addition, bcl-2 expression appears to be down-regulated by progesterone therapy through tumour cell maturation, indicating that bcl-2 may be a clinically useful marker of hormone therapy effects. Progesterone 62-74 BCL2 apoptosis regulator Homo sapiens 131-136 9380798-8 1997 However, overexpression of human bcl-2 inhibited diclofenac-mediated apoptosis by 90%, demonstrating directly that bcl-2 expression can regulate nonsteroidal antiinflammatory drug induction of cell death. Diclofenac 49-59 BCL2 apoptosis regulator Homo sapiens 115-120 9223329-9 1997 Fas-mediated apoptosis induced by the cytotoxic anti-Fas monoclonal antibody CH-11 was inhibited following adenoviral delivery of a Bcl-2 cDNA, and Bcl-2 also protected cells from acute apoptosis induced by dThd deprivation. Thymidine 207-211 BCL2 apoptosis regulator Homo sapiens 132-137 9339128-3 1997 To determine the bcl-2 immunoreactivity, we used a monoclonal antibody directed against the bcl-2 protein by immunohistochemistry from paraffin-embedded tissue in a series of 91 women with breast cancer. Paraffin 135-143 BCL2 apoptosis regulator Homo sapiens 92-97 9223329-9 1997 Fas-mediated apoptosis induced by the cytotoxic anti-Fas monoclonal antibody CH-11 was inhibited following adenoviral delivery of a Bcl-2 cDNA, and Bcl-2 also protected cells from acute apoptosis induced by dThd deprivation. Thymidine 207-211 BCL2 apoptosis regulator Homo sapiens 148-153 9223329-9 1997 Fas-mediated apoptosis induced by the cytotoxic anti-Fas monoclonal antibody CH-11 was inhibited following adenoviral delivery of a Bcl-2 cDNA, and Bcl-2 also protected cells from acute apoptosis induced by dThd deprivation. ammonium ferrous sulfate 0-3 BCL2 apoptosis regulator Homo sapiens 132-137 9223329-9 1997 Fas-mediated apoptosis induced by the cytotoxic anti-Fas monoclonal antibody CH-11 was inhibited following adenoviral delivery of a Bcl-2 cDNA, and Bcl-2 also protected cells from acute apoptosis induced by dThd deprivation. ammonium ferrous sulfate 0-3 BCL2 apoptosis regulator Homo sapiens 148-153 9223330-0 1997 The antisense bcl-2-IgH transcript is an optimal target for synthetic oligonucleotides. Oligonucleotides 70-86 BCL2 apoptosis regulator Homo sapiens 14-19 9223329-9 1997 Fas-mediated apoptosis induced by the cytotoxic anti-Fas monoclonal antibody CH-11 was inhibited following adenoviral delivery of a Bcl-2 cDNA, and Bcl-2 also protected cells from acute apoptosis induced by dThd deprivation. 4-dimethylamino-3',4'-dimethoxychalcone 77-82 BCL2 apoptosis regulator Homo sapiens 132-137 9223330-4 1997 A variety of sense-oriented oligonucleotides have been designed that target the antisense transcript in regions endowed with a sequence specificity presumably restricted to an individual cell line (the bcl-2-IgH fusion regions) or extended to all t(14;18) cells (the ectopic bcl-2 segment upstream from the major breakpoint region and the IgH segment). Oligonucleotides 28-44 BCL2 apoptosis regulator Homo sapiens 202-207 9223330-4 1997 A variety of sense-oriented oligonucleotides have been designed that target the antisense transcript in regions endowed with a sequence specificity presumably restricted to an individual cell line (the bcl-2-IgH fusion regions) or extended to all t(14;18) cells (the ectopic bcl-2 segment upstream from the major breakpoint region and the IgH segment). Oligonucleotides 28-44 BCL2 apoptosis regulator Homo sapiens 275-280 9224736-7 1997 Ascorbate (Asc) and alpha-tocopherol (alphaTOH) can prevent lipid peroxidation and apoptosis caused by serum withdrawal, when added to culture media, even in the absence of Bcl-2. alpha-Tocopherol 20-36 BCL2 apoptosis regulator Homo sapiens 173-178 9206994-10 1997 Although Bcl-2 is a highly efficient inhibitor of mitochondrial alterations (large amplitude swelling + DeltaPsim collapse + release of AIF) induced by prooxidants or cytosols from ceramide-treated cells, it has no effect on the ICE-induced mitochondrial PT and AIF release. Ceramides 181-189 BCL2 apoptosis regulator Homo sapiens 9-14 9206994-12 1997 In addition, they provide a plausible explanation of why Bcl-2 fails to interfere with Fas-triggered apoptosis in most cell types, yet prevents ceramide- and prooxidant-induced apoptosis. ammonium ferrous sulfate 87-90 BCL2 apoptosis regulator Homo sapiens 57-62 9206994-12 1997 In addition, they provide a plausible explanation of why Bcl-2 fails to interfere with Fas-triggered apoptosis in most cell types, yet prevents ceramide- and prooxidant-induced apoptosis. Ceramides 144-152 BCL2 apoptosis regulator Homo sapiens 57-62 9223368-9 1997 Flow cytometric analysis indicates that the mechanism of staurosporine-induced apoptosis may be through decrease of Bcl-2 in treated DP cells or through modulation of cell cycle regulators. Staurosporine 57-70 BCL2 apoptosis regulator Homo sapiens 116-121 9223368-9 1997 Flow cytometric analysis indicates that the mechanism of staurosporine-induced apoptosis may be through decrease of Bcl-2 in treated DP cells or through modulation of cell cycle regulators. dp 133-135 BCL2 apoptosis regulator Homo sapiens 116-121 9201973-3 1997 In the present study, Bcl-2 suppressed cell death of N18TG neuroglioma cells caused by various apoptotic stresses, including etoposide, staurosporine, anisomycin, and ultraviolet irradiation. Etoposide 125-134 BCL2 apoptosis regulator Homo sapiens 22-27 9201973-3 1997 In the present study, Bcl-2 suppressed cell death of N18TG neuroglioma cells caused by various apoptotic stresses, including etoposide, staurosporine, anisomycin, and ultraviolet irradiation. Staurosporine 136-149 BCL2 apoptosis regulator Homo sapiens 22-27 9201973-3 1997 In the present study, Bcl-2 suppressed cell death of N18TG neuroglioma cells caused by various apoptotic stresses, including etoposide, staurosporine, anisomycin, and ultraviolet irradiation. Anisomycin 151-161 BCL2 apoptosis regulator Homo sapiens 22-27 9201973-5 1997 Bcl-2 also prevented the etoposide-induced stimulation of MEKK1. Etoposide 25-34 BCL2 apoptosis regulator Homo sapiens 0-5 9219694-5 1997 Bcl-2, in contrast, triggered carboxyfluorescein release at acidic pH only. 6-carboxyfluorescein 30-48 BCL2 apoptosis regulator Homo sapiens 0-5 9230884-0 1997 Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. Oligodeoxyribonucleotides 71-91 BCL2 apoptosis regulator Homo sapiens 106-111 9271217-0 1997 Bcl-2 antagonizes apoptotic cell death induced by two new ceramide analogues. Ceramides 58-66 BCL2 apoptosis regulator Homo sapiens 0-5 9226155-8 1997 We also observed prominent concentration-dependent downregulation of bcl-2 mRNA after 24 hours of exposure to melarsoprol in WSU-CLL, I83CLL, and JVM-2 cells. Melarsoprol 110-121 BCL2 apoptosis regulator Homo sapiens 69-74 22358653-1 1997 Mouse hybridoma 2E3 transfected with human bcl-2 gene survived longer with increasing expression level of bcl-2 when cultured in DME medium supplemented with 9% serum. dme medium 129-139 BCL2 apoptosis regulator Homo sapiens 43-48 9230856-5 1997 Monoclonal antibodies against bcl-2 protein were applied using the avidin-biotin complex immunoperoxidase method. avidin-biotin 67-80 BCL2 apoptosis regulator Homo sapiens 30-35 22358653-1 1997 Mouse hybridoma 2E3 transfected with human bcl-2 gene survived longer with increasing expression level of bcl-2 when cultured in DME medium supplemented with 9% serum. dme medium 129-139 BCL2 apoptosis regulator Homo sapiens 106-111 22358653-6 1997 Overexpression of bcl-2 also suppressed apoptosis of the hybridoma induced by glutamine deprivation. Glutamine 78-87 BCL2 apoptosis regulator Homo sapiens 18-23 9204972-0 1997 Apoptosis of human myeloid leukemia cells induced by an inhibitor of protein phosphatases (okadaic acid) is prevented by Bcl-2 and Bcl-X(L). Okadaic Acid 91-103 BCL2 apoptosis regulator Homo sapiens 121-126 9301455-4 1997 We used monoclonal antibody 124 to investigate Bcl-2 expression in paraffin sections of 62 primary breast carcinomas. Paraffin 67-75 BCL2 apoptosis regulator Homo sapiens 47-52 9204972-3 1997 Since phosphorylation/dephosphorylation reactions have been suggested to be involved in the regulation of Bcl-2, we planned to investigate whether the expression of Bcl-2, Bcl-X(L) and Bax, a protein that antagonizes the antiapoptotic function of Bcl-2, are regulated in myeloid leukemia cell lines (K562, KU812 and HL-60) treated with okadaic acid. Okadaic Acid 336-348 BCL2 apoptosis regulator Homo sapiens 165-170 9204972-3 1997 Since phosphorylation/dephosphorylation reactions have been suggested to be involved in the regulation of Bcl-2, we planned to investigate whether the expression of Bcl-2, Bcl-X(L) and Bax, a protein that antagonizes the antiapoptotic function of Bcl-2, are regulated in myeloid leukemia cell lines (K562, KU812 and HL-60) treated with okadaic acid. Okadaic Acid 336-348 BCL2 apoptosis regulator Homo sapiens 165-170 9204972-4 1997 Our results indicate that exposure of all three leukemic cell lines to nanomolar concentrations of okadaic acid causes a loss of viability by activation of an apoptotic process accompanied by a marked decrease in the expression of Bcl-2, Bcl-X(L) and Bax at both mRNA and protein level, but not of c-fos, vimentin and epsilon-globin, ruling out a non-specific effect of okadaic acid. Okadaic Acid 99-111 BCL2 apoptosis regulator Homo sapiens 231-236 9204972-5 1997 Furthermore, constitutive expression of either Bcl-X(L) or Bcl-2 by gene transfer inhibited apoptosis triggered by okadaic acid in K562 cells. Okadaic Acid 115-127 BCL2 apoptosis regulator Homo sapiens 59-64 9195941-5 1997 Of the bcl-2 family members, IFN-gamma directly induced bak but notably not bax, which is activated by p53. bakuchiol 56-59 BCL2 apoptosis regulator Homo sapiens 7-12 15624332-6 1997 9-cis RA was more potent than all-trans retinoic acid (ATRA) did in inducing terminal differentiation associated apoptosis and in downregulation of Bcl-2 expression. Radium 6-8 BCL2 apoptosis regulator Homo sapiens 148-153 15624332-6 1997 9-cis RA was more potent than all-trans retinoic acid (ATRA) did in inducing terminal differentiation associated apoptosis and in downregulation of Bcl-2 expression. Tretinoin 40-53 BCL2 apoptosis regulator Homo sapiens 148-153 15624332-6 1997 9-cis RA was more potent than all-trans retinoic acid (ATRA) did in inducing terminal differentiation associated apoptosis and in downregulation of Bcl-2 expression. Tretinoin 55-59 BCL2 apoptosis regulator Homo sapiens 148-153 9194490-0 1997 Altered sensitivity to retinoid-induced apoptosis associated with changes in the subcellular distribution of Bcl-2. Retinoids 23-31 BCL2 apoptosis regulator Homo sapiens 109-114 9192772-3 1997 We investigated whether there is a correlation between expression of high levels of Bcl-2 and susceptibility of human Burkitt"s lymphoma cell lines to H2O2-induced killing. Hydrogen Peroxide 151-155 BCL2 apoptosis regulator Homo sapiens 84-89 9192772-5 1997 However, expression of high levels of endogenous Bcl-2 did not protect the cells from H2O2-induced killing, even though it was effective in protecting the cells from apoptosis induced by agents such as A23187. Calcimycin 202-208 BCL2 apoptosis regulator Homo sapiens 49-54 9194490-1 1997 In the acute promyelocytic leukemia cell line NB4, Bcl-2 downregulation occurred as a late event of retinoid-induced differentiation. Retinoids 100-108 BCL2 apoptosis regulator Homo sapiens 51-56 9194490-8 1997 A human Bcl-2 transgene was transiently overexpressed in NB4-R1 cells which showed increased resistance to apoptosis induced by retinoids. Retinoids 128-137 BCL2 apoptosis regulator Homo sapiens 8-13 9194490-11 1997 This work demonstrates that the ability of retinoid-induced cells to undergo apoptosis depends on the level of expression and the functional interaction between Bcl-2 and Bax. Retinoids 43-51 BCL2 apoptosis regulator Homo sapiens 161-166 9187115-1 1997 We have evaluated the influence of anchorage status together with endogenous levels of bcl-2 family members on the ability of the topoisomerase I inhibitor, topotecan (TPT), to induce programmed cell death (PCD) in human colon, breast, lymphoid, and cervical cancer cell lines. Topotecan 157-166 BCL2 apoptosis regulator Homo sapiens 87-92 9185697-0 1997 The Bax alpha:Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia. Dexamethasone 52-65 BCL2 apoptosis regulator Homo sapiens 14-19 9187115-1 1997 We have evaluated the influence of anchorage status together with endogenous levels of bcl-2 family members on the ability of the topoisomerase I inhibitor, topotecan (TPT), to induce programmed cell death (PCD) in human colon, breast, lymphoid, and cervical cancer cell lines. Topotecan 168-171 BCL2 apoptosis regulator Homo sapiens 87-92 9191791-6 1997 DEX thus appears to control a common, bcl-2-independent death pathway in glioma cells that is not limited to specific drug actions. Dexamethasone 0-3 BCL2 apoptosis regulator Homo sapiens 38-43 11324502-3 1997 In MDA-MB-231 cells which possess a mutant p53, adriamycin-induced G1 arrest and apoptosis was also associated with a concomitant up-regulation of WAF1/CIP1 mRNA while these cells did not express bax or bcl-2 messages. Doxorubicin 48-58 BCL2 apoptosis regulator Homo sapiens 203-208 9180899-3 1997 In this article, we report that Na+/ K(+)-ATPase pump activity, as measured by the uptake of Rubidium-86 (86Rb+), is significantly higher in Bcl-2 overexpressing PW cells than in control PW cells, and that pump activity following irradiation with doses > or = 500 cGy was reduced to a lesser extent in the Bcl-2 transfectants than in the control cells. Rubidium 93-101 BCL2 apoptosis regulator Homo sapiens 141-146 9209521-6 1997 There was an inverse relationship between bcl-2 oncoprotein expression and apoptosis in 5-FU-treated patients, but no significant correlation between histological effect and apoptosis. Fluorouracil 88-92 BCL2 apoptosis regulator Homo sapiens 42-47 9209521-8 1997 CONCLUSIONS: Apoptosis may be induced by 5-FU administered preoperatively and bcl-2 oncogene expression may suppress 5-FU-induced apoptosis. Fluorouracil 117-121 BCL2 apoptosis regulator Homo sapiens 78-83 9195893-6 1997 Finally, recent evidence suggests that bryostatin 1 may act, through modification of Bcl-2 phosphorylation status, at a distal site in the cell death pathway. bryostatin 1 39-51 BCL2 apoptosis regulator Homo sapiens 85-90 9191602-12 1997 Treatment of RPE cells in serum-free medium with flupirtine (flupirtine gluconate, 100 microM) for 72 hours caused an upregulation of bcl-2 protein. flupirtine 49-59 BCL2 apoptosis regulator Homo sapiens 134-139 9191602-12 1997 Treatment of RPE cells in serum-free medium with flupirtine (flupirtine gluconate, 100 microM) for 72 hours caused an upregulation of bcl-2 protein. Flupirtine gluconate 61-81 BCL2 apoptosis regulator Homo sapiens 134-139 9210957-0 1997 Suppression of nitric oxide-induced apoptosis by N-acetyl-L-cysteine through modulation of glutathione, bcl-2, and bax protein levels. Nitric Oxide 15-27 BCL2 apoptosis regulator Homo sapiens 104-109 9210957-0 1997 Suppression of nitric oxide-induced apoptosis by N-acetyl-L-cysteine through modulation of glutathione, bcl-2, and bax protein levels. Acetylcysteine 49-68 BCL2 apoptosis regulator Homo sapiens 104-109 9210957-7 1997 In summary, our results suggest that the protective effect of LNAC may be linked to its inducement of increases in cellular GSH and bcl-2 protein levels and to its suppression of cellular bax protein in treated cells. N-acetylcysteine lysinate 62-66 BCL2 apoptosis regulator Homo sapiens 132-137 9188860-2 1997 We now show that costimulation of 2B4 cells, in the absence or presence of transgenic Bcl-2, with anti-CD3 epsilon and forskolin, an activator of cAMP signaling, resulted in antagonism of Fas-dependent activation-induced cell death that was always accompanied by selective downregulation of the nuclear levels of NF-kappa B p65-p50 (RelA-p50) transcription factor. Colforsin 119-128 BCL2 apoptosis regulator Homo sapiens 86-91 9135001-2 1997 Forty-eight h after 10 J/m2 irradiation, only 4% of the cyclobutane pyrimidine dimers were removed in the BCL2-overexpressing cells, in contrast to 38% removal in control cells. cyclobutane pyrimidine 56-78 BCL2 apoptosis regulator Homo sapiens 106-110 9144199-3 1997 Using chloride efflux from KCl-loaded unilamellar lipid vesicles as an assay, purified recombinant Bcl-2 protein exhibited pore-forming activity with properties similar to those of the bacterial toxins, diphtheria toxin, and colicins, i.e., dependence on low pH and acidic lipid membranes. Chlorides 6-14 BCL2 apoptosis regulator Homo sapiens 99-104 9144199-3 1997 Using chloride efflux from KCl-loaded unilamellar lipid vesicles as an assay, purified recombinant Bcl-2 protein exhibited pore-forming activity with properties similar to those of the bacterial toxins, diphtheria toxin, and colicins, i.e., dependence on low pH and acidic lipid membranes. Potassium Chloride 27-30 BCL2 apoptosis regulator Homo sapiens 99-104 9144199-6 1997 The most frequent conductance observed (18 +/- 2 pS in 0.5 M KCl at pH 7.4) is consistent with a four-helix bundle structure arising from Bcl-2 dimers. Potassium Chloride 61-64 BCL2 apoptosis regulator Homo sapiens 138-143 9129041-3 1997 We found previously that As2O3 can trigger apoptosis of APL cell line NB4 cells, which is associated with downregulation of bcl-2 gene expression and modulation of PML-RAR alpha chimeric protein. Arsenic Trioxide 25-30 BCL2 apoptosis regulator Homo sapiens 124-129 9115213-5 1997 To test whether phosphorylation is required for Bcl-2 function, conservative serine --> alanine mutations were produced at the seven putative protein kinase C phosphorylation sites in Bcl-2. Alanine 91-98 BCL2 apoptosis regulator Homo sapiens 187-192 16465244-0 1997 Modulation of the expression of Bcl-2 and related proteins in human leukemia cells by protein kinase C activators: relationship to effects on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis. Cytarabine 142-177 BCL2 apoptosis regulator Homo sapiens 32-37 9158086-2 1997 Rapamycin treatment down-regulated bcl-2 expression on rheumatoid synovial cells in a dose-dependent manner. Sirolimus 0-9 BCL2 apoptosis regulator Homo sapiens 35-40 9158086-5 1997 Our results suggest that rapamycin augments the sensitivity of rheumatoid synovial fibroblasts to apoptosis by down-regulating bcl-2 expression. Sirolimus 25-34 BCL2 apoptosis regulator Homo sapiens 127-132 9164202-1 1997 PURPOSE: To test the hypothesis that high bcl-2 expression and accumulation of p53 protein, both of which should inhibit apoptosis, are associated with a poorer tamoxifen response and a more aggressive clinical course in estrogen receptor (ER)-positive metastatic breast cancer. Tamoxifen 161-170 BCL2 apoptosis regulator Homo sapiens 42-47 9164202-6 1997 Higher bcl-2 expression was associated with higher levels of ER (P = .02), better response to tamoxifen (62% v 49%; P = .07), longer TTF (median, 9 v 5 months; P = .002), and better survival (median, 40 months v 25 months; P = .009). Tamoxifen 94-103 BCL2 apoptosis regulator Homo sapiens 7-12 9164202-10 1997 Contrary to expectation, high bcl-2 identifies a relatively indolent phenotype of ER-positive metastatic breast cancer, in which patients experience a better clinical response to tamoxifen and a longer survival. Tamoxifen 179-188 BCL2 apoptosis regulator Homo sapiens 30-35 16465244-10 1997 When cells were co-incubated with bryostatin 1 and calcium ionophore (A23187), an identical pattern of expression of Bcl-2 family members was observed, despite the loss of bryostatin 1"s capacity to potentiate apoptosis, and the restoration of its ability to induce differentiation. bryostatin 1 34-46 BCL2 apoptosis regulator Homo sapiens 117-122 16465244-10 1997 When cells were co-incubated with bryostatin 1 and calcium ionophore (A23187), an identical pattern of expression of Bcl-2 family members was observed, despite the loss of bryostatin 1"s capacity to potentiate apoptosis, and the restoration of its ability to induce differentiation. Calcium 51-58 BCL2 apoptosis regulator Homo sapiens 117-122 16465244-10 1997 When cells were co-incubated with bryostatin 1 and calcium ionophore (A23187), an identical pattern of expression of Bcl-2 family members was observed, despite the loss of bryostatin 1"s capacity to potentiate apoptosis, and the restoration of its ability to induce differentiation. Calcimycin 70-76 BCL2 apoptosis regulator Homo sapiens 117-122 16465244-11 1997 Finally, treatment of cells with bryostatin 1+/-ara-C (but not ara-C alone) resulted in a diffuse broadening of the Bcl-2 protein band, whereas exposure of cells to taxol (250 nM, 6 h) led to the appearance of a distinct Bcl-2 species with reduced mobility, phenomena compatible with protein phosphorylation. bryostatin 1 33-45 BCL2 apoptosis regulator Homo sapiens 116-121 9225073-0 1997 Modulation of p53, WAF1/p21 and BCL-2 expression during retinoic acid-induced differentiation of NB4 promyelocytic cells. Tretinoin 56-69 BCL2 apoptosis regulator Homo sapiens 32-37 16465244-11 1997 Finally, treatment of cells with bryostatin 1+/-ara-C (but not ara-C alone) resulted in a diffuse broadening of the Bcl-2 protein band, whereas exposure of cells to taxol (250 nM, 6 h) led to the appearance of a distinct Bcl-2 species with reduced mobility, phenomena compatible with protein phosphorylation. bryostatin 1 33-45 BCL2 apoptosis regulator Homo sapiens 221-226 16465244-11 1997 Finally, treatment of cells with bryostatin 1+/-ara-C (but not ara-C alone) resulted in a diffuse broadening of the Bcl-2 protein band, whereas exposure of cells to taxol (250 nM, 6 h) led to the appearance of a distinct Bcl-2 species with reduced mobility, phenomena compatible with protein phosphorylation. Cytarabine 48-53 BCL2 apoptosis regulator Homo sapiens 116-121 16465244-11 1997 Finally, treatment of cells with bryostatin 1+/-ara-C (but not ara-C alone) resulted in a diffuse broadening of the Bcl-2 protein band, whereas exposure of cells to taxol (250 nM, 6 h) led to the appearance of a distinct Bcl-2 species with reduced mobility, phenomena compatible with protein phosphorylation. Cytarabine 48-53 BCL2 apoptosis regulator Homo sapiens 221-226 16465244-12 1997 Together, these findings indicate that the ability of bryostatin 1 to facilitate drug-induced apoptosis in human myeloid leukemia cells involves factors other than quantitative changes in the expression of Bcl-2 family members, and raise the possibility that qualitative alterations in the Bcl-2 protein, such as phosphorylation status, may contribute to this capacity. bryostatin 1 54-66 BCL2 apoptosis regulator Homo sapiens 290-295 9109491-1 1997 It is not known how the protein Bcl-2 inhibits cell death induced by calcium signalling and growth-factor withdrawal. Calcium 69-76 BCL2 apoptosis regulator Homo sapiens 32-37 9113013-2 1997 Antisense oligonucleotides targeted at the open reading frame of the BCL-2 mRNA cause a specific down-regulation of BCL-2 expression which leads to increased apoptosis. Oligonucleotides 10-26 BCL2 apoptosis regulator Homo sapiens 69-74 9113013-2 1997 Antisense oligonucleotides targeted at the open reading frame of the BCL-2 mRNA cause a specific down-regulation of BCL-2 expression which leads to increased apoptosis. Oligonucleotides 10-26 BCL2 apoptosis regulator Homo sapiens 116-121 9113013-3 1997 Lymphoma grown in laboratory animals responds to BCL-2 antisense oligonucleotides with few toxic effects. Oligonucleotides 65-81 BCL2 apoptosis regulator Homo sapiens 49-54 9113013-5 1997 METHODS: A daily subcutaneous infusion of 18-base, fully phosporothioated antisense oligonucleotide was administered for 2 weeks to nine patients who had BCL-2-positive relapsed non-Hodgkin lymphoma. 18-base 42-49 BCL2 apoptosis regulator Homo sapiens 154-159 9113013-5 1997 METHODS: A daily subcutaneous infusion of 18-base, fully phosporothioated antisense oligonucleotide was administered for 2 weeks to nine patients who had BCL-2-positive relapsed non-Hodgkin lymphoma. Oligonucleotides 84-99 BCL2 apoptosis regulator Homo sapiens 154-159 9141489-10 1997 Our present results, together with previous observations, strongly suggest that apoptosis regulatory genes differ according to cell type and apoptosis induction through sphingosine is accompanied by inhibition of either bcl-2 or bcl-X(L) activity in these cells. Sphingosine 169-180 BCL2 apoptosis regulator Homo sapiens 220-225 9109491-2 1997 Here we report that Bcl-2 forms a tight complex with calcineurin, resulting in the targeting of calcineurin to Bcl-2 sites on cytoplasmic membranes, and show that this interaction is dependent on the BH4 domain of Bcl-2. sapropterin 200-203 BCL2 apoptosis regulator Homo sapiens 20-25 9109491-2 1997 Here we report that Bcl-2 forms a tight complex with calcineurin, resulting in the targeting of calcineurin to Bcl-2 sites on cytoplasmic membranes, and show that this interaction is dependent on the BH4 domain of Bcl-2. sapropterin 200-203 BCL2 apoptosis regulator Homo sapiens 111-116 9109491-2 1997 Here we report that Bcl-2 forms a tight complex with calcineurin, resulting in the targeting of calcineurin to Bcl-2 sites on cytoplasmic membranes, and show that this interaction is dependent on the BH4 domain of Bcl-2. sapropterin 200-203 BCL2 apoptosis regulator Homo sapiens 111-116 9130713-7 1997 Deletion of 16 amino acids including the conserved BH3 region abolished the ability of Hrk to interact with Bcl-2 and Bcl-X(L) in mammalian cells. BH 3 51-54 BCL2 apoptosis regulator Homo sapiens 108-113 9102220-0 1997 Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L). edelfosine 68-78 BCL2 apoptosis regulator Homo sapiens 162-167 9102220-0 1997 Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L). edelfosine 80-90 BCL2 apoptosis regulator Homo sapiens 162-167 9102220-8 1997 Overexpression of bcl-2 or bcl-xL by gene transfer in the human erythroleukemic HEL cells abrogated apoptosis induced by ET-18-OCH3. et-18 121-126 BCL2 apoptosis regulator Homo sapiens 18-23 9150390-0 1997 Influence of Bcl-2 overexpression on the ceramide pathway in daunorubicin-induced apoptosis of leukemic cells. Ceramides 41-49 BCL2 apoptosis regulator Homo sapiens 13-18 9150390-0 1997 Influence of Bcl-2 overexpression on the ceramide pathway in daunorubicin-induced apoptosis of leukemic cells. Daunorubicin 61-73 BCL2 apoptosis regulator Homo sapiens 13-18 9150390-7 1997 In contrast, Bcl-2 overexpression protected the cells against apoptosis induced by ceramide treatment, without preventing the early SM hydrolysis nor the ceramide generation in these cells. Ceramides 83-91 BCL2 apoptosis regulator Homo sapiens 13-18 9150390-8 1997 Our results strongly suggest that Bcl-2-mediated protection of DNR-induced apoptosis is effected downstream of the SM-ceramide signaling pathway. sm-ceramide 115-126 BCL2 apoptosis regulator Homo sapiens 34-39 9108094-13 1997 The synergistic therapeutic effect of Taxol with (90)Y-ChL6 may relate to the p53 mutant status and BCL2 expression in HBT 3477 cells, observations that increase the likelihood that the results of this study are relevant to therapy for breast cancer in patients. Paclitaxel 38-43 BCL2 apoptosis regulator Homo sapiens 100-104 18634067-8 1997 The overexpression of bcl-2 protein also significantly extended the cell integrity and viability by the suppression of apoptosis in conditions of hypoxia, hyperoxia, glutamine deprivation, glucose deprivation, and serum limitation. Glutamine 166-175 BCL2 apoptosis regulator Homo sapiens 22-27 18634067-10 1997 In conditions of excess thymidine, which suppressed cell proliferation, Ml cell density and specific mAb productivity were further enhanced by the overexpression of bcl-2, which suggests the possibility of accomplishing a controlled proliferation in immortalized cell lines without invoking cell death. Thymidine 24-33 BCL2 apoptosis regulator Homo sapiens 165-170 9116289-0 1997 Upregulation of intracellular glutathione by fibroblast-derived factor(s): enhanced survival of activated T cells in the presence of low Bcl-2. Glutathione 30-41 BCL2 apoptosis regulator Homo sapiens 137-142 9116289-6 1997 The GSH-rescued T cells do not proliferate and express only low levels of Bcl-2, resembling W138 fibroblast-rescued T cells. Glutathione 4-7 BCL2 apoptosis regulator Homo sapiens 74-79 9096388-9 1997 In contrast, changes in Bcl-2 level due to expression of sense and antisense vectors influenced the sensitivity to Fas killing and Fas-induced JNK activation. ammonium ferrous sulfate 115-118 BCL2 apoptosis regulator Homo sapiens 24-29 9209397-2 1997 Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS), we find that expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia) and that the cell death does not involve ROS, suggesting that Bcl-2 or Bcl-xL exerts an anti-cell death function by a mechanism other than through regulation of ROS activity. Reactive Oxygen Species 71-94 BCL2 apoptosis regulator Homo sapiens 53-58 9209397-2 1997 Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS), we find that expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia) and that the cell death does not involve ROS, suggesting that Bcl-2 or Bcl-xL exerts an anti-cell death function by a mechanism other than through regulation of ROS activity. Reactive Oxygen Species 71-94 BCL2 apoptosis regulator Homo sapiens 129-134 9209397-2 1997 Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS), we find that expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia) and that the cell death does not involve ROS, suggesting that Bcl-2 or Bcl-xL exerts an anti-cell death function by a mechanism other than through regulation of ROS activity. Reactive Oxygen Species 71-94 BCL2 apoptosis regulator Homo sapiens 129-134 9209397-2 1997 Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS), we find that expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia) and that the cell death does not involve ROS, suggesting that Bcl-2 or Bcl-xL exerts an anti-cell death function by a mechanism other than through regulation of ROS activity. Reactive Oxygen Species 96-99 BCL2 apoptosis regulator Homo sapiens 53-58 9209397-2 1997 Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS), we find that expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia) and that the cell death does not involve ROS, suggesting that Bcl-2 or Bcl-xL exerts an anti-cell death function by a mechanism other than through regulation of ROS activity. Reactive Oxygen Species 96-99 BCL2 apoptosis regulator Homo sapiens 129-134 9209397-2 1997 Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS), we find that expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia) and that the cell death does not involve ROS, suggesting that Bcl-2 or Bcl-xL exerts an anti-cell death function by a mechanism other than through regulation of ROS activity. Reactive Oxygen Species 96-99 BCL2 apoptosis regulator Homo sapiens 129-134 9209397-2 1997 Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS), we find that expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia) and that the cell death does not involve ROS, suggesting that Bcl-2 or Bcl-xL exerts an anti-cell death function by a mechanism other than through regulation of ROS activity. Oxygen 80-86 BCL2 apoptosis regulator Homo sapiens 53-58 9209397-2 1997 Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS), we find that expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia) and that the cell death does not involve ROS, suggesting that Bcl-2 or Bcl-xL exerts an anti-cell death function by a mechanism other than through regulation of ROS activity. Oxygen 80-86 BCL2 apoptosis regulator Homo sapiens 129-134 9209397-2 1997 Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS), we find that expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia) and that the cell death does not involve ROS, suggesting that Bcl-2 or Bcl-xL exerts an anti-cell death function by a mechanism other than through regulation of ROS activity. Oxygen 80-86 BCL2 apoptosis regulator Homo sapiens 129-134 9209397-2 1997 Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS), we find that expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia) and that the cell death does not involve ROS, suggesting that Bcl-2 or Bcl-xL exerts an anti-cell death function by a mechanism other than through regulation of ROS activity. Reactive Oxygen Species 248-251 BCL2 apoptosis regulator Homo sapiens 129-134 9209397-2 1997 Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS), we find that expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia) and that the cell death does not involve ROS, suggesting that Bcl-2 or Bcl-xL exerts an anti-cell death function by a mechanism other than through regulation of ROS activity. Reactive Oxygen Species 248-251 BCL2 apoptosis regulator Homo sapiens 129-134 9209397-2 1997 Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS), we find that expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia) and that the cell death does not involve ROS, suggesting that Bcl-2 or Bcl-xL exerts an anti-cell death function by a mechanism other than through regulation of ROS activity. Reactive Oxygen Species 248-251 BCL2 apoptosis regulator Homo sapiens 129-134 9209397-2 1997 Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS), we find that expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia) and that the cell death does not involve ROS, suggesting that Bcl-2 or Bcl-xL exerts an anti-cell death function by a mechanism other than through regulation of ROS activity. Reactive Oxygen Species 248-251 BCL2 apoptosis regulator Homo sapiens 129-134 9209397-5 1997 The anti-apoptotic proteins Bcl-2 and Bcl-xL effectively inhibit KCN-induced cell death which is characterized by necrotic features including apparently intact chromatin, remarkable mitochondrial swelling with loss of crista structure and loss of plasma membrane integrity. Potassium Cyanide 65-68 BCL2 apoptosis regulator Homo sapiens 28-33 9168435-7 1997 DTctGMCSF also efficiently killed AML cells deficient in p53 expression, as well as radiation-resistant AML cells and mixed lineage leukemia cells expressing high levels of bcl-2. dtctgmcsf 0-9 BCL2 apoptosis regulator Homo sapiens 173-178 9096388-9 1997 In contrast, changes in Bcl-2 level due to expression of sense and antisense vectors influenced the sensitivity to Fas killing and Fas-induced JNK activation. ammonium ferrous sulfate 131-134 BCL2 apoptosis regulator Homo sapiens 24-29 9067263-0 1997 Tumor growth inhibition, apoptosis, and Bcl-2 down-regulation of MCF-7ras tumors by sodium phenylacetate and tamoxifen combination. phenylacetic acid 84-104 BCL2 apoptosis regulator Homo sapiens 40-45 10743138-2 1997 The results indicated that after treated with ST and RA, the cells became well-differentiated, the cell growth was suppressed, contact suppress was partially recovered, colony forming was decreased, protooncogenes (C-myc bcl-2) protein was decreased, tumor suppressor gene (p53) protein was increased. Tretinoin 53-55 BCL2 apoptosis regulator Homo sapiens 221-226 9067280-1 1997 Paclitaxel has been shown to activate Raf-1 and cause phosphorylation of Bcl-2, which has been correlated with paclitaxel-induced apoptosis of cancer cells. Paclitaxel 0-10 BCL2 apoptosis regulator Homo sapiens 73-78 9067280-1 1997 Paclitaxel has been shown to activate Raf-1 and cause phosphorylation of Bcl-2, which has been correlated with paclitaxel-induced apoptosis of cancer cells. Paclitaxel 111-121 BCL2 apoptosis regulator Homo sapiens 73-78 9079623-5 1997 This apoptotic pathway is modulated by Bcl-2 through a novel mechanism that regulates Rb phosphorylation. Rubidium 86-88 BCL2 apoptosis regulator Homo sapiens 39-44 9067263-0 1997 Tumor growth inhibition, apoptosis, and Bcl-2 down-regulation of MCF-7ras tumors by sodium phenylacetate and tamoxifen combination. Tamoxifen 109-118 BCL2 apoptosis regulator Homo sapiens 40-45 9067280-2 1997 In the present studies, we demonstrate that in human AML HL-60 cells that express Bcl-2 but little Bcl-xL (HL-60/neo cells), paclitaxel-induced phosphorylation of Bcl-2 is followed by increased intracellular free Bax levels. Paclitaxel 125-135 BCL2 apoptosis regulator Homo sapiens 82-87 9067280-2 1997 In the present studies, we demonstrate that in human AML HL-60 cells that express Bcl-2 but little Bcl-xL (HL-60/neo cells), paclitaxel-induced phosphorylation of Bcl-2 is followed by increased intracellular free Bax levels. Paclitaxel 125-135 BCL2 apoptosis regulator Homo sapiens 163-168 9067263-7 1997 Furthermore, in vitro administration of 4-OH-tamoxifen induced a Bcl-2 up-regulation in MCF-7ras cells, which was completely abolished by NaPA pretreatment. 4-oh-tamoxifen 40-54 BCL2 apoptosis regulator Homo sapiens 65-70 9067263-7 1997 Furthermore, in vitro administration of 4-OH-tamoxifen induced a Bcl-2 up-regulation in MCF-7ras cells, which was completely abolished by NaPA pretreatment. Acecainide 138-142 BCL2 apoptosis regulator Homo sapiens 65-70 9137448-5 1997 The expression of c-myc and bcl-2 decreased significantly within 3 h of the start of the treatment of HL-60 cells with 50 microM GGO. (4r,5r)-5-Amino-1-[2-(1,3-Benzodioxol-5-Yl)ethyl]-4-(2,4,5-Trifluorophenyl)piperidin-2-One 129-132 BCL2 apoptosis regulator Homo sapiens 28-33 9060818-6 1997 Thus, contrary to a priori expectations, the expression of the anti-apoptotic proteins Bcl-2 and Mcl-1 was significantly higher in astrocytomas than in GMs. gms 152-155 BCL2 apoptosis regulator Homo sapiens 87-92 9084855-11 1997 Fas-mediated apoptosis in HCRC cell lines may be regulated by bcl-2 and may correlate with the degree of differentiation. ammonium ferrous sulfate 0-3 BCL2 apoptosis regulator Homo sapiens 62-67 9067579-8 1997 Levels of Bcl-2 strongly decreased in HL-60 WT and LX after treatment by retinoids, while no change in expression occurred in HL-60 R. Neither KH 1060 nor 9-cis RA induced apoptosis of HL-60 R, but these agents did induce apoptosis in HL-60 LX WT. Retinoids 73-82 BCL2 apoptosis regulator Homo sapiens 10-15 9088975-4 1997 Ligation of DC CD40 by culture on CD40L-transfected fibroblastic cells up-regulates the expression of bcl-2 and, concomitantly, renders DC virtually resistant to Fas-induced apoptosis. ammonium ferrous sulfate 162-165 BCL2 apoptosis regulator Homo sapiens 102-107 9088975-6 1997 Thus, upon encountering antigen-specific T cells, DC become resistant to Fas-induced apoptosis, as a consequence of CD40 ligation and possibly by mechanisms associated to the up-regulation of bcl-2 protein expression. ammonium ferrous sulfate 73-76 BCL2 apoptosis regulator Homo sapiens 192-197 9092950-0 1997 Glucose deprivation-induced cytotoxicity in drug resistant human breast carcinoma MCF-7/ADR cells: role of c-myc and bcl-2 in apoptotic cell death. Glucose 0-7 BCL2 apoptosis regulator Homo sapiens 117-122 9232607-0 1997 Enhanced expression of bcl-2 following antisense oligonucleotide mediated growth factor deprivation. Oligonucleotides 49-64 BCL2 apoptosis regulator Homo sapiens 23-28 10743071-7 1997 CONCLUSION: In human breast cancer cells the induction of apoptosis by taxol was closely associated with mitotic arrest of cell cycle, and altered expression of bcl-2 and bax gene, possibly playing an important role in regulating taxol-induced apoptosis. Paclitaxel 71-76 BCL2 apoptosis regulator Homo sapiens 161-166 9058596-0 1997 6-Mercaptopurine decreases the Bcl-2/Bax ratio and induces apoptosis in activated splenic B lymphocytes. Mercaptopurine 0-16 BCL2 apoptosis regulator Homo sapiens 31-36 9058596-6 1997 The ratio between the amounts of Bcl-2 and Bax, two proteins involved in the control of apoptosis in mature B cells, markedly decreased as result of mercaptopurine treatment. Mercaptopurine 149-163 BCL2 apoptosis regulator Homo sapiens 33-38 10743071-7 1997 CONCLUSION: In human breast cancer cells the induction of apoptosis by taxol was closely associated with mitotic arrest of cell cycle, and altered expression of bcl-2 and bax gene, possibly playing an important role in regulating taxol-induced apoptosis. Paclitaxel 230-235 BCL2 apoptosis regulator Homo sapiens 161-166 10743081-2 1997 METHODS: Four-stage peroxidase antiperoxidase complex (PAP) method was applied to comparatively investigate the expression and distribution of Bcl-2 protein in formalin-fixed, paraffin-embedded lymph node tissue comprising 12 cases of reactive follicular hyperplasia and 71 cases of NHL. Formaldehyde 160-168 BCL2 apoptosis regulator Homo sapiens 143-148 10743081-2 1997 METHODS: Four-stage peroxidase antiperoxidase complex (PAP) method was applied to comparatively investigate the expression and distribution of Bcl-2 protein in formalin-fixed, paraffin-embedded lymph node tissue comprising 12 cases of reactive follicular hyperplasia and 71 cases of NHL. Paraffin 176-184 BCL2 apoptosis regulator Homo sapiens 143-148 9044846-11 1997 Both gadd153 mRNA level increase and internucleosomal DNA fragmentation were inhibited by N-tosyl-L-phenylalanine chloromethylketone, a serine threonine protease inhibitor, N-acetyl-leucyl-leucyl-norleucinal, an inhibitor of calpain, N-acetylcysteine, an inhibitor of oxidative metabolism, and overexpression of Bcl-2. Tosylphenylalanyl Chloromethyl Ketone 90-132 BCL2 apoptosis regulator Homo sapiens 312-317 9030519-8 1997 bcl-2-overexpressing cells were recoverable with high plating efficiency even after prolonged exposure to 2,4-dinitrophenol. 2,4-Dinitrophenol 106-123 BCL2 apoptosis regulator Homo sapiens 0-5 9030519-12 1997 Prolonged metabolic arrest and resistance to ATP depletion facilitated by bcl-2 are both reversible. Adenosine Triphosphate 45-48 BCL2 apoptosis regulator Homo sapiens 74-79 9091316-0 1997 Bcl-2 prevents nitric oxide-mediated apoptosis and poly(ADP-ribose) polymerase cleavage. Nitric Oxide 15-27 BCL2 apoptosis regulator Homo sapiens 0-5 9151319-5 1997 This paper provides mechanistic support for the occurrence of apoptosis in this disease: There was marked upregulation of Bcl-2 in brain from the late infantile and juvenile types at the protein and RNA levels both by immunocytochemistry and by Northern blot analysis; there were also a 42% to 197% increase in brain ceramide determinations in brains from three patients with the juvenile type and three patients with the late infantile type. Ceramides 317-325 BCL2 apoptosis regulator Homo sapiens 122-127 9053448-0 1997 Cytokine response modifier A (CrmA) inhibits ceramide formation in response to tumor necrosis factor (TNF)-alpha: CrmA and Bcl-2 target distinct components in the apoptotic pathway. Ceramides 45-53 BCL2 apoptosis regulator Homo sapiens 123-128 9053448-4 1997 Bcl-2 inhibited ceramide-induced death, but not ceramide generation. Ceramides 16-24 BCL2 apoptosis regulator Homo sapiens 0-5 9009089-9 1997 In contrast, enforced and much higher expression of Bcl-2 in HL-60/Bcl-2 (five-fold) or Bcl-xL in HL-60/Bcl-xL cells (10-fold) significantly reduced paclitaxel-induced apoptosis and the loss of cell viability, without affecting its intracellular accumulation. Paclitaxel 149-159 BCL2 apoptosis regulator Homo sapiens 52-57 9009089-9 1997 In contrast, enforced and much higher expression of Bcl-2 in HL-60/Bcl-2 (five-fold) or Bcl-xL in HL-60/Bcl-xL cells (10-fold) significantly reduced paclitaxel-induced apoptosis and the loss of cell viability, without affecting its intracellular accumulation. Paclitaxel 149-159 BCL2 apoptosis regulator Homo sapiens 67-72 9009089-12 1997 In addition, these findings suggest that, for Bcl-2 and Bcl-xL, enforced overexpression to high levels is necessary to induce paclitaxel resistance in HL-60 cells. Paclitaxel 126-136 BCL2 apoptosis regulator Homo sapiens 46-51 9009090-9 1997 In addition, exposure of cells from three patients with B-CLL to bFGF showed an upregulation of bcl-2 protein after 4-8 h. Our data demonstrate that bFGF upregulates the expression of bcl-2 in these cells, suggesting that this increase in bcl-2 expression may play a role in the delay of fludarabine-induced apoptosis. fludarabine 288-299 BCL2 apoptosis regulator Homo sapiens 96-101 9009090-9 1997 In addition, exposure of cells from three patients with B-CLL to bFGF showed an upregulation of bcl-2 protein after 4-8 h. Our data demonstrate that bFGF upregulates the expression of bcl-2 in these cells, suggesting that this increase in bcl-2 expression may play a role in the delay of fludarabine-induced apoptosis. fludarabine 288-299 BCL2 apoptosis regulator Homo sapiens 184-189 9009090-9 1997 In addition, exposure of cells from three patients with B-CLL to bFGF showed an upregulation of bcl-2 protein after 4-8 h. Our data demonstrate that bFGF upregulates the expression of bcl-2 in these cells, suggesting that this increase in bcl-2 expression may play a role in the delay of fludarabine-induced apoptosis. fludarabine 288-299 BCL2 apoptosis regulator Homo sapiens 184-189 9105161-2 1997 The bcl-2 levels determined by mean fluorescence intensity were diminished in most lymphocyte subsets when the samples were preserved at 4 degrees C for 6 hours or more without 1% paraformaldehyde (PFA) fixation. paraform 180-196 BCL2 apoptosis regulator Homo sapiens 4-9 9105161-2 1997 The bcl-2 levels determined by mean fluorescence intensity were diminished in most lymphocyte subsets when the samples were preserved at 4 degrees C for 6 hours or more without 1% paraformaldehyde (PFA) fixation. paraform 198-201 BCL2 apoptosis regulator Homo sapiens 4-9 9105161-3 1997 However, the bcl-2 levels were kept constant for a week or more in the samples preserved at 4 degrees C after immediate staining of cell surface markers and subsequent fixation with PFA. paraform 182-185 BCL2 apoptosis regulator Homo sapiens 13-18 9007205-9 1997 The expression of anti-apoptotic protein Bcl-2 was partially downregulated in MOLT-4/IIIB cells after treatment with stavudine. Stavudine 117-126 BCL2 apoptosis regulator Homo sapiens 41-46 8995081-9 1997 We concluded that the P53 and BCL2 expression detected by immunohistochemistry in routinely processed, paraffin-embedded tissues: (1) has no prognostic significance; and (2) was not correlated with pathologic disease stage, histologic grade, or vascular invasion. Paraffin 103-111 BCL2 apoptosis regulator Homo sapiens 30-34 9000505-0 1997 Ceramides induce a form of apoptosis in human acute lymphoblastic leukemia cells that is inhibited by Bcl-2, but not by CrmA. Ceramides 0-9 BCL2 apoptosis regulator Homo sapiens 102-107 9016759-5 1997 We studied the effect of receptor-selective retinoid treatment on the expression of Bcl-2 and Bax oncogenes by reverse-transcription polymerase chain reaction (RT-PCR) and immunoblot analysis in RARs and RXR alpha transfected HL-60 cells. Retinoids 44-52 BCL2 apoptosis regulator Homo sapiens 84-89 9000527-1 1997 The cytotoxic effect of the new potential intercalating anticancer drug oracin was studied on Burkitt"s lymphoma cell line that overexpressed bcl-2 (BL bcl-2) and a control transfectant without the bcl-2 gene (BL SV2). oracine 72-78 BCL2 apoptosis regulator Homo sapiens 142-147 9012846-6 1997 Furthermore, the herpesvirus Bcl-2 homologs including KSbcl-2, BHRF1, and ORF16 of herpesvirus saimiri contain poorly conserved Bcl-2 homology 3 (BH3) domains compared with other mammalian Bcl-2 homologs, implying that BH3 may not be essential for anti-apoptotic function. BH 3 146-149 BCL2 apoptosis regulator Homo sapiens 29-34 9012846-6 1997 Furthermore, the herpesvirus Bcl-2 homologs including KSbcl-2, BHRF1, and ORF16 of herpesvirus saimiri contain poorly conserved Bcl-2 homology 3 (BH3) domains compared with other mammalian Bcl-2 homologs, implying that BH3 may not be essential for anti-apoptotic function. BH 3 146-149 BCL2 apoptosis regulator Homo sapiens 128-133 9012846-6 1997 Furthermore, the herpesvirus Bcl-2 homologs including KSbcl-2, BHRF1, and ORF16 of herpesvirus saimiri contain poorly conserved Bcl-2 homology 3 (BH3) domains compared with other mammalian Bcl-2 homologs, implying that BH3 may not be essential for anti-apoptotic function. BH 3 146-149 BCL2 apoptosis regulator Homo sapiens 128-133 9000560-3 1997 Comparison of the effects of taxol and its analogue, taxotere, indicates that taxotere is capable of inducing bcl2 phosphorylation and apoptotic cell death at 100-fold lower concentrations than taxol. Paclitaxel 29-34 BCL2 apoptosis regulator Homo sapiens 110-114 9000560-3 1997 Comparison of the effects of taxol and its analogue, taxotere, indicates that taxotere is capable of inducing bcl2 phosphorylation and apoptotic cell death at 100-fold lower concentrations than taxol. Docetaxel 53-61 BCL2 apoptosis regulator Homo sapiens 110-114 9000560-3 1997 Comparison of the effects of taxol and its analogue, taxotere, indicates that taxotere is capable of inducing bcl2 phosphorylation and apoptotic cell death at 100-fold lower concentrations than taxol. Docetaxel 78-86 BCL2 apoptosis regulator Homo sapiens 110-114 9008715-5 1997 We have used two cell-permeable inhibitors of IRPs, Z-Val-Ala-Asp.fluoromethylketone (ZVAD.fmk) and t-butoxy carbonyl-Asp.fluoromethylketone (BD.fmk), to demonstrate a critical role for IRPs in mammalian apoptosis induced by several disparate mechanisms (deregulated oncogene expression, ectopic expression of the Bcl-2 relative Bak, and DNA damage-induced cell death). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 52-84 BCL2 apoptosis regulator Homo sapiens 314-319 9000527-2 1997 Oracin showed a marked cytostatic effect on both BL SV2 and BL bcl-2 cells. oracine 0-6 BCL2 apoptosis regulator Homo sapiens 63-68 9000505-7 1997 In contrast, tetracycline-regulated overexpression of Bcl-2 protected CEM-C7H2 sublines stably transfected with corresponding constructs from ceramide-induced apoptosis. Tetracycline 13-25 BCL2 apoptosis regulator Homo sapiens 54-59 9000505-7 1997 In contrast, tetracycline-regulated overexpression of Bcl-2 protected CEM-C7H2 sublines stably transfected with corresponding constructs from ceramide-induced apoptosis. Ceramides 142-150 BCL2 apoptosis regulator Homo sapiens 54-59 9000505-8 1997 Thus, in these human leukemia cells, ceramides induce a relatively slow death response that can be prevented by Bcl-2, but is independent of CrmA-inhibitable proteases. Ceramides 37-46 BCL2 apoptosis regulator Homo sapiens 112-117 9038883-3 1997 A large number of proapoptotic agents were ineffective in inducing apoptosis in rat or human cholangiocytes in culture; in contrast, beauvericin, a K+ ionophore, caused apoptosis in both cell lines, despite their expression of Bcl-2. beauvericin 133-144 BCL2 apoptosis regulator Homo sapiens 227-232 9038883-9 1997 Our data suggest that beauvericin-induced apoptosis occurs by a Ca(2+)-dependent CPP-32 protease-sensitive pathway despite cholangiocyte expression of Bcl-2. beauvericin 22-33 BCL2 apoptosis regulator Homo sapiens 151-156 8988042-5 1997 Bcl-2-mediated inhibition of ceramide-induced delta psi m disruption is observed in normal as well as anucleate cells, indicating that bcl-2 acts on an extranuclear pathway of apoptosis. Ceramides 29-37 BCL2 apoptosis regulator Homo sapiens 0-5 14646556-3 1997 Here we studied Adriamycin (ADM)-induced apoptosis in four human bladder cancer cell lines in respect of p53, p21WAF1/CIP1 and Bcl-2 family proteins. Doxorubicin 16-26 BCL2 apoptosis regulator Homo sapiens 127-132 14646556-3 1997 Here we studied Adriamycin (ADM)-induced apoptosis in four human bladder cancer cell lines in respect of p53, p21WAF1/CIP1 and Bcl-2 family proteins. Doxorubicin 28-31 BCL2 apoptosis regulator Homo sapiens 127-132 14646558-7 1997 The Bax/Bcl-2 expression ratio was gradually elevated for up to 72 h in MKN-74 and MKN-45 cells treated with 1mM 5-FU; in contrast, it was unchanged in MKN-28 and KATO-III cells, and MKN-74 treated with 50 microM 5-FU. Fluorouracil 113-117 BCL2 apoptosis regulator Homo sapiens 8-13 14646558-7 1997 The Bax/Bcl-2 expression ratio was gradually elevated for up to 72 h in MKN-74 and MKN-45 cells treated with 1mM 5-FU; in contrast, it was unchanged in MKN-28 and KATO-III cells, and MKN-74 treated with 50 microM 5-FU. mkn-74 72-78 BCL2 apoptosis regulator Homo sapiens 8-13 14646558-7 1997 The Bax/Bcl-2 expression ratio was gradually elevated for up to 72 h in MKN-74 and MKN-45 cells treated with 1mM 5-FU; in contrast, it was unchanged in MKN-28 and KATO-III cells, and MKN-74 treated with 50 microM 5-FU. Fluorouracil 213-217 BCL2 apoptosis regulator Homo sapiens 8-13 14646558-8 1997 These results might indicate that (1) 1mM 5-FU induces apoptosis in cultured gastric cancer cells carrying the wild-type p53 gene, but not those carrying the mutated type or a gene deletion, and (2) the elevated Bax/Bcl-2 expression ratio plays a more crucial role than the higher expression of P21/Waf1 in the induction of p53- gene dependent apoptosis. Fluorouracil 42-46 BCL2 apoptosis regulator Homo sapiens 216-221 9020491-7 1997 In the group of patients receiving 5-fluorouracil-based chemotherapy bcl-2 expression did not influence response to chemotherapy; nor did it effect failure-free or overall survival. Fluorouracil 35-49 BCL2 apoptosis regulator Homo sapiens 69-74 9116321-6 1997 Estradiol-induced four-fold increase in the ratio of the p26Bcl-2 to p21Bax levels caused a significant decline in the lethal, kilobase size DNA fragments of apoptosis, which had resulted when MCF-7 cells were cultured in a medium without estrogen. Estradiol 0-9 BCL2 apoptosis regulator Homo sapiens 60-65 9116321-7 1997 In addition, in MCF-7 cells, estradiol-induced increase in the intracellular p26Bcl-2 to p21Bax ratios was associated with a significant reduction in the large-sized DNA fragmentation induced by treatment with taxol. Estradiol 29-38 BCL2 apoptosis regulator Homo sapiens 80-85 9116321-7 1997 In addition, in MCF-7 cells, estradiol-induced increase in the intracellular p26Bcl-2 to p21Bax ratios was associated with a significant reduction in the large-sized DNA fragmentation induced by treatment with taxol. Paclitaxel 210-215 BCL2 apoptosis regulator Homo sapiens 80-85 9116321-9 1997 These results suggest that by modulating p26Bcl-2 levels, estrogens may affect the antitumor activity of taxol and potentially of other anti-breast cancer drugs against estrogen responsive human breast cancer cells. Paclitaxel 105-110 BCL2 apoptosis regulator Homo sapiens 44-49 9020491-3 1997 We analysed bcl-2 expression in 231 colorectal tumours from patients that were treated by surgery alone or with 5-fluorouracil-based chemotherapy. Fluorouracil 112-126 BCL2 apoptosis regulator Homo sapiens 12-17 8988053-1 1997 Recent studies have shown that paclitaxel leads to activation of Raf-1 kinase and have suggested that this activation is essential for bcl-2 phosphorylation and apoptosis. Paclitaxel 31-41 BCL2 apoptosis regulator Homo sapiens 135-140 8988053-2 1997 In the present study, we demonstrate that, in addition to paclitaxel, other agents that interact with tubulin and microtubules also induce Raf-1/bcl-2 phosphorylation, whereas DNA-damaging drugs, antimetabolites, and alkylating agents do not. Paclitaxel 58-68 BCL2 apoptosis regulator Homo sapiens 145-150 8988053-5 1997 The requirement for disruption of microtubules in this signaling cascade was strengthened further using paclitaxel analogues by demonstrating a correlation between tubulin polymerization, Raf-1/bcl-2 phosphorylation, and cytotoxicity. Paclitaxel 104-114 BCL2 apoptosis regulator Homo sapiens 194-199 8988042-5 1997 Bcl-2-mediated inhibition of ceramide-induced delta psi m disruption is observed in normal as well as anucleate cells, indicating that bcl-2 acts on an extranuclear pathway of apoptosis. Ceramides 29-37 BCL2 apoptosis regulator Homo sapiens 135-140 9010276-5 1997 A phosphorothioate antisense oligonucleotide targeted at the ATG translation initiation codon of bcl-2 (10(-5) M) could significantly block the supportive effect of rhIL-5 (0.25 ng/ml) for eosinophil survival compared with sense cDNA of bcl-2 on 96 h culture (inhibition rate 28.01 +/- 4.56% versus 0.07 +/- 1.73%; n = 4, P < 0.05). Parathion 2-18 BCL2 apoptosis regulator Homo sapiens 97-102 9054611-0 1997 Bcl-2 deregulation leads to inhibition of sodium butyrate-induced apoptosis in human colorectal carcinoma cells. Butyric Acid 42-57 BCL2 apoptosis regulator Homo sapiens 0-5 9054611-2 1997 We investigated the role of Bcl-2 deregulation on the sensitivity of colorectal carcinoma cells to undergo butyrate-induced apoptosis. Butyrates 107-115 BCL2 apoptosis regulator Homo sapiens 28-33 9054611-3 1997 Here we report an inverse relationship between the levels of Bcl-2 and the sensitivity of colorectal carcinoma cell lines to undergo apoptosis in response to butyrate. Butyrates 158-166 BCL2 apoptosis regulator Homo sapiens 61-66 16465208-0 1997 Bcl-2 prevents activation of CPP32 cysteine protease and cleavage of poly (ADP-ribose) polymerase and U1-70 kD proteins in staurosporine-mediated apoptosis. Staurosporine 123-136 BCL2 apoptosis regulator Homo sapiens 0-5 9054611-4 1997 Overexpression of Bcl-2 in colorectal carcinoma DiFi cells resulted in suppression of butyrate-induced apoptosis and enhanced cell survival in response to butyrate. Butyrates 86-94 BCL2 apoptosis regulator Homo sapiens 18-23 9054611-4 1997 Overexpression of Bcl-2 in colorectal carcinoma DiFi cells resulted in suppression of butyrate-induced apoptosis and enhanced cell survival in response to butyrate. Butyrates 155-163 BCL2 apoptosis regulator Homo sapiens 18-23 9054611-5 1997 Butyrate-induced apoptosis was accompanied by inhibition of expression of a 30 kDa protein (p30, immunorecognized by anti-Bcl-2 mAb) and this cellular effect of butyrate was inhibited by Bcl-2 overexpression. Butyrates 0-8 BCL2 apoptosis regulator Homo sapiens 122-127 9054611-5 1997 Butyrate-induced apoptosis was accompanied by inhibition of expression of a 30 kDa protein (p30, immunorecognized by anti-Bcl-2 mAb) and this cellular effect of butyrate was inhibited by Bcl-2 overexpression. Butyrates 0-8 BCL2 apoptosis regulator Homo sapiens 187-192 9054611-5 1997 Butyrate-induced apoptosis was accompanied by inhibition of expression of a 30 kDa protein (p30, immunorecognized by anti-Bcl-2 mAb) and this cellular effect of butyrate was inhibited by Bcl-2 overexpression. Butyrates 161-169 BCL2 apoptosis regulator Homo sapiens 122-127 9054611-5 1997 Butyrate-induced apoptosis was accompanied by inhibition of expression of a 30 kDa protein (p30, immunorecognized by anti-Bcl-2 mAb) and this cellular effect of butyrate was inhibited by Bcl-2 overexpression. Butyrates 161-169 BCL2 apoptosis regulator Homo sapiens 187-192 9054611-6 1997 These findings suggest that deregulation of Bcl-2 in human colorectal carcinoma cells confers resistance to induction of apoptosis by butyrate, a dietary micronutrient. Butyrates 134-142 BCL2 apoptosis regulator Homo sapiens 44-49 9010276-5 1997 A phosphorothioate antisense oligonucleotide targeted at the ATG translation initiation codon of bcl-2 (10(-5) M) could significantly block the supportive effect of rhIL-5 (0.25 ng/ml) for eosinophil survival compared with sense cDNA of bcl-2 on 96 h culture (inhibition rate 28.01 +/- 4.56% versus 0.07 +/- 1.73%; n = 4, P < 0.05). Parathion 2-18 BCL2 apoptosis regulator Homo sapiens 237-242 9010276-5 1997 A phosphorothioate antisense oligonucleotide targeted at the ATG translation initiation codon of bcl-2 (10(-5) M) could significantly block the supportive effect of rhIL-5 (0.25 ng/ml) for eosinophil survival compared with sense cDNA of bcl-2 on 96 h culture (inhibition rate 28.01 +/- 4.56% versus 0.07 +/- 1.73%; n = 4, P < 0.05). Oligonucleotides 29-44 BCL2 apoptosis regulator Homo sapiens 97-102 9010276-5 1997 A phosphorothioate antisense oligonucleotide targeted at the ATG translation initiation codon of bcl-2 (10(-5) M) could significantly block the supportive effect of rhIL-5 (0.25 ng/ml) for eosinophil survival compared with sense cDNA of bcl-2 on 96 h culture (inhibition rate 28.01 +/- 4.56% versus 0.07 +/- 1.73%; n = 4, P < 0.05). Oligonucleotides 29-44 BCL2 apoptosis regulator Homo sapiens 237-242 9474804-2 1997 The bcl-2/bag-1 transfectant survived maintaining viability above 75% for almost 5 days when the cells were treated with excess (30 mM) thymidine for arresting cell cycle, whereas the mock transfectant survived for only 2 days, and the bcl-2 alone transfectant lived for 4 days. Thymidine 136-145 BCL2 apoptosis regulator Homo sapiens 4-9 22358524-5 1997 We also present new data which demonstrates that bcl-2 can protect cells from apoptosis induced by oxygen deprivation, a finding which has important implications for large scale and intensive cultivation of cells. Oxygen 99-105 BCL2 apoptosis regulator Homo sapiens 49-54 9474804-3 1997 Owing to this extended viable culture period, the bcl-2/bag-1 transfectant produced twofold amount of antibody in comparison with the mock transfectant in non-proliferating state prepared by the excess thymidine treatment. Thymidine 202-211 BCL2 apoptosis regulator Homo sapiens 50-55 9323493-0 1997 Changes in levels of expression of p53 and the product of the bcl-2 in lines of gastric cancer cells during cisplatin-induced apoptosis. Cisplatin 108-117 BCL2 apoptosis regulator Homo sapiens 62-67 9323493-2 1997 After incubation with cisplatin, apoptotic cells were detected more frequently among MKN-45 and MKN-74 cells with a wild-type gene for p53 and without expression of the bcl-2 protein than among HSC-39, MKN-28, and KATO-III cells with a mutation or complete deletion of the gene for p53 and with overexpression of the bcl-2 protein. Cisplatin 22-31 BCL2 apoptosis regulator Homo sapiens 169-174 9323493-2 1997 After incubation with cisplatin, apoptotic cells were detected more frequently among MKN-45 and MKN-74 cells with a wild-type gene for p53 and without expression of the bcl-2 protein than among HSC-39, MKN-28, and KATO-III cells with a mutation or complete deletion of the gene for p53 and with overexpression of the bcl-2 protein. Cisplatin 22-31 BCL2 apoptosis regulator Homo sapiens 317-322 9323493-4 1997 However, levels of bcl-2 protein were reduced in KATO-III after treatment with cisplatin. Cisplatin 79-88 BCL2 apoptosis regulator Homo sapiens 19-24 9107076-0 1997 Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs. Chlorambucil 121-133 BCL2 apoptosis regulator Homo sapiens 0-5 8958131-5 1997 Enforced expression of BCL-2 induced resistance to 0.5 and 0.1 mM H2O2 but had no effect on cytotoxicity induced by 5 and 10 mM. Hydrogen Peroxide 66-70 BCL2 apoptosis regulator Homo sapiens 23-28 8958131-7 1997 These data indicate that distinct pathways of H2O2-induced cytotoxicity can be distinguished by their different concentration dependences, and that BCL-2 can protect against some forms of H2O2-induced cytotoxicity. Hydrogen Peroxide 46-50 BCL2 apoptosis regulator Homo sapiens 148-153 8958131-7 1997 These data indicate that distinct pathways of H2O2-induced cytotoxicity can be distinguished by their different concentration dependences, and that BCL-2 can protect against some forms of H2O2-induced cytotoxicity. Hydrogen Peroxide 188-192 BCL2 apoptosis regulator Homo sapiens 148-153 9030234-4 1997 Introduction of bcl 2 gene into human small cell lung cancer cells conferred resistance to mitomycin C and irinotecan. Mitomycin 91-102 BCL2 apoptosis regulator Homo sapiens 16-21 9030234-4 1997 Introduction of bcl 2 gene into human small cell lung cancer cells conferred resistance to mitomycin C and irinotecan. Irinotecan 107-117 BCL2 apoptosis regulator Homo sapiens 16-21 9107076-0 1997 Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs. purine 138-144 BCL2 apoptosis regulator Homo sapiens 0-5 11091754-2 1996 The bcl-2 protein was detected by immunohistochemistry on paraffin embedded tissue sections and its presence was confirmed by Western blot analysis of whole cell lysates. Paraffin 58-66 BCL2 apoptosis regulator Homo sapiens 4-9 9043921-2 1997 To investigate a role for apoptosis at the maternal-fetal interface, we have immunolocalized the bcl-2 protein in formalin-fixed decidual and placental tissue collected from women undergoing surgical termination of pregnancy (n = 22), from women undergoing a sporadic miscarriage (n = 16) and from women with a history of recurrent pregnancy loss (more than three consecutive pregnancy losses; n = 22) undergoing a further miscarriage. Formaldehyde 114-122 BCL2 apoptosis regulator Homo sapiens 97-102 9406233-8 1997 Overexpression of the bcl-2 oncogene protects these cells against dexamethasone-mediated apoptosis and prevents the decrease in antioxidant enzyme activity. Dexamethasone 66-79 BCL2 apoptosis regulator Homo sapiens 22-27 27405232-6 1997 Western analysis of bcl-2 and bax protein levels revealed that combinations of the vitamin D and retinoid compounds decreased bcl-2 in HL-60 but not U937 cells, suggesting a change in the bcl-2/bax heterodimeric ratio in the former which would favour apoptosis. Vitamin D 83-92 BCL2 apoptosis regulator Homo sapiens 20-25 27405232-6 1997 Western analysis of bcl-2 and bax protein levels revealed that combinations of the vitamin D and retinoid compounds decreased bcl-2 in HL-60 but not U937 cells, suggesting a change in the bcl-2/bax heterodimeric ratio in the former which would favour apoptosis. Vitamin D 83-92 BCL2 apoptosis regulator Homo sapiens 126-131 27405232-6 1997 Western analysis of bcl-2 and bax protein levels revealed that combinations of the vitamin D and retinoid compounds decreased bcl-2 in HL-60 but not U937 cells, suggesting a change in the bcl-2/bax heterodimeric ratio in the former which would favour apoptosis. Vitamin D 83-92 BCL2 apoptosis regulator Homo sapiens 126-131 27405232-6 1997 Western analysis of bcl-2 and bax protein levels revealed that combinations of the vitamin D and retinoid compounds decreased bcl-2 in HL-60 but not U937 cells, suggesting a change in the bcl-2/bax heterodimeric ratio in the former which would favour apoptosis. Retinoids 97-105 BCL2 apoptosis regulator Homo sapiens 20-25 27405232-6 1997 Western analysis of bcl-2 and bax protein levels revealed that combinations of the vitamin D and retinoid compounds decreased bcl-2 in HL-60 but not U937 cells, suggesting a change in the bcl-2/bax heterodimeric ratio in the former which would favour apoptosis. Retinoids 97-105 BCL2 apoptosis regulator Homo sapiens 126-131 27405232-6 1997 Western analysis of bcl-2 and bax protein levels revealed that combinations of the vitamin D and retinoid compounds decreased bcl-2 in HL-60 but not U937 cells, suggesting a change in the bcl-2/bax heterodimeric ratio in the former which would favour apoptosis. Retinoids 97-105 BCL2 apoptosis regulator Homo sapiens 126-131 8989276-0 1997 Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. Progesterone 90-102 BCL2 apoptosis regulator Homo sapiens 24-29 8989276-8 1997 In monolayer cultures of uterine leiomyoma cells under a serum-free condition, the addition of progesterone (100 ng/mL) resulted in a striking increase in Bcl-2 protein expression in the cultured leiomyoma cells relative to that in control cultures, whereas the addition of 17 beta-estradiol (10 ng/mL) resulted in a reduction in Bcl-2 protein expression in the cells. Progesterone 95-107 BCL2 apoptosis regulator Homo sapiens 155-160 8989276-8 1997 In monolayer cultures of uterine leiomyoma cells under a serum-free condition, the addition of progesterone (100 ng/mL) resulted in a striking increase in Bcl-2 protein expression in the cultured leiomyoma cells relative to that in control cultures, whereas the addition of 17 beta-estradiol (10 ng/mL) resulted in a reduction in Bcl-2 protein expression in the cells. Progesterone 95-107 BCL2 apoptosis regulator Homo sapiens 330-335 8989276-8 1997 In monolayer cultures of uterine leiomyoma cells under a serum-free condition, the addition of progesterone (100 ng/mL) resulted in a striking increase in Bcl-2 protein expression in the cultured leiomyoma cells relative to that in control cultures, whereas the addition of 17 beta-estradiol (10 ng/mL) resulted in a reduction in Bcl-2 protein expression in the cells. Estradiol 277-291 BCL2 apoptosis regulator Homo sapiens 155-160 15622746-5 1997 Furthermore, As2O3 effectively down-regulated the expression of bcl-2 gene without changing the mRNA levels of other apoptosis-associated genes (including p53, c-myc, bax and bcl-XL). Arsenic Trioxide 13-18 BCL2 apoptosis regulator Homo sapiens 64-69 9018084-3 1996 Apoptotic DNA ladders could be detected when cancer cells were treated with GL331 for 24 h even if the Bcl-2 and Bax protein levels were not altered during the period. GL 331 76-81 BCL2 apoptosis regulator Homo sapiens 103-108 9013793-4 1996 Infection with the bcl-2 expressing vector 24 h prior to glutamate treatment effectively prevented the cell death that normally follows this treatment. Glutamic Acid 57-66 BCL2 apoptosis regulator Homo sapiens 19-24 8943258-1 1996 Bax, a member of the Bcl-2 family of proteins, has been shown to accelerate apoptosis induced by growth factor withdrawal, gamma-irradiation, and the chemotherapeutic agent, etoposide. Etoposide 174-183 BCL2 apoptosis regulator Homo sapiens 21-26 8997628-0 1996 Vitamin C and E prevent lipopolysaccharide-induced apoptosis in human endothelial cells by modulation of Bcl-2 and Bax. Ascorbic Acid 0-9 BCL2 apoptosis regulator Homo sapiens 105-110 8997628-5 1996 The reduction of lipopolysaccharide-induced apoptosis by vitamin C and E was paralleled by an increase in Bcl-2 and a decrease in Bax protein levels. Ascorbic Acid 57-66 BCL2 apoptosis regulator Homo sapiens 106-111 8997628-6 1996 Thus, vitamin C and E seem to interfere with the Bcl-2 family of apoptosis regulators in human umbilical venous endothelial cells. Ascorbic Acid 6-15 BCL2 apoptosis regulator Homo sapiens 49-54 8959330-0 1996 Bleomycin-induced differentiation of bcl-2-transfected U937 leukemia cells. Bleomycin 0-9 BCL2 apoptosis regulator Homo sapiens 37-42 8959330-2 1996 Sublethal concentrations of bleomycin (1 microgram/ml) induced a decrease in cell growth in both vector-only and bcl-2-transfected U937 cells. Bleomycin 28-37 BCL2 apoptosis regulator Homo sapiens 113-118 8959330-5 1996 In contrast, bcl-2-transfected U937 cells maintained viable cell numbers and colony forming cells for up to 2 weeks in the presence of bleomycin. Bleomycin 135-144 BCL2 apoptosis regulator Homo sapiens 13-18 8959330-8 1996 In contrast, differentiated bcl-2-transfected U937 cells remained viable for 2 weeks following bleomycin treatment. Bleomycin 95-104 BCL2 apoptosis regulator Homo sapiens 28-33 9267464-6 1996 The cAMP-increasing reagents and butyrate also showed different effects on expression of members of the bcl-2 family; PGE2 decreased bcl-2 and bax levels, whereas butyrate increased the bcl-2 level. Cyclic AMP 4-8 BCL2 apoptosis regulator Homo sapiens 104-109 9267464-6 1996 The cAMP-increasing reagents and butyrate also showed different effects on expression of members of the bcl-2 family; PGE2 decreased bcl-2 and bax levels, whereas butyrate increased the bcl-2 level. Cyclic AMP 4-8 BCL2 apoptosis regulator Homo sapiens 133-138 9267464-6 1996 The cAMP-increasing reagents and butyrate also showed different effects on expression of members of the bcl-2 family; PGE2 decreased bcl-2 and bax levels, whereas butyrate increased the bcl-2 level. Cyclic AMP 4-8 BCL2 apoptosis regulator Homo sapiens 133-138 9267464-6 1996 The cAMP-increasing reagents and butyrate also showed different effects on expression of members of the bcl-2 family; PGE2 decreased bcl-2 and bax levels, whereas butyrate increased the bcl-2 level. Butyrates 33-41 BCL2 apoptosis regulator Homo sapiens 104-109 9267464-6 1996 The cAMP-increasing reagents and butyrate also showed different effects on expression of members of the bcl-2 family; PGE2 decreased bcl-2 and bax levels, whereas butyrate increased the bcl-2 level. Butyrates 33-41 BCL2 apoptosis regulator Homo sapiens 133-138 9267464-6 1996 The cAMP-increasing reagents and butyrate also showed different effects on expression of members of the bcl-2 family; PGE2 decreased bcl-2 and bax levels, whereas butyrate increased the bcl-2 level. Butyrates 33-41 BCL2 apoptosis regulator Homo sapiens 133-138 9267464-6 1996 The cAMP-increasing reagents and butyrate also showed different effects on expression of members of the bcl-2 family; PGE2 decreased bcl-2 and bax levels, whereas butyrate increased the bcl-2 level. Dinoprostone 118-122 BCL2 apoptosis regulator Homo sapiens 104-109 9267464-6 1996 The cAMP-increasing reagents and butyrate also showed different effects on expression of members of the bcl-2 family; PGE2 decreased bcl-2 and bax levels, whereas butyrate increased the bcl-2 level. Dinoprostone 118-122 BCL2 apoptosis regulator Homo sapiens 133-138 9267464-6 1996 The cAMP-increasing reagents and butyrate also showed different effects on expression of members of the bcl-2 family; PGE2 decreased bcl-2 and bax levels, whereas butyrate increased the bcl-2 level. Dinoprostone 118-122 BCL2 apoptosis regulator Homo sapiens 133-138 9267464-6 1996 The cAMP-increasing reagents and butyrate also showed different effects on expression of members of the bcl-2 family; PGE2 decreased bcl-2 and bax levels, whereas butyrate increased the bcl-2 level. Butyrates 163-171 BCL2 apoptosis regulator Homo sapiens 104-109 8946932-10 1996 Steady-state levels of bcl-2 protein were measured by Western blot and synthesis by incorporation of 35S methionine into protein. 35s methionine 101-115 BCL2 apoptosis regulator Homo sapiens 23-28 8943385-9 1996 Transfection-enforced hyperexpression of the apoptosis-inhibitory proto-oncogene bcl-2 also inhibits PPIX-induced delta psi(m) disruption, hyperproduction of reactive oxygen species, and nuclear DNA loss. protoporphyrin IX 101-105 BCL2 apoptosis regulator Homo sapiens 81-86 8943385-9 1996 Transfection-enforced hyperexpression of the apoptosis-inhibitory proto-oncogene bcl-2 also inhibits PPIX-induced delta psi(m) disruption, hyperproduction of reactive oxygen species, and nuclear DNA loss. Reactive Oxygen Species 158-181 BCL2 apoptosis regulator Homo sapiens 81-86 8950193-9 1996 Immunoblot analysis showed that the level of the antiapoptotic protein Bcl-2 was decreased to 30% after 6 h treatment with curcumin, and was subsequently reduced to 20% by a further 6 h treatment. Curcumin 123-131 BCL2 apoptosis regulator Homo sapiens 71-76 9049973-0 1996 Liposomal targeting of bcl-2 antisense oligonucleotides with enhanced stability into human myeloma cell lines. Oligonucleotides 39-55 BCL2 apoptosis regulator Homo sapiens 23-28 8959986-4 1996 Other research has shown that (-)-deprenyl can induce altered expression of a number of genes in preapoptotic neurons both in vitro and in vivo, including the genes for superoxide dismutase (SOD) 1 and 2, BCL-2 and BCL-XL, nitric oxide synthase, c-JUN, and nicotinamide adenine dinucleotide dehydrogenase. Selegiline 30-42 BCL2 apoptosis regulator Homo sapiens 205-210 8959985-13 1996 In addition, selegiline may act through a mechanism unrelated to MAO-B to increase neurotrophic factor activity and upregulate molecules such as glutathione, SOD, catalase, and BCL-2 protein, which protect against oxidant stress and apoptosis. Selegiline 13-23 BCL2 apoptosis regulator Homo sapiens 177-182 8950193-10 1996 Furthermore, overexpression of bcl-2 in HL-60 cells resulted in a delay of curcumin-treated cells entering into apoptosis, suggesting that bcl-2 plays a crucial role in the early stage of curcumin-triggered apoptotic cell death. Curcumin 75-83 BCL2 apoptosis regulator Homo sapiens 31-36 8950193-10 1996 Furthermore, overexpression of bcl-2 in HL-60 cells resulted in a delay of curcumin-treated cells entering into apoptosis, suggesting that bcl-2 plays a crucial role in the early stage of curcumin-triggered apoptotic cell death. Curcumin 75-83 BCL2 apoptosis regulator Homo sapiens 139-144 8950193-10 1996 Furthermore, overexpression of bcl-2 in HL-60 cells resulted in a delay of curcumin-treated cells entering into apoptosis, suggesting that bcl-2 plays a crucial role in the early stage of curcumin-triggered apoptotic cell death. Curcumin 188-196 BCL2 apoptosis regulator Homo sapiens 31-36 8950193-10 1996 Furthermore, overexpression of bcl-2 in HL-60 cells resulted in a delay of curcumin-treated cells entering into apoptosis, suggesting that bcl-2 plays a crucial role in the early stage of curcumin-triggered apoptotic cell death. Curcumin 188-196 BCL2 apoptosis regulator Homo sapiens 139-144 9042262-3 1996 The expression of p53 and bcl-2 gene products was studied immunohistochemically using formalin-fixed paraffinembedded tumor samples of 31 locally confined RCC of patients treated with radical nephrectomy. Formaldehyde 86-94 BCL2 apoptosis regulator Homo sapiens 26-31 8934572-4 1996 On the other hand, the tyrosine in the YXXQ motifs essential for STAT3 activation was required for bcl-2 induction and anti-apoptosis. Tyrosine 23-31 BCL2 apoptosis regulator Homo sapiens 99-104 9042218-3 1996 The regulatory and controlling influence of Tamoxifen on numerous genes involved in apoptosis (p53, Bcl 2, c-myc, erb-B2 and others) will be discussed in this review. Tamoxifen 44-53 BCL2 apoptosis regulator Homo sapiens 100-105 8918887-8 1996 A BH3 mutant of BID that still heterodimerized with BCL-2 failed to promote apoptosis, dissociating these activities. BH 3 2-5 BCL2 apoptosis regulator Homo sapiens 52-57 8892676-0 1996 Intracellular metabolism of Ara-C and resulting DNA fragmentation and apoptosis of human AML HL-60 cells possessing disparate levels of Bcl-2 protein. Cytarabine 28-33 BCL2 apoptosis regulator Homo sapiens 136-141 8892676-1 1996 We examined the effects of high intracellular levels of Bcl-2 on the metabolism and DNA incorporation of high-dose Ara-C (HIDAC) as well as on Ara-C-induced DNA strand breaks and apoptosis of human AML HL-60 cells. Cytarabine 115-120 BCL2 apoptosis regulator Homo sapiens 56-61 8892676-9 1996 These results indicate that high intracellular levels of Bcl-2 operate distally to inhibit the final apototic cell death pathway by preventing the conversion of HIDAC-induced early DNA damage into lethal DNA fragmentation associated with apoptosis. hidac 161-166 BCL2 apoptosis regulator Homo sapiens 57-62 8840993-12 1996 High Bcl-2 and Bcl-xL levels in these cells also inhibited Yama protease activity, PARP degradation, and apoptosis due to clinically relevant concentrations of etoposide and mitoxantrone. Mitoxantrone 174-186 BCL2 apoptosis regulator Homo sapiens 5-10 18629863-9 1996 Results presented here suggest that suppression of apoptosis by bcl-2 under the condition of excess thymidine allows the maintenance of cells in a growth-arrested state for much longer than would otherwise be possible.When cells were transferred to a range of commercial serum-free media, cell growth was, in all cases, much better for the bcl-2 transfected cell line. Thymidine 100-109 BCL2 apoptosis regulator Homo sapiens 64-69 8840993-12 1996 High Bcl-2 and Bcl-xL levels in these cells also inhibited Yama protease activity, PARP degradation, and apoptosis due to clinically relevant concentrations of etoposide and mitoxantrone. Etoposide 160-169 BCL2 apoptosis regulator Homo sapiens 5-10 8830674-3 1996 We show here that bax protein also declined with a time course similar to the downregulation of bcl-2 following treatment of HL60 with phorbol myristate acetate (PMA), dimethyl sulphoxide (DMSO) or retinoic acid (RA). Tetradecanoylphorbol Acetate 135-160 BCL2 apoptosis regulator Homo sapiens 96-101 8830674-3 1996 We show here that bax protein also declined with a time course similar to the downregulation of bcl-2 following treatment of HL60 with phorbol myristate acetate (PMA), dimethyl sulphoxide (DMSO) or retinoic acid (RA). Tetradecanoylphorbol Acetate 162-165 BCL2 apoptosis regulator Homo sapiens 96-101 8830674-3 1996 We show here that bax protein also declined with a time course similar to the downregulation of bcl-2 following treatment of HL60 with phorbol myristate acetate (PMA), dimethyl sulphoxide (DMSO) or retinoic acid (RA). Dimethyl Sulfoxide 168-187 BCL2 apoptosis regulator Homo sapiens 96-101 8830674-3 1996 We show here that bax protein also declined with a time course similar to the downregulation of bcl-2 following treatment of HL60 with phorbol myristate acetate (PMA), dimethyl sulphoxide (DMSO) or retinoic acid (RA). Dimethyl Sulfoxide 189-193 BCL2 apoptosis regulator Homo sapiens 96-101 8830674-3 1996 We show here that bax protein also declined with a time course similar to the downregulation of bcl-2 following treatment of HL60 with phorbol myristate acetate (PMA), dimethyl sulphoxide (DMSO) or retinoic acid (RA). Tretinoin 198-211 BCL2 apoptosis regulator Homo sapiens 96-101 8830674-3 1996 We show here that bax protein also declined with a time course similar to the downregulation of bcl-2 following treatment of HL60 with phorbol myristate acetate (PMA), dimethyl sulphoxide (DMSO) or retinoic acid (RA). Tretinoin 213-215 BCL2 apoptosis regulator Homo sapiens 96-101 18629863-6 1996 However, the bcl-2 transfected cell cultures continued to grow even though glutamine had been exhausted, and a significant decline in viability only occurred when glucose had also been completely exhausted.When cells were cultured in suspension without prior adaptation, the bcl-2 transfected cells grew significantly better, suggesting that the bcl-2 gene protected the cells from apoptosis triggered by either the lack of substrate or the hydrodynamic environment. Glutamine 75-84 BCL2 apoptosis regulator Homo sapiens 13-18 8839847-2 1996 Through the use of Bcl-2 specific antisense oligonucleotides we herein report the biologic importance of Bcl-2 expression in primary human CD34+ hematopoietic progenitor cells committed to the myeloid lineage. Oligonucleotides 44-60 BCL2 apoptosis regulator Homo sapiens 19-24 8839847-2 1996 Through the use of Bcl-2 specific antisense oligonucleotides we herein report the biologic importance of Bcl-2 expression in primary human CD34+ hematopoietic progenitor cells committed to the myeloid lineage. Oligonucleotides 44-60 BCL2 apoptosis regulator Homo sapiens 105-110 8898945-2 1996 CD40 ligation protected cells from apoptosis induced by calcium ionophore through an initial, rapid and apparently Bcl-2-independent mechanism, associated with up-regulation of Bcl-XL. Calcium 56-63 BCL2 apoptosis regulator Homo sapiens 115-120 8891335-7 1996 Bcl-2, a protein that is thought to inhibit apoptosis by regulating reactive oxygen species and calcium fluxes in the cell, inhibits this apoptotic pathway. Reactive Oxygen Species 68-91 BCL2 apoptosis regulator Homo sapiens 0-5 8891335-7 1996 Bcl-2, a protein that is thought to inhibit apoptosis by regulating reactive oxygen species and calcium fluxes in the cell, inhibits this apoptotic pathway. Calcium 96-103 BCL2 apoptosis regulator Homo sapiens 0-5 8891735-3 1996 Here we demonstrate that Dex and CsA, at concentrations that markedly inhibit phytohemagglutinin (PHA)-induced proliferation of normal human peripheral blood lymphocytes, suppress the activation-dependent expression of interleukin 2 (IL-2) and the alpha-chain IL-2 receptor in a dose-dependent fashion without affecting the inducible accumulation and kinetics of either bcl-2 or fas mRNAs. Dexamethasone 25-28 BCL2 apoptosis regulator Homo sapiens 370-375 8891735-3 1996 Here we demonstrate that Dex and CsA, at concentrations that markedly inhibit phytohemagglutinin (PHA)-induced proliferation of normal human peripheral blood lymphocytes, suppress the activation-dependent expression of interleukin 2 (IL-2) and the alpha-chain IL-2 receptor in a dose-dependent fashion without affecting the inducible accumulation and kinetics of either bcl-2 or fas mRNAs. Cyclosporine 33-36 BCL2 apoptosis regulator Homo sapiens 370-375 8816467-9 1996 Treatment of the mature B-cell line BAL-17 with either anti-immunoglobulin M or phorbol 12-myristate 13-acetate leads to an increase in bcl-2 expression that is mediated by the CRE site. Tetradecanoylphorbol Acetate 80-111 BCL2 apoptosis regulator Homo sapiens 136-141 8847894-8 1996 In the BL lines, the most DXM-sensitive cell lines lacked Bcl-2 expression, and the DXM-resistant cell lines always expressed Bcl-2. Dexamethasone 84-87 BCL2 apoptosis regulator Homo sapiens 126-131 8847894-9 1996 While none of the DXM-resistant cell lines lacked Bcl-2 expression, several pre-B or FL lines that expressed [correction of expessed] Bcl-2 were sensitive to DXM. Dexamethasone 158-161 BCL2 apoptosis regulator Homo sapiens 134-139 8816467-11 1996 bcl-2 expression is increased following phorbol ester treatment, and the increased expression is dependent on the CRE site. Phorbol Esters 40-53 BCL2 apoptosis regulator Homo sapiens 0-5 8816500-5 1996 Bax and Bak are Bcl-2 family members which contain Bcl-2 homology regions 1, 2, and 3 (BH1, BH2, and BH3), which interact with E1B 19K and Bcl-2 and promote apoptosis. bh2 92-95 BCL2 apoptosis regulator Homo sapiens 16-21 8831713-0 1996 Oxysterols induced apoptosis in cultured smooth muscle cells through CPP32 protease activation and bcl-2 protein downregulation. Oxysterols 0-10 BCL2 apoptosis regulator Homo sapiens 99-104 8816500-5 1996 Bax and Bak are Bcl-2 family members which contain Bcl-2 homology regions 1, 2, and 3 (BH1, BH2, and BH3), which interact with E1B 19K and Bcl-2 and promote apoptosis. bh2 92-95 BCL2 apoptosis regulator Homo sapiens 51-56 8816500-5 1996 Bax and Bak are Bcl-2 family members which contain Bcl-2 homology regions 1, 2, and 3 (BH1, BH2, and BH3), which interact with E1B 19K and Bcl-2 and promote apoptosis. bh2 92-95 BCL2 apoptosis regulator Homo sapiens 51-56 8798665-4 1996 The BH1 sequence in 19K is degenerate but nevertheless contains a conserved glycine residue found in all family members that when mutated to alanine in Bcl-2 results in loss of Bcl-2 function and ability to dimerize with Bax (Yin, X.-M., Oltvai, Z. N., and Korsmeyer, S. J. bh1 4-7 BCL2 apoptosis regulator Homo sapiens 152-157 8798665-4 1996 The BH1 sequence in 19K is degenerate but nevertheless contains a conserved glycine residue found in all family members that when mutated to alanine in Bcl-2 results in loss of Bcl-2 function and ability to dimerize with Bax (Yin, X.-M., Oltvai, Z. N., and Korsmeyer, S. J. bh1 4-7 BCL2 apoptosis regulator Homo sapiens 177-182 8798665-4 1996 The BH1 sequence in 19K is degenerate but nevertheless contains a conserved glycine residue found in all family members that when mutated to alanine in Bcl-2 results in loss of Bcl-2 function and ability to dimerize with Bax (Yin, X.-M., Oltvai, Z. N., and Korsmeyer, S. J. Glycine 76-83 BCL2 apoptosis regulator Homo sapiens 152-157 8798665-4 1996 The BH1 sequence in 19K is degenerate but nevertheless contains a conserved glycine residue found in all family members that when mutated to alanine in Bcl-2 results in loss of Bcl-2 function and ability to dimerize with Bax (Yin, X.-M., Oltvai, Z. N., and Korsmeyer, S. J. Glycine 76-83 BCL2 apoptosis regulator Homo sapiens 177-182 8798665-4 1996 The BH1 sequence in 19K is degenerate but nevertheless contains a conserved glycine residue found in all family members that when mutated to alanine in Bcl-2 results in loss of Bcl-2 function and ability to dimerize with Bax (Yin, X.-M., Oltvai, Z. N., and Korsmeyer, S. J. Alanine 141-148 BCL2 apoptosis regulator Homo sapiens 152-157 8798665-4 1996 The BH1 sequence in 19K is degenerate but nevertheless contains a conserved glycine residue found in all family members that when mutated to alanine in Bcl-2 results in loss of Bcl-2 function and ability to dimerize with Bax (Yin, X.-M., Oltvai, Z. N., and Korsmeyer, S. J. Alanine 141-148 BCL2 apoptosis regulator Homo sapiens 177-182 8831713-3 1996 We show that both 7-ketocholesterol and 25-hydroxycholesterol induced apoptosis, followed by a rapid decrease in bcl-2 protein in the cells. 7-ketocholesterol 18-35 BCL2 apoptosis regulator Homo sapiens 113-118 8831713-3 1996 We show that both 7-ketocholesterol and 25-hydroxycholesterol induced apoptosis, followed by a rapid decrease in bcl-2 protein in the cells. 25-hydroxycholesterol 40-61 BCL2 apoptosis regulator Homo sapiens 113-118 8798441-2 1996 An in vivo footprint over a cAMP response element (CRE) in the bcl-2 5"-flanking sequence was identified on the translocated allele. Cyclic AMP 28-32 BCL2 apoptosis regulator Homo sapiens 63-68 8798441-6 1996 Treatment with phorbol 12-myristate 13-acetate (PMA) led to an increase in both the amount of phosphorylated CREB and the bcl-2 promoter activity. Tetradecanoylphorbol Acetate 48-51 BCL2 apoptosis regulator Homo sapiens 122-127 8798441-6 1996 Treatment with phorbol 12-myristate 13-acetate (PMA) led to an increase in both the amount of phosphorylated CREB and the bcl-2 promoter activity. Tetradecanoylphorbol Acetate 15-46 BCL2 apoptosis regulator Homo sapiens 122-127 8790427-0 1996 Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. Calcium 30-37 BCL2 apoptosis regulator Homo sapiens 0-5 8790427-5 1996 Mitochondria from Bcl-2 expressors were also much more resistant to inhibition of NADH-dependent respiration caused by sequestration of large Ca2+ loads. NAD 82-86 BCL2 apoptosis regulator Homo sapiens 18-23 8790371-4 1996 Purified bcl-2 is cleaved by HIV protease between phenylalanine 112 and alanine 113. Phenylalanine 50-63 BCL2 apoptosis regulator Homo sapiens 9-14 8888015-1 1996 The proto-oncogene bcl-2 is involved in the regulation of cell death and may be able to block apoptosis in neurons through reduced generation of reactive oxygen species (ROS). Reactive Oxygen Species 145-168 BCL2 apoptosis regulator Homo sapiens 19-24 8790371-4 1996 Purified bcl-2 is cleaved by HIV protease between phenylalanine 112 and alanine 113. Alanine 56-63 BCL2 apoptosis regulator Homo sapiens 9-14 8888015-1 1996 The proto-oncogene bcl-2 is involved in the regulation of cell death and may be able to block apoptosis in neurons through reduced generation of reactive oxygen species (ROS). Reactive Oxygen Species 170-173 BCL2 apoptosis regulator Homo sapiens 19-24 8888015-5 1996 Since oxidative stress may be involved in neurogenerative disorders, accumulation of bcl-2 may reflect a mechanism for counterbalancing ROS-mediated damage, or it might represent the impairment of bcl-2-dependent protection from ROS in parkinsonian brain. Reactive Oxygen Species 136-139 BCL2 apoptosis regulator Homo sapiens 85-90 8888015-5 1996 Since oxidative stress may be involved in neurogenerative disorders, accumulation of bcl-2 may reflect a mechanism for counterbalancing ROS-mediated damage, or it might represent the impairment of bcl-2-dependent protection from ROS in parkinsonian brain. Reactive Oxygen Species 229-232 BCL2 apoptosis regulator Homo sapiens 197-202 8826891-0 1996 Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression. Tretinoin 52-65 BCL2 apoptosis regulator Homo sapiens 19-24 8781438-0 1996 Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Doxorubicin 81-92 BCL2 apoptosis regulator Homo sapiens 26-31 8781438-0 1996 Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Etoposide 94-103 BCL2 apoptosis regulator Homo sapiens 26-31 8781438-0 1996 Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Hydrogen Peroxide 109-126 BCL2 apoptosis regulator Homo sapiens 26-31 8781438-3 1996 Doxorubicin, etoposide, and hydrogen peroxide consistently induced a concentration- and time-dependent upregulation of BCL-2 expression in all myeloma target cell types assayed by flow cytometry and Western blot analysis. Doxorubicin 0-11 BCL2 apoptosis regulator Homo sapiens 119-124 8781438-3 1996 Doxorubicin, etoposide, and hydrogen peroxide consistently induced a concentration- and time-dependent upregulation of BCL-2 expression in all myeloma target cell types assayed by flow cytometry and Western blot analysis. Etoposide 13-22 BCL2 apoptosis regulator Homo sapiens 119-124 8781438-3 1996 Doxorubicin, etoposide, and hydrogen peroxide consistently induced a concentration- and time-dependent upregulation of BCL-2 expression in all myeloma target cell types assayed by flow cytometry and Western blot analysis. Hydrogen Peroxide 28-45 BCL2 apoptosis regulator Homo sapiens 119-124 8826891-2 1996 The sensitivity of AML blasts to drugs such as Ara-C can be increased by the down-regulation of bcl-2 expression by antisense oligonucleotides. Cytarabine 47-52 BCL2 apoptosis regulator Homo sapiens 96-101 8781438-6 1996 An reverse transcriptase-polymerase chain reaction assay showed increased levels of BCL-2 RNA in 8226 cells as early as 4 hours after treatment with doxorubicin at a time when cell recoveries were not decreased. Doxorubicin 149-160 BCL2 apoptosis regulator Homo sapiens 84-89 8781438-7 1996 Thus, doxorubicin stimulates BCL-2 expression in individual 8226 cells rather than simply allowing a selected survival of high BCL-2-expressing cells in culture. Doxorubicin 6-17 BCL2 apoptosis regulator Homo sapiens 29-34 8826891-2 1996 The sensitivity of AML blasts to drugs such as Ara-C can be increased by the down-regulation of bcl-2 expression by antisense oligonucleotides. Oligonucleotides 126-142 BCL2 apoptosis regulator Homo sapiens 96-101 8781438-8 1996 Doxorubicin-treated 8226 cells with upregulated BCL-2 expression were relatively resistant to a second exposure of doxorubicin. Doxorubicin 0-11 BCL2 apoptosis regulator Homo sapiens 48-53 8826891-3 1996 All-trans retinoic acid (ATRA) has been reported to increase the sensitivity of AML cell lines to Ara-C and to induce differentiation in the HL60 promyelocytic cell line, with both effects being accompanied by a decrease in bcl-2 expression. Tretinoin 0-23 BCL2 apoptosis regulator Homo sapiens 224-229 8781438-8 1996 Doxorubicin-treated 8226 cells with upregulated BCL-2 expression were relatively resistant to a second exposure of doxorubicin. Doxorubicin 115-126 BCL2 apoptosis regulator Homo sapiens 48-53 8781438-9 1996 In addition, BCL-2-transfected IM-9 cells, with enhanced expression of BCL-2 which was comparable to that achieved by initial exposure to doxorubicin, were resistant to doxorubicin and etoposide cytotoxicity. Doxorubicin 138-149 BCL2 apoptosis regulator Homo sapiens 13-18 8826891-3 1996 All-trans retinoic acid (ATRA) has been reported to increase the sensitivity of AML cell lines to Ara-C and to induce differentiation in the HL60 promyelocytic cell line, with both effects being accompanied by a decrease in bcl-2 expression. Tretinoin 25-29 BCL2 apoptosis regulator Homo sapiens 224-229 8781438-9 1996 In addition, BCL-2-transfected IM-9 cells, with enhanced expression of BCL-2 which was comparable to that achieved by initial exposure to doxorubicin, were resistant to doxorubicin and etoposide cytotoxicity. Doxorubicin 169-180 BCL2 apoptosis regulator Homo sapiens 13-18 8781438-9 1996 In addition, BCL-2-transfected IM-9 cells, with enhanced expression of BCL-2 which was comparable to that achieved by initial exposure to doxorubicin, were resistant to doxorubicin and etoposide cytotoxicity. Etoposide 185-194 BCL2 apoptosis regulator Homo sapiens 13-18 8826891-4 1996 Using flow cytometry and a monoclonal antibody to bcl-2, we have investigated the effects of ATRA (1 microM) on bcl-2 expression in the blast cells of 25 AML patients and the K562 cell line after incubation for 72 or 24 h, respectively. Tretinoin 93-97 BCL2 apoptosis regulator Homo sapiens 112-117 8826891-5 1996 Using Kolmogorov-Smirnov statistical analysis where a D value of > 0.12 was statistically significant, we found that in 8/25 AML samples and the K562 cells there was a significant decrease in bcl-2 protein expression after incubation with ATRA (D value range 0.14-0.44). Tretinoin 242-246 BCL2 apoptosis regulator Homo sapiens 195-200 8752171-0 1996 Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Etoposide 31-40 BCL2 apoptosis regulator Homo sapiens 79-84 8826891-6 1996 The mean peak fluorescence (MPF) values for the bcl-2 levels of the ATRA responders (n = 8) was reduced to 35.5 +/- 6.9 following incubation with ATRA compared to 47.6 +/- 8.2 (mean +/- SEM) for control samples incubated in the absence of ATRA (P = 0.014). Tretinoin 68-72 BCL2 apoptosis regulator Homo sapiens 48-53 8752171-1 1996 The Bcl-2 oncoprotein, which is expressed in a variety of human malignancies, blocks apoptosis induced by chemotherapeutic drugs, including the topoisomerase II inhibitor, etoposide. Etoposide 172-181 BCL2 apoptosis regulator Homo sapiens 4-9 8826891-6 1996 The mean peak fluorescence (MPF) values for the bcl-2 levels of the ATRA responders (n = 8) was reduced to 35.5 +/- 6.9 following incubation with ATRA compared to 47.6 +/- 8.2 (mean +/- SEM) for control samples incubated in the absence of ATRA (P = 0.014). Tretinoin 146-150 BCL2 apoptosis regulator Homo sapiens 48-53 8752171-3 1996 In agreement with previous studies, Bcl-2 inhibited loss of cell viability (by trypan blue exclusion), the appearance of morphologically apoptotic cells, and the amount of low molecular weight DNA extracted after etoposide exposure (25 microns, 4 h). Trypan Blue 79-90 BCL2 apoptosis regulator Homo sapiens 36-41 8826891-8 1996 The down-regulation of bcl-2 expression by ATRA was particularly associated with CD34-negative AML and of the eight AML patients" cells that responded to ATRA by down-regulating bcl-2, seven were CD34 negative (P < 0.05). Tretinoin 43-47 BCL2 apoptosis regulator Homo sapiens 23-28 8752171-3 1996 In agreement with previous studies, Bcl-2 inhibited loss of cell viability (by trypan blue exclusion), the appearance of morphologically apoptotic cells, and the amount of low molecular weight DNA extracted after etoposide exposure (25 microns, 4 h). Etoposide 213-222 BCL2 apoptosis regulator Homo sapiens 36-41 8752171-6 1996 Although Bcl-2 inhibited etoposide-induced apoptosis, it had no effect on the formation of giant, multinucleated cells characteristic of mitotic catastrophe. Etoposide 25-34 BCL2 apoptosis regulator Homo sapiens 9-14 8826891-8 1996 The down-regulation of bcl-2 expression by ATRA was particularly associated with CD34-negative AML and of the eight AML patients" cells that responded to ATRA by down-regulating bcl-2, seven were CD34 negative (P < 0.05). Tretinoin 154-158 BCL2 apoptosis regulator Homo sapiens 23-28 8826891-8 1996 The down-regulation of bcl-2 expression by ATRA was particularly associated with CD34-negative AML and of the eight AML patients" cells that responded to ATRA by down-regulating bcl-2, seven were CD34 negative (P < 0.05). Tretinoin 154-158 BCL2 apoptosis regulator Homo sapiens 178-183 8826891-9 1996 Our data suggest that the addition of ATRA to combination chemotherapy would increase the chemosensitivity of some patients with AML, particularly CD34-negative AML, due to down-regulation of bcl-2 expression. Tretinoin 38-42 BCL2 apoptosis regulator Homo sapiens 192-197 8905402-2 1996 Bcl-2 transfected and Neomycin selected Hut78 cells expressed about ten-fold greater Bcl-2 protein than the neo-transfected controls. Neomycin 22-30 BCL2 apoptosis regulator Homo sapiens 85-90 8814273-5 1996 Burkitt lymphoma (BL)-derived, Bcl-2- B cells were induced into apoptosis either by the Ca(2+)-ionophore ionomycin or by the inhibitor of protein synthesis cycloheximide. Ionomycin 105-114 BCL2 apoptosis regulator Homo sapiens 31-36 8814273-5 1996 Burkitt lymphoma (BL)-derived, Bcl-2- B cells were induced into apoptosis either by the Ca(2+)-ionophore ionomycin or by the inhibitor of protein synthesis cycloheximide. Cycloheximide 156-169 BCL2 apoptosis regulator Homo sapiens 31-36 8713132-7 1996 Furthermore, RA induced bcl-2 but prevented the processing of actin, whereas 4-HPR had little effect on bcl-2 but increased the specific processing of actin. Tretinoin 13-15 BCL2 apoptosis regulator Homo sapiens 24-29 8787680-5 1996 The evaluation of bcl-2 protein expression suggests that this different effect of lonidamine treatment in drug-resistant and -sensitive cell lines might not simply be due to dissimilar expression levels of bcl-2 protein. lonidamine 82-92 BCL2 apoptosis regulator Homo sapiens 18-23 8704214-0 1996 In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Arsenic Trioxide 57-73 BCL2 apoptosis regulator Homo sapiens 188-193 8704214-0 1996 In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Arsenic Trioxide 75-80 BCL2 apoptosis regulator Homo sapiens 188-193 8704214-0 1996 In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Arsenic Trioxide 132-137 BCL2 apoptosis regulator Homo sapiens 188-193 8704214-5 1996 (2) As2O3 does not influence bax, bcl-x, c-myc, and p53 gene expression, but downregulates bcl-2 gene expression at both mRNA and protein levels. Arsenic Trioxide 4-9 BCL2 apoptosis regulator Homo sapiens 91-96 8758928-0 1996 Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. 20-epi-vitamin d3 24-41 BCL2 apoptosis regulator Homo sapiens 133-138 8758928-0 1996 Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Alitretinoin 66-85 BCL2 apoptosis regulator Homo sapiens 133-138 21541525-0 1996 bcl-2 plays a major role in resistance to dexamethasone induced apoptosis in multiple myeloma cell lines. Dexamethasone 42-55 BCL2 apoptosis regulator Homo sapiens 0-5 21541525-3 1996 We have recently studied the steady-state levels of mRNA transcripts for bcl-2, bar and P53 in 8 MM cell lines and found inverse correlation between the levels of bcl-2 mRNA transcripts and sensitivity to dexamethasone (DEX) induced apoptosis. Dexamethasone 205-218 BCL2 apoptosis regulator Homo sapiens 163-168 21541525-3 1996 We have recently studied the steady-state levels of mRNA transcripts for bcl-2, bar and P53 in 8 MM cell lines and found inverse correlation between the levels of bcl-2 mRNA transcripts and sensitivity to dexamethasone (DEX) induced apoptosis. Dexamethasone 220-223 BCL2 apoptosis regulator Homo sapiens 163-168 21541525-4 1996 Moreover, we have also shown that mRNA transcripts for bcl-2 were further down-regulated in 2 DEX sensitive cell lines in the course of DEX induced apoptosis, whereas mRNA transcripts for bcl-2 were unchanged in 2 DEX-resistant MM cell lines (Int J Oncol 8: 719-726, 1996). Dexamethasone 94-97 BCL2 apoptosis regulator Homo sapiens 55-60 21541525-4 1996 Moreover, we have also shown that mRNA transcripts for bcl-2 were further down-regulated in 2 DEX sensitive cell lines in the course of DEX induced apoptosis, whereas mRNA transcripts for bcl-2 were unchanged in 2 DEX-resistant MM cell lines (Int J Oncol 8: 719-726, 1996). Dexamethasone 136-139 BCL2 apoptosis regulator Homo sapiens 55-60 21541525-4 1996 Moreover, we have also shown that mRNA transcripts for bcl-2 were further down-regulated in 2 DEX sensitive cell lines in the course of DEX induced apoptosis, whereas mRNA transcripts for bcl-2 were unchanged in 2 DEX-resistant MM cell lines (Int J Oncol 8: 719-726, 1996). Dexamethasone 136-139 BCL2 apoptosis regulator Homo sapiens 55-60 21541525-5 1996 In this study, we determined the steady-state levels of bcl-2, P53 and bar proteins in 4 myeloma cell lines, and the levels were correlated with sensitivity to DEX induced apoptosis. Dexamethasone 160-163 BCL2 apoptosis regulator Homo sapiens 56-61 21541525-10 1996 Induction of apoptosis in the DEX sensitive cells resulted in an early down-regulation of bcl-2 and P53 protein, whereas the levels of bar protein were only slightly decreased. Dexamethasone 30-33 BCL2 apoptosis regulator Homo sapiens 90-95 21541525-11 1996 In contrast to the DEX sensitive cell lines, the levels of bcl-2, bar and P53 proteins in the DEX resistant cell lines were unchanged during 72 h of treatment with DEX. Dexamethasone 94-97 BCL2 apoptosis regulator Homo sapiens 59-64 21541525-11 1996 In contrast to the DEX sensitive cell lines, the levels of bcl-2, bar and P53 proteins in the DEX resistant cell lines were unchanged during 72 h of treatment with DEX. Dexamethasone 94-97 BCL2 apoptosis regulator Homo sapiens 59-64 8856092-0 1996 Quantitation of resistance to cytosine arabinoside by myeloid leukemic cells expressing bcl-2. Cytarabine 30-50 BCL2 apoptosis regulator Homo sapiens 88-93 8856092-2 1996 The present study focuses on the quantitation of resistance to increasing doses of 1-beta-d-arabinofuranosylcytosine (Ara-C) by using hematological tumors expressing different levels of bcl-2. Cytarabine 83-116 BCL2 apoptosis regulator Homo sapiens 186-191 8856092-2 1996 The present study focuses on the quantitation of resistance to increasing doses of 1-beta-d-arabinofuranosylcytosine (Ara-C) by using hematological tumors expressing different levels of bcl-2. Cytarabine 118-123 BCL2 apoptosis regulator Homo sapiens 186-191 8856092-7 1996 Upregulation of bcl-2 by myeloid leukemic cells increased the resistance by 3 logs to Ara-C when comparing LD50 values from clonogenic assays, and decreased apoptosis by at least 3 logs when measuring dUTP positive cells by flow cytometry. Cytarabine 86-91 BCL2 apoptosis regulator Homo sapiens 16-21 8856092-7 1996 Upregulation of bcl-2 by myeloid leukemic cells increased the resistance by 3 logs to Ara-C when comparing LD50 values from clonogenic assays, and decreased apoptosis by at least 3 logs when measuring dUTP positive cells by flow cytometry. deoxyuridine triphosphate 201-205 BCL2 apoptosis regulator Homo sapiens 16-21 8713132-8 1996 These results suggest that RA promotes neutrophil differentiation and the establishment of a semi apoptosis-resistant state, possibly through the overexpression of the bcl-2 gene. Tretinoin 27-29 BCL2 apoptosis regulator Homo sapiens 168-173 8710376-6 1996 In Bcl-2-expressing cells in which apoptosis was repressed, Rb remained hyperphosphorylated, even during G1-arrest induced by ionomycin. Rubidium 60-62 BCL2 apoptosis regulator Homo sapiens 3-8 8710376-6 1996 In Bcl-2-expressing cells in which apoptosis was repressed, Rb remained hyperphosphorylated, even during G1-arrest induced by ionomycin. Ionomycin 126-135 BCL2 apoptosis regulator Homo sapiens 3-8 8663439-0 1996 Fas-induced activation of the cell death-related protease CPP32 Is inhibited by Bcl-2 and by ICE family protease inhibitors. ammonium ferrous sulfate 0-3 BCL2 apoptosis regulator Homo sapiens 80-85 8663439-7 1996 Heterologous expression of Bcl-2 in Jurkat cells prevents Fas-induced cell death as well as proteolytic processing and activation of CPP32. ammonium ferrous sulfate 58-61 BCL2 apoptosis regulator Homo sapiens 27-32 8700536-3 1996 In an effort to identify potential upregulators of bcl-2 activity in t(14;18) cells, we found, by strand-specific RT-PCR, a bcl-2 antisense transcript that is present in the t(14;18) DOHH2 and SU-DHL-4 but not in the t(14;18)-negative Raji and Jurkat lymphoid cell lines, and thus appears to be dependent on the bcl-2/IgH fusion. dohh2 183-188 BCL2 apoptosis regulator Homo sapiens 51-56 8663307-4 1996 In this work, we examined the effect of BCL-2 overexpression on acidification mediated by cycloheximide treatment or Fas ligation in Jurkat T-lymphoblasts. Cycloheximide 90-103 BCL2 apoptosis regulator Homo sapiens 40-45 8700536-3 1996 In an effort to identify potential upregulators of bcl-2 activity in t(14;18) cells, we found, by strand-specific RT-PCR, a bcl-2 antisense transcript that is present in the t(14;18) DOHH2 and SU-DHL-4 but not in the t(14;18)-negative Raji and Jurkat lymphoid cell lines, and thus appears to be dependent on the bcl-2/IgH fusion. dohh2 183-188 BCL2 apoptosis regulator Homo sapiens 124-129 8700549-1 1996 Bcl-2, Bcl-xL, CrmA and tetrapeptide ICE inhibitor reduce the extent of necrotic cell death induced by cyanide, which primarily damages mitochondria. Cyanides 103-110 BCL2 apoptosis regulator Homo sapiens 0-5 8700549-2 1996 Although none of them affects the drastic decrease in ATP levels induced by cyanide, Bcl-2 and Bcl-xL but not CrmA or ICE inhibitor inhibit the cyanide-induced decrease in mitochondrial membrane potential. Adenosine Triphosphate 54-57 BCL2 apoptosis regulator Homo sapiens 85-90 8700536-3 1996 In an effort to identify potential upregulators of bcl-2 activity in t(14;18) cells, we found, by strand-specific RT-PCR, a bcl-2 antisense transcript that is present in the t(14;18) DOHH2 and SU-DHL-4 but not in the t(14;18)-negative Raji and Jurkat lymphoid cell lines, and thus appears to be dependent on the bcl-2/IgH fusion. dohh2 183-188 BCL2 apoptosis regulator Homo sapiens 124-129 8700549-2 1996 Although none of them affects the drastic decrease in ATP levels induced by cyanide, Bcl-2 and Bcl-xL but not CrmA or ICE inhibitor inhibit the cyanide-induced decrease in mitochondrial membrane potential. Cyanides 144-151 BCL2 apoptosis regulator Homo sapiens 85-90 8700536-3 1996 In an effort to identify potential upregulators of bcl-2 activity in t(14;18) cells, we found, by strand-specific RT-PCR, a bcl-2 antisense transcript that is present in the t(14;18) DOHH2 and SU-DHL-4 but not in the t(14;18)-negative Raji and Jurkat lymphoid cell lines, and thus appears to be dependent on the bcl-2/IgH fusion. su-dhl-4 193-201 BCL2 apoptosis regulator Homo sapiens 51-56 8700536-3 1996 In an effort to identify potential upregulators of bcl-2 activity in t(14;18) cells, we found, by strand-specific RT-PCR, a bcl-2 antisense transcript that is present in the t(14;18) DOHH2 and SU-DHL-4 but not in the t(14;18)-negative Raji and Jurkat lymphoid cell lines, and thus appears to be dependent on the bcl-2/IgH fusion. su-dhl-4 193-201 BCL2 apoptosis regulator Homo sapiens 124-129 8700536-3 1996 In an effort to identify potential upregulators of bcl-2 activity in t(14;18) cells, we found, by strand-specific RT-PCR, a bcl-2 antisense transcript that is present in the t(14;18) DOHH2 and SU-DHL-4 but not in the t(14;18)-negative Raji and Jurkat lymphoid cell lines, and thus appears to be dependent on the bcl-2/IgH fusion. su-dhl-4 193-201 BCL2 apoptosis regulator Homo sapiens 124-129 8818693-2 1996 To investigate whether overexpressed bcl-2 and abnormally stabilized p53 are associated with reduced apoptosis in paraffin sections of non-small cell lung carcinoma, apoptotic, mitotic, and Ki-67 labelling indices were determined and correlated with bcl-2 and p53 immunoreactivity in 54 squamous cell carcinomas and 22 adenocarcinomas. Paraffin 114-122 BCL2 apoptosis regulator Homo sapiens 37-42 8679463-2 1996 Expression of Bcl-2 was determined using immunohistochemistry on paraffin-embedded sections in a series of 441 premenopausal, lymph node-negative breast cancers of patients randomised to receive perioperative chemotherapy (5-fluorouracil, doxorubicin, cyclophosphamide) or no perioperative chemotherapy. Paraffin 65-73 BCL2 apoptosis regulator Homo sapiens 14-19 8679463-2 1996 Expression of Bcl-2 was determined using immunohistochemistry on paraffin-embedded sections in a series of 441 premenopausal, lymph node-negative breast cancers of patients randomised to receive perioperative chemotherapy (5-fluorouracil, doxorubicin, cyclophosphamide) or no perioperative chemotherapy. Doxorubicin 239-250 BCL2 apoptosis regulator Homo sapiens 14-19 8679463-2 1996 Expression of Bcl-2 was determined using immunohistochemistry on paraffin-embedded sections in a series of 441 premenopausal, lymph node-negative breast cancers of patients randomised to receive perioperative chemotherapy (5-fluorouracil, doxorubicin, cyclophosphamide) or no perioperative chemotherapy. Cyclophosphamide 252-268 BCL2 apoptosis regulator Homo sapiens 14-19 17180102-0 1996 Imidazole antifungals Miconazole and Econazole induce apoptosis in mouse lymphoma and human T cell leukemia cells: regulation by Bcl-2 and potential role of calcium. imidazole 0-9 BCL2 apoptosis regulator Homo sapiens 129-134 17180102-0 1996 Imidazole antifungals Miconazole and Econazole induce apoptosis in mouse lymphoma and human T cell leukemia cells: regulation by Bcl-2 and potential role of calcium. Miconazole 22-32 BCL2 apoptosis regulator Homo sapiens 129-134 17180102-0 1996 Imidazole antifungals Miconazole and Econazole induce apoptosis in mouse lymphoma and human T cell leukemia cells: regulation by Bcl-2 and potential role of calcium. Econazole 37-46 BCL2 apoptosis regulator Homo sapiens 129-134 8666983-2 1996 WHen the cells were treated with 12-O-tetradecanoylphorbol 13-acetate (TPA) or retinoic acid, the level of Bcl-2 protein was increased compared with the control. Tetradecanoylphorbol Acetate 33-69 BCL2 apoptosis regulator Homo sapiens 107-112 21541497-2 1996 In recent studies, we have investigated the steady-state levels of bcl-2 mRNA transcripts and bcl-2 protein in 8 MM cell lines and found inverse correlation between the levels of bcl-2 and sensitivity to dexamethasone (DEX)-induced apoptosis. Dexamethasone 204-217 BCL2 apoptosis regulator Homo sapiens 67-72 21541497-2 1996 In recent studies, we have investigated the steady-state levels of bcl-2 mRNA transcripts and bcl-2 protein in 8 MM cell lines and found inverse correlation between the levels of bcl-2 and sensitivity to dexamethasone (DEX)-induced apoptosis. Dexamethasone 204-217 BCL2 apoptosis regulator Homo sapiens 94-99 21541497-2 1996 In recent studies, we have investigated the steady-state levels of bcl-2 mRNA transcripts and bcl-2 protein in 8 MM cell lines and found inverse correlation between the levels of bcl-2 and sensitivity to dexamethasone (DEX)-induced apoptosis. Dexamethasone 204-217 BCL2 apoptosis regulator Homo sapiens 94-99 21541497-3 1996 Moreover, we have shown that bcl-2 was further down-regulated in DEX sensitive cell lines, but not in DEX resistance cell lines, in the course of DEX-induced apoptosis (Int J Oncol 8: 719-726, 1996). Dexamethasone 65-68 BCL2 apoptosis regulator Homo sapiens 29-34 21541497-5 1996 Thus, switching-on of bcl-2 by IPTG resulted in increased bcl-2 protein in the cells, enhancement of cell growth, and a decrease in spontaneous apoptosis, concomitant with increased resistance to DEX. Isopropyl Thiogalactoside 31-35 BCL2 apoptosis regulator Homo sapiens 22-27 21541497-5 1996 Thus, switching-on of bcl-2 by IPTG resulted in increased bcl-2 protein in the cells, enhancement of cell growth, and a decrease in spontaneous apoptosis, concomitant with increased resistance to DEX. Isopropyl Thiogalactoside 31-35 BCL2 apoptosis regulator Homo sapiens 58-63 21541497-5 1996 Thus, switching-on of bcl-2 by IPTG resulted in increased bcl-2 protein in the cells, enhancement of cell growth, and a decrease in spontaneous apoptosis, concomitant with increased resistance to DEX. Dexamethasone 196-199 BCL2 apoptosis regulator Homo sapiens 22-27 21541497-6 1996 Switching-off of bcl-2 protein expression by removal of IPTG resulted in restoration of sensitivity to DEX-induced apoptosis. Isopropyl Thiogalactoside 56-60 BCL2 apoptosis regulator Homo sapiens 17-22 21541497-6 1996 Switching-off of bcl-2 protein expression by removal of IPTG resulted in restoration of sensitivity to DEX-induced apoptosis. Dexamethasone 103-106 BCL2 apoptosis regulator Homo sapiens 17-22 8683246-8 1996 Bcl2 was the strongest independent prognostic value in a multivariate analysis, with a relative risk (RR) of 3.0 in comparison to p53 expression and the clinical factors of the IPI. diprotin A 177-180 BCL2 apoptosis regulator Homo sapiens 0-4 8647905-2 1996 Bcl-2 transfected cells were significantly more radioresistant than control cells and were significantly hyperpolarized compared to parental and neomycin control transfected PW and HL60 cells. Neomycin 145-153 BCL2 apoptosis regulator Homo sapiens 0-5 8647905-3 1996 Hyperpolarization of the parental and neomycin control transfected cells by valinomycin significantly increased the radioresistance of these cells to such an extent that there was no longer a significant difference in the survival of the valinomycin treated and irradiated control cells compared to similarly irradiated Bcl-2 transfected cells. Neomycin 38-46 BCL2 apoptosis regulator Homo sapiens 320-325 8647905-3 1996 Hyperpolarization of the parental and neomycin control transfected cells by valinomycin significantly increased the radioresistance of these cells to such an extent that there was no longer a significant difference in the survival of the valinomycin treated and irradiated control cells compared to similarly irradiated Bcl-2 transfected cells. Valinomycin 76-87 BCL2 apoptosis regulator Homo sapiens 320-325 8666983-2 1996 WHen the cells were treated with 12-O-tetradecanoylphorbol 13-acetate (TPA) or retinoic acid, the level of Bcl-2 protein was increased compared with the control. Tetradecanoylphorbol Acetate 71-74 BCL2 apoptosis regulator Homo sapiens 107-112 8666983-2 1996 WHen the cells were treated with 12-O-tetradecanoylphorbol 13-acetate (TPA) or retinoic acid, the level of Bcl-2 protein was increased compared with the control. Tretinoin 79-92 BCL2 apoptosis regulator Homo sapiens 107-112 8666983-4 1996 In contrast, the level of Bcl-2 protein was decreased by treatment with dibutyryl cAMP (diBu-cAMP), forskolin, or cholera toxin, and the effects of diBu-cAMP were inhibited by pretreatment with a protein kinase A (PKA) inhibitor, H-89. Bucladesine 72-86 BCL2 apoptosis regulator Homo sapiens 26-31 8666983-4 1996 In contrast, the level of Bcl-2 protein was decreased by treatment with dibutyryl cAMP (diBu-cAMP), forskolin, or cholera toxin, and the effects of diBu-cAMP were inhibited by pretreatment with a protein kinase A (PKA) inhibitor, H-89. Bucladesine 88-97 BCL2 apoptosis regulator Homo sapiens 26-31 8666983-4 1996 In contrast, the level of Bcl-2 protein was decreased by treatment with dibutyryl cAMP (diBu-cAMP), forskolin, or cholera toxin, and the effects of diBu-cAMP were inhibited by pretreatment with a protein kinase A (PKA) inhibitor, H-89. Colforsin 100-109 BCL2 apoptosis regulator Homo sapiens 26-31 8666983-4 1996 In contrast, the level of Bcl-2 protein was decreased by treatment with dibutyryl cAMP (diBu-cAMP), forskolin, or cholera toxin, and the effects of diBu-cAMP were inhibited by pretreatment with a protein kinase A (PKA) inhibitor, H-89. Bucladesine 148-157 BCL2 apoptosis regulator Homo sapiens 26-31 8666983-4 1996 In contrast, the level of Bcl-2 protein was decreased by treatment with dibutyryl cAMP (diBu-cAMP), forskolin, or cholera toxin, and the effects of diBu-cAMP were inhibited by pretreatment with a protein kinase A (PKA) inhibitor, H-89. N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide 230-234 BCL2 apoptosis regulator Homo sapiens 26-31 8666983-6 1996 Furthermore, the nucleosomal DNA fragmentation induced by serum depletion for 4 h was observed in SH-SY5Y cells when the level of Bcl-2 protein was down-regulated by treatment with 1 mM diBu-cAMP for 3 days, although the DNA fragmentation by serum depletion for 4 h was not observed in nontreatment cells, indicating that Bcl-2 proteins whose expression is regulated by PKC and PKA play important roles in serum depletion-induced apoptosis. Bucladesine 186-195 BCL2 apoptosis regulator Homo sapiens 130-135 8903423-7 1996 The effects of the vitamin D compounds on the expression of two oncoproteins which may regulate apoptosis, bcl-2 and p53 were examined by Western analysis. Vitamin D 19-28 BCL2 apoptosis regulator Homo sapiens 107-112 8666983-6 1996 Furthermore, the nucleosomal DNA fragmentation induced by serum depletion for 4 h was observed in SH-SY5Y cells when the level of Bcl-2 protein was down-regulated by treatment with 1 mM diBu-cAMP for 3 days, although the DNA fragmentation by serum depletion for 4 h was not observed in nontreatment cells, indicating that Bcl-2 proteins whose expression is regulated by PKC and PKA play important roles in serum depletion-induced apoptosis. Bucladesine 186-195 BCL2 apoptosis regulator Homo sapiens 322-327 8683994-11 1996 We used OCI/AML-2 cells transfected with bcl-2 to look for the place in this sequence where bcl-2 protein protects cells against apoptosis; bcl-2 transfectants showed an increase in ROI generation similar to controls, but were able to maintain GSH levels in the face of this oxidative stress. Glutathione 244-247 BCL2 apoptosis regulator Homo sapiens 92-97 8683994-11 1996 We used OCI/AML-2 cells transfected with bcl-2 to look for the place in this sequence where bcl-2 protein protects cells against apoptosis; bcl-2 transfectants showed an increase in ROI generation similar to controls, but were able to maintain GSH levels in the face of this oxidative stress. Glutathione 244-247 BCL2 apoptosis regulator Homo sapiens 92-97 8683994-13 1996 These studies complement previous work showing how regulators of AML growth affect the sensitivity of blast cells to Ara-C by changing the concentration or stability of bcl-2 protein. Cytarabine 117-122 BCL2 apoptosis regulator Homo sapiens 169-174 8684002-2 1996 We have studied three B-NHL cell lines (DoHH2, VAL and ROS 50) and show that concurrent activation of BCL2 and MYC may follow translocation of both oncogenes to the same IGH allele. ros 55-58 BCL2 apoptosis regulator Homo sapiens 102-106 8811935-5 1996 However, the expression of bcl-2 was higher in PBMC from SDAT patients than in cells from MID patients or from MISC patients, whereas the MIXED group showed an intermediate expression; a high bcl-2 expression correlated with a low DEX-sensitivity. Dexamethasone 231-234 BCL2 apoptosis regulator Homo sapiens 27-32 8692837-3 1996 HS prevented H2O2-induced alterations in mitochondrial membrane potential and cristae formation while increasing expression of HSPs and the protein product of bcl-2. Hydrogen Peroxide 13-17 BCL2 apoptosis regulator Homo sapiens 159-164 8649764-5 1996 Induction of necrotic cell death by KCN also induces activation of ICE(-like) proteases but not of CPP32/Yama(-like) proteases, and Bcl-2 and Bcl-xL inhibit the activation and the cell death, suggesting that the functional site of Bcl-2 and Bcl-xL is also upstream of ICE(-like) proteases in at least some forms of necrosis. Potassium Cyanide 36-39 BCL2 apoptosis regulator Homo sapiens 132-137 8649764-5 1996 Induction of necrotic cell death by KCN also induces activation of ICE(-like) proteases but not of CPP32/Yama(-like) proteases, and Bcl-2 and Bcl-xL inhibit the activation and the cell death, suggesting that the functional site of Bcl-2 and Bcl-xL is also upstream of ICE(-like) proteases in at least some forms of necrosis. Potassium Cyanide 36-39 BCL2 apoptosis regulator Homo sapiens 231-236 8649765-5 1996 Treatment with adriamycin was accompanied by a sustained rise in cytoplasmic Ca2+ in control and bcl-2 transfected cells. Doxorubicin 15-25 BCL2 apoptosis regulator Homo sapiens 97-102 8727098-3 1996 Digoxigenin (DIG)-labeled dUTP is incorporated in a standard PCR method for amplification of bcl-2 major breakpoint region (mbr) rearrangements. Digoxigenin 0-11 BCL2 apoptosis regulator Homo sapiens 93-98 8727098-3 1996 Digoxigenin (DIG)-labeled dUTP is incorporated in a standard PCR method for amplification of bcl-2 major breakpoint region (mbr) rearrangements. Digoxigenin 13-16 BCL2 apoptosis regulator Homo sapiens 93-98 8727098-3 1996 Digoxigenin (DIG)-labeled dUTP is incorporated in a standard PCR method for amplification of bcl-2 major breakpoint region (mbr) rearrangements. deoxyuridine triphosphate 26-30 BCL2 apoptosis regulator Homo sapiens 93-98 8709622-0 1996 Retinoid-regulated expression of BCL-2 and tissue transglutaminase during the differentiation and apoptosis of human myeloid leukemia (HL-60) cells. Retinoids 0-8 BCL2 apoptosis regulator Homo sapiens 33-38 8840159-5 1996 Staining of paraffin sections of Merkel cell carcinomas with an anti-bcl-2 monoclonal antibody revealed strong bcl-2 protein immunoreactivity in all 5 tumors tested. Paraffin 12-20 BCL2 apoptosis regulator Homo sapiens 69-74 8840159-5 1996 Staining of paraffin sections of Merkel cell carcinomas with an anti-bcl-2 monoclonal antibody revealed strong bcl-2 protein immunoreactivity in all 5 tumors tested. Paraffin 12-20 BCL2 apoptosis regulator Homo sapiens 111-116 8667251-0 1996 Prostaglandin E2 induces apoptosis in resting immature and mature human lymphocytes: a c-Myc-dependent and Bcl-2-independent associated pathway. Dinoprostone 0-16 BCL2 apoptosis regulator Homo sapiens 107-112 8667251-10 1996 In conclusion, PGE2 induces apoptosis with different kinetics on immature and mature T cells: this induction is associated with the increase of c-Myc protein expression and seems to be independent from Bcl-2 regulation. Dinoprostone 15-19 BCL2 apoptosis regulator Homo sapiens 202-207 8709622-3 1996 In the present studies we have characterized the effect of retinoids on the expression of two apoptosis-linked gene products, BCL-2 and tissue transglutaminase. Retinoids 59-68 BCL2 apoptosis regulator Homo sapiens 126-131 8668330-0 1996 Bcl-2 inhibits hydrogen peroxide-induced ER Ca2+ pool depletion. Hydrogen Peroxide 15-32 BCL2 apoptosis regulator Homo sapiens 0-5 8671959-5 1996 The immunohistochemical strept.ABC method was performed on paraffin sections for the detection of bcl-2 protein with a monoclonal antibody after microwave pretreatment. Paraffin 59-67 BCL2 apoptosis regulator Homo sapiens 98-103 8643573-0 1996 Bcl-2 interrupts the ceramide-mediated pathway of cell death. Ceramides 21-29 BCL2 apoptosis regulator Homo sapiens 0-5 8643573-2 1996 In this study, we examine the relationship between the ceramide-mediated pathway of growth suppression and the bcl-2 protooncogene. Ceramides 55-63 BCL2 apoptosis regulator Homo sapiens 111-116 8643573-5 1996 Overexpression of bcl-2 resulted in near total protection of cell death in response to vincristine. Vincristine 87-98 BCL2 apoptosis regulator Homo sapiens 18-23 8643573-7 1996 Overexpression of bcl-2 prevented apoptosis in response to ceramide, suggesting that bcl-2 acts at a point downstream of ceramide. Ceramides 59-67 BCL2 apoptosis regulator Homo sapiens 18-23 8643573-7 1996 Overexpression of bcl-2 prevented apoptosis in response to ceramide, suggesting that bcl-2 acts at a point downstream of ceramide. Ceramides 59-67 BCL2 apoptosis regulator Homo sapiens 85-90 8643573-7 1996 Overexpression of bcl-2 prevented apoptosis in response to ceramide, suggesting that bcl-2 acts at a point downstream of ceramide. Ceramides 121-129 BCL2 apoptosis regulator Homo sapiens 18-23 8643573-7 1996 Overexpression of bcl-2 prevented apoptosis in response to ceramide, suggesting that bcl-2 acts at a point downstream of ceramide. Ceramides 121-129 BCL2 apoptosis regulator Homo sapiens 85-90 8645213-2 1996 Over-expression of Bcl-2 inhibited ceramide-induced poly(ADP-ribose) polymerase proteolysis and protected cells from ceramide-induced death. Ceramides 35-43 BCL2 apoptosis regulator Homo sapiens 19-24 8645213-2 1996 Over-expression of Bcl-2 inhibited ceramide-induced poly(ADP-ribose) polymerase proteolysis and protected cells from ceramide-induced death. Ceramides 117-125 BCL2 apoptosis regulator Homo sapiens 19-24 8668330-8 1996 H2O2 treatment produced a significant reduction in the TG-mobilizable Ca2+ pool in WEH17.2 and W.Hb13 cells, but not in W.Hb12 cells, indicating that overexpression of Bcl-2 preserves the integrity of the ER Ca2+ pool in cells exposed to reactive oxygen species. Hydrogen Peroxide 0-4 BCL2 apoptosis regulator Homo sapiens 168-173 8668330-8 1996 H2O2 treatment produced a significant reduction in the TG-mobilizable Ca2+ pool in WEH17.2 and W.Hb13 cells, but not in W.Hb12 cells, indicating that overexpression of Bcl-2 preserves the integrity of the ER Ca2+ pool in cells exposed to reactive oxygen species. Thapsigargin 55-57 BCL2 apoptosis regulator Homo sapiens 168-173 8668330-8 1996 H2O2 treatment produced a significant reduction in the TG-mobilizable Ca2+ pool in WEH17.2 and W.Hb13 cells, but not in W.Hb12 cells, indicating that overexpression of Bcl-2 preserves the integrity of the ER Ca2+ pool in cells exposed to reactive oxygen species. Reactive Oxygen Species 238-261 BCL2 apoptosis regulator Homo sapiens 168-173 8792010-6 1996 However, 24 h after exposing the cell lines to 1 ng/ml dolastatin 10, bcl-2 expression was abolished but there was no significant change in c-myc protein expression. dolastatin 10 55-68 BCL2 apoptosis regulator Homo sapiens 70-75 8623923-10 1996 Labeling of paraffin sections with PG-B6p proved useful for differentiating proliferation centers in B-CLL (BCl-2+/BCL-6-) from trapped germinal centers in mantle cell lymphomas (BCL-2-/BCL-6+) and for identifying neoplastic cells in cases of nodular, lymphocyte-predominance Hodgkin"s disease. Paraffin 12-20 BCL2 apoptosis regulator Homo sapiens 108-113 8623923-10 1996 Labeling of paraffin sections with PG-B6p proved useful for differentiating proliferation centers in B-CLL (BCl-2+/BCL-6-) from trapped germinal centers in mantle cell lymphomas (BCL-2-/BCL-6+) and for identifying neoplastic cells in cases of nodular, lymphocyte-predominance Hodgkin"s disease. Paraffin 12-20 BCL2 apoptosis regulator Homo sapiens 179-184 8647264-6 1996 Both ionomycin and anti-IgM trigger activation of CPP32 and cleavage of PARP prior to the onset of apoptosis; this process is abrogated by treatment with anti-CD40 and is independent of Bcl-2 expression. Ionomycin 5-14 BCL2 apoptosis regulator Homo sapiens 186-191 8792010-9 1996 Given the above, dolastatin 10 induction of cell arrest is the initiating signal to downregulate the antiapoptotic bcl-2 and reactivate the apoptotic pathway. 2-[[2-(dimethylamino)-3-methylbutanoyl]amino]-N-[4-methoxy-6-[2-[1-methoxy-2-methyl-3-oxo-3-[[2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-2-methyl-6-oxohexan-3-yl]-N,3-dimethylbutanamide 17-27 BCL2 apoptosis regulator Homo sapiens 115-120 8616869-2 1996 We have found that Bcl-2 and p53, two proteins implicated in the control of apoptosis, are differently expressed in the ovarian cell line A2780 and its cisplatin-resistant variant 2780CP, with the resistant line overexpressing both proteins. Cisplatin 152-161 BCL2 apoptosis regulator Homo sapiens 19-24 8780936-2 1996 Paraffin-embedded tissues of 46 bone marrow biopsies were stained with a monoclonal antibody to bcl-2 protein using the supersensitive streptavidin biotin immunoperoxidase method after a microwave heating of the sections. Paraffin 0-8 BCL2 apoptosis regulator Homo sapiens 96-101 8622078-8 1996 Moreover, the simultaneous p53 overexpression and lack of PgR identified patients at maximum risk of relapse, whereas bcl-2 overexpression, associated with a low 3H-dT LI or the presence of PgR, improved the prognostic resolution for low-risk patients. 3h-dt 162-167 BCL2 apoptosis regulator Homo sapiens 118-123 8616869-3 1996 Transfection of the A2780 cells with a Bcl-2- or p53-expressing plasmid increases resistance to various drugs, including cisplatin, suggesting that Bcl-2 and p53 expression may influence the sensitivity of ovarian cancer cell lines to chemotherapy. Cisplatin 121-130 BCL2 apoptosis regulator Homo sapiens 39-44 8616869-3 1996 Transfection of the A2780 cells with a Bcl-2- or p53-expressing plasmid increases resistance to various drugs, including cisplatin, suggesting that Bcl-2 and p53 expression may influence the sensitivity of ovarian cancer cell lines to chemotherapy. Cisplatin 121-130 BCL2 apoptosis regulator Homo sapiens 148-153 9172801-16 1996 Some authors have reported down-regulation of bcl-2 protein expression in B-CLL B-cells undergoing SA or in steroid-treated cells with IL4 preventing this down-regulation. sa 99-101 BCL2 apoptosis regulator Homo sapiens 46-51 9172801-16 1996 Some authors have reported down-regulation of bcl-2 protein expression in B-CLL B-cells undergoing SA or in steroid-treated cells with IL4 preventing this down-regulation. Steroids 108-115 BCL2 apoptosis regulator Homo sapiens 46-51 8649997-8 1996 These results indicate that a natural sequence in the human bcl-2 promoter can form a stable triplex with a synthetic oligonucleotide under pseudo-physiological conditions, and suggest that triple helix formation might provide an approach to the artificial repression of bcl-2 transcription. Oligonucleotides 118-133 BCL2 apoptosis regulator Homo sapiens 271-276 8733762-4 1996 bcl-2 was present in 21% of the TCs, 91% of the ACs, and 100% of the SCLCs (P = 0.0001). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 32-35 BCL2 apoptosis regulator Homo sapiens 0-5 8733771-4 1996 The bcl-2 protein was detected after antigen retrieval with bcl-2 monoclonal antibody using archival formalin-fixed, paraffin-embedded tissue material. Formaldehyde 101-109 BCL2 apoptosis regulator Homo sapiens 4-9 8733771-4 1996 The bcl-2 protein was detected after antigen retrieval with bcl-2 monoclonal antibody using archival formalin-fixed, paraffin-embedded tissue material. Paraffin 117-125 BCL2 apoptosis regulator Homo sapiens 4-9 8633098-4 1996 The Paju cell line displays moderate expression of BCL2, the level of which increases in parallel with further neural differentiation induced by treatment with phorbol 12-myristate 13-acetate. Tetradecanoylphorbol Acetate 160-191 BCL2 apoptosis regulator Homo sapiens 51-55 8649997-8 1996 These results indicate that a natural sequence in the human bcl-2 promoter can form a stable triplex with a synthetic oligonucleotide under pseudo-physiological conditions, and suggest that triple helix formation might provide an approach to the artificial repression of bcl-2 transcription. Oligonucleotides 118-133 BCL2 apoptosis regulator Homo sapiens 60-65 8619857-4 1996 Although Bcl-2 has been shown to act as an antioxidant under certain conditions, additional functions have emerged from studies under low oxygen pressure. Oxygen 138-144 BCL2 apoptosis regulator Homo sapiens 9-14 8612815-0 1996 Nitric oxide induced poly(ADP-ribose) polymerase cleavage in RAW 264.7 macrophage apoptosis is blocked by Bcl-2. Nitric Oxide 0-12 BCL2 apoptosis regulator Homo sapiens 106-111 8605321-7 1996 Al is the only known Bcl-2 family member that is inducible by inflammatory cytokines, suggesting that it may play a protective role during inflammation. Aluminum 0-2 BCL2 apoptosis regulator Homo sapiens 21-26 8620501-0 1996 Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Etoposide 47-56 BCL2 apoptosis regulator Homo sapiens 124-129 8622946-0 1996 Inhibition of apoptosis by overexpressing Bcl-2 enhances gene amplification by a mechanism independent of aphidicolin pretreatment. Aphidicolin 106-117 BCL2 apoptosis regulator Homo sapiens 42-47 8603522-7 1996 RA-mediated interruption of the IL-6 autocrine loop was associated with a decrease of bcl-2 oncoprotein expression and apoptosis of the myeloma cells which was RA concentration- and time-dependent. Tretinoin 0-2 BCL2 apoptosis regulator Homo sapiens 86-91 8622946-1 1996 To study the effect of apoptosis on gene amplification, we have constructed HeLa S3 cell lines in which the expression of bcl-2 (BCL2) can be controlled by tetracycline in the growth medium. Tetracycline 156-168 BCL2 apoptosis regulator Homo sapiens 122-127 8622946-1 1996 To study the effect of apoptosis on gene amplification, we have constructed HeLa S3 cell lines in which the expression of bcl-2 (BCL2) can be controlled by tetracycline in the growth medium. Tetracycline 156-168 BCL2 apoptosis regulator Homo sapiens 129-133 8622946-2 1996 Induction of Bcl-2 expression caused a temporary delay of apoptosis and resulted in roughly a 3-fold increase in the frequency of resistant colonies when cells were selected with trimetrexate. Trimetrexate 179-191 BCL2 apoptosis regulator Homo sapiens 13-18 8622946-6 1996 When Bcl-2-expressing cells were pretreated with aphidicolin, the resulting increase in gene amplification frequency was approximately the product of the increases caused by aphidicolin pretreatment or Bcl-2 expression alone, indicating that Bcl-2 increases gene amplification through a mechanism independent of that of aphidicolin pretreatment. Aphidicolin 49-60 BCL2 apoptosis regulator Homo sapiens 5-10 8622946-6 1996 When Bcl-2-expressing cells were pretreated with aphidicolin, the resulting increase in gene amplification frequency was approximately the product of the increases caused by aphidicolin pretreatment or Bcl-2 expression alone, indicating that Bcl-2 increases gene amplification through a mechanism independent of that of aphidicolin pretreatment. Aphidicolin 49-60 BCL2 apoptosis regulator Homo sapiens 202-207 8622946-6 1996 When Bcl-2-expressing cells were pretreated with aphidicolin, the resulting increase in gene amplification frequency was approximately the product of the increases caused by aphidicolin pretreatment or Bcl-2 expression alone, indicating that Bcl-2 increases gene amplification through a mechanism independent of that of aphidicolin pretreatment. Aphidicolin 49-60 BCL2 apoptosis regulator Homo sapiens 202-207 8622946-6 1996 When Bcl-2-expressing cells were pretreated with aphidicolin, the resulting increase in gene amplification frequency was approximately the product of the increases caused by aphidicolin pretreatment or Bcl-2 expression alone, indicating that Bcl-2 increases gene amplification through a mechanism independent of that of aphidicolin pretreatment. Aphidicolin 174-185 BCL2 apoptosis regulator Homo sapiens 5-10 8622946-6 1996 When Bcl-2-expressing cells were pretreated with aphidicolin, the resulting increase in gene amplification frequency was approximately the product of the increases caused by aphidicolin pretreatment or Bcl-2 expression alone, indicating that Bcl-2 increases gene amplification through a mechanism independent of that of aphidicolin pretreatment. Aphidicolin 174-185 BCL2 apoptosis regulator Homo sapiens 5-10 8790944-0 1996 Induction of mcl1/EAT, Bcl-2 related gene, by retinoic acid or heat shock in the human embryonal carcinoma cells, NCR-G3. Tretinoin 46-59 BCL2 apoptosis regulator Homo sapiens 23-28 8790944-7 1996 The expression of mcl1/EAT, the Bcl-2 related gene, was increased at an early stage of the retinoic acid-induced differentiation and preceded the up-regulation of cytokeratin and hCG genes after ratinoic acid treatment. Tretinoin 91-104 BCL2 apoptosis regulator Homo sapiens 32-37 8790944-7 1996 The expression of mcl1/EAT, the Bcl-2 related gene, was increased at an early stage of the retinoic acid-induced differentiation and preceded the up-regulation of cytokeratin and hCG genes after ratinoic acid treatment. ratinoic acid 195-208 BCL2 apoptosis regulator Homo sapiens 32-37 8620503-0 1996 Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Paclitaxel 0-5 BCL2 apoptosis regulator Homo sapiens 47-52 8620503-5 1996 Recently, taxol was reported to induce Bcl-2 phosphorylation and inactivation. Paclitaxel 10-15 BCL2 apoptosis regulator Homo sapiens 39-44 8602624-0 1996 In vitro culture with prednisolone increases BCL-2 protein expression in adult acute lymphoblastic leukemia cells. Prednisolone 22-34 BCL2 apoptosis regulator Homo sapiens 45-50 8602624-3 1996 In this study, we aimed to evaluate whether in vitro culture with prednisolone (PDN) could modify the expression of BCL-2 protein. Prednisolone 66-78 BCL2 apoptosis regulator Homo sapiens 116-121 8602624-3 1996 In this study, we aimed to evaluate whether in vitro culture with prednisolone (PDN) could modify the expression of BCL-2 protein. Prednisolone 80-83 BCL2 apoptosis regulator Homo sapiens 116-121 17180085-0 1996 Over-expression of Bcl-2 protects against apoptosis induced by the bioreductive cytotoxic drug SR4233 (Tirapazamine). Tirapazamine 95-101 BCL2 apoptosis regulator Homo sapiens 19-24 17180085-0 1996 Over-expression of Bcl-2 protects against apoptosis induced by the bioreductive cytotoxic drug SR4233 (Tirapazamine). Tirapazamine 103-115 BCL2 apoptosis regulator Homo sapiens 19-24 17180085-3 1996 The viability of Bcl-2 transfected cells was significantly greater than that of parental PW cells treated with the bioreductive cytotoxin SR4233 under aerobic conditions. Tirapazamine 138-144 BCL2 apoptosis regulator Homo sapiens 17-22 17180085-8 1996 The TBARS assay for lipid peroxidation showed that Bcl-2 transfectants had a significantly lower level of lipid peroxidation than parental PW cells following a 24 hour constant exposure to SR4233 under aerobic conditions. Thiobarbituric Acid Reactive Substances 4-9 BCL2 apoptosis regulator Homo sapiens 51-56 17180085-8 1996 The TBARS assay for lipid peroxidation showed that Bcl-2 transfectants had a significantly lower level of lipid peroxidation than parental PW cells following a 24 hour constant exposure to SR4233 under aerobic conditions. Tirapazamine 189-195 BCL2 apoptosis regulator Homo sapiens 51-56 8631771-2 1996 Both BH1 and BH2 in the Bcl-2 protein are required for its function as an inhibitor of cell death and for heterodimerization with the proapoptotic protein Bax. bh1 5-8 BCL2 apoptosis regulator Homo sapiens 24-29 8617478-3 1996 The authors postulated that the indolent variants of BCC, namely, the superficial and circumscribed subtypes, might exhibit greater bcl-2 expression than their aggressive counterparts, and used a monoclonal antibody to identify its protein product in formalin-fixed tissue from 30 BCCs. Formaldehyde 251-259 BCL2 apoptosis regulator Homo sapiens 132-137 21544419-3 1996 We, therefore, decided to conduct a detailed study of the role of the bcl-2/bax/p53 network in dexamethasone (DEX) induced apoptosis in MM cells. Dexamethasone 95-108 BCL2 apoptosis regulator Homo sapiens 70-75 21544419-3 1996 We, therefore, decided to conduct a detailed study of the role of the bcl-2/bax/p53 network in dexamethasone (DEX) induced apoptosis in MM cells. Dexamethasone 110-113 BCL2 apoptosis regulator Homo sapiens 70-75 21544419-9 1996 Induction of apoptosis in 8226 and ARP-1 cells (DEX sensitive) resulted, within 24 h, in a transient but marked down-regulation of mRNA transcripts for bcl-2 and p53, whereas the level of expression of bax mRNA transcripts were unchanged, except for ARP-1 cells (lacking p53), where slight down-regulation of mRNA transcripts for bax, was observed. Dexamethasone 48-51 BCL2 apoptosis regulator Homo sapiens 152-157 21544419-10 1996 In contrast to the DEX sensitive cell lines, the level of expression of bcl-2, bax and p53 mRNA transcripts in the DEX resistant cell lines, were unchanged during 72 h of treatment with DEX (up to 10 mu M). Dexamethasone 115-118 BCL2 apoptosis regulator Homo sapiens 72-77 21544419-10 1996 In contrast to the DEX sensitive cell lines, the level of expression of bcl-2, bax and p53 mRNA transcripts in the DEX resistant cell lines, were unchanged during 72 h of treatment with DEX (up to 10 mu M). Dexamethasone 115-118 BCL2 apoptosis regulator Homo sapiens 72-77 21544419-11 1996 We, therefore, conclude that bcl-2 and perhaps p53 are involved in resistance to DEX in myeloma cell lines. Dexamethasone 81-84 BCL2 apoptosis regulator Homo sapiens 29-34 8666911-13 1996 Second, transfection-enforced hyperexpression of Bcl-2 directly abolishes the induction of mitochondrial PT in response to a protonophore, a pro-oxidant, as well as to the ANT ligand atractyloside, correlating with its apoptosis-inhibitory effect. Atractyloside 183-196 BCL2 apoptosis regulator Homo sapiens 49-54 8734919-5 1996 Staining of paraffin sections of Merkel cell carcinomas with an anti-bcl-2 monoclonal antibody revealed strong bcl-2 protein immunoreactivity in all 5 tumors tested. Paraffin 12-20 BCL2 apoptosis regulator Homo sapiens 69-74 8734919-5 1996 Staining of paraffin sections of Merkel cell carcinomas with an anti-bcl-2 monoclonal antibody revealed strong bcl-2 protein immunoreactivity in all 5 tumors tested. Paraffin 12-20 BCL2 apoptosis regulator Homo sapiens 111-116 8784816-7 1996 Transfection of neural cells with the anti-apoptotic gene, bcl-2, confers partial resistance to a variety of neurotoxins, including methyl mercury. methyl mercury 132-146 BCL2 apoptosis regulator Homo sapiens 59-64 8631771-2 1996 Both BH1 and BH2 in the Bcl-2 protein are required for its function as an inhibitor of cell death and for heterodimerization with the proapoptotic protein Bax. bh2 13-16 BCL2 apoptosis regulator Homo sapiens 24-29 8631771-9 1996 This region in Bax contains a stretch of 15 amino acids that is highly homologous in several members of the Bcl-2 protein family, suggesting the existence of a novel functional domain which we have termed BH3. BH 3 205-208 BCL2 apoptosis regulator Homo sapiens 108-113 8640809-0 1996 Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Paclitaxel 0-5 BCL2 apoptosis regulator Homo sapiens 14-19 8640809-1 1996 Treatment of prostate cancer cell lines expressing bcl-2 with taxol induces bcl-2 phosphorylation and programmed cell death, whereas treatment of bcl-2-negative prostate cancer cells with taxol does not induce apoptosis. Paclitaxel 62-67 BCL2 apoptosis regulator Homo sapiens 51-56 8640809-1 1996 Treatment of prostate cancer cell lines expressing bcl-2 with taxol induces bcl-2 phosphorylation and programmed cell death, whereas treatment of bcl-2-negative prostate cancer cells with taxol does not induce apoptosis. Paclitaxel 62-67 BCL2 apoptosis regulator Homo sapiens 76-81 8833328-2 1996 Here we demonstrate the quantitative control of the expression of the luciferase gene, dihydrofolate reductase gene, and bcl-2 gene in HeLa S3 or Chinese hamster ovary AA8 cells using the tetracycline-controlled gene expression system. Tetracycline 188-200 BCL2 apoptosis regulator Homo sapiens 121-126 8640809-1 1996 Treatment of prostate cancer cell lines expressing bcl-2 with taxol induces bcl-2 phosphorylation and programmed cell death, whereas treatment of bcl-2-negative prostate cancer cells with taxol does not induce apoptosis. Paclitaxel 62-67 BCL2 apoptosis regulator Homo sapiens 76-81 8640809-2 1996 bcl-2 phosphorylation seems to inhibit its binding to bax since less bax was observed in immunocomplex with bcl-2 in taxol-treated cancer cells. Paclitaxel 117-122 BCL2 apoptosis regulator Homo sapiens 0-5 8640809-2 1996 bcl-2 phosphorylation seems to inhibit its binding to bax since less bax was observed in immunocomplex with bcl-2 in taxol-treated cancer cells. Paclitaxel 117-122 BCL2 apoptosis regulator Homo sapiens 108-113 8640809-3 1996 These findings support the use of the anticancer drug taxol for the treatment of bcl-2-positive prostate cancers and other bcl-2-positive malignancies, such as follicular lymphoma. Paclitaxel 54-59 BCL2 apoptosis regulator Homo sapiens 81-86 8640809-3 1996 These findings support the use of the anticancer drug taxol for the treatment of bcl-2-positive prostate cancers and other bcl-2-positive malignancies, such as follicular lymphoma. Paclitaxel 54-59 BCL2 apoptosis regulator Homo sapiens 123-128 8695923-7 1996 Immunohistochemistry was performed with an anti-bcl-2 monoclonal antibody on paraffin sections. Paraffin 77-85 BCL2 apoptosis regulator Homo sapiens 48-53 8634443-5 1996 Furthermore, this spectral change was diminished in Bcl-2 overexpressing HL-60 cell cultures treated with doxorubicin, which were relatively resistant to apoptosis, as compared to apoptotic HL-60 cultures. Doxorubicin 106-117 BCL2 apoptosis regulator Homo sapiens 52-57 8600035-1 1996 The immunohistochemical expression of bcl-2 and p53 proteins was evaluated in formalin-fixed, paraffin-embedded surgical specimens from 212 patients with primary gastric lymphoma. Formaldehyde 78-86 BCL2 apoptosis regulator Homo sapiens 38-43 8838861-7 1996 The observed relationship between the down-regulation of Bcl-2 and induction of apoptosis was not causal because stable overexpression of Bcl-2 resulted in protection of MCF-7 cells from the cytotoxic morphological changes and growth-inhibitory effects of butyrate (15% growth inhibition compared to 60% growth inhibition in the parental cells). Butyrates 256-264 BCL2 apoptosis regulator Homo sapiens 138-143 8838861-8 1996 In addition, Bcl-2-overexpressing MCF-7 cells exhibited a significant suppression in butyrate-induced stimulation of apoptosis (5-fold increase in apoptosis compared to 27-fold in parental MCF-7 cells). Butyrates 85-93 BCL2 apoptosis regulator Homo sapiens 13-18 8838861-9 1996 These findings demonstrate that the levels of Bcl-2 expression regulate the butyrate-induced apoptosis in breast cancer cells and that butyrate may potentially be useful in sensitizing the breast cancer cells to chemotherapy-induced apoptosis. Butyrates 76-84 BCL2 apoptosis regulator Homo sapiens 46-51 9384686-11 1996 LMP expression provides resistance towards hydrocortisone-induced apoptosis in vitro, possible through upregulation of BCL-2. Hydrocortisone 43-57 BCL2 apoptosis regulator Homo sapiens 119-124 8838861-0 1996 Bcl-2 expression regulates sodium butyrate-induced apoptosis in human MCF-7 breast cancer cells. Butyric Acid 27-42 BCL2 apoptosis regulator Homo sapiens 0-5 8838861-6 1996 The butyrate-induced apoptosis in MCF-7 cells was closely linked with the down-regulation of expression of Bcl-2 mRNA and Bcl-2 protein, a gene product known to be involved in the regulation of apoptosis in mammalian cells. Butyrates 4-12 BCL2 apoptosis regulator Homo sapiens 107-112 8838861-6 1996 The butyrate-induced apoptosis in MCF-7 cells was closely linked with the down-regulation of expression of Bcl-2 mRNA and Bcl-2 protein, a gene product known to be involved in the regulation of apoptosis in mammalian cells. Butyrates 4-12 BCL2 apoptosis regulator Homo sapiens 122-127 8838861-7 1996 The observed relationship between the down-regulation of Bcl-2 and induction of apoptosis was not causal because stable overexpression of Bcl-2 resulted in protection of MCF-7 cells from the cytotoxic morphological changes and growth-inhibitory effects of butyrate (15% growth inhibition compared to 60% growth inhibition in the parental cells). Butyrates 256-264 BCL2 apoptosis regulator Homo sapiens 57-62 8600035-1 1996 The immunohistochemical expression of bcl-2 and p53 proteins was evaluated in formalin-fixed, paraffin-embedded surgical specimens from 212 patients with primary gastric lymphoma. Paraffin 94-102 BCL2 apoptosis regulator Homo sapiens 38-43 8622689-2 1996 To map the sequences in Bcl2 that are necessary for its activity, we created a library of deletion-scanning mutants of this 239-amino-acid protein and tested their abilities to block staurosporine-induced fibroblast apoptosis, using a novel transient-transfection assay. Staurosporine 183-196 BCL2 apoptosis regulator Homo sapiens 24-28 8596025-7 1996 Finally, cyclosporin A blocked both IL-2 secretion and bcl-2 induction in response to CD3 plus CD28 stimulation, suggesting a role for endogenous lymphokine production in the induction of bcl-2. Cyclosporine 9-22 BCL2 apoptosis regulator Homo sapiens 55-60 8596025-7 1996 Finally, cyclosporin A blocked both IL-2 secretion and bcl-2 induction in response to CD3 plus CD28 stimulation, suggesting a role for endogenous lymphokine production in the induction of bcl-2. Cyclosporine 9-22 BCL2 apoptosis regulator Homo sapiens 188-193 8642855-6 1996 We found that the half-life of bcl-2 protein is markedly shortened after treatment with ATRA. Tretinoin 88-92 BCL2 apoptosis regulator Homo sapiens 31-36 8622689-6 1996 The larger, more C-terminal region (within residues 90 to 203) encompassed, but extended beyond, two oligopeptide motifs called BH1 and BH2, which are known to mediate dimerization of Bcl2 and related proteins. bh1 128-131 BCL2 apoptosis regulator Homo sapiens 184-188 8622689-6 1996 The larger, more C-terminal region (within residues 90 to 203) encompassed, but extended beyond, two oligopeptide motifs called BH1 and BH2, which are known to mediate dimerization of Bcl2 and related proteins. bh2 136-139 BCL2 apoptosis regulator Homo sapiens 184-188 8635587-4 1996 We report here that apoptosis induced by PMA, sphingosine, and N,N-dimethylsphingosine (DMS) was accompanied by a concomitant decrease of bcl-2 expression in both RNA and protein levels in HL-60 cells, while expression of bcl-XL and bax mRNA did not change, and neither sphingosine nor DMS induced differentiation of HL-60 cells. N,N-dimethylsphingosine 63-86 BCL2 apoptosis regulator Homo sapiens 138-143 8882579-2 1996 Several authors have proposed that Bcl-2 is an antioxidant that suppresses the formation or action of reactive oxygen species (ROS) and in this way inhibits PCD. Reactive Oxygen Species 102-125 BCL2 apoptosis regulator Homo sapiens 35-40 8882579-2 1996 Several authors have proposed that Bcl-2 is an antioxidant that suppresses the formation or action of reactive oxygen species (ROS) and in this way inhibits PCD. Reactive Oxygen Species 127-130 BCL2 apoptosis regulator Homo sapiens 35-40 8882579-3 1996 However, three recent papers indicate that ROS are not required for PCD and that Bcl-2 can protect against cell death even under conditions where ROS are unlikely to be produced. Reactive Oxygen Species 146-149 BCL2 apoptosis regulator Homo sapiens 81-86 9816168-5 1996 The expression of bcl-2 was analyzed by immunohistochemistry on paraffin-embedded sections from 71 consecutive stage I-II SCCHN patients treated with curative RT. Paraffin 64-72 BCL2 apoptosis regulator Homo sapiens 18-23 8758442-3 1996 RESULTS: Temporary expression of antisense bcl-2 gene could effectively reduce levels of intrinsic bcl-2 protein of CEM cells and render it more sensitive to etoposide-induced cytotoxicity. Etoposide 158-167 BCL2 apoptosis regulator Homo sapiens 43-48 8758442-4 1996 Moreover, a great deal of apoptotic bodies and ladder DNA was always produced during etoposide-mediated killing of CEM and when CEM expressing bcl-2 antisense RNA served as target cells in particular, the amount of ladder DNA increased to around 40%. Etoposide 85-94 BCL2 apoptosis regulator Homo sapiens 143-148 8758442-5 1996 CONCLUSION: Programmed cell death is one of the mechanisms by which etoposide kills leukemic cells and is modulated by cellular intrinsic bcl-2 protein. Etoposide 68-77 BCL2 apoptosis regulator Homo sapiens 138-143 8635587-0 1996 Suppression of bcl-2 gene expression by sphingosine in the apoptosis of human leukemic HL-60 cells during phorbol ester-induced terminal differentiation. Sphingosine 40-51 BCL2 apoptosis regulator Homo sapiens 15-20 8635587-0 1996 Suppression of bcl-2 gene expression by sphingosine in the apoptosis of human leukemic HL-60 cells during phorbol ester-induced terminal differentiation. Phorbol Esters 106-119 BCL2 apoptosis regulator Homo sapiens 15-20 8635587-4 1996 We report here that apoptosis induced by PMA, sphingosine, and N,N-dimethylsphingosine (DMS) was accompanied by a concomitant decrease of bcl-2 expression in both RNA and protein levels in HL-60 cells, while expression of bcl-XL and bax mRNA did not change, and neither sphingosine nor DMS induced differentiation of HL-60 cells. Tetradecanoylphorbol Acetate 41-44 BCL2 apoptosis regulator Homo sapiens 138-143 8635587-4 1996 We report here that apoptosis induced by PMA, sphingosine, and N,N-dimethylsphingosine (DMS) was accompanied by a concomitant decrease of bcl-2 expression in both RNA and protein levels in HL-60 cells, while expression of bcl-XL and bax mRNA did not change, and neither sphingosine nor DMS induced differentiation of HL-60 cells. Sphingosine 46-57 BCL2 apoptosis regulator Homo sapiens 138-143 8635587-4 1996 We report here that apoptosis induced by PMA, sphingosine, and N,N-dimethylsphingosine (DMS) was accompanied by a concomitant decrease of bcl-2 expression in both RNA and protein levels in HL-60 cells, while expression of bcl-XL and bax mRNA did not change, and neither sphingosine nor DMS induced differentiation of HL-60 cells. N,N-dimethylsphingosine 88-91 BCL2 apoptosis regulator Homo sapiens 138-143 8635587-4 1996 We report here that apoptosis induced by PMA, sphingosine, and N,N-dimethylsphingosine (DMS) was accompanied by a concomitant decrease of bcl-2 expression in both RNA and protein levels in HL-60 cells, while expression of bcl-XL and bax mRNA did not change, and neither sphingosine nor DMS induced differentiation of HL-60 cells. Sphingosine 75-86 BCL2 apoptosis regulator Homo sapiens 138-143 8635587-4 1996 We report here that apoptosis induced by PMA, sphingosine, and N,N-dimethylsphingosine (DMS) was accompanied by a concomitant decrease of bcl-2 expression in both RNA and protein levels in HL-60 cells, while expression of bcl-XL and bax mRNA did not change, and neither sphingosine nor DMS induced differentiation of HL-60 cells. N,N-dimethylsphingosine 286-289 BCL2 apoptosis regulator Homo sapiens 138-143 8635587-5 1996 In contrast, in apoptotic cells induced by pharmaceutical PKC inhibitors H7 or staurosporine, expression of bcl-2 did not change nor did the intracellular sphingosine concentration. Staurosporine 79-92 BCL2 apoptosis regulator Homo sapiens 108-113 8635587-6 1996 These results suggest that sphingosine may function as an endogenous mediator of apoptotic signaling in PMA-induced terminal differentiation of HL-60 cells through bcl-2 down-regulation, probably independent from PKC inhibition. Sphingosine 27-38 BCL2 apoptosis regulator Homo sapiens 164-169 8551333-1 1996 Previous studies have demonstrated that overexpression of the proto-oncogene bcl-2 can protect neuron and neuron-like cell lines from growth factor deprivation, calcium ionophores, glutamate excitotoxicity, hypoglycemia, free radicals, and lipid peroxidation. Calcium 161-168 BCL2 apoptosis regulator Homo sapiens 77-82 8551333-1 1996 Previous studies have demonstrated that overexpression of the proto-oncogene bcl-2 can protect neuron and neuron-like cell lines from growth factor deprivation, calcium ionophores, glutamate excitotoxicity, hypoglycemia, free radicals, and lipid peroxidation. Glutamic Acid 181-190 BCL2 apoptosis regulator Homo sapiens 77-82 8551333-1 1996 Previous studies have demonstrated that overexpression of the proto-oncogene bcl-2 can protect neuron and neuron-like cell lines from growth factor deprivation, calcium ionophores, glutamate excitotoxicity, hypoglycemia, free radicals, and lipid peroxidation. free 221-225 BCL2 apoptosis regulator Homo sapiens 77-82 8551333-3 1996 Infection of hippocampal cultures with Bcl-2 vectors enhanced neuron survivorship after exposure to adriamycin, a potent oxygen radical generator. Doxorubicin 100-110 BCL2 apoptosis regulator Homo sapiens 39-44 8551333-3 1996 Infection of hippocampal cultures with Bcl-2 vectors enhanced neuron survivorship after exposure to adriamycin, a potent oxygen radical generator. Oxygen 121-127 BCL2 apoptosis regulator Homo sapiens 39-44 8551333-5 1996 Bcl-2 vectors also enhanced survival in cultured neurons after exposure to glutamate and hypoglycemia. Glutamic Acid 75-84 BCL2 apoptosis regulator Homo sapiens 0-5 8639245-4 1996 The capacity of oligodeoxynucleotides (ODN) to modulate gene expression specifically has been exploited to downregulate the overexpression of BCL-2 protein in the SU-DHL-4 human follicular B-cell lymphoma line by the use of sense ODN or antisense ODN or antisense ODN designed to encompass the unique nucleotide sequence in the fusion region of the hybrid transcript. Oligodeoxyribonucleotides 16-37 BCL2 apoptosis regulator Homo sapiens 142-147 8910675-4 1996 Four conserved domains are present in Bcl-2 and several of its homologs: BH1 (residues 136-155), BH2 (187-202), BH3 (93-107) and BH4 (10-30). bh1 73-76 BCL2 apoptosis regulator Homo sapiens 38-43 8910675-4 1996 Four conserved domains are present in Bcl-2 and several of its homologs: BH1 (residues 136-155), BH2 (187-202), BH3 (93-107) and BH4 (10-30). bh2 97-100 BCL2 apoptosis regulator Homo sapiens 38-43 8910675-4 1996 Four conserved domains are present in Bcl-2 and several of its homologs: BH1 (residues 136-155), BH2 (187-202), BH3 (93-107) and BH4 (10-30). BH 3 112-115 BCL2 apoptosis regulator Homo sapiens 38-43 8910675-4 1996 Four conserved domains are present in Bcl-2 and several of its homologs: BH1 (residues 136-155), BH2 (187-202), BH3 (93-107) and BH4 (10-30). sapropterin 129-132 BCL2 apoptosis regulator Homo sapiens 38-43 8910675-7 1996 Deletion of either BH1 or BH2 nullifies the ability of Bcl-2 to: (a) suppress death in mammalian cells: (b) block Bax-induced lethality in yeast; and (c) heterodimerize with Bax. bh1 19-22 BCL2 apoptosis regulator Homo sapiens 55-60 8910675-7 1996 Deletion of either BH1 or BH2 nullifies the ability of Bcl-2 to: (a) suppress death in mammalian cells: (b) block Bax-induced lethality in yeast; and (c) heterodimerize with Bax. bh2 26-29 BCL2 apoptosis regulator Homo sapiens 55-60 8910675-8 1996 In contrast, deletion of the BH4 domain of Bcl-2 nullifies anti-apoptotic function and homodimerization, but does not impair binding to the pro-apoptotic protein Bax. sapropterin 29-32 BCL2 apoptosis regulator Homo sapiens 43-48 8910675-10 1996 Homodimerization of Bcl-2 with itself involves a head-to-tail interaction, in which an N-terminal domain where BH4 resides interacts with the more distal region of Bcl-2 where BH1, BH2, and BH3 are located. sapropterin 111-114 BCL2 apoptosis regulator Homo sapiens 20-25 8910675-10 1996 Homodimerization of Bcl-2 with itself involves a head-to-tail interaction, in which an N-terminal domain where BH4 resides interacts with the more distal region of Bcl-2 where BH1, BH2, and BH3 are located. sapropterin 111-114 BCL2 apoptosis regulator Homo sapiens 164-169 8910675-10 1996 Homodimerization of Bcl-2 with itself involves a head-to-tail interaction, in which an N-terminal domain where BH4 resides interacts with the more distal region of Bcl-2 where BH1, BH2, and BH3 are located. bh1 176-179 BCL2 apoptosis regulator Homo sapiens 20-25 8910675-10 1996 Homodimerization of Bcl-2 with itself involves a head-to-tail interaction, in which an N-terminal domain where BH4 resides interacts with the more distal region of Bcl-2 where BH1, BH2, and BH3 are located. bh1 176-179 BCL2 apoptosis regulator Homo sapiens 164-169 8910675-10 1996 Homodimerization of Bcl-2 with itself involves a head-to-tail interaction, in which an N-terminal domain where BH4 resides interacts with the more distal region of Bcl-2 where BH1, BH2, and BH3 are located. bh2 181-184 BCL2 apoptosis regulator Homo sapiens 20-25 8910675-10 1996 Homodimerization of Bcl-2 with itself involves a head-to-tail interaction, in which an N-terminal domain where BH4 resides interacts with the more distal region of Bcl-2 where BH1, BH2, and BH3 are located. BH 3 190-193 BCL2 apoptosis regulator Homo sapiens 20-25 8910675-10 1996 Homodimerization of Bcl-2 with itself involves a head-to-tail interaction, in which an N-terminal domain where BH4 resides interacts with the more distal region of Bcl-2 where BH1, BH2, and BH3 are located. BH 3 190-193 BCL2 apoptosis regulator Homo sapiens 164-169 8639245-4 1996 The capacity of oligodeoxynucleotides (ODN) to modulate gene expression specifically has been exploited to downregulate the overexpression of BCL-2 protein in the SU-DHL-4 human follicular B-cell lymphoma line by the use of sense ODN or antisense ODN or antisense ODN designed to encompass the unique nucleotide sequence in the fusion region of the hybrid transcript. su-dhl-4 163-171 BCL2 apoptosis regulator Homo sapiens 142-147 8639245-4 1996 The capacity of oligodeoxynucleotides (ODN) to modulate gene expression specifically has been exploited to downregulate the overexpression of BCL-2 protein in the SU-DHL-4 human follicular B-cell lymphoma line by the use of sense ODN or antisense ODN or antisense ODN designed to encompass the unique nucleotide sequence in the fusion region of the hybrid transcript. Oligodeoxyribonucleotides 39-42 BCL2 apoptosis regulator Homo sapiens 142-147 17180067-0 1996 BCL-2 suppresses ceramide-induced cell killing. Ceramides 17-25 BCL2 apoptosis regulator Homo sapiens 0-5 8547651-13 1996 Thus bcl-2 protein expression, as demonstrated in routinely paraffin-embedded tissue, appears to be predictive of poor DFS, in agreement with the role of bcl-2 in chemotherapy-induced apoptosis. Paraffin 60-68 BCL2 apoptosis regulator Homo sapiens 5-10 8564847-6 1996 These results demonstrate that Bcl-2 is able to protect from in vivo Fas-mediated cytotoxicity, and could be of significance for preventing fulminant hepatic failure due to viral hepatitis in humans. ammonium ferrous sulfate 69-72 BCL2 apoptosis regulator Homo sapiens 31-36 8961379-5 1996 We conclude that bcl-2- B lymphocytes are submitted to antigen selection in the inflamed SMs while bcl-2 protein expression provides survival signals for their persistence in the infiltrates. Samarium 89-92 BCL2 apoptosis regulator Homo sapiens 17-22 8685041-2 1996 Expression of bcl-2 protein was analyzed in 54 cases of primary non-Hodgkin"s malignant lymphomas of the oral cavity by immunohistologic staining of paraffin-embedded tissue. Paraffin 149-157 BCL2 apoptosis regulator Homo sapiens 14-19 8788920-0 1995 1-methyl-4-phenyl-pyridinium ion (MPP+) causes DNA fragmentation and increases the Bcl-2 expression in human neuroblastoma, SH-SY5Y cells, through different mechanisms. 1-Methyl-4-phenylpyridinium 0-28 BCL2 apoptosis regulator Homo sapiens 83-88 8788920-0 1995 1-methyl-4-phenyl-pyridinium ion (MPP+) causes DNA fragmentation and increases the Bcl-2 expression in human neuroblastoma, SH-SY5Y cells, through different mechanisms. mangion-purified polysaccharide (Candida albicans) 34-37 BCL2 apoptosis regulator Homo sapiens 83-88 8788920-8 1995 A protein kinase inhibitor, staurosporine, inhibited the MPP(+)-induced increase in the Bcl-2 protein level, but not the MPP(+)-induced cell death. Staurosporine 28-41 BCL2 apoptosis regulator Homo sapiens 88-93 7585564-0 1995 Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7ras cells in vitro and in nude mice. phenylacetic acid 0-20 BCL2 apoptosis regulator Homo sapiens 51-56 21552969-5 1995 All 17 Bcl-2-positive carcinomas were resistant to doxorubicin (p=0.018; chi(2)-test). Doxorubicin 51-62 BCL2 apoptosis regulator Homo sapiens 7-12 8609716-7 1995 After incubation with ATRA, cell survival was not altered and was correlated with a concomitant absence of apoptosis, despite a significant decrease of the BcL-2 protein in APL differentiated cells. Tretinoin 22-26 BCL2 apoptosis regulator Homo sapiens 156-161 8750153-4 1995 PATIENTS AND METHODS: A series of 133 primary breast cancers was investigated for expression of the Bcl-2 protein by immunohistochemistry of paraffin-embedded tissue sections. Paraffin 141-149 BCL2 apoptosis regulator Homo sapiens 100-105 8750153-7 1995 High proliferative activity as assessed by Ki-67 staining correlated inversely with Bcl-2 expression (p < 0.001). ki-67 43-48 BCL2 apoptosis regulator Homo sapiens 84-89 7595537-0 1995 Bcl-2 protects neural cells from cyanide/aglycemia-induced lipid oxidation, mitochondrial injury, and loss of viability. Cyanides 33-40 BCL2 apoptosis regulator Homo sapiens 0-5 7585564-3 1995 Western blot analysis showed a Bcl-2 down-regulation after 48 h treatment with 5 mM NaPA, together with apparition of apoptotic nuclei by DAPI staining. Acecainide 84-88 BCL2 apoptosis regulator Homo sapiens 31-36 7592801-6 1995 In contrast, L-[35S]methionine pulse-chase analysis indicated a marked increase in the half-life (t1/2) of the p21Bax protein in BCL-2-transfected 697 cells compared to control-transfected cells (t1/2 > 24 h versus approximately 4 h), whereas the rate of Bax degradation was unaltered in Bcl-2-transfected CEM cells. L-Methionine-35S 13-30 BCL2 apoptosis regulator Homo sapiens 129-134 7585531-3 1995 We have constructed a HeLa S3 cell line in which the expression of bcl-2 can be controlled by the concentration of tetracycline in the medium. Tetracycline 115-127 BCL2 apoptosis regulator Homo sapiens 67-72 7585531-8 1995 Therefore, with aphidicolin treatment, cells were committed to the death program upstream of the point of Bcl-2 action. Aphidicolin 16-27 BCL2 apoptosis regulator Homo sapiens 106-111 8593745-9 1995 Bcl-2 can delay cell death caused by azide, and inhibit apoptotic changes seen by electron microscopy, but cannot prevent the eventual death of the cells. Azides 37-42 BCL2 apoptosis regulator Homo sapiens 0-5 9815937-2 1995 Recent studies have also shown that Taxol-induced apoptosis, but not Taxol-induced microtubular bundling or mitotic arrest, is significantly inhibited in cells that overexpress the bcl-2 gene product p26BCL-2. Paclitaxel 36-41 BCL2 apoptosis regulator Homo sapiens 181-186 9815937-3 1995 In the present studies we examined the effects of several modulators of activities of protein kinases on Taxol-induced DNA fragmentation and apoptosis in human pre-B leukemia 697 cells transfected with the cDNA of the bcl-2 gene and expressing high intracellular levels of p26BCL-2 (697/BCL-2 cells). Paclitaxel 105-110 BCL2 apoptosis regulator Homo sapiens 218-223 9815937-3 1995 In the present studies we examined the effects of several modulators of activities of protein kinases on Taxol-induced DNA fragmentation and apoptosis in human pre-B leukemia 697 cells transfected with the cDNA of the bcl-2 gene and expressing high intracellular levels of p26BCL-2 (697/BCL-2 cells). Paclitaxel 105-110 BCL2 apoptosis regulator Homo sapiens 276-281 7553653-6 1995 Marked induction of bcl-2 in NB cells followed RA-induced differentiation, whereas in cell lines failing to differentiate, bcl-2 was not detected. Tretinoin 47-49 BCL2 apoptosis regulator Homo sapiens 20-25 7595224-6 1995 We also report that, under conditions in which the morphological features of apoptosis were prevented (macromolecular synthesis inhibition, overexpression of Bcl-2 or Abl), the appearance of PS on the external leaflet of the PM was similarly prevented. Phosphatidylserines 191-193 BCL2 apoptosis regulator Homo sapiens 158-163 7472523-5 1995 When these mice were crossed with transgenic mice that overexpress human Bcl-2, there was a rescue of the facial motoneurons with a concomitant restoration of their normal soma size and expression of choline acetyltransferase. Choline 200-207 BCL2 apoptosis regulator Homo sapiens 73-78 7553620-6 1995 Overexpression of bcl-2 prevented free radical-induced apoptosis and induced a partially transformed phenotype in MCF10A cells. Free Radicals 34-46 BCL2 apoptosis regulator Homo sapiens 18-23 7564507-0 1995 Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the Ara-C sensitivity of leukemic stem cells. Tretinoin 68-81 BCL2 apoptosis regulator Homo sapiens 41-46 7671257-10 1995 The bcl-2-transfected clones were altered, however, with regard to their growth rate in charcoal-stripped serum lacking dihydrotestosterone. Dihydrotestosterone 120-139 BCL2 apoptosis regulator Homo sapiens 4-9 7671257-11 1995 Additionally, in contrast to the parental or control-transfected cell lines, LNCaP/bcl-2 cells were highly resistant to a variety of apoptotic stimuli in vitro including serum starvation and 10 nM phorbol ester (phorbol 12-myristate 13-acetate) supplementation of the medium. Phorbol Esters 197-210 BCL2 apoptosis regulator Homo sapiens 83-88 7671257-11 1995 Additionally, in contrast to the parental or control-transfected cell lines, LNCaP/bcl-2 cells were highly resistant to a variety of apoptotic stimuli in vitro including serum starvation and 10 nM phorbol ester (phorbol 12-myristate 13-acetate) supplementation of the medium. Tetradecanoylphorbol Acetate 212-243 BCL2 apoptosis regulator Homo sapiens 83-88 17180030-0 1995 Inhibition of ceramide-induced apoptosis by Bcl-2. Ceramides 14-22 BCL2 apoptosis regulator Homo sapiens 44-49 17180030-5 1995 Here we show that exposure to synthetic ceramides triggers apoptosis in the human T lymphoblastoid cell lines, CEM and Jurkat, and that overexpression of the apoptosis-repressor protein, Bcl-2, renders these cells resistant to the apoptosis-inducing effects of ceramide, as well as to several other stimuli. Ceramides 40-49 BCL2 apoptosis regulator Homo sapiens 187-192 17180030-5 1995 Here we show that exposure to synthetic ceramides triggers apoptosis in the human T lymphoblastoid cell lines, CEM and Jurkat, and that overexpression of the apoptosis-repressor protein, Bcl-2, renders these cells resistant to the apoptosis-inducing effects of ceramide, as well as to several other stimuli. Ceramides 40-48 BCL2 apoptosis regulator Homo sapiens 187-192 17180030-6 1995 Since exposure to ceramides can result in either cell proliferation, differentiation, cycle arrest, or death, the level of Bcl-2 expression in a cell may be an important factor in determining the outcome of signals that result in intracellular generation of this sphingolipid. Ceramides 18-27 BCL2 apoptosis regulator Homo sapiens 123-128 17180030-6 1995 Since exposure to ceramides can result in either cell proliferation, differentiation, cycle arrest, or death, the level of Bcl-2 expression in a cell may be an important factor in determining the outcome of signals that result in intracellular generation of this sphingolipid. Sphingolipids 263-275 BCL2 apoptosis regulator Homo sapiens 123-128 7474920-6 1995 We designed a novel digoxigenin-labeled oligonucleotide probe complementary to bcl-2 mRNA for nonisotopic in situ hybridization. Digoxigenin 20-31 BCL2 apoptosis regulator Homo sapiens 79-84 7474920-6 1995 We designed a novel digoxigenin-labeled oligonucleotide probe complementary to bcl-2 mRNA for nonisotopic in situ hybridization. Oligonucleotides 40-55 BCL2 apoptosis regulator Homo sapiens 79-84 7564507-0 1995 Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the Ara-C sensitivity of leukemic stem cells. Cytarabine 89-94 BCL2 apoptosis regulator Homo sapiens 41-46 7564507-6 1995 Lines with sense-oriented transfected bcl-2 were significantly less sensitive to Ara-C or H2O2 than the parental lines; the cells with anti-sense transfected genes were more sensitive than their parent but the difference did not reach statistical significance. Cytarabine 81-86 BCL2 apoptosis regulator Homo sapiens 38-43 7564507-6 1995 Lines with sense-oriented transfected bcl-2 were significantly less sensitive to Ara-C or H2O2 than the parental lines; the cells with anti-sense transfected genes were more sensitive than their parent but the difference did not reach statistical significance. Hydrogen Peroxide 90-94 BCL2 apoptosis regulator Homo sapiens 38-43 7564507-7 1995 The effect of ATRA on bcl-2 expression was compared in sense-transfected cells and their parents; by Northern blotting it was shown that the endogenous but not the transfected genes were down-regulated after ATRA exposure. Tretinoin 14-18 BCL2 apoptosis regulator Homo sapiens 22-27 7564507-7 1995 The effect of ATRA on bcl-2 expression was compared in sense-transfected cells and their parents; by Northern blotting it was shown that the endogenous but not the transfected genes were down-regulated after ATRA exposure. Tretinoin 208-212 BCL2 apoptosis regulator Homo sapiens 22-27 7564507-10 1995 We conclude that data from the transfectants provides evidence that expression of bcl-2 is a determinant of sensitivity to Ara-C and H2O2; and that the effect of ATRA on sensitivity requires the presence of bcl-2 genes in association with regulatory elements. Cytarabine 123-128 BCL2 apoptosis regulator Homo sapiens 82-87 8552577-5 1995 Thirty-six esophageal resection specimens were studied, using a monoclonal antibody to the bcl-2 protein on fixed paraffin-embedded specimens. Paraffin 114-122 BCL2 apoptosis regulator Homo sapiens 91-96 7564507-10 1995 We conclude that data from the transfectants provides evidence that expression of bcl-2 is a determinant of sensitivity to Ara-C and H2O2; and that the effect of ATRA on sensitivity requires the presence of bcl-2 genes in association with regulatory elements. Hydrogen Peroxide 133-137 BCL2 apoptosis regulator Homo sapiens 82-87 7564507-10 1995 We conclude that data from the transfectants provides evidence that expression of bcl-2 is a determinant of sensitivity to Ara-C and H2O2; and that the effect of ATRA on sensitivity requires the presence of bcl-2 genes in association with regulatory elements. Tretinoin 162-166 BCL2 apoptosis regulator Homo sapiens 207-212 7544648-7 1995 High bcl-2 expression was found in KMS12PE, which showed resistance to Fas-mediated apoptosis despite its Fas expression. ammonium ferrous sulfate 71-74 BCL2 apoptosis regulator Homo sapiens 5-10 7545682-2 1995 Inhibition of Fas-induced cell death by the bcl-2 oncogene has been demonstrated to be only partial. ammonium ferrous sulfate 14-17 BCL2 apoptosis regulator Homo sapiens 44-49 7488387-1 1995 The distribution of Bcl-2 oncoprotein was studied immunohistochemically in formaldehyde-fixed and paraffin-embedded reactive and neoplastic lymphoid tissue. Formaldehyde 75-87 BCL2 apoptosis regulator Homo sapiens 20-25 7488387-1 1995 The distribution of Bcl-2 oncoprotein was studied immunohistochemically in formaldehyde-fixed and paraffin-embedded reactive and neoplastic lymphoid tissue. Paraffin 98-106 BCL2 apoptosis regulator Homo sapiens 20-25 8520001-4 1995 The expression of bcl-2 protein was evaluated using an immunoalkaline phosphatase technique in 54 pre-operative breast cancer aspirates and in paraffin-embedded sections from 20 matched surgical specimens. Paraffin 143-151 BCL2 apoptosis regulator Homo sapiens 18-23 7641210-10 1995 In the absence of estrogen, MCF-7 cells transfected with Bcl-2 expression plasmids display a marked increase in resistance to Adriamycin. Doxorubicin 126-136 BCL2 apoptosis regulator Homo sapiens 57-62 7641210-11 1995 In the presence of estrogen, MCF-7 cells expressing Bcl-2 antisense transcripts are rendered twice as sensitive to acute Adriamycin cytotoxicity as a control clone. Doxorubicin 121-131 BCL2 apoptosis regulator Homo sapiens 52-57 7557262-4 1995 Inhibition by PKC of store-operated calcium entry mechanisms, which are sensitive to the oncoprotein bcl-2, should block the activation of calcium-dependent enzymes triggering the apoptotic cell death. Calcium 36-43 BCL2 apoptosis regulator Homo sapiens 101-106 7557262-4 1995 Inhibition by PKC of store-operated calcium entry mechanisms, which are sensitive to the oncoprotein bcl-2, should block the activation of calcium-dependent enzymes triggering the apoptotic cell death. Calcium 139-146 BCL2 apoptosis regulator Homo sapiens 101-106 8522289-3 1995 Expression of bcl-2 protein was analysed in 30 cases of thymoma by immunohistological staining of paraffin-embedded tissue. Paraffin 98-106 BCL2 apoptosis regulator Homo sapiens 14-19 7660512-13 1995 CONCLUSIONS: These results suggest that azatyrosine inhibits prostate tumorigenic growth; it has a high reversion efficiency on human prostate cancer cells; and the K-rev-1 suppressor gene and the bcl-2 proto-oncogene could be potentially involved in the reversion mechanism mediated by azatyrosine. beta-(5-hydroxy-2-pyridyl)alanine 40-51 BCL2 apoptosis regulator Homo sapiens 197-202 7660512-13 1995 CONCLUSIONS: These results suggest that azatyrosine inhibits prostate tumorigenic growth; it has a high reversion efficiency on human prostate cancer cells; and the K-rev-1 suppressor gene and the bcl-2 proto-oncogene could be potentially involved in the reversion mechanism mediated by azatyrosine. beta-(5-hydroxy-2-pyridyl)alanine 287-298 BCL2 apoptosis regulator Homo sapiens 197-202 7632063-7 1995 Routine paraffin sections of formalin-fixed tissue were labeled with anti-bcl-2 monoclonal antibody, and expression of bcl-2 was detected by a biotin-avidin-immunoperoxidase procedure. Biotin 143-149 BCL2 apoptosis regulator Homo sapiens 119-124 17180041-4 1995 Secondly, we demonstrate that apoptosis in this model is amenable to modulation by exogenous factors present in the culture medium, such as phorbol ester, and by tranfected genes, as shown by overexpression of bcl-2. Phorbol Esters 140-153 BCL2 apoptosis regulator Homo sapiens 210-215 7629499-10 1995 Transfection with the antiapoptotic protooncogene Bcl-2 simultaneously inhibits mitochondrial alterations and apoptotic cell death triggered by steroids or ceramide. Steroids 144-152 BCL2 apoptosis regulator Homo sapiens 50-55 7629499-10 1995 Transfection with the antiapoptotic protooncogene Bcl-2 simultaneously inhibits mitochondrial alterations and apoptotic cell death triggered by steroids or ceramide. Ceramides 156-164 BCL2 apoptosis regulator Homo sapiens 50-55 7658701-5 1995 Northern blot analysis revealed that the levels of expression of the c-myc and bcl-2 genes in HL60 cells decreased with time after treatment with bufalin. bufalin 146-153 BCL2 apoptosis regulator Homo sapiens 79-84 7795258-4 1995 Downregulation of protein kinase (PK) by a 24-hour incubation in 100 nmol/L 12-O-tetradecanoyl-phorbol-13-acetate (TPA) in the presence of IL-3 dramatically reduced bcl-2 mRNA levels, and induced apoptosis in the presence of IL-3. Tetradecanoylphorbol Acetate 76-113 BCL2 apoptosis regulator Homo sapiens 165-170 7795258-4 1995 Downregulation of protein kinase (PK) by a 24-hour incubation in 100 nmol/L 12-O-tetradecanoyl-phorbol-13-acetate (TPA) in the presence of IL-3 dramatically reduced bcl-2 mRNA levels, and induced apoptosis in the presence of IL-3. Tetradecanoylphorbol Acetate 115-118 BCL2 apoptosis regulator Homo sapiens 165-170 7795258-5 1995 We have also found that even in the presence of IL-3, two inhibitors of PKC, light-activated calphostin and H-7, substantially reduced the levels of bcl-2 mRNA between 8 and 24 hours as measured by a semi-quantitative reverse transcriptase/polymerase chain reaction assay method; however, the cyclic nucleotide-dependent PK inhibitor HA 1004, that is a structural analog of H-7 but a poor inhibitor of PKC, did not reduce bcl-2 levels in the presence of IL-3. Nucleotides, Cyclic 293-310 BCL2 apoptosis regulator Homo sapiens 149-154 7780952-2 1995 We found that the bcl-2 mRNA levels in the cells exposed to 17 beta-estradiol were higher than those of control cells. Estradiol 63-77 BCL2 apoptosis regulator Homo sapiens 18-23 7558935-6 1995 Interestingly, IL-7 inhibited the downregulation of bcl-2 gene product expression that appeared on TCCs after IL-2 withdrawal and also shared with IL-2 the ability to induce the upregulation of CD25 antigen on activated T lymphocytes in the presence of DEX. Dextromethorphan 253-256 BCL2 apoptosis regulator Homo sapiens 52-57 7630193-10 1995 NB4 cells treated with either all-trans or 9-cis retinoic acid (1 microM) were induced to differentiate and the level of Bcl-2 protein decreased to undetectable levels during terminal maturation when only a few apoptotic cells were detected. Tretinoin 49-62 BCL2 apoptosis regulator Homo sapiens 121-126 7630193-11 1995 In NB4-R1 cells, while treatment with retinoids does not induce maturation, as much as 64% of cells became apoptotic, and immunocytological labelling of NB4-R1 showed a strong cytoplasmic labelling of Bcl-2. Retinoids 38-47 BCL2 apoptosis regulator Homo sapiens 201-206 7541577-0 1995 Implication of cyclosporine in up-regulation of Bcl-2 expression and maintenance of CD8 lymphocytosis in cytomegalovirus-infected allograft recipients. Cyclosporine 15-27 BCL2 apoptosis regulator Homo sapiens 48-53 7541577-8 1995 Conversely, we showed that overexpression of Bcl-2 protein in lymphocytes from uninfected allograft recipients, and culture of unstimulated normal lymphocytes with 0.5 micrograms/ml cyclosporine led to an increase in the expression of intracellular Bcl-2. Cyclosporine 182-194 BCL2 apoptosis regulator Homo sapiens 45-50 7541577-8 1995 Conversely, we showed that overexpression of Bcl-2 protein in lymphocytes from uninfected allograft recipients, and culture of unstimulated normal lymphocytes with 0.5 micrograms/ml cyclosporine led to an increase in the expression of intracellular Bcl-2. Cyclosporine 182-194 BCL2 apoptosis regulator Homo sapiens 249-254 7541577-9 1995 This up-regulation of Bcl-2 protein by cyclosporine suggests the acquisition of resistance to apoptosis. Cyclosporine 39-51 BCL2 apoptosis regulator Homo sapiens 22-27 7780971-7 1995 Bcl-2 expression was restricted to cells of chromaffin lineage, whereas Bcl-xL was seen in both chromaffin and nonchromaffin lines. chromaffin 44-54 BCL2 apoptosis regulator Homo sapiens 0-5 7670136-0 1995 The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. bryostatin 1 51-63 BCL2 apoptosis regulator Homo sapiens 4-9 7540278-10 1995 These data suggest an involvement of PLA2 in both TNF- and Fas-mediated cytotoxicity and a novel mechanism of action for bcl-2 and bcl-x, i.e. inhibition of arachidonic acid metabolism, by which they may, in addition of apoptosis, modulate inflammation. Arachidonic Acid 157-173 BCL2 apoptosis regulator Homo sapiens 121-126 7670136-0 1995 The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. dolastatins 68-79 BCL2 apoptosis regulator Homo sapiens 4-9 7669718-0 1995 Regulation of bcl-2, bcl-XL and bax in the control of apoptosis by hematopoietic cytokines and dexamethasone. Dexamethasone 95-108 BCL2 apoptosis regulator Homo sapiens 14-19 7669718-1 1995 Treatment of M1 myeloid leukemic cells with interleukin 6 (IL-6) or dexamethasone (DEX), both of which induce differentiation in these cells, down-regulated expression of the apoptosis-suppressing gene bcl-2 and the apoptosis-promoting gene bax but up-regulated expression of the apoptosis-suppressing gene bcl-XL. Dexamethasone 68-81 BCL2 apoptosis regulator Homo sapiens 202-207 7669718-1 1995 Treatment of M1 myeloid leukemic cells with interleukin 6 (IL-6) or dexamethasone (DEX), both of which induce differentiation in these cells, down-regulated expression of the apoptosis-suppressing gene bcl-2 and the apoptosis-promoting gene bax but up-regulated expression of the apoptosis-suppressing gene bcl-XL. Dexamethasone 83-86 BCL2 apoptosis regulator Homo sapiens 202-207 7669718-6 1995 Another myeloid leukemia that shows barely detectable expression of bcl-2 also showed up-regulated expression of bcl-XL but no change in bax after induction of differentiation with granulocyte-macrophage colony-stimulating factor, and this reduced cell susceptibility to induction of apoptosis by Adriamycin or cycloheximide. Doxorubicin 297-307 BCL2 apoptosis regulator Homo sapiens 68-73 7669718-6 1995 Another myeloid leukemia that shows barely detectable expression of bcl-2 also showed up-regulated expression of bcl-XL but no change in bax after induction of differentiation with granulocyte-macrophage colony-stimulating factor, and this reduced cell susceptibility to induction of apoptosis by Adriamycin or cycloheximide. Cycloheximide 311-324 BCL2 apoptosis regulator Homo sapiens 68-73 7747803-5 1995 Only faint Bcl-2 staining was detected in cultured keratinocytes exposed to IFN-gamma and TPA compared with the prominent expression of Bcl-x. Tetradecanoylphorbol Acetate 90-93 BCL2 apoptosis regulator Homo sapiens 11-16 7664626-11 1995 We conclude that optimal bcl-2 analysis is achieved using ethanol fixation and that flow cytometry provides a rapid and reliable technique for the measurement of these parameters. Ethanol 58-65 BCL2 apoptosis regulator Homo sapiens 25-30 7753834-2 1995 Using the phosphatase inhibitor okadaic acid or the chemotherapeutic drug taxol, we found that Bcl-2 was phosphorylated in lymphoid cells. Okadaic Acid 32-44 BCL2 apoptosis regulator Homo sapiens 95-100 7753834-2 1995 Using the phosphatase inhibitor okadaic acid or the chemotherapeutic drug taxol, we found that Bcl-2 was phosphorylated in lymphoid cells. Paclitaxel 74-79 BCL2 apoptosis regulator Homo sapiens 95-100 7753834-3 1995 Phospho amino acid analysis revealed that Bcl-2 was phosphorylated on serine. Serine 70-76 BCL2 apoptosis regulator Homo sapiens 42-47 7539458-5 1995 Forced expression of bcl-2 also attenuated TNF alpha-mediated cytotoxicity of glioma cell lines in the presence of actinomycin D and cycloheximide and conferred partial protection from irradiation and the cancer chemotherapy drugs, cisplatin and BCNU. Dactinomycin 115-128 BCL2 apoptosis regulator Homo sapiens 21-26 7539458-5 1995 Forced expression of bcl-2 also attenuated TNF alpha-mediated cytotoxicity of glioma cell lines in the presence of actinomycin D and cycloheximide and conferred partial protection from irradiation and the cancer chemotherapy drugs, cisplatin and BCNU. Cycloheximide 133-146 BCL2 apoptosis regulator Homo sapiens 21-26 7539458-5 1995 Forced expression of bcl-2 also attenuated TNF alpha-mediated cytotoxicity of glioma cell lines in the presence of actinomycin D and cycloheximide and conferred partial protection from irradiation and the cancer chemotherapy drugs, cisplatin and BCNU. Cisplatin 232-241 BCL2 apoptosis regulator Homo sapiens 21-26 7539458-5 1995 Forced expression of bcl-2 also attenuated TNF alpha-mediated cytotoxicity of glioma cell lines in the presence of actinomycin D and cycloheximide and conferred partial protection from irradiation and the cancer chemotherapy drugs, cisplatin and BCNU. Carmustine 246-250 BCL2 apoptosis regulator Homo sapiens 21-26 7742543-2 1995 Here we show that topotecan stabilizes topoisomerase I/DNA cleavable complexes in radiation-resistant human B-lineage acute lymphoblastic leukemia (ALL) cells, causes rapid apoptotic cell death despite high-level expression of bcl-2 protein, and inhibits ALL cell in vitro clonogenic growth in a dose-dependent fashion. Topotecan 18-27 BCL2 apoptosis regulator Homo sapiens 227-232 7769841-4 1995 Exposure of OCI/AML-2 or OCI/AML-5 cells to retinoic acid (all-trans retinoic acid, ATRA) led to a down-regulation of bcl-2 expression that was first seen after 2 h of exposure and was complete after a day. oci 12-15 BCL2 apoptosis regulator Homo sapiens 118-123 7720813-5 1995 Iron-deprivation produced a small increase in the endogenous expression of bcl-2 protein. Iron 0-4 BCL2 apoptosis regulator Homo sapiens 75-80 7769841-16 1995 Left unexplained are the action of HC, which does not affect bcl-2 expression and the mechanism by which ara-C prevents down-regulation of bcl-2 by ATRA. Tretinoin 148-152 BCL2 apoptosis regulator Homo sapiens 139-144 7769841-4 1995 Exposure of OCI/AML-2 or OCI/AML-5 cells to retinoic acid (all-trans retinoic acid, ATRA) led to a down-regulation of bcl-2 expression that was first seen after 2 h of exposure and was complete after a day. oci 25-28 BCL2 apoptosis regulator Homo sapiens 118-123 7769841-4 1995 Exposure of OCI/AML-2 or OCI/AML-5 cells to retinoic acid (all-trans retinoic acid, ATRA) led to a down-regulation of bcl-2 expression that was first seen after 2 h of exposure and was complete after a day. Tretinoin 44-57 BCL2 apoptosis regulator Homo sapiens 118-123 7769841-4 1995 Exposure of OCI/AML-2 or OCI/AML-5 cells to retinoic acid (all-trans retinoic acid, ATRA) led to a down-regulation of bcl-2 expression that was first seen after 2 h of exposure and was complete after a day. Tretinoin 59-82 BCL2 apoptosis regulator Homo sapiens 118-123 7769841-4 1995 Exposure of OCI/AML-2 or OCI/AML-5 cells to retinoic acid (all-trans retinoic acid, ATRA) led to a down-regulation of bcl-2 expression that was first seen after 2 h of exposure and was complete after a day. Tretinoin 84-88 BCL2 apoptosis regulator Homo sapiens 118-123 7769841-5 1995 The down-regulation could be prevented by exposing the cells to ara-C either before or after ATRA; decrease in bcl-2 protein was moderate and only obvious after 36 h of ATRA treatment. Cytarabine 64-69 BCL2 apoptosis regulator Homo sapiens 111-116 7769841-5 1995 The down-regulation could be prevented by exposing the cells to ara-C either before or after ATRA; decrease in bcl-2 protein was moderate and only obvious after 36 h of ATRA treatment. Tretinoin 93-97 BCL2 apoptosis regulator Homo sapiens 111-116 7769841-5 1995 The down-regulation could be prevented by exposing the cells to ara-C either before or after ATRA; decrease in bcl-2 protein was moderate and only obvious after 36 h of ATRA treatment. Tretinoin 169-173 BCL2 apoptosis regulator Homo sapiens 111-116 7769841-15 1995 ATRA regulates ara-C toxicity by its action on bcl-2. Tretinoin 0-4 BCL2 apoptosis regulator Homo sapiens 47-52 7739519-4 1995 Finally, overexpression of bcl-2 or crmA conferred resistance to apoptosis mediated by TNF-alpha, as did the addition of the antioxidant N-acetylcysteine. Acetylcysteine 137-153 BCL2 apoptosis regulator Homo sapiens 27-32 7769841-16 1995 Left unexplained are the action of HC, which does not affect bcl-2 expression and the mechanism by which ara-C prevents down-regulation of bcl-2 by ATRA. Cytarabine 105-110 BCL2 apoptosis regulator Homo sapiens 139-144 7536895-0 1995 Programmed cell death and Bcl-2 protection in very low oxygen. Oxygen 55-61 BCL2 apoptosis regulator Homo sapiens 26-31 7536895-3 1995 It has been suggested that PCD involves the generation of reactive oxygen species (ROS) and that Bcl-2 protects against PCD by inhibiting the generation or action of ROS. Reactive Oxygen Species 166-169 BCL2 apoptosis regulator Homo sapiens 97-102 7547679-4 1995 The increase of Bcl-2 expression induced by TNF-alpha was inhibited by chelerythrine, a specific inhibitor of protein kinase C (PKC), suggesting that Bcl-2 expression was dependent on PKC activation. chelerythrine 71-84 BCL2 apoptosis regulator Homo sapiens 16-21 7723826-3 1995 Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS), expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia), which drastically decreases the net formation of oxygen free radicals and does not increase oxidized lipid, protein or DNA. Reactive Oxygen Species 71-94 BCL2 apoptosis regulator Homo sapiens 53-58 7723826-3 1995 Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS), expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia), which drastically decreases the net formation of oxygen free radicals and does not increase oxidized lipid, protein or DNA. Reactive Oxygen Species 71-94 BCL2 apoptosis regulator Homo sapiens 116-121 7723826-3 1995 Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS), expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia), which drastically decreases the net formation of oxygen free radicals and does not increase oxidized lipid, protein or DNA. Reactive Oxygen Species 96-99 BCL2 apoptosis regulator Homo sapiens 53-58 7723826-3 1995 Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS), expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia), which drastically decreases the net formation of oxygen free radicals and does not increase oxidized lipid, protein or DNA. Reactive Oxygen Species 96-99 BCL2 apoptosis regulator Homo sapiens 116-121 7723826-3 1995 Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS), expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia), which drastically decreases the net formation of oxygen free radicals and does not increase oxidized lipid, protein or DNA. Oxygen 80-86 BCL2 apoptosis regulator Homo sapiens 53-58 7723826-3 1995 Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS), expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia), which drastically decreases the net formation of oxygen free radicals and does not increase oxidized lipid, protein or DNA. Oxygen 80-86 BCL2 apoptosis regulator Homo sapiens 116-121 7723826-3 1995 Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS), expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia), which drastically decreases the net formation of oxygen free radicals and does not increase oxidized lipid, protein or DNA. oxygen free radicals 244-264 BCL2 apoptosis regulator Homo sapiens 116-121 7547679-6 1995 The effect of CsA on Bcl-2 expression is controlled by calcineurin since we have shown that FK506 but not rapamycin had the same effect on Bcl-2 expression, whereas okadaic acid, an inhibitor of phosphatases 1, 2A and 2C, was ineffective. Okadaic Acid 165-177 BCL2 apoptosis regulator Homo sapiens 21-26 7547679-4 1995 The increase of Bcl-2 expression induced by TNF-alpha was inhibited by chelerythrine, a specific inhibitor of protein kinase C (PKC), suggesting that Bcl-2 expression was dependent on PKC activation. chelerythrine 71-84 BCL2 apoptosis regulator Homo sapiens 150-155 7547679-5 1995 Furthermore, we show that phorbol esters and cyclosporin A (CsA), which prevent Ca(2+)-dependent apoptosis, up-regulated Bcl-2 expression. Phorbol Esters 26-40 BCL2 apoptosis regulator Homo sapiens 121-126 7547679-5 1995 Furthermore, we show that phorbol esters and cyclosporin A (CsA), which prevent Ca(2+)-dependent apoptosis, up-regulated Bcl-2 expression. Cyclosporine 60-63 BCL2 apoptosis regulator Homo sapiens 121-126 7547679-6 1995 The effect of CsA on Bcl-2 expression is controlled by calcineurin since we have shown that FK506 but not rapamycin had the same effect on Bcl-2 expression, whereas okadaic acid, an inhibitor of phosphatases 1, 2A and 2C, was ineffective. Cyclosporine 14-17 BCL2 apoptosis regulator Homo sapiens 21-26 7547679-6 1995 The effect of CsA on Bcl-2 expression is controlled by calcineurin since we have shown that FK506 but not rapamycin had the same effect on Bcl-2 expression, whereas okadaic acid, an inhibitor of phosphatases 1, 2A and 2C, was ineffective. Cyclosporine 14-17 BCL2 apoptosis regulator Homo sapiens 139-144 7547679-6 1995 The effect of CsA on Bcl-2 expression is controlled by calcineurin since we have shown that FK506 but not rapamycin had the same effect on Bcl-2 expression, whereas okadaic acid, an inhibitor of phosphatases 1, 2A and 2C, was ineffective. Tacrolimus 92-97 BCL2 apoptosis regulator Homo sapiens 21-26 7547679-6 1995 The effect of CsA on Bcl-2 expression is controlled by calcineurin since we have shown that FK506 but not rapamycin had the same effect on Bcl-2 expression, whereas okadaic acid, an inhibitor of phosphatases 1, 2A and 2C, was ineffective. Tacrolimus 92-97 BCL2 apoptosis regulator Homo sapiens 139-144 7790991-2 1995 Expression of the bcl-2 protein within the Hodgkin and Reed-Sternberg (HRS) cells was investigated in 86 cases of HD by immunohistochemistry on cryostat or paraffin sections. Paraffin 156-164 BCL2 apoptosis regulator Homo sapiens 18-23 7706495-0 1995 Splenic B lymphocyte programmed cell death is prevented by nitric oxide release through mechanisms involving sustained Bcl-2 levels. Nitric Oxide 59-71 BCL2 apoptosis regulator Homo sapiens 119-124 7706495-4 1995 Regarding the mechanisms by which nitric oxide prevents apoptosis in B cells, we have observed that nitric oxide release prevents the drop in the expression of the protooncogene bcl-2, both at the mRNA and protein levels, suggesting the existence of an unknown pathway that links nitric oxide signaling with Bcl-2 expression. Nitric Oxide 34-46 BCL2 apoptosis regulator Homo sapiens 178-183 7706495-4 1995 Regarding the mechanisms by which nitric oxide prevents apoptosis in B cells, we have observed that nitric oxide release prevents the drop in the expression of the protooncogene bcl-2, both at the mRNA and protein levels, suggesting the existence of an unknown pathway that links nitric oxide signaling with Bcl-2 expression. Nitric Oxide 34-46 BCL2 apoptosis regulator Homo sapiens 308-313 7706495-4 1995 Regarding the mechanisms by which nitric oxide prevents apoptosis in B cells, we have observed that nitric oxide release prevents the drop in the expression of the protooncogene bcl-2, both at the mRNA and protein levels, suggesting the existence of an unknown pathway that links nitric oxide signaling with Bcl-2 expression. Nitric Oxide 100-112 BCL2 apoptosis regulator Homo sapiens 178-183 7706495-4 1995 Regarding the mechanisms by which nitric oxide prevents apoptosis in B cells, we have observed that nitric oxide release prevents the drop in the expression of the protooncogene bcl-2, both at the mRNA and protein levels, suggesting the existence of an unknown pathway that links nitric oxide signaling with Bcl-2 expression. Nitric Oxide 100-112 BCL2 apoptosis regulator Homo sapiens 308-313 7706495-4 1995 Regarding the mechanisms by which nitric oxide prevents apoptosis in B cells, we have observed that nitric oxide release prevents the drop in the expression of the protooncogene bcl-2, both at the mRNA and protein levels, suggesting the existence of an unknown pathway that links nitric oxide signaling with Bcl-2 expression. Nitric Oxide 100-112 BCL2 apoptosis regulator Homo sapiens 178-183 7706495-4 1995 Regarding the mechanisms by which nitric oxide prevents apoptosis in B cells, we have observed that nitric oxide release prevents the drop in the expression of the protooncogene bcl-2, both at the mRNA and protein levels, suggesting the existence of an unknown pathway that links nitric oxide signaling with Bcl-2 expression. Nitric Oxide 100-112 BCL2 apoptosis regulator Homo sapiens 308-313 7867010-0 1995 Suppression of Bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor alpha, and ceramide. Ceramides 127-135 BCL2 apoptosis regulator Homo sapiens 15-20 7887447-4 1995 Bcl-2+ epidermal cells also reacted with the monoclonal anti-melanocyte antibody NKI/beteb, and were absent from lesional skin in vitiligo, confirming that they represented epidermal melanocytes. beteb 85-90 BCL2 apoptosis regulator Homo sapiens 0-5 7867010-4 1995 Apoptotic DNA fragmentation after exposure to TNF-alpha and C2-ceramide was also associated with down-regulation of Bcl-2 mRNA in HL-60 and U-937 cells, while Bcl-X mRNA production was unaffected. N-acetylsphingosine 60-71 BCL2 apoptosis regulator Homo sapiens 116-121 7867010-5 1995 These results suggest that modulation of Bcl-2 gene expression may be a target for ceramide-mediated apoptosis following exposure to ionizing radiation and TNF-alpha. Ceramides 83-91 BCL2 apoptosis regulator Homo sapiens 41-46 7867011-2 1995 Furthermore, it has been proposed that Bcl-2 acts to inhibit apoptosis induced by a wide variety of stimuli by preventing the production of oxygen-derived free radicals. oxygen-derived free radicals 140-168 BCL2 apoptosis regulator Homo sapiens 39-44 7695015-4 1995 In this study, we analyzed bcl-2 protein expression in cutaneous malignant melanoma (MM) (29 cases) and benign melanocytic nevi (BMN) (35 cases) using a high specific anti-bcl-2 monoclonal antibody with a standard three-step immunoperoxidase technique on formalin-fixed, paraffin-embedded tissue sections. Formaldehyde 255-263 BCL2 apoptosis regulator Homo sapiens 27-32 7532659-4 1995 Bcl-2 in target cells blocked apoptotic cell death induced either by cytotoxic granule extracts or by CTL killing under conditions in which the fas pathway is blocked. ammonium ferrous sulfate 144-147 BCL2 apoptosis regulator Homo sapiens 0-5 7782105-5 1995 Further changes evoked by enhanced ammonia concentration were 5) an accumulation of lipofuscin-like material ("fatty degeneration") revealed by lipophilic stain, 6) reduced immunoreactivity for cathepsin D, and increased immunoreactivity for 7) glial fibrillary acidic protein, 8) glutamine synthetase, and 9) bcl-2 protooncogene protein. Ammonia 35-42 BCL2 apoptosis regulator Homo sapiens 310-315 7896880-8 1995 Overall, the mcl-1 and bcl-2 proteins have some properties in common and others tht are distinct. tetrahydrothiophene 80-83 BCL2 apoptosis regulator Homo sapiens 23-28 7850782-7 1995 The interaction between androgen and etoposide was mediated through the BCL-2 protein, since bcl-2 antisense oligonucleotides blocked the protective effect of androgens on etoposide cytotoxicity. Etoposide 37-46 BCL2 apoptosis regulator Homo sapiens 72-77 7850782-7 1995 The interaction between androgen and etoposide was mediated through the BCL-2 protein, since bcl-2 antisense oligonucleotides blocked the protective effect of androgens on etoposide cytotoxicity. Etoposide 37-46 BCL2 apoptosis regulator Homo sapiens 93-98 7850782-7 1995 The interaction between androgen and etoposide was mediated through the BCL-2 protein, since bcl-2 antisense oligonucleotides blocked the protective effect of androgens on etoposide cytotoxicity. Oligonucleotides 109-125 BCL2 apoptosis regulator Homo sapiens 72-77 7850782-7 1995 The interaction between androgen and etoposide was mediated through the BCL-2 protein, since bcl-2 antisense oligonucleotides blocked the protective effect of androgens on etoposide cytotoxicity. Oligonucleotides 109-125 BCL2 apoptosis regulator Homo sapiens 93-98 7850782-7 1995 The interaction between androgen and etoposide was mediated through the BCL-2 protein, since bcl-2 antisense oligonucleotides blocked the protective effect of androgens on etoposide cytotoxicity. Etoposide 172-181 BCL2 apoptosis regulator Homo sapiens 72-77 7850782-7 1995 The interaction between androgen and etoposide was mediated through the BCL-2 protein, since bcl-2 antisense oligonucleotides blocked the protective effect of androgens on etoposide cytotoxicity. Etoposide 172-181 BCL2 apoptosis regulator Homo sapiens 93-98 7695015-4 1995 In this study, we analyzed bcl-2 protein expression in cutaneous malignant melanoma (MM) (29 cases) and benign melanocytic nevi (BMN) (35 cases) using a high specific anti-bcl-2 monoclonal antibody with a standard three-step immunoperoxidase technique on formalin-fixed, paraffin-embedded tissue sections. Paraffin 271-279 BCL2 apoptosis regulator Homo sapiens 27-32 9815973-5 1995 bcl-2 protein was present in 65% of the carcinomas (117/180) and it was significantly associated with ER and progesterone receptor and inversely associated with p53 in both the groups of patients treated with adjuvant chemotherapy and tamoxifen. Tamoxifen 235-244 BCL2 apoptosis regulator Homo sapiens 0-5 9815973-6 1995 In patients treated either with adjuvant chemotherapy or tamoxifen, relapse-free survival at 5 years was significantly better among patients with bcl-2-positive tumors than in those with bcl-2 negative ones (P = 0.05 and 0.02, respectively). Tamoxifen 57-66 BCL2 apoptosis regulator Homo sapiens 146-151 9815973-6 1995 In patients treated either with adjuvant chemotherapy or tamoxifen, relapse-free survival at 5 years was significantly better among patients with bcl-2-positive tumors than in those with bcl-2 negative ones (P = 0.05 and 0.02, respectively). Tamoxifen 57-66 BCL2 apoptosis regulator Homo sapiens 187-192 9815973-9 1995 In the group treated with tamoxifen, lack of expression of ER and of bcl-2 was the only significant and independent predictor for poor relapse-free survival (P < 0.01). Tamoxifen 26-35 BCL2 apoptosis regulator Homo sapiens 69-74 9815973-11 1995 In the cyclophosphamide-methotrexate-fluorouracil-treated group, bcl-2 absence was significant for poor overall survival (P = 0.02) as well as a number of nodes above 3 (P = 0.04) and a tumor size above 2 cm (P = 0.05). Cyclophosphamide 7-23 BCL2 apoptosis regulator Homo sapiens 65-70 9815973-11 1995 In the cyclophosphamide-methotrexate-fluorouracil-treated group, bcl-2 absence was significant for poor overall survival (P = 0.02) as well as a number of nodes above 3 (P = 0.04) and a tumor size above 2 cm (P = 0.05). Methotrexate 24-36 BCL2 apoptosis regulator Homo sapiens 65-70 9815973-11 1995 In the cyclophosphamide-methotrexate-fluorouracil-treated group, bcl-2 absence was significant for poor overall survival (P = 0.02) as well as a number of nodes above 3 (P = 0.04) and a tumor size above 2 cm (P = 0.05). Fluorouracil 37-49 BCL2 apoptosis regulator Homo sapiens 65-70 7745620-3 1995 We demonstrate that bcl-2 inhibits the necrosis of neural cells induced by glutathione depletion. Glutathione 75-86 BCL2 apoptosis regulator Homo sapiens 20-25 7745116-2 1995 METHODS: The expression of p53, Rb and bcl-2 proteins in paraffin wax embedded tonsil tissue sections was detected by immunohistochemistry using an (APAAP) technique following microwave irradiation. Paraffin 57-69 BCL2 apoptosis regulator Homo sapiens 39-44 7742922-0 1995 Antigen retrieval for bcl-2 protein in formalin-fixed, paraffin-embedded sections. Formaldehyde 39-47 BCL2 apoptosis regulator Homo sapiens 22-27 7742922-0 1995 Antigen retrieval for bcl-2 protein in formalin-fixed, paraffin-embedded sections. Paraffin 55-63 BCL2 apoptosis regulator Homo sapiens 22-27 7742922-2 1995 In order to overcome the difficulty in identifying bcl-2 protein in formalin-fixed, paraffin-embedded sections, its antigenicity was retrieved by a variety of pretreatments. Formaldehyde 68-76 BCL2 apoptosis regulator Homo sapiens 51-56 7834747-3 1995 In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of BAG-1 and Bcl-2 provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either BAG-1 or Bcl-2 protein alone. Staurosporine 196-209 BCL2 apoptosis regulator Homo sapiens 97-102 7732891-0 1995 Effect of PGE2 on c-Myc and Bcl-2 production and programmed cell death in human lymphocytes. Dinoprostone 10-14 BCL2 apoptosis regulator Homo sapiens 28-33 7814152-3 1995 Bcl-2 protein was detected by immunohistochemistry on paraffin-embedded tissue sections. Paraffin 54-62 BCL2 apoptosis regulator Homo sapiens 0-5 7795171-1 1995 We have shown that the ability of the human follicular lymphoma-derived cell line SU-DHL-6 to proliferate and survive in vitro depends on both Bcl-2 expression and multiple autocrine growth factors. su-dhl-6 82-90 BCL2 apoptosis regulator Homo sapiens 143-148 7856728-3 1995 We describe an immunohistochemical analysis of fixed, paraffin-embedded tissue using both a polyclonal rabbit and a monoclonal mouse antibody to the Bcl-2 protein. Paraffin 54-62 BCL2 apoptosis regulator Homo sapiens 149-154 17180017-0 1995 Bcl-2 relieves deoxyadenylate stress and suppresses apoptosis in pre-B leukemia cells. 2'-deoxy-5'-adenosine monophosphate 15-29 BCL2 apoptosis regulator Homo sapiens 0-5 17180017-1 1995 The influence of bcl-2 activity on 2"-deoxyadenosine-induced apoptosis was investigated in 697 human pre-B leukemia cells stably transfected with expression plasmid pHeBo-BCL-2alpha (697/BCL2 cells). 2'-deoxyadenosine 35-52 BCL2 apoptosis regulator Homo sapiens 17-22 17180017-2 1995 Apoptosis was induced by the 2"-deoxyadenosine analogue, 2-chloro-2"-deoxyadenosine (Cl-dA), with the concentration for apoptosis in one-half of the cells at 24 hours (LD(50)) being 10 microM for 697 cells and 120 microM for 697/Bcl 2 cells. 2-chloro-2"-deoxyadenosine 57-83 BCL2 apoptosis regulator Homo sapiens 229-234 17180017-2 1995 Apoptosis was induced by the 2"-deoxyadenosine analogue, 2-chloro-2"-deoxyadenosine (Cl-dA), with the concentration for apoptosis in one-half of the cells at 24 hours (LD(50)) being 10 microM for 697 cells and 120 microM for 697/Bcl 2 cells. cl-da 85-90 BCL2 apoptosis regulator Homo sapiens 229-234 17180017-4 1995 When 697 cell and 697/Bcl 2 cell lines were treated with 5 microM Cl-dA, Cl-dATP did not significantly accumulate in the latter. cl-da 66-71 BCL2 apoptosis regulator Homo sapiens 22-27 17180017-5 1995 The Cl-dATP/dATP ratio was 0.03 in Cl-dA treated 697/Bcl 2 cells but nearly 6 in treated 697 cells. cl-datp 4-11 BCL2 apoptosis regulator Homo sapiens 53-58 17180017-5 1995 The Cl-dATP/dATP ratio was 0.03 in Cl-dA treated 697/Bcl 2 cells but nearly 6 in treated 697 cells. 2'-deoxyadenosine triphosphate 7-11 BCL2 apoptosis regulator Homo sapiens 53-58 17180017-5 1995 The Cl-dATP/dATP ratio was 0.03 in Cl-dA treated 697/Bcl 2 cells but nearly 6 in treated 697 cells. cl-da 4-9 BCL2 apoptosis regulator Homo sapiens 53-58 17180017-6 1995 Bcl 2 overproduction also suppressed the accumulation of dAMP, dADP and dATP in cells exposed to 2"-deoxyadenosine in the presence of pentostatin to abrogate the pronounced inversion of ATP/dATP pools associated with 2"-deoxyadenosine exposure. 2'-deoxyadenosine triphosphate 72-76 BCL2 apoptosis regulator Homo sapiens 0-5 17180017-6 1995 Bcl 2 overproduction also suppressed the accumulation of dAMP, dADP and dATP in cells exposed to 2"-deoxyadenosine in the presence of pentostatin to abrogate the pronounced inversion of ATP/dATP pools associated with 2"-deoxyadenosine exposure. 2'-deoxyadenosine 97-114 BCL2 apoptosis regulator Homo sapiens 0-5 17180017-6 1995 Bcl 2 overproduction also suppressed the accumulation of dAMP, dADP and dATP in cells exposed to 2"-deoxyadenosine in the presence of pentostatin to abrogate the pronounced inversion of ATP/dATP pools associated with 2"-deoxyadenosine exposure. Pentostatin 134-145 BCL2 apoptosis regulator Homo sapiens 0-5 17180017-6 1995 Bcl 2 overproduction also suppressed the accumulation of dAMP, dADP and dATP in cells exposed to 2"-deoxyadenosine in the presence of pentostatin to abrogate the pronounced inversion of ATP/dATP pools associated with 2"-deoxyadenosine exposure. Adenosine Triphosphate 73-76 BCL2 apoptosis regulator Homo sapiens 0-5 17180017-6 1995 Bcl 2 overproduction also suppressed the accumulation of dAMP, dADP and dATP in cells exposed to 2"-deoxyadenosine in the presence of pentostatin to abrogate the pronounced inversion of ATP/dATP pools associated with 2"-deoxyadenosine exposure. 2'-deoxyadenosine triphosphate 190-194 BCL2 apoptosis regulator Homo sapiens 0-5 17180017-6 1995 Bcl 2 overproduction also suppressed the accumulation of dAMP, dADP and dATP in cells exposed to 2"-deoxyadenosine in the presence of pentostatin to abrogate the pronounced inversion of ATP/dATP pools associated with 2"-deoxyadenosine exposure. 2'-deoxyadenosine 217-234 BCL2 apoptosis regulator Homo sapiens 0-5 17180017-7 1995 These results suggest that one consequence of bcl-2 activity is suppression of 2"-deoxyadenosine phosphorylation and elevation in the apoptotic target cells. 2'-deoxyadenosine 79-96 BCL2 apoptosis regulator Homo sapiens 46-51 17180017-8 1995 Relief from deoxyadenylate stress imbalances implies a novel upstream site of bcl-2 activity. 2'-deoxy-5'-adenosine monophosphate 12-26 BCL2 apoptosis regulator Homo sapiens 78-83 7895505-0 1995 A link between the antioxidant defense system and calcium: a proposal for the biochemical function of Bcl-2. Calcium 50-57 BCL2 apoptosis regulator Homo sapiens 102-107 7713486-1 1995 Bcl-2 protein expression was studied in a series of 58 MALT lymphomas using a monoclonal antibody which recognises this protein in routinely processed paraffin embedded tissue. Paraffin 151-159 BCL2 apoptosis regulator Homo sapiens 0-5 7775402-7 1995 This hypothesis was confirmed by experiments using antisense oligonucleotides, i.e., blocking the recovery of bcl-2 mRNA by antisense oligonucleotides could result in the induction of apoptosis in HL-60 cells from which PDBu was removed within 24 h. Moreover, overexpression of BCL-2 in HL-60 cells could block apoptosis during differentiation without any significant effect on differentiation itself. Oligonucleotides 61-77 BCL2 apoptosis regulator Homo sapiens 110-115 7775402-7 1995 This hypothesis was confirmed by experiments using antisense oligonucleotides, i.e., blocking the recovery of bcl-2 mRNA by antisense oligonucleotides could result in the induction of apoptosis in HL-60 cells from which PDBu was removed within 24 h. Moreover, overexpression of BCL-2 in HL-60 cells could block apoptosis during differentiation without any significant effect on differentiation itself. Oligonucleotides 61-77 BCL2 apoptosis regulator Homo sapiens 278-283 7775402-7 1995 This hypothesis was confirmed by experiments using antisense oligonucleotides, i.e., blocking the recovery of bcl-2 mRNA by antisense oligonucleotides could result in the induction of apoptosis in HL-60 cells from which PDBu was removed within 24 h. Moreover, overexpression of BCL-2 in HL-60 cells could block apoptosis during differentiation without any significant effect on differentiation itself. Oligonucleotides 134-150 BCL2 apoptosis regulator Homo sapiens 110-115 7775402-7 1995 This hypothesis was confirmed by experiments using antisense oligonucleotides, i.e., blocking the recovery of bcl-2 mRNA by antisense oligonucleotides could result in the induction of apoptosis in HL-60 cells from which PDBu was removed within 24 h. Moreover, overexpression of BCL-2 in HL-60 cells could block apoptosis during differentiation without any significant effect on differentiation itself. Oligonucleotides 134-150 BCL2 apoptosis regulator Homo sapiens 278-283 7845007-7 1995 In these seven cases the decreased expression of bcl-2 was accompanied by increased apoptosis and the susceptibility of the blasts to apoptosis induced by Ara-C was increased in the presence of bcl-2 antisense. Cytarabine 155-160 BCL2 apoptosis regulator Homo sapiens 49-54 7845007-0 1995 Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Oligonucleotides 35-51 BCL2 apoptosis regulator Homo sapiens 14-19 7845007-7 1995 In these seven cases the decreased expression of bcl-2 was accompanied by increased apoptosis and the susceptibility of the blasts to apoptosis induced by Ara-C was increased in the presence of bcl-2 antisense. Cytarabine 155-160 BCL2 apoptosis regulator Homo sapiens 194-199 7845007-0 1995 Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Cytarabine 117-122 BCL2 apoptosis regulator Homo sapiens 14-19 7841373-1 1994 The proto-oncogene bcl-2 is involved in the regulation of cell death and is able to block apoptosis in neurones through reduced generation of reactive oxygen species (ROS). Reactive Oxygen Species 142-165 BCL2 apoptosis regulator Homo sapiens 19-24 7845007-4 1995 Here we have investigated the role of bcl-2 expression in mediating resistance to apoptosis induced by cytosine arabinoside in vitro. Cytarabine 103-123 BCL2 apoptosis regulator Homo sapiens 38-43 7845007-6 1995 Incubation of the blasts with antisense oligonucleotides directed against bcl-2 mRNA resulted in a significant decrease in expression of the bcl-2 protein in seven of the 17 samples. Oligonucleotides 40-56 BCL2 apoptosis regulator Homo sapiens 74-79 7845007-6 1995 Incubation of the blasts with antisense oligonucleotides directed against bcl-2 mRNA resulted in a significant decrease in expression of the bcl-2 protein in seven of the 17 samples. Oligonucleotides 40-56 BCL2 apoptosis regulator Homo sapiens 141-146 7986096-11 1994 Approximately 500 micrograms purified bcl-2 protein could be recovered as estimated by silver staining and immunoblotting. Silver 87-93 BCL2 apoptosis regulator Homo sapiens 38-43 7977649-2 1994 The prognostic significance of Bcl-2 protein expression was investigated by immunocytochemistry from paraffin-embedded tissue in a series of 174 women with breast cancer, treated with radical surgery with or without regional radiotherapy, and who had been followed up for the median of 31 years or until death. Paraffin 101-109 BCL2 apoptosis regulator Homo sapiens 31-36 7654318-3 1994 Using the phosphatase inhibitor okadaic acid (OA) or chemotherapeutic agents such as Taxol and 5"-fluorouracil, we found that bcl-2 can be phosphorylated. Okadaic Acid 32-44 BCL2 apoptosis regulator Homo sapiens 126-131 7654318-3 1994 Using the phosphatase inhibitor okadaic acid (OA) or chemotherapeutic agents such as Taxol and 5"-fluorouracil, we found that bcl-2 can be phosphorylated. Okadaic Acid 46-48 BCL2 apoptosis regulator Homo sapiens 126-131 7654318-3 1994 Using the phosphatase inhibitor okadaic acid (OA) or chemotherapeutic agents such as Taxol and 5"-fluorouracil, we found that bcl-2 can be phosphorylated. Paclitaxel 85-90 BCL2 apoptosis regulator Homo sapiens 126-131 7654318-3 1994 Using the phosphatase inhibitor okadaic acid (OA) or chemotherapeutic agents such as Taxol and 5"-fluorouracil, we found that bcl-2 can be phosphorylated. Fluorouracil 95-110 BCL2 apoptosis regulator Homo sapiens 126-131 7654318-4 1994 Since OA or Taxol treatment leads to apoptosis, it seems that phosphorylation of bcl-2 leads to its inactivation. Paclitaxel 12-17 BCL2 apoptosis regulator Homo sapiens 81-86 7654318-8 1994 Treatment with the phosphatase inhibitor or with chemotherapeutic agents (Taxol, 5"-fluorouracil) led to severe apoptosis of these cells, along with hyperphosphorylation of bcl-2. Paclitaxel 74-79 BCL2 apoptosis regulator Homo sapiens 173-178 7654318-8 1994 Treatment with the phosphatase inhibitor or with chemotherapeutic agents (Taxol, 5"-fluorouracil) led to severe apoptosis of these cells, along with hyperphosphorylation of bcl-2. Fluorouracil 81-96 BCL2 apoptosis regulator Homo sapiens 173-178 7654318-9 1994 Phosphoamino acid analysis reveals that bcl-2 is phosphorylated at a serine residue. Phosphoamino Acids 0-17 BCL2 apoptosis regulator Homo sapiens 40-45 7654318-9 1994 Phosphoamino acid analysis reveals that bcl-2 is phosphorylated at a serine residue. Serine 69-75 BCL2 apoptosis regulator Homo sapiens 40-45 7654319-11 1994 Interestingly, the C-terminal end of BH2 encompasses the Bcl-2 alpha/beta splice site, as well as part of domain X in Bcl-2 alpha. bh2 37-40 BCL2 apoptosis regulator Homo sapiens 57-62 7654319-11 1994 Interestingly, the C-terminal end of BH2 encompasses the Bcl-2 alpha/beta splice site, as well as part of domain X in Bcl-2 alpha. bh2 37-40 BCL2 apoptosis regulator Homo sapiens 118-123 7526093-2 1994 Since overexpression of the bcl-2 gene has been reported to retard apoptosis due to a variety of anticancer agents, we examined and compared taxol-induced intracellular microtubular bundling and apoptosis in pre-B human leukemia 697 cells and their counterparts which have been transfected with and overexpress cDNA derived from the bcl-2 gene. Paclitaxel 141-146 BCL2 apoptosis regulator Homo sapiens 28-33 7526093-3 1994 Treatment with 0.1 or 1.0 mumol/l taxol for 24 h resulted in internucleosomal DNA fragmentation and morphologic features of apoptosis in 697 cells, but not in 697/BCL-2 cells. Paclitaxel 34-39 BCL2 apoptosis regulator Homo sapiens 163-168 7526093-4 1994 However, indirect immunofluorescent staining with anti-tubulin antibody revealed that taxol treatment produces stable microtubule bundles resistant to calcium-mediated disassembly in 697, as well as 697/BCL-2 cells. Paclitaxel 86-91 BCL2 apoptosis regulator Homo sapiens 203-208 7526093-12 1994 The delayed onset of taxol-induced DNA fragmentation and apoptosis in 697/BCL-2 cells without down-regulation of p26BCL-2 levels suggests that an alternative mechanism of taxol-mediated apoptosis might be triggered which is unimpeded by high p26BCL-2 levels, or taxol-induced prolongation of mitotic arrest may lead to the inactivation or inhibition of that mechanism by which p26BCL-2 is able to block apoptosis. Paclitaxel 21-26 BCL2 apoptosis regulator Homo sapiens 74-79 7825961-7 1994 P26-bcl-2 is an antioxidant; this property could explain the anti-apoptotic activity since peroxides seem to be important mediators of apoptosis. Peroxides 91-100 BCL2 apoptosis regulator Homo sapiens 4-9 7825961-8 1994 Bcl-2 antisense oligonucleotides are able to reverse the apoptosis inhibition. Oligonucleotides 16-32 BCL2 apoptosis regulator Homo sapiens 0-5 7524301-4 1994 By univariate analysis, expression of the bcl-2 gene product in RS cells was observed in a significantly greater proportion of NS Hodgkin"s disease cases than MC cases (P < .009), a finding that may have implications on the pathogenesis of this disorder. Methylcholanthrene 159-161 BCL2 apoptosis regulator Homo sapiens 42-47 7841373-1 1994 The proto-oncogene bcl-2 is involved in the regulation of cell death and is able to block apoptosis in neurones through reduced generation of reactive oxygen species (ROS). Reactive Oxygen Species 167-170 BCL2 apoptosis regulator Homo sapiens 19-24 7841373-3 1994 In all cases, bcl-2 was strongly enriched within lipofuscin and autophagic vacuoles of neurones, glial and vascular cells. Lipofuscin 49-59 BCL2 apoptosis regulator Homo sapiens 14-19 7841373-4 1994 Our data show that accumulation of bcl-2 is not disease-specific and represents a general cellular response which accompanies the increased formation of lipofuscin. Lipofuscin 153-163 BCL2 apoptosis regulator Homo sapiens 35-40 7841373-5 1994 Since oxidative stress is directly involved in lipofuscinogenesis, accumulation of bcl-2 may reflect a mechanism for counterbalancing ROS-mediated damage, or it might represent the impairment of bcl-2-dependent protection from ROS. Reactive Oxygen Species 134-137 BCL2 apoptosis regulator Homo sapiens 83-88 7841373-5 1994 Since oxidative stress is directly involved in lipofuscinogenesis, accumulation of bcl-2 may reflect a mechanism for counterbalancing ROS-mediated damage, or it might represent the impairment of bcl-2-dependent protection from ROS. Reactive Oxygen Species 227-230 BCL2 apoptosis regulator Homo sapiens 195-200 7838002-1 1994 Recent information about apoptosis or programmed cell death, the anti-apoptotic gene, BCL2, its interaction with reactive oxygen species and the role of these agents in senescence and apoptosis, suggests a discussion of their relationships could be of interest. Reactive Oxygen Species 113-136 BCL2 apoptosis regulator Homo sapiens 86-90 8092400-4 1994 All six of the specimens (from five patients) for which paraffin tissue was available marked as B cell phenotype and were positive for bcl-2 protein. Paraffin 56-64 BCL2 apoptosis regulator Homo sapiens 135-140 7940596-0 1994 bcl-2 expression decreases methyl mercury-induced free-radical generation and cell killing in a neural cell line. methyl mercury 27-41 BCL2 apoptosis regulator Homo sapiens 0-5 7940596-3 1994 Cells transfected with an expression construct for the anti-apoptotic proto-oncogene, bcl-2, displayed attenuated ROS induction and negligible cell death. Reactive Oxygen Species 114-117 BCL2 apoptosis regulator Homo sapiens 55-91 7940596-6 1994 The data suggest that MeHg-mediated cell killing correlates more closely with ROS generation than with GSH levels and that bcl-2 protects MeHg-treated cells by suppressing ROS generation. Reactive Oxygen Species 172-175 BCL2 apoptosis regulator Homo sapiens 123-128 7847852-7 1994 Flow immunocytometry revealed reduced levels of c-myc and bcl-2 oncoproteins in RA and PMA treated cells. Tetradecanoylphorbol Acetate 87-90 BCL2 apoptosis regulator Homo sapiens 58-63 8051205-5 1994 A truncation mutant of bcl-2 alpha lacking the last 33 amino acids (T3.1) including the hydrophobic COOH terminus shows full activity in blocking apoptosis of nerve growth factor-deprived sympathetic neurons or TNF-alpha-treated L929 fibroblasts. Carbonic Acid 100-104 BCL2 apoptosis regulator Homo sapiens 23-28 7519477-10 1994 These results suggest that anti-Fas-mediated cell death may, in part, be determined by bcl-2 expression status in Fas+ lymphoid and hematopoietic cells. ammonium ferrous sulfate 32-35 BCL2 apoptosis regulator Homo sapiens 87-92 7519782-7 1994 In the presence of anti-c-kit antibody, the tyrosine kinase inhibitor genistein, or bcl-2 antisense oligonucleotide, the protective effect of KL on the survival of CD56bright NK cells is dramatically reduced. Oligonucleotides 100-115 BCL2 apoptosis regulator Homo sapiens 84-89 8068950-3 1994 In this panel, 10- to 15-fold differences in basal adenosine triphosphate (ATP) content and adenosine diphosphate (ADP)/ATP ratio were correlated with up to fivefold differences in bcl-2 protein (in human cells) and approximately 25-fold difference in bcl-2 mRNA content (all cell lines). Adenosine Triphosphate 51-73 BCL2 apoptosis regulator Homo sapiens 181-186 8068950-3 1994 In this panel, 10- to 15-fold differences in basal adenosine triphosphate (ATP) content and adenosine diphosphate (ADP)/ATP ratio were correlated with up to fivefold differences in bcl-2 protein (in human cells) and approximately 25-fold difference in bcl-2 mRNA content (all cell lines). Adenosine Triphosphate 75-78 BCL2 apoptosis regulator Homo sapiens 181-186 8068950-3 1994 In this panel, 10- to 15-fold differences in basal adenosine triphosphate (ATP) content and adenosine diphosphate (ADP)/ATP ratio were correlated with up to fivefold differences in bcl-2 protein (in human cells) and approximately 25-fold difference in bcl-2 mRNA content (all cell lines). Adenosine Diphosphate 92-113 BCL2 apoptosis regulator Homo sapiens 181-186 8068950-3 1994 In this panel, 10- to 15-fold differences in basal adenosine triphosphate (ATP) content and adenosine diphosphate (ADP)/ATP ratio were correlated with up to fivefold differences in bcl-2 protein (in human cells) and approximately 25-fold difference in bcl-2 mRNA content (all cell lines). Adenosine Diphosphate 115-118 BCL2 apoptosis regulator Homo sapiens 181-186 8068950-3 1994 In this panel, 10- to 15-fold differences in basal adenosine triphosphate (ATP) content and adenosine diphosphate (ADP)/ATP ratio were correlated with up to fivefold differences in bcl-2 protein (in human cells) and approximately 25-fold difference in bcl-2 mRNA content (all cell lines). Adenosine Triphosphate 120-123 BCL2 apoptosis regulator Homo sapiens 181-186 8058342-3 1994 Here we show that Bcl-2 can be co-immunoprecipitated with the serine/threonine-specific Raf-1 kinase both in a mammalian hemopoietic cell 32D.3 and when the two proteins are produced in Sf9 insect cells using recombinant baculoviruses. Serine 62-68 BCL2 apoptosis regulator Homo sapiens 18-23 8058342-3 1994 Here we show that Bcl-2 can be co-immunoprecipitated with the serine/threonine-specific Raf-1 kinase both in a mammalian hemopoietic cell 32D.3 and when the two proteins are produced in Sf9 insect cells using recombinant baculoviruses. Threonine 69-78 BCL2 apoptosis regulator Homo sapiens 18-23 8183370-7 1994 Substitution of Gly 145 in BH1 domain or Trp 188 in BH2 domain completely abrogated Bcl-2"s death-repressor activity in interleukin-3 deprivation, gamma-irradiation and glucocorticoid-induced apoptosis. Glycine 16-19 BCL2 apoptosis regulator Homo sapiens 84-89 7950302-5 1994 Both synthetic bcl-2-As oligonucleotides and inducible expression plasmids that produce bcl-2-As transcripts induced reductions in bcl-2 expression, resulting in a marked enhancement in the sensitivity of neoplastic cells to conventional chemotherapeutic drugs such as cytosine arabinoside (ara-C) and methotrexate (MTX). Cytarabine 269-289 BCL2 apoptosis regulator Homo sapiens 88-93 7950302-5 1994 Both synthetic bcl-2-As oligonucleotides and inducible expression plasmids that produce bcl-2-As transcripts induced reductions in bcl-2 expression, resulting in a marked enhancement in the sensitivity of neoplastic cells to conventional chemotherapeutic drugs such as cytosine arabinoside (ara-C) and methotrexate (MTX). Cytarabine 269-289 BCL2 apoptosis regulator Homo sapiens 88-93 7950302-5 1994 Both synthetic bcl-2-As oligonucleotides and inducible expression plasmids that produce bcl-2-As transcripts induced reductions in bcl-2 expression, resulting in a marked enhancement in the sensitivity of neoplastic cells to conventional chemotherapeutic drugs such as cytosine arabinoside (ara-C) and methotrexate (MTX). Cytarabine 291-296 BCL2 apoptosis regulator Homo sapiens 88-93 7950302-5 1994 Both synthetic bcl-2-As oligonucleotides and inducible expression plasmids that produce bcl-2-As transcripts induced reductions in bcl-2 expression, resulting in a marked enhancement in the sensitivity of neoplastic cells to conventional chemotherapeutic drugs such as cytosine arabinoside (ara-C) and methotrexate (MTX). Cytarabine 291-296 BCL2 apoptosis regulator Homo sapiens 88-93 7950302-5 1994 Both synthetic bcl-2-As oligonucleotides and inducible expression plasmids that produce bcl-2-As transcripts induced reductions in bcl-2 expression, resulting in a marked enhancement in the sensitivity of neoplastic cells to conventional chemotherapeutic drugs such as cytosine arabinoside (ara-C) and methotrexate (MTX). Methotrexate 302-314 BCL2 apoptosis regulator Homo sapiens 88-93 7950302-5 1994 Both synthetic bcl-2-As oligonucleotides and inducible expression plasmids that produce bcl-2-As transcripts induced reductions in bcl-2 expression, resulting in a marked enhancement in the sensitivity of neoplastic cells to conventional chemotherapeutic drugs such as cytosine arabinoside (ara-C) and methotrexate (MTX). Methotrexate 302-314 BCL2 apoptosis regulator Homo sapiens 88-93 7950302-5 1994 Both synthetic bcl-2-As oligonucleotides and inducible expression plasmids that produce bcl-2-As transcripts induced reductions in bcl-2 expression, resulting in a marked enhancement in the sensitivity of neoplastic cells to conventional chemotherapeutic drugs such as cytosine arabinoside (ara-C) and methotrexate (MTX). Methotrexate 316-319 BCL2 apoptosis regulator Homo sapiens 88-93 7950302-5 1994 Both synthetic bcl-2-As oligonucleotides and inducible expression plasmids that produce bcl-2-As transcripts induced reductions in bcl-2 expression, resulting in a marked enhancement in the sensitivity of neoplastic cells to conventional chemotherapeutic drugs such as cytosine arabinoside (ara-C) and methotrexate (MTX). Methotrexate 316-319 BCL2 apoptosis regulator Homo sapiens 88-93 7947459-9 1994 Messenger RNA for bcl-2 was detected after treatment with forskolin. Colforsin 58-67 BCL2 apoptosis regulator Homo sapiens 18-23 8205548-7 1994 Clones expressing high levels of Bcl-2 were resistant to cisplatin- and etoposide-induced cytotoxicity in a dose-dependent manner. Cisplatin 57-66 BCL2 apoptosis regulator Homo sapiens 33-38 8205548-7 1994 Clones expressing high levels of Bcl-2 were resistant to cisplatin- and etoposide-induced cytotoxicity in a dose-dependent manner. Etoposide 72-81 BCL2 apoptosis regulator Homo sapiens 33-38 8205548-8 1994 Analysis of propidium iodide-stained nuclei by flow cytometry after cisplatin or etoposide treatment revealed marked DNA degradation in vector-transfected controls whereas bcl-2 transfectants showed a dose-dependent inhibition of DNA degradation. Propidium 12-28 BCL2 apoptosis regulator Homo sapiens 172-177 7772249-7 1994 Comparisons of the wild-type and cysteine-minus human Bcl-2 proteins in S49 lymphoma cells revealed equivalent ability to block glucocorticoid-induced cell death and DNA fragmentation, indicating that these two conserved cysteines are not critical for Bcl-2 oncoprotein function. Cysteine 33-41 BCL2 apoptosis regulator Homo sapiens 54-59 7772249-7 1994 Comparisons of the wild-type and cysteine-minus human Bcl-2 proteins in S49 lymphoma cells revealed equivalent ability to block glucocorticoid-induced cell death and DNA fragmentation, indicating that these two conserved cysteines are not critical for Bcl-2 oncoprotein function. Cysteine 221-230 BCL2 apoptosis regulator Homo sapiens 54-59 7951907-3 1994 However, data recently published demonstrate that expression of the anti-apoptotic gene bcl-2 decreases the net cellular generation of reactive oxygen species, and that reactive oxygen species serve as mediators of apoptosis in at least some cases. Reactive Oxygen Species 135-158 BCL2 apoptosis regulator Homo sapiens 88-93 7910376-4 1994 Here we report that, by contrast, the ced-9(n1950) gain-of-function mutation affects the open reading frame of ced-9 and results in a glycine-to-glutamate substitution in a region highly conserved among all ced-9/bcl-2 family members. Glycine 134-141 BCL2 apoptosis regulator Homo sapiens 213-218 7910376-4 1994 Here we report that, by contrast, the ced-9(n1950) gain-of-function mutation affects the open reading frame of ced-9 and results in a glycine-to-glutamate substitution in a region highly conserved among all ced-9/bcl-2 family members. Glutamic Acid 145-154 BCL2 apoptosis regulator Homo sapiens 213-218 7910376-5 1994 We conclude that this glycine has an important function in ced-9 regulation, and we suggest that alteration of this glycine in other members of the ced-9/bcl-2 family might lead to oncogenic activation. Glycine 22-29 BCL2 apoptosis regulator Homo sapiens 154-159 7910376-5 1994 We conclude that this glycine has an important function in ced-9 regulation, and we suggest that alteration of this glycine in other members of the ced-9/bcl-2 family might lead to oncogenic activation. Glycine 116-123 BCL2 apoptosis regulator Homo sapiens 154-159 8183370-7 1994 Substitution of Gly 145 in BH1 domain or Trp 188 in BH2 domain completely abrogated Bcl-2"s death-repressor activity in interleukin-3 deprivation, gamma-irradiation and glucocorticoid-induced apoptosis. Tryptophan 41-44 BCL2 apoptosis regulator Homo sapiens 84-89 8161792-5 1994 After treatment of HL-60/BCL2 cells with all-trans retinoic acid or phorbol myristic acid, Bcl2 levels did not decrease as in normal HL-60 cells but, rather, increased because of activation of the viral promoter. Tretinoin 51-64 BCL2 apoptosis regulator Homo sapiens 25-29 8161792-5 1994 After treatment of HL-60/BCL2 cells with all-trans retinoic acid or phorbol myristic acid, Bcl2 levels did not decrease as in normal HL-60 cells but, rather, increased because of activation of the viral promoter. Tretinoin 51-64 BCL2 apoptosis regulator Homo sapiens 91-95 8161792-5 1994 After treatment of HL-60/BCL2 cells with all-trans retinoic acid or phorbol myristic acid, Bcl2 levels did not decrease as in normal HL-60 cells but, rather, increased because of activation of the viral promoter. phorbol-12-myristate 68-89 BCL2 apoptosis regulator Homo sapiens 25-29 8161792-5 1994 After treatment of HL-60/BCL2 cells with all-trans retinoic acid or phorbol myristic acid, Bcl2 levels did not decrease as in normal HL-60 cells but, rather, increased because of activation of the viral promoter. phorbol-12-myristate 68-89 BCL2 apoptosis regulator Homo sapiens 91-95 8133533-4 1994 METHODS: The expression of Bcl-2 and p53 was detected by immunohistochemistry on paraffin-embedded sections from 283 node-negative resectable breast cancers treated with local-regional therapy alone until relapse. Paraffin 81-89 BCL2 apoptosis regulator Homo sapiens 27-32 8045037-9 1994 Both SALT- and mucosa-associated lymphoid tissue (MALT)-related B-cell lymphoma share with a peculiar nodal lymphoma of follicle mantle origin (parafollicular-monocytoid lymphoma) the nonaggressive clinical behavior and the uniform phenotype (CD5-, CD10-) and genotype (lack of bcl-2 gene rearrangement) of neoplastic B cells, despite the wide variability of cytomorphologic appearances. Sodium Chloride 5-9 BCL2 apoptosis regulator Homo sapiens 278-283 7907395-7 1994 Following treatment with clinically relevant concentration of taxol (1.0 microM for 24 h), HL-60 but not HL-60/TAX1000 cells display intracellular microtubular bundling, markedly enhanced accumulation of the cells in G2/M phase of cell-cycle and internucleosomal DNA fragmentation associated with apoptosis which is independent of bcl-2 gene expression. Paclitaxel 62-67 BCL2 apoptosis regulator Homo sapiens 331-336 7907352-5 1994 During mitotic arrest due to taxol, bcl-2 remains associated with condensed chromosomes but is lost after > 2 days at approximately the same time as the appearance of apoptotic features in these cells. Paclitaxel 29-34 BCL2 apoptosis regulator Homo sapiens 36-41 9419766-11 1994 Treatment of JEG-3 cells with 8-Br-cAMP, which induces genes characteristic of the syncytiotrophoblast, raised BCL-2 protein approximately twofold, whereas p53 mRNA declined. 8-Bromo Cyclic Adenosine Monophosphate 30-39 BCL2 apoptosis regulator Homo sapiens 111-116 9419766-12 1994 CONCLUSIONS: We conclude that: 1) There is a differentiation-dependent pattern of BCL-2 expression in the placenta, with the protein being most abundant in terminally differentiated trophoblast cells; 2) there appears to be an inverse relation between BCL-2 and p53 expression in trophoblast; and 3) cAMP regulates BCL-2 protein in trophoblast cells. Cyclic AMP 300-304 BCL2 apoptosis regulator Homo sapiens 82-87 7517174-3 1994 Dibutyryl cyclic AMP neither induced differentiation nor down-regulated bcl-2 expression, but it sensitized the cells to induction of apoptosis by some of these agents. Bucladesine 0-20 BCL2 apoptosis regulator Homo sapiens 72-77 7517174-4 1994 Although dexamethasone induced differentiation and down-regulated bcl-2 expression, it did not sensitize the cells to induction of apoptosis and inhibited the apoptosis sensitizing effect of the cytokines and dibutyryl cyclic AMP. Dexamethasone 9-22 BCL2 apoptosis regulator Homo sapiens 66-71 8195931-3 1994 BCL-2 protein was detected in all the 46 formalin-fixed, paraffin-embedded samples from 34 patients representing all clinical stages and sites of involvement. Formaldehyde 41-49 BCL2 apoptosis regulator Homo sapiens 0-5 8195931-3 1994 BCL-2 protein was detected in all the 46 formalin-fixed, paraffin-embedded samples from 34 patients representing all clinical stages and sites of involvement. Paraffin 57-65 BCL2 apoptosis regulator Homo sapiens 0-5 8063271-4 1994 In the Fourth Meeting of the Italian Society of Experimental Hematology "Discutiamone Insieme", authors reported the use of in vitro synthesized oligonucleotides to inhibit normal and chimeric gene expression of bcl-2 in normal and neoplastic cell lines, respectively, that carry the t(14;18) translocation. discutiamone 73-85 BCL2 apoptosis regulator Homo sapiens 212-217 8063271-4 1994 In the Fourth Meeting of the Italian Society of Experimental Hematology "Discutiamone Insieme", authors reported the use of in vitro synthesized oligonucleotides to inhibit normal and chimeric gene expression of bcl-2 in normal and neoplastic cell lines, respectively, that carry the t(14;18) translocation. Oligonucleotides 145-161 BCL2 apoptosis regulator Homo sapiens 212-217 8313913-9 1994 We found that Bcl-2 expressed by B cells is a long-lived protein with a half-life of approximately 10 h. Importantly, susceptibility to apoptosis mediated by the glucocorticoid hormone dexamethasone is stage-dependent in developing B cells and correlates with the levels of Bcl-2 protein. Dexamethasone 185-198 BCL2 apoptosis regulator Homo sapiens 14-19 8019487-4 1994 The reported bcl-2 up regulation in malignant lymphoid cells was confirmed in haemo- and lymphopoietic progenitor cells as well as in TPA/PHA activated peripheral blood lymphocytes. Tetradecanoylphorbol Acetate 134-137 BCL2 apoptosis regulator Homo sapiens 13-18 8313913-9 1994 We found that Bcl-2 expressed by B cells is a long-lived protein with a half-life of approximately 10 h. Importantly, susceptibility to apoptosis mediated by the glucocorticoid hormone dexamethasone is stage-dependent in developing B cells and correlates with the levels of Bcl-2 protein. Dexamethasone 185-198 BCL2 apoptosis regulator Homo sapiens 274-279 8313913-10 1994 Furthermore, expression of a bcl-2 transgene rescued pre-B and immature B cells from dexamethasone-induced cell death, indicating that Bcl-2 can inhibit the apoptotic cell death of progenitors and early B cells. Dexamethasone 85-98 BCL2 apoptosis regulator Homo sapiens 29-34 8313913-10 1994 Furthermore, expression of a bcl-2 transgene rescued pre-B and immature B cells from dexamethasone-induced cell death, indicating that Bcl-2 can inhibit the apoptotic cell death of progenitors and early B cells. Dexamethasone 85-98 BCL2 apoptosis regulator Homo sapiens 135-140 8219202-4 1993 In addition, intracellularly, mitoxantrone-induced PCD was associated with a marked induction of c-jun and significant repression of c-myc and BCL-2 oncogenes. Mitoxantrone 30-42 BCL2 apoptosis regulator Homo sapiens 143-148 8207068-6 1994 The expression and distribution of Bcl-2 is influenced by treatment with excessive thymidine. Thymidine 83-92 BCL2 apoptosis regulator Homo sapiens 35-40 7508535-7 1994 In addition, the difference in response was unrelated to expression of the apoptosis-modulating protein bcl-2, which appeared unchanged following 48 h exposure to DMSO. Dimethyl Sulfoxide 163-167 BCL2 apoptosis regulator Homo sapiens 104-109 8279627-8 1994 Five demonstrated light-chain restriction; one was an immunoglobulin-negative B-cell neoplasm; and six, in which only formalin-fixed, paraffin-embedded tissue was available, demonstrated overexpression of the bcl-2 protein. Paraffin 134-142 BCL2 apoptosis regulator Homo sapiens 209-214 7847793-4 1994 The bcl-2 protein exhibits two main biochemical properties: it acts in an antioxidant metabolic pathway aimed at eliminating oxygene free radicals that induce lesions in DNA, lipids and proteins; it modulates intracellular Ca++ fluxes. oxygene free radicals 125-146 BCL2 apoptosis regulator Homo sapiens 4-9 7903532-0 1993 BCL-2 prevents killing of neuronal cells by glutamate but not by amyloid beta protein. Glutamic Acid 44-53 BCL2 apoptosis regulator Homo sapiens 0-5 7903532-6 1993 Bcl-2 protected all 3 cell lines from glutamate induced cell death but had no effect on killing mediated by ABP. Glutamic Acid 38-47 BCL2 apoptosis regulator Homo sapiens 0-5 7833141-0 1994 Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Tamoxifen 95-104 BCL2 apoptosis regulator Homo sapiens 14-19 7833141-1 1994 The expression of the bcl-2 proto-oncogene, which is associated with prolonged cell survival and prevention of programmed cell death, was investigated in human primary breast carcinomas prior to and following endocrine therapy with the anti-oestrogen, tamoxifen. Tamoxifen 252-261 BCL2 apoptosis regulator Homo sapiens 22-27 7833141-3 1994 In a cross-sectional study, the immunohistochemical expression of Bcl-2 was observed in 32% of invasive breast cancers, but in 65% of tumours treated with tamoxifen (P = 0.009). Tamoxifen 155-164 BCL2 apoptosis regulator Homo sapiens 66-71 7833141-4 1994 There was a significant association of Bcl-2 with ER status, with 64% of untreated and 88% of tamoxifen-treated Bcl-2-positive tumours being ER+ve. Tamoxifen 94-103 BCL2 apoptosis regulator Homo sapiens 39-44 7833141-4 1994 There was a significant association of Bcl-2 with ER status, with 64% of untreated and 88% of tamoxifen-treated Bcl-2-positive tumours being ER+ve. Tamoxifen 94-103 BCL2 apoptosis regulator Homo sapiens 112-117 7833141-5 1994 A significantly lower Ki-67 score was found in tamoxifen-treated tumours which were Bcl-2-positive compared with Bcl-2-negative (9.3 versus 24.6%, P = 0.01). Tamoxifen 47-56 BCL2 apoptosis regulator Homo sapiens 84-89 7833141-5 1994 A significantly lower Ki-67 score was found in tamoxifen-treated tumours which were Bcl-2-positive compared with Bcl-2-negative (9.3 versus 24.6%, P = 0.01). Tamoxifen 47-56 BCL2 apoptosis regulator Homo sapiens 113-118 7833141-6 1994 In a separate series of sequential Trucut biopsies from 18 patients, the frequency of Bcl-2 expression was increased in ER+ve tumours from 3/12 to 8/11 following tamoxifen (P = 0.04). Tamoxifen 162-171 BCL2 apoptosis regulator Homo sapiens 86-91 8144145-1 1994 The expression of BCL-2 protein was analysed in 10 fetal and 45 infant breast specimens by immunocytochemical staining of methacarn-fixed, paraffin-embedded tissue. methacarn 122-131 BCL2 apoptosis regulator Homo sapiens 18-23 8144145-1 1994 The expression of BCL-2 protein was analysed in 10 fetal and 45 infant breast specimens by immunocytochemical staining of methacarn-fixed, paraffin-embedded tissue. Paraffin 139-147 BCL2 apoptosis regulator Homo sapiens 18-23 7894619-5 1994 Treatment of U251 cells with ACNU for 24 h induced increased Bcl-2 protein expression; induction was dose dependent. Nimustine 29-33 BCL2 apoptosis regulator Homo sapiens 61-66 8262155-0 1993 1,25-Dihydroxyvitamin D3 protects HL60 cells against apoptosis but down-regulates the expression of the bcl-2 gene. Calcitriol 0-24 BCL2 apoptosis regulator Homo sapiens 104-109 8238244-4 1993 Immunostaining for BCL-2 on paraffin material was performed using microwave treatment of tissue sections before the application of the primary monoclonal antibody. Paraffin 28-36 BCL2 apoptosis regulator Homo sapiens 19-24 8402648-4 1993 Fractionation of light-membrane fractions using discontinuous sucrose-gradients revealed association of Bcl-2 protein primarily with lighter-density microsomes (smooth endoplasmic reticulum) as opposed to heavy-density microsomes (rough endoplasmic reticulum). Sucrose 62-69 BCL2 apoptosis regulator Homo sapiens 104-109 8244314-9 1993 These results demonstrate the utility of the commercially obtained bcl-2 antibody in distinguishing FL from FH in B5-fixed, paraffin-embedded tissue sections. Paraffin 124-132 BCL2 apoptosis regulator Homo sapiens 67-72 7503812-2 1993 Bcl-2 is localized to intracellular sites of oxygen free radical generation including mitochondria, endoplasmic reticula, and nuclear membranes. Oxygen 45-51 BCL2 apoptosis regulator Homo sapiens 0-5 7503812-4 1993 Bcl-2 protected cells from H2O2- and menadione-induced oxidative deaths. Hydrogen Peroxide 27-31 BCL2 apoptosis regulator Homo sapiens 0-5 7503812-4 1993 Bcl-2 protected cells from H2O2- and menadione-induced oxidative deaths. Vitamin K 3 37-46 BCL2 apoptosis regulator Homo sapiens 0-5 7503812-9 1993 We propose a model in which Bcl-2 regulates an antioxidant pathway at sites of free radical generation. Free Radicals 79-91 BCL2 apoptosis regulator Homo sapiens 28-33 8226783-3 1993 Herbimycin A, a protein tyrosine kinase inhibitor, blocks the ability of IL-2 and IL-3 to up-regulate bcl-2 mRNA levels and induces apoptosis. herbimycin 0-12 BCL2 apoptosis regulator Homo sapiens 102-107 8226783-4 1993 Transfection of a bcl-2 expression vector not only prolongs survival following growth factor withdrawal but also confers resistance to the effect of herbimycin A. herbimycin 149-161 BCL2 apoptosis regulator Homo sapiens 18-23 8226783-5 1993 We conclude that herbimycin A-sensitive protein tyrosine kinases are involved in the regulation of apoptosis and bcl-2 expression, but these protein tyrosine kinases appear not to be required for the action of Bcl-2 since Bcl-2 can exert its growth survival effect even in the presence of herbimycin A. herbimycin 17-29 BCL2 apoptosis regulator Homo sapiens 113-118 8402688-4 1993 Furthermore, stimulation of one of the N-type clones, SH-SY5Y, with the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate, induced differentiation toward a more neuronal-like phenotype and resulted in a 5- to 10-fold elevation in the relative levels of Bcl-2 protein. Phorbol Esters 72-85 BCL2 apoptosis regulator Homo sapiens 255-260 8402688-4 1993 Furthermore, stimulation of one of the N-type clones, SH-SY5Y, with the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate, induced differentiation toward a more neuronal-like phenotype and resulted in a 5- to 10-fold elevation in the relative levels of Bcl-2 protein. Tetradecanoylphorbol Acetate 87-123 BCL2 apoptosis regulator Homo sapiens 255-260 8402688-9 1993 Consistent with this inverse correlation between Bcl-2 protein levels and S-type characteristics, stimulation of an I-type clone derived from the SK-N-BE(2) line with 5-bromodeoxyuridine was accompanied by an accumulation of S-type cells in these cultures, decreased Bcl-2 protein, diminutions in the neuronal markers neurofilament-M and neuron-specific enolase, and an increase in the relative levels of the S-type marker proteins vimentin and beta-2-microglobulin. Bromodeoxyuridine 167-186 BCL2 apoptosis regulator Homo sapiens 49-54 8402688-10 1993 Conversely, stimulation of this I-type clone with retinoic acid resulted in an accumulation of N-type cells (which are thought to represent embryonic precursors of sympathetic neurons), decreased vimentin and beta-2-microglobulin, increased neurofilament-M, and a marked elevation in p26-Bcl-2. Tretinoin 50-63 BCL2 apoptosis regulator Homo sapiens 288-293 8395979-0 1993 bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Etoposide 23-32 BCL2 apoptosis regulator Homo sapiens 0-5 7691610-8 1993 Consistent with these results, herbimycin A (5 microM) abolished the expression of the 26 kDa bcl-2 protooncogene product, which confers resistance to apoptosis, normally observed following culture with anti-CD40. herbimycin 31-43 BCL2 apoptosis regulator Homo sapiens 94-99 8395979-1 1993 Previous studies have shown that bcl-2 overexpression can inhibit apoptosis induced by DNA-damaging agents widely used in cancer chemotherapy, including X-irradiation, alkylating agents (hydroperoxycyclophosphamide, etc. perfosfamide 187-214 BCL2 apoptosis regulator Homo sapiens 33-38 8395979-4 1993 In this study, we examined whether bcl-2 overexpression could have effects on etoposide-induced DNA damage and its repair. Etoposide 78-87 BCL2 apoptosis regulator Homo sapiens 35-40 8395979-6 1993 Overexpression of bcl-2 protein inhibited etoposide-induced apoptosis and cytotoxicity. Etoposide 42-51 BCL2 apoptosis regulator Homo sapiens 18-23 8395979-8 1993 These findings indicate that (a) apoptosis or cytotoxicity induced by etoposide can be separated into early events (formation of double-strand breaks, DNA single-strand breaks, and double-strand breaks) and later events (secondary DNA fragmentation or cell death) and (b) bcl-2 inhibits apoptosis and cytotoxicity induced by etoposide at some steps between these events. Etoposide 70-79 BCL2 apoptosis regulator Homo sapiens 272-277 8400801-0 1993 Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. Oligonucleotides 28-44 BCL2 apoptosis regulator Homo sapiens 62-67 21573386-5 1993 Further, the 19 kD and Bcl2 proteins also function similarly to suppress DNA fragmentation and cell death induced by the DNA damaging agents cisplatin and UV. Cisplatin 141-150 BCL2 apoptosis regulator Homo sapiens 23-27 8394449-4 1993 The expression of Bcl-2 in primary B cells infected with the B95-8 strain of EBV varied between 1 and 1.8 times that in uninfected cells when 50% of the cells were infected, expressed LMP, and incorporated 20-fold more [3H]thymidine than did uninfected cells. Tritium 220-222 BCL2 apoptosis regulator Homo sapiens 18-23 8394449-4 1993 The expression of Bcl-2 in primary B cells infected with the B95-8 strain of EBV varied between 1 and 1.8 times that in uninfected cells when 50% of the cells were infected, expressed LMP, and incorporated 20-fold more [3H]thymidine than did uninfected cells. Thymidine 223-232 BCL2 apoptosis regulator Homo sapiens 18-23 8371594-0 1993 Bcl-2 protein in centrocytic lymphoma; a paraffin section study. Paraffin 41-49 BCL2 apoptosis regulator Homo sapiens 0-5 8324744-11 1993 5-Fluorodeoxyuridine treatment reduced TTP synthesis, induced strand breaks in nascent DNA, measured by alkaline elution, and increased the synthesis of thymidylate synthase; these changes preceded the onset of apoptosis and were identical in the vector controls and bcl-2 transfectants. Floxuridine 0-20 BCL2 apoptosis regulator Homo sapiens 267-272 8400801-3 1993 Here we describe the effects of an 18-mer phosphodiester oligonucleotide that is complementary to the first 6 codons of the bcl-2 mRNA"s open reading frame. Oligonucleotides 57-72 BCL2 apoptosis regulator Homo sapiens 124-129 8467505-0 1993 Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Mechlorethamine 49-65 BCL2 apoptosis regulator Homo sapiens 33-38 8476431-0 1993 Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Mitomycin 66-69 BCL2 apoptosis regulator Homo sapiens 100-105 8467505-0 1993 Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Camptothecin 70-82 BCL2 apoptosis regulator Homo sapiens 33-38 8476431-0 1993 Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Irinotecan 71-77 BCL2 apoptosis regulator Homo sapiens 100-105 8476431-6 1993 Treatment with CDDP resulted in the same degree of DNA fragmentation in SBC-3 and SBC-3/Bcl2. cddp 15-19 BCL2 apoptosis regulator Homo sapiens 88-92 8467505-2 1993 We examined whether constitutive expression of transfected human bcl-2 conferred resistance to two different DNA damaging drugs, nitrogen mustard (HN2) and camptothecin (CPT) in a murine, IL-3 dependent cell line (FL5.12). Camptothecin 170-173 BCL2 apoptosis regulator Homo sapiens 65-70 8467505-2 1993 We examined whether constitutive expression of transfected human bcl-2 conferred resistance to two different DNA damaging drugs, nitrogen mustard (HN2) and camptothecin (CPT) in a murine, IL-3 dependent cell line (FL5.12). Mechlorethamine 129-145 BCL2 apoptosis regulator Homo sapiens 65-70 8467505-2 1993 We examined whether constitutive expression of transfected human bcl-2 conferred resistance to two different DNA damaging drugs, nitrogen mustard (HN2) and camptothecin (CPT) in a murine, IL-3 dependent cell line (FL5.12). Camptothecin 156-168 BCL2 apoptosis regulator Homo sapiens 65-70 8417786-6 1993 Although high levels of Bcl-2 protein protected 697 cells from the acute cytotoxic effects of DEX and the other drugs tested, Bcl-2 did not prevent these drugs from suppressing the proliferation of 697 cells. Dexamethasone 94-97 BCL2 apoptosis regulator Homo sapiens 24-29 8096557-3 1993 In addition, taxol treatment decreased BCL-2 oncogene expression, which is known to block PCD. Paclitaxel 13-18 BCL2 apoptosis regulator Homo sapiens 39-44 8417786-7 1993 However, when 697 cells were treated with DEX or MTX for 3 days, then washed and cultured in semisolid media without drugs, bcl-2-virus-infected cells gave rise to colonies at much higher frequencies than 697 cells stably infected with control virus. Dexamethasone 42-45 BCL2 apoptosis regulator Homo sapiens 124-129 8417786-7 1993 However, when 697 cells were treated with DEX or MTX for 3 days, then washed and cultured in semisolid media without drugs, bcl-2-virus-infected cells gave rise to colonies at much higher frequencies than 697 cells stably infected with control virus. Methotrexate 49-52 BCL2 apoptosis regulator Homo sapiens 124-129 8417786-8 1993 These results indicate that by protecting 697 leukemic cells from the acute cytotoxicity of DEX and some other chemotherapeutic drugs, high levels of p26-Bcl-2 can create the opportunity for re-initiation of cell growth when drugs are withdrawn. Dexamethasone 92-95 BCL2 apoptosis regulator Homo sapiens 154-159 1427749-3 1992 We have studied the expression of this protein in different subtypes of Hodgkin"s disease using monoclonal antibodies directed against a formalin-resistant epitope of the bcl-2 protein and also have investigated these cases by polymerase chain reaction for evidence of the t(14;18) translocation. Formaldehyde 137-145 BCL2 apoptosis regulator Homo sapiens 171-176 1458483-8 1992 Addition of exogenous testosterone with, or without, flutamide demonstrated that the increased bcl-2 mRNA resulted from androgen ablation. Testosterone 22-34 BCL2 apoptosis regulator Homo sapiens 95-100 1458483-8 1992 Addition of exogenous testosterone with, or without, flutamide demonstrated that the increased bcl-2 mRNA resulted from androgen ablation. Flutamide 53-62 BCL2 apoptosis regulator Homo sapiens 95-100 1459737-8 1992 Expression of the bcl-2 protein in BL group-I cells following gene transfer affords protection from apoptosis induced by ionomycin or anti-Ig. Ionomycin 121-130 BCL2 apoptosis regulator Homo sapiens 18-23 1459737-9 1992 In the present study, bcl-2 was additionally found to protect from apoptosis driven by staurosporine. Staurosporine 87-100 BCL2 apoptosis regulator Homo sapiens 22-27 8449825-0 1993 bcl-2 gene rearrangement analysis of Japanese follicular lymphomas by polymerase chain reaction in formalin-fixed, paraffin-embedded tissue specimens. Formaldehyde 99-107 BCL2 apoptosis regulator Homo sapiens 0-5 8449825-0 1993 bcl-2 gene rearrangement analysis of Japanese follicular lymphomas by polymerase chain reaction in formalin-fixed, paraffin-embedded tissue specimens. Paraffin 115-123 BCL2 apoptosis regulator Homo sapiens 0-5 8260751-0 1993 Effect of Bcl-2 on ionizing radiation and 1-beta-D-arabinofuranosylcytosine-induced internucleosomal DNA fragmentation and cell survival in human myeloid leukemia cells. Cytarabine 42-75 BCL2 apoptosis regulator Homo sapiens 10-15 8260751-5 1993 Bcl-2 was capable of inhibiting 40-50% of the ara-C and ionizing radiation-induced internucleosomal DNA fragmentation at all tested concentrations. Cytarabine 46-51 BCL2 apoptosis regulator Homo sapiens 0-5 8260751-6 1993 However, cell survival following exposure to these agents was only increased in the bcl-2 transfectants at relatively low doses of ara-C and ionizing radiation. Cytarabine 131-136 BCL2 apoptosis regulator Homo sapiens 84-89 8260751-7 1993 These data demonstrate that although bcl-2 is capable of inhibiting ara-C and ionizing radiation-induced DNA fragmentation in myeloid cells, it increases cell survival only at low doses of these agents. Cytarabine 68-73 BCL2 apoptosis regulator Homo sapiens 37-42 1374590-1 1992 Expression of bcl-2 protein was analyzed in 140 cases of follicular lymphoma by immunohistologic staining of paraffin-embedded tissue; 85% of cases were positive, the frequency being related to histologic grade (100% for the small-cleaved cell type, 86% for the mixed cell type, and 76% for the large cell group). Paraffin 109-117 BCL2 apoptosis regulator Homo sapiens 14-19 1502141-7 1992 Metabolic labeling of insect cells expressing the full-length and the truncated form of BCL2 with 32P(i) demonstrated that BCL2 is a phosphoprotein. Phosphorus-32 98-101 BCL2 apoptosis regulator Homo sapiens 88-92 1502141-7 1992 Metabolic labeling of insect cells expressing the full-length and the truncated form of BCL2 with 32P(i) demonstrated that BCL2 is a phosphoprotein. Phosphorus-32 98-101 BCL2 apoptosis regulator Homo sapiens 123-127 1378321-7 1992 The strongest effect on bcl-2 was obtained by transfection with LMP, or infection with the nondefective virus. (2~{s},3~{r},4~{s})-2-[(2~{s},3~{r})-1,3-Bis(Oxidanyl)-1-Oxidanylidene-Butan-2-Yl]-4-[(3~{s},5~{s})-5-(Dimethylcarbamoyl)pyrrolidin-3-Yl]sulfanyl-3-Methyl-3,4-Dihydro-2~{h}-Pyrrole-5-Carboxylic Acid 64-67 BCL2 apoptosis regulator Homo sapiens 24-29 1375120-4 1992 Activation of 173 and 183 B-CLL cells by phorbol esters (12-O-tetradecanoylphorbol-13-acetate [TPA]) to IgM secretion without concomitant DNA synthesis resulted in a rapid but transient downregulation of bcl-2 expression. Phorbol Esters 41-55 BCL2 apoptosis regulator Homo sapiens 204-209 1375120-4 1992 Activation of 173 and 183 B-CLL cells by phorbol esters (12-O-tetradecanoylphorbol-13-acetate [TPA]) to IgM secretion without concomitant DNA synthesis resulted in a rapid but transient downregulation of bcl-2 expression. Tetradecanoylphorbol Acetate 57-93 BCL2 apoptosis regulator Homo sapiens 204-209 1375120-4 1992 Activation of 173 and 183 B-CLL cells by phorbol esters (12-O-tetradecanoylphorbol-13-acetate [TPA]) to IgM secretion without concomitant DNA synthesis resulted in a rapid but transient downregulation of bcl-2 expression. Tetradecanoylphorbol Acetate 95-98 BCL2 apoptosis regulator Homo sapiens 204-209 1588282-6 1992 We propose that the chi-like signal sequences of BCL2 represent a distinct class of recognition sites for the recombinase complex, responsible for initiating interactions between regions of DNA separated by great distances, and that BCL2 translocation begins by a recombination event between mbr and DXP chi signals. dxp 300-303 BCL2 apoptosis regulator Homo sapiens 49-53 1899539-5 1991 bcl-2 translocation was determined with Southern blot analysis and the polymerase chain reaction using biotin labeled probes to the major breakpoint region and the alkaline phosphatase reaction. Biotin 103-109 BCL2 apoptosis regulator Homo sapiens 0-5 1633729-2 1992 We have developed a sensitive immunofluorescence assay for the single- and multicolor flow cytometric analysis of bcl-2 protein in relation to other markers and cell cycle, based on a fixation-permeation step of cells with paraformaldehyde and Triton X100 and the use of a bcl-2 specific monoclonal antibody (MoAb). paraform 223-239 BCL2 apoptosis regulator Homo sapiens 114-119 1633729-2 1992 We have developed a sensitive immunofluorescence assay for the single- and multicolor flow cytometric analysis of bcl-2 protein in relation to other markers and cell cycle, based on a fixation-permeation step of cells with paraformaldehyde and Triton X100 and the use of a bcl-2 specific monoclonal antibody (MoAb). Octoxynol 244-255 BCL2 apoptosis regulator Homo sapiens 114-119 1654915-2 1991 The studies demonstrated the reliability of digoxigenin-labeled probes for the detection of single-copy genes after Southern blotting of genomic DNA: 1 microgram and sometimes even 0.2 microgram of restriction endonuclease-digested DNA could be detected either by JH, C beta or bcl-2 probes. Digoxigenin 44-55 BCL2 apoptosis regulator Homo sapiens 278-283 2011401-3 1991 In unstimulated proliferating JURKAT cells, high levels of C-MYC, N-RAS, and BCL2 mRNAs were found that diminished rapidly following TPA-induced cessation of growth. Tetradecanoylphorbol Acetate 133-136 BCL2 apoptosis regulator Homo sapiens 77-81 2011401-8 1991 Thus, although C-MYC and BCL2 proto-oncogene expression correlated with proliferation in TPA-treated JURKAT cells, continuous over-expression of even the combination of these oncogenes was insufficient for abrogating the effects of TPA in these leukemic T cells. Tetradecanoylphorbol Acetate 89-92 BCL2 apoptosis regulator Homo sapiens 25-29 1311213-10 1992 Rather, three of 10 evaluable nBTs had bcl-2 rearrangements. Nitroblue Tetrazolium 30-34 BCL2 apoptosis regulator Homo sapiens 39-44 1339299-10 1992 Interestingly, two of the patients contained an identical C----T transition that resulted in a nonconservative aa substitution (proline----serine) at position 59 of the BCL2 protein. proline----serine 128-145 BCL2 apoptosis regulator Homo sapiens 169-173 2119549-0 1990 BCL-2 alpha encodes a novel small molecular weight GTP binding protein. Guanosine Triphosphate 51-54 BCL2 apoptosis regulator Homo sapiens 0-5 2176281-6 1990 Here we demonstrate that the breakpoints at the 5" flanking region of bcl-2 gene are surrounded by multiple alternating purine-pyrimidine elements (potential Z-DNA). purine 120-126 BCL2 apoptosis regulator Homo sapiens 70-75 2176281-6 1990 Here we demonstrate that the breakpoints at the 5" flanking region of bcl-2 gene are surrounded by multiple alternating purine-pyrimidine elements (potential Z-DNA). pyrimidine 127-137 BCL2 apoptosis regulator Homo sapiens 70-75 2121338-1 1990 The role of bcl-2 in the signal transduction pathway was assessed by studying the inositol phospholipid metabolism in fibroblasts transfected by this oncogene. Phosphatidylinositols 82-103 BCL2 apoptosis regulator Homo sapiens 12-17 2121338-2 1990 The rate of accumulation of water soluble inositol phosphates in response to several growth factors was much higher in bcl-2 transfected NIH3T3 clones than in untransfected control. Water 28-33 BCL2 apoptosis regulator Homo sapiens 119-124 2121338-2 1990 The rate of accumulation of water soluble inositol phosphates in response to several growth factors was much higher in bcl-2 transfected NIH3T3 clones than in untransfected control. Inositol Phosphates 42-61 BCL2 apoptosis regulator Homo sapiens 119-124 2121338-3 1990 Moreover, bcl-2 transfected clones express elevated levels of phosphatidic acid, a phospholipid produced during receptor stimulated breakdown of phosphoinositides. Phosphatidic Acids 62-79 BCL2 apoptosis regulator Homo sapiens 10-15 2121338-3 1990 Moreover, bcl-2 transfected clones express elevated levels of phosphatidic acid, a phospholipid produced during receptor stimulated breakdown of phosphoinositides. Phospholipids 83-95 BCL2 apoptosis regulator Homo sapiens 10-15 2121338-3 1990 Moreover, bcl-2 transfected clones express elevated levels of phosphatidic acid, a phospholipid produced during receptor stimulated breakdown of phosphoinositides. Phosphatidylinositols 145-162 BCL2 apoptosis regulator Homo sapiens 10-15 2121338-4 1990 Our findings suggest that the expression of bcl-2 in NIH3T3 fibroblasts leads to the coupling of growth factor receptors to stimulate inositol phosphate production, henceforth establishing its role in the growth factor receptor mediated signal transduction pathway. Inositol Phosphates 134-152 BCL2 apoptosis regulator Homo sapiens 44-49 2263590-2 1990 We studied 115 cases of lymphoproliferative disease with the polymerase chain reaction for bcl-2 oncogene using biotin and radiolabeled probes to the major breakpoint and minor cluster regions. Biotin 112-118 BCL2 apoptosis regulator Homo sapiens 91-96 2208117-1 1990 Antisense oligodeoxynucleotides specific for sequences in mRNAs from the B-cell lymphoma/leukemia-2 (BCL2) gene were used to inhibit the growth in culture of a human leukemia cell line, 697. Oligodeoxyribonucleotides 10-31 BCL2 apoptosis regulator Homo sapiens 73-99 2208117-1 1990 Antisense oligodeoxynucleotides specific for sequences in mRNAs from the B-cell lymphoma/leukemia-2 (BCL2) gene were used to inhibit the growth in culture of a human leukemia cell line, 697. Oligodeoxyribonucleotides 10-31 BCL2 apoptosis regulator Homo sapiens 101-105 2208117-4 1990 Specificity was further confirmed by quantitative immunofluorescence studies, showing that PO and PS antisense BCL2 oligodeoxynucleotides (when used at appropriate concentrations) reduced levels of BCL2 protein without influencing expression of HLA-DR and other control antigens. Polonium 91-93 BCL2 apoptosis regulator Homo sapiens 198-202 2208117-4 1990 Specificity was further confirmed by quantitative immunofluorescence studies, showing that PO and PS antisense BCL2 oligodeoxynucleotides (when used at appropriate concentrations) reduced levels of BCL2 protein without influencing expression of HLA-DR and other control antigens. Parathion 98-100 BCL2 apoptosis regulator Homo sapiens 111-115 2208117-4 1990 Specificity was further confirmed by quantitative immunofluorescence studies, showing that PO and PS antisense BCL2 oligodeoxynucleotides (when used at appropriate concentrations) reduced levels of BCL2 protein without influencing expression of HLA-DR and other control antigens. Parathion 98-100 BCL2 apoptosis regulator Homo sapiens 198-202 2208117-8 1990 Taken together, these data indicate that PO and PS oligodeoxynucleotides targeted against the human BCL2 protooncogene can be sequence-specific inhibitors of leukemic cell growth and survival. Polonium 41-43 BCL2 apoptosis regulator Homo sapiens 100-104 2208117-8 1990 Taken together, these data indicate that PO and PS oligodeoxynucleotides targeted against the human BCL2 protooncogene can be sequence-specific inhibitors of leukemic cell growth and survival. ps oligodeoxynucleotides 48-72 BCL2 apoptosis regulator Homo sapiens 100-104 2114553-4 1990 To test the suggestion that GTP-binding by Bcl-2 may mediate its biological effects we characterized the GTP-binding proteins in lymphoid cells expressing Bcl-2. Guanosine Triphosphate 28-31 BCL2 apoptosis regulator Homo sapiens 43-48 2114553-4 1990 To test the suggestion that GTP-binding by Bcl-2 may mediate its biological effects we characterized the GTP-binding proteins in lymphoid cells expressing Bcl-2. Guanosine Triphosphate 28-31 BCL2 apoptosis regulator Homo sapiens 155-160 2114553-4 1990 To test the suggestion that GTP-binding by Bcl-2 may mediate its biological effects we characterized the GTP-binding proteins in lymphoid cells expressing Bcl-2. Guanosine Triphosphate 105-108 BCL2 apoptosis regulator Homo sapiens 43-48 2114553-4 1990 To test the suggestion that GTP-binding by Bcl-2 may mediate its biological effects we characterized the GTP-binding proteins in lymphoid cells expressing Bcl-2. Guanosine Triphosphate 105-108 BCL2 apoptosis regulator Homo sapiens 155-160 2194586-4 1990 One of these junctions had an unusual configuration with the bcl-2 and JH sequences separated by a recognizable DH region. Dihydrotestosterone 112-114 BCL2 apoptosis regulator Homo sapiens 61-66 2119549-1 1990 Despite little sequence homology other than the GDP/GTP binding region, bcl-2 and ras proteins behave in similar fashion in many physiological and biochemical aspects. Guanosine Diphosphate 48-51 BCL2 apoptosis regulator Homo sapiens 72-77 2119549-1 1990 Despite little sequence homology other than the GDP/GTP binding region, bcl-2 and ras proteins behave in similar fashion in many physiological and biochemical aspects. Guanosine Triphosphate 52-55 BCL2 apoptosis regulator Homo sapiens 72-77 33826130-3 2021 PDE4 is an isoenzyme that degrades 3"-5"-cyclic adenosine monophosphate (cAMP), which serves as a neuroprotective agent by promoting neuronal recovery through protein kinase (PKA)-mediated phosphorylation of cAMP response element-binding protein (CREB) and subsequent expression of the neurotrophic factor brain-derived neurotrophic factor (BDNF) and anti-apoptotic B cell lymphoma (Bcl-2). Adenosine 48-57 BCL2 apoptosis regulator Homo sapiens 383-388 33824975-5 2021 However, we show that TP53 mutated or deficient myeloid and lymphoid leukemias outcompete isogenic controls with intact TP53, unless sufficient concentrations of BH3-mimetics targeting BCL2 or MCL1 are applied. BH 3 162-165 BCL2 apoptosis regulator Homo sapiens 185-189 27457296-3 1990 The specificity of the amplification allowed visual identification of the bcl-2/JH PCR-products in ethidium bromide stained agarose gels. Ethidium 99-115 BCL2 apoptosis regulator Homo sapiens 74-79 27457296-3 1990 The specificity of the amplification allowed visual identification of the bcl-2/JH PCR-products in ethidium bromide stained agarose gels. Sepharose 124-131 BCL2 apoptosis regulator Homo sapiens 74-79 33826130-3 2021 PDE4 is an isoenzyme that degrades 3"-5"-cyclic adenosine monophosphate (cAMP), which serves as a neuroprotective agent by promoting neuronal recovery through protein kinase (PKA)-mediated phosphorylation of cAMP response element-binding protein (CREB) and subsequent expression of the neurotrophic factor brain-derived neurotrophic factor (BDNF) and anti-apoptotic B cell lymphoma (Bcl-2). Cyclic AMP 73-77 BCL2 apoptosis regulator Homo sapiens 383-388 33761607-4 2021 Then we also found that [Mn(PaPy2Q)(NO)]ClO4 increased the expression of apoptosis-related proteins (PARP, Bax, Caspase 3/9), inhibited the expression of BCl-2 and increased the activity level of Caspase 3/7, which showed [Mn(PaPy2Q)(NO)]ClO4 promoted prostate cancer cells apoptosis. perchlorate 40-44 BCL2 apoptosis regulator Homo sapiens 154-159 33777189-0 2021 miR-23a-3p regulates the proliferation and apoptosis of human lens epithelial cells by targeting Bcl-2 in an in vitro model of cataracts. mir-23a-3p 0-10 BCL2 apoptosis regulator Homo sapiens 97-102 33777189-9 2021 The results of the present study revealed that the expression levels of miR-23a-3p were significantly upregulated, while the expression levels of BCL2 were significantly downregulated in H2O2-induced HLE-B3 cells compared to untreated control cells. Hydrogen Peroxide 187-191 BCL2 apoptosis regulator Homo sapiens 146-150 33777189-11 2021 The miR-23a-3p inhibitor subsequently attenuated H2O2-induced apoptosis and increased the proliferation of HLE-B3 cells, which was partially reversed by siRNA-BCL2. mir-23a-3p 4-14 BCL2 apoptosis regulator Homo sapiens 159-163 33777189-11 2021 The miR-23a-3p inhibitor subsequently attenuated H2O2-induced apoptosis and increased the proliferation of HLE-B3 cells, which was partially reversed by siRNA-BCL2. Hydrogen Peroxide 49-53 BCL2 apoptosis regulator Homo sapiens 159-163 33777189-12 2021 In conclusion, the findings of the current study suggested that the inhibition of miR-23a-3p may attenuate H2O2-induced cataract formation by targeting BCL2, thus providing a novel therapeutic target for the treatment of patients with cataracts in the clinic. Hydrogen Peroxide 107-111 BCL2 apoptosis regulator Homo sapiens 152-156 33773191-11 2021 DS-1 treatment in combination with cisplatin could enhance activated p-p53 (Ser15) and p53 downstream signaling (Bax, Bcl-2, and Akt), leading to a higher level of apoptosis. Cisplatin 35-44 BCL2 apoptosis regulator Homo sapiens 118-123 33811596-5 2021 Moreover, Dio upregulated the levels of Bax and cleaved Caspase-3 and PARP while downregulating the level of Bcl2. diosmetin 10-13 BCL2 apoptosis regulator Homo sapiens 109-113 33939846-11 2021 Moreover, siHOTAIRM1 significantly increased expression of pro-apoptotic agents, such as Bad and Bax, while it decreased expressions of Bid and Bcl-2 (anti-apoptotic agents). sihotairm1 10-20 BCL2 apoptosis regulator Homo sapiens 144-149 33777218-9 2021 Albendazole also decreased the mRNA expression of catenin beta1 and transcription factor 4, which regulate Wnt/beta-catenin signaling and its associated targets, Twist family BHLH transcription factor 1 and BCL2. Albendazole 0-11 BCL2 apoptosis regulator Homo sapiens 207-211 33761607-4 2021 Then we also found that [Mn(PaPy2Q)(NO)]ClO4 increased the expression of apoptosis-related proteins (PARP, Bax, Caspase 3/9), inhibited the expression of BCl-2 and increased the activity level of Caspase 3/7, which showed [Mn(PaPy2Q)(NO)]ClO4 promoted prostate cancer cells apoptosis. papy2q 28-34 BCL2 apoptosis regulator Homo sapiens 154-159 33236943-1 2021 Navitoclax, a novel BCL-2 and BCL-XL inhibitor, demonstrated promising antitumor activity in the dose-escalation part of a phase 1/2a study (NCT00406809) in lymphoid tumors. navitoclax 0-10 BCL2 apoptosis regulator Homo sapiens 20-25 33808343-6 2021 Treatment of differentiated SH-SY5Y cells with 6-OHDA brought cell death, and specifically, apoptosis, which was significantly inhibited by the preincubation with MJe through caspase 3 blockage and the modulation of p53, Bax, and Bcl-2 genes. Oxidopamine 47-53 BCL2 apoptosis regulator Homo sapiens 230-235 33823883-5 2021 Palmitate inhibited starvation-induced ER-phagy by increasing the level of B-cell lymphoma 2 (Bcl-2) protein, which inhibits autophagy initiation. Palmitates 0-9 BCL2 apoptosis regulator Homo sapiens 75-92 33823883-5 2021 Palmitate inhibited starvation-induced ER-phagy by increasing the level of B-cell lymphoma 2 (Bcl-2) protein, which inhibits autophagy initiation. Palmitates 0-9 BCL2 apoptosis regulator Homo sapiens 94-99 33825398-6 2021 Immunohistochemical analysis of tumor tissues was performed to evaluate the effects of BSJP alone, sorafenib alone, and their combination on the expression of caspase-3, caspase-9, and Bcl-2. Sorafenib 99-108 BCL2 apoptosis regulator Homo sapiens 185-190 33825398-10 2021 In vivo and in vitro experiments showed that BSJP combined with sorafenib could significantly decrease the expression of Bcl-2. Sorafenib 64-73 BCL2 apoptosis regulator Homo sapiens 121-126 33588013-6 2021 Under the same condition, CdCl2 treatment increased Bax/Bcl-2 ratios by up-regulating Bax expression and down-regulating Bcl-2 expression, and activated apoptotic executive molecule caspase-3, which irreversibly induced HTR-8/SVneo cell apoptosis. Cadmium Chloride 26-31 BCL2 apoptosis regulator Homo sapiens 56-61 33588013-6 2021 Under the same condition, CdCl2 treatment increased Bax/Bcl-2 ratios by up-regulating Bax expression and down-regulating Bcl-2 expression, and activated apoptotic executive molecule caspase-3, which irreversibly induced HTR-8/SVneo cell apoptosis. Cadmium Chloride 26-31 BCL2 apoptosis regulator Homo sapiens 121-126 33812419-0 2021 [Up-Regulation of Bax/BCL-2 Ratio by 2-Methoxyestradiol Induces Apoptosis in Lymphoma Raji Cells]. 2-Methoxyestradiol 37-55 BCL2 apoptosis regulator Homo sapiens 22-27 33812419-5 2021 Western blotting was used to detect the effect of 2-ME2 to the expression of BCL-2, Bax, Caspase-3 and C-myc proteins in Raji cells. 2-Methoxyestradiol 50-55 BCL2 apoptosis regulator Homo sapiens 77-82 33812419-9 2021 After treated with 2.5 mumol/L 2-ME2 for 12 h, the expression of Bax protein was up-regulated, BCL-2 protein was down-regulated, caspase-3 protein expression was up-regulated, and C-myc protein expression was down-regulated, all of them showed a time-dependent relationship. 2-Methoxyestradiol 31-36 BCL2 apoptosis regulator Homo sapiens 95-100 33768318-3 2021 In this study, we aim to validate the diagnostic performance of multiplex BCL2/BCL6 FISH approach in formalin-fixed paraffin-embedded FLs and DBCLs and cytological samples of DLBCL comparing to the classic set of single break-apart probes. Formaldehyde 101-109 BCL2 apoptosis regulator Homo sapiens 74-78 33774859-6 2021 SS-31 inhibited apoptosis through the downregulation of Bax and the upregulation of Bcl-2. arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide 0-5 BCL2 apoptosis regulator Homo sapiens 84-89 33768318-3 2021 In this study, we aim to validate the diagnostic performance of multiplex BCL2/BCL6 FISH approach in formalin-fixed paraffin-embedded FLs and DBCLs and cytological samples of DLBCL comparing to the classic set of single break-apart probes. Paraffin 116-124 BCL2 apoptosis regulator Homo sapiens 74-78 33800911-6 2021 Dinaciclib was shown to elicit a bimodal action in EC cell lines, disrupting both cell cycle progression and phosphorylation of the RNA polymerase carboxy terminal domain, with a concomitant reduction in Bcl-2 expression. dinaciclib 0-10 BCL2 apoptosis regulator Homo sapiens 204-209 33805658-10 2021 Moreover, alpha-solanine downregulated proliferative cellular nuclear antigen (PCNA) and Bcl-2 levels and promoted the expression of Bax. alpha-solanine 10-24 BCL2 apoptosis regulator Homo sapiens 89-94 33803402-10 2021 Functional assessment of BCL-2 inhibition via Bax translocation assay revealed slightly increased pro-apoptotic signaling after combined MK-2206 and venetoclax incubation. MK 2206 137-144 BCL2 apoptosis regulator Homo sapiens 25-30 33807853-6 2021 Moreover, PHE treatment downregulated the transcriptional levels of Bcl-2, AMPK, and p-Akt, whereas it significantly upregulated the levels of cleaved caspase-3, cleaved caspase-9, and cleaved-PARP. Phenylalanine 10-13 BCL2 apoptosis regulator Homo sapiens 68-73 33763175-6 2021 According to the results of the apoptosis assay, a farrerol pretreatment decreased the protein expression of the Bax/Bcl-2, cleaved caspase-3, PARP, caspase-8, and caspase-9 proteins. farrerol 51-59 BCL2 apoptosis regulator Homo sapiens 117-122 33806619-0 2021 Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma. mir-193b-3p 106-117 BCL2 apoptosis regulator Homo sapiens 70-75 33806619-1 2021 BH3-mimetics targeting anti-apoptotic proteins such as MCL-1 (S63845) or BCL-2 (venetoclax) are currently being evaluated as effective therapies for the treatment of multiple myeloma (MM). BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 73-78 33793811-7 2021 KEY FINDINGS: Eupafolin induced apoptosis in this cell line evidenced by the caspases activation, cleavage of PARP and downregulation of Bcl-2 and Bcl-xl. eupafolin 14-23 BCL2 apoptosis regulator Homo sapiens 137-142 33235611-5 2021 Further investigation revealed that BCL2-antagonist/killer 1 (BAK1) was a predicted target gene of miR-345-3p, and the expression of BAK1 was significantly increased in patients with GDM compared with healthy pregnant women. mir-345-3p 99-109 BCL2 apoptosis regulator Homo sapiens 36-40 33785100-6 2021 The results proved the presence of ROS that triggered the intrinsic apoptotic pathway, which was confirmed through a decrease in (Bcl-2), the release of cytochrome c, activation of caspase-9, and caspase-3. ros 35-38 BCL2 apoptosis regulator Homo sapiens 130-135 33235611-6 2021 In vitro analysis revealed that miR-345-3p mimic significantly increased cell viability, migration and invasion, inhibited apoptosis, upregulated Bcl-2 and matrix metallopeptidase 9 expression, and decreased Bax expression compared with the control group. mir-345-3p 32-42 BCL2 apoptosis regulator Homo sapiens 146-151 32886819-7 2021 In addition, crocin was also participated in a halting of the proteins related to cell cycle, cyclin D1, and pro-apoptotic proteins; Bax and caspase-3 expression, together with the elevation of anti-apoptotic factor Bcl-2. crocin 13-19 BCL2 apoptosis regulator Homo sapiens 216-221 33236136-0 2021 LINC00473 rescues human bone marrow mesenchymal stem cells from apoptosis induced by dexamethasone through the PEBP1-mediated Akt/Bad/Bcl-2 signaling pathway. Dexamethasone 85-98 BCL2 apoptosis regulator Homo sapiens 134-139 33032835-4 2020 We present an overview of the antagonism between BH3 mimetics and antiapoptotic BCL2 proteins. BH 3 49-52 BCL2 apoptosis regulator Homo sapiens 80-84 33232417-5 2020 Our findings indicated that IOT significantly inhibited neurotoxicity reduced apoptotic cell numbers, reactive oxygen species (ROS) overproduction and mitochondrial membrane potential, and modulated the expression of apoptosis-related proteins, including Bcl-2, Bax and caspase-3, which were induced by 6-OHDA. homoorientin 28-31 BCL2 apoptosis regulator Homo sapiens 255-260 33236136-9 2021 Of note, the regulatory effects of LINC00473 on the Akt/Bad/Bcl-2 signaling pathway and its anti-apoptotic effects were similar to those of SC79 (an Akt activator), and were inhibited by MK-2206 (an Akt inhibitor). MK 2206 187-194 BCL2 apoptosis regulator Homo sapiens 60-65 33235697-5 2020 In addition, GA promoted cell apoptosis in a concentration-dependent manner with the up-regulation of pro-apoptotic proteins (Bax, cleaved caspase-3, and cleaved caspase-9) and nuclear YAP/TAZ, as well as the down-regulation of anti-apoptotic protein Bcl-2 and the levels of p-YAP and p-TAZ. Gallic Acid 13-15 BCL2 apoptosis regulator Homo sapiens 251-256 31924677-0 2020 Withdrawal: Activation of AMP-activated protein kinase alpha1 alleviates endothelial cell apoptosis by increasing the expression of anti-apoptotic proteins Bcl-2 and Survivin. Adenosine Monophosphate 26-29 BCL2 apoptosis regulator Homo sapiens 156-161 33034216-8 2021 Annexin V-Cy3 staining suggested that APTE induced apoptosis in these cells which was further validated by attenuation of antiapoptotic Bcl-2 and induction of pro-apoptotic Bax, Caspase-7 expression and cleavage of PARP. apte 38-42 BCL2 apoptosis regulator Homo sapiens 136-141 30472432-5 2019 Western blot analysis showed that CCOP increased the expression of Bcl-2-associated X protein (Bax), cleaved caspase 3 and 9, while decreased B-cell lymphoma 2 (Bcl-2), cyclins D and E, cyclin dependent kinases (CDKs) 2, 4 and 6, along with the inactivation of the upstream phosphoinositide 3-kinase (Pi3k)/protein kinase B (Akt) signaling. ccop 34-38 BCL2 apoptosis regulator Homo sapiens 142-159 33763603-2 2019 Here we report a method for the rapid labelling of a protein using a ruthenium-bipyridyl (Ru(II)(bpy)3)-modified peptide designed to mimic an interacting BH3 ligand within a BCL-2 family protein-protein interactions. ruthenium-bipyridyl (ru(ii)(bpy)3) 69-103 BCL2 apoptosis regulator Homo sapiens 174-179 33817118-6 2018 Furthermore, the generation of reactive oxygen species (ROS) was up-regulated in KLE cells upon treatment with emodin, while the anti-oxidant agent N-acetyl cysteine (NAC) can inhibit emodin-induced apoptosis and promote the activation of AKT and Bcl-2. Reactive Oxygen Species 31-54 BCL2 apoptosis regulator Homo sapiens 247-252 33817118-6 2018 Furthermore, the generation of reactive oxygen species (ROS) was up-regulated in KLE cells upon treatment with emodin, while the anti-oxidant agent N-acetyl cysteine (NAC) can inhibit emodin-induced apoptosis and promote the activation of AKT and Bcl-2. Reactive Oxygen Species 56-59 BCL2 apoptosis regulator Homo sapiens 247-252 33817118-6 2018 Furthermore, the generation of reactive oxygen species (ROS) was up-regulated in KLE cells upon treatment with emodin, while the anti-oxidant agent N-acetyl cysteine (NAC) can inhibit emodin-induced apoptosis and promote the activation of AKT and Bcl-2. Emodin 111-117 BCL2 apoptosis regulator Homo sapiens 247-252 30472432-5 2019 Western blot analysis showed that CCOP increased the expression of Bcl-2-associated X protein (Bax), cleaved caspase 3 and 9, while decreased B-cell lymphoma 2 (Bcl-2), cyclins D and E, cyclin dependent kinases (CDKs) 2, 4 and 6, along with the inactivation of the upstream phosphoinositide 3-kinase (Pi3k)/protein kinase B (Akt) signaling. ccop 34-38 BCL2 apoptosis regulator Homo sapiens 67-72 33817118-6 2018 Furthermore, the generation of reactive oxygen species (ROS) was up-regulated in KLE cells upon treatment with emodin, while the anti-oxidant agent N-acetyl cysteine (NAC) can inhibit emodin-induced apoptosis and promote the activation of AKT and Bcl-2. Acetylcysteine 148-165 BCL2 apoptosis regulator Homo sapiens 247-252 33817118-6 2018 Furthermore, the generation of reactive oxygen species (ROS) was up-regulated in KLE cells upon treatment with emodin, while the anti-oxidant agent N-acetyl cysteine (NAC) can inhibit emodin-induced apoptosis and promote the activation of AKT and Bcl-2. Acetylcysteine 167-170 BCL2 apoptosis regulator Homo sapiens 247-252 26540186-9 2015 This up-regulation of bcl2 protein in MCF-7 cells was wtp53 dependent as pifithrine-alpha, a small molecule inhibitor of wtp53 function, completely reversed CPT resistance, suggesting that wtp53 and bcl2 proteins played important roles in CPT resistance. pifithrine 73-83 BCL2 apoptosis regulator Homo sapiens 22-26 33817118-6 2018 Furthermore, the generation of reactive oxygen species (ROS) was up-regulated in KLE cells upon treatment with emodin, while the anti-oxidant agent N-acetyl cysteine (NAC) can inhibit emodin-induced apoptosis and promote the activation of AKT and Bcl-2. Emodin 184-190 BCL2 apoptosis regulator Homo sapiens 247-252 27667548-5 2016 Furthermore, baicalein blocked the TNF-alpha-induced expression of NF-kappaB target genes involved in anti-apoptosis (cIAP-1, cIAP-2, FLIP and BCL-2), proliferation (COX-2, cyclin D1 and c-Myc), invasion (MMP-9), angiogenesis (VEGF) and major inflammatory cytokines (IL-8 and MCP1). baicalein 13-22 BCL2 apoptosis regulator Homo sapiens 143-148 29459573-11 2018 A Bcl-2 inhibitor, ABT-199, induced an apoptotic response in ASC-knockdown cells, and dasatinib, a Src inhibitor, blocked cell invasiveness. venetoclax 19-26 BCL2 apoptosis regulator Homo sapiens 2-7 25744098-8 2015 In H2O2-treated RGCs, the inhibition of miR-134 significantly elevated the expression of CREB and its downstream genes, including brain-derived neurotrophic factor (BDNF) and Bcl-2. Hydrogen Peroxide 3-7 BCL2 apoptosis regulator Homo sapiens 175-180 26629245-5 2015 Furthermore, the up-regulation of Bax/Bcl-2 ratio, the activation of caspase-3 and increased cleaved PARP was also observed in K562 cells treated with resveratrol. Resveratrol 151-162 BCL2 apoptosis regulator Homo sapiens 38-43 25284608-0 2015 Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. ibrutinib 15-24 BCL2 apoptosis regulator Homo sapiens 168-172 25284608-0 2015 Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. venetoclax 30-37 BCL2 apoptosis regulator Homo sapiens 168-172 23737847-0 2013 Inclusion Complex of Zerumbone with Hydroxypropyl- beta -Cyclodextrin Induces Apoptosis in Liver Hepatocellular HepG2 Cells via Caspase 8/BID Cleavage Switch and Modulating Bcl2/Bax Ratio. zerumbone 21-30 BCL2 apoptosis regulator Homo sapiens 173-177 22552048-5 2013 MATERIALS AND METHODS: A randomized phase II trial of men with mCRPC treated with DP + AT-101 (bcl-2 inhibitor) vs. DP plus placebo was analyzed. dp + at-101 82-93 BCL2 apoptosis regulator Homo sapiens 95-100 25157103-2 2014 The level of basal reactive oxygen species (ROS) is extremely low in transformed cells in correlation with elevated expressions of both antioxidant enzymes (catalase, SOD1, and SOD2) and antiapoptotic proteins (Bcl-2/Bcl-xL). Reactive Oxygen Species 19-42 BCL2 apoptosis regulator Homo sapiens 211-216 25157103-2 2014 The level of basal reactive oxygen species (ROS) is extremely low in transformed cells in correlation with elevated expressions of both antioxidant enzymes (catalase, SOD1, and SOD2) and antiapoptotic proteins (Bcl-2/Bcl-xL). Reactive Oxygen Species 44-47 BCL2 apoptosis regulator Homo sapiens 211-216 25157103-5 2014 The binding activities of Nrf2 on the antioxidant response element promoter regions of p62/Bcl-2/Bcl-xL were dramatically increased in the cadmium-exposed transformed cells. Cadmium 139-146 BCL2 apoptosis regulator Homo sapiens 91-96 24549762-6 2014 Furthermore, it prevented the decreased ratio of Bax/Bcl-2 caused by rotenone treatment. Rotenone 69-77 BCL2 apoptosis regulator Homo sapiens 53-58 21364630-7 2010 Western blotting revealed significantly upregulated oxygen-sensitive transcription factors hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha, while producing a biphasic response within HIF targets, including erythropoietin, vascular endothelial growth factor and Bcl-2 family members, during hypoxia and subsequent reoxygenation. Oxygen 52-58 BCL2 apoptosis regulator Homo sapiens 266-271 21380726-4 2011 Trichostatin A induced nuclear damage, decrease in Bid and Bcl-2 protein levels, increase in Bax levels, cytochrome c release, activation of caspases (8, 9, and 3) and increase in tumor suppressor p53 levels. trichostatin A 0-14 BCL2 apoptosis regulator Homo sapiens 59-64 12538495-9 2003 Therefore, it is suggested that a decrease of the ceramide level via activation of GCS and SMS is associated with the chemoresistant condition in leukemia, probably in relation to Bcl-2 but not to MDR-1 expression. Ceramides 50-58 BCL2 apoptosis regulator Homo sapiens 180-185 12416266-0 2002 Z-ajoene induces apoptosis of HL-60 cells: involvement of Bcl-2 cleavage. (Z)-Ajoene 0-8 BCL2 apoptosis regulator Homo sapiens 58-63 12416266-4 2002 The caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-[OMe]-fluoromethylketone inhibited Bcl-2 cleavage and apoptosis induced by Z-ajoene. benzyloxycarbonyl-val-ala-asp-[ome]-fluoromethylketone 22-76 BCL2 apoptosis regulator Homo sapiens 87-92 12416266-4 2002 The caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-[OMe]-fluoromethylketone inhibited Bcl-2 cleavage and apoptosis induced by Z-ajoene. (Z)-Ajoene 127-135 BCL2 apoptosis regulator Homo sapiens 87-92 12416266-6 2002 Hence, the transmission of apoptotic signal induced by Z-ajoene involved a reactive oxygen species-dependent pathway leading to caspase-dependent Bcl-2 cleavage. (Z)-Ajoene 55-63 BCL2 apoptosis regulator Homo sapiens 146-151 12416266-6 2002 Hence, the transmission of apoptotic signal induced by Z-ajoene involved a reactive oxygen species-dependent pathway leading to caspase-dependent Bcl-2 cleavage. Reactive Oxygen Species 75-98 BCL2 apoptosis regulator Homo sapiens 146-151 9407975-0 1997 Correspondence re: G. Palumbo et al., the tyrphostin AG17 induces apoptosis and inhibition of cdk2 activity in a lymphoma cell line that overexpresses bcl-2. Tyrphostins 42-52 BCL2 apoptosis regulator Homo sapiens 151-156 11167744-0 2000 Antisense oligonucleotides complementary to immunoglobulin sequences of BCL-2/immunoglobulin fusion transcript induce apoptosis of t(14;18) lymphoma cells. Oligonucleotides 10-26 BCL2 apoptosis regulator Homo sapiens 72-77 11167744-1 2000 Antisense oligodeoxyribonucleotides directed at the bcl-2 translational start site downregulate bcl-2 and inhibit growth of the t(14;18)-positive lymphoma line WSU-FSCCL. Oligodeoxyribonucleotides 10-35 BCL2 apoptosis regulator Homo sapiens 52-57 11167744-1 2000 Antisense oligodeoxyribonucleotides directed at the bcl-2 translational start site downregulate bcl-2 and inhibit growth of the t(14;18)-positive lymphoma line WSU-FSCCL. Oligodeoxyribonucleotides 10-35 BCL2 apoptosis regulator Homo sapiens 96-101 11167744-5 2000 Here, we have demonstrated that antisense oligodeoxyribonucleotides targeted to immunoglobulin c(mu) sequences downregulate bcl-2 protein expression and induce apoptosis of WSU-FSCCL cells. Oligodeoxyribonucleotides 42-67 BCL2 apoptosis regulator Homo sapiens 124-129 34931711-0 2022 BCL-2-family protein tBID can act as a BAX-like effector of apoptosis. tBID 21-25 BCL2 apoptosis regulator Homo sapiens 0-5 34931711-1 2022 During apoptosis, the BCL-2-family protein tBID promotes mitochondrial permeabilization by activating BAX and BAK and by blocking anti-apoptotic BCL-2 members. tBID 43-47 BCL2 apoptosis regulator Homo sapiens 145-150 34931711-3 2022 This previously unrecognized activity of tBID depends on helix 6, homologous to the pore-forming regions of BAX and BAK, and can be blocked by pro-survival BCL-2 proteins. tBID 41-45 BCL2 apoptosis regulator Homo sapiens 156-161 34931711-6 2022 Our findings define tBID as an effector of mitochondrial permeabilization in apoptosis and provide a new paradigm for BCL-2 proteins, with implications for anti-bacterial immunity and cancer therapy. tBID 20-24 BCL2 apoptosis regulator Homo sapiens 118-123 34875417-8 2022 Furthermore, we found that the regulation of PI3K/AKT and Bcl-2/Bax pathways, oxidative stress-triggered mitochondrial depolarization, and the activation of caspase cascade were identified as the underlying mechanisms for the enhanced apoptosis ratio in GES-1 cells when exposed to chlorinated PS-MPs. ps-mps 294-300 BCL2 apoptosis regulator Homo sapiens 58-63 34813895-10 2022 When 786-O cells were treated with paeonol, the expression of Bax increased while Bcl-2 and VEGFA decreased. paeonol 35-42 BCL2 apoptosis regulator Homo sapiens 82-87 34813895-11 2022 CONCLUSION: The present study demonstrated that paeonol might play an essential role in RCC by regulating cell proliferation, apoptosis, metastasis, and invasion through the Bcl-2/Bax signaling pathway and VEGFA, providing a theoretical and experimental scientific basis for future investigations of the antitumor effects of paeonol against RCC. paeonol 48-55 BCL2 apoptosis regulator Homo sapiens 174-179 34801392-4 2022 Combined with previously defined vibrational frequency trends, this analysis reveals key features of a 30-nucleotide unimolecular variant of the Bcl-2 proximal promoter that are consistent with its reported structure. 30-nucleotide 103-116 BCL2 apoptosis regulator Homo sapiens 145-150 34715300-10 2022 It also inhibited H2O2-induced apoptosis in SRA01/04 cells, increased the expression of Bcl-2 protein and decreased the expressions of Caspase-3 and Bax proteins. Hydrogen Peroxide 18-22 BCL2 apoptosis regulator Homo sapiens 88-93 34976158-7 2022 The results revealed that Anlotinib impaired cell viability and colony formation, reduced proliferating cell nuclear antigen, Ki-67, MMP2, MMP9 and Bcl-2 expression levels, and inhibited cell migration and invasion. anlotinib 26-35 BCL2 apoptosis regulator Homo sapiens 148-153 34968404-2 2022 Beef semimembranosus (SM) muscles at 45 min postmortem were treated with nitric oxide (NO) donor, control (NaCl solution), or nitric oxide synthase (NOS) inhibitor for 24 h at 4 C. Bcl-2 expression and mitochondrial membrane potential were significantly increased by the NO donor treatment at 6 h postmortem, while the NOS inhibitor group exhibited a lower Bcl-2 level and mitochondrial membrane potential in comparison with the control (P < 0.05). Nitric Oxide 73-85 BCL2 apoptosis regulator Homo sapiens 182-187 34968404-2 2022 Beef semimembranosus (SM) muscles at 45 min postmortem were treated with nitric oxide (NO) donor, control (NaCl solution), or nitric oxide synthase (NOS) inhibitor for 24 h at 4 C. Bcl-2 expression and mitochondrial membrane potential were significantly increased by the NO donor treatment at 6 h postmortem, while the NOS inhibitor group exhibited a lower Bcl-2 level and mitochondrial membrane potential in comparison with the control (P < 0.05). nacl solution 107-120 BCL2 apoptosis regulator Homo sapiens 182-187 34878156-6 2022 Exosomal prostaglandin E2 (PGE2)-mediated ERK1/2 and GSK-3beta phosphorylation were revealed to increase Bcl-2 and decrease Bax expression with mitochondrial permeability transition pore-inhibition which may be considered a prime mechanism of exosome-mediated hepatoprotection. Dinoprostone 9-25 BCL2 apoptosis regulator Homo sapiens 105-110 34878156-6 2022 Exosomal prostaglandin E2 (PGE2)-mediated ERK1/2 and GSK-3beta phosphorylation were revealed to increase Bcl-2 and decrease Bax expression with mitochondrial permeability transition pore-inhibition which may be considered a prime mechanism of exosome-mediated hepatoprotection. Dinoprostone 27-31 BCL2 apoptosis regulator Homo sapiens 105-110 34913075-13 2022 Furthermore, niclosamide upregulated protein expression of cleaved caspase-3 and LC3B, while downregulated those of Bcl-2 and p62, in a dose-dependent manner in both Jurkat and CCRF-CEM cells. Niclosamide 13-24 BCL2 apoptosis regulator Homo sapiens 116-121 34922028-5 2022 Effects on the expression of apoptosis-related molecules such as Bcl2, Bcl-XL, caspase-3, caspase-9 and FADD suggested that PMMB-302 has tumor suppressive roles in lung cancer cells. pmmb 124-128 BCL2 apoptosis regulator Homo sapiens 65-69 34636125-8 2022 RESULTS: Under high glucose conditions, the viability of ARPE-19 was decreased and the apoptosis rate increased, the protein expressions of Bax, Caspase-3, LC3-II/LC3-I, and p-p53 were all increased and the expressions of Bcl-2, p62, and p-mTOR decreased, and autophagic flux was increased compared with that of the controls. Glucose 20-27 BCL2 apoptosis regulator Homo sapiens 222-227 34332791-12 2022 To our best knowledge, we have reported the first BCL2 G101V mutation in an RS patient treated with venetoclax. venetoclax 100-110 BCL2 apoptosis regulator Homo sapiens 50-54 34992683-8 2022 Additionally, it was demonstrated that paclitaxel-induced degradation of the inhibitor of NF-kappaB, activation of NF-kappaB in a dose-dependent manner, and Bcl-2 and Bcl-xL upregulation. Paclitaxel 39-49 BCL2 apoptosis regulator Homo sapiens 157-162 34800879-6 2022 Generally, both cell lines treated with the combination of Flutamide and ATO showed a decrease in expression of KLK2, angiogenesis genes (VEGFA and VEGFC), and apoptosis gene (Bcl2), and an increase in expression of E-cadherin and P53 genes; however, contradictory findings were found regarding SNAIL expression in LNCaP and PC3 cells. Flutamide 59-68 BCL2 apoptosis regulator Homo sapiens 176-180 34942456-10 2022 Our results confirmed that ZJC inhibited cycle progression, migration and induced apoptosis by targeting candidate genes (CDKN1A, Bcl2, E2F1, PRKCB, MYC, CDK2, and MMP9). zjc 27-30 BCL2 apoptosis regulator Homo sapiens 130-134 34942456-12 2022 CONCLUSIONS: In summary, combined network pharmacology and biological experiments proved that the main ingredients of ZJC such as quercetin, (R)-Canadine, palmatine, rutaecarpine, evodiamine, beta-sitosterol and berberine can target CDKN1A, Bcl2, E2F1, PRKCB, MYC, CDK2 and MMP9 to combat colorectal cancer. zjc 118-121 BCL2 apoptosis regulator Homo sapiens 241-245 34942456-12 2022 CONCLUSIONS: In summary, combined network pharmacology and biological experiments proved that the main ingredients of ZJC such as quercetin, (R)-Canadine, palmatine, rutaecarpine, evodiamine, beta-sitosterol and berberine can target CDKN1A, Bcl2, E2F1, PRKCB, MYC, CDK2 and MMP9 to combat colorectal cancer. Quercetin 130-139 BCL2 apoptosis regulator Homo sapiens 241-245 34942456-12 2022 CONCLUSIONS: In summary, combined network pharmacology and biological experiments proved that the main ingredients of ZJC such as quercetin, (R)-Canadine, palmatine, rutaecarpine, evodiamine, beta-sitosterol and berberine can target CDKN1A, Bcl2, E2F1, PRKCB, MYC, CDK2 and MMP9 to combat colorectal cancer. (R)-Canadine 141-153 BCL2 apoptosis regulator Homo sapiens 241-245 34942456-12 2022 CONCLUSIONS: In summary, combined network pharmacology and biological experiments proved that the main ingredients of ZJC such as quercetin, (R)-Canadine, palmatine, rutaecarpine, evodiamine, beta-sitosterol and berberine can target CDKN1A, Bcl2, E2F1, PRKCB, MYC, CDK2 and MMP9 to combat colorectal cancer. palmatine 155-164 BCL2 apoptosis regulator Homo sapiens 241-245 34942456-12 2022 CONCLUSIONS: In summary, combined network pharmacology and biological experiments proved that the main ingredients of ZJC such as quercetin, (R)-Canadine, palmatine, rutaecarpine, evodiamine, beta-sitosterol and berberine can target CDKN1A, Bcl2, E2F1, PRKCB, MYC, CDK2 and MMP9 to combat colorectal cancer. gamma-sitosterol 192-207 BCL2 apoptosis regulator Homo sapiens 241-245 34942456-12 2022 CONCLUSIONS: In summary, combined network pharmacology and biological experiments proved that the main ingredients of ZJC such as quercetin, (R)-Canadine, palmatine, rutaecarpine, evodiamine, beta-sitosterol and berberine can target CDKN1A, Bcl2, E2F1, PRKCB, MYC, CDK2 and MMP9 to combat colorectal cancer. Berberine 212-221 BCL2 apoptosis regulator Homo sapiens 241-245 34871825-7 2022 Furthermore, the activity of Caspase-3 was reinforced, and the ratio of Bcl-2 to Bax was markedly reduced after miR-10b-5p silencing. mir-10b-5p 112-122 BCL2 apoptosis regulator Homo sapiens 72-77 34906889-7 2022 Overexpression of BCL-2 rescues cell death triggered by Ulixertinib/S63845 co-treatment, confirming that combined inhibition of ERK1/2 and MCL-1 effectively induces cell death of RMS cells via the intrinsic mitochondrial apoptotic pathway. ulixertinib 56-67 BCL2 apoptosis regulator Homo sapiens 18-23 34800879-6 2022 Generally, both cell lines treated with the combination of Flutamide and ATO showed a decrease in expression of KLK2, angiogenesis genes (VEGFA and VEGFC), and apoptosis gene (Bcl2), and an increase in expression of E-cadherin and P53 genes; however, contradictory findings were found regarding SNAIL expression in LNCaP and PC3 cells. Arsenic Trioxide 73-76 BCL2 apoptosis regulator Homo sapiens 176-180 34906889-5 2022 Mechanistically, Ulixertinib-mediated upregulation of BIM and BMF in combination with MCL-1 inhibition by S63845 shifts the balance of BCL-2 proteins towards a pro-apoptotic state resulting in apoptosis induction. ulixertinib 17-28 BCL2 apoptosis regulator Homo sapiens 135-140 34906889-7 2022 Overexpression of BCL-2 rescues cell death triggered by Ulixertinib/S63845 co-treatment, confirming that combined inhibition of ERK1/2 and MCL-1 effectively induces cell death of RMS cells via the intrinsic mitochondrial apoptotic pathway. S63845 68-74 BCL2 apoptosis regulator Homo sapiens 18-23 34861246-17 2022 Furthermore, the combination of ZCL-082 and BCL-2 inhibitor ABT-199 has a synergistic apoptosis-inducing effect against double-hit lymphoma cell line OCI-Ly10. zcl-082 32-39 BCL2 apoptosis regulator Homo sapiens 44-49 34953212-5 2022 A structural model of the Bcl-xL/octenidine complex revealed that octenidine binds to Bcl-xL in a similar manner to that of the well-known Bcl-2 family protein antagonist ABT-737. octenidine 33-43 BCL2 apoptosis regulator Homo sapiens 139-144 34953212-5 2022 A structural model of the Bcl-xL/octenidine complex revealed that octenidine binds to Bcl-xL in a similar manner to that of the well-known Bcl-2 family protein antagonist ABT-737. octenidine 66-76 BCL2 apoptosis regulator Homo sapiens 139-144 34953212-5 2022 A structural model of the Bcl-xL/octenidine complex revealed that octenidine binds to Bcl-xL in a similar manner to that of the well-known Bcl-2 family protein antagonist ABT-737. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 171-174 BCL2 apoptosis regulator Homo sapiens 139-144 34861246-17 2022 Furthermore, the combination of ZCL-082 and BCL-2 inhibitor ABT-199 has a synergistic apoptosis-inducing effect against double-hit lymphoma cell line OCI-Ly10. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 60-63 BCL2 apoptosis regulator Homo sapiens 44-49 34861246-19 2022 The combination of ZCL-082 with BCL-2 inhibitor may represent a novel strategy to improve the outcome of double-hit or double-expressor lymphoma. zcl-082 19-26 BCL2 apoptosis regulator Homo sapiens 32-37 34454850-1 2022 BACKGROUND: PNT2258 is a liposomal formulation that encapsulates multiple copies of PNT100, a native, chemically unmodified, 24-base DNA oligonucleotide designed to target the regulatory region upstream of the B-cell lymphoma 2 (BCL2) gene. Oligonucleotides 137-152 BCL2 apoptosis regulator Homo sapiens 210-227 34952259-6 2022 RESULTS: Astaxanthin at lower doses than melatonin reduced cell viability and Bcl2 expression, induced apoptosis and DNA damage in MDA-MB-231 and T47D. astaxanthine 9-20 BCL2 apoptosis regulator Homo sapiens 78-82 34952259-6 2022 RESULTS: Astaxanthin at lower doses than melatonin reduced cell viability and Bcl2 expression, induced apoptosis and DNA damage in MDA-MB-231 and T47D. Melatonin 41-50 BCL2 apoptosis regulator Homo sapiens 78-82 34668210-9 2022 Alsevirone and abiraterone significantly increased annexin V-positive, caspase 3/7-positive, and activated Bcl-2-positive cells. alsevirone 0-10 BCL2 apoptosis regulator Homo sapiens 107-112 34668210-9 2022 Alsevirone and abiraterone significantly increased annexin V-positive, caspase 3/7-positive, and activated Bcl-2-positive cells. abiraterone 15-26 BCL2 apoptosis regulator Homo sapiens 107-112 34454850-1 2022 BACKGROUND: PNT2258 is a liposomal formulation that encapsulates multiple copies of PNT100, a native, chemically unmodified, 24-base DNA oligonucleotide designed to target the regulatory region upstream of the B-cell lymphoma 2 (BCL2) gene. Oligonucleotides 137-152 BCL2 apoptosis regulator Homo sapiens 229-233 34664399-6 2022 In addition, XNT treatment alters the DeltaPsim, thereby induces apoptosis was closely coordinated with the induction of pro-apoptotic markers Bax, Bad, caspase- 3, 9 and cytochrome c, and suppression of anti-apoptotic (Bcl-2, Bcl-XL) protein expression. xanthorrhizol 13-16 BCL2 apoptosis regulator Homo sapiens 220-225 34883226-3 2022 Through cell culture, virus infection, and RT-qPCR, we found that LiCl could down-regulate the apoptosis-related genes Caspase-3 and Bax, up-regulate Bcl-2, and down-regulate the inflammatory-related genes (NF-kappaB, NLRP3, TNF-alpha, and IL-1beta) via inhibiting virus replication. Lithium Chloride 66-70 BCL2 apoptosis regulator Homo sapiens 150-155 34719826-0 2022 Loperamide potentiates doxorubicin sensitivity in triple-negative breast cancer cells by targeting MDR1 and JNK and suppressing mTOR and Bcl-2: In vitro and molecular docking study. Loperamide 0-10 BCL2 apoptosis regulator Homo sapiens 137-142 34719826-0 2022 Loperamide potentiates doxorubicin sensitivity in triple-negative breast cancer cells by targeting MDR1 and JNK and suppressing mTOR and Bcl-2: In vitro and molecular docking study. Doxorubicin 23-34 BCL2 apoptosis regulator Homo sapiens 137-142 34304248-1 2022 Standard chemotherapies for diffuse large B-cell lymphoma (DLBCL), based on the induction of exogenous DNA damage and oxidative stress, are often less effective in the presence of increased MYC and BCL-2 levels, especially in the case of double hit (DH) lymphomas harboring rearrangements of the MYC and BCL-2 oncogenes, which enrich for a patient"s population characterized by refractoriness to anthracycline-based chemotherapy. Anthracyclines 396-409 BCL2 apoptosis regulator Homo sapiens 198-203 34724282-9 2022 Eriocitrin induced apoptosis via suppression of STAT3 signaling regulated proteins, activating proapoptotic factors Bax, caspase 7, 8, 9 and suppressing Bcl-2, Bcl-x expression in MCF-7 cells. eriocitrin 0-10 BCL2 apoptosis regulator Homo sapiens 153-158 34910369-0 2022 Bcl-2 hijacks the arsenic trioxide resistance in SH-SY5Y cells. Arsenic Trioxide 18-34 BCL2 apoptosis regulator Homo sapiens 0-5 34910369-3 2022 To further dissect the mechanism of ATO resistance, we selected the ATO-resistant SH-SY5Y cells and found that Bcl-2 controlled the sensitivity of ATO in SH-SY5Y cells. ato 36-39 BCL2 apoptosis regulator Homo sapiens 111-116 34910369-3 2022 To further dissect the mechanism of ATO resistance, we selected the ATO-resistant SH-SY5Y cells and found that Bcl-2 controlled the sensitivity of ATO in SH-SY5Y cells. ato 68-71 BCL2 apoptosis regulator Homo sapiens 111-116 34910369-3 2022 To further dissect the mechanism of ATO resistance, we selected the ATO-resistant SH-SY5Y cells and found that Bcl-2 controlled the sensitivity of ATO in SH-SY5Y cells. ato 147-150 BCL2 apoptosis regulator Homo sapiens 111-116 34728569-13 2022 Co-treatment with venetoclax can overcome BCL2-mediated resistance to S63845, and enhance efficacy of MCL1 inhibitors in BCL2-positive aggressive B-NHL. venetoclax 18-28 BCL2 apoptosis regulator Homo sapiens 42-46 34728569-13 2022 Co-treatment with venetoclax can overcome BCL2-mediated resistance to S63845, and enhance efficacy of MCL1 inhibitors in BCL2-positive aggressive B-NHL. venetoclax 18-28 BCL2 apoptosis regulator Homo sapiens 121-125 34727403-2 2022 DHL/THL is called as "high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements" in the World Health Organization 2017 Classification of Tumors of Hematopoietic and Lymphoid Tissues. Orlistat 4-7 BCL2 apoptosis regulator Homo sapiens 62-66 34663943-8 2022 In this Review, we outline the current state of BH3-mimetic drugs targeting various prosurvival BCL-2 family proteins and discuss emerging data regarding primary and acquired resistance to these agents and approaches that may overcome this. BH 3 48-51 BCL2 apoptosis regulator Homo sapiens 96-101 34738628-9 2022 The potential effects of GLUT-1 inhibition on the expression of proteins in the glycolysis (GLUT-1, hexokinase 2, pyruvate kinase M2 and lactate dehydrogenase) and apoptosis pathways (Bcl-2, cleaved PARP, caspase-3 and caspase-9) in imatinib-resistant cells were then investigated following gene silencing and treatment using the GLUT-1 inhibitor WZB117 by western blotting. Imatinib Mesylate 233-241 BCL2 apoptosis regulator Homo sapiens 184-189 34738628-14 2022 WZB117 administration significantly downregulated AKT phosphorylation and Bcl-2 expression in imatinib-resistant cells, whereas the combined administration of imatinib and WZB117 conferred synergistic growth inhibition effects in apoptosis assay. WZB117 0-6 BCL2 apoptosis regulator Homo sapiens 74-79 34738628-14 2022 WZB117 administration significantly downregulated AKT phosphorylation and Bcl-2 expression in imatinib-resistant cells, whereas the combined administration of imatinib and WZB117 conferred synergistic growth inhibition effects in apoptosis assay. Imatinib Mesylate 94-102 BCL2 apoptosis regulator Homo sapiens 74-79 34820006-6 2022 The present study revealed that tanshinone IIA markedly potentiated the cytotoxic and apoptotic induction effects of imatinib by regulating the AKT-MDM2-P53 signaling pathway and inhibiting the anti-apoptotic proteins BCL2 and MCL1 apoptosis regulator, BCL2 family member in Ph+ ALL cell lines. Imatinib Mesylate 117-125 BCL2 apoptosis regulator Homo sapiens 218-222 34820006-6 2022 The present study revealed that tanshinone IIA markedly potentiated the cytotoxic and apoptotic induction effects of imatinib by regulating the AKT-MDM2-P53 signaling pathway and inhibiting the anti-apoptotic proteins BCL2 and MCL1 apoptosis regulator, BCL2 family member in Ph+ ALL cell lines. Imatinib Mesylate 117-125 BCL2 apoptosis regulator Homo sapiens 253-257 34710737-4 2022 MATERIALS AND METHODS: Anti-leukemic activity of multikinase inhibitor olverembatinib (HQP1351), alone or in combination with BCL-2 inhibitor lisaftoclax (APG-2575), was evaluated in FLT3-ITD mutant AML cell lines in vitro and in vivo. Lisaftoclax 142-153 BCL2 apoptosis regulator Homo sapiens 126-131 34710737-4 2022 MATERIALS AND METHODS: Anti-leukemic activity of multikinase inhibitor olverembatinib (HQP1351), alone or in combination with BCL-2 inhibitor lisaftoclax (APG-2575), was evaluated in FLT3-ITD mutant AML cell lines in vitro and in vivo. Lisaftoclax 155-163 BCL2 apoptosis regulator Homo sapiens 126-131 34710737-11 2022 CONCLUSIONS: FLT3 inhibition by HQP1351 downregulates MCL-1 and synergizes with BCL-2 inhibitor APG-2575 to potentiate cellular apoptosis in FLT3-ITD mutant AML. apg 96-99 BCL2 apoptosis regulator Homo sapiens 80-85 34896434-6 2022 Ruthenium-phloretin complex could modulate p53 intervene apoptosis in the breast carcinoma, initiated by the trail of intrinsic apoptosis facilitated through Bcl2 and Bax and at the same time down regulating the PI3K/Akt/mTOR pathway coupled with MMP9 regulated tumor invasive pathways. ruthenium-phloretin 0-19 BCL2 apoptosis regulator Homo sapiens 158-162 34735897-7 2022 Pictilisib treatment inhibited the protein kinase B (AKT) cell survival pathway and promoted a pro-apoptotic phenotype as evidenced by quantitative real time polymerase chain reaction (qRT-PCR) analysis of the B-cell lymphoma 2 (BCL2) protein family members (P<0.01). 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 0-10 BCL2 apoptosis regulator Homo sapiens 210-227 34896432-9 2022 Furthermore, curcumin was found that it could not only reduce the mRNA and protein levels of mitophagy (PINK1, Parkin, LC3, p62) and pro-apoptotic genes (p53, Bax, Caspase-3, Cytc), but also increased the levels of anti-apoptotic genes (Bcl-2). Curcumin 13-21 BCL2 apoptosis regulator Homo sapiens 237-242 34735897-7 2022 Pictilisib treatment inhibited the protein kinase B (AKT) cell survival pathway and promoted a pro-apoptotic phenotype as evidenced by quantitative real time polymerase chain reaction (qRT-PCR) analysis of the B-cell lymphoma 2 (BCL2) protein family members (P<0.01). 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 0-10 BCL2 apoptosis regulator Homo sapiens 229-233 34974288-8 2022 However, a higher concentration (160 microg/mL) of Cys-ZnO NPs led to apoptotic cell death marked by nuclear condensation, mitochondrial membrane depolarization, actin filament condensation, lysosomal damage LDH leakage, intracellular ROS production, blebbing, upregulation of Bax and downregulation of Bcl-2 gene expression. Cysteine 51-54 BCL2 apoptosis regulator Homo sapiens 303-308 34967073-9 2022 Further rescue experiments revealed that CN-3 induced apoptosis and autophagy through ROS-mediated cytochrome C, cleaved-caspase 3, Bcl-2, P-AKT, PARP-1, and LC3-II. Reactive Oxygen Species 86-89 BCL2 apoptosis regulator Homo sapiens 132-137 34614506-1 2021 Adding the selective BCL-2 inhibitor venetoclax to reduced intensity conditioning (RIC) chemotherapy (fludarabine and busulfan, FluBu2) may enhance anti-leukemic cytotoxicity and thereby reduce the risk of post-transplant relapse. venetoclax 37-47 BCL2 apoptosis regulator Homo sapiens 21-26 34614506-1 2021 Adding the selective BCL-2 inhibitor venetoclax to reduced intensity conditioning (RIC) chemotherapy (fludarabine and busulfan, FluBu2) may enhance anti-leukemic cytotoxicity and thereby reduce the risk of post-transplant relapse. fludarabine 102-113 BCL2 apoptosis regulator Homo sapiens 21-26 34614506-1 2021 Adding the selective BCL-2 inhibitor venetoclax to reduced intensity conditioning (RIC) chemotherapy (fludarabine and busulfan, FluBu2) may enhance anti-leukemic cytotoxicity and thereby reduce the risk of post-transplant relapse. Busulfan 118-126 BCL2 apoptosis regulator Homo sapiens 21-26 34614506-1 2021 Adding the selective BCL-2 inhibitor venetoclax to reduced intensity conditioning (RIC) chemotherapy (fludarabine and busulfan, FluBu2) may enhance anti-leukemic cytotoxicity and thereby reduce the risk of post-transplant relapse. flubu2 128-134 BCL2 apoptosis regulator Homo sapiens 21-26 34967955-4 2022 Then, TUNEL analysis showed that the 5% oxygen concentration group significantly inhibited apoptosis of cumulus-oocyte complexes (COCs) compared to the other group, and the transcription and protein levels of pro-apoptotic factor Bax, HIF-1alpha and VEGF in yak COCs significantly reduced, while anti-apoptotic factor Bcl-2 significantly increased. Oxygen 40-46 BCL2 apoptosis regulator Homo sapiens 318-323 34966948-4 2021 Treatment of 5-HTR1E stable cells with NF-alpha1/CPE increased pERK 1/2 and pCREB levels which prevented a decrease in pro-survival protein, BCL2, during H2O2-induced oxidative stress. Hydrogen Peroxide 154-158 BCL2 apoptosis regulator Homo sapiens 141-145 34966948-10 2021 Thus, NF-alpha1/CPE uniquely interacts with serotonin receptor 5-HTR1E to activate the beta-arrestin/ERK/CREB/BCL2 pathway to mediate stress-induced neuroprotection. Serotonin 44-53 BCL2 apoptosis regulator Homo sapiens 110-114 34974288-8 2022 However, a higher concentration (160 microg/mL) of Cys-ZnO NPs led to apoptotic cell death marked by nuclear condensation, mitochondrial membrane depolarization, actin filament condensation, lysosomal damage LDH leakage, intracellular ROS production, blebbing, upregulation of Bax and downregulation of Bcl-2 gene expression. Zinc Oxide 55-58 BCL2 apoptosis regulator Homo sapiens 303-308 34915630-11 2021 The survival fraction (0.462) and protein level of Bcl-2 (0.44+-0.04) in the triptolide group were lower than those of the control group (0.702 and 0.93+-0.09, P<0.05). triptolide 77-87 BCL2 apoptosis regulator Homo sapiens 51-56 34962083-7 2022 Finally, mitochondrial membrane potential (MMP) decreased, fluorescence intensity of Hoechst33258 increased, and the protein expression ratio of Bax/Bcl-2 increased significantly after the treatment of MGO. Pyruvaldehyde 202-205 BCL2 apoptosis regulator Homo sapiens 149-154 34959015-7 2021 Besides, arsenic-treatment obviously increased the levels of mitophagy (PINK1, Parkin, LC3, P62) and pro-apoptotic (Caspase-3, Caspase-9, Cleaved Caspase-3, Cytc, Bax, P53) indexes, and simultaneously resulted in reductions in anti-apoptosis index (Bcl-2). Arsenic 9-16 BCL2 apoptosis regulator Homo sapiens 249-254 34939720-5 2022 We found that capsaicin increased TOS, 8-OHdG, CASP3, CYC, Bax, and NOX4 levels, and decreased Bcl-2, GSH, and SIRT1 in a concentration-dependent manner in HepG2 cells. Capsaicin 14-23 BCL2 apoptosis regulator Homo sapiens 95-100 34915631-14 2021 The expression levels of ENO1, PI3K/Akt signaling pathway related proteins including p-PI3K and p-Akt and the expression levels of PCNA, MMP-9 and Bcl-2 in siRNA-ENO1 group and paclitaxel+ siRNA-NC group were lower than those in siRNA-NC group (P<0.05). Paclitaxel 177-187 BCL2 apoptosis regulator Homo sapiens 147-152 34915631-15 2021 The expression levels of ENO1, p-PI3K, p-Akt, PCNA, MMP-9 and Bcl-2 in paclitaxel+ siRNA-ENO1 group were lower than those in siRNA-ENO1 group or paclitaxel+ siRNA-NC group (P<0.05). Paclitaxel 71-81 BCL2 apoptosis regulator Homo sapiens 62-67 34951372-10 2021 In addition, beta-estradiol-induced apoptosis is accompanied by the loss of mitochondrial potential, activation of the Caspase family, and altered Bax/Bcl-2 ratio. Estradiol 13-27 BCL2 apoptosis regulator Homo sapiens 151-156 34915631-15 2021 The expression levels of ENO1, p-PI3K, p-Akt, PCNA, MMP-9 and Bcl-2 in paclitaxel+ siRNA-ENO1 group were lower than those in siRNA-ENO1 group or paclitaxel+ siRNA-NC group (P<0.05). Paclitaxel 145-155 BCL2 apoptosis regulator Homo sapiens 62-67 34931561-7 2022 Further investigation revealed that inhibition of CCAT2 expression dramatically increased the activity of miR-204-3p and thereby signally suppressed the IGFBP2/AKT/Bcl2 pathway. mir-204-3p 106-116 BCL2 apoptosis regulator Homo sapiens 164-168 34956386-5 2021 Our results showed that PA-induced oxidative stress, calcium disequilibrium, and subsequent endoplasmic reticulum stress (ERS) mediated cellular injury, with elevated protein levels of GRP78, GRP94, CHOP, and hyperphosphorylation of PERK and IRE1alpha as well as the increased ratio of Bax/Bcl-2, which was restored by PCB2 in a concentration-dependent manner, proving the excellent antiapoptosis effect. Protactinium 24-26 BCL2 apoptosis regulator Homo sapiens 290-295 34942200-0 2021 Expression differences in BCL2 family members between uveal and cutaneous melanomas account for varying sensitivity to BH3 mimetics. BH 3 119-122 BCL2 apoptosis regulator Homo sapiens 26-30 34942200-3 2021 BH3 mimetics are small molecule drugs that mimic pro-apoptotic BCL2 family members. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 63-67 34926196-9 2021 The Western blot results showed that the protein expression levels of the DR5, a-caspase-3, and BAX increased, while the expression levels of the anti-apoptosis-related proteins XIAP and BCL-2 were suppressed when TRAIL and oridonin simultaneously administered to MUM-2B cells. oridonin 224-232 BCL2 apoptosis regulator Homo sapiens 187-192 34921482-10 2022 Combinatorial regimens or neferine/isoliensinine treatments downregulated the cell survival protein expression (PI3K/pAkt/mTOR) and activated mitochondria-mediated apoptosis by upregulating Bax, cytochrome c, caspase-3, and PARP cleavage expression while downregulating the BCl-2 expression in CSCs. neferine 26-34 BCL2 apoptosis regulator Homo sapiens 274-279 34921482-10 2022 Combinatorial regimens or neferine/isoliensinine treatments downregulated the cell survival protein expression (PI3K/pAkt/mTOR) and activated mitochondria-mediated apoptosis by upregulating Bax, cytochrome c, caspase-3, and PARP cleavage expression while downregulating the BCl-2 expression in CSCs. isoliensinine 35-48 BCL2 apoptosis regulator Homo sapiens 274-279 34956386-5 2021 Our results showed that PA-induced oxidative stress, calcium disequilibrium, and subsequent endoplasmic reticulum stress (ERS) mediated cellular injury, with elevated protein levels of GRP78, GRP94, CHOP, and hyperphosphorylation of PERK and IRE1alpha as well as the increased ratio of Bax/Bcl-2, which was restored by PCB2 in a concentration-dependent manner, proving the excellent antiapoptosis effect. procyanidin B2 319-323 BCL2 apoptosis regulator Homo sapiens 290-295 34975454-8 2021 Treatments with 7,8-DHF, quercetin, and apigenin rescued the reduced HSPB1 and NRF2 and activated TRKB-mediated extracellular signal-regulated kinase (ERK) signaling to upregulate cAMP-response element binding protein (CREB) and its downstream antiapoptotic BCL2 apoptosis regulator (BCL2). 6,7-dihydroxyflavone 16-23 BCL2 apoptosis regulator Homo sapiens 258-282 34530384-3 2021 In this review, we summed up the recent advances of sulfonamide derivatives as potential anti-cancer agents based on the anti-cancer targets, such as aromatase, carbonic anhydrase (CA), anti-apoptotic B-cell lymphoma-2 (Bcl-2) proteins, topoisomerase and phosphatidylinositol 3-kinase (PI3K), and elucidated the corresponding structure-activity relationships (SARs) of most sulfonamide derivatives. Sulfonamides 52-63 BCL2 apoptosis regulator Homo sapiens 219-225 34975454-8 2021 Treatments with 7,8-DHF, quercetin, and apigenin rescued the reduced HSPB1 and NRF2 and activated TRKB-mediated extracellular signal-regulated kinase (ERK) signaling to upregulate cAMP-response element binding protein (CREB) and its downstream antiapoptotic BCL2 apoptosis regulator (BCL2). Quercetin 25-34 BCL2 apoptosis regulator Homo sapiens 258-282 34975454-8 2021 Treatments with 7,8-DHF, quercetin, and apigenin rescued the reduced HSPB1 and NRF2 and activated TRKB-mediated extracellular signal-regulated kinase (ERK) signaling to upregulate cAMP-response element binding protein (CREB) and its downstream antiapoptotic BCL2 apoptosis regulator (BCL2). 6,7-dihydroxyflavone 16-23 BCL2 apoptosis regulator Homo sapiens 284-288 34975454-8 2021 Treatments with 7,8-DHF, quercetin, and apigenin rescued the reduced HSPB1 and NRF2 and activated TRKB-mediated extracellular signal-regulated kinase (ERK) signaling to upregulate cAMP-response element binding protein (CREB) and its downstream antiapoptotic BCL2 apoptosis regulator (BCL2). Quercetin 25-34 BCL2 apoptosis regulator Homo sapiens 284-288 34975454-8 2021 Treatments with 7,8-DHF, quercetin, and apigenin rescued the reduced HSPB1 and NRF2 and activated TRKB-mediated extracellular signal-regulated kinase (ERK) signaling to upregulate cAMP-response element binding protein (CREB) and its downstream antiapoptotic BCL2 apoptosis regulator (BCL2). Apigenin 40-48 BCL2 apoptosis regulator Homo sapiens 258-282 34910385-9 2021 The protease inhibitor camostat mesylate and thapsigargin induced autophagic response and mitochondrial stress with altered mitochondrial membrane potential, Bcl2 and cytochrome C. camostat 23-40 BCL2 apoptosis regulator Homo sapiens 158-162 34975454-8 2021 Treatments with 7,8-DHF, quercetin, and apigenin rescued the reduced HSPB1 and NRF2 and activated TRKB-mediated extracellular signal-regulated kinase (ERK) signaling to upregulate cAMP-response element binding protein (CREB) and its downstream antiapoptotic BCL2 apoptosis regulator (BCL2). Apigenin 40-48 BCL2 apoptosis regulator Homo sapiens 284-288 34928497-7 2022 Prostate luminal cells within atrophied acini adapted to decreased DHT conditions by increasing NF-kappaB signaling and anti-apoptotic BCL2 expression, which may explain their survival. Dihydrotestosterone 67-70 BCL2 apoptosis regulator Homo sapiens 135-139 34910385-9 2021 The protease inhibitor camostat mesylate and thapsigargin induced autophagic response and mitochondrial stress with altered mitochondrial membrane potential, Bcl2 and cytochrome C. Thapsigargin 45-57 BCL2 apoptosis regulator Homo sapiens 158-162 34970579-9 2021 Syringic acid selectively developed apoptosis in a dose-dependent manner via enhanced regulation of caspase-3, caspase-9 and Poly ADP-ribose Polymerase (PARP) whereas decreasing the expression levels of p53 and BCL-2. syringic acid 0-13 BCL2 apoptosis regulator Homo sapiens 211-216 34948255-7 2021 MSC-CM restored H2O2-induced damage to hBMSC by increasing the antioxidant enzyme-SOD production and the mRNA expression level of the anti-apoptotic BCL-2. Hydrogen Peroxide 16-20 BCL2 apoptosis regulator Homo sapiens 149-154 34934357-10 2021 We analyzed SIM-CB effect on apoptosis and cell cycle using flowcytometry, and investigated its effect on Bcl-2, caspase 3, ROS, reduced glutathione (GSH), lipid peroxides and GPX4 enzyme. sim-cb 12-18 BCL2 apoptosis regulator Homo sapiens 106-111 34934357-16 2021 Moreover, SIM-CB remarkably increased caspase-3, ROS, and lipid peroxide levels but decreased antiapoptotic Bcl-2 protein, GSH, and GPX4 compared with free SIM. sim-cb 10-16 BCL2 apoptosis regulator Homo sapiens 108-113 34977076-4 2021 LaCl3 induced more cell death and apoptosis caused by DDP in two cell lines, accompanied by upregulation of Bax and Cleaved caspase 3 proteins, and downregulation of Bcl-2 protein. lanthanum chloride 0-5 BCL2 apoptosis regulator Homo sapiens 166-171 34970530-3 2021 In this study, we utilized a rapid synthetic route to synthesize two novel hybrid spirooxindole-based p53-MDM2 inhibitors endowed with Bcl2 signaling attenuation. Spirooxindole 82-95 BCL2 apoptosis regulator Homo sapiens 135-139 34970530-4 2021 The adducts mimic the thematic features of the chemically stable potent spiro (3H-indole-3,2"-pyrrolidin)-2(1H)-ones p53-MDM2 inhibitors, while installing a pyrrole ring via a carbonyl spacer inspired by the natural marine or synthetic products that efficiently inhibit Bcl2 family functions. (3h-indole-3,2"-pyrrolidin)-2(1h)-ones 78-116 BCL2 apoptosis regulator Homo sapiens 270-274 34806536-7 2022 The decrease of HepG2/C3A cells survival can also be due to downregulation of antiapoptotic BCL-2 expression, thus promoting the induction of apoptosis by SAL. salinomycin 155-158 BCL2 apoptosis regulator Homo sapiens 92-97 34970530-4 2021 The adducts mimic the thematic features of the chemically stable potent spiro (3H-indole-3,2"-pyrrolidin)-2(1H)-ones p53-MDM2 inhibitors, while installing a pyrrole ring via a carbonyl spacer inspired by the natural marine or synthetic products that efficiently inhibit Bcl2 family functions. Pyrroles 157-164 BCL2 apoptosis regulator Homo sapiens 270-274 34970530-8 2021 Mechanistically, 2b induced apoptosis-dependent anticancer effect (43%) higher than that of 5-fluorouracil (34.95%) in three studied cancer cell lines, activated p53 (47%), downregulated the Bcl2 gene (1.25-fold), and upregulated p21 (2-fold) in the treated cancer cells. Fluorouracil 92-106 BCL2 apoptosis regulator Homo sapiens 191-195 34821900-5 2021 Western blot experiment results also showed that appropriate concentrations of LPSs and beta-sitosterol could up-regulate the expression of the anti-apoptotic protein Bcl-2 and down-regulate the pro-apoptotic proteins Bax and caspase-3 in GES-1 cells. gamma-sitosterol 88-103 BCL2 apoptosis regulator Homo sapiens 167-172 34924752-14 2021 SA also impacted the levels of the cell survival protein Bcl-2. stearic acid 0-2 BCL2 apoptosis regulator Homo sapiens 57-62 34906420-8 2022 The H2O2-induced apoptosis cell model, established to simulate the post-frostbite injury, was inhibited by EVs, with concomitant increase in the expression of Bcl-2 and decreased expression of Bax, further confirming the findings. Hydrogen Peroxide 4-8 BCL2 apoptosis regulator Homo sapiens 159-164 34959424-10 2021 The results also indicated that treatment with THQ formula significantly increased caspase-3, Bax, Bcl-2, and p53 mRNA expression compared to plain formula and THQ. thymoquinone 47-50 BCL2 apoptosis regulator Homo sapiens 99-104 34876239-5 2021 However, the expression levels of other tumor-related factors, including Ki67, p27, p53, Bcl-2-associated X protein (Bax), B-cell lymphoma 2 (Bcl-2), caspase-3 (Cas-3), matrix metallopeptidase 2 (MMP2) and vascular endothelial growth factor (VEGF) proteins, were constantly maintained in the tumors of all three substrains after cisplatin treatment. Cisplatin 329-338 BCL2 apoptosis regulator Homo sapiens 123-140 34876239-5 2021 However, the expression levels of other tumor-related factors, including Ki67, p27, p53, Bcl-2-associated X protein (Bax), B-cell lymphoma 2 (Bcl-2), caspase-3 (Cas-3), matrix metallopeptidase 2 (MMP2) and vascular endothelial growth factor (VEGF) proteins, were constantly maintained in the tumors of all three substrains after cisplatin treatment. Cisplatin 329-338 BCL2 apoptosis regulator Homo sapiens 142-147 34882068-10 2021 Immunoblot analyses of MKN-45 and KATO-III cells revealed that dovitinib decreased phospho-FGFR, phospho-AKT, phospho-ERK, phospho-p70S6K, phospho-4EBP1, Bcl-2 and increased cleaved PARP-1, cleaved-caspase-3, p27, Bax, Bim, with an additive effect from combination therapy. 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 63-72 BCL2 apoptosis regulator Homo sapiens 154-159 34418511-12 2021 Investigation about the underlying mechanism revealed that Gaillardin exerts its action through inhibition of NF-kappaB activation and subsequently down-regulation of genes (COX-2, MMP-9, TWIST-1, and BCl-2) regulated by NF-kappaB. gaillardin 59-69 BCL2 apoptosis regulator Homo sapiens 201-206 34861701-7 2021 1,3,5-Tri-O-caffeoyl quinic acid downregulated the overexpression of proapoptotic proteins, including Bax, cytochrome c, cleaved caspase-9, and cleaved caspase-3 as well as promoted the expression of the antiapoptotic protein Bcl-2. 1,3,5-tri-o-caffeoyl quinic acid 0-32 BCL2 apoptosis regulator Homo sapiens 226-231 34917264-8 2021 Additionally, KYP-2047 was able to increase Bax, Bad and caspase-3 expression, whereas Bcl-2 and p53 expression were reduced. 3-hydroxy-2-({4-[4-(pyrimidin-2-yl)piperazine-1-carbonyl]phenyl}methyl)-1-benzofuran-7-carboxamide 14-17 BCL2 apoptosis regulator Homo sapiens 87-92 34959382-3 2021 Cell cycle analysis proved that Pt-8AQ significantly affected the cell cycle pattern by increasing the apoptotic cells represented by the sub G0/G1 region related with a downregulation of p53 and Bcl-2. pt-8aq 32-38 BCL2 apoptosis regulator Homo sapiens 196-201 34899944-11 2021 Conclusion: The possible mechanisms of the components of the Zhishi-Baizhu herb pair in treating gastric cancer might be related to luteolin and naringenin, which intervened with the targets AKT1, MMP9, IL-6, CCND1, BCL2, MTOR, and MDM2, and are linked with the PI3K-Akt and IL-17 signaling pathways. naringenin 145-155 BCL2 apoptosis regulator Homo sapiens 216-220 34219464-9 2021 The expression levels of phosphorylated phosphatidylinositol 3-kinasep (p-PI3K), phosphorylated protein kinase B (p-Akt), phosphorylated mammalian target of rapamycin (p-mTOR), and B-cell lymphoma-2 (Bcl-2) evidently decreased when treated with Isov, while the levels of Bcl2-associated X (Bax), and caspase-3 significantly increased. isovitexin 245-249 BCL2 apoptosis regulator Homo sapiens 181-198 34848467-5 2021 RESULTS: The expression of anti-apoptotic proteins Bcl-2 and phosphorylated Bad (p-Bad) was attenuated with an increasing flaccidoxide concentration, while the expression of proapoptotic proteins Bax, Bad, cleaved caspase-3, cleaved caspase-9 and cleaved PARP-1 was found increased. flaccidoxide 122-134 BCL2 apoptosis regulator Homo sapiens 51-56 34219464-9 2021 The expression levels of phosphorylated phosphatidylinositol 3-kinasep (p-PI3K), phosphorylated protein kinase B (p-Akt), phosphorylated mammalian target of rapamycin (p-mTOR), and B-cell lymphoma-2 (Bcl-2) evidently decreased when treated with Isov, while the levels of Bcl2-associated X (Bax), and caspase-3 significantly increased. isovitexin 245-249 BCL2 apoptosis regulator Homo sapiens 199-205 34219464-10 2021 After Isov treatment, the tumor volume and weight were decreased, the levels of p-PI3K, p-Akt, p-mTOR, and Bcl-2 significantly decreased in tumor tissues. isovitexin 6-10 BCL2 apoptosis regulator Homo sapiens 107-112 33622177-9 2021 Chrysophanol treatment greatly decreased the Bcl-2/Bax expression ratio and increased the expressions of cleaved caspase-3 and -9, and the activities of caspase-3 and -9. chrysophanic acid 0-12 BCL2 apoptosis regulator Homo sapiens 45-50 34794098-7 2021 The most balanced potent and safe derivatives; 5i and 5q were more active than 5-fluorouracil, exhibited low mumrange MDM2 binding (KD=1.32and 1.72 mum, respectively), induced apoptosis-dependent anticancer activities up to 50%, activated p53 by 47-63%, downregulated the BCL2 gene to 59.8%, and reduced its protein level (13.75%) in the treated cancer cells. 5i 47-49 BCL2 apoptosis regulator Homo sapiens 272-276 34151717-4 2021 The results showed that 1 mM Bupivacaine was available to signally inhibit CRC cell vitality, promoted apoptosis rate and apoptosis gene expression, like Bax, and caspase-3, inhibited Bcl-2 expression, inhibited cancer cell migration, promoted autophagy-related protein LC3B II/LC3B I ratio and beclin-1 expression, and inhibited p62 expression. Bupivacaine 29-40 BCL2 apoptosis regulator Homo sapiens 184-189 34346829-9 2021 Importantly, Ramelteon attenuated MPP+-induced apoptosis, accompanied by a decreased ratio of Bax/Bcl-2, inhibition of cytochrome C release, and downregulation of cleaved caspase-3. ramelteon 13-22 BCL2 apoptosis regulator Homo sapiens 98-103 34346829-9 2021 Importantly, Ramelteon attenuated MPP+-induced apoptosis, accompanied by a decreased ratio of Bax/Bcl-2, inhibition of cytochrome C release, and downregulation of cleaved caspase-3. mangion-purified polysaccharide (Candida albicans) 34-38 BCL2 apoptosis regulator Homo sapiens 98-103 34546847-0 2021 Protective effects of Schisandrin B against D-GalN-induced cell apoptosis in human hepatocyte (L02) cells via modulating Bcl-2 and Bax. schizandrin B 22-35 BCL2 apoptosis regulator Homo sapiens 121-126 34546847-10 2021 Furthermore, schisandrin B inhibited D-GalN-induced apoptosis in L02 cells (P<0.05), regulated the expression of Bax and Bcl-2 (P<0.05). schizandrin B 13-26 BCL2 apoptosis regulator Homo sapiens 121-126 34546847-11 2021 The results indicated that schisandrin B decreased the D-GalN-induced intracellular oxidative stress indexes generation, and inhibited the down-regulation of Bcl-2 and up-regulation of Bax induced by D-GalN. schizandrin B 27-40 BCL2 apoptosis regulator Homo sapiens 158-163 34546847-12 2021 In conclusion, schisandrin B was shown to exert protective effect against oxidative damage of L02 cells, which, in part, was achieved by regulating the mRNA and protein levels of Bax and Bcl-2. schizandrin B 15-28 BCL2 apoptosis regulator Homo sapiens 187-192 34781823-7 2021 Secondly, cell proliferation of imatinib-resistant renal cell carcinoma cells was suppressed by PDIA6 silencing, and the apoptosis was promoted with reduced Bcl-2, enhanced Bax and cleaved caspase-3. Imatinib Mesylate 32-40 BCL2 apoptosis regulator Homo sapiens 157-162 34794098-0 2021 Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators. Spirooxindole 54-67 BCL2 apoptosis regulator Homo sapiens 103-107 34794098-3 2021 Herein, we employed a rapid combinatorial approach to generate a novel series of hybrid spirooxindole-based MDM2 inhibitors (5a-s) endowed with BCL2 signaling attenuation. Spirooxindole 88-101 BCL2 apoptosis regulator Homo sapiens 144-148 34794098-3 2021 Herein, we employed a rapid combinatorial approach to generate a novel series of hybrid spirooxindole-based MDM2 inhibitors (5a-s) endowed with BCL2 signaling attenuation. 5a-s 125-129 BCL2 apoptosis regulator Homo sapiens 144-148 34794098-4 2021 The adducts were designed to mimic the thematic features of the chemically stable potent spiro(3H-indole-3,2"-pyrrolidin)-2(1H)-ones MDM2 inhibitors while installing a pyrrole ring on the core via a carbonyl spacer inspired by the natural product marinopyrrole A that efficiently inhibits BCL2 family functions by various mechanisms. 3h-indole-3,2"-pyrrolidin)-2(1h) 95-127 BCL2 apoptosis regulator Homo sapiens 289-293 34794098-4 2021 The adducts were designed to mimic the thematic features of the chemically stable potent spiro(3H-indole-3,2"-pyrrolidin)-2(1H)-ones MDM2 inhibitors while installing a pyrrole ring on the core via a carbonyl spacer inspired by the natural product marinopyrrole A that efficiently inhibits BCL2 family functions by various mechanisms. Pyrroles 168-175 BCL2 apoptosis regulator Homo sapiens 289-293 34794098-4 2021 The adducts were designed to mimic the thematic features of the chemically stable potent spiro(3H-indole-3,2"-pyrrolidin)-2(1H)-ones MDM2 inhibitors while installing a pyrrole ring on the core via a carbonyl spacer inspired by the natural product marinopyrrole A that efficiently inhibits BCL2 family functions by various mechanisms. marinopyrrole A 247-262 BCL2 apoptosis regulator Homo sapiens 289-293 34794242-0 2021 The endocytic pathway of Pt nanoclusters and their induced apoptosis of A549 and A549/Cis cells through c-Myc/p53 and Bcl-2/caspase-3 signaling pathways. Platinum 25-27 BCL2 apoptosis regulator Homo sapiens 118-123 34794098-7 2021 The most balanced potent and safe derivatives; 5i and 5q were more active than 5-fluorouracil, exhibited low mumrange MDM2 binding (KD=1.32and 1.72 mum, respectively), induced apoptosis-dependent anticancer activities up to 50%, activated p53 by 47-63%, downregulated the BCL2 gene to 59.8%, and reduced its protein level (13.75%) in the treated cancer cells. CHEMBL3739943 54-56 BCL2 apoptosis regulator Homo sapiens 272-276 34794098-7 2021 The most balanced potent and safe derivatives; 5i and 5q were more active than 5-fluorouracil, exhibited low mumrange MDM2 binding (KD=1.32and 1.72 mum, respectively), induced apoptosis-dependent anticancer activities up to 50%, activated p53 by 47-63%, downregulated the BCL2 gene to 59.8%, and reduced its protein level (13.75%) in the treated cancer cells. Fluorouracil 79-93 BCL2 apoptosis regulator Homo sapiens 272-276 34526359-11 2021 Moreover, our in-silico DSS showed that not only t(11;14) but also chr(1q)gain/amps and CYLD inactivation predicted differential expression of transcripts of the BCL2-axis and response to venetoclax. dss 24-27 BCL2 apoptosis regulator Homo sapiens 162-166 34117376-6 2021 By targeting antiapoptotic proteins with specific BH3 mimetics in organoid models of CRC progression, we found that BCL-2 is essential only during ISC transformation while MCL1 inhibition did not affect adenoma outgrowth. BH 3 50-53 BCL2 apoptosis regulator Homo sapiens 116-121 34875729-11 2021 Western blotting experiments showed that lidocaine decreased the protein expression of BCL-2, and that NTP conserved the expression of BCL-2, even when used with lidocaine. Lidocaine 41-50 BCL2 apoptosis regulator Homo sapiens 87-92 34417162-1 2021 BACKGROUND: PNT2258 consists of a native, chemically unmodified, 24-base DNA oligonucleotide designed to target the regulatory region upstream of the BCL2 gene, delivered in a protective liposome. Oligonucleotides 77-92 BCL2 apoptosis regulator Homo sapiens 150-154 34417162-2 2021 Derangement of BCL2-regulated control mechanisms is a defining characteristic of certain malignancies, and it was hypothesized that the oligonucleotide would promote anticancer activity via suppression of BCL2 transcription. Oligonucleotides 136-151 BCL2 apoptosis regulator Homo sapiens 15-19 34417162-2 2021 Derangement of BCL2-regulated control mechanisms is a defining characteristic of certain malignancies, and it was hypothesized that the oligonucleotide would promote anticancer activity via suppression of BCL2 transcription. Oligonucleotides 136-151 BCL2 apoptosis regulator Homo sapiens 205-209 34086253-0 2021 Study on effects of miR-141-3p in proliferation, migration, invasion and apoptosis of colon cancer cells by inhibiting Bcl2. mir-141-3p 20-30 BCL2 apoptosis regulator Homo sapiens 119-123 34086253-5 2021 MTT assay, wound assay, Transwell and flow cytometry were used to detect the effect of Bcl2 on miR-141-3p on colon cancer proliferation, migration, invasion and apoptosis. mir-141-3p 95-105 BCL2 apoptosis regulator Homo sapiens 87-91 34086253-10 2021 miR-141-3p targets the negative regulation of Bcl2. mir-141-3p 0-10 BCL2 apoptosis regulator Homo sapiens 46-50 34086253-12 2021 Knockdown of Bcl2 significantly enhanced the inhibition effect of miR-141-3p inhibitor on proliferation, migration and invasion of colon cancer cells. mir-141-3p 66-76 BCL2 apoptosis regulator Homo sapiens 13-17 34086253-13 2021 CONCLUSIONS: In conclusion, miR-141-3p can inhibit the cancer by regulating Bcl2, and miR-141-3p has the potential to become a potential therapeutic target for colon cancer. mir-141-3p 28-38 BCL2 apoptosis regulator Homo sapiens 76-80 34931871-13 2021 AK003290 promoted p-AKT and bcl-2 expression and inhibited p-ERK1/2, Bax, cytoplasmic cyto-c, and c-caspase-3 expression. ak003290 0-8 BCL2 apoptosis regulator Homo sapiens 28-33 34926269-9 2021 SF2535 induced apoptosis in B-ALL by downregulation of BCL-2 and increased cleavage of caspase-3, caspase-7, and PARP. sf2535 0-6 BCL2 apoptosis regulator Homo sapiens 55-60 34945511-7 2021 BDA-Nb induced the proliferative inhibition of K562 and A549 cells due to abnormal cell morphology, the increased cell population in G1 phase and apoptosis rate, the downregulation of Bcl-2, and the upregulation of Bax and caspase-3/8/9. bda-nb 0-6 BCL2 apoptosis regulator Homo sapiens 184-189 34258700-8 2021 BBR and UMB reduced the expression of pro-apoptotic protein Bax and apoptotic protein caspase-3 as well as increased the expression of anti-apoptotic protein Bcl-2. Berberine 0-3 BCL2 apoptosis regulator Homo sapiens 158-163 34258700-8 2021 BBR and UMB reduced the expression of pro-apoptotic protein Bax and apoptotic protein caspase-3 as well as increased the expression of anti-apoptotic protein Bcl-2. 7-hydroxycoumarin 8-11 BCL2 apoptosis regulator Homo sapiens 158-163 34583845-1 2021 Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. taxane 0-6 BCL2 apoptosis regulator Homo sapiens 40-45 34583845-1 2021 Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. Platinum 81-89 BCL2 apoptosis regulator Homo sapiens 40-45 34926454-8 2021 We determined that the inhibition of each anti-apoptotic Bcl-2 family member lowers mitochondrial calcium retention capacity and sensitizes MPTP opening. Calcium 98-105 BCL2 apoptosis regulator Homo sapiens 57-62 34926454-0 2021 Inhibition of the Anti-Apoptotic Bcl-2 Family by BH3 Mimetics Sensitize the Mitochondrial Permeability Transition Pore Through Bax and Bak. BH 3 49-52 BCL2 apoptosis regulator Homo sapiens 33-38 34647221-2 2021 The aim of this study was to elucidate the modulation patterns between apoptosis and autophagy following dual inhibition by Akt inhibitor erufosine and Bcl-2 inhibitor ABT-737 in castration-resistant prostate cancer (CRPC) cell lines, PC-3 (Bax+) and DU-145 (Bax-). ABT-737 168-175 BCL2 apoptosis regulator Homo sapiens 152-157 34314648-9 2021 Furthermore, after combining both of the drug treatments, the proteins levels of Smo, G1i-1, PI3K, p-AKT, Bcl2, and Cyclin Dl were significantly downregulated, and Caspase-3 is upregulated, indicating that jervine with its combination of decitabine might be effective for controlling the proliferation, apoptosis, and cell cycle. Decitabine 238-248 BCL2 apoptosis regulator Homo sapiens 106-110 34619275-4 2021 In addition, the cell assays showed that Se-OVA could induce apoptosis of HepG2 cells by arresting cell cycle in S phase, generating intracellular reactive oxygen species, reducing the mitochondrial transmembrane potential, and triggering the Bax- and Bcl-2-mediated mitochondria apoptosis pathway. se-ova 41-47 BCL2 apoptosis regulator Homo sapiens 252-257 34634322-5 2021 We highlight that estrogen treatment or increased expression of ERs or ERRs are generally associated with higher cisplatin resistance in cancer in vitro, mostly due to decreased caspase activity, increased anti-apoptotic protein levels such as BCL-2, higher drug efflux and higher levels of antioxidant enzymes. Cisplatin 113-122 BCL2 apoptosis regulator Homo sapiens 244-249 34637097-6 2021 METHOD AND RESULTS: Different single and combined concentrations of 5-FU and Quer were applied to MCF 7 cells for 48 h. Cell viability, apoptosis, gene expression of Bax, Bcl2, and p53, caspase activity, and colony number were assessed using MTT assay, flow cytometry, quantitative real-time PCR, enzyme-linked immunosorbent (ELISA), and Colony formation assay, respectively. Fluorouracil 68-72 BCL2 apoptosis regulator Homo sapiens 171-175 34637097-7 2021 The combination of 5-FU and Quer compared to 5-FU alone improved apoptosis by increasing the gene expression of Bax and p53 and caspase-9 activity and decreasing the Bcl2 gene expression. Fluorouracil 19-23 BCL2 apoptosis regulator Homo sapiens 166-170 34637097-7 2021 The combination of 5-FU and Quer compared to 5-FU alone improved apoptosis by increasing the gene expression of Bax and p53 and caspase-9 activity and decreasing the Bcl2 gene expression. Fluorouracil 45-49 BCL2 apoptosis regulator Homo sapiens 166-170 34132136-7 2021 Flow cytometry assay and western blot assay were applied to examine the apoptosis and apoptosis related protein Bcl-2, Bax, Cleaved caspase-3 expression levels of Ishikawa and HEC-1-B cells after treatment with GA. ginkgolic acid 211-213 BCL2 apoptosis regulator Homo sapiens 112-117 33345633-3 2021 In this manner, the present studies developed a series of novel isatin-indole conjugates (7a-j and 9a-e) as potential anticancer Bcl2 and BclxL inhibitors. isatin-indole 64-77 BCL2 apoptosis regulator Homo sapiens 129-133 34711645-0 2021 Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 148-151 BCL2 apoptosis regulator Homo sapiens 132-137 34711645-7 2021 When combined with chemotherapy or the BCL-2 inhibitor ABT-199, IGM-8444 exhibited synergistic in vitro tumor cytotoxicity and enhanced in vivo efficacy, without augmenting in vitro hepatotoxicity. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 55-58 BCL2 apoptosis regulator Homo sapiens 39-44 34622385-7 2021 Further, COS significantly reduced the expression of Bax and upregulated Bcl-2. carbonyl sulfide 9-12 BCL2 apoptosis regulator Homo sapiens 73-78 34562506-7 2021 When HYPX exposure and TRPV4 agonist (GSK1016790A)-induced TRPV4 activity were inhibited by the treatment of ruthenium red or MLT, the increase of mROS, lipid peroxidation, apoptosis, Zn2+ concentrations, TRPV4, caspase -3, caspase -9, Bax, and Bcl-2 expressions were restored via upregulation of reduced glutathione, glutathione peroxidase and total antioxidant status. N-(1-((4-(2-(((2,4-dichlorophenyl)sulfonyl)amino)-3-hydroxypropanoyl)-1-piperazinyl)carbonyl)-3-methylbutyl)-1-benzothiophene-2-carboxamide 38-49 BCL2 apoptosis regulator Homo sapiens 245-250 34562506-7 2021 When HYPX exposure and TRPV4 agonist (GSK1016790A)-induced TRPV4 activity were inhibited by the treatment of ruthenium red or MLT, the increase of mROS, lipid peroxidation, apoptosis, Zn2+ concentrations, TRPV4, caspase -3, caspase -9, Bax, and Bcl-2 expressions were restored via upregulation of reduced glutathione, glutathione peroxidase and total antioxidant status. Ruthenium Red 109-122 BCL2 apoptosis regulator Homo sapiens 245-250 34799660-8 2021 Mechanistically, our findings suggest that PKR controls paclitaxel chemosensitivity through repressing Bcl2 expression. Paclitaxel 56-66 BCL2 apoptosis regulator Homo sapiens 103-107 34671429-6 2021 In addition, treatment with COH-203 resulted in downregulated expression of Bcl-2. coh-203 28-35 BCL2 apoptosis regulator Homo sapiens 76-81 34799660-9 2021 Pharmacological inhibition of Bcl2 with FDA-approved agent venetoclax overcomes paclitaxel resistance in preclinical animal models of ovarian cancer. Paclitaxel 80-90 BCL2 apoptosis regulator Homo sapiens 30-34 34709688-3 2021 Moracin D attenuated the expression of caspase-3, poly (ADP-ribose) polymerase (PARP), B-cell lymphoma 2 (Bcl-2), and B-cell lymphoma-extra-large (Bcl-xL) in DU145 cells. Moracin D 0-9 BCL2 apoptosis regulator Homo sapiens 87-104 34709688-3 2021 Moracin D attenuated the expression of caspase-3, poly (ADP-ribose) polymerase (PARP), B-cell lymphoma 2 (Bcl-2), and B-cell lymphoma-extra-large (Bcl-xL) in DU145 cells. Moracin D 0-9 BCL2 apoptosis regulator Homo sapiens 106-111 34928029-6 2021 The CPD regulates the expression levels of Caspase-3, p53, and Bcl-2 genes by increasing intracellular reactive oxygen species (ROS) levels and reducing mitochondrial membrane potential, which indicates that mitochondrial-mediated pathways are involved in apoptosis. Reactive Oxygen Species 103-126 BCL2 apoptosis regulator Homo sapiens 63-68 34928029-6 2021 The CPD regulates the expression levels of Caspase-3, p53, and Bcl-2 genes by increasing intracellular reactive oxygen species (ROS) levels and reducing mitochondrial membrane potential, which indicates that mitochondrial-mediated pathways are involved in apoptosis. Reactive Oxygen Species 128-131 BCL2 apoptosis regulator Homo sapiens 63-68 34884765-9 2021 Moreover, primaquine and chloroquine induce the apoptosis of breast cancer cells through c-Myc/Bcl-2 downregulation, induce early endosome damage and reduce nEGFR levels, and induce apoptosis in breast cancer through nEGFR/Stat3-dependent c-Myc downregulation. Primaquine 10-20 BCL2 apoptosis regulator Homo sapiens 95-100 33905668-0 2021 Alisol A 24-acetate protects oxygen-glucose deprivation-induced brain microvascular endothelial cells against apoptosis through miR-92a-3p inhibition by targeting the B-cell lymphoma-2 gene. alisol A 24-acetate 0-19 BCL2 apoptosis regulator Homo sapiens 167-184 33905668-0 2021 Alisol A 24-acetate protects oxygen-glucose deprivation-induced brain microvascular endothelial cells against apoptosis through miR-92a-3p inhibition by targeting the B-cell lymphoma-2 gene. mir-92a-3p 128-138 BCL2 apoptosis regulator Homo sapiens 167-184 33905668-12 2021 However, alisol A 24-acetate treatment suppressed inflammation, improved migration and invasion abilities, increased Bcl-2 expression, inhibited Bax expression, and repressed apoptosis and miR92a-3p overexpression in OGD-induced BMECs. alisol A 24-acetate 9-28 BCL2 apoptosis regulator Homo sapiens 117-122 33905668-13 2021 MiR-92a-3p overexpression promoted cell apoptosis and suppressed Bcl-2 expression, whereas its inhibitor reversed the tendency. -92a- 3-8 BCL2 apoptosis regulator Homo sapiens 65-70 33905668-16 2021 CONCLUSIONS: These findings suggest that alisol A 24-acetate exerts antiapoptotic effects on OGD-induced BMECs through miR-92a-3p inhibition by targeting the Bcl-2 gene, indicating its potential for BMECs protection and as a novel therapeutic agent for the treatment of cerebrovascular disease. alisol A 24-acetate 41-60 BCL2 apoptosis regulator Homo sapiens 158-163 33905668-16 2021 CONCLUSIONS: These findings suggest that alisol A 24-acetate exerts antiapoptotic effects on OGD-induced BMECs through miR-92a-3p inhibition by targeting the Bcl-2 gene, indicating its potential for BMECs protection and as a novel therapeutic agent for the treatment of cerebrovascular disease. mir-92a-3p 119-129 BCL2 apoptosis regulator Homo sapiens 158-163 34893112-6 2021 Compared with 0 mumol/L Eriodictyol, the proliferation activity of DG-75, SOD activity, MMP, phosphorylation levels of PI3K, AKT and mTOR in 20 and 40 mumol/L Eriodictyol treatment groups were significantly decreased (P<0.05), while cells apoptosis rate, Cleaved-Caspase-3/Caspase-3, Bax/Bcl-2 and MDA level were significantly increased (P<0.05). eriodictyol 159-170 BCL2 apoptosis regulator Homo sapiens 288-293 34884765-9 2021 Moreover, primaquine and chloroquine induce the apoptosis of breast cancer cells through c-Myc/Bcl-2 downregulation, induce early endosome damage and reduce nEGFR levels, and induce apoptosis in breast cancer through nEGFR/Stat3-dependent c-Myc downregulation. Chloroquine 25-36 BCL2 apoptosis regulator Homo sapiens 95-100 34837558-9 2021 In vitro experiments showed that OST and lobaplatin could significantly induce apoptosis in the MDA-MB-231 cells (P < 0.05), as indicated by elevation in the translation level of p53/Bax/caspase-3 p17 and downregulation of the Bcl-2 protein. osthol 33-36 BCL2 apoptosis regulator Homo sapiens 227-232 34844644-8 2021 By qRT-PCR, we observed that verbascoside treatment (100, 117 and, 130 muM) increases the expression of caspase-3 and Bax while reduces the expression of Bcl-2. acteoside 29-41 BCL2 apoptosis regulator Homo sapiens 154-159 34885077-3 2021 Bcl-2 inhibition initiate mitochondrial apoptosis, but also respiration and cellular ATP production in AML. Adenosine Triphosphate 85-88 BCL2 apoptosis regulator Homo sapiens 0-5 34837558-9 2021 In vitro experiments showed that OST and lobaplatin could significantly induce apoptosis in the MDA-MB-231 cells (P < 0.05), as indicated by elevation in the translation level of p53/Bax/caspase-3 p17 and downregulation of the Bcl-2 protein. lobaplatin 41-51 BCL2 apoptosis regulator Homo sapiens 227-232 34837956-11 2021 Network pharmacology revealed that ITGA2B, ITGB3, VWF, PLEK, TLR2, BCL2, BCL2L1 and TNF were the core targets of DMAG. 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin 113-117 BCL2 apoptosis regulator Homo sapiens 67-71 34837558-10 2021 Finally, combined treatment with OST and lobaplatin had an enhanced anti-tumor effect (P < 0.05) on proliferation and apoptosis, as well as more obvious effects on the related proteins (p53, Bax, Bcl-2, and caspase-3 p17). osthol 33-36 BCL2 apoptosis regulator Homo sapiens 196-201 34837558-10 2021 Finally, combined treatment with OST and lobaplatin had an enhanced anti-tumor effect (P < 0.05) on proliferation and apoptosis, as well as more obvious effects on the related proteins (p53, Bax, Bcl-2, and caspase-3 p17). lobaplatin 41-51 BCL2 apoptosis regulator Homo sapiens 196-201 34899304-2 2021 The results revealed that DIP pretreatment inhibited NaAsO2 induced L-02 cells apoptosis by increasing anti-apoptotic Bcl-2 expression and decreasing pro-apoptotic Bax expression. dip 26-29 BCL2 apoptosis regulator Homo sapiens 118-123 34899304-2 2021 The results revealed that DIP pretreatment inhibited NaAsO2 induced L-02 cells apoptosis by increasing anti-apoptotic Bcl-2 expression and decreasing pro-apoptotic Bax expression. sodium arsenite 53-59 BCL2 apoptosis regulator Homo sapiens 118-123 34943140-2 2021 Berberine also appears to reduce the bcl-2 and XIAP expression-proteins responsible for the inhibition of apoptosis. Berberine 0-9 BCL2 apoptosis regulator Homo sapiens 37-42 34829119-10 2021 Additionally, CSO can cause apoptosis in cancer cells by activating caspase-3, up-regulating Bax, and down-regulating Bcl-2. CSO 14-17 BCL2 apoptosis regulator Homo sapiens 118-123 34586865-6 2021 OLX and ABT-737 mediated inhibition of Bcl-2 correlated with reduced expression levels of thymidine kinase 1 (TK1), cyclin A2 (CCNA2), and cyclin B1 (CCNB1) cell cycle regulators. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 8-11 BCL2 apoptosis regulator Homo sapiens 39-44 34586865-13 2021 In addition, we show that Bcl-2 inhibitor ABT-737 exhibited moderate anti-mammarenavirus activity in vivo, and that Bcl-2 inhibitors displayed broad-spectrum antiviral activities against different mammarenaviruses and SARS-CoV-2. ABT-737 42-49 BCL2 apoptosis regulator Homo sapiens 26-31 34832966-12 2021 Bcl-2 levels were reduced only in SK-N-FI cells after treatment with cisplatin. Nitrogen 36-39 BCL2 apoptosis regulator Homo sapiens 0-5 34832966-12 2021 Bcl-2 levels were reduced only in SK-N-FI cells after treatment with cisplatin. Cisplatin 69-78 BCL2 apoptosis regulator Homo sapiens 0-5 34581757-2 2021 We report results of a phase 1b dose-escalation study of the novel, subcutaneous BET inhibitor RO6870810 (RO) combined with the BCL-2 inhibitor venetoclax, and rituximab, in recurrent/refractory DLBCL (NCT03255096). venetoclax 144-154 BCL2 apoptosis regulator Homo sapiens 128-133 34795418-2 2022 Here, we use single and combinatorial drug response profiling to show that the combined inhibition of the anti-apoptotic protein Bcl-2 and of the tyrosine kinase BTK with the small molecules venetoclax and ibrutinib efficiently kills DLBCL cells in vitro. ibrutinib 206-215 BCL2 apoptosis regulator Homo sapiens 129-134 34795418-5 2022 Combinatorial treatment further efficiently overcomes both primary and acquired resistance to venetoclax, which we could link to reduced expression of the Bcl-2 family members Bcl-XL and Bcl-2A1 under ibrutinib. ibrutinib 201-210 BCL2 apoptosis regulator Homo sapiens 155-160 34795418-6 2022 We found in a Swiss DLBCL cohort that ~15% of patients are projected to respond to the venetoclax/ibrutinib combination based on their high Bcl-2 expression and nuclear NF-kappaB localization. venetoclax 87-97 BCL2 apoptosis regulator Homo sapiens 140-145 34795418-6 2022 We found in a Swiss DLBCL cohort that ~15% of patients are projected to respond to the venetoclax/ibrutinib combination based on their high Bcl-2 expression and nuclear NF-kappaB localization. ibrutinib 98-107 BCL2 apoptosis regulator Homo sapiens 140-145 34784951-12 2021 Subsequently, BCL2 expression was elevated in patients with PCOS and positively regulated by circ-FURIN. circ 93-97 BCL2 apoptosis regulator Homo sapiens 14-18 34781947-3 2021 BH3 profiling can be utilized to study the readiness of living cancer cells to undergo apoptosis and their dependency on pro-survival BCL-2 family proteins. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 134-139 34783293-0 2021 miR-148-3p inhibits gastric cancer cell malignant phenotypes and chemotherapy resistance by targeting Bcl2. mir-148-3p 0-10 BCL2 apoptosis regulator Homo sapiens 102-106 34785631-2 2021 In this article, they found that astrocytes that were pretreated with paeonol significantly rescued MPP+-induced cell viability reduction, and inhibited up-regulation of cell apoptosis, caspase-1 activity, COX2, iNOS, and Bax/Bcl-2 ratio, as well as p-JNK and p-ERK. paeonol 70-77 BCL2 apoptosis regulator Homo sapiens 226-231 34785631-7 2021 Compared with the control group, Bax protein level was increased, while Bcl-2 protein level was decreased after treatment with MPP+, and these changes were not reversed by paeonol. mangion-purified polysaccharide (Candida albicans) 127-131 BCL2 apoptosis regulator Homo sapiens 72-77 34830893-6 2021 BCP treatment reduced cell proliferation through CB2R stimulation; notably, BCP considerably increased the pro-apoptotic protein Bax and decreased the anti-apoptotic molecule Bcl-2. caryophyllene 0-3 BCL2 apoptosis regulator Homo sapiens 175-180 34784951-13 2021 Furthermore, circ-FURIN was served as a sponge of miR-195-5p to directly target to BCL2. circ-furin 13-23 BCL2 apoptosis regulator Homo sapiens 83-87 34784951-13 2021 Furthermore, circ-FURIN was served as a sponge of miR-195-5p to directly target to BCL2. -195-5p 53-60 BCL2 apoptosis regulator Homo sapiens 83-87 34785791-7 2022 Overexpression of miR-15a-5p inhibited cell growth and induced apoptosis by decreasing Bcl-2 and Bcl-xl levels. mir-15a-5p 18-28 BCL2 apoptosis regulator Homo sapiens 87-92 34293698-0 2021 Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways. Platinum 0-8 BCL2 apoptosis regulator Homo sapiens 168-172 34812274-7 2021 LM-021 exhibited antiaggregative, antioxidative, and neuroprotective effects mediated by the upregulation of CREB phosphorylation and its downstream brain-derived neurotrophic factor and BCL2 apoptosis regulator genes in Abeta-GFP- and DeltaK280 tauRD-DsRed-expressing SH-SY5Y cells. lm-021 0-6 BCL2 apoptosis regulator Homo sapiens 187-211 34563497-8 2021 In recent years, inhibiting the interaction of acetyl-lysine residues and bromodomain proteins on chromatin has served as an interesting target to regulate the expression of various pathological genes, including BCL-2, MYC, and NF-kappaB. N(alpha)-acetyllysine 47-60 BCL2 apoptosis regulator Homo sapiens 212-217 34758330-3 2021 TIAM1 depletion or RAC1 inhibition reduces viability and tumorigenicity of SCLC cells by increasing apoptosis associated with conversion of BCL2 from its pro-survival to pro-apoptotic function via BH3 domain exposure. BH 3 197-200 BCL2 apoptosis regulator Homo sapiens 140-144 34764434-3 2022 We aimed to evaluate the prognostic value of BCL2 expression determined by immunohistochemistry (IHC), incorporating both the staining intensity and proportion, in patients with de novo DLBCL who received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as first-line treatment. Cyclophosphamide 216-232 BCL2 apoptosis regulator Homo sapiens 45-49 34764434-3 2022 We aimed to evaluate the prognostic value of BCL2 expression determined by immunohistochemistry (IHC), incorporating both the staining intensity and proportion, in patients with de novo DLBCL who received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as first-line treatment. Doxorubicin 234-245 BCL2 apoptosis regulator Homo sapiens 45-49 34831318-5 2021 By activating TRKB-mediated extracellular signal-regulated kinase (ERK) and AKT serine/threonine kinase 1 (AKT) signaling, these two ZN compounds also upregulated the cAMP-response-element binding protein (CREB) and its downstream BDNF and anti-apoptotic B-cell lymphoma 2 (BCL2). Zinc 133-135 BCL2 apoptosis regulator Homo sapiens 255-272 34831318-5 2021 By activating TRKB-mediated extracellular signal-regulated kinase (ERK) and AKT serine/threonine kinase 1 (AKT) signaling, these two ZN compounds also upregulated the cAMP-response-element binding protein (CREB) and its downstream BDNF and anti-apoptotic B-cell lymphoma 2 (BCL2). Zinc 133-135 BCL2 apoptosis regulator Homo sapiens 274-278 34830153-0 2021 New Bioactive Fused Triazolothiadiazoles as Bcl-2-Targeted Anticancer Agents. triazolothiadiazoles 20-40 BCL2 apoptosis regulator Homo sapiens 44-49 34830153-1 2021 A series of 3-(6-substituted phenyl-(1,2,4)-triazolo(3,4-b)-(1,3,4)-thiadiazol-3-yl)-1H-indoles (5a-l) were designed, synthesized and evaluated for anti-apoptotic Bcl-2-inhibitory activity. 5a-l 97-101 BCL2 apoptosis regulator Homo sapiens 163-168 34830153-5 2021 The most potent 6-(2,4-dimethoxyphenyl) substituted analogue (5k) showed selective IC50 values of 0.31-0.7 microM against Bcl-2-expressing cell lines without inhibiting the Bcl-2-negative cell line (Jurkat). 6-(2,4-dimethoxyphenyl) 16-39 BCL2 apoptosis regulator Homo sapiens 122-127 34764434-3 2022 We aimed to evaluate the prognostic value of BCL2 expression determined by immunohistochemistry (IHC), incorporating both the staining intensity and proportion, in patients with de novo DLBCL who received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as first-line treatment. Vincristine 247-258 BCL2 apoptosis regulator Homo sapiens 45-49 34764434-3 2022 We aimed to evaluate the prognostic value of BCL2 expression determined by immunohistochemistry (IHC), incorporating both the staining intensity and proportion, in patients with de novo DLBCL who received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as first-line treatment. Prednisone 264-274 BCL2 apoptosis regulator Homo sapiens 45-49 34732441-6 2021 Moreover, high risk, defined as co-expression of BTK and either or both BCL2/MYC, independently predicted shorter progression-free survival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) (all R-CHOP-treated patients: hazard ratio=2.565, p=0.044; R-CHOP-treated non-GCB subgroup: HR=3.833, p=0.019). Cyclophosphamide 180-196 BCL2 apoptosis regulator Homo sapiens 72-76 34769400-9 2021 Molecular analysis showed changes in BAX, BCL2, TP53, and CDKN1 expression in tested cell lines following incubation with ciprofloxacin and levofloxacin. Ciprofloxacin 122-135 BCL2 apoptosis regulator Homo sapiens 42-46 34769400-9 2021 Molecular analysis showed changes in BAX, BCL2, TP53, and CDKN1 expression in tested cell lines following incubation with ciprofloxacin and levofloxacin. Levofloxacin 140-152 BCL2 apoptosis regulator Homo sapiens 42-46 34765011-8 2021 Fluorescence real-time quantitative PCR and western blot analysis showed that episamarcandin increased the expression of PTEN, p53, and Bax and decreased the expression of P-Akt, Akt, mTOR, Bcl-xl, and Bcl-2. Nevskin 78-92 BCL2 apoptosis regulator Homo sapiens 202-207 34988167-16 2021 DFO significantly increased the expression level of Bcl-2, and reduced the expression level of Bad. Deferoxamine 0-3 BCL2 apoptosis regulator Homo sapiens 52-57 34795760-0 2021 Nrf3 Promotes 5-FU Resistance in Colorectal Cancer Cells via the NF-kappaB/BCL-2 Signaling Pathway In Vitro and In Vivo. Fluorouracil 14-18 BCL2 apoptosis regulator Homo sapiens 75-80 34481877-4 2021 Compared to the ISO group, 1, 8-cineole highly attenuated the generation of ISO-induced reactive oxygen species (ROS), the depolarization of psim, suppression of the Bax/Bcl-2 ratio, and p-caspase 3 expression, in vitro. Eucalyptol 27-39 BCL2 apoptosis regulator Homo sapiens 171-176 34481877-4 2021 Compared to the ISO group, 1, 8-cineole highly attenuated the generation of ISO-induced reactive oxygen species (ROS), the depolarization of psim, suppression of the Bax/Bcl-2 ratio, and p-caspase 3 expression, in vitro. Isoproterenol 76-79 BCL2 apoptosis regulator Homo sapiens 171-176 34416282-16 2021 Additionally, mir-5189-3p mimics significantly increased Bcl-2 while decreased Bax protein. mir-5189-3p 14-25 BCL2 apoptosis regulator Homo sapiens 57-62 34732441-6 2021 Moreover, high risk, defined as co-expression of BTK and either or both BCL2/MYC, independently predicted shorter progression-free survival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) (all R-CHOP-treated patients: hazard ratio=2.565, p=0.044; R-CHOP-treated non-GCB subgroup: HR=3.833, p=0.019). Doxorubicin 198-209 BCL2 apoptosis regulator Homo sapiens 72-76 34732441-6 2021 Moreover, high risk, defined as co-expression of BTK and either or both BCL2/MYC, independently predicted shorter progression-free survival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) (all R-CHOP-treated patients: hazard ratio=2.565, p=0.044; R-CHOP-treated non-GCB subgroup: HR=3.833, p=0.019). Vincristine 211-222 BCL2 apoptosis regulator Homo sapiens 72-76 34732441-6 2021 Moreover, high risk, defined as co-expression of BTK and either or both BCL2/MYC, independently predicted shorter progression-free survival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) (all R-CHOP-treated patients: hazard ratio=2.565, p=0.044; R-CHOP-treated non-GCB subgroup: HR=3.833, p=0.019). Prednisone 227-237 BCL2 apoptosis regulator Homo sapiens 72-76 34607979-6 2021 Accordingly, the p27 and p21 promoter activities were enhanced while Bcl-2 and IL-6 activities were significantly reduced by metformin treatment. Metformin 125-134 BCL2 apoptosis regulator Homo sapiens 69-74 34560542-5 2021 Flow cytometry and Western blotting analyses were used to detect the degree of CRC cell apoptosis and the expression of the apoptosis-related proteins Bcl-2, Bax and caspase-3 after PMTZ treatment. Promethazine 182-186 BCL2 apoptosis regulator Homo sapiens 151-156 34837933-9 2021 In addition, mRNA analyses demonstrated that MOLT4 and jurkat cells, expressed p53 gene more than 10-fold higher compared with untreated cells in three independent experiments while the cells suppressed the expression of a subset of functionally related genes including MYC, BCL2, APEX, SIRT1, SNAIL1 and vimentin to some extent, following 5-AZA treatment. Azacitidine 340-345 BCL2 apoptosis regulator Homo sapiens 275-279 34400171-5 2021 We demonstrate that human Bcl-2 via its BH4 domain could functionally interact with CO.IP3R-A, thereby suppressing Ca2+ flux through CO.IP3R-A channels. sapropterin 40-43 BCL2 apoptosis regulator Homo sapiens 26-31 34400171-6 2021 The BH4 domain of Bcl-2 was sufficient for interaction with CO.IP3R-A channels. sapropterin 4-7 BCL2 apoptosis regulator Homo sapiens 18-23 34400171-7 2021 Moreover, mutating the Lys17 of Bcl-2"s BH4 domain, the residue critical for Bcl-2-dependent modulation of mammalian IP3Rs, abrogated Bcl-2"s ability to bind and inhibit CO.IP3R-A channels. sapropterin 40-43 BCL2 apoptosis regulator Homo sapiens 32-37 34400171-7 2021 Moreover, mutating the Lys17 of Bcl-2"s BH4 domain, the residue critical for Bcl-2-dependent modulation of mammalian IP3Rs, abrogated Bcl-2"s ability to bind and inhibit CO.IP3R-A channels. sapropterin 40-43 BCL2 apoptosis regulator Homo sapiens 134-139 34939761-0 2021 Restoration of MiR-34a Expression by 5-Azacytidine Augments Alimta -Induced Cell Death in Non-Small Lung Cancer Cells by Downregulation of HMG B1, A2 and Bcl-2 Pathway. Azacitidine 37-50 BCL2 apoptosis regulator Homo sapiens 154-159 34520332-6 2021 Sequentially, saikosaponin-A triggered the mitochondrial-mediated apoptosis demonstrated by deficiency of MMP, induction of Bax/Bcl-2 ratio, leakage of cytochrome c to cytoplasm, and activation of caspase-3. saikosaponin D 14-28 BCL2 apoptosis regulator Homo sapiens 128-133 34939761-9 2021 Sequential exposure of the cells to 5-aza and Alimta enhanced miR-34a expression and significantly downregulated HMGB1, HMGA2 and BCL-2 expressions. Azacitidine 36-41 BCL2 apoptosis regulator Homo sapiens 130-135 34939761-9 2021 Sequential exposure of the cells to 5-aza and Alimta enhanced miR-34a expression and significantly downregulated HMGB1, HMGA2 and BCL-2 expressions. Pemetrexed 46-52 BCL2 apoptosis regulator Homo sapiens 130-135 34606419-6 2021 Moreover, we found that forskolin induced mitochondrion-dependent apoptosis which was accompanied by the increase of pro-apoptotic proteins Bax, Bad, Bim and Bid, the decrease of anti-apoptotic proteins Bcl-2 and Bcl-xl, the changes of the mitochondrial membrane potential (MMP) and increase of cleaved caspase-9, cleaved caspase-3 and cleaved PARP. Colforsin 24-33 BCL2 apoptosis regulator Homo sapiens 203-208 34939761-0 2021 Restoration of MiR-34a Expression by 5-Azacytidine Augments Alimta -Induced Cell Death in Non-Small Lung Cancer Cells by Downregulation of HMG B1, A2 and Bcl-2 Pathway. Pemetrexed 60-66 BCL2 apoptosis regulator Homo sapiens 154-159 34844720-10 2021 Simultaneously, ALO promoted an increase in the percentage of apoptotic HeLa cells by increasing the Bax/Bcl-2 ratio. aloperine 16-19 BCL2 apoptosis regulator Homo sapiens 105-110 34139443-6 2021 Further studies showed that Difenoconazole induced DNA double-strand breaks, intracellular generation of ROS, cleaved PARP, mitochondrial membrane potential collapse, induced Cyt c release, and Bax/Bcl-2 ratio increase in SH-SY5Y cells. difenoconazole 28-42 BCL2 apoptosis regulator Homo sapiens 198-203 34547276-5 2021 Here, Z-ligustilide elevated high glucose/high palmitic acid (HG/P)-inhibited cell viability and attenuated HG/P-induced cell apoptosis, caspase-3 activity, pro-apoptotic Bax and anti-apoptotic Bcl-2 protein expression. ligustilide 6-19 BCL2 apoptosis regulator Homo sapiens 194-199 34156614-6 2021 NAC also significantly increased the expression and distribution of zonula occludens 1 (ZO-1), decreased the relative mRNA and protein expression levels of Bax, Bid, caspase-3, and caspase-9, and increased Bcl-2 expression level and inhibited the decrease of mitochondrial membrane potential. Acetylcysteine 0-3 BCL2 apoptosis regulator Homo sapiens 206-211 34226167-7 2021 Specifically, the use of venetoclax in targeting BCL2 has been promising in BPDCN treatment. bpdcn 76-81 BCL2 apoptosis regulator Homo sapiens 49-53 34582963-3 2021 Western blot analysis indicated that C3G and PCA minimized PhIP-induced cell damage by reversing the abnormal expression of Bax/Bcl-2, Cytochrome c, cleaved Caspase-3, XIAP, Nrf2, HO-1, LC3 and p62 involved in intrinsic apoptotic and Nrf2/p62 pathways. 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 59-63 BCL2 apoptosis regulator Homo sapiens 128-133 34517121-5 2021 Besides, up-regulating the expression level of Bax /Bcl-2, a reduction in mitochondrial membrane potential, caspase-9/-3 activation and the release of cytochrome-c are contributed to the toxicological effects of TCP on HepG2 cells. tcp 212-215 BCL2 apoptosis regulator Homo sapiens 52-57 34760016-11 2021 Sinomenine accelerated the expression of Bax and caspase-3 but decreased the expression of Bcl-2. sinomenine 0-10 BCL2 apoptosis regulator Homo sapiens 91-96 34370268-10 2021 STAT3 inhibitor further down-regulated the expression of MMP2, MMP9, ROR1, ABCB1 and BCl2, while up-regulated the expression of p53, bax and cleaved caspase3 in HCC827 Ge-r cells treated with gefitinib, which was partially reversed by ROR1 overexpression. Gefitinib 192-201 BCL2 apoptosis regulator Homo sapiens 85-89 34603517-10 2021 In addition, compared with those in the group treated with sirtinol, expression of SIRT1, Bcl-2 and AMPK activity were elevated in MAF-treated H/R-A549 cells, whereas the expression of Bax, cleaved caspase-3 and cleaved caspase-9 was suppressed. sirtinol 59-67 BCL2 apoptosis regulator Homo sapiens 90-95 34603522-10 2021 ETO also promoted cell apoptosis and decreased the expression of the anti-apoptotic protein Bcl-2, whilst increasing that of pro-apoptotic proteins Bax and cleaved caspase 3 in a dose-dependent manner. Etomidate 0-3 BCL2 apoptosis regulator Homo sapiens 92-97 34549307-8 2021 The results revealed that SPHK1 was positively correlated with cisplatin resistance in bladder cancer cells, exhibiting an antiapoptotic effect that was reflected by the downregulation of apoptosis-related proteins (Bax and cleaved caspase-3) and the upregulation of an antiapoptotic protein (Bcl-2) in SPHK1-overexpression cell lines. Cisplatin 63-72 BCL2 apoptosis regulator Homo sapiens 293-298 34555641-8 2021 In addition, ISL alleviated LPS/D-GalN-induced hepatocytes apoptosis by increasing the Bcl-2/Bax ratio and suppressing the expression of cleaved caspase-3. Galactosamine 32-38 BCL2 apoptosis regulator Homo sapiens 87-92 34146182-8 2021 Higenamine attenuated IL-1beta-induced decrease of Bcl-2 and increase of Bax and cleaved caspase-3. higenamine 0-10 BCL2 apoptosis regulator Homo sapiens 51-56 34514729-9 2021 Further investigations revealed that crocetin treatment inhibited the expression of STAT3 regulated genes (Bcl-2, Bcl-xL, cyclin D1, survivin, VEGF, COX-2, and MMP-9). crocetin 37-45 BCL2 apoptosis regulator Homo sapiens 107-112 34330053-8 2021 Lithium pretreatment 3 days also prevented the DNA fragmentation induced by glutamate, and significantly increased the antiapoptotic phospho-B-Raf and Bcl-2 proteins in BD-ONPs compared to non-BD-ONPs. Lithium 0-7 BCL2 apoptosis regulator Homo sapiens 151-156 34330053-11 2021 Lithium is associated with a greater increase of anti-apoptotic B-Raf and Bcl-2 expression in BD-ONPs. Lithium 0-7 BCL2 apoptosis regulator Homo sapiens 74-79 34337761-7 2021 Docking studies revealed the high binding affinity of Nuatigenin at significant sites with apoptotic proteins Bcl-2, Bax, caspase-3, caspase-8, p53 and apoptosis inducing factor along with cell surface receptors estrogen receptor, projesterone receptor, epidermal growth factor receptor, and human epidermal growth factor receptor-2. nuatigenin 54-64 BCL2 apoptosis regulator Homo sapiens 110-115 34580047-9 2021 Moreover, MPP+ exposure increased the mitochondrial expressions of parkin, PINK1, Beclin 1 and p62, and decreased TOM20, cytochrome c and Bcl-2 expressions. mangion-purified polysaccharide (Candida albicans) 10-14 BCL2 apoptosis regulator Homo sapiens 138-143 34580047-11 2021 CONCLUSION: KRG effectively prevents MPP+-induced SH-SY5Y cell death by regulating cytochrome c release from mitochondria and PINK1/parkin-mediated mitophagy, through regulation of the Bcl-2 family. mangion-purified polysaccharide (Candida albicans) 37-41 BCL2 apoptosis regulator Homo sapiens 185-190 34630671-11 2021 Moreover, compared with the control group, gigantol treatment decreased Ki-67 and Bcl-2 expression levels, increased Bax expression levels and inactivated the Wnt/beta-catenin signaling pathway, as assessed by RT-qPCR and/or western blot. gigantol 43-51 BCL2 apoptosis regulator Homo sapiens 82-87 34630671-13 2021 To conclude, the results of the present study suggested that gigantol inhibited cell proliferation and induced apoptosis by decreasing Ki-67 and Bcl-2 expression, increasing Bax expression and activating the Wnt/beta-catenin signaling pathway by regulating DEK. gigantol 61-69 BCL2 apoptosis regulator Homo sapiens 145-150 34580047-8 2021 RESULTS: MPP+ induced cell death by cytochrome c release and caspase-3 activation; however, this effect was suppressed by KRG"s regulation of the expressions of Bcl-2 and Bax. mangion-purified polysaccharide (Candida albicans) 9-13 BCL2 apoptosis regulator Homo sapiens 161-166 34482001-7 2021 The data of co-culture system showed that 1-MT-pretreated dMphi decreased the proliferation and the expression of Ki-67 and Bcl-2, and increased cell apoptosis of HTR-8/Snveo cells. dmphi 58-63 BCL2 apoptosis regulator Homo sapiens 124-129 34571432-9 2021 Our results suggest that Bcl-2 protein family member Bax was active in the apoptotic response of CLL cells after DHA treatment. artenimol 113-116 BCL2 apoptosis regulator Homo sapiens 25-30 34490473-10 2021 In addition, naringenin notably inhibited the proliferation of RCC cells by decreasing Ki67 expression, blocked cell cycle progression in the G2 phase by regulating expression of cell cycle proteins, and increased apoptosis by upregulating caspase-8 expression, downregulating Bcl-2 expression and altering the cellular morphology. naringenin 13-23 BCL2 apoptosis regulator Homo sapiens 277-282 34476500-5 2021 In SKOV3/DDP cells, HAND2-AS1 overexpression inhibited cell viability and promoted cell apoptosis upon DDP treatment through the Bcl-2/caspase-3 apoptotic signaling. Cisplatin 103-106 BCL2 apoptosis regulator Homo sapiens 129-134 34486189-6 2021 Harpagoside prevented Ang II-induced apoptosis via keeping Bax/Bcl-2 balance, decreasing cytochrome c release, and inactivation of caspase-8, caspase-9, and caspase-3 (the mitochondria-dependent and death receptor-mediated apoptosis pathways). harpagoside 0-11 BCL2 apoptosis regulator Homo sapiens 63-68 34476501-7 2021 ANP also inhibited the H2O2-induced alterations in the expression levels of cleaved-caspase-3, Bax and Bcl-2. Hydrogen Peroxide 23-27 BCL2 apoptosis regulator Homo sapiens 103-108 34490484-10 2021 Further mechanistic studies demonstrated that Nar blocked the PI3K/AKT pathway, activated cell autophagy and stimulated the expression of apoptosis-associated protein cleaved caspase 3 and Bax, but decreased the expression of Bcl-2. naringin 46-49 BCL2 apoptosis regulator Homo sapiens 226-231 34555757-7 2021 Dietary supplementation with tributyrin decreased the cell apoptosis rate and downregulated caspase 9 expression in LR breeders (P(Interaction) < 0.05), up-regulated the Bcl-2 expression in both 2 breeders (P(TRI) < 0.05). tributyrin 29-39 BCL2 apoptosis regulator Homo sapiens 170-175 34636157-5 2021 In vitro biomolecular experiments showed that by crosslinking grafted polyethylene glycol acrylate liposomes loaded with DFO, the functional electrospun fibers can release DFO locally to activate Hif-1 in BMSCs, which can regulate the balance of Bcl-2/Bax to protect mitochondria and upregulate the expression of VEGF to reconstruct microcirculation. polyethylene glycol acrylate 70-98 BCL2 apoptosis regulator Homo sapiens 246-251 34106437-8 2021 Progesterone stimulation alone as well as co-stimulation with TNF-alpha, NGAL, IL-18, IL-1beta, or thrombin with progesterone either increased, decreased, or did not change the expression of Bcl-2, Bcl-XL, or XIAP genes (anti-apoptotic factors). Progesterone 0-12 BCL2 apoptosis regulator Homo sapiens 191-196 34106437-8 2021 Progesterone stimulation alone as well as co-stimulation with TNF-alpha, NGAL, IL-18, IL-1beta, or thrombin with progesterone either increased, decreased, or did not change the expression of Bcl-2, Bcl-XL, or XIAP genes (anti-apoptotic factors). Progesterone 113-125 BCL2 apoptosis regulator Homo sapiens 191-196 34636157-5 2021 In vitro biomolecular experiments showed that by crosslinking grafted polyethylene glycol acrylate liposomes loaded with DFO, the functional electrospun fibers can release DFO locally to activate Hif-1 in BMSCs, which can regulate the balance of Bcl-2/Bax to protect mitochondria and upregulate the expression of VEGF to reconstruct microcirculation. Deferoxamine 121-124 BCL2 apoptosis regulator Homo sapiens 246-251 34636157-5 2021 In vitro biomolecular experiments showed that by crosslinking grafted polyethylene glycol acrylate liposomes loaded with DFO, the functional electrospun fibers can release DFO locally to activate Hif-1 in BMSCs, which can regulate the balance of Bcl-2/Bax to protect mitochondria and upregulate the expression of VEGF to reconstruct microcirculation. Deferoxamine 172-175 BCL2 apoptosis regulator Homo sapiens 246-251 34754326-7 2021 The level of antiapoptotic protein Bcl-2 was promoted by DMF treatment in LPS-challenged NPCs. Dimethyl Fumarate 57-60 BCL2 apoptosis regulator Homo sapiens 35-40 34365218-5 2021 Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2. Platinum 29-37 BCL2 apoptosis regulator Homo sapiens 324-328 34365218-5 2021 Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2. Irinotecan 51-61 BCL2 apoptosis regulator Homo sapiens 324-328 34365218-5 2021 Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2. Platinum 93-101 BCL2 apoptosis regulator Homo sapiens 324-328 34365218-5 2021 Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2. Paclitaxel 102-107 BCL2 apoptosis regulator Homo sapiens 324-328 34821090-7 2021 Results: Compared with the control group, the expressions of miR-133b and Bcl-2 in EVC-304 cells were decreased significantly after oxLDL induction, while the expression levels of SGTB and Bax were sincreased ignificantly (P<0.05), the MDA content and apoptosis rate were increased significantly (P<0.05), and the activities of SOD and GSH-Px were decreased significantly (P<0.05). gsh-px 336-342 BCL2 apoptosis regulator Homo sapiens 74-79 34770968-0 2021 Effect of Resveratrol Treatment on Human Pancreatic Cancer Cells through Alterations of Bcl-2 Family Members. Resveratrol 10-21 BCL2 apoptosis regulator Homo sapiens 88-93 34768523-9 2021 We found that 253 genes were significantly altered in expression, and upregulation of CERS4, PPP2R2C, GNAZ, PRKCG, BCL2, MAPK12, and MAPK11 suggests the involvement of the sphingolipid signaling pathway, known to be activated by phosphorylated-FTY720. Sphingolipids 172-184 BCL2 apoptosis regulator Homo sapiens 115-119 34711685-5 2021 Up-regulation of SIRT1 induced by 17beta-E2 increased the expression level of LC3, Beclin-1, Bcl-2, p-AMPK, FOXO3a but decreased caspase-3 and p-mTOR expression, and then promoted autophagy and inhibited apoptosis. 17beta-e2 34-43 BCL2 apoptosis regulator Homo sapiens 93-98 34706861-9 2021 cMYC/BCL2 double-expressor DLBCLs had a poorer DSS than non-double-expressor DLBCLs (5-year DSS, 25% vs 78%) (HR 0.23; 95% CI 0.06 to 0.85; p=0.014). dss 47-50 BCL2 apoptosis regulator Homo sapiens 5-9 34706861-9 2021 cMYC/BCL2 double-expressor DLBCLs had a poorer DSS than non-double-expressor DLBCLs (5-year DSS, 25% vs 78%) (HR 0.23; 95% CI 0.06 to 0.85; p=0.014). dss 92-95 BCL2 apoptosis regulator Homo sapiens 5-9 34834209-1 2021 The present study demonstrated that 2"-hydroxycinnamaldehyde (2"-HCA) induced apoptosis in human promyelocytic leukemia HL-60 cells through the activation of mitochondrial pathways including (1) translocation of Bim and Bax from the cytosol to mitochondria, (2) downregulation of Bcl-2 protein expression, (3) cytochrome c release into the cytosol, (4) loss of mitochondrial membrane potential (DeltaPsim), and (5) caspase activation. 2"-hydroxycinnamaldehyde 36-60 BCL2 apoptosis regulator Homo sapiens 280-285 34478517-1 2021 Anti-apoptotic Bcl-2 family members recently (re)emerged as key drug targets in cancer, with a tissue and tumour specific activity profile of available BH3 mimetics. BH 3 152-155 BCL2 apoptosis regulator Homo sapiens 15-20 34478517-7 2021 These manifestations depend on the BH3-profile of parental cells which guide the enhanced formation of Bcl-2:BIM and/or dynamic (i.e. treatment-induced) formation of Bcl-xL:BIM and Bcl-xL:BAK complexes. BH 3 35-38 BCL2 apoptosis regulator Homo sapiens 103-108 34478517-8 2021 Accordingly, an unbiased high-throughput drug (n=528) screening approach highlighted alternative BH3 mimetics as top combination partners for MCL-1 inhibitors in sensitive and resistant cells (Bcl-xL>Bcl-2 inhibition), whereas established drug classes were mainly antagonistic (e.g. anti-mitotic agents). BH 3 97-100 BCL2 apoptosis regulator Homo sapiens 200-205 34478517-10 2021 Finally, we demonstrate heterogeneous Bcl-2 family deregulation and MCL-1 inhibitor cross-resistance in carfilzomib resistant cells, a phenomenon linked to MDR1-driven drug efflux of MCL-1 inhibitors. carfilzomib 104-115 BCL2 apoptosis regulator Homo sapiens 38-43 34697301-5 2021 Further analysis suggests that Lnc-DC is able to reduce tamoxifen-induced apoptosis by upregulation of anti-apoptotic genes such as Bcl2 and Bcl-xL. Tamoxifen 56-65 BCL2 apoptosis regulator Homo sapiens 132-136 34834209-1 2021 The present study demonstrated that 2"-hydroxycinnamaldehyde (2"-HCA) induced apoptosis in human promyelocytic leukemia HL-60 cells through the activation of mitochondrial pathways including (1) translocation of Bim and Bax from the cytosol to mitochondria, (2) downregulation of Bcl-2 protein expression, (3) cytochrome c release into the cytosol, (4) loss of mitochondrial membrane potential (DeltaPsim), and (5) caspase activation. 2"-hca 62-68 BCL2 apoptosis regulator Homo sapiens 280-285 34770786-7 2021 Pro-apoptotic markers including Bax, cleaved-caspase-3 and cleaved-caspase-9 were increased while anti-apoptotic marker Bcl-2 was decreased after BA treatment. betulinic acid 146-148 BCL2 apoptosis regulator Homo sapiens 120-125 34739183-6 2022 Incubation of the SMG-ONP-O system with ALLO 0.06 microm led to an increase in the BAX/BCL-2 ratio and a reduction of FAS-L mRNA levels. smg-onp-o 18-27 BCL2 apoptosis regulator Homo sapiens 87-92 34675185-7 2021 Accordingly, co-administration of a FASNi synergistically augments the apoptosis-inducing activity of the dual BCL-XL/BCL-2 inhibitor ABT-263 (navitoclax) and the BCL-2 specific BH3-mimetic ABT-199 (venetoclax). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 134-137 BCL2 apoptosis regulator Homo sapiens 118-123 34675185-11 2021 Combining next-generation FASNis with BCL-2-specific BH3 mimetics that directly activate the apoptotic machinery might generate more potent and longer-lasting antitumor responses in a clinical setting. fasnis 26-32 BCL2 apoptosis regulator Homo sapiens 38-43 34673986-9 2022 Interestingly, transcripts FDXR (P = 0.01), DDB2 (P = 0.03), BCL2 (P = 0.003), and SESN1 (P < 0.0003) maintained differential expression 15 days after 131I-mIBG treatment. 3-Iodobenzylguanidine 156-160 BCL2 apoptosis regulator Homo sapiens 61-65 34822529-9 2021 In addition, FKA enhanced Bcl2 activation while suppressing apoptosis marker proteins. flavokawain A 13-16 BCL2 apoptosis regulator Homo sapiens 26-30 34755675-12 2021 An increased expression of Bcl-2 in PA lesions and a decreased cell fat content in PH lesions can facilitate the detection of HPT glands by 99mTc-MIBI SPECT/CT. technetium 99m methoxyisobutylisonitrile 140-150 BCL2 apoptosis regulator Homo sapiens 27-32 34671894-7 2021 Molecular docking analysis, which was employed to make some predictions on the interaction of the most active derivatives with the binding site of Bcl-2 and Bcl-xL proteins, suggested that the compounds may be well accommodated within the binding sites of these anti-apoptotic proteins via hydrogen-bonding and hydrophobic interactions. Hydrogen 290-298 BCL2 apoptosis regulator Homo sapiens 147-152 34744716-4 2021 Additionally, UV-B exposure increased the expression of cleaved caspase-3, as well as the ratio of Bax/Bcl-2 at protein levels, while pretreatment with DHPM 1 significantly reversed these changes. ethyl 6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate 152-156 BCL2 apoptosis regulator Homo sapiens 103-108 34768743-0 2021 Bcl-2 Modulation in p53 Signaling Pathway by Flavonoids: A Potential Strategy towards the Treatment of Cancer. Flavonoids 45-55 BCL2 apoptosis regulator Homo sapiens 0-5 34712389-9 2021 Breeder plasma Zn concentration and erythrocytic 5"-NT activities at week 6 were positively correlated with GSH-Px activity and GPx, MT1, and BCL2 mRNA expressions in embryonic livers on E29. Zinc 15-17 BCL2 apoptosis regulator Homo sapiens 142-146 34768743-8 2021 Flavonoids inhibit B-cell lymphoma 2 (Bcl-2) via the p53 signaling pathway, which is a significant apoptotic target in many cancer types, hence suppressing a major dysregulated pathway in cancer. Flavonoids 0-10 BCL2 apoptosis regulator Homo sapiens 38-43 34768743-9 2021 To date, there have been no studies reported which extensively highlight the role of flavonoids and especially the different classes of flavonoids in the modulation of Bcl-2 in the P53 signaling pathway. Flavonoids 85-95 BCL2 apoptosis regulator Homo sapiens 168-173 34768743-9 2021 To date, there have been no studies reported which extensively highlight the role of flavonoids and especially the different classes of flavonoids in the modulation of Bcl-2 in the P53 signaling pathway. Flavonoids 136-146 BCL2 apoptosis regulator Homo sapiens 168-173 34768743-10 2021 Herein, we discuss the modulation of Bcl-2 in the p53 signaling pathway by different classes of flavonoids and highlight different mechanisms through which this modulation can occur. Flavonoids 96-106 BCL2 apoptosis regulator Homo sapiens 37-42 34682865-13 2021 Furthermore, the Bax/Bcl-2 expression ratio was increased in response to diosmetin treatment, which would result in increased apoptosis. diosmetin 73-82 BCL2 apoptosis regulator Homo sapiens 21-26 34914264-11 2021 CONCLUSIONS: Silencing HMGB1 combined with DTX chemotherapy can inhibit the proliferation and promote the apoptosis of PCa cells, which may be attributed to its regulatory effect on the expressions of the Bcl-2 family-related proteins. Docetaxel 43-46 BCL2 apoptosis regulator Homo sapiens 205-210 34684868-6 2021 PKE decreased the apoptosis of SW1353 cells treated with H2O2 and could upregulate the gene expression of antioxidant enzymes (SOD-2, GPx, and CAT) and the Bcl-2/Bax ratio, as well as regulate PARP, thus conferring resistance to H2O2 attack. Hydrogen Peroxide 57-61 BCL2 apoptosis regulator Homo sapiens 156-161 34657232-8 2022 Exposure to H2O2 increased the expression of Bax, cleaved caspase-3, and extracellular matrix (ECM) proteins, accompanied by reduced Bcl-2 expression. Hydrogen Peroxide 12-16 BCL2 apoptosis regulator Homo sapiens 133-138 34773965-8 2022 Furthermore, the data revealed that curcumin nanoformulation induces apoptosis in MDA-MB-468 cells through modulation of the expression of Bax, Bcl-2, Survivin, and Caspase-3. Curcumin 36-44 BCL2 apoptosis regulator Homo sapiens 144-149 34681736-5 2021 ROS-induced endoplasmic reticulum (ER) stress by OSMI-1 not only upregulated CHOP-DR5 signaling but also activated Jun-N-terminal kinase (JNK), resulting in a decrease in Bcl2 and the release of cytochrome c from mitochondria. ros 0-3 BCL2 apoptosis regulator Homo sapiens 171-175 34533954-5 2021 The lead PZ703b exhibits high potency in inducing BCL-XL degradation and in inhibiting but not degrading BCL-2, showing a hybrid dual-targeting mechanism of action that is unprecedented in a PROTAC molecule. PZ703b 9-15 BCL2 apoptosis regulator Homo sapiens 105-110 34533954-6 2021 As a result, PZ703b is highly potent in killing BCL-XL dependent, BCL-2 dependent, and BCL-XL/BCL-2 dual-dependent cells in an E3 ligase (VHL)-dependent fashion. PZ703b 13-19 BCL2 apoptosis regulator Homo sapiens 66-71 34533954-6 2021 As a result, PZ703b is highly potent in killing BCL-XL dependent, BCL-2 dependent, and BCL-XL/BCL-2 dual-dependent cells in an E3 ligase (VHL)-dependent fashion. PZ703b 13-19 BCL2 apoptosis regulator Homo sapiens 94-99 34533954-7 2021 We further found that PZ703b forms stable {BCL-2:PROTAC:VCB} ternary complexes in live cells that likely contribute to the enhanced BCL-2 inhibition by PZ703b. PZ703b 22-28 BCL2 apoptosis regulator Homo sapiens 43-48 34533954-7 2021 We further found that PZ703b forms stable {BCL-2:PROTAC:VCB} ternary complexes in live cells that likely contribute to the enhanced BCL-2 inhibition by PZ703b. PZ703b 22-28 BCL2 apoptosis regulator Homo sapiens 132-137 34533954-7 2021 We further found that PZ703b forms stable {BCL-2:PROTAC:VCB} ternary complexes in live cells that likely contribute to the enhanced BCL-2 inhibition by PZ703b. PZ703b 152-158 BCL2 apoptosis regulator Homo sapiens 43-48 34533954-7 2021 We further found that PZ703b forms stable {BCL-2:PROTAC:VCB} ternary complexes in live cells that likely contribute to the enhanced BCL-2 inhibition by PZ703b. PZ703b 152-158 BCL2 apoptosis regulator Homo sapiens 132-137 34533954-8 2021 With further optimization, analogues of PZ703b could potentially be developed as effective antitumor agents by co-targeting BCL-XL and BCL-2. PZ703b 40-46 BCL2 apoptosis regulator Homo sapiens 135-140 34644781-9 2021 RESULTS: In our results, 6-shogaol not only suppressed proliferation and anchorage-independent cell growth in OSCC cells, but also induced apoptosis by regulating the apoptosis-associated factors such as p53, Bax, Bcl-2, and cleaved caspase-3. shogaol 25-34 BCL2 apoptosis regulator Homo sapiens 214-219 34636440-0 2022 Thymoquinone and quercetin induce enhanced apoptosis in non-small cell lung cancer in combination through the Bax/Bcl2 cascade. thymoquinone 0-12 BCL2 apoptosis regulator Homo sapiens 114-118 34636440-0 2022 Thymoquinone and quercetin induce enhanced apoptosis in non-small cell lung cancer in combination through the Bax/Bcl2 cascade. Quercetin 17-26 BCL2 apoptosis regulator Homo sapiens 114-118 34636440-4 2022 Molecular docking followed by molecular dynamics (MD) simulation of thymoquinone (Tq) and quercetin (Qu) with Bax and Bcl2 were carried out to explore their interactions and stability under explicit solvent conditions. thymoquinone 68-80 BCL2 apoptosis regulator Homo sapiens 118-122 34636440-4 2022 Molecular docking followed by molecular dynamics (MD) simulation of thymoquinone (Tq) and quercetin (Qu) with Bax and Bcl2 were carried out to explore their interactions and stability under explicit solvent conditions. Quercetin 90-99 BCL2 apoptosis regulator Homo sapiens 118-122 34681608-7 2021 BPA induced neurotoxicity by down-regulating Bcl-2 and initiating apoptosis and autophagy flux inhibition (featured by nuclear translocation of apoptosis-inducing factor (AIF), light chain 3B (LC3B) aggregation, and p62 accumulation). bisphenol A 0-3 BCL2 apoptosis regulator Homo sapiens 45-50 34712690-8 2021 Propionate reduction of apoptosis was associated with improving mitochondria dysfunction and oxidative stress in a manner involving reducing Caspase-3 expression, ROS production, and increasing the Bcl-2/Bax level. Propionates 0-10 BCL2 apoptosis regulator Homo sapiens 198-203 34633547-0 2021 Difference in the binding mechanisms of ABT-263/43b with Bcl-xL/Bcl-2: computational perspective on the accurate binding free energy analysis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 40-43 BCL2 apoptosis regulator Homo sapiens 64-69 34633547-7 2021 Nonetheless, compared with the Bcl-2 and 43b complex, the Bcl-2 and ABT-263 system had greater number of key residues interacting with ABT-263, in particular, contribute favorably, resulting in a stronger binding ability for the Bcl-2 and ABT-263 systems. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 68-71 BCL2 apoptosis regulator Homo sapiens 229-234 34633547-7 2021 Nonetheless, compared with the Bcl-2 and 43b complex, the Bcl-2 and ABT-263 system had greater number of key residues interacting with ABT-263, in particular, contribute favorably, resulting in a stronger binding ability for the Bcl-2 and ABT-263 systems. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 135-138 BCL2 apoptosis regulator Homo sapiens 31-36 34633547-7 2021 Nonetheless, compared with the Bcl-2 and 43b complex, the Bcl-2 and ABT-263 system had greater number of key residues interacting with ABT-263, in particular, contribute favorably, resulting in a stronger binding ability for the Bcl-2 and ABT-263 systems. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 135-138 BCL2 apoptosis regulator Homo sapiens 58-63 34633547-7 2021 Nonetheless, compared with the Bcl-2 and 43b complex, the Bcl-2 and ABT-263 system had greater number of key residues interacting with ABT-263, in particular, contribute favorably, resulting in a stronger binding ability for the Bcl-2 and ABT-263 systems. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 135-138 BCL2 apoptosis regulator Homo sapiens 229-234 34660789-9 2021 Compared with the control NP cells, high glucose significantly increased cell apoptosis ratio and caspase-3/caspase-9 activity and decreased mRNA expression of Bcl-2, whereas it increased mRNA or protein expression of Bax, caspase-3, cleaved caspase-3, cleaved PARP, and autophagy-related molecules (Atg3, Atg5, Beclin-1, and LC3-II) and decreased protein expression of p-Akt compared with the control cells. Glucose 41-48 BCL2 apoptosis regulator Homo sapiens 160-165 34633547-7 2021 Nonetheless, compared with the Bcl-2 and 43b complex, the Bcl-2 and ABT-263 system had greater number of key residues interacting with ABT-263, in particular, contribute favorably, resulting in a stronger binding ability for the Bcl-2 and ABT-263 systems. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 239-242 BCL2 apoptosis regulator Homo sapiens 31-36 34633547-7 2021 Nonetheless, compared with the Bcl-2 and 43b complex, the Bcl-2 and ABT-263 system had greater number of key residues interacting with ABT-263, in particular, contribute favorably, resulting in a stronger binding ability for the Bcl-2 and ABT-263 systems. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 239-242 BCL2 apoptosis regulator Homo sapiens 58-63 34383044-8 2021 KEY FINDINGS: Sevo improved the abnormal morphology, promoted the cell viability and the expressions of Bcl-2 and miR-27a-3p, but reduced the apoptosis and Bax and C-caspase-3 levels of H/R-induced cardiomyocytes. Sevoflurane 14-18 BCL2 apoptosis regulator Homo sapiens 104-109 34622346-8 2021 Simulations revealed that the greatest magnitude of pharmacodynamic drug interactions between bortezomib and vorinostat occurred at caspase-9, AKT, and Bcl-2. Bortezomib 94-104 BCL2 apoptosis regulator Homo sapiens 152-157 34622346-8 2021 Simulations revealed that the greatest magnitude of pharmacodynamic drug interactions between bortezomib and vorinostat occurred at caspase-9, AKT, and Bcl-2. Vorinostat 109-119 BCL2 apoptosis regulator Homo sapiens 152-157 34608124-4 2021 The expressions of Bcl2 family members such as Bcl2, Bcl-xl, and Puma could be seen in U2OS and MG63 cells with or without doxorubicin, bortezomib, or paclitaxel treatment. Doxorubicin 123-134 BCL2 apoptosis regulator Homo sapiens 19-23 34612529-9 2021 We also observed that 9-ethynyl noscapine (5) treatment leads to disruption in tubulin polymerization and induction of apoptosis by decreasing expression of bcl2, pro-caspase 3, and activation of cytochrome C. 9-ethynyl noscapine 22-41 BCL2 apoptosis regulator Homo sapiens 157-161 34077833-8 2021 N17 exposure for 48 h decreased expression of anti-apoptotic protein BCL-2 and increased the expression of apoptogenic BAX. 3-(4-Methyl-1h-Imidazol-1-Yl)-N-[4-(Pyridin-4-Yloxy)phenyl]benzamide 0-3 BCL2 apoptosis regulator Homo sapiens 69-74 34607550-9 2022 Marked increments in levels of Bax and caspase-3 were detected together with declines in Bcl-2 levels in Caco-2 cells submitted to BER-ZnNPs therapy. ber-znnps 131-140 BCL2 apoptosis regulator Homo sapiens 89-94 34608124-7 2021 Using a BH3-mimetic, ABT-263, to inhibit Bcl2 or Bcl-xl produced a limited apoptotic response in U2OS and MG63 cells, suggesting that this BH3-mimetic cannot activate the Bax/Bak pathway efficiently. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 21-24 BCL2 apoptosis regulator Homo sapiens 41-45 34608124-4 2021 The expressions of Bcl2 family members such as Bcl2, Bcl-xl, and Puma could be seen in U2OS and MG63 cells with or without doxorubicin, bortezomib, or paclitaxel treatment. Doxorubicin 123-134 BCL2 apoptosis regulator Homo sapiens 47-51 34608124-4 2021 The expressions of Bcl2 family members such as Bcl2, Bcl-xl, and Puma could be seen in U2OS and MG63 cells with or without doxorubicin, bortezomib, or paclitaxel treatment. Bortezomib 136-146 BCL2 apoptosis regulator Homo sapiens 19-23 34608124-4 2021 The expressions of Bcl2 family members such as Bcl2, Bcl-xl, and Puma could be seen in U2OS and MG63 cells with or without doxorubicin, bortezomib, or paclitaxel treatment. Bortezomib 136-146 BCL2 apoptosis regulator Homo sapiens 47-51 34608124-4 2021 The expressions of Bcl2 family members such as Bcl2, Bcl-xl, and Puma could be seen in U2OS and MG63 cells with or without doxorubicin, bortezomib, or paclitaxel treatment. Paclitaxel 151-161 BCL2 apoptosis regulator Homo sapiens 19-23 34693118-12 2021 As in mammalian homologues, the role of long-range interactions and nonhotspot residues has to be taken into account while designing specific BH3-mimetic inhibitors for vBcl-2 homologues. BH 3 142-145 BCL2 apoptosis regulator Homo sapiens 169-175 34608124-4 2021 The expressions of Bcl2 family members such as Bcl2, Bcl-xl, and Puma could be seen in U2OS and MG63 cells with or without doxorubicin, bortezomib, or paclitaxel treatment. Paclitaxel 151-161 BCL2 apoptosis regulator Homo sapiens 47-51 34837676-8 2021 The rate of apoptosis in the myeloma cells after BTZ treatment considerably increased, which indicated an increase in the mRNA of SOCS3, PTEN, BCL-2, and CDKN1. Bortezomib 49-52 BCL2 apoptosis regulator Homo sapiens 143-148 34173255-0 2021 Another structural correction for 1-oxo-1H-phenalene-2,3-dicarbonitriles: Synthesis of a potent BCL-2 inhibiting 7-phenoxy derivative. 1-oxo-1H-phenalene-2,3-dicarbonitrile 34-72 BCL2 apoptosis regulator Homo sapiens 96-101 34173255-2 2021 1-Oxo-1H-phenalene-2,3-dicarbonitrile-based compounds have been described as inhibitors of the BCL-2 family of proteins, and this core structure represents numerous possibilities for modifications that could lead to improved inhibitory potencies. 1-oxo-1H-phenalene-2,3-dicarbonitrile 0-37 BCL2 apoptosis regulator Homo sapiens 95-100 34173255-8 2021 The most potent 1-oxo-1H-phenalene-2,3-dicarbonitrile derivatives inhibited BCL-2 in the nanomolar range and showed double-digit micromolar cytotoxicity against four different cancer cell lines. 1-oxo-1H-phenalene-2,3-dicarbonitrile 16-53 BCL2 apoptosis regulator Homo sapiens 76-81 34536651-0 2021 Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton. acyl sulfonamide 56-72 BCL2 apoptosis regulator Homo sapiens 34-39 34536651-2 2021 Herein, a series of novel derivatives with acyl sulfonamide skeleton was designed, synthesized, and evaluated as Bcl-2 inhibitors by means of bioisosteric replacement. acyl sulfonamide 43-59 BCL2 apoptosis regulator Homo sapiens 113-118 34334687-6 2021 Compared with FL3A, FL3U exhibited higher MUM1 and Ki67 expression, less BCL2 breaks and more BCL6 rearrangements, together with a higher number of cases without any BCL2, BCL6 or MYC rearrangement. fl3u 20-24 BCL2 apoptosis regulator Homo sapiens 73-77 34790781-4 2021 Studies have confirmed that chidamide can downregulate the expression levels of Bcl-2 and Mcl-1 and induce apoptosis. N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 28-37 BCL2 apoptosis regulator Homo sapiens 80-85 34837685-10 2021 In addition, HEnSCs resulted in upregulation of Bcl-2 and downregulation of Tnf-alpha in the cisplatin-induced AKI. Cisplatin 93-102 BCL2 apoptosis regulator Homo sapiens 48-53 34165247-8 2021 Proteins involved in the extrinsic and intrinsic pathways of apoptosis, such as death receptor, caspase-3, caspase-8, caspase-9, and Bcl-2 family proteins (Bax, t-Bid, Bcl-2, and Bcl-xL), were downregulated and upregulated after treatment with luteolin-7-O-glucoside, respectively. luteolin-7-O-glucoside 244-266 BCL2 apoptosis regulator Homo sapiens 133-138 34303041-0 2021 Arsenic trioxide induces expression of BCL-2 expression via NF-kappaB and p38 MAPK signaling pathways in BEAS-2B cells during apoptosis. Arsenic Trioxide 0-16 BCL2 apoptosis regulator Homo sapiens 39-44 34303041-3 2021 In this study, we clarify that BCL-2, as a pro-apoptotic factor, participates in As2O3-induced apoptosis in BEAS-2B cells. Arsenic Trioxide 81-86 BCL2 apoptosis regulator Homo sapiens 31-36 34303041-4 2021 Specifically, As2O3 stimulated the expression of BCL-2 mRNA and protein in a dose-dependent manner which was highly accumulated in the nucleus of BEAS-2B cell together with chromatin condensation and DNA fragmentation during apoptosis. Arsenic Trioxide 14-19 BCL2 apoptosis regulator Homo sapiens 49-54 34303041-6 2021 Additionally, BAY11-7082, actinomycin D, and cycloheximide have inhibitory effects on As2O3-induced expression of BCL-2 mRNA and protein, and restore the cell viability of BEAS-2B cells. 3-(4-methylphenylsulfonyl)-2-propenenitrile 14-24 BCL2 apoptosis regulator Homo sapiens 114-119 34303041-6 2021 Additionally, BAY11-7082, actinomycin D, and cycloheximide have inhibitory effects on As2O3-induced expression of BCL-2 mRNA and protein, and restore the cell viability of BEAS-2B cells. Dactinomycin 26-39 BCL2 apoptosis regulator Homo sapiens 114-119 34303041-6 2021 Additionally, BAY11-7082, actinomycin D, and cycloheximide have inhibitory effects on As2O3-induced expression of BCL-2 mRNA and protein, and restore the cell viability of BEAS-2B cells. Cycloheximide 45-58 BCL2 apoptosis regulator Homo sapiens 114-119 34303041-6 2021 Additionally, BAY11-7082, actinomycin D, and cycloheximide have inhibitory effects on As2O3-induced expression of BCL-2 mRNA and protein, and restore the cell viability of BEAS-2B cells. Arsenic Trioxide 86-91 BCL2 apoptosis regulator Homo sapiens 114-119 34303041-7 2021 Suppression of BCL-2 protein activation by ABT-199 also restored viability of BEAS-2B cell in As2O3-induced apoptosis. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 43-46 BCL2 apoptosis regulator Homo sapiens 15-20 34303041-8 2021 Furthermore, As2O3 increased the level of BCL-2 phosphorylation. Arsenic Trioxide 13-18 BCL2 apoptosis regulator Homo sapiens 42-47 34303041-9 2021 These results suggest that in BEAS-2B cells, As2O3-induced apoptosis is mainly dominated by BCL-2 upregulation, nuclear localization and phosphorylation. Arsenic Trioxide 45-50 BCL2 apoptosis regulator Homo sapiens 92-97 34165247-8 2021 Proteins involved in the extrinsic and intrinsic pathways of apoptosis, such as death receptor, caspase-3, caspase-8, caspase-9, and Bcl-2 family proteins (Bax, t-Bid, Bcl-2, and Bcl-xL), were downregulated and upregulated after treatment with luteolin-7-O-glucoside, respectively. luteolin-7-O-glucoside 244-266 BCL2 apoptosis regulator Homo sapiens 168-173 34504572-14 2021 Furthermore, shikonin significantly decreased caspase-9 and caspase-3 activities, increased Bcl-2 expression and decreased Bax and cytochrome c expression levels in H2O2-induced HT29 cells. shikonin 13-21 BCL2 apoptosis regulator Homo sapiens 92-97 34459988-4 2021 The new Ru(II) complexes could also trigger apoptosis through activating caspase-3 and poly (ADP-ribose) polymerase (PARP), increasing the Bax/Bcl-2 ratio, enhancing reactive oxygen species (ROS) generation, decreasing mitochondrial membrane potential (MMP), and inducing cytochrome c release from mitochondria. ru(ii) 8-14 BCL2 apoptosis regulator Homo sapiens 143-148 34308732-6 2021 RESULTS: Quercetin significantly improved cell viability and apoptosis by reversing LPS-induced upregulation of Bax and downregulation of Bcl-2 in hOMK107 cells. Quercetin 9-18 BCL2 apoptosis regulator Homo sapiens 138-143 34302634-0 2021 Lactucin induces apoptosis through reactive oxygen species-mediated BCL-2 and CFLARL downregulation in Caki-1 cells. lactucin 0-8 BCL2 apoptosis regulator Homo sapiens 68-73 34302634-0 2021 Lactucin induces apoptosis through reactive oxygen species-mediated BCL-2 and CFLARL downregulation in Caki-1 cells. Oxygen 44-50 BCL2 apoptosis regulator Homo sapiens 68-73 34302634-6 2021 Western blotting, reverse transcription polymerase chain reaction, and protein stability analyses were performed to analyze the effect of lactucin on the expression of apoptosis-related proteins such as B-cell lymphoma 2 (BCL-2) and CFLAR (CASP8 and FADD like apoptosis regulator) long isoform (CFLARL) in Caki-1 human renal cancer cells. lactucin 138-146 BCL2 apoptosis regulator Homo sapiens 203-220 34302634-6 2021 Western blotting, reverse transcription polymerase chain reaction, and protein stability analyses were performed to analyze the effect of lactucin on the expression of apoptosis-related proteins such as B-cell lymphoma 2 (BCL-2) and CFLAR (CASP8 and FADD like apoptosis regulator) long isoform (CFLARL) in Caki-1 human renal cancer cells. lactucin 138-146 BCL2 apoptosis regulator Homo sapiens 222-227 34302634-10 2021 Pretreatment with N-acetyl-1-cysteine, a ROS scavenger, attenuated the lactucin-induced apoptosis and restored the BCL-2 and CFLARL expression to basal levels. n-acetyl-1-cysteine 18-37 BCL2 apoptosis regulator Homo sapiens 115-120 34302634-11 2021 Lactucin-facilitated BCL-2 downregulation was regulated at the transcriptional level through the inactivation of the NF-kappaB pathway. lactucin 0-8 BCL2 apoptosis regulator Homo sapiens 21-26 34302634-12 2021 CONCLUSIONS: Our study is the first to demonstrate that lactucin-induced apoptosis is mediated by ROS production, which in turn activates the caspase-dependent apoptotic pathway by inhibiting BCL-2 and CFLARL expression in Caki-1 cells. lactucin 56-64 BCL2 apoptosis regulator Homo sapiens 192-197 34302634-12 2021 CONCLUSIONS: Our study is the first to demonstrate that lactucin-induced apoptosis is mediated by ROS production, which in turn activates the caspase-dependent apoptotic pathway by inhibiting BCL-2 and CFLARL expression in Caki-1 cells. Reactive Oxygen Species 98-101 BCL2 apoptosis regulator Homo sapiens 192-197 34435645-7 2021 In addition, proteasome inhibitors combined with paclitaxel led to decreased MCL1 apoptosis regulator, BCL2 family member/Caspase-9/poly (ADP-ribose) polymerase apoptosis signaling triggered by CDK1/cyclin B1. Paclitaxel 49-59 BCL2 apoptosis regulator Homo sapiens 103-107 34117917-5 2021 RESULTS: Our results demonstrated that co-administration of HPRP-A1 with iRGD increased the apoptosis, while these two peptides in combination with 5FU increased the intracellular level of p53 that upregulate the pro-apoptotic gene BAX and downregulate the anti-apoptotic gene BCL2. Fluorouracil 148-151 BCL2 apoptosis regulator Homo sapiens 277-281 34464498-6 2021 The mechanism of PIP was associated with ROS increase and mitochondrial damage, simultaneously, the expression of key proteins of apoptosis was affected, including Bcl-2, Bax, Cyt-c, Caspase-9 and Caspase-3. piperine 17-20 BCL2 apoptosis regulator Homo sapiens 164-169 34579880-8 2021 During the course of treatment with WGA-Lep-AS-IV-NF-1-PS-liposomes, the combined activity of AS-IV and NF-1 and recognition capability simultaneously decreased the expression of Bax, and increased the expressions of Bcl-2, tyrosine hydroxylase and dopamine transporter. Dopamine 249-257 BCL2 apoptosis regulator Homo sapiens 217-222 34492530-9 2021 As the photodamage to Bcl-2 after PDT with PS2@PVP and PS3@PVP was accompanied by the further activation of pro-caspase-3, we assumed that upon irradiation the photogenerated reactive oxygen species (ROS) were able to activate a caspase-dependent apoptotic response as a consequence of a post-mitochondrial event. Reactive Oxygen Species 175-198 BCL2 apoptosis regulator Homo sapiens 22-27 34492530-9 2021 As the photodamage to Bcl-2 after PDT with PS2@PVP and PS3@PVP was accompanied by the further activation of pro-caspase-3, we assumed that upon irradiation the photogenerated reactive oxygen species (ROS) were able to activate a caspase-dependent apoptotic response as a consequence of a post-mitochondrial event. Reactive Oxygen Species 200-203 BCL2 apoptosis regulator Homo sapiens 22-27 34487292-11 2021 The cytoprotective effect of neoxanthin was associated with increased expression of the anti-apoptotic protein, Bcl-2 and decreased pro-apoptotic protein Bax. neoxanthin 29-39 BCL2 apoptosis regulator Homo sapiens 112-117 34253595-6 2021 Enhanced anti-tumor efficacy was also observed with the combination of ABBV-744 and the BCL-2 inhibitor, venetoclax compared to monotherapies of either agent alone. ABBV-744 71-79 BCL2 apoptosis regulator Homo sapiens 88-93 34283274-10 2021 Furthermore, flow cytometry and western blot analysis revealed that arctigenin significantly reduced CCA cell viability and induced apoptosis via the Bax/Bcl-2/caspase-3 pathway. arctigenin 68-78 BCL2 apoptosis regulator Homo sapiens 154-159 34683888-6 2021 The expression levels of E2F2 and Bcl-2 genes were found to be suppressed after treatment with both WO3-Cys and WO3-Trp NPs more than 5-FU-treated cells. wo3-cys 100-107 BCL2 apoptosis regulator Homo sapiens 34-39 34466155-0 2021 Pioglitazone mediates apoptosis in Caki cells via downregulating c-FLIP(L) expression and reducing Bcl-2 protein stability. Pioglitazone 0-12 BCL2 apoptosis regulator Homo sapiens 99-104 34466155-7 2021 The protein expression levels of cellular FLICE (FADD-like IL-1beta-converting enzyme)-inhibitory protein (c-FLIP)(L) and Bcl-2, which were determined by western blotting, decreased after pioglitazone treatment in Caki cells. Pioglitazone 188-200 BCL2 apoptosis regulator Homo sapiens 122-127 34466155-10 2021 Of note, it was found by western blot analysis that Bcl-2 protein expression was downregulated by the decreased protein stability of Bcl-2 in pioglitazone-treated Caki cells. Pioglitazone 142-154 BCL2 apoptosis regulator Homo sapiens 52-57 34466155-10 2021 Of note, it was found by western blot analysis that Bcl-2 protein expression was downregulated by the decreased protein stability of Bcl-2 in pioglitazone-treated Caki cells. Pioglitazone 142-154 BCL2 apoptosis regulator Homo sapiens 133-138 34466155-11 2021 In conclusion, these findings indicated that pioglitazone-induced apoptosis is regulated through caspase-mediated degradation of FLIP(L) and reduction of Bcl-2 protein stability, suggesting that pioglitazone is a feasible apoptotic agent that could be used in the treatment of human RC. Pioglitazone 45-57 BCL2 apoptosis regulator Homo sapiens 154-159 34466155-11 2021 In conclusion, these findings indicated that pioglitazone-induced apoptosis is regulated through caspase-mediated degradation of FLIP(L) and reduction of Bcl-2 protein stability, suggesting that pioglitazone is a feasible apoptotic agent that could be used in the treatment of human RC. Pioglitazone 195-207 BCL2 apoptosis regulator Homo sapiens 154-159 34683888-6 2021 The expression levels of E2F2 and Bcl-2 genes were found to be suppressed after treatment with both WO3-Cys and WO3-Trp NPs more than 5-FU-treated cells. Tryptophan 116-119 BCL2 apoptosis regulator Homo sapiens 34-39 34683888-6 2021 The expression levels of E2F2 and Bcl-2 genes were found to be suppressed after treatment with both WO3-Cys and WO3-Trp NPs more than 5-FU-treated cells. Fluorouracil 134-138 BCL2 apoptosis regulator Homo sapiens 34-39 34339756-11 2021 Gene and protein detection showed that DG-8d or DG-8d combined with LY294002 could down-regulate signaling molecules of Bcl-2, PI3k, p-Akt, p-FoxO3a and up-regulate signaling molecules of Bax snd Bim. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 68-76 BCL2 apoptosis regulator Homo sapiens 120-125 34450376-7 2021 RESULTS: Artematrolide A inhibited cell viability, proliferation, migration and invasion in a dose-dependent manner, caused cell cycle arrest in G2/M phase, and induced cell apoptosis via Bcl-2/PARP-1. artematrolide a 9-24 BCL2 apoptosis regulator Homo sapiens 188-193 34670666-9 2021 TA significantly induced LX-2 cells apoptosis by down-regulating the expression of the anti-apoptotic protein Bcl2 and up-regulating the expression of the pro-apoptotic protein Bax. euscaphic acid 0-2 BCL2 apoptosis regulator Homo sapiens 110-114 34638779-7 2021 Among the various strategies that have been proposed to block Bcl-2, BH3-mimetics have appeared as a novel group of compounds thanks to their favorable effects on many cancers within several clinical settings. BH 3 69-72 BCL2 apoptosis regulator Homo sapiens 62-67 34320168-3 2021 BH3-mimetics act by inhibiting the pro-survival BCL2 proteins to enable the activation of BAX and BAK, apoptosis effectors which permeabilize the outer mitochondrial membrane, triggering apoptosis directly in many cells and sensitizing others to cell death when combined with other anti-neoplastic drugs. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 48-52 34630855-9 2021 Coadministration of atorvastatin showed remarkable improvement in the histopathological picture with a significant increase in Ki-67 and Bcl-2, a significant decrease in NF-kappaB protein and gene expression, and a significant increase in Nrf2 gene expression. Atorvastatin 20-32 BCL2 apoptosis regulator Homo sapiens 137-142 34580235-6 2021 Subsequently, the assays suggested that melatonin significantly induced apoptosis in gallbladder cancer cells and altered the expression of the apoptotic proteins, including Bax, Bcl-2, cytochrome C, cleaved caspase-3, and PARP. Melatonin 40-49 BCL2 apoptosis regulator Homo sapiens 179-184 34638596-7 2021 Additionally, significant changes in Bcl-2, Bcl-xL, Bax protein levels, activation of caspase-3, and cleavage of poly (ADP-ribose) polymerase were observed, indicating the apoptotic effects of DFMO. Eflornithine 193-197 BCL2 apoptosis regulator Homo sapiens 37-42 34817343-9 2021 Betulin prompted mitochondrial apoptosis which was also associated with alteration in the apoptosis-related protein expression (Bax, Bad and Bcl-2 and Bcl-xL). betulin 0-7 BCL2 apoptosis regulator Homo sapiens 141-146 34630074-8 2021 It was determined that gracillin could fight against gastric cancer cells by inhibiting the cell proliferation participated by the PI3K/AKT pathway and cell cycle arrest, suppressing the EMT pathway-regulating cell migration, and inducing bcl2-associated mitochondrial apoptosis. gracillin 23-32 BCL2 apoptosis regulator Homo sapiens 239-243 34790046-4 2021 Here, we found that the expression of lncRNA CEBPA-DT/CEBPA/BCL2 was upregulated in cisplatin resistance OSCC cells (Cal27-CisR and HSC4-CisR) compared with their parental cells (Cal27 and HSC4). Cisplatin 84-93 BCL2 apoptosis regulator Homo sapiens 60-64 34790046-7 2021 In addition, we identified that CEBPA-DT regulates cisplatin chemosensitivity through CEBPA/BCL2-mediated cell apoptosis. Cisplatin 51-60 BCL2 apoptosis regulator Homo sapiens 92-96 34790046-8 2021 Knockdown of CEBPA and BCL2 could alleviate the increasement of cisplatin resistance induced by CEBPA-DT overexpression. Cisplatin 64-73 BCL2 apoptosis regulator Homo sapiens 23-27 34790046-8 2021 Knockdown of CEBPA and BCL2 could alleviate the increasement of cisplatin resistance induced by CEBPA-DT overexpression. Thymidine 102-104 BCL2 apoptosis regulator Homo sapiens 23-27 34567410-9 2021 In addition, we found that the expression of antiapoptotic protein B-cell lymphoma 2 protein (BCL-2) was also upregulated by artemisinin. artemisinin 125-136 BCL2 apoptosis regulator Homo sapiens 94-99 34548471-6 2021 BH3 profiling demonstrated increased dependence of mutant cells on BCL2. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 67-71 34548471-9 2021 These data mechanistically link the common leukemia-associated mutation ASXL1 to enhanced sensitivity to VEN and AZA via epigenetic upregulation of BCL2 expression and widespread alterations in DNA methylation. Azacitidine 113-116 BCL2 apoptosis regulator Homo sapiens 148-152 34603598-8 2021 Following up this result, we identified a BCL-2 inhibitor Navitoclax (ABT-263), which was highly effective in decreasing cell viability and inducing apoptotic cell death in wogonin-induced senescent cells. navitoclax 70-77 BCL2 apoptosis regulator Homo sapiens 42-47 34603598-8 2021 Following up this result, we identified a BCL-2 inhibitor Navitoclax (ABT-263), which was highly effective in decreasing cell viability and inducing apoptotic cell death in wogonin-induced senescent cells. wogonin 173-180 BCL2 apoptosis regulator Homo sapiens 42-47 34351351-10 2021 Meanwhile, after curcumin treatment, mitochondrial membrane depolarization led to cytochrome c release from the mitochondria to the cytoplasm, and the ratio of Bax to Bcl-2 in HaCaT cells was also increased, which subsequently initiated the activation of caspase-3. Curcumin 17-25 BCL2 apoptosis regulator Homo sapiens 167-172 34573418-7 2021 Overexpression of G0S2 significantly induced apoptosis of macrophages in a dose-dependent manner and blunted the function of the crucial anti-apoptotic gene Bcl-2, which was significantly reduced by metformin. Metformin 199-208 BCL2 apoptosis regulator Homo sapiens 157-162 34572126-6 2021 Rapamycin preconditioning resulted in activated autophagy and improved survival of ADSCs achieved by increased autophagosomes, upregulated autophagy-specific LC3-II gene, decreased protein degradation/ubiquitination by downregulated p62 gene, downregulated mTOR gene, and finally, upregulated antiapoptotic BCL-2 gene. Sirolimus 0-9 BCL2 apoptosis regulator Homo sapiens 307-312 34604209-4 2021 In the current study, we demonstrated that tunicamycin (a novel ERS inducer) can induce the apoptosis of HSCs and increase the concentration of intracellular Ca2+ and the expression of ERS protein GRP78, apoptosis protein caspase-12, and Bax, while it can decrease the antiapoptosis protein expression of Bcl-2. Tunicamycin 43-54 BCL2 apoptosis regulator Homo sapiens 305-310 34576119-8 2021 Application of CBD partially attenuated these effects of UVB irradiation both in healthy and psoriatic keratinocytes, reducing the levels of 15-d-PGJ2, p-p38 and caspase 8 while increasing Bcl2 expression. Cannabidiol 15-18 BCL2 apoptosis regulator Homo sapiens 189-193 34133989-4 2021 The results indicated that mGluR4 activation by using VU0155041 (mGluR4-specific agonist) markedly attenuated the OGD-induced alterations in TUNEL staining, apoptosis rate, cleavages of pro-caspase-8, -9, -3, and Bcl-2/Bax expression balance. VU 0155041 54-63 BCL2 apoptosis regulator Homo sapiens 213-218 34573088-9 2021 Dox and the drug combination selectively reduced (p < 0.05) a recently reported anti-apoptotic Bcl-2 protein isoform p15-20-Bcl-2 in MOLM-13 by our group, without affecting the usually reported p26-Bcl-2-alpha. Doxorubicin 0-3 BCL2 apoptosis regulator Homo sapiens 95-100 34573088-9 2021 Dox and the drug combination selectively reduced (p < 0.05) a recently reported anti-apoptotic Bcl-2 protein isoform p15-20-Bcl-2 in MOLM-13 by our group, without affecting the usually reported p26-Bcl-2-alpha. Doxorubicin 0-3 BCL2 apoptosis regulator Homo sapiens 124-129 34616521-12 2021 Scoparone also increased the expression levels of Bax and cleaved caspase-3, decreased the levels of MMP9 and Bcl-2, and suppressed the phosphorylation of Akt without affecting total PI3K and Akt. scoparone 0-9 BCL2 apoptosis regulator Homo sapiens 110-115 34667663-12 2021 In this paper, we discuss the role of a new anti-apoptotic B cell leukemia 2 (Bcl-2) inhibitor, Navitoclax, for the treatment of myelofibrosis. navitoclax 96-106 BCL2 apoptosis regulator Homo sapiens 59-76 34667663-12 2021 In this paper, we discuss the role of a new anti-apoptotic B cell leukemia 2 (Bcl-2) inhibitor, Navitoclax, for the treatment of myelofibrosis. navitoclax 96-106 BCL2 apoptosis regulator Homo sapiens 78-83 34479596-8 2021 RESULTS: CAP treatment resulted in a significant downregulation of p53 and apoptotic protease activating factor (APAF)-1, caspase (CASP)9, CASP3, BCL2 Antagonist/Killer (BAK)1, and B-Cell Lymphoma (BCL)2 mRNA expression at 1 d. An inhibitory effect of CAP on apoptotic genes was also shown under inflammatory and apoptotic conditions. cap 9-12 BCL2 apoptosis regulator Homo sapiens 181-203 34493661-4 2021 Here, we exploit a model membrane system that recapitulates key features of MOM to demonstrate that the proapoptotic Bcl-2 protein BAX and antiapoptotic Bcl-xL have an inherent ability to interact with membranes in the absence of BH3 effectors, but only in the presence of cellular concentrations of Mg2+/Ca2+ Under these conditions, BAX and Bcl-xL are selectively targeted to membranes, refolded, and activated in the presence of anionic lipids especially the mitochondrial-specific lipid cardiolipin. magnesium ion 300-304 BCL2 apoptosis regulator Homo sapiens 117-122 34493661-5 2021 These results provide a mechanistic explanation for the mitochondrial targeting and activation of Bcl-2 proteins in cells lacking BH3 effectors. BH 3 130-133 BCL2 apoptosis regulator Homo sapiens 98-103 34508613-6 2021 Low doses of BTZ enhanced the anti-cancer effect induced by the low dose of BGB-3111 by downregulating the expression levels of PARP and Bcl-2 and increasing the expression levels of cleaved PARP and cleaved caspase-9. Bortezomib 13-16 BCL2 apoptosis regulator Homo sapiens 137-142 34579396-9 2021 Furthermore, the binding affinities and interactions of the n-hexane fraction"s major metabolites were predicted against EGFR and BCL2 molecular targets using the molecular docking technique. n-hexane 60-68 BCL2 apoptosis regulator Homo sapiens 130-134 34313786-7 2021 Furthermore, the proportions of Bax/Bcl-2, cleaved caspase-3 and caspase-9 proteins production were up-regulated, indicating that tonkinensine B acted on intrinsic mitochondrial-mediated apoptosis pathway. Tonkinensine B 130-144 BCL2 apoptosis regulator Homo sapiens 36-41 34552976-10 2021 The expression of GSK3, NF-kappaB p65, p-NF-kappaB p65, and BAD was also increased with favipiravir treatment, while the expression of CREB, p-CREB, p-GSK3, and Bcl-2 was slightly decreased. favipiravir 88-99 BCL2 apoptosis regulator Homo sapiens 161-166 34493899-14 2021 Pretreatment of AngII and LPS regulated the activity of ACE2, increased the expression of proinflammatory cytokines and cell apoptosis and regulated the expression of Bax, Bcl-2 and cleaved caspase-3 in BEAS-2B cells, which could be reversed by transfecting miR-143-3p inhibitor. mir-143-3p 258-268 BCL2 apoptosis regulator Homo sapiens 172-177 34085721-7 2021 The mechanism of action of lupeol was further explored by measuring its effect on key players in cancer development and progression, BCL-2 anti-apoptotic and BAX pro-apoptotic proteins. lupeol 27-33 BCL2 apoptosis regulator Homo sapiens 133-138 34085721-8 2021 Lupeol significantly (p < .01) downregulated BCL-2 gene expression in parental and resistant Hep3B cells by 33 and 3.5 times, respectively, contributing to the induction of apoptosis in Hep3B cells, whereas it caused no effect on BAX. lupeol 0-6 BCL2 apoptosis regulator Homo sapiens 45-50 34153472-0 2021 Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold. 2-(1H-indol-4-yl)benzoic acid 83-112 BCL2 apoptosis regulator Homo sapiens 52-57 34198048-5 2021 Moreover, through modulation of a number of proteins such as NF-kB, PARP, STAT3, Bax, Bcl-2, COX2, and cytokines, quercetin has beneficial effects in neurodegenerative disorders, liver diseases and diabetes. Quercetin 114-123 BCL2 apoptosis regulator Homo sapiens 86-91 34328859-1 2021 Series of imidazo(1,2-a)pyridines designed from gossypol modification based on Groebke-Blackburn-Bienayme reaction were discovered as potent Bcl-2 inhibitors. imidazo(1,2-a)pyridine 10-33 BCL2 apoptosis regulator Homo sapiens 141-146 34328859-1 2021 Series of imidazo(1,2-a)pyridines designed from gossypol modification based on Groebke-Blackburn-Bienayme reaction were discovered as potent Bcl-2 inhibitors. Gossypol 48-56 BCL2 apoptosis regulator Homo sapiens 141-146 34568834-6 2021 Further, screens to rescue BETi sensitivity identified BCL2 and CDK6 as druggable vulnerabilities. beti 27-31 BCL2 apoptosis regulator Homo sapiens 55-59 34697748-10 2021 Andrographolide inhibited the colony formation abilities in SGC7901 in a p53-dependent manner followed by induction of mitochondrial intrinsic apoptosis through activation of caspases-9 and -3, cleavage of PARP, and inhibition of pro-apoptotic Bcl-2. andrographolide 0-15 BCL2 apoptosis regulator Homo sapiens 244-249 34257082-5 2021 Cell line-specific sensitivity to combinations of alpelisib and BH3 mimetics depended on which BCL-2 family members were highly expressed. Alpelisib 50-59 BCL2 apoptosis regulator Homo sapiens 95-100 34257082-5 2021 Cell line-specific sensitivity to combinations of alpelisib and BH3 mimetics depended on which BCL-2 family members were highly expressed. BH 3 64-67 BCL2 apoptosis regulator Homo sapiens 95-100 34288263-8 2021 Moreover, all-trans-retinoic acid, which enhances CD38 expression and induces cell differentiation in myeloma cells, reduced B-cell marker expression and the BCL2/BCL2L1 ratio in myeloma cell lines, leading to reduced efficacy of venetoclax. Tretinoin 10-33 BCL2 apoptosis regulator Homo sapiens 158-162 34076332-6 2021 Furthermore ELISA and real time PCR reaction determined that brucine were down regulated inflammatory (TNF-alpha, NF-kB, IL-6 & COX-2) cell proliferation (Cyclin D1) and apoptotic marker Bax, caspase-3, PI3K (phosphoinosital 3 kinase), AKT, mTOR (mammalian target of rapamycin) and over expression Bcl-2, associated death promoter. brucine 61-68 BCL2 apoptosis regulator Homo sapiens 298-330 34165231-7 2021 MEHP exposure can up-regulate the expression of C-MYC, Cyclin D1, Bcl-2 and affected the Notch pathway. mono-(2-ethylhexyl)phthalate 0-4 BCL2 apoptosis regulator Homo sapiens 66-71 34602453-6 2021 The cytotoxic effects of leonurine on HL-60 and U-937 cells were associated with an increased ratio of Bax/Bcl-2, activation of caspase-3, caspase-8 and caspase-9, and increased expression of cytochrome c in the cytoplasm. leonurine 25-34 BCL2 apoptosis regulator Homo sapiens 107-112 34229024-5 2021 CoQ0 induced apoptosis by activation of caspase-3, cleavage of PARP, and dysregulation of Bax and Bcl-2 in both cell lines. ubiquinone-O 0-4 BCL2 apoptosis regulator Homo sapiens 98-103 34697781-11 2021 Western blotting results showed that JB and LY294002 treatment significantly inhibited the levels of Bcl-2, p-PI3K, and p-Akt while the levels of Bax, cleaved caspase-3, and PTEN protein significantly increased. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-52 BCL2 apoptosis regulator Homo sapiens 101-106 34410949-13 2021 Gadodiamide at 5.2 mM and 13.0 mM inhibited antiapoptotic protein expression levels of Bcl-2 and Bcl-XL, while promoted pro-apoptotic protein expression levels of Bax, BAD, cytochrome c, Apaf-1, cleaved-caspase-9 and cleaved-caspase-3. gadodiamide 0-11 BCL2 apoptosis regulator Homo sapiens 87-92 34309113-9 2021 In OC cells treated with LTX-315, the viability, migration, invasion and the expression of Bcl-2 of were repressed, but the apoptotic rate and the expression of cleaved caspase 3, cleaved PARP and Bax were increased, and the cell cycle was arrested. LTX-315 25-32 BCL2 apoptosis regulator Homo sapiens 91-96 34338401-5 2021 The Cell-Counting Kit-8 assay and western blot analysis showed that treatment with 10 mul PACs significantly increased cell proliferation and the expression level of Bcl-2 in ARPE-19 cells under high-glucose conditions. Glucose 200-207 BCL2 apoptosis regulator Homo sapiens 166-171 34402163-5 2021 BAG1-depleted cells show an increased sensitivity to the common chemotherapeutic agents, dexamethasone or daunorubicin, and to the BCL2 inhibitor ABT-737. ABT-737 146-153 BCL2 apoptosis regulator Homo sapiens 131-135 34097977-0 2021 Curcumin loaded chitosan-protamine nanoparticles revealed antitumor activity via suppression of NF-kappaB, proinflammatory cytokines and Bcl-2 gene expression in the breast cancer cells. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 137-142 34097977-0 2021 Curcumin loaded chitosan-protamine nanoparticles revealed antitumor activity via suppression of NF-kappaB, proinflammatory cytokines and Bcl-2 gene expression in the breast cancer cells. Chitosan 16-24 BCL2 apoptosis regulator Homo sapiens 137-142 34318539-3 2021 In the present study, we verified the neuroprotective role of estradiol against amyloid-beta 42 in SH-SY5Y cells through inhibiting TXNIP expression, promoting cell viability and DNA synthesis ability, inhibiting cell apoptosis, and affecting caspase and Bax/Bcl-2 apoptotic signaling. Estradiol 62-71 BCL2 apoptosis regulator Homo sapiens 259-264 34331475-6 2021 Furthermore, curcumin promoted the overproduction of intracellular ROS and apoptosis induced by activating p53 and Bcl-2 signal pathways. Curcumin 13-21 BCL2 apoptosis regulator Homo sapiens 115-120 34331475-6 2021 Furthermore, curcumin promoted the overproduction of intracellular ROS and apoptosis induced by activating p53 and Bcl-2 signal pathways. ros 67-70 BCL2 apoptosis regulator Homo sapiens 115-120 34500742-10 2021 UF extract (25 and 50 mug) and UDCA (50 and 100 muM) significantly increased the expression of Bax, caspase-3, cytochrome c, and PARP and inhibited the expression of Bcl-2, TGF-beta, VEGF, N-cadherin, and sirtuin-1 in FRO cells. UD 0-2 BCL2 apoptosis regulator Homo sapiens 166-171 34278473-10 2021 In addition, the knockdown of MAD2L2 caused by siMAD2L2 or oxaliplatin treatment increased the expression levels of the pro-apoptotic proteins Bax and Bak and decreased the expression levels of the anti-apoptotic protein Bcl-2, compared with the negative control group. Oxaliplatin 59-70 BCL2 apoptosis regulator Homo sapiens 221-226 34836872-5 2021 All the synthesized compounds containing (6H-Dibenzo(b,d)pyran-6-one) framework were subjected to molecular docking studies for the inhibition of CYP1B1 and BCL2 proteins using Auto Dock Vina software and the interacting amino acid residues were visualized using Discovery Studio, to look into the binding modalities that might influence their anticancer properties. 6H-dibenzo-(b,d)-pyran-6-one 41-68 BCL2 apoptosis regulator Homo sapiens 157-161 34331013-5 2021 Because addition of the BCL2 inhibitor venetoclax resulted in compensatory upregulation of MCL1, we established a three-drug combination composed of sirolimus, venetoclax, and the MCL1 inhibitor S63845. venetoclax 39-49 BCL2 apoptosis regulator Homo sapiens 24-28 34386088-10 2021 The inhibitory effect of niclosamide was mediated by apoptosis induction and Bcl-2 downregulation. Niclosamide 25-36 BCL2 apoptosis regulator Homo sapiens 77-82 34862868-11 2021 The expression of Bcl-2 in oxaliplatin group was significantly lower and the value of Bcl-2/Bax in curcumin plus oxaliplatin group was decreased most obviously. Oxaliplatin 27-38 BCL2 apoptosis regulator Homo sapiens 18-23 34862868-11 2021 The expression of Bcl-2 in oxaliplatin group was significantly lower and the value of Bcl-2/Bax in curcumin plus oxaliplatin group was decreased most obviously. Oxaliplatin 27-38 BCL2 apoptosis regulator Homo sapiens 86-91 34862868-11 2021 The expression of Bcl-2 in oxaliplatin group was significantly lower and the value of Bcl-2/Bax in curcumin plus oxaliplatin group was decreased most obviously. Curcumin 99-107 BCL2 apoptosis regulator Homo sapiens 18-23 34862868-11 2021 The expression of Bcl-2 in oxaliplatin group was significantly lower and the value of Bcl-2/Bax in curcumin plus oxaliplatin group was decreased most obviously. Curcumin 99-107 BCL2 apoptosis regulator Homo sapiens 86-91 34862868-11 2021 The expression of Bcl-2 in oxaliplatin group was significantly lower and the value of Bcl-2/Bax in curcumin plus oxaliplatin group was decreased most obviously. Oxaliplatin 113-124 BCL2 apoptosis regulator Homo sapiens 18-23 34862868-11 2021 The expression of Bcl-2 in oxaliplatin group was significantly lower and the value of Bcl-2/Bax in curcumin plus oxaliplatin group was decreased most obviously. Oxaliplatin 113-124 BCL2 apoptosis regulator Homo sapiens 86-91 34107382-4 2021 This is associated with an elevation of GSH/GSSG ratio which leads to inhibition of mitochondrial dysfunction by induction of BCL2/BCL-XL in high glucose conditions. Glutathione 40-43 BCL2 apoptosis regulator Homo sapiens 126-130 34107382-4 2021 This is associated with an elevation of GSH/GSSG ratio which leads to inhibition of mitochondrial dysfunction by induction of BCL2/BCL-XL in high glucose conditions. Glutathione Disulfide 44-48 BCL2 apoptosis regulator Homo sapiens 126-130 34488595-12 2022 Meanwhile, the expression of Bax increased, and that of Bcl-2 decreased by carvacrol treatment. carvacrol 75-84 BCL2 apoptosis regulator Homo sapiens 56-61 34107382-4 2021 This is associated with an elevation of GSH/GSSG ratio which leads to inhibition of mitochondrial dysfunction by induction of BCL2/BCL-XL in high glucose conditions. Glucose 146-153 BCL2 apoptosis regulator Homo sapiens 126-130 34126112-7 2021 Along with that, p53 could be modulated by the ruthenium-rifampicin complex to interfere with apoptosis in colon carcinoma, initiated by the intrinsic apoptotic trail facilitated through Bcl2 and Bax, thus controlling the Akt/mTOR/VEGF pathway coupled through the WNT/beta-catenin trail. ruthenium-rifampicin 47-67 BCL2 apoptosis regulator Homo sapiens 187-191 34157415-5 2021 Moreover, the expression levels of mRNA of pro- and antiapoptotic genes also supported the effectiveness of cobalt complexes by modifying the ratio of Bax: Bcl-2. Cobalt 108-114 BCL2 apoptosis regulator Homo sapiens 156-161 34466064-7 2021 The Tilianin-triggered apoptosis in PA-1 cells was correlated with elevated generation of ROS, loss of mitochondrial membrane potential, alterations in pro-apoptotic (upregulated mRNA expression of Bax) and anti-apoptotic (downregulated mRNA expression of Bcl2) factors and activation of caspase-8, -9 and -3. tilianin 4-12 BCL2 apoptosis regulator Homo sapiens 256-260 34466065-9 2021 Dieckol also regulated the proliferative (cyclin D1), inflammatory (COX-2, IL-6, TNF-alpha, and NF-kappaB), and apoptotic (caspase-3, Bax, Bcl-2) markers in the MG-63 cells. dieckol 0-7 BCL2 apoptosis regulator Homo sapiens 139-144 34581088-8 2021 As revealed by Annexin V/PI staining, LPS delayed the early apoptosis of neutrophils compared with the control group, while bufotenine promoted the apoptosis of neutrophils in a dose-dependent manner, which might be related to the elevated expression of apoptosis-related protein Bax/Bcl-2. Bufotenin 124-134 BCL2 apoptosis regulator Homo sapiens 284-289 34216662-6 2021 Also, growing the cells in the scaffold sensitize the hepatocytes to the anti-tumor effect of cisplatin, by a mechanism involving the activation of ERK/p38alpha-MAPK and dysregulation of NF-kB/STAT3/Bcl-2 pathways. Cisplatin 94-103 BCL2 apoptosis regulator Homo sapiens 199-204 34816660-8 2021 Conclusion: Within a certain range of concentrations, betulinic acid induces cell apoptosis by regulating the expression of Bcl-2, Bax and Caspase-3 in human gastric cancer. betulinic acid 54-68 BCL2 apoptosis regulator Homo sapiens 124-129 34816662-9 2021 Compared with the Magnolol group or Gefitinib group, the Magnolol+Gefitinib group further promoted the above changes (P<0.05), and the apoptosis rate, the ratio of Bax/Bcl-2, SOX2 and OCT4 all showed interactions between magnolol and gefitinib (P<0.05). magnolol 57-65 BCL2 apoptosis regulator Homo sapiens 168-173 34816662-9 2021 Compared with the Magnolol group or Gefitinib group, the Magnolol+Gefitinib group further promoted the above changes (P<0.05), and the apoptosis rate, the ratio of Bax/Bcl-2, SOX2 and OCT4 all showed interactions between magnolol and gefitinib (P<0.05). Gefitinib 66-75 BCL2 apoptosis regulator Homo sapiens 168-173 34816662-9 2021 Compared with the Magnolol group or Gefitinib group, the Magnolol+Gefitinib group further promoted the above changes (P<0.05), and the apoptosis rate, the ratio of Bax/Bcl-2, SOX2 and OCT4 all showed interactions between magnolol and gefitinib (P<0.05). magnolol 221-229 BCL2 apoptosis regulator Homo sapiens 168-173 34816662-9 2021 Compared with the Magnolol group or Gefitinib group, the Magnolol+Gefitinib group further promoted the above changes (P<0.05), and the apoptosis rate, the ratio of Bax/Bcl-2, SOX2 and OCT4 all showed interactions between magnolol and gefitinib (P<0.05). Gefitinib 234-243 BCL2 apoptosis regulator Homo sapiens 168-173 34126102-4 2021 Deferoxamine-mediated suppression of apoptosis correlated with the level of pro-apoptotic Bcl-2 family proteins Bax, Bid, and Puma, which stimulate mitochondrial apoptotic pathway through permeabilization of the outer mitochondrial membrane and cytochrome c release. Deferoxamine 0-12 BCL2 apoptosis regulator Homo sapiens 90-95 34153682-4 2021 Bcl2 expression and mitochondrial membrane potential were also both markedly increased in FosB-KO clones, which suggests the involvement of Bcl2 in the doxorubicin mediated increase in cell viability demonstrated the FosB-KO clones. Doxorubicin 152-163 BCL2 apoptosis regulator Homo sapiens 0-4 34153682-4 2021 Bcl2 expression and mitochondrial membrane potential were also both markedly increased in FosB-KO clones, which suggests the involvement of Bcl2 in the doxorubicin mediated increase in cell viability demonstrated the FosB-KO clones. Doxorubicin 152-163 BCL2 apoptosis regulator Homo sapiens 140-144 34575429-3 2021 ABT-263, known as navitoclax, mimics the BH3-only proteins of the BCL-2 family and has a high affinity towards pro-survival BCL-2 family proteins (i.e., BCL-XL, BCL-2, BCL-W) to induce cell apoptosis effectively. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 66-71 34575429-3 2021 ABT-263, known as navitoclax, mimics the BH3-only proteins of the BCL-2 family and has a high affinity towards pro-survival BCL-2 family proteins (i.e., BCL-XL, BCL-2, BCL-W) to induce cell apoptosis effectively. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 124-129 34575429-3 2021 ABT-263, known as navitoclax, mimics the BH3-only proteins of the BCL-2 family and has a high affinity towards pro-survival BCL-2 family proteins (i.e., BCL-XL, BCL-2, BCL-W) to induce cell apoptosis effectively. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 0-3 BCL2 apoptosis regulator Homo sapiens 161-166 34659521-5 2021 Both Met and ATO effectively inhibited the proliferative activity of HeLa cells and induced apoptosis by activating Bax and inhibiting Bcl-2. Arsenic Trioxide 13-16 BCL2 apoptosis regulator Homo sapiens 135-140 34471510-1 2021 In recent years, one of the most successful advances in treating acute myeloid leukaemia (AML) has been the combination of the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax with hypomethylating agents (decitabine or azacytidine). Decitabine 203-213 BCL2 apoptosis regulator Homo sapiens 127-144 34471510-1 2021 In recent years, one of the most successful advances in treating acute myeloid leukaemia (AML) has been the combination of the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax with hypomethylating agents (decitabine or azacytidine). Decitabine 203-213 BCL2 apoptosis regulator Homo sapiens 146-151 34513827-7 2021 Furthermore, flubendazole downregulated the expression of BCL2, P62, and phosphorylated-mTOR, but it upregulated LC3-I/II and Beclin-1 expression, which are the main genes associated with autophagy. flubendazole 13-25 BCL2 apoptosis regulator Homo sapiens 58-62 34405891-10 2022 Apatinib enhanced apoptosis, diminished migration and invasion of HGC-27R cells, elevated proapoptotic protein expression, and reduced Bcl-2, vimentin, snail, MMP-3, MMP-2, and MMP-9 expressions. apatinib 0-8 BCL2 apoptosis regulator Homo sapiens 135-140 34426943-9 2021 Agents of interest include the BCL2 antagonist venetoclax, the CXCR4 inhibitor mavorixafor, and the non-covalent BTK inhibitors pirtobrutinib and ARQ-531. venetoclax 47-57 BCL2 apoptosis regulator Homo sapiens 31-35 34242793-4 2021 Mechanistically, this protective autophagy is regulated by intracellular reactive oxygen species (ROS) accumulation, which triggers the downstream signals of JNK, Bcl-2 and Beclin-1. Reactive Oxygen Species 73-96 BCL2 apoptosis regulator Homo sapiens 163-168 34242793-4 2021 Mechanistically, this protective autophagy is regulated by intracellular reactive oxygen species (ROS) accumulation, which triggers the downstream signals of JNK, Bcl-2 and Beclin-1. Reactive Oxygen Species 98-101 BCL2 apoptosis regulator Homo sapiens 163-168 34242793-5 2021 More importantly, soft substrate-induced activation of ROS/JNK signaling promotes cell apoptosis through the mitochondrial pathway, whereas it increases protective autophagy by suppressing the interaction of Bcl-2 and Beclin-1. Reactive Oxygen Species 55-58 BCL2 apoptosis regulator Homo sapiens 208-213 34424320-7 2021 Lastly, we show that the B-cell lymphoma 2 (BCL2)-dependent cytotoxicity of huXBR1-402-G5-PNU can be leveraged by combined treatment strategies with the BCL2 inhibitor venetoclax. huxbr1-402-g5-pnu 76-93 BCL2 apoptosis regulator Homo sapiens 25-42 34424320-7 2021 Lastly, we show that the B-cell lymphoma 2 (BCL2)-dependent cytotoxicity of huXBR1-402-G5-PNU can be leveraged by combined treatment strategies with the BCL2 inhibitor venetoclax. huxbr1-402-g5-pnu 76-93 BCL2 apoptosis regulator Homo sapiens 44-48 34424320-7 2021 Lastly, we show that the B-cell lymphoma 2 (BCL2)-dependent cytotoxicity of huXBR1-402-G5-PNU can be leveraged by combined treatment strategies with the BCL2 inhibitor venetoclax. huxbr1-402-g5-pnu 76-93 BCL2 apoptosis regulator Homo sapiens 153-157 34424320-7 2021 Lastly, we show that the B-cell lymphoma 2 (BCL2)-dependent cytotoxicity of huXBR1-402-G5-PNU can be leveraged by combined treatment strategies with the BCL2 inhibitor venetoclax. venetoclax 168-178 BCL2 apoptosis regulator Homo sapiens 25-42 34424320-7 2021 Lastly, we show that the B-cell lymphoma 2 (BCL2)-dependent cytotoxicity of huXBR1-402-G5-PNU can be leveraged by combined treatment strategies with the BCL2 inhibitor venetoclax. venetoclax 168-178 BCL2 apoptosis regulator Homo sapiens 44-48 34424320-7 2021 Lastly, we show that the B-cell lymphoma 2 (BCL2)-dependent cytotoxicity of huXBR1-402-G5-PNU can be leveraged by combined treatment strategies with the BCL2 inhibitor venetoclax. venetoclax 168-178 BCL2 apoptosis regulator Homo sapiens 153-157 34429133-12 2021 Moreover, apatinib upregulated Cleaved Caspase 3, Cleaved Caspase 9 and Bax, and downregulated Bcl-2 in NSCLC cells. apatinib 10-18 BCL2 apoptosis regulator Homo sapiens 95-100 34423383-12 2021 The anti-apoptotic Bcl2 gene expression, the mitochondrial membrane potential, and the cellular ATP levels were significantly decreased than in case of ifosfamide. Ifosfamide 152-162 BCL2 apoptosis regulator Homo sapiens 19-23 34485154-5 2021 Our results show that ASP inhibited 5-FU-induced the decrease in Bcl-2 protein and the increase in Bax protein. Aspartic Acid 22-25 BCL2 apoptosis regulator Homo sapiens 65-70 34426809-6 2021 OLX and ABT-737 mediated inhibition of Bcl-2 correlated with reduced expression levels of thymidine kinase 1 (TK1), cyclin A2 (CCNA2), and cyclin B1 (CCNB1) cell cycle regulators. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 8-11 BCL2 apoptosis regulator Homo sapiens 39-44 34426809-13 2021 In addition, we show that Bcl-2 inhibitor ABT-737 exhibited moderate anti-mammarenavirus activity in vivo , and that Bcl-2 inhibitors displayed broad-spectrum antiviral activities against different mammarenaviruses and SARS-CoV-2. ABT-737 42-49 BCL2 apoptosis regulator Homo sapiens 26-31 34439278-1 2021 The purpose of this study was to assess in vitro whether the biological effects of 5-aminolevulinic acid (5-ALA)-based photodynamic therapy are enhanced by inhibition of the anti-apoptotic Bcl-2 family proteins Bcl-2 and Bcl-xL in different glioblastoma models. 5-amino levulinic acid 83-104 BCL2 apoptosis regulator Homo sapiens 189-194 34439278-1 2021 The purpose of this study was to assess in vitro whether the biological effects of 5-aminolevulinic acid (5-ALA)-based photodynamic therapy are enhanced by inhibition of the anti-apoptotic Bcl-2 family proteins Bcl-2 and Bcl-xL in different glioblastoma models. 5-amino levulinic acid 83-104 BCL2 apoptosis regulator Homo sapiens 211-216 34439278-1 2021 The purpose of this study was to assess in vitro whether the biological effects of 5-aminolevulinic acid (5-ALA)-based photodynamic therapy are enhanced by inhibition of the anti-apoptotic Bcl-2 family proteins Bcl-2 and Bcl-xL in different glioblastoma models. 5-amino levulinic acid 106-111 BCL2 apoptosis regulator Homo sapiens 189-194 34439278-1 2021 The purpose of this study was to assess in vitro whether the biological effects of 5-aminolevulinic acid (5-ALA)-based photodynamic therapy are enhanced by inhibition of the anti-apoptotic Bcl-2 family proteins Bcl-2 and Bcl-xL in different glioblastoma models. 5-amino levulinic acid 106-111 BCL2 apoptosis regulator Homo sapiens 211-216 34439278-2 2021 Pre-clinical testing of a microcontroller-based device emitting light of 405 nm wavelength in combination with exposure to 5-ALA (PDT) and the Bcl-2/Bcl-xL inhibitor ABT-263 (navitoclax) was performed in human established and primary cultured glioblastoma cells as well as glioma stem-like cells. navitoclax 166-173 BCL2 apoptosis regulator Homo sapiens 143-148 34485154-5 2021 Our results show that ASP inhibited 5-FU-induced the decrease in Bcl-2 protein and the increase in Bax protein. Fluorouracil 36-40 BCL2 apoptosis regulator Homo sapiens 65-70 34492839-7 2021 Additionally, CuSO4 induced apoptosis which was featured by MMP depolarization and up-regulated levels of cleaved-caspase-3, cleaved-caspase-8, cleaved-caspase-9, caspase-12, cleaved-PARP and Bax, whereas down-regulated Bcl-2 expression. Copper Sulfate 14-19 BCL2 apoptosis regulator Homo sapiens 220-225 34383763-4 2021 In addition, norcycloartocarpin activated apoptosis caspase cascade associating with restoration of p53, down-regulated Bcl-2 and augmented Bax in A549 and H460 cells. norcycloartocarpin 13-31 BCL2 apoptosis regulator Homo sapiens 120-125 34440193-7 2021 COS significantly increased Bax and decreased Bcl2 levels in treated cells. costunolide 0-3 BCL2 apoptosis regulator Homo sapiens 46-50 34381064-7 2021 RT-qPCR for apoptotic genes (BCL2, CASP3 and CASP8) and necrosis genes (MLKL, RIPK1 and RIPK3) did not show significant differences between control and treated cells of both types, with the exception of eugenol-treated HeLa cells in which expression of BCL2, MLKL and RIPK1 was significantly higher than controls. Eugenol 203-210 BCL2 apoptosis regulator Homo sapiens 253-257 34369898-5 2022 Finally, the effect of ginsenoside Rh1 on the levels of BAX and BCL-2, and the Nrf2/HO-1 signaling pathway were determined by qRT-PCR and western blot assays. ginsenoside Rh1 23-38 BCL2 apoptosis regulator Homo sapiens 64-69 34364387-9 2021 At a molecular level, 3Br-P + DCA treatment remarkably down-regulated the expression of Bcl-2, while up-regulated the expression of Bax. 3br-p 22-27 BCL2 apoptosis regulator Homo sapiens 88-93 34364387-9 2021 At a molecular level, 3Br-P + DCA treatment remarkably down-regulated the expression of Bcl-2, while up-regulated the expression of Bax. Dichloroacetic Acid 30-33 BCL2 apoptosis regulator Homo sapiens 88-93 34646528-9 2021 Shikonin reversed the expression of the inflammatory cytokines TNF-alpha and IL-1beta and apoptosis-related molecules Bax, Bcl-2, and cleaved caspase 3 in LPS-induced NP cells. shikonin 0-8 BCL2 apoptosis regulator Homo sapiens 123-128 34245298-9 2021 Western blotting analysis further confirmed that ACh decreased the ratio of pp38 MAPK/p38 MAPK, p-NF-kappaB/NF-kappaB, Bax/Bcl-2 and cleaved caspase-3/caspase-3. Acetylcholine 49-52 BCL2 apoptosis regulator Homo sapiens 123-128 34358285-8 2021 EphA2 up-regulation caused an up-regulation of Bcl-2, and repressed the expression of Bax and Cleaved-caspase-3 in the SRA01/04 cells following H2O2 treatment. Hydrogen Peroxide 144-148 BCL2 apoptosis regulator Homo sapiens 47-52 34376999-12 2021 Furthermore, dimethoxycurcumin suppressed apoptotic marker, BCL-2 to promote apoptosis in LN229 and GBM8401 glioma cells. dimethoxycurcumin 13-30 BCL2 apoptosis regulator Homo sapiens 60-65 34354046-0 2021 Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway. gemcitabine 0-11 BCL2 apoptosis regulator Homo sapiens 62-67 34354046-0 2021 Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway. Pelcitoclax 16-24 BCL2 apoptosis regulator Homo sapiens 62-67 34394831-10 2021 The results showed that compared with the control group, the expression of p-PI3K, p-Akt, and Bcl-2 was significantly decreased, while the expression of caspase-3 and Bax was significantly increased in the PQ group. pq 206-208 BCL2 apoptosis regulator Homo sapiens 94-99 34394831-11 2021 In the AEE group, AEE pretreatment could upregulate the expression of p-PI3K, p-Akt, and Bcl-2 and downregulate the expression of caspase-3 and Bax in SH-SY5Y cells. aspirin eugenol ester 7-10 BCL2 apoptosis regulator Homo sapiens 89-94 34394831-11 2021 In the AEE group, AEE pretreatment could upregulate the expression of p-PI3K, p-Akt, and Bcl-2 and downregulate the expression of caspase-3 and Bax in SH-SY5Y cells. aspirin eugenol ester 18-21 BCL2 apoptosis regulator Homo sapiens 89-94 34394836-8 2021 At the same time, LEO treatment significantly promoted the phosphorylation level of angiogenic protein PI3K, Akt, and eNOS and the expression level of survival factor Bcl2 and decreased the expression level of death factor Bax and caspase3. leonurine 18-21 BCL2 apoptosis regulator Homo sapiens 167-171 34532394-12 2021 Western blot analysis showed that O3 exposure reduced B-cell lymphoma 2 (BCL-2) expression and increased cleaved poly ADP-ribose polymerase (PARP), cytochrome C (Cyt-C), caspase-3, caspase-9, and p-JNK expression. Ozone 34-36 BCL2 apoptosis regulator Homo sapiens 54-71 34488389-11 2021 However, the expression of Bcl-2 increased when HC-030031, pifithrin-alpha, or FK506 was used alone, and HC-030031 combined with pifithrin-alpha or FK506 further improved the expression of Bcl-2. pifithrin 59-68 BCL2 apoptosis regulator Homo sapiens 27-32 34334076-6 2022 AST inhibited the oxidative stress by improving the levels of superoxide dismutase (SOD), total antioxidant capacity (TAOC) and suppressing malondialdehyde (MDA) in serum, and increasing the protein of PPARgamma, Bax/Bcl-2, Caspase-3 in esophagus tissue, especially in the 50 mg/kg of AST intervention group (all P < 0.05). astaxanthine 0-3 BCL2 apoptosis regulator Homo sapiens 217-222 34334076-6 2022 AST inhibited the oxidative stress by improving the levels of superoxide dismutase (SOD), total antioxidant capacity (TAOC) and suppressing malondialdehyde (MDA) in serum, and increasing the protein of PPARgamma, Bax/Bcl-2, Caspase-3 in esophagus tissue, especially in the 50 mg/kg of AST intervention group (all P < 0.05). astaxanthine 285-288 BCL2 apoptosis regulator Homo sapiens 217-222 34488389-11 2021 However, the expression of Bcl-2 increased when HC-030031, pifithrin-alpha, or FK506 was used alone, and HC-030031 combined with pifithrin-alpha or FK506 further improved the expression of Bcl-2. pifithrin 59-68 BCL2 apoptosis regulator Homo sapiens 189-194 34532394-12 2021 Western blot analysis showed that O3 exposure reduced B-cell lymphoma 2 (BCL-2) expression and increased cleaved poly ADP-ribose polymerase (PARP), cytochrome C (Cyt-C), caspase-3, caspase-9, and p-JNK expression. Ozone 34-36 BCL2 apoptosis regulator Homo sapiens 73-78 34488389-11 2021 However, the expression of Bcl-2 increased when HC-030031, pifithrin-alpha, or FK506 was used alone, and HC-030031 combined with pifithrin-alpha or FK506 further improved the expression of Bcl-2. Tacrolimus 79-84 BCL2 apoptosis regulator Homo sapiens 27-32 34488389-11 2021 However, the expression of Bcl-2 increased when HC-030031, pifithrin-alpha, or FK506 was used alone, and HC-030031 combined with pifithrin-alpha or FK506 further improved the expression of Bcl-2. Tacrolimus 148-153 BCL2 apoptosis regulator Homo sapiens 27-32 34087693-3 2021 Through regulating several proteins such as melatonin upregulated mRNAs and proteins of downregulated Bcl-2-associated X protein (Bax), and B-cell lymphoma 2 (Bcl-2), as well as cytoplasmic protein such as calcium-binding proteins calmodulin or tubulin, and nuclear receptors, including RORalpha/RZR, and acts by non-receptor-regulated mechanisms, melatonin can exert anti-cancer efficacy. Melatonin 44-53 BCL2 apoptosis regulator Homo sapiens 140-157 34488389-11 2021 However, the expression of Bcl-2 increased when HC-030031, pifithrin-alpha, or FK506 was used alone, and HC-030031 combined with pifithrin-alpha or FK506 further improved the expression of Bcl-2. Tacrolimus 148-153 BCL2 apoptosis regulator Homo sapiens 189-194 34087693-3 2021 Through regulating several proteins such as melatonin upregulated mRNAs and proteins of downregulated Bcl-2-associated X protein (Bax), and B-cell lymphoma 2 (Bcl-2), as well as cytoplasmic protein such as calcium-binding proteins calmodulin or tubulin, and nuclear receptors, including RORalpha/RZR, and acts by non-receptor-regulated mechanisms, melatonin can exert anti-cancer efficacy. Melatonin 44-53 BCL2 apoptosis regulator Homo sapiens 159-164 34087693-3 2021 Through regulating several proteins such as melatonin upregulated mRNAs and proteins of downregulated Bcl-2-associated X protein (Bax), and B-cell lymphoma 2 (Bcl-2), as well as cytoplasmic protein such as calcium-binding proteins calmodulin or tubulin, and nuclear receptors, including RORalpha/RZR, and acts by non-receptor-regulated mechanisms, melatonin can exert anti-cancer efficacy. Melatonin 348-357 BCL2 apoptosis regulator Homo sapiens 140-157 34087693-3 2021 Through regulating several proteins such as melatonin upregulated mRNAs and proteins of downregulated Bcl-2-associated X protein (Bax), and B-cell lymphoma 2 (Bcl-2), as well as cytoplasmic protein such as calcium-binding proteins calmodulin or tubulin, and nuclear receptors, including RORalpha/RZR, and acts by non-receptor-regulated mechanisms, melatonin can exert anti-cancer efficacy. Melatonin 348-357 BCL2 apoptosis regulator Homo sapiens 159-164 34250604-5 2021 High glucose decreased cells viability and suppressed Bcl-2 mRNA expression. Glucose 5-12 BCL2 apoptosis regulator Homo sapiens 54-59 34075659-6 2021 Also, geraniol potently diminished caspase-9, Bax, Bcl-2, and caspase-3 expression in AGS cells. geraniol 6-14 BCL2 apoptosis regulator Homo sapiens 51-56 34075698-0 2021 Diosgenin Protects Against Kidney Injury and Mitochondrial Apoptosis Induced by 3-MCPD Through the Regulation of ER Stress, Ca2+ Homeostasis and Bcl2 Expression. Diosgenin 0-9 BCL2 apoptosis regulator Homo sapiens 145-149 34382859-6 2021 GA treatment decreased the survival and invasive capacity of 5-8F and CNE2 and induced their apoptosis, which varied with dose; this was accompanied by downregulation of B cell lymphoma (Bcl)2, upregulation of Bcl2-associated X protein, and activation of poly-ADP ribose polymerase, and caspase-9/-3. ginkgolic acid 0-2 BCL2 apoptosis regulator Homo sapiens 170-192 34075698-0 2021 Diosgenin Protects Against Kidney Injury and Mitochondrial Apoptosis Induced by 3-MCPD Through the Regulation of ER Stress, Ca2+ Homeostasis and Bcl2 Expression. alpha-Chlorohydrin 80-86 BCL2 apoptosis regulator Homo sapiens 145-149 34075698-8 2021 Furthermore, we demonstrated that the maintenance of Ca2+ homeostasis and Bcl2 expression, two main targets of ER stress, contributed to the protection role of DIO on mitochondrial-dependent apoptosis. Diosgenin 160-163 BCL2 apoptosis regulator Homo sapiens 74-78 34075698-10 2021 CONCLUSION: Our study demonstrated that DIO exerted protective effect against kidney injury, mitochondrial dysfunction and apoptosis through the inhibition of ER stress and the further maintenance of Ca2+ homeostasis and Bcl2 expression. Diosgenin 40-43 BCL2 apoptosis regulator Homo sapiens 221-225 34110092-7 2021 Our findings suggest that p-gliadin composed of supramolecular structures triggers significant mRNA up-regulation (p < 0.05) of pro-apoptotic biomarkers (ratio Bcl2/Bak-1), chemokines (CCL2, CCL3, CCL4, CCL5, CXCL8) and the chemokine receptor CXCR3. p-gliadin 26-35 BCL2 apoptosis regulator Homo sapiens 160-164 34149899-6 2021 Compared with the PBS control group, the A549, A549/DDP and A549/Taxol cells treated with NaI131, GA or a combination of the drugs exhibited G2/M arrest and increased percentages of total apoptotic cells, as well as significantly decreased protein levels of CDK1, cyclin B, mtp53, HSP90, Bcl-2 and P-gp, increased protein levels of Bax and decreased mRNA levels of p53 and HSP90. pbs 18-21 BCL2 apoptosis regulator Homo sapiens 288-293 34149899-6 2021 Compared with the PBS control group, the A549, A549/DDP and A549/Taxol cells treated with NaI131, GA or a combination of the drugs exhibited G2/M arrest and increased percentages of total apoptotic cells, as well as significantly decreased protein levels of CDK1, cyclin B, mtp53, HSP90, Bcl-2 and P-gp, increased protein levels of Bax and decreased mRNA levels of p53 and HSP90. nai131 90-96 BCL2 apoptosis regulator Homo sapiens 288-293 34290399-5 2021 In addition, we highlight recent findings pointing to the role of the dysregulated activity of BCL-2 proteins and protein tyrosine phosphatases (PTPs) in the generation of hepatic oxidative stress and ROS-mediated dysfunctional signaling, respectively. Reactive Oxygen Species 201-204 BCL2 apoptosis regulator Homo sapiens 95-100 34149899-6 2021 Compared with the PBS control group, the A549, A549/DDP and A549/Taxol cells treated with NaI131, GA or a combination of the drugs exhibited G2/M arrest and increased percentages of total apoptotic cells, as well as significantly decreased protein levels of CDK1, cyclin B, mtp53, HSP90, Bcl-2 and P-gp, increased protein levels of Bax and decreased mRNA levels of p53 and HSP90. gambogic acid 98-100 BCL2 apoptosis regulator Homo sapiens 288-293 34193942-2 2021 Here, we demonstrate that PD-L1 depletion enhances JNK activity resulting in increased BimThr116 phosphorylation and its sequestration by MCL-1 and BCL-2. bimthr116 87-96 BCL2 apoptosis regulator Homo sapiens 148-153 34296546-0 2021 Upregulation of MicroRNA-34a Sensitizes Ovarian Cancer Cells to Resveratrol by Targeting Bcl-2. Resveratrol 64-75 BCL2 apoptosis regulator Homo sapiens 89-94 34174982-4 2021 Venetoclax, a highly selective BCL2 inhibitor, has high affinity to the BH3-binding grove of BCL2. BH 3 72-75 BCL2 apoptosis regulator Homo sapiens 31-35 34174982-4 2021 Venetoclax, a highly selective BCL2 inhibitor, has high affinity to the BH3-binding grove of BCL2. BH 3 72-75 BCL2 apoptosis regulator Homo sapiens 93-97 34406846-7 2021 After silencing Bcl-2 with siRNA, the sensitivity of the cells to cisplatin (CDDP) increased. Cisplatin 66-75 BCL2 apoptosis regulator Homo sapiens 16-21 34406846-7 2021 After silencing Bcl-2 with siRNA, the sensitivity of the cells to cisplatin (CDDP) increased. Cisplatin 77-81 BCL2 apoptosis regulator Homo sapiens 16-21 34354443-8 2021 The real-time qRT-PCR results showed that the EGFR protein (bcl-2) in human breast cancer cell line (MCF7) was negatively expressed with a value of -0.69297105 after treatment with EAE (100 microg/mL). EAE 181-184 BCL2 apoptosis regulator Homo sapiens 60-65 34296546-13 2021 Further investigations revealed that overexpression of Bcl-2 significantly abolished the anti-tumor effects of REV on OC cells. Resveratrol 111-114 BCL2 apoptosis regulator Homo sapiens 55-60 34362486-10 2021 The proliferation of Nalm6 cells and the number of cell clones could be inhibited by miR-142-3p mimic after 48 and 72 hours of transfection (P<0.05), which causing G1 phase arrest of Nalm6 cells and inhibiting the expression of CyclinD1 and CDK4 protein (P<0.01), promoting the apoptosis of Nalm6 cells, and inhibiting the expression of BCL-2 protein, moreover, promoting the expression of Bax and Caspase-3 protein (P<0.05). mir-142-3p 85-95 BCL2 apoptosis regulator Homo sapiens 337-342 34361006-4 2021 Here we focus on the interaction between two core Bcl-2 family members, the executor pore-forming protein Bax and the truncated form of the activator protein Bid (tBid), which we imaged at the single particle level in a mitochondria-like planar supported lipid bilayer. tBID 163-167 BCL2 apoptosis regulator Homo sapiens 50-55 34451846-2 2021 BH3 mimetics, drugs that mimic the activity of pro-apoptotic BCL2 family proteins, have recently achieved remarkable success in the clinical setting. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 61-65 34361036-6 2021 In addition, hinokitiol increased the number of apoptotic cells and increased the protein expression of cleaved-poly-ADP-ribose polymerase (PARP) and active cleaved-caspase-3, as well as the ratio of Bcl-2-associated X protein (Bax) to B-cell lymphoma 2 (Bcl-2). beta-thujaplicin 13-23 BCL2 apoptosis regulator Homo sapiens 236-253 34361036-6 2021 In addition, hinokitiol increased the number of apoptotic cells and increased the protein expression of cleaved-poly-ADP-ribose polymerase (PARP) and active cleaved-caspase-3, as well as the ratio of Bcl-2-associated X protein (Bax) to B-cell lymphoma 2 (Bcl-2). beta-thujaplicin 13-23 BCL2 apoptosis regulator Homo sapiens 255-260 34451846-5 2021 Using a combination of cell viability assay, BCL2 family knockdown cell lines, live cell imaging, and sphere formation assay, we found that combining inhibition of MCL1, an anti-apoptotic BCL2 protein, with azacitidine had substantial pro-apoptotic effects in multiple melanoma cell lines. Azacitidine 207-218 BCL2 apoptosis regulator Homo sapiens 45-49 34321365-5 2022 Moreover, shikonin enhanced mitochondrial membrane depolarization and Bax expression and also decreased Bcl-2 expression with translocation of cytochrome c from mitochondria into the cytosol. shikonin 10-18 BCL2 apoptosis regulator Homo sapiens 104-109 34439474-9 2021 Moreover, the ability of G. cambogia to inhibit ROS production suppressed apoptosis by normalizing the Bcl-2/BAX ratio and PARP cleavage. Reactive Oxygen Species 48-51 BCL2 apoptosis regulator Homo sapiens 103-108 34349560-0 2021 Long Non-Coding RNA BLACAT1 Induces Tamoxifen Resistance in Human Breast Cancer by Regulating miR-503/Bcl-2 Axis (Retraction). Tamoxifen 36-45 BCL2 apoptosis regulator Homo sapiens 102-107 34440505-6 2021 DAPI and Mitotracker red staining revealed that rutin induced significant apoptotic effects via caspase-3/9 activation, ROS generation, and alteration in Bax/Bcl2 mRNA expression. Rutin 48-53 BCL2 apoptosis regulator Homo sapiens 158-162 34394837-13 2021 Meanwhile, Bcl2, Bax, and p-38 were involved in apoptosis induced by PQ. Paraquat 69-71 BCL2 apoptosis regulator Homo sapiens 11-15 34367280-11 2021 We also found that downregulation of ECT2 increased 5-FU sensitivity in GC cells by downregulating P-gp, MRP1, and Bcl-2. Fluorouracil 52-56 BCL2 apoptosis regulator Homo sapiens 115-120 34309458-10 2022 In addition, when the anti-apoptotic Bcl-2, mTOR, and Akt gene expression levels were normalized as 1 in the control group, they were 0.28, 0.41, and 0.22 with 5-FU + L treatment, and 0.32, 0.46, and 0.39, respectively, with 5-FU + Q treatment. Fluorouracil 160-164 BCL2 apoptosis regulator Homo sapiens 37-42 34309458-10 2022 In addition, when the anti-apoptotic Bcl-2, mTOR, and Akt gene expression levels were normalized as 1 in the control group, they were 0.28, 0.41, and 0.22 with 5-FU + L treatment, and 0.32, 0.46, and 0.39, respectively, with 5-FU + Q treatment. Leucine 167-168 BCL2 apoptosis regulator Homo sapiens 37-42 34309458-10 2022 In addition, when the anti-apoptotic Bcl-2, mTOR, and Akt gene expression levels were normalized as 1 in the control group, they were 0.28, 0.41, and 0.22 with 5-FU + L treatment, and 0.32, 0.46, and 0.39, respectively, with 5-FU + Q treatment. Fluorouracil 225-229 BCL2 apoptosis regulator Homo sapiens 37-42 34309458-10 2022 In addition, when the anti-apoptotic Bcl-2, mTOR, and Akt gene expression levels were normalized as 1 in the control group, they were 0.28, 0.41, and 0.22 with 5-FU + L treatment, and 0.32, 0.46, and 0.39, respectively, with 5-FU + Q treatment. Glutamine 232-233 BCL2 apoptosis regulator Homo sapiens 37-42 34315868-6 2021 The BH3 mimetic navitoclax, which antagonizes BCL-xL, BCL-w, and BCL-2, consistently primed NSCLC tumors in vitro and in vivo. BH 3 4-7 BCL2 apoptosis regulator Homo sapiens 65-70 34394837-15 2021 Bcl2/Bax and P-p38/p38 pathways mediated the cross-talk between ferroptosis and apoptosis induced by PQ. Paraquat 101-103 BCL2 apoptosis regulator Homo sapiens 0-4 34280220-5 2021 Furthermore, in influenza A virus-infected cells, TG6-44 treatment led to suppression of virus-induced cell death as evidenced by decreased caspase-3 activation, decreased proportion of Annexin V+PI+ cells, and increased Bcl-2 phosphorylation. tg6-44 50-56 BCL2 apoptosis regulator Homo sapiens 221-226 34304400-1 2021 We previously reported that M. tb on its own as well as together with HIV inhibits macrophage apoptosis by upregulating the expression of Bcl2 and Inhibitor of Apoptosis (IAP). Terbium 31-33 BCL2 apoptosis regulator Homo sapiens 138-142 34373755-17 2021 Combination of BKA-073 with Bcl-2 inhibitor venetoclax exhibits strong synergy against lung cancer in vivo. bka-073 15-22 BCL2 apoptosis regulator Homo sapiens 28-33 34337019-12 2021 After incubation with the concentration of 50 mug/ml of ZEO for 24 and 48 hours, caspase 3 and 9 gene expressions in the treated group increased compared to those in the control group (P < 0.001), while the Bcl-2 expression decreased. zeo 56-59 BCL2 apoptosis regulator Homo sapiens 207-212 34337019-13 2021 The results showed that having anticancer compounds, ZEO can increase C3 and C9 and decrease Bcl-2 expressions, causing apoptosis in HT-29 cells in vitro. zeo 53-56 BCL2 apoptosis regulator Homo sapiens 93-98 34298797-5 2021 We observed that following TMZ treatment, c-IAP2 and Bcl-2 were upregulated. Temozolomide 27-30 BCL2 apoptosis regulator Homo sapiens 53-58 34257274-0 2021 Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy. navitoclax 23-30 BCL2 apoptosis regulator Homo sapiens 0-5 34111614-10 2021 Under specific circumstances, SMI depressed autophagic process by reducing the Beclin 1-Bcl-2 complex dissociation which was activated by DOX via stimulating the JNK signaling pathway. Doxorubicin 138-141 BCL2 apoptosis regulator Homo sapiens 88-93 34336680-1 2021 Background: Existing research shows that ABT-199, as a first-line drug, have been widely used in hematological malignancies, especially in leukemia, but the clinical efficacy of single drug therapy was limited part of the reason was that BCL-2 inhibitors failure to target other anti-apoptotic BCL-2 family proteins, such as MCL-1. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 41-44 BCL2 apoptosis regulator Homo sapiens 238-243 34336680-1 2021 Background: Existing research shows that ABT-199, as a first-line drug, have been widely used in hematological malignancies, especially in leukemia, but the clinical efficacy of single drug therapy was limited part of the reason was that BCL-2 inhibitors failure to target other anti-apoptotic BCL-2 family proteins, such as MCL-1. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 41-44 BCL2 apoptosis regulator Homo sapiens 294-299 34259934-9 2021 Two new compounds, ZINC00000255131 and ZINC00013298233, were found to be potential inhibitors of BCL2. zinc00000255131 19-34 BCL2 apoptosis regulator Homo sapiens 97-101 34259934-9 2021 Two new compounds, ZINC00000255131 and ZINC00013298233, were found to be potential inhibitors of BCL2. zinc00013298233 39-54 BCL2 apoptosis regulator Homo sapiens 97-101 34336656-7 2021 PCB downregulated the expression levels of proteins involved in cell cycle progression and apoptosis, including cyclinB1, Cdc2, PARP1, Bcl-2, and survivin, and upregulated protein levels of cleaved PARP1, cleaved caspase3, cleaved caspase9, and BAX. pinocembrin 0-3 BCL2 apoptosis regulator Homo sapiens 135-140 34372579-6 2021 An Arg located in the structurally equivalent BH1 region of ORFV125 forms an ionic interaction with the conserved Asp in the BH3 motif in a manner that mimics the canonical ionic interaction seen in host Bcl-2:BH3 motif complexes. Arginine 3-6 BCL2 apoptosis regulator Homo sapiens 204-209 34372579-6 2021 An Arg located in the structurally equivalent BH1 region of ORFV125 forms an ionic interaction with the conserved Asp in the BH3 motif in a manner that mimics the canonical ionic interaction seen in host Bcl-2:BH3 motif complexes. Aspartic Acid 114-117 BCL2 apoptosis regulator Homo sapiens 204-209 34372579-6 2021 An Arg located in the structurally equivalent BH1 region of ORFV125 forms an ionic interaction with the conserved Asp in the BH3 motif in a manner that mimics the canonical ionic interaction seen in host Bcl-2:BH3 motif complexes. BH 3 125-128 BCL2 apoptosis regulator Homo sapiens 204-209 34372579-6 2021 An Arg located in the structurally equivalent BH1 region of ORFV125 forms an ionic interaction with the conserved Asp in the BH3 motif in a manner that mimics the canonical ionic interaction seen in host Bcl-2:BH3 motif complexes. BH 3 210-213 BCL2 apoptosis regulator Homo sapiens 204-209 34251414-2 2021 Oblimersen (G3139) is a phosphorothioate 18-mer antisense oligonucleotide directed against the first 6 BCL2 codons. 4-nitrophenyl phosphorothioate 24-40 BCL2 apoptosis regulator Homo sapiens 103-107 34251414-2 2021 Oblimersen (G3139) is a phosphorothioate 18-mer antisense oligonucleotide directed against the first 6 BCL2 codons. Oligonucleotides 58-73 BCL2 apoptosis regulator Homo sapiens 103-107 34251414-3 2021 In a phase 1 study of AML patients treated with G3139, cytarabine, and daunorubicin induction with cytarabine consolidation, no antisense-related toxicity was reported, and BCL2 downregulation occurred in patients achieving complete remission. oblimersen 48-53 BCL2 apoptosis regulator Homo sapiens 173-177 34251414-3 2021 In a phase 1 study of AML patients treated with G3139, cytarabine, and daunorubicin induction with cytarabine consolidation, no antisense-related toxicity was reported, and BCL2 downregulation occurred in patients achieving complete remission. Cytarabine 55-65 BCL2 apoptosis regulator Homo sapiens 173-177 34251414-3 2021 In a phase 1 study of AML patients treated with G3139, cytarabine, and daunorubicin induction with cytarabine consolidation, no antisense-related toxicity was reported, and BCL2 downregulation occurred in patients achieving complete remission. Daunorubicin 71-83 BCL2 apoptosis regulator Homo sapiens 173-177 34257274-4 2021 Of note, inhibition of Bcl-2 and Bcl-xL by BH3-mimetic ABT-263 enhanced the sensitivity of HCT116 colon cancer and NCI-H460 lung cancer cells to the cytotoxic action of ionizing radiation. BH 3 43-46 BCL2 apoptosis regulator Homo sapiens 23-28 34257274-4 2021 Of note, inhibition of Bcl-2 and Bcl-xL by BH3-mimetic ABT-263 enhanced the sensitivity of HCT116 colon cancer and NCI-H460 lung cancer cells to the cytotoxic action of ionizing radiation. navitoclax 55-62 BCL2 apoptosis regulator Homo sapiens 23-28 34257274-7 2021 Targeting the Bcl-2 rheostat with ABT-263, therefore, is a particularly promising approach to overcome radioresistance of cancer cells exposed to acute or chronic hypoxia with intermittent reoxygenation. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 34-37 BCL2 apoptosis regulator Homo sapiens 14-19 34257274-8 2021 Moreover, we found intrinsic as well as ABT-263- and irradiation-induced regulation of Bcl-2 family members to determine therapy sensitivity. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 40-43 BCL2 apoptosis regulator Homo sapiens 87-92 34238175-8 2022 To determine the mechanisms underlying SAR131675 induced apoptosis, the mitochondrial membrane potential, ROS generation, the activity of caspase-3, and expression of apoptosis-related proteins such as Bcl-2, Bax, and cytochrome c were evaluated in HUVECs. SAR131675 39-48 BCL2 apoptosis regulator Homo sapiens 202-207 34189904-7 2021 Treatment with CEF-FK506-nilotinib-GSH-CL-liposomes reduced the expression of Bax and alpha-syn and promoted the expression of Bcl-2, tyrosine hydroxylase, and the dopamine transporter. cef-fk506 15-24 BCL2 apoptosis regulator Homo sapiens 127-132 34189904-7 2021 Treatment with CEF-FK506-nilotinib-GSH-CL-liposomes reduced the expression of Bax and alpha-syn and promoted the expression of Bcl-2, tyrosine hydroxylase, and the dopamine transporter. nilotinib 25-34 BCL2 apoptosis regulator Homo sapiens 127-132 34189904-7 2021 Treatment with CEF-FK506-nilotinib-GSH-CL-liposomes reduced the expression of Bax and alpha-syn and promoted the expression of Bcl-2, tyrosine hydroxylase, and the dopamine transporter. gsh-cl 35-41 BCL2 apoptosis regulator Homo sapiens 127-132 34299042-7 2021 A significant increase in caspase-3 activity and decrease in Bcl-2 protein concentration was noted in both MS13-treated cells in a time- and dose-dependent manner. ms13 107-111 BCL2 apoptosis regulator Homo sapiens 61-66 34298658-9 2021 Additionally, KYP-2047 at the concentrations of 50 microM and 100 microM was able to increase the pro-apoptotic protein Bax, p53 and caspase-3 expression whereas Bcl-2 expression was reduced. 3-hydroxy-2-({4-[4-(pyrimidin-2-yl)piperazine-1-carbonyl]phenyl}methyl)-1-benzofuran-7-carboxamide 14-17 BCL2 apoptosis regulator Homo sapiens 162-167 34305590-5 2021 Triclabendazole activates apoptosis by regulating the apoptoic protein levels including Bax, Bcl-2, and enhanced cleavage of caspase-8/9/3/7 and PARP. Triclabendazole 0-15 BCL2 apoptosis regulator Homo sapiens 93-98 34299490-5 2021 DML6, at 5 muM, induced intrinsic apoptosis by significantly (1) increasing the levels of the pro-apoptotic proteins, Bak and Bax, and (2) decreasing the levels of l the anti-apoptotic protein, Bcl-2, compared to cell incubated with a vehicle. dml6 0-4 BCL2 apoptosis regulator Homo sapiens 194-199 34238196-12 2022 Overexpression of miR-125b inhibited proliferation and promoted apoptosis in SW480 colon cancer cells and was accompanied by upregulated Bax expression and downregulated Bcl-2 expression (P<0.05). mir-125b 18-26 BCL2 apoptosis regulator Homo sapiens 170-175 34238175-10 2022 Moreover, SAR131675 induced mitochondrial dysfunction, ROS generation, Bcl-2 down-regulation, Bax up-regulation, cytochrome c release, and caspase-3 activation, which displays features of the mitochondria-dependent apoptosis signaling pathway. SAR131675 10-19 BCL2 apoptosis regulator Homo sapiens 71-76 34080212-0 2021 Combination of cyanidin-3-O-glucoside and cisplatin induces oxidative stress and apoptosis in HeLa cells by reducing activity of endogenous antioxidants, increasing bax/bcl-2 mRNA expression ratio, and downregulating Nrf2 expression. Cisplatin 42-51 BCL2 apoptosis regulator Homo sapiens 169-174 34298882-6 2021 Measuring different BCL2-family proteins before and after treatment with daunorubicin revealed that PMPs downregulated the pro-apoptotic PUMA protein. Daunorubicin 73-85 BCL2 apoptosis regulator Homo sapiens 20-24 34319043-0 2021 MiRNA-Mediated Knock-Down of Bcl-2 and Mcl-1 Increases Fludarabine-Sensitivity in CLL-CII Cells. fludarabine 55-66 BCL2 apoptosis regulator Homo sapiens 29-34 34319043-1 2021 BACKGROUND: Over-expression of anti-apoptotic proteins such as Bcl-2 and Mcl-1 is associated with resistance to chemotherapeutic agents such as fludarabine. fludarabine 144-155 BCL2 apoptosis regulator Homo sapiens 63-68 34319043-11 2021 CONCLUSIONS: Our data propose that suppression of Bcl-2 and Mcl-1 by miRNA-15a can effectively inhibit the cell proliferation and sensitize CLL cells to fludarabine. fludarabine 153-164 BCL2 apoptosis regulator Homo sapiens 50-55 34565029-6 2021 Curcumin treatment downregulated Bcl-2 and upregulated Bax in PTC cells. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 33-38 34137412-9 2021 The synergistic effect jointly caused a burst generation of mitochondrial ROS, which significantly down-regulated Bcl-2 protein expression, accelerated cytochrome c release and triggered a cascade of apoptosis-related proteins of Caspase-3 and Caspase-9. ros 74-77 BCL2 apoptosis regulator Homo sapiens 114-119 34262258-16 2021 The results also revealed that tetrandrine can downregulate the expression of Bcl-2 and upregulate the expression of Bax at the mRNA level. tetrandrine 31-42 BCL2 apoptosis regulator Homo sapiens 78-83 34196024-7 2022 Moreover, the expression of PCNA, MMP9, Bcl-2 were decreased, but Bax was up-regulated in Sodium Danshensu-treated A549 and NCI-H1299 cells. Sodium Danshensu 90-106 BCL2 apoptosis regulator Homo sapiens 40-45 34185112-6 2021 RESULTS: Compared with the high glucose group, the proliferation rate, migration rate, and the expression of alpha-SMA, bcl-2, TLR4, NF-kappaB, TNF-alpha, IL-6, IL- and IL-1 were significantly decreased in the high glucose + MSC-Exo-miR-26a mimics group, while the apoptosis rate and the expression of miR-26a, cleaved-caspase 3, cleaved-caspase 9 and Bax were significantly increased. Glucose 215-222 BCL2 apoptosis regulator Homo sapiens 120-125 34903979-0 2021 Novel Cytotoxic Phenanthro-triazine-3-thiol Derivatives as Potential DNA Intercalators and Bcl-2 Inhibitors. phenanthro-triazine-3-thiol 16-43 BCL2 apoptosis regulator Homo sapiens 91-96 34903979-1 2021 Novel phenanthro-triazine-3-thiol derivatives were designed as potential DNA intercalators and Bcl-2 inhibitors. phenanthro-triazine-3-thiol 6-33 BCL2 apoptosis regulator Homo sapiens 95-100 34903979-5 2021 Furthermore, to confirm the potential DNA intercalation and Bcl-2 inhibitory activities of phenanthro-triazine scaffolds, molecular docking analysis was performed. phenanthro-triazine 91-110 BCL2 apoptosis regulator Homo sapiens 60-65 34903979-7 2021 Therefore, P1 and P11 having phenanthro-triazine-3-thiol scaffold could be presented as cytotoxic agents with dual DNA intercalation and Bcl-2 inhibitory activities. phenanthro-triazine-3-thiol 29-56 BCL2 apoptosis regulator Homo sapiens 137-142 34903991-6 2021 The result indicated that zebularine and TSA changed the expression level of the Bax, Bak, Bim Bcl-2, Bcl-xL, Mcl-1, DR4, DR5, FAS, FAS-L, TRAIL, DNA methyltransferase 1, 3a, and 3b, histone deacetylase inhibitors 1, 2, and 3 by which induced cell apoptosis and inhibit cell growth in all three cell lines. pyrimidin-2-one beta-ribofuranoside 26-36 BCL2 apoptosis regulator Homo sapiens 95-100 34903991-6 2021 The result indicated that zebularine and TSA changed the expression level of the Bax, Bak, Bim Bcl-2, Bcl-xL, Mcl-1, DR4, DR5, FAS, FAS-L, TRAIL, DNA methyltransferase 1, 3a, and 3b, histone deacetylase inhibitors 1, 2, and 3 by which induced cell apoptosis and inhibit cell growth in all three cell lines. trichostatin A 41-44 BCL2 apoptosis regulator Homo sapiens 95-100 34318435-8 2021 Also, expression level of Bax protein was increased while Bcl-2 level was reduced in cells treated with miR-125b-5p, miR-145-5p and miR-221-3p mimics. mir-125b-5p 104-115 BCL2 apoptosis regulator Homo sapiens 58-63 34187946-8 2021 Vanillin oxime exposure suppressed levels of Bcl-2, survivin, Bcl-xL, cFLIP, and IAPs proteins in A549 and NCI-H2170 cells. Vanillin Oxime 0-14 BCL2 apoptosis regulator Homo sapiens 45-50 34318435-8 2021 Also, expression level of Bax protein was increased while Bcl-2 level was reduced in cells treated with miR-125b-5p, miR-145-5p and miR-221-3p mimics. mir-221-3p 132-142 BCL2 apoptosis regulator Homo sapiens 58-63 34279368-9 2021 Western blotting revealed that both copper(II) complexes induced apoptosis by regulating the expression of the Bcl-2(Bcl-2, B cell lymphoma 2) protein family. cupric ion 36-46 BCL2 apoptosis regulator Homo sapiens 111-116 34335941-5 2021 Also significant effects of quercetin on Bax, Bcl-2 and caspase-3 were observed, that can prove its ability to induce apoptosis. Quercetin 28-37 BCL2 apoptosis regulator Homo sapiens 46-51 34279368-9 2021 Western blotting revealed that both copper(II) complexes induced apoptosis by regulating the expression of the Bcl-2(Bcl-2, B cell lymphoma 2) protein family. cupric ion 36-46 BCL2 apoptosis regulator Homo sapiens 117-122 34192476-12 2021 On retrospection of the synergistic effect of upregulated c-MYC and BCL-2 in cancer, we have also reported a new pathway (MYC-E2F-1-BCL-2-axis) through which Curcumin trigger apoptosis in cancer cells.Communicated by Ramaswamy H. Sarma. Curcumin 158-166 BCL2 apoptosis regulator Homo sapiens 68-73 34192476-12 2021 On retrospection of the synergistic effect of upregulated c-MYC and BCL-2 in cancer, we have also reported a new pathway (MYC-E2F-1-BCL-2-axis) through which Curcumin trigger apoptosis in cancer cells.Communicated by Ramaswamy H. Sarma. Curcumin 158-166 BCL2 apoptosis regulator Homo sapiens 132-137 34077701-6 2021 H2O2-induced elevation of the Bax/Bcl-2 ratio and cleaved caspase-3 and caspase-7 levels were lowered by formononetin treatment. Hydrogen Peroxide 0-4 BCL2 apoptosis regulator Homo sapiens 34-39 34077701-6 2021 H2O2-induced elevation of the Bax/Bcl-2 ratio and cleaved caspase-3 and caspase-7 levels were lowered by formononetin treatment. formononetin 105-117 BCL2 apoptosis regulator Homo sapiens 34-39 34203307-10 2021 Mechanistically, MT dramatically suppressed H2O2-induced Bcl-2 downregulation, Bax upregulation, apoptotic factor caspase-3 activation, Mitogen-activated protein kinase (MAPK) (JNK, ERK, and p38), and Nuclear factor-kappaB (NF-kappaB) activation, thereby preventing H2O2-induced neurotoxicity. Hydrogen Peroxide 44-48 BCL2 apoptosis regulator Homo sapiens 57-62 34173723-0 2022 A novel polyethylene glycol (PEG)-drug conjugate of Venetoclax, a Bcl-2 inhibitor, for treatment of acute myeloid leukemia (AML). Polyethylene Glycols 8-27 BCL2 apoptosis regulator Homo sapiens 66-71 34173723-0 2022 A novel polyethylene glycol (PEG)-drug conjugate of Venetoclax, a Bcl-2 inhibitor, for treatment of acute myeloid leukemia (AML). Polyethylene Glycols 29-32 BCL2 apoptosis regulator Homo sapiens 66-71 34173723-0 2022 A novel polyethylene glycol (PEG)-drug conjugate of Venetoclax, a Bcl-2 inhibitor, for treatment of acute myeloid leukemia (AML). venetoclax 52-62 BCL2 apoptosis regulator Homo sapiens 66-71 34173723-7 2022 In a series of in vitro studies, PEG-VTX selectively induced potent growth inhibition of MV4-11 human AML cells via the inducement of Bcl-2-mediated apoptosis. peg-vtx 33-40 BCL2 apoptosis regulator Homo sapiens 134-139 34170852-9 2021 There was a binding site between miR-143 and B cell CLL/lymphoma-2 (Bcl-2) and ZQD treatment reduced Bcl-2 expression. 3-[(2S)-1-(methanesulfonyl)pyrrolidin-2-yl]-5-methyl-1,2-oxazole 79-82 BCL2 apoptosis regulator Homo sapiens 45-66 34170852-9 2021 There was a binding site between miR-143 and B cell CLL/lymphoma-2 (Bcl-2) and ZQD treatment reduced Bcl-2 expression. 3-[(2S)-1-(methanesulfonyl)pyrrolidin-2-yl]-5-methyl-1,2-oxazole 79-82 BCL2 apoptosis regulator Homo sapiens 68-73 34170852-9 2021 There was a binding site between miR-143 and B cell CLL/lymphoma-2 (Bcl-2) and ZQD treatment reduced Bcl-2 expression. 3-[(2S)-1-(methanesulfonyl)pyrrolidin-2-yl]-5-methyl-1,2-oxazole 79-82 BCL2 apoptosis regulator Homo sapiens 101-106 34206951-6 2021 The combined action of both cisPt derivatives and anti-MUC1 was more effective than monotherapy in relation to Bad, Bcl-xL, Bcl-2, caspase-9, caspase-3, as well as pro- and cleaved caspase-3 protein, and T, sialyl Tn sugar antigens in cell lysates, and Tn, T, sialyl Tn, sialyl T antigens in culture medium. Cisplatin 28-33 BCL2 apoptosis regulator Homo sapiens 124-129 34172833-6 2021 Midostaurin resistance can be overcome by a combination of midostaruin, the BCL-2 inhibitor venetoclax and the RAC1 inhibitor Eht1864 in midostaurin-resistant AML cell lines and primary samples, providing the first evidence of a potential new treatment approach to eradicate FLT3-ITD + AML. midostaurin 0-11 BCL2 apoptosis regulator Homo sapiens 76-81 34184213-0 2022 Borax Pentahydrate and Disodium Pentaborate Decahydrate Are Candidates as Anti-leukemic Drug Components by Inducing Apoptosis and Changing Bax/Bcl-2 Ratio in HL-60 Cell Line. Borax pentahydrate 0-18 BCL2 apoptosis regulator Homo sapiens 143-148 34250023-11 2021 Furthermore, Propofol treatment elevated Bcl-2/Bax ratio and lowered Caspase-3 expression. Propofol 13-21 BCL2 apoptosis regulator Homo sapiens 41-46 34184213-0 2022 Borax Pentahydrate and Disodium Pentaborate Decahydrate Are Candidates as Anti-leukemic Drug Components by Inducing Apoptosis and Changing Bax/Bcl-2 Ratio in HL-60 Cell Line. sodium pentaborate 23-55 BCL2 apoptosis regulator Homo sapiens 143-148 34184213-12 2022 Although BP showed greater apoptosis-inducing capacity, we observed that both DPD (6 mM) and BP (24 mM) treatment showed anti-leukemic effect by triggering apoptotic pathway through increasing Bax/Bcl-2 ratio for the first time. Benzo(a)pyrene 9-11 BCL2 apoptosis regulator Homo sapiens 197-202 34184213-12 2022 Although BP showed greater apoptosis-inducing capacity, we observed that both DPD (6 mM) and BP (24 mM) treatment showed anti-leukemic effect by triggering apoptotic pathway through increasing Bax/Bcl-2 ratio for the first time. Benzo(a)pyrene 93-95 BCL2 apoptosis regulator Homo sapiens 197-202 34248622-5 2021 Treatment with BZBS reduced lipid deposition by reducing the numbers of CD68+ and CD3+ cells, the level of ICAM-1 and VCAM-1, and the ratio of cleaved caspase-3/caspase-3, and increasing the ratio of Bcl2/Bax as compared with the control group. bzbs 15-19 BCL2 apoptosis regulator Homo sapiens 200-204 34238736-8 2021 Treatment with DTS below 30 mumol/L concentrationdependently promoted apoptosis (P < 0.01) and lowered the MMP (P < 0.01) of HN30 cells, and after treatment for 24 h, the cells showed significantly increased cleaved caspase-3 (P < 0.01) and decreased Bcl-2 expression (P < 0.01). dibenzyl trisulfide 15-18 BCL2 apoptosis regulator Homo sapiens 251-256 34168229-12 2021 Moreover, radotinib decreased the expression of Bcl-2 and Bcl-xL, and increased the expression of Bax and Bak in MM cells. 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 10-19 BCL2 apoptosis regulator Homo sapiens 48-53 34205602-5 2021 Moreover, sildenafil has been reported to increase the sensitivity of tumor cells of different origins to the cytotoxic effect of chemotherapeutic agents with augmented apoptosis mediated through inducing the downregulation of Bcl-xL and FAP-1 expression, enhancing reactive oxygen species (ROS) generation, phosphorylating BAD and Bcl-2, upregulating caspase-3,8,9 activities, and blocking cells at G0/G1 cell cycle phase. Sildenafil Citrate 10-20 BCL2 apoptosis regulator Homo sapiens 332-337 34234678-11 2021 The combination treatment with CM and ponesimod reduced the expression of caspase-3, caspase-8, Bax, and Annexin V proteins and increased the relative BCL-2/Bax ratio, indicating inhibition of apoptosis as a possible mechanism of action. ponesimod 38-47 BCL2 apoptosis regulator Homo sapiens 151-156 34238751-7 2021 Fucoxanthin dose-dependently decreased ATP level and the total antioxidant capacity of PC-3 cells, increased the contents of H2O2, MDA and superoxide (all P < 0.05), enhanced the protein expressions of Bax and cytochrome c in the cytoplasm, and lowered the protein expressions of Bcl-2 and cytochromes in the mitochondria (P < 0.05). fucoxanthin 0-11 BCL2 apoptosis regulator Homo sapiens 280-285 34205237-7 2021 Furthermore, physiological burst stimulation led to an elevated peak in intracellular calcium and an increase in the expression level of classical activity-dependent targets but also decreased Bax/BCL-2 expression ratio and reduced caspase 3/7 activity. Calcium 86-93 BCL2 apoptosis regulator Homo sapiens 197-202 34195018-16 2021 The expression of apoptosis regulatory genes assessed by PCR revealed an upregulation of p53 by ME, accompanied by downregulation of Bcl-2 and high expression of Bax after treatment with curcumin. Curcumin 187-195 BCL2 apoptosis regulator Homo sapiens 133-138 34150534-6 2021 RESULTS: Under high glucose conditions, the viability of ARPE-19 was decreased, and the apoptosis rate increased, the protein expressions of Bax, Caspase-3, and LC3-II/LC3-I were all increased and the expressions of Bcl-2, p62 and p-mTOR decreased, and autophagic flux was increased compared with that of the controls. Glucose 20-27 BCL2 apoptosis regulator Homo sapiens 216-221 34096286-6 2021 Changes in the expression of apoptosis-associated proteins (Bcl2, Bax, and cytochrome c) and intracellular reactive oxygen species levels showed that isorhamnetin inhibited GC apoptosis. 3-methylquercetin 150-162 BCL2 apoptosis regulator Homo sapiens 60-64 34132104-4 2021 Results: TQ and TQ + DOX increased Bax levels in HCT116 cells and decreased Bcl2 levels in MDA-MB-231-Luc cells. Doxorubicin 21-24 BCL2 apoptosis regulator Homo sapiens 76-80 34120620-9 2021 DOX combined with SM can enhance the anti-tumor effect, and induce apoptosis of lymphoma cells and inhibit the expression of inflammatory factors related to tumorigenesis depending on the regulation of Bcl-2 family-mediated mitochondrial pathways, such as TNF-alpha and IL-1beta. Doxorubicin 0-3 BCL2 apoptosis regulator Homo sapiens 202-207 34120620-9 2021 DOX combined with SM can enhance the anti-tumor effect, and induce apoptosis of lymphoma cells and inhibit the expression of inflammatory factors related to tumorigenesis depending on the regulation of Bcl-2 family-mediated mitochondrial pathways, such as TNF-alpha and IL-1beta. Samarium 18-20 BCL2 apoptosis regulator Homo sapiens 202-207 34204834-4 2021 In FaDu cells, combined CisPt + RSV treatment induced an increase in apoptosis, which was associated with an increase in c-MYC and TP53 and a decrease in BCL-2 expression. Resveratrol 32-35 BCL2 apoptosis regulator Homo sapiens 154-159 34204834-4 2021 In FaDu cells, combined CisPt + RSV treatment induced an increase in apoptosis, which was associated with an increase in c-MYC and TP53 and a decrease in BCL-2 expression. Cisplatin 24-29 BCL2 apoptosis regulator Homo sapiens 154-159 34204834-5 2021 While CisPt + RSV treatment induced apoptosis in PE/CA-PJ49 cells by inhibition of BCL-2 associated with high levels of MDM-2 and subsequently led to inhibition of TP53 gene expression. Cisplatin 6-11 BCL2 apoptosis regulator Homo sapiens 83-88 34204834-5 2021 While CisPt + RSV treatment induced apoptosis in PE/CA-PJ49 cells by inhibition of BCL-2 associated with high levels of MDM-2 and subsequently led to inhibition of TP53 gene expression. Resveratrol 14-17 BCL2 apoptosis regulator Homo sapiens 83-88 34110565-0 2022 Silica Nanoparticles Induce Hepatotoxicity by Triggering Oxidative Damage, Apoptosis, and Bax-Bcl2 Signaling Pathway. Silicon Dioxide 0-6 BCL2 apoptosis regulator Homo sapiens 94-98 34306367-0 2021 CHOP overexpression sensitizes human non-small cell lung cancer cells to cisplatin treatment by Bcl-2/JNK pathway. Cisplatin 73-82 BCL2 apoptosis regulator Homo sapiens 96-101 34306367-7 2021 CHOP increased the therapeutic effect of cisplatin on NSCLC cells through the Bcl-2/JNK pathway. Cisplatin 41-50 BCL2 apoptosis regulator Homo sapiens 78-83 34306367-8 2021 In summary, CHOP regulated cisplatin resistance in cells of NSCLC by promoting the expression of apoptotic proteins and inhibiting the Bcl-2/JNK signaling pathway, indicating the antitumor effects of CHOP. Cisplatin 27-36 BCL2 apoptosis regulator Homo sapiens 135-140 34112754-9 2021 Synergistic activity was demonstrated when fadraciclib was combined with the BCL-2 inhibitor venetoclax, or the conventional chemotherapy agents, cytarabine, or azacitidine, with the combination of fadraciclib and azacitidine having the most favorable therapeutic window. CYC065 43-54 BCL2 apoptosis regulator Homo sapiens 77-82 34102995-12 2022 Further apoptotic studies revealed that the upregulation of pro-apoptotic Bax, downregulation of anti-apoptotic Bcl-2 and elevation of Bax/Bcl-2 ratio were found in MDA-MB-231 cells treated with zebularine and MCF-7 cells treated with all drug regimens. pyrimidin-2-one beta-ribofuranoside 195-205 BCL2 apoptosis regulator Homo sapiens 112-117 34112754-9 2021 Synergistic activity was demonstrated when fadraciclib was combined with the BCL-2 inhibitor venetoclax, or the conventional chemotherapy agents, cytarabine, or azacitidine, with the combination of fadraciclib and azacitidine having the most favorable therapeutic window. venetoclax 93-103 BCL2 apoptosis regulator Homo sapiens 77-82 34102995-12 2022 Further apoptotic studies revealed that the upregulation of pro-apoptotic Bax, downregulation of anti-apoptotic Bcl-2 and elevation of Bax/Bcl-2 ratio were found in MDA-MB-231 cells treated with zebularine and MCF-7 cells treated with all drug regimens. pyrimidin-2-one beta-ribofuranoside 195-205 BCL2 apoptosis regulator Homo sapiens 139-144 34277781-11 2021 The experiment shows that ROPPIP can up-regulate the expression levels of MMP2, Ki67, and Bcl2 in HTR-8/Svneo cells, down-regulate the expression of caspase-3, promote the proliferation and migration of HTR-8/Svneo cells and inhibit the apoptosis induced by cisplatin, the activation of the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway may be associated with the function of ROPPIP. roppip 26-32 BCL2 apoptosis regulator Homo sapiens 90-94 34089613-8 2022 Gem + HY inhibits the expression of Bcl-2 but stimulates Bax level, triggering caspase activation and PARP cleavage and thus promoted apoptosis of Capan-2 cells. gemcitabine 0-3 BCL2 apoptosis regulator Homo sapiens 36-41 34089613-8 2022 Gem + HY inhibits the expression of Bcl-2 but stimulates Bax level, triggering caspase activation and PARP cleavage and thus promoted apoptosis of Capan-2 cells. hypericin 6-8 BCL2 apoptosis regulator Homo sapiens 36-41 34083287-9 2021 Pemetrexed decreased Bcl-2 expression, while Bax expression was increased, and cytochrome c was released. Pemetrexed 0-10 BCL2 apoptosis regulator Homo sapiens 21-26 34188682-13 2021 bcl-2 (protein) and p53 significantly correlated with Luminal B and TNBC (p < 0.01). Phenobarbital 54-61 BCL2 apoptosis regulator Homo sapiens 0-5 34277781-11 2021 The experiment shows that ROPPIP can up-regulate the expression levels of MMP2, Ki67, and Bcl2 in HTR-8/Svneo cells, down-regulate the expression of caspase-3, promote the proliferation and migration of HTR-8/Svneo cells and inhibit the apoptosis induced by cisplatin, the activation of the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway may be associated with the function of ROPPIP. Cisplatin 258-267 BCL2 apoptosis regulator Homo sapiens 90-94 34277781-11 2021 The experiment shows that ROPPIP can up-regulate the expression levels of MMP2, Ki67, and Bcl2 in HTR-8/Svneo cells, down-regulate the expression of caspase-3, promote the proliferation and migration of HTR-8/Svneo cells and inhibit the apoptosis induced by cisplatin, the activation of the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway may be associated with the function of ROPPIP. roppip 441-447 BCL2 apoptosis regulator Homo sapiens 90-94 34254227-0 2021 The effects of the esterified Quercetin with omega3 and omega6 fatty acids on viability, nanomechanical properties, and BAX/BCL-2 gene expression in MCF-7 cells. Quercetin 30-39 BCL2 apoptosis regulator Homo sapiens 124-129 34206129-12 2021 Fotemustine and dexamethasone administration had anti-apoptotic activity, restoring the impaired mechanism (TUNEL assay and Western blot analysis of Bax and Bcl-2). fotemustine 0-11 BCL2 apoptosis regulator Homo sapiens 157-162 34206129-12 2021 Fotemustine and dexamethasone administration had anti-apoptotic activity, restoring the impaired mechanism (TUNEL assay and Western blot analysis of Bax and Bcl-2). Dexamethasone 16-29 BCL2 apoptosis regulator Homo sapiens 157-162 34156605-5 2021 Myricitrin treatment reduced the mitochondrial membrane potential (22.95%), increased DNA fragmentation (90.4%), inhibited the cell survival proteins (RAS, B-RAF, & BCL-2) and also induced pro-apoptotic proteins (p38, pro-caspase-3, pro-caspase-9 and caspase-3) in the HL-60 cells. myricitrin 0-10 BCL2 apoptosis regulator Homo sapiens 165-170 34254227-1 2021 Quercetin is one of the major flavonoids and it appears to have cytotoxic effects on various cancer cells through regulating the apoptosis pathway genes such as BAX and BCL2. Quercetin 0-9 BCL2 apoptosis regulator Homo sapiens 169-173 34060446-9 2021 After BAY11-7082 treatment alone, Bcl2, BAX, c-caspase-3, NF-kappaB p65 protein expression trend was consistent with that of the 300 mmol/L BET treated group, and Bcl2, NF-kappaB p65 protein expression levels were lower and BAX and c-caspase-3 protein expression levels were higher in BET combined with BAY11-7082 treated group. 3-(4-methylphenylsulfonyl)-2-propenenitrile 303-313 BCL2 apoptosis regulator Homo sapiens 34-38 34078517-3 2021 High concentration of metformin promoted osteoclast apoptosis and upregulated the expression of Bax/Bcl-2 and caspase-3; BV/TV, BS/TV, Tb.N and BMD were increased while Tp.Sp decreased in the group of intraperitoneal metformin+femoral intramedullary osteoclast injection (Met+OC) compared with the control group, 1 nM metformin downregulated Akt, p44/42 MAPK, JNK, p38 MAPK phosphorylation, 5 nM metformin down regulated ERK and Akt phosphorylation. Metformin 22-31 BCL2 apoptosis regulator Homo sapiens 100-105 34078517-3 2021 High concentration of metformin promoted osteoclast apoptosis and upregulated the expression of Bax/Bcl-2 and caspase-3; BV/TV, BS/TV, Tb.N and BMD were increased while Tp.Sp decreased in the group of intraperitoneal metformin+femoral intramedullary osteoclast injection (Met+OC) compared with the control group, 1 nM metformin downregulated Akt, p44/42 MAPK, JNK, p38 MAPK phosphorylation, 5 nM metformin down regulated ERK and Akt phosphorylation. Metformin 217-226 BCL2 apoptosis regulator Homo sapiens 100-105 34078517-3 2021 High concentration of metformin promoted osteoclast apoptosis and upregulated the expression of Bax/Bcl-2 and caspase-3; BV/TV, BS/TV, Tb.N and BMD were increased while Tp.Sp decreased in the group of intraperitoneal metformin+femoral intramedullary osteoclast injection (Met+OC) compared with the control group, 1 nM metformin downregulated Akt, p44/42 MAPK, JNK, p38 MAPK phosphorylation, 5 nM metformin down regulated ERK and Akt phosphorylation. Metformin 318-327 BCL2 apoptosis regulator Homo sapiens 100-105 34060394-5 2022 Moreover, this agent induced ROS-mediated apoptosis by altering the expression of Bax, Bim, Caspase3, Bcl2, and XIAP. ros 29-32 BCL2 apoptosis regulator Homo sapiens 102-106 34060446-9 2021 After BAY11-7082 treatment alone, Bcl2, BAX, c-caspase-3, NF-kappaB p65 protein expression trend was consistent with that of the 300 mmol/L BET treated group, and Bcl2, NF-kappaB p65 protein expression levels were lower and BAX and c-caspase-3 protein expression levels were higher in BET combined with BAY11-7082 treated group. 3-(4-methylphenylsulfonyl)-2-propenenitrile 303-313 BCL2 apoptosis regulator Homo sapiens 163-167 34070493-5 2021 The application of 5-ALA led to a significant increase in apoptotic cells, enhancement of Bax and p53 expressions, reduction in Bcl-2 expression, and an increase in ROS generation. 5-amino levulinic acid 19-24 BCL2 apoptosis regulator Homo sapiens 128-133 34071132-12 2021 Immunohistochemical analysis was used to measure protein expression of tumors and results showed that DMC treatment led to lightly staining with anti-Bcl-2 and -XIAP and 60 mg/kg treatment of DMC has lighter staining with anti-Bcl-2 and -XIAP than that of 30 mg/kg. demethoxycurcumin 102-105 BCL2 apoptosis regulator Homo sapiens 150-155 34071132-12 2021 Immunohistochemical analysis was used to measure protein expression of tumors and results showed that DMC treatment led to lightly staining with anti-Bcl-2 and -XIAP and 60 mg/kg treatment of DMC has lighter staining with anti-Bcl-2 and -XIAP than that of 30 mg/kg. demethoxycurcumin 192-195 BCL2 apoptosis regulator Homo sapiens 227-232 34073780-10 2021 The enhanced cytotoxic and anti-proliferative effect of RLX-EMLs relative to raw drug was authenticated through increased Bax/Bcl-2 ratio, caspase-9 activation and depletion of mitochondrial membrane potential. Raloxifene Hydrochloride 56-59 BCL2 apoptosis regulator Homo sapiens 126-131 34064109-4 2021 Inhibition of apigenin-induced reactive oxygen species (ROS) generation by a ROS scavenger N-acetyl-L-cysteine blocked the lipid raft membrane localization and activation of ASM and formation of ceramide-enriched lipid raft membranes, returned PI3K-Akt-GTP-Rac1-modulated CDK1-cyclin B1 activity, and subsequently restored the BCL-2/BCL-xL-regulated ER-mitochondrial bioenergetic activity. Apigenin 14-22 BCL2 apoptosis regulator Homo sapiens 327-332 34063867-7 2021 Finally, we demonstrated the synergistic cytotoxic effect of EE-84 with a BH3 mimetic, the Mcl-1 inhibitor A-1210477, against imatinib-sensitive and resistant K562 cells, highlighting the inhibition of antiapoptotic Bcl-2 proteins as a promising novel senolytic approach against chronic myeloid leukemia. ee-84 61-66 BCL2 apoptosis regulator Homo sapiens 216-221 34064109-4 2021 Inhibition of apigenin-induced reactive oxygen species (ROS) generation by a ROS scavenger N-acetyl-L-cysteine blocked the lipid raft membrane localization and activation of ASM and formation of ceramide-enriched lipid raft membranes, returned PI3K-Akt-GTP-Rac1-modulated CDK1-cyclin B1 activity, and subsequently restored the BCL-2/BCL-xL-regulated ER-mitochondrial bioenergetic activity. Reactive Oxygen Species 56-59 BCL2 apoptosis regulator Homo sapiens 327-332 34064109-4 2021 Inhibition of apigenin-induced reactive oxygen species (ROS) generation by a ROS scavenger N-acetyl-L-cysteine blocked the lipid raft membrane localization and activation of ASM and formation of ceramide-enriched lipid raft membranes, returned PI3K-Akt-GTP-Rac1-modulated CDK1-cyclin B1 activity, and subsequently restored the BCL-2/BCL-xL-regulated ER-mitochondrial bioenergetic activity. Acetylcysteine 91-110 BCL2 apoptosis regulator Homo sapiens 327-332 34065546-5 2021 The overexpression of Bcl-2 or Bcl-xL blocks edelfosine-induced apoptosis. edelfosine 45-55 BCL2 apoptosis regulator Homo sapiens 22-27 34093648-8 2021 Functionally, both blocking circ_0136474 and upregulating miR-766-3p could rescue cell viability and levels of PCNA, Bcl-2, reduced glutathione (GSH), and total superoxide dismutase (SOD), and attenuate apoptosis rate and levels of Bax, reactive oxygen species (ROS), and lipid peroxidation malondialdehyde (MDA). mir-766 58-65 BCL2 apoptosis regulator Homo sapiens 117-122 34141087-2 2021 Here, we describe the synthesis and identification of a new class of palmitoylated peptide BH3 analogues derived from the core region (h1-h4) of BH3 domains of proapoptotic Bcl-2 proteins and as alternative PTP1B inhibitors with antidiabetic potency in vitro and in vivo. peptide bh3 83-94 BCL2 apoptosis regulator Homo sapiens 173-178 34134955-5 2021 OBJECTIVE: Curcumol at 10, 20, 40, 80 and 160 mg/L all reduced the protein expressions of cyclin D1, PCNA and Bcl-2, inhibited the expressions of fibrotic marker proteins Col1A1, Col3A1 and alpha-SMA, decreased the levels of ERK signaling pathway proteins p-ERK1/2, p-MEK and p-c-Raf, and increased the expressions of Bax and cleaved caspase-3 proteins (P < 0.05). curcumol 11-19 BCL2 apoptosis regulator Homo sapiens 110-115 34134960-6 2021 The results of Western blotting showed that curcumin also concentration-dependently increased the cellular expressions of caspase-3, caspase-9 and Bax and lowered the expressions of Bcl-2, cyclin B1, CDK1 and beta-catenin along with the downstream proteins cyclin D1 and c-myc in the Wnt/beta-catenin signaling pathway (P < 0.05). Curcumin 44-52 BCL2 apoptosis regulator Homo sapiens 182-187 34134962-11 2021 The nanoparticles significantly increased the intracellular expression level of miR-16 (P < 0.001) and decreased the expression of Bcl-2 and Chk-1 proteins in ovarian cancer cells, thus enabling miR-16 to promote apoptosis and enhance cisplatin sensitivity of the cells. Cisplatin 235-244 BCL2 apoptosis regulator Homo sapiens 131-136 34149993-8 2021 The mAb against MOR also enhanced the cisplatin-induced apoptosis of HCC cells by downregulating p-ERK, Bcl-2 and upregulating Bax. Cisplatin 38-47 BCL2 apoptosis regulator Homo sapiens 104-109 34141086-3 2021 This molecule contains structural elements of selective BCL-XL inhibitor A-1155463 and the dual BCL-XL/BCL-2 inhibitors ABT-737 and navitoclax, while representing a distinct pharmacophore as assessed by an objective cheminformatic evaluation. ABT-737 120-127 BCL2 apoptosis regulator Homo sapiens 103-108 34150114-7 2021 The Bax and Bcl-2 levels in the quercetin intervention group showed a tendency to increase progressively in comparison with the blank control group, and Cyclin D1 showed a tendency to decrease progressively (P<0.05). Quercetin 32-41 BCL2 apoptosis regulator Homo sapiens 12-17 34602402-5 2021 The docetaxel with radiation group obtained a higher expression of p21 and bax protein than the docetaxel group and the radiation group (P<0.05), and a higher ratio of bcl-2/bax than the others (P<0.05). Docetaxel 4-13 BCL2 apoptosis regulator Homo sapiens 168-173 34093999-8 2021 More significantly, PAMAMs induce substantial cell apoptosis, accompanied by the up-regulation of apoptotic markers (Bax, Caspases-3, 8 and 9) in addition to down-regulation of Bcl-2. pamams 20-26 BCL2 apoptosis regulator Homo sapiens 177-182 34063233-0 2021 The Impact of Chlorambucil and Valproic Acid on Cell Viability, Apoptosis and Expression of p21, HDM2, BCL2 and MCL1 Genes in Chronic Lymphocytic Leukemia. Valproic Acid 31-44 BCL2 apoptosis regulator Homo sapiens 103-107 34063233-6 2021 At the same time, the cultures under CLB treatment showed visibly higher expression of BCL2 than the cultures with VPA alone. Chlorambucil 37-40 BCL2 apoptosis regulator Homo sapiens 87-91 34063233-6 2021 At the same time, the cultures under CLB treatment showed visibly higher expression of BCL2 than the cultures with VPA alone. Valproic Acid 115-118 BCL2 apoptosis regulator Homo sapiens 87-91 34602402-5 2021 The docetaxel with radiation group obtained a higher expression of p21 and bax protein than the docetaxel group and the radiation group (P<0.05), and a higher ratio of bcl-2/bax than the others (P<0.05). Docetaxel 96-105 BCL2 apoptosis regulator Homo sapiens 168-173 34602402-7 2021 p21, bax, bcl-2 and other related proteins can regulate cell cycle phase distribution and induce cell apoptosis, thereby increasing the radiosensitivity effect of docetaxel in ECA109 cell line. Docetaxel 163-172 BCL2 apoptosis regulator Homo sapiens 10-15 34093801-9 2021 Lastly, we found that decreased COX-2 protein level affected PGE2 production, leading to lower Bcl-2, Caspase-3, MMP2 and MMP9 expression but higher Bax and E-cadherin expression, which in turn culminated in higher rates of cell death and lower rates of cell migration. Dinoprostone 61-65 BCL2 apoptosis regulator Homo sapiens 95-100 34093803-8 2021 In addition, the expressions of Cyclin B1, Cyclin D1, Bcl-2, PARP1 and Survivin were decreased after starch demethylation. Starch 101-107 BCL2 apoptosis regulator Homo sapiens 54-59 34063628-5 2021 Interestingly, pretreatment with jorunnamycin A at 0.5 muM for 24 h considerably sensitized lung CSCs to cisplatin-induced apoptosis, as evidenced by upregulated p53 and decreased Bcl-2 in jorunnamycin A-pretreated CSC-enriched spheroids. jorunnamycin A 33-47 BCL2 apoptosis regulator Homo sapiens 180-185 34063628-5 2021 Interestingly, pretreatment with jorunnamycin A at 0.5 muM for 24 h considerably sensitized lung CSCs to cisplatin-induced apoptosis, as evidenced by upregulated p53 and decreased Bcl-2 in jorunnamycin A-pretreated CSC-enriched spheroids. Cisplatin 105-114 BCL2 apoptosis regulator Homo sapiens 180-185 34183962-10 2021 Piperine (20 muM) and cisplatin (5 muM) for 24 h induce apoptosis strongly through reduction of Bcl-2 and increase of caspase 3, p53, caspase 9, and Bax. piperine 0-8 BCL2 apoptosis regulator Homo sapiens 96-101 34183962-10 2021 Piperine (20 muM) and cisplatin (5 muM) for 24 h induce apoptosis strongly through reduction of Bcl-2 and increase of caspase 3, p53, caspase 9, and Bax. Cisplatin 22-31 BCL2 apoptosis regulator Homo sapiens 96-101 34136985-7 2021 Esmolol was found to be the most ineffective blocker and the increases in Bcl-2 protein levels were appeared to be effective in resistance to this drug. esmolol 0-7 BCL2 apoptosis regulator Homo sapiens 74-79 34234893-5 2021 In addition, BA induced the cytosolic release of cytochrome c by reducing the mitochondrial membrane potential with an increasing Bax/Bcl-2 expression ratio. betulinic acid 13-15 BCL2 apoptosis regulator Homo sapiens 134-139 34306264-8 2021 Further, the percentages of apoptotic MGC-803 and BGC823 cells increased in a concentration-dependent manner, and the expression of apoptosis regulator Bax increased, whereas that of Bcl-2 decreased in response to 8-NICD treatment. 8-nicd 214-220 BCL2 apoptosis regulator Homo sapiens 183-188 34141150-6 2021 Ursolic acid treatment downregulated the gene expression of survival factors BCL-2, SURVIVIN, NFKB and SP1, while upregulated the growth-restricting genes BAX, P21 and P53. ursolic acid 0-12 BCL2 apoptosis regulator Homo sapiens 77-82 34076978-3 2021 Apoptosis changes influenced by nuclear paraspeckle assembly transcript 1 (NEAT1)/miR-335/c-Met axis after sorafenib treatment in lung cancer cells were examined by detecting apoptotic rate, as well as relative levels of Bcl-2 and Bax. Sorafenib 107-116 BCL2 apoptosis regulator Homo sapiens 221-226 34151288-4 2021 Dasatinib-sensitive T-ALLs exhibited high BCL-XL and low BCL2 activity and venetoclax resistance. Dasatinib 0-9 BCL2 apoptosis regulator Homo sapiens 57-61 34907714-10 2021 After 48 h treatment, EACE increased the pro-apoptotic BAX and decreased the anti-apoptotic Bcl-2, Survivin and c-Myc gene expressions. eace 22-26 BCL2 apoptosis regulator Homo sapiens 92-97 34077029-9 2021 Western blot showed that flavokawain-B resulted in downregulation of Bcl-2 and upregulation of Bax in a dose dependent manner. flavokawain B 25-38 BCL2 apoptosis regulator Homo sapiens 69-74 34151288-5 2021 Discordant sensitivity of T-ALL to dasatinib and venetoclax is strongly correlated with T-cell differentiation, particularly with the dynamic shift in LCK vs. BCL2 activation. Dasatinib 35-44 BCL2 apoptosis regulator Homo sapiens 159-163 34078815-9 2021 In human renal proximal tubular cells, cisplatin induced cell apoptosis by activating pro-apoptotic proteins (ERK1/2 and caspase 3), and reducing the anti-apoptotic protein (Bcl-2). Cisplatin 39-48 BCL2 apoptosis regulator Homo sapiens 174-179 34077030-12 2021 Additionally, Heptaphylline caused increase in Bax and decrease in Bcl-2 expression. heptaphylline 14-27 BCL2 apoptosis regulator Homo sapiens 67-72 34077031-9 2021 The anticancer effects of Withaferin-A were mainly due to the induction of apoptosis which was linked with upsurge of Bax and depletion of BCl-2. withaferin A 26-38 BCL2 apoptosis regulator Homo sapiens 139-144 34528583-1 2021 AIM: This study was aimed at determining Bcl-2 and Bax proteins expression before and after reconstructive-repairing operations in patients with atherosclerosis obliterans of lower extremities and at assessing the effect of an antioxidant (vitamin E at a dose of 100 mg once daily for 1 month after surgery) on the dynamics of changes of Bcl-2 and Bax proteins in the postoperative period. Vitamin E 240-249 BCL2 apoptosis regulator Homo sapiens 338-343 34528583-14 2021 On the background of using vitamin E at a dose of 100 mg once daily for 1 month, there was a decrease in level of the Bax propapoptotic protein (p=0.003) and an increase in level of the anti-apoptotic Bcl-2 protein level (p=0.0007). Vitamin E 27-36 BCL2 apoptosis regulator Homo sapiens 201-206 34218775-7 2021 In addition, Chidamide blocked cells in the G0/G1 phase via downregulating cyclin-dependent kinase 4, and induced apoptosis via upregulating Bax and downregulating of Bcl-2. N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 13-22 BCL2 apoptosis regulator Homo sapiens 167-172 34193693-9 2021 In addition, pyoluteorin induced autophagy through c-Jun N-terminal kinase/B-cell lymphoma-2 (JNK/Bcl-2) signal pathway. pyoluteorin 13-24 BCL2 apoptosis regulator Homo sapiens 98-103 34193693-10 2021 Blocking JNK/Bcl-2 pathway significantly attenuated pyoluteorin-induced autophagy. pyoluteorin 52-63 BCL2 apoptosis regulator Homo sapiens 13-18 34853271-8 2021 TEL induced cell death in a dose-dependent manner and increased the percentage of cells with high chromatin condensation and Bax/Bcl-2 ratio in both cell lines. Telmisartan 0-3 BCL2 apoptosis regulator Homo sapiens 129-134 34223631-10 2021 Cells treated with BEZ235 exhibited downregulation of Bcl-2 and upregulation of Bax. dactolisib 19-25 BCL2 apoptosis regulator Homo sapiens 54-59 34352784-0 2021 Astragalus Polysaccharide Regulates miR-182/Bcl-2 Axis to Relieve Metabolic Memory through Suppressing Mitochondrial Damage-Mediated Apoptosis in Retinal Pigment Epithelial Cells. Polysaccharides 11-25 BCL2 apoptosis regulator Homo sapiens 44-49 34273265-7 2021 Platycodin D also increased caspase-9, caspase-8, caspase-3, and p53 expression and decreased Bcl-2 expression in tumour tissues. platycodin D 0-12 BCL2 apoptosis regulator Homo sapiens 94-99 34326967-11 2021 Endothelial cell apoptosis was decreased by the reduction of pro-apoptotic factor Bax and increase of Bcl-2 following the incubation with resveratrol (P < 0.05). Resveratrol 138-149 BCL2 apoptosis regulator Homo sapiens 102-107 34352784-8 2021 RESULTS: Treatment with high glucose followed by normal glucose significantly upregulated the expression of miR-182 and downregulated the expression of its target Bcl-2, and APS treatment reversed the above effects. Glucose 29-36 BCL2 apoptosis regulator Homo sapiens 163-168 34352784-8 2021 RESULTS: Treatment with high glucose followed by normal glucose significantly upregulated the expression of miR-182 and downregulated the expression of its target Bcl-2, and APS treatment reversed the above effects. Glucose 56-63 BCL2 apoptosis regulator Homo sapiens 163-168 34352784-11 2021 CONCLUSION: APS alleviated mitochondrial damage and apoptosis induced by metabolic memory by regulating the miR-182/Bcl-2 axis, which might serve as a new strategy for the treatment of diabetic retinopathy. aps 12-15 BCL2 apoptosis regulator Homo sapiens 116-121 34976246-11 2021 Conclusions: Colicin E7 decreased the expression of bcl2 and increased P53. colicin e7 13-23 BCL2 apoptosis regulator Homo sapiens 52-56 34520298-0 2021 miR-342-3p Regulates the Proliferation and Apoptosis of NSCLC Cells by Targeting BCL-2. mir-342-3p 0-10 BCL2 apoptosis regulator Homo sapiens 81-86 34109916-9 2021 Pseudo-G-Rh2 was observed to significantly increase the expressions of BAX, cleaved-caspase-3, and cleaved-caspase-9, while it decreased the Bcl-2 expression. 3-O-glucopyranosyl-3,12,25-trihydroxydammar-20(22)-ene 0-12 BCL2 apoptosis regulator Homo sapiens 141-146 34522245-11 2021 After cisplatin treatment, down-regulation of BANCR could consequently attenuate TU686-DDP-R and TU177-DDP-R cell proliferation, and the expression of MRP1, Bcl-2, and p-PKB was decreased and Bax was increased. Cisplatin 6-15 BCL2 apoptosis regulator Homo sapiens 157-162 35512494-0 2022 Discovery and structure-activity relationship studies of novel Bcl-2/Mcl-1 dual inhibitors with indole scaffold. indole 96-102 BCL2 apoptosis regulator Homo sapiens 63-68 35569198-5 2022 2a and 2b not only stabilize the G-quadruplex structure but also induce the G-rich sequences (bcl-2, HRCC and KSS) to fold into the mixed-type G-quadruplex in Na+/K+ free Tris-HCl buffer at pH 7.0, and 2b presents the higher stabilization to G-quadruplex than 2a by a FRET-melting assay. Tris hydrochloride 171-179 BCL2 apoptosis regulator Homo sapiens 94-99 35512494-2 2022 We identified novel Bcl-2/Mcl-1 dual inhibitors with indole scaffold by the optimization of hit 1. indole 53-59 BCL2 apoptosis regulator Homo sapiens 20-25 35636179-12 2022 PGG induced apoptosis and autophagy in NPC cells and elevated the Bax/Bcl-2 ratio and the protein levels of LC3B. pentagalloylglucose 0-3 BCL2 apoptosis regulator Homo sapiens 70-75 35487445-6 2022 Phthalates changed methylation pattern of the tested genes, decreased expression of P16 and TP53 genes and increased the expression of BCL2 and CCND1. phthalic acid 0-10 BCL2 apoptosis regulator Homo sapiens 135-139 35551953-0 2022 Free fatty acid-induced miR-181a-5p stimulates apoptosis by targeting XIAP and Bcl2 in hepatic cells. Fatty Acids, Nonesterified 0-15 BCL2 apoptosis regulator Homo sapiens 79-83 35500680-9 2022 Low concentrations of 4 mug/ml cisplatin and 2.8 mug/ml sunitinib showed significant Bcl-2 down-regulation and Bax up-regulation. Cisplatin 31-40 BCL2 apoptosis regulator Homo sapiens 85-90 35500680-9 2022 Low concentrations of 4 mug/ml cisplatin and 2.8 mug/ml sunitinib showed significant Bcl-2 down-regulation and Bax up-regulation. Sunitinib 56-65 BCL2 apoptosis regulator Homo sapiens 85-90 35551953-3 2022 In this study, we showed that free fatty acids stimulate apoptosis by upregulating miR-181a-5p expression, which in turn targets XIAP and Bcl2. Fatty Acids, Nonesterified 30-46 BCL2 apoptosis regulator Homo sapiens 138-142 35421577-0 2022 New synthetic phenylquinazoline derivatives induce apoptosis by targeting the pro-survival members of the BCL-2 family. 2-PHENYLQUINAZOLINE 14-31 BCL2 apoptosis regulator Homo sapiens 106-111 35421577-5 2022 Furthermore, when MCF-7-CR cells were treated with SMS-IV-20 and SMS-IV-40 in the presence of ABT-737, a BCL-XL and BCL-2 inhibitor, enhanced chemo-sensitization was observed, suggesting SMS-IV-20 and SMS-IV-40 exert antagonistic activity to regulate the functional activity of BCL-2 and BCL-XL. sms-iv-20 51-60 BCL2 apoptosis regulator Homo sapiens 116-121 35421577-5 2022 Furthermore, when MCF-7-CR cells were treated with SMS-IV-20 and SMS-IV-40 in the presence of ABT-737, a BCL-XL and BCL-2 inhibitor, enhanced chemo-sensitization was observed, suggesting SMS-IV-20 and SMS-IV-40 exert antagonistic activity to regulate the functional activity of BCL-2 and BCL-XL. sms-iv-20 51-60 BCL2 apoptosis regulator Homo sapiens 278-283 35421577-5 2022 Furthermore, when MCF-7-CR cells were treated with SMS-IV-20 and SMS-IV-40 in the presence of ABT-737, a BCL-XL and BCL-2 inhibitor, enhanced chemo-sensitization was observed, suggesting SMS-IV-20 and SMS-IV-40 exert antagonistic activity to regulate the functional activity of BCL-2 and BCL-XL. sms-iv-40 65-74 BCL2 apoptosis regulator Homo sapiens 116-121 35421577-5 2022 Furthermore, when MCF-7-CR cells were treated with SMS-IV-20 and SMS-IV-40 in the presence of ABT-737, a BCL-XL and BCL-2 inhibitor, enhanced chemo-sensitization was observed, suggesting SMS-IV-20 and SMS-IV-40 exert antagonistic activity to regulate the functional activity of BCL-2 and BCL-XL. sms-iv-40 65-74 BCL2 apoptosis regulator Homo sapiens 278-283 35421577-5 2022 Furthermore, when MCF-7-CR cells were treated with SMS-IV-20 and SMS-IV-40 in the presence of ABT-737, a BCL-XL and BCL-2 inhibitor, enhanced chemo-sensitization was observed, suggesting SMS-IV-20 and SMS-IV-40 exert antagonistic activity to regulate the functional activity of BCL-2 and BCL-XL. ABT-737 94-101 BCL2 apoptosis regulator Homo sapiens 116-121 35421577-5 2022 Furthermore, when MCF-7-CR cells were treated with SMS-IV-20 and SMS-IV-40 in the presence of ABT-737, a BCL-XL and BCL-2 inhibitor, enhanced chemo-sensitization was observed, suggesting SMS-IV-20 and SMS-IV-40 exert antagonistic activity to regulate the functional activity of BCL-2 and BCL-XL. ABT-737 94-101 BCL2 apoptosis regulator Homo sapiens 278-283 35421577-5 2022 Furthermore, when MCF-7-CR cells were treated with SMS-IV-20 and SMS-IV-40 in the presence of ABT-737, a BCL-XL and BCL-2 inhibitor, enhanced chemo-sensitization was observed, suggesting SMS-IV-20 and SMS-IV-40 exert antagonistic activity to regulate the functional activity of BCL-2 and BCL-XL. sms-iv-20 187-196 BCL2 apoptosis regulator Homo sapiens 116-121 35405327-0 2022 Lipase-triggered drug release from BCL2 inhibitor ABT-199-loaded nanoparticles to elevate anti-leukemic activity through enhanced drug targeting on the mitochondrial membrane. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 50-53 BCL2 apoptosis regulator Homo sapiens 35-39 35561756-0 2022 BCL2 inhibitor ABT-199 and BCL2L1 inhibitor WEHI-539 coordinately promote NOXA-mediated degradation of MCL1 in human leukemia cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 15-18 BCL2 apoptosis regulator Homo sapiens 0-4 35561756-2 2022 Compared with their parental cells, U937/HQ cells were less sensitive to ABT-263 (BCL2/BCL2L1 inhibitor)/ABT-199 (BCL2 inhibitor) cytotoxicity. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 73-76 BCL2 apoptosis regulator Homo sapiens 82-86 35561756-2 2022 Compared with their parental cells, U937/HQ cells were less sensitive to ABT-263 (BCL2/BCL2L1 inhibitor)/ABT-199 (BCL2 inhibitor) cytotoxicity. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 105-108 BCL2 apoptosis regulator Homo sapiens 114-118 35176168-5 2022 WEE1 inhibitor AZD1775 reduced IKK/RELA phosphorylation and the expression of NF-kappaB-dependent pro-survival proteins Cyclin D1 and BCL2. adavosertib 15-22 BCL2 apoptosis regulator Homo sapiens 134-138 35405009-6 2022 Accordingly, treatment with CDK4/6 and BCL2 inhibitors sensitized PRRX2-expressing, castration-resistant tumors to enzalutamide. enzalutamide 115-127 BCL2 apoptosis regulator Homo sapiens 39-43 35405327-1 2022 Selective BCL2 inhibitor ABT-199 has been approved to treat hematological malignancies including acute myeloid leukemia (AML). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 25-28 BCL2 apoptosis regulator Homo sapiens 10-14 35366141-7 2022 The administration of Ki16425 triggered apoptosis by down-regulating the expression of Bcl2 and up-regulating p53, Bax, cleaved caspase-3, and Cyt c expression. 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid 22-29 BCL2 apoptosis regulator Homo sapiens 87-91 35431285-6 2022 LicB treatment not only decreased the levels of Bcl-2, p62, Caspase-3, and Ki67 protein in MG-63 and U2OS cell lines but also increased the levels of Cleaved Caspase-3, Beclin1, Bax, Atg7, and LC3B. licochalcone B 0-4 BCL2 apoptosis regulator Homo sapiens 48-53 35439536-7 2022 Besides, BPA significantly increased reactive oxygen species production, LDH leakage and apoptosis, with reduced cell viability and mitochondrial membrane potential, in both cell lines, whereas Z-YVAD-FMK and ICI182.780 significantly alleviated the induction of Bak1, Bax, Bcl-2 and caspase-3 proteins by BPA. bisphenol A 9-12 BCL2 apoptosis regulator Homo sapiens 273-278 35142421-7 2022 Moreover, the results demonstrated that the ERK inhibitor (PD98059) and TGF-beta1 inhibitor (LY364947) could inhibit the activation of the ERK signaling pathway, thereby reducing the mitochondrial membrane potential, the total apoptosis rate, and the expression of pro-apoptosis-related genes in the cells, while the expression of the antiapoptosis gene Bcl-2 was significantly increased (P < .05). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 59-66 BCL2 apoptosis regulator Homo sapiens 354-359 35439536-7 2022 Besides, BPA significantly increased reactive oxygen species production, LDH leakage and apoptosis, with reduced cell viability and mitochondrial membrane potential, in both cell lines, whereas Z-YVAD-FMK and ICI182.780 significantly alleviated the induction of Bak1, Bax, Bcl-2 and caspase-3 proteins by BPA. benzyloxycarbonyltyrosyl-valyl-alanyl-aspartic acid fluoromethyl ketone 194-204 BCL2 apoptosis regulator Homo sapiens 273-278 35421410-4 2022 Cell experiments demonstrated YL-11 EPS treatment up regulated the ratio of Bax/Bcl-2 and induced the decrease in mitochondrial membrane potential and improved the expression of cleaved caspases-3 and cleaved PARP proteins, and finally induced HT-29 cells apoptosis, suggesting the involvement of mitochondrial pathway. yl-11 30-35 BCL2 apoptosis regulator Homo sapiens 80-85 35421410-4 2022 Cell experiments demonstrated YL-11 EPS treatment up regulated the ratio of Bax/Bcl-2 and induced the decrease in mitochondrial membrane potential and improved the expression of cleaved caspases-3 and cleaved PARP proteins, and finally induced HT-29 cells apoptosis, suggesting the involvement of mitochondrial pathway. exophthalmos producing substance 36-39 BCL2 apoptosis regulator Homo sapiens 80-85 35620309-11 2022 In addition, treatment with amlodipine resulted in increased caspase-3/7 levels in MDA-MB-231 cells, which was accompanied by the downregulation of the anti-apoptotic protein, Bcl-2. Amlodipine 28-38 BCL2 apoptosis regulator Homo sapiens 176-181 35483142-4 2022 Secondly, citrinin inhibits proliferation and promotes apoptosis of L02 cells via disruption of mitochondria membrane potential, increase Bax/Bcl-2 ration, activation of caspase-3, 9, and enhance lactate dehydrogenase (LDH) release. Citrinin 10-18 BCL2 apoptosis regulator Homo sapiens 142-147 35266250-9 2022 The fucoxanthin effectively inhibited the PI3K/Akt/mTOR cascade along with the expression of TNF-alpha, NF-kappaB, Cox-2, and IL-6 and antiapoptotic genes cyclin D1 and Bcl-2 in the HEC-1A cells. fucoxanthin 4-15 BCL2 apoptosis regulator Homo sapiens 169-174 35524577-5 2022 Treatment with solasonine resulted in significant down-regulation of Bcl-2 and Caspase-3 protein expression and reduced Bax and Bcl-xL protein expression in SGC-7901 cells. alpha-solamargine 15-25 BCL2 apoptosis regulator Homo sapiens 69-74 35142421-7 2022 Moreover, the results demonstrated that the ERK inhibitor (PD98059) and TGF-beta1 inhibitor (LY364947) could inhibit the activation of the ERK signaling pathway, thereby reducing the mitochondrial membrane potential, the total apoptosis rate, and the expression of pro-apoptosis-related genes in the cells, while the expression of the antiapoptosis gene Bcl-2 was significantly increased (P < .05). Ly-364947 93-101 BCL2 apoptosis regulator Homo sapiens 354-359 35364607-4 2022 Both cells with acquired resistance to venetoclax and to AMG176 express increased levels of BCL-2 and BCL-2A1, decreased BAX, and/or altered levels of other BCL-2 proteins. AMG 3 57-63 BCL2 apoptosis regulator Homo sapiens 92-97 35383271-4 2022 Further, fadraciclib was synergistic with the Bcl-2 antagonist venetoclax, inducing more profound CLL cell death, especially in samples with 17p deletion. CYC065 9-20 BCL2 apoptosis regulator Homo sapiens 46-51 35383271-4 2022 Further, fadraciclib was synergistic with the Bcl-2 antagonist venetoclax, inducing more profound CLL cell death, especially in samples with 17p deletion. venetoclax 63-73 BCL2 apoptosis regulator Homo sapiens 46-51 35411095-5 2022 Inhibition of JAK3 led to loss of MEK, ERK and BCL2 phosphorylation, and BH3 profiling revealed that JAK3-mutant primary T-ALL patient samples were characterized by a dependence on BCL2. BH 3 73-76 BCL2 apoptosis regulator Homo sapiens 181-185 35364607-4 2022 Both cells with acquired resistance to venetoclax and to AMG176 express increased levels of BCL-2 and BCL-2A1, decreased BAX, and/or altered levels of other BCL-2 proteins. AMG 3 57-63 BCL2 apoptosis regulator Homo sapiens 157-162 35364607-5 2022 Co-targeting BCL-2 and MCL-1 was highly synergistic in AML cell lines with intrinsic or acquired resistance to BH3 mimetics or engineered to genetically-overexpress BCL-2 or BCL-2A1 or downregulate BAX. BH 3 111-114 BCL2 apoptosis regulator Homo sapiens 13-18 35364607-10 2022 Our results support co-dependence on multiple anti-apoptotic BCL-2 proteins and suppression of BAX as mechanisms of AML resistance to individual BH3 mimetics. BH 3 145-148 BCL2 apoptosis regulator Homo sapiens 61-66 35334451-7 2022 Vitamin C decreased the gene expression of apoptosis (BAX) and increased the expression of genes associated with nuclear reprogramming (NANOG, POU5F1, SOX2, c-Myc, Klf4, and TEAD4), antioxidation (SOD1), anti-apoptotic (Bcl2), and trophectoderm (CDX2). Ascorbic Acid 0-9 BCL2 apoptosis regulator Homo sapiens 220-224 35487055-9 2022 Generally, both cell lines treated with the combination of Curcumin and As2O3 displayed decreased angiogenesis genes (VEGFA and VEGFC), apoptosis genes (BAX and Bcl2), and prostate cancer marker (KLK2), the zinc-finger protein (SNAIL); and an increase in expression (P < 0.05) of cell-cell adhesion molecule (E-cadherin) and tumor suppressor gene (P53) genes. Curcumin 59-67 BCL2 apoptosis regulator Homo sapiens 161-165 35220126-9 2022 gamma-Al2O3-5-FU inhibited cell growth in two-dimensional (2D) and three-dimensional (3D) cell culture and increased apoptosis as detected by DAPI stainning via modulation of caspases, BAx, BCl2 and cyclinD1. gamma-al2o3-5-fu 0-16 BCL2 apoptosis regulator Homo sapiens 190-194 35288263-10 2022 Pendulone also caused the loss of mitochondrial membrane potential, inhibited the anti-apoptotic proteins BCL-2 and activated the pro-apoptotic protein BAX, which promoted the release of cytochrome c to activate caspase 9. pendulone 0-9 BCL2 apoptosis regulator Homo sapiens 106-111 35487055-9 2022 Generally, both cell lines treated with the combination of Curcumin and As2O3 displayed decreased angiogenesis genes (VEGFA and VEGFC), apoptosis genes (BAX and Bcl2), and prostate cancer marker (KLK2), the zinc-finger protein (SNAIL); and an increase in expression (P < 0.05) of cell-cell adhesion molecule (E-cadherin) and tumor suppressor gene (P53) genes. Arsenic Trioxide 72-77 BCL2 apoptosis regulator Homo sapiens 161-165 35636434-5 2022 In addition, qRT-PCR results showed that the expressions of miR-181 and P53, CYLD, CBX7 and BCL2 genes change in MG63 cells after treatment with the combination of cisplatin and melatonin, so that the expression of P53, CYLD and CBX7 increased and the expression of BCL2 and miR-181b decreases significantly. Cisplatin 164-173 BCL2 apoptosis regulator Homo sapiens 92-96 35567907-8 2022 Ultrasound microbubble-mediated miR-503-5p downregulation relative to pure liposome-mediated miR-503-5p downregulation better decreased viability, inhibited migration, invasion and tube formation, enhanced apoptosis, upregulated SALL1, E-cadherin and Cleaved caspase-3, and downregulated miR-503-5p, N-cadherin, Vimentin and Bcl-2 in CRC cells. mir-503-5p 32-42 BCL2 apoptosis regulator Homo sapiens 325-330 35567907-8 2022 Ultrasound microbubble-mediated miR-503-5p downregulation relative to pure liposome-mediated miR-503-5p downregulation better decreased viability, inhibited migration, invasion and tube formation, enhanced apoptosis, upregulated SALL1, E-cadherin and Cleaved caspase-3, and downregulated miR-503-5p, N-cadherin, Vimentin and Bcl-2 in CRC cells. mir-503-5p 93-103 BCL2 apoptosis regulator Homo sapiens 325-330 35636434-5 2022 In addition, qRT-PCR results showed that the expressions of miR-181 and P53, CYLD, CBX7 and BCL2 genes change in MG63 cells after treatment with the combination of cisplatin and melatonin, so that the expression of P53, CYLD and CBX7 increased and the expression of BCL2 and miR-181b decreases significantly. Cisplatin 164-173 BCL2 apoptosis regulator Homo sapiens 266-270 35636434-5 2022 In addition, qRT-PCR results showed that the expressions of miR-181 and P53, CYLD, CBX7 and BCL2 genes change in MG63 cells after treatment with the combination of cisplatin and melatonin, so that the expression of P53, CYLD and CBX7 increased and the expression of BCL2 and miR-181b decreases significantly. Melatonin 178-187 BCL2 apoptosis regulator Homo sapiens 92-96 35636434-5 2022 In addition, qRT-PCR results showed that the expressions of miR-181 and P53, CYLD, CBX7 and BCL2 genes change in MG63 cells after treatment with the combination of cisplatin and melatonin, so that the expression of P53, CYLD and CBX7 increased and the expression of BCL2 and miR-181b decreases significantly. Melatonin 178-187 BCL2 apoptosis regulator Homo sapiens 266-270 35608363-10 2022 Acetyl royleanone, 6,7-dehydroroyleanone, carnosic acid, and cryptotanshinone were found to have anticancer potential based on their modulating effects on the expression levels of Bax and Bcl-2 proteins which play important roles in the regulation of apoptosis. acetyl royleanone 0-17 BCL2 apoptosis regulator Homo sapiens 188-193 35283426-6 2022 In addition, gossypol facilitated the cleavage of caspase-3 via protein kinase RNA-like ER kinase (PERK), CHOP, and Bax/Bcl-2 upregulation in both cells, whereas the upregulation of ATF was limited to BxPC-3 cells. Gossypol 13-21 BCL2 apoptosis regulator Homo sapiens 120-125 35608363-10 2022 Acetyl royleanone, 6,7-dehydroroyleanone, carnosic acid, and cryptotanshinone were found to have anticancer potential based on their modulating effects on the expression levels of Bax and Bcl-2 proteins which play important roles in the regulation of apoptosis. 6,7-dehydroroyleanone 19-40 BCL2 apoptosis regulator Homo sapiens 188-193 35608363-10 2022 Acetyl royleanone, 6,7-dehydroroyleanone, carnosic acid, and cryptotanshinone were found to have anticancer potential based on their modulating effects on the expression levels of Bax and Bcl-2 proteins which play important roles in the regulation of apoptosis. salvin 42-55 BCL2 apoptosis regulator Homo sapiens 188-193 35608363-10 2022 Acetyl royleanone, 6,7-dehydroroyleanone, carnosic acid, and cryptotanshinone were found to have anticancer potential based on their modulating effects on the expression levels of Bax and Bcl-2 proteins which play important roles in the regulation of apoptosis. cryptotanshinone 61-77 BCL2 apoptosis regulator Homo sapiens 188-193 35631459-5 2022 With regard to its mechanism of action, artonin F downregulated c-Met expression, consequently suppressed the phosphatidylinositol-3 kinase/Akt/mammalian target of rapamycin signaling, increased Bax expression, decreased Bcl-2 expression, and activated caspase-3. artonin F 40-49 BCL2 apoptosis regulator Homo sapiens 221-226 35598030-1 2022 Venetoclax is a new type of BH3 mimetic compound that can target the binding site in the BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial apoptotic pathway. BH 3 28-31 BCL2 apoptosis regulator Homo sapiens 89-94 35598030-9 2022 In addition to changes in BCL-2 family genes, mutations in other oncogenes can also confer resistance to apoptosis induced by venetoclax. venetoclax 126-136 BCL2 apoptosis regulator Homo sapiens 26-31 35620928-8 2022 Cancer cells take up the nanocomposite via endocytosis and can generate intracellular reactive oxygen species (ROS) to increase mitochondrial membrane potential loss (Deltapsim) and enable cytochrome-c release, followed by the dysregulation of Bcl-2 into the cytosol and activation of caspase-3 to induce cancer cell apoptosis. Reactive Oxygen Species 86-109 BCL2 apoptosis regulator Homo sapiens 244-249 35620928-8 2022 Cancer cells take up the nanocomposite via endocytosis and can generate intracellular reactive oxygen species (ROS) to increase mitochondrial membrane potential loss (Deltapsim) and enable cytochrome-c release, followed by the dysregulation of Bcl-2 into the cytosol and activation of caspase-3 to induce cancer cell apoptosis. Reactive Oxygen Species 111-114 BCL2 apoptosis regulator Homo sapiens 244-249 35594184-1 2022 The oral BCL-2 inhibitor venetoclax has demonstrated promising efficacy in patients with t(11;14) plasma cell disorders, both as a single-agent and in combination. venetoclax 25-35 BCL2 apoptosis regulator Homo sapiens 9-14 35599423-15 2022 After 72 hours of culture, compared with those in negative control group, the protein expressions of Bcl-2 of cells in 0.300 mg/mL sodium ferulate group was significantly decreased (P<0.01), the protein expressions of Bax of cells in 0.030 mg/mL sodium ferulate group and 0.300 mg/mL sodium ferulate group were significantly increased (P<0.05), and the protein expression of caspase-3 of cells in 0.300 mg/mL sodium ferulate group was significantly increased (P<0.01). ferulic acid 246-261 BCL2 apoptosis regulator Homo sapiens 101-106 35599423-15 2022 After 72 hours of culture, compared with those in negative control group, the protein expressions of Bcl-2 of cells in 0.300 mg/mL sodium ferulate group was significantly decreased (P<0.01), the protein expressions of Bax of cells in 0.030 mg/mL sodium ferulate group and 0.300 mg/mL sodium ferulate group were significantly increased (P<0.05), and the protein expression of caspase-3 of cells in 0.300 mg/mL sodium ferulate group was significantly increased (P<0.01). ferulic acid 131-146 BCL2 apoptosis regulator Homo sapiens 101-106 35599423-15 2022 After 72 hours of culture, compared with those in negative control group, the protein expressions of Bcl-2 of cells in 0.300 mg/mL sodium ferulate group was significantly decreased (P<0.01), the protein expressions of Bax of cells in 0.030 mg/mL sodium ferulate group and 0.300 mg/mL sodium ferulate group were significantly increased (P<0.05), and the protein expression of caspase-3 of cells in 0.300 mg/mL sodium ferulate group was significantly increased (P<0.01). ferulic acid 284-299 BCL2 apoptosis regulator Homo sapiens 101-106 35599423-15 2022 After 72 hours of culture, compared with those in negative control group, the protein expressions of Bcl-2 of cells in 0.300 mg/mL sodium ferulate group was significantly decreased (P<0.01), the protein expressions of Bax of cells in 0.030 mg/mL sodium ferulate group and 0.300 mg/mL sodium ferulate group were significantly increased (P<0.05), and the protein expression of caspase-3 of cells in 0.300 mg/mL sodium ferulate group was significantly increased (P<0.01). ferulic acid 409-424 BCL2 apoptosis regulator Homo sapiens 101-106 35617878-6 2022 Further, the HeLa cells were treated with the polymer encapsulated curcumin and Bcl2 siRNA (Pol-Cur-siRNA) for 24 h, which effectively suppressed the Bcl2 and simulated the autophagic pathway. Curcumin 67-75 BCL2 apoptosis regulator Homo sapiens 150-154 35590119-0 2022 Candesartan Protects Against Cadmium-Induced Hepatorenal Syndrome by Affecting Nrf2, NF-kappaB, Bax/Bcl-2/Cyt-C, and Ang II/Ang 1-7 Signals. candesartan 0-11 BCL2 apoptosis regulator Homo sapiens 100-105 35590119-8 2022 Moreover, candesartan attenuated Cd hepatorenal apoptosis by upregulating Bcl-2 and downregulating Bax and Cyt-C proteins. candesartan 10-21 BCL2 apoptosis regulator Homo sapiens 74-79 35590119-10 2022 Overall, our findings revealed that candesartan could attenuate Cd-induced hepatorenal intoxication through modulation of Nrf2, NF-kappaB/IkappaB, Bax/Bcl-2/Cyt-c, and Ang II/Ang 1-7 signaling pathways. candesartan 36-47 BCL2 apoptosis regulator Homo sapiens 151-156 35620405-5 2022 In addition, NO.20 inhibited H2O2-induced mitochondrial dysfunctions: it alleviated mitochondrial membrane potential loss and cytochrome c release, decreased the Bax/Bcl-2 ratio, and reduced caspase-3 expression. Hydrogen Peroxide 29-33 BCL2 apoptosis regulator Homo sapiens 166-171 35584771-11 2022 GW9508 rescues the viability of HRMCs and reduces cell apoptosis by preventing an increase in Bax expression and the reduction in Bcl-2 expression. GW9508 0-6 BCL2 apoptosis regulator Homo sapiens 130-135 35577568-0 2022 The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies. venetoclax 19-29 BCL2 apoptosis regulator Homo sapiens 4-8 35486494-7 2022 20 muM and 40 muM lupeol induced cell apoptosis, enhanced oxidative stress and restrained immune response in nasopharyngeal carcinoma cells to some extent, as evidenced by the elevation of apoptotic rate, Bax and cleaved caspase-3 expression, ROS production and malondialdehyde level, and reduction of levels of Bcl-2, MMP, superoxide dismutase, TNF-alpha, IL-6 and IL-1beta. lupeol 18-24 BCL2 apoptosis regulator Homo sapiens 312-317 35577568-0 2022 The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies. mag 99-102 BCL2 apoptosis regulator Homo sapiens 4-8 35570553-6 2022 Apoptotic activity of SA was showed by DAPI staining, caspase-3, Bax, and Bcl-2 mRNA expressions. syringic acid 22-24 BCL2 apoptosis regulator Homo sapiens 74-79 35576232-11 2022 Blocking Hh signaling with the inhibitor Vismodegib, induced a pro-apoptotic cellular program defined by decreased mitochondria membrane potential, significant reductions in BCL-2, activation of caspase 3 and 9, and increased apoptotic cells. HhAntag691 41-51 BCL2 apoptosis regulator Homo sapiens 174-179 35568768-2 2022 Indeed, we detected increased activation of AKT accompanied by upregulation of MYC/BCL2 in post-therapy CLL cells from patients treated with idelalisib/ofatumumab. idelalisib 141-151 BCL2 apoptosis regulator Homo sapiens 83-87 35561277-9 2022 Furthermore, the expression of Caspase-3 and Bax (p < 0.05) were significantly lower, whereas the expression of BCL-2 (p < 0.05) was greater than the control group when adding 10 muM riboflavin to the extender. Riboflavin 183-193 BCL2 apoptosis regulator Homo sapiens 112-117 35551214-6 2022 However, the mitochondrial membrane potential, and the expression levels of antioxidant genes (CAT, SOD1 and SOD2) and anti-apoptotic gene Bcl-2 in the oocytes in the BPA+Asta group were significantly higher. bisphenol A 167-170 BCL2 apoptosis regulator Homo sapiens 139-144 35551214-6 2022 However, the mitochondrial membrane potential, and the expression levels of antioxidant genes (CAT, SOD1 and SOD2) and anti-apoptotic gene Bcl-2 in the oocytes in the BPA+Asta group were significantly higher. Cyclophosphamide 171-175 BCL2 apoptosis regulator Homo sapiens 139-144 35491624-2 2022 The approval of the antiapoptotic BCL2 antagonist venetoclax has finally validated the potential of targeting apoptotic pathways in patients with cancer. venetoclax 50-60 BCL2 apoptosis regulator Homo sapiens 34-38 35579133-12 2022 Moreover, enzalutamide downregulated the expression of the anti-apoptosis genes, mcl1 and bcl2, in MDA-MB-231 cells. enzalutamide 10-22 BCL2 apoptosis regulator Homo sapiens 90-94 35579133-14 2022 On the other hand, DHT upregulated the expression of the anti-apoptosis genes, mcl1 and bcl2, in both cell lines. Dihydrotestosterone 19-22 BCL2 apoptosis regulator Homo sapiens 88-92 35579133-15 2022 CONCLUSION: DHT increases the expression of the anti-apoptosis mcl1 and bcl2 in the TNBC cells, presumably leading to cell survival via the prevention of doxorubicin-induced apoptosis. Dihydrotestosterone 12-15 BCL2 apoptosis regulator Homo sapiens 72-76 35579133-15 2022 CONCLUSION: DHT increases the expression of the anti-apoptosis mcl1 and bcl2 in the TNBC cells, presumably leading to cell survival via the prevention of doxorubicin-induced apoptosis. Doxorubicin 154-165 BCL2 apoptosis regulator Homo sapiens 72-76 35579133-16 2022 On the other hand, enzalutamide may sensitize the cells to doxorubicin through downregulation of the bid/bcl2/mcl1 axis that normally activates the executive caspases, caspase 3/7. enzalutamide 19-31 BCL2 apoptosis regulator Homo sapiens 105-109 35579133-16 2022 On the other hand, enzalutamide may sensitize the cells to doxorubicin through downregulation of the bid/bcl2/mcl1 axis that normally activates the executive caspases, caspase 3/7. Doxorubicin 59-70 BCL2 apoptosis regulator Homo sapiens 105-109 35572840-11 2022 In addition, alisol B 23-acetate notably enhanced the apoptotic effect of bufalin on liver cancer cells through mediation of Mcl-1, Bax, Bcl-2, and cleaved caspase-3. alisol B 23-acetate 13-32 BCL2 apoptosis regulator Homo sapiens 137-142 35572840-11 2022 In addition, alisol B 23-acetate notably enhanced the apoptotic effect of bufalin on liver cancer cells through mediation of Mcl-1, Bax, Bcl-2, and cleaved caspase-3. bufalin 74-81 BCL2 apoptosis regulator Homo sapiens 137-142 35601667-6 2022 VC inhibited neomycin-induced apoptosis, ameliorated neomycin reduced antiapoptotic Bcl-2 expression, and suppressed neomycin increased expression of proapoptotic Bax, caspase-3 cleavage and caspase-8. Ascorbic Acid 0-2 BCL2 apoptosis regulator Homo sapiens 84-89 35586688-1 2022 Objective: To investigate the clinical effect of minocycline plus zinc oxide eugenol cement in the treatment of acute pulpitis and its effect on the levels of HIF-1alpha, Bcl-2, and tumor necrosis factor alpha. Minocycline 49-60 BCL2 apoptosis regulator Homo sapiens 171-176 35586688-1 2022 Objective: To investigate the clinical effect of minocycline plus zinc oxide eugenol cement in the treatment of acute pulpitis and its effect on the levels of HIF-1alpha, Bcl-2, and tumor necrosis factor alpha. Zinc Oxide 66-76 BCL2 apoptosis regulator Homo sapiens 171-176 35586688-6 2022 Minocycline plus zinc oxide eugenol cement was associated with significantly lower positive rates of HIF-1alpha and Bcl-2 and lower levels of TNF-alpha versus minocycline alone (p < 0.05). Minocycline 0-11 BCL2 apoptosis regulator Homo sapiens 116-121 35586688-6 2022 Minocycline plus zinc oxide eugenol cement was associated with significantly lower positive rates of HIF-1alpha and Bcl-2 and lower levels of TNF-alpha versus minocycline alone (p < 0.05). Zinc Oxide 17-27 BCL2 apoptosis regulator Homo sapiens 116-121 35586688-6 2022 Minocycline plus zinc oxide eugenol cement was associated with significantly lower positive rates of HIF-1alpha and Bcl-2 and lower levels of TNF-alpha versus minocycline alone (p < 0.05). Eugenol 28-35 BCL2 apoptosis regulator Homo sapiens 116-121 35586688-8 2022 Conclusion: Minocycline plus zinc oxide eugenol cement offers a viable alternative for acute pulpitis as it mitigates the pain of patients, alleviates inflammatory responses, and lowers the positive rate of HIF-1alpha and Bcl-2, so it is worthy of clinical promotion. Minocycline 12-23 BCL2 apoptosis regulator Homo sapiens 222-227 35586688-8 2022 Conclusion: Minocycline plus zinc oxide eugenol cement offers a viable alternative for acute pulpitis as it mitigates the pain of patients, alleviates inflammatory responses, and lowers the positive rate of HIF-1alpha and Bcl-2, so it is worthy of clinical promotion. Zinc Oxide 29-39 BCL2 apoptosis regulator Homo sapiens 222-227 35586688-8 2022 Conclusion: Minocycline plus zinc oxide eugenol cement offers a viable alternative for acute pulpitis as it mitigates the pain of patients, alleviates inflammatory responses, and lowers the positive rate of HIF-1alpha and Bcl-2, so it is worthy of clinical promotion. Eugenol 40-47 BCL2 apoptosis regulator Homo sapiens 222-227 35525902-5 2022 TFOBO increases Bax/Bcl2 levels, caspase9, and caspase3/7 activity and decreases mitochondrial membrane potential. tfobo 0-5 BCL2 apoptosis regulator Homo sapiens 20-24 35563442-0 2022 Deoxyelephantopin Induces Apoptosis and Enhances Chemosensitivity of Colon Cancer via miR-205/Bcl2 Axis. deoxyelephantopin 0-17 BCL2 apoptosis regulator Homo sapiens 94-98 35499276-9 2022 The protein and gene expressions of cleaved Caspase 3 and Bax were elevated, and those of Bcl-2 and Bcl-XL were reduced after NiSO4 treatment. nickel sulfate 126-131 BCL2 apoptosis regulator Homo sapiens 90-95 35195784-7 2022 In conjunction, guanabenz also attenuated the AD-related oxidative stress, impaired mitochondrial functionality (MMP, cytochrome-c translocation, ATP level, and mitochondrial complex I activity), endoplasmic reticulum stress (GRP78, GADD153, cleaved caspase-12), neuronal apoptosis (Bcl-2, Bax, cleaved caspase-3), and DNA fragmentation. Guanabenz 16-25 BCL2 apoptosis regulator Homo sapiens 283-288 35502476-10 2022 Furthermore, Western blot results showed that regorafenib down-regulated the expression of B-cell lymphoma-2 (Bcl-2) and concurrently up-regulated the expression of Bcl-2-associated X (Bax), and regorafenib inhibited the phosphorylation pathway of AKT in CAFs. regorafenib 46-57 BCL2 apoptosis regulator Homo sapiens 91-108 35502476-10 2022 Furthermore, Western blot results showed that regorafenib down-regulated the expression of B-cell lymphoma-2 (Bcl-2) and concurrently up-regulated the expression of Bcl-2-associated X (Bax), and regorafenib inhibited the phosphorylation pathway of AKT in CAFs. regorafenib 46-57 BCL2 apoptosis regulator Homo sapiens 110-115 35240234-6 2022 2) Both DEX and GSI synergistically inhibited BCL2 and suppressed the survival of T-ALL cells. Dexamethasone 8-11 BCL2 apoptosis regulator Homo sapiens 46-50 35240234-6 2022 2) Both DEX and GSI synergistically inhibited BCL2 and suppressed the survival of T-ALL cells. 2-(5-Chlorothiophen-2-Yl)-N-[(3s)-1-(4-{2-[(Dimethylamino)methyl]-1h-Imidazol-1-Yl}-2-Fluorophenyl)-2-Oxopyrrolidin-3-Yl]ethanesulfonamide 16-19 BCL2 apoptosis regulator Homo sapiens 46-50 35174895-0 2022 Upregulation of BAX and caspase-3, as well as downregulation of Bcl-2 during treatment with indeno(1,2-b)quinoxalin derivatives, mediated apoptosis in human cancer cells. indeno(1,2-b)quinoxalin 92-115 BCL2 apoptosis regulator Homo sapiens 64-69 35187951-0 2022 PALVEN: phase 1b trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer. venetoclax 53-63 BCL2 apoptosis regulator Homo sapiens 90-94 35413622-6 2022 The levels of procaspase-3 and Bcl-2 had fallen in a concentration-dependent manner and Bax was significantly increased at 60, 80 and 100 muM concentration compared with no CdCl2 treatment respectively, which activated the mitochondrial apoptosis pathway. Cadmium Chloride 173-178 BCL2 apoptosis regulator Homo sapiens 31-36 35219693-6 2022 We then confirmed the effect of D4476 on the interaction between Beclin 1 and B-cell lymphoma-2 (Bcl-2) through immunoprecipitation with an anti-Bcl-2 antibody. 4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide 32-37 BCL2 apoptosis regulator Homo sapiens 78-95 35219693-6 2022 We then confirmed the effect of D4476 on the interaction between Beclin 1 and B-cell lymphoma-2 (Bcl-2) through immunoprecipitation with an anti-Bcl-2 antibody. 4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide 32-37 BCL2 apoptosis regulator Homo sapiens 96-102 35219693-6 2022 We then confirmed the effect of D4476 on the interaction between Beclin 1 and B-cell lymphoma-2 (Bcl-2) through immunoprecipitation with an anti-Bcl-2 antibody. 4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide 32-37 BCL2 apoptosis regulator Homo sapiens 145-150 35219693-8 2022 Furthermore, CQ trapped Beclin 1 with Bcl-2, disturbing autophagy initiation and autolysosome formation. Chloroquine 13-15 BCL2 apoptosis regulator Homo sapiens 38-43 35219693-9 2022 However, D4476 alleviated CQ-induced effects by rescuing ARPE-19 cells from CQ-induced toxicity by modulating the association between Beclin 1 and Bcl-2. 4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide 9-14 BCL2 apoptosis regulator Homo sapiens 147-152 35219693-9 2022 However, D4476 alleviated CQ-induced effects by rescuing ARPE-19 cells from CQ-induced toxicity by modulating the association between Beclin 1 and Bcl-2. Chloroquine 76-78 BCL2 apoptosis regulator Homo sapiens 147-152 35266008-11 2022 Cyclopamine treatment was found to arrest 786-O cells in the G2/M phase and decreased the expression levels of GLI1, BCL2, VEGFA and CCND1. cyclopamine 0-11 BCL2 apoptosis regulator Homo sapiens 117-121 35266008-12 2022 RU-SKI43 inhibited cell migration and decreased the expression levels of BCL2, MYC and CCND1 in ACHN cells. Ethanone, 1-[4-[(4-chloro-3-Methylphenoxy)Methyl]-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-2-[(3-Methoxypropyl)aMino]- 0-8 BCL2 apoptosis regulator Homo sapiens 73-77 35179667-11 2022 CONCLUSIONS: We concluded that the GSK-3beta inhibitor SB216763 protected mitochondrial membrane potential to delay nucleus pulposus cell apoptosis by inhibiting the interaction between GSK-3beta and Bcl-2 and subsequently reducing cytochrome c(Cyto-C) release and caspase-3 activation. SB 216763 55-63 BCL2 apoptosis regulator Homo sapiens 200-205 35352453-5 2022 By using in vitro and in vivo models of primary and secondary ibrutinib resistance as well as post-ibrutinib treatment clinical samples, we show that dual targeting of the BCL-2 and PI3-kinase signalling pathways results in synergistic anti-tumour activity. ibrutinib 62-71 BCL2 apoptosis regulator Homo sapiens 172-177 35352453-5 2022 By using in vitro and in vivo models of primary and secondary ibrutinib resistance as well as post-ibrutinib treatment clinical samples, we show that dual targeting of the BCL-2 and PI3-kinase signalling pathways results in synergistic anti-tumour activity. ibrutinib 99-108 BCL2 apoptosis regulator Homo sapiens 172-177 35352453-6 2022 Clinically relevant doses of venetoclax, a BCL-2 inhibitor, in combination with duvelisib, a PI3Kdelta/gamma dual inhibitor, resulted in significant inhibition of these compensatory pathways and apoptosis induction. venetoclax 29-39 BCL2 apoptosis regulator Homo sapiens 43-48 35600774-6 2022 The cell viability after KGC11o treatment was determined using BPH-1 cells, and, androgen receptor, Bax, Bcl-2, and TGF-beta were confirmed by western blotting. kgc11o 25-31 BCL2 apoptosis regulator Homo sapiens 105-110 34558536-7 2022 These effects on Bax, Bcl-2, and Caspase-3 were blocked by pretreatment with the PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 96-104 BCL2 apoptosis regulator Homo sapiens 22-27 35277788-7 2022 However, negative correlations were found between IL-33 and urea and sodium concentrations and between Bcl-2 and HbA1c% and creatinine levels. Creatinine 124-134 BCL2 apoptosis regulator Homo sapiens 103-108 35174920-6 2022 CaFB treatment was found to be most effective on Caco-2 cells at 10 mM concentration for 24 h. Decreased Bcl-2 levels and increased Bax levels at 10 mM were evaluated as an indicator of apoptotic effects of CaFB. calcium fructoborate 0-4 BCL2 apoptosis regulator Homo sapiens 105-110 35174920-6 2022 CaFB treatment was found to be most effective on Caco-2 cells at 10 mM concentration for 24 h. Decreased Bcl-2 levels and increased Bax levels at 10 mM were evaluated as an indicator of apoptotic effects of CaFB. calcium fructoborate 207-211 BCL2 apoptosis regulator Homo sapiens 105-110 35398618-9 2022 Consistently, Nanog suppression combined with Cisplatin led to upregulation of Caspase-3 apoptotic gene and Bax/Bcl-2 ratio. Cisplatin 46-55 BCL2 apoptosis regulator Homo sapiens 112-117 35403090-10 2022 In silico data suggest that TFMG significantly blocked the entry, exit, and amino acids at catalytic active-site of more than thirty proteins including viral (nsp1,nsp2,Mainpro,~-9.0 kcal/mol) and host inflammatory, oxidants, apoptotic, vaso-destabilizer molecules (FAS, CD40R, BCL2, TLR2, ~ -10 and ACE1or2 ~ -9.0 and AT1or2~ -7.5 kcal/mol and more). tfmg 28-32 BCL2 apoptosis regulator Homo sapiens 278-282 35218152-11 2022 Unlike the proliferation-inhibiting effect of PI3K/Akt inhibitors, the Bcl-2 inhibitor navitoclax promptly promoted apoptosis in ImGNCs. navitoclax 87-97 BCL2 apoptosis regulator Homo sapiens 71-76 35531702-15 2022 This study indicates that miltirone can inhibit the proliferation and promote the apoptosis of THP-1 cells, by down-regulating NCOA2 and PARP1, raising Bax/Bcl-2 ratio, and activating caspase-3. miltirone 26-35 BCL2 apoptosis regulator Homo sapiens 156-161 35397781-4 2022 In this study, we found that treatment of embryos with 1.5% DMSO significantly decreased the cleavage and blastocyst rates, total cell number of blastocysts and the anti-apoptotic gene BCL-2 transcription level; however, the percentage of apoptotic cells and the expression levels of the pro-apoptotic gene BAX were not changed. Dimethyl Sulfoxide 60-64 BCL2 apoptosis regulator Homo sapiens 185-190 35531698-8 2022 Deoxyaconitine and benzoylmesaconine changed the ROS level(P<0.001), mitochondrial membrane potential(P<0.001), and protein expression of Bcl-2(P<0.001, P<0.01) and Bax(P<0.001), and deoxyaconitine increased the expression of PGC-1alpha protein(P<0.01). deoxyaconitine 0-14 BCL2 apoptosis regulator Homo sapiens 138-143 35259676-0 2022 Punicalagin promotes autophagic degradation of human papillomavirus E6 and E7 proteins in cervical cancer through the ROS-JNK-BCL2 pathway. Reactive Oxygen Species 118-121 BCL2 apoptosis regulator Homo sapiens 126-130 35566180-6 2022 The result showed that dioscin pre-treatment counters MPP+-mediated autophagic flux impairment and alleviates MPP+-induced apoptosis by downregulating activated caspase-3 and BCL2 associated X, apoptosis regulator (Bax) expression while increasing B-cell lymphoma 2 (Bcl-2) expression. dioscin 23-30 BCL2 apoptosis regulator Homo sapiens 248-265 35531698-8 2022 Deoxyaconitine and benzoylmesaconine changed the ROS level(P<0.001), mitochondrial membrane potential(P<0.001), and protein expression of Bcl-2(P<0.001, P<0.01) and Bax(P<0.001), and deoxyaconitine increased the expression of PGC-1alpha protein(P<0.01). benzoylmesaconine 19-36 BCL2 apoptosis regulator Homo sapiens 138-143 35531698-8 2022 Deoxyaconitine and benzoylmesaconine changed the ROS level(P<0.001), mitochondrial membrane potential(P<0.001), and protein expression of Bcl-2(P<0.001, P<0.01) and Bax(P<0.001), and deoxyaconitine increased the expression of PGC-1alpha protein(P<0.01). deoxyaconitine 183-197 BCL2 apoptosis regulator Homo sapiens 138-143 35217022-4 2022 MP12 sequence showed a significant binding score and has multiple hydrogen bond interactions with the proteins that play a vital role in apoptotic pathways such as Bcl-2, caspase-3, caspase-7, and XIAP. Hydrogen 66-74 BCL2 apoptosis regulator Homo sapiens 164-169 35566180-6 2022 The result showed that dioscin pre-treatment counters MPP+-mediated autophagic flux impairment and alleviates MPP+-induced apoptosis by downregulating activated caspase-3 and BCL2 associated X, apoptosis regulator (Bax) expression while increasing B-cell lymphoma 2 (Bcl-2) expression. dioscin 23-30 BCL2 apoptosis regulator Homo sapiens 267-272 35478473-5 2022 In MCF-7 cells, atractylodin administration decreased Bcl-2 expression while activating the expression of p53, Bax, cleaved caspase-3, caspase-8, and caspase-9 apoptotic members. atractylodin 16-28 BCL2 apoptosis regulator Homo sapiens 54-59 35482553-5 2022 Inhibition of CAMKIIdelta and CAMKIIgamma by either berbamine (BBM) or one of its derivatives (PA4) led to the down regulation of c-Myc and BCL2 proteins. berbamine 52-61 BCL2 apoptosis regulator Homo sapiens 140-144 35491088-10 2022 Flow cytometry analysis, Hoechst 33258 fluorescence staining assay and the assessment of the changes in the Bcl-2 family protein expression level revealed that SSA could significantly induce cell apoptosis, which was associated with apoptosis via the mitochondrial pathways. saikosaponin D 160-163 BCL2 apoptosis regulator Homo sapiens 108-113 35478276-6 2022 The FSK treatment also significantly induced apoptosis in cancer cells by modulating the expression of apoptotic markers like caspase-3, cleaved caspase-3, caspase-9, cleaved caspase-9, full length-poly ADP ribose polymerase (PARP), cleaved-poly ADP ribose polymerase (C-PARP) and Bcl2 in dose dependent manner. Colforsin 4-7 BCL2 apoptosis regulator Homo sapiens 281-285 35482553-5 2022 Inhibition of CAMKIIdelta and CAMKIIgamma by either berbamine (BBM) or one of its derivatives (PA4) led to the down regulation of c-Myc and BCL2 proteins. Santowhite powder 63-66 BCL2 apoptosis regulator Homo sapiens 140-144 35482553-5 2022 Inhibition of CAMKIIdelta and CAMKIIgamma by either berbamine (BBM) or one of its derivatives (PA4) led to the down regulation of c-Myc and BCL2 proteins. GP 4 95-98 BCL2 apoptosis regulator Homo sapiens 140-144 35448920-17 2022 The protein expression levels of Bax, Caspase-3 and Caspase-9 in KYSE150 and KYSE410 cells in DMY group were higher than those in DMSO group, while the protein expression level of Bcl-2 was lower than that in DMSO group (P<0.05). dihydromyricetin 94-97 BCL2 apoptosis regulator Homo sapiens 180-185 35477179-4 2022 Venetoclax, a B-cell lymphoma 2 (BCL-2) inhibitor for B-cell malignancy, induces phosphatidylserine (PS) extracellular exposure, representing an "eat-me" signal for macrophages. Phosphatidylserines 81-99 BCL2 apoptosis regulator Homo sapiens 14-31 35477179-4 2022 Venetoclax, a B-cell lymphoma 2 (BCL-2) inhibitor for B-cell malignancy, induces phosphatidylserine (PS) extracellular exposure, representing an "eat-me" signal for macrophages. Phosphatidylserines 81-99 BCL2 apoptosis regulator Homo sapiens 33-38 35477179-4 2022 Venetoclax, a B-cell lymphoma 2 (BCL-2) inhibitor for B-cell malignancy, induces phosphatidylserine (PS) extracellular exposure, representing an "eat-me" signal for macrophages. Phosphatidylserines 101-103 BCL2 apoptosis regulator Homo sapiens 14-31 35477179-4 2022 Venetoclax, a B-cell lymphoma 2 (BCL-2) inhibitor for B-cell malignancy, induces phosphatidylserine (PS) extracellular exposure, representing an "eat-me" signal for macrophages. Phosphatidylserines 101-103 BCL2 apoptosis regulator Homo sapiens 33-38 35477179-4 2022 Venetoclax, a B-cell lymphoma 2 (BCL-2) inhibitor for B-cell malignancy, induces phosphatidylserine (PS) extracellular exposure, representing an "eat-me" signal for macrophages. eat-me 146-152 BCL2 apoptosis regulator Homo sapiens 14-31 35477179-4 2022 Venetoclax, a B-cell lymphoma 2 (BCL-2) inhibitor for B-cell malignancy, induces phosphatidylserine (PS) extracellular exposure, representing an "eat-me" signal for macrophages. eat-me 146-152 BCL2 apoptosis regulator Homo sapiens 33-38 35528614-6 2022 2-ME2 induced cell apoptosis by downregulating antiapoptotic protein expressions of Bcl-xl and Bcl-2. 2-Methoxyestradiol 0-5 BCL2 apoptosis regulator Homo sapiens 95-100 35528614-12 2022 Moreover, 2-ME2 could induce cell apoptosis by downregulating the C-myc gene and exert an apoptotic effect by downregulating Bcl-xl and Bcl-2 which act as antiapoptotic proteins. 2-Methoxyestradiol 10-15 BCL2 apoptosis regulator Homo sapiens 136-141 35490311-7 2022 Moreover, rotenone toxicity is caused by complex I inhibition, which leads to mitochondrial dysfunction, increased BAX while down regulating the Bcl2 expression and cyt c release and then finally caspases activation. Rotenone 10-18 BCL2 apoptosis regulator Homo sapiens 145-149 35529935-6 2022 The effect of RREs on cell mitochondrial membrane potential was evaluated by mitochondrial membrane potential assay kit with JC-1 (JC-1 assay), and western blot was used to detect the expression of apoptosis-related proteins (B-cell lymphoma-2 (Bcl-2), Bcl-2-associated x (Bax), and Caspase-3), thus investigating the effect of RREs on the molecular mechanism of HepG2 cell apoptosis. rres 14-18 BCL2 apoptosis regulator Homo sapiens 245-250 35515507-3 2022 Recently, the United States FDA has approved venetoclax, a selective oral BCL-2 inhibitor, for use in conjunction with hypomethylating agents (azacitidine or decitabine) or low-dose cytarabine as a first-line treatment option for those AML patients ineligible for standard induction chemotherapy. venetoclax 45-55 BCL2 apoptosis regulator Homo sapiens 74-79 35448920-17 2022 The protein expression levels of Bax, Caspase-3 and Caspase-9 in KYSE150 and KYSE410 cells in DMY group were higher than those in DMSO group, while the protein expression level of Bcl-2 was lower than that in DMSO group (P<0.05). Dimethyl Sulfoxide 209-213 BCL2 apoptosis regulator Homo sapiens 180-185 35497928-9 2022 The expression levels of Ki-67, Bcl-2, beta-catenin, and c-myc in the Rab23, LCA, and Rab23 + LCA groups were greatly lower versus those of BC group. licochalcone A 94-97 BCL2 apoptosis regulator Homo sapiens 32-37 35460011-6 2022 Treatment with TBT induces higher Bcl-2 and caspase-9 mRNA transcripts in DFF40 KO Jurkat cells, as well as enhanced Bcl-2 phosphorylation. tributyltin 15-18 BCL2 apoptosis regulator Homo sapiens 34-39 35566044-8 2022 A real-time PCR study showed that 6-Gingerol induces the simultaneous transcription of Bax with TP53 genes in large excess to BCL-2. gingerol 34-44 BCL2 apoptosis regulator Homo sapiens 126-131 35460011-6 2022 Treatment with TBT induces higher Bcl-2 and caspase-9 mRNA transcripts in DFF40 KO Jurkat cells, as well as enhanced Bcl-2 phosphorylation. tributyltin 15-18 BCL2 apoptosis regulator Homo sapiens 117-122 35566044-9 2022 In contrast, 5 nM Paclitaxel induces TP53 transcription in excess of BCL-2 and Bax. Paclitaxel 18-28 BCL2 apoptosis regulator Homo sapiens 69-74 35443750-0 2022 The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 20-23 BCL2 apoptosis regulator Homo sapiens 4-9 35443029-0 2022 Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia. Ceramides 0-8 BCL2 apoptosis regulator Homo sapiens 54-59 35443750-3 2022 The small molecule drug ABT-199 mimics the pro-apoptotic BCL-2 homology domain 3 of BH3-only proteins and blocks the hydrophobic BC-groove in BCL-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 24-27 BCL2 apoptosis regulator Homo sapiens 57-62 35443750-2 2022 Targeting of BCL-2 with the specific inhibitor ABT-199 (Venetoclax) has significant clinical activity in malignant diseases such as chronic lymphocytic leukemia and multiple myeloma. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 47-50 BCL2 apoptosis regulator Homo sapiens 13-18 35443750-3 2022 The small molecule drug ABT-199 mimics the pro-apoptotic BCL-2 homology domain 3 of BH3-only proteins and blocks the hydrophobic BC-groove in BCL-2. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 24-27 BCL2 apoptosis regulator Homo sapiens 142-147 35443750-9 2022 Thus, NOXA potentiates the efficacy of the BCL-2 inhibitor ABT-199 by simultaneous inhibition of MCL-1. venetoclax 59-66 BCL2 apoptosis regulator Homo sapiens 43-48 35531132-8 2022 The expression of XIAP, cyclin D1, and Bcl-2 genes and proteins in the groups treated with ALT, Cis, and ZnONPs as a single agent, double and triple combination were significantly reduced compared to the control, while Bax was generally shown an increase. alantolactone 91-94 BCL2 apoptosis regulator Homo sapiens 39-44 35443750-10 2022 Hence, ABT-199 has a double impact by directly blocking anti-apoptotic BCL-2 and inhibiting MCL-1 via transactivated NOXA. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 7-10 BCL2 apoptosis regulator Homo sapiens 71-76 35380798-5 2022 The relevant functional nucleic acids, including the antisequence of mRNA Bcl-2, the antisequence of piRNA-36026, and aptamer AS1411, are designed in the customized oligonucleotides with the signal reporters Cy3 and Cy5. Oligonucleotides 165-181 BCL2 apoptosis regulator Homo sapiens 74-79 35440079-0 2022 Correction to: Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy. navitoclax 38-45 BCL2 apoptosis regulator Homo sapiens 15-20 35430637-9 2022 In addition, melatonin downregulated the expression of an invasive marker, MMP-9, an antiapoptotic protein, Bcl-2, and upregulated the expression of pro-apoptotic protein, Bax at both transcriptional and translational levels. Melatonin 13-22 BCL2 apoptosis regulator Homo sapiens 108-113 35531132-8 2022 The expression of XIAP, cyclin D1, and Bcl-2 genes and proteins in the groups treated with ALT, Cis, and ZnONPs as a single agent, double and triple combination were significantly reduced compared to the control, while Bax was generally shown an increase. cis, and znonps 96-111 BCL2 apoptosis regulator Homo sapiens 39-44 35422087-5 2022 SHMT2 deficiency promoted the accumulation of intracellular reactive oxygen species (ROS) by decreasing the NADH/NAD+, NADPH/NADP+, and GSH/GSSG ratios, leading to a loss in mitochondrial membrane potential, release of cytochrome c, translocation of Bcl-2 family protein and activation of caspase-3. Reactive Oxygen Species 60-83 BCL2 apoptosis regulator Homo sapiens 250-255 35422087-5 2022 SHMT2 deficiency promoted the accumulation of intracellular reactive oxygen species (ROS) by decreasing the NADH/NAD+, NADPH/NADP+, and GSH/GSSG ratios, leading to a loss in mitochondrial membrane potential, release of cytochrome c, translocation of Bcl-2 family protein and activation of caspase-3. Reactive Oxygen Species 85-88 BCL2 apoptosis regulator Homo sapiens 250-255 35456673-4 2022 TFBPC bound to DNA and formed DNA crosslinks that resulted in DNA degradation, triggering the cell death program through the PARP/Bax/Bcl-2 apoptosis and LC3-related autophagy pathway. tfbpc 0-5 BCL2 apoptosis regulator Homo sapiens 134-139 35431006-5 2022 In addition, HN5 cells were also treated with curcumin to evaluate its effect on the caspase-8, -9, Bcl-2, Bax, and Stat3 genes expression. Curcumin 46-54 BCL2 apoptosis regulator Homo sapiens 100-105 35431006-7 2022 Curcumin treatment caused decreased expression of Bcl2, with simultaneous upregulation of the Bax/Bcl2 ratio. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 50-54 35431006-7 2022 Curcumin treatment caused decreased expression of Bcl2, with simultaneous upregulation of the Bax/Bcl2 ratio. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 98-102 35431006-10 2022 The induction of the mitochondria-dependent apoptosis pathway of curcumin happened by the modulation in the expression of Bcl2 and Bax genes, resulting in the caspase-9 activation, also curcumin causes the decreasing the expression of the Stat3 in HN-5 cells. Curcumin 65-73 BCL2 apoptosis regulator Homo sapiens 122-126 35431006-10 2022 The induction of the mitochondria-dependent apoptosis pathway of curcumin happened by the modulation in the expression of Bcl2 and Bax genes, resulting in the caspase-9 activation, also curcumin causes the decreasing the expression of the Stat3 in HN-5 cells. Curcumin 186-194 BCL2 apoptosis regulator Homo sapiens 122-126 35431006-11 2022 CONCLUSIONS: In conclusion, curcumin showed marked anticancer effects in the HN-5 cell line by modulation of Stat-3; Bax/Bcl 2 expression in vitro. Curcumin 28-36 BCL2 apoptosis regulator Homo sapiens 121-126 35412302-5 2022 The introduction of iodine not only enhances the CT imaging signal with a much lower dose of Pt but also overcomes the resistance of tumor cells to Pt-containing nanomedicine by inhibiting the expression of Bcl-2. Iodine 20-26 BCL2 apoptosis regulator Homo sapiens 207-212 35412302-5 2022 The introduction of iodine not only enhances the CT imaging signal with a much lower dose of Pt but also overcomes the resistance of tumor cells to Pt-containing nanomedicine by inhibiting the expression of Bcl-2. Platinum 148-150 BCL2 apoptosis regulator Homo sapiens 207-212 35393436-3 2022 We focused on studying the use of BH3 mimetics to specifically inhibit pro-survival BCL-2 family proteins, overwhelm resistance to therapy and prevent relapse. BH 3 34-37 BCL2 apoptosis regulator Homo sapiens 84-89 35389600-10 2022 The proapoptotic effects of isoalantolactone were evident from morphological assessments and improved expressions of caspase-3, -8, and -9 and Bax while antiapoptotic Bcl-2 was reduced significantly. isoalantolactone 28-44 BCL2 apoptosis regulator Homo sapiens 167-172 35454865-7 2022 Combination with ABT-199 (venetoclax), an inhibitor of Bcl2, has a synergistic effect, suggesting that mitochondrial Kv1.3 inhibitors could potentially be used as combination partner to venetoclax, even in the treatment of t(11;14) negative multiple myeloma, which represent the major part of cases and are rather resistant to venetoclax alone. venetoclax 17-24 BCL2 apoptosis regulator Homo sapiens 55-59 35458590-7 2022 RESULTS: The combination of EPO and TAM suppressed the VEGF level, VEGF gene expression and Cyclin D1 signaling pathways, arrested the cell cycle, and induced the apoptotic signaling pathways by increasing the Bax/Bcl-2 ratio and caspase 3 activity; this revealed significant anti-tumor activity. evening primrose oil 28-31 BCL2 apoptosis regulator Homo sapiens 214-219 35458590-7 2022 RESULTS: The combination of EPO and TAM suppressed the VEGF level, VEGF gene expression and Cyclin D1 signaling pathways, arrested the cell cycle, and induced the apoptotic signaling pathways by increasing the Bax/Bcl-2 ratio and caspase 3 activity; this revealed significant anti-tumor activity. tam 36-39 BCL2 apoptosis regulator Homo sapiens 214-219 35409370-3 2022 A ceramide-S1P rheostat regulates ROS-induced mitochondrial dysfunction, apoptotic/anti-apoptotic Bcl-2 family proteins and signaling pathways, leading to apoptosis, survival, cell proliferation, inflammation and fibrosis in the kidney. Ceramides 2-10 BCL2 apoptosis regulator Homo sapiens 98-103 35379798-4 2022 ML264 significantly restored oxaliplatin sensitivity in CRC PDOs by restoring the apoptotic response, and this effect was achieved by inhibiting the KLF5/Bcl-2/caspase3 signaling pathway. ML264 0-5 BCL2 apoptosis regulator Homo sapiens 154-159 35379798-4 2022 ML264 significantly restored oxaliplatin sensitivity in CRC PDOs by restoring the apoptotic response, and this effect was achieved by inhibiting the KLF5/Bcl-2/caspase3 signaling pathway. Oxaliplatin 29-40 BCL2 apoptosis regulator Homo sapiens 154-159 35450041-6 2022 Indeed, after CI treatment, the protein level of CDK1 and Bcl-2/Bax decreased, indicating that CI induced the cell cycle of MDA-MB-231 arrest in the G2/M phase and increased the rate of apoptosis. morin 14-16 BCL2 apoptosis regulator Homo sapiens 58-63 35450041-6 2022 Indeed, after CI treatment, the protein level of CDK1 and Bcl-2/Bax decreased, indicating that CI induced the cell cycle of MDA-MB-231 arrest in the G2/M phase and increased the rate of apoptosis. morin 95-97 BCL2 apoptosis regulator Homo sapiens 58-63 35409370-3 2022 A ceramide-S1P rheostat regulates ROS-induced mitochondrial dysfunction, apoptotic/anti-apoptotic Bcl-2 family proteins and signaling pathways, leading to apoptosis, survival, cell proliferation, inflammation and fibrosis in the kidney. Reactive Oxygen Species 34-37 BCL2 apoptosis regulator Homo sapiens 98-103 35409370-4 2022 Ceramide inhibits the mitochondrial respiration chain and induces ceramide channel formation and the closure of voltage-dependent anion channels, leading to mitochondrial dysfunction, altered Bcl-2 family protein expression, ROS generation and disturbed calcium homeostasis. Ceramides 0-8 BCL2 apoptosis regulator Homo sapiens 192-197 35409370-9 2022 Thus, a ceramide-SphKs/S1P rheostat modulates oxidant-induced kidney injury by affecting mitochondrial function, ROS production, Bcl-2 family proteins, calcium homeostasis and their downstream signaling pathways. Ceramides 8-16 BCL2 apoptosis regulator Homo sapiens 129-134 35406117-6 2022 Vitamin K2 played a significant part in apoptosis by upregulating and downregulating Bcl-2 and Bax protein expressions, respectively, which inhibited mitochondrial depolarization, and ROS accumulation to maintain mitochondrial structure and functional stabilities. Vitamin K 2 0-10 BCL2 apoptosis regulator Homo sapiens 85-90 35006631-10 2022 The down-regulation of Bcl-2 and up-regulation of caspase3 were seen in GCs with DOR. doramectin 81-84 BCL2 apoptosis regulator Homo sapiens 23-28 35406117-6 2022 Vitamin K2 played a significant part in apoptosis by upregulating and downregulating Bcl-2 and Bax protein expressions, respectively, which inhibited mitochondrial depolarization, and ROS accumulation to maintain mitochondrial structure and functional stabilities. Reactive Oxygen Species 184-187 BCL2 apoptosis regulator Homo sapiens 85-90 35419059-8 2022 Besides, the presence of MSCs suppressed cell apoptosis induced by dexamethasone via the regulation of BCL-2 (B cell lymphoma 2). Dexamethasone 67-80 BCL2 apoptosis regulator Homo sapiens 103-108 35419059-8 2022 Besides, the presence of MSCs suppressed cell apoptosis induced by dexamethasone via the regulation of BCL-2 (B cell lymphoma 2). Dexamethasone 67-80 BCL2 apoptosis regulator Homo sapiens 110-127 35473552-11 2022 Mechanistically, miR-655-3p inhibits cell viability and induces apoptosis by inhibiting Bcl-2 expression. mir-655-3p 17-27 BCL2 apoptosis regulator Homo sapiens 88-93 35266887-12 2022 Propranolol treatment elevated the activity of caspase-3 and expression of bax, Wee1, GADD153 and apoptosis-inducing factor, but decreased bcl-2 which is an antiapoptotic protein. Propranolol 0-11 BCL2 apoptosis regulator Homo sapiens 139-144 35416117-0 2022 Discoidin domain receptor 1a (DDR1a) confers 5-fluorouracil cytotoxicity in LoVo cell via PI3K/AKT/Bcl-2 pathway. Fluorouracil 45-59 BCL2 apoptosis regulator Homo sapiens 99-104 35347000-7 2022 Single BCL2 apoptosis regulator (BCL2) gene mutation and 9p21 copy-number deletions including S-methyl-5"-thioadenosine phosphorylase (MTAP) deficiency were identified as key characteristics for high sensitivity to satraplatin. satraplatin 215-226 BCL2 apoptosis regulator Homo sapiens 7-37 35114189-0 2022 Nigericin exerts anticancer effects through inhibition of the SRC/STAT3/BCL-2 in osteosarcoma. Nigericin 0-9 BCL2 apoptosis regulator Homo sapiens 72-77 35114189-9 2022 Nigericin can down regulate STAT3 and Bcl-2. Nigericin 0-9 BCL2 apoptosis regulator Homo sapiens 38-43 35114189-10 2022 In order to further elucidate the inhibitory effect of nigericin on SRC / STAT3 / Bcl-2 signal transduction mechanism, we established human osteosarcoma cancer cells stably expressing STAT3. Nigericin 55-64 BCL2 apoptosis regulator Homo sapiens 82-87 35473552-12 2022 The high expression of Bcl-2 reversed the impact of miR-655-3p on the inhibition of cell bioactivity and induction of apoptosis in A549 cells. mir-655-3p 52-62 BCL2 apoptosis regulator Homo sapiens 23-28 35487599-6 2022 EGCG and ECG decreased Bcl-2 expression and upregulated Caspase-3 protein level, indicating the development of apoptosis. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 23-28 35220889-9 2022 After Salidroside treatment, cell proliferation decreased and apoptosis increased, Bax protein expression increased and Bcl-2 decreased; miR-4262 expression level in nasopharyngeal carcinoma tissues was lower than that in adjacent tissues. rhodioloside 6-17 BCL2 apoptosis regulator Homo sapiens 120-125 35220889-12 2022 The level of Bax was increased and Bcl-2 was decreased in Salidroside group. rhodioloside 58-69 BCL2 apoptosis regulator Homo sapiens 35-40 35150958-4 2022 Especially, compound M23 exhibited good selectivity over Bcl-xL, whereas compound M24 possessed good selectivity over both Bcl-2 and Bcl-xL. 5'-O-[(R)-[({3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]phenyl}carbonyl)oxy](hydroxy)phosphoryl]adenosine 82-85 BCL2 apoptosis regulator Homo sapiens 123-128 35571660-11 2022 The principal finding of this research was that lovastatin still suppressed A549 cell growth after LPS+ATP stimulation via modulation of ERK1/2, c-JUN, COX-2, BCL-2, and BAX protein levels (P<0.05). Lovastatin 48-58 BCL2 apoptosis regulator Homo sapiens 159-164 35353612-0 2022 Gastric Cancer Cell-Derived Kynurenines Hyperactive Regulatory T Cells to Promote Chemoresistance via the IL-10/STAT3/BCL2 Signaling Pathway. Kynurenine 28-39 BCL2 apoptosis regulator Homo sapiens 118-122 35353612-4 2022 The activation of STAT3/BCL2 signaling pathways in gastric cells cocultured by Treg was illustrated by western blotting. treg 79-83 BCL2 apoptosis regulator Homo sapiens 24-28 35353612-7 2022 STAT3 and BCL2 knockout significantly abrogated Treg supernatant- or IL-10-induced chemoresistance in SGC7901 and BGC823 cell lines. treg 48-52 BCL2 apoptosis regulator Homo sapiens 10-14 35353612-9 2022 Our data suggested that tumor-derived Kyn may hyperactivate Tregs and induce chemoresistance through the IL-10/STAT3/BCL2 signaling pathway. tregs 60-65 BCL2 apoptosis regulator Homo sapiens 117-121 35385883-9 2022 TQ and MTX can induce the expression level of pro-apoptotic factors, Bax and caspase-9 while inhibiting anti-apoptotic protein BCL-2. Methotrexate 7-10 BCL2 apoptosis regulator Homo sapiens 127-132 35286533-9 2022 Besides, captopril significantly reduced apoptotic Bax and raised anti-apoptotic Bcl-2 protein levels. Captopril 9-18 BCL2 apoptosis regulator Homo sapiens 81-86 35131713-0 2022 Corrigendum to "Co-delivery of VP-16 and Bcl-2-targeted antisense on PEG-grafted oMWCNTs for synergistic in vitro anti-cancer effects in non-small and small cell lung cancer" (Colloids Surf. Polyethylene Glycols 69-72 BCL2 apoptosis regulator Homo sapiens 41-46 35123771-2 2022 In preclinical studies, we previously demonstrated the promising activity of ABT-737, a Bcl-2/Bcl-xL anti-apoptotic protein inhibitor, in chemo-resistant ovarian cancer cells and tumors, suggesting its potential activity in platinum-resistant patients. ABT-737 77-84 BCL2 apoptosis regulator Homo sapiens 88-93 35152538-9 2022 Ethanol enhanced recruitment of SATB2 to promoters of Bcl-2, Nanog, c-Myc, Klf4 and Oct4. Ethanol 0-7 BCL2 apoptosis regulator Homo sapiens 54-59 35152538-10 2022 Ethanol also induced activation of the Wnt/TCF-LEF1 pathway and its targets (Bcl-2, Cyclin D1, AXIN2 and Myc). Ethanol 0-7 BCL2 apoptosis regulator Homo sapiens 77-82 35147204-10 2022 The apoptotic rate, caspase-3 activity and protein expression levels of Bax and cleaved caspase-3 were significantly reduced following donepezil treatment, which was accompanied by Bcl-2 upregulation. Donepezil 135-144 BCL2 apoptosis regulator Homo sapiens 181-186 35558260-9 2022 Results: PA inhibited the proliferation, migration, and invasion, and induced the apoptosis of the DU145 and PC-3 cells in a concentration-dependent manner, and was accompanied by mitochondrial membrane potential depolarization, the upregulation of cleaved caspase-3, cleaved poly ADP-ribose polymerase (PARP) and Bcl-2-associated X protein (Bax), and the downregulation of B-cell lymphoma-2 (Bcl-2), Ki67, and Mcl-1. patchouli alcohol 9-11 BCL2 apoptosis regulator Homo sapiens 393-398 35432301-6 2022 Furthermore, the c-di-GMP enhanced the response of bone marrow plasma cells and upregulated the expression of Bcl-2 and Mcl-1, which have been identified as anti-apoptotic regulatory genes of germinal center and memory B cells. bis(3',5')-cyclic diguanylic acid 17-25 BCL2 apoptosis regulator Homo sapiens 110-115 35408508-8 2022 Moreover, 3-HT and CDA upregulated the anti-apoptotic Bcl2 protein. 3-hydroxyterphenyllin 10-14 BCL2 apoptosis regulator Homo sapiens 54-58 35353498-3 2022 Small-molecule inhibitors such as ABT-263 (ABT), which can promote mitochondrial-mediated cell apoptosis by selectively inhibiting the function of Bcl-2 and Bcl-xl, have been proven to be promising anticancer agents in clinical trials. navitoclax 34-41 BCL2 apoptosis regulator Homo sapiens 147-152 35353498-3 2022 Small-molecule inhibitors such as ABT-263 (ABT), which can promote mitochondrial-mediated cell apoptosis by selectively inhibiting the function of Bcl-2 and Bcl-xl, have been proven to be promising anticancer agents in clinical trials. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 43-46 BCL2 apoptosis regulator Homo sapiens 147-152 35433741-12 2022 Moreover, ISL markedly increased the protein levels of Bcl-2 and SOD2, which were reduced by cisplatin stimulation. Cisplatin 93-102 BCL2 apoptosis regulator Homo sapiens 55-60 35541911-4 2022 Alizarin induced cell cycle arrest and promoted cell apoptosis by inhibiting TNF-alpha-stimulated NF-kappaB activity and nuclear translocation, and inactivated its related TNF-alpha-TAK1-NF-kappaB signaling cascade followed by downregulation of NF-kappaB target genes involved in cell apoptosis (Bcl-2, Bcl-xL, XIAP) and in the cell cycle and growth (cyclin D, c-myc). alizarin 0-8 BCL2 apoptosis regulator Homo sapiens 296-301 35406478-0 2022 Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins. gemcitabine 0-11 BCL2 apoptosis regulator Homo sapiens 172-177 35406478-0 2022 Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins. Everolimus 28-38 BCL2 apoptosis regulator Homo sapiens 172-177 35406478-0 2022 Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins. navitoclax 129-139 BCL2 apoptosis regulator Homo sapiens 172-177 35408691-13 2022 (4) Conclusions: our findings indicate that rutin plays an important role in anti-pancreatic cancer effects through a rutin-miR-877-3p-Bcl-2 axis and suggests a potential therapeutic strategy for pancreatic cancer. Rutin 44-49 BCL2 apoptosis regulator Homo sapiens 135-140 35458468-6 2022 Thus, the presence of the readily identifiable conserved BH1 motif sequence "NWGR" of KsBcl-2, as well as highly conserved Arg residue (R86) forms an ionic interaction with the conserved Asp in the BH3 motif in a manner that mimics the canonical ionic interaction seen in host Bcl-2:BH3 motif complexes. Aspartic Acid 187-190 BCL2 apoptosis regulator Homo sapiens 277-282 35458468-6 2022 Thus, the presence of the readily identifiable conserved BH1 motif sequence "NWGR" of KsBcl-2, as well as highly conserved Arg residue (R86) forms an ionic interaction with the conserved Asp in the BH3 motif in a manner that mimics the canonical ionic interaction seen in host Bcl-2:BH3 motif complexes. BH 3 198-201 BCL2 apoptosis regulator Homo sapiens 277-282 35455419-8 2022 Our study provides evidence that synthesized triazolo- and amino-tomentosin derivatives show neuroprotective effects by increasing cellular viability, decreasing ROS production, and increasing the Bcl-2/Bax ratio in NMDA-induced excitotoxicity. triazolo 45-53 BCL2 apoptosis regulator Homo sapiens 197-202 35455419-8 2022 Our study provides evidence that synthesized triazolo- and amino-tomentosin derivatives show neuroprotective effects by increasing cellular viability, decreasing ROS production, and increasing the Bcl-2/Bax ratio in NMDA-induced excitotoxicity. amino-tomentosin 59-75 BCL2 apoptosis regulator Homo sapiens 197-202 35455419-8 2022 Our study provides evidence that synthesized triazolo- and amino-tomentosin derivatives show neuroprotective effects by increasing cellular viability, decreasing ROS production, and increasing the Bcl-2/Bax ratio in NMDA-induced excitotoxicity. N-Methylaspartate 216-220 BCL2 apoptosis regulator Homo sapiens 197-202 35408508-9 2022 In conclusion, 3-HT and CDA represent fungus-derived bioactive compounds that have a novel protective effect on PA-induced human podocyte apoptosis via mechanisms involving free radical scavenging and Bcl2 upregulation. 3-hydroxyterphenyllin 15-19 BCL2 apoptosis regulator Homo sapiens 201-205 35275845-11 2022 Additionally, P53, CASPASE 3, and BAX were down-regulated and BCL2 was up-regulated in the 3-NPA and Ex-527 groups; opposite trends were observed after resveratrol treatment. Resveratrol 152-163 BCL2 apoptosis regulator Homo sapiens 62-66 35368934-8 2022 Osthole treatment significantly suppressed TGF-beta1-induced 16HBE cell apoptosis, verified by a reduced percentage of apoptotic cells, decreased expression of proapoptotic proteins (cleaved-caspase3 and Bax), and enhanced antiapoptotic factor (Bcl-2) expression. osthol 0-7 BCL2 apoptosis regulator Homo sapiens 245-250 35318303-5 2022 Mechanism dissection suggested that a high-dose-DHT can suppress the circular RNA-BCL2 (circRNA-BCL2) expression via transcriptional regulation of its host gene BCL2. Dihydrotestosterone 48-51 BCL2 apoptosis regulator Homo sapiens 161-165 35406150-9 2022 Zn-BTC@CS stimulated the apoptotic process through up-regulating P53 expression and down-regulating Bcl-2 expression. zn-btc 0-6 BCL2 apoptosis regulator Homo sapiens 100-105 35406150-9 2022 Zn-BTC@CS stimulated the apoptotic process through up-regulating P53 expression and down-regulating Bcl-2 expression. Chitosan 7-9 BCL2 apoptosis regulator Homo sapiens 100-105 35326689-11 2022 Moreover, 5-FU/VD3/Met revealed maximal inhibitions of cell cycle inducers (CCND1/CCND3), cell survival (BCL2), and the PI3K/Akt/mTOR molecules alongside the highest expression of cell cycle inhibitors (p21/p27), proapoptotic markers (BAX/cytochrome C/caspase-3), and PTEN in both cell lines. Fluorouracil 10-14 BCL2 apoptosis regulator Homo sapiens 105-109 35170591-7 2022 The augmented therapeutic efficacy appeared to be associated with the concomitant suppression of prosurvival CDK1 and anti-apoptotic proteins including CDK9, cFLIP, MCL-1, BCL-2 and Survivin by Dina@EV-T treatment. ev-t 199-203 BCL2 apoptosis regulator Homo sapiens 172-177 35245447-7 2022 Functional analyses reveal that Mito-AML is metabolically wired toward stronger complex I-dependent respiration and is more responsive to treatment with the BCL2 inhibitor venetoclax. venetoclax 172-182 BCL2 apoptosis regulator Homo sapiens 157-161 35408492-11 2022 Western blotting showed that artonin E increased the proapoptotic protein, Bax, and decreased anti-apoptotic proteins" (Bcl-2 and Bcl-x) expression. artonin E 29-38 BCL2 apoptosis regulator Homo sapiens 120-125 35326640-7 2022 Taken together, these data suggest that the NIK inhibitor, CW15337, exerts its effects via suppression of the non-canonical NF-kappaB signaling pathway, which reverses BCL2 family-mediated resistance in the context of CD40L stimulation. cw15337 59-66 BCL2 apoptosis regulator Homo sapiens 168-172 35202708-6 2022 Moreover, ROS-associated abnormal levels of caspase pathway-associated proteins (Bcl-2, Bax, cleaved-caspase3 and cleaved-caspase9) and apoptosis were suppressed. Reactive Oxygen Species 10-13 BCL2 apoptosis regulator Homo sapiens 81-86 35298964-9 2022 RESULTS: Compared with the control group, with the gradual increasing dose of NaAsO2, cell viability was considerable reduced, and increased rate of apoptosis, intracellular GSH level was decreased significantly, ROS was increased, mitochondrial structure was damaged, mitochondrial membrane potential DeltaPsim and Bcl2/BAX lowered, the expression of Caspase3 and cleaved-caspase3 were significantly increased, resulting in mitochondrial apoptosis. sodium arsenite 78-84 BCL2 apoptosis regulator Homo sapiens 316-320 35298964-11 2022 When BSO increased the inhibitory effect of NaAsO2 on GCLC, Compared with NaAsO2 group, the DeltaPsim and protein of Bcl-2/BAX, caspase3 and cleaved-capsase3 were increased. Buthionine Sulfoximine 5-8 BCL2 apoptosis regulator Homo sapiens 117-122 35298964-11 2022 When BSO increased the inhibitory effect of NaAsO2 on GCLC, Compared with NaAsO2 group, the DeltaPsim and protein of Bcl-2/BAX, caspase3 and cleaved-capsase3 were increased. sodium arsenite 44-50 BCL2 apoptosis regulator Homo sapiens 117-122 35298964-11 2022 When BSO increased the inhibitory effect of NaAsO2 on GCLC, Compared with NaAsO2 group, the DeltaPsim and protein of Bcl-2/BAX, caspase3 and cleaved-capsase3 were increased. sodium arsenite 74-80 BCL2 apoptosis regulator Homo sapiens 117-122 35336786-5 2022 Although the BCL-2 proteins are controlled by a complex regulatory network, a specific mechanism for the inhibition of tBID remained unknown. tBID 119-123 BCL2 apoptosis regulator Homo sapiens 13-18 35336786-8 2022 In contrast to general apoptosis inhibition by anti-apoptotic BCL-2 proteins, hexokinase I and hexokinase 2 specifically inhibit tBID and thus the mitochondrial apoptosis pathway in response to death receptor signaling. tBID 129-133 BCL2 apoptosis regulator Homo sapiens 62-67 35256597-0 2022 Correction to: Survival of midbrain dopamine neurons depends on the Bcl2 factor Mcl1. Dopamine 36-44 BCL2 apoptosis regulator Homo sapiens 68-72 35099408-8 2022 The expression of cleaved caspase-3 and bcl-2 were, respectively, decreased and increased by the combination of norepinephrine and cisplatin in SCC-9 and Cal27 cells. Norepinephrine 112-126 BCL2 apoptosis regulator Homo sapiens 40-45 35099408-8 2022 The expression of cleaved caspase-3 and bcl-2 were, respectively, decreased and increased by the combination of norepinephrine and cisplatin in SCC-9 and Cal27 cells. Cisplatin 131-140 BCL2 apoptosis regulator Homo sapiens 40-45 35235756-9 2022 Moreover, the terminal deoxynucleotidyl Transferase-mediated dUTP nick end labeling (TUNEL) apoptosis assay revealed that Memantine protected oxaliplatin-induced apoptosis through mitigating the ratio of Bax/Bcl-2 and Caspase-3 cleavage. Memantine 122-131 BCL2 apoptosis regulator Homo sapiens 208-213 35240000-11 2022 Western blot analysis indicated that zerumbone significantly upregulated BAX, caspase-7, and caspase-9 expression and decreased BCL-2 expression, thereby inducing proapoptotic protein-mediated cell death combined with PTX. zerumbone 37-46 BCL2 apoptosis regulator Homo sapiens 128-133 35240000-11 2022 Western blot analysis indicated that zerumbone significantly upregulated BAX, caspase-7, and caspase-9 expression and decreased BCL-2 expression, thereby inducing proapoptotic protein-mediated cell death combined with PTX. Paclitaxel 218-221 BCL2 apoptosis regulator Homo sapiens 128-133 35188170-4 2022 The results show that the as-prepared alpha-Fe2O3@PEDOT core-shell NPs with a uniform particle size exhibit positively charged surfaces, facilitating efficient siRNA Bcl-2 (B-cell lymphoma-2) uptake for delivery to breast cancer cells. alpha-fe2o3 38-49 BCL2 apoptosis regulator Homo sapiens 166-171 35246010-10 2022 bupivacaine inhibited the expression of Bcl-2 and increased the expression of Bax and cytochrome C. Bupivacaine 0-11 BCL2 apoptosis regulator Homo sapiens 40-45 34966123-1 2022 PURPOSE OF REVIEW: Venetoclax is a BCL-2 inhibitor that was approved in combination therapy with hypomethylating agents or low dose cytarabine for newly diagnosed acute myeloid leukemia (AML). hypomethylating agents 97-119 BCL2 apoptosis regulator Homo sapiens 35-40 35222709-6 2022 Western blot analysis demonstrated decreased expression of Bcl2, and increased expression of Bax in liver cancer cells treated with a combination of sorafenib and wh-4. Sorafenib 149-158 BCL2 apoptosis regulator Homo sapiens 59-63 35122929-5 2022 Meanwhile, we found o,p"-DDT induced mitochondria-dependent apoptosis, which is characterized by the loss of of mitochondrial membrane potential (Deltapsim), decreased Bcl-2 expression, and increased protein levels of Bax, cytochrome c, activated-caspase-9, and activated-caspase-3. o,p'-DDT 20-28 BCL2 apoptosis regulator Homo sapiens 168-173 35241510-11 2022 Compared to sorafenib or bufalin treatment alone, the combination treatment resulted in lower Bcl-2 expression but higher Bax, Bad, APAF-1, caspase-3, and caspase-9. Sorafenib 12-21 BCL2 apoptosis regulator Homo sapiens 94-99 35241510-11 2022 Compared to sorafenib or bufalin treatment alone, the combination treatment resulted in lower Bcl-2 expression but higher Bax, Bad, APAF-1, caspase-3, and caspase-9. bufalin 25-32 BCL2 apoptosis regulator Homo sapiens 94-99 35241512-9 2022 Gadodiamide also inhibited Bcl-2 expression and promoted Bax expression. gadodiamide 0-11 BCL2 apoptosis regulator Homo sapiens 27-32 35033536-8 2022 Evaluation of pro-apoptotic (cleaved caspase-3 and Bax) and anti-apoptotic markers (BCL-2) suggested an enhanced apoptotic rate in CsA- compared to Tac-treated cells as well. Cyclosporine 131-134 BCL2 apoptosis regulator Homo sapiens 84-89 35170373-9 2022 In addition, KCNQ1OT1-siRNA reversed the effects of H2O2 on SRA01/04 cells, evidenced by enhanced cell viability, inhibited apoptotic cells, promoted Bcl-2 expression, and reduced Bax levels. Hydrogen Peroxide 52-56 BCL2 apoptosis regulator Homo sapiens 150-155 34980601-6 2022 RESULTS: We found that MYC/BCL2 double-high-expression (DhE) had significant adverse prognostic impact within the EZB genetic subtype and LymphGen-unclassified DLBCL cases but not within MCD and ST2 genetic subtypes. Dihydroergotamine 56-59 BCL2 apoptosis regulator Homo sapiens 27-31 35085532-5 2022 Berberine had an antagonistic effect for the majority of genes mutual for AD and toxic metal mixture: ACHE, APP, BAX, BCL2, CASP3, HMOX1, IL1B, MAPT, SOD2, TNF. Berberine 0-9 BCL2 apoptosis regulator Homo sapiens 118-122 35177309-0 2022 Corrigendum to "Anti-apoptotic genes Bcl-2 and Bcl-xL overexpression can block iridovirus serine/threonine kinase-induced Bax/mitochondria-mediated cell death in GF-1 cells" (Fish Shellfish Immunol. Serine 90-96 BCL2 apoptosis regulator Homo sapiens 37-42 34966123-1 2022 PURPOSE OF REVIEW: Venetoclax is a BCL-2 inhibitor that was approved in combination therapy with hypomethylating agents or low dose cytarabine for newly diagnosed acute myeloid leukemia (AML). Cytarabine 132-142 BCL2 apoptosis regulator Homo sapiens 35-40 35088889-12 2022 After treatment with 4-OHT, knockdown of ATG4A suppressed proliferation, triggered apoptosis, decreased the expression of Bcl-2, beta-catenin, cyclin D1 and c-myc, and increased the expression of Bax and p-GSK3beta in MCF7/R cells. 4,17 beta-dihydroxy-4-androstene-3-one 21-26 BCL2 apoptosis regulator Homo sapiens 122-127 34999393-8 2022 Mechanistically, PRP had the similar effects as miR-181a-5p antagomir on RSV-induced apoptosis and inflammation in HEp-2 cells via upregulating BCL2, MLL3 and SIRT1, which could be reversed by miR-181a-5p mimic. mir-181a-5p 48-59 BCL2 apoptosis regulator Homo sapiens 144-148 35187882-13 2022 Moreover, glutamate decreased bcl-2 and increased bax expressions, while quercetin alleviated these changes. Glutamic Acid 10-19 BCL2 apoptosis regulator Homo sapiens 30-35 35187882-14 2022 The alleviative effect of quercetin in bcl-2 family protein expression was more remarkable in non-transfected cells. Quercetin 26-35 BCL2 apoptosis regulator Homo sapiens 39-44 35039875-9 2022 EGCG also reduced UVB-stimulated Bax, cytochrome c, caspase-9 and caspase-3 expression, and elevated Bcl-2 expression, suggesting that EGCG may possess free radical-scavenging properties, thus increasing cell viability. epigallocatechin gallate 0-4 BCL2 apoptosis regulator Homo sapiens 101-106 35039875-9 2022 EGCG also reduced UVB-stimulated Bax, cytochrome c, caspase-9 and caspase-3 expression, and elevated Bcl-2 expression, suggesting that EGCG may possess free radical-scavenging properties, thus increasing cell viability. epigallocatechin gallate 135-139 BCL2 apoptosis regulator Homo sapiens 101-106 35085581-7 2022 Piperlongumine treatment significantly upregulated the expression of genes BAX, P21, P53, and SMAD4; while the BCL-2, SURVIVIN, TNFA, and NFKB genes expression was found down-regulated. piperlonguminine 0-14 BCL2 apoptosis regulator Homo sapiens 111-116 35241842-6 2022 Further, patients with MDS who progressed after failure to frontline HMA therapy and whose HSCs upregulated BCL-2 achieved improved clinical responses to venetoclax-based therapy in the clinical setting. 5-(N,N-hexamethylene)amiloride 69-72 BCL2 apoptosis regulator Homo sapiens 108-113 35241842-6 2022 Further, patients with MDS who progressed after failure to frontline HMA therapy and whose HSCs upregulated BCL-2 achieved improved clinical responses to venetoclax-based therapy in the clinical setting. venetoclax 154-164 BCL2 apoptosis regulator Homo sapiens 108-113 35601773-12 2022 The RT-PCR results also showed an increase in Bax and a decrease in Bcl-2 expressions in mesalazine-treated cells. Mesalamine 89-99 BCL2 apoptosis regulator Homo sapiens 68-73 35278900-16 2022 Moreover, we observed that combination of TBMS1 and TMZ induced apoptosis was accompanied by robust DSB, gammaH2AX Foci formation and increasing cleaved PARP, as well as the heightened ratio of Bax/Bcl-2, cleavages of caspase-3 and caspase-9. tbms1 42-47 BCL2 apoptosis regulator Homo sapiens 198-203 35278900-16 2022 Moreover, we observed that combination of TBMS1 and TMZ induced apoptosis was accompanied by robust DSB, gammaH2AX Foci formation and increasing cleaved PARP, as well as the heightened ratio of Bax/Bcl-2, cleavages of caspase-3 and caspase-9. Temozolomide 52-55 BCL2 apoptosis regulator Homo sapiens 198-203 35210368-6 2022 PKC in chronic Cr(VI)-treated cells stabilizes Bcl-2 to mitigate doxorubicin (an anti-cancer drug)-mediated apoptosis. Doxorubicin 65-76 BCL2 apoptosis regulator Homo sapiens 47-52 35164499-8 2022 Furthermore, we observed channel closure through steric blockage by a drug shown to selectively bind to the channel, the Bcl2-antisense oligonucleotide G3139. Oligonucleotides 136-151 BCL2 apoptosis regulator Homo sapiens 121-125 35164499-8 2022 Furthermore, we observed channel closure through steric blockage by a drug shown to selectively bind to the channel, the Bcl2-antisense oligonucleotide G3139. oblimersen 152-157 BCL2 apoptosis regulator Homo sapiens 121-125 35197069-12 2022 Overexpression of Bcl-2 in the docetaxel-resistant PCa cells enhanced cell proliferation of docetaxel-resistant PCa cells under combination treatment. Docetaxel 31-40 BCL2 apoptosis regulator Homo sapiens 18-23 35193476-8 2022 Further, the molecular docking and molecular dynamics simulation studies result shows that 7-hydroxy flavone has the better binding ability with anti-apoptotic Bcl-2 protein with the estimated free energy of binding of -6.3 kcal/mol. 7-hydroxyflavone 91-108 BCL2 apoptosis regulator Homo sapiens 160-165 35197069-12 2022 Overexpression of Bcl-2 in the docetaxel-resistant PCa cells enhanced cell proliferation of docetaxel-resistant PCa cells under combination treatment. Docetaxel 92-101 BCL2 apoptosis regulator Homo sapiens 18-23 35197069-14 2022 CONCLUSIONS: Combination treatment of docetaxel with CAPE effectively suppressed the proliferation and survival of docetaxel-resistant PCa cells via inhibition of Bcl-2 and c-Myc as well as induction of metabolism interference. Docetaxel 38-47 BCL2 apoptosis regulator Homo sapiens 163-168 35197069-14 2022 CONCLUSIONS: Combination treatment of docetaxel with CAPE effectively suppressed the proliferation and survival of docetaxel-resistant PCa cells via inhibition of Bcl-2 and c-Myc as well as induction of metabolism interference. caffeic acid phenethyl ester 53-57 BCL2 apoptosis regulator Homo sapiens 163-168 35193595-13 2022 Decreased frequencies and recovery functions of BCL-2+T cells were observed in CLL patients in complete remission after treatment with venetoclax. venetoclax 135-145 BCL2 apoptosis regulator Homo sapiens 48-53 35193595-14 2022 CONCLUSION: BCL-2 expression in the T cells of CLL patients is associated with immunosuppression via promotion of Treg abundance and CTL exhaustion. treg 114-118 BCL2 apoptosis regulator Homo sapiens 12-17 35185150-1 2022 Despite high initial response rates, acute myeloid leukemia (AML) treated with the BCL-2-selective inhibitor venetoclax (VEN) alone or in combinations commonly acquires resistance. venetoclax 109-119 BCL2 apoptosis regulator Homo sapiens 83-88 35187677-13 2022 In addition, the expression levels of cleaved caspase-3 and Bax were decreased, while Bcl-2 expression was increased in alpha-mangostin- or MCC950-treated NPCs. mangostin 120-135 BCL2 apoptosis regulator Homo sapiens 86-91 35185150-1 2022 Despite high initial response rates, acute myeloid leukemia (AML) treated with the BCL-2-selective inhibitor venetoclax (VEN) alone or in combinations commonly acquires resistance. venetoclax 121-124 BCL2 apoptosis regulator Homo sapiens 83-88 35074488-5 2022 DHT induced apoptosis and G2 cell cycle arrest accompanied by reduced expression of Bcl-2, Caspase-3, and increased Bax. Dihydrotestosterone 0-3 BCL2 apoptosis regulator Homo sapiens 84-89 35216449-8 2022 Conversely, Dox-induced CD133 expression diminished apoptosis in both trametinib-treated cell lines, coincident with elevated p-AKT, p-BAD, BCL-2, and BCL-xL and decreased activation of BAX and caspases-3 and -9. Doxorubicin 12-15 BCL2 apoptosis regulator Homo sapiens 140-145 35204304-5 2022 LGSP-treated HeLa cells showed a reduction in mitochondrial membrane potential, upregulation of the Bax/Bcl-2 ratio, release of cytochrome c into the cytoplasm, and activation of cleaved caspase-9/3 and cleavage of PARP, thus indicating that LGSP induced apoptosis through the intrinsic mitochondrial/caspase-mediated pathway. lgsp 0-4 BCL2 apoptosis regulator Homo sapiens 104-109 35188042-3 2022 We demonstrated the synergism of (Bis + ABT199/venetoclax) in combination with panobinostat (Pano), decitabine (DAC), or olaparib (Ola), known inhibitors of BCL2, histone deacetylase, DNA methyltransferase, and poly(ADP-ribose) polymerase, respectively, in AML cells. bis + abt199 34-46 BCL2 apoptosis regulator Homo sapiens 157-161 35188042-3 2022 We demonstrated the synergism of (Bis + ABT199/venetoclax) in combination with panobinostat (Pano), decitabine (DAC), or olaparib (Ola), known inhibitors of BCL2, histone deacetylase, DNA methyltransferase, and poly(ADP-ribose) polymerase, respectively, in AML cells. venetoclax 47-57 BCL2 apoptosis regulator Homo sapiens 157-161 35188042-3 2022 We demonstrated the synergism of (Bis + ABT199/venetoclax) in combination with panobinostat (Pano), decitabine (DAC), or olaparib (Ola), known inhibitors of BCL2, histone deacetylase, DNA methyltransferase, and poly(ADP-ribose) polymerase, respectively, in AML cells. Panobinostat 79-91 BCL2 apoptosis regulator Homo sapiens 157-161 35188042-3 2022 We demonstrated the synergism of (Bis + ABT199/venetoclax) in combination with panobinostat (Pano), decitabine (DAC), or olaparib (Ola), known inhibitors of BCL2, histone deacetylase, DNA methyltransferase, and poly(ADP-ribose) polymerase, respectively, in AML cells. Panobinostat 93-97 BCL2 apoptosis regulator Homo sapiens 157-161 35188042-3 2022 We demonstrated the synergism of (Bis + ABT199/venetoclax) in combination with panobinostat (Pano), decitabine (DAC), or olaparib (Ola), known inhibitors of BCL2, histone deacetylase, DNA methyltransferase, and poly(ADP-ribose) polymerase, respectively, in AML cells. Decitabine 100-110 BCL2 apoptosis regulator Homo sapiens 157-161 35188042-3 2022 We demonstrated the synergism of (Bis + ABT199/venetoclax) in combination with panobinostat (Pano), decitabine (DAC), or olaparib (Ola), known inhibitors of BCL2, histone deacetylase, DNA methyltransferase, and poly(ADP-ribose) polymerase, respectively, in AML cells. olaparib 121-129 BCL2 apoptosis regulator Homo sapiens 157-161 35188042-3 2022 We demonstrated the synergism of (Bis + ABT199/venetoclax) in combination with panobinostat (Pano), decitabine (DAC), or olaparib (Ola), known inhibitors of BCL2, histone deacetylase, DNA methyltransferase, and poly(ADP-ribose) polymerase, respectively, in AML cells. olaparib 131-134 BCL2 apoptosis regulator Homo sapiens 157-161 35216449-8 2022 Conversely, Dox-induced CD133 expression diminished apoptosis in both trametinib-treated cell lines, coincident with elevated p-AKT, p-BAD, BCL-2, and BCL-xL and decreased activation of BAX and caspases-3 and -9. trametinib 70-80 BCL2 apoptosis regulator Homo sapiens 140-145 35216449-9 2022 AKT1/2 siRNA knockdown or inhibition of BCL-2 family members with navitoclax (ABT-263) in BAKP-KO cells further enhanced caspase-mediated apoptotic PARP cleavage. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 78-81 BCL2 apoptosis regulator Homo sapiens 40-45 35365454-8 2022 Compared with melatonin treatment alone, melatonin treatment combined with 3-MA significantly decreased the expressions of Beclin1 (P < 0.001), LC3-II/LC3-I (P < 0.05), Bax (P < 0.01), and E-cadherin (P < 0.001) and increased the expressions of Bcl2 (P < 0.05), Snail, and Bcl2/Bax ratio (P < 0.01). Melatonin 41-50 BCL2 apoptosis regulator Homo sapiens 245-249 35365454-5 2022 The effects of melatonin treatment alone or in combination with 3-methyladenine (3-MA) on the expressions of the proteins associated with autophagy (LC3, P62 and Beclin1), apoptosis (Bcl2 and Bax) and epithelial-mesenchymal transition (E-cadherin and Snail) were examined with Western blotting. Melatonin 15-24 BCL2 apoptosis regulator Homo sapiens 183-187 35365454-5 2022 The effects of melatonin treatment alone or in combination with 3-methyladenine (3-MA) on the expressions of the proteins associated with autophagy (LC3, P62 and Beclin1), apoptosis (Bcl2 and Bax) and epithelial-mesenchymal transition (E-cadherin and Snail) were examined with Western blotting. 3-methyladenine 64-79 BCL2 apoptosis regulator Homo sapiens 183-187 35365454-8 2022 Compared with melatonin treatment alone, melatonin treatment combined with 3-MA significantly decreased the expressions of Beclin1 (P < 0.001), LC3-II/LC3-I (P < 0.05), Bax (P < 0.01), and E-cadherin (P < 0.001) and increased the expressions of Bcl2 (P < 0.05), Snail, and Bcl2/Bax ratio (P < 0.01). Melatonin 41-50 BCL2 apoptosis regulator Homo sapiens 273-277 35216449-11 2022 Targeting nodes of the CD133, AKT, or BCL-2 survival pathways with trametinib highlights the potential for combination therapies for NRAS-mutant melanoma stem cells for the development of more effective treatments for patients with high-risk melanoma. trametinib 67-77 BCL2 apoptosis regulator Homo sapiens 38-43 35365454-8 2022 Compared with melatonin treatment alone, melatonin treatment combined with 3-MA significantly decreased the expressions of Beclin1 (P < 0.001), LC3-II/LC3-I (P < 0.05), Bax (P < 0.01), and E-cadherin (P < 0.001) and increased the expressions of Bcl2 (P < 0.05), Snail, and Bcl2/Bax ratio (P < 0.01). 3-methyladenine 75-79 BCL2 apoptosis regulator Homo sapiens 245-249 35365454-8 2022 Compared with melatonin treatment alone, melatonin treatment combined with 3-MA significantly decreased the expressions of Beclin1 (P < 0.001), LC3-II/LC3-I (P < 0.05), Bax (P < 0.01), and E-cadherin (P < 0.001) and increased the expressions of Bcl2 (P < 0.05), Snail, and Bcl2/Bax ratio (P < 0.01). 3-methyladenine 75-79 BCL2 apoptosis regulator Homo sapiens 273-277 35365454-5 2022 The effects of melatonin treatment alone or in combination with 3-methyladenine (3-MA) on the expressions of the proteins associated with autophagy (LC3, P62 and Beclin1), apoptosis (Bcl2 and Bax) and epithelial-mesenchymal transition (E-cadherin and Snail) were examined with Western blotting. 3-methyladenine 81-85 BCL2 apoptosis regulator Homo sapiens 183-187 35365454-7 2022 Melatonin treatment alone significantly increased the expressions of Bax (P < 0.05), E-cadherin, LC3-II/LC3-I, and Beclin1 and lowered the expressions of Bcl2 (P < 0.05), Snail, P62 (P < 0.05), and Bcl2/Bax ratio (P < 0.01) in the cells, and caused enhanced positive staining of Beclin1 protein and attenuated staining of P62 protein. Melatonin 0-9 BCL2 apoptosis regulator Homo sapiens 154-158 35365454-7 2022 Melatonin treatment alone significantly increased the expressions of Bax (P < 0.05), E-cadherin, LC3-II/LC3-I, and Beclin1 and lowered the expressions of Bcl2 (P < 0.05), Snail, P62 (P < 0.05), and Bcl2/Bax ratio (P < 0.01) in the cells, and caused enhanced positive staining of Beclin1 protein and attenuated staining of P62 protein. Melatonin 0-9 BCL2 apoptosis regulator Homo sapiens 198-202 35215023-8 2022 Surprisingly, Cur@affi-F/GQs significantly enhance the expression and activity of apoptosis-associated proteins in Bcl-2/Bax-caspase 8, 9-caspase 3 apoptotic pathway, which is the main factor in the death of tumor cells induced by FUdR. Floxuridine 231-235 BCL2 apoptosis regulator Homo sapiens 115-120 35182347-7 2022 Flow cytometric and PCR analyses revealed that SeNPs-apigenin treatment induced apoptosis in MCF-7 cells, demonstrating that SeNPs-apigenin treatment could directly target Bcl-2, Bax, and caspase-3 and result in the discharge of cytochrome C from mitochondria into the cytosol, accompanied by the initiation of cell death, leading to permanent DNA damage and killing of MCF-7 cells. Apigenin 53-61 BCL2 apoptosis regulator Homo sapiens 172-177 35242748-8 2022 Curcumin/TPP-CZL nanomicelles could significantly reduce the mitochondrial membrane potential, increase the expression of pro apoptotic protein Bcl-2, and reduce the expression of antiapoptotic Bax protein, and these results were significantly better than curcumin/CZL nanomicelles and curcumin. Curcumin 0-8 BCL2 apoptosis regulator Homo sapiens 144-149 35215358-10 2022 Furthermore, 12b-treated HepG2 cells expressed a low level of anti-apoptotic BCL-2 and over-expressed proapoptotic Bax genes, respectively. 12b 13-16 BCL2 apoptosis regulator Homo sapiens 77-82 35300350-5 2021 Caffeine arrests GBM cell cycle in G0/G1 phase by cyclin-dependent kinases (CDK) complex inhibition and by decreasing BCL-2 and increasing FOXO1 expression levels causing greater apoptotic activity. Caffeine 0-8 BCL2 apoptosis regulator Homo sapiens 118-123 35242748-8 2022 Curcumin/TPP-CZL nanomicelles could significantly reduce the mitochondrial membrane potential, increase the expression of pro apoptotic protein Bcl-2, and reduce the expression of antiapoptotic Bax protein, and these results were significantly better than curcumin/CZL nanomicelles and curcumin. tpp-czl 9-16 BCL2 apoptosis regulator Homo sapiens 144-149 35237157-10 2022 XBS also down-regulated the expression of p-Akt (Ser473)/Akt, Bax and Caspase-3 and up-regulated the expression of Bcl-2, indicating that regulating Akt1 and Caspase-3 to achieve anti-apoptotic effect is also the mechanism of XBS for treating pediatric pneumonia. CHEMBL4082603 0-3 BCL2 apoptosis regulator Homo sapiens 115-120 35186478-10 2022 Whereas 7,8-DHF treatment downregulated Bax and cleaved caspase-3 but upregulated Bcl-2. 6,7-dihydroxyflavone 8-15 BCL2 apoptosis regulator Homo sapiens 82-87 35154579-4 2022 We, therefore, determined the synergistic cytotoxicity of various combinations of the alkylating agents busulfan (Bu) and 4-hydroperoxycyclophosphamide (4HC), the nucleoside analog fludarabine (Flu) and the BCL2 inhibitor ABT199/venetoclax in AML cells. Busulfan 104-112 BCL2 apoptosis regulator Homo sapiens 207-211 35149956-6 2022 We further investigated the effects of Cu in modulating the pro- and anti-apoptotic proteins, such as Bax, Bcl-2, etc. Copper 39-41 BCL2 apoptosis regulator Homo sapiens 107-112 35189631-11 2022 Moreover, the Bcl-2/Bax ratio was higher in cells that were treated with curcumin before doxazosin or carvedilol. Curcumin 73-81 BCL2 apoptosis regulator Homo sapiens 14-19 35189631-11 2022 Moreover, the Bcl-2/Bax ratio was higher in cells that were treated with curcumin before doxazosin or carvedilol. Doxazosin 89-98 BCL2 apoptosis regulator Homo sapiens 14-19 35189631-11 2022 Moreover, the Bcl-2/Bax ratio was higher in cells that were treated with curcumin before doxazosin or carvedilol. Carvedilol 102-112 BCL2 apoptosis regulator Homo sapiens 14-19 35151247-9 2022 To verify the mechanism of cell death induced by artemisinin in A-253 cells, we found an increased level of Bax, Bim, Bad, Bak and reduced level of antiapoptotic protein Bcl-2, Bcl-XL with concomitant release of mitochondrial resident protein cytochrome c into the cytoplasm. artemisinin 49-60 BCL2 apoptosis regulator Homo sapiens 170-175 35215394-9 2022 Hesperetin is able to upregulate Bcl-2 protein expression, downregulate Bax expression, and decrease caspase-12/-9/-3 activity as well, indicating that it inhibits ER stress-mediated neuronal apoptosis. hesperetin 0-10 BCL2 apoptosis regulator Homo sapiens 33-38 35154579-4 2022 We, therefore, determined the synergistic cytotoxicity of various combinations of the alkylating agents busulfan (Bu) and 4-hydroperoxycyclophosphamide (4HC), the nucleoside analog fludarabine (Flu) and the BCL2 inhibitor ABT199/venetoclax in AML cells. Busulfan 114-116 BCL2 apoptosis regulator Homo sapiens 207-211 35118741-8 2022 The expressions of CDK1, BCL2, MYC, and survivin were reduced, while the expressions of BAX and PARP were increased in DDZ treated cells. daidzin 119-122 BCL2 apoptosis regulator Homo sapiens 25-29 35211416-7 2022 Our ex vivo study also showed that midostaurin alone could inhibit proliferation and induce apoptosis of Kasumi-1 cells (e.g. Midostaurin induced G2 phase cell arrest, down-regulated p-KIT and BCL-2, while Bax protein levels were up-regulated) and observed a synergistic anti effect when the two drugs were combined. midostaurin 35-46 BCL2 apoptosis regulator Homo sapiens 193-198 35211416-7 2022 Our ex vivo study also showed that midostaurin alone could inhibit proliferation and induce apoptosis of Kasumi-1 cells (e.g. Midostaurin induced G2 phase cell arrest, down-regulated p-KIT and BCL-2, while Bax protein levels were up-regulated) and observed a synergistic anti effect when the two drugs were combined. midostaurin 126-137 BCL2 apoptosis regulator Homo sapiens 193-198 35093886-4 2022 RESULTS: We observed an increase in O2 - production only in BCL2KO NB cells treated with cisplatin (three-fold) and CasIIIia (five-fold), whereas the production of H2O2 in BCL2KO NB cells treated with cisplatin and CasIIIia increased five-fold and three-fold, respectively. Cisplatin 89-98 BCL2 apoptosis regulator Homo sapiens 60-64 35201512-10 2022 Co-inhibition of MCL-1 and BCL-2 with MCL-1 selective inhibitor S63845 and BCL-2 selective inhibitor ABT-199 inhibited NPC cell proliferation but the effect on cell viability was more profound with co-inhibition of MCL-1 and BCL-XL with S63845 and A-1331852, implying that MCL-1 and BCL-XL are crucial for NPC cell survival. S63845 64-70 BCL2 apoptosis regulator Homo sapiens 27-32 35201512-10 2022 Co-inhibition of MCL-1 and BCL-2 with MCL-1 selective inhibitor S63845 and BCL-2 selective inhibitor ABT-199 inhibited NPC cell proliferation but the effect on cell viability was more profound with co-inhibition of MCL-1 and BCL-XL with S63845 and A-1331852, implying that MCL-1 and BCL-XL are crucial for NPC cell survival. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 101-104 BCL2 apoptosis regulator Homo sapiens 27-32 35201512-10 2022 Co-inhibition of MCL-1 and BCL-2 with MCL-1 selective inhibitor S63845 and BCL-2 selective inhibitor ABT-199 inhibited NPC cell proliferation but the effect on cell viability was more profound with co-inhibition of MCL-1 and BCL-XL with S63845 and A-1331852, implying that MCL-1 and BCL-XL are crucial for NPC cell survival. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 101-104 BCL2 apoptosis regulator Homo sapiens 75-80 35201512-10 2022 Co-inhibition of MCL-1 and BCL-2 with MCL-1 selective inhibitor S63845 and BCL-2 selective inhibitor ABT-199 inhibited NPC cell proliferation but the effect on cell viability was more profound with co-inhibition of MCL-1 and BCL-XL with S63845 and A-1331852, implying that MCL-1 and BCL-XL are crucial for NPC cell survival. S63845 237-243 BCL2 apoptosis regulator Homo sapiens 27-32 35201512-10 2022 Co-inhibition of MCL-1 and BCL-2 with MCL-1 selective inhibitor S63845 and BCL-2 selective inhibitor ABT-199 inhibited NPC cell proliferation but the effect on cell viability was more profound with co-inhibition of MCL-1 and BCL-XL with S63845 and A-1331852, implying that MCL-1 and BCL-XL are crucial for NPC cell survival. A-1331852 248-257 BCL2 apoptosis regulator Homo sapiens 27-32 35093886-4 2022 RESULTS: We observed an increase in O2 - production only in BCL2KO NB cells treated with cisplatin (three-fold) and CasIIIia (five-fold), whereas the production of H2O2 in BCL2KO NB cells treated with cisplatin and CasIIIia increased five-fold and three-fold, respectively. Oxygen 36-40 BCL2 apoptosis regulator Homo sapiens 60-64 35093886-4 2022 RESULTS: We observed an increase in O2 - production only in BCL2KO NB cells treated with cisplatin (three-fold) and CasIIIia (five-fold), whereas the production of H2O2 in BCL2KO NB cells treated with cisplatin and CasIIIia increased five-fold and three-fold, respectively. Oxygen 36-40 BCL2 apoptosis regulator Homo sapiens 172-176 35093886-4 2022 RESULTS: We observed an increase in O2 - production only in BCL2KO NB cells treated with cisplatin (three-fold) and CasIIIia (five-fold), whereas the production of H2O2 in BCL2KO NB cells treated with cisplatin and CasIIIia increased five-fold and three-fold, respectively. (4,4-dimethyl-2,2-bipyridine)(acetylacetonate)copper(II) 116-124 BCL2 apoptosis regulator Homo sapiens 60-64 35093886-4 2022 RESULTS: We observed an increase in O2 - production only in BCL2KO NB cells treated with cisplatin (three-fold) and CasIIIia (five-fold), whereas the production of H2O2 in BCL2KO NB cells treated with cisplatin and CasIIIia increased five-fold and three-fold, respectively. Hydrogen Peroxide 164-168 BCL2 apoptosis regulator Homo sapiens 60-64 35093886-4 2022 RESULTS: We observed an increase in O2 - production only in BCL2KO NB cells treated with cisplatin (three-fold) and CasIIIia (five-fold), whereas the production of H2O2 in BCL2KO NB cells treated with cisplatin and CasIIIia increased five-fold and three-fold, respectively. Hydrogen Peroxide 164-168 BCL2 apoptosis regulator Homo sapiens 172-176 34747319-6 2022 Also, GA treatment significantly decreased the Bax/Bcl2 protein ratio and the expression of Cyclin D1, CDK2, CDK4, MMP-9, N-cadherin, and vimentin in SW620 and HT29 cells. Glycyrrhizic Acid 6-8 BCL2 apoptosis regulator Homo sapiens 51-55 35093886-4 2022 RESULTS: We observed an increase in O2 - production only in BCL2KO NB cells treated with cisplatin (three-fold) and CasIIIia (five-fold), whereas the production of H2O2 in BCL2KO NB cells treated with cisplatin and CasIIIia increased five-fold and three-fold, respectively. Cisplatin 201-210 BCL2 apoptosis regulator Homo sapiens 60-64 35093886-4 2022 RESULTS: We observed an increase in O2 - production only in BCL2KO NB cells treated with cisplatin (three-fold) and CasIIIia (five-fold), whereas the production of H2O2 in BCL2KO NB cells treated with cisplatin and CasIIIia increased five-fold and three-fold, respectively. Cisplatin 201-210 BCL2 apoptosis regulator Homo sapiens 172-176 35068334-10 2022 In diabetic thoracic aorta, HG- and CCCP-induced HUVECs, Sal B distinctly increased Bcl-2 expression and reduced BAX, Beclin1, Parkin and Pink1 expression, thereby protecting endothelial cells from apoptosis and mitophagy. salvianolic acid B 57-62 BCL2 apoptosis regulator Homo sapiens 84-89 35069862-8 2022 Briefly, the present data indicated that 2-benzoyl-3-hydroxy-4-methyl-9H-xanthen-9-one could suppress proliferation, induce early apoptosis and inhibit invasion in MCF-7 cells by suppressing the expression of Bcl-2 and promoting the expression of Bax, caspase-9, and caspase-3. 2-benzoyl-3-hydroxy-4-methyl-9h-xanthen-9-one 41-86 BCL2 apoptosis regulator Homo sapiens 209-214 35225471-9 2022 Quantitative real-time PCR analysis demonstrated that BA increased p53, Bax and caspase-3 expression whilst it decreased Bcl-2 expression in the HuCCA cells in a dose dependent manner. betulinic acid 54-56 BCL2 apoptosis regulator Homo sapiens 121-126 35069862-9 2022 These findings indicated that 2-benzoyl-3-hydroxy-4-methyl-9H-xanthen-9-one could induce apoptosis by inhibiting the activation of AKT and TAK1, and affecting the Bcl-2/Bax-caspase-9-caspase-3 pathway by competitively binding with TRAF6. 2-benzoyl-3-hydroxy-4-methyl-9h-xanthen-9-one 30-75 BCL2 apoptosis regulator Homo sapiens 163-168 35573641-5 2022 Baicalin-induced apoptosis was confirmed by enhanced Bax, cleaved caspase-3, and cleaved PARP levels and decreased Bcl-2 levels. baicalin 0-8 BCL2 apoptosis regulator Homo sapiens 115-120 35380485-9 2022 HIF-1alpha reduces H2O2-induced apoptosis by upregulating Bcl-2 and Bcl-XL, downregulating Bax, Bak, and caspase-9, stabilizing intracellular ROS levels, and promoting the repair of H2O2-induced DNA damage to reduce apoptosis. Hydrogen Peroxide 19-23 BCL2 apoptosis regulator Homo sapiens 58-63 35140891-2 2022 Human Bfk is a novel Bcl-2 family protein owing to its unique domain composition involving BH2 and BH3. bh2 91-94 BCL2 apoptosis regulator Homo sapiens 21-26 35101006-12 2022 The expression of Bcl-2 mRNA was down-regulated by the high(3000 mug/ml) dose group of ethyl acetate extract. ethyl acetate 87-100 BCL2 apoptosis regulator Homo sapiens 18-23 35067933-12 2022 Our findings also showed an opposite mRNA expression of Bcl-2 (anti-apoptotic marker) and Bax2 (pro-apoptotic marker) when k-562 cells were treated with SMB. sodium metabisulfite 153-156 BCL2 apoptosis regulator Homo sapiens 56-61 35099591-2 2022 Recently, approval of the BCL-2 inhibitor venetoclax (VEN) in combination with hypo-methylating agents (HMA) led to a significant improvement of response rates and survival. 5-(N,N-hexamethylene)amiloride 104-107 BCL2 apoptosis regulator Homo sapiens 26-31 35140891-2 2022 Human Bfk is a novel Bcl-2 family protein owing to its unique domain composition involving BH2 and BH3. BH 3 99-102 BCL2 apoptosis regulator Homo sapiens 21-26 35153769-4 2021 Our screening revealed that both the bromodomain and extra-terminal domain (BET) inhibitor, I-BET151, and kinase inhibitor, sunitinib, decreased the BCL-2 family protein expression and significantly synergized with venetoclax, enhancing KMT2A-r AML cell line death. Sunitinib 124-133 BCL2 apoptosis regulator Homo sapiens 149-154 35155508-6 2021 alpha-Mangostin significantly inhibited oxidative stress-induced cell death in neuronal cells by reducing BAX protein, decreasing caspase-3/7 activation, and increasing anti-apoptotic BCL-2 protein. mangostin 0-15 BCL2 apoptosis regulator Homo sapiens 184-189 34978808-6 2022 Also, Sal downregulated the Bcl-2, MMP-2, MMP-9, PI3K, and AKT and upregulated BAX proteins. rhodioloside 6-9 BCL2 apoptosis regulator Homo sapiens 28-33 35155225-8 2022 Crizotinib and sunitinib induced apoptosis via the mitochondrial pathway, which was characterized by decreasing Bcl2/Bax ratio to dissipate the mitochondrial membrane potential, and increasing apoptotic markers levels. Crizotinib 0-10 BCL2 apoptosis regulator Homo sapiens 112-116 35155225-8 2022 Crizotinib and sunitinib induced apoptosis via the mitochondrial pathway, which was characterized by decreasing Bcl2/Bax ratio to dissipate the mitochondrial membrane potential, and increasing apoptotic markers levels. Sunitinib 15-24 BCL2 apoptosis regulator Homo sapiens 112-116 35127282-18 2022 We also found that miR-148a-3p induced cell apoptosis by regulating the expression of Bcl-2. mir-148a-3p 19-30 BCL2 apoptosis regulator Homo sapiens 86-91 35079096-6 2022 Overexpression of anti-apoptotic Bcl-2 family members decrease both metformin effects. Metformin 68-77 BCL2 apoptosis regulator Homo sapiens 33-38 35111687-5 2021 CAP treatment induced intense phenotypic changes and apoptosis in both ER+ and ER- cells, which is associated with the mitochondrial pathway as evidenced by the increased Bax/Bcl-2 ratio and cleavage of PARP-1. cap 0-3 BCL2 apoptosis regulator Homo sapiens 175-180 35057867-9 2022 Mito-DHA5 could down-regulate the expression of Bcl-2, mitochondrial Cyt-C, Caspase-3, PARP and up-regulate the expression of Bax and cleaved Caspase-3. mito-dha5 0-9 BCL2 apoptosis regulator Homo sapiens 48-53 35111001-5 2021 Consequently, elamipretide could prevent neural apoptosis (cytochrome c, Bax, caspase 9, and caspase 3) and enhance neural pro-survival (Bcl2, BDNF, and TrkB) in neurodegeneration. arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide 14-26 BCL2 apoptosis regulator Homo sapiens 137-141 35173836-5 2022 RESULTS: Cell viability and proliferation were suppressed, and apoptosis was promoted in CRPC cells after Cabazitaxel treatment alone, accompanied with upregulated expressions of Bax and cleaved caspase 3 and downregulated Bcl-2 expression. cabazitaxel 106-117 BCL2 apoptosis regulator Homo sapiens 223-228 35173836-7 2022 Meanwhile, Cabazitaxel enhanced the effects of IR on suppressing survival and promoting apoptosis in CRPC cells through downregulating Bcl-2 and upregulating Bax and cleaved caspase 3. cabazitaxel 11-22 BCL2 apoptosis regulator Homo sapiens 135-140 35173828-6 2022 MiR-24 targets and regulates numerous genes in various cancer types and enhances the expression of several oncogenes (e.g., cMyc, BCL2 and HIF1), which are challenging in terms of druggability. mir-24 0-6 BCL2 apoptosis regulator Homo sapiens 130-134 35013156-3 2022 BH3 mimetics neutralize the antiapoptotic function of Bcl-2 proteins and are highly promising compounds inducing apoptosis in several cancer entities including pediatric malignancies. BH 3 0-3 BCL2 apoptosis regulator Homo sapiens 54-59 35013120-6 2022 Additional investigation revealed that acting transcription factor 4 (ATF4) triggered CEMIP transcription and enhanced protein kinase C alpha (PKCalpha) membrane translocation, which regulated the serine70 phosphorylation of Bcl-2, while the subsequent dissociation of the Bcl-2/Beclin1 complex led to autophagy. serine70 197-205 BCL2 apoptosis regulator Homo sapiens 225-230 35154350-6 2022 Immunoblotting revealed that paeoniflorin significantly increased the already elevated Bax/Bcl2 protein expression ratio and the caspase 3 activity levels, both induced by tamoxifen. peoniflorin 29-41 BCL2 apoptosis regulator Homo sapiens 91-95 35154350-6 2022 Immunoblotting revealed that paeoniflorin significantly increased the already elevated Bax/Bcl2 protein expression ratio and the caspase 3 activity levels, both induced by tamoxifen. Tamoxifen 172-181 BCL2 apoptosis regulator Homo sapiens 91-95 35052646-7 2022 Furthermore, N-acyl dopamines prevented cell death 24 h after OS induction and promoted the expression of antioxidant enzymes GPX1, GPX7, SOD1, SOD2 and CAT, as well as reduced the BAX/BCL2 mRNA ratio. n-acyl dopamines 13-29 BCL2 apoptosis regulator Homo sapiens 185-189 35013156-10 2022 Treatment with either the Bcl-XL inhibitor A1331852 or the Mcl-1 inhibitor S63845 increased the cytotoxicity of NK cells and reduced spheroid size, while the Bcl-2 inhibitor ABT-199 had no effect on NK cell-mediated killing. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 174-177 BCL2 apoptosis regulator Homo sapiens 158-163 34986346-5 2022 Accordingly, in vitro and in vivo studies reveal synergy between the direct AMPK activator GSK621 and the Bcl-2 inhibitor venetoclax. GSK621 91-97 BCL2 apoptosis regulator Homo sapiens 106-111 35056723-10 2022 The concurrent apoptotic effect of 7HF on the treated cells was mediated via both intrinsic and extrinsic modes through the upregulation of Bax and active cleaved caspase-7-9 expression and downregulation of Bcl-2 and full-length caspase-7-9 expression. 7alpha-hydroxyfrullanolide 35-38 BCL2 apoptosis regulator Homo sapiens 208-213 34994335-10 2022 These compounds combined with cisplatin caused upregulation in the pro-apoptotic Bax, Bid, caspase-3, caspase-8, caspase-9, Fas, and p53 gene expressions while downregulating anti-apoptotic DFFA, NFkB1, and Bcl2 gene expressions. Cisplatin 30-39 BCL2 apoptosis regulator Homo sapiens 207-211 34624089-0 2022 Oncogenic role of SOX9-DHCR24-cholesterol biosynthesis axis in IGH-BCL2 positive diffuse large B-cell lymphomas. Cholesterol 30-41 BCL2 apoptosis regulator Homo sapiens 67-71 35154466-6 2022 Meanwhile, CP-25 and 5-Fu activated the intrinsic mitochondrial apoptosis pathway induced by P53, inhibited anti-apoptotic B-cell lymphoma (Bcl-2), induced the pro-apoptotic Bcl-2-associated X protein (Bax), Cytochrome-C and caspases. Fluorouracil 21-25 BCL2 apoptosis regulator Homo sapiens 140-145 35008959-4 2022 Furthermore, BDMC induced apoptosis via inhibited Bcl-2 (anti-apoptotic protein) and increased Bax (pro-apoptotic proteins) and cytochrome c release in GBM 8401/luc2 cells in vitro. bisdemethoxycurcumin 13-17 BCL2 apoptosis regulator Homo sapiens 50-55 35008959-8 2022 Meanwhile, treatment with BDMC up-regulated the expressions of BAX and cleaved caspase-3, while it down-regulated the protein expressions of Bcl-2 and XIAP in the tumor tissues compared with the control group. bisdemethoxycurcumin 26-30 BCL2 apoptosis regulator Homo sapiens 141-146 34897340-4 2022 Treatment with MPTE also induced apoptosis in a concentration-dependent manner in human cancer cell lines (HeLa and U2OS), as evidenced by the enhanced activation of caspase 3 and the cleavage of PARP along with the downregulation of the antiapoptotic protein Bcl-2. mpte 15-19 BCL2 apoptosis regulator Homo sapiens 260-265 34949154-6 2022 Moreover, H2O2 inhibited Bcl-2 expression in A549 cells, but increased Bax and the activity of Caspase-3. Hydrogen Peroxide 10-14 BCL2 apoptosis regulator Homo sapiens 25-30 34980181-10 2022 Knockdown of miR-125a-5p or miR-125b-5p significantly enhanced the proliferation and migration of MM.1S and U266 cells, and co-transfection of sh-Bcl-2 and miR-125a/b-5p inhibitor inhibited cell proliferation compared with that in miR-125a/b-5p inhibitor group. mir-125a-5p 13-24 BCL2 apoptosis regulator Homo sapiens 146-151 34980181-10 2022 Knockdown of miR-125a-5p or miR-125b-5p significantly enhanced the proliferation and migration of MM.1S and U266 cells, and co-transfection of sh-Bcl-2 and miR-125a/b-5p inhibitor inhibited cell proliferation compared with that in miR-125a/b-5p inhibitor group. mir-125b-5p 28-39 BCL2 apoptosis regulator Homo sapiens 146-151 34898367-12 2022 Additionally, Octreotide attenuated the apoptotic capacity of LPS-induced BEAS-2B cells, led to the up-regulation of Bcl-2 protein level while cut down the protein levels of Bax and cleaved caspase3. Octreotide 14-24 BCL2 apoptosis regulator Homo sapiens 117-122 35176901-10 2022 Celecoxib also increased the expression of pro-apoptosis proteins PARP and BAX and reduced the expression of antiapoptosis protein Bcl2. Celecoxib 0-9 BCL2 apoptosis regulator Homo sapiens 131-135 35049427-11 2022 The Bcl-2 protein level was significantly downregulated, and the caspase-3 protein level was significantly upregulated, indicating that lenvatinib@H-MnO2-PEG-FA promoted the apoptosis of 9810 cells. lenvatinib 136-146 BCL2 apoptosis regulator Homo sapiens 4-9 34261915-0 2022 Atractylenolide III induces apoptosis by regulating the Bax/Bcl-2 signaling pathway in human colorectal cancer HCT-116 Cells in vitro and in vivo. atractylenolide III 0-19 BCL2 apoptosis regulator Homo sapiens 60-65 34261915-5 2022 Mechanistic studies further showed that atractylenolide III could regulate the Bax/Bcl-2 apoptotic signaling pathway through promoting the expression of proapoptotic related gene/proteins Bax, caspase-9 and caspase-3 but inhibiting the expression of antiapoptotic related gene/protein Bcl-2 in HCT-116 cells. atractylenolide III 40-59 BCL2 apoptosis regulator Homo sapiens 83-88 34261915-5 2022 Mechanistic studies further showed that atractylenolide III could regulate the Bax/Bcl-2 apoptotic signaling pathway through promoting the expression of proapoptotic related gene/proteins Bax, caspase-9 and caspase-3 but inhibiting the expression of antiapoptotic related gene/protein Bcl-2 in HCT-116 cells. atractylenolide III 40-59 BCL2 apoptosis regulator Homo sapiens 285-290 35220934-6 2022 Further investigation revealed that ND-16 inhibited the downstream cascades of JAK2, including STATs, PI3K/AKT/mTOR, and MAPK pathways, followed by regulation of Bcl-2 family members and cell cycle proteins CDK/- Cyclins. ND-16 36-41 BCL2 apoptosis regulator Homo sapiens 162-167 35049427-11 2022 The Bcl-2 protein level was significantly downregulated, and the caspase-3 protein level was significantly upregulated, indicating that lenvatinib@H-MnO2-PEG-FA promoted the apoptosis of 9810 cells. h-mno2-peg-fa 147-160 BCL2 apoptosis regulator Homo sapiens 4-9 35056993-0 2022 Making Sense of Antisense Oligonucleotide Therapeutics Targeting Bcl-2. Oligonucleotides 26-41 BCL2 apoptosis regulator Homo sapiens 65-70 35257357-13 2022 The treatment of psoralen resulted in an increase in ATF-6 and CHOP protein levels as well as a decrease in Bcl-2 protein level, indicating that cell apoptosis induced by psoralen was associated with ER stress. Ficusin 17-25 BCL2 apoptosis regulator Homo sapiens 108-113 35257357-13 2022 The treatment of psoralen resulted in an increase in ATF-6 and CHOP protein levels as well as a decrease in Bcl-2 protein level, indicating that cell apoptosis induced by psoralen was associated with ER stress. Ficusin 171-179 BCL2 apoptosis regulator Homo sapiens 108-113 35417658-8 2022 We found that the expression level of FOXO3, Bax, and Bim increased, whereas Bcl-2, caspase-3, and caspase-7 decreased by remdesivir in SKOV3 cells. remdesivir 122-132 BCL2 apoptosis regulator Homo sapiens 77-82 35378005-13 2022 The treatment with AS-AgNPs considerably elevated the caspase-9 and -3 activities and Bax expression, while decreasing the Bcl-2 expression in MCF-7 cells. as-agnps 19-27 BCL2 apoptosis regulator Homo sapiens 123-128 34995473-5 2022 Pyrrole molecules comprising prominent targeting capacities against microtubule polymerization, tyrosine kinases, cytochrome p450 family 1, histone deacetylase and bcl-2 proteins were reported. Pyrroles 0-7 BCL2 apoptosis regulator Homo sapiens 164-169 35291620-8 2022 Furthermore, combination treatment of GBM cells with ATO and Bay 11-7082 significantly induce apoptotic cell death coupled with downregulation of NF-kappaB anti-apoptotic target genes including Bcl-2 and IAP family members. Arsenic Trioxide 53-56 BCL2 apoptosis regulator Homo sapiens 194-199 35291620-8 2022 Furthermore, combination treatment of GBM cells with ATO and Bay 11-7082 significantly induce apoptotic cell death coupled with downregulation of NF-kappaB anti-apoptotic target genes including Bcl-2 and IAP family members. 3-(4-methylphenylsulfonyl)-2-propenenitrile 61-72 BCL2 apoptosis regulator Homo sapiens 194-199